id|nct_id|intervention_type|name|description
76027568|NCT02357641|Other|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
75373920|NCT02492750|Biological|Anakinra|Given SC
75700788|NCT00741195|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
75700789|NCT00741195|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
75700790|NCT05338632|Drug|Narcan 40 MG/ML Nasal Spray|naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
75700791|NCT05338632|Drug|Naloxone Hydrochloride|naloxone 0.4mg/ml, up to 4 doses 2mg intramuscularly, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
75700792|NCT02597816|Radiation|Three dimensional ultrasound|
75700793|NCT04078932|Behavioral|Violence Prevention Conversation Script to Discuss Safely Navigating Police Encounters|A conversation script to facilitate conversations on safely navigating police encounters as anticipatory guidance and violence prevention strategy. The conversation script will be created using expert recommendations from existing resources and using recommendations (determined from focus groups) from black male youth and their caregivers. The script will be patient-centered.
76027569|NCT05048771|Other|Questionnaire|Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
75373921|NCT02492750|Drug|Dexamethasone|Given PO
75537386|NCT04625491|Other|Observational|Observational
75537387|NCT04625335|Other|No Massage Protocol|Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.
75537388|NCT04625335|Other|Prophylactic Therapeutic Massage|Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.
75537389|NCT00219752|Drug|Imatinib mesylate 400 mg|
75700794|NCT00732758|Dietary Supplement|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
75700795|NCT00732758|Dietary Supplement|Placebo Tablet|Placebo Tablet once daily for 6 months
75700796|NCT00741351|Drug|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
75700797|NCT00741351|Drug|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
75864036|NCT03203980|Other|Triple antithrombotic therapy|patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)
75864037|NCT02447380|Drug|AZD6094|AZD6094 600MG qd
75700798|NCT00741351|Drug|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
76027570|NCT02352181|Procedure|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if fibrinogen <1gram per liter~Platelet concentrate :~if platelets <50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~if platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~if prothrombin<40% before transfusion at anhepatic phase or in case of bleeding.~if prothrombin<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
76027571|NCT02352181|Procedure|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM <8 mm~Platelet concentrate :~If MCF EXTEM <40mm or A10<35 mm and MCF or A10 FIBTEM >8mm.~If platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~2 Fresh frozen plasma if CT EXTEM >100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~if fibrinolysis in EXTEM~Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes >15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
76027572|NCT02357563|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
76027573|NCT02357563|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
75537390|NCT04625452|Behavioral|BBCC+5A's+GS|"It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information."
75700799|NCT02582268|Device|intrauterine device TCu 380A|
75700800|NCT02582268|Radiation|Trans-abdominal sonography|
75700801|NCT02582190|Drug|Colchicine group|antiarrhythmic therapy plus colchicine & antiarrhythmic therapy alone.
75700802|NCT00699153|Drug|Loteprednol Etabonate|Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
75700803|NCT00699153|Drug|Vehicle of Ophthalmic Loteprednol Etabonate|Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
75700804|NCT02582112|Other|Active Comparator: Warming group|Placebo Comparator: Control group
75700805|NCT05742243|Drug|Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)|Abatacept injected subcutaneously once per week and nasal insulin inhaled for 10 consecutive days initially and twice per week thereafter
75373922|NCT02492750|Other|Laboratory Biomarker Analysis|Correlative studies
75537391|NCT00242697|Procedure|spinal analgesia and anesthesia for coronary artery surgery|
75715480|NCT02539719|Drug|SC-003|
75715481|NCT02539719|Drug|SC-003 in combination with ABBV-181|
75715482|NCT04007614|Other|Questionnaire|Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
75715483|NCT05178628|Drug|Innohep|Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
75715484|NCT05178628|Drug|Chemotherapy: Gemcitabine + Nab-Paclitaxel|All patients will receive chemotherapy per clinical practice
75537392|NCT04625179|Other|Melatonin and hyaluronic acid and sinus membrane elevation|3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.
75537393|NCT04625179|Procedure|sinus membrane elevation without any materials|No materials will be placed at the sinus space.
75537394|NCT00219791|Drug|glucarpidase (50 Units/kg)|
75537395|NCT04624867|Drug|HP-1050 Patch|Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
75537396|NCT04624516|Other|self-structured foot exercise|The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
75537397|NCT02962232|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|treatment group
75537398|NCT02962232|Device|PTA catheter|control group
75537399|NCT04624711|Drug|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
75537400|NCT04624711|Drug|Anlotinib hydrochloride|Anlotinib 12mg, administered orally on Days 1-14 of each 21 day cycle.
75537401|NCT00246909|Drug|Pantoprazole|
75537402|NCT04624594|Other|Artificial Intelligence Feedback|AI mobile application provides feedback to participants randomized to artificial intelligence group.
75537403|NCT04624594|Other|Physical Therapist Feedback|PT provides feedback to participants randomized to physical therapist group.
75537404|NCT04624282|Diagnostic Test|different diseases|Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
75537405|NCT00219869|Drug|Galantamine|
75537406|NCT00246948|Procedure|Active conservative treatment of sciatica|
76027574|NCT04478929|Diagnostic Test|Gastroscopy|Routine gastroscopy
75537407|NCT04624360|Drug|Dexamethasone|Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
75537408|NCT04624360|Other|Placebo|2cc 0.9% Saline
75864038|NCT02447380|Drug|Docetaxel|Docetaxel 60 mg/m2
76027575|NCT02361541|Procedure|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
76027576|NCT03160105|Drug|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
75537409|NCT04624438|Other|Isometric training with electromyostimulation|"Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score."
76027577|NCT03160105|Other|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
76027578|NCT02640053|Procedure|Cryotherapy|Applied topically
75537410|NCT04624438|Other|Isometric training with voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
75537411|NCT04624438|Other|Isometric training with combination of electromyostimulation and voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
75537412|NCT00219908|Drug|Mitoxantrone|
75537413|NCT00242736|Drug|Esomeprazole|
75700806|NCT05742243|Drug|Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)|Abatacept injected subcutaneously once per week and nasal placebo inhaled for 10 consecutive days initially and twice per week thereafter
75700807|NCT04077918|Dietary Supplement|protein diet|100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
75700808|NCT04076748|Drug|Sufentanil|The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.
75700809|NCT04076748|Drug|EMONO|In the control group, patients will receive EMONO then IV morphine as soon as possible.
76027579|NCT02640053|Drug|Paclitaxel|Given IV
75537414|NCT04624048|Diagnostic Test|COVID-19 survey|Participants should complete a survey to analyze the impact of COVID-19 on University population.
75537415|NCT01580605|Drug|somatropin|"Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment"
75864039|NCT02447224|Drug|1 gm IV ertapenem at enrollment|
76027580|NCT02640053|Other|Quality-of-Life Assessment|Ancillary studies
76027581|NCT02640053|Other|Questionnaire Administration|Ancillary studies
76027582|NCT03160261|Drug|Exenatide Injection|Single injection of Exenatide 10μg subcutaneously
75537416|NCT04623970|Procedure|Dental Treatment|Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation
75537417|NCT00219947|Other|blood draw|"T cell subset enumeration~Serologic reactivity with HIV antigens~Viral load assays by bDNA, PCR, or RT-PCR~Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~HIV-1 Resistance Testing"
75700810|NCT00698997|Behavioral|Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
75700811|NCT00698997|Behavioral|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
75700812|NCT00711087|Drug|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
75864040|NCT02447224|Drug|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
75864041|NCT02447224|Procedure|Appendectomy|
75373923|NCT02492750|Drug|Lenalidomide|Given PO
75700813|NCT00711087|Other|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
75864042|NCT03199690|Drug|Dolutegravir|Antiviral (integrase inhibitor)
75864043|NCT03199690|Drug|Rifampicin|Antibiotic
75864044|NCT03203902|Other|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
75537418|NCT04623892|Drug|TQB2618 injection|TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline [0.9% (w/v) sodium chloride solution], and the infusion time is 60 ± 10 min.
75537419|NCT00242775|Drug|Budesonide/formoterol Turbuhaler|
75373924|NCT02492750|Other|Placebo|Given SC
75373925|NCT00363337|Drug|aripiprazole|open label treatment with aripiprazole
75537420|NCT00242775|Drug|Salmeterol/fluticasone Diskus|
75537421|NCT00562081|Behavioral|Education|24/7 access to a Certified Asthma Educator
75537422|NCT00562081|Behavioral|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
75537423|NCT00219986|Drug|Potent HAART during acute or early HIV-1 infection|
75537424|NCT04623619|Dietary Supplement|Acetyl L-Carnitine|Administering 2 gr of Acetyl L-Carnitine orally in addition to the standard of care therapy for 14 days
75537425|NCT00562198|Drug|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
75537426|NCT00562198|Drug|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
75537427|NCT00220025|Device|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
75537428|NCT03454594|Device|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
75537429|NCT00246987|Drug|Muraglitazar|
75537430|NCT04623463|Behavioral|Physical activity intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
75537431|NCT04623814|Other|Food|HEC113995 20mg will be taken orally fasted or with food
75537432|NCT04623814|Drug|HEC113995|HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
75700814|NCT04078308|Biological|Intravenous Injection of autologous mesenchymal stem cells|Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 & 3
75700815|NCT04078308|Other|Intravenous injection of placebo|Intravenous injection of normal saline (sodium chloride 0.9%)
75700816|NCT02582034|Radiation|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~A dose at the treated healthy liver < 120 Gy in case of lobar treatment~Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve > 30%~A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
75700817|NCT02582034|Radiation|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
75864045|NCT03204058|Drug|Placebos|Oral prophylaxis followed by placement of placebo gel
75373926|NCT02453347|Device|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
75373927|NCT02493452|Drug|Plecanatide|
75373928|NCT02493452|Drug|Placebo|
75373929|NCT02428309|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|
75373930|NCT02429869|Drug|everolimus|
75373931|NCT02430337|Behavioral|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
75373932|NCT02430337|Behavioral|SafeCare|SafeCare, an evidence-based home visiting program
75373933|NCT02493608|Device|scalpel|used to cut the abdominal wall.
75373934|NCT02493608|Device|Diathermy|Diathermy used to cut , coagulate the tissue
75373935|NCT02494076|Drug|EzPAP|
75373936|NCT02494076|Other|Standard Care|
75373937|NCT02431273|Drug|TDF IVR|
75373938|NCT02431273|Drug|TDF-FTC IVR|
75537433|NCT04623814|Drug|placebo|The placebo will be administered fasted or with food for 10 days.
75864046|NCT03204058|Drug|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
75864047|NCT03204058|Drug|Metformin|Oral prophylaxis followed by placement of metformin gel
75864048|NCT03199846|Other|Non-Interventional|Non-Interventional
75373939|NCT02431273|Drug|TDF-FTC-MVC IVR|
75373940|NCT02428478|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
75373941|NCT02428478|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
75373942|NCT04341493|Drug|Nitazoxanide 500 MG|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs
75373943|NCT04341493|Drug|Hydroxychloroquine|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug
75373944|NCT02431741|Device|Mepilex Transfer Ag|
75373945|NCT02432287|Drug|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
75537434|NCT00220064|Drug|Irinotecan, 5-Fluorouracil, Leucovorin|
75537435|NCT01580644|Drug|GLPG0187 prodrug|
75537436|NCT04623151|Behavioral|Online leaflet about foot care|Short text-based leaflet about foot care, presented online
75537437|NCT04623073|Procedure|Total Hip arthroplasty via a Direct Anterior Approach|Total Hip arthroplasty via a Direct Anterior Approach
75700818|NCT02581956|Behavioral|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
75700819|NCT02581956|Behavioral|No walking exercise|no exercise
75700820|NCT05275920|Other|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
75700821|NCT05275920|Other|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
75864049|NCT03203824|Dietary Supplement|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
75864050|NCT03203824|Other|non dark chocolate|No dark chocolate will be given to this group during the procedures.
75864051|NCT03118414|Other|Physical Exercise|"Participants were trained by exercise program based on their initial muscle strength and balance condition.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
75864052|NCT03118414|Other|Virtual Reality|"Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
75700822|NCT04250688|Device|Ekso Training with FES|
75700823|NCT00738530|Drug|Bevacizumab [Avastin]|10 mg/kg IV every 2 weeks
75700824|NCT00738530|Drug|Interferon alfa 2a [Roferon]|9 MIU SC 3 times/week
75700825|NCT00738530|Drug|Placebo|IV every 2 weeks
75864053|NCT03118414|Other|Brain Exercise|Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
75864054|NCT03203746|Drug|Lycopene + SRP|
75864055|NCT03203746|Procedure|SRP only|
75864056|NCT02447068|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
75373946|NCT02432287|Drug|Placebo|there is no other name we used for the placebo
75373947|NCT02532998|Drug|AZD9977 oral suspension|AZD9977 oral suspension, single dose
75373948|NCT02532998|Drug|AZD9977 placebo oral suspension|oral suspension, single dose
75537438|NCT00220103|Drug|epirubicin, capecitabine, cisplatin|
75537439|NCT00220103|Procedure|Surgical resection|
75537440|NCT04623307|Diagnostic Test|Non-contact DCS-Speckle multi-parameter imaging|The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
75537441|NCT00247026|Drug|curcumin; coenzyme q10|
75537442|NCT00562237|Biological|S205 placebo|2 i.m. injections per subject (0.5 mL each)
75537443|NCT00562237|Biological|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
75537444|NCT00562237|Biological|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
75537445|NCT00562237|Biological|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
75700826|NCT00711009|Drug|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
75700827|NCT00711009|Drug|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
75700828|NCT00711009|Drug|raltegravir (RAL)|RAL 400 mg BID
75700829|NCT04076124|Device|Active rTMS-DLPFC|Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
75700830|NCT04076124|Device|Active iTBS-DLPFC|Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
75537446|NCT00562237|Biological|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
75537447|NCT00562237|Biological|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
75537448|NCT00562237|Biological|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
75537449|NCT00562276|Procedure|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
75537450|NCT01580683|Drug|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
75864057|NCT02447068|Device|Luma Light|NBUVB light
75537451|NCT01580683|Other|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
75700831|NCT04076124|Device|Sham TBS-DLPFC or Sham rTMS-DLPFC|Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
75700832|NCT02592902|Procedure|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
75700833|NCT02592902|Procedure|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
76027583|NCT05036837|Drug|OZOPROMAF_SEQ1|"OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ."
76027584|NCT02361775|Device|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
76027585|NCT02361775|Device|opioid iv pca|opioid pca consisting of hydromorphone
76027586|NCT02361775|Drug|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
76027587|NCT02361775|Device|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
76027588|NCT05036759|Drug|68Ga-FAPI|intravenously injected with 68Ga-FAPI
76027589|NCT02361619|Drug|Caffeine|probe
76027590|NCT02361619|Drug|Diclofenac|probe
76027591|NCT02361619|Drug|Esomeprazole|probe
76027592|NCT02361619|Drug|Metoprolol|probe
76027593|NCT02361619|Drug|Midazolam|probe
75373949|NCT02532998|Drug|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
75373950|NCT02532998|Drug|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
75373951|NCT00363194|Drug|Pazopanib (GW786034)|Pazopanib (GW786034)
75537452|NCT04623229|Procedure|MCS|Manual Cataract Surgery
75537453|NCT04623229|Procedure|ReLACS Early|ReLACS with early administration of anesthesia
75864058|NCT02447068|Device|Occlusive Dressing|Off-the-shelf occlusive dressing
75864059|NCT02447146|Other|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
75864060|NCT02447146|Other|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
76027594|NCT02361619|Drug|Dabigatran|probe
76027595|NCT02361619|Drug|Clarithromycin|perpetrator
76027596|NCT02361463|Device|3D vision|Laparoscopic simulator training to proficiency under 3D conditions
76027597|NCT02361463|Device|2D vision|Laparoscopic simulator training to proficiency under 2D conditions
76027598|NCT05048303|Procedure|Arthroscopic modified individualized flexible Latarjet procedure|The modifications were as follows: (1)the coracoid graft and conjoint tendon were prepared using a mini-open technique with an incision of 2.5 cm and coracoacromial ligament were preserved. A total of 2 bone tunnels were drilled. (2)The anterior (including part of the incision used for obtaining the graft), standard antelateral, and posterior portals were set. (3) The glenoid was marked at the 4-o'clock position, and then the subscapularis muscle was split. (4)The glenoid tunnel was drilled where the suture linked to the graft was passed, and the graft was pulled to the glenohumeral joint via the sutures. A knotless suture anchor for antirotation (PushLock; Arthrex) was fixed to the glenoid to prevent rotation of the graft.
76027599|NCT02352025|Drug|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
76027600|NCT01950364|Drug|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
75373952|NCT02453581|Drug|OZ439|OZ439 Powder for Oral Suspension
75373953|NCT02533466|Other|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
75373954|NCT02533466|Other|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
75373955|NCT02454127|Behavioral|Atkins Diet|Dietary counseling for 1 year
75537454|NCT04623229|Procedure|ReLACS Standard|ReLACS with standard time administration of anesthesia
75537455|NCT04623112|Device|Hearing aid feature: Frequency Compression|FC Deactivated/Activated & set to default/Activated & set to hearing loss
75537456|NCT04623385|Combination Product|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
75537457|NCT04623385|Drug|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
75537458|NCT04623346|Procedure|Observation for study group|Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)
75537459|NCT04623034|Drug|Ademetionine|
75373956|NCT02454127|Behavioral|Zone Diet|Dietary counseling for 1 year
75373957|NCT02454127|Behavioral|Weight Watchers Diet|Dietary counseling for 1 year
75537460|NCT00220220|Drug|olmesartan medoxomil|
75700834|NCT04062513|Other|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
75864061|NCT03199456|Device|Zip surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
75537461|NCT00220220|Drug|amlodipine|
75864062|NCT03199456|Device|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
75864063|NCT03203668|Radiation|18F-choline PET/CT|18F-choline PET/CT imaging (neck, mediastinum)
75864064|NCT02446678|Device|PillCam ESO2|Capsule endoscopy
75537462|NCT04622800|Other|Exercise, proprioceptive neuromuscular fasilition (PNF) techniques|PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
75537463|NCT00242853|Procedure|Power doppler ultrasonography|
75373958|NCT02454127|Behavioral|Ornish Diet|Dietary counseling for 1 year
75537464|NCT00242853|Procedure|High frequency ultrasonography|
75537465|NCT00242853|Procedure|Exhaled nitric oxide assessment|
75373959|NCT02974244|Drug|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
75537466|NCT04622878|Procedure|thrombectomy and PTA|open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
75537467|NCT00220259|Drug|Fluticasone or placebo|
75537468|NCT04622956|Drug|Methotrexate Injectable Solution|"Phase 1:~Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~Level 0 [Starting Dose]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial"
75537469|NCT00242892|Procedure|Intra coronary measures of pressure|Intra coronary measures of pressure
75537470|NCT04622566|Drug|Lenvatinib, Pembrolizumab|After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
75537471|NCT04622488|Drug|Diclofenac Potassium|- In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
75537472|NCT00220298|Drug|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
75700835|NCT04062513|Other|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
75864065|NCT03203434|Diagnostic Test|Urinary volatile organic compound analysis|
75864066|NCT02446756|Other|acupuncture|
75373960|NCT02974244|Drug|basal insulin|basal insulin treatment in the customary clinical care in USA
75373961|NCT04743986|Biological|Platelet Rich Plasma (PRP)|RegenLab, Lausanne, Switzerland
75373962|NCT04743986|Drug|Corticosteroid (CS)|40mg/ml triamcinolone in 2 ml 0.5% bupivicaine
75373963|NCT03016897|Other|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
75373964|NCT02974322|Drug|GED-0301|GED-0301
75373965|NCT02974322|Drug|Placebo|Placebo
75373966|NCT02436031|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
75373967|NCT02436031|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
75373968|NCT02454283|Drug|Vanoxerine HCl|
75700836|NCT04062513|Other|Standard care|Preterm infants will receive sucrose during heel prick.
75700837|NCT04075890|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
75864067|NCT02446756|Other|physiotherapy|
75864068|NCT03199534|Drug|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
75373969|NCT02454283|Drug|Placebo|
75373970|NCT02437669|Drug|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
75373971|NCT02430818|Drug|ketamine|
75373972|NCT02430818|Drug|morphine|
75537473|NCT04622761|Drug|Cabazitaxel|"Patients will receive Cabazitaxel 25 mg/m2 * intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~*Cabazitaxel dose should be capped at 50mg (BSA=2)"
75537474|NCT00247104|Drug|Cranberries - Vaccinium macrocarpon|
75537475|NCT04622371|Other|Moderate exercises|Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
75537476|NCT00247143|Drug|Kaletra (drug)|
75537477|NCT04622215|Diagnostic Test|ICIQ questionnaire|questionnaire
75537478|NCT04622137|Procedure|Kinesiotaping therapy|The investigators used kinesiotaping strips in formations such as the Y, I, X, fan, web, and donut formations ove fractured clavicula.
75537479|NCT00412412|Drug|CNF2024|Oral doses of CNF2024 as specified in the protocol.
75537480|NCT00412412|Drug|CNF2024 + trastuzumab|Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
75537481|NCT00242931|Other|Nonmyeloablative stem cell conditioning regimen|"Conditioning:~Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0~Hematopoeitic Stem Cell Transplantation:~Infusion of peripheral blood stem cells, day 0~Immunosuppression:~For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
75537482|NCT04622098|Procedure|Endoscopic ultrasound|"this is an endoscopic procedure for the assessment of the lesions, the following will be recorded:~the tumor location,~layer of origin,~maximal diameter,~regularity of extraluminal border,~echopattern,~presence of cystic spaces or echogenic foci."
75537483|NCT00412490|Behavioral|Questionnaire|Written survey at 1 Month & 6 Months post surgery.
75537484|NCT00412490|Behavioral|Interview|One-on-One meeting lasting about one hour, at 1 Month & 6 Months post surgery.
75537485|NCT00247182|Behavioral|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
75537486|NCT00247182|Behavioral|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
75537487|NCT00247182|Behavioral|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
75537488|NCT04622059|Behavioral|acoustic stimulation|"An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes."
75700838|NCT04087850|Behavioral|Making Socially Accepting Inclusive Classrooms|Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
75537489|NCT04621903|Other|Shanshamani Vati Plus|Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.
75537490|NCT04621942|Other|inertial rehabilitation|Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Exercises were conducted by the same 2 researchers. Each training session included warm-up and 4 sets of shoulder ﬂexors, extensors, abductors, and adductors, with the right and left arms worked separately (16 sets for left and 16 sets for right arm). Each set lasted 15 seconds, a 2-minute break occurred between consecutive sets (without rest period between right and left arm). For all trained muscles 5 kg load was applied. During the training participants developed 70% of their maximal force achieved during the strength measurement. Participants observed developed during training force value displayed on-line on the screen. Cyklotren software allows to set the upper and lower limit of force; when developed strength was to low or to high a beep signal was emitted to correct participant force.
75537491|NCT04621942|Other|gymnastic rehabilitation|All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
75700839|NCT03825510|Radiation|Stereotactic Body Radiotherapy|"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to <=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
75373973|NCT02455453|Drug|18F-FFNP|
75373974|NCT02455453|Device|CTI/Siemens Biograph 40 PET/CT Scanner|"Will include (1) 18-FDG-PET/CT scan~Will include (2) 18F-FFNP-PET/CT scans"
75537492|NCT04621591|Device|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.
75373975|NCT02455453|Drug|Estradiol|
75373976|NCT02455453|Drug|18F-FDG|
75373977|NCT02997865|Behavioral|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
75373978|NCT02457403|Device|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
75864069|NCT03199534|Drug|Botulinum toxin A 100u|Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
75373979|NCT02457403|Other|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
75537493|NCT04621474|Diagnostic Test|Narrow band imaging (NBI)|Narrow-band imaging uses specific light wavelengths of 415 nm (blue) and 540 nm (green) due to a special filter which is electronically activated by a switch in the endoscope.
75537494|NCT04621552|Device|WEB embolization|Treatment of intracranial aneurysms with WEB with the use of the virtual simulation before implantation of the device
75537495|NCT00412568|Procedure|Photorefractive Keratectomy (PRK)|vision correction with PRK
75537496|NCT00242970|Device|3-Dimensional Color Scanning|Color imaging of the face and neck.
75537497|NCT04621669|Drug|SHR3680|240 mg
75700840|NCT00921219|Drug|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
75864070|NCT03199534|Drug|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
75864071|NCT03203356|Drug|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
75864072|NCT04280705|Other|Placebo|The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.
75864073|NCT04280705|Drug|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
75864074|NCT03199378|Other|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
75864075|NCT03199222|Device|Prosthetic smart socket technology with patient prompting|The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
76027601|NCT01950364|Drug|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
76027602|NCT05047991|Drug|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
76027603|NCT05047991|Drug|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
75373980|NCT02533934|Drug|Harvoni|Treatment of Hepatitis C with sofosbuvir based HCC therapy
75373981|NCT02983513|Behavioral|Early Intervention|
75373982|NCT02459119|Drug|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
75373983|NCT02956525|Drug|Dexibuprofen|Dexibuprofen 200 mg
75373984|NCT02519023|Drug|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
75373985|NCT02519023|Drug|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
75373986|NCT02519023|Device|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
75373987|NCT02519023|Drug|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
75373988|NCT02519023|Drug|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
75373989|NCT02519023|Drug|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
75373990|NCT02519023|Drug|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
75373991|NCT02535572|Device|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
75373992|NCT02535572|Device|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
75373993|NCT02497040|Drug|Levobupivacaine|local injection
75373994|NCT02497040|Drug|Bupivacaine|local injection
75537498|NCT04621669|Drug|digoxin|0.25 mg
75537499|NCT04621669|Drug|Rosuvastatin calcium|10 mg
76027604|NCT05047991|Drug|Leucovorin|Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
76027605|NCT05047991|Drug|Oxaliplatin|Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
75373995|NCT02497040|Drug|placebo|local injection
75537500|NCT04621669|Drug|metformin hydrochloride|500 mg
75537501|NCT00412646|Drug|TMC125|
75537502|NCT00247221|Behavioral|MI/Family Check-up|The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
75537503|NCT00247221|Behavioral|MI only|An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
75700841|NCT04076514|Procedure|central neck dissection|dissection of central cervical lymph node grope in low grade papillary thyroid cancer
75700842|NCT02567097|Behavioral|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
75700843|NCT02580552|Drug|Cobomarsen|
76027606|NCT05047991|Drug|Nab paclitaxel|Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
75700844|NCT02567331|Drug|Capecitabine|Participants will receive 1250 mg/m^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
75700845|NCT02580396|Device|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
75700846|NCT04077606|Other|ceramo-metallic crown prepartion|tooth will be prepared to receive ceramo-metallic crowns
75700847|NCT04077606|Other|full anatomical monolithic zirconia crown|tooth will be prepared to receive monolithic zirconia crowns
75700848|NCT04077450|Behavioral|Online Heart-Focused Breathing Intervention|Participants will receive an online standardized HeartMath© heart-focused breathing intervention.
75700849|NCT00577005|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
76027607|NCT05047991|Drug|Gemcitabine|Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
75700850|NCT00577005|Drug|Placebo|
75700851|NCT05162157|Device|NuvoAir platform|Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
75700852|NCT04077060|Diagnostic Test|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
75864076|NCT03203590|Drug|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
75864077|NCT03203590|Drug|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
76027608|NCT00014443|Drug|thalidomide|
76027609|NCT00014443|Drug|topotecan hydrochloride|
76027610|NCT05035979|Drug|BaidI Quzhi granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
76027611|NCT05035979|Drug|Ju Yin cream|Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
76027612|NCT05035979|Drug|Baidi Quzhi placebo granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
76027613|NCT05035979|Drug|Ju Yin placebo cream|Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
75373996|NCT02523235|Drug|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
75537504|NCT00562393|Other|Nutritional|Overfeeding high fat diet for 28 days
75537505|NCT00562432|Device|Plexisyl-AF|Plexisyl-AF implants
75537506|NCT00562432|Other|No Treatment|CABG without the experimental treatment
75700853|NCT04077060|Diagnostic Test|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
75700854|NCT02581566|Drug|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
75700855|NCT02581566|Drug|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
75537507|NCT00562471|Other|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
75537508|NCT00562471|Other|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
75537509|NCT00220376|Drug|SPM 907|
75537510|NCT00243009|Drug|cyclosporine|
75537511|NCT00243009|Drug|fludarabine phosphate|
75537512|NCT00243009|Drug|mycophenolate mofetil|
75537513|NCT00243009|Procedure|allogeneic bone marrow transplantation|
75700856|NCT02581566|Drug|Bupivacaine|Intrathecal Bupivacaine
75700857|NCT02567019|Other|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
75700858|NCT05237076|Diagnostic Test|Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)|Hyperinsulemic-Euglycemic Clamp as described by deFronzo et al.
75700859|NCT04077216|Dietary Supplement|Extra Virgin Olive Oil (EVOO)|This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
75700860|NCT00576927|Drug|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
75700861|NCT00576927|Drug|Placebo|
75700862|NCT05742087|Other|Clinical examination|The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
75700863|NCT05742087|Other|electroneuromyography (ENMG)|Data from the ENMGs will be extracted from the cohort and analyzed.
75373997|NCT02498522|Drug|Metformin|83 patients will continue metformin until end of 1st trimester
75373998|NCT02459197|Behavioral|Heat Pain Stimuli A|
75537514|NCT00243009|Procedure|peripheral blood stem cell transplantation|
75537515|NCT00243009|Radiation|radiation therapy|
75537516|NCT00562510|Drug|Raltegravir|Raltegravir 400 mg BID added to stable HAART
75537517|NCT00562510|Drug|Placebo|Placebo BID added to stable HAART
75700864|NCT05674578|Behavioral|Patient Navigation|Assigned a patient navigator and receive coaching
75700865|NCT05674578|Other|Quality-of-Life Assessment|Ancillary studies
75537518|NCT00562666|Other|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
75537519|NCT00220415|Drug|SPM 927|
75373999|NCT02459197|Behavioral|Heat Pain Stimuli B|
75700866|NCT05674578|Other|Questionnaire Administration|Ancillary studies
76027614|NCT05047367|Behavioral|cross-sectional survey study|Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, Visual Analogue Scale and PainDETECT Questionnaire for pain, Pittsburgh Sleep Quality Scale and Epworth Sleepiness Scale for sleep quality
75700867|NCT02580630|Behavioral|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
75700868|NCT02580630|Other|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
75700869|NCT02580630|Drug|Ultrasound guided injection with Glucocorticosteroid|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
75700870|NCT02580630|Drug|Ultrasound guided injection with local anaestethic|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
75700871|NCT00698841|Drug|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m^2 over 60 minutes.
75700872|NCT03787290|Drug|Tocilizumab|participants will receive a single subcutaneous injection of tocilizumab (162 mg)
75700873|NCT03787290|Drug|Placebo|participants will receive a single subcutaneous injection of saline
75700874|NCT03787290|Device|Whole-Body Hyperthermia|subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
75374000|NCT02459197|Behavioral|Positive Video|
75374001|NCT02459197|Behavioral|Neutral Video|
75374002|NCT02459197|Drug|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
75374003|NCT02459197|Drug|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
75374004|NCT02431052|Drug|Olumacostat Glasaretil|
75700875|NCT00577395|Drug|placebo|oral tablet once a month for 12 months
75700876|NCT00577395|Drug|risedronate|tablet, 150 mg once a month for 12 months
75374005|NCT02431052|Other|Vehicle|
75374006|NCT02919787|Drug|5-FU|Neoadjuvant treatment
75374007|NCT02919787|Drug|Oxaliplatine|Neoadjuvant treatment
75374008|NCT02919787|Drug|Irinotecan|Neoadjuvant treatment
75374009|NCT02919787|Procedure|Pancreatic surgery|All patients
75374010|NCT02919787|Drug|5-FU|Adjuvant treatment
75374011|NCT02919787|Drug|Oxaliplatine|Adjuvant treatment
75374012|NCT02919787|Drug|Irinotecan|Adjuvant treatment
75537520|NCT00243048|Dietary Supplement|soy protein isolate|
75537521|NCT00243048|Radiation|radiation therapy|
75537522|NCT04621396|Other|Observational screening study|
75537523|NCT04621513|Device|laser acupuncture (RJ laser S/N 1813458)|use a low-level-laser acupuncture on acupoint
75537524|NCT04621513|Drug|western medicine|Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
75537525|NCT00220454|Drug|Climara|
75537526|NCT00220454|Drug|Hydrocortone|
75537527|NCT00562705|Behavioral|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|"A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention"
75537528|NCT00562705|Behavioral|"growth hormone-Genotropin or NorditropinSimplex or Biotropin"|"Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin)."
75537529|NCT00247260|Device|32P BioSilicon|
75700877|NCT04062357|Drug|Lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
75700878|NCT04062357|Other|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
75700879|NCT05190120|Procedure|Femoral Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
75374013|NCT02459275|Other|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
75700880|NCT05190120|Procedure|Adductor Canal Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
75700881|NCT05190120|Drug|preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine|
75700882|NCT05190120|Drug|Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.|
75700883|NCT02581332|Behavioral|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
75700884|NCT03896061|Device|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
75700885|NCT00738374|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
75700886|NCT00738374|Drug|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
75374014|NCT02459275|Drug|Metoclopramide|Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
75374015|NCT02498834|Behavioral|Educational Video and Question Prompt List|Educational Video and Question Prompt List
75374016|NCT02524561|Drug|CEE pill|Conjugated equine estrogens 0.45 mg/day
75537530|NCT04621084|Behavioral|Eating habits|Questionnary online
75537531|NCT04621162|Behavioral|Positive Expectations (initial)|"A positive expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will generate hypoalgesia"
75537532|NCT04621162|Behavioral|Negative Expectations (initial)|"A negative expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will not generate hypoalgesia"
75374017|NCT02524561|Drug|Estradiol patch|Climara 50 mcg/day
75374018|NCT02524561|Drug|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
75374019|NCT02524561|Other|Placebo tablet|Placebo tablet
75537533|NCT04621162|Behavioral|Neutral Expectations (initial)|This group will act as a control. No expectations will be given that will influence the participant.
75537534|NCT04621162|Behavioral|Positive Expectations (during intervention)|"A positive expectation will be given during the performance of the mental practice. This is working very well"
75537535|NCT04621162|Behavioral|Experimental: Negative Expectations (during intervention)|"A negative expectation will be given during the performance of the mental practice. This is working very bad"
75537536|NCT04621162|Behavioral|Neutral Expectations (during intervention)|This group will act as a control. No expectations will be given that will influence the participant.
75537537|NCT00243087|Drug|BI 2536|
75537538|NCT04621357|Radiation|Brain MRI|Brain MRI will include differents sequences.
75374020|NCT02524561|Other|Placebo patch|placebo patch
75374021|NCT02524561|Other|Placebo progesterone|placebo progesterone
75537539|NCT04621357|Biological|Biological biomarkers|Biological biomarkers will include a set of systemic inflammatory markers
75537540|NCT04621123|Biological|Convalescent anti-SARS-CoV-2 MBT plasma|Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
75537541|NCT04621123|Other|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
75557448|NCT01050764|Drug|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
75557449|NCT00464607|Drug|hMG-IBSA|
75557450|NCT00464607|Procedure|Ovarian stimulation|
75557451|NCT00472485|Procedure|eye movement therapy|
75557452|NCT00434096|Drug|rimonabant (SR141716)|oral administration once daily
75557453|NCT00434096|Drug|placebo|oral administration once daily
75557454|NCT00472524|Procedure|Mydriasis/cycloplegia via different modes of administration|
75557455|NCT01050569|Drug|Nicotine Patch|21 mg
75557456|NCT01050569|Other|VLNC Cigarette|Cigarette where the tobacco contains <0.1 mg of nicotine yield.
75557457|NCT01050569|Other|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing <0.1 mg nicotine yield.
75557458|NCT00464724|Procedure|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
75557459|NCT04702490|Drug|MET409 Active|MET409 Active (50mg)
75557460|NCT04702490|Drug|MET409 Placebo|MET409 Placebo (50mg)
75557461|NCT04702490|Drug|Empagliflozin|Empagliflozin (10mg)
75557462|NCT00464763|Drug|Dexmedetomidine|
75557463|NCT00464763|Drug|Placebo|
75557464|NCT00434135|Drug|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1&8
75557465|NCT00472563|Drug|Bicarbinate 150 mEq/L|75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
75557466|NCT01050530|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
75537542|NCT04621240|Behavioral|Online SMART & Stress Solutions|1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
75700887|NCT04076982|Dietary Supplement|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
75700888|NCT04076982|Other|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
75700889|NCT04088474|Dietary Supplement|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
75700890|NCT04088474|Dietary Supplement|Placebo|Maltodextrin was used as a placebo
75700891|NCT05016999|Dietary Supplement|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion)
75700892|NCT02594930|Procedure|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
75700893|NCT02581176|Drug|Apixaban|
75700894|NCT03746184|Other|Treatment course|Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
75700895|NCT04075500|Device|24-h Holter monitoring|Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).
75700896|NCT05119608|Behavioral|CBT/ACT|10-session ACT-re-enforced CBT intervention.
75537543|NCT00243126|Behavioral|Family-Based Risk Reduction Intervention|The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
75700897|NCT00697593|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
75700898|NCT05012475|Behavioral|Modified Virtual Reality Gaming|Investigators customize each gaming session based on the motivators and interests of each participant. The intervention facilitates independent hand separations (minimizing stereotypies) and encourages independent arm/hand movement that serves to activate or control the computer-generated activities.
75700899|NCT05325021|Diagnostic Test|Axial length measurement in millimeter (mm) by optical biometry device|Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.
75700900|NCT05325021|Diagnostic Test|Autorefractometer to measure the refractive error in both eyes.|Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).
75864078|NCT02446522|Procedure|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
76027615|NCT05036057|Other|Questionnaire|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
75537544|NCT04620967|Drug|Insulin aspart|Insulin aspart (Iasp) in insulin pump
75537545|NCT04620967|Drug|Fast-acting insulin aspart|Fast-acting insulin aspart (Fiasp) in insulin pump
75537546|NCT00220493|Drug|Ritalin|
75537547|NCT04620655|Drug|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
75537548|NCT00247299|Device|IPL Quantum Product manufactured by Luminis Ltd.|
75557467|NCT01050530|Drug|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
75557468|NCT03272880|Behavioral|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
75700901|NCT04075578|Drug|OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States|Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
75700902|NCT05741931|Device|mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)|The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
75700903|NCT04445025|Drug|Elagolix 200 MG|Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation
75700904|NCT04445025|Drug|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation
75700905|NCT04445025|Diagnostic Test|Lab work|Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw
75700906|NCT02580474|Drug|Daclatasvir plus Asunaprevir|
75700907|NCT04061811|Diagnostic Test|Diagnostic biomarker study|Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
75700908|NCT00697515|Drug|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
75700909|NCT00697515|Drug|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
75700910|NCT03951636|Procedure|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
75700911|NCT03951636|Procedure|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Er:YAG laser will be used for the implant surface decontamination.
75700912|NCT03951636|Procedure|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
75700913|NCT00738062|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
75700914|NCT00738062|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
75700915|NCT04156074|Dietary Supplement|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|Vitamin D enriched (20 mcg/day) olive oil emulsion drink. 30 mL drink daily
75864079|NCT02446522|Procedure|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
75537549|NCT04620616|Other|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
75537550|NCT04620616|Other|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
75537551|NCT04620616|Other|Subject Usual Brand ENDS|Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
75700916|NCT04156074|Dietary Supplement|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink 30 mL drink daily
75700917|NCT04156074|Dietary Supplement|Placebo coconut oil emulsion drink|Placebo coconut oil emulsion drink 30 mL drink daily
75700918|NCT04156074|Dietary Supplement|Vitamin D supplement (20 mcg/day)|Vitamin D supplement (20 mcg/day) Pill consumed daily
75700919|NCT04061889|Other|intervention name is not applicable|Another intervention is not applicable either, due to the observational study design
75700920|NCT04076670|Other|Psychological intervention for family caregivers of patients at the end of life|The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
75700921|NCT04062045|Drug|Ropivacaine Hcl 0.2% Inj Vil 10Ml|Group A will receive the medicine through the erector spinae catheter.
75700922|NCT04062045|Drug|Saline 0.9%|Group B will receive Saline 0,9% through the erector spinae catheter.
75537552|NCT00247338|Drug|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
75537553|NCT00220532|Drug|Folic acid with riboflavin|
75715485|NCT00896571|Drug|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
75715486|NCT00896727|Genetic|gene expression analysis|
75715487|NCT00896727|Genetic|protein expression analysis|
75715488|NCT00896727|Other|fluorescent antibody technique|
75715489|NCT00896727|Other|laboratory biomarker analysis|
75537554|NCT04620694|Device|Choice of arterial cannulation site at the beginning of the surgery|Choice of arterial cannulation site at the beginning of the surgery is at the discretion of the anesthesia physician.
75537555|NCT04620499|Device|EEG|PEER EEG
75700923|NCT05007015|Procedure|Transanal Irrigation|Each participant will receive a mailed package of TAI materials, given access to the LARS website, and have two scheduled virtual visits with a trained research nurse to learn how to use TAI once assigned to the intervention arm. These sessions will include one on one session with the nurse for review of the material, discussion of the device and any questions. TAI involves introducing an applicator into the anus for irrigation. An initial volume of 1000 mL will be suggested but can be increased to 1500 mL or reduced to 500 mL as per patient preference and tolerance. Applicators are single-use instruments that can be disposed of into standard waster receptacle after each treatment. The irrigation system is multiple-use and can be used for the duration recommend by the manufacturer manual. Daily irrigation can take anywhere between 20 and 90 minutes depending on individual patient experience.
75700924|NCT04064073|Drug|DWP16001|Tablets, Oral, once daily single dose
75700925|NCT04064073|Drug|Metformin IR|Metformin IR 1000mg, Tablets, Oral, BID for 7 days
75700926|NCT04064073|Drug|DWP16001+Metformin IR|Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
75700927|NCT04075344|Other|Multimodal Infection control programme|12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
75700928|NCT02580942|Device|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
75864080|NCT03203278|Behavioral|Web-based exercise programme|Aerobic, resistance and balance exercises
75374022|NCT02431598|Drug|gadoxetate disodium|
75374023|NCT02431598|Drug|gadoterate dimeglumine|
75374024|NCT02431598|Drug|Saline|
75374025|NCT00363974|Drug|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
75864081|NCT02450344|Behavioral|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
75864082|NCT02450344|Behavioral|Passive health promotion|An electronic package of information related to alcohol
75864083|NCT04362449|Combination Product|Shortened hydration time and dispensary of Akynzeo|Hydration is reduced to 1 hour and 40 minutes and Akynzeo is administered as an oral drug instead of Ondansetron being given as an IV before chemotherapy.
75374026|NCT04743739|Drug|Rituximab|Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.
75374027|NCT04743739|Drug|cyclosporine|cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA. CsA will be tapered after 6 months and discontinued over a three month period.
75374028|NCT02499380|Device|PneumRx Coil System|
75374029|NCT02461693|Drug|Caffeine|200mg delivered as pill; one-time dose
75374030|NCT02461693|Drug|Placebo|Lactose-based pill; one-time dose
75864084|NCT04362449|Combination Product|Standard of care|Hydration remains at around 6 hours and 30 minutes due to no oral fluids being consumed prior to treatment and normal saline being administered for 90 minutes before cisplatin and then for 2 hours after cisplatin and before gemcitabine administration
75864085|NCT02446210|Device|Magstim 200|Transcranial Magnetic Stimulation
75374031|NCT02525263|Biological|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
75537556|NCT00243165|Behavioral|Lifemel honey intake every day|
75537557|NCT04620772|Drug|Cyclophosphamide injection|Cyclophosphamide vs placebo
75537558|NCT00220571|Device|Coronary Angioplasty (PTCA)|
75537559|NCT04620421|Other|Rhythm-based Multitask Training|Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
75537560|NCT00243204|Drug|talabostat mesylate|
75537561|NCT00243204|Drug|docetaxel|
75537562|NCT04620577|Other|antibiotic|normal saline
75537563|NCT04620850|Device|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time)
75537564|NCT00562744|Other|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
75537565|NCT00220610|Device|Transcranial magnetic stimulation|
75537566|NCT04620460|Device|Low-intensity Focused Ultrasound(LIFUS)|Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.
75537567|NCT04620031|Drug|HSK3486|Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
75537568|NCT04620031|Drug|Propofol|"Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h"
75537569|NCT00243282|Behavioral|Relaxation Response (instruction, pocket practice card prov)|
75864086|NCT02446210|Device|Digitimer electrical stimulator|Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
75700929|NCT02580942|Device|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
75864087|NCT02077166|Drug|Ibrutinib|
75864088|NCT02077166|Drug|Lenalidomide|
75864089|NCT02077166|Drug|Rituximab|
75864090|NCT05186350|Procedure|ERCP+ SpyGlass|SpyGlass direct Vision guided laser lithotripsy
75864091|NCT05186350|Procedure|ESWL+ ERCP|ESWL + Stone removal through ERCP
75864092|NCT03198832|Procedure|Non-surgical periodontal treatment|Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
75864093|NCT04273217|Drug|AV-1|Single dose, administered by IV infusion (volume: 250 mL)
75700930|NCT02580942|Drug|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
75700931|NCT02565927|Device|Traditional airway stent|process airway stenting
75864094|NCT04273217|Drug|Placebo|0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
75864095|NCT05234086|Combination Product|InbioDerm + C plus advanced healing|For patients who are assigned to experimental treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section, through an enzymatic process and cell proliferation for a period of approximately fourteen days, the cells that are integrated in the InbioDerm+C will be obtained and used to treat the foot ulcer.
75864096|NCT05234086|Procedure|Advanced healing|Patients who are assigned to active comparator correspond to the control treatment, which will be received advanced healing.
75374032|NCT02525575|Behavioral|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
75700932|NCT02565927|Drug|Iodine-125 seeds|process intraluminal brachytherapy
75864097|NCT02450188|Drug|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
75864098|NCT02450188|Behavioral|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
75864099|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
75864100|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
75374033|NCT02525653|Drug|albumin-bound paclitaxel|
75864101|NCT03198676|Drug|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
75864102|NCT03198676|Drug|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
75864103|NCT03749369|Drug|Salvadora Persica Root|Salvadora Persica Gel
75864104|NCT03749369|Procedure|Scaling and root planing|Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
75864105|NCT03202966|Other|Rehabilitation therapy|Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
75864106|NCT04264949|Other|Education in the use of smartphone app (Mon coach dos)|In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
75864107|NCT04264949|Other|conventional care|conventional care and the therapeutic education program
75374034|NCT02525653|Drug|gemcitabine|
75374035|NCT02431754|Drug|Tadalafil|Administered orally
75700933|NCT04137354|Other|Intermittent placebo iron supplement|Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
75700934|NCT04137354|Other|Intermittent iron supplement|Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
75864108|NCT04484506|Drug|pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone|Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
75864109|NCT02449564|Drug|sirolimus|sirolimus 1mg daily
75864110|NCT05668871|Drug|Danning Tablet|3 times each day, 5 tablets each time, take orally after meals.
75700935|NCT04137354|Other|Placebo Vitamin A|Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
75864111|NCT02449720|Drug|Ropivacaine|Intraperitoneal instillation and infusion
75864112|NCT02449720|Drug|0.9% Saline|Intraperitoneal instillation and infusion
75864113|NCT03194620|Other|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
75700936|NCT04137354|Other|High-dose Vitamin A supplement|Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
75864114|NCT03194620|Other|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
75864115|NCT03194620|Other|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
75864116|NCT03194620|Other|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (-)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
75864117|NCT03194620|Other|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (-)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
75864118|NCT03194620|Other|(-)-Epicatechin (EC)|Single oral intake of 120 µmol of (-)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
75700937|NCT05006859|Other|Cohorte|Assessment of postural wheelchair disorders, as well as PW pain, and pressure ulcers associated with sitting
75864119|NCT03194620|Other|(-)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (-)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
75864120|NCT03194620|Other|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
75864121|NCT03203122|Other|IPL laser|IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type
75864122|NCT03203122|Other|No sham treatment|The treatment is slightly painful, and noisy. Sham treatment impossible
75864123|NCT04384523|Drug|OsrHSA 20 mg/kg IV|A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
75864124|NCT04384523|Drug|OsrHSA 40 mg/kg IV|A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
75864125|NCT04384523|Drug|OsrHSA 80 mg/kg IV|A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
75864126|NCT04384523|Drug|OsrHSA 140 mg/kg IV|A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
76027616|NCT02351635|Other|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
75374036|NCT02431754|Drug|Placebo|Administered orally
75374037|NCT02431754|Drug|Alpha1 Blocker|Administered orally
75374038|NCT02499692|Device|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
75374039|NCT02526277|Device|MMF07 Foot Massager|
75374040|NCT02526277|Device|Heat Therapy|
75374041|NCT02500628|Drug|Metformin|500 mg orally after baseline testing of heart rate
75700938|NCT02566629|Other|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
75700939|NCT02566941|Device|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
75700940|NCT05000073|Other|dialysis and socio-aesthetic care|dialysis and socio-aesthetic care
75700941|NCT05000073|Other|dialysis|dialysis
75700942|NCT04130958|Device|Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
75864127|NCT04384523|Drug|OsrHSA 200 mg/kg IV|A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
75374042|NCT02526667|Drug|Chlorhexidine gluconate|2% CHG solution on cloth
75864128|NCT04384523|Other|Placebo|Normal Saline (0.9% Sodium Chloride)
75864129|NCT02446054|Dietary Supplement|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
75864130|NCT03202888|Behavioral|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
76027617|NCT05047133|Drug|Tranexamic acid|TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
76027618|NCT02357251|Other|Enhanced recovery protocol|
76027619|NCT05035355|Procedure|a weaning protocol|a weaning protocol that is combined spontaneous breathing trial (SBT) with the high-flow nasal cannula (HFNC)
75374043|NCT02526667|Drug|DynaHex-2|2% CHG solution
75374044|NCT02526667|Other|Vehicle|Excipients of CHG product only
75864131|NCT02446288|Device|TMJ Next Generation|
75864132|NCT02446288|Device|DSG Relaxer|
75864133|NCT02445976|Drug|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
75864134|NCT03198442|Procedure|F-18 FDG breast PET scan|
75864135|NCT03198364|Behavioral|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
76027620|NCT04334863|Drug|WP1066|"WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."
76027621|NCT02357407|Drug|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
76027622|NCT02357407|Drug|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
75864136|NCT03198364|Behavioral|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
75864137|NCT03198208|Drug|Fentanyl dose administration|
75864138|NCT01044056|Drug|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
75864139|NCT01044056|Drug|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
75864140|NCT01044056|Drug|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
75864141|NCT03198286|Other|Informational Intervention|Receive treatment summary and survivor care plan
75864142|NCT03203044|Other|Soylent and water diet|A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
75864143|NCT01005056|Drug|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
75864144|NCT04796714|Drug|Double antiplatelet therapy|One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
75864145|NCT04796714|Drug|Aspirin|One sachet of aspirin 160 mg per day during 3 months
75864146|NCT04796714|Device|Brain MRI|Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).
75864147|NCT04796714|Other|Neurological tests|Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
75864148|NCT04382651|Drug|MAS825|MAS825 liquid solution for intravenous infusion
75864149|NCT04382651|Other|Placebo|Placebo liquid solution for intravenous infusion
75864150|NCT04382651|Drug|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
75864151|NCT02445898|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
76027623|NCT05035433|Procedure|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
75864152|NCT02445898|Drug|Isotonic Sodium Chloride|Placebo
75864153|NCT03202576|Device|Nasal Bridle|Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
75537570|NCT00243282|Behavioral|Mindfulness training using model developed from UMass|
75864154|NCT03749291|Other|Obemat2.0 therapy|"Lifestyle (diet & physical activity) structured recommendations through a motivational interview.~Duration: 12(+3) months Description: 1 visit/month & 3 Workshops in primary care centers Providers: pediatricians and nurses trained to perform motivational interview The interviews are structured as follows: First, checking the accomplishment of objectives to motivate the participant. Second, a specific topic per visit is explained to the participant. Third, a task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight & physical activity are defined to be accomplished until the next visit."
75864155|NCT03749291|Other|Usual Clinical Practice|Lifestyle (diet and physical activity) Duration: 12 (+3) months Description: 1visit/month to the primary care centers. Providers: pediatricians & nurses. Children assigned to the control group receive the usual treatment conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity [Spanish Ministry of Science and Innovation], 2009). At visits, the family receive recommendations to carry out a balanced diet, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports is advised.
76027624|NCT05035433|Procedure|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
75864156|NCT02445820|Drug|HES|2500 mL of balanced HES 130/0.4
75864157|NCT02445820|Drug|Crystalloid|2500 mL of balanced crystalloid.
75374045|NCT02535806|Drug|Velcade|4 doses of study drug will be given.
75374046|NCT02535806|Drug|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
75374047|NCT02535806|Drug|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
75374048|NCT02535806|Drug|Dexamethasone|Days 1-5 and 15-19
75557469|NCT01050257|Drug|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
75864158|NCT03749213|Drug|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
75700943|NCT04130958|Device|Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)|The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
76027625|NCT02038699|Drug|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
75374049|NCT02535806|Drug|Mitoxantrone|Days 1 and 2
75700944|NCT04063917|Device|ZENS|ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
75700945|NCT04075032|Dietary Supplement|Pomegranate extract|Pomegranate extract consumption (900 mg/day) for 4 weeks
75700946|NCT04075032|Other|Placebo|Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
75864159|NCT04484116|Diagnostic Test|Intraoperative Paratohormone|Three IOPTH determinations were withdrawn: at anesthetic induction (PTH0), 15 minutes (PTH15), and 30 minutes (PTH30) after completion gland resection. Another sample was taken 24 hours after the procedure (PTH24), values <150pg/mL defined a successful surgery and patients were assigned to the successful or unsuccessful group. IOPTH drop was analyzed to predict successful surgery with drops of 70% and 90% at 15 and 30 minutes.
75864160|NCT04614428|Behavioral|RESILIENCE Program|"In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective."
75700947|NCT04245345|Device|Accelerometer Sensing for Micra AV Study|Characterize AV synchrony in subjects implanted with Micra AV device. The study will be conducted upon market approval of the Micra AV Transcatheter Pacing System.
75864161|NCT03198130|Drug|REGN2810|Intravenous (IV) use
75864162|NCT03202654|Other|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
75864163|NCT03202654|Other|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
75864164|NCT04238780|Procedure|Erector Spinae Plane Block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine needle was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml local anesthetics is done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
75864165|NCT04238780|Procedure|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
75864166|NCT03197974|Behavioral|Mindfulness for Bipolar|Brief online self-management program with email coaching support
75864167|NCT03197974|Behavioral|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
75864168|NCT00944216|Drug|Salkera Emollient Foam|application of the Salkera emollient foam twice a day during the 12 week study period.
75700948|NCT02580786|Behavioral|Breastfeeding peer support|
75864169|NCT03202732|Other|DiabetesFlex|"DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk."
75864170|NCT00878462|Drug|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
75864171|NCT00878462|Drug|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
75864172|NCT00878462|Drug|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
76027626|NCT05046743|Other|Colonic gas load|Colonic infusion of gas via an anal cannula
76027627|NCT05046743|Other|Sham load|Sham infusion of gas via an anal cannula
75374050|NCT02535806|Drug|Vincristine|Days 1, 8, 15, 22
75700949|NCT03900507|Procedure|endometriosis surgery|"Medical treatment was initiated in patients with abdominal incision due to endometriotic focus in the incision line.~however, patients with surgical excision indications were the study group."
75700950|NCT05741775|Other|Aerobic training|The warm-up exercise will include light aerobic activity and some dynamic stretching movements. Similarly, the cool down exercises will include buttock stretch, hamstring stretch, inner thigh stretch, calf stretch and thigh stretch. Each stretch to be performed for 5 repetitions with a hold time of 15 seconds for each. An elastic band secured around the head will be used to apply local pressure over the area. Kettler Computeranleitung Advanced display will be used to train static cycling. ProAction BH Treadmill G6700 instrument will be used for aerobic training.
75700951|NCT05741775|Other|Biofeedback Training|Neurotrac myoplus 4 pro instrument will be used for EMG biofeedback training.
75700952|NCT05741619|Other|Long-term outcome|Autonomy, physical examination, behavioural disorders
75374051|NCT02535806|Drug|Pegaspargase|Days 3 and 17
75864173|NCT03197818|Drug|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
75864174|NCT03197818|Drug|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
75864175|NCT00754520|Device|Ceramic On Metal|Ceramic on Metal articulation using M2a-38™ mm cup
75864176|NCT00754520|Device|Metal on Metal|Metal on Metal articulation using M2a-38™ mm cup
75864177|NCT01562249|Other|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
75864178|NCT01562249|Other|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
75700953|NCT00921297|Procedure|Immediate Cataract Surgery|Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
75864179|NCT01562249|Other|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
75864180|NCT03197896|Other|Educational Intervention|Review prostate cancer information
75864181|NCT03442088|Drug|Apremilast|Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
75864182|NCT03202420|Other|TOPS|Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
75864183|NCT03746795|Device|Spirometric examinations realized using the EIT|Spirometric examinations will be realized using the EIT alone.
75864184|NCT03746795|Device|Simultaneous measurement by spirometer and EIT|Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
75864185|NCT03202498|Device|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
75864186|NCT03202498|Other|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
75700954|NCT04902729|Drug|Carbetocin|Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
75700955|NCT04902729|Drug|Oxytocin|Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
75700956|NCT03674814|Drug|Enzalutamide|Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
76027628|NCT03160651|Drug|Methylprednisolone or placebo|Patients will receive 28 days of methylprednisolone 32 mg/day
76027629|NCT05046977|Procedure|Single osteotomy|Single tibial osteotomy
76027630|NCT05046977|Procedure|Double Osteotomy|Double Tibial Osteotomy
75700957|NCT03674814|Drug|Relacorilant|Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
75700958|NCT03912558|Procedure|Butterfly device implantation|The Butterfly device will be positioned and deployed with cystoscopy guidance
75700959|NCT05087394|Other|Comorbidities|Risk factors (comorbidities), requirements of respiratory suppot and chest imaging will are considered exposure for primary outcomes
75700960|NCT00698685|Drug|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
75700961|NCT00698685|Biological|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
75700962|NCT00698685|Procedure|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
75700963|NCT00737672|Device|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
75864187|NCT03202498|Device|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
75864188|NCT03202498|Other|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
75864189|NCT01562405|Drug|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
75864190|NCT01562405|Drug|Lenalidomide|15 to 25 mg days 1-21, given orally
75374052|NCT02865343|Device|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
75700964|NCT00737672|Procedure|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
75864191|NCT01562405|Drug|Dexamethasone|40 mg days 1,8,15,22; given orally
75864192|NCT01562405|Drug|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
75864193|NCT03194386|Other|Reassurance|At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.
75700965|NCT03649308|Device|Negative Pressure Wound Therapy|An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
75700966|NCT03649308|Procedure|Conventional treatment|Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
75864194|NCT03194386|Other|Eye-Movement Desensitization and Reprocessing (EMDR)|At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
75864195|NCT03748745|Drug|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
75864196|NCT03748745|Drug|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
75864197|NCT03748745|Drug|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
76027631|NCT02357095|Procedure|monitoring|uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
76027632|NCT05026307|Procedure|Excision of pterygium|Simple surgical excision of pterygium with bare sclera
75374053|NCT02865343|Device|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
75374054|NCT02536040|Drug|38% diammine silver fluoride|treatment of cavity with study agent
75864198|NCT03748745|Drug|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
76027633|NCT02351713|Other|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
76027634|NCT05034965|Drug|hyaluronic acid filler injection|quantitative surface electromyography before injection(baseline) and one week after injection
75864199|NCT03298334|Biological|Vaginal Seeding|A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
75864200|NCT03298334|Other|No Vaginal Seeding|A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
75864201|NCT03194230|Other|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
75864202|NCT03746717|Device|occlusive wound closure|skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
75864203|NCT03746717|Device|conventional wound closure|wound closure with surgical staples
75864204|NCT03119194|Drug|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
76027635|NCT03160339|Biological|PXVX0047 Vaccine|PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
76027636|NCT03160339|Biological|Teva Ad4/Ad7 Vaccine|Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
76027637|NCT03094091|Other|News items with spin|Interpretation of news items with spin
76027638|NCT03094091|Other|News items without spin|Interpretation of news items without spin
75374055|NCT02536040|Other|Water|Fluoride free, distilled water
75374056|NCT02536196|Device|Embolic Protection Device|Embolic protection
75374057|NCT02536196|Procedure|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
75374058|NCT02461771|Drug|Pegcetacoplan|On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
75864205|NCT05582564|Other|abstract vs concrete texts|The main experiment involved two groups of participants and two different articles about vaccine-related thrombosis taken from two Italian newspapers. One article used a more abstract descriptive style and language, while the other used a more anecdotical style and concrete language: each group read only one of these articles. Both articles are the same length and describe an episode of vaccine-related thrombosis. The abstract text uses a more formal and impersonal language, reporting more scientific considerations; the concrete text uses a more familiar and emotional style and provides a more anecdotical description of the case. Texts were also weighted according to a concreteness semantic vocabulary. French received translated versions.Two other groups were assigned categorization tasks; one was asked to complete a concrete categorization task and the other an abstract categorization task.
75864206|NCT03194152|Dietary Supplement|Peanut|Dietary Supplement: Peanut
75864207|NCT03194152|Dietary Supplement|Control|Dietary Supplement: High carbohydrate snacks
75864208|NCT03107338|Drug|DEXKETOPROFEN TROMETAMOL|Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
75864209|NCT03107338|Other|Placebo|Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
75864210|NCT05581940|Combination Product|Group A Caudal Epidural Anesthesia with bupivacaine 0.25% and group B with opioid intervenors|(CEB) in group A using drugs bupivacaine 0.25% commonly used in children including neonates in group A In infraumbilical operations, it is used as a supplement to GA and to control postoperative pain It is a safe, easy, and effective type of central neuraxial block.[ The patient will be intubated and the caudal block will be performed under GA after securing the airway. The patient's position will be turned onto the lateral decubitus then a landmark-based, blind technique will be used. In children, the success rate with the blind technique is above 96% but the occurrence of side effects is reported. Group B uses general anesthesia (GA) alone for intraoperative and perioperative pain control used the opioid intervious without caudal block .
75864211|NCT04223687|Other|Sugar-Sweetened Beverage Warning Label|Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.
75537571|NCT04620109|Drug|KDR2-2|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization."
75864212|NCT04223687|Other|Neutral label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
75864213|NCT02445742|Drug|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
75864214|NCT03748589|Device|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
75864215|NCT02445508|Drug|Sevelamer|
75864216|NCT02445508|Drug|Cholecystokinin|
75864217|NCT02445508|Drug|Sevelamer placebo|
75864218|NCT02445508|Drug|Isotonic saline|
75864219|NCT03746639|Other|physiotherapy modalities|"The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 ."
75864220|NCT03197584|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
75864221|NCT03197584|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
75864222|NCT03197584|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75864223|NCT03197584|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75864224|NCT03197584|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
75864225|NCT03197584|Drug|Fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
75864226|NCT03197584|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
75537572|NCT04620109|Drug|Placebo|Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .
75537573|NCT00220649|Drug|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
75537574|NCT04620265|Other|Antigravity treadmill training 100% weight bearing|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
75864227|NCT03197584|Drug|Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
75864228|NCT03197584|Drug|omega-3 acid ethyl esters|omega-3 acid ethyl esters
76027639|NCT05025839|Other|No Intervention|No Intervention takes place, Patients are being observed and classified according to disease severity
76027640|NCT05034887|Drug|Trastuzumab Deruxtecan (T-DXd)|T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.
75537575|NCT04620265|Other|Antigravity treadmill training 75% weight bearing|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
75864229|NCT03197584|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
75864230|NCT03197584|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy (SBRT)
75864231|NCT03197584|Biological|ALT-803|Recombinant human super agonist IL-15 complex
75864232|NCT03197584|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2 vaccine
75864233|NCT03197584|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
75864234|NCT03197584|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1 vaccine
75864235|NCT03197584|Biological|GI-4000|Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins
75700967|NCT02580084|Procedure|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
75864236|NCT03197584|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
75700968|NCT02580084|Procedure|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
75700969|NCT05673954|Diagnostic Test|C-Read test|C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
75864237|NCT03197584|Biological|haNK®|NK-92 [CD16.158V, ER IL-2]
75864238|NCT03722576|Drug|Vidofludimus calcium|During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
75864239|NCT02445664|Behavioral|Educational video|Video: Information on osteoporosis and alendronate treatment.
75864240|NCT03416348|Drug|Aluminum Chloride 20% (deodorant)|Aluminum Chloride (deodorant)
75864241|NCT03416348|Drug|Alcohol|Placebo
75864242|NCT03202342|Other|Water|Water, 300 ml, at room temperature
75864243|NCT03202342|Other|Glucose|Water containing 50 g glucose, 300 ml, at room temperature
75864244|NCT03202342|Other|Ethyl butyrate|Water containing ethyl butyrate (pineapple flavour) 300 ml, at room temperature
75864245|NCT03202342|Other|Glucose + ethyl butyrate|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
75864246|NCT03202342|Other|Glucose + ethyl butyrate 0 C|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
75864247|NCT03236012|Drug|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
75864248|NCT02449486|Drug|Ropivacaine|
75864249|NCT03625154|Procedure|ankle open reduction internal fixation|Open Reduction and Internal Fixation with plates and screws
75864250|NCT03625154|Other|non operative management|closed reduction and splinting followed by progressive weight bearing
75864251|NCT03202186|Drug|Progesterone oral capsule|Oral capsule treatment
75864252|NCT03202186|Drug|Placebo oral capsule|Oral capsule treatment
75864253|NCT03625076|Drug|Intra-articular Lidocaine|20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
75864254|NCT03625076|Drug|Procedural Sedation with etomidate or propofol|Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
75864255|NCT03202108|Dietary Supplement|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian."
75864256|NCT03197272|Procedure|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
75864257|NCT02445352|Drug|Rosuvastatin 5mg|
75864258|NCT02445352|Drug|DP-R207 5/10mg|
75864259|NCT02445352|Drug|Rosuvastatin 10mg|
75864260|NCT02445352|Drug|DP-R207 10/10mg|
75700970|NCT02594696|Other|Proactive Psychiatry Consultation (PPC)|"The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.~The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.~The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks~The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).~Recommendations are documented in the medical record and communicated directly to the oncology team"
75715490|NCT00981838|Drug|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients > 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
75374059|NCT02815345|Device|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
75374060|NCT04341649|Other|Manual Head Massage|Duration 10 minutes.
75864261|NCT02445352|Drug|Rosuvastatin 20mg|
75864262|NCT02445352|Drug|DP-R207 20/10mg|
75374061|NCT04341649|Device|BREO Helmet Massager|Duration 10 minutes.
75374062|NCT04341649|Device|Low Laser Therapy (LLT)|Duration 7 minutes.
75864263|NCT02445352|Drug|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
75864264|NCT02445352|Drug|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
75537576|NCT04620265|Other|Antigravity treadmill training 50% weight bearing|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
75537577|NCT04620265|Other|Antigravity treadmill training 25% weight bearing|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
75715491|NCT03931330|Device|Percutaneous neurostimulation|Percutaneous neurostimulation using NSS-2 Bridge device
75715492|NCT00901329|Device|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
75864265|NCT02445352|Drug|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
75864266|NCT03693989|Drug|Difluprednate 0.05%|Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
75864267|NCT03693989|Drug|Prednefrin|"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic"
75374063|NCT04341649|Device|Sham LLT|Duration 7 minutes.
75715493|NCT00901329|Device|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
75864268|NCT02786186|Drug|Secikinumab|
75864269|NCT02445274|Procedure|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
75864270|NCT03746561|Diagnostic Test|deep learning|detect and classify spinal stenosis by deep learning
75864271|NCT02445118|Other|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
76027641|NCT05035121|Dietary Supplement|milk supplement|Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
75537578|NCT04620265|Other|The conventional exercise program|This group received the conventional exercise program only.
75374064|NCT04341649|Device|TENS ear stimulation|Duration 7 minutes.
75374065|NCT04341649|Behavioral|Deep and Slow breathing|A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.
75374066|NCT04341649|Behavioral|Relaxed Reading time|Duration 10 minutes.
75374067|NCT02463799|Drug|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
75374068|NCT02463799|Biological|Sipuleucel-T|3 infusions of sipuleucel-T alone
75374069|NCT02537444|Drug|Acalabrutinib|
75374070|NCT02537444|Drug|acalabrutinib and pembrolizumab combination|
75374071|NCT02464033|Drug|GAD-Alum|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
75537579|NCT00243321|Procedure|high dose-rate brachytherapy|High dose-rate brachytherapy
75537580|NCT00243321|Procedure|intensity-modulated radiation therapy|intensity-modulated radiation therapy
75537581|NCT04620226|Other|Quality Improvement|Rapid Point-of-Care testing will provide participants with a HCV antibody and RNA result within 2 hours. If the participant is HCV RNA+, they will receive an inpatient consultation from a liver specialist prior to discharge. We hypothesize that this model will minimize losses in the continuum-of-care and improve linkages to care.
75537582|NCT04620148|Drug|TAK-242|TAK-242 concentrate solution 80 mg/mL for dilution and infusion
75537583|NCT04620148|Drug|Placebo|Matching placebo concentrate solution
75715494|NCT01048957|Behavioral|Real Time Feedback Training|
75715495|NCT01051999|Dietary Supplement|Glutamine|Oral glutamine powder
75864272|NCT04944212|Diagnostic Test|Measuring vitamin D serum level using ELIZA|Venous blood will be obtained from pregnant women at the time of admission and from the umbilical cord veins of the newborns immediately after their delivery. The quantitative measurement of 25OHD in serum will be performed using ELIZA.
75374072|NCT02464033|Drug|Vitamin D|
75374073|NCT02464033|Drug|Etanercept|
75374074|NCT02432300|Behavioral|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
75537584|NCT00220688|Device|Acupressure Wristbands|
75537585|NCT04619641|Device|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
75864273|NCT05234242|Procedure|inguinal hernia repair|inguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting
75864274|NCT04206293|Device|Juvederm® VOLITE|1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).
75864275|NCT03197350|Diagnostic Test|cMR|cardiac MRI done to complete the diagnosis
75864276|NCT03197350|Biological|biomarker|Biomarker correlation with cMR parameters Prognostic information
75864277|NCT04939532|Behavioral|Text-Messaging (TM)|"Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes."
75864278|NCT04939532|Behavioral|Patient Navigation (PN)|"Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty."
75864279|NCT03197740|Drug|Donepezil patch|Treatment
75864280|NCT03197740|Drug|aricept Tab|Comparator
75864281|NCT03197428|Other|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
75864282|NCT03197428|Other|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
75864283|NCT04050878|Device|Facial scanner (Bellus3D) to assess perioral alterations|Use of a digital caliper for conventional measurements and a facial scanner (Bellus3D) to analyse the modifications induced by the use of implant supported dental prostheses in the lip support
75715496|NCT01051999|Dietary Supplement|L-alanine|L-alanine oral powder
75864284|NCT02450266|Device|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
75864285|NCT02450266|Device|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
75864286|NCT03197116|Other|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
75864287|NCT03197116|Other|No other|No additional reminder will be offered
75864288|NCT02444962|Device|HAVD-implant|hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
75864289|NCT04200989|Biological|Peanut allergen|Intralymphatic immunotherapy injections.
75864290|NCT02450110|Device|Spinal cord stimulation|
75374075|NCT02432456|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
75864291|NCT03748355|Genetic|Pharmacogentic Analysis|Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
75374076|NCT02432456|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
75715497|NCT00894777|Other|Clinical record review|
75715498|NCT00981994|Behavioral|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
75715499|NCT01049113|Drug|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
75715500|NCT04017585|Dietary Supplement|diet containing gluten|gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days
75864292|NCT02444884|Drug|MLN8237|
75864293|NCT02450032|Biological|G17DT|
75864294|NCT03201796|Drug|Prulifloxacin 600 mg|Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
75864295|NCT03201796|Drug|Levofloxacin 500mg|Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
75864296|NCT03107260|Other|To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients|Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
75864297|NCT02727998|Drug|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
75864298|NCT02727998|Drug|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
75864299|NCT02444806|Other|Full polysomnography|Full sleep and respiratory monitoring with EEG
75864300|NCT02444806|Other|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
75864301|NCT02636270|Drug|Increlex|Treat PAPP-A2 deficient patients with Increlex
75864302|NCT04366349|Biological|melrilimab (GSK3772847) 70 milligram (mg)|melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.
75864303|NCT04366349|Biological|melrilimab (GSK3772847) 140 milligram (mg)|Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)
75864304|NCT04366349|Other|Placebo|Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
75864305|NCT02108990|Drug|Acetaminophen|
75374077|NCT02432456|Procedure|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
75374078|NCT02432456|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
75374079|NCT02432456|Drug|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate > 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
75374080|NCT02432456|Drug|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
75374081|NCT02432456|Drug|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
75374082|NCT02432456|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
75374083|NCT02531971|Drug|Intravenous fentanyl citrate|100 micrograms (2 millilitres) via intravenous injection
75374084|NCT02531971|Drug|Duragesic®|TDDS dosage is 25 micrograms/hour (worn for 72 h)
75374085|NCT02531971|Drug|Mylan generic fentanyl|TDDS dosage is 25 micrograms/hour (worn for 72 h)
75700971|NCT00737438|Drug|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. > 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
75374086|NCT02464657|Drug|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
75700972|NCT00737282|Drug|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
75700973|NCT00737282|Drug|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
75700974|NCT03884478|Behavioral|Personalized Normative Feedback|Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
75700975|NCT03448458|Procedure|CT (Computed Tomography)|Undergo PET/CT
75700976|NCT03448458|Drug|Gallium Ga 68-DOTATATE|Given IV
75700977|NCT03448458|Procedure|Positron Emission Tomography|Undergo PET/CT
75700978|NCT04075422|Drug|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
75700979|NCT04075968|Other|Cognitive exercise|Cognitive exercise will be applied
75700980|NCT04075968|Other|Home exercise|Home exercise will be applied
75715501|NCT04017585|Dietary Supplement|Diet containing placebo|Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
75715502|NCT02533765|Drug|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
75864306|NCT01766648|Device|Far Cortical locking screw fixation|Standard screw fixation
75864307|NCT01766648|Device|Standard screw fixation|
76027642|NCT05035121|Dietary Supplement|soy milk supplement|Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
75537586|NCT04619641|Device|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
75700981|NCT03414372|Behavioral|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
75700982|NCT03414372|Behavioral|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.
76027643|NCT05035121|Behavioral|resistance exercise|The participants joined the resistance exercise training program, three times per week (30 min/time)
75700983|NCT03414372|Behavioral|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
75700984|NCT00582816|Device|Clinimacs Cell Separation System|Depletion of T-cells
76027644|NCT05034653|Other|Intermittent Fasting|During fasting day, no food or drink allowed from dawn to dusk
75374087|NCT02464657|Drug|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
75700985|NCT00582816|Drug|conditioning chemotherapy|Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
75700986|NCT00582816|Other|DLI|NK Cell selected DLI
75700987|NCT00737048|Drug|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
75700988|NCT00737048|Drug|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
75700989|NCT00737048|Drug|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
75700990|NCT00737048|Drug|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
75700991|NCT03627624|Other|Pulmonary rehabilitation|Stable COPD inpatients undergoing 30-STST and 6-minute walk test (6MWT) before and after PR were included. Responsiveness to PR was determined by pre-to-post PR (Δ) evaluation of 30-STST.
75700992|NCT00731822|Drug|GW685698/GW642444|GW685698/GW642444
75700993|NCT04076358|Behavioral|Tab-CBI|Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
75700994|NCT02593448|Procedure|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~30 minutes after anaesthesia induction,~directly after the sternotomy,~during CPB - 20 minutes after aortic cross-clamping ,~40 minutes after aortic cross-clamping,~20 minutes after the release of the aortic cross-clamp,~45 minutes after weaning of CPB."
75864308|NCT03194074|Drug|Propofol|In propofol/remifentanil group, propofol at a rate 75~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
75864309|NCT03194074|Drug|Desflurane|In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
75864310|NCT03748277|Procedure|Decompression|Bilateral decompression
75864311|NCT03748277|Procedure|PLIF|Traditional open surgery
75864312|NCT03748277|Procedure|MIS TLIF|On the one side - Wiltse approach, on the other side - percutaneous
76027645|NCT05034653|Other|Healthy Plate|Quarter-quarter-half meal concept
75374088|NCT02464657|Drug|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
75374089|NCT02464657|Drug|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
75374090|NCT02464657|Drug|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
75864313|NCT03748277|Procedure|Screw Fixation|Transpedicular Screw Fixation
75374091|NCT02533063|Device|VibeTech One|"Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
76027646|NCT02357017|Dietary Supplement|NaCl tablets|
76027647|NCT05025917|Dietary Supplement|Shatavari|Shatavari root powder
76027648|NCT05025917|Dietary Supplement|Magnesium stearate|Magnesium stearate powder
75864314|NCT01163864|Behavioral|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
75864315|NCT01163864|Behavioral|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
75864316|NCT03201952|Drug|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
75864317|NCT03201952|Drug|Placebos|Ileostomy administration of 5cc saline placebo once
75864318|NCT04179461|Drug|Cholecalciferol|Oral administration
75864319|NCT04179461|Drug|antihistamine|Oral administration
75864320|NCT04179461|Drug|Azithromycin|Oral administration
75864321|NCT04179461|Drug|emollient cream|Topical
75864322|NCT04179461|Drug|Fluticasone Propionate|Nasal spray
75864323|NCT04179461|Drug|Asthma Controller Medication|Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
75864324|NCT03193840|Procedure|posterior wall osteotomy|posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
75864325|NCT03748199|Drug|POL6014|"DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)"
75864326|NCT03748199|Drug|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
75864327|NCT03201484|Other|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
75864328|NCT04017611|Device|INVSENSOR00038|Noninvasive regional oximeter
76027649|NCT02039011|Drug|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
76027650|NCT02039011|Drug|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
75700995|NCT02593448|Procedure|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
75864329|NCT03119350|Other|Physical Training|"Intervention with concurrent physical training: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
75864330|NCT04844528|Drug|Nicotinamide|oral nicotinamide 500 mg twice daily (BID)
75864331|NCT04844528|Drug|Placebo|oral placebo twice daily for first year. Cross over to oral nicotinamide 500 mg twice daily (BID) for year two.
75864332|NCT03117296|Other|Post procedure daily PT and OT|PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
75864333|NCT03117296|Other|PT post procedure|post procedure day one: PT and OT assessment, education and intervention.
75864334|NCT03117296|Other|OT post procedure|PT and OT Daily until goals met or patient discharge.
75864335|NCT03117296|Other|Routine PT or OT|Routine PT or OT consulted by physician when identified discharge disposition of home
75864336|NCT03196882|Drug|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
75864337|NCT03196882|Drug|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
75864338|NCT03196882|Drug|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
75864339|NCT04172831|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
75864340|NCT04172831|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
75864341|NCT03196804|Drug|LC28-0126|LC28-0126
75864342|NCT03196804|Drug|Placebo|Placebo
75864343|NCT04839770|Device|Axonpen system|"The Axonpen™ system, containing the Axonpen and the Axonmonitor, has been cleared for the illumination and visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum.~The Axonpen is a neuroendoscope integrated with suction (sourced from hospital vacuum) and irrigation (sourced from third-party saline infusion bag) functions. The Axonmonitor is used for view and storage of the endoscopic image. The Axonpen™ system is intended to optimize the procedure of minimally invasive neurosurgery for early ICH evacuation."
76027651|NCT04449055|Device|Transcranial Magnetic Stimulation|Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder.
76027652|NCT05025215|Behavioral|Precise Aerosol Inhalation Nursing Program|The precise aerosol inhalation nursing program was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc.
76027653|NCT05025215|Behavioral|Traditional Aerosol Inhalation Nursing Method|The traditional aerosol inhalation nursing method is carried out according to the operation of aerosol inhalation.
76027654|NCT02361385|Other|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
75864344|NCT02444650|Device|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
75864345|NCT02444650|Device|tonometer|
75864346|NCT03118960|Device|Freedom Bed|This is an automatic rotational system in a bed designed to disburse capillary pressure
75864347|NCT03118960|Device|Group II Low Air Loss/Alternating Pressure Mattress|Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
75537587|NCT04619758|Other|Emollient (sunflower oil)|In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
75864348|NCT01562717|Drug|Ibuprofen|3 times a day
75864349|NCT01562717|Drug|Placebo|3 times a day
75864350|NCT03196648|Other|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
75864351|NCT03196648|Other|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
75864352|NCT03196648|Other|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
75864353|NCT03111914|Diagnostic Test|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
75864354|NCT03744923|Procedure|transmuscular QL block|"Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate)."
75374092|NCT02467075|Drug|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
75374093|NCT02467075|Drug|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
75864355|NCT03744923|Procedure|Transversus Abdominus Plane block|"Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning."
75864356|NCT03193138|Drug|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
75864357|NCT03625310|Drug|Sodium Fluoride|
75864358|NCT03625310|Drug|Sodium Fluoride with TCP|
75864359|NCT03625310|Drug|Sodium Fluoride with CXP|
75864360|NCT03625310|Drug|Sodium Fluoride with CPP-ACP|
75864361|NCT03192982|Device|A-V impulse 6000 Series|foot pad and pump
75864362|NCT03192982|Device|Standard treatment (compression)|Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
75864363|NCT03118336|Drug|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
75864364|NCT02444572|Drug|Enoxaparin 4000 IU|
76027655|NCT03093857|Diagnostic Test|Determination of biomarker|Liquor, blood, and urine samples will be drawn and measured at different time points.
75864365|NCT03196726|Behavioral|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
75864366|NCT03196726|Behavioral|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
76027656|NCT02356627|Other|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
75537588|NCT00247455|Drug|Low fibre breakfast cereal (puffed rice/cornflakes)|
75537589|NCT00247455|Drug|High fibre cereal (All Bran/Bran Flakes)|
75537590|NCT04619914|Drug|Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt|CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy] triethylamine citrate (1:1)
75864367|NCT04165031|Drug|LY3499446|Administered orally
75864368|NCT04165031|Drug|Abemaciclib|Administered orally
75864369|NCT04165031|Drug|Cetuximab|Administered IV
75864370|NCT04165031|Drug|Erlotinib|Administered orally
75864371|NCT04165031|Drug|Docetaxel|Administered IV
75864372|NCT03118258|Behavioral|'Pap smear' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility."
75864373|NCT03118258|Behavioral|'Self-collected vaginal swab for HPV testing + pap smear triage' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
75864374|NCT05480150|Drug|Escitalopram Oxalate Tablets|Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks
75864375|NCT05480150|Drug|Quetiapine Fumarate Tablets|Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.
75864376|NCT05480150|Drug|Lurasidone|Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.
76027657|NCT05025137|Other|Flexi-Bar Exercise|"In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot)."
75700996|NCT02593448|Procedure|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
75374094|NCT02533921|Other|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
75374095|NCT02533921|Other|Standard of Care|Usual care defined as including both a PCP and neurologist
75374096|NCT02535481|Device|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
75374097|NCT02535481|Procedure|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
75374098|NCT00363961|Behavioral|Resistance exercise|resistance exercise vs sham comparison
75374099|NCT02535949|Drug|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
75374100|NCT02535949|Other|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
75374101|NCT02536105|Drug|Methylphenidate HCl ER tablets 1|
75374102|NCT02536105|Drug|Placebo|
75374103|NCT02536105|Drug|Methylphenidate HCl ER tablets 2|
75700997|NCT00731666|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
75700998|NCT05015166|Behavioral|Experimental: Internet delivered self-help program with therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
75700999|NCT05015166|Behavioral|Internet delivered self-help program without therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises.
75374104|NCT02536105|Drug|Methylphenidate HCl ER for suspension|
75701000|NCT02592746|Drug|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
75701001|NCT02592746|Drug|Exemestane|Exemestane 25mg, orally once daily
75701002|NCT02592746|Drug|Leuprolide Acetate|Leuprolide Acetate 3.75mg SC q 4weeks
75701003|NCT02592746|Drug|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
75701004|NCT02833428|Device|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
75537591|NCT04619914|Drug|letrozole (Femara; Novartis pharma AG, Basle, Switzerland)|Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
75537592|NCT00220766|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
75537593|NCT00220766|Drug|Dextrose, 5% in Water|
75537594|NCT04619875|Other|KB5|KB5, a novel glycan, is a Kaleido laboratory code for KB174
75701005|NCT03922464|Device|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV-associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
75701006|NCT03375216|Behavioral|sensory testing (Heat, cold, and pressure)|sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
75864377|NCT03196570|Behavioral|Physical Activity Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
75701007|NCT03375216|Behavioral|Promis Survey|PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
75701008|NCT00731120|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
75864378|NCT03196570|Behavioral|Wellness Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
75864379|NCT05464628|Drug|Atorvastatin|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
75864380|NCT05464628|Drug|ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
75864381|NCT03196492|Other|No intervention|No intervention
75864382|NCT04829630|Biological|rabies vaccine|"day 0 : questionnaire, blood sampling and vaccine booster (a single session of two intradermal doses of 0.1 mL)~day 7 : questionnaire and blood sampling"
75864383|NCT02712424|Biological|DAR-901|
75701009|NCT00731120|Drug|Placebo|Vortioxetine placebo-matching capsules
75701010|NCT02580006|Drug|EPORON|single dose administration subcutaneously
75701011|NCT02580006|Drug|EPREX|single dose administration subcutaneously
75864384|NCT02712424|Biological|Sterile saline placebo|
75537595|NCT04619875|Other|SG1|SG1 is a novel glycan
75701012|NCT00731042|Drug|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
75701013|NCT00731042|Drug|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
75537596|NCT04619875|Other|Lactulose|Lactulose is a synthetic dissacharide
75537597|NCT00243360|Behavioral|diagnostic and treatment clinical algorithms|
75537598|NCT04619290|Drug|Sublingual Methylene blue|Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
75537599|NCT04619290|Other|Control patients|Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
75537600|NCT04619563|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
75537601|NCT04619329|Device|GSMs-TACE|TACE using Lobaplatin (30-40mg/m2) and gelatin sponge microspheres (150-350μm, 350-560μm, 560-710μm or 710-1000μm)
75701014|NCT02787642|Drug|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
75864385|NCT03196414|Biological|CART-138/BCMA/19/more|Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
75864386|NCT02449408|Other|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
75864387|NCT02449330|Drug|Teneligliptin|
75864388|NCT03648814|Procedure|Intracameral injection|A/C injection of 1.25 mg/0.05 mL bevacizumab
75864389|NCT03648814|Procedure|Intravitreal injection|Vitreous injection of 1.25 mg/0.05 mL bevacizumab
75864390|NCT02968004|Drug|MOD-4023|Once weekly subcutaneous injection using pre-filled pen device.
75864391|NCT02968004|Drug|Somatropin|Once daily subcutaneous injection of Genotropin using pre-filled pen device.
75864392|NCT03192592|Other|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
75864393|NCT05234164|Device|EXIST 6F NiTi Stent System FLEX|Subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent FLEX type. Subjects requiring treatment of the SFA will undergo an additional calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2 will be treated with the Exist 6F NiTi Stent FLEX type.
75864394|NCT05234164|Device|EXIST 6F NiTi Stent System PULL|Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli grade 3 and 4 will be treated with the Exist 6F NiTi Stent PULL type.
75864395|NCT03705260|Other|Usual Care|Usual care from Primary Care Physician and dietitian.
75864396|NCT03705260|Behavioral|Intensive Behavioral Intervention|The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
75864397|NCT03705260|Other|Monthly Screening for Risk|Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
75864398|NCT03118180|Biological|CD19 targeted chimeric antigen receptor T cells|CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
75864399|NCT03705182|Device|Fluorescence visualization (feedback)|UVA-light will illuminate the skin of head, neck, arms and hands and the fluorescent areas will be recorded and quantified by a computer vision system each time the participant leaves a production area. The intervention group will be shown the fluorescent areas on their skin, the control group will not have this opportunity
75537602|NCT04619329|Procedure|Surgical Resection|Surgical Resection of HCC
75864400|NCT03193762|Other|Anxiety VAS|Anxiety will be measure with a 10-points visual analogic scale (VAS)
75864401|NCT05455502|Drug|VX-548|Tablet for oral administration.
75374105|NCT02758951|Other|Perioperative systemic therapy|Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
75537603|NCT00220844|Drug|Desipramine|
75537604|NCT00220844|Drug|Amitriptyline|
75537605|NCT04619212|Device|breast pumping as per SoC but on new software for the pump|breast pumping as per SoC but on new software for the pump
75701015|NCT02787642|Radiation|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
75864402|NCT03193918|Drug|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
75864403|NCT03193918|Drug|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
75864404|NCT03193918|Drug|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
75864405|NCT05427812|Drug|ISB 1442 SC injection escalating doses|Participants will receive escalating SC doses of ISB 1442
75864406|NCT05427812|Drug|ISB 1442 SC injection at RP2D|ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
75864407|NCT02449096|Device|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
75864408|NCT02449096|Other|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
75864409|NCT03117790|Drug|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
75864410|NCT03117790|Drug|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
75864411|NCT03117712|Diagnostic Test|Delirium Scores|"Confusion Assessment method for the ICU (CAM-ICU) and~The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~Postoperative day (POD) 1~POD 2~POD 5"
75864412|NCT03117712|Diagnostic Test|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~Before induction of anaesthesia~Before going on cardiopulmonary bypass (CBP)~During CPB, 5 min after aortic cross clamping~After CPB~24 hours after CPB"
75864413|NCT03117712|Diagnostic Test|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~During cannulation of the ascending aorta~After aortic cross-clamp~After opening of the aortic cross-clamp~During decannulation"
75864414|NCT03193372|Drug|Azelaic Acid (Finacea Foam, BAY39-6251)|Finacea Foam, Active substance Azelaic acid
75864415|NCT03034772|Drug|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
75864416|NCT03034772|Other|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
75864417|NCT03196336|Other|Pharmacotherapy follow-up care|The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
75864418|NCT03196258|Behavioral|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
75864419|NCT03704870|Diagnostic Test|Chest Xray|Daily chest xray
75864420|NCT03704870|Diagnostic Test|No daily chest xray|Chest xray will be done post chest tube removal only
75864421|NCT03196102|Behavioral|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
75864422|NCT03196102|Behavioral|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
75864423|NCT03196102|Behavioral|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
75864424|NCT03192514|Other|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions"
75864425|NCT02448940|Dietary Supplement|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
75864426|NCT02448940|Dietary Supplement|lactose|2 capsule a day containing lactose
75864427|NCT03193294|Diagnostic Test|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
75701016|NCT02740218|Other|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
75374106|NCT02758951|Combination Product|Perioperative CAPOX-bevacizumab|Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area [BSA] of oxaliplatin, intravenously [IV] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
75864428|NCT03193450|Behavioral|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
75864429|NCT03193450|Behavioral|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
75864430|NCT03193606|Other|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
75864431|NCT03032198|Device|Imagio OA/US|Diagnostic opto-acoustic gray-scale ultrasound
75537606|NCT00247494|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
75537607|NCT04619251|Drug|BI 1323495|BI 1323495
75537608|NCT04619251|Drug|Placebo|Placebo
75537609|NCT04619251|Drug|Itraconazole|Itraconazole
75864432|NCT02448784|Drug|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
75864433|NCT04050488|Drug|Zinc Sulfate|At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
75864434|NCT04050488|Drug|Placebos|At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
75864435|NCT02448628|Drug|CS-3150|
75864436|NCT02449252|Radiation|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
75864437|NCT02449252|Radiation|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
75864438|NCT02449252|Drug|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
75864439|NCT02449252|Drug|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
75864440|NCT02449252|Drug|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
75864441|NCT02449252|Drug|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
75864442|NCT04779554|Drug|Mitomycin C, flat dose 40 mg|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
75864443|NCT04779554|Drug|Mitomycin C, weight-based dose 12.5 mg/m2|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
75864444|NCT02444260|Drug|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
75864445|NCT02444260|Drug|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
75864446|NCT02444260|Drug|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
75864447|NCT02444260|Drug|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
75864448|NCT03010930|Other|Supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
75864449|NCT03010930|Other|No supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
75864450|NCT02448472|Other|Observational study, none intervention|
75864451|NCT03195634|Drug|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day
75864452|NCT02448394|Other|Community Support Worker|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
75864453|NCT02448550|Drug|Bivalirudin|
75864454|NCT02448550|Drug|Unfractionated heparin|
75374107|NCT02758951|Combination Product|Perioperative FOLFOX-bevacizumab|Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area [BSA] of oxaliplatin, intravenously [IV] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
75374108|NCT02758951|Combination Product|Perioperative FOLFIRI-bevacizumab|Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area [BSA] of irinotecan, intravenously [IV] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
75537610|NCT04619407|Diagnostic Test|Nasopharyngeal swab|SARS-CoV-2 PCR
75537611|NCT04619407|Diagnostic Test|Serum testing|Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
75864455|NCT02431364|Drug|Verdinexor|Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
75864456|NCT02431364|Other|Placebo|Participants received placebo matched to verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
75864457|NCT03701750|Drug|Low Molecular Weight Heparin (enoxaparin sodium)|enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
75864458|NCT03704402|Other|Alcohol policy|Introduction of new mutual alcohol policy
75864459|NCT03704246|Drug|Anti-PD-1 monoclonal antibody|HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.
75864460|NCT05273684|Other|High intensity interval training|Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.
75864461|NCT05239910|Drug|Tenalisib|Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.
75864462|NCT03701672|Other|Opioid Analgesic Treatment|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
75864463|NCT03624998|Other|Cognitive and physiatric testing|Neuropsychological test battery and physiatric tests
75864464|NCT03704090|Behavioral|Occupational therapy intervention|Prevention of postoperative delirium by occupational therapy intervention
75864465|NCT03704090|Behavioral|Standard non-pharmacological prevention intervention|Prevention of postoperative delirium using standard non-pharmacological prevention measures
75864466|NCT03704012|Behavioral|Protocol of massage therapy and kinesiotherapy|Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
75864467|NCT03034460|Drug|CD5024 1% cream|500 µL on half-face, five days a week during 6 weeks
75864468|NCT03034460|Drug|CD5024 cream placebo|500 µL on half-face, five days a week during 6 weeks
75864469|NCT03034460|Drug|CD0271/CD1579 gel|500 µL on half-face, five days a week during 6 weeks
75864470|NCT03034460|Drug|CD0271/CD1579 gel placebo|500 µL on half-face, five days a week during 6 weeks
75864471|NCT04162769|Drug|Etrasimod 1 mg|Etrasimod 1 mg tablet taken by mouth, once daily
75864472|NCT04162769|Drug|Etrasimod 2 mg|Etrasimod 2 mg tablet taken by mouth, once daily.
75864473|NCT04162769|Drug|Etrasimod matching placebo|Etrasimod matching placebo tablet by mouth, once daily.
75864474|NCT04593602|Behavioral|Early Mobilization|Nurse-driven early mobilization activities twice daily
75864475|NCT04593602|Behavioral|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
75864476|NCT04161131|Behavioral|ONBOARD|Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
75864477|NCT03703700|Drug|Zishen Yutai Pill|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
75864478|NCT03703700|Drug|Placebo|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
75864479|NCT04743518|Other|Aortic pulse wave velocity|Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness
75701017|NCT02594774|Other|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
75701018|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
75701019|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
75701020|NCT02580162|Behavioral|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
75701021|NCT04075188|Drug|Aflibercept Injection|Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
75701022|NCT00726986|Drug|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
75701023|NCT00726986|Drug|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
75701024|NCT00726986|Drug|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
75864480|NCT04743518|Other|carotid intima media thickness (CIMT)|carotid intima media thickness (CIMT)
75537612|NCT00562783|Drug|Vitaliver|
75537613|NCT00562783|Drug|Placebo|
75701025|NCT02594852|Device|+ laser|Use of laser in the treatment
75701026|NCT02594540|Device|Mechanical Peripheral Stimulation (GONDOLA)|
75701027|NCT02594306|Device|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
75701028|NCT02594306|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
75701029|NCT02594306|Procedure|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
75864481|NCT04155047|Combination Product|Glyocopyrrolate Inhalation Solution administered by Magnair|glycopyrrolate Inhalation Solution 25mcg, single dose
75864482|NCT04155047|Drug|Placebo administered by Magnair|Placebo Inhalation Solution
75864483|NCT03624530|Drug|Tyrosine kinase inhibitor (TKIs)|TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
75864484|NCT03624452|Other|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
75864485|NCT03624452|Other|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
75537614|NCT00243399|Drug|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
75537615|NCT00562822|Procedure|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
75864486|NCT03746327|Drug|Sivextro 200 milligrams Oral Tablet|200 mg milligram per day during 4 weeks
75864487|NCT03746249|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75864488|NCT03746249|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
75864489|NCT03624686|Other|peripheral blood|draw peripheral blood
75864490|NCT04152083|Drug|Eptinezumab|Injection for IV administration
75864491|NCT04152083|Drug|Placebo|Injection for IV administration
75864492|NCT03698474|Drug|Natrium picosulfate / Magnesium citrate|bowel preparation formula
75864493|NCT03698474|Drug|Polyethylene glycol / Ascorbic acid|bowel preparation formula
75864494|NCT03698474|Drug|Natrium/ Kalium/ Magnesium sulfate|bowel preparation formula
75864495|NCT02711956|Drug|ZEN003694|
75864496|NCT02711956|Drug|Enzalutamide|
75864497|NCT03698396|Biological|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
75864498|NCT03703622|Behavioral|Video-debriefing with standard HBB training compared with standard HBB training only|"We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, & OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances."
75864499|NCT04149353|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
76027658|NCT05025137|Other|Multi-Component exercise|Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
75537616|NCT00562822|Other|Physical and medical therapy|Treatment with physical and medical therapy alone
75537617|NCT00220922|Procedure|Alcohol Wipes vs. No Alcohol Wipes|
75537618|NCT00243438|Device|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
75537619|NCT04618939|Biological|BR-TD-1001|0.5 mL, IM
75701030|NCT02594306|Procedure|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
75701031|NCT03334266|Behavioral|Family Spirit Nurture (FSN)|The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
75701032|NCT03334266|Other|Injury Prevention Education (IPE)|The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
76027659|NCT02351479|Behavioral|Hula|
76027660|NCT05024669|Combination Product|Gluma desensitiser|Gluma desensitiser was used before restoration.
76027661|NCT05024669|Combination Product|Sheildforce Plus desensitiser|Sheildforce Plus desensitiser was used before restoration.
75537620|NCT04618939|Biological|Td-pur inj|0.5 mL, IM
75537621|NCT00562900|Procedure|robotic assisted cholecystectomy|robotic assisted cholecystectomy
75537622|NCT00562900|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
75864500|NCT02711800|Drug|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
75864501|NCT03701594|Other|Yoga-based physical therapy group|All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
75864502|NCT03701594|Other|Seated Rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
75864503|NCT03701594|Other|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
75864504|NCT02091154|Behavioral|USDA Regulations|"Implement new USDA regulations assigned school cafeterias.~Fruit or vegetable on every tray~Meet requirements for vegetable varieties~50% of all grains must be whole grain~Milk must be 1% or skim; flavored milk must be skim"
75864505|NCT02091154|Behavioral|Marketing Kit|"This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~56''x72'' vinyl sign with the words [school mascot] Cafe~8.5''x11'' signs describing the foods offered on a specific day~2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift."
75864506|NCT02091154|Behavioral|Smarter Lunchrooms Makeover (SLM)|"Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take."
75864507|NCT02444026|Behavioral|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
75864508|NCT01526668|Behavioral|Follow-up strategy|Comparison of different follow-up strategies
75864509|NCT01526668|Behavioral|No contact after discharge|
75864510|NCT01194622|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
75864511|NCT01194622|Drug|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
75864512|NCT01194622|Drug|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
75864513|NCT02448316|Procedure|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
75864514|NCT02448316|Drug|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
75864515|NCT02448316|Drug|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
75864516|NCT02448316|Behavioral|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
75864517|NCT03698318|Dietary Supplement|Tested product n°1|1 capsule (26% of gingerol/shogaol in 100 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
75864518|NCT03698318|Dietary Supplement|Tested product n°2|1 capsule (38.6% of gingerol/shogaol in 74.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
75864519|NCT03698318|Dietary Supplement|Tested product n°3|2 capsules (6.8% of gingerol/shogaol in 424.3 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
75864520|NCT03698318|Dietary Supplement|Tested product n°4|1 capsule (27% of gingerol/shogaol in 104.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
75864521|NCT03698318|Dietary Supplement|Tested product n°5|6 capsules (1.6% of gingerol/shogaol in 1806.25 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
75864522|NCT03698240|Behavioral|Mindfulness-based program|The program includes 9 mindfulness-based sessions for children and their parents.
75864523|NCT05200858|Device|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device (delivers 100% of the dose) to wear for 1 hour daily for up to 4 weeks.
75864524|NCT05200858|Device|Electrical Stimulation - Placebo|Subjects will receive a placebo electrical stimulation device (delivers 10% of the dose) to wear for 1 hour daily for up to 4 weeks.
75537623|NCT04618900|Procedure|Sinus floor elevation with a grafting material|The use of grafting material for sinus floor elevation
75864525|NCT05178238|Other|Fecal sample|Fecal sample taken to investigate intestinal microbiota
75864526|NCT03697928|Other|Exercise metabolism|Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
75864527|NCT03703388|Dietary Supplement|Arctigenin|Arctigenin capsule
75864528|NCT02443714|Device|Needle-free jet injection with insulin lispro|Subjects injected by jet injectors which deliver insulin lispro
75864529|NCT02443714|Device|Conventional pen injection with insulin lispro|Subjects injected by conventional insulin pens which deliver insulin lispro
75537624|NCT00221000|Drug|Methoxsalen|
75864530|NCT03703310|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
75864531|NCT03703310|Drug|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
75537625|NCT00221000|Procedure|Extracorporeal Photopheresis|
75537626|NCT04619134|Other|NCSR Program|flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
75537627|NCT04619134|Other|conventional physical therapy|hot pack,flexibility training,strengthening exercise.
75537628|NCT00243477|Drug|Escitalopram|Escitalopram 10mg or placebo once a day
75701033|NCT03334266|Other|Optimized Standard Care (OSC)|OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
75701034|NCT00696657|Drug|semaglutide|0.1 mg, once weekly, s.c. injection
75701035|NCT00696657|Drug|semaglutide|0.2 mg, once weekly, s.c. injection
75701036|NCT00696657|Drug|semaglutide|0.4 mg, once weekly, s.c. injection
75701037|NCT00696657|Drug|semaglutide|0.8 mg, once weekly, s.c. injection
75701038|NCT00696657|Drug|semaglutide|0.8 mg with titration, once weekly, s.c. injection
75701039|NCT00696657|Drug|semaglutide|1.6 mg with titration, once weekly, s.c. injection
75701040|NCT00696657|Drug|placebo|0.1 mg, once weekly, s.c. injection
75701041|NCT00696657|Drug|placebo|0.2 mg, once weekly, s.c. injection
75701042|NCT00696657|Drug|placebo|0.4 mg, once weekly, s.c. injection
75701043|NCT00696657|Drug|placebo|0.8 mg with titration, once weekly, s.c. injection
75701044|NCT00696657|Drug|placebo|1.6 mg, once weekly, s.c. injection
75701045|NCT00696657|Drug|liraglutide|1.2 mg with titration, once daily, s.c. injection
75701046|NCT00696657|Drug|liraglutide|1.8 mg with titration, once daily, s.c. injection
75701047|NCT00730886|Device|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
75537629|NCT04619173|Other|Thoracic manipulation|hot pack ,transcutaneous electrical nerve stimulation and manipulation along with stretching'
75537630|NCT04619173|Other|Conventional physical therapy Program|hot pack ,transcutaneous electrical nerve stimulation and stretching
75537631|NCT04618783|Biological|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
75701048|NCT00730886|Procedure|Myomectomy|Invasive surgical procedure for fibroid removal
75701049|NCT01877772|Procedure|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
75701050|NCT01877772|Procedure|Control|The control group will undergo standard rotator cuff repair.
75715503|NCT00979342|Device|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
75864532|NCT03190408|Other|Fluids|Fluids Administered in Shock
75864533|NCT03703232|Device|Investigational prosthetic foot|Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
75864534|NCT04483570|Procedure|Redo-tethering operation|
75864535|NCT03703154|Drug|Envarsus|Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
75864536|NCT03703154|Drug|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
75864537|NCT03188380|Diagnostic Test|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
75864538|NCT03188380|Diagnostic Test|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
75864539|NCT02443558|Other|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
75864540|NCT02443558|Device|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
75864541|NCT04701164|Drug|ANX005|Solution for intravenous infusion
75864542|NCT04701164|Drug|Placebo|Solution for intravenous infusion
75864543|NCT03192670|Device|Low-level light therapy device|Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
75864544|NCT03703544|Other|High glycemic index|Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
75864545|NCT03703544|Other|Low glycemic index|Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
75864546|NCT02434276|Biological|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
75864547|NCT02434276|Biological|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
75864548|NCT03624842|Drug|Trappsol (R) Cyclo (TM)|
75864549|NCT03697694|Dietary Supplement|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
75864550|NCT03697694|Other|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
75864551|NCT03190642|Drug|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
75864552|NCT03697616|Device|Ridge augmentation with sticky bone and GBR|"Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~Periosteal releasing incision will be done to provide flap advancement for tension free closure~Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures"
75864553|NCT02439892|Behavioral|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
75864554|NCT02439892|Behavioral|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
75864555|NCT03702686|Device|FEEDBACK System|Smart Nipple Shield and Monitor Unit
75864556|NCT03701438|Biological|Influenza Vaccine|Administered per standard of care using a vaccine licensed and recommended in the site's country
75701051|NCT02592590|Behavioral|Group A|"This condition receives three study components:~The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.~The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.~The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser)."
75864557|NCT02440048|Device|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
75864558|NCT02440048|Device|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
75864559|NCT04050332|Behavioral|Stair Walking|Walking up and down stairs for four minutes at a comfortable pace
75864560|NCT03188458|Other|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 [approximately 4-8 weeks of age]).
75864561|NCT03702530|Biological|3x 50 L3 larvae immunisation with albendazole treatment|Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
75864562|NCT03702530|Other|3x placebo immunisation with albendazole treatment|Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
75864563|NCT03702530|Biological|2x 50 L3 larvae infection|After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
75864564|NCT02443246|Drug|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
75864565|NCT02443246|Drug|Placebo|
75864566|NCT03702452|Other|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
75864567|NCT03702452|Other|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
75864568|NCT03188302|Other|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
75864569|NCT02443168|Drug|AG-221|Part 1: oral solution containing 100 mg [14C]-AG-221
75864570|NCT02443168|Radiation|14C AG-221|5 mL of 100 micrograms [14C] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
75864571|NCT02443948|Other|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
75864572|NCT02439580|Dietary Supplement|Annona muricata extract|ethanol-soluble fraction of water extract
75864573|NCT02439580|Dietary Supplement|Placebo|maltose
75701052|NCT02592590|Behavioral|Group B|"This condition receives two study components:~The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription."
75537632|NCT04618783|Biological|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
75537633|NCT04618783|Biological|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
75537634|NCT04618783|Biological|Three doses of control wIPV, vaccinated within one-month interval between doses|Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
75864574|NCT03031496|Drug|GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)|"GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side."
75537635|NCT04618783|Biological|Three doses of control sIPV, vaccinated within one-month interval between doses|Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
75537636|NCT00221039|Drug|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
75537637|NCT00243516|Device|PREtest Consult|
75864575|NCT03031496|Drug|Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)|"Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917."
75864576|NCT03190486|Other|functional Magnetic Resonance Imaging (fMRI)|During fMRI, healthy volunteers will listen 80 baby's cry.
75864577|NCT03187990|Drug|[68Ga]PSMA-11|PET/MRI with [68Ga]PSMA will be compared to mpMRI for biopsy guidance.
75864578|NCT03187990|Drug|[18F]PSMA-1007|18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.
75864579|NCT03697382|Behavioral|Very Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
76027662|NCT05024669|Combination Product|Telio CS desensitiser|Telio CS desensitiser was used before restoration.
75537638|NCT00562939|Biological|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
75537639|NCT00562939|Biological|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
75864580|NCT03697382|Behavioral|Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
75864581|NCT03697382|Behavioral|Moderate Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
76027663|NCT02039167|Device|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
75864582|NCT03187912|Drug|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
75864583|NCT03701204|Behavioral|DynamiCare Rewards|"Participants assigned to the DynamiCare Rewards group will receive the following:~App on their smartphone~Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~Next Step debit card to receive financial incentives~Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~The amount of coins and funds are available on a progressive variable reward schedule."
75864584|NCT03188224|Other|MyTransition app|MyTransition app is designed to support youth moving from pediatric to adult healthcare.
75864585|NCT03697226|Drug|Topical ABI-1968|Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
75864586|NCT03189940|Behavioral|Life style modification by using and app with a wrist-worn activity tracker|The mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. At the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital EMR and reviewed by both physicians and app users. Further lifestyle modification was encouraged on the basis of the electronically collected data.
75864587|NCT03189940|Behavioral|Conventional Life style modification|Physician's usual consultation for life style modification at 0 week, and 2 weeks of enrollment
75864588|NCT04681742|Behavioral|CO-OP Group|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
75864589|NCT03192124|Device|Bactisure|"Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may be present in patient specimen (bacteria and fungi) and includes test for resistance factors to vancomycin and methicillin.~Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order to establish what type of bacterial and fungal species are present."
75864590|NCT03190252|Other|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
75864591|NCT03190252|Other|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
75864592|NCT03702296|Other|Ear plugs and eye masks|Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
75864593|NCT03192280|Drug|Leukotriene B4|Leukotriene B4 (LTB4)
75864594|NCT03192280|Device|FLIR One|Thermal imaging attachment to iPhone
75864595|NCT03192280|Device|SCIO|Handheld near-IR molecular spectroscopy device
75864596|NCT03192280|Device|MS Band 2|"Wearable watch-like device with multiple sensors"
75864597|NCT03192280|Device|AGE reader|Portable bench top device for in-clinic near UV assessment
75864598|NCT03192280|Device|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
75864599|NCT03192280|Device|iPhone 7|Smart phone
75537640|NCT04618510|Device|SEED 1-dayPure EDOF soft contact lens|Centre-distance contact lens with peripheral add power working on extended depth of focus principle to control myopia
76027664|NCT05024825|Drug|Gabapentin|Patients in the gabapentin arm may at any point call the Pediatric ENT clinic if pain is not adequately controlled. Patients will be prescribed hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14 yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain. Patients will be informed to stop taking gabapentin.
76027665|NCT05024825|Drug|hydrocodone, acetaminophen and ibuprofen|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
76027666|NCT02361151|Behavioral|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
76027667|NCT02361151|Behavioral|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
76027668|NCT05033795|Dietary Supplement|Water A|2 L of water A per day
76027669|NCT05033795|Dietary Supplement|Water B|2 L of water B per day
75537641|NCT04618510|Device|Single Vision Spectacles|These are the type of glasses that correct vision for a single distance
75864600|NCT03190018|Device|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
75864601|NCT02443012|Drug|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
75864602|NCT02443012|Procedure|Laser|Grid/Focal Laser Photocoagulation
75864603|NCT02443090|Drug|fispemifene|
75864604|NCT02443090|Other|Placebo|
75864605|NCT03624764|Procedure|Laparostopic promontofixation using surgical glue|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
75864606|NCT03624764|Procedure|Laparostopic promontofixation using threads|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
75864607|NCT03701126|Procedure|Transversus Abdominis Plane Block|ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
75864608|NCT03701126|Procedure|Caudal Block|ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
75864609|NCT03701126|Drug|Bupivacaine 0.25% Injectable Solution|Dose 1ml /kg of patient body weight
75864610|NCT03701126|Device|Ultra-sound guidance|using superficial high frequency probe to guide regional anesthesia
75864611|NCT02439736|Other|Blood draw within 12 hours of head injury|
75864612|NCT02442934|Other|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
75864613|NCT02442934|Other|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
75864614|NCT02442934|Other|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
75864615|NCT02439502|Device|Fuse® system|Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
75864616|NCT03187600|Procedure|Mucosa/submucosa Pharyngeal Flap|Included in study arm description
75537642|NCT04618627|Other|lung ultrasound|Role of lung ultrasonography in prediction of the seveity and the need for surfactant administration in neonates with respiratory distress syndrome.
75864617|NCT03187600|Procedure|Standard of Care Pharyngeal Flap|Included in study arm description
75864618|NCT03696836|Device|Trammpolin® meniscus prosthesis|Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
75864619|NCT02442544|Dietary Supplement|Prebiotic|1:1 oligofructose: inulin 8 g orally /day
75537643|NCT04618549|Procedure|Direct Anterior Approach Hemiarthroplasty|Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach
75864620|NCT02442544|Dietary Supplement|Placebo|maltodextrin 3.3g orally/day
75864621|NCT03187522|Device|TREO Stent-Graft System|The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
75864622|NCT03702140|Drug|"Teriparatide, Forteo® or Teribon"|To examine the effects of terimaratide less than 6 months in osteoporosis
75864623|NCT02433886|Procedure|Gamma Ventral Capsulotomy|
75864624|NCT03700814|Drug|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
75864625|NCT02433964|Other|Grupo LED|
75864626|NCT02433964|Other|Placebo|ledterapia off + price
75864627|NCT02433808|Drug|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
75864628|NCT02433808|Other|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
75864629|NCT02434042|Dietary Supplement|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
75864630|NCT02434042|Other|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
75864631|NCT02439346|Drug|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
75864632|NCT03702062|Diagnostic Test|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
75864633|NCT02439424|Device|Reactive ATP|"Reactive ATP turned to on"
75864634|NCT03701984|Drug|Lidocaine|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
75864635|NCT03701984|Drug|Tramadol|an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
75864636|NCT03701984|Drug|placebo|a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
75864637|NCT03190096|Procedure|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
75864638|NCT02439190|Drug|BMS-986120|
75864639|NCT02439190|Drug|Aspirin|
75864640|NCT02439190|Drug|Clopidogrel|
75864641|NCT02442466|Drug|Endothelin Receptor B inhibitor BQ788|
75864642|NCT02442466|Drug|PBS|
75864643|NCT02439034|Drug|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
75864644|NCT02439034|Drug|Ketoprofen|Ketoprofen* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
75864645|NCT03700580|Drug|Hydrogel treatment|Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.
75864646|NCT03700580|Drug|P1G10|P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
75864647|NCT02439112|Other|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly >65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
75864648|NCT03696602|Diagnostic Test|bronchial provocation test|
75864649|NCT03701906|Dietary Supplement|Lactobacillus PS11603 & Bifidobacterium PS10402|Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1*10E9 CFU of L.salivarius PS11603 and 1*10E8 CFU of B.longum PS10402.
75864650|NCT03701906|Dietary Supplement|Placebo|8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
75864651|NCT02438956|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
75864652|NCT02438956|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
75864653|NCT02438800|Behavioral|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
75864654|NCT03692858|Drug|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using Ropivacaine
75864655|NCT03692858|Drug|Adductor Canal Block|Adductor Canal Block using Ropivacaine
75537644|NCT04618549|Procedure|Mini Posterior Approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach
75864656|NCT03692780|Drug|Careseng 1370|4,000mg granules in sachet
75864657|NCT03692780|Drug|Placebo|4,000mg granules in sachet
75864658|NCT04483492|Drug|Caffeine citrate|diaphragm contractility after administration
75864659|NCT02442154|Procedure|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
75864660|NCT04483336|Other|Virtual Reality Distraction|Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.
75864661|NCT04483336|Other|TV Screen Distraction|A cartoon video was played on a regular TV screen.
75864662|NCT02438878|Behavioral|Baby Behavior|
75537645|NCT04618549|Procedure|Lateral approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
75864663|NCT03186976|Behavioral|Aggressive Risk Factor Control|"1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting).~3) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4) An OMRON BP monitor will be supplied to each patient. A target SBP of <140/80 mm/Hg will be targeted.~5) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c<6.5%"
75864664|NCT03186976|Other|Standard of Care|Recommendations based on current guidelines
75864665|NCT02442388|Procedure|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
75864666|NCT02442388|Procedure|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
75864667|NCT02442388|Procedure|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
75864668|NCT03186742|Drug|Eplerenone 50 mg Tab|Eplerenone 50 mg Tab once a day
75864669|NCT02441998|Other|Education intervention: Training in Narrow Band Imaging|Two hour training session in interpretation and application of narrow band imaging technology
76027670|NCT03149965|Other|transperineal ultrasound|transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
75864670|NCT03186664|Device|Lokomat training|The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.
75864671|NCT03186664|Drug|Sativex|"Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.~Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient."
75864672|NCT03189784|Other|mobilization with movement techniques|patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
75864673|NCT02441842|Drug|atenolol|administered 60 minutes pre procedure
75864674|NCT02441842|Drug|lisinopril|administered 60 minutes pre procedure
75864675|NCT02441842|Other|glucose|administered 60 minutes pre procedure
75864676|NCT02438566|Drug|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
75864677|NCT02438566|Drug|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
75864678|NCT02433652|Biological|Recombinant live attenuated trivalent dengue vaccine|Contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10^3.0 PFU of each component.
75864679|NCT02433652|Biological|Placebo|
75864680|NCT02433652|Biological|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10^3 PFU
75864681|NCT03186586|Drug|Ulipristal acetate|5mg/day/five days
75864682|NCT03186586|Drug|Placebo|Placebo one pill a day for 5 days at the bleeding episode
75864683|NCT02441608|Device|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
75864684|NCT02433574|Radiation|Neoadjuvant Stereotactic body radiation (SBRT)|"Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.~The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments."
75864685|NCT02438176|Procedure|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
75864686|NCT02438176|Procedure|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
75864687|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
75864688|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
75864689|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
75864690|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
75864691|NCT02433418|Procedure|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
75864692|NCT02433418|Drug|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
75864693|NCT04484038|Radiation|hypofractionated postoperative radiation therapy|The patients included in the study will undergo intensity-modulated radiotherapy, of any modality, and image-guided (IGRT) with an emphasis on tissue preservation and administration precision through the use of devices that guarantee the stability and reproducibility of the same.
75864694|NCT02433730|Drug|Testosterone|intramuscular injection
75864695|NCT02433730|Drug|placebo|intramuscular injection
75864696|NCT02438098|Drug|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
76027671|NCT02356549|Behavioral|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
75701053|NCT02592590|Behavioral|Group C|"This condition receives two study components:~The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets."
75701054|NCT02592590|Behavioral|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
75864697|NCT02433262|Other|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
75864698|NCT02433262|Other|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
75864699|NCT02441530|Dietary Supplement|Vitamin D|
75864700|NCT02441530|Dietary Supplement|Vitamin E|
76027672|NCT02356549|Behavioral|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
75701055|NCT02712762|Other|Cross-sectional study|
75701056|NCT03301116|Behavioral|Healthy Moves for Aging Well (Healthy Moves)|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.
75701057|NCT03301116|Behavioral|Active Mind for Aging Well (Active Mind)|A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
75701058|NCT00726752|Drug|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
75701059|NCT00917930|Behavioral|physical training|intensive cardiac rehabilitation program
75864701|NCT02441530|Drug|Ibuprofen|
75864702|NCT02433184|Drug|Etanercept|Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
75864703|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
75864704|NCT02433184|Drug|Sulfasalazine|Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
75864705|NCT02433184|Drug|Hydroxychloroquine|Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
75864706|NCT02433184|Drug|Etanercept|Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
75864707|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
75864708|NCT02433106|Other|GAA 15|Neuromuscular injury prevention training
75864709|NCT02433106|Other|Control|Usual training
75864710|NCT02438020|Drug|Metformin|One tablet of 500 mg will be ingested before the main meal
75864711|NCT02438020|Other|Placebo|A placebo tablet will be ingested daily before main meal.
75864712|NCT02437942|Other|Biomechanics led physical therapy rehabilitation|Rehabilitation intervention will consist of movement control (3 days per week), whole body strength and power (2 days per week), linear running mechanics (3 days per week), multi-directional mechanics (3 days per week), conditioning sessions (2 days per week). Rehabilitation will continue until physical therapist deems the athlete ready to return to sport.
75864713|NCT02441452|Other|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
75864714|NCT02441140|Procedure|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
75864715|NCT02441140|Procedure|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
75864716|NCT02441140|Procedure|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
75864717|NCT02441140|Procedure|Blood collection|Intravenous blood collection will be drawn from an IV
75864718|NCT02441140|Procedure|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
75864719|NCT02437786|Drug|GRAZAX|GRAZAX
75864720|NCT02437552|Device|ergometer cycle exercise|
75864721|NCT02437552|Other|routine physiotherapy|routine physiotherapy
75864722|NCT02441296|Other|Formula with lactose|
75864723|NCT02441296|Other|Formula with maltodextrins|
75864724|NCT03189628|Biological|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
75864725|NCT03189628|Drug|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
75864726|NCT03186820|Other|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
75864727|NCT02441374|Device|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
75864728|NCT02441374|Other|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
75864729|NCT03186274|Behavioral|Facilitated Group Session|Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.
75864730|NCT03186274|Behavioral|CELA Session|Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
75864731|NCT02437474|Behavioral|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
75864732|NCT02437474|Behavioral|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
75864733|NCT02437474|Behavioral|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
75864734|NCT02437708|Procedure|REP with L-PRF|
75864735|NCT02437708|Procedure|REP|
75864736|NCT02437708|Biological|stem and progenitor cells|
75864737|NCT03186430|Behavioral|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
75864738|NCT02440984|Procedure|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
75864739|NCT02432794|Procedure|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
75864740|NCT02440906|Behavioral|Patient-Directed Wellness Account|The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
75864741|NCT02440906|Behavioral|Health Navigator|The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
75864742|NCT02437630|Procedure|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
75864743|NCT02437630|Procedure|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
75864744|NCT02437630|Other|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
76027673|NCT02356549|Behavioral|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
75864745|NCT02437630|Procedure|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
75537646|NCT00221078|Device|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
75537647|NCT04618588|Procedure|Low Window Sinus Lift technique|"Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement"
75537648|NCT00247533|Procedure|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
75864746|NCT02437630|Procedure|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
75864747|NCT02437630|Other|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
75864748|NCT02440750|Procedure|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
75864749|NCT02440750|Drug|Dienogest|21 days administration of dienogest 2 mg/die
75537649|NCT04618159|Other|lactobacillus reuteri DSMZ 17648|to evaluate if this product can eradicate helicobacter pylori
75537650|NCT04618120|Other|Virtual reality-based exercise|"Virtual reality-based exercises with Microsoft Xbox 360 Kinect and breathing exercises.~Patient education"
75537651|NCT04618120|Other|Exercise|Shoulder range of motion, stretching, posture and breathing exercises. Patient education
75537652|NCT00221156|Drug|Acarbose|
75864750|NCT02440750|Drug|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
75864751|NCT03186196|Dietary Supplement|Diet containing Folate|
75864752|NCT03186352|Procedure|photoactivated disinfection|"After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying"
75864753|NCT02432872|Drug|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
75864754|NCT02432872|Drug|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
76027674|NCT05024435|Device|Surfactant Administration|Laryngoscopy, intratracheal catheter placement and surfactant administration
75864756|NCT03189472|Device|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
76027675|NCT02360917|Other|Emerging from the Haze|A 6 week psycho-educational class
76027676|NCT03093467|Behavioral|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
76027677|NCT03093467|Drug|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
75537653|NCT04618276|Other|Photodynamic Therapy|PDT with two different photosensitizers
75537654|NCT04618042|Drug|FX06|FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
75537655|NCT04618042|Drug|Placebo of FX06|Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
75537656|NCT04618003|Behavioral|Adaptation of autonomic nervous system to activity in virtual reality|heart rate variability assessed at rest and during a physical activity in virtual reality.
75537657|NCT00243555|Procedure|allergy skin testing|
75537658|NCT00243555|Procedure|venepuncture|
75537659|NCT00221234|Behavioral|Print materials, pedometers/logbooks|
75537660|NCT00221234|Behavioral|Print materials, pedometers/logbooks, telephone counselling|
75537661|NCT04617691|Drug|Guselkumab|Guselkumab will be administered as IV solution derived from FVP or PFS-U.
75537662|NCT04617613|Drug|Omeprazole, Amoxicillin, Metronidazole and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
75557470|NCT01050257|Drug|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
75864757|NCT03189472|Device|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
75537663|NCT04617613|Drug|Omeprazole, Amoxicillin and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
75864758|NCT03189550|Procedure|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
75864759|NCT03189550|Procedure|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
75864760|NCT03189550|Procedure|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
75864761|NCT03189394|Behavioral|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
75537664|NCT04617652|Drug|Magnesium sulfate|Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
75864762|NCT03189394|Behavioral|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
75864763|NCT03189394|Behavioral|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
75864764|NCT02437006|Other|exercise|cycle ergometry
75864765|NCT02437240|Behavioral|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
75864766|NCT02437240|Behavioral|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
75864767|NCT02436850|Procedure|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
75864768|NCT02436928|Biological|AT-501 High Dose vaccine|Comparison of each dose of vaccine
75864769|NCT02436928|Biological|AT-501 High Dose vaccine with Adjuvant|Comparison of each dose of vaccine
75864770|NCT02436928|Biological|AT-501 Low Dose vaccine|Comparison of each dose of vaccine
75864771|NCT02436928|Biological|AT-501 Low Dose vaccine with Adjuvant|Comparison of each dose of vaccine
75864772|NCT02436538|Other|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
75864773|NCT02432014|Behavioral|PMTO-PTC Group clinic-based|
75537665|NCT04617652|Drug|Normal saline|Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
75864774|NCT02432014|Behavioral|PMTO Individual home-based|
75864775|NCT02432014|Behavioral|PMTO Individual clinic-based|
75864776|NCT02432014|Behavioral|Services as Usual|
75537666|NCT02961738|Behavioral|Cognitive Analytic Therapy (CAT)|Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
75864777|NCT03191968|Behavioral|Supervised Physical Activity Plus Behavioral Counseling|In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
75864778|NCT03191968|Behavioral|Supervised Physical Activity Plus Exercise Counseling|In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
75864779|NCT02436694|Drug|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
75864780|NCT02436694|Drug|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
75864781|NCT02436616|Device|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
75864782|NCT02436460|Biological|AbGn-168H|Humanized monoclonal antibody
75864783|NCT03191422|Behavioral|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
75864784|NCT03186040|Drug|Lacosamide|Sodium channel blocker
76027678|NCT03093467|Behavioral|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
76027679|NCT02356237|Other|No episiotomy|Avoidance of episiotomy
75537667|NCT00221273|Procedure|ACL surgery|
75864785|NCT03191734|Device|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
75864786|NCT03191500|Device|steerable catheter|peripheral vascular disease
75864787|NCT02432170|Device|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
75864788|NCT02440516|Other|Early treatment group|Physical- and occupational Therapy
75864789|NCT02440516|Other|Late treatment group|Waiting list - then Physical- and occupational Therapy
75864790|NCT02659020|Drug|Olaratumab|Administered IV
75864791|NCT02659020|Drug|Gemcitabine|Administered IV
75864792|NCT02659020|Drug|Docetaxel|Administered IV
75537668|NCT04617730|Device|Mepitel® film|This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.
75864793|NCT02659020|Drug|Placebo|Administered IV
75864794|NCT02436382|Other|change in temperature|increase in ambient room temperature
75864795|NCT03482011|Drug|Mirikizumab|Administered SC
76027680|NCT03095261|Behavioral|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
75537669|NCT04617730|Other|Flamigel®|The control arm will be treated according to the standard of care.
75864796|NCT03482011|Drug|Placebo|Administered SC
75864797|NCT02436148|Other|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
75864798|NCT02436070|Behavioral|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
75864799|NCT02436070|Behavioral|General text messages|Subjects received text messages generalized to children with asthma
75864800|NCT03189238|Biological|Peri-urethral and clitoral injections|Peri-urethral and clitoral injections
75864801|NCT03189082|Procedure|Microbotox|Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
75864802|NCT02431858|Device|E-Catheter (Pajunk)|
75864803|NCT02431858|Device|Sonolong Catheter (Pajunk)|
75864804|NCT01374126|Drug|Artesunate|Artesunate alone
75864805|NCT01374126|Drug|Azithromycin + Artesunate|Combination of azithromycin + artesunate
75864806|NCT02431624|Drug|BTDS|
75864807|NCT02584920|Drug|HLX01|
75864808|NCT02584920|Drug|Rituximab|
75864809|NCT03185650|Device|tPAD Device|A novel, transnasal aerosol generator
75864810|NCT03185650|Device|PARI LC Star Nebulizer|Standard oral nebulizer
75864811|NCT01371318|Other|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
75537670|NCT04617223|Procedure|Endoscopic sinus evacuation|Evacuation of the sinus by using endoscope
75864812|NCT03639103|Procedure|Distal Metatarsal Metaphyseal Osteotomy (DMMO)|The scalpel is advanced at an oblique angle of about 45° until it reaches the dorsal aspect of the distal metatarsal bone to undergo osteotomy. First a bone rasp specific for percutaneous surgery is used to separate the periosteum at the level of the osteotomy site. A Shannon Isham burr is introduced until it reaches the metatarsal neck where the periosteum was previously removed. Fluoroscopy is used to confirm the correct position of the osteotomy site. The lateral cortical surface is cut first, then the plantar, medial, and lastly, the dorsal cortical surface. During the osteotomy process, the incision site is irrigated by normal saline, as the burr can cause excessive heat, causing skin burn and resulting subsequently in fibrosis and pseudoarthrosis at the bone level.
75864813|NCT02431936|Drug|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
75864814|NCT02431936|Drug|Placebo|Sugar pill made to look identical to Prazosin intervention.
75864815|NCT03916770|Device|Sham vibrator|The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.
75864816|NCT03916770|Device|Real vibrator|The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
75864817|NCT03185806|Device|Puncture and drainage|The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
75864818|NCT03481309|Device|anodal tDCS|The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
75864819|NCT03481309|Device|cathodal tDCS|The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
75864820|NCT03481309|Device|sham tDCS|The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
75864821|NCT03185884|Other|Control|control carbohydrate blend
75864822|NCT03185884|Other|Experimental|experimental carbohydrate blend
75864823|NCT03185494|Biological|anti-CD19/22-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
75864824|NCT03480841|Behavioral|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
75864825|NCT02440828|Drug|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
75864826|NCT02440828|Drug|placebo|NaCl 0.9% inhalation 4 ml twice daily
75537671|NCT04617184|Other|NO INTERVENTION|THERE IS NO INTERVENTION TO THIS TRIAL. THIS IS A REGISTRY
75864827|NCT01311037|Other|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
75864828|NCT02431390|Device|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
75864829|NCT02431390|Behavioral|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
75864830|NCT02440438|Biological|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
75864831|NCT02431546|Behavioral|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
75864832|NCT03191110|Other|No intervention: observational study|
75864833|NCT02431312|Biological|INO-1800|INO-1800 delivered by EP
75864834|NCT02431312|Biological|INO-9112|INO-9112 delivered by EP
75864835|NCT02431312|Drug|Nucleos(t)ide Analogue Treatment|Continued treatment with nucleos(t)ide analogue
75864836|NCT02431234|Other|serum RANKL|
75864837|NCT03191344|Behavioral|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
75864838|NCT02431156|Other|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
75864839|NCT02709538|Drug|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks
75864840|NCT02709538|Drug|GSP 301 Placebo NS pH 3.7|2 spray in each nostril twice daily for 52 weeks
75864841|NCT02709538|Drug|GSP 301 Placebo NS pH 7.0|2 spray in each nostril twice daily for 52 weeks
75864842|NCT03789318|Drug|CA-008 5 mg|5 mg CA-008 reconstituted in saline.
75864843|NCT03789318|Drug|Placebo|Each cohort will use placebo reconstituted in saline.
75864844|NCT03789318|Drug|Bupivacaine Hydrochloride|0.25% administered pre-surgery
75537672|NCT00247572|Drug|NRP104|
75537673|NCT00221312|Drug|Fosamax|
75864845|NCT03789318|Drug|Hydromorphone|0.02 mg/kg IV administered intraoperatively
75864846|NCT03789318|Drug|Fentanyl|100 mcg IV administered intraoperatively
75864847|NCT03789318|Drug|Acetaminophen|1000 mg IV administered intraoperatively
75864848|NCT03789318|Drug|Oxycodone|5-10 mg PO administered post-surgery
75864849|NCT03789318|Drug|CA-008 10 mg|10 mg CA-008 reconstituted in saline.
75864850|NCT03789318|Drug|CA-008 15 mg|15 mg CA-008 reconstituted in saline.
75864851|NCT02431078|Procedure|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
75864852|NCT02435602|Procedure|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
75864853|NCT02435602|Procedure|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions >= 5 mm diameter Pathologic examination of all biopsy tissue specimens
75864854|NCT03773952|Drug|PBF-677|oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
75864855|NCT03773952|Drug|Placebo oral capsule|Oral capsules
75864856|NCT02431000|Procedure|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
75864857|NCT03191188|Drug|Levothyroxine Sodium|Thyroid hormone supplement
75864858|NCT03191188|Drug|Placebo Oral Tablet|Placebo
75864859|NCT02435446|Device|Cone-beam computed tomography|Cone-beam computed tomography
75864860|NCT03613662|Drug|SP-102|Injection
75864861|NCT02435368|Drug|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
75537674|NCT04616989|Behavioral|Psycho-education|Provide psycho-education to members of the community
75864862|NCT01698294|Other|Clinical Observation|Participants maintain usual diet and undergo clinical observation
75864863|NCT01698294|Dietary Supplement|Flaxseed|Given PO
75864864|NCT01698294|Other|Laboratory Biomarker Analysis|Correlative studies
75537675|NCT04616989|Behavioral|Comparator|Distribution of COVID-19 leaflets to members of the community
75537676|NCT04617106|Procedure|Radial artery cannulation|cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
75864865|NCT01698294|Other|Questionnaire Administration|Ancillary studies
75864866|NCT03191032|Other|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
75864867|NCT03190876|Procedure|Variable drain usage|Influence of drain usage on seroma formation rate
75864868|NCT05160090|Drug|Bupropion HCl MR tablets 300mg|In each study period, a single 300 mg dose of Bupropion will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
75864869|NCT03190720|Device|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
75864870|NCT03538002|Device|Blue-light filtering spectacle lenses|This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
75537677|NCT04617145|Other|Aerobic exercise|resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.
75537678|NCT00221351|Procedure|CRP point of care testing|
75537679|NCT00243594|Biological|Peptide-pulsed dendritic cells|peptide-pulsed dendritic cells
75537680|NCT04616911|Procedure|Rerouting seton|Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
75537681|NCT04616911|Procedure|LIFT|Ligation of the intersphincteric fistula tract
75537682|NCT04616638|Behavioral|Resistance Training for Empowerment (RT-POWER)|The EG intervention was designed using the Social Cognitive Theory and its four sources of self-efficacy to promote a participant's (a) involvement in exercise planning, (b) muscular strength, and (c) independent functional performance. It consisted of three phases, which were adapted from the Self-Determined Learning Model of Instruction (Wehmeyer et al., 2000). This model draws from theory and research on self-management and self-control (Bandura, 1986; Martin et al., 1988). Participants were taught by their coaches how to (a) set a goal to meet fitness needs (Phase 1), (b) make a plan to meet goals (Phase 2), and (c) adjust actions to complete the plan (Phase 3).
75864871|NCT03692702|Behavioral|WE PLAY|WE PLAY is an online preschool teacher training that is based in theory and implementation science. It contains six components: (1) online training; (2) video library; (3) game sheets; (4) teacher self-assessment; (5) supervisor support; and (6) activity packs containing low cost physical activity equipment
75864872|NCT03117946|Other|Biological samples|blood and tumor tissue sample
75864873|NCT04516616|Drug|Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)|PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
75864874|NCT00511134|Drug|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
75864875|NCT00511134|Drug|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
75864876|NCT02435056|Other|IEPR Approach|"Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~Minimum Data Set for supporting the diagnosis~Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~Second opinion system for improving the management"
75864877|NCT02435134|Other|no intervention|
75864878|NCT03634722|Device|PHENIX4-8-8 PLUS|transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
75864879|NCT03118024|Drug|Crystalloid Solutions|crystalloid restrictive anesthesia protocol
75864880|NCT03118024|Drug|Catecholamines|catecholamine restrictive anesthesia protocol
75864881|NCT03117868|Other|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
75864882|NCT03634644|Drug|Omega 3 fatty acid|Omega 3 fatty acid,mainly composed of EPA and DHA.
75864883|NCT03634644|Drug|Placebo oral capsule|mainly composed of corn oil
75864884|NCT05103228|Drug|Follitropin Alfa|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
75864885|NCT05103228|Drug|Follitropin delta|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
75864886|NCT05103228|Drug|human menopausal gonadotropin|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
75864887|NCT01372384|Drug|erlotinib [Tarceva]|150 mg orally daily
75864888|NCT03185416|Other|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
75864889|NCT03190798|Drug|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
75864890|NCT03190798|Drug|Placebo|Placebo for Canagliflozin
75864891|NCT03117478|Other|Magneto-encephalography (MEG)|Magneto-encephalography
75864892|NCT03117478|Other|Electro-encephalography (EEG)|Electro-encephalography
76027681|NCT03095261|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
76027682|NCT03095261|Behavioral|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
76027683|NCT03095261|Behavioral|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
76027684|NCT03149653|Drug|ClinOleic (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
75864893|NCT03117478|Other|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
75537683|NCT04616638|Behavioral|A traditional RT intervention|The control intervention also consisted of a three-phase instructional process. Consistent with traditional RT interventions (ACSM, 2009), the coaches rather than the participants, were the primary agents for goal-setting, exercise planning, goal attainment monitoring, and readjusting of the exercise plan. Neither the visual activity schedules nor the system of least-to-most prompts was used in this intervention.
75537684|NCT04616872|Drug|Methotrexate-LDE|MTX-LDE 40mg/m2 (250mL total volume) IV and Folic acid 5mg by mouth (the day after MTX-LDE) weekly for 12 weeks
76027685|NCT03149653|Drug|ClinOleic + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
75864894|NCT03117478|Other|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
76027686|NCT03149653|Drug|Lipoplus (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
75537685|NCT04616872|Drug|Placebo-LDE|Placebo-LDE (250mL total volume) IV and Folic acid 5mg by mouth (the day after Placebo-LDE) weekly for 12 weeks
75537686|NCT00221390|Drug|Ropinirole (+ physical therapy)|
75537687|NCT00221390|Drug|(vs.) Placebo + physical therapy|
75864895|NCT03117478|Other|Meditation|Meditation
75864896|NCT03115476|Drug|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
75864897|NCT03115476|Drug|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
75864898|NCT03115476|Other|Vehicle gel|Vehicle to ingenol disoxate gel with no active ingredient
76027687|NCT03149653|Drug|Lipoplus + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
76027688|NCT03149653|Drug|SMOFlipid (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
76027689|NCT03149653|Drug|SMOFlipid + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
76027690|NCT03093545|Biological|Equine Rabies Immunoglobulin|40 IU per kg of body weight of ERIG at Day 0
76027691|NCT03093545|Biological|Purified chick-embryo cell rabies vaccine|1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
76027692|NCT02351401|Behavioral|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
76027693|NCT03093623|Behavioral|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
76027694|NCT02360761|Procedure|VATS|Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
76027695|NCT02360761|Procedure|Thoracotomy|Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
76027696|NCT05024357|Drug|Dasatinib|Take Dasatinib orally for 1 year or 6 months post-HSCT.
76027697|NCT03095183|Device|Grape flavored Puritan Junior tongue depressor|
75537688|NCT00247650|Drug|Zoledronic Acid; Letrozole|
76027698|NCT03095183|Device|Traditional unflavored Puritan Regular Tongue Depressor|
76027699|NCT02356315|Other|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
76027700|NCT03095339|Other|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
76027701|NCT03149731|Device|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
76027702|NCT03095105|Drug|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
76027703|NCT02351323|Drug|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
76027704|NCT02351323|Behavioral|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
76027705|NCT05024123|Dietary Supplement|Placebo|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 ~ 180 min to measure 1) nitrate and 2) cGMP content."
76027706|NCT05024123|Dietary Supplement|AstraGin|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 ~ 180 min to measure 1) nitrate and 2) cGMP content."
76027707|NCT02360449|Behavioral|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
76027708|NCT05033951|Other|Standard care|Both groups: standard care+ questionnaires
76027709|NCT01968070|Drug|LY3127760|Administered orally
75537689|NCT04616755|Other|Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.|Measuring changes occurred under 2 years which the retention devices have been in place between the groups
76027710|NCT01968070|Drug|Celecoxib|Administered orally
76027711|NCT01968070|Drug|Placebo|Administered orally
76027712|NCT02351089|Dietary Supplement|Capsules placebo|Capsules
75537690|NCT04616716|Drug|FMTN|Single dose of FMTN after high-fat meal,low-fat meal and fast
75864899|NCT03117556|Procedure|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
76027713|NCT02351089|Dietary Supplement|Capsules probiotic powder and corn starch|
76027714|NCT03093311|Other|NIRS based protocol|Each desaturation episode will be managed according to a standardized protocol - correction of extreme head position will be followed by optimisation of mean arterial pressure (MAP), arterial hemoglobin oxygen saturation, end tidal carbon dioxide concentration and a level of hemoglobine concentration.
76027715|NCT02351245|Other|observation|
76027716|NCT05033405|Behavioral|NEURO-LINGUISTIC PROGRAMMING (NLP)|● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
76027717|NCT02351011|Biological|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
76027718|NCT02351011|Biological|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
76027719|NCT02351011|Biological|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
76027720|NCT03093233|Other|no intervention|only descriptive data analysis
76027721|NCT02350855|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
76027722|NCT02350855|Other|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
76027723|NCT02350855|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
76027724|NCT03093389|Drug|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
76027725|NCT03093389|Drug|Placebo|Matching placebo capsules
76027726|NCT05033249|Diagnostic Test|Immature granulocyte count|Automatically calculated immature granulocyte count in white blood cell count
76027727|NCT05033249|Diagnostic Test|Immature granulocyte percentage|Automatically calculated immature granulocyte percentage in white blood cell count
76027728|NCT02356081|Other|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
76027729|NCT01918774|Behavioral|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
76027730|NCT02355925|Drug|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
76027731|NCT02355925|Drug|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
76027732|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
76027733|NCT03092999|Drug|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
76027734|NCT02355847|Other|Lectures|Lectures
75864900|NCT02435290|Behavioral|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
75864901|NCT02434978|Device|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
76027735|NCT03093077|Device|DePuy ATTUNE total knee arthroplasty system|A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
76027736|NCT02350933|Procedure|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
75537691|NCT04616521|Procedure|Deep brain stimulation|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
75537692|NCT00251043|Behavioral|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
75537693|NCT00251043|Behavioral|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
75864902|NCT02434978|Drug|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
75864903|NCT02434978|Other|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
76027737|NCT03092921|Device|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
76027738|NCT03092921|Device|F&P Mask|Investigative Mask to be used for OSA therapy
76027739|NCT05024201|Behavioral|THERAPEUTİC TOUCH FOR HEMODİALYSİS PATİENTS|Therapeutic touch was applied to hemodialysis patients for 3 days every other day.
76027740|NCT04408183|Drug|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
75864904|NCT01371396|Other|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
76027741|NCT04408183|Drug|Placebo|Placebo is given as a nasal spray using an atomizer
75701060|NCT02594462|Drug|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
75701061|NCT02664558|Drug|ubenimex|
75864905|NCT01371396|Other|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
75864906|NCT03696290|Drug|Aztreonam lysine|Nebulised aztreonam lysine 75mg
75701062|NCT02664558|Other|placebo|
75701063|NCT02566707|Drug|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
75701064|NCT02566707|Drug|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
75864907|NCT03696290|Other|Placebo|Nebulised lactose monohydrate 5mg
75864908|NCT03633942|Device|LMA Supreme|Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
75864909|NCT02434666|Drug|CPC-201|
75864910|NCT03696212|Drug|grapiprant and pembrolizumab|Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab
75864911|NCT05048160|Drug|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
75864912|NCT03803280|Procedure|ERAS program|ERAS pathway according to the Spanish Via RICA
76027742|NCT01949116|Drug|LDMTX|"LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly"
76027743|NCT01949116|Drug|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly"
76027744|NCT01949116|Dietary Supplement|Folic acid|1-mg tablet of folic acid by mouth once a day
75701065|NCT02566707|Drug|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
75701066|NCT04063683|Drug|Anlotinib Hydrochloride, Paclitaxel, cisplatin|"anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."
75701067|NCT02578290|Other|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
75864913|NCT03692624|Behavioral|Biofeedback|Heart Rate Variability Biofeedback
75864914|NCT02430922|Device|iVolution nitinol stent|
75864915|NCT03692546|Drug|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
75864916|NCT03248388|Device|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
75864917|NCT03248388|Device|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
75864918|NCT02434588|Device|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
75864919|NCT03480763|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
75864920|NCT03480763|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose
76027745|NCT01673009|Drug|Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
76027746|NCT02355535|Drug|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
76027747|NCT05033015|Procedure|Mouth rinse|To test a novel mouth rinse containing enzymes to prevent development of WSL with a control
76027748|NCT02350387|Procedure|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
75864921|NCT03480763|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
76027749|NCT02350387|Procedure|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
76027750|NCT05023499|Drug|SYMPT-X Glutamine, Oral Powder for Reconstitution|erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
76027751|NCT02350621|Procedure|ACDF|
76027752|NCT02350621|Procedure|minimal invasive Posterior Cervical Foraminotomy|
76027753|NCT05023421|Other|no intervention|no intervention
75864922|NCT02434432|Behavioral|music therapy selected by mothers|mothers' choice of music
76027754|NCT02350543|Drug|Aspirin|
76027755|NCT05033093|Drug|Root Canal Sealants|it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
76027756|NCT02359747|Genetic|Polymerase Chain Reaction and Whole Genome Amplification|Polymerase Chain Reaction and Whole Genome Amplification
76027757|NCT05023577|Drug|Rabeprazole|20mg bid
75864923|NCT02434432|Behavioral|Music therapy recorded lullaby|recorded lullaby
75864924|NCT04223804|Drug|ABBV-181|Intravenous (IV) Infusion
75864925|NCT04223804|Drug|Placebo|Intravenous (IV) infusion
76027758|NCT05023577|Drug|Bismuth potassium citrate|0.6g bid
76027759|NCT05023577|Drug|Metronidazole|0.4g qid
76027760|NCT05023577|Drug|Clarithromycin|0.5g bid
76027761|NCT05023577|Drug|Levofloxacin|0.5g qd
76027762|NCT03149497|Procedure|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
75864926|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
75864927|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
75864928|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
75864929|NCT03692390|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
75864930|NCT02430766|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
75864931|NCT02430766|Device|NanoKnife|
75864932|NCT03700502|Diagnostic Test|resting-state functional Magnetic Resonance Imaging|The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
75864933|NCT03123120|Drug|Spesolimab|12 weeks treatment
75864934|NCT03123120|Drug|Placebo|12 weeks treatment
75864935|NCT03692234|Dietary Supplement|125 mg L-homoarginine|capsules for oral supplementation
75864936|NCT03692234|Other|placebo|capsules for oral supplementation
76027763|NCT05032625|Procedure|Surgery|Patients who undergo surgery for NSTI will be followed in hospital and for 1- year in the office. We will asses the quality of life and there functionality. This will help us in determining the predictors of poor outcome.
76027764|NCT03149419|Drug|Paroxetine|
76027765|NCT03149419|Drug|Placebo oral capsule|
76027766|NCT03092765|Drug|E6011|Intravenous administration
76027767|NCT03092765|Drug|Placebo|Intravenous administration
76027768|NCT02355223|Other|FAST|See information in arm description
76027769|NCT05032391|Biological|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Three times orally in a volume of 2.5 ml (1 dose)
76027770|NCT05032391|Drug|Placebo|Three times orally in a volume of 2.5 ml (1 dose)
76027771|NCT02359981|Behavioral|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
76027772|NCT02359981|Behavioral|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
75864937|NCT02430688|Procedure|Irreversible electroporation (IRE)|
75864938|NCT02430688|Device|NanoKnife|
75864939|NCT03185338|Behavioral|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
75864940|NCT03185338|Behavioral|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
76027773|NCT02359981|Device|Smartphone|An Android Smartphone with operating system version higher than 2.2
76027774|NCT01939366|Drug|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
76027775|NCT01939366|Drug|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
76027776|NCT01939366|Drug|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
76027777|NCT01939366|Drug|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
76027778|NCT01939366|Drug|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
76027779|NCT04434365|Drug|Berberine|Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).
76027780|NCT04434365|Drug|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
76027781|NCT04434365|Drug|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
76027782|NCT04434365|Drug|Statin|Statins once daily for 12±1 weeks.
76027783|NCT02359669|Behavioral|StimuLearn Intervention|"StimuLearn apps~Cognitive questionnaires"
75374109|NCT02758951|Procedure|CRS-HIPEC, experimental arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
75374110|NCT02758951|Procedure|CRS-HIPEC, control arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after randomisation.
75374111|NCT02752165|Other|TEAM-ED|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
75374112|NCT02752165|Other|Enhanced Usual Care|Report of symptoms to primary care physician
75374113|NCT02436668|Drug|Ibrutinib|
75374114|NCT02436668|Drug|Gemcitabine|
75701068|NCT03895281|Diagnostic Test|FilmArray Meningitis/Encephalitis (ME) Panel|The FilmArray ME pouch is a closed system disposable that houses all the chemistry required to isolate, amplify and detect nucleic acid from multiple meningitis and encephalitis pathogens within a single CSF specimen obtained from a lumbar puncture. The rigid plastic component (fitment) of the FilmArray ME pouch contains reagents in freeze-dried form. The flexible plastic portion of the pouch is divided into discrete segments (blisters) where the required chemical processes are carried out. The user of the FilmArray ME Panel loads the sample into the FilmArray ME pouch, places the pouch into the FilmArray instrument/Module, and starts the run. All other operations are automated.
75864941|NCT03185338|Behavioral|Active school recess|Teachers will design games and activities and will encourage children for being active
75864942|NCT03185338|Behavioral|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
75864943|NCT03185338|Behavioral|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
75864944|NCT03624296|Device|MRI 7T|MRI 7T
75864945|NCT03624296|Other|TEST EDSS|EDSS - Expanded Disability Status Scale
75374115|NCT02436668|Drug|Nab-paclitaxel|
75374116|NCT02503982|Drug|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
75374117|NCT02438540|Drug|metformin|metformin tablet 500 mg
75374118|NCT02438540|Other|acupuncture|Electro body acupuncture and auricular acupuncture
75701069|NCT02578524|Other|Survey|
75701070|NCT00921531|Drug|Thalidomide|"Thalidomide is used for adjuvant therapy for TACE~Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day."
75701071|NCT00921531|Drug|TACE|TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
75701072|NCT04072692|Other|Hybrid rehabilitation training|Hybrid rehabilitation training is modified tendon gliding exercise with median nerve mobilization.
75701073|NCT04072692|Other|Traditional rehabilitation training|Traditional rehabilitation training uses traditional physiotherapy, such as splint, therapeutic ultrasound and electrotherapy.
75701074|NCT04072692|Other|Wearable anti-bowstringing orthosis (WABO)|WABO is a custom-designed orthosis to restrict the bowstringing effect of the flexor tendon in the carpal tunnel.
75864946|NCT03624296|Other|TEST MSFC|MSFC - Multiple Sclerosis Functional Composite
76027784|NCT02359669|Behavioral|Without StimuLearn intervention|Cognitive Questionnaires
76027785|NCT02359591|Other|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
76027786|NCT05032469|Other|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
76027787|NCT02350075|Procedure|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
76027788|NCT02350075|Device|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
75374119|NCT02506634|Drug|Esomeprazole MUPS, 20 mg|According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
75374120|NCT02506868|Drug|Darbepoetin alfa|Weekly sc administration of darbepoetin alfa
75374121|NCT02541422|Dietary Supplement|N Acetyl Cysteine|
75374122|NCT02541422|Other|placebo|
75374123|NCT02541812|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
75374124|NCT02542046|Drug|Barium|Administration of barium oral contrast agent prior to CT scan
75374125|NCT02542046|Drug|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
75374126|NCT02542046|Drug|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
76027789|NCT02359279|Device|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
75864947|NCT03692832|Procedure|LH|Laparoscopic hysterectomy following AAGL class IV E, vault closed vaginally
75374127|NCT02439164|Drug|Midazolam|specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
75864948|NCT03692832|Procedure|VH|Vaginal hysterectomy following Heaney technique
75864949|NCT03696134|Other|questionnaire|questionnaire
76027790|NCT02359357|Drug|FDL169|
76027791|NCT02359357|Drug|Placebo|
75374128|NCT02542280|Procedure|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
75864950|NCT01371474|Drug|Paroxetine|
76027792|NCT05023265|Radiation|Stereotactic body radiotherapy|SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.
76027793|NCT05031923|Procedure|SMV and antimicrobial photodynamic therapy|Application of SMV and antimicrobial photodynamic therapy in intrabony defects
76027794|NCT05031923|Procedure|SMV application|Application of SMV without antimicrobial photodynamic therapy in intrabony defects
76027795|NCT02354755|Device|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
76027796|NCT02354989|Device|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
76027797|NCT02354989|Device|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
76027798|NCT02354911|Biological|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (~10 million cells/injection).
76027799|NCT02354911|Other|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
76027800|NCT05023187|Behavioral|SCOT|"A 8-week social and cognitive online training to improve both cognitive and social functioning, which includes 2 sessions (~45 minutes each) of individual cognitive training through the BrainHQ© program 2020 (BrainHQ© Posit Science) and a psycho-educational group session for each week (24 sessions in total).~In the experimental intervention, all activities are focused on enhancing executive functions (working memory, processing speed, inhibitory control etc.) and social cognition abilities (identifying/recognizing facial expressions, styles attribution, drawing conclusions etc.)."
76027801|NCT05023187|Behavioral|CON|"A 8-week active control intervention consisting of 2 sessions (~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics."
76027802|NCT05032001|Drug|Biguanide, DPP4 inhibitors, SGLT2 inhibitors|Oral antidiabetic treatment during twelve weeks
76027803|NCT05022875|Device|Healthcare CEO app- for experimental app intervention|The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q&A
76027804|NCT05022875|Device|Healthcare CEO app-for control app intervention|consists of 2 interfaces: CEO's profile, Health Tracking.
76027805|NCT03149263|Behavioral|distraction|Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
76027806|NCT03149341|Other|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
76027807|NCT04963517|Behavioral|Exercise therapy|8 weeks personalized, multi-modal exercise with focus on lower extremity
75374129|NCT02542280|Procedure|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
75374130|NCT02542280|Drug|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
75537694|NCT00221429|Drug|lithium sodium divalproex|
75374131|NCT02439710|Other|Quality of life measure (survey)|The QoL tool is a questionnaire
75374132|NCT04341272|Device|Intermittent Pneumatic Compression Device (FDA approved)|Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
75374133|NCT02440022|Combination Product|Lutonix DCB|
75374134|NCT02440022|Device|Standard Balloon Angioplasty Catheter|
75537695|NCT00563017|Drug|Long-acting Risperidone microspheres injection|
75537696|NCT00563056|Drug|Flutiform|
75537697|NCT00563056|Drug|Flixotide plus Foradil|
75701075|NCT04114851|Device|NoL|NoL active
75864951|NCT03184948|Device|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
76027808|NCT04963517|Other|Information|"Initial consultation with recommendations for general physical activity~Brochure with exercise recommendations."
75864952|NCT03696056|Behavioral|Kirtan Kriya meditation|The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
75864953|NCT03696056|Behavioral|Music listening program|"The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log."
76027809|NCT03159715|Behavioral|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
76027810|NCT03159715|Behavioral|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
76027811|NCT03159715|Behavioral|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
76027812|NCT05031689|Biological|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
76027813|NCT05031689|Biological|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract|Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
76027814|NCT03147469|Procedure|Flexion|After changing the position of head and neck of subjects to flexion, the variables were measured.
76027815|NCT03147469|Procedure|Extension|After changing the position of head and neck of subjects to extension, the variables were measured.
76027816|NCT03147469|Procedure|Right rotation|After changing the position of head and neck of subjects to right flexion, the variables were measured.
76027817|NCT05022953|Other|Education, dijital storytelling|Digital story
76027818|NCT03159013|Other|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
76027819|NCT05031377|Behavioral|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
76027820|NCT05031377|Behavioral|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.
76027821|NCT02350231|Drug|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
76027822|NCT02350231|Drug|Tonics group|Those patients will receive only tonics
76027823|NCT03092141|Other|Physical training|
75374135|NCT02440022|Procedure|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
75374136|NCT02440178|Drug|Micafungin|
75374137|NCT02543840|Other|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
75374138|NCT02543840|Other|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
75374139|NCT05078606|Device|IJV Ultrasonography|"Patient will be in supine position, The linear probe with frequency of 7- 12 M hz; depth of 3 cm. maximum IJV diameter (IJV-D) and area (IJV-A) will be recorded. M-mode will be used to obtain the distance between the 2 walls of the vein during inspiration and expiration.~Then, the patient will be positioned 10° Trendelenburg and similar ultrasonographic measurements will be again performed"
76027824|NCT05031299|Behavioral|Standard care|Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
75537698|NCT00563095|Procedure|Transcatheter Arterial Chemoembolization (TACE)|
75537699|NCT00563095|Procedure|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
75537700|NCT00563134|Drug|GR270774|
75537701|NCT00563173|Drug|CHRONVAC-C®|DNA vaccine, solution for injection, i.m. administration in combination with electroporation
76027825|NCT05031299|Behavioral|Health-promotion application for self-management|Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
76027826|NCT05031299|Device|Wearables and devices|Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
76027827|NCT03147391|Device|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
76027828|NCT03147547|Other|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
76027829|NCT03147547|Other|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
75864954|NCT03185104|Drug|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
76027830|NCT03147547|Other|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
76027831|NCT03147547|Other|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
76027832|NCT01918306|Drug|cisplatin|"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~--------------------------------------------------------------------------------"
76027833|NCT01918306|Other|laboratory biomarker analysis|correlative studies
76027834|NCT01918306|Other|pharmacological study|correlative studies
76027835|NCT01918306|Procedure|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
76027836|NCT01918306|Drug|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
76027837|NCT05031611|Behavioral|Intuitive Eating Treatment|"Participants received a brief web-based intervention for disordered eating which focused on a style of eating behavior called intuitive eating. Please see arm description for more details."
76027838|NCT05031533|Radiation|Dose-Painting Radiation|"Radiation therapy:~Delineation of target area:~The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~Exposure dose:~1) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy"
76027839|NCT02348515|Procedure|Heart failure or coronary disease|Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
76027840|NCT02348515|Procedure|Heart transplant patients|Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
76027841|NCT02348515|Procedure|Orthotopic Heart Transplant Patients|Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
76027842|NCT02348515|Procedure|Heart Surgery Patients|Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
75374140|NCT05078606|Device|Carotid Intima Media Thickness|"US Probe is slided superiorly (toward the head) or inferiorly (toward the feet) until the bifurcation of the common carotid artery (CCA) appears on the left side of the screen. This is the ideal location for imaging and CIMT measurements.~IMT is assessed in longitudinal view from the arterial far wall, along a 10mm length. CIMT will appear as two parallel lines (leading edges of two anatomical boundaries) from it: lumen- intima and media- adventitia interfaces perpendicular to ultrasound beams."
75374141|NCT05078606|Procedure|Spinal anesthesia|Spinal anesthesia will be performed in the sitting position at level of L3-4 or L4- 5 interspaces with a 25-gauge spinal needle. Local infiltration of skin and subcutaneous tissue with 2% lignocaine will be applied. After confirming cerebrospinal fluid flow, 10 mg of 0.5% hyperbaric bupivacaine plus 25 mcg fentanyl will be injected. The degree of sensory block (cold test by alcohol gauze) will be assessed in the study with a goal of T8 dermatomal level block.
75374142|NCT02546570|Drug|Oxytocin|See arm/group descriptions for dosage amount and procedure.
76027843|NCT02348515|Procedure|Blood Draw|All subjects will have 20 ml of blood drawn for further analysis.
76027844|NCT05022797|Drug|Glucarpidase 1000 UNT [Voraxaze]|2 vials of 1000 units per vial
76027845|NCT01917526|Device|oxygen mask|
75374143|NCT02546570|Drug|Placebo|See arm/group descriptions for dosage amount and procedure.
75374144|NCT02743351|Biological|ProTmune|Ex-vivo, programmed mobilized peripheral blood (mPB) cells
75374145|NCT02743351|Biological|Control Arm|Untreated mobilized peripheral blood (mPB) cells
75374146|NCT02548910|Procedure|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
75537702|NCT00221468|Drug|quetiapine|100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
76027846|NCT01917526|Device|oxygen cannula|
76027847|NCT05031143|Drug|Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease|Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
75374147|NCT02548910|Device|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
76027848|NCT01948258|Device|Clearblue Advanced Fertility Monitor|Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
76027849|NCT02354677|Other|In vitro experiments on bronchial epithelial cells|
76027850|NCT02354521|Other|NO INTERVENTIONS|
76027851|NCT02348437|Procedure|Repair|An on-going suture technique with minimum four stitches.
76027852|NCT02348437|Procedure|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
76027853|NCT01916980|Drug|Desloratadine 5 mg|Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
76027854|NCT05021627|Procedure|Cardiac autonomic nerve modification|Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP[LSGP]), the leftinfer oposterior area(left inferior GP[LIGP]), the right superoanterior area (rightanterior GP[RAGP]), the right inferoposterior area(right inferior GP[RIGP]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.
76027855|NCT05021627|Procedure|Pacemaker implantation|Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.
76027856|NCT02348281|Drug|Bicalutamide|150mg, po, qd, d1-28
76027857|NCT05021783|Diagnostic Test|Pressure pain threshold|The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
76027858|NCT05021783|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
76027859|NCT05021783|Other|Spondyloarthritis Research Consortium of Canada scoring system|SPARCC scoring consists of two subcomponents to detect sacroiliitis activation and structural damage. In the short tau inversion recovery (STIR) sequence, 6 consecutive coronal sections will be examined and the signal increase will be scored as 0 = normal signal and 1 = increased signal. In this way, the maximum score can be 12 in a single coronal section. Evaluations Total maximum score of 72 in 6 consecutive coronal sections. In structural scoring, similar to sacroiliitis scoring, the SI joint is divided into four quadrants to evaluate whether there is fatty change, erosion, backfill and ankylosis. Each lesion is scored as 0=absent or 1=present. In this way, fatty change and erosion can be scored between 0-40 and backfill and ankylosis can be scored between 0-20 in 5 consecutive sections in total scoring.
76027860|NCT05021783|Diagnostic Test|Temporal Summation|TS will be evaluated over the trapezius muscle and sacroiliac joints with manuel algometer. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
75537703|NCT00563212|Drug|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
75864955|NCT03185104|Drug|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
75374148|NCT02538523|Device|Erchonia FX-635|The Erchonia FX-635 is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
75374149|NCT02538523|Device|Placebo Laser|The Placebo Laser is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
75374150|NCT02510144|Drug|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
75374151|NCT02510144|Drug|Skin Prep Benzoyl Peroxide|3 day preoperative skin prep prior to surgery
75537704|NCT00563251|Drug|Azithromycin|
75537705|NCT00563251|Drug|Placebo tablet|
75537706|NCT03454516|Other|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
75537707|NCT02961543|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
75701076|NCT04094415|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
76027861|NCT05021783|Diagnostic Test|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 7 Celsius water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
76027862|NCT03147313|Device|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
76027863|NCT03147313|Device|Sham|Extracorporeal shock wave treatment will be faked.
76027864|NCT02354287|Procedure|Cold forceps polypectomy with pre lift|"Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue."
76027865|NCT03094949|Procedure|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
76027866|NCT03094949|Procedure|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
76027867|NCT02349919|Drug|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
76027868|NCT02349919|Drug|Placebo|Placebo twice daily for 4 weeks
76027869|NCT03091985|Device|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
76027870|NCT03091985|Device|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
75864956|NCT03700424|Drug|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
76027871|NCT03147235|Behavioral|vitrectomy with music listening|Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
76027872|NCT02349763|Drug|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
75701077|NCT00730028|Drug|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child > 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child < 40 kg dose). Study drug will be administered for 10 days.
75864957|NCT03700424|Drug|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
75864958|NCT01319994|Drug|Metformin|Metformin 850mg TDS (12 weeks)
75701078|NCT00730028|Other|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
75701079|NCT00730028|Drug|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
75864959|NCT01319994|Drug|Placebo|Placebo 850mg TDS (12 weeks)
75864960|NCT02430298|Drug|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
75864961|NCT02430298|Drug|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
76027873|NCT02349763|Drug|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
76027874|NCT02349841|Drug|Meropenem|To administer 2g daily 8 hourly for 14 days
76027875|NCT02349841|Drug|Faropenem|To adminster 600mg 8 hourly daily for 14 days
76027876|NCT02349841|Drug|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
76027877|NCT02349841|Drug|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
76027878|NCT02349997|Other|no interventions|This is an observational study and no intervention applied.
76027879|NCT05020925|Drug|SHR-1701|Intravenous (IV) on Day 1 of each cycle
76027880|NCT05020925|Drug|Famitinib|Famitinib, po, qd
76027881|NCT02349373|Behavioral|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
76027882|NCT02349373|Behavioral|16 week training period|Receipt of a weekly running schedule through an online training diary.
75374152|NCT02538679|Other|Placebo|The usual intraoperative and postoperative pain control; NO TAP block performed
75701080|NCT05673642|Other|Myofascial Release Techniques|Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
75864962|NCT03624218|Behavioral|Prolonged Exposure Therapy|Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
75864963|NCT03626376|Drug|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily|Treatment used in standard of care
75864964|NCT03626376|Drug|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops|Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
75864965|NCT03714139|Procedure|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden & Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
76027883|NCT02349529|Behavioral|Psychosocial Intervention Group|6 group sessions
76027884|NCT02349529|Other|Waiting list control|Treatment as usual
76027885|NCT05021159|Other|MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)|the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
76027886|NCT02353975|Drug|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
76027887|NCT05020613|Procedure|Procedure: Early removal group|Participants assigned this arm will have their urethral catheters removed at 2 days after low anterior resection of the rectum
76027888|NCT05020613|Procedure|Procedure: Late removal group|Participants assigned this arm will have their urethral catheters removed after 48.th hours after Low anterior resection of the rectum
76027889|NCT03159247|Behavioral|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
76027890|NCT03094559|Device|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
76027891|NCT02354053|Drug|Switch to Triumeq|
76027892|NCT02354053|Behavioral|Adherence support + current ART|
76027893|NCT05029037|Drug|High doses of intravenous vitamin C|Two (2) High doses of intravenous vitamin C for seven (7) days.
76027894|NCT05029037|Drug|Dextrose 500 mL|"Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.~Twice a day for seven days."
75374153|NCT02538679|Drug|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
75701081|NCT02594228|Behavioral|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
76027895|NCT05028959|Other|Multidisciplinary monitoring of healthy women|Multidisciplinary monitoring
76027896|NCT02353741|Drug|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
75701082|NCT02594228|Behavioral|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
76027897|NCT02353741|Radiation|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
76027898|NCT03092063|Behavioral|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
76027899|NCT03092063|Behavioral|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
76027900|NCT03092063|Behavioral|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
76027901|NCT03092063|Behavioral|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
76027902|NCT02353663|Other|Echocardiography|Echocardiography examination
75864966|NCT03714139|Procedure|non implant loading|Control implants will receive a healing screw and will remain unloaded
75864967|NCT02430454|Behavioral|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
76027903|NCT02347969|Dietary Supplement|X34|Dietary supplement named X34
75864968|NCT03700346|Device|microdialysis|Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
76027904|NCT05028803|Drug|sodium phenylbutyrate|same as arm/group
75374154|NCT02538679|Drug|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
75864969|NCT01373034|Dietary Supplement|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
75864970|NCT01373034|Dietary Supplement|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
75864971|NCT03189316|Other|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
75864972|NCT05631613|Procedure|cTACE(conventional transarterial chemoembolization)|transarterial chemoembolization with lipiodol-idarubicin emulsion
75864973|NCT03624608|Device|AuryzoN Family of Devices|The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
75864974|NCT02430064|Other|Low PAMP diet|
76027905|NCT03146923|Other|Current Low Phosphorus Diet Prescription|"Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides <15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition & Dietetic Institute (INDI) in 2010 and includes following main components:~Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~Restricting dairy intake (1-1.5 portions per day)~Avoiding foods high in phosphate~Avoiding foods with phosphate additives"
76027906|NCT03146923|Other|Modified Low Phosphorus Diet Prescription|"Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~Increased focus on avoiding additives~Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~Avoiding over-prescription of protein which carries an obligatory phosphorus load.~Focus on high protein foods with a low phosphorus to protein ratio"
76027907|NCT05020223|Other|Vital pulp therapy|Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
76027908|NCT03147001|Other|Protein ingestion|A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
76027909|NCT03147001|Other|Non-caloric placebo ingestion|A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
76027910|NCT03094481|Procedure|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
76027911|NCT03094481|Procedure|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
76027912|NCT03094481|Procedure|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
76027913|NCT03094481|Drug|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
76027914|NCT04438837|Drug|Hydroxychloroquine|Hydroxychloroquine post exposure prohylaxis
75864975|NCT03716089|Procedure|Laparoscopic resection|Laparoscopic surgery under general anesthesia
75864976|NCT03692078|Other|OTDN product 1|Oral tobacco-derived nicotine product
75864977|NCT03692078|Other|OTDN product 2|Oral tobacco-derived nicotine product
75864978|NCT03692078|Other|Tobacco Cessation|Tobacco Cessation
75864979|NCT03189160|Biological|PEG-rhGH low dose|PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
75557471|NCT03272802|Drug|Edaravone|Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
75557472|NCT03272802|Drug|Riluzole|Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
75557473|NCT00472719|Biological|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
75557474|NCT00472719|Biological|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
75557475|NCT00472719|Biological|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
75864980|NCT03189160|Biological|PEG-rhGH high dose|PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
75864981|NCT03189160|Other|Non-treatment control group|
75864982|NCT03208530|Behavioral|Brief motivational interview intervention|A brief (<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
75864983|NCT03695822|Drug|Mirabegron 25mg|The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
75864984|NCT03718507|Drug|Fentanyl|atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
75864985|NCT03718507|Drug|Sucrose 24% Oral Solution|0.5 ml given orally 2 minutes before LISA procedure
75557476|NCT01050062|Drug|Telmisartan 80mg|Combination tablet
75557477|NCT01050062|Drug|Telmisartan 40mg|Combination tablet
75557478|NCT01050062|Drug|Hydrochlorothiazide 12.5mg|Combination tablet
75557479|NCT00464802|Drug|MOA-728|
75557480|NCT00464841|Procedure|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
75557481|NCT00464841|Procedure|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
75557482|NCT00464880|Drug|Aliskiren|
76027915|NCT05020067|Radiation|superficial parotid lobe-sparing intensity-modulated radiotherapy|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
75537708|NCT02961543|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
75537709|NCT00221507|Behavioral|Reminder-Recall-Outreach|
75537710|NCT00221507|Behavioral|Case Management|
75537711|NCT00221507|Behavioral|Patient Navigator|
76027916|NCT02348125|Drug|Mitochondrial Cocktail|
75864986|NCT03700268|Other|Manual intervention to programme Cochlear Implant electrodes|The Clinician test the 22 electrodes so that the patient is able to hear the language
75864987|NCT03188692|Biological|DPT-IPV-Hib (Combined Vaccine)|0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
76027917|NCT05019911|Device|Polysomnography|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome.
76027918|NCT05019911|Device|Millimeter wave radar equipment|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by millimeter wave radar equipment for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome. In the cohort part, both groups of patients will be continuously monitored by millimeter wave radar equipment for vital signs for months in order to establish a model to predict acute exacerbations of COPD combined with sleep apnea hypopnea syndrome.
76027919|NCT02353273|Drug|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
75374155|NCT02511236|Behavioral|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
75374156|NCT02511236|Behavioral|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
75374157|NCT02511236|Drug|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
75537712|NCT03454477|Procedure|conventional open surgery|conventional open surgery
75537713|NCT03454477|Procedure|endoscopic thyroidectomy|endoscopic thyroidectomy
75537714|NCT03454477|Device|robotic thyroidectomy|robotic thyroidectomy
75537715|NCT03454399|Procedure|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
75537716|NCT03454360|Device|ACURATE neo™ Aortic Bioprosthesis|TAVI; Transcatheter Aortic Valve Replacement. Transapical Access.
75537717|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
75537718|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
75864988|NCT03716011|Device|EXCROSSAL|a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent
75864989|NCT04940832|Device|pulsed radiofrequency modulation|a percutaneous needle electrode to apply pulsed RF signals that modulate the activity of sensory nerves. The pulsing of the RF signal permits a maximum temperature to be achieved - usually 42 Celsius. This helps prevent collateral damage from occurring during the procedure and should help reduce procedural complications.
75537719|NCT00251082|Drug|Placebo|Placebo
75537720|NCT00221546|Drug|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
75537721|NCT04616092|Drug|FEFINJECT|FEFINJECT injection
75537722|NCT04616482|Behavioral|Digital therapeutic carbohydrate restriction (TCR) program|A 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction as for obesity and/or T2D (or risk of T2D). The program is intended to enhance the usual clinical care provided for patients.
75537723|NCT00221585|Behavioral|Psychosocial treatment/Psychodynamic treatment|
75537724|NCT04616404|Dietary Supplement|500 mg of artichoke extract|Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)
75537725|NCT04616404|Other|Placebo|Tablets with no active ingredient
75537726|NCT04720482|Diagnostic Test|Somatosensory Evoked Potentials|SSEP performed bilaterally with stimulation of the median nerve
75537727|NCT04720482|Diagnostic Test|Automated Pupillometry|PLR quantified as NPi using a handheld automated pupillometer
75537728|NCT00221624|Drug|Peginterferon alfa-2a|
75537729|NCT00221624|Drug|ribavirin|
75537730|NCT00221624|Drug|amantadine|
75557483|NCT00464919|Drug|Sorafenib|
75374158|NCT02467387|Drug|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
76027920|NCT05028335|Other|Carbamide Peroxide (PC) 22%) + placebo gel|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
76027921|NCT05028335|Other|Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
76027922|NCT02353351|Device|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
76027923|NCT04434053|Device|MIETHKE M.blue®|The programmable shunt will be adjusted through the MIETHKE M.blue® valve.
76027924|NCT04434053|Device|MIETHKE proGAV 2.0® (with SA 2.0®)|The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
76027925|NCT02348047|Device|Hamilton T1|
76027926|NCT03094403|Drug|Azelaic Acid 15% topical gel|Gel
76027927|NCT03094403|Drug|Finacea® (azelaic acid) Gel, 15%|Gel
76027928|NCT03094403|Drug|Placebo|Gel
76027929|NCT03148873|Device|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
76027930|NCT02347891|Drug|Belimumab|Randomized phase: Week 0 - Week 36
76027931|NCT02347891|Drug|Placebo|Randomized phase: Week 0 - Week 36
76027932|NCT02347735|Other|No interventions, only data collection|Only data is collected from the subjects in both groups.
75374159|NCT02467387|Drug|Lactated Ringer's Solution|One time infusion 1.5mL/kg
75374160|NCT05073068|Behavioral|Timing of exercise|An acute exercise bout of cycling performed in the morning at 9 AM or at 5 PM
75374161|NCT05073068|Behavioral|Control|No exercise
75701083|NCT03356223|Drug|Abemaciclib|"400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
75701084|NCT04087694|Procedure|Microdecompression|comparative surgical treatment
75864990|NCT02430610|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
76027933|NCT03091517|Behavioral|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
76027934|NCT03147157|Other|tacrolimus regimen guided by HLA matching rate|required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
75374162|NCT02974478|Dietary Supplement|Orange juice with meals|orange juice (20% of energy requirement/day)
75374163|NCT02974478|Dietary Supplement|Orange juice between meals|orange juice (20% of energy requirement/day)
75374164|NCT02974478|Dietary Supplement|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
75864991|NCT02430610|Device|NanoKnife|
75864992|NCT03714061|Other|Pain Neuroscience Education|"The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
76027935|NCT05028023|Biological|Apneic oxygenation - supplemental high flow oxygen administration by an apneic way|In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
76027936|NCT03146767|Device|Tetanus stabilization of baseline|Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
76027937|NCT02347501|Drug|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
76027938|NCT05020301|Device|external meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
76027939|NCT05020301|Device|internal meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
75701085|NCT04060875|Device|Karuna Labs Virtual Reality Software|The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
75701086|NCT04088084|Dietary Supplement|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
76027940|NCT03155581|Behavioral|User intervention|To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation
76027941|NCT03155581|Behavioral|Health professional intervention|To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
75701087|NCT02593370|Drug|Lidocaine-epinephrine added gadoterate meglumine|
75864993|NCT03714061|Other|Self-Management Education|"Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
76027942|NCT04130165|Other|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
76027943|NCT03148717|Drug|Misoprostol|Cytotec
76027944|NCT03148717|Other|Placebo|Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
76027945|NCT02349607|Drug|PF-05089771 300mg|PF-05089771 300 mg
75864994|NCT01373112|Procedure|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
76027946|NCT02349607|Drug|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
76027947|NCT02349607|Drug|Placebo|Placeco
75864995|NCT01373112|Procedure|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
76027948|NCT02349607|Drug|pregabalin 300 mg|pregabalin 300 mg
76027949|NCT02349607|Drug|ibuprofen 600 mg|ibuprofen 600 mg
76027950|NCT05019755|Drug|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
76027951|NCT05019755|Drug|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
76027952|NCT04478461|Drug|PD-1 monoclonal antibody|"The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W"
76027953|NCT04115501|Other|Fraction of Inspired Oxygen|Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
76027954|NCT02039089|Drug|E2006 2.5 mg|
76027955|NCT02039089|Drug|E2006 10 mg|
76027956|NCT02039089|Drug|E2006 25 mg|
76027957|NCT02039089|Drug|Placebo|
76027958|NCT02353507|Device|Opticell Ag+|
76027959|NCT02353507|Device|Aquacel Ag+|
76027960|NCT03148561|Drug|Misoprostol|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
76027961|NCT05027555|Other|Multisensory training|Multisensory training included marching on the foam with visual deprivation and treadmill training with visual deprivation
76027962|NCT05027555|Other|Conventional training|Conventional training included strengthening, balance training and gait training
76027963|NCT05027321|Behavioral|Preparation in Self-Hypnosis by anchoring|Preparation in Self-Hypnosis by anchoring just before examination
75374165|NCT02512874|Other|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
76027964|NCT05027321|Behavioral|Conversational Hypnosis|Conversational Hypnosis during examination
76027965|NCT05027321|Behavioral|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|Preparation in Self-Hypnosis by anchoring just before examination combied with Conversational Hypnosis during examination
76027966|NCT02348983|Behavioral|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
76027967|NCT02353429|Drug|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
76027968|NCT05019989|Behavioral|Intervention group on diet and physical activity|"The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)"
76027969|NCT05019989|Behavioral|Control group: only public recommendation an lifestyle|"Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~Dissemination of the information on the study by media~Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
76027970|NCT04478305|Drug|Duavive 0.45Mg-20Mg Tablet|Duavee, marketed as Duavive in Canada.
76027971|NCT05027243|Procedure|bilateral temporomandibular joint arthroscopy|The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.
76027972|NCT05027243|Drug|Xeomin® (Merz)|For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
76027973|NCT03147079|Behavioral|Lifestyle intervention|
76027974|NCT03148639|Behavioral|Avatar therapy|Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
76027975|NCT03148639|Other|Treatment-as-usual|Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
75537731|NCT04616053|Behavioral|IMPACT intervention|A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
76027976|NCT05019599|Other|low protein diet|Low protein diet (<0.8g/kg/BW/day)
76027977|NCT03112135|Drug|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
75374166|NCT02512874|Device|Dynamometer|Grip Test
75701088|NCT04061109|Drug|Recombinant Human Coagulation FVIII|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
75557484|NCT00464919|Drug|tegafur/uracil (UFUR®)|
75557485|NCT00434174|Drug|Everolimus|"RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed."
75864996|NCT03695666|Other|Clerical policy|Clerical policy introduction
75864997|NCT03188848|Drug|BPI-3016|Single-dose subcutaneous injection of BPI-3016
75374167|NCT02512874|Radiation|DEXA|Body Composition Testing
75374168|NCT02512874|Other|Gait Speed Test|15 foot walk test
75374169|NCT02512874|Device|Activity Monitor|Measures energy expenditure and activity
75557486|NCT00434174|Drug|Pemetrexed|Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
76027978|NCT03112135|Drug|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
76027979|NCT03112135|Drug|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
76027980|NCT03090893|Drug|ATryn continuous infusion|replenish serum thrombin levels
76027981|NCT03112759|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
76027982|NCT05019287|Biological|Allogeneic human menstrual blood stem cells secretome|This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.
76027983|NCT05019287|Other|Intravenous saline injection|Intravenous saline injection in addition to standard care
76027984|NCT03094169|Drug|AVID100 IV|AVID100 is administered once every 3 weeks
76027985|NCT04477993|Drug|Janus Kinase Inhibitor (ruxolitinib)|5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils < 500/mm3 or platelets <50,000/mm3.
76027986|NCT04477993|Other|Placebo|Placebo tablets P.O. b.i.d. for 14 days.
76027987|NCT03094013|Other|Assessment|Assessment
76027988|NCT03112447|Procedure|absorbable cartilage nail|The experiment group patients were fixed with absorbable cartilage nails
76027989|NCT03112447|Procedure|traditional Kirschner wires|The control group were fixed with traditional Kirschner wires
75374170|NCT02512874|Other|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
75374171|NCT02721979|Drug|Apalutamide|Given PO
75864998|NCT03188848|Drug|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
76027990|NCT05019443|Device|Wedge Scoring Balloon|Scoring balloon
76027991|NCT05019443|Device|Conventional Balloon|Conventional balloon
76027992|NCT03146533|Drug|Fludarabine|Fludarabine 30 mg/m2/day IV for 3 days.
75374172|NCT02721979|Other|Laboratory Biomarker Analysis|Correlative studies
75374173|NCT02721979|Other|Quality-of-Life Assessment|Ancillary studies
75374174|NCT02721979|Other|Questionnaire Administration|Ancillary studies
75374175|NCT02551094|Drug|colchicine|0.5 mg tablet taken once a day
75864999|NCT01311271|Device|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~Real: unaffected M1 hotspot~Sham: coil perpendicular to scalp"
76027993|NCT03146533|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
76027994|NCT03146533|Biological|CD19 CART|CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
76027995|NCT03093935|Device|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
76027996|NCT03148483|Other|Early PT|Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
76027997|NCT03148483|Other|Delayed PT|Women will receive conventional non-surgical PT delayed until after delivery.
76027998|NCT03148483|Dietary Supplement|Fortified Milk|participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
76027999|NCT03148483|Dietary Supplement|Plain Milk|Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
76028000|NCT02353117|Behavioral|Congenital Syphilis Intervention Group|
75374176|NCT02551094|Drug|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
75374177|NCT02513498|Drug|Ixazomib Citrate|Given PO
76028001|NCT03093779|Other|Health Information Assessment|Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
75374178|NCT02513498|Other|Laboratory Biomarker Analysis|Correlative studies
75374179|NCT02513498|Other|Quality-of-Life Assessment|Ancillary studies
75374180|NCT02513498|Other|Questionnaire Administration|Ancillary studies
75865000|NCT01374282|Drug|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
76028002|NCT02353195|Other|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
76028003|NCT03090971|Drug|Diclofenac Sodium|Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
76028004|NCT03090971|Drug|Saline Solution|Following microporation, control neurofibromas will receive treatment with topical saline
75701089|NCT04087616|Behavioral|ICBIT|The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.
75701090|NCT04087616|Behavioral|waiting list|Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
75701091|NCT00918320|Drug|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
75865001|NCT02429986|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
75374181|NCT00363740|Drug|GW685698X Aqueous Nasal Spray|
75374182|NCT04787354|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m2/day
75374183|NCT04787354|Drug|Capecitabine|Capecitabine: 2,000 mg/m2/day
75374184|NCT02514044|Drug|Dexedrine|10 mg immediate release of Dexedrine
75374185|NCT02514044|Device|Active tDCS|1.5 mA tDCS anodal tDCS
75537732|NCT04615975|Dietary Supplement|Ketogenic diet with phytoextracts|Patients were provided with an individualized nutritional ketogenic plan during hospitalization
75537733|NCT04615897|Procedure|new tecnology intervention|"The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes."
76028005|NCT03154177|Behavioral|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
75865002|NCT03691922|Procedure|Erector Spinae Plane (ESP) Block|"Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
75865003|NCT03691922|Procedure|Periarticular Infiltration (PAI)|"Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
75374186|NCT02514044|Behavioral|Speech Therapy|60 min of speech therapy
75374187|NCT02514044|Drug|Placebo|
75374188|NCT02514044|Device|Sham tDCS|
75374189|NCT02515058|Device|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
75374190|NCT02515058|Device|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
75701092|NCT02593292|Behavioral|PROSPERO|"The intervention is carried out in 3 steps:~At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
75865004|NCT03453151|Drug|splanchnic nerve anesthesia with a local anesthetic|regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
75865005|NCT03433248|Drug|EMPA/LINA 10/5 mg QD (n=22)|Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
75865006|NCT03433248|Drug|LINA/EMPA 5/10 mg QD (N=22)|Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
75865007|NCT03433248|Drug|Gliclazide 30 mg QD/BID (N=22)|Once daily or twice daily treatment with oral glicazide MR 30mg
75865008|NCT02430142|Other|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
75865009|NCT03691766|Other|Photobiomodulation Therapy|Photobiomodulation therapy, a mix of red lights thought to improve mitochondrial function will be applied in and acute and chronic manner to test whether muscle fatigue improves in persons with MS.
75865010|NCT03691766|Other|Placebo|Device with sham light source
75865011|NCT03691688|Drug|Aspirin 100 mg|Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
75537734|NCT00221663|Device|surgery techniques (sternotomy for aortic valve replacement)|
75865012|NCT03691688|Drug|Clopidogrel 75mg|Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
75865013|NCT03619304|Dietary Supplement|coffee|coffee beverage
75865014|NCT02425462|Drug|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
75865015|NCT03700112|Other|JUUL Virginia Tobacco flavored 5.0% ENDS|Virginia Tobacco Flavored 5.0% ENDS product is administered using a controlled method and adlibitum
76028006|NCT03154177|Procedure|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention."
76028007|NCT05018741|Procedure|liver transplantation|liver transplantation for chronic liver disease or acute liver failure
76028008|NCT03146689|Drug|Topical NSAID|Applied four times daily
75865016|NCT03700112|Other|PMI iQOS Heat sticks|PMI IQOS Heat sticks is administered using a controlled method and ad-libitum
75865017|NCT03700112|Other|Reynolds VUSE Solo ENDS - Original|Reynolds VUSE solo ENDS - Original is administered using a controlled method and ad-libitum
75865018|NCT03700112|Other|Imperial MyBlu ENDS - Original|Imperial MyBlu ENDS- original is administered using a controlled method and ad-libitum
76028009|NCT03146689|Drug|Topical Capsaicin|Applied four times daily
75374191|NCT02552810|Device|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
75374192|NCT02552810|Device|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
75374193|NCT02553512|Other|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
75374194|NCT02553746|Device|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
75537735|NCT04615741|Behavioral|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
75537736|NCT04615741|Behavioral|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
75537737|NCT04615663|Behavioral|Score SMI|the investigator will complete the SMI score
75557487|NCT00464958|Drug|sublingual tizanidine 12 mg|Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
75865019|NCT03700112|Other|Altria MarkTen ENDS - Bold Classic|Altria MarkTen ENDS - Bold Classic is administered using a controlled method and ad-libitum
75374195|NCT02553746|Procedure|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
75865020|NCT03700112|Other|MLV PHIX ENDS - Original Tobacco|MLV PHIX ENDS - Original Tobacco is administered using a controlled method and ad-libitum
75865021|NCT03700112|Other|NJOY Daily EXTRA ENDS - Rich Tobacco|NJOY Daily EXTRA ENDS - Rich Tobacco is administered using a controlled method and ad-libitum
75865022|NCT03700112|Other|Altria Marlboro combustible cigarette - Red|Altria Marlboro combustible cigarette - Red is administered using a controlled method and ad-libitum
75865023|NCT04482868|Procedure|Percutaneous screw fixation through K-wire-assisted reduction and maintenance|Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
75865024|NCT03307824|Device|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
75865025|NCT03307824|Procedure|Glue-Free Suture Technique|Suture Technique
76028010|NCT02347267|Behavioral|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
76028011|NCT02347267|Behavioral|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
76028012|NCT05025995|Behavioral|Serious health game|Serious health game
75865026|NCT03452527|Biological|ICON-1|ICON-1 0.6 mg by intravitreal injection
75865027|NCT03452527|Biological|aflibercept|aflibercept 2 mg by intravitreal injection
76028013|NCT05255575|Drug|Ertapenem|Patients will receive ertapenem therapy.
76028014|NCT05026229|Drug|dasatinib plus consolidation chemotherapy with vincristine and prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
76028015|NCT05026229|Drug|dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
76028016|NCT02343679|Drug|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
76028017|NCT03148249|Other|interview|control group: interview, study group: explanation and exploration
76028018|NCT05026073|Behavioral|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia|age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
76028019|NCT05026073|Procedure|Blood and endometrial tissue sampling|"All women will undergo planned hysterectomy.~Venous blood sample will be collected prior to surgery.~Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation."
76028020|NCT05026073|Procedure|Lymph node sampling|"Lymph nodes will be excised if recommended as part of the standard treatment for endometrial cancer.~Each node will be cut in half or in quarters, depending on size, to expose the core. Wet and dry spectral analysis will be performed, followed by staining for histopathological confirmation."
76028021|NCT03148171|Other|WERK Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
75557488|NCT01055912|Drug|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
75557489|NCT01055912|Drug|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
75557490|NCT00472758|Biological|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
76028022|NCT04478149|Device|SafelyYou|technology to detect and prevent falls
76028023|NCT04478149|Other|Control|technology present but not activated
76028024|NCT02347423|Biological|Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI|
76028025|NCT02347423|Biological|IPV Vaccine SSI|
76028026|NCT05018429|Procedure|nerve sparing|When resect the bladder and prostate, the neurovascular bundles around the prostate will be preserved.
76028027|NCT03146611|Diagnostic Test|nCD64|neutrophil CD64
76028028|NCT03146611|Diagnostic Test|Neutrophil/Lymphocyte Ratio|Neutrophil/ lymphocyte ratio
76028029|NCT03146299|Procedure|TLH vs LAVH|"TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more"
76028030|NCT05009693|Other|White Light Application|White Light Therapy
76028031|NCT02343601|Device|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
75865028|NCT02429908|Device|TM-Ardis Interbody|The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
75537738|NCT04615780|Other|mouthwash with green tea|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.
75865029|NCT03226470|Biological|T512|T512 suppository contain 500 µg of T512 and suppocire.
75865030|NCT03188926|Procedure|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment of impending or pathologic fracture in the extremities
75865031|NCT03718351|Procedure|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
75374196|NCT02554760|Device|The ZELTIQ CoolSculpting System|The CoolSculpting device and CoolCore applicator with and without the Crown Cooling Insert will be used to perform the treatments.
75374197|NCT02555228|Drug|Simethicone|100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
75374198|NCT02555228|Other|Water|5mls of water is given at least 30 minutes before the gastroscopy.
75865032|NCT03718351|Procedure|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
76028032|NCT03090815|Genetic|Sequencing of ctDNA in plasma|Sequencing of ctDNA in plasma
76028033|NCT02348905|Drug|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
76028034|NCT02348905|Drug|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
76028035|NCT04954157|Diagnostic Test|Phase-1: Breath Holding Test|In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
76028036|NCT04954157|Diagnostic Test|Phase 2: 6-Minute Walk Test (6MWT)|In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
76028037|NCT02347033|Drug|Sertraline|"Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.~We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks."
75374199|NCT04654130|Other|Neurofeedback|"NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks."
75374200|NCT02555306|Drug|0.5 mg of DE-122|DE-122 Injectable Solution
75374201|NCT02555306|Drug|1.0 mg of DE-122|DE-122 Injectable Solution
75374202|NCT02555306|Drug|2.0 mg of DE-122|DE-122 Injectable Solution
75537739|NCT04615780|Other|mouthwash with tap water group|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
75557491|NCT00472758|Other|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
75865033|NCT03713827|Device|tooth restoration|restoration of non carious cervical lesions with two different restorative materials
76028038|NCT02347033|Behavioral|Cognitive Behavioural Therapy|"CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent."
76028039|NCT04949633|Drug|Prostaglandins|Second cervical ripening lasting a maximum of 24 hours
76028040|NCT04949633|Drug|Oxytocin|Induction of labor with oxytocin.
76028041|NCT02343367|Behavioral|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
76028042|NCT02343367|Other|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
76028043|NCT02343367|Behavioral|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
76028044|NCT02343367|Behavioral|Text messages|regularly scheduled cell phone text messages for 12 months
76028045|NCT02343367|Behavioral|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
76028046|NCT02343367|Behavioral|Newsletters|12 monthly newsletters mailed to participant homes
76028047|NCT03146377|Drug|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
76028048|NCT03146377|Drug|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
76028049|NCT03146377|Drug|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
76028050|NCT05018195|Procedure|Excise adipose tissue|Perform partial omentectomy to obtain one 5*5 cm omental fat and excise one 3*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
76028051|NCT02343055|Other|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
76028052|NCT05009615|Dietary Supplement|Green coffee extract|150 mg polyphenols from green coffee, twice daily
76028053|NCT05009615|Dietary Supplement|Beta glucan|2.5 g BG twice daily
76028054|NCT05009615|Dietary Supplement|Green coffee + beta-glucan|150 mg polyphenols from green coffee + 2.5 g BG, twice daily
76028055|NCT02343133|Biological|HemaMax|
76028056|NCT02343133|Drug|Placebo|
76028057|NCT02349139|Drug|ASN001: Escalating dose Part A|Androgen inhibitor
76028058|NCT02348827|Behavioral|Family psychoeducation|
75374203|NCT02555306|Drug|4.0 mg of DE-122|DE-122 Injectable Solution
76028059|NCT02348827|Behavioral|Social support group|
76028060|NCT03090581|Procedure|Biopsies CP|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
76028061|NCT03090581|Procedure|Biopsies FC|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
75374204|NCT02555930|Other|No Intervention|No intervention - observational only
75865034|NCT02429674|Behavioral|TranS-C and IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
75865035|NCT03028142|Drug|1.5 mg RPL554 plus tiotropium|
75374205|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
75374206|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
75537740|NCT06178250|Other|3D sonography|Fetal liver, placenta, and ductus venosus were defined in 3 orthogonal multi-plane images in the voluson 4D view vocal program.
75537741|NCT06178237|Device|Purabond|Application of Purabond to surgical field
75537742|NCT06178211|Drug|Immunotherapy: Adebrelimab|Adebrelimab 1200mg Q3W
75537743|NCT06178211|Drug|chemotherapy: carboplatin plus nab-paclitaxel|carboplatin plus nab-paclitaxel
75557492|NCT01055444|Drug|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
75557493|NCT01055015|Drug|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
75865036|NCT03028142|Drug|6 mg RPL554 plus tiotropium|
75865037|NCT03028142|Drug|Placebo plus tiotropium|
75865038|NCT03188614|Drug|Fluid resuscitation|The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
75865039|NCT02866812|Other|questionnaires assessing the state of fatigue, depression and anxiety|
75865040|NCT03713749|Device|Robot esophagectomy (RE)|Patients in RE group will receive Robotic-assisted surgery in thoracic phase.
75865041|NCT03182842|Device|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
75865042|NCT03182842|Device|SMBG - Blinded Sensor|Insulin dosing based on SMBG
75865043|NCT02800824|Drug|Budesonide|
75865044|NCT02800824|Drug|Uceris|
75374207|NCT02556788|Drug|CD5789 (trifarotene) 50µg/g Cream|CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
75374208|NCT02556788|Drug|Placebo Cream|Placebo cream applied once daily during 12 weeks.
75374209|NCT02516150|Drug|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
75374210|NCT02516150|Drug|Glucagon|injection of 50 micrograms of glucagon
75865045|NCT03695588|Procedure|Quadratus lumborum block|Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)
75865046|NCT03695588|Procedure|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
75865047|NCT04806360|Procedure|ACRF surgery|A new surgical procedure that previously proposed by our team.
76028062|NCT02348671|Other|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
76028063|NCT03079583|Dietary Supplement|Intervention-group|Biofortified Rice is grown by foliar Zn application
76028064|NCT03079583|Dietary Supplement|Control-group|Control Rice with normal zinc levels
76028065|NCT02346955|Biological|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
76028066|NCT02346955|Biological|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
76028067|NCT03079505|Drug|Dasatinib 100 MG [Sprycel]|Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
76028068|NCT03079505|Drug|Nilotinib 150mg oral capsule [Tasigna]|Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
76028069|NCT02343211|Drug|Immunoglobulin|
76028070|NCT03090503|Drug|Aripiprazole|Initial dose: 10 mg.
76028071|NCT03090503|Drug|Risperidone|Initial dose: 2 mg.
76028072|NCT02343289|Drug|Esketamine|28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.
76028073|NCT02343289|Drug|Clarithromycin|500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
76028074|NCT03090113|Drug|Shuxuetong Injection|intravenous drip
76028075|NCT03090113|Drug|Placebo Injection|intravenous drip
76028076|NCT02346799|Behavioral|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
76028077|NCT02346799|Behavioral|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
76028078|NCT02346799|Behavioral|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
76028079|NCT02346799|Behavioral|Partner Assignment|"Participants will be required to have same workout window as partners."
76028080|NCT03146221|Other|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
76028081|NCT03090269|Drug|Methylphenidate Pill|3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
76028082|NCT02342899|Device|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
75374211|NCT04025060|Behavioral|Commercially-available caffeine-free soda|Subjects are asked to consume caffeine-free soda daily for two weeks
75374212|NCT04025060|Behavioral|Carbonated water|Subjects are asked to consume unsweetened, carbonated water daily for two weeks
75374213|NCT04025060|Behavioral|Regular soda|Subjects are asked to consume regular soda daily for two weeks
75374214|NCT04542434|Drug|Niclosamide Oral Tablet|Niclosamide tablets 400 mg 3 times daily for 14 days
75374215|NCT04542434|Drug|Placebo|Matching placebo tablets 3 times daily for 14 days
75374216|NCT02557178|Behavioral|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
75557494|NCT01055015|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
75557495|NCT00472875|Drug|Glibenclamide|
75557496|NCT00434291|Drug|TG-873870(Nemonoxacin)|
75557497|NCT03275051|Other|Safety and Efficacy assessments|Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
75557498|NCT00434369|Drug|CoFactor (ANX-510)|
75557499|NCT00472914|Device|portable surface electromyography|
75557500|NCT00434447|Drug|Zoledronic acid|
75557501|NCT00472953|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
75557502|NCT00472953|Drug|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
75557503|NCT02957630|Drug|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
75865048|NCT04806360|Procedure|conventional anterior surgery|Anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
75865049|NCT04806360|Procedure|conventional posterior surgery|Laminectomy and fusion surgery or laminoplasty surgery.
75557504|NCT02957630|Drug|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
75865050|NCT02429752|Other|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
76028083|NCT02342899|Device|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
75374217|NCT04415528|Other|Emotion-Focused Mindfulness Therapy|"EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention."
75701093|NCT02593292|Other|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
75701094|NCT03960632|Diagnostic Test|Abbott SD Bioline Malaria Pf Plus (05FK150) and Abbott SD Bioline Malaria Pf/Pv Plus (05FK160))|Qualitative in vitro tests for the detection of Plasmodium antigens
75865051|NCT03713359|Biological|Trial arm (MRVAC)|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
75557505|NCT02957630|Drug|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
75557506|NCT00465036|Dietary Supplement|Whole flaxseeds, flaxseed mucilage, glucomannan|
75865052|NCT03713359|Biological|Control arm|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
75865053|NCT03695432|Biological|Flubio|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
75865054|NCT03695432|Dietary Supplement|Lacidofil|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
75865055|NCT03695432|Other|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
75865056|NCT03695432|Other|Placebo probiotic|Capsul
76028084|NCT05008679|Drug|Oseltamivir|at a dose of 75 mg twice daily
75701095|NCT00729560|Drug|Flutamide|250 mg twice daily for 4 weeks
75701096|NCT00729560|Drug|Placebo|Placebo twice daily for 4 weeks
76028085|NCT03090035|Drug|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
76028086|NCT03090035|Drug|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
76028087|NCT03147781|Device|True AT with magnetic pellets|Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
76028088|NCT03147781|Device|Sham AT with Medulla Junci|Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
76028089|NCT03147703|Behavioral|Food Timing|the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way
76028090|NCT03079349|Other|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
76028091|NCT03079349|Other|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
75374218|NCT03943628|Behavioral|Familias Unidas|
75374219|NCT04186286|Drug|Ivabradine 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
75701097|NCT03202017|Procedure|Expiratory Muscle Strength Training (EMST)|EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
75865057|NCT03715777|Drug|Clostridium botulinum type A (BoNTA)|"Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:"
76028092|NCT03147625|Behavioral|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
75537744|NCT06178198|Procedure|Ablative radioembolization using Yttrium-90 resin microspheres|Based on 99mTc-MAA mapping, a partition model (multi-compartment MIRD) is employed to plan for a radiation dose of 400 (± 30%) to the tumor. If delivering this dose to the tumor is challenging due to lung dose limitations, the maximum feasible dose is administered to the tumor while maintaining the estimated lung dose below 15 Gy. While treating the entire tumor with a single high-dose radioembolization session is preferred, if necessary due to considerations like estimated lung dose, the treatment can be divided into two sessions, keeping the cumulative lung dose below 25 Gy. For any methods not covered in this discussion, refer to the SIR-Sphere user manual by Sirtex.
75865058|NCT03695354|Device|whole body vibration plus conventional therapy|"Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise."
75865059|NCT03695354|Procedure|conventional therapy|conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
75865060|NCT03715699|Drug|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
76028093|NCT05008367|Drug|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
76028094|NCT05008367|Drug|Isotonic saline|6 ml of isotonic saline
76028095|NCT02346175|Drug|SHR3824|
76028096|NCT02346175|Drug|Placebo|
76028097|NCT02342587|Drug|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
76028098|NCT02346331|Other|WHO algorithm of fluid boluses guided by physical examination|
76028099|NCT02346331|Other|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
76028100|NCT02346331|Other|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
76028101|NCT02346331|Other|Oxygen delivery|
76028102|NCT02346331|Other|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
76028103|NCT02346331|Other|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
76028104|NCT05017259|Dietary Supplement|calorie restriction diet|The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
76028105|NCT02342509|Drug|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
76028106|NCT02342509|Drug|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
76028107|NCT02342509|Drug|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
76028108|NCT02342431|Device|Forced air warming compressible|Warming with a compressible forced air mattress
76028109|NCT02342431|Device|Forced air non-compressible|Warming with a non-compressible forced air mattress
76028110|NCT03079271|Drug|Lacrisert, 5 Mg Ophthalmic Insert|
76028111|NCT02342353|Drug|Pacritinib|
76028112|NCT02342353|Drug|Erlotinib|
76028113|NCT02337127|Drug|Lamivudine|Lamivudine, 100mg/day, per os
76028114|NCT02336971|Behavioral|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
76028115|NCT02336971|Behavioral|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
76028116|NCT02337205|Drug|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
76028117|NCT05007587|Drug|Lenvatinib|8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) QD
76028118|NCT05007587|Drug|mFOLFOX regimen|HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.
75374220|NCT04186286|Drug|Propranolol 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
75537745|NCT06178172|Other|Remote home monitoring|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
75865061|NCT03715699|Drug|Prednisone and Leflunomide|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months."
75865062|NCT02708524|Device|Senofilcon C Contact Lens|
76028119|NCT05007587|Drug|ROX regimen|HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
76028120|NCT03078959|Other|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
76028121|NCT05015933|Procedure|Pump refill procedure at home|Implantable pump refill is performed at home
76028122|NCT03146143|Procedure|ultrafiltration|ultrafiltration after cardiopulmonary bypass
76028123|NCT05015465|Diagnostic Test|Anterior Segment OCT|AS-OCT for juvenile SLE patients and compare them with normal subjects
75374221|NCT04186286|Drug|Placebo 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
75537746|NCT06178159|Drug|Disitamab Vedotin Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
75537747|NCT06178159|Drug|Pertuzumab Injection|Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks
75537748|NCT06178159|Drug|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
75537749|NCT06178146|Drug|Thymosin Alpha1|Based on the conventional treatment, subcutaneous injection of Tα-1 (1.6 mg, qd) in Week 1; and in Week 2, subcutaneous injection of thymalfasin 1.6 mg, 3 times a week, followed by twice a week for 1 month since Week 3.
76028124|NCT05015777|Other|Emil Jaques-Dalcroze's Eurhythimcs Exercise Program|"Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece."
76028125|NCT02039323|Drug|Tenofovir|
76028126|NCT02039323|Drug|Maraviroc|
75537750|NCT06178146|Drug|Immunosuppressant|Grade 2 irAEs: corticosteroid alone Grade 3 and above irAEs: corticosteroids combined with other immunosuppressants Steroid-refractory irAE: After 48-72 hours of systemic steroid therapy, the symptoms do not improve or worsen, and the second-line immunosuppressant therapy is adopted.
75537751|NCT06178107|Dietary Supplement|LP-LDL Probiotic|LP-LDL a dietary food supplement probiotic
75537752|NCT06178107|Dietary Supplement|Placebo Comparator|Placebo comparator Maltodextrin
75537753|NCT06178081|Other|Periodontal Healthy|Non surgical periodontal therapy
75865063|NCT02708524|Device|Comfilcon A Contact Lens|
75865064|NCT02708524|Device|Lotrafilcon B Contact Lens|
75865065|NCT02708524|Device|Samfilcon A Contact Lens|
76028127|NCT05015699|Device|HT Supreme|HT Supreme ( R&D by Sinomed, Tianjin, China)
75537754|NCT06178068|Device|Comparison of bronchodilator effectiveness of nebulizer therapy devices|The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.
75865066|NCT03699800|Other|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
75865067|NCT04776408|Device|Lung recruitment combined inhaled Nitric oxide|Ventilator combined inhaled Nitric oxide and Electrical Impedance Tomography monitor the V/Q mismatch
75865068|NCT04776408|Device|Lung recruitment|Ventilator and Electrical Impedance Tomography monitor the V/Q mismatch
75865069|NCT03695198|Drug|LY3361237 - SC|LY3361237 administered SC
75865070|NCT03695198|Drug|LY3361237 - IV|LY3361237 administered IV
76028128|NCT04958161|Other|Exercise Therapy|Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
76028129|NCT02342119|Other|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
75865071|NCT03695198|Drug|Placebo - SC|Placebo administered SC
75865072|NCT03695198|Drug|Placebo - IV|Placebo administered IV
75865073|NCT02773524|Drug|Regorafenib|Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
75865074|NCT02773524|Other|Placebo|Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
75537755|NCT06178042|Combination Product|MI Paste Plus|Briefly, a pea-sized amount of the cream was used once a day and was allowed to remain on the teeth for three minutes after conventional tooth brushing. Patient was advised to not to spit out the cream for 30 seconds to activate the product with saliva. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
75865075|NCT02429596|Drug|Experimental|Switch from brand to generic
76028130|NCT02342119|Other|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
75865076|NCT03418675|Drug|Rexulti|Atypical antipsychotic
75865077|NCT03418675|Drug|Placebo|Pill that contains no medicine
75865078|NCT03695120|Other|Change of treatment plan|Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
75865079|NCT03694964|Drug|ProteoCIT®|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
75865080|NCT03694964|Drug|Placebo Oral Tablet|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
75865081|NCT02421406|Behavioral|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
76028131|NCT03079115|Drug|High-dose Atorvastatin|high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
76028132|NCT03079115|Drug|Conventional-dose Atorvastatin|conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
76028133|NCT02342041|Drug|SUVN-G3031|
76028134|NCT02342041|Drug|Placebo|
76028135|NCT05014997|Other|no intervention|this study was designed as retrospective observational study
75865082|NCT02421406|Behavioral|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
76028136|NCT05255185|Procedure|domino therapy|The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
75865083|NCT02653092|Drug|Insulin|
75865084|NCT02653092|Drug|Intralipid|
75865085|NCT02653092|Drug|Dextrose|
75865086|NCT02653092|Drug|Heparin|
75865087|NCT02653092|Drug|GnRH|
75865088|NCT02653092|Procedure|Hyperinsulinemic Euglycemic Clamp|
75865089|NCT03691454|Drug|Docetaxel|Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.
75865090|NCT03691454|Drug|Oxaliplatin|Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.
75865091|NCT02421484|Biological|Allogeneic mesenchymal stromal cells|The allogeneic mesenchymal stromal cells will be administered intravenously.
76028137|NCT05015075|Behavioral|cardiac rehabilitation|cardiac rehabilitation after pacemaker implantation
75865092|NCT02736318|Biological|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
76028138|NCT04919863|Drug|NTP42:KVA4|Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
76028139|NCT04919863|Drug|Placebo|Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
76028140|NCT05015231|Diagnostic Test|Echocardiography and MRI|Echocardiography and renal MRI before and after fistula closure
76028141|NCT04909177|Other|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
76028142|NCT05917483|Diagnostic Test|Ultrasonography|Collect shoulder rotator cuff tendon ultrasound image during isotonic motion
76028143|NCT05917431|Combination Product|SBRT plus tislelizumab and regorafenib|Participants will receive SBRT plus tislelizumab and regorafenib concurrently
76028144|NCT05917418|Dietary Supplement|nutritional support|nutritional support
76028145|NCT05917405|Drug|Fludarabine|30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
76028146|NCT05917405|Drug|Busulfan|130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
76028147|NCT05917405|Drug|ATG|Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
76028148|NCT05917405|Drug|Clofarabine|30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
76028149|NCT05917392|Dietary Supplement|Fermented Vegetables (Kimchi) supplementation|Fermented Vegetables (Kimchi) supplementation with 50 gm daily for two months and effects of DNA methylation, serum proteome and microbiota
75537756|NCT06178042|Combination Product|Remin Pro|The cream must remain on the teeth for at least three minutes once daily after conventional tooth brushing. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
75537757|NCT06178042|Combination Product|Control|Patients instructed to follow a routine home care.
75865093|NCT03182764|Other|No intervention|No intervention
75865094|NCT03691142|Other|Questionnaire|Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
75865095|NCT03699722|Behavioral|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
75865096|NCT03699722|Behavioral|Information|Format: Information handouts
75865097|NCT02425228|Device|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
76028150|NCT05917392|Dietary Supplement|probiotic|Supplementation with Kimchi plus LGG 50 grams daily for two months
76028151|NCT05917392|Dietary Supplement|polyphenol|Supplementation with Kimchi plus polyphenol 50 grams daily for two months
76028152|NCT05917379|Biological|fecal microbiota|FMT utilizing stool from healthy donor
76028153|NCT05917366|Other|Exercises|Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
76028154|NCT05917366|Other|Coccyx Manipulation|Application of manipulation to relax the levetor ani muscle
76028155|NCT05917314|Other|Slimbiotic Probiotic|"SlimBiotics Probiotic formula contains three probiotic strains of L. fermentum:~Limosilactobacillus fermentum K7-Lb1~Limosilactobacillus fermentum K8-Lb1~Limosilactobacillus fermentum K11-Lb3 The product also contains Microcrystalline cellulose."
76028156|NCT05917314|Other|Placebo|The placebo capsule contains microcrystalline cellulose.
76028157|NCT05917288|Biological|Belimumab|Belimumab will be administered
76028158|NCT05917288|Drug|Standard of care|Standard of care will be administered
75865098|NCT03715543|Procedure|Surgical Resection of the Greater Splanchnic Nerve|"Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated."
75865099|NCT03690908|Other|no intervention (descriptive study)|no intervention (descriptive study)
75865100|NCT03718273|Drug|Ivabradine|"Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good"
75865101|NCT03718273|Drug|Digoxin|The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance <60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
75865102|NCT03690830|Other|metabolomics analysis|collect blood samples and endometrial cells
75865103|NCT02421640|Drug|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
75865104|NCT02421640|Drug|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
75865105|NCT01311193|Other|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
75865106|NCT03417505|Device|Scleral lenses treated with Tangible Hydra-PEG|Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
75865107|NCT03417505|Device|Untreated scleral lenses|Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
76028159|NCT05917249|Device|Capacitive-Resistive Noninvasive Radiofrequency|The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
76028160|NCT05917236|Procedure|hepato-portoentostomy|the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation)
76028161|NCT05917197|Other|survey based information|Only survey based information collected
75865108|NCT02421562|Procedure|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
75865109|NCT02421328|Device|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
75865110|NCT02421328|Device|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
75865111|NCT02425150|Procedure|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
75865112|NCT02425150|Procedure|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
75865113|NCT03715387|Drug|Tacrolimus Topical 0.1% Topical Ointment|Topical tacrolimus ointment
75865114|NCT03715387|Drug|Polysporin Ointment|Polysporin ointment
75865115|NCT02425072|Device|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
75865116|NCT03715309|Drug|Revlimid|Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
75865117|NCT02424994|Other|No intervention|
75865118|NCT02429206|Other|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
75865119|NCT02429206|Other|standard moisturizing cream (Glaxal Base)|
75865120|NCT03182608|Diagnostic Test|Noninvasive ultrasound assessment|An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
75865121|NCT03182530|Device|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
75865122|NCT03182530|Device|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
75865123|NCT03182530|Device|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
75537760|NCT06178016|Other|Bystander Intervention Program for Dating Violence|"The Bystander Intervention Program for Dating Violence includes the following topics: Dating violence and its types (Session 1), risk factors and consequences of dating violence (Session 2), bystander intervention in dating violence and barriers to intervention (Session 3), bystander intervention strategies for dating violence (Session 4), self-care for bystanders witnessing dating violence (Session 5).~Each session is planned to last 60-90 minutes. Materials will be used in the Bystander Intervention Program for Dating Violence are PPT (PowerPoint Presentations) slides, videos, interactive scenarios, and group discussions. The Bystander Intervention Program for Dating Violence is planned to be applied face-to-face in 4 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group."
76028162|NCT05917184|Other|Telehealth|Two video telehealth visits will be conducted and recorded within 3 days of one another (+/- 1 day)
75865124|NCT03179254|Drug|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
75865125|NCT03179254|Drug|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
76028163|NCT05917158|Drug|RC48-ADC and JS001|Patients in group will receive 6 x 2 week cycles of JS001 (Toripalimab) 3mg/kg in combination with RC48-ADC (Disitamab Vedotin) 2mg/kg intravenously.
75374222|NCT02560922|Behavioral|Pain Coping Skills Training (CST)|The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
75865126|NCT02953639|Drug|Basmisanil|Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
75865127|NCT02953639|Drug|Placebo|Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
75865128|NCT04147715|Drug|S-648414|Tablet for oral administration
75865129|NCT04147715|Drug|Placebo|Tablet for oral administration
75865130|NCT04147715|Drug|Midazolam|Solution for oral administration
75865131|NCT04147715|Drug|Dolutegravir|Tablet for oral administration
75865132|NCT02420938|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
75865133|NCT02420938|Drug|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
75865134|NCT02429440|Biological|peptide vaccine|subcutaneous
75865135|NCT02429440|Drug|Granulocyte Macrophage Colony Stimulating Factor|intradermal
76028164|NCT05991674|Diagnostic Test|patch test for diagnosing allergic contact dermatitis|European Baseline Series (EBS) System of allergens
75865136|NCT02429440|Drug|Montanide ISA-51|subcutaneous
75865137|NCT03182452|Other|Alarm Advisor|Providing advice on alarm limits as part of routine medical care
75865138|NCT02429518|Drug|Miltefosine|
75865139|NCT00708526|Other|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
76028165|NCT05991648|Procedure|Kangaroo Care (skin-to-skin contact)|Skin-to-skin contact between the mother and the child. The naked newborn, wearing only a diaper and a hat, is placed in a vertical position in direct contact between the mother's breasts. An elastic fabric support (made of cotton or synthetic elastic fiber) will be used to facilitate the position.
75865140|NCT00708526|Device|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
75374223|NCT04341038|Drug|Tacrolimus|the necessary dose to obtain blood levels of 8-10 ng / ml
75374224|NCT04341038|Drug|Methylprednisolone|120mg of methylprednisolone daily for 3 consecutive days
75537762|NCT06177990|Other|Caregiver as Navigator: Develop Skills Online (CAN-DO) program|"Online, asynchronous psychoeducation program for dementia family caregivers. The program is meant to enhance caregivers' knowledge and skills for navigating healthcare, financial, legal, and family systems.~The program has three main sections.~The first section provides information and how to prepare for using the healthcare system and community-based services in dementia care and support.~The second provides information about how to be more effective when using the financial and legal system either for yourself or your person.~The third section of the course provides information about ways to manage and navigate family dynamics present in various caregiving scenarios more effectively."
75537763|NCT06177990|Other|Healthy Living online course|"Online program for dementia family caregivers about Healthy Living for the first 4 months post-randomization."
75537764|NCT06177964|Drug|Lerapolturev|"Lerapolturev (intratumoral) will be dosed at 2x108 TCID50 in 3.0 mL x 2 doses (total dose 4x108 TCID50) by Convection Enhanced Delivery.~For the patients randomized to the lerapolturev Arm 1 of Stage 2, seven days (±2 days) following completion of the 2nd intratumoral infusion of lerapolturev, patients will begin cervical perilymphatic subcutaneous injection of lerapolturev at a dose of 2 x 108 TCID50 (in 0.5 ml diluent) around the cervical lymph node chain ipsilateral to the intracranial tumor."
75537765|NCT06177964|Drug|Lomustine Pill|Lomustine will be given as a single oral dose of 110 mg/m2 every six weeks for up to 9 cycles.
75865141|NCT03712735|Drug|Bupivacaine 0.08% - fentanyl 2mcg|In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
75865142|NCT02428816|Other|MRI acquisition|MRI acquisitions
75537766|NCT06177951|Other|NICU Discharge Passport|"The NICU discharge passport contains a discharge checklist highlighting important go-to information for infants (feeding plan, medications, pharmacy information, pediatrician, and follow ups post-discharge). It also provides key anticipatory guidance for newborns."
76028166|NCT05991622|Drug|Combined LAI Treatment: Cabenuva and Sublocade|A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
75865143|NCT02428816|Behavioral|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
75865144|NCT03718195|Other|Pediatric Formula|One week intake diary, one week tolerance diary, product intake
75537767|NCT06177951|Other|NICU Infant Care Class|The class will be provided once or twice weekly to eligible study participants. It will be conducted in a small group format. Class teachers will focus on providing key anticipatory guidance to aid in the transition home during the first month of life . Topics related to infant care will be discussed, including feeding, elimination, skincare, hygiene, soothing, development, and when to see a doctor/emergencies.
76028167|NCT05991583|Drug|IBB0979|IBB0979 should be subcutaneous injected，qw
75537768|NCT06177938|Dietary Supplement|Lactose solution/Glucose solution|Single ingestion of a lactose/glucose solution.
75865145|NCT03182218|Drug|Direct oral anticoagulant|Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
75865146|NCT02452554|Other|Laboratory Biomarker Analysis|Correlative studies
75865147|NCT02452554|Biological|Lorvotuzumab Mertansine|Given IV
75865148|NCT02452554|Other|Pharmacological Study|Correlative studies
75865149|NCT03712501|Behavioral|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
75865150|NCT03182374|Device|nSTRIDE APS|Intra-articular injection
75865151|NCT03182374|Device|Synvisc-One|Intra-articular injection
75865152|NCT01319682|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
75865153|NCT01319682|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
75865154|NCT03715075|Procedure|Caesarean Section|Caesarean Section
75537769|NCT06177925|Drug|Adebrelimab|Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
75537770|NCT06177925|Drug|Carboplatin/Cisplatin|Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
75865155|NCT03182062|Procedure|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
75865156|NCT03182062|Procedure|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
75865157|NCT03182062|Procedure|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
75701098|NCT03202017|Procedure|EMST + Lung Volume Recruitment (LVR)|"EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique."
76028168|NCT05991518|Combination Product|Injection of IAH0968+Gemcitabine+Cisplatin|Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.
76028169|NCT05991518|Combination Product|Gemcitabine+Cisplatin|Gemcitabine is administered at a dose of 1000 mg/m2 on the second day (D2) and ninth day (D9) of each cycle. At least 6 hours after the completion of gemcitabine infusion, cisplatin is administered at a dose of 70 mg/m2 on the second day (D2) of each cycle.
75701099|NCT00918008|Genetic|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
75701100|NCT03960320|Other|questionnaire|questionnaire to assess the quality of life of children using KINDL, SDQ and SF-36
75701101|NCT04088162|Device|Postoperative Negative Pressure Wound Therapy KCI NANOVA|
75701102|NCT00736190|Drug|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
75701103|NCT04060797|Device|endovascular denervation|multi-electrode catheter-based endovascular denervation
75865158|NCT02424916|Biological|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
75865159|NCT04009577|Drug|LEM 5 mg|LEM tablet.
75865160|NCT04009577|Drug|LEM 10 mg|LEM tablet.
75865161|NCT03714841|Other|CRP|Knowledge of CRP value
75865162|NCT02176668|Drug|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
75865163|NCT02176668|Drug|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
76028170|NCT05991505|Other|Physical exercise|Multimodal exercises twice a week
75701104|NCT02565771|Other|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
75701105|NCT00729326|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
75701106|NCT00729326|Drug|sitagliptin|oral administration (100mg), once a day in the morning
75701107|NCT00729326|Drug|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
75701108|NCT00729326|Drug|placebo|oral administration (100mg), once a day in the morning
75701109|NCT02565303|Procedure|Intervertebral space|
75865164|NCT02176668|Drug|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
75865165|NCT02176668|Drug|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
75865166|NCT02424838|Procedure|EUS-FNA of pancreatic masses|EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
75865167|NCT02424838|Device|22 gauge needle|
75865168|NCT02424838|Device|25 gauge needle|
75865169|NCT03714763|Drug|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
75865170|NCT03714763|Other|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
75865171|NCT04640532|Drug|KRT-232|KRT-232, administered by mouth
75865172|NCT04640532|Drug|TL-895|TL-895, administered by mouth
75537771|NCT06177925|Drug|Etoposide|Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
75537772|NCT06177925|Radiation|Radiation therapy|IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase
75537773|NCT06177899|Procedure|Splitting of bone and fixation of bone laminae differ between the 3 groups.|In split-box technique, all osteotomies were made using with piezoelectric surgery. Horizontal and vertical osteotomies were performed 1.5 mm away from adjacent teeth. Lower border osteotomy of the vestibular cortical bone was performed. A chisel osteoma was used to separate completely and mobilize the segmented bone. This separated, corticocancellous block was stabilized on the distance to the native alveolar crest with micro screws. The space between the block and the alveolar crest was filled with allograft. In reverse split box technique, differs from the split-box technique as follows: it involves reversing the separated corticocancellous bone block before fixation. In sliding split box technique, differs from the split-box technique as follows: horizontal osteotomy is performed at the level where the bone thickness reaches at least 3 mm. Separated corticocancellous bone block is slid toward the coronal of alveolar crest and fixed in line with the native alveolar bone.
75557507|NCT04702061|Other|Erector spina plane block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
75557508|NCT04702061|Other|Thoracic epidural block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
75701110|NCT02565303|Drug|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
75701111|NCT05476809|Behavioral|smart-cloth assisted home nursing|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
75701112|NCT00696423|Biological|Infanrix™|Intramuscular injection, one dose
75865173|NCT03712423|Drug|Cripec Docetaxel|89 Zirconium Cripec Docetaxel PET
75865174|NCT02424760|Device|Shoulder hemi-arthroplasty|
75865175|NCT03717805|Other|POAM|The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
75865176|NCT02421016|Device|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
75701113|NCT00696423|Biological|Hiberix™|Intramuscular injection, one dose
75865177|NCT02421016|Device|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
75865178|NCT04620252|Drug|Inactive supplement|Chewable candy (negative control), chewed for 30 seconds.
75865179|NCT04620252|Drug|Tricalcium phosphate supplement|Chewable tricalcium phosphate supplement, chewed for 30 seconds.
76028171|NCT05991466|Drug|Dexmedetomidine|"All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications. The required laboratory work will be: complete blood count (CBC); prothrombin time and concentration (PT&PC); partial thromboplastin time (PTT); bleeding time (BT); clotting time (CT); liver function tests and kidney function tests.~Before arrival to the operation room (OR), women will be premedicated by metoclopramide 10mg and ranitidine 50 mg intravenous. Intra operatively, hemodynamics will be recorded baseline before spinal anaesthesia , after its performance, every 3 minutes until delivery and then every 10 minutes till the end of the CS. Any change within 20% of baseline will be accepted and any changes more than 20% will be managed according to guidelines. All groups will be anaesthetized to preform CS with conventional spinal anaesthesia. The TAP block group will receive a landmark orientated Ultrasound guided bilateral TAP block."
76028172|NCT05991388|Drug|Odronextamab|CD20xCD3 bispecific antibody
75374225|NCT04743050|Drug|Fatty Acids, Unsaturated|All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
75537774|NCT06177873|Other|foot bath|On the morning of surgery, the purpose of the study will be explained to the patients and their written consent will be obtained. Then, Introductory Information Form, STAI and VASS were applied. The pain level of the patients will be evaluated with VAS-Pain 4 hours after the surgery. SAI and VAS-Comfort will be applied to patients with pain level 4 and above. Then, patients in the experimental group will receive a hot water foot bath for 20 minutes. Before the hot water foot bath, patients will be lifted from their beds and placed on the chair in the room. Hot water will be poured into the foot bath tub and the patient will be asked to put his feet in the water. The water level will be adjusted to include the patients ankles. The temperature of the water will be constantly checked with a water thermometer and kept at 41-42 °C. A hot water foot bath will be applied for 20 minutes and then the patients feet will be dried with a towel.
75537775|NCT06177847|Device|BIS|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
75537776|NCT06177834|Device|Alisklamp|Alisklamp
75865180|NCT04620252|Drug|Calcium carbonate supplement|Chewable calcium carbonate supplement, chewed for 30 seconds.
76028173|NCT05991388|Drug|Loncastuximab tesirine|CD-19-directed antibody-drug conjugate
75537777|NCT06177834|Other|Dorsal slit circumcision technique|In this group, included the patients who will operated with dorsal slit circumcision technique
75537778|NCT06177821|Device|Rezum®|Rezum® Water vaporization device
75537779|NCT06177808|Device|Wolverine cutting balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Wolverine cutting balloon for calcium modification.
75537780|NCT06177808|Device|Non-compliant balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Non-compliant balloon for calcium modification.
75537781|NCT06177782|Device|Tooth modified scan bodies|Tooth modified scan bodies are used during scanning for full arch implant cases.
75537782|NCT06177782|Device|Conventional scan bodies|Conventional scan bodies will be used for scanning the full arch implant cases.
76028174|NCT05991388|Drug|Rituximab|Modified R-ICE chemotherapy
76028175|NCT05991388|Drug|Ifosfamide|Modified R-ICE chemotherapy
76028176|NCT05991388|Drug|Carboplatin|Modified R-ICE chemotherapy
76028177|NCT05991388|Drug|Etoposide|Modified R-ICE chemotherapy
76028178|NCT05991388|Drug|Etoposide Phosphate|Modified R-ICE (Treatment Arm II)
75537783|NCT06177769|Device|LMA classic|Airway is secured with LMA clasic
76028179|NCT05991388|Drug|Dexamethasone|Modified R-ICE chemotherapy
75865181|NCT04620252|Drug|Calcium citrate supplement|Chewable calcium citrate supplement, chewed for 30 seconds.
76028180|NCT05991388|Biological|CAR T-cells (TBC)|Modified R-ICE chemotherapy
76028181|NCT05991375|Drug|DEXmedetomidine|28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL
76028182|NCT05991375|Other|saline|28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL
76028183|NCT05991336|Genetic|Gene therapy|Autologous edited hematopoietic stem cell transplantation
76028184|NCT05991297|Other|Deep sensory assisted rehabilitation|"A new PTR plan called deep sensory assisted rehabilitation was created: it was aimed to develop a sensory and deep sense in the adult age group by making use of sensory integration exercises, which are mostly applied in the childhood age group. Whether these exercises are effective on walking and balance will be evaluated. Patients will be dressed in a vest with an equally distributed weight of 4-6 kg according to their weight, and exercises will be done while walking and standing.~- the so-called deep sensory pathway; The patients will be given standing and walking exercises on sand and stone floors, soft floors made of sponge, hard plastic floors with different sizes of grooves and shapes, and hot-cold floors formed by placing hot packs and cold packs."
76028185|NCT05991297|Other|classical rehabilitation|Muscle strengthening in all four extremities; strengthening of trunk and abdominal muscles; providing and maintaining joint range of motion; independent and safe standing, turning, and stepping; able to walk alone on flat ground and on different surfaces (such as sloping-handicapped-soil-stone-sand-grass-rough-stepped)
76028186|NCT05991245|Other|Collecting datas|Blood, Tissue and Urine samples
76028187|NCT05991141|Other|Apnea|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.
76028188|NCT05991141|Other|Control Intervention|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
75537784|NCT06177769|Device|LMA Proseal|Airway is secured with LMA proseal
75537785|NCT06177769|Device|I-gel|Airway is secured with I-gel
75865182|NCT04620252|Drug|Inactive supplement and fluoride mouthwash|A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
75557509|NCT00465075|Drug|Bazedoxifene/conjugated estrogens combination|
75557510|NCT00434486|Drug|SKI-606|
75557511|NCT00465114|Procedure|Hemodynamic Monitoring|
75557512|NCT00434525|Procedure|Laparoscopic restrictive procedure|Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
75557513|NCT00434525|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
75865183|NCT04620252|Drug|Calcium carbonate supplement and fluoride mouthwash|A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
75865184|NCT04620252|Drug|Calcium citrate supplement and fluoride mouthwash|A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
75537786|NCT06177756|Behavioral|Nutritional and lifestyle counseling|"At risk children Intervention Arm: schedule at least four visits/year with anthropometric monitoring, educate parents on the appropriate diet, active lifestyle from the first year of life, regular self-monitoring of their child's anthropometry and appropriate dietary composition and portion control, provide tailor-made nutritional suggestions.~Not-at-risk children Intervention Arm: educational website with interactive tools for growth self-monitoring and diverse lifestyle suggestions."
75537787|NCT06177743|Device|Coroflex ISAR NEO stent|Percutaneous coronary intervention with Coroflex ISAR NEO stent
76028189|NCT05991115|Behavioral|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
75865185|NCT03694886|Drug|Caffeine Anhydrous with small sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
76028190|NCT05991037|Biological|Blood sampling for psychoactive drugs dosage|4 blood samples for psychoactive drugs identification and dosage will be taken on arrival at the emergency room during fall management
75865186|NCT03694886|Other|Placebo - large sucrose pill|sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups
76028191|NCT05991011|Other|Immersive and Interactive Wall Exergames|This intervention will be performed using the Neo One device. It was chosen because of the variety and quality of the games offered which are accessible to older people. The target intensity of core workout will be moderate. Five to 7 five-minutes games will be selected from 19 games. A variety of materials will be used (e.g., basketball, rugby, handball ball, balloon, chair, hoop, rhythm ladder, tennis racket). The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity. Interventions will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Neo One device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants.
75865187|NCT03694886|Drug|Caffeine Anhydrous with large sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
75865188|NCT03694886|Other|Placebo - small sucrose pill|sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
75865189|NCT04146467|Device|Renuvion APR Device|The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
75865190|NCT02429128|Other|14 weeks exercise training|
75865191|NCT05602675|Drug|LY3871801|Administered orally.
75865192|NCT05602675|Drug|Methotrexate|Administered orally.
75865193|NCT05602675|Drug|Warfarin|Administered orally.
75865194|NCT05602675|Drug|Dextromethorphan|Administered orally.
75537788|NCT06177730|Other|Pre-Hospital ECPR|Implementation of pre-Hospital ECPr in OHCA
75537789|NCT06177678|Drug|TFC-003|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
75865195|NCT05602675|Drug|Midazolam|Administered orally.
76028192|NCT05991011|Other|Complex Cognitive and Motor Activities program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving cooperation and opposition exercises inspired by team sports (basketball, volleyball, rugby) and individual sports (boxing, weight training), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants. The target intensity of body workout will be moderate. The first part will be focused on endurance and the second on muscle strengthening and coordination work in the form of circuit training. A variety of equipment will be used (e.g., tennis balls, basketballs, volleyballs, rugby balls, balloons, elastics, chairs, blocks). The number of partners and/or opponents will be changed regularly.
76028193|NCT05991011|Other|exergames program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, physically active (standing). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Nintendo Switch device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants. The games (Fitness Boxing 2, Switch Sport, Just Dance 2020, 2021, 2023, Let's Get Fit, Mario and Sonic at the Olympic Games Tokyo 2020, Instant Sport, Ring Fit, Zumba Burn It Up!) will be carried out in the form of circuit training, in pairs or groups of 4. The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity.
75537790|NCT06177678|Drug|COSOPT ophthalmic solution|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
75537791|NCT06177626|Behavioral|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day
75537792|NCT06177626|Behavioral|Balance Training|Training 5x a week for 30 minutes. Standard of care.
75537793|NCT06177613|Procedure|Blank culture transfer|A maximum of 0.1 ml of gassed embryo culture medium preheated to 37°C is injected into the uterine cavity transcervically using an embryo transfer catheter placed just beyond the internal os, two to 3 days before transfer of the thawed embryo
75537794|NCT06177613|Procedure|Sham transfer|An intermediate transfer step is added two or three days before the planned transfer of the frozen embryo but with an empty catheter.
75865196|NCT05602675|Drug|Repaglinide|Administered orally.
75865197|NCT02421250|Device|Radical-7 Noninvasive Hgb Monitor|
75865198|NCT03714685|Drug|Firibastat|Firibastat (QGC001) 500 mg
75865199|NCT03699566|Other|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
75865200|NCT03699566|Other|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
75537795|NCT06177587|Other|Assesment of biomarkers in acute coronary syndromes|Collection of 20ml of blood from peripheral vein.
75865201|NCT03699566|Other|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
75865202|NCT03714607|Device|Erbium Yttrium Aluminum Garnet (Er:YAG) laser|5 Er:YAG laser therapies vaginally administered at monthly intervals
75865203|NCT03694730|Other|Exercise Treatment|Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
75865204|NCT03694730|Other|Pain- Guided Activity Modification|Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
75865205|NCT03444181|Behavioral|Music lessons|Also described as neurocognitive music therapy. Singing lessons will be provided once a week for a period of 12 months by a person with a qualification in music therapy, or by a person with a different relevant qualification (e.g. psychology and music teaching) under the supervision of a music therapist. Additionally, participants will have the opportunity to meet regularly (1-2 times per month) as a choir to sing the song they have learned together in a group.
76028194|NCT05991011|Other|video games program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, while being inactive (sitting). The sessions will consist in one-hour single and multi-players games, using the Nintendo Switch device, in groups of 6 participants.
76028195|NCT05991011|Other|Bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this active comparator intervention, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike at about 50% of Heart Rate Reserve, and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
76028196|NCT05991011|Other|Video games + bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this experimental arm, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike (like BIKE program at about 50% of Heart Rate Reserve) and at the same time playing on a Nintendo Switch (like VG program), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
76028197|NCT05990998|Drug|68Ga-DOTATATE and 68Ga-FAPI|Each patient receive a single intravenous injection of 68Ga-FAPI or 68Ga-DOTATATE (2-4mCi) , and undergo PET/CT scan at 40-60 min post injection.
76028198|NCT05990972|Procedure|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation (FMT) is a therapeutic method to transplant the microbiota from the feces of healthy people into the intestinal tract of patients. This treatment aims to improve a range of diseases associated with the gut microbiota by restoring the balance of the gut microbiota.
76028199|NCT05990959|Other|No intervention for research purpose|No any intervention will be applied under research purpose. All procedure or drugs would be given to the patient under best clinical judgment, not for research purpose.
76028200|NCT05990946|Procedure|ePRO based Remote Symptom Management|Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management.
75537796|NCT06177574|Drug|BIC/FTC/TAF|TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
75865206|NCT03444181|Behavioral|Training intervention|Cognitive training that is comparable in scope and extent to the music lessons, but not using music. Group training sessions will be provided once a week for a period of 12 months by a person with a qualification in physiotherapy or occupational therapy. Group activities may include group tours such as mountain hikes and the like (about 2 times per month) and will follow an established program for the elderly.
75865207|NCT03690752|Device|unweighting using Alter-G Anti-Gravity Treadmill|The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
76028201|NCT05990933|Drug|Adrenaline|Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
75374226|NCT04743050|Diagnostic Test|Diagnostic Tests|All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
75537797|NCT06177561|Procedure|Lymphoplasma exchange|The LPE treatment regimen is: LPE*2 times (20-30ml/kg, treatment interval of 2 days);CD20 monoclonal antibody 375mg/m2*2 times, gamma globulin 0.4g/kg/d*5d.
75865208|NCT03690752|Device|normal weight using Alter-G Anti-Gravity Treadmill|The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
75865209|NCT02705716|Other|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
75865210|NCT02705716|Other|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
76028202|NCT05990907|Procedure|Remote ischemic preconditioning|The empty tourniquet (VBM Tourniquet Touch®, Sulz a.N. Germany) is attached to the right upper arm. The measurement starts from this point in time. After lying flat for 10 minutes, the upper arm tourniquet is inflated to 250 mmHg. In all subjects, the ischemia was verified by palpation and Doppler signal of the radial artery. The ischemia phase is carried out for 10 minutes, so the tourniquet is opened and a 10-minute reperfusion phase is started, followed by a total of 3 cycles. After the 3rd ischemia phase, the tilting table test is followed by a 15-minute lying interval.
76028203|NCT05990881|Drug|Botulinum toxin|Patients in this group will receive an injection of Botulinum toxin.
76028204|NCT05990881|Drug|Standard-of-care corticosteroid injections|Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.
76028205|NCT05990868|Drug|Tylenol|Rectal tylenol will be placed at the time of oocyte retrieval
76028206|NCT05990842|Drug|Antibiotic|the individual will receive 1 dose of antibiotic during anesthetic induction
76028207|NCT05990842|Other|placebo|the individual will receive 10 ml of saline during anesthetic induction
76028208|NCT05990829|Drug|Ozurdex|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of Ozurdex will be performed at the end of the surgery.
75374227|NCT02561702|Other|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
75374228|NCT02561702|Drug|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
75537798|NCT06177548|Procedure|Minimally invasive Bentall procedure|The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
75537799|NCT06177535|Dietary Supplement|Kavalactones|Three 75 mg capsules orally once daily within one hour of bedtime (225 mg total/day)
75537800|NCT06177535|Drug|Placebo|Three capsules orally once daily within one hour of bedtime. Looks exactly like the study drug, but it contains no active ingredient.
75537801|NCT06177522|Drug|Adbelimumab|1200mg，i.v. , q3w
75537802|NCT06177522|Drug|albumin-bound paclitaxel|125 mg/m2, i.v.,d1,d8, q3w
75537803|NCT06177522|Drug|Gemcitabine|1.0 g/m2, i.v.,d1, d8, q3w
75557514|NCT00465153|Dietary Supplement|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
76028209|NCT05990829|Drug|Aflibercept|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of aflibercept will be performed at the end of the surgery.
75865211|NCT01374672|Other|laboratory biomarker analysis|Correlative studies
75865212|NCT03714529|Biological|PD-L1|IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
75374229|NCT02563496|Drug|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
75865213|NCT04138043|Drug|Placebo|Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
75865214|NCT04138043|Drug|GSK2330811|GSK2330811 will be available as SC injection 150 mg/mL.
75865215|NCT03699488|Behavioral|psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
75865216|NCT03116620|Other|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
76028210|NCT05990816|Diagnostic Test|Blood works for homocysteine levels|In a single patient group of 80 people, the natural course of homocysteine after total joint arthroplasty will be examined by blood work analyzes at the 1,2,3,4 and 6th weeks after operation
76028211|NCT05990725|Biological|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
76028212|NCT05990712|Dietary Supplement|Omega-3|Omega-3 is a fatty acid and there is evidence that the consumption of re-esterified oral omega-3 supplements over the course of 6 to 8 weeks aid in reducing inflammation, dry eye, and optimizing tear osmolarity. The oral omega-3 supplement taken daily.
76028213|NCT05990712|Drug|Trehalose|Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.
76028214|NCT05990712|Drug|Zocular Eyelid System Treatment|A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.
75865217|NCT02429050|Drug|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
75557515|NCT00465153|Behavioral|Resistance exercise training|Resistance training
75557516|NCT02957552|Biological|Mesenchymal Stem Cells|Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
75557517|NCT00465192|Drug|estradiol, 10 mcg|
75557518|NCT00465192|Drug|estradiol, 25 mcg|
75557519|NCT00465192|Drug|placebo|
75557520|NCT00434564|Procedure|Stress nuclear scan|
75865218|NCT02429050|Drug|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
75865219|NCT04479488|Other|Hospital admission|Usual care.
75865220|NCT04479488|Other|Non-hospitalization procedures|Usual care.
75865221|NCT01311427|Behavioral|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
75557521|NCT00434603|Behavioral|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
75557522|NCT00434681|Drug|paracetamol 4.8% paediatric oral suspension|
75557523|NCT00473070|Drug|Tobradex AF|
75557524|NCT03272646|Procedure|surgery|gastric resection or total gastrectomy
75701114|NCT05325944|Behavioral|Self-guided digital intervention for NSSI|"Psychoeducational content, skill-based practice, and daily ecological momentary assessments will be delivered over an 8-week period.~Psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies."
75701115|NCT05325944|Behavioral|Digital intervention for NSSI with coaching|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies. Human coaching will be used to support intervention use and engagement twice per week via text, call or email.
75374230|NCT02563496|Drug|Chloroquine|Subjects may receive chloroquine according to local/national treatment guidelines.
75701116|NCT05325944|Behavioral|Active control|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies.
75701117|NCT02592668|Device|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
75374231|NCT02563808|Other|Standard Decision Aid|Females will receive standard decisions aid for early stage breast cancer.
75374232|NCT02563808|Other|Post-surgical Regret Decision Aid|Females will receive anticipated regret-augmented version for early breast cancer.
75374233|NCT02540161|Drug|Sym004 - 18 mg/kg|Sym004 was dosed at 18 mg/kg intravenously every two weeks.
75374234|NCT02540161|Drug|Sym004 - 24 mg/kg|Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
75374235|NCT02467465|Other|Physical therapy modalities|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
75374236|NCT02467465|Device|Invasive Physical therapy modalities|Dry needling added to massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
75374237|NCT02564354|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
75865222|NCT01311427|Behavioral|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
75865223|NCT02417142|Drug|Exenatide|Exenatide SQ 2mg/week for 24 weeks.
75865224|NCT02417142|Drug|Placebo|Placebo SQ 1x/week for 24 weeks.
75865225|NCT03179098|Other|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
75374238|NCT02467777|Device|Bair Hugger|
75374239|NCT02467777|Device|VitaHeat|
76028215|NCT05990712|Other|Blephadex cleansing eyelid wipes|Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.
75374240|NCT02540629|Procedure|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
75865226|NCT03179098|Other|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
75701118|NCT00736034|Dietary Supplement|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
75701119|NCT00918164|Drug|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
75374241|NCT02568644|Dietary Supplement|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).
75865227|NCT03179098|Other|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
75865228|NCT04477928|Diagnostic Test|Sera and whole blood sampling|"Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry.~2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies~5 years old: T1D and celiac autoantibodies~9-16 year old: one-time T1D and celiac autoantibodies~Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies"
75865229|NCT04477928|Diagnostic Test|Differential Gene Expression (DGE)|Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
75374242|NCT02568644|Other|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
75374243|NCT02568644|Drug|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
75865230|NCT01374750|Drug|Sirolimus|Sirolimus
75865231|NCT01374750|Drug|m-TOR inhibitor free|calcineurin inhibitors
75865232|NCT03106792|Dietary Supplement|Hairfinity #1|Main Hairfinity formulation
75374244|NCT02541409|Drug|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
75865233|NCT03106792|Dietary Supplement|Hairfinity #2|Variation to main formulation
75374245|NCT02541409|Drug|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
75374246|NCT02541409|Drug|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
75537804|NCT06177509|Other|Graded Aerobic Exercise|Participants will follow a sub-symptom aerobic exercise program (approx. 30 min) 3 - 5 times pr week for twelve weeks. Sub-symptom threshold aerobic exercise means to exercise at 80-90% of the maximum threshold heart rate achieved during the BCTT. To ensure proper exercise dose and progression, participants will be retested every three weeks. During the first three weeks, the participants will be offered one weekly guided exercise session. The other 2 - 4 weekly sessions the participants will carry out on their own, choosing activities based on experience, preferences and possibilities (e.g. walking, jogging, stationary bike, swimming). The intensity of the sub-symptom threshold aerobic exercise will be monitored using a heart rate monitor and the BORG scale. Compliance with the sub-symptom threshold aerobic exercise program will be recorded by the patients in an exercise diary, which is followed up by a weekly reminder over the phone/sms by a physiotherapist in the project.
75537805|NCT06177496|Procedure|local ablation|treatment of HCC
75537806|NCT06177496|Procedure|TACE|treatment of HCC
75865234|NCT03106792|Dietary Supplement|Hairfinity #3|Variation to main formulation
75865235|NCT03106792|Dietary Supplement|Placebo|No active ingredients
75865236|NCT03443713|Device|Dexcom G6 CGM|Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
75865237|NCT03106558|Device|Total Knee Arthroplasty using Manual Instrumentation|
75865238|NCT03106558|Device|Total Knee Arthroplasty using Robotic Arm|
75865239|NCT03694574|Behavioral|instruction to suppress|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, & Hoffmann, 2011)"
75865240|NCT03694574|Behavioral|instruction to reappraise|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning. (Szasz et al., 2011)"
75865241|NCT03694574|Behavioral|control|No instruction
75865242|NCT01977144|Other|Comprehensive Chromosomal Screening|
75865243|NCT03717649|Device|Conventional 2-stage venous cannula|venous cannula
75374247|NCT02569112|Device|multipolar RF, varipulse|Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
75865244|NCT03717649|Device|Conventional 3-stage venous cannula|venous cannula
75374248|NCT02569112|Device|cryolipolysis|Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
75374249|NCT02569658|Drug|Tranexamic Acid|
75374250|NCT02569658|Drug|Placebo|
75374251|NCT02541565|Drug|Cyclophosphamide|Given IV
75374252|NCT02541565|Drug|Doxorubicin Hydrochloride|Given IV
75374253|NCT02541565|Other|Laboratory Biomarker Analysis|Correlative studies
75374254|NCT02541565|Biological|Pembrolizumab|Given IV
75537807|NCT06177496|Drug|Sorafenib|treatment of HCC
75374255|NCT02541565|Drug|Prednisone|Given PO
75374256|NCT02541565|Biological|Rituximab|Given IV
75374257|NCT02541565|Drug|Vincristine Sulfate|Given IV
75537808|NCT06177470|Device|Accelerated deep iTBS|Accelerated intermittant teta burst deep Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
75374258|NCT04708184|Drug|GLPG3970 oral solution|GLPG3970 for oral administration
75537809|NCT06177470|Device|Accelerated Sham iTBS|Sham accelerated intermittant teta burst Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
75537810|NCT06177444|Drug|Antibiotic|Postoperative antibiotic treatment
75537811|NCT06177431|Drug|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
75537812|NCT06177405|Drug|genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors|drug therapy
75865245|NCT03717649|Device|Fenestrated 3-stage venous cannula|venous cannula
75374259|NCT04708184|Drug|GLPG3970 tablet|GLPG3970 for oral administration
75537813|NCT06177379|Other|healthy volunteer|Volunteers age between 50 and 75 years
75537814|NCT06177366|Diagnostic Test|Blood sampling|Blood samples will be collected at diagnosis, in the same time as BOM is performed
75537815|NCT06177353|Other|Sampling|Blood sampling Skin biopsy Collection of soiled bandages
75537816|NCT06177340|Device|visualization of the sacrospinous ligament|visualization of the sacrospinous ligament by the Nanoscope system during sacrospinofixation
75865246|NCT03182140|Drug|Kyleena|Kyleena - intrauterine delivery system containing 19.5 mg LNG
75865247|NCT03694496|Behavioral|peer-led theory-based intervention group|"We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader."
76028216|NCT05990686|Drug|Tramadol Hydrochloride|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)"
75537817|NCT06177327|Other|Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.|Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
75557525|NCT00434798|Biological|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10^6-10^9 CFU
75865248|NCT01374828|Drug|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
76028217|NCT05990686|Drug|Fentanyl injection|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~."
75537818|NCT06177314|Other|correlate the molecular signatures of active lesions of contact dermatitis with allergological results|Data will be collected retrospectively and prospectively from patients' medical records, and will include: clinical information (history, treatments, lifestyle, exposures, lesion location and appearance), patch-test results, histological analysis results, molecular analysis results.
75537819|NCT06177288|Combination Product|DEBIRI Combined With Chemotherapy and Bevacizumab|After dissolving 100 mg of irinotecan in water for injection or 4ml of 5% glucose water.use 2mL of 70μm uniform particle size microspheres for loading and adsorption for 5minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
75537820|NCT06177275|Procedure|Placement of BLX implants 2 mm sub-crestal i|Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
75865249|NCT04133519|Device|Arm 1 - Active behavioral Treatment Arm (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD)|The active treatment consists of 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks (SaMD). Since subjects in both the active and comparator treatment arms receive a behavioral treatment, the subjects are blinded to active treatment.
75537821|NCT06177275|Procedure|Placement of BLX implants equicrestal|Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
76028218|NCT05990673|Drug|Remimazolam|remimazolam is given intravenously
76028219|NCT05990647|Diagnostic Test|Dynamometric tension assessment|"Tension dynamometry was carried out using the Back-Check 600 diagnostic complex by Dr.WOLFF® (GmbH, Germany). The dynamometric stress assessment included tasks for flexion and extension of the body. The functional assessment of the abdominal wall muscles was assessed when preparing the patient for surgery (1-10 days before AWR-abdominal wall reconstruction) and 6 months after AWR."
76028220|NCT05990647|Diagnostic Test|Postural balance|"Postural balance was assessed using raster photostereography and baropodometry on the DIERS diagnostic complex by Formetric-4D (GmbH, Germany). When analyzing the topography of the optical field, muscle imbalance is revealed in the form of lateral deviation and inclination of the trunk and pelvis, as well as the values of the angle of kyphosis and lordosis. When conducting baropodometry, the level of displacement of the pressure area on the feet of patients in a static and dynamic position was assessed. Diagnosis of postural balance in patients with incisional ventral hernia was performed a few days before surgical treatment and 6 months after AWR."
76028221|NCT05990647|Diagnostic Test|Assessment of the hernia defect size|"Parameters of the hernial defect, including the volume of the hernial sac, the diameter of the hernial orifice, the ratio of hernia volume to the abdominal cavity volume, were performed using preoperative (1-10 days before AWR) multispiral computed tomography on a GE BrightSpeed 16 tomograph (General Electric©, USA)"
76028222|NCT05990647|Diagnostic Test|Physical activity of patients|"To analyze the physical activity of patients, the measurement of the number of steps was used. The measurements of steps and the amount of distance traveled were carried out using a physical activity monitor - a fitness bracelet MiBAND (China). Measurements were taken 10 days before AWR and within 6 months after AWR."
76028223|NCT05990634|Device|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart t-shirt, smart scale, location home sensor, and a micro-computer, with which they will need to interact with the devices for three months in the respective study phase (pre-pilot/feasibility trial). Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. The smart t-shirt should as well be worn daily as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home sensor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
76028224|NCT05990621|Biological|Anti-CD70 CAR-T cells|0.6×106/Kg ～ 5.0×106/Kg; cells will be infused intravenously.
75865250|NCT04133519|Device|Arm 2 - Active Comparator behavioral treatment arm (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)|The comparator treatment consists of an identical treatment platform, scheduling platform, and reminder platform as the Active Treatment Arm, but in place of Gut-Directed Hypnotherapy there is a comparator relaxation treatment administered on an identical schedule: 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks.
75865251|NCT05567497|Procedure|trigeminal nerve block|ultrasound guided trigeminal nerve block
75537822|NCT06177262|Behavioral|cognitive behavioral therapy|Cognitive behavioral therapy for eating disorders.
75537823|NCT06177249|Biological|Control vaccine|A group of 652 subjects were vaccinated with the control vaccine at 0, 3, 7, 14 and 28 days (5 doses in total). Blood samples were collected from the subjects at 0, 7/14 and 35/42 days for antibody detection.
75537824|NCT06177249|Biological|Experimental vaccine|A total of 652 subjects received 5 doses of the vaccine at 0, 3, 7, 14 and 28 days. Blood samples were collected on 0, 7/14 and 35/42 days for antibody detection.
75537825|NCT06177236|Diagnostic Test|cervical cancer screening|The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.
75537826|NCT06177223|Behavioral|Cognitive Behavioral therapy|CBT-based treatment plan would be designed to address PTSD and associated problems.
75865252|NCT03181906|Other|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
75865253|NCT03714295|Other|Use of interdental brushes|No intervention they just use interdental brushes as it should be done routinely
75865254|NCT02424682|Other|No intervention|No intervention administered in this study
75865255|NCT01373502|Device|DES Limus Carbostent|DES Limus Carbostent Carbofilm Coated Coronary Stent
75865256|NCT01373502|Device|Taxus Liberté Stent|Taxus Liberté Coronary Stent
75865257|NCT03690362|Drug|VNRX-5133 and VNRX-5022|intravenous infusion
75865258|NCT03714217|Behavioral|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
75865259|NCT03746171|Diagnostic Test|Colonic polyp characterization by BLI|"All rectosigmoid <5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated."
76028225|NCT05990608|Other|Peabody Developmental Motor Scales-2, PDMS|"The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as very low, low, below average, above average, high, very high."
75537827|NCT06177197|Device|Physiomer|"Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~Infant < 6 months: half a dose to a single dose administered per nostril 8 times a day.~Infant > 6 months: one single dose administered per nostril 6 times a day."
76028226|NCT05990582|Diagnostic Test|CBCL|A questionnaire on behaviour
76028227|NCT05990582|Diagnostic Test|SDQ|A questionnaire on behaviour
76028228|NCT05990582|Diagnostic Test|CCC-2-NL|A questionnaire on communcational skills
76028229|NCT05990582|Diagnostic Test|MCH Feeding scale|A questionnaire on feeding problems
76028230|NCT05990582|Diagnostic Test|TRF|A questionnaire on behaviour
76028231|NCT05990582|Diagnostic Test|WISC-5-NL|An IQ test for children
76028232|NCT05990582|Diagnostic Test|Movement ABC|A test to assess motor function
76028233|NCT05990582|Diagnostic Test|CELF-5-NL|A test to assess language development
76028234|NCT05990582|Diagnostic Test|Emma Toolbox|Test of executive functions
76028235|NCT05990556|Procedure|interventional procedure to block bilateral meningeal blood supply|"The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue (liquid embolic system). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging."
76028236|NCT05990543|Drug|Nelmastobart and Capecitabine|"Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle.~Capecitabine is administered orally for two weeks followed by a one-week rest period"
76028237|NCT05990530|Biological|YD02-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
76028238|NCT05990517|Biological|YD01-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
76028239|NCT05990374|Drug|Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc|The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.
76028240|NCT05990348|Other|difficult weaning patients|intercostal thickening fraction values during PSV and NAVA modalities in patients with difficult weaning from MV admitted in ICU.
75865260|NCT03717493|Behavioral|Affect Regulation Training|Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking & Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
75865261|NCT04477694|Procedure|colonoscopy under sedoanalgesia|Colonoscopy is a widely used method for diagnosing and treating colonic diseasea with a thin, flexible camera.
76028241|NCT05990322|Behavioral|Project EMPOWER|Experimental Condition
76028242|NCT05990309|Diagnostic Test|skin biopsy|skin biopsy for immunohistochemical staining and assessment of tissue expression of tristetraprolin
75537828|NCT06177197|Device|Saline solution|"Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~Infant < 6 months: half a dose to a single dose administered per nostril 8 times a day.~Infant > 6 months: one single dose administered per nostril 6 times a day."
75557526|NCT00473109|Procedure|Dialysis without systemic heparinization|Dialysis without systemic heparinization
75865262|NCT03634332|Drug|PEGPH20|PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
75865263|NCT03634332|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
75865264|NCT03744767|Drug|Spironolactone 50 MG|oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
76028243|NCT05990296|Behavioral|Multiprong CDS with referral to pharmacist co-management|Accepting the clinician-facing BPA default recommendation will have eligible patients within this arm referred to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
75557527|NCT00434915|Drug|DHEA|
75557528|NCT00473148|Procedure|BNP-guided weaning|BNP-guided weaning
75557529|NCT00473148|Procedure|Standard physician-directed weaning|Standard physician-directed weaning
75557530|NCT00435032|Procedure|early appendectomy|Appendectomy within 24 hours of admission
75865265|NCT02428972|Drug|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
75865266|NCT02428972|Drug|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
75374260|NCT04707950|Drug|Tranexamic Acid 100 milligram/Milliliter|"Participants will be divided into two groups: a study group & a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~Bleeding continues after 30 minutes~Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
75865267|NCT03634254|Other|Satisfaction survey of communication quality:|a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
75374261|NCT04707950|Drug|Oxytocin|both groups will be given oxytocin as a standard management
75374262|NCT03681236|Procedure|Alveolar recruitment maneuver|Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
76028244|NCT05990296|Behavioral|Multiprong CDS with GDMT order set|Accepting the clinician-facing BPA default recommendation will open an order set for GDMT that lists common recommended options in such a way that facilitates optimal prescribing. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
75557531|NCT00435032|Procedure|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
75865268|NCT02428660|Genetic|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
75865269|NCT02428660|Other|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
75865270|NCT02428660|Other|MTM|Medication Therapy Management
75865271|NCT03694340|Other|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
75865272|NCT03699332|Drug|Indium-111-DOTA-Labetuzumab-IRDye800CW injection|Tracer injection
75865273|NCT03699332|Radiation|SPECT/CT scan|Abdominal and thoracic SPECT/CT scan.
75865274|NCT03699332|Procedure|CRS extended with dual-modality imaging|cytoreductive surgery will be performed extended with the use of dual-modality imaging.
75865275|NCT03179176|Other|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
75865276|NCT04007159|Other|Serum|Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square [mL/cm^2] of serum in an individual cell of patch)
75865277|NCT04007159|Other|Lotion|Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of lotion in an individual cell of patch)
75865278|NCT04007159|Other|Cream|Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of cream in an individual cell of patch)
75865279|NCT04007159|Other|Normal Saline|Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of normal saline in an individual cell of patch)
75865280|NCT04483024|Dietary Supplement|Collagen hydrolysate and chicken extract|One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
75865281|NCT03690128|Behavioral|I-EWS with incorporated clinical assessment (Trigger Tool)|In relation to systematic measurement of vital parameters the nursing staff will perform an individual clinical assessment of the patient and adjust the I-EWS score accordingly.
76028245|NCT05990296|Behavioral|Focused education|A series of focused, interactive education sessions will train clinicians in why, when, and how to prescribe GDMT to patients, with incentives such as continuing medical education (CME) credits, and with virtual and recorded options available to those who are unable to attend in-person meetings.
76028246|NCT05990270|Behavioral|education|Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
76028247|NCT05990218|Device|Artificial intellegence. CADe syste,|The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.
76028248|NCT05990218|Device|control|The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.
76028249|NCT05990205|Drug|Life Style Intervention + Metformin|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours
75865282|NCT03690128|Behavioral|Standard EWS - Control (Trigger Tool)|Standard EWS - Based on principles of National Early Warning Score (NEWS)
75865283|NCT03119688|Other|Test Product|Micellar cleanser (0.09 ml)
75865284|NCT03119688|Other|Positive Control|Bar Soap (rubbed for 6 seconds to generate a lather)
75865285|NCT03119688|Other|Reference Product|Sterile Water (0.09 ml)
75865286|NCT03119688|Other|No Treatment|Unwashed area of the forearm
75865287|NCT03389893|Drug|Dupilumab|Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
75557532|NCT00435071|Procedure|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
75557533|NCT00435071|Procedure|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
75865288|NCT03389893|Drug|Placebo|Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
75865289|NCT03178708|Drug|Group A amantadine sulfate|infusion solution for slowly intravenous application 3 hours preoperative
75557534|NCT00473187|Drug|somatropin|
75557535|NCT00435110|Procedure|standard ventilatory settings|
75557536|NCT00435110|Procedure|PEEP and FiO2|
75557537|NCT00473304|Device|Johnson&Johnson Acuevue daily disposable lenses|
75557538|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
75557539|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
75865290|NCT03178708|Other|Group B ringer lactate|infusion solution for intravenous application 3 hours preoperative
75865291|NCT03694106|Behavioral|TEAM PSYCHOTHERAPY|Patients data will be collected from the first to the final psychotherapy session as performed normally by TEAM trained clinicians. The treatment-as-usual includes therapy sessions of 50 to 110minutes long, typically once or twice per week for an average of 8-12 sessions. Treatment as usual by these clinicians includes the use of psychological symptoms survey immediately before and after each psychotherapy session. Typically patients will fill out these surveys in the clinic's waiting area before and after each session.
75865292|NCT02424292|Other|Physical activity|Physical activity in a personalised program.
75865293|NCT04473872|Other|respiratory rehabilitation|intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
76028250|NCT05990205|Behavioral|Life Style Intervention|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (>150 min medium intensity per week)
76028251|NCT05990179|Other|Genome sequencing-based newborn screening|Dried blood spots collected at birth for routine newborn screening will be used for genome sequencing based screening of a defined set of conditions.
75865294|NCT01373658|Device|Yinyi stent|subjects with Yinyi stent implantation
75865295|NCT04128293|Drug|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
75865296|NCT04128293|Drug|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
76028252|NCT05990153|Other|Myofascial Release (MR)|Myofascial release therapy is a type of gentle, constant massage that releases tightness and pain throughout myofascial tissues.
76028253|NCT05990153|Drug|clinical practice drug treatment|drug treatment according to the medical indications of clinical practice
76028254|NCT05990153|Other|Manual therapy (MT)|The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
76028255|NCT05990153|Other|Therapeutic exercise (TE)|The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
76028256|NCT05990140|Other|peppermint flavored mouthwash|The Effect of Peppermint Flavored Mouthwash Applied to Patients in the First 30 Days After Bariatric Surgery on Nausea-Vomiting, Anxiety and Biochemical Parameters
76028257|NCT05990127|Drug|AK104|AK104 IV, q3w
76028258|NCT05990127|Drug|Tislelizumab|Tislelizumab IV, q3w
76028259|NCT05990127|Drug|carboplatin|carboplatin IV, q3w
76028260|NCT05990127|Drug|Pemetrexed|Pemetrexed IV, q3w (for Nonsquamous NSCLC)
76028261|NCT05990127|Drug|Paclitaxel|Paclitaxel IV, q3w (for squamous NSCLC)
76028262|NCT05990114|Other|The structured caregiver support program|It consists of 8 sessions in total. It is planned as once a week and 45 minutes.
76028263|NCT05990101|Behavioral|Awake prone position (APP)|Awake prone position for 4 or more hours per day for the first 72 hours following randomisation.
75865297|NCT02428582|Device|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
75865298|NCT02428582|Device|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
75865299|NCT05197686|Device|Oxygen theraphy with high flow nasal cannule|Oxygen theraphy with high flow nasal cannule
75374263|NCT03593564|Behavioral|KINDER|KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.
75374264|NCT04044560|Biological|blinatumomab|Continuous intravenous infusion
75374265|NCT02569892|Device|Pascal Retinal Laser Photocoagulator|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
75374266|NCT02571218|Device|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
75374267|NCT02571218|Device|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
75537829|NCT06177184|Other|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking Association of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
75537830|NCT06177171|Drug|Olaparib|Given orally
75537831|NCT06177171|Drug|ASTX727|Given Orally
75537832|NCT06177158|Behavioral|oral hygiene instructions|"Standardized motivation and oral hygiene instructions regarding the tooth brushing will be demonstrated to all three groups using modified bass technique and a standardized brush, medium bristled brush with toothpaste, the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily. For interdental cleaning aids each patient will be instructed to use the suitable methods regarding the space between teeth.~clinically for each patient to ensure that the patients understood the instruction sessions. Before receiving oral hygiene instructions and motivation, the salivary sample will be collected and clinical periodontal parameters will be measured at a base line visit then, after 3 weeks, saliva will be collected and the same clinical measurements will be taken."
75537833|NCT06177145|Other|HASCV-R program|"Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
75537834|NCT06177119|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
75537835|NCT06177119|Drug|Placebos during SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning with the first SRP session.
75537836|NCT06177119|Drug|Placebos after SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning after the last SRP session.
75537837|NCT06177119|Drug|Metronidazole during SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning with the first SRP session.
75537838|NCT06177119|Drug|Amoxicillin during SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning with the first SRP session.
75537839|NCT06177119|Drug|Metronidazole after SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning after the last SRP session.
75537840|NCT06177119|Drug|Amoxicillin after SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning after the last SRP session.
75537841|NCT06177093|Radiation|MR Linac delivered Radiotherapy|All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
75537842|NCT06177080|Other|transperineal ultrasound|descent angle and head symphysis distances by transperineal ultrasound of active phase of labor women.
75865300|NCT05197686|Device|Oxygen theraphy with mask with reservoir|Oxygen theraphy with mask with reservoir
75865301|NCT03179020|Other|Checklist use|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
75537843|NCT06177067|Drug|Revumenib|Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
75537844|NCT06177067|Drug|Venetoclax|Given by mouth (tablet)
75537845|NCT06177067|Drug|Azacitidine|Given intravenously (IV) infusion
75537846|NCT06177067|Drug|intrathecal (IT) chemotherapy|Given intrathecal (IT)
75537847|NCT06177067|Drug|Cytarabine|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
75374268|NCT02573402|Device|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
75537848|NCT06177067|Drug|Methotrexate|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
75537849|NCT06177054|Behavioral|Rotation guided by ultrasound|Instruction to avoid areas with hyperechogenicity - after two weeks observation
75537850|NCT06177041|Drug|M108 monoclonal antibody|M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion.
75865302|NCT03179020|Other|Usual care|Management of the potential donor according usual care.
75865303|NCT02428894|Device|LVAD|
75374269|NCT02573402|Device|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
75374270|NCT03791060|Drug|Secukinumab|Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
75374271|NCT00364364|Drug|Radiolabeled humanized PAM4 IgG|
76028264|NCT05990088|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on the software algorithms|The patients will receive complete removable dentures designed based on the software algorithms and digitally manufactured using a milling machine.
76028265|NCT05990088|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machineز
75374272|NCT03256916|Drug|Nelfinavir|Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.
76028266|NCT05990062|Device|K-Socket-Harness|"A transradial socket and harness design that offers a hybrid polymer and textile-based design derived from advanced athletic shoe technology. The KSH integrated socket, frame, and wrist, the variable compliance prosthetic socket with breathable matrix, creates a dynamic and secure attachment with a combination of two lacing systems. The lacing systems lengthen and shorten six flexible hinges at the elbow, maintaining a secure attachment throughout the range of motion and accounting for volume changes in the soft tissue of the elbow that would otherwise restrict range of motion or cause the socket to separate from the residual limb."
76028267|NCT05990023|Other|Traditional vestibule rehabilitation training|"Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements."
76028268|NCT05990023|Other|Dual-task vestibule rehabilitation training|"Adding a dual task of digit countdown and recitation to clinical balance training exercises.~Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements."
76028269|NCT05989984|Dietary Supplement|ODF Iron Supplement|ODF iron supplement will be admistered daily for 8 weeks.
76028270|NCT05989984|Dietary Supplement|Iron Supplement in Capsules|Iron supplement in capsule will be admistered daily for 8 weeks.
75865304|NCT00787176|Drug|Group A Intravenous bolus of 1000 ml lactated ringers solution|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
75374273|NCT03256916|Drug|Cisplatin|Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.
75374274|NCT03256916|Radiation|Pelvic EBRT and Brachytherapy|Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 45- 50Gy/23-25 #/5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
75374275|NCT02579876|Drug|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
75865305|NCT00787176|Drug|Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
75865306|NCT00787176|Drug|Group C 125 mL/hr of lactated ringers|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
75865307|NCT00787176|Drug|Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
75865308|NCT03711487|Drug|Foeniculum Vulgare Seed Ironing|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
75865309|NCT02424370|Procedure|TAVR|Percutaneous aortic valve replacement
75701120|NCT00576693|Device|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
75865310|NCT03633864|Biological|Fecal microbiota transplantation|Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
76028271|NCT05989971|Other|continuous renal replacement therapy|continuous veno-venous hemofiltration or continuous veno-venous hemodialysis set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion
76028272|NCT05989893|Behavioral|Language-based tasks|In either the MRI suite, or the Epilepsy Monitoring Unit, or the operating room, epilepsy and tumor subjects are asked to perform a variety of language-based tasks as neural recordings are made from and/or neural stimulations are delivered to various language areas of the brain.
76028273|NCT05989880|Device|SafeLM as a supraglottic airway device with video capability|The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
76028274|NCT05989880|Device|SafeLM as a supraglottic airway device without video capability|The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
75865311|NCT05560555|Drug|Tafamidis|61 milligrams (mg) as received in studies B3461028 and B3461045
76028275|NCT05989880|Device|SafeLM as a conduit for intubation using an endotracheal tube with video capability|The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.
76028276|NCT05989880|Device|SafeLM as a conduit for intubation using a bougie with video capability|The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.
76028277|NCT05989867|Diagnostic Test|blood test|"Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors"
76028278|NCT05989867|Device|Continuous Glucose Monitor|blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control )
76028279|NCT05989854|Behavioral|Exercise|8 week exercise intervention, 3x/wk
75865312|NCT03744689|Procedure|Erector Spinae Plane block|Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
75865313|NCT03744689|Procedure|Sham block|Sham block will be done with serum physiologic.
75865314|NCT03744689|Drug|Bupivacaine Hydrochloride|20 ml 0,25% Bupivacaine will be used for block performances
75865315|NCT03744689|Device|PCA|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
75865316|NCT02424214|Other|Artificial Oocyte activation|
75865317|NCT02424214|Drug|Ca Ionophore|
75865318|NCT02424214|Drug|Strontium Chloride|
75865319|NCT05559541|Drug|AK119|AK119 is an anti-CD73 monoclonal antibody.
75374276|NCT02579876|Drug|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
75865320|NCT05559541|Drug|AK104|AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
75537851|NCT06177041|Drug|Placebo|Placebo will be administered as a minimum 2-hour IV infusion.
76028280|NCT05989841|Behavioral|RISE Guide|Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
76028281|NCT05989841|Behavioral|Relaxation Control|"Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention."
75537852|NCT06177041|Drug|Oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
75865321|NCT02428426|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
75865322|NCT03691571|Device|Esophageal Cooling|The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
75865323|NCT03691571|Device|Control|Standard of care involves standard temperature probe monitoring.
75865324|NCT03113916|Behavioral|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
76028282|NCT05989815|Other|Muscle damage protocol training|The adopted protocol of muscle damage will follow the recommendations from American College of Sports Medicine (ACSM) in 2009 for trained individuals. It consists of 8-12 repetitions above 70% of 1 Repetition Maximum (1RM) with 1 minute of rest between sets and 2 minutes between exercises. The protocol will be composed as follows: 3 sets of 10 repetitions for each exercise, with an emphasis on producing microlesions in the muscle tissue (muscle damage protocol).
76028283|NCT05989815|Device|Photobiomodulation therapy (PBMT)|PBMT will be administered using the Joovv Elite System, which has 6 panels of red LEDs (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 milliwatt (mW)/cm². The PBMT Sham dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm².
76028284|NCT05989789|Device|Radioactive Seed Implantation|In patients where initially the tumour lesion could not be identified, a radioactive seed was implanted and intraoperatively detected with a geiger counter sonde.
76028285|NCT05989698|Device|C-mo System|Patients will use C-mo System for a period of 24h, to assess cough characteristics.
76028286|NCT05989659|Other|Exposure: Home dialysis or facility-hemodialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
76028287|NCT05989646|Device|Sacral TENS|Sacral TENS applied two hours daily for 10 weeks
76028288|NCT05989633|Other|Dermocosmetic product: Selenium Disluphide Shampoo (Dercos DS)|to assess the benefit of Dercos DS in subjects with dandruff
75374277|NCT00364052|Drug|oral Valganciclovir vs oral Ganciclovir|
75537853|NCT06177041|Drug|Capecitabine|Capecitabine will be administered orally twice daily (bid).
75537854|NCT06177028|Drug|Lenalidomide 10 mg|Lenalidomide is a cancer drug, It is also known by it's brand name Revlimid.
75537855|NCT06177002|Diagnostic Test|Collection of biological data|Biological sample will be collected from the COVID19 patients and from healthy donors
75537856|NCT06176976|Dietary Supplement|Lugol's iodine solution 5%|4 drops of LS every 8 hours for 10 days preoperatively will be given
75537857|NCT06176950|Other|Oral History Interviews|I will ask interview subjects about their educational and career path, their research interests and clinical work in the field of neonatology. I will also ask them about their personal and professional motivations and thoughts about their work. And we will discuss how their interactions with colleagues and patients/caregivers shaped their work experience and decision making.
75865325|NCT03712111|Drug|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
75865326|NCT03712111|Drug|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
75865327|NCT03712111|Drug|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
75865328|NCT03712111|Drug|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
75865329|NCT02925494|Drug|Estradiol/Norethindrone Acetate|capsules
75865330|NCT02925494|Drug|Elagolix|film-coated tablets
75865331|NCT03711409|Other|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of pectoralis major, pectoralis minor, teres major, teres minor, infraspinatus and posterior deltoid muscles. Subjects are supine on the bed. The muscle release technique is applied at the end available range and the acceptable intensity. The time of muscle release intervention is about 30 min and hot-pack about 15 min.
75537858|NCT06176937|Drug|Hyaluronic acid|Alveolar ridge preservation by atraumatic tooth extraction and socket curettage then application hyaluronic acid gel after extraction and covering the socket by collagen membrane.
75701121|NCT00576693|Other|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
75865332|NCT03711409|Other|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. GH joint mobilization includes anterior to posterior glide, caudal glide and distraction. The intensity of joint mobilization is grade III to IV. The time of joint mobilization is about 30 min and hot-pack for 15 min.
76028289|NCT05989607|Other|Lower sugar flavored water|A commercially available low sugar flavored water (2.88kcal/100ml; 0.57(sugar) +0.03 (stevia)=0.60g/100ml; sodium 7.9mg/100ml).
75537859|NCT06176937|Other|empty socket|Alveolar ridge preservation by atraumatic tooth socket without application any drug but just covering the socket by collagen membrane.
75537860|NCT06176924|Device|tDCS|tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.
75537861|NCT06176924|Other|Relaxation technique|Relaxation technique
75537862|NCT06176911|Drug|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments are made throughout the study based on individual platelet counts.
75537863|NCT06176911|Drug|Danazol|200 mg twice daily.
75537864|NCT06176898|Device|Neurostimulating device|"A trained practitioner will apply the neurostimulator to the patient's ear. The patient will wear the neurostimulator for a period of three week with the position of the neurostimulator moving from one ear to the other on a weekly basis. After 3 weeks the neurostimulator will be removed and the patient will then undergo further clinical assessment at week 8.~At the 8 week clinical assessment, the patient will undergo the same assessments, namely:~Six minute walking test (6MWT)~Quality of life assessment using both generic (Short form 12) and disease specific (Vascuqol) questionnaires"
75701122|NCT00698451|Drug|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
75701123|NCT00921375|Drug|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
75701124|NCT00697827|Device|Interspinous Spacer device|Device: In-Space
75865333|NCT02428348|Other|Interview about prototype EEG-cap|
76028290|NCT05989607|Other|Plain Water|Commercially available bottled, spring water.
75537865|NCT06176872|Diagnostic Test|Cardiac Computed Tomography Angiography|Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
75865334|NCT03744533|Other|head-down position treatment|the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.
75865335|NCT03744533|Other|guideline-based treatment|guideline-based treatment
75537866|NCT06176859|Other|HIV PrEP Delivery|To test an end-to-end decentralized delivery service for pre-exposure prophylaxis (PrEP) to safely increase PrEP access and use among priority populations in South Africa.
75865336|NCT02420704|Procedure|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
75865337|NCT03744455|Biological|Axillary Plexus|Axillary plexus anesthesia technique for hand surgery
75865338|NCT03181672|Procedure|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
75865339|NCT03181672|Procedure|control group|Deltoid muscle injection with 1% lidocaine 10ml
75865340|NCT05658445|Other|evacuation|after complete evacuation of uterus follow abortion
76028291|NCT05989594|Behavioral|Home-based mobile guided exercise-based cardiac rehabilitation|Discharge preparation, telerehabilitation, scheduled onsite follow-ups, telephone follow-ups, self-reporting, health education, online communication, family and peer support, mailing letters, institutional referrals, and security management.
76028292|NCT05989594|Behavioral|Routine Care|Discharge preparation, scheduled onsite follow-ups, telephone follow-ups
75537867|NCT06176846|Behavioral|Immersive Virtual Reality Exergaming Program|"Oculus Quest 3 glasses will be used as hardware for the IVR exergame program, and Boxing, HIIT, Combat, Sculpt and Dance, among the Fit-XR games that offer virtual reality experience for fitness, will be selected according to the physical fitness level of the subjects and personalized multicomponent ( balance, strength, agility, endurance) IVR exergame program will be created. The exercise program is limited to 25-30 minutes a day and will be applied 2 days a week for 8 weeks in the clinic under the supervision of a physiotherapist. The exergaming program will be progressed according to the difficulty level, duration and technical characteristics of the games."
75537868|NCT06176846|Behavioral|Home-Based Exercise Program|In the home-based exercise program, a personalized multicomponent (balance, strength, agility, endurance) exercise program will be applied according to the physical fitness level of the subjects. The exercises will progress by increasing the difficulty level and number of repetitions of the exercises. An e-brochure will be given to the subjects for the exercises, the exercises will be shown to the subjects on the 1st day, and exercise control will be carried out in the 1st week and the 4th week.
75537869|NCT06176833|Procedure|Body Weight Supported Treadmill Training|For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
75537870|NCT06176807|Radiation|Venous Excess Ultrasound Score|"-- The IVC diameter : Grade 0: <5 mm with respiratory variation Grade I: 5-9 mm with respiratory variation Grade II: 10-19 mm with respiratory variation Grade III: >20 mm with respiratory variation Grade IV: >20 mm with minimal or no respiratory variation~- Hepatic vein (HV) interrogation by pulsed wave Doppler identification and analysis of A, S, and D waves.~Grade 0: normal S > D Grade I: S < D with antegrade S Grade III: S flat or inverted or biphasic trace - Portal vein Doppler (PD)as follow: Grade 0: <0.3 pulsatility index Grade I: 0.3-0.49 pulsatility index Grade III: 0.5-1.0 pulsatility index Pulsatility index is calculated as (Vmax - Vmin)/Vmax~- VEXUS staging of venous congestion. (VEXUS ) Grade 0: IVC grade <III, HD grade 0, PV grade 0 Grade I: IVC grade IV, but normal HV/PV pattern Grade II: IVC grade IV with mild flow pattern abnormalities in HV/PV Grade III: IVC grade IV with severe flow pattern abnormalities in HV/PV"
75701125|NCT00697827|Device|Interspinous Process Distraction Device|Device: X STOP
75701126|NCT02566551|Procedure|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
75701127|NCT02566551|Device|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
75701128|NCT02566551|Procedure|TURP|Bipolar transurethral resection of the prostate
75701129|NCT02566551|Device|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
75701130|NCT00728936|Drug|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
75701131|NCT00728936|Drug|Saline placebo|saline placebo given subcutaneously
75701132|NCT03980925|Drug|Nivolumab|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
75701133|NCT03980925|Drug|Carboplatin|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
75865341|NCT04006145|Drug|Elobixibat|Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
76028293|NCT05988879|Drug|Peginterferon alfa-2b Injection|The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.
75865342|NCT04006145|Drug|Placebo oral tablet|Placebo identical in appearance to active drug
75865343|NCT03717337|Procedure|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
75537871|NCT06176794|Drug|immediate release torsemide 20mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 2omg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
75865344|NCT03717337|Procedure|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
75537872|NCT06176781|Drug|Edaravone Dexborneol Sequential Therapy|Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).
75865345|NCT03689816|Procedure|sleeve gastrectomy|sleeve gastrectomy
75865346|NCT03689816|Procedure|gastric bypass|gastric bypass
75865347|NCT03386773|Behavioral|16-week program|16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
75865348|NCT03386773|Behavioral|Patient generated health data|Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
75701134|NCT03980925|Drug|Etoposide|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
75865349|NCT04207866|Other|Teleconferencing|Use of video/audio stream to provide auditory training at a remote site.
75537873|NCT06176781|Drug|Placebo|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
75865350|NCT04207866|Other|Auditory training services|"Participants will engage in regular visits with a specialist to: 1) facilitate auditory training exercises; 2) work with the family/friends to encourage optimal communication strategies in the home; 3) evaluate and assess achievement of listening goals.~Auditory training assess/reviews skills associated with but not necessarily limited to: 1) developing strategies to repair communication breakdowns; 2) listening in quiet; 3) listening in noise; 4) listening to a degraded signal."
75701135|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
75701136|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
75701137|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
75701138|NCT02565693|Drug|Apixaban|
75537876|NCT06176742|Other|Active Cycle Breathing Technique|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group A will be treated with ACBT. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
75701139|NCT02565693|Drug|Aspirin|
75701140|NCT02565693|Drug|Carbasalate calcium|
75865351|NCT04126343|Drug|Padsevonil|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period"
75865352|NCT04126343|Drug|Moxifloxacin|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive moxifloxacin once during the Treatment Period"
75865353|NCT04126343|Drug|Placebo|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding"
75865354|NCT04207710|Drug|Gebauer Pain Ease Top Aerosol Mist Spray|Topical numbing spray
75865355|NCT04207710|Drug|Gebauer Ethyl Chloride|Topical numbing spray
75865356|NCT02952313|Device|Nasal Implant|
75865357|NCT03119610|Drug|Oxytocin nasal spray|Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
75865358|NCT03119610|Drug|Placebo nasal spray|Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
75865359|NCT03689738|Other|Potato (Resistant Starch)|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
75865360|NCT03689738|Other|CHO-matched (Low-fiber, RS-free)|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
75865361|NCT04005755|Drug|Maxigesic® IV|acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
75865362|NCT03699176|Drug|Vilaprisan (BAY1002670)|2 mg, once daily, oral
75865363|NCT03699176|Drug|Placebo|Once daily, oral
75865364|NCT03442777|Device|Allevyn® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith&Nephew (Allevyn® brand).
75865365|NCT03442777|Device|Mepilex® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
75865366|NCT01373736|Drug|123I-meta-iodobenzylguanidine|
75537877|NCT06176742|Other|Bubble Positive Expiratory Pressure Device|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group B will be treated with bubble-PEP. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
75701141|NCT02565693|Drug|Clopidogrel|
75701142|NCT02565693|Drug|Dipyridamole|
75701143|NCT02565693|Other|No antithrombotic treatment|
76028294|NCT05988593|Dietary Supplement|placebo|consume one bottle (30 mL) per day
75537878|NCT06176729|Drug|Polatuzumab Vedotin, Rituximab, Lenalidomide|polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
75701144|NCT04603989|Drug|HNC042 for Injection|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
76028295|NCT05988593|Dietary Supplement|MelaGene+|consume one bottle (30 mL) per day
75865367|NCT03746093|Dietary Supplement|Water|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
76028296|NCT05987826|Drug|Furmonertinib|Furmonertinib 80mg QD oral 8 weeks.
75537879|NCT06176716|Drug|ET-26|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
75701145|NCT04603989|Drug|Placebo Comparator|Placebo , Intravenous route , multiple ascending doses
75701146|NCT00728468|Drug|PF-00299804|PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
75701147|NCT04061655|Drug|Iron Isomaltoside 1000|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
75701148|NCT04061655|Other|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
75865368|NCT03746093|Dietary Supplement|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
75865369|NCT03689348|Dietary Supplement|Avena sativa|A supplement derived from wild green oat
75865370|NCT03689348|Dietary Supplement|Placebo|Maltodextrin
75865371|NCT03689270|Procedure|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
75865372|NCT03689270|Procedure|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
75865373|NCT01375062|Other|analyse and proliferate the cells|"Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.~Digestion of the biopsies through controlled enzymes~Replication of the cells~Selection undifferentiated cells~Expansion of the purification cells population~Characterization of the cell population~Assessment of pluripotent and germinal cell potential.~Possible maturation of the cells."
75865374|NCT03401749|Drug|Chlorhexidine Gluconate 2% Wipe|Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
76028297|NCT05985993|Device|low-intensity transcranial ultrasound stimulation (TUS)|The rTUS was administered using an immersion-type focused ultrasound transducer (V391-SU, Olympus NDT, Waltham, USA). Low-intensity transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
75374278|NCT02787668|Other|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO <10%; fat >65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
75374279|NCT02787668|Other|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
75701149|NCT04061265|Drug|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|Local anesthetic agent
75701150|NCT04061265|Drug|lidocaine hydrochloride 2% and epinephrine 1:100000|Local anesthetic agent
75865375|NCT03401749|Other|Theraworx Bath Wipes|Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
75865376|NCT03689114|Drug|Low dose carbamazepine|Carbamazepine, 300 mg/die
75865377|NCT03689114|Drug|Standard dose carbamazepine|Carbamazepine 600 mg/die
75865378|NCT03689114|Drug|Low dose levetiracetam|Levetiracetam 500 mg/die
75865379|NCT03689114|Drug|Standard dose levetiracetam|Levetiracetam 1000 mg/die
76028298|NCT05985824|Procedure|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
76028299|NCT05985421|Other|Fecal collection|approximate volume of 2 ml
76028300|NCT05985421|Other|Blood sampling|1 EDTA tube (7 ml) to test for chronic low-grade inflammation + 1 EDTA tube (7 ml) to test for intestinal inflammation, digestive permeability and microbial translocation
76028301|NCT05985421|Other|Polysomnography|Polysomnography
76028302|NCT05985421|Other|Auto questionnaires|International RLS Study Group Severity Scale, Epworth Sleepiness Scale, Insomnia Severity Index, Beck Depression Inventory-II, Autonomic symtoms scale (SCOPA-AUT)
75701151|NCT02592980|Genetic|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
75701152|NCT02592980|Drug|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
76028303|NCT05985356|Device|iTBS|iTBS targeting the left dorsolateral prefrontal cortex; 20 sessions over 4 weeks.
75537880|NCT06176690|Biological|C7R.CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
76028304|NCT05980286|Behavioral|Piano Improvisation|Piano Improvisation taught by a professional instructor for 16 weeks.
76028305|NCT05980286|Behavioral|Music Listening|Music Listening facilitated by a professional instructor for 16 weeks.
76028306|NCT05979701|Other|Simulation training|The intervention will consist of training participants through simulation in addition to theoretical training. The simulation will cover 3 themes, including diagnosis of haemorrhage, communication between healthcare providers, management of post-partum haemorrhage and transfusion monitoring.
76028307|NCT05973838|Behavioral|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention."
75537881|NCT06176664|Device|Low flow oxygen|Standard nasal cannula oxygen up to 2 liters/minute
75537882|NCT06176664|Device|High-flow nasal cannula oxygen|High-flow nasal cannula with heating and humidification up to 2 liters/kilogram/minute
75701153|NCT03963284|Procedure|cardiac surgery|pediatric cardiac surgery with cardiopulmonary bypass
75701154|NCT03963284|Device|NephroCheck test|Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test
75701155|NCT00727844|Drug|Immediate Start Linezolid|
75701156|NCT00727844|Drug|Delayed Start Linezolid|
75865380|NCT03689114|Drug|Low dose valproate|Valproate 300 mg/die
75557540|NCT03272568|Drug|Recombinant FVIII Fc fusion product Eloctate|Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
75865381|NCT03689114|Drug|Standard dose valproate|Valproate 600 mg/die
75865382|NCT03689114|Drug|Low dose zonisamide|Zonisamide 150 mg/die
75865383|NCT03689114|Drug|Standard dose zonisamide|Zonisamide 300 mg/die
75865384|NCT03689114|Drug|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
76028308|NCT05968131|Other|Conventional Physical Therapy|"The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions."
76028309|NCT05968131|Other|Conventional Physical Therapy with Proprioceptive Training Exercises|"Interventional group will receive strengthening intervention as well as proprioceptive training for 32 sessions. ROM and Strengthening exercise will be performed same as in control group.~Exercises For Proprioceptive Training: Intervention group will practice an additional 24 minutes of proprioceptive training (two minutes rest prior to performing this training). A circuit with different floor texture composed of 6 stations of exercises to stimulate the sole of foot where participant had to improve gait by stepping with alternate feet marker placed on ground and progression will be done by modify the speed and direction. Material used to build the circuit are in following order: 10 cm thick foam, a wood box with beans, a 2 cm thick mat with density lower than foam, a wooden box filled with sand, balance board to train the lateral balance reactions, a wooden box filled with cotton. Duration of this training is 24 minutes; patient will spend 4 minutes on each station."
75865385|NCT03689114|Drug|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
75865386|NCT03689114|Drug|Low dose topiramate|Topiramate 100 mg/die
75865387|NCT03689114|Drug|Standard dose topiramate|Topiramate 200 mg/die
76028310|NCT05967858|Other|observation|no intervention
76028311|NCT05965505|Drug|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
75865388|NCT03689114|Drug|Low dose lamotrigine|Lamotrigine 100 mg/die
75865389|NCT03689114|Drug|Standard dose lamotrigine|Lamotrigine 200 mg/die
75865390|NCT03689114|Drug|Low dose gabapentin|Gabapentin 450 mg/die
75865391|NCT03689114|Drug|Standard dose gabapentin|Gabapentin 900 mg/die
76028312|NCT05964647|Drug|LSD (150 µg) + ketanserin (40 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Ketanserin (40 mg) per os, single dose"
76028313|NCT05964647|Drug|LSD (150 µg) + olanzapine (10 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Olanzapine (10 mg) per os, single dose"
75865392|NCT03634176|Diagnostic Test|optical nerve sheet diameter|The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
75865393|NCT01311583|Behavioral|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
75865394|NCT03029624|Device|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
75865395|NCT02952001|Drug|4 mg CLS-TA Suprachoriodal Injection|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
75865396|NCT02952001|Drug|Sham procedure|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
75374280|NCT02582216|Device|3D augmented reality|Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
75701157|NCT00735878|Drug|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
75701158|NCT02594150|Other|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
75865397|NCT05196594|Diagnostic Test|collection of stools for genetic analysis|Intestinal microbiome analysis
75865398|NCT03699098|Diagnostic Test|TSH, T3, T4 and thyroid gland DVH|measuring thyroid functions and DVH parameters of thyroid gland
75865399|NCT01372020|Other|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
76028314|NCT05964647|Drug|LSD (150 µg) + lorazepam (2 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Lorazepam (2 mg) per os, single dose"
75865400|NCT03744299|Other|Questionnaire|Patients and caregivers are asked to complete a questionnaire
75865401|NCT01311739|Drug|Cyanocobalamin|
75865402|NCT05196438|Other|Collecting statistics about congenital heart patterns and investigations done and interventions done to them|Collecting statistics about congenital heart patterns and investigations done and treatment given or interventions e.g. catheterization or surgical operations done to them
75865403|NCT03744221|Dietary Supplement|Corn protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
75865404|NCT03744221|Dietary Supplement|Bovine plasma protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
75865405|NCT03744221|Dietary Supplement|Whey protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
75865406|NCT05507359|Other|clove gel|4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel
75865407|NCT05507359|Other|Benzocaine gel|20% Benzocaine gel (Opahl gel)
76028315|NCT05964647|Drug|LSD (150 µg) + placebo|"Drug: LSD (150 µg) per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
76028316|NCT05964647|Drug|Placebo + placebo|"Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
76028317|NCT05963230|Other|Ultrasound scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
75374281|NCT02582840|Drug|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
75865408|NCT05196360|Drug|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
75865409|NCT04123067|Drug|Pioglitazone 45 mg|45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
75865410|NCT04123067|Drug|Placebo oral tablet|placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
75865411|NCT05193006|Other|No intervention|No intervention
75374282|NCT02582840|Drug|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
75374283|NCT02582840|Drug|Placebo tablet|Placebo tablet. Oral dose
75865412|NCT03711955|Other|Exercise|Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
75865413|NCT05192928|Device|Ripple Health Smart Pill Cap|The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
75865414|NCT01375218|Other|Pavlik Brace|Pavlik Brace
75701159|NCT02593838|Other|CT-MPI and SPECT-MPI|All patients undergo CT-MPI plus SPECT-MPI
76028318|NCT05959018|Device|Arrow Three-Lumen Central Venous Catheter|Participants in the Non-impregnated CVC arm will receive Arrow Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
75701160|NCT00695955|Drug|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
75865415|NCT01375218|Other|Plastizote Brace|Plastizote Brace
75701161|NCT00695955|Drug|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
75865416|NCT05196282|Other|Smoking cessation|Patients are forced to stop smoking
75865417|NCT03688958|Drug|Placebo|Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
75865418|NCT03688958|Drug|iodine|Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).
76028319|NCT05959018|Device|Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter|Participants in the Antimicrobial-impregnated CVC arm will receive Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
76028320|NCT05949190|Dietary Supplement|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline)|Balanced energy protein supplement with added DHA/EPA/choline, micronutrients
75701162|NCT04547205|Drug|AK109|AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)
75701163|NCT00693225|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
75865419|NCT03688958|Drug|FEC/TE Placebo|The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).
75865420|NCT03688958|Drug|FEC/TE iodine|The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
75865421|NCT05192616|Device|Covered stent implantation|Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
76028321|NCT05949190|Dietary Supplement|M-RUSF (Maternal Ready-to-Use Supplementary Food)|Balanced energy protein supplement with added micronutrients
76028322|NCT05949190|Drug|Azithromycin|1g dose
75701164|NCT03773757|Behavioral|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
76028323|NCT05949190|Drug|Albendazole|400mg dose
76028324|NCT05949190|Drug|Sulfadoxine pyrimethamine|Monthly, 1,500/75mg dose
76028325|NCT05949190|Behavioral|Cognitive behavioral therapy|Novel program developed for illiterate end-users
76028326|NCT05949190|Other|Insecticide-treated mosquito net|Bed net to prevent malaria
76028327|NCT05945017|Dietary Supplement|Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748|
76028328|NCT05940077|Behavioral|Exercise|Community-based exercise involving non-contact boxing and individualized balance training
76028329|NCT05918601|Other|Health-risk behaviors|Participants will be asked about the priority they place on engagement in health-related lifestyles, such as quitting drugs, alcohol, smoking or exercising regularly.
76028330|NCT05918601|Other|Theory of planned behavior, Self-determination theory|The participants will be asked to quit drugs immediately or progressively with the ultimate goal of quitting drugs completely.
76028331|NCT05918601|Other|Assist them to adhere to their schedule of quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period.
76028332|NCT05918601|Other|Assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period.
76028333|NCT05918601|Other|(AWARD) model|Participants receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model
76028334|NCT05918601|Other|Receive four independent 1-minute videos|The participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.
76028335|NCT05918159|Other|Sarcopenia Assessment|The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.
76028336|NCT05915949|Drug|Dapagliflozin 10mg Tab|Forxiga 10mg Tab once daily will be given to participants for 24 weeks.
75701165|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
75701166|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
76028337|NCT05915949|Drug|Lobeglitazone 0.5 mg|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
75865422|NCT03698942|Device|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
75865423|NCT05196204|Other|Trunk-oriented task training combined with functional electrical stimulation|Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
76028338|NCT05915949|Drug|Dapagliflozin + Lobeglitazone|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
76028339|NCT05910437|Other|Hospitalized patient for decompensated heart failure|Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.
76028340|NCT05902455|Procedure|Punch biopsy|Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.
76028341|NCT05888441|Other|Obstacle characteristics|"In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast."
75701167|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
75701168|NCT00735644|Biological|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
75701169|NCT00735644|Biological|Hepatitis A vaccine|0.5 mL, Intramuscular
76028342|NCT05874037|Drug|Fluvoxamine|Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.
76028343|NCT05864573|Biological|ZGGS15|ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
75701170|NCT03718299|Drug|Injections of tildrakizumab|given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
75701171|NCT02591888|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
76028344|NCT05855941|Diagnostic Test|FDG-PET/CT and FDG-PET/MRI|Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.
76028345|NCT05840198|Behavioral|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
76028346|NCT05840198|Other|Treatment as usual|Youth in this condition receive treatment as usual from their health care providers
76028347|NCT05825365|Drug|Selumetinib|Selumetinib
76028348|NCT05825365|Drug|Placebo|Placebo (Transfer to selumetinib on REiNS-defined PD)
76028349|NCT05814939|Drug|VC005 tablets|VC005 groups repeat administration for 12 weeks
76028350|NCT05814939|Drug|Tofacitinib Citrate Tablets|Tofacitinib Citrate groups repeat administration for 12 weeks
76028351|NCT05814939|Drug|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
76028352|NCT05811234|Drug|CAL/BDP PAD Cream|As provided in real-world clinical practice.
76028353|NCT05795049|Other|Stool and saliva sample collection|Stool and saliva samples collection
75865424|NCT05196204|Other|Trunk-oriented task training alone|"The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises."
75865425|NCT03688646|Dietary Supplement|Intensive Nutrition Intervention|
75865426|NCT05196048|Other|No Intervention|No Intervention
75865427|NCT04080050|Drug|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy|No investigational product will be administered in this study. All participants have previously received a one-time intravenous infusion of RGX-501 in a separate clinical trial
75865428|NCT04117607|Other|Placebo|5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
75865429|NCT04117607|Drug|Rezafungin|Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
75701172|NCT02591888|Drug|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
75701173|NCT00724958|Biological|Infliximab|Not specified in the protocol.
75701174|NCT04086836|Device|TAVR|Patient recieving a TAVR
75374284|NCT02583230|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
75865430|NCT04117607|Drug|Rezafungin|Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
75865431|NCT03657654|Other|No intervention: observational only|No intervention: observational only
75865432|NCT03688568|Drug|Imatinib Mesylate|Imatinib given orally as dose escalation treatment.
75374285|NCT00364988|Drug|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
75374286|NCT00364988|Drug|losartan|losartan (100 mg daily)
75374287|NCT00365222|Drug|Temozolomide|temozolomide 75 mg/m2 /d
75374288|NCT04340804|Behavioral|Kcal labelling|Real-time kcal counter synchronised with the food amount changes
75374289|NCT04340804|Behavioral|PACE labelling|Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
75374290|NCT02580188|Drug|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
75374291|NCT04741958|Diagnostic Test|Ultrasound Guided Peripheral Thoracic Tumors|Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
75701175|NCT03717441|Diagnostic Test|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
75701176|NCT04088006|Device|Injection of STYLAGE® HydroMax|"STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject."
75865433|NCT05192304|Drug|TPN-672|single dose of TPN-672 maleate tablet
75865434|NCT01375296|Device|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
75374292|NCT02584790|Device|Laryngoscope with NBI system|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
75374293|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
75374294|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
75537883|NCT06176638|Behavioral|RRF4H Combination Intervention|"MFG: is a family strengthening model where children and their parents sit together in groups of 8 to 10 families to discuss important issues. MFG approach provides a social support mechanism and strengthens family relationships by allowing families to share common experiences as well as effective strategies for addressing difficult issues; and focuses on reducing stigma and normalizing common experiences.~TAHC: This is a peer-led program that allows younger students to talk with peers about important issues that they face, gain role models, and identify positive social norms from older peers. It provides age-appropriate lessons and is delivered in a structured fashion. The curriculum consists of sixteen 50-minute lessons spread out over two academic years. Topics delivered in the curriculum include substance use, positive outlook on life, forming a positive self-concept, decision making and problem solving, coping with depression, bullying and social media."
75865435|NCT01375296|Other|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
75537884|NCT06176625|Behavioral|Communication Signage|Pink signage regarding effective communication strategies posted on door to patient's room.
75865436|NCT03527862|Other|Treatment according to lung ultrasonography|Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
75865437|NCT04430660|Other|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
75865438|NCT04430660|Device|Continuous glucose monitoring|Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
75374295|NCT02586896|Behavioral|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
75374296|NCT02586896|Behavioral|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
75374297|NCT02586974|Device|Humigard|warmed and humidified CO2 insufflation
75374298|NCT05249504|Other|VIVIFRAIL|"VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/"
75374299|NCT05249504|Other|Nutrition|Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.
75374300|NCT05249504|Behavioral|Psychology|Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.
75374301|NCT05249504|Behavioral|Personal autonomy|Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.
75374302|NCT05249504|Other|Community resources|Learn about community resources
75374303|NCT05249504|Other|Standard recommendations|Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
75374304|NCT02791568|Procedure|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
75374305|NCT02791568|Procedure|MRI Scan|MR imaging will take approximately 30 minutes.
75374306|NCT02791568|Drug|Ferumoxytol|A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
75537885|NCT06176625|Behavioral|Communication Signage & Amplifier Use|Patient is provided amplification device and blue signage regarding effective communication strategies with reminder to utilize the amplification device posted on door to patient's room.
75701177|NCT02593136|Dietary Supplement|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
75537886|NCT06173284|Drug|611|subcutaneous injection
75537887|NCT06173284|Drug|Matching placebo|subcutaneous injection
75537888|NCT06171802|Drug|Empagliflozin|10 mg empagliflozin daily for six months
75537889|NCT06171802|Drug|Placebo|Placebo capsule once daily for six months
75374307|NCT05372432|Other|Handgrip strengths measurements with Jamar-type hand dynamometer and, tip pinch strengths measurements with pinchmeter|The handgrip strength and tip pinch strength of the participants were measured using the Jamar-type hand dynamometer and pinch meter available in our clinic. The handgrip strengths were measured with shoulders in adduction and neutral rotation, elbows in 90 degrees flexion, and forearms and wrists in a neutral position, while the tip pinch strengths were measured by squeezing a pinch meter between the thumb and index finger. Participants took a deep breath and then applied gripping force with maximal force while exhaling. In the analysis, the average of the three measurements made with an interval of five minutes was taken as the basis for the analysis.
75374308|NCT05372432|Other|The Nine Hole Peg Test|This test was used to evaluate the hand dexterity of the participants. This test consists of a square area and nine holes in this area, nine cylinders suitable for these holes, and a storage box. Participants quickly took the nine cylinders from the storage box and placed them in the holes, and after placing all the cylinders, they put the cylinders back in the storage box one by one. In the evaluation of the test, the time elapsed during these operations was measured in seconds with a chronometer, and shorter times were considered to indicate better hand dexterity.
75374309|NCT05371730|Drug|NCR300|Intravenous infusion of NK cells（NCR300）
75865439|NCT03744143|Procedure|longitudinal suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
75374310|NCT05247944|Procedure|Fenestrated and branched endovascular aortic repair (F-BEVAR)|Fenestrated and branched endovascular aortic repair (F-BEVAR)
75374311|NCT05247944|Procedure|Open repair|Open surgery for complex abdominal aortic aneurysm
75374312|NCT05247554|Drug|Hydroxychloroquine + low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
75701178|NCT02593136|Other|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
75865440|NCT03744143|Procedure|transverse suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
75865441|NCT03744143|Procedure|Removal of vaginal endometriotic nodule|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
75701179|NCT04087928|Device|FMV_flex|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to flexor muscles of the upper limb (brachial biceps and carpal flexors).
75701180|NCT04087928|Device|FMV_ext|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to extensors muscles of the upper limb (triceps brachial and carpus extensors).
75701181|NCT00695565|Drug|Placebo Gel|TID x 12 weeks
75701182|NCT00695565|Drug|Clonidine Topical Gel (ARC-4558)|TID x 12 weeks
75701183|NCT00727532|Drug|Sorafenib|400mg by mouth twice daily for 28 consecutive days
75701184|NCT00742599|Drug|NPO-11|20 ml NPO-11
75701185|NCT00742599|Drug|Placebo|20 ml NPO-11(Placebo)
75701186|NCT00742677|Procedure|nutritional support|Given orally
75865442|NCT05191992|Other|CPR training with e-learning with a handmade mannequin.|The group, who was given theory training with the e learning method, will be taught to make pillows and plastic bottles and cpr mannequins, and they will be asked to practice. Knowledge and skills assessment will be made before, immediately after and 1 month after the training.
75865443|NCT03693638|Drug|Bupivacaine-fentanyl|2,5 ml total anesthetic drug dose were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
75865444|NCT03693638|Drug|Bupivacaine-fentanyl|1,5 ml of total anesthetic drug dose followed by 1 ml remaining dose after 90 s interval were given
75865445|NCT04112303|Drug|SOF/VEL|Tablets administered orally once daily
75865446|NCT01319838|Drug|Isotretinoin|>12 kg: 160 mg/m2/day, given PO, divided BID <=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
75865447|NCT05195580|Device|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
75374313|NCT05247554|Drug|Prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to 6 months ).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
75374314|NCT05217368|Other|mandala painting|In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
76028354|NCT05795049|Other|Questionnaire completion|"Questionnaire on;~demographic, ethnicity, IBS subtype, post-infection onset, previous surgeries~IBS severity score for adults~Hospital Anxiety and Depression scores for adults~Somatization score for adults~Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~Quality of Life as measured by the PedsQL™ GI Symptoms Module~GI symptoms as measured by the PedsQL™ GI Symptoms Module~Anxiety, Depression as measured by the Pediatric PROMIS®"
75865448|NCT03693482|Diagnostic Test|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
76028355|NCT05786014|Behavioral|High Intensity Interval Exercise|Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home. The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose. Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.
75865449|NCT03634566|Drug|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
75865450|NCT03634566|Drug|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
75865451|NCT03998189|Other|Breath Collection|Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
75374315|NCT05217368|Other|antenatal education|Routine antenatal education will be given.
75865452|NCT03998189|Other|Saliva Collection|Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
75865453|NCT03998189|Other|Blood Collection|Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
75865454|NCT03998189|Other|Urine Collection|Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
75374316|NCT02596022|Drug|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
75374317|NCT02596022|Drug|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
75374318|NCT05208320|Behavioral|Adherence|"Patients received interventions as follow:~The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~Home health education by Community Health Workers every month for 6 months"
75374319|NCT00364442|Drug|fluticasone propionate/salmeterol|investigational drug
76028356|NCT05786014|Behavioral|Moderate Intensity Walking|Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity. Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test). The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging. Participants will also receive a gift card to be used to purchase a pair of walking shoes to facilitate their engagement.
75374320|NCT00364520|Other|Shanghai workers|
75374321|NCT02597582|Procedure|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
75374322|NCT00364598|Drug|Anginera, a human tissue replacement therapy|
76028357|NCT05783505|Other|Multicomponent intervention program|Non-pharmacological interventions combined with goal directed sedation using dexmedetomidine if needed
76028358|NCT05782686|Procedure|Margin shaving|In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.
76028359|NCT05780034|Drug|AC676|AC676 will be given orally (PO) on a 28-day cycle.
75865455|NCT03998189|Other|Tumor Collection|During surgical tumor removal, a tumor tissue sample will be collected
75374323|NCT05371574|Drug|clonidine group|Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision
75374324|NCT02599766|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
75374325|NCT02599766|Other|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
75374326|NCT05371418|Procedure|surgical (guided tissue regeneration)|In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion
75865456|NCT03998189|Other|Medical History Data Collection|Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
75701187|NCT02593058|Behavioral|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
75865457|NCT01372098|Behavioral|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
75374327|NCT05371418|Device|orthodontic intrusion followed by guided tissue regeneration GTR|. In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
75865458|NCT03688412|Device|Cook lead extraction devices|The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
75374328|NCT05371340|Dietary Supplement|Quercetin (500 mg)|Once-daily 500 mg Quercetin
75374329|NCT05371340|Other|Placebo (500 mg)|Once-daily 500 mg methylcellulose 9E4M)
75374330|NCT02601170|Biological|Platelet-Rich Plasma Intra-Articular Injection|
75374331|NCT02601170|Drug|Hyaluronic Acid Viscosupplementation|
75374332|NCT05371262|Drug|Levothyroxin|Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
75374333|NCT02602496|Other|Fruits and Vegetables|5 servings of fruits or vegetables
75374334|NCT02602496|Other|Whole Grain|3 servings of whole grain
75374335|NCT02602496|Other|Control|3 servings of refined grain
75374336|NCT02603666|Device|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
75374337|NCT00366002|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
75374338|NCT00422240|Drug|Adapalene/Benzoyl Peroxide|
75374339|NCT05366972|Device|Ultrasonographic measurements|"Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles"
75865459|NCT01373892|Procedure|Bariatric surgery|
75865460|NCT03355872|Drug|HLX01|Biosimilar of Rituximab
75865461|NCT03744065|Procedure|lumbar plexus block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle
75374340|NCT00365534|Procedure|MEI|
75374341|NCT02605304|Drug|Ledipasvir/sofosbuvir|Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
75374342|NCT02605304|Drug|Ribavirin|"Based on weight at entry:~For weight <75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally."
75374343|NCT05365880|Drug|Liquid Lidocaine|The investigational treatment is 2 mL of aqueous 2% lidocaine.
75374344|NCT05365880|Drug|Placebo|The active placebo comparator will be provided to participant.
75374345|NCT04741490|Drug|Camrelizumab|PD-1antibodies，200mg ivgtt Q3W
75374346|NCT04741490|Radiation|radiotherapy|45-55Gy/1.8～2.0Gy
75374347|NCT05603468|Drug|platelet rich plasma|Platelet rich plasma group: after the surgery of rotator arthroscopic rotator cuff repair, 3ml PRP (LongTai Biological Company) was injected into the rotator cuff tear under the rotator arthroscope for a time. PRP production process: before anesthesia, 20ml arterial blood was drawn and injected into the PRP tube. The blood was fully oscillated in the tube, and then placed in a centrifuge with 1500g for 9min to remove excess plasma and make 5ml PRP. 3ml is used for injection and 2ml is used for quality control.
75374348|NCT05603468|Drug|Corticosteroid|Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
75374349|NCT05603468|Drug|Normal saline|Normal saline
75374350|NCT02606708|Radiation|Accelerated intensity modulated radiation therapy (AIMRT)|
75374351|NCT05365256|Behavioral|Standard distraction during chemotherapy treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care
75537890|NCT06171763|Other|Telemedicine|The telehomecare solution involves an early discharge with continued home monitoring through the use of telemedicine utilizing an user-friendly mobile. Additionally, there were a clinical reassessment in person 72 hours after discharge to evaluate the outcomes and results of the intervention.
75374352|NCT05365256|Behavioral|Virtual distraction during chemotherapy treatment period|A virtual reality headset will be worn for 15 minutes per hour of treatment
75374353|NCT05584904|Other|volunteer anesthesiologists and nurses|18 not expert in electroencephalography digestive endoscopy and operating room nurses, and 8 anesthesiologists interpreting EEGs obtained with a single electrode EEG
75537891|NCT06171698|Device|Research Prototype Monitor|Continuous vital sign is collected via a research prototype monitor
75537892|NCT06171503|Behavioral|letter of invitation on MI in PMTCT service|A non randomized control trial for the total of six month duration will be employed: the first phase is base line survey (pretest) to determine the magnitude of MI and qualitative method using FGD, IDI and KI with selected group to complement the base line will be conducted. Phase 2 Simultaneously with base line, the intervention will be employed to evaluate the effectiveness of invitation letter through mother support group to pregnant women attending antenatal clinic with out her partner as a strategy for male involvement in PMTCT/ANC services. End line data using qualitative approaches will be collected from partners attending antenatal care clinic following letter of invitation to evaluate the effectiveness of letter of invitation.
75374354|NCT02607254|Drug|Pregabalin|Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
75374355|NCT02607254|Drug|Placebo|Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
75537893|NCT06171269|Radiation|Radiation|Radiation to the prostate gland will be given daily (Mon-Friday) for 4 weeks.
75537894|NCT06171269|Radiation|MRI|The study doctor will use an MRI scan to take pictures of the prostate gland. These images of the prostate gland will let the study doctor know which areas of the prostate contain cancer cells that need to be targeted with higher doses of radiation and which uninvolved areas to target with lower doses of radiation.
75701188|NCT02593058|Behavioral|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
75701189|NCT02565459|Biological|Mesenchymal Stromal Cells|
75701190|NCT03957824|Diagnostic Test|PREVENTION-ACHD risk score|The predicted risk of sudden cardiac death according to a risk score will be tested by the actual rate of sudden cardiac death
75701191|NCT03957512|Procedure|Heart surgery|All invasive procedures
75537895|NCT06171269|Other|Androgen Deprivation Therapy|Treatment of treating physician choice will be given for 6-24 months.
75537896|NCT06170697|Drug|Camrelizumab|200mg, iv, d1, q3w
75374356|NCT02609204|Diagnostic Test|Diopsys NOVA|Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
75374357|NCT02611154|Drug|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
75374358|NCT05140538|Other|SRP + toothpaste + mouthwash|Use of domiciliary products twice a day
75374359|NCT05140538|Other|SRP + toothpaste|Use of domiciliary products twice a day
75374360|NCT05548244|Behavioral|Behavioral Activation Therapy|Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
75374361|NCT05548244|Behavioral|Baseline assessment procedures|Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Intelligence Scale for Children-Short Form to assess IQ.
75374362|NCT02613338|Device|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
75374363|NCT02614274|Dietary Supplement|Nutraceutical joint health formulation|A Proprietary Blend
75374364|NCT05104502|Behavioral|Dietary Fasting|"The study will consist of two days of eating a controlled habitual diet and one 36-hour period of water-only fasting with glucose monitoring as a measure of compliance. Water intake will be limited to 2 liters/day to prevent electrolyte abnormalities. Subjects will undergo 4 separate blood-draws consisting of an overnight fasted sample (Baseline), a 2-hour postprandial sample (Fed), a 36-hour fasted sample (Fasted), and final 2-hour postprandial sample after the fasting period (Refed)."
75537897|NCT06170697|Drug|Cisplatin|80-100mg/m2, iv, q3w, 2-3 cycles in total
75537898|NCT06170697|Drug|Carboplatin|AUC 2, iv, q1w, 5-7 cycles in total
75537899|NCT06170697|Drug|Lobaplatin|30mg/m2, iv, q3w, 2-3 cycles in total
75537900|NCT06170697|Drug|Nedaplatin|25-30 mg/m2, iv, q1w, 5-7 cycles in total
75537901|NCT06170697|Radiation|Radiotherapy|PGTVp/PGTVnd 66-70Gy/2-2.2Gy/30-35F；PTV1 60Gy/1.8-2.0Gy/30-33F；PTV2 50Gy/1.8-20Gy/25-28F；Start 1-2 weeks after the start of immunotherapy, 1 time before the start of simultaneous chemotherapy, up to 3 times during the concurrent chemoradiotherapy
75374365|NCT05083988|Device|virtual reality glasses|a system composed of a head-mounted wide view display placed in front of the eyes and headphones placed in ears, it has the ability to block the real-world stimuli. This could distract the patient from the dental environment, which helps reduce anxiety
75374366|NCT05083988|Device|music|Music can be used to distract patients from the anxiety provoking stimulus. It helps the patient to escape from the stressful reality as it activates imaginary. Psychosocially music can offer peace and comfort to patients during dental treatment as it helps in making the environment less threatening.
75374367|NCT02617784|Drug|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
75374368|NCT05537168|Procedure|Pediatric cardiac surgery under cardiopulmonary bypass|All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 operated at our institution
75374369|NCT00366158|Device|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
75374370|NCT00366158|Device|Ventricular Intrinsic Preference|Programming of pacemaker
75374371|NCT04955756|Diagnostic Test|mNGS|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
75374372|NCT04955756|Diagnostic Test|Multiplex PCR|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
75537902|NCT06170476|Drug|HSK21542-60μg|HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
75537903|NCT06170476|Drug|HSK21542-120μg|HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
75537904|NCT06170476|Drug|HSK21542-180μg|HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
75537905|NCT06170476|Drug|Placebo|A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
75537906|NCT06170463|Drug|Metformin Hydrochloride|Met Group Received metformin hydrochloride 500 mg tab 3 times Daily
75537907|NCT06170463|Drug|MI/DCI combination in 40:1 ratio|MI-group received MI/DCI combination in 40:1 ratio twice daily
75537908|NCT06170463|Drug|Combination of Metformin hydrochloride and MI/DCI|MM Group Received both Met and MI Groups Treatment
75537909|NCT06170398|Diagnostic Test|Wideband tympanometry|Wideband tympanometry
75537910|NCT06170398|Diagnostic Test|Electrocochleography|Electrocochleography
75537911|NCT06170398|Diagnostic Test|Vestibular Evoked Myogenic potentials|Vestibular Evoked Myogenic potentials
75537912|NCT06170372|Drug|200 ppm Nitric Oxide|NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
75537913|NCT06170372|Drug|Sham treatment|Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
75374373|NCT05732012|Behavioral|Sexual Health Psychoeducation Program|"62 adolescents were included in the study. Adolescents were assigned to intervention and control groups by randomization using simple numbers table. The intervention group was divided into 3 groups of 10 and included in a six-week psychoeducation program that lasted for one hour once a week, and 55 adolescents completed the program. The data on the sociodemographic characteristics of the adolescents constituting the sample were collected with the Participant Information Form. Data on the effectiveness of the psychoeducation program on sexual health knowledge and attitudes were collected with the Sexual Health Knowledge and Attitude Inventory before the psychoeducation, at the end of the training and at the 3rd month of follow-up."
75374374|NCT00365612|Drug|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
75374375|NCT02974166|Other|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
75374376|NCT02974166|Other|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
75374377|NCT02974166|Drug|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
75701192|NCT00742755|Behavioral|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
75701193|NCT03567213|Device|Surgical implantation of CortiCom system|Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
75701194|NCT00721214|Drug|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
75701195|NCT02564601|Behavioral|Piano Training|The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
75701196|NCT02564601|Behavioral|Computer Cognitive Training|The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
75865462|NCT03744065|Procedure|suprainguinal fascia iliaca block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
75865463|NCT05191914|Drug|Chidamide+ Fulvestrant|"Drug: Chidamide chidamide 30mg orally，Biw~Drug: Fulvestrant Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1"
75374378|NCT02974166|Drug|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
75374379|NCT05493098|Other|dry needling|"The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes."
75374380|NCT05493098|Other|sham (placebo) dry needling:|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
75374381|NCT05731778|Drug|Stannous Fluoride Toothpaste|0.454% stannous fluoride toothpaste
75374382|NCT05731778|Drug|Colgate fluoride toothpaste|0.76 % Sodium MonoFluorophosphate (MFP)
75374383|NCT05477264|Drug|Tislelizumab|"Induction therapy: Tislelizumab combined with radiation~Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance."
75374384|NCT00422318|Drug|Benzbromarone (drug)|
75374385|NCT00364676|Drug|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
75374386|NCT00364676|Drug|VLI|Patients are dosed on Day 1 of a 21-day cycle.
75374387|NCT00364754|Drug|Tesmilifene (YMB 1002)|
75374388|NCT05731700|Device|Drug Eluting Balloon|PCI of in-stent restenosis
75865464|NCT04060394|Drug|Phase I and Phase II: LAE001/prednisone + afuresertib|In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
75865465|NCT03688334|Drug|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
75865466|NCT03688334|Drug|Medical air (sham O2)|Medical air supplementation via Venturi mask
75374389|NCT00366236|Drug|Nitazoxanide|
75374390|NCT05731466|Device|CardioMems HF System|"Implantation CardioMems device.~Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements."
75374391|NCT04622540|Procedure|External biliary drainage|Application of external biliary drainage through duct-to-duct anastomosis
75537914|NCT06169748|Device|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
75701197|NCT02592512|Other|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
76028360|NCT05732389|Drug|Nivolumab|Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.
75537915|NCT06169748|Device|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
75537916|NCT06169748|Device|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
75537917|NCT06169254|Device|Transcranial current stimulation (tCS)|Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
75701198|NCT02592512|Other|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
75701199|NCT02593214|Device|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
75701200|NCT02592200|Dietary Supplement|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
76028361|NCT05732389|Drug|Ipilimumab|Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
75537918|NCT06169020|Device|Resting and maximal oxygen consumtion|All subjects will undergo tests for resting and maximal oxygen consumption while simoultaneously wearing a number of wearables and a heart rate monitor. They will also be tested for health related physical fitness and resting blood pressure. Their body composition will also be measured.
75701201|NCT02592200|Dietary Supplement|Placebo|Two doses per day for 28 days
75865467|NCT05191836|Behavioral|Evaluation of the effectiveness of Video Game Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during watching video game.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
75701202|NCT00720902|Procedure|Blood draws|Subjects will have serum cardiovascular markers assessed
75701203|NCT00720902|Drug|growth hormone releasing hormone (GHRH) & arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
75374392|NCT04741880|Drug|Lidocaine IV|"Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
75374393|NCT04741880|Drug|Saline|"Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
75374394|NCT05447234|Biological|Tcrx T cell|Sequential IV infusion
75865468|NCT05191836|Behavioral|Evaluation of the effectiveness of Audio Video Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during audio video distraction.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
75374395|NCT05433818|Behavioral|Group A|Skin-to-Skin Contact (SSC) contributes to mother-infant interaction and can increase breastfeeding success
75374396|NCT05433818|Other|Group B|education with a structured and expert opinion-based breastfeeding brochure
75374397|NCT04621838|Other|Assigned interventions.|"Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing.~The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited."
75374398|NCT04615130|Other|Rehabilitation|Rehabilitation, exercise training
75374399|NCT04551326|Other|manual hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
75374400|NCT04490486|Biological|UCMSCs|100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.
75374401|NCT04490486|Other|Placebo|Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion
75374402|NCT05421728|Behavioral|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
75701204|NCT00720902|Procedure|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
75701205|NCT00720902|Procedure|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
75701206|NCT00720902|Procedure|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
75701207|NCT02592278|Drug|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
76028362|NCT05716841|Other|Ballistic exercises|stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 Sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
75701208|NCT02592278|Drug|Control Group|Twice a day brush with fluoride toothpaste.
75701209|NCT00695019|Drug|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
75701210|NCT00695019|Drug|placebo lozenges|200 mg matching placebo lozenges
76028363|NCT05712408|Behavioral|800g Challenge|The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
75537919|NCT06169020|Device|Free living energy expenditure|All subjects will ingest a dose of doubly labelled water after which they will be fitted with several wearables. They will live their ordinary lives except that they will collect daily urine samples.
75537920|NCT06168565|Device|Intermittent pneumatic compression (AirRelax)|Moderate pressure (around 80mmHg); high pressure (around 200mmHg), both applied on the lower-limbs
75537921|NCT06168045|Diagnostic Test|Cerebral tissue oxygenation and blood pressure measurement|Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth
76028364|NCT05699538|Behavioral|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
75701211|NCT00918398|Drug|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
75865469|NCT05191836|Other|Evaluation of the anxiety in pediatric patients during dental treatment without using any type of distraction aids|"The child will be provided dental treatment without using any type of distraction aids.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
75865470|NCT04099277|Drug|LY3435151|Administered IV
76028365|NCT05698511|Drug|Psilocybin|Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
75701212|NCT00918398|Drug|AZD1981|514 mg oral solution, single dose
75701213|NCT00918398|Drug|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
75701214|NCT00918398|Drug|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
75865471|NCT04099277|Drug|Pembrolizumab|Administered IV
75865472|NCT03698786|Behavioral|Exercise|Participants will be required to complete two, 8-hours trials (exercise & control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
75865473|NCT03311256|Diagnostic Test|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
75865474|NCT03743987|Procedure|control group|a procedure used to prevent or resolves apical periodontitis.
75865475|NCT03743987|Procedure|MTA group|a procedure used to prevent or resolves apical periodontitis.
75865476|NCT03743987|Procedure|PRF group|a procedure that is used for wound healing
75865477|NCT03743987|Procedure|MTA + PRF group|a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
75537922|NCT06167525|Device|Real-time feedback through the device. Bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will be recorded|"During the first stage of the study the device will be set to record cervical spine positioning without bio-feedback signals. This will be used to record duration of time surgeons held maladaptation postures.~The second stage will involve real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will also be recorded.~The Neck Disability index score will be used to assess for neck pain and the functional implications in relation to reported neck pain. This will be completed following study completion."
75537923|NCT06167395|Dietary Supplement|Beta Alanine high dose|Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.
75537924|NCT06167395|Dietary Supplement|Beta Alanine low dose|Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.
75537925|NCT06167395|Dietary Supplement|Control product|Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
75537926|NCT06167330|Other|Progressive rehabilitation program|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
75374403|NCT05421728|Behavioral|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
75865478|NCT03688256|Device|Obalon Balloon System|6 month Obalon Intragastric Balloons
76028366|NCT05690672|Diagnostic Test|Delirium Screening|Either 3D-CAM or 4AT
76028367|NCT05675488|Diagnostic Test|Ultrasound|Thickness of flexor tendon and A1 pulley at MCP joint level
76028368|NCT05671029|Drug|Pritelivir and moxifloxacin placebo|oral administration
75374404|NCT00365924|Drug|Forteo|Open label single arm study with Forteo as an intervention
75374405|NCT05731310|Drug|Angong Niuhuang Pill|Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
75374406|NCT05360030|Drug|Naloxone|The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
75374407|NCT05360030|Drug|Saline|The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
75537927|NCT06167330|Other|Stimulation devices|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
75865479|NCT05171322|Device|WARD|"The following monitoring devices are included in the WARD monitoring system (as intervention):~Isansys Life Touch patch: Measures heart rate (HR), respiratory rate (RR) and electrocardiogram (ECG)~Wearable, wireless Pulse Oximeter (Model 3150 WristOx from Nonin): Measures peripheral oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR)~Blood pressure monitor (Meditech BlueBP-05): Measures BP every 30 minutes during daytime and every 60 minutes during the night~All included patients are set up with the monitoring devices after surgery when they are back at their ward (with a maximum of 24 hours postoperative). Afterwards they wear the devices for up to 5 days. All measurements are sent through bluetooth to a tablet serving as a gateway which in turn sends data to a central server where the algorithmic processing ensures."
76028369|NCT05671029|Drug|Pritelivir placebo, moxifloxacin and moxifloxacin placebo|oral administration
75374408|NCT05360030|Drug|Ketamine Hydrochloride|The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
75374409|NCT05360030|Device|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
75374410|NCT05360030|Device|pcTBS of DLPFC|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left DLPFC at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
75374411|NCT05360030|Device|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
75374412|NCT05731232|Dietary Supplement|Vivatlac Synbiotikum|Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
75374413|NCT05731154|Other|taking periorbital selfie images using smartphones|taking periorbital selfie images using smartphones
75374414|NCT05731076|Behavioral|Self-management support nutrition and exercise intervention|Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
75374415|NCT00364910|Behavioral|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
75537928|NCT06167083|Diagnostic Test|Machine Learning to Estimate Mortality|Using deep learning we try to develop an algorithm and anticipate mortality
75865480|NCT04053842|Diagnostic Test|PET Scan|PET imaging uses small amounts of a radioactive substance called a tracer to look for disease in the body. The radioactive substance used in this study is [18F]PSMA-1007.
75865481|NCT04053842|Drug|[18F]PSMA-1007 Injection|[18F]PSMA-1007 is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.
75537929|NCT06167057|Drug|Mitomycin/Gemcitabine|UTUC treatment
75537930|NCT06167057|Drug|Saline|UTUC treatment
75537931|NCT06166394|Drug|Spinal hypobaric Mepivacaine Local Anesthetic Injection|• Administration of a hypobaric spinal mixture for Day-Surgery patients: 3.4ml of 1.5% mepivacaine created by 3ml 2% mepivacaine with 1ml sterile water, and then discarding 0.6ml
75537932|NCT06166394|Drug|Spinal hypobaric Bupivacaine Local Anesthetic Injection|"Administration of a hypobaric spinal mixture for In-patients:~3ml of 0.33% bupivacaine created by 2ml 0.5% bupivacaine with 1ml sterile water"
75537933|NCT06166368|Other|Diurnal variation|Venous blood samples were obtained under standardized circumstances from 24 healthy young men every third hour through 24 hours, nine time points in total.
76028370|NCT05671029|Drug|Pritelivir placebo, moxifloxacin placebo and moxifloxacin|oral administration
76028371|NCT05669443|Device|conventional PEEP|Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
75701215|NCT04019600|Other|Echocardiography|Demographic data and health risk factors will be collected on day of screening, together with the above tests. Right heart catheterization will be separately arranged in patients with a high echocardiographic probability of PAH. For those with a low-intermediate echocardiographic probability, screening will be repeated within 1 year to ensure true negativity of the original scan.
75865482|NCT04053842|Diagnostic Test|Sodium MRI|Sodium MRI uses magnetic waves and a specially-designed rectal probe to measure the sodium concentration (amount of salt) in the prostate. Previous research has shown that higher sodium concentrations in the prostate might be a sign of more aggressive cancer.
75865483|NCT04053842|Diagnostic Test|Multiparametric MRI|MRI is a common medical diagnostic tool that uses magnetic waves and a contrast agent (dye) called Gadovist to take pictures of body tissue.
75865484|NCT03990389|Device|Chatbot Intervention|a chatbot will be used to monitor depression severity
75865485|NCT03168360|Procedure|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
75865486|NCT04037462|Drug|Dexamthasone|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
75701216|NCT04086602|Drug|IZD334|Active Drug
75701217|NCT04086602|Drug|Placebos|Placebo to Match
75701218|NCT00742833|Drug|KUC-7483|
75701219|NCT00742833|Drug|Placebo|
75701220|NCT04060953|Other|Health-Related Quality of Life Report|Subject report and interpretation guide based on SPADE cluster scores
75701221|NCT03472989|Device|Radial extracorporeal shock wave|"Patients will receive treatment once a week for 3 weeks. Treatment will be administered by using the rESWT device named Swiss DolorClast (EMS). 2000 impulses are implied via the power hand piece to the area of max tenderness at the insertion of the plantar fascia, with a pressure of 1.5-3 bars depending on what the patient tolerates. The treatments will be given by a trained physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
75701222|NCT03472989|Device|Sham-radial extracorporeal shock wave|"Patients will receive the same treatment as the patients in the group receiving real shock waves, but no real shock waves are conducted. The probe is similar in design, sound and shape.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
75701223|NCT03472989|Behavioral|Standardized high-load exercise program|"Patients will be instructed to do 2 exercises: Unilateral heel raise and unilateral leg squat three times a week for 12 weeks. The patients will have a total of 8 sessions supervised by a physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
75701224|NCT03472989|Behavioral|Usual care|Patients will get standardized information as in the other three intervention groups with information on pathogenesis, etiology and prognosis, and they will get custom made foot orthosis
75374416|NCT00364910|Behavioral|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
75374417|NCT05730998|Dietary Supplement|ANTHOCRAN FITOSOMA|The product (Anthocran phytosome or placebo) will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
75374418|NCT05730998|Dietary Supplement|PLACEBO|Placebo will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
75374419|NCT05341778|Other|Shoulder bridge|The shoulder bridge is great for, strengthening your gluteal muscles, quadriceps, hamstrings, pelvic floor, abdominals and back muscles; most notably the tiny ones which control movement of each individual vertebrae and can weaken after episodes of back pain.
75865487|NCT05194878|Drug|neoadjuvant chemotherapyI|mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
75537934|NCT06166316|Device|overdenture retained by locator attachments.|"• Implant-retained overdenture construction procedures:~Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing."
75537935|NCT06164522|Other|Abdominal ultrasound|Abdominal ultrasound to detect sliding sign
75537936|NCT06164470|Behavioral|Support Group|monthly virtual patient support with multidisciplinary education for 12 sessions
75865488|NCT05194878|Procedure|Colectomy|Radical colectomy
75865489|NCT05194878|Drug|adjuvant chemotherapy|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
76028372|NCT05669443|Device|optimized PEEP|Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
76028373|NCT05653921|Other|In vivo confocal microscopy (IVCM)|In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
76028374|NCT05643469|Other|Self-determination theory-based intervention plus instant messaging|subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Follow-up booster intervention with WhatsApp/WeChat messages to help them to adhere to their schedules and independent 1-minute videos will be delivered.
76028375|NCT05643469|Other|AWARD model|Subjects will receive a brief intervention using the AWARD model and all of them will advise to quit immediately. Only general health advice via WhatsApp/WeChat will be delivered.
76028376|NCT05638581|Biological|LTOWB|Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.
76028377|NCT05638581|Biological|Components|Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.
76028378|NCT05633615|Biological|Axicabtagene Ciloleucel|Given IV
76028379|NCT05633615|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
76028380|NCT05633615|Procedure|Computed Tomography|Undergo PET-CT or CT
75374420|NCT05341778|Other|Clam shell|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
76028381|NCT05633615|Drug|Cyclophosphamide|Given IV
76028382|NCT05633615|Drug|Fludarabine|Given IV
75865490|NCT03693326|Drug|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
76028383|NCT05633615|Biological|Lisocabtagene Maraleucel|Given IV
76028384|NCT05633615|Biological|Mosunetuzumab|Given IV
76028385|NCT05633615|Other|Patient Observation|Undergo observation
76028386|NCT05633615|Drug|Polatuzumab Vedotin|Given IV
76028387|NCT05633615|Procedure|Positron Emission Tomography|Undergo PET-CT
76028388|NCT05633615|Biological|Tisagenlecleucel|Given IV
75374421|NCT05341778|Other|Scissors|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
75374422|NCT05341778|Other|Adductor squeeze|Adductor Squeeze exercise The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees.
75374423|NCT05341778|Other|Pelvic clock supine|The pelvic clock is a brilliant exercise to help achieve flexibility and strength in the lower back, pelvic floor, and core-in order to prevent pain and injury.
75374424|NCT05341778|Other|urine hold and tummy tuck in|During tummy tuck patients are able to strategically tighten and reinforce the muscles around the pelvic floor, urethra, and other structures. This increased strength and support greatly reduces stress urinary incontinence
75374425|NCT05341778|Other|Bridging|A bridge exercise isolates and strengthens your gluteus (butt) muscles - the gluteus maximus, medius and minimus - and hamstrings, which are the main muscles that make up the posterior chain. It is done by lying on your back with your knees bent, feet flat on the ground and at a comfortable distance from your butt.
75374426|NCT05341778|Other|Split table top|To strengthen your abs, shoulders, arms and legs. The most important part of this move is to contract your abs fully before you start to lower your hips
76028389|NCT05619510|Behavioral|PRIME Intervention|Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
75374427|NCT05341778|Device|Electrical muscle stimulation|Electric stimulation works by mimicking the natural way by which the body exercises its muscles. The electrodes attached to the skin deliver impulses that make the muscles contract. It is beneficial in increasing the patient's range of motion and improves the circulation of the body.
75374428|NCT04742426|Other|WHO recommended PPE|Uses polycarbonate safety spectacles, fluid-resistant (Type IIR) surgical mask and disposable surgical gown. No head or foot cover.
75374429|NCT04742426|Other|Super-safe setup|Uses surgical cap, FFP3 respirator covered by surgical mask, face shield, whole-body suit (Tyvec), 3 pairs of gloves typed to suit sleeves and disposable foot cover.
75374430|NCT04740944|Behavioral|Salutogenic Approach Based Interview|Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
75374431|NCT05730686|Procedure|Registry of Therapy of patient's diagnosed with FibroLamellar|Registry of Therapy of patient's diagnosed with FibroLamellar
75374432|NCT05297552|Drug|RC48-ADC|Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
75374433|NCT05297552|Drug|JS001|Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
75374434|NCT05272202|Drug|Propofol|STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
75865491|NCT01319916|Drug|ATX-101|ATX-101 2mg/cm2
75865492|NCT03988907|Drug|Risdiplam|Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results
76028390|NCT05608070|Drug|Oxytocin|Oxytocin 30 IU in 500 ml IV at a rate of 5 IU/h (83.33 ml/h). The infusion will be started intra-operative once the uterus is removed and will continue to run until completion of the medication or discharge from PACU criteria are met, whichever occurs first.
76028391|NCT05608070|Drug|Placebo|0.9% saline infusion at the rate of 83.3 ml/h.
76028392|NCT05587543|Behavioral|PK Blood Collection|All subjects were subjected to PK blood sampling as prescribed by the protocol.
76028393|NCT05587543|Drug|CAR|Target A positive subjects will receive CAR-T cell therapy.
76028394|NCT05587543|Drug|TCR|Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.
75537937|NCT06164457|Other|ePROM Survey|The APPROACH ePROM survey consists of several well validated PROM instruments, including the Seattle Angina Questionnaire 7-item version,[4] the EuroQol EQ5D-5L,[5] the Medical Outcomes Study Social Support Scale (8 item version),[6] the Patient Health Questionnaire 2-item and 9-item (PHQ2/9) depression screening tools[7], and the Self-Care of Coronary Heart Disease Inventory (SC-CHDI-V3).[8]
75701225|NCT00742911|Drug|Disulfiram|"Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram."
75701226|NCT00742911|Drug|Copper Gluconate|"Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily"
75701227|NCT00742989|Other|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
75701228|NCT00742989|Other|Sham OLT|Therapeutic massage performed
75701229|NCT02678871|Device|Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
75701230|NCT02678871|Device|WATCHMAN|LAA closure with the WATCHMAN device
75701231|NCT02565069|Device|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
75701232|NCT00694707|Drug|Placebo|Placebo was supplied in capsules.
75701233|NCT00694707|Drug|Cariprazine|Cariprazine was supplied in capsules
75701234|NCT00694707|Drug|Risperidone|Risperidone was supplied in capsules
75701235|NCT00692913|Drug|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
75701236|NCT00692913|Dietary Supplement|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day)."
75701237|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
76028395|NCT05587504|Other|E-cigarette with sweetness type 1 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 1."
76028396|NCT05587504|Other|E-cigarette with sweetness type 1 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 2."
76028397|NCT05587504|Other|E-cigarette with sweetness type 2 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 1."
76028398|NCT05587504|Other|E-cigarette with sweetness type 2 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 2."
76028399|NCT05579470|Behavioral|NIATx|For each country, the learning collaborative will be comprised of a Chief Narcologist from each region where the investigators will initially train them and the coaches using all the tools from the NIATx Academy (2-3-day training). The national coach for each country will receive ongoing and in-depth coaching from a US-based super coach. A nationwide Nominal Group Technique (NGT) will be conducted to assess barriers and potential targets to guide decision-making about changes. At the end of the initial meeting, each Chief Narcologist (CN) will be able to identify a change target for Plan, Do, Study, Act (PDSA) (entry, retention) and create a Change Project Form to state what will be done (e.g. flowcharting), who is involved (team), what are the measures and timeframe (<4 weeks).
76028400|NCT05564130|Drug|Sodium bicarbonate|Sodium bicarbonate 1 mmol/ml
75701238|NCT00743067|Drug|GSK1363089 (formerly XL880)|GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
75701239|NCT00743223|Other|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
75701240|NCT00743301|Other|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
75865493|NCT03988907|Drug|Midazolam|single dose administration of 2 mg midazolam
75701241|NCT00694551|Biological|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
76028401|NCT05564130|Drug|Sodium chloride|Sodium chloride 9 mg/mL
75701242|NCT00694551|Drug|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
75701243|NCT00743379|Drug|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
75701244|NCT00689871|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
75701245|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
75701246|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
76028402|NCT05553691|Drug|SPL026|Intravenous
76028403|NCT05530655|Drug|Lisinopril Tablets|This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.
76028404|NCT05528926|Other|Non-Violent Resistance|"The program's core features are parental self-control and emotional support. In the NVR program, parents recruit supporters to help them deal with their children's problematic behaviours. Developing emotional control means that the parent opposes non-violent resistance to his child's behaviour, not escalating the explosive situation.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
75701247|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
75701248|NCT00793793|Drug|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
75701249|NCT00793793|Drug|Placebo|
75701250|NCT00743457|Device|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
75701251|NCT02483637|Device|RejuvenAir|Device: RejuvenAir
75701252|NCT02602613|Device|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
75701253|NCT02602379|Other|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
75701254|NCT03999593|Procedure|Resection of perihilar cholangiocarcinoma|Resection of perihilar cholangiocarcinoma
75701255|NCT02603705|Drug|Oxycodone extended-release|
75701256|NCT00776789|Other|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
75701257|NCT00776789|Other|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
75865494|NCT03693248|Drug|Two cycles of neoadjuvant chemotherapy|Two and three cycles of neoadjuvant chemotherapy will be administered in experimental and control groups, respectively
75865495|NCT03987191|Drug|Multiple daily ijnection using Insulin Degludec and Insulin Aspart|Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
75865496|NCT04098809|Device|16 French urinary catheter|16 French urinary catheter
75865497|NCT04098809|Device|20 French urinary catheter|20 French urinary catheter
75701258|NCT00776555|Drug|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
75865498|NCT03122184|Behavioral|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
75865499|NCT03122184|Behavioral|Motivational Interviewing Health Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
75701259|NCT00776555|Drug|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
75701260|NCT05538533|Radiation|46 Gy Radiation Therapy|Dose per fraction of 4.6.
75701261|NCT05538533|Radiation|40 Gy Radiation Therapy|Dose per fraction 5.7.
75701262|NCT05538533|Radiation|35 Gy Radiation Therapy|Dose per fraction 7.0.
75701263|NCT00915785|Drug|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
75701264|NCT04104581|Other|Control Refined Grain Diet|Subjects will be fed the average American diet except it will be free of whole grains
75865500|NCT03745781|Drug|Placebos|placebo pills
75865501|NCT01372176|Other|Early Goal-Directed Nutrition|"Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).~Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.~Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
76028405|NCT05528926|Other|Parent Management Training|"The gold-standard treatment for disruptive behaviour disorder in children and adolescents. The objective is to train parents to cope with the difficult situations they encounter, to teach them effective control strategies that are coherent and adapted to the 'deviant' behaviour of their children to reduce the intensity of events and their repercussions within the family.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
76028406|NCT05528926|Drug|Treatment As Usual|The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
75537938|NCT06163846|Diagnostic Test|Assess the role of baseline image mining, ctDNA data and their combination in patient staging and risk stratification|Assess the combination of baseline and follow-up image mining, together with ctDNA, in predicting disease relapse and progression.
75865502|NCT01372176|Other|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
75865503|NCT04396106|Drug|AT-527|One 550 mg tablet of AT-527 administered every ~12 hours (twice a day) for a total of 5 days
75865504|NCT04396106|Other|Placebo|One placebo tablet administered every ~12 hours (twice a day) for a total of 5 days
75865505|NCT04396106|Drug|AT-527|Two 550 mg tablets of AT-527 administered every ~12 hours (twice a day) for a total of 5 days
75865506|NCT04396106|Other|Placebo|Two placebo tablets administered every ~12 hours (twice a day) for a total of 5 days
75865507|NCT03743831|Device|orotracheal intubation by direct laryngoscopy|Orotracheal intubation by direct laryngoscopy by metal blade type Macintosch
75865508|NCT03743831|Device|orotracheal intubation by indirect laryngoscopy|orotracheal intubation by indirect laryngoscopy by Airtraq
75865509|NCT01373970|Drug|Placebo|Placebo, one tablet daily for 12 weeks
75865510|NCT01373970|Drug|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
75865511|NCT03743675|Behavioral|Diet-Induced Weight Loss|Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.
75865512|NCT03743675|Behavioral|Aerobic Exercise Training|"Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months."
75865513|NCT04050098|Drug|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
75374435|NCT05272202|Device|Median nerve stimulation|The right-hand median nerve will be stimulated in the same way as for measurement with a conduction velocity or for an evoked potential. Two stimulation electrodes will be placed on the right-hand wrist according to the standards.The stimulation is transcutaneous and painless using the specific Micromed device Sd Ltm Stim Energy (Micromed, Mˆacon, France). The stimulus intensity will range between 3 and 14 mA. The stimulation duration will be 100 ms with a frequency of 0.1 Hz.
75374436|NCT05272202|Device|EEG measurements|Changes in ERD and ERS patterns during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. EEG signals will be acquired using the OpenViBE platform with a Biosemi Active Two 64-channel EEG system, arranged in the Biosemi's ABC system covering the entire scalp at 2048 Hz. Among all recorded sites, some of the electrodes will be localized around the primary motor cortex, the motor cortex, the somatosensory cortex, and the occipital cortex.
75374437|NCT01575834|Drug|Romosozumab|Administered by subcutaneous injection once a month (QM)
75374438|NCT01575834|Drug|Placebo|Administered by subcutaneous injection once a month (QM)
75374439|NCT01575834|Drug|Denosumab|Administered by subcutaneous injection once every 6 months (Q6M)
75374440|NCT05251454|Procedure|Brain Stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase).
75701265|NCT04104581|Other|Low Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain oats
75865514|NCT04050098|Drug|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
75865515|NCT03745625|Drug|HSK3486|"First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h."
75865516|NCT03745625|Drug|Propofol|"First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h."
75374441|NCT04741100|Other|Ex-vivo analysis|Ex-vivo analysis
75374442|NCT05726474|Behavioral|Combined exercise|Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
75701266|NCT04104581|Other|High Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain oats
75701267|NCT04104581|Other|Low Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain wheat
75701268|NCT04104581|Other|High Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain wheat
75701269|NCT04104737|Device|Spire Medical Health Tag|"Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References."
75865517|NCT04021706|Drug|Anamorelin Hydrochloride|Ghrelin receptor agonist
75865518|NCT04021706|Drug|Placebo|placebo is a inert substance
75865519|NCT05194020|Other|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
75865520|NCT03698630|Drug|Prednisolone Sodium Phosphate|Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
75865521|NCT03698630|Drug|Dexamethasone|"Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon* on the other containing 2 mg dexamethasone."
75865522|NCT01375452|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
75701270|NCT00720434|Drug|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
75865523|NCT03053466|Drug|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
75865524|NCT03687944|Other|Validity and reliability|Test-retest method and concurrent validity
75865525|NCT05131308|Other|leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA|All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.
75537939|NCT06161987|Behavioral|Early comprehensive rehabilitation|Patients randomized to the rehabilitation intervention group will be offered comprehensive rehabilitation plan containing 18 sessions of a structured outpatient-based exercise program over 6 weeks (3 times per week).
75537940|NCT06160713|Drug|Itraconazole 65 MG|Two capsules of suba-itraconazole 65 mg twice daily for 6 months
75701271|NCT00720434|Drug|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
75865526|NCT03624140|Device|blood measurement|Hemoglobin measurement
75865527|NCT03624140|Device|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
75865528|NCT03624140|Device|hemoCue|non invasive method of hemoglobin measurement
75865529|NCT04091087|Drug|crisaborole ointment|crisaborole ointment
75865530|NCT04091087|Other|vehicle ointment|vehicle ointment
75865531|NCT03687866|Genetic|non invasive prenatal testing|
75865532|NCT03046836|Drug|Oxytocin|40 IU oxytocin nasal spray
75865533|NCT03046836|Drug|Placebo|Saline
76028407|NCT05526534|Device|heated humidified high flow nasal cannula oxygen therapy, HFNC|HFNC can accurately provide 21% ~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
76028408|NCT05526534|Device|Nasal cannula oxygen|Nasal cannula oxygen has become a routine part of postoperative treatment
75374443|NCT05726474|Behavioral|High interval training|Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
75701272|NCT00720434|Drug|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
75374444|NCT04668638|Other|Respiratory rehabilitation|Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.
75374445|NCT05707442|Procedure|Stent Implantation|Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
75537941|NCT06160713|Other|Standard care|Standard care for bronchiectasis
75537942|NCT06160687|Procedure|PSV mode during NIV|NIV will be delivered using PSV mode of ventilation
75537943|NCT06160687|Procedure|ASV intellisync|ASV intellisync mode will be used to deliver NIV
75865534|NCT03687788|Behavioral|Laughter Therapy|Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
76028409|NCT05515848|Other|No intervention|There is no intervention in this retrospective study.
76028410|NCT05509972|Device|total knee prosthesis implantation|Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living
76028411|NCT05455606|Other|Best Practice|Receive usual care
75537944|NCT06159699|Other|Online Survey|The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
75865535|NCT03400033|Drug|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
75865536|NCT03400033|Drug|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
76028412|NCT05455606|Other|Chart Abstraction|Ancillary studies
76028413|NCT05455606|Other|Educational Intervention|Physicians access genomic testing education materials
75701273|NCT00720434|Drug|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
75701274|NCT00776009|Drug|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
75701275|NCT00776009|Drug|Placebo|Placebo Comparator
75701276|NCT00694161|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
75701277|NCT00720356|Drug|bevacizumab|10mg/kg administered intravenously every 2 weeks
75701278|NCT00720356|Drug|erlotinib hydrochloride|150 mg/daily orally
75865537|NCT03400033|Drug|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
76028414|NCT05455606|Procedure|Genomic Profile|Patients undergo genomic testing
76028415|NCT05455606|Other|Interview|Ancillary studies
76028416|NCT05455606|Other|Questionnaire Administration|Ancillary studies
76028417|NCT05455606|Other|Tumor Board Review|Patients undergo genomic tumor board review
76028418|NCT05453188|Device|Experimental|Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
76028419|NCT05453188|Genetic|Control|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
75701279|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
75701280|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
75701281|NCT02564913|Other|clinical evaluation|
75701282|NCT00745953|Drug|Valsartan|Valsartan 320mg PO daily for 8 months
76028420|NCT05448573|Diagnostic Test|Fatigue Screening and assessment|(Newly) diagnosed cancer-patients from any cancer entity. No intervention.
75865538|NCT03400033|Drug|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
75701283|NCT00745953|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
75701284|NCT00720278|Drug|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
75701285|NCT00720278|Drug|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
75701286|NCT00720278|Drug|Placebo|0 mcg Placebo daily
75537947|NCT06155318|Diagnostic Test|68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included|Patients meeting the inclusion criteria will undergo 68Ga-DOTATOC PET(PET/MRI or PET/CT) as part of their routine work-up, according to the referral clinicians' indication.PET/MRI will be performed on a 3.0T time of flight PET/MRI. Simultaneous PET/MRI will start approximately 60 minutes after the injection of 68Ga-DOTATOC.
75701287|NCT00743613|Behavioral|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
75865539|NCT02995902|Device|FLT-PET|
75865540|NCT02995902|Device|MRI|
75865541|NCT05123820|Drug|Treatment period A|Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
76028421|NCT05439668|Other|Classic abdominal strengthening exercises|Classic abdominal strengthening exercises (Curl-up, sit-ups and leg-rise), balance exercises, general mobility and upper limb strengthening exercises.
75537948|NCT06154174|Dietary Supplement|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
76028422|NCT05439668|Other|Hypopressive abdominal exercises program|Hypopressive abdominal exercises, balance exercises, general mobility and upper limb strengthening exercises
75701288|NCT00743613|Procedure|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
76028423|NCT05425030|Dietary Supplement|Low-Sodium Salt Substitute|Tata SuperLite low-sodium salt substitute has 30% of the weight of the product replaced with potassium chloride (KCl) which is itself a non-prescription dietary supplement. Each household randomized to the intervention arm will receive one bag (1.5kg) per month to utilize instead of their usual table/cooking salt.
76028424|NCT05425030|Behavioral|Information/Education|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
76028425|NCT05421949|Other|Exercise group|Incremental Shuttle Walking Test
76028426|NCT05384171|Behavioral|Measurement-Based Transition Assistance|Measurement-Based Transition Assistance (MBTA) provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
76028427|NCT05384171|Behavioral|Assessment Only|Veterans randomized to this condition will complete a well-being assessment only
75537949|NCT06154174|Dietary Supplement|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
75701289|NCT00743691|Other|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
75701290|NCT00746031|Drug|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
75701291|NCT00746031|Drug|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
75701292|NCT00720122|Drug|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
76028428|NCT05374564|Drug|(18F)Flutemetamol|18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)
75537950|NCT06154174|Drug|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
75537951|NCT06151418|Drug|Novel hormonal therapy|As provided in real-world setting
75537952|NCT06151236|Drug|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
75537953|NCT06150716|Drug|ION356|Administered as intrathecal (IT) injection.
76028429|NCT05370599|Drug|Anti-hypertensive agent: amlodipine|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
75374446|NCT05707442|Drug|Acetazolamide-based medical therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
75374447|NCT05707442|Behavioral|Weight loss|The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
75374448|NCT04604132|Drug|Derazantinib|Derazantinib will be administered orally at a dose of 300 mg once a day and at a dose of 200 mg twice daily as monotherapy in the Substudy 1.
75374449|NCT04604132|Drug|Derazantinib-paclitaxel-ramucirumab|"Derazantinib will be administered at the RP2D for derazantinib-paclitaxel-ramucirumab determined in Substudy 2 in combination with paclitaxel and ramucirumab.~Paclitaxel will be administered intravenously at the RP2D for derazantinib-paclitaxel-ramucirumab determined in Substudy 2 on days 1, 8, and 15 of a 28-day cycle in combination with derazantinib and ramucirumab.~Ramucirumab will be administered intravenously at the RP2D for derazantinib-paclitaxel-ramucirumab determined in Substudy 2 every 2 weeks in combination with derazantinib and paclitaxel."
75374450|NCT04604132|Drug|Derazantinib-atezolizumab|"Derazantinib will be administered orally at a dose of 300 mg once a day in combination with atezolizumab.~Atezolizumab will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with derazantinib."
75557541|NCT03272568|Drug|Recombinant FIX Fc fusion product Alprolix|Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
75701293|NCT00746109|Procedure|Wound packing|"1/4 non-iodoform packing loosely placed inside abscess cavity."
76028430|NCT05370599|Drug|Anti-hypertensive agent: Chlorthalidone|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
76028431|NCT05370599|Drug|Anti-hypertensive agent: Losartan|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
75374451|NCT04604132|Drug|Paclitaxel-ramucirumab|"Paclitaxel will be administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab will be administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
76028432|NCT05370599|Device|Home BP monitoring with cuffed device|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
76028433|NCT05370599|Device|Home BP monitoring with cuffed device + BP patch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
75701294|NCT00746109|Procedure|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
75701295|NCT03961490|Other|No interventional study|No interventional study
76028434|NCT05370599|Device|Home BP monitoring with cuffed device + BP watch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
76028435|NCT05365529|Behavioral|Time-Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
75537954|NCT06146530|Device|Treatment|The intervention consists of 7 sessions of CBT for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will be applicable to them. The intervention is based on an evidence-based treatment protocol; hence the sessions will flow from one to the other and the user will complete the sessions in a progressive direction. However, they can repeat a session before going on to the next session. Once all sessions have been completed, the user can go back over any of the sessions. There are anxiety management exercises, which the user can go to whenever they wish. There are also a therapy reflection journal and self-care resources including further anxiety management techniques, resources, and podcasts that the user will have access to whenever they want.
75537955|NCT06145555|Behavioral|Acute psychological sleep stabilization|See above (arm description)
75865542|NCT05123820|Drug|Treatment period B|ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
75374452|NCT05193188|Drug|Anlotinib hydrochloride|Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
75374453|NCT05193188|Drug|PD-1 inhibitor|Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
75537956|NCT06145555|Behavioral|Sleep hygiene education|See above (arm description)
75537957|NCT06144671|Drug|GT201|Autologous tumor infiltrating lymphocyte injection
75865543|NCT04089761|Device|Nerivio|Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
75865544|NCT03118518|Device|Cryoablation|Pulmonary vein isolation via ablation with cryoballoon catheter
75865545|NCT03118518|Drug|Antiarrhythmic drug|Antiarrhythmic drug initiation
75374454|NCT04799262|Drug|Tofacitinib 5 MG|Oral tofacitinib at the dose of 5mg twice a day was given for 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if<10 the daily GC dosage was decreased by 2.5mg; if>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
75374455|NCT01196130|Behavioral|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
76028436|NCT05365529|Behavioral|Standard of Care|Participants in the Standard of Care group will continue to follow their physician's treatment plan for type II diabetes mellitus.
75537958|NCT06140186|Drug|Topical Timolol|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.
75537959|NCT06140186|Drug|Betamethasone Valerate|Betamethasone valerate 0.1% cream application twice daily
75865546|NCT03984305|Device|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~An application to configure the data logger and transfer the acquired data at the end of a recording."
75865547|NCT03984305|Device|Personal KinetiGraph® (PKG®) Report|"The Personal KinetiGraph (PKG®) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by GKC.~The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~• A series of algorithms that analyze the uploaded data, producing a PDF that is delivered to the clinician. The PDF contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
76028437|NCT05331482|Other|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
76028438|NCT05331482|Other|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with conventional training protocol.
76028439|NCT05301712|Drug|Naloxone hydrochloride 5.0mg/5ml|"Initial dose: 4mg, Intravenous injection~Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~Total dose: 4mg+8mg/day*7=60mg"
76028440|NCT05301712|Drug|Sodium Chloride 45mg/5ml|"Initial dose: 4ml, Intravenous injection~Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~Total dose: 4ml+8ml/day*7=60ml"
76028441|NCT05288712|Other|Training protocol with the device cervical for treatment (CDAT)|Training protocol with the cervical device for treatment (CDAT)
76028442|NCT05288712|Other|Conventional training protocol|Conventional training protocol
76028443|NCT05268939|Diagnostic Test|LumiraDx SARS-CoV-2 & Flu A/B test|Swab Samples for Diagnostic test
76028444|NCT05268939|Diagnostic Test|LumiraDx SARS-CoV-2 & RSV test|Swab Samples for Diagnostic test
76028445|NCT05266612|Drug|VG2025|"1.0×108PFU Day 1 and 15~2.0×108PFU Day 1 and 15~3.0×108PFU Day 1 and 15~4.0×108PFU Day 1 and 15"
76028446|NCT05266612|Drug|Nivolumab Injection [Opdivo]|Flat dose of 240 mg every two weeks.
75374456|NCT01196130|Other|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
75374457|NCT01041534|Other|Survey|Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
75374458|NCT00851136|Drug|bevacizumab|Intravenous repeating dose
75374459|NCT00851136|Drug|FOLFOX|Intravenous repeating dose
75374460|NCT00851136|Drug|PRO95780|Intravenous repeating dose
75537960|NCT06138119|Behavioral|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/ she belongs. Stereotype threat manipulation will be performed on the male and female participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare fiberoptic intubation performance between male and female anesthesiologists. Additionally, we are investigating whether the high inclination of males towards computer games has any impact on their fiberoptic intubation success. The other participants (Control Group) will not be given any prior information."
75865548|NCT03397771|Drug|Litoxetine|oral study medication provided in a dose titration manner
75865549|NCT03397771|Drug|placebo|placebo medication provided in a dose titration manner
76028447|NCT05222191|Drug|Spironolactone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
76028448|NCT05222191|Drug|Chlorthalidone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
75537961|NCT06138002|Device|LumbaCure®|LumbaCure®is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
75537962|NCT06138002|Procedure|Physical Exercises supervised by the physiotherapist|A set of core stability/active qualitative mobilization exercises have been defined, corresponding to standard exercises proposed in center rehabilitation program
75865550|NCT05009160|Device|dreaMS App R2.1|The Healios+Me platform App which contains the dreaMS App will be downloaded by all participants and all participants (PwMS and HC) will follow the same schedule
75701296|NCT04087382|Device|thrombectomy|Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.
75865551|NCT03711721|Dietary Supplement|Food basket|
75865552|NCT03711721|Dietary Supplement|Ready-to-Use Therapeutic Food|
75865553|NCT02876835|Drug|Daprodustat|The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
75865554|NCT02876835|Drug|Darbepoetin alfa|The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
75865555|NCT02876835|Drug|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
76028449|NCT05222191|Drug|Placebo|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
76028450|NCT05189015|Drug|Olmesartan|- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
76028451|NCT05161845|Biological|Measles, Mumps and Rubella Combined Vaccine, Live|0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.
76028452|NCT05161169|Genetic|Genome Sequencing|20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
76028453|NCT05153070|Drug|Cyclosporin|• Ciclosporin: 3.5mg/kg, twice a day, oral, between Day 1 and Day 60
76028454|NCT05153070|Drug|ILT101|• ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.
76028455|NCT05153070|Drug|Placebo|• Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.
76028456|NCT05138705|Biological|Quadrivalent Influenza Virus Split Vaccine|0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains
76028457|NCT05129631|Behavioral|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
75537963|NCT06137170|Drug|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
75537964|NCT06137066|Dietary Supplement|200mg GCE +200mg ALA|200mg green coffee extract + 200mg alpha-lipoic acid
75537965|NCT06137066|Dietary Supplement|200mg GCE +400mg ALA|200mg green coffee extract + 400mg alpha-lipoic acid
75537966|NCT06137066|Dietary Supplement|200mg GCE + 200mg DHB|200mg green coffee extract + 200mg dihydroberberine
75537967|NCT06137066|Dietary Supplement|Placebo|microcrystalline cellulose with 5 mg magnesium stearate and 5 mg silicon dioxide
75701297|NCT04087382|Other|non intervention group|medical treatment (Asprin, statin, nootropic drug)
75701298|NCT03880929|Other|no intervention|no intervention
75865556|NCT02876835|Drug|Iron Therapy|Participants will receive supplemental iron therapy if ferritin is <=100 ng/mL or TSAT is <=20%. The investigator will choose the route of administration and dose of iron.
75865557|NCT04086641|Device|Crossover foot|A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
76028458|NCT05119556|Behavioral|Video Telehealth Pulmonary Rehabilitation|Participant will be asked to exercise 3 times a week at their home for 60 minutes each session, via live two-way videoconferencing using a data-enabled smart phone or similar device. A total of 36 sessions will be administered over 13 weeks post-discharge. Sessions will be administered by exercise physiologists located at the University of Alabama at Birmingham. Each session will be scheduled with up to three other participants at a time to mimic group sessions as delivered at center-based pulmonary rehabilitation programs. Exercise sessions will include aerobics, strength or resistance training, breathing exercises, and education sessions. The exercise plans will be tailored according to the participants' baseline exercise tolerance as determined by an initial six minute walk test and their answers to the questionnaires at the baseline visit.
76028459|NCT05107661|Behavioral|Telephone Prompt|Scripted messaging to remind subjects to complete their colorectal screening (colonoscopy or fecal test)
75537968|NCT06136000|Other|Sacral erectör spinae plane block|Group S will be placed on their side. Asepsis is fifth in the transverse plane under antisepsis standards. high-frequency linear USG probe into the spinous process . The USG probe will be shifted caudally to visualize the first and second median sacral crest. The USG probe is then placed on the second medial It will be placed 3-4 cm lateral to the sacral apex and the mid-sacral apex will be imaged. On the USG screen, from top to bottom, erector spinae muscle, multifidus muscle and sacral intermediate The crest will be displayed. 0.25% bupivacaine will be administered in a total volume of 0.5ml/kg (maximum 20 cc ) by applying negative aspiration with the in-plane technique with a 50 mm Stimuplex A needle.
75537969|NCT06136000|Other|Ring Block|The patient is under general anesthesia. Before the surgical procedure begins, the pediatric surgeon administers 0.5ml/kg (maximum 20cc) 0.25% bupivacaine to the base of the root of the penis with a 25-gauge needle at 3, 6, 9, and 12 o'clock.
75701299|NCT02564835|Other|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
75865558|NCT04086641|Device|Energy Storing Foot|A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
75865559|NCT03503318|Drug|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm.
75865560|NCT03503318|Drug|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm.
75865561|NCT03396913|Device|IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
75865562|NCT03396913|Device|Sham IPL|Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
76028460|NCT05097287|Drug|Dupilumab|solution for injection subcutaneous
76028461|NCT05097287|Drug|Placebo|solution for injection subcutaneous
75537970|NCT06134323|Device|medication-combined transcutaneous vagus nerve stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for active stimulation
75537971|NCT06134323|Device|medication-combined sham stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for sham stimulation
76028462|NCT05065671|Drug|Tolcapone 100 MG|Tolcapone 100 mg by mouth once
76028463|NCT05065671|Drug|Duloxetine 20 MG|Duloxetine 20 mg by mouth once
76028464|NCT05057741|Behavioral|Multimodal prehabilitation|"Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given."
76028465|NCT05045638|Drug|Rosuvastatin|Oral dose
76028466|NCT05045638|Drug|Sotorasib|Oral dose
76028467|NCT05040360|Drug|Capecitabine|Given PO
76028468|NCT05040360|Drug|Temozolomide|Given PO
76028469|NCT05017948|Other|Risk score based intervention|Targeted interventions based off of risk score software
76028470|NCT05011734|Other|Fast Track recovery pathway|Multidisciplinary approach alongside the orthopedic surgeon
76028471|NCT05011513|Drug|PF-07321332|PF-07321332 (tablet)
76028472|NCT05011513|Drug|Ritonavir|Ritonavir (capsule)
76028473|NCT05011513|Drug|Placebo|Placebo (tablet)
76028474|NCT05011513|Drug|Placebo|Placebo (capsule)
75865563|NCT03396913|Procedure|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
75865564|NCT01375920|Drug|Metyrapone|500 milligrams to be taken twice a day orally
75865565|NCT01375920|Drug|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
75865566|NCT03982433|Behavioral|Motivation and Cognitive Behavioral Management for Alcohol and Pain|Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
75537972|NCT06129552|Procedure|Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation|Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.
75537973|NCT06126328|Device|Materna Prep Device|Subjects are treated with Materna Prep Device prior to vaginal delivery
75865567|NCT03396835|Device|INVSENSOR00009|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
75865568|NCT01375998|Drug|EE20/DRSP(YAZ, BAY86-5300)|Patients in daily life treatment receiving YAZ for dysmenorrhea.
75865569|NCT03743597|Device|SOCKNLEG|"Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other"
75865570|NCT03743597|Device|Sigvaris COTTON|"Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other"
75865571|NCT03683108|Drug|Resveratrol and Carbossimetyl Beta Glucan|Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
75865572|NCT03683108|Other|Saline Solution|Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
75865573|NCT05137860|Drug|Bortezomib|Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
75865574|NCT03682952|Drug|Alprostadil Injection|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.
75865575|NCT03682952|Drug|Beraprost sodium tablets|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
75865576|NCT03682718|Device|Transcervical Foley catheter|combined methods of induction of labor Floey Catheter with misoprstol
75865577|NCT03682718|Drug|Misoprostol|Misoprstol inserted vaginally for induction of labor
75865578|NCT03682640|Drug|Azithromycin Monohydrate|Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
75865579|NCT03682640|Drug|Insulin Lispro|Solution for intravenous or subcutaneous use
75865580|NCT03682640|Behavioral|Dietician support|Dietary advice
75701300|NCT02564835|Other|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
75701301|NCT04085666|Drug|CDX 6114|CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
75865581|NCT03682562|Diagnostic Test|DNA Integrity Index|"This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones."
75537974|NCT06123598|Behavioral|Therapeutic exercise program plus action observation training|Participants make an observation of actions related to the training they are going to perform before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
75865582|NCT03687476|Drug|VTS-270|VTS-270 200 mg/mL administered as described in the arm group description.
75865583|NCT01376076|Drug|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
75865584|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
75865585|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
75865586|NCT03687398|Diagnostic Test|genetic testing with nanoclonal technique|endometrial sampling
75865587|NCT03121950|Other|Dance|The primary intervention is a dance class
76028475|NCT05010317|Behavioral|Mindfulness and acceptance based therapy|This is a behavioral intervention that is aimed at building psychological flexibility among adolescents. It involves careful use of language, metaphors, experiential learning and mindfulness to develop skills that support values guided living. Participants learn to relate with their inner thoughts, feelings and urges in an open and elaborative way as conscious human beings and make choices that improve their lives even in the presence of such difficult experiences.
76028476|NCT05010317|Behavioral|Standard of care|Usual clinic based counselling offered as routine care to adolescents
75537975|NCT06123598|Behavioral|Therapeutic exercise program plus sham action observation training|Participants make a sham observation before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
76028477|NCT04983771|Device|Annotate ultrasound scans|Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
76028478|NCT04960787|Other|Educational Intervention|Watch online educational videos
76028479|NCT04960787|Behavioral|Patient Navigation|Meet with CENTS counselor and PAF case manager
76028480|NCT04960787|Other|Quality-of-Life Assessment|Ancillary studies
76028481|NCT04960787|Other|Questionnaire Administration|Complete questionnaires
76028482|NCT04958759|Other|Functional Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 4 weeks of foundation inspiratory muscle training and 6 weeks of functional inspiratory muscle training
76028483|NCT04958759|Other|Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 10 weeks of foundation inspiratory muscle training
75865588|NCT03121950|Other|Music|the secondary intervention is listening to live music
75865589|NCT03395353|Drug|Duloxetine Hydrochloride|Administered orally
75865590|NCT03687242|Drug|SPR001|Open label SPR001
75865591|NCT05760066|Other|Resistance Training Preconditioning|Resistance training prior to disuse-induced atrophy followed by another period of resistance training
75537981|NCT06119048|Dietary Supplement|L-Phenylalanine|100 mg/kg
76028484|NCT04958759|Other|Breathing exercises|The program will be consist of 10 weeks of breathing exercises
75865592|NCT05760066|Other|Control|Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
76028485|NCT04956978|Other|Patient Decision Support Tool|Patient decision support tool is a web based educational material that informs a patient on the risk and benefits of oral anticoagulation. In addition, such a tool aims to assess patient values and preferences in the decision making process for oral anticoagulation for stroke reduction.
76028486|NCT04944862|Biological|CDX-0159|administered intravenously
76028487|NCT04944862|Drug|Normal saline|administered intravenously
76028488|NCT04920552|Device|Elastic abdominal binder|"The ABDO-SYNCRO 3-BAHNIG is an elastic abdominal binder with a 3-stripes Velcro fastening, capable of developing a 20 ± 2 mmHg pressure on the abdominal wall. This device will be tested as potentially beneficial with respect to the mentioned primary and secondary outcomes. The investigators anticipate to use this elastic abdominal binder, since participants of a previous trial reported this device to be comfortable enough and to have used it regularly during the open-label follow-up phase. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer (SYNCRO-MED GmbH)."
76028489|NCT04920552|Device|Placebo binder|"Clima Care is a simple body warmer, developing maximal 3±2 mmHg pressure on the abdominal wall. This device will be used as placebo comparator of the present clinical trial. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer."
76028490|NCT04832022|Other|Biological samples|Serum and plasma samples. At baseline, 3, 6 and 12 months
75374461|NCT02618642|Radiation|Irradiations of the biceps brachii muscle with PILER light. The participants were randomized into 4 groups: group v - no filter/ group x - red filter/ group y - blue filter/ group z - placebo.|"Biceps brachii examination was carried out before (examination 1) and after (examination 2) a series of 10 PILER light treatments. It included a traditional electrodiagnostic examination and the assessment of the pressure pain threshold (PPT).~The electrodiagnostic examination of the muscle was performed using the unipolar stimulation method from the direct motor point. The passive electrode (6 cm x 6 cm) was attached to the side of the distal part of the forearm, and the distal edge of the electrode was adjacent to the proximal edge of the ulnar styloid process. The examination was performed with a Multitronic MT3 electrotherapy apparatus set.~PPT at the direct motor point was determined using an algometer (Algometer commander TM ITECH Medical Industries). A head with a rubber jacket with a surface area of 0.5 cm2 was used to cause pressure pain. Pressure was exerted until the participant reported pain, at which time the force (lbs) marked by the algometer was recorded."
75701302|NCT04085666|Other|Matching Placebo|The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
75865593|NCT03687164|Other|Group Medical Visits|Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
76028491|NCT04818034|Drug|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
76028492|NCT04812028|Drug|Magnesium sulfate|Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
76028493|NCT04807972|Drug|ABBV-927|Intravenous (IV) Infusion
76028494|NCT04807972|Drug|Budiglimab|Intravenous (IV) Infusion
76028495|NCT04807972|Drug|modified FOLFIRINOX|Intravenous (IV) Infusion
76028496|NCT04792190|Drug|dapagliflozin|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
76028497|NCT04792190|Drug|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
76028498|NCT04789044|Drug|NTX-001|• PEG fusion is the application of a polyethylene glycol (PEG) using a combination of sequenced reagents to a freshly performed nerve coaptation, or neurorrhaphy, to allow the axonal membranes of the proximal and distal axonal stumps to fuse back together and re-establish full axonal continuity.
75865594|NCT05074758|Diagnostic Test|alveolar dead-space quantification|measurement of alveolar dead-space based on volumetric capnography
75865595|NCT05074758|Diagnostic Test|Coagulation activation and impaired fibrinolysis explorations|"blood sampling:~Fibrinolytic components~NETs components~Elastase-derived fragments of proteins of interest"
76028499|NCT04775199|Behavioral|Language Intervention|The examiners will target vocabulary and grammar in the context of preschool science instructions.
76028500|NCT04770012|Drug|Placebo|patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
76028501|NCT04770012|Drug|aspirin|patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment
76028502|NCT04770012|Drug|Clopidogrel|patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
76028503|NCT04755244|Drug|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
76028504|NCT04755244|Drug|venetoclax|BCL-2 inhibitor
75865596|NCT05074758|Diagnostic Test|Endothelial activation / endothelial senescence|circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )
76028505|NCT04755244|Drug|azacitidine|Hypomethylating agent (HMA)
76028506|NCT04750239|Drug|Nivatrotamab|Anti GD2×CD3 monoclonal bi-specific antibody
75865597|NCT04082663|Device|Dental Mouthpiece|Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
75865598|NCT01376154|Drug|Lamivudine|
76028507|NCT04718740|Drug|fluzoparib|Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
76028508|NCT04717544|Behavioral|Intervention Arm|The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
75701303|NCT00746265|Behavioral|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
75701304|NCT00743769|Drug|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
75701305|NCT00743769|Other|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
75865599|NCT01562951|Drug|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
76028509|NCT04699305|Device|ActiGraft|Whole blood clot (WBC) gel
75701306|NCT02563977|Device|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
75701307|NCT00743847|Drug|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
75701308|NCT00743847|Drug|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
75701309|NCT00743847|Drug|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
75865600|NCT01562951|Drug|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
75865601|NCT01375842|Drug|Atezolizumab|Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure </= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
75865602|NCT03682367|Drug|Gabapentin|Use of Gabapentin peri- and post-operatively.
75865603|NCT03682367|Drug|Placebo - Concentrate|Use of sugar-free Placebo peri- and post-operatively.
75865604|NCT03677570|Diagnostic Test|postural stability|Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
75865605|NCT05170464|Behavioral|Acute Exercise|Brisk walking on a treadmill at ⅔ maximum heart rate as defined by 220-age (in years).
75865606|NCT05170464|Drug|Caffeine Powder|Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
75865607|NCT03677492|Other|Medium Supplemented with Cytochalasin D|A medium with in-house supplementation of Cytochalasin D to decrease oocyte degeneration after ICSI and improve the survival rate
75865608|NCT03681353|Behavioral|Mobile Contingency Management, active|Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
75865609|NCT03394885|Drug|Atezolizumab|1200mg IV q3weeks
75865610|NCT03394885|Drug|Carboplatin|5-6mg/ML IV q3 weeks
75865611|NCT03394885|Drug|Paclitaxel|70-80 mg/m2 IV q1 week
75865612|NCT03394885|Drug|Bevacizumab|15 mg/kg IV q3 weeks
75865613|NCT03682484|Drug|MA-0211|oral
75865614|NCT03682484|Drug|Placebo|oral
75865615|NCT05168592|Behavioral|Threat conditioning|Day 1: The participant is repeatedly shown two stimulus (CS+,CS-), one at a time. CS+ is paired with an electric shock. CS- acts as a control stimulus. The stimuli consist of photos of two different objects. Stimuli will be counterbalanced between participants.
75374462|NCT04774848|Device|High Frequency Jet Ventilator|HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
75537982|NCT06113185|Other|survey|Demographic and clinical information of the participants will be recorded using a standardized form. The cognitive status of the patient will be evaluated according to the answers to the questions asked to the patient during the questioning of demographic data and reading and signing the consent form. The participants will be asked to complete a series of questionnaires to assess pain intensity and characteristics, pain-related functional disability, and pain-related fear-avoidance behavior. To record the presence and severity of pain behaviors exhibited during physical performance tests, patients will be asked to complete 5 functional tests (repetitive trunk flexion, repetitive sit-to-stand, timed get-up-and-go test, reach with load, 50-step walk test) and observers will simultaneously complete the Pain Behavior Scale. Each participant will be asked to attend two testing sessions separated by one week and occurring before the start of treatment.
75701310|NCT00746343|Behavioral|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
75865616|NCT05168592|Behavioral|Imaginal extinction|Day 1: Participants are repeatedly instructed to produce mental imagery of the two stimuli used during threat conditioning. Imagery is prompted through different written instructions presented in pseudo-randomized order on a screen. No shocks will be delivered.
76028510|NCT04663828|Other|Structured counseling|Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder
76028511|NCT04663828|Device|Hearing aids|Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
76028512|NCT04663828|Other|Cognitive behavioral therapy|This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
76028513|NCT04663828|Other|Sound therapy|Several sounds and music are used for tinnitus disorder
76028514|NCT04659122|Biological|AT-100|reconstituted AT-100 for intratracheal administration
76028515|NCT04652063|Other|Osteopathic Manipulative Medicine|Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
76028516|NCT04647916|Biological|Sacituzumab Govitecan|Given IV
76028517|NCT04615546|Behavioral|Use of Continuous Glucose Monitor (CGM)|Participants will wear CGM
76028518|NCT04615546|Other|"Use of Cardea Solo monitoring"|"Participants will wear a Cardea Solo patch during blinded CGM use"
75374463|NCT04774848|Device|High Frequency Oscillatory Ventilator|HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
75374464|NCT00366392|Device|Optical Aids|
75537983|NCT06112613|Other|Electronic Health Record Review|Ancillary studies
75537984|NCT06112613|Other|Health Promotion and Education|Receive access to educational materials
75537985|NCT06112613|Procedure|Health Telemonitoring|Utilize the WiseBag medication dispenser
75701311|NCT00746343|Behavioral|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
75701312|NCT00717860|Drug|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
75865617|NCT01361373|Drug|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
75865618|NCT01361373|Drug|placebo|placebo for 2 weeks
76028519|NCT04605809|Device|combined motor and cognitive training|The combined motor and cognitive training group will receive physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training for 45 minutes per session, 3 times a week for 4 weeks.
75537986|NCT06112613|Other|Interview|Complete an interview
75865619|NCT03677336|Drug|Dydrogesterone Oral Tablet|Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
75374465|NCT04774458|Procedure|Fluoroscopic-guided cervical epidural access|After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
75374466|NCT00366470|Drug|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
75374467|NCT00366470|Other|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
75374468|NCT04773210|Device|Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment
75374469|NCT04773210|Device|Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment
75374470|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^6 TCID50
75374471|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^5 TCID50
75374472|NCT00366782|Biological|Placebo|Placebo for rB/HPIV3 vaccine
75374473|NCT01116804|Procedure|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
75374474|NCT01116804|Procedure|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
75374475|NCT01116804|Procedure|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
75374476|NCT01116804|Procedure|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
75374477|NCT04537286|Drug|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
75374478|NCT02620904|Drug|Mifepristone|
75537987|NCT06112613|Behavioral|Patient Navigation|Receive healthcare provider follow ups as part of the CONCURxP program
75374479|NCT02620904|Drug|placebo|
75374480|NCT00300768|Drug|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
75374481|NCT00300768|Drug|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
75374482|NCT00300768|Drug|4 mg moxidectin|Single dose, tablets encapsulated for blinding
75374483|NCT00300768|Drug|8 mg moxidectin|single dose, tablets encapsulated for blinding
75374484|NCT02621060|Drug|Placebo|Placebo: 1200 mg per day for three months
75374485|NCT02621060|Drug|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
75374486|NCT04740788|Device|Monofocal IOL|Patients are already implanted with a monofocal lens
75374487|NCT04740554|Behavioral|Duchenne Muscular Dystrophy group with Deflazacort|Subjects with duchenne muscular dystrophy undergoing drug therapy with Deflazacort
75537988|NCT06112613|Other|Survey Administration|Ancillary studies
75537989|NCT06112613|Other|Text Message-Based Navigation Intervention|Receive personalized text message reminders related to their medication tracking as part of the CONCURxP program
75865620|NCT03677336|Drug|Micronized progesterone|Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
75374488|NCT04740554|Behavioral|Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Subjects with duchenne muscular dystrophy undergoing drug therapy with Prednisona/Predinisolone
75537990|NCT06111235|Drug|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
75374489|NCT04740554|Behavioral|Duchenne Muscular Dystrophy group without Corticosteroids therapy|Control group with duchenne muscular dystrophy without the use of corticosteroid drug therapy.
75537991|NCT06111235|Other|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
75374490|NCT04740554|Behavioral|Control Group Typically Developing|Control group with tipical development.
75374491|NCT02624180|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
75374492|NCT02624180|Drug|Placebo|A substance containing no medication
75374493|NCT04339946|Diagnostic Test|Three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
75537993|NCT06106919|Other|surveys (Fertiqol and WHOQOL-BREF)|surveys (Fertiqol and WHOQOL-BREF)
75537994|NCT06105801|Procedure|Endobronchial ultrasound with transbronchial needle aspiration|Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration
75537995|NCT06105801|Procedure|Bronchoscopy|Participants will undergo Bronchoscopy
75537996|NCT06105801|Procedure|Cryobiopsy|Participants will undergo Cryobiopsy
75537997|NCT06102876|Other|Physical activity (PA) program|The PA program is specific for each patient according to their mobility profile assessed using a decision tree comprising 3 tests: 1) the number of repetitions in the 30-second sit-to-stand test, 2) the score in the Short Physical Performance Battery (SPPB) test and 3) grip strength. The PA program has to be performed once daily.
75865621|NCT03677336|Drug|Placebo Dydrogesterone oral tablet|Tablet, indistinguishable from dydrogesterone oral tablet
75865622|NCT03677336|Drug|Placebo Micronized progesterone|Capsule, indistinguishable from micronized vaginal progesterone capsules
75374494|NCT04339946|Diagnostic Test|Two-dimensional rectal water contrast transvaginal ultrasonography (2D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution.
75374495|NCT05068232|Radiation|Ablative Radiation|Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.
75374496|NCT05068232|Drug|Durvalumab|Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.
75374497|NCT05068232|Drug|Etoposide|Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
75374498|NCT05068232|Drug|Carboplatin|Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
75374499|NCT02625428|Drug|Optison|
75537998|NCT06100146|Dietary Supplement|Folic acid and vitamin B12 fortified flour|Standard bags of fortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. The dose of vitamins will be added to the flour of the intervention group and mixed with batch mixing technique. The concentration of folic acid and vitamin B12 per 1kg of flour will be 2mg and 0.02mg, respectively. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
75701313|NCT00717860|Drug|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
75865623|NCT03634995|Drug|BMS-986256|Specified dose on specified days
75865624|NCT03634995|Other|Placebo|Specified dose on specified days
75701314|NCT02564679|Procedure|Laparoscopic Sleeve gastrectomy (LSG)|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated."
75865625|NCT01559805|Behavioral|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
75865626|NCT01559805|Behavioral|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
75537999|NCT06100146|Other|Unfortified cereal flour|Standard bags of unfortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
75538000|NCT06097273|Biological|mRNA-1083|Suspension for injection
75865627|NCT02877927|Drug|Omadacycline|po tablets
75538001|NCT06097273|Biological|Placebo|0.9% sodium chloride suspension for injection
75538002|NCT06097273|Biological|Influenza Vaccine|Commercially available formulation (Suspension for injection [pre-filled syringe])
75865628|NCT02877927|Drug|Linezolid|po tablets
75865629|NCT02706886|Drug|Lumasiran|Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
75865630|NCT02706886|Drug|Placebo|Matching placebo (sterile saline: 0.9% sodium chloride [NaCl]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
75865631|NCT01357707|Genetic|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
75701315|NCT02564679|Behavioral|Lifestyle Intervention|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment."
75538003|NCT06097273|Biological|COVID-19 Vaccine|Commercially available formulation (Suspension for injection)
75701316|NCT00746499|Drug|Raltegravir|400mg raltegravir BID x 7 days
75538004|NCT06095661|Other|REAL System i-Series VR head-mounted display (HMD) from Penumbra, Inc.|The VR intervention will use the REAL System i-Series VR head-mounted display (HMD) with built-in audio purchased from Penumbra, Inc. The i-Series is a gazed-controlled and fully immersive VR headset preloaded with immersive environments that promote positive distraction and relaxation through interactive experiences. These VR experiences include mindful meditation, travel, various nature scenes, and game experiences. REAL i-Series is classified as an unclassified product with product code PWC, a general wellness product FDA #3005168196.
75538005|NCT06095531|Device|Tetranite for Cranial Flap Fixation (TN-CFF)|Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
75701317|NCT03888417|Device|Therapeutic plasma exchange (TPE)|All TPEs were performed by the centrifugation technique using the Fresenius Kabi COMTEC machine
75701318|NCT02592122|Drug|Salbutamol Aerosol|
75865632|NCT01318239|Procedure|DCE MRI|"MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy."
76028520|NCT04605809|Device|motor training alone|The motor training alone group will receive the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
76028521|NCT04605809|Device|cognitive training alone|The cognitive training alone group will receive the same set of cognitive training while sitting as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
75538006|NCT06095323|Device|compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg)|The intervention group will wear compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg) during the day for 12 months.
75538007|NCT06091215|Device|Sciton Joule System|Sciton Joule System
75538008|NCT06089161|Other|Standard of Care|Participants in this group will receive standard of care treatment for sleep apnea.
75538009|NCT06089161|Behavioral|Personalized OSA Treatment|Participants in this group will receive standard of care treatment plus the personalized treatment that consists of videos approximately three minutes long, virtual, accessed through web based application, that the participant watches weekly. The purpose of the video is tailored educational content for sleep apnea.
75538010|NCT06088277|Behavioral|TM HIV|Participants will receive 5 intervention text messages (TM) about HIV risk and testing per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
75701319|NCT02592122|Drug|No drugs|
75865633|NCT01357785|Procedure|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
75865634|NCT03116932|Behavioral|PrEP knowledge and acceptability questionnaire|This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
75865635|NCT01357863|Drug|Treatment|Patients treated with Lapatinib-capecitabine after Trastuzumab progression
75374500|NCT02625428|Diagnostic Test|Ultrasound (US)|A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.
76028522|NCT04590248|Drug|Adavosertib|The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
75374501|NCT02625428|Diagnostic Test|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.
75374502|NCT05055596|Behavioral|Tai Chi|Qigong/Tai Chi Easy is a manualized intervention with formal training for instructors through the Institute of Integral Qigong and Tai Chi (IIQTC). The protocol can be modified based on participant needs and physical abilities. Qigong/Tai Chi Easy uses a series of repeated and simple-to-learn movements (rather than long forms with complicated choreography).
75374503|NCT05055596|Behavioral|Health Coaching|The Health Education group will be adapted from a previously developed time and attention control condition used in HIV research. Additional health education material will be based on information learned in the qualitative interviews conducted prior to the start of this study. Examples of session material include the following: sleep hygiene, healthy diet, sun safety, and healthy homes.
75374504|NCT04326764|Drug|Panobinostat|"Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules."
75374505|NCT05187546|Drug|[18F]-PI2620|[18F]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of [18F]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
75374506|NCT02628236|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
75374507|NCT02628236|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
75374508|NCT02629094|Drug|Inspra /Eplerenone|Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
75374509|NCT02630030|Drug|Ixazomib|Given PO
76028523|NCT04586231|Drug|Belzutifan|Immediate-release 40 mg tablet
76028524|NCT04586231|Drug|Lenvatinib|Capsule available in 4 mg and 10 mg dosages
76028525|NCT04586231|Drug|Cabozantinib|Tablet available in 20 mg, 40 mg and 60 mg dosages
76028526|NCT04572139|Diagnostic Test|Pituitary stimulation test|Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
75701320|NCT01497015|Behavioral|memory training|10 1-hour sessions over 6-8 weeks
75865636|NCT02809131|Drug|polymixin/bacitracin|Antibacterial irrigation
76028527|NCT04565457|Device|Research CBCT|Each study participant will receive one additional CBCT scan, with 2D antiscatter grid in place. This is the only intervention in the study, referred as research CBCT scan, and it will be performed on one of the days during the participant's radiation treatment course. This additional research CBCT scan will be used strictly for the objectives of this study. It will not be used as part of the standard clinical care, such as imaging guidance of participant's radiation treatment or diagnostic purposes. To deliver participant's radiation treatment under CBCT guidance, a standard clinical CBCT scan will be acquired, as in standard clinical care protocols.
76028528|NCT04560816|Drug|ALXN1840|ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
76028529|NCT04560816|Drug|Placebo|Placebo will be administered orally.
76028530|NCT04560816|Drug|Moxifloxacin|Moxifloxacin (400 milligrams) will be administered orally.
76028531|NCT04530682|Biological|Biological samples|Serum and plasma samples. At baseline, 6, 12 and 24 months
75374510|NCT04325282|Device|Active rTMS|1Hz rTMS delivered for 15-20 minutes
75374511|NCT04325282|Device|Sham rTMS|sham rTMS delivered for 15-20 minutes
75865637|NCT02809131|Drug|cephalexin, or levofloxacin, or clindamycin|Post operative oral antibiotics
76028532|NCT04520425|Procedure|Osteopathic manipulative therapy|"Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck."
76028533|NCT04511013|Drug|Binimetinib|Given PO
75374512|NCT04289792|Drug|nab-Paclitaxel+Gemcitabine|Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.
75374513|NCT04289792|Radiation|split-course SBRT|Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).
75701321|NCT01497015|Behavioral|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
75701322|NCT01497015|Behavioral|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
75701323|NCT02564445|Behavioral|Gamification|All participants will be entered with their teammate into a game that includes points and levels
75701324|NCT02564445|Behavioral|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
75701325|NCT02564445|Behavioral|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
75865638|NCT02809131|Drug|Saline|Saline irrigation
76028534|NCT04511013|Drug|Encorafenib|Given PO
76028535|NCT04511013|Biological|Ipilimumab|Given IV
76028536|NCT04511013|Biological|Nivolumab|Given IV
76028537|NCT04510597|Procedure|Cytoreductive Nephrectomy|Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization
76028538|NCT04510597|Drug|Active Comparator|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
76028539|NCT04504318|Drug|Apixaban 2.5 MG Oral Tablet|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
75865639|NCT05046054|Device|transcutaneous electrical nerve stimulation|transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
75865640|NCT05046054|Device|Placebo transcutaneous electrical nerve stimulation|Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
76028540|NCT04504318|Drug|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
76028541|NCT04477603|Device|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
76028542|NCT04468061|Drug|Sacituzumab Govitecan|Intravenous Infusion
76028543|NCT04468061|Drug|Pembrolizumab|Intravenous Infusion
76028544|NCT04465591|Diagnostic Test|troponin T fragmentation test|laboratory test from blood sample
75374514|NCT02631590|Drug|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
76028545|NCT04442646|Behavioral|multidisciplinary lessons|the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
76028546|NCT04417517|Drug|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
76028547|NCT04417517|Drug|azacitidine|Hypomethylating agent (HMA)
76028548|NCT04381806|Drug|5-ALA|Patients enrolled in this study will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed. Patients are followed through day 56 for adverse event and efficacy measures.
76028549|NCT04374760|Behavioral|SMS-intervention|SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.
76028550|NCT04337177|Drug|VAL-413|a flavored preparation of orally administered irinotecan
75374515|NCT02631590|Drug|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
75374516|NCT02631590|Drug|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
75538011|NCT06088277|Behavioral|TM HL|Participants will receive 5 intervention text messages (TM) about promoting healthy living (HL) per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
75865641|NCT03633318|Device|electrical impedance myography (EIM)|EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
75538012|NCT06087354|Other|The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.
75701326|NCT02564445|Behavioral|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
75374517|NCT02253654|Drug|Epoetin alfa|Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
75374518|NCT02252406|Drug|Ranolazine|Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
75865642|NCT05009628|Procedure|automated oxygenation with a sitting patient position in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2> 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
76028551|NCT04337177|Drug|Temozolomide|alkylating oral chemotherapy agent used to treatment brain cancers
75374519|NCT02252406|Other|Placebo|Matching placebo tablets daily for 24 weeks.
75374520|NCT05178186|Procedure|Thyroidectomy|Surgery for thyroid carcinoma
75374521|NCT05101200|Other|High Dose Neural Mobilization Technique|Patients in This Group will receive the high dose neural mobilization along with hot pack, strengthening exercises, Neural mobilization technique (slump, sciatic). Participants in the NMG will be asked to actively perform knee extension, ankle dorsiflexion, and head extension in a slumped posture (body and neck semi flexion) followed by simultaneous ankle plantar flexion together with knee and head flexion, Hot pack for 15 minutes, Strengthening exercises of muscles with 10 /8sets. Strengthening exercises of quadriceps with10 rep/8sets, Static stretching exercise for hamstring muscle with 10 rep/8sets, Group A will be given session of 40 min/day, 2 days/week for 4 weeks.
75374522|NCT05101200|Other|Low Dose Neural Mobilization Technique|Patients in this Group will receive the same treatment as group A but with less intensity and low dosage. Hot pack: 15 minutes, Strengthening exercises of muscles with 10 rep/4sets, Static stretching exercise for hamstring muscle with 10 rep/4sets. Group B will be given session of 40min/day, 2 days/week for 4weeks.
75865643|NCT05009628|Procedure|Automated oxygenation with the patient lying down in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2> 94%. The patient's position in the ICU will be a recumbent position with the head elevated to a maximum of 10
75865644|NCT05009628|Procedure|Oxygenation is controlled with the patient in a sitting position in the ICU.|ICU. Oxygenation will be done via the same interface in manual mode where the post-interventional monitoring room nurse modifies the flow to maintain oxygen saturation above 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
76028552|NCT04327609|Device|SELUTION SLR™ DEB|Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.
76028553|NCT04327609|Device|Control Arm|The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.
75374523|NCT02246478|Drug|TAS-205|"Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
76028554|NCT04315324|Drug|AKR1C3-activated Prodrug OBI-3424|Given IV
75374524|NCT02246478|Drug|Placebo|"Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
75374525|NCT02252016|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
75538013|NCT06086951|Behavioral|Pai.ACT Group|The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors. The app also offers 4-6 video-based individual ACT sessions with a dedicated counseling team and a referral system for intensive psychological support, all underpinned by empirical evidence from a previous ACT trial in Hong Kong.
75374526|NCT02252016|Drug|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
75374527|NCT05066100|Other|Prenatal Use of Supple Cups|For pregnant women identified with FIRN and providing consent to participate in this study, Supple Cup usage will be initiated at 32 weeks gestation to begin to elongate the nipples in preparation for breastfeeding.
75374528|NCT04784442|Drug|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
76028555|NCT04310202|Other|Abbreviated Profile of Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on two occasions.
76028556|NCT04310202|Other|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on two occasions.
75865645|NCT02784951|Drug|Red blood cells (0Rh D-neg)|Fresh produced RBC
75865646|NCT02784951|Drug|Whole blood (O Rh D-neg K-neg)|Fresh produced WB
75865647|NCT02784951|Drug|Freeze dried plasma (LyoPlas)|(LyoPlas N-w (German Red Cross)
75865648|NCT05002062|Device|"RehaCom computer-based cognitive training in addition to Conventional physical therapy program"|"Rehacom procedure: It is a computer-based intensive cognitive rehabilitation test used to assess patient's cognitive functions. It includes 32 assessment tasks for attention, memory , logical reasoning& executive functioning. It composes of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel & printer .The Rehacom software version is (patient enpult (1990-1997) EN/ISO-13485-certified). It is characterized by easy handling, close to reality , motivating for patients."
75865649|NCT05002062|Other|Conventional physical therapy program|Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program
75865650|NCT01442649|Drug|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
75865651|NCT01442649|Drug|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
75865652|NCT01442649|Drug|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
75538014|NCT06086951|Other|Control Group|Both the Pai.ACT group and the control group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
75538015|NCT06084013|Other|Non-Interventional Study|Non-interventional study
75865653|NCT01442649|Drug|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
75865654|NCT01442649|Drug|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
75865655|NCT01442649|Drug|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
75865656|NCT05199792|Diagnostic Test|Dotarem|(Dotarem) (0.4 ml/kg (0.2 mmol/kg))
75865657|NCT01354587|Drug|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
75865658|NCT04995120|Drug|chemotherapy TP regimen combined with Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
75865659|NCT03745469|Device|Smartphone|A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
75865660|NCT03988998|Drug|Radiofrequency ablation with radiotherapy|Radiofrequency ablation with radiotherapy
76028557|NCT04310202|Other|Additional follow-up visits after surgery|There are 1-2 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
75865661|NCT03988998|Drug|Radiofrequency ablation alone|Radiofrequency ablation without radiotherapy
75374529|NCT04784442|Drug|120mg of ETC-1002(bempedoic acid)|120mg, tablet, once daily, for 12 weeks
75374530|NCT04784442|Drug|60mg of ETC-1002(bempedoic acid)|60mg, tablet, once daily, for 12 weeks
75374531|NCT04784442|Drug|Placebo|placebo, tablet, once daily, for 12 weeks
75374532|NCT02249832|Device|seated robot-assisted ankle therapy|The MIT anklebot provides over one thousand total dorsi/plantar flexion and inversion/eversion robot-assisted movements of the ankle while in a seated position.
75374533|NCT02248974|Other|LVAD Decision Aid|"Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE)."
75374534|NCT02246166|Drug|Test tablet|The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
75538016|NCT06083948|Drug|Noradrenalin|Infusion of noradrenaline during anesthesia and surgery
75865662|NCT01318785|Other|Compression Armsleeves|"Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient."
75865663|NCT01376232|Drug|GSK1278863|GSk1278863 100mg
76028558|NCT04205968|Drug|Fluorouracil|Given IV bolus or IV
76028559|NCT04205968|Drug|Irinotecan|Given IV
76028560|NCT04205968|Drug|Irinotecan Hydrochloride|Given IV
76028561|NCT04205968|Drug|Leucovorin|Given IV
76028562|NCT04205968|Drug|Leucovorin Calcium|Given IV
76028563|NCT04205968|Drug|Paclitaxel|Given IV
76028564|NCT04205968|Biological|Ramucirumab|Given IV
76028565|NCT04146922|Other|Step down to oral antimicrobial therapy|Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
75538017|NCT06083948|Drug|Phenylephrine|Infusion of phenylephrine during anesthesia and surgery
75865664|NCT01376232|Drug|GSK1278863 + food|High Fat meal + 100 mg GSK1278863
75374535|NCT02246166|Other|Placebo|The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
75374536|NCT02706847|Drug|Placebo|Tablet; Oral
75374537|NCT02706847|Drug|Upadacitinib|Tablet; Oral
75374538|NCT02245620|Drug|Elamipretide|Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
75374539|NCT02245620|Drug|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
75374540|NCT02244996|Dietary Supplement|Lycium Barbarum|Traditional Chinese Herbs
75374541|NCT02244996|Dietary Supplement|Placebo|Placebo
75538018|NCT06083870|Drug|Oba01|Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
75865665|NCT01376232|Drug|Gemfibrozil|600 mg Gemfibrozil
75865666|NCT01354665|Biological|Interferon beta-1b (Betaferon, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
76028566|NCT04146922|Other|IV antimicrobial therapy|No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
76028567|NCT04141020|Procedure|Microsurgical clipping|Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.
76028568|NCT04141020|Procedure|Endovascular treatment|Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.
76028569|NCT04141020|Drug|Sirolimus|Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
76028570|NCT04097743|Behavioral|Coping Statement|Daily practice of coping statement
76028571|NCT04092582|Drug|MTPS9579A|MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
76028572|NCT04092582|Drug|Placebo|Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
76028573|NCT04071457|Drug|Lenalidomide|Commercially available intervention
76028574|NCT04071457|Drug|Daratumumab/rHuPH20|SWOG-Held IND
76028575|NCT04060719|Drug|BI 894416|tablet
76028576|NCT04060719|Drug|Rifampicin|tablet
75374542|NCT02470741|Drug|Letrozole|
75374543|NCT02470741|Other|Placebo|
75865667|NCT01354743|Drug|Dysport|"Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits."
75374544|NCT02543437|Device|Trident Acetabular X3 Insert|
75538019|NCT06082492|Diagnostic Test|18F FDG PET/CT|Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
75538020|NCT06082492|Diagnostic Test|CT scan|CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
75538021|NCT06081998|Other|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
75865668|NCT01354743|Device|Perlane L|The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
75865669|NCT01361529|Drug|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
75865670|NCT05018403|Drug|Intravenous AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
75865671|NCT05018403|Drug|Intravenous placebo|Isotonic glucose solution identical in appearance to AON-D21.
75865672|NCT04944108|Procedure|LISA approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter) or the INSURE approach (tracheal tube)
75865673|NCT04944108|Procedure|Insure approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
75865674|NCT05008575|Biological|anti-CD33 CAR NK cells|6×10^8, 12×10^8, 18×10^8/KG Treatment follows a lymphodepletion
75865675|NCT05008575|Drug|Fludarabine|recommendation: 30mg/m2 (D-5~D-3),determined by tumor burden at baseline.
75865676|NCT05008575|Drug|Cytoxan|recommendation: 300-500mg/m2 (D-5~D-3),determined by tumor burden at baseline.
75865677|NCT03971994|Behavioral|Facial expression recognition task|We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
75865678|NCT04069715|Dietary Supplement|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)|A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.
75865679|NCT04069715|Other|Placebo|Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
75865680|NCT03970512|Device|Apioc-A and Apioc-S Contact Lenses|Appropriately fit, document and dispense a new spherical and toric contact lens design worn for up to 35 days.
75865681|NCT01319487|Drug|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
75865682|NCT01319487|Drug|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
75865683|NCT01319487|Drug|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
75374545|NCT02544607|Drug|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
75374546|NCT02544607|Other|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
75374547|NCT02243280|Drug|ABT-493|Tablet
75374548|NCT02243280|Drug|ABT-530|Tablet
75374549|NCT02549365|Drug|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
75374550|NCT02549365|Procedure|Surveillance (nasal swabbing) during influenza season|
75374551|NCT00363571|Drug|GTN, Diamox|
75374552|NCT04744675|Drug|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.
75374553|NCT04744675|Drug|Saline Injection|Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.
75374554|NCT02471521|Other|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
75538022|NCT06081998|Other|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
75865684|NCT03681119|Behavioral|Dementia symptom management at home hospice edition|Quality assurance performance improvement program
75865685|NCT03681119|Behavioral|Education and Training|Education and training
75865686|NCT03111108|Drug|EBR/GZR (50 mg/100 mg) FDC|One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
75865687|NCT03677375|Device|INVSENSOR00026|Noninvasive pulse oximeter sensor
75374555|NCT02471521|Drug|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
75374556|NCT02624479|Drug|Sodium thiosulfate|oral administration of thiosulfate
75374557|NCT02623075|Biological|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
75374558|NCT04341337|Other|interview|questionnaire about ethics in surgery
75374559|NCT02554435|Device|EAM|The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.
75374560|NCT02554435|Behavioral|5 A's counseling|Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.
75374561|NCT02554435|Device|Pedometer|The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
75374562|NCT02555449|Drug|[¹⁴C]-LY3202626|Administered as solution by mouth
75374563|NCT02248818|Drug|AZD8108|Drug: AZD8108 Single or Multiple doses administered orally as a solution.
75374564|NCT02248818|Drug|Placebo|Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
75374565|NCT02472223|Drug|Betadine 5%|"One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
75374566|NCT02472223|Drug|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
75538023|NCT06078540|Other|USeeBP|"USeeBP is a low risk mobile medical app that proposes to do no more than:~Help patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions;~Provide patients with simple tools to organize and track their health information;~Provide easy access to information related to patients' health conditions or treatments;~Help patients document, show, or communicate potential medical conditions to health care providers;"
76028577|NCT04024488|Behavioral|TI-CBT Intervention Arm|"TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial."
75538024|NCT06077591|Other|Patient-Derived Tumor Organoids|Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
75701327|NCT02564367|Drug|S-1|"18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m^2 BSA, D1-14, q 3 wks"
75865688|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
75865689|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
75865690|NCT00702520|Drug|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
76028578|NCT04024488|Behavioral|Discussion Control Arm|Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
75865691|NCT00702520|Biological|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
75865692|NCT00702520|Biological|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
75865693|NCT05198856|Drug|Thalidomide Combined With Chemotherapy and Monotherapy|"Combined period：chemotherapy + T ：Thalidomide tablets: 100mg/d~Maintenance period: 100 mg/d, qn, orally. Sustained to disease progression or intolerable adverse reactions."
75865694|NCT04067141|Device|somofilcon A|Contact Lens
76028579|NCT04011384|Behavioral|Behavioral economic intervention of online purchasing at a food pantry|This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
76028580|NCT03910413|Diagnostic Test|Duel Energy CT|Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
75538025|NCT06069544|Biological|BNT165e|Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection
75538026|NCT06069544|Other|Placebo|Isotonic NaCl solution (0.9%)
75865695|NCT04067141|Device|nelfilcon A|Contact Lens
75865696|NCT03887910|Other|Enhanced Intervention|Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
76028581|NCT03877406|Drug|Empagliflozin 10 MG|addition of empagliflozin 10 MG
76028582|NCT03877406|Drug|Hypoglycemics Oral|dose escalation of hypoglycemics oral
75538027|NCT06064474|Behavioral|High ventilation breathwork with retention (HVBR)|Intervention
75538028|NCT06064474|Behavioral|Placebo HVBR|Placebo
75374567|NCT02596087|Other|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
75538029|NCT06063031|Dietary Supplement|Active|Active nutritional supplement plus telerehabilitation
75865697|NCT03887910|Other|Intervention|Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
75865698|NCT03184714|Device|NIPPV|BiPAP treatment for 3 years
75865699|NCT02876601|Drug|Defibrotide|6.25mg/kg bodyweight over 2h infusion
76028583|NCT03808675|Behavioral|Aerobic walking|The investigators will use self-administered continuous walking exercise at a moderate intensity level, defined as 40-59% of heart rate reserve or 64-77% of heart rate at gas exchange threshold (HRGET) by ACSM as in the investigators' preliminary study (PMID: 24991037 PMCID: PMC4132568). The HRGET will be determined as the heart rate at VO2max during graded cycle ergometry. The total duration of the exercises will be 150 min/week per 2008 Physical Activity Guidelines for Americans and American Heart Association recommendations, conducted in three 50 min sessions. The aerobic walking intervention will take place outdoors (e.g., trails, sidewalks, parks) or indoors (e.g., track in a local gym or a mall) depending on the preferences of the subject and weather. Session duration will be 20 min the first week and will be advanced by 5 min per week over 6 weeks.
75374568|NCT02247960|Drug|Ciprofloxacin|
75538030|NCT06063031|Other|Placebo|Placebo nutritional supplement plus telerehabilitation
75538031|NCT06062810|Drug|Crizotinib - Usual|"XALKORI - crizotinib capsule (high dose)~XALKORI 250 mg taken orally twice daily"
75538032|NCT06062810|Drug|Crizotinib - Study|"XALKORI - crizotinib capsule (low dose)~XALKORI 200 mg taken orally twice daily"
75538033|NCT06057922|Drug|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
75538034|NCT06056050|Biological|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)|1 dose of Tdcp vaccine (0.5ml) on Day 0
75538035|NCT06056050|Biological|23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）|1 dose of PPV23 vaccine (0.5ml) on Day 0
75865700|NCT02876601|Drug|Placebo (0.9% sodium chloride)|(0.9% sodium chloride) infusion over 2h infusion
75538036|NCT06056050|Biological|Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)|1 dose of DT vaccine (0.5ml) on Day 0
75538037|NCT06054425|Drug|Risankizumab|Infusion; intravenous
75374569|NCT02472457|Other|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
75374570|NCT02472457|Other|Free Diet|This diet contains no restrictions.
75374571|NCT02473783|Drug|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
75374572|NCT02473783|Other|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
75374573|NCT02557555|Other|educational information|patients will receive pamphlet on labor analgesia options.
75374574|NCT02543749|Biological|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
75374575|NCT02632526|Drug|AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Oral suspension single dose
75374576|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Single and multiple doses
75374577|NCT02632526|Drug|AZD5718 placebo oral suspension|Single and multiple doses
75374578|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)|Single and multiple doses
75374579|NCT04740866|Radiation|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. ([50Gy in 25 fractions conventional fractionation including tumor bed & pelvic lymph nodes]
75374580|NCT04340414|Device|Low flow ECMO driving by CVVH machine|With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS
75374581|NCT02247804|Drug|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
75374582|NCT02247804|Drug|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
75374583|NCT02247804|Other|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
75374584|NCT02247804|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
75374585|NCT00366860|Behavioral|Soy bread|
75374586|NCT02635880|Device|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
75865701|NCT02876601|Drug|Lipopolysaccharide|bolus infusion of 2ng/kg bodyweight lps
75374587|NCT04943822|Other|A new APP|A new APP for prevention and treatment of complications of intestinal peristomal skin
75374588|NCT00366938|Drug|Lumiracoxib|
75374589|NCT05026320|Drug|Naproxen gel|10%, bid for 5 days (final application on morning of Day 6)
75374590|NCT05026320|Drug|Diclofenac gel|2.32% bid for 5 days (final application on morning of Day 6)
75374591|NCT05026320|Drug|Placebo gel|bid for 5 days (final application on morning of Day 6)
75374592|NCT00367328|Device|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
75538038|NCT06050187|Procedure|implant casts fabrication|four implant casts fabricated
75865702|NCT02876601|Drug|Placebo (0.9% sodium chloride bolus)|(0.9% sodium chloride) bolus infusion
75374593|NCT04840784|Drug|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
75374594|NCT02640716|Behavioral|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
75374595|NCT02640716|Behavioral|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
75374596|NCT04086056|Other|NIRS monitoring|Regional cerebral oxygen saturation (rScO₂) will be collected by NIRS monitoring before anesthesia induction, during surgery and after extubation, in children with craniosynostosis.
75374597|NCT04068272|Drug|Bosentan|Eyedrop
75374598|NCT04068272|Drug|Placebo|Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
75865703|NCT04059536|Device|Roxwood Anchoring Catheters|Anchoring catheters
75865704|NCT04059536|Drug|Acetylsalicylic Acid|Oral Tablet
75865705|NCT04059536|Drug|Heparin|Intravenous Injection
75865706|NCT05714982|Other|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
75374599|NCT02243202|Drug|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
75538039|NCT06046495|Drug|PLB1004|PLB1004 will be orally self-administered by the patient as a mono-therapy.
75374600|NCT02243202|Drug|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
75374601|NCT02243202|Drug|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
75374602|NCT02243202|Drug|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
75865707|NCT05714982|Other|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
75865708|NCT05714982|Other|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
75865709|NCT03178318|Procedure|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
75865710|NCT03745391|Diagnostic Test|MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)|After randomization, a MULTIMODAL MR will be performed to select treatment patient
75865711|NCT03745391|Diagnostic Test|MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)|After randomization, a MULTIMODAL CT will be performed to select treatment patient
75374605|NCT02243046|Drug|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
75374606|NCT02243046|Drug|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
75865712|NCT03178396|Dietary Supplement|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
75865713|NCT03677258|Device|Collagen for injections 7%|Injection of medical device
75374607|NCT02243046|Drug|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
75865714|NCT03677258|Device|Hyaluronic acid for injections 2%|Injection of medical device
75865715|NCT03682328|Procedure|vertebroplasty|Cement augmentation of the vertebral body
75865716|NCT03682328|Procedure|kyphoplaty|Cement augmentation of the vertebral body
75865717|NCT01361763|Drug|Dabigatran|110 mg twice daily
75865718|NCT01361763|Drug|Antiplatelets|100mg once a day
75865719|NCT02420782|Drug|ASP6282|oral
75865720|NCT02420782|Drug|Itraconazole|oral
75865721|NCT02420782|Drug|Pilocarpine|oral
75865722|NCT02420782|Drug|Placebo|oral
75865723|NCT02420782|Drug|Midazolam|oral
75701328|NCT00923637|Drug|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
75701329|NCT00717314|Drug|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
75701330|NCT00717314|Drug|CNI (50%)|50% reduction from BL
75701331|NCT00717314|Drug|CNI (≥75%)|≥75% reduction from BL
75701332|NCT01090089|Drug|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
75701333|NCT01090089|Drug|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
75701334|NCT00689793|Drug|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
75701335|NCT00689793|Drug|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
75701336|NCT04086290|Procedure|RARP|Radical prostatectomy + extended pelvic lymph node dissection
75701337|NCT04086290|Radiation|SBRT|Stereotactic body radiotherapy to osseous lesions
75701338|NCT04086290|Drug|ADT|six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
75701339|NCT05431491|Device|Ultrafiltration|Ultrafiltration through much smaller intravenous cannula than what has previously been used.
75701340|NCT00723944|Device|Osseotite Certain Prevail|Root form titanium dental implant
75701341|NCT00723944|Device|Osseotite Certain|Dental implant without the lateralized design
75865724|NCT03677024|Procedure|SLN arm|Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
76028584|NCT03808675|Behavioral|Usual care with PD specific health education|"In this study, patients will receive their usual medical treatment for motor and non-motor symptoms from their~primary neurologist. The investigators will use a streamlined form of PD specific health education prepared by the VA: My Parkinson's Story, which consists of a series of short videos prepared by the VA PADRECCs addressing various aspects of PD. These 6-12 minutes long videos are freely available on YouTube. The investigators can also provide them on a CD if subjects desire. They start with a patient testimony about the topic of the episode, followed by comments of experts in the field. The title of the episodes are: Early Parkinson's, Medications, Exercise, Memory, Visual Disturbances, Depression, Sleep, Speech and Swallowing, Impulsive Behaviors, Driving, Pain, Dyskinesias, Deep Brain Stimulation, Advanced Parkinson's Disease, Falls, The Caregiver, Hospitalization, Genetics, Environmental Exposure, Atypical Parkinsonism"
75701342|NCT04086134|Other|Fruit Products|Fruit Products with the potential to improve constipation-related outcomes
76028585|NCT03795818|Behavioral|Interpersonal Psychotherapy for Adolescents|IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
75701343|NCT04060329|Behavioral|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
75701344|NCT02591264|Other|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
75701345|NCT04060563|Device|INSPIRSTAR IS02 MICROCURRENT STIMULATOR|"Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes."
75701346|NCT00744315|Procedure|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
75701347|NCT00689481|Drug|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
75701348|NCT00689481|Drug|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
75701349|NCT00744393|Drug|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
76028586|NCT03752203|Drug|Sodium Fluorescein|Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
75538040|NCT06044857|Drug|68-Ga PSMA11|Will be injected/assessed in line with its FDA label.
75538041|NCT06040723|Device|EndoMind|The EndoMind system is equipped with an AI model for predicting the Hill grade during gastroscopy.
75865725|NCT04054193|Drug|Fosaprepitant Dimeglumine|Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).
76028587|NCT03752203|Device|Microscopic Resection|Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
76028588|NCT03746106|Drug|Trimethoprim|300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.
76028589|NCT03746106|Drug|Metformin|1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
75538042|NCT06036225|Behavioral|Prehabilitation|Remote prehabilitation multi-component.
76028590|NCT03746106|Dietary Supplement|Vitamin B1|5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.
76028591|NCT03737461|Drug|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
75374608|NCT04034810|Device|Intracranial aneurysm treated with Silk vista and silk vista baby|Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.
75374609|NCT04016636|Other|Standard of Care|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.
75374610|NCT02207946|Drug|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
75374611|NCT02207946|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
75374612|NCT03976076|Drug|JBPOS0101|JBPOS0101 (investigational product)
75374613|NCT04933500|Device|Whitacre spinal needle|25G Whitacre spinal needle
75374614|NCT05588726|Behavioral|Sleep Hygiene|Once weekly coaching calls with advice on sleep hygiene
75374615|NCT05588726|Behavioral|Mindfulness|Once weekly coaching calls with advice on mindfulness
75374616|NCT04235036|Drug|Rituximab|Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).
75374617|NCT04235036|Drug|Ibrutinib|Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
75374618|NCT03875300|Behavioral|Foodwise in Pregnancy|A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
75374619|NCT02560051|Drug|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
75374620|NCT02560051|Drug|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
75374621|NCT02560051|Drug|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
75538043|NCT06035744|Drug|CLN-617|Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences
75538044|NCT06035744|Drug|Pembrolizumab|Humanized IgG4 anti-PD-1 monoclonal antibody
75701350|NCT00744393|Drug|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
75701351|NCT00746577|Other|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
75374622|NCT02560051|Drug|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
75374623|NCT02560051|Drug|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
75374624|NCT03786770|Biological|DaxibotulinumtoxinA for injection|Intramuscular injection
75374625|NCT00367718|Drug|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
75374626|NCT02474407|Drug|diazepam nasal spray|
75374627|NCT02474407|Drug|diazepam rectal gel|
75374628|NCT05588492|Drug|Rifamycin-containing regimen|Rifamycin-containing regimen
75374629|NCT05588492|Drug|Rifamycin-free regimen|Rifamycin-free regimen
75374630|NCT02475031|Device|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
75374631|NCT02475031|Drug|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
75374632|NCT03777956|Drug|Lacosamide|Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
75374633|NCT03777956|Drug|Placebo|Identical placebo are given as capsules and taken orally twice a day.
75374634|NCT02476357|Device|Harmonic scalpel|
75374635|NCT02519491|Other|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
75538045|NCT06035536|Device|Symphony™ plus Off-loading|Application of Symphony™
75538046|NCT06035536|Device|Wound Dressing comprising of calcium alginate Fibracol|Application of Wound Dressing comprising of calcium alginate Fibracol.
75538047|NCT06032286|Device|Skinstylus microneedling device|Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.
75538048|NCT06028334|Behavioral|GetUp&Go|A behavioral treatment combining personalized activity planning and a mobile health application for supporting adherence to activity plans.
75538049|NCT06028334|Behavioral|GetUp&Go with 10-Week Delay|No assigned treatment during the waitlist phase. Participants in the WL group will be offered the GetUp&Go intervention, which combines personalized activity planning and a mobile health application, after collection of the primary outcome measure.
75538050|NCT06019000|Combination Product|CYR-064|CYR-064 is a nasal solution.
75538051|NCT06017817|Device|Lumoral Treatment|Anti-infective photodynamic therapy for plaque-induced oral conditions
75538052|NCT06017817|Procedure|Standard oral hygiene instructions|Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use
75538053|NCT06017817|Procedure|Scaling and root planing (SRP|non-surgical anti-infective treatment by scaling and root planing
75538054|NCT06017817|Procedure|surgical anti-infective peri-implantitis treatment|surgical anti-infective peri-implantitis treatment
75538055|NCT06015750|Drug|methotrexate|Methotrexate will be administered SC or orally weekly for 104 weeks.
75374636|NCT02519491|Other|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
75374637|NCT02560753|Drug|T3D-959|The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
75374638|NCT02481505|Drug|Chloroprocaine HCl 1%|Intrathecal Route
75374639|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
75374640|NCT02563093|Biological|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
75374641|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular
75865726|NCT04054193|Drug|5-HT3 antagonist|All participants received an oral 5-hydroxytryptamine (serotonin; [5-HT]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.
75374642|NCT02563093|Biological|Fluzone High-Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
75374643|NCT02564029|Drug|PF-06372865|Single dose
75374644|NCT02564029|Drug|Placebo|Placebo for PF-06372865 and placebo for lorazepam
75374645|NCT02564029|Drug|Lorazepam|2 mg single oral dose
75374646|NCT05588336|Drug|Morphine|In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
75374647|NCT05588258|Other|Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.|Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.
75538056|NCT06015750|Drug|rituximab|Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
75538057|NCT06015750|Drug|bortezomib|Bortezomib will be administered via IV bolus or SC, as needed.
75865727|NCT04054193|Drug|Dexamethasone|Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
75865728|NCT03394027|Drug|ONC201|625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
75865729|NCT03682172|Drug|GLP-2 (1pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
76028592|NCT03737461|Other|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
75374648|NCT02564497|Biological|Process E Belatacept|
75374649|NCT02564497|Biological|Process C Belatacept|
75374650|NCT03957278|Device|DAISe System|The DAISe System is indicated for revascularization of patients with acute ischemic stroke for the removal of fresh thrombi from vessels in the neurovasculature.
75374651|NCT02565901|Drug|Carboplatin|Given IV
75374652|NCT02565901|Drug|Docetaxel|Given IV
75374653|NCT02565901|Other|Laboratory Biomarker Analysis|Correlative studies
75374654|NCT02565901|Drug|Sirolimus|Given PO
75374655|NCT03926624|Drug|DFP-10917|DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
75374656|NCT03926624|Drug|Cytarabine|cytosine arabinoside (ara-C)
76028593|NCT03723928|Other|Usual care disease monitoring|Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
75374657|NCT03926624|Drug|Azacitidine|Azacitidine
75374658|NCT03926624|Drug|Decitabine|Decitabine
75374659|NCT03926624|Drug|Mitoxantrone|Mitoxantrone
75374660|NCT03926624|Drug|Etoposide|Etoposide
75374661|NCT03926624|Drug|Fludarabine|Fludarabine
75374662|NCT03926624|Drug|Idarubicin|Idarubicin
75374663|NCT03926624|Drug|Venetoclax|Venetoclax
75374664|NCT03926624|Drug|Cladribine|Cladribine
75374665|NCT02566135|Device|Tracheal Intubation using I-gel and ventilating bougie|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
75538058|NCT06015750|Drug|IVIg|IVIg will be administered via IV monthly through initial 74 weeks.
75538059|NCT06015750|Drug|Folic Acid|Folic acid will be given orally as long as methotrexate is being dosed.
75538060|NCT06015659|Drug|Zentalis|Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
75538061|NCT06015659|Drug|Gemzar|Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
75701352|NCT02563353|Other|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week."
75701353|NCT02563353|Drug|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
75701354|NCT00688701|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
76028594|NCT03723928|Other|Serum Tumor Marker directed disease monitoring|Serum tumor markers every 4-8 weeks without imaging
76028595|NCT03723928|Other|Quality-of-Life Assessment|Ancillary studies
76028596|NCT03723928|Other|Anxiety Questionnaire Administration|Ancillary studies
75374666|NCT02566135|Device|Tracheal Intubation using C-LMA and ventilating bougie|Following general anaesthesia C-LMA was inserted. After proper placement of C-LMA, ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
75865730|NCT03682172|Drug|GLP-2 (10pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min
75865731|NCT03682172|Drug|Placebo|Four hour intravenous infusion with saline water
75865732|NCT03184480|Drug|Arnuity Ellipta|The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
75865733|NCT03136107|Other|Physiogel Daily Defence Protective Day Cream Light|Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.
75374667|NCT03565640|Device|Capio Slim Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
75701355|NCT00688701|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
75374668|NCT03565640|Device|Anchorsure Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
75701356|NCT00688701|Device|Pen auto-injector|
75701357|NCT02563743|Behavioral|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
75865734|NCT03136107|Other|ISO 24444:2010 P3 Standard Sunscreen|Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
75865735|NCT01376466|Other|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
75865736|NCT03686852|Other|same medications but different dosages|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
75865737|NCT03184402|Drug|DWJ1252|tablet
75865738|NCT03184402|Drug|Gasmotin|tablet
76028597|NCT03723460|Other|Passive Dietary Monitoring|Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
76028598|NCT03722173|Drug|Itraconazole|Oral solution
76028599|NCT03722173|Drug|BI 894416|Tablet
76028600|NCT03717194|Drug|Ertugliflozin|Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
76028601|NCT03717194|Drug|Placebo|Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
76028602|NCT03695380|Drug|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
76028603|NCT03695380|Drug|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
75374669|NCT05588024|Device|Head Up CPR based bundle of care|All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
75374670|NCT04744441|Procedure|CHOLECYSTECTOMY|Surgical treatment
75374671|NCT04744441|Procedure|PERCUTANEOUS CHOLECYSTOSTOMY|Patients treated with a percutaneous cholecystostomy
75701358|NCT02563743|Behavioral|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
75701359|NCT00999609|Biological|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
75701360|NCT02563119|Procedure|Gastric Bypass or Sleeve gastrectomy|
75701361|NCT00744549|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
75701362|NCT00744549|Drug|Placebo|Twice a day with meals.
75865739|NCT03184402|Drug|Placebo of Gasmotin|tablet
75865740|NCT03184402|Drug|Placebo of DWJ1252|tablet
75865741|NCT01318395|Drug|Aliskiren|orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
75865742|NCT01318395|Drug|Placebo|orally once per day
75865743|NCT01376544|Device|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
75865744|NCT02329925|Device|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
76028604|NCT03695380|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
76028605|NCT03678025|Drug|Abiraterone|Given PO
76028606|NCT03678025|Drug|Bicalutamide|Given PO
76028607|NCT03678025|Drug|Degarelix|Given via injection
76028608|NCT03678025|Drug|Docetaxel|intravenous
76028609|NCT03678025|Drug|Flutamide|Given PO
75374672|NCT04744441|Procedure|EXCLUSIVE ANTIBIOTICS|Patients that are treated only with i.v. antibiotics
76028610|NCT03678025|Drug|Goserelin Acetate|Given SC
75538062|NCT06012981|Behavioral|ACT|"The treatment is based on a variant of CBT, as briefly referred to before, ACT. In short, the treatment consists of identifying central and important areas of life, and how to approach these even though you are also struggling with persistent and challenging problems. In this study, the treatment intervention is flexibly constructed, focusing on several central principles based on ACT. These can be applied during one or numerous sessions.~The intervention is a flexible application of clinical functional analysis, as well as a couple of selected interventions which, in terms of experience and in previous studies, have been shown to work well for the current group (24-hour psychiatric patients with complex problems) and which are individually adaptable to the nature of the problem and degree."
75538063|NCT06008912|Other|Calisthenic Exercises|Exercises for upper extremity, lower extremity and trunk which applying just patient's own body weight via using body mechanics. There is no need for any tools for exercises.
76028611|NCT03678025|Drug|Histrelin Acetate|Receive SC
76028612|NCT03678025|Drug|Leuprolide Acetate|Receive SC or IM
76028613|NCT03678025|Drug|Nilutamide|Given PO
76028614|NCT03678025|Procedure|Orchiectomy|Undergo bilateral orchiectomy
76028615|NCT03678025|Drug|Prednisone|Given PO
76028616|NCT03678025|Other|Quality-of-Life Assessment|Ancillary studies
76028617|NCT03678025|Radiation|Radiation Therapy|Standard radiation
76028618|NCT03678025|Procedure|Radical Prostatectomy|Standard surgery
76028619|NCT03678025|Drug|Triptorelin|injection
76028620|NCT03636256|Drug|NanoDoce (direct injection)|Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
76028621|NCT03636256|Drug|NanoDoce (intravesical instillation) - Visit 2 Instillation|All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
75374673|NCT04744597|Behavioral|Real execution of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task
75374674|NCT04744597|Behavioral|Motor imagery of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.
75374675|NCT04744597|Behavioral|Skip counting|Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
76028622|NCT03636256|Other|Institutional Standard of Care|Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.
76028623|NCT03636256|Drug|NanoDoce (intravesical instillation) - Induction and Maintenance Instillations|Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
75374676|NCT03551210|Drug|Nemonoxacin|Solution for infusion, 500 mg (250 ml)
75374677|NCT03551210|Drug|Nemonoxacin|Capsules, 250 mg
76028624|NCT03633201|Device|Cruciate Retaining|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
76028625|NCT03633201|Device|Medial Congruent|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
76028626|NCT03614676|Procedure|Blood sample collection|Venous blood samples will be collected from the maternal subjects at Day 1 and Day 56 of the study and at delivery.
76028627|NCT03614676|Procedure|Cord blood sample collection|Collection of cord blood samples from maternal subjects will occur, at delivery
76028628|NCT03614676|Other|Maternal Diary Card|Completion of Diary Card about health by pregnant woman/ mother, from enrolment through week 6 post delivery.
76028629|NCT03614676|Procedure|Nasal Swab collection|Collection of nasal swabs from infants with potential LRTIs, from birth to 12 months of age.
76028630|NCT03614676|Other|Infant Diary Card|Completion of Diary Card about health of infant from birth to 12 months of age.
75865745|NCT03686774|Drug|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
75374678|NCT03551210|Drug|Tavanic|Solution for infusion, 500 mg (100 ml)
75374679|NCT03551210|Drug|Tavanic|Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
75701363|NCT00746655|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
75865746|NCT03686774|Other|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
75865747|NCT02420392|Drug|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
75865748|NCT01318551|Drug|BAY85-3934|single dose, 20 mg
75865749|NCT01318551|Drug|BAY85-3934|single dose, 40 mg (optional)
75865750|NCT01318551|Drug|BAY85-3934|single dose, 80 mg (optional)
75374680|NCT03551210|Drug|Placebo (250 ml)|0.9% NaCl (250 ml), solution for infusion
75374681|NCT03551210|Drug|Placebo (100 ml)|0.9% NaCl (100 ml), solution for infusion
75374682|NCT02482675|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
75701364|NCT00746655|Procedure|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
75374683|NCT02482675|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
75538064|NCT06008912|Other|Aerobic Exercises|Exercises which loading cardiovascular, respiratory and muscular system at the same time. Treadmill training will apply in the study.
75538065|NCT06008704|Diagnostic Test|Clinical assessment|The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population
76028631|NCT03559946|Device|percutaneous tibial nerve stimulation (PTNS)|The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
76028632|NCT03559946|Device|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
76028633|NCT03480581|Behavioral|Forward First ICARE Training|Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
75374684|NCT02482675|Other|Glucose with Whey Protein Isolate|Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
75538066|NCT06008704|Diagnostic Test|Pain characteristics assessment|The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment
75538067|NCT06008704|Diagnostic Test|MRI|The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers
75538068|NCT06008704|Diagnostic Test|Thermotest|The thermotest is performed to assess the pain perception threshold
75701365|NCT02564133|Device|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
75865751|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
75701366|NCT00746811|Drug|P-OM3|4 grams/day - 4 one gram capsules
75701367|NCT00746811|Drug|Placebo|4 grams/day - 4 one gram capsules
75701368|NCT04060173|Drug|ABP-671|ABP-671 is an investigational drug
75701369|NCT04060173|Other|Placebo|Matching placebo
75701370|NCT00741429|Drug|Technosphere Insulin Inhalation Powder|Subjects previously treated with Technosphere Insulin Inhalation Powder
75865752|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
75865753|NCT01562795|Drug|corticosteroids|corticosteroids plus artificial tear substitute
75865754|NCT01562795|Drug|artificial tear substitute|artificial tear substitute alone
75865755|NCT02424448|Procedure|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
75374685|NCT02482675|Other|Glucose with Sodium Caseinate|Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
75865756|NCT01311817|Biological|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
75374686|NCT04339088|Other|Questionnaires|Questionnaires to assess quality of life
75538069|NCT06008704|Diagnostic Test|UPDRS-III Scale|The UPDRS-III scale allows to asses motor functionality of PD patients
75865757|NCT01354821|Procedure|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
75538070|NCT06008704|Diagnostic Test|[18F]-MPPF PET scan|The PET scan after injection of [18F]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors
75538071|NCT06008093|Drug|Durvalumab|Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles. Durvalumab will also be given during the maintenance phase q4w until disease progression or unacceptable toxicity and at week 16.
75374687|NCT00364195|Drug|Tesmilifene (YMB1002)|
75374688|NCT03466424|Radiation|preoperative short-course radiotherapy|Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
75374689|NCT02566369|Drug|CD5789 (trifarotene) 50μg/g cream|CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
75374690|NCT02566369|Drug|Placebo cream|Placebo cream applied once daily for 12 weeks
75374691|NCT05587790|Behavioral|Weight Management Intervention|Participants attend virtual dietary education sessions and over time create a diet plan that satisfies their individual needs. Participants aim to lose 1-2 pounds weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and anthropometric measures of waist and hip circumference, and body composition.
75374692|NCT02569411|Other|Financial Incentive|money
75374693|NCT04743427|Other|hot pack and exercises|20-minute hot pack,and three active exercises: (a) chin tucks in supine lying with the head in contact with the floor, (b) active Standing Shoulder pull back , and (c) scapular plane shoulder elevation. (3 sets of 10 repetitions for all the 3 exercises)
75374694|NCT04743427|Device|body blade(BB)|The Body-blade (Classic, Mad Dogg Athletics, USA), an elastic pole exercise tool with 122 cm in length, 0.68 kg, 4.3 cm in width,based on oscillatory/vibration motions that have been used in training or rehabilitation.The body blade works by rapidly changing directions at a low-frequency rhythm of approximately 4.5 Hz (cycles per second )
75374695|NCT02569723|Drug|Carbon C 14 Oxaliplatin|Intravenous infusion
75374696|NCT02569723|Drug|Oxaliplatin|Intravenous infusion
75538072|NCT06008093|Drug|Tremelimumab|Participants will receive IV Tremelimumab q3w for four 21-day cycles. Tremelimumab will also be given during the maintenance therapy phase at week 16.
75538073|NCT06008093|Drug|Pemetrexed|Participants will receive IV pemetrexed q3w for four 21-day cycles and q4w until disease progression or unacceptable toxicity. During the maintenance therapy phase, participants may receive an additional cycle of pemetrexed, where applicable, at Week 16.
75538074|NCT06008093|Drug|Pembrolizumab|Participants will receive IV pembrolizumab q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
75538075|NCT06008093|Drug|Carboplatin|Participants will receive IV Carboplatin on Day 1 of each 21-day cycle for 4 cycles.
75865758|NCT01354821|Procedure|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
75865759|NCT02424136|Other|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
75865760|NCT02424136|Other|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
75865761|NCT02424136|Other|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
75374697|NCT02570425|Device|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
75374698|NCT02570425|Device|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
75374699|NCT02571439|Procedure|Surgical TAP block|surgeon administered TAP block
75374700|NCT02571439|Procedure|Conventional TAP block|Anesthesiologist administered TAP block
75374701|NCT02571439|Drug|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
75374702|NCT02573857|Drug|DSM265|Oral suspension from bulk powder
75374703|NCT02573857|Drug|OZ439|Oral suspension from powder in a bottle
75374704|NCT02576041|Drug|Bilastine|Bilastine tablets once a day for 7+3 days
75538076|NCT06008093|Drug|Cisplatin|Participants will receive IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles.
75538077|NCT06008093|Drug|Pemetrexed|Participants will receive IV pemetrexed q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
75701371|NCT00741429|Drug|Comparator|Subjects previously treated with other anti-diabetic medications
75374705|NCT02576041|Drug|Placebo|Placebo tablets once a day during 7+3 days run in period
75374706|NCT02576899|Behavioral|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
75374707|NCT02576899|Behavioral|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
75374708|NCT03678428|Drug|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
75374709|NCT03678428|Drug|Oxaliplatin HAI|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
75374710|NCT03678428|Drug|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
75374711|NCT03678428|Drug|Leucovorin|Leucovorin 200mg/m2 IV on Day 1 and 15.
75374712|NCT03678428|Drug|5-FU|5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.
75374713|NCT03678428|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
75374714|NCT02577601|Drug|Ulipristal Acetate|
75374715|NCT02577601|Drug|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
75374716|NCT02577991|Drug|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
75374717|NCT02577991|Drug|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
75374718|NCT05024227|Behavioral|Experimental: nursing education interventions (including e-health platform assistance)|Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.
75374719|NCT04956133|Behavioral|Physical Activity|Participants will receive the IMPACT program, which includes a combination of aerobic, resistance, balance, and flexibility exercises conducted 1:1 and delivered online by a physical activity specialist via Zoom. The IMPACT program follows basic physical activity progression principles (i.e., principles of frequency, intensity, time, type, overload and progression). Tailoring will be used to promote fitness and wellness benefits, while ensuring safety. In addition, prominent behaviour change techniques will be provided by physical activity specialists within each 1:1 session. Discussions and worksheets will be provided, depending on participants needs.
75374720|NCT04847167|Procedure|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
75701372|NCT02563197|Device|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
75701373|NCT00741507|Behavioral|Alcohol drinking|Never drinking of alcohol
75865762|NCT02424136|Other|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
75374721|NCT02207634|Biological|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
75374722|NCT02207634|Drug|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
75374723|NCT02207634|Drug|Background Statin Therapy|Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
75538078|NCT06007352|Drug|Gentamicin|Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy
75538079|NCT06007352|Other|Placebo|3 L of NaCl irrigation typically used for ureteroscopy surgery
75538080|NCT06006559|Drug|EYU688|EYU688 administered by oral route
75538081|NCT06006559|Drug|Placebo|Matching placebo administered orally as capsules
75538082|NCT06004479|Other|Carotenoid Intake|Carotenoid intake assess by 24 hour dietary recalls
75701374|NCT00741507|Behavioral|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
75701375|NCT00741507|Behavioral|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
75701376|NCT00741507|Behavioral|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
75701377|NCT00741507|Behavioral|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
75701378|NCT00688623|Drug|Everolimus|Everolimus 5 mg tablets were supplied in blister packs
75701379|NCT02563821|Procedure|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
75701380|NCT02563821|Drug|Levobupivacaine|
75701381|NCT02563821|Drug|sufentanil|
75701382|NCT02563821|Drug|clonidine|
75701383|NCT02563821|Device|epidural catheter|
75701384|NCT02563587|Other|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
75865763|NCT02424136|Other|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
75865764|NCT02424136|Other|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
75865765|NCT02424136|Other|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
75865766|NCT02916056|Drug|Azeliragon 5mg|
75374724|NCT04712383|Combination Product|Fitbit Care intervention arm|Entire suite of Fitbit Care.
75374725|NCT02485561|Behavioral|Health communication intervention|This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
75538083|NCT06004479|Other|Serum carotenoid concentration|Serum total carotenoid concentration
75538084|NCT05996185|Drug|Mogamulizumab|Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
75865767|NCT03770676|Dietary Supplement|Selenium-fortified biscuits|Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
75865768|NCT03181438|Procedure|TAP Block|It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation
75865769|NCT03181438|Procedure|Saline Group|t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
75865770|NCT01355133|Biological|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
75865771|NCT02424058|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
75865772|NCT02424058|Behavioral|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
75865773|NCT02420158|Device|Trans-cutaneous vagal nerve electrical stimulation|
75374726|NCT02485561|Behavioral|Education information|Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
75374727|NCT00364039|Drug|AV650|
75374728|NCT02486263|Other|Study Arm - acid suppression plus feeding bundle|"Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~Total fluid volume restriction (120-140 milliliters/kilogram/day)~Feeding duration over 30 minutes~Infant feeds with right side down~Infant is placed on back following feeds"
75374729|NCT02486263|Other|Conventional arm - acid suppression only|-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
75374730|NCT00422149|Drug|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
75374731|NCT00422149|Drug|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
75374732|NCT00422149|Drug|Placebo treatment|Placebo treatment
75374733|NCT03452228|Drug|evinacumab|Administered by Intravenous (IV)
75374734|NCT03452228|Drug|Placebo|Administered by Intravenous (IV)
75374735|NCT02974231|Radiation|Intensity-modulated radiation therapy|
75374736|NCT04341727|Drug|Hydroxychloroquine Sulfate|anti-rheumatic drug (DMARD)
75538085|NCT05996185|Drug|DA-EPOCH Protocol|EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
75865774|NCT01361841|Drug|Latanoprost, bimatoprost, travoprost|topic drops, once a day at bedtime, for years
75865775|NCT01361841|Drug|travoprost, latanoprost and bimatoprost|one drop once a day for life
75865776|NCT02420236|Behavioral|High-intensity resistance training|
75865777|NCT02420236|Behavioral|General physical activity|
75865778|NCT02420236|Behavioral|Multidisciplinary rehabilitation program|
75865779|NCT02583789|Drug|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
75538086|NCT05988671|Drug|normal Saline|Intraperitoneal route
75538087|NCT05988671|Drug|Dexamethasone|Intraperitoneal route
75538088|NCT05988671|Drug|Dexmedetomidine|Intraperitoneal route
75538089|NCT05988671|Drug|Combination of dexamethasone + dexmedetomidine|Intraperitoneal route
75538090|NCT05979584|Device|Platelet Fibrin Plasma|Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
75865780|NCT02583789|Drug|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
75374737|NCT04341727|Drug|Azithromycin|Antibiotic
75374738|NCT04341727|Drug|Chloroquine Sulfate|Antimalarial
75538091|NCT05979584|Device|Platelet Rich Plasma|Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
75538092|NCT05975047|Drug|LIV001|Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;
75538093|NCT05975047|Drug|Placebo|Participants will receive matching placebo across Part A and B of the study
75538094|NCT05966766|Other|Mozart selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections by Mozart of previously studied and shown to reduce anxiety.
75865781|NCT01358019|Drug|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
75865782|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^6 TCID50/mL.
75865783|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^7 TCID50/mL.
75865784|NCT01355367|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
75865785|NCT05759520|Biological|13-valent pneumococcal conjugate vaccine (multivalent conjugate)|the 2-month-old experimental group and the 3-month-old group received the experimental vaccine
75865786|NCT05759520|Biological|Prevenar 13|the 2-month-old control group received the active control vaccine
75374739|NCT04320901|Device|Ligasure|Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm
75374740|NCT04320901|Device|Harmonic|Harmonic ACE 7+
75538095|NCT05966766|Other|Patient-preferred music selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections of patient choice.
75701385|NCT02563587|Other|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
75865787|NCT02423902|Biological|Ad-RTS-hIL-12|Approximately 1.0x10^12 viral particles (vp) per injection
75865788|NCT02423902|Drug|Veledimex|7 oral doses of veledimex
75865789|NCT02427880|Drug|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
75865790|NCT02427880|Drug|Furosemide and Hydrochlorothiazide Followed by Furosemide|
75374741|NCT04272385|Other|Observational|Observational
75374742|NCT04247737|Other|gluten free diet|Participants keep a gluten free diet for six weeks
75865791|NCT02567643|Radiation|Stereotactic Radiosurgery|
76028634|NCT03480581|Behavioral|Reverse First ICARE Training|Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
75538096|NCT05955482|Other|NuvoAir Clinical Service|The NuvoAir clinical service offers comprehensive monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and their clinical risk. Furthermore, it involves virtual interaction with a NuvoAir Coach who provides guidance and assistance in navigating and utilizing the service. A dedicated NuvoAir care coordinator is available to offer self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to provide medical intervention, advice and triage as required.
75374743|NCT03437018|Other|moderate diabetic retinopathy follow-up by tele-expertise|"Consultation by an orthoptist to measure visual acuity, eye tone by pulsed air tonometer, and retinography images after pupillary dilatation (9 photographs: one of the posterior pole and 8 of the peripheral retina) and optical coherence tomography (OCT).~The results are immediately evaluated on site by an ophthalmologist. The results are sent through a secure online medical application to a diabetic retinopathy specialist ophthalmologist for evaluation."
75538097|NCT05955352|Procedure|Perineal warm compression Technique|There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care to asses the pain intensity and perineal tear
75538098|NCT05953870|Other|Music Therapy|slower tempo music that can quiet mind and make patients feel soothed
75538099|NCT05950841|Drug|Low dose IHAT|Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)
75538100|NCT05950841|Drug|High Dose IHAT|Twice daily dose of 1 capsule (100mg per capsule IHAT)
75538101|NCT05950841|Drug|Carob flour|Twice daily dose of 1 capsule (carob flour)
75538102|NCT05949294|Drug|ARO-SOD1 Injection|single doses of ARO-SOD1 Injection by IT infusion
75538103|NCT05941897|Drug|Ceralasertib|Participants will receive ceralasertib oral tablets.
76028635|NCT03451331|Drug|Nivolumab|Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting ~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
76028636|NCT03451331|Drug|Gemcitabine|1000 mg/m^2
76028637|NCT03451331|Drug|Carboplatin|AUC 4.5 (based on the Calvert formula)
76028638|NCT03451331|Drug|Oxaliplatin|130 mg/m^2
76028639|NCT03418961|Drug|Carvedilol|Given PO
75865792|NCT04789200|Drug|NX9 Oral Contrast Agent|Distension and marking of the bowel lumen will be compared between the 1st and 2nd scan. Ability to see IV contrast enhancement will be assessed on the 3rd scan in relationship to the 2nd scan.
75374744|NCT04244227|Device|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
75374745|NCT04340102|Behavioral|BecomeAnEx|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
75374746|NCT00367094|Drug|Benazepril plus hydrochlorothiazide|
75701386|NCT02563587|Drug|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
75701387|NCT00717236|Drug|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
75865793|NCT02423746|Behavioral|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
75865794|NCT02423746|Behavioral|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
75865795|NCT01355445|Drug|Vincristine, Irinotecan|"D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~D1 to D5: Irinotecan 50 mg/m²/d, IV~cycle / 21 days"
75374747|NCT02581111|Drug|Naloxone|Naloxone 8-mg IV bolus
75374748|NCT02581111|Drug|Normal saline|
75374749|NCT05587400|Behavioral|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
75374750|NCT05587400|Drug|dobutamine test|infusion dobutamine
75701388|NCT00717236|Other|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
75701389|NCT04085354|Drug|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
75701390|NCT04085354|Drug|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
75701391|NCT04085354|Drug|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
75865796|NCT01355445|Drug|Vincristine, Irinotecan, Temozolomide|"D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience > grade 3 toxicity of any kind)~D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~D1 to D5: Irinotecan 50 mg/m²/d, IV~cycle / 21 days"
75865797|NCT02420080|Drug|Brincidofovir|Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
75865798|NCT01355601|Other|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
75865799|NCT01355601|Other|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
75865800|NCT04772118|Other|Carevive PROmpt™|Patient Reported Outcomes Mobile Patient (Carevive PROmpt™), a digital cancer symptom monitoring platform.
75865801|NCT04483258|Procedure|Sedation with sevoflurane insufflation|Induction with %8sevoflurane after adequate sedation reducing %3
75865802|NCT04483258|Procedure|intravenous sedation|midazolam +ketamine + atropine
76028640|NCT03418961|Other|Laboratory Biomarker Analysis|Correlative studies
75374751|NCT05587400|Drug|inhaled nitric oxide|nitric oxide inhalation
75374752|NCT04339868|Drug|Terlipressin|Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
75374753|NCT04339868|Drug|Placebo|0.9% NaCl plus norepinephrine and/or epinephrine
75374754|NCT00367172|Behavioral|Directly Administered Antiretroviral Therapy|
75374755|NCT05585216|Drug|platelet-rich plasma|intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
75374756|NCT03334526|Other|physical training|workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)
75374757|NCT03334526|Other|mental training|The task to imagine for the training group will be an abduction of the thumb
75374758|NCT03334526|Other|electrical stimulation|electrical stimulation of the muscles
75374759|NCT00367250|Drug|Cetuximab|weekly i.v.
75374760|NCT00367250|Drug|Trastuzumab|weekly i.v.
75374761|NCT02489227|Drug|CHS-1420|
75374762|NCT02489227|Drug|Adalimumab|
75538104|NCT05941897|Drug|Durvalumab|Participants will receive durvalumab as an intravenous infusion
75538105|NCT05938283|Device|Implantable Cardioverter Defibrillator implant|ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
75538106|NCT05936359|Drug|INCA033989|INCA033989 will be administered at protocol defined dose.
75538107|NCT05936359|Drug|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
75374763|NCT02490631|Drug|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
75374764|NCT02207556|Drug|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:~Patient has completed 1 year of doxycycline therapy~Patient develops any grade 3-4 toxicity related to doxycycline use."
75374765|NCT03732638|Drug|Rimegepant|Rimegepant 75 mg tablet EOD
75374766|NCT03732638|Drug|Placebo|Placebo tablet to match rimegepant tablet EOD
75374767|NCT02572609|Drug|Ambroxol hydrochloride soft pastille|
75538108|NCT05931861|Device|T2769|T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
75538109|NCT05930067|Device|Pinnacle Gription Acetabular Cup|Pinnacle Gription cup with Corail/ACTIS stem
75374768|NCT02572609|Drug|Mucosolvan ® adult syrup|
75374769|NCT02587117|Drug|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
75865803|NCT02419768|Other|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
75865804|NCT03178474|Other|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
76028641|NCT03418961|Other|Patient Observation|Undergo observation
75374770|NCT02587117|Drug|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
75374771|NCT03266588|Drug|Rimegepant|75 mg oral tablet
75374772|NCT02587351|Drug|Metoprolol succinate|Extended release Metoprolol succinate
75374773|NCT02587351|Other|Placebo|Matching placebo
75374774|NCT00364117|Behavioral|Timely Discharge (Remote Presence Technology)|
75374775|NCT05249491|Diagnostic Test|Microbiological evaluation of dental plaques with children with or without black tooth stain|Evaluation of the etiological factors of black tooth stain according to the questionnaire
75374776|NCT05538338|Other|Platelet Rich Plasma Intrauterine infusion|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants
75374777|NCT05538338|Other|Normal saline Intrauterine infusion|an intrauterine infusion of normal saline will be administered to this group of participants
75374778|NCT05249413|Procedure|Early 23-gauge pars-plana vitrectomy|pars-plana vitrectomy for management of acute post-operative endophthalmitis.
75374779|NCT05249335|Drug|OST|The subject will receive Orafang for colonoscopy
75374780|NCT05249335|Drug|2L-PEG/Asc|The subject will receive 2L-PEG/Asc for colonoscopy
75374781|NCT00422396|Drug|Fenofibrate (drug)|
75374782|NCT04034797|Other|Photography teletransmission|A photography of the trauma is teletransmitted to SAMU's physician
75374783|NCT04034797|Other|No photo|Usual management without photography teletransmission
75538110|NCT05930067|Device|Pinnacle Dual Mobility|Bi-Mentum AltrX liner
75538111|NCT05926765|Genetic|AAV2-hAQP1 Concentration 1|Administration of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
75538112|NCT05926765|Genetic|AAV2-hAQP1 Concentration 2|Administration of concentration 2 of AAV2-hAQP1 via Stensen's duct to each parotid gland
75538113|NCT05926765|Other|Placebo|Administration of diluent via Stensen's duct to each parotid gland
75538114|NCT05922943|Behavioral|Harmony & Health program|Harmony & Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
75538115|NCT05922904|Drug|Brentuximab vedotin|Given by IV (vein)
75538116|NCT05922904|Drug|Doxorubicin Hydrochloride|Given by IV (vein)
75538117|NCT05922904|Drug|Pembrolizumab|Given by IV (vein)
75538118|NCT05922904|Drug|Dacarbazine|Given by IV (vein)
75538119|NCT05918523|Biological|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
75865805|NCT03178474|Other|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
75865806|NCT03178474|Other|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
75865807|NCT01355757|Device|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
76028642|NCT03406884|Biological|c-kit+ cells|The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
76028643|NCT03386357|Combination Product|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases. Only metastases that perspectively require radiotherapy will be treated. The irradiated tumor volume must be at least 10cm³. Radiotherapy of brain metastases is not allowed.
76028644|NCT03386357|Drug|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w)
75374784|NCT03992209|Other|Standard care|Usual operating room practice
75374785|NCT03992209|Other|Protocolized care|Hand washing per protocol
75865808|NCT01355757|Drug|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
75374786|NCT03704701|Diagnostic Test|Cardiac MRI and contrast-enhanced cardiac CT|Cardiac MRI Contrast-enhanced cardiac CT
75374787|NCT00364273|Drug|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
75374788|NCT00364273|Drug|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
75374789|NCT00364273|Drug|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
75538120|NCT05913648|Other|Tool Translation|The Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with the help of two professional translators and then it will be back-translated into English to cross-check the clarity of the text. The translation will focus more on the context and understanding of the text rather than literal word-to-word meanings. The translation will be done according to the WHO guidelines. The Urdu version of MENQOL will be used to assess content validity on menopausal women.
75538121|NCT05912647|Behavioral|MTM|Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.
76028645|NCT03293784|Combination Product|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
75865809|NCT02507505|Procedure|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
75538122|NCT05912647|Behavioral|CHW|Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one ~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive ~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.
75865810|NCT02507505|Procedure|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
75865811|NCT03181360|Drug|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
75865812|NCT03181360|Other|Control|Best standard treatment
75374790|NCT02495467|Drug|Glyceryl trinitrate|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
75865813|NCT04769856|Other|State-Trait Anxiety Inventory (STAI) scale|State-Trait Anxiety Inventory (STAI) scale
75374791|NCT02495467|Drug|MED Placebo|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
75538123|NCT05911958|Drug|SHR-A1811 for injection|SHR-A1811 for injection
75538124|NCT05907135|Dietary Supplement|Beet|Beet-based powder with other ingredients
75538125|NCT05907135|Dietary Supplement|Placebo|Placebo powder.
75538126|NCT05906784|Other|group acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
75538127|NCT05906784|Other|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
75865814|NCT04769856|Other|Satisfaction scale|Satisfaction scale
75865815|NCT04275531|Drug|Anesthesia Agent|various anesthetic agents used in both general and regional anesthesia
75865816|NCT04764864|Procedure|Angioembolization|"Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials."
75538128|NCT05895045|Behavioral|Yoga|Restorative Vinyasa Yoga
75701392|NCT04085354|Drug|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
75701393|NCT00719810|Drug|delafloxacin|300 mg intravenous every 12 hours
75865817|NCT04764864|Procedure|Preperitoneal Pelvic Packing|"Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours."
75865818|NCT01355835|Device|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
75701394|NCT00719810|Drug|delafloxacin|450 mg intravenous every 12 hours
75701395|NCT00719810|Drug|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
75701396|NCT02591498|Behavioral|Computerized cognitive training|
75701397|NCT00719732|Device|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
75538129|NCT05893537|Drug|Active Comparator CT1812|123 participants will receive a single daily dose of CT1812 (200 mg)
75538130|NCT05893537|Drug|Placebo Comparator|123 participants will receive a single daily dose of placebo
75538131|NCT05887609|Drug|Mirvetuximab Soravtansine|is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 [FOLR1] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
75538132|NCT05887609|Drug|Olaparib|Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
75538133|NCT05886894|Device|Lotrafilcon B multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
75701398|NCT02590718|Procedure|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
75865819|NCT04804527|Other|Intensified physiotherapy|Physiotherapy x2
75865820|NCT04804527|Other|Usual care physiotherapy|Physiotherapy x1
75865821|NCT03384745|Drug|M1095 (Sonelokimab)|M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
75865822|NCT03384745|Drug|Placebo|Placebo contains no active drug.
75865823|NCT03384745|Drug|Secukinumab|Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
75865824|NCT03180814|Other|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
75865825|NCT01361997|Biological|chlorhexidine in isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
75701399|NCT00723710|Biological|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
75538134|NCT05886894|Device|Comfilcon A multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
75538135|NCT05886881|Device|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
75701400|NCT04085198|Procedure|Light physics enhanced 'no-touch' hysteroscopy|The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.
75701401|NCT04085198|Procedure|Standard hysteroscopy|Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
75701402|NCT02590796|Other|No intervention given to participants|This is an observational study. Participants will receive no intervention.
75701403|NCT00688545|Drug|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
75701404|NCT00688545|Drug|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
75701405|NCT02563275|Other|motion analysis system|
75701406|NCT02563275|Other|parabolic flight|
75865826|NCT01361997|Biological|Isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
75865827|NCT03180892|Other|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
75865828|NCT04750824|Drug|Afatinib|Afatinib
75701407|NCT04060407|Drug|CD24Fc|CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
75701408|NCT04060407|Drug|Ipilimumab|Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.
75865829|NCT04750824|Drug|other systemic therapy|other systemic therapy
75865830|NCT01362075|Procedure|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
75865831|NCT01362075|Procedure|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
75865832|NCT03180970|Drug|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
75865833|NCT03180970|Drug|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
75865834|NCT03180970|Drug|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
75701409|NCT04060407|Drug|Nivolumab|Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
75701410|NCT00741585|Drug|Any antihypertensive medication alone or in combination|All drugs on awakening
75701411|NCT00741585|Drug|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
75538136|NCT05886881|Device|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
75538137|NCT05886881|Device|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
75538138|NCT05886881|Device|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
75538139|NCT05886881|Device|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
75538141|NCT05884762|Other|electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~Calibration phase at rest.~Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~In the Neurofeedback group, the patient will receive visual feedback of a virtual hand moving on a computer screen in front of him/her, depending on his/her brain activations. He will also receive haptic feedback (vibrations) in the flexor muscles of his wrist."
75865835|NCT03180970|Drug|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
75865836|NCT03180970|Drug|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
75865837|NCT05676528|Other|Exercise intervention|The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
75865838|NCT01319097|Other|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
75865839|NCT03631446|Drug|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Combination powder for oral solution
75865840|NCT03178240|Behavioral|photoaging mirroring intervention|selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
76028646|NCT03293784|Combination Product|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
76028647|NCT03279029|Biological|blood samples|blood samples
75701412|NCT00741585|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
75374792|NCT03432247|Behavioral|Interactive Music Therapy|Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
75374793|NCT03432247|Behavioral|Verbal support|Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
75374794|NCT05249179|Other|Pacifier|Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.
75374795|NCT05249179|Other|Oral stimulation|Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
75538142|NCT05884762|Other|SHAM electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~Calibration phase at rest.~Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~In the SHAM group, the visual feedback and haptic feedback are randomly generated"
75701413|NCT00746967|Drug|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
75701414|NCT02563041|Drug|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
75701415|NCT02563041|Drug|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
75701416|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
75701417|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
75865841|NCT03383887|Drug|Placebo oral capsule|Placebo before sleep
76028648|NCT03279029|Biological|biopsy|biopsy of aortic valve
76028649|NCT03263091|Drug|Roxadustat|Oral tablets
76028650|NCT03263091|Drug|Placebo|Oral tablets
76028651|NCT03230890|Device|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
75865842|NCT03383887|Drug|DAW1033D oral capsule|DAW1033D before sleep
75865843|NCT03184168|Drug|[14C]lorlatinib|Extemporaneously compounded oral solution of [14C]lorlatinib (approximately 100 mg/100 µCi)
75865844|NCT04709874|Other|Paravertebral block|Paravertebral block using nerve stimulator guidance will be done at C7-T1
75374796|NCT05249023|Other|Sodium butyrate bolus|On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.
75374797|NCT04743037|Behavioral|iSMART|This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
75374798|NCT02495623|Drug|SYN-010 21 mg|
75374799|NCT02495623|Drug|SYN-010 42 mg|
76028652|NCT03043716|Other|PAP therapy with telemonitoring|Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
75374800|NCT02495623|Drug|Placebo|
75374801|NCT05248087|Device|The bonded McNamara-type appliance|The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.
75374802|NCT05248087|Device|The removable palatal expansion appliance|The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
75374803|NCT02495779|Drug|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
75374804|NCT02495779|Behavioral|CBT-based counseling|Brief CBT-based counseling to promote adherence
75374805|NCT02502019|Device|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
75701418|NCT00745017|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
75701419|NCT00745017|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
75865845|NCT04709874|Other|Suprascapular block|Paravertebral block using nerve stimulator guidance will be done
75865846|NCT01362153|Drug|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
75865847|NCT01362153|Drug|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
75865848|NCT03184324|Drug|DWP14012|tablet
75865849|NCT03184324|Drug|Esomeprazole|tablet
75865850|NCT03184324|Drug|DWP14012 placebo|tablet
75865851|NCT03184324|Drug|Esomeprazole placebo|tablet
75865852|NCT02427334|Drug|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
75865853|NCT02427334|Drug|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
75865854|NCT02427334|Drug|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
75865855|NCT03379753|Other|music and positive images|The diad of misic and positive image will be administered to the standard care by adding a Bluetooth capable speaker with selections of music and a soothing nature landscape into the hospital room.
75865856|NCT03620253|Drug|Modafinil|Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
75865857|NCT03620253|Drug|Placebo|Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
76028653|NCT03041220|Procedure|cesarean section|obese patients (BMI of 30 or greater) who have had a cesarean section
75374806|NCT05247931|Diagnostic Test|TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine|Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
76028654|NCT03013218|Drug|Evorpacept (ALX148)|Evorpacept (ALX148)
75701420|NCT00745017|Drug|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
76028655|NCT03013218|Drug|Pembrolizumab|Keytruda
76028656|NCT03013218|Drug|Trastuzumab|Herceptin
75374807|NCT05247775|Procedure|Profilometry|Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
75538143|NCT05869799|Dietary Supplement|Vigiis 101 Lactobacillus Capsules|Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.0 x 10^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
75538144|NCT05869799|Dietary Supplement|Placebo Capsules|Maltodextrin was used as a placebo
75701421|NCT00688467|Drug|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
75701422|NCT00688467|Drug|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
76028657|NCT03013218|Drug|Rituximab|Rituxan
75374808|NCT02828839|Procedure|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
75701423|NCT00741741|Drug|TMC278|
75701424|NCT02562807|Drug|TAS-303 18mg single-dose|
75701425|NCT02562807|Drug|Placebo 18mg single-dose|
75701426|NCT02562807|Drug|TAS-303 9mg single-dose|
75701427|NCT02562807|Drug|Placebo 9mg single-dose|
76028658|NCT03013218|Drug|Ramucirumab + Paclitaxel|Standard of care chemotherapy
76028659|NCT03013218|Drug|5-FU + Cisplatin|Standard of care chemotherapy
76028660|NCT02996487|Drug|Vancomycin|
76028661|NCT02996487|Other|Placebo|
76028662|NCT02980276|Drug|Metformin Hydrochloride|Women randomised to the metformin group will receive metformin 500mg once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.
75374809|NCT05217277|Diagnostic Test|Humans ELISA kits|"ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones.~The saliva of the patients included in the study will be examined with ELISA kits after they are taken."
75701428|NCT00745173|Drug|Premarin|
75701429|NCT00747045|Other|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
75374810|NCT05216497|Drug|Ingavirin®, 90 mg capsules|90-180 mg/day for 7 days on top of standard therapy
75374811|NCT05216497|Drug|Placebo|1-2 capsules for 7 days on top of standard therapy
75374812|NCT02502487|Procedure|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
75701430|NCT04060095|Procedure|standardized noxious stimulus under general anesthesia.|"50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient."
75701431|NCT02562885|Device|Acoustic pulses|"Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB."
75701432|NCT00745329|Other|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
75865858|NCT03177928|Device|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
75374813|NCT02502487|Drug|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
75865859|NCT01355991|Drug|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
75865860|NCT01355991|Drug|Salmeterol|50mcg inhalation twice daily for two weeks
75865861|NCT03180658|Procedure|GTR + CGF + bone graft|Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
75865862|NCT03180658|Procedure|CGF + bone graft|CGF combined with bone graft to treat mandibular furcation involvements
75865863|NCT01356069|Other|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
75865864|NCT01356069|Other|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
75865865|NCT03180424|Drug|L Carnitine|L Carnitine liquid, single daily dose of 2g orally.
75865866|NCT03180424|Behavioral|Supervised exercise|Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
75865867|NCT03180424|Drug|Placebos|Liquid substance, similar to the one containing L carnitine, in the same presentation
75865868|NCT03180424|Behavioral|Exercise at home|A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
75865869|NCT01319175|Other|Hip flexion strength training|
76028663|NCT02980276|Other|Placebo|Women randomised to the placebo group will receive 1 placebo tablet once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
75865870|NCT01358253|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
75865871|NCT01358253|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
75701433|NCT00741897|Drug|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
75701434|NCT00688155|Behavioral|Physical Activity Training|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
75701435|NCT00688155|Behavioral|Cognitive Training|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
75865872|NCT01358253|Drug|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
75865873|NCT01358253|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
75538145|NCT05868421|Behavioral|Support Person Coaching Call|Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The session will be delivered by research staff by phone or video call. Support persons in the intervention group and the control/no intervention group will receive existing written material resources on support strategies to stop smoking, and resources on how to stop smoking by postal mail or email.
75701436|NCT00688155|Behavioral|Healthy Aging Education|One 1-hour lecture each week for 3 months, then monthly.
75701437|NCT00741975|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
75701438|NCT00741975|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
75701439|NCT00745407|Drug|fenofibrate|
75701440|NCT00745485|Drug|zoledronic acid|
75701441|NCT02562729|Procedure|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
75538146|NCT05868421|Behavioral|SP written materials|Written materials covering tips on effective supportive strategies for smoking cessation
75865874|NCT01358253|Drug|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
75865875|NCT01358253|Drug|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
75865876|NCT01358253|Drug|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month."
75865877|NCT01358253|Drug|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
75865878|NCT01358253|Drug|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
75865879|NCT01358253|Drug|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
75865880|NCT03180346|Device|PICO|Single Use Negative Pressure Dressing
75865881|NCT03180346|Device|Aquacel|Occlusive surgical dressing infused with ionized silver
75865882|NCT03180112|Genetic|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
75701442|NCT00745563|Device|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
75865883|NCT01356225|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
75865884|NCT01356225|Drug|Placebo|IN placebo
75701443|NCT00742131|Drug|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid [5 milligrams/milliliter] or 1000 milligrams of GSK1363089 in 50 milliliters liquid [20 milligrams/milliliter]) or as solid capsules of 20, 100, and/or 200 milligrams.
75701444|NCT00747201|Behavioral|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
75701445|NCT00747201|Behavioral|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
75701446|NCT03884283|Device|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)
75701447|NCT02563509|Biological|HIV-specific CD8 cells|Based on HAART, receive HIV-specific CD8 cells transfuion.
75701448|NCT00747279|Other|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
75865885|NCT03379675|Drug|JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
75865886|NCT03379675|Drug|JNJ-53718678 80 mg|Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
75865887|NCT03379675|Drug|Placebo|In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
75865888|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
75865889|NCT02427412|Drug|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
76028664|NCT02920671|Other|Tracer-enhanced oral glucose tolerance test (OGTT*)|Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.
76028665|NCT02920671|Other|Muscle MRI|Non-invasive muscle MRI will be performed to evaluated metabolic capacity.
76028666|NCT02920671|Other|Dual energy x-ray absorptiometry (DXA)|DXA will be performed to evaluate body composition.
75865890|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
75374814|NCT02502487|Drug|Tetracaine|1% Tetracaine gel instilled into urethra
75374815|NCT03238196|Drug|Erdafitinib|4mg - 8mg
75374816|NCT03238196|Drug|Palbociclib|125 mg
75701449|NCT00747279|Drug|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
75701450|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
75701451|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
75374817|NCT03238196|Drug|Fulvestrant|500 mg
75374818|NCT05473832|Other|Day Cream cosmetic product compared to untreated side|Applied once daily in the morning
75374819|NCT05473832|Other|Night cream cosmetic product compared to untreated side|Applied once daily in the evening
75701452|NCT00747513|Behavioral|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
75701453|NCT00745719|Procedure|parathyroidectomy|total parathyroidectomy with forearm autografting
75865891|NCT01356303|Drug|cisplatin, docetaxel|"All patients met the eligibility criteria will undergo treatment with chemotherapy.~Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles."
76028667|NCT02920671|Other|Questionnaires|Questionnaires will be used to evaluate participants' health and habits.
76028668|NCT02914600|Drug|Filgotinib|Tablet(s) administered orally once daily
76028669|NCT02914600|Drug|Placebo|Tablet(s) administered orally once daily
75374820|NCT05473832|Other|Eye cream cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening around the eye area
75374821|NCT05473832|Other|Serum cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening
75374822|NCT02632045|Drug|LEE-011|600 mg capsule (3x 200 mg capsules)
75374823|NCT02632045|Drug|Fulvestrant|500 mg injection
75374824|NCT02632045|Drug|Placebo|600 mg capsule (3x 200 mg capsules)
75374825|NCT02503735|Drug|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
76028670|NCT02727478|Other|HiBalance training program|The program consists of physiotherapist led highly challenging balance exercises, which are adapted and progressed on both a group and individual basis throughout the training period.
76028671|NCT02614794|Drug|tucatinib|300 mg orally twice daily
76028672|NCT02614794|Drug|capecitabine|1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
75374826|NCT04001881|Other|Transthoracic echocardiography|A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
75374827|NCT04001881|Drug|Spinal anesthesia|Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
75374828|NCT03019640|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
75701454|NCT00745797|Radiation|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
75374829|NCT03019640|Drug|Carmustine|Given IV
75374830|NCT03019640|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
75701455|NCT00742287|Dietary Supplement|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
76028673|NCT02614794|Drug|trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
76028674|NCT02614794|Drug|placebo|Oral dose twice daily
76028675|NCT02517294|Device|Parker flex-tip nasotracheal tube|specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
76028676|NCT02517294|Device|Standard nasotracheal tube|standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
76028677|NCT02495896|Drug|Cisplatin|Given IV
75374831|NCT03019640|Drug|Cytarabine|Given IV
75374832|NCT03019640|Drug|Etoposide|Given IV
75374833|NCT03019640|Biological|Filgrastim|Given SC
75374834|NCT03019640|Drug|Lenalidomide|Given PO
75701456|NCT00742287|Dietary Supplement|Placebo|placebo
75374835|NCT03019640|Drug|Melphalan|Given IV
75701457|NCT00747669|Drug|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
75701458|NCT00742365|Device|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
75701459|NCT00742365|Device|Red light placebo|One hour of exposure to red light.
75701460|NCT00690573|Biological|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
75701461|NCT00742443|Drug|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
75701462|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
76028678|NCT02495896|Drug|Docetaxel|Given IV
75374836|NCT03019640|Biological|Rituximab|Given IV
75374837|NCT02456389|Other|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
75374838|NCT02456389|Other|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
75374839|NCT02456389|Other|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
75374840|NCT02456389|Other|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
75374841|NCT02456389|Other|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
75374842|NCT02456389|Other|Standard postoperative care|Routine postoperative care, as medically indicated
75538147|NCT05868421|Behavioral|Written Smoking Cessation Materials|Written materials on resource and referral information for VHA and non-VHA EBCT options
75538148|NCT05867251|Drug|ARTS-021|ARTS-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with CCNE1-amplified solid tumors.
75538149|NCT05867251|Drug|Palbociclib 125mg|Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor
75374843|NCT02339779|Procedure|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
75374844|NCT02339779|Procedure|breast implant|"Implant-based reconstruction typically will occur as follows:~During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
75538150|NCT05867251|Drug|Fulvestrant 50 MG/ML Prefilled Syringe|Antineoplastic agent, estrogen receptor antagonist
76028679|NCT02495896|Drug|Gemcitabine Hydrochloride|Given IV
75538151|NCT05867251|Drug|Letrozole 2.5mg|Antineoplastic agent, aromatase inhibitor
75701463|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
75865892|NCT03184012|Device|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
75701464|NCT00719264|Drug|RAD001(everolimus)|10 mg qd
75865893|NCT03184012|Device|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
75865894|NCT02220309|Drug|Pramipexole Oral Tablet|Pramipexole is an oral Dopamine agonist.
75865895|NCT02419534|Drug|Polyethylene glycol|Laxative to treat constipation
75865896|NCT02419534|Drug|Polyethylene glycol with Diltiazem|Laxative and topical calcium channel blocker
75865897|NCT04674852|Device|Research Marker|The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.
75865898|NCT01362231|Drug|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
75865899|NCT03527316|Drug|MDMA|125 mg MDMA per os, single dose
76028680|NCT02495896|Other|Laboratory Biomarker Analysis|Correlative studies
75865900|NCT03527316|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs.
76028681|NCT02495896|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
76028682|NCT02495896|Other|Pharmacological Study|Correlative studies
76028683|NCT02495896|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
75538152|NCT05867251|Drug|Carboplatin|Alkylating agent
75538153|NCT05860543|Diagnostic Test|C2i-WGS-MRD Test|The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD) in patients diagnosed with muscle-invasive bladder cancer (MIBC) and histopathologically classified as stage II-IIIA
75538154|NCT05856266|Procedure|Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)|Ultrasound examination
75701465|NCT00719264|Drug|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
75701466|NCT00719264|Drug|bevacizumab|10 mg/kg every 2 weeks
75701467|NCT00749151|Behavioral|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
75701468|NCT00687609|Drug|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
75701469|NCT00742521|Procedure|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
75701470|NCT00742521|Procedure|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
75374845|NCT02136901|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
75374846|NCT02136901|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
75374847|NCT02136901|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
75374848|NCT02136901|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
75701471|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
75701472|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
75374849|NCT00585338|Device|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
75374850|NCT00581204|Device|Near-Infrared Diffuse Optical Spectroscopy|Early predictor of hemorrhagic shock
75701473|NCT00747825|Drug|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
75538155|NCT05856266|Other|Haemophilia Joint Health Score (HJHS)|Functional joint examination
75374851|NCT02506309|Device|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
75374852|NCT02506309|Device|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
75374853|NCT00580892|Device|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
75374854|NCT00580736|Device|Optical Clearing|Optical Clearing
75374855|NCT02507011|Drug|Carvedilol|Beta-adrenergic receptor blocker
75374856|NCT02507011|Drug|Placebo|Placebo
75538156|NCT05848557|Behavioral|mSaada|mSaada is an integrated digital platform to support patients, community health volunteers (CHVs), providers and health systems in an HPV-based cervical cancer screening strategy. mSaada is hosted on an open-source platform (Dimagi, CommCare) as a mobile health application to support patient data collection, protocol support and counseling aids. mSaada will include an education module, patient and specimen tracking, screening reminders, and messaging functionality.
75374857|NCT05379218|Device|Remote Ischemic Conditioning|"Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected."
75701474|NCT00751959|Drug|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
75701475|NCT00751959|Drug|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
75701476|NCT00723554|Drug|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
75374858|NCT02977286|Drug|Naloxegol Oral Tablet|Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
75701477|NCT00723554|Drug|Iloprost PD-15|"Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day"
75374859|NCT02977286|Drug|Placebo Oral Tablet|Placebo Oral Tablet po (enteral) twice daily
75374860|NCT02977286|Drug|Docusate Sodium 100 Mg oral capsule [Colace]|Docusate Sodium 100 mg po (enteral) twice daily
75701478|NCT00687219|Biological|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
75374861|NCT02977286|Drug|Senna 217 Mg Oral Tablet|Senna 127 mg oral tablet daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=6 days after scheduled opioid initiation.
75374862|NCT02977286|Drug|Polyethylene Glycols|Polyethylene Glycols 17 g daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
75538157|NCT05842434|Device|Felix|Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
75701479|NCT00687219|Drug|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening >=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening >=12g/dL and <14g/dL; treatment duration is 48 weeks
75701480|NCT02562105|Procedure|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
75701481|NCT00749229|Device|balloon kyphoplasty|During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
75374863|NCT02977286|Drug|Bisacodyl 10 mg Suppository|Insert one suppository if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
75374864|NCT02977286|Drug|Magnesium Citrate Oral Liquid Product|Administer one 10 oz bottle if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation.
75374865|NCT02977286|Drug|Methylnaltrexone|Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
75374866|NCT05345210|Drug|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
75374867|NCT05345210|Drug|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
75374868|NCT05345210|Drug|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
75538158|NCT05837845|Drug|MDMA|Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
75701482|NCT04085120|Procedure|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
75701483|NCT04085120|Procedure|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
75701484|NCT00747903|Drug|aminolevulinic acid hydrochloride|
75701485|NCT00749307|Dietary Supplement|Docosahexaenoic acid (DHA)|
75701486|NCT00749307|Dietary Supplement|Placebo|
75701487|NCT02562573|Drug|PBI4050|
75374869|NCT05345210|Drug|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
75374870|NCT05345210|Drug|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
75374871|NCT00540566|Device|Optical Biopsy imaging|Optical Biopsy imaging
75374872|NCT02976896|Drug|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
75538159|NCT05837845|Behavioral|Cognitive Processing Therapy|Participants will receive 12-16 sessions of Cognitive Processing Therapy
75701488|NCT02562183|Drug|kallikrein|Using kallikrein
75701489|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"30 quality of life questions for the participant to answer~The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
75865901|NCT03184246|Device|GlideScope|videolaryngoscopy (GlideScope) will be used for intubation
75865902|NCT03184246|Device|Direct laryngoscopy|direct laryngoscopy will be used for intubation
75865903|NCT01358409|Drug|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
75865904|NCT02423590|Drug|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
75865905|NCT02423590|Drug|Gemcitabine|"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
75865906|NCT02423590|Drug|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
75865907|NCT01362309|Drug|d-cycloserine.|50 mg administered on two occasions.
75865908|NCT03710941|Drug|REGN2477+REGN1033|Single, sequential, repeat-dose Intravenous (IV) or matching placebo
75865909|NCT03710941|Drug|Matching placebo|Single, sequential, repeat-dose Intravenous (IV)
75865910|NCT05114356|Device|TIDAL Cervical Interbody Fusion implant|Cervical interbody fusion device
75865911|NCT05760768|Behavioral|Individualized exercise guidance|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
75865912|NCT03710863|Drug|CM082|Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.The treatment period is tentatively set at 1 year.
75865913|NCT02930889|Device|Prostate Artery Embolization|Prostate Artery Embolization
75865914|NCT02423668|Procedure|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
75865915|NCT02423668|Procedure|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
75865916|NCT02423668|Procedure|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
75865917|NCT04604496|Drug|PF-06882961 20MG|PF-06882961 in 20 mg oral tablet will be administered on Day 1
75865918|NCT03178084|Drug|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
75865919|NCT03178084|Drug|Efavirenz QD + Zidovudine/Lamivudine BID|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
75865920|NCT03178084|Drug|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
75865921|NCT02875977|Other|Educational video|A 4-minute educational video describing PFPT
75865922|NCT02875977|Other|Educational handout|A 2-page educational handout describing PFPT
75374873|NCT01810705|Drug|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
75374874|NCT01712191|Device|NUsurface Meniscus Implant|
75374875|NCT02508103|Drug|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
75374876|NCT02508103|Drug|Placebo|Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
75701490|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"13 quality of life questions for the participant to answer~The answers range from 1 (Not at All) to 4 (Very Much)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
75701491|NCT02562027|Behavioral|Modified Medical Research Council|"Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
75374877|NCT02508259|Drug|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
75374878|NCT02508259|Drug|Saline|50 ml IV over 30 minutes
75374879|NCT04707859|Diagnostic Test|Head to head comparison: Rubidium vs 15O-water PET|Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation
75374880|NCT04708093|Device|whole body vibration training|Oscillating platform
75374881|NCT05237180|Other|spatial localisation training|8 spatial localization training sessions MBAA and SSQ tests before and after training sessions.
75374882|NCT02509585|Drug|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
75374883|NCT02240706|Procedure|Best Supportive Care|At Discretion of the Investigator (Transfusions)
75374884|NCT02240706|Drug|BI 836858|Monotherapy with BI 836858
75374885|NCT00534469|Biological|aldesleukin|
75374886|NCT00534469|Biological|filgrastim|
75374887|NCT00534469|Drug|busulfan|
75374888|NCT00534469|Drug|cytarabine|
75374889|NCT00534469|Drug|etoposide|
75374890|NCT00534469|Drug|idarubicin|
75374891|NCT00534469|Procedure|autologous hematopoietic stem cell transplantation|
75374892|NCT00534469|Procedure|bone marrow transplantation|
75374893|NCT00534469|Procedure|peripheral blood stem cell transplantation|
75701492|NCT02562027|Behavioral|EQ-5D|"5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
75701493|NCT02562027|Behavioral|Center for Epidemiological Studies Depression Scale|"20 quality of life questions for the participant to answer~Answers range from Rarely or none of the time to Most or all of the time~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
75374894|NCT00534469|Radiation|total-body irradiation|
75374895|NCT03757351|Drug|DNL747|Repeating oral dose
75374896|NCT03757351|Drug|Placebo|Repeating oral dose
75374897|NCT04341805|Procedure|PrevOmega|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of AGHO depending on the randomization performed.
75374898|NCT04341805|Procedure|Physiological saline|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of SSF depending on the randomization performed.
75374899|NCT03654859|Other|cardiopulmonary resuscitation|no pre-specified
75374900|NCT01600092|Biological|RotaTeq™ experimental formulation|
75374901|NCT01600092|Biological|RotaTeq™ existing formulation|
75374902|NCT00364975|Behavioral|gourmet cooking workshop|
75374903|NCT02588599|Device|Erchonia LUNULA|Active low level laser light therapy
75374904|NCT02240628|Device|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
75701494|NCT02562027|Behavioral|Medical Outcomes Study Social Support Survey|"19 quality of life questions for the participant to answer~Answers from from 1 (None of the time) to 5 (All of the time)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
75374905|NCT02240628|Drug|Saline|Patients in arm 2 will receive Saline with the Propofol.
75374906|NCT02240628|Drug|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
75374907|NCT02589067|Drug|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
75374908|NCT02589067|Drug|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
75374909|NCT02511379|Other|Propylene Glycol 0.6% eye drops|
75701495|NCT00723398|Dietary Supplement|Lovaza 4gm oral|Dietary supplement; Take 4 mg oral capsules daily
75374910|NCT02207400|Drug|Sodium bicarbonate and sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
75701496|NCT00723398|Drug|Raloxifene 60 Mg Oral Tablet|60 mg orally every day for two years
75374911|NCT02207400|Drug|Sodium fluoride|Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
75374912|NCT02511535|Biological|TBE booster vaccination|
75374913|NCT04341961|Other|Pomegranate Juice|Drinking 8 oz of pomegranate juice daily for 2 weeks.
75374914|NCT03545035|Drug|idelalisib and rituximab|patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
75374915|NCT03539341|Behavioral|PLH-Thailand parenting programme|Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.
75701497|NCT00723398|Drug|Raloxifene 30 Mg Oral Tablet|30 mg orally daily for two years
75701498|NCT00723398|Drug|Lovaza 4gm & Raloxifene 30mg|Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
75701499|NCT00716456|Drug|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
75374916|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
75701500|NCT03945890|Other||
75701501|NCT00684645|Drug|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
75701502|NCT04054869|Other|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
75374917|NCT02589847|Biological|RBX2660|suspension of intestinal microbes
75374918|NCT02589847|Drug|Standard of Care Antibiotics|Standard of Care Antibiotics
75374919|NCT02512393|Device|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
75701503|NCT04054869|Other|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
75374920|NCT02512393|Device|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
75701504|NCT00752037|Drug|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
75701505|NCT00747981|Procedure|Thoracic CT Scan|Perform a CT Scan and an endoscopy
75701506|NCT05416983|Procedure|Discussion|Attend discussion
75701507|NCT05416983|Other|Questionnaire Administration|Complete questionnaire
75701508|NCT00716144|Drug|Talarozole|Oral Capsule Once Daily
75701509|NCT00752115|Drug|sildenafil|50mg, day1,8 and 15 in each cycle
75701510|NCT00752115|Drug|placebo|1 tab, day 1,8 and 15 in each cycle.
75701511|NCT00752115|Drug|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
75701512|NCT00752115|Drug|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
75701513|NCT00918476|Drug|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
75374921|NCT04743115|Drug|BS HH 002.SA|"The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL"
75701514|NCT00749385|Drug|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
75374922|NCT02592421|Drug|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
75374923|NCT02592421|Drug|Placebo|Placebo Comparator
75374924|NCT02512783|Drug|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
75374925|NCT02512783|Drug|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
75701515|NCT00749385|Drug|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
75701516|NCT00749385|Drug|EC naproxen|Enteric-coated naproxen tablet (500mg)
75701517|NCT00749385|Drug|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
75701518|NCT02592044|Procedure|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
75701519|NCT02592044|Procedure|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
75374926|NCT02512783|Drug|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
75374927|NCT02513095|Drug|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
75374928|NCT02592655|Device|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
75374929|NCT02592655|Device|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
75374930|NCT02592655|Device|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
75538160|NCT05837845|Behavioral|MDMA-assisted Therapy|Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
75374931|NCT02592655|Device|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
76028684|NCT02442297|Biological|HER2-specific T cells|"Dosing Schedule 1:~Cycle 1 A: 1x10^7 cells~Cycle 2 A: 1x10^7 cells~Cycle 3 A: 1x10^7 cells~Dosing Schedule 2:~Cycle 1 A: 1x10^7 cells~Cycle 2 B: 3x10^7 cells~Cycle 3 B: 3x10^7 cells~Dosing Schedule 3:~Cycle 1 A: 1x10^7 cells~Cycle 2 B: 3x10^7 cells~Cycle 3 C: 1x10^8 cells~Subsequent cycles*~*Additional cycles may be administered at ≤ the final cell dose reached in cycle 3, provided that the subject continues to meet eligibility criteria and does not have confirmed progressive disease."
76028685|NCT02411253|Drug|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
75538163|NCT05835544|Other|Active Comparator: HIIT Control|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets.
75701520|NCT02592044|Procedure|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
75701521|NCT00748059|Procedure|Standing or upright tilt|stand upright or tilt table test
76028686|NCT02411253|Drug|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
76028687|NCT02361944|Drug|Oxygen - normoxia|Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
75701522|NCT00748059|Procedure|Microneurography|Recording from sympathetic nerve
75701523|NCT00748059|Procedure|QSweat|quantitative sweat testing
76028688|NCT02361944|Drug|Oxygen - hyperoxia|Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
75701524|NCT00748059|Device|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
75701525|NCT00748059|Drug|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
75701526|NCT00748059|Drug|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
75701527|NCT00748059|Procedure|BodPod|Determination of body composition
75701528|NCT00748059|Procedure|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~0.5% proparacaine (Alcaine, Allergan, Inc)~Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~0.5%, 1% tropicamide (Mydriacyl, Alcon)~Over-the-counter preservative-free artificial tears~0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~1% cyclopentolate hydrochloride (Alcon)"
75701529|NCT00748059|Procedure|Sleep study|Recording of sleep pattern overnight
75701530|NCT00748059|Procedure|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
75701531|NCT00748059|Procedure|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
75701532|NCT00748059|Procedure|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
75701533|NCT00748059|Procedure|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
75701534|NCT00576381|Drug|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
75701535|NCT00748137|Device|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
75701536|NCT00748137|Other|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
75701537|NCT02562417|Drug|Normal saline|
75701538|NCT02562417|Drug|IV dexamethasone|
75701539|NCT00748293|Other|Low-residue diet|Commercialized (not yet marketed)low-residue diet
76028689|NCT02266745|Drug|PT-112 Injection|
76028690|NCT02125968|Other|interactive video game|short- and medium-term therapeutic effects
76028691|NCT02125968|Other|therapeutic exercise|short- and medium-term therapeutic effects
76028692|NCT02100904|Procedure|Radiofrequency ablation of fibroids|
76028693|NCT02100904|Procedure|Myomectomy of fibroids|
75374932|NCT02592655|Device|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
75374933|NCT00365131|Drug|Cerezyme (imiglucerase for injection)|
75374934|NCT02513641|Device|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of ~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
75701540|NCT00749619|Other|Catheter Lock Solution Taurolidine and Citrate|
75701541|NCT00749619|Other|Catheter Lock Solution :Taurolidine and Citrate and Heparin|
75701542|NCT00749619|Other|Catheter Lock Solution : Heparin|
75374935|NCT02513719|Device|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
75374936|NCT00363727|Drug|ropinirole controlled-release (REQUIP CR) for RLS|
75538164|NCT05835544|Other|Experimental: HIIT + BFR between cycling sets|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied for 2 minutes during the passive rest at 80% of limb occlusion pressure.
75701543|NCT00749697|Other|SPECT scan|SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
75701544|NCT02561403|Behavioral|EVO multitask video game|Participants will play a multitasking game for 4 weeks
75701545|NCT02561403|Behavioral|EVO words video game|Participants will play a word puzzle game for 4 weeks
75701546|NCT00752349|Procedure|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
75701547|NCT00748371|Drug|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
75701548|NCT00748371|Drug|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
75701549|NCT00748371|Drug|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
75374937|NCT02514889|Behavioral|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
75701550|NCT03879291|Other|pinpointIQ|The study will utilize physIQ's multivariate analytical methods that detect vital sign relationship changes compared to a patient's individual baseline. Changes in vital signs relationships may be indicative of current or future important clinical events. These changes are indicated through the Multivariate Change Index (MCI), which is a scalar index between 0 and 1, where values close to 0 indicate no significant change from baseline and values close to 1 indicated greater changes from baseline
75374938|NCT02514889|Behavioral|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits & vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
75374939|NCT03230773|Device|Defibrillator model|Comparison of the performance of different public access defibrillators
75374940|NCT02515825|Device|CADence|
75374941|NCT04340869|Other|Theobromine|Natural extract from Cocoa
75374942|NCT04340869|Other|Remin Pro|Remin Pro
75538165|NCT05835544|Other|Experimental: HIIT + BFR moderate occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 50% of limb occlusion pressure and deflated during passive rest periods.
75538166|NCT05835544|Other|Experimental: HIIT + BFR high occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 80% of limb occlusion pressure and deflated during passive rest periods.
75538167|NCT05833828|Procedure|on-pump surgery|"the surgery will be performed on-pump"
75538168|NCT05833828|Procedure|off-pump surgery|"the surgery will be performed off-pump"
75865923|NCT02419222|Behavioral|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
75865924|NCT05122572|Biological|Oncolytic Virus Injection (RT-01）|Intravenous injection of RT-01 with or without Nivolumab
75538169|NCT05830318|Other|P-STEP Mobile Application|A mobile application that allows you track your walking habits while keeping you up to date with air quality information.
75538170|NCT05820893|Drug|Resistant Potato Starch|MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
75538171|NCT05814835|Drug|2-4 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
75538172|NCT05814835|Drug|4-6 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
75538173|NCT05814835|Drug|6-8 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
75538174|NCT05814588|Other|Anodal TDCS|"RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads)."
75374943|NCT05668819|Device|TH-001|TH001 is a software program intended to treat adults with prediabetes.
75374944|NCT00366067|Drug|Phenytoin|
75374945|NCT02343757|Device|PET/MRI|
75538175|NCT05814588|Other|Sham Anodal TDCS|rehacom cognitive therapy will be provided to this group participants
75374946|NCT00364429|Drug|[123]I-CNS 1261|Study Drug
75374947|NCT00364429|Drug|Lorazepam|Study Drug
75374948|NCT00364429|Drug|Risperidone|Study Drug
75374949|NCT00364585|Device|GreenLight Model 120 Laser System|
75374950|NCT02593903|Drug|Septra|
75374951|NCT02596321|Drug|Mitizax|Allergen extract
75374952|NCT02596321|Drug|Placebo|Placebo tablet
75374953|NCT02596867|Drug|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
75374954|NCT02597101|Drug|Metformin|background drug
75538176|NCT05804526|Drug|RC88|1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
75701551|NCT00749853|Drug|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
75865925|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
75865926|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
75865927|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
75374955|NCT02597101|Drug|saxagliptin|background drug
75374956|NCT02597101|Drug|AZD9668|study drug
75374957|NCT02597101|Drug|placebo|placebo for AZD9668 to be added to background drugs
75374958|NCT05578261|Device|intermittent theta burst stimulation|stimulatory protocol
75374959|NCT02600611|Drug|iclaprim|Experimental treatment
75538177|NCT05804526|Drug|JS001|JS001 240mg by intravenous (IV) infusion
75538178|NCT05796505|Behavioral|ADVANCE Steering Committee interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
75865928|NCT01356381|Drug|Vildagliptin|Dosage 50mg b.i.d.
75374960|NCT02600611|Drug|vancomycin|Active comparator
75374961|NCT02600767|Drug|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
75374962|NCT00365287|Drug|anti-thymocyte globulin|
75374963|NCT00365287|Drug|cyclophosphamide|
75374964|NCT00365287|Drug|cyclosporine|
75374965|NCT00365287|Drug|fludarabine phosphate|
75374966|NCT00365287|Drug|mycophenolate mofetil|
75374967|NCT00365287|Procedure|radiation therapy|
75374968|NCT00365287|Procedure|umbilical cord blood transplantation|
75374969|NCT00365443|Biological|V502|
75374970|NCT00365521|Procedure|Photodynamic Therapy|
75374971|NCT04743193|Other|2.5 %sevoflurane|for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration
75374972|NCT04743193|Other|8% sevoflurane low flow anesthesia|For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .
75374973|NCT05371171|Procedure|skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing [Alleyvn, Smith, & Nephew] was placed on the regrafted skin for fixation
75374974|NCT05371171|Procedure|no skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing [Alleyvn, Smith, & Nephew] was placed on the regrafted skin for fixation
75374975|NCT05366491|Diagnostic Test|Il-38 serum level|measurement of serum levels of IL-38
75374976|NCT05572645|Drug|Pyrotinib Plus Trastuzumab|treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
75374977|NCT05572645|Drug|Pertuzumab Plus Trastuzumab|treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
75374978|NCT05362591|Procedure|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
75374979|NCT05362591|Procedure|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation of tooth enamel
75374980|NCT02608177|Drug|Linagliptin|Receives 4 weeks of study drug linagliptin
75374981|NCT02608177|Drug|Glipizide|Receives 4 weeks of study drug glipizide
75374982|NCT04742335|Other|Survey|Survey will be applied to the participants.
75374983|NCT05555095|Behavioral|digital health delivered multicomponent intervention|The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.
75374984|NCT02608489|Drug|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
75374985|NCT02608489|Drug|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
75374986|NCT02609113|Device|Strong Magnetic Wristband|
75374987|NCT02609113|Device|Weaker Magnetic Wristband|
75701552|NCT00749853|Drug|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
75701553|NCT00748449|Procedure|Colonoscopy|1 Colonoscopy
75701554|NCT00748449|Procedure|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
75701555|NCT02561325|Drug|Sodium Bicarbonate and Sodium chloride|
75701556|NCT02562495|Device|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
75374988|NCT02611765|Drug|Benzathine penicillin G intramuscular 7.2 million units|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
75374989|NCT02611765|Drug|Benzathine penicillin G intramuscular 2.4 million units|A single dose of intramuscular 2.4 million units of benzathine penicillin G
75374990|NCT02612857|Drug|IMO-8400 Dose Group 1|IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
75374991|NCT02612857|Drug|IMO-8400 Dose Group 2|IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
75374992|NCT02612857|Drug|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
75374993|NCT05553769|Other|Resistance training, detraining, retraining|Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
75374994|NCT05550571|Device|Nautilus Intrasaccular Bridging System|Patients will be treated with the Nautilus, then followed-up for 12 months
75374995|NCT05226169|Drug|Ferinject|"Patients will receive an IV FCM (1,000 mg iron) infusion on the first day (visit 1) of chemotherapy. FCM (FerinjectTM; Vifor Pharma, Glattbrugg, Switzerland) will be diluted in 250 ml of sterile 0.9% normal saline by an aseptic technique and infused over 15 min under the supervision of a clinician.~Patients with a Hb level ≤ 10 g/dL and ID (serum ferritin < 100 ng/mL or TSAT < 50% and serum ferritin 100-500 ng/mL) will receive an additional dose of 500 mg of IV FCM at 6, 12, 24, 36, and 48 weeks. FCM will be diluted in 100 ml of sterile 0.9% normal saline by an aseptic technique and infused over 6 min under the supervision of a clinician."
75865929|NCT01356381|Drug|Placebo|50mg bid
75865930|NCT03117166|Drug|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
75701557|NCT00684567|Radiation|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
75701558|NCT00684567|Drug|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
75701559|NCT00752427|Drug|Paliperidone ER OROS®|
75701560|NCT04053621|Dietary Supplement|Thiamine pyrophosphate|12 weeks of weekly dose of 1 gram of thiamine pyrophosphate administered in an intravenous manner with saline solution
75701561|NCT04053621|Other|Placebo|12 weeks of weekly dose of 275 ml of saline solution administered in an intravenous manner
76028694|NCT02015325|Behavioral|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health & Hygiene education program.
75701562|NCT04053621|Drug|Metformin|All participants will continue taking metformin in their previous established tolerated dose for the duration of the study
75701563|NCT00684411|Drug|Imatinib mesylate|
75374996|NCT05226169|Other|Conservative management|"Patients with absolute (must be administered) or functional (according to the physician's choice) IDA in the control arm will be received oral iron, administered as Feroba-You 256mg once or twice a day. Advice will be given regarding ingestion without food and with liquid high in ascorbic acid to maximize enteric absorption.~If patients in the control arm still meet the absolute or functional IDA at the end of study (at 48 weeks), they can receive IV FCM (1,000 mg) according to the physician's decision."
75374997|NCT02615743|Behavioral|Daily Text message reminder|Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.
75701564|NCT02561793|Drug|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
75865931|NCT03117166|Drug|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
75865932|NCT01356459|Device|Mepilex Border Dressing|Soft silicone self adherent dressing
75865933|NCT05189613|Biological|Mepolizumab|Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
75865934|NCT03183700|Device|Self sampling device|The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
75865935|NCT03183700|Other|Cervical ThinPrep sampling|Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
75865936|NCT03632928|Other|Ultrasound Elastography|Measuring muscle hardness at the trapezius and neck bilateral
75865937|NCT03632928|Other|Pressure Pain threshold|Measuring Pressure pain threshold at the trapezius and neck bilateral
75538179|NCT05793827|Behavioral|Adapted Hatha Yoga|Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
75538180|NCT05793827|Behavioral|Low-Impact Exercise|This includes low-intensity exercise, which is matched to the estimated metabolic costs of yoga, 2.5 Metabolic Equivalent of Task (MET). Sessions include warm up, cool down, and five, 10-minute exercise stations, (e.g., walking, balance, resistance bands, weight-bearing exercise, and core work). Control exercise will be prescribed between 2.0 to 3.0 METs, equating to 30 to 40% heart rate reserve. Heart rate zones are calculated for each participant and monitored to ensure proper intensity
75701565|NCT02561793|Drug|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
75701566|NCT02562651|Drug|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
75701567|NCT02562651|Other|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
75701568|NCT00748527|Drug|carboplatin|Given IV
75701569|NCT00748527|Drug|decitabine|Given IV
75701570|NCT00686829|Drug|Vicriviroc maleate|VCV 30 mg tablet once daily by mouth.
75865938|NCT01358487|Behavioral|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
75701571|NCT00687297|Drug|vandetanib induction|100 mg daily by mouth
75701572|NCT00687297|Drug|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
75701573|NCT00687297|Drug|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
75701574|NCT00687297|Drug|Placebo|
75701575|NCT00687297|Drug|Vandetanib maintenance|300 mg daily by mouth
75701576|NCT00748683|Other|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
75701577|NCT00684177|Drug|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
75701578|NCT00684177|Drug|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
75701579|NCT00684021|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
75701580|NCT00684021|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
75374998|NCT02615743|Device|Inhaled steroid canister monitor|An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
75374999|NCT02616523|Drug|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
75701581|NCT00748761|Behavioral|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
75701582|NCT00748761|Behavioral|Waitlist|Contact waitlist weekly for 12 weeks
75701583|NCT04057911|Device|Active NIBS|Cathodal noninvasive brain stimulation will be given for 20 mins.
75701584|NCT04057911|Device|Sham NIBS|The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
75701585|NCT02561871|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 in Group 2.
75701586|NCT02561871|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 85 in Group 2.
75701587|NCT02561871|Drug|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
75865939|NCT01358487|Behavioral|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
75375000|NCT02616523|Drug|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
75701588|NCT02561949|Behavioral|YRI|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
75701589|NCT02561949|Other|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
75701590|NCT02562339|Behavioral|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
75701591|NCT00750009|Other|educational intervention|Patients receive a tailored intervention or generic information
75701592|NCT03879369|Diagnostic Test|Hormonal assay|LH , FSH and Free testosterone index (FTI) levels
75701593|NCT00755703|Biological|Pandemic Influenza Vaccine|Undetermined
76028695|NCT01997502|Device|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.~Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.~No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
76028696|NCT01997502|Other|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
75701594|NCT00755703|Biological|Placebo|
75701595|NCT00752661|Drug|Tramadol Hydrochloride; JNS013|
75701596|NCT00576303|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
75701597|NCT00752739|Dietary Supplement|selenium|Given orally
75701598|NCT00752739|Other|placebo|Given orally
75701599|NCT00755781|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
75701600|NCT00755859|Drug|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
75701601|NCT00755859|Drug|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
75865940|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
75865941|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
75865942|NCT02419300|Device|ultrasoungraphy|pelvic ultrasonography and Doppler
75865943|NCT02419144|Behavioral|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
75865944|NCT01356615|Drug|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
75865945|NCT01356615|Drug|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
75865946|NCT03117322|Biological|agave inulin|Duration: four weeks Dosage: powder 4 g/d
75865947|NCT03117322|Biological|Lactobacillus reuteri DSM 17938|Duration: four weeks Dosage: 5 drops/d
75865948|NCT03117322|Other|maltodextrin|Duration: four weeks Dosage: powder 4 g/d
75865949|NCT03117322|Other|Oil mix (medium chain triglycerides and sunflower oil)|Duration: four weeks Dosage: 5 drops/d
75865950|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
75865951|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
75865952|NCT03620175|Drug|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.
76028697|NCT01886391|Behavioral|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
76028698|NCT01803165|Procedure|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
75375001|NCT02616523|Other|placebo|The participants will be given infusion of normal saline intravenously.
75375002|NCT02616523|Drug|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
75701602|NCT00752817|Other|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
75865953|NCT03180190|Drug|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
76028699|NCT01782443|Drug|Ziv-aflibercept|
76028700|NCT01736072|Procedure|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
76028701|NCT01736072|Procedure|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
76028702|NCT01712815|Other|laboratory biomarker analysis|Correlative studies
76028703|NCT01712815|Other|pharmacological study|Correlative studies
76028704|NCT01712815|Other|questionnaire administration|Ancillary studies
76028705|NCT01712815|Radiation|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
76028706|NCT01712815|Procedure|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
76028707|NCT01649232|Device|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
75375003|NCT05732155|Drug|methylenedioxymethamphetamine|The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of MDMA HCl, in participants with PTSD and moral injury, in individual and group treatment settings
75375004|NCT05528419|Drug|Sacubitril-valsartan|sacubitril valsartan 100mg initiated, and titrated to 200mg according to mean clinic blood pressure at 1-month follow-up
75375005|NCT05528419|Drug|Valsartan|valsartan 80mg initiated, and titrated to 160mg according to mean clinic blood pressure at 1-month follow-up
75865954|NCT01356693|Drug|Bromelin|Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
75865955|NCT01356693|Drug|Placebo|Placebo with mimicking characteristics of experimental drug
75865956|NCT03183856|Device|Morning walk|a end-effector typed gait robot with a saddle
75865957|NCT03183856|Other|no Morning walk|ambulation voluntary or with a help of walker
75865958|NCT03179878|Drug|Placebo|Placebo
75865959|NCT03179878|Drug|SYNB1020|Investigational Product
75865960|NCT01362387|Other|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
76028708|NCT01555632|Drug|atorvastatin calcium|Given PO
76028709|NCT01555632|Drug|placebo|Given PO
75701603|NCT00752817|Other|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
75865961|NCT04583592|Drug|Camostat Mesilate|Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
75701604|NCT00756015|Other|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
75865962|NCT04583592|Drug|Placebo|Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
75375006|NCT04340713|Other|information support program|According to the established information support program for prostate cancer patients during hormonal therapy, information support and guidance on disease knowledge, symptom management, life care and other aspects are provided to patients through face-to-face communication, telephone, written information, network and other ways.
75375007|NCT04741867|Other|Education|Patients will be educated to determine their level of coping with stress and their adaptation.
75375008|NCT04340791|Behavioral|Increased proportion of lower energy density items|The proportion of lower energy density vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (D and DL) (33% lower - 67% higher). Lower energy density items will be defined as lower energy density ≤ median of energy density distribution within a food category.
75538181|NCT05776563|Other|Magnetic Resonance Spectroscopy Imaging (MRSI)|baseline 1HMRSI imaging study, then will undergo intensification of their diabetes management for a period of 12-week and at the end of the intervention they will undergo 1H MRSI scanning to measure intracerebral and plasma glucose levels at euglycemia and following 2 hours of hyperglycemia using the clamp technique (target glucose 220 mg/dl) in the occipital region
75538182|NCT05774041|Device|SIS System|FDA-cleared software that enhances standard clinical images for the visualization of structures in the basal ganglia area of the brain which are commonly targeted for DBS lead placement.
75865963|NCT01358643|Other|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI > 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
75865964|NCT03179722|Behavioral|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
76028710|NCT01337921|Dietary Supplement|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
76028711|NCT01274026|Drug|sapropterin dihydrochloride|"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."
76028712|NCT01225757|Device|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
75865965|NCT03179722|Behavioral|Additional data collection: questionnaires|"Pre-post study design.~At three timepoints, data is collected:~before the medication review (T-1week)~during the review (Tweek 3)~after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
75865966|NCT01362465|Procedure|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
75375009|NCT04340791|Behavioral|Labelling|"When energy density of an item ≤ median of ED distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions when logging-into the platform will introduce the badges to the participants: In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
75375010|NCT02974465|Procedure|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
75865967|NCT03117088|Other|Checklist ISBAR3|"Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool"
75865968|NCT03117088|Other|Checklist VICUR|"Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool"
76028713|NCT01186029|Drug|aprepitant|Emend 40mg by mouth 30 minutes before procedure x 1
76028714|NCT00955968|Drug|Highly active antiretroviral therapy (HAART)|"A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant."
76028715|NCT00955136|Device|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
76028716|NCT00896012|Procedure|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
75375011|NCT02974465|Procedure|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
75865969|NCT01362543|Other|Cognitive behavioural therapy (stress management)|Following a manual
75865970|NCT01362543|Other|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
75865971|NCT02418988|Drug|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
76028717|NCT00896012|Drug|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
75375012|NCT02974465|Procedure|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,…), exercise programs, electrotherapy, myofascial techniques, etc…
75375013|NCT05483413|Behavioral|progressive relaxation exercises|Progressive relaxation exercises are a cognitive behavioral technique that provides relaxation in the muscles that individuals can do alone.
75375014|NCT05480293|Drug|Ranibizumab|ranibizumab，0.5mg,IVT
75375015|NCT05480293|Drug|SCT510A|SCT510A，1.25mg,IVT
75375016|NCT05731609|Other|Resistance Intensive Personal Training|Personalized power training program focused on participant goals.
76028718|NCT00896012|Drug|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
75375017|NCT05461417|Device|D-SAD|Patients equipped with Panthera D-SAD® orthosis will be recruited.
75375018|NCT05731531|Device|ELECTROGASTROGRAPHY|Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.
75375019|NCT04901143|Device|Advanced hybrid closed loop system|Phase 1: meals in open loop- 3 weeks Phase 2: closed loop conventional meal announcement- 3 weeks Phase 3: closed loop, pre define universal bolus- 3 weeks
75375020|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
76028719|NCT00876226|Drug|Citalopram|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
75375021|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
75375022|NCT05731375|Diagnostic Test|31-MRS at 7 Tesla (T)|31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.
75375023|NCT00365755|Drug|carboplatin|
75375024|NCT00365755|Drug|cisplatin|
75375025|NCT00365755|Drug|cyclophosphamide|
75375026|NCT00365755|Drug|etoposide|
75538183|NCT05769582|Biological|Anti-BK polyomavirus (AntiBKV)|Participants in the study arm will each receive 4 doses (1,000 mg) administered at 4 weekly intervals administered on Days 1, 29, 57 and 85.
75375027|NCT00365755|Drug|melphalan|
75701605|NCT00756015|Other|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
75701606|NCT00686517|Biological|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
75375028|NCT00365755|Drug|vincristine sulfate|
75701607|NCT00686517|Drug|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
76028720|NCT00816413|Drug|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
75375029|NCT00365755|Procedure|autologous bone marrow transplantation|
75701608|NCT00686205|Device|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
75701609|NCT00571701|Drug|celebrex (celecoxib)|Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight >25 kg
75375030|NCT00365755|Procedure|conventional surgery|
76028721|NCT00816413|Drug|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
76028722|NCT00816413|Drug|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
75538186|NCT05761964|Behavioral|Harmony & Health|Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
75701610|NCT00571701|Drug|placebo|similar appearing capsules containing inert ingredients
76028723|NCT00816413|Genetic|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
75375031|NCT00365911|Procedure|Taking blood sample|A blood sample will be taken.
75375032|NCT00364741|Drug|Oxygen|During and 2 hours after surgery
75375033|NCT04743817|Device|OtoSet - Ear Cleaning System|Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
75538187|NCT05761964|Behavioral|Health Education|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
75538188|NCT05758701|Combination Product|Iodinated Contrast Agent (Omnipaque)|Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
75538189|NCT05758701|Device|Dual Energy CT|Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
75538190|NCT05750992|Procedure|surgical TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
75865972|NCT02418988|Drug|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
75865973|NCT04579146|Other|coronary computed tomographic angiographic (CCTA)|x-ray examination with contrast by a 64-slice CT coronary angiography.
76028724|NCT00816413|Genetic|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
76028725|NCT00816413|Genetic|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
76028726|NCT00816413|Other|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
76028727|NCT00816413|Other|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
76028728|NCT00816413|Other|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
75538191|NCT05750992|Procedure|US guided TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
75538192|NCT05750433|Dietary Supplement|PreforPro+B. subtilis DE111 probiotics|PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.
75538193|NCT05750433|Dietary Supplement|Placebo|Maltodextrin is rice based powder which was used as placebo.
75538194|NCT05750433|Dietary Supplement|B. subtilis DE111|Bacillus subtilis probiotics.
75701611|NCT00686127|Drug|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
75701612|NCT00686127|Drug|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
75701613|NCT02561715|Behavioral|Questionnaires|Pre and post deep brain surgery questionnaires
75865974|NCT01356771|Other|Surveys & Mailed Materials|"Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~Current and past skin cancer screening practices~Current and past sun protection practices~Attitudes about skin cancer and sun protection~Knowledge of melanoma"
75865975|NCT01358799|Device|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
75375034|NCT05731219|Biological|B7-H3 target, CAR gene modified gdT cell injection|After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
75375035|NCT05730985|Dietary Supplement|Miotrof® formula|1 sachet per day for 4 months
75538195|NCT05747196|Device|WhiteSwell eLym System|The WhiteSwell eLym™ System is designed to treat congestion in Acute Decompensated Heart Failure (ADHF) patients. The device comprises two endovascular components, a Catheter and a Sheath, that are used in combination with a Console. The device is designed to create a low-pressure zone at the Thoracic Duct Outflow which is located adjacent to the venous angle (junction of the left subclavian vein and left internal jugular vein). This low-pressure region facilitates movement of fluid (lymph) from the interstitial compartment through the lymphatic system and the Thoracic Duct and into the intravascular space, while removal of fluids from the intravascular space is enabled using diuretic therapy. The treatment duration will be up to 72 hours.
75538196|NCT05745636|Dietary Supplement|Broccoli, mustard, vitamin C|2 capsules per day for 4 weeks
75538197|NCT05745636|Dietary Supplement|Placebo|2 capsules per day for 4 weeks.
75538198|NCT05742971|Device|Virtual reality intervention performed through the Oculuc Go VR glasses|The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
75865976|NCT05189301|Diagnostic Test|first pass study|Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)
75538199|NCT05739292|Biological|EuNmCV-5|0.5mL single intramuscular dose on Day 0
75538200|NCT05739292|Biological|Menveo|0.5mL single intramuscular dose on Day 0
75375036|NCT05730985|Dietary Supplement|Placebo formula|1 sachet per day for 4 months
75375037|NCT05730907|Drug|Levosimendan|examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR
75375038|NCT04541875|Other|MAR-Scale|The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
75375039|NCT05729191|Biological|Anti Covid 19 vaccination campaign for pregnat women|Assessment of vaccine hesitancy and Covid-19 disease knowledge
75701614|NCT00718718|Drug|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
75701615|NCT00718718|Drug|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
76028729|NCT00816413|Other|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .~Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .~Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.~Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.~Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
75538201|NCT05737225|Device|Near Infrared Spectroscopy (NIRS)|We will place Near Infrared Spectroscopy (NIRS) electrode on the foot to evaluate regional tissue oxygen saturation in both lower extremities before the performing regional anesthesia (popliteal sciatic nerve block) and then during the procedure.
75701616|NCT00718718|Drug|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
75701617|NCT00718718|Drug|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
75701618|NCT00718718|Drug|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
75865977|NCT05189301|Diagnostic Test|cardiopulmonary exercise testing|to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)
75865978|NCT01356927|Drug|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
75865979|NCT01356927|Drug|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
76028730|NCT00816413|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
75375040|NCT05728255|Diagnostic Test|ABPM plys SCAFB|24-hour ambulatory blood pressure monitoring (ABPM) and of tilt-table Short Cardiovascular Autonomic Function Battery (SCAFB) which consists in carotid sinus massage (CSM) and head-up tilt test (HUT) performed one after the other in an uninterrupted sequence as a single procedure on a tilt table
75865980|NCT02703532|Behavioral|CARE-CITE Education Program|"CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.~If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.~Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.~Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete."
75865981|NCT02703532|Behavioral|Traditional Education|Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
75375041|NCT04340401|Drug|SHR-1210|Patients will receive 3 cycles induction CapeOX and SHR-1210
76028731|NCT00816413|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
75375042|NCT04340401|Drug|Oxaliplatin|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
75375043|NCT04340401|Drug|Capecitabine|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
75375044|NCT04340401|Radiation|Intensity modulated radiotherapy|patients will receive intensity modulated radiotherapy with capecitabine
75375045|NCT04340401|Procedure|Total mesorectal excision|Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
75375046|NCT05726149|Device|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
75538202|NCT05711615|Procedure|Biopsy|Undergo tissue biopsy
75375047|NCT05726149|Device|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
75375048|NCT05726149|Device|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
75375049|NCT04340635|Other||Without intervention
75538203|NCT05711615|Procedure|Biospecimen Collection|Undergo blood sample collection
75375050|NCT04143607|Drug|ASK120067|ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
75375051|NCT04143607|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
75375052|NCT04143607|Drug|Gefitinib|Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
75375053|NCT04143607|Drug|Placebo ASK120067|Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
75375054|NCT04126291|Behavioral|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
75375055|NCT04110067|Other|Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)|Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
75375056|NCT04802863|Drug|XNW4107, Imipenem/Cilastatin|Five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin
75538204|NCT05711615|Procedure|Computed Tomography|Undergo CT scan
75538205|NCT05711615|Procedure|Magnetic Resonance Imaging|Undergo MRI
75538206|NCT05711615|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75538207|NCT05711615|Drug|Peposertib|Given PO
75538208|NCT05698524|Drug|PCI 24781|Patients will take the PCI-24781/Abexinostat on days 1-4, 8-11, 15-18, and 22-25 of each 28-day cycle.
75538209|NCT05698524|Drug|Temozolomide|Patients will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.
76028732|NCT00816413|Radiation|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
75375057|NCT04756843|Device|Quad-helix|Fixed orthodontic appliance
75538210|NCT05695560|Other|No Intervention|As this is an observational study, no intervention will be administered.
75538211|NCT05692401|Behavioral|Nutrition and Exercise Instruction|Eating and exercise patterns. Educational handouts and instructions will be provided, which are intended as a guide for subjects in intervention group. Subjects will also be given a Patient Diary to complete their daily meal intake and physical exercises. Use of and return of the diary is optional but encouraged. It has been found that use of a patient diary to record food intake keeps one from eating more than they planned and can be a useful tool in weight control.
75701619|NCT04085822|Device|SMA-001|Intra-dermal injection of SMA-001 and control device.
75701620|NCT00683787|Drug|docetaxel|Given IV once every 3 weeks
75701621|NCT00683787|Drug|vandetanib|Oral vandetanib once daily
76028733|NCT00734838|Device|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
75375058|NCT04677751|Device|Acupuncture intervention|Participants will undergo 12 weeks of acupuncture therapy. There will be one 40 minute-1 hour. session per week.
75375059|NCT04652869|Device|Transcranial direct current stimulation|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
75538212|NCT05688657|Device|Lens A|Monthly Replacement Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
75538213|NCT05688657|Device|Lens B|Daily Disposable Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
75375060|NCT04652869|Behavioral|Mindfulness|Mindfulness is a type of meditation in which you focus on being intensely aware of what you're sensing and feeling in the moment, without interpretation or judgment.
75538214|NCT05685602|Procedure|Biopsy|Undergo a tumor biopsy
75538215|NCT05685602|Procedure|Biospecimen Collection|Undergo blood sample collection
75538216|NCT05685602|Procedure|Computed Tomography|Undergo a CT scan
75701622|NCT02560935|Drug|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
75538217|NCT05685602|Biological|Emavusertib|Given PO
75538218|NCT05685602|Drug|Gemcitabine Hydrochloride|Given IV
75538219|NCT05685602|Procedure|Magnetic Resonance Imaging|Undergo MRI
75865982|NCT02703532|Behavioral|Constraint-Induced Movement Therapy (CIMT)|"Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.~Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete."
75865983|NCT03439670|Drug|Vamorolone|Oral administration of 2.0 mg/kg/day for the duration of the study.
75865984|NCT03439670|Drug|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
75865985|NCT03439670|Other|Placebo|Oral administration of placebo daily for 24 weeks.
75375061|NCT04622839|Other|Tylenol and NSAIDS (Ibuprofen, diclofenac)|"This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~Agents used in nerve block (lidocaine vs ropivacaine)~Location of injection for analgesic~Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~Number of pills in the initial opioid prescription~Instructions for sling wear (duration of use or type of sling)~Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage."
75865986|NCT03439670|Drug|Vamorolone|Oral administration of 6.0 mg/kg/day for the duration of the study.
75538220|NCT05685602|Drug|Nab-paclitaxel|Given IV
75375062|NCT00366379|Drug|GK Activator (2)|25-200mg po bid for 20 weeks
75375063|NCT02619799|Drug|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
75538221|NCT05685602|Procedure|Positron Emission Tomography|Undergo a PET scan
75538222|NCT05685602|Procedure|X-Ray Imaging|Undergo an x-ray
75538223|NCT05679024|Drug|Apixaban 2.5 milligram Oral Tablet|Oral Tablet
75538224|NCT05677282|Drug|Rifaximin 550 MG|Rifaximin 550 mg as a single dose administered orally.
75538225|NCT05677282|Drug|Azithromycin 500 MG|Azithromycin 500 mg as a single dose administered orally.
75538226|NCT05677282|Drug|Loperamide|4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
75538227|NCT05675345|Device|HFNC only|HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
75538228|NCT05675345|Device|HFNC + CNEP10|HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
75538229|NCT05675345|Device|HFNC + CNEP20|HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
75538230|NCT05675345|Device|HFNC + CNEP30|HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
75865987|NCT03439670|Drug|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
75865988|NCT03439670|Other|Placebo|Oral administration of placebo daily for 24 weeks.
75865989|NCT03439670|Drug|Vamorolone|Oral administration of 2.0 mg/kg/day for 20 weeks.
75865990|NCT03439670|Drug|Vamorolone|Oral administration of 6.0 mg/kg/day for 20 weeks.
75865991|NCT01357005|Other|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
75865992|NCT02930343|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
75538231|NCT05672303|Behavioral|Palmar grasp reflex|The reflex can be stimulated by moving an object distally across the palm. In the study, at the beginning of the vaccine administration, the right hand of the infant will be moved distally along the palm with the researcher's index finger, thus providing reflex stimulation.
75701623|NCT02560935|Drug|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
75701624|NCT00723008|Device|Alpha Stim 100 (Cranial Electrotherapy Stimulation)|cranial electrical stimulation 100 microamps
75701625|NCT00750399|Drug|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
75538232|NCT05665335|Device|Renuvion APR System|"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."
75538234|NCT05657119|Behavioral|MI FSN - Lethal Means Reduction|"Motivational Interviewing lethal means reduction, firearm storage supplies, Tailored text messages~Participate in a 15-20-minute motivational interviewing (MI) session conducted by trained University of Michigan research staff focused on encouraging suicide lethal means~Be offered to take home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~Receive 4 weeks of tailored text message reminders and encouragement"
75538235|NCT05657119|Behavioral|Scripted FSN - Lethal Means Reduction|"Scripted lethal means reduction, firearm storage supplies, tailored text messages~Participate in a 10-15-minute scripted session focused on gun safety and lethal means reduction~Be offered to home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~Receive 4 weeks of tailored text message reminders and encouragement"
75865993|NCT02930343|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
75538236|NCT05657119|Behavioral|General Firearm Safety Intervention - General Firearm Safety|"General information on gun safety, firearm storage supplies, tailored text messages~Participate in a 10-minute scripted conversation about safe gun storage practice~Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes~Receive 4 weeks of tailored text message reminders and encouragement"
75701626|NCT00750399|Drug|ranibizumab|intravitreal ranibizumab 0.5 mg
75865994|NCT02930343|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
75375064|NCT02619799|Drug|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
75865995|NCT02930343|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
75865996|NCT02930343|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
75538237|NCT05657119|Behavioral|General Firearm Comparison - General Firearm Safety|"firearm storage supplies~* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes"
75538238|NCT05654662|Drug|Corsodyl Original Dentifrice|It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million [ppm] Fluoride ion [F])
75701627|NCT00756171|Drug|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
75701628|NCT00756171|Drug|placebo|2 times 3 625mg tablets daily
75865997|NCT02930343|Drug|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
75865998|NCT03681938|Procedure|Autograft|Autograft
75375065|NCT02621983|Behavioral|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
75701629|NCT00750477|Dietary Supplement|NEM|see Treatment Arms
75701630|NCT00750477|Dietary Supplement|Placebo|Placebo comparator containing inactives
75701631|NCT00718640|Drug|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
75701632|NCT00718640|Drug|Bortezomib|Bortezomib 1.3 milligram per meter^2 (mg/m^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
75701633|NCT00756249|Drug|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
75701634|NCT00756249|Drug|Placebo|Vials with solution for IV infusion
75701635|NCT02591810|Procedure|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
75865999|NCT02703454|Procedure|FIRM-guided RF ablation|
75701636|NCT02591810|Procedure|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
75701637|NCT02591810|Procedure|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
75701638|NCT00753051|Drug|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
75701639|NCT00753051|Drug|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
75866000|NCT02703454|Procedure|Conventional RF ablation|
75866001|NCT03686618|Drug|Secretin|Drug to stimulate pancreatic secretion
75866002|NCT03103542|Biological|Recombinant coagulation factor (rFVIIIFc)|"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously."
75866003|NCT02426866|Drug|Efavirenz|
75538239|NCT05654662|Drug|Colgate Cavity Protection Dentifrice|It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
75375066|NCT02621983|Behavioral|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
75538240|NCT05650567|Drug|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.
75538241|NCT05650567|Drug|Placebo|Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
75375067|NCT04741165|Drug|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
75375068|NCT04741165|Drug|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
75538242|NCT05640323|Device|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
75701640|NCT02591108|Device|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
75866004|NCT03686540|Procedure|ExtraCorporeal Membrane Oxygenation (ECMO)|The objective of this study is to determine the average cost of stay of a patient supported by ExtraCorporeal Membrane Oxygenation from the point of view of the hospital facility, during the hospitalization in which the ECMO was implanted.
75866005|NCT00706498|Drug|BI 2536|
75375069|NCT04741165|Drug|Lenvatinib|Administered orally once a day during each 21-day cycle
75538243|NCT05633459|Drug|QRL-201 - Dose 1|"Drug: Dose 1 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
75375070|NCT04741243|Device|Extracorporeal Shock wave|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
75375071|NCT05138497|Other|HILIT|A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
75375072|NCT02623855|Behavioral|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
75375073|NCT02623855|Behavioral|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
75375074|NCT02623855|Device|Pedometry|Participants will record their daily pedometry.
75375075|NCT02623855|Behavioral|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
75375076|NCT04340011|Other|Colposcopy|prospective resident education for colposcopy
75538244|NCT05633459|Drug|QRL-201 - Dose 2|"Drug: Dose 2 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)~Diluent: artificial cerebrospinal fluid (aCSF)"
75701641|NCT02591108|Device|Standard of Care: Microstim Plus|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
75701642|NCT00753129|Procedure|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
75701643|NCT00753207|Drug|epirubicin hydrochloride|
75701644|NCT00753207|Drug|lapatinib ditosylate|
75375077|NCT02625181|Procedure|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
75375078|NCT02625181|Procedure|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
75375079|NCT02625181|Procedure|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
75538245|NCT05633459|Drug|QRL-201 - Dose 3|"Drug: Dose 3 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
75538246|NCT05633459|Drug|QRL-201 - Dose 4|"Drug: Dose 4 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
75375080|NCT02625181|Procedure|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
75375081|NCT02625181|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
75375082|NCT02625181|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
75375083|NCT02625181|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
75375084|NCT02625181|Procedure|Elective surgery|Surgical procedures that are scheduled and not an emergency.
75375085|NCT02625181|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
75375086|NCT02625181|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
75375087|NCT02625181|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
75375088|NCT02625181|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
75375089|NCT02625181|Drug|Scopolamine|Prophylactic antiemetic
75375090|NCT02625181|Drug|Droperidol|Prophylactic antiemetic & rescue antiemetic
75375091|NCT02625181|Drug|Haloperidol|Prophylactic antiemetic & rescue antiemetic
75538247|NCT05633459|Drug|QRL-201 - Dose 5|"Drug: Dose 5 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
75375092|NCT02625181|Drug|Dexamethasone|Prophylactic antiemetic & rescue antiemetic
75375093|NCT02625181|Drug|Promethazine|Prophylactic antiemetic & rescue antiemetic
75375094|NCT02625181|Drug|Meclizine|Prophylactic antiemetic & rescue antiemetic
75375095|NCT02625181|Drug|Aprepitant|Prophylactic antiemetic & rescue antiemetic
75375096|NCT02625181|Drug|Metoclopramide|Rescue antiemetic
75375097|NCT02625181|Drug|Fentanyl|Analgesic drug / Opioid
75375098|NCT02625181|Drug|Sufentanil|Analgesic drug / Opioid
75375099|NCT02625181|Drug|Alfentanil|Analgesic drug / Opioid
75375100|NCT02625181|Drug|Remifentanil|Analgesic drug / Opioid
75375101|NCT02625181|Drug|Morphine|Analgesic drug / Opioid
75375102|NCT02625181|Drug|Meperidine|Analgesic drug / Opioid
75375103|NCT02625181|Drug|Hydromorphone|Analgesic drug / Opioid
75375104|NCT02625181|Drug|Methadone|Analgesic drug / Opioid
75375105|NCT02625181|Drug|Oxycodone|Analgesic drug / Opioid
75375106|NCT02625181|Drug|Oxymorphone|Analgesic drug / Opioid
75866006|NCT01358955|Other|group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
75538248|NCT05633459|Drug|QRL-201 - Dose 6|"Drug: Dose 6 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
75538249|NCT05633459|Drug|QRL-201 - Dose 7|"Drug: Dose 7 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
75538250|NCT05633459|Drug|QRL-201- Dose 8|"Drug: Dose 8 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
75538251|NCT05626634|Drug|LP352|LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
75375107|NCT02625181|Drug|Hydrocodone|Analgesic drug / Opioid
75375108|NCT02625181|Drug|Ketamine|Analgetic / Analgesic drug
75375109|NCT02625181|Drug|Ondansetron|Prophylactic antiemetic & rescue antiemetic
75375110|NCT02625181|Drug|Granisetron|Prophylactic antiemetic & rescue antiemetic
75375111|NCT02625181|Drug|Dolasetron mesylate|Prophylactic antiemetic & rescue antiemetic
75375112|NCT02625181|Drug|Palonosetron|Prophylactic antiemetic & rescue antiemetic
75375113|NCT02625181|Drug|Tropisetron|Prophylactic antiemetic & rescue antiemetic
75375114|NCT02625181|Drug|Ramosetron|Prophylactic antiemetic & rescue antiemetic
75375115|NCT05442229|Other|establish a new Chinese children's speech and language norm|1063 normally developing children and 96 abnormally developing children will be retrospectively enrolled from the medical records of stratified, randomly selected centers. A total of 4137 children with normal development and 448 children with abnormal development aged from 2 to 6 years old will be selected from 11 hospitals in China by multi-center, stratified, unequal proportion random sampling and face-to-face survey. Children's speech and language development was assessed by the Speech and Language Development Scale for children aged 2 to 6, compiled by the Linguistics and Language Research Centre of the Education University of Hong Kong.
75538252|NCT05625412|Drug|BMS-986360|Specified dose on specified days
75866007|NCT01358955|Other|Home-based cognitive intervention|The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
75866008|NCT04960722|Device|OIF/β-TCP|bone graft implantation
75375116|NCT02625571|Behavioral|Phase-based treatment of sexual behavior problems of children|
75375117|NCT05046223|Procedure|The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.|cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions
75375118|NCT05046223|Procedure|postoperative recovery|anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1
75375119|NCT04741321|Other|VascuQol-6 questionnaire Spanish version|VascuQol-6 questionnaire was translated by two professional translators into Spanish.
75538253|NCT05625412|Drug|Docetaxel|Specified dose on specified days
75538254|NCT05625412|Drug|Nivolumab|Specified dose on specified days
75538255|NCT05625412|Drug|Capecitabine|Specified dose on specified days
75538256|NCT05607095|Biological|Lifileucel (LN-144)|Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.
75538257|NCT05604365|Behavioral|FearLess Intervention|8-12 weekly telehealth sessions one hour in length.The intervention includes psychotherapy techniques varying from relaxation response to self-regulation targeted to the specific fears of patients with glioma.
75538258|NCT05602636|Drug|bupivacaine, midazolam|Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
75701645|NCT00753207|Other|biomarker analysis|
75701646|NCT00753207|Other|immunohistochemistry staining method|
75701647|NCT00753207|Other|liquid chromatography|
75701648|NCT00753207|Other|mass spectrometry|
75701649|NCT00715910|Biological|Nimenrix|One dose, as intramuscular injection
75866009|NCT02418598|Genetic|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10^11 vg/subject.
75866010|NCT02418598|Genetic|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10^11 vg/subject.
75866011|NCT03428828|Behavioral|Amygdala Neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
75538259|NCT05601284|Behavioral|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
75701650|NCT00715910|Procedure|Blood sampling|Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
75866012|NCT03428828|Behavioral|Parietal Neurofeedback|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
75375120|NCT04740853|Behavioral|Sensory Integration Therapy+Special Education|Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
75375121|NCT02628223|Procedure|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
75375122|NCT02628223|Device|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
75375123|NCT02630017|Drug|ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
75866013|NCT04874922|Behavioral|Gestational Diabetes Training Intervention based on Planned Behavior Theory|On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
75866014|NCT04874922|Behavioral|Gestational Diabetes Training Intervention based on standart|Standard training for gestational diabetes will be given once at 28 weeks of gestation.
75375124|NCT02630017|Drug|ADHD placebo first, methylphenidate second|double-blind, counter-balanced administration
75375125|NCT02630017|Drug|Non-ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
75538260|NCT05601284|Behavioral|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
75538261|NCT05599048|Drug|Hyperpolarized 13C-Pyruvate|Given IV
75538262|NCT05599048|Procedure|Magnetic Resonance Imaging (MRI)|Imaging procedure
75538263|NCT05598333|Drug|AB-1002|Intracoronary Infusion of AB-1002 or placebo
75538264|NCT05571410|Behavioral|HTN Chat bot|Remote monitoring via automated messaging program
75538265|NCT05570539|Drug|BLU-5937 IR|Each subject will receive two single and multiple administrations of Immediate Release reference formulation
75375126|NCT02630017|Drug|Non-ADHD placebo first, methylphenidate second|
75375127|NCT00366925|Device|Adacolumn®|
75375128|NCT02630719|Drug|Timolol eye drops|eye drops
75375129|NCT02630719|Drug|Artificial tears|Placebo drop
76028734|NCT00579241|Procedure|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
76028735|NCT00488943|Device|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
75538266|NCT05570539|Drug|BLU-5937 ER|Each subject will receive single and multiple oral administrations of Extended Release formulation
75866015|NCT03686462|Device|Virtual reality-based interactive treadmill training|During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
75375130|NCT02630953|Behavioral|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
75375131|NCT02630953|Behavioral|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
75375132|NCT02633371|Drug|Oxybutynin 3% gel|
75538267|NCT05564273|Combination Product|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may receive supplements, diet recommendations, and app coaching.
75538268|NCT05564273|Dietary Supplement|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may receive supplements, diet recommendations, and app coaching.
75538269|NCT05563857|Combination Product|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
75866016|NCT03686462|Device|Treadmill training without VR-based interaction|Treadmill training without VR-based interaction
75538270|NCT05563857|Dietary Supplement|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
75538271|NCT05562011|Device|Caretaker Device placement|a continuous non-invasive blood pressure and vital signs monitor that is worn on the wrist
75538274|NCT05557110|Drug|Blinatumomab|Reduced-intensity chemotherapy followed by Blinatumomab
75538275|NCT05554640|Device|Acuvue® Oasys MAX 1-Day|TEST Lens
75538276|NCT05554640|Device|Dailies Total 1|CONTROL Lens
75538277|NCT05550727|Other|PorchLight|The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
75538278|NCT05548712|Device|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
75538279|NCT05548712|Device|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
75375133|NCT04159519|Drug|Symbicort®|Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation and Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
75538280|NCT05540665|Drug|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
75866017|NCT02423824|Biological|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
75866018|NCT04548570|Procedure|approximation of both rectus muscles|closure of both rectus muscle before closure of rectus sheeth
75375134|NCT04159519|Drug|Fasenra®|Participants received Benralizumab 30 mg/mL, 1 mL fill volume via Subcutaneous every 4 weeks for first 3 doses.
75375135|NCT04159519|Drug|Ventolin®|Participants received Salbutamol sulfate 100 μg per inhalation as needed.
75375136|NCT04079491|Other|questionnaire survey|A web-based questionnaire will be send by the trade union for dental hygienists
75866019|NCT02423434|Other|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
75375137|NCT04871659|Other|Online Survey completion|Eligible participants will complete surveys electronically via Amazon's mTurk platform
75375138|NCT02634073|Drug|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
75375139|NCT02634073|Drug|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
75375140|NCT00366613|Procedure|Cataract surgery with Perfect Capsule and Sodium Chloride|
75375141|NCT00366691|Drug|Acular LS|
75375142|NCT00366691|Drug|Lotemax|
75375143|NCT00366769|Device|Wavefront-guided LASIK using CustomVue platform|
75375144|NCT02637427|Biological|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
75538281|NCT05540665|Drug|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
75538282|NCT05540665|Drug|Placebo (Normal Saline)|Placebo will be administered subcutaneously as two injections for each dose.
75538283|NCT05540327|Drug|M5049 low dose|Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 48 weeks.
75538284|NCT05540327|Drug|M5049 medium dose|Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 48 weeks.
75866020|NCT01012167|Drug|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
75866021|NCT01012167|Drug|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
75375145|NCT04400071|Behavioral|Active Music Engagement|Weekly 45-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
75538285|NCT05540327|Drug|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 48 weeks.
75866022|NCT01012167|Other|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
75866023|NCT01012167|Other|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
75866024|NCT04522518|Device|PmP-C App|"The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to."
75866025|NCT02426710|Device|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
75866026|NCT03424850|Radiation|HDR brachytherapy|"Dose constraints for 21 Gy:~Bladder and rectum: V70 < 1 cc~Urethra: V115 < 1 cc~V135: 0%~Dose constraints for 23 Gy:~Bladder and rectum: V65 < 1 cc~Urethra: V105 < 1 cc~V125: 0%~Dose constraints for 25 Gy:~Prostate V100 >90% (>95% preferred)~Bladder and rectum: V70 < 1 cc, Dmax <115%~Urethra: V110 < 1 cc, Dmax <120%"
75866027|NCT05758974|Procedure|dental treatment|Extraction, pulp therapy or both
75701651|NCT04056663|Behavioral|Health-Circuit mobile application|Health-Circuit as a collaborative tool between professionals and patient and professionals
75701652|NCT00750711|Procedure|Radiofrequency ablation for atrial flutter by catheters|
75701653|NCT00750789|Dietary Supplement|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
75701654|NCT02590484|Procedure|The cervix as a natural tamponade (cervical inversion)|Suturing an inverted lip(s) of the cervix over the bleeding placental bed to control the bleeding.
75701655|NCT04086914|Procedure|Nerve Block|This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
75701656|NCT00715676|Drug|Placebo|oral, once daily
75701657|NCT00715676|Drug|DP001|oral, once daily
75701658|NCT05163470|Other|early on filed functional rehabilitation|Intervention 1 ,called ''On FI.RE. framework '' included a on filed functional rehabilitation framework ,with early return of the player on the field activities during injury recovery. Involve a specific 5 stages framework of functional rehabilitation on filed. Criteria of inclusion and exclusion for each stage are included based on pain, oedema and range of motion specific to nature of injury . Additional included a daily session planning framework for on field functional rehabilitation with a content ,duration and the description of each content.
75701659|NCT05163470|Other|traditional on filed functional rehabilitation|Intervention 2 ,called 'traditional rehabilitation' include a on field functional rehabilitation framework ,as the late phase of injury recovery .The framework described as a 5 stages on filed rehabilitation framework based on load monitoring usingGlobal positioning system.No criteria for the player to return to activity on the field cited ,but referred criteria for progression in each stage based on Strength/power depending of the nature of injury.
75538286|NCT05540327|Drug|Placebo|Participants will receive M5049 matching placebo orally, BID for up to 48 weeks.
75538287|NCT05540327|Drug|M5049 very high dose|Participants will receive film-coated tablets of M5049 at a very high dose orally, BID for up to 48 weeks.
75701660|NCT00718328|Drug|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
75866028|NCT02426944|Drug|NOAC|Medical arm, patients will be treated by NOAC.
75538290|NCT05536856|Drug|a new effervescent mixture 5-florouracil formula|30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
75866029|NCT02426944|Device|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
75538291|NCT05536856|Drug|5-Fluorouracil plain powder|30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
75866030|NCT03376321|Drug|Pimodivir 600 mg|Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
75866031|NCT03376321|Drug|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
75538292|NCT05534464|Other|Milk|Twenty grams of the deuterium (2H) - labelled skimmed milk powder mixed with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. Protein free cookies are served alongside to equal macronutrient composition with the other two protein sources.
75538293|NCT05534464|Other|Sorghum|Twenty grams of the deuterium (2H) - labelled whole grain sorghum cooked with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference.
75701661|NCT00718328|Drug|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
75701662|NCT05346848|Drug|Association of darolutamide and EBRT|"Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~78 Gy with classical 2 Gy/fractions, 5 days/7~Or 60 Gy with 3 Gy/fractions, 5 days/7~Use of IMRT and IGRT is mandatory~Clinical Target Volume Definition according to GETUG Guidelines~Organ at risk dose constraints according to RECORAD"
75866032|NCT03376321|Other|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
75866033|NCT02418520|Device|Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
75866034|NCT04437732|Device|Apioc-P and Apioc-PT Contact Lens Design|Novel soft contact lens design
75375146|NCT04400071|Behavioral|Audio Storybooks|Weekly 45-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
75375147|NCT02638051|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
75375148|NCT02638051|Dietary Supplement|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
75375149|NCT02638051|Drug|IPCI (CDDP+5FU)|Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
75375150|NCT00367393|Drug|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
75375151|NCT00367471|Drug|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
75375152|NCT00367471|Drug|carboplatin|An alkylating agent used in the treatment of some cancers
75375153|NCT00367471|Drug|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
75375154|NCT00367471|Drug|paclitaxel|A mitotic inhibitor used in cancer treatment
75866035|NCT03183622|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
75866036|NCT05760534|Drug|Remimazolam|0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
75866037|NCT02418364|Other|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
75866038|NCT02418364|Other|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
75866039|NCT01362699|Drug|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
75701663|NCT05346848|Drug|Association of ADT and EBRT|"Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~78 Gy with classical 2 Gy/fractions, 5 days/7~Or 60 Gy with 3 Gy/fractions, 5 days/7~Use of IMRT and IGRT is mandatory~Clinical Target Volume Definition according to GETUG Guidelines~Organ at risk dose constraints according to RECORAD"
75701664|NCT02591186|Procedure|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
75538294|NCT05534464|Other|Black beans|Twenty grams of the deuterium (2H) - labelled black beans cooked with water and mashed into a puree, will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. A carbohydrate drink is served alongside to equal macronutrient composition with the other two protein sources.
75701665|NCT04087070|Device|Biosignal measurements|"Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~PAT(time between R peak of ECG and beginning of the pulse of PPG)~PEP(time between R peak of ECG and peak of accelerometer signal)~PTT(PAT-PEP)"
75701666|NCT02590874|Drug|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
75701667|NCT02590874|Drug|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
76028736|NCT05917080|Other|Manual Therapy|"Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia & applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time."
75538295|NCT05534126|Procedure|Stellate Ganglion Block Treatment|Stellate ganglion block procedure is a treatment that involves injection of local anesthetic around the stellate ganglion (located at the base of the neck) to block its transmission of pain signals.
75538296|NCT05534126|Procedure|Placebo|Sham
75866040|NCT01362699|Drug|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
75701668|NCT02590952|Drug|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
75866041|NCT03686072|Procedure|Cataract surgery with endoscopic goniosynechialysis|Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
75866042|NCT02423278|Procedure|Radical Gastrectomy Plus D2 Lymphadenectomy|"This surgical procedure is performed by the same high-experienced surgical team as the control arm.~All lymph nodes around stomach (station 1&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams."
76028737|NCT05917054|Other|use of bipolar vascular sealing method on the renal allograft at the back-table stage|Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.
75866043|NCT02423278|Procedure|Radical Gastrectomy Plus D4 Lymphadenectomy|"This surgical procedure is also performed by the same high-experienced surgical team as the control arm.~Lymph nodes around stomach (station 1&2 LNs) and para-aortic lymph nodes must be removed during the operation."
75866044|NCT02423278|Drug|S-1+Oxaliplatin|"A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
75375155|NCT04380883|Device|InnoSEAL+TRB|InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.
75375156|NCT04380883|Device|TRB alone|TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
75375157|NCT03643003|Behavioral|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
75538297|NCT05518721|Procedure|Hallux Rigidus Treatment|Participants will receive either a synthetic cartilage implant or dermal interposition arthroplasty
75538298|NCT05517785|Other|Motor performance tests|Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance
75538299|NCT05516147|Behavioral|SAFE at Home|SAFE at Home will enable community-dwelling PWD to participate in videoconference-based group activities with their peers, that is, other PWD. SaH sessions will be facilitated by highly trained Engagement Professionals.
75538300|NCT05510908|Other|Non-Interventional|Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
76028738|NCT05917041|Device|SAT-001(Software as Medical Device)|Using SAT-001 application for 48 weeks and wearing glasses or not
75538301|NCT05510908|Other|Non-Interventional Follow-up|Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
75538302|NCT05510674|Diagnostic Test|OWL-EVO1|EVOC probe
75866045|NCT01365429|Device|XPS™ with Steen Solution™|The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
75866046|NCT02423356|Procedure|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
75866047|NCT02950506|Device|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
76028739|NCT05917015|Dietary Supplement|Treatment|Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
76028740|NCT05917015|Other|Placebo|Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
76028741|NCT05917002|Device|Real TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system).
75866048|NCT02950506|Other|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
75866049|NCT03183466|Procedure|arthroscopic repair|
75866050|NCT03183466|Procedure|arthroscopic debridement|
75866051|NCT05189067|Drug|Paclitaxel|i.v. 80mg/m^2
75866052|NCT05189067|Drug|Trastuzumab|i.v. loading dose of 8 mg/kg, followed by 6mg/kg
75866053|NCT05189067|Drug|Docetaxel|i.v. 100mg/m2
75866054|NCT03374995|Other|Best Practice|Receive standard of care
75866055|NCT03374995|Other|Quality-of-Life Assessment|Ancillary studies
75866056|NCT03374995|Device|Topical Keratin|Given topically
75866057|NCT02418208|Diagnostic Test|Performint EEG tests and BNA analysis|
75866058|NCT02828982|Device|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
75866059|NCT02828982|Device|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
75866060|NCT01362777|Behavioral|In-patient rehabilitation|"Individualized exercise training (IET):~Duration : 24 sessions during 4 weeks~IET session (2h) contains:~15' start warming up muscles~30' muscle strengthening exercise for arms and abdominal muscles~45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.~15' stretching~15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.~Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe."
76028742|NCT05917002|Device|Sham TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system). The Magventure MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
76028743|NCT05916976|Diagnostic Test|cardiac MRI|Multiparametric MRI of the heart
75538303|NCT05503992|Other|Intervention package|The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
75538304|NCT05497453|Drug|OTX-2002|OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.
75538305|NCT05497453|Drug|Tyrosine kinase inhibitor One|Tyrosine Kinase Inhibitor
75538306|NCT05497453|Drug|Tyrosine kinase inhibitor Two|tyrosine kinase inhibitor
75538307|NCT05497453|Drug|Checkpoint Inhibitor, Immune|monoclonal antibody that binds to PD-1 or PD-L1
75538308|NCT05497284|Drug|LTP001|LTP001 will be administered once daily in the morning
76028744|NCT05916937|Drug|omalizumab 300 mg every four weeks|"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
75701669|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS)|Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single-pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post-training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
75538309|NCT05497284|Drug|Placebo|Placebo to LTP001 will be administered once daily in the morning
75538310|NCT05497284|Drug|Standard of Care (SoC)|nintedanib, pirfenidone, or neither
75538311|NCT05481190|Behavioral|Tele-Exercise Program|Data collection tools were applied to the tele-exercise group and control group at the beginning of the study. For the tele-exercise group, by the researcher, Exp. A 6-week exercise program was created under the consultancy of a physiotherapist. Children who met the research criteria were asked to do these exercises for 20 minutes, 3 times a week for 6 weeks. The exercises were performed online with the researcher at the scheduled time one day a week, and by the children twice a week. On the days they exercised, diaries consisting of semi-structured questions were sent to the children's addresses by cargo and they were allowed to keep a diary. Phone calls were made once a week to provide motivation and increase compliance with exercise. A smart watch was sent to the children by cargo to increase motivation. The children were asked to fill in the follow-up form, which was sent via weekly google forms.
75538312|NCT05481190|Behavioral|Just observation|Standard care was given to the children in the control group.
75538313|NCT05472168|Other|Olfactory Stimulation|Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.
75538314|NCT05465629|Combination Product|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
75538315|NCT05465629|Dietary Supplement|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
75538316|NCT05465616|Dietary Supplement|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
75538317|NCT05463770|Drug|SEP-363856|SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
76028745|NCT05916937|Drug|omalizumab 300 mg every six weeks|"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
75538318|NCT05457608|Device|Lens A|monthly replacement multifocal silicone hydrogel contact lens 15 minutes of daily wear
75538319|NCT05457608|Device|Lens B|daily disposable multifocal silicone hydrogel contact lens 15 minutes of daily wear
75538320|NCT05452772|Drug|Psilocybin|Participants will received two psilocybin sessions, 1 week apart
75538321|NCT05452772|Drug|Niacin|Participants will received two niacin sessions, 1 week apart
75538322|NCT05452447|Device|Transfluthrin|Passive emanator with formulated transfluthrin
75538323|NCT05452447|Device|Placebo|Passive emanator with formulated inert ingredients
75538324|NCT05447884|Other|A zero impedance mode, controlling a wearable bilateral hip exoskeleton|The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.
75538325|NCT05447884|Other|A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton|The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.
75701670|NCT00715520|Drug|Carbidopa-Levodopa|"Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant."
75866061|NCT01362777|Behavioral|Educational activities alone|"Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :~Physiological mechanisms of apneas/hypopneas~Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)~Beneficials effects of CPAP and/or advanced mandibular orthosis~Description of sleep stages and physiological roles of sleep~Known effects of exercise on sleep and metabolism~Importance of good nutritional status and sleep hygiene on quality of life~How to apply theses lessons of rehabilitation in daily life"
76028746|NCT05916924|Other|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting
75538326|NCT05447884|Other|A free walking mode, without wearing a wearable bilateral hip exoskeleton|The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.
75538327|NCT05447663|Drug|Siremadlin|30-40 mg QD siremadlin capsules, orally (1-5 days of 28 or 42 days cycle)
75538328|NCT05445583|Behavioral|Motivational Enhancement System (MES)|MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
75701671|NCT00715520|Drug|Methylphenidate|"Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant."
75375158|NCT03643003|Behavioral|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
75375159|NCT02207244|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
75538329|NCT05445583|Behavioral|Supportive Accountability (SA)|Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
75538330|NCT05445583|Behavioral|Text Messaging (SMS)|SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
75538331|NCT05445583|Behavioral|Physical Activity Tracking (PAT)|All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
75538332|NCT05439772|Drug|Ondansetron|Patient will take one dissolvable tablet of ondansetron prior to initiating PEG consumption.
75538333|NCT05433181|Drug|ACE2 Chewing Gum|The IP is formulated as an oral plant powder, which is packaged into a chewing gum. No specific excipient, buffer, salt or pH is required. CTB-ACE2, with efficient binding to both GM1 and ACE2 receptors, effectively blocks binding of the spike protein and viral entry into human cells. Oral epithelial cells are enriched with both receptors. In addition, ACE2 directly binds to the spike protein and inactivates SARS-CoV-2 virus. Therefore, CTB-ACE2 chewing gum is being evaluated for impact on entry and transmission of SARS-CoV-2.
75538334|NCT05433181|Other|Placebo Chewing Gum|Chewing gum containing wild-type lyophilized plant cells manufactured to match the IP.
75538335|NCT05432271|Behavioral|Exposure to calorie information|Calories for all beverages and foods
75701672|NCT00715520|Drug|Amphetamine Sulfate|"Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant."
75701673|NCT00715520|Drug|Placebo|"Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant."
75701674|NCT00715520|Other|Sham Transcranial Magnetic Stimulation (TMS)|Sham TMS pulses will be randomly administered during TMS sessions.
75866062|NCT02427022|Other|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
75538336|NCT05432271|Behavioral|Exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
75538337|NCT05432271|Behavioral|Exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
75538338|NCT05432271|Behavioral|Exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
75538339|NCT05432271|Behavioral|"Exposure to high in nutrient warning labels"|Warning labels only for beverages and foods that exceed the thresholds for sugar, sodium, saturated fat, or calorie content
75538340|NCT05423691|Drug|CK0804|CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
75538341|NCT05418673|Drug|BIIB122|Administered as specified in the treatment arm.
75538342|NCT05418673|Drug|BIIB122-Matching Placebo|Administered as specified in the treatment arm.
76028747|NCT05916898|Device|PCI with support of Shockwave Intravascular Lithotripsy|Coronary artery angioplasty of the primary lesion or optimization of the previously implanted stent with the support of Shockwave Intravascular Lithotripsy device
75538343|NCT05417763|Device|Randomized physiological measurements by the two systems|To measure physiological indices (FFR, cRR and RFR), either pressure microcatheter or pressure wire enters one patient's body. Whether it is the pressure microcatheter or pressure wire firstly to enter is randomized. After completion of one system's physiological assessment, the other system will follow for its physiological assessment.
75538344|NCT05417022|Device|Diamondback 360TM orbital atherectomy system|Use of the Diamondback 360TM orbital atherectomy system in the preparation of calcified coronary lesions before implantation of a coronary endoprothesis
75538345|NCT05414175|Drug|Mavacamten|Specified dose on specified days
75538346|NCT05407064|Drug|MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
75538347|NCT05407064|Other|Placebo|A substance that is designed to have no therapeutic value.
75538348|NCT05402111|Drug|SEP-363856|SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
75538349|NCT05402111|Drug|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
75866063|NCT03711643|Procedure|Periprostatic nerve block|4 injections of 2 cc of lidocaine for a Periprostatic nerve block
76028748|NCT02342977|Drug|Placebo|Patients will randomly receive placebo
75538350|NCT05400408|Diagnostic Test|VOX|Breath Biopsy Analysis
75538351|NCT05396638|Behavioral|Contingency Management|Participants will be paid for abstinence at each study visit.
76028749|NCT02342977|Drug|Lacosamide|Patients will randomly receive lacosamide
76028750|NCT05916859|Other|Group 2 PDT (10 s)|- Conventional endodontic treatment associated with PDT (10 s)
76028751|NCT05916859|Other|Group 3 PDT 20 s|Conventional endodontic treatment associated with PDAT (20 s)
76028752|NCT05916859|Other|Group 1. Placebo|Conventional endodontic treatment
75375160|NCT02207244|Drug|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
75375161|NCT02207244|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
75375162|NCT02207244|Drug|Placebo for adalimumab|Placebo for adalimumab [two 0.8 milliliter (mL) injections] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
75375163|NCT02638207|Drug|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
75375164|NCT04863222|Device|Biodentine|During a patients procedure, one tooth will receive Biodentine instead of MTA.
75538352|NCT05378620|Behavioral|Project Dulce + Dulce Digital|Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.
75538353|NCT05371613|Drug|tividenofusp alfa|Intravenous repeating dose
75538354|NCT05371613|Drug|idursulfase|Intravenous repeating dose
75538355|NCT05362292|Drug|Tolterodine Tartrate ER|Anticholinergic
75538356|NCT05362292|Drug|Mirabegron|Beta-3-adrenergic agonist
75538357|NCT05362292|Drug|Placebo|matching placebo pill
75538358|NCT05360706|Genetic|AAV5-hFIX|AAV5 containing a codon-optimized human factor IX gene
76028753|NCT05916846|Procedure|EUS-guided radiofrequency ablation of pancreatic cyst|EUS-RFA is performed with an 19 Gauge RFA needle (STARMed/TaeWoong Medical USA) applying up to 30 Watt (W) current with Continuance Mode setting. RFA confirmation is confirmed endoscopically via EUS (white bubbles on EUS imaging) and impedance monitoring on the VIVA™ Combo System. Impedance has a maximum value up 800 Ohms. Sequential doses of electrical energy at 10W-30W are applied to ablate the PCN.
76028754|NCT05916846|Device|FDA-cleared device (EUS-RFA probe)|FDA-cleared device (EUS-RFA probe).
76028755|NCT05916833|Other|hypopressive breathing|Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.
76028756|NCT05916833|Other|noble technique|Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
75538359|NCT05360238|Biological|MB-106|T-cells derived from autologous leukapheresis that are genetically modified.
75538360|NCT05351554|Drug|Namilumab|Namilumab administered subcutaneously
76028757|NCT05916781|Drug|Mycophenolate Mofetil|During the first 18 months, participants will take MMF+TAC. After 18 months, participants without lupus flare will randomly stop MMF or TAC.
75538361|NCT05351554|Drug|Placebo|Placebo administered subcutaneously to match namilumab dosing
75538362|NCT05351554|Drug|Open label Namilumab|Namilumab administered subcutaneously
76028758|NCT05916781|Drug|Tacrolimus|During the first 18 months, participants will take MMF+TAC. After 18 months, participants without lupus flare will randomly stop MMF or TAC.
75538363|NCT05351554|Drug|Prednisone|Prednisone or equivalent
76028759|NCT05916781|Drug|Glucocorticoid|Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months. Participants in steroid maintenance group will consistently take glucocorticoid.
75538364|NCT05351268|Radiation|Radioactive seed brachytherapy|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
75538365|NCT05348005|Device|Ovira Transcutaneous Electrical Nerve Stimulation Unit|TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
75701675|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS) Training|TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
75375165|NCT04863222|Biological|mineral trioxide aggregate (MTA)|mineral trioxide aggregate (MTA)
75375166|NCT04363879|Procedure|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
75701676|NCT05306132|Drug|ASKC202|Dosage Forms: Tablets; Administration: Oral administration
75375167|NCT04363879|Procedure|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
75375168|NCT02207088|Drug|ombitasvir/paritaprevir/ritonavir|tablet
75375169|NCT02207088|Drug|dasabuvir|tablet
75375170|NCT02207088|Drug|Ribavirin|tablet
75375171|NCT02638597|Drug|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
75375172|NCT02638597|Behavioral|smoking cessation counseling|smoking cessation counseling
75375173|NCT03585595|Other|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
75375174|NCT04333615|Behavioral|Exercise|Three conditions will be tested: self-selected exercise, walking with pain exercise, and control session.
75375175|NCT04339309|Procedure|Non-surgical periodontal treatment with interdental hygiene devices|
75375176|NCT04339309|Procedure|Non-surgical periodontal treatment without interdental hygiene devices|
75701677|NCT05684978|Drug|Perampanel|The purpose of this study is to determine the efficacy of Perampanel, an approved antiseizure medication, in the treatment of refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
75701678|NCT00756873|Drug|Administration of placebo|Placebo qd orally day 0-14
75701679|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
75375177|NCT02206620|Drug|Donepezil|
75375178|NCT02239926|Drug|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
75375179|NCT02239926|Drug|Placebo|
75375180|NCT02239692|Drug|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
75375181|NCT00367705|Dietary Supplement|VSL#3®|1-2 sachets/day per os, 6 months
75375182|NCT00367705|Dietary Supplement|Placebo|1-2 sachets/day per os, 6 months
75375183|NCT04340089|Behavioral|squatting on the toilet|the patients could go to squatting on the toilet at any time as they want to after taking the capsule
75375184|NCT02641249|Device|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
75375185|NCT04860414|Biological|Blood sampling|Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
75375186|NCT04860414|Other|Cognitive Assessment|QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
75701680|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
75701681|NCT00790205|Drug|Sitagliptin|Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
75701682|NCT00790205|Drug|Placebo|Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
75701683|NCT04056039|Drug|Atorvastatin|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
75701684|NCT04056039|Drug|Colchicine|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
75701685|NCT00750945|Other|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
75701686|NCT00750945|Other|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
75538366|NCT05347407|Procedure|Colonoscopy|Patients will be provided with a kit and be asked to bring a stool sample to their colonoscopy appointment. Mucosal biopsies will be collected with standard forceps during colonoscopy. If the physician determines that the patient will need colonoscopy with biopsy as part of their routine clinical care, they will take 6-8 additional biopsies for use in the research study. If the physician determines that the patient will need colonoscopy without biopsy as part of their routine clinical care, they will take 6-8 biopsies for use in the research study only. The collection of additional biopsies will add an estimated two minutes to the whole procedure.
75538367|NCT05345444|Device|IRE & MRgRT|Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
75538368|NCT05343000|Behavioral|Home-based pulmonary rehabilitation (PR) system|Technology to facilitate remote health coaching through PAP management, sleep scheduling, sleep duration, diet, exercise, medication and more. The tablet and sensors upload the patient's activities, physiological data, and answers to the daily self-report questions to a secure website. This website also allows health coaches to view patient data via overview, weekly, daily, and trend reports. Health coaches call patients regularly to celebrate progress, assist with any issues, and set new goals.
75538369|NCT05337982|Other|Downhill Eccentric Treadmill Training with Electrical Stimulation|Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
75538370|NCT05331625|Behavioral|Offering Additional Resources to Promote Symptom Management|Participants will be offered additional resources to promote symptom management.
75701687|NCT00750945|Other|Home program|Home walking program 6 days/wk x 4 weeks
75701688|NCT04104815|Other|Experimental Thickener|Use to thicken liquids
76028760|NCT05916768|Other|Pelargonium sidoides extract EPs® 7630|Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).
76028761|NCT05916768|Other|usual care|symptomatic treatments
76028762|NCT05916755|Diagnostic Test|Whole Genome Sequencing|Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
76028763|NCT05916755|Diagnostic Test|RNA-Sequencing|RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
75701689|NCT00715208|Drug|rituximab|
75701690|NCT00715208|Drug|cyclophosphamide|
75701691|NCT00715208|Drug|doxorubicin|
75701692|NCT00715208|Drug|VELCADE|
75538373|NCT05322044|Behavioral|Financial incentives|Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
75538374|NCT05317546|Drug|Cannabidiol|In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.
75538375|NCT05313243|Drug|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.
75538376|NCT05313243|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
75538377|NCT05311670|Behavioral|Patient-reported outcomes monitoring|o Patient-reported outcomes will be collected from patients through web or telephone and alerts sent to providers.
75538378|NCT05310565|Procedure|HVLA cervical chiropractic adjustments|Chiropractic high velocity low amplitude adjustment
75538379|NCT05295290|Diagnostic Test|Cardiac Imaging|ECG, echocardiogram, ambulatory monitor, exercise stress test
75538380|NCT05292365|Behavioral|RE-PACT Intervention|"Create respiratory illness action plan~Weekly mHealth text messages~Monthly study assessments~Action planning and JIT coaching"
76028764|NCT05916755|Diagnostic Test|Microbiome analysis|Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
75701693|NCT00715208|Drug|prednisone|
75538381|NCT05289661|Drug|Topical Ripasudil|To determine the effect of rho-kinase inhibitors on endothelial cell loss
75538382|NCT05289661|Drug|Topical Placebo|topical Placebo
75538383|NCT05286853|Biological|Renal Autologous Cell Therapy (REACT)|Participants will receive either 2 REACT injections or 2 Sham REACT injections into biopsied and non-biopsied contralateral kidneys 3 months apart.
75538384|NCT05286541|Procedure|Lateralized buccal cortex with xenograft|the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance
76028765|NCT05916755|Diagnostic Test|ctDNA analysis|ctDNA analysis will be performed in plasma before and during NACT.
76028766|NCT05916755|Diagnostic Test|TCR-β repertoire sequencing|TCR-β repertoire sequencing will be performed in plasma before and during NACT.
76028767|NCT05916755|Diagnostic Test|PBMCs phenotyping|PBMCs phenotyping will be performed in plasma before and during NACT.
75538385|NCT05286541|Procedure|Lateralized buccal cortex with autogenous particulate|lateralized buccal cortex with autogenous particulate
75538386|NCT05275972|Drug|Ripasudil|Topical Ripasudil 0.4%
75538387|NCT05275972|Drug|Placebo|Topical Placebo
75538388|NCT05264207|Behavioral|Nursing students' home-visit programme|"12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~Self-care of chronic conditions and medication management~Healthy habits: physical activity and healthy eating~Access to social support resources~Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours."
76028768|NCT05916755|Drug|Pembrolizumab|Pembrolizumab will be given in combination with standard NACT.
76028769|NCT05916755|Drug|Chemotherapy|Standard NACT will be given.
76028770|NCT05916742|Procedure|CAF|Periodontal surgical technique to treat gingival recessions
75701694|NCT04104503|Drug|Lu AF11167|Lu AF11167 - 2 mg modified release tablets (reference formulation), up to 5 prototype MR tablet formulations (test formulations)
75701695|NCT04104503|Drug|[14C]-Lu AF11167|single iv microdose administered as a 15 minutes infusion
75701696|NCT04104503|Drug|Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)|Single oral dose
75701697|NCT05186870|Other|Outcome measures|Observational study
76028771|NCT05916742|Procedure|i-PRF|Blood-derived biomaterial. Two sterile plastic tubes (Process for PRF, Nice, France) with a volume of 10 ml will be used to generate fluid blood concentrate. After blood collection, the tubes will be centrifuged using a Duo centrifuge (Process for PRF, Nice, France) (fixed angle rotor with a radius of 110 mm) following the protocol proposed by Choukroun et al. (2018) (600 rpm; 8 min).
76028772|NCT05916742|Device|VCMX|Porcine derived collagen matrix.
75538389|NCT05264207|Behavioral|Standard care from Public Andalusian Health Service|Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
76028773|NCT05916742|Drug|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
75375187|NCT04860414|Other|Subjective taste tests|Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
75375188|NCT04860414|Other|Objective taste tests|Recording of gustatory evoked potentials
75375189|NCT00367783|Drug|CP-741,952|
75375190|NCT02641561|Drug|Indomethacin|Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
75538390|NCT05263245|Other|Light breakfast|Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
75538391|NCT05263037|Device|EaseVRx|VR software with interactive content
76028774|NCT05916742|Drug|Chlorhexidine rinse|All participants will be instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
76028775|NCT05916742|Drug|Amoxicillin 500mg|Participants enrolled in the CAF+VCMX and CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
76028776|NCT05916729|Drug|Miconazole|Protocol for active control groups includes use of Miconazole Oral gel for 14 days with frequency of four time per day.
76028777|NCT05916729|Dietary Supplement|CandBerrol® lozenges|Protocol for experimental groups includes use of Miconazole Oral gel and CandBerrol® lozenges for 14 days with frequency of four time per day
75538392|NCT05263037|Device|Sham VR|VR with neutral non-interactive content
75375191|NCT02641561|Drug|Lactated Ringer's Solution|Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
75375192|NCT02641561|Drug|Normal Saline|standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
75375193|NCT02641561|Drug|Placebo|Placebo would be a suppository 50 mg x 2
75375194|NCT02206152|Drug|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
75375195|NCT02206152|Drug|Placebo|
75701698|NCT00919178|Biological|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
75538393|NCT05250856|Drug|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of ~5 μg of PPE per mg of PLGA.
75538394|NCT05250856|Drug|Placebo|Placebo, (0.9% Sodium Chloride for IV infusion)
75701699|NCT00919178|Biological|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
75701700|NCT05184140|Procedure|Sentinel node detection|"Injection of the radiotracer to infundibulo-pelvic and utero-ovarian ligament in patients with high suspicion of malignancy adnexal mass. Injection of green indocyanine r to infundibulo-pelvic and utero-ovarian stumps only in case of malignancy after the adnexectomy.~Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer diagnosis."
75375196|NCT00367081|Drug|TMX-SMX (Bactrim(R))|
75375197|NCT00367081|Drug|Pyrimethamine plus Sulfadiazine plus leucoverin|
75375198|NCT00367159|Procedure|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
75375199|NCT04146571|Drug|Ensartinib|Oral, ALK inhibitor
75375200|NCT05342376|Drug|Dexmedetomidine Hydrochloride|The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
75375201|NCT05342376|Drug|Normal Saline|The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
75538398|NCT05244278|Device|Medtronic-GI genius (CADe system for detecting colorectal polyps)|Medtronic-GI genius: AI will provide real-time feedback throughout each colonoscopy procedure and alert endoscopists to the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.
75538399|NCT05226689|Device|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert
75701701|NCT04083872|Drug|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
75701702|NCT04083872|Drug|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
75701703|NCT05183672|Procedure|Telecare consultation|Using Zoom to communicate with patients
75375202|NCT03954535|Behavioral|Free2b|The intervention will consist of a website and 9 sessions. The intervention sessions will facilitate youths' acquisition of personal and social cognitive-behavioral skills. The intervention will focus on goal setting, decision making, enhancing self-worth, coping with stress, combating distorted thinking, communication skills, using alcohol and other drugs and a review session. Each session will require approximately 20 minutes and must be finished in a single sitting. Sessions will be delivered on a weekly basis. The website will include entertainment features and resources.
75375203|NCT03954535|Behavioral|Attention-Placebo|Access to the website with entertainment features and resources - but no session content.
75375204|NCT02239536|Procedure|hot snare polypectomy|hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
75375205|NCT02239536|Procedure|hot snare polypectomy after saline injection|hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
75375206|NCT02239224|Biological|Placebo|Concentrate for solution for infusion
75375207|NCT02239224|Biological|ATYR1940|Concentrate for solution for infusion
75375208|NCT01600014|Drug|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
75375209|NCT01600014|Drug|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
75375210|NCT02237196|Biological|AMG 157|AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
75375211|NCT02237196|Biological|Cat Immunotherapy|A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
75375212|NCT02237196|Biological|Cat Immunotherapy Placebo|Placebo for allergen-specific immunotherapy administered subcutaneously
75538400|NCT05221645|Drug|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications because of its mechanism of action to bind the PD-1 receptor on the T cell.
75538401|NCT05221645|Drug|Rituximab|Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
75538402|NCT05221645|Drug|Ifosfamide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
75375213|NCT02237196|Biological|AMG 157 Placebo|Placebo for AMG 157 administered intravenously
75701704|NCT05183672|Procedure|Usual face-to-face consultation|Face-to-face communication with patients
75375214|NCT03953755|Procedure|Tricuspid valve repair|Tricuspid valve repair
75375215|NCT04740619|Procedure|Natural Orifice Specimen Extraction|Natural Orifice Specimen Extraction via transanal
75375216|NCT04418310|Procedure|Lay open and curettage|Lay open and curettage
75375217|NCT04418310|Procedure|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method
76028778|NCT05916716|Procedure|Restorative procedure|Under local anesthesia, a rubber dam isolation will be placed at the site and a coronal bevel will be performed at the incisal margin of the NCCL allowing a correct tooth emergence profile. In sequence, acid etching with 35% phosphoric acid will be applied to the area and washed for 30 seconds with a water-air jet. The lesion will be dried with sterile cotton pellets to prevent dehydration. Active application of the adhesive will be performed for 20 seconds, followed by light curing for 30 seconds. The apical margin of the restoration will be placed 1 mm beyond the estimated position of the cementoenamel junction(CEJ) in order to rebuild only the anatomical part of the crown destroyed by the NCCL and 1 mm of the root surface to give the appropriate emergence profile. After rubber dam removal, the restoration will be finished with ultrafine-grained burs, and 48 hours after the restoration procedure, polishing will be completed with diamond paste and felt discs.
75375218|NCT04776096|Drug|Bepotastine Besilate 1.5% PF|Bepotastine besilate 1,5% Preservative free ophthalmic solution
75375219|NCT04776096|Drug|Olopatadine Hydrochloride 0.2% BAK|Olopatadine hydrochloride 0.2% with BAK as preservative
75701705|NCT05684354|Other|Patient Reported Outcomes (PROs)|"The day before or the morning before surgery, the patient filled the first QoR-15 scale alone or could be helped by one of the investigators in case of questions or difficulties.~The second QoR-15 scale was distributed the day before or the day of discharge from the hospital"
75701706|NCT02590250|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
75375220|NCT02237118|Device|Mepitel One|
75375221|NCT02237118|Device|UrgoTul|
75375222|NCT02234622|Behavioral|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
75375223|NCT02234622|Behavioral|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
75375224|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
75538403|NCT05221645|Drug|Carboplatin|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
75701707|NCT05293418|Other|data collection|data collection from medical records and the microbiological surveillance system of the enrolled patients
75701708|NCT02589782|Drug|Bedaquiline|
75701709|NCT02589782|Drug|Pretomanid|
75701710|NCT02589782|Drug|Moxifloxacin|
75701711|NCT02589782|Drug|Linezolid|
75701712|NCT02589782|Drug|Clofazimine|
75701713|NCT02589782|Drug|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
75538404|NCT05221645|Drug|Etoposide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
75538405|NCT05217693|Drug|BB-1705|BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
75538407|NCT05205967|Other|MCED|Multi-cancer early detection (MCED) test
75375225|NCT05588947|Other|Take Charge session|A 'talk therapy' session designed to harness the person's self-determination, re-establishing purpose, identity, autonomy, and skills to Take Charge of their recovery after stroke
75375226|NCT05588947|Other|Active Control|Life After Stroke educational video
75375227|NCT02203032|Drug|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
75538408|NCT05205967|Other|SOC|Standard of care cancer screening
75538409|NCT05191823|Drug|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
75538410|NCT05191823|Dietary Supplement|Placebo|400 mg corn oil per day for 6 months
75375228|NCT02203032|Drug|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
75375229|NCT02203032|Drug|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
75538411|NCT05183477|Other|fast track|short cut for the request of xrays directly at triage
75701714|NCT00587795|Device|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
76028779|NCT05916716|Procedure|Coronally Advanced Flap (CAF).|Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
76028780|NCT05916716|Device|Volume-stable collagen matrix (VCMX)|VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction (CEJ) level and stabilized in the adjacent surgical papillae by interrupted sutures.
76028781|NCT05916716|Drug|Amoxicillin 500mg|Participants enrolled in the PR +CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
76028782|NCT05916716|Drug|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
75375230|NCT02203032|Drug|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
75375231|NCT02169414|Drug|BIA 9-1067 5 mg|OPC, Opicapone
75375232|NCT02169414|Drug|BIA 9-1067 25 mg|OPC, Opicapone
75375233|NCT02169414|Drug|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
75375234|NCT02169414|Drug|Placebo|PLC, Placebo
75375235|NCT02169414|Drug|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
75538412|NCT05183477|Other|normal pathway|x-ray would be required according to doctor's clinical evaluation.
75701715|NCT00587795|Other|Placement of sugar tong splint or plaster cast|Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
75701716|NCT00587639|Device|rTMS Treatment|Active rTMS treatment.
75701717|NCT00916175|Dietary Supplement|P1&P2|"First period (4 weeks) intake food product P1&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~Second period, cross over from AG&CC group, 4 weeks intake food product P1&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
75701718|NCT00916175|Dietary Supplement|P1&CC|"First period (4 weeks) intake food product P1&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from AG&P2 group, 4 weeks intake food product P1&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
75375236|NCT02201940|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
75375237|NCT02201940|Drug|Placebo|Tablet administered orally once daily
75375238|NCT05588869|Other|observation of the adverse outcomes of Cyclosporine in steroid dependent and frequent relapsing nephrotic syndrome in children|The interventions that will be done include collection of the following data : age at disease onset, disease duration, type of steroid response, age at the start of CsA treatment, dose and duration of CsA treatment, mean values of the maintenance doses of CsA and their trough blood levels and observation of the side effects. serum creatinine at regular intervals before and after CsA treatment and renal biopsy for those who are on CsA for more than 2-3 years would be done.
75375239|NCT03568435|Other|Non-Interventional|Non-Interventional
75375240|NCT05588791|Diagnostic Test|whole-body computed tomography|whole-body computed tomography prescription in the emergency department : an identification tool for low risk patients
75538413|NCT05183230|Behavioral|WellPATH-PREVENT|WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
75375241|NCT03085069|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
75375242|NCT03485365|Drug|GSK3858279 IV|GSK3858279 will be available as solution for injection to be administered via IV route.
75375243|NCT03485365|Drug|GSK3858279 SC|GSK3858279 will be available as solution for injection to be administered via SC route.
75701719|NCT00916175|Dietary Supplement|AG&P2|"First period (4 weeks) intake food product AG&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from P1&CC group, 4 weeks intake food product AG&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
75701720|NCT00916175|Dietary Supplement|AG&CC|"First period (4 weeks) intake food product AG&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~Second period, cross over from P1&P2 group, 4 weeks intake food product AG&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
75538414|NCT05183230|Behavioral|Optimized WellPATH-PREVENT|The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
75375244|NCT03485365|Drug|Placebo matching to GSK3858279 (SC or IV)|Placebo will be available as sodium chloride solution to be administered via SC or IV route.
75538415|NCT05174312|Device|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
75538416|NCT05174312|Drug|Diuretic|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
75701721|NCT00916175|Dietary Supplement|TA (concentrated 5:1 aloe vera gel)|"First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
75375245|NCT03485365|Drug|Placebo matching to GSK3858279 (SC)|Placebo will be available as sodium chloride solution to be administered via SC route.
75375246|NCT03059407|Behavioral|Dog therapy only|Canine assisted therapy only during echocardiogram
75375247|NCT03059407|Behavioral|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echo
75375248|NCT03059407|Behavioral|Standard distraction techniques only|Standard distraction techniques (such as watching a movie) only during echocardiogram
75375249|NCT02169336|Drug|Intranasal Dexmedetomidine|
75375250|NCT02169336|Other|Intranasal Placebo|
75538417|NCT05170724|Drug|Remibrutinib|Remibrutinib should be taken in accordance with the recommendations in the treatment plan.
75538418|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
75538419|NCT05166837|Drug|Placebo|Intravenous injection
76028783|NCT05916703|Diagnostic Test|SOLUS examination|"The examination of each subject will include: i) B-mode US, ii), color Doppler US, iii) shear wave elastography, and iv) SOLUS multimodal imaging.~For each subject various ultrasound images (modalities i-iii) will be taken and these images will determine the location for the SOLUS measurements (iv).~All measurements (i-iv) will be taken at the lesion location, in the normal breast tissue around the lesion, and in the mirror location of the contralateral breast.~Optically derived data (blood volume, blood oxygen saturation, water, lipid and collagen concentrations, tissue scattering parameters) will be obtained. Every subject included in the study will be evaluated separately by 3 radiologists, with different level of experience in breast imaging."
75538420|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
75538421|NCT05166837|Drug|Placebo|Intravenous injection
75375251|NCT03043807|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
76028784|NCT05916638|Other|blood sample|blood sample collection
76028785|NCT05916599|Device|ultrasound|a device which is used in intensive care units,
75375252|NCT03043807|Drug|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.
75538422|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
76028786|NCT05916573|Drug|HSK16149|single oral adminiatration, 20mg
76028787|NCT05916521|Drug|0.454% stannous fluoride|Brush two times daily
75375253|NCT03043807|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
75375254|NCT03043807|Radiation|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
75375255|NCT03043807|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
75375256|NCT02609828|Drug|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
75538423|NCT05166837|Drug|Placebo|Intravenous injection
75538424|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
75538425|NCT05166837|Drug|Placebo|Intravenous injection
75538426|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
75538427|NCT05166837|Drug|Placebo|Intravenous injection
75538428|NCT05149131|Drug|ADT (Eligard®*) with or without treatment intensification|"Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix"
75538429|NCT05146765|Device|Mobile application|Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.
75538430|NCT05146765|Other|Treatment as usual|The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
76028788|NCT05916521|Drug|0.76% sodium monofluorophosphate|Brush two times daily
75538431|NCT05144763|Device|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
75375257|NCT05588635|Other|Identification of predictive factors|Evaluation of the following variables : mother age (years), father age (years), serum progesterone (ng/ml), mother body mass index (kg/m2), serum Antimüllerian hormone (AMH) (ng/ml), infertility etiology (yes/no): 4 categories: idiopathic etiology, mixed origin infertility, male infertility, female infertility; smoker status among mothers (yes/no).
75375258|NCT05588557|Drug|Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection|"Subjects in this arm will receive a single administration of Marcaine® at the 150 mg.~Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
75538432|NCT05140252|Behavioral|Breast cancer decision aid|The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.
75538433|NCT05136846|Drug|Carboplatin|Given IV
75701722|NCT00916175|Dietary Supplement|P3|"First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
75701723|NCT00916487|Dietary Supplement|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
76028789|NCT05916521|Drug|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
76028790|NCT05916508|Drug|0.454% stannous fluoride|Brush two times daily
76028791|NCT05916508|Drug|0.76% sodium monofluorophosphate|Brush two times daily
76028792|NCT05916508|Drug|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
75538434|NCT05136846|Biological|Durvalumab|Given IV
75538435|NCT05136846|Drug|Paclitaxel|Given IV
75538436|NCT05136846|Drug|Papaverine|Given IV or SC
75538437|NCT05136846|Radiation|Radiation Therapy|Undergo RT
75538438|NCT05136846|Drug|Pemetrexed|Given IV
75538439|NCT05130463|Drug|empagliflozin/linagliptin|tablet
75538440|NCT05129358|Drug|Dehydration|The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.
75538441|NCT05129358|Dietary Supplement|Rehydration|The subject is rehydrated by oral intake of 1.5 liters Resorb Sport (Nestlé). The subject is monitored for 60 minutes following intake.
75375259|NCT05588557|Drug|ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension|"Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg).~ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
75538442|NCT05126693|Other|Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.|BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks. During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
76028793|NCT05916469|Drug|Levonorgestrel Intrauterine System|52 mg levonorgestrel intrauterine system
75375260|NCT01632306|Drug|LY2090314|LY2090314 administered IV
75375261|NCT01632306|Drug|FOLFOX|FOLFOX administered IV
75375262|NCT01632306|Drug|Gemcitabine|Gemcitabine administered IV
75375263|NCT01632306|Drug|Nab-paclitaxel|Nab-paclitaxel administered IV
75375264|NCT02346565|Procedure|Exercise ECG|
75375265|NCT02346565|Procedure|Stress Echocardiography|
75375266|NCT02600065|Other|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
75375267|NCT02201784|Drug|Levobupivacaine|Comparison of Equipotent doses
75538443|NCT05110261|Drug|Nirsevimab|Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight < 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
75701724|NCT00774995|Biological|EngerixTM-B|Intramuscular injection, one dose.
75375268|NCT02201784|Drug|Ropivacaine|Comparison of equipotent doses
75538444|NCT05110261|Drug|Placebo|Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight <5 kg) or 1.0 mL (if weight >=5 kg)
75538445|NCT05108831|Device|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
75538446|NCT05106894|Behavioral|smartphone application to promote nurturing care|see arm description
75538447|NCT05106894|Behavioral|printed caregiving materials|see arm description
75538448|NCT05101759|Procedure|Comprehensive Geriatric Assessment|A systematic reassessment of geriatric parameters will be performed at 3 and 6 months post-inclusion.
75538449|NCT05096169|Drug|Clomiphene Citrate 25mg|clomiphene citrate at a dose of 25mg daily
75538450|NCT05096169|Drug|Clomiphene Citrate 50mg|clomiphene citrate at a dose of 50mg every other day
75538451|NCT05089708|Drug|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
75538452|NCT05089708|Drug|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
76028794|NCT05916469|Drug|Norethindrone Acetate|norethindrone acetate 5 mg daily
76028795|NCT05916456|Diagnostic Test|The Hand10 Questionnaire|The Hand10 Questionnaire is a questionnaire consisting of 10 short questions used in the evaluation of upper extremity diseases. These questions are easy to understand and illustrated questions. Unlike other questionnaires, thanks to these features, it can be used in adults as well as in the elderly and children. Tore et al. In their study, the internal consistency of Hand10 was evaluated with Cronbach's alpha value according to statistical results and found it to be 0.919. According to these results, it has been determined that Hand10 is a reliable and valid assessment tool for patients with upper extremity disorders in the Turkish population.
76028796|NCT05916456|Diagnostic Test|DASH Questionnaire|DASH Questionnaire is one of the widely used questionnaires consisting of 30 items. There are five options for each answer. While getting answers ranging from 1 to 5; 1 means no symptoms and 5 means very severe symptoms. The total DASH score ranges from 0 to 100; 0 means no injury and 100 means serious injury. Contrary to the Hand10 questionnaire, DASH was not suitable for assessing upper extremity disorders in patients over 65 years of age.
76028797|NCT05916456|Diagnostic Test|Boston carpal tunnel syndrome questionnaire|Boston carpal tunnel syndrome questionnaire (BKTSA) will be used to evaluate the functionality level and symptom severity of the patients. In this questionnaire, which consists of 2 parts: symptom severity and functional capacity, the average score for each part will be calculated by dividing the total score obtained by the number of questions. An increased score indicates decreased functional capacity and increased symptom severity.
76028798|NCT05916430|Diagnostic Test|EarliPoint Investigational Device|Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
76028799|NCT05916391|Genetic|FT-003|Administration via intraocular injection
76028800|NCT05916365|Biological|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously
76028801|NCT05916339|Drug|Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication|"Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid~Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)"
76028802|NCT05916339|Drug|Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.|"If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex"
76028803|NCT05916326|Biological|Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)|Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm
76028804|NCT05916326|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
76028805|NCT05916274|Biological|Blood and fecal samples|Blood and fecal samples will be performed
76028806|NCT05916274|Procedure|Coolonic biopsies|colonic biopsies will be analysed
76028807|NCT05916248|Biological|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
76028808|NCT05916209|Procedure|Peripheral nerve blocks|Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.
76028809|NCT05916105|Drug|Ciprofloxacin Tablets|Ciprofloxacin antibiotic
75538453|NCT05088980|Device|VOLBELLA with Lidocaine|Facial Injection
75538454|NCT05088460|Drug|REGN4461|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
75538455|NCT05088460|Drug|Matching Placebo|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
75538456|NCT05075590|Diagnostic Test|Coronary Angiography|Following TAVR, the operators will attempt to selectively engage both the right and left coronary arteries. Catheter choice and engagement technique will be at the discretion of the operator.
75538457|NCT05071768|Behavioral|Focused ACT|Brief acceptance and commitment therapy
75538458|NCT05071014|Drug|Pembrolizumab|Pembrolizumab: 200mg/dose delivered by IV infusion
75538459|NCT05071014|Procedure|Image-guided cryoablation|Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
75538460|NCT05067634|Drug|Xcopri|Age groups 12 to <18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to <12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to <6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to <4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
75538461|NCT05066178|Behavioral|CAS Treatment for Minimally Verbal Children with Autism|Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
75538462|NCT05063565|Device|TheraSphere Y-90 glass microsphere therapy|TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.
75375269|NCT04340479|Diagnostic Test|Ultrasound lung imaging as part of FAST+ evaluation|"FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~Anterior midclavicular right and left (apical, medial, basal)~Posterior paraspinal right and left* (apical, medial, basal)~*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings."
75375270|NCT02201472|Device|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
75375271|NCT02162329|Behavioral|Questionnaires|"Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit."
75375272|NCT02162329|Procedure|Electroencephalography (EEG)|"Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions."
75375273|NCT02162329|Procedure|Magnetic Resonance Imaging (fMRI|"Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit."
75375274|NCT02162329|Behavioral|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
75538463|NCT05063565|Drug|Durvalumab (Imfinzi) immunotherapy|"1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~Absence of clinical symptoms or signs indicating clinically significant disease progression~No decline in performance status~Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~No other treatment discontinuation criteria are met"
75538464|NCT05063565|Drug|Tremelimumab immunotherapy|300 mg, single administration
76028810|NCT05916066|Dietary Supplement|Nicotinamide|Tabletts of 500mg Nicotinamide (B3-vitamin)
75538465|NCT05063162|Drug|Rozanolixizumab|"Pharmaceutical form: Solution for infusion~Route of administration: subcutaneous infusion~Participants will receive pre-specified doses of rozanolixizumab."
76028811|NCT05916027|Behavioral|The 15-Method|The 15-Method is a Screening and Brief Intervention method for identifying and treating alcohol problems in primary care. The method combines evidence-based approaches from specialized addiction treatment with screening and readily available treatment options in general practice to help identify and treat alcohol problems. The 15-method is based on Motivational Interviewing, Cognitive Behavioral Therapy and utilizes the Alcohol Use Disorder Identification Test (AUDIT) as a screening tool. The 15-Method contains three flexible steps: Identification of clinical problem related to alcohol; feedback and clinical work-up as needed; treatment. Treatment includes structured consultations (maximum of four) with patient home-work assignments, and can be combined with pharmacological treatment for alcohol problems.
76028812|NCT05916014|Diagnostic Test|Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
75538466|NCT05063162|Other|Placebo|"Pharmaceutical form: Solution for infusion~Route of administration: subcutaneous infusion~Participants will receive placebo."
76028813|NCT05916001|Other|Placebo|A Placebo will be administered per os 3 times per day for 10 days before colorectal surgery
75375275|NCT02647346|Device|Daily use of podimetrics smart-foot mat|
75375276|NCT05441995|Other|Cryotherapy|Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
75375277|NCT02554838|Other|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
75538467|NCT05061017|Drug|Pixatimod|Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.
75538468|NCT05061017|Drug|Nivolumab|Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer
76028814|NCT05916001|Dietary Supplement|Oral Impact Nestle|Oral Impact Nestle will be administered per os 3 times per day for 10 days before colorectal surgery
75375278|NCT02554838|Other|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
75375279|NCT02554838|Behavioral|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
76028815|NCT05916001|Procedure|Colorectal surgery|Colorectal surgery will include right colectomy, left colectomy, transverse colectomy, anterior rectal resection. All procedures will be performed according to the standard clinical practice.
76028816|NCT05915962|Procedure|collecting a Nanofat-type microfat autograft|"Collecting and preparing a Nanofat autograft.~The protocol provides for the fat sample to be taken in a doctor's office during a consultation. The preparation will then be carried out at the MEARY center for cell and gene therapy of the AP-HP, at the Saint Louis hospital in Paris."
76028817|NCT05915936|Procedure|LVMR|laoparoscopic ventral mesh rectopexy
76028818|NCT05915936|Procedure|PSR|perineal stapler resection
75375280|NCT05588089|Other|Training group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers."
75375281|NCT05588011|Device|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
75375282|NCT05588011|Device|LivaNova|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
75866064|NCT03711643|Device|hypnosis mask|"The mask HYPNOS pro stimulates the imagination of the user by means of 6 diodes among 3 by eye.~Just before the introduction of ultrasound probe, the patient put the hypnotic mask and choose a session.Twenty minutes after the removal of the probe, an healthworker assess the painful patient with the visual analogue scale VAS, after this the patient fulfill the STATE- TRAIT Anxiety Inventory (STAI) form Y-A."
75866065|NCT02418286|Other|expose to any drugs or procedures based on traditional Korean medicine theory|There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
75866066|NCT03133767|Drug|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
75866067|NCT03133767|Drug|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
75866068|NCT02422966|Drug|Paracetamol|
75866069|NCT02422966|Drug|Ibuprofen|
75866070|NCT02422888|Drug|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
75866071|NCT02422888|Drug|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
75375283|NCT05587933|Procedure|cholecystectomy|cholecystectomy
75375284|NCT05587933|Drug|Antispasmodic|Antispasmodic
75375285|NCT02200705|Device|Ice-Sense3TM/ ProSenseTM|
75375286|NCT02018263|Drug|Cocaine hydrochloride|
75375287|NCT02018263|Behavioral|Exercise|
75375288|NCT02018263|Drug|Nicotine|
75375289|NCT05442073|Other|PEEP adjustment|adjusting PEEP about 3-5cmH2O (increase or decrease)
75375290|NCT02649608|Drug|0.04 mg Lu AE04621|0.04 mg dose group
75375291|NCT02649608|Drug|0.08 mg Lu AE04621|0.08mg dose group
75375292|NCT02649608|Drug|0.2 mg Lu AE04621|0.2 mg dose group
75866072|NCT03633552|Drug|Temozolomide|The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
75375293|NCT02649608|Drug|0.4 mg Lu AE04621|0.4 mg dose group
75375294|NCT02649608|Drug|0.6 mg Lu AE04621|0.6 mg dose group
75866073|NCT02426632|Drug|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
75866074|NCT02426632|Drug|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
75375295|NCT02649608|Drug|0.8 mg Lu AE04621|0.8 mg dose group
75375296|NCT02649608|Drug|1.0 mg Lu AE04621|1.0 mg dose group
75375297|NCT02649608|Drug|1.2 mg Lu AE04621|1.2 mg dose group
75375298|NCT02168946|Drug|Vabomere|Vabomere for IV injection, administered as a 2 g/2 g dose
75375299|NCT02168946|Drug|Best Available Therapy|Antibiotic(s) chosen by Investigator
75866075|NCT02426632|Drug|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
75866076|NCT02426632|Drug|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
75866077|NCT02426632|Drug|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
76028819|NCT05915923|Procedure|1 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)
76028820|NCT05915923|Procedure|10 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)
75538469|NCT05061017|Drug|Cyclophosphamide (low dose)|Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
75375300|NCT02649842|Device|TECNIS Toric Models ZCT450, ZCT525 or ZCT600|Approved toric intraocular lens
75375301|NCT02650856|Drug|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
75375302|NCT02650856|Biological|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
75538470|NCT05058898|Other|blood samples|5 mL
75375303|NCT02168478|Drug|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
75375304|NCT02168478|Other|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
75375305|NCT02168478|Other|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
75375306|NCT00367874|Drug|Buprenorphine|
75866078|NCT02426632|Drug|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
75866079|NCT02426632|Drug|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
75866080|NCT02426632|Drug|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
75866081|NCT02426632|Drug|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
75866082|NCT02426632|Drug|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
75866083|NCT02426632|Drug|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
75538471|NCT05058898|Other|Scabs and pus samples|if available
75538472|NCT05057546|Drug|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
75538473|NCT05053646|Procedure|Meniscal repair|The meniscus is trimmed with an arthroscopic punch followed by an electric shaver to expose the margins of the tear and remove damaged tissue. Vertical sutures are made using TRUESPAN™ Meniscal Repair System (DePuy Synthes) to approximate both the femoral and tibial surfaces of the torn meniscus.
75375307|NCT00367874|Drug|Valproate|
75375308|NCT00367562|Drug|ENALAPRIL VALSARTAN METHYLPREDNISONE|
75375309|NCT02302976|Drug|cocaine hydrochloride|
75375310|NCT02302976|Drug|exenatide|
75375311|NCT02302976|Drug|placebo|
75866084|NCT02426632|Drug|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
75866085|NCT03633474|Biological|N. lactamica|Stocks of N. lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) in Frantz medium containing 30% (v/v) glycerol have been previously prepared using the Good Manufacturing Practices pharmaceutical manufacturing facilities at Public Health England (Porton Down, United Kingdom).
75866086|NCT03633474|Other|PBS only|Sterile PBS only containing no bacteria
75866087|NCT05760456|Drug|DIDALA hard capsules|DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
75866088|NCT05760456|Drug|Metformin|Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
75866089|NCT02418130|Drug|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
75866090|NCT02418130|Drug|Placebo|
75375312|NCT05075564|Drug|Part 1 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
75375313|NCT05075564|Drug|Part 2 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
75375314|NCT02244164|Drug|Incretinomimetics|
75866091|NCT02426788|Behavioral|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
75866092|NCT03179956|Drug|Ribociclib|Treatment with ribociclib [600mg] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
76028821|NCT05915923|Procedure|Sham Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
76028822|NCT05915871|Drug|Tegoprazan|Tablet for oral administration
75375315|NCT02244164|Drug|DPP-4 inhibitors|
75538474|NCT05053646|Procedure|Marrow venting procedure|After meniscal repair, a bone marrow venting procedure will be performed: a 45° micro-fracture awl is repeatedly penetrated through the bone of the intercondylar notch at the PCL origin until marrow elements are seen to enter the joint.
76028823|NCT05915871|Drug|Bismuth|Capsule for oral administration
75375316|NCT02152670|Drug|Methylphenidate|
75375317|NCT02152670|Drug|Alpha Methyl Para Tyrosine (AMPT)|
75375318|NCT02152670|Other|[11C]PHNO|
75375319|NCT02152670|Other|[11C]raclopride|
75375320|NCT02652416|Drug|BI 1026706|oral administration
76028824|NCT05915871|Drug|Amoxicilli|Capsule for oral administration
75375321|NCT02652416|Drug|Placebo|placebo
75538475|NCT05046717|Device|ADAMTS13 Activity Assays|"In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits:~HemosIL AcuStar ADAMTS13 Activity Assay (Instrumentation Laboratory, Bedford, Massachusetts, United States)~ELISA, DG-EIA ADAMTS13 Activity (Diagnostic Grifols®, Spain)~FRETS-VWF73 for ADAMTS13 Activity Assay~Three kits will be used with all patients."
75538476|NCT05032066|Drug|HZN-825|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
76028825|NCT05915871|Drug|Clarithromycin|Tablet for oral administration
76028826|NCT05915858|Other|muscle energy technique|"Group 1: Group 2:~Muscle energy technique (Reciprocal inhibition) Stretching exercises Static stretching 2 weeks (twelve treatment session) patient supine, the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra-lateral knee (the leg on the side to be treated is crossed over the other, straight leg).~The angle of hip flexion should not exceed 60 degree.~The practitioner places one hand on the contra-lateral ASIS to prevent pelvis motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis for 7-10 seconds."
75538477|NCT05032066|Drug|Placebo|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
75538478|NCT05029284|Behavioral|teleABLE|Participants will be guided to self-monitor their daily activities, schedule personally meaningful non-sedentary activities, collaboratively problem solve to overcome barriers to the activity, and self-assess their progress. Participants may be asked to self-monitor their activity levels and complete planned activities between sessions.
75701725|NCT00918554|Drug|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
75701726|NCT00918554|Drug|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
76028827|NCT05915858|Other|stretching exercise|"Following the contraction the practitioner eases the treated side leg into adduction until a sense of resistance is noted; this is held for 10-30 seconds. 2 week (twelve treatment session) practitioner manual stretches the piriformis:~The patient lies in supine position the affected leg is placed into flexion at hip and knee so that the foot rests on the table lateral to the contra-lateral knee.~The practitioner places one hand over the contra-lateral ASIS to stabilize the pelvis during the exercise and passively abducts and internally rotates the hip medially till the pain is bearable.~The process is repeated 3-5 times with a 30"
76028828|NCT05915845|Other|Laura Mitchell's Relaxation technique|This technique was used to eliminate muscular tension. Patients were taught to contract muscles opposite to the strained muscle groups, eventually to 'cease' shrunken them, and then to roster the position adaptation of the body structure. Patient was comfortably positioned.
75375322|NCT02028806|Drug|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
75375323|NCT01756118|Drug|BEZ235|A minimum of 3 dose levels
75375324|NCT04339712|Drug|Anakinra|In case of diagnosis of MAS treatment with anakinra
75375325|NCT04339712|Drug|Tocilizumab|In case of diagnosis of immune dysregulation treatment with tocilizumab
75375326|NCT02656160|Drug|Placebo|Placebo 3 hrs before sleep
75375327|NCT02656160|Drug|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
75375328|NCT02684396|Drug|TAK-648|TAK-648 Solution
75375329|NCT02684396|Drug|TAK-648 Placebo|TAK-648 placebo-matching solution
75375330|NCT02657252|Drug|Glucose|Sclerotherapy of telangiectasis in one lower limb.
75538479|NCT05028374|Drug|"A single booster dose of the Moderna mRNA COVID-19 vaccine"|All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
75701727|NCT05684822|Other|Acupuncture|Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
75701728|NCT04104113|Other|Modified Xiang Bei Yang Rong Tang|Modified Xiang Bei Yang Rong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
75375331|NCT02657252|Drug|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
75375332|NCT02657564|Drug|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
75701729|NCT04104113|Other|Placebo|Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
75866093|NCT03391765|Drug|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
75538480|NCT05023369|Drug|Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)|Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
75538481|NCT05022251|Procedure|Lumbar discectomy|surgically removing a hernia
75866094|NCT03391765|Drug|Placebo solution for IV infusion on Day 15|0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
75538482|NCT05020990|Device|Lens A (delefilcon A)|Daily disposable for one week
76028829|NCT05915845|Other|Papworth exercise|"The Papworth Method integrates five components, the principal one being specific breathing training:~• Breathing training, including teaching of appropriate minute and tidal volume and the development of a pattern of breathing suitable to current metabolic activity.~Elimination of dysfunctional breathing, including hyperinflation and hyperventilation patterns is discussed. A specific Papworth method diaphragmatic breathing technique is taught to replace the use of inappropriate accessory muscles of respiration. When relaxed, is placed on calm slow nasal expiration. Patients are encouraged to nose-breathe rather than mouth-breathe and eradication or reduction of habits such as yawning, sighing, etc. is taught and practiced."
75538483|NCT05020990|Device|Lens B (stenfilcon A)|Daily disposable for one week
75538484|NCT05008055|Drug|Capivasertib|Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.
75538485|NCT05001776|Procedure|Endovenous laser ablation|Laser ablation of the great saphenous vein close to sapheno-femoral junction
75866095|NCT02802228|Drug|Ifetroban|thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
75866096|NCT02802228|Drug|Placebo|matched placebo delivered as infusion and oral capsule
75538486|NCT05001776|Drug|Fondaparinux Sodium|Fondaparinux sodium for 7 days or 45 days
75866097|NCT02426554|Dietary Supplement|DDU-supplement|DDU: Vitamin D, DHA, Uridine
75866098|NCT02426554|Dietary Supplement|Placebo supplement|
75866099|NCT03179488|Device|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
75538487|NCT04981678|Drug|Buprenorphine|Patients randomized to this group will reduce their buprenorphine dose prior to surgery.
75538488|NCT04981678|Drug|Buprenorphine|Patients randomized to this group will continue their buprenorphine at the full prescribed dose.
75538489|NCT04974710|Diagnostic Test|Outpatient MRI|All participants will undergo a standardised imaging protocol in a MRI scanner. This will take place during the same visit or following the transvaginal ultrasound (TVUS) and in advance of any surgical procedure (laparoscopy).
75538490|NCT04970901|Drug|Loncastuximab Tesirine|Intravenous (IV) infusion
75538491|NCT04970901|Drug|Polatuzumab Vedotin|IV infusion
75538492|NCT04970901|Drug|Glofitamab|IV infusion
75538493|NCT04970901|Drug|Mosunetuzumab|Subcutaneous (SC) injection
75538494|NCT04970901|Drug|Obinutuzumab|IV infusion
75538495|NCT04962126|Drug|Obinutuzumab 25 MG/1 ML Intravenous Solution|"For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 & Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles."
75866100|NCT03179488|Device|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
75866101|NCT03130257|Diagnostic Test|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure once within the subsequent three weeks.
75866102|NCT03130257|Diagnostic Test|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to two measurements in the morning and two in the evening for at least 5 days over three weeks.
76028830|NCT05915832|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
76028831|NCT05915832|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
76028832|NCT05915819|Other|Plyometric Training|Exercise prescription according to weeks, sets and repetition. Weeks 1 and 2 1-2 sets / 10 repetitions Double leg jump Medicine ball(MB) stuffer flutter MB overhead throw MB single leg dip, Arrow cone drill Figure 8 drill Weeks 3 and 4 1-2 sets / 8 repetitions Ankle jumps Lateral cone hops Zigzag jump drill MB chest pass Jump & turn 90° High-5 drill MB split squat Power skipping Clock drill T-drill Weeks 5 and 6 1-2 sets / 6 repetitions Dot drill Single leg cone hops Long jump and sprint Single leg zigzag drill MB lunge chest pass Jump and turn 180° Split squat jump Alternate bounding X-drill Shuttle drill
75701730|NCT00713648|Drug|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
75866103|NCT03130257|Diagnostic Test|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
75538496|NCT04962126|Drug|Atezolizumab 1200 MG/40mL Intravenous Solution|For intravenous infusion during induction phase only day 1 of each cycle q3/52 for up to 6 cycles.
75538497|NCT04962126|Radiation|4 Gy in 2 fractions|Involved site radiotherapy will only be administered to participants to achieve a PR/SD after at restaging after cycle 2, treatment will be between cycle 3 and 4 of induction treatment.
75538498|NCT04959526|Diagnostic Test|Shear-wave elastography|Ultrasound based imaging of diaphragm muscle activity
75538499|NCT04947397|Diagnostic Test|Pupillometry|Pupillometry prior to extubation
75538501|NCT04940013|Drug|Misoprostol|Study participants are given misoprostol alone for menstrual regulation.
75701731|NCT04102085|Other|no intervention|no intervention
75538502|NCT04929249|Drug|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
75701732|NCT02590016|Drug|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
75866104|NCT03130257|Diagnostic Test|24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)|Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.
75866105|NCT02801448|Drug|sulforaphane|sulforaphane-containing broccoli sprout extracts
75866106|NCT02801448|Drug|Placebo|Maltodextrine-based placebo without sulforaphane
75538503|NCT04926779|Diagnostic Test|Biozek Covid-19 Antigen Rapid Test (Saliva)|Self-collection of nasopharyngeal and saliva samples and self test performance - Biozek Covid-19 Antigen Rapid Test (Saliva) and Biozek Covid-19 Antigen Rapid Test (Nasopharyngeal Swab). Both procedures are supervised by trained study personnel.
75701733|NCT00768053|Drug|Etanercept|Etanercept 50 mg once a week
75701734|NCT00683475|Biological|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
75701735|NCT00683475|Drug|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m^2) or until there is evidence of disease progression, death, or intolerable toxicity.
75701736|NCT00683475|Drug|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
75538504|NCT04924270|Biological|Faecal microbiota transplantation|The capsule FMT transplant consists of faeces obtained from a thoroughly screened, unpaid, anonymous stool donor. Each FMT product is made from 50g faeces diluted in sterile saline (0.9% NaCl) and glycerol, blended, centrifuged and filtered to remove particulate material before transfer to double-layered capsules. The FMT capsules will be stored at - 80 ⁰C until use. On the day of the FMT, the FMT capsules will be thawed to room temperature before treatment.
76028833|NCT05915819|Other|Eccentric Training|The eccentric training will be Pull-ups 3-5 sets X 6-8 reps Glute-ham raise 3-5 sets x 10rep Manual glute-ham raise 3-5 sets x 10rep single-leg Romanian dead lift or good morning(barbell or dumbbell) 3-5 sets x 10rep Glute-bridge and hip thrust (can also perform single leg movement) 3-5 sets x 10rep Half-kneel-bottom-up press-eccentric only. 3-5 sets x 8rep The eccentric exercise technique will be 2/1 technique, Two-movement technique, Slow/super slow, Negative (supramax)
75375333|NCT04740086|Procedure|Calcium alginate hydrogel|"The external and internal fistulous orifice and fistulous tract were explored without applying any product, including hydrogen peroxide or povidone-iodine.~The seton was removed and FT cannulation was performed using a needle for cleaning with a gauze impregnated with saline.~Calcium chloride was applied through the EFO until it exits through the IFO, and then the IFO was obturated.~Alginate was applied, and the pressure at the IFO was stopped, until the alginate solution partial exits through the IFO.~The IFO was closed with a 3/0 braided resorbable suture.~The EFO was removed with an electric scalpel and closed with a 3/0 braided resorbable suture."
75375334|NCT04857008|Device|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
75375335|NCT04339400|Drug|TQ05105|TQ05105 is a JAK2 inhibitor.
75538505|NCT04924270|Other|Placebo|Placebo capsules consist of NaCl (0.9%) and glycerol added brown food colouring.
75538506|NCT04916197|Drug|Dexmedetomidine prolonged sedation|Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
75538507|NCT04916197|Drug|0.9% saline|An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
75538508|NCT04910269|Biological|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.
76028834|NCT05915793|Other|Diaphragm strengthening and accessory muscles stretchings|Diaphragm strengthening and accessory muscles stretchings
76028835|NCT05915793|Other|Diaphragm strengthening|Diaphragm strengthening
76028836|NCT05915780|Device|Cycling|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
76028837|NCT05915780|Device|Balance Board|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
76028838|NCT05915754|Other|Hip abductors stretching and strengthening exercises|Treatment consist of four stretches for the ITB including: ITB stretch with trunk side bend, ITB stretch with trunk side bend and upward lateral reach, trunk side bend with downward lateral reach and side lying leg adduction and Strengthening exercise plan involving the gluteal muscle groups. These exercises include clams, side-lying abduction, reverse clams and supine bridge
75538509|NCT04910269|Other|Placebo|Infusion of 35 milliliters standard isotonic saline
75538510|NCT04886258|Drug|DFV890|DFV890
75538511|NCT04886258|Drug|Placebo|Placebo
75866107|NCT03179332|Drug|BioChaperone® insulin lispro|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
75866108|NCT03179332|Drug|Fiasp®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
75538512|NCT04883008|Device|CorPath GRX with technIQ automated movements enabled (technIQ ON)|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be enabled and used at the discretion of the interventionalist."
75538513|NCT04883008|Device|CorPath GRX with technIQ automated movements disabled (technIQ OFF).|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be disabled."
75538514|NCT04879732|Device|ACTIS|ACTIS Hip stem
75375336|NCT04693832|Device|5inD|Interactive Mobile Application which is includes five different game (mandala, puzzle, tetris, music, breath exercise)
75538515|NCT04857034|Drug|Deucravacitinib|Specified dose on specified days
75538516|NCT04857034|Drug|Placebo|Specified dose on specified days
75538517|NCT04854278|Other|Massive Open Online Course (MOOC)|Combination of knowledge training with video scenarios and game-based learning provided to endovascular team members: surgeons, nurses and anesthetists
75538518|NCT04853017|Drug|ELI-002 2P|Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
75538519|NCT04848584|Biological|Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine|prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study
75538520|NCT04848584|Biological|Bivalent vaccinated|Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.
75701737|NCT00683475|Biological|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
75538521|NCT04822571|Other|Reliability of 3D motion analysis protocol|The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.
75538522|NCT04822298|Drug|AMG 160|AMG 160 administered as an intravenous (IV) infusion
75866109|NCT03179332|Drug|Novorapid®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
75375337|NCT02684630|Device|Trima Accel System|Platelet Apheresis Procedure
75375338|NCT04670042|Device|SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)|Same as Arm Description.
75557542|NCT03272568|Device|Patient-operated diagnostic device for anemia AnemoCheck.|Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
75701738|NCT02589158|Drug|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
75375339|NCT04739618|Drug|Keytruda Injectable Product|PD-1 inhibitor antibody
75701739|NCT02589158|Drug|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
75866110|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 1|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
75866111|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 2|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
76028839|NCT05915754|Other|Posterior oblique sling strengthening exercises|Treatment consists of treatment A plus the intervention program of POSS consisted of four different exercises utilizing activation of the POSS. The intervention program focuses on one specific exercise each week that will progress in difficulty over the 4 weeks. The equipment used in the exercise progression included a blue, latex-free, medium-resistance theraband (TB), and the final exercise of the progression will include the use of a step stool. The TB will be used to increase the activation of the latissimus dorsi while simultaneously performing lower-extremity exercise to increase gluteal muscle involvement. The exercises are to be used in the 4-week progression.
75866112|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 3|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
75866113|NCT03674177|Drug|Placebo (Normal Saline)|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
75866114|NCT03717259|Procedure|Open nephrectomy|The surgical technique for open nephrectomy consists of placing the donor in the lateral decubitus position and making an incision with or without rib resection that allows retroperitoneal access.
76028840|NCT05915676|Diagnostic Test|Leukocyte Immunoglobulin-like receptors A3|Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.
76028841|NCT05915663|Other|nasogastric tube and orogastric tube|nasogastric tube in period 1 and orogastric tube in period 2
76028842|NCT05915663|Other|orogastric tube and nasogastric tube|orogastric tube in period 1 and nasogastric tube in period 2
76028843|NCT05915650|Behavioral|Pain Neuroscience Education|Carry out pain neuroscience education intervention for TKA patients
76028844|NCT05915650|Behavioral|Routine Education|Carry out routine education intervention for TKA patients
76028845|NCT05915624|Other|telephone counseiling|One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
76028846|NCT05915611|Other|Combined physical and psychological intervention|"Physical therapy components will include splinting, tendon and nerve gliding exercises.~Psychological components will include cognitive-behavioral therapy (CBT), delivered in individual sessions, targeting pain catastrophizing and fear of movement.~Participants will attend 2 physical therapy sessions and one CBT session per week. for a period of 12 weeks"
76028847|NCT05915611|Other|Standard care|Participants will be asked to wear a prefabricated wrist splint during the night and during strenuous activity. Also, they will receive tendon and nerve gliding exercises
76028848|NCT05915598|Other|Right/left discrimination training|"Participants will use recognize app by Neuro-orthopedic institute (NOI) for daily right/left discrimination training.~The training will include visual and auditory stimuli, with tasks such as identifying the laterality of images and sounds.~Participants will engage in training for 20 minutes per day, 5 days per week, over a six-week period.~Weekly monitoring and feedback will be provided by the research team"
76028849|NCT05915598|Other|usual care|"Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group.~Follow-up assessments: Participants in the control group will undergo the same follow-up assessments as the intervention group to evaluate changes in pain perception, functional disability, and cognitive function."
75866115|NCT03717259|Procedure|Hand-assisted laparoscopic nephrectomy|The hand-assisted technique begins with the incision for the introduction port of the hand, the renal artery and vein are divided using endoscopic staples and the graft is manually removed.
75375340|NCT04739618|Drug|Yervoy Injectable Product|Anti-CTLA-4 antibody
75375341|NCT04739618|Drug|GM-CSF|1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
75701740|NCT04083482|Procedure|continous venovenous hemofiltraion|CVVH
75701741|NCT04083716|Drug|ABI-H2158 Reference Formulation|ABI-H2158 tablets Reference Formulation
75701742|NCT04083716|Drug|ABI-H2158 Test Formulation|ABI-H2158 tablets Test Formulation
75701743|NCT00918788|Other|biologic sample preservation procedure|Ex vivo samples of normal and malignant breast tissue; biopsy specimens are then fixed in formalin and submitted for histopathologic studies
75375342|NCT04739618|Procedure|Non-ablative Cryosurgical freezing|To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
75538524|NCT04786184|Behavioral|CALM Breathing|CALM Breathing is a mind-body breathing therapy that links CO2 changes to dyspnea and anxiety symptoms and targets breathing efficiency and self-efficacy in COPD. CALM Breathing: Individual interoception- based breathing therapy with capnography (non- exercise training) Home Program: Monitored home- based breathing exercises; RR biofeedback; goal setting; exercise logging. Coaching: Motivational interviewing. Personnel: PT, EP, occupational therapist, or nurse. Frequency: 1-hour sessions, twice per week for 4 weeks. Exercises: • 10 core breathing exercises with ETCO2 biofeedback in recovery postures at rest and with body movement (gentle stretches and brief low-moderate intensity physical activity). • Breathing biofeedback (ETCO2, RR, airflow pattern). Education: Education on anxiety; COPD Patient Guide.
75557543|NCT00435227|Biological|Motavizumab|A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
75557544|NCT00435227|Other|Placebo|A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
75701744|NCT00918788|Other|immunohistochemistry staining method|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
75866116|NCT03717259|Procedure|Laparoscopic nephrectomy|In the pure laparoscopic technique the patient is placed in the same position of lateral decubitus and after introducing the trocars in the abdomen, the colon is mobilized and the renal capsule is divided, the kidney is removed after performing the cut of the renal artery and vein through a suprapubic incision.
75375343|NCT02684942|Drug|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
75557545|NCT02956512|Drug|Dexibuprofen|Dexibuprofen 300mg
75557546|NCT00465309|Procedure|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat < 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH > 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
75701745|NCT00918788|Other|light microscopy|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC).
75701746|NCT00918788|Other|medical chart review|Medical records are reviewed to obtain information from the pathology report on patient demographics, pathological characteristics of the surgical specimen, and clinical indication for the surgical procedure.
75866117|NCT02675790|Drug|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
75701747|NCT00918788|Procedure|histopathologic examination|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
75701748|NCT00918788|Procedure|needle biopsy|Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle.
75375344|NCT02684942|Drug|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
75538525|NCT04786184|Behavioral|Traditional outpatient PR|"After referral to Columbia's outpatient pulmonary rehabilitation (PR) program, participants randomized to the Wait-List control group will be put on a PR wait list (usual care). In Phase II, all participants will receive PR of 1-hour sessions, twice per week for 10 weeks. Traditional outpatient PR: Group exercise training (ET) combined with pursed lips breathing (PLB) training; 1:2 therapist to patient ratio. Home Program: Unmonitored walking exercise 1-2 days/week; no biofeedback monitoring. Coaching: Traditional monitoring and verbal cueing. Personnel: PT or EP. Frequency:~1-hour sessions, twice per week for 10 weeks. Exercises: • ET of muscles of ambulation with exercise equipment, such as on a treadmill or cycle ergometer (30-min), plus 15-min strengthening and posture exercises; O2 supplementation as needed. No breathing biofeedback. • PLB instruction only during exercise training. Education: Verbal and written information."
75538526|NCT04781543|Drug|HZN-825 BID|300 mg oral tablets BID
75538527|NCT04781543|Drug|Placebo|Placebo BID
75538528|NCT04781543|Drug|HZN-825 QD|300 mg oral tablets QD
75866118|NCT02675790|Drug|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
75866119|NCT01359189|Device|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
75866120|NCT02417896|Drug|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
75866121|NCT01365663|Drug|SPC4955|3 Weekly SC injections
76028850|NCT05915585|Device|High-Intensity Laser Therapy|"The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session"
76028851|NCT05915520|Behavioral|baduinjuin activities|in this 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)
76028852|NCT05915520|Other|pantoprazole|in this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
75538529|NCT04773158|Behavioral|Clinical Decision Support|The intervention clinic sites will be provided access to a Clinical Decision Support System (CDSS) that incorporates the Rome IV criteria for evidence-based care recommendations for functional gastrointestinal disorders (FGIDs)
76028853|NCT05915507|Other|pranayama plus acupoint stimulation by laser|"This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for eight weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )"
76028854|NCT05915507|Other|acupoint stimulation by laser|This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints, the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
75701749|NCT00918788|Procedure|spectroscopy|Optical spectra are acquired from ex vivo samples of normal and malignant breast tissue using diffuse reflectance, fluorescence, and Raman spectroscopy. Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle. After the probes are withdrawn through the needle, cutting biopsies are obtained and the tissue is marked at the site of the spectral measurements.
75538530|NCT04756037|Drug|Relugolix Combination Therapy|Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
75701750|NCT00756951|Drug|Placebo|Placebo
75701751|NCT00756951|Drug|SCV-07|0.02 mg/kg
75701752|NCT00756951|Drug|SCV-07|0.10 mg/kg
75866122|NCT01365663|Drug|SPC4955|3 Weekly SC injections
75866123|NCT01365663|Drug|SPC4955|3 Weekly SC injections
75866124|NCT01365663|Drug|SPC4955|3 Weekly SC injections
75866125|NCT01365663|Drug|SPC4955|3 Weekly SC injections
75866126|NCT01365663|Drug|Saline 0.9%|3 Weekly SC injections
75866127|NCT03183544|Combination Product|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
75866128|NCT04380090|Drug|Propylene Glycol|Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
75866129|NCT04380090|Drug|Docusate Sodium|Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
75866130|NCT05191563|Drug|HCP1904-1|Take it once per period.
75866131|NCT05191563|Drug|RLD2006|Take it once per period.
75866132|NCT05191563|Drug|RLD2001-2|Take it once per period.
75866133|NCT03711565|Device|Regular Nasal CPAP using a conventional ventilator|The Nasal CPAP is connected to the patient via prongs in the nose. Pressure adjustments are made to improve lung inflation. The frequency and pressure can be adjusted as needed to improve the patient's oxygen and carbon dioxide levels
75866134|NCT03711565|Device|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The Bronchotron produces a pressure that is variable with an adjustable frequency that is equal or greater than 500 times per minute connecting to prongs in the patient's nose. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation.
75701753|NCT00916253|Drug|Modafinil|"Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~during 3 days at home~during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil)."
75538531|NCT04729907|Drug|Nusinersen|Administered as specified in the treatment arm
75538532|NCT04722250|Device|Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems|TAVR treatment with Medtronic Evolut PRO, PRO+ System or Evolut FX System (where commercially available)
76028855|NCT05915481|Drug|Cadonilimab|Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.
75538533|NCT04722250|Device|Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems|TAVR treatment with Edwards SAPIEN 3 or SAPIEN 3 Ultra System
75538534|NCT04707248|Drug|DS-6000a|Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
75538535|NCT04707248|Drug|DS-6000a|Intravenous administration at RDE on Day 1 of Cycle 1
75538536|NCT04703595|Genetic|To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.|"To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.~For the molecular study of the DNA sample of the patients, two techniques will be used: standard Polymerase chain reaction amplification with primers flanking the intron 2 fragment of the RFC1 gene and amplification using Repeated Primed Polymerase chain reaction in 3 independent reactions."
75538537|NCT04690010|Procedure|Ambulatory tubeless PCNL|Patients will be discharged the same day of surgery. No nephrostomy tube will be left in place. A ureteral stent on a string may be left for up to 5 days.
75538538|NCT04690010|Procedure|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days. A nephrostomy tube will be placed at the time of surgery that will be removed prior to discharge.
75538539|NCT04681105|Drug|Acetaminophen|Given PO
75538540|NCT04681105|Drug|Dexamethasone|Given IV
75538541|NCT04681105|Drug|Diphenhydramine|Given IV or PO
75538542|NCT04681105|Biological|Flotetuzumab|Given IV
75538543|NCT04681105|Drug|Ibuprofen|Given PO
75538544|NCT04681105|Drug|Ranitidine|Given IV
75538545|NCT04668924|Procedure|Epi-on PiXL in high oxygen|After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for < 45 Diopters (D) 7.2J/cm^2 will be used; for 45-50D 10J/cm^2 will be used; for > 50D 15 J/cm^2 will be used.
75538546|NCT04666467|Device|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
75538547|NCT04656535|Drug|AB122|AB122 is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1 immune checkpoint.
75538548|NCT04656535|Drug|AB154|AB154 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT immune checkpoint.
75538549|NCT04656535|Drug|Placebo|Saline placebo comparator for pre-surgery treatment in cohort B4
75538550|NCT04648709|Diagnostic Test|ELISPOT|measure of immune response by ELISPOT
75538551|NCT04648709|Diagnostic Test|QUANTIFERON|measure of immune response by QUANTIFERON
75538552|NCT04647890|Drug|FT011|Two x 100mg capsules once daily for 12 weeks
75538553|NCT04647890|Drug|FT011|Two x 200mg capsules once daily for 12 weeks
75538554|NCT04647890|Drug|Placebo|Two placebo capsules once daily for 12 weeks
75538555|NCT04642638|Drug|INO-4800|INO-4800 was administered ID on Day 0 and Day 28.
75538556|NCT04642638|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
75866135|NCT02418052|Procedure|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
75866136|NCT03685916|Other|Control|Plain rice with plain water
75538557|NCT04642638|Drug|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
75538558|NCT04642638|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
75538559|NCT04634825|Biological|Enoblituzumab|Anti-B7-H3 antibody
75538560|NCT04634825|Biological|Retifanlimab|Anti-PD-1 antibody
75538561|NCT04634825|Biological|Tebotelimab|PD-1 X LAG-3 bispecific DART molecule
75866137|NCT03685916|Other|Cumin Rice|Cumin rice with plain water
75866138|NCT03685916|Other|Cumin Drink|Cumin drink with plain rice
75866139|NCT03685916|Other|Cornsilk Rice (Low dose)|Low dose cornsilk rice with plain water
76028856|NCT05915481|Radiation|Stereotactic body radiotherapy|Participants will receive SBRT to one lesion or more lesions.
75538562|NCT04614974|Drug|Famotidine|Famotidine will be prescribed based on patients' weight. Caregivers will purchase this medication and dosage will be given to families in easy-to-understand language.
75538563|NCT04614974|Other|Speech Language Therapy|Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.
75557547|NCT04702334|Drug|Hyaluronic Acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
75866140|NCT03685916|Other|Cornsilk Rice (High dose)|High dose cornsilk rice with plain water
75538564|NCT04609020|Device|JUVÉDERM|JUVÉDERM VOLBELLA with Lidocaine Treatment of any fine lines and medium-sized skin depressions. Can also be used for enhancement and pouting of the lips to correct structural defects such as asymmetry, contour deformities, volume loss. JUVÉDERM VOLIFT with Lidocaine Intended for the treatment of any deep skin depressions due to conditions such as premature aging. Can also be used for face contouring and volume restoration to correct facial structural defects such as asymmetry, contour deformities, volume loss in the lips, cheeks, chin, lower face. JUVÉDERM VOLUMA with Lidocaine Intended to restore volume of the face JUVÉDERM VOLITE with Lidocaine Intended for treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity. JUVÉDERM VOLUX with Lidocaine Intended to restore and generate facial volume in chin and mandible areas
75538565|NCT04609020|Drug|BOTOX|Indicated for the treatment of hyperkinetic facial lines.
75538566|NCT04609020|Device|HArmonyCA Lidocaine|HArmonyCa Lidocaine injectable gel is a dermal filler intended for facial soft tissue augmentation.
75538567|NCT04603482|Behavioral|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
75538568|NCT04603482|Behavioral|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
75538569|NCT04603482|Behavioral|Diversional Activites|An audiovisual format presenting 12 activities for adults including but not limited; crossword puzzles, reading, gardening, exercise, cooking/baking, board games, learning a new language, social activities, online games, etc.
75538570|NCT04590001|Device|MobiusHD|The MobiusHD device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
75701754|NCT00916253|Drug|Placebo|"Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~during 3 days at home~during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo."
75701755|NCT04087226|Device|PTFE Retraction Cord|Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
75701756|NCT02561637|Behavioral|Case management|
75701757|NCT02561637|Behavioral|Control group|
75701758|NCT00757029|Genetic|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
75866141|NCT03685916|Other|Cornsilk Drink (Low dose)|Low dose cornsilk drink with plain rice
75866142|NCT03685916|Other|Cornsilk Drink (High dose)|High dose cornsilk drink with plain rice
75866143|NCT03685916|Other|Tamarind Rice|Tamarind rice with plain water
75866144|NCT03685916|Other|Tamarind Drink|Tamarind drink with plain rice
75701759|NCT04101929|Drug|Apatinib|Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
75866145|NCT03745235|Other|stress reduction program based on mindfulness|a two and a half hour session per week for 8 weeks
75866146|NCT03745235|Biological|venipunctures|1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months
75866147|NCT03745235|Other|psychometric questionnaires|"Cohen PSS' perceived stress scale~Beck's anxiety and depression questionnaires~Watson's affectivity questionnaire, positive affect and negative affect schedule~optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~IN-OUT DASQ dispositional affective style questionnaire"
75866148|NCT03116776|Procedure|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
75866149|NCT03116776|Drug|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
75866150|NCT02505204|Other|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
75866151|NCT02505204|Other|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
75866152|NCT01359267|Drug|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
75866153|NCT03183232|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
75375345|NCT04339010|Other|Hypopressive exercise|The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.
75375346|NCT04339010|Other|Pelvic floor muscle contraction|Pelvic floor muscle contraction (PFMC) is performed through a sequence of contraction and relax the PFM. It will improve PFM strength and is effective for treating urinary incontinence.
75538571|NCT04585425|Behavioral|Sleep hygiene advice|Participants receive standard sleep hygiene advice.
75538572|NCT04585425|Behavioral|Bedtime music listening|Participants in the intervention group listen to their preferred sleep playlist daily at bedtime for minimum 30 minutes.
75538573|NCT04583514|Behavioral|Control|Weight-stable Control group
75375347|NCT04739774|Drug|CHF6001 DPI|Single dose of CHF6001
75375348|NCT04739774|Drug|Itraconazole|Repeated doses of oral Itraconazole
75701760|NCT04101929|Drug|S-1 capsule|Patients receive S-1 capsule According to the body surface area <1.25m2 60mg/d, 1.25 ~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
75375349|NCT02685956|Device|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
75375350|NCT02660918|Drug|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
75375351|NCT02660918|Other|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
75375352|NCT02687126|Device|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
75375353|NCT04564196|Procedure|Breath Sample|breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
75538574|NCT04583514|Behavioral|Overfeeding|30% Overfeeding group
75538575|NCT04573439|Dietary Supplement|Dietary Supplement: Dietary supplement: Protein intake|"Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."
75866154|NCT03183232|Biological|γδ T cell|γδ T cells will be used against Lung Cancer
75866155|NCT03183232|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
75866156|NCT01362933|Procedure|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
75375354|NCT02688218|Behavioral|Aerobic Exercise|Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
75866157|NCT03681626|Procedure|no tracheal suction|No tracheal suctioning during extubation
75866158|NCT03681626|Procedure|tracheal suction|tracheal suctioning during extubation
75866159|NCT05056714|Other|Questionaries|The patient will answer several questionaries
75866160|NCT01359345|Drug|gadollinum|use of on injection gadollinum Iv for imaging
75866161|NCT02417584|Device|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
75866162|NCT01359423|Drug|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
75538576|NCT04540432|Other|Stool collection at the patient's home.|Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
75866163|NCT01359423|Drug|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
75866164|NCT03179566|Behavioral|Information Sheet|Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
75866165|NCT03179566|Behavioral|Deterra Drug Deactivation System|This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
75866166|NCT01363089|Drug|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
75866167|NCT01363089|Drug|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
75866168|NCT03354637|Drug|ATI-50002 high dose|Topical solution
75866169|NCT03354637|Drug|ATI-50002 low dose|Topical solution
75866170|NCT03354637|Drug|Placebo|Topical solution
75538577|NCT04540432|Diagnostic Test|Blood test|7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
75538578|NCT04522271|Other|Resistant Starch|7.5 g resistant starch/m2 oral consumption
75538579|NCT04522271|Other|Placebo|Placebo oral consumption of food-grade cornstarch
75538580|NCT04520607|Drug|Placebo|Healthcare professional-administered intra-articular injection of vehicle.
75538581|NCT04520607|Drug|Lorecivivint|Healthcare professional-administered intra-articular injections of lorecivivint.
75538582|NCT04520594|Other|Resistant Starch|7.5 g resistant starch/m2 oral consumption
75538583|NCT04520594|Other|Placebo|Placebo oral consumption of food-grade cornstarch
75538584|NCT04517435|Drug|ME-401|ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
75538585|NCT04517435|Drug|Rituximab|"375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines."
75538586|NCT04517435|Drug|Cyclophosphamide|750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
75538587|NCT04517435|Drug|Doxorubicin|50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
75538588|NCT04517435|Drug|Vincristine|1.4 mg/m2 (max 2 mg) IV Vincristine
75538589|NCT04517435|Drug|Prednisone|100mg PO Prednisone Days 1-5 of 21-day cycle
75538590|NCT04488133|Drug|Nusinersen|Administered as specified in the treatment arm.
75866171|NCT03685838|Other|Compression Stockings|Class II above knee compression stockings
75866172|NCT02422576|Other|cinnamon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
75866173|NCT02422576|Other|lemon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
75866174|NCT02422576|Other|lemon extract plus eucalyptus extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
75375355|NCT02688218|Behavioral|Resistance Exercise|Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
75538591|NCT04473365|Other|Intestinal parasite|Pre-existing intestinal parasite infection present or absent at time of admission
75866175|NCT02422576|Other|Thicken Up clear: TUC|
75375356|NCT00367315|Drug|Lumiracoxib|
75375357|NCT02662244|Device|Nd:YAG laser|Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
75375358|NCT01328587|Drug|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
75538592|NCT04470011|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
75538593|NCT04470011|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
75375359|NCT01192555|Biological|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|"1x10^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
75538594|NCT04468399|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
75866176|NCT04053023|Drug|GSK2330672 (linerixibat)|GSK2330672 is available as a tablet with unit dose strength of 45 mg.
75866177|NCT04053023|Drug|Obeticholic acid|Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
75866178|NCT01365741|Other|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
75866179|NCT03361748|Biological|bb2121|: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
75375360|NCT01192555|Drug|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
75375361|NCT02087449|Device|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
75538595|NCT04468399|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
75538596|NCT04459299|Device|Robotic-PCI (CorPath GRX System)|Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
75538597|NCT04448054|Other|MRI|"Case 1: Routine care protocol not requiring injection~Realization of the non-injected MRI protocol adapted to the indication~+ Addition of a 3D bFFE-Xd sequence (+ 2 min) The protocol will last the examination time usually provided by the current treatment according to the indication + 2 min of complementary sequence Case 2: Routine treatment protocol requiring an injection~Realization of the injected MRI protocol adapted to the indication~Before gadolinium injection:~Addition of a 3D bFFE-Xd sequence (+ 2 min) before injection~After gadolinium injection:~Option 1: if olfaction disorder, addition of DCE perfusion sequence (T1-WI) which will be the 1st post injection sequence (+ 4 min 30)~FABIR 0.9 3D sequence (+ 4 min)~3D sequence T1 TSE 0.7 (+ 2 min 30)~FLAIR HR coronal sequence (+ 3 min 30)~Option 2: if hearing / balance disorder, adding 3D FLAIR labyrinth sequence (+ 6min) which will be the 1st post injection sequence"
75538598|NCT04443530|Drug|Ultimaster™ Tansei™ stents|Patients receiving Ultimaster™ Tansei™ stents
75538599|NCT04421950|Dietary Supplement|Wild blueberry containing foods|Foods that contain wild blueberry supplement to deliver up to 30 grams of blueberry powder
75866180|NCT02426320|Other|Sedation Interruption Protocol|
75866181|NCT02426320|Other|Standard Sedation Protocol|
75866182|NCT05191173|Procedure|Cardiac Surgery|No intervention, just observation is performed.
75866183|NCT02422732|Other|Neuropsychological assessments|"IQ (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
75866184|NCT02422732|Radiation|morphological and functional MRI (fMRI)|"The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location."
75866185|NCT02422732|Genetic|genetic analysis|Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
75866186|NCT03623906|Procedure|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
75866187|NCT03623906|Procedure|Air insufflation colonoscopy|Room air insufflation colonoscopy
75538600|NCT04421950|Dietary Supplement|Placebo containing foods|Foods that do not contain the blueberry powder but a placebo
75538601|NCT04418596|Radiation|bi-planer radiography (EOS), Conventional radiography (Hip+pelvis)|low dose radiation medical imaging to visualise the hip joint and lumbo-pelvic complex specifically.
75538602|NCT04411758|Dietary Supplement|Propolis|Four capsules (400mg/day) containing concentrated and standardized dry EPP-AF® green propolis extract for 2 months and after washout, more two months crossover
75866188|NCT05416788|Other|cervical manipulation|high-velocity, low-amplitude cervical manipulation
75866189|NCT05416788|Other|Sham intervention|lateral flexion and cervical rotation without manipulation
75866190|NCT01359501|Drug|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
75866191|NCT01359501|Drug|Placebo|Start to take the powder of Placebo 3g*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
75866192|NCT02422420|Behavioral|Financial Incentives|Use of financial incentives to promote health behaviors.
75866193|NCT03681548|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
75866194|NCT02417506|Other|E-OA-07 (Lanconone)|
75866195|NCT02417506|Drug|Ibuprofen|
75866196|NCT05188911|Drug|Abiraterone|Patients would be treated with 1000mg abiraterone qd.
75866197|NCT05188911|Drug|Prednisone|Patients would be treated with 5mg prednisone bid.
75538603|NCT04398537|Device|5mm retraction of clip deployment apparatus.|Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.
75538604|NCT04398537|Device|No retraction of clip deployment apparatus.|This is one method of standard of care and the clip will be deployed at the biopsy site.
75538607|NCT04392011|Drug|Midazolam HCl|Oral syrup, 2 mg/mL
75538608|NCT04392011|Drug|Dextromethorphan HBr|Oral liquid capsules, 15 mg
75538609|NCT04392011|Dietary Supplement|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
75538610|NCT04365569|Behavioral|Nutrition and physical activity counseling program|"6-month interventional, counseling program based on nutrition and physical activity consisting of:~1. Nutritional counseling by a Registered Dietitian (RD) 2) Implementation of an adequate physical activity program"
75538611|NCT04334070|Drug|Lamprene®/Clofazimine|All participants will receive Lamprene/clofazimine 50 mg capsules. The recommended dose of clofazimine for this program is 100 mg once daily, administered orally, preferably with meals. Duration of treatment will be decided by the treating physician. When considering clofazimine for the treatment of NTM infection, clofazimine is to be administered as part of a multi-drug regimen.
75866198|NCT05188911|Drug|Androgen deprivation therapy|Patients would get medical or surgical castration.
75538612|NCT04329429|Drug|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
75866199|NCT03676946|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
75538613|NCT04324294|Drug|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
75866200|NCT03676946|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
75866201|NCT03676946|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
75375362|NCT05441761|Drug|liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."
75375363|NCT02685007|Other|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
75375364|NCT00581503|Device|diagnostic|oct imaging
75375365|NCT05587621|Drug|statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran|dietary advice for low cholesterol food
75375366|NCT04739215|Drug|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg / day oral
75375367|NCT04739215|Drug|Placebo|One Placebo capsule daily oral
75375368|NCT02665364|Biological|IFNα-Kinoid|
75375369|NCT02665364|Other|Placebo|
75375370|NCT02665364|Other|ISA 51 VG|
75375371|NCT02688829|Device|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
75375372|NCT00556309|Device|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
75538614|NCT04323046|Biological|Nivolumab|Given IV
75538615|NCT04323046|Other|Quality-of-Life Assessment|Ancillary studies, given in person or online
75538616|NCT04323046|Other|Questionnaire Administration|Ancillary studies, given in person or online
75866202|NCT02426242|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
75866203|NCT03352453|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
75866204|NCT03352453|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
75866205|NCT03623438|Behavioral|Self-administered acupressure group|Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.
75866206|NCT03623438|Behavioral|Sleep hygiene education (SHE) group|Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
76028857|NCT05915416|Behavioral|Child Abuse and Neglect Prevention Program|The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
76028858|NCT05915403|Diagnostic Test|Fibromyalgia Impact Questionnaire|diagnostic tests
75866207|NCT03128931|Device|Pediatric SedLine forehead EEG sensor|Pediatric EEG sensor.
75866208|NCT02417662|Radiation|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
75866209|NCT02417662|Other|Non-investigational SACT|There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
75375373|NCT02689063|Drug|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
75375374|NCT02689063|Drug|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
75375375|NCT02689063|Drug|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
75375376|NCT02689063|Drug|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
75375377|NCT02690935|Drug|2LALERG|Homeopathic drug
75375378|NCT02690935|Drug|Placebo|Placebo
75375379|NCT00367861|Drug|interruption of Glivec®|interruption of Glivec®
75538617|NCT04303260|Behavioral|Physical exercises|The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.
75538618|NCT04298593|Device|Cardiostat|This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
75538619|NCT04288414|Diagnostic Test|functional near-infrared spectroscopy|Functional near-infrared spectroscopy (fNIRS) is a non-invasive method that can evaluate the brain function by measuring the change in brain metabolic activity and hemodynamics during a given task with near-infrared spectroscopy.
75538620|NCT04283604|Drug|MPH|The treatment will include taking the patient's own medication by the patient himself in the treatment session 60-180 minutes before the beginning of the tests, according to their prescription given by their own physician. Participants must have consumed this medication at least 3 months before the first session as their regular treatment for ADHD. Note, we are not planning on giving the medication to the participant, rather he/she will consume their own prescribed MPH by them self.
76028859|NCT05915286|Drug|Furosemide|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
76028860|NCT05915286|Drug|Chlorthalidone|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
75375380|NCT02666846|Drug|Ibuprofen|
75375381|NCT02666846|Drug|Diclofenac|
75375382|NCT02666846|Drug|Methyl-salicylate / Menthol|
75375383|NCT02666846|Drug|Placebo|
76028861|NCT05915273|Other|Computer Aided Design/ Computer Aided Manufacturing Retainers|Custom-bent fixed retainer wires from an in-office CAD/CAM system with FixR software and the BenderI machine (YOAT Corporation, Lynwood, WA). Dentaflex wires- round, 0.5mm in diameter, three-stranded Stainless Steel (Dentaurum GmbH & Co., Ispringen, Germany)- were used for the CAD/CAM group
76028862|NCT05915273|Other|Lab-based Retainers|The lab group used the same type of wire as the CAD/CAM group but was manually bent by a lab technician
76028863|NCT05915273|Other|Chairside Retainers|The chairside group used three-stranded Stainless Steel, 0.974mm x 0.402 mm, flexible Ortho-FlexTech wires (Reliance, Itasca, IL)
75375384|NCT02643979|Drug|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
75375385|NCT02643979|Drug|Propofol|100mg of Propofol
75375386|NCT02643979|Drug|Saline|1mL of saline
75375387|NCT02667392|Procedure|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
76028864|NCT05915260|Diagnostic Test|All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion|This is a observational follow up study accordingly all subjects will undergo the same examinations
75538621|NCT04273048|Other|Diet Intervention - Group 1|They will be provided with a Mediterranean diet plan.
75538622|NCT04273048|Other|Exercise Intervention - Group 1|They will be provided with an exercise plan to follow.
75538623|NCT04271072|Other|No intervention|No intervention
75538624|NCT04250753|Other|Walking task|30 meters walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30 meters walking task twice. Inertial sensors are put on each participant foot.
75538625|NCT04242264|Other|Placebo|0.9% Sterile Normal Saline, USP
75538626|NCT04242264|Biological|Shigella sonnei strain 53G|1.5 x 10^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
75538627|NCT04242264|Biological|WRSs2|10^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
76028865|NCT05915234|Device|Crushed ice|Each participant will receive two active devices and one sham comparator in a crossover design.The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of crushed ice. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
76028866|NCT05915234|Device|Frozen peas|Each participant will receive two active devices and one sham comparator in a crossover design. The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of frozen peas. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
75538628|NCT04206852|Procedure|Balloon pulmonary angioplasty|Balloon pulmonary angioplasty is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
75538629|NCT04185038|Biological|SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel|Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
75538630|NCT04176939|Biological|HZ/su vaccine (GSK1437173A)|2 intramuscular (IM) doses of the HZ/su vaccine administered - first dose at Month 24 and second dose at Month 25.
75538631|NCT04170374|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
75538632|NCT04170374|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
76028867|NCT05915234|Device|Room temperature gel|Each participant will receive two active devices and one sham comparator in a crossover design. The sham comparator device used consists of an opaque bag with an external plastic cover and an aluminum interior filled with 80 grams of ultrasound gel at room temperature. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed.
76028868|NCT05915221|Procedure|SMS|Receive SMS
75701761|NCT04101929|Drug|Irinotecan|"Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded."
75866210|NCT03676790|Other|Group I|"Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
76028869|NCT05915169|Other|Topical haemoglobin wound care spray|It is a wound care spray used in the care of chronic wounds.
75701762|NCT04083638|Diagnostic Test|IFAB|Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
76028870|NCT05915156|Other|Post-acute home physiotherapy program|This health services research assessed the effects of a post-acute home physiotherapy program that was designed to provide physical rehabilitation services to older adults recently discharged from acute or post-acute care. Under this program, every patient was attended by a physiotherapy technologist within 48 hours of being discharged and received home physiotherapy for a minimum of three days per week for a maximum of eight weeks.
76028871|NCT05915130|Behavioral|Gait training|They will negotiate (natural or virtual) obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
76028872|NCT05915117|Dietary Supplement|Polyphenols of pomegranate fruit peel extract (PoPex)|PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
75538633|NCT04168242|Device|Scalp cooling Paxman Orbis II system|The experimental arm will have scalp cooling that starts 30 minutes before the chemotherapy, continues throughout the infusion of the chemotherapy, and lasts for 20-90 minutes more depending on the type of regimen.
75538634|NCT04168242|Other|Standard treatment|The control arm will not have scalp cooling before, during and after chemotherapy.
76028873|NCT05915117|Drug|Placebo|Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
76028874|NCT05915091|Diagnostic Test|Dry Needling|Dry needling is a treatment that healthcare providers use for pain and movement issues associated with myofascial trigger points. With this technique, a provider inserts thin needles into or near your trigger points. The needles stimulate your muscles, which causes them to contract or twitch
75375388|NCT02667392|Procedure|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
75375389|NCT05587231|Drug|Dextenza 0.4Mg Ophthalmic Insert|The experimental group will have the Dextenza Insert implanted immediately after surgery
75375390|NCT05587231|Drug|Topical Fluorometholone|Steroid drops will be administered by the subject according to the standard of care taper
75375391|NCT02667704|Drug|Bosentan|
75375392|NCT02667704|Drug|Nintedanib|
76028875|NCT05915091|Other|Cross Friction Massage|Cross friction massage breaks down scar tissue and remodels the tissue into more flexible, pliable, and functional, healthy soft tissue. Also known as transverse friction massage, this technique is a deep tissue massage technique performed at the site of injury
75538635|NCT04151667|Drug|Daratumumab Injection|Patient will receive daratumumab (1800 mg in 15 ml) administered by manual subcutaneous injections weekly for the first 8 weeks, every other week for the next 16 weeks and every 4 weeks after.
75538636|NCT04151667|Drug|Dexamethasone Oral|The dexamethasone starting dose will be 20 mg PO once a week. Commercial dexamethasone will be used. Dexamethasone is often supplied in 4 mg tablets. Accordingly, patients will take 5 (4 mg tablets) one day of the week prior to the administration of daratumumab if this corresponds to a daratumumab dosing days. In non daratumumab dosing days, dexamethasone will be taken by the patient at home, usually in the morning with breakfast.
75538637|NCT04151667|Drug|Lenalidomide Pill|"Lenalidomide will be given orally on days 1-21 of a 28 days cycle. The starting dose of lenalidomide will be based on the patient creatinine clearance per the package insert.~Specifically patients with a creatinine clearance ≥ 50 ml/min will receive 25 mg of lenalidomide PO Days 1-21. Patients with a creatinine clearance ≥ 30 but less than 50 ml/min will receive 10 mg of lenalidomide.~Patients with a creatinine clearance < 30 ml/min are not eligible but patients who experience a deterioration in the renal function during screening or treatment may continue on lenalidomide therapy as long as the risk / benefit profile is deemed acceptable, that study therapy is in the best interest of the patient and after discussion with the study principal investigator / sponsor."
76028876|NCT05915065|Device|Coapt Phantom Limb Pain Management System|The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
75375393|NCT02645617|Drug|Varnish|Topical application to the teeth
75701763|NCT00757107|Device|Taperloc Microplasty|primary total hip arthroplasty
75701764|NCT00757107|Device|Taperloc standard|primary total hip arthroplasty
75701765|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> B -> C. Each of these treatments will be separated by a 7 day washout period.
75701766|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> C -> B. Each of these treatments will be separated by a 7 day washout period.
75701767|NCT00918632|Drug|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> C -> A. Each of these treatments will be separated by a 7 day washout period.
75375394|NCT02668952|Drug|0.9% Normal Saline (0.9% Sodium Chloride) injection|
75375395|NCT02668952|Drug|Isolyte S injection|
75375396|NCT02648971|Procedure|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
75538638|NCT04151667|Drug|Bortezomib Injection|Bortezomib will be given weekly subcutaneously in an effort to decrease the toxicity of the therapy. Specifically patients will receive a starting dose of bortezomib of 1.3 mg/m^2 Days 1,8,15 of a 28 day cycle. Bortezomib will be administered in the cancer center per standard of care procedures.
75701768|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> A -> C. Each of these treatments will be separated by a 7 day washout period.
75375397|NCT02648971|Procedure|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
75538639|NCT04148911|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.
75538640|NCT04148911|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
75538641|NCT04146909|Diagnostic Test|Hyperinsulinemic-euglycemic clamp|After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ∼90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.
75866211|NCT03676790|Other|Group II|"Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
76028877|NCT05915052|Procedure|B-type suture ileostomy|Type B suture stoma group：2-0 stitched sutures were placed in the center of the incision, from the anterior rectus sheath on the left side of the incision → the posterior rectus sheath on the left side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the right side of the incision → the anterior rectus sheath on the right side of the incision→ the posterior rectus sheath on the right side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the left side of the incision →the anterior rectus sheath on the left side of the incision sutures were sewn through in the sequence, tightened and knotted .
76028878|NCT05915052|Procedure|the traditional ileostomy|Then take the right lower abdominal incision to cut a circular incision of 3 cm in diameter, round excision of subcutaneous fat, cross incision of rectus sheath and peritoneum, enter the abdomen, raise the marked ileum out of the body, interrupt suture of ileum with peritoneum and posterior sheath of rectus abdominis for one week, then interrupt suture of ileum with anterior sheath of rectus abdominis for one week, transverse incision of 2 cm in diameter, interrupted with 3-0 absorbable thread, The ileocecal incision and the skin of the right lower abdominal circular incision were sutured for one week to complete the double-lumen stoma at the end of the ileum.
76028879|NCT05915013|Drug|Ketamine|Intravenous ketamine
76028880|NCT05915013|Drug|Perampanel|Oral perampanel (6 mg)
76028881|NCT05915013|Drug|Placebo|Oral placebo
76028882|NCT05915000|Diagnostic Test|Lumbar CSF protein marker determination|The cerebrospinal fluid levels of the Aβ1-42 amyloid, h-tau and phospho-tau proteins will be assessed. The response of patients to the possible implantation of a ventricular peritoneal shunt will be assessed through neuropsychological, gait and ventricular size studies assessed through cerebral magnetic resonance studies.
76028883|NCT05914948|Device|Medtronic 8-contact Vectris subcompact or compact electrode.|Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.
75375398|NCT02689154|Device|W8Loss2Go|The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
75375399|NCT02694445|Other|observation|The study is non-interventional.
75375400|NCT02690168|Behavioral|Fasting|72 hour fasting
76028884|NCT05914935|Drug|Recombinant L-IFN adenovirus injection|The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
75375401|NCT02694601|Dietary Supplement|Control|4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
75375402|NCT02694601|Dietary Supplement|Caffeine low dose|4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
75375403|NCT02694601|Dietary Supplement|Caffeine high dose|4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
75375404|NCT02694835|Device|Delefilcon A contact lenses with UV Absorber|
75375405|NCT02694835|Device|Delefilcon A contact lenses|
75375406|NCT02696083|Device|Provant Therapy System|
75538642|NCT04144933|Drug|Acetaminophen, Gabapentin|975 mg, 300 mg
75538643|NCT04144933|Drug|Acetaminophen, Gabapentin|975 mg, 300 mg
75375407|NCT05585203|Behavioral|Contingency management|"The investigators will implement a prize-based contingency management protocol in which residents will complete three pre-planned recovery-oriented activities each week for a period of up to 12 weeks. Upon verified completion of the activities each week, participants may earn prize incentives through drawing from a prize fishbowl or spinning a virtual prize wheel.~Prizes will be money added to a debit card. On the first week and individual has completed pre-planned activities, s/he can receive up to 1 draw per activity completed (3 total), and each week the number of prize draws per activity will escalate by 1. If a participant fails to complete any activities, he/she will not receive the draws for the uncompleted activities, and the prize draws would be reset to 1 in the next week. Participants can earn up to $75 in incentives in total."
75538644|NCT04144933|Drug|Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine|1.5 mg/kg, 0.5 mcg/kg, 0.5 mg/kg
75375408|NCT05585203|Behavioral|Usual Care|Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
75375409|NCT02650219|Genetic|genetic analyses|
75375410|NCT05574439|Behavioral|TCOC treatment|The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.
76028885|NCT05914922|Other|Educational Tool|20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
75538645|NCT04144933|Drug|Dexamethasone, Ondansetron|6 mg, 4 mg
75538646|NCT04144933|Drug|Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate|Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes
75538647|NCT04144933|Drug|Lidocaine 1% Injectable Solution, Sufentanil|0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)
75538648|NCT04144933|Drug|Sevoflurane, Sufentanil|Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
76028886|NCT05914909|Biological|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
76028887|NCT05914909|Other|Placebo|Placebo
76028888|NCT05914896|Drug|HighOsmo|This group received a priming solution with high osmolality
76028889|NCT05914805|Drug|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
76028890|NCT05914805|Drug|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
75866212|NCT03676790|Other|Group III|"Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
75538649|NCT04130854|Drug|APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days|"APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~Short course radiation therapy 5 Gy x 5 days~Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~Leucovorin 400mg/m2 IV Day 1 of each cycle~5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
75701769|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> A -> B. Each of these treatments will be separated by a 7 day washout period.
75701770|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> B -> A. Each of these treatments will be separated by a 7 day washout period.
75701771|NCT00751257|Drug|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
76028891|NCT05914753|Drug|Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
76028892|NCT05914753|Drug|Epirubicin, Cyclophosphamide, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
75538650|NCT04130854|Drug|mFOLFOX and Radiation Therapy 5Gy x 5 days|"Short course radiation therapy 5 Gy x 5 days~Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~Leucovorin 400mg/m2 IV Day 1 of each cycle~5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
75538651|NCT04124120|Procedure|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
75538652|NCT04124120|Procedure|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
76028893|NCT05914740|Procedure|Ultrasound guided functional remodeling of lower extremity superficial vein valve|Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.
75538653|NCT04106258|Drug|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
76028894|NCT05914727|Diagnostic Test|eNose|Collection of breath profile with eNose
76028895|NCT05914727|Diagnostic Test|Volatile exhaled breath sample|Collection of exhaled breath in Tedlar bag
76028896|NCT05914727|Diagnostic Test|Condensate sample|Collection of exhaled breath condensate with EcoScreen
76028897|NCT05914714|Drug|Ruxolitinib 5 MG BID Oral Tablet|ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
75557548|NCT04702334|Drug|Lidocain|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
76028898|NCT05914701|Drug|Letermovir for secondary prophylaxis|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen duration of dosing was approximately 120 days or 16 weeks. Or physicians could adjust regimen duration according to the CMV infection risk factors.
76028899|NCT05914675|Drug|Letermovir|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen would start between +7~+14d after transplantation. The total duration of dosing was approximately 100 days or 14 weeks.
75557549|NCT00473421|Procedure|Barium Sulphate and Zirconium Oxide|
75701772|NCT00751257|Drug|Placebo|"Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules"
75701773|NCT00753441|Procedure|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
75701774|NCT00753441|Procedure|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
75701775|NCT05685134|Device|Radiofrequency catheter ablation|Radiofrequency application via catheter to burn the electroanatomic substrate implicated in Brugada syndrome
75701776|NCT05685134|Device|Sham procedure|Venous and epicardial punctions, catheter insertions, programmed electrical stimulation and electroanatomical mapping
75375411|NCT05574439|Drug|Semaglutide 3 mg|Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
75375412|NCT02698033|Drug|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
75375413|NCT02698033|Other|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
75375414|NCT02690948|Biological|Pembrolizumab|Given IV
75375415|NCT02690948|Drug|Vismodegib|Given PO
75375416|NCT02698735|Drug|Gentamicin|Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
75375417|NCT02698735|Drug|Placebo|There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
75375418|NCT02691260|Behavioral|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
75375419|NCT02691260|Behavioral|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
75701777|NCT00757185|Drug|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
75701778|NCT00757185|Drug|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
75375420|NCT02691260|Behavioral|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
75375421|NCT02691416|Drug|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
75375422|NCT02691416|Drug|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
75866213|NCT03676790|Other|Group IV|"Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
75866214|NCT03676790|Other|Group V|"Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
75375423|NCT02650999|Drug|Pembrolizumab|200mg intravenously (IV)
75375424|NCT02691962|Device|Xen Matrix AB|Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
75375425|NCT02701387|Device|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
75375426|NCT02701387|Device|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
75557550|NCT04702412|Other|The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure|HIV patients will complete the I-Score PROM via Opal (patient portal) prior to three consecutive clinic visits with their HIV physician who is expected to access their PROM results in time for the visit. The clinic visits will be held at Time 1, Time 2 (3 months) and Time 3 (6 months).
75557551|NCT00465387|Behavioral|Falls, Fractures & Osteoporosis Risk Assessment & Management|
75538654|NCT04092673|Drug|eFT226|eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
75538655|NCT04092673|Drug|Sotorasib|Recommended dosage: 960 mg orally once daily
75538656|NCT04092673|Drug|Fulvestrant|500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter
75538657|NCT04092673|Drug|Abemaciclib|Dose in combination with fulvestrant: 150 mg twice daily
75866215|NCT01363167|Dietary Supplement|400 IU Cholecalciferol- Vitamin D Daily|Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
75538658|NCT04092673|Drug|Trastuzumab|600 mg every 3 weeks
75538659|NCT04091048|Device|Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)|Aortic valve replacement
75538660|NCT04090398|Procedure|Biospecimen Collection|Correlative studies
75538661|NCT04090398|Procedure|Bone Scan|Undergo bone scan
75538662|NCT04090398|Procedure|Computed Tomography|Undergo CT scan
75538663|NCT04090398|Other|Electronic Health Record Review|Ancillary studies
75538664|NCT04090398|Procedure|Magnetic Resonance Imaging|Undergo MRI
75538665|NCT04090398|Drug|Paclitaxel|Given IV
75866216|NCT03710707|Drug|DNL201|Oral repeating dose
75866217|NCT03710707|Drug|Placebo|Oral repeating dose
75538666|NCT04090398|Radiation|Radium Ra 223 Dichloride|Given IV
75538667|NCT04090398|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT
75538668|NCT04082572|Biological|Pembrolizumab|Given IV
75538669|NCT04079751|Procedure|Neutral Mechanical Alignment|Hip-knee-ankle angle of 180° ± 3°.
75866218|NCT03107052|Drug|Fremanezumab|Fremanezumab
75866219|NCT01359579|Drug|varespladib methyl|Single oral 500 mg dose
75375427|NCT02693132|Behavioral|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
75375428|NCT02693132|Behavioral|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
75375429|NCT02693132|Behavioral|Step-based (STEP)|"Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day."
75866220|NCT02422654|Drug|eliglustat|"Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion"
75866221|NCT05668793|Diagnostic Test|GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
75866222|NCT05188833|Device|Deep Transcranial Magnetic Stimulation|Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.
75866223|NCT05188833|Drug|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
75866224|NCT02426164|Drug|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
75866225|NCT02426164|Drug|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
75375430|NCT05502211|Drug|Fentanyl|induction of anaesthesia using fentanyl
75375431|NCT05502211|Drug|Lidocaine IV|induction of anesthesia using lidocaine
75866226|NCT03640013|Procedure|Hall Technique PMC|Hall Technique primary fitted crowns to restore carious primary molars
75866227|NCT02417428|Dietary Supplement|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
75866228|NCT02417428|Other|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
76028900|NCT05914662|Drug|Zanubrutinib, Bendamustine and Rituximab|Zanubrutinib, 160mg orally, twice a day; Bendamustine 70 mg/m2 on days 1 and 2 of each cycle; Rituximab (375 mg/m2 intravenously on day 0 of each cycle. ZBR was administered every 4 weeks for a total of 6 cycles, followed by maintenance therapy with zanubrutinib monotherapy for another 6 months.
76028901|NCT05914623|Procedure|Repetitive transcranial magnetic stimulation|After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
75538670|NCT04079751|Procedure|Anatomical Alignment|Restoring a patient's pre-diseased limb alignment
75866229|NCT02417428|Behavioral|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
75375432|NCT04339244|Other|RALRP under lower mean BP|RALRP under regulation of lower mean BP
75701779|NCT04084808|Dietary Supplement|Solution ingestion|Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
75866230|NCT02417428|Other|without exercise|No exercise program will be assigned to participants.
75866231|NCT02015897|Procedure|Physical TherapyA|"Group A:~Skin care~Manual lymphatic drainage~Bandaging using Coban™2Lite~Guidance on physical activity"
75866232|NCT02015897|Procedure|Physical TherapyB|"Group B:~Skin care~Bandaging using Coban™2Lite~Guidance on physical activity"
75866233|NCT04249674|Diagnostic Test|Dextrometorphan|Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)
75557552|NCT00435266|Procedure|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
75557553|NCT00473460|Drug|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
75557554|NCT00473460|Drug|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
75557555|NCT00435305|Drug|Meropenem|
75557556|NCT00435305|Drug|Vancomycin|
75557557|NCT00435305|Drug|Linezolid|
75557558|NCT00435305|Drug|Piperacillin/Tazobactam|
75557559|NCT00435305|Drug|Cefepim|
75375433|NCT04339244|Other|RALRP under lower mean BP|RALRP under regulation of highly normal mean BP
75375434|NCT02673944|Device|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
75375435|NCT02674412|Drug|Buspirone|
75557560|NCT00435305|Drug|Ceftazidim|
76028902|NCT05914623|Procedure|Sham repetitive transcranial magnetic stimulation|After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
76028903|NCT05914610|Drug|Envolimab|Envolizumab 300mg, D1, ih, Q3W 4-6cycles
76028904|NCT05914610|Drug|Fruquintinib|Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
76028905|NCT05914610|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
75866234|NCT04249674|Genetic|Genotyping by single nulcetoide polymorphism.|Single nucleotide polymorphism determination
75866235|NCT03745157|Drug|Insulin Degludec/Insulin Aspart|Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
75866236|NCT02426008|Other|Growth Factors and Cytokine adding to embryo culture media|
75866237|NCT02426008|Other|No Intervention|Nothing to Add
75866238|NCT04050371|Drug|200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate|All study participants received daily observed therapy with FTC/TDF.
75701780|NCT04084808|Behavioral|Cognitive flexibility|"Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise."
75866239|NCT04189536|Other|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
75375436|NCT02674412|Drug|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
75375437|NCT00367952|Drug|apricitabine|800mg apricitabine twice daily orally for 96 weeks
75375438|NCT04708106|Other|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS Tobacco Flavor product
75375439|NCT04708106|Other|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS Menthol product
75375440|NCT04708106|Other|RELX ENDS Tobacco and Menthol Flavors|Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products
75866240|NCT04183764|Drug|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
75866241|NCT04447287|Drug|ASP8062|Oral
75866242|NCT04447287|Drug|Placebo ASP8062|Oral
75866243|NCT04447287|Drug|buprenorphine/naloxone|Sublingual
75375441|NCT02697188|Drug|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
75375442|NCT02697188|Drug|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
75557561|NCT00435344|Behavioral|Pediatric Practice-Based Smoking Intervention|
75557562|NCT00473499|Device|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
75557563|NCT00465465|Biological|MVA 85A|i.d. injection
75866244|NCT01879319|Biological|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
75866245|NCT01879319|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
75375443|NCT04707560|Procedure|EUS fine needle biopsy with heparin wet suction|"EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion."
75538671|NCT04075266|Drug|Ocrelizumab|"Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg"
75375444|NCT05421104|Other|Ruxolitinib|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
75375445|NCT02652481|Device|ImageReady MR Conditional Defibrillation System|"ImageReady MR Conditional Defibrillation System Components:~Device Name Device Model Number Pulse Generators Phase I and II Phase II Only * CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD* AUTOGEN EL ICD* AUTOGEN X4 CRT-D* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI* Suture Sleeve for INGEVITY MRI* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)* Suture Sleeve for RELIANCE 4-FRONT leads*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads~* May only be used internationally outside the US"
75557564|NCT00465504|Procedure|iontophoresis|See Detailed Description.
75557565|NCT00435422|Procedure|Stroke volume optimization|Stroke volume optimization
75557566|NCT00465543|Other|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
75866246|NCT04165122|Biological|HDIT101|i.v. Infusion
75375446|NCT05420714|Device|Dexcom Professional Continuous Glucose Monitoring|Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
75375447|NCT02697890|Device|FDBA (MinerOss®) + Mucograft® seal|Collagen matrix membrane for soft-tissue regeneration
75538672|NCT04073225|Device|MindPod Dolphin|"The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience."
75557567|NCT00465543|Other|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
75557568|NCT00435500|Drug|Fluoride varnish|
75866247|NCT04165122|Drug|Valaciclovir|oral application of encapsulated Valaciclovir tablets
75375448|NCT02697890|Device|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|Standard of Care
75375449|NCT05419154|Procedure|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
75557569|NCT03272412|Diagnostic Test|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
75866248|NCT04165122|Biological|HDIT101 placebo|i.v. Infusion
75866249|NCT04165122|Drug|Valaciclovir placebo|oral application of encapsulated Valaciclovir placebo tablets
76028906|NCT05914610|Drug|Tegafur|Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time Q3W 4-6cycles
76028907|NCT05914597|Other|Setting up home delivery of Colon capsule endoscopy|Feasibility study of home delivery of CCE
76028908|NCT05914584|Drug|Baricitinib 4 MG|Reference drug
75866250|NCT02417350|Other|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
75375450|NCT02653183|Device|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
75375451|NCT02653183|Device|Experimental: Mepilex Border Post-Op|"Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
75375452|NCT05418920|Procedure|left-opening single-flap technique|left-opening single-flap technique
75375453|NCT05418920|Procedure|double-flap group technique|double-flap group technique
75375454|NCT02701400|Biological|Durvalumab|Given IV
75375455|NCT02701400|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75375456|NCT02701400|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75375457|NCT02701400|Biological|Tremelimumab|Given IV
75375458|NCT00368173|Drug|rhIGF-I/rhIGFBP-3|
75866251|NCT02417350|Other|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
75866252|NCT02422030|Drug|Lipitor Tab. 40mg|
75866253|NCT02422030|Drug|Trilipix 135mg|
76028909|NCT05914558|Diagnostic Test|Clinical appointment|One clinical interview and examination to confirm the diagnosis of trigeminal neuralgia and temporomandibular disorder.
76028910|NCT05914545|Drug|FZ-AD004|"Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles."
75375459|NCT05403710|Drug|Botulinum toxin|Standard-of-care administration of botulinum toxin (50 units/axilla injected intradermally) will be performed for routine treatment of Hidradenitis Suppurativa
75375460|NCT05400824|Diagnostic Test|Blood, DNA, feces, urine, hair and skin microbiota collection|See above
75375461|NCT04738994|Dietary Supplement|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
75375462|NCT04738994|Other|Control group|Standard hospital diet
75375463|NCT02653417|Drug|RAD1901|RAD1901
75375464|NCT02653417|Other|Placebo|Placebo
75375465|NCT02677766|Other|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
75375466|NCT02677766|Other|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
75538673|NCT04073225|Device|Hand Bike|The control intervention in this study is a hand bike, a single-component upper-arm aerobic exercise device. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
75538674|NCT04064112|Procedure|S-BLR|Surgery of slanted bilateral LR recession for CI-IXT patients
75538675|NCT04064112|Procedure|C-BLR|Surgery of conventional bilateral lateral rectus recession for CI-IXT patients
75375467|NCT04338997|Drug|IZD174|Small molecule inhibitor of NLRP3
75375468|NCT02705365|Other|Patient Navigation|One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
75538676|NCT04053816|Drug|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
75557570|NCT00435578|Drug|Glufosfamide|
75375469|NCT02705365|Other|Usual Care|Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
75866254|NCT04159350|Device|Rectal Expulsion Device (RED) - Feasibility|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their side and RED is gently inserted into the rectum. The patient is then given one minute to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
75866255|NCT04159350|Device|Rectal Expulsion Device (RED) - Validation|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their LEFT side and RED is gently inserted into the rectum. The patient then attempts to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
75866256|NCT05668715|Other|Transcutaneous tibial nerve stimulation (TTNS)|PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
75375470|NCT02703350|Drug|LY900014|Administered subcutaneously (SC)
75375471|NCT02703350|Drug|Insulin Lispro|Administered SC
75375472|NCT02682056|Device|Microneedle patch|The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
75866257|NCT04158726|Behavioral|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
75866258|NCT02425930|Procedure|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
75866259|NCT02425930|Drug|S-1+Oxaliplatin|"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
75701781|NCT04084808|Procedure|Brain oxygenation|"Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). ] Measured with near-infrared spectroscopy (NIRS)."
75866260|NCT03685682|Biological|recombinant subunit Herpes zoster vaccine|Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
75866261|NCT01365897|Drug|Modafinil|Modafinil 200mg
75866262|NCT02422108|Drug|Denosumab|
75866263|NCT03685604|Drug|CHX disinfection|CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
75866264|NCT03685604|Drug|PI Disinfection|PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
75866265|NCT03685526|Device|Cinenses Lung Volume Reduction Reverser System|Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
75866266|NCT02422342|Device|Pulse Oximeter CMS50FW (Contec Medical)|"The patients will be wearing the pulse oximeter during the test period (20-30 minutes).~The data from the oximeter will be sent by Bluetooth to the mobile application"
75701782|NCT04084808|Other|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
76028911|NCT05914519|Procedure|Ejaculatory Preserving Transurethral resection of prostate|Transurethral resection of prostate with preservation of 1cm safety area above verumontanum and without paracollicular digging
76028912|NCT05914519|Procedure|Standard Transurethral Resection of prostate|Transurethral resection of prostate including whole adenoma till the capsule.
76028913|NCT05914493|Other|The effect of posture on cognitive function in early adolescence athletes|"Posture evaluation:~The form of Corbin et al. will be applied.~Evaluation of cognitive functions:~Basically, the Stroop test will be used, which evaluates the concentration and maintenance of attention depending on time and the task given."
76028914|NCT05914454|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|anakinra 100 mg per day for 14 days
75701783|NCT04084808|Procedure|Blood glucose|Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
75866267|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
75538677|NCT04015765|Procedure|Hybrid Argon Plasma Coagulation and EMR procedure|Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications
75866268|NCT01359657|Biological|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
75866269|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
76028915|NCT05914441|Other|Standard clinical practice|The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.
76028916|NCT05914428|Other|ALDH2 rs671 mutation|We selected blood samples from sepsis patients from the biological bank of Qilu hospital and tested their genotypes. The intervention group was ALDH2 rs671 mutation patients
76028917|NCT05914415|Other|Supportive care and education before surgery|we will give supportive and informative education before surgery in order to increase patient' recovery rates
76028918|NCT05914402|Procedure|axillary surgery de-escalation after NAT|the process of axillary surgical evaluation will be spared after NAT using the prediction model if the probability is more than 90%.
76028919|NCT05914363|Other|Sealed washable floor plus behaviour change|Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling, combined with support for behaviour change through 'floor clubs'.
75375473|NCT02682056|Device|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
75375474|NCT02682056|Device|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
75375475|NCT02706925|Drug|BI 443651|
75375476|NCT02706925|Drug|Placebo|
75701784|NCT04084808|Behavioral|Perceived exertion|Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, & Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
75866270|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
76028920|NCT05914350|Procedure|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
76028921|NCT05914350|Drug|methylprednisolone acetate and lidocaine|40 mg methylprednisolone acetate and 1 mL lidocaine
75375477|NCT05378438|Other|Microbe literacy Program in the form of workshop|Two to Three hours of workshop on microbe literacy will be conducted as an intervention. Workshop includes discussion on various common microorganisms causing diseases, their sources, relationship with surroundings and management. Prime focus of the session will be on management via treatments and risk reduction via vaccination.
75375478|NCT04739228|Behavioral|Guided Written Disclosure Protocol Group|The writing task consists of three sessions of 20 minutes each, with an interval of one week between each other. In the first session, patients were asked to describe the onset of illness, describing chronologically and detailed places, images, sounds and actions, as they are followed and detached from the emotions. In the second session, the patients were asked to write about thoughts and emotions felt during the illness experience, talking about the impact that illness had on their daily lives and how it had changed their personal attitude to life itself. In the third and final session, the patients were asked to analyze subjective new skills acquired.
75375479|NCT04739228|Behavioral|Active Control Group|The writing task also consists of three sessions of 20 minutes each, with an interval of one week between each other. In all three writing sessions, patients were asked to report the daily activities during the last week, without focusing on the emotional aspects.
75866271|NCT01359657|Biological|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
75866272|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
75866273|NCT02417116|Other|Tear supplement|Application as required to improve comfort
75866274|NCT02417116|Other|Tear supplement 2|Application as required to improve comfort
75866275|NCT02417116|Dietary Supplement|Omega 3 nutrition supplement|Taken each day
75375480|NCT05470465|Drug|Placebo and Oxycodone|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
75866276|NCT02417116|Device|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
75866277|NCT02417116|Other|Saline|Application as required to improve comfort
75866278|NCT03685370|Procedure|LOS|placement of epidural catheters with LOS technique
75866279|NCT03685370|Procedure|X-ray placement|placement of epidural catheters with x-ray guide
76028922|NCT05914350|Drug|PRP and lidocaine|3 mL PRP and 1 mL lidocaine
76028923|NCT05914350|Drug|medical ozone|10 ml of medical ozone
76028924|NCT05914337|Behavioral|exercise|A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.
76028925|NCT05914337|Biological|gene expressions of miRNA|In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
76028926|NCT05914324|Device|Phefumla device|The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.
76028927|NCT05914324|Device|LB-01 device|The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
76028928|NCT05914298|Diagnostic Test|blood and buccal swab genetic test|blood samples and buccal swabs will be obtained from patients with HME in order to analyze the genotype (EXT1 or EXT2 mutations) and correlate the genotypic pattern with the phenotypic presentation
76028929|NCT05914298|Diagnostic Test|PUL|measurement of ulnar length with anthropometer and patient's height
76028930|NCT05914298|Diagnostic Test|Range of motion|measurement of range of motion of elbow, forearm and wrist
75375481|NCT05470465|Drug|Paroxetine and Oxycodone|Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
75375482|NCT05470465|Drug|Escitalopram and Oxycodone|Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
75375483|NCT00368030|Drug|Eszopiclone|Eszopiclone 3 mg QD
75375484|NCT00368030|Other|Placebo|Placebo tablet
75375485|NCT02656069|Drug|G-Pen (glucagon injection)|1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
75375486|NCT02656069|Drug|Lilly Glucagon (glucagon injection [rDNA origin])|1 mg of Lilly glucagon reconstituted from lyophilized powder
75375487|NCT00368186|Biological|Pneumo 23|
75375488|NCT02707172|Behavioral|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
75375489|NCT02707172|Behavioral|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
75375490|NCT05351762|Drug|Nimotuzumab Combined With Neoadjuvant Chemotherapy|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
75375491|NCT05346536|Other|Detection of circulating tumor cells expressing Axl: CTC-AXL(+)|"Detection of CTC-AXL(+) using 2 techniques:~CellSearch®, FDA-USA approved technology~EPIDROP System~CellSearch® (Menarini Company) The current gold-standard CellSearch® technique requires the use of CellSave tubes. This technique allows the isolation of fixed CTCs. This technique uses a positive (CellSearch® Epithelial Cell Kit) enrichment method from total blood using magnetic beads coupled to an EpCAM capture antibody. CTCs are then detected (anti-panCK antibodies, DAPI, anti-CD45 and characterized (anti-AXL antibody) by immunofluorescence (IF).~EPIDROP It requires the use of EDTA tubes. This technique is based on a method of negative enrichment of CTCs from total blood using a cocktail of tetrameric antibodies to eliminate unwanted blood cells and to preserve only purified tumor cells (RosetteSep - StemCell Technology).Then, cells are loaded in a microfluidic chip. The detection and characterization is done by IF to the single cell in micro-droplets."
75375492|NCT02683772|Device|Astral|Astral ventilator
76028931|NCT05914285|Drug|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
76028932|NCT05914285|Drug|2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline|After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
76028933|NCT05914272|Drug|Osmotic drugs|Patients had used osmotic drugs within 72 hours of admission.
75701785|NCT04084808|Behavioral|High Intensity Interval Training bouts|6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
76028934|NCT05914246|Device|VIOLA proximal seal|VIOLA proximal seal system for maintenance of hemostasis when suturing the aortic anastomoses
76028935|NCT05914220|Device|AI Insights Application|Predictive AI Model Risk score
75375493|NCT02708641|Drug|pembrolizumab|200 mg IV given every three weeks
75538678|NCT04008797|Drug|E7386|E7386, tablets, orally.
75538679|NCT04008797|Drug|Lenvatinib|Lenvatinib, capsules, orally.
75538680|NCT03999229|Drug|SNO|S-nitrosylating agent (SNO) Inhalation
75538681|NCT03999229|Drug|Normal Saline|Normal Saline transfusion
75538682|NCT03999229|Drug|Red Blood Cell|Blood transfusion (RBCs)
75866280|NCT05416398|Other|Aerobic Exercise, High Intensity Interval Training|Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.
75866281|NCT03685292|Behavioral|Behavioral Advisory System|Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.
75866282|NCT03685292|Drug|Behavioral Treatment|This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
75866283|NCT03685292|Device|Behavioral Division|This study is relative to minimal contact control (MCC).
75701786|NCT00751413|Drug|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
75701787|NCT00757263|Genetic|polymorphism analysis|
75701788|NCT00757263|Other|laboratory biomarker analysis|
75701789|NCT00757263|Other|questionnaire administration|
75701790|NCT00919334|Device|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
75866284|NCT05416164|Radiation|Omission of radiotherapy|Omission of radiotherapy
75866285|NCT03177694|Device|Wireless bed sensor|Remote data collection
75866286|NCT01363245|Behavioral|Telephone Counseling|Telephone counseling: 7 calls over 6 weeks
75866287|NCT01363245|Behavioral|Fax-to-quit|referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
75866288|NCT03685214|Drug|0.9% saline|we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
75866289|NCT03685214|Drug|lactated Ringer's solution|we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
75866290|NCT01359813|Drug|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
76028936|NCT05914207|Behavioral|Lifestyle modifications|Written suggestions on lifestyle modifications including duration of sleep, meal frequency, reduce screen time, exercise duration, food to avoid.
76028937|NCT05914207|Other|Vestibular rehabilitation exercise|Each participant will be taught simple home-based vestibular rehabilitation exercise, which needs to be repeated
76028938|NCT05914168|Device|Breast Tomosynthesis|Three dimensional mammography
75538683|NCT03994601|Drug|BMS-986288|Specified dose on specified days
75538684|NCT03994601|Drug|Nivolumab|Specified dose on specified days
75538685|NCT03994601|Drug|Regorafenib|Specified dose on specified days
75538686|NCT03978598|Drug|Etonogestrel|Immediate v. Standard insertion.
75538687|NCT03978598|Device|Nexplanon|Implant.
76028939|NCT05914129|Other|Diaphragm, Stomach and Liver techniques|"Diaphragm Stretching:~The participant is seating down and the researcher will be behind, placing their hands on the inferior costal border. Cephalic traction is performed during inhalation, remaining during exhalation. Procedure is repeated 2 times, for 10 respiratory cycles, with 1-minute intervals.~Inferior Mobilization of the Stomach:~The participant is seating down with slight flexion of the torso, while the investigator stands behind them, placing the thumbs on the epigastric region. The volunteer will extend their body while the researcher performs a caudal traction. This procedure lasts 5 minutes.~Liver Pump:~Participant is laying on their back, and the investigator is standing on the participants side. The researcher places one hand on the right side inferior costal border posteriorly and the other one bellow the costal border anteriorly. Researcher compresses during exhalation and releases their hands abruptly during inhalation. This procedure lasts 5 minutes."
76028940|NCT05914129|Other|Stomach and Liver techniques|In this group, techniques are the exact same as described previously but only liver and stomach ones will be performed.
76028941|NCT05914129|Other|Sham technique|In the sham group, manual contact without any therapeutic intention will be performed in the same regions as the experimental groups. This contact will be maintained during the same amount of time as for the experimental group A.
76028942|NCT05915494|Other|intermittent pneumatic compression, physiotherapy, and walking|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
75538688|NCT03969056|Behavioral|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
75538689|NCT03969056|Behavioral|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
76028943|NCT05915494|Other|physiotherapy and walking|in this children group, n = 20, for 12 weeks, traditional physical therapy program (chest physical therapy, flexibility exercises, range of motion exercises) will be handled. Also, free walking for 30 minutes daily will be performed by children.
76028944|NCT05914103|Procedure|ERAS|The primary endpoint is the rate of composite outcomes. The composite outcomes include the major adverse cardiac events (MACE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI)
75701791|NCT00751491|Drug|Adenosin|Intracoronary Adenosin 50 microg;
75701792|NCT00751491|Other|placebo|no intervention
75701793|NCT00751491|Drug|Clopidogrel|Clopidogrel 300/600 mg
75701794|NCT05685056|Behavioral|Text messages|Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
75701795|NCT02561169|Drug|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
75866291|NCT03183310|Drug|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
75866292|NCT03183310|Device|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
75866293|NCT03183310|Drug|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
76028945|NCT05914064|Device|Gravitas FT and Gravitas FT Monitor guidance|FT placed with guidance from the Gravitas FT system
76028946|NCT05914064|Device|Gravitas FT System without placement guidance|SOC placement
76028947|NCT05914051|Other|Colloid preload|250 cc of colloid preload solution will be infused in the intervention group
76028948|NCT05914025|Behavioral|Behavioral Activation|Individuals will be provided with information about maladaptive patterns of behavior and how to correct these cycles with activity scheduling to elicit more positive emotional experiences. Participants will be provided with categories/lists of activities and a downloadable calendar after receiving the psychoeducation.
76028949|NCT05914012|Other|Telerehabilitation based on Otago Exercise Program|It took a total of 21 sessions, 7 days a week for 3 weeks. The sessions lasted 30 minutes. It is recommended to do exercises with comfortable shoes at least 1 hour after a meal. Each of his exercises will be videotaped and numbered and delivered to the intervention group via social networks and the Internet or by memory. In each exercise session, the physiotherapist followed the exercise sessions through social networks and answered questions from the older adults.
75375494|NCT02657629|Other|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
76028950|NCT05913986|Dietary Supplement|LUDLEV®300 mg/46.2 mg|LUDLEV®300 mg/46.2 mg once day
75866294|NCT03685058|Device|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
75375495|NCT02657629|Other|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
75375496|NCT02683928|Biological|GBR 830|
75538690|NCT03953976|Radiation|Intensity modulated radiation therapy (IMRT)|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). 6.5-7 weeks of radiotherapy or chemoradiotherapy
75866295|NCT03685058|Other|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
76028951|NCT05913986|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
76028952|NCT05913960|Device|sham stimulation|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
76028953|NCT05913960|Device|accelerated intermittent theta burst stimulation|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
75375497|NCT02683928|Biological|Placebo|
76028954|NCT05913960|Device|high frequency stimulation|"Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
75375498|NCT02708186|Drug|Nelotanserin|once daily, oral, 20-mg tablets
75375499|NCT02708186|Drug|Placebo|once daily, oral, matching tablets
75375500|NCT02710591|Drug|Rimeporide|"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight > 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight > 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight > 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight > 30kg at Baseline"
75375501|NCT04339322|Other|Follow up|Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
75375502|NCT02710981|Drug|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
75375503|NCT02710981|Drug|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
75375504|NCT04189796|Dietary Supplement|Cheese|Daily oral intake of cheese
75866296|NCT05415930|Other|Psychosocial assistance|Firs evaluation at Acceptess-T locals by a health mediator specialised in transidentity : advice for administrative procedures (health insurance, residency permit, housing, etc.) management of others social issues Orientation to Acceptess-T sexual health space for medical evaluation Orientation to Acceptess-T mental health space if needed : special focus on sexual health and gender related issues
75375505|NCT02711839|Dietary Supplement|Commercial diabetic formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
75866297|NCT05415930|Other|Medical care|Sexual health clinics at Acceptess-T health space First STI risk evaluation: HIV, HCV, HBV, syphilis TROD realisation Spanish speaking Infectious Diseases (ID) specialist (from ID Department of Bichat hospital) first evaluation Proposition of PrEP if indicated Orientation for hospital follow-up in dedicate PrEP clinics Prescription and follow-up of a feminazing hormonal therapy if needed
75375506|NCT02711839|Dietary Supplement|White sweet potato formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
75375507|NCT04738838|Drug|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
75538691|NCT03951649|Drug|Occipital Nerve Block|This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
75538692|NCT03949855|Drug|Belimumab|"Belimumab is a recombinant, human, IgG1λ monoclonal antibody.~Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.~Standard Weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
75866298|NCT05415930|Other|Legal-Administrative Assistance|Legal counselling, provided by a sex worker union representative Access to FAST (fond action social trans) which give an economic help to TW in high precarity situations
76028955|NCT05913947|Drug|Lithium|The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
76028956|NCT05913947|Drug|Cariprazine|The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
76028957|NCT05913934|Behavioral|Gait analysis|Walk over 25 meters in a gym (GaitUp) Walk over 6 meters with footscan v9 in the office
76028958|NCT05913856|Other|Normal saline|Normal saline will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
76028959|NCT05913856|Other|Chlorhexidine|15ml of 0.12% chlorhexidine will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
76028960|NCT05913843|Device|Take photo|We will use the camera to take 2 front and side images of the participant, and select one of the better images to upload to the facial analysis system (GestaltMatcher Database) for analysis.
76028961|NCT05913830|Other|Auricular pressure|The seeds of blancia blanc were fixed on the acupoints with patches. The intervention measure in the experimental group was auricular point sticking. The two groups received four measurements before the intervention and 2 weeks, 4 weeks, and 6 weeks after the start; while the control group received no Auricular pressure.
75375508|NCT04738838|Drug|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
75375509|NCT04738916|Device|Whole-body vibration training|Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
75866299|NCT05415930|Other|Focus Group|"A group of 10-15 TW, identified through convenience sampling, along with the Acceptess-T Health Space multidisciplinary team will be invited to participate in an Human Centered Design (HCD) project.~The project will be led by a team of anthropologists and sociologists and exchanges will be recorded and fully transcribed and analysed by a person competent in qualitative methodology.~The objective will be to co-create tailored solutions that meet the needs of TW and are viable to implement within the health system, so TW can be better managed The solutions ideated will work synergistically towards improving TW PrEP access and adherence and health system retention.This is an adaptative program : if new solutions to face PrEP barriers are created during the study follow-up, new mesures will be added to the intervention."
75375510|NCT05362123|Other|non interventional|Online google form questioner
75538693|NCT03949855|Drug|Placebo for Belimumab|"The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.~Standard weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
75375511|NCT05331404|Radiation|PET examination|PET examinations with auditory stimuli such as human voice and environmental sounds.
75557571|NCT00435617|Device|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
75557572|NCT00435695|Drug|GSK163090|
75866300|NCT03177850|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
75866301|NCT03177850|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
75866302|NCT03102918|Drug|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
75866303|NCT03102918|Drug|Placebo|Participants will receive placebo over a 6-week treatment period.
76028962|NCT05913804|Biological|YTS104 Cells injection|YTS104 Cell injection is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
76028963|NCT05913778|Device|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
76028964|NCT05913765|Device|Air cleaner|Austin Air Healthmate air cleaner with or without standard filter
75375512|NCT05331404|Other|Quality of life assessment|"quality of life assessment by :~Speech, Spatial and Qualities of Hearing~Hearing Handicap Inventory For The Elderly Screening~Short Form Health Survey"
75375513|NCT04739917|Biological|Vaccine PvCS N+C+R 150 mcg|Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
75866304|NCT03676712|Device|scoliosis brace|Wear at least 18 hours a day
75375514|NCT04739917|Other|Placebo SSN Montanide ISA-51 1 mL|SSN Montanide ISA-51 1 mL
75557573|NCT00473538|Behavioral|Structured exercise training|
75538694|NCT03949855|Drug|Rituximab|"Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6."
75701796|NCT02561169|Other|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
75538695|NCT03920267|Drug|BMS-986165|Specified dose on specified days
75701797|NCT00753597|Drug|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
75701798|NCT00751569|Other|blood donation|obtaining cord blood
75701799|NCT00757341|Drug|SKI-606|
75701800|NCT00751647|Other|Physical Therapy|Treatment
75701801|NCT00757419|Drug|AZD3355|capsules, oral, single or twice daily dose
75701802|NCT00757419|Drug|Placebo|To match dosing of AZD3355
75701803|NCT00757497|Behavioral|Electrical Polarization|
75701804|NCT00757653|Device|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
75701805|NCT00757653|Device|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
75701806|NCT00757653|Device|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
76028965|NCT05913674|Drug|Modified early post-operative intraperitoneal chemotherapy (mEPIC)|"On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2."
75538696|NCT03918915|Drug|SYD-101 Dose 1|Sterile topical ophthalmic solution
75538697|NCT03918915|Drug|SYD-101 Dose 2|Sterile topical ophthalmic solution
75538698|NCT03918915|Drug|Vehicle|Sterile topical ophthalmic solution without active ingredient
75538699|NCT03913455|Drug|Guadecitabine|Guadecitabine 30 mg/m2 subcutaneously Days 1-5
75538700|NCT03913455|Drug|Carboplatin|Carboplatin AUC 4 IV Day 5
75538701|NCT03896945|Drug|Placebo|oral capsules
75538702|NCT03896945|Drug|AVP-786|oral capsules
75538703|NCT03894891|Drug|Nivolumab|Nivolumab is a type of immunotherapy.
75538704|NCT03894891|Drug|Cisplatin|Cisplatin is a chemotherapy drug.
75538705|NCT03894891|Drug|Docetaxel|Docetaxel is a chemotherapy drug.
75538706|NCT03894891|Radiation|Intensity-modulated radiotherapy|IMRT is definitive treatment for head and neck cancer.
75701807|NCT03877887|Diagnostic Test|echo cardiogram|Assessment of left ventricular systolic and diastolic function
75375515|NCT02713711|Radiation|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
75375516|NCT02713711|Procedure|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
75375517|NCT02713711|Procedure|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
75701808|NCT00757731|Drug|milnacipran|hard capsule
75375518|NCT02659501|Drug|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
75701809|NCT00757731|Drug|Placebo|hard capsule
75375519|NCT02659501|Drug|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
75557574|NCT00473538|Behavioral|Hypocaloric hyperproteic diet|
75557575|NCT00473577|Drug|CRA-24781|
75557576|NCT00473616|Drug|AZD7762|intravenous infusion
75557577|NCT00473616|Drug|Irinotecan|intravenous injection
75557578|NCT00435734|Behavioral|obesity intervention|
75557579|NCT00481221|Procedure|Observation of results from laboratory tests|Laboratory data summary only
75557580|NCT00435773|Procedure|Single Leeching|
75557581|NCT00435773|Procedure|Repeated Leeching after 4 weeks|
75557582|NCT00435773|Procedure|Placebo Leeching|
75557583|NCT00473733|Procedure|GLP receptors expression|
75701810|NCT00757809|Drug|neratinib|HKI-272
75866305|NCT03684902|Procedure|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
75375520|NCT02659501|Drug|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
75375521|NCT02659501|Drug|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
75375522|NCT02659501|Drug|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
75375523|NCT02718157|Device|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
75375524|NCT00367939|Drug|valsartan + amlodipine|
75375525|NCT02720107|Drug|fingolimod|
75375526|NCT02662387|Device|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
75375527|NCT02662387|Other|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
75375528|NCT02722837|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
75701811|NCT00753831|Procedure|Aurosling|Silicon rod to be used in frontalis suspension surgery
75866306|NCT03183154|Other|no intervention|no intervention
75866307|NCT03128307|Device|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
75866308|NCT03102762|Drug|Botulinum Toxin Type A|Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
75866309|NCT03102762|Drug|Normal saline|The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
75701812|NCT00753909|Drug|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
75866310|NCT03684824|Drug|Long luteal phase GnRH agonist protocol|Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
75375529|NCT02710526|Drug|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
75375530|NCT04339231|Procedure|sphenopalatine ganglion block|"The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa."
75538707|NCT03883490|Diagnostic Test|ECG|A 12-lead ECG will be taken for each participant.
75701813|NCT00753909|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
75701814|NCT00753909|Drug|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
75866311|NCT03684824|Drug|Gonadotropins|Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
76028966|NCT05913661|Drug|Pemigatinib|Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
76028967|NCT05913661|Drug|PD-1 Inhibitors|The dosing regimen is 200 mg IV Q3W
75557584|NCT00473733|Procedure|ESOPHAGOGASTRODUODENOSCOPY|
75557585|NCT00481260|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
75557586|NCT00435851|Drug|Thyrogen, thyroid hormone withdrawal, iode 131|
75701815|NCT04015544|Dietary Supplement|Watermelon|Pureed whole (100%) watermelon
75538708|NCT03883490|Diagnostic Test|Blood test and biobanking|All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.
76028968|NCT05913635|Behavioral|Consumption of lunch and dinner, with no breakfast|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-breakfast intervention day, participants are instructed to fast and only be allowed to consume water until 1.00 p.m. and consume the above-designed lunch and dinner at 1.00 p.m. and 8.00 p.m. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. the following day.
75538709|NCT03883490|Diagnostic Test|Trans-thoracic Echocardiogram|A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.
75701816|NCT00685035|Device|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
75375531|NCT02724787|Behavioral|Manage Emotions to Reduce Aggression (MERA)|MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
75375532|NCT02725645|Other|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
75538710|NCT03883490|Diagnostic Test|Vicorder recording|Measurement of carotid-femoral PWV will be made using the Vicorder technique.
75538711|NCT03883490|Diagnostic Test|Magnetic Resonance Imaging|Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.
75538712|NCT03883412|Other|Exercise|16 weeks of treatment
75538713|NCT03883412|Drug|Liraglutide|16 weeks of Liraglutide
75557587|NCT00435890|Behavioral|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
75557588|NCT00435968|Drug|CVT E002 (Cold-fX)|
75557589|NCT00481338|Procedure|X-rays|X-rays (hip and knee) every 2 years
75557590|NCT00481338|Biological|biological samples|biological sample (blood and urine) every 2 years
75557591|NCT00481338|Other|medical information about osteoarthritis|several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
75866312|NCT02421874|Behavioral|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
75701817|NCT00685035|Device|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
75375533|NCT02664961|Drug|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
75375534|NCT02664961|Drug|Bevacizumab|Bevacizumab will be dosed every two weeks.
75375535|NCT02725801|Device|Allergen one-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
75375536|NCT02725801|Device|AlloX2 two-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
75375537|NCT02665273|Procedure|Greater occipital nerve block|Bilateral greater occipital nerve block
75375538|NCT02665273|Drug|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
75375539|NCT02713178|Drug|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
75375540|NCT02713178|Drug|Placebo|Normal saline.
75375541|NCT02665741|Device|Olympus transparent cap|distal colonoscope attachment
76028969|NCT05913635|Behavioral|Consumption of breakfast and lunch, with no dinner|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-dinner intervention day, participants are instructed to consume the above-designed breakfast and lunch at 7.30 a.m. and 1.00 p.m., and no dinner. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. on the following day.
75866313|NCT02421874|Behavioral|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
75866314|NCT03681002|Behavioral|structured lifestyle program|Intensive Lifestyle counseling during one year
75701818|NCT02560857|Other|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
75538714|NCT03866707|Other|One-time blood draw|"Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size.~Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing.~Metabolomic analysis will be performed by mass spectrometry when funds are available."
75538715|NCT03866707|Other|Evaluation of CpG methylation|Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray.
75538716|NCT03866707|Other|Metabolomic analysis|Metabolomic analysis will be performed by mass spectrometry when funds are available.
75538717|NCT03864614|Drug|SAGE-217|SAGE-217
75538718|NCT03863080|Drug|RVT-1401|Subcutaneous administration of RVT-1401
75701819|NCT00753987|Drug|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
75701820|NCT00757887|Biological|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
75701821|NCT00757965|Genetic|polymorphism analysis|
75538719|NCT03863080|Drug|Placebo|Subcutaneous administration of Placebo
75538720|NCT03843723|Other|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
75538721|NCT03840837|Drug|Rivastigmine transdermal patch|Titration of transdermal rivastigmine, as per arm description.
75538722|NCT03834493|Biological|Pembrolizumab|IV infusion
75538723|NCT03834493|Drug|Enzalutamide|Capsules/Tablets
75538724|NCT03834493|Drug|Placebo|IV infusion
75701822|NCT00757965|Other|laboratory biomarker analysis|
75701823|NCT00757965|Other|questionnaire administration|
75866315|NCT03177538|Drug|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
76028970|NCT05913622|Device|Intra-aortic balloon pump|An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
75538725|NCT03833154|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met.
75538726|NCT03833154|Other|Placebo|Matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met.
75866316|NCT03177538|Drug|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
75866317|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 1
75866318|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 2
75866319|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 3
75866320|NCT01363323|Drug|Placebo|
75866321|NCT01363323|Drug|Moxifloxacin|
75538727|NCT03833154|Drug|Osimertinib (single-arm, open-label)|Osimertinib 80 mg every day [qd] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
75538728|NCT03827057|Behavioral|Reconsolidation of Traumatic Memories (RTM)|"RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with traditional exposure therapies."
76028971|NCT05913596|Drug|Daratumumab|After successful enrollment, the patient will receive daratumumab of 16mg/kg once every two weeks (0-22 weeks) for a total of 12 times. Peripheral blood samples were collected from 0 to 24 weeks (weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24) for routine blood tests, liver and kidney function electrolytes, tacrolimus or cyclosporine trough concentrations, HLA antibody quantification (weeks 0, 4, 8, 12, 16, 20, and 24), infection indicators (weeks 0, 8, and 24), immune status assessments (weeks 0, 4, 8, 12, 16, 20, and 24), and biopsy of transplanted kidneys was performed at 24 weeks to assess pathological changes.
75375542|NCT02665741|Device|Medivators Endocuff|distal colonoscope attachment
75538729|NCT03827057|Behavioral|Prolonged Exposure (PE)|PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.
75538730|NCT03820687|Other|Clinical Trial Educational Video|Bilingual, culturally tailored educational video, low literacy booklet, and support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trial participation.
75538731|NCT03820687|Other|Clinical Trial Fact Sheet|General Clinical Trial fact sheet with usual care information regarding Clinical Trials.
75538732|NCT03820687|Other|Low literacy booklet|A bilingual low-literacy booklet with educational content about clinical trials.
75538733|NCT03820687|Other|Navigator|Support will be provided by a patient navigator to empower cancer patients to make an informed decision about cancer clinical trial participation by increasing awareness of clinical trials and MCC services, positive attitudes, and intentions to consider clinical trials as an appropriate treatment option for cancer.
75866322|NCT03183076|Other|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
75866323|NCT03183076|Drug|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
75866324|NCT04388553|Procedure|single shot lumbar Erector Spinae Plane block|unilateral (operative side), performed at L1 level, under ultrasound guidance
75866325|NCT05415852|Device|Laser|Laser
75557592|NCT00436085|Behavioral|Cognitive behavioral stress management training|
75557593|NCT00473772|Device|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
75557594|NCT03272165|Drug|MEDI1341|Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
75866326|NCT03117244|Other|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
75866327|NCT03117244|Other|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
75866328|NCT01366287|Drug|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
75557595|NCT03272165|Drug|Placebo|Participants will receive IV infusion of placebo matched to MEDI1341.
75557596|NCT00481377|Procedure|ablation|
75557597|NCT00436124|Drug|oseltamivir [Tamiflu]|
75557598|NCT00473811|Behavioral|Low GI|low-GI education
75557599|NCT00473811|Behavioral|ADA diet|ADA dietary education
75557600|NCT01240473|Drug|Randomized trial for treatment of kala azar in Bangladesh|dose of SAG 20 mg/kg body weight, with a maximum dose of 850 mg/day, for 28 days
75866329|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
75375543|NCT02665741|Device|Control|No distal colonoscope attachments
75375544|NCT05267756|Device|(kurki-application),VR glasses|it is virtual reality immersive based-exercise game
75375545|NCT02726971|Drug|Femoston|Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
75375546|NCT04121936|Other|There will be no intervention|There will be no intervention
75375547|NCT04048850|Drug|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Daily medication
75557601|NCT02957474|Drug|GED-0301|
75557602|NCT02957474|Drug|Omeprazole|
75557603|NCT00481416|Device|PillCam Eso|
75538734|NCT03818854|Biological|Human Mesenchymal Stromal Cells|Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.
75538735|NCT03818854|Biological|Cell Reconstitution Media|300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
75538736|NCT03810196|Device|CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback|Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.
75538737|NCT03808558|Drug|TVB-2640|TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.
75538738|NCT03774082|Drug|INC424|Ruxolitinib is taken orally either as 5mg tablets or as pediatric formulation (dosage based on age group)
75538739|NCT03770416|Drug|Ibrutinib|Given PO
75538740|NCT03770416|Biological|Nivolumab|Given IV
75866330|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
75866331|NCT03177382|Radiation|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
75866332|NCT03177382|Radiation|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
75866333|NCT03177382|Procedure|TME|The TME operation will be given after the end of the neoadjuvant treatment.
75375548|NCT02727751|Drug|Tenapanor|
75866334|NCT03177382|Drug|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
75866335|NCT05190861|Diagnostic Test|droplet digital PCR method|The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.
75866336|NCT05190861|Diagnostic Test|blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.
75866337|NCT03177304|Other|Web based IPT Training|
75866338|NCT05760222|Other|Acupuncture|Acupuncture for prevention/early treatment of vasomotor symptoms and sleep impairment in LHRHa induced amenorrhea in Breast Cancer patients
75866339|NCT03106948|Drug|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
75375549|NCT05165329|Combination Product|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder. Probiotic will be prepared under strict Food Manufacturing Regulations. The daily dose of 2x10^10 cfu will be packed individually in sachets. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic must be stored at 4 degrees Celsius
75538741|NCT03762590|Other|Doxy.me genetic education +/- Color Genomics genetic education|"Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website."
75538742|NCT03762590|Other|Color Genomics genetic education|Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
75538743|NCT03729518|Radiation|Radiation Therapy (IMRT or IMPT)|"Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling."
75538744|NCT03694158|Drug|Dupilumab|anti-IL4 receptor antagonist
75538745|NCT03694158|Other|Placebo|Placebo for Dupilumab (packaged/administered the same as the active drug)
75701824|NCT05435079|Device|high-flow oxygen therapy device for tracheotomized patients|From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher & Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
75538746|NCT03682081|Device|Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)|An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
75557604|NCT00434720|Device|GlideScope Specific Stylet|
75866340|NCT03106948|Drug|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
75866341|NCT03106948|Drug|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
75866342|NCT01366365|Drug|methylnaltrexone|
75375550|NCT05165329|Combination Product|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
75375551|NCT05165329|Combination Product|PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
75375552|NCT02713256|Drug|CFZ533|CFZ533 intravenously over approximately one hour
75866343|NCT01366365|Drug|placebo|
75866344|NCT01881048|Dietary Supplement|Omega-3 fatty acid|Given PO
75866345|NCT01881048|Drug|Celecoxib|Given PO
75866346|NCT03177148|Behavioral|Intervention by Clinicians|PCPs deliver 4 sessions of MI in person, and RDs deliver 6 sessions of MI via telephone. PCPs and RDs will receive 2 days of MI training.
75375553|NCT05153551|Other|Play-based assessment (RITA-T)|"The RITA-T is a play-based assessment that involves nine different activities that can be done safely with a child seated in the exam room. After scoring the RITA-T, the PEARS PCP will immediately provide feedback to the parent regarding results and next steps.~In addition, parents will complete certain assessments/surveys during the study to evaluate the program."
75375554|NCT05152849|Drug|AXA1125|AXA1125 administered BID with or without food
75375555|NCT05152849|Drug|Placebo|Matching Placebo administered BID with or without food
75866347|NCT03177148|Behavioral|Usual Care|PCPs provide care as normal
75375556|NCT02714504|Drug|Voriconazole or posaconazole|Azole with activity against molds
75557605|NCT00465231|Drug|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
75557606|NCT00465231|Drug|preservative free saline|10mL saline solution
75375557|NCT02665975|Behavioral|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
75375558|NCT02665975|Behavioral|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
75375559|NCT02718248|Device|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
75375560|NCT02718248|Behavioral|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
75538747|NCT03682081|Device|Biotene Oral Balance Gel|Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.
75538748|NCT03681223|Device|Vertessa® Lite Y mesh|Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
75538749|NCT03681223|Device|Restorelle® Y mesh|Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
75538750|NCT03681223|Procedure|Laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
75538751|NCT03681223|Procedure|Robotic assisted laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
75538752|NCT03675282|Drug|(11C)PE2I|Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
76028972|NCT05913583|Drug|Immune checkpoint inhibitor|"Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1."
75538753|NCT03675282|Drug|Ioflupane|Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
75538754|NCT03643861|Radiation|5 Fraction Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
75538755|NCT03631043|Procedure|Biopsy Specimen Radiography|Undergo collection of blood and bone marrow
75538756|NCT03631043|Drug|Lenalidomide|Given PO
75701825|NCT02560155|Drug|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
76028973|NCT05913570|Drug|Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody|10mg/kg, Q3W for 4 cycles
75538757|NCT03631043|Biological|Vaccine Therapy|Given personalized vaccine SC
75538758|NCT03613103|Device|Video laryngoscopy|Intubation with videolaryngoscopy with highly curved blade
75538759|NCT03613103|Device|Direct laryngoscopy|Intubation with direct laryngoscopy with macintosh blade
75538760|NCT03609580|Drug|Tamsulosin - 1 week|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
75538761|NCT03609580|Drug|Tamsulosin - 3 days|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
75557607|NCT00436202|Behavioral|Iron supplement|
75557608|NCT00473928|Drug|POT-4|Single intravitreal injection.
75557609|NCT00436241|Drug|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
75701826|NCT02560155|Drug|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
75375561|NCT02668003|Behavioral|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
75375562|NCT00368576|Drug|SB 480848, tablets|
75375563|NCT02724800|Behavioral|CBTI|28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
75375564|NCT02724800|Behavioral|BBTI|28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
75375565|NCT02730247|Drug|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
75375566|NCT02730247|Drug|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
75375567|NCT03889106|Drug|Ribavirin|Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
75375568|NCT04738604|Other|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany|The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
75375569|NCT04738604|Other|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
75375570|NCT00369200|Drug|AFP464|Given IV
75375571|NCT00369200|Other|laboratory biomarker analysis|Correlative study
75375572|NCT00369200|Other|pharmacological study|Correlative study
75375573|NCT02730403|Other|Treatment As Usual|
75375574|NCT05207618|Dietary Supplement|ARBOX (QUEBRACHO AND CHESNUT EXTRACT)|ARBOX TWICE A DAY FOR 60 days
75375575|NCT02669329|Device|CoolSculpting device with vacuum applicator.|The CoolSculpting device with a vacuum applicator will be used to perform the treatments.
75375576|NCT02727842|Device|CP950 Sound Processor|An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
75375577|NCT02727842|Device|Wireless programming pod|The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
75375578|NCT00368329|Drug|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg & 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
75375579|NCT00368329|Drug|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
75375580|NCT00368329|Drug|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
75375581|NCT00368329|Drug|Carboplatin|AUC 2, based onCalvert formula IV infusion
75538762|NCT03602521|Other|Interpersonal stress|"Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"
75538763|NCT03584932|Behavioral|LINK2 Youth Services Navigation Intervention|There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
75538764|NCT03583710|Drug|Cisplatin|Given IV
75538765|NCT03583710|Drug|Etoposide|Given IV
75538766|NCT03583710|Drug|Mitotane|Given PO
75538767|NCT03583710|Other|Quality-of-Life Assessment|Ancillary studies
75538768|NCT03577522|Device|Avenir cementless hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
75538769|NCT03577522|Device|Corail HA-coated hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
75538770|NCT03569891|Genetic|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
75538771|NCT03569891|Biological|Factor IX (FIX)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
75538772|NCT03564093|Drug|Intranasal Drug|1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
75538773|NCT03564093|Drug|Intranasal Drug|Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
75538774|NCT03520101|Procedure|TAVI_ViV procedure with Edwards valve|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is >18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.
75538775|NCT03520101|Procedure|TAVI_ViV procedure with CoreValve system|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.
75538776|NCT03500991|Biological|HER2-specific chimeric antigen receptor (CAR) T cell|Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
75538777|NCT03483103|Biological|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
75375582|NCT02670343|Drug|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
75375583|NCT02730260|Behavioral|Nondirective smoking cessation coaching|Quitline coach allows participant to set agenda for each call.
75375584|NCT02730260|Behavioral|Directive smoking cessation coaching|Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
75538778|NCT03482479|Drug|Naltrexone Hydrochloride|Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks
75375585|NCT00368407|Device|308-nm excimer laser|
75538779|NCT03482479|Other|Placebo Comparator|A placebo tablet which matches the drug will be taken daily for 6 weeks.
75375586|NCT00367549|Dietary Supplement|Energy-containing soft drink|Commercial energy/sports drink
75375587|NCT05128370|Other|Visual observation of arm swing during walking|The gait pattern of the stroke patients will be scored based on a visual observation scale. Additional components concerning the arm swing have been added to an existing scale.
75375588|NCT02730884|Drug|Rigosertib|Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
76028974|NCT05913557|Behavioral|Radically Open Dialectical Behavior Therapy (RO DBT)|Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
75538782|NCT03449108|Biological|Aldesleukin|Given IV
75538783|NCT03449108|Biological|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
75538784|NCT03449108|Biological|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Given IV
75538785|NCT03449108|Drug|Cyclophosphamide|Given IV
75866348|NCT01363557|Other|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
75538786|NCT03449108|Drug|Fludarabine|Given IV
75538787|NCT03449108|Biological|Ipilimumab|Given IV
75538788|NCT03449108|Biological|Nivolumab|Given IV
75538789|NCT03449108|Other|Quality-of-Life Assessment|Ancillary studies
75866349|NCT01363557|Drug|Gefitinib (IRESSA)|250 mg/day
75375589|NCT02730884|Behavioral|Questionnaire|Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
75375590|NCT02732587|Drug|Saracatinib|Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
75375591|NCT02731820|Dietary Supplement|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
75375592|NCT02731820|Dietary Supplement|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
75375593|NCT02731820|Dietary Supplement|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
75375594|NCT02731820|Dietary Supplement|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
75375595|NCT02732899|Drug|Sirolimus|
75375596|NCT02732899|Drug|EYLEA|
75375597|NCT04339153|Behavioral|Parent Training for Disruptive Behaviours|Critically, PT also involves education about autism during the initial sessions, and thus benefits of PT are inferred to come from the specific training.
75375598|NCT03647462|Device|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
75375599|NCT02733757|Drug|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
75375600|NCT00368264|Drug|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
75375601|NCT00368264|Drug|placebo|azathioprine (2 mg/kg) plus four placebo infusions
75375602|NCT05086406|Other|Combination of Video and Virtual Pre-operative Counseling|Intervention will be a pre-operative counseling video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications.
75375603|NCT02734147|Drug|Ascorbic Acid|
75375604|NCT02734147|Other|Normal Saline|
75375605|NCT00368342|Drug|Erythromycin, Azithromycin , Clarithromycin|
75375606|NCT02673541|Device|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
75375607|NCT02673541|Device|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
75375608|NCT02732366|Behavioral|Group-based exercise and peer coaching|Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
75375609|NCT02732366|Other|Usual PT and attention control grp class|The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
75375610|NCT03609320|Behavioral|The STOP-HPV Trial 5: Bundle Intervention|This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
75375611|NCT03609008|Drug|Levcromakalim|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
75375612|NCT03609008|Drug|Saline|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
75375613|NCT02732600|Other|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation
75538790|NCT03449108|Other|Questionnaire Administration|Ancillary studies
75375614|NCT02734238|Drug|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
75375615|NCT02734238|Drug|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
75375616|NCT02734849|Drug|AK001 low dose|25 mg AK001 will be administered as multiple doses
75375617|NCT02734849|Drug|AK001 high dose|250 mg AK001 will be administered as multiple doses
75538791|NCT03415685|Device|PicoPlus laser system|Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
75538792|NCT03414242|Other|Cervical spine musculature|Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
75375618|NCT02734849|Drug|Placebo|Placebo will be administered as multiple doses
75375619|NCT04707547|Biological|immunotherapy with Nivolumab|After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.
75375620|NCT04707547|Procedure|Radiofrequency Ablation|The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
75375621|NCT02735551|Drug|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
75538793|NCT03412747|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
75557610|NCT00436241|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
75375622|NCT02735551|Other|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
75375623|NCT02735551|Other|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
75375624|NCT02736175|Drug|Dexamethasone|
75701827|NCT05331638|Behavioral|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
75866350|NCT02416336|Device|Sentinella Intraoperative imaging protocol|"There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.~In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed."
75866351|NCT01360125|Genetic|proteomic profiling|
75866352|NCT01360125|Other|flow cytometry|
75866353|NCT01360125|Other|laboratory biomarker analysis|
76028975|NCT05913544|Other|SINTYA|10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session
76028976|NCT05913505|Behavioral|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
75375625|NCT02736175|Other|Placebo Vehicle|
75375626|NCT02735174|Device|Sensor cap system for inhalers|All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
75375627|NCT02735174|Other|App for SmartPhone|All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
75375628|NCT02735174|Behavioral|Motivational interviews|All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
75375629|NCT02735174|Other|Telehealth clinic visits|All subjects will have asthma medical visits via telehealth technology to assess asthma control.
75375630|NCT02735642|Behavioral|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
75866354|NCT02425540|Device|Pelvic MRI|
75375631|NCT02735642|Behavioral|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
75375632|NCT02735642|Behavioral|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
75866355|NCT01804296|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
75866356|NCT01346475|Drug|valacyclovir|1000 mg orally three times daily for 5 weeks
75866357|NCT01346475|Drug|Valacyclovir|500 mg orally once daily for 5 weeks
75866358|NCT02416414|Device|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
75866359|NCT02416414|Device|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
75538794|NCT03412747|Drug|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
75701828|NCT05331638|Behavioral|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
75701829|NCT00758121|Device|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
75701830|NCT02559921|Biological|rhRIG（20 IU/kg）|
75701831|NCT02559921|Biological|rhRIG（40 IU/kg）|
75701832|NCT02559921|Biological|HRIG（20 IU/kg）|
75866360|NCT05415306|Behavioral|Attention Bias Modification|Attention bias modification (ABM) is a procedure for treatment of depression, with the intention of supplementing cognitive behavioural therapy (CBT) or as a treatment on its own. ABM procedures modify attention biases in emotional disorders, resulting in subjects learning to deploy their attention toward the more positive stimuli (Jonassen et al., 2018). A computerized attention bias modification intervention for depression involves repeatedly redirecting the attention of the subject away from emotionally relevant threat cues, and towards neutral (non-threatening) stimuli (Amir et al., 2009). The location of the probe will replace the relatively positive stimulus in the pair with 100% probability.
76028977|NCT05913505|Behavioral|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
75375633|NCT02735642|Behavioral|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
75375634|NCT02735642|Behavioral|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
75375635|NCT02735642|Other|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
75375636|NCT03449576|Other|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
75375637|NCT03449576|Other|Exposure Therapy with Psychotherapy group|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
75375638|NCT05446610|Other|Fermented product of Pleurotus eryngii mushroom|I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
75375639|NCT02736955|Drug|Valbenazine|
75375640|NCT00369356|Drug|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
75375641|NCT00369356|Device|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
75701833|NCT02559921|Biological|rhRIG（20 IU/kg） and vaccine|
75701834|NCT02559921|Biological|rhRIG（40 IU/kg） and vaccine|
75701835|NCT02559921|Biological|HRIG（20 IU/kg） and vaccine|
75701836|NCT02559921|Biological|placebo and vaccine|
75701837|NCT00754143|Drug|FG-3019|Placebo every 2 weeks IV for all infusions
75701838|NCT00754143|Drug|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
75701839|NCT00754143|Drug|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
75701840|NCT02588768|Device|Photobiomodulation therapy (Phototherapy)|PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
75701841|NCT04083248|Behavioral|Feasibility group|Same as arm description
75701842|NCT05266040|Drug|Valacyclovir 500 MG|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
75701843|NCT05266040|Drug|Placebo|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
75701844|NCT02588924|Other|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
75701845|NCT02588924|Other|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
76028978|NCT05913492|Behavioral|Simulation training|"Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later."
75375642|NCT00369356|Device|Bare metal coronary stent|Stenting with BMS only
75538795|NCT03412747|Other|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
75538796|NCT03410992|Drug|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
75701846|NCT05325710|Behavioral|Study nurse intervention|Contact everay 4 months with a dedicated study nurse
75701847|NCT00773747|Drug|Vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
75701848|NCT00773747|Drug|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
76028979|NCT05913466|Drug|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
75701849|NCT00773747|Drug|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
75701850|NCT04104269|Diagnostic Test|Heart rupture|Free wall rupture and Ventricular septal rupture
75701851|NCT04104191|Device|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
75701852|NCT00784277|Drug|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
75701853|NCT00784277|Drug|oxycodone IR|10mg for 14 days
76028980|NCT05913466|Drug|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
75538797|NCT03410992|Other|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
75701854|NCT00784277|Drug|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
75701855|NCT00784277|Drug|Tapentadol IR (CG5503)|50mg for 14 days
75701856|NCT00784277|Drug|Tapentadol IR (CG5503)|75mg for 14 days
75701857|NCT00784277|Drug|placebo|1 capsule for 14 days
75866361|NCT05415306|Behavioral|Deep-breathing training|In most deep breathing studies, participants are required to alter their breathing pattern to a specific frequency for a specific duration of time. In the present study, participants will be required to perform deep-breathing at a rate of 6 breaths per minute for 9 minutes.
75866362|NCT05415306|Behavioral|Sham Training|This condition is identical to the Attention Bias Modification condition with the except of the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
75375643|NCT03409562|Behavioral|motor control training|Exercises to strengthen the lumbar musculature and control the posture.
75538798|NCT03394079|Procedure|PCI|Percutaneous Coronary Intervention
75538799|NCT03386396|Dietary Supplement|High protein/low carbohydrate|A high protein/low carbohydrate shake will be given to the child.
75538800|NCT03386396|Dietary Supplement|High carbohydrate/low protein|A high carbohydrate/low protein shake will be given to the child
75701858|NCT00784277|Drug|placebo|Tablets and capsules 2 x a day for 28 days
75701859|NCT05116748|Biological|COVID19 mRNA vaccine|Administration of COVID19 mRNA vaccine
75701860|NCT05254964|Procedure|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
75701861|NCT05071274|Device|Skinpen Prescision System|Skinpen Precision is an automated nonsurgical micro needling device designed for use by licensed health care practitioners or individuals directed by practitioners. The device incorporates a sterile Microneedle cartridge and Biosheath for single use only.
75701862|NCT02588534|Device|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
75701863|NCT02588534|Other|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
75375644|NCT03409562|Behavioral|pain neurophysiology education|Educational sessions to improve patient's neurophysiology of pain knowledge.
75701864|NCT05103878|Drug|BT051 100mg|Single oral dose of 100mg BT051
75701865|NCT05103878|Drug|BT051 300mg|Single oral dose of 300mg BT051
75701866|NCT05103878|Drug|BT051 700mg|Single oral dose of 700mg BT051
75701867|NCT05103878|Drug|BT051 1500mg|Single oral dose of 1500mg BT051
75701868|NCT05103878|Drug|BT051 3500mg|Single oral dose of 3500mg BT051
75701869|NCT05103878|Drug|Matching Placebo|Placebo Matching BT051
75701870|NCT00682929|Drug|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
75701871|NCT00682929|Drug|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
75866363|NCT02417038|Device|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
75375645|NCT05446441|Procedure|Endoscopic surgery;|Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.
75375646|NCT03357224|Drug|Atezolizumab|Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
76028981|NCT05913427|Drug|Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG|"EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.)."
75375647|NCT02677753|Radiation|Fluoroscopy|
75866364|NCT02425384|Behavioral|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
75375648|NCT04958798|Behavioral|Culturally Centered MOUD Implementation Intervention|Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
75375649|NCT02679469|Drug|nalmefene hydrochloride 10 mg|
75701872|NCT00682929|Drug|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
75866365|NCT02425384|Behavioral|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
75701873|NCT00682929|Drug|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
75701874|NCT02588690|Procedure|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
75701875|NCT02588690|Other|Atherosclerosis Cardiovascular Disease Risk assessment|"This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol <190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status."
75701876|NCT02588690|Procedure|Blood pressure measurement|Blood pressure measurement
75701877|NCT00758199|Drug|Bromfenac|Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
75701878|NCT00758199|Drug|Moxifloxacin hydrochloride|Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
75701879|NCT00758199|Drug|Prednisolone Acetate|Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
75866366|NCT02425384|Other|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
75375650|NCT05445973|Procedure|Percutaneous Radiofrequency Ablation|In brief, ablation was performed using a 200-W multichannel generator and a switching monopolar technique with separate clustered electrodes. Tumor targeting was done under the guidance of CEUS-CT/MRI FI, and the ablation procedure was monitored with US-FI. The ablation procedure was terminated when the operator expected to complete the ablation of the index tumor with a minimum 5-mm ablative margin on the US-FI images.
75866367|NCT05754060|Other|Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
75375651|NCT05445986|Procedure|flap elevation and guided bone regeneration|to rebuild the alveolar ridge convexity
76028982|NCT05913427|Drug|Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
75375652|NCT05445986|Procedure|gap filling|to use biomaterials to fill the jumping gap
75375653|NCT05445986|Procedure|connective tissue graft|to change the soft tissue phenotype by connective tissue graft
76028983|NCT05913414|Drug|Iron Isomaltoside 1000|Patients receive Iron isomaltoside after IC and CCRT
76028984|NCT05913414|Drug|Polysaccharide Iron Complex Pill|Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
75375654|NCT02681809|Drug|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
75375655|NCT02681809|Drug|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
75375656|NCT02681809|Drug|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
75375657|NCT05445661|Device|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
75375658|NCT05445661|Other|Normal Saline|Sham Comparator
75538801|NCT03383445|Procedure|Edwards|The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20, 23 or 26 mm).
75538802|NCT03383445|Procedure|CoreValve|The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).
75538803|NCT03383445|Procedure|Acurate neo|The TAVR procedure will be performed with the ACURATE neo aortic valve.
75538804|NCT03383445|Procedure|Standard|The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.
75538805|NCT03370913|Biological|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
75538806|NCT03364660|Device|Epidural Stimulation|Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord.
75538807|NCT03364660|Biological|Stand Training|Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame.
75538808|NCT03348150|Procedure|Cytoreductive surgery + Gastrecomy|Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.
75538809|NCT03348150|Drug|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
75538810|NCT03342404|Drug|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
75538811|NCT03342404|Other|Placebo|Placebo, Subcutaneous, every 21 days
75538812|NCT03342404|Other|Best Supportive Care (BSC)|Best Supportive Care (BSC)
75538813|NCT03329599|Drug|Polycap|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
75538814|NCT03277196|Drug|Ivacaftor|Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the morning dose of the Week 96 Visit.
75538815|NCT03272698|Drug|Ketamine|IV Ketamine 0.50 mg/kg
75538816|NCT03272698|Procedure|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
76028985|NCT05913414|Radiation|Intensity-modulated radiotherapy|All patients received intensity-modulated radiotherapy before enrolled.
76028986|NCT05913362|Behavioral|IVUS based ultralow contrast PCI|IVUS based ultralow contrast PCI
75375659|NCT05445271|Diagnostic Test|Optic nerve sheath diameter measurement with linear ultrasound|In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.
75375660|NCT04805125|Biological|Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)|intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
75557611|NCT00481455|Drug|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
75557612|NCT00481455|Drug|Temozolomide|Fixed dose
75701880|NCT05683808|Drug|Apixaban|Open label
75701881|NCT02559999|Other|Painful tonic stimuli|
75701882|NCT02559999|Other|non-painful stimuli|
75701883|NCT00919490|Drug|ABT-333|Tablet, see arms for interventional description
75701884|NCT00919490|Drug|Placebo|Tablet, see arms for interventional description.
76028987|NCT05913349|Behavioral|Group Cognitive Behavioral Therapy (GCBT)|Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
76028988|NCT05913336|Drug|Remimazolam Tosilate|Loading dose: 0.08mg/kg , Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
76028989|NCT05913323|Device|Rapid Expiratory Occlusion Monitor (REOM)|Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.
75538817|NCT03235492|Device|SmartAlbu|"Plan:~Consent an individual~Measure and record temperature, blood pressure, heart rate, height and weight~Obtain two samples of saliva for the SmartAlbu portable salivary sensor~Take a venous blood sample for HbA1c and~Glycated albumin~Obtain blood sample from a finger stick for point of care HbA1c device"
75866368|NCT03177226|Device|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
75866369|NCT03177226|Device|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
75866370|NCT02416960|Other|Low Glycemic Index Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
75866371|NCT02416960|Other|Conventional Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
75866372|NCT01338636|Drug|Ambrisentan|5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
75538818|NCT03231657|Diagnostic Test|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
75538819|NCT03225482|Behavioral|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
75538820|NCT03225482|Behavioral|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
75866373|NCT02416726|Device|Nextseq500 sequencer|The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
76028990|NCT05913323|Diagnostic Test|Standard oscillometry|tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada
75538821|NCT03213457|Drug|Estradiol/Norethindrone Acetate|Tablets
75538822|NCT03213457|Drug|Placebo for Elagolix|Tablet
76028991|NCT05913323|Diagnostic Test|Standard pulmonary function test|Standard-of-care respiratory test.
75538823|NCT03213457|Drug|Elagolix|Tablet
75701885|NCT05683652|Device|TRAINING BOOKLET|Cancer patients in the intervention group, who will receive immunotherapy for the first time, will be given face-to-face training with the prepared training booklet and followed up by phone. Patients who received immunotherapy after the 1st, 2nd and 3rd cycles, respectively, will be called by phone. The researcher's phone number will be given to the intervention group patients and they will be told that they can call 24/7 if they experience any symptoms. The telephone interview form created by the researcher will be used during the monitoring by telephone.
75701886|NCT05434611|Diagnostic Test|S100A12|The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
75701887|NCT05081570|Device|telecare consultation|Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
75866374|NCT02416258|Drug|LP0113 aerosol spray|
75866375|NCT02416258|Drug|Aerosol spray vehicle|
75866376|NCT02416258|Drug|LEO 90100 aerosol foam|
75866377|NCT02416258|Drug|Betamethasone dipropionate aerosol spray|
75866378|NCT02416258|Drug|Calcipotriol aerosol spray|
75866379|NCT02416258|Drug|Daivobet® gel|
75866380|NCT02410720|Other|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
75866381|NCT02410720|Other|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
75866382|NCT02410720|Other|Explanation of paper and application instructions|The research fellow will explain instructions to patients
75866383|NCT02410720|Other|Picoprep solution|
75866384|NCT02416570|Drug|Clarithromycin|
75866385|NCT02416570|Drug|Placebo|
75866386|NCT02410642|Procedure|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
75538824|NCT03213457|Drug|Placebo for E2/NETA|Tablets
75866387|NCT03176914|Behavioral|prevention and management of childhood illnesses at community level|provision of critical health education and targeted promotion services to the participants in their locality
75866388|NCT03176914|Behavioral|conventional community interventions|community health programs as the sole source of health education
75538825|NCT03207503|Procedure|fMRI|Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
75866389|NCT02416024|Device|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
75375661|NCT04805125|Biological|Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)|intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
75375662|NCT04339075|Other|Questionnaires|Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
75375663|NCT05445115|Device|Mollie device|medical device
75538826|NCT03198078|Drug|Brexpiprazole (OPC-34712)|Once-daily, tablets
75538827|NCT03198078|Drug|Aripiprazole|Once-daily, tablets
75538828|NCT03198078|Drug|Placebo|Once-daily, tablets
75866390|NCT00322218|Drug|Zevalin|"Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one [90Y]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m^2 immediately followed by [90Y]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes."
75866391|NCT02410564|Behavioral|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
75538829|NCT03190057|Device|BIOFREEDOM™ FAMILY stent|Percutaneous coronary intervention with BIOFREEDOM™ FAMILY stent
75866392|NCT02410564|Behavioral|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
75866393|NCT05046730|Device|Ileostomy Reversal using Self Forming Magnets (SFM)|The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
75866394|NCT05200494|Procedure|Recruiting Maneuver|Airway pressure will be increased to 30 cmH2O for 30 seconds at the end of the bronchoscopy
75866395|NCT03176992|Drug|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
75866396|NCT05328336|Drug|Tislelizumab Nab paclitaxel|"Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will"
75866397|NCT02410408|Device|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
75866398|NCT02410408|Other|information package|Information on PSC and RCA
75866399|NCT03176680|Procedure|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
75538830|NCT03181984|Drug|Hemoporfin|Hemoporfin mediated photodynamic therapy
75538831|NCT03165994|Drug|APX005M|APX005M intravenous (IV) infusion
75538832|NCT03165994|Radiation|Radiation Therapy|Radiation therapy, total dose 5040cGy in 180cGy fractions
75538833|NCT03165994|Drug|Paclitaxel|Paclitaxel IV infusion
75538834|NCT03165994|Drug|Carboplatin|Carboplatin IV infusion
75538835|NCT03165994|Procedure|Surgical resection of tumor|Surgical removal of the tumor will occur between weeks 10-16
75538836|NCT03145545|Device|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
75538837|NCT03131817|Device|Activa PC+S Prefrontal|
75375664|NCT05444959|Dietary Supplement|HMB supplementation|Group taking oral HMB free acid supplementation in a blinded liquid form.
75375665|NCT05444959|Dietary Supplement|Placebo treatment|Group taking oral supplementation with placebo (in a blinded liquid form).
75375666|NCT00368017|Drug|pioglitazone|30 mg once a day for 12 weeks
75701888|NCT02589470|Other|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
75701889|NCT02588378|Procedure|multi-modal cSLO imaging|
75701890|NCT00680745|Drug|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
75701891|NCT00680745|Drug|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
75375667|NCT00368017|Drug|placebo|1 pill once a day for 12 weeks
75538838|NCT03105713|Other|Patient Safety Checklist|The intervention is developed, validated and to be implemented in seven surgical clusters in two hospitals, in a stepped wedge cluster randomized controlled trial of the PASC for patients to use.
75375668|NCT04672447|Dietary Supplement|L-Citrulline|Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
75375669|NCT04672447|Dietary Supplement|L-Citrulline|Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
75375670|NCT04672447|Dietary Supplement|Placebo|Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
75538839|NCT03069638|Drug|Dexmedetomidine|Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
75538840|NCT03069638|Drug|Sedatives/Hypnotics,Other|Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
75701892|NCT00680745|Drug|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
75701893|NCT00680745|Drug|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
75701894|NCT00680745|Drug|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
75701895|NCT05434377|Other|ergocalciferol supplementation|Participants in both groups will recieve ergocalciferol with different supplementation regimens for 6 months.
75701896|NCT05434377|Other|dialysis techniques|Both groups will have participants treated with maintenance hemodialysis and peritoneal dialysis.
75701897|NCT05434377|Other|sunlight exposure time|Both groups will be advised to receive similar hours of daily sunlight exposure time.
75701898|NCT05428293|Drug|A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)|Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
75866400|NCT02873754|Behavioral|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
75866401|NCT02873754|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
75866402|NCT02873754|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
76028992|NCT05913310|Drug|Kui-Yuan Chewable Tablets|Kui-Yuan chewable tablets are the optimal ingredients found in sunflower dish that can reduce uric acid and anti-gout, including flavonoids, Coumarin (including scopolamine) and phenolic acids.
75375671|NCT04672447|Dietary Supplement|Glutathione|Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
75866403|NCT02873754|Drug|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
75375672|NCT00367627|Drug|Albendazole|
75375673|NCT05444647|Procedure|stool and blood collection|Patients will collect fecal and blood samples prior to treatment and at the time of response evaluation, and completion of therapy using a standard stool-collection-kit. At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
75375674|NCT04739137|Diagnostic Test|DDiVAT Testing|Participants will self examine his/her distance visual acuity via application in a simulation room of our department with certain predetermined environmental lighting conditions using the same smart devices.
75375675|NCT04739137|Diagnostic Test|Distance visual acuity assessment via ETDRS chart|The distance visual acuity of each participant will be measured with the conventional method via ETDRS chart
75375676|NCT00368485|Device|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
75375677|NCT00368563|Drug|Helioblock SX|
75375678|NCT04633759|Other|Blood Flow Restriction Exercise|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
75375679|NCT05436223|Drug|Human CD19Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
75538841|NCT03054584|Other|Collecting Nevi|Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
75538842|NCT03053791|Procedure|Deep brain stimulation in mesencephalic locomotor region|Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait
75701899|NCT05428293|Drug|A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
75701900|NCT05428293|Drug|A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
75701901|NCT05427825|Other|ERAS anesthetic care|The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
75701902|NCT05427825|Other|Standard anesthetic care|The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
75375680|NCT04536103|Diagnostic Test|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in healthy patients and patients with ACL injury.
75375681|NCT05444179|Behavioral|Mommies can Eat & Exercise with No Stress (MomEENS)|This intervention involving behaviour modification, incorporates nutrition and physical activity modification. The intervention encourages participants to consume a healthy diet and active lifestyle during postpartum period. For nutrition modification, a general advice on healthy nutrition were given and several nutrients are highlighted which evidenced can reduce postpartum depression. While for physical activity, the mothers are encouraged to do exercise, targeting aerobic, flexibility, and strength type of exercise. The exercise protocol is progressive. During the first month, the participants will be advised to conduct flexibility and strength exercises for 8 repetitions (1 set), at least 3 days per week for both aerobic and flexibility exercise. While during the second month, participants are asked to increase repetitions and frequency of exercises, up to 16 repetitions (2 set) for each flexibility exercise, and conduct exercise at least 5 days per week.
75701903|NCT00680121|Drug|Benfotiamine|Benfotiamine 600 mg
75375682|NCT04738903|Procedure|Femtosecond laser assisted LASIK eye surgery|FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.
75701904|NCT00680121|Drug|Placebo|Placebo
75866404|NCT02873754|Drug|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
75866405|NCT02873754|Drug|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
75866406|NCT03287414|Drug|VAY736|300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks
75866407|NCT03287414|Drug|Placebo|Placebo administered subcutaneously every 4 weeks for 48 weeks
75375683|NCT05434897|Drug|AK3280 Cream|Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
75375684|NCT05434897|Drug|Placebo cream|Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
75375685|NCT05443789|Behavioral|Proton pump inhibitor education|A 15 minutes (preferable) one-on-one educational visit about deprescription of proton pump inhibitor
75375686|NCT05443789|Behavioral|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
75538843|NCT03053791|Device|Implantation of a Deep brain stimulation system|Implantation of a Medtronic Activa SC Impulse Generator for chronic Stimulation of the selected target.
75538844|NCT03036098|Biological|Nivolumab|Specified Dose on Specified Days
75538845|NCT03036098|Biological|Ipilimumab|Specified Dose on Specified Days
75538846|NCT03036098|Drug|Gemcitabine|Specified Dose on Specified Days
75538847|NCT03036098|Drug|Cisplatin|Specified Dose on Specified Days
75538848|NCT03036098|Drug|Carboplatin|Specified Dose on Specified Days
75701905|NCT00754533|Other|Continuous versus interval training|Influence of different exercise training programs
75701906|NCT00754689|Drug|Rimonabant|Tablet, oral administration
75701907|NCT00754689|Drug|Metformin|Tablet, oral administration
75701908|NCT00754689|Drug|placebo|Tablet, oral administration
75701909|NCT05375175|Other|Hybrid Snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Hybrid snack: combination of legumes in the highest proportion and lean meat.~It will have the following composition:~Ingredients (%):~Chickpea flour 45.40% Natural emulsifier 0.40% Meat 15.50% Olive oil 1.00% Sunflower oil 4.00% Water 22.50% Onion powder 0.30% Garlic powder 0.20% Thyme 0.60% Tomato powder 10.00%"
75866408|NCT03287414|Drug|Standard of Care (SoC)|Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy
75866409|NCT03174886|Drug|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
75866410|NCT03174886|Drug|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
75866411|NCT05348460|Dietary Supplement|Ketone ester drink (DeltaG®, 500 mg/kg body weight)|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
75866412|NCT05348460|Dietary Supplement|Taste-matched, isovolumic placebo drink|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
75866413|NCT02415790|Drug|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
75866414|NCT02415790|Drug|E2027 matching placebo|E2027 matching placebo capsule will be administered.
76028993|NCT05913310|Drug|Placedo of Kui-Yuan Chewable Tablets|Placedo of Kui-Yuan Chewable Tablets are composed of L-arabinose, food starch and a few auxiliary materials.
76028994|NCT05913297|Diagnostic Test|Magnetic Resonance|Magnetic Resonance
76028995|NCT05913297|Diagnostic Test|Polysomnographic evaluation|Polysomnographic evaluation
75375687|NCT04738747|Behavioral|WHOOP fitness tracker|WHOOP is a device that uses a wristband or arm band to track heart rate, heart rate variability (HRV), and sleep to calculate proprietary strain and recovery scores for its users. Heart rate variability is an important metric for correlation with acute stress
75375688|NCT05443477|Dietary Supplement|Hericium Erinaceus Mycelium|participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
75866415|NCT03644160|Behavioral|Physical activity and behaviour change|The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
75701910|NCT05375175|Other|Meat snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Snack sausage:~Composed solely of meat from loin tape~It will have the following composition:~Ingredients (%):~Shoulder meat 4 mm 94.13% Low sodium salt 3.30% Maltodextrin 1.65% Spices 0.28% Natural dye 0.64%"
75701911|NCT00767819|Drug|Everolimus|2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
75701912|NCT00758277|Drug|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
75701913|NCT00758277|Drug|Placebo|Sugar Pill
75701914|NCT04022447|Drug|Dupilumab|retrospective data collection
75866416|NCT03669614|Drug|Inhaled AR-501|single and multiple ascending doses of inhaled AR-501
75866417|NCT03669614|Drug|Inhaled Placebo|single and multiple ascending doses of inhaled placebo
75866418|NCT02415946|Procedure|Sinus floor augmentation (lateral)|
75866419|NCT02415946|Procedure|Sinus floor augmentation (transcrestal)|
75866420|NCT05200260|Procedure|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
75375689|NCT05443477|Dietary Supplement|Probiotic|participants received two oral capsules containing Probiotic powder every day for the 3 months.
75375690|NCT05443477|Dietary Supplement|control|participants received two oral capsules containing control powder every day for the 3 months.
75375691|NCT05424523|Drug|Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
75375692|NCT05443243|Procedure|Total Hip Arthroplasty|Patient were operated, a Total hip arthroplasty was performed
75557613|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
75866421|NCT05200260|Procedure|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
75866422|NCT05200260|Drug|PARP inhibitor|For patients with CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors. In this trial, Niraparib 200mg po qd is suggested after the front-line therapy.
75866423|NCT02415634|Other|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~Part 2: A rehabilitation goal setting care plan~Part 3: A patient communication forum~Part 4: Useful supports and contact information~Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
75866424|NCT02415634|Other|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
75866425|NCT03680768|Other|Health Assessment|The protocol includes measurements of body composition, strength test, functional and fitness test as well as biochemical measurements from blood samples and AGEreader
75866426|NCT05579106|Device|Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel|"The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient.~These parameters are:~Temperature~Galvanic skin response~Accelerometer~Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude)~All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement."
75557614|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
75557615|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
75375693|NCT05413759|Other|Pharmaceutical care in multiprofessional collaboration|"In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 & 6 months).~Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization.~Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills.~Objective of interviews (2 & 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment."
75375694|NCT04147039|Behavioral|MINISTOP 2.0|The MINISTOP 2.0 is a behavioural change program aiming to promote healthier diet and physical activity among 2.5-year-old children. The program consists of features such as information, monitoring and feedback (dietary key variables, physical activity, screen time) and it is built around 13 themes during the 6-month period.
75375695|NCT04338607|Procedure|Subtalar (Talocalcaneal) arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
75375696|NCT04338607|Device|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
75375697|NCT05442931|Drug|Pregabalin 150mg|The oral tablet half an hour preoperative 150 milligrams
75375698|NCT05442931|Drug|Magnesium Sulfate|Intravenous administration half an hour preoperative 2 grams
75375699|NCT05442931|Drug|Nitroglycerin|measure total dose of nitroglycerine in milligrams using a syringe pump
75375700|NCT05442931|Other|surgeon satisfaction|surgeon satisfaction measured according to Likert's scale
75375701|NCT05442541|Behavioral|not included any interventions(Evaluation of menstrual well-being in women of reproductive age, field survey study)|This is a prospective cross-sectional analytical study conducted through a questionnaire.
75375702|NCT05393479|Behavioral|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is a psychological treatment recommended by the World Health Organization for perinatal depression. The THP is based on the basic tenets of cognitive behavioural therapy (CBT) that aims to identify unhealthy thoughts and the vicious effects it has on the emotions and behaviour of a person and transform to healthy thinking style that ultimately impacts one's emotions and behaviour, too. The intervention aims to bring positive outcomes in three areas - a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. A randomized controlled trial (RCT) showed that the intervention was effective in reducing depressive symptoms and disability and improving functioning. Additionally, women receiving THP had higher rate of exclusive breastfeeding, and engaging more with their infants. Similarly, infants of these women were also less likely to have diarrhoeal episode and more likely to complete immunization.
75375703|NCT05442385|Other|Evidence based management|clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment
75538849|NCT02990819|Device|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
75375704|NCT05442307|Behavioral|asthma education|A 15 minutes (preferable) one-on-one educational visit about asthma treatment. The main points being: Every person with asthma should be treated with inhaled corticosteroids (ICS). Most patients with asthma should be treated with Bufomix Easyhaler either as needed and/or regularly. Patients should not use short-acting bega2-agonist (SABA) unless they use a medium-ICS-dosis.
75375705|NCT05442307|Behavioral|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
75375706|NCT05440513|Device|Renal Pelvic Denervation (bilateral)|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
75375707|NCT05439967|Other|Augmented and Virtual Reality Gait and balanceTraining|C-Mill VR+ device used for training. The training was carried out 3 days a week for 6 weeks, with each exercise session lasting approximately 1.5 hours, accompanied by a physiotherapist. Training started with conventional exercises, continued with C-Mill VR+ training, and ended with stretching and relaxation exercises. The patients in the intervention group were applied the exercises with the same principles with conventional training, except the exercises performed in standing and walking. Patients performed 10 exercises in AR and VR gait training for 4 minutes and resting the individuals by sitting for 1 minute between exercises.
75375708|NCT05439967|Other|Conventional Training|Conventional training was applied to the patients in the control group. Conventional training was planned taking into account the following goals: increasing mobility by improving the impaired kinesthetic sensation; improving axial rotation, coordination, flexibility of soft tissues, mobility in and out of bed; increasing body image perception by improving upright and proper posture; and improving balance and gait. The training was applied 3 days a week for 6 weeks, with each exercise session lasting 40-50 minutes, accompanied by a physiotherapist. Each of the exercises was done in 2 sets of 10 repetitions. In gait training, each exercise was performed for 4 minutes.
75375709|NCT05439811|Procedure|Swan-Ganz Catheter|Swan-Ganz Catheter
75538850|NCT02978118|Device|Immune cell and CTC detection procedures|Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)
75866427|NCT05579106|Device|Bispectral index (BIS)|The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.
75538851|NCT02973594|Drug|Ivabradine|
75538852|NCT02973594|Drug|Placebo|
75538853|NCT02938442|Biological|P10s-PADRE with MONTANIDE™ ISA 51 VG + Doxorubicin + Cyclophosphamide + Paclitaxel|Eligible subjects will be enrolled and immunized by SC administration of P10s-PADRE vaccine on each of 3 separate occasions over a three-week period in combination with standard neoadjuvant chemotherapy.
75375710|NCT05439499|Drug|FCN-437c, Letrozole or anastrozole, Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
75375711|NCT05439499|Drug|Placebo, Letrozole or anastrozole, Goserelin acetate|"Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。~Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；~Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。"
75375712|NCT04003987|Drug|Liposomal bupivacaine|20ml
75375713|NCT04003987|Drug|bupivacaine, 0.125%|60ml
75375714|NCT03984331|Device|Fish skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
75375715|NCT03984331|Device|Cadaver skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
75375716|NCT05448001|Drug|JP-1366 20mg|JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
75375717|NCT05448001|Drug|Lansoprazole 30mg|JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
75375718|NCT05366257|Other|CAR-T|infusion of CAR-T therapy among patients with r/r DLBCL
75866428|NCT05579106|Other|Questionnaire perception of the nurse on pain patient|The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.
76028996|NCT05913258|Device|Er:YAG laser system (Doctor smile, Pluser, Italy)|The Er:YAG laser offers a virtually painless alternative to conventional methods of caries removal, and its adoption in clinical practice could greatly reduce children's fear of going to the dentist. Caries removal is one of the leading reasons for dentist visits among children, and many children become fearful at the mere thought of a drill touching their teeth, before they even hear the sound. Laser caries removal could go a long way toward eliminating children's fear of going to the dentist; it is virtually painless, and most children are able to get through the entire procedure without needing local anesthesia.
75375719|NCT05366257|Other|Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
75375720|NCT05447845|Diagnostic Test|Computerized visual acuity assessment program|Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program
75375721|NCT05447767|Device|KIT BMAC AND at-SVF FIDIA|intra-articular infiltration or intra-articular and intra-osseous infiltration
75375722|NCT05447455|Procedure|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
75375723|NCT05447455|Procedure|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
75375724|NCT00369109|Other|biologic sample preservation procedure|
75538854|NCT02938442|Drug|Doxorubicin + Cyclophosphamide + Paclitaxel|Eligible subjects will be enrolled and receive standard neoadjuvant chemotherapy alone
75375725|NCT00369109|Other|immunohistochemistry staining method|
75701915|NCT03984617|Other|Emergency visit in a French tertiary Maternity hospital (Maternity of Nancy)|total number of visits (hospitalizations and consultations)
75701916|NCT00584870|Drug|Naproxen|Oral naproxen 500 mg twice daily for Weeks 1-12.
75866429|NCT03684746|Other|No Intervention|It is an observational Study with staff
75375726|NCT00369109|Other|laboratory biomarker analysis|
75375727|NCT00369109|Procedure|biopsy|
75375728|NCT00369187|Drug|large protein molecule|
75375729|NCT03831139|Behavioral|TIM&SARA|
75375730|NCT05446987|Other|Position change and back massage|Changing the patient's position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the researcher applied a simple stroke of lower back massage for 5 minutes every 2 hours
75375731|NCT05446987|Other|Early ambulation|The patient ambulated after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle
75375732|NCT05446753|Dietary Supplement|Animal-based meats|Animal-based meats from beef, pork and chicken
75375733|NCT05446753|Dietary Supplement|Plant-based meat alternatives|Plant-based meat alternatives of beef, pork and chicken
75375734|NCT00369733|Drug|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
75538855|NCT02924402|Biological|XmAb13676|Biological
75701917|NCT00584870|Drug|Placebo|Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
75701918|NCT00584870|Drug|PF-04383119 (RN624)|Single IV infusion of 200 micrograms/kg RN624 on Day 1
75375735|NCT05234281|Other|Interdisciplincary concentrated group rehabilitation|"All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~Concentrated group intervention (2-5 days): (further described below)~Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~Initiate treatment when the patient is ready for change~Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~Assist the patient when breaking the patterns.~Use long sessions to ensure that they face a broad range of potential micro-choices~Work side-by side with others going through an analogous pattern of change~Prepare them for taking responsibility for integrating the change into every-day living"
75375736|NCT05222737|Device|medency diode laser|intra pocket application of diode laser
75375737|NCT05222737|Drug|spirazole forte|adminstration of spirazole forte with a dose 17 mg per kg
75375738|NCT05446675|Procedure|Endoscopic eTEP|Endoscopic extended view totally extraperitoneal prosthesis repair.
75375739|NCT05446675|Procedure|Open Rives-Stoppa|Open Rives-Stoppa repair with retromuscular mesh placement.
75375740|NCT00368719|Drug|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
75375741|NCT05445193|Behavioral|PEaters Choice Module|There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
75375742|NCT00369811|Drug|Oxycodone, fentanyl|
75375743|NCT03647761|Device|Tetra-grip|Tetra-grip is a tubular elastic bandage that provides both compression and support
75375744|NCT03615547|Drug|Clomifene Citrate|"After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day."
75375745|NCT03615547|Other|Placebo|The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
75375746|NCT00422539|Drug|70% trichloroacetic acid|
75375747|NCT05166655|Behavioral|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
75375748|NCT05120791|Dietary Supplement|Placebo vegetable bouillon|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
75375749|NCT05120791|Dietary Supplement|microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
75375750|NCT05120791|Dietary Supplement|From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
75375751|NCT05120791|Dietary Supplement|A combination of the vegetable bouillon, the microalgae and the beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
76028997|NCT05913258|Device|Master Torque high/low-speed air rotor handpiece (KaVo Dental, Charlotte, North Carolina, USA)|Mechanical removal of carious lesions with a rotating handpiece and bur instruments is the most often used approach for treating dental caries because it is cost-effective, timesaving, and simple. However, these procedures have many drawbacks, including the potential for removing healthy tooth structures, vibration and noise, which can cause the patient anxiety and pain, thus necessitating local anesthesia.
75375752|NCT03562897|Dietary Supplement|Ocoxin-Viusid|Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
75538856|NCT02923193|Device|Shockwave Lithoplasty® Peripheral Lithoplasty System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
76028998|NCT05913245|Dietary Supplement|Maltodextrin 12.5%|Preoperative Maltodextrin 12.5%
76028999|NCT05913245|Other|Water|Preoperative water
75375753|NCT03559543|Dietary Supplement|Ocoxin-Viusid|"An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study."
75375754|NCT05431309|Diagnostic Test|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
75375755|NCT05431309|Other|Standard Treatment|Traditional cardiovascular disease prevention strategy based on Chinese guideline
75866430|NCT02416648|Behavioral|Clinician Client Centered (CCC) Counseling|"Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action."
75375756|NCT05429047|Biological|Tozinameran|Tozinameran during pregnancy
75375757|NCT05429047|Other|COVID-19|SARS-CoV-2 infection during pregnancy
75375758|NCT05429047|Other|No SARS-CoV-2 exposure|No SARS-CoV-2 exposure during pregnancy
75375759|NCT05119387|Other|Observation|Observation of genetic characteristics
75375760|NCT03475147|Device|eyeFusion|Smartphone app based flicker fusion test.
75375761|NCT03443167|Behavioral|Training on emergency telephone numbers and mnemonics|"The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students."
75375762|NCT03443167|Behavioral|Sham generic formation on the cardiopulmonary arrest.|The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
75375763|NCT05066737|Procedure|lateral suspension via V-NOTES surgery|pop-q, pisq-12 assesment of patients with pelvic organ prolapse before and 6 or 12 month after lateral suspension surgery performed via V-NOTES technique.
75866432|NCT03684668|Behavioral|Psychoeducational intervention|The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University.
75866433|NCT03174964|Drug|IVIg|Patients will take a dose of 400mg/kg of IVIg 2 days before ET.
75866434|NCT03684434|Behavioral|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
75866435|NCT03684434|Behavioral|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
75375764|NCT05367583|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
75375765|NCT03105128|Drug|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
75375766|NCT03105128|Drug|risankizumab IV|Risankizumab administered by intravenous infusion
75375767|NCT03105128|Drug|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
75375768|NCT03331393|Other|Non-interventional|Non-interventional
75375769|NCT03122509|Drug|durvalumab|1500 mg durvalumab via IV infusion
75375770|NCT03122509|Drug|tremelimumab|75 mg tremelimumab via IV infusion
75375771|NCT03122509|Radiation|Radiotherapy (RT)|Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
75538857|NCT02923193|Drug|Medtronic IN.PACT (DCB)|The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
75375772|NCT03122509|Procedure|ablation|Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
75375773|NCT03113695|Drug|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
75375774|NCT03113695|Drug|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
75375775|NCT03113695|Drug|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
75375776|NCT04892329|Other|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
75375777|NCT00369434|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|
75375778|NCT05286385|Device|CP1150 Sound Processor|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor
75375779|NCT05286385|Device|CP1150 (modified firmware)|Speech perception tests whilst the subject is fitted with the CP1150 modified firmware.
75375780|NCT05286385|Device|CP1150 + FF|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor with ForwardFocus.
75375781|NCT05286385|Device|CP1110|Speech perception tests whilst the subject is fitted with the CP1110 Sound Processor.
75375782|NCT04828928|Procedure|electromyogram|Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
75538858|NCT02910531|Dietary Supplement|Alpha lipoic acid|Already mentioned in arm/group descriptions.
75538859|NCT02910531|Drug|Placebo|Already mentioned in arm/group descriptions.
75538860|NCT02883062|Drug|Atezolizumab|Given IV
75538861|NCT02883062|Procedure|Biospecimen Collection|Undergo collection of blood samples
75538862|NCT02883062|Drug|Carboplatin|Given IV
75375783|NCT00368797|Drug|XRP0038 (NV1FGF)|
75375784|NCT04847323|Device|V-bend Bonded Retainer|Traditional stainless steel retainer commonly bonded in the anterior teeth of the mandibular arch to maintain their alignment after orthodontic treatment.
75375785|NCT04847323|Device|Vacuum-formed Retainer|Removable retainers made of plastic and derivatives. Currently gaining popularity due to the increased use of esthetic aligners. These clear retainers have the objective to maintain stable the results obtained after orthodontic treatment. They cover all the surfaces of the teeth up to the first or second molars.
75375786|NCT04796558|Other|AVAS Classification|Validation of AVAS classification
75538863|NCT02883062|Procedure|Lumpectomy|Undergo lumpectomy
75538864|NCT02883062|Procedure|Mastectomy|Undergo mastectomy
75538865|NCT02883062|Drug|Paclitaxel|Given IV
75538866|NCT02875314|Drug|Induction|vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
75538867|NCT02875314|Drug|Single Cycle Intensive Chemotherapy|Carboplatin, thiotepa, etoposide
76029000|NCT05913206|Behavioral|Ambiguity|The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
76029001|NCT05913206|Behavioral|Complexity|The intervention is a novel communication approach to communicate complexity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
76029002|NCT05913206|Behavioral|Normalizing language|The intervention is a novel communication approach to normalize and explain the inherent uncertainty faced by parents of children with medical complexity during clinical decision making.
76029003|NCT05913206|Behavioral|Narrative|Parent and caregiver narratives about their decision making experiences for the care of their child with medical complexity.
76029004|NCT05913193|Other|Oral Nutritional Supplement (ONS)|Diabetes specific oral nutritional supplement
75375787|NCT04784234|Dietary Supplement|GlaucoCetin|GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
76029005|NCT05913180|Drug|Ascorbic Acid 1000 MG|1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
75375788|NCT04784234|Other|Placebo|The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
75375789|NCT04774796|Other|Cognitive Behavioural Therapy|Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.
76029006|NCT05913180|Drug|Placebo|Placebo tablet daily starting day of elective gynecological surgery for 10 days
75538868|NCT02875314|Drug|Tandem 3 Cycle Intensive Chemotherapy|Carboplatin, thiotepa
75538869|NCT02821286|Other|Observational study|Blood sampling
76029007|NCT05913167|Procedure|laparoscopic nephrectomy|laparoscopic nephrectomy
75538870|NCT02808650|Other|Laboratory Biomarker Analysis|Correlative studies
75538871|NCT02808650|Other|Pharmacokinetic (PK) study|Correlative studies
76029008|NCT05913141|Other|Drug screen with PDO/PDO-TIL/PDOTS|Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.
75866436|NCT02416804|Drug|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -> 10 μg/hr -> 15 (5+10) μg/hr -> 20 μg/hr
75866437|NCT02416804|Drug|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -> 200 mg/d -> 250 mg/d -> 300 mg/d
75866438|NCT04933812|Behavioral|Facebook discussions and Virtual group meetings|Participants must join a study-specific private Facebook group and engage in discussion. Once the discussion is complete, participants have the opportunity to join virtual group sessions via Zoom
76029009|NCT05913128|Procedure|Glandular Urethral Disassembly technique|For Primary Distal Hypospadius Repair
76029010|NCT05913115|Drug|FPA144|FPA144 will be administered intravenously Q2W.
76029011|NCT05913102|Drug|PDLLA|Administer PDLLA/saline every 2 weeks for 2.5 months
76029012|NCT05913076|Device|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group|"The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
76029013|NCT05913076|Device|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
75375790|NCT05444738|Drug|oral lollipop with oxytocin (24IU)|Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.
75375791|NCT05444738|Drug|oral lollipop with placebo|Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
75866439|NCT03684356|Procedure|socket shield technique|immediate implant placement with buccal part of the root is retained
75866440|NCT03684356|Procedure|xenograft|immediate implant placement with filling the buccal gap with xenograft
75538872|NCT02808650|Drug|Prexasertib|Given IV
75538873|NCT02797548|Drug|Aspirin only|Aspirin only during surgery
75538874|NCT02797548|Drug|No antiplatelet therapy|No antiplatelet therapy will be during surgery
75538875|NCT02778997|Procedure|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
75375792|NCT05253859|Other|No intervention|Registry study: No intervention
75538876|NCT02727803|Biological|Allogeneic Natural Killer Cell Line NK-92|Given IV
75538877|NCT02727803|Biological|Anti-Thymocyte Globulin|Given IV
75538878|NCT02727803|Drug|Busulfan|Given IV
75866441|NCT02416882|Other|Aerobic Exercise|Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
75866442|NCT02416882|Other|Resistance Exercise|Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
75866443|NCT02416882|Other|Sedentary Option|Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
75375793|NCT04734158|Other|corneal imaging|corneal imaging using AS-OCT
75866444|NCT04792320|Dietary Supplement|Active bamboo charcoal|4g particle
75866445|NCT04792320|Dietary Supplement|probiotics|0.8g powder
75866446|NCT03176758|Drug|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
75866447|NCT03176758|Drug|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
75866448|NCT03176758|Device|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
75375794|NCT05243953|Drug|Levcromakalim|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
75375795|NCT05243953|Drug|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
75375796|NCT02741258|Device|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
75375797|NCT02741258|Drug|skin cream|cream to treat skin erythema due to radiotherapy
75375798|NCT02757313|Drug|Low dose THC marijuana|
75538879|NCT02727803|Drug|Clofarabine|Given IV
75538880|NCT02727803|Drug|Cyclophosphamide|Given IV
75538881|NCT02727803|Drug|Fludarabine Phosphate|Given IV
75538882|NCT02727803|Other|Laboratory Biomarker Analysis|Correlative studies
75538883|NCT02727803|Drug|Melphalan|Given IV
75538884|NCT02727803|Biological|Rituximab|Given IV
75538885|NCT02727803|Radiation|Total-Body Irradiation|Undergo total body irradiation
75375799|NCT02757313|Drug|High dose THC marijuana|
75375800|NCT02757313|Drug|Placebo marijuana|
75538886|NCT02727803|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplantation
75538887|NCT02677896|Drug|Enzalutamide|Oral
75538888|NCT02677896|Drug|Placebo|Oral
75538889|NCT02676960|Other|MRI without sedation|
75538890|NCT02630693|Drug|Palbociclib 100mg|100mg PO daily
75538891|NCT02630693|Drug|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
75538892|NCT02630693|Drug|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
75538893|NCT02626338|Drug|Crenolanib|
75538894|NCT02626338|Drug|Mitoxantrone|
75538895|NCT02626338|Drug|Cytarabine|
75538896|NCT02626338|Drug|Etoposide|
75538897|NCT02626338|Drug|Fludarabine|
75538898|NCT02626338|Drug|G-CSF|
75538899|NCT02626338|Drug|Idarubicin|
75538900|NCT02622100|Device|Bioresorbable Vascular Scaffold|
75538901|NCT02603146|Drug|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
75538902|NCT02603146|Drug|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
75538903|NCT02532621|Device|Venous InterGraft Connector|The device is designed for transcatheter delivery within a vein and connection to an AVG that has been tunneled under the skin in a standard manner. The connection is made via a small skin incision.
75866449|NCT04203537|Drug|CA-008|Local administration during surgery
75866450|NCT04203537|Drug|Placebo|Local administration during surgery
75866451|NCT05565612|Dietary Supplement|Normodigest Classic|Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
75866452|NCT05565612|Dietary Supplement|Placebo|Compound based on maltodextrin and other excipients
75866453|NCT03177070|Drug|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
75866454|NCT03174808|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
75866455|NCT03680690|Procedure|hysteroscopy|office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
75866456|NCT05190393|Procedure|hemivertebra resection on convex side|Patients were used hemivertebra resection procedure to treat congenital cervical scoliosis.
75701919|NCT00679341|Drug|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
75375801|NCT02672293|Drug|Phoslax|Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
75701920|NCT00679341|Drug|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
75701921|NCT00679341|Drug|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
75701922|NCT00679263|Drug|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
75375802|NCT04738591|Device|DIABE-TEXT|Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
75866457|NCT05190393|Procedure|concave distraction group|Patients were used distraction and lateral opening procedure to treat congenital cervical scoliosis.
76029014|NCT05913076|Device|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
75375803|NCT02379806|Drug|Enoxaparin|
75375804|NCT02379806|Drug|Placebo|
75538904|NCT02532621|Procedure|sutured arterial anastomosis of an implanted vascular graft for hemodialysis|The arterial anastomosis of the implanted vascular graft for hemodialysis is formed using standard suturing technique.
75538905|NCT02532621|Procedure|hemodialysis|The implanted vascular graft is intended as a vascular access for performing hemodialysis treatments.
75701923|NCT00679263|Drug|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
75701924|NCT00679263|Drug|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
75866458|NCT03101592|Other|Three-month ART dispensing|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
75866459|NCT03101592|Other|Six-month ART dispensing|Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
75701925|NCT02588300|Procedure|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
75866460|NCT02410174|Radiation|Stereotactic Body Radiotherapy (SBRT)|
75866461|NCT03275402|Biological|131I-omburtamab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
75866462|NCT01360203|Other|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
75866463|NCT02415478|Other|endoscopic lung volume reduction by valves|"Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.~Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust."
75866464|NCT03684200|Other|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
75866465|NCT01366599|Drug|HEC or MEC|Any HEC or MEC, including aprepitant
75375805|NCT02636647|Biological|Fecal transplant|
75375806|NCT02358356|Drug|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
75375807|NCT02358356|Drug|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
75375808|NCT02358356|Drug|Temozolomide|temozolomide 75mg/m2 b.i.d.
75375809|NCT04700761|Procedure|Opioid-free anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker
76029015|NCT05913063|Device|Structured Light Imaging Microscopy|Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
75701926|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
75701927|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
75701928|NCT00680043|Drug|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
75701929|NCT00918944|Other|Control|"The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~A data entry tool for capturing asthma control data~Standardized documentation templates to facilitate severity classification~Order sets to facilitate ordering controller medications~An asthma care plan that can be supplied to families"
75701930|NCT00918944|Other|Intervention|"Three alerts and two reminders will be programmed:~Alert providers to enter asthma severity classification if none is on file~Alert providers to prescribe controller medications for persistent asthma if none on file~Alert providers to complete an asthma care plan if none on file~Remind providers to review the asthma care plan if it is already on file by providing a link to the form~Remind providers that educational content is available on-line by providing a web link"
75701931|NCT02589392|Other|Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash|
75701932|NCT02589392|Other|Cetaphil® Restoraderm® body wash|
75701933|NCT02560545|Drug|Cannabis oil|Cannabis oil 20% THC
76029016|NCT05913037|Drug|Test group (Group A): FCN-159 8 mg, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
76029017|NCT05913037|Drug|Control group (Group B): Placebo, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
75701934|NCT02560467|Drug|Echo and myocardial contrast echocardiography perfusion imaging|"Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses."
75866466|NCT03172000|Diagnostic Test|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
75866467|NCT03680612|Drug|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Experimental drug
75866468|NCT03680612|Drug|cefepime 1 g or cefepime 2 g|cefepime monotherapy
75866469|NCT01360281|Other|Neuromuscular Electrical Stimulation|
75866470|NCT01360281|Other|ECR|Resisted exercises
75866471|NCT02410096|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
76029018|NCT05912998|Procedure|cartilage regeneration technique|autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
76029019|NCT05912985|Other|different oxygenation methods|Different oxygenation methods are used in bronchoscopy procedures under sedation.
75866472|NCT02410096|Other|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
76029020|NCT05912972|Other|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
75375810|NCT04700761|Procedure|Opioid-using anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
75375811|NCT05206201|Drug|ZY19489 Capsule|Two part study with single and multiple dose
75375812|NCT05206201|Drug|Placebo Capsule|Two part study with single and multiple dose
75866473|NCT02410096|Dietary Supplement|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
75866474|NCT02410096|Dietary Supplement|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
75866475|NCT01366677|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
75866476|NCT03684122|Biological|Injection of Umbilical cord derived MSCs|Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
75866477|NCT05188209|Drug|MRG003|Administered intravenously
75866478|NCT03171922|Behavioral|Internet Diet|ID group have online dietary coach every 2 weeks
75866479|NCT03171922|Behavioral|Clinic Diet|CD group have every 2 weeks visit at clinic
75866480|NCT04046939|Drug|Dexpramipexole|dexpramipexole twice daily oral dosing for up to 12 weeks
75866481|NCT04046939|Drug|Placebo|placebo twice daily oral dosing for up to 12 weeks
75701935|NCT05352633|Drug|Intensive BP Arm|Participants in the Intensive BP treatment group have a goal of SBP <120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
75701936|NCT05352633|Drug|Standard BP Arm|Participants in the Standard BP treatment group have a goal of SBP <140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
75701937|NCT05058092|Device|Immediate Remedee Solution|"D0 to M3: Remedee Solution + medical care~M3 to M6: Remedee Solution without personalized support + medical care~M6 to M9: medical care only"
75701938|NCT05058092|Device|Delayed Remedee Solution|"D0 to M3: medical care only~M3 to M6: Remedee Solution + medical care~M6 to M9: Remedee Solution without personalized support + medical care"
75701939|NCT05435937|Behavioral|Partnering for change (P4C-Swe)|"P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation."
75701940|NCT05435937|Behavioral|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
75701941|NCT05057078|Behavioral|mindfulness-based stress reduction program|groups of 10 people will be formed among the patients included in the mindfulness program group. A mindfulness-based stress reduction program will be done once a week for eight weeks and will take approximately 60-120 minutes. A plan will be made with the patients for the day and time of the session. During this process, no application will be made to the control group. Meetings will be held as an online session via Zoom Video Communications.
75701942|NCT02587754|Device|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
75701943|NCT00682539|Drug|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
75866482|NCT05188131|Drug|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
75866483|NCT05188131|Drug|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
75866484|NCT03172156|Genetic|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
75866485|NCT01360359|Other|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
75866486|NCT01360359|Other|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
75375813|NCT04689776|Behavioral|Dual-Task Training|The programs are based on dual-task trainings which contain cognitive training and exercise simultaneously. For physical exercise, we will design the programs that involve balance or strength training components in the aerobic exercises. In terms of cognitive training, we will design self-made teaching aids and board games to train different domains of cognitive functions. We plan to assess the participants before and after the intervention programs. We expect that elders receiving dual-task training will improve on outcome measures, and the group with more frequency will have better performance. The results of the study will provide evidence of interventions for elderly with cognitive decline, thereby reducing the burden on their caregivers and the cost of medical resource.
75375814|NCT05194033|Dietary Supplement|Probiotics daily|Probiotics 1 time/day for 7 consecutive days
75375815|NCT05194033|Dietary Supplement|Placebo daily|Placebo 1 time/day for 7 consecutive days
75866487|NCT02409940|Biological|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
75866488|NCT01363791|Other|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
75375816|NCT04668391|Procedure|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament|Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.
75866489|NCT02415322|Other|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
75866490|NCT03680534|Procedure|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
75375817|NCT04668391|Procedure|Thoracic epidural analgesia|A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
75375818|NCT04658888|Device|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cancer cells for screening purposes.
75375819|NCT05192551|Other|Bowel-prep (Plenvu as experimental arm)|In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
75375820|NCT05192395|Drug|DWJ1525|DWJ1525
75375821|NCT05192395|Drug|DWP16001|DWP16001
75538906|NCT02484859|Drug|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
75375822|NCT05192395|Drug|DWC202101|DWC202101
75375823|NCT02350699|Device|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
75538907|NCT02484859|Drug|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
75538908|NCT02484859|Drug|Metoprolol|0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
75538909|NCT02482870|Device|Macintosh laryngoscope|Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
75538910|NCT02482870|Device|King Vision video laryngoscope|Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
75538911|NCT02482168|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody
75538912|NCT02452918|Drug|Oritavancin|Administered intravenously
75538913|NCT02452918|Drug|Warfarin|Administered as a concomitant medication at a standard dose and dosing schedule
75538914|NCT02431507|Device|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
75538915|NCT02412787|Drug|Idursulfase-IT|Participants will receive 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (>8 months to 30 months of age) and 10 mg (>30 months to 3 years of age).
75538916|NCT02412787|Drug|Elaprase|Participants will receive intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
75538917|NCT02379520|Genetic|HPV Specific T Cells|"Dose escalation study with 5 dose levels: DL1-1×10^7 cells/m2, DL2-3×10^7 cells/m2, and DL3-1×10^8 cells/m2, DL4- 2 to 3×10^8 cells/m2, DL5- 0.8 to 1×10^9 cells/m2~Group A -HPVST cells Group B -lymphodepletion & nivolumab & HPVST cells.~First, treatment in Group A will be completed for DL1 and DL2. Only if DL2 in Group A proves safe, Group B will be treated on DL2, DL3, DL4, and DL5.~Group A will be treated at DL3, DL4, and DL5 only if there is excessive toxicity in cohorts treated with lymphodepletion.~HPVSTs will be given by IV injection over 1-10 minutes through a peripheral or a central line on day 0.~If patients have clinical benefit (as determined by symptoms, physical exam or radiological studies) & no significant toxicities, they may get up to 5 repeat infusions (for max total of 6 infusions) of HPVSTs at or below the same dose level."
75538918|NCT02379520|Drug|Cytoxan|500mg/m^2/day x 3 days (on days -4, -3 and -2)
75866491|NCT00704782|Drug|dimebon|
75375824|NCT00368498|Drug|teicoplanin|
75375825|NCT02108899|Behavioral|Retrieval practice effect using descriptive stories and free-call tests without feedback|"In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts."
75538919|NCT02379520|Drug|Fludarabine|30mg/m^2/day x 3 days (on days -4, -3, and -2)
75538920|NCT02379520|Biological|Nivolumab|240mg every 2 weeks (+/- 3 days) starting on day -1
75538921|NCT02356653|Device|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
75866492|NCT03676400|Other|conditioned media of umbilical cord blood-derived stem cells|Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
75866493|NCT03676400|Other|Placebo|Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
75866494|NCT01360437|Drug|Prasugrel|Prasugrel 10mg/day
75866495|NCT01360437|Drug|Ticagrelor|Ticagrelor 90mg twice a day
75375826|NCT05172817|Drug|Advixa (Adalimumab)|Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
75375827|NCT04600622|Behavioral|Rural Diabetes One-Day Education and Care program (R-D1D)|One time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
75375828|NCT04600622|Behavioral|Diabetes Education Materials|Diabetes Education Materials
75375829|NCT05145907|Biological|TJ107 +Pembrolizumab|TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV
75866496|NCT04042103|Drug|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
75375830|NCT05142163|Other|Intraoperative SVV Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV <11%, for values >11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
75375831|NCT05142163|Other|Intraoperative PVI Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI <10%, for values >10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
75375832|NCT04559737|Other|Case Management|"Population management platforms capable of automatically risk stratifying patients (eg, automatically identifying poor users) may be another cost-effective technology-based tool by enabling a management by exception (MBE) follow-up intervention. This intervention concentrates provider effort on patients most at need by allowing providers to passively observe successful users and actively intervene only in CPAP strugglers. Therefore, in addition to Usual Care we will implement this population management process by identifying CPAP strugglers only and further follow-up encounters will be triggered for these select patients for troubleshooting. Additionally, throughout the 1-year period, Q1 window of <70% nights >4 hours will trigger a phone call and at the discretion of the sleep provider convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year."
75866497|NCT03172078|Procedure|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
75866498|NCT01363869|Dietary Supplement|green tea extracts 2 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 2 grams per day."
75375833|NCT05443958|Other||
75375834|NCT00961142|Drug|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
75375835|NCT05443646|Drug|HLX10|"HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
75375836|NCT05443646|Radiation|hypofractionated radiotherapy|45Gy/1.5F/3week
75866499|NCT01363869|Dietary Supplement|green tea extracts 4 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 4 grams per day."
75866500|NCT01363869|Dietary Supplement|green tea extracts 6 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 6 grams per day."
75375837|NCT05443646|Radiation|Prophylactic Cranial Irradiation (PCI)|25Gy/2.5Gy/2week
75375838|NCT04338373|Combination Product|"0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain)"|"nightly instillations of 0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain) in both eyes for 12 months"
75375839|NCT00368953|Device|Yukon Choice stent system|coronary stent implantation
75375840|NCT00368953|Device|Taxus Liberté stent system|coronary stent implantation
75375841|NCT00900055|Genetic|microarray analysis|
75375842|NCT00900055|Genetic|polyacrylamide gel electrophoresis|
75375843|NCT00900055|Genetic|polymerase chain reaction|
75375844|NCT00900055|Genetic|protein expression analysis|
75375845|NCT00900055|Genetic|reverse transcriptase-polymerase chain reaction|
75375846|NCT00900055|Genetic|western blotting|
75866501|NCT03883646|Behavioral|Mindfulness|Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).
75866502|NCT03883646|Behavioral|Relapse Prevention|Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).
75866503|NCT03174730|Behavioral|Growth Mindset|The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
75866504|NCT03174730|Behavioral|SmartQuit|This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
75375847|NCT00900055|Other|chromatography|
75375848|NCT00900055|Other|high performance liquid chromatography|
76029021|NCT05912907|Other|potassium nitrate in polycarboxilate cement|5% potassium nitrate in polycarboxylate; pre-weighed 95 mg zinc oxide powder and 5mg of KNO3 will be placed on a glass slab followed by mixing by polyacrylic acid (liquid) in a 1:1 P/L ratio
75375849|NCT00900055|Other|immunoenzyme technique|
75375850|NCT02200614|Drug|Darolutamide (Nubeqa, BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
75375851|NCT02200614|Drug|Placebo|Matching placebo 2 tablets twice daily with food.
75375852|NCT00369031|Biological|Human Immunodeficiency Virus glycoprotein 140 (vaccine)|Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
75375853|NCT00369031|Biological|HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
75375854|NCT00369031|Biological|Labile Toxin mutant LTK63 adjuvant|Labile Toxin mutant LTK63 adjuvant alone
75375855|NCT05452382|Procedure|Partial colecctomy|Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
75375856|NCT05452382|Procedure|Hemicolectomy|Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
75375857|NCT05061901|Drug|Lisinopril tablet 20 mg|Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.
75375858|NCT05061901|Drug|Zestril® tablet 20 mg|Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.
75375859|NCT04398056|Drug|Chemotherapy plus radiotherapy and Toripalimab|"Chemotherapy:~The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
75375860|NCT04383145|Device|endovascular repair|Endovascular repair of thoracoabdominal aneurysm using stent grafts.
75375861|NCT00368888|Device|Urine collection bag for infants|
75375862|NCT05443100|Other|Whole-body cryostimulation (WBC)|Multidisciplinary rehabilitation program consisting of 10 WBC sessions.
75375863|NCT05443100|Other|Rehabilitation program|Multidisciplinary rehabilitation program consisting of diet and physical exercise.
75866505|NCT03676322|Drug|M5049|Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
75866506|NCT03676322|Drug|Placebo|Participants will receive placebo matched to M5049.
75375864|NCT05452603|Device|96-hour off IBP wireless pH monitoring capsule|The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
75375865|NCT05451992|Dietary Supplement|Placebo|The group will have to consume a jar every day (approx. 75 ml) which contain (water, malt-dextrins, 0.1% starch, 0.1% guar gum, flavorings and colorants)
75375866|NCT05451992|Dietary Supplement|SuperFood|The group will have to consume a jar of superfood (vegetable smoothie) every day. The jar will be filled with approx. 75 ml which corresponds to about 75 g. The superfood formulated by the University of Bolzano on the basis of the results and evidence acquired in collaboration with the Istituto Superiore di Sanità. Composition: pomegranate, walnuts, moringa, broccoli, according to the proportions indicated in Annex 2. This mixture has been analyzed by an external laboratory and authorized for human use
75375867|NCT05443022|Radiation|Photobiomodulation|Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
75375868|NCT05443022|Radiation|Simulation of Photobiomodulation|The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
75375869|NCT04338919|Procedure|Percutaneous coronary intervention|PCI with stent implantation
75866507|NCT02409862|Drug|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
75375870|NCT04338919|Drug|Ticagrelor plus aspirin|Ticagrelor plus aspirin
75375871|NCT05442944|Procedure|Physiotherapeutic procedures|As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
75375872|NCT05451758|Other|Mindfulness-based stress reduction (MBSR)|The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
75538922|NCT02342691|Drug|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
75538923|NCT02342691|Drug|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
75538924|NCT02332902|Drug|Everolimus|Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
75538925|NCT02324608|Biological|cetuximab|Given IV
75538926|NCT02324608|Other|laboratory biomarker analysis|Correlative studies
75538927|NCT02323867|Device|Alpha Beta T cell depletion|
75866508|NCT02409862|Drug|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
75866509|NCT02415010|Device|Enterprise 2 Vascular Reconstruction Device|Stenting Assisted coiling procedure
75866510|NCT01366989|Device|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
75866511|NCT02415088|Procedure|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
75866512|NCT02415088|Procedure|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
75866513|NCT01360671|Drug|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
75375873|NCT04351009|Procedure|sentinel lymph node mapping|Through on-table colonoscopy indocyanine green solution will be injected in the submucosa at 2-4 points around the tumor for laparoscopic surgeries. Dye will be injected in the subserosa at 2-4 points for open surgeries. Lymphatic flow from the tumor will be mapped in real time with near-infrared fluorescence imaging scope and sentinel lymph nodes will be identified.
75375874|NCT02231892|Device|TMS|HAC coil (real rTMS or sham rTMS)
75538928|NCT02305654|Procedure|ILND - Inguinal Lymph Node Dissection|Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.
76029022|NCT05912881|Other|Olfactory training|Participants perform olfactory training using sticks filled with scented essential oils.
76029023|NCT05912881|Other|Placebo training|Participants perform olfactory training using sticks filled with unscented medium chain triglycerides.
75538929|NCT02305654|Drug|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
75701944|NCT00682539|Drug|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
75538930|NCT02305654|Drug|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
75538931|NCT02305654|Drug|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
75538932|NCT02305654|Radiation|Intensity modulated radiation treatment (IMRT)|Treatment with very high energy X-rays (radiotherapy).
75866514|NCT03676244|Device|immediate implant in defected anterior maxillary esthetic zone|"Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment."
75866515|NCT01363947|Drug|DNIB0600A|Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
75866516|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
75866517|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
75866518|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
76029024|NCT05912868|Device|Endoscopic Mini/Less Open Sublay Repair|The traditional techniques are open sublay or transabdominal intraperitoneal onlay mesh (IPOM) repair. In order to avoid the risks -large trauma to the abdominal wall with pain and infection, lesion of intraabdominal organs - a new hybrid technique - small skin incision, wide endoscopic dissection of the retrorectus space with implantation of a large mesh - was developed (EMILOS -Endoscopic Mini/Less Open Sublay).
76029025|NCT05912855|Device|qNOX|Non
76029026|NCT05912842|Behavioral|Organizational Partnerships for Healthy Living|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled.
76029027|NCT05912842|Behavioral|Standard of Care|Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
76029028|NCT05912816|Drug|RC48 Combined With Tislelizumab|"In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour."
76029029|NCT05912751|Other|Exercise Then Foam Roll|Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.
76029030|NCT05912751|Other|Foam Roll Then Exercise|Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
75701945|NCT00682539|Drug|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
75701946|NCT00682539|Procedure|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
75375875|NCT05442476|Other|Kinesiotaping|For the KT application, participants will be asked to stand with keeping their feet at shoulder level in a comfortable manner. The patient will be in a standing position with lumbar spine flexion. A 5 cm wide long I-shaped piece of tape will be applied with 80% tension transverse to the patient's painful area and the bilateral SIJ region, with no tension applied to the ends of the tape. Another short piece of tape will be applied with 80% tension at an angle from the painful point to the hip, and no tension will be applied to the ends of the tape. An identical application will be performed on the other side of the sacroiliac region
75701947|NCT02587910|Dietary Supplement|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
75375876|NCT05442476|Other|Muscle Energy Technique|The subject will be asked for the sitting on the treatment table, back towards the therapist. Then the subject will be taken into flexion, rotation and side bending. When the subject will reach the tolerated limit of flexion, the therapist will ask him to perform extension, sidebending and rotation to the opposite side while holding the breath for 7-10 seconds and rest for 2-3 seconds, then the patient will be asked to release the breath. The therapist will wait for the participant's full exhalation and then will take her further in all the directions of restriction, towards the new barrier. MET will be performed for 10 repetitions.
75375877|NCT05442476|Other|conventional physiotherapy|conventional physiotherapy
75375878|NCT05451290|Drug|Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur|Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
75375879|NCT05452135|Other|Observation of visual, audotory and motor reaction time|Visual, auditory and motor reaction time will be measured as a result of the measurements made during the dual task evaluation.
75538933|NCT02305654|Procedure|Prophylactic PLND - pelvic lymph node dissection|Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
75701948|NCT02587910|Dietary Supplement|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
75701949|NCT00682461|Drug|Nicotine|Marketed nicotine replacement therapy formulation
75701950|NCT00682461|Drug|Nicotine|Nicotine prototype
75866519|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
76029031|NCT05912725|Procedure|Implant placement|"4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar"
75375880|NCT04284865|Other|Web Platform|The intervention involves the use of the web platform for 12 months combined with a monthly phone follow-up.
75375881|NCT04322162|Other|ASAP Intervention Quality Improvement Protocol|The intervention program includes: (1) a systems redesign Virtual Collaborative, and; (2) data monitoring and is designed to aid each of the 6 participating VAMCs in developing, implementing, and evaluating the implementation of an acute OSA testing and treatment protocol for ischemic stroke/TIA patients. The sites will choose a diagnostic strategy (i.e., unattended polysomnography [PSG]/home sleep test [HST], in-laboratory PSG, direct to auto-titrating [auto]-PAP) and a therapeutic strategy (i.e., in-laboratory PAP titration, auto-PAP). The intervention will employ 3 implementation strategies: (1) local adaptation; (2) external facilitation, and; (3) audit and feedback.
75538934|NCT02229084|Biological|Chemovax - P10s-PADRE/ MONTANIDE™ ISA 51 VG + Doxorubicin + Cyclophosphamide + Docetaxel (or Paclitaxel)|Eligible subjects will be enrolled and immunized by SC administration of P10s-PADRE vaccine on each of 3 separate occasions over a three-week period.
75538935|NCT02213497|Radiation|18F-FDG (Fluorodeoxyglucose) PET|
75538936|NCT02213497|Drug|Carboplatin|
75538937|NCT02213497|Drug|Paclitaxel|
75538938|NCT02153307|Device|Implantable loop recorders system Reveal ICM LINQ®,|
75538939|NCT02138721|Procedure|Radical Prostatectomy (RP)|Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
75701951|NCT05684588|Diagnostic Test|Magnetic Resonance|After enrollment a Magnetic Resonance without medium contrast, at 1 year from previous hospitalization
75701952|NCT02589002|Other|Sucralose|
75701953|NCT00755001|Device|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
75701954|NCT00755001|Device|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
75701955|NCT04082546|Procedure|Surgical unroofing of muscle-briged coronary artery|Medical therapy with beta-blockers or calcium-channels blockers
75701956|NCT02560311|Other|observation|
75701957|NCT02587364|Drug|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
75701958|NCT02587364|Drug|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
76029032|NCT05912712|Other|Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment|10 mL PRP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PRP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PRP leakage. The outflow was observed, and the amount of outflow was recorded.
75701959|NCT02587364|Drug|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
75701960|NCT02587364|Drug|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
75701961|NCT02587364|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
75701962|NCT02587364|Drug|Placebo|Placebo once daily (QD)
75375882|NCT00369889|Drug|bevacizumab|iv every 21 days
75375883|NCT00369889|Drug|Erlotinib|oral daily
75375884|NCT00369044|Drug|prednisone|
75375885|NCT00370045|Drug|Bivalirudin with and without eptifibatide|
75375886|NCT05442320|Device|Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)|Toothpaste with 500 or 1000 ppm of fluoride
75375887|NCT05451056|Drug|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.
75375888|NCT04304690|Other|blood sample|2 blood samples at T0 and 3 months
75375889|NCT02231580|Drug|BN82451B|BN82451B capsule
75538940|NCT02038660|Device|Balloon angioplasty|
75538941|NCT01897168|Device|No intervention|
76029033|NCT05912712|Other|Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment|10 mL PPP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PPP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PPP leakage. The outflow was observed, and the amount of outflow was recorded.
75538942|NCT01800760|Dietary Supplement|Probiotics|Probiotics once a day for three weeks.
75538943|NCT01792583|Drug|Modafinil/armodafinil|
75538944|NCT01750073|Drug|Cyclophosphamide|Given IV
75701963|NCT00921765|Drug|Saline|Saline single bolus dose followed by saline single bolus dose iv
75375890|NCT02231580|Drug|Placebo|Placebo capsule
75538945|NCT01750073|Drug|Doxorubicin Hydrochloride|Given IV
75538946|NCT01750073|Other|Laboratory Biomarker Analysis|Correlative studies
75538947|NCT01750073|Drug|Paclitaxel|Given IV
75538948|NCT01750073|Radiation|Radiation Therapy|Undergo RT
75701964|NCT00921765|Drug|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
75701965|NCT00921765|Drug|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
75375891|NCT05442242|Procedure|Unicompartmental knee arthroplasty|Medial Unicompartmental knee arthroplasty
75375892|NCT05442242|Procedure|High tibial osteotomy|Medial open wedge high tibial osteotomy
75375893|NCT05441150|Drug|Low dose ketamine infusion|Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
75375894|NCT05441150|Drug|0.9% NaCl infusion|Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
75375895|NCT04270214|Drug|Dysport Injectable Product|Dysport injections optimized using kinematics
75375896|NCT05018689|Other|Aevidum curriculum|The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.
75375897|NCT05018689|Other|Club|Schools will identify ten students interested in participating in an Aevidum club. Following training of interested students, schools are asked to commit to running two Aevidum club activities during the school year.
75538949|NCT01750073|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
75538950|NCT01750073|Biological|Trastuzumab|Given IV
75538951|NCT01723774|Drug|PD0332991|
75538952|NCT01723774|Drug|Anastrozole|
75538953|NCT01723774|Drug|Goserelin|
75538954|NCT01723774|Procedure|Surgery (standard of care)|-Breast and axillary lymph node surgery
75538955|NCT01723774|Procedure|Tumor biopsy|
75538956|NCT01674140|Drug|anastrozole|Given orally
75538957|NCT01674140|Drug|everolimus|Given PO
75538958|NCT01674140|Drug|exemestane|Given orally
75538959|NCT01674140|Drug|goserelin acetate|Given subcutaneously or intramuscularly
75538960|NCT01674140|Drug|letrozole|Given orally
75538961|NCT01674140|Drug|leuprolide acetate|Given subcutaneously or intramuscularly
75538962|NCT01674140|Drug|tamoxifen citrate|Given PO
75538963|NCT01674140|Other|placebo|Given PO
75538964|NCT01433198|Other|Aquatic training|Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
75538965|NCT01356628|Drug|PD-0332991|PD-0332991, 125mg, 3 cycles
75701966|NCT00921765|Drug|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
75701967|NCT05435781|Drug|Hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
75866520|NCT05554068|Drug|Shingrix|Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
75375898|NCT04217707|Behavioral|Pre- and Post-Surgical Transgender Therapeutic Support Group|Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
75375899|NCT05144022|Behavioral|Bungee jump|Bungee jump from a cran
75375900|NCT05450510|Other|Accelerated (ACCEL) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings.
75375901|NCT05450510|Other|Slow (SLOW) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings.
75375902|NCT04746703|Radiation|Magnetic Resonance Imaging|Pancreatic MRI will be performed in severe-obese patients with a planned bariatric surgery, before and 6 months after bariatric surgery.
75375903|NCT05438810|Drug|FCN-437c,Fulvestrant,Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
75375904|NCT05438810|Drug|Placebo,Fulvestrant,Goserelin acetate|Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
75375905|NCT04738513|Procedure|Vertical preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.
75538966|NCT01294072|Dietary Supplement|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
75538967|NCT01294072|Dietary Supplement|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
75866521|NCT03680378|Drug|Cefepime 2 gram|Combination of cefepime 2 gram with AAI101 1 gram
75538968|NCT01294072|Other|No intervention|no treatment
75866522|NCT01319331|Drug|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
76029034|NCT05912712|Drug|Mesalazine Suppository Treatment|For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
75538969|NCT01087554|Drug|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
75538970|NCT01087554|Drug|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
75538971|NCT01087554|Drug|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
75538972|NCT01087554|Drug|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
75538973|NCT01012817|Other|Laboratory Biomarker Analysis|Correlative studies
75538974|NCT01012817|Other|Pharmacogenomic Study|Correlative studies
75538975|NCT01012817|Other|Pharmacological Study|Correlative studies
75538976|NCT01012817|Drug|Topotecan Hydrochloride|Given IV
75538977|NCT01012817|Drug|Veliparib|Given PO
75538978|NCT00920582|Biological|Teplizumab Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
75866523|NCT04913298|Device|Cytosorb therapy|Start of Cytosorb therapy is at the discretion of the attending physician
75538979|NCT00920582|Drug|Placebo|IV dosing daily for 14 days repeated at Week 26
75538980|NCT00920582|Biological|Teplizumab 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
75538981|NCT00920582|Biological|Teplizumab Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
75866524|NCT02406352|Device|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
75538982|NCT00898638|Other|biologic sample preservation procedure|
75538983|NCT00898638|Other|medical chart review|
75538984|NCT00867048|Drug|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
75538985|NCT00735423|Device|No intervention|IDE used for outcome measurement not intervention
75866525|NCT02409628|Device|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
75866526|NCT03676166|Drug|Cannabis|Inhaled cannabis
75375906|NCT04738513|Procedure|Conventional Preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
75375907|NCT04338854|Procedure|Restorative Treatment|9 groups were formed as 6 restorative and 3 protective applications. The restorative treatment groups included procedures with- and without-local anesthesia (LA). Procedures with LA included the groups as root canal treatment, pulpotomy, two-surface restoration and one-surface restoration. Procedures without LA included the groups as two-surface restoration and one-surface restoration. The protective application groups included the groups as fluoride application (by disposable arch tray or by cotton roll) and fissure sealant.
76029035|NCT05912712|Biological|Infliximab Treatment|Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).
76029036|NCT05912699|Other|Slimbiotics Postbiotic|"SlimBiotics postbiotic formula contains the following ingredients:~Heat-inactivated L. fermentum K8 Postbiotic.~Microcrystalline cellulose."
76029037|NCT05912699|Other|Placebo|The placebo capsules contain microcrystalline cellulose only.
75375908|NCT02166606|Device|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
75375909|NCT04730401|Biological|Convalescent plasma from COVID-19 donors|Convalescent plasma from COVID-19 donors
75375910|NCT04730401|Biological|Placebo|200mL saline
76029038|NCT05912686|Drug|Atorvastatin 80mg|The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
76029039|NCT05912686|Drug|Atorvastatin 20mg|The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
76029040|NCT05912660|Device|Aortic Valve Replacement|Aortic Valve Replacement (surgically or TAVI)
76029041|NCT05912621|Drug|Tirzepatide|Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.
75375911|NCT05451121|Drug|Propofol|patient sedation with a propofol (sedative agent) after cardiac surgery
75375912|NCT05451121|Drug|Dexmedetomidine|patient sedation with dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) after cardiac surgery
75375913|NCT05451121|Drug|Propofol and dexmedetomidine|Patients sedation with a drug combination: propofol and dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist)
75538986|NCT00616395|Device|No intervention|
76029042|NCT05912582|Radiation|Intensity modulated radiation therapy (IMRT) combined with chemotherapy|Intensity modulated radiation therapy (IMRT) combined with chemotherapy
76029043|NCT05912569|Procedure|Delay sentinel node biopsy|In the case of a patient undergoing breast-conserving surgery for intraductal carcinoma, the sentinel lymph node is not excised during the primary surgery but only marked for identification. I
76029044|NCT05912543|Procedure|Titration of FiO2|The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
75701968|NCT05435781|Drug|Placebo for hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
76029045|NCT05912530|Other|no intervention|there is no intervention will done
76029046|NCT05912491|Diagnostic Test|Transperineal ultrasonography|Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
76029047|NCT05912478|Other|Videogame-Based Therapy|The Nintendo Switch (Version 2) will be used to play video games. Within the scope of the study, Nintendo Switch games were analyzed with respect to their technical and fictional characteristics, required and optional movement patterns, difficulty levels, transitions between difficulty levels, and compatibility with priority problems. The selected activities will prioritize the activation of the scapular muscles. Throughout the activities, the participant will be required to mimic the on-screen avatar's movements. The player will receive a higher score if his or her movements in the game resemble the avatar's in terms of angular, velocity, and fluidity.
76029048|NCT05912478|Other|Waiting list|The participants who were placed on a waiting list for eight weeks and constituted the control group will be asked to carry on with their normal activities. Participants in the control group will be contacted by phone in the fourth week to inquire about their status and to remind them that the exercise program will begin in the coming weeks. At the end of the 8-week study, the participants from the control group will participate in the exercise program.
75375914|NCT04967443|Drug|Prazosin HCl 2mg|Prazosin HCL 1 X 2 mg capsule.
75375915|NCT04967443|Drug|Prazosin HCl 1 mg|Prazosin HCl 2 X 1 mg capsule.
75375916|NCT04967443|Drug|Prazosin HCl 5 mg|Prazosin HCL 1 X 5 mg capsule.
75375917|NCT04724317|Procedure|Steroid Group|Ultrasound guided shoulder intra-articular steroid injection
75375918|NCT04724317|Procedure|Ozone Group|Ultrasound guided shoulder intra-articular Ozone injection
75375919|NCT04724317|Procedure|PRF Group|Ultrasound guided shoulder intra-articular pulsed radiofrequency application
75375920|NCT04697017|Other|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
75375921|NCT04943419|Diagnostic Test|Level of Myeloid-Derived Suppressor Cells|Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
75375922|NCT02230956|Biological|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
75538987|NCT00568490|Procedure|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
75538988|NCT00568490|Procedure|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
75538989|NCT00439049|Drug|modafinil|400 mg daily
75375923|NCT02230956|Drug|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
75375924|NCT02230410|Device|CryoBalloon Focal Ablation|
75375925|NCT05447936|Dietary Supplement|Jarlsberg cheese|Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
75701969|NCT02560233|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
75701970|NCT02560233|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
75701971|NCT05435625|Procedure|FCO2|Fractional Carbon dioxide laser
75866527|NCT02406118|Procedure|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
75866528|NCT03101514|Drug|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
76029049|NCT05912465|Other|Stress Reduction Training|A subgroup of patients from Vienna will undergo an additional PET/CT scan after the first follow-up PET/CT, which takes place one month after stress reduction training. The stress reduction training involves performing a breathing technique.
76029050|NCT05912439|Behavioral|SidekickHealth|Usage of mobile application called SidekickHealth.
75375926|NCT04739384|Drug|Ticagrelor 90mg|Ticagrelor 90 mg followed by Ticagrelor 60 mg
75375927|NCT04739384|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg followed by Ticagrelor 90 mg
75538990|NCT00439049|Drug|d-amphetamine|60mg daily
75701972|NCT05435625|Procedure|FRF|Fractional Microneedling Radiofrequency
75866529|NCT03101514|Drug|chemotherapy|Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
75866530|NCT02406040|Other|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
76029051|NCT05912387|Drug|Rosuvastatin|Rosuvastatin 20 mg tablet once daily by mouth
76029052|NCT05912374|Behavioral|standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.
76029053|NCT05912374|Behavioral|enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
76029054|NCT05912348|Behavioral|Obesogenic Lifestyle Group|Young men will transition into a sedentary lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups. One of the control groups will undergo a sedentary intervention.
76029055|NCT05912348|Behavioral|Sedentary Control|Young men will transition into a sedentary lifestyle for 10 days.
75375928|NCT05450575|Drug|Amosartan Q tablet|Amlodipine, Losartan, Rosuvastatin
75375929|NCT04704596|Device|anesthesia ventilator machine|dynamic lung compliance measurements will be used for detection of the optimum PEEP after alveolar recruitment
75375930|NCT04704596|Device|lung ultrasound|lung ultrasound views will be used for detection of the optimum PEEP after alveolar recruitment
75375931|NCT05450497|Drug|Propofol|comparing sedative agents
75375932|NCT05450497|Drug|Dexmedetomidine|comparing sedative agents
75375933|NCT05450497|Drug|Dexmedetomidine and propofol|comparing sedative agents
75375934|NCT02230332|Drug|Alendronate|
75375935|NCT02230332|Drug|Placebo|
75375936|NCT04928989|Other|convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
75375937|NCT02230254|Device|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
75375938|NCT04927819|Device|BTI Implant|BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).
75538991|NCT00439049|Drug|L-Dopa|800/200mg daily
75538992|NCT00439049|Drug|Naltrexone|50mg daily
75538993|NCT00254423|Drug|Dasatinib|Given PO
75538994|NCT00254423|Other|Laboratory Biomarker Analysis|Correlative studies
75538995|NCT00254423|Other|Pharmacological Study|Correlative studies
75538996|NCT00254423|Other|Quality-of-Life Assessment|Ancillary studies
75538997|NCT00254423|Other|Questionnaire Administration|Ancillary studies
75538998|NCT04720092|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Granules for oral suspension, 10 mg, oral, single dose
75538999|NCT04720092|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 10 mg, oral, single dose
75539000|NCT00221702|Drug|PegIntron|100 mcg SC/week for 36 months
75539001|NCT00221702|Drug|intron A|3mui TIWW SC for 18 months
75701973|NCT00755157|Drug|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
75701974|NCT00755157|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
75701975|NCT00919880|Drug|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
75701976|NCT00919880|Drug|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
75701977|NCT02560077|Other|placebo|Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
76029056|NCT05912335|Drug|Topical anesthetic|The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
75375939|NCT05447468|Other|Strength of lower trapezius|Ask the patient to raise arm above the head with upper extremity in line with lower trapezius muscle fibers in prone position with the shoulder joint at 135 degrees. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
75701978|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 120 mg/day after meal
75701979|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 240 mg/day after meal
75375940|NCT05447468|Other|Strength of middle trapezius|Shoulder external rotation with the shoulder abducted 90ₒ and elbow flexed 90ₒ in prone position with elbow supported on the table. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
75375941|NCT05447468|Other|Strength of serratus anterior|"Ask the patient to raise the arm on a wall in the plane of the scapula in standing position.~The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks."
75375942|NCT05447468|Other|Pulsed ultrasound|With a 20% duty cycle, frequency of 1 MHz and intensity of 1.5 w/cm² for 5 minutes 3 times per week for 6 weeks.
75375943|NCT05447468|Other|Stretching of extensor carpi radialis brevis muscle|Put the elbow in extension, forearm in pronation and wrist in flexion with ulnar deviation. Hold for 30s and repeat 3 times with 30s rest in between. Three times per week for 6 weeks.
75701980|NCT00755313|Biological|trastuzumab|
75701981|NCT00755313|Drug|aromatase inhibition therapy|
75701982|NCT00755313|Drug|carboplatin|
75701983|NCT00755313|Drug|cyclophosphamide|
75701984|NCT00755313|Drug|docetaxel|
75701985|NCT00755313|Drug|doxorubicin hydrochloride|
75701986|NCT00755313|Other|metabolic assessment|
75701987|NCT00755313|Other|questionnaire administration|
75701988|NCT00755313|Other|study of socioeconomic and demographic variables|
75701989|NCT00755313|Procedure|cognitive assessment|
75701990|NCT00755313|Procedure|positron emission tomography|
75701991|NCT00755313|Radiation|fludeoxyglucose F 18|
75701992|NCT00755391|Behavioral|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
76029057|NCT05912322|Dietary Supplement|Black chokeberry juice|100ml black chokeberry juice/day
76029058|NCT05912309|Behavioral|Time Restricted Eating (TRE)|Participants will be required to reduce their eating time window to ≤ 8 hours/day. Women can choose when to begin eating, but the last meal should be completed before or at 20:00 hours (concentrating the eating window towards the active phase confers higher cardiometabolic health benefits). Our preliminary results suggest that this eating window is feasible and safe. Participants will receive dietary advice regarding the daily amount of high quality protein and meal-specific protein quantities. All the participants will attend a lifestyle education program based on Mediterranean diet and WHO physical activity recommendations every two weeks.
76029059|NCT05912309|Behavioral|Exercise|Sport sciences specialists will design, supervise and monitor the concurrent exercise intervention following the 2020 WHO recommendations. The program will be tailored to the participant's ability and health, and will be focused on a gradual increase to levels that are safe. Resistance training: 3 times/week designed to manage, attenuate and even prevent the loss of skeletal muscle tissue and function. Endurance training: 2 times/week, performed as high intensity interval training which is time-efficient, safe and effective reducing visceral adipose tissue in postmenopausal women. The exercise sessions will be scheduled within or immediately after their eating window in order to maximize muscular muscle protein synthesis. Morning and afternoon training schedules will be offered to participants.
75375944|NCT05447468|Other|Eccentric exercises of wrist extensors|Ask the patient to extend elbow, pronate forearm, extend wrist and then flex the wrist slowly until full flexion is achieved. Patients should apply 3 sets of 10 repetitions 3 times per week for 6 weeks.
75375945|NCT04587739|Combination Product|Surgery with Neoadjuvant stereotactic body radiation therapy|Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).
75375946|NCT05449652|Other|To prescribe exercise prescription for CVD patients|To prescribe exercise intensity, frequency, session duration, program duration, and exercise type (endurance or strength training) for the same three patient cases
75375947|NCT05449574|Diagnostic Test|Scale for the Assessment of Sensory Integration in Adults|In people with MS and people with health of similar age, a test was performed to assess sensory integration in adults
75375948|NCT04579159|Device|Preventicus heartbeat app in combination with wearables|CE certified devices
75375949|NCT05447390|Diagnostic Test|Handgrip strength test|The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
75701993|NCT00755391|Behavioral|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
75701994|NCT04082858|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions
75701995|NCT04082858|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
75701996|NCT05213858|Diagnostic Test|CAPS questionnaire|PTSD diagnosis and severity will be done using the CAPS-5 questionnaire.
75701997|NCT05213858|Diagnostic Test|Beck Depression Inventory|depression symptoms will be measured by the BDI-II. The BDI-II consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression.
75701998|NCT05213858|Diagnostic Test|The Fibromyalgia Impact Questionnaire|The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.
75701999|NCT05213858|Diagnostic Test|The Pittsburgh Sleep Quality Index|"sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates poor from good sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality."
75702000|NCT05213858|Diagnostic Test|Depression, Anxiety and Stress Scale-21 items|The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.
75702001|NCT05213858|Diagnostic Test|Traumatic Events Questionnaire|"The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from not at all to severely/extremely. The TEQ has previously been used in Israel."
75702002|NCT05213858|Diagnostic Test|Clinician Administered Dissociative States Scale|The CADSS is a 28-item structured clinical interview to assess state dissociation.
75702003|NCT05213858|Diagnostic Test|A diary will be used for seven consecutive nights|"A diary will be used for seven consecutive nights for the evaluation of:~Mean sleep latency~The number and duration of awakenings.~Subjective total sleep time~Subjective wake after sleep onset~Sleep efficiency"
75702004|NCT05213858|Diagnostic Test|MRI|Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.
75702005|NCT05213858|Diagnostic Test|Functional brain imaging|Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.
76029060|NCT05912309|Behavioral|Caloric Restriction|Individualised intensive behavioural intervention weight loss program including CR, exercise training and lifestyle education designed according to the current guidelines. CR will be tailored to participants (objectively assessed). Diet will provide 600 kcal/day less than the individual energy requirements based on measured resting energy expenditure (indirect calorimetry) and multiplied by an activity factor obtained by accelerometry. Experienced nutritionists will design personalized and balanced CR diet, and will train the participants through the food exchange system to follow the treatment. In those cases in which the CR compromised a protein intake of at least 1.2 g/kg/day, the macronutrient percentage distribution will be modified prioritizing achieving this minimum protein intake.
76029061|NCT05912296|Drug|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
76029062|NCT05912296|Drug|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
75375950|NCT04577287|Device|Transcranial direct current stimulation|Cathodal/Anodal tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
75375951|NCT05449184|Procedure|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|Under local or general anesthesia, insert a balloon into one Eaustachian tube and inflate it for up to two minutes. The balloon is then removed. Subsequently, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
75375952|NCT05449184|Procedure|Tympanostomy Tube Insertion|Under local or general anesthesia, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
75375953|NCT04569175|Other|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
75375954|NCT04338542|Genetic|Tumor biobsies analysis|Analysis on archived tumor biopsies
75375955|NCT05449951|Other|Dry needling|In dry needling filiform needle without a bore is used to mimic acupuncture t beyond the use of medicines. On the basis of purpose process and skill level it differs from acupuncture. DN is frequently used to treat pain caused by musculoskeletal structures, including as myofascial pain disorders
75375956|NCT05449951|Other|sustained stretching|sustained stretching is a treatment protocol in which muscle goes into a stretch position for period of time which reduce spasticity
76029063|NCT05912296|Drug|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
76029064|NCT05912296|Drug|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
76029065|NCT05912218|Biological|MEI6570|Saline Control
76029066|NCT05912205|Drug|Disitamab Vedotin|Four cycles of neoadjuvant therapy with Vidiximab (2.0mg/kg) were administered first, followed by bladder sparing therapy using maximized TURBT combined with radiotherapy and chemotherapy. The patient will receive vidiximab combined with local radiotherapy after maximizing TURBT surgery. The subjects received treatment with Vidixitol every two weeks for six consecutive treatment cycles, and simultaneously received 1 month of radiation therapy (SBRT, total dose of bladder irradiation field greater than 50 Gy)
76029067|NCT05912205|Radiation|radiotherapy|radiotherapy
75375957|NCT02198664|Biological|AR101 - Peanut protein capsule|Study product provided as peanut protein in pull-apart capsules at 5 dosage strengths (0.5, 1, 10, 100, and 475 mg) or sachets at 2 dosage strengths (300 and 1000 mg)
75375958|NCT05449028|Drug|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
75375959|NCT05449028|Drug|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
75375960|NCT05449028|Drug|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
75375961|NCT05449028|Drug|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
75375962|NCT05449028|Drug|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
75375963|NCT04543825|Device|Cardiopulmonary exercise testing|Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath.
75375964|NCT04338841|Other|HOME-CoV rule implementation|"HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.~Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments."
75375965|NCT04538287|Device|AtaCor StealthTrac Lead|Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
75375966|NCT04338464|Behavioral|Psychosocial therapy for South Asian women experiencing mood disorders|"The 12 week intervention has four major components:~Relational theory (Belgrave, 2002) & South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek & Ehrenriech-May, 2012; Ritschel, Noriel & Lindsay, 2015).~Psychoeducation on mental health, sexual health, and substance use.~Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support."
75702006|NCT05213858|Diagnostic Test|EEG analysis|EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.
75866531|NCT02405884|Other|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
75866532|NCT03010176|Drug|Ulevostinag|IT injection
75866533|NCT03010176|Biological|Pembrolizumab|IV infusion
75866534|NCT02405728|Device|Centrally inserted central catheters (CICCs)|Randomization between two well established clinical routine vascular access devices
75375967|NCT05448794|Other|injection|ultrasound-guided hydrodilatation with hypertonic Dextrose
75539002|NCT04615702|Diagnostic Test|serum lipase or amylase|"Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis~Acute pancreatitis is diagnosed when two of three criteria are present including:~Clinically (abdominal pain consistent with acute pancreatitis),~Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits)~Imaging criteria of acute pancreatitis"
76029068|NCT05912192|Drug|Elonide Nasal Spray|50mcg/dose One puff for each nostrils twice daily
76029069|NCT05912192|Drug|Nasonex Nasal Spray|50mcg/dose One puff for each nostrils twice daily
76029070|NCT05912192|Drug|Normal saline|50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
76029071|NCT05912179|Diagnostic Test|Liver biopsy - percutaneous|liver biopsy obtained using percutaneous ultrasound guided technique
75539003|NCT04615702|Device|ultrasound|helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)
75539004|NCT04615702|Device|CT|helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis
76029072|NCT05912179|Diagnostic Test|Liver biopsy - transjugular|liver biopsy obtained using an interventional transjugular approach
75539005|NCT04615702|Diagnostic Test|Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.|help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis
75866535|NCT02405728|Device|Peripherally inserted central catheters (PICCs)|Randomization between two well established clinical routine vascular access devices
75866536|NCT04897698|Dietary Supplement|LB001|Probiotics
75866537|NCT02702518|Drug|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
76029073|NCT05912179|Diagnostic Test|liver biopsy - EUS guided|liver biopsy obtained during endoscopic ultrasound
76029074|NCT05912140|Other|TRACE 2|"The first version of TRACE2 will be retrospectively verified through its application by experts on 150 photos of scoliosis patients who agreed to use the material produced for clinical use for retrospective research. Both intra-operator and inter-operator repeatability will be evaluated and a first Rasch analysis will be performed.~The new version of TRACE2 (TRACE2.2) obtained following the retrospective validation on the photos will be verified prospectively through its application by the experts on 150 patients in specialist medical examination. Both intra-operator and inter-operator repeatability will be evaluated and further Rasch analysis will follow. On the basis of the results obtained from the analysis, the new TRACE2 scale (TRACE2.3) will then be applied to a further 150 patients, its intra- and inter-operator repeatability will be calculated and a final Rasch analysis will be performed to arrive at the final version of the scale (TRACE2.4)."
76029075|NCT05912127|Device|implant supported fixed full arch prosthesis|the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
75375968|NCT05446922|Other|Diffusion MRI|All procedures will be performed during a single visit. Subjects will be invited to lie on the scanning bed that will be moved head first into the scanner such as the head lie under the scanner magnets. Hearing protection will be provided to each subject to muffle the noise produced by the MRI scanner. Subjects will also be provided with pillows and blankets to keep them comfortable. They will also be given a call button that they can push to stop the procedure at any time. MRI acquisition will be performed on 1.5T or 3.0T MRI scanners depending on centre's equipment. Acquisition protocol will include the following sequences with the best parameters chosen by local radiologist and technical BrainTale team.
75375969|NCT04845139|Drug|Nivolumab|Nivolumab given intraventricularly
75375970|NCT05446844|Other|A nurse caring behavior protocol|"Nursing interventions based on caring behaviors protocol was provided as follows:~Caring behaviors during ICU admission and orientation processes included orienting patients to time, place, and person.~Caring behaviors during physical care informing patients regarding the purpose and expected duration of mechanical ventilator use.~Caring behaviors during psychological care included offering religious sound meditation.~Caring behaviors during social interaction included maintaining eye contact during nurse-patient interaction.~Caring behaviors during health teaching included providing health teaching for patients.~Caring behaviors during maintaining a safe healing environment included providing patients with an explanation regarding nursing activities."
75375971|NCT05446844|Other|Routine nursing care|Routine nursing care was concentrated mainly on hard skills of physically demanding care such as monitoring vital signs.
75375972|NCT04738669|Other|mHealth|The mHealth intervention includes telephonic call and SMS.
75375973|NCT04738669|Behavioral|Teach-back|While the teach-back includes counselling session related to discharge instruction including medication adherence.
75375974|NCT05446688|Drug|6MW3211|6MW3211 injection, 45mg/kg, Q2W
75375975|NCT04563806|Device|Magnetic Resonance Imaging|Undergo MRI-guided surgery
75375976|NCT04563806|Procedure|Therapeutic Conventional Surgery|Undergo spinal surgery
75375977|NCT04738526|Other|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate ceramic crown
75375978|NCT04738526|Other|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|conjunction with the two zirconium oxide raw materials 3Y-TZP and 5Y-TZP is responsible for producing a continuous, seamless progression of the shade and translucency within the material
75375979|NCT04738526|Other|natural tooth|natural tooth is composed of enamel. Enamel is on the surface of every tooth and it has a natural hue of white. However, the underlying dentin layer has a slightly yellowish color. This yellowish hue shows through the enamel in almost everyone
75375980|NCT05449483|Drug|tislelizumab+ Paclitaxel + Cisplatin|tislelizumab combined with chemotherapy
75375981|NCT05448482|Procedure|Transobturator tape|Mid urethral sling for treatment of female stress urinary incontinence
75375982|NCT05448404|Drug|18F-PSMA-1007|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
75375983|NCT05448404|Drug|18F-FDG|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
75539006|NCT04615702|Device|EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)|helpful in idiopathic acute pancreatitis diagnosis
75866538|NCT02702518|Drug|Vehicle|Drug vehicle 4 times a day for 8 weeks
75866539|NCT04935060|Behavioral|A guide to inform the process of delivering the outcomes of a dementia assessment|The guide provides information that informs the approach taken to assessing people for dementia. It aims to guide clinicians. patients and their companions to think about how the diagnostic process is carried out, taking into account patient preferences, particularly around how they would like diagnostic decisions to be communicated to them.
76029076|NCT05912114|Drug|Mannitol|Mannitol, as an osmotic laxative, increases the colloid osmotic pressure in the intestinal lumen, which results in a hyperosmolar state in the intestine, thus allowing easy elimination of stools.
75375984|NCT05449093|Other|Periodontal clinical measurements and gingival crevicular fluid sampling|"Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe.~Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device."
75375985|NCT05448326|Other|Questionnaire to assess expectations of a diagnosis|Duration 45 minutes
75375986|NCT05448326|Other|Questionnaire to assess understanding of previously reported results and expectations of a diagnosis|Duration 30 minutes
75375987|NCT05448326|Biological|Blood sample +/- skin biopsy|8 ml of blood biopsy: size 3 to 5 mm
75375988|NCT04338308|Device|new-DES|with ot without embolic protection device
75375989|NCT04338308|Device|BMS|with ot without embolic protection device
75375990|NCT04438759|Device|Oncomfort, commercially available Virtual Reality headset|Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
75375991|NCT04793659|Drug|Oral Fasudil 90 mg/day|Oral tablet
75375992|NCT04793659|Drug|Oral Fasudil 180 mg/day|Oral tablet
75702007|NCT05213858|Diagnostic Test|Autonomic nervous system monitors|"Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.~Data collected from the band will include:~ACC - Data from 3-axis accelerometer sensor in the range [-2g, 2g]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)"
75702008|NCT05198817|Drug|SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection|Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
75702009|NCT02587286|Other|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
75702010|NCT00919022|Drug|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
75375993|NCT04793659|Drug|Oral Placebo|Oral tablet
75375994|NCT05448937|Procedure|Lesion sterilization and tissue repair|Pulp therapy for necrotic primary molars
75375995|NCT05448937|Procedure|zinc oxide and eugenol pulpectomy|Pulp therapy for necrotic primary molars
75702011|NCT04082156|Device|electrical stimulation|electrical stimulation
75375996|NCT00370201|Drug|colchicine|
75375997|NCT00422552|Drug|Indacaterol (QAB149)|
75375998|NCT00370279|Procedure|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
75375999|NCT05448859|Procedure|intracytoplasmic sperm injection|injection of sperm into an oocyte in assisted reproductive technology
75376000|NCT03203954|Behavioral|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
75376001|NCT03203954|Behavioral|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
75702012|NCT04082156|Device|Sham|no stimulation
75702013|NCT05191953|Procedure|Bilateral ultrasound-guided ESPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
75376002|NCT03203954|Behavioral|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
75376003|NCT05448781|Drug|Endostatin|Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
75376004|NCT03187652|Diagnostic Test|CT Perfusion Study|Brain and cardiac CT perfusion scan
75376005|NCT03187652|Diagnostic Test|Echocardiogram|Speckle tracking Echocardiography
75376006|NCT03187652|Diagnostic Test|neuro-cognitive assessment|Cambridge Brain Sciences neuro-cognitive assessment
75376007|NCT03187652|Diagnostic Test|MRI|MRI to assess white matter changes
75376008|NCT05448625|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
75866540|NCT04935060|Behavioral|Usual Care|Clinicians conduct the dementia assessment as per standard protocols
76029077|NCT05912114|Drug|Polyethylene glycol electrolyte|Polyethylene glycol electrolyte is an inert polymer that cannot be absorbed by the body itself. Due to its high permeability, it retains water in the intestinal tract, increasing the amount of fluid retained in the intestine and softening the stool, thus acting as a diuretic.
76029078|NCT05912075|Drug|mFOLFIRINOX|prior to tolinapant (ASTX660) for 6 cycles over 12 weeks
75376009|NCT05448079|Other|Sexual counseling according to the PLISSIT model, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
75376010|NCT03219697|Behavioral|Parenting education program|8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
75376011|NCT03133208|Procedure|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
75376012|NCT05442788|Biological|HB0017 150mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
75376013|NCT05442788|Biological|HB0017 300mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
75702014|NCT05191953|Procedure|Bilateral ultrasound-guided ESPB and superficial PIPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
75702015|NCT02588066|Procedure|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
75702016|NCT02559219|Other|Questionniares|
75702017|NCT05141955|Other|Group Erector Spinae Plane Block (ESPB)|"Patients will receive general anesthesia initially then bilateral ESPB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed (not exceeding toxic dose) 150 mg "
75702018|NCT05141955|Other|Group Quadratus Lumborum Block (QLB)|"Patients will receive general anesthesia initially then bilateral QLB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed not exceeding toxic dose150 mg "
75376014|NCT05442788|Biological|HB0017 450mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
75376015|NCT03182101|Behavioral|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
75702019|NCT05141955|Other|Group (C) (Control group)|Where patients will be operated under general anesthesia.
75702020|NCT02559531|Device|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
75702021|NCT05122221|Drug|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
75702022|NCT05122221|Drug|Interleukin-2|Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.
75702023|NCT05122221|Biological|CRTE7A2-01 TCR-T Cell|On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
75702024|NCT05119647|Device|Thrombus Aspiration Catheter(Ton-bridgeMT)|Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.
75702025|NCT02559453|Procedure|Debridement|Removing dead tissue from infected wounds.
75702026|NCT03802305|Device|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~anesthesia of the interdental papilla,~positioning of the needle and perforating of the interdental space,~Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
75702027|NCT03802305|Device|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
75702028|NCT00755469|Procedure|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
76029079|NCT05912075|Radiation|Pelvic radiotherapy LCRT|50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks
76029080|NCT05912075|Drug|Capecitabine|800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
75702029|NCT02587442|Drug|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
75702030|NCT04084184|Drug|HGP1812|Dapagliflozin (Forxiga) 10mg
75702031|NCT04084184|Drug|HGP1602|Dapagliflozin 10mg
75866541|NCT04482946|Diagnostic Test|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
76029081|NCT05912075|Drug|TOLINAPANT (ASTX660)|starting from 14 days before the first dose of radiotherapy, for 10 weeks.
76029082|NCT05912075|Radiation|Pelvic radiotherapy SCRT|total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)
76029083|NCT05912075|Drug|FOLFOX4|given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
76029084|NCT05912075|Drug|CAPOX|every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
75376016|NCT05442164|Behavioral|DANAKIR support network|"The DANAKIR intervention will consist of:~Structured written discharge information~Invitation to the DANAKIR monthly information meeting DANAKIR meetings The monthly meetings are a core component of the support network. One time each month, a meeting will be held at Herlev Hospital with the participation of an emergency surgeon, an emergency surgery dedicated nurse, a dietician, and a physiotherapist. Each professional (surgeon, nurse, dietician, physiotherapist) will host an informative 15 minute session regarding the postoperative course after major emergency surgery. Following the presentations time for questions in plenum and private with the different experts will be held. Furthermore, there will be an opportunity for networking at the DANAKIR meeting. Each meeting is planned to last 2 hours. At the end of each meeting the patients will be asked to evaluate the meeting and content."
75376017|NCT03123835|Procedure|Endoscopic Intervention|After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
75376018|NCT02958943|Behavioral|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
75376019|NCT04475822|Behavioral|Intermittent fasting|Intermittent fasting group:During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
75702032|NCT00755547|Other|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
75702033|NCT02587052|Drug|Generic tacrolimus|Generic tacrolimus
75702034|NCT02587052|Drug|Prograf|Prograf, the original tacrolimus
75702035|NCT02587130|Drug|Ketamine|ketamine administered in bolus by subcutaneous injection
75866542|NCT03683888|Behavioral|HealthSnap|HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
75702036|NCT00677235|Device|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
75702037|NCT00677235|Procedure|PTA|Treatment of stenoses with PTA only
75702038|NCT04084418|Other|Control Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
75866543|NCT03683888|Behavioral|dietary counseling|Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
75866544|NCT03683732|Behavioral|Individual semi-structured interviews|Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
75702039|NCT04084418|Other|VLCHF Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
75702040|NCT02559141|Drug|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
75702041|NCT05679440|Behavioral|Postural interventions based on pulmonary imaging|The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
75702042|NCT04969965|Drug|aumolertinib|EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
75702043|NCT03680625|Device|Passive Distraction|Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal and/or removal of sutures. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.
75702044|NCT03680625|Device|Virtual Reality Distraction|Patients in this group will be offered virtual reality distraction through the use of Oculus Quest® while they undergo their pins' removal and/or removal of sutures. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus head-mounted device and computer will be available in the procedure room and ready for immediate use. The head-mounted device will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin and/or suture removal in order for the child to get acquainted with the game and immersed in the virtual environment.
75702045|NCT02561013|Device|3M™ Coban™ Custom Fit Compression System|"3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.~The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together."
75866545|NCT03739229|Biological|Placebo|2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
75866546|NCT03739229|Biological|H7N9 LAIV|2 intranasal administrations of H7N9 live influenza vaccine
75866547|NCT03683654|Other|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
75866548|NCT03680300|Other|Post Facilitation Stretch|"The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition."
76029085|NCT05912036|Behavioral|CRT|CA-CRT treatment will entail exercises aimed to improve cognitive strategies, encourage subjects' reflection on their way of thinking, and explore the possibility of implementing new schemas in everyday life. The CA-CRT program will employ a range of cognitive exercises and tasks to address cognitive inflexibility and weak central coherence. The treatment will consist of 10 individual CA-CRT sessions, 2 times per week for 5 weeks, for a duration of 40 minutes per session with 15 individual CA-CRT sessions, 3 times a week for 5 weeks, with a duration of 30 minutes per session
76029086|NCT05912010|Diagnostic Test|NP/OP swab|NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.
76029087|NCT05911984|Drug|9MW3811 Injection|Intravenous injection
76029088|NCT05911971|Other|Experimental|specific reeducation (not detailed to maintain blinding of participants)
75376020|NCT04475822|Behavioral|Low carb diet|Low carb diet:The daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
75376021|NCT04475822|Behavioral|Low carbon diet and intermittent fasting group|Low carbon diet and intermittent fasting group:Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
76029089|NCT05911971|Other|Sham comparator|sham reeducation (not detailed to maintain blinding of participants)
75376022|NCT04338451|Other|Music during the first part of ESWL|Music listening during first part of ESWL
75376023|NCT04338451|Other|Music during the second part of ESWL|Music listening during second part of ESWL
75376024|NCT02992574|Radiation|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
75376025|NCT02848027|Biological|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
75539007|NCT04615702|Drug|Ringer lactate|"The initial infusion rate for mild cases :~For patients without dehydration is (130-150mL/h).~In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~For patients without dehydration is (130-150mL/h).~In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~A mean arterial pressure of 65mmHg or more,~Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters."
75376026|NCT02829229|Behavioral|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials & 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
75376027|NCT05439044|Other|Data collection|Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
75376028|NCT04256083|Biological|Biological analysis|Two blood samples of 4 ml each (total: 8 ml) for IGFBP1 assay and metabolic phenotyping and proteomic analysis.
75376029|NCT00370825|Drug|Combination therapy with AmBisome and miltefosine|
75376030|NCT05428046|Behavioral|MHL intervention|The current MHL intervention is a brief online intervention and comprises two modules. The first module is a short video introducing a teenage girl with bulimia nervosa. The second module is an online lecture comprising information about eating disorders including the prevalence, symptoms, type, cause, treatment, a related symptom checker, and sources of help. The above two modules are implemented in a single session lasting approximately 2 hours.
75376031|NCT05428046|Behavioral|Waiting list|Participants assigned to the waiting list group will not receive any intervention until the end of the 12 weeks follow-up. They received the same intervention as the MHL intervention group after the 12 weeks follow-up test.
75376032|NCT04445870|Other|data record|Data record on registers without medical files
75376033|NCT04040101|Device|smartphone-based balance training system|use smartphone application to training balance
75539008|NCT04615702|Combination Product|NSAID / paracetamol +/- opiates+/- epidural analgesia|"Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h.~Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h~Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia"
75539009|NCT04615702|Combination Product|Quinolones + Metronidazole /Carbapenems ± Metronidazole|"Mild attack: no antibiotic prophylaxis administered.~Severe attack:~Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset.~Duration: Not more than 2 weeks~Antibiotics given:~Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h~Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h~b. Therapeutic (in cases with pancreatic or extrapancreatic infections)~In case of pancreatic infection, Carbapenems ± metronidazole were given."
75376034|NCT00370136|Drug|ultrasound contrast|
75376035|NCT02602093|Procedure|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
75376036|NCT02602093|Procedure|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
75376037|NCT05419778|Device|Osteogen plug®|A type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)
75539010|NCT04615702|Dietary Supplement|Fresubin 2Kcal fiber drink|"Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications.~Route: Nasogastric tube Nutrients: Polymeric feeding formula~Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml)~Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion~The nutrition started with small amount and increased gradually over 16hrs~Infusion rate ꞊ Total caloric requirements / 16hrs"
75539011|NCT04615702|Device|nasogastric tube|in case of ileus or vomiting
75376038|NCT05419778|Device|MInerOss®|A cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane.
75376039|NCT00370357|Drug|3% w/w SPL7013 Gel (VivaGel™)|
75702046|NCT02561013|Device|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
75866549|NCT03680300|Other|Post Isometric Relaxation|"The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times."
75376040|NCT02808962|Procedure|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
75376041|NCT02165826|Drug|Roflumilast|Roflumilast tablets
75376042|NCT02165826|Drug|Roflumilast Placebo|Roflumilast placebo-matching tablets
75376043|NCT02165826|Drug|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
75376044|NCT02535247|Drug|MK-3475|
75376045|NCT02535247|Drug|Copanlisib|
75376046|NCT00370916|Behavioral|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
75866550|NCT03680300|Other|Friction Massage|Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
75376047|NCT00370916|Behavioral|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
75376048|NCT02509897|Other|Hypoxic training|Hypoxic training 3 times per week four four weeks
75376049|NCT02509897|Other|Normoxic training|Normoxic training 3 times per week four four weeks
75376050|NCT04337996|Diagnostic Test|COVID-19 diagnostic test|COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
75866551|NCT02414620|Device|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
75376051|NCT04417920|Procedure|Express implant device|"Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock."
75376052|NCT02626130|Procedure|Cryosurgery|Undergo cryoablation
75376053|NCT02626130|Other|Laboratory Biomarker Analysis|Correlative studies
75866552|NCT03680222|Procedure|Reversed Tracking Method|Reversed Tracking Method
75866553|NCT02414542|Device|MINIMA stem|
75539012|NCT04615702|Procedure|retroperitoneal necrosectomy|"General anesthesia , Supine position with 30 degree tilt towards the right side~A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially~Then, aspiration is done from the possible collection.~After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously.~At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube~After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures"
75866554|NCT03176524|Drug|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
75866555|NCT03176524|Drug|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
75866556|NCT03176524|Drug|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
75376054|NCT02626130|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75376055|NCT02626130|Biological|Tremelimumab|Given IV
75376056|NCT02198040|Other|Manual Therapy|"5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~15 minutes. Passive muscle stretching (within the limits of mobility).~15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
75376057|NCT02198040|Other|Educational group|"Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
75376058|NCT02618720|Drug|ornidazole|
75376059|NCT02618720|Drug|Placebo|
75539013|NCT04615702|Procedure|open necrosectomy|"Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain.~The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis."
75702047|NCT04081844|Drug|HCP1306|Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
75702048|NCT04081844|Drug|HGP0904|Amlodipine 5mg(Norvasc)
75702049|NCT04081844|Drug|HGP0608|Losartan 100mg(Cozaar)
75702050|NCT00676689|Device|SAPIEN Transcatheter Valve Implantation|Device Implantation
75702051|NCT02589314|Device|Mechanical periodontal therapy|
75539014|NCT04615702|Procedure|Endoscopic transmural cystogastrostomy|"for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance.~The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis"
75702052|NCT02589314|Procedure|nonsurgical periodontal therapy|
75702053|NCT04978844|Behavioral|IWOTCH|Arm 1
75702054|NCT04978844|Behavioral|Dyadic therapy|Arm 2
75702055|NCT02587988|Drug|HCP1302|
75702056|NCT02587988|Drug|HGP0904|
75702057|NCT02587988|Drug|Placebo (for HCP1302)|
75702058|NCT02587988|Drug|Placebo (for HGP0904)|
75702059|NCT00678795|Drug|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
75702060|NCT00678795|Drug|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
75702061|NCT04774952|Drug|RMC-5552|RMC-5552 for IV administration
75702062|NCT00678639|Other|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
75376060|NCT04338139|Procedure|bone regeneration|bone regeneration using bio-oss collagen
75376061|NCT05359328|Device|Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line|Measurement of physiological parameters
75702063|NCT02587208|Device|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
75702064|NCT02587208|Procedure|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
75702065|NCT02559063|Behavioral|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
75376062|NCT02197806|Drug|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
75376063|NCT02197806|Drug|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
75376064|NCT02197806|Drug|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
75376065|NCT03660085|Behavioral|PC-PEP|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
75702066|NCT02559063|Behavioral|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
75702067|NCT04190342|Other|control group|A booklet on the self-management of cancer symptoms. After the pilot RCT is completed, if the participants allocated to the control group are interested in practising tai chi, the intervention will be provided
75702068|NCT04190342|Behavioral|tai chi group|Around 60 minutes practising easy tai chi movements/postures twice per week
75376066|NCT02323165|Other|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
75376067|NCT02171845|Other|surgical biopsies|
75376068|NCT05306756|Diagnostic Test|Fetal Blood Sampling (FBS)|Vaginal examination, insert amnioscope through cervix, visualise fetal scalp, clean fetal scalp, apply ethyl chloride spray, wipe scalp with petroleum gel, small scalp scratch with sharp instrument, collect sample in heparinised capillary tube, analyse sample.
75376069|NCT05306756|Diagnostic Test|digital Fetal Scalp Stimulation (dFSS)|Vaginal examination, insert one or two fingers through cervix onto fetal scalp, rub fetal scalp digitally for approximately 30-60 seconds, withdraw fingers and observe CTG for 5-10 minutes.
75376070|NCT04109599|Behavioral|PlaySmart|Participants played the developed PlaySmart game over the course of a week.
75376071|NCT04109599|Behavioral|PlaySmart Storyline|Participants played through one PlaySmart Storyline during one 1-1.5 hour session.
75702069|NCT04772690|Other|A resource-oriented intervention|The intervention is delivered by an interdisciplinary team of occupational therapist, physiotherapist, nurse, psychologist, physician and social worker. It consists of a five-day residential stay at REHPA and a two-day follow-up stay after seven weeks at home. The residential stays include both workshops and engagement in physical and creative activities.
75702070|NCT03417687|Drug|129Xe MRI|Evaluation of pulmonary function
75376072|NCT04109599|Behavioral|Play Smart Mini-Game|Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
75376073|NCT02229864|Device|Coronary artery stenting: Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm"
75702071|NCT03417687|Drug|133 Xe scintigraphy|Evaluation of pulmonary function
75702072|NCT04767698|Drug|Belimumab|200 mg SC weekly for 36 months
75702073|NCT04767698|Drug|Short-course Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
75702074|NCT04767698|Drug|Continued Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
75702075|NCT04785807|Other|Post traumatic, Anxiety and depression evaluation|Family member of person or trust of patient who had a limitation or discontinuation of treatments will be identified and asked to fulfilled a hospitalized anxiety and depression scale and the revised Impact Event scale 7 and 30 days after the limitation or discontinuation of treatments announcement
75376074|NCT04273802|Drug|CPX-351 in cohort A|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1."
75376075|NCT04273802|Drug|CPX-351 in cohort B|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1."
75376076|NCT02229552|Other|Standardized Assessments|Children were asked to attend appointments without consuming study foods 24 hours previously, as habituation measurements are sensitive to recent consumption. Children were provided access to snack prior to completing questionnaires or cognitive assessments. Habituation to food, questionnaires and cognitive assessments were re-measured at 1-year and 2-year follow up.
76029090|NCT05911945|Procedure|Flexible Ureterorenoscopy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.
75539015|NCT04615702|Procedure|open cystogastrostomy|"for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa.~First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way."
75539016|NCT04615702|Procedure|percutaneous catheter drainage (PCD) for infected necrosis|"PCD~The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F.~After placement of the percutaneous catheter, aspirate was sent for microbiological assessment~The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection"
75539017|NCT04615702|Procedure|Endoscopic ultrasound (EUS) guided aspiration for infected necrosis|endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual
75539018|NCT04615585|Other|Aloe vera after SRP|Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.
75702076|NCT04707573|Drug|Vadadustat|oral capsules
75376077|NCT02042989|Drug|MLN9708|"Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase."
75376078|NCT02042989|Drug|Vorinostat|"Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
75376079|NCT02214134|Genetic|Tumour markers testing|
75376080|NCT04248686|Behavioral|CoED Online Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity
75376081|NCT04093531|Drug|Ustekinumab|Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.
75376082|NCT05272670|Behavioral|A digital foot self-management program|A 4-week digital foot self-management program based on Bandura's Self-Efficacy model. The proposed functions include checking conditions of foot, cleaning, cutting or removing corns and calluses, trimming, clipping nails, foot exercise, dietary related to foot care, foot care logs, etc. Which was developed for older adults with diabetic foot self-management by the study team. Week 1 one-hour face-to-face training session after participant recruitment and allocation. The outline session is 30 min to introduce key topics and function in the app platform, 15 min to install the app and to demonstrate the use of the app, 15min to discuss and practice. Week 2 to week 4 following phone call once per week at the end of week and LINE messages 3 times per week.by research nurse, who will encourage and monitor participant's compliance with the program at home by using the digital platform. Participants are informed that technical phone support is available during the trial.
75376083|NCT04186520|Biological|8/12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
75376084|NCT04186520|Biological|8/12-Day Production of Cryopreserved Car-T Cells|A fixed cryopreserved dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
75376085|NCT04186520|Biological|12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
75376086|NCT04172948|Device|Oculus go headset/virtual reality headset|10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.
75376087|NCT04172948|Behavioral|Diaphragmatic breathing|10 minute tutorial on diaphragmatic breathing by a medical professional.
75539019|NCT04615585|Procedure|Scaling and root planing (SRP)|Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.
75702077|NCT02589080|Behavioral|Non-invasive sensory feedback|"A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback."
75702078|NCT04082702|Behavioral|Faith-enhanced diabetes prevention program|The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
75539020|NCT04615468|Drug|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
75539021|NCT00221741|Drug|Fresh Frozen Plasma (blood product)|
75539022|NCT04615858|Dietary Supplement|Genepro Generation 3 Protein|Generation 3 Genepro Protein. Micronized protein. Zero lactose. No gluten. All Natural. No flavor. No Sugar. FODMAP Certified protein. 11g in weight, scoop.
75702079|NCT04082702|Behavioral|Standard diabetes prevention program|The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
75702080|NCT03301311|Other|Specific Carbohydrate Diet (SCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
75376088|NCT04059757|Biological|Fecal Microbiota Transplantation (FMT)|1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
75376089|NCT04164680|Diagnostic Test|Multimodal Neuroimaging|fludeoxyglucose (FDG-)PET/MR imaging
75376090|NCT05224076|Other|Home Air Quality|This study will assess the feasibility and usability of ecological momentary assessment (EMA) to capture the context of real time behaviors and environmental exposures that impact indoor environments. In addition, the study will assess the feasibility and usability of providing participants with a readily available indoor home air quality monitor to continuously capture total volatile organic compounds (VOCs) and particulates (PM2.5).
75376091|NCT05208944|Drug|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
75376092|NCT05208944|Drug|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
75376093|NCT01809379|Drug|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
75539023|NCT04615858|Dietary Supplement|Whey Protein|Nutrition industries number 1 selling whey protein powder. No flavor. Gluten Free. 30g scoop.
75539024|NCT04615351|Drug|Metformin|Medication
75539025|NCT04615156|Drug|18F-2-fluoro-2-deoxy-D-glucose|Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
75539026|NCT00221780|Device|left ventricular pacing|
75539027|NCT04615312|Drug|a CDK4 / 6 inhibitor and a MEK inhibitor|Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
75702081|NCT03301311|Other|Modified Specific Carbohydrate Diet (MSCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
75539028|NCT04614961|Other|Lifestyle therapy - individual|Individual therapy
75702082|NCT04082624|Behavioral|Nutrition condition|Received nutritional information in in-person PowerPoint presentations.
75702083|NCT04082624|Behavioral|Affective condition|Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.
75866557|NCT03676088|Procedure|root coverage|recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
75539029|NCT04614961|Other|Lifestyle therapy - group|Group therapy
75539030|NCT04614961|Other|Medical therapy|Medical therapy
75539031|NCT04614961|Procedure|Bariatric surgery|Surgical and endoscopic therapy
75539032|NCT04618666|Procedure|laparoscopic and open surgery intervention|laparoscopic and open surgery to remove an inflammed appendix in chronic appendicitis
75539033|NCT00251121|Other|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
75539034|NCT00251121|Other|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
75539035|NCT04614883|Device|Volatile Organic Compounds analysis|VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.
75539036|NCT04614883|Other|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
75866558|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
75866559|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
75539037|NCT00221819|Device|heated humidifier (device)|
75539038|NCT00221819|Device|Heat and moisture exchanger (device)|
75539039|NCT04614727|Combination Product|polymeric nano calcium fluoride containing varnish NANO SEAL|It consists of four components Silicone polymer provides excellent adhesion to enamel and dentine, with transparent formula. NANO-fluoroapatite flows into enamel micro cracks & seals it, penetrating into the dentinal tubules closing them eventually. As for the NANO-calcium fluoride it behaves as a fluoride reservoir, provides gradual and long-term fluoride release. The fourth component Amine fluoride (Olaflur) provides immediate fluoride ion release and accelerates natural remineralization.
75539040|NCT04614415|Device|Autocrosslinked Hyaluronic aid|IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
75702084|NCT04082624|Behavioral|Instrumental condition|Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.
75702085|NCT04082624|Behavioral|Self-regulation condition|Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
75702086|NCT04049253|Drug|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
75376094|NCT01802840|Dietary Supplement|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
75376095|NCT01723969|Genetic|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
75376096|NCT02229396|Drug|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
75376097|NCT02229396|Drug|Exentide|2 mg
75376098|NCT02229396|Drug|Dapagliflozin|10 mg once daily Dapagliflozin
75376099|NCT05202158|Procedure|Addition of gentamicin to irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, 80 mg of gentamicin will be added to 3 liters of irrigation fluid while the stone is being fragmented.
75702087|NCT00919958|Biological|PLX-PAD IM injection|Single treatment; multiple injections
75702088|NCT03217851|Diagnostic Test|Blood Collection|blood smear and/or rapid diagnostic
75702089|NCT03217851|Diagnostic Test|Dried Blood Spot|Dried Blood Spot on filter paper
75866560|NCT02414464|Other|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
75539041|NCT04614415|Other|placebo|The placebo consists in an isotonic saline solution (NaCl 0.9%)
75702090|NCT04082000|Drug|BOL-DP-o-04|BOL-DP-o-04
75702091|NCT04082000|Drug|Placebo|Placebo
75702092|NCT03205137|Drug|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
76029091|NCT05911945|Procedure|Mini Percutaneous Nephrolithotomy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
76029092|NCT05911919|Device|brainQuant module of brainTale-care platform|brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
75539042|NCT04614688|Behavioral|Patient Education Platform|The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
75539043|NCT00247923|Procedure|Hysteroscopic resection of endometrial polyps. (TCRP)|
75702093|NCT03205137|Drug|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
75539044|NCT04614298|Drug|KHK4827-Active|Single SC administration
75702094|NCT03205137|Drug|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
75702095|NCT03205137|Drug|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
75702096|NCT04953650|Behavioral|Intermittent fasting|The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.
75702097|NCT04953650|Other|No intervention|The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
75702098|NCT05189522|Device|Innova Breeze®-based roadmap|An Innova Breeze® bolus chase acquisition is realized to assess the final result of the Revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm
75702099|NCT05189522|Other|Control Group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
75702100|NCT02588144|Procedure|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
75376100|NCT05202158|Procedure|Only irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, only irrigation fluid will be used while the stone is fragmented.
75376101|NCT00370370|Drug|bevacizumab|Injection of intravitreal bevacizumab
75376102|NCT00370370|Drug|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
75539045|NCT04614298|Drug|KHK4827-Placebo|Single SC administration
75539046|NCT04613986|Device|therapeutic plasmaexchnage|established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)
75702101|NCT02588144|Procedure|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
75702102|NCT02586740|Procedure|Pulmonary artery rehabilitation|
75702103|NCT04951544|Other|LetSync v1.0|Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.
75702104|NCT04951544|Other|LetSync v2.0|LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.
75702105|NCT02589236|Drug|Cavosonstat|GSNOR inhibitor
75702106|NCT02589236|Drug|Placebo|Control sample with only capsule excipients and fillers
75702107|NCT04082468|Diagnostic Test|Blood sample collection for coagulation profile|Factor VIII Activity Level, Factor VIII Antigen Level, Interleukin 6, vWF Antigen Level, Thrombin Activity, Protein C Activity, Protein C Antigen Level, CRP, PT/PTT/INR ,T & B lymphocyte panel at above time points
75702108|NCT00920036|Device|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
75702109|NCT04684550|Drug|Stabilized hypochlorous acid|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
75702110|NCT04684550|Drug|Placebo|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
75702111|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
75702112|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
75702113|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
75702114|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
75702115|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
75702116|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
75702117|NCT00678561|Drug|Placebo Vehicle|Topical treatment once daily for 28 days
75702118|NCT00678561|Drug|Placebo Vehicle|Topical treatment twice daily for 28 days
75702119|NCT05613296|Drug|Fostamatinib|Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
75702120|NCT04081532|Procedure|surgical removal of superficial peritoneal endometriosis|In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
75866561|NCT02961582|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
75376103|NCT01457833|Device|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
75376104|NCT01457833|Device|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
75376105|NCT00370435|Drug|GW274150|
75376106|NCT01107613|Behavioral|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
75376107|NCT01269164|Procedure|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
76029093|NCT05911893|Dietary Supplement|high caloric oral nutritional supplements|High caloric oral nutritional supplements (which can supplement 30% of the energy requirement) is given daily, and the recommended amount of energy and protein is referred to the 2013 Chinese Dietary Nutrient Reference Intake Table. At 6 months of enrollment, participants will be asked to evaluate whether to continue feeding according to the experimental group protocol or to stop to ensure proper nutritional intake.
76029094|NCT05911893|Behavioral|nutritional education|After enrollment,health education information is pushed approximately every 4 weeks through the WeChat platform or/and short text messages to parents.
75376108|NCT00370513|Drug|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
75376109|NCT05179382|Other|Control protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position.
75702121|NCT04731350|Device|radial extracorporeal shock wave|Radial shock wave device, Swiss DolorClast (EMS Electro Medical Systems, Nyon, Switzerland)
75702122|NCT04731350|Device|iontophoresis|Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED):
75702123|NCT04731350|Other|Exercise|strengthening exercise
75702124|NCT04081766|Behavioral|SUGAR Handshake|"An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~Signs and symptoms of hypoglycemia.~Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~Acknowledgement by the patient~Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit."
75702125|NCT04950686|Behavioral|Media Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.
76029095|NCT05911893|Behavioral|dietary guidance|At follow-up visits at 0, 1, 2, 3, 6,and 12 months after enrollment, a professionally trained pediatrician give the participant's guardian dietary instructions appropriate to the age stage and physical condition of the child. Each session lasts approximately 10 minutes.
75376110|NCT05179382|Other|Hydration protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position. V. Water ingestion distributed in 10 equal portions, administered at regular intervals of 15 minutes from the 15th minute of exercise until the end of the recovery period.
75702126|NCT04950686|Behavioral|Health Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
75376111|NCT02197416|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
75702127|NCT02587832|Device|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
75376112|NCT00370591|Drug|Salmeterol/fluticasone propionate and fluticasone propionate|
75702128|NCT02587832|Device|NCPAP|Bubble CPAP System.
75702129|NCT00920114|Biological|blood sample|
75376113|NCT05166044|Biological|EV71 Inactivated Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co,And inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
75866562|NCT02961582|Other|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
75376114|NCT00598988|Procedure|traditional Chinese acupuncture|10 treatments over 6 weeks
75866563|NCT04039503|Drug|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
75866564|NCT04039503|Drug|Placebo|Administered SC as add-on to the pre-trial background medication.
75866565|NCT02414308|Drug|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
75866566|NCT02860728|Behavioral|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
75866567|NCT03679910|Diagnostic Test|CEMIP , CA19-9 ,CEA|CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
75866568|NCT03679910|Diagnostic Test|A) CBC . B) RBG. C)KFT. D) LFT.|A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
76029096|NCT05911867|Other|combination of mobilization with movement and muscle energy techniques|"The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range."
75376115|NCT00598988|Other|standard medical care|standard care as provided by primary physician
75376116|NCT03956173|Other|Hypoglycemic combined with either normo or hyperglycemic clamp.|Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
75376117|NCT03080311|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
75376118|NCT00371527|Drug|ipratropium|
75376119|NCT00392756|Drug|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
75376120|NCT05143658|Procedure|LLS versus LP|Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
75376121|NCT04027322|Drug|Budesonide 0.25 MG/ML Inhalant Solution|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
75702130|NCT04691180|Drug|BRII-196 and BRII-198|BRII-196 and BRII-198 given intravenously
75702131|NCT04691180|Drug|Placebo|Placebo given intravenously
75702132|NCT04912622|Diagnostic Test|Clinical Trial|Retinal image acquisition with Cellularis version 2.0
75702133|NCT04081376|Drug|Hydromorphone Hydrochloride|4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
75702134|NCT04890158|Other|Prone positioning for a total of 6 hours daily|Prone positioning for 6 hours daily
75702135|NCT00920192|Drug|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
75866569|NCT05418114|Drug|Magnesium sulfate|. One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
75866570|NCT03683420|Behavioral|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
75376122|NCT04027322|Drug|Dexamethasone|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
75702136|NCT02584400|Drug|Injection with the hypoxia tracer [18F]HX4,|The [18F]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) [18F]HX4 via a bolus IV injection.
75702137|NCT00676143|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
76029097|NCT05911867|Other|muscle energy techniques Interventions:|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applied manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
75376123|NCT04027322|Drug|Normal saline|Placebo for the control group.
75376124|NCT00371215|Biological|rThrombin|1000 U/mL applied topically
75376125|NCT03845257|Diagnostic Test|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as >300/µl (or >150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
75376126|NCT05454475|Other|Change the water injection temperature|Water injection is a routine procedure for endoscopy of small probe ultrasound, and our intervention is to change the water temperature and observe the effects of different water temperatures on patient safety and comfort.
75376127|NCT00371072|Procedure|trabeculectomy with mitomycin-C|
75376128|NCT03056365|Procedure|Advanced Nurse (AN)|Protocoled AN-based management of detox
75376129|NCT03056365|Procedure|General Practitioner (GP)|'As usual' medical management of detox
75376130|NCT00370448|Behavioral|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
75376131|NCT00371228|Procedure|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
75702138|NCT00676143|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
75702139|NCT02586272|Device|Daifert|
75702140|NCT02586272|Procedure|Control Group|
75702141|NCT02586428|Other|what patients elect noninvasive prenatal testing (NIPT)|what percentages of patients elect noninvasive prenatal testing (NIPT), amniocentesis, or no testing before and after genetic counseling.
75702142|NCT04082390|Dietary Supplement|RELEASE|Dietary supplement
75702143|NCT04082390|Dietary Supplement|Placebo|Placebo
75702144|NCT02587676|Other|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
75702145|NCT02586350|Drug|Anlotinib|
75702146|NCT02586350|Drug|Placebo|Placebo p.o. qd
75702147|NCT04504071|Drug|Dacomitinib|Patients will receive continuous oral therapy with the study drugs (dacomitinib 45 mg) until disease progression or unacceptable toxicity.
75702148|NCT02586194|Drug|ASP015K|Oral
75702149|NCT04079660|Diagnostic Test|Capillary blood glucose blood draw|Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
75702150|NCT02559375|Other|Survey|
75866571|NCT03683264|Other|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
75702151|NCT02584166|Behavioral|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
75702152|NCT02559843|Dietary Supplement|pomegranate juice|
75702153|NCT02559843|Behavioral|lifestyle modification|
75702154|NCT02586116|Device|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
75702155|NCT02586116|Device|C-Plus|C-Plus PEEK IBF Device with autograft
75376132|NCT05454644|Other|Person-Centred Prescription Model|"Step 1: Identify patients with advanced chronic condition and limited life expectancy.~Step 2: Interview with patients or closes caregiver.~Step 3: Medication Review~The clinical pharmacist conduct a structured medication review based on the medication appropriateness index (MAI):~Indication/effectiveness: Product information, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.~Dosage adjustment: Product Information and Lexi-Comp's Geriatric Dosage Handbook.~Correct and practical directions: Medication Regimen Complexity Index (MRCI).~Drug-drug interactions: Bot Plus/Beers Criteria and drug burden index (DBI), which measures dose-dependent anticholinergic and sedative loads.~Drug-disease interactions: Beers Criteria.~Duplication, duration and cost-effectiveness: Product information.~Step 4: Treatment Plan"
75866572|NCT01364025|Procedure|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
75376133|NCT05118698|Drug|Gynostemma|Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
75702156|NCT00761163|Other|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
75866573|NCT03225716|Drug|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
75376134|NCT05118698|Other|Spinach|For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
75376135|NCT00370526|Procedure|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
75376136|NCT05454397|Other|Observational study, no intervention|Observational study, no intervention
75376137|NCT05454332|Drug|Early Caffeine administration|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
75539047|NCT04614259|Drug|Bupivacain|"The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). [104] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis"
75539048|NCT04614259|Combination Product|i.v. analgesia|"Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes"
75702157|NCT00761163|Other|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
75866574|NCT03225716|Drug|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
75866575|NCT03672812|Drug|Liraglutide|liraglutide 3mg 6/6 hours
75866576|NCT05417880|Drug|Oral Hypoglycemic Agents,Oral|Control group with routine current oral hypoglycemic agents for 3-6 months
75866577|NCT05417880|Drug|Voreta|Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
75866578|NCT05417880|Drug|Voreta plus SunnyD PRO|Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
75866579|NCT05186883|Biological|Allogenic parathyroid cells|Allogenic parathyroid cells
75866580|NCT05186883|Other|Standard treatment according to the Clinical protocols|Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
75866581|NCT05007652|Drug|KRN125(pegfilgrastim), PLR001(plerixafor)|7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
75866582|NCT05007652|Drug|KRN8601(filgrastim), PLR001(plerixafor)|400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
75866583|NCT03675932|Other|Rapid Cadence Cycling on a Solo-Rider Spin Bicycle|Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
75866584|NCT01367145|Drug|OMACOR|4 capsules OMACOR 1g per day
75702158|NCT00761163|Other|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
75702159|NCT02584322|Other|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
75702160|NCT00761241|Drug|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
75702161|NCT00761241|Biological|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
75702162|NCT00761241|Radiation|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
75702163|NCT00761241|Procedure|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
75702164|NCT02558907|Other|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
75702165|NCT04585022|Device|Magnum, Zimmer Biomet, Warsaw, IN|
75376138|NCT05454332|Other|Control Group|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
75376139|NCT03977714|Device|Zirconia implants with G3-coated abutments (test implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
75702166|NCT04585022|Device|Recap, Zimmer Biomet, Warsaw, IN|
75376140|NCT03977714|Device|Zirconia implants with control abutments (test implants, negative control abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
75702167|NCT02981979|Drug|Leflunomide 10mg Tab|20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).
75702168|NCT02981979|Drug|Prednisone Acetate|basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）
75702169|NCT02981979|Drug|Placebos|used in control group during the induced remission therapy for 24 weeks.
75702170|NCT04081064|Behavioral|10-week exercise programme based on aerobic interval and resistance training|The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
75702171|NCT04049409|Drug|CMAB809|CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
75702172|NCT04049409|Drug|Trastuzumab|Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
75702173|NCT04568252|Device|Wristband with millimeter wave emission.|Wristband treatment with millimeter wave emission twice a day for 3 months.
75866585|NCT01367145|Drug|Placebo|4 capsules placebo per day
75866586|NCT03679754|Biological|Ad-RTS-hIL-12|"2.0 x 10^11 viral particles (vp) per injection~intratumoral injection of Ad-RTS-hIL-12"
75866587|NCT03679754|Drug|veledimex|"20mg/day~15 oral daily doses of veledimex"
75866588|NCT02405572|Other|infant formula|infant formulas
76029098|NCT05911867|Other|mobilization with movement|Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.
75376141|NCT03977714|Device|Titanium implants with G3-coated abutments (control implants, test abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
75702174|NCT04568252|Device|Placebo of wristband with millimeter wave emission.|Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
75702175|NCT00920660|Drug|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
75702176|NCT00920660|Drug|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
75702177|NCT00920660|Drug|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
75702178|NCT00920660|Drug|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
75702179|NCT00920660|Drug|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
75702180|NCT00920660|Drug|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
75702181|NCT02903355|Drug|D-methionine|D-methionine, oral liquid suspension
75702182|NCT02903355|Drug|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
75702183|NCT02583464|Drug|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
75866589|NCT01319409|Procedure|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
75866590|NCT01319409|Procedure|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
75866591|NCT02405806|Dietary Supplement|low carbohydrate food|low carbohydrate food
75866592|NCT02405806|Dietary Supplement|standard food|standard food
75866593|NCT03632772|Drug|Solifenacin 5Mg|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
75866594|NCT03632772|Drug|Mirabegron 50 MG|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
75866595|NCT01360749|Drug|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
75866596|NCT01360749|Drug|Placebo|Placebo dose: 2 g for 10 cm2.
75866597|NCT02960516|Device|MRI of 3.0T|Diffusion Tensor Testing for peripheral nerve monitoring
75866598|NCT01367223|Dietary Supplement|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
75866599|NCT01367223|Dietary Supplement|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
75866600|NCT03171766|Diagnostic Test|Mini-Mental State Examination (MMSE)|It is simple scored form of the cognitive mental status examination which includes eleven questions and requires only 5 to 10 minutes.
75866601|NCT03171766|Diagnostic Test|Visual Analog Scale (VAS)|Visual Analog Scale (VAS) for pain score (including aphasia, motor disability, major neurocognitive disorder, etc)
75866602|NCT03171766|Diagnostic Test|Mini Cog test|The Mini-Cog© test is another validated and simple tool to screen for dementia and cognitive dysfunction. It measures the cognitive reserve at the time of acute stress with a low degree of interobserver variability.
75866603|NCT03171532|Procedure|Strands of Hamstring Autograft in ACL reconstruction|The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
75866604|NCT03672656|Device|lasercoagulation by Pascal system|pattern scanning laser system Pascal given in a single-session
75866605|NCT03672656|Device|conventional laser|conventional laser multiple-session treatment
76029099|NCT05911854|Device|Multi-waved Locked System Laser|The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.
75702184|NCT00675597|Drug|Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)|Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
75702185|NCT00761397|Behavioral|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
75702186|NCT00761397|Behavioral|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
75702187|NCT00761397|Other|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
75376142|NCT03977714|Device|Titanium implants with control abutments (negative control implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
75376143|NCT03977714|Device|Zirconia implants and titanium implants, for histological and histomorphometric evaluation.|"6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary."
75376144|NCT03924518|Drug|Granisetron Hydrochloride|Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
75376145|NCT03924518|Drug|Placebo（Normal saline）|therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
76029100|NCT05911854|Device|Cold Compression therapy|The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.
76029101|NCT05911854|Other|complete decongestive therapy|"Complete decongestive therapy consists of:~Meticulous skin care with the use of emollients~Using short stretch bandages or continuous wearing of a pressure garment~Manual lymphatic drainage therapy~Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)"
75376146|NCT05454163|Other|SNOT 22 questionnaire|22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
75376147|NCT05037344|Behavioral|Cognitive-behavioral psychotherapy|The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
76029102|NCT05911828|Drug|ZY19489 + Ferroquine (FQ)|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
75376148|NCT05454085|Dietary Supplement|Bisphenol-A|measurement of BPA levels in maternal blood and amniotic fluid
75376149|NCT05453786|Drug|SID1903|Single oral administration of SID1903 after an overnight fast
75376150|NCT05453786|Drug|SID1903-R1/SID1903-R2|Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
75376151|NCT03893396|Device|Coronary angioplasty|Procedure used to open clogged heart arteries. Involves the insertion of a tiny balloon and/or a stent to widen the artery.
75376152|NCT00369902|Procedure|acupuncture|
75702188|NCT00761397|Other|Questionnaire|Day 1 of study, 10 weeks after starting study, & 12 months after starting study
75376153|NCT03886922|Drug|Levcromakalim|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
75376154|NCT03886922|Drug|Saline|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
75376155|NCT00370058|Procedure|ECT treatment|
75376156|NCT03864224|Behavioral|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
75376157|NCT04738370|Other|Sample collection|Bloods +/- urine +/- vaginal swabs taken
75702189|NCT04292301|Device|STrategically Acquired Gradient Echo (STAGE)|The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
75702190|NCT04255563|Device|DCB treatment|DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
75866606|NCT03675854|Drug|Cefazolin|3 weeks
75866607|NCT03672578|Other|loss-frame|loss frame label
75866608|NCT03672578|Other|gain-frame|gain frame label
75866609|NCT03672578|Other|text-only|text-only label
75866610|NCT03672578|Other|icon|label with icon and text
75866611|NCT03672578|Other|attribution|label with attribution
75702191|NCT04078646|Other|Intervention with soy protein isolate|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
75376158|NCT05453552|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
75376159|NCT05453552|Drug|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
75376160|NCT05453552|Drug|Busulfan|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
75702192|NCT04078646|Other|Intervention with whey protein|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
76029103|NCT05911828|Drug|Placebo|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
75702193|NCT04078646|Other|Intervention without protein addition|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
75702194|NCT04049565|Diagnostic Test|Procalcitonin biomarker and CRP biomarker|collecting blood samples to measure serum CRP and Procalcitonin
76029104|NCT05911815|Radiation|hysterosalpingography|hysterosalpingogram (HSG) is an X-ray visualization of the lumen of the uterus and fallopian tubes, which can detect abnormalities including blockage, polyps, and salinities
76029105|NCT05911750|Diagnostic Test|Anal pap smear and oral swab for cytology and HPV testing|Anal and oral swab sampling for HPV detection (polymerase chain reaction) and cytology
76029106|NCT05911737|Behavioral|Short video and Questionnaire|A 10-minute video in a foreign language (not English or Greek) with greek subtitles will be presented and a questionnaire will follow to assess the level of concentration during the video
75376161|NCT05453552|Drug|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
75376162|NCT05453552|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
75376163|NCT05453552|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
75376164|NCT05453474|Genetic|Whole genome amplification|DNA is amplified by whole genome amplification
75376165|NCT05453318|Procedure|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
75376166|NCT05018624|Behavioral|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
75376167|NCT05018624|Behavioral|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
75376168|NCT05018624|Behavioral|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
75376169|NCT05018624|Behavioral|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
75702195|NCT02677545|Drug|Ticagrelor|
76029107|NCT05911711|Other|Prognostic factor|normal person (no sepsis group)
76029108|NCT05911685|Device|SeaLA™ left atrial appendage occluder|"Guided by esophageal ultrasound (TEE) and angiography, the diameter of the left atrial appendage anchoring zone and the longest depth of the left atrial appendage were measured to determine the appropriate size of the left atrial appendage occluder.~Maintain Activated Clotting Time (ACT) greater than 250 seconds after atrial septal puncture to the completion of the entire procedure.~Before the plugging device is released, confirm whether there is a residual peri-device leak, and if there is a residual peri-device leak, consider retracting the occluder to reposition the release or retract the occluder to choose a larger size occluder to re-occlusion. If ultrasound confirms residual peri-device leak greater than 5 mm, do not release and implant the left atrial appendage occluder.~Before and after release, confirm the position and stability of the occluder under ultrasound (TEE), and confirm that the occluder completely occludes the left atrial appendage."
75702196|NCT02677545|Drug|Clopidogrel|
75702197|NCT02677545|Drug|Aspirin|
75702198|NCT04479644|Drug|BRII-198|BRII-198 given intravenously
75702199|NCT04479644|Drug|Placebo|Placebo given intravenously
75702200|NCT04079426|Other|Sampling of Blood and bronchoalveolar lavage|Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.
75702201|NCT00921921|Drug|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
75702202|NCT00921921|Drug|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
75702203|NCT02602119|Drug|OTL38|Infusion of OTL38 prior to surgery
75702204|NCT00761475|Procedure|mesh supported closure|onlay mesh supported closure midline laparotomy
75702205|NCT00761475|Procedure|primary closure|primary closure of the midline
76029109|NCT05911672|Device|PRICE|Working closely with 51 cancer patients, medical and paramedical personnel, we co-designed an intelligent personalized mobile application to first collect ecologically momentary assessment data on symptoms like pain and fatigue and Health-Related Quality of Life and subsequently enhance symptom management of cancer patients at home. The full description is available here: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa_token=tC5fSN8-k5EAAAAA:56_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
76029110|NCT05911659|Drug|Ticagrelor|Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI
76029111|NCT05911646|Other|OSA-18 Survey|"OSA 18 is an 18-item questionnaire that uses a Likert-type scoring system to collect information about 5 subscales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. On the basis of this information, a summary score is calculated and scores are divided into three categories:~Mild (40-60), moderate (61-80) and severe >81."
75376170|NCT05018624|Behavioral|General health through IM Apps|After baseline, they will receive regular e-message through IM Apps with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
76029112|NCT05911646|Other|Decisional Conflict (DCS)|The DCS is a 16-item survey in which participants are asked to respond to statements related to their decision on a five-point ordinal Likert scale: 0) strongly agree, 1) agree, 2) neither agree nor disagree, 3) disagree, and 4) strongly disagree. Scores are summed, divided by 16, and multiplied by 25. Scores range from 0, signifying that the respondent has complete certainty about the best choice, to 100, which signifies that the respondent feels extremely uncertain about the best choice.
76029113|NCT05911633|Device|BioPearl™|TACE
75376171|NCT05018624|Behavioral|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
75376172|NCT03851120|Dietary Supplement|Probiotics and LC-PUFA (480 mg DHA)|Probiotics and LC-PUFA (480 mg DHA)
75376173|NCT03851120|Dietary Supplement|Placebo probiotics and control LC-PUFA (120 mg DHA)|Placebo probiotics and control LC-PUFA (120 mg DHA)
75376174|NCT03851120|Behavioral|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
75376175|NCT05011838|Other|1. Health Services Redesign|"1.1. Healthy Hearts service: a nursing station providing blood pressure measurement, cardiovascular risk assessment, preventive counselling and effective follow-up in extended opening hours.~1.2. Hypertension screening: All adults attending health care facilities who did not have their blood pressure measured in the previous year will be referred to the Healthy Hearts Service for screening.~1.3. Clinical management: 1.3.1. Creation of the cardiovascular risk team: a group of doctors supervising hypertension management and coordinating improvement.~1.3.2. Guideline-based standardized diagnostic and treatment protocols: a simplified diagnostic and treatment algorithm will identify a core set of primary and secondary antihypertensive medications.~1.3.3. Availability of antihypertensive medications: it will be assured through procurement mechanisms and its availability will be communicated to clinicians at the beginning of each week and ad hoc in case of stock-outs."
76029114|NCT05911607|Procedure|Low power laser|Phototherapy for extraction sockets using two different lasers.
75702206|NCT00761475|Procedure|mesh supported closure|sublay mesh supported closure midline laparotomy
75702207|NCT04477538|Other|Post-mastectomy breast reconstruction physical well-being survey|-The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.
75702208|NCT00675441|Drug|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
76029115|NCT05911581|Other|intra-arterial flushing|"The catheter will be flushed to prevent occlusion after radial artery catheterization.~intra-arterial flushing with heparinized fluid kept in room air"
76029116|NCT05911581|Other|intra-arterial flushing|Intra-arterial flushing with heparinized fluid at patient body temperature
75702209|NCT00761553|Other|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
75702210|NCT00761553|Dietary Supplement|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
75702211|NCT02559297|Drug|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
75702212|NCT02559297|Drug|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
75702213|NCT01413399|Drug|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
75702214|NCT04049487|Other|Exercise|Both groups will participate in group exercise as previously described
75866612|NCT03672578|Other|no attribution|label with no attribution
76029117|NCT05911542|Behavioral|Survey|Participants complete survey about pain management practices
75376176|NCT05011838|Other|2. Clinical Staff Training|"2.1. Training on good clinical management of hypertension: focused on correct blood pressure measurement, use of evidence-based guidelines, cardiovascular risk assessment, use of a standardized diagnostic and treatment algorithm, correct prescription of pharmacological and non-pharmacological treatment, patient counselling, and how to tackle clinical inertia.~2.2. Training on communication skills and patients' needs assessment for all health workers involved in hypertension care. This training will be designed under the patient-centred medicine framework, aiming at equipping health providers with tools for understanding patients' feelings and experience of illness, and to improve their capacity to address social, psychological, and behavioural dimensions of hypertension care."
75376177|NCT05011838|Other|3. Patient and Community Engagement|"3.1. Patient empowerment: expert hypertensive patients , under the supervision of a social worker, will provide support and transmit their know-how to other patients in need, particularly those newly diagnosed or non-adherent to treatment or presenting uncontrolled hypertension.~3.2. Community engagement: a Community Hypertension Outreach Group will be set up, composed of existing voluntary community health workers, who will be trained and certified. This group will conduct blood pressure measurements in selected public areas of the commune, referring those with positive screening to the nearest health facility for diagnosis confirmation. It will also provide health information with emphasis on healthy lifestyles. Existing local communication channels such as the community radio and the local newspaper will be engaged."
75376178|NCT04976972|Device|NAVIO/CORI Surgical System|Total knee replacement with robotic assistance
75376179|NCT04976972|Procedure|Non-robotic conventional instrumentation|Total knee replacement with non-robotic conventional instrumentation
75376180|NCT04976738|Drug|Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
75376181|NCT04951934|Device|EmoLED|This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
75376182|NCT04951934|Procedure|Standard treatment|"The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging."
75376183|NCT04950296|Other|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
75702215|NCT02558517|Drug|prednisone discontinuation|randomization
75702216|NCT00674973|Drug|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
75702217|NCT00674973|Drug|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
75702218|NCT00673179|Drug|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m^2.
75702219|NCT00673179|Drug|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m^2/day for 2 days continuous infusion.
75702220|NCT00673179|Drug|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m^2, max 20 gm over 4 hours.
75866613|NCT03672578|Other|No label|No label
75866614|NCT02414074|Behavioral|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
75866615|NCT02414074|Behavioral|Parent Education|Everyday Parenting is a parent training curriculum.
75866616|NCT01367379|Procedure|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
76029118|NCT05911529|Behavioral|Motivational Interviewing|In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
75866617|NCT01367379|Other|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2~4 times/month)
75866618|NCT02409472|Other|surveillance program after completion of primary treatment|These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
75376184|NCT04950296|Other|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
75702221|NCT00673179|Drug|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
75702222|NCT00673179|Drug|Dexrazoxane|Dose 900 mg/m^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
75376185|NCT04950296|Other|Microcrystalline cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
75376186|NCT03787082|Drug|Nitrates|1,000 mg/11.18 mmol, oral
75376187|NCT03787082|Drug|Chlorhexidine Gluconate Mouthwash|chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
75376188|NCT03787082|Drug|Placebo Mouthwash|sterile water (15mL) mouth rinse for 1 minute
75376189|NCT05451134|Other|Catecholamines|Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
75376190|NCT05449886|Procedure|TVC|Tidal volume challenge from 6ml/kg to 10ml/kg for 1 min.
75376191|NCT04945304|Procedure|magnetic bariatric surgery|Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance
75376192|NCT04945304|Procedure|Magnetic gastric bypass|Using the magnetic assistance to perform a gastric bypass
75376193|NCT02165202|Drug|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
75376194|NCT02165202|Drug|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
75376195|NCT01628874|Device|J-Tip|Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
75539049|NCT00251160|Procedure|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
75702223|NCT00673179|Drug|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2. Dose 2.8 grams m^2/day.
75866619|NCT01364103|Other|volume expansion|fluid loading of 10 mL/kg colloid (voluven)
75866620|NCT03679520|Other|New programme|"Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~Introduction, life-change of becoming a parent and co-parenting~Early parenthood~Breastfeeding, caring for the baby and early parenthood~and 5 Labour, birth and postnatal care"
76029119|NCT05911529|Behavioral|Supportive conversations|"In the control intervention patients should also be given four sessions, in which no MI techniques take place. They will be carried out in the sense of supportive conversations (i. e. conver-sations that do not follow a specific psychotherapy concept).~Since we want to check whether the patients really benefit from the specific intervention and not from getting more speaking time, the patient in the control group will also be given four conver-sations. It is known that supportive conversations can have a certain effect on the well-being and recovery process of patients, as the therapeutic relationship, i.e. appreciation, attention and/or attention, is an important efficacy factor (e. g. Grawe, 1995)."
75702224|NCT00673179|Behavioral|Questionnaire|Questionnaires to be completed on 5 different days during the study.
75702225|NCT00673179|Drug|Gemcitabine|IV over 1 hour, every other week.
75702226|NCT00673179|Drug|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
75702227|NCT00673179|Procedure|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
75702228|NCT00673179|Drug|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2/day.
75702229|NCT02584088|Other|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
75702230|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
75702231|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
75702232|NCT00758433|Drug|Placebo patch|Placebo patch q.d. 24 hours for 7 days
75702233|NCT00758511|Procedure|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
75702234|NCT00758511|Procedure|facilitated tucking|facilitated tucking before, during and after heel stick
75702235|NCT00758511|Procedure|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
75376196|NCT01628874|Drug|EMLA|In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
75702236|NCT00584012|Drug|Lovastatin|Given PO
75702237|NCT00584012|Drug|Docetaxel|Given IV
75376197|NCT01628874|Drug|Lidocaine|5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
75376198|NCT04891718|Biological|MVC-101|Intratumoural microdose injection by the CIVO device.
75376199|NCT04891718|Biological|Nivolumab|Intratumoural microdose injection by the CIVO device.
75376200|NCT04891718|Combination Product|MVC-101 + Nivolumab|Intratumoural microdose injection by the CIVO device.
75376201|NCT03770689|Drug|Peposertib 50 mg|Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
75376202|NCT03770689|Drug|Peposertib 100 mg|Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
75376203|NCT03770689|Drug|Peposertib 150 mg|Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
75702238|NCT05435846|Drug|Capmatinib|Given orally
75376204|NCT03770689|Drug|Peposertib 250 mg|Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
75376205|NCT03770689|Drug|Capecitabine|Participants received capecitabine at a dose of 825 milligram per square meter (mg/m^2) twice daily 5 days per week up to 5.5 weeks.
75376206|NCT03770689|Radiation|Radiotherapy (RT)|Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
75702239|NCT05435846|Drug|Trametinib|Given orally
75702240|NCT00920270|Drug|nebulized colistin|nebulized colistin 75 mg every 12 hours
75702241|NCT00920270|Drug|antibiotics|conventional parenteral antibiotics
76029120|NCT05911503|Drug|2% Ganciclovir Eye Drops|Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
76029121|NCT05911490|Behavioral|Prolonged sitting|In the laboratory, after consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
75702242|NCT04080674|Other|Feed-back controlled deep brain stimulation|Feed-back controlled deep brain stimulation
75702243|NCT04078724|Dietary Supplement|5-HTP|5-HTP that have Good Manufacturing Practice certification will be used and participants will be suggested to be take the 5-HTP supplementation at bedtime.
75702244|NCT04078724|Other|Without 5-HTP|Subject will not take 5-HTP
75702245|NCT02583386|Behavioral|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
75866621|NCT03679520|Other|Regular programme|"Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~(or 1 and 2) Labour, birth and postnatal care~or 3 Breastfeeding, caring for the baby and early parenthood"
75376207|NCT00371306|Drug|Insulin versus glucovance (glyburide/metformin)|
75376208|NCT00371384|Procedure|massage|UP to 10 massages over 10 weeks
75376209|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
75376210|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
75376211|NCT02196714|Drug|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
75376212|NCT02196714|Drug|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
75376213|NCT03620474|Drug|PRI-724|twice a week for 4 hours continuous intravenous administration of PRI-724
75376214|NCT04337905|Device|ADHD-VR diagnosis tool|"Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments."
75376215|NCT03566264|Other|Non-Interventional|Non-Interventional
75376216|NCT00370760|Drug|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
75376217|NCT00370760|Drug|placebo|
75702246|NCT02583386|Other|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
75702247|NCT04454450|Diagnostic Test|PET/MRI|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
75702248|NCT04454450|Diagnostic Test|Contrast enhanced CT|Standard of care contrast enhanced CT
75702249|NCT02585882|Other|Fluoride table salt|
75702250|NCT04080596|Drug|Dorzagliatin|GKA for T2DM currently under clinical development
75702252|NCT00920738|Other|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
75702253|NCT00920738|Other|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
75702254|NCT02585648|Device|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
75702255|NCT02585648|Device|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
75702256|NCT02584010|Other|Silicon-based aerosol|Apply twice a day over the postoperative scar
75702257|NCT02584010|Other|Silicon-based gel|Apply twice a day over the postoperative scar
75376218|NCT05227508|Dietary Supplement|BRIZO|A capsule containing 400 mg. SC012 (unique soy extract)
75702258|NCT02585804|Drug|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
75866622|NCT02413840|Behavioral|Baduanjin qigong|
75866623|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
75376219|NCT05227508|Other|placebo|Comprecel microcrystalline cellulose
75376220|NCT05203562|Procedure|Suction evacuation|both groups underwent complete mole evacuation using suction curettage.
75866624|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
75866625|NCT03171610|Drug|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
75376221|NCT05203562|Drug|Letrozole tablets|Group II Patients received 5mg(2tablets 2.5gm) daily letrozole for 10 days after complete mole evacuation
75376222|NCT04844138|Behavioral|Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program|The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
75376223|NCT05453383|Drug|Anlotinib;Toripalimab|Anlotinib Hydrochloride;Toripalimab injiection
75413767|NCT04924010|Behavioral|Education and Mindfulness|To control for differences in attention between the two interventions, patients in the mindfulness group will also have two meetings before the surgery and two meetings afterward. As the same person will be providing the CBT-CP and educational interventions, this confounding factor will be controlled for. The control intervention consists of discussing pain education, as derived from the self-management section of the chronic pain Ireland website (https://www.chronicpain.ie/our-services/self-management) and the persistent pain section of the pain toolkit website (https://www.paintoolkit.org/persistent-pain). Four mindfulness-based stress reduction exercises will be completed including an introductory session on mindful breathing, a guided meditation, progressive muscle relaxation, and a body scan. These sessions will last about half an hour.
75702259|NCT02585726|Device|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
75702260|NCT04079270|Other|Nutrition intervention|The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
75702261|NCT05674760|Device|Trancutaneous CO2 monitoring (using TCM5 device)|Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)
75702262|NCT05674760|Other|Arterial Blood Gas (ABG) sampling|Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
75866626|NCT03171610|Drug|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
75866627|NCT03675698|Other|Nasotracheal Intubation|side of nostril and size of endotracheal tube estimation for nasotracheal intubation will be done based on radiological imaging ( CT/MRI head)
75866628|NCT01364181|Drug|Udenafil|Udenafil 50mg qd po
75702263|NCT02582996|Drug|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
75702264|NCT02582996|Drug|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
75702265|NCT00674817|Drug|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
75702266|NCT00674817|Drug|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
75702267|NCT04078802|Procedure|VNOTES/VH|same as above
75702268|NCT02585570|Drug|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
75702269|NCT02583932|Drug|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
75702270|NCT02583932|Behavioral|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
75376224|NCT05453305|Procedure|Control group: Traditional venipuncture, on the stretcher.|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.
75376225|NCT05453305|Procedure|Intervention group: DAK method venipuncture, simulating a hug|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
75376226|NCT04766762|Procedure|Acupuncture combined with placebo|This group will include 48 patients. Patients in this group will receive acupuncture combined with placebo. Participants are in the supine position. The bilateral Tianrong (SI 17) acupoints are needled for 1-1.5 inch with the direction tilted back 45±5 degrees. The bilateral Fengchi (GB 20) acupoints are needled for 0.5-1 inch with the direction tilted to nose. The bilateral Neiguan (PC 6) acupoints are also needled for 0.5-1 inch with the straight direction. In addition, 4-6 additional acupoints can be identified according to different syndrome types of patients. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Meanwhile, the dosage of placebo is 1 capsule twice a day and the treatment duration also lasts 8 weeks.
75376227|NCT04766762|Procedure|Sham acupuncture combined with flunarizine hydrochloride|This group will include 48 patients. Participants in this group will receive sham acupuncture plus flunarizine hydrochloride. Participants are in the supine position and sham acupuncture is conducted. The bilateral Tianrong (SI 17) acupoints, Fengchi (GB 20) acupoints and Neiguan (PC 6) acupoints are selected, and 4-6 additional acupoints can be identified according to the syndrome type of the participants. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Moreover, the dosage of flunarizine hydrochloride is 5mg twice a day and the treatment duration also lasts 8 weeks.
75376228|NCT04750304|Behavioral|Application ARTHe|Patient will use ARTHe Application for 3 months
75376229|NCT04330040|Drug|Olaparib|Tablet
76029122|NCT05911490|Behavioral|Breaking prolonged sitting|In the laboratory, after consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
75376230|NCT02737891|Drug|Tesofensine/Metoprolol|Tesofensine 0.5 mg + Metoprolol 100 mg
75376231|NCT02737891|Drug|Placebo|
75376232|NCT04994834|Dietary Supplement|Probiotics|Once a day daily intake of probiotics for at least 28 consecutive starting within 24 hours after birth
75376233|NCT02196558|Drug|E6011|
75376234|NCT04941092|Other|no intervention|no intervention, retrospective comparison
75376235|NCT05453149|Behavioral|Integrated Physical Activity and Behavioural Change Intervention|"Physical Activity (PA) Component: A group-based PA program geared to the level of injury and mobility delivered through web conferencing software. Participants select at three sessions weekly over 10 weeks. Sessions include 45 mins of exercise (i.e boxercise; aerobics; yoga) and 15 mins of social interaction with the group.~Behavioural Change Component: Participants will also receive synchronous 1:1 sessions (approximately 20 mins/week) with a trained clinician on behavioural strategies to initiate and maintain engagement in PA over the 10-week period. Content of the sessions includes: providing information on PA and the self-management of impairments and related symptoms; evaluating barriers to engagement (e.g. fear of injury); and behavioural strategies."
75702271|NCT02583854|Device|RY-STOP hemostasis device|
75702272|NCT02583854|Device|TR-Band, Terumo|
75702273|NCT02583074|Procedure|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
75702274|NCT02583074|Procedure|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
75702275|NCT00764907|Drug|asparaginase|Given IV during reinduction
75702276|NCT00764907|Drug|cyclophosphamide|Given IV during reinduction
75702277|NCT00764907|Drug|cytarabine|Given IV during reinduction
75702278|NCT00764907|Drug|daunorubicin hydrochloride|Given IV during reinduction
76029123|NCT05911477|Drug|RhBMP-2|1mg RhBMP-2 for one fusion-level
76029124|NCT05911464|Drug|HS-10386|Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
75702279|NCT00764907|Drug|dexamethasone|Given IV or orally during reinduction
75702280|NCT00764907|Drug|doxorubicin hydrochloride|Given IV during reinduction
75702281|NCT00764907|Drug|etoposide|Given IV during reinduction
75702282|NCT00764907|Drug|ifosfamide|Given IV during reinduction
75702283|NCT00764907|Drug|leucovorin calcium|Given IV during reinduction
75702284|NCT00764907|Drug|mercaptopurine|Given orally during reinduction
75702285|NCT00764907|Drug|methotrexate|Given orally during reinduction
75376236|NCT04902404|Other|First Pathways Game|The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
75376237|NCT04338217|Device|Bionator|This is a functional appliance that is used to overcome the functional problems and to correct the open bite deformity
75376238|NCT04338217|Device|Removable Appliance with Posterior Bite Planes|This is a one-jaw appliance that is used in conjunction with a tongue crib to control the faulty positions of the tongue and to help in closing the open bite through the use of posterior bite planes.
75376239|NCT05452993|Device|Analysed Retinophotography|taking 2 retinophotographs per eye, and then analysed by AI software to detect Diabetic retinopathy
75702286|NCT00764907|Drug|prednisone|Given intrathecally during reinduction
75376240|NCT02740153|Other|No Intervention Given|
75376241|NCT04809662|Drug|Imiquimod|"Patients with a diagnosis of actinic keratosis or warts that would be prescribed imiquimod as standard of care will be asked to apply 2 packets (or 2 full pumps) of imiquimod once daily before bedtime for two weeks and then leave on overnight for ~8 hours.~(a) A biopsy will be performed at the baseline visit on the pre-treatment skin and the skin where the medication will not be applied. The skin where the medication will not be applied will act as the negative control. A biopsy will then again be performed on day 10 of imiquimod treatment on the treated skin only, where the study drug was applied."
75376242|NCT02196324|Drug|serlopitant|NK1 receptor antagonist
75376243|NCT02196324|Drug|Placebo|Placebo
75376244|NCT03618979|Biological|PPP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP. The physician will then repeat the procedure on the opposite side.
75702287|NCT00764907|Drug|thioguanine|Given orally during reinduction
75702288|NCT00764907|Drug|vincristine sulfate|Given IV during reinduction
75702289|NCT00764907|Drug|vindesine|Given IV during reinduction
75702290|NCT02585492|Other|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
75702291|NCT02585492|Other|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
76029125|NCT05911438|Drug|Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)|Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
75376245|NCT03618979|Biological|PRP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.
75413768|NCT04905979|Drug|AD113|Two oral capsules administered before bed
75413769|NCT04905979|Drug|Atomoxetine|Two oral capsules administered before bed
75413770|NCT04905017|Device|Transcatheter Tricuspid Valve Replacement|Replacement of the tricusupid valve using Trisol System in a transcatheter approach
75539050|NCT00251160|Procedure|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
75539051|NCT00563329|Procedure|Reduction Intervention + Adherence Intervention|
75702292|NCT00672633|Drug|Lovaza|Lovaza , 4 grams/day orally for 6 months
75539052|NCT00563329|Behavioral|Reduction Intervention|
75702293|NCT00672633|Drug|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
75702294|NCT00672555|Procedure|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
75702295|NCT00758823|Device|Paranix|pediculicide product
75702296|NCT00758901|Device|Knee Replacement (with ROCC Knee prosthesis)|Knee Replacement (with ROCC Knee prosthesis)
75539053|NCT00563329|Procedure|control|
76029126|NCT05911438|Other|Basic Treatment|Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
76029127|NCT05911425|Drug|envolizumab , sovalteinib|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
75702297|NCT02583698|Drug|Carvedilol|
75702298|NCT02583698|Drug|Placebo|
75702299|NCT05317143|Other|Evaluation of prostate cancer margins|Evaluation of prostate cancer margins
75702300|NCT00762099|Drug|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
75702301|NCT00762099|Drug|Placebo|Placebo/sugar tabs will look identical to active drug.
75702302|NCT00762255|Drug|Vorinostat|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
75702303|NCT00762255|Drug|Bevacizumab|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
75702304|NCT00762255|Drug|Irinotecan|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
75702305|NCT04078958|Dietary Supplement|Salmon fishmeal|Salmon fishmeal with high protein content
76029128|NCT05911412|Behavioral|Mindfulness-based cognitive therapy using neuroscience (NMBCT)|Mindfulness-based cognitive therapy using neuroscience (NMBCT) is a standardized 8-week course taught by trained instructors. The NMBCT is a group therapy that takes place once a week for about 90 minutes per session. The program consists of mental education for each session, 2-3 mindfulness meditation practice, mindfulness practice in daily life, and about 30 minutes of daily home mindfulness meditation task. While participating in the program, the subjects will receive psychoeducation and various mindfulness meditation techniques (eating meditation, breathing meditation, sedentary meditation, viewing meditation, and listening meditation, etc.).
75376246|NCT03618979|Biological|PRP and PL Combo treatment|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
75376247|NCT03448016|Radiation|[C-11]|Radiolabel
75376248|NCT03448016|Drug|NOP-1A|Tracer
75376249|NCT03390530|Drug|Thyroxine|8 µg/kg/day divided into two doses intravenous every 12 hours
75376250|NCT03390530|Drug|Placebo|Placebo
75376251|NCT03534739|Other|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
75376252|NCT03534739|Other|Light Touch Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
75376253|NCT03534739|Other|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
75376254|NCT05450419|Dietary Supplement|Vitamin D3|8pc (576,000 IU/40ml) vitamin D3 on week 1, then 1pc (72,000 IU/5ml) vitamin D3 on week 2, week 3 & week 4.
75376255|NCT05450419|Dietary Supplement|placebo|8pc placebo on week 1, then 1pc placebo on week 2, week 3 & week 4.
75376256|NCT03507049|Procedure|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
75376257|NCT03507049|Procedure|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
75376258|NCT03507049|Radiation|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
75376259|NCT03345446|Diagnostic Test|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
75376260|NCT02195700|Drug|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
75376261|NCT02195700|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks.
75376262|NCT00370669|Drug|bevacizumab|
75376263|NCT00370669|Drug|triamcinolone acetonide|
75376264|NCT04738214|Other|Neoadjuvant CCRT+operation +/- adjuvant treatment|Patients receive neoadjuvant CCRT and operation. Adjuvant treatment after operation is performed depending on pathologic response. The patients showing pathologic complete response after neoadjuvant CCRT are not treated with any adjuvant treatment.
75376265|NCT05349344|Other|Aerobic circuit training|Aerobic Exercise Training, 3 times a week for 8 weeks, (Tuesday, Thursday & Saturday, 24 sessions Total) 30 min each time, at 60-80 % of HR max (moderate intensity).
75376266|NCT05349344|Other|Outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
75376267|NCT02740543|Drug|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
75376268|NCT02228460|Drug|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
75376269|NCT05349266|Biological|ThisCART19A|each patient will receive a dose level per body weight(kg) for only once.
75376270|NCT00370747|Drug|Ecabet|ophthalmic solution 2.83%
75376271|NCT00370747|Drug|Ecabet|ophthalmic solution 3.70%
75376272|NCT00370747|Drug|Placebo|
75376273|NCT02752256|Drug|Tissue Plasminogen Activator|
75376274|NCT05368909|Dietary Supplement|Sleep Supplement|Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.
75376275|NCT05368909|Dietary Supplement|Placebo|Placebo product
75539054|NCT04613908|Device|neuro muscular electro stimulation|We used a commercial equipment of electro stimulation with a pulse width of 300 micro seconds, a frequency of 50 Hz, with symmetrical balanced biphasic rectangular wave and with an intensity of up to 80 milliampere.
75702306|NCT04078958|Dietary Supplement|Whey|Whey with high protein content
75376276|NCT03454555|Behavioral|Shared Decision Making|The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. The intervention will have both clinician and patient educational components. The content of the clinician component will be based on the Agency for Healthcare Research and Quality (AHRQ) SHARE Approach, which is a 5-step process for shared decision making that includes exploring and comparing the benefits, harms, and risks of each option through meaningful dialogue about what matters most to the patient (Agency for Healthcare Research and Quality, 2017). Participants randomized to Arm 1 will have their study visits and opioid use managed by an SDM-trained clinician at their practice.
75702307|NCT04080206|Drug|188-0551 Spray|Applied topically twice daily for two weeks
75702308|NCT04080206|Drug|RLD|Applied topically twice daily for two weeks
75702309|NCT00765219|Behavioral|CBT|10-12 weekly sessions of CBT in person or over the telephone.
75702310|NCT00765219|Other|Usual Care|Treatment as usual provided by participants' physician(s)
75702311|NCT02585180|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
75376277|NCT03454555|Behavioral|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention (Monticone et al., 2015), including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. One individual MI session will focus on patient engagement and enhancing a patient's own intrinsic motivation for CBT-CP participation. MI will also be woven into the group CBT-CP sessions. We will deliver 8 sessions of CBT-CP, as is standard in a group setting, in-person or virtually.
75376278|NCT04104542|Behavioral|Mindfulness based stress reduction|on-line training on the website = www.palousemindfulness.com
75702312|NCT02585180|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
75702313|NCT00765297|Device|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
75702314|NCT00765297|Device|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
75376279|NCT04104542|Behavioral|Healthy Lifestyle|Diet and Exercise
76029129|NCT05911386|Other|study of biological samples and echocardiographic data and link with need of hemodynamic support|observational study : there is no intervention
75702315|NCT02583542|Drug|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
75702316|NCT02583542|Drug|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
75702317|NCT02557971|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
75702318|NCT02583776|Device|Unblinded - CGM|Data from device will be readable and alarms on
75702319|NCT02583776|Device|Blinded - CGM|Data from device will be blinded and alarms off
75702320|NCT04048785|Other|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
76029130|NCT05911373|Other|group serratus plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml saline
76029131|NCT05911373|Other|group serratus and parasternal plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml %0.25 Bupivacaine
76029132|NCT05911347|Dietary Supplement|Psyllium|15g psyllium added to inulin solution to form a gel
76029133|NCT05911347|Dietary Supplement|Methylcellulose|15 g methylcellulose added to inulin solution to form a gel
76029134|NCT05911347|Dietary Supplement|Maltodextrin|15g maltodextrin added to inulin solution to form a gel
76029135|NCT05911308|Drug|Durvalumab|1,500 mg Durvalumab IV infusion will be given on day 1 of each cycle for 3 cycles.
76029136|NCT05911308|Drug|Carboplatin|Carboplatin IV infusion will be given on day 1 of each cycle for 3 cycles. The dose will be AUC 5.
76029137|NCT05911308|Drug|Abequolixron|100 or 120 mg Abequolixron will be administered by mouth twice a day for 5 days followed by 2 days off throughout your treatment (5 days a week for up to 9 weeks).
76029138|NCT05911308|Drug|Abraxane|100 mg/m2 Abraxane will be given by IV infusion on days 1, 8, and 15 of each cycle for 3 cycles.
76029139|NCT05911308|Drug|Pemetrexed|500 mg/m2 pemetrexed will be given by IV infusion on day 1 of each cycle for 3 cycles.
75376280|NCT02227446|Drug|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
75702321|NCT05674682|Procedure|HIV testing|venipuncture or digital puncture for HIV testing
75376281|NCT00371371|Procedure|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
75376282|NCT00371371|Procedure|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
75376283|NCT00371371|Procedure|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
75702322|NCT02557815|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
75376284|NCT04738058|Drug|Bovine Lactoferrin Supplement|Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level
75376285|NCT04738058|Drug|placebo|placebo
75376286|NCT02227368|Drug|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
75376287|NCT02227368|Drug|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
75376288|NCT02162862|Behavioral|Behavioral Counseling|
75376289|NCT02162862|Drug|bupropion-SR|
75376290|NCT02752490|Drug|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
75376291|NCT02752490|Drug|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
75376292|NCT03402607|Procedure|Percutaneous Local Ablation|Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.
75376293|NCT03402607|Radiation|Hypofractionated Image Guided Radiation Therapy|HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
75376294|NCT02752880|Drug|YH1 group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
75376295|NCT02752880|Drug|placebo group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
75376296|NCT05277727|Dietary Supplement|Fucoidan 500mg|1 capsule to be taken twice daily with food (morning and evening).
75376297|NCT05277727|Dietary Supplement|Placebo|1 capsule to be taken twice daily with food (morning and evening).
75376298|NCT04054232|Other|High PAD risk Alert|"In this message sent via the electronic health record, a participant's primary care physician will receive a message that details the following:~Participant flagged as having a high risk of peripheral artery disease based on their electronic health record data~What peripheral artery disease is and why diagnosis may be important~Recommendation to refer to a vascular medicine specialist or order ankle brachial index for definitive diagnosis~The option to opt out if the potential participant is not deemed a candidate for inclusion in the study with a short explanation of why the potential participant should not be included."
75376299|NCT02226198|Drug|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
75376300|NCT02226198|Drug|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
75376301|NCT02754518|Drug|Entresto|
75376302|NCT05177029|Drug|Lu AG06466|Lu AG06466 will be administered per schedule specified in the arm.
75702323|NCT02583620|Genetic|blood sample|A blood test is realized on the subject
75702324|NCT00765453|Other|Bone marrow derived progenitor cells or placebo infusion|Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
75376303|NCT05177029|Drug|Placebo|Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
75376304|NCT05169307|Drug|CPX-351|This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.
75376305|NCT02751385|Drug|Microgynon|
75376306|NCT02751385|Drug|Nintedanib|
75376307|NCT05349032|Dietary Supplement|Curcumin|Oral supplement
75702325|NCT00765453|Other|Placebo infusion|Placebo infusion
75702326|NCT05332730|Drug|BAT2506 injection|50 mg, subcutaneous administration
75702327|NCT05332730|Drug|Simponi® (EU commercially available product)|50 mg, subcutaneous administration
75702328|NCT05332730|Drug|Simponi® (US commercially available product)|50 mg, subcutaneous administration
75702329|NCT02581904|Device|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
75702330|NCT02581904|Device|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
75866629|NCT02409550|Other|CARATKids Questionnaire|
75376308|NCT05057689|Drug|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.
75376309|NCT05057689|Drug|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
75702331|NCT02581826|Drug|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
75702332|NCT02581826|Drug|Placebo|No column specified.
75702333|NCT00765687|Drug|bisphosphates|any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
75702334|NCT04340882|Drug|Docetaxel|Given IV
75702335|NCT04340882|Biological|Pembrolizumab|Given IV
75702336|NCT04340882|Biological|Ramucirumab|Given IV
75702337|NCT00765921|Drug|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
75702338|NCT02583308|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
75702339|NCT02583308|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
75376310|NCT05057689|Drug|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
75376311|NCT05348954|Other|EX-PLISSIT MODEL|The content of the program will include information about the anatomy and physiology of the male-female reproductive system, sexuality and sexual cycle physiology, factors affecting sexuality, postpartum changes, hormonal changes, breastfeeding and their effects on sexuality, and methods of contraception.
75376312|NCT02754674|Procedure|type of anterior cruciate ligament reconstruction|comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation
75376313|NCT04737980|Drug|Liposomal bupivacaine|Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
75376314|NCT04737980|Drug|Bupivacaine Hcl 0.5% Inj|Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
75702340|NCT02582606|Other|Regular meal pattern|a 14-day period of eating 6 meal per day
75702341|NCT02582606|Other|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
75702342|NCT02582762|Drug|Nail gel|apply nail gel on affected nails twice daily for 2 months
75702343|NCT00672477|Drug|Methylnaltrexone|
75376315|NCT04737980|Drug|Ropivacaine 0.5% Injectable Solution|Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
75376316|NCT04737980|Drug|Dexamethasone|Injection of 8mg (2ml) dexamethasone injectable as admixture
75376317|NCT00371696|Drug|diclofenac|
75376318|NCT00371696|Drug|paracetamol|
75376319|NCT00371696|Device|heat retaining knee support|
75376320|NCT00371696|Device|standard knee support|
75376321|NCT03459170|Biological|BPX-501 T cells|Biological: T cells transduced with CaspaCIDe® safety switch
75702344|NCT00672477|Drug|Placebo|
75376322|NCT03459170|Drug|rimiducid|administered to eliminate BPX-501 cells in the event of GVHD
75376323|NCT05348798|Other|Web based survey|Web-based survey on exercise addiction and personality traits
75376324|NCT02756624|Drug|AC-170 0.24%|
75376325|NCT02756624|Drug|AC-170 Vehicle|
75376326|NCT02753413|Biological|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
75702345|NCT04080362|Device|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
75376327|NCT02753413|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
75702346|NCT02585336|Behavioral|Brief intervention|An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
75702347|NCT00766155|Drug|capecitabine|Given orally
75376328|NCT04335422|Device|Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)|"Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given."
75702348|NCT00766155|Drug|oxaliplatin|Given IV
75376329|NCT04335422|Behavioral|Control group (routine physical and rehabilitation medicine program)|Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
75376330|NCT02958800|Other|Intervention|"The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A."
75376331|NCT04937491|Device|New medical device (ReBalans)|Body worn, battery powered bioimpedance measuring patch device.
75376332|NCT00372086|Drug|Rosiglitazone|
75376333|NCT04850521|Other|Remote monitoring|patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
75376334|NCT03380000|Drug|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
75376335|NCT03380000|Drug|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
75376336|NCT02754427|Behavioral|Prospective Surveillance Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.
75376337|NCT02754427|Behavioral|Education Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
75376338|NCT02973932|Behavioral|Cognitive-bahavioral psychotherapy|
75376339|NCT04777669|Other|Noise Reduction|In within subject design, listeners will have background noise removed by a noise reduction algorithm
75376340|NCT04759885|Drug|Phase II: NTC015 low dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
75376341|NCT04759885|Drug|Phase II: NTC015 medium dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
75702349|NCT05314868|Device|PhotoFix|Surgical repair with patch.
75702350|NCT00766233|Other|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
75702351|NCT00766311|Other|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
75702352|NCT00766311|Other|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
75866630|NCT02414230|Drug|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
75376342|NCT04759885|Drug|Phase II: NTC015 high dose|Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
75376343|NCT04759885|Drug|Phase III: NTC015 selected dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
75376344|NCT04759885|Drug|Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)|"The instructions for product administration are followed according to the Summary of Product Characteristics.~One treatment consists of two litres of Moviprep® taken according to split-dose regimen.~The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure."
75376345|NCT02754661|Device|COLON Capsule endoscopy|
75376346|NCT02754661|Device|Computed Tomographic Colonography|
75376347|NCT02757092|Other|Home-based Pulmonary Rehabilitation|(1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
75376348|NCT04728295|Device|Exablate 4000|Exablate Pallidothalamic Tractotomy
75376349|NCT04738045|Drug|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
76029140|NCT05911282|Drug|N Acetylcysteine|"The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study."
76029141|NCT05911282|Other|Lemon juice|"The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study."
76029142|NCT05911230|Diagnostic Test|Advanced diffusion-weighted MRI (ADW-MRI)|An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.
76029143|NCT05911100|Diagnostic Test|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
75376350|NCT04738045|Drug|Lopinavir/ Ritonavir and Remdesivir combination|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
75376351|NCT02755129|Other|Walking Exercises-Six Minute Walk (6MW) Test|The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
75866631|NCT03679442|Drug|N-acetylcysteine|Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
75376352|NCT02755129|Other|Walking Exercises-4 Meter Gait Speed (4MGS) Test|"The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.~It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm"
75376353|NCT02755129|Other|Walking Exercises-Five Times Sit to Stand (FTSTS) Test|The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
75866632|NCT01367535|Drug|SC Methylnaltrexone (MNTX)|
75866633|NCT01367535|Drug|IV Methylnaltrexone (MNTX)|
75866634|NCT01367535|Drug|Oral Paroxetine|
75866635|NCT01367535|Drug|SC Placebo|
75866636|NCT02414776|Drug|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
75866637|NCT03174418|Procedure|Coronary angiography and optical coherence tomography|Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
75866638|NCT02413762|Other|No intervention|No intervention
75376354|NCT02755129|Other|Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test|The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
75539055|NCT04613908|Other|Early Mobilization protocol|"The protocol consisted in applying a specific treatment based on different levels of treatment to each subject. Admission to them was carried out according to the maximum capacity of each subject, the conditions of each level being the following:~Level 1: MRC (shoulder) <3 + MRC <3 (hip).~Level 2: MRC (shoulder) ≥ 3 + MRC (hip) <3.~Level 3: MRC (shoulder) ≥ 3 + MRC (hip) ≥ 3 + sitting on the edge of the bed without assistance (minimum 15 minutes).~Level 4: Standing without assistance and walking with or without assistance."
75539056|NCT04613908|Other|standard care or usual rehabilitation|routine, non-protocolized rehabilitation treatment performed by the physiotherapist assigned to intensive care
75539057|NCT00412763|Drug|Silymarin (Silybum marianum)|
75376355|NCT02755129|Other|Reveal LINQ accelerometer|Walking exercises test
75539058|NCT00251199|Drug|VX-950|
75702353|NCT00766311|Other|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
75376356|NCT02755129|Other|3D accelerometer|Walking exercises test
75539059|NCT00251199|Drug|peginterferon|
75702354|NCT00766311|Other|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
75702355|NCT00766311|Other|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
75702356|NCT00766311|Other|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
75702357|NCT00766311|Other|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
75702358|NCT00762489|Other|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
75702359|NCT04078100|Procedure|Transseptal approach.|surgical approach to the mitral valve through the Fossa Ovalis by way of the right atrium.
75539060|NCT04614181|Dietary Supplement|Nestle Resource drink|Beverage (Nestle RESOURCE). Each serving is 237ml containing 53.6g of carbohydrate and 9g of protein. Intervention group will consume two servings of the carbohydrate beverage (53.6g each, total of approximately 100g) on the day before surgery and one serving up to 6 hours prior to scheduled surgery time.
75702360|NCT00762567|Drug|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
75702361|NCT04338620|Drug|camrelizumab、albumin-bound paclitaxel and platinum|Experimental Group：camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
75702362|NCT04338620|Drug|albumin-bound paclitaxel and platinum|"Control group：albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle.~Platinum included Cisplatin/carboplatin/Nedaplatin"
75702363|NCT00759057|Device|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
75376357|NCT04670263|Device|Tear Film Imager|Tear Film Imager recording
75376358|NCT02755285|Device|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
75539061|NCT04614181|Other|Usual care|Usual fracture care as determined by clinical team
75539062|NCT00563446|Drug|Darbepoetin alfa|
75539063|NCT00563485|Drug|Doxazosin GITS (Cardura XL)|
75539064|NCT00563485|Drug|Terazosin (Hytrin)|
75702364|NCT00923234|Drug|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
75702365|NCT00923234|Drug|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
75702366|NCT00674661|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
75702367|NCT00674661|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
75702368|NCT00766545|Drug|cilostazol|oral tablet 100 mg, twice daily, over 1 year
75702369|NCT00766545|Drug|placebo of cilostazol|oral tablet, 0 mg twice daily, over 1 year
75702370|NCT00766623|Dietary Supplement|high fat meal|milkshake containing 95g fat
75702371|NCT00766623|Dietary Supplement|control meal|milkshake comparable with a normal breakfast
75702372|NCT00766701|Procedure|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
75702373|NCT04314128|Diagnostic Test|TOS and TCD|TOS: Transorbital sonography TCD: Transcranial Doppler
75376359|NCT02226120|Drug|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
75376360|NCT02973919|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, & Renssen, 1999; de Jongh, Holmshaw, Carswell, & van Wijk, 2011; Lapsekili & Yelboga, 2014; Muris, Merckelbach, van Haaften, & Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
75376361|NCT02973919|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger & Pauli, 2011).
75376362|NCT04587973|Procedure|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group
75376363|NCT04587973|Procedure|Group Ropivacaine|Plain ropivacaine group
75376364|NCT04587973|Procedure|Group Control|Control group
75376365|NCT02756689|Other|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
75376366|NCT02756689|Other|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
75376367|NCT04766580|Behavioral|Placebo and nocebo effect|The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
75376368|NCT04558177|Device|Direct current stimulator|HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.
75702374|NCT02558205|Radiation|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
75702375|NCT02558205|Radiation|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
75702376|NCT00759369|Other|Water prescription|Water prescription in 12 to 16 equally divided doses
75376369|NCT02757326|Drug|Opaganib|Opaganib, [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt] is an orally available inhibitor of the enzyme SK2.
75376370|NCT02757950|Biological|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
75376371|NCT05348408|Drug|platelet rich plasma|perineural PRP injection under ultrasound guidance in addition to medical treatment
75376372|NCT02753881|Drug|whole liver lobe cTACE doxorubicin|Doxorubicin CTACE administered in a whole liver lobe manner.
75376373|NCT02753881|Drug|superselective cTACE doxorubicin|Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
75376374|NCT00425360|Biological|sargramostim|
75376375|NCT00425360|Biological|telomerase peptide vaccine GV1001|
75376376|NCT00425360|Drug|capecitabine|
75702377|NCT00766779|Procedure|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
75702378|NCT00766779|Drug|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
75376377|NCT00425360|Drug|gemcitabine hydrochloride|
75702379|NCT00759447|Device|Genesis and Gemini|3 dimensional breast mammography system
75702380|NCT00759447|Device|Investigational 3D Mammography system|3 dimensional breast mammography system
75376378|NCT05349253|Dietary Supplement|Garlic extracts|One intake in total
75376379|NCT05349253|Dietary Supplement|Placebo|One intake in total
75376380|NCT04337437|Drug|Genakumab|150 mg/1ml/bottle, single subcutaneous injection.
75376381|NCT04337437|Drug|Placebo for this trial|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
75376382|NCT05348096|Drug|Low-dose ibrutinib|Daily ibrutinib (140mg QD) and itraconazole (100mg BID) for six months.
75376383|NCT04337359|Drug|Ruxolitinib|5 mg. Tablet
75702381|NCT02557737|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
75702382|NCT00766857|Drug|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
75702383|NCT00766857|Drug|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
75702384|NCT02558673|Other|TMAO dietary precursors|
75702385|NCT02558673|Other|Control (or active comparator)|
75702386|NCT02558283|Device|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
75702387|NCT02558283|Device|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
75702388|NCT04624256|Procedure|Discussion|Patients and physicians engage in discussion
75702389|NCT04624256|Radiation|Hypofractionated Radiation Therapy|Undergo conventional hypofractionated radiation therapy
75702390|NCT04624256|Radiation|Hypofractionated Radiation Therapy|Undergo moderate hypofractionated radiation therapy
75702391|NCT04624256|Other|Laboratory Biomarker Analysis|Correlative studies
75702392|NCT04624256|Other|Quality-of-Life Assessment|Ancillary studies
75376384|NCT04337606|Drug|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
75376385|NCT04337606|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
75376386|NCT04337606|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
75376387|NCT02759354|Other|Blood Sample|Blood sample at approx. 4 years of age
75376388|NCT01190306|Device|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
75376389|NCT01190306|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
75539065|NCT00251277|Drug|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
75376390|NCT02759575|Drug|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
75376391|NCT02759575|Radiation|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
75376392|NCT02759575|Drug|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
75376393|NCT02760056|Drug|Liothyronine sodium|Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
75376394|NCT02760056|Drug|Placebo|Patient will receive a matching placebo to take twice daily for one week.
75376395|NCT02764970|Drug|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
75376396|NCT05336006|Other|High-intensity aerobic training with high protein diet|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
75376397|NCT05336006|Other|Control group|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
75376398|NCT05320718|Drug|Ropivacaine|20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
75539066|NCT00412802|Drug|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
75539067|NCT00412802|Drug|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
75539068|NCT00563524|Drug|ILV-094|SC and IV administration on days 1, 14, 28, and 42
75539069|NCT04613869|Drug|High-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
75702393|NCT04624256|Other|Questionnaire Administration|Ancillary studies
75702394|NCT04624256|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75702395|NCT02585102|Other|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
75702396|NCT02585102|Other|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
75376399|NCT05314166|Other|meditation practice|Description: meditation practice
75376400|NCT05302544|Other|Mixed Reality training|Mixed Reality training: Mixed Reality game with appearance of virtual balloons in the game area that the subject must find and pierce with finger
75376401|NCT05302544|Other|motor activities|motor activities usually performed
75376402|NCT02739698|Drug|Paclitaxel|
75376403|NCT02739698|Procedure|Radical surgery-peritonectomy|
75376404|NCT00371618|Procedure|Fluoroscopy|
75702397|NCT00767013|Other|DSCT, TTE|One assessment each
75702398|NCT00759837|Drug|Bosutinib|
75702399|NCT00767091|Drug|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
75702400|NCT00767091|Drug|placebo|transdermal patch of placebo
75702401|NCT00767169|Device|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
75376405|NCT02766374|Behavioral|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
75376406|NCT02766374|Behavioral|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
75376407|NCT05284760|Drug|Soticlestat|Soticlestat T4 tablets.
75376408|NCT05284760|Drug|Soticlestat|Soticlestat T3 mini-tablets.
75376409|NCT05284760|Drug|Soticlestat|Soticlestat commercial tablets.
75376410|NCT04336904|Drug|Favipiravir|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
75376411|NCT04336904|Other|Placebo|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
75376412|NCT02767934|Other|Laboratory Biomarker Analysis|Correlative studies
75376413|NCT02767934|Biological|Pembrolizumab|Given IV
75376414|NCT02194998|Drug|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)|PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day
75376415|NCT02194998|Drug|Dasabuvir (DSV)|DSV: 250 mg orally twice a day
75376416|NCT02194998|Drug|Ribavirin (RBV)|RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))
75376417|NCT05257850|Device|High-flow nasal therapy|A high-flow nasal therapy for 30 minutes.
75376418|NCT05257850|Device|Airflow directed to face by a fan|A fan directed to the face for 30 minutes
75376419|NCT02194062|Drug|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
75376420|NCT02194062|Drug|Budesonide head upright|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
75702402|NCT05256381|Drug|SOT101|Subcutaneous (SC) injection.
76029144|NCT05911100|Diagnostic Test|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
75376421|NCT02194062|Drug|Budesonide head forward|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
76029145|NCT05911100|Diagnostic Test|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
75376422|NCT02768558|Radiation|Radiation Therapy (RT)|2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
75376423|NCT02768558|Drug|Cisplatin|Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
75376424|NCT02768558|Drug|Etoposide|Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
75376425|NCT02768558|Drug|Nivolumab|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
75376426|NCT02768558|Other|Placebo|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
75376427|NCT00372164|Procedure|American Society of Interventional Pain Physician Guidelines|
75376428|NCT00372242|Behavioral|Prospective Longitudinal Interventional Stury|
75376429|NCT02193828|Biological|Collagenase clostridium histolyticum|Single injection into nodule
75376430|NCT02193828|Biological|Placebo|Single injection into nodule
75376431|NCT04738136|Drug|S-1226|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8%, or 12% CO2
75376432|NCT02772302|Device|mindBEAGLE EEG-based brain-computer interface|
75376433|NCT02192970|Drug|Bevacizumab|
75376434|NCT05173532|Other|Balance Training|static and dynamic balance and gait stability exercises
75376435|NCT05173532|Other|Breathing and Stretching Exercises|static stretching while performing diaphragmatic breathing
75702403|NCT05256381|Drug|Pembrolizumab|Intravenous (IV) infusion via peripheral or central venous line.
75702404|NCT02582528|Behavioral|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
75376436|NCT05162144|Procedure|Proximal Medial Gastrocnemius Recession|Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
75539070|NCT04613869|Drug|Low-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
76029146|NCT05911100|Diagnostic Test|Heart echocardiography|It's a specific method of ultrasound examination, which consists in examining the heart in real time and usually does not cause any unpleasant feelings
75376437|NCT05149352|Behavioral|Treatment as usual (TAU) for depression|TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.
75376438|NCT05149352|Behavioral|Trauma-focused therapy (TFT)|The content of TFT, delivered by another therapist than the therapist that will provide TAU, depends on the type of CT the patient reports. If the patient predominantly reports experiences of abuse, there are often clear memories of this abuse ('target images') present and Eye Movement Desensitization and Reprocessing (EMDR) is recommended as the treatment strategy. If the patient predominantly reports experiences of neglect, memories are often less identifiable, although these experiences can have a big impact on the development of maladaptive schemas. In this case, imagery rescripting (ImRs) is recommended as treatment strategy. If the patient reports both experiences of abuse and neglect, the therapist will discuss with the patient which type of CT has the greatest impact on the current depressive symptoms and starts with the indicated therapy. If indicated, the therapist can switch between EMDR and ImRs after a minimum of 4 sessions.
75376439|NCT05457296|Drug|Hydrocortisone (capsule)|salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
75376440|NCT04336514|Device|Semi-compressed felt pad (SCF)|Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
75376441|NCT04336592|Behavioral|Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)|Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.
75539071|NCT04613869|Drug|Hydromorphone|No esketamine added
75539072|NCT00251355|Drug|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
75539073|NCT00251355|Drug|5-Fluorouracil|5-FU via continuous IV infusion.
75539074|NCT00251355|Procedure|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
75539075|NCT02962388|Drug|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
76029147|NCT05911100|Other|SF-36 Quality of Life Questionnaire|https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
75539076|NCT02962388|Drug|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
75539077|NCT02962388|Drug|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
75539078|NCT04613167|Drug|Alirocumab|The first group will receive alirocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
75539079|NCT04613167|Drug|Evolocumab|The second group will receive evolocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
75702405|NCT02582528|Behavioral|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
76029148|NCT05911100|Diagnostic Test|Demographic and antropometric measures|Age, sex, height. weight, body mass index (BMI)
76029149|NCT05911100|Other|Indicators characterizing the severity of the underlying disease|"Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease)~Medications taken."
76029150|NCT05911022|Drug|Colchicine 0.5 MG|three times per day for three days and subsequently twice per day for four days
76029151|NCT05911022|Dietary Supplement|Probiotic Formula|oral sachets once daily for two weeks
76029152|NCT05911022|Other|Standard protocol|the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks
76029153|NCT05910931|Drug|ICG angiography|"A first injection with the patient asleep before starting the intervention to visualize the vascular anatomy of each patient and assess the pedicles and incisions.~A second bolus after breast resection to assess the viability of skin flaps and glandular pedicles.~A third injection to obtain an angiography after implant placement and wound closure.~For angiography, the SPY System with the SPY-Q software will be used."
75376442|NCT04338230|Other|Progressive muscle relaxation exercise|"Relaxation Exercises CD Audio Records prepared by Turkish Psychological Association is used. Before starting the PMR exercises, the woman in the intervention group is provided to lie on a comfortable seat or bed, stretching the muscles of the face and all body for about 10 seconds starting from the hands to the foot in line with the sound recordings of the PKG exercises and then holding the deep breath while each muscle group is stretching, It is applied as a slow release of this breath during relaxation. In this way, the muscle groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, the face and the whole body are tensioned and relaxed, and the woman is relaxed. During the eight-week period, the women are called by the researcher once a week and the exercises are reminded. Home visit There are 2 home visits at week 1 and at week 8. In case of need, repeated home visits are provided to ensure the continuity of the application."
75376443|NCT04336436|Behavioral|Mindfulness training|Mindfulness training
75376444|NCT04336436|Behavioral|Nutritional consult|Nutrition counseling and development of a personalized nutrition plan
75376445|NCT05456906|Other|No intervention|No interventions
75376446|NCT04336358|Other|Telemedicine|Telemedicine consultation online
75376447|NCT04335266|Drug|SHR2554|SHR2554
75376448|NCT05456438|Other|İntervention 1|Group 1 applied coconut oil to the nipple
75376449|NCT05456438|Other|İntervention 2|Group 2 applied tea tree oil to the nipple
75376450|NCT04737824|Procedure|"An adaptation of the balloon-blowing exercise"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
75413771|NCT04902469|Behavioral|Pleasant Odor|Each participant in the pleasant odor condition will sniff an odor that they rated as the most intense out of a sample of odors rated to be pleasant. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated to be pleasant. Odors are generic and commercially available in supermarkets such as vanilla, coconut, and chocolate. Importantly, the investigators are not testing the specific odors, rather the participant's idiosyncratic response to a menu of odors. In other words, the key is that each participant in the experimental condition receives the odor that they like the best, regardless of which one it is.
75539080|NCT04613167|Drug|Control group|The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
75539081|NCT04613284|Drug|Recombinant human endostatin (Endostar)|Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
75539082|NCT04613284|Radiation|Thoracic irradiation of 50 Gy with 3DCRT or IMRT|Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.
75539083|NCT00248079|Device|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
75539084|NCT00221858|Procedure|Ultrasound guided blocks|
75702406|NCT00767403|Behavioral|Internet Intervention + Stepped Care|"Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones."
76029154|NCT05910918|Behavioral|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
76029155|NCT05910905|Procedure|Prefabricated pediatric zirconia crown group|Zirconia crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
76029156|NCT05910905|Procedure|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
76029157|NCT05910892|Drug|Aromatherapy packet|5 deep breaths from packet prior to treatment
76029158|NCT05910892|Drug|Placebo packet|5 deep breaths from packet prior to treatment
75376451|NCT04737824|Procedure|"An adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
75376452|NCT02743442|Device|da Vinci® Si™|
75866639|NCT05187663|Procedure|Photodynamic (PDT) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the photodynamic (PDT) group, after careful removal of granulation tissue and mechanical debridement of the implant surface, decontamination of implant surfaces and peri-implant tissues was performed using the photodynamic therapy, PDT (HELBO, Photodynamic Systems GmbH, Wels, Austria). The implant surface and the surrounding tissue were exposed to the laser light by means of fibres (HELBO ® TheraLite Laser HELBO ® 2D Spot Probe; bredent medical GmbH & Co KG) for the 30s/spot, which operates on the wavelength of 660 nm and irradiance of 100 Mw. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
76029161|NCT05910710|Genetic|Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)|Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
76029162|NCT05910684|Diagnostic Test|Aegis CDM Test and Educational Materials|The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.
75376453|NCT02760277|Drug|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 weeks.
75376454|NCT02760277|Drug|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 weeks.
75376455|NCT02760277|Drug|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 weeks.
75376456|NCT02760277|Drug|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 weeks.
75376457|NCT02776904|Other|Immediate Post-concussion Assessment and Cognitive Testing|Computerized assessment that provides information related to visual reaction time and visual memory.
75376458|NCT02776904|Other|Gait with single and dual task|Walking alone and then walking while performing a memory task on a tablet.
75376459|NCT02776904|Other|Y-Balance test|Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
75376460|NCT02776904|Other|Psychomotor Vigilance Task|Assessment measuring reaction time based on auditory cues.
75376461|NCT02744534|Drug|FACBC PET-CT Scan|"One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist."
75539085|NCT04613401|Other|questionnaire (observational study)|questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)
75539086|NCT00563602|Other|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
76029163|NCT05910593|Diagnostic Test|Dexterity Assessment Tool|Measures finger dexterity using pressure sensor pads.
75376462|NCT02744534|Procedure|Three-dimensional ultrasound-guided biopsy|"A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.~The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.~This biopsy process is estimated to take about 10 minutes."
75539087|NCT00563641|Other|Very early surfactant and bubble NCPAP|For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
76029164|NCT05910138|Diagnostic Test|Serum Interlukin-15|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
76029165|NCT05910138|Diagnostic Test|Serum Interlukin-21|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
75376463|NCT02744534|Procedure|Standard transrectal ultrasound (TRUS) guided biopsy|A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
75376464|NCT04335565|Other|sugar replacements|Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
75702407|NCT00767403|Behavioral|Internet Intervention|"As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses."
75376465|NCT04335409|Diagnostic Test|Questionnaire|The patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
75376466|NCT04335409|Other|Mobile Application|In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with pneumonitis.
75376467|NCT00371852|Drug|lactoserum|
75702408|NCT00767403|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
75702409|NCT04383314|Behavioral|10-week exercise program on HA accumulation|A 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (2010), will be individually prescribed to 25 T2DM patients.Exercise training will be performed on Days 1 and 2 of each week under the supervision of licensed physical therapists. Participants will have the choice of using a treadmill or a recumbent stepper. The physical therapists will monitor blood glucose level, blood pressure, heart rate, and RPE during each exercise session. Participants will be asked to exercise at home on Day 3 of each week, and will not be supervised by the study team.
76029166|NCT05909306|Other|Education Group|Two online meetings were planned with the education group. In the first meeting, an average of 35-minute-long live lecturing was performed on filling out the data forms and using the partograph e-learning tool through e-learning tool created in the first interview. The researcher held the second interview one week after the first one. In the second interview, a live lecture lasting 30 minutes was given to talk about and solve the problems that students experienced with the partograph e-learning tool and answer the questions. The partograph e-learning tool was kept open for one month for the students in the education group. At the end of the one-month education, the students were asked to fill out the post-test (Academic Achievement Test) defined in the system. After the post-test was completed, the system was closed to the access of the students in the education group and made available to the students in the control group.
75376468|NCT04337125|Other|Neuropsychological and attachment/parenting assessment|"Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment."
75376469|NCT02744846|Drug|Antibiotics exposure|
75376470|NCT02762071|Drug|Liposomal bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
76029167|NCT05909241|Drug|BA1202|"BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B."
75376471|NCT02762071|Drug|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
75376472|NCT05456282|Device|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
75376473|NCT05456282|Device|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
75702410|NCT00767481|Drug|Travoprost/Brinzolamide|Eye drop suspension, once daily
76029168|NCT05909098|Combination Product|autologous NK cell|autologous NK cell
75376474|NCT04336891|Drug|Testosterone gel|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
75376475|NCT04336891|Drug|Estradiol ovules|Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
75702411|NCT00767481|Drug|Cosopt|Eye drop solution, one drop BID
75702412|NCT04306874|Dietary Supplement|Ensure Max Protein|Liquid shake with 30 g protein per serving
75702413|NCT02557893|Behavioral|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
75702414|NCT02557893|Other|Education|Bimonthly pregnancy education classes
75376476|NCT04336891|Drug|Moisturizer|Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed
75866640|NCT05187663|Procedure|Chlorhexidine (CHX) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the chlorhexidine (CHX) group, after careful removal of granulation tissue and mechanical debridement of the implant surface 1% gel of chlorhexidine (Chlorhexamed® - Direkt) was applied on the implant surface for one minute and irrigated for 1 min by saline. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
75376477|NCT04336891|Drug|Testosterone gel + Estradiol ovules|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
75376478|NCT05456048|Drug|VAH regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
75376479|NCT05456048|Drug|VEN+HMA regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
75376480|NCT05348707|Other|epidemiology|To review medical records to describe diagnosis and severity of the disease.
75866641|NCT03672422|Diagnostic Test|Blood sample|Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits
75866642|NCT03672422|Behavioral|Patient questionnaires|Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
75376481|NCT05348707|Other|epidemiology|To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
75376482|NCT02745626|Device|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
75376483|NCT02763865|Device|MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil|"Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output."
75376484|NCT02763865|Device|eSHAM system|implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
75866643|NCT03672422|Diagnostic Test|Saliva sample|2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.
75866644|NCT03672422|Diagnostic Test|Urine sample|50 ml of urine in collection container.
76029169|NCT05908825|Drug|Vitamin C with AHA Exfoliative Serum|Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.
76029170|NCT05908825|Drug|Placebo serum|Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
75376485|NCT04337528|Other|Osteopathic manipulation type thrust|The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
75376486|NCT04337528|Other|Osteopathic manipulation type muscle-energy|The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
75376487|NCT04337528|Other|Placebo technique|The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
75376488|NCT02746406|Device|Peritron+|Peritron+ device to measure intravesical pressure
75376489|NCT04337918|Drug|NORS (Nitric Oxide Releasing Solution)|NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
75413772|NCT04902469|Behavioral|Odor Blank|Each participant in the odor blank condition will sniff a neutral olfactory cue (odor blank). This involves a container with no added scent. This serves as the control condition.
75413773|NCT04889859|Procedure|long Roux limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and 50 cm-long biliopancreatic limb.
76029171|NCT05908578|Other|High Frequency Exercise Training|Two sessions per week of high-intensity interval training (30 min each) and two sessions per week of continuous endurance exercise (30 min each). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
76029172|NCT05908578|Other|Low Frequency Exercise Training|One session per week of high-intensity interval training (60 min) and one session per week of continuous endurance exercise (60 min). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
76029173|NCT05908136|Other|restorative materials|two types of composite with strip crown in primary molars
76029174|NCT05908123|Behavioral|The Blank Center CARE Model(TM) for Individuals who Stutter|The over-arching goal of the Blank Center CARE Model is to ensure individuals who stutter communicate effectively, advocate for themselves in a manner that maintains agency, and ensure their quality of life does not depend on producing, or attempting to control, stuttered speech.
76029175|NCT05908071|Drug|SHEN26 capsule|Capsule administered orally after meals.
75376490|NCT04337918|Drug|NORS (Nitric Oxide Releasing Solution)|"Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
75376491|NCT02765269|Device|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
75376492|NCT02747186|Drug|Lidocaine|Intraoral maxillary field block
75376493|NCT02766517|Drug|Capsaicin|Administered topically
75702415|NCT02557893|Other|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
75539088|NCT00563641|Other|bubble NCPAP|"Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria."
75539089|NCT00248118|Drug|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
75702416|NCT00671931|Drug|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
75702417|NCT00671931|Drug|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
75702418|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
75866645|NCT03171376|Procedure|Root canal treatment and coronal restoration|After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
75702419|NCT00671931|Drug|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
75866646|NCT03171298|Procedure|Laparoscopic Assisted Transanal Total Mesorectal Excision|"Abdominal approach with laparoscopic mobilization of the left colon~Laparoscopic isolation and transection of inferior mesenteric vessels .~Transabdominal dissection of the upper rectum and mesorectam.~Insertion of transanal platform and the creation of pneumorectum.~Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~Transanal dissection of lower and mid mesorectam~The specimen will be extracted transanally"
75866647|NCT03675542|Drug|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
76029176|NCT05908071|Drug|SHEN26 placebo|Capsule administered orally after meals.
75702420|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
75702421|NCT00767559|Drug|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
75866648|NCT03171454|Procedure|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
75866649|NCT03171454|Procedure|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
75376494|NCT04335344|Other|Observation of suPAR plasma and salivary levels|Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
75539090|NCT04613011|Device|Ultrasound|Checking vein width snd copression using US
75539091|NCT04612894|Drug|Camrelizumab and Apatinib|All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
75866650|NCT03679286|Device|PCM and ROTEM|Test of blood sample by both PCM and ROTEM
75866651|NCT04482712|Drug|Rapamycin|Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
75866652|NCT04482712|Drug|Placebo|Administration of investigational drug placebo for up to 4 weeks while hospitalized
75539092|NCT04612894|Procedure|surgery|Perform surgery if operable after neoadjuvant therapy
75539093|NCT04612894|Procedure|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
75539094|NCT00251394|Drug|Rituxan|Given intravenously once weekly for four weeks.
75539095|NCT00251394|Drug|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
75539096|NCT00221936|Behavioral|Self-administration or nurse administered medication|
75702422|NCT00767559|Drug|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
75376495|NCT05348239|Drug|Sodium Copper Chlorophyllin|Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
75376496|NCT02766673|Drug|Albuterol Sulfate|Subjects will receive a dose of study medication every 4 hours for 24 total hours
75376497|NCT02766673|Drug|Sterile Saline|Subjects will receive a dose of study medication every 4 hours for 24 total hours
75376498|NCT05455736|Other|Stereotactic salvage radiotherapy for macroscopic prostate bed relapse|Stereotactic prostate salvage radiotherapy administered on prostate bed macroscopic recurrence. Different techniques will be allowed provided that treatment respects doses and fractionation indicated per-protocol (35 Gy in 5 fractions)
75866653|NCT03679208|Device|Investigational device coded KIO014|Innovative chitosan-based biomaterial intended for intraarticular injection.
75866654|NCT03679208|Device|Durolane(r) as control device|Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
76029177|NCT05907876|Other|Functional Test|UULEX uses a table of horizontal parallel lines with 8 levels. Each level is 84 cm wide and 8 cm high. The distance between the levels is 15 cm. The subject is seated on a straight chair with his/her feet on the floor facing the wall with the UULEX table. He/she holds a bar weighing 0.2 kg and lifts the bar at hip level. Keeping his/her arms shoulder-width apart, he/she raises the bar to different levels of the chart. As a warm-up, he/she is instructed to raise the bar to the first level and hold this position for 2 minutes. Then the bar is moved to each level and the levels are increased for 1 minute. The starting and ending point of each level is the hip joint. As the exercise progresses each minute, the weight of the bar is increased by 0.5 kg up to a maximum of 2 kg. During the test, a subject can move up to a maximum of a 2kg bar in a maximum of 12 minutes. The subject is instructed to continue the test until limited by the occurrence of symptoms.
75866655|NCT02409394|Drug|Hetrombopag Olamine|
75866656|NCT02409004|Drug|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
75866657|NCT02409004|Drug|Rifampin|Capsule 2x3oo mg Oral
75866658|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
75376499|NCT05455580|Behavioral|Nurses Taking On Readiness Measures (N-TORM)|The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
75866659|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
75866660|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
75866661|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
75376500|NCT02766907|Device|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
75376501|NCT00372320|Genetic|Gene Transfer|
75376502|NCT00372320|Drug|AdhAQP1|
75376503|NCT00371930|Procedure|application of a dye suspension followed by a laser intervention|
75376504|NCT02767609|Device|Magnetic Resonance Imaging|All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
75376505|NCT00372008|Drug|Testosterone|
75376506|NCT05348161|Procedure|Samples including blood and tissue collection|Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
75376507|NCT05348161|Procedure|CTC detection|Peripheral blood collected from patients will be administrated to CTC detection.
75866662|NCT03671876|Device|Intervention plus therapy|Task oriented exercise plan to improve mobility for stroke patients
75866663|NCT04039919|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
75866664|NCT04039919|Drug|Placebo (PSL)|Placebo will be provided matching Padsevonil to maintain the blinding.
75866665|NCT02405494|Dietary Supplement|Beverage 1|
75866666|NCT02405494|Dietary Supplement|Beverage 2|
75866667|NCT02405494|Dietary Supplement|Beverage 3|
75866668|NCT02405494|Dietary Supplement|Beverage 4|
75866669|NCT02405494|Dietary Supplement|Beverage 5|
75866670|NCT02405494|Dietary Supplement|Beverage 6|
75866671|NCT02405494|Dietary Supplement|Beverage 7|
75866672|NCT02405494|Dietary Supplement|Beverage 8|
75866673|NCT02405494|Dietary Supplement|Beverage 9|
75376508|NCT05348161|Procedure|ctDNA detection|DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
75376509|NCT05348161|Procedure|10×genomics single cell RNA sequence|Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
75376510|NCT05348161|Procedure|Whole exon sequence|DNA will be extracted from patients' tissue and administrated to whole exon sequence.
75702423|NCT00767559|Drug|warfarin|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
75702424|NCT00767637|Drug|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
75702425|NCT00767715|Drug|olanzapine|physician determined dose, oral, daily, 5 months
75702426|NCT00767715|Drug|haloperidol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
75702427|NCT00767715|Drug|zuclopentixol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
75376511|NCT05348161|Procedure|Proteomics detection|Peripheral blood collected from patients will be administrated to proximity extension assay .
75376512|NCT05349578|Diagnostic Test|swab RUT|rapid urease test using swab instead of biopsied tissue
75376513|NCT02973763|Drug|Alflutinib|
75376514|NCT04335734|Procedure|Nissen Fundoplication with wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures. Wrap was fixated to both diaphragmatic crura or to the body of stomach using two non-absorbable stitches on each side.
75376515|NCT04335734|Procedure|Nissen Fundoplication without wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures.
75376516|NCT02767843|Device|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
75376517|NCT04337593|Drug|Basiliximab|20mg d1,8, repeated every 3 weeks
75376518|NCT04337593|Drug|Pegaspargase|2500IU/㎡, d1,repeated every 3 weeks
75539097|NCT04612777|Behavioral|Opening Doors to Recovery|Opening Doors to Recovery (ODR) was created by a large, collaborative group in southeast Georgia as a recovery-oriented approach that navigates clients into services that may in some cases be fragmented and seemingly inaccessible. The team of three Community Navigation Specialists (CNSs) strives to help clients reduce institutional (e.g., hospital, jail) recidivism and embrace recovery. Their process of community navigation is a broader function than traditional case management as it includes mapping out and connecting clients to all available local resources, which requires being embedded in the community. The work of the CNSs benefits from commitments of diverse collaborative ODR partners, including local treatment providers, law enforcement, employers, and housing programs. Each CNS was expected to meet with the client at home or in community settings at least monthly, with the client having contact with at least one CNS weekly.
75702428|NCT02584946|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
75702429|NCT00762957|Drug|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
75702430|NCT00762957|Drug|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
75866674|NCT02409160|Procedure|Standard Roux-en-Y gastric bypass|
75702431|NCT00762957|Drug|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
75866675|NCT05171595|Device|Lifetouch single-lead ECG monitoring|The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
75866676|NCT05171595|Diagnostic Test|high-sensitive TnT measurements|Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
75866677|NCT03174340|Behavioral|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
75866678|NCT01367613|Drug|SC Methylnaltrexone|
75866679|NCT03174106|Device|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
76023359|NCT05109689|Behavioral|T4C|T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
75413774|NCT04889859|Procedure|long biliopancreatic limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 50 cm-long Roux limb and 100 cm-long biliopancreatic limb.
75413775|NCT04885400|Behavioral|iJobs|During the program, the participants will learn and exercise successful job search strategies. The web-based adaptation of the Jobs program will allow self-administration. After each session, they will receive written feedback from trainers on the platform.
75413776|NCT04880590|Other|Sex intercourse|A heterosexual sexual relationship
75413777|NCT04870827|Drug|13N Amonia|Administered during PET/CT scans
75413778|NCT04860765|Device|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
75376519|NCT04790864|Behavioral|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet with questions aimed at enhancing the processing of what was learned during treatment in terms of expectancy violation. For example, they are asked if what they were most worried about occured and what actually happened compared to what they predicted to happen. This should highlight the discrepancy between anticipated and actual outcomes. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
75376520|NCT04790864|Behavioral|Online large-group one-session treatment with post-treatment control exercise|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet that addresses basic contentual information concerning the treatment without a specific attempt to highlight the discrepancy between anticipated and actual outcomes. For example, participants will be asked how they would explain public speaking anxiety and exposure therapy to a friend and what advantages they see in conducting treatments like this in groups. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
75376521|NCT04737902|Procedure|Erector spinae plane block|Unilateral ESP block was performed between T3 and T7 levels depending on the thoracic surgical incision. The patient is placed in lateral decubitus position, under sterile conditions, a high frequency (6-15 MHz) linear-array transducer (Sonosite® Edge II, Bothell, USA) was placed in a longitudinal parasagittal orientation 2 cm from the posterior midline to visualise the tips of the transverse processes deep to the erector spinae muscle (ESM). A 21 G, 50 mm or 100 mm needle (Pajunk UniPlex NanoLine; Germany) was advanced in-plane with the ultrasound beam. The needle tip was directed to the plane between the transverse process and the posterior fascia of the ESM. Correct needle tip location was confirmed by ultrasound visualisation of linear fluid spread in the fascial plane. The injection of 0.5 to 1 ml of bupivacaine was 0.5% with epinephrine 5 µg/ml; then, a total of 20-30 ml of the same local anaesthetic was administered.
75413779|NCT04854512|Drug|Metformin DR|Delay-Release Metformin
75413780|NCT04854512|Drug|Metformin IR|Immediate Release Metformin
75413781|NCT04854512|Drug|Metformin DR Placebo|Metformin DR Placebo
75702432|NCT04295720|Device|Transcranial magnetic stimulation (TMS)|"Subjects will undergo testing at baseline prior to TMS treatments and once more at the end of the 2-week intervention.After the conclusion of baseline data acquisition, the research team will analyze each participant's unique structural and functional connectivity patterns to determine stimulation site for TMS in future study sessions.~The subjects will receive 10-sessions (1 session per day, M-F over 2 consecutive weeks).~The treatment itself lasts approximately only 190 seconds."
75702433|NCT00763113|Device|Vanguard PS Knee|Vanguard PS Knee
75702434|NCT00763113|Device|Vanguard CR Knee|Vanguard CR Knee
75702435|NCT05292014|Device|ANGIOLITE|Patients in whom treatment with ANGIOLITE has been attempted
75413782|NCT04854512|Drug|Metformin IR placebo|Metformin IR placebo
75413783|NCT04804072|Drug|Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)|MOUD for OUD
75413784|NCT04804072|Diagnostic Test|HIV testing|HIV testing
75702436|NCT02558127|Genetic|Asthma patients|Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
75702437|NCT00763191|Other|examination of ocular movements|
75702438|NCT00763191|Other|MATTIS test|
75702439|NCT00763191|Other|UPDRS test|
75702440|NCT00763191|Other|CRST test|
75702441|NCT00759993|Drug|chromium piccolinate|1000mg tab
75702442|NCT00759993|Drug|placebo for chromium piccolinate|
75702443|NCT00673881|Drug|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
75702444|NCT00763347|Drug|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
75702445|NCT00763347|Drug|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
75702446|NCT00763347|Drug|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
75702447|NCT00763347|Drug|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
75702448|NCT00763347|Drug|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
75702449|NCT00763347|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
75702450|NCT00767793|Drug|Placebo|One drop in each eye every 12 hours for seven days
75702451|NCT00767793|Drug|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
75702452|NCT00767793|Drug|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
75376522|NCT04336813|Other|Audience Response system|In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
75376523|NCT04707638|Other|No intervention used|No intervention used
75376524|NCT04337671|Other|Moderate intensity aerobic training|"The exercise program consisted of 5 minutes warm-up, 15-30 minutes of moderate aerobic exercises and 10 minutes cool-down, respectively.~Frequency: 3 sessions/week , and Duration:12 weeks."
75376525|NCT04337047|Other|questionnaire assesment|questionnaire assesment
75702453|NCT00767793|Drug|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
75376526|NCT05339581|Radiation|intensity-modulated radiotherapy|Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.
75376527|NCT05339581|Combination Product|Pembrolizumab|Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.
75866680|NCT03739151|Behavioral|Behavioral Obesity Treatment|"Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week."
75866681|NCT02405182|Other|Magnetic Resonance Imaging|
75866682|NCT03745001|Drug|EHP-101 Liquid single dose|One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
76023360|NCT02701777|Other|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
75376528|NCT05339581|Drug|Sintilimab|Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
75376529|NCT05339581|Drug|Camrelizumab|Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
75376530|NCT05339581|Drug|Tislelizumab|Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
75376531|NCT05339581|Drug|Lenvatinib Mesylate Capsule|Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
75376532|NCT04336579|Behavioral|Diaphragmatic Breathing|Simple diaphragmatic breathing exercise
75376533|NCT05335525|Device|Closure of the femoral arterial puncture site|Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.
76023361|NCT02701777|Behavioral|Training|The participant will be asked to perform exercises using their hands and arms.
75702454|NCT00767871|Drug|Lexapro|12 week treatment with lexapro
75702455|NCT00760149|Drug|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
75702456|NCT00767949|Biological|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
75702457|NCT00671853|Drug|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
75702458|NCT00671853|Drug|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
76023362|NCT02701777|Other|Sham STDP|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
76023363|NCT02701777|Other|Multisite-STDP|Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
75413785|NCT04804072|Drug|HIV treatment for participants living with HIV not already in care|HIV treatment for participants living with HIV not already in care
75413786|NCT04804072|Drug|PrEP for participants without HIV|PrEP for participants without HIV
75702459|NCT00760227|Other|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
75702460|NCT00760227|Other|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
75702461|NCT00760227|Other|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
75866683|NCT03745001|Drug|EHP-101 Liquid multiple doses|One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
75866684|NCT03745001|Drug|Matching placebo|Oral liquid administration daily
76029178|NCT05907785|Behavioral|Educational intervention|The intervention will consist of recommendations to improve physical activity (PA) and dietary habits. It is based on the PAIDO Programme (www.programapaido.es), an outpatient family-based multidisciplinary programme that combines PA, education on nutrition, and behavioural therapy. It will last 6 months and improvement of metabolic health and body weight loss is expected, particularly in the groups with overweight and obesity. The dietary intervention will be focused on the promotion of the Mediterranean diet, with follow-up and advice from a dietitian-nutritionist. Participants will be encouraged in reducing sedentary behaviour (watching television, playing computer games, playing board games). Performance of aerobic and strength physical exercises will be scheduled, progressively increasing the intensity. Volunteers and their parents will participate in monthly sessions to follow-up on adherence to the PA and dietary recommendations and give personalized advice.
75866685|NCT01367691|Device|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
75376534|NCT04064684|Drug|Budesonide|Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
75376535|NCT04064684|Drug|Placebo|Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
75376536|NCT04064684|Device|Nebulizer|The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
75376537|NCT05334199|Device|Biodegradable stent|Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
75376538|NCT05325385|Other|There are no interventions - this is a database study only|There are no interventions - this is a database study only
75376539|NCT04715906|Behavioral|UP-Caregiver|The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
75376540|NCT02192190|Drug|LY2951742|Administered subcutaneously (SC)
75376541|NCT02192190|Other|Placebo- oral|Administered orally
75376542|NCT02192190|Other|Placebo - SC|Administered SC
75376543|NCT02192190|Drug|Celecoxib|Administered orally
75376544|NCT03911726|Radiation|Single PET/MR-measurement|A single PET/MR-measurement using [18F]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.
75376545|NCT02748889|Drug|Carboplatin|Standard chemotherapy
75376546|NCT02748889|Drug|Etoposide|Standard chemotherapy
75376547|NCT02748889|Biological|MPDL3280A|Experimental biologic
75376548|NCT02749201|Device|Gastrisail|Light Intensity and gastric wall thickness assessment
75866686|NCT02405338|Biological|WT1/PRAME vaccination|
76029179|NCT05907655|Drug|Nitroglycerin 0.3 MG|Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.
75376549|NCT05402228|Diagnostic Test|temporomandbular joint disorders|no intervention
75376550|NCT04334720|Other|Comprehensive treatment of tumor|According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
75376551|NCT02224638|Device|TheraHoney HD|Honey
75376552|NCT02224638|Device|SkinTegrity|Hydrogel
75702462|NCT00768105|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
75702463|NCT00768105|Drug|Placebo|Dosing to match AZD1656
75702464|NCT00768183|Drug|KADIAN Capsule + alcohol (under fasting conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
75376553|NCT04334642|Other|A mindfulness based intervention|It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
75376554|NCT04690868|Drug|AD-213-A|1 tablet administered before the breakfast during 5 days
75376555|NCT04690868|Drug|AD-2131|1 tablet administered before the breakfast during 5 days
75376556|NCT04654988|Drug|Prednisone|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months
75376557|NCT04654988|Drug|Azathioprine|Azathioprine: 2 mg/kg daily for 12 months
75376558|NCT04654988|Drug|Placebo Prednisone|Placebo Prednisone
75376559|NCT04654988|Drug|Placebo Azathioprine|Placebo Azathioprine
75376560|NCT02749903|Drug|enzalutamide|oral
75376561|NCT04631432|Diagnostic Test|Pre-screening|Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
75702465|NCT00768183|Drug|KADIAN Capsule + water (under fasting conditions)|Capsules 100mg + 240 mL in 4 shots of 60 mL
75866687|NCT03738839|Device|Quantitative Light-Induced Fluorescence|White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
75866688|NCT03738839|Procedure|Direct bonding|The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
75866689|NCT03738839|Procedure|Indirect bonding|For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
75866690|NCT01364337|Other|DASH diet|DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
75866691|NCT01364337|Other|lower carbohydrate DASH diet|lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
75866692|NCT05166993|Device|MostCareUp|Pressure transducers have been connected to the MostCareUp and the hemodynamic parameters compared as follows: no filter, electronic filter, no electronic filter plus Accudynamic (our reference system). Invasive pressure values have been then compared with the non-invasive ones.
75866693|NCT02405416|Procedure|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
75376562|NCT04631432|Behavioral|Task session|"The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino & Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)"
75376563|NCT02224560|Drug|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
75376564|NCT02224560|Drug|Placebo control|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
75376565|NCT00372710|Drug|Zoledronic acid|
75376566|NCT02973776|Drug|LEO 90100 aerosol foam|
75376567|NCT02973776|Drug|Dermoval®/Dermovate®|
75376568|NCT02973776|Drug|Diprosone|
75539098|NCT04612777|Behavioral|Case Management|Case Management (CM) services, as defined by the State mental health agency, consist of providing essential environmental support and care coordination to assist the individual with improving his/her functioning, gaining access to necessary services, and creating an environment that promotes recovery as identified in his/her Individual Recovery Plan (IRP). The focus of interventions include assisting the individual with: (1) developing natural supports to promote community integration, (2) identifying service needs, (3) referring and linking to services and resources identified through the service planning process, (4) coordinating services identified on the IRP to maximize service integration and minimize service gaps, and (5) ensuring continued adequacy of the IRP to meet his/her ongoing and changing needs. Contact must be made with the individual ≥2 times per month, at least one of which must be in-person, in a non-clinic setting.
75866694|NCT02405416|Procedure|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
75866695|NCT02405416|Procedure|Portal triad clamping|Portal triad are clamped in hepatectomy.
75866696|NCT01361295|Procedure|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
75376569|NCT02973776|Drug|Elocon|
75376570|NCT02973776|Drug|Locoid|
75376571|NCT02973776|Other|LEO 90100 foam vehicle|
75702466|NCT00768183|Drug|morphine sulfate IR oral solution + water|Morphine sulfate IR oral solution + water (under fasting conditions)
75702467|NCT00768183|Drug|KADIAN Capsule + alcohol (under fed conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
75702468|NCT00763425|Procedure|cold polypectomy|The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
75702469|NCT00763425|Procedure|conventional polypectomy|The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
75702470|NCT00760305|Behavioral|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
75866697|NCT01361295|Procedure|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
76029180|NCT05907655|Diagnostic Test|MRI|The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.
76029181|NCT05907655|Diagnostic Test|Blood sampling|Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.
75866698|NCT03671720|Biological|personalized DC vaccine|personalized vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous tumor cells, administered intranodally on day 1,8,15, with a combination of oral cyclophosphamide (50mg) every day except the day of vaccine administrations.Cycles are repeated every 21 days. Treatment is continued until disease progression or exhaustion of vaccine supply, whichever comes first.
75866699|NCT02405104|Drug|chlorzoxazone|ATC-code: M03BB03
75866700|NCT02405104|Drug|Placebo|Placebo
75866701|NCT02405104|Procedure|THA|Surgical treatment of osteoarthrosis in the hip, by replacement.
75866702|NCT02405104|Procedure|TKA|Surgical treatment of osteoarthrosis in the knee, by replacement.
75702471|NCT00768339|Drug|AEG35156 antisense IV infusion|"AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion"
75376572|NCT02161458|Drug|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
75376573|NCT02161458|Drug|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
75702472|NCT00768417|Behavioral|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
75702473|NCT00768417|Behavioral|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
75702474|NCT00768417|Behavioral|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
76029182|NCT05907655|Device|Sleep profiler|Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.
75702475|NCT02557581|Other|No training|
75702476|NCT02557581|Other|Endurance training|
75702477|NCT02557581|Other|Resistance Training|
75702478|NCT02557581|Drug|Terbutaline|
75702479|NCT02557581|Drug|Clenbuterol|
75702480|NCT02557581|Drug|Placebo|
75702481|NCT04077944|Diagnostic Test|maternal serum concentration of trace elements and heavy metals levels|The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
75702482|NCT02558751|Biological|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
75376574|NCT02161458|Drug|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
75376575|NCT02161458|Drug|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
75376576|NCT04336657|Other|Questionnaire|Survey to identify number of people who got unusual severe flu- like illness in last October- November
75376577|NCT04336657|Diagnostic Test|IgG|Measure the past immunity of the disease (if possible)
75376578|NCT05144828|Device|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYOS-L cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
75702483|NCT02558751|Biological|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
75702484|NCT00768573|Drug|sildenafil|Oral suspension of sildenafil.
75702485|NCT02558361|Drug|Treatment with Apremilast|Standard dosing with apremilast (Otezla) will be used. [30mg po BID after initial titration]
75702486|NCT02558595|Dietary Supplement|Niacinamide|
75702487|NCT02558595|Other|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
75702488|NCT02585024|Drug|Cytisine|
75702489|NCT00760695|Drug|dronabinol|tablets, twice daily, for 4 weeks
75702490|NCT00760695|Drug|placebo|tablets, twice daily, for 4 weeks
75702491|NCT04617314|Drug|RC108|RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
75702492|NCT04048629|Device|Point-of-care (POC) viral load (VL) testing plus refresher training|VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
75702493|NCT04048629|Other|Standard of care central laboratory VL testing plus refresher training|VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
75702494|NCT02582372|Drug|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
75702495|NCT02582372|Drug|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
75866703|NCT01364415|Drug|Pasireotide LAR|
75866704|NCT03176368|Other|Coconut Oil|Coconut Oil
75866705|NCT03522129|Drug|CT1812|Active Study Drug
75866706|NCT03522129|Drug|Placebo|Non-active study drug
75702496|NCT03926468|Diagnostic Test|Liquid biopsy|Before onset of treatment, cell-free DNA (cfDNA) is extracted from venous blood sample for next-generation DNA sequencing (NGS) using a commercially available platform (Roche Foundation ACT) For this purpose, 4 x 10 ml of venous blood will be collected from each patient. Two tubes (Streck) will be sent to service provider (Roche), one tube will be used for droplet digital polymerase chain reaction (ddPCR, QX200 Droplet Digital PCR System, BioRad) and ddPRC/NGS analyses and one is collected and stored in Auria Biobank (www.auria.fi) for possible future analyses.
75702497|NCT00768729|Drug|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
75702498|NCT00768729|Drug|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
75702499|NCT04266080|Other|Fitbit Inspire HR|assessing step counts
75702500|NCT04266080|Other|Questionaires|Patient-Reported Outcomes Measurement Information System (PROMIS)
75702501|NCT00760773|Drug|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
75702502|NCT00760773|Drug|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
75702503|NCT00760773|Drug|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
75702504|NCT00768807|Device|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
75702505|NCT04077554|Genetic|gene expression|determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
75702506|NCT00768885|Device|PureVision 1|Currently marketed PureVision soft contact lens.
75702507|NCT00768885|Device|PureVision 2|Alternate design soft contact lens.
75702508|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
75702509|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
75702510|NCT00769041|Drug|moxifloxacin|400mg
75866707|NCT03176446|Device|Local anesthesia with traditional technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
75376579|NCT05144828|Drug|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
75539099|NCT04612777|Behavioral|Intensive Case Management|Intensive Case Management (ICM) is very similar to CM, but four in-person visits are required monthly. Additional contacts may be either face-to-face or via telephone, depending on the individual's needs. At least 60% of total contacts must be face-to-face with the individual, and at least 50% must be delivered in non-clinic/community-based settings. An ICM team includes nine professionals: a licensed clinician, four masters-level clinicians, two bachelors-level clinicians, and two paraprofessionals. The team's maximum case load is 200 in rural settings and 300 in urban settings (22-33 per team member).
75539100|NCT04612543|Device|Genial Posterior Composite with Polyethylene Fiber|Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
75702511|NCT00769041|Drug|avanafil|100mg single dose
75702512|NCT00769041|Drug|avanafil|800mg single dose
75702513|NCT00769041|Drug|sugar pill|single dose
75702514|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
75866708|NCT03176446|Device|Local anesthesia with computerized technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
75702515|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
75866709|NCT03176446|Device|Local anesthesia with DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
75866710|NCT03176446|Drug|Topic anesthesia|Application of topical anesthetic for 60 seconds with benzocaine
75702516|NCT00763659|Dietary Supplement|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
75702517|NCT04077476|Behavioral|Online Yoga + Facebook|Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
75702518|NCT04077476|Behavioral|Online Yoga|Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
75702519|NCT00760851|Other|probiotic strain Bb-12|10^9 CFU Bb-12 per 4 oz yogurt
75702520|NCT00760851|Other|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
75376580|NCT05455255|Other|Experimental|FL was applied by Jonathan Bergmann and Aaron Sams in 2007 for high school students who had to be absent from chemistry class. Bergmann and Sams published all the learning activities they used during the lesson as videos. Bergmann and Sams (2012) stated that in this model, which they developed over time, it is not compulsory for the trainer to explain the entire course content in the videos, and the important thing is to allocate time to active learning methods during the course. In the FL model, the summary of the course content is presented to the individuals outside the classroom with tools such as video and power point presentations. In the lesson, activities are carried out for the active participation of the student. The student performs the course content outside of the classroom, and the homework and learning the course in the classroom.
75376581|NCT02223858|Behavioral|Positive Activities (PA) Program|6-week program of at-home activities (1 per week) that have been shown to increase positivity. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
75376582|NCT02223858|Behavioral|Attention Control (AC) Program|6-week program of at-home activities (1 per week) based on affectively neutral activities from control conditions in studies of positive activities interventions. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
75376583|NCT04336501|Biological|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
75376584|NCT05041400|Other|Evaluation of the strength of knee flexors and extensors|Each participant will benefit from a clinical evaluation and an evaluation of the strength of knee flexors and extensors using an isokinetic dynamometer after a 10-minute warm up.
75702521|NCT04019678|Procedure|Omission of Axillary dissection|In Group 1 and 2: Axillary dissection won't be performed
75866711|NCT03176446|Drug|Local anesthetic|2% lidocaine with epinephrine 1: 100000 1.8 mL
75866712|NCT03176212|Dietary Supplement|Milk fat globule membrane|
75866713|NCT03176290|Diagnostic Test|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml-1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 - platelet count (×109 l-1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
75376585|NCT02223390|Behavioral|Improving AIDS Care after Trauma (ImpACT)|
75376586|NCT05454865|Dietary Supplement|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack PO bid for 2 treatment cycles (1 cycle = 3 weeks)
75376587|NCT05454865|Dietary Supplement|Placebo|Placebo 1 1pack PO bid for 1 treatment cycle (1 cycle = 3 weeks) and followed by Jin Si Herbal Tea 1 pack PO bid for the 2nd treatment cycle
75376588|NCT04507646|Other|True auricular acupuncture|The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
75376589|NCT04507646|Other|sham auricular acupuncture|The participant in control group will receive acupuncture on ineffective point at ear.
75866714|NCT02408614|Other|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
75866715|NCT02408614|Other|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
75866716|NCT02408614|Other|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
75866717|NCT02408614|Device|Treadmill|
75866718|NCT03171142|Drug|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
75866719|NCT03171142|Drug|Air|Air 21% via nasal cannula 2 litter per minutes
75866720|NCT04035473|Drug|HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules|"HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules"
75866721|NCT02408848|Other|Observational|This is an observational study. There is no intervention.
75866722|NCT02413528|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
75702522|NCT00770445|Drug|Pioglitazone and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
75702523|NCT00770445|Drug|Pioglitazone and metformin and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
75866723|NCT02413528|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
75376590|NCT02973841|Device|Sono-ease device|insertion of US guided IJV using sono-ease device
75376591|NCT04507022|Drug|Estradiol Valerate|2mg three times daily
75866724|NCT04032977|Device|PN40082|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
75866725|NCT04032977|Device|Restylane Silk|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
75866726|NCT02408926|Biological|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
75866727|NCT02408926|Biological|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
75866728|NCT02408926|Biological|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
75866729|NCT02408926|Biological|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
75376592|NCT04507022|Drug|Progesterone|100 mg daily intramuscular
75376593|NCT04507022|Drug|Aromatase inhibitor|2.5 mg twice daily for 5 days
75376594|NCT00372788|Drug|AZD6244|oral vial
75539101|NCT04612543|Device|Genial Posterior Composite|Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
75866730|NCT04030247|Drug|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
75866731|NCT00704158|Drug|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
75866732|NCT04481698|Other|Mesoglycan|Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days
75376595|NCT00372788|Drug|Pemetrexed|oral
75376596|NCT04957316|Device|Triple-effect blood purification filter|Blood purification using the oXiris filter to remove endotoxin, cytokines, and uremic toxins.
75376597|NCT02774941|Device|Jet Nebulizer|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
75376598|NCT02774941|Device|Vibrating Mesh Nebulizer|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
75376599|NCT04334018|Device|conventional CRT|"Conventional CRT or biventricular pacing resynchronizes left ventricular contraction by pacing the right and left ventricles (LV) simultaneously"
75376600|NCT04334018|Device|MPP CRT|CRT with Multipoint pacing (MPP) where pacing can occur from more than one LV site simultaneously
75376601|NCT05253001|Device|smartphone|Use the mobile chatbot approach for intervention groups to improve prenatal education.
75376602|NCT05441293|Procedure|flap reconstruction|received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities
75376603|NCT04759794|Diagnostic Test|Cytology staining|"Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~conventional cytology staining method~new cytology staining method using the antibody of aminoacyl-tRNA synthetases"
75376605|NCT04336423|Diagnostic Test|Obtain samples from sputum and feces|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
75376606|NCT05211505|Device|WO 2707|Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
75376607|NCT00372151|Dietary Supplement|L-Theanine|400 mg/day, caps.
75376608|NCT00372151|Other|Placebo|caps.
75376609|NCT04336267|Device|Transcranial direct current stimulation (tDCS) group|Patients randomized to the tDCS group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity of anodal stimulation.
75539102|NCT04612816|Other|Prehospital ultrasound|Feasibility of real time PEU transmission in a university affiliated preclinical emergency system.
75539103|NCT02961387|Device|Hydrogen generator treatment|The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
75539104|NCT02961387|Device|Oxygen-making machine treatment|The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
75539105|NCT00221975|Drug|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
75702524|NCT00770445|Drug|Metformin and insulin|Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
75702525|NCT04077398|Drug|Ropivacaine 0.5% Injectable Solution|There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
75702526|NCT00763737|Procedure|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
75702527|NCT04078256|Other|Proprioceptive exercise program|Group A will carry out two sessions of proprioceptive training per week, in a total of 8 weeks, during the pre-season period (September-October). Each session will last approximately 30 minutes and will include 6 exercises. The execution of the exercises will be supervised by a physiotherapist and a national trainer of athletics.
75702528|NCT04078256|Other|Usual training routine|The subjects of the control group (group B) will be informed so that they do not include any change in their usual training routine.
75866733|NCT03738761|Drug|Amlessa®|Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
75376610|NCT04336267|Device|Sham group|In the sham group, the stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session.
75376611|NCT00372476|Drug|Imatinib and Vinorelbine|
75866734|NCT03738761|Drug|Co-Amlessa®|Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
75376612|NCT04457492|Other|Application of FES to the Face|Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.
75376613|NCT04334096|Behavioral|quality of life pathway|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
75376614|NCT04737967|Drug|Venlafaxine|Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
75376615|NCT04737967|Drug|Memantine|Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
75376616|NCT05350111|Behavioral|lifestyle education|education on healthy lifestyle through group sessions and telemedicine tools
75376617|NCT03464630|Behavioral|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
75376618|NCT03464630|Behavioral|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
75376619|NCT04766918|Procedure|Sono-guided injection with high molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (Aragan Plus, 20 mg/2 ml, 3000kDa) between carpal tunnel and median nerve
75376620|NCT04766918|Procedure|Sono-guided injection with low molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2 ml, 600-1200kDa) between carpal tunnel and median nerve
75376621|NCT04334564|Drug|Ginkgo biloba capsule|Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
75702529|NCT04079972|Behavioral|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
75702530|NCT04079972|Behavioral|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
75866735|NCT02413216|Behavioral|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
75866736|NCT02413216|Other|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
75866737|NCT03671642|Device|Q-ICG|Quantitative perfusion assessment with indocyanine green on a touch screen tablet
75866738|NCT03671642|Procedure|White light perfusion assessment|Traditional visual perfusion assessment in white light
75866739|NCT03671642|Procedure|Fluorescence angiography|Perfusion assessment with fluorescence angiography - without quantification
75702531|NCT04048707|Drug|Angiotensin II|Intravenous
75866740|NCT03623282|Drug|Synatura® 15 mL|All subjects will receive Synatura® 15 mL every day three times for 3 months.
75866741|NCT03738605|Device|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
75866742|NCT04482790|Procedure|Conventional celluloid matrix technique in management of black triangle|conventional restorative technique in management of black triangle
75376622|NCT04334564|Drug|Placebos|Placebos were controls.
75376623|NCT04334551|Drug|Doravirine|switches from etravirine to doravirine, in experienced HIV patients
75376624|NCT04334785|Device|cryo-ablation|Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.
75376625|NCT03365414|Biological|Albumin (Human) 5%, USP|Albumin (Human) 5%, USP. Intravenous Solution. Plasma Substitute/Blood Derivative
75376626|NCT03365414|Drug|Normal Saline 0.9% Infusion Solution Bag|Placebo Normal Saline 0.9% Infusion Solution Bag.
75376627|NCT00373022|Behavioral|exercise intervention|
75376628|NCT00373022|Other|flow cytometry|
75702532|NCT04048707|Drug|Midodrine|Pill
75702533|NCT04048707|Drug|Octreotide|Subcutaneous
75702534|NCT04048707|Drug|Albumin solution|Intravenous suspension
75702535|NCT05346458|Device|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients planned for an invasive coronary physiology (pressure-wire) study and who meet the inclusion criteria and none of the exclusion criteria can be enrolled. Participants will undergo preparation for their clinical procedure (angiogram with pressure wire study) in the normal manner. Arterial cannulation will be performed via the radial or femoral artery) under local anaesthesia. The sheath will be inserted and a pre-procedure blood sample taken for Troponin T level. A coronary angiogram will be performed as per standard clinical practice prior to cannulating the coronary artery to be studied. The pressure studies will be performed sequentially, first with a pressure wire before using the iKOs™ microcatheter. Following withdrawal of the iKOs™ microcatheter. A pressure wire assessment is repeated after the microcatheter is withdrawn. The case will then proceed as clinically indicated. Post-procedure the participant will be managed according to standard clinical practice.
75702536|NCT03925844|Other|Classification according to the cardiovascular risk|All patients are cognitively assessed at the beginning of the study and their cardiovascular risk is calculated. After 5 years of follow-up, patients are re-evaluated cognitively and their cardiovascular risk is recalculated.
75702537|NCT00769353|Behavioral|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
75702538|NCT00769353|Behavioral|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
75702539|NCT00769431|Other|educational intervention|
75702540|NCT00769431|Other|study of socioeconomic and demographic variables|
75702541|NCT00763893|Drug|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
75702542|NCT00763893|Drug|Losartan|50 mg/day if < weight 50 kg 100 mg/day if weight > 50 kg
75702543|NCT04019366|Other|Balance Training|Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.
75376629|NCT00373022|Other|laboratory biomarker analysis|
75702544|NCT04019366|Other|Conventional Training|Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
75376630|NCT00373022|Procedure|management of therapy complications|
75702545|NCT00770835|Drug|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
75702546|NCT00770835|Drug|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
75702547|NCT04228016|Device|Device: nastent™|Patients with Nasal obstruction at night, will be used intrasal stent during 15 nights. These are flexible silicone tubes that are lubricated and easy to insert into the nasal cavities, which would restore the permeability of the nasal cavities.
75539106|NCT00221975|Drug|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
75539107|NCT00221975|Drug|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (<2 months versus ≥2 months).
75702548|NCT00769509|Other|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
75702549|NCT00769509|Other|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
75702550|NCT00769587|Drug|thalidomide|
75702551|NCT00769665|Other|Systane Ultra|Re-wetting ocular eye drop
75702552|NCT00769665|Other|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
75866743|NCT04482790|Procedure|Bioclear cervical matrix with injection molding technique|New restorative technique in management of black triangle restorative papilla regeneration
75539108|NCT04612582|Drug|Thalidomide|Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.
75539109|NCT04612582|Drug|Cyclophosphamide|Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
75539110|NCT00248157|Drug|Octreotide acetate in microspheres|
75539111|NCT04612855|Other|Groupwise comparison of primary and secondary outcomes|Statistical comparison of cohorts. Cfr supporting information on statistical plan.
75539112|NCT00222014|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
75702553|NCT00764049|Device|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
75866744|NCT03738527|Drug|Tranexamic Acid 100mg/mL, 20mL topical|"Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure"
75376631|NCT00373022|Procedure|psychosocial assessment and care|
75376632|NCT00373022|Procedure|quality-of-life assessment|
75376633|NCT05131399|Device|Phase A1|Plastic standard ankle foot orthosis
75539113|NCT00222014|Procedure|Paracenthese|Paracenthese
75376634|NCT05131399|Device|Phase B1|carbon medical device ankle foot orthosis
75376635|NCT05131399|Device|Phase A2|Plastic standard ankle foot orthosis
75376636|NCT05131399|Device|Phase B2|carbon medical device ankle foot orthosis
75376637|NCT03305588|Device|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
75376638|NCT03233594|Other|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
75702554|NCT04048083|Behavioral|Mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.
75376639|NCT03233594|Other|Healthy Control Group|Participants will not receive any interventions.
75376640|NCT05107609|Behavioral|Acute Self-Compassion Intervention|Participants will be guided through a 30-minute behavioural self-compassion intervention that seeks to mitigate their psychobiological responses to the subsequent weight stigma induction. The intervention is intended to induce a flexible self-compassionate mindset that will facilitate more adaptive psychological responding to stress and activate affiliative/self-soothing physiological systems that can dampen psychobiological stress reactivity. This acute self-compassion intervention will employ a multimodal, experiential approach that is regularly utilized in self-compassion training, drawing from approaches developed in Compassion-Focused Therapy and Mindful Self-Compassion.
75376641|NCT04328558|Other|Clavipectoral fascia plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
75376642|NCT05350033|Device|tDCS - tDCS|active-tDCS administered during 10 sessions, in Phase 1 and Phase 2
75376643|NCT05350033|Device|tDCS - Sham|active-tDCS administered during 5 sessions, in Phase 1
75376644|NCT05350033|Device|Sham - tDCS|active-tDCS administered during 5 sessions, in Phase 2
75376645|NCT05350033|Device|Sham - Sham|sham-tDCS administered during 10 sessions, in Phase 1 and Phase 2
75376646|NCT04247672|Device|Total Knee Arthroplasty (uncemented rotating platform ATTUNE)|All patients receive an uncemented ATTUNE rotating platform knee system.
75376647|NCT05456971|Device|Art Filler Volume|Midface correction with injectable hyaluronic acid based-filler
75702555|NCT04048083|Behavioral|Computer-aided trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.
75702556|NCT04048083|Behavioral|Computer-aided and mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).
75702557|NCT04048083|Other|No trainings|Healthy controls without any kind of training
75866745|NCT03738527|Drug|Normal Saline Flush, 0.9%, 20mL topical|"Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure"
75866746|NCT03738449|Drug|CKD-387|Test drug
75376648|NCT05456971|Device|Art Filler Lips|Lipscorrection with injectable hyaluronic acid based-filler
75376649|NCT04737590|Device|Bioactive glass|Comparison of bioactive glass to allogenic bone in pediatric bone cysts
75376650|NCT04737434|Device|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
75376651|NCT04737434|Device|electromagnetic field with no wave|electromagnetic field with no wave
75376652|NCT05349877|Behavioral|Expressive writing|Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
75376653|NCT05349877|Behavioral|Self-affirmation|Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
75376654|NCT05349877|Behavioral|Placebo|Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
75376655|NCT02590640|Device|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
75376656|NCT02590640|Device|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
75376657|NCT04233476|Drug|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg
75376658|NCT00371995|Drug|Liposomal amphotericin B and Miltefosine|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
75376659|NCT05456737|Other|assessment|Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
75702558|NCT05674604|Procedure|Cryoneurolysis|This is on observational study. All participants are already candidate for cryoneurolysis. Cryoneurolysis uses a cold probe to generate an ice ball, which initiates Wallerian Degeneration, a process where axon is destroyed but the epineurium and perineurium remain intact. The treated nerve is able to regenerate over time due to this preserved tube.
76029183|NCT05907512|Drug|Endostar|The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.
75376660|NCT04333940|Procedure|periapical surgery|clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
75376661|NCT04335877|Other|Private sector component + modified BCC|Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
75376662|NCT05297539|Other|Point light display|Visualization of point-light human actions
75376663|NCT00372307|Drug|Application of pimecrolimus|
75376664|NCT04137133|Diagnostic Test|collection|bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
75702559|NCT00570921|Drug|Everolimus|Everolimus tablets, two-5 mg tablets a day
75376665|NCT04647110|Drug|crizotinib|as provided in real world practice
75376666|NCT04647110|Drug|alectinib|as provided in real world practice
75376667|NCT04647110|Drug|brigatinib|as provided in real world practice
75376668|NCT04647110|Drug|ceritinib|as provided in real world practice
75376669|NCT04647110|Drug|lorlatinib|as provided in real world practice
75376670|NCT05455957|Other|exercise|neuromuscular and vestibulo-ocular training
75376671|NCT04061785|Other|Judo4Balance - 12 week judo inspired exercise program|12 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
75376672|NCT05455801|Device|negative preassure wound therapy|wound treated with negative pressure therapy dressing
75376673|NCT04061330|Drug|Ketamine|Initial bolus of ketamine 0.3 mg/kg IV (maximum 30 mg) followed by ketamine infusion of 0.25mg/kg/hr (maximum 25mg/kg/hr) for 6 hours or until patient leaves the emergency department (ED),whichever occurs first.
75376674|NCT04061330|Drug|Morphine|Bolus doses of morphine 0.1 mg/kg (maximum 8 mg) intravenously every 2 hours for 6 hours or until patient leaves the ED, whichever occurs first.
75376675|NCT00372632|Drug|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
75376676|NCT00372632|Drug|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
75702560|NCT00570921|Drug|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
75702561|NCT04077242|Diagnostic Test|"Hysteroscopic Fallopian tube assessment using the Parryscope technique"|A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present [10]. At least 30 seconds of observation per ostia is performed if patency is not observed.
75702562|NCT04077242|Diagnostic Test|"Hysteroscopic Fallopian tube assessment using the Tubal flow technique"|"a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
75702563|NCT00769821|Other|questionnaire administration|
75702564|NCT00769821|Procedure|assessment of therapy complications|
75702565|NCT00769821|Procedure|bioimpedance spectroscopy|
75702566|NCT00769821|Procedure|quality-of-life assessment|
75702567|NCT04076930|Drug|angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)|The use of ACEI/ARB within a 90-day after the date of PD initiation (exposure ascertainment window period).
75702568|NCT02557425|Other|No intervention in PROTECT|
75702569|NCT05233826|Biological|COVI-VAC|Intranasal, live attenuated vaccine against SARS-CoV-2
75702570|NCT00769899|Drug|AZD7325|Capsule for oral, single dose
75376677|NCT05455723|Procedure|Tracheal Intubation|Inflation-Deflation Technique Versus Magill Forceps Technique for Nasal Intubation by Video-assisted Laryngoscope
75376678|NCT05455645|Other|targeted intrinsic foot muscle exercises|4 targeted intrinsic foot muscle exercises
75376679|NCT04525352|Biological|RP-L401|CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
75376680|NCT03991195|Dietary Supplement|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
75376681|NCT03991195|Dietary Supplement|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
75702571|NCT00769899|Drug|Placebo|Placebo capsule for oral, single dose
75702572|NCT00770055|Other|medical chart review|
75702573|NCT00770055|Other|questionnaire administration|
75702574|NCT00770055|Other|survey administration|
75702575|NCT00770055|Procedure|psychosocial assessment and care|
75866747|NCT03738449|Drug|D484|reference drug
76023364|NCT05109533|Other|Lactobacillus rhamnosus BMX 54, Lactobacillus reuteri RC-14, Lactobacillus rhamnosus GR-1|Probiotics implementation
76023365|NCT05109377|Diagnostic Test|Endocan|Endocan will measured before and after treatment
76023366|NCT05109377|Drug|tadalafil|tadalafil
76029184|NCT05907512|Drug|Toripalimab|3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).
75376682|NCT04821115|Device|Low intensity choc waves therapy (active applicator)|At each of the 4 sessions, 4000 shockwaves will be delivered at level 8 (EFD = 0.133 mJ/mm2), over a period of 15 to 20 minutes. The probe will be applied directly to the plaque, on the flaccid penis. The device will stop automatically after the 4000 shock waves.
75702576|NCT04048317|Drug|HepaSphere Microspheres/Doxorubicin Hydrochloride|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours."
75702577|NCT04048317|Drug|Lipiodol|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration"
75702578|NCT00764283|Device|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
75702579|NCT00764283|Device|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
75702580|NCT00764283|Device|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
75702581|NCT02582294|Other|Questionnaire|
75702582|NCT04363034|Biological|Convalescent Plasma|1-2 units (200-400 mL per unit, not to exceed 550 mL total) of ABO compatible, low isohemagglutinin titer, COVID-19 convalescent plasma
75702583|NCT00920504|Behavioral|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
75702584|NCT00920504|Other|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
75702585|NCT02584712|Other|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
75702586|NCT02582450|Other|Patients with haemophilia|Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
75376683|NCT04821115|Device|Sham (sham applicator)|At each of the 4 sessions, a sham applicator will be used. The sham applicator has an internal foam pad that disperses the shockwave energy, but is not visible from the outside. The sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted.
75376684|NCT04333693|Procedure|Vascular surgery|Open vascular, endovascular or hybrid procedures
76029185|NCT05907460|Device|transesophageal echocardiography examination during cardiopulmonary resuscitation|Perform transesophageal echocardiography in patients with out-of-hospital cardiac arrest during cardiopulmonary resuscitation and adjust the chest compression site to compress the left ventricle and avoid left ventricular outflow tract.
76029186|NCT05907434|Diagnostic Test|Nephrocheck (AKI score)|Early biomarker of AKI
76029187|NCT05907421|Behavioral|Acceptance mindset|Brief training of acceptance versus emotional reactivity as emotion regulation strategy.
76029188|NCT05907356|Other|sciatic nerve slider technique in supine lying position|The patient will be in a supine position. The therapist will hold the patient's limb passively and then move the hip into flexion with the ankle in plantar flexion and the knee in extension, stretching the nerve at the hip and relaxing at the ankle, Then reversing the movement with the hip into extension, maintaining the knee in extension and the ankle in dorsiflexion, relaxing the nerve at the hip and stretching at the ankle. Provide five sets in every session; the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions, and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
75702587|NCT02584556|Drug|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
75702588|NCT02584556|Drug|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
75702589|NCT04353986|Drug|Sofosbuvir and Ledipasvir|fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir
75702590|NCT04077008|Procedure|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
75702591|NCT04077008|Procedure|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
75702592|NCT05325554|Behavioral|Multimodal rehabilitation|Multimodal rehabilitation
75866748|NCT03174262|Behavioral|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
75866749|NCT02413060|Other|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
75866750|NCT02413060|Behavioral|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
75376685|NCT04809883|Diagnostic Test|Endoflip measurement of gastric and pyloric function|Endoflip device to measure gastric and pyloric functions
75702593|NCT02581436|Other|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
75866751|NCT03738371|Other|In situ simulation|Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
75702594|NCT02581436|Other|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine >25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
75702595|NCT00670449|Drug|Fingolimod|Fingolimod was supplied in capsules.
75702596|NCT04168970|Procedure|PSGB|Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.
75702597|NCT04160390|Other|Biospecimen Collection-Blood|Undergo collection of blood
75702598|NCT04160390|Other|Biospecimen Collection-Stool|Undergo collection of stool
75376686|NCT04792021|Drug|N-acetylcysteine|Oral formulation: 600 mg sachets of N-acetylcysteine
75702599|NCT00771147|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
75702600|NCT00771225|Procedure|fascial repair|surgery to treat genital prolapse with fascia repair
75702601|NCT00771225|Procedure|mesh repair|surgery to genital prolapse with mesh
75702602|NCT04155710|Biological|IOV-2001|Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
75702603|NCT04155710|Drug|Low dose IL-2|6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
75866752|NCT03176056|Dietary Supplement|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
76023367|NCT05109299|Other|Miswak toothpaste|Dabur Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica'
76023368|NCT05109299|Other|Fluoride toothpaste|1450 ppm fluoride toothpaste
76023369|NCT03172351|Device|EDoF1|extended depth of focus IOL - EDoF1
75376687|NCT05093413|Behavioral|Sleep deprivation|Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
75702604|NCT04155710|Drug|High dose IL-2|6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
75702605|NCT04155710|Drug|IL-2|6 doses of IL-2 will follow the infusion of IOV-2001
75702606|NCT02557659|Device|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
75702607|NCT00775047|Other|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
75702608|NCT00775047|Other|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
75702609|NCT00775125|Drug|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
75702610|NCT02557503|Drug|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
75702611|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
75413787|NCT04804072|Diagnostic Test|Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)|Testing and referral for vaccination or treatment for HAV and HBV
75702612|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
75702613|NCT00771303|Other|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
76023370|NCT03172351|Device|Monofocal|Monofocal IOL
76023371|NCT03172351|Device|EDoF2|Comparison EDoF2 IOL
76023372|NCT05108753|Other|Procedure/Surgery|Transanal Total Mesorectal Excision
76023373|NCT03170089|Behavioral|Oral Health Educational Program|Oral Hygiene methods learned
76023374|NCT02396719|Device|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
76023375|NCT04673591|Drug|Tregalizumab|a monoclonal antibody designed for the treatment of allergic asthma indication
75413788|NCT04804072|Diagnostic Test|Testing and referral for treatment for hepatitis C virus (HCV)|Testing and referral for treatment for HCV
75413789|NCT04804072|Diagnostic Test|Sexually transmitted infection (STI) testing and treatment|STI testing and treatment
75413790|NCT04804072|Other|Primary care|Primary care
75413791|NCT04804072|Behavioral|Harm reduction services|Harm reduction services
75376688|NCT03905629|Other|None (retrospective observational study)|"This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay >15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors"
75702614|NCT02558049|Other|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
75376689|NCT04334161|Combination Product|Administration of glucose and controlled induction of hypoglycaemia.|Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
75702615|NCT00771381|Drug|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
75376690|NCT04978285|Other|Anemia|Depends on Day 3 Hb result
75376691|NCT04957303|Device|sublingual microcirculation video recording|The sublingual microcirculation videos were recorded by video microscope
75376692|NCT00372463|Behavioral|6-week Online Diabetes Self-Management Educational Program|
75376693|NCT04926961|Device|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
75376694|NCT04926961|Device|Real transcranial magnetic stimulation (TMS)|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
75376695|NCT04737811|Other|Turkish Version of Swallowing Disturbance Questionnaire|The Turkish Version of Swallowing Disturbance Questionnaire consists of 15 questions related with dysphagia.
75376696|NCT04540003|Other|Access to School Based Health Centre|The SBHC will be staffed by a family physician, two pediatricians and a developmental pediatrician, each with at least one half-day of clinic time per week from September through June. The SBHC is also staffed by a clinic coordinator who is responsible for booking appointments on a first-referral, first-serve basis.
75702616|NCT00771381|Drug|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
75702617|NCT00771459|Drug|Ropivacaine 0.5 %|Local infiltration analgesia
75376697|NCT04333927|Drug|Chemotherapy|Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
75376698|NCT04333927|Other|Observation|Patients in observation group will not receive any anti-cancer therapy.
75376699|NCT04333927|Procedure|Immunotherapy|Camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal.
75376700|NCT04333927|Radiation|Radiotherapy|45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed.
75376701|NCT04334005|Dietary Supplement|Vitamin D|The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
75376702|NCT04445233|Device|COVID-19 IgM-IgG Rapid Test|Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
75376703|NCT00373009|Behavioral|Traditional Army training|As usual training for Soldiers
75376704|NCT00373009|Behavioral|Core stabilization exercise only|Core stabilization exercise
75413792|NCT04804072|Behavioral|Peer navigation|Peer navigation
75702618|NCT00771459|Drug|Isotonic NaCl|Local infiltration analgesia
75702619|NCT00775359|Drug|Fenofibrate 160 mg tablets|
75702620|NCT02557347|Behavioral|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
75702621|NCT04048005|Diagnostic Test|Fractional flow reserve|
75702622|NCT02582138|Other|Multicomponent intervention (MCI)|"The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .~The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:~a daily total energy intake of 25-30 kcal/kg body weight;~an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.~The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme."
75702623|NCT02582138|Other|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
76029189|NCT05907356|Other|sciatic nerve slider technique in slump position|The patient will be sitting at the edge of the couch with the posterior aspect of the knee at the edge, the thighs parallel to each other, and flexion at the thoracic and lumbar spines (slouch position). The therapist will be standing at the bedside of the patient with a proximal arm over the patient's shoulder and one hand guiding the neck movements of the patient and the other hand guiding the knee movements, passively performing cervical neck flexion with knee flexion (stretching the nerve proximally and relaxing at the distal end) and then moving into cervical extension with knee extension. Provide five sets in every session: the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions; and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
75702624|NCT00775515|Procedure|laparoscopic prostatectomy|laparoscopic prostatectomy
75376705|NCT00373009|Behavioral|Psychosocial education class only|Psychosocial education class
75376706|NCT00373009|Behavioral|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
75376707|NCT00966914|Drug|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
75376708|NCT00966914|Drug|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
75376709|NCT00505544|Behavioral|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
76029190|NCT05907356|Other|Conventional physiotherapy|The patient will receive conventional physiotherapy, which includes: a moist hot pack, TENS, and back strengthening exercises (as a home program).
76029191|NCT05907200|Other|combination ultrasound therapy and manual therapy|The proposed manual therapy lasted 90 minutes and involved a combination of three different techniques: McMennel manipulation, connective tissue massage and mobilization technique of pumping. Patients in the treatment group also received a treatment with US (I-Tech medical device certified UT2 CE0476) in combination with manual therapy. Dipping technique was applied with a frequency of 1 MHz, intensity of 1W/cm2, duty cycle of 60% and a duration of 15 minutes per session.
75376710|NCT00505544|Device|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
75376711|NCT04430959|Drug|Candesartan|Candesartan 4 mg, tablets, orally, once daily for 4 weeks
75376712|NCT04430959|Drug|Placebo|Candesartan placebo-matching tablets, orally, once daily for 4 weeks
75376713|NCT03821870|Diagnostic Test|Inditreat|Tumoroid formation and drug sensitivity analysis
75376714|NCT03821870|Drug|Experimental drug|Second line treatment based on drug sensitivity analysis
75376715|NCT04430101|Procedure|Minimally invasive stabilization of Lisfranc injuries|Patients with positive weightbearing radiographs will be operated by minimally invasive stabilization (eg, isolated homerun screw)
75376716|NCT04430101|Procedure|Conservative treatment|Patients with negative weightbearing radiographs will be treated conservatively
75376717|NCT04820413|Other|Faecal microbiota transplantation|FMT by daily enema with donor faeces
75376718|NCT03045289|Behavioral|Plant-Based Diet|Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
75376719|NCT04737655|Drug|TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation|Evaluate Trimbow associated with the standard of care in comparison with the standard of care alone.
75376720|NCT05063396|Procedure|opioid free anesthesia|Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
75376721|NCT05063396|Procedure|Opioid-sparing anesthesia|patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
75376722|NCT04737499|Behavioral|CASCADe|Culturally tailored diabetes self-management and education sessions with mHealth integration
75376723|NCT05055752|Drug|Pharmaceutical-lipid aspirin (PL-ASA)|Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
75376724|NCT05042492|Device|gekoTM|The gekoTM device is a small, transcutaneous nerve stimulator that is placed non-invasively on the skin, whereby the surface electrodes will be attached close to the peroneal nerve. Activation of the peroneal nerve causes contraction of the calf muscle pump, which will increase blood circulation that corresponds to 60% of walking. The increased blood circulation reduces the pressure difference between capillaries and the surrounding tissue and transfers the tissue fluid back into the veins and lymph fibers
75376725|NCT05441059|Drug|Mepolizumab 100 MG|Treatment with mepolizumab for severe asthma
75539114|NCT04612426|Device|Brain-computer Interface-Pedaling Training System|The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.
75539115|NCT04612426|Device|Traditional Pedaling Training System|The patient will wear the same EEG equipment that will only collect data, but not guide training.
75539116|NCT04612504|Biological|SynOV1.1|SynOV1.1 will be administered intratumorally.
75702625|NCT05338502|Drug|Selpercatinib|Administered orally.
75702626|NCT05338502|Drug|Ranitidine|Administered orally.
75702627|NCT05338502|Drug|Omeprazole|Administered orally.
75702628|NCT04078334|Other|MATCH|In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.
75376726|NCT00373100|Drug|Zinc acetate|
75376727|NCT00373100|Drug|Placebo|Placebo
75376728|NCT04223323|Dietary Supplement|Almonds|Participants in the intervention group will consume 2oz of almonds daily over the course of 12 weeks.
75376729|NCT04223323|Dietary Supplement|Pretzels|Participants in the control group will consume an isocaloric amount of pretzels daily over the course of 12 weeks.
75376730|NCT04960748|Behavioral|WOMEN FIGHTING TO STOP CERVICAL CANCER|The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
75376731|NCT04943510|Other|Physical exercices|"surface EMG: surface electrodes will be positioned on the muscles to evaluate the level of muscle activation~non invasive muscular neurostimulations : application of a percutaneous electrical stimulation of the motor nerve of the considered muscle and a direct electrical stimulation of the muscle"
75702629|NCT04078334|Other|PATH|In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can be completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.
75376732|NCT02973698|Other|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
75702630|NCT04078334|Other|PATH 2.0|"In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.~In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions."
76029192|NCT05907200|Other|manual therapy|manual treatment lasting 90 minutes which involved a combination of three different techniques: McMennel manipulation, connective tissue massage and pumping mobilization technique.
76029193|NCT05906446|Other|Multicomponent (Exercise + Protein Supplementation)|"Exercises selected from a pre-specified list, reassessed weekly~Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week)~Participants will also be offered a protein supplement within 30 min of exercise.~Sessions will be supervised"
75376733|NCT02973698|Other|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
75376734|NCT02973698|Other|Control|No intervention will do
75376735|NCT04209140|Drug|lithium treatment|"Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe."
75376736|NCT00372541|Drug|ceftriaxone|
75376737|NCT04334486|Other|Super Smash Brothers Melee (Gamecube)|10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
75376738|NCT04334473|Procedure|phacoemulsification and Intraocular lens implantation|Standartd surgical procedure with small incision to remove catarct using ultrasound waves. it can be done by topica, local or general anaesthesia acoording to patients general fitness and preference.
75376739|NCT04334473|Diagnostic Test|Ultrasound Biomicrosopy (UBM)|A diagnostic test using ultrasound waves to evaluate the anterior chamber depth, angle and lens vault.
75376740|NCT03522740|Other|Decision Aid for Renal Therapy|DART is a web-based decision aid that informs older adults with advanced kidney disease of kidney disease treatment options and prompts them to consider their preferences and raise questions to discuss with their kidney disease providers.
75376741|NCT04762381|Drug|Dexamethasone phosphate|24 mg dexamethasone infused peroperatively
76029194|NCT05906407|Other|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
75539117|NCT03454321|Other|Infiltration|The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.
75376742|NCT04762381|Other|Placebo|Saline
75376743|NCT01547468|Procedure|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
75376744|NCT01547468|Procedure|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
75376745|NCT04717687|Procedure|Irreversible electroporation|Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
75376746|NCT04333628|Drug|chloroquine|oral treatment of chloroquine
75376747|NCT04333628|Other|standard care|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
75376748|NCT00373412|Biological|VCL CT02 pDNA vaccine|
75376749|NCT00373412|Biological|Towne CMV vaccine|
75376750|NCT03409328|Behavioral|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
75376751|NCT02241967|Device|4 Real sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp.
75376752|NCT02241967|Device|2 Real Sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 2 real sessions of tDCS and 2 sham.
75376753|NCT02241967|Device|1 Real Session of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 1 real sessions of tDCS and 3 sham.
75702631|NCT05337722|Behavioral|SFT 2.0|The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person
75866753|NCT03176056|Dietary Supplement|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI > 24 and 30 kcal/day for underweight subjects with a BMI <18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
75376754|NCT02241967|Device|Sham Transcranial Direct Current Stimulation|Four sessions of sham tDCS; control intervention.
75866754|NCT02915978|Drug|Fentanyl|Fentanyl delivered via sublingual spray
75376755|NCT03315728|Other|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
75376756|NCT02088931|Biological|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease <50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
75376757|NCT00373178|Drug|rosiglitazone|
75866755|NCT02915978|Drug|Placebo|Matching placebo delivered via sublingual spray
75376758|NCT00373178|Drug|metformin|
75376759|NCT00373178|Drug|Anti-diabetic medications|
75376760|NCT03254732|Drug|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
75376761|NCT03254732|Drug|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
75376762|NCT04611451|Other|classic lumbar home exercise|classic lumbar home exercise
75376763|NCT04611451|Device|Whole body vibration|Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point
75376764|NCT04611451|Other|Whole body vibration exercise|Whole body vibration exercise
75376765|NCT02923466|Biological|VSV-IFNβ-NIS|Intratumoral injection of a single dose of VSV-IFNβ-NIS
75376766|NCT02923466|Biological|VSV-IFNβ-NIS and avelumab|Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
75702632|NCT05337722|Behavioral|Active control|Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
75866756|NCT02412904|Drug|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
76023376|NCT04673591|Other|Placebo|Matched Placebo
75376767|NCT01052168|Other|skills training|participants will train using different performance goals (based on different metrics)
75376768|NCT00813566|Drug|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
75376769|NCT00813566|Drug|3'-deoxy-3'-[18F]fluorothymidine (FLT)|Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
75376770|NCT00813566|Drug|[15O]-H2O|Brain scan with imaging agent to determine tumor blood flow
75702633|NCT00673257|Other|pharmacological study|pharmacological studies
75702634|NCT00673257|Procedure|dual x-ray absorptimetry|
75376771|NCT00813566|Drug|[11C]Acetate|Brain scan with imaging agent to determine growth activity of tumor
75376772|NCT03908359|Procedure|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
75376773|NCT03908359|Procedure|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
75376774|NCT03879733|Behavioral|Thrive by Three|"The intervention consists of the following components:~Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~Feedback to group staff on 8 CLASS-quality dimensions~Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~Written material to parents, supervisors, and staff~Web page for staff and parents: tf3.no"
75702635|NCT02582060|Other|Thromboelastography/Thromboelastometry-Guided Treatment Regimen|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
75702636|NCT04344392|Diagnostic Test|Ultrasonographic study|Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.
75702637|NCT04344392|Diagnostic Test|Videofluoroscopic study temporal parameters|Glossopalatine junction opening and closing time, velopharyngeal junction opening and closing time, laryngeal vestibule opening and closing time, upper esophageal sphincter opening and closing time in seconds.
75702638|NCT04344392|Diagnostic Test|Videofluoroscopic study distance parameters|Hyoid bone horizontal and vertical replacement, thyroid-hyoid approximation (THA) in millimeters.
75702639|NCT02557269|Drug|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
75702640|NCT02557269|Drug|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
75866757|NCT02412904|Drug|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
76029195|NCT05906082|Behavioral|E-cigarette cessation text-messaging intervention|This is the intervention for e-cigarette cessation using text messages targeting young adults in rural areas.
75376775|NCT03879733|Behavioral|Treatment as usual (TAU)|The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
76029196|NCT05906082|Behavioral|Standard care control using standard national resources|This is the standard care with national resources from smokefree.gov.
75376776|NCT02885012|Drug|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
75376777|NCT04555915|Other|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
75376778|NCT02885246|Other|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
75376779|NCT03802435|Procedure|two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval)
75376780|NCT03802435|Procedure|One-sessions of ultrasound-guided PIT|One-session of ultrasound-guided PIT with 10cc D5W and 10cc normal saline separately (3 months interval)
75376781|NCT03802435|Procedure|Placebo ultrasound-guided injection with nerve hydrodissection|Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
75376782|NCT05005663|Other|surgical management of incisional hernia|surgical repair of the incisional hernia
75376783|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
75702641|NCT02557269|Drug|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
75702642|NCT02557269|Drug|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
75702643|NCT02557269|Other|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
75866758|NCT02412826|Device|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
75866759|NCT02404948|Other|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
76029197|NCT05906056|Device|Continuous Passive Motion (CPM)|CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)
76029198|NCT05906056|Other|Conventional physiotherapy (PT)|Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)
76029199|NCT05906056|Drug|Zoledronic Acid Injection|one dose of intravenous zoledronic acid will be administered
75376784|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
75376785|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
75376786|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
75376787|NCT02885636|Drug|Albuterol|": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
75702644|NCT02557269|Drug|Bilastine 20 mg|1 tablet per os - as needed
75702645|NCT02557269|Drug|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
75702646|NCT02581358|Other|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
75702647|NCT00771771|Other|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
75702648|NCT00771771|Other|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
75702649|NCT00772083|Behavioral|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
75702650|NCT00772083|Behavioral|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
75702651|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a high total daily dose
75702652|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
75866760|NCT03675230|Device|Tomotherapy HD|Patients with Medulloblastoma receiving Tomotherapy
75866761|NCT03675230|Device|3DCRT|Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
75376788|NCT02885636|Other|Saline placebo|Saline inhaled through a nebulizer as a single dose
75376789|NCT03691129|Behavioral|Participation in the elderly yoga program|Yoga participant groups will practice elderly yoga for four months.
75376790|NCT03625921|Behavioral|Powered device with physical therapy|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.
75376791|NCT03625921|Behavioral|Powered device with standard of practice|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
75376792|NCT00373087|Drug|entacapone|entacapone
75376793|NCT00373087|Drug|l dopa versus placebo|l dopa versus placebo
75376794|NCT02892110|Drug|Varenicline|2 mg daily
75866762|NCT02404714|Device|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
75866763|NCT03671408|Other|clinical measurements|only clinical parameters were recorded
75376795|NCT02892110|Drug|Placebo|2 mg daily
75866764|NCT03174028|Device|laparoscopic pull-through|laparoscopic pull-through
75866765|NCT02701192|Other|Coccygectomy|Patient receiving coccygectomy surgery.
75376796|NCT02778152|Device|Laser depilation|Laser depilation of natal cleft (pilonidal region)
75376797|NCT02779166|Drug|Celecoxib|Received 400mg celecoxib prior to surgery
75376798|NCT02779166|Drug|placebo|
75376799|NCT03597607|Behavioral|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
75376800|NCT03597607|Behavioral|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
75376801|NCT02898740|Behavioral|Structural exercise|Exercise instruction and encouragement
75376802|NCT02898740|Behavioral|Health education|Provision of general information about a variety of health topics
75539118|NCT00251472|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
75539119|NCT04612270|Other|Venous blood collection|Two venous blood collections in within one week. No drug-related intervention in-vivo.
75539120|NCT00222053|Drug|Thalidomide|Per os thalidomide
75539121|NCT00222053|Drug|Biphosphonates|Biphosphonates
75539122|NCT04612153|Other|Epidemiologic|Epidemiologic study. Observational, transverse study
75376803|NCT00373165|Drug|Ganciclovir|
75376804|NCT02898974|Behavioral|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
75376805|NCT04400227|Other|Family Talk|"Family Talk is an evidence-based, parent-youth dyadic approach that uses psychoeducation and skills building to help families make meaning of a parent's adversity, increase resilience, and improve family functioning.~The Family Talk model comprises two components: the first involves a series of cognitive-behavioral techniques to bolster problem solving and communication skills among family members; the second involves a facilitated family meeting to develop a shared narrative for discussing each family member's experience of the parent's illness."
75539123|NCT00251511|Drug|Arsenic Trioxide|
75376806|NCT00372931|Drug|AL-37807|
75702653|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a low total daily dose
75702654|NCT00779181|Drug|Placebo|Placebo taken three times a day
75702655|NCT00779337|Biological|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
75702656|NCT02556411|Drug|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
75702657|NCT02556411|Drug|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
75702658|NCT04085276|Drug|JS001|JS001 240mg, i.v., q3w; Other name: Toripalimab
75702659|NCT04085276|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
75702660|NCT04085276|Drug|Placebo|Placebo, i.v., q3w;
75702661|NCT04085276|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
75702662|NCT00775827|Drug|fenofibrate 160 mg tablets|
75702663|NCT02580032|Other|No treatment given|No treatment given.
75702664|NCT00775905|Drug|amlodipine 10 mg tablet|
75702665|NCT00772161|Drug|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
75702666|NCT04075838|Other|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
75702667|NCT00776139|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
75702668|NCT03810560|Device|laser device Er,Cr:YSGG laser|laser device with open flap debridement
75376807|NCT02901080|Device|Alpha Stim AID cranial electrotherapy stimulation|- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
75702669|NCT00779493|Dietary Supplement|curcumin|curcumin 900mg twice daily by mouth
75376808|NCT02901080|Behavioral|Pregnancy test|- Pregnancy test x 1 (day 1)
75702670|NCT00779493|Dietary Supplement|placebo|placebo capsule to simulate 900mg curcumin capsule
75702671|NCT00772239|Device|Rotation thromboelastometry (ROTEM)|Coagulation measurement
76029200|NCT05906043|Behavioral|Exercise Intervention|Exercise intervention
76029201|NCT05906043|Behavioral|Acceptance and Commitment Therapy|ACT will be used for patients with psychological disability as well as for those with sleep disturbance
75376809|NCT02901080|Other|Anxiety questionnaire|- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
75702672|NCT00772239|Procedure|Standard coagulation managment procedure|Standard coagulation managment procedure
76029202|NCT05906043|Dietary Supplement|Probiotic|Use of a probiotic
76029203|NCT05905770|Drug|Alemtuzumab Injection [Campath]|Alemtuzumab 1mg/kg
76029204|NCT05905627|Behavioral|exercise|intervention group
76029205|NCT05905510|Drug|Lumbar Erector spinae plane block (L-ESPB)|The fourth lumbar vertebral level will be determined using the conventional method (the imaginary line between two crista iliacas). The convex transducer will be placed at the mid-vertebral line in the sagittal plane. The transducer will be shifted from the midline, 3.5-4 cm laterally, to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-of-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthesia solution (30 ml bupivacaine 0.25%) will be administered, leading to hydro dissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when administering local anesthesia. All local anesthesia will be administered to this location between the transverse process and the erector spinae muscle
75376810|NCT02901080|Other|Quality of life questionnaire|- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
75376811|NCT02901080|Other|Work and social questionnaire|- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
75376812|NCT02901080|Other|Sleep questionnaire|- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
75376813|NCT02901080|Other|Depression questionnaire|- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
75376814|NCT02901080|Other|Quality of life and financial questionnaire|- CSRI questionnaire x 3 (day 1, week 12 and week 24)
75376815|NCT04866589|Behavioral|Distribution of free face masks|"Corona hosts will be placed at the entrance of the intervention stores, and hand out face masks to customers entering the store."
75376816|NCT04333550|Drug|Deferoxamine|Intravenous infusion of Deferoxamine
75702673|NCT00779571|Behavioral|Crispbread|8 week low calorie diet
75702674|NCT02580344|Drug|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
75702675|NCT00779649|Other|MoviPrep Kit|"Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption."
75866766|NCT02404480|Drug|PTC596|PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
75866767|NCT02412514|Biological|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
75866768|NCT02412514|Biological|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
75866769|NCT02412514|Biological|IPV|IPV administered at 6 weeks of age
75376817|NCT04737733|Other|The dementia friendly program|Implementation of a systematic screening and risk modification and management plan, to identify and enhance the management of patients with cognitive impairment and risk of delirium.
75413793|NCT04804072|Diagnostic Test|COVID-19 testing and referral for further evaluation, care and/or treatment|COVID-19 testing and referral for further evaluation, care and/or treatment
75413794|NCT04798365|Behavioral|Intervention group|medical education and distribution of educations materials
75866770|NCT02408458|Device|MIROMESH®|
75413795|NCT04795089|Procedure|Shunt surgery|Patients are evaluated before and after shunt surgery which is a standard intervention in the clinical practice. HI do not undergo intervention.
75413796|NCT04778670|Diagnostic Test|AI CAD|The Lunit INSIGHT MMG will be used as the AI CAD in our study. Initially, version 1.6.1.1 will be installed. The software version will be continuously updated with subsequent software releases, after confirming in a historic calibration dataset that the performance is improved. The operating point will be set based on a historic calibration dataset to attain a joint sensitivity of breast cancer detection of AI and first reader which is 2% higher than for first and second reader.
76029206|NCT05905510|Drug|Fascia iliaca compartment block (FICB)|The transducer will be placed laterally to the femoral nerve. It then rotated 90 degrees to the sagittal plane, under ultrasound guidance, a regional block needle (22 G, 80 mm) will be introduced in the cranial direction. Once good needle alignment with the ultrasound beam is achieved, the needle will be inserted deep into the tissues until an optimal position of the needle tip is obtained. Needle location will be additionally verified by injecting 0.5-1 ml of the prepared local anesthesia solution and observing the solution spread within the tissues. Once the correct position of the needle tip is confirmed, the local anesthetic will be deposited under the iliac fascia to force its flow towards the lumbar plexus. 30 ml of bupivacaine 0.25% solution will be used for the block. local anesthesia will be administered as 5 mL boluses with a 20 second interval.
75376818|NCT04863625|Behavioral|a peer-led educational intervention based on theory of planned behavior on substance use intentions and behaviors|The intervention will be a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).The intervention aims to encourage anti-substance attitudes and beliefs; foster perceptions of normative support for anti-substance behavior; increase perceptions of control/self-efficacy to resist substance use, increase knowledge and risk perceptions on substance and decrease in intention to use substance and actual substance use behaviors. Six education sessions will be delivered, with one session occurring each week. Each session will be lasted 40-55 minutes. The intervention will be conducted in 30 groups of selected students from grade 9-12, a pair of peer educators will educate a 30 sized group weekly (30 students /group)/ classrooms at pre-assigned time during class periods. The six sessions will be guided by four student training modules.
75376819|NCT02827838|Biological|Durvalumab|Given IV
76029207|NCT05905510|Drug|spinal anesthesia plane block|Patients will receive spinal anesthesia alone
76029208|NCT05904964|Drug|Disitamab vedotin|Disitamab Vedotin 2mg/kg was injected every 2 weeks,
76029209|NCT05904964|Other|Endocrine therapy|Doctors choose endocrine therapy independently
76029210|NCT05904483|Other|PFA|PFA
75376820|NCT02827838|Other|Laboratory Biomarker Analysis|Correlative studies
75376821|NCT02827838|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75376822|NCT00373243|Drug|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
75376823|NCT02758184|Device|ROTEM-based coagulation monitoring|
75376824|NCT02758184|Procedure|Spine surgery|
75376825|NCT03099733|Other|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
75376826|NCT02915185|Procedure|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
75413797|NCT04778670|Diagnostic Test|Radiologist reading|Standard of care, each radiologist will assess the mammography examination, making a binary flagging decision (flag the examination to continue to consensus discussion, or not)
75413798|NCT04774445|Behavioral|MyCancerGene|Interactive Health Communication Application
75539124|NCT04611958|Drug|ERCP with Bupivacaine infusion|"Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom."
75539125|NCT00412919|Drug|Azacitidine|
75539126|NCT04611646|Behavioral|Heat-suit endurance training|Participants (elite cyclists) will conduct five 50-minute low-intensity cycling sessions with heat suit per week for five weeks. These sessions will complement their habitual training routines, which will consist of endurance training with intensities at or below lactate threshold. Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
75539127|NCT04611646|Behavioral|Non-heat-suit endurance training|Participants (elite cyclists) will conduct low-intensity cycling without heat suit for five weeks (volume- and intensity-matched to the heat-suit arm). Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
75539128|NCT04611490|Procedure|Spine Fusion|Each patient will undergo a spine fusion for a evolutive idiopathic scoliosis with the help of the surgivisio system.
75539129|NCT00222170|Drug|Rabeprazole|
75539130|NCT04611724|Drug|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
75539131|NCT00563758|Drug|tegaserod|
75413799|NCT04773275|Device|Pulsed electric field treatment using the Aliya system|Patients will undergo pulsed electric field (PEF) treatment of up to 5 tumors (new or progressing) measuring ≤ 2cm in longest diameter.
75413800|NCT04772664|Dietary Supplement|Multispecies-Probiotic|Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.
75376827|NCT02915185|Device|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
75376828|NCT00373477|Procedure|Generalist Care Manager vs Usual Care|
75376829|NCT02909647|Procedure|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
75376830|NCT02909647|Procedure|Osteosynthesis|osteosynthesis using volar locking plate
75376831|NCT02887885|Drug|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
75376832|NCT02902172|Drug|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
75376833|NCT02902172|Drug|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
75702676|NCT00779649|Other|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|"Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed"
75702677|NCT04074980|Diagnostic Test|Venous and Fingerstick blood draws|Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
76029211|NCT05904418|Other|Robot-assisted US Scan of the vertebra L1 to S1|A standardized robot-assisted US-Scan of the vertebra L1 to the S1 is executed. The two probe trajectories are generated automatically by an optical camera or RedGreenBlue-Depth (RGB-D) camera. Then the robot will scan at two mm/s, automatically following the trajectory. A 6 degrees of freedom (DoF) force sensor (Nano25, Ati Industrial Automation Inc.) was assembled at the US probe. During the scanning, it measures the interaction force and torque between the US probe and volunteers' skin to ensure volunteer safety. The US images and corresponding robot poses are recorded for the reconstruction. A previously developed algorithm is used to obtain a preliminary 3D reconstruction that will be used to adapt the scanning pattern in case of incomplete scanning.
75376834|NCT02663102|Other|Data collection|Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.
76029212|NCT05904418|Other|Handheld US scan of the vertebra L1 to S1|A handheld US-Scan of the vertebra L1 to S1 is executed. An optical marker for an Atracsys Camera is mounted to the US probe to track its position. Simultaneously, the optical tracking allows for standardization of the US-Scan through navigation. The acquired US images and corresponding poses are used to reconstruct the lumbar spines and compared to the ground truth (CT scan). Handheld US scanning will be performed at around two mm/s in two scanning trajectories. The US probe orientation will be adjusted during the scanning by comparing the optical marker orientation with the initial probe orientation. This combination leads to different scanning patterns. For each pattern, the scanning procedure will be repeated three times. At least once per volunteer, each handheld scanning pattern will be performed with a higher manual speed to assess the reconstruction quality with faster scanning. A graphical user interface (GUI) will synchronize and store the data during the scanning.
75376835|NCT02784548|Other|Virtual Reality|Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
75376836|NCT02402894|Other|no intervention|
75376837|NCT02777749|Drug|Bupivacaine|15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
75376838|NCT02785172|Drug|IDP-118 Vehicle Lotion|Vehicle
75376839|NCT02785172|Drug|IDP-118 Vehicle Cream|Vehicle
75376840|NCT02785172|Drug|IDP-118 Lotion|Lotion
75702678|NCT04074980|Diagnostic Test|Venous blood draw|Venepuncture to collect blood samples from subjects
75702679|NCT00776217|Drug|loratadine 10 mg orally disintegrating tablets|
75702680|NCT00772317|Device|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
75702681|NCT02556957|Behavioral|HealthScouts|
75702682|NCT02556957|Other|Standard of Care|
75376841|NCT02785172|Drug|Ultravate Cream|Cream
75376842|NCT02582125|Drug|ONO-4538|
75376843|NCT02906696|Drug|Bosutinib|Given PO
75376844|NCT02906696|Other|Laboratory Biomarker Analysis|Correlative studies
75376845|NCT02503657|Drug|tipelukast|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
75376846|NCT02503657|Drug|Placebo|Excipients of MN-001/tipelukast
75376847|NCT02779543|Device|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
76029213|NCT05904418|Radiation|ULD CT scan of the vertebra L1 to S1|A ULD CT scan (CT, Siemens Naeotom Alpha: A-207883-62) of the lumbar spine (L1-S1) is performed at the Swiss Center for Musculoskeletal Imaging (SCMI) at Balgrist Campus, Zurich. The total duration estimate for the CT examination is 30 minutes, whereas the scan takes 15 minutes. The volunteers lie on their abdomen during this procedure to simulate the spine's position during the subsequent US examination. The vertebrae (L1-S1) in the CT Scans are manually segmented with global thresholding and the region growing tool in a standard segmentation software (Materialise Mimics, Leuven, Belgium). The 3D surface models are then exported as Standard Triangle Language (STL) files.
75376848|NCT02779543|Device|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
75376849|NCT02779543|Device|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
75376850|NCT02785406|Drug|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
75376851|NCT02785406|Drug|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
75376852|NCT02062489|Drug|Tamoxifen|20 mg(2#)/day, PO, daily
75702683|NCT02580500|Procedure|epidural catheter|epidural anaesthesia application for spinal catheter will be used
75376853|NCT02062489|Drug|Placebo|2#/day, PO, daily
75376854|NCT02786810|Drug|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
75539132|NCT00563836|Drug|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
75702684|NCT02580500|Procedure|spinal catheter|spinal anesthesia application for spinal catheter will be used
75702685|NCT04074200|Procedure|Open Inguinal Hernia Repair|With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
75376855|NCT02908178|Procedure|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
75376856|NCT02780869|Device|HEMOBLAST Bellows|
75376857|NCT02780869|Device|Absorbable gelatin sponge, USP with thrombin|
75376858|NCT02908490|Drug|Sildenafil|Sildenafil 50 mg once daily
75539133|NCT00222209|Behavioral|Experimental heat pain model|
75866771|NCT02404558|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
75866772|NCT02404558|Drug|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
75866773|NCT02404636|Other|Interview|Brief structured interview
76029214|NCT05904353|Procedure|Ambulant nurse-assisted administration of zoledronic acid|Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.
75376859|NCT02908490|Other|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
75376860|NCT00374036|Drug|ECC|capecitabine
75376861|NCT00374036|Drug|FOLFIRI|Irinotecan
75376862|NCT02345018|Procedure|Mechano-chemical ablation|Treatment with mechano-chemical ablation
75376863|NCT02910362|Device|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
75376864|NCT02910362|Device|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
75376865|NCT02910674|Device|Dario Blood Glucose Monitoring System|Accuracy with usability assessment
75376866|NCT02911844|Drug|Fulvestrant|Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
75376867|NCT02911922|Device|Endorectal Balloon|"Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
75376868|NCT02911922|Device|Rectal Spacer|"Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
75376869|NCT02911922|Radiation|Radiation therapy|Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
75376870|NCT02790788|Drug|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
75376871|NCT02790788|Drug|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
75539134|NCT00563875|Drug|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
75539135|NCT00248196|Device|Reprieve Endovascular Temperature Therapy System|
75539136|NCT04611685|Drug|NSAID|Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.
75376872|NCT02793674|Device|Fisher & Paykel high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
75376873|NCT02793674|Device|Vapotherm high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
75376874|NCT03001778|Other|Usability Testing|"Usability testing of ready made workouts in a group format."
75702686|NCT04074200|Procedure|Laparoscopic Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
75376875|NCT02888665|Drug|Doxorubicin Hydrochloride|Given IV
75376876|NCT02888665|Other|Laboratory Biomarker Analysis|Correlative studies
75376877|NCT02888665|Biological|Pembrolizumab|Given IV
75376878|NCT02918396|Device|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as <0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
75539137|NCT04611685|Drug|Tramadol|Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
75702687|NCT04074200|Device|Robotic-Assisted Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
75702688|NCT00667875|Drug|Placebo|placebo
75702689|NCT00667875|Drug|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
75376879|NCT02918396|Device|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
75702690|NCT00667875|Drug|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
75702691|NCT05056610|Other|food antigens on duodenal mucosa|Administration of food antigens on duodenal mucosa and determining the response through confocal laser endomicroscopy
75539138|NCT04611412|Other|Risk Factors|BMI in children and adolescents was compared with percentile charts developed by who for children from 5 to 19 years of age (WHO Growth Reference, 2007). Body mass index was defined as the ratio of body weight (in kg) to body length in the supine position or height in the standing position (m2).
75539139|NCT00222248|Behavioral|Pelvic floor muscle training and bladder training|
75539140|NCT00248235|Behavioral|Exercise|
75702692|NCT00779727|Procedure|Placement of drainages|
76029215|NCT05904353|Procedure|Usual care|General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
76029216|NCT05903469|Other|Implicit Attitude Test|The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.
75376880|NCT02918396|Device|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
75539141|NCT00563914|Drug|ferroquine (SSR97193)|associated with artesunate
75376881|NCT02781571|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
75376882|NCT02918630|Drug|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
75539142|NCT00563914|Drug|amodiaquine|associated with artesunate
75376883|NCT02918630|Drug|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
75376884|NCT02781649|Drug|Zepatier|Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
75539143|NCT00563953|Drug|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
75539144|NCT00563992|Drug|Lithium|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
75539145|NCT00563992|Drug|Valproic acid|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
75539146|NCT00251550|Drug|Pemetrexed|
75539147|NCT00251550|Drug|Cisplatin|
75376885|NCT02781649|Drug|Ribavirin|Ribavirin 1200 mg/d (> 75 kg) or 1000 mg/d (< 75 kg) by mouth daily in two divided doses
75376886|NCT02781649|Drug|Sofosbuvir|Sofosbuvir 400 mg daily
75376887|NCT02794766|Drug|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
75376888|NCT02794766|Drug|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
75702693|NCT02579642|Drug|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
75702694|NCT02579642|Drug|Placebo|Normal saline administered with usual induction drugs for ECT
75376889|NCT02794766|Drug|Placebo|Placebo 1 gum each 12 hours for 10 days
75376890|NCT02794844|Drug|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
75376891|NCT01709539|Procedure|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
75376892|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
75376893|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
75376894|NCT02795780|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
75376895|NCT02795780|Procedure|PET Scan|positron emission tomography (PET) scan
75702695|NCT00779805|Drug|Pseudoephedrine hydrochloride 120 mg ER tablets|
75376896|NCT02783443|Other|General anesthesia|General anesthesia
75376897|NCT02783443|Other|Regional anesthesia|Regional anesthesia
75376898|NCT02796092|Device|Fibered platinum coils|
75539148|NCT04611373|Drug|Acetazolamide Levamisole|Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
75702696|NCT00772395|Drug|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
75702697|NCT00772395|Drug|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
75702698|NCT03468998|Device|Socket Grafting with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
75702699|NCT03468998|Device|Socket Grafting with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
75702700|NCT03468998|Device|Lateral ridge augmentation with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
75702701|NCT03468998|Device|Lateral ridge augmentation with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
75866774|NCT04481854|Procedure|cricoid pressure|cricoid pressure during laryngoscopy
76029217|NCT05903274|Drug|JSP191|Subjects will receive intravenous JSP191
75376899|NCT02796092|Device|Vascular plugs|
75376900|NCT02889289|Other|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
75376901|NCT02784613|Drug|Ospemifene|FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
75376902|NCT00373568|Drug|miltefosine: 2.5 mg/kg/day for 42 days|
75376903|NCT02890303|Device|Zepto System|Anterior Capsulotomy using the Zepto System.
75376904|NCT03002012|Drug|Sertraline|sertraline 400mg/day
75376905|NCT03002012|Drug|Placebo Oral Tablet|matched placebo tablet
75376906|NCT03002012|Drug|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
75376907|NCT02798354|Behavioral|Quality Improvement Collaborative|1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
75376908|NCT02890381|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
75376909|NCT02890381|Biological|Placebo|Isotonic diluent, administered as nose drops
75376910|NCT00373646|Drug|Thalidomide, Pharmion|200 mg p.o. daily
75413801|NCT04772664|Dietary Supplement|Placebo Supplement|Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.
75702702|NCT05325398|Dietary Supplement|HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada|"The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.~All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)."
75376911|NCT03005054|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
75539149|NCT00222287|Behavioral|Feldenkrais Movement class|
75376912|NCT03005054|Procedure|Autograft|The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
75376913|NCT02891629|Device|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
75376914|NCT02891863|Device|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
75376915|NCT03001453|Drug|Liposomal Bupivacaine|266mg liposomal bupivacaine
75376916|NCT03001453|Drug|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
75376917|NCT03001453|Drug|Saline|Normal saline
75376918|NCT03001843|Drug|Ketamine|Anesthesia of only Ketamine
75539150|NCT04611256|Biological|MSC|Two intravenous infusion of 1*10E6 adipose tissue derived-MSCs /kg body weight reach
75866775|NCT04481854|Procedure|left paratracheal pressure|left paratracheal pressure during laryngoscopy
75866776|NCT02408302|Drug|Midazolam|comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
75376919|NCT03001843|Drug|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
75376920|NCT03001843|Behavioral|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
75376921|NCT03003793|Diagnostic Test|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
75539151|NCT04611256|Drug|Control|Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
75539152|NCT04611061|Drug|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
75539153|NCT04611061|Drug|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
75539154|NCT04610983|Dietary Supplement|Experimental: Control|2 x algal oil gel capsules delivering 400mg DHA in total
75539155|NCT04610983|Dietary Supplement|Experimental: Treatment 1 - Semi-Solid food matrix|"Test Food 1: 200g serve soup + ingredient"
75539156|NCT04610983|Dietary Supplement|Treatment 2 - Solid food matrix|"Test Food 2: 50g serve extruded snack (savoury snack) + ingredient"
75539157|NCT04611178|Device|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
75539158|NCT00222326|Behavioral|Pelvic floor muscle training and lifestyle modification|
75539159|NCT00564031|Drug|Femanest|2mg/day
75376922|NCT02784925|Device|Ultrasound (US) B mode image|"Ultrasound (US) B mode image is an alternative method to measure tissue structure~and has proven to be an accurate technique to measure subcutaneous fat thickness."
75376923|NCT02785159|Drug|IDP-118 Lotion|Lotion
75376924|NCT02785159|Drug|Tazorac Cream|Cream
75376925|NCT02785159|Drug|IDP-118 Vehicle Lotion|Lotion
75376926|NCT02785159|Drug|IDP-118 Vehicle Cream|Cream
75376927|NCT02786719|Drug|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
75376928|NCT02786719|Drug|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
75376929|NCT02786719|Drug|Cisplatin|Cycle 3+5 (given daily x 4 days)
75376930|NCT02786719|Drug|Etoposide|Cycle 3+5 (given daily for 3 days)
75376931|NCT02786719|Drug|Vincristine|Cycle 4+6 (given daily for 3 days)
75376932|NCT02786719|Drug|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
75376933|NCT02786719|Drug|Doxorubicin|Cycle 4+6 (given daily for 3 days)
75376934|NCT02786719|Drug|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
75376935|NCT03003949|Drug|Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release|Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
75376936|NCT03003949|Drug|Placebo Patch|Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
75376937|NCT03003949|Drug|Progesterone Capsule|Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week
75376938|NCT03003949|Drug|Placebo Oral Capsule|Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.
75376939|NCT02896075|Other|30 Minute Comedy Video|The intervention is a 30 minute video of a comedy
75376940|NCT02896075|Other|30 Minute Documentary Video|The intervention is a 30 minute video of an uninteresting documentary
75376941|NCT02787655|Behavioral|Aerobic exercise + Cognitive Training Group|stationary bicycling
75539160|NCT00564031|Drug|gestapuran|5mg/day
75539161|NCT00564031|Drug|placebo|daily
75539162|NCT00564031|Drug|Femanest plus Gestapuran|combined daily
75539163|NCT04610632|Diagnostic Test|home pregnancy test|use of home pregnancy test
75539164|NCT00564109|Procedure|retrospective Observation|retrospective Observation
75539165|NCT00222365|Drug|Arnica montana, 5 CH|
75539166|NCT00222365|Drug|Bryonia alba, 5 CH|
75539167|NCT00222365|Drug|Hypericum perforatum, 5 CH|
75539168|NCT00222365|Drug|Ruta graveolens, 3 DH|
75539169|NCT04610437|Procedure|Arthrodesis interphalangeal with intramedullary resorbable fixation system|Interphalangeal arthrodesis of lesser toes with two different fixation systems.
75702703|NCT05325398|Dietary Supplement|placebo|"13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)"
75702704|NCT00667251|Biological|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
75376942|NCT02787655|Behavioral|Cognitive training Only|20 minutes of cognitive training using Mindfit program
75702705|NCT00667251|Drug|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
75376943|NCT02798978|Drug|GSK1795091|GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
75376944|NCT02798978|Drug|Placebo|Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
75702706|NCT00667251|Drug|lapatinib ditosylate|1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
75702707|NCT00667251|Drug|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
75702708|NCT04063124|Drug|Dasatinib + Quercetin|Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
75376945|NCT02898103|Device|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 5 minutes in the recovery room
75376946|NCT02898103|Device|Sham stimulation|Sham (placebo) stimulation for 5 minutes in the recovery room
75376947|NCT02898103|Device|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 2-4 weeks at home
75539170|NCT02961426|Drug|sofosbuvir + ravidasvir|combination of sofosbuvir + ravidasvir
75702709|NCT00776529|Other|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
75702710|NCT00776529|Other|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
75702711|NCT00779883|Biological|ISF35|Subjects participating in this study will receive a single dose of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells.
75702712|NCT05673746|Procedure|Acupuncture|acupuncture administration
75702713|NCT05673746|Drug|treatment of physician choice, according to the standard of care|treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
75376948|NCT03005041|Other|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
75702714|NCT00772473|Other|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
75702715|NCT00776607|Drug|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
75702716|NCT00776607|Drug|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
75702717|NCT04054544|Dietary Supplement|Gluten powder 4g|Gluten powder 4g oral BID
75702718|NCT00776685|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
75702719|NCT00780039|Drug|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
76023377|NCT05108597|Drug|Misoprostol|400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
75539171|NCT04610359|Drug|MR-MC-01|Submucosal injection of 2.0 x 10,000,000/5ml (1mL * 5 sites)
75376949|NCT03005041|Other|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
75413802|NCT04772651|Other|Mediterranean Diet|Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
75413803|NCT04772651|Other|Normal hospital diet|Normal hospital diet
75413804|NCT04772651|Other|dietary coaching|dietary coaching
75413805|NCT04772651|Other|Psychoeducation on depression|Psychoeducation on depression (50minutes once a week for 4 weeks)
75539172|NCT04610281|Device|Inner Garden|"Care actions adapted to the intensity of the states of agitation (The child can be removed from the group while remaining in the same room on a chair with a caregiver. If the problems are too serious, the child can be accompanied to a soothing room where the carer will take care of him/her individually. In units equipped with Inner Garden, the child can use it under semi- supervision of nurses.)"
75539173|NCT04610008|Other|No intervention. Purely observation|Retrospective image analysis of the shape of the optic nerve head in both groups
75539174|NCT04610164|Drug|Tranexamic acid|Prior to surgery, the patient will receive 1 gram of IV TXA
75539175|NCT00222443|Drug|Irinotecan|
75539176|NCT04610203|Dietary Supplement|25 g Nutralys Pea Protein|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose +25g Nutralys S85 Plus
75702720|NCT00780039|Drug|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
75702721|NCT03436550|Procedure|mpMRI|Multiparametric MRI
75702722|NCT03436550|Procedure|ARFI US|Acoustic radiation force impulse is a type of ultrasound elastography
75376950|NCT03007225|Drug|Trans-arterial chemoembolization (TACE)|"TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved."
75376951|NCT03007225|Drug|TACE with Drug Eluting Beads procedure|"The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan)."
75376952|NCT02799290|Biological|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
75376953|NCT02799290|Biological|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
75376954|NCT02800148|Drug|Azelaic acid foam|
75376955|NCT02800148|Drug|Azelaic acid foam|
75376956|NCT02800148|Drug|Azelaic acid foam - Placebo|
75376957|NCT03008707|Procedure|Laparoscopic Peritoneal Lavage|LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites
75376958|NCT02801006|Device|stenfilcon A|contact lens
75376959|NCT02801006|Device|etafilcon A|contact lens
75376960|NCT02790463|Behavioral|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
75376961|NCT02791399|Behavioral|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
75376962|NCT02902081|Drug|Cannabidiol|
75539177|NCT04610203|Dietary Supplement|50 g Nutralys S85 Plus.|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose+50 g Nutralys S85 Plus .
75539178|NCT04610203|Dietary Supplement|50 g Glucose|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose
75539179|NCT04609969|Diagnostic Test|RT-qPCR test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
75376963|NCT02902081|Drug|Placebo|
75539180|NCT04609969|Diagnostic Test|COVID-VIRO® test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
75539181|NCT00222482|Drug|Depakote ER|
75539182|NCT04610125|Biological|Auto CAR-T|Biological: Auto CAR-T
75539183|NCT04610125|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
75539184|NCT04610125|Procedure|Leukapheresis|Leukapheresis
75376964|NCT02801942|Procedure|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
75376965|NCT02801942|Procedure|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
75376966|NCT02801942|Procedure|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
75376967|NCT02801942|Other|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
75702723|NCT00669903|Drug|AZD0328|
75702724|NCT00669903|Drug|Placebo|
76029218|NCT05903014|Drug|n-acetylcysteine|we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
75376968|NCT02791945|Behavioral|Medical Management Counseling|Brief alcohol counseling
75376969|NCT02791945|Drug|N-acetylcysteine|Experimental supplement
75376970|NCT02791945|Drug|Placebo|Placebo comparator
75376971|NCT02793817|Drug|KPI-121 1% Ophthalmic Suspension dosed BID|
75376972|NCT02793817|Drug|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
75376973|NCT00374114|Procedure|cervical conization|
76029219|NCT05903014|Behavioral|Motivational Enhancement Therapy|Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
76029220|NCT05901818|Drug|Autologous induced neural stem cell-derived DA precursor cells|The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
75376974|NCT00374114|Procedure|ultrasonic surgical aspiration of the cervix|
75702725|NCT00776763|Drug|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
75702726|NCT00772551|Drug|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
75702727|NCT00772551|Drug|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
75702728|NCT00776841|Drug|Aramchol|1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
75702729|NCT00776841|Drug|Aramchol|Oral Aramchol at dose 30 mg to 900 mg
75702730|NCT00776841|Drug|Aramchol|Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
75702731|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
75702732|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
75702733|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
75702734|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
75702735|NCT04047615|Other|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
76029221|NCT05896098|Other|Ultrasound|Measurement of the airway by ultrasound in obese patients.
76029222|NCT05895500|Drug|Injection for SC administration (120mg/syringe)|Injection
75376975|NCT03007394|Drug|Lorcaserin|Lorcaserin Capsule
76029223|NCT05895500|Drug|Tablet (50mg/tablet), oral|Tablet
76029224|NCT05893680|Other|Group to play online games|Playing games in children is one of the non-pharmacological pain relief methods. In this study, the effect of playing an online game on pain level in children who underwent orthopedic surgery for pain management after the surgery was measured.
76029225|NCT05893680|Other|Group that received cold application|Previous studies have demonstrated that cold application has anti-inflammatory, muscle spasm reducing, and pain relieving properties. In this study, the effect of cold application on pain level in children who underwent orthopedic surgery was investigated.
76029226|NCT05893680|Drug|Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)|The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
75376976|NCT03007394|Drug|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
75702736|NCT03759392|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
75702737|NCT03759392|Drug|Placebo|Oral placebo twice daily for up to 20 weeks
75702738|NCT02556879|Biological|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
75702739|NCT02556879|Biological|Serum bank|Additional samples for serum bank at each visit if possible
75702740|NCT02556879|Biological|DNA bank|Additional sample for DNA bank at inclusion visit if possible
75702741|NCT02556879|Procedure|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
75702742|NCT02556879|Procedure|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
75702743|NCT00777075|Drug|L-arginine|
76029227|NCT05893680|Other|Group that played an online game and received cold application at the same time|To investigate the combined effect of online gaming and cold application as two separate non-pharmacological interventions, both interventions were applied together in this group
76029228|NCT05890404|Behavioral|LGBTQ-Affirmative CBT Training: Materials Only|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment."
75376977|NCT00374192|Drug|Eszopiclone|3 mg per day
75376978|NCT00374192|Drug|Placebo|Placebo
75376979|NCT00374270|Behavioral|Lifestyle Counselling; Opinion Leader Influence Statements|
75376980|NCT02806544|Drug|Tamoxifen|Tamoxifen 20mg by mouth daily
75376981|NCT03008174|Other|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
75376982|NCT02809430|Device|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
75702744|NCT00777075|Drug|Placebo|
75702745|NCT00772863|Drug|docetaxel and cisplatin|4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
75702746|NCT04075760|Procedure|Coils + Cyanoacrylate Group + beta-blocker|"EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group."
75702747|NCT04075760|Drug|beta blocker therapy|A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
75702748|NCT05674058|Other|No intervention|According to clinical practice.
75702749|NCT02580656|Behavioral|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
75376983|NCT00374348|Drug|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
75376984|NCT03014492|Device|Q Collar|Collar designed to mitigate slosh in the brain
75376985|NCT02928380|Device|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
75376986|NCT02928380|Device|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
75376987|NCT02928536|Other|no intervention|This is an observational study. No intervention is considered
75376988|NCT02930174|Device|noninvasive positive pressure ventilation|Application of various levels of positive pressure
75376989|NCT02933372|Drug|Varenicline|Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
75702750|NCT03741920|Device|Personal KinetiGraph™ (PKG™)|"The Personal KinetiGraph™ (PKG™) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by Global Kinetics (GKC).~The Personal KinetiGraph™ (PKG™) Movement Recording System consists of the following:~A wrist-worn data logger designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~An application to configure the data logger and transfer the acquired data at the end of a recording.~A series of algorithms that analyze the uploaded data, producing a report that is delivered to the clinician. The report contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
75702751|NCT00667719|Drug|Aliskiren|300 mg tablet
75702752|NCT00667719|Drug|Amlodipine|5 mg tablet
75376990|NCT02933450|Drug|Patiromer 25.2 g|Single dose of Patiromer 25.2 g
75376991|NCT02902237|Biological|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
75866777|NCT02404324|Other|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
75866778|NCT03170986|Behavioral|Multisectoral agriculture and Microfinance Intervention|
76029229|NCT05890404|Behavioral|LGBTQ-Affirmative CBT Training: Direct Training|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers."
75866779|NCT02412358|Device|toothbrush|
75866780|NCT02412280|Other|retrospecive observational|
75376992|NCT02903407|Drug|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
75376993|NCT02903407|Drug|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
75376994|NCT02903407|Drug|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
75376995|NCT02811302|Device|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
75376996|NCT02905981|Drug|Fer-In-Sol|Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.
75376997|NCT02905981|Drug|Shohl's solution|Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
75866781|NCT03173716|Procedure|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
75866782|NCT03115372|Other|Educational Intervention|Attend CRC education session
75866783|NCT03115372|Other|Educational Intervention|Attend healthy nutrition session
76029230|NCT05890404|Behavioral|LGBTQ-Affirmative CBT Training: Local Supervision|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center."
76029231|NCT05888753|Procedure|Adrenalectomy|Scheduled adrenal surgery
75376998|NCT02905981|Drug|Triferic|Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
75376999|NCT02907073|Drug|BF4|Single IV dose of 9-11 millicurie (mCi) sodium [Fluorine-18] radiolabeled B4^F
76029232|NCT05887739|Diagnostic Test|Inertial gait analysis|All groups will be evaluated with inertial gait analysis
75377000|NCT02812160|Device|Spatz3 Adjustable Balloon|An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
75377001|NCT00374023|Drug|Zinc, or Vitamin A or both|
75377002|NCT02812238|Dietary Supplement|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
75377003|NCT02812238|Drug|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
75377004|NCT03015649|Device|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
75377005|NCT03015961|Drug|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
75377006|NCT03015961|Drug|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
75377007|NCT02814656|Drug|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
76029233|NCT05881603|Other|" VExUS score  (Venous Excess Ultrasound Score)"|" VExUS score  (Venous Excess Ultrasound Score)"
76029234|NCT05880771|Other|Immediate Implant Placement|Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.
75377008|NCT02814656|Drug|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
75377009|NCT03018223|Drug|Fludarabine|Myeloablative conditioning: 40 mg/m^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
75377010|NCT03018223|Drug|Busulfan|Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
75377011|NCT03018223|Drug|Cyclophosphamide|Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
75377012|NCT03018223|Radiation|Total body irradiation (TBI)|Reduced intensity conditioning: 200 centigray (cGy) on day -1.
75377013|NCT03018223|Procedure|Peripheral Blood Hematopoietic Cell Transplantation (HCT)|On day 0, patients will receive a peripheral blood hematopoietic cell graft.
75866784|NCT03115372|Other|Informational Intervention|Receive CRC screening brochure
75866785|NCT03115372|Other|Survey Administration|Ancillary studies
75866786|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about CRC screening
75866787|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
75866788|NCT04481542|Diagnostic Test|MRI|check MRI quality in aorta
75866789|NCT03173872|Procedure|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
75866790|NCT02412202|Other|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
75377014|NCT03018223|Drug|Sirolimus (SIR)|GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
75377015|NCT03018223|Drug|Mycophenolate mofetil (MMF)|GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
75377016|NCT03018223|Drug|Granulocyte-colony stimulating factor (G-CSF)|Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is > 1,000/mm^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
75377017|NCT03018925|Drug|Golimumab|The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
75539185|NCT04610242|Diagnostic Test|skin test|"For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours."
75539186|NCT00564148|Drug|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
75539187|NCT00222521|Drug|Glargine insulin|
75702753|NCT00667719|Drug|Hydrochlorothiazide|12.5 mg and 25 mg capsule
75702754|NCT00922077|Behavioral|standard physical therapy program with emphasis on dynamic balance exercises|
75702755|NCT00777387|Procedure|slow-freeze|Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures
75702756|NCT00777387|Procedure|vitrification|Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
75702757|NCT00780351|Device|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
75866791|NCT02408146|Procedure|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
75377018|NCT02814890|Procedure|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
75539188|NCT04609774|Other|Severe Acute Respiratory Syndrome CoronaVirus 2 detection|Severe Acute Respiratory Syndrome CoronaVirus 2 Detection by Real-Time Polymerase Chain Reaction and cell culture
75539189|NCT04609540|Drug|Trastuzumab|Dual anti-HER2 therapy
75702758|NCT03429296|Other|Autohypnosis learning|Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
75539190|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
75702759|NCT00780585|Drug|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
75702760|NCT00780663|Drug|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
75702761|NCT02581514|Other|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
75702762|NCT04030910|Other|'LIFEView'|A prototype audiovisual technology in development by Motitech AS.
75702763|NCT00669669|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal IMRT
75702764|NCT00669669|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
75702765|NCT00669669|Drug|Carmustine|Given IV
75702766|NCT00669669|Biological|Filgrastim|Given SC
75702767|NCT00669669|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
75702768|NCT00669669|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D conformal IMRT
75702769|NCT00669669|Other|Laboratory Biomarker Analysis|Correlative studies
75702770|NCT00669669|Drug|O6-Benzylguanine|Given IV
75702771|NCT00669669|Drug|Plerixafor|Given SC
75702772|NCT00669669|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
75702773|NCT00669669|Drug|Temozolomide|Given PO
75866792|NCT02408146|Drug|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
75377019|NCT02814890|Procedure|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
75702774|NCT02579564|Drug|Gemcitabine|
75702775|NCT02579564|Drug|Vinorelbine|
75702776|NCT02579564|Drug|Paclitaxel|
75702777|NCT02579564|Drug|Pemetrexed|
75702778|NCT02579564|Drug|Oncorine|
75702779|NCT02579564|Drug|Endostar|
75539191|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
75539192|NCT00222560|Behavioral|Intensive physical activity counselling by an integrated physical activity counsellor|
75539193|NCT04609462|Procedure|Conventional oxygen therapy|Oxygen therapy by conventional nasal cannula / prongs, venturi mask, or mask with reservoir
75702780|NCT02579564|Drug|Cisplatin|
75702781|NCT00467779|Drug|cobimetinib|Repeating oral dose
75702782|NCT00467779|Drug|dextromethorphan|In Stage III only: single dose of dextromethorphan
75702783|NCT00467779|Drug|midazolam|In Stage III only: single dose of midazolam
75702784|NCT04076306|Other|iSTEP exercise testing|iSTEP 10 minute step test, up and down on a commercial standard 3-height adjustable step Undertaking the 10m-MSWT 20-30 minutes Procedure takes place on testing track at Great Ormond Street Hospital; a 5 minute walk from the Haemophilia Centre. One of the research team accompanies the family with child to the track and will accompany them back to the Centre once testing is finished. Muscle Myometry 10 minutes, carried out by one of the research team at the end of the physiotherapy clinical assessment in the Haemophilia Centre. Wearing of accelerometer (activity/ step counter)7 days Device will be set up and provided at the end of the testing on the day of attendance at clinic. They will be instructed to wear this throughout the week at home when they are awake (at least 8 hours). Haemophilia Joint Health Score (HJHS) - a standardised outcome measure of joint health in people with Haemophilia, undertaken by the Clinical Specialist Physiotherapists in Haemophilia.
75702785|NCT04075214|Device|transcutaneous auricular neurostimulation (tAN)|Phoenix tAN system
75702786|NCT04076774|Device|Wondaleaf Female Condom|Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
76029235|NCT05879224|Combination Product|Revised case management package|"Point-of-care quantitative G6PD testing using G6PDSTANDARD (SD Biosensor) prior to use of primaquine (Day 0)~Prescription of short course primaquine (7 mg/kg total)(Day 0):~PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~PQ14 (0.5 mg/kg/day for 14 days) if G6PDactivity is 30-70 percent~PQ8w (0.75 mg/kg/week for 8 weeks) if G6DPactivity less than 30 percent~Participant counselling at the health facility (Day 0):~Supervision of first dose of primaquine~Education regarding the importance and risks of primaquine therapy and necessity to take primaquine with food~Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
76029236|NCT05877716|Device|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
75539194|NCT04609462|Procedure|High flow nasal cannula|Breathing support with High-flow nasal cannula
75539195|NCT04609267|Diagnostic Test|PHQ-9 - Mirror format|The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.
75539196|NCT00222638|Drug|Influenza vaccination|
75702787|NCT04076774|Device|FC2 Female Condom|FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
75702788|NCT00570687|Drug|Technosphere Insulin|Inhalation 15U/30U
75702789|NCT01021891|Drug|Technosphere®/Insulin|
75702790|NCT04075058|Radiation|Hypofractionated Radiation therapy|
75702791|NCT01029223|Drug|ivabradine|
75702792|NCT01029223|Drug|metoprolol|
75702793|NCT01029223|Drug|placebo|
75539197|NCT04609384|Device|Alcohol rub timer device|A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
75702794|NCT02556723|Drug|Intravitreal injections of ziv-aflibercept|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
75377020|NCT03019783|Drug|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
75539198|NCT04609150|Other|Bone marrow fat quantification by MRI|Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty
75702795|NCT03836677|Combination Product|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
75702796|NCT03836677|Combination Product|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
75539199|NCT00222677|Drug|aspirin|100 mg daily
75702797|NCT00777543|Other|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
75702798|NCT00777543|Dietary Supplement|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
75702799|NCT00777543|Dietary Supplement|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
75702800|NCT03410654|Drug|Tacrolimus, Extended Release, (Envarsus Xr)|After conversion of tacrolimus immediate release to tacrolimus extended release.
75539200|NCT00564343|Other|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
75539201|NCT00564382|Procedure|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
75702801|NCT03401840|Radiation|postoperative hypofractionated stereotactic radiotherapy|total dose of 36Gy in 6 fractions over 11-13 days
75702802|NCT02556645|Other|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
75702803|NCT02556645|Other|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
75702804|NCT01032421|Procedure|IVF procedure|
75702805|NCT04008758|Diagnostic Test|Ultrasound|Evaluate participant's lung condition using ultrasound. Using lung ultrasound scoring, more than 1 point needs recruitment maneuver
75702806|NCT01021969|Other|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
75539202|NCT00564460|Drug|Finasteride|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
75539203|NCT00564460|Drug|Placebo|Placebo once daily for 8 weeks
75539204|NCT04609033|Drug|Bupivacaine|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
75539205|NCT04609033|Drug|isotonic saline|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
75702807|NCT01032499|Drug|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
75702808|NCT01032499|Drug|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
75702809|NCT01022047|Drug|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
75702810|NCT01022047|Drug|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
75377021|NCT03019783|Other|Placebo|The control group will stay on their baseline regimen
75377022|NCT02815982|Behavioral|NOURISH-T|Overweight/obesity family intervention
75377023|NCT02815982|Behavioral|Enhanced Usual Care|Publicly available overweight/obesity materials
75377024|NCT03019939|Drug|Isavuconazole|Given PO or IV
75377025|NCT03017924|Device|Q collar|q-collar concussion prevention device
75377026|NCT03020095|Drug|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
75377027|NCT03020095|Drug|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
75539206|NCT04609033|Drug|Bupivacaine + morphine|instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure
75539207|NCT04609033|Drug|Bupivacaine + morphine + ketamine|instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure
75539208|NCT00222716|Behavioral|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
75539209|NCT04608799|Drug|Perampanel|Efficacy of epilepsy drugs
75702811|NCT01029301|Device|Device: EndyMed Pro System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);"
75702812|NCT04001036|Drug|1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One bag for nocturnal (long-dwell) exchange.
75377028|NCT03020095|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
75377029|NCT03020095|Drug|Ribavirin|Ribavirin(RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)administered orally
75377030|NCT02818244|Device|Fit Bit Blaze Heart Rate Monitoring Device|
75377031|NCT02818244|Device|Garmin Forerunner 235 Heart Rate Monitoring Device|
75377032|NCT02818244|Device|Tom Tom Spark Cardio Heart Rate Monitoring Device|
75377033|NCT02818244|Device|Apple Watch Heart Rate Monitoring Device|
75377034|NCT02818244|Device|Scosche Rhythm + Heart Rate Monitor|
75377035|NCT02934698|Drug|Ivacaftor|Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
75377036|NCT03019796|Drug|MEDICATION AND EXERCISE TRAINING|"PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE)."
75377037|NCT03020719|Drug|Oral Glutathione|Oral Glutathione oral powder
75539210|NCT04608565|Device|Remote biomonitoring sensor device|Same as described in arm descriptions. Safety was ensured by getting radiant warmer and multichannel probe examined and services by the biomedical engineering department; calibration certificates were obtained and these were used routinely in care of other neonates. An adverse event reporting and resolution protocol for the wearable sensor devices to capture number and severity of adverse events; individual clinical management and feedback for changes into device design. Adverse events recorded were: dermatitis, infection, thermal injury, radiation injury, device leak/burst and others.
76029237|NCT05877716|Behavioral|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
75377038|NCT03020719|Drug|Placebo|Placebo oral powder
75539211|NCT00248313|Drug|Rapamune®|
75539212|NCT00222755|Behavioral|Disease Management|Self-management, care management, guidelines
75539213|NCT04608760|Drug|Meksibel|2 ml solution
75539214|NCT04608370|Behavioral|Active tPBM session|In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
75377039|NCT02935088|Device|Fractional Flow Reserve|Measurement of physiologic parameters
75377040|NCT03021343|Drug|Colchicine|colchicine given as per trial protocol
75377041|NCT03022435|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
75377042|NCT03022435|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
75377043|NCT03022435|Biological|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
75377044|NCT02936648|Other|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
75377045|NCT03023683|Biological|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
75377046|NCT03020498|Biological|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
75377047|NCT03020498|Biological|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
75377048|NCT03025945|Drug|Nepafenac 0.3%|
75377049|NCT03025945|Drug|Saline Solution|
75377050|NCT02937194|Behavioral|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) and oral health pamphlets distribution
75539215|NCT04608370|Behavioral|Sham tPBM session|In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
75377051|NCT02937194|Behavioral|Pamphlets distribution|Oral health pamphlets distribution
75377052|NCT02937506|Drug|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
75377053|NCT02937506|Drug|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
75377054|NCT03026803|Drug|Oxaliplatin|Given IV
75377055|NCT03026803|Drug|Capecitabine|Given PO
75377056|NCT02938052|Behavioral|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
75377057|NCT03027661|Drug|Bupivacaine|Inject 10 mL of 0.5% bupivacaine into cervical stroma
75377058|NCT03027661|Drug|0.9% Sodium Chloride|Inject 10 mL of 0.9% NaCl into cervical stroma
75377059|NCT03022526|Procedure|CSE|
75377060|NCT03022526|Procedure|Epidural|
75377061|NCT03022526|Drug|Bupivacaine / fentaNYL|
75377062|NCT02794441|Drug|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
75377063|NCT02794441|Other|Placebo|Matched oral solution
75377064|NCT02941640|Procedure|E group|The securing the base of appendix by endoloop.
75377065|NCT02941640|Procedure|S group|The securing the base of appendix by Stapler.
75377066|NCT02941640|Procedure|H group|The securing the base of appendix by Hem-o-lok clip.
75377067|NCT02941640|Procedure|DS group|The securing the base of appendix by DS clip.
75377068|NCT02941640|Device|Endoloop|
75377069|NCT02941640|Device|Stapler|
75377070|NCT02941640|Device|Hem-o-lok clip|
75377071|NCT02941640|Device|DS clip|
75377072|NCT02794597|Behavioral|SHINE intervention group|Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
75377073|NCT00373555|Procedure|Bronchoscopy|
75377074|NCT02822612|Device|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
75377075|NCT03028363|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
75539216|NCT04608526|Diagnostic Test|Fractal analysis|Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
75539217|NCT00248352|Behavioral|Consultation with Endocrinologist|
75377076|NCT03028363|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
75377077|NCT02823080|Drug|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
75377078|NCT03028987|Biological|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
75377079|NCT03028987|Biological|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
75377080|NCT03022916|Drug|Nail Polish + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish
75377081|NCT03022916|Other|Nail polish|Application of nail polish only to both big toe nails
75377082|NCT03022916|Drug|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat
75377083|NCT03022916|Drug|Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
75377084|NCT03031795|Drug|Ketorolac|Oral Tablet
75377085|NCT03031795|Drug|Placebo|Oral Tablet
75377086|NCT02942654|Drug|LY900014|Administered subcutaneously (SC)
75377087|NCT02942654|Drug|Insulin Lispro|Administered SC
75377088|NCT02825966|Device|AUDICOR then LifeVest then AUDICOR|Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
75377089|NCT03028220|Device|Dexcom G5 Continuous Glucose Monitor|Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values
75377090|NCT03028220|Device|Abbott Freestyle Libre|Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
75539218|NCT00248352|Behavioral|Counseling from Dietician|
75539219|NCT00248352|Behavioral|Counseling from Diabetes Educator|
75377091|NCT02909959|Drug|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
75377092|NCT02909959|Drug|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
75377093|NCT00373724|Procedure|radiofrequency denervation|
75377094|NCT00373802|Drug|Phenylephrine|
75377095|NCT04333394|Dietary Supplement|Probiotic|The probiotic capsules will be administrated once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with probiotic supplementation.
75539220|NCT00222794|Drug|Atomoxetine (Strattera)|
75539221|NCT04608253|Diagnostic Test|11C-choline PET/CT|11C-choline PET/CT
75539222|NCT04608643|Diagnostic Test|CBC _inflammatory markers _ platelet function test|CBC , Erythrocte sedimentation rate (ESR) ,CRP, platlet functions tests ( adhesions, 'aggregations ristocetin).
75539223|NCT04608175|Other|Acupuncture|Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation.
75539224|NCT00222833|Drug|Aripiprazole|
75377096|NCT04333394|Other|Placebo|The placebo capsules will be administered once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with placebo supplementation.
75377097|NCT00373633|Procedure|Thoracic Epidural|Gold standard for post thoracotomy pain
75377098|NCT00373633|Procedure|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
75377099|NCT02945150|Drug|elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those <75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
75377100|NCT02911753|Other|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
75702813|NCT04001036|Drug|0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One to three, daily (short-dwell) exchanges
75377101|NCT02911753|Other|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
75377102|NCT02911753|Other|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
75377103|NCT02829320|Drug|GSK1278863|GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
75377104|NCT02829320|Drug|Iron|Subjects will receive supplemental iron therapy if ferritin is <=100 ng/mL and TSAT is <=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
75377105|NCT03032263|Device|Video Laryngoscopy for nasal intubation|The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
75866793|NCT02408146|Procedure|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
75377106|NCT03032263|Device|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy
75377107|NCT03032965|Drug|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
75377108|NCT03032965|Drug|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
75377109|NCT03030638|Drug|Olodaterol|Drug
75866794|NCT02408146|Drug|fentanyl citrate+ ondansetron hydrochloride + normal saline|
75377110|NCT03030638|Drug|Indacaterol|Drug
75377111|NCT02949518|Other|Enhanced Recovery Pathway (ERP) for Spine|The study team emphasizes that all components of the ERP are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERP will receive these standard of care components.
75377112|NCT02949674|Drug|Ropivacaine|It will be used as a analgesic dose in surgical site before surgery.
75377113|NCT02949674|Drug|Bupivacaine|It will be used as a analgesic dose in surgical site before surgery.
75377114|NCT03033511|Drug|Placebo for dexamethasone|Placebo for dexamethasone PO twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
76029238|NCT05877716|Other|Early Psychosis Coordinated Specialty Care|Participants will continue to engage in treatment as usual at their early psychosis coordinated specialty care clinic. These clinics may follow the NAVIGATE model, as an example.
75377115|NCT03033511|Drug|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
75377116|NCT03033511|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
75377117|NCT03033511|Drug|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
75377118|NCT03033134|Device|BSJ003W|BSJ003W implant
75377119|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 25mg|25 μg oral inhalation via eFlow Nebulizer, once daily
75377120|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 75mg|75 μg oral inhalation via eFlow Nebulizer, once daily
75539225|NCT04608097|Behavioral|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
75539226|NCT04608097|Behavioral|Attention Placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
75702814|NCT01022125|Drug|TMC435|
75866795|NCT02408146|Drug|celecoxib|
75866796|NCT02412124|Procedure|Supportive Care|Complete W2W mentoring program
75866797|NCT02412124|Other|Quality-of-Life Assessment|Complete the FACT-G
76029239|NCT05877625|Procedure|Expectoration care|"Endotracheal aspiration: from discarded samples after expectoration care~BALF (bronchoalveolar lavage fluid): if patients with fiber bronchoscope examination, take the rest of the BALF after examination~Oropharyngeal swabs"
75377121|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg|200 μg oral inhalation via eFlow Nebulizer, once daily
75377122|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg Jet|200 μg oral inhalation via inhalation via jet nebulizer, once daily
75377123|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 500mg|500 μg oral inhalation via eFlow nebulizer, once daily
75377124|NCT02951312|Drug|Glycopyrrolate Inhalation Solution1000mg|1000 μg oral inhalation via eFlow nebulizer, once daily
75377125|NCT02951312|Drug|Placebo|Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
75377126|NCT02796625|Other|Painful Stimuli|warm or painful heat administration
75377127|NCT03035929|Drug|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
75377128|NCT02951702|Drug|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
75377129|NCT02911909|Device|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
75377130|NCT02911909|Other|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
75377131|NCT02952872|Behavioral|Brief Tablet-based Intervention to Address Heavy Alcohol Use|The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
75377132|NCT02799667|Device|Standard Dressing|Patients are randomized to the standard dressing at the time of fascial closure.
75377133|NCT02799667|Device|Negative Pressure Wound Therapy Dressing|Patients are randomized to the NPWT at the time of fascial closure.
75377134|NCT02914795|Other|diagnostic analysis of platelet function|analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
75377135|NCT02953418|Device|Radiofrequency ablation|RFA
75377136|NCT02915029|Other|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
75539227|NCT04607902|Behavioral|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
75539228|NCT04607902|Behavioral|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
75539229|NCT04607902|Behavioral|Growth Mindset SSI|Online, 30-minute self-administered program for youth
75539230|NCT00251628|Other|Standard Care|standard care
75702815|NCT01032655|Drug|susceptibility test guided sequential therapy|"susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~Klaricid, 500 mg, bid~Cravit, 250 mg, bid~Tetracycline, 500 mg, bid"
75866798|NCT02412124|Other|Questionnaire Administration|Complete the W2W Patient Survey
75377137|NCT02831660|Drug|idarucizumab|
75377138|NCT02831816|Drug|ZuraPrep|Apply topically.
75377139|NCT02831816|Drug|ChloraPrep|Apply topically.
75377140|NCT02831816|Drug|ZP Vehicle|Apply topically.
75377141|NCT02832284|Device|iNod System|The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
75377142|NCT03036163|Drug|PBTZ169 - 40 mg|40 mg of PBTZ169 (1 capsule) orally once in fasting state
75377143|NCT03036163|Drug|PBTZ169 - 80 mg|80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
75377144|NCT03036163|Drug|PBTZ169 - 160 mg|160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
75377145|NCT03036163|Drug|PBTZ169 - 320 mg|320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
75377146|NCT03036163|Drug|PBTZ169 - 640 mg|640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
75377147|NCT03036163|Drug|PBTZ169 - 320 mg (multiple administration)|320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
75377148|NCT03036163|Drug|PBTZ169 - 640 mg (multiple administration)|640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
75539231|NCT00251628|Other|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
75539232|NCT00251628|Other|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
75539233|NCT00251628|Other|As needed dosing|"As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain."
75539234|NCT04608058|Behavioral|Digital storytelling training|"The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes."
75539235|NCT04608058|Behavioral|Routine training|The control group received the clinics' routine training include face to face class education.
75539236|NCT00564538|Drug|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
75539237|NCT00564538|Drug|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
75377149|NCT02832674|Device|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
75377150|NCT02973607|Procedure|Nephrectomy|This is observational in design.
75377151|NCT03034928|Device|Contact lens with investigational coating 1|Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
75377152|NCT03034928|Device|Balafilcon A contact lens|Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS
75377153|NCT03034928|Device|OPTI-FREE® RepleniSH® MPDS|Multipurpose contact lens solution
75377154|NCT03034928|Device|Contact lens with investigational coating 2|Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS
76029240|NCT05874492|Other|Thermal cure with a primary dermatological indication|The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
75377155|NCT03038815|Device|VACOped|restriction of ankle joint motion
75866799|NCT04482010|Other|Local community-based HIV care|"Compared to the classic HIV care, community-based HIV care includes:~Individual interviews with a psychosocial agent;~Support groups conducted by psychosocial agents;~Culinary workshops gathering PLWHIV and healthcare professionals;~Home visits by a community worker;~Emergency relief based on a funding for patients with urgent needs~As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment."
75377156|NCT03038815|Device|Ortho Tri|restriction of ankle joint motion
75866800|NCT03175900|Drug|Naoan dripping pills|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）"
75377157|NCT02800213|Device|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
75377158|NCT02800213|Device|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
75377159|NCT02953886|Device|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
75377160|NCT03035318|Device|DePuy Global® Anchor Peg Glenoid Instrumentation|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.
75377161|NCT03035318|Device|DePuy Global® Anchor Peg Instrumentation with SmartBone™|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.
75539238|NCT00251706|Drug|amiodarone|
76029241|NCT05873361|Other|Questionnaire|The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
75539239|NCT00199121|Drug|Zidovudine (drug)|
76029242|NCT05872321|Other|Complication|whether or not complications occur
76029243|NCT05871840|Other|Repeated Low-Level Red-Light (RLRL) Therapy|This treatment device was made by Eyerising SuzhouXuanjia Optoelectronics Technology, which has been on the market and used widely for amblyopia treatment for the past decade in China. This device is certified as a class IIa device by the China National Medical Products Administration. It consists of semiconductor laser diodes, which deliver low-level red light with a wavelength of 650 ±10 nm at an illuminance level of approximately 1600 lux through the pupil to the fundus. Based on calculations completed by an independent lab, the light power going through a 4-mm pupil is 0.29 mW and is classified as class 1 under the International Electrotechnical Commission 60825-1:2014 standard, which is at a level considered safe for direct ocular exposure that would not create retinal thermal hazard.
75377162|NCT03035318|Device|IRI with SmartBone™|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.
75377163|NCT03035318|Device|RTI with SmartBone™|Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.
75539240|NCT04607824|Behavioral|Duchenne Muscular Dystrophy group|Assessment of heart rate variability at rest and during computational task in people with Duchenne muscular dystrophy
75539241|NCT04607824|Behavioral|Typical Development group|Assessment of heart rate variability at rest and during computational task in people with typical Development
75539242|NCT04607863|Diagnostic Test|Case control|Is a case-control research
75539243|NCT04607785|Drug|Miswak mouthwash group|Twice daily for seven days for two months
75539244|NCT04607785|Device|Chlorhexidine gluconate mouthwash|Twice daily for seven days for two months
75539245|NCT00248391|Behavioral|upright feeding|
75377164|NCT03035318|Device|IRI with SmartBase|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
75377165|NCT03035708|Drug|Varenicline|1 mg BID
75377166|NCT03035708|Drug|Placebo oral capsule|1 mg BID
75377167|NCT00374426|Drug|sertraline|
75377168|NCT03040154|Other|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
75377169|NCT03040154|Other|Usual Care Video that is publicly available|
75377170|NCT02916745|Drug|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
75377171|NCT02916745|Device|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
75539246|NCT00199160|Drug|BAY 43-9006|
75539247|NCT04607629|Biological|Genolar® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
75702816|NCT03654248|Behavioral|Let's Get Organized group intervention|Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
75866801|NCT03175900|Drug|Placebo|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)"
75866802|NCT03175666|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
75866803|NCT03175666|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
75866804|NCT03175666|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75866805|NCT03175666|Drug|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
75866806|NCT03175666|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75866807|NCT03175666|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
75377172|NCT02954198|Drug|Tacrolimus|goal trough level 5-12ng/mL
75377173|NCT02954198|Drug|Prednisone|goal dose 5mg QD
75377174|NCT02954198|Drug|Mycophenolate mofetil|goal dose 1g BID
75377175|NCT02954198|Drug|Everolimus|goal trough level 3-8ng/mL
75377176|NCT02956070|Drug|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
75413806|NCT04759144|Device|CamAPS FX using faster insulin aspart|"CamAPS FX closed loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~Cloud upload system to monitor CGM/insulin data"
75413807|NCT04759144|Device|CamAPS FX using standard insulin aspart|"CamAPS FX closed loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~Cloud upload system to monitor CGM/insulin data"
75413808|NCT04757701|Other|Social Behavioral surveys, interviews, and focus groups|Surveys with dentists/hygienists, interviews/focus groups with service learning center directors and key staff at federally qualified health centers.
75413809|NCT04737200|Dietary Supplement|Time-of-day of enteral nutrition provision (daytime first)|Enteral nutrition (tube feeds) will be provided during the daytime followed by nighttime.
75866808|NCT03175666|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
75866809|NCT03175666|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
75866810|NCT03175666|Drug|Lovaza|omega-3-acid ethyl esters)
75866811|NCT03175666|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
75539248|NCT04607629|Biological|Xolair® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
75377177|NCT02956070|Drug|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch [50%], lactose monohydrate [35%], dibasic calcium phosphate [14%], and magnesium stearate [1%]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
76029244|NCT05869149|Behavioral|Multilevel restaurant intervention to improve the food environment|FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
75377178|NCT02956616|Drug|ketorolac|Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
75377179|NCT02956616|Other|Chewing Gum|Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
75377180|NCT02956616|Procedure|Enhanced Recovery Protocol|enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
75377181|NCT02809183|Drug|Placebo|oral suspension
75377182|NCT02809183|Drug|TRC101|oral suspension
75377183|NCT02958956|Drug|Pioglitazone|Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
75377184|NCT02833922|Behavioral|Women using Dot to avoid pregnancy|Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
75377185|NCT02917447|Behavioral|DESTRESS-WV|This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives. Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the program.
75377186|NCT02917447|Behavioral|Phone Monitoring|A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
75377187|NCT05829616|Drug|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
75377188|NCT05829590|Diagnostic Test|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture bowel segment images and prompt abnormal lesions based on speech recognition and deep learning.
75377189|NCT05829551|Drug|RAY1216 dose 1|RAY1216 dose 1 or Placebo
75377190|NCT05829551|Drug|RAY1216 dose 2|RAY1216 dose 2 or Placebo
75377191|NCT05829551|Drug|RAY1216 dose 3|RAY1216 dose 3 or Placebo
75377192|NCT05829551|Drug|RAY1216 dose 4 &ritonavir|RAY1216 dose 4 &ritonavir or Placebo
75377193|NCT05829551|Drug|RAY1216 dose 5|RAY1216 dose 5 or Placebo
75539249|NCT00251784|Drug|Sildenafil|
75539250|NCT04607473|Device|automated breast ultrasound (ABUS)|Both HHUS and ABUS will be performed on each patient for preoperative staging. Breast radiologists each independently will read HHUS and ABUS images obtained from one patient. The radiologists will be blinded to the findings of the other US mode.
75539251|NCT05558852|Procedure|Laparoscopic Meshless Sacrocolpopexy Technique|Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
75866812|NCT03175666|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
75866813|NCT03175666|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-CEA (carcinoembryonic antigen)
75377194|NCT05829551|Drug|RAY1216 dose 6|RAY1216 dose 6 or Placebo
75377195|NCT05829551|Drug|RAY1216 dose 7|RAY1216 dose 7 or Placebo
75377196|NCT05829551|Drug|RAY1216 dose 8|RAY1216 dose 8 or Placebo
75377197|NCT05829551|Drug|RAY1216 dose 9|RAY1216 dose 9 or Placebo with high fat meal
75377198|NCT05829551|Drug|RAY1216 dose 10|RAY1216 dose 10 or Placebo with high fat meal
75377199|NCT05829538|Behavioral|SuJok|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale.
75377200|NCT05829538|Behavioral|Massage|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale
75377201|NCT05829473|Other|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
75377202|NCT05829473|Other|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
75377203|NCT05829447|Device|G-EYE 760 R endoscope|The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
75377204|NCT05829382|Dietary Supplement|DailyColors™|Capsule containing active ingredient administred daily by the participant during the trial period
75377205|NCT05829382|Dietary Supplement|Placebo|Capsule containing placebo administered daily by the participant during the trial period
75377206|NCT05829369|Other|Intrinsic foot muscle strengthening exercises|participants will perform specific toe and foot motions that recruit plantar intrinsic foot muscles, 3 sets of 10 for each exercise, 5 days per week
75377207|NCT05829369|Other|Minimal footwear with prescribed walking|Participants will be provided minimal footwear. They will walk 30 minutes per day, 5 days per week, and be prescribed a gradual increased time in minimal footwear during daily activities (up to a maximum of 7.5 hours per day).
75377208|NCT05829369|Other|Control|Participants will perform seated upper and lower extremity active range of motion activities 5 days per week. They will also be given a brochure on fall prevention tips.
75377209|NCT05829304|Other|MTA based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A&B will be at the same patient.
75377210|NCT05829304|Other|Collagen based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A&B will be at the same patient.
75377211|NCT05829278|Procedure|Acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36(Zusanli ), KI3 (Taixi), and etc.
75377212|NCT05829265|Behavioral|A digital social intervention by primary care clinicians.|"The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs)."
75377213|NCT05829213|Procedure|"arch-bridge-type esophagogastric reconstruction after proximal gastrectomy"|"The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~Creating the seromuscular flap (arch-bridge)~The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis."
75539252|NCT04607512|Drug|telaglenastat|glutaminase inhibitor
75866814|NCT03175666|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
75377214|NCT05829200|Device|Transcranial Doppler (TCD)|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
75377215|NCT05829161|Behavioral|no intervention|no intervention
75377216|NCT05829148|Drug|Dexmedetomidine|Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus
75377217|NCT05829148|Drug|Melatonin|Melatonin
75377218|NCT05829148|Drug|Pregabalin|Pregabalin
75377219|NCT05829148|Drug|Placebo|Placebo
75539253|NCT04607512|Other|telaglenastat placebo|matching placebo for telaglenastat
75539254|NCT04607512|Other|moxifloxicin|positive control
75539255|NCT04607239|Procedure|Telemonitoring|"A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~A monthly call by the attending physician for treatment titration and side effects check."
75866815|NCT03175666|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 (MUC1)
75866816|NCT03175666|Biological|GI-4000|RAS yeast vaccine
75866817|NCT03175666|Biological|GI-6207|CEA yeast vaccine
75377220|NCT05829122|Procedure|Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty|In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, corrected visual acuity, intraocular pressure, pupil diameter, pupil area, corneal endothelial cell count fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage. The modified iris cerclage was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.
75377221|NCT05829096|Other|The COMBINED approach|"Patient-level intervention:~Assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~Brief intervention to support health behaviour change: smoking cessation, increasing physical activity levels and consuming a healthy diet~Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring.~Clinician-level implementation toolkit:~Training package including a face-to-face workshop, training manual, recorded role play simulations and an online follow-up training session~Additional supporting resources; a step-by-step guide to The COMBINED approach, scripts, patient signposting information to support services and a lay summary infographic to explain the links between the health behaviours and RC disorders to patients~Audit and feedback via observations of consultations to address any 'drift' from the intervention delivery as intended"
75377222|NCT05829057|Biological|Intravenous injection of P-IL-2|Ia :Single dose intravenous injection of P-IL-2；
75377223|NCT05829057|Biological|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
75377224|NCT05829018|Diagnostic Test|Mixed meal test|Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
75377225|NCT05828862|Procedure|hypotension prediction index guidance|using hypotension prediction index guidance to prevent intraoperative hypotension
75702817|NCT03654248|Device|Individual Occupational Therapy|Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
75377226|NCT05828862|Procedure|no hypotension prediction index guidance|silencing hypotension prediction index guidance during surgery
75377227|NCT05828784|Device|Intersomatic arthrodesis|"Arthrodesis is an operative modality also used in the treatment of multiple recurrences of herniated discs, stenosis (narrowing) of the spinal anal, degenerative and malformative spondylolisthesis.~The procedure can be performed with different surgical techniques, but in all cases it aims to achieve the same goal: to re-establish, through the use of spacers, the correct distance between two vertebral somes, in cases of disc degeneration, that are no longer able to fulfill their function; that is, they no longer absorb mechanical stresses and/or compress the nerve structures of the spine causing almost always unbearable (disabling) pain."
75539256|NCT04607239|Procedure|Usual Care without Telemonitoring|"Attending the follow up visits after inclusion at Day 90 (D-90) & Day 180 (D-180) for face to face consultation with the attending physician.~Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check."
75702818|NCT02581280|Other|Residual blood|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
75866818|NCT03175666|Biological|GI-6301|Brachyury yeast vaccine
75866819|NCT03175666|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
75377228|NCT05828771|Procedure|THIN FREE FLAP|Flap design will be performed on the basis of the preoperative perforator mapping. Freestyle flap elevation will be performed under loupe magnification from one of the incisions until the perforators are reached
75377229|NCT05828745|Drug|CB06-036|CB06-036 capsule
75377230|NCT05828745|Drug|Placebo|Placebo capsule
75377231|NCT05828732|Other|Using a mobile app that integrates with wearable devices|Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
75377232|NCT05828680|Other|Observation|No intervention
75377233|NCT05828576|Diagnostic Test|MRI|Patients will be asked for two additional control visits in the hospital. Overview of measurements: Included subject will visit the UMCU at two occasions. The first MRI scan will be the baseline MRI, and the second MRI will take place after 2 years of follow-up. Additional follow-up data will be collected through medical records reporting on regular follow-up.
75377234|NCT05828563|Diagnostic Test|Blood sample test|Blood sample will be taken to determine immunological indices
75377235|NCT05828550|Diagnostic Test|antibiotic sensitivity|"The resistance pattern of the isolates will be detected by disc diffusion method.~Detection of efflux pump genes responsible for the resistance ( norA , norB , norC ) by PCR"
75377236|NCT05828498|Dietary Supplement|THE Mediterranean diet|The Mediterranean diet was applied to the patients with bacterial vaginitis selected randomly. diet content and application techniques were explained to the patient.
75377237|NCT05828485|Drug|MY008211A tablets|A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
75377238|NCT05828446|Device|MRI|To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
75377239|NCT05828433|Other|Epley-Canalith Repositioning|Epley-Canalith Repositioning The intervention was given for approximately 15min, for 2 times in a week, for 4 weeks.
75377240|NCT05828433|Other|Vestibular Rehabilitation Therapy|"Vestibular Rehabilitation Therapy Habituation exercises: The patients were asked to repeat the exercises 5 -10 times for 5 to 10 min, for 2 days in a week, for 4 weeks.~Gaze stability exercises and balance training: The exercises were performed in 3 sets or 5 repetitions, for 2 days in a week, for 4 weeks."
75377241|NCT05828420|Other|White noise|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
75539257|NCT04607395|Radiation|pre-operative radiograph|"Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio)."
75539258|NCT00248430|Biological|aldesleukin|
75539259|NCT00248430|Biological|therapeutic allogeneic lymphocytes|
75539260|NCT00248430|Drug|melphalan|
75539261|NCT00248430|Procedure|bone marrow ablation with stem cell support|
75866820|NCT03101358|Drug|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
75539262|NCT00248430|Procedure|peripheral blood stem cell transplantation|
75539263|NCT05558189|Device|Vibrotactile Coordinated Reset (vCR)|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants who have refractory Parkinson's disease post surgical treatment
75866821|NCT02404246|Behavioral|Peer support program|
75866822|NCT02404090|Radiation|CT-osteoarbsorptiometry|Conventional CT-scan analyzed by means of a specific tool (Analyze, Mayo Clinic).
75866823|NCT05236218|Other|Discrete Choice Experiment (DCE) Patients DCE Questionnaire|Discrete Choice Experiment (DCE) Patients
75866824|NCT05236218|Other|Semi-Structured Interview Patients Interview|First version of questionnaire (readability/comprehension check)
75866825|NCT03173794|Other|CommunityRx-H|"CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources."
75866826|NCT03171220|Biological|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
75866827|NCT03171220|Biological|SHR-1210|SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
76029245|NCT05868057|Drug|SHR7280 tablets|SHR7280 tablets 1 time
76029246|NCT05868057|Drug|SHR7280 dry suspension|SHR7280 dry suspension 1 time
75377242|NCT05828420|Other|Heart sound|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
75377243|NCT05828420|Other|Music|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
75377244|NCT05828394|Procedure|DFGG|Depithelised free gingival graft harvesting technique
75702819|NCT03374072|Behavioral|Siblings FORWARD program|Siblings will participate in a program developed by the researchers designed to engage adults with their autistic sibling and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with autistic adults. The program will involve a series individual and joint sessions with siblings and autistic adults using Zoom.
75702820|NCT03374072|Behavioral|Information Only Condition|Siblings will be provided with online information about services for adults with ASD and future planning.
75702821|NCT05673980|Drug|Vitamin D2|Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
75377245|NCT05828394|Procedure|SCTG|Subepithelial connective tissue graft harvesting technique
75866828|NCT03171220|Drug|Fludarabine|Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
75377246|NCT05828381|Drug|Envafolimab|300mg,sc,d1,q3w; for a total of 2 cycles.
75377247|NCT05828381|Drug|Abraxane|100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles
75866829|NCT03171220|Drug|Cyclophosphamide|Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
75866830|NCT03171220|Biological|Interleukin-2|Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
76029247|NCT05862909|Other|CHD-specific web-based emotion regulation intervention|CHD-specific web-based emotion regulation intervention with ten video-based sessions covering emotional challenges of CHD and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in the daily life of patients with CHD, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
76029248|NCT05862909|Other|General web-based emotion regulation intervention|General web-based emotion regulation intervention with ten video-based sessions covering topics related to emotional awareness and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in daily life, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
76029249|NCT05860140|Other|Education video|Six minutes long education video focusing on protein and energy meals
76029250|NCT05858268|Genetic|Whole-genome sequencing|Whole-genome sequencing
76029251|NCT05856656|Behavioral|Music therapy|Music therapy is a technique of care, accompaniment and support, which aims to improve health and well-being.
76029252|NCT05856058|Drug|SHR0302|SHR0302 oral solution 1 time, SHR0302 tablets 1 time
76029253|NCT05855421|Device|Auricular Acupuncture|Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.
75377248|NCT05828381|Drug|Cisplatin|75 mg/m2 vigtt D1 , q3w , for a total of 2 cycles
75377249|NCT05828316|Behavioral|Resilience-based intervention|resilience-based intervention is a curriculum that offers a careful selection of evidence-based exercises to build coping skills and promote thriving. The resilience-based intervention philosophy is that there are many routes to achieving greater resiliency. Each participants choose from a menu of exercises in the areas of goal-setting, emotional skills, social connection, health, meaning, and self-talk. The ability to choose exercises that fit their specific goals, interests, and schedules is important, because the most effective strategies are the ones that people actually do, which tend to be the ones that are most enjoyable and personally relevant. No single practice is going to work for everyone regardless of its proven benefits. resilience-based intervention makes improving well-being accessible, manageable and fun, by introducing a variety of bite-sized, exercises that participants can experiment with and find what works for them.
75413810|NCT04737200|Dietary Supplement|Time-of-day of enteral nutrition provision (nighttime first)|Enteral nutrition (tube feeds) will be provided during the nighttime followed by daytime.
75413811|NCT04734847|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Non-invasive magnetic stimulation of the brain
75539264|NCT04607161|Other|no intervention|no intervention
75866831|NCT03170830|Diagnostic Test|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
75377250|NCT05828264|Behavioral|Quantum touch|this group by the nurse who is included in the study and who has a practice certificate before vascular access is established. In this process, the treatment process of the patient will continue and will not create an obstacle. While the child is in a comfortable position (lying or sitting position) during the application, the child's back/shoulder/head will be touched by the practitioner and guantum touch energy will be applied. Then, vascular access will be performed by the nurse included in the study. The child will be asked to rate the level of pain during the procedure with 'FPS-R', the level of fear with 'CDS', and the level of anxiety with 'ÇAS-D'.
75377251|NCT05828251|Procedure|Vitrectomy (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
75377252|NCT05828251|Procedure|Combined phako-vitrectomy|Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.
75377253|NCT05828251|Procedure|Phako (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
75377254|NCT05828238|Drug|[18F]SF-DEVD-2|Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
75377255|NCT05828238|Drug|[18F]-FDG|Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
75377256|NCT05828225|Drug|CD19 CAR-T cells injection|CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
75377257|NCT05828212|Drug|CD19 CAR-T cells injection|CD19 CAR-T cells in the treatment of R/R neuromyelitis optica
75377258|NCT05828199|Drug|Ketamine Hydrochloride|Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.
75377259|NCT05828199|Drug|Dexmedetomidine|bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr
75866832|NCT03175822|Behavioral|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements [e.g., colour and line] and principles [e.g., proportion and balance] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
75377260|NCT05828121|Behavioral|POINT1|Receiving treatment
75377261|NCT05828056|Device|Wearable activity tracker|Garmin smartwatch will record features, such as activities, heart rate, sleep, through smartphone App
75377262|NCT05827991|Device|1565nm Non-ablative Fractional Laser|1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
75702822|NCT05673980|Other|placebo|This group will not do any intervention
75702823|NCT02581124|Drug|JTZ-951|
76029254|NCT05854069|Behavioral|FAMS-T1D|"FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.~Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly."
76029255|NCT05854069|Behavioral|Digital resources for diabetes|Quality digital resources about diabetes management provided upon enrollment and during the study.
76029256|NCT05847608|Dietary Supplement|Omega-3|Daily consumption of 500 mg DHA and 750 mg EPA in liquid form
76029257|NCT05847608|Dietary Supplement|Placebo|Oleic Acid, Linoleic Acid
75702824|NCT02581124|Drug|Lapatinib|
75702825|NCT02580968|Device|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
75702826|NCT02580968|Drug|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
75539265|NCT04607278|Dietary Supplement|Probiotic|Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
75377263|NCT05827991|Drug|5% minoxidil external use|The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
75539266|NCT04607278|Dietary Supplement|Prebiotic|The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
75539267|NCT04607278|Dietary Supplement|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
75377264|NCT05827991|Device|1565nm Non-ablative Fractional Laser combined with 5% minoxidil|The two treatment mentioned above
75377265|NCT05827939|Other|Covid19 Vaccination dose|Participants above or below 2 dose Covid19 Vaccination
75539268|NCT00564577|Biological|CFA/I and CS17 challenge strain|Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
75539269|NCT04719975|Other|Mental Fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
75866833|NCT03173482|Other|questionnaire|asking about details of indication of cesarean section
75413812|NCT04734847|Device|Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)|Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.
75413813|NCT04731870|Other|Survey research|This is not an intervention study. It involves social science research of surveys and focus groups.
75413814|NCT04729985|Device|CGM device with diabetic education, CGM education and a follow up protocol.|Blind CGM placed and recorded for 14 days after discharge and data downloaded
75866834|NCT04847934|Behavioral|distraction methods|distraction methods
75866835|NCT03116386|Other|run-in period|observational time i.e. baseline situation
75413815|NCT04724031|Drug|PARP inhibitor|use at any line of treatment in patients with advanced ovarian cancer
75413816|NCT04715542|Drug|Stibium metallicum praeparatum 6x|Stibium metallicum praeparatum 6x will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
75413817|NCT04715542|Drug|Placebo|Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
75866836|NCT03116386|Device|Control period|neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
75866837|NCT03116386|Device|Etolya-F ® devices|Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
75377266|NCT05827913|Device|Polylevolactic Acid Injection|The patient was placed in a flat recumbent position and subjected to topical anesthesia with lidocaine cream for those who were unable to tolerate pain. According to the location and degree of indentation of the atrophic stria, a conventional disinfection towel is placed and injected into the subcutaneous and deep dermis. Use left thumb and index finger to press or tighten the skin from both sides to the middle. Depending on the location of the SD, determine the injection direction. During linear injection, the injection starts from the distal end of the SD, and then the injection is withdrawn until the SD subsides. Apply uniform force and withdraw the needle at a uniform speed. Stop the injection before the needle is pulled out of the skin, To avoid too shallow an injection.
75377267|NCT05827913|Device|1565nm Non-ablative Fractional Laser|M22-ResurFx laser (Lumenis Medical Company, USA) was used for treatment, with a wavelength of 1565 nm, a selected energy of 45 mJ, and a lattice density of 200 dots/cm2. The end point reaction was erythema and wind masses at the treatment site.
75377268|NCT05827913|Device|Polylevolactic Acid Injection combined with 1565nm Non-ablative Fractional Laser|combination of the two treatments described above
75377269|NCT05827848|Device|Percutaneous peripheral nerve stimulation system|All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
75866838|NCT05200650|Combination Product|TumoCure|TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.
75377270|NCT05827835|Drug|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
75377271|NCT05827835|Other|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
75866839|NCT03116542|Device|Diagnostic (18F-FLT PET/CT)|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
75377272|NCT05827796|Drug|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
75377273|NCT05827796|Drug|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
75866840|NCT03632694|Behavioral|Health Coaching and Tech Support|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior."
75377274|NCT05827796|Drug|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
75377275|NCT05827796|Drug|KN046|KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
75377276|NCT05827783|Procedure|Implementation of Bee Buzzy|"Implementation of Bee Buzzy It is defined as the use of a device called Bee Buzzy, which applies cold and vibrates in the form of a toy bee, by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this application, the researcher puts the Bee Buzzy device on the child's arm just above the area from which blood was taken, and remains attached to the arm during the phlebotomy procedure. This device applies cold and vibrates. Pain and fear during the procedure are evaluated by the researcher, the nurse, and the child's parent."
75377277|NCT05827783|Procedure|Implementation of Puppet Zuzu|"Implementation of puppet zuzu It is defined as the use of a puppet that is seized and made to talk by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this practice, a puppet is seized by the researcher and made to talk, and the child's attention is tried to be drawn. While this procedure is in progress, the researcher, the nurse, and the child's parent evaluate the pain and fear during the procedure."
75377278|NCT05827770|Drug|Toripalimab combined with Temozolomide|Toripalimab combined with Temozolomide
75377279|NCT05827731|Behavioral|cesarean section|According to the different outcomes of pregnancy, the patients were divided into natural delivery group and cesarean section group
75377280|NCT05827692|Behavioral|Intervention group A|The forest bath sessions will be led by a specialized guide and will be conceived as a silent walk of about 3 km along a path and forest track with an average gradient of 3%, with three 10-minute stops (at the beginning, in the middle and at the end) to practice deep breathing and awareness of the 5 senses.
75377281|NCT05827666|Dietary Supplement|2% milk beverage|Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.
75377282|NCT05827666|Dietary Supplement|Almond milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.
75377283|NCT05827666|Dietary Supplement|Soy milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.
75377284|NCT05827666|Dietary Supplement|Rice milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.
75377285|NCT05827640|Other|data recording using conventional ventilation strategies (PCV and VCV)|no intervention
75377286|NCT05827588|Device|AWAK PD|Daily 7- or 9-hour therapy (with or without a last fill) that is a form of automated peritoneal dialysis being done by subjects who are already on daily PD therapy
75866841|NCT03632694|Behavioral|Tech Support Only|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching."
75377287|NCT05827575|Device|Transcutaneous Auricular Vagal Nerve Stimulation|stimulation on both ear within different area for 4 weeks；parameter：2s on，3s off,0.5ms，25hz
75377288|NCT05827562|Diagnostic Test|flow cytometry|"Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~CD3+CD4-CD8αα+~CD3+CD4-CD8α+CD8βlow~CD3+CD4-CD8α+CD8βhigh~CD3+CD4+CD8αβhigh~CD3+CD4+CD8αα+"
75539270|NCT04719975|Other|Control (Documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial.
75866842|NCT04814550|Diagnostic Test|FFR|FFR measured by pressure wire, AccuFFRangio computed by coronary angiographic images
75539271|NCT00564616|Device|video cell phone|"the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone"
75539272|NCT00564655|Procedure|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
75539273|NCT00564655|Procedure|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
75866843|NCT03170674|Other|FT21039|an electronic cigarette product
75866844|NCT03170674|Other|FT21092|an electronic cigarette product
75866845|NCT03170674|Other|FT21018|an electronic cigarette product
76029258|NCT05846776|Device|DigiPrehab system|Using an Artificial Intelligence-Machine Learning (AI-ML) DSS platform, which analyzes a large collection of data (screening and local data) from different sources, the DigiPrehab system will allow to predict the risk of falling in the elderly subjects. Once the screening will be completed, to carry out the prevention of falls, the system will assign to the participants a personalised exercise program that the patient will carry out at home for 12 weeks. The exercises will be chosen from the following: squat at door, squat on chair, squat with knee-lift, squat with heel-raise, stand-no support, toe-raise with support, toe-raise, one leg balance, weight-shift with support, weight-shift without support, lunge with support, lunge, step on book, step over book, step onto box or stair, step forward-sideways, step forward-sideways-backwards, knee to elbow, timed up and go.
76029259|NCT05840666|Other|Mulligan Sustained Natural Apophyseal Glide (SNAG)|Application of the MWM technique developed by Brian R. Mulligan. The clinical researcher will perform and holds sustained passive segmental glide at the target joint maintaining the slack whereas the patient will actively move in the direction of pain or stiffness. These MWM techniques when applied to spinal segments or joint is called sustained natural apophyseal glide (SNAG).
75539274|NCT00564694|Procedure|psychosocial assessment and care|
75539275|NCT00564694|Procedure|quality-of-life assessment|
75539276|NCT04719546|Other|Observation of related perinatal factors|Data described in Primary outcome measures will be collected in both groups
75539277|NCT04607083|Diagnostic Test|Polyp carachterization by combing endoscopist evaluation and Ai output|A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.
75539278|NCT04606849|Other|Physician Survey|Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.
75866846|NCT03170596|Drug|tazarotene gel 0.1%|Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.
75866847|NCT03170596|Device|Microneedling|Microneedling is a method of percutaneous collagen induction
75377289|NCT05827510|Device|BTL-585F|BTL-585F device with BTL-585-4 applicator
75377290|NCT05827497|Drug|Baricitinib 2 MG|baricitinib 2 mg once daily
75377291|NCT05827497|Drug|Methotrexate 25mg|25mg daily
75377292|NCT05827471|Diagnostic Test|Diagnosis of colon cancer|Clinical diagnosis results
75377293|NCT05827393|Procedure|muscle transplantation|the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique
75377294|NCT05827380|Behavioral|Gait adaptability training|During a period of approximately 5 weeks participants will receive 10 one hour training sessions aimed at improving gait adaptability, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be offered.
75539279|NCT04606849|Device|ePNa-CheXED|ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in <1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
75377295|NCT05827315|Diagnostic Test|Echocardiography|Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
75539280|NCT01580722|Procedure|early reconstruction|patients underwent < 8 weeks reconstruction after injury
75377296|NCT05827315|Diagnostic Test|T1 Cardiovascular Magnetic Resonance|T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
75539281|NCT01580722|Procedure|delay reconstruction|patients underwent > 8 weeks reconstruction after injury
75539282|NCT04606810|Other|multidisciplinary educational intervention|At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
75539283|NCT04606888|Device|Transcutaneous electrical acupoint stimulation|According to the traditional Chinese medicine 15,three acupuncture points were selected as the target points: bilateral Neiguan ,Yintang and bilateral Zusanli.. A transcutaneous electrical stimulator was used to provide an altered frequency 2/100 Hz,disperse-dense waves,and adjusted intensity which was less than 10mA.
75539284|NCT04606537|Drug|Itraconazole|200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.
75866848|NCT03170752|Behavioral|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
75866849|NCT03173404|Procedure|Hysteroscopy|The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
75377297|NCT05827315|Diagnostic Test|Right heart catheterisation and coronary sinus blood sampling|10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
75377298|NCT05827263|Diagnostic Test|T-Scan occlusal recording No. I|Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
75539285|NCT04606537|Drug|Rifampin|600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.
75539286|NCT04606537|Drug|KBP-5074|0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21
75377299|NCT05827263|Device|Usage of the hydrostatic appliance|The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
75539287|NCT00248469|Behavioral|In-school Sexual Health Education|
75866850|NCT05194176|Device|Virtual Reality|For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
75377300|NCT05827263|Diagnostic Test|T-Scan occlusal recording No. II|The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
75866851|NCT03173638|Procedure|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
75866852|NCT03175354|Drug|ALX-101 Gel 1.5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
75377301|NCT05827250|Device|imPulse Tor|"The imPulse-Tor system passively collects audible sounds and inaudible vibrations spanning the infrasound-to-ultrasound frequency range, as well as cardiac electrical signals. The device can be safely placed directly on the chest wall to obtain readings.~imPulse System vibroacoustic recording (VAR) will be performed twice daily till discharge. An attempt will be made to have at least a 6+/-2 hr gap between the two recordings."
75377302|NCT05827120|Device|Mechanical / pharmacomechanical thrombectomy plus local catheter directed thrombolysis|"Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;~Mechanical thrombectomy: mechanical aspiration of fresh thrombus;~Pharmacomechanical thrombectomy (PMT): combination of mechanical disruption of the thrombus, and its aspiration, with simultaneous application of alteplase via dedicated catheter - instilation of acute/subacute thrombus with its subsequent aspiration;"
75413818|NCT04687969|Drug|[18F]DCFPyL|will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination
75413819|NCT04687969|Radiation|PET/MRI scanner|PET/MRI Scan with [18F]DCFPyL as directed by protocol
75539288|NCT00248469|Behavioral|Youth-friendly health services|
75539289|NCT00248469|Behavioral|Youth condom promotion & distribution|
75539290|NCT00248469|Behavioral|Community activities related to adolescent sexual health|
75539291|NCT04606654|Other|Handgrip strength training without Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.
75866853|NCT03175354|Drug|ALX-101 Gel 5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
75866854|NCT03173326|Procedure|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
75377303|NCT05827120|Device|Local catheter directed thrombolysis alone|- Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;
75377304|NCT05825846|Device|Virtual- reality active shooter drill|"The stress protocol used for this experiment utilized a previously studied virtual reality active shooter drill (VR-ASD). The VR-ASD scenario (~2 min) involves the participant physically walking down a ~10-foot-long virtual hallway where they will encounter wounded victims. Once at the threshold of to the attack room, they will observe one victim on the ground with a traumatic head injury and the shooter firing his handgun at the last victim, the participant will fire a shot, and the shooter will fall after being shot."
75377305|NCT05825495|Drug|Dinalbuphine sebacate|A single dose of 150 mg dinalbuphine sebacate will be intragluteally administrated at least 12 hours before surgery.
75377306|NCT05825495|Other|Routine practice|Within 3 days after surgery, paracoxib will be administrated twice a day. Ketorolac will intravenously give once breakthrough pain occurring. Enteral acetaminophen will be take regularly within 14 days after surgery.
75377307|NCT05825443|Drug|Camrelizumab|Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.
75377308|NCT05824169|Genetic|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
75377309|NCT05824104|Other|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
75377310|NCT05824052|Other|Ozone injection|Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.
75413820|NCT04679376|Drug|Atorvastatin|40 mg daily administered orally in tablet or capsule form
75866855|NCT03173326|Procedure|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
75866856|NCT02411968|Other|111In-Girentuximab DOTA SPECT|
76029260|NCT05840666|Other|McKenzie Method|An active therapy technique involving repeated movements or sustained positions along with an educational component prescribed to the patient for of minimizing the pain and disability and increase the spinal range of motion. The method will involve the assessment of symptomatic and mechanical responses to repeated movements and sustained positions in the direction of preference. The method will be used for assessment and treatment of patients and with derangement syndrome.
76029261|NCT05840666|Other|Conventional Physical Therapy|It includes usual physical therapy care such as Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises.
75413821|NCT04679376|Drug|Placebo|Administered daily orally in tablet or capsule form, contains no active medicine
75866857|NCT04481776|Other|Breakfast consumption|Standardised breakfast consumption across seven days
76029262|NCT05839184|Device|therapeutic toy|Neonates in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
75866858|NCT04481776|Other|Breakfast omission|No breakfast consumed across seven days
75866859|NCT03172858|Device|Intracervical balloon catheter|cervical ripening balloon
76029263|NCT05836792|Other|Cycle Ergometer|Patients will attend cycle ergometer exercise. Volunteers will monitor their pedaling forces as right and left force. They will try to make these forces equal while they are pedaling.
76029264|NCT05836792|Device|Transcutaneous electrical nerve stimulation|Transcutaneous electrical nerve stimulation will be used for the reduction of pain. TENS will be used 5 times in a week for 3 weeks. Each procedure will take 20 minutes.
76029265|NCT05836792|Device|Ultrasound|Ultrasound will be used for increase the permeability of cells to treat pain and inflammation. US will be used 5 times in a week for 3 weeks. Each procedure will take 5 minutes
76029266|NCT05836792|Other|Isometric exercises|The aim of the isometric exercises is increasing muscle strength. Each session patients will do quadriceps isometric exercises 5 times in a week for 3 weeks
76029267|NCT05835895|Genetic|GNSC-001|intra-articular injection
75413822|NCT04678999|Behavioral|Mind-body exercise and education|The intervention will delivered via a secure Zoom video platform.
75377311|NCT05824039|Dietary Supplement|Tea infusion|Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
75377312|NCT05823090|Device|light box (Carex DayLight Classic Model)|The active light box is a white fluorescent 4000 Kelvin unit that emits 10,000 lux and measures 33cm x 40cm. The placebo box emits 50 lux dim red light and appears identical to the active unit. Subjects were instructed to position themselves 30-36 cm from the box with their faces fully exposed to the light. The actigraphy device is a Phillips Spectrum Plus Actigraphy watch which collects activity level and sleep information along with multiple light measurements and wearer adherence.
75377313|NCT05822934|Drug|Carboplatin-Gemcitabine Cisplatin-Gemcitabine|Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer
75377314|NCT05821972|Drug|Nebulization of dexmedetomidine and ketamine|Pre-operative nebulization of dexmedetomidine and ketamine
75377315|NCT05821972|Drug|Nebulization of dexmedetomidine|Pre-operative nebulization of dexmedetomidine
75866860|NCT03172858|Drug|Oxytocin|medication used to induce contractions
75866861|NCT02403934|Device|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
75866862|NCT02403856|Drug|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
75866863|NCT02403856|Drug|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
75866864|NCT02403856|Procedure|Ultrasound-guided Needling and Lavage|
75866865|NCT03170284|Drug|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
75866866|NCT02411734|Behavioral|Rehabilitation|Rehabilitation after hospitalization
75866867|NCT02411890|Procedure|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
76029268|NCT05835895|Drug|transient immune-modulation|oral
75413823|NCT04677959|Drug|Fluticasone propionate/salmeterol (FS)|FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
75702827|NCT03640520|Device|FACETS: Pediatric Resuscitation|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
75702828|NCT03640520|Device|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
75702829|NCT03610646|Drug|MYL-1701P|"Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
76029269|NCT05835895|Drug|Placebo|intra-articular injection
76029270|NCT05834426|Diagnostic Test|Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)|For metabolomic analysis, different portions of the blood (plasma and lymphocytes) will be subjected to metabolite extraction by the extraction method defined by Glasgow Polyomics. With protein precipitation, 200 microliters (uL) of the fluid with the metabolites is transferred to a new microtube and must be maintained at -80 °C until the time of metabolomic analysis.
76029271|NCT05832411|Device|Endoangle|there is additional information presented to endoscopists:（1）the virtual stomach model monitoring；（2）time;（3）scoring.
76029272|NCT05831904|Device|whole-body vibration|After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
75377316|NCT05821764|Other|Blood sample and data collection|"Solicitation of parturients during a prenatal visit between 22 and 41 weeks of gestation or during their hospitalization in a high-risk pregnancy sector and at the latest on the day of their delivery.~Blood sample :~Maternal sample within 72 hours before or after delivery during a care-based venipuncture (additional 10 mL sample) ;~The cord blood sample (10 mL) immediately after delivery.~Data collection :~A data collection sheet for the attention of the investigator (doctor or midwife) ;~Additional data relating to the history of vaccination and infection completed by the patients included during their stay in the maternity ward and before their discharge from the hospital (Delay between 0 and 6 days after inclusion)."
75377317|NCT05816525|Procedure|Partial removal of carious tissue|Nonselective carious tissue excavation will be performed in the periphery of the cavity to achieve a good marginal seal. In the pulpal wall selective, partial carious tissue excavation is performed to the soft dentin, removing tissue only the amount that is necessary for placing the restoration. The tooth is restored with high-viscosity glass-ionomer cement.
75377318|NCT05816525|Procedure|Final restoration|The teeth will be restored with composite resin after 12 months follow up, if the tooth is asymptomatic, responds to sensibility tests and there are no periapical changes radiographically. Glass ionomer cement will be only partially removed to create space for the final restoration.
75377319|NCT05815446|Device|CT|NON CONTASR COMPUTED TOMOGRAPHY
75702830|NCT03610646|Drug|Eylea|"Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
75702831|NCT04075448|Other|Control|100 grams breakfast cereal
75702832|NCT04075448|Other|50 g Walnut|50 grams walnuts mixed with 50 gram breakfast cereal.
75702833|NCT00434161|Drug|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 & 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
75702834|NCT00434161|Drug|Placebo|"One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing."
75702835|NCT00434161|Drug|Palifermin before and after|"One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing."
75702836|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
75702837|NCT00441103|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
75702838|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
75702839|NCT01029613|Drug|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
75866868|NCT02411890|Procedure|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
75866869|NCT02411890|Procedure|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
75377320|NCT05812976|Other|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
75377321|NCT05812976|Other|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
75866870|NCT02411890|Procedure|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
75866871|NCT02407912|Drug|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
75377322|NCT05811598|Device|repeated ultra low lever red light|Myopia indoor lighting therapy
75702840|NCT03540212|Drug|Daclatasvir and sofosbuvir|"Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2."
75377323|NCT05807516|Other|Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)|Combined both retrospective and prospective observational design
75377324|NCT05803616|Diagnostic Test|Liquid biopsy|ctDNA measured in the plasma and analyse by next generation sequencing (NGS) for minimal residual disease (MRD)
75377325|NCT05794178|Behavioral|Education|Education about health benefits of physical activity, 2018 US Physical Activity Guidelines, assigned goals tailored to baseline step counts, and worksheet to develop action and coping plans (three of each)
75377326|NCT05794178|Behavioral|Activity tracker|Fitbit activity tracker and mobile app to provide ad libitum behavioral feedback and self-regulatory support
75377327|NCT05794178|Behavioral|Text messaging (random timing and selection)|Four text messages/day at random times within a participant's availability window and drawn at random from one of three content libraries (move more [40%], sit less [40%], inspirational quotes [20%])
75866872|NCT02411500|Drug|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
75377328|NCT05794178|Behavioral|Text messaging (precision dosing)|Up to four text messages/day within a participant's availability window, timed and selected from one of three content libraries (move more, sit less, inspirational quotes) based on a person-specific dynamic model and contextual data
75702841|NCT03268057|Drug|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
75702842|NCT03337100|Behavioral|Co-Dispensing|"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."
75866873|NCT03170128|Procedure|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
75866874|NCT03170128|Behavioral|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
75866875|NCT03170050|Device|YYD701-2|HA Filler
75866876|NCT03170050|Device|Restylane Perlane Lidocaine|HA Filler
75866877|NCT02407834|Other|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
75377329|NCT05787392|Behavioral|Chamas cha MamaToto program|Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.
76029273|NCT05830669|Procedure|Remote ischemic preconditioning (RIPC)|3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.
75377330|NCT05774236|Device|Cook´s balloon|Cervical ripening for induction of labor with a mechanical method (Cook´s balloon)
75377331|NCT05774236|Drug|Vaginal dinoprostone|Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
75702843|NCT01033903|Drug|misoprostol|800 micrograms intravaginally ONCE
75377332|NCT05764473|Other|The impact of MedDiet on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
75377333|NCT05764473|Other|The impact of UCLP on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
75377334|NCT05762068|Other|Delphi procedure|The study involves generating consensus statements by experts on airway management in critically ill patients on the definition and management of a physiologically difficult airway (PDA) using a Delphi process.
75377335|NCT05759468|Drug|Investigational Product - MIB 626|The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, >75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
75377336|NCT05759468|Drug|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
75377337|NCT05755698|Behavioral|Emotional Awareness and Expression Therapy|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
75377338|NCT05755269|Procedure|Biospecimen Collection|Undergo collection of blood samples
75377339|NCT05755269|Procedure|Genotyping|Undergo genotyping
75377340|NCT05755269|Other|Survey Administration|Complete surveys
75702844|NCT03331094|Procedure|Surgery with graft|arthrodesis with autologous bone graft and using pedicular ilio-sacred EUROS ® screw
75866878|NCT02407834|Other|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
76029274|NCT05830669|Procedure|Sham RIPC|3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
75377341|NCT05748587|Diagnostic Test|Serum Iron|Serum iron levels in study groups
75377342|NCT05748587|Diagnostic Test|RBCs Alpha-synuclein|α-syn levels in RBCs
75377343|NCT05748587|Diagnostic Test|Serum Soluble lymphocyte activation gene|sLAG-3 in the serum of study groups
75377344|NCT05748587|Radiation|Brain computed tomography|Brain CT of patients after admission
75702845|NCT03331094|Procedure|surgery without graft|arthrodesis without bone graft using pedicular ilio-sacred EUROS ® screw
75866879|NCT02407834|Other|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
75866880|NCT02407834|Other|S4|Immersion in Saline solution for 20 minutes, during 7 days.
75866881|NCT02407678|Genetic|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
76029275|NCT05825651|Other|no interventions|This is an observational study without any intervention.
76029276|NCT05824884|Behavioral|Visual Feedback|Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
75866882|NCT02411266|Other|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
75377345|NCT05748587|Diagnostic Test|Brain Iron|Iron in brain homogenate of rats
75377346|NCT05748587|Diagnostic Test|Brain Alpha-synuclein|α-syn expression in rat's brain
75377347|NCT05748587|Diagnostic Test|Brain lymphocyte activation gene|LAG-3 expression in rat's brain
75377348|NCT05748587|Drug|Deferoxamine|intramuscular deferoxamine (200 mg/kg) injection to rats
75377349|NCT05739019|Other|frozen embryo transfer|transfer one or two embryos in frozen embryo transfer cycles
75377350|NCT05728814|Drug|Dostarlimab|"The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles."
75377351|NCT05727241|Diagnostic Test|Ultrasound|The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.
75377352|NCT05710315|Drug|Relizorb|Relizorb cartridges will be used with routine enteral feedings for 5 days
75377353|NCT05710315|Other|Placebo|Placebo cartridges will be used with routine enteral feedings for 5 days
75377354|NCT05707468|Drug|ADT combined with abiraterone|The patients will receive long-term ADT combined with abiraterone.
75377355|NCT05707468|Radiation|neoadjuvant hormone and RT|The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
75377356|NCT05706389|Dietary Supplement|Ca-AKG|Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.
75377357|NCT05706324|Biological|Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation|0.2mL/dose, Inhalation using a nebulizer
75377358|NCT05703412|Behavioral|Transition-FOCUS mHealth Intervention|tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience
75377359|NCT05703412|Behavioral|Check-In|Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
75377360|NCT05698381|Dietary Supplement|Liquid vinegar|2 tablespoons consumed twice daily with meals
75377361|NCT05698381|Dietary Supplement|Vinegar pill|2 pills consumed upon waking
75377362|NCT05694611|Diagnostic Test|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
75377363|NCT05694611|Drug|Sulfur Hexafluoride|To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
75702846|NCT03329924|Other|Activity level measurement by accelerometer|Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
75866883|NCT02407522|Dietary Supplement|Black rice|They asked to keep their normal life style during intervention
75413824|NCT04677959|Drug|Albuterol|Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
75413825|NCT04677959|Drug|Standard of Care Asthma Medication|Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
75413826|NCT04677959|Drug|Standard of Care Rescue Medication|Current rescue medication
75413827|NCT04677946|Other|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 9g of linoleic acid) 1 per day for 8 weeks
75702847|NCT00433771|Device|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
75866884|NCT02407522|Other|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
75377364|NCT05689385|Other|eHealth-based cardiac rehabilitation|"The 12-wk case manager-led eHCR program includes:~Individualized exercise prescription according to the results of cardiopulmonary exercise test.~At least one session of in-person physical therapy to familiarize participants with the process of exercise training before the initiation of telerehabilitation.~Telerehabilitation: a 30-minute moderate aerobic exercise training with remote monitoring and instruction using video conferencing. (Frequency: twice per week in the first 4 weeks, once per week in the 5th-8th week, once every 2 weeks in the 9th-12th week)~Additional self-exercise to achieve the target volume of 150-minute moderate aerobic exercise and 2 sessions of resistance training per week.~Patient education for secondary prevention delivered regularly via a communication app on the smartphone.~Weekly follow-up call from a case manager via phone call or communication app."
75377365|NCT05686954|Other|CSO LOW|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.
75377366|NCT05686954|Other|CSO MID|Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.
75539292|NCT04606654|Other|Handgrip strength training with Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
75866885|NCT02411188|Behavioral|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
75377367|NCT05686954|Other|CSO HIGH|Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.
75377368|NCT05686954|Other|CONTROL|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
75866886|NCT03169738|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
75866887|NCT03169738|Biological|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
75866888|NCT03169738|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75866889|NCT03169738|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
75866890|NCT03169738|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75866891|NCT03169738|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
75866892|NCT03169738|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
76029277|NCT05824884|Behavioral|Self-efficacy enhancement:|specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).
76029278|NCT05824884|Behavioral|placebo intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
76029279|NCT05824884|Behavioral|No visual feedback|Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
75377369|NCT05683535|Drug|Atropine Sulfate|0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.
75539293|NCT04606147|Procedure|Serratus Anterior Plane Block|The block is performed with full aseptic precautions.in lateral position &arm abduction. US probe placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib.With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, the skin and subcutaneous tissue can be topicalized. Then, using ultrasound guidance, A regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib.Correct location of the needle tip in the fascial plane deep to serratus anterior muscle will be confirmed by injecting 0.5-1 ml normal saline and seeing hydrodissection of fascial plane between SAM and 5th rib. After aspiration to avoid intravascular injection 30 ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.
75539294|NCT04606147|Procedure|Erector spinae plane block|The block is performed with full aseptic precautions at T5 level. T5 transverse process is identified by us as flat, squared-off acoustic shadows with only a very faint image of the pleura.In longitudinal us view following layers will be visible superficial to transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle.Skin is topicalised , then echogenic block needle inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% was injected and separation was seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm was used
75539295|NCT00251823|Drug|Eptifibatide facilitated PCI|
75539296|NCT04606225|Drug|Losartan|administration of losartan (50 mg) (oral) Cozaar Oral Tablet
75377370|NCT05678244|Drug|Acetaminophen|IV acetaminophen will be added to standard of care opioid based pain regimes.
75539297|NCT04606225|Drug|Placebo Oral Tablet|administration of placebo (oral)
75377371|NCT05678244|Drug|Placebo|In control group placebo will be added to standard of care opioid based pain regimes.
76029280|NCT05824546|Procedure|Intervention Arm (uSINE-PAMS technique):|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
75377372|NCT05677074|Dietary Supplement|Fish oil|The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
75377373|NCT05677074|Dietary Supplement|Cod oil|The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
75377374|NCT05677074|Dietary Supplement|Krill oil|The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).
76029281|NCT05824546|Procedure|Control Arm (traditional landmark-based technique):|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be similarly identified by palpation of external landmarks of iliac crests and spinous process of lumbar vertebrae L3, L4 and L5. Markings on the patients' skin surface will be made with a washable marker or any other methods according to the operator's preference to enable relocation of the site of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted into marked entry site.
75377375|NCT05675800|Drug|Psilocybin|Psilocybin administered with psychological support
75377376|NCT05675319|Drug|Allogeneic Stem Cells|Allogeneic Stem Cell Transplantation
76029282|NCT05823896|Drug|Nirmatrelvir/ritonavir|300/100 mg tablet twice daily (q12h) administered orally for 15 days
76029283|NCT05823896|Drug|Placebo/ritonavir|100mg tablet twice daily (q12h) administered orally for 15 days
76029284|NCT05822154|Other|comprehensive geriatric assessment|The clinical, biological and functional characteristics will be collected in elderly subjects attending the hospitals of participating centers.
75377377|NCT05675319|Drug|carfilzomib/lenalidomide/dexamethasone (KRD)|triple regimen for first relapse should be applied according to latest Summary of Product Characteristics (SmPC) version
75377378|NCT05675319|Drug|elotuzumab/lenalidomide/dexamethasone (ERD)|triple regimen for first relapse should be applied according to latest SmPC version
75377379|NCT05675319|Drug|daratumumab/bortezomib/dexamethasone (DVD)|triple regimen for first relapse should be applied according to latest SmPC version
75377380|NCT05675319|Drug|daratumumab/lenalidomide/dexamethasone (DRD)|triple regimen for first relapse should be applied according to latest SmPC version
75377381|NCT05675319|Drug|ixazomib/lenalidomide/dexamethasone (IRD)|triple regimen for first relapse should be applied according to latest SmPC version
75377382|NCT05675319|Drug|pomalidomide/bortezomib/dexamethasone (PVD)|triple regimen for first relapse should be applied according to latest SmPC version
75377383|NCT05675319|Drug|carfilzomib/daratumumab/dexamethasone (KDD)|triple regimen for first relapse should be applied according to latest SmPC version
75377384|NCT05675319|Drug|Autologous Stem Cells|Autologous Stem Cell Transplantation
75377385|NCT05666804|Drug|Brolucizumab 6mg|Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T&E) regimen up to Week 56
75377386|NCT05666804|Drug|Brolucizumab 6mg|Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
75377387|NCT05650580|Drug|TR115|TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
75377388|NCT05649345|Drug|TR64|TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
75377389|NCT05649332|Device|Argogen|Spray in short intervals, lightly pressing the dispenser button and pointing the spray on the area to be treated.
75377390|NCT05648812|Diagnostic Test|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
75377391|NCT05648812|Drug|Sulfur Hexafluoride|To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
75539298|NCT05528549|Other|Exercise|The investigators are looking at how blood flow and blood pressure are regulated in individuals with Down syndrome, who have a reduced ability to do work. This study will compare individuals with Down syndrome to a control group without Down syndrome.
75539299|NCT04606108|Drug|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with Liposome doxorubicin and Ifosfamide
75866893|NCT03169738|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
75539300|NCT04719507|Procedure|erector spinae block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.
76029285|NCT05821413|Behavioral|Data to care|Participants meet with a case manager who asks about health, basic needs such as housing and finances, and relationships and support systems. A score is assigned that reflects how much support is needed. A care plan is developed to address areas of need. The case manager meets regularly with participants to determine if needs are being met and identify strategies for meeting those needs. Participants with higher scores will receive more intensive contact with case managers, typically every month, until their level of need goes down. All participants will have their level and types of needs reassessed to determine if they need additional support or are moving toward self-management. Participants work with case managers for 6 months.
75866894|NCT03169738|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
76029286|NCT05821413|Behavioral|Standard of Care|Participants can use standard case management and other services offered by the clinic.
76029287|NCT05821088|Procedure|Biopsy|Undergo tissue biopsy
76029288|NCT05821088|Procedure|Biospecimen Collection|Undergo blood sample collection
75377392|NCT05648695|Device|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
75377393|NCT05648695|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
75866895|NCT03169738|Biological|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
75866896|NCT03169738|Drug|Lovaza|Omega-3-acid ethyl esters
75866897|NCT03169738|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
75866898|NCT03169738|Radiation|Stereotactic Body Radiation Therapy|(SRBT)
75866899|NCT03169738|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL15N72D:IL-15RαSu/IgG1 Fc complex]
75866900|NCT03169738|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
75866901|NCT03169738|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
75866902|NCT03169738|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
75866903|NCT03169738|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
75866904|NCT03169738|Biological|GI-4000|Ras yeast vaccine
75866905|NCT03169738|Biological|GI-6207|CEA yeast vaccine
75866906|NCT03169738|Biological|GI-6301|Brachyury yeast vaccine
76029289|NCT05821088|Drug|Carboplatin|Given IV
76029290|NCT05821088|Procedure|Computed Tomography|Undergo CT
76029291|NCT05821088|Drug|Etoposide|Given IV
76029292|NCT05821088|Drug|Ifosfamide|Given IV
76029293|NCT05821088|Drug|Lenalidomide|Given PO
75866907|NCT03169738|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
75377394|NCT05644080|Radiation|177Lu-PSMA I&T|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
75377395|NCT05641376|Drug|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. Treatment will be stopped when the nebulizer began to sputter. At end of nebulizer administration, they will be observed for 30 min before induction of general anaesthesia. then the children will be transferred to the operation room and will receive intravenous (IV) normal saline 0.9% in 10 ml volume over 10 minutes after anesthesia induction.
75377396|NCT05641376|Drug|Intravenous Dexmedetomidine|Children will receive nebulized 3 ml of 0.9% normal saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. then the children will be transferred to the operation room and will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
75377397|NCT05634356|Behavioral|vocal-social reinforcement|experimental manipulation of social reinforcement in response to vocalizations
75377398|NCT05628766|Other|complete blood count|Thiol/disulphide levels in the blood will be checked by taking complete blood count
75539301|NCT04719507|Procedure|thoracic paravertebral block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.
75377399|NCT05622734|Behavioral|VOCALE LBD+|Intervention employs a web-based platform that allows participants to engage asynchronously in an eight-week online intervention involving didactic training, peer-to-peer support, and moderated problem-solving skill enactment.
75377400|NCT05615805|Other|OSDI questionnaire|Ocular Surface Disease Index
75539302|NCT04719507|Drug|Pethidine Only Product in Parenteral Dose Form|pethidine (1 mg/kg ) once
76029294|NCT05821088|Procedure|Positron Emission Tomography|Undergo PET
75377401|NCT05615805|Other|SPEEDII questionnaire|Standardized Patient Evaluation of Eye Dryness II questionnaire
75377402|NCT05615311|Dietary Supplement|Vitamin D supplementation|Study participants assigned to the intervention group will receive 800 IU/ day of vitamin D plus 200-300 IU/day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
75539303|NCT04605757|Other|Clinical, functional and radiological lung involvement evolution|Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
75866908|NCT02407600|Drug|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
75866909|NCT02407600|Drug|Placebo|
75866910|NCT02403544|Radiation|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
75866911|NCT02403544|Drug|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
75866912|NCT02403544|Drug|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
75866913|NCT02411032|Behavioral|Reminder|Customer gets mailing that reminds them to take their medication.
76029295|NCT05821088|Biological|Tafasitamab|Given IV
76029296|NCT05807750|Other|Post-discharge income supplement|$300 income supplement
76029297|NCT05807750|Other|Enhanced care planning|Enhanced care planning provided by a nurse care manager
76029298|NCT05807529|Drug|2ccPA|"2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
76029299|NCT05807529|Drug|Placebo|"Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
76029300|NCT05802966|Behavioral|Mindfulness-Based Cognitive Therapy|MBCT will be offered according to the MBCT manual developed for relapse prevention in MDD (Zindel V. Segal, Williams, & Teasdale, 2002). Thus, MBCT will consist of 8-weekly sessions of 2,5 hours, a 6-hour silent day, and daily home practice (± 45min). MBCT will be taught by a certified MBCT teacher meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (Belgium) which are in concordance with the Good Practice guidelines of the UK Network of Mindfulness-Based Teacher Trainers (Crane et al., 2012).
76029301|NCT05802654|Radiation|SBRT|The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
76029302|NCT05795699|Drug|Ripasudil|K-321 ophthalmic solution
76029303|NCT05795699|Drug|Placebo|Placebo ophthalmic solution
75539304|NCT04605835|Diagnostic Test|ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.|The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
75539305|NCT04605952|Diagnostic Test|Repeat SARS-CoV-2 IgG antibodies at 45-65 days|All cases who initially tested positive for SARS-CoV-2 IgG antibodies would undergo a repeat test at 45-65 days
75539306|NCT04605640|Behavioral|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
75539307|NCT04605562|Drug|GP+DDP|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
75702848|NCT03281954|Drug|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
75702849|NCT03281954|Drug|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
75702850|NCT03922256|Other|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
75702851|NCT00433537|Drug|bortezomib|Given IV
75702852|NCT00433537|Biological|rituximab|Given IV
75702853|NCT00433537|Drug|cyclophosphamide|Given IV
75539308|NCT04605562|Drug|Palbociclib|Administered orally
75539309|NCT04605562|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
75539310|NCT04605562|Drug|PD-1 blocking antibody|Administered every 3 weeks
75539311|NCT04605562|Drug|Galunisertib|Administered orally
75702854|NCT00433537|Drug|doxorubicin hydrochloride|Given IV
75702855|NCT00433537|Drug|vincristine|Given IV
75702856|NCT00433537|Drug|dexamethasone|Given IV
75702857|NCT00433537|Biological|filgrastim|Given SC
75702858|NCT00433537|Biological|pegfilgrastim|Given SC
75702859|NCT00433537|Procedure|Autologous stem cell transplantation (ASCT)|
75702860|NCT03935282|Other|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
75702861|NCT02580110|Other|Sucrose|
75377403|NCT05615311|Other|No additional vitamin D supplementation|Study participants assigned to the control group will receive 200-300 IU/ day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
75377404|NCT05607615|Drug|Hydroxypropyl Beta Cyclodextrin|Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
75377405|NCT05607615|Drug|Placebo|0.5N saline as an intravenous (IV) infusion once every 28 days
75539312|NCT00248586|Behavioral|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
76029304|NCT05795439|Behavioral|Low-fat, vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
76029305|NCT05794581|Drug|CT-868|CT-868
76029306|NCT05794581|Drug|Placebo|Placebo as SC Injection
76029307|NCT05794581|Drug|Victoza|Victoza as active comparator as SC Injection
75866914|NCT02411032|Behavioral|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
75702862|NCT02580110|Other|Stevia glycosides|
75866915|NCT02411032|Behavioral|Fresh start framing|The fresh start event will be highlighted in the mailings.
75377406|NCT05597683|Procedure|Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)|"Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs,nefopam, and rescue opioids~Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs, nefopam, and rescue opioids"
75413828|NCT04677920|Other|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 10g of grapeseed oil) 1 per day for 2 weeks
75702863|NCT02580110|Other|saccharin|
75702864|NCT00570765|Drug|Placebo|Matching placebo tablets were administered orally once daily.
75866916|NCT02411344|Drug|Pertuzumab|"Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."
75866917|NCT02407444|Other|Physiotherapy treatment & leg cycling|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale."
75866918|NCT02407444|Other|Physiotherapy treatment & music listening|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes."
75866919|NCT03657095|Drug|Esuberaprost|Sodium tablets
75413829|NCT04671043|Dietary Supplement|Caffeine and glucose|Caffeine and glucose powder dissolved in water
75702865|NCT00570765|Drug|Obeticholic Acid (OCA)|Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
75702866|NCT00777621|Other|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
75702867|NCT00777621|Other|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
75866920|NCT03657095|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
75866921|NCT03100344|Drug|Nemolizumab|Injection every 4 weeks during 24 weeks (last injection at week 20)
76029308|NCT05794438|Behavioral|Static Approach Bias Modification|In the static approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc).
75413830|NCT04671043|Dietary Supplement|Glucose alone|Glucose powder dissolved in water
75866922|NCT03100344|Drug|Placebo|Injection every 4 weeks during 24 weeks (last injection at week 20)
76029309|NCT05794438|Behavioral|Adaptive Approach Bias Modification|In the adaptive approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc). An algorithm continuously monitors the performance of the user and adjusts the ratio of congruent and incongruent trials accordingly to attain a desired difficulty curve.
76029310|NCT05791318|Drug|VYD222|Monoclonal antibody
76029311|NCT05791318|Other|Placebo|Matching Placebo
76029312|NCT05790915|Combination Product|Standardized interventions|Standardized interventions according organ dysfunction
76029313|NCT05785949|Procedure|Microfracture|Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5~7 mm.
75702868|NCT00777621|Other|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
75377407|NCT05593939|Behavioral|Exercise|Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., ~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., ~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
75702869|NCT00777699|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
75702870|NCT00777699|Drug|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
75866923|NCT02403700|Device|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
76029314|NCT05785949|Device|Chondro-Gide bilayer collagen membrane|After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
76029315|NCT05785390|Drug|NP-101|NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
76029316|NCT05785390|Other|Placebo|Identical placebo
76029317|NCT05776498|Procedure|immediate implant placement with particulate bone graft using the dual zone technique.|Tooth extraction and immediate implant placement as mentioned, then particulate bone graft will be packed in the gap between the implant and the buccal plate of bone and the tissue (dual zone), then will be covered by a customized healing abutment.
75413831|NCT04671043|Dietary Supplement|Placebo|Artificial sweetener dissolved in water
75413832|NCT04656899|Behavioral|Reminders messages to improve adherence.|"If the participant does not take their medicine at the correct time, a light on the smart pill cap begins to flash. If the bottle is not opened within 20 minutes, the Pillsy application sends an SMS text reminder to the participant's phone. If the bottle is not opened within 60 minutes, the participant receives an automated phone call. The participant may also receive brief motivational phrases or craving surveys that can be tailored to participant needs and preferences. Also, based on pre-populated and adjustable craving and withdrawal levels, the participants' provider could be contacted automatically based on the thresholds being crossed. Pillsy also includes a Pillsy Helpers feature in which the patient can name friends and family members who will also receive a text message notification one hour after a missed dose."
75702871|NCT00667563|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
75702872|NCT00667563|Genetic|DNA analysis|Weeks 0, 2, 10, 26, and 52.
75702873|NCT00667563|Genetic|polymerase chain reaction|Screening, week 36, and week 52.
75702874|NCT00667563|Other|cytology specimen collection procedure|Screening, week 36, and week 52.
75702875|NCT00667563|Procedure|colposcopic biopsy|Screening, week 36, and week 52.
76029318|NCT05776498|Procedure|immediate implant placement with connective tissue grafting|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supraperiosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
76029319|NCT05770518|Behavioral|Biofeedback|Biofeedback is a strategy used in the treatment of PVFM, which involves allowing patients to directly visualize their breathing patterns during laryngoscopy.
76029320|NCT05770518|Behavioral|Laryngeal control therapy (LCT)|This treatment typically involves 2 guided therapy sessions that include patient education, relaxation techniques, and training in specific breathing techniques.
75539313|NCT00248586|Behavioral|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
75702876|NCT00777777|Device|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
75866924|NCT02407366|Drug|Icotinib|Icotinib (125 mg ,Three times daily)
76029321|NCT05769517|Diagnostic Test|Germinal BRCA|We will conduct a multicenter prospective observational study aimed at automatically implementing the predictive model and collecting US images of healthy ovaries from patients tested for germline BRCA pathogenetic variants according to current indications.
76029322|NCT05767944|Other|local anaesthesia infiltration|Infiltration of 150 mg of lidocaine solution per ray at site of surgical incision for flexor tendon repair in the palm, the 2 proximal & distal phalanges
76029323|NCT05767944|Other|brachial plexus block|ultrasound-guided infiltration of local aesthetics around brachial plexus trunks & divisions
76029324|NCT05766787|Device|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
76029325|NCT05766787|Device|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
76029326|NCT05766787|Device|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
76029327|NCT05765253|Device|Scorpion Portal Vein Access Kit|Portal Vein Access with Scorpion or Scorpion X set
76029328|NCT05765253|Device|Cook Transjugular Liver Access Set|Portal Vein Access with Ring or Rosch-Uchida set
76029329|NCT05765253|Procedure|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Transjugular Intrahepatic Portosystemic Shunt (TIPS)
75377408|NCT05593939|Behavioral|Time restricted feeding|Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
75539314|NCT00402857|Behavioral|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
76029330|NCT05764135|Behavioral|SCI-Lynx Mobile Application|. The SCI-Lynx application will enable people to find others with the same chronic condition who have similar exercise interests and goals. Individuals can make social connections, set, and track their exercise goals and support one another in their physical activities. It provides content customized for each condition to encourage participant's belief in the benefits of exercise and improve their self-efficacy for exercise through tracking of their own progress. An additional feature of SCI-Lynx is the ability to direct messages to other individuals or create subgroups within their network providing a further social support for individuals with SCI.
76029331|NCT05754190|Device|SOMA pain manager smartphone application|SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
76029332|NCT05753839|Procedure|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
76029333|NCT05753839|Procedure|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
76029334|NCT05753839|Other|Human-derived materials sampling|Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.
75377409|NCT05593939|Dietary Supplement|Nicotinamide riboside|Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
75377410|NCT05577845|Drug|Ramosetron|Ramosetron, 4 weeks
76029335|NCT05753085|Device|Conavi Medical Novasight Hybrid System intervention|Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
75377411|NCT05540847|Procedure|Interfascial Injection|Interfascial Injection on Ultrasound-guided Obturator Nerve Block
75377412|NCT05540847|Procedure|Subpectineal Injection|Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
75413833|NCT04645342|Device|Baylis Versacross RF wire|Baylis Versacross radiofrequency wire is used for transseptal puncture during cardiac ablation procedure.
75413834|NCT04645342|Device|Baylis RF needle|Baylis radiofrequency needle is used for transseptal puncture during cardiac ablation procedure.
75413835|NCT04642586|Diagnostic Test|multimodal magnetic resonance imaging|Brain MRI exam (without contrast injection)
75413836|NCT04642586|Diagnostic Test|blood test|Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .
75413837|NCT04642586|Diagnostic Test|neuropsychological assessment|neuropsychological assessment
75539315|NCT04605523|Procedure|blood withdrawal|Additional blood sample will be taken within blood collection as part of standard care
75702877|NCT00780819|Device|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
75413838|NCT04639297|Device|NeuroVision® IONM|Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
75413839|NCT04639297|Device|Hospital Based IONM|Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
75413840|NCT04637035|Other|Supportive Oncology Care at Home|Intervention entailing remote monitoring of patients' symptoms, vital signs, and body weight with home-based care.
75539316|NCT04605601|Other|Virtual reality treatment|Tennis, boxing, and baseball games of the Wii Sports package sre used for activating the upper extremity functions of the patients. In the tennis game, patients represent people holding rackets.
75539317|NCT04605601|Other|conventional physiotherapy|As the conventional physiotherapy, neuromuscular electrical stimulation and strengthening exercises for the deltoid, infraspinatus, triceps, biceps, supinator, and wrist extensor muscles, and passive, active, active assistive joint Rage of Motion, and stretching exercises for the shoulder, elbow and wrist joints are applied to the patients in the standardized program for the upper extremity in 10 repetitions.
75702878|NCT05118477|Device|Ambulatory monitoring system|Patients will use AMS.
75702879|NCT05118477|Device|Active alerting system|Clinical staff alerted if AMS detects deterioration
75702880|NCT00667095|Drug|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
75413841|NCT04633590|Behavioral|Home-based exergaming|Participants will undertake one of two 6-week training interventions. In both groups participants will be asked to train 3 times per week (18 sessions total), during which adherence to the training will be measured. To monitor adherence to training and training load (exercise completion, exercise duration and heart rate achieved during workouts) throughout the 6 weeks participants will be given a heart rate monitor.
75702881|NCT00667095|Drug|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
75702882|NCT00777933|Drug|tacrolimus|
75702883|NCT00777933|Drug|cyclosporine|
75413842|NCT04618198|Other|Immediate anti-TB therapy|Study participants will receive immediate empiric anti-TB therapy
75413843|NCT04618198|Other|Sepsis-specific dose anti-TB therapy|Study participants will receive conventional WHO weight-based dose anti-TB therapy
75702884|NCT00773331|Drug|epoetin beta|As prescribed
76029336|NCT05751265|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
75377413|NCT05527912|Drug|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy|"All subjects received two courses of the following treatment:~Rituximab ，375mg/m²， D1； Chidamiade ，20mg ，biw， d1-14； Zanubrutinib ，160mg， bid， d1-21；~three weeks for a period of treatment, all subjects complete tumor assessment after two courses of treatment, patients which achieve complete remission continue for up to 8 sessions, patients achieve partial response and stable disease combined use of the following CHOP threapy to 6 courses, Patients with progressive disease dropped out of this research.~CHOP Therapy:~Cyclophosphamide， 750mg/m² ，D1； Vincristine， 1.4mg/m² ，D1 (maximum：2mg)； Doxorubicin or pirarubicin， 50mg/m²， D1； Prednisone ，30mg ，tid， D1-5."
75377414|NCT05502588|Behavioral|Self-Guided Forest Bathing|Participants will participate in two, 60-90 minute self-guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails and be given prompts to consciously use their five senses in the forest.
75377415|NCT05502588|Behavioral|Guided Forest Bathing|Participants will participate in two, 60-90 minute guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails. They will be invited by a certified forest therapy guide to consciously use their five senses in the forest.
75377416|NCT05496920|Diagnostic Test|FD-PET/CT|Standard of care PET/CT with full dose (FD) of the radiopharmaceutical
75377417|NCT05496920|Diagnostic Test|LD-PET/CT|Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
75377418|NCT05492786|Behavioral|Alert|Non-interruptive best practice alert in the electronic health record
75377419|NCT05492786|Behavioral|Salient alert features|Larger alert header and body font size, use of different font colors and boldface
75377420|NCT05492786|Behavioral|High-risk Text|Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)
75377421|NCT05492786|Behavioral|Risk factors|Alert body indicates the top 3 factors contributing to the high risk
76029337|NCT05751265|Drug|5Fu|Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w
76029338|NCT05751265|Drug|Paclitaxel injection|Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
76029339|NCT05746988|Other|Mouthwash gargling|15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.
75377422|NCT05492045|Drug|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
75377423|NCT05492045|Drug|Other|Standard treatment of NSCLC.
75377424|NCT05491187|Drug|0.5% bupivacaine heavy|Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
75866925|NCT02407366|Drug|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
75377425|NCT05491187|Drug|0.5% bupivacaine heavy with fentanyl|Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
75377426|NCT05480878|Drug|Placebo|Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
75377427|NCT05480878|Drug|Nitazoxanide 500Mg Oral Tablet|All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
75377428|NCT05480878|Drug|Escitalopram 10mg|All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
75377429|NCT05463289|Diagnostic Test|Point of Care Autonomous AI diabetic retinopathy exam|Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.
76029340|NCT05744687|Drug|SPH4336 Tablets 400mg|"SPH4336 Tablets ：Orally, 400mg once a day; 28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
75377430|NCT05462236|Drug|AUM001|MNK inhibitor
75377431|NCT05462236|Drug|Pembrolizumab|PD-1 Inhibitor
75866926|NCT02407366|Drug|Carboplatin|Carboplatin (AUC，5) every 21 days
75866927|NCT02407366|Radiation|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
75866928|NCT03738137|Device|Narotrend|Narcotrend motoring
76029341|NCT05744687|Drug|SPH4336 Tablets Placebo|"SPH4336 Tablets Placebo：Orally,28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
75377432|NCT05462236|Drug|Irinotecan|Topoisomerase inhibitor
75377433|NCT05461222|Device|"Balt Goldballoon"|"Fetal endoscopic tracheal occlusion (FETO) is a procedure where a balloon is placed in the main airway or windpipe of the fetus, to help with the development of the lungs. This is performed using a fetoscope, a small camera that is inserted into the amniotic cavity and deploying the FETO Goldballoon into the fetal trachea."
75377434|NCT05448963|Device|da Vinci SPⓇ Single-port System|Nipple-sparing mastectomy with or without axillary lymph node dissection using da Vinci SP single-port system
75702885|NCT00773331|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks
75866929|NCT03738137|Device|BIS|Bispectral index monitoring
75866930|NCT03738137|Drug|Sufentanil|sufentanil is applied.
75866931|NCT03738137|Drug|Lidocaine|Topical Anesthesia
75866932|NCT03738137|Drug|Midazolam|midazolam is applied.
75866933|NCT02410876|Procedure|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
75866934|NCT02410876|Procedure|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
76029342|NCT05743413|Procedure|Armeo Spring physiotherapy|Study subjects will undergo physiotherapy sessions using the Armeo Spring device.
76029343|NCT05743413|Procedure|Standard physiotherapy|Study subjects will undergo standard physiotherapy sessions.
75377435|NCT05430906|Drug|AK104 - Chemotherapy|AK104 10mg/kg then [paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)] and [carboplatin (AUC5 or 6) or cisplatin (75mg/m²)] of each 21-day cycle
75377436|NCT05429242|Other|Ultrasonographic examination|Measurement of placental volume at the first trimester of pregnancy by using ultrasound.
75377437|NCT05419986|Genetic|Blood collection|Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy
75702886|NCT00778011|Drug|Ondansetron|dosage
75377438|NCT05414331|Other|Discontinuing all beta-blocker|All beta-blockers will be stopped 2 months after CABG
75377439|NCT05404256|Other|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface
75377440|NCT05404256|Other|Radical gastrectomy +D2 lymphadenectomy|Radical gastrectomy +D2 lymphadenectomy
75377441|NCT05403567|Other|Bootle Blast Home Intervention|Children will play BB at home for 8 continuous weeks. Participants will be asked to stop playing at the end of week 8 and the game will be programmatically locked to prevent further play until the post-intervention interviews and assessments are complete.
75377442|NCT05398367|Dietary Supplement|Galactagogue Supplement for Treatment of Low Milk Supply|Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply
75377443|NCT05396378|Dietary Supplement|Oral glucose in liquid form|A glucose containing drink that has a fixed dose of 25 g of glucose per can.
75377444|NCT05383716|Drug|Pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
75377445|NCT05380570|Radiation|Occupational radiation exposure|Ionizing radiation in workplaces
75702887|NCT00778011|Drug|Ondansetron|4 mg
75377446|NCT05378945|Drug|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
75377447|NCT05378945|Drug|Placebo (vehicle)|Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
75702888|NCT00778011|Drug|Metoclopramide|10 mg IV
75702889|NCT02556021|Drug|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
75866935|NCT03737279|Behavioral|Meditation|Routine care + twice daily meditation per schedule, to start on the day of randomization
75377448|NCT05376644|Drug|99mTc-ADAPT6|One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
75377449|NCT05376644|Drug|99mTc-DARPinG3|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
75377450|NCT05362877|Device|Earplug|Using earplugs to reduce the symptoms of temporomandibular disorder
75702890|NCT02556021|Drug|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
75702891|NCT02556021|Drug|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
75702892|NCT00778089|Device|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
75702893|NCT00773487|Other|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
75702894|NCT00433381|Biological|Bevacizumab|Given IV
75702895|NCT00433381|Drug|Irinotecan Hydrochloride|Given IV
75702896|NCT00433381|Drug|Temozolomide|Given orally
75866936|NCT03737279|Behavioral|Routine Care|"Routine care including ACOG educational pamphlets:~Day 1: Nutrition in Pregnancy~Day 2: Heart Health for Women~Day 3: Exercise after Pregnancy"
75377451|NCT05362877|Device|occlusal splint|Using occlusal splints to reduce the symptoms of temporomandibular disorder
75377452|NCT05362877|Other|exercise|Applying exercise to reduce the symptoms of temporomandibular disorder
75377453|NCT05357638|Behavioral|High Intensity Interval Training (HIIT)|8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer
75377454|NCT05357638|Behavioral|Continuous Aerobic Training (CAT)|8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer
75377455|NCT05357638|Behavioral|Movement Advice|Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention
75377456|NCT05352724|Dietary Supplement|Hydration drink|Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice
75377457|NCT05347966|Other|Brain Health PRO|BHPro is a 45-week, multidomain web-based formal educational program which has been designed to increase dementia literacy, convey best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health.
75377458|NCT05345314|Procedure|Narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
75377459|NCT05334732|Behavioral|SIS TALK Back Intervention|The participants in this arm will be seen by a trained survivor coach and receive culturally tailored intervention materials.
75377460|NCT05333835|Drug|HR17031 injection|HR17031 injection
75377461|NCT05333835|Drug|INS068 injection|INS068 injection
75377462|NCT05333835|Drug|SHR20004 injection|SHR20004 injection
75377463|NCT05330377|Drug|Gilteritinib 40 MG Oral Tablet|Gilteritinib is an oral FLT3 inhibitor, and is active against both FLT3-ITD and FLT3-TKD mutations. Gilteritinib will be given orally according to the assigned phase I dose cohort starting day 6 until day 19. Participants will be given the daily dose with water as at the same time each morning. Gilteritinib should be taken at least 2 hours after or 1 hour before consuming food.
75702897|NCT00781053|Drug|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
75702898|NCT00773565|Dietary Supplement|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
75702899|NCT00667017|Biological|RFT5-dgA immunotoxin|
75702900|NCT00667017|Other|fluorescence activated cell sorting|
75702901|NCT00667017|Other|immunohistochemistry staining method|
75377464|NCT05330377|Drug|Cladribine|Cladribine is given intravenously at a dose of 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5.
75702902|NCT00781131|Drug|Pregabalin|pregabalin 75 or 150 mg
75702903|NCT00781131|Drug|Placebo|lactulose placebo
75377465|NCT05330377|Drug|Cytarabine|Cytarabine is given intravenously at a dose of 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.
75377466|NCT05330377|Drug|Filgrastim|Filgrastim (GCSF) or biosimilar, will be given at a dose of 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.
75377467|NCT05330377|Drug|Mitoxantrone|Mitoxantrone is given intravenously at a dose of 10 mg/m2 I.V. over 2 hours once per day on days 1 to 3.
75377468|NCT05326087|Drug|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
75377469|NCT05326087|Drug|MPA|oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
75377470|NCT05323435|Biological|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
75377471|NCT05323435|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|Milky-white suspension.Stratified precipitate may form which can be dispersed by shaking
75377472|NCT05322252|Drug|Mifepristone|200mg orally
75377473|NCT05322252|Drug|Misoprostol|Per clinician
75377474|NCT05318820|Drug|HMPL-523|This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test [T]/Reference[R]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product [i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
75377475|NCT05311917|Other|home vision therapy|a group of vision therapy procedures in home to improve convergence insufficiency
75377476|NCT05311917|Other|base in prism prescription|base in prism prescription according to sheards criterion
75377477|NCT05311917|Other|conventional placebo|using near glasses with aimless eye training
75377478|NCT05293912|Drug|SG2501|During study treatment, subjects will receive SG2501 treatment via IV infusion once every week at doses of: 0.01, 0.03, 0.1, 0.3, 1, 2, 4 and 6mg/kg.
75377479|NCT05259423|Other|Enriched Education Program|Enriched play activity education including 9 different activities each with 3 levels depending on the infant's current head and trunk control. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
75413844|NCT04617925|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose
75702904|NCT00778245|Drug|cefprozil 500mg tablets|
75702905|NCT00778323|Procedure|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
75702906|NCT00778401|Drug|Gabapentin tablets 800 mg|
75702907|NCT00773643|Other|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
75866937|NCT02407210|Drug|azilsartan|
75866938|NCT02407210|Drug|Olmesartan medoxomil|
75866939|NCT03737201|Other|ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
75866940|NCT03737201|Other|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
75866941|NCT03737201|Other|Control|without any cavity disinfectant
75866942|NCT02951533|Drug|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.
75866943|NCT02951533|Drug|Fumaric Acid Esters|Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.
76029344|NCT05742711|Device|Primary Relief|Continuous neurostimulation with a set of pre-assigned stimulation parameters.
76029345|NCT05742711|Device|Primary Relief - Sham Device|Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
76029346|NCT05738252|Diagnostic Test|Clinical Frailty Scale|A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
75377480|NCT05259423|Other|Typical Education Program|Typical play activity education including 9 activities commonly described by popular parenting websites, mobile applications, and books. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
75377481|NCT05251272|Diagnostic Test|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
75377482|NCT05246943|Diagnostic Test|D-dimer and lower limb venous duplex|D-dimer blood test- The D-dimer assay detects the presence of fibrin degradation products, which can indicate the breakdown of a fibrin clot Lower Limb Venous Duplex- Using an ultrasound to visually look for a clot
75866944|NCT03175042|Device|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
75866945|NCT03738059|Drug|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
75866946|NCT03738059|Other|normal saline 0.9%|will receive intravenous normal saline 0.9%
75866947|NCT05233462|Other|standardized dose|intrathecal anesthesia with 10 mg of bupivacaine
75866948|NCT05233462|Other|adjusted dose|intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
75866949|NCT02700412|Drug|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
75866950|NCT03115606|Device|C-Mac D Blade|Videolaryngoscope
76029347|NCT05738252|Diagnostic Test|Frailty Phenotype|Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
76029348|NCT05737823|Behavioral|Carers-ID online support programme|The Carers-ID online programme, which consists of ten modules which cover topics including: promoting resilience, reducing anxiety, managing stress, accessing local supports, managing family conflict and information for siblings who are carers.
76029349|NCT05737823|Behavioral|Carers-ID online support programme - Wait-list control|The same programme as above delivered to the wait-list control after the T2 follow-up data has been collected.
76029350|NCT05735730|Other|Blood draw|The study intervention consists of a blood draw for genetic analysis.
75702908|NCT00773721|Device|CPAP mask|"Current CPAP masks are mainly silicone elastomers, which though well understood and accepted, are often uncomfortable.~Test Units: The test unit is a foam seal component which directly replaces the patients existing silicone mask cushion, and is fitted to the patients existing mask frame.~Subjects will wear the test unit mask, instead of their current CPAP mask, each night whilst sleeping."
75702909|NCT00778479|Device|Sepraspray|Max. 10g of Sepraspray
75702910|NCT00666705|Drug|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
75377483|NCT05246904|Other|Fitting algorithm|The best fitting algorithm will be selected by the audiologist (arm 1) or software.
75413845|NCT04612920|Drug|Ibuprofen, acetaminophen, oxycodone|The timing of medications is the intervention.
75413846|NCT04581135|Other|COVID-19|Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
75702911|NCT00666705|Drug|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
76029351|NCT05733845|Other|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
76029352|NCT05733520|Behavioral|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
75702912|NCT00666705|Drug|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
75702913|NCT00666705|Drug|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
75702914|NCT00433147|Drug|Afegostat tartrate|
75702915|NCT04047849|Drug|Antibiotics, oral Azithromycin and oral Amoxicillin|Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
75702916|NCT04047381|Other|Measurement of Quality of Life|Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
75702917|NCT04047927|Device|EpiFinder|The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
75702918|NCT00778557|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
75702919|NCT00774033|Device|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
75702920|NCT00774033|Procedure|classic skin grafts|classic skin grafts used for the treatment of acute burn
75702921|NCT02556567|Other|Fitbit® Charge Heart Rate (HR) wristband|The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
75702922|NCT00778713|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
75866951|NCT03115606|Device|Fastrach LMA|Laryngeal mask airway
75866952|NCT02403466|Behavioral|Resident Handoff Bundle|1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
75866953|NCT02403388|Other|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
75866954|NCT02407288|Device|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
75866955|NCT02407288|Device|Sham tDCS|
75866956|NCT02406898|Device|morcellator uterine system (MH)Karl Storz, Tuttligen- Germany|
75866957|NCT02351544|Drug|Botulinum Toxin Type A|
75866958|NCT02351544|Procedure|Surgery|
75866959|NCT02351544|Other|Daily headache diary|
76029353|NCT05733520|Behavioral|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
75702923|NCT00781209|Procedure|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
75377484|NCT05241600|Behavioral|Mindfulness-Based Childbirth and Parenting|MBCP is an adaptation of MBSR that incorporates both standard mindfulness practices (body scan, sitting meditation, mindful movement) and preparation for mindful birthing and parenting an infant. The class is taught by experienced midwives or social workers who have completed MBCP training requirements, which include ongoing cultivation of a personal mindfulness practice as well as education and supervision specific to the MBCP program. See Bardacke (2012) for further description of the MBCP curriculum.
75377485|NCT05241600|Behavioral|Non-Mindfulness-Based Childbirth Class|Other childbirth preparation classes available either in-person in the local community or online that do not involve formal mindfulness training will serve as the comparator condition.
75539318|NCT04605367|Device|Transcranial stimulation|For both tasks, the training modalities are the same. After the pre-test, this group will physically repeat the correct sequence as many times as possible, during 12 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the real anodal stimulation. The intensity of the current will gradually increase for 30s until it reaches 1mA, will remain constant for 15min, then will gradually decrease for 30s until 0mA is reached. The current density during stimulation will be 0.04 mA/cm². For the manual task the anode will be centered above C4 (according to the international 10-20 EEG system) that is located near the hand area of M1. The cathode will be placed on the supraorbital region ipsilateral to the trained hand (Fp1). For the body task, the anode will be placed in the center of the cortex (Cz) and the cathode will be placed at the medial supraorbital region (Fpz).
75539319|NCT04605289|Drug|lemongrass essential oil gel|"The lemongrass oil gel will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
75702924|NCT00781287|Drug|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
75702925|NCT00781287|Drug|Raltegravir|400 mg BID PO
75702926|NCT00774111|Drug|GSK1349572|GSK1349572 50 mg in combination with Etravirine
75702927|NCT02557191|Other|Observational study|
75702928|NCT00778791|Drug|metformin HC1 750 mg extended-release tablets|
75702929|NCT00774189|Drug|clarithromycin 250 mg tablets|
76029354|NCT05732896|Device|Nociception Leve Indeks|During TIVA-TCI, propofol (Schnider) effect site concentration (Ce) was titrated to BIS score between 40-60 and remifentanil (Minto) Ce to standard hemodynamic parameters in the control group and NOL index value between 10-25 in the study group.
75702930|NCT00774423|Drug|Riluzole|50 mg per day during 24 months
75702931|NCT00781521|Drug|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
76029355|NCT05727436|Dietary Supplement|Dentoblis|Dissolve the tablets in the mouth once a day for 4 weeks
76029356|NCT05727436|Dietary Supplement|Placebo|Dissolve the tablets in the mouth once a day for 4 weeks
76029357|NCT05723289|Device|MI-E Telemonitoring|Daily telemonitoring using a ad-hoc communicating device
75702932|NCT02557113|Procedure|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
75702933|NCT02557113|Procedure|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
75866960|NCT02351544|Other|Migraine Disability Assessment Test (MIDAS)|
75377486|NCT05235334|Device|MySOLIUS|MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.
75702934|NCT00778947|Procedure|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
75377487|NCT05229016|Behavioral|Reflection on health-related experiences|This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
75702935|NCT00778947|Procedure|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
75866961|NCT02351544|Other|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
76029358|NCT05716854|Drug|Clarithromycin|"Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD)."
75866962|NCT02351544|Other|Migraine-Specific Quality of Life Questionnaire (MSQ)|
76029359|NCT05716854|Drug|Pimozide|"Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day."
76029360|NCT05716854|Drug|Placebo (Part 1)|Subjects receive matching placebo for treatments.
76029361|NCT05716854|Drug|Moxifloxacin|Subjects receive Moxifloxacin 800 mg orally once on day 1.
75377488|NCT05214612|Combination Product|Drug treatment of myasthenia gravis and treatment of crisis|Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis
75377489|NCT05212454|Drug|Capecitabine|capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
76029362|NCT05716854|Drug|Cobicistat|Subjects receive Cobicistat 450 mg orally once on day 1.
76029363|NCT05716854|Drug|Moxifloxacin and Cobicistat|Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.
76029364|NCT05716854|Drug|Placebo (Part 2)|Subjects receive matching placebo for treatments.
76029365|NCT05714553|Drug|Fosifloxuridine Nafalbenamide|Intravenous infusion
75377490|NCT05207189|Biological|UVT|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
75377491|NCT05204901|Device|Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position|In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
75377492|NCT05201820|Device|Cryoanalgesia|Cryoanalgesia will be applied during surgery on 6 intercostal nerves each side
75377493|NCT05168969|Other|Questionnaire|The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
75377494|NCT05157581|Device|Extracorporeal photopheresis (ECP)|Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
75377495|NCT05157581|Drug|Methoxsalen Injection|Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
75377496|NCT05145920|Behavioral|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 5 videos (~ 7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
75377497|NCT05140837|Diagnostic Test|Psychometric hepatic encephalopathy score & Stroop test|MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.
75377498|NCT05140837|Drug|Drug therapy|Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
75866963|NCT02406976|Other|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3."
75377499|NCT05135598|Other|Partners for Life health behavior change program|A health behavior change intervention based on partner learning, utilizing low-tech media and a workbook.
76029366|NCT05714553|Drug|Leucovorin|Intravenous infusion
75702936|NCT00774501|Procedure|image guidance with general anesthesia and suspended ventilation during treatment delivery|"All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.~Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.~The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery."
75377500|NCT05113030|Other|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED|Test group(1st) enrollment criteria in PCOS group will be females of adolescent age newly diagnosed with PCOS, with >16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
75866964|NCT02406976|Behavioral|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3."
76029367|NCT05714553|Drug|Pembrolizumab|Intravenous infusion
76029368|NCT05714553|Drug|Docetaxel|Intravenous infusion
76029369|NCT05713760|Drug|Tirbanibulin Ointment 1%|Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
76029370|NCT05704205|Device|NB-UVB phototherapy|Narrowband ultraviolet B irradiation 3 times a week
75377501|NCT05113030|Other|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED|Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with >16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
75377502|NCT05109598|Biological|Recombinant new coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).
75377503|NCT05100485|Diagnostic Test|Esophagogasrtoduodendoscopy|Esophagogasrtoduodendoscopy was used to detech the presence of varices.
75377504|NCT05100485|Diagnostic Test|Hepatic venous pressure gradient|A method used to eveluate the portal pressure
75377505|NCT05096845|Biological|Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|"Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively.~Storage condition: store at 2~8°C protected from light Expiry date: 24 months after production date"
75702937|NCT04047147|Other|Enrollment in the Million Hearts CVD Risk Reduction Model|"The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~Risk stratify eligible Medicare FFS beneficiaries~Provide CVD care management to high-risk beneficiaries~Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries."
75539320|NCT04605289|Drug|Placebo|"The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
75539321|NCT04605289|Procedure|Scaling and root planing|Conventional mechanical treatment by ultra-sonic scalers
75539322|NCT04605328|Other|Two dimension and three dimension ultrasound|Patient will undergo 2D and 3D ultrasound evaluation after CS for detection of CSD
75539323|NCT00251901|Drug|Esomeprazole|
75539324|NCT04605133|Device|Electrical impedance tomography|Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
75702938|NCT04047147|Other|Enrollment in control provider organizations|Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
75702939|NCT00784407|Device|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
75702940|NCT00784485|Drug|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
75702941|NCT00781755|Drug|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
75702942|NCT00781755|Behavioral|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
75702943|NCT00781833|Device|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
75702944|NCT00774735|Drug|GSK1349572|30 mg given in combination with lopinavir/ritonavir
75702945|NCT00774735|Drug|GSK1349572|30 mg in combination with darunavir/ritonavir
75702946|NCT00666237|Procedure|Tube shunt surgery|The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.
75866965|NCT02406976|Other|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
75702947|NCT00666237|Procedure|Trabeculectomy|The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.
76029371|NCT05704205|Combination Product|Optimal topical therapy|A combination of detailed instructions about the disease and treatments by trained nurses, bathing and washing advices, adequate emollients use, avoidance of triggers (including possible and proven contact allergens), fingertip unit explanation for active topical therapy, and personalized topical therapy with different potency topical steroids, calcineurin inhibitors and tar ointments
75377506|NCT05096845|Other|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
75377507|NCT05091866|Other|Quality-of-Life Assessment|Ancillary studies
75377508|NCT05091866|Other|Questionnaire Administration|Ancillary studies
75702948|NCT00666237|Drug|Mitomycin C|A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes
75702949|NCT00774813|Device|Nexalin 1.3mA Device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of placebo antidepressant"
75702950|NCT00774813|Device|Nexalin 15mA device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of a placebo antidepressant"
75702951|NCT00774813|Drug|placebo device and Citalopram|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of a a SSRI (Citalopram or similar)"
75702952|NCT00784797|Drug|mifepristone and misopristol|200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
75702953|NCT00784797|Drug|mifepristone and oxytocin|200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
76029372|NCT05701488|Drug|Durvalumab|Intravenous infusion
76029373|NCT05701488|Drug|Tremelimumab|Intravenous infusion
76029374|NCT05701488|Device|SIRT|SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.
76029375|NCT05700461|Combination Product|Implantable Microdevice (IMD)|"Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib."
75377509|NCT05091866|Biological|Therapeutic Progesterone|Given SC
75377510|NCT05084989|Biological|Part1:Recombinant two-component COVID-19 vaccine (CHO cell)|2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
75377511|NCT05084989|Biological|Part1: Placebo|2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
75377512|NCT05084989|Biological|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
75377513|NCT05084989|Biological|Part2: COVID-19 Vaccine, mRNA|1 dose. Intramuscular injection, 30 μg/0.3 mL.
75377514|NCT05080881|Diagnostic Test|phonocardiographic measurement: InnoVital Systems|The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.
75702954|NCT00774969|Drug|Metronidazole|Metronidazole 10% ointment three times a day 7 days
75702955|NCT00785031|Other|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
75702956|NCT00785109|Dietary Supplement|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
75702957|NCT00662025|Drug|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
75702958|NCT00662025|Drug|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
75866966|NCT02288832|Other|-self-collected vaginal samples|
75866967|NCT02288832|Drug|zithromax|
75866968|NCT02288832|Other|usual practices|
75866969|NCT03175588|Other|Virtual Rehabilitation|Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
75866970|NCT03173014|Device|EEG|EEG monitoring
75866971|NCT02401906|Other|MRI|
75866972|NCT02401984|Other|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
75377515|NCT05080881|Diagnostic Test|phonocardiographic measurement: ThinkLabs StethOne|This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
75377516|NCT05080881|Diagnostic Test|physiological measurements: BIOPAC|Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.
75377517|NCT05080881|Diagnostic Test|physiological measurements: Masimo Radical-7|A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.
75702959|NCT00789945|Other|Control|Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.
75702960|NCT00789945|Other|Study Arm B|"Study Arm B will include participants with type 1 diabetes which will utilize Timing to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor."
75702961|NCT00785187|Device|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
75702962|NCT00785265|Behavioral|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
75702963|NCT00785265|Behavioral|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
75377518|NCT05080881|Diagnostic Test|physiological measurements: CoVa Monitoring System 2|This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.
75702964|NCT05013645|Other|Sterilized probiotic LfQi601|Sterilized probiotic topically administered.
75702965|NCT05013645|Other|Placebo|Gel control product
75702966|NCT00782145|Other|educational intervention|
75702967|NCT00782145|Other|informational intervention|
75702968|NCT00782145|Other|internet-based intervention|
75702969|NCT00782145|Other|questionnaire administration|
75702970|NCT00782145|Other|study of socioeconomic and demographic variables|
75702971|NCT00782145|Other|survey administration|
75702972|NCT00782145|Procedure|psychosocial assessment and care|
75702973|NCT00782145|Procedure|quality-of-life assessment|
75702974|NCT00782145|Procedure|standard follow-up care|
75702975|NCT00790101|Drug|Risedronate|
75702976|NCT00790101|Drug|Raloxifene|
75702977|NCT00790101|Other|Placebo|
75702978|NCT02555085|Biological|BIIB063|Single ascending IV dose
75702979|NCT02555085|Other|Placebo|Single dose
75702980|NCT00782301|Drug|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
75702981|NCT00782301|Drug|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
75702982|NCT00785343|Device|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
75702983|NCT00785343|Procedure|Conventional Therapy|Occupational therapy that is the current standard of care
76029376|NCT05700279|Procedure|Stellate Ganglion Block|Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
76029377|NCT05700279|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.
76029378|NCT05698433|Other|No intervention|No intervention
76029379|NCT05692973|Behavioral|Role of Knowledge Retrieval|Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
75702984|NCT00785421|Drug|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
75702985|NCT00785421|Drug|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
75702986|NCT00785421|Drug|only chemotherapy|observation, no treatment with LMWH
75702987|NCT00790179|Procedure|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
75702988|NCT00790257|Device|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
75377519|NCT05080881|Diagnostic Test|Thoracic impedance|Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
75377520|NCT05079828|Diagnostic Test|18F-PSMA-1007|PET/CT scan using 18F-PSMA-1007
75866973|NCT02403232|Procedure|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
75866974|NCT02403232|Device|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
75866975|NCT02403232|Device|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
75377521|NCT05079828|Diagnostic Test|68Ga-PSMA-11|PET/CT scan using 68Ga-PSMA-11
75377522|NCT05068492|Diagnostic Test|CT|enhanced CT with standard procedure
75377523|NCT05068492|Diagnostic Test|MRI|enhanced MRI with standard procedure
75377524|NCT05068492|Diagnostic Test|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
75377525|NCT05068492|Diagnostic Test|Ultrasound|Digestive ultrasound with standard procedure
75377526|NCT05052892|Diagnostic Test|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
75377527|NCT05050474|Biological|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
75377528|NCT05042700|Drug|Melatonin|Enema with 25 mg melatonin
75377529|NCT05042700|Drug|Placebo|Enema without melatonin
75702989|NCT00785499|Behavioral|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
75866976|NCT02406820|Device|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
75866977|NCT03116308|Drug|Opicapone (OPC)|50 mg OPC capsules; oral route
75377530|NCT05042401|Drug|SHR-1703|SHR-1703 low dose
75377531|NCT05042401|Drug|placebo|placebo low dose
75377532|NCT05042401|Drug|SHR-1703|SHR-1703 high dose
75377533|NCT05042401|Drug|placebo|placebo high dose
75866978|NCT02402998|Drug|Eltrombopag|Eltrombopag 50 mg/daily.
75377534|NCT05039450|Drug|EFX|Investigational drug, Efruxifermin
75377535|NCT05039450|Drug|Placebo|Placebo
75377536|NCT05028582|Drug|ARQ-154 Foam 0.3%|ARQ-154 Foam 0.3%
75377537|NCT05028582|Drug|ARQ-154 Vehicle|Vehicle
75866979|NCT03665441|Drug|eryaspase|L-asparaginase encapsulated in erythrocytes (red blood cells)
75866980|NCT03665441|Drug|Gemcitabine plus Abraxane|gemcitabine, Abraxane
75866981|NCT03665441|Drug|Irinotecan plus 5-FU plus leucovorin|irinotecan, 5-FU, leucovorin
75377538|NCT05010954|Drug|LXI-15028 50mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks
75377539|NCT05010954|Drug|Lansoprazole 30mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.
75377540|NCT05001724|Biological|KN046|KN046 is 5 milligram per kilogram, every 3 weeks.
75377541|NCT05001724|Drug|Lenvatinib|Lenvatinib is RP3D milligram per day, every day.
75377542|NCT05001724|Drug|Docetaxel|Docetaxel is 75 milligram per Square meter, every 3 weeks.
75377543|NCT05001022|Drug|ALG-020572|Single or multiple doses of ALG-020572
75866982|NCT03169660|Drug|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
75866983|NCT02401828|Drug|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
75866984|NCT02699866|Device|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
75866985|NCT03663569|Drug|Spiolto® Respimat®|Drug
75866986|NCT02401438|Other|5D ultrasound|
75866987|NCT02401438|Other|2D ultrasound|
76023378|NCT02397187|Behavioral|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
75377544|NCT05001022|Drug|Placebo|Single or multiple doses of Placebo
75377545|NCT04996368|Drug|Tranexamic acid injection|Randomized comparison of two doses of tranexamic acid as prophylactic before start of incision in open heart surgery use for prevention of bleeding.
75377546|NCT04994444|Drug|Nicoderm CQ 21Mg/24Hr Transdermal System|Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
75377547|NCT04987892|Device|UroLift System|Prostatic lift
75377548|NCT04987892|Drug|Tamsulosin Hydrochloride|Tamsulosin HCl 0.4mg
75377549|NCT04986280|Diagnostic Test|[18F]PSMA-1007|PSMA PET/CT using the intervention.
75377550|NCT05019222|Drug|Sevoflurane based inhalation anesthesia|Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.
75702990|NCT00782457|Procedure|RECTAL CANCER RESECTION|
75702991|NCT00790413|Drug|iodine I 131 metaiodobenzylguanidine|
75702992|NCT00790413|Drug|Fludarabine|
75702993|NCT00790413|Drug|Thiotepa|
75702994|NCT00790413|Procedure|T-cell depletion|
75702995|NCT00790413|Procedure|Haploidentical stem cell transplantation|
75702996|NCT00790413|Procedure|Donor Lymphocyte Infusion|
75702997|NCT00790413|Drug|Rituximab|
75702998|NCT00790413|Procedure|Co-transplantation of mesenchymal stem cells|
75702999|NCT00785655|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
75703000|NCT00790491|Behavioral|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
76023379|NCT02396485|Other|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
75377551|NCT05019222|Drug|Remimazolam based total intravenous anesthesia|Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.
75703001|NCT00790725|Other|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
75703002|NCT00790725|Other|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
75703003|NCT00785811|Drug|L-arginine aspartate (Targifor)|3g of L-arginine taken orally in a single daily dose for 8 weeks
75703004|NCT00785811|Drug|Placebo L-arginine aspartate (Targifor)|Placebo of L-arginine taken orally in a single daily dose for 8 weeks
75703005|NCT00782613|Drug|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
75703006|NCT00782613|Drug|Placebo|Placebo in a cream formulation
75703007|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
75703008|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
75703009|NCT00790881|Drug|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
75377552|NCT04985318|Drug|Cablivi®|Intervention with Cablivi® take place outside of the study
75703010|NCT00790881|Drug|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
75703011|NCT00782691|Other|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
75703012|NCT01029769|Drug|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
76023380|NCT03167593|Dietary Supplement|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
76023381|NCT03167593|Other|Control placebo|Maltodextrin
75703013|NCT02557945|Drug|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
75703014|NCT02557945|Drug|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
75377553|NCT04966663|Drug|Nivolumab|Antineoplastic agent
75377554|NCT04966663|Drug|Pemetrexed|Antineoplastic agent
75377555|NCT04966663|Drug|Gemcitabine|Antineoplastic agent
75377556|NCT04966663|Drug|Cisplatin|Antineoplastic agent
75377557|NCT04966663|Drug|Carboplatin|Antineoplastic agent
75377558|NCT04966663|Procedure|ctDNA blood test|Blood will be collected for ctDNA testing
75377559|NCT04960917|Behavioral|Evaluation of ehealth literacy workshop|Intervention components will include a three session workshop, enabling participants to raise their knowledge of the different available health resources and how to find them, their ability to determine which health resource is reliable, their ability to use the health information online to make health decisions, their knowledge of the online services offered by HMOs/Ministry of Health, and their ability to navigate HMO and preform actions such as set an appointment, find a doctor, and find contact information
75377560|NCT04957875|Device|emergency endoscopic therapy|When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.
75377561|NCT04927988|Other|Ringer's Lactated|Using of Ringer's Lactated In Autologous Blood Cell Transfusion
75377562|NCT04922593|Drug|LY03010; paliperidone palmitate|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
75377563|NCT04922593|Drug|INVEGA SUSTENNA|INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
75377564|NCT04914000|Behavioral|Self-help Materials|Self-help booklet targeted by cancer type to increase smoking cessation motivation
75703015|NCT03268070|Device|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
75703016|NCT03268070|Device|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
75377565|NCT04902950|Drug|Tranexamic acid|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
75377566|NCT04902950|Drug|Saline|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
75377567|NCT04889118|Biological|Pembrolizumab|IV infusion
75377568|NCT04889118|Drug|Lenvatinib|Oral capsule
75377569|NCT04889118|Drug|Placebo for lenvatinib|Oral capsule
75377570|NCT04844125|Drug|SHR-1209|SHR-1209
75377571|NCT04844125|Drug|SHR-1209 Placebo|SHR-1209 Placebo
75377572|NCT04831138|Procedure|MRI with ASL|"T0 (Week 0): MRI with ASL will be performed either for research alone or along with patient's standard of care imaging session including contrast-enhancement.~T1 (Day 7+-2): contrast-enhanced research MRI with ASL T2 (Day 14+-2): contrast-enhanced research MRI with ASL T3: MRI with ASL will be performed along with patient's standard of care imaging session.~T4: MRI with ASL will be performed along with patient's standard of care imaging session.~T5: MRI with ASL will be performed along with patient's standard of care imaging session."
75377573|NCT04820296|Other|Solution-Oriented Approach|First Session: Sharing thoughts about perception of childbirth, Creating positive goals, Informing about Birth, Birth Process, Basic Breathing Exercises and Deep Relaxation Exercises, Homework Second Session: Evaluating homework, Sharing thoughts about fear of childbirth, Miracle Question Technique, Evaluating with the Rating Questions Technique, Reframing the problem, Briefing on 'Body-Mind Connection at Birth, Fear-Tension-Pain Cycle, Hormones of Birth' and Breathing exercises, Homework Third session: Evaluating homework, Sharing thoughts about positive birth story, Information on symptoms indicating that the childbirth is approaching, pushing techniques, delivery positions, endorphin massage and breathing exercises (4/8 breaths, full breath when baby moves), Homework Fourth Session: Evaluating homework, Mother Baby Friendly Caesarean and Breathing exercises (3 candles a feather breath), Sharing feelings about the counseling process
75703017|NCT03268070|Device|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
76029380|NCT05692973|Behavioral|Inference Intervention|The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
75377574|NCT04819971|Drug|Tirelizumab|tislelizumab (intravenously, 200 mg on day 1 of every cycle for 4 preoperative and 12 postoperative cycles)
76029381|NCT05690334|Drug|Crystalloid - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
76029382|NCT05690334|Drug|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
76029383|NCT05690334|Drug|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75377575|NCT04819971|Drug|Trastuzumab|Trastuzumab(intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle for 4 preoperative and 12 postoperative cycles)
75377576|NCT04819971|Drug|Docetaxel|docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle for 3 preoperative cycles)
75377577|NCT04819971|Drug|S1|S1 (orally, 400mg/m2 BID on day 1~14 of every cycle for 3 preoperative and 3 postoperative cycles )
75377578|NCT04819971|Drug|Oxaliplatin|Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle for 3 preoperative cycles ;130mg /m2 on day 1 of every cycle for 3 postoperative cycles.
75703018|NCT03268070|Device|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
75703019|NCT03268070|Device|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
75539325|NCT04605250|Other|Respiratory variability before and after surgery|The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
75703020|NCT03241082|Device|ultrasound|validation of portable ultrasound to measure body composition
75539326|NCT00564772|Drug|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
75866988|NCT02401516|Device|Reprogramming insoles|1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
75866989|NCT03596762|Drug|Elinzanetant (BAY3427080)|BAY3427080 capsules
75866990|NCT03596762|Drug|Placebo|Placebo capsules
75866991|NCT04481386|Device|Vitargus, BFC-1401|A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.
75866992|NCT02401594|Drug|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
75703021|NCT00664521|Biological|Rituximab|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
75539327|NCT00564811|Dietary Supplement|Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)|Agaricus blazei powder, 10 grams/day, for 5 months
75703022|NCT00664521|Drug|Atacicept|Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
75866993|NCT02401594|Drug|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
76029384|NCT05689411|Device|Musical Toy|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
75703023|NCT00664521|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
75703024|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
75703025|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
75703026|NCT02581046|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
75703027|NCT02580890|Device|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
75703028|NCT02580890|Device|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
75866994|NCT02406508|Device|Melphalan/HDS|
75866995|NCT02406508|Drug|Sorafenib|
75866996|NCT02401360|Drug|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
75866997|NCT02401360|Drug|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
75377579|NCT04800874|Drug|BBP-418|BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.
75377580|NCT04790890|Device|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
75377581|NCT04785573|Dietary Supplement|Mastiha oil|1 soft gel capsule of Mastiha oil every day for 3 months
75377582|NCT04782050|Device|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
75377583|NCT04772820|Behavioral|Telephone-based coaching|A telephone-based brief behavioral activation coaching program that will involve 10 sessions over 4 months. Sessions will focus on helping people to identify meaningful activities that they can safely do to decrease loneliness, increase physical activity and improve nutrition.
75377584|NCT04727632|Drug|[18F]Fluoroestradiol (FES) PET/CT|[18F]Fluoroestradiol (FES) PET/CT
75377585|NCT04724148|Drug|Fentanyl|To assess the accuracy of HVPG in TIPS after injecting a dose of 1~2 mg/kg fentanyl.
75377586|NCT04716244|Other|interview/focus group/questionnaire|"Prior to the meetings, participants will be asked to fill in a questionnaire with demographic data including age, family status, number of pregnancies, number of children, education, and employment, history of preeclampsia or GDM, family history of CVD, and self-reported height and weight We will conduct up to 8 groups or until we reach saturation of themes. For the teleconference focus groups, the number of participants will be limited to 6 women per group, as recommended from previous research on teleconference focus groups51. The face to face focus groups will include up to -12 women. The expected duration of each group, will last 1-2 hours.~We will conduct up to 36 in-depth interviews. The expected duration of each interview will last 30 minutes to -1.5 hours.~Participants will be asked for their consent to record the meetings, audio only. The discussions will be then transcribed. An interview guide will be followed."
75377587|NCT04712214|Device|Intra-operative multispectral / hyperspectral analysis|During surgery, the operating surgeon will be using standard NHS neurosurgical equipment such as an endoscope and/or a microscope. This equipment is operated in exactly the same way as with any other procedure, but either the microscope or the endoscope in use will be connected to the system of camera and filters for multispectral/hyperspectral analysis. During each surgical intervention, tissue-specific spectral data will be collected at specific stages - mostly once the brain surface is exposed and at the end of the resection on the surgical cavity. The operation will be visually recorded in order to sync visual data with the spectral data obtained at the same moment in time. The video recording will not be patient identifiable and will be viewed only by members of the research team working on this project (see below). The use of video recording equipment will be included in the patient information sheet given to all patients prior to gaining consent
75377588|NCT04703803|Combination Product|1% lidocaine injection in trigger points|The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
75377589|NCT04693221|Other|Choice of VNS set of parameters based on the lowest PLI|Vagal nerve stimulation according to PLI results.
75377590|NCT04693221|Other|EEG|Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.
75377591|NCT04686383|Drug|CAL056 mesylate|Dosage form: 20 mg CAL056 mesylate/tablet
75703029|NCT00664209|Drug|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
75703030|NCT00664209|Drug|placebo|placebo therapy
75377594|NCT04670978|Drug|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxe, 260mg/m2, every 3 weeks, 6cycles, bevacizumab biosimilar, 10mg/kg, every 3 weeks, continue until PD or unaccceptable toxicity
75377595|NCT04668768|Drug|Glucarpidase|Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
75377596|NCT04664075|Biological|Respiratory infections|With biological samples and longitudinal observations, the aim is to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection.
75377597|NCT04657835|Device|cardiac Magnetic Resonance Imaging (MRI)|Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
75377598|NCT04657835|Biological|Blood sample|Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
75377599|NCT04657835|Procedure|Cardiac muscle biopsy|Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
76029385|NCT05688592|Procedure|PET-CT|"This is a before-and-after study (not a clinical trial)~in the case of fungemia, 2 weeks after the initial staging 18F-FDG PET-CT.~in the case of focal IFIs, 2-4 and 12 weeks after the initial staging 18F-FDG PET-CT"
76029386|NCT05685407|Drug|Caffeine|300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
76029387|NCT05685407|Other|Placebo|A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
76029388|NCT05684276|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, sodium chloride and glucose 5% solution solution or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of ech center."
76029389|NCT05684276|Drug|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hydroxy-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
75377600|NCT04657835|Device|Holter-electrocardiogram (ECG)|Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
76029390|NCT05684276|Drug|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains. Route of administration: Intravenous infusion. Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 3 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
75377601|NCT04657835|Other|medical examination|medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
75377602|NCT04639323|Diagnostic Test|Endoscopic ruler|"Endoscopic ruler for varices in portal hypertension~Product uses: measuring the diameter of the veins under the endoscopy for the assessment of the risk of variceal haemorrhage in patients with portal hypertension~Black and white measuring rule is highly recognizable under the endoscopy~The width of each cell is 1 mm, and the measuring range is 0-10 mm~With smooth edge, safe and reliable"
75703031|NCT05254977|Drug|Standard Preparation|Any kind of intervention received to reduce adverse effects
76029391|NCT05683262|Procedure|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection|Ultrasound guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position with a pillow under the abdomen to flatten the lumbar curvature. Lower extremities should be internally rotated while feet are inverted to help flatten the gluteal region. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Ultrasonography gel was applied on the probe and the probe was wrapped with a transparent thin sheath and cleaned with povidone iodine. Sterile gel is applied on the skin. The sacrococcygeal ligament, the sacrococcygeal and intercoccygeal joints were visualized. The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When it was seen that the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
75703032|NCT04074434|Device|Study Watch|Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
75703033|NCT00785889|Procedure|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
75703034|NCT03192332|Device|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
75539328|NCT00564967|Behavioral|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
75539329|NCT00564967|Behavioral|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
75703035|NCT03192332|Drug|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
75703036|NCT02555943|Drug|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
75703037|NCT02555943|Drug|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
75377603|NCT04639206|Behavioral|HOBSCOTCH|HOBSCOTCH (Home Based Self-management and Cognitive Training Changes lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The HOBSCOTCH intervention consists of 8 weekly sessions conducted in-person, over the telephone, or via video-conferencing. A smart phone application will be used to collect data on seizure frequency, medication adherence, and patient engagement.
75377604|NCT04639180|Drug|Camrelizumab|Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
75377605|NCT04639180|Drug|Rivoceranib (Apatinib)|Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
75377606|NCT04611698|Device|Baha sound processor BA400|Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.
75377607|NCT04607486|Diagnostic Test|3DfUS and IPSA of leg muscles|"3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~clinical functional capacity = clinical evaluation of degree of independence, mobility and gait"
75377608|NCT04570722|Other|Ipsilateral peripheral IV insertion|Patients with successful ipsilateral intravenous access will be provided a patient education sheet describing signs and symptoms that should be reported to the study team. All participants will be contacted by the study team at twelve week intervals for 12 months after their radiology encounter for completion of symptom assessments. If a subject reports new signs or symptoms of lymphedema during follow-up, a clinic appointment for volumetric measurements and thorough evaluation will occur
75377609|NCT04546360|Procedure|Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.|Time frame between elastography measurement and esophagogastroduodendoscopy is within 2 weeks.
75377610|NCT04531943|Drug|Estrogen|Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.
75377611|NCT04531943|Drug|Estrogen plus Progesterone|Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
75377612|NCT04530825|Other|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
75377613|NCT04530825|Other|PREVENT Tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
75377614|NCT04517565|Diagnostic Test|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.
75377615|NCT04517565|Behavioral|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
75377616|NCT04516850|Genetic|Expression of receptors and activating proteases|Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19
75377617|NCT04516850|Genetic|Polymorphism of the HSD3B1|Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)
75377618|NCT04504383|Drug|PN-943|Administered by the oral route BID for the duration of the study.
75377619|NCT04504383|Drug|Placebo|Administered by the oral route BID for 12 weeks.
75703038|NCT02555943|Drug|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
75703039|NCT02555943|Drug|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
75377620|NCT04503460|Drug|Salmeterol Xinafoate|All participants will receive inhaled salmeterol xinafoate 50 μg twice in the morning and twice in the evening for 2 weeks; this will be followed by a 2-week washout period during which time no beta-agonists will be administered. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
75377621|NCT04503460|Drug|Salmeterol Fluticasone|Following the 2-week washout period, all participants will receive inhaled salmeterol xinafoate 50 μg combined with fluticasone propionate 250 μg twice in the morning and twice in the evening for 2 weeks. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
75377622|NCT04500977|Behavioral|leadership empowerment|In the leadership program, women were taught more about the manner in which to bring about a change in one's health by adapting a healthy life style, leadership and facilitation skills and the development, implementation and evaluation process required to conduct a community program that will impact society. Women learned how to map needs and resources, define goals and objectives, develop, implement and evaluate a community based program.
75539330|NCT03454243|Drug|RXDX-106|Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
75539331|NCT00251940|Drug|Tesaglitazar 0.5 or 1 mg|
75539332|NCT00251940|Drug|Glibenclamide 2.5, 5, 10 or 15 mg|
75703040|NCT02555943|Drug|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
75703041|NCT00790959|Behavioral|SASA!|"A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention."
75703042|NCT00790959|Other|Control|"Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers."
75703043|NCT02580812|Other|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
75703044|NCT04047459|Other|Tissue samples collection and cells isolation|During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
76029392|NCT05683262|Procedure|Ultrasound-guided coccygeal nerve block|Patients are placed in the prone position with a pillow under the abdomen. Lower extremities are internally rotated while feet are inverted. Injection site and the probe are cleaned thrice with povidone iodine %10 solution. Sterile gel is applied. The prob was placed on coccygeal cornu and the coccygeal nerve was visualized superomedial to the CC in the subcutaneous tissue layer. Hydrodissection was made by administering 5 ml of 5% dextrose + 1 ml of 2% lidocaine via an in-plane approach with a 23 gauge 6 cm long needle, targeting the short axes of the bilateral coccygeal nerves.
76029393|NCT05683262|Procedure|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection after coccygeal nerve block|After the coccygeal nerve block, when the pain with palpation of the coccygeal region was reduced by at least 50%, the sacrococcygeal ligament, sacrococcygeal and intercoccygeal joints were visualized.The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
76029394|NCT05679427|Radiation|radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively|Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared
75377623|NCT04486573|Diagnostic Test|Cardiac Magnetic Resonance Imaging|A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
75703045|NCT00782847|Behavioral|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
75413847|NCT04570293|Drug|5% lidocaine medicated plaster|The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
75377624|NCT04436198|Device|MORCHER® EYEJET® CTR Types 14, 14A, and 14C|"Intervention. Toric IOL + CTR. Whether the subject receives 14, 14A, or 14C is an either or scenario depending on the eye's axial length and is a single intervention:~Axial length > 28.0 mm: CTR model 14A Axial length 24.0-28.0 mm: CTR model 14C Axial length < 24.0 mm: CTR model 14~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
75377625|NCT04436198|Device|Toric IOL Only|"Control. Toric IOL only. Standard of care cataract surgery without placement of a capsular tension ring.~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
75377626|NCT04414748|Drug|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger
75377627|NCT04414748|Drug|oral Duphaston|oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
75703046|NCT00785967|Biological|Various vaccines|VAQTA: 1.0ml IM at weeks 24 & 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
75703047|NCT03923504|Other|Physical Activity Intervention (PAI)|Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 & 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.
75866998|NCT02402686|Drug|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
76029395|NCT05676385|Dietary Supplement|First concept product (containing 50 grams of carbohydrates)|Fasted intake of First concept product (randomised)
76029396|NCT05676385|Dietary Supplement|Second concept product (containing 50 grams of carbohydrates)|Fasted intake Second concept product (randomised)
76029397|NCT05676385|Dietary Supplement|Reference product (containing 50 grams of carbohydrates)|Fasted intake of Reference product (randomised)
75377628|NCT04397419|Dietary Supplement|Red Bull Energy Drink|"The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~2-3 hours after surgery: 250 ml~Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
75377629|NCT04397419|Other|Still water|"The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~2-3 hours after surgery: 250 ml~Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
76029398|NCT05669820|Dietary Supplement|Salovum|Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
75377630|NCT04395196|Dietary Supplement|Choline bitartrate|Provided in beverage form
75377631|NCT04395196|Dietary Supplement|Placebo|Provided in beverage form
75377632|NCT04371900|Behavioral|Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES randomized vouchers for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred from March 4, 2019, forward.
75377633|NCT04371900|Behavioral|Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES randomized vouchers for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after November 4, 2019.
75377634|NCT04371783|Procedure|Immediate FET|FET is performed in the first menstrual cycle following the stimulated IVF cycle
75377635|NCT04371783|Procedure|Delayed FET|FET is performed in the second menstrual cycle following the stimulated IVF cycle
75377636|NCT04368104|Diagnostic Test|Darwish test (office hysteroscopic bubble suction and tubal peristalsis)|Testing Darwish test (office hysteroscopic bubble suction test and proximal tubal peristalsis) in women using minipills versus other cases not using hormones..
75377637|NCT04702568|Drug|BCX9930|BCX9930 for oral administration
75377638|NCT04307264|Procedure|Esophagogasrtoduodendoscopy, liver stiffness measurement|Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
75377639|NCT04297189|Behavioral|Coaching and health information intervention|8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
75703048|NCT03923504|Other|Healthy Living Control|Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
75703049|NCT02555553|Behavioral|CBT-GSH with Noom Monitor|This intervention is cognitive behavioral treatment with a smartphone application
76029399|NCT05669820|Dietary Supplement|Placebo egg yolk powder|Egg yolk powder derived from hen fed with normal feed.
75377640|NCT04294381|Behavioral|Decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
75377641|NCT04287283|Other|Hyperbaric Oxygen|40-60 daily hyperbaric sessions, 5 days per week. Each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ATA.
75377642|NCT04283786|Other|Qualitative Interview|A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.
75377643|NCT04259710|Behavioral|Goal-setting intervention|The participant will meet weekly with the investigator, report steps and set goals for the following week.
75377644|NCT04259710|Behavioral|Goal setting with implementation intentions|In addition to the standard goal-setting intervention, the participant will fill out a form that directs them to perform implementation intentions at weeks 1, 5 and 9.
75377645|NCT04259710|Behavioral|Pedometer only|the participant will be given a pedometer and instructed how to use it.
75377646|NCT04233515|Drug|Oral anticoagulant|Clinical visit to a physician to assess stroke and bleeding risk and to possibly initiate OAC therapy or refer for left atrial appendage occlusion
76029400|NCT05665322|Procedure|Thermoablation with standard CT guidance|Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
76029401|NCT05665322|Procedure|Thermoablation with porto-scanner guidance with Angio-CT|Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
75866999|NCT03736577|Other|Drug reviews with NorGeP-NH|Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
75377647|NCT04228549|Device|MyPADMGT|Online tracking and feedback to help patients adopt healthy lifestyles
75377648|NCT04228549|Device|MyPADMGT + Nudging|Online tracking and feedback to help patients adopt healthy lifestyles plus nudging support to assist in making decisions
75377649|NCT04169373|Drug|Upadacitinib|Upadacitinib tablet administered orally
75377650|NCT04169373|Drug|Placebo|Placebo for upadacitinib tablet administered orally
75377651|NCT04154930|Device|Restylane-L®|Intradermal injection.
75377652|NCT04150042|Drug|Melphalan|Intravenous melphalan (to be given in conjunction with the other listed drugs).
75377653|NCT04150042|Drug|BCNU|Intravenous BCNU (to be given in conjunction with the other listed drugs).
75867000|NCT02402608|Dietary Supplement|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
75867001|NCT02402608|Dietary Supplement|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
75867002|NCT02401282|Behavioral|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
75867003|NCT02401282|Behavioral|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
76023382|NCT02396173|Other|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
75377654|NCT04150042|Drug|Vitamin B12B|Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
75377655|NCT04150042|Drug|Vitamin C|Intravenous vitamin C (to be given in conjunction with the other listed drugs).
75377656|NCT04150042|Drug|Ethanol|Intravenous ethanol (to be given in conjunction with the other listed drugs).
75377657|NCT04150042|Device|Autologous Hematopoietic Stem Cells|After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.
75377658|NCT04137705|Other|Multiparametric MRI|A standardised MRI protocol that provides a number of quantitative metrics on liver and other organs relevant to type 2 Diabetes - pancreas, kidneys, spleen, heart, lungs and aorta
75377659|NCT04125927|Drug|Mercaptamine|Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
76023383|NCT04524767|Behavioral|SBIRT|Screening Brief Intervention and Referral to Treatment (SBIRT) is an evidence-based approach designed to provide screening, brief intervention, and referral to more intensive treatment for people at risk of developing mental disorders, including depression. SBIRT is composed of three core components: screening with a validated instrument, brief intervention, referral to treatment. Motivational Interviewing (MI) is the brief intervention most commonly used in SBIRT. MI is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. Subjects enrolled in the experimental SBIRT arm will receive up to a maximum of six sessions of MI.
76023384|NCT04524767|Behavioral|Referral as Usual|We will utilize depression educational brochures describing the nine hallmark symptoms of depression symptoms and the importance of seeking treatment from pamphlets from the National Institute of Mental Health (NIMH). Subjects will also receive a list of referral sites in the study's catchment area of Upper Manhattan
76029402|NCT05664698|Behavioral|SKILLS-ER|The intervention (SKILLS-ER) has been developed by the research group, and aims to increase a participant's emotion regulation capacity by targeting different stages of the emotion regulation process proposed by the extended process model of emotion, i.e. identification, selection, implementation and monitoring (Sheppes, Suri & Gross, 2015). SKILLS-ER will comprise of eight sessions and include identification and differentiation of emotions, tolerance/acceptance of emotions, education of different regulatory skills, as well as on how to select, implement and monitor strategies. Sessions will take place at the Uppsala child- and adolescent psychiatry outpatient unit and consist of activating and experiential exercises administered by a clinical psychologist. Participants will gain access to internet-delivered material, such as homework assignments in-between sessions. SKILLS-ER will be delivered individually to the participants, where their parents will be involved in some sessions.
76029403|NCT05663203|Other|Internet-Based Intervention|Attend CRCWeb intervention
76029404|NCT05663203|Other|Interview|Complete interview
76029405|NCT05663203|Other|Survey Administration|Complete survey
76029406|NCT05663203|Other|Electronic Health Record Review|Medical records are reviewed
76029407|NCT05662540|Device|Positron Emission Tomography/Magnetic Resonance (PET/MR)|18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
76029408|NCT05661006|Dietary Supplement|Use of food supplement|"On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight & height Collecting data regarding the palatability of the product"
76029409|NCT05661006|Dietary Supplement|Use of placebo food supplement|On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
76029410|NCT05659797|Device|BPET/DBT imaging|Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of [18F]-Fluoroestradiol (FES).
76029411|NCT05659797|Drug|18F-FES|Radiolabelled fluoroestradiol for PET imaging
76029412|NCT05659173|Diagnostic Test|Blood taking|Blood test for vitamin D level and DNA extraction for VDR gene polymorphism
75703050|NCT00786045|Other|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
75703051|NCT02631044|Biological|JCAR017 (lisocabtagene maraleucel) single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
75377660|NCT04124471|Behavioral|Open-ended semi-structured interviews|Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
75377661|NCT04121520|Other|Questionnaire|"Comprehensive perioperative assessment~Questionnaire administration"
75377662|NCT04114669|Behavioral|Control Condition|3 in-person study visits, approximately one hour each. These will take place at baseline, 6 months, and 12 months.
75377663|NCT04114669|Behavioral|Regret Lottery|"Delivered by the Way to Health platform, installed on a smartphone and communicates with participants via text message.Participants are eligible to receive a potential cash reward if they are adherent with their antihypertensive medication the day before, which is monitored via electronic monitoring device (EMD) from AdhereTech. Each participant is assigned a 2-digit number for the trial, and each day the Way to Health platform randomly generates a 2-digit number. Participants will receive a prize if both digits match (1 in 100 chance) and will receive a prize of lesser value if one digit matches (18 in 100 chance). If they are not adherent with their medication, but would have won if they were adherent, they receive a text message that they would have won (regret component)."
75703052|NCT02631044|Biological|JCAR017 (lisocabtagene maraleucel) 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
76029413|NCT05658952|Other|Microcatheter-derived FFR|FFR pullback trace is obtained through the manual retrieval performed after the positioning of the microcatheter FFR in the distal portion of the vessel. The pullback speed should be steady and the overall duration would be between 20 and 40 seconds. Then, the Interventional Cardiologist has to decide the procedural plan according to the pullback trace aiming to obtain an optimal post-PCI result in terms of physiology. FFR with pullback can be repeated after stenting to check and correct the result if needed.
75377664|NCT04093024|Drug|Nintedanib|Capsule
75703053|NCT02580578|Other|No Intervention|No intervention is administered in this study.
75377665|NCT04093024|Drug|Placebo|Capsule
75377666|NCT04091503|Drug|Intranasal Modified Temozolomide|"Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated"
75377667|NCT04085406|Device|Deep Brain Stimulation of the Subgenus Cingulate Cortex|The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.
75377668|NCT04067752|Other|high dialysate sodium concentration (138 mEq/L)|high dialysate sodium concentration (138 mEq/L)
75377669|NCT04067752|Other|Low dialysate sodium concentration|low dialysate sodium concentration (132 mEq/L)
75377670|NCT04067388|Other|Rapid Evaporative Ionisation Mass Spectrometry (REIMS)|Use of iKnife instrument during standard operative practice
75413848|NCT04570293|Drug|vehicle plaster|Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
75539333|NCT04604977|Behavioral|Mindfulness|Patients are followed with a standardized program including: education and support for behavioral measures, behavioral sessions, by mindfulness, once per week for 45 minutes for 6 weeks which usually delivered in groups of 4 - 8 patients.
76029414|NCT05658952|Other|Angiography-derived FFR|FFR pullback trace is automatically obtained after the 3-Dimensional reconstruction of the vessel through angiography derived FFR. Then, Interventional Cardiologist has to decide the procedural plan according to the pullback result aiming to obtain an optimal post-PCI result in terms of physiology. Angiography-derived FFR can be repeated after stenting to check and correct the result if needed.
76029415|NCT05658952|Other|Angiography-guided PCI|Interventional Cardiologist will perform PCI plan according to his/her the evaluation of angiography.
76029416|NCT05641051|Drug|Metoclopramide|Cases will receive 10 mg intravenous metoclopramide every 6 hours.
76029417|NCT05641051|Drug|Placebo|Cases will receive the same volume of IV placebo / 6 hours.
76029418|NCT05639400|Device|Thoraflex Hybrid|Thoraflex Hybrid is designed for the open surgical repair of aneurysms and/or dissections in the aortic arch and descending aorta with or without involvement of the ascending aorta. There are two types of Thoraflex Hybrid implants, namely the Plexus 4 and the Ante-Flo versions. Each patient receives one Thoraflex Hybrid device (either the Plexus 4 or Ante-Flo).
76029419|NCT05639400|Device|RelayPro NBS|The RelayPro NBS Thoracic Stent-Graft System is an endovascular device intended for treatment of thoracic aortic pathologies such as aneurysms, pseudoaneurysms, dissections, penetrating ulcers and intramural hematoma.
76029420|NCT05638334|Drug|89Zr-S095012 tracer and S095012 will be administered via an IV infusion|"Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C."
75539334|NCT04604938|Drug|Losartan|administration of losartan (50 mg) (oral)
75539335|NCT04604938|Drug|Placebo oral tablet|administration of placebo (oral)
75539336|NCT00248742|Behavioral|Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods
75539337|NCT00565006|Drug|MK0859|
75703054|NCT02618252|Device|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
75703055|NCT02618252|Device|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
75703056|NCT02557412|Device|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
75703057|NCT02557412|Behavioral|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
75703058|NCT02557412|Other|Conventional treatment|Hygiene and diet recommendations on sleep
75703059|NCT02542202|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
75377671|NCT04052841|Procedure|Thermal pulsation|Participants underwent a single LipiFlow® thermal pulsation system (TearScience Inc., Morrisville, NC,USA) treatment on the first visit: after lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) and instillation of anesthetic eye drops (Alcaine, proparacaine hydrochloride 0.4 ml/2mg) in both eyes, sterile eye cups were placed on to the conjunctival sac as instructed by the manufacturer, after 12 minutes of upper and lower palpebral conjunctival surfaces heat while simultaneously graded pulsatile pressure applying, eye cups were removed slightly.
75539338|NCT04604587|Drug|1. amyloid PET；2. T807 PET|"Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB~Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807"
75539339|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
75703060|NCT02487134|Device|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
75703061|NCT02487134|Device|Control|Closure of the abdomen with conventional technique
76029421|NCT05633329|Procedure|single level|injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)
76029422|NCT05633329|Procedure|dual level|injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)
76029423|NCT05632926|Drug|40 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
76029424|NCT05632926|Drug|60 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
76029425|NCT05632926|Drug|80 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
76029426|NCT05631626|Drug|CTx-1301 - Dexmethylphenidate 25mg|25mg CTx-1301 (Dexmethylphenidate tablet)
75539340|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
75539341|NCT00252018|Behavioral|Daily intake of broccoli sprouts|
76029427|NCT05631626|Drug|CTx-1301 - Dexmethylphenidate 37.5mg|37.5mg CTx-1301 (Dexmethylphenidate tablet)
76029428|NCT05631626|Drug|CTx-1301 - Dexmethylphenidate 50mg|50mg CTx-1301 (Dexmethylphenidate tablet)
76029429|NCT05631626|Drug|Placebo|Placebo
76029430|NCT05630040|Device|Non-invasive vagus nerve stimulation|Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.
76029431|NCT05630040|Device|Sham Intervention|Participants will take a placebo device home for 6 weeks and use daily.
76029432|NCT05627128|Other|DAIN|Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef.
76029433|NCT05626673|Behavioral|Prayer app|Participants will be given the Pray.com app and directed to use it daily.
76029434|NCT05626218|Other|stress ball|The woman is usually laid in the last side position during the procedure. A stress ball will be given to the right hand of the participants during the NST procedure (average 15-20 minutes). This stress ball will be squeezed for 2-3 seconds, and then the hand and arm will be told to relax. This process will be repeated throughout the NST. Hospital protocol will also be applied to these participants.
76029435|NCT05623488|Drug|huCART-meso cells|Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains
76029436|NCT05623488|Device|Mesothelin Expression Testing|Laboratory Developed Test
76029437|NCT05621967|Behavioral|Tonation Breathing Techniques|Tonation and Breathing Techniques (TBT): consist of a combination of organic inhalation and controlled exhalation with tonation. This will be guided by a trained facilitator, and the entire exercise will take 20 minutes. This will include guided relaxed breathing, mindful breathing, patterned tonation, nasal tonation, and pursed lip tonation.
76029438|NCT05621967|Behavioral|Music Driven Vocal Exercises|Music Driven Vocal Exercises (MDVE): A Music Therapy procedure will be implemented by a trained facilitator, utilizing an accompanying instrument (ie, guitar or Autoharp) and moving stepwise up and down within a scale of 8 whole steps. The total length of the procedure is 20-25 minutes. This will include vocal exercises, and melodic exercises alternating with speaking,
76029439|NCT05621967|Behavioral|Silent Breathing|Patient will sit in a quiet room and focus on silent breathing x 20 min.
75539342|NCT05467943|Drug|Tazemetostat|All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
75703063|NCT00440557|Drug|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
75867004|NCT03663179|Device|Transcranial Magnetic Stimulation (TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
75867005|NCT03663179|Device|Sham Transcranial Magnetic Stimulation (Sham TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
75867006|NCT03662789|Drug|Iron Isomaltoside 1000|Intravenous infusion
75867007|NCT03662789|Other|Placebo: NaCl 0,9%|Intravenous infusion
75867008|NCT03115996|Drug|REGN3918|Intravenous (IV) or Subcutaneous (SC)
75867009|NCT03115996|Drug|Placebo|Matching Placebo
76029440|NCT05618444|Behavioral|Automated Management (AM)|A tele-management intervention that will deliver two-way messages to participants via a bot - a computer program that simulates human activity. Programmed AM messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
75703064|NCT00440557|Drug|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
75703065|NCT00440557|Drug|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
75703066|NCT02528227|Other|Know Your Baby Language Curriculum|Early language activities that parents can do with their infants
76029441|NCT05618366|Drug|Venetoclax|Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
76029442|NCT05618366|Drug|Tazemetostat|Tazemetostat 800mg taken orally, twice daily.
76029443|NCT05610683|Device|Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer|Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
76029444|NCT05600985|Procedure|FS-LASIK|Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.
76029445|NCT05599399|Dietary Supplement|Gum acacia|25 grams of gum acacia powder is administered on daily-basis
75703067|NCT02528227|Other|Reading Aloud Language Curriculum|Early language activity that parents can do with their infants
75703068|NCT02528227|Other|Sing A Long Language Curriculum|Early language activity that parents can do with their infants
75703069|NCT02528227|Other|Mimicking First Sounds Language Curriculum|Early language activity that parents can do with their infants
75703070|NCT02528227|Other|Language Games and Narrating Your Day Language Curriculum|Early language activity that parents can do with their infants
75703071|NCT02528227|Other|Feeding Safety|Part of Health and Safety Curriculum
75703072|NCT02528227|Other|Car Seat Safety|Part of Health and Safety Curriculum
75703073|NCT02528227|Other|Bath Safety|Part of Health and Safety Curriculum
75703074|NCT02528227|Other|Back to Sleep/SIDS prevention|Part of Health and Safety Curriculum
75703075|NCT02528227|Other|Taking a Temperature and Signs of Infection|Part of Health and Safety Curriculum
75703076|NCT02528227|Other|Infection Control Measures and Vaccine Information|Part of Health and Safety Curriculum
76029446|NCT05599373|Device|Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
75377672|NCT04052841|Procedure|Intense pulsed light therapy|Lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) before treatment. Intense pulsed light (IPL) with a range of wavelength (570 or 620 nm) was performed every 3 weeks，3 times in total (0, 3w, 6w). 10 pulses were transmited from one tragus through nose to the other tragus was a single pass, each treatment needed to do 2 passes. Manual lid massage was done after per IPL treatment.
75377673|NCT04052841|Procedure|Manual warm compresses|Lids hygiene of both eyes with wet cotton swabs(OCuSOFT, Inc., Texas, USA).Commercial heated eye patch was use for 10 min. Manual lid massage every 2 weeks, 5 times in total(0，2w, 4w, 4w, 8w).
75377674|NCT04048941|Procedure|One Needle Hand Acupuncture with Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
75377675|NCT04048941|Procedure|One Needle Hand Acupuncture without Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.
75703077|NCT01029847|Drug|Adalimumab|Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
75703078|NCT01029847|Drug|Placebo|"sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines."
75867010|NCT02401204|Other|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected."
75867011|NCT03736421|Procedure|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
75867012|NCT03736421|Procedure|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
75377676|NCT04048941|Procedure|Control Acupuncture with Movement|Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
75377677|NCT04014790|Drug|RGI-2001|Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
75377678|NCT04014790|Drug|Standard of Care|Standard of care prophylaxis regimen will be administered according to institutional guidelines
75867013|NCT03736421|Diagnostic Test|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
75867014|NCT02401126|Dietary Supplement|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
76029447|NCT05599373|Device|Left Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
75377679|NCT04009031|Device|Bootle Blast|During the baseline assessment, an occupational therapist will calibrate the video game to the child's therapy needs and functional abilities. Within a week of the first assessment, the research team will set up the video game in the participant's home where it will remain for 12 weeks. Training on how to play the game and a user manual will be provided. The researcher will work with each family to establish a play objective (minutes/day and days/week) that considers the family's schedule. Five-minute telephone check-in calls will be done weekly.
75413849|NCT04565275|Drug|Drug ICP-192|"Dose Escalation Phase ICP-192 will be taken by patients with advanced solid tumor and will be treated follow the 3+3 dose escalation scheme~Dose Expansion Phase ICP-192 will be taken by patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations and will be treated at a single dose defined from the Dose Escalation Phase."
75703079|NCT02452268|Drug|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
75867015|NCT02401126|Dietary Supplement|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
75867016|NCT04481932|Drug|Trastuzumab combined with Pyrotinib and chemotherapy|"Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth"
75867017|NCT03169582|Drug|Avanafil|Drug administration (Avanafil)
75413850|NCT04543045|Other|not an intervention|not an intervention
75413851|NCT04531462|Drug|Empagliflozin|Empagliflozin
75413852|NCT04531462|Drug|Placebo|Placebo
75703080|NCT02452268|Drug|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
75703081|NCT03872492|Other|Digital Assessment on mobile|"The digital assessment is composed on 5 tests:~My daily survey~My evaluation~My cognition~My emotions~My voice~Data will also be collected passively."
75867018|NCT03169582|Drug|Sildenafil|Drug administration (Sildenafil)
75867019|NCT02406664|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
75867020|NCT02402374|Device|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
75867021|NCT02402374|Device|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
75867022|NCT02402140|Other|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
75867023|NCT03655691|Biological|Vehicle|Vehicle Formulation
75867024|NCT03655691|Biological|botulinum toxin, Type A|botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
75413853|NCT04527016|Procedure|Microbiota and eosinophils based therapy|"Blood eosinophils ≥3%+ mixed airway microbiota: 3 month course of FP 50 ug twice daily via spacer~Blood eosinophils<3%+ Moraxella species>40% in airway microbiota: Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~Blood eosinophils ≥3%+ Moraxella species>40% in airway microbiota: 3 month course of FP 50 ug twice daily via spacer and Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~Blood eosinophils<3%+ mixed airway microbiota: intermittent budesonide inhalation suspension (1mg twice daily) and terbutaline inhalation suspension for 7 days during wheeze episode.~The participants will be followed up for one year after the intervention."
75413854|NCT04527016|Drug|Clinical guidelines based therapy|"The children will be treated as directed by their paediatrician ( The clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016).The treatment protocols include:~regular inhaled FP 50 ug twice daily via spacer for 3 months;~montelukast(4mg od for 3 months)~intermittent budesonide inhalation suspension (1mg twice daily for 7 days during wheeze episode).~The participants will be followed up for one year after the intervention."
75413855|NCT04520139|Drug|N-Acetyl-Cysteine|Given PO
75867025|NCT03655691|Biological|botulinum toxin, Type A|botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
75867026|NCT03169504|Other|Acupuncture|Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30*25 mm, 0.30*40 mm or 0.30*50 mm will be used 3 times weekly for 12 weeks.
76029448|NCT05599373|Device|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
76029449|NCT05591898|Behavioral|Progressive relaxation exercises|Training booklet and CD as a guide on the implementation of Progressive Relaxation Exercises prepared by the Turkish Psychological Association; muscle relaxation exercises, rhythmic breathing and music recital. In the first 10 minutes of this three-part CD, the definition and purpose of deep relaxation and the practices to be considered during exercise are explained. In the second part of 30 minutes; relaxation exercises are explained with the sound of the stream and verbal instructions. The third part, consisting of 30 minutes; it contains only relaxation music without instructions.
76029450|NCT05589740|Behavioral|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
76029451|NCT05589740|Behavioral|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations from USDA My Plate
76029452|NCT05588739|Behavioral|Cognitive Behavioral Therapy|The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
75413856|NCT04520139|Other|Placebo|Given PO
75703082|NCT02524249|Drug|Caffeine|
76029453|NCT05587998|Drug|AZD4041 and morphine|Participants will receive 2 doses of morphine (IV administration) and multiple doses of AZD4041 (Oral solution)
76029454|NCT05587998|Other|Placebo and morphine|Participants will receive 2 doses of morphine (IV administration) and multiple doses of Placebo (Oral solution)
76029455|NCT05585398|Drug|IncobotulinumtoxinA|Intradermal injections using different delivery methods (conventional needle and microneedles)
76029456|NCT05579860|Drug|Olezarsen|Olezarsen will be administered by SC injection.
76029457|NCT05573555|Drug|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
75413857|NCT04512105|Drug|Pitavastatin|Given PO
75413858|NCT04512105|Drug|Venetoclax|Given PO
75703083|NCT02524249|Drug|Placebo (dextrose)|
75703084|NCT01033981|Drug|Sunitinib|Treatment for mRCC as indication approved and physician criterium
75703085|NCT02430194|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
75703086|NCT02430194|Drug|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
75377680|NCT03995966|Behavioral|Noncontingent Reinforcement (NCR)|This treatment for ASIB is based on reinforcer competition. Noncontingent Reinforcement (NCR) will consist of first conducting a competing stimulus assessment (CSA) to identify stimuli (toys, massagers, etc.) associated with reductions in ASIB and high levels of engagement. Treatment then involves NCR in which alternative sources of reinforcement are made freely available to compete with reinforcement maintaining ASIB. Providing additional sources of reinforcement is thought to decrease ASIB by producing a shift in the allocation of responding toward accessing the newly available reinforcement. Additional, more restrictive components may be added if the competing stimuli (CS) are ineffective in reducing ASIB. These additional components are applied in accordance to the least-restrictive treatment model and include response blocking, response reduction procedures, protective equipment, or mechanical restraint.
75377681|NCT03995966|Behavioral|Combination Treatment|Combination Treatment is based on the same principles as NCR, but differs in three ways: 1) It includes three pre-treatment assessments that seek to establish competing stimuli, tasks, and self-control equipment through prompting and reinforcement; ; 2) Intensive training in each of these components is conducted to strengthen skills needed to fully access available reinforcement to compete with ASIB; and 3) Combination treatment is assessed, which includes the noncontingent delivery of competing stimuli and differential reinforcement of alternative behavior to reinforce engagement with competing tasks, and use of alternative self-control equipment. This will increase the amount and vary the sources of alternative reinforcement to more effectively reduce ASIB and self-restraint. Restrictive components may be applied as described for the NCR treatment.
75377682|NCT03978130|Other|mHealth-CR|Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
75867027|NCT03169504|Drug|Conventional drug|"Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks."
75867028|NCT03169504|Other|Acupuncture plus conventional drug|Both acupuncture and conventional drug will be used for 12 weeks treatment.
75867029|NCT03169426|Drug|Beta Blockers Carvedilol Phosphate|Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
75867030|NCT03658811|Device|intense pulsed light|Use of 6 mm SapphireCool light guide to treat upper lid margins from tragus to tragus including the nose
76029458|NCT05573555|Drug|Ribociclib|Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
75703087|NCT02430194|Drug|Pegylated interferon-alfa-2a|immunomodulator
75539343|NCT04604392|Procedure|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
75377683|NCT03973606|Other|Heath literacy assessment in Arab women in East Jerusalem|A 4-sessions intervention to increase the participant's self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
75703088|NCT00582608|Drug|131I-8H9|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein]
75703089|NCT00582608|Drug|8H9|administration of 50mg/1.73m^2 of unlabeled 8H9.
75377684|NCT03969628|Diagnostic Test|ICCMS|Risk caries assessment will consider ICCMS criteria
76029459|NCT05571735|Biological|Pfizer-BioNTech COVID-19 vaccine|Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)
76029460|NCT05571735|Biological|AstraZeneca vaccine|AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)
75539344|NCT00252096|Device|Nucleic acid amplification test|
75539345|NCT04604470|Other|Decision tool|no intervention.
75539346|NCT00565162|Drug|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
75539347|NCT05439707|Device|transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
75377685|NCT03965234|Drug|Cisplatin|Given via infusion
75377686|NCT03965234|Procedure|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
75539348|NCT05439707|Device|fake transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
75703090|NCT02579798|Device|PEEP (positive end-expiratory pressure)|
75703091|NCT03918824|Other|Data extraction from medical files|Data extraction from medical files
75703092|NCT02579330|Device|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
75703093|NCT02579330|Other|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
75703094|NCT03918902|Behavioral|Qestinnaires|Questionnaires
76029461|NCT05571735|Biological|Janssen Ad26.COV2.S COVID-19 vaccine|"Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)"
75377687|NCT03965234|Procedure|Metastasectomy|Undergo metastasectomy
75377688|NCT03947723|Device|Radiofrequency ablation|The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
75377689|NCT03921060|Drug|Denosumab|treatment with denosumab every 6 months for up to 5 years
75703095|NCT03087656|Drug|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
75703096|NCT03087656|Drug|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
75703097|NCT03870776|Drug|MAP4343|Daily oral administration of MAP4343
75703098|NCT03870776|Drug|Placebo|Daily oral administration of Placebo
75703099|NCT03918668|Behavioral|Women with recent diagnosis of breast cancer|To evaluate dietary habits of a group of women with pre and post-surgical breast cancer
76029462|NCT05569005|Other|THS use|Subjects who are not willing to quit smoking during the study duration will switch from cigarettes to using THS
75867031|NCT02406430|Procedure|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
75377690|NCT03907891|Behavioral|Motivational social support from nurse|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
75377691|NCT03907891|Behavioral|Motivational social support from nurse with additional support from significant other|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
75377692|NCT03907891|Behavioral|Attention control|A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
75377693|NCT03872752|Behavioral|FL lay leader training and workshop implementation|Intervention components will include a training course for community lay leaders, enabling them to acquire the skills to lead food literacy workshops. This includes raising their knowledge about nutrition recommendations and food labels, raisin self efficacy, and improving nutrition related organization and preparation skills.
75377694|NCT03862924|Device|Standardized Research Electronic Cigarette|Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
75377695|NCT03861156|Drug|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
75377696|NCT03827070|Drug|Afatinib|Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (<5 μm) - only 19%
75377697|NCT03827070|Drug|Talcum powder|Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (<5 μm) - only 11%
75377698|NCT03812718|Device|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
75377699|NCT03812718|Device|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
75377700|NCT03752073|Device|Trans-cervical cervical balloon|Insertion of Foley Catheter
75377701|NCT03752073|Device|Hygroscopic cervical dilator|Insertion of Dilapan-s
75377702|NCT03748303|Drug|Allopregnanolone|Administration of weekly IM injections of Allopregnanolone.
75377703|NCT03735004|Device|Transcranial electrostimulation (TES)|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
75377704|NCT03723473|Device|Magnetic Resonance Imaging (MRI)|MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
75377705|NCT03710538|Dietary Supplement|Snack beverage|Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
75377706|NCT03710538|Behavioral|Exercise|3min walk at 60% VO2max every 30 minutes,(x5)
75377707|NCT03681314|Other|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
75703100|NCT03014570|Behavioral|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
75703101|NCT03014570|Behavioral|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
75703102|NCT03869372|Device|rTMS|In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
75703103|NCT04073654|Procedure|Placement of dental implants (surgical procedure)|The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
75867032|NCT03732521|Other|Educational therapy|educational intervention to the caregiver and individualization according to their family and social context
76029463|NCT05569005|Other|Cigarette|Subjects who are not willing to quit smoking during the study duration will continue smoking their own preferred brand of commercially available cigarettes.
76029464|NCT05569005|Other|Smoking Abstinence|Subjects who are willing to quit smoking may be prescribed an NRT to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
76029465|NCT05561491|Biological|ONCOS-102|Oncolytic virus
76029466|NCT05561491|Biological|Balstilimab|Anti PD-1
76029467|NCT05558527|Behavioral|social support|social support is provided in the form of social touch (hand holding)
76029468|NCT05556252|Other|Hydrogenated water consumption|Participants will start consuming hydrogenated water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml hydrogenated water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) hydrogenated water in total. In this way, participants will be provided with hydrogenated water for three cycles.
75377708|NCT03680053|Drug|Duphaston|Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
75377709|NCT03680053|Drug|Cetrorelix|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
75377710|NCT03673007|Behavioral|Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred between August 18, 2018, and March 3, 2019.
75703104|NCT04076228|Drug|Pembrolizumab|pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
75377711|NCT03673007|Behavioral|Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after March 3, 2019.
75377712|NCT03671902|Device|Fluid shift|We are using lower body negative and positive pressure to create a fluid shift in the body. This study is investigating if there are changes in phonocardiographic parameters related to changes in blood volume caused by this fluid shift
75377713|NCT03657602|Drug|Kyleena Intrauterine System|Participant will be randomly allocated to this intervention
75703105|NCT02579252|Biological|AADvac1|
75703106|NCT02579252|Drug|Placebo|
75703107|NCT02580734|Dietary Supplement|melatonin|Cross-over randomized clinical trials
75703108|NCT05673434|Biological|TM4SF1-positive chimeric antigen receptor T-cell therapy|"Specification: 50mL/bag. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)<71> and <85> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 10-20 min."
75377714|NCT03657602|Drug|Mirena Intrauterine System|Participant will be randomly allocated to this intervention
75703109|NCT04073576|Device|AHCL|Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
75377715|NCT03648359|Procedure|multiparametric MRI Diagnostics|Patients with newly diagnosed prostate cancer enrolled in active surveillance following standard protocol including PSA, DRE and TRUS biopsies and intervention with multiparametric MRI + additional biopsies if suspicious lesions are found
75377716|NCT03633929|Other|KIOS OUD|Study Participants will evaluate software known as KIOS-OUD
75377717|NCT03632369|Diagnostic Test|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.
75377718|NCT03629626|Procedure|ERAS protocol|"preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function."
75377719|NCT03625687|Drug|Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks|8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
75377720|NCT03584399|Other|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
75377721|NCT03574194|Dietary Supplement|Methionine-restricted diet|The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
75377722|NCT03523468|Procedure|uniportal sleeve lobectomy|central lung cancer sleeve resection performed by uniportal VATS
75377723|NCT03523468|Procedure|open sleeve lobectomy|central lung cancer sleeve resection performed by open chest
75377724|NCT03504683|Behavioral|Early Time-Restricted Feeding|Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
75377725|NCT03504683|Behavioral|Mid-day Time-Restricted Feeding|Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
75377726|NCT03504683|Behavioral|Control Schedule|Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
75377727|NCT03469284|Other|Best Practice|Given standard of care therapy
75377728|NCT03469284|Drug|Methylene Blue|Given lower dose PO
75377729|NCT03469284|Drug|Methylene Blue|Given medium dose PO
75377730|NCT03469284|Drug|Methylene Blue|Given higher dose PO
75703110|NCT04073576|Device|SAP+PLGM|Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
75377731|NCT03465072|Other|Exercise training|8 weeks, 3 times per week, 30-40 minutes
75377732|NCT03452150|Drug|D-0316|If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
75377733|NCT03447340|Behavioral|Canteen and Behavior intervention|"canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes"
75377734|NCT03447340|Other|Canteen Only|canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
75377735|NCT03425331|Drug|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
75377736|NCT03425331|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
75867033|NCT03115528|Behavioral|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
75867034|NCT03732443|Diagnostic Test|FAM-CAM|Family Confusion Assessment Method
75539349|NCT00248820|Procedure|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
75377737|NCT03358797|Behavioral|Attention-control|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics
75377738|NCT03358797|Behavioral|Community based intervention with resilience training|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
75377739|NCT03358797|Behavioral|intervention-HPP|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.
75377740|NCT03358797|Behavioral|Pilot|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
75377741|NCT03348280|Diagnostic Test|Blood draw|Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
75377742|NCT03344770|Device|Active rESWT|5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
75377743|NCT03344770|Device|Sham rESWT|5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
75377744|NCT03313115|Behavioral|Sleep/Wake Protocol|"Day RN observes if completed per pt: no caffeine after 3 pm, encourage activities to prevent napping (chart % day spent napping), Lights on blinds/door open, Reasonable effort for some noise in room, Eye glasses hearing aids applied, Chair position/mobility at least 2x30 minutes.~Night RN observe if completed per pt: Appropriate pain control, Optimize room temp, Warm bath before 2200, TV off by 2200, Prevent extra alarms after 2200, Close room curtain by 2200, Dim room lights by 2200, Family out by 2200, Door half/fully closed after 2200, # RN interruptions after 2200, Offer eye mask/ear plugs, Meds administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other), Dim hallway lights by 2200, Nurses station quiet"
75377745|NCT03295136|Behavioral|Health Promotion Training for Women Employees|Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
75377746|NCT03283826|Biological|ATA188|ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
75377747|NCT03283826|Drug|Placebo|Placebo matching to ATA188
75539350|NCT04603885|Behavioral|Aerobic exercise program|A randomized controlled trial will be used to test the feasibility of a home-based exercise program to improve BDNF DNA demethylation among individuals with T2DM. A total of 42 participants will be randomized 2:1 to receive aerobic exercise intervention (n=28) or attention control (n=14) for 3 months. This ratio is used to offset an anticipated attrition imbalance across groups.
75539351|NCT04603885|Behavioral|Stretching exercise|stretching exercise
75539352|NCT04603768|Other|Theraband exercises|Group A performed theraband exercises for 6 weeks.In the first 2 weeks theraband with low resistance was used to perform exercises and then we proceeded gradually with higher resistance therabands.Theraband exercises was performed for Shoulder Flexion,Shoulder Extension Strengthening, Shoulder Internal Rotation Strengthening, Shoulder External Rotation Strengthening, Shoulder Abduction, Empty Can Exercise & Rowing Exercise with 8-10 reps, 3sec hold and 2-3 sets With each of these exercises
75867035|NCT03573206|Device|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
75867036|NCT03169348|Drug|sofosbuvir daclatasvir|oral tablets
76029469|NCT05556252|Other|Drinking water consumption|Participants will start consuming drinking water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml drinking water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) drinking water in total. In this way, participants will be provided with drinking water for three cycles.
76029470|NCT05554237|Drug|Placebo|Placebo
76029471|NCT05554237|Drug|PF-07612577|PF-07612577
75867037|NCT03169348|Drug|Ledipasvir/sofosbuvir|oral tablets
75377748|NCT03270163|Diagnostic Test|Transcutaneous electrical stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~three simple electrical stimulations,~three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
76029472|NCT05554237|Drug|PF-06264006|PF-06264006
76029473|NCT05550870|Dietary Supplement|Raw fenugreek seed powder|It will be given to group 1
76029474|NCT05550870|Dietary Supplement|Roasted fenugreek seed powder|It will be given to group 2
76029475|NCT05546151|Drug|BMS-986322|Specified dose on specified days
75377749|NCT03270163|Diagnostic Test|Magnetic stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~three simple magnetic stimulations,~three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
75377750|NCT03270163|Diagnostic Test|ultrasound measurement|The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
75377751|NCT03260647|Other|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
76029476|NCT05546151|Other|Placebo for BMS-986322|Specified dose on specified days
76029477|NCT05544695|Device|intravesical sodium hyaluronate (Cystistat®)|Cystistat will be instilled into the bladder according to the instructions for use and in line with the routine clinical practice.
76029478|NCT05538312|Drug|ARV-471|Participants will receive a single dose of ARV-471 by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of ARV-471
76029479|NCT05538312|Drug|Itraconazole|Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
76029480|NCT05537519|Biological|Phage Therapy|3-phage cocktail comprised of HP3, HP3.1 and ES19
75867038|NCT03172546|Genetic|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
75867039|NCT03631355|Drug|Tranexamic Acid|One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
76029481|NCT05529862|Genetic|Pre-treatment biopsy|Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET
75867041|NCT02411422|Device|Conventional endotracheal tube|Conventional endotracheal tube
76029482|NCT05529862|Genetic|Post treatment biopsy|Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.
76029483|NCT05529862|Genetic|Pre treatment blood sampling|Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)
76029484|NCT05529862|Genetic|Post treatment blood sampling|Sampling of 2 Streck tubes (10ml)
75377752|NCT03214029|Diagnostic Test|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
75377753|NCT03205293|Behavioral|Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren|
75377754|NCT03201523|Other|Socio-ecologial, community-based intervention|Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
75377755|NCT03167489|Behavioral|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
75377756|NCT03149211|Drug|UB-421|Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).
75377757|NCT03149211|Drug|current standard HAART treatment|Subjects will receive current standard HAART treatment as the active control group.
75377758|NCT03141671|Drug|GnRH|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
75377759|NCT03141671|Drug|Bicalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
75377760|NCT03141671|Radiation|Salvage radiation|Radiation
76029485|NCT05529277|Other|Dementia Care Management|Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
76029486|NCT05529043|Behavioral|MINISTOP app|The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.
75377761|NCT03141671|Drug|Abiraterone|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
75377762|NCT03141671|Drug|Prednisone|Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
75377763|NCT03141671|Drug|Apalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
75377764|NCT03108820|Behavioral|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
75867042|NCT02411422|Device|Reinforced endotracheal tube|Reinforced endotracheal tube
75867043|NCT03169192|Drug|Zoledronic Acid|intravenous injections once every 3 months
75377765|NCT03108820|Other|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
75377766|NCT03043430|Drug|Ketamine 100 MG/ML|Administer ketamine via mucosal atomization device
75377767|NCT03043430|Drug|Midazolam 5 MG/ML|Administer midazolam via mucosal atomization device
76029487|NCT05529043|Behavioral|MINISTOP Plus Program|Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
76029488|NCT05520593|Dietary Supplement|Complex Carbohydrate Drink|Patients will drink a complex carbohydrate drink 3 hours before surgery. Drink to be given at the preoperative holding area.
76029489|NCT05516316|Drug|EP395|Capsule for oral use
75703111|NCT02924870|Other|Health education program|"2 sessions, at 15 and 30 days after hospital discharge. The first session will consist of four stages:~Basic formation: basic lung anatomy and physiology, COPD concept, importance of tobacco, diagnostic tests for COPD, and how COPD is treated.~Care in COPD: diet, breathing exercises, physical exercise (walking, cycle, treadmill ...), lifestyle (clothing, hygiene, preening, exercise, rest, sexuality, social relations).~Management of conventional treatment: inhalers, oxygen therapy and smoking cessation.~Action Plan: the patient and the nurse will establish a target about the activities that the patient must perform as well as their frequency and duration, according to WHO guidelines.~Second session: changes from the previous session; compliance with the physical activity plan and the deviation causes; weaknesses of the patient; skills in the management of inhalers, oxygen, and breathing exercises; and a new physical activity plan."
76023385|NCT02396407|Behavioral|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children < 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
76029490|NCT05516316|Drug|Placebo|Capsule for oral use
76029491|NCT05515393|Drug|XY03-EA|The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.
76029492|NCT05515393|Drug|XY03-EA Placebo|XY03-EA Placebo
75377768|NCT03035890|Radiation|Radiation|Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
75377769|NCT03035890|Drug|Immuno-Therapeutic Agent|"Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity."
76029493|NCT05507476|Drug|Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray|The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery.
75703112|NCT02924870|Other|Conventional management|Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
76029494|NCT05507476|Drug|Epinephrine topical 1:100,000 Nasal Packs|The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
75703113|NCT00427999|Drug|imatinib mesylate|
76029495|NCT05507450|Biological|V181 High-Potency Level|0.5 mL SC dose of V181 High-Potency vaccine
75377770|NCT03004261|Biological|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
75703114|NCT00427999|Drug|Treosulfane|
75703115|NCT00427999|Drug|etoricoxib|
75703116|NCT00427999|Drug|pioglitazone|
76029496|NCT05507450|Biological|V181 Mid-Potency Level|0.5 mL SC dose of V181 Mid-Potency vaccine
76029497|NCT05507450|Biological|V181 Low-Potency Level|0.5 mL SC dose of V181 Low-Potency vaccine
76029498|NCT05507450|Biological|Placebo|0.5 mL SC dose of placebo
76029499|NCT05507138|Device|AKL-T01|AKL-T01 is an iPad-based video game designed to improve executive dysfunction and depression symptoms by targeting executive skills (multitasking) and ECN abnormalities.
75703117|NCT00427999|Drug|dexamethasone|
75703118|NCT01032967|Procedure|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
75377771|NCT03004261|Drug|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
76029500|NCT05507138|Behavioral|Metacognitive Strategy Training|Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties
75377772|NCT03004261|Drug|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
75377773|NCT02908061|Procedure|Surgery Radical Cystectomy|All surgeries will be performed in an open or laparoscopic fashion.
75377774|NCT02908061|Procedure|Ultrapro mesh|Surgery Mesh Placement. All surgeries will be performed in an open or laparoscopic fashion.
75377775|NCT02883972|Other|Intervention letter|Behavioural-insight informed letter template
75377776|NCT02883972|Other|Control letter|Invitation letter used by local area last year (updated as required)
75377777|NCT02883972|Other|Reminder|Behavioural-insight informed SMS/email reminder message to return consent form
75377778|NCT02856425|Drug|Nintedanib|Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
76023386|NCT02403739|Other|No Intervention|No Intervention
76023387|NCT05080907|Other|Observational|Subjects for observational study Various conditions & healthy subjects
75377779|NCT02856425|Drug|Pembrolizumab|Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
75377780|NCT02785952|Biological|Ipilimumab|Given IV
75377781|NCT02785952|Other|Laboratory Biomarker Analysis|Correlative studies
75377782|NCT02785952|Biological|Nivolumab|Given IV
75377783|NCT02785952|Other|Quality-of-Life Assessment|Ancillary studies
75377784|NCT02785952|Other|Questionnaire Administration|Ancillary studies
75377785|NCT02769117|Procedure|Ultrasound on fractured bone|A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures
75377786|NCT02769117|Procedure|Ultrasound on contralateral intact bone|A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
76029501|NCT05505838|Drug|Patisiran|Patisiran administered by intravenous (IV) infusion
75377787|NCT02763085|Device|Basic Filling Material|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
75377788|NCT02757573|Procedure|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
75377789|NCT02748798|Drug|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
75377790|NCT02748798|Drug|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
75377791|NCT02748798|Drug|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
76029502|NCT05502757|Other|Fruit and vegetable provision|Fresh fruits and vegetables are provided to families at no cost
76029503|NCT05495282|Other|Microvideo|Asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted.
76029504|NCT05494125|Other|Ropivacaine|Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
76029505|NCT05494125|Other|Placebo|Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
76029506|NCT05492422|Device|Central Executive Training (CET)|Central Executive Training (CET)
75377792|NCT02748798|Drug|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
75377793|NCT02748798|Device|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
75377794|NCT02748798|Device|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
75377795|NCT02748798|Device|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
75377796|NCT02654236|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
75377797|NCT02654236|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
75377798|NCT02604563|Other|Cognitive Assessment|-Baseline and no more frequently than every 6 months until death
75377799|NCT02604563|Other|Activities of Daily Living Questionnaire|"10 items about daily functional status~Baseline and no more frequently than every 6 months until death"
75377800|NCT02604563|Other|Instrumental Activities of Daily Living, subscale of the OARS|"7 items about daily functional status~Baseline and no more frequently than every 6 months until death"
75377801|NCT02604563|Other|Karnofsky Self-reported Performance Rating Scale|"1 item about daily functional status~Baseline and no more frequently than every 6 months until death"
76029507|NCT05492422|Behavioral|Behavioral Parent Training (BPT)|Behavioral Parent Training (BPT)
76029508|NCT05492006|Behavioral|Indirect contact with nature|The participants will watch a video with validated images of nature from e-Nature Positive Emotions Photography Database (e-NatPOEM). Four fifteen-minute sessions will be held on four consecutive days, totaling 1 hour.
76029509|NCT05492006|Behavioral|Intentional contact with nature|The participants will take a light walk in a park with green spaces guided by research team in a single 1-hour session, with an emphasis on sense-directed appreciation.
76029510|NCT05484401|Drug|Ibuprofen 200Mg Oral Cap|2 x 200mg Liquid Capsules once in 12 hours
75377802|NCT02604563|Other|Number of Falls|"1 item about daily functional status~Baseline and no more frequently than every 6 months until death"
75377803|NCT02604563|Other|Physical Health Section, subscale of the OARS|"13 items about comorbidity~Baseline and no more frequently than every 6 months until death"
75377804|NCT02604563|Other|MOS Social Activity Survey|"4 items about social activity~Baseline and no more frequently than every 6 months until death"
75377805|NCT02604563|Other|Unintentional Weight Loss|"2 items about nutrition~Baseline and no more frequently than every 6 months until death"
75377806|NCT02604563|Genetic|Peripheral Blood Draw|-Baseline and no more frequently than every 6 months until death
75377807|NCT02604563|Genetic|Buccal Swab|"Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~Baseline and no more frequently than every 6 months until death"
75377808|NCT02604563|Other|Heart Health and Smoking History from BRFSS questionnaire|"7 items about heart health and smoking history~Baseline and no more frequently than every 6 months until death"
75377809|NCT02604563|Other|Gait Speed|"Research coordinator will test gait speed~Baseline and no more frequently than every 6 months until death"
75539353|NCT04603768|Other|Co-contraction exercises|"Muscle co-contraction is the simultaneous contraction of the muscles acting around a joint. Subject stood upright & contracted both the groups (agonist and antagonist) simultaneously without bringing movement at shoulder joint with 6-8 reps , 3sets & 5- 15 seconds duration of sustained self-arm bracing or stiffening was maintained.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
75377810|NCT02604563|Other|Grip Strength|"Research coordinator will test grip strength~Baseline and no more frequently than every 6 months until death"
75377811|NCT02604563|Other|Height and Weight measurements|-Baseline and no more frequently than every 6 months until death
75377812|NCT02604563|Other|Blood pressure measurement|-Baseline and no more frequently than every 6 months until death
75377813|NCT02604563|Procedure|Optional bone marrow biopsy|-1 optional bone marrow biopsy
75539354|NCT04603768|Other|Isometric exercises|"Isometric exercises of shoulder were performed in subjects for 6 weeks which included isometric Shoulder flexion, shoulder abduction isometric exercise, isometric shoulder external rotation, isometric shoulder internal rotation & isometric shoulder extension with 8-10 reps, 5 sec hold and 2 sets.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
75539355|NCT04603963|Device|power breathe|respiratory muscle training 1 time a day with power breathe 3 sets of 10 repetitions
76029511|NCT05484401|Drug|Ibuprofen 200Mg Oral Tablet|2 x 200mg Tablets once in 12 hours
76029512|NCT05484401|Other|Placebo Liquid Capsule|2 x Liquid Capsules once in 12 hours
76029513|NCT05484401|Other|Placebo Tablets|2 x Tablets once in 12 hours
76029514|NCT05474651|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, the Fagerstrom Test of Nicotine Dependence,Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, smoking hazard questionnaire, motivation to quit smoking sheet, ability to quit smoking sheet, alcohol consumption, International Physical Activity Questionnaire.
75377814|NCT02604563|Procedure|Blood draw for trauma measurements|-For Arm E only
75377815|NCT02597491|Behavioral|TLC monthly|Tobacco longitudinal care monthly
75377816|NCT02597491|Behavioral|TLC quarterly|Tobacco longitudinal care quarterly
75377817|NCT02597491|Behavioral|MTM|Medication management therapy
75377818|NCT02597491|Behavioral|4 week assessment|4 week assessment
75377819|NCT02597491|Behavioral|8 week assessment|8 week assessment
75539356|NCT04604002|Device|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
75539357|NCT04604002|Device|Color Fundus Photography|Non-contact white light photography
76023388|NCT03170011|Behavioral|Exercise using the Biodex Sit2Stand Trainer|Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
76029515|NCT05473117|Diagnostic Test|Coronary Magnetic Resonance Angiography (CMRA)|A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis
75539358|NCT04604002|Device|Optical Coherence Tomography|A non-contact test that uses light waves to take cross-sectional pictures of the retina
75539359|NCT04603729|Drug|Dexamethasone 2 MG/ML|Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
75539360|NCT04603729|Drug|Methylprednisolone Injection|methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
75539361|NCT04604080|Other|service of questionnaire|Respondents will be given a survey form only and after filling this will be collected back
76029516|NCT05468814|Procedure|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
75703119|NCT01032967|Radiation|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
75703120|NCT02579018|Behavioral|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
75703121|NCT04825652|Drug|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles.
75703122|NCT04825652|Drug|PSMA-11|Patients will receive a dose of gallium (68Ga) gozetotide that is 1.8-2.2 MBq/kg of body weight (0.049-0.059 mCi/kg), with a minimum dose of 111 MBq (3mCi) up to a maximum dose of 259 MBq (7 mCi).
75703123|NCT03847220|Diagnostic Test|BOMET-QoL questionnaire|study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
75703124|NCT00661713|Biological|rMenB+OMV NZ|
75867044|NCT05000957|Device|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1.5 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
75867045|NCT05000957|Diagnostic Test|Blood analysis|Taking blood from a vein for clinical blood analysis, glucose test, hepatitis B, C viruses, human immunodeficiency viruses and syphilis test, blood clotting tests, blood type and rhesus factor determination (to include the participant in the study).
76029517|NCT05468814|Procedure|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
76029518|NCT05461547|Diagnostic Test|Lung Ultrasound|LUS will be performed and interpreted in real-time to guide acute management.
76029519|NCT05461547|Other|Usual Care|Usual care to decide diagnosis and treatment
76029520|NCT05459961|Dietary Supplement|oral spermidine|oral supplement
76029521|NCT05457101|Other|AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS. The system is an non-invasive AI system .
76029522|NCT05456139|Behavioral|Treatment as Usual|"Families in the Treatment as Usual (TAU) condition will receive usual care and EI services in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course."
75377820|NCT02584270|Device|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis improves speech and swallowing function through reshaping the palatal contours in order to obtain contact of the tongue to the hard palate during function. It is intended to be fabricated after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and associated articulation therapy are necessary for this therapy to be effective.
75703125|NCT00661713|Biological|Placebo|
75703126|NCT02578472|Drug|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
75703127|NCT02578472|Drug|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
75703128|NCT02578472|Drug|Placebo|Matching Placebo will be administered orally.
75703129|NCT00786123|Dietary Supplement|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
75703130|NCT00786123|Dietary Supplement|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
75703131|NCT04047225|Device|THE ANALGESIA NOCICEPTIVE INDEX (ANI)|Utilisation of the ANI during the operation
75377821|NCT02584270|Other|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy regardless of which arm they are matched.
75377822|NCT02565537|Procedure|LASIK|WFG vs. WFO LASIK
75377823|NCT02443727|Drug|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
75703132|NCT00782925|Other|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
75867046|NCT05000957|Diagnostic Test|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
75867047|NCT05000957|Diagnostic Test|Electrocardiography|Electrocardiography investigation to determine cardiac abnormalities (to include the participant in the study).
75377824|NCT02443727|Other|Placebo|Dosage and details described in arm.
75703133|NCT00782925|Other|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
75703134|NCT00782925|Other|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
75703135|NCT04073888|Procedure|Semen collection|Semen collection for seminogram and spermocytogram
75703136|NCT04072796|Behavioral|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
75377825|NCT02429700|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
75703137|NCT03835975|Biological|13vPnC|Pneumococcal conjugate vaccine
75703138|NCT03835975|Biological|PPSV23|Pneumococcal polysaccharide vaccine
75867048|NCT05000957|Diagnostic Test|Vaginal smear|Vaginal smear for flora investigation, oncocytology (to include the participant in the study).
75867049|NCT05000957|Diagnostic Test|Colposcopy|Colposcopy investigation to determine pre-malignant and malignant lesions of cervix, vagina or vulva (to include the participant in the study).
75703139|NCT03835975|Biological|20vPnC|Pneumococcal conjugate vaccine
75703140|NCT04072718|Radiation|Radiotherapy|34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
75867050|NCT05000957|Diagnostic Test|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
75867051|NCT05000957|Diagnostic Test|Doppler ultrasonography|Ultrasound investigation for assessing blood flow in the tissues of vulva region (to evaluate procedure efficiency).
75867052|NCT05000957|Diagnostic Test|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
75539362|NCT04603534|Other|Aged Simulation Suit|The aged simulation suit (Sakamoto Model M716, Tokyo, Japan) will be worn by students. The simulation suit consist of a several items such as loads, a soft material band with Velcro, glasses, ear plugs, gloves, belts and a cane. All the items are need to simulate one's posture just like in elderly person. Small, medium and large sizes of suits are provided by the company thereby each suit is suitable for each student related to their wearing size. Prior to this study, a total of three sets of suits will be gathered. Then, each student will perform each pre-defined scenarios step by step after the suit is worn. During the activities no help or leading will be given to the students. However, one of the researchers will supervise the students during the activities so that to integrate a safe platform. In addition, each student will be informed that if he/she can terminate the activity whenever it is required.
75377826|NCT02429700|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
75377827|NCT02429700|Drug|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
75377828|NCT02429700|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
75377829|NCT02429700|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
75377830|NCT02429687|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
75377831|NCT02429687|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
75377832|NCT02429687|Drug|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
75377833|NCT02429687|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
76029523|NCT05456139|Behavioral|Early Social Interaction Mobile Coaching (ESI-MC)|The ESI-MC coach will offer 24 weekly sessions for the 6-month ESI-MC condition. The parent will be the focus of training. Each session includes: setting the stage to develop that session's agenda; intervention implementation with these coaching steps: a) review the target, b) use guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to support caregiver reflection and independence in the activity, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and summarize plans for deliberate practice between sessions. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided online course and companion to the online group education meetings to engage families in the content of the online course and provide support through interaction with other families. Families will also participate in TAU usual care and EI services in their community.
75377834|NCT02429687|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
75377835|NCT02372136|Dietary Supplement|Individualized Nutrition|"Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91)."
76029524|NCT05454241|Drug|Anti-CD7 CAR-T|Universal CAR-T cells targeting CD7
75377836|NCT02372136|Dietary Supplement|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
75377837|NCT02268552|Drug|branaplam|
75377838|NCT02207777|Procedure|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose approximately 16-18% (with a range of 16-25%) of their body weight.
75377839|NCT02207777|Behavioral|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over approximately 6 months to lose approximately 16-18% (with a range of 16-25%) of their body weight.
75377840|NCT02194829|Drug|AZD1775|Given PO
75377841|NCT02194829|Drug|Gemcitabine|Given IV
75377842|NCT02194829|Drug|Nab-paclitaxel|Given IV
75377843|NCT02168400|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
75377844|NCT02087046|Device|ANS Totally Implantable Deep Brain Stimulation System|ANS Totally Implantable Deep Brain Stimulation System will be implanted in the VIM nucleus of the thalamus
75377845|NCT01891994|Drug|Eltrombopag|Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months
75539363|NCT00248898|Procedure|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
75539364|NCT04603378|Other|KB195|KB195 is a novel glycan
75539365|NCT04603378|Other|Polydextrose|Polydextrose is an oligosaccharide
75539366|NCT04603378|Other|Pullulan|Pullulan is an oligosaccharide
75539367|NCT04603378|Other|Maltodextrin|Maltodextrin is a digestible carbohydrate
75867053|NCT05000957|Diagnostic Test|Biopsy of the vaginal wall|Sampling of the vaginal wall material in the posterior fornix area including the mucous membrane and muscle layer will be performed during colporrhaphy or any pelvic surgical procedure for histological, immunohistochemical studies, and optical coherence tomography (elastography) (to evaluate procedure efficiency)
75867054|NCT05000957|Diagnostic Test|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
75539368|NCT04603573|Device|fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride )|5% Sodium Fluoride Varnish is a fluoride varnish which is applied to tooth surfaces for sealing dentinal tubules and treatment of hypersensitive teeth. The varnish is applied in a thin layer over the tooth with an applicator brush, and moisture from saliva cures the varnish for adhesion to the tooth surface.
75867055|NCT05000957|Diagnostic Test|Pelvic Floor Distress Inventory Questionnaire|Pelvic Floor Distress Inventory Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
75867056|NCT05000957|Diagnostic Test|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
75867057|NCT05000957|Diagnostic Test|Pelvic Floor Impact Questionnaire|Pelvic Floor Impact Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
75867058|NCT05000957|Procedure|Anterior and/or posterior colporrhaphy|Surgical procedure to repair pelvic organ prolapse followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
75539369|NCT04603573|Device|Resin based fissure sealant (3M Clinpro sealant )|"teeth will be isolated with coton rolls and saliva ejector then etching for pits and fissure then tooth will be washed then apply resin based fissure sealant on occlusal surface.~resin fissure sealant is a more sensitive for saliva."
75377846|NCT01751490|Other|physiotherapy|physiotherapy
75703141|NCT03838562|Other|Vestibular rehabilitation with virtual reality|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group."
75703142|NCT03838562|Other|Standard optokinetic stimulator or dynamic visual surround|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group."
75867059|NCT05000957|Procedure|Pelvic surgical procedure|Any pelvic surgical procedure which do not affect condition of vagina, vulva and paraurethral region followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
75539370|NCT00252213|Drug|Human BNP|
75703143|NCT04038086|Diagnostic Test|oral glucose tolerance test|Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
75867060|NCT05000957|Other|Physical examination|Pelvic examination (to include the participant in the study and observe throughout the study)
75867061|NCT05000957|Other|Сonsultation|Сonsultation of a therapist about the absence of contraindications for surgical treatment (to include the participant in the study)
75867062|NCT05000957|Genetic|Buccal smear|"Buccal smear to performing genetic testing.~The following markers will be analyzed:~ESR1 rs2234693, ESR1 rs2228480, COL3A1 rs1800255, COL14A1 rs4870723, MMP9 rs3918253, MMP10 rs17435959, LOXL1 rs2304719, WNT4 rs3820282, MMP2 rs243865, TIMP2 rs2277698, CD31 / PECAM1 rs1131012, Ki67 rs11016076."
75867063|NCT04482166|Other|Training|20-times training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
75867064|NCT04482166|Device|supraglottic airway device|supraglottic airway device
75867065|NCT03679052|Drug|Mirtazapine|Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
75867066|NCT03679052|Drug|Clonidine|Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
75867067|NCT03679052|Drug|Placebo|Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
75867068|NCT03172312|Procedure|Different range of thyroid surgery|Observe and record parathyroid status during thyroid surgery
75867069|NCT03675074|Device|Neujia|Neujia devices endoscopically deployed for jejunoileal compression anastomosis
76029525|NCT05448196|Other|Coordinated Financial Navigation Program|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
75867070|NCT03172390|Device|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
75867071|NCT03678974|Behavioral|Exercise Prescription|The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
75377847|NCT01751490|Procedure|shoulder stabilisation surgery|arthroscopic stabilisation surgery
75703144|NCT04038086|Other|circadian rhythm|Blood and CSF will be collected five times throughout the day.
76029526|NCT05447676|Drug|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose.
76029527|NCT05447676|Other|Placebo drug|The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.
75539371|NCT00565201|Drug|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
75867072|NCT03540914|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
75867073|NCT03540914|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
75867074|NCT02400970|Other|malignant cells|
75867075|NCT03671252|Drug|FOLFOXIRI|Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
75867076|NCT03671252|Drug|XELOX|XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
76029528|NCT05447676|Other|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
76029529|NCT05447676|Behavioral|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
76029530|NCT05442580|Drug|3x10(6) CART-38 cellls|3x10(6) CART-38 cells via intravenous infusion
76029531|NCT05442580|Drug|7x10(5) CART-38 cells|7x10(5) CART-38 cells via intravenous infusion
76029532|NCT05442580|Drug|7x10(6) CART-38 cells|7x10(6) CART-38 cells via intravenous infusion
76029533|NCT05442580|Drug|3x10(7) CART-38 cells|3x10(7) CART-38 cells via intravenous infusion
76029534|NCT05442580|Drug|Cyclophosphamide|Lymphodepleting chemotherapy administered at physician discretion
76029535|NCT05442580|Drug|Fludarabine|Lymphodepleting chemotherapy administered at physician discretion
76029536|NCT05441462|Procedure|Silastic Joint Replacement|Participants who have had silastic joint replacement surgery for degenerative or inflammatory arthritis within the last three years
76029537|NCT05439603|Drug|ANC-501|Five 10 mg capsules per day
75539372|NCT00565201|Drug|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
75867077|NCT03671252|Other|Chemoradiotherapy|"Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks."
75867078|NCT03671252|Procedure|TME operation|TME operation
76029538|NCT05437640|Behavioral|Protein Redistribution Diet|PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.
76029539|NCT05437640|Behavioral|Protein Consistent Diet|PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
75867079|NCT03671252|Procedure|efficacy evaluation|chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
75703145|NCT04038086|Drug|effect of insulin on peptide transport|Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
75703146|NCT03177577|Device|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
75867080|NCT02400892|Other|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
75703147|NCT03177577|Device|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
75867081|NCT03629249|Drug|Placebo once daily|Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
75867082|NCT03629249|Drug|QAW039 150 mg once daily|QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
75867083|NCT03629249|Drug|QAW039 450 mg once daily|QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
75867084|NCT02396524|Behavioral|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
75377848|NCT01390038|Device|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
75539373|NCT05361824|Drug|Ketorolac Injection|dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
75703148|NCT04072640|Drug|Voriconazole 200mg|Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
75703149|NCT04072640|Drug|amphotericin B deoxycholate (0.4-0.5mg/kg/d)|Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
75703150|NCT04072640|Drug|Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)|Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
75703151|NCT01566487|Drug|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
75703152|NCT04819646|Dietary Supplement|Marine Lipid Oil Concentrate Formulation|Marine Lipid Oil Concentrate softgels
75703153|NCT04819646|Dietary Supplement|Dietary Supplement|Dietary Supplement capsules
75703154|NCT04073264|Procedure|monofilament|In the intervention group,monofilament absorbable suture,will be used.
75703155|NCT04019210|Procedure|MODIFIED TRABECULECTOMY|Rectangular scleral flap
75703156|NCT02576288|Drug|Sitagliptin|anti-inflammatory properties
75703157|NCT02576288|Drug|Placebo|No anti-inflammatory properties
75867085|NCT03671174|Drug|Prednisone|10mg once daily orally
75867086|NCT03671174|Drug|Hydroxychloroquine|100mg to 200mg twice daily orally
75867087|NCT03671174|Drug|Aspirin|50mg once daily orally
75539374|NCT05361824|Drug|Paracetamol|dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
75703158|NCT00427921|Biological|adalimumab|160 mg loading dose, 80 mg at week 2, 40 mg every other week
75539375|NCT04603612|Procedure|Primary TURBT|"As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT."
75539376|NCT00248937|Behavioral|Positive affect and self-affect induction|
75867088|NCT03671174|Drug|low molecular weight heparin|Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
75867089|NCT03172234|Other|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
75867090|NCT03172234|Drug|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
75867091|NCT03172234|Drug|Placebo Oral Tablet|in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
75703159|NCT04794374|Other|Telerehabilitation|Telerehabilitation will consists of physiotherapist-guided exercises. Exercises will be designed by physiotherapists for COVID-19 survivors using the current guidelines. Exercise brochure will be prepared and will be sent to participants. Repetitions and sets of exercises will be modified according to the patients.
75867092|NCT02396836|Other|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
75867093|NCT02396836|Other|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
75867094|NCT03671096|Other|Intrastromal TCA Inlay|An intrastromal inlay that will be provided to correct the required hyperopic correction
75867095|NCT03623360|Diagnostic Test|Free breathing DCE-MRI|Free breathing DCE-MRI
76023389|NCT05086913|Other|Lifestyle medicine smartphone booklets|Participants will receive a pocket size 6-page booklet weekly over 8 weeks that covers 8 lifestyle medicine, mental health and CBT themes including stress, relaxation, diet, exercise, sleep hygiene, worry management, mindfulness, and positive psychology, and guides participants to set and meet short term and long-term goals.
76023390|NCT05086913|Other|Lifestyle medicine smartphone app|The lifestyle medicine app offers 8 modules with identical content as the wellness booklets, in addition to videos, relaxation, exercise and cooking demonstrations, daily challenges, record of goals, and ecological momentary assessments of diet, physical activity, sleep, stress and mood.
76023391|NCT05086913|Other|Waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
76023392|NCT05745805|Device|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
75377849|NCT01370460|Drug|Tranexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
75539377|NCT04603222|Device|SUMMIT BRUSH|SUMMIT BRUSH used for the treatment of blepharitis
75539378|NCT04603222|Other|Ocusoft Lid Scrub Original Foaming Eyelid Cleanser|treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
75539379|NCT04603339|Other|Multidisciplinary rehabilitation programme delivered via telehealth|"12 week programme of;~1) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions"
75703160|NCT00432991|Drug|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
76023393|NCT03169855|Diagnostic Test|Slit lamp (LOCS III Score)|Diagnostic procedure only
75867096|NCT03628781|Other|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
75377850|NCT01370460|Drug|Placebo|100mL 0.9% sterile saline
75377851|NCT01008241|Behavioral|Paper questionnaire|Participants will complete a paper and pencil questionnaire that measures 4 domains of interest (advanced care planning; end of life care; hospice care and death and dying) as well as demographic factors (age, marital status, education etc.)
75377852|NCT00965302|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
75539380|NCT05314829|Other|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a phase-based evidence-based treatment method for children and adolescents between 6-18 years who experience posttraumatic stress symptoms following trauma exposure. Parents or other close caregivers receive parallel sessions. It is normally provided through 12-16 sessions.
75539381|NCT00252252|Device|VPAP non-invasive ventilator|
76023394|NCT04436627|Device|Amadeo-assisted training-1|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
75377853|NCT00965302|Behavioral|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
75377854|NCT00621192|Drug|meropenem|"Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants <32 weeks GA and PNA < 2 weeks 20 mg/kg every 8 hours in infants <32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA < 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks"
75539382|NCT00252252|Device|AutoVPAP non-invasive ventilator|
75539383|NCT04603456|Drug|Lacteol fort|Lacteol fort is a drug containing lactobacilli
75539384|NCT04603456|Drug|Standardized Timothy Grass Pollen|SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .
75539385|NCT04603456|Drug|Lacteol fort and Standardized Timothy Grass Pollen|Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
75539386|NCT00252291|Drug|Aridol|
75539387|NCT00252291|Drug|Methacholine|
75377855|NCT00278200|Biological|Inactivated EBV-infected vaccine|
76022964|NCT05094635|Diagnostic Test|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: < 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
76029540|NCT05436028|Device|Transcatheter Tricuspid Valve Intervention|Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
76029541|NCT05432635|Biological|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
76029542|NCT05432635|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHSCT
76029543|NCT05432635|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
76029544|NCT05432635|Procedure|Myeloablative Conditioning|Given standard conditioning regimen
75377856|NCT00255346|Drug|Dasatinib (BMS-354825)|70 mg orally twice daily
75377857|NCT00114894|Other|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
75377858|NCT00114894|Other|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
75377859|NCT02834624|Drug|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
75377860|NCT02834624|Drug|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
75377861|NCT02917603|Behavioral|Web Conferencing|Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
75539388|NCT00252291|Procedure|Exercise challenge|
75539389|NCT04602793|Diagnostic Test|ultrasonography|All ultrasonographic examinations were performed by a single physiatrist experienced in musculoskeletal sonography. The full course of the sciatic nerve (SN), tibial nerve (TN), and common peroneal nerve (CPN) was assessed in a craniocaudal direction starting from the subgluteal fold to the popliteal fossa. The probe was placed axially on the nerves (perpendicular to the nerve) and the cross-sectional area (CSA) was measured at the same level proximal to the bifurcation for the SN , and at a point distal to the bifurcation of the SN for the TN and CPN (Figure 2). The values from the normal sides were accepted as controls.
75539390|NCT04602676|Diagnostic Test|Rehydration calculator application with DEP algorithm|4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.
75703161|NCT00432991|Drug|Saline Placebo|0.5 mL, IM (in the muscle), one time
76029545|NCT05426863|Behavioral|DeVI|A multi-component intervention is devised from the components of PM+ developed by WHO incorporating the components of violence prevention. The intervention is anticipated to provide behavioral skills to the participants in the intervention arm which will enhance their coping skills with past experiences of violence, stress management skills, problem-solving skills and safety planning skills. Further, they will be shared the best practices and lessons learned which will aid in danger assessments and prevention of future violence. The intervention will be given to intervention arm in 5 different sessions, one in each week. The 1st session of the intervention is about understanding the multi-component intervention. The 2nd session is identifying and managing problem, 3rd session is about stress management, followed by development of safety plan in 4th session and last session is about promotion of social support.
76029546|NCT05426629|Device|Venus Glow|"The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore."
75539391|NCT04602676|Diagnostic Test|Rehydration calculator application|4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
75539392|NCT04602832|Other|Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19|ENHANCE is a 12-session program designed to help improve subjective well-being, especially through the challenges of a pandemic. The ENHANCE program introduces and teaches people about the evidence-based principles and skills that have been shown across decades of research to improve overall health and well-being.
75539393|NCT05285501|Behavioral|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Conducted by a physiotherapist in group form.
76022965|NCT03310697|Other|Collection of blood and urine samples|For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
76022966|NCT03310697|Other|Clinical examination|The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
76022967|NCT02699749|Drug|TAK-931|TAK-931 oral capsules.
76022968|NCT02409199|Drug|Docetaxel|
76022969|NCT02409199|Drug|apatinib|
76022970|NCT02405923|Other|HRF|The subject will take the formula for a period of 12 months.
75377862|NCT02837744|Device|Axiostat®|Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
75377863|NCT02918617|Drug|Control toothpaste containing Novamin® technology|
75377864|NCT02918617|Drug|Control toothpaste containing 1500 ppm fluoride as MFP|
75377865|NCT02918617|Drug|Test toothpaste with nano-HAP (high concentration)|
75377866|NCT02918617|Drug|Test toothpaste with nano-HAP (low concentration)|
75703162|NCT00432835|Device|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
75867097|NCT03628781|Other|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
75703163|NCT00580970|Drug|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
75867098|NCT02717078|Other|Diet Therapy|The intervention for both study groups will be a change in diet.
75867099|NCT03371251|Drug|BOS161721|SC administration
75867100|NCT03371251|Drug|Placebo|SC administration
75539394|NCT05285501|Behavioral|Group relaxation and psychoeduaction|A single session of relaxation (10 minutes) psychoeducation (10 minutes) will contain minilectures about mental well-being and psychohygiene. In summary 20 minutes.
75703164|NCT01030081|Drug|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
75703165|NCT01030081|Drug|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
75703166|NCT00665925|Drug|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
75867101|NCT03370471|Behavioral|Retrieval Practice + Moderate Intensity Exercise|Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
75867102|NCT03370471|Behavioral|Retrieval Practice + Gentle Stretching|Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
76029547|NCT05425901|Other|biopsy|endoscopy biopsies (6)
76029548|NCT05423340|Other|E-cigarette Flavor|Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
76029549|NCT05423340|Other|Tobacco Free Nicotine Pouch|participants will use tobacco free oral nicotine pouches
76029550|NCT05418582|Drug|DZD9008 and intraconazole|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
76029551|NCT05418582|Drug|DZD9008 and carbamazepine|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
76029552|NCT05417425|Combination Product|Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant|The three omeza products were designed to be used in combination for the treatment of chronic wounds
76029553|NCT05414617|Device|Intra-articular single injection|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
76029554|NCT05414617|Device|Intra-articular three injections|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15."
76029555|NCT05414526|Other|InterCARE package|"The InterCARE package includes:~Healthcare Provider HTN/CVD Curriculum A new HTN curriculum will be developed in collaboration with local stakeholders using KITSO Master trainer program documents (Healthcare provider HIV curriculum), Primary Care Guidelines, HTN/CVD curriculum/protocols trialled in Kweneng District and the CDC Prevention Hypertension Management Curriculum.~Adaptation of HIV care EHR for HTN/CVD care EHR modifications will be done to enhance data collection around HTN/CVD care, with input from MoH.~Patient and treatment partner sessions Clinic staff will provide in-clinic education and counselling on HTN/CVD to all PLWHIV with a diagnosis of hypertension during their routine HIV clinic visit. All patients will be provided a take-home easy-to-read pamphlet on HTN/CVD risk factor management. All PLWHIV will be asked to bring a treatment partner from their social network at the 2nd study visit so that they can practice role-plays with each other."
76029556|NCT05412628|Diagnostic Test|Oral swab test|In this study, we will perform tissue biopsy at esophageal tumor site in esophageal cancer patients and perform random biopsy at middle esophagus in patients without esophageal cancer. Besides, we will take oral swab in all participants.
76029557|NCT05394103|Drug|Q901|The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
75377867|NCT02918617|Drug|Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3|
75377868|NCT02918617|Drug|Control toothpaste without nano-HAP|
76029558|NCT05394103|Drug|Pembrolizumab|Pembrolizumab will be administered Q6W
76029559|NCT05389618|Other|Diagnostic Tests|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
76029560|NCT05388474|Other|No ibalizumab or Pre-ibalizumab treatment|Patient registry
76029561|NCT05388474|Biological|On ibalizumab treatment|Patient registry
76029562|NCT05384769|Procedure|Liquid Biopsy|Undergo liquid biopsy
75703167|NCT00665925|Drug|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
75703168|NCT00665925|Drug|Placebo|Placebo, orally, either once a day, or twice a day
75703169|NCT02578004|Other|biochemical and molecular analysis|
75867103|NCT03370471|Behavioral|Study Only + Moderate Intensity Exercise|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
75867104|NCT03370471|Behavioral|Study Only + Gentle Stretching|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
75703170|NCT02578160|Procedure|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
75703171|NCT02578784|Device|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
75703172|NCT02578784|Device|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
75703173|NCT00426751|Drug|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
76029563|NCT05384769|Procedure|Low Dose Computed Tomography of the Chest|Undergo low dose CT
76029564|NCT05384769|Other|Survey Administration|Ancillary studies
75377869|NCT02918617|Drug|Test toothpaste with nano-HAP (medium concentration)|
76029565|NCT05383976|Other|Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program|This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
75377870|NCT02918617|Drug|Test cream with nano-HAP (higher concentration)|
75377871|NCT02918617|Drug|Control cream without nano-HAP|
76029566|NCT05379699|Other|TOR-BSST© eLearning Training|An online self-directed training program for TOR-BSST© dysphagia screeners.
75377872|NCT02839772|Other|Current skin care regimen plus 2% glycerine added to soaking water|
75377873|NCT02839772|Other|Current skin care regimen|
75539395|NCT05285501|Device|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
75539396|NCT04602910|Device|a web-based shared decision-making tool|Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
75539397|NCT00248976|Behavioral|Net-present value of individual health behaviors in years|
75703174|NCT00426751|Drug|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
75703175|NCT02576366|Drug|Voriconazole|
75377874|NCT02918773|Device|Smartphone otoscope|A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
75377875|NCT02918773|Device|Conventional otoscope|A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
75377876|NCT03040466|Device|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
75377877|NCT03040466|Device|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
75377878|NCT02918851|Biological|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
75377879|NCT02918851|Biological|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
75377880|NCT02918851|Biological|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
75377881|NCT03041636|Drug|Ruxolitinib|Given PO
75377882|NCT03041636|Drug|Ruxolitinib Phosphate|Given PO
75377883|NCT03042715|Behavioral|Qualitative Interviews|phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
75377884|NCT02844998|Behavioral|physical activity|patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
75377885|NCT02844998|Drug|dapoxetine 30 mg on demand|Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
75703176|NCT02576366|Drug|Rifampin|
75703177|NCT01030159|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
76029567|NCT05379699|Other|Standard TOR-BSST© Training|Standard 4-hour in-person TOR-BSST© screener training conducted by a Speech-Language Pathologist.
75377886|NCT03043105|Drug|Thalidomide, cyclophosphamide and prednisone|"Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year."
75867105|NCT03709849|Drug|experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo|the same as group description including dosage, frequency and duration
75539398|NCT04602715|Drug|MET-2|Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
75539399|NCT04602715|Drug|Placebo|Placebo Control
75703178|NCT01030237|Other|FID 114657|1 drop both eyes four times a day for 6 weeks
75703179|NCT01030237|Other|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
76029568|NCT05379439|Other|Structured Family Deliberation|Intervention families will be guided through the six modules included in the web-based decisional aid using a Structured Family Deliberation Tool. Parents will view narrated videos corresponding to each module and will be asked a series of questions related to their own lives and values. The process will continue until all modules are reviewed and all questions are completed.
75703180|NCT04046679|Drug|Bleomycin|Skin bleomycin infusion through tattoo machine
75703181|NCT04046679|Other|Saline Solution|Saline solution infusion through tattoo machine
75703182|NCT01323439|Device|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
75539400|NCT04602403|Procedure|rigid ureteroscopy|endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
75539401|NCT00565240|Drug|Marvelon|oral contraceptive
75703183|NCT00786279|Other|ethanol|15 gm ethanol daily for 6 months
75867106|NCT03709849|Drug|control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo|the same as group description including dosage, frequency and duration
75867107|NCT05343325|Drug|Tislelizumab|Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
75539402|NCT00565240|Drug|Nuvaring|contraceptive vaginal ring
75539403|NCT00565240|Drug|Letrozole|Aromatase Inhibitors
75703184|NCT00786279|Other|Ethanol-free beverage|0 grams ethanol daily for 6 months.
75703185|NCT01030315|Drug|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
75703186|NCT00791193|Drug|Paliperidone ER|
75703187|NCT00791271|Drug|Decitabine|Starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
75703188|NCT00791271|Drug|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
75867108|NCT05343325|Radiation|Low-dose radiotherapy|Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.
75539404|NCT04719780|Behavioral|Emotionally Focused Therapy for Individuals|Emotionally Focused Therapy for Individuals (EFIT) is formulated as a transdiagnostic treatment to treat depression and anxiety, adapted from the well-studied Emotionally Focused Therapy. EFIT has been formulated as an attachment-based alternative to current cognitive approaches (e.g., Cognitive Behavioural Therapy). The strong evidence for insecure attachment as an underlying factor in psychopathology, especially depression and anxiety, positions this theory well as a foundational principle to support psychotherapy for these conditions.
75539405|NCT04719780|Behavioral|Self-Help CBT Training|Individuals in the Waitlist Control Group will receive access to MoodGym, a self-help online program that helps teach CBT interventions. This access will last 15 weeks and is self-driven, meaning participants proceed through the program at their own pace.
75539406|NCT00565279|Drug|ASF1057|Twice daily, topical
75539407|NCT00565279|Drug|ASF1057|Twice daily, Topical
75539408|NCT04602637|Other|Training load|Monitoring training load during covid
76022971|NCT02405923|Other|eHF|The subject will take the formula for a period of 12 months.
76022972|NCT02409121|Behavioral|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
76022973|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
76029569|NCT05374044|Diagnostic Test|pelvic MRI for establishing new mrTRG method|they will received two pelvic MR examinations before and after neoadjvant therapy. The MRI before neoadjvant therapy is considered as baseline MRI, which is usually taken within 3 weeks before NAT. The MRI after neoadjvant therapy is considered as preoperative MRI, which is usually taken within 3-8 weeks before NAT.
76029570|NCT05372744|Other|Active Placebo labelled as antidepressant|Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.
76029571|NCT05372159|Other|none, observational study|none, observational study
75867109|NCT03709693|Device|SternaLock Blu|Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
75867110|NCT03709615|Behavioral|Internet delivered CBT for social anxiety disorder|"An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."
75867111|NCT03349645|Biological|4 mL injection of AMPION™|4 mL injection of AMPION™
75867112|NCT03678896|Behavioral|CrewD Program|The CrewD Program - Creative reading and writing in Diabetes Program - is a Diabetes self-management education and support program to help people with Diabetes coping with the disease.
75867113|NCT03678896|Behavioral|Classical structured education|The Classical educational approach consists in an educational method based on the presentation of relevant theoretical information to help people with Diabetes coping with the disease.
75539409|NCT04602442|Drug|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.
75539410|NCT04602442|Drug|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.
75867114|NCT03349333|Drug|pralatrexate|Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
75539411|NCT04602442|Drug|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
75539412|NCT00249015|Behavioral|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
75539413|NCT04602247|Dietary Supplement|SIC|Sodium Iron Chlorophyllin, whose bioavailability is to be studied
75539414|NCT04602247|Dietary Supplement|SIC + AA combined|Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
75539415|NCT04602247|Dietary Supplement|FeSO4|Ferrous sulfate serves as a positive control, whose iron bioavailability is known
75539416|NCT04602247|Dietary Supplement|FeSO4 + AA combined|Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
75539417|NCT04602247|Other|EP + FeSO4 combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
75539418|NCT04602247|Other|EP + FeSO4 + AA combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
75867115|NCT03349333|Dietary Supplement|Vitamin B12 and folic acid|The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
75867116|NCT03349099|Device|Cook Flexor|ureteral access sheath
75867117|NCT03349099|Device|Boston Scientific Navigator|ureteral access sheath
75867118|NCT03707665|Diagnostic Test|Compression ultrasound testing|Compression ultrasound testing, screening technique for diagnosing deep venous thrombosis
75867119|NCT03348163|Drug|B/FTC/TAF|B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)
75867120|NCT03348163|Drug|Current ART|Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
75377887|NCT02845700|Behavioral|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
75377888|NCT02845700|Behavioral|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
75377889|NCT03043885|Device|FDBA|Graft material used to graft extraction socket
75539419|NCT04601896|Other|SF36 questionnaire via telephone interview|SF36 questionnaire via telephone interview
75539420|NCT04602130|Other|Control|"The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
75539421|NCT04602130|Other|Massage|"The researcher applied massage (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
75539422|NCT04602130|Other|Sponge Bathing|"The researcher applied sponge bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
75703189|NCT02555163|Device|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
76029572|NCT05368883|Other|Exercise- One-Legged|"One-legged cycling ergometer training will consist of 5 minutes of warm-up, 10 minutes for each leg in the first 2 weeks, 15 minutes of cycling training in the following weeks (5-10 minutes of rest while switching from one leg to the other leg) and a 5 minutes cool-down period. In the one-legged cycling ergometer training, it will be determined randomly that the patients start the exercise with the dominant or non-dominant leg.~One-legged and two-legged exercise training will be maintained at moderate intensity (64-76%) according to maximum heart rate.~Both groups will be given walking on flat ground once a week, with an exercise intensity of 11-13 according to the Borg scale, as home exercise."
76029573|NCT05368883|Other|Exercise-Two-Legged|"Two-legged cycling ergometer training will consist of 5 minutes of warm-up, 20 minutes for the first 2 weeks, 30 minutes of cycling training in the following weeks, and a 5 minutes cool-down period.~One-legged and two-legged exercise training will be maintained at moderate intensity (64-76%) according to maximum heart rate.~Both groups will be given walking on flat ground once a week, with an exercise intensity of 11-13 according to the Borg scale, as home exercise."
76029574|NCT05363540|Procedure|pre-incisional parasternal intercostal block|LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
75539423|NCT04602130|Other|Tub Bathing|"The researcher applied tub bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
75539424|NCT00252330|Drug|SR58611A|
75539425|NCT04602052|Procedure|Dilation and evacuation|Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
75703190|NCT02555163|Device|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
75703191|NCT00786357|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
75703192|NCT00786357|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
75703193|NCT00791349|Drug|Immediate release (IR) Paliperidone|
75377890|NCT03043885|Device|PRF|Autologous blood product used to graft extraction socket
75377891|NCT03043885|Procedure|Blood Clot|Surgical treatment of extraction socket without addition of graft material
75703194|NCT00440401|Drug|fibrinogen (human) + thrombin (human)|
75703195|NCT00440401|Drug|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
76029575|NCT05363540|Procedure|post-incisional parasternal intercostal block|LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
76029576|NCT05360069|Device|Linear stapler|Linear stapler is adopted in esophagojejunostomy
76029577|NCT05360069|Device|Circular stapler|Circular stapler is adopted in esophagojejunostomy
76029578|NCT05347771|Drug|Dupilumab|Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
76029579|NCT05347771|Drug|Placebo|The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
75377892|NCT00374647|Drug|mycophenolate mofetil|
75377893|NCT00374647|Drug|sirolimus|
75377894|NCT02961062|Drug|SAF312|
75377895|NCT02961062|Drug|Placebo|
75377896|NCT00374725|Behavioral|Administration of probiotic (L. rhamnosus and L. acidophilus)|
75377897|NCT02962934|Other|Non CRRT group|Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.
75377898|NCT02962934|Other|CRRT group|"CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.~Ultrafiltrate samples at 1 hr,2h 4h 6h 8h"
75377899|NCT02919007|Device|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
75377900|NCT02964416|Drug|Injection Tramadol|
76029580|NCT05344170|Drug|30 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.
76029581|NCT05344170|Drug|300 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.
76029582|NCT05344170|Drug|Placebo|Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
75703196|NCT00783003|Drug|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
75703197|NCT00783003|Drug|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
75703198|NCT00783003|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
75703199|NCT00783003|Drug|Placebo|Matching placebo.
75703200|NCT01034215|Behavioral|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
75377901|NCT02964416|Other|placebo|0.9% Normal saline in 10 ml syringe
75377902|NCT02812771|Drug|Efinaconazole|Solution
75703201|NCT01034215|Behavioral|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
75867121|NCT03347695|Procedure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure(selected patients)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
75377903|NCT02967458|Drug|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
75377904|NCT03046225|Device|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
75377905|NCT03046225|Device|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
75377906|NCT03046225|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
75377907|NCT02813473|Radiation|Coronary Angiography|Coronary angiography is an X-ray test to diagnose diseases of the arteries that supply blood to the heart. Coronary angiography can detect weakened blood vessel walls and narrowed or blocked vessels. X-rays are taken after a special dye has been injected into the bloodstream, making the vessels and blood flow through the vessels visible on X-rays.
75703202|NCT00791427|Drug|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
75867122|NCT03347695|Procedure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
75867123|NCT02892019|Drug|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
75867124|NCT02892019|Drug|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
75539426|NCT04602208|Procedure|Retrospectively review of medical data in patients treated by focal HIFU for primary localized prostate cancer|This study concern the patients with localized prostate cancer treated by Focal HIFU for low or intermediate risk disease. Three surgeons experienced in HIFU performed the procedures. Patients were treated with the Ablatherm device [EDAP TMS S.A., Vaulx-en-Velin, France] until July 2013 and then with the Focal-One device [EDAP TMS S.A.]. The data of all the patients treated between November 2009 to December 2016, at Edouard Herriot Hospital (Lyon, France), were prospectively maintain within a central database and retrospectively reviewed. The study primary outcome was retreatment-free survival (RFS) defined as any additional further treatment: local (FT/PGA for in-field or out-of-field recurrences or radical prostatectomy or external beam radiotherapy or whole gland HIFU) or systemic salvage treatment, a positive biopsy revealing PCa with an ISUP grade≥ 2 in nontreated patients, PCa metastasis or PCa specific death. The adverse events and functional outcomes were also evaluated.
75539427|NCT04602013|Drug|Sintilimab|Body weight <60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle
75703203|NCT00786513|Other|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
75703204|NCT00786513|Other|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
75703205|NCT00791505|Drug|ciprofloxacin|1500 mg a day for 10 days
75377908|NCT02813473|Radiation|Computed Tomography (CT) scan|A CT scan is an X-ray imaging technique that uses a computer to produce cross-sectional images. It can be used to examine the heart and blood vessels for problems
75539428|NCT04602013|Drug|Chemotherapy|"Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)"
75539429|NCT04602013|Radiation|Radiation Therapy|The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
75539430|NCT04601701|Drug|Bevacizumab Ophthalmic and Intravitreal Dexamethasone.|Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
75539431|NCT04601701|Drug|Bevacizumab Ophthalmic.|Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
75539432|NCT05233748|Device|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
75539433|NCT00252369|Drug|Infliximab|
75539434|NCT00252369|Procedure|Instillation of fibrin glue|
75539435|NCT04601662|Procedure|Corticision|A special instrument will be used to cut the cortex of the alveolar bone at different locations between the lower anterior teeth
75539436|NCT04601662|Other|Traditional Non-accelerated Treatment|The normal sequence of treatment steps will be followed in this group without using any kind of acceleration methods
75703206|NCT00791505|Drug|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
75867125|NCT03709537|Behavioral|Mental Health Peer Workforce Support|"Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency."
75867126|NCT03710629|Other|Patients with driver genes|Patients with driver genes
75703207|NCT02598960|Drug|BMS-986156|
75703208|NCT02598960|Drug|Nivolumab|
75867127|NCT03710551|Other|Experimental Infant Formula|Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
75867128|NCT03710551|Other|Standard Infant Formula|Standard bovine milk-based infant formula, fed ad libitum
75703209|NCT00426361|Biological|Boostrix ® Polio|One dose of vaccine administered intramuscularly
75703210|NCT00426361|Biological|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
75377909|NCT02969876|Drug|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
75377910|NCT02970032|Drug|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
75377911|NCT02970032|Drug|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
75377912|NCT02813551|Drug|Torsemide|
75377913|NCT02813551|Drug|Placebo|
75703211|NCT00665847|Drug|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
75867129|NCT03365791|Biological|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
75867130|NCT03365791|Biological|LAG525|LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
75867131|NCT03365011|Drug|Nitrous oxide gas for inhalation|Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
75377914|NCT02970422|Other|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
75377915|NCT02817763|Procedure|Connective tissue graft (CTG)|Periodontal surgical technique to treat gingival recessions
75703212|NCT00665847|Drug|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir [LPV], darunavir [DRV], atazanavir [ATV] or saquinavir [SQV]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N[t]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
75867132|NCT03365011|Drug|Placebo gas for inhalation|Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
75867133|NCT03627767|Drug|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
75867134|NCT03627767|Drug|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
75867135|NCT03627767|Drug|Placebo|Placebo, administered as two tablets to be taken orally once daily for 40 weeks
75377916|NCT02817763|Procedure|CTG plus resin composite restoration|Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss
75377917|NCT02817763|Drug|sodium dipyrone|sodium dipyrone was recommended for all participants after the surgical procedures.
75703213|NCT01030393|Drug|human chorionic gonadotrophin|intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
75703214|NCT00783081|Drug|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
75703215|NCT00783081|Drug|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
75867136|NCT03732365|Combination Product|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
75867137|NCT03732365|Drug|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
75867138|NCT03627065|Drug|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
75867139|NCT05665985|Drug|Moringa Oleifera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
75867140|NCT03732287|Device|Cooling Anesthesia|Application of cooling anesthesia device prior to intravitreal injection
75377918|NCT03049501|Behavioral|Caregiving condition|The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.
75703216|NCT00783081|Drug|Placebo|Placebo BID for 26 weeks.
75703217|NCT00426127|Drug|Docetaxel|
75867141|NCT05665907|Other|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
75867142|NCT02142738|Drug|Pembrolizumab|Pembrolizumab IV solution
75867143|NCT02142738|Drug|Paclitaxel|Paclitaxel IV solution
75377919|NCT03049501|Behavioral|Nutrition condition|The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
75377920|NCT03050203|Other|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
75377921|NCT03050203|Other|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
75377922|NCT02970812|Device|Electrical Muscle Stimulation|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
75703218|NCT00426127|Drug|Liposomal Doxorubicin|
75377923|NCT02970812|Device|Transcutaneous Electrical Nerve Stimulation|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
75377924|NCT02846714|Behavioral|FLARE|
75377925|NCT02921737|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
75377926|NCT02819011|Device|MBB AFO|Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO
75377927|NCT02819011|Other|Control|Subjects will be provided with a pair of New Balance 813 shoes
75377928|NCT02846792|Biological|Nivolumab|Given IV
75377929|NCT02846792|Drug|Plinabulin|Given IV
75377930|NCT02850068|Device|Geniculate Artery Embolization|Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
75377931|NCT02819323|Drug|PEG-ELS|polyethylene glycol based bowel preparation
75377932|NCT02819323|Drug|BLI800|BLI800 bowel preparation
75703219|NCT00426127|Drug|Enoxaparin|
75703220|NCT02578212|Other|Placebo|
75703221|NCT02578056|Device|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
75377933|NCT03053401|Procedure|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
75377934|NCT03053401|Procedure|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
75377935|NCT03053401|Device|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
75703222|NCT02578056|Procedure|Genital prolapse surgery|Surgical correction of genital prolapse
75377936|NCT03053401|Device|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
75377937|NCT03053401|Drug|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
75377938|NCT03053401|Drug|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
75377939|NCT02819557|Drug|Ataluren|White to off-white powder for oral suspension.
75377940|NCT02820181|Device|novel tracheostomy bi-ties|The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
75377941|NCT02820181|Device|traditional Tracheostomy ties|Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
75377942|NCT02860286|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
75377943|NCT03054103|Drug|Midazolam + Ketamine 10 MG/ML: 0.5 ML|5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
75703223|NCT00783159|Procedure|Power Training|Power training, Vitamin D substitution
75703224|NCT00783159|Procedure|Strength Training|Strength training, Vitamin D substitution
75703225|NCT00783159|Other|Control|Vitamin D substitution, Lifestyle consultation
75703226|NCT02555709|Drug|VTP-43742|VTP-43742 administered as an oral capsule once daily
75703227|NCT02555709|Drug|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
75703228|NCT02555709|Drug|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
75703229|NCT04047069|Behavioral|Awareness Training and Person-Centered Occupational Therapy Intervention|Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.
75703230|NCT04047069|Behavioral|Awareness Training|"Exp.~General information about HD~Approaches to Coping with HD Symptoms~Self care skills (eg hygiene)"
75867144|NCT02142738|Drug|Carboplatin|Carboplatin IV solution
75867145|NCT02142738|Drug|Pemetrexed|Pemetrexed Lyophilized Powder for Infusion
75867146|NCT02142738|Drug|Cisplatin|Cisplatin IV solution
75867147|NCT02142738|Drug|Gemcitabine|Gemcitabine Lyophilized Powder for Infusion
75377944|NCT03054103|Drug|Midazolam + Ketamine 10 MG/ML: 1 ML|10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
75377945|NCT03054103|Drug|Midazolam + Normal saline|Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
75539437|NCT04601545|Behavioral|Pulmonary rehabilitation|"Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation."
75539438|NCT04601545|Device|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
75539439|NCT00565318|Drug|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
75703231|NCT00425503|Drug|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
75703232|NCT00786669|Drug|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
75703233|NCT00786669|Drug|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
75703234|NCT00786669|Drug|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
75377946|NCT02860988|Behavioral|MCCC treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
75377947|NCT02822287|Drug|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
75703235|NCT00786669|Drug|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
75867148|NCT03617861|Drug|Human Secretin|Injected once over one minute
75867149|NCT03617861|Drug|Placebo|Injected once over one minute
75867150|NCT03732053|Other|GPR Intervention Research group|The research intervention consisted in the reappointment of three GPR therapeutic postures.
75377948|NCT03043274|Drug|Cangrelor|Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
75377949|NCT03054649|Device|HARMONI® Modular Intraocular Lens System|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
75867151|NCT03614975|Biological|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
75703236|NCT00786669|Drug|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
75703237|NCT01030471|Behavioral|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
76029583|NCT05343611|Behavioral|Combination of High Protein Diet and Physical Exercise protocol|"A high Protein Diet (HPro) will be provided to maintain individual caloric endpoint and to adjust protein intake to 0.9-1.0 g/Kg ideal body weight. Each participant will receive a tailored diet (taking into account personal preference) which will follow common general guidelines. Servings of food high in polyphenols will be limited to one per day.~Physical exercise will be undertaken three times each week for about 50 minutes per session. The intervention will consist of both aerobic and strength training exercises. Aerobic exercise will consist of walking on a treadmill with 4 x 4 minutes at (85-95% of HRmax), interrupted by 3-minute active recovery periods (60-70% of HRmax). Strength exercise consists of maximal strength training, using a seated leg press with 4 sets of 4 repetitions at ~90% of maximal strength (1RM). Rest periods between the sets will be 3-4 min."
75539440|NCT00565318|Drug|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
75539441|NCT00249054|Device|ASR hip prosthesis|Implantation of resurfacing prosthesis
75539442|NCT00249054|Device|ReCap hip prosthesis|Implantation of resurfacing prosthesis
75539443|NCT00565357|Device|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
75377950|NCT03054649|Procedure|Intraoperative optic exchange|Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
75377951|NCT04333316|Procedure|large head|implantation of large head total hip
75377952|NCT04333316|Procedure|dual mobility cup|implantation of dual mobility total hip
75539444|NCT00565357|Other|Control|Standard care in the neonatal intensive care unit
75539445|NCT05201144|Drug|Sildenafil Oral Suspension|Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
75539446|NCT05201144|Other|Placebo|Equal volume of placebo
75539447|NCT00252408|Drug|Hormone replacement therapy|
75539448|NCT04601389|Biological|"Omalizumab (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
75539449|NCT04601389|Biological|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
75539450|NCT04600843|Other|Physical therapy with Patient education|patient manual was translated and validated in Urdu which was provided to patients so that they can follow it at home
75539451|NCT04600843|Other|Physical Therapy without patient Education|Group B was only treated with proper physical therapy treatment protocol according to patient presenting condition
75539452|NCT00565396|Drug|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
75539453|NCT00252447|Procedure|Pre-Operative Conformal Radiotherapy|
75539454|NCT04600765|Diagnostic Test|hsCRP serum measurement of inflammation|hsCRP inflammation change as result of non-contaminated diet
75539455|NCT04601116|Drug|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg per day for 2 years
75703238|NCT00786747|Behavioral|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
75703239|NCT00786747|Behavioral|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
75377953|NCT02975804|Device|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
75377954|NCT03054805|Drug|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight < 15 kg, 500 mg per day for weight <15-30 kg, and 1000 mg per day for weight > 30 kg
75377955|NCT03054805|Drug|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight < 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight > 30 kg
75703240|NCT00791739|Drug|trazodone, pregabalin|"phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
75703241|NCT00425269|Behavioral|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
75703242|NCT02555475|Other|community based hepatitis C care and treatment|
75703243|NCT00791895|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme
75703244|NCT01807728|Other|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
75703245|NCT01807728|Other|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
75867152|NCT03614975|Biological|Fluzone inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
75867153|NCT03613649|Drug|AZD0914|Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
75377956|NCT00374101|Drug|omeprazole|
75377957|NCT00374101|Drug|pantoprazole|
75377958|NCT00374738|Behavioral|Guided Imagery for Trauma (GIFT)|Guided Imagery for Trauma (GIFT) - music and voice narration over a 12-week intervention. The control intervention included a relaxing music audio (the same music used in the guided imagery audio but without the narrative voiceover), PDA to log audio use, orientation and weekly phone consults, but did not have access to the patient advocate or to the guided imagery instructions provided on the GIFT audio.
75377959|NCT00374179|Drug|CT-322|IV solution, weekly or bi-weekly
75377960|NCT00374257|Procedure|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
75539456|NCT04601116|Drug|Placebo oral tablet|Placebo 1 tablet per day for 2 years
75539457|NCT04600687|Other|Placebo tablets|Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
75539458|NCT00249093|Drug|oxygen|
75867154|NCT03613649|Drug|Moxifloxacin|Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.
75539459|NCT04600726|Other|no intervention|no interventioni
76029584|NCT05343611|Dietary Supplement|HPP Choko|Participants add to their diet with 30 g/day of 85% dark chocolate high in polyphenols
76029585|NCT05343611|Dietary Supplement|HPP/VE Choko|Participants add to their diet 30 grams of 85% dark chocolate high in polyphenols, functionalized with 100 mg of Vitamin E per day.
75377961|NCT02979626|Procedure|Respiratory nasal swab|Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
75377962|NCT02822599|Drug|RiaStAP|To decrease post-operative bleeding volume.
75377963|NCT02822599|Drug|Saline|Placebo consisting of normal saline 0.9%
75377964|NCT04737421|Device|NobelActive TiUltra implant|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
75377965|NCT04737421|Device|NobelParallel CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
75539460|NCT04600453|Other|Physical Exercise|The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
75539461|NCT04600297|Device|ELS Even Stronger (3D Printed Resin Composite)|Missing of one premolar cases will be restored using the 3D Printed resin composite (ELS Even Stronger, Saremco, Switzerland). The steps of the procedure: Preparation, scanning, colour determination, design of the restoration, printing the restoration, adjusting occlusion, finishing and polishing, cementation.
75867155|NCT03613649|Other|Placebo|Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
75867156|NCT04652856|Device|Electrical Brain Stimulation|Electrical Brain Stimulation (EBS) will be used to disrupt local neural activity in inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of EBS will be examined on attention and eye movement behavior, and all participants will receive both EBS and sham electrical brain stimulation.
75867157|NCT04652856|Device|Sham Electrical Brain Stimulation|Sham electrical brain stimulation (SEBS) will be applied to inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of SEBS will be examined on attention and eye movement behavior, and all participants will receive both SEBS and EBS.
75867158|NCT03096288|Drug|Evolocumab|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
75867159|NCT03096288|Other|Placebo|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
76029586|NCT05342844|Drug|Dexmedetomidine 0.5 mcg|0.5 mcg/kg
76029587|NCT05342844|Drug|Dexmedetomidine 1 mcg|1 mcg/kg
75377966|NCT04737421|Device|NobelReplace CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
75377967|NCT04737421|Device|Nobel Biocare N1 TiUltra TCC implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
75377968|NCT00373789|Drug|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
75377969|NCT00373789|Drug|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
75377970|NCT03045926|Drug|Diosmectite (Smecta®)|
75377971|NCT02928055|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
76029588|NCT05339087|Drug|Riociguat Oral Tablet|Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study
75377972|NCT02983058|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner
76029589|NCT05339087|Other|Placebo|Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
75377973|NCT02983058|Device|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
75377974|NCT00373867|Behavioral|Standard physical therapy|Treatment-based classification physical therapy
75377975|NCT00373867|Behavioral|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
75377976|NCT00373867|Other|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
75377977|NCT02983448|Device|transcutaneous vagus nerve stimulation|All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
75377978|NCT03061513|Drug|Ubiquinol|Ubiquinol caplets 600mg/day
75539462|NCT04600024|Diagnostic Test|Ultrasound guided diagnostic injection|4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
75539463|NCT00249132|Drug|risperidone|
75539464|NCT05154461|Other|Alginate|BHB covered in alginate will be realised in stomach-duodenum
75539465|NCT05154461|Other|Pea-protein|BHB covered in pea-protein will be released in ileum-colon
76029590|NCT05333133|Dietary Supplement|high calorie formula (oral nutritional supplement/ONS)|"every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90."
75539466|NCT00565474|Drug|Fluvastatin|Graft vasculopathy
75539467|NCT00252486|Drug|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
76029591|NCT05332509|Device|C-BRACE|The C-BRACE is a custom made Knee-Ankle-Foot-Orthosis with a microprocessor-controlled hydraulic knee-joint articulation. The C-BRACE technology offers to a patient with knee locking deficiencies the following advantages: approximation of the physiological gait pattern, stability while standing and walking, adaptation to various surfaces, inclines, gait situations and walking speeds.
75539468|NCT04600492|Drug|Riociguat Oral Tablet|Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo
76029592|NCT05332509|Device|SCO|The SCO is a custom made Knee-Ankle-Foot-Orthosis with a knee-joint locked during stance phase and released during swing phase.
75539469|NCT00402935|Other|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
75539470|NCT00402935|Procedure|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
75539471|NCT00402935|Procedure|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
75539472|NCT00402935|Procedure|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
75867160|NCT03731975|Procedure|CTZ Paste|Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
76029593|NCT05323617|Drug|Romiplostim|Administered as a subcutaneous injection.
76029594|NCT05323617|Drug|Antithymocyte Globulin|Horse or rabbit antithymocyte globulin administered as an intravenous infusion.
75377979|NCT03061513|Dietary Supplement|Placebo|placebo
75377980|NCT03046472|Other|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day."
75377981|NCT03062605|Drug|Iodine (Betadine)|
75377982|NCT03062605|Biological|NaOCL|
75377983|NCT03062917|Diagnostic Test|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
75377984|NCT03047174|Other|Mepitel® Film|Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.
75377985|NCT03047174|Other|Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily."
75539473|NCT04600063|Procedure|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
75703246|NCT01030627|Device|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
76029595|NCT05323617|Drug|Cyclosporine A|Administered orally.
76029596|NCT05322161|Behavioral|yoga classes|"There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~Yoga postures (Asana) = low impact gentle postures meant to be done individually~Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~Meditation (Dhyana) = guided meditation"
76029597|NCT05316012|Device|Smart diapers|"Residents receive standard continence care while using the smart diaper (without the alerting system) - fase 1~Diapers are changed as usual, e.g., after morning care, visual soiling, unpleasant odor, saturation, leakage.~Residents receive continence care while using the smart diaper with the alerting system - fase 2"
76029598|NCT05315297|Device|PEMF device|PEMF device wear overnight daily for four weeks
76029599|NCT05315297|Device|Sham PEMF device|Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
76029600|NCT05310877|Behavioral|Values-Affirmation|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. Following the intervention session, participants will receive electronic pill box(es) that are labeled with the participants' most important core value(s) and will be asked to use these pill box(es) to take their HF medications for 4 weeks.
76029601|NCT05302765|Other|Normal Saline Intravenous Fluids|Administration of normal saline intravenous fluids (20 milliliters/kilogram).
76029602|NCT05293431|Other|Transcranial Alternate Current Stimulation|tACS utilizes low-amplitude alternating currents to modulate brain activity and entrain specific brain oscillations depending on the applied stimulation frequency
75703247|NCT00786981|Other|Epidural steroid injection plus physical therapy|Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
75703248|NCT00786981|Other|Epidural steroid injection|Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
76029603|NCT05293431|Other|Sham stimulation|Sham stimulation will simulated the real tACS stimulation
76029604|NCT05292508|Diagnostic Test|C-reactive Protein Rapid Diagnostic Test|In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed. In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained. This will be added to specimen dilution buffer. Then the sample will be mixed by inverting the tube upside down 10-15 times. Then the yellow dip area of the dipstick will be placed into the diluted sample. It will be held there until the liquid rises to the result area by capillary action. The the dipstick is removed from the solution and placed in a horizontal position. The timer will be started and result will be interpreted in 5 minutes. Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
76029605|NCT05291169|Device|Omeza® Collagen Matrix|"Omeza® Collagen Matrix is a wound care matrix comprised of hydrolyzed fish collagen infused with cod liver oil, which acts as an anhydrous skin protectant. When applied to a wound surface, the matrix is naturally incorporated into the wound over time. Omeza® Collagen Matrix is designed for intimate contact with both regular and irregular wound beds, to provide a conducive environment for the patient's natural wound healing process.~Contains: Fish collagen, cod liver oil, medium chain triglyceride oil, coconut oil, hemp seed oil, triethyl citrate, ethyl linoleate, caprylic acid, red palm concentrate, monolaurin, cetyl esters NF, beeswax, ascorbyl palmitate, sea salt Omeza® Collagen Matrix is supplied in a sterile single use vial."
75703249|NCT00430573|Drug|D-cycloserine|Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
75703250|NCT00430573|Drug|Placebo|Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
75703251|NCT00783315|Behavioral|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
75703252|NCT00783315|Behavioral|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
75703253|NCT00783315|Behavioral|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
75867161|NCT03731975|Procedure|GP Paste|Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
76029606|NCT05290766|Procedure|placement of four dental implants|"placement of four dental implants according to the  All on four concept"
76029607|NCT05290766|Procedure|placement of two dental implants|"placement of two dental implants according to  All on two concepts"
75539474|NCT04600063|Procedure|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
75703254|NCT04073940|Behavioral|Targeted Ballet Program|All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
75703255|NCT00783393|Drug|Temozolomide|Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
75867162|NCT05417256|Device|Tappa Endobronchial Blocker|After intubation, the Tappa bronchial blocker will be advanced either through the intubation tube or outside the tube using a fiberoptic broncoscope. Once the position of the blocker is confirmed, the cuff of the blocker will be inflated with 1-3 mL of air. Since Tappa blocker has an autoinflation system, the anaesthetist can both inflate the cuff with one hand and operate the fiberoptic broncoscope at the same time.
75703256|NCT00783471|Drug|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
75703257|NCT00783471|Drug|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
75703258|NCT00792051|Biological|Inactivated influenza vaccine|0.5ml intramuscular single dose
75703259|NCT00792051|Biological|Saline|0.5ml intramuscular, one dose
75703260|NCT00787215|Other|observational: no treatment involved|observational: no treatment involved
76029608|NCT05290766|Device|mandibular full arch prosthesis|loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis
76029609|NCT05290610|Other|Functional mapping|Intracranial EEG data acquisition, observation and behavioral testing, and intracranial electrical stimulation
76029610|NCT05278533|Dietary Supplement|BioPlete™ Advanced Formula|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
76029611|NCT05278533|Dietary Supplement|Placebo|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
76029612|NCT05276674|Device|ZNN Bactiguard Retrograde Femoral Nail|Femoral fracture internal fixation.
76029613|NCT05275699|Drug|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
76029614|NCT05263674|Drug|Rapid sedation|High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
75539475|NCT04599985|Other|star excursion balance training (SEBT)|The SEBT is aimed to be maintained the single limb stance on one leg while reaching farthest possible with the swing leg. An individual can reach farthest with the swing leg while maintaining the balance on the stance leg
75867163|NCT05417256|Device|Arndt Endobronchial Blocker|After intubation, the endobronchial blocker will be passed through a multiport airway adapter that is placed at the proximal end of the tracheal tube.The fiberoptic broncoscope will be passed through the port and then through the guidewire loop at the end of the blocker. The bronchial blocker and the broncoscope will be advanced as a single unit into the target part of a right or left lung. The broncoscope will be withdrawn into the trachea and the blocker cuff will be inflated and the position of the blocker will be confirmed using the fiberoptic broncoscope. The wire loop will be removed after correct placement of the blocker. Once the guide wire is removed, the blocker can't be replaced.
75539476|NCT04599985|Other|Simplified star excursion balance training (SSEBT)|It is one of the training protocols, in a simplified way, with respect to star excursion balance test. It consists a series of reaching tasks for the lower limbs in three-directions i.e., anteromedial, medial and posteromedial.
75703261|NCT00792129|Device|The Atavi System|"The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used."
75703262|NCT00792207|Other|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
75703263|NCT00792207|Other|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
76029615|NCT05259085|Drug|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
76029616|NCT05257668|Other|High Intensity Interval Exercise Training|High Intensity Interval Training Group
75539477|NCT04599712|Drug|Amivantamab|Amivantamab will be administered intravenously at the recommended doses based on weight (1050 milligram [mg] or 1400 mg) once weekly for the first 4 week cycle (1 cycle equals to 28 days), then every 2 weeks thereafter.
75539478|NCT04599673|Drug|AMNIOGEN|"AmnioGen® amnion matrix allograft is a bioactive tissue matrix processed from 100% human amniotic tissue. The allograft is processed with advanced technology so the graft can be suspended in liquids and applied through needles and syringes.~Amniotic tissue is composed of structural extracellular matrix, which is rich in various types of collagen, growth factors, cytokines, and specialized proteins. Thus, the application of amniotic tissue is known to modulate localized tissue inflammation, reduce scar tissue formation and promote the healing of soft tissue."
75539479|NCT04599673|Other|normal saline|10 ml normal saline
75703264|NCT00787293|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
76029617|NCT05257668|Other|Moderate Intensity Exercise Training|Moderate Intensity Training Group
75867164|NCT05665829|Procedure|Awake transnasal laser-assisted surgery (TNLS)|The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.
75703265|NCT02460900|Drug|Varenicline|
75703266|NCT02460900|Behavioral|Positively Smoke Free|
75703267|NCT02460900|Drug|Placebo|
75867165|NCT05665829|Procedure|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
75867166|NCT03731897|Other|5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
75867167|NCT03731897|Other|9 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
75867168|NCT02072148|Procedure|PET/CT|PET scan or CT scan q 4 months for 5 years
75703268|NCT02460900|Behavioral|Standard of Care|
75703269|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
75703270|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
75867169|NCT02072148|Radiation|Radiotherapy|Postoperative XRT 5000 cGy
75867170|NCT02072148|Radiation|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy"
75867171|NCT02072148|Radiation|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy"
75539480|NCT04599595|Device|Peristeen (Coloplast)|"Patients with severe intestinal dysfunction impairment (PAC QoL score ≥ 32) will be offered the adoption of the TAI (Transanal Irrigation) with Peristeen Device as a way to manage their own evacuation, replacing any other measure used until that moment (suppositoires, clisms exceptionally cc) with the exception of the possible intake of macrogols and/or prebiotics and/or probiotics which instead patients can continue. This treatment will be proposed to all patients with severe impairment of intestinal function.~The TAI training with Peristeen will be carried out at the surgical clinic of the Surgical Department of the Ferrara University Hospital, Italy, by the health personnel involved in the study, usually in a single session, but more sessions may be necessary, with the continuation of the TAI for 4 weeks or with patient's exclusion from the study if the guarantees of appropriate use of the device will not be reached."
75539481|NCT00565513|Procedure|blood test|cord blood and maternal milk test
75539482|NCT00565552|Drug|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
75703271|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
75703272|NCT00783549|Drug|an undetermined dose of GSK1292263|GSK investigational product or placebo
75703273|NCT00783549|Drug|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
75703274|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
75867172|NCT01735812|Device|IceSense3 system|The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
75703275|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposures.
75703276|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
75703277|NCT00783627|Procedure|Angiography|Angiography done at the J1 visit
75867173|NCT05451030|Device|remote ischemic preconditioning|The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
75703278|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
75703279|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
75703280|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
75703281|NCT00430495|Drug|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
75703282|NCT02554695|Drug|placebo|subcutaneous saline injection
75703283|NCT02554695|Drug|denosumab|single subcutaneous injection of denosumab 60 mg
75703284|NCT00792285|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
75703285|NCT00792363|Drug|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
75703286|NCT00792363|Drug|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
75703287|NCT00787683|Device|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
75703288|NCT00425113|Drug|Metronidazole|
75703289|NCT00425113|Procedure|Blood Draw|
75703290|NCT00425113|Procedure|CT Scan|
75703291|NCT00425113|Procedure|PET Scan|
75539483|NCT00414687|Drug|Ventavis (Iloprost, BAYQ6256)|
75539484|NCT04599244|Other|emergency pulpotomy|removal of coronal pulp
75867174|NCT03611075|Other|No Intervention|No interventions are administered in this study
76029618|NCT05251181|Drug|Normal Saline|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
75867175|NCT05430204|Device|Group 1: one-hour GCT|Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be diagnosed with GDM and treated according to the standard of care. This group will also receive the CGM.CGM data will not be observed until completion of study and will not be available to provider. Participants will return transmitter at follow up visit after completion of 7 days.Group I will receive routine prenatal care follow-up depending upon one-hour glucose results as written above.
76029619|NCT05251181|Drug|Centhaquine|Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
76029620|NCT05248009|Device|Semi-Permanent Tattoo Ink|Subjects will receive semi-permanent tattoo ink in place of the permanent ink utilized in the standard of care. Subjects will be monitored during their treatment course and for 15 months following treatment completion.
76029621|NCT05247034|Dietary Supplement|Cocoa|Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.
76029622|NCT05247034|Other|Placebo|Each capsule contains 500 mg of methylcellulose
75539485|NCT04599283|Device|MenHealth Uroflowmeter|MenHealth Uroflowmeter is a mobile application and FDA cleared medical device that analyzes the sound of urine hitting the toilet water when a male urinates and generates voiding data (maximum flow, average flow, and voided volume) and a flow curve. All test results are saved in an automated voiding diary.
75377986|NCT02829307|Drug|89Zr-GSK3128349 1 mg|89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
75539486|NCT04599322|Other|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
76029623|NCT05236348|Device|Aktiia.product-us|The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
76029624|NCT05231837|Behavioral|Experimental: Fee Waiver|Fees are waived for youth sports programs at the park and recreation center
76029625|NCT05231837|Behavioral|Fee Waiver Plus Intensive Outreach|Fees are waived for youth sports programs at the park and recreation center and intensive outreach is conducted in the neighborhood through community advisory boards and partner engagement.
76029626|NCT05230030|Behavioral|Improvisation Workshop|Each improvisation workshop will involve a series of exercises derived from an improvisation game book previously developed by study investigators, followed by a reflective debrief of the experience.
76029627|NCT05229965|Drug|Paracetamol|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
76029628|NCT05229965|Drug|Paracetamol Codeine|14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
75377987|NCT02985710|Device|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
75539487|NCT04599205|Drug|Tranexamic acid|fractional co2 laser, microneedling and topical tranexamic acid gel
75703292|NCT00792441|Device|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
75703293|NCT01034293|Dietary Supplement|low feeding frequency (3x)|3 meals a day
75703294|NCT01034293|Dietary Supplement|High feeding frequency (14x)|14 meals a day
76029629|NCT05229965|Drug|Paracetamol caféine|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
76029630|NCT05229120|Behavioral|Episodic Future Thinking|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
76029631|NCT05227391|Procedure|Oral Letrozole|Oral Letrozole at a dose of 2.5mg daily will be started on days 3-5 of the menstrual cycle and will be continued for 5 days.
76029632|NCT05227391|Procedure|Oral estradiol valerate|Oral estradiol valerate at a dose of 3mg twice daily will be started on days 3-5 of the menstrual cycle.
76029633|NCT05220631|Behavioral|Technology intervention|Older Adult Technology Services (OATS) 5-week technology intervention
76029634|NCT05220631|Behavioral|Digital Nutrition Intervention|15-week nutrition intervention delivered completely online
75539488|NCT04599127|Other|Mobilization with movement|The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation
75539489|NCT04599127|Other|Conventional physical therapy|The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
75539490|NCT04599400|Other|There is no intervention in our study|There is no intervention in our study
75703295|NCT03919032|Other|This is an observational study without intervention|This is an observational study without intervention
75703296|NCT00792519|Behavioral|HIV support group|group support
76029635|NCT05215600|Device|Anaverse Shoulder System|Reverse Shoulder Arthroplasty
75377988|NCT02985710|Procedure|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
75539491|NCT04598737|Procedure|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
75539492|NCT04598737|Procedure|Lithium disilicate|Lithium disilicate laminate veneer treatment
75703297|NCT00792519|Behavioral|CBT|group cognitive behavioral treatment
75703298|NCT03994783|Drug|Rituximab|2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
76029636|NCT05211986|Drug|IMM01-STEM|IMMUNA (IMM01-STEM) is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
76029637|NCT05209880|Behavioral|ED GOAL|The emergency department clinician-led, behavioral intervention (ED GOAL) is designed to engage seriously ill yet clinically stable older adults in the emergency department to address their values and preferences towards end-of-life care with their outpatient clinicians. The intervention consists of an interview to discuss participants' values and preferences for end-of-life care. The participants will receive coaching on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and outpatient clinicians. The participants' outpatient clinicians will also receive a summary of what participants disclosed via email or mailed letter.
76029638|NCT05207709|Drug|Ribociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
75703299|NCT03994783|Drug|Methylprednisolone|Intravenous infusion of methylprednisolone
76029639|NCT05207709|Drug|Palbociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
75377989|NCT02985710|Procedure|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
75703300|NCT03994783|Drug|Intravenous Immunoglobulin|High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
75703301|NCT03994783|Procedure|Plasma Exchange|Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
75703302|NCT04072536|Device|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
76029640|NCT05207709|Drug|Paclitaxel +/- Tislelizumab|Patients in this arm could receive as the first line of therapy
76029641|NCT05207033|Other|Regulated ad condition|This intervention will determine if restriction of appealing features in e-cigarette ads deter young adults from trying the product.
76029642|NCT05207033|Other|Unregulated ad condition|This intervention will determine if unrestricted appealing features in e-cigarette ads deter young adults from trying the product.
75377990|NCT03063385|Behavioral|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
75377991|NCT03063385|Behavioral|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
75377992|NCT02931565|Drug|Olinciguat|oral tablet
75377993|NCT02931565|Drug|Matching Placebo|oral tablet
75377994|NCT02986958|Other|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
75539493|NCT00565591|Drug|Albuterol sulfate|Single dose dry powder by inhalation
75539494|NCT00252603|Drug|Galantamine|
75539495|NCT00565630|Device|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
75539496|NCT00565708|Other|placebo|Placebo Comparator
75539497|NCT00565708|Drug|Acetylsalicylic acid|Adjuvant Therapy
75703303|NCT04072536|Device|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
75539498|NCT05011526|Biological|MVC-COV1901|Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
75703304|NCT00440011|Drug|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
75703305|NCT00440011|Drug|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
75703306|NCT03105102|Drug|Placebo for Risankizumab SC|Placebo for Risankizumab SC Subcutaneous (SC) Injection
75703307|NCT03105102|Drug|Risankizumab IV|Risankizumab IV Intravenous (IV) infusion
75703308|NCT03105102|Drug|Placebo for Risankizumab IV|Placebo for Risankizumab IV Intravenous (IV) infusion
75703309|NCT03105102|Drug|Risankizumab SC|Risankizumab SC Subcutaneous (SC) injection
75703310|NCT03105102|Drug|Risankizumab On-Body Injector (OBI)|Subcutaneous (SC) injection; on-body injector (OBI)
75703311|NCT00877448|Biological|Adjuvanted Multimeric-001 250 Mcg|
75703312|NCT00877448|Biological|Multimeric-001 250 Mcg|
75377995|NCT02986958|Other|Usual care|routine primary care
75703313|NCT00877448|Biological|Phosphate Buffered saline|
75377996|NCT02829463|Radiation|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
75377997|NCT03050294|Behavioral|Phone calls|Phone calls twice daily
75377998|NCT03050294|Drug|Desoximetasone 0.25% spray|Desoximetasone 0.25% spray applied twice daily
75377999|NCT02831569|Drug|Loxoprofen sodium|
75703314|NCT00877448|Biological|Adjuvanted PBS|
75703315|NCT00877448|Biological|Adjuvanted Multimeric-001 500 Mcg|
75867176|NCT05430204|Device|Group 2: CGM placement|"CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after placement.The device will be reviewed by the Diabetes team 48 hours after CGM is removed. The recommended range for glucose during pregnancy is defined as 63-140 mg/dL .The time above range has been defined as ≥ 140 mg/dL, greater than 10% of total CGM placement time. The following criteria will currently be used to diagnose gestational diabetes in the CGM group:~Time above range (≥140 mg/dL) ≥ 10% of the time while using CGM or~Average glucose≥130 mg/dL or~Any glucose value ≥200 mg/dL"
76022974|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
75378000|NCT02831569|Drug|Methocarbamol|
75378001|NCT03050918|Behavioral|Follow-up Phone Call|Patients will receive a first call attempt within 72 hours discharge.
75378002|NCT03065179|Drug|Nivolumab/Ipilimumab|IV immunotherapy
75378003|NCT03065179|Radiation|SBRT|SBRT will be delivered in conjunction with immunotherapy
75378004|NCT02988050|Drug|Remifentanil|Remifentanil used for conscious sedation.
75378005|NCT02988050|Drug|Dexmedetomidine|Dexmedetomidine used for conscious sedation.
75378006|NCT02988050|Drug|Propofol|Used for conscious sedation.
75378007|NCT02988050|Drug|Bupivacaine|Local anaesthetics
75378008|NCT02988050|Drug|Lidocaine|Local anaesthetic
75378009|NCT02988050|Drug|Epinephrine|With local anaesthetic for skin infiltration.
75378010|NCT03065647|Device|Expedited Transport With Mechanical CPR|Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
75703316|NCT00877448|Biological|Multimeric-001 500 Mcg|
75703317|NCT00877448|Biological|Multimeric-001 125 Mcg|
75703318|NCT00783861|Drug|Lactic Acid|Lactic Acid (Dermacyd Femina)
75703319|NCT01034371|Procedure|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
75378011|NCT02988986|Drug|TAK-228|MTORC1/2 inhibitor
75378012|NCT02988986|Drug|Tamoxifen|Non-steroidal anti-estrogen
75378013|NCT02832115|Drug|Topical Nitroglycerine|Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
75703320|NCT01034371|Procedure|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
75703321|NCT01034371|Procedure|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
75703322|NCT04971213|Device|Non invasive ventilation|Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)
75703323|NCT04971213|Device|High-flow nasal cannula heated and humidified oxygen|AirVO2 device (Fisher and Paykel, New Zealand)
75703324|NCT00783939|Drug|Lactic Acid|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
75703325|NCT04739930|Procedure|Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
75703326|NCT04739930|Procedure|Control group incision|0.5cm sham incision over the iliac crest
75703327|NCT00788229|Drug|AT01|eye drop for 12 weeks
75703328|NCT00788229|Drug|AT02|eye drop for 12 weeks
75378014|NCT02832115|Drug|Topical Lidocaine|Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
75378015|NCT02862080|Device|cathode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
75378016|NCT02862080|Device|Ekso|Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
75378017|NCT02862080|Device|anode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
75378018|NCT00373945|Drug|Observational Study|
75378019|NCT03054506|Device|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
75378020|NCT03054506|Device|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
75378021|NCT03054506|Device|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
75378022|NCT03068611|Behavioral|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
75378023|NCT03068611|Behavioral|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
75703329|NCT00788229|Drug|AT03|eye drop for 12 weeks
75703330|NCT00788229|Drug|AT04|eye drop for 12 weeks
75703331|NCT01937468|Other|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
75703332|NCT01937468|Drug|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
75703333|NCT00663117|Drug|Naltrexone-HCl|naltrexone 4.5 mg
75378024|NCT02835625|Radiation|Synthetic Mammography + Digital Breast Tomosynthesis|Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
75378025|NCT02835625|Radiation|Digital mammography|Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
75539499|NCT05011526|Biological|AZD1222|Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
75539500|NCT00565786|Device|ArCom® Polyethylene|Argon packaged compression molded polyethylene
75539501|NCT00565786|Device|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
75703334|NCT00663117|Drug|Placebo|Placebo
76029643|NCT05203731|Behavioral|Exercise|Moderate intensity exercise (typically a brisk walk or light run) will occur for 20 minutes after the emotional learning procedures on Day 1.
75378026|NCT03071887|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
75378027|NCT02935699|Drug|Test Drug (JDP-205)|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
75378028|NCT02935699|Drug|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
75378029|NCT04333381|Other|Educational and organizational intervention|"Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~The educational intervention will consist:~Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~The organizational intervention will consist:~Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~Review organizational strategies and definition of new improvement measures~Audit the delays in STEMI~Periodic multi-disciplinary update sessions"
75378030|NCT04333381|Other|Common Practice|Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
75378031|NCT03073759|Device|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
75378032|NCT03073759|Device|Sham device|The device will administer a sham.
75378033|NCT02936479|Drug|C1-INH (Berinert)|
75378034|NCT02841241|Drug|Esmolol|Esmolol infusion
75378035|NCT00374881|Drug|Morphine|Morphine
75539502|NCT00252642|Drug|Peginterferon Alpha-2a|
76029644|NCT05203731|Behavioral|Sitting|Sitting will occur for 20 minutes after the emotional learning procedures on Day 1.
75378036|NCT00374881|Drug|Morphine|Morphine low dose
75378037|NCT00374881|Drug|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
75378038|NCT00374881|Drug|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
75378039|NCT00374881|Drug|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
75539503|NCT00565942|Procedure|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
75703335|NCT02578628|Other|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
75703336|NCT04072328|Drug|Propofol|Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
75703337|NCT04072328|Drug|Midazolam|midazolam with propofol
75703338|NCT00792753|Device|Medtronic Endeavor Coronary Stent System|coronary stent implantation
75703339|NCT00792753|Device|DESyne BD Novolimus Stent System|coronary stent implantation
75703340|NCT00792753|Device|DESyne Novolimus Stent System|coronary stent implantation
76029645|NCT05203315|Drug|Duobrii 0.01 % / 0.045 % Topical Lotion|Duobrii® lotion (halobetasol propionate [HP] and tazarotene [Taz] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
75378040|NCT00374959|Drug|ceftriaxone|
76029646|NCT05203315|Drug|CeraVe, Topical Cream|CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
76029647|NCT05203276|Drug|Envafolimab|300mg，SC，Q3W，d1
76029648|NCT05203276|Drug|Endostar|210mg，CIV，Q3W，d1-3
76029649|NCT05201066|Drug|decitabine|Solution for intravenous infusion
76029650|NCT05201066|Drug|Spartalizumab|Solution for intravenous infusion
75703341|NCT00495716|Drug|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
75703342|NCT00495716|Drug|acyclovir|400 mg acyclovir orally twice daily for 1 year
75703343|NCT00793065|Other|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
76029651|NCT05201066|Drug|Sabatolimab|Solution for intravenous infusion
75378041|NCT00374959|Device|Endotracheal tube for aspiration of subglottic secretions.|
75378042|NCT02865434|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
75378043|NCT02865434|Procedure|SPECT Imaging (60 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.
75378044|NCT02865434|Procedure|SPECT Imaging (180 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.
75378045|NCT02865434|Procedure|Whole body planar SPECT imaging (15 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.
75378046|NCT02865434|Procedure|Whole body planar SPECT imaging (60 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.
75378047|NCT02865434|Procedure|Whole body planar SPECT imaging (180 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.
75703344|NCT00793065|Other|Medical Home redesign|Implementation of NCQA Level III Medical Home
75703345|NCT00788385|Device|ShuntCheck test|
75703346|NCT00784017|Drug|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
75378048|NCT02865434|Procedure|Whole body planar SPECT imaging (18-20 Hours post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.
75378049|NCT02865434|Procedure|Blood Collection for PK Testing (15 Mins Before Injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
75378050|NCT02865434|Procedure|Blood Collection for PK Testing (after injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)
75378051|NCT02865434|Procedure|Blood Collection for PK Testing (15 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept
75703347|NCT00784017|Drug|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
75703348|NCT04074122|Diagnostic Test|Adenosine and epinephrine, isoprenaline provocation|High-resolution electromechanical mapping at baseline and after provocative measures.
75703349|NCT04073342|Genetic|Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).|Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
75703350|NCT00570141|Device|OASIS Wound Matrix|OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
75703351|NCT02579694|Device|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
75703352|NCT02578550|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
75703353|NCT02578550|Drug|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
76029652|NCT05201066|Drug|Azacitidine|Solution for subcutaneous injection or intravenous infusion
76029653|NCT05201066|Drug|Venetoclax|Tablet for oral administration
76029654|NCT05201066|Drug|INQOVI (oral decitabine)|Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
76029655|NCT05186714|Behavioral|Tai Chi versus wellness education|12 weeks of Tai Chi (2x/week) or a wellness education (2x/week)
76029656|NCT05171348|Drug|CM326|a humanized monoclonal antibody
76029657|NCT05171348|Drug|Placebo|Placebo
75378052|NCT02865434|Procedure|Blood Collection for PK Testing (60 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept
76029658|NCT05167487|Drug|Cisplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
76029659|NCT05167487|Drug|Carboplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
75378053|NCT02865434|Procedure|Blood Collection for PK Testing (180 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept
75378054|NCT02865434|Procedure|Blood Collection for PK Testing (18-20 hours post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept
75378055|NCT02865434|Procedure|Planar Image with both Hands in Field of View|Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.
75378056|NCT00375037|Behavioral|feedback|
75378057|NCT00375037|Behavioral|Education|
75378058|NCT00375037|Other|usual care|
75378059|NCT02841397|Device|Masimo Pulse CO-Oximeter|Noninvasive pulse oximeter with various features for measurement of hemoglobin, pleth variability index, and oxygen reserve index
75378060|NCT02846233|Drug|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
75378061|NCT02846233|Drug|basal insulin|The participant will continue with the basal insulin.
75378062|NCT02846233|Drug|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
75378063|NCT02846233|Drug|Metformin|The participant will continue with metformin.
75378064|NCT02865590|Device|sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)|
75378065|NCT02865590|Device|Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)|
75703354|NCT02578550|Drug|Darunavir|A single tablet containing darunavir 800 mg will be administered.
75703355|NCT02578550|Drug|Cobicistat|A single table containing cobistat 150 mg will be administered.
75703356|NCT00788463|Drug|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
75703357|NCT00788463|Drug|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
75703358|NCT00579254|Drug|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
75378066|NCT02867150|Device|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
75378067|NCT03075085|Behavioral|WISE (We Inspire Smart Eating)|An enhanced implementation strategy for evidence-based obesity prevention in childcare
75378068|NCT02867618|Drug|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
75378069|NCT02867618|Drug|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
75378070|NCT02868242|Drug|LDV/SOF|Tablet(s) administered orally once daily
75378071|NCT03075553|Other|Laboratory Biomarker Analysis|Correlative studies
75378072|NCT03075553|Biological|Nivolumab|Given IV
75378073|NCT03076333|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
75378074|NCT02869334|Device|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
75378075|NCT02869334|Device|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
75378076|NCT02869334|Behavioral|Auditory Remediation|Computer program designed to improve discrimination between sounds
75378077|NCT02869334|Behavioral|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
75378078|NCT03077893|Device|Active Provant Therapy System|Treatment with active Provant Therapy System
75378079|NCT03077893|Device|Inactive (sham) Provant Therapy System|Treatment with Inactive (sham) Provant Therapy System
75378080|NCT03054740|Drug|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
75378081|NCT03054740|Drug|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
75378082|NCT02997722|Drug|Ketamine|IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
75378083|NCT02997722|Drug|Normal Saline|IV infusion of 100 ml of normal saline over 45 minutes.
75378084|NCT03078127|Other|Baseline (Huff-Cough alone)|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
76029660|NCT05162638|Procedure|thoracic duct cannulation|"Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel & advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN & OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter & advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath & pulled out. Catheter then threaded & advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling."
75703359|NCT02574806|Procedure|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
75539504|NCT00565942|Procedure|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
75703360|NCT00793221|Device|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
75703361|NCT00793221|Device|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
75703362|NCT02578134|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
75703363|NCT02578134|Other|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
75703364|NCT04072562|Drug|AZD7594|"Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation."
75703365|NCT00784329|Device|Optical Frequency Domain Imaging (OFDI) System|Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
75703366|NCT04072484|Other|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
75703367|NCT00793299|Behavioral|Video Illness Narrative|video
75378085|NCT03078127|Device|Oscillatory Positive Expiatory Pressure Device|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
75539505|NCT04598542|Drug|Lorecivivint (LOR)|0.07 mg
75539506|NCT04598542|Drug|Triamcinolone acetonide (TA)|40 mg
75703368|NCT04072406|Other|Mindfulness meditation|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
75539507|NCT04995263|Behavioral|Sueña component 1: Sleep Hygiene Promotion|The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.
75539508|NCT04995263|Behavioral|Sueña component 2: Periodic Anxiety and Pain Screening|Every night, nursery staff will include anxiety and pain screenings as part of vital signs assessments, using visual analog scales for each one. If any screening is altered, clinical actions will be performed to alleviate symptomatology if deemed necessary, using clinical judgement.
75539509|NCT04995263|Behavioral|Sueña component 3: Hypnotics and Caffeine Regulation|The use of hypnotics will be standardized to be administered no later than at 22:00 PM; in the case of melatonin, its administration will be suggested at sundown, at 20:00 PM. Caffeinated drinks will be prohibited after 15:00 PM.
75703369|NCT04072406|Other|Usual care packet|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
75703370|NCT00788619|Procedure|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
75703371|NCT00788619|Procedure|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
75539510|NCT04995263|Behavioral|Sueña component 4: Sleep Masks and Ear Plugs|Sleep masks and ear plugs will be available to all patients if they wish to use them. The nursery team will reinforce its use between 23:00 PM and 07:00 AM.
75539511|NCT04995263|Other|Sueña component 5: Personalized Psychoeducation|Two individualized, nurse-led psychoeducation PowerPoint presentations on sleep hygiene will be presented to patients, supported by educational material aimed at the patient and their families.
75539512|NCT04995263|Device|Sueña component 6: Sleep Reports|Objective and subjective reports of sleep quality will be handed to attending psychiatrist, using data gathered with wearable devices (Fitbit Charge 4) and self-report questionnaires regarding perceived sleepiness and overall sleep. The psychiatrist in charge uses said information in the routine case management
75703372|NCT00661089|Drug|Botulinum Toxin Type A - OnabotulinumtoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
76029661|NCT05159778|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
76029662|NCT05159778|Biological|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
75703373|NCT00661089|Drug|Placebo (Saline)|Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
75703374|NCT03098082|Device|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
75703375|NCT01773278|Drug|Antioxidants|Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.
75703376|NCT01773278|Drug|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels > 100 mg/dl if possible
75703377|NCT00788853|Other|No treatment given|No treatment is given
75867177|NCT05074290|Drug|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
75378086|NCT03078127|Device|Whole-Body Vibration Platform|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
75539513|NCT04598581|Radiation|Low Dose Radiation Therapy (LD-RT)|Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray
75539514|NCT04598581|Other|Sham irradiation|Sham irradiation
75539515|NCT00252681|Procedure|laparotomy|
75539516|NCT00252681|Procedure|primary peritoneal drainage|
75703378|NCT04071002|Other|12 weeks physical therapy programme|The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
75703379|NCT00788931|Drug|IV LBH589|
75703380|NCT00788931|Drug|Oral LBH589|
75703381|NCT00788931|Drug|trastuzumab|
75703382|NCT00788931|Drug|paclitaxel|
75703383|NCT00709514|Drug|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
75703384|NCT00709514|Drug|Placebo|Placebo
75703385|NCT00709670|Procedure|MSCT and stress echocardiography|tests MSCT and stress echocardiography
75703386|NCT00709748|Device|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
75703387|NCT00709748|Device|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
75703388|NCT02574650|Device|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
75703389|NCT04072094|Procedure|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
75378087|NCT03078127|Device|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
75378088|NCT03056144|Device|whole body vibration therapy|"The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min >5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
75703390|NCT04072094|Procedure|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
75703391|NCT02577848|Drug|GLP-1|GLP-1 were taken daily for 7 days
75539517|NCT04598503|Other|full history and clinical examination|For each case, a detailed perinatal and maternal and family history were obtained by interviewing questionnaire. Diagnosis of congenital anomalies was based on clinical evaluation of newborn babies by the neonatologist and other appropriate investigations such as radiography, ultrasonography, echocardiography and chromosomal analysis etc... Classification of anomalies is done by systems according to WHO international classification of diseases (ICD10) [10]. Data was entered into excel data sheet and appropriate statistical analysis was performed. The prevalence was calculated by dividing the number of CA during the 6 months (173) by the total number of admission during this period (753).
75539518|NCT04598191|Drug|Iloprost|"Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
75539519|NCT04598191|Drug|Control (Normal saline)|"Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
75539520|NCT04598113|Device|Cervical Traction Device|"While The patient is lie on the back his or her head is housed within the specific head portion of the device. The investigator inflate progressively the device using a valve and ensuring the patient's relaxation. The process of inflation is continued until the level of 12 Kg of pressure is reached. This maximum level of traction is maintained for 10 minutes then the process of deflation is started until the pressure decreased to 0 Kg. This maneuver is reproduced once again after 5 minutes of rest.~The balance assessment using the force plate-from is done just before the intervention and 5 minutes after its end."
75539521|NCT04956848|Device|iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed for transfer.
75703392|NCT02577848|Drug|Placebo|Placebo were taken daily for 7 days
75378089|NCT02943499|Behavioral|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
75703393|NCT00582426|Drug|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
75703394|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
75703395|NCT02574572|Biological|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
75703396|NCT02575898|Other|First Session|Creative Practice and Positive Re-enforcement
75703397|NCT02575898|Other|Second Session|Disease Related
75703398|NCT02575898|Behavioral|Third through Sixth Sessions|Life Review and Legacy
75703399|NCT04019184|Drug|L-Alanyl/L-Glutamine|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
75703400|NCT04019184|Drug|Placebo|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
75703401|NCT00709982|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
75703402|NCT02387970|Procedure|Immediate provisionalization|Stage one protocol: Individuals will receive temporary crowns at the same day as implant surgery, and a final restoration at four months after surgery.
75378090|NCT02943499|Behavioral|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
75378091|NCT02943499|Device|Smartphone|
75378092|NCT03000608|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
75378093|NCT03000608|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
75378094|NCT02847169|Device|filcon IV1 toric lens|toric contact lens
75378095|NCT02847169|Device|ocufilcon D toric lens|toric contact lens
75378096|NCT00374582|Device|Bodystat Quadscan 4000|device determining body composition and nutritional status
75378097|NCT00374582|Device|bodystat quadscan 400|device determining body composition and nutritional status
75378098|NCT03108482|Drug|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
75378099|NCT03108482|Drug|Tramadol (Ultram®)|Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
75539522|NCT04598308|Diagnostic Test|absolute flow and resistance measurements|"This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis~Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.~Intention to measure Q and Rmicro are mandatory to be included in this registry.~Use of drugs either during or after the procedure should also exactly identical to normal routine."
75539523|NCT04598230|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
75539524|NCT04598230|Drug|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
75539525|NCT00249171|Drug|risperidone|
75539526|NCT04598464|Other|Home based exercise|The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
75539527|NCT00565981|Drug|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
75539528|NCT00565981|Drug|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
75539529|NCT04952519|Drug|Amantadine|Patients are treated with high doses of amantadine.
75539530|NCT04598035|Diagnostic Test|Diagnostic Tests|"Blood and Urine laboratory tests~ECG and blood pressure for cardiovascular measurements~Self-report questionnaires about pain"
75539531|NCT00414921|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
75539532|NCT00414921|Drug|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
75539533|NCT00414921|Other|placebo|inactive substance
75539534|NCT04597762|Drug|Cyclosporin|Cyclosporin eyedrops
75539535|NCT04597762|Drug|Hydrocortisone|Hydrocortisone eyedrops
75539536|NCT04597645|Other|Therapeutic elastic band resistance training|A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
75378100|NCT03108482|Drug|Celecoxib (Celebrex®)|Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
75378101|NCT03108482|Drug|Placebo|Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
75378102|NCT03079375|Other|basic intervention|medication review
75378103|NCT03079375|Other|extended intervention|medication review, medication interview before discharge and follow-up
75539537|NCT00249210|Drug|levofloxacin|
75378104|NCT02871128|Dietary Supplement|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
75378105|NCT02871128|Dietary Supplement|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
75867178|NCT05074290|Drug|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
75378106|NCT02871128|Drug|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
75378107|NCT02850601|Drug|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
75378108|NCT02871440|Drug|Omega 3|
75378109|NCT02871440|Drug|Optive Advanced|
75378110|NCT02871440|Drug|Optive|
75378111|NCT03079531|Drug|Secukinumab|Secukinumab 300 mg administered subcutaneously.
75378112|NCT03056456|Drug|LY900014|Administered subcutaneously (SC)
75378113|NCT03056456|Drug|Insulin Lispro (Humalog)|Administered SC
75378114|NCT03057704|Drug|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
75378115|NCT03057704|Drug|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
75378116|NCT02874092|Drug|Ticagrelor|
75378117|NCT02874092|Drug|MTX therapy|
75539538|NCT04597957|Dietary Supplement|Fresh Rx Intervention group|"Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy."
75867179|NCT03095508|Drug|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
75378118|NCT03059810|Device|etafilcon A|Investigational Contact Lens
75378119|NCT02876900|Drug|Low Dose Asenapine maleate transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patch
75378120|NCT02876900|Drug|High Dose Asenapine maleate transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patch
75378121|NCT02876900|Drug|Placebo|The study will evaluate placebo transdermal patch.
75378122|NCT03063476|Drug|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
75378123|NCT03063476|Drug|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
75378124|NCT02878382|Other|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
75378125|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
75539539|NCT04597723|Drug|oxygen|Patients will be given different concentrations of oxygen.
75703403|NCT02387970|Procedure|Delayed provisionalization|Stage two protocol: Individuals will receive temporary crowns 3 months after implant surgery, and a final restoration at four months after surgery.
75703404|NCT02387970|Device|NobelParallel CC implant|Supports the comprehensive range of dental prosthetics as well as full range of prefabricated abutments.
75378126|NCT02880176|Other|Financial Incentive to Increase Ambulation|Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
75378127|NCT02880254|Device|Kurbo|health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
75378128|NCT02880254|Device|Personal Health Coach|weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
75539540|NCT00252798|Drug|Gefitinib|
75539541|NCT00252798|Drug|Carboplatin|
75539542|NCT00252798|Drug|Paclitaxel|
75539543|NCT00252798|Procedure|Radiation|
75539544|NCT04597567|Procedure|Metal removal|Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures
75539545|NCT04597216|Device|sample of blood and saliva|sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
75703405|NCT02387970|Device|Dental crown|"A tooth-shaped cap that is placed over a tooth or implant for teeth restoration and improvement in appearance."
75703406|NCT00710060|Behavioral|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
75703407|NCT00710060|Behavioral|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
75378129|NCT03115580|Device|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
75539546|NCT04597255|Device|Holographic optical coherence tomography|Descriptive wavefront analysis with holographic optical coherence tomography
75539547|NCT04597489|Procedure|Fractional flow reserve|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
75539548|NCT04597489|Procedure|Angiography-only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
75539549|NCT02961660|Drug|Odalasvir|Participants will receive odalasvir 25 mg tablet, orally.
75539550|NCT04870151|Procedure|Anterolateral approach|Cemented hemiarthroplasty using an anterolateral approach.
75539551|NCT04870151|Procedure|Direct lateral approach|Cemented hemiarthroplasty using a direct lateral approach.
75539552|NCT04597177|Radiation|ST-IMRT SW-IMRT|
75539553|NCT04596904|Other|Lavender oil application group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
75539554|NCT04596904|Other|Distilled water application group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
75703408|NCT04070690|Procedure|Concentration of dialysate bicarbonate|Adjust the dialysate bicarbonate concentration
75539555|NCT04596787|Procedure|Bilateral Thoracic paravertebral block|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
75703409|NCT03086850|Behavioral|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~<6000 steps/day: increase by 3000 steps/day~6000 - 10000 steps/day: reach 10000 steps/day~> 10000 steps/day: maintain or increase steps"
75539556|NCT00252837|Drug|Tesaglitazar|
75703410|NCT03086850|Other|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
75703411|NCT00710138|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
75539557|NCT00252837|Behavioral|Dietary and Lifestyle counseling|
75539558|NCT04596748|Dietary Supplement|Probiotic|Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
75703412|NCT04072172|Device|Mole Freckle Pen|Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
75703413|NCT00580034|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
75539559|NCT04596748|Dietary Supplement|Placebo|Placebo caps
75539560|NCT00403013|Procedure|Positioning and anesthesia|Positioning during axillary plexus block
75539561|NCT04597060|Device|Thermomechanical system with corticosteroids|The device in this study using Novoxel - Tixel®
75539562|NCT04597060|Other|corticosteroid injection|corticosteroid injection using TA 10mg/ml
75539563|NCT00566176|Device|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
75867180|NCT03095508|Drug|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
75378130|NCT03115580|Device|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
76029663|NCT05159050|Drug|Paclitaxel-loaded tumor penetrating microparticles|"Paclitaxel-loaded TPM, suspended in 0.5 L of 0.1% (w/v) polysorbate 80 in 0.9% sodium chloride is instilled into the peritoneal cavity over 3 to 5 minutes. Mixing of TPM is achieved by putting patient in 5 different positions for about 80 minutes.~Dose escalation, the starting dose of TPM is 50 mg/m^2 paclitaxel-equivalents. Dose escalation will follow the Accelerated Titration Design. The dose levels to which patients will be assigned in sequential cohorts are listed below.~Dose escalation schedule of TPM, Dose Level 1*: 50 mg/m^2; Dose Level 2: 100 mg/m^2; Dose Level 3: 135 mg/m^2; Dose Level 4: 175 mg/m^2; Dose Level 5: 200 mg/m^2~*Starting Dose"
76029664|NCT05152888|Drug|Evolocumab|Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
75378131|NCT03117140|Drug|Ropivacaine 0.75%|Only ropivacaine 0.75% is administered for this arm of the interscalene block
75378132|NCT03117140|Drug|Ropivacaine 0.75% + 300 mcg Buprenorphine|Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
75378133|NCT03117140|Drug|Ropivacaine 0.75% + 75 mcg clonidine|Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
75378134|NCT03117140|Drug|Ropivacaine 0.75% + 8 mg dexamethasone|Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
75378135|NCT03118466|Drug|Etoposide|A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
76029665|NCT05151484|Drug|Teriparatide|Participants will receive 20 μg teriparatide per day via subcutaneous injections. Participants, and if needed a caregiver, will be trained in the subcutaneous administration of teriparatide according to the manufacturer's guidelines. The investigators will measure serum calcium, BSAP and TRAP-5b levels via blood draws at quarterly monitoring visits. If BSAP or TRAP-5b do not increase compared to baseline or decrease after any quarter, participants will be contacted and correct administration will be reviewed. Serum calcium is measured for safety to avoid hypo- and hypercalcemia. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
75378136|NCT03118466|Drug|Cytarabine|Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
75378137|NCT03118466|Drug|Lenalidomide|It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
75539564|NCT00566215|Procedure|Duodenal exclusion plus omentectomy|"Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed."
75703414|NCT00580034|Procedure|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
75703415|NCT00710216|Drug|Lamivudine|100 mg/day
75703416|NCT00710216|Drug|Telbivudine|600 mg/day
75703417|NCT02575820|Procedure|Old red blood cells transfusion|Red blood cells (shelf life > 14 days) transfusion during the operation (total hip replacement arthroplasty)
75703418|NCT02575820|Procedure|New red blood cells transfusion|Red blood cells (shelf life =< 14 days) transfusion during the operation (total hip replacement arthroplasty)
75703419|NCT02577692|Other|Oxygen|breathing oxygen
75378138|NCT03118466|Drug|Mitoxantrone|It interfere with cell reproduction
75703420|NCT02577692|Other|Ambient|breathing ambient air
75703421|NCT03913598|Other|patient questionnaire|self-administered patient questionnaire regarding the different aspects of internet and social media use in dermatology patients
75378139|NCT03068312|Drug|Ivacaftor|IVA 150 mg tablet.
75378140|NCT03068312|Drug|Placebo|Placebo matched to IVA tablet.
75378141|NCT03119168|Drug|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
75378142|NCT03119168|Other|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
75378143|NCT02881112|Device|Provant Therapy System|Treatment with the Provant Therapy System
75378144|NCT02881658|Dietary Supplement|Plant sterols-enriched soya beverage provided by Vitasoy|the study product is a 2g plant sterols-enriched in 250ml soya beverage
75378145|NCT02881658|Dietary Supplement|Soya beverage provided by Vitasoy|the placebo product is a 250 ml soya beverage
75378146|NCT05405972|Behavioral|The Connected Family Series - For Foster Families|A 4-week program involving videos and activities for both the parent and child in the home.
75378147|NCT03070730|Drug|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
75378148|NCT03070730|Drug|Atenolol|Atenolol: 50 mg Q.D.
75378149|NCT03070730|Drug|Placebos|Placebo: t.i.d
75703422|NCT00710294|Device|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.~Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
75378150|NCT04736498|Other|Inferior venacava Ultrasonography (IVC USG) guided fluid management|The IVC will be visualized using a paramedian long-axis view via a subcostal approach. A two-dimensional image of the IVC as it enters the right atrium will be first obtained. Variations in IVC diameter with respiration will be assessed using M-mode imaging performed 2 to 3 cm distal to the junction of right atrium and IVC. Maximum and minimum diameter will be measured from inner wall to inner wall and collapsibility index(CI) will be calculated using formula: CI = [(dIVCmax - dIVCmin)/dIVCmax] x 100% CI of ˃36% will be accepted as predicted fluid responder and ≤36% will be regarded as predicted fluid non responders. Predicted fluid responders will receive a bolus of 500 ml of Ringer's lactate over a time period of 15 min, after which the IVC diameter variation will be reassessed. Additional 250ml of Ringer's lactate bolus will be applied until a non fluid responder pattern is observed during IVC USG. Thereafter,spinal anaesthesia will be performed.
75703423|NCT00710372|Biological|CYT006-AngQb|s.c. injection
76029666|NCT05151484|Drug|Alendronate|Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
75378151|NCT05405348|Behavioral|Intervention|The patients did not eat anything during hemodialysis.
75378152|NCT03121820|Drug|Memantinol tablets, 20 mg|"Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition"
75378153|NCT03121820|Drug|Akatinol Memantine® tablets, 20 mg|Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
75378154|NCT03123614|Drug|Loteprednol Etabonate 0.5% Oph Gel|
75378155|NCT03123614|Drug|Prednisolone Acetate 1% Oph Susp|
75378156|NCT03123848|Drug|Darunavir/Cobicistat|Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
75378157|NCT03124550|Behavioral|Exergame Experience|Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
75378158|NCT02946073|Drug|buprenorphine|
75378159|NCT02946073|Other|Placebo|
75378160|NCT03071744|Drug|Lazanda|Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
75539565|NCT00566215|Procedure|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
75378161|NCT03073148|Device|Tangible Boost|Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
75539566|NCT00566332|Drug|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
75539567|NCT00566332|Drug|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
75539568|NCT00403052|Drug|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
75703424|NCT00773513|Drug|Darbepoetin Alfa|Darbepoetin alfa will be administered as per approved label.
75703425|NCT00773513|Drug|Epoetin Alfa|Epoetin alfa will be administered as per approved label.
75703426|NCT00773513|Drug|Epoetin Beta|Epoetin beta will be administered as per approved label.
75378162|NCT03073148|Other|Placebo saline|"Participants will treat their lenses with a placebo Tangible Boost kit, which contains saline in place of the Tangible Boost solution."
75378163|NCT02946229|Device|Ultrasound scan|Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
75378164|NCT03074630|Drug|Dapagliflozin|5 weeks 10mg dapagliflozin once daily
75539569|NCT04596943|Diagnostic Test|[68Ga]Ga-DOTA-(RGD)2 PET/CT|We have developed a dimeric cyclic RGD peptide conjugated with DOTA as a chelator. If labeled with the positron emitting radionuclide Gallium-68 (68Ga), [68Ga]Ga-DOTA-(RGD)2 can be used to visualize αvβ3 integrin expression with PET
75378165|NCT03074630|Drug|Rosuvastatin|9 weeks 10mg dapagliflozin once daily
75378166|NCT03086707|Other|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
75378167|NCT03125018|Device|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
75539570|NCT00252876|Drug|tesaglitazar|
75703427|NCT00773513|Drug|methoxy polyethylene glycol-epoetin beta|Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
75703428|NCT00710528|Drug|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
75703429|NCT04070612|Other|Blood sample|A blood sample of 2 times 2 to 5 ml additional maximum
75703430|NCT00711074|Drug|AZD5672|single dose 200mg aqueous solution
75703431|NCT02574416|Other|There is no intervention|The study is observational and there is no intervention
75703432|NCT00711152|Other|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
75703433|NCT00711152|Other|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
76029667|NCT05151380|Device|CO2 laser MonaLisa Touch ®|"3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.~The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice"
75703434|NCT00711230|Biological|DermaVir|
75703435|NCT00711230|Biological|Placebo|glucose/dextrose
75378168|NCT05404334|Diagnostic Test|Androgen receptor status and BRCA mutation|Androgen receptor status by IHC and germ line BRCA mutation
75703436|NCT00711308|Drug|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
75378169|NCT00374894|Drug|2,3-dimercaptosuccinic acid|
75378170|NCT03088267|Drug|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
75378171|NCT03088267|Drug|Placebo extended-release oral suspension|6, 7 or 8 mL PO
75378172|NCT03127358|Device|AiCure|Smartphone App
75378173|NCT03127358|Device|AiCure with gamification|Smartphone App with gaming.
75539571|NCT04597021|Device|use of a wiresless US transducer|to (evaluate the practicability of applying a wireless US transducer for central venous catheter-placement in these patients.
75539572|NCT04596709|Dietary Supplement|Vitalose|dissolved in water
75539573|NCT04596709|Dietary Supplement|isomaltulose|dissolved in water
75378174|NCT03088345|Drug|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
75539574|NCT04596709|Dietary Supplement|sucrose|dissolved in water
75539575|NCT04596709|Dietary Supplement|glucose|dissolved in water
75539576|NCT04596358|Other|Observational|Evaluation of adherence to the Mediterranean diet through the administration of the Med Diet Score questionnaire.
75703437|NCT00711308|Drug|acenocoumarol|acenocoumarol for 6 months
75378175|NCT03088345|Drug|Placebo|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
75378176|NCT02855437|Device|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
75378177|NCT02855437|Device|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm."
75703438|NCT02601911|Drug|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
75703439|NCT02601911|Drug|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
75703440|NCT02601911|Other|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
75703441|NCT00711386|Drug|GSK706769|50mg, 100mg, 200mg, or 400mg
75703442|NCT00711386|Other|Placebo|Placebo
75703443|NCT04101773|Procedure|RBL versus sutured mucopexy versus haemorrhoidectomy.|All 3 interventions are part of Dutch usual care, and serve as each other's control.
75703444|NCT00711542|Biological|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
75703445|NCT00711542|Biological|placebo medium|intracoronary infusion of placebo medium
75703446|NCT04104347|Other|Metacognitive training (MCT)|Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz & Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
75703447|NCT04104347|Other|Support group|Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
75703448|NCT00711620|Drug|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
75703449|NCT02577380|Behavioral|IPV/GBV HTC|Participants will be interviewed after receiving their services.
75703450|NCT02577614|Drug|FEIBA|Administration of FEIBA after cardiopulmonary bypass
75703451|NCT02577614|Drug|Normal Saline|Administration of placebo after cardiopulmonary bypass
75378178|NCT02948257|Device|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
75378179|NCT03127514|Drug|AMX0035|AMX0035
75378180|NCT03127514|Other|Placebo|Matching Placebo Comparator
75378181|NCT02858713|Drug|Calcipotriene + Betamethasone Dipropionate|Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
75378182|NCT02858713|Device|App|App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
75378183|NCT00375050|Drug|Riluzole|
75378184|NCT00375050|Drug|Placebo|placebo
75703452|NCT02577458|Drug|CM082|CM082 tablets taken orally once a day on 28-day cycles
75703453|NCT02577458|Drug|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
75703454|NCT00767039|Drug|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
75703455|NCT00767039|Drug|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
75703456|NCT01640522|Other|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
75703457|NCT01640522|Other|Enhanced usual Care|
75703458|NCT04071938|Other|Teaching to GPs|Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
75703459|NCT04071938|Other|Site visits to GP practices|Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
75703460|NCT00662649|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
75703461|NCT00662649|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
75703462|NCT02577770|Device|acupuncture|therapeutic acupuncture treatment with actual needles
75703463|NCT02577770|Dietary Supplement|200mg caffeine|8g coffee, po
75703464|NCT02577770|Dietary Supplement|400mg caffeine|16g coffee, po
75703465|NCT02577770|Dietary Supplement|Decaffeinated|decaffeinated coffee, po
75378185|NCT03128372|Device|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
75378186|NCT02860507|Drug|sugammadex|
75703466|NCT00766493|Device|GORE® Embolic Filter|Embolic protection during carotid stenting
75703467|NCT00129896|Drug|Myocet|Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
75703468|NCT00129896|Drug|Taxotere|Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
75703469|NCT00129896|Drug|Herceptin|Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles
75703470|NCT02602535|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
75703471|NCT02602535|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
75703472|NCT02574338|Device|Foley's Catheter|intracervical extraamniotic Foley's catheter
75703473|NCT02574338|Drug|prostaglandin E1 analogue|intravaginal misoprostol
75703474|NCT03070392|Biological|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
75703475|NCT03070392|Drug|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
75703476|NCT03070392|Biological|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
75703477|NCT03070392|Biological|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
75378187|NCT02860507|Drug|Neostigmine|
75703478|NCT00711698|Procedure|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
75703479|NCT00711698|Drug|nurse-administered intermittent IV bolus opioid therapy (NAIBOD)|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
75378188|NCT02860507|Drug|Glycopyrrolate|
75378189|NCT03082196|Drug|Test varnish|Topical application of test varnish to the teeth 4 times per year.
75703480|NCT00784043|Device|Cochlear Implant|Bilateral Implantation in children
75703481|NCT02555241|Behavioral|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
75703482|NCT02555241|Behavioral|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
75703483|NCT02555241|Behavioral|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
75867181|NCT05416866|Procedure|Retrolaminar block on the operative side|After the skin near the puncture site was disinfected, 2ml of 1% lidocaine was injected into the puncture site for local infiltration. The needle was inserted beneath the ultrasound probe using an in-plane orientation to contact the lamina of the T8-T11 vertebra. Then we retracted the tip of needle to the lamina about 1 mm and withdrew to make sure that there was no blood or cerebrospinal fluid. Then, 30-40 mL mixture was injected posterior to the lamina of T8-T11.
75867182|NCT05416866|Procedure|Quadratus lumborum block on the operative side|In our study, we applied a transmuscular approach to the QLB. After the patients were placed in the lateral position, the skin near the puncture site was disinfected, a low-frequency (3-5 MHz), curvilinear probe is used and is located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. After the local infiltration for puncture site, the 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the QL muscle is confirmed, 30 ml mixture is injected into the interfascial plane.
76029668|NCT05147324|Behavioral|"MyPlan - Individualized Eating Pattern"|Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating plan adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of eating plan at three months is based on weight status, adherence according to logs, and youth/guardian acceptability.
75378190|NCT03082196|Drug|Standard varnish|Topical application of test varnish to the teeth 4 times per year
75378191|NCT03092089|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
75378192|NCT03092089|Device|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
75378193|NCT03092089|Procedure|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
75378194|NCT03134144|Device|"Exoskeleton Chairless Chair"|One solution to reduce the exposure of employees to associated risks for developing work-related musculoskeletal disorders is to use exoskeletons. Using such a device in dynamic environments has the advantage over, e.g., robotics because it does not need any programming or teaching of robots. Moreover, exoskeletons are worn at the body and do not have to overcome spatial issues. In a recent review, 26 different exoskeletons have been described of which only two were designed to support the lower body during heavy work (de Looze et al. 2015). For lower intensive work tasks, like assembly tasks in the automobile industry, no study has focused on using exoskeletons to relieve employees while performing the work standing.
75378195|NCT02861131|Drug|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
75378196|NCT02861131|Drug|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
75378197|NCT03134768|Other|This is not an interventional study|This is an observational study
75703484|NCT04071548|Other|HIIT Exercise|"HIIT exercise bike protocol~3 minute warm up~Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age~10x60 second Recovery period~5 minute cool-down"
75703485|NCT00789087|Procedure|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
75703486|NCT00789087|Procedure|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
75703487|NCT00711776|Drug|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
75703488|NCT00711776|Drug|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
75703489|NCT00795171|Drug|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
76029669|NCT05132322|Behavioral|Educational Outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for pulse oximetry use in bronchiolitis.
76029670|NCT05132322|Behavioral|Audit & Feedback (unit level)|Weekly unit-level feedback of each hospital's guideline-concordant practice will be distributed to sites in the form of a visual dashboard that includes comparisons over time and between hospitals. The dashboard will then be shared locally on a weekly basis with clinicians in person and electronically.
76029671|NCT05132322|Behavioral|Audit & Feedback (real time, individual-level)|Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.
76029672|NCT05132322|Behavioral|Clinical Pathway Integrated into Electronic Health Record|Clinical pathways guide clinicians step-by-step through evidence-based care. Based on the existing guidelines for physiologic monitoring in bronchiolitis, the pathway will clearly specify (a) situations when it is appropriate to initiate intermittent SpO2 measurement instead of continuous SpO2 monitoring, and (b) when it is appropriate to discontinue continuous SpO2 monitoring altogether, and transition to intermittent SpO2 measurement. In order to be visible to clinicians as they perform patient care, the pathway will be integrated into the electronic health record at sites randomized to this intervention.
75867183|NCT05416866|Procedure|Transversus abdominis plane block on the nonoperative side|After placing the patients in the supine position, the skin was disinfected. A linear probe was placed in the transverse plane at the midaxillary line between the lower costal margin and iliac crest. When the external oblique, internal oblique, and transversus abdominis muscles were observed, 2ml of 1% lidocaine was injected into the puncture site for local infiltration.Then, a 22-gauge, 80-mm needle was advanced using an in-plane technique in an anteromedial to posterolateral direction toward the TAP (the fascial plane between the internal oblique and transversus abdominis muscles). After the correct position of the needle tip was verified, 20 ml mixture was injected into the TAP. The ultrasound showed that the local anesthetic separated the internal oblique and transversus abdominis muscles, confirming the success of the block.
76029673|NCT05128227|Behavioral|Pharm-SAVES|A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
75378198|NCT05172206|Other|symptom-focused rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
75378199|NCT05172206|Other|usual care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
75378200|NCT05098886|Drug|DA-5210 10/1000mg|single dose administration (one tablet once a day)
75378201|NCT05098886|Drug|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
75378202|NCT03093025|Drug|TS-121 10 mg|Orally taken once daily
75378203|NCT03093025|Drug|TS-121 50 mg|Orally taken once daily
75378204|NCT03093025|Drug|Placebo|Orally taken once daily
75378205|NCT05098262|Drug|DA-5210 10/500mg|single dose administration (one tablet once a day)
75378206|NCT05098262|Drug|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
75378207|NCT02950753|Drug|Lactated Ringer Solution|Fluid bolus of Lactated Ringer solution (30ml/kg).
75378208|NCT02950753|Drug|Normal Saline|Fluid bolus or Normal Saline (30ml/kg).
75703490|NCT00795171|Drug|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
75703491|NCT00795171|Drug|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
75703492|NCT00711854|Drug|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
75703493|NCT00711854|Drug|Linezolid|Linezolid (600 mg IV or PO twice daily)
75867184|NCT03632538|Diagnostic Test|"Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)"|Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).
76029674|NCT05128227|Behavioral|Interactive video cases|Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
76029675|NCT05124574|Other|Samples concern SARS-COV-2 + pregnant women at the time of childbirth|"nasopharyngeal PCR in the mother (performed systematically in this epidemic context),~Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology).~Sampling of amniotic fluid in case of cesarean section~Sampling of the placenta for histological and virological study."
76029676|NCT05124574|Other|Samples concern newborns of SARS-COV-2 + mothers at birth|"In the birth room:~Collection of gastric fluid (PCR SARS-COV-2),~Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~In the newborn at D3 of life:~- 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN.~In symptomatic newborns:~1 yellow tube (SARS-COV-2 + RT-qPCR serology).~nasopharyngeal PCR,"
76029677|NCT05121831|Drug|DGX-001Dose 1|Dose level 1 of DGX-001
76029678|NCT05121831|Drug|DGX-001 Dose 2|Dose level 2 of DGX-001
76029679|NCT05121831|Drug|DGX-001 Dose 3|Dose level 3 of DGX-001
76029680|NCT05121831|Drug|DGX-001 Dose 4|Dose level 4 of DGX-001
76029681|NCT05121831|Drug|MAD dose panel of DGX-001|Dose levels confirmed through SAD and MAD
76029682|NCT05118009|Other|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
76029683|NCT05113537|Drug|Abemaciclib|Given Orally
76029684|NCT05113537|Drug|Lutetium Lu 177-PSMA-617|Given IV
76029685|NCT05110300|Device|Body weight support system control group|Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
75378209|NCT03082586|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
75703494|NCT00711854|Drug|Rifampicin|Rifampicin (600 mg IV or PO once daily)
75703495|NCT00795249|Behavioral|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
75703496|NCT00795327|Device|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
75867185|NCT05416242|Device|Traditional braces|MBT 0.022 perception traditional braces will be used without any acceleration method.
75378210|NCT03082586|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
75539577|NCT00566371|Drug|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
75539578|NCT00566371|Drug|placebo|placebo
75539579|NCT04825769|Device|LLLT（Low Level Laser Therapy）|2 times a day, 3 minutes each time, with an interval of more than 4 hours. During the semester: From Monday to Friday, set up an intervention room in the school; For winter and summer vacation: everyday at home
75539580|NCT04596397|Other|Inpatient setting|These women stay at the hospital.
75539581|NCT04596397|Other|Outpatient setting|These women can leave the hospital.
75539582|NCT00252915|Biological|GM-CSF (verum)|sagramostim
75539583|NCT04596280|Procedure|Colonic Resection|Resection of the colonic tract which has been interested by the acute diverticulitis
75539584|NCT04595929|Procedure|Staging laparoscopy|All patients undergo staging laparoscopy and peritoneal lavage.
75539585|NCT04595929|Drug|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
75539586|NCT04595929|Drug|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
75539587|NCT04595929|Drug|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
75539588|NCT04595929|Drug|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
75378211|NCT03082586|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
75378212|NCT03082586|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
75703497|NCT00773279|Device|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
75703498|NCT00773279|Device|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
75867186|NCT05416242|Device|Self-ligating braces|MBT 0.022 perception Self-ligating braces will be used without any acceleration method.
75378213|NCT03082586|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
75378214|NCT03082586|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
75867187|NCT05416242|Procedure|Self-ligating braces + piezocision|Flapless corticotomy will be applied for the upper anterior teeth.
75867188|NCT00973830|Other|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
75867189|NCT03607487|Drug|INCB054707|INCB054707 tablet administered orally once daily at the protocol-defined dose.
75378215|NCT03086408|Device|THRIVE|active nasal oxygen delivery system
75378216|NCT03086408|Device|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
75378217|NCT02951143|Drug|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
75703499|NCT05003882|Other|Commercially available, orally ingestible CBD product|botanically-derived CBD extract product
75703500|NCT00795405|Behavioral|Exposure to sporting events|Exposure to sporting events
75703501|NCT00795405|Behavioral|No exposure to sporting events|No exposure to sporting events
75703502|NCT02579304|Procedure|transbronchial lung cryobiopsy|bronchoscopic sampling
75703503|NCT04046211|Drug|Hydrogen|Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
75703504|NCT00712088|Behavioral|Project ICARE|Group-level intervention (Project ICARE)
75703505|NCT00712088|Behavioral|HCT|Offer of HIV counseling and testing
75703506|NCT02579226|Drug|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
75703507|NCT00795483|Drug|Zoledronic acid|Zoledronic Acid 5mg/year
75703508|NCT00795483|Behavioral|Lifestyle modifications|Lifestyle modifications
75703509|NCT00795483|Drug|Zoledronic acid|Zoledronic acid (5mg/2years)
75703510|NCT00712400|Drug|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
75703511|NCT00712400|Drug|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
75867190|NCT03607487|Drug|Placebo|Placebo tablet administered orally once daily.
75867191|NCT03731741|Drug|Pentoxifylline|a known drug of xanthine derivatives used in intermittent claudication
75378218|NCT02951143|Drug|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
75378219|NCT05040152|Behavioral|Dietary Counseling and Surveillance|Receive dietary recommendations
75378220|NCT05040152|Other|Exercise Intervention|Complete home exercises
75378221|NCT05040152|Other|Informational Intervention|Receive education brochures
75378222|NCT05040152|Other|Questionnaire Administration|Ancillary studies
75378223|NCT05040152|Behavioral|Telephone-Based Intervention|Receive telephone-based weight loss intervention
75378224|NCT04707404|Procedure|Cranioplasty|The surgery implanted artificial material to repair the skull defect.
75378225|NCT04707092|Drug|Antibiotic|Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week
75378226|NCT04707014|Behavioral|Hypnosis|Rapid conversational hypnosis
76029686|NCT05110300|Device|Body weight support system with balance perturbations|Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
76029687|NCT05104554|Dietary Supplement|Iron and folic acid (IFA)|IFA: Weekly regimen of one tablet containing iron (60 mg) and folic acid (2800 μg)
76029688|NCT05104554|Dietary Supplement|Multiple Micronutrient Supplement (MMS)|MMS: Daily regimen of one multiple micronutrient tablet containing fifteen micronutrients in the United Nations International Multiple Micronutrient Preparation (UNIMMAP) preparation. Composition includes vitamin A (800 ug), vitamin D (5 ug), vitamin E (10 mg), vitamin C (70 mg), vitamin B1 (1.4 mg), vitamin B2 (1.4 mg), niacin (18 mg), vitamin B6 (1.9 mg), vitamin B12 (2.6 ug), folic acid (400 ug), iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 ug), and iodine (150 ug).
76029689|NCT05103345|Drug|SGN1|SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.
76029690|NCT05092542|Behavioral|Refugee and Immigrant Well-being Project (RIWP)|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
75378227|NCT04707014|Behavioral|Attention-distracting techniques|i-pad with movies, games and music
75378228|NCT02867059|Drug|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20_SJ733_Challenge Protocol_v2.0_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
75378229|NCT04985708|Other|data collection of clinically available procedures|when to place Impella related to PCI in patients with AMICS
75378230|NCT03088748|Device|Journey II posterior cruciate retaining total knee arthroplasty|
75703512|NCT00766415|Drug|AZD1981|Oral tablet, twice daily, 4 weeks treatment
76029691|NCT05088252|Drug|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and 0.05-0.3 μg/kg/min remifentanil.
76029692|NCT05088252|Drug|Propofol|After induction, anesthesia will be maintained with 4-6mg/kg/h propofol and 0.05- 0.3 μg/kg/min remifentanil.
75378231|NCT03088748|Device|Journey II posterior bi-cruciate retaining total knee arthroplasty|
75378232|NCT02953561|Drug|Avelumab|Given IV
75378233|NCT02953561|Drug|Azacitidine|Given SC or IV
75378234|NCT02953561|Other|Laboratory Biomarker Analysis|Correlative studies
75378235|NCT03090620|Drug|Physostigmine|Administration of physostigmine bolus followed by an infusion
75378236|NCT03090620|Drug|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
75378237|NCT04938752|Drug|DA-2811|single dose administration (one tablet once a day)
75703513|NCT00766415|Drug|Placebo|Placebo
76029693|NCT05073575|Procedure|Hyaluronic acid|"After local anesthesia, an access flap will be prepared. Scaling and root planning will be performed combining the use of metal curettes and power-driven instrumentation by means of ultrasonic scaler.~Hyaluronic acid gel will be applied to exposed roots surface, followed by a tension-free primary closure of the surgery wound by means of 5-0 monofilament (polypropylene) non-resorbable suturing material."
75703514|NCT04071834|Diagnostic Test|ELISA|Detection of blood orphanin and norepinephrine in patients
75539589|NCT04595929|Procedure|Radical surgery|Radical gastrectomy with D2 - lymph node dissection.
75378238|NCT04938752|Drug|DA-2811-R|single dose administration (one tablet once a day)
75378239|NCT02953873|Drug|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
75378240|NCT02953873|Drug|Mycophenolate mofetil|≥500mg twice a day
76029694|NCT05073575|Procedure|No-hyaluronic acid|"An access flap will be prepared in order to perform scaling and root planning therapy with the use of metal curettes.~After intervention, a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 monofilament (polypropylene) non-resorbable suturing materia will be performed"
75378241|NCT02953873|Drug|Prednisone|goal dose 5mg daily
75378242|NCT02953873|Drug|Mycophenolate Sodium|≥360mg twice a day
75378243|NCT03141242|Behavioral|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
75378244|NCT03141242|Behavioral|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
75378245|NCT03095053|Procedure|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA)."
75703515|NCT03015792|Drug|Dexamethasone|Given PO
76029695|NCT05069298|Dietary Supplement|Silibinin A|The compound will be administered following a 300 mg / 3 day schedule, before each main meal.
76029696|NCT05068258|Procedure|Lymphovenous bypass, including lymphaticovenular anastomosis/implantation|Lymphovenous bypass (LVB) is a supermicrosurgical technique by diverting lymphatic drainage into venous system. Simultaneously, we performed LVB at ipsilateral foot dorsum and debride the VLUs and resurface the wound primarily or by skin graft depending on defect size.
76029697|NCT05065632|Diagnostic Test|Wantai kit Elisa|to mesure antibodies against SARSCov-2 recombinant antigen
76029698|NCT05062759|Drug|Tezepelumab|210 mg SC injection Q4W.
75378246|NCT00375115|Drug|Sambucol|
75378247|NCT03098173|Procedure|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
75539590|NCT04595929|Procedure|PIPAC|Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².
75539591|NCT04595929|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy according to indications.
75539592|NCT00249327|Behavioral|education|
75539593|NCT04596085|Dietary Supplement|Investigational Product - ViraCide|Viracide
75539594|NCT04596085|Other|Placebo - Starch Powder Soft gels|Starch Powder Soft gels
75539595|NCT00566410|Drug|Dichloroacetate|Continuous daily oral dosage (bid).
75703516|NCT03015792|Drug|Ibrutinib|Given PO
75703517|NCT03015792|Other|Laboratory Biomarker Analysis|Correlative studies
75703518|NCT03015792|Drug|Lenalidomide|Given PO
75703519|NCT03015792|Other|Pharmacological Study|Correlative studies
75703520|NCT03015792|Other|Quality-of-Life Assessment|Ancillary studies
75703521|NCT00789165|Drug|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
75703522|NCT00789165|Drug|no therapy|No therapy; this is not a placebo-controlled trial
75703523|NCT00712556|Radiation|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
75703524|NCT00795561|Procedure|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
76029699|NCT05062759|Drug|Placebo|SC injection Q4W.
76029700|NCT05057715|Biological|VCN-01|Intravenous administration of VCN-01
76029701|NCT05057715|Biological|huCART-meso Cells|Intravenous administration of huCART-meso cells
76029702|NCT05056454|Behavioral|Online therapy with coaching|"Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or Rainfrog's ParentMood course. Lesson content is presented as illustrated stories about characters who are anxious and depressed then gain mastery over their problems using CBT techniques. The efficacy of each online course will be compared for equivalency.~Following each lesson, participants are provided a document that summarizes key lesson information and practical homework exercises that reinforce the content of the lesson. Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson."
75378248|NCT03098173|Procedure|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
75378249|NCT03091478|Drug|Pembrolizumab|200mg every 3 weeks
75378250|NCT02867605|Dietary Supplement|Hyaluronan|
75378251|NCT03092024|Other|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
75378252|NCT03092960|Behavioral|Minimal intensity intervention|The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
75539596|NCT04596007|Drug|HEC83518 tablets|Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
75539597|NCT04596007|Drug|Placebo|placebo
75539598|NCT00252954|Drug|Levetiracetam|Tablets 2000-3000 mg per day
75539599|NCT04595812|Drug|Misoprostol 200mcg Tab vaginal|2 tablets vaginally 1 hour before surgery
76029703|NCT05056454|Behavioral|Clinical care|Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider and will be comparable to that provided in the TAU arm.
76029704|NCT05050240|Other|Cooling Vest Procedure|"A cold vest will be placed on the participant (consisting of a water-perfused CFA wearable vest, size S-M or M-L with adjustable straps Polar Products, Stow, OH; attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler; Product link: https://www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm This product is safe and recommended by experimental guidelines and BARCIST criteria for human BAT studies. Note, the cooling vest will be cleaned between participants according to the manufacturer's guidelines found here: https://www.polarproducts.com/polarshop/pc/catalog/pdf/Polar_CoolFlow_Manual.pdf.~Briefly, the vest will be hand washed with a mild detergent and warm soapy water and air-dried. The vest will then be stored in a clean, dry environment with ventilation."
76029705|NCT05050240|Other|Fasting overnight|Participants will be requested to refrain from food and caloric drinks overnight (starting at 10pm) prior to the hospital visit. Blood will then be drawn the following morning (between 8 and 9am) and 3hrs later (between 11am and noon). Participants will be sat in a room with ambient temperature (room temperature w/o cooling) between the two blood draws.
75539600|NCT04595812|Drug|Oxytocin|30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h
75539601|NCT04595812|Drug|Carbetocin|100 μg IV Carbetocin (1ml) in 5 ml saline over 1 minute
75867192|NCT03736187|Drug|Cephalexin|Giving cephalexin and metronidazole in one group &cephalexin alone in another group
76029706|NCT05047640|Biological|BNT162b2 vaccine|Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle
76029707|NCT05047640|Biological|JNJ-78436735 Vaccine|Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
76029708|NCT05047224|Behavioral|Tele-assessment + in-person assessment|Participants will complete a tele-assessment using the TAP. They will complete a traditional, in-person autism spectrum disorder assessment approximately two weeks later.
76029709|NCT05047224|Behavioral|Tele-assessment only|Participants will complete a tele-assessment using the TAP. They will complete a second, shorter tele-assessment approximately two weeks later.
75539602|NCT04595812|Procedure|pericervical hemostatic tourniquet|a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision,The time of tourniquet administration will be recorded, and will be released not later than 45 minutes after its application. For those requiring multiple applications, the tourniquet will be reapplied after a period of at least 15 minutes.
76029710|NCT05043714|Biological|NG-641 in combination with Nivolumab|"NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.~Nivolumab is a human monoclonal antibody that targets the PD-1 cluster of differentiation 279 cell surface membrane receptor."
75539603|NCT04596046|Procedure|steroid injecting|Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
75703525|NCT00795561|Procedure|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
75703526|NCT00772967|Drug|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
75867193|NCT03731663|Behavioral|Exposure to pictures of appetizing food (known as Foodporn)|- Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.
75867194|NCT03731663|Behavioral|Exposure to neutral pictures|Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
75867195|NCT03605693|Behavioral|Written Exposure Therapy|Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
76029711|NCT05039073|Drug|Brentuximab Vedotin|Given IV
75867196|NCT03736109|Genetic|Soluble and genetic biomarkers measurements|Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
76029712|NCT05039073|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
76029713|NCT05039073|Biological|Nivolumab|Given IV
76029714|NCT05039073|Other|Quality-of-Life Assessment|Ancillary studies
76029715|NCT05039073|Other|Questionnaire Administration|Ancillary studies
75378253|NCT03092960|Behavioral|HOMBRE|HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
75378254|NCT02870101|Diagnostic Test|Nucleic acid amplification test 1 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
75378255|NCT02870101|Diagnostic Test|Nucleic acid amplification test 2 for NG and CT|A combination test using target amplification to detect RNA from NG and CT.
75539604|NCT00252993|Drug|DDP225|
75539605|NCT04595539|Behavioral|Behavioral Activation treatment with Attention Training Technique|"The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life."
75378256|NCT02870101|Diagnostic Test|Nucleic acid amplification test 3 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
75539606|NCT00566566|Other|sample without DNA|family history, anthropometric measurements and blood sampling
75378257|NCT00375596|Drug|Ketotifen/vasoconstrictor|
75378258|NCT03143894|Device|tDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
75378259|NCT03143894|Other|Sham tDCS|Sham Transcranial direct current stimulation (tDCS)..
75378260|NCT03144518|Other|Positive Affect Intervention|See Previous Description
75703527|NCT00772967|Drug|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
75703528|NCT00772967|Drug|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
76029716|NCT05037669|Biological|PACE CART19|PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
76029717|NCT05033262|Other|Our Memory Care Wishes|Our Memory Care Wishes is a web-based advance care planning platform designed for persons living with dementia in nursing homes to discuss and document healthcare and daily life preferences with the help of shared decision-makers. Penn researchers meet via Zoom with PLWD and their SDMS and nursing home staff to facilitate website completion.
76029718|NCT05029999|Drug|PLD Chemotherapy|PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
76029719|NCT05029999|Drug|CDX-1140|CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
75378261|NCT03144518|Other|Neutral Control Intervention|See Previous Description
75703529|NCT02363010|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
75703530|NCT02363010|Behavioral|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
75867197|NCT03605303|Device|Test/Control|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
75378262|NCT03144518|Biological|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
75378263|NCT03148262|Device|The Comfort Flo system|The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
75378264|NCT03148262|Device|The Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
75378265|NCT03099655|Device|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
75378266|NCT03093272|Drug|Leuprolide Acetate|a GnRH agonist
75378267|NCT03093272|Drug|Prednisone|Prednisone is a corticosteroid
75867198|NCT03605303|Device|Control/Test|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
75703531|NCT02363010|Behavioral|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
75867199|NCT03735953|Diagnostic Test|Retroflexion in the total colon|retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
75867200|NCT03731507|Device|Assessment of Range of Motion with Kinect Controller|A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
75867201|NCT03604523|Device|Dilation by Balloon|Esophageal dilation by balloon device.
75378268|NCT03093272|Drug|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
75378269|NCT03093272|Drug|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
75539607|NCT04595695|Behavioral|Transparent mask|A transparent mask worn by the surgeons in customary fashion will be used.
75703532|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
75703533|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
75703534|NCT01419704|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
75867202|NCT03604523|Device|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device
76029720|NCT05029999|Drug|CDX-301|CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
76029721|NCT05025956|Drug|Fisetin|Oral Fisetin 20 mg/kg taken for 8 days total.
76029722|NCT05025956|Drug|Placebo|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 8 days total.
76029723|NCT05023967|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
76029724|NCT05023967|Drug|Extended Release Metformin Hydrochloride|Given PO
76029725|NCT05023967|Other|Monitoring|Use continuous glucose monitoring system
76029726|NCT05023967|Other|Nutritional Assessment|Receive nutritional counseling
76029727|NCT05023967|Other|Short-Term Fasting|Perform intermittent fasting
76029728|NCT05022264|Diagnostic Test|RIA-VS|Measuring vital signs with a new contactless camera technique
76029729|NCT05012254|Drug|Ipilimumab|"Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion."
76029730|NCT05012254|Drug|Nivolumab|"Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion."
76029731|NCT05012254|Drug|Carboplatin|"Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
75703535|NCT00789243|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
75867203|NCT03621059|Behavioral|habit reversal training (HRT)|"The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)"
76029732|NCT05012254|Drug|Cisplatin|"Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center."
76029733|NCT05012254|Drug|Paclitaxel|"Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
75703536|NCT00712634|Biological|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
75703537|NCT00662259|Drug|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
75703538|NCT00662259|Drug|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
75703539|NCT04070222|Other|Hysteroscopy|"Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~ART will be carried out with standard protocol and the clinical outcome will be recorded;~The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate."
75703540|NCT00712790|Drug|Sorafenib|Tablet, 400mg orally, twice daily
75867204|NCT03731429|Drug|Lidocaine|prior to extubation
75867205|NCT03731429|Drug|Saline Solution|Prior to extubation
75867206|NCT03735641|Procedure|Expanded Pedicled Deltopectoral Flap|Expanded Pedicled Deltopectoral Flap is a type of surgical flap
75703541|NCT00712790|Radiation|SIR-Spheres|one time treatment and capped at 3.0 Gbq
76029734|NCT05012254|Drug|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol [2,3 d]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
76029735|NCT05012241|Diagnostic Test|Nine Hole Peg Test|At first, each patient will be asked to fill in the questionnaire. Then he/she will be tested by the Nine Hole Peg Test according to the new Czech version of extended manual for this test. Audio recording of verbal instructions will be used.
75539608|NCT04595695|Behavioral|Typical surgical covered mask|A standard covered surgical mask worn by the surgeons in in customary fashion will be used.
75378270|NCT03093662|Device|Ventilation with nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
75378271|NCT03093662|Device|Ventilation without nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
75539609|NCT04595578|Device|Cerebellar repetitive transcranial magnetic stimulation|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
75539610|NCT00249366|Drug|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
75703542|NCT02574104|Other|Simulate a functional NICU prior to moving patients|Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
75703543|NCT02577744|Other|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
75703544|NCT02577744|Other|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
75703545|NCT00712868|Drug|Lactic acid|Once a day
75867207|NCT03602339|Drug|Gadoterate (Dotarem/Clariscan)|Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
75378272|NCT03100123|Drug|Aspirin 81 mg|Aspirin 81 mg po daily in tablet form.
75378273|NCT03100123|Drug|Low-molecular-weight heparin|The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
75539611|NCT00249366|Drug|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
75703546|NCT00660699|Drug|Gemcitabine|
75703547|NCT00660699|Drug|Docetaxel|
75703548|NCT00660699|Radiation|Radiation|
75703549|NCT02577068|Drug|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
75703550|NCT02577068|Drug|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
75539612|NCT04595461|Other|Video Education|Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
75539613|NCT04595461|Other|Control|Standard patient education with verbal and written education
75539614|NCT04595227|Device|Computerized pupillary light reflex assessment device|CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.
75539615|NCT04635683|Drug|Lenalidomide|Given PO
75539616|NCT04635683|Biological|Ublituximab|Given IV
75539617|NCT04635683|Drug|Umbralisib|Given PO
75703551|NCT02576834|Behavioral|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
75703552|NCT02576834|Other|Services as Usual|Services as usually provided in the community
75703553|NCT00582114|Drug|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
75703554|NCT00582114|Drug|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
75539618|NCT04595383|Device|ti.care|Electronic platform for doctor-patient communication
75539619|NCT04595110|Other|Observational study|Coagulation factors, Hypercoagulation biomarkers, Endothelial, Fibrinolysis and neutrophil activation biomarkers
75539620|NCT00253032|Device|PRIMA|
75539621|NCT04595344|Other|Listening to Pure Binaural Beats|"The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves."
75703555|NCT04071080|Drug|fluorescein sodium|Fluorescein sodium in 500mL Gatorade
75867208|NCT03602339|Drug|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
75539622|NCT04595344|Other|Listening to classical music|The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.
75539623|NCT04595344|Other|No audio only headphone|The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
75703556|NCT04071080|Drug|Placebo|500mL Gatorade
75539624|NCT00403091|Behavioral|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
75703557|NCT01719666|Procedure|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
76023395|NCT04436627|Device|Amadeo-assisted training-2|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).
75539625|NCT00403091|Behavioral|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
75539626|NCT00566605|Procedure|Penetrating keratoplasty with IntraLase|penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty [IEK])
75539627|NCT00566605|Procedure|Penetrating keratoplasty with vacuum trephine|Group 2 - penetrating keratoplasty with vacuum trephine
75539628|NCT04594954|Dietary Supplement|Diet|A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
75539629|NCT04594954|Other|FMT|"Stool Administration Procedure (ILBS FMT Protocol)~500 mL filtrates will be delivered through the UGI Endoscopy into proximal jejunum [(2 to 3 minutes per 50 ml).]~The recipient will be kept nil per oral for at least 4 hours prior to the stool instillation.~100 mL freshly thawed sample will be given once in 15 days for 3 doses~Non-absorbable antibiotics will be avoided in the patient from the time of enrollment into the study and therapy initiation.~Intravenous antibiotics will be continued as per institutional protocol in the event of active sepsis based on culture and sensitivity.~The patient will be allowed to consume liquid diet two hours after the procedure."
75703558|NCT01719666|Procedure|conventional surgery|conventional surgery: MPFL reconstruction
75703559|NCT00582036|Drug|Regular Insulin|Use of sliding scale insulin as per Appendix 1
75703560|NCT00582036|Device|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
76023396|NCT04436627|Device|Amadeo-assisted training-3|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
76023397|NCT02396329|Drug|Chlorhexidine|
76023398|NCT02396329|Drug|Povidone-Iodine|
75378274|NCT04700150|Other|Tai Chi 2 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
75378275|NCT04700150|Other|Tai Chi 4 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
75378276|NCT03097484|Drug|lavender and chamomile essential oils|Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
75378277|NCT02872909|Device|Ambulight (Ambicare Health)|"battery-operated low irradiance red light LED (skin cancer plaster)"
75378278|NCT04695236|Device|ZOLL Intravascular Temperature Management system, Quattro catheter|ZOLL Intravascular Temperature Management system, Quattro catheter
75378279|NCT04695236|Other|Standard Treatment|Standard Treatment for Ischemic Strokre
75703561|NCT00581360|Drug|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
76029736|NCT05009121|Diagnostic Test|Box and Block Test|"At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions."
75378280|NCT02957305|Drug|Misoprostol 400mcg Tab|400µg of misoprostol (2 tablets)
75378281|NCT02957305|Drug|Misoprostol 200mcg Tab|200µg of misoprostol (1 tablet)
75378282|NCT02873923|Drug|undefined|Chemotherapy drug (meta-analyses of randomized trials)
76029737|NCT05009108|Diagnostic Test|Purdue Pegboard Test|"At first, each person will be asked to fill in the informed agreement and answer short questionnaire. Than he/she will be tested by the Purdue Pegboard Test according to the Czech version of extended manuals for those tests in only one session. Audio recording of verbal instructions will be used and whole testing process will be video recorded which is necessary for establishing the internal variability and variability of results of the Purdue Pegboard Test.~The results will be used only for establishing of the variability and inter-rater reliability of the Purdue Pegboard Test, not for patients' other interventions."
76029738|NCT05006404|Device|Pulmonary Valve Replacement Surgery|Pulmonary valve replacement surgery with the Autus Valve
75378283|NCT04590092|Device|Cooper Surgical Ring Pessary with Incontinence Knob|A pessary is a silicone ring with a knob that in inserted into the vagina to treat urinary incontinence by providing urethral support.
75378284|NCT03104647|Other|VRP-Clinic|Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
75378285|NCT03104725|Drug|N-Acetylcysteine|Oral
75378286|NCT03104725|Procedure|Lumbar Puncture|Each participant undergoes a baseline lumbar puncture (LP 1) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP (LP 2) is completed after the PD participant has taken at least 5 doses of NAC (2 grams orally twice per day) and approximately 2 hours after the last NAC dose. For the HV participant, LP 2 occurs approximately 48 hours after LP 1 (no NAC administered).
75378287|NCT03104725|Radiation|Fluoroscopy|If needed for lumbar puncture
75378288|NCT03153956|Device|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
75378289|NCT03153956|Device|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
75378290|NCT02876575|Device|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
75378291|NCT03154658|Drug|Ropivacaine 0.35%|The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
76023399|NCT04964921|Other|Device: ANSiScope Plus|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
76023400|NCT04053049|Other|Diet|Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
76023401|NCT04648553|Behavioral|Task-Based Grounding|Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.
75378292|NCT03157232|Device|Rainbow DCI and R1-25 sensor|Noninvasive Measurement of SpHb
75378293|NCT02958787|Radiation|Radiation Therapy|Radiation Therapy Using MRI Based Treatment Planning
75378294|NCT03098420|Drug|2mg Dexamethasone|0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
75378295|NCT03098420|Drug|4mg Dexamethasone|1 mL (4mg) of dexamethasone
75378296|NCT03098420|Drug|Ropivacaine (TAP blocks)|20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
75378297|NCT03098420|Drug|Morphine|
75378298|NCT03098420|Drug|Bupivacaine Hydrochloride|
75703562|NCT05673564|Procedure|Anatomical Resection|Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
75703563|NCT02574182|Radiation|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters"
75378299|NCT03098420|Drug|Normal saline 1ml|1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
75378300|NCT03098420|Drug|Normal saline 0.5ml|0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
75539630|NCT04594954|Other|Physical Activity|"Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min."
76029739|NCT05005052|Drug|Vessel|Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
75539631|NCT00253071|Behavioral|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
75539632|NCT00249405|Drug|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
75539633|NCT00249405|Behavioral|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
76029740|NCT05005052|Drug|Placebo|Placebo and no compression or venopharmaceutical regimen
76029741|NCT05001139|Device|Relizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
76029742|NCT04995978|Drug|Pioglitazone 30 mg|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
76029743|NCT04995978|Drug|placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
76029744|NCT04995952|Behavioral|Gross motor training|Gross motor training activity (1 hour session, 3 times a week for 3 months). Pre ad post assessments will be taken. The Gross motor training activity will include: sit to stand, step-ups and walking. The sit to stand will be performed for 20 minutes involving 20 repetitions. We will progress from high seat sit to stand to low seat sit to stand. The step up will progress initially from a bench having low height to high height and then to stepping of stairs for 20 minutes involving 30 repetitions. The walking will occur from 3m walk and then increasing the distance
76029745|NCT04995952|Behavioral|Trunk targeted training|"Trunk targeted training (1hour session, 3 times a week for 3 months). Pre and Post assessment will be evaluated. The trunk targeted training will include: weight supported treadmill walk, specific trunk exercises with vibration therapy and reaching forward to the limits of stability.~Specific trunk exercises will involve stride sitting to standing, sitting on a roll and moving the roll in diagonal and forward backward directions along with giving vibrational therapy on wobble board, side sitting. This activity will be performed for 30 minutes with 30 repetitions. Reaching forward to the limits of stability exercises will be performed. Asking the children to hold objects from right hand while reaching for an object on left side and vice versa. This will be performed for 20 minutes having 20 repetitions."
75539634|NCT00566644|Device|levonorgestrel-releasing intrauterine system|
75703564|NCT01650792|Drug|Aspirin|
75378301|NCT02876887|Drug|Cocoa|
75378302|NCT02876887|Drug|Placebo|
75378303|NCT03158714|Behavioral|Couples Connecting Mindfully|
75539635|NCT00566644|Other|questionnaire administration|
75378304|NCT03158714|Behavioral|ELEVATE|
75378305|NCT03108469|Drug|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
75378306|NCT03108469|Other|Placebo|Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
75378307|NCT03159260|Device|Theraworx|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
75378308|NCT03159260|Other|Placebo|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
75378309|NCT02878057|Drug|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
75539636|NCT00566644|Procedure|observation|
75703565|NCT00713180|Procedure|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
75703566|NCT03918018|Device|BORA Band SpO2 Validation Study|"Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. Reference sensor(s) will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk.~Simultaneous data collection will be set up for device under test and the control pulse oximeter. The data from the test device will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.~The investigational device will only be placed on the wrist. The control pulse oximeter may be alternated through fingers between subjects."
76029746|NCT04993781|Behavioral|eSTEPS CDS|Primary care clinics at Brigham and Women's Hospital will be randomized to receive the eSTEPS CDS or usual care. The University of Texas Medical Branch (UTMB) will be the replication site, with all participating primary care practices receiving the eSTEPS CDS.
76029747|NCT04993157|Drug|FIA586|FIA586 capsule
76029748|NCT04988867|Drug|Trofinetide|Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
76029749|NCT04987294|Drug|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
75703567|NCT05673122|Device|Implant(Flotecno)|"The implants It has a tapered body design and Sandblasting with Large grit that facilitates the osseointergration process.~made in Italy Flotecno srl via.Turati,38 20121 MILANO (Italia)"
75703568|NCT00660387|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
75703569|NCT00660387|Drug|Placebo Gel|
76029750|NCT04987294|Drug|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
76029751|NCT04987242|Drug|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
75378310|NCT00422617|Drug|Alefacept (Amevive)|
76029752|NCT04987242|Drug|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
76029753|NCT04984005|Behavioral|Low intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a low-intensity exercise training.
75378311|NCT03104738|Other|25% reduction of basal insulin dose|"Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital."
75378312|NCT03162458|Drug|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
75867209|NCT03735485|Other|Conventional Physiotherapy|"The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program."
75867210|NCT03735485|Other|Shoulder Mobilization|In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.
76029754|NCT04984005|Behavioral|Moderate intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a moderate-intensity exercise training.
76029755|NCT04984005|Behavioral|Intermittent high intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a high-intensity exercise training.
76029756|NCT04977050|Diagnostic Test|Quidel quickvue antigen test for COVID-19|rapid antigen test on nasal swab specimen for COVID-19
76029757|NCT04976192|Combination Product|TEV-45779|TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
76029758|NCT04976192|Combination Product|XOLAIR® Injection|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
75378313|NCT03162458|Drug|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
75378314|NCT03163472|Procedure|Axillary brachial plexus block with 10 mL oof local anaesthetic|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
75703570|NCT00660387|Drug|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
76029759|NCT04973553|Other|upper limb rehabilitation|the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.
75539637|NCT04625660|Device|PQ Bypass System|Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
75539638|NCT04594447|Device|Physica Kinematic Retaining knee replacement|modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation
75378315|NCT03163472|Procedure|Axillary brachial plexus block with 30 ml of local anaesthetic|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
75378316|NCT02880475|Drug|OXN PR tablet|Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
75378317|NCT04468568|Drug|Atosiban|Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
76029760|NCT04970290|Device|Definisse threads free floating and definisse threads double needle|Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30
75867211|NCT03735485|Other|Proprioceptive Neuromuscular Facilitation|"In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist."
75703571|NCT00660387|Drug|Placebo (PBO) oral capsules|
75703572|NCT00660387|Device|CADD-Legacy® 1400 ambulatory infusion pump|
75703573|NCT00660387|Device|PEG tube|percutaneous endoscopic gastrostomy tube
75867212|NCT03653429|Drug|Tranexamic Acid|administered prior to surgical incision
75867213|NCT03653429|Drug|Normal saline|administered prior to surgical incision
75539639|NCT04594447|Device|Physica Cruciate Retaining knee replacement|modular knee prosthesis with posterior cruciate ligament (PCL) preservation
76029761|NCT04967677|Diagnostic Test|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|At first, each person will be asked to fill in the questionnaire. Than he/she will be tested by the Nine Hole Peg Test, Purdue Pegboard Test and the Box and Block Test according to the Czech version of extended manuals for those tests. Audio recording of verbal instructions will be used.
75867214|NCT03601715|Other|Coplanar|The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
76029762|NCT04963062|Device|Holmium laser with Moses lasers|The holmium laser with Moses is FDA approved. It emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed. The goal is to increase stone ablative volume and decrease retropulsion of the stone.
76029763|NCT04963062|Device|Holmium laser with thulium lasers|The holmium laser with thulium laser is FDA approved. It has a different wavelength then the holmium laser with Moses and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns
76029764|NCT04958551|Other|No intervention|No intervention
75378318|NCT04468568|Drug|Terbutaline|Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
75378319|NCT03106844|Drug|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
75703574|NCT00660387|Device|J-tube|jejunal tube
75703575|NCT00582738|Drug|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
75378320|NCT03168308|Drug|Sugammadex|Sugammadex 2 mg/kg
75378321|NCT03168308|Drug|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
75703576|NCT00582738|Drug|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
75703577|NCT00713336|Drug|ZD4054|ZD4054 10mg Tablet
75703578|NCT00713336|Drug|Moxifloxacin|400 mg capsule
75703579|NCT00713336|Drug|ZD4054 Placebo|3 tablets
75703580|NCT00713336|Drug|Moxifloxacin placebo|1 capsule
75378322|NCT00375128|Biological|FP9-PP (FP9 polyprotein)|
75378323|NCT00375128|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
75378324|NCT03168542|Device|JJVC Fitting Guides|Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.
75703581|NCT00713336|Drug|ZD4054 Placebo|2 tablets
75703582|NCT00713336|Drug|ZD4054|30mg tablet
75703583|NCT00713336|Drug|ZD4054|10mg tablet
75703584|NCT00789711|Drug|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
75539640|NCT04594720|Other|Identification group|papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)
76029765|NCT04958486|Drug|5-Azacytidine and trastuzumab infusion|Patients will receive once weekly 10 mg intraventricular 5-Azacytidine infusions for six consecutive weeks followed by observation in the infusion suite for a minimum of 30 minutes and once weekly 21 mg intraventricular trastuzumab infusions for six consecutive weeks followed by observation for a minimum of 2 hour after each infusion for the first 2 infusions. During this monitoring period, temperature, blood pressure, heart rate, and oxygen saturation will be measured. Patients will also have a neurological examination performed to observe for neurological changes. All patients will undergo an MRI of the brain and total spine with and without gadolinium within 7 days after the final 5-AZA and trastuzumab infusion to determine treatment response and to assess for any signal changes in the brain or spine caused by the infusions and they will have a 30 day and a 90 day follow-up assessment by telephone or in person for assessment of outcome measures and safety
76029766|NCT04952961|Behavioral|Training in Vulval Self-Examination|Face-to-face training in vulval self-examination Supplemented with use of aids ( hand mirror, mobile phone with selfie-stick), patient information leaflet, reminders to self-examine
76029767|NCT04949165|Dietary Supplement|Iron Supplementation|low dose ferrous sulphate (65mg elemental iron) supplements
75539641|NCT04594720|Other|Validation group|papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
75539642|NCT04594330|Drug|virgin coconut oil (VCO)|15 mL of VCO twice a day for 14 days
75867215|NCT03601715|Other|Contraplanar|The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
76029768|NCT04944979|Biological|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
76029769|NCT04942210|Biological|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection Subcutaneous injection
75378325|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
75378326|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
75539643|NCT04594330|Other|placebo|15 mL of placebo twice a day for 14 days
75539644|NCT04618133|Behavioral|Early time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
75539645|NCT04618133|Behavioral|Late time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
75867216|NCT03601715|Other|Longitudinal|The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
76029770|NCT04942210|Biological|Yellow fever vaccine|Powder and diluent for suspension for injection Subcutaneous injection
75539646|NCT04618133|Behavioral|Active control|Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
76029771|NCT04940767|Drug|Isotretinoin|Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
76029772|NCT04940767|Drug|Amzeeq 4% Topical Foam|AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
76029773|NCT04926623|Device|FreeStyle Libre|FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)
76029774|NCT04926623|Other|SMBG|Self-Monitoring of Blood Glucose
76029775|NCT04923334|Behavioral|Brief Pain Teleconsult|The Brief Pain Teleconsult intervention includes 2 sessions provided by a licensed physical therapist over about 1 week. The sessions focus on pain education from a biopsychosocial perspective that is designed to address negative pain appraisals and catastrophizing thoughts, providing advice to be active and engage in exercise and physical activity, and reassurance that activity is beneficial and safe.
75703585|NCT00789711|Drug|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
75703586|NCT00713726|Drug|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
76029776|NCT04923334|Behavioral|Telehealth Physical Therapy|The Telehealth Physical Therapy intervention involves weekly telehealth sessions provided over 10 weeks. Telehealth Physical Therapy is provided by a licensed physical therapist. Key components of the intervention include reinforcing biopsychosocial education messages and developing an exercise and physical activity program using cognitive behavioral principles such as goal setting and positive reinforcement. Pain coping strategies including mindful breathing and progressive relaxation techniques will be included.
76029777|NCT04914117|Drug|RC118 for injection|RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
76029778|NCT04913805|Drug|Potassium Nitrate|Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
75378327|NCT04253756|Device|20-gauge BD Nexiva Diffusics|The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
75703587|NCT00713726|Drug|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
75703588|NCT00772889|Biological|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
75703589|NCT00772889|Biological|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
75703590|NCT00795795|Procedure|Preimplantation Genetic Screening|Preimplantation Genetic Screening
76029779|NCT04913805|Drug|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
75378328|NCT00375206|Biological|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
75378329|NCT04706780|Other|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
75378330|NCT03115177|Drug|Doxycycline|The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
75378331|NCT03115177|Drug|Cefazolin|
75378332|NCT04201418|Drug|Patisiran|Patisiran-lipid complex injection, for intravenous use
75378333|NCT02962609|Other|Semielevated Side-lying Position-ESL|The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
75378334|NCT02962609|Other|Semielevated Supine Position|The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
75378335|NCT02962687|Behavioral|Care management via videoconference|12-week nurse care management for medically complex Veterans with CI delivered via videoconference
75703591|NCT00795795|Procedure|IVF without PGS|IVF without PGS
75867217|NCT03735407|Device|C-Scan procedure|"The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,"
76029780|NCT04913805|Other|Potassium Chloride|Active control
76029781|NCT04912713|Other|Stress group|This group will perform the MAST stress protocol
76029782|NCT04912713|Other|Control group|This group will perform the MAST control protocol
75378336|NCT02962687|Behavioral|Care management via telephone calls|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
75378337|NCT03174158|Drug|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
75378338|NCT03174158|Behavioral|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
75703592|NCT05325983|Other|lemonade ice cubes|Mixing 1 part lemon juice and 6 parts boiling water, make 10ml lemonade ice cubes. The experimental group was given a 10ml lemonade ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the lemonade ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The experimental group was given a brand new 10ml lemonade ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
75867218|NCT03731117|Drug|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
75867219|NCT03735329|Device|Diagnostic test of SPO2|The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
75867220|NCT03735251|Other|Diuretic，Betaloc，antiplatelet drugs|According to international guidelines,we treated patinets who suffered from different disease
75378339|NCT03174158|Behavioral|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
75539647|NCT04594057|Behavioral|Gaze and Postural Retraining Exercise|"Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
75378340|NCT04736641|Other|Survey study|Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JOAHDEQ) will be applied
75378341|NCT00422630|Behavioral|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
75378342|NCT00422630|Behavioral|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
75378343|NCT00422630|Behavioral|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
75539648|NCT04594135|Drug|anti-CD5 CAR T cells|anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
75539649|NCT00253110|Drug|risperidone|
75378344|NCT03115411|Device|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
75539650|NCT00253110|Drug|haloperidol|
75703593|NCT05325983|Other|water ice cubes|make 10ml water ice cubes. The control group was given a 10ml water ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the water ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The control group was given a brand new 10ml water ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
75703594|NCT00800553|Drug|donepezil|5mg o.m. p.o. for approx. 2 weeks
75378345|NCT03176654|Procedure|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
75378346|NCT03176654|Procedure|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
75378347|NCT03115801|Drug|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
75378348|NCT03115801|Drug|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
75378349|NCT03115801|Radiation|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
75703595|NCT00800553|Drug|Placebo|5mg of placebo for approx. 2 weeks
75703596|NCT04103801|Dietary Supplement|Sucrose|Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
75703597|NCT00793767|Drug|erythropoietin|bolus of 400 IU/kg
75703598|NCT00793767|Drug|placebo (saline)|i.v
75703599|NCT04103723|Procedure|Preoperative premedication|Every patient with or without a preoperative premedication with midazolam before surgery.
75703600|NCT00796029|Drug|14C-paliperidone|
76029783|NCT04907968|Drug|XMT-1536 (Upifitamab Rilsodotin)|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~XMT-1536~UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
75378350|NCT03115801|Drug|Pembrolizumab|Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
75378351|NCT00422708|Procedure|Local anesthesia|
75703601|NCT00793845|Drug|Cyclophosphamide|First HDCT
75703602|NCT00793845|Drug|Etoposide|First HDCT
75539651|NCT04594252|Drug|ALXN1840|Administered orally as tablets.
75703603|NCT00793845|Drug|Carboplatin|First HDCT
75703604|NCT00793845|Drug|Thiotepa|Second HDCT
75703605|NCT00793845|Drug|Melphalan|Second HDCT
75703606|NCT00793845|Radiation|Total body irradiation|Second HDCT
75378352|NCT03177512|Behavioral|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
75378353|NCT03117517|Drug|Metformin|Metformin (1000 mg)
75378354|NCT03117517|Drug|Metformin, Pioglitazone|Metformin (1000 mg) Pioglitazone (30 mg)
75378355|NCT00375284|Drug|Pramipexole|
75378356|NCT02966275|Device|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
75378357|NCT02966275|Device|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
75378358|NCT02967367|Device|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
75378359|NCT02967367|Device|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
75703607|NCT04099745|Device|CGM|Continuous Glucose Monitoring System
75703608|NCT04099745|Device|FGM|Flash glucose monitoring System
75703609|NCT00800709|Drug|Memantine|Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
75703610|NCT00916331|Procedure|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
75703611|NCT00916331|Procedure|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
75703612|NCT00793923|Drug|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
75703613|NCT00793923|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
75703614|NCT01247324|Drug|Interferon beta-1a|
75703615|NCT01247324|Drug|Ocrelizumab-matching placebo|
75703616|NCT01247324|Drug|Ocrelizumab|
75703617|NCT01247324|Drug|Interferon beta-1a-matching placebo|
75703618|NCT00772577|Drug|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
75703619|NCT00772577|Drug|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
75867221|NCT03735173|Procedure|ReUnion TSA, pegged design|ReUnion total shoulder arthroplasty system, pegged design
75867222|NCT03735173|Procedure|ReUnion TSA, keeled design|ReUnion total shoulder arthroplasty system, keeled design
76029784|NCT04907968|Drug|Carboplatin|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~XMT-1536~UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
75539652|NCT04594174|Procedure|Fluid administration|"Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP <65 mm Hg or a Systolic Blood Pressure <90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase."
75539653|NCT04598672|Behavioral|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
75539654|NCT00566683|Drug|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
75539655|NCT00566683|Drug|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
75539656|NCT00566761|Drug|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
75539657|NCT00566800|Drug|erlotinib hydrochloride|
76023402|NCT04648553|Behavioral|Connected Care (Enhanced Treatment as usual)|Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
75539658|NCT00566800|Other|laboratory biomarker analysis|
75539659|NCT00566800|Procedure|biopsy|
75378360|NCT02967367|Device|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
75703620|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
75378361|NCT05405101|Procedure|ablation of aldosterone secreting adenoma|Radio frequency ablation to Conn's adenoma(s)
75378362|NCT05405101|Procedure|Unilateral adrenalectomy|Unilateral adrenalectomy for aldosterone secreting adenoma
75378363|NCT03795350|Drug|Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide|single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
75703621|NCT02345850|Procedure|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
75703622|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
76023403|NCT03167515|Device|074-6751 Lotion|Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
76023404|NCT03168139|Drug|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
76023405|NCT03168139|Drug|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
76023406|NCT02396017|Device|Capsule endoscopy|Endoscopic device
76023407|NCT02396017|Drug|Polyethylene Glycol|Bowel purgative
75378364|NCT03118843|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
75378365|NCT03724370|Behavioral|Telehealth Monitoring System|TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
75539660|NCT04593589|Other|Submandibular Gland Stem Cell Transplantation|Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
75539661|NCT04593706|Drug|Betamethasone acetate + Betamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
75539662|NCT04593706|Drug|Dexamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
75539663|NCT04593706|Drug|Methylprednisolone acetate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
75703623|NCT02345850|Drug|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
75703624|NCT02345850|Drug|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
75378366|NCT03724370|Other|VHA-SRM|Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
75378367|NCT04736732|Other|Medical follow-up|Patients will be followed for medical evaluation and for biobanking of data and biological samples.
75378368|NCT05401513|Other|Pilates Group|The individuals of the Pilates group will perform specific exercises of the method, which will involve mobility, stability and muscular resistance. The exercises will progress according to the level of difficulty (basic, intermediate and advanced), load and repetition every three or four weeks.
75539664|NCT04593706|Drug|Triamcinolone acetonide|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
75539665|NCT04593667|Device|hm-P bandage|hm-P bandage will be placed over the puncture site with the TR band positioned over the hemostatic bandage. The TR band will then be inflated per device specific instructions and to the group instructions. The arterial sheath will be removed from the body with slight device rotation.
75703625|NCT02345850|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m^2 IV bolus on Day +1, and 10 mg/m^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
76023408|NCT02395939|Procedure|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
75378369|NCT05365022|Device|ROSA® System Robotic Assisted Knee Prosthetic Surgery|Robotic Assisted Knee Prosthetic Surgery using ROSA® (Zimmer-Biomet) System
75378370|NCT03119389|Behavioral|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
75378371|NCT02967991|Device|EUS-guided liver biopsy|Endoscopic ultrasound guided liver biopsy
75539666|NCT04593238|Drug|Double Antibiotic paste|Metronidazole and Ciprofloxacin
75539667|NCT04593238|Drug|Calcium Hydroxide Paste - Non-Setting|Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
75539668|NCT04593316|Other|Saliva collection|A saliva sample will be collected before physical exercise.
75539669|NCT04593316|Behavioral|Questionnaires|The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.
76029785|NCT04902794|Device|Light Emitting Diode|Blue light-emitting diode applied to the female genital region for eight minutes, for five sessions, one per week
75539670|NCT04593316|Other|Ingestible core temperature capsule intake|The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.
75539671|NCT04593316|Other|Physical exercise|The participant will perform a walk/run test.
75539672|NCT04593316|Other|Heart rate monitoring|Heart rate will be monitored during physical exercise thanks to a chest belt.
75539673|NCT04593316|Other|Core temperature monitoring|Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.
75867223|NCT05665673|Other|Physical functions test|Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
75867224|NCT03731039|Other|Observational study|Pain assessment, Anxiety assessment, Depression assessment
76029786|NCT04902794|Device|Sham Light Emitting Diode|Sham Blue light-emitting diode turned off applied to the female genital region for eight minutes, for five sessions, one per week
76029787|NCT04900220|Drug|Betamethasone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)
76029788|NCT04900220|Drug|Methylprednisolone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
76029789|NCT04896684|Biological|blood and intestinal biopsy sampling|24 mL of blood and 10 intestinal biopsies will be sampled
76029790|NCT04896320|Drug|Tucatinib|Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
76029791|NCT04893564|Biological|bone marrow sample|8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.
76029792|NCT04893564|Biological|blood sample|20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.
76029793|NCT04887259|Biological|LAVA-051|In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion
76029794|NCT04887259|Biological|Interleukin 2|In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
76029795|NCT04877613|Drug|single dose of CART-GFRa4 cells|Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.
76029796|NCT04877613|Drug|Fludarabine|Lyphodepletion
75867225|NCT03594227|Drug|ATI-501 400mg BID (Low dose)|ATI-501 400mg BID oral low dose for oral administration
76029797|NCT04877613|Drug|Cyclophosphamide|Lyphodepletion
75539674|NCT04593433|Other|Museum virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 5 participants. They meet online one time per week for a 20 to 25 min of a visit tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
75539675|NCT04593511|Drug|LY03009 F1|a single dose of LY03009 F1
75539676|NCT04593511|Drug|LY03009 F2|a single dose of LY03009 F2
75539677|NCT04593511|Drug|LY03009 F3|a single dose of LY03009 F3
75539678|NCT04593511|Drug|LY03009 F4|a single dose of LY03009 F4
75867226|NCT03594227|Drug|ATI-501 600mg BID (Mid dose)|ATI-501 600mg BID oral mid dose for oral administration
75539679|NCT00566839|Procedure|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
75539680|NCT00566839|Procedure|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
75539681|NCT04593160|Drug|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
75539682|NCT04593160|Drug|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
75539683|NCT04593160|Drug|Placebo|Preoperative single dose of placebo
75867227|NCT03594227|Drug|ATI-501 800mg BID (High dose)|ATI-501 800mg BID high dose for oral administration
76029798|NCT04871607|Biological|Basiliximab|Given IV
76029799|NCT04871607|Drug|Carmustine|Given IV
76029800|NCT04871607|Drug|Cytarabine|Given IV
76029801|NCT04871607|Drug|Etoposide|Given IV
76029802|NCT04871607|Biological|Genetically Engineered Hematopoietic Stem Progenitor Cells|Given via infusion
76029803|NCT04871607|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC or IV
76029804|NCT04871607|Biological|Yttrium Y 90 Basiliximab|Given IV
75539684|NCT04592965|Behavioral|Clinical and neuropsychological assessments|The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.
75378372|NCT05400421|Device|System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure|Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
75378373|NCT02222922|Drug|PF-06647020 Q3W|"Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
75378374|NCT02222922|Drug|fluconazole|combination drug used for drug-drug interaction sub-study
75378375|NCT02222922|Drug|PF-06647020 Q2W|"Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
76029805|NCT04869917|Behavioral|Decision Aid intervention|"Displays information about the benefits and risks of ILI and metformin~Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~Prompts patients to commit to immediate next steps~Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen"
75378376|NCT02222922|Drug|PF-06647020 combined with Avelumab|Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
75378377|NCT03503942|Behavioral|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
75703626|NCT00800787|Biological|Nabi-HB|"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are <150 IU/ML > 75 Kg: 1,000 IU weekly"
75378378|NCT03503942|Drug|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
75703627|NCT04099433|Dietary Supplement|Vivomixx|Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
75867228|NCT03594227|Drug|Placebo|Placebo - oral administration
75867229|NCT03098550|Biological|Nivolumab|Specified dose on specified days
75867230|NCT03098550|Biological|Daratumumab|Specified dose on specified days
75378379|NCT03503942|Other|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
75378380|NCT03122587|Device|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
76029806|NCT04869917|Behavioral|Text Messaging intervention|"Defines prediabetes and includes individualized A1c values~Present benefits and risks of intensive lifestyle intervention and metformin~States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~Encourages initiating intensive lifestyle intervention or discussing metformin with provider~Include selected behavioral content from diabetes prevention program~Initial message with automatic opt-in, allows opt-out for messages~Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming"
75539685|NCT04592965|Behavioral|Induction of PH and associated bodily states|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls
75539686|NCT04592965|Other|Resting-state fMRI acquisition|Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls
75539687|NCT04592965|Other|Induction of PH and associated bodily states (MRI)|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
75539688|NCT00253149|Drug|risperidone|
75703628|NCT04099433|Other|Placebo|Individuals in the placebo arm will undergo daily oral intake of placebo supplement
75539689|NCT04592926|Device|Accuro SpineNav3D|The intervention will consist of a pre-procedural scan of the lumbar spine using the handheld image guidance device, Accuro, to determine spinal landmarks and anticipated depth of the intrathecal space.
75539690|NCT04592926|Other|Sham|The sham group will receive a pre-procedure sham scan (the handheld image guidance Accuro device will be placed on the back, but it will be turned off) followed by sham marking on the subject's back.
75703629|NCT04045977|Behavioral|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
75703630|NCT04045977|Device|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
75703631|NCT04045977|Behavioral|Standard therapeutic support|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
76029807|NCT04869917|Behavioral|Usual Care|Patients receiving care at non-intervention clinic sites will not be exposed to treatment intervention.
75378381|NCT03122587|Device|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
75378382|NCT03122587|Device|Active sham transcranial alternating current stimulation|Active sham (placebo)
75539691|NCT00566917|Procedure|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
75867231|NCT05039190|Drug|HBM9161 Injection (680mg)|HBM9161 Injection
75867232|NCT05039190|Drug|Placebo|Placebo Injection
75867233|NCT03095118|Drug|Daratumumab|Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
76029808|NCT04869397|Biological|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|"The product is provided cryopreserved by NextCell Pharma. The cells are frozen in cryobags at a concentration of 2 × 107 cells/ml in 5% Human Serum Albumin (HSA) and 10% dimethylsulfoxide (DMSO). One cryobag contains one dose. The bags are frozen in a controlled rate freezer and directly transferred to -190 ºC for storage until the time of infusion.~Cryobags are thawed at bedside and diluted in 100 ml of saline prior to administration. Cells will be delivered at a rate of 5 million cells per minute over a total of 20 minutes."
76029809|NCT04869397|Other|Placebo|Sodium chloride buffer supplemented with 5% HSA and 10% DMSO same volume and mode of administration as treatment group
76029810|NCT04865042|Drug|Gabapentin 300mg|"The patient will receive in addition to the usual analgesic treatment, the treatment under study: Gabapentin.~During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be performed.~The patient will have to take the treatment as follows:~Day 1 (1st day of hospitalization): 1 capsule/day~Day 2: 2 capsules/day~Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
76029811|NCT04865042|Drug|PLACEBO|"The patient will receive in addition to the usual analgesic treatment, the Placebo During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be made.~The patient will have to take the treatment as follows:~Day 1 (1st day of hospitalization): 1 capsule/day~Day 2: 2 capsules/day~Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
76029812|NCT04861441|Device|Aircast Cryo Cuff (Shoulder) and Aircast Cryo Cuff I/C Motorized Cooler|Patient will wear the continuous cryo cuff for a designated period of time and will record their pain and narcotic use post operatively.
76029813|NCT04861441|Device|Icepacks|Standard of care icepacks will be used postoperatively for designated amount of times and patients will record pain and narcotic use post operatively.
76029814|NCT04853368|Drug|ABBV-576|Oral capsules
76029815|NCT04853368|Drug|Galicaftor|Oral capsules
76029816|NCT04853368|Drug|Placebo|Oral capsules
76029817|NCT04853368|Drug|Navocaftor|Oral capsules
76029818|NCT04853368|Drug|ABBV-119|Oral capsules
76029819|NCT04838106|Other|Not applicable as observational study|Not applicable as observational study.
76029820|NCT04837365|Other|Three dimensional gait analysis with eyetracking|An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
76029821|NCT04833790|Behavioral|Free distribution of ORS|Provides will receive 3 months supply of ORS at the beginning of the study to dispense to their patients. They will be asked to dispense the ORS at the market rate and not to give it away to other providers.
75867234|NCT03594071|Device|The Q-Fix™ All-Suture Anchor|Observational, post-market, clinical follow-up study
76029822|NCT04833790|Behavioral|Standardized patient with ORS preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests ORS to treat their child's diarrhea.
75867235|NCT02696902|Drug|MEDI3902|Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
75867236|NCT02696902|Other|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
75867237|NCT05386758|Drug|Molnupiravir|Four 200 mg capsules administered orally as a single dose
75867238|NCT03169114|Drug|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
75867239|NCT03169114|Procedure|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
76022975|NCT02405611|Behavioral|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
76022976|NCT03169465|Procedure|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
75703632|NCT04021667|Other|educational intervention|İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
75703633|NCT04101305|Diagnostic Test|IsoPic|Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
75703634|NCT04100993|Other|No intervention used|No intervention used
75378383|NCT03791138|Other|online patient decision aid|An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
75378384|NCT05364398|Procedure|ACL reconstruction|Use of hamstring tendons graft to replace the torn ACL and being passed and fixed through the femoral and tibial sides
75378385|NCT02161146|Drug|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
75378386|NCT02161146|Drug|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
75378387|NCT02161146|Drug|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
75378388|NCT03447782|Drug|Naltrexone HCl (Bulk) Powder|For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
75539692|NCT00566917|Procedure|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
76022977|NCT03169465|Procedure|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
75539693|NCT00249483|Drug|Venlafaxine|Venlafaxiine 300mg/day
75539694|NCT00249483|Drug|Placebo|Placebo
75703635|NCT04099043|Device|Cascade Continuous Glucose Monitoring System|Continuous Glucose Monitoring for 15 days
75703636|NCT04073550|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
75703637|NCT04073550|Drug|Placebos|Anlotinib blank analog capsule.
75703638|NCT04073550|Drug|Topotecan|A topoisomerase I inhibitor.
75703639|NCT02576600|Device|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
75703640|NCT02576600|Other|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
75703641|NCT02576600|Drug|Propofol|TCI
75703642|NCT02576600|Drug|Remifentanil|TCI
76022978|NCT03169543|Behavioral|Sleep deprivation|36-hours total sleep deprivation
76022979|NCT03115489|Drug|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
75703643|NCT02863770|Other|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it increases diagnostic yield of the examination
75378389|NCT03109951|Drug|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
75703644|NCT00713804|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
75703645|NCT00713804|Behavioral|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
75703646|NCT02329470|Procedure|Withdrawal of continuous positive airway pressure treatment|Withdrawal of continuous positive airway pressure treatment
75703647|NCT00796185|Drug|Paliperidone ER|
75867240|NCT05011422|Device|Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus|Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product
75867241|NCT03169270|Other|Exercise training|All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
75867242|NCT04602936|Drug|Solriamfetol|Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.
75867243|NCT04602936|Drug|Placebo|"A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill)."
75867244|NCT02396602|Behavioral|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
75867245|NCT02694562|Device|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
75867246|NCT02874534|Behavioral|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
76029823|NCT04833790|Behavioral|Standardized patient with Antibiotic preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests Antibiotics to treat their child's diarrhea.
76029824|NCT04833790|Behavioral|Standardized patient with no preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea.
75378390|NCT03408704|Other|ASP|"It consists of one educational session where doctors and staff at the center discuss current guidelines around management of patients attending for a sore throat. At the education the following is discussed:~The Swedish guidelines~Example of cases~Statistics from previous 6 month showing how well this clinic adheres to the Swedish guidelines."
75703648|NCT02848092|Behavioral|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
76029825|NCT04833790|Behavioral|Standardized patient with no preference + no financial incentive|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea. In addition they will inform the provider that they are not going to purchase anything from the provider because they have an uncle with a drug shop where they can get a discount.
76029826|NCT04830592|Biological|NG-641|Patients receive three doses of NG-641 by intravenous infusion. NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
75378391|NCT03123055|Drug|B-701|B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
75378392|NCT03123055|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
75378393|NCT03340532|Other|THE INFORMATION + APPEARANCE VIDEO|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
75378394|NCT03340532|Other|Information SunSmart video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
75378395|NCT03340532|Other|Sleep hygiene video|Contain information on better sleep hygiene
76029827|NCT04830592|Biological|Pembrolizumab|Patients receive three doses of NG-641 by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion.
76029828|NCT04827849|Other|Structured education and follow-up|"The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period."
76029829|NCT04824131|Drug|Oral cabotegravir (CAB)|30 mg tablets
76029830|NCT04824131|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
76029831|NCT04824131|Drug|Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|300 mg/200 mg fixed-dose combination tablets
76029832|NCT04823377|Other|Usual care|Patients receiving systemic anticancer treatment in their last days of life
76029833|NCT04823377|Other|Optimization of the medical decision|Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
75378396|NCT03124069|Device|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
75378397|NCT05361200|Behavioral|Dynamic high-cadence cycling|Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
75378398|NCT02969317|Drug|Tiotropium|Fixed dose combination
75867247|NCT02874534|Behavioral|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
75867248|NCT02396446|Other|Abdominal acoustic measurement|Device meant to listen to the sounds of the gut to determine post op ileus.
75867249|NCT05417178|Other|myStrength Macropersonalization Enginge|An onboarding process that utilizes the PHQ-9, GAD-7, and WHO-5 that leads to a user of the digital program's clinical focus and primary, secondary, and tertiary intervention recommendations.
75867250|NCT03115762|Biological|bevacizumab|recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
75867251|NCT03115762|Biological|ASKB1202|
75867252|NCT03168958|Drug|Methadone|Methadone will be provided at induction of anesthesia
75867253|NCT03168958|Drug|Saline|Saline will be administered at induction of anesthesia
75867254|NCT02396056|Other|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
76029834|NCT04815707|Procedure|Occcult hernia repair|The occult hernia will be repaired during the same inguinal hernia repair
76029835|NCT04810975|Device|Muscle Strength Training|Strength training occurring specific exercise regimens using Exercise Equipment A or B
76029836|NCT04803851|Drug|Anlotinib plus AK105|Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
75378399|NCT02969317|Drug|Olodaterol|Fixed dose combination
75378400|NCT03314168|Other|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
75378401|NCT03314168|Other|Control group|The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
75867255|NCT02396056|Other|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
75867256|NCT02396368|Drug|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
75867257|NCT02396368|Radiation|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
76029837|NCT04781296|Device|CT with a photon-counting detector|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
75378402|NCT00375362|Drug|Nitroderm patch|
75378403|NCT03307226|Behavioral|Youth Development Accounts (YDA)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)
76029838|NCT04776447|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02"
75378404|NCT03307226|Behavioral|YDA + Multiple Family Groups (MFG)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development 12 Financial Management workshops on asset-building, saving and investing in Income Generating Activities (IGAs) 18 Multiple Family Groups sessions focused on strengthening family relationships and mental health
75378405|NCT03124693|Device|Rainbow DCI pulse oximeter sensor|
76029839|NCT04776447|Drug|Placlitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
75703649|NCT02848092|Other|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
75378406|NCT03288194|Behavioral|Problem-Solving Treatment|
75378407|NCT03288194|Behavioral|Time Management|
75867258|NCT03632460|Drug|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
75867259|NCT02396290|Procedure|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
75378408|NCT03124771|Device|Rainbow Resposable Adhesive Sensors|Noninvasive Measurement of SpHb
75867260|NCT02396290|Procedure|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
75378409|NCT05357300|Device|Peripheral Nerve Stimulation|Implant of percutaneous leads for peripheral nerve stimulation of the rami dorsales of the SIJ and gluteal or abdominal implant of impulse generator
75378410|NCT05347082|Drug|Cholecalciferol|Tablets of 4000 IU
75703650|NCT04070066|Other|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
75703651|NCT04070066|Other|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
75867261|NCT01567956|Drug|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
75867262|NCT01567956|Drug|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
75867263|NCT03168724|Behavioral|GMT intervention|
75867264|NCT03168646|Procedure|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
75867265|NCT03168646|Procedure|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
75867266|NCT03097614|Device|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
75867267|NCT05745766|Other|Panoramic and lateral cephalometric radiography|The 2D-based assessments of the impacted maxillary canine will be achieved using panoramic and lateral cephalometric radiographs.
75867268|NCT05745766|Other|Cone beam computed tomography|The 3D-based assessments of the impacted maxillary canine will be achieved using a cone beam computed tomography (CBCT) image.
75867269|NCT05745766|Other|Surgery|The surgical exposure will be accomplished, and the impacted maxillary canine will be assessed by a direct vision.
75867270|NCT03168802|Procedure|MRgFUS ablation|Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
75867271|NCT03168802|Procedure|Radiofrequency ablation|Radiofrequency ablation therapy under C-arm navigation for facet joint syndrome.
75867272|NCT05418660|Drug|Immunotherapy|At least 24 months with Pembrolizumab, Nivolumab or Atezolizumab in any treatment line
75867273|NCT03364309|Drug|Ixekizumab|Administered SC
75867274|NCT03364309|Drug|Placebo|Administered SC
75867275|NCT03168178|Drug|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
76029840|NCT04776447|Drug|Atezolizumab|"Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions."
76029841|NCT04768556|Other|EEG experimental sessions 1|An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.
76029842|NCT04768556|Other|EEG experimental sessions 2|An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action
76029843|NCT04768504|Drug|Tofacitinib 10 mg|Tofacitinib 10 mg PO BID for 30 days
75539695|NCT00566956|Procedure|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
75539696|NCT00567034|Drug|naltrexone|50mg naltrexone, 1 tablet a day for 12 weeks.
75378411|NCT05235139|Device|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
75703652|NCT00660309|Drug|Aliskiren|Aliskiren 300 mg tablets
75703653|NCT00660309|Drug|Irbesartan|Irbesartan 300 mg tablets
76029844|NCT04763967|Device|PedSCath Pediatric Urinary Catheter|PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.
75703654|NCT00660309|Drug|Captopril|Captopril 25 mg tablet
75703655|NCT04578002|Other|prehospital telemedical triage|Prehospital Triage of Patients with Suspected Stroke Using Onsite Mobile Telemedicine approach (interactive video and audio streaming). In patients with suspected stroke, a prehospital patient evaluation by end-to-end encrypted real-time audio- and video streaming from the pre-hospital setting to an in-hospital stroke physician, located at the University hospital of Basel, is requested and initiated (telestroke-path). The process is supervised and evaluated by an in-hospital stroke physician in real-time. Patients considered having an acute stroke will be directly transferred to cerebral imaging via CT. All other patients will follow conventional stroke path.
75703656|NCT02845518|Procedure|Cardiac magnetic resonance imaging (cMRI)|"Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9."
75703657|NCT04925388|Other|rapid molecular diagnosis|peritoneal samples will be analysed using Unyvero IAI test
75703658|NCT04925388|Other|conventional method analysis|peritoneal samples will be analysed using conventional method
75703659|NCT04046133|Drug|Pembrolizumab|Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
75703660|NCT02257554|Behavioral|education|Discussion of surgical expectations with patients
76029845|NCT04763967|Device|Standard of Care|Current Standard of Care for pediatric patients
75378412|NCT05235139|Device|IOL implantation active comparator (Acrysof Vivity)|Implantation of EDOF IOL Acrysof Vivity
75378413|NCT03124927|Device|DCI pulse oximeter sensor|
75378414|NCT03125005|Device|Rainbow Universal Pulse Oximeter Sensor|
75378415|NCT03087578|Other|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
75378416|NCT03087578|Drug|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
75539697|NCT00567034|Drug|placebo|lactose placebo, 1 capsule every day for 12 weeks
75378417|NCT02971735|Other|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
75378418|NCT02907086|Other|blood collection|Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
75378419|NCT05339282|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
75378420|NCT02975557|Drug|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
75867276|NCT03168178|Other|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
76029846|NCT04762342|Other|Power training|"First a brief warm up on a stationary bike and uni-lateral knee raises is completed.~Power training: Involves exercises performed with fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.~Functional- and balance exercises are included from week 9-24.~Progression:~Week 1-4: 3 sets of 12 repetitions at a load of 14 repetitions maximum (RM) with focus on introducing resistance exercise and familiarizing participants with exercises.~Week 5-8: 3 sets of 12 repetitions at a load of 14 RM the power training component.~Week 9-16: 3 sets of 10 repetitions at a load of 12 RM. Week 17-24: 3 sets of 8 repetitions at a load of 10 RM~Strengthening exercises:~Bilateral leg-press~Bilateral plantar flexion~Bilateral knee extension~Unilateral banded dorsal flexion~Bilateral lying leg curl~Back extension~Shoulder press~Seated row~Chest press~Lat pull-down"
75378421|NCT02975557|Drug|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
75378422|NCT02975557|Drug|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
75378423|NCT02642588|Dietary Supplement|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
75378424|NCT02976181|Device|IPG|Patient might require IPG device to be implanted under standard of care
75378425|NCT04736810|Biological|AK105|IV infusion
75867277|NCT05166096|Drug|Rho-11|Subjects will be administered 325 mg aspirin by rapid IV push
75867278|NCT05166096|Drug|aspirin 325mg|Subjects will be administered 325 mg aspirin orally
75867279|NCT03168490|Dietary Supplement|Gluten Friendly bread|parallel study
75378426|NCT04736810|Drug|Cisplatin|IV infusion
75378427|NCT04736810|Drug|Gemcitabine|IV infusion
75378428|NCT04736810|Drug|Anlotinib hydrochloride|Oral administration
75378429|NCT05267990|Diagnostic Test|Multi-Detector Computed Tomography|Coronary angiography calcium score via Multi-Detector Computed Tomography
75378430|NCT03132571|Drug|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
75703661|NCT00794079|Dietary Supplement|omega-3 fatty acids|4 grams per day for 8 weeks
75703662|NCT00794079|Dietary Supplement|corn oil|4 grams per day for 8 weeks
75867280|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
75867281|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
76029847|NCT04755452|Procedure|Low intra-abdominal pressure|7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
75378431|NCT03132571|Drug|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
75378432|NCT03132571|Other|Placebo|Oral placebo taken once daily for the course of the study (16 week)
75703663|NCT02573714|Drug|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
75703664|NCT02573714|Drug|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
75703665|NCT02573714|Other|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
75703666|NCT02573714|Other|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
75867282|NCT05110638|Drug|SKX-16 (Luliconazole 10% Solution)|SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.
75867283|NCT03700788|Drug|Chlorhexidine|2% Chorhexidine (intracranial; remains in canal until removal at next visit)
75378433|NCT02735720|Other|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
75378434|NCT02735720|Other|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
75539698|NCT03454126|Drug|BIIB095|Administered as specified in the treatment arm.
75539699|NCT03454126|Drug|Placebo|Administered as specified in the treatment arm.
75539700|NCT04592263|Other|EPD Questionnaire|A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
75539701|NCT02961309|Drug|THC|1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
75378435|NCT02374424|Drug|GA101_DHAP|"Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~Dexamethasone 40 mg day 1-4 of every cycles~Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy"
75378436|NCT03134209|Device|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
75378437|NCT03134209|Other|Monocryl + Dermabond|conventional sutures and skin adhesive glue
75378438|NCT03134209|Other|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
75378439|NCT02596412|Other|use the module with augmented reality (Mini-Docs) on tablet during TB injection|Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
75378440|NCT03134989|Device|Cochlear implant|Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
75378441|NCT02002130|Drug|Placebo GABA and Placebo GAD-alum|Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
75378442|NCT02002130|Drug|GABA and Placebo GAD-alum|Oral Active GABA with Placebo GAD-alum
75378443|NCT02002130|Drug|Active Oral GABA and Active GAD-alum injection|Active Oral GABA and Active GAD-alum injection
75378444|NCT03135379|Device|Heated ultrasound gel|"Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit)."
75867284|NCT03700788|Drug|Calcium Hydroxide|Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
76029848|NCT04755452|Procedure|High (standard) intra-abdominal pressure|12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
76029849|NCT04748172|Biological|SARS-CoV-2 virus vaccines|mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)
76029850|NCT04748172|Diagnostic Test|AMH sampling|Blood sample for AMH on recruitment and after three months
76029851|NCT04748172|Diagnostic Test|anti Covid-19 antibody levels (Serology)|Blood sample for IgG against S1 protein after three months
76029852|NCT04747041|Combination Product|CYSCONTROL/PHYTOCYST Herbal tea|Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
76029853|NCT04745871|Diagnostic Test|PSMA PET/CT|The PSMA PET/CT will be performed on an outpatient in the nuclear medicine department of the Brest University Hospital (CHRU). For this exam, the administration of 2-4 MBq/kg of 68Ga-HBED-CC-PSMA will be performed to patient by a single intravenous injection.
76029854|NCT04741646|Drug|Ferric Citrate|Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC and matching placebo will be supplied as 200 tablets in 400cc high-density polyethylene bottles.
76029855|NCT04741646|Drug|Placebo|Placebo to match Ferric Citrate tablets
76029856|NCT04736823|Drug|AK112|IV infusion
75703667|NCT02573714|Other|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
75867285|NCT02395900|Dietary Supplement|Flaxseed|
75703668|NCT00794235|Drug|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
75703669|NCT00800943|Biological|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
75703670|NCT00714116|Drug|SBI-087|Single IV or SC dose of SBI-087
75867286|NCT02395900|Other|control|
76029857|NCT04736823|Drug|Pemetrexed|IV infusion
75703671|NCT00801021|Drug|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
75867287|NCT03167398|Biological|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
75867288|NCT03334903|Drug|Gabapentin|600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
75867289|NCT03167008|Diagnostic Test|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
75867290|NCT03167008|Diagnostic Test|blood sample|blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
75867291|NCT03679026|Other|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
76029858|NCT04736823|Drug|Paclitaxel|IV infusion
76029859|NCT04736823|Drug|Carboplatin|IV infusion
76029860|NCT04736823|Drug|Docetaxel|IV infusion
76029861|NCT04732676|Other|Smartphone application|"Ecological Momentary Assessment (EMA)~: ambulatory assessment of behaviors/symptoms in real-time on smartphones"
76029862|NCT04731571|Radiation|CBCT-guided Adaptive Radiotherapy|The aim is to deliver adaptive radiotherapy using a CBCT-based radiotherapy delivery system.
76029863|NCT04729946|Device|Pure-Vu Cleansing Device|The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
75378445|NCT03135379|Device|Room temperature gel|Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
75378446|NCT01306994|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
75378447|NCT01306994|Procedure|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
75378448|NCT01306994|Other|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
75378449|NCT01306994|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
75867292|NCT05414851|Other|Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet|Participants will consume two weeks of each diet, with a 4-6 week washout period in between. Meals and snacks are provided for convenience to enhance adherence to each dietary pattern, but subjects can add or include their own home-prepared foods as long as they meet dietary guidelines. Each dietary intervention will include an education session via Zoom teleconference, and at least 2 individual contacts by phone to address questions and assess for adverse events.
75867293|NCT03168100|Drug|Elotuzumab|administered via IV infusion
76029864|NCT04729621|Combination Product|TVB-009|TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
75703672|NCT00796341|Procedure|PIPELLE ENDOMETRIAL SAMPLING|Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
75703673|NCT02575664|Drug|Buprenorphine|Buprenorphine 5 microg/h/7 days
75703674|NCT02575664|Drug|Placebo|Placebo patch
75703675|NCT02554539|Procedure|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
75703676|NCT02576522|Radiation|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
75703677|NCT00796497|Drug|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
75703678|NCT00714194|Procedure|Normal continuous sedation|Normal continuous sedation.
75703679|NCT00714194|Other|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
75703680|NCT00796575|Drug|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
75703681|NCT00796575|Drug|placebo tablets|placebo tablets matching active
75703682|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
75703683|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
75703684|NCT00801177|Biological|IMC-11F8|"Cohort 1~100 mg I.V."
75703685|NCT00801177|Biological|IMC-11F8|"Cohort 2~200 mg I.V."
75703686|NCT00801177|Biological|IMC-11F8|"Cohort 3~400 mg I.V."
75703687|NCT00801177|Biological|IMC-11F8 I.V.|"Cohort 4~600 mg I.V."
75703688|NCT00801177|Biological|IMC-11F8|"Cohort 5~800 mg I.V."
75703689|NCT00801177|Biological|IMC-11F8|"Cohort 6~1000 mg I.V."
75703690|NCT00801177|Biological|IMC-11F8|"Cohort 1~100 mg I.V."
75703691|NCT00801177|Biological|IMC-11F8|"Cohort 2~200 mg I.V."
75703692|NCT00801177|Biological|IMC-11F8|"Cohort 3~400 mg I.V."
75703693|NCT00801177|Biological|IMC-11F8|"Cohort 4~600 mg I.V."
75703694|NCT00801177|Biological|IMC-11F8|"Cohort 5~800 mg I.V."
75703695|NCT00801177|Biological|IMC-11F8|"Cohort 6~1000 mg I.V."
75703696|NCT00581100|Drug|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
75703697|NCT02554461|Other|advise for exercices given by team staff|"To respond to questions asked:~it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided"
75703698|NCT00579098|Drug|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
75867294|NCT03168100|Drug|Lenalidomide|taken by mouth
75867295|NCT03168100|Drug|Dexamethasone|taken by mouth
75867296|NCT03168100|Drug|Bortezomib|administered as a subcutaneous injection
75867297|NCT03709381|Drug|Low Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 1 mcg IV given to subjects at t=0
75867298|NCT03709381|Drug|High Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 250 mcg IV given to subjects at t=60
75703699|NCT00579098|Drug|Placebo|Placebo tablet taken by mouth once daily for 90 days
75867299|NCT01353664|Drug|Romidepsin|The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
76029865|NCT04729621|Combination Product|Prolia®|Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
75539702|NCT04484363|Drug|Pevonedistat|Pevonedistat 20 milligram per square meter (mg/m^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
75539703|NCT04484363|Drug|Azacitidine|Azacitidine 75 mg/m^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.
75539704|NCT04592302|Diagnostic Test|Blood Draw|2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body
76029866|NCT04726514|Device|SleepFlex|SleepFlex Program
76029867|NCT04707885|Device|Electrocochleography|"The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at ~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions."
75539705|NCT04592146|Device|Frailty multicomponent intervention supported by POSITIVE|This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb. Furthermore, through a tablet device, other relevant information (e.g. state of mind, activities of daily living-ADLs, etc.) is collected. The same device is used to enhance communication with the clinical team and follow the tailored intervention
75703700|NCT00794391|Behavioral|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
75703701|NCT00794391|Behavioral|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
75703702|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
76022980|NCT03115489|Drug|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
76022981|NCT02405533|Dietary Supplement|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
76022982|NCT02405533|Other|Placebo|Placebo supplementation x 12 months
75539706|NCT04592146|Other|Frailty multicomponent intervention|This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
75703703|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
76022983|NCT02409043|Other|Blood draw|Blood drawn for comparison with other groups
75703704|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
76029868|NCT04695028|Other|Data collection|"The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means."
76029869|NCT04694534|Diagnostic Test|Serious game|"The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions."
75703705|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
75378450|NCT01306994|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
75378451|NCT01306994|Other|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
75378452|NCT01306994|Other|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
75703706|NCT00801255|Drug|RO5024048|500mg po bid/100mg po q8h for 7 days
75378453|NCT03135535|Device|Avex Footbeat|Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
75703707|NCT00801255|Drug|danoprevir|500mg po bid/100mg po q8h for 14 days
75703708|NCT00801255|Drug|danoprevir|1000mg po bid/100mg po q8h for 14 days\n500mg po bid/200mg po q8h for 14 days
75703709|NCT00801255|Drug|danoprevir|1000mg po bid/200mg po q8h for 14 days
75703710|NCT00801255|Drug|danoprevir|1000mg/600mg po twice daily for 14 days
75703711|NCT00801255|Drug|danoprevir|1000mg/900mg po twice daily for 14 days
75378454|NCT02979301|Drug|Tamoxifen|5 mg or 10 mg tamoxifen per day for 30 days.
75867300|NCT04952766|Biological|Biological samples|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~Nasopharyngeal samples (not mandatory)~Associated data :~Demographic data~Description of clinical manifestations related to vaccination~Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
75867301|NCT02395744|Other|Paclitaxel administration using the OPC|
75867302|NCT02400502|Behavioral|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
75378455|NCT01930136|Behavioral|Calorie restriction (25%)|
75378456|NCT01930136|Behavioral|Ad libitum health diet|
75378457|NCT02979925|Device|Active Transcutaneous Magnetic Stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
75703712|NCT04893590|Behavioral|Fatigue self-management SMS intervention|Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
75703713|NCT02577588|Biological|re-activated T cells|autologous reactivated T cells against p53
75703714|NCT02554305|Device|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
75867303|NCT02400268|Other|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
75867304|NCT02400268|Other|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
75867305|NCT02400424|Radiation|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
75867306|NCT03168568|Drug|Valsartan/Sacubitril or placebo|tablet (double dummy)
75867307|NCT03168568|Drug|Valsartan or placebo|tablet (double dummy)
75867308|NCT05745610|Drug|Shen Hai Long Capsule|3 times/day (9 capsules/day) for 12 weeks
75378458|NCT02979925|Device|Sham Transcutaneous Magnetic Stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
75378459|NCT05171114|Diagnostic Test|Measurement of joint amplitudes|Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb
75378460|NCT04954651|Biological|Approved vaccines against Sars-Cov2|Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
75378461|NCT00375440|Drug|Tranexamic Acid|
75378462|NCT02983825|Device|Continuous positive airway pressure (CPAP); level changes|as per arm description
75378463|NCT01818986|Drug|Sipuleucel-T|
75378464|NCT01818986|Radiation|Stereotactic Ablative Body Radiation|
75378465|NCT03138577|Diagnostic Test|Ultrasound Imaging|"M-mode tracings of right diaphragm motion will be made and recorded by a skilled anesthesiologist. Patients will be examined in the supine position and scanned from a low intercostal or subcostal approach using the liver as an acoustic window. Patients will be asked to perform a voluntary sniff (VS) test, for which they will be asked to forcefully inhale through the nose in a sniffing position. The above measurement will be performed immediately preceding the brachial plexus blockade, and then at 15 minute and 30 minutes after block."
75378466|NCT03138577|Drug|Supraclavicular Block|The patient will be positioned supine with the head turned to the contralateral side. The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine. The anesthesiologist can redirect the needle and perform additional injections for complete coverage of the brachial plexus. The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.
75378467|NCT03138577|Other|Bedside Negative Inspiratory Force Meter|A bedside negative inspiratory force (NIF) meter will be used to measure negative inspiratory force prior to the block and 30 minutes after the block.
75867309|NCT05745610|Drug|Sheng Jing Capsule|3 times/day (12 capsules/day) for 12 weeks
75378468|NCT03181724|Behavioral|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
75867310|NCT02395588|Other|Guideline based care|Patient education using guideline based teaching guides
75867311|NCT02395354|Device|Placing a self-expanding metallic stent|"Income on short stay unit (SSU) post-procedure~Light sedation by the endoscopist vs anesthetist by center~Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~Clips can be placed at the distal end of the prosthesis according to the endoscopist.~Prosthesis removal time in 4 weeks."
75867312|NCT02395354|Device|A balloon dilatation|"Income on short stay unit (SSU) post-procedure~Light sedation by the endoscopist vs anesthetist by center.~Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~It shall be deemed failure to expansion if required> 2 expansions."
75867313|NCT02400112|Drug|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
75867314|NCT02694328|Drug|ALKS 3831|Daily dosing
75867315|NCT02694328|Drug|Olanzapine|Daily dosing
75867316|NCT04480996|Drug|Drugs Responsible for Cognitive Side Effects|identification of road traffic accidents associated with drugs responsible for psychomotor side effects
76029870|NCT04694534|Diagnostic Test|Usual HAS care|The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
76029871|NCT04684836|Other|Exposure to telemedicine, after the onset of the pandemic|Telemedicine exposure will be defined based on the proportion of all visits at a given clinic that are delivered via telemedicine in each month.
75867317|NCT02399878|Drug|Inspiratory oxygen|
76029872|NCT04684121|Drug|Granexin® gel (200 μM)|Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
76029873|NCT04684121|Drug|Vehicle gel|Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
76029874|NCT04672369|Biological|IBI939|IBI939 injection
76029875|NCT04672369|Biological|Sintilimab|Sintilimab injection
75867318|NCT02395276|Device|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
76029876|NCT04672356|Biological|IBI939|IBI939 injection
75867319|NCT02395510|Drug|Vortioxetine|Vortioxetine 5-20mg
75867320|NCT05745532|Biological|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
76029877|NCT04672356|Biological|Sintilimab|Sintilimab injection
76029878|NCT04668170|Biological|Blood collection on admission and longitudinally|Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
75378469|NCT05113004|Drug|Hydroxychloroquine 400mg/d|Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
75378470|NCT05113004|Drug|Leflunomide 20mg/d|Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
75378471|NCT05113004|Drug|Mycophenolate mofetil 2000mg/d|Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
75703715|NCT02554305|Device|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
75867321|NCT05745454|Biological|HER2-E-CART cells|E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein
75867322|NCT02395432|Device|orotracheal intubation|
75867323|NCT02394886|Biological|ALLO-ASC-DFU|
75867324|NCT02400034|Other|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
76029879|NCT04668170|Biological|Blood collection on their first consultation and 10 to 14 days later|Samples already collected on consultation (D0) and 14 days later
76029880|NCT04665869|Behavioral|Combined balance and brisk walking training|6-months of combined balance and brisk walking training
76029881|NCT04665869|Behavioral|Flexibility and strengthening exercise|6-months of flexibility and strengthening exercise
75378472|NCT05113004|Drug|Placebo of Hydroxychloroquine 400mg/d|Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
75867325|NCT02399956|Other|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
75378473|NCT05113004|Drug|Placebo of Leflunomide 20mg/d|Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
75867326|NCT02399800|Procedure|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
75867327|NCT02399800|Procedure|No Celiac Block|EUS but no celiac block performed
75867328|NCT02399800|Drug|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
75867329|NCT02399566|Drug|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
75867330|NCT02399644|Behavioral|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
75378474|NCT05113004|Drug|Placebo of Mycophenolate mofetil 2000mg/d|Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
75378475|NCT04707079|Drug|Duvelisib|Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
75378476|NCT02983981|Drug|Topicort Topical Spray|open label Topicort spray
75867331|NCT02399644|Other|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
75867332|NCT03167164|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
75867333|NCT03167164|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
75867334|NCT03167164|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75867335|NCT03167164|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
75867336|NCT03167164|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75867337|NCT03167164|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
75867338|NCT03167164|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
75378477|NCT03182582|Device|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
75867339|NCT03167164|Drug|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
75378478|NCT03182582|Procedure|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
75378479|NCT00375583|Drug|DEC/Albendazole|
75378480|NCT05081726|Diagnostic Test|Functional MRI|Series of MRI scans of the brain
75378481|NCT04740229|Behavioral|Yoga|Moderate-intensity flow-based yoga movements, breathing, and relaxation for 50 minutes, 3 times per week, for 8 weeks
75378482|NCT02986711|Behavioral|Motivational Text Messages|Motivational text messages in addition to survey questions about smoking status
75378483|NCT02986711|Behavioral|Control|Only survey questions about smoking status
75378484|NCT00374569|Procedure|Gymnastic Routine|A combination of gymnastic movements are performed
75378485|NCT03141931|Dietary Supplement|Supplement|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
75378486|NCT03141931|Dietary Supplement|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
75378487|NCT03143569|Device|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
75378488|NCT03143569|Device|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
75378489|NCT04631497|Diagnostic Test|test|"Beck's Test~Test STAI~Test PSS~the scale of the fascination with death~COPE"
75378490|NCT02222688|Drug|cirmtuzumab|
75378491|NCT03149887|Drug|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
75378492|NCT03149887|Drug|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
75378493|NCT04759404|Other|Deep Oscillation Treatment|Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
75378494|NCT04759404|Other|Myofascial Release Treatment|Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
75867340|NCT03167164|Drug|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
75867341|NCT03167164|Radiation|Stereotactic Body Radiation Therapy|radiation
75378495|NCT02988193|Device|optima4BP Medication Management|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
75378496|NCT02988349|Other|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
75378497|NCT04541329|Biological|Tildrakizumab|IL-23 inhibitor
75378498|NCT03150043|Device|Masimo Rainbow Pulse CO-oximeter|Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
75378499|NCT02159352|Drug|Daclatasvir|
75378500|NCT02159352|Drug|Darunavir|
75539707|NCT04592380|Drug|Stage 1: Clevidipine (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
75867342|NCT03167164|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
75867343|NCT03167164|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
75867344|NCT03167164|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
75867345|NCT03167164|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
75867346|NCT03167164|Biological|haNK|NK-92 [CD16.158V, ER IL-2] (high-affinity activated Natural Killer cells)
75378501|NCT02159352|Drug|Ritonavir|
75378502|NCT02159352|Drug|Lopinavir/Ritonavir|
75378503|NCT04499833|Procedure|liver transplant|liver transplant
76022984|NCT02409043|Other|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
76022985|NCT02699593|Device|Test Contact Lens|
76029882|NCT04664023|Procedure|Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
75378504|NCT03150199|Behavioral|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
75867347|NCT03167086|Behavioral|"Empowered Relief (ER)"|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
75867348|NCT03167086|Behavioral|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) [1& 2], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner [3].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk & Winter [4] for optional reading."
76029883|NCT04664023|Procedure|Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
76029884|NCT04642781|Diagnostic Test|reading of a text|Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
76029885|NCT04635995|Biological|LVGN7409|IV infusion once every 3 weeks (Q3W).
76029886|NCT04633889|Drug|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
76029887|NCT04633889|Drug|Normal saline|Normal saline (240mL) intravenous infusion over 12 hours
76029888|NCT04630886|Drug|Tranexamic acid injection|subcutaneous injection of 50mg/ml TXA
76029889|NCT04630886|Drug|Lidocaine Epinephrine|subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
75378505|NCT03150199|Behavioral|MI-based Health Education Intervention|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
75378506|NCT02187744|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
76022986|NCT02699593|Device|Control Contact Lens|
76022987|NCT02408731|Drug|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
76029890|NCT04626349|Other|FOCUS+ (face-to-face nurse-led intervention)|"Home-based psycho-educational intervention consisting of two 90-minute home visits and one 30-minute video-conferencing session, conducted by a trained intervention nurse over a period of 12 weeks (4 weeks between each session).~The intervention is comprehensively manualized and there is a protocol to guide delivery of the intervention for each home visit and video call. The content of the sessions is always tailored to the needs of the dyads, so certain topics can be discussed more in-depth and specific information can be shared. The nurses who will deliver the FOCUS+ intervention will receive an extensive online training and additional continuous follow-up training to provide them with the knowledge and skills required to successfully implement the intervention. A FOCUS+ core booklet is provided as a supporting guide for the dyads that they can refer to at their own discretion and reinforces key intervention messages linked to the core components of the intervention."
76022988|NCT03169309|Device|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
76022989|NCT03168997|Drug|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
76022990|NCT02405767|Other|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
76022991|NCT02408809|Behavioral|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
75703716|NCT04069988|Behavioral|Baduanjin program|This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
76029891|NCT04626349|Other|iFOCUS (web-based intervention)|"Self-managed psycho-educational intervention that is completed autonomously by the patient-caregiver dyads together. It encompasses four sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and the family caregiver, sitting side by side at a computer. Patient-caregiver dyads have flexibility as to when they want to complete the intervention session. Based on the information patients and caregivers provided at enrollment and during the web-based sessions, they receive tailored individual and dyadic messages. An online personal workbook is provided containing the results of the interactive exercises that are provided to the dyads during the web-sessions. Any information brochures, leaflets and information sheets that the dyad indicated as 'of interest to them' during the web-sessions will be included as a hyperlink in their personal workbook."
76029892|NCT04619316|Drug|Trametinib 2 MG [Mekinist]|Monotherapy with Trametinib is given in patients with BRAF wildtype.
76029893|NCT04619316|Drug|Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]|Combination therapy is given in patients with BRAF V600E mutation.
76029894|NCT04618484|Other|Biomodulation (non-pharmacological)|cryo-, photo- and electro-biomodulation
76029895|NCT04618211|Drug|Deucrictibant|deucrictibant soft capsules for oral use
76029896|NCT04618211|Drug|Placebo|Matching placebo capsules for oral use
75378507|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
75378508|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
75703717|NCT02577666|Behavioral|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
75703718|NCT02577666|Behavioral|Housing Only|receives 3 months of project supported rental assistance
76029897|NCT04610528|Drug|U3 1402|6.4 mg/kg dose
76029898|NCT04610528|Drug|U3 1402|5.6 mg/kg dose
75703719|NCT02577666|Behavioral|Treatment as Usual|receives services as normally offered within the community
75703720|NCT00796731|Drug|SAR3419|administered by intravenous infusion
75703721|NCT04891328|Other|Intensive therapy program|The intensive therapy program consists of physical therapy, occupational therapy, and speech therapy 3-6 hours x 4-5 days/week for 4 weeks. The individual therapies received will vary with the child/caregiver goals and be based on neuroplasticity and motor learning principles.
75703722|NCT00794625|Drug|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
75703723|NCT00794625|Drug|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
75703724|NCT00794625|Drug|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
75703725|NCT00794625|Drug|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
76029899|NCT04609111|Drug|No aspirin|1-month prasugrel monotherapy followed by clopidogrel monotherapy
76029900|NCT04609111|Drug|1-month DAPT|1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
75378509|NCT02187744|Biological|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
75378510|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
75378511|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
75703726|NCT00794625|Behavioral|Behavioral family counseling|Weekly behavioral counseling with a therapist
76029901|NCT04605458|Combination Product|Contingency Management|Participants will receive 3-6 counseling sessions, nicotine patches & lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
75703727|NCT00714350|Behavioral|New ICU Display Visualization|
76029902|NCT04605458|Combination Product|Standard Care|Participants will receive 3-6 counseling sessions, nicotine patches & lozenges, and CO breath test monitoring.
76029903|NCT04599062|Drug|Talimogene Laherparepvec|Talimogene Laherparepvec
76029904|NCT04599062|Radiation|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
76029905|NCT04597359|Drug|Placebo Administration|Given PO
76029906|NCT04597359|Other|Quality-of-Life Assessment|Ancillary studies
75378512|NCT03154333|Drug|diacerein 1% ointment|diacerein 1% ointment administered topically
75378513|NCT03154333|Drug|A placebo ointment|vehicle ointment administered topically
75378514|NCT04473625|Other|Stool Sample Collection|Subjects participating in the study will provide a stool sample within 30 days of enrollment.
75378515|NCT04393441|Drug|011516X (New Artificial Tear Formulation)|Topical eye drops
75378516|NCT04393441|Drug|Systane Ultra Multidose|Topical eye drops
75378517|NCT04393441|Drug|REFRESH PLUS®|Topical eye drops
75703728|NCT02577432|Drug|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
75703729|NCT02577432|Drug|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
75703730|NCT02577432|Drug|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
75703731|NCT02577432|Drug|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
75703732|NCT02577276|Device|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
76029907|NCT04597359|Other|Questionnaire Administration|Ancillary studies
76029908|NCT04597359|Drug|Sinecatechins|Given PO
75378518|NCT03160027|Device|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
75539708|NCT04592380|Drug|Stage 1: Placebo (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
75539709|NCT04592380|Drug|Stage 2: Clevidipine (open-label)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
75539710|NCT04592380|Drug|Stage 2: Standard of Care (open-label)|Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
75539711|NCT00253188|Drug|galantamine hydrobromide|
75703733|NCT00794703|Drug|micafungin (Mycamine)|Intravenous
76029909|NCT04590196|Drug|Longvida curcumin|longvida curcumin verdure sciences formulation
76029910|NCT04590196|Other|placebo|"Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide"
75703734|NCT00794703|Drug|itraconazole|oral
75703735|NCT02575430|Other|No treatment: retrospective chart review|
75703736|NCT00772031|Drug|propranolol LA|Propranolol LA up to 240 mg/day
76029911|NCT04589208|Drug|Ketamine Hydrochloride|We will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still produces a robust phBOLD response
76029912|NCT04582864|Drug|Flotetuzumab|Will be provided by MacroGenics Inc.
76029913|NCT04582864|Procedure|Donor lymphocyte infusion|DLI represents a non-specific form of adoptive cell therapy which involves infusion of a pool of allogeneic immune cells, including CD4+ T cells, CD8+ T cells, regulatory T cells (T Regs), natural killer (NK) cells and professional antigen presenting cells.
76029914|NCT04580524|Procedure|Repair of ventral hernia using biologic mesh|Ventral hernia will be repaired using biologic mesh
75539712|NCT04471220|Device|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
76029915|NCT04580524|Procedure|Repair of ventral hernia using suture repair or synthetic mesh|Ventral hernia will be repaired using the current treatment methods
76029916|NCT04566328|Drug|Bortezomib|Given SC
75539713|NCT04592497|Procedure|AF ablation|Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
75539714|NCT00249522|Behavioral|Contingency management|
75539715|NCT04438265|Drug|levobupivacaine|local anesthetic
75539716|NCT04438265|Device|ultrasound device|scream
76029917|NCT04566328|Biological|Daratumumab and Hyaluronidase-fihj|Given SC
76029918|NCT04566328|Drug|Dexamethasone|Given PO
76029919|NCT04566328|Drug|Lenalidomide|Given PO
76029920|NCT04566328|Other|Quality-of-Life Assessment|Ancillary studies
76029921|NCT04565795|Device|Uriprene® Degradable Temporary Ureteral Stent|Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
75539717|NCT04592068|Device|Retinal multi-diseases diagnosed by DL algorithm|DL algorithm automatically classify multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
75539718|NCT04592068|Other|Retinal multi-diseases diagnosed by expert panel|Expert panel classifies multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
75539719|NCT04595071|Device|Voice Activated Prosthetic Interface (VAPI) Controller|A device installed between a subjects socket quick disconnect wrist connection and multi-articulating hand which enables the use of voice as a control modality in addition to their standard two-site myoelectric control.
75539720|NCT04592107|Diagnostic Test|eGFR|estimated glomerular filtration rate
75703737|NCT00772031|Drug|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
75703738|NCT00772031|Drug|placebo|an inactive substance
76029922|NCT04563013|Device|Transcutaneous vagus nerve stimulation|the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
76029923|NCT04559724|Device|Indego Therapy|Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
76029924|NCT04559139|Drug|Cisplatin|Given IV
76029925|NCT04559139|Drug|Gemcitabine Hydrochloride|Given IV
76029926|NCT04559139|Procedure|Lymphadenectomy|Undergo portal lymphadenectomy
76029927|NCT04559139|Procedure|Partial Hepatectomy|Undergo partial hepatectomy
75703739|NCT02576262|Procedure|TCT，HPV，colposcopic inspection|
75703740|NCT00801411|Drug|cyclophosphamide|Given IV
75703741|NCT00801411|Drug|docetaxel|Given IV
75703742|NCT00801411|Drug|doxorubicin hydrochloride|Given IV
76029928|NCT04551222|Drug|probenecid|1 gr. orally of probenecid twice daily for 180 days
76029929|NCT04551222|Drug|Placebo|identical tablets to probenecid
76029930|NCT04541056|Behavioral|Goal Management Training (GMT)|The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.
75703743|NCT02579148|Biological|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.'
75867349|NCT03167086|Behavioral|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
76029931|NCT04541056|Behavioral|Brain Health Workshop (BHW)|BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.
76029932|NCT04537208|Biological|CoV2 preS dTM-AF03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
76029933|NCT04537208|Biological|CoV2 preS dTM-AF03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
76029934|NCT04537208|Biological|CoV2 preS dTM-AS03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
76029935|NCT04537208|Biological|CoV2 preS dTM-AS03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
76029936|NCT04537208|Biological|CoV2 preS dTM (high-dose) without adjuvant|Pharmaceutical form: liquid; route of administration: intramuscular injection
75703744|NCT02579148|Biological|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
75703745|NCT04577066|Other|GA2|15 volunteers will receive 50 GA2-infected mosquito bites. The GA2 parasite is a new genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and should not be able to cause malaria in humans.
76029937|NCT04537208|Biological|Placebo (0.9% normal saline)|Pharmaceutical form: liquid; route of administration: intramuscular injection
76029938|NCT04527549|Drug|Dabrafenib Mesylate|Given PO
76029939|NCT04527549|Drug|Hydroxychloroquine Sulfate|Given PO
76029940|NCT04527549|Drug|Placebo Administration|Given PO
76029941|NCT04527549|Drug|Trametinib Dimethyl Sulfoxide|Given PO
76029942|NCT04522414|Other|cries longitudinally registered|Their cries will be longitudinally registered from the age of birth to the return home using an automatic record device: Song Meter SM4.
75703746|NCT04577066|Other|GA1|10 volunteers will receive 50 GA1-infected mosquito bites. The GA1 parasite is a genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and is not able to cause malaria in humans.
75539721|NCT00249561|Behavioral|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
75539722|NCT00249561|Behavioral|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg & Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
75539723|NCT04591756|Other|Qualitative Fit Testing|Qualitative fit testing with denatonium benzoate
75539724|NCT04591795|Drug|Sahastara remedy extract|The concentration of SHT extract is 100 mg per capsule
75539725|NCT04591795|Drug|Diclofenac|Diclofenac sodium, 25 mg enteric-coated tablets
75539726|NCT04591639|Drug|Dapagliflozin 10 milligrams [Farxiga]|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
75703747|NCT04577066|Other|Placebo|5 volunteers will receive 50 uninfected mosquito bites.
75703748|NCT00794859|Drug|Sorafenib|400mg twice daily
75703749|NCT00714506|Behavioral|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
75703750|NCT00714506|Other|Physical activity control|physical activity plus successful aging health education
75703751|NCT00580866|Device|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
75867350|NCT02399488|Device|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
75867351|NCT03334747|Drug|KAE609|Exploration of different doses of KAE609 to establish safety profile.
75539727|NCT04591639|Drug|Placebo|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
75703752|NCT00801567|Device|Magnetic resonance spectroscopy (MRS)|90-minute magnetic resonance scan.
75703753|NCT00771953|Drug|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
75703754|NCT00771953|Drug|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
75703755|NCT00771953|Drug|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
75867352|NCT03334747|Drug|Coartem|Control Arm
75867353|NCT02399722|Device|WICVAC|combined wound therapy
76029943|NCT04514783|Device|Debridement with Debritom+ micro water jet device|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~Removal of old dressing~Woundworks® 3D imaging~Applying analgesic if necessary~Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~Debridement using Debritom+ micro water jet technology~Wound cleansing with NaCl 0.9% solution~Woundworks® 3D imaging~Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~Removal of old dressing~Woundworks® 3D imaging~Wound cleansing with NaCl 0.9% solution~Application of new dressing (according to the wound healing phases, medical prescription)"
76029944|NCT04514783|Other|Debridement with|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~Removal of old dressing~Woundworks® 3D imaging~Applying analgesic if necessary~Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~Debridement using scalpel and curette~Wound cleansing with NaCl 0.9% solution~Woundworks® 3D imaging~Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~Removal of old dressing~Woundworks® 3D imaging~Wound cleansing with NaCl 0.9% solution~Application of new dressing (according to the wound healing phases, medical prescription)"
76029945|NCT04512950|Drug|Ringer's lactate|Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
75378519|NCT02994979|Other|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
75867354|NCT02399722|Device|VAC mono therapy|mono therapy
75867355|NCT02394652|Drug|Metformin|Metformin is an antidiabetic agent given orally.
76029946|NCT04512950|Drug|0.9% saline|Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
75378520|NCT02994979|Other|Sham comparator|Usual care plus sham visits by CNA
75867356|NCT02394652|Drug|Cisplatin|Cisplatin is an antineoplastic agent given intravenously.
75378521|NCT02995915|Other|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
75539728|NCT04719585|Drug|Duloxetine vs. Opioid|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
75539729|NCT04592029|Drug|TACE combined with sintilimab and bevacizumab|Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg/kg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.
75539730|NCT00253227|Drug|galantamine hydrobromide|
75539731|NCT04591678|Drug|nusinersen|SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
75703756|NCT02576028|Other|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
75703757|NCT02576028|Other|standard active exercises|two sessions of 45 minutes of active exercises
75703758|NCT00714584|Drug|Naltrexone HCl.|
75539732|NCT04591444|Drug|Fluoride Varnish|Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.
75703759|NCT02554227|Other|Cytokine Profile and suPAR|Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
75867357|NCT02394652|Drug|FAZA|FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
75378522|NCT02995915|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
75378523|NCT02995915|Behavioral|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
75703760|NCT03988127|Diagnostic Test|Perfusion index|The perfusion index (PI) is the ratio of the pulsatile to the non-pulsatile blood flow in peripheral tissue. It represents a non-invasive measure of peripheral perfusion that can be continuously obtained from a pulse oximeter. We observe changes in PI before and after painful stimulation in intubated critically ill patients.
75378524|NCT02995915|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
75703761|NCT00714662|Device|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
75703762|NCT02553837|Biological|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
75703763|NCT00621244|Drug|LBH589|
76029947|NCT04512430|Drug|Atezolizumab|"Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.~First Infusion~No premedication administered for atezolizumab specifically is permitted~Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.~Subsequent Infusions:~If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles > 2 at the discretion of the treating physician.~If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes."
75703764|NCT02553759|Other|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
75703765|NCT04021901|Device|balloon dilatation|"The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)"
75867358|NCT02394496|Drug|Fulvestrant|Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
75867359|NCT02394496|Drug|Lapatinib|1500mg (TBD) O.S. qd
75867360|NCT02394496|Drug|Aromatase Inhibitors|as indicated in the Summary Product Characteristic
75867361|NCT02394496|Drug|Placebo Lapatinib|1500mg (TBD) O.S. qd
75867362|NCT03346759|Device|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
76029948|NCT04512430|Drug|Bevacizumab|Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
75703766|NCT00801645|Behavioral|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
75703767|NCT00916409|Device|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
75867363|NCT03346759|Device|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
75867364|NCT03710473|Diagnostic Test|Optical sensor, Pulse watch|Continuous blood pressure monitoring obtained by a Pulse watch
75867365|NCT03362671|Device|Implant Supported Mandibular Advancement Oral Appliance|This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
75867366|NCT03362671|Device|Orthodontic Mini Implant|Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
75867367|NCT02394418|Drug|Sevoflurane|Treatment of delirium by inhaled sevoflurane
75867368|NCT02394418|Drug|Propofol|Treatment of delirium by propofol i.v. infusion
75867369|NCT02394418|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
75378525|NCT02995915|Behavioral|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
75378526|NCT04376515|Behavioral|HOPE intervention|Online peer support community of peers trained in behavior change science
75378527|NCT02997085|Device|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
75378528|NCT02997085|Device|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
75378529|NCT03163303|Behavioral|Tobacco Status Project Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use
75378530|NCT03163303|Behavioral|Tobacco Status Project + Alcohol Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
75378531|NCT03163303|Drug|nicotine patch|14-day supply of nicotine patch
75378532|NCT04349995|Device|Amplatzer PFO Occluder|Percutaneous PFO closure using Amplatzer PFO Occluder
75539733|NCT04591444|Drug|Glass Ionomer Sealant|Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
76029949|NCT04512430|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Guidelines of Carboplatin administration: According to the standard of each center"
76029950|NCT04512430|Drug|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo[2,3 d]pyrimidine-based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
75539734|NCT04591444|Other|Placebo Group|4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.
75378533|NCT03165175|Behavioral|prescription drug-abuse education smartphone application|As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
75539735|NCT04404335|Diagnostic Test|Crevicular fluid analysis by using ELISA testing.|Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)
75539736|NCT04591522|Other|Healthy fecal bacteria liquid|Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
75539737|NCT00249600|Behavioral|Contingency management|
75539738|NCT03453970|Behavioral|Therapeutic Education Program|The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
76022992|NCT02408809|Behavioral|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
76022993|NCT02408575|Device|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
76022994|NCT02408575|Device|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering"
76022995|NCT03171727|Drug|low molecular weight heparin|After TIPS procedure was performed, low molecular weight heparin was given for three days.
75378534|NCT03000283|Drug|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
75867370|NCT03361423|Device|Nerivio Migra-1 active device|"The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site."
76029951|NCT04502433|Drug|CUROSURF® (poractant alfa)|"Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW."
76029952|NCT04499339|Drug|SLAMF7 CAR-T|Single infusion of autologous SLAMF7 CAR-T cells
76029953|NCT04495348|Drug|Doravirine|Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
76029954|NCT04485468|Other|Questionnaire|The patient answers the questionnaire directly following his consultation or teleconsultation or may arrange a telephone appointment with the clinical research associate a little later.
75378535|NCT03855163|Behavioral|Inspection visits|Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements
75378536|NCT03855163|Behavioral|Guidance workshops|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
75378537|NCT03855163|Behavioral|Online risk assessment tool|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
75378538|NCT03164629|Device|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
75378539|NCT03168295|Drug|Dapagliflozin 10mg then Placebo Oral Tablet|SGLT2 inhibitor - Dapagliflozin then Placebo
76029955|NCT04484818|Drug|Darolutamide|Given PO
76029956|NCT04484818|Drug|Goserelin Acetate|Given via injection
76029957|NCT04484818|Drug|Leuprolide Acetate|Given IV
76029958|NCT04484818|Drug|Placebo Administration|Given PO
76029959|NCT04484818|Other|Quality-of-Life Assessment|Ancillary studies
76029960|NCT04484818|Drug|Triptorelin|Given via injection
76029961|NCT04484012|Drug|Acalabrutinib|Given PO
76029962|NCT04484012|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
76029963|NCT04478370|Biological|Mosquito bites|"Participants will be exposed to mosquito bites.~For the low-dose challenge, five 5 to 7-day-old nulliparous female imagoes (i.e. that have never blood fed before) will be introduced individual into 50 mL plastic tube covered with netting material.~For high-dose challenge, 47 mosquitoes will be split into four plastic cups of 10 cm in diameter covered with netting material (three cups with 12 mosquitoes and one cup with 11 mosquitoes), and 3 mosquitoes will be introduced individually into 50 mL plastic tubes.~Mosquito bites administered on participant's arm will be used to assess immediate and delayed skin reactions. Immediate and delayed skin reactions will be recorded respectively 20-30 min and 24-36 hours after the day 14 and day 21 challenges, requiring additional visits at day 15 and 22."
75867371|NCT03361423|Device|Nerivio Migra-1 Sham device|The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
75867372|NCT02693002|Drug|Estradiol/Norethindrone acetate|Estradiol/Norethindrone acetate 1mg/0.5 mg
76029964|NCT04478227|Drug|Romiplostim|Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
76029965|NCT04477200|Drug|Mycophenolate Mofetil|500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
76029966|NCT04477200|Radiation|Radiation Therapy|40.5 Gy in 15 fractions
76029967|NCT04477200|Procedure|Re-resection (as part of standard of care)|Re-resection or biopsy of tumor as part of standard of care
76029968|NCT04477200|Drug|Temozolomide|Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
76029969|NCT04477200|Drug|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT.
75867373|NCT02693002|Drug|Placebo|inactive ingredient
75867374|NCT04480606|Behavioral|Home exercise program|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group. A video exercise protocol was created and each exercise session was planned as daily 30 minutes for 6 weeks. Individuals will ask to do their exercises. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic, balance and strengthening exercises. The exercise program consists of 3 levels and individuals will be provided to start at a level appropriate to their level of physical activity.
76029970|NCT04477200|Drug|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
76029971|NCT04477200|Radiation|Radiation Therapy|60 Gy in 30 fractions
76029972|NCT04455802|Drug|Buprenorphine or Placebo|The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
75378540|NCT03168295|Drug|Placebo Oral Tablet then Dapagliflozin 10mg|Placebo then SGLT2 inhibitor - Dapagliflozin
75378541|NCT03168841|Drug|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
75378542|NCT03822949|Device|Day Light|Patients are exposed to daylight for up to 10 days prior to surgery
75867375|NCT05408923|Drug|saline 0.9%|Control group will get normal saline for irrigation throughout the case.
75867376|NCT05408923|Drug|(0.05% chlorhexidine gluconate (CHG) in sterile water)|Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
75867377|NCT05744986|Device|SYMPICITY Spyral RENAL DENERVATION (RDN) SYSTEMTM|The second generation SYMPLICITY RDN catheterTM has 4 times electrodes that are arranged in spirally in 90-degree intervals. Theoretically, the newer generation catheter can provide more efficient and extensive denervation in a shorter period of time16. Its efficacy was confirmed in SYMPLICITY HTN ON-MED and OFF-MED trial, which confirmed a consistent and durable BP reduction that lasted into 36 months with or without adjuvant anti-hypertensive drugs
76029973|NCT04455802|Drug|Morphine or Placebo|If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
76029974|NCT04446052|Drug|GM-CSF priming|
76029975|NCT04446052|Drug|Placebo|Placebo
76029976|NCT04443088|Drug|INV-1120|INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.
76029977|NCT04443088|Combination Product|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.
76029978|NCT04428658|Behavioral|Supplemental video visits|Receiving home-based video visits with a pediatric endocrinologist monthly as a supplement to regular diabetes clinic visits.
76029979|NCT04428658|Behavioral|Standard of Care|Usual quarterly visits with the UCD Pediatric Diabetes Clinic.
76029980|NCT04428658|Behavioral|Supplemental remote monitoring|Receiving remote glucose monitoring with monthly outreach from a pediatric endocrinologist as a supplement to regular diabetes clinic visits.
76029981|NCT04426890|Biological|CT-P39|Prefilled syringe (PFS) of 1 mL solution
76029982|NCT04426890|Biological|EU-approved Xolair|Prefilled syringe (PFS) of 1 mL solution
76029983|NCT04422132|Radiation|5 days Radiation Therapy (32.5 Gy in 5 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
76029984|NCT04422132|Radiation|20 days Radiation therapy (55 Gy in 20 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
76029985|NCT04411914|Drug|Clavulanic Acid|Drug will be given in 250mg capsules.
76029986|NCT04411914|Other|Placebo|Placebo
76029987|NCT04411836|Drug|Tafenoquine|patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
76029988|NCT04411836|Drug|Primaquine|patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
76029989|NCT04392635|Device|Trocar Placement Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle and trocar during laparoscopic surgery.
75867378|NCT03707509|Drug|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance.
76029990|NCT04389671|Drug|Lucinactant|Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
75378543|NCT03822949|Device|Placebo light|Patients are exposed to placebo light for up to 10 days prior to surgery
75867379|NCT03707509|Drug|Placebos|Maximum 6 cycles for combined therapy.
75867380|NCT03707509|Drug|Gemcitabine|Maximum 6 cycles for combined therapy.
75867381|NCT03707509|Drug|Cisplatin|Maximum 6 cycles for combined therapy.
75867382|NCT03710395|Procedure|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
75867383|NCT03710395|Drug|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
75867384|NCT02399098|Behavioral|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
75867385|NCT04889950|Device|Tixel C|Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
75867386|NCT04889950|Device|LipiFlow|LipiFlow
75867387|NCT02394262|Radiation|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
75539739|NCT04591327|Procedure|The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections|Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
75539740|NCT04591132|Device|kinematic analysis|motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
75539741|NCT00253266|Drug|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
75539742|NCT00253266|Drug|Quetiapine|Quetiapine up to 200 mg/d for four weeks
75539743|NCT04591288|Other|Functional Electrical Stimulation protocol|FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
75703768|NCT00916409|Drug|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
75867388|NCT02394262|Other|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
75378544|NCT03822949|Device|ICU Intense Light|ICU Patients are exposed to daylight for up to 10 days after surgery
75867389|NCT03093870|Drug|Varlitinib|Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
75867390|NCT03093870|Drug|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
75378545|NCT03822949|Device|ICU Placebo light|ICU Patients are exposed to placebo light for up to 10 days after surgery
75378546|NCT04068493|Behavioral|Enhanced Project Health|A dissonance-based obesity intervention consisting of eight weekly groups sessions (1.5 hours).
75378547|NCT03815227|Other|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
75378548|NCT04058587|Drug|Simmitinib|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
75539744|NCT04591288|Other|Treadmill only protocol|We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
75539745|NCT00253305|Drug|Organogel of naftifine, 2%|
75539746|NCT00253305|Drug|Organogel of terbinafine, 2%|
75539747|NCT00253305|Drug|Organogel of naftifine, 6%|
75539748|NCT00253305|Drug|Organogel of terbinafine, 6%|
75703769|NCT00714740|Drug|acetazolamide|acetazolamide 2 times 250mg per day
75867391|NCT03093870|Drug|Placebo (for Varlitinib)|oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
75867392|NCT02394184|Procedure|transcatheter aortic valve replacement|
75867393|NCT05744908|Other|Pentosan Polysulphate|300mg 3 times a day
75703770|NCT00659529|Drug|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
75703771|NCT02575508|Drug|Fluorouracil|Given IV
75703772|NCT02575508|Drug|Irinotecan Hydrochloride|Given IV
76029991|NCT04389281|Combination Product|X-PACT|X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
76029992|NCT04388748|Behavioral|Stress Management and Resiliency Training for Depression (SMART-D) Therapy|6 SMART-D group therapy sessions over 8 weeks
75378549|NCT00375271|Procedure|perioperative hemodynamic optimization protocol|
75703773|NCT02575508|Other|Laboratory Biomarker Analysis|Correlative studies
75703774|NCT02575508|Drug|Oxaliplatin|Given IV
75703775|NCT02575508|Drug|pan FGFR Kinase Inhibitor BGJ398|Given IV
76029993|NCT04383457|Device|RIA-device (Remote Investigation and Assessment)|The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face.
75703776|NCT02575508|Other|Pharmacological Study|Correlative studies
75703777|NCT00795015|Drug|insulin regular IV infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
75703778|NCT00795015|Drug|IV insulin infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
75867394|NCT02394106|Drug|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
75867395|NCT02394106|Other|Placebo|Normal saline, 1000 ml, administered once
75867396|NCT01568346|Other|MRI|Breast MRI
75867397|NCT02393872|Behavioral|Feel4Diabetes-intervention|Community-based intervention.
75539749|NCT04591600|Drug|Ivermectin and Doxycyline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
75539750|NCT04591600|Drug|Standard of care|"Standard care~Acetaminophen 500mg on need~Vitamin C 1000mg twice/ day~Zinc 75-125 mg/day~Vitamin D3 5000IU/day~Azithromycin 250mg/day for 5 days~Oxygen therapy/ C-Pap if needed~dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~Mechanical ventilation, if needed"
75867398|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation ON|
75378550|NCT00375349|Procedure|Ultrasound to demonstrate existence of fatty liver|
75539751|NCT04590742|Drug|melatonin 6mg|6 weeks of melatonin (6mg) given to patient
75539752|NCT04590742|Drug|Placebo|Patient given 6 weeks of placebo tablet
75539753|NCT00253344|Drug|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
75539754|NCT00253344|Drug|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
75539755|NCT04590859|Procedure|Block performed|Comparing block performed with penile blood flow
75867399|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation OFF|
75867400|NCT02399176|Behavioral|Yoga|Subjects assume 10 physical postures for 30 seconds each
76029994|NCT04381494|Device|Multiparametric Mobile Technology|Using a spirometer, an armband, and a tablet to collect data.
76029995|NCT04364048|Drug|Induction Durvalumab|Induction durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 1 cycle,
75867401|NCT02399332|Other|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
76029996|NCT04364048|Drug|Chemotherapy|Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug
76022996|NCT02401165|Other|Blood test|blood test
76022997|NCT02401087|Procedure|Anaesthesiological procedure|
76022998|NCT02400931|Procedure|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
76022999|NCT02400931|Procedure|no mask ventilation|
75703779|NCT04045899|Device|Proseal LMA|The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.
75703780|NCT04045899|Device|Air-Q LMA|Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.
75867402|NCT05744830|Other|Overdenture|15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.
76029997|NCT04364048|Radiation|Radiation|Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons per institutional standards. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa). Therapy will be 1.8-2 Gy per day; 5 days per week, excluding holidays per institutional standard as this is a standard of care regimen for this patient population. 54-66 Gy will be delivered.
76029998|NCT04364048|Drug|Consolidation durvalumab|Durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 12 cycles
76029999|NCT04355819|Behavioral|Disclosure timing|When patients are told that a hernia was present on the CT scan
75867403|NCT05744830|Other|Complete Denture|15 patients will only receive removable complete dentures
76030000|NCT04350359|Device|Variable-dose TTNS Protocol 5 x week|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
75539756|NCT04590859|Device|LMA placement|Placement of LMA for airway securement
75867404|NCT04793646|Drug|N-acetylcysteine syrup|N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months
75867405|NCT04793646|Drug|Placebo syrup|Placebo syrup 15 mL twice a day for 3 months
75867406|NCT03106714|Diagnostic Test|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
75867407|NCT05232292|Biological|Ultrix Quadri|vaccination by Ultrix Quadri against flu
75867408|NCT02393638|Other|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
75867409|NCT02393638|Other|Lecture|Lecture
75867410|NCT03166852|Other|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
75867411|NCT02399020|Behavioral|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
75867412|NCT03596736|Procedure|Elbow Hemiarthroplasty|
75867413|NCT03596736|Procedure|Total Elbow Arthroplasty|
75867414|NCT05744752|Other|Lead Acetate|The oral LD50 of lead acetate is 390mg/kg body weight. The experimental group B, C, and D will receive a single dose of 19.5 mg/kg b.w (1/120th of LD50),31 daily dissolved in distilled water and given by oral gavage method for 12 weeks. Lead acetate Pb(CH3COO)2x3H2O, will be purchased from Sigma-Aldrich Chemie (Germany).
75867415|NCT05744752|Dietary Supplement|Moringa oleifera Extract|The method described by Hanaa Elgamily(32) with minor modifications. Fresh Leaves will be washed and dried in dry heat oven. All the preparation will be done in pharmacological department, University of Health Sciences in sterile environment. Dried leaves will be crushed to make fine powder. 1000 g powder of MO will be socked in 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Then mixture will be magnetically stirred for 24 hours and stored at 4oC for 48 hours to allow extraction of active ingredients. Then the mixture will be filtered twicely by using Whatman No 1 filter paper. The extract will be concentrated by rotary vacuum evaporator at 40 oC to evaporate the solvent. The extract will be freeze, dried and stored at -70 oC for use. Dose of MO extract will be 400 mg per kg.(33) body weight given daily in 1ml of distilled water by oral gavage method for 12 weeks.
75539757|NCT00567346|Drug|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
75539758|NCT00567346|Drug|grass pollen extract|Patients will receive matching placebo sublingually
75539759|NCT00567385|Drug|somatropin|
75539760|NCT00253383|Other|counseling intervention|
75539761|NCT00253383|Other|educational intervention|
75539762|NCT00253383|Procedure|psychosocial assessment and care|
75539763|NCT00253383|Procedure|quality-of-life assessment|
76023000|NCT02400931|Drug|Rocuronium|
76023001|NCT02408653|Device|EEG|
75378551|NCT03865615|Drug|Oxytocin|intranasal oxytocin 40IU/mL
75378552|NCT03865615|Drug|Placebo|Placebo
75539764|NCT00567424|Drug|GW273225|
75539765|NCT00567463|Device|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
75539766|NCT00253422|Drug|anastrozole|
75539767|NCT00253422|Drug|exemestane|
75539768|NCT00253422|Drug|fulvestrant|
75539769|NCT04590625|Drug|Apatinib Mesylate|apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
76023409|NCT02395939|Procedure|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
75378553|NCT03180385|Device|Neurally-Adusted Ventilatory Assist (NAVA)|Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
75378554|NCT03180385|Device|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
75378555|NCT03859297|Behavioral|Rumination-Focused CBT|"RF-CBT targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effectively coping with rumination. RF-CBT specifically targets rumination through psychoeducation, adopting a functional analytic approach to the learned habitual behavior of rumination, and a focus on shifting process style. The adolescent is taught to notice triggers to ruminate as well as the consequences of rumination and to shift into practicing a more adaptive strategy such as an attention training exercise, behavioral activation, thinking in a concrete way, or active problem-solving. RF-CBT directly teaches adolescents to recognize rumination or when the participant gets stuck in their head and to notice the influence this has on their mood."
75378556|NCT03859297|Behavioral|Relaxation-based Therapy|Sessions will include progressive muscle relaxation, simple breathing techniques, and guided imagery that focus on bodily and somatic relaxation. Adolescents randomized to Relaxation Therapy (RelaxT) will also receive exercises to do as homework in between sessions, parallel to the RF-CBT group.
75378557|NCT03735823|Other|No intervention, just collect blood samples and CSF samples|No intervention
75378558|NCT03185546|Other|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.
75378559|NCT03185546|Other|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
76023410|NCT02395783|Drug|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
75378560|NCT03185546|Other|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 13 weeks
75378561|NCT03185546|Other|Low nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
75867416|NCT05744752|Dietary Supplement|Allium sativum Extract|Fresh Allium sativum bulbs will be selected for study. The cloves will be peeled, washed with distilled water and dried under shed. Then it will be chopped into small pieces. 1000g of chopped garlic will be crushed by mortar and passel. The garlic paste will be mixed with 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Rest the procedure is same as mentioned in moringa extract. Dose of 500 mg per kg(34) body weight garlic extract will be given daily in 1ml of distilled water.
75867417|NCT05744752|Other|Placebo|1ml NaCl 0.9% daily for 12 weeks
75867418|NCT02393404|Other|PT-FMT|Physiotherapeutic functional movement-power training
75867419|NCT02393404|Other|FMT alone|Physiotherapeutic power training
75378562|NCT03185546|Other|Tobacco Flavors|Participants can choose e-liquid flavors from a selection of tobacco flavors
75378563|NCT03185546|Other|Tobacco and non-tobacco e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
75539770|NCT04590625|Drug|Abraxane|abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
75703781|NCT04045899|Device|Ambu AuraGain LMA|The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
75703782|NCT02575586|Device|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times."
75867420|NCT02393482|Drug|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
75867421|NCT02393482|Drug|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
75867422|NCT02393482|Drug|Add back therapy 1 (tibolone)|tibolone 5 mg/die
76030001|NCT04350359|Device|Fixed-dose TTNS Protocol|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.
76030002|NCT04350359|Device|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
76030003|NCT04328727|Drug|eltrombopag|Tablet 25mg and 12.5mg
76030004|NCT04328727|Drug|rabbit anti-thymocyte globulin (r-ATG)|r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
75378564|NCT05365009|Diagnostic Test|Multidisciplinary aproach|regular tests
75378565|NCT05058482|Device|embolism|Cerebral arteriovenous malformation embolism
75703783|NCT02575586|Device|Control-Dry Needling|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times."
75867423|NCT02393482|Drug|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
75867424|NCT03166774|Other|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
75867425|NCT02393560|Procedure|DECT scan|
75867426|NCT03346057|Drug|Sugammadex 2 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex 2 mg/kg for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
75867427|NCT03346057|Drug|Sugammadex 4 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 4 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
75867428|NCT03346057|Drug|Sugammadex 16 mg/kg|Following administration of NMBA (Rocuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 16 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
76030005|NCT04328727|Drug|cyclosporine A (CsA)|CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use
75539771|NCT04590625|Drug|Cis Platinum|cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
75539772|NCT04590625|Drug|Carboplatin|carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
75539773|NCT04590469|Other|COVID WHELD|COVID WHELD is a COVID-19 adapted version of an established nursing home training intervention that confers benefits in well-being and neuropsychiatric symptoms for people with dementia. The adaptations include the development of digital resources to support the programme and virtual coaching.
75539774|NCT00253461|Procedure|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
75539775|NCT00253461|Procedure|positron emission tomography|"Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.~Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan."
75539776|NCT00253461|Radiation|11C topotecan|Phase I and II: IV over 10 minutes
75539777|NCT00253461|Radiation|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
76030006|NCT04315064|Drug|Treatment with MTX110|"Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions."
76030007|NCT04311580|Combination Product|intravesical electromotive administration of mitomycin|
76030008|NCT04303182|Procedure|Standard 3 port TEP|3 port TEP inguinal hernia repair with 10mm. port under the umbilicus and two 5mm. port in line under the 10mm. port
76030009|NCT04303182|Procedure|LESS TEP|TEP inguinal hernia repair with one vertical skin incision under the umbilicus
76030010|NCT04301492|Drug|Vortioxetine|16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
75539778|NCT04590352|Procedure|nasopharyngeal and throat swab|diagnostic specimens via nasopharyngeal swab and throat swab were collected following the current standard operating procedures.
76023411|NCT02395783|Drug|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
76023412|NCT02395783|Other|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
76030011|NCT04300816|Behavioral|CBT for Uncertainty Tolerance|"Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis."
75703784|NCT00714818|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
75703785|NCT00714818|Behavioral|Genetic Counseling|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
75703786|NCT00843700|Behavioral|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
76030012|NCT04300816|Behavioral|Traditional CBT|Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
75539779|NCT04590352|Procedure|collection of mucosal lining fluid|MLF will be collected via nasal absorption at the inclusion visit by study staff and four more time points by the parents or by the children themselves. Nasal absorption is performed by maneuvering a strip of synthetic absorptive matrices (SAM) into the lumen of the nostril, avoiding rubbing against the nasal mucosa. The outside of the nose is then pressed with a finger to cause apposition of the SAM against the mucosa.
75539780|NCT04590352|Procedure|blood collection via fingerprick|Participants will be asked to wash their hands with soap and warm water. The procedure involves cleaning the ball of the fingertip with an alcohol swab, then using a sterile disposable lancet to pierce the skin (BD Microtainer Lancet or similar). The lancet is placed in a spring-loaded device, which propels the lancet a fixed distance (a few mm) into the skin when the trigger is pressed. Approximately 10-20 drops of blood (0.3 ml) will then be collected with a sterile capillary tube. The participant is given a cotton wool pad to mop up any extra blood, and an elastoplast-type bandage is placed over the finger if necessary. Fingerprick blood samples will only be collected from participants older than 6 months at 28-32 days after the first home visit (d0). Lancet length will be adjusted for age (2.0 mm for participants 8 years and older, 1.5 mm for participants older than 6 months and younger than 8 years).
76030013|NCT04297787|Device|Thrombolysis in combination with endhole aspiration|The treatment protocol the study team will be following is as follows. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
76030014|NCT04295473|Procedure|Reduced port laparoscopic gastrectomy|The ports were reduced in the surgery of intervention arm.
75703787|NCT00843700|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
75703788|NCT00796887|Drug|Extended-Release Niacin|500mg tablet once daily
75703789|NCT00796887|Drug|Extended-Release Niacin|1000mg tablet once daily
75703790|NCT00796887|Drug|Placebo|Placebo tablet once daily
75378566|NCT03657511|Behavioral|Educational Interventions to Promote Tobacco Cessation|"Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks."
75378567|NCT04613882|Device|Soft Toric Custom Made Contact lens|Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.
75378568|NCT04613882|Device|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.
75378569|NCT04613882|Device|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
75378570|NCT03713203|Device|pagetex PDT|2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
75378571|NCT02186652|Drug|Pantoprazole|
75378572|NCT03677791|Other|Virtual tour in coronary computed tomography - 360° counselling environment|Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients
75378573|NCT03677791|Other|Current practice|counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
76030015|NCT04290039|Drug|Atropine Sulfate Ophthalmic Solution|Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.
75378574|NCT03187418|Device|MicroPulse® P3 Glaucoma Device (MP3)|"Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time-0.5ms; micropulse off time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s)."
75378575|NCT03646981|Device|Leishmania Ab Rapid Test (CTK, Biotech)|Rapid diagnostic tests to detect antibodies anti-Leishmania
75378576|NCT03606889|Diagnostic Test|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
75378577|NCT03606889|Diagnostic Test|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
75378578|NCT03606889|Drug|Bupivacaine|0.2 ml/kg bupivicaine
76030016|NCT04290039|Drug|Atropine Sulphate Injection|Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
75867429|NCT03346057|Drug|Neostigmine + Glycopyrrolate|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 μg/kg; 5 mg maximum) and Glycopyrrolate (10 μg/kg; 1 mg maximum) for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
75867430|NCT03346057|Drug|Rocuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
75703791|NCT00578942|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
75703792|NCT00835822|Drug|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
75867431|NCT03346057|Drug|Vecuronium|To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
76030017|NCT04282850|Procedure|Pulmonary Vein Isolation|The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.
75378579|NCT03283969|Other|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
75867432|NCT02393326|Procedure|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
76030018|NCT04278339|Other|Evoked Related Potentials|Evoked Related Potentials are measured by means of electroencephalography. During this measure, 2 informatic task will be performed to evaluated evoked related potentials.
76030019|NCT04267211|Other|Illustrated handout at prenatal consult|Illustrated consult group will be given an illustration paper describing the majority of the issues discussed at the prenatal consult
76030020|NCT04267211|Other|Standard Prenatal Consult|Standard prenatal consult
75378580|NCT03283969|Other|Isocaloric powder|Isocaloric powder
75378581|NCT05363917|Drug|Natrunix with MTX placebo (+folate)|True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
75378582|NCT05363917|Drug|Natrunix placebo with MTX (+folate)|Natrunix placebo with MTX (+folate)
75867433|NCT02393326|Procedure|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
75867434|NCT03523962|Drug|DuraPrep|The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ [3M Health Care, St Paul, MN], will be the commercial product used.
76030021|NCT04266249|Drug|Docetaxel|Given IV
76030022|NCT04266249|Procedure|Lumpectomy|Undergo lumpectomy
76030023|NCT04266249|Procedure|Mastectomy|Undergo mastectomy
76030024|NCT04266249|Drug|Nab-paclitaxel|Given IV
76030025|NCT04266249|Drug|Paclitaxel|Given IV
76030026|NCT04266249|Biological|Pertuzumab|Given IV
75378583|NCT03187730|Behavioral|Integrated Smoking Cessation and Financial Counseling|Participants in the intervention group will receive up to nine counseling sessions that integrate two evidence-based counseling approaches: financial management counseling and smoking cessation counseling. Participants will also be eligible to receive a free four-week supply of NRT. Participants will be surveyed at baseline, 2- months, 6-months and 12-months to assess outcomes and treatment satisfaction.
75703793|NCT00835822|Drug|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
75703794|NCT02553213|Other|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
75703795|NCT02553213|Other|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
75867435|NCT03523962|Drug|ChloraPrep|The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® [CareFusion Inc., Leawood, KS, USA] will be the product used.
75867436|NCT02398708|Other|Questionnaires|Both groups will have questionnaires collected and compared.
75703796|NCT02553213|Other|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
75703797|NCT02553213|Other|easy digestible diet|
75703798|NCT02575274|Procedure|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
75867437|NCT02398708|Other|Blood Sample|Both groups will have a blood sample collected and compared.
75867438|NCT02398708|Other|Stool Sample|Both groups will have a stool sample collected and compared.
75867439|NCT02398708|Other|Clinical data|Both groups will have clinical data collected and compared.
75867440|NCT02398864|Procedure|EBUS with TBNA|endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
76030027|NCT04266249|Radiation|Radiation Therapy|Undergo radiation therapy
75378584|NCT03187730|Behavioral|Waitlist Integrated Smoking Cessation and Financial Counseling|Control participants in the waitlist control group will receive usual care for the first 6 months of the study, while the Intervention Arm receives integrated counseling. The waitlist control group will receive the same counseling program as the Intervention group 6 months after enrollment (up to nine counseling sessions and four weeks of NRT). Participants will be surveyed at baseline, 2-months, 6-months and 12-months to assess outcomes and treatment satisfaction.
75378585|NCT03187730|Drug|Nicotine Replacement Therapy (NRT)|Participants in both arms will be eligible to receive a free four-week supply of NRT.
75378586|NCT05363761|Combination Product|Neurotronic Infusion Catheter|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
75378587|NCT03189134|Drug|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
75867441|NCT03166306|Diagnostic Test|PET-CT Imaging with [89Zr]-bevacizumab|Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
75867442|NCT02398630|Radiation|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
76030028|NCT04266249|Biological|Trastuzumab|Given IV
75378588|NCT03189134|Device|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
75703799|NCT00843934|Drug|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
75867443|NCT02398630|Other|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
75867444|NCT02398630|Other|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
75867445|NCT02398630|Other|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
75867446|NCT03631914|Procedure|Infraclavicular brachial plexus block|An infraclavicular brachial plexus block is performed using ultrasound guidance.
76030029|NCT04266249|Biological|Trastuzumab Emtansine|Given IV
76030030|NCT04260126|Combination Product|Pembrolizumab and PDS0101|IV infusion of pembrolizumab 200 mg + two 0.5mL sub-cutaneous injections of PDS0101 administered on Cycle 1, 2, 3, 4 and 12. IV infusion of Pembrolizumab 200 mg monotherapy will be administered Cycles 5 - 11 and 13 - 35.
76030031|NCT04247997|Procedure|disconnect pulmonary vague nerve branches|When the operation is in the right side, the Azygous vein bow is used as the marker, and in the left side, the aortic arch is used as the marker to identify the vagus nerve trunk.Then the surgeons dissect the vagus nerve trunk. This is used as a clue to find the vagus nerve pulmonary branch leading to the hilum. The position of the detachment is after the anterior and posterior pulmonary branches of the vagus nerve separating from the trunk and before the formation of the lung plexus.
76030032|NCT04246463|Device|Thoracic|Implant of a Relay stent graft system
76030033|NCT04246463|Device|Abdominal|Implant with an Anaconda or Treo Stent graft system
76030034|NCT04246463|Device|Custom Device|Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device
76030035|NCT04246463|Device|Illiac Artery|Implant with an Anaconda Iliac leg only
75703800|NCT00843934|Drug|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
75867447|NCT02398552|Drug|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
75867448|NCT03345979|Combination Product|Aripiprazole Lauroxil|Intramuscular injection; study drug provided using a pre-filled syringe
75867449|NCT03345979|Drug|Paliperidone Palmitate|Intramuscular injection
75867450|NCT04654338|Radiation|SABR + HDR|One SABR treatment + one HDR brachytherapy treatment
75867451|NCT02696434|Drug|Naltrexone|daily dosing
75867452|NCT02696434|Drug|Placebo|daily dosing
75867453|NCT02696434|Drug|Buprenorphine|daily dosing
75703801|NCT00805701|Drug|avodart|0.5 avodart once daily for 13 weeks
75703802|NCT00805701|Drug|Placebo|placebo
76030036|NCT04246333|Other|Mode of Delivery of Feeds|Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
75703803|NCT02547610|Device|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
75378589|NCT03261193|Drug|ITM + Sham QLB|Sham subcutaneous non-anesthetic infiltration with saline
75378590|NCT03261193|Drug|ITM + Bupivacaine QLB|QL plane block with local anesthesia
75703804|NCT00805779|Device|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
76030037|NCT04241757|Diagnostic Test|ElectroCardioGram (ECG)|Collection of results ElectroCardioGram (ECG).
76030038|NCT04239573|Procedure|Computed Tomography|Undergo CT
76030039|NCT04239573|Procedure|Endoscopic Ultrasound|Undergo EUS
75378591|NCT05359705|Device|DJO 456|Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global
76030040|NCT04239573|Procedure|Magnetic Resonance Imaging|Undergo MRI
75703805|NCT00714896|Behavioral|Stepped-Care|"stage-based expert system written intervention at baseline and 3 months~in-person stage appropriate counseling at baseline and 3 months~telephone counseling sessions at weeks 2,4 and 8,~as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
75703806|NCT00714896|Behavioral|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
76030041|NCT04239573|Other|Quality-of-Life Assessment|Ancillary studies
76030042|NCT04239573|Other|Questionnaire Administration|Ancillary studies
76030043|NCT04233112|Drug|Melatonin 5 mg|Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
75703807|NCT04042948|Drug|Tylenol|when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
75703808|NCT00796965|Drug|AZD7268|Solution/Capsule, Oral, once daily
75703809|NCT00796965|Drug|Placebo|
75703810|NCT00765245|Drug|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
75378592|NCT05359705|Device|Aspen 456|Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products
75378593|NCT05359705|Device|DJO 464|Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global
75378594|NCT05359705|Device|Aspen 464|Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
75378595|NCT00375661|Drug|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
76030044|NCT04233112|Device|Osteogenic loading|Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.
76030045|NCT04233112|Device|Mock for Osteogenic Loading|Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.
75378596|NCT04736186|Drug|Loperamide|Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
75539782|NCT04590391|Device|Visual and Auditory Breathing-swallowing Coordinated Training device|This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
76030046|NCT04233112|Drug|Placebo (plant fiber) for melatonin|Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
76030047|NCT04226755|Dietary Supplement|Sodium chloride|1 gram tid (with every meal)
75378597|NCT04736186|Drug|Loperamide and golden bifid|Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
75378598|NCT04736186|Drug|Loperamide and montmorillonite powder|Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
75378599|NCT02185794|Drug|Voxilaprevir|Voxilaprevir tablets administered orally once daily
76030048|NCT04223596|Drug|Brigatinib|Brigatinib 90 mg for the first 7 days (D1-7 at cycle 1) and then 180 mg daily thereafter for QW4 cycles of duration (28 days+-3 days)
75378600|NCT02185794|Drug|Placebo to match voxilaprevir|Placebo to match voxilaprevir tablets administered orally once daily
75378601|NCT02185794|Drug|SOF/VEL|400 mg/100 mg FDC tablet administered orally once daily
75703811|NCT00765245|Drug|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
75703812|NCT00765245|Drug|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
75539783|NCT04590157|Device|Low Level Laser Therapy|Laser Acupuncture application on Neurogenic Acupoints: the treatment based upon the use of low power laser light to stimulate acupuncture points
75703813|NCT02546518|Device|Moniri Otovent|Please see Arm Description.
75539784|NCT04590157|Other|Pelvic floor muscle training|exercise prodram as follow: from supine lying position with legs slightly apart the patient asked to contract the pelvic muscles as hard as possible and hold for 10 seconds
75539785|NCT00567658|Drug|Esomeprazole|Esomeprazole or Nexium 40 mg BID is given for four months.
75703814|NCT02546518|Device|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
75703815|NCT00801879|Drug|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
75703816|NCT00801879|Drug|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
75703817|NCT00718484|Drug|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
76030049|NCT04222387|Device|OCT-B scan|OCT-B scan (Optical coherence tomography)
76030050|NCT04217954|Drug|OXA, 5-FU and bevacizumab plus Toripalimab|"concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~The concomitant treatment repeat every three week, up to 6 cycles.~Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks."
75539786|NCT04589806|Procedure|2-stage ridge splitting|two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
75539787|NCT00567697|Drug|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
75539788|NCT00567697|Drug|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
75539789|NCT04589416|Other|Dental adhesive materials.|It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
75539790|NCT04589455|Dietary Supplement|Hennep extract|Hennep extract from Becanex containing 70 mg CBD
76030051|NCT04210427|Drug|Polyethylene Glycol 3350|All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.
76030052|NCT04210427|Device|SmartPill Motility System & PillCam Patency Capsule|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
76030053|NCT04201574|Drug|ALY688 0.1%|ALY688 0.1% Ophthalmic Solution
76030054|NCT04201574|Drug|ALY688 0.4%|ALY688 0.4% Ophthalmic Solution
75539791|NCT04589494|Drug|Tramadol Hydrochloride|tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
75539792|NCT04589299|Biological|Immunoglobulin|Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.
76030055|NCT04201574|Drug|Vehicle|Vehicle Ophthalmic Solution
76030056|NCT04194034|Biological|TG6002|"Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient."
75867454|NCT05683093|Other|History of being born to hypertensive or normal pregnancy|"CLARITY is an observational study whereby participants will attend one 4-hr visit the Division of Cardiovascular Medicine, University of Oxford at the John Radcliffe Hospital in Oxford, with the option to split the study visit over two days for convenience.~Participants will be invited by the ALSPAC study team to attend a study visit in Oxford where the investigators will use MRI and other imaging modalities to study the brain, heart, liver, kidneys, and vasculature using standardised protocols. A dataset including information from previous follow-up of these cohorts and the detailed pregnancy data available within ALSPAC will be generated by the study team in Bristol and integrated with available data from the Oxford cohorts."
76030057|NCT04194034|Drug|Flucytosine (5-FC)|"Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between."
76030058|NCT04191135|Biological|Pembrolizumab|intravenous (IV) infusion
76030059|NCT04191135|Drug|Olaparib|oral tablets
75539793|NCT00253500|Biological|pegfilgrastim|6 mg in a syringe
75539794|NCT00253500|Drug|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
75539795|NCT00253500|Procedure|conventional surgery|to remove small piece of cancer
75539796|NCT04588909|Procedure|Colorectal resections|All patients admitted with colorectal cancer were subjected to various types of colorectal resections
75539797|NCT04589026|Drug|Cosentyx|Cosentyx injection will be administered subcutaneously.
75539798|NCT04589026|Drug|Candin|Candin will be administered interadermally along with NaCl solution.
75703818|NCT00718484|Drug|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
76030060|NCT04191135|Drug|Carboplatin|IV infusion
76030061|NCT04191135|Drug|Gemcitabine|IV infusion
76030062|NCT04356170|Drug|Docetaxel|Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
76030063|NCT04356170|Drug|Cisplatin|cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
76030064|NCT04356170|Drug|Fluoro Uracil|750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
75378602|NCT04941170|Drug|Bupivacain|Ultrasound-guided oblique subcostal transversus abdominis plane block will be performed in the supine position under strict aseptic precautions. placing a linear high-frequency ultrasound probe obliquely near the costal margin and xiphoid process On confirming the placement of the needle in the correct target space, 1 mL of 0.25% bupivacaine will be injected to hydro-dissect the fascia layer between the RA and TA. After confirming the separation of the transversus abdominis fascia plane, the remaining 19 mL of 0.25% bupivacaine will be administered, advancing the needle infero-laterally parallel to the subcostal margin. A similar procedure will be performed on the contralateral side of the abdomen with an injection of another 20 mL of 0.25% bupivacaine.
75378603|NCT04941170|Drug|Bupivacaine|Ultrasound-guided erector spinae plane block will be performed in the sitting position. T7 spinous process will be located To perform the block. The tip of the T7 transverse process will be then identified using the ultrasound probe that is placed in a transverse orientation The ultrasound transducer will then be placed in a longitudinal orientation 2-3 cm lateral to the midline in a longitudinal orientation to identify the hyperechoic line of the transverse process with its associated acoustic shadow. After local anaesthetic infiltration, the block needle will be inserted in a craniocaudal direction until contact will be achieved with the T 7 transverse process where the tip will lay in the inter-fascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle to confirm the proper needle position. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally.
75378604|NCT05357911|Drug|AB-106, digoxin|Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
75378605|NCT05355883|Behavioral|Remote Ischemic Conditioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
75539801|NCT04589182|Device|MHSL- SleepBand|The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.
75539802|NCT04589182|Device|Sham|Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.
75539803|NCT00249639|Behavioral|Contingency management|Rewards valued $1-$100
76023002|NCT03169387|Behavioral|Virtual Reality|For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
76030065|NCT04176133|Drug|Entolimod|Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
76030066|NCT04176133|Drug|Placebo|Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
76030067|NCT04176133|Drug|Influenza vaccine|Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
76030068|NCT04175418|Other|Supervised Exercise Program|The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.
76030069|NCT04175418|Other|Online Education Program|The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
76030070|NCT04171908|Other|Conventional therapy|Conventional Physical therapy for the upper limb
76030071|NCT04171908|Other|semi-inversive tech|Conventional Physical therapy for the upper limb plus Semi-inversive tech
76030072|NCT04166318|Drug|Capecitabine|Given PO
76030073|NCT04166318|Drug|Fluorouracil|Given IV
76030074|NCT04166318|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75539804|NCT04588987|Biological|PD-1|Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
75703819|NCT00841126|Drug|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
76030075|NCT04166318|Drug|Mitomycin|Given IV
76030076|NCT04166318|Other|Quality-of-Life Assessment|Ancillary studies
76030077|NCT04166318|Other|Questionnaire Administration|Ancillary studies
76030078|NCT04165213|Behavioral|COPE online training|"The intervention being tested is PACE staff training in COPE - accomplished with the creation of self-paced online learning modules.~The modules will include rich multimedia content and interactive assessments to keep the learner engaged and will allow for easy packaging of the content into the latest interoperability standards for such content including the latest Shareable Content Object Reference Model (SCORM) specifications, which will allow for repurposing and sharing with other institutions and will be designed using a hyperlearning model with four dimensions. The self-paced modules will be highly interactive featuring integrated multimedia content, assessments, and learner evaluations to allow PACE staff to engage with the content at a high level and practice application in simulated scenarios. Each module will require approximately 45-60 minutes/module for the learner to complete.le for the learner to complete."
75378606|NCT05355883|Behavioral|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
75378607|NCT05355883|Behavioral|Hand Arm Bimanual Intensive Therapy (HABIT)|HABIT is a child-friendly, intensive intervention directed at improving bimanual coordination and function of the affected arm. The intervention employed in this study includes various age-appropriate fine and gross motor bimanual activities that will be delivered in a play context. Children practice bimanual activities for 6 hours per day, 5 days per week, for 1 week.
75378608|NCT05355883|Behavioral|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive day.
75539805|NCT04589104|Behavioral|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to release & integrate difficult emotions~Week 3: Writing to nurture gratitude~Week 4: Writing to enhance strengths & resources~Week 5: Writing to cultivate positive meaning & savor goodness~Week 6: Writing to invite insight, perspective, & growth"
75539806|NCT04588558|Device|Flywheel exercise|Flywheel training is a strength training modality that offers the possibility of performing exercises with eccentric overload and variable resistance as compared to conventional gravity-based resistance training. Flywheel exercise applied three days a week for 8 weeks
75378609|NCT05355883|Behavioral|Balance training|All children undergo training on a balance board, learning to hold the board level with equal weight on each leg and using various bilateral upper extremity strategies. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
75378610|NCT03374839|Drug|TIL + IL-2 + Nivolumab|"The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days."
75539807|NCT04588558|Other|Home exercise|The active ROM exercise was performed via knee in extension to full-flexion, then knee in flexion to full-extension exercises, repeated 10 times. The strengthening exercises consisted of quadriceps strengthening by holding maximal isometric contractions for 10 s and performing 10 repetitions. Stretching targeted the gastrocnemius- soleus and hamstring muscle and was performed by asking the patient to stretch the muscle for 30 s and to complete three repetitions for each muscle group.
75703820|NCT00841126|Drug|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
76030079|NCT04158921|Other|Control:Diabetes mobile app|The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. > 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.
76030080|NCT04152421|Other|Software use|"The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities."
75378611|NCT04848272|Drug|Lanadelumab|Monoclonal antibody that targets active plasma kallikrein
75378612|NCT04848272|Other|Saline control|Saline control
75378613|NCT02221674|Drug|Tapentadol|
75378614|NCT04520906|Device|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
75378615|NCT04736719|Drug|Apixaban|Apixaban dispensing claim is used as the exposure group
75378616|NCT04736719|Drug|Warfarin|Warfarin dispensing claim is used as the reference group
76030081|NCT04152330|Other|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
76030082|NCT04150614|Drug|Granisetron Transdermal Patch|Antiemetic
75378617|NCT04736563|Device|Joint and muscle gel Puressentiel|To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.
75539808|NCT04588558|Device|Electrotherapy group|"The participants in the electrotherapy group received TENS (Intellect; Chattanooga Group, Hixson, TN), therapeutic ultrasound (Intellect 340 Combo) and exercise. TENS was applied via four electrodes around the knee joint: two on the medial and two on the lateral aspect on either side of the joint line for approximately 20 min. For pain relief, the devices were set to a continuous mode (110 Hz, 50 μ). Electrical pulses were asymmetric and biphasic.~Therapeutic pulsed ultrasound therapy was administered using a 1-MHz frequency, 0.8 W/cm power ultrasound device with a sound-head area of 5 cm2 and effective radiating area of 3.5-5 cm2 . Ultrasound was applied to the medial and lateral parts of the knee in circular movements for a duration of 5 min with the patient in a supine position.~All participants received the same standardized exercise program. The exercises included aerobic, active ROM, strength, and stretching exercises"
75703821|NCT00841126|Drug|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
75703822|NCT02553369|Other|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
76030083|NCT04150614|Drug|Intravenous Dexamethasone|Antiemetic
76030084|NCT04150614|Drug|Ondansetron|ondansetron
76030085|NCT04145297|Drug|Ulixertinib|"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"
76030086|NCT04145297|Drug|Hydroxychloroquine|Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
76030087|NCT04138940|Behavioral|Script Training|Participant uses a computer program to practice scripts with a virtual therapist.
76030088|NCT04131712|Other|Massage|A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
76030089|NCT04126096|Diagnostic Test|Skin Testing beta-lactams|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
76030090|NCT04125836|Drug|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
76030092|NCT04121455|Drug|Olaptesed pegol|Olaptesed pegol continuous administration for 26 weeks
76030093|NCT04121455|Radiation|Radiotherapy|Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
75378618|NCT04429646|Device|Percutaneous left atrial appendage closure-LAMax|Interventional device, LAMax left atrial appendage closure system
75378619|NCT04429646|Device|Percutaneous left atrial appendage closure-Watchman|Interventional device, Watchman® LAA Closure Device
75539809|NCT04588831|Device|Mouthguard|Protective device for orofacial complex for patients playing contact sports
75539810|NCT00567736|Drug|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
75539811|NCT00567736|Drug|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
75539812|NCT00253539|Drug|arzoxifene hydrochloride|Given orally
75539813|NCT00253539|Drug|tamoxifen citrate|Given orally
75539814|NCT00253539|Other|placebo|Given orally
75539815|NCT04180163|Drug|Lanadelumab|Lanadelumab solution, SC
75539816|NCT04588636|Behavioral|behavioral and self-care therapy|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
75539817|NCT04588636|Device|rigid occlusal splint (ROS)|Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
75539818|NCT04588636|Device|soft occlusal splint (SOS)|Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
75539819|NCT04588636|Device|non-occlusive splint (NOS)|non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
75539820|NCT04588675|Diagnostic Test|MRI|the patients will underwent dobutamine stress cardiac MRI
76030094|NCT04121455|Drug|Bevacizumab|Bevacizumab every 2 weeks i.v. for 26 weeks
76030095|NCT04121455|Drug|Pembrolizumab|Pembrolizumab every 3 weeks i.v. for 26 weeks
75378620|NCT02221284|Drug|Alogliptin|Alogliptin tablets
75378621|NCT04736407|Other|Observational sampling of CSF timed around routine clinical repositioning, or not|no true intervention
75378622|NCT04736108|Drug|Abiraterone acetate|1000 mg orally daily for 24 weeks before radical prostatectomy
75539821|NCT04720365|Device|play-based rehabilitaion|usual re-education treatment by their physiotherapist
76030096|NCT04117958|Drug|AMG 199|AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
76030097|NCT04117672|Dietary Supplement|Salovum|Active egg yolk powder
76030098|NCT04117672|Dietary Supplement|Placebo egg yolk powder|Normal egg yolk powder
75378623|NCT04736108|Drug|Prednisolone|5 mg oral low dose prednisone, once daily
75539822|NCT00567775|Drug|human insulin|
76030099|NCT04115631|Drug|Acalabrutinib|Given PO
75378624|NCT04736108|Drug|Goserelin|10.8 mg goserelin hypodermic once per 12 weeks
75539823|NCT00567775|Drug|inhaled human insulin|
75539824|NCT00567814|Drug|Metyrapone|Twice daily
75539825|NCT00567814|Drug|Oxazepam|Twice Daily
75539826|NCT00567814|Drug|Placebo|Twice daily
75539827|NCT04588753|Other|active isolated stretch|"Active Isolated Stretch (AIS);~The shortened hamstring muscle will be isolated.~The hamstring will be stretched.~This Stretches will be Repeated eight to 10 times.~Stretch will be hold for no more than two seconds.~Exhale on the stretch; inhale on the release. Other amputees training exercises;~weight-shifting~Dynamic balancing activities~Stool stepping~Braiding~Gait exercises~Climbing/descending the stairs"
75703823|NCT03987113|Other|Plasma concentration analysis during and after ex-vivo pulmonary reconditioning|The pulmonary endothelial dysfunction will be evaluated with plasma concentration of heparan sulphate, syndecan-1, endothelin-1 and i-NOS.
75703824|NCT02575040|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
76030100|NCT04115631|Drug|Bendamustine|Given IV
76030101|NCT04115631|Drug|Bendamustine Hydrochloride|Given IV
76030102|NCT04115631|Drug|Cytarabine|Given IV
76030103|NCT04115631|Biological|Rituximab|Given IV
76030104|NCT04112667|Other|Normal Macular Health|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
76030105|NCT04112667|Other|Early Macular Degeneration|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
75378625|NCT03196076|Drug|Perflutren Lipid microsphere|Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
75378626|NCT02971033|Drug|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
75378627|NCT02971033|Drug|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
75539828|NCT04588753|Other|Post Facilitation Stretch|"Participants of this group will receive Post Facilitation Stretch (PFS);~The shortened hamstring muscle will be placed between a fully stretched and a fully relaxed state.~The patient will be asked to contract the hamstring using a maximum degree of effort for 5-10 seconds while the therapist will resists thepatients force.~The patient will be then asked to relax and release the effort, whereas the therapist will apply a rapid stretch to a new barrier and is held for 10 seconds.~The patient relaxes for approximately 20 seconds and the procedure will be repeated to five times (8) (18).~2. Other amputees training exercises;~weight-shifting~Dynamic balancing activities~Stool stepping~Braiding~Gait exercises~Climbing/descending the stairs"
76030106|NCT04112667|Other|Young Normals|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
76030107|NCT04109482|Biological|MB-102|"The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered."
75378628|NCT02971033|Drug|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
75378629|NCT05406674|Drug|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2 milligram(s)/square meter
75378630|NCT05406674|Drug|Cisplatin 40 mg/l|Cisplatin 40 mg/I milligram(s)/litre
75703825|NCT03987347|Other|Observational|People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
75703826|NCT00805857|Drug|Tipranavir|
75703827|NCT00718562|Drug|AMN107|
75703828|NCT00801957|Drug|tacrolimus ointment 0.03%|topical application
75703829|NCT00801957|Drug|hydrocortisone acetate ointment 1%|topical application
75703830|NCT00801957|Drug|hydrocortisone butyrate ointment 0.1%|topical application
75703831|NCT00801957|Biological|Meningitec|im injection
75539829|NCT04588090|Procedure|The concurrent 3 weeks TP regimen|paclitaxel + cisplatin regimen (TP-TAX: 150mg/m^2, DDP: 70mg/m^2 (35mg/m^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
75539830|NCT04588090|Procedure|The concurrent weekly TP regimen|paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m^2, DDP: 25mg/m^2) 6 cycles of chemotherapy
75703832|NCT00801957|Biological|AC VAX|im injection
75703833|NCT02572544|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
75867455|NCT04615416|Behavioral|Emotion Regulation Training via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
75703834|NCT02547688|Device|Nasal High Flow|
75703835|NCT00714974|Device|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
75703836|NCT00836134|Procedure|rectus sheath block|ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
75378631|NCT05341375|Procedure|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
75378632|NCT05341375|Drug|Esketamine|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
75539831|NCT04588090|Radiation|External radiation plus intraluminal after-loading irradiation|External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
75378633|NCT05341375|Behavioral|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery
75378634|NCT05341375|Behavioral|The assessment of cognitive function|Participants were assessed for MMSE at the same period as the group C
75378635|NCT00375817|Procedure|Myoblasts injection with MyoCath catheter|
75539832|NCT00253578|Drug|sorafenib tosylate|Given PO
75539833|NCT00253578|Other|laboratory biomarker analysis|Correlative studies
75539834|NCT04153565|Drug|Pembrolizumab|Participants will receive Pembrolizumab 200 mg IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of Pembrolizumab (approximately 2 years).
75539835|NCT04153565|Drug|Pemetrexed|Participants will receive Pemetrexed 500 mg/m^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
75378636|NCT02796001|Biological|human rhinovirus|human rhinovirus
75539836|NCT04153565|Drug|Cisplatin|Participants will receive Cisplatin 75 mg/m^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
75539837|NCT04588324|Drug|SHR2150|Patients will receive escalating doses of SHR-2150 (starting dose 2 mg) in 3-week treatment cycles.
75867456|NCT03345901|Drug|Pemafibrate|0.2 mg orally BID - twice daily
75867457|NCT03345901|Drug|Placebo|orally BID - twice daily
75378637|NCT02796001|Other|no intervention|4 volunteers were not re-challenged and did not participate in the second challenge
75378638|NCT04736264|Other|Visual rehabilitation module: navigation and mobility|The visual rehabilitation regime consist of education and activity include dressing, feeding, personal hygiene and grooming activities, functional mobility, room orientation and memory, reading, eye hand coordination and also optokinetic training programme. A diary will be given to assess their compliance. Reassessment based on the number of fall, stumble etc when they go through a maze (developed in Phase 1)will be done every 2weeks for 8 weeks (4 times), every 4 weeks for next 8 weeks (2 times) and the final assessment 8 weeks later. A total study intervention will be 24 weeks
75378639|NCT04736264|Other|Visual rehabilitation module: exercise|An instruction course will be conducted and a CD (with step by step exercise demonstration) will be given to the patients in group A. They will be asked to come for another session in 2 weeks. Then they will be asked to conduct the exercise for at least three times a week for 24 weeks. Exercise diary and accelerometer will also be given to patients of both groups. They will be seen in the clinic every 8 weeks.
75539838|NCT04588324|Drug|Anti-Cancer Agent|The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.
75867458|NCT02393092|Behavioral|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
75867459|NCT02393092|Behavioral|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
75867460|NCT02393092|Behavioral|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
75867461|NCT03166462|Other|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
75539839|NCT04588324|Drug|SHR2150|Patients will receive SHR-2150 at RP2D in 3-week treatment cycles.
75867462|NCT03166540|Other|cup of espresso coffee|Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
75867463|NCT03166540|Other|cocoa-based products containing coffee|Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
75867464|NCT02950831|Other|Accelerometry|Record of activity levels using a wrist worn accelerometer
75867465|NCT02392936|Procedure|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
75867466|NCT03709147|Drug|Metformin Hydrochloride|Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)
75867467|NCT03709147|Drug|Cisplatin|Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles
75539840|NCT04587895|Behavioral|VITAAL Exergame|12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.
75539841|NCT04587895|Behavioral|Conventional Training UI|12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.
75703837|NCT00836134|Procedure|local anesthetic infiltration|Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
76030108|NCT04109482|Drug|Fludarabine|"Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min)."
75867468|NCT03709147|Drug|Carboplatin|Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles
75867469|NCT03709147|Drug|Pemetrexed|Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
75539842|NCT04587895|Behavioral|Conventional Training MI|"12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu)."
75867470|NCT03709147|Dietary Supplement|Fasting-mimicking diet|5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles
75867471|NCT03709147|Drug|Pembrolizumab|Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
75867472|NCT02392858|Other|influenza cohort|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
75539843|NCT00249678|Behavioral|Behavior Therapy|
75539844|NCT04588168|Drug|Chemotherapy|Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.
75539845|NCT04588168|Diagnostic Test|Immediate Multiparametric MRI|Within 24 hours after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive an immediate mpMRI scan.
75703838|NCT00715052|Procedure|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
75703839|NCT00782795|Drug|Pioglitazone|Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.
75703840|NCT00782795|Drug|Placebo|
75703841|NCT00841282|Procedure|Colonoscopy for colorectal cancer screening|
75703842|NCT00841282|Procedure|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
75703843|NCT00841282|Procedure|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
76030109|NCT04109482|Drug|Cyclophosphamide|Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
76030110|NCT04109196|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
75539846|NCT04588168|Procedure|Cystectomy and Lymphadenectomy|The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.
75539847|NCT04588168|Diagnostic Test|conventional Multiparametric MRI|After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.
75703844|NCT00715130|Behavioral|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
76030111|NCT04098523|Diagnostic Test|Duplex ultrasound|A one-time carotis and abdominal aorta duplex ultrasound will be performed on-site by a skilled site staff to determine the prevalence of, and risk factors associated with, CAS and AAA. A diameter measurement will be performed of the abdominal aorta as well as a determination of the carotid arteries.
75539848|NCT04588168|Diagnostic Test|Baseline Multiparametric MRI|Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.
75539849|NCT04587817|Combination Product|camrelizumab+hyperfractionated radiotherapy|Immunotherapy combined with hyperfractionated radiotherapy
76030112|NCT04094584|Drug|Vivitrol (Extended Release Naltrexone)|Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
76030113|NCT04091308|Other|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
76030114|NCT04091308|Other|Usual Care with Protein Supplementation|The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.
76030115|NCT04091308|Other|Individualized Physical Exercise Training with Protein Supplementation|Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.
75539850|NCT00253617|Drug|porfimer sodium|
75539851|NCT00253617|Procedure|adjuvant therapy|
75539852|NCT00253617|Procedure|laser therapy|
75539853|NCT00253617|Procedure|photodynamic therapy|
75703845|NCT00841360|Other|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
75703846|NCT00841360|Other|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
75539854|NCT00253617|Procedure|phototherapy|
75539855|NCT04587778|Drug|Ketamine Hydrochloride|intravenous infusion
75703847|NCT02573558|Drug|Dexmedetomidine|
75703848|NCT02573558|Drug|Propofol|
75703849|NCT00656799|Drug|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
75703850|NCT00656799|Drug|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
75703851|NCT00764699|Drug|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
75703852|NCT02547142|Other|Early Palliative Care|Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
75703853|NCT00715286|Other|timing of surgery|Surgery is followed by chemotherapy
75703854|NCT00715286|Other|timing of surgery|Chemotherapy is followed by surgery
75867473|NCT02393170|Other|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks."
75539856|NCT04587778|Drug|Esketamine|intravenous infusion
75539857|NCT04587778|Drug|Placebo|intravenous infusion
75378640|NCT04736264|Other|Visual rehabilitation module: reading|Patient in intervention group will be asked to complete a reading task (reading the given book) a day, number of pages completed in an hour per day and time taken to complete a page in given book. They are asked to complete the books within 24 weeks with follow up every 8 weeks.
75378641|NCT05406518|Other|Psychosocial intervention|Psychosocial intervention based on the model of family therapy.
75378642|NCT04373252|Biological|FMT Lower Delivery (FMP 30)|Participants will receive two fecal microbiota transplants via antegrade enema, one week apart.
75378643|NCT03235687|Diagnostic Test|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
75378644|NCT03200587|Drug|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
75867474|NCT02393170|Other|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
75539858|NCT04139564|Device|EaseVRx headset|EaseVRx is a virtual reality therapy intended to treat chronic pain
75539859|NCT04139564|Device|Active control VR sham program|VR, 2d visual wildlife scenes similar to some EaseVRx content
75703855|NCT00844012|Drug|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
75867475|NCT03709069|Dietary Supplement|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
75867476|NCT02398474|Drug|TFP block ropivacaine|
75867477|NCT02398474|Drug|ropivacaine infiltration of the iliac crest bone|
75867478|NCT02398318|Device|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
75539860|NCT04587505|Procedure|Epidural anesthesia with light general anesthesia|Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
75539861|NCT04587505|Drug|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
75867479|NCT02398318|Device|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
75378645|NCT03200587|Drug|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
75378646|NCT03198884|Drug|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
75378647|NCT01801189|Drug|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
75378648|NCT01801189|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
75378649|NCT05440838|Diagnostic Test|Next-generation sequencing|Next-generation sequencing and cytokine profile will be established in all patients before the start of treatment.
75378650|NCT04275362|Device|DJO Empowr PS Knee System|Patients will receive a DJO Empowr PS Knee System total knee replacement
75378651|NCT04275362|Device|Stryker Triathlon Total Knee System|Patients received a Stryker Triathlon Total Knee System total knee replacement
75378652|NCT04275362|Device|Biomet Vanguard Complete Knee System|Patients received a Biomet Vanguard Complete Knee System total knee replacement
75378653|NCT04275362|Device|Control|No total knee replacement
75378654|NCT05178043|Drug|Nivolumab|Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).
75378655|NCT05178043|Drug|GT90001|GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
75378656|NCT05406206|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
75867480|NCT03710317|Drug|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
75378657|NCT05406206|Procedure|Hepatic Arterial Infusion Chemotherapy|HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m*2 + 5-FU 2000 mg/m*2, Q4W
75867481|NCT03710317|Drug|Tranexamic Acid|1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
75867482|NCT03710317|Drug|misoprostol|Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
75378658|NCT00716755|Drug|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, [11C]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
75539862|NCT04587505|Procedure|General anesthesia|Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
75867483|NCT02392780|Drug|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
75867484|NCT02392780|Drug|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
75867485|NCT02392780|Drug|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
75703856|NCT00844012|Drug|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
75867486|NCT03710239|Device|Dilapan-S|Synthetic osmotic dilator
75867487|NCT03710239|Device|Laminaria|Seaweed-based osmotic dilator
75867488|NCT02393014|Procedure|Simple physical exercises|"The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
75867489|NCT04053478|Drug|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature
75867490|NCT04053478|Drug|Phenylephrine|Phenylephrine, at applicable concentrations based on literature
76030116|NCT04082338|Behavioral|VPN|"The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period."
75539863|NCT04587505|Drug|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
75539864|NCT00249717|Behavioral|Contingency management|Receive rewards (prizes) abstinence and attendance
76030117|NCT04082338|Behavioral|TM|Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
75703857|NCT02574962|Drug|H.P. Acthar® Gel|
75867491|NCT04053478|Drug|Norepinephrine|Norepinephrine, at applicable concentrations based on literature
76030118|NCT04074616|Device|High Dose|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
75539865|NCT04587544|Behavioral|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
75703858|NCT00802035|Drug|Baclofen IR|30 mg; single dose
75703859|NCT00802035|Drug|Baclofen ER|30 mg; single dose
75867492|NCT04053478|Drug|Vasopressin|Vasopressin, at applicable concentrations based on literature
76030119|NCT04074616|Device|Low dose|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
76030120|NCT04070560|Procedure|Intact cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
76030121|NCT04070560|Procedure|Early (≤ 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
76030123|NCT04053283|Biological|NG-641|NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
75703860|NCT00836212|Drug|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
75867493|NCT04474392|Other|N/A (Observational Study)|Observational study, no intervention will be administered.
75867494|NCT05744518|Other|Response monitoring|Other: Response monitoring (no intervention)
75378659|NCT05406128|Other|preoperative erector spina plane block|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
75378660|NCT05406128|Other|intraoperative erector spina plane block|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
75378661|NCT05406050|Drug|reference eldecalcitol soft capsule|0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
75378662|NCT05406050|Drug|test eldecalcitol soft capsule|0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
75378663|NCT04736095|Diagnostic Test|3D Ultrasound|Doing 3D ultrasound for diagnosis of submucous myoma
75378664|NCT04736095|Diagnostic Test|Hysteroscopy|Doing hysteroscopy for diagnosis of submucous myoma
75539866|NCT00249756|Behavioral|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments - increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
75703861|NCT00836212|Drug|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
76030124|NCT04047472|Drug|Brolucizumab 6mg|Subjects will receive Brolucizumab 3 x q4w up to Week 8 followed by q12w / q8w up to Week 40 or Week 44, depending on disease activity status.
75378665|NCT03199118|Procedure|CAF +SCTG|the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
75378666|NCT03199118|Other|platelet rich fibrin|in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
75378667|NCT03202472|Device|Implanted Medical Device|Radiofrequency tag
75378668|NCT03202472|Procedure|Mammography|Undergo mammogram for image-guided placement of radiofrequency tag
75378669|NCT03202472|Other|Questionnaire Administration|Ancillary studies
75378670|NCT03202472|Procedure|Radiofrequency (RFID) -Guided Localization|Undergo radiofrequency-guided localization
75378671|NCT03202472|Procedure|Ultrasonography|Undergo ultrasound for image-guided placement of radiofrequency tag
75378672|NCT04200404|Drug|CS1001|One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).
75378673|NCT04200404|Drug|Regorafenib|One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.
75378674|NCT04171778|Other|whole food, plant-based diet|The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
75378675|NCT04135742|Device|Transcranial Alternating Current Stimulation|Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.
75378676|NCT04135742|Behavioral|Cognitive Training|Cognitive training includes memory, reasoning, processing speed and role playing, etc.
75378677|NCT03202550|Drug|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
75378678|NCT03202550|Drug|Placebo Comparator|Placebo oral pills
75378679|NCT03203564|Drug|Modufolin (arfolitixorin)|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
75378680|NCT04123886|Drug|SCB-313|SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
75378681|NCT03285542|Device|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
75378682|NCT03285542|Device|Staples|staples for skin closure
75378683|NCT03207074|Diagnostic Test|iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry|The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
75378684|NCT04095806|Other|Stroke (exposure)|stroke case definition (exposure) listed in inclusion/exclusion criteria section
75378685|NCT04088786|Drug|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
75539867|NCT00249756|Behavioral|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
75378686|NCT03207386|Behavioral|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
75378687|NCT00392821|Drug|Sorafenib|Sorafenib
75378688|NCT00392821|Drug|RAD001|RAD001
75378689|NCT03208166|Device|Doctormate|Ischemic conditioning device
75378690|NCT03208166|Other|Usual Care|Standard medical care
75378691|NCT04051112|Drug|SCB-313|10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
75539868|NCT04587349|Other|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/ week)
75539869|NCT04587349|Other|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (3/ week)
75539870|NCT04587349|Other|Physiotherapy|Physiotherapy 2-years-long (3/week)
75378692|NCT04708171|Procedure|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
75703862|NCT04069676|Other|EEG|EEG, ECG and EDR record during a behavioral task
76030125|NCT04047472|Drug|Aflibercept 2 mg|Subjects will receive Aflibercept 3 x q4w up to Week 8 followed by q8w up to Week 40.
75378693|NCT04708171|Procedure|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
75378694|NCT04708171|Procedure|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
75703863|NCT00782717|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
75703864|NCT00782717|Other|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
75703865|NCT00782717|Drug|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
75703866|NCT00656175|Drug|raltegravir|raltegravir
75703867|NCT02572622|Other|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
75703868|NCT02572622|Other|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
75703869|NCT02572622|Other|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
76023003|NCT03169387|Behavioral|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
75703870|NCT02572622|Other|exercise|special lumbar stabilization exercises were applied in advanced protocol.
76030126|NCT04047355|Drug|Propranolol|Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
75378695|NCT02187042|Other|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
75378696|NCT02187042|Other|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
75703871|NCT02601599|Behavioral|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
75703872|NCT02572466|Other|Hemodialysis|ESRD group received long-term hemodialysis
75703873|NCT00797121|Procedure|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
75703874|NCT00715364|Drug|NTx™-265: rhCG, then rEPO|"rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
75703875|NCT00715364|Drug|Saline Placebo|"Saline SC, on Day 1, 3, and 5 of study participation, then~Saline IV, on Day 7, 8, and 9 of study participation"
75703876|NCT02601677|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
76030127|NCT04023370|Device|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
76030128|NCT04020341|Drug|Gepotidacin|Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
75703877|NCT02601677|Drug|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
76023004|NCT03116191|Drug|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
76023005|NCT03116191|Drug|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
76023006|NCT03116503|Other|diagnosis of bipolar disorder and comorbid depression|Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
76023007|NCT03171649|Device|RETRAINER-S1|"It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~anterior reaching (in a plane or in the space)~lateral elevation of the arm~hand to mouth movements with or without an object in the hand~moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
75378697|NCT03209882|Device|TILS|Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.
75378698|NCT03209882|Device|sham|The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.
75378699|NCT03290378|Drug|Tramadol|IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
75378700|NCT03290378|Other|Placebo|IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
75378701|NCT04659967|Behavioral|Virtual Training|Participants will receive a virtual training that is tailored to age-related hearing loss, use of non-custom personal amplification devices, and communication strategies.
75867495|NCT02392390|Procedure|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
75867496|NCT02392390|Drug|Metvixia cream|
76030129|NCT04020341|Drug|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
76030130|NCT04020341|Drug|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
76030131|NCT04020341|Drug|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
75539871|NCT00253695|Device|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
75539872|NCT04587310|Diagnostic Test|Laparoscopic Sleeve Gastrectomy|bariatric surgery
75539873|NCT00403208|Procedure|Analgesia based sedation in ICU patients|
75539874|NCT04586998|Device|"Exhaled drug monitor Edmon"|Taking samples of exhaled breath every minute during elective surgery in comparison to blood samples taken at predefined time points.
76030132|NCT04015141|Drug|Perampanel Oral Suspension|Perampanel oral suspension.
76030133|NCT04015141|Drug|Perampanel Tablet|Perampanel tablet.
75378702|NCT02076217|Drug|Copper T-380 IUD|
75378703|NCT02076217|Drug|LNG IUD|
75378704|NCT02076217|Device|Contraceptive implant Nexplanon|
75867497|NCT02392546|Drug|elobixibat|
75378705|NCT02076217|Drug|Depo-Provera|
75378706|NCT03290768|Device|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
75378707|NCT03290768|Device|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
76030134|NCT04014166|Other|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
75378708|NCT03290768|Behavioral|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
75378709|NCT04626661|Device|COMET measurement system|Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.
75378710|NCT04976647|Drug|HLX10+chemo|HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
76030135|NCT04011280|Drug|Varenicline|The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
76030136|NCT04002934|Drug|Bazedoxifene Acetate|40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
75867498|NCT02392546|Drug|placebo|
75867499|NCT02392702|Drug|C-10355|
75867500|NCT02392702|Drug|C-10358|
76030137|NCT03994367|Other|High animal protein isolate|Increased dietary protein content from animal protein isolates
76030138|NCT03994367|Other|High animal protein whole food|Increased dietary protein content from animal protein whole food
75378711|NCT04976647|Drug|HLX10+HLX07+chemo|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
75378712|NCT04976647|Drug|HLX10+HLX07|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W;
75378713|NCT03291080|Drug|Liquid 13-Cis Retinoic Acid|Liquid 13-Cis Retinoic Acid
75378714|NCT03291080|Drug|Extracted capsules 13-CRA|Extracted capsules 13-CRA
75867501|NCT02392702|Drug|Kalydeco|
75867502|NCT02392468|Drug|BI 409306 matching placebo|placebo
75867503|NCT02392468|Drug|BI 409306 matching placebo|placebo
75867504|NCT02392468|Drug|BI 409306|low dose
75867505|NCT02392468|Drug|BI 409306|high dose
76030139|NCT03994367|Other|High plant protein isolate|Increased dietary protein content from plant protein isolates
76030140|NCT03994367|Other|High plant protein whole food|Increased dietary protein content from animal protein whole food
76030141|NCT03990428|Behavioral|online surveys|Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
76030142|NCT03988621|Behavioral|ViCCY|Virtual Health Coaching for You
75867506|NCT02397928|Device|NovoTTF-100L device|Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
75867507|NCT02397928|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
75539875|NCT00253734|Biological|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
75539876|NCT00253734|Biological|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
75867508|NCT02397928|Drug|Cisplatin or Carboplatin|Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
75867509|NCT03593681|Device|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
75867510|NCT05744440|Drug|allogenic NK cells|The relapsed/refractory AML after allo-HSCT patients will receive allogenic NK cells infusion up to 2 dose levels (1x10^7/kg, 5x10^7/kg) after chemotherapy with azacitidine
75867511|NCT03734627|Drug|Octreotide Acetate|50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
76030143|NCT03987711|Drug|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
75539877|NCT04587115|Drug|Risperidone|Risperidone 1mg to be used in combination with other drugs
75539878|NCT04587115|Drug|Ziprasidone|Ziprasidone 80mg to be used in combination with other study drugs
75867512|NCT03734627|Drug|Saline Solution|Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
75867513|NCT03734627|Drug|Paracetamol|Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
75378715|NCT04933123|Device|indirect restorative treatement with a glass ceramic|Inlays and onlays of glass ceramic for molars and premolars are adhesively luted.
75539879|NCT04587115|Drug|Oxycodone|Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs
75539880|NCT00403247|Dietary Supplement|Capsule with folate, Vitamin B12 & pyridoxine|
75539881|NCT00403247|Other|placebo|placebo capsule
75539882|NCT04587037|Procedure|fascia lata allograft|underwent superior capsule reconstruction using fascia lata allograft
75539883|NCT04587037|Procedure|human dermal allograft|underwent superior capsule reconstruction using human dermal allograft
75867514|NCT03734627|Drug|Sulfasalazine|1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
75867515|NCT03734627|Diagnostic Test|Duodenal biopsy|Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
75867516|NCT02397850|Behavioral|phone calls 30 min|Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
76030144|NCT03987711|Drug|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
76030145|NCT03987711|Other|No oral anticoagulation|No oral anticoagulation
76030146|NCT03983967|Biological|Immuncell-LC|Activated T lymphocyte
76030147|NCT03974113|Drug|Fitusiran|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
75378716|NCT03292562|Device|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
75378717|NCT03292562|Device|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
75378718|NCT04874545|Drug|Propofol|Total intravenous inhalational anesthesia
75378719|NCT00368095|Behavioral|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
75378720|NCT03216200|Device|plasma treatment|application of cold atmospheric plasma to a fungal infected toenail
75378721|NCT04735939|Radiation|radiotherapy|Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
75378722|NCT03888092|Drug|Z650|receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
75539884|NCT04586725|Other|Encouragement a one minute intervals|Patients will perform the six exercise tests with encouragement at one minute intervals
76030148|NCT03962348|Behavioral|Specialized Early Engagement Support Service|The Specialized Early Engagement Support Service (SEESS - a Social Worker and Peer Specialist) will link detainees with first-episode psychosis (FEP), using tenets of person-centered treatment and shared decision-making, and the Critical Time Intervention model, to community-based Coordinated Specialty Care (CSC).
75378723|NCT04440865|Other|Genius® System-assisted Colonoscopy|Genius® Intelligence System is used to assist Colonoscopy
75378724|NCT04440865|Other|Standard Colonoscopy|Standard Colonoscopy without Genius® Intelligence System is performed
75378725|NCT03418064|Device|Fanfilcon A toric lens|Contact lens
75378726|NCT03418064|Device|Lotrafilcon B toric lens|Contact lens
75378727|NCT03181009|Drug|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
75378728|NCT03181009|Drug|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
75378729|NCT03292952|Drug|KP415 oral capsule|Daily dose
75378730|NCT03292952|Drug|Placebo oral capsule|Daily dose
75539885|NCT04586725|Other|Encouragement a two minute intervals|Patients will perform the six exercise tests with encouragement at two minute intervals
75539886|NCT00253773|Drug|acetominophen, sulfer amino acids; cysteine and methionine|
75539887|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
75867517|NCT02397850|Behavioral|phone calls 50 min|Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
75378731|NCT03296072|Drug|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres [mL] of tap water for 10 seconds before expectorating again.
75539888|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
75539889|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
76030149|NCT03961893|Device|G-EYE first and standard colonoscope|Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy
75539890|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
75539891|NCT00403286|Drug|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
75539892|NCT00403286|Drug|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
75539893|NCT00403286|Drug|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
75539894|NCT00403286|Drug|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
75867518|NCT02397772|Drug|albendazole|Single dose of albendazole (400 mg)
75867519|NCT03592745|Device|Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear.
75539895|NCT04587232|Diagnostic Test|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire (Mini-OAKHQoL) was derived from the Turkish version of OAKHQoL questionnaire, which was developed to assess the quality of life (QoL) in subjects with lower limb osteoarthritis. It includes five subscales: physical activities, mental health, pain, social support, social functioning; with three additional independent items addressing sexual life, professional life, and fear of being dependent. The numerical rating scales in the items range from 0 (worst) to 10 (best). Scores were obtained by computing the means of the item scores in each subscale. The last three items' score (independent items) becomes the corresponding score.
75539896|NCT04587232|Diagnostic Test|Nottingham Health Profile|Standardized questionnaire to investigate the health-related quality of life. NHP is a general is used to measure health problems perceived by the patient. It comprises 6 sections. The sum of the items within each section ranges from 0 to 100, and the total score ranges from 0 to 600. The higher score shows a worse quality of life.
75539897|NCT04587232|Diagnostic Test|Short form 36|Standardized questionnaire to investigate the general health-related quality of life. The SF-36 questionnaire is a generic quality of life questionnaire and consists of 8 subscales, with 36 items. The scores ranges from 0 to 100 and the high score indicates good health.
75539898|NCT04587232|Diagnostic Test|Western Ontario and McMaster|Standardized questionnaire to investigate the health status of patients with osteoarthritis. The WOMAC OA index assesses the symptomatic severity and disability with pain, stiffness, and physical function domains. Each subscale was summated to a maximum score of 20, 8, and 68, respectively, with the higher scores corresponding worst health status.
75703878|NCT00620776|Behavioral|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
75703879|NCT00620776|Drug|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
76030150|NCT03961893|Device|standard colonoscope first and G-EYE|Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
76030151|NCT03945669|Procedure|Intramedullary Nailing|fracture fixation of the tibial shaft fracture with an intramedullary nail.
75867520|NCT03592745|Device|Sham Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear. Sham tVNS means the patient is wearing the device, but it is turned off and not delivering current during the treatment. This is a placebo condition, which is used as a study control.
76030152|NCT03945669|Procedure|External Ring fixation|fracture fixation of the tibial shaft fracture with an external ring fixator.
76030153|NCT03940950|Biological|Autologous Adipose-Derived SVF (Stromal Vascular Fraction)|60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.
75539899|NCT00253812|Procedure|flexible sigmoidoscopy|
75539900|NCT04586764|Device|Non-Invasive Cardiac System|Non-Invasive Cardiac System (NICaS, NI Medical, Israel) is a non-invasive hemodynamic monitoring system that records various cardiovascular parameters including stroke volume, cardiac output, cardiac index (CI), total peripheral vascular resistance, body water content, and cardiac power index, a marker of myocardial contractility by employing the principles of the whole body impedance cardiography.
76030154|NCT03940950|Drug|Placebo|Saline control that contains no active ingredient
75378732|NCT03296072|Drug|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
75539901|NCT04586803|Drug|SHR4640|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
75539902|NCT04586608|Dietary Supplement|MCT/ω-3 fatty acids|The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
75539903|NCT04586608|Dietary Supplement|soybean oil-based IVFE|soybean oil-based IVFE
75539904|NCT04586491|Combination Product|Oral care protocol|Oral care protocol
76030155|NCT03938688|Procedure|Mesh placement with Transfascial Sutures|Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
75539905|NCT00223067|Drug|TAIZ|
75539906|NCT04719429|Dietary Supplement|Cricket-derived Protein|Beverage containing 25 g cricket-derived protein
75539907|NCT04719429|Dietary Supplement|Beef-derived Protein|Beverage containing 25 g beef-derived protein
75539908|NCT04586218|Behavioral|Computer guided vasopressor infusion|automated titration of vasopressor infusion to maintain a mean arterial pressure > 65mmHg
76030156|NCT03937635|Biological|Daratumumab|Given IV
76030157|NCT03937635|Drug|Dexamethasone|Given PO
76030158|NCT03937635|Drug|Lenalidomide|Given PO
76030159|NCT03937635|Other|Quality-of-Life Assessment|Ancillary studies
76030160|NCT03937635|Other|Questionnaire Administration|Ancillary studies
75539909|NCT04586218|Behavioral|Manual control of vasopressor infusion|manual adjustments of noradrenaline infusion
75539910|NCT04585867|Drug|Exparel|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
75539911|NCT04585867|Drug|Bupivacaine|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
75539912|NCT00223106|Device|Vaginal Sling|
75867521|NCT02398162|Procedure|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
75378733|NCT03296072|Drug|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
75378734|NCT03182725|Drug|Ivabradine|Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
75378735|NCT03182725|Drug|Placebo|A substance that has no therapeutic effect and will act as a control.
75378736|NCT03216512|Other|Use of Noise Cancelling Headphones|During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
75378737|NCT03185065|Drug|Amantadine|100 mg of amantadine increased to 200 mg of amantadine, if tolerated
75539913|NCT04585828|Device|Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon|The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
75539914|NCT04585828|Device|Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm|The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
75378738|NCT03185065|Drug|Modafinil|100 mg of modafinil increased to 200 mg of modafinil, if tolerated
75378739|NCT03185065|Drug|Methylphenidate|5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
75378740|NCT03185065|Drug|Placebos|1 placebo capsule increased to max of 2 capsules twice daily
75867522|NCT02398162|Procedure|Single Blood Collection|On the enrollment day
75867523|NCT03165838|Behavioral|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
75867524|NCT03165838|Behavioral|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
75867525|NCT02398006|Other|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
75867526|NCT02398006|Other|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
75867527|NCT03592277|Drug|Vitamin C|Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).
76030161|NCT03933176|Procedure|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
75378741|NCT03419780|Biological|Blood Transfusion|Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
75378742|NCT05406271|Diagnostic Test|Intraoperative fluoroscopy|Impantation of hip prosthesis with intraoperative fluoroscopy
75378743|NCT04415671|Biological|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
75378744|NCT04415671|Other|Placebo|Placebo
75378745|NCT04398199|Drug|Hypofractionated Radiation Therapy|The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
75378746|NCT04398199|Radiation|Radiation Boost|Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
75378747|NCT00375739|Drug|PEP005|
75539915|NCT00253851|Drug|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
75539916|NCT04585672|Other|Ammonia infusion|Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
75703880|NCT05479097|Drug|Anti-Hypertensive|Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
75539917|NCT04585555|Device|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
75378748|NCT05406037|Biological|Venous sample|at Day 0, Day 3, Day 7, Day 14, Day 28 (7 ml blood sample collecting on dry tube) D0 = Diagnostic day
75378749|NCT04396249|Device|Active tVNS|One electrode tip is used as their common terminal, and the other two electrode tips are respectively connected to the skin surfaces of the auricle and the external auditory meatus. Each subject will have 10 active tVNS sessions.The active tVNS group will be stimulated with a 2 mA current for 30 minutes.
75378750|NCT04396249|Device|Sham tVNS|Each subject will have 10 sham tVNS sessions.The sham tVNS group will be stimulated with a 2 mA current for 30 minutes. Except for the stimulation site, other parameters are the same as active group.
75378751|NCT03285061|Device|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
75378752|NCT02219334|Device|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
75378753|NCT03285373|Drug|NOAC|New Oral Anticoagulant
75378754|NCT02159040|Drug|Azacitidine|SC or IV AZA at 75mg/m2 7 days/28 day cycle
75378755|NCT02159040|Drug|Azacitidine plus Deferasirox|SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
75378756|NCT03285529|Device|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
75378757|NCT03285529|Device|VICRYL|Vicryl #1
75378758|NCT03189589|Drug|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
75703881|NCT00656019|Drug|Vitamin D|0, 2000, 4000, and 6000 IU per day orally
75867528|NCT03592277|Drug|Vitamin B1|Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
76030162|NCT03924778|Behavioral|DASH diet|brief description
76030163|NCT03924778|Behavioral|standard American diet|describe
75378759|NCT03189589|Drug|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
75378760|NCT02218008|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
75378761|NCT02218008|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
75378762|NCT03216902|Drug|Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
75378763|NCT03216902|Drug|Topical ultra-low dose of DE-126 Ophthalmic Solution|Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
75378764|NCT03216902|Drug|Topical low dose of DE-126 Ophthalmic Solution|Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
75378765|NCT03216902|Drug|Topical medium dose of DE-126 Ophthalmic Solution|Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
75378766|NCT03216902|Drug|Topical high dose of DE-126 Ophthalmic Solution|Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
75378767|NCT03216902|Drug|0.005% Latanoprost Ophthalmic Solution|0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
75378768|NCT03190213|Drug|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
75378769|NCT03190993|Other|Sugar Sweetened Solid Treatment|Consume Sugar Sweetened Solid Treatment (product) daily.
75378770|NCT03190993|Other|Sugar Sweetened Beverage Treatment|Consume Sugar Sweetened Beverage Treatment (product) daily.
75539918|NCT04585282|Behavioral|Plus Cognitive behavioral therapy of insomnia（CBT-I plus）|Cbt-i plus program is an enhanced version of cbt-i program, which increases the response to depression and anxiety symptoms.
75703882|NCT04282226|Device|active transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.
76030164|NCT03922971|Other|Option 1: National comparison|Ability to view center's rate compared with all others.
75539919|NCT04585282|Behavioral|Cognitive behavioral therapy of insomnia（CBT-I）|Cognitive behavioral therapy of insomnia is mainly aimed at correcting the bad behaviors and beliefs among the maintenance factors of insomnia, which is considered as the first-line treatment program of insomnia disorder. Cognitive behavioral therapy of insomnia mainly includes five important components: sleep restriction, secondary control, cognitive therapy, relaxation therapy and sleep hygiene.
75867529|NCT02398084|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
76030165|NCT03922971|Other|Option 2: National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
76030166|NCT03921554|Drug|Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
76030167|NCT03892044|Drug|Duvelisib|Given PO
75539920|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
75539921|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
75539922|NCT00249912|Drug|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
75867530|NCT03730805|Behavioral|ASSIST-linked Brief Intervention|The intervention follows the WHO's ASSIST-linked Brief Intervention (Humenik et al., 2012; Humeniuk et al., 2010), a manualized one-session intervention that can be categorised as belonging to the Screening and Brief Intervention approach. It follows the FRAMES model (Bien et al., 1993) and contains techniques from Motivational Interviewing (Miller & Rollnick, 1991).
75867531|NCT03730805|Behavioral|Induction of Deliberative Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer & Keller, 2016), a brief writing task (writing down pros and cons for an unresolved personal problem of the participant's own choice) is used to induce a specific psychological state in which the individual is cognitively open to process new information.
75539923|NCT04585438|Drug|Diclofenac Potassium|The drug will be used as a transparent disc applied to the mucosa
76030168|NCT03892044|Biological|Nivolumab|Given IV
76030169|NCT03891953|Drug|DKY709|Novel immunomodulatory agent
76030170|NCT03891953|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
76030171|NCT03886038|Biological|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
75539924|NCT00567853|Device|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
75867532|NCT03730805|Behavioral|Induction of Implemental Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer & Keller, 2016), a brief writing task (writing down steps necessary to implement a personal decision of the participant's choice that has not yet been put into practice) is used to induce a specific psychological state in which the individual is cognitively not open to process new information.
75867533|NCT03167866|Behavioral|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
75867534|NCT03167866|Behavioral|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
75867535|NCT03734471|Device|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
75867536|NCT03734471|Procedure|Tube thoracostomy|Traditional chest tube placement
75867537|NCT03730727|Behavioral|Physical activity|Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
76030172|NCT03869749|Behavioral|Learning to BREATHE Plus|Activities include psycho-education about stress and emotion regulation, and practices of body scanning, non-aerobic yoga, and meditation, which are designed to cultivate and provide opportunities to practice present-focused, non-judgmental attention.
75539925|NCT00223223|Drug|Levetiracetam, Keppra|
75539926|NCT00567931|Drug|1-methyl-d-tryptophan|Given orally
75539927|NCT00567931|Other|pharmacological study|Correlative studies
75539928|NCT00567931|Other|laboratory biomarker analysis|Correlative studies
75539929|NCT00567970|Procedure|quality-of-life assessment|
75539930|NCT00567970|Radiation|stereotactic body radiation therapy|
75539931|NCT00568009|Drug|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
75539932|NCT00223301|Drug|Mycophenolate Mofetil (cellcept)|
75539933|NCT04585516|Procedure|endoscopy|Colonoscopy or gastroscopy
75867538|NCT03730727|Dietary Supplement|Meal|Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
75378771|NCT03194503|Device|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
75378772|NCT03219320|Drug|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
75378773|NCT03219320|Drug|Placebo|Matching Placebo capsules.
75539934|NCT04585321|Drug|Diclofenac Sodium 140mg Medicated Plaster|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
76030173|NCT03869749|Behavioral|Health and wellness|The Health Education Wellness Program (modeled after Hey Durham) (Bravender, 2005) will provide didactic information on substance use, nutrition/body image, stress management, exercise, and signs of depression/suicide.
76030174|NCT03868891|Device|EMST150|The EMST150 consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Your child will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, your child will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. You will adjust the resistance of the device each week, take a picture of the device settings, and document exercise sets performed in an exercise diary. These exercises will be performed twice in each nostril 2 times a day until your child's next visit at the MEPL (at least 8 weeks). Each session should take approximately 10-15 minutes, for a total of 30 minutes per day.
76030175|NCT03867851|Drug|IBsolvMIR|Study drug IBsolvMIR
76030176|NCT03867851|Drug|Heparin|Clinical praxis
76030177|NCT03857490|Behavioral|Lower leg heat therapy|Home-based 8 weeks of lower leg repeated heating.
76030178|NCT03851250|Drug|MRx-4DP0004|Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
76030179|NCT03851250|Drug|Placebo|Participants randomised to receive placebo will take it in addition to their regular asthma medication.
75378774|NCT03194737|Device|UroLift System Procedure|Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
75539935|NCT04585321|Drug|Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
75539936|NCT00249951|Drug|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
75703883|NCT04282226|Device|sham transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
75703884|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
75703885|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
75703886|NCT04046367|Behavioral|Prehabilitation|Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.
76030180|NCT03850912|Other|eSyM App Usage|Patients (and/or proxy) will report their cancer-related symptoms and receive tailored feedback via eSyM
76030181|NCT03850912|Other|SASS Questionnaire|"A subset of eSyM+ and eSyM- patients will be asked to complete a research questionnaire called the SASS Questionnaire asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care (see PROMIS, CAHPS, IAM/AIM question banks - Appendices C through G). The questionnaire will stop being administered once 1800 total surveys have been received."
76030182|NCT03832920|Other|Analgesia Nociception Index|A monitor of nociception for patients under general anesthesia
76030183|NCT03827655|Drug|TAK-954 Placebo|TAK-954 placebo-matching intravenous infusion.
76030184|NCT03827655|Drug|TAK-954|TAK-954 intravenous infusion.
76030185|NCT03810651|Other|Proton beam radiation using pencil beam scanning|Proton beam radiation using pencil beam scanning, characterized by Bragg peak dose deposition and high conformality of dose to target regions
76030186|NCT03809780|Drug|Lenalidomide|-high dose: [lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly] -Low dose: [lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly]
76030187|NCT03809780|Drug|Dexamethasone|-high dose: [lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly] -Low dose: [lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly]
76030188|NCT03802604|Biological|Talimogene laherparepvec|Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10^6 PFU/mL. On week 3 (i.e. 21 days [± 2] days), a second talimogene laherparepvec injection will be administered at a dose of 10^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 [± 2] days). The maximum volume for each injection will be 4.0 mL.
76030189|NCT03802604|Drug|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 [± 2] days), for a total of 4 treatment courses.
76030190|NCT03801382|Device|IntelliSpace Cognition (ISC)|Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
75378775|NCT01632150|Biological|Elotuzumab|Powder for solution, 400-mg vials, for infusion
75378776|NCT01632150|Biological|Thalidomide|50-mg capsules administered orally
75378777|NCT01632150|Biological|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
75378778|NCT01632150|Biological|Cyclophosphamide|50-mg tablets administered orally
75378779|NCT03421886|Device|Aerodentis system|The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
75378780|NCT03421886|Device|Invisalign clear aligner system|Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
75378781|NCT03286465|Device|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
76030191|NCT03801382|Diagnostic Test|Paper-Pencil Tests|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
76030192|NCT03800680|Behavioral|Diabetes Management Package (DMP)|"M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~Complete all 24 GlycoLeap lessons and quizzes~Weight Monitoring: Weigh at least once a week.~Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~Medication: Take medications as prescribed."
75378782|NCT03286465|Device|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
75378783|NCT02185014|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
75378784|NCT03297944|Drug|Alprazolam 2mg (2ALP/PLC)|2mg alprazolam administered at night, placebo administered in the morning.
75539937|NCT04585360|Other|Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life|"Realization of specific questionnaires evaluating:~psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire)~fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment)~quality of life (SF36 self-assessment questionnaire)"
75539938|NCT00412997|Drug|LBH589|
75539939|NCT04585048|Behavioral|Integrated Behavioral Therapy for Selective Mutism|Cognitive Behavioral treatment including 24 weekly sessions
75539940|NCT00253929|Drug|Intra-arterial infusion of adenosine|
75378785|NCT03297944|Drug|Alprazolam 1mg (1ALP/PLC)|1mg alprazolam administered at night, placebo administered in the morning.
75378786|NCT03297944|Drug|Alprazolam 0.5mg (0.5ALP/PLC)|0.5mg alprazolam administered at night, placebo administered in the morning.
75539941|NCT00253929|Drug|intra-arterial infusion of caffeine|
75539942|NCT00253929|Drug|intra-arterial infusion of acetylcholine|
75539943|NCT00253929|Drug|intra-arterial infusion of sodium nitroprusside|
76030193|NCT03800680|Behavioral|M-POWER Rewards|A financial incentive program were participants can earn up to 516 M-Points (1 M-Point is equivalent to S$1) over the one-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
76030194|NCT03793361|Drug|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
76030195|NCT03793361|Drug|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
76030196|NCT03786406|Other|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
76030197|NCT03785873|Drug|Nivolumab|Intravenous (IV) infusion
75378787|NCT03297944|Drug|Zolpidem 10mg (ZOL/PLC)|10mg alprazolam administered at night, placebo administered in the morning.
75378788|NCT03297944|Drug|Placebo (PLC/PLC)|Placebo administered at night, placebo administered in the morning.
75378789|NCT03297944|Drug|Alprazolam 1mg (PLC/ALC)|Placebo administered at night, 1mg alprazolam administered in the morning.
75378790|NCT04333004|Drug|Pembrolizumab Combined With Chemotherapy|Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
75378791|NCT03298880|Device|Supine VM VAD|Valsalva strain delivered using VAD
75378792|NCT03298880|Device|Supine VAD manometer|supine Valsalva strain delivered using manometer
75378793|NCT03298880|Other|Modified VM VAD|modified VM using VAD
75378794|NCT03298880|Other|Modified VM Manonmeter|Postural modified position VM using manometer
75539944|NCT00253929|Procedure|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
75539945|NCT04584931|Procedure|coronally advanced flap|flap surgery to achieve root coverage at gingival recession defect
76030198|NCT03785873|Drug|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
76030199|NCT03785873|Drug|5-Fluorouracil|Intravenous (IV) infusion
76030200|NCT03785873|Drug|Leucovorin|Intravenous (IV) infusion
76030201|NCT03783507|Behavioral|Order 1|"Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)"
76030202|NCT03783507|Behavioral|Order 2|"Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)"
76030203|NCT03783507|Behavioral|Order 3|"Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)"
75378795|NCT03219866|Device|Nebulizers|Patients treated and discharged on nebulized bronchodilators
75378796|NCT03219866|Device|Dry Powder Inhaler|Patients treated and discharged on Dry Powder Inhalers
75378797|NCT03219866|Drug|Brovana|Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)
75378798|NCT03219866|Drug|Pulmicort|Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)
75378799|NCT03219866|Drug|Atrovent|Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
75378800|NCT03219866|Drug|Advair Diskus|Subjects will receive a LABA/ICS (Advair Diskus, twice daily)
75539946|NCT04584931|Procedure|restorative intervention|colored composite restoration to camouflage the gingival recession defect
75539947|NCT00223340|Behavioral|Patient Activation and Diabetes Registry|
75539948|NCT04585126|Drug|Intermediate cervical block|Local anesthesia performed in addition to the general anesthesia
75867539|NCT03115138|Other|Correlation between molecular anomalies of the primary tumor and circulating tumor DNA|The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
76030204|NCT03783507|Behavioral|Order 4|"Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)"
76030205|NCT03783195|Other|Sugar drink|A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
75378801|NCT03219866|Drug|Spiriva HandiHaler|Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
75378802|NCT03291379|Drug|BTG-002814|BTG-002814 containing 100 mg vandetanib
76030206|NCT03782064|Drug|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
75378803|NCT03300674|Drug|Hydromorphone|Hydromorphone intravenous infusion
75378804|NCT03300674|Drug|Lidocaine|Lidocaine intravenous infusion
75867540|NCT05665517|Device|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q&A) corpora were formed."
75378805|NCT02184156|Biological|4 mL injection of Ampion|4 mL injection of Ampion
75378806|NCT02184156|Drug|4 mL injection of Placebo|
75867541|NCT03106402|Drug|topical bromfenac sodium hydrate|
75867542|NCT03730571|Device|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
75867543|NCT03106168|Procedure|Extraction of mandibular molar|Patients who require extraction of mandibular molars will be submitted to surgery
75378807|NCT03291613|Other|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
75378808|NCT03300752|Behavioral|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
75378809|NCT03300752|Behavioral|Control Intervention|PCP will provide discussion of healthy lifestyles.
75378810|NCT04059913|Drug|Roxadustat|Roxadustat will be dosed orally per dose and schedule specified in the arm description.
75378811|NCT02158884|Device|IDEO brace|All participants will receive the IDEO brace.
75378812|NCT03220412|Behavioral|Movies with Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
75378813|NCT04028557|Other|Decision Support Systems, Clinical|Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
75378814|NCT03195517|Other|Physical exercise|
75539949|NCT00568048|Biological|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
75539950|NCT00568048|Drug|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
75867544|NCT03734159|Drug|Ropivacaine|Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
76030207|NCT03782064|Biological|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
76030208|NCT03773471|Behavioral|Mobile Health App|ArthritisPower App
75378815|NCT04333069|Procedure|cataract surgery|cataract surgery in form of phaco emulsification or irrigation aspiration
75378816|NCT02158806|Drug|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
75378817|NCT02158806|Drug|Placebo|Matching placebo capsule containing inert bulking agent
75378818|NCT03197389|Drug|Pembrolizumab|Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
75378819|NCT03198871|Drug|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
75378820|NCT03198871|Drug|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
75539951|NCT00249990|Drug|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
75378821|NCT03301298|Drug|SXC-2023|Oral capsule
75378822|NCT03301298|Drug|Placebo oral capsule|Placebo given as oral capsule.
75539952|NCT04584775|Other|Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)|"Acupuncture is a physical treatment modality that uses thin needles to stimulate specific points on the body in order to manipulate neurologic mechanisms to control specific symptoms and/or physiologic processes.~Chinese herbal medicine is a phytotherapeutic treatment modality that uses herbs, minerals and rarely animal products which are orally administered.~Tuina is a form of massage and physical therapy. Chinese dietetics is a nutritional therapy according to the theoretical principle of traditional Chinese medicine."
75539953|NCT04584775|Other|Standard care|Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
75539954|NCT00223379|Procedure|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
75539955|NCT00568165|Procedure|Mobile team|a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
75378823|NCT02157948|Drug|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
75378824|NCT02157948|Drug|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
75539956|NCT00568165|Procedure|Standard care|Standard care
75703887|NCT04046367|Behavioral|Control|Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
75703888|NCT00782483|Device|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
75703889|NCT00782483|Device|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
75867545|NCT03734159|Drug|sodium chloride 0.9%|Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
75867546|NCT02397382|Drug|Guselkumab|Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8.
75703890|NCT00782483|Device|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
75378825|NCT03302767|Other|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
75378826|NCT03220958|Drug|Metoclopramide|Metoclopramide 20mg
75378827|NCT03220958|Drug|Diphenhydramine|Diphenhydramine 25mg
75867547|NCT02397382|Drug|Midazolam|Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
75867548|NCT02397382|Drug|Warfarin|Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
75867549|NCT02397382|Drug|Omeprazole|Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
75867550|NCT02397382|Drug|Dextromethorphan|Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
75378828|NCT03220958|Drug|Normal saline|100ml normal saline
75378829|NCT03420625|Device|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
75378830|NCT03420625|Device|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
75867551|NCT02397382|Drug|Caffeine|Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
75378831|NCT03420625|Device|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
76030209|NCT03772522|Behavioral|dk Leadership|Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
75539957|NCT04584424|Other|The study does not required|The study is prospective multi-center COVID-19 patient cohort
75539958|NCT04584580|Drug|low-molecular-weight heparin|low-molecular-weight heparin administered via subcutaneous injection
75539959|NCT00250029|Drug|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion & the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 & the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
75539960|NCT04584658|Diagnostic Test|Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.
75378832|NCT03420625|Device|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
76030210|NCT03764488|Drug|Tofersen|Administered as specified in the treatment arm.
76030211|NCT03764488|Drug|99mTc-MAG3-BIIB067|Administered as specified in the treatment arm.
76030212|NCT03764293|Drug|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
75378833|NCT03221192|Other|VAS questionnaire|VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, >3-7 (or >30-70) as moderate disease and >7-10 (or >70-100) as severe disease.
75378834|NCT03221192|Other|SNOT-22 questionnaire|SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
75539961|NCT04584658|Diagnostic Test|Videofluoroscopy|A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.
75867552|NCT02397304|Other|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
75867553|NCT04869826|Device|Pulsewave Health Monitor (PAD-2A) Device|This is an observational, comparison study of blood pressure measurements. The objective of this study is to calibrate the blood pressure measurements of the Pulsewave Health Monitor (PAD-2A) device to be within 5±8 mmHg of the average of the dual-observer auscultatory blood pressure measurements via an aneroid sphygmomanometer (reference device), as per the ISO 81060-2: AMD_2020 universal protocol.
75703891|NCT02573090|Procedure|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
75867554|NCT03401112|Drug|IMR-687|Oral administration of IMR-687 once daily with or without HU.
75867555|NCT03401112|Drug|Placebo|Oral administration of placebo once daily with or without HU.
76030213|NCT03764293|Drug|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
75539962|NCT04584658|Other|Dysphagia Handicap Index (DHI)|This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
76030214|NCT03764293|Drug|Sorafenib|Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
75378835|NCT03221192|Other|Data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
75378836|NCT02182830|Drug|Empagliflozin low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
75378837|NCT02182830|Drug|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
75378838|NCT02182830|Drug|Empagliflozin high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
75378839|NCT03424681|Drug|Modafinil|Modafinil 300 mg by mouth daily
75378840|NCT03424681|Other|Placebo|Placebo
75378841|NCT03305653|Device|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
75378842|NCT03431012|Other|Agency Assignment framing|Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch…') or the pandemic flu virus itself (VA: 'It can infect you when you touch…')
75378843|NCT03431012|Other|Attribute framing|Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
75867556|NCT02697916|Drug|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
76030215|NCT03763708|Device|Spinal Cord Stimulation|Programming
76030216|NCT03761160|Other|Mobile Health App|mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit
76030217|NCT03761160|Other|Usual care|Usual care per hospital guidelines
76030218|NCT03755518|Drug|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
75703892|NCT02573090|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
75867557|NCT04866316|Other|There is no active intervention as this is a service evaluation|There is no active intervention as this is a service evaluation
76030219|NCT03753490|Other|ABC score guided therapy|In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.
76030220|NCT03753490|Other|Standard care|In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
75378844|NCT03427177|Behavioral|mychoice|The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
75378845|NCT03302780|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
75378846|NCT03302780|Device|tDCS active|tDCS will be applied for 20 minutes.
76030221|NCT03747042|Drug|Letrozole|Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.
75378847|NCT03302780|Device|tDCS sham|
75378848|NCT04332848|Drug|ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
75378849|NCT04332848|Drug|SGT|Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
75539963|NCT04584658|Other|Voice Symptom Scale (VoiSS)|This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.
75867558|NCT04762680|Biological|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
75378850|NCT03305887|Device|"STRATAFIX™ Symmetric Knotless Tissue"|This devices will be used in deep and intermediate layers of barbed suture group.
75378851|NCT03305887|Device|VICRYL® PLUS|This devices will be used in deep and intermediate layers of conventional suture group.
75378852|NCT03305887|Device|"STRATAFIX Spiral sutures"|This devices will be used in intradermal layer of both barbed suture and conventional suture group.
75378853|NCT03305887|Device|DERMABOND™ Advance™ Skin Closure System|This devices will be used in skin layer of both barbed suture and conventional suture group.
75378854|NCT03221738|Behavioral|App-Based Cognitive Behavioral Therapy|12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
75539964|NCT00223418|Drug|aripiprazole|
75539965|NCT04584697|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
75867559|NCT04762680|Biological|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
75539966|NCT04584697|Drug|Placebo|Diluent solution
75539967|NCT04584736|Drug|Livalo, Ezetrol|Pitavastatin+Ezetimibe Pitavastatin
75539968|NCT00250068|Drug|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
75539969|NCT04584268|Behavioral|mindfulness|in person and smart phone application mindfulness practice
76030222|NCT03739112|Biological|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
76030223|NCT03739112|Biological|Fluarix Quadrivalent® Comparator Vaccine|Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
76030224|NCT03738072|Diagnostic Test|StiMiC stimulation condition|This new condition of stimulation of electrical Brain Stimulation will be evaluate to determine if this stimulation is more efficient that standard stimulation condition
76030225|NCT03724071|Biological|TG6002|"Phase I, Arm A: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU; Phase I, Arm B: Dose escalation from 1 x 10E9 PFU to 1 x 10E10 PFU; Phase II: Established recommended Phase II dose (RP2D)~Administration intravenously on Days 1, 8 and 15 (Phase I, Arm A) or on Days 1, 3 and 5 (Phase I, Arm B). Three intravenous infusions at the Dose Recommended for Phase 2 (RP2D) in Phase IIa.~An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake."
76030226|NCT03724071|Drug|Flucytosine (5-FC, Ancotil)|"Administered orally at a dose of 200 mg/kg/day for a total of 10 days (Phase I, Arm B) or 16 days (Phase I, Arm A).~An extension of the cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms."
76030227|NCT03709446|Drug|Leflunomide|Single agent leflunomide
76030228|NCT03708965|Drug|JR-141|IV infusion (lyophilized powder)
76030229|NCT03708809|Device|Intrauterine system|13.5 mg levonorgestrel-releasing intrauterine system
75539970|NCT04584268|Other|standard medical education|standard medical education / control
75539971|NCT04584307|Drug|Elotuzumab|Elotuzumab 10-20mg/kg
75539972|NCT04584307|Drug|Pomalidomide|Pomalidomide 2mg
75539973|NCT00223457|Behavioral|Factors that influence compliance|
75539974|NCT04720521|Diagnostic Test|OE+white light|Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus
75539975|NCT04584034|Drug|Salbutamol|Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate. Ventolin contains the propellant HFA 134a.
75539976|NCT04584034|Drug|Placebo|The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
75539977|NCT04584229|Other|Intervention|Intervention: comprehensive individual or collective interview, recorded and transcribed
76030230|NCT03708809|Other|Alternative contraception to intrauterine system|Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
75539978|NCT04584073|Procedure|Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application|Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
75539979|NCT00223535|Behavioral|Cognitive Remediation|
75539980|NCT00223535|Behavioral|Social Skills Training|
75539981|NCT00250146|Behavioral|Gluten (behaviour)|
75539982|NCT04583722|Dietary Supplement|AX-olive oil-PP emulsion|single dose and plasma samples
75539983|NCT04583683|Behavioral|Very low calorie diet with Fortimel (Nutricia) supplementation|Patients will undergo a very low calorie diet
75378855|NCT03306199|Device|Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
75539984|NCT04583683|Procedure|Metabolic Surgery|Patients will undergo metabolic surgery
75539985|NCT04583605|Device|PREVENA|A negative pressure wound closure therapy is used after lymph node dissection
75867560|NCT04762680|Biological|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
76030231|NCT03705910|Other|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
75378856|NCT03303404|Device|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
75378857|NCT03224390|Other|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
75378858|NCT03303794|Drug|Exparel|1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
75378859|NCT03303794|Drug|0.25% bupivacaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
75378860|NCT03304106|Device|Commercially available cochlear implant and AI system|Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
75378861|NCT03305822|Drug|LY900014|Administered SC
76030232|NCT03705910|Other|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
76030233|NCT03701646|Device|Measurement by Clearsight device|Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
76030234|NCT03689296|Other|Questionnaires (Phase 3)|"CardioVascular Risk (CVR) questionnaire representation~SF12~Getting Better My Way~My recovery plan~Psycom~Partner In Health scale"
76030235|NCT03689296|Other|Focus groups (Phase 2)|Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.
75378862|NCT03305822|Drug|Insulin Lispro|Administered SC
75378863|NCT04706858|Dietary Supplement|Dietary fiber supplementation|Randomization to the order of first fiber: either inulin or arabinoxylan. Third cycle will include a mix of 5 fibers: inulin, arabinoxylan, resistant starch, glucomannan, and acacia gum.
75378864|NCT04706702|Behavioral|Tele-EnhanceFitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
75378865|NCT03435614|Drug|Opioids|Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
75378866|NCT03437564|Drug|Vortioxetine|Vortioxetine tablet
75539986|NCT04583566|Genetic|COVID-19 Diagnostic and Assessment Tests|Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
75539987|NCT04583410|Drug|Nicotine patch|"NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
75378867|NCT03438266|Device|JUVÉDERM VOLUMA® XC injectable gel with cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
75378868|NCT03438266|Device|JUVÉDERM VOLUMA® XC injectable gel with needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
75539988|NCT04583410|Drug|Placebo patch|"PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
76030236|NCT03689296|Other|semi-structured interviews (Phase 1)|Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist
76030237|NCT03679338|Device|Ablation Therapy|Ablation Therapy With Bipolar Radio frequency
76030238|NCT03671525|Drug|Nimodipine|Subject will receive two 30mg capsules of nimodipine during study visit.
76030239|NCT03671525|Drug|Placebo oral capsule|Two coconut oil capsules that mimic the size and color of the nimodipine capsules
76030240|NCT03653611|Other|On-site Practice Assessment|The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
76030241|NCT03653611|Other|Clinical Staff Questionnaires|"Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff."
76030242|NCT03653611|Other|Patient Opinion Surveys|200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
76030243|NCT03653611|Other|Modular online COPD Education|Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
76030244|NCT03653611|Other|COPD in Primary Care/CAPTURE Introduction Focus Groups|Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
76030245|NCT03648437|Drug|Paracetamol 10Mg/mL|Experimental drug
76030246|NCT03648437|Drug|0.45% Sodium Chloride|Placebo comparator
76030247|NCT03648437|Drug|Ibuprofen|Standard therapy
75539989|NCT00223574|Drug|Control - high carbohydrate, high glycemic index foods|
75539990|NCT00223574|Drug|high carbohydrate, low glycemic index foods|
75539991|NCT00223574|Drug|low carbohydrate, high monounsaturate fat foods|
75539992|NCT00254007|Drug|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
75539993|NCT00223613|Drug|daily intranasal administration of insulin|
75539994|NCT04583293|Other|No intervention|This study does not involve any intervention or new treatment.
75867561|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
75867562|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
76030248|NCT03648437|Drug|Indomethacin|Standard therapy
76030249|NCT03646058|Drug|Buprenorphine|Buprenorphine, 0.4mg pills, sublingual
76030250|NCT03646058|Drug|Placebo|Placebo pills, sublingual, specifically made to mimick buprenorphine pills
76030251|NCT03643042|Other|Transfusion|Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
76030252|NCT03622593|Drug|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
76030253|NCT03622593|Drug|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
76030254|NCT03622593|Procedure|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
76030255|NCT03620058|Biological|CART22-65s cells|Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
76030256|NCT03620058|Biological|huCART19 Cells|Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB
75378869|NCT03438578|Device|Efficacy Safety Score monitoring|According to data gathered from ESS and monitoring, the patients will receive needed care.
75378870|NCT03315104|Biological|FLU-IGIV|Single dose, sterile liquid formulation for IV administration.
75539995|NCT04583371|Other|MECHANICAL PULMONARY HYPERINFLUATION|For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique. In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the same way as baseline aspiration, in assisted-controlled pressure ventilation, increasing 10 cmH2O in inspiratory pressure and, in ventilatory mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, observing the peak that cannot exceed 40 cmH2O in both ventilation modes, and then three aspirations will be performed for 15 seconds and with an interval of 30 seconds.
75539996|NCT04583332|Other|Rhymes|"Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
75539997|NCT04583332|Other|Individual Items in Rhymes|"Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
75539998|NCT04583332|Other|Objects|Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
75539999|NCT04583137|Drug|Lidocain|Layngeal direct fiberoptic examination transnasaly
75540000|NCT00223691|Drug|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
75540001|NCT00223691|Drug|Acarbose|25-100 mg, PO. Single dose.
75540002|NCT00223691|Drug|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
75540003|NCT00223691|Drug|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
75540004|NCT00223691|Drug|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
75540005|NCT00223691|Drug|placebo|PO.Single dose.
75540006|NCT00223691|Drug|Modafinil|50-400 mg PO. Single dose
75540007|NCT00223691|Drug|Octreotide|5-50 µg, S.C. Single dose.
75540008|NCT00223691|Other|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
75540009|NCT00223691|Drug|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
75540010|NCT00223691|Drug|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
75540011|NCT00223691|Drug|Tranylcypromine|5 - 40 mg PO. Single dose
75378871|NCT03315104|Other|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration.
75378872|NCT03228914|Drug|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
75378873|NCT03228914|Drug|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
75378874|NCT03315572|Other|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
75378875|NCT03315572|Other|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
75378876|NCT03315572|Other|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
75378877|NCT03232580|Drug|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
75378878|NCT03316976|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
75378879|NCT03317288|Device|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
75378880|NCT03317444|Drug|TRC101|Oral suspension
75378881|NCT03317444|Drug|Placebo|Oral suspension
75378882|NCT03442868|Device|high frequency rTMS|Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
75378883|NCT03234374|Combination Product|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
75378884|NCT03234374|Drug|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
76030257|NCT03618186|Combination Product|Tau PET scan|Patient will receive a dose of flutaucipir and be scanned appropriately
76030258|NCT03614260|Device|Paradise Renal Denervation System|Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
76030259|NCT03614260|Procedure|Renal Angiogram|Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure.
76030260|NCT03602066|Drug|Chlorine Dioxide Sterilization|Given via oral rinse
75378885|NCT04332536|Other|Exercise with and without Codeine|This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
75378886|NCT03236168|Drug|Ivermectin|A single weight based dose of ivermectin
75378887|NCT03236168|Drug|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
76030261|NCT03602066|Other|Laboratory Biomarker Analysis|Correlative studies
76030262|NCT03602066|Other|Placebo|Given via oral rinse
76030263|NCT03593655|Device|Dapivirine vaginal ring|Vaginal ring containing 25 mg of dapivirine
76030264|NCT03593655|Drug|FTC/TDF|Tablet containing 200 mg FTC/300 mg TDF
76030265|NCT03591133|Drug|TS-143|
76030266|NCT03591133|Drug|Placebo|
76030267|NCT03577106|Device|Transcranial magnetic stimulation (TMS)|Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
76030268|NCT03572530|Drug|5-Azacytidine (5-AZA) group 1|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
76030269|NCT03572530|Drug|5-Azacytidine (5-AZA) group 2|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
76030270|NCT03572530|Drug|5-Azacytidine (5-AZA) group 3|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks."
75378888|NCT03236168|Drug|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
75378889|NCT03306589|Biological|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
75378890|NCT03306589|Biological|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
75378891|NCT03306589|Biological|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
75378892|NCT03306589|Drug|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
75378893|NCT03320096|Device|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
75378894|NCT03309787|Behavioral|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
75378895|NCT00376207|Behavioral|Physical exercise|
75378896|NCT03446846|Drug|MIN-117 5.0 mg|5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
75378897|NCT03446846|Drug|MIN-117 2.5 mg|2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily
75378898|NCT03446846|Drug|Placebo|Placebo administered as two Placebo capsules as a single dose once daily
75378899|NCT03312517|Drug|Suvorexant 10 mg|Subject will receive suvorexant 10mg
75378900|NCT03312517|Drug|Suvorexant 20 mg|Subject will receive suvorexant 20mg
75540012|NCT00223691|Drug|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
75540013|NCT00223691|Drug|Celecoxib|50-200 mg PO. Single dose
75378901|NCT03312517|Drug|Placebo oral capsule|Subject will receive placebo.
75378902|NCT03449342|Drug|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
75540014|NCT00223691|Drug|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
75540015|NCT00223691|Drug|Methylphenidate|5 or 10 mg PO. Single dose.
75378903|NCT03312595|Device|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
75378904|NCT03315559|Drug|[14C]-GSK2269557 IV infusion|The [14C]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
75378905|NCT03315559|Drug|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
75540016|NCT00223691|Drug|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
75703893|NCT04798521|Other|Tele-HCV|Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
75540017|NCT00223691|Drug|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
75540018|NCT00223691|Drug|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
75540019|NCT00223691|Dietary Supplement|Bovril|6-10 g, PO. Single dose.
75703894|NCT04798521|Other|Community Linkage to Care|Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
75378906|NCT03315559|Drug|[14C]-GSK2269557 oral solution|The [14C]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving [14C]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
75378907|NCT03239522|Drug|[14C]-GSK1278863 solution for IV infusion|It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of [14C]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
75378908|NCT03239522|Drug|[14C]-GSK1278863 oral solution|It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of [14C]-GSK1278863 oral solution (total dose: 25 mg).
75378909|NCT03239522|Drug|Daprodustat 6 mg oral tablet|It is a 9.0 millimeter (mm) round, white film coated tablet.
75378910|NCT03315949|Drug|Polyethylene Glycol (PEG)|Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
75867563|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
75867564|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
75867565|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
75378911|NCT03241862|Device|Restylane® Silk|Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
75378912|NCT04332770|Other|levothyroxine withdrawal|All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
75378913|NCT03328208|Other|Comfort Talk® app|Test app
75378914|NCT03328208|Other|White Noise app|White Noise app built to mimic appearance of Comfort Talk® test app
75378915|NCT03210337|Drug|A-101 Topical Solution|A-101 Topical Solution
75378916|NCT03210337|Drug|A-101 Vehicle Solution|A-101 Vehicle Solution
75378917|NCT03242408|Drug|LPCN 1021|Oral testosterone undecanoate
75540020|NCT00223691|Drug|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
75540021|NCT00223691|Drug|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
75540022|NCT00223691|Drug|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
75540023|NCT00223691|Device|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
75540024|NCT00223691|Device|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
75867566|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
75867567|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
75867568|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
75867569|NCT02392312|Drug|ATF-Fresenius S|intravenous
75378918|NCT03242954|Other|Autonomous minor consent|Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
75703895|NCT05505227|Behavioral|Stigma-reduction training|While the details will be finalized by the intervention working group after the key modifiable features of OUD-stigma among rural HCPs are isolated in Aim 1, our intervention will include several new elements that distinguish it from existing stigma-reduction interventions. The prototype intervention includes several modules aimed at decreasing stigma, increasing knowledge about medications for OUD, and increasing willingness to prescribe buprenorphine (see Table 3) among rural HCPs currently in practice.
75703896|NCT05505227|Behavioral|Placebo|HCPs affiliated with clinics in the control arm will receive no training but will be provided with a link to the SAMHSA website where prescribers can learn more about buprenorphine prescribing and apply to receive an X-waiver.
75867570|NCT03115216|Procedure|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
75378919|NCT03242954|Other|Adult permission required|Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
75378920|NCT03242954|Other|Parental permission required|Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
75378921|NCT03459794|Drug|Ivermectin|150 mcg/kg ivermectin, by mouth.
75378922|NCT03459794|Other|Placebo|An oral placebo will be administered, once
75378923|NCT03211117|Drug|Docetaxel|Given IV
75378924|NCT03211117|Drug|Doxorubicin Hydrochloride|Given IV
75378925|NCT03211117|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75378926|NCT03211117|Other|Laboratory Biomarker Analysis|Correlative studies
75378927|NCT03211117|Biological|Pembrolizumab|Given IV
75703897|NCT02546830|Device|FreeO2 v2.2 active|"Automatic adjustment of oxygen through the Free O2 device.~FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
75378928|NCT03211117|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75378929|NCT03436147|Other|POP-Q|Pelvic Organ Prolapse Quantification
75378930|NCT03245372|Procedure|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
75378931|NCT03245372|Procedure|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
75540025|NCT04583020|Drug|Camrelizumab|Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
75867571|NCT03115216|Procedure|CEIOL|Manual cataract extraction and intraocular lens placement
75867572|NCT01310153|Procedure|prone positioning|newborn babies in prone positioning
75378932|NCT03317431|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
75378933|NCT00376285|Drug|CP-742,033|
75378934|NCT00376285|Drug|Fenofibrate|
75378935|NCT03460652|Drug|KP415 oral capsule|Once-daily oral dose
75378936|NCT03321097|Device|condensed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
75378937|NCT03321097|Device|distributed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
75378938|NCT03245762|Drug|Oxytocin|4 IU/day of oxytocin administered via nasal spray device each morning.
75867573|NCT01310153|Procedure|Supine|newborn babies in supine positioning
75867574|NCT02392156|Biological|rFVIIIFc|As described in the treatment arm
75867575|NCT02392156|Biological|rFIXFc|As described in the treatment arm
75867576|NCT02392156|Drug|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
75867577|NCT02392156|Drug|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
75378939|NCT03245762|Drug|Placebo|4 IU/day of placebo administered via nasal spray device each morning
75867578|NCT03115060|Drug|intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE|intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
76030273|NCT03569280|Combination Product|Enzalutamide or Abiraterone or Apalutamid|Antitumor treatment
75378940|NCT03321253|Device|Nd: YAG laser posterior capsulotomy|Nd: YAG laser posterior capsulotomy
75540026|NCT04583020|Radiation|radiation|60Gy/30
75540027|NCT04583020|Drug|Temozolomide|Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
75378941|NCT03322657|Drug|Neostigmine|Neostigmine injection
75378942|NCT03322657|Drug|Glycopyrrolate|Glycopyrrolate injection
75378943|NCT03322657|Drug|Sugammadex|Sugammadex injection
75540028|NCT04583059|Other|Taping|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo
75867579|NCT01871220|Device|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
75867580|NCT01871220|Device|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
75867581|NCT03359473|Drug|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
75867582|NCT03359473|Drug|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
76030274|NCT03558087|Drug|Nivolumab|Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
75867583|NCT04831060|Procedure|Periodontal treatment|"For Cases :~Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~Non-surgical periodontal treatment~At 3 months = periodontal reevaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~If periodontal pockets greater than 5mm and bleeding persist: periodontal surgery and gingival explant sampling~At 3 months post-surgery = periodontal re-evaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~Maintenance~For Controls:~Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~Plastic or pre-prosthetic surgery = gingival explant sampling~Healing control at 15 days"
75378944|NCT03247322|Other|Pharmacist-led medication therapy using mHealth application|This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
75867584|NCT03632304|Procedure|Local anesthesia with minimal sedation|The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
75540029|NCT04582552|Drug|PARP inhibitors|Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
75540030|NCT00568204|Device|Mexyn-A|Atomised topical self-chilled pressurised spray
75867585|NCT02397538|Drug|Fimasartan|
76030275|NCT03558087|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four 21-day cycles.
76030276|NCT03558087|Drug|Cisplatin|Cisplatin 70mg^m2 will be administered on Day 1 for four 21-day cycles.
76030277|NCT03549442|Combination Product|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
75540031|NCT04582747|Diagnostic Test|Urinary Biomarkers (NGAL, DKK-3, IGFBP-7/TIMP-2, KIM-1)|"Validation of Urinary biomarker tests for the rapid prediction of AKI.~No intervention is being proposed as part of the study. Concentrations of Urinary biomarkers will be obtained post operatively. These concentrations will be assessed to ascertain their predictive ability for the development of Acute Kidney Injury post-operatively."
75867586|NCT02397538|Drug|Amlodipine|
75867587|NCT02397538|Drug|Rosuvastatin|
75867588|NCT02397616|Other|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
75867589|NCT01429038|Biological|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
75540032|NCT00223730|Drug|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
75540033|NCT00223730|Drug|Placebo|
75378945|NCT04332679|Device|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
75378946|NCT04332679|Device|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
75378947|NCT03324451|Behavioral|TTM Intervention for Insulin Initiation|The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management. Different intervention strategies are applied to patients according to their stages of change.
75378948|NCT03324451|Behavioral|Usual care|Regular patient education on insulin injection at the control arm hospital.
75378949|NCT03324607|Drug|hyperpolarized 129Xe gas MRI|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
75378950|NCT03324607|Drug|Bevespi Aerosphere|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
75378951|NCT03247790|Drug|Lasmiditan|Administered orally
75378952|NCT03249116|Other|animal-assisted intervention|Interaction with a therapy dog
75378953|NCT03249116|Other|active control|Interaction with a stuffed dog
75867590|NCT02396992|Other|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
75378954|NCT03437863|Device|Mobile application|Use of a mobile application (on a borrowed device) with following features: 1) strengths reflection and identification, 2) summary of registered strengths, 3) defining goals, and 4) linking strengths to goals.
75867591|NCT04418778|Behavioral|BEAR|Building Empowerment and Resilience Therapy group
75867592|NCT03589469|Drug|Loncastuximab tesirine|intravenous infusion
75378955|NCT03467048|Device|McGrath videolaryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
75378956|NCT03467048|Device|Direct laryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
75378957|NCT03249272|Drug|Regadenoson|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
75378958|NCT03249272|Drug|Adenosine|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
75378959|NCT03249584|Device|OsteoCool™ RF Ablation|The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
75540034|NCT04582630|Dietary Supplement|omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
75540035|NCT04582786|Drug|Morphine|Repeated bolus according to pain score
75540036|NCT04582786|Drug|Morphine HCl|Infusion of morphine HCl solution for intravenous administration
75867593|NCT03734081|Device|ODC system (type 1 capsule)|ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
76030278|NCT03549442|Combination Product|CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive CART-BCMA + huCART19. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
76030279|NCT03549442|Combination Product|Single-dose infusion of CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA + huCART19. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
76030280|NCT03549442|Combination Product|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
75540037|NCT04582786|Drug|STR-324|Infusion of solution for intravenous administration
75540038|NCT04582513|Other|AnCHor-Checklist implementation|a standardized checklist using the SBAR concept according to the recommendations of the DGAI
75540039|NCT00223769|Drug|Oxandrolone|
75540040|NCT04583449|Behavioral|Mental imagery|"Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery)."
75540041|NCT04582474|Other|Dengue module and rapid diagnostic tests|Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines
75867594|NCT03734081|Device|ODC system (type 2 capsule)|ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
75867595|NCT03359395|Drug|Alfentanil|Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
75867596|NCT03359395|Drug|Placebos|Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
75867597|NCT03734003|Device|liquid nitrogen|As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
75867598|NCT03734003|Device|controllable infrared bioeffect system|As an experimental arm, for patients with cutaneous warts
75378960|NCT02182440|Biological|recAP|One hour infusions once daily for three days
75540042|NCT04582123|Procedure|crossed pin configuration|comparison of two crossed pin fixation methods
75540043|NCT04582084|Drug|Etanercept|Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
75540044|NCT00254046|Drug|TMC125|2 X100 mg tablets b.i.d.96 weeks
75540045|NCT00254046|Drug|Placebo|2 tablets b.i.d.96 weeks
76030281|NCT03542695|Procedure|Computed Tomography|Undergo PET/CT
75378961|NCT02182440|Other|Placebo|1 hour IV infusion once daily for 3 days
75378962|NCT03255902|Behavioral|Parenting classes|Parenting Classes:The Incredible Years curriculum
75378963|NCT03468920|Drug|IV Acetaminophen|IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
75378964|NCT03468920|Drug|PO Acetaminophen|Acetaminophen PO 1000mg once pre-operatively
76030282|NCT03542695|Drug|Copper Cu-64-DOTA-alendronate|Given IV
76030283|NCT03542695|Other|Pharmacokinetic Study|Correlative studies
76030284|NCT03542695|Procedure|Positron Emission Tomography|Undergo PET/CT
75540046|NCT00568360|Device|Oximeter|
76030285|NCT03541876|Other|Collection of data|"The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control."
75378965|NCT03468920|Drug|PO Placebo|PO placebo capsule compounded to match PO Acetaminophen capsule
75378966|NCT03468920|Drug|IV Solution Placebo|This will serve as the placebo for the IV Acetaminophen intervention
75378967|NCT03470012|Device|Multi-Purpose Gentle Tape|The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.
75378968|NCT04758624|Device|Deep Brain Stimulation|Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
75378969|NCT03339206|Behavioral|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
76030286|NCT03524183|Behavioral|Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
75540047|NCT00223847|Behavioral|Constraint Induced Language Therapy|
75540048|NCT04582162|Other|Unsplinted implants|Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.
75540049|NCT04582162|Other|Splinted implants|Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
75540050|NCT04582396|Procedure|stellate ganglion block injection|A stellate ganglion block (SGB) is an injection of local anesthetic (numbing medicine) to block the nerves located on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
75540051|NCT04582396|Procedure|Normal saline injection|An injection of normal saline will be injected into muscle on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
76030287|NCT03512405|Biological|Blinatumomab|Given IV
76030288|NCT03512405|Other|Laboratory Biomarker Analysis|Correlative studies
76030289|NCT03512405|Biological|Pembrolizumab|Given IV
76030290|NCT03508934|Device|GTS (Continuous Glucose Monitoring)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
76030291|NCT03508934|Other|POC (Point of Care)|Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
76030292|NCT03506594|Device|Radiofrequency non ablative|The application of RF was performed by physical therapist trained in the technique of radiofrequency through the Capenergy® brand device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41graus radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
76030293|NCT03500107|Device|Blue Light Emitting Diode (LED) 401 +/- 5nm|The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
76030294|NCT03491215|Drug|Ruxolitinib|Ruxolitinib taken orally (5mg tablets) or oral pediatric formulation and dosage based on age group
76030295|NCT03490565|Behavioral|Exercise training|Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
76030296|NCT03458416|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
75703898|NCT02546830|Device|FreeO2 v2.2 with manual oxygenation|"Manual adjustment of oxygen without the assistance of the FreeO2 device.~Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
76030297|NCT03441308|Behavioral|Educational method of group treatment|
76030298|NCT03441113|Drug|MMB|Tablet(s) administered orally once daily
76030299|NCT03430219|Device|Subchondroplasty Procedure|AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
76030300|NCT03428009|Other|Magnetic Resonance Imaging|Study interventions are minimal risk.
75378970|NCT03339206|Behavioral|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
75378971|NCT03339206|Behavioral|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
76030301|NCT03419234|Drug|Abiraterone Acetate|Given PO
75378972|NCT02181816|Drug|Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets LD & HD
75378973|NCT03256136|Drug|Carboplatin|Chemotherapy
75378974|NCT03256136|Drug|Nivolumab|will allow the body's immune system to work against tumor cells
75378975|NCT03256136|Drug|pemetrexed|Chemo therapy
75378976|NCT03256136|Drug|Ipilimumab|will allow the body's immune system to work against tumor cells
75378977|NCT04735328|Behavioral|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
75703899|NCT00802269|Procedure|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
75703900|NCT02601443|Device|Cervical Pessary|
76030302|NCT03419234|Drug|Antiandrogen Therapy|Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
76030303|NCT03419234|Drug|Cabazitaxel|Given IV
76030304|NCT03419234|Other|Laboratory Biomarker Analysis|Correlative studies
76030305|NCT03419234|Procedure|Orchiectomy|Undergo standard of care surgical castration with bilateral orchiectomy
76030306|NCT03419234|Other|Pharmacological Study|Correlative studies
76030307|NCT03419234|Drug|Prednisone|Given PO
75867599|NCT03730493|Behavioral|Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
75378978|NCT04735328|Behavioral|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post Traumatic Stress Symptoms (PTSD).
75867600|NCT03730415|Procedure|Viscoelastic (VE) Guided Transfusion|A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
76030308|NCT03388242|Other|No intervention|Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
75378979|NCT04735328|Behavioral|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
76030309|NCT03364231|Drug|Umbralisib|Oral Daily Dose
75378980|NCT03260426|Dietary Supplement|Clear Liquids|Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
75378981|NCT03260426|Dietary Supplement|Regular Solid|Regular diet from postoperative day zero immediately upon return to floor and onwards
75378982|NCT03260426|Device|Abstats|Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
75378983|NCT03340610|Drug|Alflibercept|Intravitreal Injection
75867601|NCT05364307|Other|Prescreener database|Identify and characterize participants with reported memory complaints and/or cognitive impairment to determine the probability of randomization into a therapeutic AD clinical trial.
76030310|NCT03343093|Behavioral|Restore Rehabilitation Program|Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment
76030311|NCT03343093|Behavioral|Control|usual care, surveys every 3 months
76030312|NCT03335228|Device|Eclipse Easy Spin for PRP|Autologous platelet rich plasma is prepared from subject's blood with the Eclipse Easy Spin centrifuge and injected into affected areas.
76030313|NCT03303625|Biological|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1*10^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
76030314|NCT03303625|Biological|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5*10^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
76030315|NCT03303625|Drug|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
76030316|NCT03299816|Behavioral|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
76030317|NCT03299816|Behavioral|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
75540052|NCT04582396|Behavioral|Psychoeducation|"The session will be 30 minutes in duration, to be administered by a health professional with experience working with CA patients, the goal will be to establish rapport and help patient identify anxious situations, thoughts, and bodily feelings related their recent CA that could lead to avoidant behavior.~Explain how many of these feelings are common in CA survivors, and they are often unrelated to their risk of its recurrence. Explain how the body has a fight-or-flight system that is controlled in part by the stellate ganglion and explain how blocking the action of this part of the body can reduce the feelings of anxiety that commonly occur. Discuss how certain activities such as exercise can increase feelings of anxiety around bodily sensations, but continued engagement could reduce that fear and that exercise is helpful for recovering from CA"
75867602|NCT03586427|Drug|AGN-241751|AGN-241751 administered orally as a single tablet
75378984|NCT03341546|Other|A single measurement of the patient's abdominal depth|A single measurement of the patient's anterior-posterior abdominal depth
75378985|NCT03344510|Device|Kinetic Anesthesia Device|A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain
75867603|NCT03586427|Drug|Placebo|Placebo administered orally as a single tablet
76030318|NCT03297554|Behavioral|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
76030319|NCT03288493|Biological|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated."
75378986|NCT03344510|Other|Control|One injection will be administered without the kinetic anesthesia device.
75378987|NCT03264092|Procedure|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
75378988|NCT03346850|Device|Nasogastric tube (NGT) feeding|A nasogastric tube goes from the nose to the stomach.
75378989|NCT03346850|Device|Nasoduodenal tube (NDT) feeding|A nasoduodenal tube goes from the nose to the duodenum.
75540053|NCT04582240|Other|no intervention|no intervention
75867604|NCT03733769|Procedure|transmuscular quadratus lumborum block|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
75867605|NCT03648983|Procedure|arm circumference measurement|Undergo arm circumference measurement
75867606|NCT03648983|Device|Bioimpedance spectroscopy|bioimpedance spectroscopy
75867607|NCT05666453|Biological|LIV-GAMMA SN Inj.|LIV-GAMMA SN Inj. is administered at a dose of 0.6 g/kg/day from anhepatic phase to Day 2 post-operative to patients undergoing ABO-incompatible liver transplantation as an experimental group.
75867608|NCT05666453|Other|No intervention|None of investigational drugs are administered to patients.
75867609|NCT02695420|Drug|25 mg Omecamtiv Mecarbil|oral tablet
75867610|NCT02695420|Drug|Placebo|oral tablet
75867611|NCT02695420|Drug|37.5 mg Omecamtiv Mecarbil|oral tablet
75867612|NCT02695420|Drug|50 mg Omecamtiv Mecarbil|oral tablet
75867613|NCT03733613|Other|no intervention|no intervention
75867614|NCT03358147|Drug|GP MDI 28.8 μg|GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
75867615|NCT03358147|Drug|GP MDI 14.4 μg|GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
75867616|NCT03358147|Drug|GP MDI 7.2 μg|GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
75867617|NCT03358147|Drug|Placebo MDI|Placebo taken as 2 inhalations BID
75378990|NCT03478904|Drug|Enzalutamide Liquid|Enzalutamide liquid formulation given orally (160mg)
75540054|NCT04581772|Drug|DNL343|Multiple oral doses
75867618|NCT03358147|Drug|Spiriva Respimat 2.5 μg|Spiriva Respimat 2.5 μg QD (open-label)
75867619|NCT03733457|Behavioral|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
75540055|NCT04581772|Drug|Placebo|Single oral dose
75540056|NCT04581772|Drug|DNL343|Single oral dose
75540057|NCT00223925|Drug|Maribavir|
75540058|NCT00223925|Drug|Placebo|
75540059|NCT00254085|Drug|Insulin Aspart|
75540060|NCT04582006|Procedure|Bariatric surgery|Surgical treatment of morbid obesity.
75867620|NCT03093402|Drug|JBT-101|Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
75867621|NCT03093402|Drug|Placebo|Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
75867622|NCT03585959|Device|superDimension™ Navigation System Version 7.2|superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
75867623|NCT02397070|Procedure|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
75540061|NCT04581967|Genetic|polymorphism analysis|"DNA will be purified from whole blood samples by commercial DNA isolation kits.~Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR."
75540062|NCT04581967|Drug|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
76030320|NCT03288493|Drug|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
76030321|NCT03287349|Other|Blood draw|Two 12.5 mL blood draws
75540063|NCT04581577|Other|Semi-structured telephone questionnaire|Semi-structured telephone questionnaire
75540064|NCT00223964|Drug|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
75540065|NCT04581694|Diagnostic Test|TAVI without contrast|TAVI without contrast
75540066|NCT00254124|Device|The Diet Plate (R) TM portion control plate and bowl|
76030322|NCT03287349|Other|Photograph|Photograph of severe reaction, will be anonymized
75867624|NCT02397070|Device|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
75867625|NCT02397148|Radiation|Computed Tomography|imagery with ionizing radiation
75867626|NCT02397148|Radiation|Cone Beam Computed Tomography|imagery with ionizing radiation
75867627|NCT03584789|Other|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
76030323|NCT03287349|Diagnostic Test|Autoimmune testing|Autoimmune testing in patients without prior testing
76030324|NCT03267433|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
76030325|NCT03267433|Other|Laboratory Biomarker Analysis|Correlative studies
76030326|NCT03267433|Biological|Rituximab|Given IV
76030327|NCT03238690|Device|Controlled Cardiac Reloading through LVAD Speed Adjustment|LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
76030328|NCT03238300|Drug|N-Acetylcysteine|N-Acetylcysteine; 600mg capsules by mouth, two pills twice daily (total 2400 mg/day). Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
76030329|NCT03238300|Drug|Placebo Oral Capsule|N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
76030330|NCT03233191|Procedure|Digital Mammography|Undergo DM
75378991|NCT03478904|Drug|Enzalutamide Capsule|Enzalutamide gel capsule (4X 40mg)
75378992|NCT03478982|Drug|Staccato Alprazolam|single dose for inhalation
75378993|NCT03478982|Drug|Placebos|single dose for inhalation
76030331|NCT03233191|Procedure|Digital Tomosynthesis Mammography|Undergo TM
75378994|NCT03264248|Device|E-Scale|Daily bodyweight system used under legs of bed
75540067|NCT00224081|Drug|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
75540068|NCT04581265|Drug|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin|Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
75540069|NCT04581187|Other|Quality of life assessment|Quality of life questionnaires
75540070|NCT00414999|Drug|TG100801|
75540071|NCT04580875|Procedure|Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children|
75378995|NCT03270332|Drug|Albuterol|inhalation of 270μg albuterol through a spacer
75378996|NCT03270332|Drug|Placebo|inhalation of placebo through a spacer
75378997|NCT03349892|Radiation|Stereotactic Ablative Radiotherapy (SABR)|A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.
75378998|NCT03483506|Drug|BI 1467335|Film-coated tablet
75378999|NCT03483506|Drug|BI 1467335 (C-14) intravenous solution|Intravenous solution
75379000|NCT03271424|Diagnostic Test|Oraquick HIV Self Test - Choice|This is an oral swab in home HIV test.
75540072|NCT04581109|Biological|Blood sample|Twenty ml of blood will be drawn from each patient : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP.
75540073|NCT02962466|Other|CC-Test|classification of the oocyte based on the expression pattern observed in the cumulus cells
75540074|NCT04580797|Drug|PF-06700841 IR|Immediate release formulation
75540075|NCT04580797|Drug|PF-06700841 MR1|Modified release formulation 1
75540076|NCT04580797|Drug|PF-06700841 MR2|Modified release formulation 2
75540077|NCT04580797|Drug|PF-06700841 MR3|Modified release formulation 3
76030332|NCT03233191|Other|Laboratory Biomarker Analysis|Correlative studies
76030333|NCT03215511|Drug|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
76030334|NCT03214003|Radiation|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
75379001|NCT03271424|Diagnostic Test|Atomo HIV Self Test - Choice|This is a blood finger prick in home HIV test.
75379002|NCT03271424|Diagnostic Test|Oraquick HIV Self Test and Atomo HIV Self Test - Both|This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
75379003|NCT03483896|Other|Daylight Intervention|Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
75379004|NCT02156466|Drug|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
75379005|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
75540078|NCT04580797|Other|Placebo|Matching placebo
75867628|NCT03584789|Other|Patient education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
76030335|NCT03214003|Radiation|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
76030336|NCT03211663|Device|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
75379006|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
75379007|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
75379008|NCT02156466|Drug|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
75379009|NCT03353246|Device|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
75379010|NCT03274856|Drug|GLWL-01|Oral administration of 3 capsules, twice a day
75379011|NCT03274856|Drug|Placebo|Oral administration of 3 capsules, twice a day
75540079|NCT00415038|Drug|Rostafuroxin|1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
75379012|NCT02216526|Other|Cetaphil® Restoraderm|
75379013|NCT02216526|Other|Excipial|
75867629|NCT03710005|Procedure|Ascent|Dehydrated Cell and Protein Concentrate injection
75867630|NCT03710005|Procedure|Standard|Standard corticosteroid injection
75867631|NCT03733379|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
75867632|NCT03733379|Drug|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
76030337|NCT03186417|Biological|2 million hMSC/kg|2 million hMSCs/kg infusion
76030338|NCT03186417|Biological|4 million hMSC/kg|4 million hMSC/kg infusion
76030339|NCT03186417|Biological|6 million hMSC/kg|6 million hMSC/kg infusion
76030340|NCT03186417|Biological|placebo|placebo infusion
76030341|NCT03180996|Device|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
75540080|NCT00415038|Drug|Rostafuroxin|1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
75540081|NCT00415038|Drug|Rostafuroxin|1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
75540082|NCT00415038|Drug|Rostafuroxin|1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
75703901|NCT02573480|Behavioral|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
75379014|NCT03355820|Procedure|Blood sampling for antibody determination|In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (~5 mL) will be taken from all the subjects, at Day 1.
75379015|NCT03357614|Drug|Sulopenem|Antibiotic therapy for complicated UTI
75867633|NCT03733379|Drug|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
75867634|NCT03733379|Drug|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
75379016|NCT03357614|Drug|Sulopenem-Etzadroxil/Probenecid|Antibiotic therapy for complicated UTI
75379017|NCT03357614|Drug|Ertapenem|Antibiotic therapy for complicated UTI
75379018|NCT03357614|Drug|Ciprofloxacin|Antibiotic therapy for complicated UTI
75379019|NCT03357614|Drug|Amoxicillin-clavulanate|Antibiotic therapy for complicated UTI
75379020|NCT03487718|Biological|Leukocyte platelet rich fibrin plug + d-PTFE membrane|Following tooth extraction, an autologous leukocyte platelet rich fibrin plug will be placed in the socket and covered with a d-PTFE membrane
75379021|NCT03487718|Device|d-PTFE membrane|Following tooth extraction, the socket will be covered with a d-PTFE membrane
75379022|NCT03275870|Drug|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
75867635|NCT03733379|Dietary Supplement|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
75379023|NCT03276494|Device|Intraosseous|Intraosseous administration of hypertonic saline
75379024|NCT03276494|Drug|Hypertonic saline|Intraosseous administration of hypertonic saline
75379025|NCT02216214|Drug|Mirabegron|oral tablet
75379026|NCT02216214|Drug|Placebo|oral tablet
75379027|NCT03277274|Drug|TAK-954|TAK-954 intravenous infusion.
75379028|NCT03279458|Device|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
75379029|NCT02214186|Other|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
75379030|NCT03492398|Drug|HY209|6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
75379031|NCT04758546|Diagnostic Test|Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial|Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
75379032|NCT03496220|Device|Angulus|Feedback on patient recumbency
75540083|NCT00415038|Drug|Rostafuroxin|1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
75379033|NCT00376376|Drug|levofloxacin at 250, 500, 750, and 1000 mg doses|
75379034|NCT00376454|Drug|GW493838|
75540084|NCT00224159|Behavioral|Drug and Dietary behavior|
75540085|NCT00568477|Drug|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over >=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
75867636|NCT03733379|Dietary Supplement|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
75867637|NCT03708991|Diagnostic Test|IVF combined with PGT-A|trophectoderm biopsy to test the ploidy state of the IVF embryos
75867638|NCT03708991|Diagnostic Test|ICSI combined with PGT-A|trophectoderm biopsy to test the ploidy state of the ICSI embryos
75867639|NCT05733676|Device|Resin infiltration|Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.
75867640|NCT05733676|Device|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride|Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe
75867641|NCT03343639|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
75867642|NCT03343639|Drug|Matching Placebo Tablets|Placebo Tablets
76030342|NCT03178045|Other|Team Monitoring|In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.
75379035|NCT02181504|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
75379036|NCT02181504|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
75379037|NCT02181504|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
75379038|NCT03360110|Device|Phoebe test lens|Daily disposable contact lens
75379039|NCT03360110|Device|stenfilcon A lens (control)|Daily disposable contact lens
75379040|NCT02179398|Biological|Allocation to the Lab-score group|
75379041|NCT02179398|Biological|Allocation to the control group|
75379042|NCT02156076|Drug|BMS-919373|
75379043|NCT02156076|Drug|Placebo (Matching with BMS-919373)|
75379044|NCT02213094|Drug|Nicotinamide 500 mg|Nicotinamide 500 mg taken by mouth each morning
75379045|NCT02213094|Drug|Nicotinamide 1000 mg|Nicotinamide 1000 mg taken by mouth each morning
75379046|NCT02155608|Device|Active eTNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
75540086|NCT04580836|Procedure|Magnetic Resonance Imaging|Undergo MRI
75540087|NCT04580836|Other|Questionnaire Administration|Ancillary studies
75540088|NCT04580836|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75540089|NCT00415077|Procedure|PRK|PRK
75379047|NCT02155608|Device|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
75703902|NCT00841516|Other|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
75867643|NCT04479748|Drug|Dexamethasone|Treatment of pain and inflammation following ophthalmic surgery
75540090|NCT00415077|Procedure|MMC PRK|mitomycin C PRK
75379048|NCT01629966|Drug|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
75379049|NCT01629966|Drug|Vilazodone|Vilazodone, 20mg, oral administration once per day.
75379050|NCT01629966|Drug|Vilazodone|Vilazodone, 40mg, oral administration once per day.
75379051|NCT03363854|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
75540091|NCT00415077|Procedure|LASEK|LASEK
75540092|NCT00568516|Drug|ASP3550|subcutaneous administration
75703903|NCT00841516|Biological|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
75703904|NCT03985163|Other|Patient Reported Outcomes Electronic Survey|This study does not include a drug, test, behavioral or medical procedure intervention; participants will be asked to complete three surveys
75703905|NCT04069832|Behavioral|Single-Session Consultation|A single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
75703906|NCT00841594|Drug|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
75703907|NCT00841594|Drug|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
75867644|NCT04479748|Drug|Prednisolone Acetate 1% Oph Susp|Topical steroid
75867645|NCT03647267|Device|Pneumatic Vitreolysis (C3F8 injection)|Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
75867646|NCT03647267|Other|Observation|No intervention; sham injection only
75540093|NCT00224198|Procedure|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
75540094|NCT00568711|Drug|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
75379052|NCT03363854|Drug|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
75540095|NCT00568711|Drug|rifampin|a 5-day course of daily 600-mg doses of rifampin
75540096|NCT04580758|Combination Product|Fractional laser with PRP fluid or PRP gel|20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
75540097|NCT04580641|Other|Questionnaire|A self-administered questionnaire will be completed by each study subject
75540098|NCT00415116|Drug|carboplatin|
75540099|NCT00415116|Drug|docetaxel|
75540100|NCT00415116|Drug|lenalidomide|
75540101|NCT00568750|Drug|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
75867647|NCT03707353|Biological|ChAd63 ME-TRAP and MVA ME-TRAP vaccination|vaccination with ChAd63 ME-TRAP 5x10^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10^8 pfu (intramuscularly) and MVA METRAP 2x10^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.
76030343|NCT03178045|Other|Enhanced Feedback|In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.
76030344|NCT03175744|Device|Stellarex DCB|Intervention with the Stellarex DCB
76030345|NCT03175744|Device|PTA Catheter|Intervention with an uncoated Standard PTA
76030346|NCT03171311|Procedure|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
76030347|NCT03171311|Procedure|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
75379053|NCT02177838|Biological|cetuximab|Given IV
75379054|NCT02177838|Drug|cisplatin|Given IV
75379055|NCT02177838|Radiation|external beam radiation therapy|Undergo EBRT
75379056|NCT02177838|Other|laboratory biomarker analysis|Correlative studies
75379057|NCT03369158|Procedure|patient specific pedicle screw positioning guide|
75379058|NCT03369158|Procedure|Free hand technique pedicle screw positioning|
75379059|NCT03369158|Device|MUST pedicle screw|
75379060|NCT03372434|Device|Investigational Intraocular Lens Device #1: Model ZFR00|IOL replaces the natural lens removed during cataract surgery.
75540102|NCT00568789|Drug|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
75540103|NCT00254202|Drug|iloperidone|
75540104|NCT00254202|Drug|active comparator|
75540105|NCT00254202|Drug|placebo|
75540106|NCT00568945|Drug|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
75540107|NCT00568984|Drug|repaglinide|
75540108|NCT00568984|Drug|metformin|
75540109|NCT00568984|Drug|glicazide|
75540110|NCT00254241|Drug|Seroquel and Risperidone|
75540111|NCT00569023|Dietary Supplement|alga Dunaliella bardawil|"Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.~Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers"
75540112|NCT00224315|Drug|ziprasidone|
75540113|NCT00224315|Drug|risperidone|
75379061|NCT03372434|Device|Investigational Intraocular Lens Device #1: Model ZYR00|IOL replaces the natural lens removed during cataract surgery.
75379062|NCT03372434|Device|TECNIS Multifocal Intraocular Lens: Model ZLB00|IOL replaces the natural lens removed during cataract surgery.
75540114|NCT00569101|Drug|tacrolimus|during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg ~0.02 mg/kg + prednisolone tapering
76030348|NCT03168750|Device|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
75540115|NCT00569140|Drug|E10030|Intravitreal injection
75703908|NCT04068974|Drug|Camrelizumab (SHR-1210)|Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 [PD-1]). Monoclonal antibodies like SHR-1210 that can block this pathway.
75703909|NCT04068974|Drug|Apatinib|Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
75703910|NCT00836290|Behavioral|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
76030349|NCT03154307|Device|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
76030350|NCT03139825|Other|Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)|Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
76030351|NCT03139370|Drug|KITE-718|A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
76030352|NCT03139370|Drug|Cyclophosphamide|Administered intravenously
76030353|NCT03139370|Drug|Fludarabine|Administered intravenously
76030354|NCT03139370|Device|MAGE - A3/A6 Screening Test|A screening test for MAGE-A3/A6+ tumors
76030355|NCT03133221|Drug|Zydelig|Zydelig given at 150mg continuously in 28-day cycles
76030356|NCT03113500|Drug|Brentuximab Vedotin|Given IV
76030357|NCT03113500|Drug|Cyclophosphamide|Given IV
75379063|NCT03376256|Device|Compuflo Epidural Instrument|Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.
75379064|NCT03283436|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
75379065|NCT00375986|Procedure|Manual placental removal at Cesarean delivery|
75379066|NCT00375986|Procedure|Spontaneous placental removal at Cesarean delivery|
75379067|NCT03380624|Drug|Refresh Optive|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
75540116|NCT00569179|Device|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
75540117|NCT00569257|Drug|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
75703911|NCT00836290|Behavioral|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
75703912|NCT00782171|Device|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
75540118|NCT00224354|Biological|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
76030358|NCT03113500|Drug|Doxorubicin|Given IV
76030359|NCT03113500|Drug|Doxorubicin Hydrochloride|Given IV
76030360|NCT03113500|Drug|Etoposide|Given IV
76030361|NCT03113500|Drug|Etoposide Phosphate|Given IV
76030362|NCT03113500|Other|Laboratory Biomarker Analysis|Correlative studies
76030363|NCT03113500|Drug|Prednisone|Given PO
75379068|NCT03380624|Drug|Refresh Optive MEGA-3|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
75379069|NCT03380780|Drug|Emicizumab|Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
75379070|NCT00376064|Drug|Octreotide acetate and cabergoline/Octrotide and Somavert|
75379071|NCT00376142|Behavioral|Psychological theory-based behaviour change interventions|
75379072|NCT03581084|Drug|N-acetylcysteine|Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
75379073|NCT03383588|Drug|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
75379074|NCT03383588|Drug|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
75379075|NCT03383588|Drug|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
75379076|NCT03383588|Drug|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
75379077|NCT03383588|Other|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
75379078|NCT03388268|Drug|Oral Vancomycin|Oral vancomycin 125mg 4 times per day
75379079|NCT03388268|Drug|Placebo|Sugar liquid manufactured to mimic oral vancomycin 125mg
75379080|NCT03388268|Device|Toxin enzyme immunoassay|EIA assay: Wampole/Tech Lab Tox A/B II
75379081|NCT03388268|Device|Nuceleic acid amplification test|NAAT: Xpert C. difficile, Cepheid
76030364|NCT03112928|Device|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~Pain evaluation~Placement of the electrodes and fiducial marker~Practice of motor execution in Augmented Reality (AR)~Gaming using phantom movements~Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
75540119|NCT00224354|Biological|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
75379082|NCT00422786|Drug|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
75379083|NCT03581474|Device|Bronchoscopic procedure|Single-use flexible bronchoscope aScope 3 Large
75379084|NCT03390842|Drug|TRC101|Oral suspension
75540120|NCT00224354|Biological|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
76030365|NCT03112928|Device|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
76030366|NCT03089203|Biological|CART-PSMA-TGFβRDN cells|autologous CAR T cells
76030367|NCT03089203|Drug|Cyclophosphamide|300 mg/m2/day given over 3 days
76030368|NCT03089203|Drug|Fludarabine|30 mg/m2/day given over 3 days
76030369|NCT03079037|Device|Stimulation|Traditional deep brain stimulation
76030370|NCT03072602|Dietary Supplement|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
75540121|NCT00224354|Drug|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
75540122|NCT00224354|Biological|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
75540123|NCT00254280|Procedure|Intense Pulsed Light + paring versus paring alone|
75540124|NCT00569296|Biological|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
76030371|NCT03072602|Other|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
76030372|NCT03070366|Drug|Chemotherapy|"cisplatin~5FU~carboplatin~cetuximab"
76030373|NCT03070366|Radiation|Stereotactic radiotherapy|Stereotactic radiotherapy
76030374|NCT03049540|Drug|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
76030375|NCT03049540|Drug|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
75540125|NCT00569296|Biological|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
75703913|NCT02572700|Other|Clinical examination, blood sampling, ultrasonic assessment, and questionnaires|Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.
75703914|NCT00836368|Dietary Supplement|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
75703915|NCT00718796|Other|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
75703916|NCT00718796|Other|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
75703917|NCT00844168|Drug|sorafenib tosylate|Given orally
75540126|NCT00569296|Biological|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
75540127|NCT00569335|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
75540128|NCT00254319|Drug|Avastin, Alimta|
75540129|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|One basal rate
75540130|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|Multiple basal rates
75703918|NCT00844168|Other|laboratory biomarker analysis|Correlative studies
75703919|NCT02573168|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
75867648|NCT05731180|Other|Identify pathological and not pathological lung sounds|First group is the control group (CNT), second group (EXP) who will be exposed to pathological and none pathological lung sounds
76030376|NCT03012880|Biological|Daratumumab|Given IV
76030377|NCT03012880|Drug|Dexamethasone|Given PO
75379085|NCT03390842|Drug|Placebo|Oral suspension
75379086|NCT02177136|Drug|Obeticholic Acid (OCA)|
76030378|NCT03012880|Drug|Ixazomib Citrate|Given PO
76030379|NCT03012880|Other|Laboratory Biomarker Analysis|Correlative studies
75379087|NCT02177136|Drug|Placebo|
75703920|NCT02573168|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
75379088|NCT03393494|Drug|Adapalene and Benzoyl Peroxide Topical Gel|Test product
75703921|NCT02573168|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
75703922|NCT00836446|Other|physical activity|physical activity routines 5 times a weeks for 12 weeks.
75703923|NCT00841750|Procedure|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
75703924|NCT00841750|Procedure|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
75703925|NCT02574884|Procedure|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
76030380|NCT03012880|Drug|Lenalidomide|Given PO
76030381|NCT03012880|Other|Questionnaire Administration|Ancillary studies
76030382|NCT02999087|Drug|Cetuximab|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
76030383|NCT02999087|Drug|avelumab|IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
76030384|NCT02999087|Drug|Cisplatin|100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
75379089|NCT03393494|Drug|Epiduo Topical Product|RLD product
75379090|NCT03393494|Drug|Placebo|Placebo gel
75379091|NCT03588806|Drug|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
75379092|NCT02176356|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
75379093|NCT02176356|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
75379094|NCT02176356|Device|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
76030385|NCT02999087|Radiation|IMRT|RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
75379095|NCT02176356|Device|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
75379096|NCT02176356|Device|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
75379097|NCT03591068|Drug|Fluticasone Propionate|OPN-375 186 μg BID, Delivered via exhalation delivery system
75379098|NCT02210208|Device|Mepitel® Ag|"A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing."
75540131|NCT00569491|Device|TAXUS Express 2™|TAXUS Express™ Paclitaxel-Eluting Coronary Stent System
75540132|NCT00569569|Drug|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
75703926|NCT00836524|Procedure|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
75703927|NCT00764465|Drug|Maraviroc|300 mg BID
75703928|NCT00764465|Drug|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
75703929|NCT00764465|Drug|Ritonavir|100 mg BID, 100 mg QD
75703930|NCT02546752|Other|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
75703931|NCT00715832|Biological|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
75867649|NCT03708913|Device|Hypothalamic Deep Brain Stimulation|One-year continuous hypothalamic deep brain stimulation
75867650|NCT03356977|Drug|Crisaborole ointment 2%|Applied BID
76030386|NCT02983461|Drug|Sildenafil|Sildenafil, 20mg x 3 times a day for 10 weeks
75379099|NCT02210208|Device|Mepilex® Transfer Ag|"Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin."
75379100|NCT03395990|Procedure|Active comparator: chloroprocaine|15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
75379101|NCT03395990|Procedure|Sham comparator: saline|15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
75379102|NCT00376922|Procedure|music therapy|music played for patient during bone marrow biopsy collection
75379103|NCT02209506|Drug|MLN3126|MLN3126 tablets
75379104|NCT02209506|Drug|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
75540133|NCT00224432|Drug|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
75540134|NCT00569608|Other|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
75703932|NCT05525117|Behavioral|covivio (additional to treatment as usual)|Covivio is a dialogue-based online psychological intervention for patients with type 2 diabetes. This intervention includes elements that address disease literacy, physical activity and exercise, dieting and nutritional principles, coping with depression, etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
75703933|NCT05525117|Other|treatment as usual|Participants may continue with any treatment that they require (treatment as usual)
75867651|NCT02690974|Drug|LCZ696 (sacubitril/valsartan)|All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
75867652|NCT03093324|Drug|ALKS 8700|Administered as specified in the treatment arm.
75867653|NCT03093324|Drug|Dimethyl Fumarate|Administered as specified in the treatment arm.
75867654|NCT03584009|Drug|Venetoclax|Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.
75867655|NCT03584009|Drug|Fulvestrant|Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
75867656|NCT03709927|Drug|ZTI-01|6g IV fosfomycin
75867657|NCT03709927|Drug|Moxifloxacin 400mg|oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
76030387|NCT02983461|Drug|Placebo|Placebo oral tablet, 3 times a day for 10 weeks
76030388|NCT02950987|Device|Whole Body MRI|
75379105|NCT02153736|Behavioral|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
75379106|NCT02175966|Drug|DCV/ASV/BMS-791325|
75379107|NCT02175966|Drug|Ribavirin|
75379108|NCT02175966|Drug|Sofosbuvir|
75867658|NCT03709927|Other|Placebo IV|IV Placebo (0.9% Normal Saline)
75379109|NCT02175966|Drug|Peginterferon α-2a|
75540135|NCT00569647|Device|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
75867659|NCT05666375|Procedure|Percutaneous translumbar and transhepatic permcath|For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access
75867660|NCT03707275|Device|Alexa+|Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
75867661|NCT03707275|Other|Standard of Care Arm|This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
75379110|NCT02153346|Other|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
75379111|NCT02153346|Other|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
75379112|NCT04750512|Procedure|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
75379113|NCT04750512|Procedure|TAP block|"US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle."
75540136|NCT00569647|Device|Placebo|no use of device
75379114|NCT02174562|Behavioral|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
75540137|NCT00569686|Drug|lovaza|lovaza 4 gm po daily
75379115|NCT02174562|Behavioral|Enhanced Usual Care|Usual care enhanced with education and attention
75379116|NCT05138406|Other|Graded Motor Imagery|The graded motor imaging program will be set to 2 weeks each component. Participants will receive lateralization for the first 2 weeks, motor imagery for 2 weeks, and mirror therapy for 2 weeks. At the same time, standard rehabilitation will be applied for 6 weeks. Treatments will begin 24-48 hours after surgery. Treatments will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
75379117|NCT05138406|Other|Standard Rehabilitation|Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
75379118|NCT02136576|Device|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
75379119|NCT02136576|Device|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
75379120|NCT02136576|Device|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
75379121|NCT03600194|Device|PowerSleep Stim|The PowerSleep Stim device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. Soft audio tones (below 65dB) will be administered via the speakers system during deep sleep as determined by the functionality of the device. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
75379122|NCT03600194|Device|Northwestern Stim|The Northwestern Stim Device will function similarly to the PowerSleep device, but stimulation will be provided using a standard PC (computer) setup at the bedside using standard PSG electrodes. EEG will be monitored and slow wave sleep (SWS) identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves and to control acoustic stimulation in a phase-locked manner (targeting the up phase of the slow wave). Acoustic stimulation will be provided by headphones with an audible soft volume that do not result in arousals.
75379123|NCT03600194|Device|PowerSleep Sham|The PowerSleep Sham device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. There are no audio tones played in the Sham condition. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
75540138|NCT00569686|Drug|placebo|placebo
75540139|NCT00569881|Drug|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
75867662|NCT04167462|Drug|BMS-986165|Specified dose on Specified Days
75540140|NCT00224471|Biological|GSK208141 vaccine|3 IM doses
75540141|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
75540142|NCT00569920|Drug|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
75540143|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
75540144|NCT00569959|Other|fasting 12+ hours|fasting 12+ hours
75540145|NCT00569959|Other|Non-fasting|Non-fasting
75540146|NCT00569998|Device|NovoPen™ 4|
75540147|NCT00569998|Device|NovoPen® 3|
75540148|NCT00224510|Drug|lamotrigine|
75540149|NCT00570193|Drug|verteporfin (Visudyne)|Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
75703934|NCT04069598|Diagnostic Test|Statin intolerance test|Statin intolerance test
75703935|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
75867663|NCT04167462|Other|Placebo|Specified dose on Specified days
75867664|NCT03733223|Drug|Ateptidase|Treatment of ischemic stroke with Ateptidase
75867665|NCT03707197|Behavioral|Meditation|Ten minutes of meditation per day for 8 weeks using a mobile application
75867666|NCT05680441|Other|Peirodontal clinical measurements and gingival crevicular fluid sampling|The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.
75379124|NCT03600194|Device|NorthWestern Sham|The Northwestern Sham device is set up will function similarly to the PowerSleep prototype. EEG will be monitored and SWS identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves. Participant will wear headphones but no audio tones played in the Sham condition.
75379125|NCT03398330|Drug|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fed state
75379126|NCT03398330|Drug|OxyContin®|Orally taking OXYCONTIN® 40mg in fed state
75379127|NCT03398798|Device|".014"|".014 CuNiTi orthodontic arch wire"
75379128|NCT03398798|Device|".016"|".016 CuNiTi orthodontic arch wire"
75379129|NCT03398798|Device|Twin brackets|Ormco Insignia Metal Twin brackets
75379130|NCT03398798|Device|Self-ligating brackets|Ormco Insignia SL brackets
75379131|NCT03400748|Device|RF Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
75379132|NCT03505190|Drug|RO7062931|RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
75540150|NCT00570193|Drug|ranibizumab (Lucentis)|ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol
75540151|NCT00570271|Other|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
75379133|NCT03505190|Drug|Placebo|Matching placebo will be administered subcutaneously (SC).
75540152|NCT00570271|Other|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
75540153|NCT00570271|Other|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
75540154|NCT00570271|Other|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
75540155|NCT00570271|Other|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
75540156|NCT00570271|Other|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
75540157|NCT00570388|Drug|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
75540158|NCT00570427|Behavioral|Problem Solving Therapy (PST)|Counseling
75540159|NCT00570427|Behavioral|Medication Management|If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
75379134|NCT04734704|Procedure|skin swabs at lesional and non-lesional sites|It will be examined in patients skin swabs sampled at lesional and non-lesional sites
75379135|NCT04734704|Procedure|skin swabs on skin|It will be examined in patients skin swabs sampled on skin
75379136|NCT03513848|Device|Retimer|The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
75379137|NCT03513848|Device|Retimer placebo|The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
75379138|NCT03402932|Other|Auditory amplified|The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
75379139|NCT03402932|Other|Visual|The cognitive test will be administered visually by using timed computer slides.
75379140|NCT03402932|Other|Auditory unamplified|The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
75379141|NCT00376610|Device|ASR/Re-cap|
75379142|NCT03621878|Other|Neural mobilization exercises -Tensioner technique|Exercise aiming to lengthen the neural structure using more than one joint.
75379143|NCT03621878|Other|Neural mobilization exercises -Slider technique|Exercise aiming to slide/glide the neural structure using more than one joint.
75379144|NCT03621878|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device aiming to decrease patient's symptoms.
75379145|NCT00376766|Drug|levetiracetam|
75379146|NCT03403712|Drug|fosnetupitant/ palonosetron|intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
75379147|NCT03403712|Drug|netupitant/palonosetron|oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
75379148|NCT03403712|Drug|dexamethasone|Oral dexamethasone (12 mg)
75540160|NCT00570466|Behavioral|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
75703936|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
75540161|NCT00570466|Behavioral|Web and DVD knowledge|Web and DVD based knowledge games
75540162|NCT00224549|Drug|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
75540163|NCT00570544|Drug|tiotropium|18ug capsule daily for 30 days
75540164|NCT04580329|Procedure|neuromuscular electrical stimulation (NMES) in addition to routine hospital care|"Patients in the NMES group will receive NMES sessions as the electrodes will be placed around the bilateral femoral quadriceps muscles and at the site of renal arteries.~NMES(>100 Hz, 50-80 μ sec) will be performed for 55 min including 5 minutes for warm up and 5 minutes for recovery .~The intensity of electrical stimulation will be adjusted to suit the comfort level of each individual patient without producing discomfort or pain."
75540165|NCT04580329|Procedure|routine hospital care without NMES|routine hospital care include all the routine intervention done for post partum women with AKI including fluid resuscitation, diuretics, hemodialysis
75540166|NCT00254436|Drug|Procrit (epoetin alfa)|Weekly dose
75540167|NCT00224588|Drug|Ketamine (or placebo : isotonic saline solution)|
75540168|NCT00570622|Drug|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
75703937|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, <= 4 mg, Once daily, 7 days
75540169|NCT00570622|Drug|Placebo|Patients receive placebo once a day orally for 9 days
75540170|NCT00254475|Drug|simvastatin|
75540171|NCT00254475|Drug|valsartan|
75540172|NCT00570817|Other|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
75703938|NCT00836602|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
75703939|NCT00655863|Drug|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
75703940|NCT00655863|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
75703941|NCT00655863|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
75703942|NCT00718874|Other|Dietary|modification of macronutrient content
75703943|NCT05672030|Other|Non-Interventional|No intervention.
75703944|NCT02572310|Device|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
75540173|NCT00570856|Drug|Folic acid|Folic acid 5 mg/day
75540174|NCT00570856|Drug|Placebo|Placebo similar to the folic acid tablets, 1/day
75703945|NCT00836680|Device|Colorectal Stent|"Diagnosis of an internal rectal prolapse:~The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.~An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
75703946|NCT00718952|Drug|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
75703947|NCT00718952|Drug|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
75703948|NCT00718952|Drug|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
75703949|NCT00719030|Dietary Supplement|Pomegranate pill|Pomegranate extract pill
76030389|NCT02945085|Other|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
76030390|NCT02945085|Other|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
76030391|NCT02936102|Drug|FAZ053|Anti-PD-L1 Antibody
76030392|NCT02936102|Drug|PDR001|Anti-PD-1 Antibody
76030393|NCT02935543|Biological|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10^7 CART19 cells, Day 2, 30% fraction: 3x10^7-1.5x10^8 CART19 cells, Day 3, 60% fraction: 6x10^7-3x10^8 CART19 cells
76030394|NCT02925364|Radiation|magnetic resonance imaging (MRI)|all participants will undergo a functional MRI and an anatomical MRI in a single session
76030395|NCT02924727|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
76030396|NCT02924727|Drug|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
75540175|NCT00570895|Dietary Supplement|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
75867667|NCT04160520|Drug|Pramipexole|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
75867668|NCT04160520|Drug|Morphine|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
76030397|NCT02924727|Drug|Placebo of LCZ696|Matching placebo of LCZ696 tablets
76030398|NCT02924727|Drug|Placebo of ramipril|Matching placebo of ramipril capsule
76030399|NCT02924727|Drug|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
75379149|NCT03404648|Drug|C-11 choline PET tracer|C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
75379150|NCT03404648|Drug|Gadobutrol|Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
75379151|NCT03404648|Device|PET/MR scanner|C11-PET/MR and pelvic mpMRI scan for prostate cancer.
75540176|NCT00254514|Drug|somatropin|
75540177|NCT00570934|Dietary Supplement|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
76030400|NCT02924727|Drug|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
76030401|NCT02905110|Drug|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
76030402|NCT02905110|Drug|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
76030403|NCT02905110|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
76030404|NCT02901626|Device|Arabin Cervical Pessary|"The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:~Pessary Size upper diameter, lower diameter~Nulliparous 65 mm, 32 mm~Multiparous 70 mm, 32 mm~Alternative 70 mm, 35 mm"
75540178|NCT00570934|Dietary Supplement|Calcium|1 gm calcium as calcium carbonate
75540179|NCT00570934|Dietary Supplement|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
75867669|NCT04160520|Drug|Placebo oral tablet|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
76030405|NCT02893163|Behavioral|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
75540180|NCT00570934|Drug|Placebo|Placebo
75540181|NCT00570973|Procedure|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
75540182|NCT00570973|Procedure|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
75703950|NCT00719030|Dietary Supplement|Pomegranate pill placebo|Pomegranate pill placebo
76030406|NCT02893163|Other|Usual Care|Usual Care by Family Doctor
76030407|NCT02872337|Behavioral|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
75540183|NCT00571051|Behavioral|Mindfulness Based Stress Reduction|8 week course in mindfulness training
75540184|NCT00571090|Procedure|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
75540185|NCT00254553|Drug|Testim 1% (testosterone gel)|Testim_ 100 mg: two tubes of 50 mg of Testim_per day
75540186|NCT00254553|Drug|Placebo|two tubes of placebo per day
75540187|NCT00571129|Procedure|DCR with no tubes or mitomycin|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
75540188|NCT00224627|Procedure|Capsule GIVEN IMAGING LTD|
75703951|NCT00844246|Other|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
75703952|NCT00844246|Other|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
75867670|NCT03583385|Drug|Glucophage XR (Test drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.
75867671|NCT03583385|Drug|Glucophage XR (Comparator drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
76030408|NCT02872337|Behavioral|Group Preoperative Education Session (per the standard of care)|
76030409|NCT02856815|Biological|Immuncell-LC|Activated T lymphocyte : intravenous dripping of 200ml (1 x 10^9 ~ 2 x 10^10 lymphocytes / 60kg adult) for 1 hour
76030410|NCT02823652|Other|Counseling|Undergo usual care
76030411|NCT02823652|Other|Genetic Counseling|Complete remote counseling
75540189|NCT00571168|Drug|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
75540190|NCT00571168|Drug|Placebo|Placebo capsules on day 1-4
75540191|NCT00571207|Device|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
75540192|NCT00571207|Behavioral|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
75540193|NCT00571246|Drug|Topiramate|Participants are randomized to take Topiramate (250mg/day) 2 times a day
75540194|NCT00571246|Drug|lamotrigine|Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
75540195|NCT00571246|Other|Placebo|Participants are randomized to take placebo
75540196|NCT00254631|Drug|Oxycodone hydrochloride|
76030412|NCT02823652|Other|Genetic Testing|Undergo germline testing
76030413|NCT02823652|Other|Internet-Based Intervention|Complete on-line genetic education
76030414|NCT02823652|Other|Survey Administration|Ancillary studies
75540197|NCT00571285|Dietary Supplement|Vitamin D3|600 IU Vitamin D3 capsule daily
76030415|NCT02819037|Procedure|gas chromatography|
76030416|NCT02819037|Procedure|Stool analysis for detection of malabsorption|
76030417|NCT02808507|Other|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
75379152|NCT03383198|Drug|Liposomal bupivacaine right injection|Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
75379153|NCT03383198|Drug|Liposomal bupivacaine left injection|Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
75540198|NCT00571285|Dietary Supplement|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
75540199|NCT00571285|Dietary Supplement|Placebo|Placebo capsule given once a week
75540200|NCT00224666|Device|Cortex stimulation|
75540201|NCT00571363|Procedure|standard surgery|excision with 4 mm margins
76030418|NCT02798523|Drug|Methylprednisolone sodium succinate(Solu-Medrol)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
75379154|NCT03407612|Device|Continuous Passive Motion|CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
75379155|NCT03408392|Drug|Test formulation A|Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
75540202|NCT00571363|Procedure|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
75703953|NCT00781937|Drug|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
75703954|NCT00781937|Drug|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
75540203|NCT00571402|Behavioral|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
75867672|NCT03632382|Diagnostic Test|3D acquisition of maxillofacial characteristics|A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
76030419|NCT02798523|Drug|Topical methylprednisolone (Advantan emulsion 0 /1%)|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
75379156|NCT03408392|Drug|Reference formulation B|Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
75379157|NCT04735484|Device|Gait analysis|Collecting movement data whilst participants walk
75379158|NCT03413618|Drug|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
75379159|NCT03413618|Drug|Diosmin|600 mg q.d. for 12 month
75379160|NCT03413618|Other|compression stockings|above knee stocking for 12 month
75379161|NCT03522350|Device|EmbryoScope|Standard of care arm
75540204|NCT00571402|Behavioral|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
75540205|NCT00571480|Other|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
75540206|NCT00571480|Other|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
75540207|NCT00571480|Other|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
75540208|NCT00224705|Device|Molecular Adsorbent Recirculating System (MARS®)|
75540209|NCT00571558|Drug|aminolevulinic acid hydrochloride|Given PO
75540210|NCT00571558|Drug|photodynamic therapy|Undergo photodynamic therapy
75540211|NCT00571558|Other|laboratory biomarker analysis|Correlative studies
75540212|NCT02961231|Biological|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
75540213|NCT02961231|Biological|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
75540214|NCT02961231|Biological|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
76030420|NCT02797977|Drug|SRA737, gemcitabine, cisplatin|
76030421|NCT02797977|Drug|SRA737, gemcitabine|
75540215|NCT02961231|Biological|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
75540216|NCT00571636|Drug|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is > 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
75540217|NCT00571636|Drug|5% glucose solution|ev continuous infusion
76030422|NCT02786589|Biological|Blood-stage infection of P. vivax|Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
76030423|NCT02772588|Drug|ARN-509|
75703955|NCT00802581|Procedure|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
75867673|NCT05288335|Device|Circular cylindrical mirror modulated frame glasses (compact)|Circular cylindrical mirror modulated frame glasses (compact)
75867674|NCT05288335|Device|Circular cylindrical mirror modulated frame glasses (strong defocus)|Circular cylindrical mirror modulated frame glasses (strong defocus)
75540218|NCT00224744|Device|ultracision|Surgery by Ultracision
75540219|NCT00224744|Device|classical lymphadenectomy|classical lymphadenectomy
75540220|NCT00571675|Drug|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
75703956|NCT00802581|Procedure|Non-circumferential spread of local anesthetic|"The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve."
76030424|NCT02772588|Drug|Abiraterone|
76030425|NCT02772588|Drug|Leuprolide|
76030426|NCT02772588|Radiation|stereotactic, ultra-fractionated radiotherapy|
76030427|NCT02767973|Other|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
76030428|NCT02766582|Drug|Pembrolizumab|IV every 21 days at 200 mg
76030429|NCT02766582|Drug|Carboplatin|IV every 21 days
76030430|NCT02766582|Drug|Paclitaxel|IV infusion (80mg/m2) every 7 days for 6 cycles
76030431|NCT02748668|Other|Blood specimen collection|
75540221|NCT00571675|Drug|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
75379162|NCT03522350|Device|EmbryoScope+|Experimental arm
75379163|NCT03523988|Drug|Acetaminophen|Acetaminophen gel capsule
75379164|NCT03523988|Drug|Ibuprofen|Ibuprofen gel capsule
75540222|NCT02961270|Drug|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
75540223|NCT00571753|Drug|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
75540224|NCT00571753|Drug|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
75867675|NCT05288335|Device|single vision frame glasses|single vision frame glasses
75867676|NCT04350372|Device|MitraClip Procedure|MitraClip procedure with MitraClip NT System
75379165|NCT03525548|Drug|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
75379166|NCT03525548|Drug|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
75379167|NCT03525548|Drug|IVA|Participants received IVA orally once daily in the evening.
75379168|NCT03525548|Drug|Placebo|Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
75379169|NCT03525548|Drug|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
75540225|NCT00224783|Biological|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
75540226|NCT00224783|Biological|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
75540227|NCT04580173|Diagnostic Test|metabolomics analysis|Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.
75379170|NCT03528512|Drug|Ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
75379171|NCT03528512|Drug|Midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
75379172|NCT03531710|Biological|UB-311|Intramuscular injection
75379173|NCT03531710|Drug|Placebo|Intramuscular injection
75540228|NCT00254709|Drug|Sirolimus|
75540229|NCT00571831|Procedure|intraocular lens implantation|Intraocular lens implantation
75540230|NCT00224822|Drug|Aripiprazole|
75540231|NCT00571870|Drug|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
75867677|NCT03708835|Other|Transitional care model|In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
75867678|NCT04792801|Radiation|PET TDM FDG-Choline|Performing an FDG TDM PET and a Choline TDM PET at two different times
75379174|NCT03533036|Device|applied VR headset|Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
75379175|NCT02153112|Biological|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
75867679|NCT03708757|Other|Post isometric relaxation - Group I|Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
75867680|NCT03708757|Other|Eccentric Muscle contraction - Group II|and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
75867681|NCT03707119|Other|Educational programme|the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
75379176|NCT02153112|Biological|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
75540232|NCT00254748|Drug|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
75540233|NCT00254748|Drug|Placebo|placebo
75867682|NCT02949973|Drug|voclosporin|
75867683|NCT05175937|Device|smartphone APP based remote monitoring|smartphone APP to monitor remotely patients implanted with ICD
75867684|NCT05175937|Device|bedside transmitter based remote monitoring|bedside transmitter to monitor remotely patients implanted with ICD
75379177|NCT02153112|Biological|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
75379178|NCT02153112|Biological|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
75379179|NCT02153112|Drug|Placebo|Placebo saline solution
75867685|NCT04152252|Other|Real time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
75867686|NCT04152252|Behavioral|Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
75540234|NCT00571909|Procedure|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
75867687|NCT04384146|Radiation|Cyclical Hypofractionated Palliative Radiation (Quad Shot)|3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break.
75867688|NCT04384146|Behavioral|EORTC QLQ-C30 questionnaire|at baseline, each cycle of Quad Shot, and at 3 weeks, 3 months and 6 months after last cycle of Quad Shot.
75540235|NCT00224861|Behavioral|Self-Management|
75540236|NCT00224861|Behavioral|Adherence|
75540237|NCT00572026|Drug|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
75867689|NCT05420922|Drug|Lenvatinib Oral Product|Lenvatinib or Sorafenib
75379180|NCT03534986|Device|International Biophysics AffloVest|High-frequency chest wall oscillation vest
75379181|NCT03534986|Device|Hill-Rom The Vest|High-frequency chest wall oscillation vest
75379182|NCT03534986|Device|Respirtech inCourage|High-frequency chest wall oscillation vest
75867690|NCT05420922|Drug|PD-1 inhibitor|Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
75379183|NCT03534986|Device|Electromed SmartVest|High-frequency chest wall oscillation vest
75379184|NCT03536702|Other|Creative Writing Workshop|This group will participate in a writing workshop in group sessions.
75379185|NCT03536702|Other|Independent Writing - Control Group|This group will receive a book for a self writing session.
75867691|NCT05420922|Procedure|Local treatment|Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
75379186|NCT03537092|Device|Vaginal Film|"2 x 2 vaginal film with no active drug"
75379187|NCT02133924|Drug|natalizumab|Natalizumab 300mg on days 0 and 14.
75379188|NCT02133924|Drug|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
75379189|NCT03624920|Drug|THN102 Dosage A|THN102 Dosages A: placebo
75379190|NCT03624920|Drug|THN102 Dosage B|THN102 Dosage B : 200mg/2mg
75379191|NCT03624920|Drug|THN102 Dosage C|THN102 Dosage C: 200mg/18mg
75379192|NCT03537404|Drug|Narlaprevir|100 mg, film-coated tablets, taken as 200 mg per os daily
75379193|NCT03537404|Drug|Ritonavir|100 mg, film-coated tablets, taken as 100 mg per os daily
75379194|NCT03537404|Drug|Tenofovir Disoproxil Fumarate|300 mg, film-coated tablets, taken as 300 mg per os daily
75379195|NCT03537404|Drug|Raltegravir|400 mg, film-coated tablets, taken as 400 mg per os daily
75379196|NCT03417752|Other|Exposure to firearm safety PSA|Exposed to firearm safety PSA
75379197|NCT03417752|Other|Exposure to health promotion PSA|Exposed to general health promotion PSA
75867692|NCT05283096|Other|Questionnaire|A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
75867693|NCT02948959|Drug|Dupilumab|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
75867694|NCT02948959|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
75867695|NCT02948959|Drug|Asthma Controller Therapies|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral"
75867696|NCT02948959|Drug|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
75379198|NCT03626714|Drug|Sustained Release Injectable Tacrolimus|Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
75379199|NCT04332380|Drug|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
75379200|NCT03538808|Drug|Varenicline|Participants will be provided varenicline medication
75379201|NCT03538808|Other|Placebo|Participants will be provided placebo medication
75379202|NCT03540134|Device|Intracerebral Infusion of Autologous Cerebral Spinal Fluid|Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
75379203|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% gel pump|
75379204|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% tube|
75379205|NCT02173704|Biological|Bexsero®|Four doses administered in the anterolateral area of the right or left thigh.
75379206|NCT02173704|Biological|Routine vaccines|Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
75379207|NCT03542474|Behavioral|High Intensity Endurance Exercise|Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
75379208|NCT03543176|Other|UMEC/VI|UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .
75379209|NCT03543176|Other|FLUT/SAL|FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.
75379210|NCT03543176|Other|CAT|Questionnaire used to asses Condition-related well-being, for COPD subjects.
75379211|NCT03543176|Other|mMRC|Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.
75379212|NCT03543176|Device|Ellipta|It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.
75379213|NCT03543176|Device|Diskus|It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
75379214|NCT02173548|Drug|Anakinra|
75867697|NCT03582215|Drug|Part 1: Cream|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
75867698|NCT03582215|Drug|Part 1: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
75867699|NCT03582215|Drug|Part 1: Spray 1|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
75867700|NCT03582215|Drug|Part 1: Spray 2|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
75867701|NCT03582215|Drug|Part 2: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
75867702|NCT03582215|Drug|Part 2: Aerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
75540238|NCT00572065|Drug|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
75867703|NCT03582215|Drug|Part 2: Nonaerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
75867704|NCT03582215|Drug|Part 2: Pump Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
75867705|NCT03089580|Device|Intense Pulsed Light Therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
75379215|NCT02173548|Drug|Placebo|
75379216|NCT03543878|Device|Flicker|The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.
75379217|NCT02173158|Drug|lomitapide|
75379218|NCT04501640|Drug|mirabegron|Oral adminstration
75379219|NCT02152566|Device|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
75703957|NCT00842062|Device|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
75867706|NCT03089580|Procedure|Sham Treatment|The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
75867707|NCT05420610|Other|Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.|The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.
75379220|NCT04758390|Behavioral|IMARA (intervention group)|The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
75379221|NCT04758390|Behavioral|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
75379222|NCT03632954|Device|ACell Arm|Cytal® Wound Matrix and/or MicroMatrix®
75867708|NCT05420610|Other|Study group: TPTD device was implemented for monitoring.|TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.
75379223|NCT04559282|Device|New Sound Processor|The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.
75379224|NCT04734470|Diagnostic Test|Flow cytometry|The study of CD19 complex expression in lymphoproliferative disorders by flowcytometry
75379225|NCT03633344|Drug|Carbowhite|
75379226|NCT03633344|Drug|Carbowhite placebo|
75379227|NCT02171130|Drug|Nasal Glucagon|3 mg nasal glucagon powder
75379228|NCT04777214|Device|Repetitive Transcranial Magnetic Stimulation|Active TMS will be at 90% motor threshold
75379229|NCT04777214|Device|Sham TMS|Sham TMS will be administered
75379230|NCT04749810|Drug|Elizaria®|Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
75379231|NCT00377078|Drug|recombinant human lactoferrin|
75379232|NCT04495712|Drug|spironolactone|aldosterone blocker
75379233|NCT04495712|Drug|placebo|identical in appearance to spironolactone study drug
75379234|NCT04474496|Other|Assessing the impact of COVID-19|Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
75540239|NCT00572065|Drug|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
75540240|NCT00234897|Drug|adalimumab|
75540241|NCT00572104|Other|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
75540242|NCT00572104|Other|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
75540243|NCT00572143|Other|ca coli follow-up by GP|patients randomized to follow up by GP
75867709|NCT05420532|Other|Exergaming|A video game-based physical activity training applied using a commercial game console.
75379235|NCT03552536|Drug|MK-8583|A single oral dose of MK-8583 in capsule form
75379236|NCT03553940|Biological|Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine|Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.
75379237|NCT03553940|Other|Placebo|H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.
75379238|NCT03553940|Biological|Quadrivalent MDCK Inactivated Influenza Vaccine|A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
75379239|NCT04448210|Behavioral|DigiKnowIt News: Teen|Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
75379240|NCT03640832|Other|Developmental Serum|A 30millilitre (mL) bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
75379241|NCT03640832|Other|Physiogel Calming Relief Anti-Redness Serum|A 30mL bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
75540244|NCT00572182|Drug|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
75540245|NCT02961153|Other|death|
75540246|NCT00224939|Drug|Potassium Chloride|
75379242|NCT04458818|Procedure|Prolene Mesh Vocal Cord Medialization Implant|The surgery will be performed under local anesthesia (lignocaine with adrenaline 2%) and procedural sedation with propofol 25-100mcg/kg/min (only sedative dose) will be administered, so that the patient remains vocally responsive during the procedure. Incision will be made at the lower border of thyroid cartilage under aseptic measures. Skin flaps will be raised in sub-platysmal plane, strap muscles will be separated in the midline to expose the laryngeal cartilaginous framework. A simple laryngeal window approach will be used to place the Ethicon prolene mesh 6 x 6cm Swiss roll, secured with prolene 2/0 suture trimmed to the required size. Post op voice analysis will be done on 7th day and 14th post-operative day. Monthly follow up will be advised after that.
75379243|NCT04456634|Drug|20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)|Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
75379244|NCT04456634|Other|20 mg/120 mg artemether-lumefantrine (AL) + Placebo|Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
75379245|NCT04454138|Device|XEN-45 gelatin microstent|Placement either in the subconjunctival space or supratenon's area
75540247|NCT00572221|Behavioral|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
75540248|NCT00572221|Behavioral|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
75703958|NCT00836836|Other|Modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
75540249|NCT00572299|Drug|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
75540250|NCT00572338|Other|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
75379246|NCT04431908|Device|olfactory device|A quantitative non-biased olfactory device intended for the rapid identification of SARS-CoV-2 infected subjects (as identified by PCR).
75379247|NCT00377624|Drug|sodium hyaluronate|
75703959|NCT00797589|Drug|HES|20ml/kg as prime fluid
75379248|NCT03558074|Drug|ALK4290|ALK4290 400 mg tablet twice a day
75703960|NCT00797589|Drug|Ringer lactate|
75379249|NCT03558230|Behavioral|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
75379250|NCT03558230|Behavioral|Vibration|Vibration applied to the wrist.
75540251|NCT00234936|Drug|Adalimumab|
75703961|NCT00719108|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
75703962|NCT00719108|Biological|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
75703963|NCT00842140|Drug|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
75703964|NCT00842140|Drug|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
75540252|NCT00234936|Drug|Methotrexate|
75540253|NCT00572377|Drug|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
75540254|NCT00572377|Drug|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
75703965|NCT00842140|Drug|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
75703966|NCT00806169|Drug|triamcinolone and bevacizumab|
75703967|NCT02572232|Device|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
75703968|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
75703969|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
75703970|NCT02572154|Other|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
75379251|NCT03558230|Behavioral|Placebo (for vibration)|No vibration applied to the wrist.
75379252|NCT03560102|Device|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
75379253|NCT03562988|Dietary Supplement|Vitamin C gummy|vitamin C
75379254|NCT03562988|Dietary Supplement|Vitamin C tablet|vitamin C
75379255|NCT03644108|Drug|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg ER Bi-Layer tablet
75379256|NCT04713956|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
75379257|NCT04713956|Drug|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
75540255|NCT00413075|Drug|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
75540256|NCT00572494|Device|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
75703971|NCT00802815|Drug|Etanercept|50 milligrams subcutaneously every week
75703972|NCT04100759|Drug|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
75379258|NCT04713956|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
75379259|NCT04713956|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
75379260|NCT04713956|Drug|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
75379261|NCT03565874|Device|Heart rate variability biofeedback|Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
75379262|NCT03569618|Device|Tablet-based Game|Tablet-based game aimed at improving processing speed and attention.
75379263|NCT04425746|Drug|Afamelanotide|
75379264|NCT04425746|Drug|Placebo|
75379265|NCT04402970|Drug|Dornase Alfa Inhalation Solution|Nebulized dornase alfa
75703973|NCT00836914|Drug|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
75379266|NCT04392362|Drug|Adenosine|A vial of adenosine with 6mg
75703974|NCT00836914|Drug|Placebo|Placebo capsules administered orally BID for 7 days
75703975|NCT04124042|Biological|XT-150|plasmid DNA
75703976|NCT04124042|Drug|Placebo|Placebo is a sterile phosphate-buffered saline
75703977|NCT05180175|Drug|Top down treatment if patient at high risk|Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
75703978|NCT00844402|Drug|Atorvastatin|oral, 10 mg, daily, 48 weeks
75703979|NCT04117412|Other|Exercise|Same participants will undergo different one bout of exercise protocols
75703980|NCT00802971|Dietary Supplement|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
75703981|NCT02546908|Other|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
76030432|NCT02742025|Other|Inclusion visit|This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
75379267|NCT04734782|Diagnostic Test|Determination of antibodies in maternal serum IgG for respiratory syncytial virus|By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.
75379268|NCT04714034|Diagnostic Test|"to develop and validate a scale measuring online dating addiction (ODA) in sexual minorities - the ODA Scale"|"Qualitative part: scale development and validation with testing in 3 different participant samples, i.e. preliminary testing (n=10), pilot testing (n=30-60), validation (n=300).~Quantitative part: longitudinal part conducted in the validation sample of the qualitative study part (n=300) with the aim to evaluate the association of ODA Scale scores with sexual health and mental health outcomes."
75379269|NCT04390022|Drug|Ivermectin|Single dose of STROMECTOL® tablets at 400mcg/kg
75379270|NCT04390022|Drug|Placebo|Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.
76030433|NCT02742025|Other|Nurse consultation|This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
76030434|NCT02742025|Other|Telephone contact|A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
75540257|NCT00572494|Device|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of >50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
75379271|NCT04370834|Biological|Tocilizumab|Given IV
75703982|NCT04115852|Behavioral|fmri|functional magnetic resonance imaging
75703983|NCT00806247|Drug|tapentadol HCl|
75703984|NCT00803127|Device|vs-sense|detection swab
75379272|NCT03570476|Drug|Olaparib|Given orally
75379273|NCT03570476|Procedure|Radical Prostatectomy|Undergo surgery
75379274|NCT03571724|Other|Non-Menthol Very Low Nicotine Cigarettes|King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco
75379275|NCT03571724|Other|Menthol Very Low Nicotine Cigarettes|King size menthol cigarettes containing 0.4mg nicotine /g tobacco
75379276|NCT03571724|Other|Subject's UB non-mentholated filtered cigarettes|King size non-menthol cigarettes
75379277|NCT03571724|Other|Subject's UB mentholated filtered cigarettes|King size menthol cigarettes
75379278|NCT03572972|Drug|Apixaban|Treatment for NVAF patients
75379279|NCT03572972|Drug|Dabigatran|Treatment for NVAF patients
75379280|NCT03572972|Drug|Rivaroxaban|Treatment for NVAF patients
75703985|NCT00797745|Biological|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
75703986|NCT00797745|Drug|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
75703987|NCT00797745|Drug|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
75703988|NCT00797745|Drug|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
75703989|NCT04070846|Drug|[14C] LC350189|Carbon-14 labelded LC350189
75703990|NCT00659373|Drug|Tamoxifen|
75703991|NCT00659373|Drug|triptorelin|
75703992|NCT00659373|Drug|Exemestane|
75703993|NCT00837070|Procedure|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
75703994|NCT00716378|Behavioral|Teen Passenger Presence|
75703995|NCT00719342|Drug|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
76030435|NCT02742025|Procedure|Coronarography on day 0|This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
76030436|NCT02720692|Drug|N1539|
76030437|NCT02720692|Drug|Intravenous Placebo|
76030438|NCT02712151|Procedure|Abdominal Wall Block|bilateral TAP and RS blocks.
76030439|NCT02712151|Procedure|Surgical infiltration|distributed between the 4 laparoscopic port sites.
76030440|NCT02712151|Drug|Sterile saline|Placebo injection
76030441|NCT02712151|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
76030442|NCT02712151|Device|Ultrasound|For nerve localization
76030443|NCT02712151|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
75379281|NCT03572972|Drug|warfarin|Treatment for NVAF patients
76030444|NCT02707484|Drug|Thalidomide (100mg)|Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
75379282|NCT03572972|Drug|Antiplatelets|Treatment for NVAF patients
75379283|NCT05314790|Other|intervening Educational Program|The implementation of an EP is based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1;
75379284|NCT04352660|Drug|Mitomycin-C injection|MMC delivered by preoperative subconjunctival injection
75379285|NCT04352660|Drug|Mitomycin-C sponge|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
75379286|NCT03650192|Device|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest and/or back. INVSENSOR00027 measures signals regarding subject's movement and posture, heart rate, and respiratory rate.
75703996|NCT00719342|Other|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
75703997|NCT00842452|Drug|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
75379287|NCT04342130|Drug|Morphine|30 mg oral tablet
75379288|NCT04338074|Drug|Tranexamic acid tablets|Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos
75703998|NCT00842452|Other|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
76030445|NCT02707484|Drug|Thalidomide (50mg)|Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
76030446|NCT02707484|Drug|placebo|Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
76030447|NCT02692664|Device|Endovascular aorto-iliac repair|
76030448|NCT02687243|Device|Interactive Virtual Application|Online application via tablet
75379289|NCT04338074|Drug|Placebo oral tablet|2 tablets p.o. three times per day x 5 days
75867710|NCT01568580|Drug|GreenGene|Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus
75867711|NCT04107870|Behavioral|Virtual Reality Exposure Therapy sessions|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
75379290|NCT03964220|Drug|Tiotropium Respimat®|Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )
75379291|NCT03964220|Drug|Inhaled Corticosteroid/Long-acting beta-agonist|baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
75540258|NCT00572611|Drug|[14C]-bilastine|Single oral dose of 20 mg [14C]-bilastine. 1 capsule. 1 day dosing only
75540259|NCT00572650|Drug|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
75540260|NCT00413270|Drug|nilotinib|
75540261|NCT00572689|Drug|Exenatide|10 microgram injected sub-cutaneously once
75540262|NCT00572689|Genetic|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
75540263|NCT00572767|Drug|Dextro-Amphetamin|After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
75703999|NCT02552745|Drug|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
75704000|NCT02547844|Drug|efavirenz + emtricitabina + tenofovir|
75379292|NCT04337138|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination
75379293|NCT03657134|Diagnostic Test|CoVa-2 Monitoring System|Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
75379294|NCT04332614|Behavioral|Less-is-better|Email
75540264|NCT00572767|Other|Glucose|"After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.~The treatment of the control group will be the same as for the experimental group except the content of the drug capsule."
75540265|NCT00572806|Drug|insulin aspart|
75540266|NCT00572845|Other|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
75704001|NCT02547844|Drug|rilpivirina + emtricitabina + tenofovir|
75540267|NCT00224978|Drug|Chloroquine|
75540268|NCT00572884|Other|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
75704002|NCT00439777|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
75867712|NCT04107870|Behavioral|Psychomotor therapy sessions|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
75867713|NCT05175703|Device|Passeo-18 Lux Paclitaxel releasing Balloon Catheter|collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
75867714|NCT04102800|Drug|Benralizumab|subcutaneous injection
75867715|NCT03632226|Drug|18F-OGA-1|
75867716|NCT05682703|Diagnostic Test|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination
75867717|NCT05664919|Drug|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
75867718|NCT05175079|Device|Acupressure band|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
75379295|NCT04332614|Behavioral|Social proof|Email
75379296|NCT04332614|Behavioral|Endowment / decision staging|Email
75540269|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Nevirapine|Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
75540270|NCT00573001|Drug|Tenofovir/Emtricitabine/Efavirenz (Atripla)|Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
75867719|NCT05175079|Other|Standard treatment hospital protocol|Intravenous metaclopromide 10mg PRN Intravenous fluids as per protocol
75379297|NCT04332614|Behavioral|Standard email|Email
75540271|NCT00573001|Drug|Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)|Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
75540272|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Zidovudine|Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
75867720|NCT03323346|Drug|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
75379298|NCT04332757|Other|Training intervention.|The investigators have designed a phased 18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation. The rehabilitation element of the programme will specifically target pelvic floor function and core strength and stability (known collectively as Core Reconnection training) from weeks 6 to 24 postpartum, and the training element of the programme will contain resistance and high-intensity interval training (HIIT) from weeks 12 to 24 postpartum.
75379299|NCT00422773|Drug|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
75379300|NCT04326842|Procedure|Carotid artery revascularization procedure|The patients with carotid artery stenosis will be examined before and after finishing the carotid artery revascularization procedure.
76030449|NCT02674971|Behavioral|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
76030450|NCT02659215|Device|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
76030451|NCT02659215|Procedure|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
76030452|NCT02656303|Biological|Ublituximab|Ublituximab IV infusion
75540273|NCT00254787|Drug|IR (Immediate-Release) quetiapine fumarate (drug)|
76030453|NCT02656303|Drug|Umbralisib|Umbralisib tablets
75540274|NCT03453853|Device|Mitral Loop Cerclage Annuloplasty|Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty
75867721|NCT05628571|Combination Product|Zinc toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).
75704003|NCT00439777|Drug|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
75704004|NCT00842686|Drug|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
75379301|NCT04326842|Device|Optical coherence tomography angiography|Examination will be performed using optical coherence tomography angiography. This device allows quantitative analysis, since it provides numerical data about flow area and flow density maps.
75379302|NCT03329209|Drug|Vedolizumab|Vedolizumab intravenous infusion.
75379303|NCT03661346|Drug|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
75379304|NCT03661346|Drug|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
75379305|NCT03329911|Drug|EU Avastin®|100 mg/4 mL
75379306|NCT03329911|Drug|BAT1706|100 mg/4 mL
75379307|NCT03329911|Drug|Paclitaxel|200 mg/m²
75379308|NCT03329911|Drug|carboplatin|target area under the curve [AUC] 6 mg/mL•minute
75379309|NCT04322396|Drug|Azithromycin|Azithromycin
75379310|NCT04322396|Drug|Hydroxychloroquine|Hydroxychloroquine
75379311|NCT04322396|Drug|Placebo oral tablet|Placebo Azithromycin
75704005|NCT04045821|Drug|AMD3100|Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
75704006|NCT04045821|Drug|Normal saline|Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
75704007|NCT04045821|Procedure|dilation and curettage|all participants will undergo routine D&C procedure
75704008|NCT04068584|Other|Smart Angel|Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms
75867722|NCT05628571|Combination Product|Fluoride Toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).
76023008|NCT03171649|Other|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~Upper limb passive motion~Arm Cycle ergometer with or without FES~Neuro Muscular Electrical Stimulation~Upper limb exercises using augmented or virtual reality environment~Occupational therapy exercises~Constraint induced movement therapy~Upper limb active movement (reaching, grasping, elevation, spatial orientation)~Repetitive task training~Mirror therapy~Writing training~Chemodenervation Therapy"
76023009|NCT03116269|Drug|Cilostazol 100mg|
75379312|NCT04322396|Drug|Placebo oral tablet|Placebo Hydroxychloroquine
75704009|NCT00842842|Procedure|tack fixation of mesh|tack fixation of mesh
75704010|NCT00842842|Procedure|glue fixation of mesh|glue fixation of mesh
75704011|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
75704012|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
75704013|NCT00844636|Device|Sharp needle|
75704014|NCT00844636|Device|Blunt needles|
75704015|NCT02575196|Device|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
75704016|NCT00806481|Drug|Sevelamer carbonate|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
76023010|NCT03116269|Drug|Aspirin|
76023011|NCT03168763|Behavioral|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
76023012|NCT03168763|Behavioral|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
75379313|NCT03222037|Device|senofilcon A|Acuvue Oasys 1-Day
75540275|NCT03453775|Device|Ultrasound guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
75540276|NCT03453775|Device|Fluoroscopy guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
75540277|NCT00225056|Drug|docetaxel and capecitabine|
75540278|NCT03453736|Other|No intervention|This is a qualitative study involving staff interviews and observations. No intervention is being applied.
75540279|NCT00254826|Biological|YF-VAX® plus saline|YF-VAX® plus saine
75540280|NCT00254826|Biological|17D YF Vaccine plus Ig,|17D YF Vaccine plus Ig, one vaccine on day 0
75704017|NCT00806481|Drug|Placebo|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
76023013|NCT03174223|Drug|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
75704018|NCT02546596|Device|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
76023014|NCT03174067|Drug|Buprenorphine|The participant receives buprenorphine
76023015|NCT03174067|Drug|Clonidine|The participant receives clonidine
75379314|NCT03222037|Device|Control|Trial Frame with best spherocylindrical refraction (SCR)
75379315|NCT03961100|Drug|Entrectinib 600 mg (T1)|Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
75379316|NCT03961100|Drug|Entrectinib 600 mg (T2)|Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
75379317|NCT03961100|Drug|Entrectinib 200 mg (R)|Reference formulation (R): entrectinib hard capsules
75379318|NCT03961100|Drug|Entrectinib 200 mg (T)|Test formulation (T): entrectinib HPMC capsules
75379319|NCT03222427|Drug|LY3314814|Administered orally
75379320|NCT03222427|Drug|[13C415N3] LY3314814|Administered as an IV infusion
75704019|NCT00709436|Drug|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
75704020|NCT00709436|Drug|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
76023016|NCT03171571|Other|Coaching procedure|"In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~survey like FFQ, SF36, dietary habits.~actimetry measurement~one year follow-up of weight, waist measurement~nutritional biomarkers"
76030456|NCT02650622|Procedure|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
76030457|NCT02646683|Drug|vedolizumab|
75379321|NCT03442699|Behavioral|Cognitive Behavioral Therapy|Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
75379322|NCT03954158|Drug|Crisaborole ointment 2%|BID regimen
75379323|NCT03954158|Drug|Vehicle|BID regimen
76023017|NCT03168685|Device|SureSource Engage application|"Eligible patients who choose to participate in the study will be asked to wear an actigraphy device [ActiGraph GT9X Link Actigraph Link] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application."
76030458|NCT02640586|Device|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
76030459|NCT02640209|Biological|CART 19|The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
76030460|NCT02628626|Drug|Colesevelam|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
76030461|NCT02628626|Drug|Clonidine|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
76030462|NCT02628626|Other|Placebo|Placebo will be identical in appearance to the active drug.
75379324|NCT03954158|Drug|Crisaborole ointment 2%|QD regimen
75379325|NCT03954158|Drug|Vehicle|QD regimen
75379326|NCT03222505|Device|Honda Stride Assist Device ON|Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
75379327|NCT03222505|Other|No Device Worn|Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
76030463|NCT02617797|Device|Radiofrequency|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
76030464|NCT02617797|Device|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
76030465|NCT02616965|Drug|Romidepsin|Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
76030466|NCT02616965|Drug|Brentuximab vedotin|Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
76030467|NCT02609542|Other|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
76030468|NCT02588456|Biological|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
75379328|NCT03224299|Drug|OCT - clear|Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
75379329|NCT03224299|Drug|OCT- tinted|Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
75379330|NCT03224299|Other|ChloraPrep|Active Control: ChloraPrep® - Hi-Lite Orange® applicator
75379331|NCT03224299|Other|Saline|Negative Control: sterile 0.9% saline applied with single use applicator
75379332|NCT03333577|Device|SoundArc|non-surgical attachment method for wearing a bone conduction hearing system
75379333|NCT03334825|Other|Enhanced housing placement assistance|assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
75379334|NCT03334825|Other|Standard housing placement assistance|standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
75379335|NCT03442933|Other|3 hours Road Cycling Time Trial|The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
75379336|NCT03442933|Other|3 hours Mountain Biking Time Trial|The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
75704021|NCT00803673|Drug|100mcg|100mcg '719
76030469|NCT02559609|Behavioral|Contingency management for alcohol abstinence|Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.
76030470|NCT02559609|Behavioral|Contingency management for completing job related activities|Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.
76030471|NCT02559609|Behavioral|Job relelated activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
75379337|NCT03444961|Device|CAREN system training|CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
75379338|NCT03661814|Device|Prevena|The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
75379339|NCT03335761|Device|InterStim Therapy|Device Programming
75379340|NCT03662282|Drug|Omegaven|Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
75704022|NCT00803673|Drug|500mcg|500mcg '719
75704023|NCT00803673|Drug|1000mcg|1000mcg '719
75704024|NCT00803673|Drug|Placebo|Placebo '719
75704025|NCT00844792|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
75704026|NCT00844792|Drug|Placebo|Twice a day with meals.
76023018|NCT03168607|Drug|FOLFIRI Protocol|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
76023019|NCT02408185|Drug|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
76023020|NCT02408185|Drug|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
76023021|NCT02400541|Behavioral|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
76023022|NCT02400541|Other|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
76030472|NCT02555384|Other|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
76030473|NCT02555384|Other|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
76030474|NCT02554812|Drug|Avelumab|Anti-PD-L1 antibody
76030475|NCT02554812|Drug|Utomilumab|Anti-4-1BB antibody
76030476|NCT02554812|Drug|PF-04518600|OX40 Agonist
76030477|NCT02554812|Drug|PD 0360324|Anti-M-CSF
76030478|NCT02554812|Drug|CMP-001|TLR9 agonist
76030479|NCT02546167|Biological|CART-BCMA|
76030480|NCT02527707|Drug|lonafarnib|antiviral farnesyltransferase inhibitor
76030481|NCT02527707|Drug|Ritonavir|Cytochromes P450 3A4 inhibitor used to boost lonafarnib
76030482|NCT02470754|Device|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
76030483|NCT02470754|Device|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
76030484|NCT02453191|Drug|Talimogene Laherparepvec|Talimogene Laherparepvec
76030485|NCT02453191|Radiation|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
75379341|NCT03336853|Device|HybenX|"The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
75379342|NCT03336853|Other|Placebo control|"The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
75379343|NCT03954626|Biological|brolucuzumab 6 mg IVT|Single intravitreal injection (IVT) of brolucizumab 6 mg
75379344|NCT04332835|Drug|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
75379345|NCT04332835|Drug|Standard Therapy|Standard therapy defined by institutional protocol.
75867723|NCT05255016|Combination Product|PXL Platinum 330 system + Riboflavin 0.25% TE Solution|"Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution [0.25%], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min)."
76023023|NCT02408419|Drug|Bupivacaine|Bupivacaine is injected proximally to anesthetize the obturator nerve
76023024|NCT02408419|Drug|Saline|Saline is injected as a placebo
76023025|NCT00708097|Drug|NaF|Fluoride
76023026|NCT00708097|Drug|Placebo|Placebo
76023027|NCT00708097|Drug|NaMFP|Fluoride
76023028|NCT02400697|Other|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
76023029|NCT02400775|Drug|Azilsartan|Azilsartan tablets
76023030|NCT02405689|Drug|Remifentanil|
76023031|NCT02405689|Drug|Dexmedetomidine|
76023032|NCT02405689|Drug|Sevoflurane|
76023033|NCT03173989|Device|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
75867724|NCT05255016|Other|Sham CXL + Artificial Tears|Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
76030486|NCT02386371|Procedure|tumorectomy|"Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams."
76030487|NCT02386371|Radiation|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
75540281|NCT03453697|Device|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.
75540282|NCT00225173|Drug|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
75540283|NCT00225173|Drug|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
75540284|NCT00225173|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
75540285|NCT00225173|Drug|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
75540286|NCT00225173|Drug|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
76030488|NCT02367924|Drug|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
75540287|NCT00225173|Drug|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
75540288|NCT00225173|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
75540289|NCT00225173|Drug|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
75379346|NCT03662360|Other|essential oils|Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
75379347|NCT03225001|Device|Edwards SAPIEN XT transcatheter valve, Model 9300TFX|Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
75540290|NCT00225173|Drug|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
75540291|NCT00234975|Drug|Lopinavir/Ritonavir|400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
75540292|NCT00573196|Radiation|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
75540293|NCT00573274|Device|Physioflow Impedance|6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
75540294|NCT00235014|Drug|trandolapril|2 mg QD
75540295|NCT00235014|Drug|trandolapril/verapamil|180/2 mg QD
75379348|NCT03225313|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
75379349|NCT03225313|Drug|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound & locally surrounding the hernia
75379350|NCT03225313|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
75379351|NCT03949244|Drug|Latanoprost 0.005%|Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
75379352|NCT03949244|Drug|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
75379353|NCT03949244|Drug|Normal saline 0.9%|Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
75540296|NCT00235014|Drug|placebo|1 tablet QD
75540297|NCT00235014|Drug|verapamil|SR 240 mg QD
75540298|NCT00225290|Drug|Thalidomide(Thado)|
75540299|NCT00573352|Radiation|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
75540300|NCT00573547|Drug|Fluoxetine|Fluoxetine will be dosed at 90 mg once a week
75540301|NCT00573586|Device|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
75540302|NCT00225329|Procedure|Labour assessment and support|
75540303|NCT00573664|Drug|Gabapentin|single oral dose of 600mg gabapentin
75540304|NCT00573664|Other|lactose|Single dose
75540305|NCT00573703|Procedure|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
75540306|NCT00573703|Procedure|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
75540307|NCT00573742|Drug|Candesartan Cilexeotil 16mg|
75379354|NCT03949244|Diagnostic Test|Nailfold capillaroscopy|An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
75540308|NCT00254865|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
75540309|NCT00573781|Dietary Supplement|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
75540310|NCT00573781|Dietary Supplement|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
75540311|NCT00573781|Dietary Supplement|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
75867725|NCT05610397|Device|STALIF®|STALIF® C, or M, Ti or FLX
75867726|NCT05598450|Device|rTMS and MEG for auditory hallucinations via single arm|a 4 weeks, weekly 230 minutes, 1Hz, 100%RMT-rTMS protocol
75540312|NCT00225368|Device|Insecticide treated bednets|
75540313|NCT00573820|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
75540314|NCT04579822|Biological|influenza vaccine|quadrivalent influenza vaccination in the flu seasons
75379355|NCT03225859|Behavioral|Self-Management Program|This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
75379356|NCT05313932|Other|Sleep deprivation|Participants wake after six hours so that they are deprived of 2 hours of sleep
75540316|NCT04579861|Other|Prospective data collection following gynaecological oncology surgery|Prospective data collection and entry on database following gynaecological oncology surgery
75540317|NCT00225407|Drug|Smoking of cannabis cigarettes (different strength)|
75867727|NCT03645395|Drug|MT-3724|Experimental treatment with MT-3724 in combination with LEN therapy.
75379357|NCT03948386|Drug|isobaric bupivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
75540318|NCT04580056|Procedure|Uterine fundus endometrial incision during hysteroscopy|Uterine fundus endometrial scratching during hysteroscopy by incision
75540319|NCT04719468|Other|Dance with ballet elements|Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
75540320|NCT04579744|Other|EuroQol 5D questionnaire|EuroQol questionnaire (EQ-5d) facilitates to obtain values of health in the physical, psychological, and social dimensions. It is a standardized non-disease specific instrument to describe and value the health-related quality of life.
75540321|NCT00225446|Device|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
75540322|NCT00574015|Drug|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
76023034|NCT03173989|Behavioral|Orientation|Orientation for home.
76023035|NCT02405455|Procedure|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
76023036|NCT02405455|Device|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
76023037|NCT02400619|Device|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
76023038|NCT02400619|Drug|Botulinum Toxin Type A|Botulinum toxin type A Botox
75540323|NCT00574015|Drug|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
75540324|NCT00574054|Radiation|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
75540325|NCT00255021|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
75540326|NCT00225485|Drug|Effexor XR|
75540327|NCT00574093|Drug|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
75540328|NCT00574210|Drug|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
75540329|NCT00574210|Drug|Placebo|Placebo Tablets administered twice per day
75540330|NCT00574366|Drug|erlotinib|"Levels:~1 Erlotinib 50 mg/d~2 Erlotinib 50 mg/d~1 Erlotinib 100 mg/d~2 Erlotinib 100 mg/d~3 Erlotinib 150 mg/d~4 Erlotinib 150 mg/d"
75540331|NCT00574366|Drug|RAD001|"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~RAD001 2.5 mg per day~RAD001 5 mg per day~RAD001 10 mg per day~RAD001 10 mg per day"
75540332|NCT00225524|Drug|Effexor XR|
75540333|NCT00574444|Procedure|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
75540334|NCT00574483|Drug|quinacrine|100 mg day
75540335|NCT00235092|Device|Cypher Sirolimus-Eluting Stent|
76030489|NCT02364726|Procedure|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
76030490|NCT02364726|Behavioral|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
75540336|NCT00235092|Device|Taxus Paclitaxel-Eluting Stent|
75540337|NCT00574522|Radiation|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
75540338|NCT00225563|Device|Electronic Health Record|e-prescribing methods
75540339|NCT00574600|Biological|SAAVI DNA-C2 vaccine|DNA vaccine
75540340|NCT00574600|Biological|SAAVI MVA-C vaccine|Boost vaccine
75540341|NCT00574600|Biological|Placebo|Placebo vaccine
75704027|NCT04017195|Drug|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
75540342|NCT00574639|Drug|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
75540343|NCT00574639|Drug|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
75540344|NCT00574678|Other|Tear collection|"A tear sample (~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed."
75704028|NCT04017195|Drug|High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
75704029|NCT00719420|Drug|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
76030491|NCT02364726|Behavioral|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
76030492|NCT02352090|Drug|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
76030493|NCT02352090|Drug|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
75704030|NCT00719420|Drug|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
75704031|NCT00797901|Other|Collaborative Care|
75704032|NCT00844870|Behavioral|stabilization training|training of arm function with the trunk stabilized
75704033|NCT00844870|Behavioral|auditory training group|response to an auditory signal
75704034|NCT00719498|Drug|Epo-alpha|
75704035|NCT00803829|Other|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
75704036|NCT00716612|Drug|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
75704037|NCT00716612|Drug|Placebo control|po Placebo QD
75704038|NCT00842920|Drug|Simvastatin 60 mg|60 mg once daily
75704039|NCT00842920|Drug|Placebo|one tablet once daily
75704040|NCT00842920|Drug|Simvastatin 20 mg|20 mg once daily
75704041|NCT00806559|Other|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
75704042|NCT00806559|Other|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
75704043|NCT00716690|Procedure|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
75704044|NCT02552979|Other|atopic patch test|
75704045|NCT00722774|Biological|H2N2 1960 AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
75867728|NCT04074018|Other|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
75540345|NCT00574717|Procedure|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
75867729|NCT04074018|Other|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
75379358|NCT03948386|Drug|hyperbaric bupivacaine|TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
75379359|NCT03948386|Drug|isobaric mepivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
75379360|NCT03445195|Drug|Sulbactam-ETX2514|The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
75379361|NCT03445195|Drug|Placebo|Matching 1g IV solution.
75867730|NCT03342469|Other|Artificial Food Coloring|225mg mixed powdered Artificial Food Coloring (AFC)
75867731|NCT03342469|Other|Placebo|Placebo chocolate cookies
76030494|NCT02352090|Drug|Dienogest|One tablet orally for 9 weeks, continuous use
75379362|NCT03445195|Drug|Imipenem-cilastatin|All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
75379363|NCT04289714|Device|Novel Electronic Monitoring Device|Four Novel electronic Monitoring Devices were trialled
75379364|NCT04277936|Drug|Levetiracetam 500 mg|Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
75379365|NCT03666026|Behavioral|1 MyChart R/R|Up to 1 flu vaccine reminder recall notice sent via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
75379366|NCT03666026|Behavioral|2 MyChart R/R|Up to 2 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
75379367|NCT03666026|Behavioral|3 MyChart R/R|Up to 3 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
75379368|NCT03936608|Device|Programming individualized RV-LV pacing offset to optimize ECG|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
75379369|NCT03936608|Device|Nominally programming CRT device without RV-LV offset|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
75379370|NCT03670160|Drug|Phenobarbital|Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
75379371|NCT03670160|Drug|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
75540346|NCT00225602|Behavioral|Assertive Community Treatment|
75867732|NCT05178888|Drug|MRTX849|KRAS G12C inhibitor
75867733|NCT05178888|Drug|Palbociclib|CDK 4 and 6 inhibitor
75867734|NCT03581825|Device|senofilcon A Multifocal|JJVC Investigational Multifocal Contact Lens
75867735|NCT03581825|Device|senofilcon A Sphere|ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS
75867736|NCT03581825|Device|etafilcon A Multifocal|1-Day Acuvue Moist Brand Multifocal Contact Lens
76030495|NCT02277522|Biological|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
76030496|NCT02226432|Procedure|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~Comparision of both groups will be statistified"
75540347|NCT00225602|Behavioral|Treatment in Community Mental Health Center|
75867737|NCT03581825|Device|etafilcon A Sphere|1-Day Acuvue Moist Brand Contact Lens
75867738|NCT03342001|Drug|Calcitonin|calcitonin nasal spray
75867739|NCT03730025|Other|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
76030497|NCT02226432|Device|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
75379372|NCT03672032|Device|Fork-tip Needle|Fork-tip Needle will be used to obtain biopsy
75379373|NCT03672032|Device|Franseen Needle|Franseen Needle will be used to obtain biopsy
75379374|NCT03446053|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
75379375|NCT03446053|Other|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
75379376|NCT00375895|Drug|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
75379377|NCT05314322|Procedure|Deep brain stimulation with high frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
75379378|NCT05314322|Procedure|Deep brain stimulation with low frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
75379379|NCT03338803|Drug|Linagliptin|drug
75379380|NCT05314244|Procedure|Pylorus resecting pancreaticoduodenectomy|The patients in pylorus resection group will underwent pylorus resecting procedure during pancreaticoduodenectomy
75379381|NCT03452371|Behavioral|Patient Navigation|Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.
75540348|NCT00255255|Drug|Budesonide/Formoterol|
75379382|NCT03452371|Behavioral|Enhanced Traditional Care|Enhanced traditional care will include a resource card with information on quitlines, Boston Medical Center's (BMC's) Tobacco Treatment Center Program number, and websites for smoking cessation.
75704046|NCT03118063|Diagnostic Test|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
75867740|NCT03730025|Other|Auscultation without NeoTapAS|Auscultation without NeoTapAS
76030498|NCT02226432|Other|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
76030499|NCT02159742|Other|Data Collection|
76030500|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
76030501|NCT02135107|Drug|Rabeprazole|Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
76030502|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
75379383|NCT03906968|Device|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
75379384|NCT05314634|Behavioral|concurrent exercise|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cool down.
75379385|NCT05314634|Behavioral|aerobic exercise|Participants conduct warm up for 5-min, resistance training for 25-min, and 5-min cool down.
75704047|NCT00842998|Drug|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
75867741|NCT03341923|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily disposable wear
75867742|NCT03341923|Device|Etafilcon A multifocal contact lenses|Hydrogel multifocal contact lenses for daily disposable wear
75867743|NCT03579719|Drug|Balovaptan|"In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20."
75867744|NCT03579719|Drug|Itraconazole|In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
75867745|NCT03631602|Drug|antifungal prophylaxis|posaconazole oral suspension vs itraconazole oral solution
76023039|NCT02400853|Device|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
76023040|NCT02400853|Procedure|Cord blood analysis|Cord blood will be collected during deliverance and analysed
76023041|NCT02659631|Drug|PF-06671008|Dose Escalation Phase - Part 1
76023042|NCT02659631|Drug|PF-06671008|Dose Expansion Phase - Part 2
76023043|NCT03173833|Other|CAGO questionnaire outcome|Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
75379386|NCT04206800|Diagnostic Test|Ejaculatory abstinence less than 24 hours|Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
75379387|NCT03689504|Dietary Supplement|Standard of care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
75379388|NCT03689504|Behavioral|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
75379389|NCT03689504|Behavioral|Home-based family gardening|Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
75379390|NCT03455491|Drug|XC221 100 mg|once daily during 3 days.
75379391|NCT03455491|Drug|XC221 200 mg|once daily during 3 days.
75379392|NCT03455491|Drug|Placebo|once daily during 3 days.
75379393|NCT03349567|Behavioral|Audit-and-feedback|We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
75379394|NCT03691844|Drug|AMZ001|diclofenac gel
75379395|NCT03691844|Drug|Placebo|Placebo
75379396|NCT03691844|Drug|Comparator|diclofenac gel
75540349|NCT00574756|Drug|ranolazine|extended release 500 mg twice a day for two weeks
76030503|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
76030504|NCT02097706|Drug|NMDA receptor antagonist (active drug)|
76030505|NCT02097706|Other|Lactose packed capsule (inert/inactive arm)|
76030506|NCT02034526|Device|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
76030507|NCT02034526|Device|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
75379397|NCT03456427|Device|Patient-Assisted Compression (PAC)|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views Craniocaudal (CC) & Mediolateral Oblique (MLO).
75379398|NCT03456427|Device|Technologist-Controlled (TC) Compression|TC compression will be conducted per standard of care practices at the site.
75867746|NCT03732989|Device|Interactive toy prototype|The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).
75867747|NCT03732989|Device|Non-interactive toy prototype|This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
75867748|NCT03341533|Procedure|Ice packs plus usual post-op analgesia|A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
75867749|NCT03341533|Other|Usual post-op analgesia|Standard post-operative analgesia orders will be followed.
75867750|NCT03732911|Behavioral|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
75867751|NCT03631524|Device|Telerehabilitation|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period.
75867752|NCT03729791|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
75867753|NCT03708445|Diagnostic Test|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~conventional cytology staining method~new cytology staining method using antibody of aminoacyl-tRNA synthetases"
75540350|NCT03453658|Procedure|Manual instrumentation|Manual conventional files will be used in endodontic treatment of primary teeth
75867754|NCT02688088|Drug|Drug Cocktail|Administered orally
76030508|NCT02030847|Biological|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10^8 transduced CAR T cells
75379399|NCT04195880|Other|Interventions to Reduce Acute Care Transfers|Experimental CLCs were trained in INTERACT QI Intervention, containing tools, strategies and educational resources designed to catch and manage acute changes in conditions early that a Veteran may be experiencing, leading to a potential reduction in preventable hospital transfers from CLCs.
75867755|NCT02688088|Drug|Abemaciclib|Administered orally
75867756|NCT05598216|Diagnostic Test|no intervention, Serum LDL cholesterol calculation|The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)
75867757|NCT03641651|Other|Rehabilitation technology|"Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~The training can take place in an outpatient or inpatient setting.~Training will be organized in individual one-to-one or group session"
76030509|NCT02030847|Biological|CART-19|As of June 2014, dose was reduced to a single dose of 1-5x10^7 CART-19 cells.
76030510|NCT02030847|Biological|CART-19|In the protocol amendment in November 2014, the dose remained 1-5 x 10^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
76030511|NCT02030847|Biological|CART-19|In the protocol amendment in May 2015, the dose was changed to 1-5 x 10^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10^7), 30% on Day 2 (3x10^7-1.5x10^8), 60% on Day 3 (6x10^7-3x10^8).
76030512|NCT02030834|Biological|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
75379400|NCT03352609|Device|Active rTMS with MagVenture MagPro double blind rTMS system|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
75379401|NCT03352609|Device|Sham rTMS|Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
76030513|NCT01982448|Drug|Cisplatin|
75540351|NCT03453658|Procedure|Reciprocating Instrumentation|Reciprocating files system will be used in endodontic treatment of primary teeth.
75379402|NCT04191668|Device|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
75379403|NCT03354325|Behavioral|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
75379404|NCT03354325|Behavioral|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
75867758|NCT04728204|Behavioral|Depresijos terapija|Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
75379405|NCT03892460|Device|neuromuscular electrical stimulation|bilateral quadriceps exercise with neuromuscular electrical stimulation
75540352|NCT03453424|Procedure|TEA+DEX|intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
76030514|NCT01982448|Drug|Paclitaxel|
75867759|NCT03341299|Biological|LY900014|Administered SC
75867760|NCT03341299|Biological|Insulin Lispro|Administered SC
75867761|NCT05653960|Other|EMR or ESD|Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms
75867762|NCT05666219|Drug|Aminophylline Injection|Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.
75867763|NCT02949271|Other|Programmed Intermittent Epidural Bolus|
75867764|NCT02949271|Other|Continuous Epidural Infusion|
75867765|NCT02949271|Drug|Ropivacaine|
75867766|NCT02949271|Drug|Fentanyl|
75867767|NCT03732755|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
75867768|NCT03706807|Other|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
76030515|NCT01980264|Device|Harmonic Generation Microscopy|Harmonic Generation Microscopy is a nonlinear optical microscopy.
75379406|NCT03232645|Device|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
76030516|NCT01885299|Radiation|SRS/SBRT|Intervention varies by condition being treated.
76030517|NCT01839838|Radiation|Proton Therapy|
76030518|NCT01837602|Biological|cMet RNA CAR T cells|
75867769|NCT03706807|Other|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
75867770|NCT03640559|Drug|Seroguard|
75867771|NCT03640559|Drug|Placebos|
76030519|NCT01809041|Drug|Sevoflurane|
76030520|NCT01809041|Drug|propofol|
76030521|NCT01809041|Drug|remifentanil|
76030522|NCT01805466|Device|EVADO|EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.
76030523|NCT01805466|Device|Conventional CPB|conventional miniature cardiopulmonary bypass technique
75379407|NCT00377936|Drug|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
75379408|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
75379409|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
75379410|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
76030524|NCT01773421|Drug|E7820|"FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8."
75867772|NCT03339583|Behavioral|Brief behavioral therapy|"program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off."
75704048|NCT00806637|Procedure|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
75704049|NCT00806637|Procedure|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
75379411|NCT03457909|Device|DS-MCE|During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
75379412|NCT03696758|Procedure|Pulmonary Function Testing|Subjects will undergo spirometry, Plethysmography, and diffusion capacity.
75704050|NCT00716768|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
75704051|NCT00716768|Procedure|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
75379413|NCT03696758|Procedure|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
75379414|NCT03696758|Procedure|Cardiac Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
75704052|NCT01034449|Other|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
75704053|NCT00716846|Drug|simvastatin|10mg, 2 weeks
75704054|NCT00716846|Drug|atorvastatin|10mg
75704055|NCT00716846|Drug|pitavastatin|2mg
76030525|NCT01773421|Drug|E7820|"MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID."
76030526|NCT01747486|Biological|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
76030527|NCT01733238|Drug|PNT2258|
76030528|NCT01689727|Drug|Technetium Tc 99m EC20|
75379415|NCT03696758|Drug|Metoprolol|Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
75704056|NCT00797979|Device|Skull Grip bone fixation|Skull Grip bone fixation
75704057|NCT00797979|Device|sutures|Standard skull bon flap fixation, sutures
75704058|NCT00620854|Drug|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
75704059|NCT00620854|Drug|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
76030529|NCT01689714|Drug|Tc 99m EC20|
76030530|NCT01689662|Drug|Tc 99m EC20|
76030531|NCT01689636|Drug|Tc 99m EC20|
75379416|NCT03696758|Drug|Sildenafil|Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
75379417|NCT03461965|Behavioral|3D printed model|A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery
75704060|NCT00620854|Drug|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
75704061|NCT00620854|Drug|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
75704062|NCT05672966|Biological|Human papillomavirus (HPV) Vaccine|0.5mL, Intramuscular
75704063|NCT05672966|Biological|Placebo|0.5mL, Intramuscular
75704064|NCT00716924|Drug|Clopidogrel|300 mg
75704065|NCT00716924|Drug|Clopidogrel|600 mg
75704066|NCT00430027|Drug|Capecitabine|Given 650 mg/m^2 BID on days of ration therapy, 825 mg/m^2 day 1-14, day 15-20 off x 4
76030532|NCT01686256|Drug|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
76030533|NCT01684098|Drug|Tc 99m EC20|
76030534|NCT01593254|Drug|Imatinib|
76030535|NCT01593254|Drug|Dasatinib|
76030536|NCT01581489|Procedure|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
76030537|NCT01570998|Radiation|Intraoperative Radiation Therapy|Undergo IORT
76030538|NCT01570998|Other|Laboratory Biomarker Analysis|Correlative studies
76030539|NCT01559818|Biological|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
76030540|NCT01537601|Procedure|Circumcision|Circumcision
76030541|NCT01537601|Other|Antibiotic prophylaxis alone|Antibiotic prophylaxis alone
76030542|NCT01525394|Drug|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
76030543|NCT01525394|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
75867773|NCT03339583|Drug|Zopiclone|zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
75867774|NCT03639779|Drug|Sodium Thiosulfate|A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
75704067|NCT00430027|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2, 130mg/m2 IV Q 21 days x 4
75704068|NCT00430027|Drug|Cetuximab|Initial Cetuximab 400 mg/m^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
75704069|NCT04043182|Procedure|ultrassound|The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
75704070|NCT04043260|Device|Advisor Pro|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
75867775|NCT03639779|Other|Saline Solution|A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.
75867776|NCT05239195|Other|Video Laryngoscope|Laryngoscope with a camera and a video screen
75867777|NCT05239195|Other|Direct Laryngoscope|Laryngoscope without a camera or a video screen
75867778|NCT03575975|Device|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
75867779|NCT05174923|Behavioral|Short Performance Physical Battery (SPPB Test)|The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.
75867780|NCT05174923|Behavioral|30 Second Chair Stand Test (30CST)|The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.
75867781|NCT05174923|Behavioral|Hand grip dynamometry|Grip strength is used as a marker of overall muscle strength.
76030544|NCT01525394|Drug|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
75704071|NCT00717080|Procedure|IOL surgery|IOL surgery using capsular tension ring (AURORING)
75704072|NCT00717080|Procedure|IOL surgery|IOL surgery without CTR
75867782|NCT03636893|Drug|FLOT Chemotherapy|5-FU+Leucovorin+Docetaxel+Oxaliplatin
75867783|NCT03636893|Drug|SOX Chemotherapy|Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
75704073|NCT04766229|Combination Product|Citalopram +/- Gabapentin + Sleepio + support person|All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
75704074|NCT04068506|Drug|Gabapentin 600 mg Tab|Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
75704075|NCT03871335|Diagnostic Test|Investigation of the work-related musculoskeletal disorders|Structured questionnaires will be used to determine the prevalence of the work-related musculoskeletal disorders and work-related factor. Photogrammetric method will be used to evaluate working posture.
75704076|NCT00851188|Behavioral|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
75379418|NCT03461965|Behavioral|Verbal Counselling|Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
75704077|NCT00851188|Behavioral|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
75704078|NCT00851188|Other|Waiting list|Waiting list
75704079|NCT04068740|Procedure|Surgical treatment of valvular heart disease|Valve replacement or repair
75704080|NCT04068740|Diagnostic Test|Virtual treatment|Virtual valve replacement or repair surgery
75704081|NCT00803907|Drug|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
75704082|NCT00843154|Drug|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
75704083|NCT00843154|Drug|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
75704084|NCT00803985|Procedure|Total Extraperitoneal repair (TEP)|Operation for primary inguinal hernias i men
75704085|NCT00803985|Procedure|Lichtenstein|Operation for primary inguinal hernias i men
75704086|NCT00429793|Drug|temsirolimus|Given IV
75704087|NCT00851266|Biological|V512|"Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;"
75704088|NCT00851266|Biological|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
75867784|NCT05174689|Diagnostic Test|Exercise challenge in the cold chamber (ECC)|Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.
76030545|NCT01510678|Behavioral|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F&Vs is perceived cost of these foods, information regarding lower-cost options for F&Vs will be included in the manual.
76030546|NCT01510678|Behavioral|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
75704089|NCT04067570|Radiation|SBRT|Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
75704090|NCT00806871|Drug|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
75867785|NCT05174689|Diagnostic Test|mRNA profile|Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
75867786|NCT05174689|Diagnostic Test|standard diagnostic|bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
75379419|NCT03702608|Combination Product|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - (PBMA) and CarboSil®~Ridaforolimus drug"
75379420|NCT03233737|Combination Product|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
75704091|NCT00806871|Drug|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
76030547|NCT01510678|Behavioral|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
76030548|NCT01454934|Drug|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
75704092|NCT00806871|Drug|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline"
75704093|NCT00717158|Behavioral|Usual medical care|
75704094|NCT00717158|Behavioral|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
75704095|NCT00855400|Procedure|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
75540353|NCT03453424|Procedure|TEA|"Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml."
75540354|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
75867787|NCT03729635|Procedure|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
75540355|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
75540356|NCT00235131|Device|Smart Stent|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
75540357|NCT00235131|Device|Luminexx Stent|Bard® Luminexx™ 6F Vascular Stent
75867788|NCT05581693|Drug|L04RD1|1 tablet of L04RD1
75867789|NCT05581693|Drug|L04TD2|1 tablet of L04TD2
76030549|NCT01454934|Drug|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
75540358|NCT03453346|Drug|Sofosbuvir|Generic sofosbuvir tablet 400 mg
75540359|NCT03453346|Drug|Ribavirin|Ribavirin was provided in 100-mg tablets.
75540360|NCT00575068|Drug|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A & II-B - Dosage start at the MTD (up to 375 mg/m2)
75704096|NCT00855400|Procedure|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
75867790|NCT05581693|Drug|L04TD2|1 tablet of L04TD2
75867791|NCT05581693|Drug|L04RD1|1 tablet of L04RD1
75867792|NCT05568121|Drug|L04RD1|1 tablet of L04RD1
75867793|NCT05568121|Drug|L04TD1|1 tablet of L04TD1
75867794|NCT05568121|Drug|L04TD1|1 tablet of L04TD1
75867795|NCT05568121|Drug|L04RD1|1 tablet of L04RD1
75867796|NCT01353586|Device|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
75379421|NCT03233737|Device|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
75379422|NCT03233737|Device|One spray CTY-5339-P|Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
75379423|NCT05440747|Other|TFR(Treatment-Free Remission)|Withdrawal TKIs(Tyrosine kinase inhibitors: Imatinib or Flumatinib or Nilotinb or Dasatinib)
75379424|NCT04144088|Drug|Wu Ling San|assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
75379425|NCT04144088|Drug|Yin-Chen Wu Ling San|assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
75379426|NCT04144088|Drug|Placebo|1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
75379427|NCT03359629|Device|Spectrophon Glucometry Monitor|Wearable smartwatch with integrated non-invasive glucose detection system
75379428|NCT03359629|Device|YSI 2300 Stat Plus|Reference commercial glucometer
75379429|NCT03462745|Device|AccuVein AV 300|Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
75379430|NCT03711578|Drug|Tenalisib,|BID, Orally
76030550|NCT01442246|Drug|Leuprorelin Acetate|Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
76030551|NCT01439282|Drug|eribulin mesylate|Cohort I & II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
75867797|NCT03708289|Radiation|DXA scan|total and hip and spine dual energy x-ray absorptiometry
76030552|NCT01439282|Drug|capecitabine|Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
75704097|NCT00798213|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
75867798|NCT03708289|Other|Achilles bone US|
75867799|NCT03708289|Other|Medical body composition measurements|
76030553|NCT01391026|Behavioral|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
76030554|NCT01326312|Drug|GTx-758 1000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
75867800|NCT03708289|Other|Resting energy expenditure measurement|
76030555|NCT01326312|Drug|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
76030556|NCT01326312|Drug|GTx-758 2000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
76030557|NCT01321554|Drug|Lenvatinib|Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
75867801|NCT05173441|Biological|Human COVID-19 immunoglobulin (pH4) for intravenous injection|The initial infusion rate is 0.01 ~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
75867802|NCT05173441|Drug|Placebo|The initial infusion rate is 0.01 ~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
75867803|NCT05682469|Behavioral|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~All participants will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
75867804|NCT05682469|Behavioral|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
75867805|NCT03706651|Device|Infants hospitalized in health facilities performing Tele-expertise|
75704098|NCT00798213|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
75704099|NCT04069208|Drug|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
75379431|NCT03463915|Drug|Bladder instillation WITH triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
75704100|NCT04042246|Behavioral|Information Provision|Provide the information on the importance of the vaccination and tailored vaccination schedule
75379432|NCT03463915|Drug|Bladder instillation WITHOUT triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
75379433|NCT00376441|Procedure|Vaginal Surgery|patients undergoing vaginal surgery
75379434|NCT04147442|Device|Hearing aid with fine-tuned and standard programs|A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
75379435|NCT03237871|Behavioral|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
75379436|NCT04146272|Device|Hearing Aid Mermaid Current|The current hearing aid used to treat hearing loss.
75704101|NCT04067258|Diagnostic Test|EDI-OCT|"EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged."
75867806|NCT05682313|Diagnostic Test|Elastography arm|Renal ultrasound elastography to detect and classify the degree of fibrosis
75867807|NCT03708133|Drug|Nifurtimox (Lampit, BAYA2502)_Test|Orally intake of 1 *120mg new formulation tablet as test treatment
75867808|NCT03708133|Drug|Nifurtimox (Lampit, BAYA2502)_Reference|Orally intake of 1 *120mg current clinical formulation tablet as reference treatment
76030558|NCT01321554|Drug|Placebo|Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
75540361|NCT00575107|Other|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
75540362|NCT00575107|Other|Exercise|Standard training of leg extension
75704102|NCT00807027|Drug|Activated T lymphocyte(Immuncell-LC)|"Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)"
75704103|NCT00424645|Drug|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
75540363|NCT00225680|Device|drug eluting coronary stent|
75540364|NCT00575224|Drug|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
75540365|NCT00235170|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
76030559|NCT01321554|Drug|Lenvatinib|"Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg."
76030560|NCT01308437|Biological|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
76030561|NCT01308437|Biological|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
75379437|NCT04146272|Device|Hearing Aid Mermaid New|The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
75540366|NCT00590941|Procedure|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
76030562|NCT01269346|Drug|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
75379438|NCT04146272|Device|Power Hearing Aid Current|The current power hearing aid used to treat strong hearing loss.
75379439|NCT04146272|Device|Power Hearing Aid New|The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
75379440|NCT03473665|Drug|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
75540367|NCT00225719|Drug|rHDL|
75540368|NCT00255294|Drug|Cellulose sulfate vaginal gel|
75540369|NCT00591058|Drug|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
75540370|NCT00591136|Drug|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
75540371|NCT00591292|Drug|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
75540372|NCT00591331|Drug|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
75379441|NCT03473665|Drug|Diclofenac|Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
75540373|NCT00591331|Drug|placebo|
75540374|NCT00591448|Other|Virtual Reality (VR)|See above
75540375|NCT00235209|Device|Collagen ORC Antimicrobial Matrix (CAM)|
75540376|NCT00225836|Device|OVA (TENS apparatus)|
75704104|NCT00424645|Drug|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
75704105|NCT00845104|Drug|fludarabine phosphate|Given IV
75704106|NCT00845104|Biological|rituximab|Given IV
75704107|NCT00845104|Biological|bevacizumab|Given IV
75540377|NCT00591487|Drug|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
75540378|NCT03452215|Behavioral|Mobile Phone Application Educational Resources|Mobile Phone Application Educational Resources
75540379|NCT03452215|Behavioral|Mobile Phone Application GWG Tracker|Mobile Phone Application GWG Tracker
75540380|NCT00255333|Drug|INNO-105|
75540381|NCT03452059|Device|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
75540382|NCT00225875|Drug|Mabthéra|
75540383|NCT03452020|Device|Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer|Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
75704108|NCT00845104|Other|laboratory biomarker analysis|Correlative studies
75704109|NCT00845104|Other|flow cytometry|Correlative studies
75704110|NCT00845104|Genetic|polymerase chain reaction|Correlative studies
75540384|NCT03451981|Procedure|mechanical debridement and chemical decontamination|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with chlorhexidine.
75540385|NCT03451981|Procedure|Er:YAG laser|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine. Furthermore, Er:YAG laser treatment will be provided on the implant surface.
75540386|NCT03451981|Procedure|Air Powder|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Clorhexidine. Furthermore, an Air-Powder treatment will be provided on the implant surface.
76030563|NCT01268293|Drug|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
75540387|NCT03451942|Drug|FLOT regimen chemotherapy|FLOT regimen chemotherapy
75540388|NCT03451942|Procedure|D2 gastric and imaging metastases resection|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
75540389|NCT00255372|Drug|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
75540390|NCT00255372|Drug|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
75540391|NCT00225914|Drug|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
75540392|NCT00225914|Drug|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
75540393|NCT03451903|Drug|Actilyse|Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
75540394|NCT03451903|Procedure|Mechanical thrombectomy|Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
75379442|NCT03473665|Drug|Meloxicam|meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
75540395|NCT03451864|Procedure|Vaginal delivery|classic vaginal delivery
75540396|NCT03451864|Procedure|Cesarean Section|routine lower segment cesarean scetion
75704111|NCT00845104|Genetic|fluorescence in situ hybridization|Correlative studies
75704112|NCT00804063|Procedure|drawing blood sample|fasting blood sample
75867809|NCT05075161|Drug|Pirfenidone|From days 1-7: 801mg/day; from days 8-14:1602mg/day, from day 15 to ICU discharge 2403 mg/day. All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
75867810|NCT05075161|Drug|Placebo|All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
75379443|NCT03473665|Drug|Celecoxib|Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
75379444|NCT03863210|Other|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
75379445|NCT03239665|Behavioral|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
75540397|NCT00235248|Drug|Warfarin|Warfarin
75540398|NCT00235248|Drug|Clopidogrel-aspirin|Clopidogrel-aspirin
75704113|NCT02553681|Device|roflufocon D contact lenses|HPT treated rigid contact lenses
75704114|NCT02553681|Device|RGP contact lenses made from roflufocon D|
75540399|NCT04574323|Radiation|Curative radiotherapy|Standard curative radiotherapy
75704115|NCT01034605|Dietary Supplement|PinnoThin|6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
75704116|NCT03994939|Behavioral|Families Talking Together (FTT)|FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
75704117|NCT00763451|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
75704118|NCT00763451|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
75540400|NCT04574323|Other|Paleolithic lifestyle intervention|This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
75704119|NCT00763451|Device|Pen auto-injector|
75704120|NCT00763451|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
75704121|NCT00762762|Drug|Triclosan/copolymer/fluoride|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
75704122|NCT00762762|Drug|Fluoride|Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
75704123|NCT00424489|Biological|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
75704124|NCT00424489|Drug|Cyclophosphamide|
75704125|NCT00424489|Drug|ATG (rabbit)|
75704126|NCT00424489|Drug|Mesna|
75704127|NCT00424489|Drug|Methylprednisolone|
75704128|NCT00424489|Drug|G-CSF|
75704129|NCT00578864|Drug|Protracted Oral Etoposide|"Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~Hour 0: Etoposide 50 mg/m2 po daily~Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~Etoposide 50 mg/m2 po once daily"
75379446|NCT03239665|Behavioral|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
75379447|NCT03717506|Drug|GDC 268 Lotion|GDC 268 is a topical lotion
75379448|NCT03717506|Drug|Clindamycin Phosphate Lotion 1%|Clindamycin Phosphate Lotion is an FDA-approved drug product
75379449|NCT03717506|Drug|GDC Vehicle Lotion|GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
75540401|NCT00225992|Drug|Arsenic Trioxide|
75704130|NCT00578864|Drug|Doxorubicin|"Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if < 12 kg) with Mesna 400 mg/m2 (13 mg/kg if < 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if < 12 kg) IV over 15 minutes"
75867811|NCT05073055|Procedure|İnguinal Hernia Repair|After hemodynamic stability, the patient was placed in the lateral position and infiltration anesthesia with 2% lidocaine was applied. Following aseptic preparation of the skin and probe, a medium-frequency curvey USG transducer was first placed in the midline to visualize the transverse projection of the first lumbar (L1) vertebra, then moved 2.5 cm laterally in the parasagittal plane, after imaging the transverse process, in-plane spreading was injected. Hydrodissection was achieved on the TP of L1 by using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle with real-time imaging of the substance. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
76030564|NCT01268150|Drug|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
76030565|NCT01267175|Device|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
76030566|NCT01259908|Procedure|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
76030567|NCT01231841|Drug|cyclosporine|Given orally
76030568|NCT01231841|Biological|anti-thymocyte globulin|Given IV
75379450|NCT03861338|Drug|Sublocade|The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
75379451|NCT03851744|Other|Sea Level|Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
75379452|NCT03851744|Other|High Altitude|Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
76030569|NCT01133756|Drug|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
75379453|NCT00377780|Drug|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
75540402|NCT03451435|Drug|N acetyl cysteine|N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
75540403|NCT04719195|Other|Meniscus extrusion ultrasonogrphic evaluation|This study will enroll the patients with knee medial compartment osteoarthritis of the knee joint who undergo open proximal tibial osteotomy. The degree of medial and lateral meniscus extrusion will be measured through ultrasound measurements before and after surgery. Also, demographic factors and radiographic measurements will be also investigated before and after surgery. In addition, preoperative, postoperative 3, 6, and 1 year clinical results including meniscus extrusion will be compared and judged, and the evaluation will be evaluated by an orthopedic surgeon who has not participated in the operation among registered researchers.
75540404|NCT04574596|Other|no Intervention|This is an observational study. There is no intervention
75867812|NCT03706573|Drug|alpelisib|50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
75540405|NCT04575064|Other|Standard of Care (SoC)|Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
75704131|NCT00578864|Drug|IV Bolus Etoposide|"Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2"
75704132|NCT00578864|Drug|Cisplatin|Cycle 1, 2, and 4
75704133|NCT00578864|Drug|Cyclophosphamide|Cycle 3 and 5 with doxorubicin
75704134|NCT00578864|Drug|Mesna|Standard weight-based dosing with cyclophosphamide
75704135|NCT00578864|Drug|Hematopoietic Factor|Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
75704136|NCT00578864|Procedure|Primary tumor resection|Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
75867813|NCT05518357|Biological|LILRB4 STAR-T|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg。
76023044|NCT02405143|Device|Active tACS using DC-Stimulator MC|Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.
76030570|NCT01133756|Drug|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
75704137|NCT01034683|Drug|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
75704138|NCT02579070|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
75704139|NCT00717470|Drug|Prograf®|oral
75704140|NCT00717470|Drug|Advagraf®|oral
75704141|NCT00717470|Drug|Mycophenolate Mofetil|oral
75540406|NCT04575064|Drug|Remdesivir|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first
75540407|NCT03451318|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray NASONEX
75540408|NCT03451318|Procedure|tonsillar adenoidectomy|tonsillar adenoidectomy
75704142|NCT00717470|Drug|Simulect|oral
75704143|NCT00717470|Drug|methylprednisolone / prednisone|oral
75704144|NCT02577198|Other|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
75704145|NCT00631566|Drug|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
75704146|NCT00631566|Drug|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
75867814|NCT05095831|Diagnostic Test|Pancreas EUS shear wave|"EUS Shear wave elastography (SWE) is a form of ultrasound elastography used in transabdominal ultrasonography. It measures tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI). The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals [kPa] or meters per second. Also, the dispersion slope or ultrasound shear wave dispersion (SWD) will be recorded. It is the measure of viscosity [(m/sec)/kHz] using SWE.~A first endoscopist will perform EUS over pancreas tissue. Without any elastography assessment (strain ratio/histogram) , the endoscopist will take ten shear wave measurements of pancreas tissue elasticity by generating shear waves inside the pancreas using the ARFI."
76030571|NCT01133756|Drug|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
75704147|NCT04067414|Biological|BZ019|"Subjects will be enrolled in three dose-groups:~Dose 1: 1×10^6/kg CAR+ cells; Dose 2: 3×10^6/kg CAR+ cells; Dose 3: 6×10^6/kg CAR+ cells."
75704148|NCT00717548|Behavioral|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
75704149|NCT00722852|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
75704150|NCT00722852|Drug|Placebo|100 mg (b.i.d.)
75704151|NCT04838418|Procedure|Optic nerve sheath diameter measured by transorbital ultrasound|Optic nerve sheath diameter measured 3 mm behind eyeball. For every eyeball 2 measurements in axial and 2 measurements in sagital projections are performed. Summary value for every eyeball is arithmetic mean from these 4 measurements.
75704152|NCT00770315|Biological|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
75704153|NCT00770315|Biological|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
75704154|NCT04071600|Drug|Neuropeptide Y|Intranasal
75704155|NCT04071600|Other|Placebo|intranasal
75704156|NCT05657444|Drug|Tenecteplase|intra-arterial tenecteplase during endovascular treatment
76030572|NCT01126736|Drug|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
76030573|NCT01126736|Drug|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
75704157|NCT04072302|Drug|KAF156|100 mg tablet, 20 mg tablet, 50 mg tablet
76030574|NCT01126736|Drug|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
76030575|NCT01117844|Radiation|Proton Radiation|Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
75540409|NCT03451318|Procedure|Maxillary expander plus Twin-Block|Twin-block appliance combined with maxillary expander
75704158|NCT04072302|Drug|Placebo|100 mg tablet, 20 mg tablet, 50 mg tablet
75704159|NCT04103411|Other|24h-Ambulatory Blood Pressure|Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
75704160|NCT00525720|Drug|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
75540410|NCT03451240|Behavioral|Corporate Athlete® Resilience|"The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work."
75540411|NCT04573894|Diagnostic Test|Procalcitonin dosage|Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
75379454|NCT03242941|Procedure|Pulmonary vein ablation|After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
75379455|NCT03719300|Drug|inodiftagene vixteplasmid|"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
75379456|NCT00376519|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
75379457|NCT00376519|Drug|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of >200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
75379458|NCT00376519|Drug|fludarabine phosphate|Fludarabine 25 mg/m^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
75379459|NCT00376519|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
75379460|NCT00376519|Procedure|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10^6/kg, 0.3 x 10^6/kg, 1 x 10^6/kg and 3 x 10^6/kg weight (determined on the day prior to administration of the preparative therapy).
75379461|NCT00376519|Procedure|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
75379462|NCT00376519|Radiation|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
75379463|NCT00422864|Drug|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
75540412|NCT04574284|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
75540413|NCT04574284|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
75540414|NCT04574050|Other|SELF-BREATHE|A self -guided, internet -based intervention for patients with chronic breathlessness
75704161|NCT00525720|Behavioral|Questionnaire|Questionnaires taking 30 total minutes.
75704162|NCT00587171|Device|Patching|2 hours daily patching
75379464|NCT00422864|Drug|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
75540415|NCT00255450|Drug|ferumoxytol or placebo|
75540416|NCT04574128|Procedure|No retransfusion of cardiotomy blood|No retransfusion of cardiotomy blood via heart- and lung mashine
75540417|NCT00226031|Procedure|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
75379465|NCT00422864|Drug|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
75379466|NCT00422864|Procedure|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
75379467|NCT03719378|Other|Pre Operative Oral Fluids|Patients will be self hydrating prior to their total knee replacement.
75379468|NCT03368053|Procedure|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
75379469|NCT03719612|Drug|DEFINITY®|All subjects will receive a single dose of DEFINITY®
75379470|NCT04706611|Procedure|Fecal Microbiota Transplantation|Procedure: Fecal Microbiota Transplantation
75379471|NCT03373591|Drug|Liposomal Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
75379472|NCT03373591|Drug|Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
75379473|NCT03720938|Other|Active Video Games|Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
75379474|NCT03374683|Behavioral|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
75379475|NCT03374683|Behavioral|RR In-Person Workshop|Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
75379476|NCT03374683|Behavioral|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
75379477|NCT03480685|Device|IVUS and OCT Imaging|Use of an imaging catheter
75379478|NCT03378973|Drug|Dexmedetomidine|Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
75379479|NCT03380845|Device|Fraxel Restore|Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
75379480|NCT03380845|Device|Fractora|Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
75379481|NCT04121078|Drug|TAK-906|TAK-906 capsule.
75379482|NCT04121078|Drug|Rifampin|Rifampin infusion.
75379483|NCT03248947|Drug|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
75540418|NCT04573855|Biological|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
76030576|NCT01111461|Drug|Lenvatinib|Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
76030577|NCT01104155|Drug|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
76030578|NCT01104155|Drug|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
76030579|NCT01067287|Drug|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
76030580|NCT01067287|Biological|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
76030581|NCT01065597|Device|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
76030582|NCT01051856|Device|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
76030583|NCT01051856|Procedure|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
75379484|NCT03248947|Other|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
75540419|NCT04574206|Behavioral|Elaborative Reminiscence (ER)|Parents will be trained to use elaborative communication techniques in conversations with their child.
75540420|NCT04574206|Behavioral|Present Tense Talk (PTT)|Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
75540421|NCT04574011|Diagnostic Test|Passive leg raising|Raise the patient's lower limb at a 45 degree angle while lying down
75704163|NCT00587171|Procedure|Near activities|30 minutes daily near activities at home
75379485|NCT04114058|Drug|liposomal bupivicaine|local field infiltration
75379486|NCT04114058|Procedure|Fascia iliaca blockade|fascia iliaca compartment blockade
75379487|NCT03480919|Device|Shen Men acupuncture|20-minute acupuncture session
75379488|NCT03480919|Procedure|Epidural injection|Epidural injection for the relief of back pain
75379489|NCT03817580|Drug|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
75867815|NCT05095831|Diagnostic Test|Pancreas EUS-elastography and EUS-guided biopsy|"Pancreas EUS-elastography measures the pancreatic tissue stiffness through strain ratio (SR) and strain histogram (SH).~A second endoscopist blind to pancreas tissue shear wave findings will perform EUS-elastography with corresponding SR and SH measurements. The SR/SH will be measured and documented. Finally, a pancreas tissue biopsy will be performed. The impossibility of biopsy is an exclusion criterion (except in control patients). Due to ethical purposes, a biopsy will not be performed on patients from the control group."
75379490|NCT03817580|Drug|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
75379491|NCT03817580|Drug|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
75379492|NCT03862040|Drug|Cefiderocol|Administered intravenously, at a dosage determined based on renal function.
75379493|NCT03862040|Drug|Standard of Care Antibiotic|Standard of care antibiotic treatment for pneumonia
75379494|NCT03482713|Drug|Gefapixant 45 mg|Gefapixant 45 mg (film-coated tablet) to be administered orally BID
75379495|NCT03482713|Drug|Placebo|Placebo (film-coated tablet) matching gefapixant to be administered orally BID
75379496|NCT00376831|Drug|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
75704164|NCT00587171|Procedure|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
75867816|NCT03638869|Drug|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
75867817|NCT03638869|Drug|Placebo|
75704165|NCT00587171|Procedure|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
75704166|NCT04833426|Drug|Testosterone gel|Topical gel containing testosterone
75379497|NCT00376831|Drug|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
75704167|NCT04833426|Drug|Placebo|Topical gel without active substance
75704168|NCT02576964|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
75704169|NCT02576964|Drug|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
75704170|NCT00763139|Drug|Pioglitazone|45 mg by mouth once a day for 8 weeks
75704171|NCT00763139|Drug|Placebo|By mouth once a day for 8 weeks
75704172|NCT04074408|Procedure|stereotactic surgery|stereotactic aspiration surgery
75379498|NCT03857750|Drug|Rocuronium|0.6 mg/kg
75379499|NCT03491917|Device|DBT plus S-View|DBT plus S-View images
75379500|NCT03491917|Device|FFDM alone|FFDM alone images
75379501|NCT03828422|Diagnostic Test|imaging|
75379502|NCT03254719|Other|Study assessments|All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
75704173|NCT04074408|Biological|hUMSCs|single intracavitary infusion 1 day after stereotactic aspiration surgery
75704174|NCT04074408|Biological|placebo|single intracavitary infusion 1 day after stereotactic aspiration surgery
75704175|NCT01366092|Drug|Interleukin-2|Daily subcutaneous IL-2 (1 x 10^6 IU/m^2/day) for self-administration for 12 weeks followed by 4-week hiatus
75704176|NCT00781859|Drug|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
75704177|NCT00781859|Drug|Placebo|Placebo intravitreal injection
75704178|NCT02576886|Device|Gamma Camera|All images acquired with the General Electric Discovery 530c
75704179|NCT02576886|Procedure|Prone Imaging|
75704180|NCT04100915|Other|No Intervention|There is no intervention for this study
75704181|NCT01344252|Drug|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
75379503|NCT04084028|Behavioral|Active Cooking Classes|6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.
75379504|NCT04084028|Behavioral|Meal Kits|Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.
75379505|NCT04084028|Behavioral|Recipes|Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.
75704182|NCT04101383|Drug|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
75704183|NCT04101383|Drug|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
75704184|NCT02576808|Drug|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
75704185|NCT02576808|Drug|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
75704186|NCT04100681|Device|Active FlowOx™|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
75704187|NCT04100681|Device|Sham FlowOx™ (Placebo)|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
75704188|NCT04098965|Other|Pysiotherapy techniques|manual therapy techniques, postural re-education and muscle strengthening
75704189|NCT04098965|Other|physician treatment|hygienic-dietary recommendations, Kegel exercises and pain relievers
75704190|NCT02576730|Procedure|ORIF|surgery for foot and ankle fractures
75704191|NCT04098887|Radiation|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
75704192|NCT04100603|Other|No Intervention|There is no intervention for this study
75704193|NCT00580788|Drug|PTHrP (1-36)|IND # 49,175
75704194|NCT02576106|Device|Cryoablation|
75704195|NCT02575872|Behavioral|Exercise Intervention|Participate in physical activity behavioral intervention
75704196|NCT04071678|Behavioral|Careful examination during endoscopic procedures to identify lesions|When the AI model alarms, check carefully to confirm the lesion
75704197|NCT04073160|Drug|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
75379506|NCT03387319|Behavioral|Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
75379507|NCT03387319|Behavioral|Non-Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
75379508|NCT03852524|Drug|Methylnaltrexone|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
75379509|NCT03852524|Other|Placebo|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
75704198|NCT04073160|Drug|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
75379510|NCT03388645|Biological|10^6.3 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
75379511|NCT03388645|Biological|10^7 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
75704199|NCT04073160|Radiation|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
75704200|NCT04073160|Drug|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
75379512|NCT04081610|Drug|lagricel ofteno multidose|"Dosage: 1 drop 4 times a day per 7 days, both eyes~Route of administration: Ophthalmic"
75704201|NCT00417079|Drug|cabazitaxel (XRP6258) (RPR116258)|25 mg/m^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
75379513|NCT04081610|Drug|lagricel ofteno single dose|"Dosage: 1 drop 4 times a day per 7 days, both eyes~Route of administration: Ophthalmic"
75379514|NCT03390907|Device|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
75379515|NCT04713878|Other|Mesenchymal stem cells|Intravenous infusion of Mesenchymal stem cells
75379516|NCT03840278|Device|Bihormonal iLet Bionic Pancreas|Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
75379517|NCT03840278|Device|Insulin-only Bionic Pancreas|Insulin-only iLet Bionic Pancreas using just insulin
75379518|NCT03840278|Drug|Dasiglucagon|Experimental stable glucagon for use in the iLet Bionic Pancreas
75379519|NCT04735783|Dietary Supplement|Placebo breakfast|Participants will consume a very low-energy, placebo breakfast meal, but will be unaware of its near complete absence of energy until the end of the study.
75704202|NCT00417079|Drug|mitoxantrone|12 mg/m^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
76030584|NCT01044069|Biological|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed & frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, & transduced with the 19-28z chimeric receptor & expanded. All relapsed (either MRD+ or morphologic) & refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo & highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
75704203|NCT00417079|Drug|prednisone|10 mg daily administered by oral route
75704204|NCT00429169|Drug|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
75704205|NCT00429169|Drug|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
76030585|NCT01029366|Biological|CART-19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
75540422|NCT04721379|Behavioral|Meditation|"Group 1 participants with unguided session simply close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be asked to relax with eyes closed for 30 minutes. After finishing the session, they fill out meditation depth questionnaire.~Group 2 participants with guided sessions close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be guided through relaxation and meditation session for 30 minutes with a Heartfulness trainer with continued recording. After finishing the session, they also fill out meditation depth questionnaire."
75540423|NCT00226109|Drug|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
75540424|NCT04573426|Drug|Acetaminophen|1,000mg liquid acetaminophen
75540425|NCT04573426|Drug|Placebo|Liquid placebo solution
76030586|NCT00897767|Other|biologic sample preservation procedure|
76030587|NCT00879086|Drug|Eribulin Mesylate|"E7389 (eribulin mesylate) given at a dose of 1.4 mg/m^2 as a 2 to 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
75704206|NCT02575716|Device|Videolaryngoscope|Intubation with McGrath video laryngoscope after muscle relaxant
75704207|NCT01034761|Behavioral|Pop-up alert|Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
75867818|NCT03708055|Behavioral|Exercise Intervention|Undergo weight bearing exercise program
75867819|NCT03091920|Drug|IW-1973|Oral Tablet
75867820|NCT03091920|Drug|Placebo|Oral Tablet
75867821|NCT03338569|Drug|Vitamin C|Continuous infusion of vitamin C
75867822|NCT03338569|Drug|Placebo|Placebo designed to mimic intervention
75867823|NCT03338023|Drug|LY2963016|Administered SC
75867824|NCT03338023|Drug|Lantus®|Administered SC
75867825|NCT03338023|Drug|Insulin Lispro|Administered SC
76030588|NCT00879086|Drug|Ixabepilone|"Ixabepilone given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
76030589|NCT00796263|Drug|HAART|"2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily"
75379520|NCT04735783|Dietary Supplement|Typical whole-food breakfast|Participants will consume a typical whole-food breakfast meal, equating to 20% of estimated energy requirements.
76030590|NCT00715442|Drug|Sunitinib|50 mg by mouth daily for 28 consecutive days
75540426|NCT04573426|Behavioral|Weight stigma vignette|Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
76030591|NCT00715442|Procedure|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
76030592|NCT00675922|Drug|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
75540427|NCT04573426|Behavioral|Control vignette|Short vignette meant to have no effect on emotion describing a generic promotion process
75540428|NCT00235287|Drug|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
75540429|NCT00235287|Drug|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
75540430|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
75540431|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
76030593|NCT00591812|Device|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
75379521|NCT04735783|Dietary Supplement|Water-only control|Participants will consume a volume of plain water to match the water content of the very low-energy placebo breakfast and the typical whole-food breakfast.
75379522|NCT03838874|Drug|Low-Dose Bupivacaine|10 mg (2 mL of 0.5%) administered as an isobaric spinal anesthetic
76030594|NCT00466531|Biological|therapeutic autologous lymphocytes|
76030595|NCT00466531|Drug|cyclophosphamide|
76030596|NCT00458653|Biological|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
76030597|NCT00244933|Dietary Supplement|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
76030598|NCT00244933|Drug|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days
76030599|NCT00244933|Procedure|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
75379523|NCT03838874|Drug|Mepivacaine|70 mg (3.5 mL of 2%) administered as an isobaric spinal anesthetic
75379524|NCT04332302|Other|Power resistance training|Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.
75379525|NCT03815240|Other|No dressing|no dressing at sacrum
75379526|NCT03815240|Other|Mepilex® Border Sacrum|adhesive sacrum dressing
75379527|NCT03815240|Other|ALLEVYN Life Sacrum|adhesive sacrum dressing
75379528|NCT03815240|Other|Optifoam® Gentle Sacrum|adhesive sacrum dressing
75379529|NCT04071392|Procedure|Hysterosalpingogram (HSG)|An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.
75379530|NCT04045964|Drug|nicotine replacement therapy (NRT)|Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
75379531|NCT04045964|Behavioral|motivational advice|Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
75379532|NCT04045964|Behavioral|Quitline referral|Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
76030600|NCT00165425|Procedure|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
75379533|NCT03941912|Device|Erchonia EVRL|Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
75540432|NCT00226148|Procedure|Use of a membrane to cover bonedefects around implant|
75540433|NCT00226148|Device|Use of bonechips to fill up defects around implant|
76030601|NCT00121719|Drug|Lenvatinib|Lenvatinib tablets taken orally, once daily.
75540434|NCT00226148|Procedure|Use of membrane and bonechips to manage defects|
75540435|NCT04573348|Diagnostic Test|Savicell's ImmunoBiopsy™|ImmunoBiopsy and ELISA
75540436|NCT04573621|Procedure|Pelvic drain|A pelvic drain is placed
75540437|NCT04573621|Other|No pelvic drain is placed|A pelvic drain is not placed
76030602|NCT00053209|Drug|gemcitabine hydrochloride|
75540438|NCT04573465|Behavioral|Phone Coaching|Participants receiving phone coaching receive one 10-15 minute phone call each week from their randomly assigned peer-support coach. During coaching calls, the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed, asking what the participant liked/disliked about the modules, etc.).
76030603|NCT00053209|Drug|pemetrexed disodium|
76030604|NCT00039429|Drug|atrasentan hydrochloride|
76030605|NCT00014508|Biological|sargramostim|
76030606|NCT00014508|Drug|cyclophosphamide|
75540439|NCT04573465|Behavioral|Text Message Coaching|Participants receiving text message coaching receive text messages on a weekly basis from their randomly assigned peer-support coach. Text messages from the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed).
75704208|NCT01037491|Drug|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
76030607|NCT00014508|Drug|cyclosporine|
76030608|NCT00014508|Drug|fludarabine phosphate|
76030609|NCT00014508|Drug|melphalan|
76030610|NCT00014508|Procedure|peripheral blood stem cell transplantation|
76030611|NCT00006390|Biological|alemtuzumab|
76030612|NCT00006390|Biological|filgrastim|
76030613|NCT00006390|Drug|cyclophosphamide|
76030614|NCT00006390|Procedure|peripheral blood stem cell transplantation|
76030615|NCT00006390|Radiation|radiation therapy|
76030616|NCT00005962|Biological|sargramostim|
76030617|NCT00005962|Drug|cyclophosphamide|
76030618|NCT00005962|Drug|cytarabine|
75540440|NCT04573465|Behavioral|ACT Guide|ACT Guide is an online self-help program based on acceptance and commitment therapy (ACT), targeting acceptance, mindfulness, and values-based processes. It is intended to be used for 20 to 40 minutes at time, a few times a week. While using ACT Guide, participants will read about concepts relevant to ACT and engage in guided experiential exercises, with additional exercises being assigned to be completed in between sessions as homework.
75540441|NCT00255489|Drug|Gefitinib|
76030619|NCT00005962|Drug|gemtuzumab ozogamicin|
76030620|NCT00005962|Drug|liposomal daunorubicin citrate|
75540442|NCT00255489|Procedure|palliative thoracic radiotherapy|
75379534|NCT04048460|Device|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
76030621|NCT00005962|Drug|topotecan hydrochloride|
75379535|NCT04016324|Device|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
75379536|NCT04039412|Drug|Hybrid regimen|two-step (dual-quadruple) treatment
75540443|NCT04573153|Drug|Hydroxychloroquine + Metabolic cofactor supplementation|Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
75540444|NCT04573153|Drug|Hydroxychloroquine + Sorbitol|Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
76030622|NCT00005847|Biological|recombinant interferon alfa|
76030623|NCT00005847|Drug|estramustine phosphate sodium|
76030624|NCT00005847|Drug|isotretinoin|
76030625|NCT00005847|Drug|mitoxantrone hydrochloride|
76030626|NCT00005847|Drug|paclitaxel|
76030627|NCT00005847|Drug|vinorelbine ditartrate|
76030628|NCT00005644|Drug|gemcitabine hydrochloride|
76030629|NCT00005644|Drug|paclitaxel|
76030630|NCT00003871|Biological|fowlpox virus vaccine vector|
76030631|NCT00003871|Biological|recombinant vaccinia prostate-specific antigen vaccine|
76030632|NCT00003809|Biological|cetuximab|
76030633|NCT00003809|Drug|cisplatin|
76030634|NCT00003808|Drug|theophylline|
76030635|NCT00003800|Other|immunohistochemistry staining method|
75379537|NCT04039412|Drug|Reverse hybrid regimen|one-step two-phase (quadruple-dual) treatment
76030636|NCT00003800|Other|laboratory biomarker analysis|
76030637|NCT00003800|Procedure|radionuclide imaging|
75379538|NCT04039412|Drug|Levofloxacin quadruple regimen|non-Clarithromycin non-Bismuth quadruple therapy
75540445|NCT00226187|Procedure|Supplement of fatty acid (DHA and AA)|
75379539|NCT04036838|Combination Product|PyloPlus UBT System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
75379540|NCT04036838|Diagnostic Test|Histology|Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
75379541|NCT04036838|Diagnostic Test|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
76030638|NCT00003649|Biological|Ad5CMV-p53 gene|
76030639|NCT00003592|Drug|methotrexate|
76030640|NCT00003592|Drug|paclitaxel|
76030641|NCT00003518|Drug|gemcitabine hydrochloride|
75379542|NCT04036838|Diagnostic Test|H.pylori Culture|Biopsy specimen obtained and sent to lab for culture analysis
75379543|NCT03831854|Drug|Lamotrigine 300 MG|300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P<.05).
75379544|NCT03831854|Drug|Placebo|300 mg of oral Placebo
75379545|NCT03831854|Drug|Ketamine|1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
75379546|NCT03806270|Drug|Midazolam|Demizolam 15mg/ml ampules, given orally with cherry juice
75379547|NCT03806270|Drug|Hydroxyzine Dihydrochloride|Atarax 2mg/ml syrup, given orally
75379548|NCT03828734|Device|Theta TMS|TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)
75540446|NCT02277418|Device|VAVL|Videolaryngoscope
75540447|NCT02277418|Device|MIL|Direct laryngoscopy
75540448|NCT00255528|Drug|metoprolol succinate|
75540449|NCT04573270|Biological|PrimePro|Intravenous Injection
75540450|NCT04573270|Other|Placebo|Intravenous Injection
75540451|NCT00226226|Procedure|Peripherally Inserted Central Catheter Placement|
76030642|NCT00003518|Drug|paclitaxel|
76030643|NCT00003444|Biological|recombinant interferon alfa|
76030644|NCT00003444|Radiation|radiation therapy|
76030645|NCT00003388|Biological|filgrastim|
76030646|NCT00003388|Drug|cyclophosphamide|
76030647|NCT00003388|Drug|cytarabine|
76030648|NCT00003388|Drug|methotrexate|
76030649|NCT00003388|Drug|pegylated liposomal doxorubicin hydrochloride|
76030650|NCT00003388|Drug|prednisone|
76030651|NCT00003388|Drug|vincristine sulfate|
76030652|NCT00003388|Radiation|radiation therapy|
76030653|NCT00003376|Drug|carboplatin|
76030654|NCT00003376|Drug|cisplatin|
76030655|NCT00003376|Drug|doxorubicin hydrochloride|
76030656|NCT00003376|Drug|methotrexate|
76030657|NCT00003376|Drug|paclitaxel|
76030658|NCT00003376|Drug|vinblastine|
76030659|NCT00003353|Biological|filgrastim|
76030660|NCT00003353|Drug|melphalan|
76030661|NCT00003353|Procedure|bone marrow ablation with stem cell support|
76030662|NCT00003353|Procedure|peripheral blood stem cell transplantation|
76030663|NCT00003309|Biological|filgrastim|
76030664|NCT00003309|Drug|cisplatin|
76030665|NCT00003309|Drug|cyclophosphamide|
76030666|NCT00003309|Drug|etoposide|
76030667|NCT00003309|Drug|vincristine sulfate|
75540452|NCT04572919|Procedure|lateral advancement flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
75540453|NCT04572919|Procedure|classic Limberg flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
75540454|NCT04572685|Drug|Paliperidone Palmitate|A long acting extended release injectable suspension intended for monthly intramuscular administration
75704209|NCT02578836|Procedure|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
75704210|NCT03994237|Other|semi-structured interview|The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
75704211|NCT01033201|Other|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
75704212|NCT01033279|Other|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
75704213|NCT02046330|Device|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
75704214|NCT00194298|Procedure|FDG-PET Imaging|
75704215|NCT04071522|Other|no intervention|no intervention
75704216|NCT02576418|Other|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
75704217|NCT02576340|Drug|otilonium bromide|otilonium bromide was administered before the procedure
75379549|NCT03828734|Device|Alpha TMS|TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)
75379550|NCT03828734|Device|Arrhythmic TMS|TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
75379551|NCT04033640|Diagnostic Test|SD Biosensor STANDARD G6PD Test|"The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product."
75379552|NCT04033640|Diagnostic Test|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
75379553|NCT04033640|Diagnostic Test|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
75704218|NCT02578602|Drug|Gadoxetate Disodium|Given IV
75704219|NCT02578602|Device|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
75704220|NCT02574702|Procedure|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
75867826|NCT03337477|Drug|Placebo|Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
76030668|NCT00003309|Procedure|adjuvant therapy|
76030669|NCT00003309|Radiation|radiation therapy|
76030670|NCT00003308|Radiation|stereotactic radiosurgery|
76030671|NCT00003237|Drug|cisplatin|
76030672|NCT00003237|Drug|paclitaxel|
76030673|NCT00003237|Procedure|surgical procedure|
76030674|NCT00003129|Drug|valrubicin|
76030675|NCT00003027|Biological|aldesleukin|
76030676|NCT00003027|Biological|filgrastim|
76030677|NCT00003027|Biological|recombinant interferon alfa|
76030678|NCT00003027|Drug|cisplatin|
76030679|NCT00003027|Drug|dacarbazine|
76030680|NCT00003027|Drug|vinblastine|
76030681|NCT00002934|Procedure|long-term screening|
76030682|NCT00002914|Drug|piritrexim|
76030683|NCT00002872|Biological|bleomycin sulfate|
76030684|NCT00002872|Drug|doxycycline|
76030685|NCT00002872|Other|talc|
75867827|NCT03337477|Drug|Sodium Zirconium Cyclosilicate(ZS)|Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
75379554|NCT04033640|Diagnostic Test|Complete blood count (CBC)|In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
75867828|NCT03337477|Drug|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
75379555|NCT03497845|Biological|VN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
75379556|NCT03497845|Biological|IN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
75379557|NCT03497845|Biological|dk/BANG|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
75379558|NCT03497845|Biological|gf/WA|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
75704221|NCT04071444|Other|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
75379559|NCT03497845|Biological|bhg/QL|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
75379560|NCT03497845|Biological|AS03 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
75379561|NCT03497845|Biological|MF59 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
75379562|NCT04036292|Drug|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
75379563|NCT04036292|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
76030686|NCT00002868|Biological|filgrastim|
76030687|NCT00002868|Biological|recombinant interferon alfa|
76030688|NCT00002868|Drug|busulfan|
76030689|NCT00002868|Drug|cytarabine|
76030690|NCT00002868|Drug|etoposide|
75379564|NCT03501043|Drug|Dysport|Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
75704222|NCT00128856|Drug|Gemcitabine|
75867829|NCT03337477|Drug|Glucose|Glucose 25g administered IV <15 minutes before the insulin.
75867830|NCT03337477|Drug|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
75867831|NCT03337477|Drug|Glucose|Glucose 25g administered IV <15 minutes before the insulin.
75867832|NCT02687542|Drug|Placebo|Placebo
75867833|NCT02687542|Drug|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose (1 mg QD)
75867834|NCT02687542|Drug|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
75867835|NCT02687542|Drug|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751higher middle dose 2 (7 mg QD)
76030691|NCT00002868|Drug|hydroxyurea|
76030692|NCT00002868|Drug|idarubicin|
76030693|NCT00002868|Procedure|peripheral blood stem cell transplantation|
76030694|NCT00002695|Genetic|DNA stability analysis|
76030695|NCT00002695|Genetic|microsatellite instability analysis|
76030696|NCT00002695|Genetic|mutation analysis|
76030697|NCT00002695|Other|laboratory biomarker analysis|
76030698|NCT00002668|Behavioral|Observation|
76030699|NCT00002668|Behavioral|Educational Intervention and Behavioral Skills Training|
76030700|NCT00002667|Other|cytology specimen collection procedure|
76030701|NCT00002667|Other|immunoenzyme technique|
76030702|NCT00002667|Procedure|study of high risk factors|
76030703|NCT00002650|Dietary Supplement|folic acid|
76030704|NCT03145987|Dietary Supplement|Vitis vinifera extract|
75540455|NCT04572724|Drug|Sacubitril / Valsartan Oral Tablet|Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
75540456|NCT04572724|Drug|RAS Inhibitors|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
75540457|NCT00255567|Drug|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
75540458|NCT00255567|Drug|Paromomycin sulphate|Paromomycin sulphate
75704223|NCT00128856|Drug|Adriamycine|
76030705|NCT03145987|Other|Placebo|
76030706|NCT05007665|Biological|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
76030707|NCT04477915|Other|Core exercises|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
76030708|NCT04477915|Other|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
76030709|NCT05007353|Behavioral|Structured Lifestyle Intervention|Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
76030710|NCT05007353|Behavioral|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
76030711|NCT03146065|Biological|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
76030712|NCT03146065|Drug|Placebo|Comparison of Placebo to different doses of PF-06730512
75379565|NCT00377390|Biological|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
75379566|NCT03261973|Device|DV8|DV8 esophageal deviation tool
75704224|NCT00128856|Drug|Paclitaxel|
75867836|NCT02687542|Drug|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
76030713|NCT03088397|Behavioral|Patient Decision Aid|One sheet of postpartum contraceptive information arranged in a grid.
75379567|NCT03820388|Drug|Propofol 2mg/kg|2 mg/kg
75379568|NCT03820388|Drug|Etomidate 0.3 mg/kg|0.3 mg/kg
75704225|NCT00128778|Drug|Pegylated liposomal doxorubicin|
75867837|NCT03707899|Drug|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
75867838|NCT03707899|Drug|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
75379569|NCT03820388|Drug|Propofol 1 mg/kg|1 mg/kg Propofol
75379570|NCT03820388|Drug|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
75379571|NCT03264157|Drug|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
75379572|NCT03264157|Drug|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
75379573|NCT03264157|Biological|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
75379574|NCT03820544|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with SEMS placement
75379575|NCT03820544|Other|Standard of care|Undergo standard of care surgical resection
75540459|NCT00255567|Drug|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
75704226|NCT05673252|Diagnostic Test|Venous blood sample|Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
75704227|NCT05673252|Procedure|biopsy|histopathology findings
75867839|NCT05054569|Behavioral|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
75867840|NCT03336619|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
75867841|NCT03336619|Drug|Placebo|Placebo administered orally twice daily for five days
75867842|NCT03114904|Other|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
76030714|NCT03088397|Behavioral|Website|Patient directed to website with information on various contraceptive methods.
75540460|NCT04572607|Dietary Supplement|The consumption of avocado honey was analyzed|The subjects of honey group consumed 25 g of honey each day for 4 weeks.
75540461|NCT03450967|Drug|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
75867843|NCT03706339|Other|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section
75867844|NCT03706339|Drug|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
75379576|NCT03400579|Device|autoRIC® device|The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
75379577|NCT03801044|Diagnostic Test|NT-BNP, VEGF|VEGF-C levels were measured in the serum samples. R&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).
75379578|NCT03801044|Diagnostic Test|Echocardiography|Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography
75540462|NCT03450928|Procedure|Peroral Endoscopic Myotomy (POEM)|"Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips"
75540463|NCT00235365|Behavioral|meta-cognitive therapy|Meta-cognitive therapy
75540464|NCT00235365|Other|waiting list|waiting list control
75540465|NCT03450889|Procedure|Colonoscopy|"Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'."
75540466|NCT03450616|Device|PICO Negative Pressure Wound Therapy|Negative Pressure Wound Therapy Device
75540467|NCT03450616|Procedure|Compression Dressing|Standard of Care Compression Dressing
75540468|NCT04572529|Procedure|Cardiac Valve replacement|Open heart surgery to replace the valvular infective endocarditis
75540469|NCT04572334|Other|Auto and Subjective Refraction|All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
75540470|NCT00255606|Drug|docetaxel|Given in 3- or 4- week courses
75867845|NCT03706339|Drug|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
75867846|NCT03739476|Drug|Quetiapine 25 milligrams capsule|Compare the incidence of postoperative delirium.
75867847|NCT03739476|Drug|Placebo oral capsule|Compare the incidence of postoperative delirium.
75379579|NCT03801044|Radiation|Chest Radiography|All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.
75379580|NCT03801044|Diagnostic Test|Lung Ultrasound|It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.
75379581|NCT03801044|Diagnostic Test|Bioelectrical Impedence Analysis|The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG & Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
75379582|NCT04029584|Drug|rifampin IV|A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.
75379583|NCT04029584|Drug|Rifadin 300Mg Capsule|Rifadin 600mg by mouth as two 300mg rifadin capsules
75379584|NCT04029584|Drug|Fluvastatin 20 MG|one oral dose of fluvastatin (Lescol ) 20mg capsule
75379585|NCT04028960|Drug|Regular insulin (Humulin-R), intranasal route|Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
75379586|NCT04028960|Device|SipNose intranasal device|The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
75379587|NCT03401671|Drug|Lanadelumab|SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
75379588|NCT04023578|Device|RHEO KNEE XC|Microprocessor controlled knee using Magneto-Rheologic techonology.
75379589|NCT03502915|Drug|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
75379590|NCT03502915|Other|Placebo|100% oxygen via Nitronox delivery device
76030715|NCT03088397|Behavioral|Shared- Decision Making Counseling|Counseling using principles of shared-decision making
75379591|NCT03506347|Drug|Vancomycin|Antibiotic
75379592|NCT04210232|Device|TECNIS® TORIC II Intraocular Lens (IOL)|Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
75540471|NCT00255606|Drug|prednisone|Given in 3- or 4- week courses
76030716|NCT03146455|Other|no intervention|no intervention
76030717|NCT03078725|Drug|Glyburide|oral hypoglycemic agent
76030718|NCT03078725|Drug|Metformin|oral hypoglycemic agent
75379593|NCT04019990|Other|The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players|Throwers Ten exercise programme is a programme designed to improve the power, strength and endurance of large muscle groups required for the throwing activity. It consists of exercises involving the movement of upper limb joints in full range of joint motion or at specified specific angles, with the help of a resistance band and weights specific to individual athletes. In the literature, no study has demonstrated the effectiveness of Throwers Ten exercise programme in wheelchair basketball and ambulant basketball players.
76030719|NCT02346409|Device|tACS of the cerebellum|tACS of the cerebellum
75867848|NCT05000268|Other|Progressive Myofascial Relaxation Exercise|"Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed."
75540472|NCT03450577|Procedure|PCI of bifurcation lesions|Different approaches for treatment of bifurcation coronary artery disease.
75540473|NCT00226343|Drug|Depakote-ER|
75540474|NCT03450499|Drug|Ketamine|the analgesic affects of ketamine will be compared between the experimental and placebo group.
75540475|NCT03450499|Drug|Placebo|the analgesic requirement will be calculated in placebo group.
75540476|NCT03450460|Behavioral|Peer support|The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
75867849|NCT03639558|Drug|Haloperidol + Promethazine + Chlorpromazine|This is the usual treatment given by this hospital during an aggressive psychiatric episode.
76030720|NCT05007119|Procedure|Mckenzie Extension Protocol|"Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
76030721|NCT05007119|Procedure|Cupping|Cupping with blood letting
76030722|NCT02346487|Drug|LPV/RTV pellets and AZT/3TC or ABC/3TC|"Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day~Between 6 and 9.9kg: 3 capsules twice a day~Between 10 and 13.9kg: 4 capsules twice a day~Between 14 and 19.9kg: 5 capsules twice a day~Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~Between 3 and 5.9kg: 1 tablet twice a day~Between 6 and 9.9kg: 1.5 tablets twice a day~Between 10 and 13.9kg: 2 tablets twice a day~Between 14 and 19.9kg: 2.5 tablets twice a day~Between 20 and 24.9kg: 3 tablets twice a day"
76030723|NCT03086837|Behavioral|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
76030724|NCT02341963|Drug|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
76030725|NCT05007197|Behavioral|The Effect of Diabetes Education Based on Learning Modality|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet."
76030726|NCT05006651|Device|McGrath MAC|Intubaion with McGrath MAC
75867850|NCT03639558|Drug|Haloperidol + Promethazine|This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
76030727|NCT05006651|Device|Trachway|Intubaion with Trachway
76030728|NCT05014685|Drug|Rabeprazole|20mg bid
76030729|NCT05014685|Drug|Bismuth potassium citrate|0.6g bid
75379594|NCT03266419|Drug|Deep NMB using rocuronium|"Drug: rocuronium~Bolus dose: 0.7 mg/kg~Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
75379595|NCT03266419|Drug|Moderate NMB using rocuronium|"Drug: rocuronium~Bolus dose: none~Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
76030730|NCT05014685|Drug|Metronidazole|0.4g tid
75379596|NCT03270943|Behavioral|MFY|Mindful Self-Compassion course for teens
75379597|NCT03270943|Behavioral|HLG|Healthy Lifestyles course for teens
75379598|NCT03800030|Device|Theta-gamma tACS|NeuroConn technologies, direct current-stimulator plus
75379599|NCT03800030|Device|Delta-beta tACS|NeuroConn technologies, direct current-stimulator plus
75379600|NCT03800030|Device|Sham tACS|NeuroConn technologies, direct current-stimulator plus
75379601|NCT00377468|Drug|Delta9-Tetrahydrocannabinol|
75379602|NCT03799484|Drug|Botulinum toxin type A|Botulinum toxin type A will be administered to both sides
76030731|NCT05014685|Drug|Amoxicillin|1g tid
75379603|NCT03799484|Drug|2.5% lidocaine/2.5% prilocaine|2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead
75704228|NCT04901910|Behavioral|Physical Activity (PA) Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities and well-being. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
75704229|NCT04901910|Behavioral|Verdi plus PA Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities, well-being, and reducing risky behaviors. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
75704230|NCT00709488|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
75704231|NCT00709488|Procedure|Placement of device in prostate urethra|Placement of device in prostate urethra
75704232|NCT00709488|Device|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
75704233|NCT00714246|Drug|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
75704234|NCT00714246|Drug|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
76030732|NCT03111823|Behavioral|Exercise Intervention|Undergo aerobic exercise sessions
75379604|NCT03799484|Device|petrolatum ointment|petrolatum ointment will be applied to one side of the forehead
75379605|NCT04012970|Other|Manual spinal mobilisations|
75379606|NCT03508687|Drug|300mg Gemcabene|300mg Gemcabene
75540477|NCT03450421|Device|Actamax™Adhesion Barrier|Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.
75704235|NCT00714246|Drug|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
76030733|NCT03111823|Other|Quality-of-Life Assessment|Ancillary studies
76030734|NCT03111823|Other|Questionnaire Administration|Ancillary studies
75379607|NCT03508687|Drug|600mg Gemcabene|600mg Gemcabene
75379608|NCT03999944|Device|positive airway pressure system|Positive Airway Pressure System
75379609|NCT03273283|Behavioral|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
75379610|NCT00377546|Drug|Nepafenac|
75379611|NCT00377546|Drug|Ketorolac LS, Bromfenac|
76030735|NCT02346097|Device|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|"Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions"
76030736|NCT05014763|Procedure|connective tissue graft|Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.
76030737|NCT05015309|Drug|SH3765 tablet|Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
75704236|NCT04071288|Procedure|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
75379612|NCT04290494|Drug|IV rtPA (intravenous recombinant plasminogen activator)|intravenous injection
75704237|NCT02574546|Procedure|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
75704238|NCT00416455|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
75704239|NCT00416455|Procedure|positron emission tomography|Undergo FDG PET/CT
75704240|NCT00416455|Procedure|computed tomography|Undergo FDG PET/CT
76030738|NCT02345785|Other|urologic surgery and caudal block|
75704241|NCT00416455|Drug|ferumoxtran-10|Undergo femoxtran-10 MRI
75704242|NCT00416455|Procedure|magnetic resonance imaging|Undergo femoxtran-10 MRI
75704243|NCT00416455|Procedure|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
75704244|NCT00416455|Procedure|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
75704245|NCT04071210|Dietary Supplement|Probiotic tablet|Probiotic tablet twice a day for 12 weeks
75704246|NCT04071210|Dietary Supplement|Placebo tablet|Placebo tablet twice a day for 12 weeks
75704247|NCT00415909|Drug|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
75704248|NCT00415909|Drug|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
76030739|NCT05006495|Procedure|C3 laminectomy|C3 laminectomy preserving semispinalis cervicis inserted into the axis.
76030740|NCT05006495|Procedure|C3 laminoplasty|Conventional C3-6 laminoplasty, resulting in injury of semispinalis cervicis.
75379613|NCT04005404|Drug|Ropivacaine (sciatic nerve block)|injection of 20 ml ropivacaine 0.375%
75379614|NCT04005404|Drug|Ropivacaine (lumbar plexus block L2-L4)|injection of 20 ml ropivacaine 0.375%
76030741|NCT03111901|Drug|Pembrolizumab|Pembrolizumab solution
75540478|NCT00235404|Other|Multicomponent treatment|Specialized care in preparing recharge to home
76030742|NCT03111901|Drug|Interleukin-2|Interleukin-2 solution
76030743|NCT02345941|Other|Parent Action Report|Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
75540479|NCT00235404|Other|usual care|Usual recharge directly from hospital to home
75540480|NCT00226382|Drug|Pegylated Interferon-alfa-2a|Pegasys once weekly
75867851|NCT03506646|Dietary Supplement|Beetroot juice|Beetroot juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
75867852|NCT01353508|Drug|LCZ696|200 mg and 400 mg tablets
76030744|NCT02345941|Other|Parent Portal|Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
76030745|NCT05014607|Biological|Personalized multi-peptide vaccine|"Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 5-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen.~Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned.~Treatment schedule:~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses."
75540481|NCT01580839|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
76030746|NCT04816357|Other|Questionaire|only questionaire
75540482|NCT01580839|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
75540483|NCT03450382|Other|Hans Kai Education|9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
75540484|NCT03450265|Device|Hemopatch|Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
75704249|NCT00709566|Behavioral|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
75704250|NCT00709566|Behavioral|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
75867853|NCT01353508|Drug|Valsartan|160 mg tablets
76030747|NCT02341729|Drug|ticagrelor|crushed tablets and non-crushed tablets
75867854|NCT05470855|Biological|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
76030748|NCT05014373|Combination Product|Favipiravir + Standard of Care|"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care"
76030749|NCT05014373|Procedure|Standard of Care|Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
76030750|NCT02039245|Drug|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
76030751|NCT03083951|Procedure|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
75704251|NCT02573688|Behavioral|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
75704252|NCT00709644|Drug|Norgestimate; Ethinyl Estradiol; Folic acid.|
75379615|NCT04005404|Drug|Ropivacaine (lumbar plexus block Th12-L1)|injection of 20 ml ropivacaine 0.375%
75379616|NCT03232892|Drug|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
75379617|NCT03787472|Device|JJV Investigational senofilcon A Multifocal Lens1|CONTROL
75540485|NCT03450265|Device|Tachosil|Applied according to the current instruction for use (IFU).
75704253|NCT00415597|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
75379618|NCT03787472|Device|JJV Investigational senofilcon A Multifocal Lens2|TEST
75704254|NCT04071054|Diagnostic Test|Carnation Ambulatory Monitor (CAM)|7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
75379619|NCT03778190|Procedure|Corneal Foreign Body Removal|An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
75379620|NCT03510481|Biological|PfSPZ Vaccine|PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
75379621|NCT03510481|Drug|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
75379622|NCT03510481|Drug|artemether 20mg/lumefantrine 120mg (AL)|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
75379623|NCT03172520|Device|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
75379624|NCT03172520|Device|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
75379625|NCT03109418|Drug|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
75379626|NCT03109418|Procedure|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
75379627|NCT03404167|Drug|AZD0914|Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
75379628|NCT03771560|Drug|folinic acid|subject will take folinic acid daily for 12 weeks
75379629|NCT03404401|Drug|BLI4700|Oral bowel preparation
75379630|NCT03404401|Drug|Polyethylene glycol bowel preparation|Oral bowel preparation
75379631|NCT03767738|Drug|Intravitreal Aflibercept Injection (IAI)|IAI prepared and administered with a pre-filled syringe (PFS)
75379632|NCT03989570|Procedure|transversus abdominis plane block|The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
75379633|NCT03989570|Procedure|erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
75540486|NCT00235482|Drug|Coxsackievirus A21|
75704255|NCT00714480|Drug|anti-thymocyte globulin|Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
75867855|NCT01568268|Drug|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
76030752|NCT03083951|Procedure|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
76030753|NCT04762459|Drug|Almonertinib|Almonertinib 110mg PO once daily
76030754|NCT04762459|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) Pemetrexed
75379634|NCT03989570|Other|control group|placebo
75379635|NCT03273673|Other|Biofeedback Intervention|Visual and Tactile Biofeedback
75379636|NCT04331990|Other|Standard Physcial Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
75540487|NCT03450226|Drug|stellate ganglion block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
75540488|NCT04572373|Dietary Supplement|SMOFlipid|
75540489|NCT03450148|Other|Pavlok wristband with electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
76030755|NCT04762459|Drug|Cisplatin|75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
75540490|NCT03450148|Other|Pavlok wristband without electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
75540491|NCT03450109|Drug|LY01005|One gluteal IM injection
75704256|NCT00714480|Drug|anti-thymocyte globulin|anti-thymocyte globulin post-operative days -2, 0, 2 and 4
75704257|NCT00714480|Drug|anti-thymocyte globulin|Post-operative days 0, 2, 4 and 6
75379637|NCT04331990|Other|Intermittent Mechanical Traction|In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.
75704258|NCT00714558|Drug|Fentanyl citrate; Naltrexone; Naloxone|
75704259|NCT00709800|Biological|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
76030756|NCT03078569|Drug|Testosterone gel|treatment with testosterone gel
76030757|NCT03078335|Other|Glove based care|Described in Experimental Arm: Glove based care
76030758|NCT03078335|Other|Standard of Care - Hand Hygiene|Hand Hygiene - hand washing with soap and water, or alcohol based hand rub
76030759|NCT02345863|Drug|Bendamustine|"Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated."
76030760|NCT02345863|Drug|GA101|"Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg"
76030761|NCT02345863|Drug|Ibrutinib|"Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily"
76030762|NCT03078257|Drug|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
75379638|NCT04331990|Other|Continuous Mechanical Traction|Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
75704260|NCT00709800|Biological|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
75704261|NCT00709800|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
75704262|NCT00709800|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
75704263|NCT00709800|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
75379639|NCT02973620|Drug|Levosimendan|levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
75379640|NCT03512041|Behavioral|RLIC - 5 cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
75704264|NCT02574624|Procedure|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
75704265|NCT02575638|Drug|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
75704266|NCT02573610|Drug|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
75704267|NCT02573610|Drug|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
75704268|NCT02575560|Other|history data|history data of PFS after 1st line or second line theray
75704269|NCT00710190|Device|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
75704270|NCT00715182|Drug|TKI258|
75704271|NCT04070586|Device|4DCBCT images|Images are acquired and assessed offline
75704272|NCT02574468|Drug|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
75704273|NCT02574468|Procedure|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
75704274|NCT00710268|Drug|AZD2281|Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
75704275|NCT00710268|Drug|Bevacizumab|IV administration10 mg/kg every 14 days
75704276|NCT02575482|Drug|SUVN-D4010|
75704277|NCT02575482|Drug|Placebo|
75379641|NCT03512041|Behavioral|RLIC - 4 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
75379642|NCT03512041|Behavioral|RLIC - 3 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
75379643|NCT03512041|Behavioral|Sham conditioning|Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
75379644|NCT03512041|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
75379645|NCT03512041|Behavioral|Arm training|All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
75540492|NCT03450109|Drug|Zoladex|One Subcutaneous injection in the abdominal wall
75379646|NCT03512041|Behavioral|Sequence production training|All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
75379647|NCT03053960|Device|Computed Tomography|Undergo helical CT scan
75379648|NCT03053960|Device|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
75867856|NCT01568268|Drug|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
75379649|NCT03053960|Device|Cone-Beam Computed Tomography|Undergo CBCT scan
75379650|NCT03053960|Device|Magnetic Resonance Imaging|Undergo MRI scan
75540493|NCT03450031|Other|NAC (no drug/no device)|Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
75704278|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
75704279|NCT02575326|Behavioral|a provider administered, tailored discussion guide|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
75867857|NCT03636269|Drug|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
75379651|NCT03053960|Procedure|Therapeutic Conventional Surgery|Undergo resection of tumor
75379652|NCT03053960|Procedure|Histopathologic Examination|Correlative studies
75379653|NCT05313386|Drug|BXCL501|BXCL501 is given in a film form
75379654|NCT05313386|Drug|Placebo film|Placebo is given in a film form
75379655|NCT03274999|Device|TrueTear™ Application|Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.
75379656|NCT04018664|Drug|Nalbuphine HCl solution|nalbuphine solution administered at various strengths
75379657|NCT04018664|Drug|Placebo solution|Placebo
75379658|NCT03763058|Other|Music Therapy|"The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month."
75540494|NCT00226460|Drug|Fetal porcine cells, Neurocell-PD|
75704280|NCT02575248|Drug|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
75704281|NCT02575248|Drug|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
75704282|NCT02575170|Drug|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
75704283|NCT02575170|Drug|Ringer's lactate solution|200 ml of Ringer's lactate solution
75704284|NCT00710502|Procedure|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
75704285|NCT00710502|Procedure|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
75379659|NCT03031340|Drug|Pregabalin|On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
75379660|NCT03031340|Other|placebo|placebo
75867858|NCT03636269|Drug|Placebo|IV placebo administered three times/week
76030763|NCT03078257|Drug|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
75704286|NCT02573454|Behavioral|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
75704287|NCT00710658|Behavioral|WebChoice|"Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.~Patients in the control group received usual care"
75704288|NCT00710736|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
75379661|NCT03760796|Device|Corrie Health Digital Platform|The Corrie Health Digital Platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure monitor.
75379662|NCT03405259|Device|Super Seal® Desensitizer|Single dose professional application.
75379663|NCT03405259|Device|Acclean® Fluoride Varnish|Single dose professional application.
75379664|NCT03513757|Drug|propofol|propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
75379665|NCT03513757|Drug|Dexmedetomidine|single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg
75379666|NCT03513757|Drug|Glycopyrrolate|4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group
75379667|NCT03513757|Drug|Lidocaine 1% Injectable Solution|1 mg/kg intravenous administration prior to propofol administration
75379668|NCT03513757|Drug|Nitrous Oxide|Inhalation of nitrous oxide may be used for IV placement
75379669|NCT03513757|Drug|Sevoflurane|Inhalation of sevoflurane may be used for IV placement
76030764|NCT03078257|Drug|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
76030765|NCT03078257|Drug|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
76030766|NCT03078257|Drug|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
75704289|NCT00710736|Drug|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
75704290|NCT00715416|Device|Nitinol stent|Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
75704291|NCT00715416|Procedure|Nitinol Stent Placement|Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
76030767|NCT03078257|Drug|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
76030768|NCT03078257|Drug|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
75704292|NCT00715494|Behavioral|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
75704293|NCT00620542|Drug|Rosuvastatin|capsule, oral, once daily
76030769|NCT02341573|Drug|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
76030770|NCT02341573|Drug|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
76030771|NCT02346019|Procedure|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
75704294|NCT00620542|Drug|Atorvastatin|capsule, oral, one daily
75379670|NCT03760640|Drug|LY900014|Administered SC
75379671|NCT03760640|Drug|Insulin Lispro|Administered SC
75379672|NCT03407053|Dietary Supplement|Ultra-processed diet|Consuming ultra-processed diet over a 2-week period
75379673|NCT03407053|Dietary Supplement|Unprocessed diet|Consuming unprocessed diet over a 2-week period
75379674|NCT03756506|Device|Novel Microbicidal Liquid Polymer|The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
75379675|NCT03275623|Drug|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
75379676|NCT03275623|Other|Standard Prenatal Care|Continued surveillance of urinary cultures
75379677|NCT04735237|Procedure|Autogenous fat injection|Done under general anesthesia. Fat is to be harvested from the abdomen using manual liposuction. Small aliquots of fat are to be injected into the philtral column (and in the vermilion and any other area of volume insufficiency if needed).
75704295|NCT00711048|Drug|AZD1386|oral, single dose
75379678|NCT04735237|Procedure|Surgical revision with orbicularis oris muscle reconstruction.|Surgical repair done under general anesthesia. The original scar will be marked on the skin with methylene blue. The skin will be incised along the designed line with scar removal. The orbicularis oris muscle stump will be dissected medially and laterally and approximated by means of 4-0 inverted horizontal mattress sutures.
75379679|NCT03756038|Drug|Placebos|In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
75704296|NCT00711048|Drug|Placebo|Oral solution, single dose
75704297|NCT04070742|Drug|FMX101|
75867859|NCT05598060|Radiation|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
75704298|NCT04269876|Dietary Supplement|Marine Lipid Oil Concentrate|Marine Lipid Oil Concentrate softgels
75704299|NCT04269876|Dietary Supplement|Dietary Supplement|Dietary Supplement capsules
75704300|NCT04269876|Dietary Supplement|Placebo|Placebo softgels
75867860|NCT03114982|Biological|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
75704301|NCT04269876|Dietary Supplement|Placebo|Placebo capsules
75704302|NCT04069806|Dietary Supplement|preoperative oral carbohydrate, preOp|Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
75704303|NCT00851344|Drug|GSK835726 (10mg)|GSK835726 (10mg) tablet
75867861|NCT03114982|Biological|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
75867862|NCT04919707|Behavioral|Header Session|Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.
75867863|NCT04919707|Procedure|MRI Session|Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.
76030772|NCT05005715|Drug|Dexmedetomidine|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
75704304|NCT00851344|Drug|GSK835726 (50mg)|GSK835726 (50mg) tablet
75704305|NCT00851344|Drug|GSK835726 (100mg)|GSK835726 (100mg) tablet
75704306|NCT00851344|Drug|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
75704307|NCT00851344|Other|Placebo|Placebo to match active
76030773|NCT05005715|Drug|normal saline|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
76030774|NCT02341651|Other|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
76030775|NCT03083795|Behavioral|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
76030776|NCT02345707|Drug|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
76030777|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
76030778|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
76030779|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
75379680|NCT03756038|Drug|Lorazepam|The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
75379681|NCT03276637|Genetic|Whole exome sequencing|Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory on 75 enrolled individuals
75379682|NCT03754556|Device|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
75379683|NCT03276871|Procedure|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
75379684|NCT03276871|Device|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
75379685|NCT03521089|Device|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
75379686|NCT03410797|Device|Inclusion of semi-occluded mask in voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
75379687|NCT03410953|Biological|Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).|"The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
75379688|NCT03521479|Drug|Squaric Acid Dibutyl Ester|Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
75379689|NCT01495988|Drug|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
75379690|NCT01495988|Drug|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
75379691|NCT01495988|Drug|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
75379692|NCT04735003|Device|Transcatheter tricuspid valve interventions|Transcatheter repair or replacement to treat tricuspid regurgitation
75379693|NCT02934932|Drug|Brexpiprazole|Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
75379694|NCT03415243|Drug|Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg|Contents of the sachet will be emptied into a glass bottle and 225 mL of hot, but not boiling water (approximately 90-95°C), will be added to the container and mixed to dissolve the contents of the sachet. The dissolved solution will be allowed to cool to approximately 40 - 50 degree Celsius (°C). After cooling, a small volume (1 to 10 microliters [mcL]) of 99mTc-DTPA (Technetium-99m-diethylene-triamine-pentaacetate will be added to the drug solution in to achieve a maximum of 108 curie(mcCi) i.e.4 megabecquerel [MBq] per individual dose at the time of dosing. The container will be capped and maintained at a temperature between 35-45°C at time of dosing and then participants will be instructed to consume the hot drink entirely within 30 seconds.
75379695|NCT03415243|Drug|Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg|Caplet doses will be prepared by drilling hole of approximately(app.)1millimetre(mm)diameter and app.2-2.5mm deep into individual caplets.99mTc-DTPA(dissolved in normal saline)will be added into hole of each caplet as low volume liquid(0.5-2.0mcL)to achieve maximum of 54 mcCi(2MBq)per caplet at time of dosing(2caplets=108 mcCi[4MBq]dose per assessment visit).Applied liquid will be allowed to air dry,hole to be filled with equivalent powder blend from crushed caplet so drug content will remain constant for all caplets.Caplet will be sealed with appropriate material.Radiolabeled caplets will be packaged as unit doses(2 caplets per container)and maintained at room temperature until administration.Caplets will be swallowed with 225mL of noncarbonated room temperature water within 30 seconds.
75379696|NCT02892500|Drug|bupivacaine hydrochloride and betamethasone sodium phosphate|5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
75379697|NCT02892500|Drug|bupivacaine hydrochloride|5ml of bupivacaine hydrochloride into the tibiofibular ligament
75379698|NCT02904356|Device|Repetitive transcranial magnetic stimulation|High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
75379699|NCT00378872|Drug|IV Tranexamic acid 10mg/kg pt body weight|
76030780|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
75379700|NCT00378872|Drug|Quixil topical sealant|
75379701|NCT03418051|Other|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
76030781|NCT02341339|Procedure|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
76030782|NCT05005481|Other|NIL intervention|NIL intervention will be performed on patients.
76030783|NCT02345473|Genetic|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
75867864|NCT03166072|Other|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
75867865|NCT03166072|Other|No Intervention|Participants will continue to receive treatment as usual
75867866|NCT04911361|Drug|Dexamethasone|Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
75867867|NCT03166150|Other|Multi-modal rehabilitation program|Patients will receive 12 weeks of exercises.
75867868|NCT03166150|Other|Pelvic Floor Physical therapy|Pelvic Floor Physical therapy
75867869|NCT04906993|Drug|camrelizumab； famitinib malate|Camrelizumab intravenously ; Famitinib Orally
75867870|NCT04906993|Drug|platinum-based chemotherapy|Physician's choice chemotherapy
75867871|NCT03165760|Procedure|protective ventilation|the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
76030784|NCT05005637|Drug|Anti Tuberculosis Drug|ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 4RH (4 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
76030785|NCT05005637|Drug|Prednisone tablet|Oral prednisone will be given at the dose of 1 mg/kgBW/day (max 60 mg/day) until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
75704308|NCT00855478|Device|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
75867872|NCT02685202|Device|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
75867873|NCT04475731|Drug|Ponatinib|"Ponatinib 45 mg/day x 4 weeks x 3 courses.~+/- chemotherapy:~vincristine or~L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)"
75867874|NCT04479592|Other|Particle counter|Particle counter to measure the aerosol generated
75867875|NCT03087786|Drug|Nicotine Bitartrate Lozenge 4mg|Test Product
75867876|NCT03087786|Drug|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
76030786|NCT03078179|Dietary Supplement|Commercial Dairy Cow Milk|After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) for 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
75867877|NCT03635957|Biological|Pegloticase|pegloticase administered intravenously (IV)
75867878|NCT03635957|Drug|Methotrexate (MTX)|oral MTX
75704309|NCT00855556|Genetic|blood draw|"The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:~Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.~Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.~No fasting, activity or medication restrictions are required prior to or following blood collection.~Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection."
75704310|NCT00711126|Drug|GW642444|2.5mcg IV
75704311|NCT00711126|Drug|GW642444|5mcg IV
75704312|NCT00711126|Drug|GW642444|10mcg IV
75704313|NCT00711126|Drug|GW642444|100mcg inhaled
75704314|NCT00711126|Drug|GW642444|20mcg IV
75704315|NCT00711126|Drug|GW642444|500mcg oral
75704316|NCT02545036|Other|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
75704317|NCT02544958|Device|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
75704318|NCT00715572|Drug|thyroxine|monotherapy with thyroxine
75704319|NCT00715572|Drug|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
75704320|NCT02573298|Device|ice|local ice application for 30 minutes
75704321|NCT02573298|Device|cold gas|local cold gas application for 2 minutes
75704322|NCT00845260|Behavioral|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
75379702|NCT03418051|Other|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
75379703|NCT02818946|Device|MRI|Detection of cancer by MRI for pathologic nipple discharge
75379704|NCT00378404|Drug|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
75379705|NCT00378404|Radiation|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
75379706|NCT01440452|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
75379707|NCT01440452|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
75379708|NCT01440452|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
75379709|NCT01440452|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
75704323|NCT00845260|Behavioral|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
75867879|NCT03635957|Drug|Standard Gout Flare Prophylaxis|It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines [Khanna D et al.2012] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA < 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA < 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.
75379710|NCT03742154|Drug|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
75379711|NCT03284359|Behavioral|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
75379712|NCT05313230|Other|CITRASATE SLED|Applying of CITRASATE SLED
75704324|NCT00715806|Device|Open MRI scanner.|Imaging in an Open MRI scanner.
75704325|NCT00715806|Device|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
75379713|NCT03738020|Device|HA IDF (YVOIRE classic)|Treatment with HA IDF
75379714|NCT03738020|Device|Restylane|Treatment with Restylane
75379715|NCT02734940|Drug|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
75379716|NCT02734940|Drug|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
75379717|NCT02734940|Drug|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
75379718|NCT02734940|Drug|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
75379719|NCT02734940|Drug|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
75379720|NCT00378092|Drug|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
75379721|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
75379722|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
75379723|NCT00378170|Device|intubation of patients undergoing elective surgery|
75379724|NCT01347632|Drug|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
75379725|NCT02679560|Drug|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
75379726|NCT02679560|Drug|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
75379727|NCT00378248|Behavioral|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
75379728|NCT00378248|Behavioral|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
75379729|NCT03734822|Other|End tidal CO2 (EtCO2)|End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
75867880|NCT03635957|Drug|Infusion Reaction (IR) Prophylaxis|For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.
75379730|NCT03734822|Device|Transcutaneous CO2 (TCO2)|Continuous and noninvasive real-time monitoring of transcutaneous CO2.
75379731|NCT03734822|Diagnostic Test|Capillary CO2 (CapCO2)|Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
75379732|NCT03734822|Diagnostic Test|Arterial blood gas (ABG)|Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
75379733|NCT02671136|Device|Hyperbaric Oxygen therapy|
75379734|NCT02671136|Other|Conventional Wound Therapies|
75379735|NCT03728348|Diagnostic Test|mt-sDNA screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
75379736|NCT03728348|Procedure|Colonoscopy|Subjects will undergo a screening colonoscopy.
75379737|NCT02665988|Device|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
75379738|NCT02665988|Device|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
75379739|NCT03726164|Device|Remote Conditioning|A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.
75379740|NCT03726164|Device|Sham protocol|An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
75379741|NCT03723980|Drug|Propolis|it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
75704326|NCT00851500|Drug|K-604|K-604 is given for 26 weeks
75704327|NCT00851500|Other|Placebo|placebo tablets are given for 26 weeks
75704328|NCT00711204|Drug|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
75704329|NCT04042870|Behavioral|Joint Loosening Yoga|Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
75704330|NCT05810857|Diagnostic Test|Motor Relearning Program|patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance
75379742|NCT03723980|Drug|Calcium Hydroxide|it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
75379743|NCT02660528|Drug|Tocilizumab|Subcutaneous tocilizumab
75379744|NCT02633540|Radiation|IMRT Radiation|Radiation to Larynx
75379745|NCT01240304|Drug|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
75379746|NCT01240304|Radiation|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
75704331|NCT05810857|Diagnostic Test|Mirror Therapy|"Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined"
75704332|NCT05810844|Diagnostic Test|Motor Relearning Program (MRP)|MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke
75704333|NCT05810844|Diagnostic Test|Neuro Development Treatment (NDT)|Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients
75704334|NCT05810831|Diagnostic Test|Massage with post isometric relaxation exercises|Post isometric relaxation will be performed in supine position with neutrally positioned head.
75704335|NCT05810831|Diagnostic Test|Massage|conservative physiotherapy protocol including massage
75704336|NCT05810818|Diagnostic Test|Dry Needling|Dry needling treatment will be consisting of two treatments per week
75704337|NCT05810818|Diagnostic Test|Self Stretching|Self stretching groups both will receive a TrP manual interventions and stretching protocol
75704338|NCT05810805|Other|gas component of digestive tract|Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.
75867881|NCT03635957|Dietary Supplement|Folic Acid|Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
75379747|NCT01240304|Procedure|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
75379748|NCT02614586|Drug|TAK-058|TAK-058 oral solution.
75379749|NCT02614586|Drug|Ondansetron|Ondansetron capsule.
75379750|NCT02614586|Drug|TAK-058 Placebo|TAK-058 placebo-matching, solution.
75379751|NCT02614586|Drug|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
75379752|NCT01211756|Drug|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
75540495|NCT03459781|Behavioral|Cognitively-Based Compassion Training|CBCT® was designed at Emory University by Lobsang Tenzin Negi. CBCT® is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. Over the course of 8 weeks there will a total of 8 CBCT® sessions, one session per week, led by the CBCT® instructor. Dyads will attend the weekly CBCT® classes together. Each weekly session will last for 90 minutes and will begin with brief meditation to focus attention. The instructor will then articulate content and goals of the current week, after which a group discussion led by the instructor will take place. A session will end with a 20-30 minute meditation. Dyads will be encouraged to practice a minimum of 10 minutes per day at home, and together as a dyad if possible.
75379753|NCT01211756|Drug|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
75379754|NCT03591458|Drug|Amitriptyline|Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
75379755|NCT03591458|Drug|Placebo|Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
75379756|NCT03565328|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
75379757|NCT03534362|Device|Nasopore|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
75704339|NCT05810779|Other|dynamic surface exercise|Optimal arousal Physio ball Make the child bounce, active/passive on the Swiss ball, slow/fast 5 times 5 sets Combined frontal and transverse plane movements Physio ball/ bolster High sitting: one hand weight bearing followed by trunk rotation to reach the toy on opposite side 5-7 each side 1 set Combined frontal and transverse plane movements Platform swing Reaching the toy with both the hands kept overhead and 45°-60° diagonal to the mid line 5-7 times each side 1 set
75704340|NCT05810779|Other|trunk targeted training|"trunk training group (TTG) consist of exercises and activities focusing on the activation of the trunk muscles, pelvic control and proximal stabilization and these were combined with the trunk and gluteal muscle strengthening exercises.~The trunk elongation activities, the facilitation of spinal extension, weight shifting and weight-bearing activities The children in the TTG received 45-75-minute of physiotherapy twice a week for 8 weeks"
75704341|NCT05810740|Drug|Binimetinib Oral Tablet|Two-period Crossover study
75704342|NCT05810701|Other|Comprehensive geriatric assessment and individualised physical training|Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
75704343|NCT05810688|Other|eating rehabilitation training|The experimental group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education.
75867882|NCT05241067|Drug|Normal Saline|Placebo (Dose: equal volume saline) + Standard of care
75867883|NCT05241067|Drug|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
75867884|NCT03732599|Procedure|Standard Deep Anterior Keratoplasty (S-DALK)|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
75867885|NCT03732599|Procedure|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
75379758|NCT03534362|Device|Propel|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
75379759|NCT01206296|Drug|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
75379760|NCT02593682|Drug|suvorexant|
75379761|NCT02593682|Drug|placebo|
75704344|NCT05810675|Behavioral|Telehealth Early Intervention Program (TEIP)|The Telehealth Early Intervention Program (TEIP) that will be carried out by parents at home when interact with their children; and to train parents in delivering developmental and behavioral techniques to their children. The participating families will be randomized in parallel to treatment and comparison groups for teaching the knowledge and techniques: (1) Treatment group: providing the training of TEIP for parents via telehealth modalities as they learn critical skills with their child with the goal of increasing multidimensional child developments. Intervention provider will provide the training for parent-child dyad interaction to work with parents to implement these strategies at home environment.
75379762|NCT02461550|Device|Irreversible Electroporation Ablation|
75704345|NCT05810662|Other|Lactated ringer and dextrose 5%|Fluid use perioperative
75379763|NCT01200602|Drug|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
75379764|NCT01200602|Other|clinical observation|No treatment is given.
75379765|NCT01194908|Drug|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
75379766|NCT01184456|Dietary Supplement|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
75379767|NCT01184456|Drug|Placebo|1 capsule per day for 90 days.
75379768|NCT01163084|Drug|Goserelin Acetate|Given SC
75379769|NCT01163084|Other|Laboratory Biomarker Analysis|Correlative studies
75379770|NCT01163084|Drug|Leuprolide Acetate|Given IM
75379771|NCT01163084|Drug|Vismodegib|Given PO
75379772|NCT01162382|Device|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
76030787|NCT03078179|Dietary Supplement|Commercial Cow Milk with Probiotic|The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics. They will drink the milk with probiotic for 3 months. Clinical and microbiological testing of saliva will be performed. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
76030788|NCT02341183|Device|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
76030789|NCT02341183|Device|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
75379773|NCT01155518|Drug|testosterone|intramuscular every 2 weeks
75379774|NCT01155518|Drug|clomiphene|thrice a week
75379775|NCT01155518|Drug|placebo|intramuscular saline injections every 2 weeks
76030790|NCT05013515|Drug|Surufatinib|"Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator."
75704346|NCT05810636|Device|Garmin Vivosmart wearable device|Wearing smartwatches to collect data
75704347|NCT05810623|Drug|Intravesical Solution|Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
75704348|NCT05810584|Device|Revision LR femoral stem|Revision LR is a modular femoral stem used for hip replacement
75704349|NCT05810571|Procedure|preoperative remifentanil consumption|continuous remifentanil infusion will applied for peroperative analgesia
76030791|NCT02345551|Behavioral|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
75379776|NCT01155518|Drug|placebo|oral
75379777|NCT03490916|Drug|Acetazolamide|Administration of Acetazolamide
75379778|NCT03490916|Drug|Placebo|Administration of Placebo
75379779|NCT03333746|Other|Laboratory Biomarker Analysis|Correlative studies
75379780|NCT03333746|Drug|Lenalidomide|Given PO
75379781|NCT03333746|Biological|Nivolumab|Given IV
75379782|NCT03333746|Other|Pharmacological Study|Correlative studies
75379783|NCT01139996|Drug|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
75379784|NCT01139996|Drug|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
75379785|NCT02417870|Biological|aldesleukin|
75379786|NCT01131884|Drug|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
75379787|NCT01131884|Drug|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
75540496|NCT03459781|Behavioral|CHE (Cancer Health Education)|The cancer health education (CHE) intervention is an adaptation of the in-person program called Health Discussion, a protocol used by our group previously. The CHE will focus on relevant topics to health and cancer including 1) cancer advocacy, 2) health and cancer biology, 3) nutrition, 4) lifestyle interventions such as physical activity and goals for physical activity, 5) the importance of good sleep, 6) the impact of stress, and 7) mental health and social support. CHE will also discuss current events related to cancer. Over the course of 8 weeks there will be a total of 8 sessions, one session per week. Each session will last for approximately 90 minutes.
75540497|NCT03458767|Behavioral|Eight weekly 90-minute group educational sessions|Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
75540498|NCT00413309|Procedure|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
75540499|NCT03457519|Device|Children's Automated Respiration Monitor (ChARM)|The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
75540500|NCT03451552|Behavioral|Patient Navigator|Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
75540501|NCT00413348|Drug|Lactobacillus acidophilus NCFM|
75540502|NCT00413387|Drug|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
75540503|NCT00413387|Drug|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
75540504|NCT04572490|Diagnostic Test|periapical radiograph|alveolar bone loss measurement on standardized parallel periapical radiograph
75540505|NCT03458845|Diagnostic Test|Computed Tomography Scan|The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
75704350|NCT05810571|Procedure|postopeartive controlled anlagesia with morphine|postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
75379788|NCT01139294|Drug|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
75379789|NCT02402036|Drug|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
75379790|NCT05600504|Other|no intervention|no intervention
75379791|NCT02389712|Drug|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
75379792|NCT02389712|Drug|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed > 40mg.
75379793|NCT00378950|Behavioral|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
75867886|NCT05681767|Behavioral|Motivational multicomponent lifestyle intervention + Treatment as usual|"Study intervention and treatment as usual~The study intervention is a multicomponent lifestyle intervention that targets exercise, diet, and stress management, and is conducted by motivational interviewing. The study nurse provides the study intervention. The intervention is conducted by motivational interviewing and includes the key elements of lifestyle interventions identified as effective (assessment of behavior at the baseline, giving information and advising, individualized goal setting, setting an action plan, monitoring a behavioral change, and giving feedback).~The intervention consists of individual appointments (2 x 45-60 min) and a telephone session ( 2 x 15 min) for three months. The participants receive a short educational guide (A4) on the lifestyle behavior recommendations."
75379794|NCT00378950|Behavioral|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
75867887|NCT05681767|Other|Treatment as usual|Treatment as usual
75379795|NCT03530917|Drug|RO7020531|4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.
75379796|NCT03530917|Drug|Placebo|Placebo hard capsules will be administered orally as per the dosing schedules described above.
75379797|NCT02365688|Procedure|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
75379798|NCT05600348|Dietary Supplement|Pork Consumption|Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.
75867888|NCT01310309|Device|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
75379799|NCT02369744|Drug|Silodosin|8mg tablet, 1 tab PO daily for 2 weeks
75379800|NCT02369744|Drug|Tamsulosin|0.4 mg Tab, 1 tab PO daily for 2 weeks
75379801|NCT03577171|Drug|ABI-H0731|Participants will receive 300mg QD of ABI-H0731 tablets orally.
75704351|NCT05810558|Procedure|glycine powder air-powered debridement|The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
75867889|NCT01353274|Drug|Micamlo|Telmisartan plus Amlodipine T40/A5
75867890|NCT05005507|Drug|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks.
75867891|NCT05005507|Drug|PegIFN-alpha-2a|PegIFN-alpha-2a will be administered subcutaneously once weekly.
75867892|NCT05005507|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
75379802|NCT03577171|Drug|SOC ETV|Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
75379803|NCT03577171|Drug|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
75540506|NCT00413426|Drug|Darifenacin (DAR328)|
75540507|NCT00255762|Drug|carboplatin|Given IV
75540508|NCT00255762|Drug|paclitaxel|Given IV
75867893|NCT05005507|Drug|TAF|TAF film-coated tablet will be administered orally once daily.
75540509|NCT00255762|Biological|bevacizumab|Given IV
75540510|NCT00255762|Other|laboratory biomarker analysis|Correlative studies
75867894|NCT05005507|Drug|ETV|ETV film-coated tablet will be administered orally once daily.
76030792|NCT05013671|Other|repositioning maneuvers|The calcium crystals floating in the endolymphatic fluid will put back in place by putting the patient in several sitting and lying positions during specific repositioning maneuvers. During these maneuvers the calcium crystals will float from the semicircular canals back into the utriculus, after which the dizziness symptoms should disappear
76030793|NCT05013671|Other|balance|compare the balance of residents with BPPV with residents without BPPV
75379804|NCT02367170|Procedure|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation >92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
75379805|NCT02367170|Drug|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
75379806|NCT02367170|Procedure|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
75379807|NCT02367170|Device|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
75540511|NCT03456583|Device|Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
75540512|NCT03455998|Other|questionnaires|
75540513|NCT02277457|Radiation|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
75540514|NCT02277457|Drug|Erlotinib|150 mg once daily
75540515|NCT02277457|Drug|Crizotinib|250 mg twice daily
75540516|NCT00255879|Drug|Quetiapine|
75540517|NCT00255879|Drug|Risperidone|
75540518|NCT00255879|Drug|Olanzapine|
75540519|NCT00413465|Drug|Escherichia Coli Endotoxin|
75540520|NCT00199888|Drug|124-Iodine-cG250 (124I-cG250)|
75867895|NCT03729479|Behavioral|DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
76030794|NCT02341261|Behavioral|Standard Care Counseling|
75540521|NCT00413504|Drug|Fondaparinux|
75540522|NCT04721223|Drug|JAB-3068|JAB-3068 administrated orally as a tablet.
76030795|NCT02341261|Behavioral|Supervised Exercise and Counseling|
75379808|NCT02367170|Device|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
75379809|NCT02367170|Procedure|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
75867896|NCT03729479|Behavioral|Very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
75379810|NCT02367170|Other|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
75379811|NCT01104116|Radiation|[18F]-FDG PET/CT imaging|Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
75379812|NCT03579433|Device|ORA with VerifEye+|Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
75379813|NCT03579433|Other|Alcon Barrett Toric Calculator|Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.
75379814|NCT03579433|Device|Acrysof® IQ Toric IOL|Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
75379815|NCT03534427|Other|Jump rope exercise intervention|12-week jump rope exercise program
75379816|NCT02340728|Device|ERCP with SEMS plus radiofrequency ablation|
75379817|NCT02340728|Device|ERCP with SEMS alone (standard of care)|
75379818|NCT00376909|Other|educational intervention|
75379819|NCT00376909|Other|study of socioeconomic and demographic variables|
75379820|NCT01078844|Drug|memantine|memantine 5-20 mg daily
75379821|NCT01078844|Drug|Placebo|Look-alike placebo
75379822|NCT00376051|Drug|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
75379823|NCT01072526|Drug|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
75379824|NCT01072526|Drug|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
75379825|NCT03536923|Device|Leva Incontinence System For Pelvic Floor Muscle strengthening|The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
75379826|NCT05312840|Drug|Cisplatin / Carboplatin，Gemcitabine，Cindilimab|1. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.
75867897|NCT03729479|Behavioral|Extras|Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
75379827|NCT00376129|Drug|Alefacept|15 mg i.m. once weekly for 12 weeks
75379828|NCT02307188|Device|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
75379829|NCT01035944|Device|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
75379830|NCT01035944|Device|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
75379831|NCT00378638|Drug|bevacizumab combined with dose dense chemotherapy|
75379832|NCT03582553|Dietary Supplement|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
75379833|NCT03582553|Other|Placebo|Cellulose
75379834|NCT01025492|Drug|Trilipix|135 mg po daily
75379835|NCT01025492|Drug|placebo|one tablet po daily
75379836|NCT04331834|Drug|Hydroxychloroquine|"Hydroxychloroquine with the following dosage:~day 0: 400 mg (2 tablets)~day 1: 400 mg (2 tablets)~day 2: 400 mg (2 tablets)~day 3: 400 mg (2 tablets)~weekly: 400 mg (2 tablets) for a period of six months"
76030796|NCT02336893|Behavioral|Training|The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
75379837|NCT04331834|Drug|Placebos|"Placebo with the following dosage:~day 0: 400 mg (2 tablets)~day 1: 400 mg (2 tablets)~day 2: 400 mg (2 tablets)~day 3: 400 mg (2 tablets)~weekly: 400 mg (2 tablets) for a period of six months"
76030797|NCT05013203|Diagnostic Test|Tissue culture|Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic
76030798|NCT05013203|Diagnostic Test|Next Generation Sequencing|Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
75379838|NCT04735159|Device|SCS implanted with Precision SpectraTM|Analyze the relationship between neuroimaging biomarkers and the different clinical scales and variables captured from each patient
75379839|NCT02202044|Device|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
75379840|NCT03538795|Combination Product|iTBS&eCIMT|All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everyday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
75379841|NCT01023620|Drug|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
75379842|NCT01023620|Other|Observation|Participants will be observed for 16 weeks but will not receive drug
75379843|NCT03595579|Drug|AXS-05|AXS-05 taken twice daily for 6 weeks.
75379844|NCT03595579|Drug|Bupropion|Bupropion taken twice daily for 6 weeks.
75379845|NCT02200328|Drug|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
75379846|NCT02200328|Drug|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
75540523|NCT04721223|Drug|PD1 inhibitor|JS001 administrated as an intravenous(IV) infusion.
75540524|NCT00226538|Drug|Phenytoin|
76030799|NCT03082469|Device|CytoSorb|Two consecutive 24h treatments with the CytoSorb-device
75540525|NCT00226538|Drug|Rifampicin|
75540526|NCT00226538|Drug|Diclophenac|
75540527|NCT00226538|Drug|Fluconazole|
76030800|NCT02336659|Drug|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
76030801|NCT02336659|Drug|sitagliptin|DPP-4 Inhibition
76030802|NCT02336659|Other|Placebo|Saline
76030803|NCT03082625|Drug|Transdermal Magnesium|Magnesium
76030804|NCT03082625|Drug|Placebo|
76030805|NCT02336581|Behavioral|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
76030806|NCT02336581|Behavioral|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
76030807|NCT03081923|Drug|Durvalumab|anti-PD-L1 mono therapy
76030808|NCT03081923|Drug|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
76030809|NCT02345395|Procedure|Aneurysm Clipping|All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
75379847|NCT04327843|Behavioral|Customized Adherence Enhancement|Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.
75379848|NCT04327843|Drug|Haloperidol Decanoate|Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
75379849|NCT02147834|Drug|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
75379850|NCT02147834|Drug|Sugar pill|"sugar pill manufactured to mimic ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
75704352|NCT05810558|Procedure|Ultrasonic instrumentation|The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
75704353|NCT05810532|Other|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water
75704354|NCT05810532|Other|1 hour of fasting time|Oral intake is not allowed for 4 hours before sedation, while water is allowed to intake before 1 hour of sedation
75704355|NCT05810506|Other|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
75704356|NCT05810454|Device|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
75379851|NCT04343287|Drug|BRM421|The active control with BRM421 solution
75379852|NCT04343287|Drug|Placebo|The vehicle solution
75379853|NCT04369885|Device|Go Home tablet with linked GoSpiro and 3230 Pulse Oximeter|All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and QoL Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a UNC clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.
75379854|NCT00979550|Drug|Imiquimod|commercially available topical antiviral drug
75379855|NCT00979550|Drug|non-medicated petroleum cream|Over the counter topical cream used to aid the healing process in skin lesions
75704357|NCT05810454|Device|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
76030810|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 1|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
76030811|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 1|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
76030812|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 2|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
76030813|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 2|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
76030814|NCT02341105|Procedure|Catheter ablation|Pulmonary vein isolation by catheter ablation
76030815|NCT02341105|Drug|Amiodarone|antiarrhythmic therapy using Amiodarone
76030816|NCT03078101|Drug|Empagliflozin 10 MG [Jardiance]|administered orally once daily
76030817|NCT03078101|Drug|Placebo Oral Tablet|administered orally once daily
75379856|NCT04394845|Diagnostic Test|[18F]GTP1|[18F]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]), with a maximum drug mass dose of 10 microgram (μg).
75379857|NCT00966992|Drug|Zoledronic acid|
75379858|NCT02099318|Other|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
75379859|NCT02099318|Other|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
75379860|NCT04418947|Other|Communication type|Control letter vs. intervention letter
75867898|NCT05221255|Other|spinal magnetic stimulation|"Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds."
75867899|NCT04893343|Other|Antibiotic treatment|Antibiotic treatment
75867900|NCT04893343|Other|No antibiotic treatment|No antibiotic treatment
75379861|NCT05596058|Other|dual task protocol: active exercises with concomitant cognitive training in executive functions|"The active exercise tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises."
75379862|NCT05596058|Other|active exercise|Physical activity and motor task only
75379863|NCT05596058|Other|cognitive task only|cognitive exercise in executive functions
75379864|NCT00379730|Drug|Prednisolone|
75867901|NCT04831021|Procedure|Dialysis without physical exercise|Hemodialysis control condition
75867902|NCT04831021|Procedure|Dialysis with pre-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will be performed 60 minutes before connection to hemodialysis.
75867903|NCT04831021|Procedure|Dialysis with per-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will start 30 minutes after the start of dialysis.
75867904|NCT02690194|Device|Placebo Group|The placebo group will wear headphones and listen to nature sounds.
75867905|NCT02690194|Device|Buddhify Therapy|The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
75867906|NCT05593666|Drug|LXE408|Film-coated tablets
75379865|NCT02074904|Drug|Topiramate|
75867907|NCT05593666|Other|Placebo|Placebo film-coated tablets
75379866|NCT02074904|Drug|Placebo|
75379867|NCT03542305|Drug|Lorlatinib|Lorlatinib single oral dose
75379868|NCT02057276|Device|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
75379869|NCT02057276|Device|Sham Repetitive Transcranial Magnetic Stimulation|
75379870|NCT02057276|Other|Occupational Therapy|
75379871|NCT04420273|Behavioral|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
75379872|NCT04420273|Behavioral|Active control:Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
75540528|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
75540529|NCT00255918|Drug|Placebo|Placebo dosed to match active medication
75540530|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
75867908|NCT05593666|Drug|AmBisome®|Sterile lyophilised powder in a 15 mL sterile clear glass vial
75867909|NCT04986163|Device|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC and the second monitor used is MEDSTORM.
75379873|NCT05572892|Other|FAC scale|"Measurement of walking dependency according to the FAC scale :~in the first week after stroke (in neurology by physiotherapists),~then at 6 weeks, 12 weeks and 6 months (by telephone).~Trunk Control Test score (in the first week after stroke, by physiotherapists).~MRC score of hip extension and hip flexion, knee flexion/extension, ankle plantar and dorsal flexion (in the first week after stroke, by physiotherapists).~PHQ-9 depression scale (at 6 weeks by phone).~Denutrition (weight loss between neurology weight and 6-week weight, BMI +/- albumin).~Other intercurrent medical problems (at each telephone interview)."
75379874|NCT05554796|Procedure|Endoscopic classic stapedotomy|Patients in this group will undergo classic stapedotomy starting with removal of stapes superstructure then perforation of footplate and finally insertion of the Teflon piston.
76030818|NCT03082079|Procedure|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
76030819|NCT02345239|Drug|Pantoprazole|proton pump inhibitor
75379875|NCT05554796|Procedure|Endoscopic reversal stapedotomy|Patients in this group will undergo reversal stapedotomy where perforation of footplate and insertion of Teflon piston will be done at the beginning followed by removal of stapes superstructure.
75379876|NCT00929474|Device|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
75379877|NCT00929474|Device|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
75379878|NCT04734457|Drug|Levothyroxin|We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
75379879|NCT02043860|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
75867910|NCT04986163|Device|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC-PRO and the second monitor used is MEDASENSE.
75379880|NCT02043860|Procedure|Autologous Transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
76030820|NCT02340871|Genetic|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
76030821|NCT03081767|Diagnostic Test|Digital PET/CT scan|The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
76030822|NCT02340793|Dietary Supplement|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of >15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
76030823|NCT03081065|Dietary Supplement|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
76030824|NCT04688203|Drug|Magnesium Sulfate Injection|will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
75379881|NCT02043860|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant.
75379882|NCT02043860|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days.
75379883|NCT03606187|Device|Stimgenics SCS Programming Approach|Stimgenics SCS Programming approach Using Intellis(TM) SCS system
75379884|NCT03606187|Device|Standard SCS Programming Approach|Standard SCS Programming approach using Intellis(TM) SCS system
75379885|NCT01974284|Drug|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
75379886|NCT03543085|Device|GiMer Medical MN 1000 External Stimulator|Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
75540531|NCT04710264|Other|AURORA-Rec|Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.
75379887|NCT03606343|Behavioral|Teaching Academic Skills to Kids|Group treatment
76030825|NCT04688203|Drug|Labetalol Injectable Solution|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
75379888|NCT00869414|Drug|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
75379889|NCT00869414|Drug|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
75540532|NCT00226616|Drug|Zinc|
75379890|NCT00869414|Drug|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
75379891|NCT04734769|Other|Collect retrospectively clinical data on reproductive outcomes|Collect retrospectively clinical data on reproductive outcomes
75379892|NCT04536571|Device|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
75379893|NCT04536571|Device|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
75379894|NCT00843986|Drug|conivaptan|Premix bag
75379895|NCT00843986|Drug|placebo|Premix bag
75379896|NCT05514158|Drug|RC48-ADC|RC48 for injection is a novel antibody-drug conjugate, with a her-2-targeting antibody and a microtube inhibitor
75379897|NCT05514158|Drug|RC98|RC98 is a recombinant humanized IgG1 monoclonal antibody targeting programmed cell death-Ligand 1 (PD-L1)
75379898|NCT01965782|Drug|[^14C]-LY3023703|Administered orally
75379899|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
75704358|NCT05810441|Other|Evaluation of diagnostic accuracy of anti-ttg-m|Mucosal anti-ttg evaluated in intestinal biopsy samples
75379900|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
75379901|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml|0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
75379902|NCT05503160|Behavioral|Intervention|Structured (video-)call by qualified nursing staff with breast cancer patients, with the intention to overcome side effects, distress or non-adherence to endocrine therapy.
75379903|NCT03544879|Behavioral|Yoga Intervention|The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.
75379904|NCT03544879|Behavioral|Healthy Aging Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works & What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
75379905|NCT05486468|Drug|Yutiq 0.18 MG Drug Implant|YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
75379906|NCT05486468|Other|Sham Injection|Sham injection
75379907|NCT00845702|Drug|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
75379908|NCT00845702|Other|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
75379909|NCT03610399|Drug|Primaquine|Different total dose and supervision.
75379910|NCT00843830|Radiation|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
75379911|NCT00843830|Biological|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
75379912|NCT03610633|Drug|Oxytocin|The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
75379913|NCT03610633|Drug|Placebo|Saline solution.
75379914|NCT00832520|Drug|Remeron (mirtazapine)|"Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance < 50% or a bilirubin or transaminases > twice the upper limit of normal will take a 7.5 mg dose.~Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~Dose modifications: None"
75379915|NCT03545893|Drug|Ibuprofen 600 mg|Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
75379916|NCT03545893|Drug|OxyCODONE 5 Mg Oral Tablet|Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
75379917|NCT03551821|Drug|ATI-50002|Topical Solution
75379918|NCT04734691|Procedure|PIPAC|PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy
75379919|NCT00843050|Drug|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
75379920|NCT04658797|Device|somofilcon A Daily Disposable Contact Lens|Daily Disposable Contact Lens
75379921|NCT04658797|Device|Single Vision Spectacle for Vision Correction|Single Vision Spectacle
75379922|NCT04658797|Other|Personal Facemask|Personal Facemask
75379923|NCT05290844|Other|cricoid pressure|cricoid force in pediatric patients
75379924|NCT01954160|Device|Symplicity Renal Denervation|Renal denervation
75704359|NCT05810389|Combination Product|Fluoride|Application methods of delivery of topical fluoride
75379925|NCT03552289|Device|Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
75867911|NCT04986163|Device|Non-invasive analgesia monitoring with MEDSTORM monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is MEDSTORM and the second monitor used is MEDASENSE.
75379926|NCT03552289|Device|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
75379927|NCT03615001|Device|TDOC NXT|Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
75704360|NCT05810376|Behavioral|Digital-based physical activity intervention|The digital behavioral program comprises goal planning, motivational messages and video calls, social support, and routine follow-up of weekly goals.
75867912|NCT02684344|Drug|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
75379928|NCT01877564|Drug|Metformin|
75379929|NCT03615079|Behavioral|Cognitive behavioral therapy|An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
75379930|NCT03556579|Device|senofilcon A with new UV blocker|Test Lens
75867913|NCT02684344|Other|Education|Education about signs and symptoms of urinary retention
75867914|NCT03974100|Biological|GP2411|60 mg /mL subcutaneous injection every 6 months
75867915|NCT03974100|Biological|EU-Prolia (EU-authorized Prolia®)|60 mg /mL subcutaneous injection every 6 months
75867916|NCT02689804|Drug|LNG-EC|FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
75867917|NCT02689804|Drug|UPA-EC|FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
75867918|NCT02946931|Drug|Prizbind®|Prizbind®
75379931|NCT03556579|Device|senofilcon A|Control Lens
75379932|NCT00835328|Drug|Exendin (9-39)|A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
75379933|NCT00835328|Drug|Vehicle|A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
75379934|NCT00376987|Dietary Supplement|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
75379935|NCT00832598|Radiation|[18F]FACBC PET and [18F]FLT PET imaging|[18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
75379936|NCT04499599|Other|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
75704361|NCT05810376|Other|Patient education and exercise|Patient education will include information on osteoarthritis, prognosis, pain management, importance of physical activity and exercise. The exercise program will include warm up, stretching and strengthening.
75867919|NCT04360369|Device|IOP with Goldmann Applanation Tonometer|Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (>23 mmHg).
75867920|NCT04360369|Device|IOP with comparator ORA G3 and ic100 tonometers|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.
75867921|NCT04360369|Device|IOP with Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer
75867922|NCT03959202|Behavioral|ELDERFITNESS|In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks & 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps & minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
75867923|NCT03959202|Other|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
75379937|NCT04499599|Other|Fasting|Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.
75379938|NCT04499599|Other|Study food|Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).
75867924|NCT04752085|Diagnostic Test|Chitotriosidase activity|The chitotriosidase activity will be measured in all the subjects
75867925|NCT05597670|Other|traditional knee rehabilitation program|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
75867926|NCT05597670|Other|proximal stabilization|the principles of proximal stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
75867927|NCT04353271|Drug|Hydroxychloroquine|Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.
75867928|NCT04353271|Other|Placebo|Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
75867929|NCT01374568|Drug|sitagliptin|sitagliptin 100mg daily
75867930|NCT01374568|Other|Placebo|1 pill daily
75867931|NCT03706183|Diagnostic Test|Ischemia-modified albumin|The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
75379939|NCT04512703|Device|µCor|Sensor Monitor for arrhythmia and other bio-metric markers
75379940|NCT01889420|Drug|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~Everolimus daily for 28 days of a 28 day cycle;~Pomalidomide daily for 21 days of a 28 day cycle~Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
75867932|NCT03706183|Diagnostic Test|Hearing thresholds|The hearing levels will be determined for each group.
75867933|NCT03706105|Behavioral|Cardiac Rehabilitation|3 x week ~1 hour of exercise + education
75379941|NCT03557125|Other|QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
76030826|NCT03145753|Other|HIV/HCV Education plus Testing|Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
75867934|NCT03114826|Genetic|To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
75867935|NCT01312441|Drug|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
75867936|NCT01312441|Drug|Placebo|Placebo by mouth once weekly for 6 months
75867937|NCT02682784|Drug|Oxytocin|Nasal spray based on naturally occurring hormone, oxytocin.
75540533|NCT00199849|Biological|NY-ESO-1 Plasmid DNA Cancer Vaccine|NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.
75540534|NCT00255957|Drug|HES administration|
75867938|NCT02682784|Drug|Placebo|
75867939|NCT03165604|Other|standard information|The participates will be given a standard information regarding the water drink before physical activity
75867940|NCT03165604|Other|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
76023045|NCT02405143|Device|Sham stimulation using DC-Stimulator MC|Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
76023046|NCT03173911|Device|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
76030827|NCT03145753|Other|HIV/HCV Education|Only education and support will be provided in this arm
76030828|NCT04679233|Other|Prescription aerobic exercise|high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
75704362|NCT05810337|Dietary Supplement|Splenda drink|4.5g Splenda containing 1% sucralose, 95% maltodextrin, dissolved in 250ml water and consumed with a high carbohydrate breakfast.
75379942|NCT03557125|Other|Saline Skin Wheel|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
75379943|NCT03616171|Behavioral|SLEEP-Extend intervention|"One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later"
75379944|NCT03616171|Other|Control|Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
75379945|NCT00379028|Drug|Budesonide/Formoterol Turbuhaler|
75379946|NCT00379028|Drug|Salmeterol/Fluticasone Diskus|
75379947|NCT05286554|Drug|gonadotropin releasing hormone-agonist|subcutaneous injection
75379948|NCT05286554|Drug|Progesterone|vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.
75379949|NCT03558061|Drug|ALK4290|ALK4290 400 mg tablet twice a day
75379950|NCT01881932|Device|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
75379951|NCT01881932|Device|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
75379952|NCT03617419|Device|GE VScan Access R2 Ultrasound System|A diagnostic ultrasound imaging system manufactured by the study Sponsor.
75379953|NCT03617419|Device|GE Corometrics 170 Series Fetal Monitor|A reference device to record a continuous fetal heart rate.
75379954|NCT03617419|Device|GE Corometrics 170 Series Fetal Monitor|A reference device for verification of scanning the fetal heart.
75379955|NCT00379106|Procedure|Arm exercises.|Basic active exercise program at home.
75379956|NCT00379106|Procedure|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
75379957|NCT03619135|Device|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
75379958|NCT03619135|Other|Placebo|No use of the Buzzy (standard IV access techniques)
75704363|NCT05810337|Dietary Supplement|Maltodextrin drink|4.5g maltodextrin dissolved in 250ml water and consumed with a high carbohydrate breakfast.
75704364|NCT05810337|Dietary Supplement|High carbohydrate breakfast|Meal consisting of 30g cereal with 100ml skimmed milk, 1.5 slices white toast with 12g margarine, providing 386kcal, 61.4g carbohydrate, 10.4g protein and 10.1g fat.
76030829|NCT03145597|Device|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
76030830|NCT03145597|Device|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
75540535|NCT00255957|Drug|Hydroxy Ethyl Starch administration to stroke patients|
75540536|NCT00226694|Drug|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
75540537|NCT00226694|Other|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
75540538|NCT00255996|Drug|linezolid|
75540539|NCT00226733|Behavioral|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
75867941|NCT03164824|Other|questionnaire|"Cross-cultural adaptation stage:~The FRI was cross-culturally adapted to Thai (called the Thai FRI) and the pre-final version of the Thai FRI was administered to patients.~Psychometric properties testing stage:~The questionnaires were administered 3 times: the first visit, the second visit and at 2 weeks.~At the first visit: the patients with back pain completed the Thai FRI , Thai Roland-Morris Disability (Thai RM), Thai modified Oswestry Low Back Pain Disability (Thai modified ODQ), Thai multi-level Roland-Morris Disability (Thai multi-level RM). The patients with neck pain completed the Thai FRI and Thai Neck Disability Index.~At the second visit: all patients completed the Thai FRI and Global Perceived Effect Scale (GPES).~At 2 weeks: the patients completed the same questionnaires as the first visit. All patients and their treating physical therapists completed the GPES."
76030831|NCT02336035|Procedure|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
75540540|NCT00226733|Behavioral|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
76030832|NCT05254561|Biological|Intralesional antigen immunotherapy|Randomized double-blinded comparative effectiveness and safety clinical trial
76030833|NCT04536025|Other|Qualitative focus group interviews|Prosthetists and/or expert working group members will participate in qualitative focus group interviews up to 120 minutes in length.
75540541|NCT00415155|Drug|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
76030834|NCT04536025|Other|Qualitative semi-structured interviews|People with lower limb amputation and/or expert working group members will participate in qualitative individual, semi-structured interviews approximately 60 minutes in length.
76030835|NCT04509973|Drug|Dexamethasone|ATC code: H02AB02
76030836|NCT02637557|Drug|IW-3718|
76030837|NCT02637557|Drug|Matching Placebo|
76030838|NCT02637557|Drug|PPI|All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
75540542|NCT00226850|Behavioral|hypnosis|
76030839|NCT04491253|Behavioral|Social support for diabetes self-management|Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
76030840|NCT04480645|Device|CivaDerm|radioactive bandage
76030841|NCT05254249|Drug|Lactobacillus Plantarum IS-10506|Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
76030842|NCT05254249|Other|Placebo|Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets
76030843|NCT03145909|Drug|ABBV-176|Intravenous infusion
75867942|NCT03164902|Device|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
75379959|NCT04706312|Other|stem cells|hAMSCs injection via venous in the dorsum of hand
75867943|NCT03164746|Other|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
75379960|NCT03559933|Device|PEPNS System|PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
75379961|NCT00379262|Drug|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
75379962|NCT00379262|Drug|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
75540543|NCT00226889|Drug|bosentan|
75867944|NCT03164746|Other|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
75867945|NCT05367895|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|"Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use."
76030844|NCT02344927|Other|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
75540544|NCT00415272|Behavioral|Pulmonary Rehabilitation|
76030845|NCT02344927|Other|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
75540545|NCT00226928|Behavioral|Supportive-Expressive Group Therapy plus education|
75540546|NCT00226928|Behavioral|Education|
75704365|NCT05810324|Drug|18F-FAPI|Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.
75704366|NCT05810298|Other|Asana Practice|Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.
75867946|NCT03165448|Diagnostic Test|Pre-operative USOS scale testing|Patient has to self-report USOS questionnaire just before the procedure as main scale.
76030846|NCT02344849|Drug|mesenchymal stem cell|Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
76030847|NCT02336113|Behavioral|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
75379963|NCT00379262|Drug|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
75379964|NCT03620383|Procedure|Topical Heat|Warm heat pack applied topically in participant hand.
75379965|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
75379966|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
75379967|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
75379968|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
75379969|NCT03621085|Drug|Ketamine Hydrochloride|A total of 20 mg of Ketamine Hydrochloride will be administered intravenously
75379970|NCT03621085|Other|Placebo|Subjects will receive placebo
75379971|NCT00795236|Drug|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
75867947|NCT03165448|Diagnostic Test|Pre-operative SDPQ, MDAS and VAS testing|Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
75867948|NCT03165448|Diagnostic Test|Post-operative doctor's reported USOS|Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
75867949|NCT03165448|Diagnostic Test|Re-testing 4-6 weeks later|All the participants has to refill USOS questionnaire 4-6 weeks later.
75867950|NCT05681533|Procedure|CT scan|coronary calcium score measurement by CT scan
75379972|NCT04490863|Device|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
75379973|NCT00790478|Drug|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
75704367|NCT05810298|Other|Pranayam Practice (Rhythmic regulated breathing)|Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.
75704368|NCT05810298|Behavioral|Smoking Education Program|The aim of the education is to increase awareness of subjects who are chronical smokers. The subject education will be performed at least once via face to face interview. Education topics will be covered basic information about harmful effects of habitual smoking and how to reduce the side effects of nicotine withdrawal.
76030848|NCT03145363|Behavioral|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
75379974|NCT00790478|Other|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
76030849|NCT03145363|Behavioral|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
76030850|NCT02336191|Procedure|living donor liver transplantation|living donor liver transplantation
76030851|NCT02336347|Drug|AVP-786|
75379975|NCT04490239|Drug|Intranasal heparin sodium (porcine)|Intranasal heparin sodium
75379976|NCT00791336|Drug|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
75379977|NCT03621787|Device|Implant insertion device|Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
75379978|NCT03562663|Device|Transcranial direct current stimulation|A constant, low current stimulation is provided non-invasively through sponge electrodes positioned over the motor cortex of the affected arm. The stimulation is provided for 20 minutes at an intensity of 2 mA.
75379979|NCT03562663|Device|Upper extremity robotics|Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
75379980|NCT00771602|Drug|Rituximab|375 mg/m^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
75704369|NCT05810207|Procedure|Colorectal resection|Patients undergoing a colorectal resection with the construction of a primary anastomosis
75704370|NCT05810142|Drug|furquimatinib and sintilimab|furquimatinib and sintilimab
75379981|NCT00771602|Drug|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
75704371|NCT05810129|Other|Cross-education training|Concentric-eccentric cross training in a 6-week immobilization period + 12-week standard kinesic therapy (2 times a week)
76030852|NCT02336347|Drug|AVP-923|
75379982|NCT04332146|Behavioral|Mindfulness-based program (MBI-p-R)|The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.
75379983|NCT04332146|Behavioral|Booklet-based psychoeducation|The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
76030853|NCT02341027|Device|Jadelle|within 5 days of delivery and before discharge from hospital
75379984|NCT05277818|Procedure|Surgery lumbar disc herniation|Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
75379985|NCT05246384|Drug|RP7214|RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle
75379986|NCT03626623|Device|Cytal Wound Matrix 1-Layer|Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
75379987|NCT03626623|Other|Standard of Care (SOC)|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
75379988|NCT05149742|Behavioral|Cognitive and audiometry evaluation|"For both Patients and controls:~Cognitive functions evaluation~Tonal and vocal audiometry~Self questionnaires"
75379989|NCT01804166|Drug|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
75379990|NCT01804166|Drug|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
75379991|NCT04459585|Drug|Dabigatran Etexilate Mesylate|Single oral 150 mg capsule dose
75704372|NCT05810129|Other|Cross-education training|Eccentric cross training in immobilization period of 6 weeks + Standard kinesic therapy of 12 weeks (2 times a week)
75704373|NCT05810103|Drug|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
76030854|NCT02341027|Device|Jadelle|6-8 weeks (42-56 days) postpartum
75704374|NCT05810090|Procedure|Total knee arthroplasty|patient who received a TKA in our hospital
75704375|NCT05810012|Drug|PENG block|10ml of 0.125% isobaric bupivacaine injected
75379992|NCT04459585|Drug|Quizartinib|Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
75379993|NCT05080556|Drug|Carboplatin|Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
75704376|NCT05810012|Drug|FICB Block|20ml of 0.125% isobaric bupivacaine injected
75704377|NCT05809999|Procedure|Standard colonoscopy with targeted biopsies|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
75704378|NCT05809973|Diagnostic Test|VISA tool|Validation of VISA
75704379|NCT05809960|Other|Nursing support program|It was discussed about the operation and surgical menopause that the woman will undergo after hospitalization for the operation. Education was given including the problems experienced during menopause and the approaches used to cope with them. Progressive relaxation exercises were taught and practiced. In order to carry out these procedures, an interview of approximately 45-60 minutes was held with each woman. During the program, four planned meetings were held. One of them was face-to-face and the others were phone calls. During the phone calls, the symptoms experienced by the women and their coping methods were discussed and the questions of the women were answered. The average of each phone call was 20-30 minutes.
75704380|NCT05809960|Other|Routine nursing care|Routine nursing care was given to the control group. The clinical routine has not been exceeded. It includes discharge training for the surgery.
75704381|NCT05809908|Drug|Tricaprilin|"Each dose of IMP will be administered orally 30 minutes after completing a meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 3 weeks."
75704382|NCT05809908|Drug|Placebo|"Each dose of IMP will be administered orally 30 minutes after completing a meal.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of safflower oil; 80 ml total daily dose of placebo, over the course of 3 weeks."
75379994|NCT00746018|Device|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
76030855|NCT03112291|Procedure|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
76030856|NCT02340637|Behavioral|Coping Kids|The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
75704383|NCT05809882|Device|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times
75704384|NCT05809882|Device|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
75704385|NCT05809869|Drug|Durvalumab|Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles
75704386|NCT05809869|Drug|Tremelimumab|Tremelimumab 300mg intravenous infusion on week 1 only.
76030857|NCT02340637|Behavioral|TAU|Treatment as usual
76030858|NCT02335879|Biological|Gonal-F|
75704387|NCT05809869|Radiation|Yttrium-90 radioembolisation|Yttrium-90 radioembolisation on week 2 only.
75379995|NCT01797380|Drug|Placebo|Placebo daily for duration of double-blind portion of trial
75704388|NCT05809843|Device|hybrid artificial pancreas systems (CSII)|artificial device that adjust the patient's glycemic levels with insulin doses appropriate to the patient's blood glucose
75704389|NCT05809817|Procedure|Periodontal treatment|Scaling and root planing
76030859|NCT05005325|Other|Experimental group(Male)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
76030860|NCT05005325|Other|Experimental group(Female)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
76030861|NCT03077945|Behavioral|heart rate variability biofeedback and cognitive reappraisal|
76030862|NCT03077945|Behavioral|control tasks|
76030863|NCT02039479|Drug|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
76030864|NCT02039479|Drug|Placebo|Placebo as ADD-on to every necessary treatment as usual
75379996|NCT01797380|Drug|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
75867951|NCT05466994|Other|IPAD|Participant will play a game through (standard camera) participants will be able to the hospital room and decals as they appear in the real world
75379997|NCT03571555|Behavioral|Sentebale Psychosocial Programme|Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
75867952|NCT05466994|Other|Augmented Reality|Participants will play a game through (devices camera and application) let us participants view the real world
75867953|NCT05354245|Dietary Supplement|Fibre supplement (potato-pectin)|Fibre supplement
75867954|NCT05354245|Dietary Supplement|Placebo|Maltodextrin
75867955|NCT05354245|Dietary Supplement|High-protein diet|High-protein diet
75867956|NCT05464888|Behavioral|+Short AAT|Interaction with therapy dog prior to dental exam, cleaning, and simulated radiographs.
75867957|NCT05464888|Behavioral|+Long AAT|Interaction with therapy dog throughout dental exam, cleaning, and simulated radiographs.
75867958|NCT05464888|Behavioral|Active control; NO dog|Color dog picture for 3 minutes prior to dental exam, cleaning, and simulated radiographs.
75867959|NCT03165214|Device|coil|microcoils
75379998|NCT00737594|Drug|Placebo|Matching placebo capsules for oral administration
75379999|NCT00737594|Drug|Cobiprostone|Cobiprostone capsules for oral administration
75867960|NCT03165214|Device|hystoacryl glue|hystoacryl mixed with lipidol
75867961|NCT03705949|Drug|Sodium Hyaluronate 0.1% drops|Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
75867962|NCT03705949|Drug|Sodium Hyaluronate 0.2% drops|Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
76023047|NCT02408107|Behavioral|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
75380000|NCT00732680|Drug|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
75380001|NCT04441255|Drug|TAK-788|TAK-788 Capsule.
75380002|NCT00726830|Drug|methadone hydrochloride|Given orally
75380003|NCT00726830|Drug|morphine sulfate|Given orally
75380004|NCT00726830|Drug|oxycodone hydrochloride|Given orally
75867963|NCT04716127|Behavioral|Proximity-incentive strategy based on vaginal self-sampling for women 50 to 65 years who do not participate to cervical cancer screening|"Direct offer of a vaginal self-sampling kit with information to perform at home and send back to the laboratory for HR-HPV testing~The psychosocial determinants involved in decision-making process and compliance to cervical cancer screening will be collected from open questionnaires and by semi-directive phone interviews~Control ; Receive reminder to send the self-sample to the laboratory : After 3 and 6 months without return, women receive a remind letter to send the vaginal self-sample to the laboratory. We call return the receipt of the vaginal self-sample at the laboratory.~Control ; Receive reminder to perform cervical smear in case of positive HR-HPV test : In case of a positive HR-HPV test, women are asked to perform a control cervical smear. After 3, 6 months and 12 months without return, women and their health-care professional will receive a remind letter to perform a cervical smear for control. We call return the performance of a pap smear."
75380005|NCT03628885|Behavioral|Top Concern Tailored Intervention|General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.
75380006|NCT03628885|Behavioral|All Concerns Tailored Intervention|General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
75867964|NCT03162484|Behavioral|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
75867965|NCT04693039|Drug|Phenlarmide|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
76023048|NCT04459247|Drug|Vit D|Oral liquid formulation of 60000 IU
75380007|NCT00691652|Biological|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
75380008|NCT00691652|Drug|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
75380009|NCT00691652|Genetic|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
75380010|NCT00691652|Genetic|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
75540547|NCT04710225|Procedure|Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting|"Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= [SBP+10]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure."
75380011|NCT00691652|Genetic|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals << 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
75380012|NCT00691652|Genetic|polymerase chain reaction|
75540548|NCT00226967|Drug|Sandostatin|Calculated per patient
75704390|NCT05809804|Drug|Esketamine|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
76030865|NCT05013281|Procedure|Suprachoroidal hemorrhage associated with pars plana vitrectomy|SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.
76030866|NCT05013125|Diagnostic Test|ENDO-AID CADe assisted Colonoscopy|ENDO-AID is a dedicated endoscopy Computer-Aided Diagnosis (CADe) system where suspicious lesions are automatically detected and highlighted on the main monitor in real-time, alerting the endoscopist during the procedure.
76030867|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
76030868|NCT02340481|Drug|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
75540549|NCT04709913|Drug|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
75540550|NCT00199381|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
75540551|NCT00227006|Behavioral|Behavioral lifestyle/weight-loss intervention|
75867966|NCT04693039|Drug|Placebo|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
75867967|NCT03162562|Biological|Oregovomab|Monoclonal antibody against CA 125
75867968|NCT03162562|Drug|Poly ICLC|Immune adjuvant
76030869|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
76030870|NCT02340481|Drug|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
76030871|NCT05012579|Device|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
75380013|NCT00691652|Other|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
75380014|NCT00691652|Other|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
75380015|NCT00691574|Dietary Supplement|Melatonin|up to 3 mg, daily, for up to 1 year
75867969|NCT03162718|Behavioral|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
75380016|NCT00691574|Device|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
75380017|NCT03631927|Other|Observation|Observation
75380018|NCT00685880|Drug|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
76030872|NCT03077867|Procedure|sinus floor augmentation with bone graft|sinus floor augmentation with lateral approach with bone graft
76030873|NCT04426279|Other|questionnaire assesment|15-minute face-to-face questionnaire
75380019|NCT00685880|Drug|Betamethasone|CELESTONE® SOLUSPAN® * (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
75380020|NCT00681044|Biological|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
75380021|NCT00681044|Drug|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
75380022|NCT00681044|Procedure|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
75380023|NCT03632083|Device|Hy-Care Contact Lens Solution|Hy-Care Contact Lens Solution
75380024|NCT03632083|Device|Lite Contact Lens Solution|Lite Contact Lens Solution
75380025|NCT03632083|Device|fanfilcon A soft contact lens|fanfilcon A soft contact lens
75380026|NCT03632083|Device|comfilcon A soft contact lens|comfilcon A soft contact lens
75380027|NCT05010980|Other|CMR|clinical indication
75380028|NCT05010980|Other|scintigraphy|clinical indication
75380029|NCT03633487|Drug|Mucinex®|Mucinex® 1200 mg ER Bi-Layer tablet
75380030|NCT04929002|Other|No intervention|No intervention
75380031|NCT03574441|Device|Tegaderm dressing + catheter support pad|Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter
75380032|NCT03574441|Device|Tegaderm dressing + Steri-strip dressing|Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter
75380033|NCT03574441|Device|Tegaderm dressing only|Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
75380034|NCT00423020|Drug|Erythropoietin|
75380035|NCT00671606|Procedure|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
75704391|NCT05809765|Other|8-week breath training program|The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.
75704392|NCT05809726|Other|Manual lymph drainage|one session 20 minutes
75704393|NCT05809674|Device|Polarization sensitive optical coherence tomography (PS-OCT)|The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.
75704394|NCT05809661|Behavioral|implementation of the nurse navigation program|Adult patients with intestinal stoma were contacted continuously for 6 months.
75704395|NCT05809635|Other|Natural History Study|Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
76030874|NCT05012501|Diagnostic Test|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
76030875|NCT02344771|Procedure|Elective colon cancer surgery|
76030876|NCT03077633|Procedure|Cervical Cerclage placement|Cervical Cerclage placement
76030877|NCT03077633|Drug|Vaginal Progesterone|200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
75380036|NCT01756586|Drug|Dexamethasone|
75380037|NCT01756586|Drug|Bupivacaine|Control
75380038|NCT03636061|Drug|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
75380039|NCT03636061|Drug|Placebo (vehicle) nasal spray|Placebo
75380040|NCT04404907|Other|no intervention|This is a secondary analysis of registry data.
75380041|NCT00661466|Drug|Bupivacaine Collagen Sponge|
75380042|NCT00661466|Drug|Placebo|placebo
75867970|NCT03705871|Device|Differential Expansion|Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
75867971|NCT03705871|Device|Fan-Fype Expander|Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
75540552|NCT04710069|Behavioral|POINT|Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.
75540553|NCT04709991|Procedure|Endovascular procedure|Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
75540554|NCT00227084|Drug|Arista AH hemostasis powder|
75540555|NCT04709952|Device|Transcranial direct current stimulation_High real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in high real stimulation group (2mA).
75540556|NCT04709952|Device|Transcranial direct current stimulation_Low real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in Low real stimulation group (1mA).
75867972|NCT03164590|Drug|Ketamine|patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
75540557|NCT04709952|Device|Transcranial direct current stimulation_Sham|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in sham stimulation group (0mA).
75540558|NCT00227123|Drug|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
75540559|NCT00256035|Procedure|Measuring IL-4 levels|
75540560|NCT00227162|Behavioral|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
75540561|NCT00227162|Behavioral|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
75540562|NCT00227162|Behavioral|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
75380043|NCT04403113|Other|Structured neck and trunk stabilization exercises|Intensive structured neck and trunk stabilization exercises based on Neurodevelopmental therapy method-Bobath concept principles. These exercises were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
75380044|NCT04403113|Other|Feeding and oral motor intervention strategies|Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
75380045|NCT04403113|Other|Caregiver training related to feeding|In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
75540563|NCT00235521|Drug|aerosolized iloprost|
75540564|NCT00227201|Behavioral|Self-affirmation intervention|
75540565|NCT00235560|Drug|rapamycin|sirolimus
75540566|NCT00256074|Procedure|Enteral feeding formula|
75540567|NCT00227279|Biological|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
75540568|NCT00235599|Procedure|IGFBP-3 Stimulation Test|
75540569|NCT00227318|Drug|ATACAND|
75867973|NCT03164590|Drug|dexmedetomidine|patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
75867974|NCT03164590|Drug|bupivacaine|patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
75867975|NCT05119075|Other|Dopaminergic OFF-drug state|Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
75704396|NCT05809557|Other|Chemotherapy toxicity tool|"CARG is an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity. This intervention will make available a simple calculator which includes: Gender, Height and weight, Cancer Subtype, Hemoglobin, How is your hearing (with hearing aid, if needed)?, Number of falls in the past 6 months, Can you take your own medicines, Does your health limit you in walking one block., During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)? and Glomerular filtration rate.~The CARG chemotoxicity calculator will be built into the patient navigator and its use will be assessed on a monthly basis and used to inform iteration."
75380046|NCT00639626|Drug|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
75380047|NCT01718444|Drug|Progestin|
75380048|NCT01718444|Drug|Clomiphene Citrate|
75380049|NCT00641108|Drug|ADAM SPECT plus Cognitive Therapy|
75380050|NCT00641108|Drug|ADAM SPECT plus No Therapy|
75380051|NCT00638222|Other|Carvedilol and Placebo|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
75380052|NCT00634322|Drug|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
75380053|NCT00634322|Drug|leucovorin|IV or po given every 6 hours
75380054|NCT00379886|Drug|Propofol Thiopental|
75380055|NCT01705106|Drug|capecitabine|Given PO
75380056|NCT01705106|Drug|celecoxib|Given PO
75380057|NCT01705106|Other|pharmacological study|Correlative studies
75540570|NCT00227357|Drug|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
75540571|NCT00227357|Drug|Off-site - methadone or no agonist|
75704397|NCT05809557|Other|Oncology Consultation|Oncologists will consult new patient with a new diagnosis of cancer.
75380058|NCT01705106|Other|laboratory biomarker analysis|Correlative studies
75380059|NCT01705106|Other|pharmacogenomic studies|Correlative studies
75380060|NCT00626444|Drug|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
75380061|NCT00624650|Drug|Diuresis (furosemide) part I|"Goal: Overall I/O net negative 50ml/hour~Initiation:~Continuous IV furosemide at 3mg/hour or last known protocol specified dose~Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~Do not exceed 30mg/hour~Furosemide Bolus:~If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period"
75380062|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP<8 or measured PaOP <12mmHg in addition to concurrent urine output of <0.5 ml/kg/hr
75380063|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|"10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.~Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases > 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map < 60 or who are on vasopressors that also have a measured GEDI less than goal"
75380064|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use any alone or in combination)~Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~Vasopressin - 0.04 international units/hour~Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg."
75380065|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use alone or in combination)~Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~Vasopressin - 0.04 international units/hour~Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of < 60"
75540572|NCT00198133|Drug|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
75540573|NCT00256113|Drug|Saredutant succinate (SR48968C)|
75540574|NCT00227435|Drug|val-mCyd|
75540575|NCT00235677|Procedure|Endoscopic gastroplication|
75540576|NCT00227474|Drug|recombinant modified vaccinia Ankara-5T4 vaccine|
75540577|NCT00227474|Procedure|adjuvant therapy|
75540578|NCT00227474|Procedure|recombinant viral vaccine therapy|
76030878|NCT05005169|Diagnostic Test|SGB PCR|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
75540579|NCT00197236|Biological|Havrix™|2 intramuscular injections, 6 months apart
75380066|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index < 2.5"
75380067|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol."
75380068|NCT00624650|Other|Concentrate all drips and nutrition|"Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.~EVLW arm: Patients with a MAP > 60 and off vasopressors for >12 hours, as well as patients with a measured cardiac index >2.5 that also have a measured GEDI > goal."
75380069|NCT00624650|Drug|Diuresis (furosemide) part II|"Withhold furosemide if:~Significant hypokalemia (K+ <= 2.5 meq/L), or hypernatremia (Na+ >= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~Dialysis dependence~Oliguria (less than 0.5ml/kg/hour) with either creatinine > 3, or clinical suspicion of rapidly evolving ARF~More than 800mg has been given in less then 24 hours~Creatinine increases > 1.5 mg/dl in any 24 hour period"
75380070|NCT00624650|Procedure|Dialysis|"Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~EVLW arm: Fluid balance as per algorithm~When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm."
75540580|NCT00197236|Biological|Infanrix™|1 intramuscular injection
75540581|NCT00197236|Biological|ActHIB™|1 intramuscular injection
75540582|NCT00256152|Device|AF Suppression Pacing Algorithm|
75540583|NCT00227513|Drug|bortezomib|Given IV
75540584|NCT00227513|Drug|vorinostat|Given orally
75540585|NCT04709445|Diagnostic Test|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) before and after anastomosis formation, postoperative analysis of ingress and egress for specific regions of interest
75540586|NCT00256191|Drug|TPI 287 Injection|
75540587|NCT00227630|Drug|cisplatin|
75540588|NCT00227630|Drug|pemetrexed disodium|
75540589|NCT00227630|Procedure|adjuvant therapy|
76030879|NCT05005169|Diagnostic Test|SGB culture|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
76030880|NCT05253781|Drug|Low-dose aspirin|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
75540590|NCT00227630|Procedure|conventional surgery|
75540591|NCT00227630|Procedure|neoadjuvant therapy|
75540592|NCT00227630|Radiation|radiation therapy|
75540593|NCT00256230|Drug|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
75540594|NCT00227669|Drug|docetaxel|
75540595|NCT00227669|Drug|gemcitabine hydrochloride|
75540596|NCT00235794|Drug|temsirolimus|
75540597|NCT00256269|Drug|Oxaliplatin|40 mg/m2 IV over 60 minutes Every 21 days
75540598|NCT00256269|Drug|Irinotecan|60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
76030881|NCT05253781|Other|Placebo|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
76030882|NCT05012423|Drug|Placebo|"Matching Placebo~Placebo will be administered as oral capsules."
76030883|NCT05012423|Drug|ECC0509|"ECC0509 1 mg and 10 mg capsules~ECC0509 will be administered as oral capsules."
76030884|NCT05012423|Drug|Placebo|"Matching Placebo~Placebo will be given orally during each dosing day."
75540599|NCT00197002|Biological|GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)|Two doses, administered intramuscularly in the right anterolateral thigh.
76030885|NCT05012423|Drug|ECC0509|"ECC0509 1 mg and 10 mg capsules~Placebo will be given orally during each dosing day."
75540600|NCT00197002|Biological|Prevnar™|One dose, administered intramuscularly in the left anterolateral thigh.
75540601|NCT00227708|Drug|docetaxel|
75540602|NCT00227708|Procedure|quality-of-life assessment|
75540603|NCT00235911|Drug|budesonide/formoterol Turbuhaler|
75540604|NCT00196105|Device|6 mm Nitinol Zilver Stent|
75540605|NCT00196105|Device|10 mm Nitinol Zilver Stent|
75540606|NCT00196105|Device|10 mm Stainless Steel Wallstent|
75540607|NCT04722068|Other|Kinetics test|Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.
75540608|NCT00256347|Drug|intramuscular injections of morphine|
75540609|NCT00227747|Drug|capecitabine|
75540610|NCT00227747|Drug|oxaliplatin|
75540611|NCT00227747|Procedure|conventional surgery|
75540612|NCT00227747|Procedure|neoadjuvant therapy|
75540613|NCT00227747|Radiation|radiation therapy|
75540614|NCT00235950|Drug|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
75540615|NCT00227786|Behavioral|smoking cessation intervention|
75540616|NCT00227786|Other|counseling intervention|
75540617|NCT02962089|Dietary Supplement|Branched chain amino acids (BCAA)|
75540618|NCT02962089|Dietary Supplement|Placebo|
75540619|NCT00256386|Device|Electronic Medical Record (EMR) to clinician's in-basket|
75540620|NCT00256386|Device|Automated Voice Message (AVM) reminder to patient's phone|
75380071|NCT03965533|Drug|GSK2831781|GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
75380072|NCT03965533|Drug|Placebo|Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
75380073|NCT01693484|Drug|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
75540621|NCT00256386|Procedure|Pharmacy Team phone call-letter followup|
75540622|NCT00227825|Behavioral|Motivational interviewing|
75540623|NCT00227864|Behavioral|Behavior Therapy|
76030886|NCT03077477|Drug|AMXT 1501|Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
75540624|NCT00227864|Other|Treatment as Usual|
75540625|NCT00256425|Behavioral|Cognitive rehabilitation|
75540626|NCT04721990|Device|Automatic Sound Management 3.0|The investigational front-end features include those within Automatic Sound Management 3.0 (i.e., Ambient Noise and Transient-Noise Reduction, and Adaptive Intelligence). Automatic Sound Management 3.0 will be accessed in the MAESTRO system software. The investigational front-end features within Automatic Sound Management 3.0 will be programmed in the SONNET2EAS processor.
75540627|NCT00256464|Behavioral|Multi-component Yoga Intervention|
75540628|NCT00227942|Drug|Estrogen Replacement Therapy|17-b-Estradiol Patch, .05 mg/day; applied for 7 days
75704398|NCT05809544|Device|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
75540629|NCT00227942|Drug|Zolpidem|10 mg/day, po qhs
75704399|NCT05809544|Device|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
76030887|NCT03077477|Drug|Placebo Oral Tablet|"Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered"
75540630|NCT00227942|Drug|placebo|placebo
75540631|NCT00256503|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
75704400|NCT05809518|Drug|Propofol injection|sedation after cardiac surgery
75380074|NCT03637699|Behavioral|Positive Psychology|5-week positive psychology intervention
75380075|NCT01690910|Device|Rifton Gait Trainer|
75380076|NCT01690910|Device|Front Wheeled Walker|
75380077|NCT00377065|Drug|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
75704401|NCT05809518|Drug|Dexmedetomidine injection|sedation after cardiac surgery
75704402|NCT05809518|Drug|Dexmedetomidine and Propofol|sedation after cardiac surgery
75867976|NCT05119075|Other|Dopaminergic ON-drug state|Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
75867977|NCT04440046|Other|Manual therapy thoracic spine|Manual therapy mobilization directed to the costovertebral joint.
75380078|NCT00377143|Drug|Warfarin Dosing|
75380079|NCT00613886|Device|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
75380080|NCT00613886|Behavioral|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
75540632|NCT00227981|Behavioral|Interpersonal Psychotherapy|
75540633|NCT00227981|Drug|Fluoxetine|
75540634|NCT00236028|Drug|Infliximab|
75540635|NCT00256542|Drug|Alkalinized Lidocaine-Heparin|
75540636|NCT00228020|Drug|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
75540637|NCT00228020|Drug|MMF, cyclosporine, steroids|
75540638|NCT00236067|Drug|Gabitril|
75540639|NCT00228059|Drug|Licarbazepine|
75540640|NCT00195715|Biological|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
75380081|NCT03947983|Behavioral|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
75380082|NCT03947983|Behavioral|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
76030888|NCT02344615|Procedure|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
76030889|NCT02344615|Procedure|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
76030890|NCT03145519|Device|Vasofix Certo Catheter|Placement of IV-catheter
76030891|NCT03145519|Device|OptiVein Catheter|Placement of IV-catheter
75380083|NCT00610532|Drug|phenytoin|intravenous phenytoin (15 mg/kg) single dose
75380084|NCT00610532|Drug|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
75380085|NCT01669148|Device|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
75380086|NCT01669148|Device|Conventional|conventional (2D) imaging (standard mammography)
75540641|NCT00236106|Drug|tacrolimus ointment 0.1%|
75540642|NCT00236106|Drug|mometasone furoate 0.1%|
76030892|NCT02340559|Behavioral|Meta-cognitive Training|
76030893|NCT02340559|Behavioral|Psychoeducational group|
75704403|NCT05809492|Other|step test|"The step speed of 18 steps/min was chosen for the first level because it is suitable for all subjects and prevents them from being too fast at the end of the test.~the slow standardized initial tempo at Level 1 of 72 beats/min allowed familiarity with the coordinated cascading technology of the tests (step up and down in time with the metronome beat). Regular replacement of the leading leg was encouraged to prevent unilateral leg fatigue and November muscle pain.~pwCF selected 1-minute stage times for each level in accordance with the maximum exercise test (CPET) recommendations in 18; at each new level, the test speed was increased by two steps / minute to ensure a progressive change in exercise parameters; a suitable end test time of 16 minutes was achieved along with an initial speed of 18 steps/min. The fast pace of 194 beats/min (48 steps/min at Level 16), which was eventually reached, it was physically possible to perform safely."
75704404|NCT05809479|Other|No intervention|No intervention
75540643|NCT00228098|Behavioral|Smoking cessation|
75540644|NCT00236145|Drug|ACTIQ (Oral transmucosal fentanyl citrate)|
75540645|NCT00413543|Other|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
75704405|NCT05809440|Other|20-minute mindful breathing session|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
75704406|NCT05809401|Behavioral|Pragmatic Rehabilitation|A series of behavioral activities to improve specific pragmatic abilities in patients
75704407|NCT05809401|Behavioral|Neuropsychological Rehabilitation|A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
75540646|NCT00256581|Procedure|Additional rest and stress image sets on new camera|
75540647|NCT00228215|Behavioral|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
75540648|NCT00228254|Drug|Zinc (12.5 mg/day)|
75540649|NCT00228254|Drug|vitamin A 10,000 IU per week|
75540650|NCT00228293|Device|investigational monitor/defibrillator with CPR feedback|
75540651|NCT00195676|Drug|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
75540652|NCT00228332|Drug|Administration of zinkgluconaat or placebo|
75540653|NCT00194077|Drug|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
75540654|NCT00194077|Drug|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
75704408|NCT05809336|Drug|Inosine 0.2g orally 3 times/day|inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,
75704409|NCT05809336|Drug|PD-1/PD-L1 inhibitor ,chemotherapy/targeting|PD-1/PD-L1 inhibitor ± chemotherapy/targeting
75867978|NCT04440046|Other|Manual therapy glenohumeral joint|Manual therapy mobilization directed to the glenohumeral joint.
75867979|NCT04440046|Other|Sham thoracic manual therapy|Sham manual therapy directed to the costovertebral joint.
75540655|NCT00228371|Device|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
75540656|NCT00193609|Drug|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
75380087|NCT03638323|Other|Speech therapy|During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
75704410|NCT05809245|Procedure|Corneal neurotization|Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
75704411|NCT05809232|Other|CARES-guided Group|Participants randomised to the CARES-guided arm will have their CARES-score calculated and entered into the Pre-Anesthesia Assessment electronic form within the Electronic Medical Records (EMR). This score and its relevant advisories will be prominently displayed on this electronic form. (Participants on this arm will receive this intervention in addition to the routine practice).
75867980|NCT04440046|Other|Sham glenohumeral manual therapy|Sham manual therapy directed to the glenohumeral joint.
75867981|NCT04440046|Other|Therapeutic exercise|Therapeutic exercise program consisting on isometric exercise with progressive load.
75867982|NCT05309707|Device|Endovascular exclusion|Endovascular exclusion by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
75867983|NCT03387852|Drug|SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
75867984|NCT03387852|Drug|Dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
75867985|NCT03387852|Drug|Fluticasone or Fluticasone/salmeterol combination|Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
75867986|NCT03387852|Drug|Placebo for SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
75540657|NCT00193609|Drug|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
75380088|NCT03642457|Drug|Bupivacaine|20 cc 0.5%
75540658|NCT00228410|Drug|Tigecycline|
75540659|NCT00228410|Drug|vancomycin with aztreonam|
75867987|NCT03387852|Drug|Placebo for dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
75380089|NCT03642457|Drug|Bupivacaine liposome|133mg liposomal bupivacaine
75540660|NCT00228449|Drug|peginesatide|
75540661|NCT00193180|Drug|Imatinib|Imatinib
75540662|NCT00193180|Drug|Docetaxel|Docetaxel
75540663|NCT00193063|Drug|Trastuzumab|Trastuzumab
75540664|NCT00193063|Drug|Gemcitabine|Gemcitabine
75704412|NCT05809206|Other|Glutes maximus strength protocol|"The subjects attended physical therapy two times. Per week for a total of 10 visits. Each session lasted approximately 30 minutes. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) were added. Each exercise was performed for 10 repetitions. Elastic resistance was added to the fire hydrant, hip extension in prone and dead lift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
75867988|NCT02679274|Drug|Placebo|Intermittent intramuscular injections of saline (males and females).
75867989|NCT02679274|Drug|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
76023413|NCT04604015|Diagnostic Test|NeuralBot Investigational System|The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
75380090|NCT00379418|Drug|Abciximab|
75380091|NCT00379496|Procedure|Antidepressants|
76023414|NCT04604015|Diagnostic Test|Transthoracic Echocardiography (TTE)|A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
75380092|NCT00379496|Procedure|acupuncture|
75380093|NCT00378716|Drug|5-fluorouracil|
75380094|NCT00378716|Drug|leucovorin calcium|
75380095|NCT00378716|Drug|tegafur|
75380096|NCT00378716|Drug|uracil|
75380097|NCT03644095|Drug|Mucinex® SE|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
75380098|NCT03644095|Drug|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
75380099|NCT01633814|Drug|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1
75380100|NCT01633814|Drug|Placebo|placebo patch.
75540665|NCT00228488|Drug|Gefitinib|
75540666|NCT00228527|Drug|Esomeprazole (Nexium)|
75540667|NCT00191854|Drug|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
75540668|NCT00191854|Drug|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
75540669|NCT00191854|Drug|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
75867990|NCT04674319|Behavioral|external cues and cogntive movement strategies|"external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section."
75380101|NCT04332133|Procedure|laser interference,INTRAVITREAL INJECTION|sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2
75380102|NCT04713943|Dietary Supplement|>Your< Iron Syrup|Once daily dose of >Your< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks
75380103|NCT04713943|Other|Placebo|Once daily dose of placebo syrup for 12 weeks
75540670|NCT00191854|Drug|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
75540671|NCT00228605|Drug|OraVescent Fentanyl|
75540672|NCT00191815|Drug|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
75867991|NCT05162833|Device|TheraNova Neuromodulation Device|TENS device
75867992|NCT01312285|Device|Resonator device|low level magnetic fields
75380104|NCT04713865|Procedure|endovascular treatment|The bare metal stent covers the deep femoral artery lower than 50%
75380105|NCT04713865|Procedure|endovascular treatment|The bare metal stent covers the deep femoral artery in 50-90%
75380106|NCT04713865|Procedure|endovascular treatment|The bare metal stent totally covers the deep femoral artery
75380107|NCT04714099|Drug|Topical Cyclosporine A|In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution [200mg cyclosporine in 8 ml ethanol (96%)] under laminar flow.
75380108|NCT04714099|Drug|Placebo|Placebo
75380109|NCT04566770|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
75380110|NCT04566770|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo|Intramuscular other name:Ad5-nCoV
75540673|NCT00191815|Drug|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
75540674|NCT00191386|Drug|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
75540675|NCT00228683|Procedure|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
75540676|NCT00191308|Drug|pemetrexed|500 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
75540677|NCT00191308|Drug|cisplatin|75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
75540678|NCT00191308|Procedure|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
75540679|NCT00256620|Procedure|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
75540680|NCT00228839|Drug|Infliximab|
75540681|NCT00191269|Drug|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
75540682|NCT00191269|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
75540683|NCT00256659|Behavioral|Early assessment and referral to ancillary care services vs. standard care|
75540684|NCT00228878|Procedure|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
75540685|NCT00413868|Procedure|LASIK|
75540686|NCT00413868|Procedure|PRK|
75867993|NCT04961437|Other|Diaphragmatic ultrasound and electrical impedance tomography|"A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured.~- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography."
75540687|NCT00413868|Behavioral|Small target contrast sensitivity and disability glare|
75540688|NCT00228956|Drug|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
75540689|NCT00228995|Drug|epoetin alfa|
75540690|NCT00413946|Drug|Recombinant human Erythropoietin|3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
75540691|NCT00413946|Drug|saline|three doses of 1.0 ml saline per body weight
75380111|NCT04350307|Device|22-gauge needle|22-gauge Quincke needle used for epidural injection
75380112|NCT04350307|Device|25-gauge needle|25-gauge Quincke needle used for epidural injection
75380113|NCT04348357|Other|Telemedicine|A video-call application hosted by Texas Tech University Health Science Center El Paso and easily accessible from mobile phones or video-enabled PCs will be used (webex teams)
75380114|NCT04348357|Other|Office visit|Patient comes to the office to receive routine postoperative care
75380115|NCT04342663|Drug|Fluvoxamine|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
75380116|NCT04342663|Drug|Placebo|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
75380117|NCT00589550|Biological|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
75380118|NCT00589550|Drug|Sorafenib|
75380119|NCT00589550|Genetic|gene expression analysis|
75540692|NCT00229073|Drug|dapoxetine|
75540693|NCT00413985|Drug|Nutrient-enriched human milk|
75540694|NCT00229112|Drug|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
75540695|NCT00229112|Drug|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
75540696|NCT00256737|Drug|Omeprazole|
75540697|NCT00191191|Drug|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
75380120|NCT00589550|Genetic|polymerase chain reaction|
75380121|NCT00589550|Genetic|reverse transcriptase-polymerase chain reaction|
75380122|NCT00589550|Other|flow cytometry|
75540698|NCT00191191|Drug|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
75540699|NCT00229151|Behavioral|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
75540700|NCT00229151|Other|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
75540701|NCT00414024|Drug|Tegaserod|
75540702|NCT00229190|Procedure|Nasal lavage|
75867994|NCT05309473|Device|Philips SmartSleep Acoustic Stimulation Device|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive acoustic stimulation during the four hours of sleep.
75540703|NCT00229190|Procedure|Allergy skin testing|
75540704|NCT00229190|Procedure|Peak nasal inspiratory flow|
75540705|NCT00229190|Procedure|Acoustic rhinometry|
75380123|NCT00589550|Other|immunoenzyme technique|
75380124|NCT00589550|Other|laboratory biomarker analysis|
75380125|NCT01636466|Drug|Everolimus|Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
75380126|NCT00583466|Drug|Autologous blood injection|Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
75380127|NCT00583466|Drug|Normal saline|Normal saline will be injected under the lesion to create submucosal cushion
75540706|NCT00229190|Procedure|Nasal examination|
75540707|NCT00229190|Procedure|Quality of Life Questionnaire|
75540708|NCT00229190|Procedure|Physical examination|
75540709|NCT00256815|Drug|chemotherapy|
75540710|NCT00256815|Procedure|Radiation|
75540711|NCT00229229|Other|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
75540712|NCT00229229|Other|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
75540713|NCT00229229|Other|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
75540714|NCT00229229|Other|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
75540715|NCT00414102|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
75540716|NCT00414102|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
75540717|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|20 minutes exposure
75540718|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|40 minutes exposure
75540719|NCT00256893|Drug|ropinirole|
75540720|NCT00229385|Drug|Ziprasidone|40-80 mg BID
75540721|NCT00236223|Drug|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
75380128|NCT00583466|Drug|HPMC|Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
75867995|NCT05309473|Device|Sham (no Acoustic Stimulation)|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive Sham (no acoustic stimulation) during the four hours of sleep.
75380129|NCT00568802|Drug|Hydroxyurea|
75540722|NCT00236223|Drug|Placebo|Matching placebo
75540723|NCT00229424|Drug|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
75704413|NCT05809206|Other|Gluteus medius strength program|"Strengthening exercises for Gluteus Medius subdivisions:~The anterior GMED exercise: side lying abduction exercise The middle GMED exercise: wall press Exercise The posterior GMED exercise: was the pelvic drop exercise"
75704414|NCT05809206|Other|Corrective Exercises|"The following low back corrective exercises were given:~To stretch the tight lower back muscles: Seated Forward Bend and Full Squat held for 5 sec and Repeated for 3 times, once a day.~To strengthen the weak lower abdomen: Draw in and Reverse Crunch 3 seconds, repeated 5 times, once a day.~To stretch the tight hip flexors: held for 10-15 seconds repeated 5 times on both legs, once a day.~To stretch the tight quadriceps: held for 3 seconds, repeated 5 times on each side, once a day.~To strengthen weak hamstrings: Kick Butts 2 sec, repeated 8 times, once a day."
75704415|NCT05809206|Device|Ultrasound|US was administered in continuous mode at PSIS with patient in prone lying position, with a frequency of 1 MHz and intensity of 0.8 W/cm2 for 5 minutes every alternating day
75704416|NCT05809167|Drug|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day*7days."
75704417|NCT05809154|Diagnostic Test|Video-Urodynamics|Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
75540724|NCT00229424|Drug|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
75540725|NCT00229424|Other|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
75704418|NCT05809141|Diagnostic Test|thromboelastography|Thromboelastography (TEG), a whole blood viscoelastic test. TEG detects the clotting time, clotting kinetics and clot stability to more comprehensively evaluate haemostatic status by several parameters, mainly including reactive time (R), kinetic time (K), angle (α), maximum amplitude (MA) and lysis-30 .
75704419|NCT05809128|Other|surgery for breast cancer and imaging test evaluations|At the time of surgery, having completed the evaluation extemporaneous of the surgical piece, tissue samples will be collected to be stored from the material exceeding the completion of the patients' diagnosis. In addition, paramenters that can be extracted from radiodiagnostic images will be evaluated
75867996|NCT05309317|Other|Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|"A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI."
75867997|NCT05309317|Other|Ongoing education|"Only a course on Prevention of CAUTI will be given to the control group."
75867998|NCT05309239|Other|ROX index|observation of ROX index to evaluate the efficacy of non invasive ventilation
76023415|NCT04569383|Biological|MVA-SARS-2-S vaccinations (days 0 & 28)|Vaccination with MVA-SARS-2-S in two escalating dose regimens
76023416|NCT04569383|Biological|Comirnaty|Vaccination with Comirnaty (21 day interval)
75380130|NCT00568802|Drug|Placebo to match hydroxyurea|
76023417|NCT04555343|Drug|Tranexamic acid|1gm instilled instravesically
75380131|NCT00576524|Device|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
75380132|NCT00576524|Device|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
75380133|NCT03949621|Drug|Vedolizumab SC|Vedolizumab SC liquid.
76023418|NCT04450667|Dietary Supplement|Nutricia PreOp|Oral rehydration 2 hours before the scheduled cesarean section under spinal anesthesia
75380134|NCT04474730|Device|BMT Physical Activity app|This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
75380135|NCT04474730|Other|Watch Only|A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
75540726|NCT00256932|Drug|alvimopan|0.5 mg
75540727|NCT00256932|Drug|Placebo|
75540728|NCT00256971|Procedure|meniscectomy|
75540729|NCT00229541|Procedure|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
75540730|NCT00236262|Device|ventilatory strategies with pressure|
75540731|NCT00191152|Drug|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
75540732|NCT00191152|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
75380136|NCT05313919|Diagnostic Test|Comprehensive functional diagnostics of coronary circulation|"Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~echocardiography with assessment of diastolic function~flow-mediated dilation of brachial artery~coronary angiography~functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~serum level of inflammatory cytokines and chemokines"
75380137|NCT04429880|Drug|Oxytocin|Oxytocin given by intravenous route
75380138|NCT03645811|Behavioral|Music Therapy|Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
75380139|NCT03645811|Behavioral|EFT|EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
75380140|NCT05600738|Device|RNS/DBS activation|This will be performed to study the EEG responses to DBS/RNS stimulation electrical pulses. The stimulation frequencies will be sequentially increased and each stimulation will last for 2 minutes.There will be a 1-2 minute wash out period after each trial.
75380141|NCT04706078|Diagnostic Test|The biotype of gingival|The biotype of gingival was also determined by periodontal probe.
75380142|NCT01692158|Drug|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
75867999|NCT03620929|Drug|Estradiol Valerate|In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
75868000|NCT04537741|Procedure|Coronary CT angiography|all patients being included will undergo CCTA before invasive coronary angiography
75380143|NCT01570634|Drug|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
75380144|NCT03928327|Drug|TAK-788|TAK-788 Capsules
75380145|NCT03928327|Drug|Itraconazole|Itraconazole Oral solution
75380146|NCT03928327|Drug|Rifampin|Rifampin Capsules
75380147|NCT01055756|Drug|Loratadine + Pseudoephedrine sulfate|Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
75380148|NCT03648853|Device|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
75380149|NCT00652574|Drug|Dasatinib|70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
75540733|NCT00191152|Drug|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
75380150|NCT04240184|Other|Physical workload|Cohort study - The specific study aims are to investigate 1) exposure-response associations between quantity of occupational lifting and short-term (day-to-day) changes in LBP, 2) the influence of accumulated workdays and rest days during a working week on LBP, 3) long-term association between occupational lifting exposure and LBP when assessed over 1 year, and 4) the role of psychological and social factors on the above associations.
75380151|NCT03649867|Other|Semi-structured interviews|Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
75380152|NCT01550510|Drug|Ascorbic Acid|3x a week for 9 weeks
75380153|NCT01550510|Drug|Irinotecan|350mg/m2 once a week every 3 weeks
75380154|NCT04333225|Drug|Hydroxychloroquine|Weekly treatment in individuals at high risk
75380155|NCT00566462|Drug|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
75380156|NCT00566462|Drug|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
75380157|NCT00556400|Drug|Lo-Ovral Oral Contraceptive Pills|
75868001|NCT04537741|Procedure|Invasive coronary angiography|all patients being included will undergo CCTA before invasive coronary angiography
75868002|NCT05177497|Drug|SHR-1701|SHR-1701 administered by iv
75380158|NCT00556400|Drug|Placebo - sugar pill|
75380159|NCT03918811|Procedure|Positive Pressure Extubation Technique|Positive-pressure extubation is performed by only one operator. Ventilator parameters are set to pressure support ventilation mode, with an inspiratory pressure of 15 cm H2O and PEEP of 10 cm H2O. Then, the cuff is deflated, and the ETT is removed without endotracheal suction. Once the ETT is removed, a suction catheter is introduced through the mouth to suction secretions drawn to the oropharynx by the air flow from the ventilator passing between the ETT and the larynx.
75380160|NCT03918811|Procedure|Traditional Extubation Technique|Traditional extubation is performed by 2 operators. Without reconnection to the ventilator, the closed suction system catheter is introduced by one of the operators into the ETT and suctioning is initiated. The cuff is immediately deflated by the other operator, and the ETT is removed with continuous endotracheal suction during the whole procedure by the first operator.
75380161|NCT00521924|Biological|infliximab|infliximab 3 mg/kg and basic treatment
75380162|NCT00521924|Drug|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
75380163|NCT03927781|Drug|Pregabalin 300mg|One 300mg capsule will be administered PO 1 hour before surgery
75380164|NCT01553240|Device|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
75380165|NCT03907579|Behavioral|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
75540734|NCT00229580|Behavioral|3 session brief intervention with health behavior feedback|
75540735|NCT00229580|Other|treatment as usual|
75868003|NCT04470427|Biological|mRNA-1273|Sterile liquid for injection
75868004|NCT04470427|Biological|Placebo|0.9% sodium chloride (normal saline) injection
75868005|NCT04969861|Drug|Bempegaldesleukin|Specified dose on specified days
75868006|NCT04969861|Drug|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
75868007|NCT04967521|Drug|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
75868008|NCT04967521|Drug|Placebo|Placebo will be administered orally twice a day. Each cycle is 28 days.
76023419|NCT04436237|Other|Virtual reality foot placement training|The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
76023420|NCT04466657|Dietary Supplement|Antioxidation Therapy|Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
76023421|NCT04466657|Other|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
76023422|NCT04392323|Diagnostic Test|COVID-19 PCR and Serology|PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.
76023423|NCT04528667|Drug|STI-5656|STI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.
76023424|NCT04528667|Drug|Placebo|Placebo capsules
76023425|NCT04309877|Drug|Theophylline ER|Capsules of theophylline ER
75380166|NCT00379964|Drug|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC>500/mm3), and for up to 72 hours later.
75380167|NCT01545518|Drug|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
75380168|NCT04320823|Device|Updated Plasma Collection Feature|Plasma collection using a novel, patented system that supports a more individualized collection approach.
76023426|NCT04309877|Other|PO placebo|Capsules of methylcellulose
76023427|NCT04309877|Biological|Lipopolysaccharide (LPS)|Purified bacterial wall component as an inflammatory challenge
76023428|NCT04309877|Other|IV placebo|Normal (0.9%) saline
75380169|NCT04320823|Device|Current Plasma Collection Approach|Plasma collection using the current collection approach.
75380170|NCT01539590|Drug|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
75380171|NCT01539590|Drug|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
75380172|NCT00380042|Device|Cortical Stimulation|Cortical stimulation of prefrontal cortex
75380173|NCT00380042|Device|Sham|Sham stimulation
75380174|NCT04313647|Biological|1X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)
75380175|NCT04313647|Biological|2X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)
75380176|NCT04313647|Biological|4X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)
75380177|NCT04313647|Biological|6X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)
75380178|NCT04313647|Biological|8X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)
76023429|NCT04367909|Drug|Nimotuzumab|Nimotuzumab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
76023430|NCT04367909|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
75380179|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
76030894|NCT02340325|Drug|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
75380180|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
75380181|NCT01526408|Drug|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
75380182|NCT01526408|Drug|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
75380183|NCT03660787|Drug|Seroguard|Seroguard 0.41 g/L solution
75380184|NCT03660787|Drug|Placebo|Saline
75380185|NCT04713644|Drug|Standardized Propofol Administration|Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
76030895|NCT02340325|Drug|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
76030896|NCT05229367|Other|Eccentric isokinetic training|Eccentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
76030897|NCT05229367|Other|Concentric isokinetic training|Concentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
75380186|NCT00000734|Drug|Sulfamethoxazole-Trimethoprim|
76030898|NCT02340247|Other|Water|
76030899|NCT02340247|Drug|Ursodeoxycholic Acid|
75380187|NCT00000734|Drug|Zidovudine|
75380188|NCT03926065|Other|Plain Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables
76030900|NCT02340247|Drug|Chenodeoxycholic Acid|
76030901|NCT02340013|Drug|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
75380189|NCT03926065|Other|Plain Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables
75380190|NCT03926065|Other|Enhanced Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables
75380191|NCT03926065|Other|Enhanced Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
75380192|NCT03663283|Drug|Liposomal Bupivacaine|Interscalene Nerve Blocks
75380193|NCT03663283|Drug|Bupivacaine Hydrochloride|Interscalene Nerve Blocks
75380194|NCT00380198|Drug|Apadenoson|
75380195|NCT00000764|Drug|Isotretinoin|
75380196|NCT00000764|Drug|Interferon alfa-2a|
75380197|NCT03909763|Drug|Berberine plus danazol|Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
75380198|NCT00484718|Drug|celecoxib|oral, 100 mg bid
75380199|NCT00484718|Drug|Oxycodone|oral, 20 mg bid
75380200|NCT00484718|Drug|placebo|oral bid
75380201|NCT03665155|Drug|89Zr-daratumumab|2 mCi of 89Zr-daratumumab will be administered on day 0.
75540736|NCT00257049|Drug|levofloxacin|
75704420|NCT05809102|Procedure|repair of flexor tendon in Zone II|Repair of Zone II flexor tendon of the hand using minimal incisions instead of whole tendon exposure
75704421|NCT05809076|Device|real tACS|tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.
75704422|NCT05809076|Device|sham tACS|In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
75704423|NCT05809063|Other|observational|document the number , disease pattern& outcome of neonates admitted to the neonatal intensive care units
75704424|NCT05809050|Diagnostic Test|BM aspirate|Bone Marrow aspiration & Examination
75704425|NCT05809037|Device|transcutaneous auricular vagus nerve stimulation|In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.
75704426|NCT05809037|Device|Sham stimulation|In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.
75704427|NCT05809024|Drug|letrozole|Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
76023431|NCT04367909|Drug|Carboplatin|Carboplatin AUC 5 will be administered intravenously on Day 1 of each 21-day cycle.
76030902|NCT02339857|Procedure|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
75704428|NCT05808998|Radiation|Stereotactic body radiotherapy|Stereotactic body radiotherapy using TomoTherapy
75704429|NCT05808985|Drug|sodium butyrate|Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
75704430|NCT05808946|Drug|Alpha-Lipoic Acid|1200 mg of ALA daily (given as two 600 mg capsules once daily)
76030903|NCT02638337|Drug|Ospemifene|60 mg tablet
75540737|NCT01059188|Drug|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
75540738|NCT01059188|Drug|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
75540739|NCT01059188|Drug|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
75380202|NCT03665155|Device|PET/CT scans|PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
75540740|NCT01059188|Radiation|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
75380203|NCT03665155|Other|Blood draws|Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
75380204|NCT00477230|Device|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
75380205|NCT00477230|Drug|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
75380206|NCT03901105|Drug|flortaucipir F18|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES
75380207|NCT03901105|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
75380208|NCT00448682|Drug|Docetaxel|
75540741|NCT01059188|Procedure|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
75540742|NCT00236301|Drug|CLIMASTON (drug)|CLIMASTON(drug)
75704431|NCT05808946|Drug|Sepsis Supportive Care|Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
75704432|NCT05808907|Other|Questionnaire|A novel TAVI PROMs questionnaire will be created by us and used for this study.
75704433|NCT05808894|Procedure|extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy|Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
76030904|NCT02638337|Drug|Placebo|Tablet identical to the ospemifene tablet without drug
75380209|NCT00448682|Drug|Floxuridine|
75380210|NCT00448682|Drug|Leucovorin|
75380211|NCT00448682|Drug|Oxaliplatin|
75540743|NCT00236301|Drug|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
75380212|NCT04713488|Biological|Sputnik Light|solution for intramuscular injection Composition for 1 dose (0.5 ml)
75380213|NCT03675451|Drug|89ZR-DF-IAB2M|injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan
75380214|NCT03675451|Drug|68Ga-PSMA-HBED-CC|Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
75540744|NCT00236301|Drug|placebo|placebo
75540745|NCT00236340|Device|syringe aspiration|
75704434|NCT05808868|Other|Screening|"The detailed management is not different from that usually practiced in our department.~Each patient benefits from an ENT consultation where an interrogation is carried out concerning the sleep disorders, the answer to the usual questionnaires screening for sleep disorders, a detailed ENT clinical examination including a nasofibroscopy. Each patient then benefits from a sleep recording by ventilatory polygraph."
75380215|NCT03870152|Procedure|Electrocautery Ablation (EC)|For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
75380216|NCT00380120|Drug|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
75380217|NCT00380120|Drug|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
75380218|NCT03675685|Biological|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
75380219|NCT00000770|Drug|Nevirapine|
75380220|NCT00000770|Drug|Zidovudine|
75380221|NCT00000770|Drug|Didanosine|
75540746|NCT00236340|Device|Wall suction|
75540747|NCT00229697|Drug|Gefitinib|
75540748|NCT00229697|Drug|Tamoxifen|
75540749|NCT00236379|Drug|Olanzapine|Target oral dose of 20 milligrams per day for 6 months
75540750|NCT00236379|Drug|Risperidone|Target oral dose of 6 milligrams per day for for 6 months
75540751|NCT00229736|Genetic|AAV-hAADC-2|9 x 10^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
75380222|NCT03677089|Behavioral|12 ECHO Autism telehealth clinics|Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
75380223|NCT03677245|Other|Strider Balance Bike|Learning to ride a Strider balance bike
75380224|NCT00383630|Biological|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
75380225|NCT00383630|Biological|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
75380226|NCT00383630|Device|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
75380227|NCT04285411|Device|Accuracy of the VitalDetect™ pulse oximetry system|The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
75380228|NCT00368654|Drug|Methotrexate|Initial dose 5 mg, then 15 mg per week
75868009|NCT05308849|Other|Dosage of serum and peritoneal of the betalactam used for antibiotic treatment|"All patients will have antibiotherapy according to French recommendation.~Antibiotics recommended are:~cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d~Blood samples will be collected before surgery and after surgery (for all patients).~Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5.~Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method"
75380229|NCT00368654|Drug|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
75380230|NCT03888469|Device|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
75380231|NCT03888469|Device|Etafilcon A contact lenses|Commercially available daily disposable soft contact lenses
75380232|NCT00000776|Drug|Flucytosine|
75380233|NCT00000776|Drug|Fluconazole|
75380234|NCT00000776|Drug|Amphotericin B|
75380235|NCT00000776|Drug|Dexamethasone|
75380236|NCT04283773|Combination Product|p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)|Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
75380237|NCT04283773|Combination Product|Ki67 antibody (DAKO) for malignant cases only|Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
75380238|NCT00329732|Drug|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
75540752|NCT00229736|Genetic|AAV-hAADC-2|3 x 10^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
75540753|NCT00257088|Behavioral|whole day first grade program|
75868010|NCT02678416|Drug|IV Acetaminophen (Treatment A)|Acetaminophen administered by intravenous (IV) infusion
75380239|NCT00329732|Drug|Saline placebo|matching volume of saline (placebo)
75380240|NCT03438500|Device|Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)|40 - 60 spots per visit (200 shots/spot) at Energy Level 3
75380241|NCT04281901|Drug|Platelet- and extracellular vesicle-rich plasma|ear wick soaked in platelet- and extracellular vesicle-rich plasma
75540754|NCT00229775|Drug|artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine|
75540755|NCT00257127|Biological|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
75540756|NCT00257127|Biological|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
75540757|NCT00257127|Biological|Hepatitis B vaccine|0.5 mL administered intramuscularly
75540758|NCT00257127|Biological|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
75540759|NCT00190684|Drug|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
75540760|NCT00236418|Drug|topiramate|
75540761|NCT00257283|Drug|Omega-3-acid ethyl esters 90|
75540762|NCT00236457|Drug|risperidone|
75540763|NCT04721834|Device|Low-intensity Extracorporeal Shockwave Therapy|Low intensity shockwave energy would be delivered to stimulate angiogenesis in corporal tissue. Therapy would be delivered through a linear probe in 6 sessions. It would be conducted as a day procedure.
75380242|NCT04281901|Drug|Standard conservative treatment|standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
75380243|NCT00000782|Biological|gp160 Vaccine (Immuno-AG)|
75540764|NCT04721834|Device|Sham Therapy|Same device as the active treatment arm would be used, with the addition of sham probe which block all shockwaves.
75540765|NCT00236496|Drug|topiramate|
75540766|NCT00199277|Drug|i.v. iron sucrose|
75868011|NCT02678416|Drug|Oral Acetaminophen (Treatment B)|Acetaminophen administered by oral tablets
75868012|NCT02678416|Drug|Placebo (Treatment C)|Placebo administered by IV infusion or oral tablets
75868013|NCT02678416|Other|Morphine (Treatment D)|Morphine administered by IV infusion
75868014|NCT03164668|Other|menthol flavored e-cigarette|menthol flavored e-cigarette
75868015|NCT03164668|Other|tobacco flavored e-cigarette|tobacco flavored e-cigarette
75380244|NCT00000782|Biological|gp160 Vaccine (MicroGeneSys)|
75380245|NCT04280653|Device|NDE L68 StableFit® Punctal Plug|Tear lake evaluation of the planned study eye, prior to insertion of the Punctal Plug and then tear lake evaluation at days 7 and 28 after punctal plug insertion.
75380246|NCT00000800|Drug|Methadone hydrochloride|
75380247|NCT00000800|Drug|Zidovudine|
75540767|NCT00199277|Drug|Oral iron|
75380248|NCT00000806|Drug|Telinavir|
75540768|NCT00236535|Drug|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
75540769|NCT00193219|Drug|Bevacizumab|5 mg/kg IV
75540770|NCT00193219|Drug|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
75540771|NCT00193219|Drug|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
75540772|NCT00193219|Drug|Leucovorin|350 mg IV
75540773|NCT00193219|Drug|Oxaliplatin|85 mg/m2 IV
75540774|NCT00199316|Drug|spinal morphine|
75540775|NCT00196339|Drug|Cyproterone acetate 5|Cyproterone acetate 5 mg
75540776|NCT00196339|Drug|Placebo|Matching placebo
75540777|NCT00196339|Drug|Cyproterone acetate 15|Cyproterone acetate 15 mg
75540778|NCT00196339|Drug|Cyproterone acetate 25|Cyproterone acetate 25 mg
75540779|NCT00257361|Drug|D-Cycloserine|
75540780|NCT00199355|Drug|Istradefylline (KW-6002)|
75540781|NCT00179959|Drug|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
75540782|NCT00179959|Drug|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
75540783|NCT00179959|Drug|Water|Water baths twice weekly for three months
75540784|NCT00179959|Drug|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
75540785|NCT00199394|Drug|Istradefylline (KW-6002)|
75540786|NCT02961933|Other|Apneic oxygenation|Nasal cannula apneic oxygenation
75540787|NCT02961933|Other|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
75540788|NCT00257400|Behavioral|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
75540789|NCT00257400|Behavioral|Individual Psychotherapy|Individual Psychotherapy
75540790|NCT00236574|Drug|Galantamine hydrobromide|
75540791|NCT00199433|Drug|Istradefylline (KW-6002)|
75540792|NCT00199472|Procedure|Dynamic Contrast Enhanced CT & Diuretic Renogram|
75868016|NCT03164512|Drug|Oral or vaporized cannabidiol|Acute drug exposure
75868017|NCT03164512|Drug|Placebo|Placebo capsule/vapor
75868018|NCT03164200|Other|High fat breakfast|High fat breakfast
75868019|NCT03164200|Other|Higher carbohydrate breakfast|Higher carbohydrate breakfast
75868020|NCT02680834|Device|Dual Action Pneumatic Compression Device|Dual action pneumatic compression device used to treat chronic VLUs.
75540793|NCT02961972|Dietary Supplement|monohydrate and micronized creatine|oral supplementation with creatine
75540794|NCT02961972|Other|placebo|oral supplementation with maltodextrin (control group)
75540795|NCT00199511|Drug|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
75380249|NCT03679975|Drug|Riluzole Oral Soluble film (ROSF) 50 mg|Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.
75380250|NCT03887299|Combination Product|ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)|Dressing will be applied in the operating room at the end of case and be in place until postoperative day 7
75380251|NCT03887299|Other|Standard Wound Care|Wound care will be administered as standard protocol in our institution
75540796|NCT00236613|Drug|topiramate|
75540797|NCT00257478|Drug|YM155|
75704435|NCT05808855|Procedure|two-component skin adhesive Glubran Tiss 2®|After subcutaneous stitches with 4-0 Coated VicrylTM Plus PS-2, 3/8 (Ethicon Inc., USA); a two-component skin adhesive, 0.35 mL of Glubran Tiss 2® (GEM S.r.l., Viareggio, Italy), will be applied in the open wound. Before bandaging, subjects will rest for 20 seconds for a polymerization process.
75704436|NCT05808855|Procedure|skin stitched with transcutaneous nylon suture|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
75704437|NCT05808361|Other|exercises|"The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes."
75380252|NCT00244010|Device|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
75380253|NCT03684265|Drug|Meloxicam Capsule (Test)|single dose
75380254|NCT03684265|Drug|Meloxicam Tablet (Reference)|single dose
75380255|NCT00218036|Drug|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
75540798|NCT00199550|Procedure|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
75540799|NCT00199550|Procedure|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
75540800|NCT04721340|Other|Test Group|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
75540801|NCT04721340|Other|Control Grup|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
75540802|NCT00199589|Drug|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
75540803|NCT00236652|Drug|levofloxacin|
75540804|NCT00257595|Drug|Cetirizine Dry Syrup|
75704438|NCT05808361|Other|massage|Hardware massage in the electrostatic field with a frequency of 30/60 Hz of the chest area consisted of 10 procedures, daily, the duration of the procedure was 20 minutes.
75704439|NCT05808283|Other|preoperative anemia frequency|patients who applied to the outpatient clinic prospectively for 3 months
75704440|NCT05808140|Drug|Indocyanine Green|Preoperatively, a single dose of intravenous indocyanine green is administered
75704441|NCT05808140|Device|Fluorescence imaging|Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively
75868021|NCT02680834|Device|Multi-Layer Bandaging|Multi-layer bandaging used to treated chronic VLUs
75868022|NCT03343704|Drug|Idarucizumab|Intravenous
75380256|NCT00218036|Drug|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
75380257|NCT00218036|Drug|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
75380258|NCT00218036|Drug|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
75380259|NCT00218036|Drug|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
75380260|NCT03848221|Drug|Systane Complete|Systane Complete is an artificial tear.
75380261|NCT03848221|Drug|Sensitive Eyes Rewetting Drops|Sensitive Eyes Rewetting Drops is a rewetting drop.
75540805|NCT00199667|Drug|Mycophenolate Mofetil|
75540806|NCT00236691|Drug|topiramate|
75540807|NCT00199706|Drug|7.2% NaCl in 6% hydroxyethyl starch solution|
75540808|NCT00236730|Drug|topiramate|
75540809|NCT00199745|Drug|atorvastatin|
75540810|NCT04709172|Drug|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
75540811|NCT00199784|Drug|Phenylephrine|
75540812|NCT00236769|Drug|norelgestromin + ethinyl estradiol|
75540813|NCT00199823|Genetic|Intracoronary aotologous stem cell transplantation|
75868023|NCT03840642|Behavioral|Mirror Me|Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.
75380262|NCT05314699|Behavioral|resistance-aerobic exercise, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
75380263|NCT05314699|Behavioral|aerobic-resistance exercise, AR|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cold down.
75380264|NCT00205868|Device|Precision Spinal Cord Stimulation System|Stimulation on throughout study
75540814|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
75540815|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
75540816|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
75540817|NCT00199940|Drug|Ziprasidone|
75540818|NCT00236808|Drug|levofloxacin|
75540819|NCT00199979|Drug|Nevirapine|
75540820|NCT02961114|Procedure|Microcannula Harvest Adipose|Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
75540821|NCT02961114|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
75540822|NCT02961114|Biological|IV Sterile Normal Saline|Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
75868024|NCT03840642|Behavioral|Remote Coaching|Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week
75868025|NCT02680756|Drug|Ferric Maltol|
75868026|NCT02680756|Drug|Ferric Carboxy Maltose|
75540823|NCT00200018|Device|Enterra Therapy System (H9900014)|
75380265|NCT04271761|Other|Non-interventional, post-market, pilot study of Carina Cochlear System|Several objective acoustic measurements will be performed that do not require active participation from the subject.
75380266|NCT00233090|Drug|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
75380267|NCT00233090|Drug|Placebo|daily dose of placebo for four weeks.
75540824|NCT00257634|Drug|dexamethasone to injury site|
75540825|NCT00236847|Drug|topiramate|
75540826|NCT00410228|Drug|AHT956|
75540827|NCT00257673|Drug|MEM 1003|30 mg twice a day
75540828|NCT00257673|Drug|MEM 1003|90 mg MEM 1003 twice a day
75540829|NCT00257673|Drug|Placebo for MEM 1003|Placebo twice a day
75540830|NCT00410306|Drug|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
75540831|NCT00257712|Drug|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
75540832|NCT00179647|Drug|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
75540833|NCT00179647|Drug|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
75540834|NCT00257751|Procedure|Aprotinine|
75704442|NCT05807698|Behavioral|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
75704443|NCT05806073|Procedure|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
75868027|NCT03631836|Drug|Monoclonal antibody|3 doses of Monoclonal antibody could be tested
76030905|NCT02339935|Behavioral|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
75868028|NCT03631836|Drug|Bevacizumab|fixed dose of bevacizumab (10 mg/ kg every two weeks)
76030906|NCT02339935|Other|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
76030907|NCT02339623|Device|Ultrasound imaging|"- Fetal adrenal gland volume calculation using 3D ultrasound~- Assessment of the fetal central adrenal zone enlargement by 3D ultrasound~- CL measurement using 2D ultrasound"
76030908|NCT05178823|Drug|Chlorhexidine mouthwash|Comparison of oral rinses
76030909|NCT02335567|Other|there is no intervention|
76030910|NCT03105583|Drug|Medication use during pregnancy|
75704444|NCT05806073|Procedure|Therapeutic neck dissection|patient underwent Therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
75380268|NCT04266925|Behavioral|3 referees present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
75704445|NCT05802420|Drug|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
75704446|NCT05802407|Drug|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
75704447|NCT05802394|Drug|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
75704448|NCT05797272|Procedure|in-utero HSCT|Pregnant women who are diagnosed to have BHFS affected fetuses and opt for continuation of pregnancy will undergo in-utero HSCT.
75704449|NCT05783050|Device|Wei Nasal Jet Tube|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
75704450|NCT05783050|Device|Nasal Cannula Oxygen Support|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
75868029|NCT03631836|Biological|Blood sample|Evaluate the biomarkers plasma levels during administration of drug
76030911|NCT03105583|Dietary Supplement|Supplement use during pregnancy|
76030912|NCT03105583|Other|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
76030913|NCT03105115|Drug|fentanyl|intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
76030914|NCT03105115|Drug|bupivacaine only|heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
76030915|NCT03080831|Drug|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
75380269|NCT04266925|Other|1 referee present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
75380270|NCT05182502|Device|Tixel|Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
76030916|NCT03080831|Drug|Glucion 5%|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
76030917|NCT03105349|Drug|elbasvir/grazoprevir|16 weeks treatment
76030918|NCT03105349|Drug|Sofosbuvir|16 weeks treatment
75380271|NCT04247581|Device|1-lead ECG|"1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions."
75380272|NCT02921906|Other|High protein meal|Breakfast with high protein / low carbohydrate content
75380273|NCT02921906|Other|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
75380274|NCT02921906|Drug|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
75704451|NCT05778786|Device|Acuvue Oasys 1 Day for Astigmatism|CONTROL
75704452|NCT05778786|Device|TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore|TEST
76030919|NCT03105349|Drug|Ribavirin|16 weeks treatment
75380275|NCT02921906|Other|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
75704453|NCT05773456|Other|Sushi and wakame salad|One serving of mixed sushi and wakame salad
75704454|NCT05770349|Procedure|coronary artery bypass grafting|Coronary artery bypass grafting
75868030|NCT03631836|Device|Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)|Assess antiangiogenic effects by DCE-MRI
76030920|NCT03077555|Drug|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
75868031|NCT03196310|Drug|Platelet Concentrate|Platelet Rich plasma
75868032|NCT03196310|Drug|Corticosteroid injection|Kenalog
75868033|NCT03196310|Other|Normal Saline|Control Group - Placebo
75868034|NCT03162094|Drug|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
75868035|NCT03162094|Drug|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
76030921|NCT03077555|Drug|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
75380276|NCT04243369|Device|Non-diagnostic software solution|Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
75380277|NCT00000812|Drug|Thalidomide|
75704455|NCT05767840|Other|psychological interventions|"mhGap-IG Depression and self-harm module. For participants identified as has having depression, following interventions will be offered depending on nature of the participants.~Khushi Aur Khatoon - for the treatment of depression and anxiety~Learning through Play Plus - 10-session group intervention that integrates parental information about child development and Cognitive Behavior Therapy~Problem management Plus (PM+) - PM+ is for adults suffering from symptoms of common mental health problems , as well as self-identified practical problems.~Cohort identified as having a recent history of self-harm will receive; Culturally Adapted Manual Assisted Problem Solving Intervention (CMAP) - This intervention is a manual-assisted intervention, adapted from a self-help guide called Life After Self-Harm."
75868036|NCT03162094|Drug|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
75380278|NCT03849937|Behavioral|Changing Talk Online (CHATO)|Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
75380279|NCT00000818|Drug|Zidovudine|
76030922|NCT02335723|Device|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
75380280|NCT00377689|Behavioral|high intensity functional exercise|high intensity functional exercise
75380281|NCT00177866|Drug|Celebrex|"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."
75380282|NCT00177866|Drug|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
75380283|NCT03693937|Radiation|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
75380284|NCT03696589|Behavioral|Physical Activity Coaching|Based in the self-determination theory, participants will be coached on beneficial exercises, how to utilize supports and overcome barriers to PA engagement. Emphasis of exercise coaching will be on increasing aerobic exercise engagement and will include us of Fitbit devices to facilitate uptake and monitor aerobic exercise. Intervention will be delivered by a physical or occupational therapist, who will work with the participant to develop a plan, set goals and targets, and track changes. Additional resources that will support exercise engagement will be provided. Participants will have the choice to receive their face-to-face session either in person or remotely via secure video-based service.
75868037|NCT03670862|Other|CT|Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
75868038|NCT03674918|Diagnostic Test|24 h ambulatory blood pressure measurements|24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
75868039|NCT03086460|Drug|CHF 1531 pMDI|Dose Response: Test one of five different doses of CHF 1531
75868040|NCT03086460|Drug|Formoterol Inhalation Solution|Active Control
75380285|NCT00089414|Drug|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
75380286|NCT00089414|Drug|Placebo|
75380287|NCT00089414|Drug|CDB 2914|
75380288|NCT00000824|Drug|Lymphocytes, Activated|
75380289|NCT00075608|Biological|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
75380290|NCT00075608|Drug|melphalan|140-200 mcg/kg IV over two days
75380291|NCT00075608|Procedure|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
75380292|NCT00075608|Procedure|stem cell infusion|infusion of previously collected stem cells on Day 0
75380293|NCT03704467|Drug|M6620|Participants received 90 milligrams per square meter (mg/m^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m^2, or 40 mg/m^2.
75868041|NCT03086460|Drug|Placebo pMDI|Matched Placebo
75868042|NCT02674490|Device|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
75380294|NCT03704467|Drug|Avelumab|Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
75380295|NCT03704467|Drug|Carboplatin|Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
75380296|NCT03705481|Device|Remote treatment of PCI.|To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
75380297|NCT00000836|Drug|Sevirumab|
75380298|NCT05177900|Device|Study Tool Computer|Nonconventional pulses delivered with custom-ware designed by Boston Scientific
75380299|NCT00000842|Drug|Nerve Growth Factor, Recombinant Human|
75380300|NCT02145260|Drug|Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)|A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
75380301|NCT02145260|Drug|Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)|A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
75380302|NCT00000848|Drug|Indinavir sulfate|
75380303|NCT00000848|Drug|Saquinavir|
75380304|NCT01795586|Drug|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m^2; Level 2: 1.1 mg/m^2; Level 3: 1.4 mg/m^2"
75380305|NCT01795586|Drug|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
75380306|NCT03707041|Drug|P218 (1000 mg) Oral Capsules|1000 mg P218 (4 x 250 mg capsules)
75380307|NCT03707041|Drug|Placebo Oral Capsules|Placebo capsules matched to the P218 capsules with regard to appearance and taste
75868043|NCT02674490|Behavioral|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
75380308|NCT03707041|Drug|P218 (100 mg) Oral Capsules|100 mg P218 (2 x 50 mg capsules)
75380309|NCT03707041|Biological|PfSPZ Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
75380310|NCT03879044|Device|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
75380311|NCT02212574|Drug|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
75380312|NCT02212574|Drug|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
75380313|NCT02212574|Drug|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
75380314|NCT02212574|Drug|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
75380315|NCT02212574|Drug|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
75380316|NCT02212574|Drug|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
75380317|NCT03708367|Device|LipiFlow Thermal Pulsation System|Treatment at preoperative visit for study group
75380318|NCT03708367|Device|LipiFlow Thermal Pulsation System|Treatment at 3 month visit as the cross-over group
75380319|NCT00000854|Drug|Nandrolone decanoate|
75380320|NCT03862027|Device|Esophageal Balloon catheter|"Pressures [Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP.~PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP).~Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP."
75380321|NCT03856255|Device|Micro-Tech Endoscopic Gauge|Use of Micro-Tech Endoscopic Gauge to measure any polyp detected during a screening or surveillance colonoscopy.
75380322|NCT04298918|Drug|Placebo|Participants will receive oral placebo in combination with trastuzumab emtansine.
75868044|NCT02674490|Device|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
75380323|NCT04298918|Drug|Venetoclax|Participants will receive oral venetoclax.
75380324|NCT04298918|Drug|Trastuzumab emtansine|Participants will receive intravenous (IV) trastuzumab emtansine.
75380325|NCT00001676|Drug|SQ Fludarabine|
75380326|NCT03714919|Drug|Dextromethorphan|Preoperative oral dextromethorphan 1 mg/kg
75380327|NCT03714919|Drug|Acetaminophen|Preoperative oral acetaminophen 15 mg/kg
75380328|NCT03714919|Drug|Dexmedetomidine|Intraoperative intravenous dexmedetomidine 0.5 μg/kg
75868045|NCT03162250|Drug|DSTA4637S|DSTA4637S will be administered as an IV infusion at 3 dose levels.
75868046|NCT03162250|Drug|Placebo|Placebo matched to DSTA4637S IV infusion will be administered as specified.
75868047|NCT03162250|Drug|SOC|Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
75380329|NCT03714919|Drug|Ketamine|Intraoperative intravenous ketamine 0.5 mg/kg
75380330|NCT00000866|Biological|MN rgp120/HIV-1|
75704456|NCT05809375|Other|Coping Skills Training|In the intervention, it was acted in a way to include the educational content determined by the International Headache Association and with a problem-solving perspective. The coping skills training contents in the literature were combined, and the CST prepared by including the most used and related contents will be given. CST includes a targeted therapy specifically developed for this study to address the needs and expectations of individuals with migraine. The targeted CST was designed by the authors, consisting of an occupational therapist, and two physiotherapists with clinical, and academic experience. It is planned as a total of eight sessions, and two sessions per week. CST includes giving information about migraine, activity tempo, progressive muscle relaxation exercise, stress management, social participation, leisure time management, general evaluation of the program, and home program.
75868048|NCT03670706|Behavioral|Exercise|Package of care
75380331|NCT00000866|Biological|TBC-3B Vaccine|
75380332|NCT03863522|Procedure|Fine needle aspiration|Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.
75380333|NCT03863522|Device|Cancer Detection cartridge|The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
75380334|NCT04223635|Drug|Pexidartinib|Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
75380335|NCT00000872|Drug|Abacavir sulfate|
75380336|NCT00000872|Drug|Nelfinavir mesylate|
75380337|NCT00000872|Drug|Nevirapine|
75380338|NCT00000872|Drug|Lamivudine|
75704457|NCT05766163|Device|DaVinci RARP|Assisted-robotic radical prostatectomy.
75704458|NCT05766163|Device|Hugo RARP|Assisted-robotic radical prostatectomy.
75704459|NCT05766163|Device|Versius RARP|Assisted-robotic radical prostatectomy.
75704460|NCT05764876|Drug|Linezolid Oral Tablet|Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
75868049|NCT03670706|Other|analgesic optimisation|optimisation
75868050|NCT03114280|Drug|TPF2|Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
75868051|NCT03114280|Other|Radiotherapy with carboplatin|Radiotherapy (RT) combined with carboplatin
75868052|NCT03678818|Other|Medium Supplemented with Latrunculin A|A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
76030923|NCT02335723|Device|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
75380339|NCT00000872|Drug|Stavudine|
75380340|NCT00000872|Drug|Zidovudine|
75540835|NCT00200096|Procedure|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
75380341|NCT04232137|Behavioral|Postpartum coffee ceremony|The promise of a postpartum coffee ceremony
75380342|NCT00000878|Drug|Lamivudine|
75380343|NCT00000878|Drug|Stavudine|
75380344|NCT00000878|Drug|Zidovudine|
75380345|NCT04204057|Drug|Tenalisib|Tenalisib 800 mg BID, Orally
75380346|NCT00000104|Procedure|ERP measures of attention and memory|
75380347|NCT00001736|Drug|Cysteamine|
75380348|NCT00000884|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
75380349|NCT00000884|Biological|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
75380350|NCT00000884|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
75380351|NCT00001748|Procedure|Peripheral blood progenitor cell transplant|
75380352|NCT00000110|Procedure|magnetic resonance spectroscopy|
75380353|NCT00000110|Drug|dietary fat|
75380354|NCT00000896|Drug|Indinavir sulfate|
75704461|NCT05764876|Drug|Azithromycin Oral Tablet|Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
76030924|NCT05005091|Dietary Supplement|Oral carbohydrate|100 ml oral carbohydrate two hours ago preoperatively
75380355|NCT00000896|Drug|Lamivudine/Zidovudine|
75380356|NCT00000896|Biological|Hepatitis A Vaccine (Inactivated)|
75380357|NCT00000896|Drug|Interleukin-12|
75380358|NCT00000896|Drug|Nevirapine|
75380359|NCT00000896|Drug|Stavudine|
75380360|NCT00000896|Drug|Sargramostim|
75380361|NCT00001790|Drug|FK463|
75380362|NCT00000902|Drug|Ritonavir|
75380363|NCT00000902|Drug|Nelfinavir mesylate|
75380364|NCT00000902|Drug|Nevirapine|
75380365|NCT00000902|Drug|Lamivudine|
75380366|NCT00000902|Drug|Stavudine|
75380367|NCT00000902|Drug|Zidovudine|
75380368|NCT00000902|Drug|Zalcitabine|
75380369|NCT00000902|Drug|Didanosine|
75380370|NCT04331600|Drug|Chloroquine phosphate|Oral chloroquine phosphate for 14 days
75380371|NCT04331600|Other|Telemedicine|Telemedical supervision for 42 days
75380372|NCT03844321|Behavioral|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
75380373|NCT03844321|Behavioral|Brief Mindfulness|3 sessions of online mindfulness therapy
75380374|NCT00000128|Device|Bifocal Spectacle Lenses|
75380375|NCT04331678|Behavioral|Comparator App|"Participants will download and agree to use the study app at least once per week during the 3-month intervention period.~The app allows participants to invite a network of friends and family to provide emotional and logistical support during their treatment."
75380376|NCT00000188|Drug|Selegiline|
75380377|NCT00000914|Drug|Indinavir sulfate|
75380378|NCT00000914|Drug|Ritonavir|
75380379|NCT00000914|Drug|Nelfinavir mesylate|
75380380|NCT00000914|Drug|Efavirenz|
75380381|NCT00000920|Drug|Ritonavir|
75380382|NCT00000920|Drug|Saquinavir|
75380383|NCT00000920|Drug|Lamivudine|
75704462|NCT05753904|Procedure|Conjoint Tendon Resection|For conjoint tendon resection in the experimental group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved.
75380384|NCT00000920|Drug|Zidovudine|
75380385|NCT00000938|Drug|ceftriaxone|
75380386|NCT00000938|Drug|doxycycline|
75380387|NCT00001862|Drug|Enbrel|
75380388|NCT00000194|Drug|Cycloserine|
75380389|NCT00000200|Drug|Methadone|normal maintenance dose
75380390|NCT05440682|Procedure|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
75704463|NCT05749341|Diagnostic Test|Three-Dimensional Poly(dimethylsiloxane) Scaffold|The rest blood samples from patients with and without endometriosis (No. 20 VS 20) would be collected for testing on a Microchip Embedded with Three-Dimensional Poly(dimethylsiloxane) Scaffold.
75380391|NCT00000206|Drug|Buprenorphine|
75380392|NCT00000944|Drug|Indinavir sulfate|
75380393|NCT00000944|Drug|Lamivudine|
75380394|NCT00000944|Drug|Zidovudine|
75380395|NCT00000950|Drug|Ethambutol hydrochloride|
75380396|NCT00000950|Drug|Isoniazid|
75380397|NCT00000950|Drug|Pyrazinamide|
75380398|NCT00000950|Drug|Pyridoxine hydrochloride|
75704464|NCT05748678|Device|Compression pants|"Patients will have 3D photos taken each week of each buttock and thigh separately. A lymph scanner will also be used for each section to provide a percentage of water content. Weight will also be taken for each visit.~The first 2 weeks the patients will wear their regular pants, and from weeks 3-7 wear the compression pants provided. Weeks 8-9 the patients will be asked to resume to regular pants again"
75704465|NCT05747118|Behavioral|Physical training|A 12 week supervised training intervention with 1 hour physical training two times a week.
75704466|NCT05741190|Device|Pentacam Imaging|Imaging of the corneal surface
75704467|NCT05737576|Drug|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.
75380399|NCT00000950|Drug|Rifampin|
75380400|NCT00000218|Drug|Carbamazepine|
75380401|NCT00000224|Drug|Buprenorphine|
75380402|NCT00001886|Procedure|Real time 3-dimensional stress echocardiography|
75380403|NCT04332991|Drug|Hydroxychloroquine|"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course."
75380404|NCT04332991|Drug|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
75380405|NCT00000956|Biological|gp160 Vaccine (MicroGeneSys)|
75380406|NCT00000230|Drug|Buprenorphine|
75380407|NCT00000236|Drug|Buprenorphine/naloxone|
75380408|NCT00000974|Drug|Pentamidine isethionate|
75380409|NCT00000242|Drug|Carbamazepine|
75868053|NCT03678740|Other|Odyssey 2 Survey|Odyssey2 will retain the strengths (simplicity, brevity, confidentiality, and data quality assurance measures) which made Odyssey1 successful. While Odyssey2 adds some refinements based on experience learned from Odyssey1, the basic questions are changed as little as possible to maximize comparability, and the additions are limited. Odyssey1 consisted of between 16 and 23 questions, depending on skip patterns, and took an estimated 15 minutes to complete. Odyssey2 consists of between 23 and 33 questions, depending on skip patterns and we estimate that it will take approximately 20 minutes to complete.
75868054|NCT03163654|Procedure|Surgery 1|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
76023432|NCT04221425|Procedure|virtual reality rehabilitation system (VRRS)|experimental group is equipped with a telerehabilitation system which comprises a tablet (VRRS tablet) and a set of inertial magnetic sensors. participants are invited to follow a daily rehabilitation exercise program provided via VRRS tablet
76023433|NCT04221425|Procedure|standard care|participants in the control group are invited to follow a daily rehabilitation exercise program and indications for the recovery as illustrated in the dimission booklets drawn up by the rehabilitation unit
75380410|NCT03719677|Behavioral|Habit development intervention|Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
75380411|NCT00000980|Drug|Spiramycin|
75380412|NCT03831451|Behavioral|Stroke preparedness intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
75380413|NCT03831451|Behavioral|Healthy lifestyle stroke risk reduction intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
75380414|NCT00000992|Drug|Itraconazole|
75380415|NCT03721549|Biological|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
75380416|NCT00000254|Drug|40% Nitrous oxide|Used as pain assay positive control
75380417|NCT00000254|Other|Sham comparator|0% isoflurane in oxygen
75380418|NCT00000254|Drug|0.2% isoflurane|
75380419|NCT00000254|Drug|0.4% isoflurane|
75380420|NCT00000254|Drug|0.6% isoflurane|
75380421|NCT03834025|Behavioral|Phase 1 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation.
75380422|NCT03834025|Behavioral|Phase 1 Condition 2|Providers assigned to this condition will be sent recruitment materials that include an additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2).
75380423|NCT03834025|Behavioral|Phase 1 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3).
75380424|NCT03834025|Behavioral|Phase 1 Condition 4|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4).
75380425|NCT03834025|Behavioral|Phase 2 Condition 1|Providers who enroll in the study and are assigned to this condition will be in this group. Other than the opportunity to participate in a learning collaborative, participants receive no compensation.
75704468|NCT05737576|Drug|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.
75704469|NCT05737576|Drug|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.
75704470|NCT05737576|Drug|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.
76023434|NCT04058873|Drug|Levonorgestrel 1.5mg|Levonorgestrel 1.5mg for pericoital use
75704471|NCT05723458|Combination Product|Cream|A cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa
75704472|NCT05723458|Drug|Placebo|Placebo cream containing vaseline
75380426|NCT03834025|Behavioral|Phase 2 Condition 2|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.
75540836|NCT00200096|Procedure|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
75704473|NCT05722535|Behavioral|Media Discussion and Planning Tool (MDPT)|An interactive, web-based tool to support within-family media use planning will be developed and shared with families.
76030925|NCT02335645|Other|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|"Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture."
76030926|NCT03080285|Device|over-glasses patch|Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
76030927|NCT03080285|Device|Conventional patch|Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
76030928|NCT02335333|Other|No treatment|
76030929|NCT03077321|Behavioral|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
76030930|NCT03077321|Behavioral|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
76030931|NCT02335255|Drug|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
75380427|NCT03834025|Behavioral|Phase 2 Condition 3|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
75380428|NCT00000260|Drug|Nitrous oxide|
75380429|NCT00000266|Drug|Flupenthixol|
75380430|NCT03748771|Device|ApneaLink Air|"The ApneaLink Air device is indicated for use by Health Care Professionals (HCP), where it may aid in the diagnosis of sleep disordered breathing for adult patients.~ApneaLink Air records the following data: patient respiratory nasal airflow, snoring, blood oxygen saturation, pulse and respiratory effort during sleep. The device uses these recordings to produce a report for the HCP that may aid in the diagnosis of sleep disordered breathing or for further clinical investigation. The device is intended for home and hospital use under the direction of a HCP."
75380431|NCT00001016|Drug|Trimetrexate glucuronate|
75380432|NCT00001016|Drug|Leucovorin calcium|
75540837|NCT00179413|Drug|PEG -Intron|
75540838|NCT00179413|Drug|Colchicine|0.6mg twice a day
75540839|NCT00236886|Drug|topiramate|
75540840|NCT00178633|Procedure|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
75380433|NCT05228912|Drug|COVID-19 Vaccines|Each group will receive a complete scheme of the vaccine according to local government assignation
75380434|NCT03836989|Device|Electrical stimulation device (tens unit)|An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory
76030932|NCT02335255|Drug|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
75540841|NCT04571866|Other|Beta-glucan bread|Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
75380435|NCT03811951|Drug|Novolin R|Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
75380436|NCT04816526|Biological|Descartes 08|Car T-cells
75380437|NCT04332289|Other|Heavy water experiment|3 times daily heavy water (deuterated-water) and mixed meal administration for one week
75380438|NCT00001022|Drug|Zidovudine|
75540842|NCT00257790|Drug|Tobramycin once a day|
76030933|NCT02335255|Drug|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
75380439|NCT00001022|Drug|Zalcitabine|
75380440|NCT00001022|Drug|Didanosine|
75380441|NCT03816709|Device|Therapeutic Ultrasound|A therapeutic ultrasound treatment was applied to the left medial gastrocnemius muscle with the following parameters: 3 MHz, 1.0 W/cm2 for 15 minutes.
76030934|NCT02344459|Device|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
76030935|NCT05012345|Procedure|Below Elbow cast|below-elbow cast ( 4 or 6 weeks )
75540843|NCT00178399|Procedure|Stereotactic Body Radiation Therapy|
75540844|NCT00178126|Device|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
76030936|NCT02344381|Dietary Supplement|Sucrose|
75540845|NCT00178126|Device|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
76030937|NCT02344381|Dietary Supplement|Glucose|
76030938|NCT05012033|Other|No intervention - prednisolone is taken as part if routine clinical care.|Prednisolone given orally prior to taking timed samples for levels
75380442|NCT05218148|Drug|sintilimab|Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
75380443|NCT05218148|Drug|Trastuzumab|Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
75380444|NCT05218148|Drug|S-1 plus oxaliplatin|"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) < 1.25 m2, 50 mg for BSA 1.25 to <1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area &lt;1.25m2: Tegio 40mg bid day 1 ~ 14; Body surface area 1.25 ~ &lt;1.5m2: Tegio 50mg bid day 1 ~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 ~ 14; 3 cycles before surgery and 3 cycles after surgery."
75540846|NCT00236925|Drug|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
75540847|NCT00236925|Drug|Placebo|Placebo
75540848|NCT00200213|Behavioral|portion or unportioned food|
75540849|NCT00236964|Drug|Iron Sucrose + Erythropoietin|
75540850|NCT00236964|Drug|Ferrous Sulfate + Erythropoietin|
75540851|NCT00200252|Drug|oxytocin|
75540852|NCT00177307|Drug|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
76030939|NCT03145831|Drug|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
76030940|NCT05011877|Device|High-flow nasal cannula therapy|High-flow nasal cannula therapy (HFNC) (from 25 - 60 L/min based on patient's tolerance) will be used in 21 participants during one additional sleep study to investigate its acute impact on reducing sleep abnormalities. Inspired fraction of oxygen will be titrated to maintain patient SpO2 similar to the levels during standard oxygen therapy.
76030941|NCT03080051|Drug|[18F]MNI-952|Subjects will undergo PET imaging using [18F]MNI-952, a PET radioligand for imaging tau.
76030942|NCT03080051|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-952.
76030943|NCT02344303|Drug|TRV130|
76030944|NCT02344303|Drug|Moxifloxacin|
76030945|NCT02344303|Drug|Placebo|
75868055|NCT03163654|Procedure|Surgery 2|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
75540853|NCT00177307|Drug|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
75540854|NCT00177307|Drug|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
75540855|NCT00257829|Drug|Methazolamide|
76030946|NCT05011955|Behavioral|Mindfulness, compassion and intercare based Intervention|"The mindfulness based intervention was a short version of the Mindfulness based intercare program (IBAP). The intervention consists of four synchronic group sessions via ZOOM of one hour each, one peer week and home practice. A total of four groups were conducted of 15 students each.~The IBAP program was inspired by first and second generation mindfulness based interventions, such as Mindfulness based cognitive training, Self-Compassion and Cognitive based Compassion training. Also compassionate communication, conservation of resource theory and habits theory.~Each module consists in meditation practices, inquiry and self or group reflections on different topics such as mindfulness, automatic pilot, mind wandering , acceptance, gratitude and compassion, care resources and intercare."
75380445|NCT00001934|Drug|Zenapax|
75380446|NCT04183231|Drug|Anti-caries varnish|topical tooth varnish
75380447|NCT00000278|Drug|Disulfiram|
75380448|NCT00001028|Drug|Pentamidine isethionate|
75540856|NCT00257829|Drug|Cisplatin|
75540857|NCT04571983|Other|Blood Eosinophil counts - comparing historical with stable state|Comparing historical blood eosinophil counts over 24 months to stable state eosinophil count.
75540858|NCT00200291|Behavioral|hypocaloric, low-fat diet|hypocaloric, low-fat diet
75380449|NCT00001028|Drug|Dapsone|
75380450|NCT03890419|Device|Green light|Green light exposure
75380451|NCT03890419|Device|Clear light|Full spectrum light exposure
75380452|NCT03890419|Device|Blue Light|Blue light exposure
75380453|NCT00000284|Drug|Cotinine fumarate|
75380454|NCT00001940|Drug|Voriconazole|
75380455|NCT03907033|Drug|Liposomal bupivacaine|Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
75380456|NCT03907033|Drug|Bupivacaine Hydrochloride|We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
75380457|NCT00001946|Procedure|Magnetic resonance angiography|
75540859|NCT00237003|Behavioral|motivational interviewing|Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
75540860|NCT02277535|Other|Feedback/Reminder email.|
75540861|NCT02484664|Drug|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
75540862|NCT00200330|Behavioral|Behavioral weight loss treatment|
75540863|NCT00200330|Behavioral|Behavioral and home environment weight loss treatment|
75380458|NCT00001034|Drug|Ganciclovir|
75380459|NCT00001046|Biological|MF59|
75380460|NCT00001046|Biological|rgp120/HIV-1 SF-2|
75380461|NCT03818815|Combination Product|OP0201|OP0201 20mg per day in two divided doses for 10 days
75540864|NCT00257868|Drug|Rivastigmine prevention of delirium|
75540865|NCT00176605|Drug|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
76030947|NCT05011955|Behavioral|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work base on psychoeducation about stress, anxiety, selfcare and effective communication. Plus general curricular intervention. Delivered by psychologist.
75380462|NCT03818815|Combination Product|Placebo|Placebo 0mg per day in two divided doses for 10 days
75380463|NCT03818815|Drug|Amoxicillin-clavulanate|Oral Amoxicillin-clavulanate in two divided doses for 10 days
75380464|NCT00001958|Drug|Hydroxyurea|
75380465|NCT00001964|Drug|Cyclosporine A|Cyclosporine A
75380466|NCT00001964|Drug|ATG|ATG
75380467|NCT00001964|Drug|MMF|MMF
75868056|NCT03678662|Other|Hypoalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information."
76030948|NCT05011955|Other|General curricular intervention|"All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams."
76030949|NCT02335177|Behavioral|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
76030950|NCT03076931|Procedure|Microlaryngoscopy|Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
76030951|NCT03076931|Procedure|Voice Evaluation|Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
76030952|NCT03076931|Procedure|Airway Reconstruction|This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
75380468|NCT03801265|Procedure|Lumbar plexus block|Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
75380469|NCT03801265|Procedure|Quadratus lumborum type 3 block|Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
75380470|NCT03801265|Drug|Ropivacaine injection|0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
75380471|NCT00000290|Drug|Cocaine|
75380472|NCT00000296|Drug|Cotinine fumarate|
75380473|NCT00000212|Drug|Desipramine|
75380474|NCT00000302|Drug|Buprenorphine|
75380475|NCT00001052|Biological|Aluminum hydroxide|
75380476|NCT00001052|Biological|QS-21|
75380477|NCT00001052|Biological|rgp120/HIV-1MN|
75380478|NCT00001058|Drug|Indinavir sulfate|
75380479|NCT00001058|Drug|Ritonavir|
75380480|NCT00001058|Drug|Ethambutol hydrochloride|
75380481|NCT00001058|Drug|Clarithromycin|
75380482|NCT00001058|Drug|Rifabutin|
75380483|NCT00000308|Drug|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
75380484|NCT00000308|Drug|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
75380485|NCT00000308|Drug|placebo|placebo
75380486|NCT03968965|Device|3D MvIGS Spine Navigation|The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.
75380487|NCT03968965|Other|2D Fluoroscopy|Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
76030953|NCT02339467|Other|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
75380488|NCT00001064|Drug|Allogenic Dendritic Cells|
75380489|NCT00001994|Drug|Atovaquone|
75380490|NCT00000314|Drug|M-CPP|
75380491|NCT00000320|Drug|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
75380492|NCT00000326|Drug|Heroin Dependence|
75380493|NCT03978403|Drug|"M207 3.8 mg Sled (two 1.9 mg patches made on a Sled coater, foil pouches)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a Sled coater and packaged in foil pouches"
75380494|NCT03978403|Drug|"M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups"
75380495|NCT03978403|Drug|"M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches"
75380496|NCT03978403|Drug|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose
75380497|NCT00002000|Drug|Valacyclovir hydrochloride|
75380498|NCT00002000|Drug|Acyclovir|
75380499|NCT03979807|Drug|Olodaterol/Tiotropium Bromide|(Stiolto®) delivered via Respimat inhaler
75704474|NCT05721651|Drug|Fruquintinib+PD-1|"This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;"
75704475|NCT05720988|Drug|Azacitidine|Given SC
75704476|NCT05720988|Biological|Tagraxofusp-erzs|Given IV
75380500|NCT03979807|Drug|Umeclidinium/ Vilanterol|(Anoro®) delivered via Ellipta Inhaler
75704477|NCT05717478|Combination Product|rhBMP-2-BBM|Alveolar socket is filled with granules of bovine bone mineral (1.0-0.25 mm) loaded with human recombinant bone morphogenetic protein 2
75704478|NCT05717478|Device|Bio-Oss+Bio-Gide|Alveolar socket is filled with granules of bovine bone mineral (Bio-Oss 1.0-0.25 mm) and covered with porcine collagen barrier membrane (Bio-Gide)
75380501|NCT00001082|Drug|Levocarnitine|500 mg tablet taken orally daily
75380502|NCT00001082|Drug|Adefovir dipivoxil|120 mg tablet taken orally daily
75380503|NCT00001082|Drug|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
75380504|NCT00002006|Drug|Zidovudine|
75380505|NCT00002006|Drug|Sargramostim|
75380506|NCT04169113|Other|Group 1 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
75380507|NCT04169113|Other|Group 2 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
75380508|NCT00002012|Drug|Interferon alfa-n3|
75380509|NCT00380276|Drug|MPC-7869|800 mg BID Oral dosing
75380510|NCT04149925|Device|AEON Endostapler|Surgery with AEON Endostapler
75380511|NCT04149925|Device|Echelon Flex Powered Stapler|Surgery with Echelon Flex Powered Stapler
75380512|NCT00380354|Drug|GSK256066|
75380513|NCT03799783|Drug|dexmedetomidine|To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
75380514|NCT00001088|Biological|APL 400-047|
75380515|NCT00001088|Drug|Bupivacaine hydrochloride|
75380516|NCT04713566|Other|oral rinces|natural and commercial oral rinses were compared for efficacy
75704479|NCT05716763|Drug|Tramadol Hydrochloride 5 MG/ML Oral Solution|50mg (10mL) single dose
75704480|NCT05716763|Drug|Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))|50mg (20 drops) single dose
75704481|NCT05716503|Device|Negative Pressure Wound Therapy (NPWT)|Patients Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
75868057|NCT03678662|Other|Hyperalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information."
76030954|NCT02339467|Other|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
75380517|NCT00001094|Drug|Lamivudine/Zidovudine|
75868058|NCT03678662|Other|Neutral|"Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles."
75380518|NCT00001094|Drug|Nelfinavir mesylate|
75380519|NCT00001094|Drug|Saquinavir|
75380520|NCT00001094|Drug|Delavirdine mesylate|
75380521|NCT00001100|Drug|ganciclovir|
75380522|NCT00000332|Drug|Nimodipine|
75380523|NCT00000338|Drug|Lisuride|
75380524|NCT04085341|Drug|GB-102|Intravitreal injection of GB-102
75380525|NCT00002018|Drug|Interferon alfa-n3|
75380526|NCT00002024|Drug|Ganciclovir|
75380527|NCT00001106|Drug|Zidovudine|
75380528|NCT00000344|Drug|Buprenorphine/naloxone|
75380529|NCT04103515|Device|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
75380530|NCT04103515|Device|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
75380531|NCT05075018|Other|Observational|Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
75380532|NCT00002030|Drug|Pentamidine isethionate|
75380533|NCT00377377|Drug|EP1572 (ghrelin agonist) oral and duodenal application|
75380534|NCT00001112|Drug|Zidovudine|
75380535|NCT00001112|Drug|Interferon gamma-1b|
75380536|NCT00377767|Behavioral|To change structure and roles of primary care teams to optimize prevention of obesity|
75380537|NCT00002036|Drug|Anti-HIV Immune Serum Globulin (Human)|
75380538|NCT00000350|Procedure|radioactive substance|
75380539|NCT03782701|Drug|Brimonidine tartrate ophthalmic solution 0.025%|One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
75380540|NCT03782701|Other|Sterile balanced saline solution|One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
75380541|NCT05314387|Device|SMR TT Hybrid Glenoid without Cementless Finned Short Stem|The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.
75704482|NCT05716503|Other|Ordinary dressings with antibiotic ointment and gauze|Patients will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
75704483|NCT05703841|Drug|JNJ-77242113|JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
76030955|NCT02343991|Device|Transcranial ExABlate|MR Guided Focused Ultrasound
75380542|NCT05314387|Device|SMR TT Hybrid Glenoid with Cementless Finned Short Stem|"The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation."
75380543|NCT00000356|Drug|LAAM|
75380544|NCT04143373|Procedure|warm saline irrigation|The objective of this research was to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.
75380545|NCT00000374|Drug|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
75540866|NCT00176605|Drug|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
75540867|NCT00200369|Device|MEMS cap|
75540868|NCT00176488|Drug|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
75704484|NCT05700942|Device|High Dose Intervention-tsDCS|Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)
76030956|NCT02334943|Biological|Blood test|Blood test
76030957|NCT02335021|Dietary Supplement|Sucralose|2 packets per 12 fl oz
76030958|NCT02335021|Dietary Supplement|Sucrose|equisweet to sucralose
76030959|NCT02335021|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
75380546|NCT00000374|Drug|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
75380547|NCT00002042|Drug|Epoetin alfa|
75540869|NCT00176488|Drug|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
75540870|NCT00200447|Drug|carbidopa/l-dopa|
75540871|NCT00200447|Drug|carbidopa/l-dopa/entacapone|
75540872|NCT00200447|Drug|Stalevo|
75540873|NCT00200447|Procedure|[123I]-IBZM imaging|
75540874|NCT00237120|Drug|Imatinib|
75540875|NCT00175825|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
75540876|NCT00175825|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
75540877|NCT04710329|Drug|Ascorbic acid|The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
75540878|NCT00257946|Procedure|Repair of CDH w/SIS Gold|
75540879|NCT00257946|Procedure|Repair of CDH w/Alloderm|
75540880|NCT00257985|Drug|GTN|
75540881|NCT00200525|Drug|apomorphine HCl injection|
75704485|NCT05700942|Device|Low Dose Intervention-tsDCS|Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
75704486|NCT05697718|Biological|MSC|a single injection dose i.v.
76030960|NCT02335021|Dietary Supplement|Sucralose + Sucrose|half the amount of sucralose plus equicaloric sucrose
76030961|NCT02344069|Drug|Fibrinogen|Human fibrinogen concentrate as a injection
76030962|NCT02344069|Drug|Placebo|Saline 0.9% as a injection
76030963|NCT02343913|Device|PAC checklist|
76030964|NCT02334475|Biological|Platelet Rich Plasma|single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)
76030965|NCT02334475|Biological|methylprednisolone|single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
75540882|NCT00174967|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
75868059|NCT03163810|Device|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
75868060|NCT03163810|Device|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
75868061|NCT01312363|Drug|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
75868062|NCT03163888|Procedure|Navigation TKR|Traditional over Conventional TKR
75868063|NCT03674762|Device|Microgrooved dental implants|Dental Implant placement
75868064|NCT03678584|Other|Medium Supplemented with Chaetoglobosin A|A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
75868065|NCT02600234|Device|Inter-Atrial Shunt Device|An implantable device placed in the interatrial septum
75868066|NCT02600234|Other|Intracardiac Echo|Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
76030966|NCT02343835|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
76030967|NCT02334553|Drug|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
76030968|NCT02334553|Drug|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
76030969|NCT02334709|Radiation|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
75380548|NCT03789175|Dietary Supplement|Nicotinamide Riboside (NR)|Niacin is a form of vitamin B3 and has been used to treat hypercholesterolemia for many years. There is growing evidence that nicotinamide adenine dinucleotide (NAD+ can maintain mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. We have observed that culturing the fibroblasts of a LFS patient with mitochondrial deficiency in medium containing NR rescues the defect in mitochondrial respiration.
75704487|NCT05691062|Device|Titanium Fusion Device|Titanium fusion device will be utilized for one-level lumbar fusion.
76030970|NCT02334631|Drug|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
75380549|NCT00381056|Behavioral|Labor and Delivery Team Coordination Course|
76030971|NCT02334631|Drug|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
76030972|NCT02334397|Behavioral|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
75380550|NCT00002048|Drug|Zidovudine|
75380551|NCT04130425|Device|Hely & Weber MTC Fracture Brace|Prefabricated muenster orthosis
75380552|NCT04130425|Device|Thermoplastic orthosis|Muenster orthosis fabricated out of thermoplastics and secured with Velcro
75380553|NCT04130425|Device|Delta cast orthosis|Muenster orthosis fabricated out of Delta Cast and secured with Velcro
75704488|NCT05691062|Device|PEEK Fusion Device|PEEK fusion device will be utilized for one-level lumbar fusion.
75380554|NCT00001136|Biological|ALVAC-HIV MN120TMG (vCP205)|
75704489|NCT05682092|Dietary Supplement|WonderLab Collagen Tripeptide Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
75704490|NCT05682092|Dietary Supplement|Ordinary Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
76030973|NCT02334319|Drug|Ganetespib|Given IV
75704491|NCT05679648|Diagnostic Test|ultrasonography|studying degree of steatosis
75704492|NCT05678465|Procedure|Non-fixation of the mesh|3D-shaped, anatomical, standard, polypropylene mesh without fixation.
75704493|NCT05678465|Procedure|Fixation of the mesh|Glue fixation of lightweight, macroporous, polypropylene mesh.
75704494|NCT05678088|Behavioral|Oropharyngeal Exercises|The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
75868067|NCT02677714|Radiation|99mTc-rhAnnexin V-128|Kit for the preparation of 99mTc-rhAnnexin V-128
76030974|NCT02334319|Procedure|Therapeutic Conventional Surgery|Undergo surgery
76030975|NCT02334319|Other|Laboratory Biomarker Analysis|Correlative studies
76030976|NCT02338765|Behavioral|mHealth Physical Activity|
76030977|NCT02338765|Behavioral|Buddy-partnered exercise|
76030978|NCT02338531|Drug|PF-03084014|
75380555|NCT00002054|Drug|Pentamidine isethionate|
75380556|NCT00000386|Behavioral|Exposure and Response Prevention|
75380557|NCT00000386|Behavioral|Family Treatment Program|
75380558|NCT00000386|Behavioral|Relaxation Training|
75380559|NCT00000386|Behavioral|Behavior therapy|
75704495|NCT05678088|Behavioral|Sham Exercises|The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
75540883|NCT00174967|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
75540884|NCT00174967|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
75540885|NCT00174967|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
75540886|NCT00200564|Drug|ketamine|
75540887|NCT00174265|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
75704496|NCT05676177|Diagnostic Test|Ultra Low Dose CT|"Two immediately consecutive scans with either one or two breath-holds~First scan (ULD_DECT_1) 140 kilovolt peak (kVp) - fixed current 10 or 20 milliampere (mA) (if body mass index (BMI)>30), that is 5 or 10 mAs~Second scan (ULD_DECT_2) 80 kVp - fixed current 20 or 40 mA (if BMI>30), that is 10 or 20 mAs"
75380560|NCT00000386|Behavioral|Family Counseling|
75380561|NCT00000398|Behavioral|Coping skills training|
75380562|NCT00000398|Behavioral|Physical exercise training|
75380563|NCT00000398|Behavioral|Coping skills training plus physical exercise training|
75380564|NCT00002060|Drug|Inosine pranobex|
75380565|NCT00002066|Drug|Thymopentin|
75380566|NCT00002072|Drug|Epoetin alfa|
75380567|NCT00002078|Drug|Interferon alfa-n3|
75380568|NCT00000404|Behavioral|Patient education in self-care of knee OA|
75380569|NCT00000434|Behavioral|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
75380570|NCT00000440|Drug|naltrexone (Revia)|
75380571|NCT00000440|Drug|sertraline (Zoloft)|
75380572|NCT00002084|Drug|Valacyclovir hydrochloride|
75380573|NCT00002084|Drug|Acyclovir|
75380574|NCT00000446|Drug|sertraline (Zoloft)|
75380575|NCT04131517|Drug|Padsevonil|Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)
75704497|NCT05676177|Diagnostic Test|Fat quantification MRI|Dual echo scans, as well as proton density fat fraction (PDFF) scans, will be performed to assess liver fat fraction
76030979|NCT02338531|Procedure|Breast cancer surgery|
76030980|NCT02338453|Behavioral|Active Attention Bias Modification Treatment|Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
75380576|NCT04131517|Drug|Microgynon 30®|Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
75540888|NCT00174265|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
75540889|NCT00200603|Device|calcium phosphate macroporous bioceramics|
75540890|NCT00258024|Drug|IPT-sulphadoxinepyrimethamine|
75540891|NCT00200642|Device|Stretta® System|
75540892|NCT00200681|Drug|Velcade|
75540893|NCT00258063|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
75380577|NCT00001256|Drug|prednisone and methotrexate|
75380578|NCT00000452|Drug|naltrexone (Revia)|
75380579|NCT00000452|Behavioral|Compliance Enhancement Tech.|
75380580|NCT00000452|Behavioral|Cognitive Behavior Therapy|
75380581|NCT00377533|Device|wheelchair rear anti-tip device|assistive device
75380582|NCT00000458|Drug|sertraline (Zoloft)|
75380583|NCT00000458|Behavioral|cognitive behavior therapy|
75380584|NCT00000470|Procedure|cardiac surgical procedures|
75540894|NCT00200720|Behavioral|Atkins diet (low carbohydrate diet)|
75540895|NCT00200720|Behavioral|DASH diet (high carbohydrate diet)|
75540896|NCT00258102|Drug|Levofloxacin|
75704498|NCT05657665|Other|Observational measurements of skin tone|Objective and subjective skin tone measurements will be performed.
75380585|NCT00000470|Procedure|cardiopulmonary bypass|
75704499|NCT05655052|Device|Virtual Reality (VR) Group|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~An introductory information form will be filled in for women in all three groups.~While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~The Control Group will be given routine IUD application and care."
75868068|NCT03670550|Device|Ossur Rebound ACL Brace|ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
75380586|NCT03782233|Drug|A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).|50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).
75380587|NCT03782233|Drug|A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).|33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).
75704500|NCT05655052|Device|Group using distraction cards|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~An introductory information form will be filled in for women in all three groups.~While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~The Control Group will be given routine IUD application and care."
75380588|NCT00002090|Drug|Azithromycin|
75380589|NCT00002096|Drug|Zidovudine|
75380590|NCT00002096|Drug|Didanosine|
75380591|NCT00002096|Drug|Ganciclovir|
75380592|NCT04285489|Device|Hakim Shunt Programmable System|patient accept Hakim Shunt Programmable System due to HCP
75704501|NCT05651321|Other|Samples materials of basic taste stimuli and enteral nutrition preparations|Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.
75704502|NCT05648435|Diagnostic Test|Lithium measures|Measurements of lithium levels in blood and urine
76030981|NCT02338453|Behavioral|Placebo Attention Bias Modification Treatment|the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
76030982|NCT02332213|Procedure|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
76030983|NCT02332213|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
75704504|NCT05645497|Procedure|Surgery with FACET FIXATION implants|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with FACET FIXATION implants
75380593|NCT00002102|Drug|Trimetrexate glucuronate|
75704505|NCT05645497|Procedure|Surgery with Pedicle Screw|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with Pedicle Screw
75704506|NCT05642767|Diagnostic Test|culture on cetrimide agar|Samples will be inoculated on cetrimide agar using the plating out technique.
75704507|NCT05642767|Diagnostic Test|Staining with Gram stain|colonies on cetrimide agar will be spread on glass slide and stained by gram stain
75704508|NCT05642767|Diagnostic Test|Antibiotic sensitivity testing|Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI
75704509|NCT05642767|Diagnostic Test|Molecular detection to efflux genes and some virulence genes|Molecular detection to efflux genes and some virulence genes by conventional PCR
75704510|NCT05639829|Behavioral|Time-restricted eating|Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
75380594|NCT00002102|Drug|Leucovorin calcium|
75380595|NCT00380666|Procedure|PET/CT scan|
75380596|NCT00002108|Drug|Lamivudine|
75380597|NCT00002108|Drug|Zidovudine|
75380598|NCT04317313|Other|FDG PET radiomic feature evaluation|"A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features.~In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature."
75380599|NCT00381134|Drug|losartan 100 mg orally once daily|
75380600|NCT00381134|Drug|spironolactone 25 mg orally once daily|
75380601|NCT00381134|Drug|placebo once orally once daily|
75380602|NCT04714021|Other|CO2|to insufflate CO2 into the stomach instead of air during the PEG
75380603|NCT04714021|Other|air|to insufflate air into the stomach instead of CO2 during the PEG
75380604|NCT00002114|Drug|Procysteine|
75380605|NCT00378001|Drug|FSH-IBSA|
75380606|NCT00378001|Drug|GONAL-F|
76030984|NCT02332213|Procedure|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
76030985|NCT02332213|Procedure|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
76030986|NCT02332213|Procedure|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
75704511|NCT05635656|Device|Digital symptom mapping and biofeedback treatment|Digital symptom mapping and biofeedback treatment
75704512|NCT05633823|Other|Mobile Application Game Training|"Mobile application game training can be used interactively with smartphones and tablets.~A user account will be created after the application is downloaded to the mobile phone/tablet.~After logging into the application, the map of the game will be displayed.~The game will start with the first level of the game consisting of 5 levels.~At each level, first of all, educational videos prepared in the form of short (1-2 minutes) animations will be watched. The number of videos varies between 1 and 3.~After watching the videos, interactive games will be played.~Children are required to complete each stage in the game, and each stage is planned to take approximately 7-10 minutes.~After passing the first level, children will be able to move on to the next level of games and will not be able to move on to the next level until the previous level is finished."
75704513|NCT05626166|Drug|Placebo|placebo tablets twice daily
76030987|NCT02332213|Procedure|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
76030988|NCT02332135|Procedure|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
76030989|NCT02332135|Drug|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
76030990|NCT03518359|Behavioral|Enhanced Stress Resilience Training (ESRT)|ESRT involves six weekly 90-minute group classes and one 2 - 4 hour retreat. Classes focus on developing mindfulness skills (i.e. sustained attention, open monitoring, emotional regulation, meta-cognition) in the context of skills and concepts for managing stress, particularly in practicing medicine. Homework consists of 20 minutes per day of mindfulness exercises following guided meditation CDs or videos of movement-based practice, and practice will be reported periodically by text. A 3-hour outdoor retreat occurs at week six. The central exercises of ESRT are the body scan, sitting meditation, chi gong and yoga. For both arms, the weekly teaching sessions occur on a workday morning during protected time at Parnassus, Mission Bay or Zuckerberg San Francisco General Hospital campus.
75380607|NCT00000506|Drug|fenfluramine|
75704514|NCT05626166|Drug|Diosmin|diosmin 600 mg twice daily
75704515|NCT05624138|Drug|Placebo tablets|12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets
75704516|NCT05624138|Drug|Ketotifen Oral Tablet|ketotifen is a potent anti histaminic drug that may prevent oxaliplatin induced peripheral neuropathy and mucositis and will be administered 2 mg daily along with the 12 cycles of modified Folfox-6 regimen
75380608|NCT00000506|Drug|phentermine|
75380609|NCT00000512|Drug|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
75380610|NCT00000512|Drug|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
75540897|NCT00200759|Drug|Cranberry juice and capsules|
75540898|NCT00265278|Drug|Modafinil|
75540899|NCT00258141|Drug|Rupatadine|
75540900|NCT00258141|Drug|Placebo|
75540901|NCT00265356|Procedure|PET diagnostic imaging|PET diagnostic imaging
75540902|NCT00200876|Procedure|Hypertonic saline|To elicit pain
75540903|NCT00200876|Procedure|Isotonic saline|Non-painful control
75540904|NCT00258258|Drug|paricalcitol|
75704517|NCT05610800|Drug|Exenatide 2 milligram (mg) Injection|Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
75380611|NCT00000512|Drug|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
75380612|NCT00000512|Other|Placebo for colestipol|Placebo for colestipol.
75380613|NCT00000512|Other|Placebo for lovastatin|Placebo for lovastatin
75380614|NCT00000536|Behavioral|sodium, dietary|
75380615|NCT00380822|Drug|miglitol|
75380616|NCT03777865|Biological|13vPnC|All subjects receive a single dose (0.5mL) of 13vPnC
75380617|NCT00000542|Drug|Inhibitors, ACE|
75380618|NCT00000542|Drug|amlodipine|
75380619|NCT00000542|Drug|lisinopril|
75380620|NCT00000542|Drug|doxazosin|
75380621|NCT00000542|Drug|chlorthalidone|
75380622|NCT00000542|Drug|pravastatin|
75380623|NCT00000542|Behavioral|diet, fat-restricted|
75380624|NCT04109443|Behavioral|Young Men & Media Program|The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.
75380625|NCT04109443|Behavioral|Available websites on safe sex and preventing STIs|Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
75380626|NCT00000548|Procedure|mechanical ventilation|
75380627|NCT04107493|Device|Portable Oxygen Cylinder|A POC is a medical device that is indicated for patients who require supplemental oxygen, including COPD patients
75380628|NCT04107493|Device|Mobi|ResMed's variant of POC
75380629|NCT00002120|Drug|Trimetrexate glucuronate|
75380630|NCT00002120|Drug|Trimethoprim|
75380631|NCT00002120|Drug|Sulfamethoxazole|
75380632|NCT00002120|Drug|Dapsone|
75380633|NCT00002120|Drug|Leucovorin calcium|
75380634|NCT00002126|Drug|Filgrastim|
75380635|NCT03231397|Drug|Assess AAA rupture risk by PET-CTA scans|Assess AAA rupture risk by PET-CTA scans
75540905|NCT00258258|Drug|zoledronic acid|
75540906|NCT00200954|Dietary Supplement|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
75540907|NCT00200954|Dietary Supplement|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
75540908|NCT00265434|Drug|Pulmozyme|
75540909|NCT00172042|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
75540910|NCT00200993|Behavioral|physical activity|
75540911|NCT00258297|Drug|gefitinib|
75540912|NCT00258297|Procedure|conventional surgery|
75540913|NCT00258297|Procedure|enzyme inhibitor therapy|
75540914|NCT00258297|Procedure|neoadjuvant therapy|
75540915|NCT00258297|Procedure|protein tyrosine kinase inhibitor therapy|
75540916|NCT00258297|Procedure|surgery|
75540917|NCT00201110|Behavioral|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
75540918|NCT00201110|Behavioral|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
75704518|NCT05610800|Drug|Placebo|Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
75704519|NCT05610800|Drug|Nicotine patch|"Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke >10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14."
76030991|NCT03518359|Behavioral|Active Control|Control group participants will meet for 6 weeks, 90 minutes each week, for classes focuses on stress management through rest and exercise, with equivalent protected time and small group bonding but without the use of contemplative practices. Topics will include the history of surgery, patient perspective, the physician personality, technical mastery, fallibility and limits, balancing compassion and detachment and knowing when not to operate. For daily practice, control participants will be asked to devote 20 min per day to stress management through rest and exercise again reported daily by text.
76030992|NCT05134675|Dietary Supplement|Homemade beer|The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
76030993|NCT04987177|Other|Workload of Manual Wheelchair Propulsion|Participants will complete 20 one-minute manual wheelchair propulsion bouts. Each one minute propulsion bout will be followed by a 2 minute rest period. Each propulsion bout will be at a different workload. After every 10 propulsion bouts, participants will be provided with an extended rest period (5 to 30 minutes). For each participant, the maximum workload to be tested is based on their estimated maximum workload. Estimate maximum workload is based on the HR-Workload relationship documented during a prior sub maximal test to 80% of age adjusted maximum heart rate.
75380636|NCT03231397|Drug|18F-fludeoxyglucose (FDG)|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
75868069|NCT03161678|Drug|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
75380637|NCT03231397|Diagnostic Test|11C-PBR28|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
75380638|NCT03189433|Drug|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
75380639|NCT00002132|Drug|Itraconazole|
75380640|NCT00002132|Drug|Fluconazole|
75704520|NCT05610800|Behavioral|Smoking Cessation Counseling|Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
75704521|NCT05597930|Device|Wrist and Thumb orthosis|Custom 3D printed thumb and wrist orthosis
75704522|NCT05596383|Dietary Supplement|Vitamin D 5000 IU|Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet
75704523|NCT05596383|Dietary Supplement|Placebo|Placebo
75380641|NCT00002138|Drug|Tecogalan sodium|
75704524|NCT05594745|Drug|Lifitegrast Ophthalmic|eyedrop
75704525|NCT05594745|Drug|Systane Free|eyedrop
75704526|NCT05594745|Device|Lipiflow|thermal pulsation
75704527|NCT05592717|Drug|Yutiq|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
75704528|NCT05592561|Other|mental stress task|The stress protocol used for this experiment utilized a cognitive challenge and a previously studied virtual reality active shooter drill (VR-ASD). The cognitive challenge included a modified version of the Stroop challenge (2 min) and mental arithmetic calculations (2 min) presented to the subject via e-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh, PA, USA). Immediately upon completion of the cognitive challenge, the subjects completed the VR-ASD scenario (~2 min) followed by the same cognitive challenge with different questions (another 4 min). The total duration was ~10 min.
75704529|NCT05592548|Device|cold atmospheric plasma|Cold atmospheric plasma will be generated on the skin surface using an electric device
75380642|NCT03776539|Drug|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
75380643|NCT00002144|Drug|Foscarnet sodium|
75380644|NCT00000578|Drug|theophylline|
75380645|NCT00000578|Drug|beclomethasone|
75380646|NCT03774745|Drug|Mifepristone 200 MG|All subjects receive mifepristone tablet on treatment day 1.
75380647|NCT03774745|Drug|micronized Progesterone|Subjects randomized to progesterone receive treatment starting day 2.
75704530|NCT05580159|Biological|SW-BIC-213|The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.
75380648|NCT03774745|Drug|Placebo oral capsule|Subjects randomized to placebo receive treatment starting day 2.
75380649|NCT00000584|Drug|immunoglobulins|
75704531|NCT05580159|Biological|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|The patient will take a third dose of COVID-19 Inactivated vaccine.
75380650|NCT00000590|Drug|immunoglobulins|
75380651|NCT03769207|Device|Ambulatory ECG|Eligible participants are asked to wear the ambulatory ECG monitor
75380652|NCT00000614|Drug|warfarin|
75380653|NCT02973464|Drug|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
75380654|NCT02973464|Drug|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
75380655|NCT00000626|Drug|Vinblastine sulfate|
75380656|NCT00000626|Drug|Dacarbazine|
75380657|NCT00000626|Drug|Filgrastim|
75380658|NCT00000626|Drug|Bleomycin sulfate|
75380659|NCT00000626|Drug|Doxorubicin hydrochloride|
75380660|NCT03766165|Behavioral|Intervention|Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
75380661|NCT03766165|Behavioral|Control|Participants will receive job announcements only.
75380662|NCT00002150|Drug|Celgosivir hydrochloride|
75380663|NCT00001382|Biological|PROSTVAC|
75380664|NCT03109873|Radiation|External Beam Radiation Therapy|Undergo External Beam Radiation Therapy
75380665|NCT03109873|Drug|Metformin Hydrochloride|Given orally
75380666|NCT03109873|Other|Placebo|Given orally
75380667|NCT04713254|Drug|Lu AG06466|10, 20, 30 mg/day oral capsules on Day 5-18
75380668|NCT04713254|Other|Midazolam|4 mg syrup, oral single dose on Day 1 and Day 15
75380669|NCT04713254|Other|Metoprolol|100 mg tablets, oral single dose on Day 1 and Day 15
75704532|NCT05579938|Dietary Supplement|Enzyme-containing lozenge|A lozenge containing 3 active enzymes
75704533|NCT05579938|Dietary Supplement|Placebo lozenge|Identical placebo lozenge
75704534|NCT05568953|Biological|Stamaril|Stamaril is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
75380670|NCT04713254|Other|Bupropion|100 mg tablets, oral single dose on Day 3 and Day 17
75380671|NCT00002156|Drug|Fomivirsen sodium|
75380672|NCT00002156|Drug|Ganciclovir|
75380673|NCT04092907|Drug|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
75380674|NCT04092907|Drug|placebo|Ophthalmic Solution
75380675|NCT00002162|Drug|Saquinavir|
75380676|NCT00002162|Drug|Lamivudine|
75380677|NCT00002162|Drug|Stavudine|
75380678|NCT00002162|Drug|Zidovudine|
75380679|NCT00002162|Drug|Zalcitabine|
75380680|NCT00002162|Drug|Didanosine|
75380681|NCT00000638|Drug|Isoniazid|
75380682|NCT00000638|Drug|Pyrazinamide|
75380683|NCT00000638|Drug|Pyridoxine hydrochloride|
75380684|NCT00000638|Drug|Rifampin|
75380685|NCT04086433|Device|gastric tissue resection|human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment
75380686|NCT00000650|Drug|Ditiocarb sodium|
75380687|NCT00000656|Drug|Zidovudine|
75380688|NCT00000656|Drug|Didanosine|
75380689|NCT00001430|Procedure|PBSC|
75380690|NCT00001430|Drug|IL-2|
75380691|NCT00001430|Drug|EPOCH II|
75380692|NCT00000662|Drug|Zidovudine|
75704535|NCT05568953|Biological|Imojev|Imojev is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
75380693|NCT00002168|Drug|Indinavir sulfate|
75540919|NCT00201149|Behavioral|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
75380694|NCT00002168|Drug|Lamivudine|
75380695|NCT00002168|Drug|Stavudine|
75380696|NCT00002168|Drug|Zidovudine|
75540920|NCT00201188|Behavioral|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
75704536|NCT05568953|Biological|Ixiaro|Ixiaro is licensed by the Health Sciences Authority (HSA), Singapore. The Ixiaro vaccines are manufactured by Valneva and sourced from local distributor, Aenon Pharmaceuticals SEA Pte Ltd.
75704537|NCT05563896|Other|No intervention|No intervention
75380697|NCT00002168|Drug|Didanosine|
75380698|NCT00001442|Drug|paclitaxel concurrent with radiation therapy|
75380699|NCT00002174|Drug|Thalidomide|
75380700|NCT04710212|Other|No intervention.|Observational study with no intervention.
75380701|NCT00000668|Drug|Ganciclovir|
75380702|NCT00000680|Drug|Zidovudine|
75380703|NCT00000680|Drug|Aldesleukin|
75380704|NCT00000692|Drug|Butyldeoxynojirimycin|
75380705|NCT00001460|Behavioral|inpatient evaluation and management|
75380706|NCT00000698|Drug|Ganciclovir|
75380707|NCT03764449|Drug|Oral Balovaptan|"In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14."
75380708|NCT03764449|Drug|IV Balovaptan|"In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan."
75380709|NCT00002180|Drug|Tenofovir|
75380710|NCT00002186|Drug|Crofelemer|
75380711|NCT00002186|Drug|Acyclovir|
75380712|NCT00001502|Drug|RMP-7 and carboplatin|
75380713|NCT04084015|Device|Axillary Impella®|All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy
75380714|NCT00002192|Drug|Rifapentine|
75380715|NCT00002192|Drug|Ethambutol hydrochloride|
75380716|NCT00002192|Drug|Clarithromycin|
75380717|NCT00002192|Drug|Azithromycin|
75380718|NCT00002198|Drug|Abacavir sulfate|
75380719|NCT00000704|Drug|Zalcitabine|
75380720|NCT03061279|Device|Fixation by Acutrak headless screw|The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
75380721|NCT03061279|Device|Fixation by headed screws, plates, and or wires|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
75380722|NCT00000728|Drug|Zidovudine|
75380723|NCT00000728|Drug|Aldesleukin|
75380724|NCT00001520|Drug|neostigmine|
75704538|NCT05563233|Other|Helfer skin tap technique|Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.
75868070|NCT03161678|Drug|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
75704539|NCT05563233|Device|Shot Blocker|Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
75704540|NCT05558085|Behavioral|Expanded Food and Nutrition Education Program (EFNEP)|Subjects will participate in nine hands-on EFNEP lessons to teach nutrition, healthy lifestyle choices, physical activity, food preparation, food safety, and food resource management.
75868071|NCT03114670|Biological|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
75868072|NCT03670472|Other|smear of nasal fossae|1 smear of nasal fossae during a usual or scheduled visit
75868073|NCT03674684|Other|hydroxyethyl starch|After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
75380725|NCT03763747|Device|Scoreflex NC Scoring PTCA catheter|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
75380726|NCT00002204|Biological|HIV p24/MF59 Vaccine|
75380727|NCT00001526|Drug|Daclizumab (Zenapax)|
75380728|NCT00002294|Drug|Fluconazole|
75380729|NCT03758365|Drug|MC2-01 Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
75380730|NCT03758365|Drug|Clobetasol Propionate 0.05% Lotion|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
75380731|NCT03758365|Drug|Betamethasone Dipropionate 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
75380732|NCT03758365|Drug|Triamcinolone Acetonide 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
75380733|NCT03758365|Drug|Hydrocortisone Butyrate 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
75380734|NCT03758365|Drug|Desonide 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
75540921|NCT00258336|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
75704541|NCT05556200|Drug|Anti-PD-1 monoclonal antibody|Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight <50 kg)
75704542|NCT05556200|Drug|VEGFR2 Tyrosine Kinase Inhibitor|Apatinib 250 mg, po, qd
75704543|NCT05553080|Genetic|Immunohistochemistry|immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.
75704544|NCT05549622|Other|Low-soluble fiber diet|12 older adults (>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
75704545|NCT05549622|Other|High-soluble fiber diet|12 older adults (>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
75380735|NCT03758365|Drug|Vehicle|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
75540922|NCT00258336|Biological|rituximab|
75704546|NCT05542212|Device|Transcranial Magenetic Stimulation|Intermittent Theta Burst Stimulation (iTBS) treatment plan: iTBS treatment for the left dlPFC were used for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
75704547|NCT05542212|Device|Sham Transcranial Magenetic Stimulation|Sham stimulation: The coil angle is set at 90° to the scalp for Sham stimulation of the left dlPFC for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
76030994|NCT02334241|Device|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
75380736|NCT00002300|Drug|Megestrol acetate|
75380737|NCT00001538|Biological|APL 400-003|
75380738|NCT03757039|Device|Multifocal soft contact lenses|Commercially available contact lenses
75380739|NCT03757039|Other|Progressive addition lens spectacles|Per subject's habitual prescription
75380740|NCT00002306|Drug|Fluconazole|
75380741|NCT00002210|Drug|Delavirdine mesylate|
75380742|NCT00381212|Biological|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
75380743|NCT00002216|Drug|Lamivudine/Zidovudine|
75380744|NCT00002216|Drug|Abacavir sulfate|
75380745|NCT00002216|Drug|Amprenavir|
75380746|NCT00002216|Drug|Nelfinavir mesylate|
75380747|NCT00002222|Drug|Valganciclovir|
75380748|NCT00002312|Drug|Delavirdine mesylate|
75380749|NCT00002312|Drug|Zidovudine|
75380750|NCT04072237|Biological|MarzAA (marzeptacog alfa [activated])|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
75380751|NCT00002318|Drug|Doxorubicin hydrochloride (liposomal)|
75380752|NCT00002318|Drug|Bleomycin sulfate|
75380753|NCT00002318|Drug|Vincristine sulfate|
75380754|NCT00002318|Drug|Doxorubicin hydrochloride|
75380755|NCT00381290|Behavioral|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
75540923|NCT00258336|Biological|sargramostim|
75704548|NCT05540080|Device|BTL-899|Treatment with applicators C4/C5 to the BTL-899 system.
75380756|NCT00381290|Behavioral|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
75380757|NCT03743311|Procedure|Hemorrhoidectomy, Thrombectomy , Operation on Longo method|Surgical procedures for treatment of Hemorhoid
75380758|NCT03743311|Drug|Detralex|Conservative treatment of Hemorhoid
75380759|NCT03743311|Other|Combined therapy|Surgical + conservative treatment of Hemorhoid
75380760|NCT00380900|Drug|AGG-523|
75704549|NCT05532215|Drug|Misoprostol|The misoprostol tablets to be used in the study will be of the same brand and batch
75704550|NCT05532215|Drug|Oxytocin|The oxytocin ampoules to be used in the study will be of the same brand and batch
75704551|NCT05528497|Other|VR+|Use of a virtual reality helmet during ovocyte retrieval
75704552|NCT05525026|Device|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
75704553|NCT05524766|Device|BTL-785-7 Treatment|Treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
75704554|NCT05524740|Device|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for improvement of the structure of facial muscles.
75380761|NCT00002228|Drug|Enfuvirtide|
75380762|NCT04714177|Drug|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
75380763|NCT04714177|Drug|Placebo|Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
75380764|NCT00001628|Drug|Angiotensin II type 1 receptor antagonists|
75380765|NCT00002234|Drug|Efavirenz|
75380766|NCT00002234|Drug|Adefovir dipivoxil|
75380767|NCT00002234|Drug|Lamivudine|
75380768|NCT00002234|Drug|Didanosine|
75380769|NCT00002324|Drug|Nevirapine|
75704555|NCT05524662|Device|BTL-785-7|Treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
75704556|NCT05520502|Other|PILATES EXERCISE|12 WEEKS, 3 SESSIONS A WEEK 36 SESSIONS IN A TOTAL OF PLANNED MAT 1 PILATES EXERCISES
75380770|NCT00002324|Drug|Zidovudine|
75704557|NCT05519423|Behavioral|Physical Activity Incentive Program|Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
75704558|NCT05516654|Diagnostic Test|Routine bacteriological cultures|culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI
75704559|NCT05516654|Diagnostic Test|Identification of the organism and antibiotic sensitivity will be done by VITEK II|Automated identification of the organism and antibiotic sensitivity will be done by VITEK II
75704560|NCT05516654|Diagnostic Test|Detection of biofilm formation|Detection of Biofilm formation to the collected organism by tissue culture plate method.
75380771|NCT00002330|Drug|Ganciclovir|
75380772|NCT03740659|Drug|Levofloxacin + Dexamethasone|Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
75380773|NCT03740659|Drug|Levofloxacin|Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
75380774|NCT03740659|Drug|Dexamethasone|Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
75380775|NCT00002336|Drug|Clarithromycin|
75380776|NCT00001646|Drug|Voriconazole|
75380777|NCT00001646|Drug|Amphotericin B|
75380778|NCT00001658|Drug|Amoxicillin|
75380779|NCT00378469|Behavioral|45 minute exercise on ergocycle|
75380780|NCT00002252|Drug|Octreotide|
75380781|NCT03738163|Device|Epaderm Cream|The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
75380782|NCT00002342|Drug|Tecogalan sodium|
75380783|NCT02757547|Device|Transcranial magnetic stimulation - Placebo Arm|Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
75380784|NCT02757547|Device|Transcranial magnetic stimulation - Active Arm|Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
75380785|NCT00378157|Behavioral|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
75380786|NCT00002348|Drug|Mitoguazone|
75380787|NCT02721277|Drug|SMOFlipid|SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
75380788|NCT00002258|Drug|Interleukin-3|
75380789|NCT00002264|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
75380790|NCT00378235|Drug|IL13-PE38QQR|
75380791|NCT00002270|Drug|Interferon alfa-2b|
75380792|NCT00002270|Drug|Zidovudine|
75380793|NCT00002354|Drug|Indinavir sulfate|
75540924|NCT00171925|Drug|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance > 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg*hr/l).
75540925|NCT00171925|Dietary Supplement|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
75704561|NCT05516654|Diagnostic Test|Molecular detection by PCR|Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.
75704562|NCT05509322|Other|Subsidy for fertility consult|Some participants will receive a subsidy when they purchase the fertility consult.
75704563|NCT05509322|Other|Invitation to purchase fertility consult|Some participants will receive an invitation from their health center to purchase an at-home fertility consult.
76030995|NCT02334241|Device|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
75380794|NCT00002354|Drug|Stavudine|
75380795|NCT00002360|Drug|Didanosine|
75380796|NCT03733483|Behavioral|Sleep Deprivation|Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
75380797|NCT00002276|Drug|Ibuprofen|
75380798|NCT00002276|Drug|Zidovudine|
75380799|NCT05752370|Device|High flow oxygen|Use of HFO
75380800|NCT05752370|Other|Usual care|Room air or normal flow oxygen
75380801|NCT00378547|Drug|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
75704564|NCT05505240|Other|Respiratory analysis at cold temperature|Respiratory analysis at an ambient temperature of 18°C
76030996|NCT02334163|Drug|Nitazoxanide|500 mg nitazoxanide tablets twice daily
76030997|NCT02334163|Drug|Oral lactulose|Oral lactulose (65%)
75380802|NCT00378547|Drug|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
75380803|NCT00378547|Drug|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
75380804|NCT00002282|Drug|Clotrimazole|
75380805|NCT00002282|Drug|Fluconazole|
75380806|NCT02658877|Drug|Omalizumab|Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
75380807|NCT02658877|Drug|Placebo|Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
75380808|NCT00002288|Drug|Zidovudine|
75380809|NCT00002366|Drug|Ritonavir|
75380810|NCT00378313|Drug|gemcitabine, epirubicin, paclitaxel|
75380811|NCT00002372|Drug|Indinavir sulfate|
75380812|NCT00002372|Drug|Amprenavir|
75380813|NCT00002372|Drug|Nelfinavir mesylate|
75380814|NCT00002372|Drug|Saquinavir|
75380815|NCT00002378|Drug|Ritonavir|
75380816|NCT00002378|Drug|Nelfinavir mesylate|
75380817|NCT00002378|Drug|Saquinavir|
75380818|NCT00002378|Drug|Delavirdine mesylate|
75380819|NCT00002378|Drug|Lamivudine|
75380820|NCT00002378|Drug|Stavudine|
75380821|NCT00002378|Drug|Zidovudine|
75380822|NCT02589145|Drug|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I."
75540926|NCT00201227|Other|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
75540927|NCT00258453|Other|metabolic assessment|
75540928|NCT00258453|Other|physiologic testing|
75540929|NCT00258453|Procedure|biopsy|
75540930|NCT00258453|Procedure|computed tomography|
75540931|NCT00258453|Procedure|conventional surgery|
75540932|NCT00258453|Procedure|magnetic resonance imaging|
75540933|NCT00258453|Procedure|management of therapy complications|
75540934|NCT00258453|Procedure|psychosocial assessment and care|
75540935|NCT00258453|Procedure|quality-of-life assessment|
75540936|NCT00258453|Radiation|radiation therapy|
75540937|NCT00201266|Procedure|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
75540938|NCT00201305|Drug|Gemcitabine+5FU+Leucovorin|
75540939|NCT00258492|Behavioral|Aerobic exercise|
75540940|NCT00265551|Drug|SCA-136 (200 mg)|
75540941|NCT00265551|Drug|SCA-136 (400 mg)|
75540942|NCT00265551|Drug|olanzapine (15 mg)|
75540943|NCT00265551|Drug|placebo|
75540944|NCT00201344|Drug|Cisplatin,5-FU,Leucovorin|
75540945|NCT00265629|Device|RF catheter ablation|RF ablation using mesh device
75540946|NCT00201383|Drug|cisplatin|
75380823|NCT02589145|Drug|Vorinostat|1000 mg by mouth on Days -9 to -2.
75380824|NCT02589145|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
75380825|NCT02589145|Drug|Busulfan|"Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
75380826|NCT02589145|Drug|Melphalan|60 mg/m2 by vein on days -3 and -2.
75380827|NCT02589145|Drug|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
75380828|NCT02589145|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
75380829|NCT02589145|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
75380830|NCT02589145|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
75380831|NCT02589145|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
75380832|NCT02589145|Drug|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
75380833|NCT02589145|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
75380834|NCT02589145|Drug|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
75380835|NCT00002384|Drug|Cidofovir|
75380836|NCT02568007|Drug|Cyproheptadine|
75380837|NCT00002390|Drug|Abacavir sulfate|
75380838|NCT00002396|Drug|Tenofovir disoproxil fumarate|
75540947|NCT00201422|Other|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
75540948|NCT00258531|Device|Olympus ScopeGuide®, 3-dimentional magnetic imager|
75540949|NCT00201461|Device|STARFlex septal closure system|transcatheter placement of STARFlex device to close a patent foramen ovale
75540950|NCT00201461|Drug|Best medical therapy|aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
75540951|NCT00258609|Drug|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
75540952|NCT00265707|Device|Blood pressure measurement|
75540953|NCT04709367|Other|3D optical scan|The clinical protocol consisted of four test sessions in four different days for an overall duration of 3 weeks. During the 1st session, amputees' residual limb volume was measured 7 times at intervals of 10 minutes after the prosthesis removal. During the subsequent sessions, the residual limb volume was measured immediately after the prosthesis doffing and after the amputee's stabilization time, before and after 15-min of walking on a treadmill, both in the morning and in the afternoon.
75540954|NCT00265746|Drug|Metformin|
75540955|NCT00265746|Behavioral|Lifestyle intervention - diet, physical activity|
75380839|NCT02549755|Drug|11C-Acetate|"The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).~There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient"
75380840|NCT00002402|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
75540956|NCT00201539|Drug|single dose Morphine|
75540957|NCT00201539|Drug|double dose Morphine|
75704565|NCT05505240|Other|Respiratory analysis at room temperature|Respiratory analysis at an ambient temperature of 22°C
75380841|NCT00002402|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
75380842|NCT00002402|Biological|Aluminum hydroxide|
75380843|NCT00002408|Drug|Crofelemer|
75380844|NCT00002414|Drug|CPI-1189|
75380845|NCT00002420|Drug|Emivirine|
75380846|NCT00002420|Drug|Hydroxyurea|
75380847|NCT00002420|Drug|Delavirdine mesylate|
75380848|NCT00002420|Drug|Stavudine|
75380849|NCT00002420|Drug|Didanosine|
75380850|NCT00381368|Drug|Ibandronic acid|
75380851|NCT04024501|Drug|Verinurad ER8 capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
75380852|NCT04024501|Drug|Verinurad A-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
75380853|NCT04024501|Drug|Verinurad A-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
75540958|NCT00201539|Drug|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
75540959|NCT04709055|Other|Co-management|Personalized and intensive geriatric peri-operative care
75540960|NCT04709055|Other|Usual care|Pre-operative and post-operative geriatric care as per usual practice
75540961|NCT00201617|Device|Bone-anchored hearing aid|
75540962|NCT04709328|Drug|SCTA01|Diluted by 0.9% normal saline，IV
75540963|NCT04709328|Other|Placebo|IV
75380854|NCT04024501|Drug|Verinurad B-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
75380855|NCT04024501|Drug|Verinurad B-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
75540964|NCT00258687|Biological|GVAX|4 vaccines every two weeks
75540965|NCT00201656|Procedure|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
75540966|NCT00201656|Procedure|Removal of Cerclage|Immediate removal of Cerclage following randomization
75704566|NCT05505240|Other|Respiratory analysis at thermoneutral temperature|Respiratory analysis at an ambient temperature of 28°C
75704567|NCT05505240|Other|Respiratory analysis at hot temperature|Respiratory analysis at an ambient temperature of 38°C
75704568|NCT05500014|Other|Biofortified potato, not genetically modified|Cooked potato, not genetically modified, with the addition of an acqueous solution of 57FeSO4 (3 mg in total).
76030998|NCT02334163|Drug|Metronidazole|250 mg metronidazole tablets every 8 hours
76030999|NCT02334163|Drug|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
76031000|NCT02039635|Dietary Supplement|Korean Red Ginseng|Given Orally
75380856|NCT05717348|Drug|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
75540967|NCT00201656|Procedure|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
76023049|NCT02405377|Procedure|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
75380857|NCT05709626|Drug|No aspirin (Prasugurel monotherapy)|12-month prasugrel monotherapy
75380858|NCT05709626|Drug|12-month DAPT|12-month dual antiplatelet therapy with prasugrel and aspirin
75380859|NCT05707364|Behavioral|Pre-visit Lab Workflow|"Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~Patient contacted to complete labs prior to the scheduled routine physical.~Resulted labs are triaged based on urgency.~After Visit Summary used to communicate about labs and surveys."
75380860|NCT03538015|Drug|Carvedilol 3.125 mg|Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period
75380861|NCT03538015|Drug|Carvedilol 2.5 mg|Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period
75540968|NCT00265824|Drug|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
75540969|NCT00265824|Drug|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
75540970|NCT00201695|Drug|Doxil®|40 mg/m2 IV day 1
75540971|NCT00201695|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
75540972|NCT00201695|Drug|Dexamethasone|40 mg PO days 1-4
75540973|NCT00201695|Drug|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
75540974|NCT00258726|Biological|MMR-II|
75540975|NCT00258726|Biological|Pro-Quad|
75540976|NCT00258726|Biological|Varivax|
75540977|NCT00410345|Drug|Mifepristone|
75540978|NCT00265863|Drug|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
75380862|NCT03538015|Drug|Placebo capsule|Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
75380863|NCT05752214|Other|WEB Register|Observational, non-profit, multicentre longitudinal study on the assessment of quality of life and its association with demographic variables and visual function of visually impaired patients attending the visual rehabilitation service.
75540979|NCT00410462|Drug|brostallicin|
75540980|NCT00410462|Drug|doxorubicin hydrochloride|
75540981|NCT00258765|Drug|Zoledronic Acid|
75540982|NCT00258765|Drug|Docetaxel|
75540983|NCT00410501|Drug|Indacaterol (QAB149)|
75540984|NCT00265902|Procedure|diagnostic imaging|
75704569|NCT05492630|Drug|HEC73077 tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
75704570|NCT05492630|Drug|HEC73077 placebo tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
75704571|NCT05492383|Device|TAVI|Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
75704572|NCT05486975|Biological|CT0591CP Cells|CT0591CP cells
75704573|NCT05478915|Procedure|discectomy of the TMJ disc|removal of the TMJ disc
75540985|NCT00410540|Drug|OROS hydromorphone HCL ; Morphine sulfate|
75540986|NCT00258804|Drug|Insulin glargine|
75540987|NCT00201812|Drug|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
75540988|NCT00201812|Drug|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
75540989|NCT00201812|Drug|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
75540990|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
75540991|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, IM
75540992|NCT00201890|Procedure|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
75540993|NCT04709094|Drug|Danicopan|Danicopan was dosed as 2 x 100 milligram (mg) tablets.
75704574|NCT05478915|Procedure|TMJ discopexy|fixation of the TMJ disc
75704575|NCT05471947|Drug|15% Trichloroacetic acid + 3% glycolic acid|Treatment of the hand with an over-the-counter chemical peel containing 15% trichloroacetic acid + 3% glycolic acid
76023050|NCT02405377|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
76023051|NCT02405377|Drug|0.9% sodium chloride ﬂuid administration|
75380864|NCT00381446|Device|Marketed contact lens care products|
75380865|NCT03342157|Drug|senna/docusate|Stimulant laxative
75380866|NCT04331210|Drug|Diclofenac Sodium|Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
75380867|NCT00381524|Behavioral|Increase condom use|Voluntary increase in condom use
75380868|NCT04016077|Drug|PF-06651600 30 mg|PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
75380869|NCT00002426|Drug|Adefovir dipivoxil|
75540994|NCT04709094|Drug|Warfarin|Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).
75540995|NCT04709094|Drug|Bupropion|Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.
75540996|NCT04709094|Drug|Ethinyl Estradiol/Norethindrone|EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
75540997|NCT00201929|Procedure|Standard Decision Board|
75540998|NCT00201929|Procedure|Computer Decision Board|
75540999|NCT00201929|Procedure|Paper Decision Board|
76031001|NCT02039635|Dietary Supplement|Placebo|Given Orally
75704576|NCT05468567|Diagnostic Test|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHEAR protocol).
76031002|NCT02332057|Drug|Diclofenac plus lidocaine|The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
75704577|NCT05468567|Diagnostic Test|French Matrix Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
76023052|NCT02405377|Device|5-French catheter|
76023053|NCT04402463|Other|Global Postural Reeducation|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~In the treatment 3 of the therapeutic postures of GPR method to will carry out following Souchard's principles of Global Postural Reeducation"
76031003|NCT02332057|Drug|Placebo|The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
75541000|NCT00171340|Drug|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
75541001|NCT00171340|Drug|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
75541002|NCT00266019|Behavioral|Weight Management (diet, exercise, and behavior modification)|
76023054|NCT04402463|Other|Exercise Therapeutic|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~The treatment will be divided into 3 phases, where it initially starts with phase 1 (3 treatments) and progresses to phase 2 (3 treatments) until reaching stage 3 (2 treatments)."
76023055|NCT02405299|Other|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
75704578|NCT05468567|Behavioral|SSQ15 questionnaire of life : (The Speech, Spatial and Other Qualities of Hearing Scale)|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
76031004|NCT02331745|Drug|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
75380870|NCT04021771|Other|Educational Curriculum Intervention|The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
75380871|NCT00002432|Drug|Foscarnet sodium|
75541003|NCT00201968|Device|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
75541004|NCT00201968|Device|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
75541005|NCT00201968|Other|Conventional Exercise|An aerobic and resistance training program.
75541006|NCT00171301|Drug|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
75541007|NCT00266058|Drug|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
75541008|NCT00171223|Drug|STI571|STI571 oral capsules or tablets.
75541009|NCT00202124|Drug|Tryptophan|
75704579|NCT05468502|Drug|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
75704580|NCT05466032|Other|Osteopathic Manual Manipulation (OMM) Curriculum|Osteopathic medical students are enrolled in the OMM curriculum while masters students are not enrolled.
75704581|NCT05465681|Drug|HR20013 for injection；dexamethason|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
75704582|NCT05463601|Drug|Mecapegfilgrastim|Mecapegfilgrastim
75868074|NCT05596656|Diagnostic Test|skin prick test|"Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet."
75704583|NCT05463601|Drug|dalpiciclib|dalpiciclib
75704584|NCT05463601|Drug|exemestane, fulvestrant, letrozole, tamoxifen|endocrine therapy
75380872|NCT05701436|Drug|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
75380873|NCT05701436|Drug|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
75541010|NCT04571905|Device|Osteosynthesis with resorbable Material|Osteosynthesis with Magnezix screws in fractures of the Epicondylus ulnaris and Condylus radialis under General anaesthesia
75541011|NCT00266097|Drug|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
75541012|NCT00266097|Drug|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
75704585|NCT05462015|Behavioral|elastic-band exercises|The training content includes 5 minutes of warm-up exercise, 20 minutes of elastic-band resistance training, and 10 minutes of cool-down exercise.
75541013|NCT00266097|Drug|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
75541014|NCT00266097|Radiation|radiation therapy|5040 cGy, every week, up to 6 weeks
75704586|NCT05462015|Behavioral|regular rehabilitation|The training content includes 5-minute warm-up exercise, 20-minute upper and lower extremity muscle strengthening, and 10-minute cool-down exercise
75704587|NCT05438082|Drug|Antibiotic Prophylaxis|This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if < 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
75704588|NCT05438082|Other|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
75704589|NCT05432245|Device|Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)|The cataract surgery will be performed first and if successful, only then will the MINIject be placed into supraciliary space.
75868075|NCT03678272|Procedure|HERNIOPLASTY WITH PANAVALE MESH|Polypropylene mesh fixed with 3 points. Preformed polypropylene mesh will be used by fixing it with one point to the pubis, another to the inguinal ligament and another to the joint tendon.
75868076|NCT03678272|Procedure|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|"Preformed polypropylene mesh will be used which presents a self adhesive system not based on glue, but on the arrangement of the fibers of the mesh as hooks, and to which we will give a single point to the pubis."
75380874|NCT05701436|Drug|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
75380875|NCT05701436|Drug|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
75380876|NCT05701436|Drug|Oxaliplatin, Leucovorin, fluorouracil|Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
75380877|NCT05701436|Drug|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
75380878|NCT02487277|Drug|PEGPH20|
75380879|NCT02487277|Drug|Gemcitabine|
75380880|NCT02487277|Drug|Nab-paclitaxel|
75380881|NCT00002438|Drug|Itraconazole|
75380882|NCT00002444|Drug|Nitazoxanide|
75380883|NCT02436265|Drug|Dexamethasone|IV dexamethasone
75380884|NCT02436265|Drug|Ropivacaine|Ropivacaine only
75380885|NCT04016623|Device|1-day toric test contact lens|somofilcon A 1-day toric test contact lens
75380886|NCT04016623|Device|1-day toric control contact lens|somofilcon A 1-day toric control contact lens
75380887|NCT05751746|Drug|Magnesium sulfate|Magnesium sulfate will be administered following a protocol that obstetricians already use in our hospital.
75541015|NCT00266097|Drug|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
75704590|NCT05418283|Behavioral|Exercise|1 hour of aerobic exercise will be applied 3 days a week for 12 weeks.
75704591|NCT05414448|Device|ENDOCUFF|ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
75380888|NCT02973230|Other|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
75541016|NCT00266097|Drug|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
75704592|NCT05410561|Behavioral|Enhanced Usual Care (EUC)|EUC will comprise one session of brief psychoeducation and referral information to alcohol use disorder (AUD) treatment.
75704593|NCT05410561|Behavioral|TeleTx intervention|TeleTx will consist of an initial session and then 8 ~counseling sessions.
75704594|NCT05410249|Diagnostic Test|Serum IL10 By ELISA|measurement Of IL10 by ELISA
75704595|NCT05410249|Diagnostic Test|SNP -3279 A/C of FOXP3|Genotyping of -6054 del/ATT will be performed using the real-time polymerase chain reaction.
75704596|NCT05410249|Diagnostic Test|SNP-924 A/G Of FOXP3|Genotyping of -924 A/G polymorphisms was performed using the real-time polymerase chain reaction.
75868077|NCT03678272|Procedure|HERNIOPLASTY WITH ADHESIX MESH|It will use a self-adhesive mesh without giving points to fix this one, since it is a mesh that integrates the glue.
75704597|NCT05397379|Drug|HEC96719|Oral tablets
75868078|NCT03678272|Procedure|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh will be used without fixing points, since liquid cyanoacrylate (Ifabond) will be used to fix it.
75704598|NCT05397379|Drug|Placebo|Comparator
75704599|NCT05395416|Drug|HEC74647PA+HEC110114|administered orally once daily for 12 weeks
75380889|NCT03316105|Device|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
75380890|NCT00002450|Drug|Tenofovir disoproxil fumarate|
75380891|NCT03277183|Drug|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
75704600|NCT05395416|Drug|Placebo|administered orally once daily for 12 weeks
75704601|NCT05395195|Drug|Erythropoietin|Erythropoietin injections (500u/kg) x 9 doses
75704602|NCT05395195|Other|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
75704603|NCT05394207|Dietary Supplement|L. casei DG® (Lactobacillus paracasei CNCM I-1572)|L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
75868079|NCT03632070|Behavioral|Data acquisition of functional abilities|MRI data, motor evoked potentials, and behavior data acquisition
75868080|NCT03674606|Drug|Low dose aspirin|One 75 mg aspirin dose taken daily
75868081|NCT03670394|Diagnostic Test|Capillary Refill|We are measuring capillary refill to assess it's correlation with dehydration in children
75868082|NCT02677324|Drug|ABT199|Oral BCL-2 antagonist
76023056|NCT04342871|Behavioral|Fam-CT|Customized communication guidance to help parents with cancer talk about their cancer with their children.
76023057|NCT04480879|Drug|AZD8154 nebuliser|Nebuliser suspension
76023058|NCT04480879|Drug|AZD8154 Monodose DPI presented in capsules|AZD8154 Monodose DPI formulation delivered dose
76023059|NCT04480879|Drug|AZD8154 Placebo Monodose DPI presented in capsules|The dose correspond to AZD8154 Monodose DPI formulation
76023060|NCT02400229|Procedure|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
76023061|NCT02400229|Procedure|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
76023062|NCT02717663|Behavioral|Adaptive Goals|Prescribed goals change daily based on participant's performance
76023063|NCT02717663|Behavioral|Static Goals|Prescribed goals remain the same throughout study
75380892|NCT03277183|Drug|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
75380893|NCT00002456|Drug|cyclosporine|
75380894|NCT00002456|Drug|methotrexate|
75380895|NCT00002456|Procedure|allogeneic bone marrow transplantation|
75380896|NCT01525927|Drug|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
75380897|NCT01525927|Radiation|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
75380898|NCT01525927|Radiation|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
75380899|NCT00002474|Drug|carboplatin|
75541017|NCT00470236|Radiation|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
75380900|NCT00002474|Drug|cyclophosphamide|
75541018|NCT00470236|Radiation|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
75541019|NCT00470236|Radiation|Standard WB fractionation+Boost|"Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week."
75704604|NCT05394207|Other|placebo|The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
75704605|NCT05391360|Drug|Freethiadine tablets(part I)|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
75868083|NCT03670238|Device|Orogastric intubation|Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0
76023064|NCT02717663|Behavioral|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
75380901|NCT00002474|Drug|mitoxantrone hydrochloride|
75380902|NCT00002474|Procedure|autologous bone marrow transplantation|
75380903|NCT00002474|Procedure|bone marrow ablation with stem cell support|
75541020|NCT00470236|Radiation|Shorter WB fractionation + Boost|"Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week."
75541021|NCT00202163|Drug|DHEA|
75704606|NCT05391360|Drug|Freethiadine tablets (part II)|once or twice daily for consecutive 28 days
75704607|NCT05391360|Drug|Freethiadine placebo tablets|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
75704608|NCT05391360|Drug|entecavir tablets|once daily for consecutive 28 days
75380904|NCT00002480|Radiation|radiation therapy|
75380905|NCT04013737|Device|EPIC IMPOC|Clinical Decision Support System for antibiotic prescribing.
75380906|NCT05670470|Drug|CTP0303|Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
75380907|NCT05670470|Drug|Orafang Tab|Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
75380908|NCT04011631|Procedure|Internal defibrillation during cardiac surgery, using the iD-system|When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
75380909|NCT00002492|Drug|cisplatin|
75380910|NCT00002492|Drug|doxorubicin hydrochloride|
75380911|NCT00002492|Drug|isolated limb perfusion|
75380912|NCT00002492|Procedure|conventional surgery|
75380913|NCT00002492|Radiation|brachytherapy|
75380914|NCT00002492|Radiation|radiation therapy|
75380915|NCT05751512|Drug|MRG003|Administered intravenously
75380916|NCT05751512|Drug|Cetuximab injection|Administered intravenously
75380917|NCT05751512|Drug|Methotrexate Injection|Administered intravenously
75380918|NCT02373865|Drug|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
75380919|NCT02373865|Drug|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
75380920|NCT02373865|Drug|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
75380921|NCT02373865|Drug|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
75380922|NCT00002498|Drug|CMF regimen|
75380923|NCT00002498|Drug|cyclophosphamide|
75868084|NCT03670238|Device|Nasogastric intubation|After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
75868085|NCT03674450|Behavioral|Heart Rate Variability Biofeedback Training|The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
75380924|NCT00002498|Drug|fluorouracil|
75380925|NCT00002498|Drug|methotrexate|
75380926|NCT00002498|Drug|mitoxantrone hydrochloride|
75380927|NCT00002504|Biological|aldesleukin|
75868086|NCT03114748|Other|EEG|
75868087|NCT03114748|Other|DBS switched OFF and ON|
75868088|NCT02461784|Procedure|Semen & Data Collection|"If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project."
75380928|NCT00002504|Biological|recombinant interferon alfa|
75380929|NCT02360059|Drug|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
75380930|NCT02360059|Other|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
75380931|NCT02360059|Behavioral|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
75380932|NCT02360059|Other|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
75380933|NCT04006795|Other|Serum|Participants will be topically applied adhesive patch containing developmental serum
75380934|NCT04006795|Other|Lotion|Participants will be topically applied adhesive patch containing developmental lotion
75380935|NCT04006795|Other|Cream|Participants will be topically applied adhesive patch containing developmental cream
75380936|NCT04006795|Other|Normal Saline|Participants will be topically applied adhesive patch containing normal saline
75380937|NCT05665790|Radiation|radiotherapy|radiotherapy
75541022|NCT00202163|Drug|Testosterone|
75541023|NCT00258999|Device|Skin Cholesterol Testing|
75380938|NCT05665790|Procedure|palliative surgery|palliative surgery
76023065|NCT02717663|Behavioral|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
76023066|NCT02699125|Drug|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
76023067|NCT02699125|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
75380939|NCT00002510|Biological|filgrastim|
75380940|NCT00002510|Drug|cyclophosphamide|
75380941|NCT00002510|Drug|etoposide|
75380942|NCT00002510|Drug|mesna|
75380943|NCT00002510|Procedure|peripheral blood stem cell transplantation|
75380944|NCT00002510|Radiation|radiation therapy|
75380945|NCT01500109|Drug|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
75541024|NCT00476554|Drug|Sapacitabine|Sapacitabine
75541025|NCT00202202|Procedure|consultation format|
75541026|NCT04709289|Other|Aminolevulinic acid, photodynamic therapy|Aminolevulinic acid, photodynamic therapy
75541027|NCT00202241|Procedure|testosterone injection|
75704609|NCT05386407|Diagnostic Test|telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)|"After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP."
75704610|NCT05374993|Device|3TBA|Induce third molar tooth bud agenesis
75704611|NCT05374980|Dietary Supplement|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
75868089|NCT03161782|Other|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
75380946|NCT01500109|Drug|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
75380947|NCT01500109|Drug|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
75380948|NCT00002516|Biological|dactinomycin|
75380949|NCT00002516|Drug|cyclophosphamide|
75380950|NCT00002516|Drug|doxorubicin hydrochloride|
75380951|NCT00002516|Drug|etoposide|
75868090|NCT03161782|Other|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
75380952|NCT00002516|Drug|ifosfamide|
75380953|NCT00002516|Drug|mesna|
75704612|NCT05374980|Dietary Supplement|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
75704613|NCT05372523|Diagnostic Test|CAPS-5 Assessment|A validated, semi-structured clinical interview to assess core PTSD symptoms
75704614|NCT05372523|Diagnostic Test|Senseye OBCI|Using a machine learning algorithm, Senseye's DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
75704615|NCT05371743|Diagnostic Test|Plasma RNA isolation, qPCR analysis of micro RNA|qPCR will be performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Total RNAs going to be used to make cDNAs using TaqMan microRNA RT Kit. Diluted cDNAs were mixed with TaqMan Universal PCR Master Mix (No AmpErase UNG). Taqman miRNA assay will run in the 7500 Real-Time PCR System (Applied Biosystems). miR-39 also will be used as an exogenous control. All assays will be done in triplicates. The expression levels will be evaluated using the comparative cycle threshold (∆∆_Ct) method
75380954|NCT00002516|Drug|vincristine sulfate|
75380955|NCT00002516|Procedure|conventional surgery|
75380956|NCT00002516|Radiation|low-LET cobalt-60 gamma ray therapy|
75380957|NCT00002516|Radiation|low-LET photon therapy|
75380958|NCT00377845|Procedure|Regular Tampax used in 3 hours|
75380959|NCT00002522|Drug|cisplatin|
75380960|NCT00002522|Drug|cyclophosphamide|
75380961|NCT00002522|Drug|etoposide|
75380962|NCT00002522|Procedure|autologous bone marrow transplantation|
75704616|NCT05371743|Diagnostic Test|estimation of serum level of IL2|"2ml of patient serum will be used to measure IL 2 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
75704617|NCT05371743|Diagnostic Test|estimation of serum level of IL17|"2ml of patient serum will be used to measure IL17 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
76031005|NCT02331745|Drug|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
75868091|NCT03161782|Other|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
75868092|NCT03161782|Other|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
75868093|NCT03670082|Drug|Lu AF35700|20 mg Lu AF35700 single oral dose
75868094|NCT03670082|Drug|Lu AF35700 iv|100 μg [14C]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
75380963|NCT00002522|Procedure|bone marrow ablation with stem cell support|
75380964|NCT00002522|Procedure|peripheral blood stem cell transplantation|
75380965|NCT00002522|Procedure|syngeneic bone marrow transplantation|
75380966|NCT00002522|Radiation|radiation therapy|
75380967|NCT02350777|Procedure|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
75380968|NCT02350777|Device|CliniMACS Cell Selection System|
75541028|NCT00266136|Drug|Cytarabine|see protocol
75704618|NCT05366764|Drug|SAR443765|solution for injection
75704619|NCT05366764|Drug|Placebo|solution for injection
75704620|NCT05366764|Drug|Salbutamol or levosalbutamol|metered dose inhaler
75704621|NCT05359835|Drug|Calcium DTPA and Zinc DTPA|Intravenous administration of 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by 900 mL of normal saline infusion over about 90 minutes, followed by 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by infusion of the remaining 100 mL of normal saline over about 10 minutes. Procedure repeated with Zn-DTPA the following day. Two-day procedure repeated at an interval of one week or more for a total of six 2-day treatment sessions.
75868095|NCT02443220|Device|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group"
75868096|NCT02443220|Device|TEAS|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group"
75868097|NCT02443220|Device|TEAS|"The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia"
75868098|NCT03163966|Drug|CR6086|oral CR6086 capsules
76031006|NCT02638259|Drug|GP2015|Enbrel comparator
76031007|NCT02333929|Device|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
76031008|NCT02333851|Drug|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
76031009|NCT02333851|Drug|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
76031010|NCT02334007|Drug|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
75380969|NCT01482325|Device|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
75868099|NCT03163966|Drug|Methotrexate|oral Methotrexate tablets
75380970|NCT00002528|Drug|tamoxifen citrate|20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
75380971|NCT00002528|Procedure|conventional surgery|Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
75380972|NCT00002528|Radiation|radiation therapy|No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.
75380973|NCT00002528|Procedure|Axillary clearance|Axillary node dissection.
75380974|NCT02341495|Drug|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
75380975|NCT02341495|Drug|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
75868100|NCT03163966|Drug|Placebo|oral CR6086 Placebo capsules
75868101|NCT03678116|Drug|Sugar Pill (placebo)|Taken orally in capsule form
75380976|NCT02341495|Drug|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
75380977|NCT00002534|Biological|anti-thymocyte globulin|
75380978|NCT00002534|Drug|cyclophosphamide|
75380979|NCT00002534|Drug|cytarabine|
75380980|NCT00002534|Drug|methylprednisolone|
75380981|NCT00002534|Drug|thiotepa|
75868102|NCT03678116|Dietary Supplement|Caffeine (plus Teacrine and Cayenne)|Taken orally in capsule form
75868103|NCT03678116|Dietary Supplement|Caffeine (plus Teacrine)|Taken orally in capsule form
75868104|NCT03163498|Other|No intervantion. It´s a Cross-Sectional Study|No intervential
75868105|NCT03768648|Other|Clinical assessment|EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded
75868106|NCT03768648|Other|Ecological evaluation|Virtual reality task : Urban DailyCog© and Actual reality
75868107|NCT03768648|Other|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
75380982|NCT00002534|Procedure|allogeneic bone marrow transplantation|
75380983|NCT00002534|Procedure|in vitro-treated bone marrow transplantation|
75380984|NCT00002534|Radiation|low-LET electron therapy|
75380985|NCT00002534|Radiation|low-LET photon therapy|
75380986|NCT02320825|Radiation|single-fraction SRS|
75380987|NCT02320825|Radiation|high-dose hypofractionated SRS|
75380988|NCT02320825|Behavioral|Quality of Life Measures|
75380989|NCT00002546|Drug|cisplatin|
75380990|NCT00002546|Drug|ifosfamide|
75380991|NCT00002546|Procedure|adjuvant therapy|
75380992|NCT00002546|Radiation|radiation therapy|
75380993|NCT01477177|Device|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
75380994|NCT05655884|Other|Music Listening Application|"15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher via the creatone music pillow for 15 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, music will be played by the music group again for 15 minutes."
75541029|NCT00266136|Drug|Thioguanine|see protocol
75541030|NCT00266136|Drug|Daunorubicin|see protocol
75541031|NCT00266136|Drug|Cyclophosphamide|see protocol
75541032|NCT00266136|Drug|G-CSF|see protocol
75541033|NCT00266136|Procedure|Autologous stem cell transplantation|for details see protocol
75868108|NCT03768648|Other|Psychological evaluation|questionnaires for depression, anxiety and fatigue
75868109|NCT03768648|Device|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
75868110|NCT03678038|Drug|Triamcinolone (Shincort) injection to rotator interval|via rotator interval.
75868111|NCT03678038|Drug|Triamcinolone (Shincort) injection to posterior glenuhumeral recess|via posterior glenuhumeral recess
75380995|NCT05655884|Other|Foot Reflexology Practice:|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher, only to the left foot, for 10 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, foot reflexology will be applied again, only on the left foot, for 10 minutes.
75380996|NCT00378625|Drug|Artesunate|
75541034|NCT00266136|Procedure|Allogeneic stem cell transplantation|for details see protocol
75541035|NCT00230555|Behavioral|professional support model|
75541036|NCT00259038|Drug|Carperitide|
75541037|NCT00259038|Drug|Placebo|
75380997|NCT00378859|Behavioral|Skim milk|
75868112|NCT03163420|Drug|Diclofenac potassium|Diclofenac potassium 50 mg granules for oral solution
75868113|NCT03163420|Other|Placebo|Fructose
75380998|NCT00378859|Behavioral|Lean meat|
75380999|NCT04005391|Other|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
75868114|NCT04744272|Device|myAsthma|myAsthma is an online digital self-management application to support asthma patients by offering education, inhaler technique, pulmonary rehabilitation, symptoms and medication usage tracking remotely.
75868115|NCT03677960|Drug|Topical ABI-1968 cream|Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
75868116|NCT04440436|Drug|IM19 CAR-T Cells|"IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days"
76031011|NCT02334007|Other|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
76031012|NCT02333695|Device|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
76031013|NCT02338375|Biological|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
75541038|NCT00230594|Drug|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
76031014|NCT02338063|Behavioral|Virtual Reality|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
76031015|NCT02338063|Behavioral|Health Promotion|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
75381000|NCT00002552|Biological|filgrastim|
75381001|NCT00002552|Biological|sargramostim|
75541039|NCT00230594|Drug|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
75541040|NCT00259077|Drug|Omeprazole|
75541041|NCT00479674|Drug|Abraxane|100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
75541042|NCT00479674|Drug|Bevacizumab|10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
75541043|NCT00479674|Drug|Carboplatin|area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
75541044|NCT02962310|Drug|Torrent's Rosuvastatin Calcium Tablets 40 mg|oral, crossover
75541045|NCT02962310|Drug|Crestor 40 mg Tablets of AstraZeneca LP, USA|oral, crossover
75541046|NCT00259116|Drug|Relaxin|
75541047|NCT00415779|Drug|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
75541048|NCT00415779|Drug|zoledronic acid|2 mg IV every 2 weeks
75541049|NCT00230711|Behavioral|Physical activity counseling|
75541050|NCT00259155|Drug|Rifaximin|
75541051|NCT00230750|Biological|Influenza A/H5N1 Vaccine|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
75381002|NCT00002552|Drug|carmustine|
75381003|NCT00002552|Drug|cyclophosphamide|
75381004|NCT00002552|Drug|cytarabine|
75381005|NCT00002552|Drug|etoposide|
75381006|NCT00002552|Drug|leucovorin calcium|
75381007|NCT00002552|Drug|methotrexate|
75381008|NCT00002552|Drug|perfosfamide|
75381009|NCT00002552|Drug|therapeutic hydrocortisone|
75541052|NCT00230750|Drug|Placebo|Saline placebo.
75541053|NCT00479401|Drug|Pramipexol Extended Release|
75541054|NCT00479401|Drug|Pramipexol Immediate Release|
75541055|NCT00479401|Drug|Placebo|
75541056|NCT00415818|Biological|MVA-MUC1-IL2|"MVA-MUC1-IL2:~Dose of 10exp8 plaque forming units (pfu).~Chemotherapy:~Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first."
75381010|NCT00002552|Procedure|allogeneic bone marrow transplantation|
75381011|NCT00002552|Procedure|autologous bone marrow transplantation|
75381012|NCT00002552|Procedure|in vitro-treated bone marrow transplantation|
75381013|NCT00002552|Procedure|peripheral blood stem cell transplantation|
75381014|NCT00002552|Procedure|syngeneic bone marrow transplantation|
75381015|NCT00002552|Radiation|radiation therapy|
75381016|NCT00378781|Drug|Heparin|Heparin flush solution into CVC once daily.
75381017|NCT00378781|Drug|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
76031016|NCT02637323|Drug|FX006 32 mg|Single 5 mL IA injection
75381018|NCT00002564|Other|educational intervention|
75381019|NCT00002564|Procedure|therapeutic dietary intervention|
75541057|NCT00415818|Drug|1st line Chemotherapy|
75541058|NCT00230789|Drug|Tolterodine ER 4 mg QD|
75541059|NCT00230789|Behavioral|OAB Patient Behavioral Training Material|
75541060|NCT00230828|Drug|bifeprunox|
75704622|NCT05357378|Device|Hip Innovation Technology Reverse Hip Replacement System|Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
75381020|NCT00377923|Drug|Progesterone|
75868117|NCT01568814|Drug|Low volume PEG|low volume polyethylene glycol 2 liter one time
75868118|NCT01568814|Drug|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
75381021|NCT05750888|Behavioral|integrated exercise therapy with 3D printing exerciser for training intrinsic foot muscles|The therapeutic exercise program with a custom-made 3-D printing foot core exerciser, consisting of warm-up exercise, active range of motion in the foot and ankle joints, foot core system strengthening program using the 3D printing device, and stretching exercises for foot and ankle.
75381022|NCT05750888|Behavioral|regular exercises for the elderly|The regular exercise provided for the elderly in the dwelling community, including walking, simple aerobic exercises, stretching exercises
75381023|NCT03990415|Behavioral|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
75381024|NCT00002570|Drug|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
75381025|NCT00002570|Drug|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
75381026|NCT05750810|Other|Severe exacerbation frequency|A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
75381027|NCT04002973|Device|INVSENSOR00037|Noninvasive regional oximeter.
75381028|NCT00002576|Drug|cyclophosphamide|
75381029|NCT00002576|Drug|doxorubicin hydrochloride|
75868119|NCT03677882|Behavioral|Mind Body Bridging Group Session|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
75868120|NCT05405686|Drug|Lutropin alfa|addition of recombinant luteinizing hormone
75381030|NCT00002576|Drug|mitoxantrone hydrochloride|
75381031|NCT00002576|Drug|prednisolone|
75381032|NCT00002576|Drug|vincristine sulfate|
75381033|NCT03977935|Device|the second-generation MCCG|Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
75381034|NCT03985657|Device|CPAP|Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
75381035|NCT00002582|Drug|CMF regimen|
75381036|NCT00002582|Drug|cyclophosphamide|
75381037|NCT00002582|Drug|doxorubicin hydrochloride|
75381038|NCT00002582|Drug|fluorouracil|
75381039|NCT00002582|Drug|goserelin acetate|
75381040|NCT00002582|Drug|leuprolide acetate|
75381041|NCT00002582|Drug|methotrexate|
75381042|NCT00002582|Drug|tamoxifen citrate|
75381043|NCT00002582|Procedure|oophorectomy|
75868121|NCT05405686|Drug|Follitropin alfa|recombinant follicle stimulating hormone (FSH)
76031017|NCT02637323|Drug|TCA IR 40|Single 1 mL IA injection
76031018|NCT02338141|Device|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
76031019|NCT02338141|Device|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
76031020|NCT02338297|Procedure|TACE|Transarterial chemoembolisation (TACE)
76031021|NCT02338297|Drug|EGM|Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
75381044|NCT00002582|Radiation|radiation therapy|
75381045|NCT02249377|Other|Platelets-Rich-Plasma|Platelet-Rich Plasma
75381046|NCT02249377|Drug|Corticosteroid|Corticosteroid
75381047|NCT05750654|Device|Small Phlebotomy Tube Group|"In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU."
75381048|NCT05750654|Device|Standard Phlebotomy Tube Group|In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
75381049|NCT00002588|Drug|etoposide|
75381050|NCT00002588|Drug|topotecan hydrochloride|
76031022|NCT02338297|Drug|PVA|Occlude arterioportal shunts(APS) with PVA
75381051|NCT02239627|Drug|Epidural steroid|
75381052|NCT02239627|Drug|Clonidine|
75381053|NCT05750576|Device|Chlorhexidine-impregnated dressings|Sterile adhesive transparent dressings impregnated with Chlorhexidine Gluconate gel applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
75541061|NCT02962544|Procedure|FS-SMILE|The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
75541062|NCT02962544|Procedure|FS- LASIK|LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
75381054|NCT05750576|Device|Non impregnated dressings|Single transparent adhesive dressings not impregnated with Chlorhexidine Gluconate applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
75381055|NCT00002594|Biological|Sargramostim|Given IV
75541063|NCT02962544|Device|Visumax device|
76031023|NCT02338219|Other|postpartum female pelvic floor muscle affection|"transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
75541064|NCT02962544|Device|FS 200 device|
75541065|NCT00415896|Device|positive pressure ventilation|
75541066|NCT00478777|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
75541067|NCT00478777|Drug|dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
75868122|NCT05405686|Diagnostic Test|Endometrial biopsy|pipelle de cornier biopsy
76031024|NCT02338219|Other|postpartum sexual function in Egyptian women.|answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
75381056|NCT00002594|Drug|cyclophosphamide|Given IV
75381057|NCT00002594|Drug|melphalan|Given IV
75381058|NCT00002594|Procedure|autologous bone marrow transplantation|
75381059|NCT00002594|Procedure|bone marrow ablation with stem cell support|
75381060|NCT00002594|Procedure|peripheral blood stem cell transplantation|
76031025|NCT05011643|Other|Moderate-intensity exercise|Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.
76031026|NCT03111979|Dietary Supplement|beta-alanine|
76031027|NCT03111979|Dietary Supplement|Placebo|
76031028|NCT05004623|Device|Sentinel Lymph Node Biopsy|Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
76031029|NCT05004779|Procedure|human stem cell conditioned media was applied after non-ablative laser therapy|After laser treatment on hypertrophic scars, human stem cell media was applied to one side
76031030|NCT05004779|Procedure|normal saline was applied after non ablative laser therapy|physiological saline was applied to the other side.
76031031|NCT05011019|Drug|AL2846 capsules|AL2846 is a multi-target receptor tyrosine kinase inhibitor.
76031032|NCT02331823|Drug|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
75381061|NCT02234011|Drug|Ketamine|
75381062|NCT02234011|Drug|Placebo|
75381063|NCT02198833|Biological|Urine Culture|Obtain urine culture every third day
75381064|NCT02198833|Device|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
75704623|NCT05357378|Device|Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.|"Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~DePuy Synthes Corail® Total Hip System in combination with Pinnacle® Complete Acetabular Hip System.~Zimmer Biomet Taperloc® Complete Hip System in combination with G7® Acetabular System.~Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~Smith & Nephew Anthology® Total Hip System in combination with R3® Acetabular System."
75868123|NCT04711122|Drug|Third generation cephalosporin antibiotics|Assessment of antibiotic effect
75868124|NCT05272696|Drug|Nab-paclitaxel, cisplatin and Pembrolizumab combination|Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy
75381065|NCT02198833|Device|Scanning Electron Microscopy|Houston Site Only
75381066|NCT02198833|Procedure|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
75381067|NCT02198833|Procedure|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
76031033|NCT02331823|Drug|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
75381068|NCT00002600|Biological|filgrastim|
75381069|NCT00002600|Drug|carboplatin|
75381070|NCT00002600|Drug|cyclophosphamide|
75381071|NCT00002600|Procedure|autologous bone marrow transplantation|
75381072|NCT00002600|Procedure|peripheral blood stem cell transplantation|
75381073|NCT02177773|Procedure|Computed Tomography (CT)|Undergo Gallium Ga 68-DOTA-TOC PET/CT
75381074|NCT02177773|Drug|Gallium Ga 68-Edotreotide|Given Intravenously (IV) before imaging
75381075|NCT02177773|Procedure|Magnetic Resonance Imaging (MRI)|Undergo gallium Ga 68-DOTA-TOC PET/MRI
75381076|NCT02177773|Procedure|Positron Emission Tomography (PET)|Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
75381077|NCT00382226|Drug|Azopt|
75381078|NCT02144155|Drug|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
75381079|NCT02144155|Drug|Placebo|placebo drug
75381080|NCT00002618|Biological|filgrastim|
75381081|NCT00002618|Drug|cytarabine|
75381082|NCT00002618|Drug|doxorubicin hydrochloride|
75381083|NCT00002618|Drug|leucovorin calcium|
75381084|NCT00002618|Drug|mercaptopurine|
75381085|NCT00002618|Drug|methotrexate|
75541068|NCT00477607|Drug|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
75868125|NCT05272696|Procedure|surgery|Patients with PR but the maximum diameter of tumor > 3cm or SD or PD can receive surgery directly.
75868126|NCT05272696|Radiation|Adjuvant Chemoradiotherapy|After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.
76031034|NCT05011097|Drug|Y150|Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
76031035|NCT02890459|Other|Prize incentive - Low|Low expected prize value.
76031036|NCT02890459|Other|Prize incentive - High|High expected prize value.
76031037|NCT02890459|Other|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
75381086|NCT00002618|Drug|prednisone|
75381087|NCT00002618|Drug|vincristine sulfate|
75381088|NCT00002618|Radiation|low-LET cobalt-60 gamma ray therapy|
75381089|NCT00002618|Radiation|low-LET electron therapy|
75381090|NCT00002618|Radiation|low-LET photon therapy|
75381091|NCT02145169|Drug|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
75381092|NCT00002624|Procedure|adjuvant therapy|
75381093|NCT00002624|Procedure|diagnostic thoracoscopy|
75381094|NCT00002624|Procedure|therapeutic thoracoscopy|
75381095|NCT00002624|Procedure|video-assisted surgery|
75381096|NCT00002624|Radiation|radiation therapy|
75381097|NCT00002630|Biological|filgrastim|
75381098|NCT00002630|Drug|cyclophosphamide|
75381099|NCT00002630|Drug|melphalan|
75381100|NCT00002630|Procedure|peripheral blood stem cell transplantation|
75381101|NCT00002630|Radiation|low-LET cobalt-60 gamma ray therapy|
75381102|NCT00002630|Radiation|low-LET photon therapy|
75381103|NCT02047747|Drug|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
75541069|NCT00477607|Behavioral|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
75541070|NCT00477607|Biological|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
75704624|NCT05355207|Drug|TRL1068|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
75704625|NCT05337280|Device|Imagio OA/US|Imagio optoacoustic/ultrasound
75381104|NCT05750186|Other|Abdominal Massage|Abdominal massage is a noninvasive application that stimulates bowel movements by applying patting, kneading and vibration movements over the abdominal wall to the area where the intestines are located. It increases peristalsis, creates a mechanical and reflex effect on the intestines, reducing the individual's feeling of pain and discomfort.
75381105|NCT00002642|Drug|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
75381106|NCT00002642|Drug|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
75381107|NCT00002642|Procedure|conventional surgery|surgery some time between weeks 9 and 12
75381108|NCT00002642|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
75381109|NCT03983941|Drug|Ropivacaine injection|Total dose not to exceed 3 mg/kg of ropivacaine.
75381110|NCT01434511|Biological|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
75381111|NCT02973074|Dietary Supplement|OLEOvital|2sachets with 30mg iron per day for a 4 weeks period
75704626|NCT05319041|Drug|Wei's Qi Ju Gan Lu Formula|"The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
75704627|NCT05319041|Drug|Placebo|0.5g maltodextrin without any herbs medicine
75704628|NCT05314335|Other|Reflexology socks+walking|Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)
76031038|NCT02890459|Other|Travel Voucher|Travel voucher to assist with linkage to care.
75381112|NCT05750108|Device|Parasym device (active, current (mA) < discomfort threshold)|Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
75381113|NCT05750108|Device|Parasym device (sham, current (mA) = 0)|Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
75381114|NCT02020837|Procedure|Lymphaticovenous Micro-Anastomosis|
75381115|NCT02006407|Radiation|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
75541071|NCT00477607|Drug|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
75704629|NCT05314335|Other|Just walking|Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
75704630|NCT05308225|Biological|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
75704631|NCT05303844|Drug|H101|H101 intratumorally injection starts at day 0.
75381116|NCT02006407|Device|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
75381117|NCT02006407|Behavioral|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
75381118|NCT04331054|Drug|2: Usual practice + SYMBICORT RAPIHALER|2 puffs bid during 30 days by inhalation
75381119|NCT04331054|Other|1: Usual practice|Usual practice
75381120|NCT00002654|Drug|chemotherapy|
75381121|NCT00002654|Drug|cisplatin|
75381122|NCT00002654|Radiation|low-LET cobalt-60 gamma ray therapy|
75381123|NCT00002654|Radiation|low-LET electron therapy|
75381124|NCT00002654|Radiation|low-LET photon therapy|
75381125|NCT02973308|Other|Observer|Observer A and observer B
75381126|NCT01426555|Other|FES-Rowing|FES- Rowing Exercise
75704632|NCT05303844|Drug|Tislelizumab|Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
75704633|NCT05297019|Procedure|Hyperbaric Oxygen Therapy|hyperbaric oxygen therapy
75704634|NCT05291754|Device|PEEK Cranioplasty|3D printed PEEK skull implant
75381127|NCT01426555|Drug|Zoledronic acid|5 mg IV single dose
75381128|NCT01434745|Drug|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
75381129|NCT01434745|Dietary Supplement|Lactose|Lactose will be administered in a capsule formula.
75541072|NCT00259194|Behavioral|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
75541073|NCT00259194|Behavioral|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
75541074|NCT00259233|Drug|peripheral Peptide YY administration|
75541075|NCT00230867|Device|iontophoretic acyclovir|
75541076|NCT00259311|Drug|LY2422347|
75541077|NCT00259311|Drug|placebo|
75541078|NCT00230906|Procedure|Haemodialysis with either low or high flux membranes|
75541079|NCT00266214|Drug|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
75541080|NCT00259350|Drug|Skin disinfection|
75704635|NCT05291182|Drug|SY-4835|WEE1 inhibitor
76031039|NCT02890459|Other|Standard care|Includes HIV viral load and treatment adherence counseling.
75541081|NCT00230945|Behavioral|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
75541082|NCT00266253|Drug|GK Activator (2)|Escalating doses, po bid or qd for 12 weeks.
75541083|NCT00266253|Drug|Metformin|As prescribed, for 12 weeks
75541084|NCT00230984|Behavioral|education|
75541085|NCT00230984|Drug|Oral dietary supplements (563 kcal/d), RESPIFOR|
75868127|NCT05272696|Drug|Radical concurrent chemoradiotherapy|Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
75868128|NCT05563116|Diagnostic Test|Computed tomography coronary artery calcium (CAC) score (part of routine workup)|Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
75868129|NCT03520946|Drug|Ramucirumab|8 mg/kg iv over 60 min on d1+15, q4w
75541086|NCT00230984|Behavioral|exercises on an ergometric bicycle 3 to 5 times a week|
75541087|NCT00230984|Drug|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
75541088|NCT00266292|Behavioral|Fish oil (Bio-Marine, Pharma Nord)|
75541089|NCT00266292|Behavioral|n-6 PUFA intake (Margarine+sunflower oil vs. butter product+rapeseed oil)|
75541090|NCT04721678|Behavioral|Interpersonal psychotherapy|Internet-based interpersonal psychotherapy aimed at reducing symptoms of depression. The content of the intervention is divided into three parts: the assessment phase (the first four weeks), the focus phase (the following five weeks), and the end phase (the last week).
75541091|NCT00415350|Drug|Azithromycin|Azithromycin Tablet 250 mg daily
75541092|NCT00415350|Other|Placebo|Placebo tablet 1 daily
75541093|NCT00231023|Drug|Peribulbar Triamcinolone Acetonide|
75541094|NCT00266331|Drug|Reduced glutathione|
75868130|NCT03520946|Drug|TAS 102|35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
75541095|NCT00231101|Drug|Quetiapine|
75541096|NCT00231140|Drug|Thalidomide (drug)|
75541097|NCT00415389|Behavioral|interactive educational program|2-session interactive stroke educational program
75541098|NCT00415389|Behavioral|usual medical care|standard educational materials and usual care
75541099|NCT00231218|Drug|dietary supplement--echinacea, propolis, and vitamin c|
75541100|NCT02961192|Behavioral|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
75541101|NCT02961192|Behavioral|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
75541102|NCT02961192|Behavioral|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
75541103|NCT00231296|Device|Cardiac CryoCor Cryoablation System|Treatment with CryoCor Cardiac Cryoablation system
75541104|NCT00231296|Drug|Medical management|Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
75541105|NCT00266448|Drug|Chlorhexidine solution 4%|
75541106|NCT00415428|Behavioral|Patient adherence to national educational guidelines.|
75541107|NCT00231335|Drug|escitalopram|
75868131|NCT03677726|Behavioral|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
75868132|NCT03677726|Other|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
75868133|NCT05547906|Drug|ASCA101|IV infusion Twice a Week, 8 times per each Cycle
75868134|NCT03674060|Drug|SYO-1644|"100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet"
75868135|NCT03674060|Drug|Nexavar tab|Nexavar 200mg/tablet, PO, 1 tablet
75868136|NCT03163186|Procedure|Transarterial embolization|Transarterial hepatic embolization of liver cancer
75868137|NCT02049632|Procedure|Omission of axillary clearance|
75381130|NCT01401049|Drug|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
75704636|NCT05287087|Behavioral|My Symptoms 1 (MySt-1)|"The patients will get access to an eHealth programme consisting of:~A questionnaire including the BDS checklist~A brief introductory animation about how to understand symptoms in general~Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2."
75868138|NCT03163576|Drug|Niacin|tablets
75868139|NCT03163576|Drug|Phosphate Binder|tablets
75868140|NCT01971008|Device|Elastic abdominal binder|
75868141|NCT01971008|Device|Placebo binder|
75381131|NCT01401049|Drug|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
75868142|NCT04691544|Biological|Fecal microbiota transplantation (FMT)|Delivered by enema
75868143|NCT04058912|Genetic|PTEN-AKT-FOXO3 Gene Expression|In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
75381132|NCT00381758|Drug|Methylphenidate Extended Release Capsules|
75381133|NCT01402531|Drug|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
75381134|NCT00381836|Drug|Darbepoetin Alfa|
75868144|NCT02781870|Procedure|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
75381135|NCT01971853|Drug|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
75868145|NCT02781870|Procedure|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
75381136|NCT01971853|Drug|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
75381137|NCT00002678|Drug|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
75381138|NCT00002678|Drug|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
75381139|NCT00002678|Drug|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
75541108|NCT00266487|Drug|Folic acid|
75541109|NCT00266487|Drug|Vitamin B12|
75541110|NCT00266487|Drug|Vitamin B6|
75541111|NCT00231374|Procedure|Myelogram|
75868146|NCT03673982|Behavioral|iCASK|Materials and support to aid transitions
75868147|NCT04759846|Drug|Encorafenib + Binimetinib|The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses
75868148|NCT04759846|Drug|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
75868149|NCT04759846|Drug|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
75868150|NCT01810718|Drug|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond >600 or <200mg/die The MTD will be used for phase II
75868151|NCT01383798|Dietary Supplement|Placebo|100 mg lactose per day for 6 weeks
75868152|NCT01383798|Dietary Supplement|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
75541112|NCT00415467|Device|GliaSite Radiation Therapy System|Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
75541113|NCT00231452|Drug|Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)|Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
75541114|NCT00266526|Biological|Recombinant birch pollen|
75704637|NCT05287087|Behavioral|My Symptoms 2 (MySt-2)|"The patients will get access to an eHealth programme consisting of:~A questionnaire including the BDS checklist~A brief introductory animation about how to understand symptoms in general~Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~A brief animation about the interaction of body and mind.~Thorough symptom explanations~Physical energy (focus on sleep, diet and activity)~Values and choices (focus on meaning and existential issues)~Emotional health (focus on emotion regulation)~Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation."
75868153|NCT01644578|Procedure|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
75868154|NCT01374178|Drug|LY2963016|Administered subcutaneously
75868155|NCT01374178|Drug|Lantus|Administered subcutaneously
75704638|NCT05280574|Device|GE Portrait Monitor|All patients will be monitored
75704639|NCT05280574|Device|GE Portrait Monitoring with intervened by clinician|Monitoring might be intervened if clinician believe that the alarm is clinically meaningful
75704640|NCT05280574|Device|GE Portrait Monitoring randomized to blinded or unblinded|Without intervention
75704641|NCT05279313|Drug|Centanafadine Hydrochloride|Capsule
75868156|NCT03673592|Diagnostic Test|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
75868157|NCT03161314|Procedure|Conservative physical therapy treatment with strengthening exercise program, and Conservative physical therapy treatment with stretching exercise program|(Sub-project 3) conservative physical therapy treatment with self-strengthening and with self-stretching home based exercises
75868158|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
75704642|NCT05278364|Drug|SY-5007|a RET selective Inhibitor
75868159|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
75868160|NCT03161392|Diagnostic Test|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
75704643|NCT05277844|Radiation|Local Consolidative Radiation Therapy|Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
75868161|NCT03161392|Diagnostic Test|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
75868162|NCT03161470|Other|Standard Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
76023068|NCT04279535|Drug|Topical Ascorbic Acid|Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
75541115|NCT00231491|Drug|Botulinum Toxin A (Botox )|
75541116|NCT00477490|Drug|desmopressin acetate|Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
75704644|NCT05277844|Drug|TKI|TKI
75704645|NCT05274659|Drug|KJ103|Recombinant Immunoglobulin G Cleaving Enzyme
75704646|NCT05274659|Drug|Placebo|Placebo
75704647|NCT05274061|Behavioral|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy|AIM-CBCT consists of an accelerated, 2-day delivery of the first 7 sessions of CBCT for PTSD and is comprised of (a) psychoeducation about PTSD and relationship functioning; (b) instruction in conflict management skills; (c) instruction in effective communication skills with an emphasis on the identification and sharing of emotions to decrease emotional numbing and increase emotional intimacy; (d) discussion of the importance of approaching, rather than avoiding, difficult situations and identification of places, situations, people, and feelings that the couple has heretofore avoided as a result of PTSD; (e) instruction in identification of thoughts and related feelings that can maintain PTSD and relationship distress and strategies to increase cognitive flexibility, and (f) instruction in problem-solving skills to generate couple-level approach behaviors and guidance in how to select activities that double as opportunities to approach feared situations and engage in positive bonding.
75704648|NCT05272137|Device|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
75704649|NCT05263739|Drug|ESG206|Administered via intravenous (IV) infusion
75704650|NCT05262621|Other|progressive muscle relaxation|Practice muscle relaxation for 20 minutes once/a day
75381140|NCT01397695|Drug|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
75381141|NCT00002684|Drug|cisplatin|
75381142|NCT00002684|Drug|ifosfamide|
75381143|NCT00002684|Drug|paclitaxel|
75381144|NCT01982383|Device|Micropulse Laser Treatment|
75381145|NCT01982383|Other|No treatment|
75541117|NCT00477490|Drug|Placebo|Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
75381146|NCT05600647|Device|Electromagnetic Field therapy with an exercise program|"The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training"
75381147|NCT05600647|Other|exercise program|the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
75381148|NCT01356667|Behavioral|DARTNA|3-hour protocol provided 2x/week over 12 weeks
75381149|NCT01356667|Behavioral|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
75541118|NCT00415545|Behavioral|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
75381150|NCT02972918|Drug|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
75381151|NCT05600491|Drug|Temozolomide|Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).
75381152|NCT05749484|Other|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
75381153|NCT05600413|Dietary Supplement|L-Citrulline|4 weeks of L-Citrulline supplementation (6 grams/day)
75381154|NCT05600413|Dietary Supplement|Placebo|4 weeks of Placebo (crystalline cellulose)
75541119|NCT00415545|Behavioral|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
75541120|NCT00231530|Drug|topiramate|
75541121|NCT00259389|Behavioral|Directly observed therapy (DOT)|
75541122|NCT00231569|Drug|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
75541123|NCT00231569|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
75541124|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
75541125|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
75541126|NCT00231569|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
75704651|NCT05262621|Other|Listening to relaxing music once/day|Right after practising progressive muscle relaxation, the participants will listen to relaxing music for 20 minutes
75381155|NCT01934647|Drug|MK-8892|Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
75381156|NCT05440526|Procedure|Herbst Group|"Herbst Group:~Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint."
75541127|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
75541128|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
75704652|NCT05260606|Diagnostic Test|F-18 FDG PET/CT|"1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2nd scan: interim~Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3rd scan: optional (3rd scan can be performed when disease progression is suspected)~Imaging~Fasting: at least 6 hours~Blood glucose level: < 200 mg/dL~F-18 FDG 0.14 mCi/kg (IV)~Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~First and second scans have to be performed with same scan."
75381157|NCT05440526|Device|TFBC Group|"TFBC Group:~The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months."
75868163|NCT03161470|Other|Mechanical Chair Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
75868164|NCT03161470|Other|Sham Treatment|Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
75868165|NCT03161548|Drug|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
75381158|NCT01354951|Other|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
75381159|NCT00379561|Drug|PSA-Activated PSA-PAH1|
75381160|NCT00002696|Drug|CAF regimen|
76031040|NCT02890459|Behavioral|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
75381161|NCT00002696|Drug|CMF regimen|
75541129|NCT00477334|Drug|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
75541130|NCT00477334|Drug|Placebo|oral; two tablets twice a day; single day treatment
75541131|NCT00266565|Drug|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
75541132|NCT02211859|Drug|BI 2536|
75381162|NCT00002696|Drug|cyclophosphamide|
75704653|NCT05260164|Device|HIFEM+RF|Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
75381163|NCT00002696|Drug|doxorubicin hydrochloride|
75541133|NCT00231608|Drug|topiramate|
75541134|NCT00266604|Drug|Topiramate|
75541135|NCT04560985|Other|Hydrophilic fissure sealant|Hydrophilic fissure sealant on first molars
75541136|NCT04560985|Other|Hydrophobic fissure sealant|Hydrophobic fissure sealant on first molars
75704654|NCT05257538|Other|FMT|Fecal microbiota transfer from a healthy and tested volunteer
75704655|NCT05257538|Other|placebo enema|colored water enema
75868166|NCT03161548|Procedure|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
75868167|NCT03161548|Radiation|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
75381164|NCT00002696|Drug|fluorouracil|
75381165|NCT00002696|Drug|methotrexate|
75381166|NCT00002696|Procedure|adjuvant therapy|
75381167|NCT00002696|Procedure|conventional surgery|
75541137|NCT04721483|Procedure|Ramicotomy|We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
75704656|NCT05249998|Other|Program combing APA, Nutrition, and Therapeutic Education|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
75704657|NCT05248672|Drug|CT1812|Study Drug
75704658|NCT05236946|Radiation|Stereotactic radiosurgery/whole brain radiotherapy|SRS/ WBRT for asymptomatic brain metastases depending on the number of brain metastases
75704659|NCT05236946|Drug|Tyrosine kinase inhibitor|TKI
75868168|NCT03025542|Drug|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
75704660|NCT05234424|Other|THRIVE|During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.
75704661|NCT05222932|Biological|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
75868169|NCT03025542|Other|Placebo|Subjects will receive injections of Placebo.
75868170|NCT03114436|Other|Observational Data Collection|All aspects of deceased donor care in the ICU.
75381168|NCT00002696|Procedure|neoadjuvant therapy|
75381169|NCT00002696|Radiation|radiation therapy|
75381170|NCT01350583|Drug|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
75381171|NCT00002702|Biological|aldesleukin|
75381172|NCT00002702|Procedure|adjuvant therapy|
75381173|NCT00002702|Procedure|conventional surgery|
75381174|NCT00002702|Procedure|neoadjuvant therapy|
75381175|NCT00002702|Radiation|radiation therapy|
75381176|NCT01890577|Drug|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
75381177|NCT05749406|Other|Focus group|Small virtual focus group discussion about experiences/attitudes towards post-operative anal dilatation.
75381178|NCT05749406|Other|Semi-structured interview|Individual virtual interview to ascertain participant's experiences of performing anal dilatation post-operatively for their child with an anorectal malformation.
75704662|NCT05222932|Drug|Avelumab|Anti-PDL1 antibody
75381179|NCT00002708|Procedure|surgical procedure|
75381180|NCT00002708|Radiation|radiation therapy|
75381181|NCT00002708|Radiation|stereotactic radiosurgery|
75381182|NCT01315873|Drug|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m^2 after bortezomib . Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
75381183|NCT01315873|Drug|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m^2 followed by bendamustine given at 90 mg/m^2. Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
75381184|NCT01895959|Drug|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
75381185|NCT01895959|Device|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
75381186|NCT01303003|Drug|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
75381187|NCT01303003|Procedure|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
75381188|NCT01256281|Procedure|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
75541138|NCT04560946|Behavioral|Personalized Augmented Cognitive Training (PACT)|Personalized Augmented Cognitive Training (PACT) group. Intervention: Behavioral: The study neuropsychologist will use a portion of the TBI education session to describe available treatment modules and make recommendations for module selection based on results from baseline assessment. After discussion, five 60-minute CogSMART modules will be selected. PACT participants will receive guidance to complete 2 modules per week of the CogSMART app. PACT participants will also receive guidance to complete BrainHQ exercises of their choice for 30 minutes a day, 5 days per week, for a total training time of 15 hours.
75704663|NCT05216419|Drug|Cholecalciferol|"Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken."
75381189|NCT00002714|Biological|bleomycin sulfate|
75704664|NCT05212714|Device|taVNS|The non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) device that will be used in this study is a wearable TENS unit called the Vorso STIM100 System. The Vorso system consists of a wearable, external stimulator, a neural interface ear piece, and an arm band designed to be safe for human contact. The external stimulator generates electrical pulses that are transcutaneously delivered to the auricular branch of the vagus nerve through the ear canal. The ear piece contains 4 electrodes that carry current from the external stimulator to the auricular branch of vagus nerve. The external stimulator connects to a flexible arm band that attaches to the upper arm for ease of use during each stimulation session. The type of stimulation (including shape, frequency, pulse width, amplitude, total charge, and energy delivered) is comparable to the levels applied by commercially available TENS stimulators. The sham control group will not receive any stimulation.
75704665|NCT05205863|Biological|Cofact|Human prothrombin complex concentrate
76031041|NCT02890459|Behavioral|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
75704666|NCT05196529|Other|Inspiratory muscle training|All participants will undergo inspiratory muscle training.
75381190|NCT00002714|Drug|Stanford V regimen|
75381191|NCT00002714|Drug|doxorubicin hydrochloride|
75381192|NCT00002714|Drug|etoposide|
75868171|NCT03673514|Procedure|Total hip arthroplasty|Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
75381193|NCT00002714|Drug|mechlorethamine hydrochloride|
75381194|NCT00002714|Drug|prednisone|
75381195|NCT00002714|Drug|vinblastine sulfate|
75381196|NCT00002714|Drug|vincristine sulfate|
75381197|NCT00002714|Radiation|radiation therapy|
75381198|NCT05313061|Drug|MTX|MTX continuation
75381199|NCT00002720|Drug|tamoxifen citrate|
75381200|NCT00002720|Procedure|conventional surgery|
75381201|NCT01821859|Drug|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
75381202|NCT01821859|Drug|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
75381203|NCT05749328|Dietary Supplement|Carbohydrate|To ensure the safety of the trial, preoperative gastric ultrasound measurements will be performed on all patients to assess their gastric volume. See above for other details
75381204|NCT05600023|Drug|Nitrofurantoin|Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
75381205|NCT05600023|Drug|Double Antibiotic|DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
75381206|NCT05599867|Behavioral|quality of life|to assess quality among patients with patients with IBD
75704667|NCT05196464|Behavioral|Acceptance and Commitment Therapy (ACT) Workshop|ACT workshops are single-day workshops that last 5-6 hours. The workshops will 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from unhelpful thoughts) and strategies to willingly face experiences that cannot be changed; and 2) Committed Action Training to help Veterans clarify what matters most to them (e.g., valued domains including family, friends, spirituality, career) and what they want to stand for in life, how they want to behave, and what strengths and qualities they want to develop. Within this context, the workshop will encourage engagement in, rather than avoidance of, actions consistent with valued directions, including engagement in healthcare. Workshop participants will be given homework related to implementing a key coping skill.
76031042|NCT02890459|Behavioral|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
76031043|NCT02890459|Behavioral|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
75704668|NCT05196464|Behavioral|Treatment as usual (TAU)|TAU will consist of a consult to a mental health provider at their rural clinic. The patient will then be scheduled for an intake and offered traditional mental health treatment options. Treatment options are likely to include outpatient individual psychotherapy, psychotherapy groups, or medication management.
75868172|NCT03161236|Other|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
75868173|NCT03161236|Other|non exercise program|continue usual lifestyle
75868174|NCT03673436|Procedure|Lumbar spinal fusion|The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
75868175|NCT03114514|Biological|PRP|PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
75868176|NCT03673358|Behavioral|Cognitive Behavioural Therapy|"Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT"
75868177|NCT03114358|Other|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
75868178|NCT03669692|Behavioral|Caloric Restriction|Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
75868179|NCT03669692|Behavioral|Control|Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
75868180|NCT03051464|Procedure|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
75868181|NCT03051464|Radiation|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
75381207|NCT05566184|Device|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure, and the data will be collected. In the application of vascular access to children, a) before the procedure (20 minutes before), b) just before the procedure (20. minutes), c) during the procedure (between 20.-40. minutes), and d) 20 minutes after the procedure (40. minutes). Physiological variables that will be evaluated four times, once for each application, will be observed on the monitor, the FLACC Pain Assessment Scale will be recorded by the researcher and salivary cortisol level will be measured.
75381208|NCT01194427|Drug|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
75381209|NCT05749250|Device|Acoustic cavitation of ultrasound enhancing agents|Cavitation therapy
75381210|NCT05599555|Biological|mRNA BNT162b2 vaccine|mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)
75381211|NCT05599555|Biological|CoronaVac vaccine|Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)
75381212|NCT00002738|Drug|leucovorin calcium|
75381213|NCT00002738|Drug|trimetrexate glucuronate|
75868182|NCT03051464|Radiation|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
75868183|NCT03161002|Genetic|detection of genotype|detection of genotype by next generation sequencing
75868184|NCT03669848|Other|Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
75868185|NCT02664870|Procedure|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
75868186|NCT02664870|Procedure|Arthroplasty|Total hip, shoulder, or knee arthroplasty
75868187|NCT05746312|Behavioral|healing attempt|The intervention consists of pre-composed and pre-recorded guided meditations, songs, and poems that total 25 minutes in duration. The elements of the intervention were set to background music tracks that were informed by Black diasporic music traditions and anxiety reduction principles from the music therapy literature.
75868188|NCT03673280|Procedure|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
75868189|NCT04612062|Drug|CEE321|CEE321 administered to all subjects
75868190|NCT03167788|Device|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
75868191|NCT03167788|Other|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood & Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
75868192|NCT03673202|Diagnostic Test|Cx bladder Monitor test|Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
75381214|NCT04706455|Device|sodium hyaluronate 0.1%|Instillation of one drop sodium hyaluronate 0.1%
75381215|NCT04706455|Device|sodium hyaluronate 0.3%|Instillation of one drop sodium hyaluronate 0.3%
75381216|NCT00002744|Drug|asparaginase|
75381217|NCT00002744|Drug|cyclophosphamide|
75381218|NCT00002744|Drug|cytarabine|
75381219|NCT00002744|Drug|daunorubicin hydrochloride|
75381220|NCT00002744|Drug|dexamethasone|
75381221|NCT00002744|Drug|doxorubicin hydrochloride|
75381222|NCT00002744|Drug|mercaptopurine|
75381223|NCT00002744|Drug|methotrexate|
75381224|NCT00002744|Drug|pegaspargase|
75381225|NCT00002744|Drug|prednisone|
75381226|NCT00002744|Drug|therapeutic hydrocortisone|
75381227|NCT00002744|Drug|thioguanine|
75381228|NCT00002744|Drug|vincristine sulfate|
75381229|NCT00002744|Radiation|low-LET cobalt-60 gamma ray therapy|
75381230|NCT00002744|Radiation|low-LET photon therapy|
75381231|NCT01788475|Drug|Dexamethasone|Ozurdex (dexamethasone) 0.7mg steroid implant
75381232|NCT01183897|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
75381233|NCT00381914|Drug|Vitamin D|400 IU vitamin D / day
75868193|NCT01383642|Other|No intervention, observational study|
75868194|NCT03167944|Device|Low thermal electrosurgery system|PEAK Plasmablade
76031044|NCT02890459|Behavioral|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
76031045|NCT03077009|Drug|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
76031046|NCT02333773|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
75381234|NCT00381914|Drug|Vitamin D|800 IU vitamin D / day
75381235|NCT00381914|Drug|Vitamin D|1200 IU vitamin D / day
75381236|NCT00423007|Drug|Bromfenac|
75381237|NCT00423007|Drug|Placebo|
75381238|NCT00002750|Drug|melphalan|
76031047|NCT05011175|Other|Survey|Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
76031048|NCT02331979|Device|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
76031049|NCT03079817|Other|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
76031050|NCT03079817|Other|Proprioceptive Drills|Active balance and proprioception drills
75381239|NCT00002756|Biological|filgrastim|
75381240|NCT00002756|Drug|asparaginase|
75381241|NCT00002756|Drug|cyclophosphamide|
75381242|NCT00002756|Drug|cytarabine|
75381243|NCT00002756|Drug|daunorubicin hydrochloride|
75868195|NCT03167944|Device|Conventional Electrocautery|Conventional Electrocautery
75381244|NCT00002756|Drug|etoposide|
75381245|NCT00002756|Drug|leucovorin calcium|
75381246|NCT00002756|Drug|mercaptopurine|
75381247|NCT00002756|Drug|methotrexate|
75381248|NCT00002756|Drug|prednisone|
75381249|NCT00002756|Drug|therapeutic hydrocortisone|
75381250|NCT00002756|Drug|vincristine sulfate|
75381251|NCT05599477|Device|Endoscopic sutured gastroplasty with endomina|"The endomina is is used to perform endoscopic sutured gastroplasty. Two guidewires are introduced via an upper GI endoscopy down to the duodenum. The endomina system is introduced and the endoscope is inserted and fixed to the system. Next a needle preloaded with suture is introduced into the platform. The stomach wall is grasped with a forceps and pulled back. The needle is pushed through the wall, and a first tag is released. The needle is retracted, the first plicature is released and a second plicature is made with the same needle at the opposite wall. Then the pretied knot is grasped and tightened until both plicatures are firmly apposed. The same procedure is repeated along the great curvature from the incisura to the upper body.~The procedure will include the placement of 6-9 sutures. The first suture is done at the level of the incisura, at the lower part of the greater curvature. The following stitches are placed along the body of the stomach"
75381252|NCT01183429|Drug|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. *High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
75381253|NCT01157533|Drug|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
75381254|NCT01760941|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
75868196|NCT03036254|Device|HBOT intervention|"HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2"
75381255|NCT01760941|Other|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
75381256|NCT01760941|Other|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
75381257|NCT05556668|Device|Percutaneous placement of biodegradable biliary stents|Benign biliary strictures treated with polydioxanone (PPDX) stents (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography. Before stent implantation, balloon bilioplasty is be performed.
75381258|NCT05749016|Drug|inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen|Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. There was no robust evidence evaluating the combination of inetetamab with pertuzumab and neoadjuvant chemotherapy (paclitaxel + carboplatin) in the neoadjuvant setting. This study aimed to evaluate the efficacy and safety of inetetamab + pertuzumab+paclitaxel + carboplatin (TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally advanced HER2-positive breast cancer.
75381259|NCT01756573|Drug|Dexamthsone|
75868197|NCT03036254|Device|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
75381260|NCT01756573|Drug|Bupivacaine|
75381261|NCT00382304|Drug|tolevamer potassium-sodium (GT267-004)|
75381262|NCT01126801|Drug|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
75381263|NCT01126801|Other|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
75381264|NCT00002762|Behavioral|patient interviewing to obtain menstrual history|
75381265|NCT00002762|Procedure|blood sampling|
75541139|NCT04560946|Behavioral|Enhanced Treatment As Usual|"Enhanced Treatment As Usual (ETAU) group. Intervention: Behavioral: The ETAU condition was designed to replicate treatment as usual following neuropsychological assessment of post-TBI cognitive problems. Treatment as usual for mTBI patients at the VA hospital usually consists of: 1) A general evaluation by the polytrauma clinic, 2) Possible neuropsychological assessment evaluation by the TBI Cognitive Rehabilitation Clinic, and 3) If impairments are present, cognitive rehabilitation is offered. The current study's condition is considered enhanced treatment as usual because standard of care for chronic mTBI does not always involve neuropsychological assessment with feedback and psychoeducation or the provision of self-directed tools such as the CogSMART app or BrainHQ cognitive training software."
75541140|NCT04561024|Diagnostic Test|AI model|Deep Learning CNN model
75541141|NCT04561336|Drug|Avelumab|avelumab in combination with cetuximab
75541142|NCT04561336|Drug|Cetuximab|avelumab in combination with cetuximab
75541143|NCT00259428|Drug|Dronedarone (SR33589)|oral administration
75704669|NCT05195866|Diagnostic Test|CRP POCT (C-reactive protein point of care test)|"CRP POCT equipment will be supplied at healthcare centers, along with a short training in use and interpretation supporting the clinical evaluation of the child. It will be communicated that CRP levels less than 10 indicate that the disease is not severe, and antibiotics is most likely not needed, if between 10 and 50, that antibiotics might be needed, and if more than 50 that it is likely that they are needed. With CRP between 10-50 the HCW are instructed to take the clinical picture into account together with the value of the test.~The training will also include knowledge of CRP pharmacodynamics and cases where a low CRP might need to be interpreted cautiously, e.g. a history of fever lasting less than 24 hrs. HCWs will be instructed to use CRP POCT for all patients in the intervention group and use the information to guide diagnosis and treatment choice. We will use Aidian (Copenhagen, Denmark) QuickRead go CRP POCT set-up."
75868198|NCT03631212|Behavioral|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
75541144|NCT00259428|Drug|placebo|oral administration
75868199|NCT03162874|Drug|Placebo oral capsule|BID
75868200|NCT03162874|Drug|PXT002331 - dose 1|Oral
75868201|NCT03162874|Drug|PXT002331 - dose 2|Oral
75868202|NCT03672890|Other|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening & evaluation, and stroke education in patients admitted with stroke.
75868203|NCT05420220|Biological|KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)|5 mg/kg Q3W IV
75868204|NCT05420220|Combination Product|Axitinib|5mg bid po
76023069|NCT05049317|Procedure|Laparoscopic FTME surgery|Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
76023070|NCT02400151|Drug|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
75381266|NCT01727167|Drug|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
75381267|NCT01727167|Other|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
75381268|NCT05748938|Biological|RD14-01|ROR1 Targeted CAR-T cells
75381269|NCT01702909|Drug|Interleukin-2|Interleukin-2
75381270|NCT00002768|Biological|filgrastim|10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
75381271|NCT00002768|Drug|busulfan|1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
75381272|NCT00002768|Drug|cytarabine|2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
75381273|NCT00002768|Drug|etoposide|40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
75541145|NCT04560907|Procedure|Aquablation|"By means of a high-pressure saline stream, parenchymal tissue of the prostate is removed endoscopically through a heat-free mechanism called hydrodissection. The intervention is supported by live ultrasound guidance and the required depth as well as the angle of the resection is planned out prior to the resection. The bladder is accessed using a 24-Fr hand-piece, which accommodates the scope. The handpiece is supported by an articulating arm attached to the operation table. Once placed in the optimal position, the system automatically adjusts the alignment as necessary.~Hemostasis is consecutively achieved through diathermy and post procedure, a threeway catheter is inserted and bladder irrigation is initiated."
75541146|NCT04560907|Procedure|HoLEP|This is done endoscopically under general anesthesia the three lobes of the prostate that are cored out intact with the laser are pushed into the bladder before being morcellated by a special instrument inserted through the telescopic camera. A catheter is placed into the bladder to drain the urine while the raw surface heals, then left in place for around 24 hours before being removed on the day of discharge from hospital. Sterile saline fluid is also irrigated into the bladder through the catheter to dilute any blood in the urine and prevent clots from forming.
75541147|NCT00231647|Drug|topiramate|
75541148|NCT02211898|Drug|BNS003|
75541149|NCT04560751|Drug|Lenvatinib|Lenvatinib capsules will be administered orally, once daily (for patients <60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)
75541150|NCT04560751|Procedure|TACE|TACE will be performed as needed.
75541151|NCT00259467|Behavioral|Home-Based Behavorial Intervention|
75541152|NCT00231686|Behavioral|Supervised aerobic training|
76031051|NCT04477525|Procedure|Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block|The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score >5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
75381274|NCT00002768|Drug|methotrexate|For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
75381275|NCT00002768|Procedure|peripheral blood stem cell transplantation|Infusion on Day 0
75541153|NCT00231686|Behavioral|Supervised strength training|
75541154|NCT00231686|Behavioral|Unsupervised training|
75541155|NCT04560478|Device|Pro Seal Sealant|Sealant was reapplied every 3 months
75541156|NCT04560478|Device|MI Varnish|Fluoride varnish was applied every 4-6 weeks
75541157|NCT04560244|Drug|SHR1701|PD-L1 / TGF-β RII double antibody
75541158|NCT04559854|Behavioral|Mindful After Cancer|The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.
75541159|NCT00266643|Drug|duloxetine hydrochloride|
75381276|NCT00002774|Drug|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
75381277|NCT00002774|Drug|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
76031052|NCT04477525|Drug|Bupivacaine Injection|20 cc of 0.25% bupivacaine will be injected
75541160|NCT00231725|Drug|insulin lispro injection [rDNA origin] Low Mix|
76031053|NCT03079973|Drug|P-3073 (calcipotriene 0.005%)|Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
76031054|NCT03079973|Drug|Vehicle of P-3073|Once daily for 24 weeks.
76031055|NCT03076853|Other|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
76031056|NCT05004545|Drug|Propofol|Propofol infusion according to body weight will be compared with sevoflurane acording to MAC % to see the lactate level and hemodynamic parameters of CABG patients
76031057|NCT03079895|Behavioral|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
75381278|NCT00002774|Drug|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
75541161|NCT04560205|Drug|Tocilizumab|"4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation."
75704670|NCT05192226|Behavioral|Counterfactual Strategy|Participants in this intervention condition will think about their past and identify how a less than desirable physical activity event could have turned out better using counterfactual thinking (i.e., If only I... then....). After identifying actions they could have taken to reach a better outcome in their physical activity event, they will then apply those thoughts to the future upcoming week so they can be realized.
75704671|NCT05191485|Other|Qualitative interviews|We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.
75704672|NCT05187195|Other|Home-based telerehabilitation with exercise videos|Balance, walking, strengthening, posture videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
75704673|NCT05187195|Other|Exercise brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening, posture etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
75704674|NCT05177770|Drug|SRF617|SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.
75704675|NCT05177770|Drug|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
75704676|NCT05177770|Drug|zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
75541162|NCT04559971|Drug|SLN124|SLN124 for subcutaneous (s.c.) injection
75541163|NCT04559971|Drug|Placebo|Sodium chloride for s.c. injection
75704677|NCT05175313|Radiation|transthoracic ultrasonography|"lung ultrasonography~Diaphragm and respiratory muscle ultrasound~inferior vena cava ultrasound"
75541164|NCT04560049|Drug|Silver Nitrate|application of silver nitrate to sinus tract
75541165|NCT04560049|Drug|Phenol|phenolisation of sinus tract
75704678|NCT05175313|Device|spirometry|pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.
76031058|NCT02337595|Biological|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
75541166|NCT04559425|Drug|Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
75541167|NCT04559425|Other|No Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
75541168|NCT00231764|Drug|daclizumab|
75541169|NCT00259506|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|
75704679|NCT05175053|Other|Renal replacement therapy|Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
75704680|NCT05175053|Other|Best medical management|The best medical management continues until the patient meets absolute indication of renal replacement therapy
75704681|NCT05150626|Drug|DBPR108 tablets|Drug: DBPR108, tablets, oral
75704682|NCT05149625|Device|Dexcom G6|continuous glucose monitoring device
75704683|NCT05144737|Behavioral|The Diabetes Prevention Program|The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
75704684|NCT05138250|Drug|Mepolizumab 100 MG|participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks
75704685|NCT05128409|Drug|XKH001 Injection|0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
75704686|NCT05128409|Drug|XKH001Placebo Injection|1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
75704687|NCT05126927|Biological|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
75541170|NCT04559503|Other|Progressive relaxation exercises|Progressive relaxation exercises are those involving the voluntary, regular and consecutive relaxation of the muscles until there is relaxation all over the body. PMR are consisted of taking a deep breath and then tensing and relaxing muscles in both hands and arms, shoulders, chest, abdomen, hips, legs, feet, and face regions. The training was given in line with the CD that was prepared by the Turkish Psychologists Association as three-part relaxation exercises. The first part of the CD contains the definition, purpose and applications to consider when doing the exercises and a definition of 10-minute deep relaxation. In the second 30-minute section, relaxation exercises are explained accompanied by the sound of streams and oral instructions. The last section, which consists of 30 minutes, contains only relaxation music without instructions.
75541171|NCT04559776|Other|gait analysis|gait analysis with 3D optoelectronic system and surface EMG
75541172|NCT04559308|Drug|Metformin|first-line anti-diabetic drug
75541173|NCT04559308|Drug|Chemotherapy|First line neoadjuvant chemotherapy protocol
75541174|NCT00266682|Device|Pacing Lead|
75541175|NCT04559191|Device|continuous glucose monitoring (CGM)|CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States)
75541176|NCT00231803|Other|Combined CKD and CVD Prevention|Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone
75541177|NCT00231803|Other|Cardiovascular Disease prevention|Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel
76023071|NCT02400151|Drug|Placebo|Patients randomized to this group will receive placebo for 90 days.
76031059|NCT05003999|Device|HPC - SpeediCath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter
75541178|NCT00231803|Other|Treatment of Chronic Kidney Disease complications|Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate
76031060|NCT05003999|Device|Non-HPC - Self-Cath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
75541179|NCT00231803|Other|Usual care|No prescribed intervention, just those that the patient's own family physician thought indicated
75541180|NCT04559113|Drug|Methylprednisolone Injectable Product|"0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day."
75541181|NCT02211937|Drug|BI 44847 solution, low dose|
75541182|NCT02211937|Drug|BI 44847 suspension, high dose|
75541183|NCT02211937|Drug|BI 44847 tablet, low dose|
75541184|NCT02211937|Drug|BI 44847 tablet, high dose|
75541185|NCT02211937|Other|high fat breakfast|
75541186|NCT00266721|Drug|Pancrelipase (Creon) 2 tablets with each meal|
75541187|NCT04559269|Other|No intervention|patients have benefited from maintenance wakefulness tests as part of their clinical evaluation
75541188|NCT04559074|Drug|Amlodipine|Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
75541189|NCT04559152|Dietary Supplement|Zinc Supplementation Group|Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
75541190|NCT04559152|Dietary Supplement|Placebo Group|Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
75541191|NCT00231920|Biological|Fluzone|
75541192|NCT00259545|Drug|Retarded Release Phosphatidylcholine (rPC)|
75541193|NCT02211976|Drug|Bisacodyl|
75541194|NCT02211976|Drug|Simeticone|
75541195|NCT04558606|Device|Sonic Toothbrush|Sonic Toothbrush (Philips Sonicare Flexcare Platinum Toothbrush®)
75541196|NCT04558606|Device|Manual Toothbrush|Manual brushing (Technique Pro - GUM® Sunstar Italiana SRL)
75541197|NCT04558645|Other|Online Survey|Online surveys will be applied to all participants
75541198|NCT04558684|Drug|Chemotherapy|CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
75541199|NCT04558684|Drug|Immunotherapy|Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
75541200|NCT04558684|Radiation|IMRT|Radiotherapy (5 Gy x 5 fractions)
75541201|NCT00231959|Drug|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
75541202|NCT00231959|Drug|Placebo|sugar pill
75541203|NCT02278393|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
75541204|NCT02278393|Other|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
75541205|NCT00259584|Behavioral|Management and Outcome of SVCO|
75541206|NCT04558411|Behavioral|Dialectical Behavioral Therapy (DBT) Skills|14 brief videos that teach DBT skills.
75541207|NCT00231998|Drug|Pimecrolimus|Pimecrolimus cream 1 %
75541208|NCT04558333|Other|blood and exhaled breath specimens|identification of possible biomarkers
75541209|NCT02212054|Behavioral|conservative|anal dilatation; colonic lavage; oral probiotic
75541210|NCT02212054|Procedure|operative|one stage pull through radical colectomy
75541211|NCT00266838|Drug|Maxidex; Lacrystat|6 times daily, for 20 weeks.
75541212|NCT00232037|Drug|Tegaserod|
75541213|NCT02212132|Other|behavioral assessments|Neuropsychological evaluation, psychopathological assessment and fatigue
75704688|NCT05126524|Other|NO INTERVENTION|Observational study, no intervention performed
75704689|NCT05121454|Device|Serenno Sentinel, model Alpha 2.0, software version: 8.0|intra-abdominal pressure measurements compared to a Foley Manometer at different insufflation pressures between 5 and 25 cmH20 at 30seconds intervals.
75704690|NCT05118568|Device|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
75704691|NCT05117034|Drug|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
75704692|NCT05117034|Drug|Nacl 0.9%|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
75541214|NCT02212171|Other|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~Administrative staff:~Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~Nursing staff:~They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
75541215|NCT02212210|Drug|Methylprednisolone|
75704693|NCT05110105|Behavioral|Interactive board game health education|The interactive board game includes risk factors, symptoms, and acute management of stroke. It's a card game combined with (1) addition and subtraction game (risk factors). (2) gestures game (symptoms) (3) matching game (acute management), but in traditional Chinese. The game was implemented in a group (2~6 individuals) for 40 minutes.
75704694|NCT05110105|Behavioral|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the stroke prevention video was collected from the internet. Participants were assigned to read the health education flier for 20 minutes. Then watch the stroke prevention video for 20 minutes.
75704695|NCT05109078|Drug|[14C]- Rongliflozin|Patients will receive single dose of orally [14C]- Rongliflozin on Day 1
75704696|NCT05108766|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
75704697|NCT05108766|Drug|Placebo|Matching placebo to tildrakizumab administered SC
75704698|NCT05106777|Drug|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle.
75704699|NCT05096208|Biological|RSVpreF (Group 1)|RSV vaccine (RSVpreF)
75541216|NCT02212210|Drug|Normal saline|
75541217|NCT00232076|Drug|ciclosporin|
75541218|NCT04558099|Behavioral|MBSR|Described previously
75541219|NCT04558255|Diagnostic Test|A machine-learning method which can robustly discriminate early-stage lung cancer patients from controls|In our study, we intend to integrate molecular features obtained through liquid biopsy and clinical data of lung cancer patients, and develop and prospectively validate a machine-learning method which can robustly discriminate early-stage lung cancer patients from controls.
75704700|NCT05096208|Biological|RSVpreF (Group 2)|RSV vaccine (RSVpreF)
75704701|NCT05096208|Biological|RSVpreF (Group 3)|RSV vaccine (RSVpreF)
75704702|NCT05096208|Biological|Placebo|Placebo
76031061|NCT02337439|Behavioral|Sensory Information Processing Training|Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
76031062|NCT02337439|Behavioral|Active Control Training|Commercially available educational software
76031063|NCT05003765|Drug|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
75381279|NCT00002774|Radiation|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
75381280|NCT05599165|Other|Different signal processing for consonant recognition|Consonant recognition will be measured in noise with three different signal processing conditions: control (no signal processing), important frequency regions enhanced by signal processing, and combined conditions of important frequency regions enhanced and confused frequency regions removed by signal processing.
75541220|NCT00259623|Device|Radiofrequency ablation|
75541221|NCT04558060|Other|Virtual Standardized Patient|Computer program that presented a virtual human patient
75541222|NCT04558060|Other|Academic Study|Study of a summary of motivational interviewing concepts and techniques.
75381281|NCT00002780|Biological|aldesleukin|
75381282|NCT00002780|Biological|cytokine therapy|
75381283|NCT00002780|Biological|sargramostim|
75381284|NCT00002780|Drug|carboplatin|
75381285|NCT00002780|Drug|cyclophosphamide|
75381286|NCT00002780|Drug|thiotepa|
75381287|NCT00002780|Procedure|peripheral blood stem cell transplantation|
75381288|NCT01692691|Drug|Dacarbazine|Dacarbazine IV - Day 1
75381289|NCT01692691|Drug|Carmustine|Carmustine IV- Day 2
75381290|NCT01692691|Drug|Neulasta|Neulasta SC - Day 3
75381291|NCT01127503|Drug|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day [2000 mg/day if metyrosine]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
75381292|NCT01127503|Drug|Placebo|Placebo capsules were identically matched to Metyrosine.
75381293|NCT01122511|Drug|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
75381294|NCT01122511|Biological|ranibizumab|Intravitreal injection of ranibizumab into study eye
75381295|NCT01122511|Other|sham|Sham needle-less injection administered in the study eye
75381296|NCT05535218|Drug|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|"Neoadjuvant treatment: 10 mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant)."
75381297|NCT05531708|Biological|Anti-mesothelin CAR-T cells|D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
75541223|NCT00232115|Drug|Pimecrolimus|Pimecrolimus cream 1 %
75541224|NCT00232115|Drug|Placebo|Vehicle cream (placebo)
75541225|NCT02212249|Biological|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
75541226|NCT04558372|Other|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
76031064|NCT05003765|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
75541227|NCT04558372|Other|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
75541228|NCT04558372|Other|exhaled breath sampling|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
76031065|NCT05003765|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
75381298|NCT05531708|Drug|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m^2/day) will be administered intravenously for 5 days.
75381299|NCT05531708|Drug|Cyclophosphamide|D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
75381300|NCT01663285|Drug|Neoadjuvant Cisplatin and Gemcitabine|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
75381301|NCT00002786|Biological|aldesleukin|
75541229|NCT04558021|Drug|Niclosamide suspension|200mg/10ml
75541230|NCT04558021|Other|Placebo|10ml placebo(absent of niclosamide)
75541231|NCT00232154|Drug|Zithromax&#153; (azithromycin) 500mg tablets|
75541232|NCT00232154|Procedure|Endoscopic Sinus Surgery|
75541233|NCT00232154|Procedure|Blood sampling for hematology|
75541234|NCT00232154|Procedure|Blood sampling for plasma chemistry profile|
75541235|NCT00232154|Procedure|Serum pregnancy test (for women of child-bearing potential)|
75541236|NCT02212288|Other|Blood sample|Blood samples are for metabolic and genetic and biological investigation
76031066|NCT05010863|Other|Blood collection|The subject will be drawn a 5ml blood sample
75381302|NCT00002786|Biological|therapeutic tumor infiltrating lymphocytes|
75381303|NCT00378937|Drug|acetaminophen|
75381304|NCT00378937|Drug|codeine phosphate|
75381305|NCT00378937|Drug|dextropropoxyphene hydrochloride|
75381306|NCT00378937|Drug|morphine sulfate|
75381307|NCT00378937|Drug|oxycodone hydrochloride|
75381308|NCT00378937|Procedure|management of therapy complications|
75381309|NCT00378937|Procedure|quality-of-life assessment|
75381310|NCT00002792|Drug|busulfan|
75381311|NCT00002792|Drug|cyclophosphamide|
75381312|NCT00002792|Drug|cyclosporine|
75381313|NCT00002792|Drug|methotrexate|
75381314|NCT00002792|Drug|tacrolimus|
75381315|NCT00002792|Procedure|allogeneic bone marrow transplantation|
75381316|NCT00002792|Procedure|peripheral blood stem cell transplantation|
75381317|NCT01673425|Drug|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
75381318|NCT05599087|Biological|Acellular system|Regenerative Endodontic Procedure Tissue engineering procedure
75704703|NCT05093920|Drug|Doxorubicin-Eluting Beads|"The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter."
75704704|NCT05089318|Dietary Supplement|Flexofytol PLUS|2 tablets in the morning and in the evening for minimum 6 weeks.
75381319|NCT05748704|Other|Short-term modified fasting|STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
75381320|NCT05598307|Drug|magnesium bolus followed by normal saline infusion|a bolus dose of magnesium will be followed by normal saline infusion
75381321|NCT05598307|Drug|magnesium bolus followed by magnesium infusion|a bolus dose of magnesium will be followed by a magnesium infusion
75381322|NCT05598307|Drug|normal saline bolus followed by normal saline infusion|a bolus of normal saline will be followed by normal saline infusion
75381323|NCT05747612|Other|Counseling and Coaching|"Counseling is the art of helping yourself, that is, a helping relationship based on a series of interventions and stimuli for creativity, aimed at pursuing and maintaining an ever better relational, social and existential quality of life. Coaching is a fundamentally action-oriented method, aimed at concrete changes, the improvement of performance and the achievement of objectives."
75381324|NCT01090141|Drug|Micafungin|100 mg IV infusion over 1 hour
75381325|NCT01090141|Drug|Micafungin|300 mg IV infusion over 1 hour
75381326|NCT05597293|Device|Glucose monitoring using FreeStyle Libre 2|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre 2
75381327|NCT05597293|Device|Glucose monitoring using FreeStyle Libre pro iQ|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre pro iQ
75704705|NCT05088863|Other|flaxseed|40g of flaxseed per day
75704706|NCT05077982|Diagnostic Test|Spirometry|Spirometry to assess lung function
75704707|NCT05077982|Diagnostic Test|6-minute walk|Exercise tolerance
76031067|NCT05003375|Behavioral|High-challenging cognitive protocol to provoke stress and (cognitive) fatigue|"Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes).~This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT*-NBacktask**, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2.~During all these measurements, the participant will sit at a table with a computer on which the tests are performed.~*SDMT: Symbol Digit Modalities Test: see description in outcome measures~**N-Back Task: see description in outcome measures"
75381328|NCT05597059|Diagnostic Test|Machine Learning Prediction|Machine Learning Prediction
75541237|NCT02212288|Other|Urine sample|Urine sample for biological investigation
75541238|NCT04557826|Device|RD19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens
75868205|NCT03022370|Behavioral|Stepping Stones and Creating Futures|"Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending."
75868206|NCT03631758|Other|Evidence-based information|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
75381329|NCT01048723|Drug|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
75868207|NCT03631758|Behavioral|Patient Decision Aid|Patient Decision Aid for breast cancer screening decision
75868208|NCT03631758|Other|Sham information|Educational information not specific to mammography or cancer screening
75381330|NCT05513612|Biological|Autologous CAR-T cells|CAR-T cells will be infused intravenously.
75381331|NCT05513612|Drug|Fludarabine|Administered according to package insert
75868209|NCT02642562|Drug|Ferric Derisomaltose|
75868210|NCT03623204|Other|Dyspnea evaluation|
75381332|NCT05513612|Drug|Cyclophosphamide|Administered according to package insert
75381333|NCT05596045|Drug|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
75381334|NCT05596045|Drug|Placebo|Participants will be randomized to receive placebo
75381335|NCT05594407|Drug|dexmedetomidine-ketamine-lidocaine|In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
75541239|NCT00259662|Drug|atorvastatin|
75381336|NCT05594407|Drug|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
75868211|NCT04601610|Drug|KN046 （PD-L1/CTLA4 BsAb）|KN046 5mg/kg Q3W
75381337|NCT05747456|Device|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
75381338|NCT05747456|Device|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
75541240|NCT04557982|Procedure|A painful procedure (peripheral venepuncture)|The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
75868212|NCT04601610|Drug|Ningetinib Tosylate（multi-target TKI）|ningtinib QD, dose will be decided by investigator
75868213|NCT02490306|Device|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
75868214|NCT03668912|Behavioral|Guided participation discharge programme|A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
75381339|NCT00379717|Drug|Cisplatinum|
75381340|NCT00379717|Drug|Docetaxel|
75381341|NCT00379717|Device|Tomotherapy|
75381342|NCT04706377|Dietary Supplement|B12 fix 1000mcg|oral dispersible tablet with vitamin B12 1000mcg
75381343|NCT04706377|Other|Placebo|Placebo tablet
75381344|NCT04706299|Other|Resistance Exercise|Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.
75381345|NCT04450004|Biological|Intramuscular Vaccine|Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
75868215|NCT01382004|Drug|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
75381346|NCT01583647|Drug|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
75381347|NCT01583647|Drug|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
75381348|NCT05745428|Other|molecular and cellular analyses|sample blood
75381349|NCT04403516|Drug|Dexamethasone Intracanalicular Insert, 0.4mg|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.
75381350|NCT04403516|Drug|Prednisolone Acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
75381351|NCT01555489|Drug|Ascorbic Acid|3x per week
75381352|NCT01035073|Drug|Duloxetine|30-60 mg daily for 8 weeks
75704708|NCT05069727|Procedure|Regular Protocol with advanced carbohydrate counting|"Review 3 Days CGM data in Manual Mode~Carb Ratio by formula 360 / TDD~Finetune ICR~Target 100 or 110 mg/dl~AIT: 2-3 hour~Insulin Bolus for meal (advanced carb counting)~The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use)."
75381353|NCT05236868|Drug|Seltorexant|Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
75381354|NCT01561495|Radiation|Proton Therapy|
75381355|NCT04330976|Behavioral|Nutrition and physical activity intervention|Messages sent on nutrition and physical activity in pregnancy
75381356|NCT04330976|Behavioral|Control|Messages sent on general health during pregnancy
75381357|NCT04331743|Drug|Liposome-entrapped Mitoxantrone Hydrochloride Injection|Intravenous infusion
75381358|NCT05296759|Drug|botulinum toxin A|botulinum toxin A injection
75381359|NCT05296759|Drug|Gabapentin|Gabapentin oral intake
75381360|NCT05296759|Drug|Duloxetine|Duloxetine oral drug intake
75381361|NCT05546047|Drug|Acthar Gel 80 UNT/ML Injectable Solution|Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
75381362|NCT05743556|Device|HILT laserotherapy|application of high intensive laser therapy on cervical muscles
75381363|NCT05743556|Device|TRT therapy|application of radiofrekvention therapy on cervical muscles
75381364|NCT05234762|Drug|ES-481|Dose escalation during two Treatment Periods
75381365|NCT05234762|Other|Placebo|Placebo dosed at same dosing as ES-481
75381366|NCT01532635|Radiation|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
75381367|NCT01532635|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
75381368|NCT01532635|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
75381369|NCT01532635|Drug|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
75381370|NCT01532635|Drug|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
75381371|NCT01532635|Biological|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
75381372|NCT01085773|Behavioral|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
75381373|NCT01085773|Behavioral|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
75381374|NCT05295511|Other|Recreational Team Handball programme|All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
75381375|NCT00986947|Drug|IVIg and rituximab|"A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA)."
75381376|NCT00559897|Other|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
75381377|NCT00559897|Procedure|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
75381378|NCT00979147|Procedure|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
75381379|NCT00979147|Procedure|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
75381380|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
75381381|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
75381382|NCT00539617|Drug|Erlotinib|Tarceva single agent therapy: 150 mg/day PO
75381383|NCT00539617|Drug|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
75381384|NCT00539617|Drug|Leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
75541241|NCT04557943|Drug|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
75381385|NCT00539617|Drug|Oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
75541242|NCT04557943|Drug|Sodium Hyaluronate|Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
75381386|NCT05182580|Diagnostic Test|Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema|If patients receive a negative result they do not see the retina specialist
75381387|NCT05467514|Drug|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
75381388|NCT00976339|Drug|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
75381389|NCT05456828|Biological|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
75381390|NCT04579640|Dietary Supplement|Vitamin D|Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol
75381391|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
75541243|NCT04709133|Procedure|multi-ligament knee surgery|a chart review will be performed to identify patients who underwent surgical treatment for multi-ligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
76031068|NCT05010239|Other|30-minute Mindfulness-Based Supportive Therapy|The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing.
75541244|NCT00232232|Drug|Fish oil|
75541245|NCT04557904|Other|Craniocervical flexion exercises|Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible. Subject has to slightly raise his/he skull a few centimeters. Fingers should be touching the cranium but not supporting it. Subject had to respire and hold the position. Subject has the move out the chin. Stop exercise and restart again. Perform this exercise for 10 times by holding this position for 20 sec at the start of the exercise, increasing it by 10 seconds every session commonly underwent pectoralis minor stretching before every session of exercise of 4 sets with 30 second's hold
75541246|NCT04557904|Other|Scapular stabilization exercises|The scapular stabilization exercises were made up of four stages: (1) In supine position, the patient was commanded to deep respire for the sake of relaxation by maintain the cervical and shoulder in relaxing position to take a deep breath to relax the body while holding her shoulders and neck in relaxing position. (2) The patient then flex her knees and placed her feet flat on the plinth, and maintain the pose without any cervical movement. Then the patient asked to raise her dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. This position was sustained for 10 seconds before going to initial position. Three laps of 10 repetitions with one-minute interval in between were performed. (3) In quadruped position, the patient raise her arms alternatively with shoulder abduction and 120 ° flexion. That posture was held for 10 seconds before returning to the starting position. (4) In sitting position
75381392|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
75381393|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
75381394|NCT00517075|Device|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
75381395|NCT04579172|Procedure|Cervico- isthmic compression suture|Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.
76031069|NCT05010239|Other|30-minute supportive listening|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
76031070|NCT03111589|Biological|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
76031071|NCT03111589|Diagnostic Test|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
76031072|NCT05003297|Other|hemogram inflammatory parameters|Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)
76031073|NCT02337283|Drug|BI 425809|Tablets
76031074|NCT02337283|Drug|Placebo|Tablets
75381396|NCT04579172|Procedure|Anterior wall uterine resection:|After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
75381397|NCT00523939|Drug|cytarabine liposome injection|50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
75381398|NCT00382538|Drug|Addition of mifepristone 200 mg 24 hours before induction|
75381399|NCT00954187|Drug|Gabapentin|Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
75381400|NCT00954187|Drug|pregabalin|50 mg PO TID
75381401|NCT04802018|Device|Clinical decision support system based on non-invasive multimodal monitoring|Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
75381402|NCT00947791|Drug|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
75381403|NCT00947791|Drug|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
75381404|NCT05139992|Biological|COVID-19 Vaccine|Vaccination against SARS-CoV-2
75381405|NCT00504985|Behavioral|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
75381406|NCT05136326|Radiation|External-beam radiation|External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
75381407|NCT05136326|Drug|Capecitabine|825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
75381408|NCT05136326|Drug|Temozolomide|75 mg/sqm p.o. 5 days/week for 5 weeks
75381409|NCT05387941|Drug|Dexamethasone Ophthalmic|one drop daily in each eye with retinopathy of prematurity of a predefined stage.
75704709|NCT05069727|Procedure|Simplified Protocol with fixed carbohydrate content|"Review 3 Days CGM data in Manual Mode~Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD >60)~Target 100 mg/dl~AIT: 2 hours~Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits."
75541247|NCT04557475|Drug|Aspirin|Two tablets daily with dinner
76031075|NCT05010395|Behavioral|Letter intervention|Letter intervention
76031076|NCT02331433|Drug|APN1125|APN1125 orally at ascending doses
75381410|NCT00382772|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
75381411|NCT00379015|Biological|trastuzumab|
75381412|NCT00379015|Drug|cyclophosphamide|
75381413|NCT00379015|Drug|docetaxel|
75381414|NCT00379015|Drug|epirubicin hydrochloride|
75381415|NCT00379015|Procedure|conventional surgery|
75381416|NCT00379015|Procedure|neoadjuvant therapy|
75381417|NCT05447000|Behavioral|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring anxiety levels with mindfulness program
75381418|NCT05447000|Behavioral|Deep Relaxation Exercises intervention|Deep Relaxation Exercises intervention: Monitoring anxiety levels with deep Relaxation Exercises intervention
75381419|NCT05447000|Other|No Intervention|No Intervention
75381420|NCT00930787|Device|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
75381421|NCT00930787|Device|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
75381422|NCT00382382|Other|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
75541248|NCT00232271|Drug|Clexane|
75541249|NCT04557397|Drug|Fruquintinib|oral VEGFR inhibitor
75541250|NCT04557397|Drug|Itraconazole|a synthetic triazole antifungal agent
75541251|NCT04557397|Drug|Rifampin|a semisynthetic antibiotic derivative of rifamycin SV
75704710|NCT05064436|Drug|11C-BMS-986196|Specified dose on specified days
76031077|NCT02331433|Drug|Placebo|Matching Placebo
75381423|NCT05438030|Diagnostic Test|Cardiac MRI scan|Undertaken at the radiology department at Hammersmith Hospital. The scan will be performed by the MRI radiographers, under the supervision of a consultant radiologist or cardiologist.
75541252|NCT04557241|Behavioral|Brief informational infographic|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process. Infographics are preferable to narratives or text because they center visuals as part of the storytelling process and facilitate cognitive information processing, knowledge absorption, and enhanced persuasion. The study's infographic design will follow best practices in health communication. The message will be simple and jargon free. Visuals will include individuals (scientists), charts, text, and numbers. Attention will be paid to images, color, frames, representation, and composition (e.g., how the elements in the infographic are organized to show their relationship to each other).
75541253|NCT04557241|Behavioral|Placebo control (non-behavioral infographic)|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (e.g., about cats), but that is developed using the same communication and graphical style."
75541254|NCT04557319|Biological|GNR-038, 25 МЕ/kg|25 МЕ/kg once per study
75541255|NCT04557319|Biological|GNR-038, 50 МЕ/kg|50 МЕ/kg once per study
75381424|NCT05438030|Diagnostic Test|Echocardiogram scan|Undertaken at the Peart Rose research unit, by a British Society of Echocardiography accredited sonographer.
75541256|NCT04557319|Biological|GNR-038, 100 МЕ/kg|100 МЕ/kg once per study
75868216|NCT01382004|Drug|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
76031078|NCT02327221|Drug|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
75868217|NCT03669224|Other|Nano Care Gold|Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
75381425|NCT05352061|Behavioral|CBT for Syndemics and Adherence Factors|Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
75381426|NCT05119088|Other|Return to Sport testbattery|At baseline, approximately 3 weeks before surgery and 6 months after surgery: patients conduct a testbattery consisting of 2 PROMs: the NPI-No and BPII2.0-No together with three physical tests: isokinetic strength tests, hop tests and Y-balance test. For the cross-cultural validation of NPI and BPII2.0 patients also conduct KOOS, IKDC 2000 and Tampa Scale.
75381427|NCT00911053|Drug|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
75381428|NCT00911053|Behavioral|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
75541257|NCT00232310|Drug|CELIVARONE (SSR149744C)|
75541258|NCT04557514|Procedure|platelet rich plasma injection in post burn facial scar|"2 spins>>>~st spin (separate plasma from blood) 2500 for 10 minutes~nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy"
75541259|NCT04557514|Procedure|fat injection in post burn facial scar|Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
75541260|NCT02212366|Device|Active TDCS|Active Stimulation
75541261|NCT02212366|Device|Sham TDCS|Sham Stimulation
75541262|NCT04557202|Drug|Tamsulosin Oral Capsule|To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.
76031079|NCT02327221|Drug|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
76031080|NCT02327065|Device|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
76031081|NCT02327065|Device|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
76031082|NCT02333539|Behavioral|Adherence behaviors and recommendations for improvement.|
76031083|NCT02333539|Behavioral|Adherence behavior that needs improvement is targeted|
75381429|NCT00911053|Behavioral|Light|Subjects will be exposed to light.
75868218|NCT03669224|Other|No intervention|No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
75868219|NCT03669224|Other|Chlorhexidine|2 % chlorhexidine gluconate. This group will be compared with no intervention group.
75381430|NCT04755530|Dietary Supplement|Regular whole milk|400 g/day of regular whole milk
75381431|NCT04755530|Dietary Supplement|Yogurt with live bacteria|400 g/day of yogurt with live bacteria
75381432|NCT04755530|Dietary Supplement|Yogurt with inactivated bacteria|400 g/day of yogurt with inactivated bacteria
75381433|NCT04755530|Dietary Supplement|Acidified whole milk|400 g/day of yogurt with acidified whole milk
75381434|NCT04330508|Other|Depression and Cognitive Tests|Health Related Quality of Life, neurocognitive tests, PHES
75381435|NCT05424926|Other|collection of clinical parameters and blood sample|"A baseline visit, with collection of clinical parameters and blood sample to measure anti-infliximab antibodies and infliximab trough levels.~Follow-up visits at 3 months (in outpatient clinic for clinical evaluation), 6 months and 12 months (in day hospitalization for clinical evaluation and blood sample collection for ADA detection and infliximab trough level measurement)."
75381436|NCT05423912|Behavioral|Couple in Control Intervention|To assess the acceptability, feasibility, and preliminary efficacy in 4 cohorts of 6 MCI dyads each (N-48 individuals) to take part in a trial of the CiC program. Participants engaging in the pilot testing aim of the project will meet in 90-120-minute virtual intervention group meetings over the course of 8-9 consecutive weeks (depending on the program finalization to occur through Objective 1 activities). They will be asked to take part in structured quantitative interviews pre-intervention and then 4 and 8 weeks post-intervention. A purposive convenience subsample of intervention participants will be interviewed virtually over Zoom videoconference for one 30-60 minute discussion on their experiences in and perceptions of the intervention. Interview durations will be based on the participant's verbosity of response, and participants can end the interview at any point or choose to schedule a follow up call to continue the interview later should they become fatigued.
75381437|NCT05097170|Procedure|NIRS during ventricular tachycardia ablation|"NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia."
75381438|NCT05095532|Biological|Bone marrow-derived mesenchymal stem cells|MSC transplantation
75381439|NCT05095532|Other|Placebo|Standard of Care
75381440|NCT04330352|Behavioral|"Mindfulness-based STOP touching your face practice"|1. Remind yourself to STOP. Whatever you are doing in this moment (e.g. touching your month, pinching your nose, rubbing your eyes, resting your chin on your hands), pause for a minute. 2. Take a deep breath. This reconnects you with your body. Pay attention to your breathing and just allow yourself to continue to breathe normally and naturally. 3. Observe what is happening for you in this moment-including thoughts, feelings, and emotions (e.g. feel distracted, anxious or nervous?). What do you notice in your body (e.g. feel itchy or tingling on any part of your face)? You can be aware of anything: posture, sensations, tension in your body, or, once again, your breath. You might notice the sound around you. You might even notice your thoughts or emotions. 4. Proceed with whatever you were doing before you came to a STOP or something that you want to do in the moment (e.g. proceed with touching your face, or stop face-touching and take an alternative behavior).
75381441|NCT04713410|Drug|Prednisolone|Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
75868220|NCT04584528|Other|Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)|"The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:~Genotype~Individual pain plan-preferred analgesic agent, route, dose and dosing interval, last update time~Name and contact information for the SCD provider~If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits."
75868221|NCT03669458|Device|Below the Knee peripheral intervention|Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone
75868222|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients <8 weeks CA.
75868223|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients >=8 weeks CA.
75541263|NCT04557202|Drug|Placebo|Placebo - control group
75541264|NCT00232349|Drug|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
75541265|NCT00259701|Device|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
75381442|NCT04713332|Dietary Supplement|Vitamin E|Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.
75381443|NCT04713332|Dietary Supplement|Hydrogen rich water|Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
75381444|NCT04713332|Dietary Supplement|placebo|Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
75381445|NCT05087186|Behavioral|Guided imagery and FLASH technique|"Five virtual group sessions delivered by psychological therapists;~Sessions 1 and 2: Guided imagery~Sessions 3 and 4: FLASH technique~Session 5: Refresher on guided imagery and FLASH technique"
75541266|NCT02212405|Device|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
75541267|NCT02212405|Other|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
75704711|NCT05064358|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered.
75381446|NCT00476827|Drug|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
75381447|NCT00476827|Drug|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
75381448|NCT00476827|Drug|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
75381449|NCT00476827|Drug|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
76031084|NCT02333617|Other|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point [No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
75381450|NCT00476827|Drug|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
75541268|NCT04556929|Diagnostic Test|Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera|An ultra-high sensitivity camera attached to the side arm of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
75381451|NCT00476827|Drug|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
75381452|NCT05084300|Other|Pain Neuroscience Education|A total of 10 PNE sessions (Neuroscience pain education) will be carried out, two each week in addition medical treatment similar to control group (Usual care). The NPE sessions will be conducted by an experienced NPE certified physical therapist in 35 minute face-to-face group sessions. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
75381453|NCT05084300|Other|Usual care|The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.
75381454|NCT04330898|Device|Biotronik peacemakers, implantable cardioverter-defibrillators and cardiac resynchronizers|Any of these Biotronik cardiac stimulation devices with the Home Monitoring function activated for the remote control of patients
75381455|NCT00901303|Drug|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
75541269|NCT04556929|Diagnostic Test|Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera|In-built camera of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
75381456|NCT05083676|Behavioral|Acceset Intervention|". The intervention comprises of: i) Digital peer support training for youth befrienders to equip them with the knowledge and application of the four active ingredients-Mattering, selfhood, compassion, and mindfulness-to provide effective peer support as they respond to youth seekers' emotional experiences.~ii) Acceset Intervention with features or digital markers of psychological well-being, peer emotional disclosure process and community engagement."
75381457|NCT00459121|Drug|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
75381458|NCT00459121|Drug|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
75381459|NCT00459121|Drug|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
75381460|NCT00459121|Procedure|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
75381461|NCT04696796|Procedure|Mediolateral Episiotomy with BasIQ-4 Surgical Knife|Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.
75381462|NCT04696796|Procedure|Mediolateral Episiotomy with Episiotomy Scissors|Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
75381463|NCT00432445|Radiation|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
75381464|NCT00432445|Procedure|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
75381465|NCT05061680|Device|endoscopic short duration papillary large balloon dilation|During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
75541270|NCT04556929|Diagnostic Test|Biopsies|Following image capture, biopsies (approx 5x5x5mm size) will be taken from regions of the anterior, posterior, lateral and inferior walls of the resection cavity corresponding to the imaged areas.
75704712|NCT05060471|Drug|Toripalimab|Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
75704713|NCT05052879|Drug|Toronto association|Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.
75381467|NCT05347303|Other|Finding-oriented orthopedic manual therapy treatment combined with foam roller|Blind randomized controlled clinical trial, where a total of 87 people, men and women, of legal age, university athletes of collective disciplines will be evaluated. The experimental group will receive foam roller therapy and manual therapy guided by findings (n = 44) for 8 weeks.
75704714|NCT05052879|Drug|Tadalafil|Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.
75704715|NCT05052879|Other|Tadalafil placebo|Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.
75868224|NCT03668834|Procedure|Dermabrasion with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
75381468|NCT05347303|Other|Foam roller treatment|Subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
75381469|NCT05343403|Other|Family Integrated Care|The intervention will consist of FICare, including parental participation in medical rounds (FCR). Parents and healthcare professionals will be educated and supported by the four pillars of FICare: parent education, education of healthcare professionals, psychosocial support and a supportive environment of the neonatal ward.
75381470|NCT04691024|Other|Exercise|Spinal stabilization exercises
75381471|NCT00904423|Drug|Vitamin D|up to 2400 mg; oral tablet
75381472|NCT04689698|Diagnostic Test|Thomayer test|Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
75381473|NCT00904189|Radiation|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
75704716|NCT05052879|Other|Toronto association placebo|Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.
75704717|NCT05049707|Drug|IV magnesium sulfate|15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
75381474|NCT05328895|Other|Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day."
75541271|NCT04566406|Procedure|Laparoscopic adrenalectomy|Preoperative staging in all cases consisted of computed tomography or/and magnetic resonance imaging. Prior to surgery, a routine panel of laboratory tests was carried out. The catecholamines metabolites (metanephrine, normetanephrine, and methoxytyramine) were measured from 24-hour urine collection. All patients were preoperatively treated with phenoxybenzamine or alternative doxazosin.Additionally, beta-blockers in case of coexisting tachycardia were given. In the morning of the operation, preinduction blood pressure was measured. Pneumoperitoneum was achieved by insufflating CO2 gas to an intraperitoneal pressure of 12 mmHg. The operative method in our department was laparoscopic transperitoneal lateral total adrenalectomy. Intraoperatively SBP and diastolic blood pressure (DBP) were measured and recorded every 10 minutes. To treat hypertensive and hypotensive episodes, intravenous doses of urapidil, ephedrine, nitrates, MgSO4, norepinephrine, or ß-blockers were administered.
75541272|NCT00232388|Procedure|Blood draw|
75541273|NCT00267033|Procedure|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
75704718|NCT05049707|Other|Placebo|500 cc normal saline delivered in equivalent rates as the treatment group
75704719|NCT05043805|Drug|Dextromethorphan|add on therapy
75704720|NCT05043805|Other|placebo|add on therapy
75704721|NCT05033483|Dietary Supplement|Ferrous Fumarate|Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose
75704722|NCT05033483|Dietary Supplement|Placebo|Gelatin capsule containing microcrystalline cellulose
75704723|NCT05026047|Other|HPV self-sampling|HPV self-sampling in HIV-positive women
75704724|NCT05013918|Other|Observational study|No intervention
75704725|NCT05008185|Procedure|Regenerative Peripheral Nerve Interface (RPNI) surgery|Surgeons will perform neuroma resection and RPNI creation using a free muscle graft from the brachioradialis muscle harvested through a small separate incision
75704726|NCT05008185|Procedure|Traction Neurectomy|Surgeons will perform neuroma resection and traction neurectomy,
75381475|NCT00399841|Device|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
75381476|NCT00387673|Behavioral|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
75381477|NCT04669808|Drug|STP705|Dry powder for intra-and peri-lesional injection.
75381478|NCT00879619|Drug|sunitinib malate|Given PO
75381479|NCT00879619|Drug|docetaxel|Given IV
75381480|NCT00879619|Drug|prednisone|Given PO
75381481|NCT05040698|Drug|Fostamatinib|Open label Fostamatinib
75381482|NCT00382616|Drug|Phosphatidylserine-Omega3|
75381483|NCT00878605|Drug|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
75381484|NCT00878605|Drug|Placebo|Placebo control
75381485|NCT04529174|Dietary Supplement|CardioLux™HDL|"Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
75381486|NCT04529174|Dietary Supplement|Placebo|"Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
75381487|NCT00353275|Drug|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
75381488|NCT00353275|Drug|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
75381489|NCT00822679|Drug|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
75381490|NCT00822679|Other|Placebo|Subjects are given placebo for 3 consecutive nights
75381491|NCT04652180|Procedure|Esophagectomy|In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.
75381492|NCT05034614|Diagnostic Test|Papette brush collection|Cervical cell brush that gathers collects cervical cells during Pap smear collection
75381493|NCT05034614|Diagnostic Test|Spatula/cytology brush collection|Combination of extended-tip spatula with endocervical brush that collects cervical cells during Pap smear collection
75381494|NCT00323635|Drug|tolterodine|tablet, 4 mg, daily, 1 month
75381495|NCT00314353|Drug|Bevacizumab|"7.5 mg/kg IV Day 1 every 21 days for eight cycles*~*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
75381496|NCT00314353|Drug|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
75381497|NCT00314353|Drug|Capecitabine|"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles*#~*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
75381498|NCT00314353|Drug|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
75381499|NCT04642976|Device|Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters|Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
75381500|NCT00279409|Drug|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
75381501|NCT00279409|Drug|Sugar pill|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
75381502|NCT00253981|Device|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
75381503|NCT05235919|Device|repetitive transcranial magnetic stimulation (rTMS)|30 minutes rTMS session 5 days/week for 3 weeks.
75381504|NCT05235919|Other|Sham stimulation|30 minutes sham stimulation 5 days/week for 3 weeks.
75381505|NCT00804349|Device|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
75381506|NCT00178477|Procedure|MRI with breath-holding|Breath holding for diminished tumor motion.
75381507|NCT00379093|Behavioral|Brief advice|"The intervention will have the following components:~A) At the time of the recruitment visit, all intervention group patients will receive:~A personalized risk report;~An educational booklet titled Healthy Drinking as You Age;~A drinking diary;~Brief advice to reduce their drinking by their physicians;~B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.~Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
75381508|NCT00379171|Behavioral|Cow's milk with fish oil|
75381509|NCT00379171|Behavioral|Cow's milk without fish oil|
75381510|NCT00379171|Behavioral|Formula with fish oil|
75381511|NCT00379171|Behavioral|Formula without fish oil|
75381512|NCT02973373|Device|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
75381513|NCT02973373|Other|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
75381514|NCT00379249|Drug|Rosuvastatin|
75381515|NCT00801931|Drug|Alemtuzumab|Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.
75381516|NCT00801931|Radiation|Total Body Irradiation|
75381517|NCT00801931|Drug|Melphalan|Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
75381518|NCT00801931|Drug|Busulfan|(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
75381519|NCT00801931|Drug|Phenytoin|Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.
75381520|NCT00801931|Drug|Fludarabine|Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
75381521|NCT00801931|Drug|Cyclophosphamide|Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.
75381522|NCT00801931|Drug|Horse Antithymocyte Globulin|Horse Antithymocyte Globulin (ATG [horse]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.
75381523|NCT00801931|Drug|Rabbit Antithymocyte Globulin|Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.
75381524|NCT00801931|Drug|Thiotepa|Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).
75381525|NCT00382850|Procedure|Nissen fundoplication|
75381526|NCT05348642|Dietary Supplement|pasteurized A. muciniphila|pasteurized A. muciniphila - oral daily dose
75381527|NCT05348642|Dietary Supplement|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
75381528|NCT00780481|Drug|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
75381529|NCT04278326|Procedure|Vaginal Biopsy|"Vaginal biopsies~Additional cervical and vaginal biopsies~Non invasive cervico-vaginal swab like a smear"
75381530|NCT00019747|Drug|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
75381531|NCT00019747|Procedure|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
75381532|NCT00019747|Other|Placebo|oral placebo once daily
75704727|NCT05007964|Device|Spatz4 Adjustable Balloon System|The Spatz4 Adjustable Balloon System is designed to assist weight loss by partially filling the stomach and inducing satiety. The intragastrical balloon is implanted endoscopically for up to 12 months.
75541274|NCT04566055|Device|AlloSure|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
75381533|NCT02970799|Device|Intranasal Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
75381534|NCT00759577|Drug|Solifenacin|5mg and 10 mg, oral once daily
75381535|NCT05338112|Diagnostic Test|Tzanck smear|The Tzanck smear is gently taken with a sterile scalpel from the ground of erosion or bullous lesions of pemphigus vulgaris. The sample taken is examined by staining the slide.
75541275|NCT04566211|Drug|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
75541276|NCT04566211|Drug|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
75541277|NCT00232427|Procedure|Hemodynamic monitoring system PiCCO|
75541278|NCT04565626|Other|Additional weekend physiotherapy|Patients randomized to intervention would receive a Medical Exercise Bike Pedal Exerciser Mini Peddler to allow for an additional 20 minutes a day of unsupervised physiotherapy both during the week and on weekends.
75381536|NCT00748579|Drug|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
75381537|NCT00748579|Drug|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
75381538|NCT05329922|Behavioral|ALICE: Audiological rehabilitation|Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.
75704728|NCT04997187|Dietary Supplement|Bacillus coagulans group|Bacillus coagulans 400 mg/day for 12 weeks
75704729|NCT04997187|Dietary Supplement|Control group|Placebo 400 mg/day for 12 weeks
75704730|NCT04992247|Biological|COVI-MSC|"2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.~Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4~Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4~Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2~Group D: 2 MSC vials infused on D0, D2 and D4"
75704731|NCT04992247|Biological|Placebo|6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.
75704732|NCT04986501|Device|MucoPEG|Experimental
75704733|NCT04986501|Device|Biotene|Active Comparator
75381539|NCT04524962|Biological|Descartes 30|Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
75381540|NCT00746239|Drug|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
76031085|NCT02333617|Other|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
76031086|NCT02333617|Other|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
75381541|NCT00746239|Drug|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
75381542|NCT04977674|Drug|Naltrexone|Pre-treatment with naltrexone 45 min before the ketamine infusion.
75868225|NCT03668834|Procedure|Dermaroller with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit.~Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
75381543|NCT04977674|Drug|Placebo|Pre-treatment with placebo 45 min before the ketamine infusion.
75381544|NCT04977674|Drug|Ketamine|Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
75868226|NCT03668834|Procedure|Liquid nitrogen induced blister with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~The site to be grafted is outlined with a surgical marking pen.~To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~The patient is asked to visit 24 hours later.~The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
75868227|NCT04546620|Drug|R-CHOP|Arm A patients will receive R-CHOP alone.
75381545|NCT04972136|Device|Active Bilateral Theta Burst Stimulation|A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
75381546|NCT04972136|Device|Sham Bilateral Theta Burst Stimulation|A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
75381547|NCT04963790|Behavioral|Tailored COVID-19 vaccine messages|Survey responses from participants will be aggregated to create hesitant patient segments. Then, specific content messages will be created following the health belief model, in a way that is meaningful to the recipients in the different segments, to persuade them to receive the COVID-19 vaccine.
75704734|NCT04982913|Drug|HEC116094|Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
75704735|NCT04981899|Drug|Nivolumab|6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.
75704736|NCT04981899|Drug|Ifosfamide|5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.
75704737|NCT04981899|Drug|Carboplatin|Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.
75868228|NCT04546620|Drug|R-CHOP + acalabrutinib|Arm B patients will receive R-CHOP in combination with acalabrutinib.
75868229|NCT04058210|Drug|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
75868230|NCT04058210|Drug|IVA|150-mg tablet for oral administration.
75381548|NCT04963790|Other|Other health messages|Other health messages unrelated to COVID-19 will be sent to participants in the control arm
75381549|NCT04960124|Drug|JNJ-42847922|Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
75381550|NCT00402883|Drug|Bevacizumab|15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
75381551|NCT00402883|Drug|Pemetrexed|500mg/m2 week 1, 4, 16, 19 and 22.
75381552|NCT00402883|Procedure|Radiotherapy|1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
76031087|NCT02333617|Other|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
76031088|NCT02333305|Dietary Supplement|CoQ10|• 2 dosages according to patient weight: Weight < 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
75381553|NCT00402883|Other|Folic Acid|350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
75381554|NCT00402883|Other|vitamin B12|1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
75381555|NCT00402883|Drug|carboplatin|AUC=5 administered intravenously weeks 1 and 4.
75381556|NCT05311826|Procedure|STANDARD PHYSIOTHERAPY TREATMENT|"The standard postoperative rehabilitation process starts from the first postoperative day. Two sessions are provided daily, with the exception of Sunday and Saturday afternoon. A single physiotherapy session, lasting 30 minutes, can include bed exercises for upper and lower limbs and recovery of autonomy (sitting position, standing and ambulation). In this phase, the sessions are characterized by educational and counseling activities.~The patient will be encouraged to carry out the activities independently."
75381557|NCT05311826|Procedure|EXPERIMENTAL diaphragmatic breathing exercise|The subjects in the intervention group (EXP) will receive, in addition to standard physiotherapy treatment, diaphragmatic breathing exercise. Four exercises in different position (supine and side lying) will be provided for each physiotherapy session by a senior physiotherapist. Patients will be instructed to perform the same exercises independently to achieve relaxation and relief of pain symptoms.
75704738|NCT04981899|Drug|Etoposide|100 mg / m2 intravenously on 1-3 days of the NICE-40.
75381558|NCT04940312|Behavioral|App-based physical activity coaching|Individualized app-based coaching via a smartphone
75381559|NCT04939844|Drug|Isatuximab, bortezomib, lenalidomide, dexamethason|All participants will receive the same treatment as described under arm.
75704739|NCT04967872|Other|Implementing risk management and control plan for the elderly during perioperative period|Visualization technology is used for preoperative evaluation, anesthesia management, bedside real-time monitoring and intervention, etc., to achieve accurate perioperative management of elderly patients and whole-process whole-person management
75704740|NCT04960059|Other|No intervention|This is an observational study
75704741|NCT04956887|Behavioral|AKL-T01|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
75704742|NCT04956887|Other|Control Group|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning
75704743|NCT04956081|Device|Neuro-navigated Transcranial Magnetic Stimulation (TMS)|TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)
75704744|NCT04955600|Other|Implementation Study|Implementation of digital technology in two different care settings from both patients, informal caregivers, and healthcare professional's perspective.
75704745|NCT04929600|Drug|sacubitril/valsartan|Sacubitril/valsartan oral tablets (200mg) one pill a day + matching placebo of amlodipine one pill a day.
75704746|NCT04929600|Drug|Amlodipine|Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.
75704747|NCT04925648|Drug|Dasatinib|Dasatinib 100mg once daily orally for 14 Days
75704748|NCT04925648|Drug|Darolutamide|Darolumatide 600 mg twice daily orally for 14 Days
75704749|NCT04910295|Drug|COVID-19 vaccine|Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.
75704750|NCT04908553|Drug|Remimazolam Tosilate for Injection 0.1mg/kg|Remimazolam Tosilate for Injection 0.1mg/kg at induction
75704751|NCT04908553|Drug|Remimazolam Tosilate for Injection 0.15mg/kg|Remimazolam Tosilate for Injection 0.15mg/kg at induction
75381560|NCT04936568|Other|Palliative Care Referral System - PCRS|Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
75704752|NCT04908553|Drug|Remimazolam Tosilate for Injection 0.2mg/kg|Remimazolam Tosilate for Injection 0.2mg/kg at induction
75541279|NCT04565587|Other|Xanthan-gum based thickener|Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
75541280|NCT00232466|Procedure|Vertebroplasty|"Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay."
75541281|NCT02211040|Behavioral|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
75704753|NCT04906174|Other|Electronic Health Record Review|Medical records are reviewed
75868231|NCT03021668|Device|Prevena Peel & Place Dressing|Prevena Peel & Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
75381561|NCT05295212|Drug|Atezolizumab|Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles
75381562|NCT05287178|Behavioral|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
75541282|NCT00259779|Drug|budesonide/formoterol|
75541283|NCT00259779|Drug|Prednisolone|
75541284|NCT02211079|Drug|JNJ-54861911|JNJ-54861911, 50 mg (2*25 mg tablets) orally once daily from Day 2 to Day 9.
75541285|NCT02211079|Drug|Caffeine|Single oral dose of caffeine 100 mg (2*50 mg tablets), on Day 1, 2, and 9.
75541286|NCT02211079|Drug|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
75704754|NCT04899479|Drug|SGLT2 inhibitor|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
75868232|NCT03021668|Other|Standard Closure of the Surgical Incision|This would involve standard closure of the incision site
75381563|NCT04328948|Radiation|Chemoradiotherapy|Chemoradiotherapy
75381564|NCT05286320|Drug|Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
75381565|NCT00728845|Biological|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
75381566|NCT00728845|Drug|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
75381567|NCT00728845|Drug|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
75381568|NCT00728845|Drug|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
75381569|NCT04306016|Other|Sensory stimulation|Sensory stimulation can be formed in different aspects, and the most important ones are visual stimulation and auditory stimulation. Visual stimulation interventions involved providing a calendar, clock or familiar objects such as photographs of family caregivers; while auditory stimulation included calling the name of patients, helping to orientate the time and location, introducing hospital information, the ICU surrounding and treatment, and communicating with patients, who could not talk due to artificial airway, through a blackboard and use of gestures.
75381570|NCT00379873|Device|ProAdjuster|
75541287|NCT02211079|Drug|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
75704755|NCT04899479|Other|Control|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
75704756|NCT04895293|Drug|RBM-007 Injectable Solution|Sterile solution
75868233|NCT03668756|Procedure|Computer-Assisted Navigation TKA|TKAs were performed using the image-free CAS navigation system VectorVision
75868234|NCT03669380|Other||
75868235|NCT03669068|Procedure|Gastrointestinal endoscopy|"Two separated groups will be included in the registry:~Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~Patients undergoing elective gastrointestinal endoscopy."
75868236|NCT03668678|Other|iGrow Readers Curriculum|As part of the iGrow Readers curriculum, the primary teacher first reads a book as a group with a specific health behavior theme. Then, children participate in nutrition and physical activities that relate and reinforce the lessons learned in the book. Informational newsletters highlighting healthy behaviors from the stories' themes are provided to parents. All implementation strategies are reinforced by research to promote positive choices in young children's health behaviors through the use of literature and language strategies and modeling of others in the children's microsystems.
75868237|NCT03668990|Other|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
75381571|NCT00726037|Drug|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
75541288|NCT04565860|Other|Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)|"Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations)."
75541289|NCT00232622|Drug|Streptokinase|Accelerated infusion of streptokinase
75868238|NCT03668210|Procedure|Isokinetic evaluation|Isokinetics is used to measure the peak of strength of quadriceps and hamstrings, in concentric or eccentric, at slow and fast speed to determine a hamstring / quadriceps ratio to highlight a deficit or imbalance.
75868239|NCT03623126|Other|Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.
75868240|NCT03020888|Device|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
75381572|NCT04890860|Other|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
75704757|NCT04861844|Behavioral|mindfulness training|phone based mindfulness training on 4 consecutive days
75381573|NCT04928053|Genetic|ocytocine dosage and genetic analyse|All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
75381574|NCT00703885|Drug|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
75381575|NCT00703885|Drug|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
75381576|NCT00703885|Drug|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
75381577|NCT00703339|Drug|Treprostinil sodium for inhalation|"Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose~Dose:~Cohort 1: dosed at 3 breaths (18 mcg)~Cohort 2: dosed at 6 breaths (36 mcg)~Cohort 3: dosed at 9 breaths (54 mcg)~Cohort 4: dosed at 12 breaths (72 mcg)~The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events."
75381578|NCT04330586|Drug|Ciclesonide Metered Dose Inhaler [Alvesco]|Ciclesonide 320ug oral inhalation q12h for 14 days
75381579|NCT00382694|Drug|Fludarabine|
75381580|NCT04516772|Device|Visian TICL|The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
75381581|NCT04508036|Diagnostic Test|Withdrawal of blood samples for D-Dimer|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.
75381582|NCT04508036|Diagnostic Test|Withdrawal of blood samples for Fibrinogen|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.
75381583|NCT04508036|Diagnostic Test|Echocardiographic Examination|At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
75381584|NCT04495556|Diagnostic Test|MRI|The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
75381585|NCT04828057|Drug|Tafluprost, timolol maleate|Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.
76031089|NCT02333305|Other|Sanomit Placebo|• according to patient weight: Weight < 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
75381586|NCT04857866|Drug|XmAb27564|Single ascending dose of XmAb27564
75381587|NCT04857866|Drug|Placebo|Single dose of placebo
75381588|NCT00000127|Procedure|Optic Nerve Sheath Decompression Surgery|
75381589|NCT04495400|Procedure|Thoracolumbar Fracture Fixation|The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
75381590|NCT02973451|Drug|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
75381591|NCT02973451|Drug|local Bupivacaine|Bupivacaine Trocar Site Infiltration
75381592|NCT00000193|Drug|Gamma hydroxybutyric|
75381593|NCT00000199|Drug|Piracetam|
75541290|NCT00232622|Drug|Streptokinase|Standard dose streptokinase
75704758|NCT04861844|Behavioral|active listening|The active listening intervention script asks the participant to attend by relaxing their body and visualizing themself in various exotic locations and narratives described in the script; it also asks the participant to rate their attention level of various points. The active listening scripts were compiled from National Geographic article excerpts (taken from the public domain)
75704759|NCT04861415|Radiation|Sterotactic Body Radiotherapy|Hypofractionated stereotactic radiation treatment.
75704760|NCT04861415|Radiation|Conventionally Fractionated Radiation|External beam radiation therapy treatment
75704761|NCT04859426|Drug|DBPR108 tablets|Drug: DBPR108, tablet, oral
75704762|NCT04852367|Device|Focused Ultrasound|Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release
75704763|NCT04852367|Drug|Doxorubicin|Doxorubicin infusion
75704764|NCT04852367|Drug|ThermoDox|ThermoDox infusion
76031090|NCT02326909|Device|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
75381594|NCT00668785|Drug|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
75381595|NCT04844840|Drug|STP705|STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively
75381596|NCT04844840|Other|Placebo|Saline
75381597|NCT00655057|Drug|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
75381598|NCT00655057|Behavioral|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
75381599|NCT00655057|Procedure|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using [99mTc]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
75381600|NCT00000211|Drug|Buprenorphine|
75381601|NCT04358432|Drug|AK102|Administered by subcutaneous injection
75381602|NCT04358432|Drug|Placebos|Administered by subcutaneous injection
75381603|NCT04358432|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
75381604|NCT00635167|Drug|Contrast Enhanced-Transrectal Ultrasound|Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline [Visit 2]); week 5 (middle of treatment [Visit 3]); week 10 (end of treatment [Visit 4]); week 18 (2 months after end of EBRT [Visit 5]); week 26 (4 months after end of EBRT [Visit 6]); and week 36 (6 months after end of EBRT [Visit 7]).
75381605|NCT04353830|Drug|IBI939|Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
75381606|NCT04353830|Drug|IBI939+ Sintilimab|"IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
75381607|NCT04353830|Drug|IBI939+ Sintilimab|"IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
75381608|NCT00000217|Drug|Carbamazepine|
75381609|NCT00000223|Drug|Buprenorphine|
75381610|NCT00630487|Drug|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
75381611|NCT00630487|Drug|Somatropin|Fixed doses for patients: MALE: < 45y 0,4 mg, > 45y 0,2mg FEMALE: < 45y 0,5mg, >45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
75381612|NCT00000229|Drug|Buprenorphine|
75381613|NCT00000235|Drug|Buprenorphine|
75704765|NCT04850703|Device|Transcranial Radom Noise Stimulation|tRNS against Dapoxetine in LPE patients
75704766|NCT04850703|Drug|Take Dapoxetine|Dapoxetine against tRNS in LPE patients
75868241|NCT03668522|Other|Genetic testing|To determine whether H3F3AK27M exist in spinal glioma
75381614|NCT03659240|Other|Cranberry beverage|During the intervention period, research participants will consume a cranberry beverage daily.
75381615|NCT03659240|Other|Placebo beverage|During the intervention period, research participants will consume a placebo beverage daily.
75381616|NCT00379327|Procedure|Acupuncture|Acupuncture administered in last three weeks of pregnancy
75381617|NCT00379327|Device|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
75381618|NCT00000241|Drug|Flupenthixol|
75381619|NCT00000253|Drug|10% N2O|
75381620|NCT00000253|Drug|20% N2O|
75381621|NCT00000253|Drug|30% N2O|
75868242|NCT03668132|Other|ischemic brain damage|Have or not have the ischemic brain damage and the location of the damage
75868243|NCT02250300|Drug|MLN9708 (2.3 mg)|2.3 mg
76031091|NCT02326909|Device|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
75381622|NCT00000253|Drug|40% N2O|
75381623|NCT00000259|Drug|15 % Nitrous oxide|
75381624|NCT00000259|Drug|0.3 % Sevoflurane|
75381625|NCT00000259|Drug|30% Nitrous oxide|
75381626|NCT00000259|Drug|0.6% Sevoflurane|
75381627|NCT00000259|Other|Placebo|
75381628|NCT04331665|Drug|Ruxolitinib|Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
75381629|NCT00379405|Drug|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
75381630|NCT04321538|Device|Gocheck Kids|GoCheck Kids is a photoscreening device. It takes a special picture of the eyes that allows for detection of refractive error and eye misalignment.
75381631|NCT04321538|Device|Welch Allyn Spot Vision Screener|The Welch Allyn Spot Vision Screener is a photoscreening device. It takes a special picture of the eyes that allows for the detection of refractive error and eye misalignment.
75381632|NCT04321538|Diagnostic Test|Physical Exam|Retinoscopy and an oculomotor testing will constitute the physical examination.
75381633|NCT00379483|Drug|Deferasirox|
75381634|NCT00607477|Drug|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
75381635|NCT00607477|Drug|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
75381636|NCT03603314|Drug|SENS-401|29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
75381637|NCT03603314|Other|Placebo Oral Tablet|placebo, oral route, by mouth, twice a day, during 4 weeks
75381638|NCT03603314|Drug|SENS-401|43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
75381639|NCT04423861|Drug|Nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
75381640|NCT04423861|Drug|Placebo|Patients will receive matching placebo BID for 7 days.
75381641|NCT04418869|Other|Exercise bouts|Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
75381642|NCT04330196|Diagnostic Test|Oral glucose tolerance test|Participant ingests 75g of glucose
75381643|NCT04330196|Diagnostic Test|Ingestion of placebo|Participant ingests 700mg of aspartame
75381644|NCT00000271|Drug|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
75381645|NCT00000271|Drug|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
75541291|NCT04565938|Procedure|Application of adhesive for the restoration of dental lesions with resin composite|"Mechanical removal of sclerotic dentin with a round bur~Enamel beveling~Enamel (30sec) and dentin (15sec) etching with phosphoric acid~Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~Finishing and polishing"
75541292|NCT04565938|Procedure|Application of adhesive for the restoration of dental lesions with resin composite|"Mechanical removal of sclerotic dentin with a round bur~Enamel beveling~Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~Composite-resin application using a transparent cervical matrix and curing for 40sec~Finishing and polishing"
75541293|NCT04565938|Procedure|Application of adhesive for the restoration of dental lesions with resin composite|"Mechanical removal of sclerotic dentin with a round bur~Enamel beveling~Enamel (30sec) etching with phosphoric acid~Application of AdheSE One and curing for 10sec~Composite-resin application using a transparent cervical matrix and curing for 40sec~Finishing and polishing"
75541294|NCT04565548|Other|Educational program for hypertensive patients|The theory-guided program consisted of one session of health education, self-developed leaflet, and weekly text messaging for 12 weeks.
75541295|NCT04565548|Other|Usual care|One standardized health education and a leaflet developed by the Health Bureau. As similar as the intervention group, weekly text messaging will be delivered, but the content is not related to the blood pressure control.
75541296|NCT04565314|Dietary Supplement|Plumpy'Mum|Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
75868244|NCT02250300|Drug|MLN9708 (4.0 mg)|4.0 mg
75381646|NCT00000277|Drug|Mazindol|
75381647|NCT04444544|Other|High Risk Abdominal Surgery|Pancreatectomy, Esophagectomy, Gastrectomy and Hepatectomy
75868245|NCT02250300|Drug|MLN9708 (3.0 mg)|3.0 mg
75868246|NCT04403490|Behavioral|HABIT-ILE|2 weeks HABIT-ILE
75868247|NCT04403490|Behavioral|Conventional intervention|2 weeks usual intervention (waitlist group)
75868248|NCT03020966|Drug|Acetaminophen|Oral acetaminophen, intravenous placebo
75868249|NCT03020966|Drug|Acetaminophen|Intravenous acetaminophen, oral placebo
75868250|NCT01381770|Biological|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
76031092|NCT02326987|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
76031093|NCT02326987|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
76031094|NCT02039713|Device|DeSyne drug eluting stent group|
75381648|NCT00599131|Drug|Cisplatin|1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a < 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, > 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
75381649|NCT00599131|Drug|Cetuximab|1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
75381650|NCT00599131|Drug|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
75381651|NCT00599131|Drug|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
75868251|NCT01383564|Procedure|CPAP group|Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
75868252|NCT01383564|Procedure|non CPAP group|Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
75381652|NCT04302350|Procedure|nitrous oxide|During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.
75381653|NCT00584935|Drug|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
75381654|NCT04297358|Drug|Hyperbaric oxygen|40 consecutive (5/7) sessions of hyperbaric oxygen
75381655|NCT04295486|Drug|Aspirin|Non-enteric coated 81 mg Aspirin tablet.
75381656|NCT00000289|Drug|Ondansetron|
75381657|NCT00000295|Drug|Micronized Progesterone|
75541297|NCT04565002|Device|Transcutaneous Electrical Diaphragmatic Stimulation|The procedure consists of electrical stimulation in the region of the motor points of the diaphragm. Its configurations contribute to produce involuntary muscle contractions. There are four electrodes positioned superficially on the skin.
75868253|NCT03020576|Device|Amadeo Hand Robot Device|This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.
75868254|NCT03020576|Other|Conventional Therapy|This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
75381658|NCT04384939|Device|magnetic-end Double-J ureteral stent|"Inserting the ureteral stent with magnet (same process as classic ureteral stent)~Removing the ureteral stent with magnet without general anaesthesia. Usually, the classic ureteral stent removed during a general anaesthesia."
75381659|NCT00000733|Drug|Ribavirin|
75381660|NCT04246723|Drug|Narlaprevir|100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
75381661|NCT04246723|Drug|Ritonavir|100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
75381662|NCT04246723|Drug|Sofosbuvir|"400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle."
75381663|NCT00000301|Drug|Amantadine|
75381664|NCT00000307|Drug|Naltrexone|
75381665|NCT00000313|Drug|Fenfluramine|
75381666|NCT00000757|Biological|gp160 Vaccine (MicroGeneSys)|
75381667|NCT00000319|Drug|Buprenorphine|
75381668|NCT00000325|Behavioral|Gonadorelin|
75541298|NCT00259818|Drug|EM-1421|
75541299|NCT04565197|Biological|convalescent plasma|"Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~Transfuse first aliquot for 2-3 hours (~1.4 to 2 mL/min)~Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
75868255|NCT00892866|Other|Cytology Specimen Collection Procedure|Correlative studies
75868256|NCT00892866|Other|Laboratory Biomarker Analysis|Correlative studies
75868257|NCT03667976|Behavioral|SATHI|see above
75381669|NCT04415996|Other|HVLA L3/4|"The participant will be lateral decubitus and the investigator will locate the third lumbar vertebra. Then with one hand the investigator will contact the interspinous space underlying L3 and with the other hand he will take the top leg into flexion until the investigator feels tension in L3/L4 joint. Then he puls the tables´s arm until felling tension in the region to be manipulated. Afterwards the investigator will globally rotate the participant in the horizontal plane and will approach to the L3/L4 joint. With one arm the investigator will contact the deltopectoral groove and with the other one will contact the external iliac fossa. Finally, the investigator will compress and rotate the pelvis and will apply an impulse in a rapid rotation, without losing the parameters with a body drop allowed by the flexion of the knees and the contraction of the large pectorals."
75381670|NCT04415996|Other|Sham|The participant will be in lateral decubitus and the top leg and knee will be flexed until the foot reaches the popliteal region of the other leg. There won't be applied any tension in no structure. This intervention will be applied during 90 seconds each side.
75381671|NCT04181203|Drug|Apalutamide|"240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months."
75381672|NCT04181203|Radiation|Salvage radiotherapy (SRT)|"The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images."
75381673|NCT04181203|Drug|Luteinising Hormone Releasing Hormone agonist (LHRHa)|Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
75381674|NCT03521102|Drug|Acetaminophen 1000mg IV|1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push
75381675|NCT03521102|Drug|Hydromorphone 0.5 mg IV|100ml of normal saline, administered as an intravenous drip over 10 minutes, + 0.5mg of IV hydromorphone in 2ml of normal saline, administered as a slow intravenous push
75381676|NCT00000763|Drug|TNP-470|
75381677|NCT00380263|Drug|PACAP38|10 pmol/kg/min given one time
75381678|NCT00000769|Drug|Interleukin-4|
75381679|NCT00380341|Procedure|Instrument-applied spinal manipulative therapy|
75541300|NCT00232661|Drug|ARIMIDEX (anastrazole)|
75704767|NCT04850703|Combination Product|Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants|Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.
75704768|NCT04850703|Diagnostic Test|Compare LPE EEG endophenotype between participants and healthy controls|Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype
75868258|NCT04051268|Biological|Vi-DT Typhoid Conjugate Vaccine|1 dose of Investigational Product
75381680|NCT05440591|Drug|Dapagliflozin|Dapagliflozin 10mg tablets
76031095|NCT02333461|Dietary Supplement|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
75381681|NCT05440591|Drug|MetFORMIN 500 Mg Oral Tablet|Metformin 500 mg tablets twice daily
75381682|NCT05440591|Drug|Dapagliflozin / metFORMIN Pill|Combination pill
75381683|NCT04099303|Biological|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|0.5 mL, Intramuscular Other Name: DTcP
75381684|NCT04099303|Biological|Diphtheria and Tetanus Combined Vaccine, Adsorbed|2mL, Intramuscular Other Name: DT
75381685|NCT04099303|Biological|Diphtheria-tetanus-acellular pertussis vaccine|0.5 mL, Intramuscular Other Name: DTaP
75381686|NCT04099303|Biological|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|0.5 mL, Intramuscular Other Name: PENTAXIM
75541301|NCT00232661|Drug|NOLVADEX (tamoxifen)|
75704769|NCT04843787|Drug|SLV213|SLV213 oral capsule (200mg) BID
75868259|NCT04051268|Biological|PQed Typhoid Conjugate Vaccine|1 dose of Active Comparator
75868260|NCT04051268|Biological|Vi Polysaccharide Vaccine|1 dose of Active Comparator
75381687|NCT00000775|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
75541302|NCT04564924|Radiation|DXA|Bone mineral density was examined in all cases and controls
75381688|NCT00379951|Drug|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
75381689|NCT00000331|Drug|Test Drug|
75381690|NCT00000331|Drug|Placebo Drug|
75541303|NCT00267267|Drug|torcetrapib/atorvastatin|
75541304|NCT00267267|Drug|ezetimibe/simvastatin|
75381691|NCT03492476|Device|Circaid|"Three observation periods were defined with the following products:~D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system"
75381692|NCT03492476|Device|Short-stretching Bandage (Reference treatment)|"Three observation periods were defined with the following products:~D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night"
75541305|NCT04564729|Other|Shared Decision Making|The intervention group will receive a shared decision-making intervention including a decision aid and conversation with a study investigator. The intervention group will have the opportunity to choose the number of opioid pills they receive at discharge from hospital after total knee arthroplasty.
75704770|NCT04843787|Drug|SLV213|SLV213 oral capsule (400mg) BID
75381693|NCT00000337|Drug|Selegiline|
75381694|NCT00000781|Drug|Nevirapine|
75381695|NCT00000781|Drug|Zidovudine|
75381696|NCT00000781|Drug|Zalcitabine|
75381697|NCT00000781|Drug|Didanosine|
75381698|NCT04712708|Device|Rebound Therapy|Rebound therapy is the therapeutic use of full sized trampoline or mini sized trampoline. It provides opportunities for exercise recreation and therapy; and it is distinct from gymnastic trampolining. It is used for facilitating movements, improving balance, enhancing coordination and promoting motor performances in children with different disorders includes learning disabilities, communication disorders and motor dysfunction (Rebound Therapy South Africa, 2020; The Chartered society of Physiotherapists, 2016).
75541306|NCT04564651|Other|platelet transfusion|when the ADP inhibition >70%, give one unit platelet tansfusion
75541307|NCT04564690|Dietary Supplement|QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)|Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks
75704771|NCT04843787|Drug|SLV213|SLV213 oral capsule (800mg) QD
75704772|NCT04843787|Drug|Placebo|Placebo oral capsule (200mg) BID
75381699|NCT04712708|Other|Physical Therapy Program|"The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:"
75381700|NCT00000343|Behavioral|counseling|
75381701|NCT00000787|Behavioral|Pre- and post-test counseling|
75381702|NCT00000349|Drug|Flupenthixol|
75381703|NCT00000805|Drug|Ganciclovir|
75381704|NCT00000355|Drug|Buprenorphine|
75381705|NCT04022785|Drug|Azacitidine|Given IV or SC
75381706|NCT04022785|Drug|BRD4 Inhibitor PLX51107|Given PO
75381707|NCT00383006|Behavioral|Skills for affect regulation (behavior)|
75541308|NCT04564690|Dietary Supplement|Regular hen eggs|Consumption of three regular hen eggs per day for three weeks
75541309|NCT00232700|Drug|Escitalopram|
75541310|NCT04564456|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test oproduct in one study period
75541311|NCT04564456|Drug|ADVAIR DISKUS® 500/50|2 inhalations Reference product in one study period
75704773|NCT04843787|Drug|Placebo|Placebo oral capsule (400mg) BID
75704774|NCT04843787|Drug|Placebo|Placebo oral capsule (800mg) QD
75704775|NCT04836520|Drug|SHR6390+anatrozole|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
75704776|NCT04824417|Drug|Itraconazole 200 mg|Control
75704777|NCT04824417|Drug|Voriconazole 200mg|Comparator
75704778|NCT04807231|Biological|Blood withdrawal|Blood withdrawal in order to perform a bioavailable testosterone RIA (Radio-Immuno Assay).
75704779|NCT04806399|Other|Educational Materials and Decision Counseling|Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.
75704780|NCT04802070|Drug|Autologous CIK|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
76031096|NCT02333461|Dietary Supplement|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
75704781|NCT04797143|Device|multidisciplinary consultation program|The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
75868261|NCT05420298|Other|cervical mobilization|All participants will receive only single session of cervical mobilization
75381708|NCT00000361|Drug|Corticosteroids|
75381709|NCT00000361|Drug|Methotrexate|
75381710|NCT00000811|Drug|Azithromycin|
75381711|NCT00000811|Drug|Atovaquone|
75381712|NCT00000811|Drug|Sulfamethoxazole-Trimethoprim|
75381713|NCT00000367|Drug|Treatment of depression|
75381714|NCT00000367|Behavioral|Suicide prevention intervention|
75704782|NCT04791956|Dietary Supplement|Prebiotic|Daily intake of Inulin-type fructans from chicory
75704783|NCT04791956|Dietary Supplement|Placebo|Daily intake of maltodextrin
75704784|NCT04788940|Procedure|Percutaneous Coronary Intervention|Patients with AMI who underwent PCI and CMR at index hospitalization and 6-month follow-up
75868262|NCT05420298|Other|cervical manipulation|All participants will receive only single session of cervical manipulation
76031097|NCT02333461|Dietary Supplement|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
76031098|NCT02333461|Dietary Supplement|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
76031099|NCT02333461|Dietary Supplement|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
76031100|NCT02332837|Behavioral|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
76031101|NCT02332837|Behavioral|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
76031102|NCT02332837|Behavioral|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
75381715|NCT00000367|Drug|Suicide prevention treatment|
75381716|NCT04246970|Other|Prehabilitation|Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device [2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.
75381717|NCT04246970|Other|Prehabilitation and posttransplant training program|Prehabilitation will be followed by a posttransplant training program. In this, the patient will perform supervised exercise (IIa interval aerobic exercise and resistance training) 2 days / week, and a physical exercise program at home until completing a total of 5 sessions / week in the aerobic modality. In the unsupervised phase (IIb), the patient will continue with the learned physical exercise program, but without supervision, 5 sessions / week (including a minimum of 2 non-consecutive sessions to perform resistance training).
75381718|NCT00000373|Drug|olanzapine + fluoxetine|
75381719|NCT00000373|Drug|placebo + fluoxetine|
75381720|NCT00000823|Drug|Zidovudine|
76031103|NCT02326753|Device|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
75381721|NCT00000823|Drug|Didanosine|
75381722|NCT00000379|Drug|Fluoxetine|
75381723|NCT00000379|Behavioral|EMDR|
75381724|NCT03367364|Behavioral|Patient education bundle (PEB),|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
75381725|NCT03367364|Behavioral|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
75381726|NCT00000385|Drug|Lithium|Lithium 600 mg to 2700 mg per day
75381727|NCT00000385|Drug|Placebo|Matching placebo
75381728|NCT04365920|Combination Product|Recovery Management Checkups (RMC)|"The RMC model was designed to improve treatment linkage, engagement, and long-term treatment retention. The conceptual framework was based on the public health theory of chronic disease management, which utilizes ongoing assessment and monitoring through regular face-to-face checkups and early (re)intervention to facilitate detection of relapse, reduce the time to treatment re-entry, and consequently, improve long-term outcomes. The original RMC model includes: 1) a fixed schedule of face-to-face quarterly checkups to assess need for SUD treatment, 2) personalized feedback based on an assessment and motivational interviewing to increase treatment motivation, 3) problem solving around barriers to treatment access and retention, and 4) assistance with scheduling and linkage to treatment. Individuals were deemed to be in need of treatment if they reported weekly, or more frequent, substance use since the last checkup, any past-month SUD symptoms, or self-perceived need for treatment."
75381729|NCT04365920|Combination Product|RMC-Adaptive|"Participants in the RMC-Adaptive group will receive face-to-face monthly checkups during the first 2 months post-release with additional face-to-face checkups dependent upon the participant's progress. Based on the data presented in the prior section, as long as participants need treatment, they will receive monthly checkups.~In addition, for every checkup that a participant does NOT need treatment, the number of months before the next checkup will be increased by 1 month (e.g., after 2 checkups without need, they will receive the next checkup 2 months later, after 3 it will be 3 months, after 4 it will be 4 months, and so on). Based on these decision rules, individuals who have NO treatment need over 24 months will still receive 5 checkups."
75381730|NCT00000391|Drug|Peptide T|
75381731|NCT00002894|Drug|carboplatin|
75381732|NCT00002894|Drug|cisplatin|
75381733|NCT00002894|Drug|paclitaxel|
75381734|NCT00000829|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
75381735|NCT00000829|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
75381736|NCT00000829|Biological|Placebo|Administered at 0, 2, 4, and 15 months of age
75704785|NCT04782531|Other|peripheral ECG|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
75381737|NCT03282344|Drug|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
75381738|NCT03282344|Drug|Nivolumab|360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
75381739|NCT03889093|Other|Yttrium-90|This is to evaluate the immunologic effects of yttrium 90.
75381740|NCT00000403|Drug|Doxycycline|
75381741|NCT00000841|Drug|Indinavir sulfate|
75381742|NCT00000841|Drug|Lamivudine|
76031104|NCT02326753|Device|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
76031105|NCT02326753|Device|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
75381743|NCT00000841|Drug|Stavudine|
75381744|NCT00000841|Drug|Zidovudine|
75381745|NCT00002900|Procedure|management of therapy complications|
76031106|NCT02332993|Dietary Supplement|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
75381746|NCT00000415|Procedure|Physical activity|
75381747|NCT00000415|Drug|Calcium supplement|
75381748|NCT00000847|Biological|ALVAC-HIV MN120TMG (vCP205)|
75381749|NCT00000847|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
75381750|NCT00000847|Biological|rgp120/HIV-1 SF-2|
75381751|NCT00000439|Drug|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
75381752|NCT00002912|Drug|etoposide|
75381753|NCT00002912|Drug|mitoxantrone hydrochloride|
75381754|NCT00002912|Drug|valspodar|
75381755|NCT00000853|Biological|rgp120/HIV-1MN|
76031107|NCT03104881|Device|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
75381756|NCT03731845|Genetic|Blood sample for genetic test|Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause
75704786|NCT04782531|Other|Standard MRI|Standard MRI examination using a torso coil consists of morphological and phase-contrast flow sequences(standard and EPI acquisitions).
75704787|NCT04777877|Other|Pain Neuroscience Education delivered via a Virtual Reality Headset|Pain educational videos (5) and guided imagery 360 degree nature videos (5)
75704788|NCT04771091|Diagnostic Test|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist
75381757|NCT03731845|Biological|Blood sample for hormonal measurement|at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)
75381758|NCT03731845|Other|Ovarian ultrasound scan|Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
75381759|NCT04183790|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
75704789|NCT04765150|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
75704790|NCT04765150|Other|Electronic Health Record Review|Medical charts are reviewed
75704791|NCT04753021|Other|Exercise|Progressively increasing training load
75704792|NCT04751422|Other|Electronic Health Record Review|Medical data is collected
75704793|NCT04727996|Drug|Sitravatinib|120 mg will be administered orally once daily
75381760|NCT04183790|Drug|IVA|Mono tablet for oral administration.
75381761|NCT00000445|Drug|naltrexone (Revia)|
75381762|NCT00002924|Other|mutation analysis|
75381763|NCT00000451|Drug|sertraline|16 week outpatient study
75381764|NCT00000451|Drug|naltrexone|16 week outpatient study
75704794|NCT04727996|Drug|Tislelizumab|200 mg will be administered intravenously (IV) once every 3 weeks
76031108|NCT03104881|Device|2D end-effector type robot|2 dimension end-effector type upper extremity robot
76031109|NCT02326675|Other|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
76031110|NCT02326675|Other|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
76031111|NCT02331667|Other|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
75381765|NCT00000865|Drug|Abacavir sulfate|
75381766|NCT00000865|Drug|Lamivudine|
75381767|NCT00000865|Drug|Stavudine|
75381768|NCT00000865|Drug|Zidovudine|
75381769|NCT00000865|Drug|Didanosine|
75381770|NCT00000469|Drug|aspirin|
75541312|NCT04564144|Drug|Meclizine Hydrochloride|A study will be conducted on the three tested orodispersible tablets and the commercial one (control). 6 volunteers are asked to cease any medication 7 days prior to blood sampling at least. Each volunteer will undergo 4 study sessions with one week of washout period in between (cross-overed to receive the other formulation). All volunteers are asked to fast overnight before taking the tablet. The tablet should be kept for 10 min in the mouth before swallowing without water. Just before taking the tablet, three milliliters of venous blood samples will be drown (predose, 0 h) and at 30, 60, 90, 120, 240, 360, 480, 720 min and 24 h postdose and stored in tubes coated with sodium heparin. Separation of plasma from Blood samples will be carried out by centrifuging at 5000 rpm for 10 min, then, it will be frozen at -20°C until analysis. By employing high-performance liquid chromatography (HPLC), the plasma concentration of MCZ will be assayed
75541313|NCT00267306|Drug|Visilizumab|
75541314|NCT04563949|Other|Repeat Testing|Repeat Testing with the PLA will be conducted
75541315|NCT00232778|Device|GAMMA-Iridium-192 catheter|
75541316|NCT04674787|Other|Peripheral nerve stimulation provocation study|Study which measures stimulation thresholds in volunteers induced by low frequency electromagnetic gradients used in MRI scanners.
75541317|NCT04563910|Other|young mania rating scale|questionnaires to the patients and their family after their written consent
75381771|NCT00000469|Drug|lovastatin|
75381772|NCT00000889|Drug|Aldesleukin|
75541318|NCT00259896|Drug|exenatide|
75541319|NCT04675021|Drug|AZD6094 (Savolitinib) film coated tablets 600 mg|AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3
75541320|NCT04675021|Drug|[14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)|14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)
75541321|NCT04675021|Drug|[14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)|14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
75541322|NCT04564066|Biological|efgartigimod IV|intravenous infusions of efgartigimod
75541323|NCT04564066|Biological|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
75704795|NCT04921059|Diagnostic Test|Active Stand|The participant is asked to lie down for 10 mins without moving or speaking. A heart rate monitor is attached while the participant is lying down. They are then asked to stand up as quickly as possible and to remain standing unassisted for 3 minutes. The participant will be asked to describe any symptoms at 1 and 3 minutes after standing. Blood pressure and heart rate will be monitored constantly throughout the test.
75704796|NCT04720781|Drug|Vonoprazan|Vonoprazan (20mg/day) is prescribed for 4 weeks.
75381773|NCT00000505|Drug|tissue plasminogen activator|
75381774|NCT00000505|Procedure|angioplasty, transluminal, percutaneous coronary|
75381775|NCT04169672|Drug|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
75381776|NCT04169672|Drug|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
75381777|NCT00380419|Behavioral|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
75381778|NCT00000511|Dietary Supplement|mineral supplements|
75381779|NCT00000511|Dietary Supplement|Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements|
75381780|NCT00000511|Behavioral|dietary supplements|
75381781|NCT03344731|Behavioral|Cognitive evaluation|Cognitive task
75381782|NCT03344731|Device|Non-invasive brain stimulation|Transcranial Magnetic Stimulation (TMS)
75381783|NCT00000901|Drug|Indinavir sulfate|
75381784|NCT00000901|Drug|Lamivudine|
75381785|NCT00000901|Drug|Stavudine|
75381786|NCT00000523|Behavioral|exercise|
75381787|NCT00000541|Behavioral|dietary supplements|
75381788|NCT00000541|Drug|vitamin C|
75381789|NCT00000541|Drug|vitamin E|
75381790|NCT00000541|Drug|beta-carotene|
75381791|NCT00000541|Drug|folic acid/Vitamin B6/Vitamin B12|
75381792|NCT00000913|Drug|Ritonavir|
75381793|NCT00000913|Drug|Nelfinavir mesylate|
75541324|NCT04564222|Dietary Supplement|Micronutrient Enriched Crackers (MECs)|"MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product."
75541325|NCT04564222|Dietary Supplement|Placebo|"Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product."
75381794|NCT00000913|Drug|Saquinavir|
75381795|NCT03111290|Device|Direct Cortical Stimulation|A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
76031112|NCT02331667|Other|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
75381796|NCT03111290|Device|Direct Cortical Stimulation Sham|Sham trials where no electric pulse is delivered
75381797|NCT00000547|Drug|enalapril|
75704797|NCT04720781|Drug|Esomeprazole|esomeprazole (20mg/day)
75704798|NCT04704700|Device|repair of a cuff tear|Group (Treatment): Arthroscopic Implantation of the System InSpace on a repaired rotator cuff tendon
76031113|NCT02331511|Drug|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
76031114|NCT02331511|Drug|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
76031115|NCT02331511|Drug|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
76031116|NCT02326441|Drug|KX2-361|
76031117|NCT03144271|Drug|semaglutide|A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
76031118|NCT03144271|Drug|Placebo|A single dose of placebo will be administered subcutaneously (s.c. under the skin)
75381798|NCT00002930|Procedure|positron emission tomography|
75381799|NCT00002930|Radiation|fludeoxyglucose F 18|
75381800|NCT00000565|Procedure|intermittent positive-pressure breathing|
75381801|NCT03061526|Other|optical coherence tomography|measurement of reflectivity in different retinal layers based on optical coherence tomography findings
75381802|NCT00000577|Drug|Albuterol|
75381803|NCT00000577|Drug|Colchicine|
75381804|NCT00000577|Drug|Adrenal Cortex Hormones|
75381805|NCT00000577|Drug|Adrenergic-Beta Agonists|
75381806|NCT03321799|Device|Negative Pressure Wound Therapy (NPWT)|A computer randomization system will be used on the day of surgery to allocate patients to either the conventional or NPWT dressing. Due to the nature of this study, blinding of patients and surgeons to their allocated cohort will not be possible.
75381807|NCT03321799|Device|Sterile Antimicrobial Dressings|Control group, current hospital standard.
75381808|NCT03278119|Diagnostic Test|PET Scan and nocturnal polysomnography|Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables
75381809|NCT03015896|Other|Laboratory Biomarker Analysis|Correlative studies
75381810|NCT03015896|Drug|Lenalidomide|Given PO
75381811|NCT03015896|Biological|Nivolumab|Given IV
75381812|NCT00000925|Drug|Optimune oral nutritional supplement|
75381813|NCT00000583|Biological|hepatitis B vaccines|
75381814|NCT02994836|Biological|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
75381815|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
75541326|NCT00232817|Drug|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
75541327|NCT04674865|Other|Standardized Physical therapy protocol|Standardized Phase 1 protocol without for 7 days without ANB sessions.
75541328|NCT04674865|Other|Alternate nostrils breathing|Alternate nostrils breathing 2 sessions per day
75381816|NCT02994836|Biological|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
75381817|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
75381818|NCT00000937|Drug|Antibiotics|
75381819|NCT00000613|Behavioral|dietary supplements|
75541329|NCT04674943|Other|Breathing exercises|Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
75541330|NCT00267384|Drug|Oral N-Acetylcysteine|
75541331|NCT04674904|Other|Dry Needling|Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min
75541332|NCT04674904|Other|Hot pack , TENS , Stretching|"Treatments are~Hot Pack for 15 minutes~TENS for 10 minutes~Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine"
75541333|NCT04675060|Drug|TQ-B3139 capsules|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
75541334|NCT04674982|Device|a vibrating device|vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
75541335|NCT00259935|Drug|topotecan|topotecan
75541336|NCT00424736|Procedure|whole body CT scan|
75541337|NCT04674709|Drug|Oleander 4X - single|Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
75541338|NCT04674709|Drug|Oleander 4X - double|Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
75541339|NCT04674709|Drug|Oleander 4X - quadruple|Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
75541340|NCT04674709|Drug|Placebo|The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
75704799|NCT04704700|Device|repair of a cuff tear|Group (Control): standard Arthroscopic repair of the cuff rotator
75704800|NCT04695327|Biological|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
75704801|NCT04692623|Drug|Moxifloxacin 400mg|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
75704802|NCT04692623|Drug|Gemifloxacin 320 MG|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
75704803|NCT04690608|Drug|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
75704804|NCT04686435|Other|Non-surgical treatment such as physiotherapy, exercise, corticosteroid injection, medication, acupuncture|Treatment consisting of different non-surgical interventions as recommended by the orthopedic specialist and decided upon in shared decision making with the patient
75704805|NCT04686435|Procedure|Surgery|Surgery can consist of rotator cuff repair, Bankart repair, subacromial decompression, biceps tenodesis or tenotomy, acromioclavicular joint resection.
75704806|NCT04684238|Drug|Midazolam|Solution for Injection/Infusion
75704807|NCT04684238|Drug|Isoflurane|Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
75704808|NCT04638543|Drug|ABP-671|ABP-671 Tablet
75704809|NCT04638543|Drug|Placebo|Placebo
75704810|NCT04628377|Device|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
75704811|NCT04621019|Device|BTL-785F|Treatment with study device.
75704812|NCT04607005|Drug|Mepolizumab|Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
75704813|NCT04607005|Drug|Placebo|Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
75704814|NCT04607005|Drug|Standard of care|Participants will continue to receive Standard of care as they are used to before entry in the study.
75704815|NCT04592094|Device|Blueback® Physio|Blueback® Physio is monitoring the activation level of the transversus abdominis muscle in real time during the exercises
75381820|NCT00000613|Drug|genistein|
75381821|NCT00000613|Behavioral|diet, soy proteins|
75381822|NCT00000619|Procedure|catheterization, Swan-Ganz|
75381823|NCT02909348|Drug|Pembrolizumab|3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.
75381824|NCT02973529|Device|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
75381825|NCT02973529|Device|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
75381826|NCT04329416|Other|Predicted depth of insertion|A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.
75381827|NCT04329416|Other|Optimized depth of insertion|The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.
75381828|NCT04329416|Other|Adjustment of depth of insertion|If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
75381829|NCT02859727|Drug|CDZ173|140 mg/day
75381830|NCT04329338|Other|Lactobacillus pentosus KCA1|Lactobacillus pentosus KCA1 suspended in dairy and taken orally for 14 days
75381831|NCT00000949|Drug|Aldesleukin|
75704816|NCT04586348|Combination Product|Low Iodine Supplement|Multivitamin and mineral supplement with reduced iodine
75704817|NCT04586348|Combination Product|Standard Iodine Supplement|Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
75704818|NCT04577001|Drug|Letrozole|2.5 mg orally daily for 6 months
75704819|NCT04577001|Drug|Placebo|No active ingredient taken orally daily for 6 months
75704820|NCT04576078|Drug|Oral nefopam|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
75381832|NCT00002936|Drug|altretamine|
75381833|NCT00002936|Drug|etoposide|
75381834|NCT00000649|Drug|Nevirapine|
75381835|NCT00000649|Drug|Zidovudine|
75381836|NCT00002942|Procedure|autologous bone marrow transplantation|
75381837|NCT00002942|Procedure|peripheral blood stem cell transplantation|
75704821|NCT04576078|Drug|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
75541341|NCT00555841|Drug|ALC and Placebo|ALC and Placebo
75704822|NCT04561557|Biological|CT103A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×106 CAR+ T cells/kg will be infused on day 0.
75704823|NCT04561557|Drug|Cyclophosphamide and fludarabine|"Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide."
75704824|NCT04561258|Biological|AGT103-T|An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells
75704825|NCT04560127|Drug|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
75704826|NCT04555616|Behavioral|Standard Environmental Design|Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.
75704827|NCT04555616|Behavioral|Individual Environmental Design|Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.
76031119|NCT02332525|Device|Oral Vibrational Stimulation|"Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
76031120|NCT02039791|Biological|Nimotuzumab|200mg/w,weekly, 6 weeks
75381838|NCT00000955|Drug|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
75381839|NCT02789384|Other|Procedure/Surgery|"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices."
75381840|NCT00000961|Drug|Anti-HIV Immune Serum Globulin (Human)|
75381841|NCT00000961|Drug|Zidovudine|
75381842|NCT04048304|Drug|duration of standard antibiotic therapy|antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
75381843|NCT00000655|Drug|Atovaquone|
75381844|NCT00000655|Drug|Sulfamethoxazole-Trimethoprim|
75381845|NCT00002948|Biological|filgrastim|
75381846|NCT00002948|Drug|topotecan hydrochloride|
75541342|NCT00232856|Device|drug-eluting stent|PCI
75541343|NCT00259974|Drug|Rituximab|Rituximab
75381847|NCT00002948|Procedure|bone marrow ablation with stem cell support|
75381848|NCT00002948|Procedure|peripheral blood stem cell transplantation|
75381849|NCT04009148|Other|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
75381850|NCT02594293|Drug|PegIFN alfa-2a|180 μg/ 0.5 ml ,hypodermic injection once a week
75381851|NCT00000967|Drug|Interferon alfa-2a|
75381852|NCT00000967|Drug|Zidovudine|
75381853|NCT00000661|Drug|Oxazepam|
75541344|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|25 mg daily oral treatment
75704828|NCT04555616|Behavioral|Placebo|Participants' caregivers will receive a set script of placebo modifications.
75868263|NCT03017612|Device|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
76031121|NCT02039791|Drug|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
75381854|NCT00000661|Drug|Zidovudine|
75381855|NCT02749058|Procedure|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
75381856|NCT02749058|Procedure|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
75381857|NCT00000979|Drug|Zidovudine|
75381858|NCT00000979|Drug|Didanosine|
75381859|NCT00002960|Biological|recombinant adenovirus-p53 SCH-58500|
75381860|NCT00000667|Biological|gp160 Vaccine (MicroGeneSys)|
75381861|NCT00000991|Drug|Pentamidine isethionate|
75381862|NCT00000991|Drug|Sulfamethoxazole-Trimethoprim|
75381863|NCT00000991|Drug|Dapsone|
75381864|NCT00000991|Drug|Zidovudine|
75381865|NCT00000673|Drug|Ganciclovir|
75541345|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|100 mg daily oral treatment
75541346|NCT00555958|Device|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
75541347|NCT04674475|Device|Pressure guidewire, optimal coherence tomography|Pressure guidewire, optimal coherence tomography
76031122|NCT02039791|Drug|Paclitaxel|"175 mg/m2, d1~1 cycle/21d, 2 cycles."
75381866|NCT00000685|Drug|Zidovudine|
75381867|NCT00002972|Drug|paclitaxel|
75381868|NCT00000691|Drug|Foscarnet sodium|
75381869|NCT00002984|Drug|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
75381870|NCT00002984|Drug|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
75381871|NCT00002984|Drug|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
75381872|NCT00002984|Procedure|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
75381873|NCT00002984|Radiation|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
75381874|NCT02341807|Biological|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
75381875|NCT00002990|Biological|BCG vaccine|
75381876|NCT00000997|Drug|Zalcitabine|
75381877|NCT00000697|Drug|Foscarnet sodium|
75381878|NCT00001009|Drug|Dextran sulfate|
75381879|NCT00000703|Drug|Bleomycin sulfate|
75381880|NCT00000703|Drug|Vincristine sulfate|
75381881|NCT00000703|Drug|Doxorubicin hydrochloride|
75381882|NCT00000703|Drug|Cyclophosphamide|
75381883|NCT00000703|Drug|Allopurinol|
75381884|NCT00000703|Drug|Methotrexate|
75381885|NCT00000703|Drug|Cytarabine|
75381886|NCT00000703|Drug|Leucovorin calcium|
75381887|NCT00000703|Drug|Zidovudine|
75381888|NCT00000703|Drug|Dexamethasone|
75541348|NCT00232895|Drug|lipuro propofol|
75541349|NCT00232895|Drug|standard formulation propofol|
75541350|NCT04674280|Procedure|aHSCT|Autologous haematopoietic stem cell transplantation
75541351|NCT04673968|Other|prehabilitation|inhospital exercise training 5 times/week, 5~6 weeks during nCRT; home exercise 5 times/week, 5~6 weeks, between completion of nCRT and before surgery
75541352|NCT04674046|Device|Nonoperative treatment|Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
75541353|NCT04674046|Procedure|Operative treatment|Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
75868264|NCT03635099|Drug|Placebo (fasted)|Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
76031123|NCT02330887|Other|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
75381889|NCT00001015|Drug|Ribavirin|
75381890|NCT00000709|Drug|Zidovudine|
75381891|NCT00001027|Drug|Pentamidine isethionate|
75381892|NCT00000721|Drug|CD4 Antigens|
75381893|NCT00000727|Drug|Pentamidine isethionate|
75381894|NCT00000727|Drug|Pyrimethamine|
75381895|NCT00000727|Drug|Sulfamethoxazole/Trimethoprim|
75381896|NCT00000727|Drug|Sulfadoxine/Pyrimethamine|
75381897|NCT00000727|Drug|Zidovudine|
75381898|NCT00001039|Drug|Ethambutol hydrochloride|
75381899|NCT00001039|Drug|Clarithromycin|
75381900|NCT00001057|Drug|Zidovudine|
75381901|NCT00001057|Drug|Didanosine|
75381902|NCT00001705|Drug|GP100 peptide|
75381903|NCT00001705|Drug|IL-2|
75381904|NCT00002293|Drug|Nystatin|
75381905|NCT00002299|Drug|Interferon beta-1b|
75381906|NCT00002299|Drug|Ganciclovir|
75381907|NCT00380497|Drug|PEG-Lyte®|
75381908|NCT00380497|Drug|Pico-Salax®|
75381909|NCT00001063|Drug|Stavudine|
75381910|NCT00001063|Drug|Zidovudine|
75381911|NCT00001063|Drug|Didanosine|
75704829|NCT04549337|Behavioral|Exercise training|"Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate >85% of HR max will be evaluated to determine the intensity."
75381912|NCT00002305|Drug|Flucytosine|
75381913|NCT00002305|Drug|Fluconazole|
75381914|NCT00002305|Drug|Amphotericin B|
75381915|NCT00001753|Procedure|Magnetic resonance imaging|
75381916|NCT00001765|Device|Nexell Isolex with T-cell Depletion|
75381917|NCT00001765|Device|Baxter isolex 300i|
75381918|NCT00001081|Drug|Nitazoxanide|
75381919|NCT00002311|Drug|Wobenzym|
75381920|NCT00002317|Drug|Trimetrexate glucuronate|
75381921|NCT00002317|Drug|Leucovorin calcium|
75381922|NCT00001123|Drug|Ribavirin|
75381923|NCT00002323|Drug|Nevirapine|
75381924|NCT00002323|Drug|Zidovudine|
75381925|NCT00002329|Drug|Celgosivir hydrochloride|
75381926|NCT00001873|Device|Isolex 300i plus MoAbs|
75381927|NCT00380965|Drug|Cesamet™ (nabilone)|
75381928|NCT00001129|Device|Electronic Medication Reminder System|
75381929|NCT00001129|Behavioral|Medication Manager|
75381930|NCT00001135|Drug|Nevirapine|
75381931|NCT00003002|Biological|HER-2/neu peptide vaccine|
75381932|NCT00003002|Biological|sargramostim|
75381933|NCT00001891|Procedure|Myocardial contrast echocardiography|
75381934|NCT00001891|Procedure|Dobutamine echocardiography|
75381935|NCT00383864|Drug|Pegylated interferon and ribavirin|
75381936|NCT00001903|Drug|RSV Polyclonal Immunoglobulin|
75381937|NCT00002335|Drug|Emtricitabine|
75381938|NCT00002341|Drug|Itraconazole|
75381939|NCT04331431|Procedure|Spinal cord tumor resection|Excision of intradural tumors
75381940|NCT00001909|Drug|Soluble recombinantly produced IL-4R|
75381941|NCT00001189|Procedure|radiotherapy|
75381942|NCT00002347|Drug|Saquinavir|
75381943|NCT00002347|Drug|Nevirapine|
75381944|NCT00002347|Drug|Zidovudine|
75381945|NCT00002347|Drug|Zalcitabine|
75381946|NCT00001237|Drug|granulocyte-macrophage colony stimulating factor (GM-CSF)|
75381947|NCT00002353|Biological|P3C541b Lipopeptide|
75381948|NCT00002359|Biological|HIV-1 Immunogen|
75381949|NCT04925713|Biological|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~Immunomodulatory Agent~Route of Administration:~Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions)~Mechanism of Action:~Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
75381950|NCT00001933|Drug|Nefiracetam|
75381951|NCT00001249|Drug|Yttrium-90 radiolabeled anti-Tac antibody|
75381952|NCT00380575|Drug|YM087|
75381953|NCT00001951|Drug|TMTDS|
75381954|NCT00001963|Procedure|hemoglobin-transported nitric oxide|
75381955|NCT00002365|Drug|LXR015-1|
75381956|NCT00380731|Behavioral|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
75381957|NCT00002377|Drug|Valganciclovir|
75381958|NCT00002377|Drug|Ganciclovir|
75381959|NCT00380809|Procedure|Rotational Atherectomy + PES|
75381960|NCT00380809|Procedure|Standard Treatment (PES without Rotational Atherectomy)|
75381961|NCT00001339|Drug|doxorubicin, vincristine, and etoposide with mitotane|
75381962|NCT00001993|Drug|Butyldeoxynojirimycin|
75381963|NCT00001993|Drug|Zidovudine|
75381964|NCT00001999|Drug|Globulin, Immune|
75381965|NCT00001999|Drug|Ganciclovir|
75381966|NCT00002383|Drug|Saquinavir|
75381967|NCT00002389|Drug|Abacavir sulfate|
75381968|NCT00002389|Drug|Lamivudine|
75381969|NCT00002389|Drug|Zidovudine|
75381970|NCT00001357|Drug|Interleukin-2|
75381971|NCT00001381|Drug|suramin|
75868265|NCT03635099|Drug|BI 25 mg (fasted)|25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
75868266|NCT03635099|Drug|BI 50 mg (fasted)|50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
75868267|NCT03635099|Drug|BI 100 mg (fasted)|100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
75381972|NCT00002005|Drug|CD4 Antigens|
75381973|NCT00002011|Drug|Methoxsalen|
75381974|NCT00002017|Drug|Interleukin-2, Polyethylene Glycolated|
75381975|NCT00002023|Drug|Zidovudine|
75381976|NCT00002029|Drug|Fat Emulsion 2%|
75381977|NCT00002029|Drug|Fat Emulsion 20%|
75381978|NCT00002035|Drug|Zidovudine|
75381979|NCT00002035|Drug|Didanosine|
75381980|NCT00002041|Drug|Amphotericin B|
75381981|NCT04716907|Genetic|Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region|DNA extraction from blood samples, PCR and Sequencing
75381982|NCT04716907|Biological|Blood sample|Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
75381983|NCT04716907|Diagnostic Test|CT Scan|Thymus and lung imaging
75381984|NCT04716907|Biological|Bronchial fibroscopy|Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
75381985|NCT00002047|Drug|Zidovudine|
75381986|NCT00002053|Drug|Pentamidine isethionate|
75381987|NCT00002059|Drug|Inosine pranobex|
75381988|NCT00002065|Drug|Disulfiram|
75381989|NCT00002071|Drug|Epoetin alfa|
75381990|NCT00002395|Drug|Topotecan|
75381991|NCT00002401|Drug|Indinavir sulfate|
75381992|NCT00002401|Drug|Delavirdine mesylate|
75381993|NCT00002401|Drug|Lamivudine|
75381994|NCT00002401|Drug|Zidovudine|
75381995|NCT00002407|Drug|Indinavir sulfate|
75381996|NCT00002407|Drug|Nevirapine|
75381997|NCT00002407|Drug|Lamivudine|
75381998|NCT00002407|Drug|Stavudine|
75381999|NCT00002407|Drug|Didanosine|
75382000|NCT00002413|Drug|Emivirine|
75382001|NCT00002419|Drug|Abacavir sulfate|
75868268|NCT03635099|Drug|BI 200 mg (fasted)|200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
76031124|NCT02330887|Other|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
75541354|NCT04674046|Behavioral|Standardized education|All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
75382002|NCT00002419|Drug|Amprenavir|
75382003|NCT00002419|Drug|Efavirenz|
75382004|NCT00002419|Drug|Adefovir dipivoxil|
75382005|NCT00381355|Procedure|Written Action Plan for Acute Asthma|
75382006|NCT00381433|Drug|AVI-4065 Injection|
75382007|NCT00381511|Drug|low molecular weight heparin|
75382008|NCT00002425|Drug|Saquinavir|
75382009|NCT00002431|Drug|Chlorhexidine gluconate|
75382010|NCT00002077|Drug|Fluconazole|
75382011|NCT00002083|Drug|Peptide T|
75382012|NCT00002089|Drug|Azithromycin|
75382013|NCT00002095|Drug|Ganciclovir|
75382014|NCT00002101|Drug|Ethambutol hydrochloride|
75382015|NCT00002101|Drug|Clarithromycin|
75382016|NCT00002101|Drug|Rifabutin|
75541355|NCT00260013|Procedure|program of care delivery|
75541356|NCT00232934|Drug|Thalidomide|
75382017|NCT02335424|Biological|pembrolizumab|IV infusion
75382018|NCT00002107|Drug|Aldesleukin|
75382019|NCT00002113|Drug|Flucytosine|
75382020|NCT00002113|Drug|Fluconazole|
75382021|NCT00002119|Drug|WF10|
75382022|NCT00383318|Procedure|Gene mutation sample|
75382023|NCT00002437|Drug|Cidofovir|
75382024|NCT00002437|Drug|Probenecid|
75382025|NCT00002443|Drug|Indinavir sulfate|
75382026|NCT00002443|Drug|Zidovudine|
75382027|NCT00001561|Drug|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
75382028|NCT00001561|Drug|GM-CSF|
75382029|NCT00002449|Drug|Aldesleukin|
75382030|NCT00003014|Drug|carboplatin|
76031125|NCT03573817|Drug|Revefenacin|Revefenacin is administered via a nebulizer.
75382031|NCT00003014|Radiation|radiation therapy|
75382032|NCT00002125|Drug|Foscarnet sodium|
75382033|NCT00001579|Drug|5-Fluorouracil|
75382034|NCT00001579|Drug|Ethynyluracil|
75382035|NCT00001579|Drug|Leucovorin|
75382036|NCT00003020|Biological|LMB-7 immunotoxin|
75382037|NCT00002131|Drug|Vesnarinone|
75382038|NCT00001615|Drug|Corticosteroid|
75382039|NCT00002137|Drug|Tecogalan sodium|
75382040|NCT00002455|Biological|Corynebacterium granulosum P40|
75382041|NCT00002455|Procedure|adjuvant therapy|
75382042|NCT00380887|Drug|Premarin|
75382043|NCT00002461|Biological|filgrastim|
75382044|NCT00002461|Biological|sargramostim|
75382045|NCT00002461|Drug|carmustine|
75382046|NCT00002461|Drug|cisplatin|
75382047|NCT00002461|Drug|cyclophosphamide|
75382048|NCT00002461|Drug|etoposide|
75382049|NCT00002461|Procedure|autologous bone marrow transplantation|
75382050|NCT00002461|Procedure|in vitro-treated bone marrow transplantation|
75382051|NCT00002461|Procedure|peripheral blood stem cell transplantation|
75382052|NCT00002461|Radiation|radiation therapy|
75382053|NCT00003026|Drug|bicalutamide|
75704830|NCT04541914|Diagnostic Test|5-gene classification model|Peripheral blood marker-based molecular diagnostic method for AMR in ABOiKT
75382054|NCT00003026|Drug|flutamide|
75382055|NCT00003026|Drug|triptorelin|
75541357|NCT04673812|Drug|Bupivacaine-fentanyl|"Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL."
75541358|NCT00260052|Drug|Erythropoietin administration|
75541359|NCT00232973|Drug|ICXP007|
75704831|NCT04536532|Drug|HEC121120 tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
75868269|NCT03635099|Drug|Placebo (fed)|4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
76031126|NCT03573817|Drug|Placebo|Placebo version of Revefenacin is administered via a nebulizer.
75382056|NCT00003026|Radiation|radiation therapy|
75382057|NCT00002143|Drug|Acitretin|
75382058|NCT00002149|Drug|Clavulanate potassium|
75382059|NCT00002149|Drug|Pseudoephedrine hydrochloride|
75382060|NCT00002149|Drug|Amoxicillin trihydrate|
75382061|NCT03868046|Drug|Treatment with immune checkpoint inhibitors.|Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
75382062|NCT03868046|Diagnostic Test|Blood tests.|Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
75382063|NCT02973295|Drug|Silymarin|Capsules contains 100 mg of silymarin
75382064|NCT02973295|Other|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
75382065|NCT04329884|Procedure|Cooled RFA treatment with COOLIEF* device|Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
75382066|NCT04329884|Drug|intra-articular corticosteroid injection|Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
75382067|NCT00003032|Biological|filgrastim|
75382068|NCT00003032|Drug|cisplatin|
75382069|NCT00003032|Drug|cyclophosphamide|
75382070|NCT00003032|Drug|mitoxantrone hydrochloride|
75382071|NCT00003032|Drug|tamoxifen citrate|
75382072|NCT00002155|Drug|Indinavir sulfate|
75382073|NCT00002155|Drug|Lamivudine|
75541360|NCT04673500|Drug|Propofol lidocaine through large vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a large antecubital vein to assess pain severity on propofol injection during general anesthesia induction
75541361|NCT04673500|Drug|Propofol lidocaine through small vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a small vein on the dorsum of hand to assess pain severity on propofol injection during general anesthesia induction
75541362|NCT04673695|Drug|Lixiana(D006)|NOAC(Factor Xa inhibitor)
75541363|NCT04673695|Drug|CKD-344|NOAC(Factor Xa inhibitor)
75704832|NCT04536532|Drug|HEC121120 placebo tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
76031127|NCT03573817|Drug|Formoterol|Administered sequentially in both revefenacin and placebo arms using a nebulizer.
76031128|NCT03112057|Diagnostic Test|harmonic generation (HGM) microscopic methods.|a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
76031129|NCT02331043|Dietary Supplement|Plant stanol ester|
75704833|NCT04536532|Drug|entecavir tablets|Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
75704834|NCT04536532|Drug|entecavir placebo tablets|Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
75704835|NCT04533503|Device|HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter|Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
75704836|NCT04526158|Behavioral|Mobile+Group LAMP Mindfulness-Based Intervention|The Mobile+Group LAMP Mindfulness-Based Intervention (MBI) condition consists of eight 90-minute weekly group sessions, delivered via secure video-conferencing. The first session is preceded by a 90-minute technical session introducing the video-conference system and other logistics. The program consists of educational and instructional videos presented by a trained mindfulness instructor interspersed with workbook reflections and group discussions, and daily practice exercises that participants do on their own. A trained facilitator (who is not required to be an expert in mindfulness) leads the group. Participants also have access to a mobile app and a study website, with the same educational and instructional videos that are presented in the group sessions, and the accompanying workbook.
76031130|NCT02331043|Dietary Supplement|Placebo|
75382074|NCT00002155|Drug|Zidovudine|
75382075|NCT00003038|Drug|doxorubicin hydrochloride|
75382076|NCT00003038|Drug|suramin|
75868270|NCT03635099|Drug|BI 400 mg once daily (fed)|4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
75868271|NCT03635099|Drug|BI 200 mg twice daily, 400 mg total (fed)|2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
75382077|NCT00001633|Procedure|Coronary magnetic resonance angiography imaging|
75382078|NCT00002473|Procedure|conventional surgery|
75382079|NCT05752591|Diagnostic Test|Diagnostic testing|Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
75382080|NCT00003044|Drug|cisplatin-e therapeutic implant|
75382081|NCT00002485|Procedure|psychosocial assessment and care|
76031131|NCT03111511|Drug|Drospirenone/Ethinylestradiol|A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
76031132|NCT03111511|Drug|Midazolam|Midazolam 2 mg orally on Days 1 and 21.
76031133|NCT03111511|Drug|JNJ-56136379|JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
76031134|NCT02330965|Procedure|Blood Draw|Blood draws (65 mLs [~4 tablespoons] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
76031135|NCT02330965|Procedure|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
76031136|NCT03144505|Behavioral|MCT combined with RT Group|
76031137|NCT03144505|Behavioral|HIIT combined with RT Group|
76031138|NCT03144115|Drug|Oxytocin|
76031139|NCT03144115|Drug|Placebos|
75382082|NCT02047994|Drug|Triple therapy|"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~Esomeprazole 40 mg bid for 10 days~Clarithromycin 500 mg bid for 10 days~Amoxicillin 1000 mg bid for 10 days"
75382083|NCT00002161|Drug|Adefovir dipivoxil|
75382084|NCT03836378|Procedure|BioXclude™|The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
75868272|NCT03667898|Procedure|Lumbar plexus block using NTT|An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
75382085|NCT03833804|Other|Processing of clinical notes in the EHR data collected during routine care|Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
76031140|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
76031141|NCT02326285|Drug|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
76031142|NCT02326285|Drug|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
76031143|NCT02326285|Drug|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
76031144|NCT02326285|Procedure|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
75704837|NCT04526158|Behavioral|Mobile LAMP Mindfulness-Based Intervention|The Mobile LAMP MBI consists of 8 self-paced, 30- to 60-minute weekly sessions, delivered on a mobile app and available on the study website, with an accompanying workbook. The program consists of educational and instructional videos presented by a trained mindfulness instructor, with workbook reflections and daily practice exercises that participants do on their own (the same content used in Mobile+Group LAMP). Participants also participate in 3 engagement phone calls with a facilitator. The 1st call (45-60 minutes), held at the beginning of the program, includes technical and logistical information on engaging with mobile app, website, and workbook; and discussion of goals, challenges and plans for practice. The 2nd (middle of program) and 3rd call (end of program) are 25-45 minutes long and address technical/logistical issues and discussion of goals, progress, plans for practice and strategies to address challenges.
75868273|NCT03667898|Procedure|Lumbar plexus block without NTT|An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
76031145|NCT02332603|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
76031146|NCT02332603|Drug|Isotonic Sodium Chloride|Placebo
76031147|NCT02332447|Drug|naloxone|"A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
75704838|NCT04518566|Behavioral|Nudges|Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
75541364|NCT04673305|Other|Cognitive Assessment, Cytokine dosage|Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
75704839|NCT04508634|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
75704840|NCT04508634|Drug|Metformin Pill|Metformin 1000mg bid
75704841|NCT04490512|Biological|FluBHPVE6E7|Multiple subcutaneous, intradermal or intramuscular administrations
75704842|NCT04484194|Behavioral|Check Yourself - Oncology|A validated AYA-targeted electronic health assessment (eHA) screening tool for use in oncology clinics.
76031148|NCT02332447|Drug|Placebo|"Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
75541365|NCT04673344|Device|Regeneten Collagen Patch|Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
75541366|NCT00233012|Drug|Topiramate|
75868274|NCT03668444|Behavioral|TXS- Supportive Text Group|TXS participants will receive one treatment supportive text message each day for 30 days.These messages will address three domains 1) Recovery oriented messages, 2) Avoiding relapse and sanctions,and 3) Commitment to family, community and the Drug Treatment Court program. After receiving each text message, participants will receive a second message asking them to reply with a rating of how helpful the original message was. Ratings will use a 5-point Likert scale,ranging from 1-not at all helpful to 5-extremely helpful. Participants will also be asked to describe, via text message, what they liked or did not like about the original message, and suggest a better message for those they did not like.
75541367|NCT04673110|Diagnostic Test|Neutrophil to Lymphocyte Ratio and C-reactive protein|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
75541368|NCT00267540|Behavioral|cholecalciferol (D3) (vitamin)|
75704843|NCT04480502|Biological|Envafolimab|PD-L1 single domain antibody for subcutaneous injection.
75868275|NCT03668444|Behavioral|TAU- Treatment As Usual|Participants randomized to the TAU arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive one motivational text message for the 30-days.
75868276|NCT03668366|Drug|S-1|The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
75541369|NCT04672954|Drug|BI 474121|BI 474121
75541370|NCT04672954|Drug|Placebo|Placebo
75704844|NCT04480502|Drug|Ipilimumab|CTLA-4 monoclonal antibody
75704845|NCT04470726|Drug|AIV001|Intradermal/intratumoral
75704846|NCT04468334|Device|LARIAT + PVI|LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
75868277|NCT03668288|Other|Data record and questionnaires passation|Data record and questionnaires passation (SF36)
75541371|NCT04672993|Device|Urine collection device for men|Use of urine collection device for men
75541372|NCT04673188|Procedure|Reconstruction of MPFL with or without tibial tuberositas osteotomy|Reconstruction of the medial patellofemoral ligament with autologous grafts with or without osteotomy and transfer of tibial tuberosities.
75541373|NCT00233051|Drug|Salmeterol or Salmeterol/Fluticasone|
75541374|NCT04673227|Diagnostic Test|Blood draw|Blood draw and the analysis of blood in laboratory
75868278|NCT04595786|Drug|Tranexamic acid|20mg/kg TXA was prepared in a 50ml syringe for intravenous pump
75868279|NCT04595786|Drug|0.9% saline|0.9% saline was prepared in a 50ml syringe for intravenous pump
75868280|NCT04584164|Device|sialendoscopy|The patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
75868281|NCT02108652|Drug|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
75541375|NCT00260091|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
75541376|NCT00260091|Procedure|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
75868282|NCT01383408|Other|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
75868283|NCT05419752|Drug|bioceramic sealer|bioceramic based obturating sealer
75868284|NCT05419752|Drug|MTA|MTA based obturating sealer
75868285|NCT05419752|Drug|resin sealer|resin based obturating sealer
75868286|NCT03634085|Drug|BDM-2 in Bottle (50 mg - 3600 mg); oral suspension|BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
75868287|NCT05419596|Procedure|Urologic Surgery|Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
75868288|NCT04373148|Other|There is no intervention|There is no intervention
75868289|NCT01381614|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
75382086|NCT04713397|Diagnostic Test|Leg Length Discrepancy Scoliometer Test|"A scoliometer used as an indirect and quantitative method to evaluate LLD for the first time in this study, and described it as Leg Length Discrepancy Scoliometer Test. Scoliometer were used on Adams' forward bending position and the level of the pelvis accepted as equal when the scoliometer degree pointed zero on the sacral basis (angle of trunk rotation on sacrum). When considering pelvis level is high on the longer side and is low on the shorter side, if the angle of the scoliometer on the sacrum is negative (slope to the left), the left extremity was considered as shorter. In order to determine its correlation with an indirect method, scoliometer degree on the sacral basis was recorded then wooden blocks were added to the unequal leg side on the sacral basis until the pelvic equality was achieved on the scoliometer. Afterward, a correlation between the first measurement of ATRsacrum and the height of the wooden block which provides ATRsacrum to reach zero was investigated."
75382087|NCT00002167|Drug|Tin ethyl etiopurpurin|
75382088|NCT03805412|Device|DEXCOM G6 RT-CGM|CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.
75382089|NCT05752513|Procedure|Late bladder dissection|The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection
75541377|NCT04673071|Other|Thread Embedding Acupuncture (TEA)|"TEA in 1 month for 4 months The six TEA points used in this study are GV20, BL15, BL18, ST40, GV14 and GB34.~Acupuncture point Procedure Baihui (GV20) oblique insertion toward nose, 3cm Both Xin Shu (BL15) perpendicular insertion, 3cm Both Gan Shu (BL18) perpendicular insertion, 3cm Both Fenglong (ST40) perpendicular insertion, 3cm Dazhui (GV14) perpendicular insertion, 3cm Both Yanglingquan (GB34) perpendicular insertion, 3cm"
75868290|NCT03729323|Behavioral|Motivational interviewing|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be addressed based on the principles and techniques of the Motivational Interviewing.
76023072|NCT02400151|Other|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
76023073|NCT02400151|Other|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
76023074|NCT02407951|Behavioral|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians."
76023075|NCT02407951|Behavioral|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians."
76023076|NCT02400385|Drug|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
76031149|NCT02331199|Device|Amniotic fluid lamellar body count|The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
76023077|NCT02400385|Drug|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
76031150|NCT02331199|Device|Fetal pulmonary artery Doppler|A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
76031151|NCT02331121|Behavioral|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
75382090|NCT05752513|Procedure|early bladder dissection|The bladder dissection is early as in classic cesarean hysterectomy
75868291|NCT03729323|Behavioral|Nursing Consultation|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be approached in a conventional manner, as routine of the services, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in DM2 and SAH and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
76031152|NCT02331121|Behavioral|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
76031153|NCT02330809|Other|Daily extra water intake|Amount of extra daily water intake to consume
76031154|NCT02330809|Other|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
76031155|NCT05077813|Combination Product|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
75382091|NCT00002173|Biological|HIV-1 Immunogen|
75382092|NCT03805022|Drug|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
75382093|NCT03805022|Drug|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
75382094|NCT03805022|Drug|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
75868292|NCT01381536|Drug|GSK1550188 1mg/kg or 10mg/kg|IV one shot
75868293|NCT02676778|Drug|E7777|
75382095|NCT03805022|Drug|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
75868294|NCT03160924|Other|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
75382096|NCT03805022|Drug|At the discretion of the investigator|Drug at the discretion of the investigator.
75382097|NCT05752435|Procedure|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS|comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts
75382098|NCT00003050|Drug|cyclophosphamide|
75382099|NCT00003050|Drug|doxorubicin hydrochloride|
75382100|NCT00003050|Drug|paclitaxel|
75382101|NCT00003050|Drug|tamoxifen citrate|
75382102|NCT00003050|Procedure|surgical procedure|
75382103|NCT00003050|Radiation|radiation therapy|
75382104|NCT03798860|Diagnostic Test|blood samples|For performing the Luminex solid phase assay (SPA) test, 7.5 ml of patient whole blood are collected from a peripheral vein.
75868295|NCT01381458|Drug|FSC|fluticasone propionate / salmeterol xinofoate combination
75868296|NCT01381458|Drug|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
75868297|NCT05419440|Procedure|laparoscopic drainage of appendicular abscess|access to caecum and remove any adhesions with surrounding by sharp & blunt dissection , then access to appendicular abscess by sharp and blunt dissection after complete separation of the appendix from surrounding & complete drainage of pus & removal of all necrotic tissue , removal of the remnant appendix , in cases with healthy base of appendix ,we closed the stump with endo-loop , in case with unhealthy base , we closed the stump by suturing by ethibond 2/0 in two layers in case with little edema & inflammation of caecum ( sutures not cut through ) , in cases with marked edema and inflammation of caecum , we close the site of base by omental patch fixed by taking full thickness sutures in wall of caecum and pass through omental patch , we examine any leak by pressing on caecum and observe any fecal matter comes & air leak test , in all cases we put large drain at pelvis
75868298|NCT05746156|Diagnostic Test|lymphatic mapping|"Peritumoral injection of [99mTc]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine."
75868299|NCT05179486|Procedure|Biospecimen Collection|Undergo collection of tissue, and blood
75382105|NCT00002179|Drug|Indinavir sulfate|
75382106|NCT00002179|Drug|Lamivudine|
75382107|NCT00002179|Drug|Zidovudine|
75382108|NCT00003056|Drug|cyclosporine|
75382109|NCT00003056|Drug|cyclosporine and methotrexate|
75382110|NCT00002185|Drug|Nelfinavir mesylate|
75382111|NCT01923506|Radiation|stereotactic body radiation therapy|Undergo SBRT
75382112|NCT01923506|Procedure|quality-of-life assessment|Ancillary studies
75382113|NCT01923506|Other|laboratory biomarker analysis|Correlative studies
75382114|NCT00003062|Drug|temozolomide|
75382115|NCT00002191|Drug|Albendazole|
75382116|NCT00383396|Drug|Topical Cyclosporine|
75382117|NCT00002197|Drug|Abacavir sulfate|
75382118|NCT00003068|Drug|amifostine trihydrate|
75382119|NCT00003068|Drug|cyclophosphamide|
75382120|NCT00003068|Drug|mitoxantrone hydrochloride|
75382121|NCT00003068|Drug|thiotepa|
75382122|NCT00003068|Procedure|peripheral blood stem cell transplantation|
75382123|NCT00002503|Radiation|strontium chloride Sr 89|
75382124|NCT01719458|Drug|(S,S)-[11C]MRB|PET radioligand
75382125|NCT00003080|Drug|endocrine-modulating drug therapy|
75382126|NCT00003080|Drug|melphalan|
75382127|NCT00003080|Drug|mitoxantrone hydrochloride|
75382128|NCT00003080|Drug|tamoxifen citrate|
75382129|NCT00003080|Drug|thiotepa|
75382130|NCT00003080|Procedure|peripheral blood stem cell transplantation|
75382131|NCT00002203|Drug|Lamivudine/Zidovudine|
75382132|NCT00002203|Drug|Lamivudine|
75382133|NCT00002203|Drug|Zidovudine|
75382134|NCT01568918|Drug|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
75382135|NCT01568918|Other|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
75382136|NCT02973139|Other|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
75382137|NCT02973139|Other|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
75382138|NCT00003086|Biological|filgrastim|
75382139|NCT00003086|Drug|CAF regimen|
75382140|NCT00003086|Drug|carboplatin|
75382141|NCT00003086|Drug|cisplatin|
75382142|NCT00003086|Drug|cyclophosphamide|
75382143|NCT00003086|Drug|doxorubicin hydrochloride|
75382144|NCT00003086|Drug|fluorouracil|
75382145|NCT00003086|Drug|ifosfamide|
75382146|NCT00003086|Drug|melphalan|
75382147|NCT00003086|Drug|paclitaxel|
75382148|NCT00003086|Drug|thiotepa|
75382149|NCT00003086|Procedure|peripheral blood stem cell transplantation|
75382150|NCT00003086|Radiation|samarium Sm 153 lexidronam pentasodium|
75382151|NCT01334450|Device|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
75382152|NCT00002209|Drug|CPI-1189|
75382153|NCT00003092|Drug|paclitaxel|
75382154|NCT00381199|Drug|Amitriptyline Hydrochloride|
75382155|NCT00381199|Drug|Nabilone|
75382156|NCT00002509|Biological|filgrastim|
75382157|NCT00002509|Drug|carboplatin|
75382158|NCT00002509|Drug|cyclophosphamide|
75382159|NCT00002509|Drug|etoposide|
75382160|NCT00002509|Drug|mesna|
76031156|NCT05077813|Combination Product|9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
75382161|NCT00002509|Procedure|autologous bone marrow transplantation|
75382162|NCT00002509|Procedure|peripheral blood stem cell transplantation|
75382163|NCT00002515|Biological|filgrastim|
75382164|NCT00002515|Drug|carboplatin|
75382165|NCT00002515|Drug|thiotepa|
75382166|NCT00002515|Drug|topotecan hydrochloride|
75382167|NCT00002515|Procedure|autologous bone marrow transplantation|
75382168|NCT00002515|Procedure|bone marrow ablation with stem cell support|
75382169|NCT00002515|Procedure|in vitro-treated bone marrow transplantation|
75541378|NCT04673071|Other|Sham-TEA (STEA)|STEA in 1 month for 4 months All procedure of Sham-TEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
75382170|NCT00003098|Other|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
75382171|NCT00003098|Other|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
75382172|NCT00381277|Drug|Gatorade|
75382173|NCT00381277|Drug|Performance|
75382174|NCT04712630|Procedure|Non-incised papila surgical approach without grafting biomaterial|Periodontal reconstructive surgery
75382175|NCT04712630|Procedure|Non-incised papila surgical approach with grafting biomaterial|Periodontal reconstructive surgery
75382176|NCT00002521|Drug|cisplatin|
75382177|NCT00002521|Drug|cyclophosphamide|
75382178|NCT00002521|Drug|etoposide|
75382179|NCT00002521|Procedure|autologous bone marrow transplantation|
75382180|NCT00002521|Procedure|bone marrow ablation with stem cell support|
75382181|NCT00002521|Procedure|peripheral blood stem cell transplantation|
75382182|NCT00002521|Procedure|syngeneic bone marrow transplantation|
75382183|NCT00002521|Radiation|radiation therapy|
76031157|NCT05077813|Combination Product|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|Active Comparator: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D 50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
75541379|NCT04672642|Device|SpyGlass DS|Detection by the SpyGlass DS of residual pancreatic stones not detected by the standard method (CT scan and ERCP)
75541380|NCT00233129|Behavioral|Top Down|Six months
75541381|NCT00233129|Other|cognitive rehabilitation day treatment program|six months
75541382|NCT00260130|Other|food in fluid form|dietary intake of fluid forms of vegetables
75541383|NCT00260130|Other|food in solid form|dietary intake of solid forms of vegetables
75868300|NCT05179486|Other|Questionnaire Administration|Complete questionnaire
75541384|NCT04672603|Procedure|Complete Preservation of Denonvilliers' Fascia|Patients accept L-PANP surgery with complete preservation of Denonvilliers Fascia
75704847|NCT04455867|Behavioral|Diabetes Exercise and Healthy Lifestyle Program|The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.
75704848|NCT04455867|Other|Outpatient care|Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education
75704849|NCT04453072|Other|Interview|Participate in interviews
75868301|NCT05419206|Diagnostic Test|CMV DNA analysis|CMV DNA quantitative viral load levels were studied
75868302|NCT05746000|Behavioral|Intervention Group (IG)|Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.
75382184|NCT00581906|Radiation|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) & group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite & will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st & 2nd weeks of treatment & the 2nd intra-treatment DCE-MRI is recommended between the 3rd & 4th weeks of treatment.
75382185|NCT00003104|Radiation|radiation therapy|
75382186|NCT05751889|Behavioral|Serious Game|Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
75541385|NCT00233168|Behavioral|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
75541386|NCT00233168|Behavioral|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
75704850|NCT04453072|Other|Media Intervention|Receive iPhone with W8Loss2Go app
75704851|NCT04453072|Other|Questionnaire Administration|Complete questionnaires
75704852|NCT04453072|Other|Scale Device|Receive body scale and food scale
75704853|NCT04453072|Behavioral|Telephone-Based Intervention|Receive telephone calls
75704854|NCT04453072|Other|Text Message|Receive text message
75704855|NCT04447092|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
75868303|NCT05746000|Behavioral|Control Group (CG)|Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
75868304|NCT03162406|Dietary Supplement|Vitamin D3|Oral supplementation 25000 IU once per week for 6 months
75868305|NCT03162406|Dietary Supplement|Placebo|Oral supplementation once per week for 6 months
75868306|NCT02946385|Biological|Meningococcal ABCWY Vaccine|Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
76023078|NCT03173677|Dietary Supplement|Lipid Intake|90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
75704856|NCT04447092|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
75704857|NCT04447092|Drug|Pembrolizumab|Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
75704858|NCT04447092|Drug|Oxaliplatin|Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
75704859|NCT04447092|Drug|Leucovorin|Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
75704860|NCT04447092|Drug|Irinotecan|Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
75704861|NCT04447092|Drug|5FU|5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
75868307|NCT02946385|Biological|Meningococcal B Recombinant vaccine|Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
76023079|NCT03173677|Dietary Supplement|Glucose intake|300 calories of glucose
75382187|NCT05751889|Behavioral|Traditional Health Education|Reading materials regarding HCV and safe sexual practice.
76023080|NCT03173677|Dietary Supplement|Protein intake|Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
76023081|NCT02405065|Drug|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
76023082|NCT03173599|Drug|PNA 40mg|The beginning dose is 40mg.
76023083|NCT03173599|Drug|PNA 80mg|The single dose is 80mg.
76023084|NCT03173599|Drug|PNA 160mg|The single dose is 160mg.
76023085|NCT03173599|Drug|PNA 240mg|The single dose is 240mg.
76023086|NCT03173599|Drug|PNA 360mg|The single dose is 360mg.
76023087|NCT03173599|Drug|PNA 480mg|The single dose is 480mg.
76023088|NCT03173599|Drug|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
76023089|NCT03173287|Procedure|Quantification of liver fibrosis|Procedure MRI and liver biopsy
76023090|NCT02425787|Behavioral|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
75382188|NCT00003110|Biological|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
75382189|NCT00002215|Drug|Emivirine|
75382190|NCT00002215|Drug|Nelfinavir mesylate|
75382191|NCT00003116|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
75382192|NCT00003116|Drug|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
75382193|NCT00003116|Drug|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
75541387|NCT04672837|Procedure|Pediatric Integrative Manual Therapy and educational therapy|Pediatric Integrative Manual Therapy is a soft Orthopedic Manual Therapy approach por infants and children. It integrates joints soft mobilisation, myofascial release and neurodynamic mobilisation. Also the educational therapy.
75541388|NCT04672837|Procedure|Stretching and educational therapy|It is a protocol of stretching based on literature research. Also the educational therapy with counter positioning, stimulation in prone position, positional care, etc.
75541389|NCT00267579|Behavioral|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
75541390|NCT04672759|Drug|Durvalumab|Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
75541391|NCT04672759|Drug|Durvalumab|Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.
75541392|NCT04672408|Device|His bundle pacing|Pacing with capture of the His bundle
75541393|NCT04672408|Device|Right ventricular pacing|Pacing from the right ventricular lead (septal or apical)
75541394|NCT04672096|Device|Neuronoff BASMATI Injectrode|The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.
75541395|NCT00260169|Behavioral|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
75541396|NCT00260169|Behavioral|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
75541397|NCT00233207|Drug|IC14|
75382194|NCT00003116|Drug|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
75382195|NCT00003116|Procedure|bone marrow ablation with stem cell support|
75382196|NCT00003116|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
75382197|NCT00002221|Drug|Peripheral blood stem cells|
75382198|NCT00002227|Drug|Efavirenz|
75382199|NCT00002227|Drug|Lamivudine|
75382200|NCT00002227|Drug|Stavudine|
75541398|NCT04672057|Other|assessment of gait parameters|Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.
75541399|NCT00260247|Drug|carbamazepine oxcarbazepine|
75541400|NCT04671979|Diagnostic Test|Lactate Dehydrogenase|All the patients that arrived at the hospital with symptoms of mesenteric ischemia, had a registered lactate dehydrogenase. We compared the value with the patient's outcomes.
75382201|NCT00002233|Drug|Indinavir sulfate|
75382202|NCT00002233|Drug|Abacavir sulfate|
75382203|NCT00002233|Drug|Amprenavir|
75382204|NCT00002233|Drug|Lamivudine|
75541401|NCT00233246|Procedure|FFP Infusion|
75382205|NCT00002527|Drug|aspirin|
75382206|NCT00002527|Other|placebo|
75382207|NCT00002533|Drug|fluconazole|
75382208|NCT00002533|Radiation|radiation therapy|
75382209|NCT00003122|Procedure|surgical procedure|
75541402|NCT04671745|Behavioral|Music|patient receiving care with interactive music
75541403|NCT04671745|Behavioral|No music|patient receiving care without interactive music
75382210|NCT02973217|Device|Immunostimulating Interstitial Laser Thermotherapy|
75382211|NCT00002539|Biological|filgrastim|
75382212|NCT00002539|Drug|cisplatin|
75382213|NCT00002539|Drug|doxorubicin hydrochloride|
75382214|NCT00002539|Procedure|conventional surgery|
75382215|NCT00381589|Drug|ipratropium bromide 0.03% spray|
75382216|NCT00002239|Drug|Enfuvirtide|
75382217|NCT00002239|Drug|Ritonavir|
75382218|NCT00002239|Drug|Abacavir sulfate|
75382219|NCT00002239|Drug|Amprenavir|
75382220|NCT00002239|Drug|Efavirenz|
75382221|NCT00383474|Drug|Bortezomib|Given IV
75382222|NCT00383474|Other|Laboratory Biomarker Analysis|Correlative studies
75382223|NCT00383474|Drug|Tipifarnib|Given orally
75382224|NCT00002245|Drug|Abacavir sulfate|
75382225|NCT00002245|Drug|Amprenavir|
75541404|NCT00260286|Behavioral|Energy availability|
75541405|NCT04671589|Drug|Meropenem Injection|"Administration Intravenous meropenem 1gram every 8 hours together with standard care;~."
75704862|NCT04437134|Other|On-line exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. Patients are instructed in how to use alternative equipment at home for each exercise if necessary prior to the first on-line exercise session.~Education:~Patients attend two to three on-line educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
76023091|NCT02425787|Behavioral|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews &/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
75382226|NCT00002245|Drug|Lamivudine|
75382227|NCT00003128|Biological|filgrastim|
75382228|NCT00003128|Drug|ifosfamide|
75541406|NCT04671199|Other|MP 3000 monitor|Additional monitoring
75541407|NCT00260325|Drug|valdecoxib|
76023092|NCT02425787|Behavioral|Interview|The interview will be conducted by study team members and will center around legacy item-related questions.
75382229|NCT00003128|Drug|paclitaxel|
75382230|NCT04331197|Drug|Clomiphene Citrate 50mg|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
75382231|NCT04331197|Drug|Letrozole 2.5mg|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
75382232|NCT05751733|Drug|Apatinib Mesylate|Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.
75382233|NCT05751733|Drug|Sunitinib, Imatinib dosage, Dasatinib, Reveratinib|Second-line TKI drugs
75382234|NCT00002798|Drug|asparaginase|
75382235|NCT00002798|Drug|daunorubicin hydrochloride|
75382236|NCT00002798|Drug|fludarabine phosphate|
75382237|NCT00002798|Drug|therapeutic hydrocortisone|
75382238|NCT00002798|Procedure|allogeneic bone marrow transplantation|
75382239|NCT00002798|Radiation|3-dimensional conformal radiation therapy|
75382240|NCT00002798|Biological|filgrastim|Given SC
75382241|NCT00002798|Drug|cytarabine|Given IV or IT
75382242|NCT00002798|Drug|idarubicin|Given IV
75382243|NCT00002798|Drug|dexamethasone|Given PO
75382244|NCT00002798|Drug|thioguanine|Given PO
75382245|NCT00002798|Drug|etoposide|Given IV
75382246|NCT00002798|Drug|methotrexate|Given IT
75382247|NCT00002798|Drug|cyclophosphamide|Given IV
75382248|NCT00002798|Biological|aldesleukin|
75382249|NCT00002798|Drug|busulfan|
75382250|NCT00002251|Drug|Ganciclovir|
75382251|NCT00002257|Drug|Ganciclovir|
75382252|NCT00003134|Drug|irinotecan hydrochloride|
75382253|NCT00002545|Drug|carmustine|
75382254|NCT00002545|Radiation|low-LET photon therapy|
75382255|NCT00002804|Biological|filgrastim|
75382256|NCT00002804|Drug|doxorubicin hydrochloride|
75382257|NCT00002804|Drug|ifosfamide|
75382258|NCT00002804|Drug|mesna|
75541408|NCT04671277|Other|Chewing of breads|"During the video recording session, participants were asked to place the whole sample (5-6 g) in the mouth (e.g. single bite) and chew naturally until the bolus is ready for swallowing.~During the second section, participants were asked to place the whole sample in the mouth and chew naturally. After 5 chewing cycles, participants checked all the attributes that describe the texture sensations perceived at the beginning of mastication. A list of attributes and their definitions were provided to guide the participants. Participants proceeded with chewing until the swallowing point when they again checked all the attributes that characterize the texture sensations perceived at the end of mastication. The food bolus was then spat in a container."
75541409|NCT00233441|Drug|CELIVARONE (SSR149744C)|
75382259|NCT00002804|Drug|vincristine sulfate|
75382260|NCT00002804|Procedure|conventional surgery|
75382261|NCT00002804|Radiation|brachytherapy|
75382262|NCT00002804|Radiation|low-LET cobalt-60 gamma ray therapy|
75382263|NCT00002804|Radiation|low-LET electron therapy|
75382264|NCT00002804|Radiation|low-LET photon therapy|
75382265|NCT00002810|Biological|filgrastim|
75382266|NCT00002810|Drug|melphalan|
75382267|NCT00002810|Procedure|bone marrow ablation with stem cell support|
75382268|NCT00002810|Procedure|peripheral blood stem cell transplantation|
75382269|NCT00003140|Drug|letrozole|Given orally
75382270|NCT00003140|Other|placebo|Given orally
75382271|NCT00003392|Biological|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
75382272|NCT00003392|Drug|carboplatin|18 AUC IV, approximately days 21, 42
75382273|NCT00003392|Drug|cyclophosphamide|4 gm/m2 IV, day 1
75382274|NCT00003392|Drug|melphalan|140 mg/m2 IV , approximately day 63
75382275|NCT00003392|Drug|paclitaxel|170 mg/m2 IV day 1
75382276|NCT00003392|Procedure|bone marrow ablation with stem cell support|
75382277|NCT00003392|Procedure|peripheral blood stem cell transplantation|
75382278|NCT00002551|Drug|fluorouracil|See arm assignments.
75382279|NCT00002551|Drug|leucovorin calcium|See arm assignments.
75382280|NCT00002551|Drug|levamisole hydrochloride|See arm assignments.
75382281|NCT00002551|Radiation|radiation therapy|See arm assignments.
75382282|NCT00003146|Drug|busulfan|
75382283|NCT00003146|Drug|melphalan|
75382284|NCT00003146|Drug|thiotepa|
75382285|NCT00003146|Procedure|bone marrow transplantation|
75382286|NCT00003146|Procedure|peripheral blood stem cell transplantation|
75382287|NCT00003398|Biological|anti-thymocyte globulin|
75382288|NCT00003398|Biological|filgrastim|
75382289|NCT00003398|Drug|cyclophosphamide|
75382290|NCT00003398|Drug|thiotepa|
75382291|NCT00003398|Procedure|allogeneic bone marrow transplantation|
75382292|NCT00003398|Procedure|bone marrow ablation with stem cell support|
75382293|NCT00003398|Radiation|radiation therapy|
75382294|NCT00002263|Drug|Zidovudine|
75382295|NCT00002263|Drug|Sargramostim|
75382296|NCT00002816|Drug|cytarabine|Given IV
75382297|NCT00002816|Drug|dexamethasone|Given IV
76023093|NCT03173365|Drug|Brimonidine Tartrate|1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
76023094|NCT05100953|Behavioral|Physical Activity Counseling|Physical activity counseling will be provided under supervision by the researcher physiotherapist via video conference and an individual physical activity program will be organized weekly for two months.
76023095|NCT03171337|Device|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
76023096|NCT03171337|Device|Fu's Subcutaneous Needling (FSN)|Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
75382298|NCT00002816|Drug|etoposide|Given IV
75382299|NCT00002816|Drug|idarubicin|Given IV
75382300|NCT00002816|Drug|ifosfamide|Given IV
75382301|NCT00002816|Drug|leucovorin calcium|
75382302|NCT00002816|Drug|mesna|Given IV
75382303|NCT00002816|Drug|pegaspargase|Given IV
75382304|NCT00002816|Drug|therapeutic hydrocortisone|
75382305|NCT00002816|Drug|thioguanine|
75382306|NCT00002816|Drug|vincristine sulfate|Given IV
75382307|NCT00002816|Radiation|low-LET cobalt-60 gamma ray therapy|
75382308|NCT00002816|Radiation|low-LET electron therapy|
75382309|NCT00002816|Radiation|low-LET photon therapy|
75382310|NCT00002816|Drug|Methotrexate|Given IV
75382311|NCT05751499|Diagnostic Test|• Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN|"Low Back Outcome Scale~Center for Epidemiological Studies-Depression Scale (CES-D)~International Physical Activity Questionnaire~Roland-Morris Disability Questionnaire~Force Platform~Pain Self-Efficacy Questionnaire (PSEQ)~Numeric Rating Scale~Job Content Questionnaire~Pits Burgh Sleep Quality Index (PSQI)~Orebo Musculoskeletal Pain Screening Questionnaire~Gait & Balance App~Keele STarT Back Screening Tool (SBST)~Fear-Avoidance Beliefs Questionnaire (FABQ)~Pain Catastrophizing Scale"
75382312|NCT00002269|Drug|Ampligen|
75382313|NCT00002269|Drug|Zidovudine|
75382314|NCT00002275|Drug|Fat Emulsion 2%|
75541410|NCT04671160|Diagnostic Test|Assessment the activity of anti-Xa factor.|Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
75382315|NCT00002275|Drug|Fat Emulsion 20%|
75382316|NCT00003152|Biological|filgrastim|
75541411|NCT04671394|Procedure|FMUD + DLIG|Full-Mouth Ultrasonic Debridement + Diode Laser and Indocyanine Green solution
75541412|NCT04671394|Procedure|FMUD + ST|Full-Mouth Ultrasonic Debridement + Sham Treatment
75541413|NCT04671550|Diagnostic Test|questionnaire|"Questionnaire on Driving performances and Visual Field"
75382317|NCT00003152|Biological|recombinant interferon alfa|
75382318|NCT00003152|Drug|cyclophosphamide|
75382319|NCT00003152|Drug|prednisone|
75382320|NCT00003152|Drug|vincristine sulfate|
75382321|NCT00003152|Procedure|autologous bone marrow transplantation|
75382322|NCT00003152|Procedure|bone marrow ablation with stem cell support|
75382323|NCT00003152|Procedure|peripheral blood stem cell transplantation|
75382324|NCT00003152|Radiation|radiation therapy|
75541414|NCT00233558|Drug|adalimumab (up to 9 months exposure)|
75541415|NCT00233558|Drug|methotrexate|
75541416|NCT00267618|Behavioral|FHP Pain|Evidence-based psychological and behavioural Intervention
75541417|NCT04670926|Diagnostic Test|TruGraf|"TruGraf results will be available in real-time and used by the physician in conjunction with other standard of care labs to guide management of immunosuppression as follows:~Patients with a stable serum creatinine and eGFR of > 45 mL/min who also have a TruGraf TX result at month 3 will have their Mycophenolate Mofetil or Mycophenolate Sodium decreased from a standard dose of 1000 mg twice daily to 500 mg twice daily or 720 mg twice daily to 360 mg twice daily respectively.~Patients with a stable serum creatinine and estimated eGFR of > 45 mL/min who also have a TruGraf TX result at months 4, 5, and 6 will have their Tacrolimus target trough level decreased to a target between 3 and 6.~Patients with TruGraf not-TX will have no further immunosuppression reduction and continued to be monitored."
76023097|NCT03171337|Device|Sham acupuncture|Sham acupuncture at non-acupoints using Steinberger placebo needles
75382325|NCT05751421|Drug|Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution|zynrelef will be administered during surgery
75382326|NCT05751421|Drug|Bupivacaine HCl 0.5% Injectable Solution|adductor canal block will be performed using bupivacaine before surgery
75382327|NCT05751421|Procedure|primary total knee replacement|primary total knee replacement
75382328|NCT00002822|Drug|carboplatin|
75382329|NCT00002822|Drug|cisplatin|
75382330|NCT00002822|Drug|cyclophosphamide|
75382331|NCT00002822|Drug|doxorubicin hydrochloride|
75382332|NCT00002822|Drug|etoposide|
75382333|NCT00002822|Drug|ifosfamide|
75382334|NCT00002822|Drug|mesna|
75382335|NCT00002822|Drug|vincristine sulfate|
75382336|NCT00002822|Radiation|radiation therapy|
75382337|NCT00002281|Drug|Filgrastim|
75382338|NCT00002281|Drug|Epoetin alfa|
75382339|NCT00002281|Drug|Zidovudine|
75382340|NCT00002287|Drug|Zidovudine|
75382341|NCT00002828|Drug|fluorouracil|
75382342|NCT00002828|Drug|raltitrexed|
75382343|NCT00003410|Drug|motexafin gadolinium|
75382344|NCT00003410|Procedure|magnetic resonance imaging|
75382345|NCT00003410|Procedure|surgical procedure|
75382346|NCT00384020|Drug|Paroxetine (Seroxat)|
75382347|NCT00384020|Drug|Escitalopram (Lexapro)|
75382348|NCT00384098|Drug|CTA018 cream|
75382349|NCT00002557|Drug|CHOP regimen|
75382350|NCT00002557|Drug|doxorubicin hydrochloride|
75382351|NCT00002557|Drug|etoposide|
75382352|NCT00002557|Drug|leucovorin calcium|
75382353|NCT00002557|Drug|methotrexate|
75382354|NCT00003158|Drug|carboplatin|
75382355|NCT00003158|Drug|etoposide|
75382356|NCT00003158|Drug|paclitaxel|
75382357|NCT00003158|Radiation|radiation therapy|
75382358|NCT00002563|Procedure|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
75382359|NCT00002563|Procedure|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
75382360|NCT00003416|Biological|filgrastim|
75382361|NCT00003416|Biological|recombinant interferon alfa|
75382362|NCT00003416|Drug|dexamethasone|
75382363|NCT00003416|Drug|melphalan|
75382364|NCT00003416|Procedure|peripheral blood stem cell transplantation|
75382365|NCT00002569|Drug|lomustine|
75382366|NCT00002569|Drug|procarbazine hydrochloride|
75382367|NCT00002569|Drug|vincristine sulfate|
75382368|NCT00002569|Radiation|radiation therapy|
75382369|NCT00002840|Drug|lomustine|
75382370|NCT00002840|Drug|procarbazine hydrochloride|
75382371|NCT00002840|Drug|vincristine sulfate|
75382372|NCT00002840|Radiation|radiation therapy|
75382373|NCT00002846|Biological|aldesleukin|
75382374|NCT00002846|Procedure|conventional surgery|
75382375|NCT05720767|Drug|HMPL-523|HMPL-523 is a selective small-molecule SYK inhibitor.
75382376|NCT05720767|Drug|Itraconazole|Itraconazole is an FDA approved synthetic triazole antifungal agent
75382377|NCT05720767|Drug|Rifampin|Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
75382378|NCT00003170|Dietary Supplement|glutamine|
75382379|NCT00003170|Other|placebo|
75382380|NCT05751031|Drug|Raltegravir|Raltegravir exposure in pregnant women living with HIV in routine clinical care. No study intervention administrated.
75382381|NCT00002852|Drug|paclitaxel|Given IV
75382382|NCT00002852|Drug|carboplatin|Given IV
75382383|NCT00002852|Procedure|therapeutic conventional surgery|Undergo surgery
75382384|NCT05750719|Genetic|BRCA1/2 genetic testing|All patients will undergo genetic testing for BRCA 1 and BRCA 2 germline mutations, employing next generation sequencing (NGS) techniques.
75382385|NCT00003422|Drug|fluorouracil|
75382386|NCT00003422|Drug|leucovorin calcium|
75382387|NCT00003422|Procedure|adjuvant therapy|
76023098|NCT05100719|Drug|alverine-citrate + simethicone and lactase|Patients who randomized in the first arm are treated with alverine-citrate + simethicone and lactase.
76023099|NCT05100719|Drug|alverin-citrate + simethicone with placebo|Patients in the second arm receive alverin-citrate + simethicone with placebo without lactase.
75382388|NCT00003422|Procedure|conventional surgery|
75382389|NCT00003422|Procedure|neoadjuvant therapy|
75382390|NCT00003422|Radiation|radiation therapy|
75382391|NCT00003176|Drug|carmustine|
75382392|NCT00003176|Drug|temozolomide|
75382393|NCT00003428|Drug|arzoxifene hydrochloride|
75382394|NCT00002858|Drug|cisplatin|
75382395|NCT00002858|Drug|cyclophosphamide|
75382396|NCT00002858|Drug|doxorubicin hydrochloride|
75382397|NCT00002858|Drug|etoposide|
75382398|NCT00002858|Radiation|radiation therapy|
75382399|NCT00002575|Procedure|conventional surgery|
75382400|NCT00002575|Procedure|laparoscopic surgery|
75382401|NCT00002864|Drug|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
75382402|NCT00002864|Drug|tamoxifen citrate|20 mg PO for 5 years
75382403|NCT00002870|Biological|filgrastim|
75382404|NCT00002870|Drug|cyclophosphamide|
75382405|NCT00002870|Drug|epirubicin hydrochloride|
75382406|NCT00002870|Drug|fluorouracil|
75382407|NCT00002870|Drug|thiotepa|
75382408|NCT00002870|Procedure|peripheral blood stem cell transplantation|
75382409|NCT00002581|Drug|cyclophosphamide|
75382410|NCT00002581|Drug|fluorouracil|
75382411|NCT00002581|Drug|methotrexate|
75382412|NCT00002581|Drug|tamoxifen citrate|
75382413|NCT00002581|Procedure|conventional surgery|
75382414|NCT00002581|Radiation|radiation therapy|
75382415|NCT00003182|Drug|cisplatin|
75382416|NCT00003182|Drug|gemcitabine hydrochloride|
75382417|NCT00002587|Drug|paclitaxel|
75382418|NCT00002587|Drug|topotecan hydrochloride|
75382419|NCT00003434|Biological|carcinoembryonic antigen peptide 1|
75382420|NCT00003434|Biological|hepatitis B antigen peptide|
75382421|NCT05750641|Other|removing milk and dairy products from diets without medical treatment|A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
75382422|NCT05750641|Other|According to current standard algorithms and guidelines, appropriate treatment for FD types.|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
75382423|NCT00002876|Drug|cisplatin|
75382424|NCT00002876|Drug|etoposide|
75382425|NCT00002593|Drug|fluorouracil|Given IV as described in Arm Description
75382426|NCT00002593|Drug|leucovorin calcium|Given IV as described in Arm description.
75382427|NCT00002593|Drug|levamisole hydrochloride|Given as described in arm description
75382428|NCT00003194|Biological|filgrastim|
75382429|NCT00003194|Drug|carboplatin|
75382430|NCT00003194|Drug|cyclophosphamide|
75382431|NCT00003194|Drug|etoposide|
75382432|NCT00003194|Drug|thiotepa|
75382433|NCT00003194|Drug|topotecan hydrochloride|
75382434|NCT00003194|Procedure|peripheral blood stem cell transplantation|
75382435|NCT00002882|Biological|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
75382436|NCT00002882|Biological|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
75382437|NCT00002882|Drug|Cisplatin|IV Days 1-4
75382438|NCT00002882|Drug|Dacarbazine|IVPB on day 1
75382439|NCT00002882|Drug|Vinblastine|IVPB on days 1-4
75382440|NCT00002882|Procedure|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
75382441|NCT05750563|Dietary Supplement|diosmin and micronized flavonoids|the symptomatic treatment of haemorrhoids
75382442|NCT05750563|Other|Placebo|Use as comparator
75382443|NCT00002888|Drug|cisplatin|
75382444|NCT00002888|Drug|fluorouracil|
75382445|NCT00002888|Drug|paclitaxel|
75382446|NCT00002599|Biological|filgrastim|
75382447|NCT00002599|Biological|recombinant interferon alfa|
75541418|NCT04670926|Other|Standard of Care|Patient's immunosuppression will be managed per the current CPMC standard of care that includes continuation of Mycophenolate Mofetil or Mycopheonolate Sodium at 1000 mg bid or 720 mg bid respectively. The dose may be decreased at the discretion of the physician for drug adverse effects such as diarrhea or other gastrointestinal side-effects or neutropenia as is the standard of care. Patients will be maintained on Tacrolimus at target levels that are considered standard of care by the managing physician.
75541419|NCT00233636|Drug|Iressa (Gefitinib)|
75541420|NCT00233636|Procedure|Radiotherapy|
75382448|NCT00002599|Biological|sargramostim|
75382449|NCT00002599|Drug|carmustine|
75382450|NCT00002599|Drug|cyclophosphamide|
75382451|NCT00002599|Drug|doxorubicin hydrochloride|
75382452|NCT00002599|Drug|melphalan|
75382453|NCT00002599|Drug|methylprednisolone|
75382454|NCT00002599|Drug|prednisone|
75382455|NCT00002599|Drug|vincristine sulfate|
75382456|NCT00002599|Radiation|low-LET cobalt-60 gamma ray therapy|
75382457|NCT00002599|Radiation|low-LET photon therapy|
75382458|NCT05693701|Behavioral|Implementation Strategy Bundle|Bundle includes multimodal communications to notify donors about high cholesterol and its treatment, website with resources, and an optional care navigator. Resources for their primary care provider will also be disseminated.
75382459|NCT05693701|Other|Usual care notification|Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.
75382460|NCT00003440|Drug|paclitaxel|Given IV over 1 hour or 3 hours
75382461|NCT00003440|Biological|trastuzumab|Given IV
75382462|NCT00003440|Procedure|quality-of-life assessment|Ancillary studies
75382463|NCT00003440|Other|laboratory biomarker analysis|Correlative studies
75382464|NCT00003200|Drug|Taxotere|
75382465|NCT00003200|Radiation|Radiation therapy|
75382466|NCT05750485|Other|Pupilometric evaluation|Pupilometric evaluation under procedural sedation with propofol
75382467|NCT05750407|Behavioral|Lifestyle change|Three modules target healthy eating, activity, and weight control behaviors
75382468|NCT00003446|Drug|fluorouracil|
75382469|NCT00003446|Drug|leucovorin calcium|
75382470|NCT00003446|Drug|trimetrexate glucuronate|
75382471|NCT00003938|Drug|liposomal amphotericin B|
75382472|NCT05750251|Procedure|levator muscle resection surgery|conventional ptosis surgery
75382473|NCT05750251|Procedure|Müller's muscle-conjuctival resection surgery|conventional ptosis surgery
75382474|NCT05750251|Procedure|full-thickness anterior blepharotomy surgery|conventional eyelid retraction surgery
75382475|NCT00003212|Drug|doxorubicin hydrochloride|
75382476|NCT00003212|Drug|ifosfamide|
75382477|NCT00002611|Biological|dactinomycin|
75382478|NCT00002611|Biological|filgrastim|
75382479|NCT00002611|Drug|cyclophosphamide|
75541421|NCT04670887|Procedure|Delayed surgery|Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
75868308|NCT05177341|Other|Determining Preferred Walking Speed|In the beginning, sensors of the gait analysis system (RehaGait®), which can record the time-distance characteristics of consecutive multiple steps (step length, step width, double step length, and timing information, etc.) will be installed. The 7 sensors of this system are attached to the shoes of the individual, proximal to the ankle, distal thigh, and sacroiliac joint level (Aminian et al., 2014). Individuals will be required to wear casual athletic shoes and comfortable, non-knee-covering shorts. Next; Each individual will walk freely on the treadmill at their own pace. To find the preferred walking speed of the individual, Hinton et al. protocol will be used (Hinton et al., 2018). The speed of the treadmill will be increased or decreased in line with the direction of the participants. After being determined according to the protocol, the individual will practice walking at this speed for 4-5 minutes. The individual will rest as much as he or she wants.
75868309|NCT05308771|Device|VPC syringe|Use of the visual pressure control syringe for epidural space detection
75382480|NCT00002611|Drug|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; <5% in the urine. The drug has a very short initial t½ of <20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
75382481|NCT00002611|Drug|etoposide|
75382482|NCT00002611|Drug|vincristine sulfate|
75868310|NCT05676190|Combination Product|CIK combined with chemotherapy group|Combination of chemotherapy and autologous cytokine induced killer cells
75382483|NCT00002611|Procedure|conventional surgery|
75382484|NCT00002611|Radiation|radiation therapy|
75382485|NCT00003944|Biological|filgrastim|
75382486|NCT00003944|Drug|carboplatin|
75868311|NCT05676190|Combination Product|CIK combined immunotherapy group|Combination of immunotherapy and autologous cytokine induced killer cells
75382487|NCT00003944|Drug|cyclophosphamide|
75382488|NCT00003944|Drug|paclitaxel|
75382489|NCT00003944|Drug|topotecan hydrochloride|
75382490|NCT00003944|Procedure|peripheral blood stem cell transplantation|
75868312|NCT05676190|Combination Product|CIK combined targeted therapy group|Combination of targeted therapy and autologous cytokine induced killer cells
75868313|NCT05676190|Combination Product|CIK in combination with other therapies|CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
75382491|NCT00003950|Drug|cyclosporine|
75382492|NCT00003950|Drug|CPT-11|
75382493|NCT00003452|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75382494|NCT00003464|Drug|temozolomide|
75382495|NCT00003464|Radiation|radiation therapy|
75382496|NCT00003230|Drug|paclitaxel|
75382497|NCT00003956|Drug|fluorouracil|
75382498|NCT00003956|Drug|leucovorin calcium|
75382499|NCT00003956|Drug|lonafarnib|
75382500|NCT00002623|Drug|carboplatin|
75382501|NCT00002623|Drug|cisplatin|
75382502|NCT00002623|Procedure|conventional surgery|
75382503|NCT00002623|Radiation|radiation therapy|
75382504|NCT00003962|Biological|aldesleukin|
75382505|NCT00003968|Drug|bryostatin 1|
75382506|NCT00003974|Biological|lung tumor associated antigen|
75382507|NCT00003974|Drug|DetoxPC|
75382508|NCT00003974|Drug|chemotherapy|
75541422|NCT04670887|Procedure|Immediate surgery|Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
75541423|NCT04671121|Procedure|Standart pressure pneumoperitoneum|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
76023100|NCT05100563|Drug|50 mg naltrexone|Medication combined with twice a week psychotherapy
76023101|NCT05100329|Drug|Mitoxantrone Hydrochloride Liposome injection|20 mg/m^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
76023102|NCT04530539|Dietary Supplement|Vitamin C|1000mg Vitamin C, at bedtime
76023103|NCT04530539|Dietary Supplement|melatonin|10mg melatonin, at bedtime
76023104|NCT04530539|Dietary Supplement|Placebo|Placebo at bedtime
76023105|NCT04530539|Other|Symptom Survey|Daily symptom survey to be completed by patient electronically
76023106|NCT02698891|Drug|Paclitaxel|
75382509|NCT00003974|Drug|cyclophosphamide|
76031158|NCT05077813|Combination Product|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
75382510|NCT00002635|Biological|filgrastim|
75382511|NCT00002635|Drug|aminocamptothecin|
75382512|NCT00003494|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75382513|NCT00003500|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75382514|NCT00003512|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75382515|NCT00003242|Drug|bryostatin 1|
75382516|NCT00003242|Drug|cisplatin|
75382517|NCT00003242|Drug|paclitaxel|
75382518|NCT00003980|Drug|BIBX 1382|
75382519|NCT05664061|Drug|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|twice daily inhalation throughout the treatment period
75382520|NCT05664061|Drug|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the treatment period
75382521|NCT05664061|Drug|Placebo|twice daily inhalation throughout the treatment period
75382522|NCT00003248|Biological|rituximab|
75382523|NCT00003248|Drug|fludarabine phosphate|
75382524|NCT00002641|Biological|filgrastim|
75382525|NCT00002641|Drug|doxorubicin hydrochloride|
75382526|NCT00002641|Drug|ifosfamide|
75382527|NCT00002641|Drug|isolated perfusion|
75382528|NCT00002641|Procedure|adjuvant therapy|
75382529|NCT00002641|Procedure|conventional surgery|
75382530|NCT00002641|Radiation|radiation therapy|
75382531|NCT00003992|Biological|trastuzumab|
75382532|NCT00003992|Drug|cyclophosphamide|
75382533|NCT00003992|Drug|doxorubicin hydrochloride|
75382534|NCT00003992|Drug|paclitaxel|
75382535|NCT00003992|Drug|tamoxifen citrate|
75382536|NCT00002647|Drug|verteporfin|
75382537|NCT00002647|Procedure|conventional surgery|
75382538|NCT00003524|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75382539|NCT00003530|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75382540|NCT00002653|Drug|carmustine|
75382541|NCT00002653|Drug|cyclophosphamide|
75382542|NCT00002653|Drug|doxorubicin hydrochloride|
75382543|NCT00002653|Drug|melphalan|
75382544|NCT00002653|Drug|prednisone|
75382545|NCT00002653|Radiation|radiation therapy|
75382546|NCT00003254|Drug|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
75382547|NCT00003254|Drug|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
75382548|NCT05749549|Drug|BR1733|Subjects will receive oral administration of BR1733.
75382549|NCT00002659|Drug|cisplatin-e therapeutic implant|
75382550|NCT00003998|Drug|carboplatin|
75382551|NCT00003998|Drug|docetaxel|
75382552|NCT00003998|Drug|paclitaxel|
75382553|NCT00003998|Procedure|surgical procedure|
75382554|NCT00004004|Drug|procarbazine hydrochloride|
75382555|NCT05749471|Diagnostic Test|ASEX (Arizona Sexual Experience) administration|ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of > 19, any one item with a score of > 5, or any three items with a score of > 4 would have sexual dysfunction.
75382556|NCT00003260|Drug|FOLFIRI regimen|
75382557|NCT00003260|Drug|FOLFOX regimen|
75382558|NCT00003260|Drug|fluorouracil|
75382559|NCT00003260|Drug|irinotecan hydrochloride|
75382560|NCT00003260|Drug|leucovorin calcium|
75382561|NCT00003260|Drug|oxaliplatin|
75382562|NCT00002665|Drug|asparaginase|10,000 units/d IV or IM 15 - 24
75382563|NCT00002665|Drug|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
75382564|NCT00002665|Drug|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
75382565|NCT00002665|Drug|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
75382566|NCT00002665|Drug|dexamethasone|main: 10 mg/m2/day PO 1 - 28
75382567|NCT00002665|Drug|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
75382568|NCT00002665|Drug|etoposide|60 mg/kg based on ideal body weight day -3
75382569|NCT00002665|Drug|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC < 3,000 /μl
75382570|NCT00002665|Drug|mercaptopurine|con: 60 mg/m2 PO 1 - 28
75382571|NCT00002665|Drug|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
75382572|NCT00002665|Drug|prednisone|"ind: 60 mg/m2/d PO 1 - 21*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42"
75382573|NCT00002665|Drug|thioguanine|main: 60 mg/m2/day PO 1 - 14
75382574|NCT00002665|Drug|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
75382575|NCT00002665|Procedure|allogeneic bone marrow transplantation|day 0
75382576|NCT00002665|Radiation|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
75382577|NCT00003536|Drug|antineoplaston A10|
75382578|NCT00003536|Drug|methotrexate|
75382579|NCT00003536|Procedure|alternative product therapy|
75382580|NCT00003536|Procedure|biological therapy|
75382581|NCT00003536|Procedure|biologically based therapies|
75382582|NCT00003536|Procedure|cancer prevention intervention|
75382583|NCT00003536|Procedure|chemotherapy|
75382584|NCT00003536|Procedure|complementary and alternative therapy|
75382585|NCT00003536|Procedure|differentiation therapy|
75382586|NCT00003542|Biological|pegylated interferon alfa|
75382587|NCT00381667|Drug|GW642444M|M salt
75382588|NCT00381667|Drug|GW642444H|H salt
75382589|NCT00381667|Other|placebo|placebo
75382590|NCT00003548|Drug|aminocamptothecin colloidal dispersion|
75382591|NCT00381823|Behavioral|Cognitive Behavioral Therapy|
75382592|NCT00004010|Biological|bleomycin sulfate|
75382593|NCT00004010|Biological|filgrastim|
75382594|NCT00004010|Drug|ABVD regimen|
75382595|NCT00004010|Drug|cyclophosphamide|
75382596|NCT00004010|Drug|dacarbazine|
75382597|NCT00004010|Drug|doxorubicin hydrochloride|
75382598|NCT00004010|Drug|etoposide|
75382599|NCT00004010|Drug|prednisone|
75382600|NCT00004010|Drug|procarbazine hydrochloride|
75382601|NCT00004010|Drug|vinblastine sulfate|
75382602|NCT00004010|Drug|vincristine sulfate|
75382603|NCT00004010|Radiation|radiation therapy|
75382604|NCT05646979|Behavioral|EFT group|EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
75382605|NCT00004016|Biological|recombinant interferon gamma|
75704863|NCT04437134|Other|On-site exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. The exercise sessions are delivered at physiotherapy clinics in Denmark.~Education:~Patients attend two to three on-site educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
75868314|NCT04917211|Procedure|Virtual reality mask|"The virtual reality mask is a mask with a screen that is put on the patient's face in the theatre before the surgery. It offers 3D scenarios of about 20 to 40 minutes on five different themes (the Zen garden, the mountain, the forest, the beach, the scuba diving) with music. The video-headset, equipped with head movement sensors, allows the 3D vision of a natural virtual world and the audio-headset emits sounds adapted to the virtual world and music therapy. The RV mask, via multi-sensorial immersion, focuses on two therapeutic targets which are pain and anxiety. It is a non-drug approach cousin to hypnosis. Its therapeutic effects are based on a distractive effect: attentive capture, an emotional effect: playfulness and positive suggestion, and a behavioral effect: the patient participates and is an actor in his care.~"
75868315|NCT02694718|Drug|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m^2 bid orally on Days 1-14, and at a dose of 825mg/m^2 bid on Days 22-35 and 43-56.
75382606|NCT05749315|Other|Play Based Therapy|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
75868316|NCT02694718|Drug|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m^2/d intravenously on Day 1 and 50mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
76031159|NCT05077813|Combination Product|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
76031160|NCT05077813|Other|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days
76031161|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
76031162|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
76031163|NCT02325973|Device|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
76031164|NCT00914251|Drug|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
76031165|NCT00914251|Drug|Placebo|Administration of oral Placebo, 500 mg/daily
76031166|NCT02330731|Procedure|injection sclerotherapy for gastric varices|The intravariceal technique of injection
76031167|NCT05076955|Drug|vancomycin-tobramycin-itraconazole|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
75541424|NCT04671121|Procedure|Low pressure pneumoperitoneum|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
76031168|NCT02330575|Behavioral|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
76031169|NCT02330575|Behavioral|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
75382607|NCT05749315|Other|Functional Communication Training|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
75382608|NCT00004022|Biological|aldesleukin|
75382609|NCT00004022|Biological|autologous tumor cell vaccine|
75382610|NCT00004022|Biological|muromonab-CD3|
75382611|NCT00004022|Biological|therapeutic autologous lymphocytes|
75382612|NCT00004022|Procedure|surgical procedure|
75382613|NCT00381901|Biological|trastuzumab|
75541425|NCT04671316|Drug|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water"
75382614|NCT00381901|Genetic|polymorphism analysis|
75541426|NCT04671316|Drug|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab without water"
75541427|NCT04671316|Drug|Lixiana 60mg Tab|"single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water"
75382615|NCT00381901|Procedure|adjuvant therapy|
75382616|NCT00003278|Drug|dexamethasone|
75541428|NCT04670614|Procedure|Nerve Block with ropivicaine 0.5% Injectable Solution|Peripheral nerve blocks using 0.5% ropivicaine
75704864|NCT04414813|Biological|Human Amniotic Epithelial Stem Cells|Stereotactic transplantation of hAESCs for participants with PD.
75868317|NCT04378153|Other|Discontinuation of hypertonic saline (HS)|Discontinuation of current hypertonic saline (HS) therapy in Study A during 6-week study period.
76023107|NCT02698891|Drug|Neulasta|
76023108|NCT04719065|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.
75541429|NCT04670614|Procedure|Nerve Block with Placebo sham control of 0.9% Normal Saline|Peripheral Nerve Block with placebo 0.9% normal saline
75704865|NCT04379921|Device|Apple Watch and App|Participants in the Apple Watch and App arm will receive an Apple Watch and download an App (NeuroCoach). The Apple Watch and App are used for this study to record patient's mobility information (e.g., step counts, heart rate, stairs climbed, distance traveled) as well as provide an additional platform for patients to complete questionnaires.
76031170|NCT05076721|Other|Simulation training|The participants in the simulation group will receive simulation training with high-fidelity manikin to practice and implement one-hour bundle sepsis
75382617|NCT00003278|Radiation|radiation therapy|
75382618|NCT00004028|Drug|carmustine|
75704866|NCT04375826|Device|Epidural patient controlled analgesia|The device is connected to the epidural catheter prior to surgery and drug administration is started during surgery. The continuous infusion rate is 4 ml / hr. When the button is pressed, 2 ml is additionally administered and the lock time is 20 minutes.
75382619|NCT00004028|Procedure|conventional surgery|
75382620|NCT00003554|Biological|rituximab|
75382621|NCT00003554|Drug|melphalan|
75382622|NCT00003554|Drug|prednisone|
75382623|NCT04642027|Radiation|Conventional sEBRT|A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks
75382624|NCT04642027|Radiation|Hypofractionated sEBRT|A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks
75382625|NCT00003284|Biological|filgrastim|
75382626|NCT00003284|Drug|carboplatin|
75382627|NCT00003284|Drug|etoposide|
75541430|NCT04670692|Other|5G-MCE examination|The endoscopist (W.Z.) manipulated the two joysticks on the remote console (based in Shanghai). Then the remote control software and remote connection software takes the endoscopist's input and translates it into a control signal. After network transmission, the patient side cart (based in Yinchuan) translates the control signal into actual instrument manipulation and mobilize the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric and duodenum examination. Meanwhile, the images captured by the capsule are simultaneously sent back to the screen of the remote console, and thus provide guidance for better control of the capsule.
75541431|NCT04670692|Other|MCE examination|The endoscopist (W.Z.) performs the MCE examination procedure conventionally. And communicate with the volunteer face to face in the same examination room.
76031171|NCT05076721|Other|Case-based discussion training|The participants in the conventional group will only do a case-based discussion in implementing one-hour bundle sepsis
75541432|NCT00267657|Drug|Reserpine|
75541433|NCT04670809|Drug|Clevidipine Butyrate Injection|Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
75704867|NCT04375826|Device|Preperitoneal analgesia and IV-PCA|During surgery, the preperitoneal analgesia catheters are inserted into the preperitoneal space and these catheters are connected to the pump with ropivacaine.
75704868|NCT04371224|Drug|Irinotecan Liposomal Injection [Onivyde]|both arm
75704869|NCT04371224|Drug|Capecitabine|NaliCap
75704870|NCT04371224|Drug|5-fluorouracil|NAPOLI
76031172|NCT03144193|Other|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
76031173|NCT05077111|Procedure|Thoracic Epidural Anesthesia|Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.
75704871|NCT04371224|Drug|Leucovorin|NAPOLI
75704872|NCT04368663|Drug|Japanese traditional medicine group|TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
75704873|NCT04368455|Behavioral|Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)|An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.
75704874|NCT04368455|Behavioral|HPV Same Way Same Day App|An intervention that includes a self-directed app based curriculum
75704875|NCT04363242|Biological|SYN125|Administered by IV infusion
75704876|NCT04363242|Biological|SYN004|Administered by IV infusion
75704877|NCT04343183|Device|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.
76031174|NCT05077111|Procedure|General Anesthesia with One Lung Ventilation|Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
76031175|NCT02330497|Procedure|Radiofrequency Ablation under EUS|Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
75382628|NCT00003284|Drug|ifosfamide|
75382629|NCT00003284|Drug|paclitaxel|
75382630|NCT00003284|Procedure|peripheral blood stem cell transplantation|
75382631|NCT00003284|Radiation|radiation therapy|
75382632|NCT05749237|Other|respiratory exercises|respiratory exercises
75382633|NCT05749237|Other|relaxation exercises|relaxation exercises
75382634|NCT00384410|Drug|Nabilone|
75382635|NCT00384488|Behavioral|Interactive Voice Response System (IVR)|
75382636|NCT00004040|Biological|recombinant interferon alfa|
75382637|NCT00004040|Biological|rituximab|
75382638|NCT00384254|Behavioral|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
75382639|NCT00384254|Behavioral|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
75382640|NCT05630911|Other|Standing tasks with different task difficulty|The three different standing positions will include wide-base standing on foam (WBF) with low-level of task difficulty, narrow-base standing on foam (NBF) with moderate-level of task difficulty, and tandem standing on foam (TAF) with high-level of task difficulty.
75382641|NCT00004046|Drug|exatecan mesylate|
75382642|NCT00003560|Drug|carboplatin|
75382643|NCT00003560|Drug|docetaxel|
75382644|NCT00002671|Drug|aminocamptothecin|
75382645|NCT00003290|Biological|gonadotrophin releasing hormone|
75382646|NCT00003290|Radiation|radiation therapy|
75382647|NCT00002677|Drug|chemotherapy|
75382648|NCT00002677|Drug|tributyrin|
75382649|NCT05749003|Other|sensorimotor training exercise|Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
75868318|NCT04378153|Other|Continuation of hypertonic saline (HS)|Continuation of current hypertonic saline (HS) therapy in Study A during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily). The concentration of HS is according to clinical prescription (e.g., 7% sodium chloride or 3.5% sodium chloride) and at least 3%.
75704878|NCT04329364|Combination Product|Laser Haemorrhoidoplasty (LAH)|Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion
76031176|NCT05075863|Drug|Letrozole|Letrozole as 5mg from day 3 to 7 of menstrual cycle
75382650|NCT05749003|Other|conventional physical therapy program of exercise.|stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
75382651|NCT00003566|Procedure|videothoracoscopy|
75382652|NCT05748925|Drug|dapagliflozin|The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.
75382653|NCT05748925|Drug|placebo|Control group: will be maintained on their medication
75382654|NCT00003572|Biological|peripheral blood lymphocyte therapy|
75382655|NCT00003572|Drug|mycophenolate mofetil|
75382656|NCT00003572|Drug|tacrolimus|
75382657|NCT00003572|Procedure|allogeneic bone marrow transplantation|
75382658|NCT00003572|Radiation|radiation therapy|
75382659|NCT00004052|Biological|QS21|
75382660|NCT00004052|Biological|bcr-abl peptide vaccine|
75382661|NCT00004058|Drug|tetradecanoylphorbol acetate|
75382662|NCT00002689|Drug|dexamethasone|
75382663|NCT00002689|Drug|fluorouracil|
75382664|NCT00002689|Radiation|brachytherapy|
75382665|NCT00002689|Radiation|phosphorus P32|
75382666|NCT00002689|Radiation|radiation therapy|
75382667|NCT00003296|Biological|filgrastim|
75382668|NCT00003296|Drug|pegylated liposomal doxorubicin hydrochloride|
75382669|NCT00004064|Biological|oregovomab|
75382670|NCT00003302|Procedure|biopsy|
75382671|NCT00003302|Diagnostic Test|magnetic resonance imaging|
75382672|NCT00003302|Diagnostic Test|mammography|
75382673|NCT00382057|Drug|Testosterone|
75382674|NCT00382057|Drug|Anastrozole|
75382675|NCT00382057|Drug|Goserelin|
75382676|NCT00003578|Drug|CHOP regimen|
75382677|NCT00003578|Drug|carmustine|
75382678|NCT00003578|Drug|cyclophosphamide|
75382679|NCT00003578|Drug|cytarabine|
75382680|NCT00003578|Drug|doxorubicin hydrochloride|
76031177|NCT05072119|Device|Device implantation|Implantation of single chamber, dual chambers or triple chambers PM/ICD
76031178|NCT02330419|Drug|Placebo|
75382681|NCT00003578|Drug|etoposide|
75382682|NCT00003578|Drug|melphalan|
75541434|NCT04670809|Drug|Ncardipine Hydrochloride Injection|Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
75541435|NCT04670575|Procedure|Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL|Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
75541436|NCT04670341|Other|chewing tapioca pearls in bubble tea drinks|Saliva was collected on the first day before bubble tea consumption (pretest) and on the third day after bubble tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
75704879|NCT04329364|Procedure|Open milligan-morgan conventional haemorrhoidectomy|conventional excisional haemorrhoidectomy
75704880|NCT04327336|Device|Manual Non invasive ventilation titration|Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.
75704881|NCT04327336|Device|Automatic Non invasive ventilation titration|Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
75868319|NCT04378153|Other|Discontinuation of dornase alfa (dnase)|Discontinuation of current dornase alfa (dnase) therapy in Study B during 6-week study period.
75541437|NCT04670341|Other|drink tea without chewing tapioca pearls|Saliva was collected on the first day before drink tea without tapioca pearl (pretest) and on the third day after tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
76031179|NCT02330419|Drug|Naltrexone|
75868320|NCT04378153|Other|Continuation of dornase alfa (dnase)|Continuation of current dornase alfa (dnase) therapy in Study B during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily).
75868321|NCT03106090|Other|educational materials|The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
75382683|NCT00003578|Drug|prednisone|
75382684|NCT00003578|Drug|vincristine sulfate|
75382685|NCT00003578|Procedure|autologous bone marrow transplantation|
75382686|NCT00003578|Procedure|peripheral blood stem cell transplantation|
75382687|NCT05617651|Drug|IY-NT-T|Ilaprazole 20mg
76031180|NCT03143803|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
76031181|NCT03143803|Drug|Placebo|Similar looking inactive powder
76031182|NCT05076331|Diagnostic Test|PI-2620 tracer for Tau PET scan|Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
75382688|NCT05617651|Drug|IY-NT-R|Ilaprazole 10mg
75382689|NCT05615857|Device|Use of Endocuff during colonoscopy|We will be adding the Endocuff device to the proximal end of the colonoscope, adding an additional tool to facilitate the visualization of the difficult-to-see mucosal areas as well as the rectum. There will be no need for retroflexion to evaluate the colon
75382690|NCT05748691|Diagnostic Test|Clinical implementation of hs-cTnT|To investigate the clinical impact on the transition from a hs-cTnI assay to a hs-cTnT assay in consecutive patients presenting to the Emergency Department or Acute Medical Unit with suspected acute coronary syndrome.
75382691|NCT00003584|Drug|estramustine phosphate sodium|
75382692|NCT00003584|Drug|prednisone|
75382693|NCT00003584|Drug|vinorelbine tartrate|
75382694|NCT00002701|Drug|busulfan|
75541438|NCT00267735|Behavioral|Use of Computerized Decision Aid on Childbirth|
76031183|NCT05070325|Other|Cold application group|Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
76031184|NCT05070325|Other|Shotblocker group|Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
76031185|NCT05070325|Other|Control Group|Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
76031186|NCT05068141|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w
75382695|NCT00002701|Drug|cyclophosphamide|
75382696|NCT00002701|Drug|cytarabine|
75382697|NCT00002701|Drug|etoposide|
75382698|NCT00002701|Drug|idarubicin|
75382699|NCT00002701|Drug|mercaptopurine|
76031187|NCT05068141|Drug|Nab-paclitaxel|Paclitaxel for Injection (Albumin Bound), 100 mg/m^2, i.v., D1, D8, D15 of every 4-week cycle
75382700|NCT00002701|Drug|methotrexate|
75382701|NCT00002701|Drug|mitoxantrone hydrochloride|
75382702|NCT00002701|Drug|thioguanine|
76031188|NCT03142477|Other|Questionnaires|Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.
75382703|NCT00002701|Drug|tretinoin|
75382704|NCT00002701|Procedure|allogeneic bone marrow transplantation|
75382705|NCT00002701|Procedure|autologous bone marrow transplantation|
75382706|NCT00002701|Radiation|radiation therapy|
75382707|NCT00004070|Biological|IL-12|
75382708|NCT00003320|Procedure|surgical procedure|
75382709|NCT00003320|Radiation|radiation therapy|
75382710|NCT00003320|Radiation|stereotactic radiosurgery|
75382711|NCT00004076|Drug|mureletecan|
75541439|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
75541440|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
75541441|NCT04670497|Procedure|bupivacaine 0.5% with 1:200000 adrenaline|regional anesthesia to block lumbar plexus for analgesia of lower limb
76031189|NCT03142477|Other|Placebo therapeutic touch|Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.
75382712|NCT00004082|Drug|carboplatin|
75382713|NCT00004082|Drug|docetaxel|
75382714|NCT00004082|Drug|gemcitabine hydrochloride|
75382715|NCT00002707|Drug|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
75382716|NCT00002707|Drug|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
75382717|NCT00002707|Drug|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
75382718|NCT00002707|Drug|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
75382719|NCT00003596|Drug|cisplatin|
75382720|NCT00003596|Drug|fluorouracil|
75382721|NCT00003596|Drug|mitomycin C|
75382722|NCT00003596|Radiation|radiation therapy|
75382723|NCT05608993|Other|High Intensity Intervention|The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.
75382724|NCT05608993|Other|Low Intensity Intervention|The Low Intensity intervention will include clinician education and EHR changes only.
75382725|NCT05747365|Diagnostic Test|Blood and urine diagnostic evaluation|Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations
75382726|NCT00002719|Biological|filgrastim|
75382727|NCT00002719|Drug|amsacrine|
75382728|NCT00002719|Drug|carmustine|
75382729|NCT00002719|Drug|cytarabine|
75382730|NCT00002719|Drug|etoposide|
75382731|NCT00002719|Drug|idarubicin|
75382732|NCT00002719|Drug|mitoxantrone hydrochloride|
75382733|NCT00002719|Procedure|peripheral blood stem cell transplantation|
75382734|NCT00003326|Drug|paclitaxel|
75382735|NCT00002725|Drug|bryostatin 1|
75382736|NCT00002725|Drug|chemotherapy|
75382737|NCT00003602|Drug|cytarabine|
75382738|NCT00003602|Drug|etoposide|
75382739|NCT00003602|Drug|idarubicin|
75382740|NCT00003602|Drug|mitoxantrone hydrochloride|
75382741|NCT04609423|Dietary Supplement|Cod liver oil|5 ml of cod liver oil as a source of 10 ug of vitamin D and 1.2 g of long-chained n-3 polyunsaturated fatty acids (DHA 0,6g and EPA 0,4g) per day for 6 months x 1 time/day together with the first meal of the day. 5ml of Cod liver oil also contains 250ug vitamin A and 10 mg vitamin E.
75382742|NCT04609423|Dietary Supplement|Corn oil (placebo)|5 ml of corn oil per day for 6 months x 1 time/day together with the first meal of the day
75382743|NCT00003332|Drug|cisplatin|
75382744|NCT00003332|Drug|gemcitabine hydrochloride|
75382745|NCT00003332|Procedure|surgical procedure|
75382746|NCT00003332|Radiation|radiation therapy|
75382747|NCT00004094|Drug|carboplatin|
75382748|NCT00004094|Drug|fluorouracil|
75382749|NCT00004094|Drug|hydroxyurea|
75382750|NCT00004094|Drug|paclitaxel|
75382751|NCT00004094|Procedure|conventional surgery|
75382752|NCT00004094|Radiation|radiation therapy|
76031190|NCT03142477|Other|Therapeutic touch|Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
76031191|NCT02330263|Dietary Supplement|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
76031192|NCT05050435|Procedure|Early extubation|Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU
76031193|NCT03142165|Drug|BMS-986263|3 weekly doses of 90 mg infused intravenous administration
76031194|NCT03142165|Other|Placebo|Placebo
75868322|NCT03105778|Diagnostic Test|standard blood draw as part of routine and fingerprick for capillary sample|All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
75868323|NCT03161080|Device|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
75868324|NCT03161080|Device|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
75868325|NCT03161080|Device|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
75868326|NCT04923139|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Dosage at the discretion of the treating physician
75868327|NCT04891627|Diagnostic Test|Gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
75868328|NCT04365829|Device|"virtual reality headset Occulus GO"|"Use of a virtual reality headset for one week at a frequency of 3 days per week (D1, D3 and D5). During each session (1 hour), the subject will visualize a scene of natural virtual environment (a garden, animals in the wild, a grand Canyon) lasting 7 min using an virtual reality headset Occulus GO."
75541442|NCT04670302|Procedure|Tendon repair procedure|"Tendon repair procedure:~Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon.~Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity.~Then, double suturing of the supraspinatus tendon is performed."
75868329|NCT04692688|Drug|APX3330|APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
75868330|NCT04692688|Drug|Placebo|Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
75868331|NCT05681221|Other|Nano silver particles and calcium hydroxide|Combination of two materials that can possibly eradicate the mixed odontogenic infection in the periapical area and dentinal tubules in necrotic primary second molars.
76031195|NCT03142165|Drug|Diphenhydramine|50 mg intravenous administration
76031196|NCT03142165|Drug|Famotidine|20 mg intravenous administration
75382753|NCT05745571|Other|Blood sample|The study foresees a phase of patient recruitment, in which, in the hours immediately following the blood sampling, the isolation of the PBMCs, their incubation and cytofluorimetric analysis will be carried out and the conservation of the material to be analyzed subsequently by molecular biology and immunochemistry.
75382754|NCT05592769|Device|HealthBeacon Injection Care Management System (ICMS)|"All participants will receive access to the HealthBeacon ICMS to remotely monitor adherence to therapy in the home setting. The system includes the following items/services:~The HealthBeacon Smart Sharps Bin~The HealthBeacon Companion App~HealthBeacon Care Team Support (including smart dose reminders and intervention calls)~Waste Management Services~Participants will also be issued the following interventions to enable collection of the secondary endpoints:~-Participant Feedback Questionnaire (issued electronically upon study completion, to gather feedback on the HealthBeacon ICMS)"
75382755|NCT00004100|Drug|cisplatin|
75382756|NCT00004100|Drug|gemcitabine hydrochloride|
75382757|NCT00004100|Drug|vinorelbine tartrate|
75382758|NCT00002737|Biological|recombinant interferon alfa|
75382759|NCT00002737|Drug|chemotherapy|
75382760|NCT00002737|Drug|isotretinoin|
75382761|NCT00003338|Procedure|immunoscintigraphy|
75382762|NCT00003338|Radiation|technetium Tc 99m epratuzumab|
75382763|NCT05744947|Other|Data collection|"Specific Readapt -DISCO complementary questionnaire rehabilitation"
75382764|NCT00003620|Drug|alvocidib|Given IV
75382765|NCT00003620|Other|laboratory biomarker analysis|Correlative studies
75382766|NCT00003344|Drug|irinotecan hydrochloride|
76031197|NCT02330029|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
75382767|NCT00003344|Radiation|radiation therapy|
75382768|NCT00003626|Drug|dolastatin 10|
75382769|NCT00003632|Biological|filgrastim|
75382770|NCT00003632|Drug|carmustine|
75382771|NCT00003632|Drug|cytarabine|
75382772|NCT00003632|Drug|etoposide|
75382773|NCT00003632|Drug|melphalan|
75382774|NCT00003632|Drug|methotrexate|
76031198|NCT02330029|Device|Atractylodes|Atractylodes (~10-15g)
76031199|NCT02330029|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
76031200|NCT02330029|Device|Tangerine Peel|Tangerine Peel (~10g)
75382775|NCT00003632|Procedure|peripheral blood stem cell transplantation|
75541443|NCT04670302|Procedure|Tendon repair augmented with AAdMSC-HAM composite|After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.
75541444|NCT04670107|Drug|Anlotinib in combination with Immune checkpoint inhibitors|Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)
76031201|NCT02330029|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
76031202|NCT02330029|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
76031203|NCT02330029|Drug|Radix curcumae|Radix curcumae (~10g)
76031204|NCT02330029|Drug|Fingered citron|Fingered citron (~10g)
75382776|NCT05743465|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
75382777|NCT00003350|Drug|paclitaxel|Given IV
75382778|NCT00003350|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
75382779|NCT00003350|Other|laboratory biomarker analysis|Correlative studies
75382780|NCT00003350|Procedure|quality-of-life assessment|Ancillary studies
76031205|NCT02330029|Drug|Tuckahoe|Tuckahoe (15g)
76031206|NCT02330029|Drug|Placebo|Placebo is blindly given to patients.
76031207|NCT03142555|Behavioral|Health talk plus intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
76031208|NCT03142555|Behavioral|Health talk plus less intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
76031209|NCT02638103|Drug|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
76031210|NCT02638103|Drug|Placebo|Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
75382781|NCT00003356|Biological|aldesleukin|
76031211|NCT02330107|Other|MAT & LAT|"For MAT, the magnetic pellets will have ~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
75382782|NCT00003356|Biological|rituximab|
76031212|NCT03713983|Other|Observational study|Observational study
75382783|NCT00004136|Procedure|Radiofrequency Ablation|Tumors heated to target temperature by electrodes for maximum of 20 minutes
75541445|NCT00260364|Drug|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
76031213|NCT02330185|Device|ultrasonography|spinal anesthesia guided with ultrasonography
76031214|NCT03143725|Drug|GLPG1972|Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
76031215|NCT04988971|Drug|a compound glutamine capsule|A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
76031216|NCT04988971|Drug|a compound glutamine capsule simulated placebo|a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
76031217|NCT03076619|Other|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
76031218|NCT02329873|Behavioral|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
76031219|NCT03143881|Behavioral|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
76031220|NCT03076541|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
76031221|NCT04931875|Device|Total body PET/CT (uExplorer)|A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
75382784|NCT00003638|Biological|Detox-B adjuvant|
75382785|NCT00003638|Biological|THERATOPE STn-KLH vaccine|
75382786|NCT00003638|Biological|keyhole limpet hemocyanin|
75382787|NCT00003638|Drug|cyclophosphamide|
75382788|NCT00004142|Drug|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
75382789|NCT00004142|Drug|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
75382790|NCT00004142|Procedure|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
75382791|NCT00004142|Procedure|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
75382792|NCT00002749|Drug|carboplatin|
75382793|NCT00003362|Biological|QS21|
76031222|NCT03076463|Dietary Supplement|GRAPOM|The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
75382794|NCT00003362|Biological|gp100 antigen|
75382795|NCT00003362|Biological|incomplete Freund's adjuvant|
75382796|NCT00003362|Biological|sargramostim|
75382797|NCT00003362|Biological|tyrosinase peptide|
75382798|NCT00004148|Biological|recombinant vaccinia-B7.1 vaccine|
75382799|NCT00003650|Drug|asparaginase|
75382800|NCT00003650|Drug|cyclophosphamide|
75541446|NCT00260364|Drug|Capecitabine orally days 1 -21|
75868332|NCT05681221|Other|TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
75541447|NCT00260364|Drug|Erlotinib 100 mg orally days 1-28|
75868333|NCT04303507|Drug|Chloroquine or Hydroxychloroquine|A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months
75382801|NCT00003650|Drug|cytarabine|
75382802|NCT00003650|Drug|daunorubicin hydrochloride|
75382803|NCT00003650|Drug|dexamethasone|
75382804|NCT00003650|Drug|etoposide|
75382805|NCT00003650|Drug|mercaptopurine|
75382806|NCT00003650|Drug|methotrexate|
75382807|NCT00003650|Drug|methylprednisolone|
75382808|NCT00003650|Drug|mitoxantrone hydrochloride|
75382809|NCT00003650|Drug|prednisone|
75382810|NCT00003650|Drug|vincristine sulfate|
75382811|NCT00003650|Radiation|radiation therapy|
75382812|NCT00002755|Biological|filgrastim|
75541448|NCT00260364|Drug|Bevacizumab 5 mg/kg intravenously every 2 weeks|
75541449|NCT00233753|Device|Cordis Neurovascular Self-Expanding Stent|
75541450|NCT04557007|Drug|Pembrolizumab|Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.
75541451|NCT04670458|Other|no intervention|no intervention
75541452|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - fast release|
75541453|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - slow release|
75541454|NCT00260403|Procedure|Photodynamic therapy versus Transpupillary thermotherapy|
75382813|NCT00002755|Drug|CMF regimen|
75382814|NCT00002755|Drug|cyclophosphamide|
75382815|NCT00002755|Drug|doxorubicin hydrochloride|
75382816|NCT00002755|Drug|fluorouracil|
75382817|NCT00002755|Drug|methotrexate|
75382818|NCT00002755|Drug|tamoxifen citrate|
75382819|NCT00002755|Drug|thiotepa|
75382820|NCT00002755|Procedure|autologous bone marrow transplantation|
75382821|NCT00002755|Procedure|peripheral blood stem cell transplantation|
75382822|NCT00002755|Radiation|low-LET cobalt-60 gamma ray therapy|
75382823|NCT00002755|Radiation|low-LET electron therapy|
75868334|NCT04303507|Drug|Placebo|Placebo
75382824|NCT00002755|Radiation|low-LET photon therapy|
75541455|NCT04556812|Procedure|Four-in-one procedure|"four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
75541456|NCT04556812|Procedure|soft-tissue surgery|traditional soft-tissue surgery
75382825|NCT04207424|Procedure|Emblization of the gastro-epiploic arcade|Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
75382826|NCT00002761|Biological|filgrastim|
75382827|NCT00002761|Biological|recombinant interferon gamma|
75382828|NCT00002761|Drug|busulfan|
75541457|NCT04670380|Other|Posture and movement analysis during a simulated forceps vaginal operative delivery|It will be request from each volunteer to perform a vaginal operative delivery using a Suzor's forceps on a mannequin. The condition will be standardized (anterior occiput low fetal presentation). Each participant will be equipped with 34 reflecting markers allowing to record their movement using infra red cameras (VICON system).
75382829|NCT00002761|Drug|cyclophosphamide|
75382830|NCT00002761|Drug|cyclosporine|
75382831|NCT00002761|Drug|cytarabine|
75868335|NCT04296643|Device|Medical Mask|Medical Mask (known also as Surgical Mask)
75868336|NCT04296643|Device|N95 respirator|N95 respirator
75868337|NCT03202537|Drug|dexlansoprazole|dexlansoprazole treatment for Gastroesophageal Reflux symptoms
75382832|NCT00002761|Drug|idarubicin|
75382833|NCT00002761|Procedure|peripheral blood stem cell transplantation|
75382834|NCT04191122|Other|COPESS|The intervention includes brief psychotherapy to be delivered within primary care settings
75541458|NCT00556153|Drug|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
75704882|NCT04318964|Biological|TAEST16001 cells|"The patients in the dose increasing part and the expanding part received the intravenous reinfusion of TAEST16001 cells on the 5th day (i.e. the interval was 4 days) after the lymphocyte elimination chemotherapy: If the dose level of reinfusion was 1 and 2, the planned total amount of TAEST16001cells (calculated by TCR-T positive cells) was given a single reinfusion on the 1st day of the study. If the dose level of reinfusion was 3 and 4,then the total amount of TAEST16001cells (calculated by TCR-T positive cells) was planned to be reinjected in 60% and 40% proportion on the first and second day of the study.~After the first reinfusion of TAEST16001 cells, the patients will be given a small dose of IL-2 subcutaneously (study day 1 to day 14), 500000 U / time. The first injection will be carried out within 30 minutes after the cell reinfusion, twice a day (interval 10-12 hours), for 14 days."
75704883|NCT04306900|Combination Product|TTX-030, budigalimab and mFOLFOX6|Dose and schedule per protocol
75704884|NCT04306900|Combination Product|TTX-030, budigalimab and docetaxel|Dose and schedule per protocol
75704885|NCT04306900|Combination Product|TTX-030 and mFOLFOX6|Dose and schedule per protocol
75704886|NCT04306900|Combination Product|TTX-030 and budigalimab|Dose and schedule per protocol
76031223|NCT02329795|Radiation|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
75382835|NCT00382135|Drug|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
75541459|NCT00556192|Drug|rituximab|"Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
75541460|NCT00233831|Device|Generator of electromagnetic millimeter waves|
75704887|NCT04306900|Combination Product|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
75704888|NCT04306900|Combination Product|TTX-030 and pembrolizumab|Dose and schedule per protocol
75382836|NCT00382135|Drug|placebo|Placebo tablet taken by mouth once a day for 40 weeks
75382837|NCT00003662|Biological|anti-thymocyte globulin|
75382838|NCT00003662|Drug|busulfan|
75382839|NCT00003662|Drug|cyclophosphamide|
75382840|NCT00003662|Drug|cyclosporine|
75382841|NCT00003662|Drug|melphalan|
75382842|NCT00003662|Drug|methylprednisolone|
75382843|NCT00003662|Procedure|umbilical cord blood transplantation|
75382844|NCT00003662|Radiation|radiation therapy|
75382845|NCT00004154|Drug|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
75704889|NCT04306900|Combination Product|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
75704890|NCT04306900|Combination Product|Budigalimab and mFOLFOX6|Dose and schedule per protocol
75704891|NCT04296604|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
75704892|NCT04288687|Drug|Niraparib Pill|Niraparib 200 mg by mouth daily (2 x 100 mg pills)
76031224|NCT02329795|Drug|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
75382846|NCT00004154|Other|Placebo|Two placebo capsules for 25 days of 28 day cycle.
76031225|NCT05002907|Other|Questionnaire|After signing the informed consent sheet, a standardized face-to-face questionnaire will be conducted by the doctor, nurse or coordinator to collect socio-demographic data, lifestyle data, sex life and other potential risk factors and knowledge about viral hepatitis.
76031226|NCT05002907|Other|Biocollection|After answering the questionnaire, the nurse or the doctor will take a sample of capillary blood from the fingertip on the side of the distal phalanx of a middle or ring finger. The puncture site will be prepared by warming and massage to optimize blood flow and disinfected with a disposable 70% alcohol wipe. After drying, the puncture will be performed using a single use safety lancet. A total of 7 capillary blood spotswill be collected and deposited on the filter paper (each spot is about 50µL of capillary blood), 5 for the study and 2 for the biological collection.
76031227|NCT05002907|Other|Delivery of results|After receiving the individual biological analysis results, in coded form (results only identified by the anonymity number), at the investigation center and lifting the anonymity by the coordinator of the study in each study center (in Cayenne or Paramaribo depending the country where the inclusion took place) with the help of the correspondance list, the participants' results will be delivered to the referral doctor of each health centre and the infectious disease specialist responsible for each area of inclusion. All positive participants will be contacted if they do not spontaneously come to retrieve their results (within approximately 1 month after result's availability), and invited to come to the health centre to retrieve their results individually and be oriented towards the heathcare circuit.
75541461|NCT00260442|Behavioral|Resistance Training|12 weeks, 3 times a week whole body resistance training
76031228|NCT05002907|Other|Results and advices on transmission prevention methods|The results will be revealed by the health centre's doctor/infectiologist, individually and confidentially, with an explanation of the results and advices on transmission prevention methods.Non-immunized patients against HBV will be offered a status determination (Anti-HBs Ab quantification on whole blood sample) and if necessary a catch-up vaccination according to the national immunization schedule.
76031229|NCT05002907|Other|Confirmation of results on a blood test (In the event of a positive result)|In case of a positive result, the doctor will explain the need to confirm these results on a blood test, prescribe the initial assessment and take an appointment with the infectious disease specialist. He will guide the patient towards accompaniment for the opening of medical coverage rights if necessary and support by an association if desired.
75382847|NCT00002767|Biological|Detox-B adjuvant|
75382848|NCT00002767|Biological|recombinant interferon alfa|
75541462|NCT00260442|Behavioral|Sedentary|Absence of physical activity
75541463|NCT00556270|Drug|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
75541464|NCT00260481|Drug|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
75541465|NCT00260481|Drug|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
75382849|NCT04133324|Diagnostic Test|C-reactive protein|C-reactive protein at postoperative days four and two.
75382850|NCT00002773|Biological|allogeneic tumor cell vaccine|
75382851|NCT00002773|Biological|recombinant interferon alfa|
75382852|NCT00002773|Biological|sargramostim|
75382853|NCT00002773|Drug|cyclophosphamide|
75382854|NCT00004160|Drug|cisplatin|
75382855|NCT00004160|Drug|gemcitabine hydrochloride|
75382856|NCT00004160|Drug|paclitaxel|
75382857|NCT00004160|Radiation|radiation therapy|
75382858|NCT05562115|Other|Tear collection|Collection of tears by Schirmer strip (2 to 4 mm).
75382859|NCT00003368|Drug|irinotecan hydrochloride|
75382860|NCT05562037|Other|Stepped Care|Patients meeting a non-response criterion will be stepped up to the next step
75382861|NCT05509543|Drug|IY-NT-T|Ilaprazole 20mg
75382862|NCT05509543|Drug|IY-NT-R|Ilaprazole 10mg
75382863|NCT00003674|Drug|dalteparin|
75382864|NCT00003674|Drug|standard therapy|
75382865|NCT05561101|Other|Caregivers burden|Assessment of caregiver burden after admision at Emergency Department of their elderly relative
75541466|NCT00233870|Drug|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
75382866|NCT00003380|Drug|etoposide|
75382867|NCT00003380|Drug|pegylated liposomal doxorubicin hydrochloride|
75382868|NCT00002779|Drug|fludarabine phosphate|
75382869|NCT00002779|Drug|octreotide acetate|
75382870|NCT00003680|Drug|CMF regimen|
75382871|NCT00003680|Drug|cyclophosphamide|
75382872|NCT00003680|Drug|fluorouracil|
75382873|NCT00003680|Drug|methotrexate|
75382874|NCT00003680|Drug|tamoxifen citrate|
75541467|NCT00260520|Drug|Dalteparin|
75541468|NCT00233909|Drug|Zosuquidar|
75541469|NCT00233909|Drug|gemtuzumab ozogamicin|
75541470|NCT00267813|Drug|Bupropion (Zyban)|1 tablet a day increasing to 2 tablets a day after a week
75541471|NCT00234026|Drug|gemcitabine hydrochloride|
75704893|NCT04278235|Drug|Elezanumab|Solution for intravenous (IV) infusion
75868338|NCT02944513|Device|Quell|
75382875|NCT00003680|Drug|thiotepa|
75382876|NCT00003680|Procedure|peripheral blood stem cell transplantation|
75382877|NCT00003680|Radiation|radiation therapy|
75382878|NCT00002785|Biological|filgrastim|
75382879|NCT00002785|Drug|asparaginase|
75382880|NCT00002785|Drug|cyclophosphamide|
75382881|NCT00002785|Drug|cyclosporine|
75382882|NCT00002785|Drug|cytarabine|
75382883|NCT00002785|Drug|daunorubicin hydrochloride|
75382884|NCT00002785|Drug|dexamethasone|
75382885|NCT00002785|Drug|etoposide|
75382886|NCT00002785|Drug|leucovorin calcium|
75382887|NCT00002785|Drug|mercaptopurine|
75382888|NCT00002785|Drug|mesna|
75382889|NCT00002785|Drug|methotrexate|
75382890|NCT00002785|Drug|methylprednisolone|
75382891|NCT00002785|Drug|pegaspargase|
75382892|NCT00002785|Drug|prednisone|
75382893|NCT00002785|Drug|therapeutic hydrocortisone|
75382894|NCT00002785|Drug|vincristine sulfate|
75382895|NCT00002785|Procedure|allogeneic bone marrow transplantation|
75382896|NCT00002785|Radiation|low-LET cobalt-60 gamma ray therapy|
75382897|NCT00002785|Radiation|low-LET photon therapy|
75382898|NCT00004178|Biological|therapeutic autologous lymphocytes|
75382899|NCT00004184|Biological|monoclonal antibody 4B5 anti-idiotype vaccine|
75382900|NCT00004184|Biological|sargramostim|
75382901|NCT00004184|Drug|alum adjuvant|
75382902|NCT00003386|Biological|BCG vaccine|
75382903|NCT00003386|Biological|autologous tumor cell vaccine|
75382904|NCT00003386|Drug|carboplatin|
75382905|NCT00003386|Drug|cisplatin|
75382906|NCT00003386|Drug|cyclophosphamide|
75382907|NCT00003386|Drug|paclitaxel|
75382908|NCT00003386|Other|dinitrophenyl|
75382909|NCT00003386|Procedure|surgical procedure|
75382910|NCT00384566|Drug|Carvedilol|anit hypertensive medication
75382911|NCT00384566|Drug|Metoprolol|Anti hypertensive medication
75382912|NCT00004832|Drug|3,4-diaminopyridine|
75382913|NCT00384644|Device|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
75382914|NCT00002791|Biological|filgrastim|
75382915|NCT00002791|Drug|dacarbazine|
75541472|NCT00267852|Other|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
75382916|NCT00002791|Drug|doxorubicin hydrochloride|
75382917|NCT00002791|Drug|ifosfamide|
75382918|NCT00002791|Drug|mesna|
75382919|NCT00002791|Procedure|conventional surgery|
75704894|NCT04271579|Procedure|Salvage Lymphnode dissection|"A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)"
76031230|NCT05002907|Other|Information for care|A document with all contact information for a comprehensive and specialized care (professionals and associations for access to medical coverage and support, associations proposing support, general practitioners and specialists) will be given to positive participants. Patient monitoring and treatment will be carried out according to the national guidelines in each country.
75382920|NCT00002791|Radiation|brachytherapy|
76031231|NCT05002907|Other|Monitoring and treatment|Consequently, all positive participants will be able to be monitored and treated by a specialist of the disease. They will give post-test counselling and will conduct patient follow-up and treatment according to the usual standards of care of each country.
75704895|NCT04269512|Procedure|lymph node dissection|At least 10 lymph nodes must be removed.
76031232|NCT02329561|Drug|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
75382921|NCT00002791|Radiation|intraoperative radiation therapy|
76031233|NCT02329561|Behavioral|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
75704896|NCT04269161|Device|Automatic control of inspired oxygen|A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
76031234|NCT02329561|Drug|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
75704897|NCT04259047|Behavioral|Diabetes Regulation for Eyesight and Memory|Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.
76031235|NCT05000879|Behavioral|MMB for Moms|12-week program that emphasizes mindfulness and cognitive behavioral skills
75382922|NCT00002791|Radiation|radioisotope therapy|
75382923|NCT00384722|Device|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
76031236|NCT02329639|Genetic|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
75382924|NCT00004190|Drug|gemcitabine hydrochloride|
75382925|NCT00004190|Drug|oxaliplatin|
75382926|NCT00004196|Biological|recombinant interferon alfa|
75382927|NCT00004196|Procedure|lymphangiography|
75382928|NCT00004196|Drug|Observation|
75704898|NCT04259047|Behavioral|Enhanced Usual Care|Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
76031237|NCT05003063|Drug|Donepzil|Test
76031238|NCT05003063|Drug|Placebo oral tablet|Test
75382929|NCT00385034|Device|Interactive computer based health-risk survey before doctor's visit|
75382930|NCT00004838|Drug|succimer|
75382931|NCT00381979|Other|Supportive Expressive Therapy|
75382932|NCT00004844|Procedure|tissue implantation|
75382933|NCT05500807|Drug|Emicizumab|Subcutaneous injection of emicizumab for prophylaxis
75382934|NCT00004202|Drug|carboplatin|
75704899|NCT04257994|Diagnostic Test|obtaining a buccal smear sample|A sample will be taken from the inside of the participants' cheeks using a soft brush
75868339|NCT03638557|Other|Nutritious Lunch|"The intervention package consists of the following;~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
75868340|NCT04289935|Procedure|Vacuum assisted biopsy (VAB)|The trial intervention consists of a diagnostic interventional procedure, US-guided or mammographically guided VAB post-NAC, prior to the standard breast surgery.
75868341|NCT04235413|Behavioral|Real-Time Incentives Group|The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
75382935|NCT00004202|Drug|chemotherapy|
75382936|NCT00004202|Drug|efaproxiral|
75382937|NCT00004202|Drug|paclitaxel|
76031239|NCT03143491|Drug|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
75704900|NCT04245228|Behavioral|Wellness Coach|Trained in motivational interviewing who will call the patient weekly for 12 sessions for an approximately 30-minute intervention
75704901|NCT04231708|Drug|Yohimbine + Hydrocortisone|Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
76031240|NCT05002673|Device|DENTAL LOCAL ANESTHESİA|doing local and topical anesthesia with two different device
75382938|NCT00004202|Radiation|radiation therapy|
75704902|NCT04231708|Device|Active rTMS|10Hz rTMS over the left dlPFC
76031241|NCT02329717|Drug|PBI 05204|PBI 05204 daily dosing
76031242|NCT05001035|Other|Time of assessment|Immediate and after one month and after two months
76031243|NCT03076151|Drug|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
76031244|NCT05032651|Device|novel artificial intelligence assisted platform|Use of a novel artificial intelligence assisted platform
75382939|NCT00003686|Drug|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
75382940|NCT00003686|Drug|Placebo|Placebo 5 mg po qid x 4 weeks
75382941|NCT05495035|Drug|Olverembatinib, APG-2575, Dexamethasone|"Period 1: Subjects will orally take olverembatinib 40mg adult equivalent dose alone QOD from Day 1 to Day 14 (D1 - D14) =. The investigator may start the combination therapy in advance based on medical conditions of the subjects, but not earlier than Day 5/the third dose (D5).~Period 2: 1) Subjects will orally take olverembatinib 40mg adult equivalent dose QOD from Day 15 to Day 42 (D15 - D42)).~2) Subjects will orally take APG-2575 at a ramp up 200mg/400mg/600mg adult equivalent dos QD from D13 to D42 at a dose . In addition, a 3-day dose escalation from D13 to D15 will be needed, and the designated reference dose will be reached on D15.~3) Subjects will orally take dexamethasone 6 mg/m2/day, QD from D15 to D42 at 6 mg/m2/day."
75382942|NCT00004856|Biological|trastuzumab|Given IV
75382943|NCT04438057|Biological|CCP|Randomized open label study to receive 2:1 CCP to standard of care
75382944|NCT00003698|Drug|fosbretabulin disodium|
75382945|NCT04600375|Behavioral|Verbal consultation|Verbal consultation only without written information before receiving written action plan
75382946|NCT04600375|Behavioral|Written Action Plan|Written handout of treatment plan and disease management strategies
75382947|NCT00004208|Drug|ATG + CSA|Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
75382948|NCT00004208|Behavioral|Supportive care|Patients randomized to this arm will be treated as outpatients.
75382949|NCT00004862|Biological|filgrastim|
75382950|NCT00004862|Biological|oblimersen sodium|
75541473|NCT00234143|Behavioral|Darbepoetin and Filgrastim|Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response
75541474|NCT00234143|Drug|Darbepoetin|Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
75541475|NCT04670419|Other|Viral clade|Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
76031245|NCT05002517|Drug|Tociliziumab group|Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology.
75541476|NCT04670185|Behavioral|BIP SAMBA|Behavioral parent management training
75541477|NCT04670146|Diagnostic Test|ultrasound of the masseteric muscle|Ultrasound of the masseteric muscle to evaluate the thickness and rigidity of the masseteric muscle before and after oral cancer treatment. There will be no invasive investigation of the muscle.
75541478|NCT00234182|Drug|Interferon alpha-2b|
75541479|NCT04669873|Radiation|Active Comparator: Standard|Radiation: Whole Breast Irradiation + Boost Whole breast, either 40Gy, in 15 fractions, in 3 weeks
75541480|NCT04669873|Radiation|Experimental 1: Hypofractionated radiotherapy|Radiation: Hypofractionated irradiation Whole Breast Irradiation 26Gy in 5 fractions in one week
75541481|NCT04669873|Radiation|Experimental 2: Accelerated Partial Breast Irradiation|Radiation: Accelerated partial breast irradiation Tumor bed 26Gy in 5 fractions, in 5 days.
75541482|NCT04669756|Procedure|ovariopexy|if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall
75541483|NCT04669756|Procedure|placebo operation|in arm D sutures are transabdominal only
75541484|NCT00260598|Procedure|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
75382951|NCT00004862|Drug|cytarabine|
75382952|NCT00004862|Drug|fludarabine phosphate|
75541485|NCT04669912|Other|glucose control and sensor usage|Data related to glucose control and sensor usage collected from the Libreview platform
75704903|NCT04231708|Drug|Placebo|lactose (inside capsule)
75382953|NCT05533333|Behavioral|Falls prevention exercises|A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.
75382954|NCT00004220|Drug|gemcitabine hydrochloride|
75382955|NCT00004220|Drug|oxaliplatin|
75382956|NCT05492071|Device|Local Vibration Application Following Flow Mediated Dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
75382957|NCT05492071|Other|Flow mediated dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
75382958|NCT00003704|Drug|capecitabine|
75382959|NCT00003704|Radiation|radiation therapy|
75382960|NCT00004868|Drug|semaxanib|
75382961|NCT00003710|Drug|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
75382962|NCT00003710|Drug|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
75382963|NCT05232097|Behavioral|Behavioral therapy|Diaphragmatic breathing exercises
75382964|NCT05232097|Behavioral|Physiotherapy|Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
75382965|NCT00004226|Radiation|radiation therapy|
75382966|NCT05485675|Behavioral|Stand & Move at Work|Web-based platform only.
75541486|NCT04669795|Drug|Cissus Quadrangularis|Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
75541487|NCT04670029|Other|Adapted physical activity|APA sessions during chemotherapy with aerobic and anaerobic sessions on site and at home (+ home exercises book if the patient so wishes)
75541488|NCT04669951|Other|uPAR immunohistochemistry|Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
75868342|NCT04762537|Other|Standard Induction Procedure (SP)|SP includes stabilization on buprenorphine (6-8 mg) on Day 1 followed by a taper over the subsequent 4 days. After the completion of buprenorphine taper, participants will enter a washout period of at least 8 days. On the last day of the washout period, participants will be evaluated for eligibility to receive XR-NTX injection. Once found eligible, an XR-NTX injection will be given.
75541489|NCT00234221|Behavioral|Strengths Based Case Management|
75541490|NCT00234221|Behavioral|Motivational Enhancement Therapy|
75541491|NCT00234221|Behavioral|Brief Informational Feedback|
75541492|NCT04669990|Drug|Remdesivir|The objective of this Registry study is to continue to collect safety and outcome data for COVID-19 patients who are treated with Remdesivir and convalescent plasma therapy (CPT).
75541493|NCT00267930|Drug|Vernakalant (oral)|
75541494|NCT00267930|Drug|Placebo comparator|
75541495|NCT04669405|Device|High intensity laser therapy|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
75704904|NCT04231708|Device|Sham rTMS|inactive stimulation over the left dlPFC
75868343|NCT04762537|Other|Rapid Induction Procedure (RP)|RP includes 1 day of buprenorphine 6-8 mg, followed by a day of washout and 4 days of oral naltrexone titration. If the participant is able to tolerate the last dose of the naltrexone titration, an XR-NTX injection will be given
75382967|NCT05485675|Behavioral|Stand & Move at Work+|Web-based platform and support from an expert facilitator
75382968|NCT00004232|Biological|filgrastim|
75382969|NCT00004232|Drug|cyclosporine|
75382970|NCT00004232|Drug|methylprednisolone|
75382971|NCT00004232|Drug|prednisone|
75382972|NCT00004232|Procedure|allogeneic bone marrow transplantation|
75382973|NCT00004232|Procedure|peripheral blood stem cell transplantation|
75382974|NCT00004238|Drug|pralatrexate|
75382975|NCT00004874|Radiation|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
75382976|NCT05230927|Other|Multidisciplinary Rehabilitation|All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
75382977|NCT00004244|Biological|recombinant interferon alfa|
75382978|NCT00004244|Biological|recombinant interleukin-12|
75382979|NCT00004880|Biological|dendritic cell vaccine therapy|
75382980|NCT00004880|Procedure|conventional surgery|
75382981|NCT00004250|Biological|dactinomycin|
75382982|NCT00004250|Drug|isolated limb perfusion|
75382983|NCT00004250|Drug|melphalan|
75868344|NCT04755673|Other|Atrantil (Medical Food)|All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
75382984|NCT00003728|Drug|asparaginase|
75382985|NCT00003728|Drug|cyclophosphamide|
75382986|NCT00003728|Drug|cytarabine|
75382987|NCT00003728|Drug|daunorubicin hydrochloride|
75541496|NCT04669405|Other|Therapeutic Exercise|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
75541497|NCT02962271|Device|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
75541498|NCT00556348|Drug|bevacizumab|1.25mg
75541499|NCT04556539|Drug|SC10914|400mg TID, oral admination on fasting condition
75541500|NCT00556387|Drug|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
75868345|NCT03620851|Other|effect of age|effect of age on the efficiency of enhanced recovery program
75868346|NCT04920643|Procedure|Ultrafiltration|Ultrafiltration is used during cardiac surgery with cardiopulmonary bypass to remove both fluid and small molecules such as inflammatory cytokines from the patient's circulation.
75868347|NCT03631134|Drug|SGLT2 inhibitor|Patients will be gave SGLT2 inhibitor 10mg per day
75382988|NCT00003728|Drug|dexamethasone|
75382989|NCT00003728|Drug|doxorubicin hydrochloride|
75541501|NCT00556387|Drug|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
75382990|NCT00003728|Drug|etoposide|
75382991|NCT00003728|Drug|leucovorin calcium|
75382992|NCT00003728|Drug|mercaptopurine|
75382993|NCT00003728|Drug|methotrexate|
75541502|NCT00260637|Procedure|Acupuncture|
75541503|NCT04556422|Other|Aerobic exercise|15 minutes of aerobic exercise using stationary bicycle
75541504|NCT04556422|Other|Sauna bathing|Passive heat exposure
75704905|NCT04229992|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
75704906|NCT04229992|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
75868348|NCT01381380|Procedure|Manual therapy|Manual therapy, once a week for 8 weeks
75382994|NCT00003728|Drug|methylprednisolone|
75382995|NCT00003728|Drug|mitoxantrone hydrochloride|
75382996|NCT00003728|Drug|prednisolone|
75382997|NCT00003728|Drug|therapeutic hydrocortisone|
75382998|NCT00003728|Drug|thioguanine|
75382999|NCT00003728|Drug|vincristine sulfate|
75383000|NCT00003728|Drug|vindesine|
75383001|NCT00003728|Procedure|allogeneic bone marrow transplantation|
75383002|NCT00003728|Procedure|peripheral blood stem cell transplantation|
75383003|NCT00004886|Drug|docetaxel|
75383004|NCT00004886|Drug|dofequidar fumarate|
75383005|NCT00382759|Procedure|stem cell transplant|
75383006|NCT00003734|Drug|flutamide|
75383007|NCT00003734|Drug|triptorelin|
75383008|NCT00003734|Radiation|radiation therapy|
75383009|NCT04812847|Diagnostic Test|Identification of MDR characteristics|Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
75383010|NCT00003740|Biological|trastuzumab|
75383011|NCT05477875|Drug|oral cannabinoid|dronabinol
75383012|NCT05477875|Combination Product|oral codeine/acetaminophen|10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
75383013|NCT00004256|Biological|sargramostim|
75383014|NCT00004256|Procedure|quality-of-life assessment|
75383015|NCT00004256|Radiation|radiation therapy|
75383016|NCT00382525|Device|Cardiac Rhythm Management device|
75383017|NCT00004262|Procedure|conventional surgery|
75541505|NCT04669483|Other|evidence-based informed consent form|Evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures will be developed. The design of the evidence-based informed consent forms will be guided by an existing guideline on how to present evidence-based health information (guideline evidence-based health information) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo. Verbal presentations of risks lead to overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.
75383018|NCT00004262|Radiation|3-dimensional conformal radiation therapy|
75541506|NCT04552093|Drug|Floxuridine|Administration of intra-arterial floxuridine via the HAIP (HAIP chemotherapy) to the liver with concomitant Dutch standard of care systemic FOLFOX (5-FU, leucovorin and oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan).
75541507|NCT04552093|Device|Tricumed IP2000V infusion pump|Surgical implantation of hepatic artery infusion pump (HAIP) followed by administration of the combined chemotherapy (HAIP and systemic).
75541508|NCT00260676|Procedure|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
75541509|NCT04556110|Drug|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
75383019|NCT00004262|Radiation|stereotactic radiosurgery|
75383020|NCT00004262|Drug|motexafin gadolinium|Given IV
75383021|NCT00004262|Procedure|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
75383022|NCT00004262|Procedure|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
75383023|NCT05471791|Device|Back2Play App|This App uses the Apple watch to monitor activity level and heart rate and combines this with self reported symptoms and stage of recovery to send notifications, suggestions and provide resources to help participants adhere to the guidelines.
75383024|NCT00004892|Drug|O6-benzylguanine|
75383025|NCT00004892|Drug|polifeprosan 20 with carmustine implant|
75383026|NCT00004892|Procedure|conventional surgery|
75383027|NCT00004268|Drug|midodrine|
75383028|NCT00004274|Drug|Estrogen|
75383029|NCT00004904|Biological|anti-thymocyte globulin|
75383030|NCT00004904|Biological|filgrastim|
75383031|NCT00004904|Drug|cladribine|
75383032|NCT00004904|Drug|cyclophosphamide|
75383033|NCT00004904|Drug|etoposide|
75383034|NCT00004904|Drug|methylprednisolone|
75383035|NCT00004904|Drug|tacrolimus|
75383036|NCT00004904|Procedure|allogeneic bone marrow transplantation|
75383037|NCT00004904|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75383038|NCT00004286|Drug|immune globulin|
75383039|NCT00003746|Drug|2-chlorodeoxyadenosine (CDA) daily|Daily administration
75383040|NCT00003746|Drug|2-chlorodeoxyadenosine weekly|Weekly administration
75383041|NCT00003752|Drug|bexarotene|
76031246|NCT05002517|Drug|Methylprednisolone group|Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
75541510|NCT04556110|Drug|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
75541511|NCT00234299|Drug|Aspirin|325mg, one tablet orally, six months
75541512|NCT00234299|Drug|Placebo|325mg, one tablet orally every day, 6 months
75383042|NCT02973152|Procedure|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
75383043|NCT02973152|Procedure|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
75383044|NCT04092842|Device|Silicone prosthesis|Silicone prosthesis
75383045|NCT04092842|Procedure|Usual practice|Usual surgery
75383046|NCT00003758|Drug|cytarabine|
75383047|NCT00003758|Drug|idarubicin|
75383048|NCT00003758|Procedure|allogeneic bone marrow transplantation|
75383049|NCT00003758|Procedure|autologous bone marrow transplantation|
75383050|NCT00003758|Procedure|peripheral blood stem cell transplantation|
75383051|NCT00004310|Drug|Clomipramine|
75383052|NCT00004922|Drug|irinotecan hydrochloride|
75541513|NCT04556227|Behavioral|Simultaneous Cycle/Cognitive Training|Two weeks after discharge from the hospital the intervention group will complete recumbent cycle for 1 hour, 2x/wk. for 12 weeks (24 sessions). 10-minute cycle warm-up, 40-minute simultaneous cycling and cognitive training, 10-minute cool down. Cycling based on provider prescription and progression of physical recovery. Cognitive training program from Posit Science, Brain HQ (TM) progressive level of difficulty. Total duration of 60 minutes.
75541514|NCT04556032|Dietary Supplement|L-Ergothioneine 10 mg/d|L-Ergothioneine 10 mg/d
76031247|NCT03473275|Diagnostic Test|Cold Pressor test|Both feet in icy waterbath alternated with body temperature water
76031248|NCT03473275|Diagnostic Test|PinPrick test|Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
76031249|NCT05002205|Other|Questionnaires|Participants will be followed up by means of online surveys and 2 study visits.
76031250|NCT05002205|Other|spirometry|During two study visits, the lung function will be measured (FVC, FEV1)
76031251|NCT05002205|Other|ECG|During two study visits, the presence of arrhythmia will be explored.
75383053|NCT00004316|Drug|capsaicin|
75383054|NCT04712786|Other|pars plana vitrectomy|23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
75383055|NCT00004928|Dietary Supplement|calcitriol|
75383056|NCT00004928|Drug|zoledronic acid|
75383057|NCT00004328|Drug|enalapril|
75383058|NCT00004328|Drug|polystyrene sulfonate|
75383059|NCT02972684|Device|Thrombo-elastometry POC testing|Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
75383060|NCT00004934|Drug|carboplatin|
75383061|NCT00004934|Drug|epirubicin hydrochloride|
75383062|NCT00004934|Drug|paclitaxel|
75383063|NCT00004934|Procedure|conventional surgery|
75383064|NCT00003776|Biological|filgrastim|
75383065|NCT00003776|Drug|cisplatin|
75383066|NCT00003776|Drug|doxorubicin hydrochloride|
75383067|NCT00003776|Drug|ifosfamide|
75383068|NCT00003776|Drug|leucovorin calcium|
75383069|NCT00003776|Drug|methotrexate|
75383070|NCT00003776|Drug|trimetrexate glucuronate|
75383071|NCT00003776|Procedure|surgical procedure|
75383072|NCT00004940|Drug|cysteine hydrochloride|
75383073|NCT00003788|Drug|carmustine|
75383074|NCT00003788|Drug|lomustine|
75383075|NCT00003788|Drug|porfimer sodium|
75383076|NCT00003788|Drug|procarbazine hydrochloride|
75383077|NCT00003788|Procedure|neoadjuvant therapy|
75383078|NCT00003788|Procedure|surgical procedure|
75383079|NCT00003788|Radiation|radiation therapy|
75383080|NCT00385112|Procedure|Echocardiogram|2D echocardiogram with Doppler flow
75383081|NCT00004340|Drug|calcitriol|
75704907|NCT04229472|Diagnostic Test|High density electrophysiological mapping|Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.
75704908|NCT04229472|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
75383082|NCT00004340|Drug|growth hormone|
75704909|NCT04221230|Drug|BTRX-335140|Active Drug
75704910|NCT04221230|Drug|Placebo|Placebo
75383083|NCT00004982|Drug|Combination Iron Chelation Therapy|
75383084|NCT00004346|Drug|chenodeoxycholic acid|
75383085|NCT00004346|Drug|lovastatin|
75383086|NCT00003794|Procedure|psychosocial assessment and care|
75868349|NCT04909645|Diagnostic Test|Clearsight (finger cuff)|Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)*80/CO.
75868350|NCT04011618|Drug|Ellagic Acid / Pomegranate Extract|Polyphenol, ellagitannin, it is found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with 90% ellagic acid, 500 mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
75383087|NCT00003794|Procedure|quality-of-life assessment|
75383088|NCT00384800|Drug|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
75541515|NCT04556032|Dietary Supplement|L-Ergothioneine 25 mg/d|L-Ergothioneine 25 mg/d
75868351|NCT04011618|Drug|Placebo oral capsule|Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
75383089|NCT00384878|Drug|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
75383090|NCT02972762|Drug|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
75704911|NCT04218786|Drug|Colchicine|The tablet will be given once daily for the span of the study
75704912|NCT04218786|Drug|Placebo oral tablet|The tablet will be given once daily for the span of the study
75868352|NCT04163809|Device|Virtual Reality with Oculus Go headset|The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
75383091|NCT00004988|Drug|VNP20009|
75383092|NCT00004358|Drug|calcitonin|
75383093|NCT00004364|Drug|desmopressin|
75383094|NCT00005000|Drug|Nelfinavir mesylate|
75383095|NCT00005000|Drug|Efavirenz|
75383096|NCT00005000|Drug|Lamivudine|
75383097|NCT00005000|Drug|Keyhole-Limpet Hemocyanin|
75383098|NCT00005000|Drug|Stavudine|
75383099|NCT00005000|Drug|Zidovudine|
75383100|NCT00005000|Drug|Didanosine|
75383101|NCT00004376|Drug|guanfacine|
75541516|NCT04556032|Other|Placebo|0 mg/d L-Ergothioneine
75541517|NCT00260715|Behavioral|Community-Popular Opinion Leader Model|
75541518|NCT00260715|Behavioral|Diffusion of Innovations|
76031252|NCT05002205|Other|1 minute sit to stand test|Physical endurance is tested during 2 study visits.
76031253|NCT05002205|Other|Vital parameters|blood pressure, pulse, weight
75383102|NCT00005006|Drug|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
75383103|NCT00005006|Drug|Alendronate|Alendronate 70mg/week
75383104|NCT00005006|Drug|Teriparatide|Teriparatide 20mcg/day
75383105|NCT00004382|Drug|tin mesoporphyrin|
75383106|NCT00004382|Procedure|Phototherapy|
75383107|NCT00005012|Drug|Peginterferon alfa-2b|
75383108|NCT00004400|Drug|testosterone|
75383109|NCT00003812|Biological|filgrastim|
75383110|NCT00003812|Drug|carboplatin|
75383111|NCT00003812|Drug|etoposide|
76031254|NCT05002361|Drug|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
75383112|NCT00003812|Drug|paclitaxel|
75383113|NCT00003812|Drug|topotecan hydrochloride|
75383114|NCT00003812|Radiation|radiation therapy|
75383115|NCT00005018|Drug|Hydroxyurea|
75383116|NCT00005018|Drug|Abacavir sulfate|
75383117|NCT00005018|Drug|Efavirenz|
75383118|NCT00005018|Drug|Didanosine|
75383119|NCT00003824|Drug|cephalexin|500 mg oral bid for 3 days starting the night before resection
75383120|NCT00003824|Procedure|surgical procedure|
75383121|NCT00003824|Drug|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
75383122|NCT04791319|Drug|Placebo|Placebo will be administered subcutaneously.
75383123|NCT04791319|Drug|Bermekimab|Bermekimab will be administered subcutaneously.
75541519|NCT04556149|Device|imPulse™ Una e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
75868353|NCT04153279|Biological|CMV-TCR-T cells|Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
76031255|NCT05002361|Drug|Isotonic saline|6 ml of isotonic saline
75383124|NCT04791319|Drug|Dupilumab|Dupilumab will be administered subcutaneously.
75383125|NCT00004406|Drug|human parathyroid hormone|
75383126|NCT04786171|Diagnostic Test|4D X-ray Velocimetry|X-ray velocimetry uses fluoroscopy to quantify local ventilation in the lung.
75383127|NCT00005024|Drug|carboplatin|
75383128|NCT00005024|Drug|cyclophosphamide|
75383129|NCT00005024|Drug|doxorubicin hydrochloride|
75383130|NCT00005024|Drug|granisetron hydrochloride|
75383131|NCT00005030|Drug|SCH 66336|
75383132|NCT00005030|Procedure|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
75383133|NCT00004424|Drug|fentanyl|
75383134|NCT00004424|Drug|Midazolam|
75383135|NCT00004424|Drug|propofol|
75383136|NCT05196373|Drug|STP705|STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
75383137|NCT00004430|Drug|Dihematoporphyrin derivative|
75383138|NCT00004430|Drug|prednisolone|
75383139|NCT00004430|Procedure|Laser surgery|
75383140|NCT00003842|Biological|interleukin-4 PE38KDEL cytotoxin|
75383141|NCT00003842|Drug|isolated perfusion|
75383142|NCT00003842|Procedure|surgical procedure|
75383143|NCT00005036|Drug|irinotecan hydrochloride|Given IV
75383144|NCT00005036|Drug|oxaliplatin|Given IV
75383145|NCT00005036|Drug|leucovorin calcium|Given IV
75383146|NCT00005036|Drug|fluorouracil|Given IV
75383147|NCT00005036|Procedure|quality-of-life assessment|Ancillary studies
75383148|NCT05454007|Behavioral|Step length asymmetry training|Participants will engage in four, five-minute periods of step symmetry training during session 2. This training uses established sensorimotor adaptation-based methods (e.g. split-belt treadmill walking, walking with unilateral leg weighting) to elicit motor aftereffects of more equal step lengths. Two minute sitting rest breaks will be given between training blocks or at the participant's request. A video recording will be taken of the first and final two minutes of training.
75383149|NCT00003854|Other|immunohistochemistry staining method|
75383150|NCT00003854|Procedure|lymphangiography|
75383151|NCT00003854|Procedure|sentinel lymph node biopsy|
75383152|NCT00003854|Procedure|therapeutic conventional surgery|
75383153|NCT00003854|Radiation|whole breast irradiation|
75383154|NCT05450107|Procedure|Open Reduction Internal Fixation|Surgical intervention by lag screw or plate fixation
75383155|NCT05450107|Procedure|Cast immobilisation|Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
75383156|NCT05449639|Device|Relief implantation|The device will be implanted by endoscopic procedure by a standard resectoscope.
75383157|NCT00004436|Drug|leuprolide|
75383158|NCT00004436|Drug|prednisone|
75541520|NCT04556149|Device|Philips Lumify Ultrasound System|Point-of-care ultrasound
76031256|NCT02329405|Drug|Rifampicin|
76031257|NCT02329405|Drug|Placebo|
75868354|NCT04725318|Other|One-lung ventilation|One-lung ventilation as part of routine clinical care for patients undergoing thoracic surgery under general anesthesia
75868355|NCT04138615|Drug|Morphine|Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
75868356|NCT04138615|Other|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
75868357|NCT01383330|Drug|megace|800mg
75383159|NCT00005042|Drug|semaxanib|
75541521|NCT04556071|Drug|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight<77 kg and/or basal platelet count <150,000/μL will take 200 mg daily.
75704913|NCT04202692|Device|Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
75868358|NCT01383330|Drug|DW-ES(A)|625mg
75868359|NCT01383330|Drug|DW-ES(B)|625mg
75868360|NCT03018938|Drug|Insulin Analog Mid Mixture|Administered SC
75868361|NCT03018938|Drug|Basal Insulin Analog|Administered SC
75868362|NCT03631368|Drug|Botox|Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
75868363|NCT02943577|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
75868364|NCT02943577|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
75868366|NCT03174535|Drug|Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.|The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
75868367|NCT04776499|Drug|Propylthiouracil, Riociguat, Perphenazine|"Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg"
75383160|NCT00004442|Drug|chenodeoxycholic acid|
75383161|NCT00004442|Drug|cholic acid|
75868368|NCT03668054|Drug|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
75868369|NCT04698187|Drug|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
75868370|NCT04698187|Drug|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
75383162|NCT00004442|Drug|ursodiol|
75383163|NCT05444569|Drug|LY3537021|Administered SC.
75383164|NCT05444569|Drug|Liraglutide|Administered SC.
75383165|NCT05444569|Drug|Placebo|Administered SC.
75383166|NCT00004448|Drug|omega-3 fatty acids|
75383167|NCT00004448|Drug|prednisone|
75383168|NCT00003860|Biological|filgrastim|
75383169|NCT00003860|Drug|carboplatin|
75383170|NCT00003860|Drug|etoposide|
75383171|NCT00003860|Drug|ifosfamide|
75868371|NCT03667742|Diagnostic Test|analysis of sweat and serum samples for protein markers|collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
75868372|NCT03623048|Other|chlorhexidine|antibacterial and anti-inflammatory mouthwash
75541522|NCT04556071|Drug|Bevacizumab|The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
75868373|NCT03623048|Other|saline|anti-inflammatory cleansing mouthwash
75868374|NCT03623048|Other|Propolis extract|antibacterial mouthwash
75868375|NCT03623048|Other|pomegranate extract|antibacterial mouthwash
75868376|NCT01312597|Other|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
75868377|NCT03016598|Drug|Intranasal oxytocin|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
75868378|NCT03016598|Drug|Intranasal placebo|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
75868379|NCT03667664|Behavioral|Physical exercises et nutritional counseling in elderly people at risks of loss of autonomy|"Pre-program : eligibility criteria, nutritional status (MNA score, BMI, recent loss of weight), previous history, comorbidities, clinical examination, number of loss in the previous year, Rapid Assessment of Physical Activity score, activities of daily living and Instrumental activities of daily living, Medical Outcome Study Short Form 36 score, physical tests (Hand grip, Short Physical Performance Battery, Knee extension, Neurocom platform physical tests, Dual X-Ray Absorptiometry and Bio-impedance for Body Mass measurement, Muscular echography.~Implementation of a one year multimodal program based on physical exercises and nutrition counseling as a way of preventing dependence and loss of autonomy in elderly people."
76031258|NCT05002283|Other|patient specific guide|harvesting palatal free gingival graft using the patient specific guide
76031259|NCT02329171|Drug|Imiquimod|Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
76031260|NCT02329171|Procedure|LLETZ|Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
76031261|NCT05001971|Drug|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
76031262|NCT05000801|Biological|DC vaccine|Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
75383172|NCT00003860|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75383173|NCT00005048|Drug|estramustine phosphate sodium|
75383174|NCT00005048|Drug|paclitaxel|
75383175|NCT00004454|Genetic|lymphocyte gene therapy|
75383176|NCT04756765|Drug|Talazoparib Tosylate|Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.
75383177|NCT00004466|Drug|Atorvastatin|
75383178|NCT00004466|Drug|Placebo|
75383179|NCT00005054|Drug|temozolomide|
75704914|NCT04202692|Device|Placebo 1100 mg, identically-looking melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
76031263|NCT02329093|Procedure|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
76031264|NCT02329249|Behavioral|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
76031265|NCT02329249|Other|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
76031266|NCT05001893|Device|S53P4 bioactive glass putty|Bonalive putty/putty MIS paste is a synthetic, bioactive, osteoconductive, osteostimulative bone void filler for filling, reconstruction, and regeneration of bone defects.
76031267|NCT03143335|Procedure|Retropectoral immediate breast reconstruction|Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.
76031268|NCT03143335|Procedure|Prepectoral immediate breast reconstruction|Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
75383180|NCT00385346|Behavioral|Expressive writing|Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
75383181|NCT00004478|Drug|droxidopa|
75383182|NCT00003878|Drug|polifeprosan 20 with carmustine implant|
75383183|NCT00003878|Procedure|conventional surgery|
75383184|NCT00005060|Drug|Taxotere-Cisplatin-5FU|Preoperatively
75383185|NCT00005060|Drug|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
75383186|NCT04723927|Other|Older adults|The data for motor function and gait pattern analysis was obtained.
75383187|NCT00003884|Drug|zoledronic acid|
75383188|NCT00003884|Procedure|quality-of-life assessment|
75383189|NCT00003890|Drug|MG 98|
76031269|NCT05001659|Other|computer simulator and mannequin simulator|compared two different training simulators with respect to training effectiveness in ACLS training.
76031270|NCT02328781|Device|Drug-eluting stent|
76031271|NCT05000099|Other|video calls|A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time
75383190|NCT00385190|Drug|HCV-796|
76031272|NCT05000255|Behavioral|Intervention 1: According to DGP|The first intervention is designed according to a current recommendation of the Deutsche Pneumologen Gesellschaft e.V. Its approach is resource-oriented, psychoeducational and is expected to have a positive effect on the symptomatology of depression and anxiety in the short and medium term. An additional focus was added to the intervention: planning more physical activity in daily life after discharge. The DPG intervention focuses more on the current state and aims to activate patients' resources in the short and long term. To ensure randomization of study participants, interventions will alternate weekly.
75868380|NCT04052737|Drug|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
76031273|NCT05000255|Behavioral|"Intervention 2: According to Cacioppo E.A.S.E."|"The second intervention, E. A. S. E. according to Cacioppo and Patrick (2008), addresses the social action radius of patients (here assuming that loneliness is a predictor of depression). This intervention is about planning social activities against loneliness. Cacioppo's intervention aims to encourage more social activity in the long term."
75383191|NCT04717297|Behavioral|Medication Management Remote Intervention|First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.
75541523|NCT04563676|Biological|blood test|covid19 infected patient will have a blood test in order to make an autoimmune assessment (antinuclear antibodies, soluble nuclear anti-antigen, ANCA, antiphospholipid antibodies, FT3, FT4 , TSH, antithyroid antibodies, ACTH cortisol, and creation of a serotheque).
75541524|NCT00234377|Drug|Seroquel SR|
75541525|NCT04563286|Other|questionnaire on life quality|Two sets of 30 PROMs questions will be created. The v-ATTR and wt-ATTR questionnaires will be critically evaluated by the whole panel, taking into account observations and feedback from patients. The 2 scores will be administered to consecutive patients evaluated at dedicated ambulatory clinics of the 4 Institutions. To confirm score reliability and responsiveness, 2 distinct patient cohorts will be recruited. The reliability cohort will be assembled to demonstrate the instrument's test-retest reliability. A second cohort of patients (responsiveness cohort) will be assembled to demonstrate the instrument's responsiveness to changes in clinical status. Patients experiencing a heart failure hospitalization within 6 months will enter the responsiveness cohort at the time of hospital admission.
75541526|NCT00260754|Behavioral|Community-Popular Opinion Leader Model|
75541527|NCT00260754|Behavioral|Diffusion of Innovations|
75541528|NCT02211118|Drug|Intranasal dexemdetomidine (IN-DEX)|
75541529|NCT02211157|Drug|BIBR 796 BS|
75541530|NCT02211157|Drug|Placebo|
75541531|NCT02211157|Other|high fat breakfast|
75541532|NCT00234416|Drug|Gefitinib|
75541533|NCT00234416|Drug|Gemcitabine|
75868381|NCT04052737|Drug|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
75868382|NCT03017846|Drug|Cantharidin|Application of topical cantharidin
76031274|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
76031275|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
75868383|NCT04691869|Device|Achilles EXPII|Portable ultrasound machine that measures a patient's bone density at the calcaneus.
76031276|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
76031277|NCT04498741|Drug|Tacrolimus|Subjects will receive tacrolimus once daily on Day 1 and Day 24
76031278|NCT04498741|Drug|Dabigatran|Subjects will receive dabigatran once daily on Day 1 and Day 13
76031279|NCT04498741|Drug|Rosuvastatin|Subjects will receive rosuvastatin once daily on Day 1 and Day 13
76031280|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
76031281|NCT04498741|Drug|Midazolam|Subjects will receive midazolam once daily on Day 1 and Day 16
75383192|NCT04717297|Behavioral|Waitlist Control|A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.
75383193|NCT04717297|Behavioral|Medication Management In-Person Intervention|Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
75868384|NCT04613791|Biological|Blood test|Collection of epidemio-clinical, biological, radiological and therapeutic patient data. Study samples collected from 154 patients to determine whether a particular immune profile could identify individuals prone to insulin resistance
76031282|NCT04999943|Biological|DC vaccine|EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
75383194|NCT00005066|Drug|O6-benzylguanine|
76031283|NCT04999865|Other|4-part educational program to build patient-engagement methodology capacity|We created four online training sessions. Our first training for patients/caregivers only (Research 101) was an exception, however, in which we produced a 25-minute asynchronous, self-directed learning seminar intended to be viewed before the subsequent interactive PCOR sessions. Of the three following synchronous interactive training sessions, two included both learner working groups (patients/caregivers and researchers/providers) together (PCOR 101 and PCOR Team Dynamics) and one session (PCOR Study Design) was for researchers/healthcare providers only.
75383195|NCT00005066|Drug|carmustine|
75383196|NCT00004490|Drug|sodium dichloroacetate|
75541534|NCT02211196|Behavioral|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
75541535|NCT02211196|Other|survey administration|Ancillary studies
75541536|NCT02211196|Other|questionnaire administration|Ancillary studies
75868385|NCT03667118|Dietary Supplement|Food Supplement|A powder blend of 16 common allergenic proteins ([oat, milk, egg, sesame, wheat] [almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut] [cod, shrimp, salmon]) combined with 400 IU of Vitamin D3
75868386|NCT02857855|Procedure|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
76031284|NCT04938635|Drug|VIT-2763 60 mg QD|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
76031285|NCT04938635|Drug|VIT-2763 60 mg BID|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
75383199|NCT00005072|Biological|Leuvectin|1000 ug of Leuvectin injected intratumorally
75383200|NCT00004496|Drug|alpha-melanocyte stimulating hormone|
75383201|NCT05138653|Drug|Drug: CVL-354|Oral solution/suspension
75383202|NCT05138653|Drug|Drug: Placebo|Oral solution/suspension
75383203|NCT05133895|Drug|Tocilizumab monotherapy|intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
75383204|NCT00382603|Device|OptiFree Multi-Purpose Disinfecting Solution|
75383205|NCT00003902|Drug|capecitabine|
75383206|NCT00003902|Drug|vinorelbine tartrate|
75383207|NCT00003908|Drug|carboplatin|
75541537|NCT04563364|Other|Interdisciplinary hospital-home intervention|The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT
75541538|NCT04563364|Other|Convencional treatment|Control group will receive a conventional treatment given by the institutions
75541539|NCT04562857|Behavioral|Moderate intensity interval training (MITT)|interval exercises (intervention) on bicycle for patients with AF and OSA or AF with CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
75868387|NCT02857855|Procedure|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
75868388|NCT03666728|Drug|SHR-1210|SHR-1210 was administered 200 mg iv every 3 weeks
75383208|NCT00003908|Drug|docetaxel|
75383209|NCT00382837|Drug|Epratuzumab|
75383210|NCT00003914|Drug|dolastatin 10|
76031286|NCT04938635|Drug|VIT-2763 120 mg BID|Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
75383211|NCT00005078|Drug|carboplatin|
75383212|NCT00005078|Drug|paclitaxel|
75868389|NCT03666728|Drug|BP102|BP102 was administered 15 mg/kg iv every 3 weeks
76031287|NCT04938635|Drug|Placebo|Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
76031288|NCT03551743|Combination Product|PRT064445/Edoxaban|
76031289|NCT03551743|Combination Product|Placebo/Edoxaban|
76031290|NCT03551743|Drug|Placebo|
76031291|NCT04932395|Drug|Anshen Buxin Liuwei Pill|15 capsules/time, 2 times/day, orally.
75383213|NCT00005078|Drug|tirapazamine|
75383214|NCT04698031|Drug|Clopidogrel treatment|After randomization, patients will receive clopidogrel 75 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
75383215|NCT04698031|Drug|Aspirin treatment|After randomization, patients will receive Aspirin 325 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
75383216|NCT00003920|Biological|filgrastim|
75383217|NCT00003920|Drug|cyclosporine|
75383218|NCT00003920|Procedure|peripheral blood stem cell transplantation|
75383219|NCT00003920|Radiation|indium In 111 monoclonal antibody m170|
75383220|NCT00003920|Radiation|yttrium Y 90 monoclonal antibody m170|
75383221|NCT00005084|Procedure|conventional surgery|
75383222|NCT00005084|Procedure|magnetic resonance spectroscopic imaging|
75383223|NCT00005084|Radiation|radiation therapy|
75541540|NCT04563052|Behavioral|Educational Program on Air Pollution as a Health Risk Reduction Strategy|A power point presentation about the health impact of exposure to fine particulate matter (PM2.5) on health. Pm2.5 is found outdoors and indoors. Information will be reviewed about steps to take for the participants to locate the information using a smart phone and steps to take to decrease exposure to prevent illness such as heart disease or strokes.
75541541|NCT00234455|Device|drug eluting-stent|PCI
76031292|NCT04932395|Drug|Placebo|Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
75541542|NCT00234455|Device|drug-eluting stent|PCI
75541543|NCT04563169|Other|Video consultation|The first video consultation with a nurse was planned one week after start with CPAP. Three focus points were discussed during the consultations: 1) adherence (>6 hours per night); 2) rest AHI < 5 (or <10 if age >70), and 3) (improvements in) complaints. If these objectives were achieved after one week, a new consultation was planned three weeks later (four weeks after start). As long as these objectives were not achieved, video consultations were planned weekly (until after four weeks).
75541544|NCT04563091|Device|Hemodialysis with online HFR|"Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values > 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment."
75541545|NCT00234572|Drug|Lanreotide (Autogel formulation)|
76031293|NCT04932239|Other|first aid education|To teach commercial motorcyclists first aid for post-crash while waiting for medical team to reach the scene
76031294|NCT04714879|Other|Device: anodal tDCS|anodal current modulated by an oscillatory component including a fixed (0,75 Hz) versus individually adapted so-tDCS frequency with three different stimulation durations (5 min, 2 min, 30 sec)
76031295|NCT04714879|Other|Device: no stimulation|sham stimulation
76031296|NCT04698811|Behavioral|VIRTUAL ENEAGRAM|"Presentation of the Virtual Enneagram and its content and realization of the first battery of tests (World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: IDATE E and T.) .~Guidance and training on personality and the Enneagram, its classification system, personality subtypes and dynamics of stress and growth allowing self-recognition.~Second test battery ((World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: (IDATE E and T.) and Enneagram Questionnaire."
76031297|NCT03142399|Dietary Supplement|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
76031298|NCT03076307|Behavioral|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
75383224|NCT00003926|Drug|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
75383225|NCT00003926|Drug|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
75541546|NCT04562818|Diagnostic Test|Diagnosis|Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)
75541547|NCT04562818|Diagnostic Test|Molecular and Karyotype|To realize the need of having more center we the technology to perform all of these tests
75541548|NCT04562818|Diagnostic Test|Leucocytes|
75383226|NCT00003926|Drug|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
75383227|NCT00003926|Drug|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
75541549|NCT00260793|Drug|Ropinirole Hydrochloride|
75541550|NCT04562506|Device|rTMS with H-coil|Deep repetitive transcranial manetic stimulation or sham stimulation with H-coil
75541551|NCT04562506|Device|Sham rTMS stimulation with H-coil|Sham rTMS stimulation
75541552|NCT04562545|Device|Modified Twin Block|a modified twin block design including jack screws to facilitate incemental advancement
75541553|NCT04562545|Device|Twin Block Appliance set to maximum bite|a traditional twin block set to maximum bite advancement at start of treatment
76031299|NCT03076229|Behavioral|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
75383228|NCT00003926|Drug|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
75383229|NCT00003926|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
75541554|NCT00234611|Procedure|Echocardiogram guided left ventricular lead placement|
75541555|NCT00415935|Drug|methotrexate|
75704915|NCT04201119|Device|Oxiris|Oxiris membrane used on the Prismaflex device (Baxter) dedicated to that type of membrane at blood pump flow of 450 ml min-1
75704916|NCT04198831|Other|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
76031300|NCT03076073|Other|Impact of physical activity on tendons|Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
76031301|NCT02328859|Other|Virtual Reality Gait Training|A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar
76031302|NCT02328859|Other|Treadmill Gait Training|A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
75704917|NCT04198831|Other|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
75704918|NCT04198818|Drug|HH2710|HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
75868390|NCT03666871|Biological|SB-728-T|Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases
75868391|NCT03666871|Biological|Expanded unmodified autologous CD4+ T cells|Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases
75868392|NCT03014180|Device|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
75868393|NCT03638401|Procedure|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
75868394|NCT04747873|Behavioral|e-CBT|The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.
75868395|NCT04747873|Behavioral|Stepped Care|Stepped care procedure (see arm/group descriptions).
75868396|NCT03667040|Behavioral|JOOL app|Participants will use the JOOL app for 30 days
76031303|NCT04993937|Other|Intervention|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
75541556|NCT02211274|Other|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
75541557|NCT02211352|Drug|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
76031304|NCT04993937|Other|Control Group|Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
75383230|NCT05122819|Procedure|Mandibular Molar Extraction Under Local Anesthesia|"Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS)."
75383231|NCT00005090|Biological|bleomycin sulfate|10 U/m^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
75383232|NCT00005090|Drug|carmustine|150/m^2 on days -6 to -4 (4-6 days before transplant).
75541558|NCT02211352|Drug|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
75383233|NCT00005090|Drug|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
75541559|NCT00413738|Device|Antiseptic-coated central venous catheters|
75541560|NCT02211391|Other|Casein Protein|The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
75383234|NCT00005090|Drug|dacarbazine|375 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
75383235|NCT00005090|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
75541561|NCT02211391|Other|Non-caloric placebo|The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
75541562|NCT02211469|Drug|BMS-986104|
75541563|NCT02211469|Drug|Placebo|
75541564|NCT00415974|Behavioral|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
75704919|NCT04195542|Other|Questionnaire|questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
75704920|NCT04192825|Procedure|surgical treatment|surgical drainage and/or surgical reconstruction procedures to anoperineal suppurations according to the doctor's decision
75704921|NCT04177758|Drug|Vitamin D|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
75383236|NCT00005090|Drug|etoposide|60 mg/kg on day -4 (4 days before transplant).
75383237|NCT00005090|Drug|vinblastine|6 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
75383238|NCT00005090|Procedure|peripheral blood stem cell transplantation|2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight
75383239|NCT00004580|Drug|Lopinavir/Ritonavir|
75383240|NCT00004580|Drug|Nevirapine|
75383241|NCT00005096|Drug|docetaxel|
75383242|NCT00004604|Biological|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
75383243|NCT05421013|Drug|STP705|STP705 targets TGFB-1 and COX-2 mRNA respectively.
75704922|NCT04177758|Drug|Control|Patients randomized to the control will receive a placebo
75868397|NCT03666650|Drug|Edoxaban 60 MG|Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
75868398|NCT04679857|Other|TKA|Total Knee Arthroplasty
75383244|NCT00004640|Drug|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
75383245|NCT05104099|Drug|Metvixia Topical Cream|"Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.~The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.~If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones."
75383246|NCT00004646|Drug|prednisone|
76031305|NCT03143257|Device|Sophono Bone Conduction Hearing Systems|"The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of BC of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear."
75383247|NCT04330651|Procedure|ECLS|Emergency application of Extracorporeal Life Support in post-surgical patients
75383248|NCT00005108|Drug|Estradiol|
75383249|NCT00005108|Drug|Progesterone|
75383250|NCT04648579|Device|Hillrom|Hillrom Connecta solution will record vital signs in an automated way, without the need for human intervention, and activate TRR activation when at least one criteria is met. The frequency of monitoring vital signs will be defined based on the MEWS score.
75383251|NCT04648579|Other|Control|Hospital usual care regarding vital signs collection and TRR activation.
75383252|NCT00004652|Drug|pimozide|
75383253|NCT00004658|Drug|ribose|
75383254|NCT00004658|Drug|thymidine|
75383255|NCT00004658|Drug|uridine|
75383256|NCT00005120|Drug|Calanolide A|
75383257|NCT04624321|Behavioral|Health and lifestyle tool|Health and lifestyle tool used online
75383258|NCT04624321|Other|Usual care|Usual care at ordinary healthcare provider
75383259|NCT00004664|Drug|megestrol|
75383260|NCT00004664|Behavioral|Exercise|
75541565|NCT00415974|Behavioral|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
75704923|NCT04172805|Drug|anlotinib and toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
76031306|NCT04993547|Other|Parent and peer presence|Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
76031307|NCT04654429|Drug|IV Ondansetron 4mg|IV ondansetron 4mg
76031308|NCT04654429|Other|Higher OT temperature range|OT temperature set to 19-22 degree celsius
76031309|NCT04654429|Drug|Placebo|IV Normal Saline 2cc will be given
75383261|NCT00004670|Procedure|pallidotomy|
75383262|NCT05396755|Procedure|Endoscopic retrograde cholangiography (ERC)|invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)
75383263|NCT00004682|Drug|immune globulin|
75383264|NCT00004688|Drug|carmustine|
75383265|NCT00004688|Drug|mercaptopurine|
75383266|NCT00004688|Drug|streptozocin|
75383267|NCT00004694|Drug|heparin|
75383268|NCT04608409|Drug|Lapatinib and Paclitaxel|Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
75383269|NCT05091853|Device|Adhesix mesh|2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh
75383270|NCT04607551|Procedure|Prone positionning|4 to 5 persons required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube, the jugular ECMO cannula and the ventilator lines and another dedicated to the femoral ECMO cannula. The person at the head of the bed will coordinate the steps. The other persons will stand at each side of the bed. The direction of the rotation will be decided giving priority to the side of the central venous lines. The length of vascular and ventilator lines will be checked for appropriateness, the endotracheal tube and gastric tube will be secured, and the patient's knees, forehead, chest, and iliac crests will be protected using adhesive pads. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. Patients will be proned at least four times during the first days on ECMO. Each prone session will stand for at least 16 hours
75383271|NCT04607551|Procedure|Supine position|Patients assigned to supine will remain in a semi-recumbent position.
75383272|NCT00004700|Drug|insulin-like growth factor I|
75383273|NCT00004730|Drug|magnesium sulfate|
75383274|NCT00004736|Drug|Nelfinavir mesylate|
75383275|NCT00004736|Drug|Ethambutol hydrochloride|
75383276|NCT00004736|Drug|Isoniazid|
75383277|NCT00004736|Drug|Pyrazinamide|
75383278|NCT00004736|Drug|Lamivudine|
75541566|NCT00415974|Behavioral|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
75704926|NCT04159909|Device|Transcutaneous Nerve Stimulation|510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days
75704927|NCT04159909|Device|Sham Stimulation|sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days
75704928|NCT04150458|Drug|18F-fluorocholine PET/CT.|18F-fluorocholine positron emission tomography / computed tomography
75704929|NCT04147208|Drug|GLS4|Administered GLS4 120 mg orally three times daily in fed state
75704930|NCT04147208|Drug|RTV|Administered RTV 100 mg orally three times daily in fed state
75704931|NCT04147208|Drug|ETV|Administered orally ETV 0.5 mg once daily in fasted state
75704932|NCT04137510|Device|Percutaneous coronary intervention|It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
75704933|NCT04120688|Device|3D generated tooth replica|3D generated tooth replicas are compared to conventional procedure
75704934|NCT04085991|Drug|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
75704935|NCT04072991|Other|dietary therapy|participants will undertake a four week diet as part of their IBS treatment
75704936|NCT04047771|Drug|SCB-313|Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
75704937|NCT04025931|Drug|chidamide and toripalimab|"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
75704938|NCT04003103|Drug|Islatravir|Islatravir 30 mg capsules taken by mouth.
75704939|NCT04003103|Drug|Placebo|Placebo capsules taken by mouth.
75383279|NCT00004736|Drug|Rifabutin|
75704940|NCT03999216|Drug|Loop Diuretics vs. loop + thiazide diuretics|Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
75704941|NCT03989401|Other|Multimedia video health education|The experimental group conducted multimedia video education while admission.
75704942|NCT03971617|Drug|Hydrogen|each hydrogen tablet contains 80mg magnesium
75704943|NCT03971617|Drug|Placebo oral tablet|matching placebo tablet
75704944|NCT03965585|Procedure|in-office hysteroscopy|in-office hysteroscopy with miniaturized instruments
75704945|NCT03964909|Procedure|Functional Magnetic Resonance Imaging|Undergo fMRI
75704946|NCT03964909|Procedure|Magnetic Resonance Imaging|Undergo CVR MRI
75704947|NCT03964909|Procedure|Resting State Functional Connectivity Magnetic Resonance Imaging|Undergo rs-fMRI
75704948|NCT03959683|Device|Trilogy Lithotrite|The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.
75868399|NCT03011840|Other|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
76031310|NCT04654429|Other|Lower OT temperature Range|OT temperature set to 17-19 degree celsius
76031311|NCT03075683|Behavioral|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
76031312|NCT03075683|Behavioral|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
75383280|NCT00004736|Drug|Stavudine|
75383281|NCT00004736|Drug|Zidovudine|
75383282|NCT04592731|Drug|Gel containing Acetylated Natural Nucleotides|The study drug is a gel containing acetylated natural nucleotides.
75383283|NCT04592731|Drug|Vehicle Gel|The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
75383284|NCT00004748|Drug|colchicine|
75383285|NCT00004748|Drug|methotrexate|
75383286|NCT00004748|Drug|ursodiol|
75383287|NCT04585477|Device|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
75383288|NCT04585477|Drug|Durvalumab|1500mg intravenous dose or 20mg/kg if weight is 30kg or less, manufactured by AstraZeneca
75383289|NCT00004754|Drug|epoprostenol|
75383292|NCT00005576|Biological|monoclonal antibody Ch14.18|Given IV
75383293|NCT00005576|Drug|isotretinoin|Given orally
75383294|NCT00005576|Biological|aldesleukin|Given IV
75704949|NCT03959683|Device|The ShockPulse-SE Lithotripsy System|The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
75704950|NCT03958929|Other|Educational Video|The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
75868400|NCT03666572|Other|Bifidobacterium infantis|Bifidobacterium longum subsp. infantis (EVC001)
75704951|NCT03945448|Drug|Single dose liposomal Amphotericin and Fluconazole|Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
75868401|NCT03666572|Other|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]
75868402|NCT03666572|Other|Placebo (Lactose)|Placebo (Lactose)
75383295|NCT00005576|Biological|sargramostim|Given IV
75868403|NCT03667508|Procedure|Rapid Maxillary Expanding Device|The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
75704952|NCT03945448|Drug|Fluconazole|Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
75704953|NCT03941873|Drug|Sitravatinib|Study participants will receive sitravatinib capsule once daily
76031313|NCT03075995|Other|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
76031314|NCT04639999|Other|Echocardiography|LV vortex flow in Echocardiography
75704954|NCT03941873|Drug|Sitravatinib plus Tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
75704955|NCT03941873|Drug|Sitravatinib|Study participants will receive sitravatinib capsule once daily.
75704956|NCT03941873|Drug|Sitravatinib and tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
75704957|NCT03941873|Drug|Sitravatinib and tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
75704958|NCT03941873|Drug|Sitravatinib and tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
75704959|NCT03941587|Drug|Aflibercept + reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2
75868404|NCT03667508|Procedure|Slow Maxillary Expanding Device|The expansion screw will be activated every five days until correcting the crossbite.
75868405|NCT02942485|Drug|Metronidazole|P/r suppositories
75868406|NCT02942485|Drug|Tinidazole|P/o tablets
76031315|NCT03111355|Dietary Supplement|Brazil nut|one nut a day for 2 months, no intervention for 2 months
76031316|NCT04999397|Other|standards clinical management|outcomes seen in cardiac injuries post clincal care
75383296|NCT00386204|Device|Q-switched Ruby Laser|
75868407|NCT03666494|Drug|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
75868408|NCT03666494|Drug|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
75868409|NCT03666494|Drug|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
75383297|NCT00004760|Behavioral|Exercise|
75868410|NCT03622970|Device|VGBT with Nintendo® Wii and LMC games|Nintendo Wii and LMC games will be used for upper limb rehabilitation in Cerebral Palsy. The games are tennis and boxing for Nintendo Wii, Leapball and CatchApet for LMC.
75868411|NCT03622970|Behavioral|NDT-based upper limb rehabilitation|NDT-based upper limb rehabilitation includes using real materials (clothes, spoons, pencils, buttons, rope, etc.) such as getting dressed and eating etc. Also, It will practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
75868412|NCT03666884|Drug|COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
75868413|NCT03666884|Biological|AS 50% eye drops 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
75383298|NCT04713163|Drug|covid19 vaccine|Vaccine
75868414|NCT04057664|Behavioral|Learning of Coping Strategies|Group sessions with psychotherapy and physiotherapy
75868415|NCT02942407|Drug|apixaban|oral anticoagulant
75383299|NCT00004772|Drug|Immune globulin|
75383300|NCT04712929|Other|Fluconazole|( Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a rinse for 2 minute and swallowed) once a day for 14 days WHO criteria 5As and 5Rs for tobacco cessation
75383301|NCT05082961|Other|Collection of blood samples|Samples to evaluate the circulating CD8+ T cell count.
75383302|NCT00004784|Drug|methotrexate|
75383303|NCT00004784|Drug|ursodiol|
75868416|NCT02942407|Drug|warfarin|oral anticoagulant
76031317|NCT02328703|Other|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
76031318|NCT04999007|Other|Artificial intelligence algorithm|Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
75383304|NCT00004796|Drug|lactulose|
75383305|NCT00004802|Drug|dichlorphenamide|
75383306|NCT00004808|Drug|fluconazole|
75383307|NCT00004814|Drug|copolymer 1|
75383308|NCT00004826|Drug|clozapine|
75383309|NCT00423254|Biological|PSMA/PRAME|Low dose
75383310|NCT00423254|Biological|PSMA/PRAME|high dose
75383311|NCT04552327|Device|Solcera|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
75383312|NCT04552327|Device|Placebo|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
75704960|NCT03941587|Drug|Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy
76031319|NCT03979339|Procedure|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
76031320|NCT04998929|Other|complementary therapy|traditional techniques of treatment including, (a)cupping therapy, (b)Backstroke for young people, (c)Sitting on all fours while the other person holds both knees firmly with the hands, the patient is asked to bend at the back so that the abdominal muscles are stretched, (d)taking a nerve that passes under the armpit with two index fingers and thumbs and applying intense pressure to the extent that the patient goes unconscious due to the severity of the pain, (e)Hanging the patient from the horizontal bar and stretching the abdominal muscles, (f)Tie an onion-sized object such as, a bag of wheat or salt, with a scarf on the navel for one hour, (g) taking the gum of mountain pistachio tree which is the same as turpentine and halve a walnut and fill it with raw turpentine and put it inside the navel for 72 hours, and then move it in the umbilical region by twisting hand movements, (h)cupping therapy.
76031321|NCT03073499|Procedure|Oncological Home Hospitalization|
75704961|NCT03941171|Procedure|PAO|PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.
75704962|NCT03941171|Other|Usual care after PAO|Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.
75704963|NCT03941171|Other|PRT|4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
76031322|NCT03970993|Biological|R21 Matrix-M vaccination|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly
76031323|NCT03970993|Biological|R21 Matrix-M vaccination and CHMI|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite
76031324|NCT03970993|Biological|R21 Matrix-M vaccination booster|Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule
75704964|NCT03935763|Other|observational disease study|observation of routine clinical practices in mCRC
75868417|NCT03666806|Biological|Influenza vaccine|The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
75383313|NCT04552327|Drug|Solaraze|Twice daily application for a duration of 60 days
75383314|NCT00005588|Radiation|radiation therapy|
75383315|NCT04552015|Diagnostic Test|TST vs PPD microneedle test|TST vs First patch: 800 um in length, PPD1 formulation; Second patch: 1,500 um in length, PPD1 formulation; Third patch: 800 um in length, PPD2 formulation; and Fourth patch: 1,500 um in length, PPD2 formulation
75383316|NCT00004778|Drug|betamethasone|
75383317|NCT00004778|Drug|dexamethasone|
75383318|NCT00004778|Drug|thyrotropin-releasing hormone|
75383319|NCT00005594|Drug|ISIS 2503|Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
75383320|NCT00005600|Procedure|management of therapy complications|
75383321|NCT00005612|Biological|filgrastim|
75383322|NCT00005612|Drug|carboplatin|
75383323|NCT00005612|Drug|cyclophosphamide|
75383324|NCT00005612|Drug|etoposide|
75383325|NCT00005612|Drug|paclitaxel|
75383326|NCT00005612|Drug|topotecan hydrochloride|
75383327|NCT00005612|Procedure|peripheral blood stem cell transplantation|
75383328|NCT00005618|Drug|arsenic trioxide|
75383329|NCT00005624|Drug|CI-994|CI-994 as outlined in treatment arm.
75383330|NCT00382915|Device|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
75383331|NCT00385502|Drug|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
75383332|NCT00005630|Biological|ras peptide cancer vaccine|
75383333|NCT00005630|Biological|sargramostim|
75383334|NCT00005636|Drug|cisplatin|
75383335|NCT00005636|Drug|pemetrexed disodium|
75383336|NCT00005642|Drug|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
76031325|NCT04998695|Other|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
76031326|NCT04998695|Other|Sunflower oil|Volunteers consumed during 4 weeks 45 g/d of sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
75383337|NCT04524949|Drug|IMCY-0098 450 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
75383338|NCT04524949|Drug|IMCY-0098 1350 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
75383339|NCT04524949|Drug|Placebo|Solvent: alum hydroxide
76031327|NCT04998461|Biological|urine collection|To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
76031328|NCT03111121|Drug|Sugammadex|receive reversal with sugammadex 4mg/kg
75383340|NCT00005648|Drug|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
75383341|NCT00005648|Drug|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
75383342|NCT00005654|Drug|clomiphene citrate|
75704965|NCT03930524|Behavioral|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
75868418|NCT03638089|Behavioral|Fall-recovery training|Participants practice recovering from simulated, treadmill-induced slips and trips.
76031329|NCT03111121|Drug|neostigmine|receive reversal with neostigmine 0.04 mg/kg
76031330|NCT03111121|Drug|glycopyrrolate|receive reversal with glycopyrrolate (0.01 mg/kg)
76031331|NCT03073421|Other|Qualitative interview|This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
76031332|NCT04532359|Device|Implant placement|Implant placement
76031333|NCT04998383|Device|HVNI|High velocity nasal insufflation (Fisher &Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort.
76031334|NCT02328469|Drug|symptomatic therapy|patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
76031335|NCT02328469|Drug|Ceftriaxone or Doxycycline|beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
76031336|NCT02328469|Other|questionnaire|Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
76031337|NCT02328469|Drug|Acyclovir|Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
76031338|NCT03141853|Other|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
75383343|NCT00005654|Drug|metformin|
75383344|NCT00005666|Procedure|PET scan use in radiotherapy planning|
75383345|NCT00382447|Device|standard nebulizer|Standard small volume nebulizer for aerosolized medication delivery
75383346|NCT00382447|Device|breath actuated nebulizer|Nebulizer that dispenses medication only during the inspiratory phase
75383347|NCT04504747|Other|molecular analysis of blood and tumor|RNAseq, DNAseq, CTCs
75383348|NCT00005684|Drug|warfarin|
75383349|NCT00005684|Drug|heparin|
75383350|NCT00386282|Drug|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
75383351|NCT05040685|Procedure|Axillary mapping reverse|At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.
75383352|NCT05324683|Other|No intervention planned|No intervention planned; study is observational
76031339|NCT03141853|Other|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
76031340|NCT03075371|Other|Glucose|75 g of glucose dissolved in 300 ml of water
76031341|NCT03075371|Other|Placebo|300 ml of tap water
75704966|NCT03930524|Behavioral|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
75704967|NCT03930524|Behavioral|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
75704968|NCT03930524|Behavioral|Health Promotion Consultation|A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
75383353|NCT05323903|Other|Telesimulation|Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.
75868419|NCT02921035|Drug|Rebif (Interferon beta-1a)|Rebif will be administered at a dose of 44 mcg, sc, tiw.
75868420|NCT03009344|Drug|Tazemetostat|Tazemetostat tablets.
76031342|NCT04998071|Drug|Bupivacaine hydrochloride|Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC
76031343|NCT03734263|Drug|sodium phenylbutyrate|Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
76031344|NCT03075293|Other|Determination of pain management|Determine of pain management given to children with appendicitis in ER according to their medical records
75383354|NCT05323903|Other|Kahoot Game|Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.
75383355|NCT00385658|Drug|Fluvastatin extended release, fenofibrate|
75868421|NCT03322423|Device|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
75868422|NCT03322423|Device|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
75868423|NCT03322423|Device|Spherical Contact Lens 2|BioTrue ONEDay Spherical
75868424|NCT03007472|Device|CI532|Cochlear implant
76031345|NCT03145051|Other|Saline solution|a nasal irrigation care
76031346|NCT03145051|Other|Respimer Netiflow|a nasal irrigation care
75383356|NCT00385658|Drug|Fixed combination simvastatin/ezetimibe|
75383357|NCT04452955|Biological|PRL3-zumab|Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
75868425|NCT03007472|Device|Nucleus 7|Sound processor
75704969|NCT03930524|Behavioral|M-Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
75383358|NCT05305573|Biological|COVID-19 Vaccine HIPRA 40 ug/dose|Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)
75704970|NCT03923322|Drug|Botanical Tincture|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
75704971|NCT03923322|Other|Placebo|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
75704972|NCT03921528|Biological|SRK-015|SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
75868426|NCT03321721|Procedure|Suture for wound repair|Repair of wound with suture
75383359|NCT05305573|Biological|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|Subjects will receive one injection of Comirnaty Vaccine
75383360|NCT00005762|Drug|Indinavir sulfate|
75383361|NCT00005762|Drug|Ritonavir|
75383362|NCT00005762|Drug|Amprenavir|
75704973|NCT03917420|Drug|Tenofovir 300Mg Oral Tablet|Once daily dose of the combo tab x 5 days pre-sampling
75868427|NCT03321721|Device|Suture for wound repair|Repair of wound with suture
75868428|NCT04621981|Drug|Sodium Bicarbonate Ringer's Solution|This group was treated with Sodium Bicarbonate Ringer's Solution.
75383363|NCT00005762|Drug|Nelfinavir mesylate|
75383364|NCT00005762|Drug|Efavirenz|
75383365|NCT00005762|Drug|Saquinavir|
75383366|NCT04447807|Behavioral|Metacognitive Training|MCT is a structured, interactive approach that addresses cognitive biases, social cognition, and self-esteem. This study will conducted this intervention using group format, on a weekly basis, with duration of 9 weeks total.
75383367|NCT04447807|Other|Treatment as Usual|Patients will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School.
75383368|NCT00005768|Drug|Estrogen|
75868429|NCT04621981|Drug|Normal Saline|This group was treated with normal saline.
75868430|NCT03015116|Other|Stretching|Daily foot and ankle stretching protocol
75868431|NCT03015116|Other|Cryotherapy|Daily cryotherapy in conjunction with stretching
75868432|NCT03015116|Device|Photobiomodulation Low Power|Photobiomodulation treatment with 10W power output
75868433|NCT03015116|Device|Photobiomodulation High Power|Photobiomodulation treatment with 25W power output
75868434|NCT03667430|Dietary Supplement|Porous silica|The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.
75868435|NCT03667430|Dietary Supplement|Placebo (microcrystalline cellulose)|All participants starts with five days placebo run in period
75868436|NCT03667352|Procedure|Unilateral Scalp Block|Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.
75383369|NCT00005774|Drug|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
75383370|NCT00005774|Drug|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
75383371|NCT00005786|Drug|arsenic trioxide|Given IV
75383372|NCT00005786|Other|laboratory biomarker analysis|Correlative studies
75383373|NCT00005792|Drug|etoposide phosphate|Etoposide phosphate 1363 mg/m^2/day IV over 4 hours (total dose 2726 mg/m^2, or 2400 mg/m^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
75383374|NCT00005792|Drug|melphalan|Melphalan 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2), followed immediately by topotecan. Days -7, -6, -5
75383375|NCT00005792|Drug|topotecan|Topotecan 3.3 mg/m^2/day (starting total dose = 10 mg/m^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
75383376|NCT00005792|Procedure|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
75383377|NCT00005798|Drug|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
75383378|NCT00005798|Drug|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
75704974|NCT03917420|Drug|Emtricitabine 200 MG|Once daily dose of the combo tab x 5 days pre-sampling
75704975|NCT03917147|Procedure|Office Hysteroscopy|Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
75704976|NCT03902067|Biological|UC-MSC|0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability>80%, and endotoxin<0.1 EU， at the concentration of 2x10(7) cells/ml.
75704977|NCT03902067|Biological|Control Group|Routine treatment without catheter infusion
75704978|NCT03892720|Other|Quality-of-Life Assessment|Ancillary studies
75704979|NCT03892720|Other|Questionnaire Administration|Ancillary studies
75704980|NCT03892720|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75704981|NCT03886077|Drug|glecaprevir/pibrentasivir|12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
75868437|NCT03667352|Procedure|Transversus abdominis plane block|The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).
75868438|NCT03667352|Drug|Intravenous Fentanyl|Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
75868439|NCT03666338|Other|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
75868440|NCT03665948|Other|Dietary Intervention - Ketogenic Diet (KD)|The experimental procedure for each randomly assigned participant included a 4-week of KD diet.
76031347|NCT03075059|Behavioral|Child Life|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
76031348|NCT03671473|Device|Extracorporeal shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
75383379|NCT00005798|Drug|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
75383380|NCT00005810|Biological|filgrastim|
75383381|NCT00005810|Drug|carboplatin|
75383382|NCT00005810|Drug|docetaxel|
75383383|NCT00005810|Drug|estramustine phosphate sodium|
75383384|NCT00005816|Biological|therapeutic autologous dendritic cells|
75383385|NCT00005816|Procedure|conventional surgery|
75383386|NCT05303623|Other|Conventional Physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
75383387|NCT05303623|Other|Conventional Physiotherapy+ inspiratory muscle training|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
75868441|NCT03665948|Other|Dietary Intervention - Low-Glycemic Index Diet (CHO-LGI)|The experimental procedure for each randomly assigned participant included a 4-week of CHO-LGI diet.
75868442|NCT03667274|Procedure|cardiac valve surgery|cardiac double valve surgery (aortic and mitral valve)
75868443|NCT03665870|Behavioral|Hypoglycemia Education|Two in-person visits to the home of the participant and 4 phone calls will be conducted to provided education on prevention of hypoglycemia.
75557616|NCT00436319|Procedure|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2<80 pg/ml and progesterone <1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
75868444|NCT03006458|Device|comfilcon A|toric contact lens
75868445|NCT03006458|Device|omafilcon B|toric contact lens
75868446|NCT04056104|Diagnostic Test|SpO2 and PIx Measurement|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
76031349|NCT03073343|Dietary Supplement|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
75868447|NCT03320941|Drug|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally daily.
75868448|NCT03320941|Drug|Placebo|Placebo will be supplied as tablets to be taken daily orally.
75868449|NCT03005288|Drug|BYM338 10 mg/kg|intravenous infusion every four weeks
75868450|NCT03005288|Other|Placebo|intravenous infusion every four weeks
75868451|NCT04055246|Dietary Supplement|Inulin|9 grams of food grade inulin added to custom made fiber bars.
75868452|NCT04055246|Dietary Supplement|Placebo (maltodextrin)|9 grams of food grade maltodextrin - replaces inulin in fiber bars.
75868453|NCT03665792|Device|nociception index qNOX|non-invasive, real time, monitoring for nociception stimulation
75868454|NCT03533816|Drug|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
75868455|NCT03533816|Drug|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
75557617|NCT00481533|Drug|Methyl-Ergonovine-Oxytocin|
75557618|NCT00481533|Drug|Oxytocin|
75868456|NCT03666260|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block with echography
75868457|NCT03666260|Procedure|femoral block|femoral block with echography
75868458|NCT03665714|Other|Impact Oral|Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
75868459|NCT03665714|Other|Enteral Nutrition Emulsion(TPF-T)|TPF-T
75868460|NCT03003494|Drug|Spiolto® Respimat®|observations taken in a period of approximately 6 weeks
75868461|NCT03559699|Drug|AG-348|"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
75557619|NCT00436358|Other|Not applicable: none|Please refer to the detailed description section
75557620|NCT00481572|Drug|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
75557621|NCT00481572|Drug|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
75557622|NCT00481572|Drug|Norepinephrine|titrated norepinephrine over a period of 48 hrs
75557623|NCT00436397|Radiation|radiation therapy|
75557624|NCT00436514|Behavioral|diet and absorption of ColoPEG|4l of PEG during 2 days
75557625|NCT00436514|Procedure|Colonoscopy with colic videocapsule|2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
75868462|NCT04324645|Other|Noona Software|Enrolled patients will be provided with login information for their Noona account. Patients will log in to the Noona symptom monitoring system using their own computer hardware. Any type of personal computer or compatible mobile device will be allowed (i.e. iPhone, Android phone). Patients will be able to access the Noona system from any internet access point and will be provided with the hospital/clinic public WiFi information.
76031350|NCT03075137|Device|External counter pulsation (ECP)|standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
76031351|NCT03074981|Device|Combined TopClosure & Vcare Alpha|"Combined TopClosure & Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
75383388|NCT05303623|Other|inspiratory muscle training|In this group inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
75868463|NCT02449681|Drug|TH-4000 (Tarloxotinib)|
75868464|NCT03085758|Biological|Adrecizumab|Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
75868465|NCT03085758|Biological|Placebo|Single i.v. dose of placebo (control group)
75383389|NCT00385892|Device|Abdominal binder|
75383390|NCT00385970|Drug|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
75383391|NCT00385970|Drug|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
75383392|NCT00385970|Drug|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
75383393|NCT05006677|Drug|non-vitamin K antagonist oral anticoagulants (NOACs)|Collecting information of patients with VT who received NOACs
75383394|NCT05006677|Drug|vitamin K antagonists (VKAs)|Collecting information of patients with VT who received VKAs
75383395|NCT05006677|Drug|antiplatelet agents|Collecting information of patients with VT who received antiplatelet agents
75383396|NCT05006677|Other|non-antithrombotic therapy|Collecting information of patients with VT without any antithrombotic therapy
75383397|NCT00386048|Behavioral|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
75383398|NCT00386126|Drug|Iron Sucrose IV 200mg, once a week, for 5 weeks|
75383399|NCT00386126|Drug|Ferrous sulfate 200mg PO TID, for 8 weeks|
75557626|NCT00436514|Procedure|Standard colonoscopy|1l of PEG the morning just before colonoscopy
75868466|NCT02573233|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
75868467|NCT02573233|Drug|Dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
75868468|NCT02573233|Drug|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
75868469|NCT02573233|Drug|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
75557627|NCT00481650|Drug|Leios/Alesse|
75868470|NCT02573233|Drug|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
75868471|NCT03867487|Drug|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
75868472|NCT03867487|Drug|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
75868473|NCT01381224|Other|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
75383400|NCT04421443|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups every three months until two years after post-treatment, all of them will be conducted online.
75704982|NCT03883165|Other|high-intensity neck strengthening|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a higher number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions,as well as dumbbell shoulder shrugs."
75868474|NCT04127539|Behavioral|Strong & Steady exercise program|The community-based group exercise program S&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
75868475|NCT01381146|Behavioral|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
75868476|NCT01381146|Behavioral|TAU|have access to other jail programs and services
75868477|NCT01569048|Drug|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
75383401|NCT04405297|Device|Adipose-derived regenerative cells|Adipose-derived regenerative cells will be obtained from a small-volume lipoaspirate procedure. The lipoaspirate will then be enzymatically digested to produce a stromal vascular fraction (SVF) that will be injected into the targeted joint.
75383402|NCT04399993|Other|Intervention Protocol in Diaphragm|"The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements."
75868478|NCT01569048|Drug|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
76031352|NCT03340051|Behavioral|Episodic Future Thinking (EFT)|EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
75383403|NCT04399993|Other|Sham technique|In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
75557628|NCT00436592|Device|NeuroFlo™ Catheter|45 minute Treatment
75557629|NCT00473967|Biological|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
75557630|NCT04701554|Other|Qigong program|The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.
75557631|NCT04701554|Other|Information on healthy lifestyles, physical exercise and dietary recommendations.|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
75868479|NCT03941574|Drug|HLX10|HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
75868480|NCT01384344|Other|observational|Observation during a physical exercise
76031353|NCT03340051|Behavioral|Episodic Recent Thinking (ERT)|ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
76031354|NCT03073265|Device|STA-Apixaban Calibrator & Control|Measurement of apixaban level will be done using anti-Xa assay (IVD).
75868481|NCT03935880|Device|Cartiva Implant|Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.
75868482|NCT03935880|Procedure|Cheilectomy|Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a sagittal saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
75868483|NCT05304234|Diagnostic Test|Ultrasound or abbreviated MRI|Abdominal ultrasound or abbreviated MRI
75868484|NCT04008420|Other|monitoring of the oxygen reserve index|The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
75541567|NCT00415974|Behavioral|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
75541568|NCT04562584|Device|MyHomeDoc|MyHomeDoc device SpO2 measurements and parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
75557632|NCT00474006|Drug|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
76031355|NCT03145129|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
75557633|NCT04697745|Drug|Intrathecal dexamethasone|intrathecal adjuvants to bupivacaine
75557634|NCT04697745|Drug|Intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
75557635|NCT00436631|Behavioral|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
75557636|NCT00481689|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
75557637|NCT00436709|Biological|bevacizumab|
75868485|NCT01380912|Drug|methylprednisoloneacetate|Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
75868486|NCT03315793|Drug|Duloxetine Hydrochloride|Administered orally
75868487|NCT03315793|Drug|Placebo|Administered orally
75868488|NCT01569204|Drug|Etoposide|
75868489|NCT01569204|Drug|Cyclophosphamide|
75868490|NCT01569204|Drug|Doxorubicin|
75868491|NCT01569204|Drug|Prednisone|
75868492|NCT01569204|Drug|Procarbazine|
75868493|NCT01569204|Drug|Dexamethasone|
75383404|NCT05293093|Other|Wheelchair Skills Training Program|a standardized training method for users of manual and powered wheelchairs and it combines evidence on motor-skills learning with evidence on how to perform specific wheelchair skills. A recent systematic review and meta-analysis provided evidence that WSTP is a safe and effective intervention that has a clinically meaningful effect on powered wheelchair skill capacity, in particular for new wheelchair users. The WSTP has shown to be effective in several wheelchair-dependent populations and promising to be used in people with complex movement disorders. Yet, adaptation to the specific needs and capabilities of individuals with complex movement disorders is necessary as it has not been assessed in this population. During the 4-week training phase, the participants will receive 3 training sessions per week of 45 minutes, including exercises as described in the Wheelchair Skill Training Program Version 5.1.2
75383405|NCT04568330|Other|best support care|Best support care
75383406|NCT04568330|Other|moisture cream|BSC plus moisture cream
75383407|NCT04568330|Other|10% urea-based cream|BSC plus 10% urea-based cream.
75383408|NCT04569890|Drug|Certolizumab Pegol 200 MG/ML [Cimzia]|CZP 200mg twice a week subcutaneous.
75383409|NCT04569890|Drug|Hydroxychloroquine|400mg HCQ orally daily
75383410|NCT04569890|Drug|Prednisone|10mg GC orally daily
75383411|NCT04569500|Other|PETAL program|patients and their close relations will benefit from the therapeutic education program PETAL in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.
75541569|NCT04562350|Other|XatJove Anoia Aplication|All students (age 12-16 years) from middle school and high school in the sanitary region of Anoia, province of Barcelona, will access a Platform ( ABH Health), where the users will enter specific registration data ( age, sex..etc), after every visit the users will be provided with a 6 multiple choice questionary and asked to punctuate in a scale from 1 to 10, the satisfaction of the service provided. Appart from this data, researchers will use a software to register specific Health-related words and classify them as Health-problems. While Osona students will attend face-to-face consultations as usual, apart from this data,Registrations will be reviewed later and specific search techniques and strategies will be coded. A qualitative review will be performed too.
75541570|NCT04562311|Drug|Chidamide with tislelizumab|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
75541571|NCT00234650|Procedure|Colonoscopy|
75868494|NCT01569204|Drug|Dacarbazine|
75868495|NCT01569204|Drug|Brentuximab Vedotin|
75868496|NCT02676466|Dietary Supplement|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
75868497|NCT02676466|Drug|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
75868498|NCT02676466|Other|Corn Oil (Fish oil Placebo)|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
75868499|NCT02676466|Other|Cellulose Based (Losartan Placebo)|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
75868500|NCT03350269|Other|Information provision|Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
75868501|NCT01383252|Procedure|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
76031356|NCT04438915|Behavioral|Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery|The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
76031357|NCT04997837|Drug|PD-1 inhibitor|Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
75383412|NCT04485637|Other|Communication with basic table|Communication showing only the normal range of blood pressure readings, which is often used but may make it hard to interpret numbers outside of the normal range
75383413|NCT04485637|Other|Communication with enhanced table|Communication with enhanced table, with reference information showing how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
75383414|NCT04485637|Other|Communication with enhanced graph|Communication with enhanced graph, showing reference information about how to interpret blood pressure readings (adapted from Blood Pressure UK) with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
75383415|NCT04569812|Procedure|Cardiopulmonary Resuscitation|flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
75383416|NCT00423163|Drug|micafungin|
75383417|NCT00423163|Drug|voriconazole|
75383418|NCT04569656|Drug|hydrolyzed guar gum|treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
75383419|NCT04569578|Other|Policy|"The intervention will include:~i. Formalized physical activity policies implemented in preschools including the following:~A minimum of 3 hours of total daily outdoor time scheduled both in the morning and in the afternoon~At least 10 minutes teacher-led active play per day~A minimum of 1 weekly outdoor excursion~Meet the children outdoors when they arrive at preschool and/or picked up by their parents~Only use screen tablets and computers for educational teaching purposes~Communicating to, and encouraging, the parents to actively transport their children to and from preschools~ii. A study website with an activity bank also serving as a platform for inter-professional education that preschool teachers can share and communicate about engaging activities and experience~iii. Weekly follow-up and feedback by web-based questionnaires"
75383420|NCT04569188|Biological|Convalescent plasma|COVID-19 elderly patients treated with convalescent plasma
75704983|NCT03883165|Other|Control group|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting only the chest, shoulders, back, upper and lower extremities, and core, without resistance exercises specifically targeting the neck."
75383421|NCT04568876|Dietary Supplement|Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
76031358|NCT04997837|Drug|Oxaliplatin|"CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off."
75383422|NCT04568876|Combination Product|Standard Therapy|Standard therapy established for individual patients
75541572|NCT02211547|Device|Epic 10 Diode Laser by Biolase Inc.|
76031359|NCT04997837|Drug|Capecitabine|CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
75383423|NCT04375657|Combination Product|TRIIM Treatment|Personalized combination of somatropin, metformin, and DHEA
75383424|NCT04375657|Combination Product|Active Control|Metformin and DHEA
75868502|NCT01383252|Procedure|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
76031360|NCT04997837|Drug|Tegafur-gimeracil-oteracil potassium|SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
75868504|NCT01380756|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
76031361|NCT04997837|Drug|5-FU|FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
75383425|NCT02210468|Device|APIC-CF, 4 cc|
75383426|NCT02210468|Device|APIC-CF, 2 cc|
76031362|NCT04997837|Radiation|Radiotherapy|1.8 Gy/Fx, 45-50.4 Gy
75383427|NCT02210468|Other|Placebo Comparator: Saline|Placebo Comparator: Saline
75383428|NCT04265287|Other|Data collection|Demographic, clinical, microbiological, critical care support and management data will be collected.
75383429|NCT02210546|Other|Magnetic Resonance Imaging (MRI)|
75383430|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|
75383431|NCT02210624|Biological|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
75383432|NCT04569110|Other|Not applicable. Observational study. Retrospective analysis of samples.|Not applicable. Observational study. Retrospective analysis of samples.
75541573|NCT02211547|Other|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
75541574|NCT04562272|Procedure|LV mechanical unloading by Impella-CP|The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
75541575|NCT04561843|Diagnostic Test|pelvic floor ultrasound|2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons
75541576|NCT00234689|Drug|Naltrexone|
75704984|NCT03870815|Procedure|CABG|Patients who undergoing CABG
75704985|NCT03870815|Procedure|PCI|Patients who undergoing PCI with DES
75868505|NCT01380756|Drug|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
76031363|NCT04997837|Drug|Chemotherapy|Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
76031364|NCT04299295|Device|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
76031365|NCT04299295|Device|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
76031366|NCT04997603|Other|Accelerometer|Fitbit brand
76031367|NCT02328157|Device|Vitrectomy with cataract surgery and toric IOL|
76031368|NCT02328157|Device|Vitrectomy with cataract surgery and common IOL|
76031369|NCT02328313|Behavioral|Walk with Ease Program|The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
76031370|NCT04202263|Drug|Minocycline Topical|Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
75704986|NCT03853473|Procedure|Remote Ischemic Preconditioning|Remote Ischemic Preconditioning (RIPC) occurs when a limb is made transiently ischemic (5 minutes) using a simple blood pressure cuff. We are proposing that study participants in the RIPC group perform the intervention daily at home for at least 14 days prior to scheduled surgery. They will inflate a blood pressure cuff on the upper portion of their nondominant arm, inflate it to 225 mmHg for 5 minutes, release the cuff for 5 minutes, and repeat this 5 times (for a total of 45 minutes). A study coordinator will monitor compliance with phone calls and daily log sheets that must be filled out.
75704987|NCT03845244|Device|Flow reduction first|-10L/min q 1hr
75704988|NCT03845244|Device|FiO2 reduction first|- 0.1 q 1hr
76031371|NCT04202263|Drug|Placebos|Placement of minocycline cream 0%
75383433|NCT04567472|Behavioral|Helping Ease Anxiety and Depression following Stroke|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
75383434|NCT04330573|Other|No intervention. Observational study|Observational study
75383435|NCT04567316|Drug|[14C]-radiolabelled BI 1358894|Part 1
75383436|NCT04567316|Drug|BI 1358894|Part 2
75383437|NCT04569422|Drug|Benoxyl|reduce pain
75704989|NCT03845244|Device|Simultaneous (flow and FiO2) reduction|-10L/min and -0.1 q 1hr
75704990|NCT03844568|Device|nocturnal nasal continuous positive airway pressure|applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
75704991|NCT03841760|Diagnostic Test|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
75704992|NCT03833102|Other|biological analysis|ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
76031372|NCT04996979|Drug|Ropivacaine 0.5% Injectable Solution|Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
76031373|NCT04996979|Drug|Placebo|Standard care
75383438|NCT04568720|Diagnostic Test|blood sample|Isolated the blood sample and detected the CTC
75383439|NCT02210702|Drug|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
75383440|NCT02210702|Drug|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
75704993|NCT03832322|Procedure|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
75383441|NCT04568096|Combination Product|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|After randomization and standard treatment The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
75383442|NCT04568096|Other|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
75704994|NCT03832322|Procedure|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
75704995|NCT03828968|Diagnostic Test|bladder scan|Measurement of vesical volume by bladder scan
75704996|NCT03802656|Device|Anterior Vertebral Body Tethering|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
75868506|NCT04439890|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
75868507|NCT04439890|Drug|Carboplatin injection|Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
76031374|NCT03145285|Drug|Abiraterone Acetate|"Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
76031375|NCT04997291|Drug|Dexrazoxane|Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
76031376|NCT02328079|Drug|Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)|Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
76031377|NCT04190641|Device|Ambu aScope 4 Cysto and aView Urologia|Visualization of the urethra and the bladder
75704997|NCT03797482|Procedure|Intra-operative Tumor Tissue Biopsy|The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.
75383443|NCT04568018|Drug|Surfactant|Inhalation of surfactant emulsion at 150 mg
75704998|NCT03781973|Behavioral|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
75704999|NCT03773003|Dietary Supplement|Probiotics|"The administered probiotics are readily available on the market and contain~Bifidobacterium breve, B. infantis, B. lactis, B. longum~Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~Streptococcus thermophilus"
75705000|NCT03773003|Dietary Supplement|Placebo|Identically looking to verum, containing corn starch.
75705001|NCT03766438|Behavioral|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
75705002|NCT03755154|Drug|S65487- initial scheme|S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
75868508|NCT04439890|Drug|Pemetrexed disodium f Injection|Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
75868509|NCT04439890|Drug|Placebo|Placebo
75868510|NCT03695497|Procedure|Direct anterior approach|total hip arthroplasty with DAA
75868511|NCT03695497|Procedure|Direct Lateral Approach|total hip arthroplasty with DLA
76031378|NCT04992455|Other|Older Patients Receiving Chemotherapy|No Intervention
76031379|NCT03074903|Device|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
75383444|NCT04334317|Drug|TAK-071|TAK-071 tablet.
75383445|NCT04334317|Drug|Placebo|TAK-071 placebo-matching tablet.
75383446|NCT02210390|Behavioral|Psycho education|Psycho-education Sessions will be offered weekly basis
75541577|NCT04561960|Drug|Fluoride toothpaste|Fluoridated paste containing 1450ppm NaF
75705003|NCT03755154|Drug|S65487 - alternative scheme|S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
75868512|NCT02324725|Drug|Naltrexone|Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
75868513|NCT03633695|Device|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye for use over the lifetime of the patient. The IC-8 IOL implanted in the second eye for use over the lifetime of the patient.
75705004|NCT03720119|Drug|Lidocaine Hydrochloride|As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.
75868514|NCT03633695|Device|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted for lifetime use of the patient.
75868515|NCT01380678|Drug|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
75868516|NCT01380678|Drug|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
75383447|NCT02278094|Device|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
75383448|NCT02278094|Device|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
75868517|NCT02213809|Behavioral|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
75868518|NCT02213809|Behavioral|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
75868519|NCT03314233|Procedure|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
75383449|NCT02278094|Procedure|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
75383450|NCT02278094|Device|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
75868520|NCT02675998|Drug|Tenapanor|
75383451|NCT04985071|Procedure|Pancreaticoduodenectomy|Patient with periampullary cancer will be underwent pancreaticoduodenectomy in 2 types of pancreatic-jejunal anastomosis reconstructions. We describe the postoperative complications (pancreatic fistula and bleeding) and analysis the risk factors relate to those complications
75383452|NCT02278172|Dietary Supplement|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
75383453|NCT02278172|Dietary Supplement|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
75868521|NCT02675998|Drug|Placebo|
75868522|NCT01384188|Drug|ONO-5334|150 mg for 5 days administered in the morning or in the evening
75383454|NCT04983667|Dietary Supplement|Zn-AA|Oral supplementation of either 30 mg daily or Zinc-AA complex or placebo, from the study recruitment during first trimester of pregnancy, all through pregnancy and up to the sixth month after giving birth.
75383455|NCT04971031|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
75868523|NCT01384188|Drug|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
75868524|NCT04588519|Device|Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System|Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
76023109|NCT03171181|Other|Vestibular reeducation|Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
75383456|NCT04971031|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
75383457|NCT04566614|Other|ctDNA blood sampling|Screening/baseline blood sample to be analysed for ctDNA
75383458|NCT04970641|Behavioral|Three Good Things (3GT) Positive Psychology journaling activity|Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
75383459|NCT04566224|Device|Macintosh size 2 blade|intubate with Macintosh size 2 blade
75383460|NCT04566224|Device|Macintosh size 3 blade|intubate with Macintosh size 3 blade
75383461|NCT04566458|Other|No intervention|retrospective chart review study
75383462|NCT02210858|Other|Laboratory Biomarker Analysis|Correlative studies
75383463|NCT02210858|Drug|Tipifarnib|Given PO
75383464|NCT04564586|Behavioral|DPPFit|Participants issued Fitbit Device and set up Fitbit App. They are then enrolled in the automated text messaging platform. Day 1 of the intervention begins the Monday after consent. All consented participants receive the full intervention.
75541578|NCT04561960|Drug|Toothpaste Product|Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
75541579|NCT04561960|Device|Toothbrush|Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
75868525|NCT05666063|Diagnostic Test|Ambulatory Urodynamic Study|Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
75868526|NCT01380600|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10^6 pfu/kg, 1x10^7 pfu/kg, 3x10^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
75868527|NCT03264118|Procedure|Scaling and root planing|Furcation treatment by scaling and root planing
75541580|NCT04561960|Device|Miswak Stick|A miswak stick of 15 cm length
75557638|NCT00436709|Biological|pegfilgrastim|
75557639|NCT00436709|Drug|cyclophosphamide|
75557640|NCT00436709|Drug|doxorubicin hydrochloride|
75868528|NCT03264118|Drug|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
75383465|NCT04566146|Other|scapular muscle training, serratus anterior strength, scapular stabilization exercises|patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
75383466|NCT04563104|Diagnostic Test|Lung Ultrasound|We will evaluate the role of lung ultrasound on the duration of antibiotics, we hypothesize that ultrasound imaging may have a role, will be correlated with, procalcitonin (PCT). The created database will help in establishing conclusion and recommendations that will help to improve the antibiotics duration and decrease the resistance.
75868529|NCT03539406|Biological|UCB-NK cells|Intraperitoneal allogeneic UCB-NK cells infusion
75705005|NCT03713528|Drug|Intraoperative Intraosseous Vancomycin|After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees.
75383467|NCT04565912|Drug|Sage extract mouthwash|Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
75557641|NCT00436709|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
75705006|NCT03709511|Other|Cardiac rehabilitation|perioperative rehabilitation consists of education, inspiratory muscle training, active cycle of breathing techniques, and early mobilization.
75383468|NCT04565912|Drug|Chlorohexidine based mouthwash|Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
75383469|NCT04281199|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
75383470|NCT04281199|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75868530|NCT03539406|Drug|Chemotherapy|Cyclofosfamide/fludarabine treatment
75868531|NCT03064048|Dietary Supplement|Neo-ASA|Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
75868532|NCT03064048|Dietary Supplement|Placebo|Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
75383471|NCT04281199|Radiation|Tomotherapy|Undergo IMRT with tomotherapy
75383472|NCT04281199|Radiation|Total-Body Irradiation|Undergo TBI
75868533|NCT05231434|Other|water|hydration with mineral water in 10 equal portions, administered at regular intervals from the 15th minute of exercise until the end of the recovery period.
75868534|NCT05231434|Other|aerobic activity|aerobic activity
75868535|NCT03113812|Drug|ABvac40|
75868536|NCT03113812|Drug|Placebo|
76023110|NCT04567745|Diagnostic Test|Retinal fundus photography|Fundus photographs
75383473|NCT04281199|Radiation|Volume Modulated Arc Therapy|Undergo IMRT with VMAT
75383474|NCT04565678|Drug|Mitapivat tablets|Oral tablets
75383475|NCT04565678|Drug|Mitapivat coated granules|Oral coated granules
75383476|NCT04279483|Behavioral|7-11|Assigned to make a small (~$3.00) purchase from any 7-11 store(s) using a study-provided debit card during each retail environment visit
75383477|NCT04279483|Behavioral|CVS|Assigned to make a small (~$3.00) purchase from any CVS store(s) using a study-provided debit card during each retail environment visit.
75557642|NCT00436709|Other|flow cytometry|
75557643|NCT00436709|Other|immunoenzyme technique|
75557644|NCT00436709|Other|immunologic technique|
75557645|NCT00436709|Other|laboratory biomarker analysis|
75557646|NCT00436709|Procedure|adjuvant therapy|
75557647|NCT00436709|Procedure|immunoscintigraphy|
75557648|NCT00474084|Device|Intravascular Coronary Stent|
75557649|NCT00436787|Drug|Fondaparinux Sodium|
75557650|NCT00481728|Drug|Tolterodine|Single dose per patient as determined by protocol.
75557651|NCT00481728|Procedure|Filling cystometry|This is a procedure.
75557652|NCT00481728|Procedure|Intravesical neurostimulation|This is a procedure.
75557653|NCT00436865|Behavioral|Weight loss|
75557654|NCT00436943|Drug|nicotine replacement therapy and bupropion|3-6 months
75557655|NCT00436943|Behavioral|smoking cessation counseling and referrals|Organizational counseling and referrals
75383478|NCT02210936|Other|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
75383479|NCT04564352|Dietary Supplement|Adansonia digitata|Juice of AD fruit
75557656|NCT00437060|Procedure|Cognitive Assessment|Ancillary studies
75383480|NCT04564430|Drug|Catapresan|The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
75557657|NCT00437060|Procedure|Diffusion Tensor Imaging|Correlative studies
75383481|NCT04564430|Other|Saline|controlgroup receiving saline
75383482|NCT04564118|Drug|Retrospective analysis of assigned treatment|analysis of treatment assigned by physicians within routine clinical practice
75383483|NCT04274101|Other|Clinical Manifestations|Clinical manifestations in patients treated with Nifurtimox and Benznidazole
75383484|NCT04274101|Diagnostic Test|Serologic response|Serologic response in patients treated with Nifurtimox and Benznidazole
75383485|NCT04274101|Diagnostic Test|Direct method|Direct method tests in patients treated with Nifurtimox and Benznidazole
75383486|NCT04274101|Behavioral|Adverse events|Adverse events in patients treated with Nifurtimox and Benznidazole
75383487|NCT04564040|Drug|Acalabrutinib Treatment A|Participants will receive 100 mg AT suspension in water via NG tube.
75383488|NCT04564040|Drug|Acalabrutinib Treatment B|Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.
75383489|NCT04564040|Drug|Acalabrutinib Treatment C|Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.
75383490|NCT04564040|Drug|Acalabrutinib Treatment D|Participants will receive 100 mg AT orally.
75383491|NCT00005804|Drug|cyclophosphamide|
75383492|NCT00005804|Procedure|allogeneic bone marrow transplantation|
75383493|NCT00005804|Radiation|radiation therapy|
75557658|NCT00437060|Other|Laboratory Biomarker Analysis|Correlative studies
75557659|NCT00437060|Other|Pharmacological Study|Correlative studies
75541581|NCT04561804|Procedure|laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)|"The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.~The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes"
75541582|NCT00234728|Device|Occlusive dressing|
75541583|NCT04561921|Drug|Magnesium sulfate|patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
75383494|NCT04563962|Behavioral|Contingency Management-ART|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.
75383495|NCT04563962|Behavioral|Contingency Management-Methamphetamine|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
75383496|NCT04563650|Biological|blood sample|Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
75383497|NCT02211092|Behavioral|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
75383498|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
75383499|NCT04565444|Dietary Supplement|Ketone|"Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~Isocaloric carbohydrate control: dextrose + vanilla flavouring"
75541584|NCT04561921|Drug|Mepivacaine-Levonordefrin Hydrochloride|patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
75541585|NCT04561882|Device|Transcatheter exclusion of atrial septal aneurysm|"Through transseptal perforation, transcatheter reconstruction of atrial septum was achieved with PFO occluder to cover the whole ASA.~Device: Cardi-O-Fix™ patent foramen ovale occluder (Starway Medical Technology, Inc. Beijing, CN)"
75541586|NCT04561999|Device|Elastography|Performance of Ultrasound, Elastography
75541587|NCT04561687|Drug|Montelukast|Montelukast and nasal budesonide
75541588|NCT04561687|Drug|Azelastine|Azelastine and nasal budesonide
75541589|NCT04561687|Drug|Budesonide|To all groups
75383500|NCT04565444|Dietary Supplement|Ketone + Protein|"Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~10g Whey Protein~L-[ring-2H5]-phenylalanine tracer (enriched to 4%)"
75383501|NCT04565444|Dietary Supplement|Protein|"Isocaloric carbohydrate control: dextrose + stevia~10g Whey Protein~L-[ring-2H5]-phenylalanine tracer (enriched to 4%)"
75383502|NCT04563728|Behavioral|Surveillance camera(s)|the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
75383503|NCT02211248|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
75383504|NCT02211248|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
75383505|NCT04565132|Device|High Definition transcranial Direct Current Stimulation|1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)
75383506|NCT04564664|Drug|Oxygen|High-flow nasal cannula oxygen therapy vs. standard oxygen therapy
75383507|NCT02211482|Drug|dolutegravir, lamivudine|single arm
75383508|NCT04562636|Other|Environmental message|Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.
75383509|NCT04562636|Other|Health message|Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.
75383510|NCT04562636|Other|Neutral Message|Participants will be randomized to view a set of four messages about checking their credit score.
75383511|NCT04562168|Diagnostic Test|Autoderm® dermatology search engine (ML model) testing|GP using a smartphone camera will take an image of the skin problem and will use the Autoderm ML interface to upload the anonymized image. The obtained predicted diagnosis will be recorded in case report form.
75383512|NCT04929847|Other|Self-prepared emollient|The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.
75383513|NCT04561934|Drug|Silver diamine fluoride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
75383514|NCT04561934|Other|resin modified glassionomer cement|resin modified glassionomer cement
75383515|NCT04562402|Procedure|Phacoemulsification|cataract surgery via phacoemulsification
75868537|NCT04605874|Other|Package Quantity (cigarillos)|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack.
75383516|NCT04562402|Procedure|Endoscopic cyclophotocoagulation|Endoscopic ablation of the ciliary body
75383517|NCT04330495|Drug|Hidroxicloroquina|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
75383518|NCT04330495|Drug|Control group|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
75383519|NCT04563260|Drug|Normal saline injection|Normal saline 2 mL, intravenous injection
75383520|NCT04563260|Drug|Palonosetron Injection [Aloxi]|Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
75383521|NCT02211170|Drug|BIBR 796 BS, low dose|
75383522|NCT02211170|Drug|BIBR 796 BS, high dose|
75705007|NCT03708562|Device|everlinQ endoAVF System|The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
75705008|NCT03705845|Drug|placebo softgel|Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
75705009|NCT03705845|Drug|DeltaGold® Tocotrienol 70%|DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
75868538|NCT02674204|Drug|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
75868539|NCT02674204|Drug|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
75868540|NCT05675644|Drug|Drospirenone-only pill|Single dose based on adaptive dose-finding design
75868541|NCT03113890|Genetic|Phlebotomy - Folate|This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
75383523|NCT02211170|Drug|Placebo|
75383524|NCT02211170|Drug|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
75383525|NCT04180189|Other|Weighted fiber blanket|Using weighted blanket for four weeks
75383526|NCT02211560|Other|Phosphatidylserine|
75383527|NCT02211560|Other|Placebo|
75383528|NCT04173793|Drug|AK102|Administered by subcutaneous injection
75383529|NCT04173793|Drug|Placebo|Administered by subcutaneous injection
75383530|NCT04173793|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
75383531|NCT04173637|Biological|AK101|an anti-IL-12/23p40 monoclonal antibody
75383532|NCT04173637|Biological|Placebo|matching placebo
75383533|NCT04561856|Drug|Dexamethasone|Intravenous 4mg
75383534|NCT04561856|Drug|Dexamethasone|Perineural 4mg
75383535|NCT04561856|Drug|Placebo|Normal Saline 2ml
75383536|NCT02211716|Device|BeGraft Peripheral Stent Graft System|
75383537|NCT04912687|Diagnostic Test|EGFR gene mutation analysis on liquid biopsy|Blood samples will be collected at inclusion for plasma DNA collection and analysis.
75383538|NCT00382681|Device|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
75383539|NCT00382681|Device|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
75383540|NCT04173403|Drug|450mg AK102|AK102 Q4W
75383541|NCT04173403|Drug|300mg AK102|AK102 Q4W
75383542|NCT04173403|Drug|150mg AK102|AK102 Q2W
76031380|NCT04992377|Drug|R-EPOCH in Combination With Ibrutinib|"Induction:~(21-day per cycle) Ibrutinib:420mg given orally , once daily.~Details of R-DA-EPOCH are as follows:~Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.~Consolidation:~2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment~Maintenance:~Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity"
75383543|NCT04173403|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
75383544|NCT03541369|Drug|AMG 427|AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
76031381|NCT02747329|Device|BuMA Supreme™ stent|
75383545|NCT03539887|Drug|Intranasal ketamine|Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).
76031382|NCT02747329|Device|Xience V/Prime stent|
75383546|NCT03539887|Drug|Placebo|Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.
75383547|NCT04123717|Drug|Intravenous Ibuprofen|The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
75383548|NCT03472495|Drug|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is <60 kg)
75383549|NCT03472495|Drug|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
75705010|NCT03669718|Biological|ISA101b|Every 3 weeks for a total of 3 times
75705011|NCT03669718|Drug|Cemiplimab|Every 3 weeks for up to 24 months
75705012|NCT03669718|Other|Placebo|Every 3 weeks for a total of 3 times
75705013|NCT03668457|Behavioral|Intervention to Patients|"Multifaceted intervention consisting of:~A collaborative care management intervention, including depression education, medication management and behavioral activation.~Use of a medication reminder mobile app."
75705014|NCT03668457|Behavioral|Intervention to Psychiatrists|Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
75705015|NCT03668457|Other|Control|Other: Usual care Usual care for depressive disorder received in mental health units
76031383|NCT04992533|Procedure|Long-duration tourniquet|Tourniquet is used in arthroscopic exploration and high tibial osteotomy
76031384|NCT04992533|Procedure|Short-duration tourniquet|Tourniquet is only used for arthroscopic exploration
75383550|NCT04094701|Other|Control Group Regimen|Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills. This is the standard of care prescribing procedure for pain management after hip arthroscopy.
75383551|NCT04094701|Other|Opioid reduced regimen|Tylenol extra strength (1000 mg, three times daily for 10 days following surgery), Gabapentin (300 mg at night for 10 days following surgery) and Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
75383552|NCT04092829|Procedure|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
75705016|NCT03668197|Biological|microbiological analysis|microbiological analysis of the peritoneal fluid
75705017|NCT03668184|Other|preeclampsia|occurrence of pre-eclampsia
75868542|NCT03113890|Genetic|Cheek Swab|Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
75383553|NCT03459469|Drug|Tegavivint|This is an Investigational drug
75383554|NCT03428659|Other|Data acquisition of functional abilities in sub-acute stroke|MRI data, motor evoked potentials, gait function and behavior data acquisition
76031385|NCT04997213|Other|Biofeedback exercises|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program was involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and was individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
76031386|NCT04997213|Other|Conventional Exercises|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
76031387|NCT02328001|Behavioral|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
75383555|NCT04067089|Procedure|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
75705018|NCT03649555|Drug|[18F]-FTC-146|Two 5 mCi [18F]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
75383556|NCT04067089|Procedure|Surgical aortic valve replacement|Surgical aortic valve replacement
75383557|NCT03351361|Drug|Nivolumab + Ipilimumab|Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
75383558|NCT03351361|Drug|Chemotherapy|Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
75383559|NCT04056715|Device|Zio XT|ambulatory cardiac monitoring device
75541590|NCT04561687|Drug|Placebo|Placebo and nasal budesonide
75541591|NCT00234767|Device|Pulmonary Artery Catheter|
75541592|NCT00234767|Behavioral|Protocolized Fluid Management|
75541593|NCT04561414|Device|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope.
76031388|NCT04996745|Behavioral|Tablet-based educational intervention|"POSNA's Orthokids website and the article on pediatric forearm fracture will be provided on a tablet. The article provided has two separate tabs, labeled Condition and FAQs, that caregivers will be able to read through. Those who speak Spanish will have the Spanish translated version of Orthokids."
75541594|NCT04561414|Device|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use Ureteral stent (Cook Ireland Ltd.).
75541595|NCT04561726|Other|Connective Tissue Manipulation|Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
75705019|NCT03644966|Dietary Supplement|Bifidobacterium infantis|Probiotics
75705020|NCT03644966|Other|Placebo|Sugar pill manufactured to mimic probiotic tablet
75705021|NCT03644966|Drug|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
75705022|NCT03642990|Drug|Nicotinamide Riboside|Capsule
75705023|NCT03639311|Drug|CAB LA|Administered CAB LA (600 mg) Q2M, as intramuscular injection.
75705024|NCT03639311|Drug|RPV LA|Administered RPV LA (900 mg), Q2M, as intramuscular injection.
75705025|NCT03639311|Drug|RPV|Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
76031389|NCT02578069|Device|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
75541596|NCT04561726|Other|Exercise|The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
75541597|NCT04561531|Other|3%NaCl|Intervention is infusion of 3%NaCl which is defined in arms of experiment.
75705026|NCT03639311|Drug|DTG|Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
75541598|NCT00234806|Other|Health-e-Access|telemedicine intervention
75705027|NCT03633825|Behavioral|Brief help-seeking barrier reduction intervention|The BRI was designed to overcome common concerns and misconceptions (i.e., barriers) related to using crisis services. It works by first asking the user about what potential barriers may keep them from using the crisis service referrals, and then, based on the user's response, by providing information intended to help the user overcome the potential barrier(s) they selected. By exploring the menu of barriers, users could read brief messages designed to dispel common misconceptions or concerns related to each barrier. For example, a common concern among Koko users was that calls to lifelines invariably result in visits by the police or other emergency services. Users who feared this possibility could tap on the associated button and learn that active rescues such as these are extremely rare, and occur in less than one percent of all cases. Whenever possible, we used language throughout the intervention to help validate the experiences of the users.
75705028|NCT03630146|Behavioral|iPeer2Peer program|In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
76031390|NCT02578069|Device|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
76031391|NCT03141775|Other|Treatment of CDI|Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
75541599|NCT04561219|Drug|Nitazoxanide|Nitazoxanide 500mg three times a day for 5 days
76031392|NCT03142087|Other|exercises|exercise
75868543|NCT03113890|Other|Self-report surveys|At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
75868544|NCT02579044|Drug|Everolimus and lonafarnib|
75541600|NCT04561219|Drug|Placebo|Placebo three times a day for 5 days
75541601|NCT04561609|Other|Transcutaneous CO2 application|"Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only)."
75705029|NCT03630146|Other|Waitlist control|The control group will receive standard care but without the iPeer2Peer Program.
75705030|NCT03608410|Other|Weekly Internet based PRO questionnaires|If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
75868545|NCT03160690|Procedure|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy for open angle glaucoma
75541602|NCT04561609|Other|Placebo treatment|Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
75541603|NCT00424866|Drug|FGF-1|"Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"
75541604|NCT00424866|Drug|Placebo|Vehicle: 0 µg/kg
75541605|NCT00234845|Drug|adalimumab|
75541606|NCT00234845|Drug|methotrexate|
75541607|NCT02211625|Drug|Open-label TRV734 125 mg|125 mg
75541608|NCT02211625|Drug|TRV734 blinded|blinded, multiple ascending dose
75705031|NCT03582475|Drug|Carboplatin|Given IV
75705032|NCT03582475|Drug|Cisplatin|Given IV
75705033|NCT03582475|Drug|Docetaxel|Given IV
75705034|NCT03582475|Drug|Etoposide|Given IV
75705035|NCT03582475|Biological|Pembrolizumab|Given IV
75705036|NCT03579784|Drug|Paclitaxel|Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
75705037|NCT03579784|Drug|Olaparib|Olaparib 150mg bid on D1-28 Every 4 weeks
75705038|NCT03579784|Drug|Durvalumab|Durvalumab 1.5 g iv on D1 Every 4 weeks
75705039|NCT03571984|Behavioral|Moving on ABC Plus|The intervention has two components. CBT Moving on After Breast Cancer
75705040|NCT03564171|Combination Product|Prehabilitation|stress counseling, exercise, nutritional counseling, smoking cessation counseling
75705041|NCT03553563|Drug|D961H capsule 10mg|All Groups can select either capsule or sachet during the study.
75868546|NCT04461106|Other|Social Marketing Campaign|aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (<5yrs) and pregnant/lactating women
75868547|NCT05676970|Behavioral|Telehealth: Wellness and Vaccination|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.
75868548|NCT05676970|Behavioral|TeleHealth: Wellness Only|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.
75868549|NCT02941627|Device|Neuro Zti|Cochlear implant
75868550|NCT02941627|Device|Neuro One|Sound processor
75868551|NCT03525379|Drug|Resveratrol|"Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)"
75868552|NCT03525379|Drug|Placebo|Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
76031393|NCT03074825|Drug|Chiauranib|Take 50mg orally once daily
75383560|NCT04863781|Behavioral|Mobile cognitive-behavioral stress management intervention|Each weekly module will consist of a cognitive component and a relaxation component. The cognitive component during the first 3 weeks will educate users about the Transactional Model of Stress, that discrimination is a type of stressor, and the impact of stress on health. Building on this information, users will then learn how to match coping responses to the changeability of stressors during weeks 4 and 5. The cognitive component will conclude by focusing on the four most common coping strategies used by African American women in response to stress. Modules 2 through 4 will teach progressive muscle relaxation through a series of tension and relaxation cycles. Modules 5 through 8 will train users in diaphragmatic breathing. Finally, users will be trained in three types of mindfulness mediations.
76031394|NCT02327767|Device|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
75541609|NCT02211625|Drug|Oxycodone IR 10 mg|
75705042|NCT03553563|Drug|D961H sachet 10mg|All Groups can select either capsule or sachet during the study.
75541610|NCT02211625|Drug|Placebo|TRV734-matched and oxycodone placebo
75541611|NCT02211664|Device|Passeo-18 balloon|
75705043|NCT06063733|Other|Digital pursed lip breathing intervention|"After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks.~After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments.~Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities."
76031395|NCT03074747|Diagnostic Test|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
75705044|NCT06063694|Device|Synthetic electrospun fiber matrix|Electrospun fiber matrices have long been investigated as an innovative construct for use in tissue engineering and regenerative medicine research due to their ability to mimic the structure and scale of native tissue. Clinical studies have demonstrated clinical efficacy in treating both chronic and acute wounds. There is strong evidence to support the application of a synthetic electrospun fiber matrix will generate favorable wound healing and reduce infection rates when used to augment transmetatarsal amputation with primary closure.
76031396|NCT03072485|Drug|Sirolimus|Topical sirolimus applied to the skin
76031397|NCT03072485|Drug|Metformin|Topical metformin applied to the skin
76031398|NCT03072485|Drug|Diclofenac|Topical diclofenac applied to the skin
75705045|NCT06063655|Dietary Supplement|Control: Water|Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
75705046|NCT06063655|Dietary Supplement|Liquid IV hydration multiplier|Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
75868553|NCT03476551|Drug|Hydrochlorothiazide|Patients are tested for their normal prescription hydrochlorothiazide medication
75868554|NCT03521934|Drug|Sotagliflozin|"Pharmaceutical form: tablet~Route of administration: oral"
75868555|NCT03521934|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
75868556|NCT03434353|Drug|Inarigivir Soproxil|Administered orally once daily one hour before or one hour after a meal
75868557|NCT03434353|Drug|TAF|Administered orally once daily with food
75868558|NCT03374137|Biological|obinutuzumab|Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
76031399|NCT05080543|Drug|Albumin 20% and terlipressin|Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
76031400|NCT03144973|Diagnostic Test|periosafe|mouth rinsing quick-test
75541612|NCT02211664|Device|Passeo-18 Lux drug releasing balloon|
75383561|NCT04863781|Behavioral|Control|The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
75383562|NCT03234907|Drug|Vedolizumab IV|Vedolizumab IV infusion
76031401|NCT03074591|Drug|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
75383563|NCT03234907|Drug|Placebo|Vedolizumab placebo-matching
75705047|NCT06063655|Dietary Supplement|Liquid IV sugar-free hydration multiplier|Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
75383564|NCT04000243|Diagnostic Test|Endoscopic diagnosis of Hp|Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature
75868559|NCT03415776|Procedure|Hemodialysis|Renal replacement therapy
76031402|NCT03074591|Drug|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
76031403|NCT03143413|Other|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
75705048|NCT06063616|Other|Reiki|Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher, who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.
76031404|NCT03074669|Behavioral|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
76031405|NCT05080309|Dietary Supplement|carbohydrate oral intake|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
75383565|NCT04844983|Drug|STP705|The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
75383566|NCT04844983|Other|Placebo Saline|Normal Saline
75383567|NCT03155425|Drug|SHR-1210|A humanized monoclonal immunoglobulin
75383568|NCT04330027|Biological|Growth factors|A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
75383569|NCT04330027|Other|Saline|0.9% Sodium Chloride
76023111|NCT03173443|Device|single lumen tube and bronchial blocker|fiberoptic intubation with single lumen tube and bronchial blocker
76031406|NCT05080309|Other|free water only|Women will have free access to water only
75383570|NCT00002893|Drug|fluorouracil|
75383571|NCT00002893|Drug|leucovorin calcium|
75383572|NCT00002893|Drug|raltitrexed|
75383573|NCT03053245|Behavioral|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
75383574|NCT03053245|Behavioral|Attention Control|Patients in this group will receive regular wellness calls from the research team.
75383575|NCT00002899|Procedure|adjuvant therapy|
75705049|NCT06063616|Other|Sham Reiki|Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
75705050|NCT06063603|Procedure|Acupuncture Therapy|Undergo acupuncture therapy
75705051|NCT06063603|Behavioral|Cancer Pain Management|Receive pain clinic referral
75705052|NCT06063603|Behavioral|Cognitive Behavior Therapy|Undergo CBT
75705053|NCT06063603|Procedure|Discussion|Participate in focus group
75705054|NCT06063603|Other|Educational Intervention|Receive self-guided pain management education materials
76023112|NCT03173443|Device|double lumen tube|fiberoptic intubation with double umen tube
76023113|NCT05087147|Device|0.7 mm stainless steel orthodontic wire|0.7 mm stainless steel orthodontic wire
76023114|NCT05087147|Device|Banded space maintainer|band and loop space maintainer
75705055|NCT06063603|Other|Exercise|Participate in exercise
75705056|NCT06063603|Other|Interview|Complete interview
75705057|NCT06063603|Procedure|Massage Therapy|Receive massage
75868560|NCT02914184|Biological|HRV PCV-free liquid vaccine|Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
75868561|NCT02914184|Biological|Rotarix|Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
75868562|NCT01380522|Drug|Metronidazole|Capsules, single-dose, fed
76031407|NCT04991675|Behavioral|pelvic floor muscle exercises|During the first visit, the anatomy of the pelvic floor and the purpose of the program were explained. Exercises were taught in the supine position, as described by Kegel (1948), it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
76031408|NCT04991675|Behavioral|diaphragmatic breathing exercises|During the first visit, the anatomy of the diaphragm and abdominal wall and the purpose of the program were explained. Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
75383576|NCT00002899|Radiation|radiation therapy|
75383577|NCT00002899|Radiation|stereotactic radiosurgery|
75383578|NCT00383227|Biological|Hepatitis B adjuvanted vaccine|
75383579|NCT02775331|Other|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
75383580|NCT02775331|Other|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
75383581|NCT03841981|Diagnostic Test|Anthropometric and physical examination|"Weight and height.~Waist-to-hip ratio.~Body composition: Bioelectrical impedance and [Dual energy X-ray absorptiometry (DEXA)]."
75705058|NCT06063603|Behavioral|Mindfulness Relaxation|Practice mindfulness
75383582|NCT03841981|Diagnostic Test|Indirect calorimetry, accelerometer and seven-day dietary recall|Energy availability assessment.
75383583|NCT03841981|Diagnostic Test|Biochemical, hormonal and metabolic phenotyping|"Lipid profile.~Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~Sex steroid profile.~Hypothalamic-pituitary-adrenal axis study.~Ferrokinetic study.~Subclinical chronic inflammatory markers."
75541613|NCT02211664|Device|Pulsar-18 stent|
75541614|NCT00234923|Drug|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
75541615|NCT00234923|Drug|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
75541616|NCT04551937|Other|Lactose Free 1% Milk|8 oz of study beverage daily
75705059|NCT06063603|Procedure|Pain Therapy|Receive pain treatment/medicine
75705060|NCT06063603|Other|Palliative Therapy|Receive palliative care referral
75705061|NCT06063603|Behavioral|Patient Navigation|Undergo visits with PCM and CHW for pain management
75705062|NCT06063603|Other|Referral|Receive pain management referrals
75705063|NCT06063603|Procedure|Spiritual Therapy|Receive spiritual support
75705064|NCT06063603|Procedure|Spiritual Care Referral|Receive spiritual care referral
75705065|NCT06063603|Other|Survey Administration|Ancillary studies
75868563|NCT01380522|Drug|Flagyl|Capsules, single-dose, fed
75868564|NCT03611712|Drug|Astragalus Polysaccharides 500 mg|PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)
75868565|NCT03633227|Drug|Obeticholic Acid (OCA)|OCA will be administered per dose and schedule specified in the arm description.
75868566|NCT03633227|Drug|Placebo|OCA matching placebo will be administered per the schedule specified in the arm description.
75868567|NCT03665324|Other|Evaluation of the relationship between atrial remodeling evaluated by ECG and ETT with the occurrence of supraventricular arrhythmias|"Subjects will be retrospectively retrieved from the Sport Medicine Service of Rennes University Hospital database.~Medical data will then be collected from the athletes' medical records. The ECG present in the medical file will be reinterpreted to obtain the resting heart rate, the amplitude of the P wave, the morphology of the P wave and the duration of the PR space.~The data from the stress test will be found from reports in the medical records: resting heart rate, maximum heart rate, sustained peak load, arrhythmia during the test.~ETTs will be retrieved from the local server. They will be reinterpreted to collect anatomical and functional cardiac data necessary for the study."
76031409|NCT05080153|Dietary Supplement|Ocufolin forte|start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)
76031410|NCT04991909|Drug|HRS4800|HRS4800
76031411|NCT04991909|Drug|Placebo|Placebo
75383584|NCT03841981|Diagnostic Test|Sonographic studies|"Polycystic ovarian morphology.~Carotid intima-media thickness.~Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness."
75383585|NCT03841981|Diagnostic Test|24-hour Ambulatory blood pressure monitoring|A&D TM2430EX oscillometric devices (A&D Company Limited, Tokyo, Japan).
75705066|NCT06063564|Behavioral|PREVENT|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
75705067|NCT06063564|Behavioral|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool.
75383586|NCT03841981|Procedure|Percutaneous biopsy|Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
75383587|NCT03841981|Diagnostic Test|Cardiovascular autonomic function studies|Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.
75383588|NCT03841981|Diagnostic Test|Oral smear and feces specimen|Microbiome studies.
75705068|NCT06063551|Procedure|Testicular Biopsy|Testicular biopsy for clinical storage and laboratory research.
75705069|NCT06063525|Other|Structural anatomy|images acquired with 3T MRI system with 32 channel head coil
75705070|NCT06063512|Other|sweet orange oil inhalation|sweet orange oil with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes
75705071|NCT06063473|Drug|Trifarotene Cream 0.005%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
75705072|NCT06063473|Drug|Placebo|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
75705073|NCT06063473|Drug|AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
75383589|NCT03818581|Drug|Suvorexant|10-mg or 20-mg Suvorexant capsules
75383590|NCT03818581|Other|Placebo|Matching placebo capsules
75383591|NCT03793855|Behavioral|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
75383592|NCT03793855|Behavioral|Dietary Prescription|Dietary prescription according to guidelines.
75383593|NCT00002905|Drug|cyclophosphamide|
75383594|NCT00002905|Drug|didanosine|
75383595|NCT00002905|Drug|doxorubicin hydrochloride|
75383596|NCT00002905|Drug|etoposide|
75383597|NCT00002905|Drug|mitoxantrone hydrochloride|
75383598|NCT00002905|Drug|prednimustine|
75383599|NCT00002905|Drug|zidovudine|
75383600|NCT00002911|Drug|marimastat|
75383601|NCT00002917|Drug|paclitaxel|
75383602|NCT00383695|Biological|cetuximab|
75383603|NCT00383695|Drug|capecitabine|
75383604|NCT00383695|Drug|oxaliplatin|
75383605|NCT00383695|Procedure|adjuvant therapy|
75383606|NCT00383695|Procedure|conventional surgery|
75383607|NCT00383695|Procedure|neoadjuvant therapy|
75383608|NCT00383695|Radiation|radiation therapy|
75383609|NCT00383773|Procedure|Retinal endo vascular surgery|
75383610|NCT00383851|Drug|ATN-224|
75383611|NCT00383851|Drug|Temozolomide|
75383612|NCT00002923|Drug|KRN5500|
75383613|NCT03779581|Other|Self Correction exercises|Active self-correction exercises to restore movements in different planes as close to physiologically normal as possible.
75383614|NCT03779581|Device|orthotic devices|the orthotic devices designed to correct the scoliosis curve
75383615|NCT03766321|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
75705074|NCT06063447|Other|Examination|Posture Evaluation, Scoliosis Examination, Pelvic Floor Assesments
75383616|NCT03766321|Biological|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
75383617|NCT02636569|Drug|topical diclofenac daily|"Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed."
75383618|NCT02636569|Drug|placebo|"placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
75705075|NCT06063421|Device|Electronic Cigarette (EC)|The intervention consists of the use of an Electronic cigarette device namely the Vaporesso Gen Air 40 Vape Kit. This is a complete kit including the EC device, integrated battery, refillable tank, charging cable, coil replacements and user manual. Three e-liquid flavours will be provided; tobacco, menthol and fruit flavour.
75383619|NCT03736447|Biological|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
75383620|NCT03736447|Biological|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
75705076|NCT06063421|Drug|Nicotine Replacement Therapy|NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
75705077|NCT06063408|Behavioral|Cognitive Functional Therapy|"Cognitive functional therapy (CFT) is a novel intergraded behavioral approach for individualizing the management of spinal pain, targeting the bio-psycho-social factors of rehabilitation, and enabling the patient to self-manage the condition.~CFT lies within the broad spectrum of the biopsychosocial approach for the management of spinal pain. CFT uses a multidimensional clinical reasoning framework with aim to enable the clinician to identify modifiable components of the condition, evaluate patients' behavioral responses to pain, and compose and drive a tailored rehabilitation program mainly based on self-management. The intervention is comprised by the interplay on making sense of pain, exposure with control, and lifestyle change."
75383621|NCT03723655|Drug|mavacamten|mavacamten capsules
75383622|NCT00002935|Drug|porfimer sodium|
75705078|NCT06063408|Behavioral|Conventional Therapy|Each individual session involve a combination of pain management with electrotherapy, massage and relaxation techniques. Also include some posture exercise these will be targeted on body alignment to the neutral position, and strengthening the whole neck area. strengthening program will be include isometrics on all cervical movements with a band which progressively increase the resistance of the band by change it and process to exercise against the band resistant. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
75705079|NCT06063395|Procedure|open surgery on the abdominal aorta by laparotomy|Laparotomy aortic surgery for the management of an abdominal aortic aneurysm has several distinct stages which will not be altered by the performance of this study. The patient arrives in the operating room and is taken care of by the anesthetic team. The patient is then placed in the correct position for optimal surgical management and a skin cleansing procedure is carried out. A sterile drape is applied and the preoperative checklist in force in the establishment is completed. Initial dissection of the aneurysm and its proximal and distal control is left to the discretion of the principal surgeon. Once the aortic aneurysm has been controlled, the main surgeon places self-static retractors and then prepares to clamp the aorta. The surgeon initiates aortic clamping to create the aorto-biliac or bifemoral bypass. Once the bypass has been created, the operation is completed by closing the surgical approach and the skin incision. The bandage is then applied.
75705080|NCT06063369|Drug|Palmitoylethanolamide|"Dose: PEA 1200 mg given in 400 mg capsules (3 capsules per day) or Placebo Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA and placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
75705081|NCT06063291|Drug|ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
75705082|NCT06063291|Drug|Placebo of ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
75705083|NCT06063278|Behavioral|l Group Therapy for BN.|9 to 10 group sessions of 90 to 120min each
75383623|NCT00002941|Drug|carmustine|
75383624|NCT00002941|Drug|cyclophosphamide|
75383625|NCT00002941|Drug|etoposide|
75383626|NCT00002941|Drug|mesna|
75705084|NCT06063265|Behavioral|Integrated Attention Training Program|Integrated Attention Training Program (IATP) specifically aims at training attentional control, which involves the coordination of complex behaviours, such as planning, reasoning, selection and information inhibition.
75383627|NCT00002941|Procedure|peripheral blood stem cell transplantation|
75383628|NCT04329793|Device|Assisted gait training with Walkbot System|The experimental group will receive at least 3 treatment sessions per week consisting of 40 minutes in robot-assisted gait training with Walkbot System in addition to their usual Physical therapy sessions. In total, the number of Walkbot sessions will be 20, in uninterrupted weeks.
75705085|NCT06063252|Behavioral|NISMA|"The intervention NISMA is a nine-month intervention and consisted of four individual sessions and two group sessions. The theoretical frame is Social Cognitive Theory, along with Acceptance and Commitment Therapy (ACT), to support the enhancement of self-efficacy. It involves four individual face-to-face sessions with a nurse and two group sessions (5-7 patients) with a nurse, an occupational therapist (OT), and a physiotherapist (PT), with the nurse being the facilitator. Every session has a specific topic and, in every session, a person-centered approach was used to address current problems and secure relevance.~Participants in the control group receive usual care, and the intervention group receives both usual care supplemented with the intervention."
75705086|NCT06063200|Drug|Methylphenidate Pill|Single encapsulated pill
75705087|NCT06063174|Behavioral|Education Program|12-week online psychoeducation program on environmental pollution exposures, the health impacts and sources of these exposures, and practical ways to reduce these exposures. Participants in the active control group will receive this form of intervention.
75705088|NCT06063174|Behavioral|Think Well Program|12-week online program in which participants learn to identify negative emotion and thinking patterns and participate in live online group coaching. Participants whose thinking style domain is dysregulated will be assigned to this intervention program.
75383629|NCT04329793|Other|Physical Therapy|The control group will receive their usual Physical therapy sessions during 6 weeks.
75705089|NCT06063174|Behavioral|Be Well Program|12-week online program in which participants learn about the importance of social relationships, connectedness, and interpersonal conflicts, and participate in live online group coaching. Participants whose social relationship/conflict domain is dysregulated will be assigned to this intervention program.
75705090|NCT06063174|Behavioral|Eat Well Program|12-week online program in which participants learn about mindful eating and participate in live online group coaching. Participants whose diet domain is dysregulated will be assigned to this intervention program.
75868568|NCT03665246|Behavioral|Integrated Mothers and Babies Course|The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
75868569|NCT03297372|Device|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
75383630|NCT00383305|Device|Cool-Cap|
75383631|NCT04329637|Other|Integrative healt care|Meditation and use of a care cordinator
75383632|NCT00002953|Drug|cyclophosphamide|
75383633|NCT00002953|Drug|epirubicin hydrochloride|
75383634|NCT00002953|Drug|paclitaxel|
75541617|NCT04551937|Other|Lactose Free 1% Milk + 10 g prebiotic|8 oz of study beverage supplemented with 5 grams of fructooligosaccharide and 5 grams of galactooligosaccharide
75541618|NCT00268125|Device|Acupression's bracelet|
75541619|NCT00268125|Behavioral|Hygiene and dietetic advices|
76031412|NCT05079997|Device|MAGNETIC RESONANCE IMAGING|s a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body. MRI scanners use strong magnetic fields, magnetic field gradients, and radio waves to generate images of the organs in the body. MRI does not involve X-rays or the use of ionizing radiation, which distinguishes it from CT and PET scans. MRI is a medical application of nuclear magnetic resonance (NMR) which can also be used for imaging in other NMR applications, such as NMR spectroscopy.
75705091|NCT06063174|Behavioral|Sleep Well Program|12-week online program in which participants learn about the importance of good sleep and participate in live online group coaching. Participants whose sleep domain is dysregulated will be assigned to this intervention program.
75383635|NCT03705637|Drug|Exparel|"Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation."
75705092|NCT06063174|Behavioral|Move Well Program|12-week online program in which participants learn about the importance of adequate physical activity for health and participate in live online group coaching. Participants whose physical activity domain is dysregulated will be assigned to this intervention program.
75868570|NCT05042232|Other|SARS-CoV-2 Positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms
75868571|NCT05042232|Other|SARS-CoV-2 Negative|Participants who have tested negative for SARS-CoV-2
76031413|NCT04082377|Procedure|Recruitment maneuver with tidal volume (RM TV)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905*((height in cm)-152.4) for men, and = 45.5+0.905*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM."
76031414|NCT04082377|Procedure|Recruitment maneuver by PEEP (RM PEEP)|The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
75383636|NCT03693781|Drug|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (>70 kg or <71 kg) for 30 weeks of duration.
76031415|NCT04073875|Diagnostic Test|18F-GP1|18F-GP1 PET-CT scan
75383637|NCT03693781|Drug|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (>70 kg or <71 kg) for 30 weeks of duration.
75383638|NCT03693781|Drug|Placebo Oral Tablet|Corresponding tablets for 30 weeks
75705093|NCT06063148|Device|Enrolled Participant|Participant will undergo at most 10 SpO2 measurements paired with at most 10 routine blood gas samples.
75705094|NCT06063122|Device|smallTalk NICU Active|The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold.
75705095|NCT06063096|Dietary Supplement|D-allulose|Fruit-flavoured drink with d-allulose at 2 dosages
75705096|NCT06063096|Dietary Supplement|Placebo|Fruit-flavoured drink with high fructose corn syrup
75705097|NCT06063070|Drug|Fluzoparib Capsules|oral
75868572|NCT02913326|Drug|Dabigatran etexilate|
75868573|NCT02913326|Drug|Warfarin|
75383639|NCT02283853|Drug|dimethyl fumarate|administered orally
75868574|NCT01384110|Dietary Supplement|Reduction of glycemic index of ingested foods|Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
75383640|NCT02283853|Drug|Interferon β-1a|administered by intramuscular injection
75383641|NCT03670849|Device|LapAR|LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
75383642|NCT02401789|Device|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
75383643|NCT04329247|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
75541620|NCT04552054|Device|Mixed Reality+ 3D printing guided localization|Researchers project a three-dimensional reconstructed image of the patient's chest through MR glasses, then overlay the virtual chest with the actual chest. Finally, researchers put the three-dimensional printing navigational template on the surface of the body to guide for percutaneous lung puncture localization.
75541621|NCT04552054|Device|Computerized Tomography guided localization|CT-guided percutaneous lung puncture staining marker localization.
76031416|NCT03144739|Other|Training in management of children's mental health problems|"General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating."
76031417|NCT03144739|Other|Current collaborative care protocol|General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
76031418|NCT03072407|Biological|PB-119 injection|
75541622|NCT02213887|Drug|Pantoprazole|40 mg PO QAM
76031419|NCT03072407|Biological|PB-119 injection placebo|
75383644|NCT02263417|Device|Deep Brain Stimulation (DBS) of Gpi|
75383645|NCT02263417|Device|Deep Brain Stimulation (DBS) of STN|
75541623|NCT02213887|Drug|Pantoprazole|0 mg PO QAM
75541624|NCT00234962|Drug|Lopinavir/Ritonavir|
75541625|NCT04551859|Other|Dynamic Pelvic Floor MRI|6 months after surgery, a Dynamic Pelvic Floor MRI is performed
75541626|NCT00424905|Drug|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
75541627|NCT04551703|Drug|Adrenaline saline irrigation|The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
75541628|NCT04551976|Behavioral|Mindfulness|Pay attention to the present moment, on purpose, in a nonjudgemental way.
75541629|NCT00235001|Drug|trandolapril/verapamil|180/2 mg QD
75541630|NCT04551781|Drug|20 Mg Prednisone for 14 days|20 Mg Prednisone for 14 days
75541631|NCT04551781|Drug|control|symptomatic ttt
75541632|NCT00424944|Biological|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
75868575|NCT03666182|Other|No Intervention|No Intervention
75541633|NCT00424944|Biological|GMZ2 malaria vaccine|100 micrograms of GMZ2
75541634|NCT00424944|Biological|Verorab vaccine|Anti-rabies vaccine
75541635|NCT04551625|Device|High Resolution Colonic Manometry and 3D-Transit system.|Not performed as an intervention, the study is observational.
75541636|NCT02214004|Drug|Trastuzumab|"- Eight times IV administration of trastuzumab per 3 weeks~Trastuzumab 8mg/kg on Day 1 of Cycle 1~Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
75541637|NCT02214004|Drug|Letrozole|- Daily letrozole 2.5 mg/day for 24 weeks
75868576|NCT01384032|Dietary Supplement|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
75541638|NCT04551274|Behavioral|Music Therapy|Music Therapy interventions involve the use of live music (performed or created by the therapist and/or patient), and a process that includes patient-specific assessment, treatment, and evaluation
75541639|NCT00268164|Drug|lactobacilus acidophilus & bifidobacterium animalis/lactis|
75705098|NCT06063070|Drug|Bevacizumab|Injectable solution
75868577|NCT01384032|Dietary Supplement|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
75705099|NCT06063057|Biological|low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml
75868578|NCT01384032|Dietary Supplement|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
75383646|NCT02116699|Other|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
75383647|NCT02116699|Other|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
75705100|NCT06063057|Biological|medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml
75705101|NCT06063057|Biological|high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml
76031420|NCT03144895|Procedure|Laying a radial or femoral arterial catheter|Laying a radial or femoral arterial catheter
76031421|NCT03144661|Drug|INCB062079|In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
75383648|NCT00002971|Drug|O6-benzylguanine|
75383649|NCT00002977|Biological|filgrastim|
75383650|NCT00002977|Drug|melphalan|
75383651|NCT00002977|Drug|thiotepa|
75383652|NCT00002977|Procedure|peripheral blood stem cell transplantation|
75383653|NCT00003391|Biological|monoclonal antibody muJ591|
75383654|NCT00003397|Biological|filgrastim|
75383655|NCT00003397|Biological|rituximab|
75557660|NCT00437060|Procedure|Psychosocial Assessment and Care|Ancillary studies
75383656|NCT00003397|Biological|sargramostim|
75383657|NCT00003397|Drug|carmustine|
75383658|NCT00003397|Drug|cisplatin|
75383659|NCT00003397|Drug|cyclophosphamide|
75383660|NCT00003397|Drug|dexamethasone|
75383661|NCT00003397|Drug|etoposide|
75383662|NCT00003397|Drug|gemcitabine hydrochloride|
75383663|NCT00003397|Drug|melphalan|
75557661|NCT00474162|Drug|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
75557662|NCT00474162|Drug|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
75557663|NCT00437099|Drug|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
75557664|NCT00437099|Drug|Placebo|Placebo
76031422|NCT04991441|Dietary Supplement|Controlled Dietary Sodium Restriction|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
76031423|NCT04991441|Dietary Supplement|Control Diet & Controlled Dietary Sodium Restriction|Participants will follow a Observational Control Diet (CON) diet (Months 1-5) followed by an Controlled Dietary Sodium Restriction (INT) diet (Months 6-7).
76031424|NCT03111433|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 soft gelatin capsule 100mg
76031425|NCT03111433|Drug|Insulin|multiple dose insulin injection therapy
76031426|NCT04915313|Device|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 200mmHg and 5-min deflation.
76031427|NCT04915313|Device|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
75383664|NCT00003397|Drug|paclitaxel|
76031428|NCT03143023|Drug|arginine toothpaste|acid neutralizer toothpaste
75383665|NCT00003397|Procedure|bone marrow ablation with stem cell support|
76031429|NCT03143023|Drug|fluoride toothpaste|bactericidal toothpaste
76031430|NCT04914455|Diagnostic Test|Echocardiography and transhepatic inferior vena cava assessment using ultrasound.|"For all participant :~Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;"
76031431|NCT05079529|Drug|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
76031432|NCT05079529|Drug|Placebo Group|Takes placebo capsule 3 times daily for 90 days
76031433|NCT03074435|Device|Insecticidal paint|Houses will be painted with insecticidal paint
75383666|NCT00003397|Procedure|peripheral blood stem cell transplantation|
75383667|NCT00384319|Device|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
75383668|NCT00003403|Drug|GPX-100|
75383669|NCT00383383|Biological|Hepatitis B adjuvanted vaccine|
75383670|NCT00383383|Biological|Engerix-B|
75383671|NCT00003409|Drug|motexafin gadolinium|
76031434|NCT03074435|Device|Larvicide|Larval breeding sites will be treated with larvicide
75383672|NCT00003409|Radiation|radiation therapy|
75383673|NCT00003415|Drug|amifostine trihydrate|
76031435|NCT03074435|Biological|Ivermectin|Doses of Ivermectin will be injected to peri-domestic animals
75383674|NCT00003415|Drug|topotecan hydrochloride|
75383675|NCT00002989|Drug|busulfan|
75383676|NCT00002989|Drug|cyclophosphamide|
75383677|NCT00002989|Drug|idarubicin|
75383678|NCT00002989|Drug|melphalan|
75383679|NCT00002989|Radiation|radiation therapy|
75705102|NCT06063057|Biological|Enterovirus type EV71 vaccine (Vero cell), Inactivated|Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)
75705103|NCT06063018|Drug|RC48 + Tislelizumab|RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
75705104|NCT06062992|Diagnostic Test|Contrast Enhanced Stereotactic Biopsy|Stereotactic breast biopsy using CEM as targeting modality
75705105|NCT06062953|Drug|Melatonin|3-9 mg flexible dosing before bed time
75705106|NCT06062953|Drug|Quetiapine|50-150 mg flexible dosing before bed time
76031436|NCT03074435|Behavioral|IEC|A reinforced information, education and communication strategy will be implemented.
75705107|NCT06062953|Drug|Placebo|1-3 capsules flexible dosing before bed time
75705108|NCT06062940|Behavioral|SHARE Approach|The SHARE Approach training was given at each of these centers, teaching skills to clinicians about shared decision making.
75705109|NCT06062901|Other|Educational Intervention|Receive educational intervention
76031437|NCT03142945|Other|Traditional Physical Therapy|Physical therapy-based interventions
76031438|NCT03142945|Other|MDT based physical therapy|MDT based physical therapy
76031439|NCT04996277|Procedure|angiography|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
75383680|NCT00002995|Biological|dactinomycin|
75383681|NCT00002995|Biological|filgrastim|
75383682|NCT00002995|Biological|sargramostim|
75383683|NCT00002995|Drug|cyclophosphamide|
75383684|NCT00002995|Drug|vincristine sulfate|
75383685|NCT00002995|Radiation|radiation therapy|
75383686|NCT00003001|Drug|fluorouracil|
75383687|NCT00003001|Drug|gemcitabine hydrochloride|
75383688|NCT00003001|Drug|leucovorin calcium|
75383689|NCT00003421|Biological|bleomycin sulfate|
75383690|NCT00003421|Drug|ABVD regimen|
75383691|NCT00003421|Drug|chlorambucil|
75383692|NCT00003421|Drug|dacarbazine|
75383693|NCT00003421|Drug|doxorubicin hydrochloride|
75705110|NCT06062901|Other|Interview|Participate in one-on-one interview
75383694|NCT00003421|Drug|etoposide|
75383695|NCT00003421|Drug|prednisolone|
75383696|NCT00003421|Drug|procarbazine hydrochloride|
75383697|NCT00003421|Drug|vinblastine sulfate|
75383698|NCT00003421|Drug|vincristine sulfate|
75383699|NCT00003421|Radiation|radiation therapy|
75383700|NCT01588015|Biological|tetanus-CMV fusion peptide vaccine|Given SC
75383701|NCT01588015|Other|laboratory biomarker analysis|Correlative studies
75383702|NCT00003427|Drug|irinotecan hydrochloride|
75383703|NCT00003427|Drug|oxaliplatin|
75383704|NCT00002947|Radiation|indium In 111 pentetreotide|
75383705|NCT00003433|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
75383706|NCT00003439|Biological|recombinant interleukin-12|
75383707|NCT00003007|Biological|recombinant interferon alfa|
75383708|NCT00003007|Biological|sargramostim|
75705111|NCT06062901|Other|Survey Administration|Ancillary studies
75705112|NCT06062875|Drug|Adalimumab|Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
75705113|NCT06062862|Device|The Incentive Spirometer|Tri-flow device flow-oriented incentive spirometer .
75705114|NCT06062862|Device|The breather respiratory muscle training device|The breather respiratory muscle training device which allows for adjustable levels of resistance using easy-to-read dials, which allows to adjust the device to the settings require
75705115|NCT06062823|Drug|Afatinib 40 MG|Afatinib 40mg administered orally daily.
76031440|NCT04996277|Procedure|Thrombus suction|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
76031441|NCT04996277|Procedure|Fibrinolytic therapy|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
75868579|NCT03665558|Device|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
75383709|NCT00003007|Drug|cyclophosphamide|
75383710|NCT00003007|Drug|dexamethasone|
75383711|NCT00003007|Drug|melphalan|
75868580|NCT01382862|Other|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
75868581|NCT03630978|Procedure|Liver resection|Major or minor, open or laparoscopic liver resection
75868582|NCT03665480|Drug|G-SCF|In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
75868583|NCT03725891|Drug|Aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
75868584|NCT03725891|Drug|Aspirin 81 mg|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
75868585|NCT03725891|Drug|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
75868586|NCT01383876|Behavioral|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
75868587|NCT01383876|Behavioral|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
75868588|NCT03751163|Drug|Tranexamic Acid Oral Product|Encapsulated tranexamic acid 250 mg
75868589|NCT03751163|Drug|Hydroquinone 4% Cream|Hydroquinone 4% Cream
75868590|NCT03751163|Other|Sunscreen|Sunscreen SPF 30
75868591|NCT03751163|Device|Placebo|Encapsulated placebo
75383712|NCT00003007|Procedure|peripheral blood stem cell transplantation|
75383713|NCT01478035|Drug|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
75541640|NCT04551118|Device|Transcranial alternating current stimulation (tACS) -active|Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique of the brain with an AC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
75868592|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intramuscularly
75868593|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intradermal
76031442|NCT04996277|Behavioral|Medication stabilized the condition|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
75383714|NCT01478035|Drug|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
75383715|NCT00003013|Drug|CMF regimen|
75383716|NCT00003013|Drug|cyclophosphamide|
75383717|NCT00003013|Drug|doxorubicin hydrochloride|
75383718|NCT00003013|Drug|fluorouracil|
75383719|NCT00003013|Drug|methotrexate|
75383720|NCT00003013|Drug|paclitaxel|
75868594|NCT01380444|Procedure|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
75383721|NCT00003013|Drug|tamoxifen citrate|
75383722|NCT00003013|Procedure|conventional surgery|
75383723|NCT00003013|Radiation|radiation therapy|
75383724|NCT00003445|Drug|docetaxel|
75383725|NCT00003451|Biological|recombinant interferon alfa|
75383726|NCT00003451|Biological|recombinant interleukin-12|
75383727|NCT00003463|Drug|carmustine|
75383728|NCT00003463|Drug|irinotecan hydrochloride|
75383729|NCT00003463|Drug|polifeprosan 20 with carmustine implant|
75383730|NCT00003463|Procedure|surgical procedure|
75868595|NCT01380444|Procedure|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
75383731|NCT01338649|Device|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
75868596|NCT03639545|Drug|Empagliflozin 25mg|The patients receive empagliflozin (25 mg daily) for 12 weeks.
75383732|NCT01338649|Device|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
75383733|NCT00003019|Drug|methotrexate|
75868597|NCT03639545|Drug|Metformin|The patients receive metformin (2000 mg daily) for 12 weeks.
75383734|NCT00003019|Drug|vinblastine sulfate|
75383735|NCT01247233|Radiation|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50 Gy + Boost 16 Gy or Whole breast, either 40 Gy in 15 fractions in 3 weeks or 42.5 Gy in 16 fractions in 3 weeks
75383736|NCT01247233|Radiation|Accelerated partial breast irradiation|Tumor bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5 to 7 days.
75383737|NCT00003493|Drug|dexamethasone|
75383738|NCT00003493|Drug|pegylated liposomal doxorubicin hydrochloride|
75383739|NCT00003493|Drug|vincristine sulfate|
75383740|NCT00003505|Drug|antineoplaston A10|
75868598|NCT03639545|Drug|Empagliflozin/Metformin|The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
75868599|NCT03639545|Drug|Placebos|The patients receive for 12 weeks.
75383741|NCT00003505|Drug|antineoplaston AS2-1|
75383742|NCT00003505|Procedure|alternative product therapy|
75383743|NCT00003505|Procedure|biological therapy|
75383744|NCT00003505|Procedure|biologically based therapies|
75383745|NCT00003505|Procedure|cancer prevention intervention|
75383746|NCT00003505|Procedure|complementary and alternative therapy|
75868600|NCT03181386|Drug|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
75383747|NCT00003505|Procedure|differentiation therapy|
75383748|NCT00003025|Biological|vitespen|
75383749|NCT00003031|Drug|amphotericin B deoxycholate|
75383750|NCT00003031|Drug|voriconazole|
75383751|NCT00003517|Drug|antineoplaston A10|
75383752|NCT00003517|Drug|antineoplaston AS2-1|
75383753|NCT00003517|Drug|bicalutamide|
76031443|NCT03111199|Other|Cryotherpy|Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
75383754|NCT00003517|Drug|flutamide|
75383755|NCT00003517|Drug|leuprolide acetate|
75383756|NCT00003517|Procedure|alternative product therapy|
75383757|NCT00003517|Procedure|antiandrogen therapy|
75383758|NCT00003517|Procedure|biological therapy|
75383759|NCT00003517|Procedure|biologically based therapies|
75868601|NCT03181386|Drug|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
75868602|NCT03181386|Drug|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
75868603|NCT02912468|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
75868604|NCT02912468|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
75868605|NCT02912468|Drug|Mometasone furoate 50 micrograms|"Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal"
75868606|NCT03725813|Other|Person-centred inpatient care|"The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention."
75868607|NCT04835298|Other|Dyspnea|questionnaires
76031444|NCT03111199|Other|TENS Burst|The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
76031445|NCT03111199|Other|TENS Burst Placebo|The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
76031446|NCT03111199|Other|Education|After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
76023115|NCT03173209|Behavioral|professional development in Calm Moments Cards program|Professional development (lecture and coaching)was used in combination with informal coaching by occupational therapy practitioners to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
75868608|NCT03639467|Drug|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
75705116|NCT06062797|Device|Mixed Reality Viewer|The Mixed Reality Viewer from Brainlab (Germany) enables the visualization of the fracture via a 3D hologram. In contrast to virtual reality, where the user is in a completely virtual world, the user of the mixed reality viewer sees the 3D hologram implemented in his real environment.
75868609|NCT03729167|Procedure|Scaling and root planing|Non-surgical instrumentation will be performed with specific instruments prior to treatment planned extraction by another provider.
75383760|NCT00003517|Procedure|cancer prevention intervention|
75383761|NCT00003517|Procedure|complementary and alternative therapy|
75868610|NCT01382706|Drug|docetaxel|Given IV
75868611|NCT01382706|Drug|lapatinib ditosylate|Given PO
76031447|NCT03833089|Combination Product|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Potassium supplementation, 3) mineralocorticoid receptor antagonists,
76031448|NCT03071939|Other|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
75383762|NCT00003517|Procedure|differentiation therapy|
75383763|NCT00003517|Procedure|endocrine therapy|
75383764|NCT00003517|Procedure|hormone therapy|
75383765|NCT00003523|Drug|aminocamptothecin colloidal dispersion|
75705117|NCT06062797|Device|X-ray or CT scan|X-ray or CT scan enables the visualization of the fracture in 2D.
75705118|NCT06062771|Device|FIDIAL PLUS|1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).
75705119|NCT06062771|Device|IAL®-F|Animal derived 1.8% sodium hyaluronate equivalent to FIDIAL PLUS
75383766|NCT00383461|Behavioral|smoking cessation intervention|
75705120|NCT06062758|Behavioral|ECT Simulation Training|Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.
75705121|NCT06062745|Drug|18F-fluciclovine|18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body
75705122|NCT06062745|Device|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
75705123|NCT06062732|Behavioral|Face It|School-based intervention delivered over 6 weeks, including an intensive 5-day programme of activities, and pre-programme and post-programme group and 1:1 sessions. Each programme is tailored to participants' needs and uses art, storytelling, 1:1 and group experiential techniques, delivered by trained dramatherapists.
76031449|NCT03142789|Drug|Initial bolus (Certa and standard catheter groups)|10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
76031450|NCT03142789|Drug|Initial bolus (Single bolus group)|20 ml of ropivacaine 0.75%
75705124|NCT06062732|Behavioral|Control|Services as usual
75705125|NCT06062719|Drug|PPI group|80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
75705126|NCT06062719|Drug|PPI plus octreotide|octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
75705127|NCT06062706|Procedure|Donor hepatectomy|"Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach."
75705128|NCT06062693|Device|smart sensor egg training|The portable hand trainer has three principal functionalities: (I) Grasping, (II) Pronosupination, and (III) wrist and finger extension. Different exercises can be done.
75705129|NCT06062680|Drug|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
75705130|NCT06062654|Other|Hospital-assisted Rehabilitation|Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.
75705131|NCT06062654|Other|Home-based Rehabilitation|Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.
75705132|NCT06062615|Procedure|Total knee replacement using Omnibot Knee System|total knee replacement with robotic assistance
75868612|NCT01382706|Other|immunohistochemistry staining method|Correlative studies
75383767|NCT00383461|Other|counseling intervention|
75383768|NCT00003037|Drug|cisplatin|
75383769|NCT00003037|Drug|docetaxel|
75383770|NCT00003037|Drug|gemcitabine hydrochloride|
75383771|NCT00002803|Drug|cyclophosphamide|
75383772|NCT00002803|Drug|doxorubicin hydrochloride|
75383773|NCT00002803|Drug|vincristine sulfate|
75383774|NCT00002803|Procedure|conventional surgery|
75383775|NCT00383929|Drug|Candesartan cilexetil|32mg oral
75383776|NCT00383929|Drug|Hydrochlorothiazide|12.5 mg oral
75868613|NCT01382706|Genetic|fluorescence in situ hybridization|Correlative studies
75868614|NCT01382706|Other|laboratory biomarker analysis|Correlative studies
75868615|NCT03725735|Behavioral|CBT for problem gambling with emotion regulation|CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
75868616|NCT03665402|Drug|Isoniazid|One of the first line anti-tubercolosis drug
75868617|NCT03665090|Behavioral|Diabetic eye disease screening|Community-based, prospective cohort study from three consecutive years (2016 to 2018) to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.
75868618|NCT01380288|Drug|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
75868619|NCT03665012|Other|Pediatric Development Clinic (PDC)|All children enrolled in PDC will be at screened for any medical condition they may have and be referred for treatment as required. Nutrition and development support are also provided to clinic enrollees, based on clinic protocols which include regular monitoring and intervention.
75383777|NCT00383929|Drug|Hydrochlorothiazide|25 mg oral
76031451|NCT03142789|Drug|Intermittent boluses (Certa and standard catheter groups)|20 ml of ropivacaine 0.2% every 8 hour in the catheter
76031452|NCT03142789|Drug|Intermittent boluses (Single bolus group)|0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
76031453|NCT04996355|Other|comprehensive treatment after MDT discussion|"The comprehensive treatment plan was determined through MDT discussion, which was completed by the Department of Gastrointestinal Surgery, Peking University People's Hospital.~The following regimens will be tested with organoids-on-a-chip：~5-FU~Oxaliplatin~Irinotecan~5-FU+ Oxaliplatin~5-FU+ Irinotecan~5-FU+ Oxaliplatin+ Irinotecan~5-FU+Cetuximab~Cetuximab~Regorafenib"
76031454|NCT03072329|Procedure|Pudendal nerve block|
75383778|NCT00003541|Biological|filgrastim|
75868620|NCT03110484|Drug|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
75868621|NCT03110484|Drug|Erlotinib|Erlotinib 100mg once daily
75383779|NCT00003541|Drug|CHOP regimen|
75705133|NCT06062615|Procedure|Conventional Total knee replacement|Conventional total knee replacement without robotic assistance
75705134|NCT06062615|Device|Omnibot Robotic Knee System|utilizes an active motorized knee spacer to measure ligament tension and gap balance after the tibia has been cut during surgery
75868622|NCT03110328|Drug|MK3475|anti-PD1 immunotherapy
75868623|NCT04438499|Device|eSense 7fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
75868624|NCT01562015|Drug|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
75383780|NCT00003541|Drug|carboplatin|
75868625|NCT03751085|Device|AW frame|AW stereotactic frame for intracranial lesion biopsy
75383781|NCT00003541|Drug|cyclophosphamide|
75383782|NCT00003541|Drug|doxorubicin hydrochloride|
75383783|NCT00003541|Drug|etoposide|
75383784|NCT00003541|Drug|ifosfamide|
75383785|NCT00003541|Drug|prednisone|
75383786|NCT00003541|Drug|vincristine sulfate|
75383787|NCT00003541|Procedure|peripheral blood stem cell transplantation|
75383788|NCT00003541|Radiation|radiation therapy|
75383789|NCT00002809|Biological|anti-thymocyte globulin|
75383790|NCT00002809|Biological|filgrastim|
75383791|NCT00002809|Biological|sargramostim|
75383792|NCT00002809|Biological|therapeutic immune globulin|
75383793|NCT00002809|Drug|cyclophosphamide|
75383794|NCT00002809|Drug|methotrexate|
75383795|NCT00002809|Drug|tacrolimus|
75383796|NCT00002809|Procedure|allogeneic bone marrow transplantation|
75383797|NCT00002809|Radiation|radiation therapy|
75383798|NCT00003553|Other|HLA Matched Peripheral BLood Stem Cells|Cell Product
75383799|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 1
75383800|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 2
75868626|NCT03729089|Other|Modified Biophysical Profile scan|Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
75868627|NCT00002874|Drug|bicalutamide|One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
75868628|NCT00002874|Radiation|radiation therapy|64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
75868629|NCT00002874|Drug|placebo|One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
75868630|NCT03001076|Drug|Bempedoic acid|bempedoic acid 180 mg tablet
75868631|NCT03001076|Drug|Ezetimibe|ezetimibe 10 mg tablet
76031455|NCT03072329|Drug|Bupivacaine|
76031456|NCT02327689|Drug|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
76031457|NCT03141697|Device|Carbon Dioxide|Insufflation of Carbon Dioxide
76031458|NCT03141697|Device|Room air|Insufflation of room air
76031459|NCT03072017|Behavioral|MBAT|Breathing-based intervention
76031460|NCT02327923|Drug|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
76031461|NCT02327923|Drug|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
76031462|NCT02327923|Drug|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
76031463|NCT02327923|Drug|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
76031464|NCT02327923|Drug|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
76031465|NCT02327923|Drug|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
76031466|NCT02327923|Drug|Vecuronium|Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
76031467|NCT02327923|Drug|Atropine|Inj Atropine 0.4 mg IV will be given for bradycardia (HR < 50/min)
76031468|NCT02327923|Drug|Ephedrine|
76031469|NCT02327923|Drug|Morphine|
76031470|NCT02327923|Drug|Ketorolac|
76031471|NCT02327923|Drug|Ondansetron|
76031472|NCT02327923|Drug|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
76031473|NCT02327923|Drug|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
76031474|NCT02327923|Drug|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
76031475|NCT02327923|Drug|Glycopyrrolate|10 mcg/kg with neostigmine
75868632|NCT03001076|Other|Placebo|matching placebo tablet
75383801|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 3
75383802|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Control Vaccine
75383803|NCT00002827|Biological|bleomycin sulfate|Given IV
75383804|NCT00002827|Biological|filgrastim|Given IV
75868633|NCT03555305|Drug|Insulin Glargine|Administered SC
76031476|NCT04991207|Drug|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
76031477|NCT04991207|Drug|bosentan|Oral Tracleer (bosentan) 125 mg film coated tablets
76031478|NCT03072173|Drug|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
76031479|NCT03072173|Drug|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
76031480|NCT03141463|Biological|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
76031481|NCT03072095|Behavioral|Text-only|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.
76031482|NCT03072095|Behavioral|Text + Lottery|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
76031483|NCT02327611|Drug|Custodiol|
75868634|NCT03555305|Drug|Lantus|Administered SC
75705135|NCT06062589|Radiation|Iodine-125 particle brachytherapy|All enrolled patients' relapsed or metastatic lesions underwent image-guided radiation I-125 particle implantation brachytherapy (single implantation, half-life of 60 days, 99% of total dose given after 90 days). The prescribed dose is above 130Gy. Technical process: positioning and preoperative planning design; Template reset and particle implantation under the guidance of image system; Rapid and real-time intraoperative optimization; Postoperative dose validation.
75705136|NCT06062589|Drug|AK104|AK104 treatment (6mg/kg Q2W) starting within 1 week of particle implantation, for a total of 6 cycles or until disease progression, intolerable toxicity, investigator decision, withdrawal of informed consent, death, or other reasons as specified in the protocol.
75705137|NCT06062563|Drug|Anlotinib Hydrochloride Capsule and Penpulimab|"Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.~Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC."
75705138|NCT06062524|Device|Aorta Vascular Plug System|The Aorta Vascular Plug System for false lumen is composed of a vascular plug system and an adjustable bend conveyor. The plug system is composed of a patch and a conveying steel cable. The plug is pre-installed on the conveying steel cable.
75705139|NCT06062498|Drug|elacestrant, palbociclib, abemaciclib, ribociclib|Given orally
75705140|NCT06062485|Drug|Surufatinib+Toripalimab+AG|"This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）"
75705141|NCT06062459|Other|Motor Control Exercise|Motor control exercises focusing on the activation and control of deep spinal muscles
75705142|NCT06062459|Other|Balance Training|Balance training exercises on to enhance proprioception and stability
75868635|NCT01310387|Behavioral|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
75868636|NCT03725579|Drug|mepivicane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
75868637|NCT03725579|Drug|articane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
75868638|NCT03728855|Behavioral|Self-administration of medication (SAM)|Patients use medication from their own stock, self-administered.
75383805|NCT00002827|Drug|dexrazoxane hydrochloride|Given IV
75868639|NCT03018834|Drug|ANAKINRA 100 mg/daily subcutaneously|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
75868640|NCT03018834|Drug|Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
75868641|NCT03553823|Procedure|Skin biopsies|At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
76031484|NCT02327611|Drug|Enriched Ringer's lactate solution|
75383806|NCT00002827|Drug|doxorubicin hydrochloride|Given IV
75383807|NCT00002827|Drug|etoposide|Given IV
75383808|NCT00002827|Drug|vincristine sulfate|Given IV
75383809|NCT00002827|Radiation|low-LET cobalt-60 gamma ray therapy|
75383810|NCT00002827|Radiation|low-LET electron therapy|
75383811|NCT00002827|Radiation|low-LET photon therapy|
75383812|NCT00384475|Drug|Ciclesonide Nasal Spray|
75383813|NCT00003565|Drug|docetaxel|
75383814|NCT00003049|Drug|fluorouracil|
75383815|NCT00003049|Drug|leucovorin calcium|
75383816|NCT00003049|Procedure|conventional surgery|
75383817|NCT00003049|Radiation|radiation therapy|
75383818|NCT00003055|Drug|cisplatin|
75383819|NCT00003055|Drug|irinotecan hydrochloride|
75383820|NCT00002833|Biological|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
76031485|NCT03826849|Behavioral|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
76031486|NCT03072641|Dietary Supplement|ProBion Clinica|
75383821|NCT00002833|Drug|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
75705143|NCT06062459|Other|Control Group|Participants received hot pack and stretching exercise
76031487|NCT03074279|Other|Interview with a psychologist and self-reported questionnaires|The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
76031488|NCT04991363|Procedure|Bleaching|Digital images for each patient will be taken once with the camera fixed on the classic tripod and again when the camera was fixed on the ISD , then horizontal and vertical measurements of the canines will be recorded by using a computer software on the digital images, then bleaching will be fine for all patients, then a second set of images will be taken again with the tripod and then with ISD, then measurements will be repeated and compared with the first set of images
75705144|NCT06062355|Drug|HRS-9815 injection|HRS-9815 injection
75705145|NCT06062303|Other|Usual care (UC)|- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, heart rate (HR) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
76031489|NCT03764371|Diagnostic Test|KAPA Hyper Prep Kit + Agilent SureSelectQXT|We initiated this prospective clinical study to detect lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules). At the same time, application of KAPA Hyper Prep Kit + Agilent SureSelectQXT technology to test lung cancer related genes in patients' tumor tissues and blood, patients with lung cancer drive genes were followed up to explore whether different drive genes had an impact on patients' disease progression. In order to investigate the type of gene that causes disease recurrence in patients, tissue or blood test was performed again when disease recurrence occur.
76031490|NCT03074123|Diagnostic Test|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
75383822|NCT00002833|Drug|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
75383823|NCT00002833|Drug|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
75541641|NCT04551118|Device|Transcranial direct current stimulation (tDCS)-active|Transcranial direct current stimulation (tDCS) is a non- invasive neuromodulation technique of the brain with a DC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
75705146|NCT06062277|Drug|Colchicine 0.5 MG|one oral tablet daily for 30 days
75705147|NCT06062264|Behavioral|Portal-based Video Message|Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.
75705148|NCT06062264|Behavioral|Portal-based Infographic Message|Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.
75705149|NCT06062238|Biological|M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine|Participants will receive an intramuscular dose of M72 (recombinant fusion protein) reconstituted with AS01E-4 (an adjuvant system), on Day 1 and Day 29.
75383824|NCT00002833|Drug|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
75383825|NCT00002833|Drug|Idarubicin|IV Days -6, -5 and -4.
75383826|NCT00002833|Drug|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
75383827|NCT00002833|Procedure|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
75383828|NCT00003061|Drug|cytarabine|
75383829|NCT00003061|Drug|methotrexate|
75383830|NCT00003061|Radiation|radiation therapy|
75383831|NCT00003571|Genetic|mutation analysis|
75383832|NCT00003571|Genetic|tumor replication error analysis|
75383833|NCT00003577|Drug|CMF regimen|
75383834|NCT00003577|Drug|cyclophosphamide|
75383835|NCT00003577|Drug|epirubicin hydrochloride|
75383836|NCT00003577|Drug|fluorouracil|
75383837|NCT00003577|Drug|methotrexate|
75383838|NCT00003577|Procedure|adjuvant therapy|
75383839|NCT00003577|Radiation|radiation therapy|
75383840|NCT00002839|Drug|cisplatin|
75383841|NCT00002839|Drug|fluorouracil|
75383842|NCT00002839|Procedure|conventional surgery|
75383843|NCT00002839|Procedure|neoadjuvant therapy|
75383844|NCT00002839|Radiation|radiation therapy|
75383845|NCT00003583|Drug|amifostine trihydrate|
75383846|NCT00003583|Drug|cisplatin|
75383847|NCT00003583|Drug|etoposide|
75383848|NCT00003583|Radiation|radiation therapy|
75383849|NCT00002845|Biological|aldesleukin|
75705150|NCT06062238|Biological|Placebo|Participants will receive an intramuscular dose of normal saline (0.9 percent [%] sodium chloride [NaCl]), on Day 1 and Day 29.
75705151|NCT06062212|Procedure|Transpulmonary pressure|Use transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.
75705152|NCT06062186|Dietary Supplement|Placebo|650 mg of placebo, given as two capsules containing maltodextrin
75705153|NCT06062186|Dietary Supplement|AmaTea Guayusa Extract|650 mg of AmaTea Guayusa Extract, given as two capsules
75705154|NCT06062186|Dietary Supplement|Lion's Mane|1000 mg of Lion's Mane, given as two capsules
75705155|NCT06062160|Other|Therapeutic Touch|Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
75705156|NCT06062147|Behavioral|Teacher training|Training for teachers in the intervention arm in the learning process, SLLD and early warning signs, with an identification grid. Observation of identified pupils and implementation of educational and environmental adjustments.
75705157|NCT06062121|Device|Motor-cable-driven Rehabilitation Robotic System|Subjects will wear the motor-cable-driven system and receive 30 minutes (including preparation time) wrist and forearm robot-assisting exercise
76031491|NCT05078749|Other|Exercise training group|A regular advanced exercise program will be given and followed.
76031492|NCT05078749|Other|Control training group|Basic exercises will be given at the beginning and will do the same exercises
75705158|NCT06062082|Procedure|adrenalectomy|laparoscopic exeresis of the adrenal gland
75705159|NCT06062030|Drug|DWJ1609|Drug of test group
75705160|NCT06062030|Drug|DWC202304|Drug of control group
75705161|NCT06062004|Procedure|Small Incision Lenticule Extraction (SMILE)|"All surgeries will be performed under topical anesthesia using the VisuMax femtosecond laser with the following parameters:~Cap thickness of 120 μm~Cap diameter of 1 mm larger than the lenticule diameter~Cap side cut angle 70°~3 mm incision positioned at 100° and angled at 45°~Transition zone of 0.1 mm and clearance of 0.5 mm~Lenticule side cut angle of 90° and edge lenticule thickness of 15 μm"
75383850|NCT00003067|Biological|aldesleukin|
75383851|NCT00003067|Biological|lymphokine-activated killer cells|
75383852|NCT00003589|Drug|cisplatin|
75383853|NCT00003589|Drug|gemcitabine hydrochloride|
75383854|NCT00003589|Drug|paclitaxel|
75383855|NCT00002851|Procedure|adjuvant therapy|
75383856|NCT00002851|Radiation|low-LET electron therapy|
75383857|NCT00002851|Radiation|low-LET photon therapy|
75383858|NCT00003595|Biological|filgrastim|
75383859|NCT00003595|Biological|rituximab|
75383860|NCT00003595|Drug|CHOP regimen|
75383861|NCT00003595|Drug|cyclophosphamide|
75383862|NCT00003595|Drug|doxorubicin hydrochloride|
75383863|NCT00003595|Drug|prednisone|
75383864|NCT00003595|Drug|vincristine sulfate|
75383865|NCT00003073|Drug|liposomal cytarabine|
75383866|NCT00002863|Drug|chemotherapy|
75383867|NCT00002863|Procedure|conventional surgery|
75383868|NCT00002863|Procedure|cryosurgery|
75383869|NCT00003079|Drug|bryostatin 1|
75383870|NCT00003079|Drug|cytarabine|
75868642|NCT05422716|Device|Epidural implant stimulation device|Individuals randomized to the Baclofen pump device group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments). The epidural implant group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity.
75868643|NCT03728777|Dietary Supplement|Resveratrol|Resveratrol supplementation 1000 mg /day or placebo
75705162|NCT06060522|Diagnostic Test|CT, CBCT|"Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline."
75541642|NCT04551118|Device|Transcranial electrical stimulation (TES)-sham|Transcranial electrical stimulation (TES) is a non-invasive neuromodulation technique of the brain with micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min for 7 consecutive days.
75383871|NCT00002869|Biological|recombinant interferon alfa|
75383872|NCT00002869|Drug|cytarabine|
75383873|NCT00002869|Drug|hydroxyurea|
75383874|NCT00002875|Biological|filgrastim|
75541643|NCT04551079|Drug|TAK-994|TAK-994 tablets.
75383875|NCT00002875|Drug|cisplatin|
75541644|NCT04551079|Drug|Placebo|TAK-994 placebo-matching tablets.
75541645|NCT00235040|Behavioral|Smart Form|Computer Decision Support System
75541646|NCT00260949|Procedure|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
75541647|NCT02214082|Other|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
75868644|NCT05422404|Procedure|Anti-Reflux Mucosectomy|ARMS will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. The upper gastrointestinal tract will be evaluated in detail first. Then Endoscopic mucosal resection(EMR) will performed at E-C junction, gastric cardia side. About 50%-70% of the EGJ circumference will be resected to create artificial ulcer which will lead to mucosal contraction during the healing process.
75541648|NCT00235079|Drug|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
75541649|NCT00235079|Drug|Placebo|Placebo comparator
75541650|NCT00268281|Device|Left Ventricular Capture Management Software|
75383876|NCT00002875|Drug|cyclophosphamide|
75383877|NCT00002875|Drug|lomustine|
75383878|NCT00002875|Drug|mesna|
75383879|NCT00002875|Drug|vincristine sulfate|
75383880|NCT00002875|Radiation|low-LET electron therapy|
75383881|NCT00002875|Radiation|low-LET photon therapy|
75383882|NCT00003607|Radiation|radiation therapy|
75383883|NCT00003613|Drug|O6-benzylguanine|Given IV
75383884|NCT00003613|Drug|carmustine|Given topically
75383885|NCT00003613|Other|laboratory biomarker analysis|Correlative studies
75383886|NCT00003085|Procedure|laparoscopy|
75383887|NCT00003085|Procedure|ultrasound imaging|
75383888|NCT00002881|Drug|flutamide|
75383889|NCT00002881|Drug|goserelin acetate|
75383890|NCT00002881|Drug|leuprolide acetate|
75383891|NCT00002881|Drug|suramin|
75383892|NCT00002881|Drug|therapeutic hydrocortisone|
75541651|NCT00235118|Device|Cordis AAA Bilateral Device|
75705163|NCT06060353|Behavioral|Regulation Focused Psychotherapy (RFP-C)|Regulation-focused psychotherapy for children (RFP-C; Hoffman, Rice, & Prout, 2016) is a manualized, psychodynamic play therapy. Through 20 sessions (16 with the child and four parent meetings), RFP-C allows the child to understand the ways distressing affects are avoided and to explore alternative ways of coping with unpleasant affect. The clinician works to increase the child's understanding that all behavior, especially oppositional and disruptive behavior, has meaning in the service of emotional and behavioral regulation. This work is also done with the parents to better support the child in achieving symptom reduction and increased emotion regulation.
75705164|NCT06060353|Behavioral|Parental Awareness and Child Social Skills Group|Parental awareness and child social skills group is a manualized group psychotherapy that involves twelve parallel sessions conducted separately with parents and children. The parent group involves modules related to psycho-education, role-play and awareness building activities on child needs & rights, child temperament, praise & acceptance, child play, limit setting, anger management, transmission of parenting styles through genograms and family trees. With children, the groups involve psycho-education and play based activities to build awareness on children's rights, temperament, feelings, play & relationship skills, empathy & praise, anger management.
75705165|NCT06060236|Drug|Ibuprofen 800 mg|Ibuprofen 800 Mg İv
75705166|NCT06060236|Drug|Dexketoprofen|Dexketoprofen 50 Mg İV
75705167|NCT06059820|Other|rehabilitation treatment|3-month immobilization period, hyperextension braces for specific fractures, therapeutic exercises, and gradual activity restoration.
75705168|NCT06059820|Procedure|Spine fusion|Pedicle screw fixation or fusion; anterior plate fusion
75868645|NCT05422404|Procedure|Anti-reflux mucosal ablation|ARMA will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. Mucosal ablation will be performed in retroflex fashion following. Then APC with soft coagulation(effect 2, 40W) will be used to mark the area that not going to be ablated at gastric carida over the great curvature direction, about 1.5 scope width. Then submucosa injection with saline and indigo carmine dye will be performed using a 25 guage needle.
76031493|NCT04433663|Other|Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis|"To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome."
76031494|NCT02327299|Dietary Supplement|Bouillon fortified with FePP|
76031495|NCT02327299|Dietary Supplement|Bouillon fortified with FePP + Stabilizer|
76031496|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4|
75383893|NCT00002881|Procedure|orchiectomy|
75383894|NCT00003091|Biological|aldesleukin|
75383895|NCT00003091|Biological|recombinant interferon alfa|
75705169|NCT06059378|Device|Artificial intelligence-assisted classification (CADx)|CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.
75383896|NCT00003619|Biological|filgrastim|
75868646|NCT03000686|Biological|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
75868647|NCT03000686|Other|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
75383897|NCT00003619|Dietary Supplement|vitamin E|
75383898|NCT00003619|Drug|busulfan|
75383899|NCT00003619|Drug|cytarabine|
75383900|NCT00003619|Drug|etoposide|
75383901|NCT00003619|Drug|fludarabine phosphate|
75541652|NCT04550884|Diagnostic Test|neuromascular ultrasound|neuromascular ultrasound of foot and ankle
75541653|NCT00260988|Drug|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
75541654|NCT00260988|Drug|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
75383902|NCT00003619|Drug|isotretinoin|
75383903|NCT00003619|Drug|topotecan hydrochloride|
75383904|NCT00003619|Procedure|bone marrow ablation with stem cell support|
75383905|NCT00003619|Procedure|peripheral blood stem cell transplantation|
75383906|NCT00002887|Drug|cisplatin|
75383907|NCT00002887|Drug|etoposide|
75383908|NCT00002887|Drug|hydroxyurea|
75383909|NCT00002887|Drug|vinblastine sulfate|
75383910|NCT00002887|Drug|vindesine|
75383911|NCT00002887|Drug|vinorelbine tartrate|
75383912|NCT00002887|Procedure|drug resistance inhibition treatment|
75383913|NCT00003937|Drug|cisplatin|
75383914|NCT00003937|Drug|dexrazoxane hydrochloride|
75383915|NCT00003937|Drug|doxorubicin hydrochloride|
75705170|NCT06059274|Other|Topical serum|Participants are asked to apply the topical serum twice daily for 84 days.
75705171|NCT06058975|Other|Observational|Review the management of duodenal trauma in France
76031497|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4 + Stabilizer|
76031498|NCT03494569|Drug|Fludarabine|Given IV
76031499|NCT03494569|Other|Laboratory Biomarker Analysis|Correlative studies
76031500|NCT03494569|Drug|Melphalan|Given as per City of Hope Standard Operating Procedure
76031501|NCT03494569|Radiation|Total Marrow Irradiation|Undergo TMLI
76031502|NCT03071627|Other|New items with spin|Interpretation of news items with spin
76031503|NCT03071627|Other|New items without spin|Interpretation of news items without spin
76031504|NCT03071783|Device|Vacuum extraction intelligent system|Vacuum extraction intelligent system - this is the intervention
76031505|NCT02327377|Behavioral|Online Cognitive Behavior Therapy|
76031506|NCT02327377|Behavioral|Online Education|
75541655|NCT04550416|Other|ProMark Information and Test Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
75868648|NCT02646228|Other|molecular profiling, patient derived cells|"molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer."
76031507|NCT03071549|Drug|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
75541656|NCT04550533|Other|Therapeutic Adherence|To measure adherence to treatment in oncohematological patients in treatment with oral anti-cancer drugs
75541657|NCT00235157|Device|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
75868649|NCT04701138|Dietary Supplement|SPM Active|Each capsule contains 145 mg of SPMs (fractionated marine lipids standardized to 18-HEPE, 14-HDHA, and 17-HDHA). All subjects will take 4 capsules orally each day for a total daily dose of 580 mg.
75383916|NCT00003937|Drug|etoposide|
75383917|NCT00003937|Drug|ifosfamide|
75383918|NCT00003937|Drug|methotrexate|
75383919|NCT00003937|Procedure|conventional surgery|
75383920|NCT00003625|Drug|cyclosporine|
75383921|NCT00003625|Drug|etoposide|
75383922|NCT00003625|Drug|vincristine sulfate|
75541658|NCT04550338|Drug|Tranexamic acid|Oral administration of blinded medications
75541659|NCT04550338|Drug|Placebo|Oral administration of blinded medications
75541660|NCT02214199|Other|Manipulative Therapy Techniques|
75541661|NCT02214199|Other|Home Exercises|
75541662|NCT00268320|Device|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
76031508|NCT03071549|Drug|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
76031509|NCT03144817|Other|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
75383923|NCT00003625|Radiation|radiation therapy|
75383924|NCT00003637|Drug|cisplatin|
75383925|NCT00003637|Drug|fluorouracil|
75383926|NCT00003637|Radiation|radiation therapy|
75383927|NCT00003097|Other|preventative dietary intervention|
75383928|NCT00003943|Biological|filgrastim|5 ug/kg
76031510|NCT04995575|Procedure|collection of the biopsy, blood samples|"for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals.~For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples"
76031511|NCT03074201|Procedure|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
76031512|NCT03074201|Device|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
76031513|NCT03734965|Device|AWAKEN INTUBATION|Intubation
76031514|NCT04994951|Drug|Triamcinolone Acetonide Acetate and Urea Cream.|10g/tube and CalcipotriolOintment,10g/tube are used alternately.
76031515|NCT04994951|Drug|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
76031516|NCT03717181|Drug|Lixivaptan|Daily dose of lixivaptan optimized using a predetermined titration protocol.
76031517|NCT03073889|Procedure|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
76031518|NCT03073889|Procedure|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
75541663|NCT04550611|Other|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
75383929|NCT00003943|Drug|carboplatin|AUC 5
75383930|NCT00003943|Drug|cyclophosphamide|3 gm/m2
75383931|NCT00003943|Drug|paclitaxel|250 mg/m2
75383932|NCT00003943|Drug|topotecan hydrochloride|10 mg/m2
75541664|NCT04550611|Other|plasma exchange|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
75705172|NCT06058169|Device|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate (equipped with stabilizing bars) to take home for training which will last for up 12 weeks. For this test the participant will be asked to stand on a vibration plate for up to 20 minutes. Participants will be instructed to remove any footwear and stand mid-center on the platform in a standing position with feet shoulder width apart. The participant will be asked to step on and off of the vibration plate. During the first four weeks, participants will be asked to complete 5-10 minutes of WBV per day, at least 4-5 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 15 minutes and/or reduce the duration of rest. Beginning at week 9, based on how the participant feels, the study team may adjust the WBV time/duration up to 20 minutes per session, 4-5 days per week.
75705173|NCT06057311|Other|Hippotherapy|The participants in HT Group; received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
75705174|NCT06057311|Other|Equine-Assisted Activities Therapy|The participants in the EAAT Group received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
75705175|NCT06057311|Other|Control|The Control Group (CG) did not receive any training. The assessments were applied twice to CG at baseline and after 6 weeks. The treatments and assessments were performed by the same physiotherapist in the same environment.
75383933|NCT00003943|Procedure|peripheral blood stem cell transplantation|harvest via apheresis
75383934|NCT00003955|Biological|dactinomycin|
75383935|NCT00003955|Biological|filgrastim|
75383936|NCT00003955|Biological|pegfilgrastim|
75383937|NCT00003955|Biological|sargramostim|
75383938|NCT00003955|Drug|cyclophosphamide|
75383939|NCT00003955|Drug|irinotecan hydrochloride|
75383940|NCT00003955|Drug|vincristine sulfate|
75383941|NCT00003955|Radiation|radiation therapy|
75383942|NCT00003103|Biological|oblimersen sodium|
75383943|NCT00003103|Drug|docetaxel|
75383944|NCT00003109|Drug|irinotecan hydrochloride|
75383945|NCT00003109|Drug|raltitrexed|
75383946|NCT00003643|Biological|bleomycin sulfate|
75868650|NCT01382550|Drug|long-lasting OAT or 12-month OAT|"The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded."
75868651|NCT05421936|Drug|Osimertinib|Treatment as the first EGFR-TKI
75383947|NCT00003643|Biological|filgrastim|
75383948|NCT00003643|Drug|cisplatin|
75383949|NCT00003643|Drug|etoposide|
75383950|NCT00003643|Drug|paclitaxel|
75383951|NCT00003961|Biological|sargramostim|
75383952|NCT00003661|Biological|anti-thymocyte globulin|
75383953|NCT00003661|Drug|busulfan|
75383954|NCT00003661|Drug|cyclosporine|
75868652|NCT01380132|Procedure|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
76031519|NCT03073889|Drug|Ropivacaine|
75383955|NCT00003661|Drug|melphalan|
75383956|NCT00003661|Drug|methylprednisolone|
75383957|NCT00003661|Procedure|umbilical cord blood transplantation|
75383958|NCT00003661|Radiation|radiation therapy|
75383959|NCT00003967|Drug|etoposide|
75383960|NCT00003967|Drug|topotecan hydrochloride|
75383961|NCT00003115|Drug|hydromorphone hydrochloride|
75868653|NCT02493660|Device|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
75383962|NCT00003667|Drug|cyclophosphamide|
75383963|NCT00003667|Drug|dexrazoxane hydrochloride|
75383964|NCT00003667|Drug|disaccharide tripeptide glycerol dipalmitoyl|
75383965|NCT00003667|Drug|doxorubicin hydrochloride|
75383966|NCT00003667|Drug|vincristine sulfate|
75383967|NCT00003667|Procedure|surgical procedure|
75868654|NCT02493660|Procedure|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
75868655|NCT01382472|Drug|Rosuvastatin|40 mg per operative in PPCI, the 40 daily during hospital stay
75868656|NCT01382472|Drug|Simvastatin|No statin acutely. Simvastatin 20 mg from day 2.
75868657|NCT05421468|Other|L-Thyroxine time B (5-15 minutes Before dawn)|Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
76031520|NCT03071471|Device|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.~The MID-C System inherent benefits are:~Only two screws are used~Incision size is much smaller~Simpler operation with shorter operative time~Less complication thanks to the three points above.~Minimal spinal mobility loss"
76031521|NCT03645967|Device|ReadyCleanse Cloths|ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
75383968|NCT00003667|Radiation|radiation therapy|
75383969|NCT00003979|Drug|CHS 828|
75383970|NCT00003673|Drug|chemotherapy|
75383971|NCT00003673|Drug|gemtuzumab ozogamicin|
75383972|NCT00003679|Drug|cyclophosphamide|
75383973|NCT00003679|Drug|docetaxel|
75383974|NCT00003679|Drug|doxorubicin hydrochloride|
75383975|NCT00003679|Drug|tamoxifen citrate|
75383976|NCT00003679|Procedure|conventional surgery|
75383977|NCT00003679|Radiation|radiation therapy|
75383978|NCT00003985|Drug|KRN7000|
75383979|NCT00384553|Drug|Rituximab|
75383980|NCT00384553|Drug|DHAP|
75383981|NCT00384553|Drug|TEC|
75383982|NCT00384553|Drug|autologous stem cell transplantation|
75383983|NCT00003991|Biological|aldesleukin|
75383984|NCT00003991|Drug|histamine dihydrochloride|
75383985|NCT00003997|Drug|irofulven|
75383986|NCT00384631|Other|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
75383987|NCT00384631|Drug|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
75383988|NCT00003127|Drug|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
75383989|NCT00003127|Drug|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
75383990|NCT00003127|Drug|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
75383991|NCT00004003|Drug|cisplatin|
75383992|NCT00004003|Drug|fluorouracil|
75383993|NCT00004003|Drug|gemcitabine hydrochloride|
75383994|NCT00004009|Drug|tipifarnib|
75541665|NCT00235196|Device|Collagen ORC Antimicrobial Matrix (CAM)|
75541666|NCT04550026|Other|HTP inhalation|Sham inhalation for 30 minutes
75541667|NCT04550299|Other|Surgical technique combined with a specific choice of the material for the ligament reconstruction|The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice
75868658|NCT03552029|Drug|Quizartinib|20 or 30 mg tablets for oral administration
75868659|NCT03552029|Drug|Milademetan|5, 20, 80 or 200 mg capsules for oral administration
76031522|NCT03570931|Drug|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
76031523|NCT05078515|Diagnostic Test|PREDICT score|Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
75383995|NCT00003133|Biological|filgrastim|
75383996|NCT00003133|Drug|cisplatin|
75383997|NCT00003133|Drug|doxorubicin hydrochloride|
75383998|NCT00003133|Drug|gemcitabine hydrochloride|
75383999|NCT00003133|Drug|paclitaxel|
75384000|NCT00003685|Procedure|fatigue assessment and management|
75384001|NCT00003685|Procedure|nausea and vomiting therapy|
75384002|NCT00003685|Procedure|pain therapy|
75384003|NCT00003685|Procedure|quality-of-life assessment|
75384004|NCT00003685|Radiation|radiation therapy|
75384005|NCT00004015|Drug|sodium borocaptate|
75384006|NCT00004015|Procedure|adjuvant therapy|
75384007|NCT00003691|Biological|filgrastim|
75541668|NCT00261027|Drug|Exemestane|
75541669|NCT00235235|Procedure|Biopsy|core biopsy
75541670|NCT00235235|Procedure|Serum Collection|serum collection
75541671|NCT00235235|Procedure|Urine Collection|urine collection
75541672|NCT00235235|Drug|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
75541673|NCT00235235|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
75868660|NCT03552029|Drug|Milademetan|5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
76031524|NCT04477369|Drug|DWJ1439|300mg single dose
76031525|NCT04477369|Drug|DWJ1464|300mg single dose
76031526|NCT04477369|Drug|DWC202003|300mg single dose
76031527|NCT04477369|Drug|DWC202004|300mg single dose
76031528|NCT02636699|Biological|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
76031529|NCT02636699|Biological|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
75384008|NCT00003691|Drug|cisplatin|
75384009|NCT00003691|Drug|doxorubicin hydrochloride|
75384010|NCT00003691|Drug|paclitaxel|
75384011|NCT00003139|Drug|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
75384012|NCT00003139|Other|Placebo|
75384013|NCT00003697|Drug|vadimezan|
75384014|NCT00004033|Drug|liposomal NDDP|
75384015|NCT00004033|Procedure|therapeutic thoracoscopy|
75384016|NCT00003703|Drug|SarCNU|
75384017|NCT02972983|Drug|Daptomycin|Adjuvant therapy for up to five days
75384018|NCT02972983|Other|Placebo|Placebo
75384019|NCT00003709|Drug|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
75384020|NCT00003145|Drug|Fludarabine Phosphate|Given IV
75384021|NCT00003145|Radiation|Total-Body Irradiation|Undergo TBI
75384022|NCT00003145|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
75384023|NCT00003145|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
75384024|NCT00003145|Drug|Cyclosporine|Given PO or IV
75384025|NCT00003145|Drug|Mycophenolate Mofetil|Given PO or IV
75384026|NCT00003145|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
75384027|NCT00003145|Other|Laboratory Biomarker Analysis|Correlative studies
75384028|NCT00004039|Biological|recombinant interferon alfa|
75384029|NCT00004039|Biological|rituximab|
75384030|NCT00004039|Drug|cyclophosphamide|
75384031|NCT00004039|Drug|doxorubicin hydrochloride|
75384032|NCT00004039|Drug|prednisone|
75384033|NCT00004039|Drug|vincristine sulfate|
75384034|NCT00003151|Dietary Supplement|bismuth subcitrate|
75384035|NCT00003151|Drug|amoxicillin|
75541674|NCT00235235|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
75541675|NCT00235235|Drug|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
75541676|NCT00235235|Drug|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
75868661|NCT03725423|Drug|Apatinib|250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
75868662|NCT06171646|Behavioral|breathing exercise|The patients in the intervention group will first be informed by the researcher about pursed lips and diaphragmatic breathing exercises through a face-to-face interview technique, and then the breathing exercises will be taught practically to each patient for approximately 30 minutes, and the first session will be held. Each session takes place once a day in the morning, lasts 10-15 minutes and is applied every day; Sessions other than the first session will consist of 10 pursed lip breathing exercises, relaxation (2 minutes) and 10 diaphragmatic breathing exercises; Three days a week, the researcher will be reminded via online video call once a day in the morning, and on the other days, the patients will be reminded by phone call that they will be asked to do themselves, and breathing exercises will be performed for a total of four weeks.
75868663|NCT06171620|Device|Virtual reality headset|Distraction therapy using a virtual reality headset. Participants will access a digitally created environment such as a forest or sub sea exploration with relaxing auditory cues.
75384036|NCT00003151|Drug|clarithromycin|
75384037|NCT00003151|Drug|metronidazole hydrochloride|
75868664|NCT06171620|Other|Standard of care|Elective procedure performed as planned according to current standard of care in the hospital.
75868665|NCT06171607|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
75868666|NCT06171607|Drug|Perflutren Lipid Microspheres|Given IV
75868667|NCT06171607|Drug|Sulfur Hexafluoride Lipid Microspheres|Given IV
75868668|NCT06171594|Combination Product|Chlorhexidine mouthwash|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of Chlorhexidine (CHX) mouthwash on healthy control and people with dental erosion (PwDE). This study aims to explore mouthwash's effect on oral microbiome recovery in WMS and salivary pellicle and its impact on blood pressure and arterial stiffness in healthy controls PwDE
76031530|NCT05080855|Procedure|modified Millard technique vs Tennison-Randall technique|evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
76031531|NCT03140839|Behavioral|Imaginal Rescripting|A stand-alone single session intervention for social anxiety disorder
76031532|NCT03140839|Behavioral|Imaginal Exposure|A stand-alone single session intervention for social anxiety disorder
76031533|NCT03140839|Other|Supportive Counselling|Non-specific talk therapy focused on non-directive and empathic listening and on supporting patients' existing coping skills and strategies.
76031534|NCT03071705|Drug|Metformin|500 mg PO BID
76031535|NCT03071705|Drug|TKI|standard dose
76031536|NCT04995185|Radiation|(18)F-fluoromisonidazole (FMISO)|Patients do not need to be fasted prior to intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole. Scanning will be performed two hours after the injection. Patients will be scanned with their thermoplastic shell used in routine radiotherapy treatment for 10 minutes, followed by approximately 5 minutes scan of the upper chest.
76031537|NCT03351439|Drug|Zopiclone|Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
76031538|NCT03351439|Drug|Gabapentin|Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
76031539|NCT03351439|Drug|Celebrex|Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
75384038|NCT00003151|Drug|omeprazole|
75541677|NCT04549714|Procedure|High AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
75541678|NCT04549714|Procedure|Middle AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
76031540|NCT03351439|Drug|Percocet|Standard of Care
76031541|NCT03351439|Drug|Naprosyn|Standard of Care
75868669|NCT06171568|Other|Tests and questionnaires|"1 year after discharge from neurosurgery department, included patients will answer to the:~Modified Rankin Scale;~Instrumental Activities of Daily Living (IADL) questionnaire;~Montreal Cognitive Assessment (MoCA);~Frontal assessment battery (BREF);~Rivermead questionnaire;~Short Form (36) Health Survey (SF-36)~Community Integration Questionnaire - Revised (CIQ-R)~Posttraumatic stress disorder CheckList (PCL-5)"
75868670|NCT06171555|Device|CTM|decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act.
75384039|NCT00003151|Drug|tetracycline hydrochloride|
75384040|NCT00004045|Drug|exatecan mesylate|
75384041|NCT00003715|Biological|BCG vaccine|
75384042|NCT00003715|Biological|autologous tumor cell vaccine|
75384043|NCT00003715|Biological|recombinant interferon alfa|
75384044|NCT00003715|Drug|chemotherapy|
75384045|NCT00003715|Drug|cyclophosphamide|
75384046|NCT00004051|Drug|irinotecan hydrochloride|
76031542|NCT04990661|Behavioral|intradialytic massage|intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
75384047|NCT00003721|Drug|incyclinide|This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
75384048|NCT00003727|Biological|filgrastim|
75384049|NCT00003727|Biological|recombinant interferon alfa|
75384050|NCT00003727|Biological|sargramostim|
75384051|NCT00003727|Biological|therapeutic autologous lymphocytes|
75384052|NCT00003727|Drug|carmustine|
75868671|NCT06171555|Drug|Celestone|standard of care
75541679|NCT04549714|Procedure|Low AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
75541680|NCT04549909|Other|collect retrospectively data|Analyse the incidence of BPL in these populations
75705176|NCT06056843|Other|Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.|Women screened for breast cancer by clinical breast examination (CBE). Those with positive CBE will be triaged by portable ultrasound device by non-radiologists. All recruited women will receive a diagnostic mammography and, if necessary, an ultrasound performed by a radiologist. The radiologist will be blinded to the portable ultrasound device findings. Those with suspected lesions either on mammography or ultrasound will have fine needle aspiration cytology (FNAC) or core biopsy. The women with confirmed diagnosis of breast cancer will be staged and appropriately treated as per the policy of the hospital.
75705177|NCT06055530|Diagnostic Test|Artificial Intelligence Digital Pathology|School aged children will be asked to leave a stool sample. The samples will be prepared with the Kato-Katz method and scanned and processed by an artificial intelligence digital pathology system to determine the infection level of soil transmitted helminths and schistosomiasis. The samples will also be analyzed by a human microscopist for comparison.
75705178|NCT06055049|Other|Intervention (Kinesio Taping) group|It is the group to which Kinesio Taping applied.
75705179|NCT06054217|Drug|Vehicle of TP-03|The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
75705180|NCT06049927|Biological|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
75868672|NCT06171542|Device|CTM Injection|All glenohumeral joint injections will be performed by a physician under the guidance of either ultrasound or fluoroscopy to ensure and document intra-articular needle placement. 2cc of CTM Flow will be injected. The glenohumeral joint will be injected with the medication under the discretion of the treating surgeon.
75868673|NCT06171529|Device|CTM|CTM Flow is stored in 1cc vials and is stable at room temperature and does not need to be refrigerated. CTM Flow will be supplied to and stored at the IHTSC Beltway Surgery Center. Product will be stored at room temperature without continued temperature control. All product will be kept in the Beltway Surgery Center and will not be separated from the marketed non-study CTM. Treating Surgeons will remain blinded to the treatment group, but will ensure that only the injection is billed to patients and the CTM or saline are provided at no cost. Lexie Reissaus, CCRP will track drug accountability.
75868674|NCT06171529|Other|Placebo|placebo/Saline control injection
76031543|NCT03141385|Other|remote ischemic preconditioning|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
76031544|NCT03141385|Other|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
75384053|NCT00003727|Drug|cyclophosphamide|
75384054|NCT00003727|Drug|etoposide|
75384055|NCT00003727|Drug|gemcitabine hydrochloride|
75384056|NCT00003727|Drug|melphalan|
75384057|NCT00003727|Procedure|bone marrow ablation with stem cell support|
75384058|NCT00003727|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75384059|NCT00003157|Drug|cisplatin|
75384060|NCT00003157|Drug|gemcitabine hydrochloride|
75384061|NCT00003157|Radiation|radiation therapy|
75384062|NCT00384007|Procedure|Hydrodiscectomy with Spinejet|
75384063|NCT00004057|Drug|L-778,123|
75384064|NCT00004057|Drug|paclitaxel|
75384065|NCT00004063|Biological|recombinant interferon alfa|
75384066|NCT00004063|Drug|cisplatin|
75384067|NCT00004063|Drug|gemcitabine hydrochloride|
75384068|NCT00004063|Procedure|hyperthermia treatment|
75384069|NCT00003733|Drug|carboplatin|
75384070|NCT00003733|Drug|paclitaxel|
75384071|NCT00003733|Drug|topotecan hydrochloride|
75384072|NCT00003739|Biological|filgrastim|
75384073|NCT00004075|Drug|tanespimycin|
75384074|NCT00003745|Drug|topotecan hydrochloride|
75868675|NCT06171516|Behavioral|iCBT|All participants will undergo 10 guided therapy sessions (once-weekly) with each session lasting 20 minutes. The therapy module will be given as an online self-learning source via videos in a website specifically developed for this training. The videos will divide the module content into several parts with each video lasting about 10 minutes.
75868676|NCT06171490|Other|NP2-4mg|NP2-4 mg is a new product containing tobacco-derived nicotine.
75541681|NCT04549675|Behavioral|Sun Safe Partners Online|Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
75541682|NCT04549675|Behavioral|Generic Online Sun Safety Information intervention|4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
75868677|NCT06171490|Other|NP2-6 mg|NP2-6 mg is a new product containing tobacco-derived nicotine.
75868678|NCT06171490|Other|Loz-4mg|The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
76031545|NCT03139747|Drug|Lenvatinib|Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
75384075|NCT00003163|Biological|filgrastim|
75384076|NCT00003163|Biological|sargramostim|
75384077|NCT00003163|Drug|cyclophosphamide|
75384078|NCT00003163|Drug|melphalan|
76031546|NCT03139747|Drug|Everolimus|It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
75384079|NCT00003163|Procedure|autologous bone marrow transplantation|
75384080|NCT00003163|Procedure|peripheral blood stem cell transplantation|
75384081|NCT00003163|Radiation|radiation therapy|
75384082|NCT00004081|Drug|docetaxel|
75384083|NCT00003751|Drug|penicillamine|
75384084|NCT00003751|Radiation|radiation therapy|
75384085|NCT04097119|Dietary Supplement|Dietary supplementation|Subjects receive a specific dietary supplementation designed to support HDL function daily for 12 weeks
75384086|NCT00004087|Biological|filgrastim|as prescribed by physician
75384087|NCT00004087|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
75384088|NCT00004087|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
75384089|NCT00004087|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
75384090|NCT00004087|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
75384091|NCT00003757|Biological|rituximab|
75384092|NCT00003175|Drug|fluorouracil|
75384093|NCT00004099|Drug|cisplatin|
75384094|NCT00004099|Drug|fluorouracil|
75384095|NCT00004099|Drug|leucovorin calcium|
75384096|NCT00004099|Procedure|neoadjuvant therapy|
75384097|NCT00003763|Procedure|radionuclide imaging|
75384098|NCT00003763|Radiation|indium In 111 folic acid|
75384099|NCT04712695|Other|Exercise Based Interventions|Proprioception Training Interventions
75384100|NCT00003181|Biological|aldesleukin|
75384101|NCT00003181|Biological|sargramostim|
75541683|NCT04549948|Procedure|0.017X0.025 Stainless steel|Leveling curve of Sppe using 0.017X0.025 SS archwire
75541684|NCT04549948|Procedure|0.019X0.025 Stainless steel|Leveling curve of Sppe using 0.019X0.025 Stainless steel archwire
75541685|NCT04549948|Procedure|0.021X0.025 B-Titanium archwire|Leveling curve of Sppe using 0.019X0.025 B-Titanium archwire
75541686|NCT00268359|Biological|bevacizumab|
75541687|NCT00268359|Drug|irinotecan hydrochloride|
75541688|NCT00235274|Drug|Subcutaneous Secretin|
75541689|NCT04549987|Device|Space closure without changing working archwire monthly|Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
75868679|NCT06171490|Other|Gum-4mg|The Gum-4mg reference product is a commercially available 4mg nicotine gum.
75868680|NCT06171477|Device|Ventilation 20-40-60|The respiratory rate during mechanical ventilation will be altered from 20 to 40 and finally to 60 breaths per minute.
76031547|NCT04433429|Dietary Supplement|Liposcudil Plus|
76031548|NCT02037919|Other|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
75705181|NCT06049927|Biological|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
75705182|NCT06049927|Biological|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.
75705183|NCT06049927|Biological|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.
75868681|NCT06171477|Device|Ventilation 60-40-20|The respiratory rate during mechanical ventilation will be altered from 60 to 40 and finally to 20 breaths per minute.
76031549|NCT02037919|Other|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
76031550|NCT04990583|Behavioral|Face-to-Face PrEP Adherence Intervention Based on LifeSteps|This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.
76031551|NCT04990583|Behavioral|Adherence Coaching Facilitated by Carium Adherence App|The Carium app will be used to deliver medication reminders to participants, track medication adherence, engage in two-way secure messaging with participants, and connect with participants through a secure video feature. The adherence coach will use the secure messaging feature to support the participant with their adherence
76031552|NCT04990271|Drug|Conbercept ophthalmic injection|Monthly injection of Conbercept from 0~5 months
76031553|NCT04911049|Diagnostic Test|Blood Pressure measurement|Blood Pressure measurement
76031554|NCT04990193|Other|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.
76031555|NCT04990193|Other|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was applied for eight hours every day for twelve consecutive weeks.
76031556|NCT03141541|Behavioral|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
76031557|NCT03071315|Other|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
75541690|NCT04549987|Device|Space closure withchanging working archwire monthly|Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
75705184|NCT06047951|Procedure|Stereotactic RadioSurgery (SRS)|"All treatments will be performed using the Gamma Knife Perfexion or Icon system (Elekta). The following treatment parameters will be used:~The head will be immobilized using a stereotactic Leksell Model G frame, installed using local protocols~Targeting will be performed by using a stereotactic CTA. No MRI will be performed.~Only one aneurysm will be treated per patient~The aneurysm, including its neck, will be contoured and targeted using a combination of 4mm isocenters as deemed appropriate by the treating team~A prescription dose of 25 Gy at the margin of the target will be used~The maximal dose on optic pathways will be kept below 10 Gy~The brainstem 12-Gy volume will be kept below 1cc"
75705185|NCT06033820|Drug|ZR2-ICE|"Drug: zanubrutinib Oral Capsule~Drug: lenalidomide Oral Capsule~Drug: R-ICE chemotherapy"
75868682|NCT06171477|Device|Ventilation 40-60-20|The respiratory rate during mechanical ventilation will be altered from 40 to 60 and finally to 20 breaths per minute.
75868683|NCT06171451|Diagnostic Test|PET with 11C-Fe-CIT|Use of the PET11C-Fe_CIT method for the early diagnosis of Parkinson's and in the differential diagnosis between Parkinson's and parkinsonism.
75868684|NCT06171438|Diagnostic Test|Urine Biomarkers|Biomarkers of kidney damage in donors, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), beta2-microglobulin, alpha1-microglobulin, alpha2-macroglobulin and transferrin will be measured by ELISA.
76031558|NCT03071315|Other|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
75384102|NCT00003181|Drug|vinblastine sulfate|
75384103|NCT00004105|Drug|estramustine phosphate sodium|
75868685|NCT06171438|Diagnostic Test|Gene expression profiling of donor kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
75868686|NCT06171438|Diagnostic Test|Gene expression profiling of recipient kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
75868687|NCT06171412|Behavioral|Glu-COACH|peer-mentoring support from a peer of the same cultural identity and access to a private social media group for all Black and Latinx teens
75868688|NCT06171412|Behavioral|Enhanced standard-of-care (ESOC)|This group will receive ESOC including additional training and support on CGM beyond routine clinical practice.
75868689|NCT06171347|Other|Oral cold spray (tap water)|Oral cold spray (tap water)
75868690|NCT06171334|Device|Remote ischemic conditioning|The intervention consists in Remote Ischemic conditioning (RIC), one session of 40-minutes duration per day for 12 months. The procedure will be performed by using an electric auto-control device by SnapDx Inc (Calgary, Canada) with a blood pressure cuff that inflates up to a pressure of 200 mmHg during the ischemic period. Participant will self-administer the RIC procedure at their home. The device records and documents each RIC cycle.
75384104|NCT00004105|Drug|paclitaxel|
75384105|NCT00004105|Drug|vinorelbine ditartrate|
75868691|NCT06171321|Drug|S-1(Intravenous combined with oral)|Oral combined with intravenous S-1 for ctDNA-positive patients (escalating treatment strategy)
75868692|NCT06171308|Device|Traditional Chinese moxibustion apparatus|"The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks."
75868693|NCT06171295|Diagnostic Test|Blood draw|The blood draws in specified time points
75384106|NCT00003187|Biological|filgrastim|
75384107|NCT00003187|Drug|cyclophosphamide|
75384108|NCT00003187|Drug|cyclosporine|
75384109|NCT00003187|Drug|cytarabine|
75384110|NCT00003187|Drug|methotrexate|
75384111|NCT00003187|Drug|methylprednisolone|
75384112|NCT00003187|Procedure|allogeneic bone marrow transplantation|
75868694|NCT06171282|Drug|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
75868695|NCT06171243|Drug|Lidocaine topical|"Patients who agree to participate, will be given the Lidocaine 23%/Tetracaine 7% formulation. The application of the cream will be carried out by a researcher in charge:~A skin area of 200 cm2 will be delimited for the application of the formulation throughout the study period.~10 grams will be applied every 12 hours for a period of 48 hours."
75868696|NCT06171230|Other|Eye Movement Desensitization and Reprocessing|Using the LEC and PCL-5, emotionally charged images are selected at the onset of the EMDR intervention. Initially, events meeting the criteria for PTSD (A-criterion worthy events) are processed. Subsequently, pain-related experiences, including any distressing images, are addressed. If the emotional charge of the events diminishes (SUD=0) before the completion of the six EMDR sessions, the participant is categorized as an 'early completer,' and the post-assessment is conducted immediately. The duration of each EMDR session is 90 minutes.
75384113|NCT00003187|Procedure|in vitro-treated bone marrow transplantation|
75384114|NCT00003187|Radiation|radiation therapy|
75384115|NCT00003769|Drug|perillyl alcohol|
75384116|NCT00003769|Procedure|surgical procedure|
75384117|NCT00003775|Drug|leflunomide|
75384118|NCT00004123|Drug|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
75384119|NCT00004123|Procedure|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
75384120|NCT00004123|Radiation|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
75384121|NCT00004123|Radiation|Radiation Therapy (RT)|5 days a week for 4 weeks
75384122|NCT00003781|Drug|docetaxel|
75384123|NCT00003781|Procedure|pain therapy|
75384124|NCT00003781|Procedure|quality-of-life assessment|
75384125|NCT00003787|Behavioral|educational/counseling intervention|
75868697|NCT06171230|Other|Attention control phase|Prior to EMDR, there is a two-week attention control phase. During this phase, the participant is asked to daily record their activities, emotions, and thoughts when experiencing pain. This information is further explored and evaluated in two sessions lasting 45 minutes each, involving in-depth discussions with the participant.
75868698|NCT06171217|Drug|Hydroxyurea|Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression
75868699|NCT06171217|Drug|Hydroxyurea|Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
75868700|NCT06171204|Procedure|Injection of SVF in fat pad of the knee|Knee fat pad injection with SVF at orthopaedics/physical medicine outpatient clinic
75868701|NCT06171165|Diagnostic Test|Yale Swallow Protocol|"All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status."
75384126|NCT00003787|Behavioral|therapeutic dietary intervention|
75384127|NCT00003193|Drug|amifostine trihydrate|
75384128|NCT00003193|Drug|paclitaxel|
75384129|NCT00003193|Procedure|conventional surgery|
75384130|NCT00003193|Radiation|radiation therapy|
75384131|NCT00004129|Radiation|brachytherapy|
75384132|NCT00004129|Radiation|phosphorus P32|
75384133|NCT00003793|Genetic|clonality analysis|
75384134|NCT00003793|Genetic|microsatellite instability analysis|
75384135|NCT00003793|Genetic|mutation analysis|
75384136|NCT00384787|Biological|VRC-HIVDNA009-00-VP|HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
75384137|NCT00384787|Biological|VRC-HIVADV014-00-VP|Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
75384138|NCT00004135|Biological|filgrastim|
75384139|NCT00004135|Biological|therapeutic allogeneic lymphocytes|
75384140|NCT00004135|Drug|cyclophosphamide|
75384141|NCT00004135|Drug|fludarabine phosphate|
75384142|NCT00004135|Procedure|peripheral blood stem cell transplantation|
75868702|NCT06171139|Other|Counseling Tool|Non-therapeutic educational intervention
75868703|NCT06171139|Other|Questionnaires|Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.
75868704|NCT06171126|Dietary Supplement|Faeces|Faeces from donor selected based on European guidelines, compared to own faeces (placebo)
75868705|NCT06171113|Drug|GSK4024484C|Doses administrated orally with 240 mL of water.
75868706|NCT06171113|Drug|Placebo|Doses administrated orally with 240 mL of water.
75868707|NCT06171100|Drug|Tolvaptan|"Oral ingestion of low dose Tolvaptan (7.5mg daily) for management of inpatient hyponatraemia for 1st dose Tolvaptan group.~Oral ingestion of low dose Tolvaptan (7.5mg daily) or standard dose Tolvaptan (15mg daily) for 2nd dose Tolvaptan group."
75868708|NCT06171087|Drug|Domperidon|oral
75868709|NCT06171087|Drug|Placebo|oral tablet
75868710|NCT06171074|Biological|CM310|CM310 injection
75868711|NCT06171061|Drug|Yangxinshi tablet|In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
75868712|NCT06171061|Other|Basic medication|The control group will be given basic medication only. The treatment period is 24 weeks.
75868713|NCT06171048|Biological|CM310|CM310 injection
75384143|NCT00384943|Behavioral|Moderate-intensity Exercise|
75384144|NCT00004141|Drug|Cisplatin|
75541691|NCT04549636|Other|V/Q SPECT-CT|At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
75541692|NCT04549636|Other|St. George's Respiratory Questionnaire (SGRQ)|At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
75384145|NCT00004141|Drug|dacarbazine|
75705186|NCT06027905|Other|E3 Remote Monitoring and Social Intervention|Patients are enrolled in a 12 week remote blood pressure monitoring program composed of a community health worker, nurse, pharmacist and social worker. Participants will receive a home cellular blood pressure cuff for remote monitoring and will receive tele-health calls from their community health worker to assist with blood pressure taking technique and adherence, medication adherence, education around diet and activity. Social work is available to provide institutional and community resources to patients with social needs. Patients will be screened pre intervention and post intervention for medication adherence and social determinants of health needs. The team nurse monitors and triages home blood pressures on the remote portal. The pharmacist assists with medication reconciliation, adherence, and titration of medications according to standards or care.
75705187|NCT06019325|Procedure|RIB|After endotracheal intubation, patients will be positioned in lateral decubitus position. A RIB will be performed at the level of T5-T6 by ultrasound guidance. A single shot block will be performed by injecting 30 ml of 0.25% bupivacaine to the interfacial plane between rhomboid major muscle and intercostal muscle.
75705188|NCT06018467|Drug|Dasatinib 100 Mg Oral Tablet|"Dasatinib tablets in blister packs of 10 tablets, from either: Sandoz, STADA Nordic, Zentiva or Bristol-Myers Squibb"
75705189|NCT06018467|Dietary Supplement|Quercetin 1.250 mg (oral)|five 200mg Quercetin Phytosome capsules, from Thorne
75705190|NCT06018467|Dietary Supplement|Nicotinamide Riboside 1g (oral)|four 250mg Nicotinamide Riboside Capsules, from Elysium Health
75705191|NCT06018311|Behavioral|Exercising together|The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
75705192|NCT06010836|Behavioral|Script guided conversation|Patients getting script guided intervention of 3 domains in the preoperative period
75868714|NCT06171022|Other|Cherry seed pillow|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of heated cherry seed pillow will be applied to the participant's back area.
75868715|NCT06171022|Other|Control|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of hotpack will be applied to the participant's back area.
75384146|NCT00004141|Drug|Granulocyte-macrophage colony-stimulating factor|
75384147|NCT02972905|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
75384148|NCT02972905|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose
75384149|NCT00004147|Drug|incyclinide|
75541693|NCT04549636|Other|mMRC (Modified Medical Research Council) Dyspnea Scale|At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
75541694|NCT04549636|Other|Six-minute walk test (6MWT)|At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
75541695|NCT04549636|Other|Spirometry|At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
75541696|NCT04549636|Other|Plethysmography & DLCO|At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
75384150|NCT00003799|Drug|fluorouracil|Given IV
75384151|NCT00003799|Drug|oxaliplatin|Given IV
75384152|NCT00003799|Radiation|radiation therapy|Undergo radiotherapy
75384153|NCT00003799|Drug|leucovorin calcium|Given IV
75384154|NCT00003799|Procedure|therapeutic conventional surgery|Undergo surgery
75384155|NCT00003205|Drug|bryostatin 1|
75384156|NCT00004153|Genetic|reverse transcriptase-polymerase chain reaction|
75384157|NCT00004153|Procedure|sentinel lymph node biopsy|
75384158|NCT00003211|Biological|filgrastim|
76031559|NCT02888821|Behavioral|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
75541697|NCT04549636|Other|Airwave Oscillometry|At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
75541698|NCT04549441|Procedure|Distal radius fracture plating surgery|We performed open reduction and plating surgery for the distal radius fracture.
75384159|NCT00003211|Drug|amifostine trihydrate|
75384160|NCT00003211|Drug|cisplatin|
75384161|NCT00003211|Drug|cyclophosphamide|
75868716|NCT06171009|Behavioral|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
76031560|NCT03073655|Other|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
75868717|NCT06171009|Behavioral|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
75868718|NCT06170996|Behavioral|Internet-Assisted behavioral parent training (IA-BPT)|Internet-Assisted behavioral parent training in group format, 8 sessions over 2 months, delivered by systematically trained and supervised psychologists.
75384162|NCT00003211|Drug|vincristine sulfate|
75384163|NCT00003211|Procedure|peripheral blood stem cell transplantation|
75384164|NCT00003211|Radiation|radiation therapy|
76031561|NCT03073655|Other|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
76031562|NCT03073655|Other|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
75868719|NCT06170983|Drug|Azithromycin|500 mg once daily for 3 days
75868720|NCT06170983|Diagnostic Test|Biopsy|Skin punch biopsy
75384165|NCT00003805|Drug|piperacillin sodium|
75384166|NCT00003805|Drug|piperacillin-tazobactam|
75384167|NCT00003805|Drug|tazobactam sodium|
75384168|NCT00003805|Drug|vancomycin|
75384169|NCT00004159|Drug|gemcitabine hydrochloride|
75384170|NCT00004159|Drug|paclitaxel|
75384171|NCT00003811|Biological|bleomycin sulfate|
75384172|NCT00003811|Drug|amifostine trihydrate|
75384173|NCT00003811|Drug|cisplatin|
75384174|NCT00003811|Drug|etoposide|
75384175|NCT00003811|Procedure|conventional surgery|
75384176|NCT00004177|Biological|filgrastim|as prescribed by physician
75384177|NCT00004177|Procedure|peripheral blood stem cell transplantation|1-2 weeks from treatment
75384178|NCT00004177|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
75384179|NCT00004177|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
75384180|NCT00003817|Drug|dolasetron mesylate|
75384181|NCT00003817|Drug|granisetron hydrochloride|
75384182|NCT00003817|Drug|ondansetron|
75384183|NCT00003817|Drug|tropisetron|
76031563|NCT04770805|Procedure|Fetoscopy|After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
76031564|NCT03139591|Drug|lidocaine inhalation; intravenous dexamethasone|1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
75384184|NCT00003817|Procedure|quality-of-life assessment|
75541699|NCT00268398|Drug|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1&2) continuous 5FU 600mg/m² (day 1 to 2)
75705193|NCT05997368|Other|Survey1|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
75705194|NCT05997368|Other|Survey2|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
75705195|NCT05997368|Other|Survey3|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
75705196|NCT05992896|Drug|Bupivacaine liposome|Injection into pelvic area and into the edges of wound at the end of the procedure.
75705197|NCT05992896|Drug|Placebo|Looks exactly like the study drug, but contains no active ingredients. Injection into pelvic area and into the edges of wound at the end of the procedure .
75705198|NCT05953207|Other|Medical hypnosis|Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
75705199|NCT05953207|Other|Standard Of Care|Sleep hygiene and safety education session
75705200|NCT05937386|Drug|AGMB-129|Oral capsule
75705201|NCT05937386|Drug|MDZ|Pre-filled oral syringes
75705202|NCT05922865|Device|KNEESUP smart knee assistive device + KNEESUP care APP|In KNEESUP smart knee assistive device + KNEESUP care APP group, participants used the KNEESUP intelligent knee assistive device. Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation.
75384185|NCT00003829|Drug|cyclophosphamide|
75384186|NCT00003829|Drug|fludarabine phosphate|
75384187|NCT04329403|Drug|Adapalene 0.1% Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
75384188|NCT04329403|Drug|Differin 0.1% Topical Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
75384189|NCT04329403|Other|Placebo|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
75384190|NCT00003217|Biological|filgrastim|
75384191|NCT00003217|Drug|cyclophosphamide|
75541700|NCT00268398|Drug|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
75868721|NCT06170983|Other|Skin inflammation model|LPS- or imiquimod induced skin inflammation
75384192|NCT00003217|Drug|cytarabine|
75384193|NCT00003217|Drug|dexamethasone|
75541701|NCT00235313|Procedure|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
75705203|NCT05922865|Device|KNEESUP care APP|In KNEESUP care APP group, the participants only used the KNEESUP care APP which was installed in the mobile phone. The APP was designed with an individualized exercise program. Participants could follow the APP to do the exercise program according to their own conditions.
75705204|NCT05922865|Behavioral|Healthy consulation|In Healthy consulation group, participants received routine outpatient health education.
75705205|NCT05920798|Procedure|Biopsy|Undergo biopsy
75705206|NCT05920798|Procedure|Biospecimen Collection|Undergo blood sample collection
75705207|NCT05920798|Procedure|Computed Tomography|Undergo CT
75705208|NCT05920798|Procedure|Magnetic Resonance Imaging|Undergo MRI
75384194|NCT00003217|Drug|doxorubicin hydrochloride|
75384195|NCT00003217|Drug|methotrexate|
75384196|NCT00003217|Drug|vincristine sulfate|
75384197|NCT00004183|Drug|capecitabine|
75705209|NCT05920798|Biological|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
75705210|NCT05920798|Biological|Pembrolizumab|Given IV
75705211|NCT05920798|Procedure|Pheresis|Undergo apheresis
75705212|NCT05919082|Drug|LEO 90100|Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
75705213|NCT05919082|Drug|Daivobet® ointment|Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
75705214|NCT05914311|Device|Suture|secures SCS trial leads with a suture
75705215|NCT05914311|Device|Dermabond|secures SCS trial leads with dermabond
75705216|NCT05907980|Drug|ROSE12|ROSE12 as a IV infusion
75705217|NCT05907980|Drug|Atezolizumab|Atezolizumab as a IV infusion
75868722|NCT06170970|Drug|Solriamfetol|solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)
75868723|NCT06170970|Drug|Placebo|Four weeks of oral placebo
76031565|NCT03071237|Procedure|Gastrectomy|Patients with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
76031566|NCT02553967|Device|Functional MRI|Functional MRI
75384198|NCT00003223|Drug|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
75384199|NCT00004189|Biological|filgrastim|
75384200|NCT00004189|Drug|becatecarin|
75384201|NCT00004189|Drug|cisplatin|
75384202|NCT00003229|Biological|aldesleukin|
75384203|NCT00003229|Biological|gp100 antigen|
75384204|NCT00003229|Biological|tyrosinase peptide|
75384205|NCT00003835|Drug|leucovorin calcium|Given IV
75384206|NCT00003835|Drug|fluorouracil|Given IV
75384207|NCT00003835|Drug|irinotecan hydrochloride|Given IV
75384208|NCT00003835|Other|laboratory biomarker analysis|Correlative studies
75384209|NCT00003847|Drug|biricodar dicitrate|
75384210|NCT00003847|Drug|doxorubicin hydrochloride|
75384211|NCT00003847|Drug|vincristine sulfate|
75384212|NCT00004195|Drug|eniluracil|Will be given to either subject pre-operative and metastatic disease
75384213|NCT00004195|Procedure|conventional colon surgery|Only if the subject is amenable to surgical resections
75384214|NCT00003853|Drug|4'-iodo-4'-deoxydoxorubicin|
76031567|NCT04990115|Other|root canal shaping|root canal treatment
75705218|NCT05906615|Drug|Lidocaine IV|Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.
75705219|NCT05901493|Behavioral|Perceptual category training|Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories
75705220|NCT05889013|Device|Nasal Nitric Oxide testing|Collection of already performed clinical data and nNO testing
76031568|NCT04756375|Device|Virtual Reality|Use of virtual reality in the management of sickle cell patients with VOS
75705221|NCT05884853|Behavioral|PEERS|The Program for the Education and Enrichment of Relational Skills (PEERS®) studies is an evidence-based 16-week group-based social skill training program developed for adolescents and young adults with ASD.
75705222|NCT05880355|Drug|Dapansutrile|Oral inhibitor of NLRP3
75868724|NCT06170957|Other|Modified pacifier|"In this project, a pacifier produced from a modified pacifier shield made of polypropylene (PP), a biocompatible polymer, which is made suitable for intubation tube in newborns connected to mechanical ventilator, will be used in the light of literature information. No study on the modification of the pacifier shield has been found in the literature, and a utility model application (file number 2020/03477 dated 06 March 2020) was made for this pacifier shield, which is planned to be modified, and the utility model application was accepted on 04.02.2022.~In the application of heel blood collection to newborns, a) before the procedure (20 minutes before), b) immediately before the procedure (20. minutes), c) during the procedure (between the 20th and 40th minutes), and d) 20 minutes after the procedure (40 minutes) will be evaluated once for each application, a total of four times."
75868725|NCT06170944|Device|Remote ischemic preconditioning|The patients in experiment group will receive treatment with RIC (5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg) for 1 year as an adjunct to guideline-based treatment.
75868726|NCT06170931|Procedure|posterior cruciate ligament-retaining prostheses|Posterior cruciate ligament protective approach in patients with knee osteoarthritis
75868727|NCT06170931|Procedure|posterior cruciate ligament-substituting prostheses|Posterior cruciate ligament transection approach in patients with knee osteoarthritis
76031569|NCT04756375|Other|Usual Care|Usual management of sickle cell patients with VOS
76031570|NCT04987619|Dietary Supplement|Beetroot juice|Subjects will drink juice 120 minutes before each visit
76031571|NCT04987619|Other|Capri-Sun|70 mL of blackcurrant beverage, which is depleted of NO3- will be taken 120 min before each visit.
76031572|NCT03139357|Other|GAD7, SF12, medical utilization, helpfulness questionnaire|The questionnaires are administered to track stress level and medical utilization over a 2 year period.
76031573|NCT03140917|Diagnostic Test|Multimodal liver function assessment|HBS, MRI, CE-CT and ICG
76031574|NCT04469101|Procedure|Lumbar Epidural|Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
76031575|NCT04987853|Diagnostic Test|Clinical and functional analysis|"General blood analysis - Complete blood count on an analyzer with differentiation of 5 classes of cells, the ratio of neutrophils to lymphocytes; Blood chemistry - ALT, AST, total bilirubin, direct, LDH, CRP, alpha-amylase, creatinine, urea, glucose, ferritin, glycosylated hemoglobin, vitamin 25 - OH vitamin D, vitamin B12; Coagulogram - D-dimers, fibrinogen, INR, APTT; Other - NT-pro BNP, Homocysteine, IL 6, Troponin, blood group determination; Linked immunosorbent assay - Determination of IgG and IgM antibodies to SARS-CoV-2 coronavirus (COVID-19) in blood serum, RBD; Functional diagnostics • ECG~EchoCG + strain~CT scan of the lungs~Holter~SMAD~Kidney ultrasound~Ultrasound~Doppler ultrasonography of veins and arteries~Chalder Scale, EQ Questionnaire"
75541702|NCT00235313|Drug|nicotine patch|normal following with a nicotine patch
75705223|NCT05880355|Other|Placebo|Non-active placebo
75705224|NCT05879367|Drug|Eflornithine (Dose Level 1)|Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
76031576|NCT04987853|Diagnostic Test|Neurological analysis|"Neurological examination with the isolation of neurological syndromes (motor, cognitive impairments, sleep disorders, asthenic-depressive syndromes, etc.).~2. Neuropsychological methods - research on the scales of anxiety and depression, MMSE, etc.~3. Instrumental method - EEG, polysonography, ultrasound of the neck vessels, CT perfusion.~4. Laboratory research methods:~The study of antibodies to some neurospecific antigens - myelin basic protein (MBP), neurospecific enolase (NSE).~Study of cellular immunity (CD3 +, CD4 +, CD8 +) and general indicators of humoral immunity (IgG, IgA, IgM, circulating immune complexes)."
75384215|NCT00385021|Drug|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
75868728|NCT06170918|Drug|Remimazolam|remimazolam is given intravenously
75705225|NCT05879367|Drug|Eflornithine (Dose Level 2)|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
75705226|NCT05879367|Drug|Eflornithine (Dose Level -1)|Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
75868729|NCT06170892|Other|Kangaroo method|The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
75868730|NCT06170866|Behavioral|Socially supported physical activity|Use of a culturally and linguistically tailored intervention that uses mobile health technology plus social support to increase engagement in physical activity in the management of Parkinson´s disease.
75868731|NCT06170853|Other|Exercise with augmented reality glasses|Three days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
75868732|NCT06170827|Drug|AIO-001|AIO-001 Solution for SC injection.
75384216|NCT00004201|Drug|carboplatin|
75384217|NCT00004201|Drug|cisplatin|
75384218|NCT00004201|Drug|gemcitabine hydrochloride|
75384219|NCT00003241|Drug|phenylacetate|
75384220|NCT00003859|Drug|carboplatin|
75384221|NCT00003859|Drug|cyclophosphamide|
75384222|NCT00003859|Drug|etoposide|
75384223|NCT00003859|Drug|vincristine sulfate|
75384224|NCT00003859|Procedure|surgical procedure|
75384225|NCT00003859|Radiation|radiation therapy|
75384226|NCT00003865|Drug|toremifene|
75384227|NCT00004207|Drug|liposomal daunorubicin citrate|
75384228|NCT00004213|Drug|triapine|
75384229|NCT00004219|Drug|granisetron hydrochloride|
75384230|NCT00004219|Drug|lerisetron|
75384231|NCT00004219|Radiation|radiation therapy|
75705227|NCT05879367|Drug|Temozolomide|Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
75384232|NCT00003877|Biological|filgrastim|
75384233|NCT00003877|Drug|carboplatin|
75384234|NCT00003877|Drug|cyclophosphamide|
75384235|NCT00003877|Drug|paclitaxel|
75384236|NCT00003877|Drug|thiotepa|
75384237|NCT00003877|Procedure|in vitro-treated bone marrow transplantation|
75384238|NCT00003877|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75384239|NCT00003883|Drug|fluconazole|
75705228|NCT05863507|Dietary Supplement|Grape powder supplementation|The participants will be willing to consume the grape powder dissolve in water daily for 6 weeks
75705229|NCT05863507|Dietary Supplement|Placebo|The participants will be willing to consume the placebo powder, similar to the grape powder, dissolve in water daily for 6 weeks
75705230|NCT05853367|Drug|MK-0472|Oral Administration
75705231|NCT05853367|Biological|Pembrolizumab|IV infusion
75384240|NCT00003883|Drug|itraconazole|
75384241|NCT00003253|Drug|paclitaxel|
75705232|NCT05849493|Behavioral|Metacognitive Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
75705233|NCT05849493|Behavioral|Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
75705234|NCT05847439|Drug|[14C]BMS-986419|Specified dose on specified days
75384242|NCT00003253|Other|antitumor drug screening assay|
75384243|NCT00004225|Biological|Ad5CMV-p53 gene|
75384244|NCT00004225|Radiation|radiation therapy|
75384245|NCT00004237|Drug|cyclophosphamide|
75384246|NCT00004237|Drug|doxorubicin hydrochloride|
75384247|NCT00004237|Drug|epirubicin hydrochloride|
75384248|NCT00004237|Drug|mitoxantrone hydrochloride|
75384249|NCT00004237|Drug|vinorelbine tartrate|
75384250|NCT00004237|Procedure|conventional surgery|
75384251|NCT00004237|Radiation|radiation therapy|
75384252|NCT00003259|Drug|vinorelbine tartrate|
75384253|NCT00003913|Biological|anti-thymocyte globulin|
75384254|NCT00003913|Biological|filgrastim|
75384255|NCT00003913|Drug|busulfan|
75384256|NCT00003913|Drug|cyclophosphamide|
75384257|NCT00003913|Drug|methylprednisolone|
75384258|NCT00003913|Procedure|umbilical cord blood transplantation|
75384259|NCT00003913|Radiation|radiation therapy|
75384260|NCT00004243|Drug|docetaxel|
75384261|NCT00004243|Drug|oxaliplatin|
75384262|NCT00004249|Biological|QS21|
75384263|NCT00004249|Biological|keyhole limpet hemocyanin|
75384264|NCT00004249|Drug|polysialic acid|
75384265|NCT00003925|Drug|gemcitabine hydrochloride|
75384266|NCT00003925|Drug|leucovorin calcium|
75384267|NCT00003925|Drug|tegafur-uracil|
75384268|NCT00004255|Biological|anti-thymocyte globulin|
75384269|NCT00004255|Biological|filgrastim|
75384270|NCT00004255|Drug|cyclophosphamide|
75384271|NCT00004255|Drug|fludarabine phosphate|
75384272|NCT00004255|Drug|methylprednisolone|
75705235|NCT05846022|Other|Dry Needling|This dry needling study involves bilaterally insertion of a fine sterile needle into upper trapezius muscle fibers using a clean needling technique.
75384273|NCT00004255|Drug|tacrolimus|
75384274|NCT00004255|Procedure|allogeneic bone marrow transplantation|
75384275|NCT00004255|Procedure|in vitro-treated bone marrow transplantation|
75384276|NCT00004255|Radiation|radiation therapy|
75384277|NCT00003931|Genetic|reverse transcriptase-polymerase chain reaction|
75705236|NCT05846022|Other|Sham Needle|"Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube."
75868733|NCT06170814|Other|Exercise|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. One group will be given external focus stimuli, the other group will be given internal focus stimuli.
75384278|NCT00004261|Drug|EF5|
75384279|NCT00004261|Other|flow cytometry|
75384280|NCT00004261|Other|fluorescent antibody technique|
75384281|NCT00004261|Other|immunohistochemistry staining method|
75384282|NCT00004261|Procedure|biopsy|
75384283|NCT00004831|Drug|cysteine hydrochloride|
75384284|NCT00004285|Device|Standard dose, low flux hemodialysis|
75384285|NCT00004285|Device|Standard dose, high flux hemodialysis|
75384286|NCT00004285|Device|High dose, low flux hemodialysis|
75384287|NCT00004285|Device|High dose, high flux hemodialysis|
75384288|NCT00004843|Procedure|parathyroidectomy|Standard parathyroidectomy with a bilateral approach
75384289|NCT00004843|Other|Observation|Usual care
75384290|NCT00004297|Drug|diazepam|
75384291|NCT00004297|Drug|lorazepam|
75384292|NCT00004855|Drug|Lopinavir/Ritonavir|
75384293|NCT00004855|Drug|Abacavir sulfate|
75384294|NCT00004855|Drug|Nevirapine|
75384295|NCT00004855|Drug|Lamivudine|
75384296|NCT00004855|Drug|Stavudine|
75384297|NCT00003289|Drug|7-hydroxystaurosporine|
75384298|NCT00004861|Drug|gemcitabine hydrochloride|
75384299|NCT00004861|Drug|tacedinaline|
75384300|NCT00004315|Drug|ursodiol|
75384301|NCT04074343|Drug|TAS-102|Given PO
75384302|NCT04074343|Drug|Irinotecan|Given IV
75384303|NCT00003301|Drug|irinotecan hydrochloride|
75384304|NCT00003307|Drug|amifostine trihydrate|
75384305|NCT00003307|Radiation|radiation therapy|
75384306|NCT00004327|Drug|octreotide|
75384307|NCT00003313|Biological|filgrastim|
75384308|NCT00003313|Drug|amifostine trihydrate|
75384309|NCT00003313|Drug|carboplatin|
75384310|NCT00003313|Drug|paclitaxel|
76031577|NCT04987853|Diagnostic Test|Immunological analysis:|A comprehensive immunological analysis will be carried out to determine the level of the immune response. Calculation of the level of CD4 +, CD8 + and NK cells. The level of antibodies of the IgG and IgM classes to the proteins of the coronavirus S1, RBD and N was determined
75384311|NCT00003313|Radiation|radiation therapy|
75705237|NCT05825092|Drug|Androgel Topical Product|AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
76031578|NCT04987853|Diagnostic Test|Genetic analysis:|Isolation (extraction) of DNA will be performed from whole blood using commercial kits according to the manufacturer's instructions. To analyze a large number of genetic markers, it is planned to carry out genome-wide sequencing followed by analysis of genetic polymorphisms of candidate genes encoding coronavirus receptors and immunological factors.
75384312|NCT00004867|Procedure|conventional surgery|
75705238|NCT05825092|Drug|Placebo|Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
75705239|NCT05825092|Diagnostic Test|Physical performance|"Physical performance at 3, 6 months and 1 year after ICU admission~6 minute walk distance 3 months after ICU admission, at 6 months and at 1 year Percentage of patients with Short Physical Performance Battery < 10 at 3, 6 months and 1 year Physical component of SF 36 (Medical Outcomes Study 36 Item Short Form Health Survey) at 3, 6 months and 1 year"
75705240|NCT05825092|Diagnostic Test|Muscle strength|"Muscle strength at ICU discharge at 3, 6 months and 1 year after ICU admission~Handgrip: Kg and percent of the predicted force Medical Research Council testing (MRC)"
75705241|NCT05825092|Diagnostic Test|Muscular mass|"Muscular mass at 3, 6 months and 1 year after ICU admission~Mid-arm muscle circumference (MAMC)"
75705242|NCT05825092|Diagnostic Test|Test: Functional status|"Functional status at 3, 6 months and 1 year after ICU admission~• Composite score of 11 items of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)"
75705243|NCT05825092|Diagnostic Test|Oxygen muscular consumption|"Oxygen muscular consumption at ICU discharge and at 3 months after ICU admission~Ventilation free days at day 28 Length of stay in ICU Length of stay in hospital Mortality rate at day 28 Mortality rate at day 90 ICU mortality rate Hospital mortality rate"
75705244|NCT05824702|Behavioral|Peer education & communications|The intervention trains peer educators to promote medication-assisted drug treatment among peer who inject drugs and are living with HIV.
75705245|NCT05824702|Behavioral|Standard of care educational|This is an educational equal attention control group
75384313|NCT00004867|Procedure|positron emission tomography|
75384314|NCT00004867|Procedure|radionuclide imaging|
75384315|NCT00004867|Radiation|fludeoxyglucose F 18|
76031579|NCT05154565|Behavioral|Guided meditation|App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
76031580|NCT02634983|Drug|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
76031581|NCT02634983|Drug|Placebo|Matching placebo
75384316|NCT00004867|Drug|chemotherapy|
75384317|NCT00004867|Radiation|Radiotherapy|
75384318|NCT00004873|Drug|cisplatin|
75384319|NCT00004873|Drug|docetaxel|
75384320|NCT00004873|Drug|epirubicin hydrochloride|
75384321|NCT00004873|Drug|fluorouracil|
75384322|NCT00004333|Drug|NTBC|
75384323|NCT00004879|Biological|panitumumab|
75384324|NCT00003325|Procedure|Sentinel lymph node mapping|Sentinel lymph node mapping
75384325|NCT00004339|Drug|tetrathiomolybdate|
75384326|NCT00004339|Drug|trientine|
75384327|NCT00385099|Drug|GW876008|
75384328|NCT00003331|Drug|fluorouracil|
75384329|NCT00003331|Drug|leucovorin calcium|
75384330|NCT00003331|Drug|topotecan hydrochloride|
75384331|NCT00004885|Drug|FOLFIRI regimen|
75384332|NCT00004885|Drug|fluorouracil|
75384333|NCT00004885|Drug|irinotecan hydrochloride|
75384334|NCT00004885|Drug|leucovorin calcium|
75384335|NCT00004891|Drug|chemotherapy|
75384336|NCT00004891|Procedure|computed tomography|
75384337|NCT00004891|Procedure|conventional surgery|
75384338|NCT00004891|Procedure|neoadjuvant therapy|
75384339|NCT00004891|Procedure|positron emission tomography|
75384340|NCT00004891|Procedure|radionuclide imaging|
75384341|NCT00004891|Radiation|fludeoxyglucose F 18|
76031582|NCT05115799|Other|Manual Therapy, Physiotherapy, Kinesiology, Scar Massage|"The physiotherapist performs passive kinesitherapy on the mastectomized patient with lymphatic thrombus, and scar massage when the arm maintains its greater range of mobility.~The patient will never present pain during the rehabilitation session above 5 in Pain Scale Analog Scale."
76031583|NCT05115799|Other|Kinesiotherapy, Physiotherapy, Health Education|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
76031584|NCT02405845|Radiation|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
75705246|NCT05820568|Behavioral|ICBT-IU|Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
75705247|NCT05819749|Behavioral|Diabetes Homelessness Medication Support Program in Spanish|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
75705248|NCT05818709|Device|HAC 22L|Subcutaneous and/or Supraperiosteal injection
75705249|NCT05805397|Behavioral|Motivation Skills Training|Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
75705250|NCT05805397|Behavioral|Healthy Behaviors Control Group|Participants will complete a baseline assessment, receive weekly HBC sessions in a group format for a duration of 12 weeks, and will repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
75705251|NCT05802615|Behavioral|PARITY|The PARITY program reinforces strengths through consistent, community-based Black doula support and protective asset (personal strengths) focused messaging. PARITY promotes wellness-related behaviors (nutrition, physical activity, sleep, and healthcare adherence) and promotes and builds empowered strengths (self-efficacy, social support, motivation, resilience, problem-solving, and self-regulation) through mobile technology and doula support.
75705252|NCT05802615|Other|Usual Care|Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
75705253|NCT05795101|Drug|Trastuzumab deruxtecan|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
75705254|NCT05795101|Drug|Durvalumab|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
75705255|NCT05794789|Behavioral|Social Identity|This group will receive the same content as the education+planning as well as two additional sessions. This includes short overviews of the benefits of PA as a family, brainstorming how a family can each assist each other in PA, and an activity for developing a family PA action plan. Behavior change techniques such as identity salience, identity similarity, and identity fit and contrast are included in the coaching session include. This will be supplemented by an organization of fun family PA roles for all members (e.g., activity planner, goal setter, supporter, etc.) to instill involvement as well as items (creation of a family PA t-shirt, family PA photos and display, etc.) to instill distinctiveness, which is a central feature of a social identity. Worksheets and discussion will be included. The second session will involve only the parent(s) to focus on parental support identity and the content is based on the behavior change principles of self-identity theory.
75384342|NCT00004891|Radiation|radiation therapy|
75705256|NCT05782894|Drug|Remimazolam besylate|0~2.0mg/kg/h
75705257|NCT05782894|Drug|Propofol|0.3~4.0mg/kg/h
75705258|NCT05782894|Drug|Remifentanil|1.5~12μg/kg/h
75705259|NCT05767970|Behavioral|Integrated Stress Toolbox for Healthcare Providers (ISTH)|The ISTH is a 12-week meditation-based well-being training. In weeks 1-8, participants engage in weekly 2-hour class sessions that are recorded and posted on a private Youtube channel for one week. There is a final two-hour session at week 12. In-class learning is augmented and extended through content in a special version of the Healthy Minds Program smartphone app that participants are asked to use on a daily basis throughout the intervention.
75705260|NCT05765578|Biological|Moderna COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
75705261|NCT05765578|Biological|Moderna mRNA1273.222 Booster|Sterile liquid for injection. Intervention not administered through this study.
75705262|NCT05765578|Biological|Pfizer COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
75705263|NCT05765578|Biological|Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
75705264|NCT05765578|Biological|Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
75705265|NCT05732740|Behavioral|Empower@Home:Connected|Cognitive behavioral therapy
75705266|NCT05722769|Behavioral|CSTOP Now!|Child sex trafficking stops with you. Implement and evaluate the effectiveness of a multi-level bystander-informed program (CSTOP Now!) aimed at Kentucky public middle school staff. Participants will be trained to use the See It To Stop It Indicator Tool (SITSII) by using tiers of concern (clear concern, possible concern, and monitor of emerging concern). The SITSII tool directs the bystander actions to Decide, Directly Intervene, Disrupt, Delegate, and Document.
75705267|NCT05722769|Behavioral|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed videos we invite active comparator schools to review which also include how to identify and report child sex trafficking.
75705268|NCT05719350|Other|Exercises for Knee|Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
75705269|NCT05714007|Drug|Ferric derisomaltose|Single intravenous dose ferric derisomaltose
75384343|NCT00003337|Procedure|immunoscintigraphy|
75384344|NCT00003337|Radiation|technetium Tc 99m epratuzumab|
75384345|NCT00003343|Drug|endocrine-modulating drug therapy|
75384346|NCT00003343|Drug|mitoxantrone hydrochloride|
75384347|NCT00003343|Drug|prednisone|
75384348|NCT00003343|Drug|prinomastat|
75384349|NCT00004903|Biological|filgrastim|
75384350|NCT00004903|Biological|recombinant interferon alfa|
75384351|NCT00004903|Drug|cisplatin|
75384352|NCT00004903|Drug|cyclophosphamide|
76031585|NCT04037215|Other|STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|"Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~children controls not achieved with normal BMI;~children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders."
76031586|NCT04987151|Other|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups
76031587|NCT04987151|Other|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
76031588|NCT04987151|Other|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
76031589|NCT03141229|Behavioral|Mindfulness based stress reduction|
76031590|NCT04412291|Drug|Anakinra Prefilled Syringe|A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
76031591|NCT04412291|Drug|Tocilizumab Prefilled Syringe|8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).
76031592|NCT04412291|Drug|Standard-of-care treatment|"SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)"
76031593|NCT03141073|Drug|HMS5552|BID oral administration
76031594|NCT03141073|Drug|Placebo|BID oral administration
75384353|NCT00004903|Drug|cytarabine|
75384354|NCT00004903|Drug|etoposide|
75384355|NCT00004903|Drug|melphalan|
76031595|NCT04456361|Biological|Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords|Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
76031596|NCT03139513|Drug|Cobimetinib|Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
76031597|NCT03139513|Drug|Vemurafenib|Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
76031598|NCT03071081|Drug|TOP1288|Oral TOP1288
76031599|NCT03071081|Drug|Placebo to TOP1288|Oral placebo to TOP1288
76031600|NCT04986995|Drug|Opicapone|Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
76031601|NCT04987073|Procedure|skin biopsy|A skin biopsy to cultivate fibroblasts.
76031602|NCT03139435|Procedure|Biopsy|Undergo skin biopsy
76031603|NCT03139435|Other|Questionnaire Administration|Ancillary studies
76031604|NCT03139435|Diagnostic Test|Ultrasound Tomography|Undergo peripheral nerve ultrasound
75705270|NCT05714007|Drug|Ferrous succinate|Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
75541703|NCT04549285|Biological|Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)|"Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):~hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue that is digested and expanded in culture, cryopreserved and banked. Doses contain 2x10^6 cells/kg (up to a maximum dose of 100x10^6 cells) diluted in plasmalyte-A with 5% HSA to a volume of 20-40mL."
75705271|NCT05713838|Drug|Durvalumab|1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)
75384356|NCT00004903|Procedure|peripheral blood stem cell transplantation|
75541704|NCT04549753|Device|Transcranial direct current simulation|Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
75541705|NCT02214316|Other|Hypertonic Saline|
75541706|NCT00235352|Drug|CX516 (Ampakine)|
75705272|NCT05713838|Drug|FLOT|50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles
76031605|NCT03070067|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
76031606|NCT03971929|Drug|SHR0532|once daily(QD) for 4weeks
76031607|NCT03971929|Drug|SHR placebo|once daily(QD) for 4weeks
75705273|NCT05713838|Drug|mFOLFOX-6|85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
75705274|NCT05713838|Radiation|Radiotherapy|5 weeks with 5 days a week radiotherapy (25 daily fractions with 2.0 Gy = ∑50Gy)
75705275|NCT05712512|Behavioral|Neurodevelopmental assessment|individual behavioral and socio-communicative assessment from 6 to 36 months
75705276|NCT05712512|Other|Electrophysiological and eyetracking recordings|Investigation of neural and behavioral biomarkers of autism from 6 to 24 months
76031608|NCT03971929|Drug|Hydrochlorothiazide 25 mg|once daily(QD) for 4weeks
75705277|NCT05712187|Drug|ALTO-100|ALTO-100 tablet BID
76031609|NCT03071159|Device|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
76031610|NCT03626389|Other|Physiotherapy|
76031611|NCT03071003|Drug|SENS-401|Oral Administration
75705278|NCT05712187|Drug|Placebo|Placebo tablet BID
75384357|NCT00004357|Drug|Methylprednisolone|IV
75384358|NCT00004357|Drug|Prednisolone|Oral
75384359|NCT00004363|Drug|chlorpropamide|
75384360|NCT00004363|Drug|desmopressin|
75384361|NCT04069117|Drug|letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)|letrozole /antagonist protocol
75384362|NCT00004921|Biological|filgrastim|
75705279|NCT05711290|Dietary Supplement|Oxygen Nanobubble|This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)
75705280|NCT05711290|Other|Placebo|The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).
76031612|NCT03071003|Drug|Placebo|Oral Administration
76031613|NCT03139201|Device|OxyAqua|OxyAqua (olifilcon D) silicone hydrogel soft contact lens
76031614|NCT03139201|Device|Si-Hy|Si-Hy (oliflcon B) silicone hydrogel soft contact lens
76031615|NCT04986761|Procedure|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
76031616|NCT03139123|Other|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
76031617|NCT03070925|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
76031618|NCT05067829|Device|Train of four(TOF)|Train of four(TOF) monitoring after anesthesia induction
75384363|NCT00004921|Drug|carboplatin|
75384364|NCT00004921|Drug|cyclophosphamide|
75541707|NCT04555876|Device|high tone external muscle stimulation- stationary bicycle|high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
75541708|NCT02212444|Device|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
75541709|NCT02212444|Device|Off -the-shelf triplanar orthoses|
75541710|NCT00235469|Drug|SPM 927|
75541711|NCT04549012|Drug|Tranexamic acid|comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
75541712|NCT04549012|Drug|Oxytocin|Oxytocin
75541713|NCT04555954|Other|surveys and questionnaires|The study practised the physical activity levels of healthy adults aged 18-65 years in Turkey during the novel type of coronavirus pandemic by the International Physical Activity Questionnaires-Short Form (IPAQ-SF). Communication with the participants of the study was conducted via online survey software (Google Forms) and social media communication application (WhatsApp).
75541714|NCT02214394|Other|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
75868734|NCT06170801|Behavioral|Kiesler Circle Training (KCT)|Kiesler Circle Training is a transdiagnostic modular group treatment, which comprises a baseline module and four additional independent modules (nonverbal communication, verbal communication, conflict training and empathy and corrective interpersonal experiences). KCT is based on a heuristic model to explain and anticipate interactions developed by Donald Kiesler and other representatives of the interpersonal theory. The circumplex model arranges the variety of interpersonal behaviors in terms of a circular continuum allocated on two orthogonal axes: The vertical axis addresses interpersonal control (agency), the horizontal axis addresses interpersonal communion. The model further allows illustrating complementary action tendencies to anticipate other's reactions and to guide own behavior to achieve interpersonal goals. KCT is designed for increasing the awareness of such interpersonal action tendencies and for improving interpersonal behavioral flexibility.
75384365|NCT00004921|Drug|melphalan|
75868735|NCT06170801|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is based on the interrelationships of thoughts, actions and feelings. Presumably, individual CBT will address intrapersonal therapeutic foci such as behavioral activation, identification of dysfunctional thoughts, overcoming fears by exposure, etc. Individual CBT may also include interpersonal functioning as therapeutic foci. Disorder-specific treatment manuals are available for all diagnoses included in the study. Of note, state-of-the-art CBT does not necessarily mean, that individual CBT-sessions strictly adhere to a manual. However, because both study sites are CBT training institutes, which guarantee supervision at least every four hours, it can be estimated that state-of-the-art CBT is realized.
75384366|NCT00004921|Drug|paclitaxel|
75384367|NCT00004921|Procedure|adjuvant therapy|
75868736|NCT06170775|Other|Pulp therapy|Pulp capping material
75541715|NCT02214394|Device|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
75541716|NCT00261105|Drug|telithromycin|
75868737|NCT06170775|Drug|Sodiumhexametaphosphate|Sodiumhexametaphosphate
75868738|NCT06170775|Other|MTA|MTA
75868739|NCT06170762|Other|Pulp capping|Pulp capping material for immature permanent teeth in case of carious or traumatic pulp expures
75868740|NCT06170762|Drug|Sodiumhexametaphosphate|Sodiumhexametaphosphate
75868741|NCT06170762|Other|MTA|MTA
75868742|NCT06170736|Procedure|Doppler-Guided Haemorrhoidal Artery Ligation|The principle consists of locating the signal emitted by the haemorrhoidal arteries using a Doppler probe. Once identified, the arteries are ligated in order to remove the arterial vascularization of the haemorrhoidal bundles. The treatment of the prolapse is reinforced by a folding of the mucosa of the lower rectum, called mucopexy.
76031619|NCT04986371|Drug|Niraparib|Usage following drug insert is recommended
76031620|NCT05066971|Combination Product|Self-adjustment of medication|Each week, based on the information provided by HM (heart rate and hours of activity each day), the rate control medication is adjusted to increase the total of activity time.
76031621|NCT04989023|Other|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
76031622|NCT05021965|Procedure|different combined of tooth bleaching procedure|The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
76031623|NCT03069833|Diagnostic Test|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
75384368|NCT00004921|Procedure|bone marrow ablation with stem cell support|
75384369|NCT00004921|Procedure|peripheral blood stem cell transplantation|
75384370|NCT00004375|Procedure|ultraviolet A-1 light treatment|
75384371|NCT00004927|Drug|ixabepilone|
75384372|NCT00004933|Drug|hydroxyurea|0.5 to 5 grams PO per day
75384373|NCT00004933|Drug|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
75541717|NCT00235508|Drug|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
75541718|NCT04548856|Procedure|Microsurgical clipping|Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.
75384374|NCT00004939|Drug|,4-diaminopyridine|
75384375|NCT00004981|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
75384376|NCT00004981|Drug|Lamivudine/Zidovudine|
75384377|NCT00004981|Drug|Abacavir sulfate|
75384378|NCT00004987|Drug|Dextrin 2-sulfate|
75384379|NCT00004993|Drug|Parathyroid hormone (hPTH 1-34)|
75384380|NCT00004999|Drug|Lamivudine/Zidovudine|
75384381|NCT00004999|Drug|Capravirine|
75384382|NCT00004999|Drug|Nelfinavir mesylate|
75384383|NCT00003361|Drug|decitabine|
75384384|NCT00003367|Dietary Supplement|green tea|
75384385|NCT00003367|Dietary Supplement|soy protein isolate|
75384386|NCT00003367|Dietary Supplement|vitamin E|
75384387|NCT00003379|Drug|cisplatin|
75384388|NCT00003379|Drug|paclitaxel|
75384389|NCT00003379|Radiation|brachytherapy|
75384390|NCT00003379|Radiation|radiation therapy|
75868743|NCT06170736|Procedure|Radiofrequency ablation|The principle consists of inserting a metal probe under the mucosa of the anus, in contact with the haemorrhoidal bundles to be treated. A source of radiofrequency is then delivered through this probe in contact with the haemorrhoidal veins which will be sclerosed. The procedure is repeated for each haemorrhoidal bundle to be treated.
75868744|NCT06170723|Drug|BMS-986368|Specified dose on specified days
75868745|NCT06170723|Drug|Itraconazole|Specified dose on specified days
75868746|NCT06170723|Drug|Famotidine|Specified dose on specified days
75868747|NCT06170710|Drug|Anti-PD-1 monoclonal antibody|"Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W"
75868748|NCT06170710|Other|Postoperative CCRT|Postoperative chemoradiotherapy
75384391|NCT00003385|Drug|carboplatin|
75384392|NCT00003385|Drug|paclitaxel|
75384393|NCT00003385|Drug|pegylated liposomal doxorubicin hydrochloride|
75705281|NCT05705544|Device|ILLUMISITE™ Platform (EMN bronchoscopy)|Providers will utilize the ILLUMISITE™ Platform (EMN) machine to perform a diagnostic bronchoscopy procedure.
75705282|NCT05705544|Device|Ion™ Endoluminal System (SSCB bronchoscopy)|Providers will utilize the Ion™ Endoluminal System (SSCB) machine to perform a diagnostic bronchoscopy procedure.
75705283|NCT05697809|Drug|OXU-001|Suprachoroidal sustained release dexamethasone acetate
76031624|NCT04986007|Behavioral|Digital Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia is an automated, internet-based delivery system for the core components of cognitive behavioral therapy for insomnia (CBT-I). For this trial, dCBT-I will be delivered using Sleep Healthy Using the Internet (SHUTi), which delivers the core content of CBT-I in 6 interactive lessons called Cores: Getting Ready; Sleep Scheduling; Sleep Practices; Thinking Differently; Sleep Hygiene; and Moving On. The primary therapeutic approaches deployed through these cores are stimulus control and sleep restriction. The minimum acceptable dose for this study is completion of 4 out of 6 cores; completion of fewer than 4 cores will be considered a dropout.
76031625|NCT03070847|Drug|Tranexamic Acid|Dose: 5mg/kg
76031626|NCT03070847|Drug|Tranexamic Acid|Dose: 10mg/kg
76031627|NCT03070847|Drug|Sodium Chloride|Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
75384394|NCT00004381|Drug|tin mesoporphyrin|
75384395|NCT00005005|Drug|PTH|
75541719|NCT04548856|Procedure|Endovascular embolization|Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.
75705284|NCT05697809|Device|Semi-automated suprachoroidal illuminated microcatheter|Ophthalmic administration device
75705285|NCT05697809|Drug|Ozurdex® Ophthalmic Intravitreal Implant|Ophthalmic dexamethasone intravitreal implant
75705286|NCT05669859|Procedure|Exercise|"The rehabilitation program designed in our study was based on the development of core muscle control and dynamic stabilization of the spine, which is generally required by patients. All exercises were combined with controlled breathing, focusing on the mobility of the extremities and the activity of multiple muscle groups.~Our program created in this direction will start with face-to-face patient education; For 8 weeks, will be carried out remotely online under the supervision of a physiotherapist.On non-telerehabilitation days, they will be asked to keep an exercise diary, instructed to practice the exercise approach presented in sessions at home daily in 20-minute periods. The exercise diary will be checked during online sessions."
75705287|NCT05655520|Drug|SAGE-718|Oral softgel lipid capsules
75705288|NCT05651295|Behavioral|Checking the Facts|Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.
75705289|NCT05651295|Behavioral|Opposite to Emotion Action|Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).
75868749|NCT06170658|Device|Test Lenses|Daily disposable, silicone hydrogel investigational lenses for one week
76031628|NCT03140995|Behavioral|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
76031629|NCT03069911|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
76031630|NCT03069911|Biological|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
76031631|NCT03069755|Other|No intervention|No intervention
75384396|NCT00005005|Drug|Alendronate|
75384397|NCT00004387|Procedure|fetal nigral transplantation|
75384398|NCT00004393|Drug|risperidone|
75384399|NCT00004399|Drug|magnesium sulfate|
75384400|NCT00004399|Drug|nimodipine|
75384401|NCT00004423|Drug|-aminosalicylic acid|
75384402|NCT00005017|Drug|Ritonavir|
75384403|NCT00005017|Drug|Abacavir sulfate|
75384404|NCT00005017|Drug|Amprenavir|
75384405|NCT00005017|Drug|Efavirenz|
75384406|NCT00005017|Drug|Lamivudine|
75384407|NCT00005017|Drug|Stavudine|
75384408|NCT00005023|Biological|HER-2/neu peptide vaccine|
75384409|NCT00005023|Biological|sargramostim|
75384410|NCT00005029|Drug|topotecan hydrochloride|
75384411|NCT00005035|Drug|oxaliplatin|
75384412|NCT00004429|Drug|growth hormone|
75384413|NCT00005041|Drug|tipifarnib|
75384414|NCT00004441|Drug|tauroursodeoxycholic acid|
75541720|NCT04548895|Device|Observational measurement of biometric data. No change to health care provided.|"Emfit devices will be installed once after enrollment under each participant's mattress and left to record automatically without further intervention. The participants will wear their Biostrap wristbands consistently, ideally 24 hours a day, 7 days a week, for 2 months.~A virus panel will be upon enrollment (baseline) and then every two weeks (± 3 days, or on the closest convenient sampling day if the LTCF is testing all residents on the same day) for a maximum of 5 times during the two-month period. Using polymerase chain reaction or next generation sequencing, the virus panel will detect COVID-19 and 12 other common respiratory viruses that may cause similar symptoms and similar biometric signatures. These include influenza A and B, parainfluenza types 1 through 4, respiratory syncytial virus, non-COVID coronavirus, rhinovirus, adenovirus, bocavirus and metapneumovirus."
75868750|NCT06170658|Device|Control Lenses|Daily disposable, hydrogel commercially available lenses for one week
75868751|NCT06170593|Drug|Triamcinolone Injection|0.1mL of triamcinolone 1% solution per lesion
75868752|NCT06170580|Diagnostic Test|Conventional duplex|Conventional carotid duplex measurement
75868753|NCT06170580|Diagnostic Test|Ultrasound-based flow imaging using plane wave imaging|Ultrasound-based flow imaging using plane wave imaging
75541721|NCT04548934|Device|Personal protective equipment (PPE)|Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
75541722|NCT04548934|Device|No Personal protective equipment (PPE)|Standard CPR without wearing PPE
75541723|NCT00268515|Drug|cyclosporine|
75541724|NCT00268515|Drug|tacrolimus|
75541725|NCT00268515|Drug|prednisone|
75541726|NCT00268515|Drug|azathioprine|
75868754|NCT06170580|Diagnostic Test|Ultrasound-based flow imaging using cascaded wave imaging|Ultrasound-based flow imaging using cascaded wave imaging
75868755|NCT06170567|Other|The effect of puzzles on students' course success|The effect of puzzles on students' course success
75705290|NCT05651295|Behavioral|Mindfulness of Current Emotions|Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.
75705291|NCT05639894|Biological|RSV mRNA LNP CL-0059 Low dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
75705292|NCT05639894|Biological|RSV mRNA LNP CL-0137 Low dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
75705293|NCT05639894|Biological|RSV mRNA LNP CL-0059 Medium Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
75384415|NCT00004441|Drug|ursodiol|
75384416|NCT00005053|Drug|glufosfamide|
75384417|NCT00004465|Drug|SYNSORB Pk|
75384418|NCT00004465|Drug|Placebo|
75705294|NCT05639894|Biological|RSV mRNA LNP CL-0137 Medium Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
75705295|NCT05639894|Biological|RSV mRNA LNP CL-0059 High Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
75384419|NCT00005569|Drug|SLPI (Secretory Leukocyte Protease Inhibitor)|
75384420|NCT00005575|Drug|Imipramine|
75384421|NCT00005575|Behavioral|Cognitive-behavior therapy|
75384422|NCT00385333|Procedure|Feasibility Study - Imaging System|
75384423|NCT00004471|Genetic|pGT-1 gene lipid complex|
75384424|NCT00005059|Drug|carboplatin|
75384425|NCT00005059|Drug|paclitaxel|
75384426|NCT00005065|Drug|paclitaxel|Given IV
75384427|NCT00005065|Drug|carboplatin|Given IV
75384428|NCT00005065|Drug|motexafin gadolinium|Given IV
75384429|NCT00005065|Procedure|conventional surgery|Undergo complete surgical resection
75384430|NCT00005065|Radiation|radiation therapy|Undergo radiation therapy
75384431|NCT00386191|Drug|clopidogrel (SR25990C)|oral administration
75384432|NCT00386269|Drug|Codeine Phosphate Analgesia|
75384433|NCT00005071|Procedure|biopsy|
75384434|NCT00005071|Procedure|bronchoscopy|
75384435|NCT00005071|Procedure|computed tomography|
75384436|NCT00005071|Procedure|quality-of-life assessment|
75705296|NCT05639894|Biological|RSV mRNA LNP CL-0137 High RSV mRNA LNP CL-0137 High Dose Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
75705297|NCT05639894|Other|Placebo|Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
75705298|NCT05628675|Other|Baby CHAT|Baby CHAT is an approximately 90-minute group intervention to be delivered during pregnancy. The group is comprised of psychoeducational material about a baby's social development after birth and while the baby is growing in the womb. Attendees are encouraged to think about when an infant's social development begins and consider whether this occurs before or after birth. Participants are then shown a video clip of Reissland et al.'s (2016) study showing 4D ultrasound images of foetuses mouthing in response to sounds that are presented to them outside the womb. During Baby CHAT, parents are encouraged to reflect on this information in the context of their own baby's development, including their likes and dislikes, routine and personality. The final section of the group involves generating ideas for social activities that parents can try with their baby prior to birth, such as singing to, massaging or reading to their baby.
75384437|NCT00423241|Device|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
75705299|NCT05621096|Radiation|Bridging radiation therapy|Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.
75705300|NCT05621096|Biological|Liso-cel|"Day 0: Patients will receive an infusion of liso-cel CAR T-cell product.~Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures."
75705301|NCT05621096|Radiation|Post-infusion radiation|Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.
75705302|NCT05619913|Drug|Eribulin Mesylate|Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates.
75705303|NCT05619913|Drug|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
75705304|NCT05611957|Drug|LY3437943|Administered SC.
75705305|NCT05602454|Other|Digital Heart Failure Medication Titration|Story Health Platform, which is a remote, digital tool that provides treating clinicians collected data to make clinical decisions regarding heart failure medication titration.
75384438|NCT00423241|Device|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
75384439|NCT00385177|Drug|SN2310 Injectable Emulsion|Escalating doses given IV every three weeks
75384440|NCT00005581|Drug|cyclophosphamide|
75384441|NCT00005581|Drug|epirubicin hydrochloride|
75384442|NCT00005581|Drug|fluorouracil|
75384443|NCT00005581|Drug|paclitaxel|
75384444|NCT00005077|Drug|oxaliplatin|
75384445|NCT00004489|Drug|alendronate sodium|
75384446|NCT00004489|Drug|calcium carbonate|
75384447|NCT00004489|Drug|cholecalciferol|
75384448|NCT00005083|Procedure|conventional surgery|
75384449|NCT00005083|Procedure|magnetic resonance imaging|
75384450|NCT00005083|Procedure|magnetic resonance spectroscopic imaging|
75384451|NCT00005587|Radiation|radiation therapy|
75384452|NCT00005593|Drug|carboplatin|Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
75705306|NCT05601024|Behavioral|Laughter Therapy|The first component of intervention is the laughter therapy that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy with whatsapp group call. Each group will consist of at least 5 people. Each session of laughter therapy will be offered one a weekly and 30-40 minutes each time.
76031632|NCT04109521|Other|Training, certification and marketing|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
75384453|NCT00005593|Drug|fludarabine phosphate|Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
75384454|NCT00005593|Drug|topotecan hydrochloride|This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
75384455|NCT00004495|Drug|cyanocobalamin|
76031633|NCT04989257|Drug|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
75384456|NCT00004495|Drug|folic acid|
75384457|NCT00004495|Drug|pyridoxine|
75384458|NCT00005089|Biological|rituximab|375 mg/m^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
75384459|NCT00005089|Drug|cyclophosphamide|750 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
75384460|NCT00005089|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
75384461|NCT00005089|Drug|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
75384462|NCT00005089|Drug|vincristine sulfate|1.4 mg/m^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
76031634|NCT04989257|Drug|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
76031635|NCT03140527|Drug|PTI-801|Active
76031636|NCT03140527|Drug|Placebo|Placebo
76031637|NCT03140527|Drug|PTI-808|Active
75384463|NCT00005089|Radiation|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
75384464|NCT00004549|Procedure|Magnetic resonance imaging|
75384465|NCT00005599|Drug|bryostatin 1|
75384466|NCT00005599|Drug|paclitaxel|
75384467|NCT00004561|Behavioral|exercise|
75384468|NCT00005611|Drug|BMS-188797|
75384469|NCT00004567|Drug|Mycophenolate Mofetil|
75384470|NCT00005113|Drug|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
75384471|NCT00005113|Drug|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
75384472|NCT00005113|Drug|Tacrolimus|dosage is in oral form titrated to target trough level
75384473|NCT00005617|Biological|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
76031638|NCT03140527|Drug|Placebo|Placebo
76031639|NCT03070769|Procedure|Venous blood collection for biomarkers measurements|Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
75384474|NCT00005617|Procedure|leukapheresis|Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
75384475|NCT00004573|Drug|ganciclovir|
75384476|NCT00005623|Drug|cyproterone acetate|
75384477|NCT00005623|Procedure|quality-of-life assessment|
75384478|NCT00005119|Procedure|Measures of calcium and bone turnover|
75868756|NCT06170541|Device|Aquilion Precision|Ultra-High Resolution CT (UHR CT) capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today's CT technology, with an all-new detector as well as tube, gantry and reconstruction technologies.
75868757|NCT06170541|Device|Conventional Computed Tomography|Conventional reconstruction Computed Tomography (CT) represents a pivotal approach in medical imaging.
75384479|NCT02972749|Behavioral|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
76031640|NCT03069443|Other|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
75557665|NCT00481884|Other|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
75384480|NCT00005629|Biological|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
75384481|NCT00004579|Biological|gp160 MN/LAI-2|
75384482|NCT00004579|Biological|ALVAC-HIV MN120TMG (vCP205)|
76031641|NCT04025983|Dietary Supplement|GastimunHp Plus|Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
76031642|NCT04025983|Other|Placebo|The placebo contains neither IgY nor L. johnsonii.
76031643|NCT04892069|Drug|Insulin Degludec/Insulin Aspart|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
75868758|NCT06170528|Device|AURA_ALZ|AURA_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
75868759|NCT06170515|Diagnostic Test|CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor)|BGM Test
75868760|NCT06170515|Diagnostic Test|Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)|HbA1c Test
76031644|NCT04986059|Other|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
75384483|NCT00004585|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
75384484|NCT00004585|Drug|Lamivudine/Zidovudine|
75384485|NCT00004585|Drug|Abacavir sulfate|
75384486|NCT00004585|Drug|Efavirenz|
75384487|NCT00005635|Biological|trastuzumab|
75384488|NCT00005635|Drug|paclitaxel|
75384489|NCT00005137|Other|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
75384490|NCT00004639|Procedure|Furlow double z-plasty palatoplasty palate repair|
75384491|NCT00004639|Procedure|Von Langenbeck palatoplasty palate repair|
75384492|NCT00005641|Biological|anti-thymocyte globulin|
75384493|NCT00005641|Drug|busulfan|
75384494|NCT00005641|Drug|cyclophosphamide|
75384495|NCT00005641|Drug|cyclosporine|
75384496|NCT00005641|Drug|leucovorin calcium|
75384497|NCT00005641|Drug|methotrexate|
75384498|NCT00005641|Drug|methylprednisolone|
75384499|NCT00005641|Procedure|allogeneic bone marrow transplantation|
75384500|NCT00005641|Procedure|in vitro-treated bone marrow transplantation|
75384501|NCT00005641|Radiation|radiation therapy|
75384502|NCT00004645|Procedure|Plasma exchange|
75384503|NCT00005647|Drug|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
75384504|NCT00005647|Drug|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
75384505|NCT00005665|Drug|interferon alpha|
75384506|NCT00004669|Drug|hydrocortisone|
76031645|NCT03140449|Drug|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
76031646|NCT03140449|Drug|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
76031647|NCT03140449|Drug|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
76031648|NCT03138811|Drug|CSJ117|inhaled once daily dose
75541727|NCT04548700|Drug|Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle."
75384507|NCT00385411|Drug|valproate microgranules|20 to 30 mg/kg/day
75384508|NCT00004699|Drug|insulin-like growth factor I|
76031649|NCT03138811|Drug|Placebo Comparator|inhaled once daily dose
75384509|NCT00385489|Drug|LXR-623|
75384510|NCT00004705|Drug|amiloride|
75384511|NCT00004705|Drug|uridine|
76031650|NCT02895451|Behavioral|Extended behavioral intervention|The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
76031651|NCT02659813|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
75541728|NCT04548700|Drug|Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day."
75541729|NCT02214433|Drug|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
76031652|NCT04095143|Diagnostic Test|Portal vein flow|Doppler assessment performed on day 0, 3 and 7.
75541730|NCT02214433|Drug|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
75541731|NCT02214433|Drug|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
76031653|NCT04095143|Diagnostic Test|Intra-renal flow|Doppler assessment performed on day 0, 3 and 7.
75541732|NCT02214433|Drug|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
75541733|NCT02214433|Drug|Debio 1450 Capsule|Debio 1450 40 mg capsules
76031654|NCT04095143|Diagnostic Test|Hepatic vein flow|Doppler assessment performed on day 0, 3 and 7.
76031655|NCT04095143|Diagnostic Test|Pulmonary B-lines|Ultrasound assessment of performed on day 0, 3 and 7.
76031656|NCT04095143|Diagnostic Test|Dimensions of the inferior vena cava|Ultrasound assessment of performed on day 0, 3 and 7.
75384512|NCT00004729|Behavioral|Ketogenic diet|
75384513|NCT00004735|Biological|Tetanus toxoid|
75384514|NCT00004735|Biological|Hepatitis A Vaccine (Inactivated)|
75384515|NCT00004747|Drug|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
75384516|NCT00004759|Drug|methylprednisolone|
75384517|NCT00004759|Drug|tirilazad|
75384518|NCT00005713|Behavioral|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
75384519|NCT02972827|Device|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
75384520|NCT02972827|Other|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
75384521|NCT00004771|Drug|leuprolide|
75384522|NCT00004771|Drug|testosterone|
75384523|NCT00004789|Drug|heme arginate|
75384524|NCT00004789|Drug|tin mesoporphyrin|
75384525|NCT00004795|Drug|dehydroepiandrosterone|
75384526|NCT00005743|Behavioral|exercise|
75384527|NCT00005743|Behavioral|weight loss|
75384528|NCT00004801|Drug|monoclonal factor IX replacement therapy|
75384529|NCT00004807|Drug|dextromethorphan|
75384530|NCT00004807|Drug|topiramate|
75384531|NCT00004807|Drug|Donepezil|
75384532|NCT00004825|Drug|recombinant human insulin-like growth factor I|
76031657|NCT04095143|Diagnostic Test|Left ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
75384533|NCT00385567|Drug|PEHRG214|
75384534|NCT00385645|Drug|Combivir+Kaletra|
75384535|NCT00385645|Drug|Combivir+Reyataz|
75384536|NCT00385879|Behavioral|Case management|
75384537|NCT00005305|Other|No interventions - observational study|
75384538|NCT00385957|Drug|AZT+3TC+IDV+RTV|
75384539|NCT00385957|Drug|AZT+3TC+EFV|
75384540|NCT00386035|Drug|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
75384541|NCT00386035|Drug|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
75384542|NCT00386113|Biological|Fluarix and adjuvanted influenza vaccine|
75384543|NCT00005107|Drug|N-monomethyl-L-arginine|
75384544|NCT00005773|Drug|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had <=20 mm Hg increase in PaO2 (less than full response).
75384545|NCT00005773|Drug|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
76031658|NCT04095143|Diagnostic Test|Right ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
76031659|NCT04917445|Behavioral|Spikes-focused bad news protocol|Nurses trained to deliver bad news to IVF patients based on the Spikes-protocol for compassionately delivering bad news to patients.
75384546|NCT00005779|Drug|Interleukin-12|
75384547|NCT00005779|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
75384548|NCT00005785|Drug|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
75384549|NCT00005791|Drug|cisplatin|
76031660|NCT04904653|Device|Hemopatch|"HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~HEMOPATCH 27 x 27 mm~HEMOPATCH 45 x 45 mm~HEMOPATCH 45 x 90 mm"
76031661|NCT04904653|Other|Control group|No sealant (liquid, gel or patch) + suction drain
76031662|NCT03070691|Drug|LDE225B|Cream, 2x daily
76031663|NCT03070691|Drug|Vehicle|cream, 2x daily
76031664|NCT03137953|Procedure|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
76031665|NCT03137953|Diagnostic Test|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
75384550|NCT00005791|Drug|fluorouracil|
75384551|NCT00005791|Drug|irinotecan hydrochloride|
75384552|NCT00005797|Drug|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
75384553|NCT00005797|Drug|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
75384554|NCT00005797|Drug|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is >/= 150% of IBW, in which case adjusted body weight will be used.
75384555|NCT00005797|Radiation|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
75384556|NCT00386347|Drug|GSK364735 oral solution and oral tablets|
75384557|NCT00005809|Procedure|computed tomography|
75384558|NCT00005809|Procedure|diagnostic colonoscopy|
75384559|NCT00005815|Drug|temozolomide|
75384560|NCT00005815|Drug|thalidomide|
75384561|NCT02132754|Biological|MK-4166|
75384562|NCT02132754|Biological|Pembrolizumab|
75384563|NCT02151786|Drug|Lansoprazole|Lansoprazole intravenous 30 mg
75384564|NCT02132130|Drug|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
75384565|NCT02131662|Drug|BAY1002670|Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
75384566|NCT02131662|Drug|BAY1002670|Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
75384567|NCT02131662|Drug|BAY1002670|Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
75384568|NCT02131662|Drug|BAY1002670|Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
75384569|NCT02131662|Drug|Placebo|Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
75541734|NCT02214433|Drug|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
75384570|NCT04188366|Behavioral|FAMES|Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).
76031666|NCT04985591|Procedure|Liposuction|A small, inconspicuous incision was made in the liposuction group to dislodge fat out of the body.
76031667|NCT04985591|Procedure|Other plastic surgery|Other plastic surgery like blepharoplasty or keloid excision.
76031668|NCT04985435|Drug|Filgotinib|200 mg tablet once daily or 100 mg once daily
76031669|NCT04985435|Drug|Anti-Tumor Necrosis Factor Alpha Drug (Product)|Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
76031670|NCT04985435|Behavioral|50 patients will have a Free Choice between Filgotinib and anti TNF|50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.
76031671|NCT03070457|Other|Early discharge|Patients randomised to early discharge or not
75705307|NCT05592132|Other|Virtual reality headset|Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.
75384571|NCT04188366|Behavioral|Treatment-as-Usual|Participants will receive usual services and family-based treatment offered
75384572|NCT02106156|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
75384573|NCT02106156|Drug|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
75384574|NCT05137002|Drug|CIN-107|CIN-107 tablets by mouth once daily
75384575|NCT05137002|Drug|Placebo|Placebo tablets by mouth once daily
75384576|NCT01598610|Device|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
75384577|NCT04738812|Drug|Intensified TB treatment (initial phase)|"8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R.~6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg."
75384578|NCT04738812|Drug|WHO standard TB treatment (initial phase)|8 weeks of RHEZ with FDC.
75384579|NCT04737954|Diagnostic Test|Venepuncture|Venous blood draw
75384580|NCT04737954|Diagnostic Test|Fingerstick|Capillary blood draw
75384581|NCT01625988|Drug|LY2951742|
75384582|NCT01625988|Drug|Placebo|
75384583|NCT02131272|Drug|Insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
75384584|NCT02131272|Drug|Insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
75384585|NCT02131272|Behavioral|Diet/exercise|Intervention will be performed through family based changes in eating and activity behaviours.
75541735|NCT02214433|Drug|Pantoprazole|Pantoprazole 40 mg orally
75541736|NCT04710407|Drug|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
75541737|NCT00261144|Drug|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
75541738|NCT00261144|Biological|Biological|Collagenase injection
75705308|NCT05581212|Other|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack|Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
75705309|NCT05579431|Drug|VX-634|Suspension for oral administration.
75705310|NCT05579431|Drug|Placebo|Suspension for oral administration.
76031672|NCT03070457|Other|Conventional protocol|Discharge as usually done 48-72 hours after surgery
76031673|NCT03140683|Device|non-stress test|antepartum fetal monitoring
76031674|NCT03070613|Drug|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
76031675|NCT03441139|Other|Cryotherapy + Medical analgesics|"Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion"
76031676|NCT03441139|Drug|Medical Analgesics|Best analgesic therapy at investigator's discretion
76031677|NCT04988789|Drug|Paclitaxel Drug Coated Balloon|Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database
76031678|NCT04985279|Device|Position and Angle Marking System|Position and Angular Marking System (PAMS) attaches on to the ultrasound probe. When the desired insertion site is identified by ultrasound, the doctor gently presses PAMS into the patient's back to create skin indentations demarcating the needle insertion point. These indentations are not affected by skin sterilisation, and may improve accuracy and reduce the time taken to perform the epidural procedure. Next, the angle between the ultrasound probe and the patient's back can be measured using PAMS, and this angle can be maintained using a needle guide during the epidural procedure.
76031679|NCT04985279|Device|Standard clinical practice|When the desired insertion site is identified by ultrasound, the doctor demarcate the needle insertion point using marker pens.
76031680|NCT04985669|Drug|Prucalopride 2mg|one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
76031681|NCT05083897|Other|hip adduction isometric contraction|addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
76031682|NCT04988711|Diagnostic Test|Hb Oxymeter|Measurement of Hb Oximeter
76031683|NCT04753957|Drug|micronized Progesterone|200mg micronized progesterone placed vaginally
76031684|NCT03070379|Procedure|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
76031685|NCT03227263|Drug|Bevacizumab|Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations
76031686|NCT03227263|Drug|sodium chloride 0.9%|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
76031687|NCT04985201|Drug|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 60 mg/m^2 on Day 1,8 of each 21-day cycle.
75705311|NCT05577559|Procedure|intermediate cervical plexus block|patients will receive bilateral ultrasound guided intermediate cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
75384586|NCT02130882|Drug|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
75384587|NCT02130882|Other|Placebo|A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
75384588|NCT02130570|Other|Multi-Model Intensive Discharge Intervention|"Inpatient medication safety interventions~Inpatient discharge advocate~Structured visiting nurse (VNA) appointments~Post-discharge phone call by primary care personnel within 2 business days of discharge~Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~Improved communication between inpatient and primary care teams~High-risk patients will receive additional interventions as needed:~Home pharmacist visit~Enrollment in the Partners integrated Care Management Program (iCMP)~Enrollment in telemedicine programs for patients with CHF~Palliative care consultation regarding goals of care~Novel health information technology to facilitate communication and transfer of clinical information"
75384589|NCT02149836|Drug|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
75384590|NCT02130024|Drug|Ranibizumab 0.5 mg|Administered as an intravitreal injection
75384591|NCT02130024|Drug|Aflibercept 2.0 mg|Administered as an intravitreal injection
75541739|NCT04555681|Diagnostic Test|Collection of subgingival dental plaque|Identification and quantification using q-PCR of the 21 bacteria most frequently found in the dental plaque (including the periopathogenic bacteria) and Candida albicans.
75705312|NCT05577559|Procedure|Cervical Erector spinae block|patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
75384592|NCT02105688|Drug|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
75705313|NCT05555875|Behavioral|IntelliCare Plus|Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.
75705314|NCT05544357|Other|Short set configuration resistance training|Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
75705315|NCT05544357|Other|Long set configuration resistance training|Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
75868761|NCT06170502|Device|Using the mobile application and applying the survey|"In the study, The Form for Determining the Educational Needs of Parents Administering Medicines at Home, Introductory Information Form, Parental Drug Preparation Information Evaluation Form, Parent Evaluation Form in Suspension Drug Administration, Capsule Drug Application Parent Evaluation Form, developed by the researchers in line with the literature, Tablet Pharmaceutical Application Parent Evaluation Form, Mobile Application Usability Questionnaire, AkilMobil Expert Opinion Evaluation Form and STAI State Anxiety Inventory developed by Spielberger et al. will be used."
75705316|NCT05534022|Device|Test myopia control lenses (BSL)|Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
75868762|NCT06170450|Device|Cyclic SNM|SNM cycling: 8 hours on, 16 hours off
75868763|NCT06170450|Device|Continuous SNM|Continuous SNM: on continuously, no 'off' period
76031688|NCT04985201|Drug|Simvastatin|Simvastatin 40 mg daily oral tablet taken.
75868764|NCT06170424|Procedure|spray skin|The patients who used the autologous skin cell suspension combined with skin grafting.
75868765|NCT06170424|Procedure|Control group|The patients who used skin grafting.
76031689|NCT03156595|Behavioral|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
76031690|NCT03156595|Behavioral|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
76031691|NCT04985123|Device|Pre-Formed Penile Silicone Block Implant|Implantation of Pre-Formed Penile Silicone Block Implant
76031692|NCT03092713|Behavioral|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
76031693|NCT03092713|Behavioral|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
75384593|NCT02105688|Drug|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
75384594|NCT02105454|Drug|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
75384595|NCT02105454|Drug|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
75384596|NCT02105454|Drug|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
75384597|NCT01625910|Behavioral|Behavioral counseling|Counseling of parents to improve their child's diet and physical activity
75384598|NCT02104752|Drug|Curcumin|360 mg/day (divided into twice daily oral doses)
75384599|NCT02104752|Drug|Placebo|"Inactive, matched placebo (Sugar Pill)"
75384600|NCT02102724|Dietary Supplement|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
75384601|NCT02102724|Dietary Supplement|Placebo|Gelcaps that contain 1 gram of oleic sunflower oil
75384602|NCT02102490|Drug|Abemaciclib|Administered orally
75384603|NCT02101554|Drug|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
75384604|NCT02101554|Drug|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
75384605|NCT02128932|Drug|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
75384606|NCT02128932|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
75384607|NCT02128542|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
76031694|NCT04985045|Other|Evaluation|Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.
75541740|NCT04548622|Device|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to both the left and right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
75541741|NCT04710251|Device|Speedometer|We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
75705317|NCT05531812|Other|G2R with individual coaching|"Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~A one-time asset transfer of US$300 delivered ~7 months into the program;~Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~Individual coaching at home from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; Water, Sanitation and Hygiene (WASH) practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
75705318|NCT05531812|Other|G2R with group coaching|"Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~A one-time asset transfer of US$300 delivered ~7 months into the program;~Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~Group coaching in a community setting from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; WASH practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
75705319|NCT05521113|Behavioral|Home Rehabilitation Monitoring System|The system consists of a small activity monitor worn on the wrist and a pulse oximeter worn on the finger while exercising. Simple exercises will be completed daily and the monitors will send information to a rehabilitation coach during a 12-week period.
75705320|NCT05521113|Behavioral|Health coaching calls|12 telephone-based health coaching calls over a 12-week period
75705321|NCT05515198|Other|Patient Education|Patients will be provided educational opportunities.
75384608|NCT02128542|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75384609|NCT02127372|Drug|Docetaxel, Cisplatin and STI571|"Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.~Phase 1 dose levels are:~Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg~Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg~Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg~Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg~Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg~Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg~Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II."
75384610|NCT02127372|Drug|Docetaxel|
75541742|NCT02212561|Drug|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
75541743|NCT02212561|Drug|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
75384611|NCT02127372|Drug|Cisplatin|
75705322|NCT05515198|Other|Nurse Navigation|A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.
75541744|NCT02212561|Drug|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
75705323|NCT05515198|Other|ChatBot|"A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a conversational agent, that will provide education and encouragement to manage their symptoms."
75705324|NCT05513560|Drug|Ibudilast|10mg pills, 2 pills twice per day
75705325|NCT05513560|Drug|Pentoxifylline|400mg pill 3 times per day
75705326|NCT05513560|Other|Placebo|Placebo matching ibudilast, 2 pills twice per day OR placebo matching pentoxifylline 1 pill 3 time per day.
75705327|NCT05507515|Drug|ONO-2020|ONO-2020 tablets
75705328|NCT05507515|Drug|Placebo|Placebo tablets matching ONO-2020 tablets
75705329|NCT05502913|Drug|Antibiotics|Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
75384612|NCT04747548|Behavioral|Kurbo Only|Kurbo is a structured behavioral weight management program for youth that focuses on diet, physical activity and mindset skills and is based on the traffic light diet developed at Stanford University. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories consumed. Foods are categorized into the colors of a traffic light signal based on their nutritional and caloric content, such that youth are encouraged to eat more of green and yellow foods, and less of red foods. Participants will log their daily food intake and self-monitor dietary and physical activity behaviors, incorporating behavior substitution and habit formation. Participants will also have 15 minute weekly individualized coaching sessions.
75384613|NCT04747548|Behavioral|Kurbo + PolyRules!|In addition to Kurbo, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
75868766|NCT06170411|Device|Elexir (program1)|The Elexir is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as Trigeminal Nerve Stimulation. The Elexir will deliver trigeminal nerve stimulation.
75868767|NCT06170411|Device|sham device|The sham device will deliver sham trigeminal nerve stimulation.
75705330|NCT05502913|Other|FMT (Fecal Microbiota Transplantation)|FMT involves the transplantation of fecal bacteria from a screened donor to a recipient. This will be achieved per os in the form of a capsule containing freeze-dried stool obtained from the donor.
75705331|NCT05497401|Biological|MesenCure|Enhanced mesenchymal cell-based product
75541745|NCT02212561|Drug|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
75868768|NCT06170385|Behavioral|Physical Therapy|Each physical therapy session will commence with a 5-minute warm-up, with fun activities to mobilize the joints and activate the muscles, using the videos available in the HEAL-ME platform. The warm-up session will be followed by a 20 to 40-min program with tailored activities and games comprising jumping, squatting, skipping, balancing, and jogging. The session will finish with a 5-minute cool down with stretching exercises and a relaxation video from the HEAL-ME platform.
76031695|NCT04988243|Other|All aortic valve products on the market|"Subjects with severe aortic valve stenosis~Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement~The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up;~Be able to contact the subjects or their legal guardians / relatives;~The medical record records the subjects who have died and can't get any contact information of the subjects（ (for dead cases only)~Sign the informed consent form, then check the inclusion and exclusion criteria, register after meeting the criteria, obtain the registration number, perform aortic valve replacement surgery, follow-up 24 hours, discharge, 30 days, 1 year, 2 years, 3 years, 4 years and 5 years after operation according to the test requirements, and carry out relevant follow-up according to the scheme requirements to collect data"
75384614|NCT04751682|Biological|BBV154 Vaccine|Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10^10 Virus Particle.
75384615|NCT04751682|Biological|Placebo|Placebo
75384616|NCT02126826|Drug|BI 1026706|Multiple Rising Doses (oral solution, tablet)
75384617|NCT02126826|Drug|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
75384618|NCT02126670|Drug|ACT01|
75384619|NCT02126670|Drug|Comp01|
75384620|NCT02126670|Drug|Comp02|
75384621|NCT02126670|Drug|Comp03|
75384622|NCT02126670|Drug|Comp04|
75384623|NCT02125734|Drug|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
75384624|NCT02125734|Drug|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
75384625|NCT02124798|Device|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
75705332|NCT05497401|Other|Placebo|Saline
75705333|NCT05497024|Behavioral|Interviews|"Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material"
75384626|NCT02146326|Behavioral|Motivational Interviewing (MI)|MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
75384627|NCT02146326|Behavioral|Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)|BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
75384628|NCT02146248|Drug|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
75384629|NCT02146248|Drug|DepoProvera|injectable hormonal contraceptive
75541746|NCT00268554|Drug|dipyridamole|
75705334|NCT05497024|Behavioral|Surveys|Participants may answer questions that are sensitive in nature.
75868769|NCT06170359|Procedure|robotic surgery under general anaesthesia|During robotic surgery, the standard 45-degree upright Trendelenburg position and for postoperative analgesia, 0.06 mg/kg morphine, 1 gram (g) paracetomol and 8 mg onasetron are administered iv to all patients 30 minutes before the end of the operation. At the end of surgery and after extubation, patients are taken from the recovery unit to the service. In the service, all patients are given paracetamol 1g every 8 hours and tenoxicam 20 mg every 24 hours for pain treatment. Tramadol 1 mg/kg iv is administered as rescue analgesic to patients with a VAS score >4.
75868770|NCT06170333|Drug|8% sulphur and A. vera soap|Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
75868771|NCT06170307|Diagnostic Test|two-dimensional speckle tracking echocardiography|The structural and functional parameters of the left atrial were obtained by conventional echocardiography, and the left atrial strain parameters were obtained by two-dimensional speckle tracking echocardiography.
75868772|NCT06170294|Drug|TCR-MAGE-A4 T-Cells|"Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~MAGE-A4-directed T cell receptor-engineered T Cells"
76031696|NCT02031601|Drug|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
75384630|NCT02145468|Drug|Losmapimod 7.5 mg twice daily|Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
75384631|NCT02145468|Drug|Placebo twice daily|Subjects will receive placebo as film-coated, round, plain faced tablets.
75541747|NCT00268554|Drug|caffeine|
75541748|NCT04555993|Procedure|lower abdominal surgery|Patients will undergo lower abdominal surgery under general anesthesia.
75705335|NCT05486312|Device|CT-155 smartphone app|The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
75384632|NCT02145468|Drug|Standard therapy|Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
75384633|NCT02124564|Drug|Lacosamide|"Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day."
75384634|NCT02145390|Procedure|Transurethral Resection of the Bladder Tumor & Cystoscopy|"TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~Cystoscopic evaluation~Bimanual examination under anesthesia,~Transurethral resection of the bladder tumor,~Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop."
75705336|NCT05481502|Procedure|Tumor biopsy|3 biopsies will be collected: at baseline, at day+15 and optionally at relapse
75705337|NCT05481502|Procedure|Blood sample|7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse
75705338|NCT05481502|Procedure|Bone marrow sample|If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
75384635|NCT02145390|Radiation|Intensity Modulated Radiation Therapy|"For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume."
75384636|NCT02145390|Behavioral|Expanded Prostate Cancer Index Composite Short Form 12|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
75384637|NCT02145390|Behavioral|International Prostate Symptom Score|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
75384638|NCT02100696|Drug|Etrozulimab|Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
75705339|NCT05476224|Biological|Blood sample of 30 ml|The parameters analyzed on this blood sample: Fasting blood glucose, HbA1C, creatinine, creatinine clearance (MDRD), fasting lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
75384639|NCT02100696|Drug|Placebo|Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
75705340|NCT05452122|Other|Auditory and Electrical Stimulation|Electrical and auditory stimulation will be applied during sleep.
75705341|NCT05432258|Device|Bulk-fill composite resin|Restoration of the mandibular first molars with bulk-fill composite resin as the manufacturer advises after the cavity preparation
75384640|NCT02145156|Behavioral|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
75384641|NCT02145156|Behavioral|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
75705342|NCT05432258|Device|Nano-fill composite resin|Restoration of the mandibular first molars with nano-fill composite resin as the manufacturer advises after the cavity preparation
75705343|NCT05427539|Device|TEST LENS|AO1DfA manufactured with PG hydration
75384642|NCT02145156|Behavioral|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
75705344|NCT05427539|Device|CONTROL LENS|AO1DfA manufactured with IPA hydration
75705345|NCT05417581|Procedure|adipose surgery|A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
75705346|NCT05412953|Other|Questionnaire Administration|Complete questionnaire
75705347|NCT05412953|Behavioral|Tonation Breathing Technique|Participate in tonation breathing techniques
75705348|NCT05412082|Radiation|Intensity-modulated radiation therapy|MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.
75384643|NCT02123472|Drug|Cephalexin|Administered Orally
75384644|NCT02145078|Drug|docetaxel|Given IV
75384645|NCT02145078|Drug|pemetrexed disodium|Given IV
75384646|NCT02145078|Drug|gemcitabine hydrochloride|Given IV
75384647|NCT02145078|Other|laboratory biomarker analysis|Correlative studies
75384648|NCT02144610|Biological|HGF Plasmid (AMG0001)|IM
75384649|NCT02144610|Biological|Matching Placebo|IM
75384650|NCT02100228|Drug|Apixaban|Oral, 2.5 or 5 mg BID
75384651|NCT02100228|Drug|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
75384652|NCT02099838|Drug|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
75868774|NCT06170268|Other|Routine Care Documentation|Routine Care Documentation
75868775|NCT06170255|Behavioral|Behavioral Activation (BA)|Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
75384653|NCT02099838|Drug|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
75384654|NCT02144220|Other|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
75384655|NCT02099682|Drug|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
75384656|NCT05182944|Drug|A：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
75541749|NCT04555993|Other|Erector spinae plane block|patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
75868776|NCT06170242|Drug|EDP-323 Dose Regimen 1|EDP-323 capsule
76031697|NCT02031601|Drug|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
76031698|NCT02031601|Drug|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
75868777|NCT06170242|Drug|EDP-323 Dose Regimen 2|EDP-323 capsule
75384657|NCT05182944|Drug|B：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
75384658|NCT05182944|Drug|A：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
76031699|NCT02031601|Drug|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
76031700|NCT02031601|Drug|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
76031701|NCT02031601|Drug|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
76031702|NCT02031601|Drug|Erlotinib|150mg po once a day daily until disease progression
75384659|NCT05182944|Drug|B：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
75384660|NCT02142894|Device|CST001|
75384661|NCT02098746|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
75868778|NCT06170242|Drug|Placebo|Placebo capsule
75868779|NCT06170216|Drug|immunochemotherapies|Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
75868780|NCT06170203|Other|Personalised Follow-up Pathway|Discharge from routine oncology Follow-Up 2 years following radical treatment for a head and neck cancer
76031703|NCT02031601|Drug|Gefitinib|250mg po once a day daily until disease progression
76031704|NCT02031601|Drug|Icotinib|125mg po three times a day daily until disease progression
76031705|NCT04988165|Drug|Traditional Chinese Medicine|It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
76031706|NCT02772679|Biological|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10^6 cells. The second cohort will receive 20x10^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
76031707|NCT04456127|Procedure|Fractional CO2 Laser|The UltraPulse® fractional ablative CO2 Laser will be employed with the DeepFX™ hand piece. Number of passes and laser settings, including fluency, density, spot size, will be chosen during the time of treatment as determined by the operating surgeon.
75384662|NCT02122770|Drug|MLN4924|MLN4924 intravenous solution.
75384663|NCT02122770|Drug|Fluconazole|Fluconazole tablets.
75384664|NCT02122770|Drug|Itraconazole|Itraconazole oral solution.
75384665|NCT02122770|Drug|Docetaxel|Docetaxel intravenous solution.
75384666|NCT02122770|Drug|Carboplatin|Carboplatin intravenous solution.
75384667|NCT02122770|Drug|Paclitaxel|Paclitaxel intravenous solution.
75384668|NCT02122380|Drug|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
75384669|NCT02122380|Drug|Placebo|1 placebo pill by mouth per day for 30 days
75868781|NCT06170190|Biological|IBI133|"IBI133:~The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the course of the study. Q3W"
75868782|NCT06170177|Procedure|Radical Cystectomy|A radical cystectomy is an operation to remove the whole bladder
75868783|NCT06170164|Diagnostic Test|Diagnostic accuracy|The aim of the study is to evaluate whether the pathological stage of the disease, Gleason score, age at diagnosis, serum PSA value and PET parameters (SUV, MTV) are predictive factors of choline PET examination.
75868784|NCT06170151|Diagnostic Test|Diagnostic accuracy|evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment in patients with relapsed/refractory multiple myeloma.
75868785|NCT06170138|Other|Test product 1 - Test product 2 - Comparator product|"Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4)."
76031708|NCT04984577|Drug|Compound Edaravone Injection-Low dose|Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days
75384670|NCT02122146|Drug|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
75384671|NCT02122146|Drug|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
75384672|NCT02121834|Drug|LY3050258|
75868786|NCT06170125|Other|Tiotropium treated patients|Patients who are not satisfied with their COPD treatment and will be on additional tiotropium scheme.
75384673|NCT02121834|Drug|Placebo|
75868787|NCT06170112|Other|Spinal Orthosis Application|Spinal orthosis treatment is to prevent secondary curvature and provide correction. Corrective pressure forces in spinal orthosis are basically; There are pressure points on the material of the spinal orthosis, pressure pads, and velcros used to adjust the tightness and ensure the stability of the orthosis. The duration of use of spinal orthoses varies from patient to patient; It is known that using it for an average of 23 hours a day gives the best results. Orthosis use is required for 12 weeks during the study.
75868788|NCT06170099|Radiation|low level laser therapy|irradiation with LLLT by the following regimen 0, 3, 7 and 14 from the activation of the bony supported Distal Jet and then every 15 days till completion of distalization
76031709|NCT04984577|Drug|Compound Edaravone Injection-High dose|Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days
76031710|NCT04984577|Drug|Edaravone Injection|Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days
76031711|NCT04984577|Drug|Placebo injection|Placebo injection, one dose every 12 hours, continue for 14 days
75868789|NCT06170099|Device|bonny supported distal jet|distal jet distalizing appliance is supported on two paramedian screw
76031712|NCT04984187|Other|high intensity laser plus exercise|high intensity laser plus exercise
76031713|NCT04984187|Device|high intensity laser only|high intensity laser only
76031714|NCT04984187|Other|exercise|exercise only
75384674|NCT02121756|Drug|Dipyridamole|Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
76031715|NCT05088343|Drug|Rosuvastatin|Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
76031716|NCT05088343|Drug|Hetrombopag|7.5 mg hetrombopag was administered on Day 6 to Day 11.
76031717|NCT04984265|Radiation|Stereotactic Body Radiation Therapy|SBRT targeting the area of the circuit of Ventricular Tachycardia
76031718|NCT03070145|Other|Exercise Intervention|12-week moderate-intensity aerobic and strength training exercise intervention
76031719|NCT03137485|Procedure|Conventional open lumbar discectomy|Removal of single level lumbar disc herniation through conventional discectomy.
76031720|NCT03137485|Procedure|Percutaneous Endoscopic Translaminar lumbar discectomy.|Removal of single level Lumbar disc herniation using endoscope.
75384675|NCT02121756|Drug|Placebo, then Dipyridamole|Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
75384676|NCT02142504|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
75384677|NCT02142504|Drug|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
75384678|NCT02121522|Drug|BI 144807|twice daily
75384679|NCT02121210|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
75384680|NCT02141490|Drug|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
75384681|NCT02141490|Diagnostic Test|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
75868790|NCT06170047|Behavioral|Chicago Parent Program for Foster Care|CPP-FC consists of 12 two-hour sessions delivered virtually by two trained group leaders over 16 weeks (11 concurrent weeks, 1 one-month booster) in a group-based format. Foster and kinship caregivers of young children are systematically taught parenting skills through group discussions, videotaped vignettes, structured role play and weekly homework assignments.
75868791|NCT06170047|Other|Usual Care|The Usual Care control will receive services from the county, CHECK clinic, and for licensed caregivers, their licensing agency per usual care. Caregivers receive training and support from their county and/or private licensing agency, children are referred to community services by the caseworker when behaviors emerge, and support from behavioral health specialists is available when caregivers request them.
75868792|NCT06170034|Behavioral|Satisfaction questionnaire|Satisfaction questionnaire to assess how TIA patients feels about their medical care.
75384682|NCT02097108|Drug|Raltegravir|
75705349|NCT05412082|Drug|5-fluorouracil|"5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.~During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week."
75868793|NCT06170034|Other|Medical care questionnaire|Recording appointments and results of examinations and consultations in TIA management
75868794|NCT06170008|Device|Physical microstructure-modified transparent silicone film sheet|The main component of the physical microstructure-modified transparent silicone film sheet is transparent silicone rubber, which has a three-dimensional microstructure on its trauma contact surface through physical mechanics treatment, which can provide effective mechanical stimulation for trauma healing. And after testing, the silicone film sheet is breathable, light-permeable, non-toxic and non-allergenic. It is expected to significantly reduce the number of dressing changes, reduce the damage to the wound and the painful stimulation to the patient during dressing changes, and promote the healing of the wound to a certain extent, thus improving the quality of wound repair and saving medical costs.
75384683|NCT02097030|Device|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
75384684|NCT02097030|Device|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
75705350|NCT05412082|Drug|Leucovorin|Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
75705351|NCT05412082|Drug|Oxaliplatin|Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.
75868795|NCT06170008|Device|Decellularized pig skin|Decellularized pig skin is an allogeneic trauma covering from pigs and is a commonly used trauma covering for second-degree burn wounds. It adheres to clean superficial wounds, creates a temporary barrier to the wound, reduces wound exudation, limits loss of body components, improves microcirculatory stasis, provides a microenvironment suitable for wound healing, protects inter-ecological tissue, promotes repair and regeneration, and reduces pain. Its disadvantages are: soft structure, difficult to fix the trauma; opaque, unable to observe the trauma; pigskin needs to be stored under suitable temperature and humidity, and has a limited time. When used, decellularized pig skin is directly covered on conventionally treated second-degree burn wounds.
75868796|NCT06170008|Device|Vaseline gauze|Vaseline gauze is the most commonly used conventional dressing for the implant area, which is mainly made of skimmed cotton gauze impregnated with petroleum jelly and paraffin oil, which has a lubricating effect and can promote the growth of granulation and wound healing. However, its moisturizing time is relatively short and requires frequent dressing changes; moreover, petroleum jelly gauze often adheres to the wound surface severely, which may cause bleeding and new epidermal damage during dressing changes and affect the wound healing; the wound surface is constantly oozing blood and fluid, and the dressing cannot be effectively isolated from the outside world after wetting, which increases the chance of infection. Vaseline gauze is applied directly to the post-operative skin grafting wound.
75868797|NCT06169956|Drug|Neoadjuvant nivolumab in combination with platinum-based chemotherapy|Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
75705352|NCT05412082|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
75705353|NCT05412082|Radiation|Accelerated Radiation Therapy|"MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :~Dose level -1: 10 Gy delivered in 4 fractions~Dose level 0: 12 Gy delivered in 4 fractions~Dose level 1: 14 Gy delivered in 4 fractions~Dose level 2: 16 Gy in delivered 4 fractions"
75705354|NCT05408715|Other|Natural History Study|Longitudinal assessment of symptoms and development of complications in type II collagen disorders
75384685|NCT02097030|Device|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
75384686|NCT02096952|Drug|Methylphenidate extended-release liquid formulation|
75384687|NCT02120898|Drug|Imiquimod|Cream, generic formulation of the brand product.
75384688|NCT02120898|Drug|Zyclara®|Cream, brand product.
75705355|NCT05402943|Behavioral|Nursing Care Program for Endometriosis|Nursing Care Program for Endometriosis, developed in line with Health Promotion Model
75705356|NCT05402943|Behavioral|EHP-5 Endometriosis Health Promotion Model.|EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis
75705357|NCT05402943|Behavioral|Healthy Life Style Behaviours Scale II.|A questionnaire used to measure the Healthy Life Style Behaviours.
76031721|NCT03137485|Device|Easy Go system Endoscopy|This system will be used to remove herniated disc in endoscopic group
75384689|NCT02120898|Drug|Vehicle Cream|Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
75384690|NCT02120664|Drug|Florbetapir (18F)|
75384691|NCT02120664|Drug|11C-PiB|
76031722|NCT03068507|Behavioral|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
75384692|NCT01627860|Drug|Topiramate add-on therapy|Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
75384693|NCT01627860|Drug|Topiramate monotherapy|Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
75384694|NCT01627782|Drug|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
76031723|NCT03137641|Other|Nurses urine samples|Collected urine samples from nurses in contact with antineoplastic drugs.
76031724|NCT04983641|Other|Pre-Visit Messages|"Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits"
76031725|NCT03068429|Drug|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
76031726|NCT03068351|Drug|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram [mg/kg] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
76031727|NCT03068351|Biological|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
75541750|NCT04555993|Other|Transversus abdominis plane block|patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
75705358|NCT05402943|Behavioral|The Satisfaction Questionnaire for Nursing Care Program for women with Endometriosis.|A questionnaire used to measure the satisfaction levels of women with endometriosis who applied the Nursing Care Program for women with endometriosis.
75384695|NCT01627782|Drug|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
75384696|NCT01598532|Device|MedX Health Phototherapy (light therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
75384697|NCT02119650|Drug|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
75384698|NCT02119650|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
75384699|NCT02119650|Drug|Pemetrexed|500 mg/m^2 administered as an intravenous infusion over 10 minutes
75384700|NCT02119650|Drug|Cisplatin|75 mg/m^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
75541751|NCT00235586|Procedure|10 vit. D deficient subjects take vit. D for 3 months.|
75541752|NCT00268593|Drug|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
75868798|NCT06169943|Other|mHealth social support program|This is a 3-month program comprises mobile app, group discussion, individual telephone contact, and reminders.
75868799|NCT06169943|Other|Control|The same mobile app as the intervention group but with limited function.
75868800|NCT06169930|Other|This was an observational study without any intervention|This was an observational study without any intervention
75705359|NCT05386017|Other|Anthropometric measurements and sociodemographic and health data collection|"Anthropometric measurements : weight, height, abdominal circumference, abdominal circumference, percentage of fat mass, percentage of lean body mass, and estimated visceral fat level, visceral fat.~Sociodemographic and health data collection : Collect over a 7-year period changes in physical activity practices, eating habits and behaviours and the motivations for these changes or the initiatives to change the weight, Perceived stress and control, Life courses, events and impact perception Status, level of education, social background, place of residence, relationship with family Diet, tobacco and alcohol consumptions Physical activity behaviour and barriers, sedentary behaviour, quality of life perceived, exploring possible behavioural eating disorders, anxiety, depression"
75705360|NCT05372354|Drug|CC-92480|Specified dose on specified days
76031728|NCT03137563|Other|questionnaire|The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
76031729|NCT03140293|Drug|Lidocaine injection|Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.
76031730|NCT03140293|Drug|Gebauer Ethyl Chloride Spray|Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
76031731|NCT04983563|Device|Actigraphy, eTact|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy.
75384701|NCT02119416|Drug|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
75705361|NCT05372354|Drug|Tazemetostat|Specified dose on specified days
75384702|NCT02119416|Drug|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
75705362|NCT05372354|Drug|BMS-986158|Specified dose on specified days
76031732|NCT03137329|Behavioral|Exercise program|Physical therapy for aerobic and resistance training exercises
75384703|NCT02119416|Drug|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
75705363|NCT05372354|Drug|Trametinib|Specified dose on specified days
75705364|NCT05372354|Drug|Dexamethasone|Specified dose on specified days
75705365|NCT05320835|Behavioral|HIV, HCV and overdose prevention|HIV, HCV and overdose prevention
75705366|NCT05312983|Other|Audiological and vestibular tests|"6h of audiological and vestibular tests divide in 3 sessions :~Session A : objective audiological tests~Session B ; subjective audiological tests~Session C : balance tests."
75705367|NCT05312983|Other|Blood sampling|A 10 mL blood sample will be collected during the study.
75705368|NCT05312983|Other|neurocognitive self-questionnaire|Four self-questionnaires to fill out to measure sleep quality, memory and emotional state
76031733|NCT03137329|Dietary Supplement|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
76031734|NCT03137329|Procedure|WLS|Weight loss surgery as planned
76031735|NCT04452695|Device|Doctor Spot|Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
76031736|NCT04584541|Biological|blood tests|Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)
76031737|NCT04584541|Biological|Nasopharyngeal swabs|SarS-Cov-2 viral load assessment
76031738|NCT04584541|Biological|Stools|SarS-Cov-2 viral load assessment
75384704|NCT02140164|Drug|Minocycline|Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
76031739|NCT04982861|Drug|Cefixime Trihydrate 100 mg/5 mL Dry Syrup|Participants received a single dose of 5 mL of cefixime dry syrup with 240 mL of water
76031740|NCT04982861|Drug|Suprax 100 MG in 5 mL Oral Suspension|Participants received a single dose of 5 mL of Suprax with 240 mL of water
76031741|NCT04456049|Drug|Enzalutamide|40 mg oral tablets once daily for a maximum of 28 days.
76031742|NCT04572217|Drug|Topiramate|Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
75384705|NCT04745208|Behavioral|Simulation based education|high fidelity simulation with moulage
75384706|NCT02119260|Drug|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
75384707|NCT02119260|Drug|GSK2798745 suspension|Aqueous suspension of GSK2798745 (>=0.5 mg)
75384708|NCT02119260|Drug|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (>=0.5 mg)
75384709|NCT02119260|Drug|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
75541753|NCT00268593|Drug|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
76031743|NCT04572217|Drug|Phentermine|Phentermine (starting dose 8 mg, max dose 16 mg)
76031744|NCT04455503|Drug|EVX-02A|Up to 8 patients will receive EVX-02A administered IM.
76031745|NCT04455503|Drug|EVX-02B|Up to 8 patients will receive EVX-02B administered IM.
76031746|NCT04455503|Drug|EVX-02A OR EVX-02B|EVX-02A or EVX-02B will be used. Patients: 24 to 30
76031747|NCT04553809|Procedure|ENB|ENB for biopsy sampling of peripheral lung lesion
75705369|NCT05307068|Other|No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
75384710|NCT02119260|Drug|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
75384711|NCT02119260|Drug|Placebo capsule|Matching white opaque placebo blend filled capsule
75384712|NCT02119104|Drug|Prevenar (13v)|Prevenar (13v)
75705370|NCT05302154|Behavioral|Distraction by dentist|Basic behavior orientation techniques (tell-show-do) is applied by the dentist during the treatment.
76031748|NCT04553809|Procedure|ENB in combination with rEBUS|The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions
75705371|NCT05302154|Behavioral|Distraction by cartoon movie|Children watch cartoons on a screen mounted dental unit during the treatment.
75868801|NCT06169917|Behavioral|Paced Resonance Frequency Breathing|Participants are required to pace their breathing to their pre-determined individual resonance frequency.
75868802|NCT06169917|Behavioral|Paced Breathing at Natural Frequency|Participants are required to pace their breathing to their pre-determined individual breathing frequency at rest.
76031749|NCT05083195|Other|Home-based Telerehabilitation|Balance, walking, strengthening exercise videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
76031750|NCT05083195|Other|Exercise Brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
76031751|NCT03137251|Device|TENS 1|A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
76031752|NCT03137251|Device|TENS 2|An intervention similar to arm 1 will be performed but with different doses.
75384713|NCT02119026|Drug|Capecitabine|"800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
75384714|NCT02119026|Drug|Capecitabine|1000mg/m2 bid d1-14,
75384715|NCT02119026|Drug|Bevacizumab|7,5 mg/kg given on d1 q3w
75384716|NCT02119026|Drug|Oxaliplatin|130mg/m2 iv. d 1 q3w
75384717|NCT02119026|Drug|Irinotecan|200mg/m2 iv. d 1 q3w .
75384718|NCT02095158|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
75384719|NCT02094612|Device|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
75384720|NCT02094612|Behavioral|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
75384721|NCT02139306|Drug|Ataluren (PTC124®)|Oral Ataluren TID
75384722|NCT02139306|Drug|Placebo|Oral Placebo TID
75541754|NCT00268593|Drug|prednisone|5 mg twice a day orally
75541755|NCT04555525|Drug|sarecycline|sarecycline tablet
75868803|NCT06169917|Other|Heat Stimulations|Participants will undergo a heat stimulation procedure on their left and right foot (the order of which is counterbalanced across participants). During this procedure, there are 10 blocks, with an inter-stimulus interval of 30 seconds between two blocks. During a block, six 6-second heat stimulations (48 degrees) are given. Between the stimulations, the temperature quickly returns to baseline (32 degrees).
75868804|NCT06169904|Drug|Cisplatin injection|We observed the UC patients from Zhongshan Hospital receiving or not receiving adjuvant cisplatin-based chemotherapy after radical cystectomy.
75868805|NCT06169891|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|one s.c. injection of SSGJ-613 once, on Day 1.
75868806|NCT06169891|Other|Placebo|Participants will receive Placebo matching Compound Betamethasone Injection to maintain the blinding of the Investigational Medicinal Products.
75384723|NCT02094300|Device|Zenith® Dissection Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
75384724|NCT02118792|Drug|AN2728 Topical Ointment, 2%|
75384725|NCT02118792|Drug|Matching vehicle control|
75384726|NCT02118714|Drug|Atrasentan|Atrasentan
75384727|NCT02138916|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
75384728|NCT02138916|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
75384729|NCT02138916|Drug|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
75384730|NCT02118012|Drug|Chlorcyclizine HCl|Chlorcyclizine HCl (75 mg twice daily)
75384731|NCT02118012|Drug|Ribavirin|RBV was dosed via a weight-based regimen of 1000 mg daily<75 kg and 1200 mg daily ≥75 kg.
75384732|NCT02093520|Procedure|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
75384733|NCT02093520|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
75384734|NCT02138838|Drug|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
75384735|NCT02138838|Dietary Supplement|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
75541756|NCT04555525|Dietary Supplement|Centrum Adult Multivitamin|Centrum Adult Mulltivitamin tablet
75541757|NCT00235625|Drug|Curcuminoids C3 Complex®|
75541758|NCT02212600|Other|Observational|observational cohort of proximal humerus fractures
75868807|NCT06169891|Drug|Compound Betamethasone Injection|1 mL i.m. once on Day 1
75868808|NCT06169891|Other|Placebo|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
75868809|NCT06169878|Device|Adjustable lower limb abduction apparatus|"To ensure abduction in the lower extremities after total hip replacement surgery, a specially adjustable apparatus developed according to the height and weight of each individual was used.~This developed product was used by patients while they were lying down and walking."
75868810|NCT06169865|Other|cross sectional study|cross sectional study to explore magnitude of peripheral vascular diseases and presentations in patients with autoimmune diseases in sohag society.
75868811|NCT06169839|Behavioral|Providing BLS and AED trainings given by the Ministry of Health with Low Realism Simulation.|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with Low Realism Simulation (1 hour) Basic CPR Manikin (classical training given by the Ministry of Health),
75868812|NCT06169839|Behavioral|Providing BLS and AED trainings given by the Ministry of Health with High Reality Simulation|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with High Reality Simulation (1 hour) SimMan® 3G (Laerdal medical)
75384736|NCT02138214|Procedure|Thyroidectomy|Undergo total thyroidectomy
75384737|NCT02138214|Procedure|entral lymph node dissection (CLND)|Undergo total thyroidectomy with ipsilateral prophylactic CND
75384738|NCT02138214|Other|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
75384739|NCT02092662|Other|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
75384740|NCT02092662|Other|Healthy controls|no treatment
75384741|NCT02092350|Drug|Grazoprevir|Grazoprevir 100 mg tablet
75384742|NCT02092350|Drug|Elbasvir|Elbasvir 50 mg tablet
75384743|NCT02092350|Drug|Placebo to Grazoprevir|Placebo tablet matched to grazoprevir
75384744|NCT02092350|Drug|Placebo to Elbasvir|Placebo tablet matched to elbasvir
75384745|NCT02117544|Device|Lotrafilcon B multifocal contact lenses (new)|
75541759|NCT04555486|Drug|DCR-PHXC|Intervention, drug, DCR-PHXC
75541760|NCT04555486|Drug|Sterile Normal Saline (0.9% NaCl)|Placebo comparator
75541761|NCT04555213|Drug|NOX66|NOX66 Suppository
75541762|NCT04555369|Genetic|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
75541763|NCT00261183|Drug|Melatonin|
75868813|NCT06169839|Behavioral|Providing BLS and AED trainings given by the Ministry of Health with Virtual Reality|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with Virtual Reality Application Supported Simulation (1 hour) Application training will be given with 3D MedSim.
75705372|NCT05302154|Behavioral|Distraction by virtual reality glasses|During the treatment visual and auditory stimuli provide information about treatment to the patient with the help of avatars (characters) and environmental elements placed within the VRG application. In a vivid dentist room, the explanatory introduction part takes place while the movies are watched in a fairy world or a futuristic world to separate the user from the actual location and context. The application was designed to function in such a way as not to require outside intervention. From start to finish, the application interacts with the user through gaze selection and head tracking mechanisms. The avatar characters provide information related to the dental treatment in a joyful manner. Gamification elements such as gaining stars and collecting rewards have been used to keep the patient engaged. Motion blur feature ensures the patient to keep head still as sudden movements are dangerous and undesired by the dentist during the treatment.
75705373|NCT05293951|Device|Mirror Strengthening Device|"Participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~The initial resistance will be chosen based on the participants initial outcome measure results.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
75384746|NCT02117544|Device|Lotrafilcon B multifocal contact lenses|
75705374|NCT05293951|Device|Mirror Therapy|"Participants will perform non-resisted task-specific upper limb exercises. During the exercises, participants will be watching their non affected arm reflected in a mirror covering their affected arm.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
76031753|NCT03137251|Device|Placebo TENS|An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
75384747|NCT02138136|Drug|Lubiprostone|12 or 24 mcg soft capsules for oral administration
76031754|NCT05635955|Drug|Remimazolam|"Total intravenous anaesthesia will be induced with 0.3mg/kg remimazolam and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores > 1 or body movements occur, supplemental 0.2 mg/kg remimazolam (IV) will be administrated."
76031755|NCT05635955|Drug|Propofol|"Total intravenous anaesthesia will be induced with 2mg/kg propofol and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores > 1 or body movements occur, supplemental 0.25 mg/kg propofol (IV) will be administrated."
75384748|NCT04726020|Other|Intensive monitoring|periodic and planned monitoring nurse intervention with phone call
75384749|NCT04726020|Other|Standard monitoring|standard monitoring of adverse event reaction
75384750|NCT01626690|Device|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
75384751|NCT01626690|Device|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
75384752|NCT01626456|Drug|ALKS 9072, Low|IM injection, given monthly
75384753|NCT01626456|Drug|ALKS 9072, High|IM injection, given monthly
75384754|NCT02116608|Drug|Betadine|Apply locally as needed.
75384755|NCT02116608|Drug|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
75384756|NCT02116608|Drug|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
75384757|NCT04742088|Device|ankleSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
75384758|NCT02092116|Drug|Romidepsin|Latency reversing agent
75541764|NCT00235664|Procedure|Collection of stool and endotracheal aspirate samples|collection of samples
76031756|NCT05635955|Drug|Esketamine|0.3mg/kg esketamine will be co-administrated in both arms
75384759|NCT02092116|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
75384760|NCT02092116|Biological|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
75705375|NCT05286034|Behavioral|Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms|"Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels."
75384761|NCT02091726|Procedure|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
75384762|NCT02091414|Drug|mycophenolate mofetil (MMF)|1.0 g PO BID
75705376|NCT05273918|Other|cognitivo-comportmental therapy|15 workshops once a week during 90 minutes
75868814|NCT06169826|Drug|l-Histidine|In the outpatient setting, one chewable tablet multivitamin (Zn and folic acid containing) plus a titrated dosing of L-histidine powder or capsules starting at 2g consumed before noon escalating every 2 weeks up to 4, 6, then 8 g per day as tolerated for up to 3 months.
76031757|NCT03137017|Drug|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
75384763|NCT02091414|Drug|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
75384764|NCT02091414|Drug|corticosteroids|As per the practice of each participating center
75705377|NCT05273918|Other|body mediation|15 workshops once a week during 90 minutes
75705378|NCT05257772|Device|AV Delay Optimised RV Pacing|AV Delay Optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems) and Echo to assess LVOT gradient change.
75705379|NCT05254730|Device|macro-micro tetrodes for intracranial recording|novel design of tetrode micro electrodes within the standard macro intracranial electrodes used clinically for identification of the epileptogenic zone
75868815|NCT06169826|Other|Control|Control
75868816|NCT06169813|Other|Nicotine Replacement Therapy (NRT)|NRT (daily patches and lozenges). NRT strength will be according to the established dosing guidelines for tobacco treatment. NRT is the standard of care in tobacco treatment and helped reduce CPD in prior trials
75868817|NCT06169813|Other|E-Cigarette (EC)|EC with single-use pods. Nicotine - 48 mg/ ml (4.8% nicotine) concentration.
75868818|NCT06169813|Behavioral|Counseling|Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.
75868819|NCT06169527|Drug|Dupilumab|Dupilumab cohort
76031758|NCT03137017|Drug|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
76031759|NCT04412681|Diagnostic Test|Enhanced PE Screening|To better identify women at risk for pre-eclampsia during pregnancy.
75384765|NCT04731558|Drug|enoxaparin or tinzaparin or dalteparin|Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
75384766|NCT04731558|Drug|No intervention|No preoperative thromboprophylaxis.
75384767|NCT02116530|Drug|Olanzapine|oral
75384768|NCT02116530|Drug|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
75384769|NCT02116530|Drug|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
75384770|NCT02116530|Other|Placebo|oral
75384771|NCT02072226|Drug|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
75384772|NCT02072226|Drug|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
75384773|NCT02072226|Drug|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
75541765|NCT04555447|Dietary Supplement|Agavins (prebiotic fiber)|Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
75541766|NCT04555447|Dietary Supplement|Placebo|Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
75541767|NCT00268632|Drug|risedronate|
75541768|NCT04554979|Drug|Hydroxychloroquine Pill|hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
75705380|NCT05236790|Diagnostic Test|Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye|Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
75541769|NCT00235703|Device|Antimicrobial Prescribing Decision Support|
75541770|NCT04555057|Procedure|Music therapy|Music selected according to the patient's individual preferences.
75541771|NCT00261222|Drug|Amodiaquine|
75868820|NCT06169462|Procedure|PENG block|Patients underwent ultrasound-guided PENG Block for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
75541772|NCT04554628|Diagnostic Test|ELISA test in urine|enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
76031760|NCT05635565|Other|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
75541773|NCT00235781|Drug|Thymoglobulin|
75541774|NCT04554823|Behavioral|Health Education|Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
75541775|NCT04554823|Behavioral|Physical Exercise|Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
76031761|NCT05635565|Other|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
75384774|NCT02072226|Drug|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
75384775|NCT04730856|Drug|Tinzaparin|"day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home."
75541776|NCT04554589|Drug|Glycopyrrolate 0.2 MG|injections
75541777|NCT04554589|Drug|normal saline|normal saline
75541778|NCT00268671|Drug|Docetaxel|
75541779|NCT04554433|Drug|Ethanol with Asprin|"Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~Inhaling alcohol vapor through nostrils .~Inhalation of Alcohol vapor driven by Oxygen .~Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results ."
75541780|NCT04721054|Drug|Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)|patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
75541781|NCT04721054|Drug|general anesthesia effect on heart rate in Laparoscopic Cholecystectomy|patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
75541782|NCT02212639|Drug|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
76031762|NCT03013933|Drug|Brentuximab Vedotin|Given IV
76031763|NCT03013933|Drug|Cyclosporine|Given PO
75384776|NCT02090634|Behavioral|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
75384777|NCT02090634|Behavioral|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
75384778|NCT02114892|Drug|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
75384779|NCT02114892|Drug|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
75384780|NCT02070978|Drug|Atacicept 75 mg|Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
75384781|NCT02070978|Drug|Atacicept 150 mg|Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
75868821|NCT06169462|Procedure|PENG block+ SIFCB|Patients underwent ultrasound-guided PENG Block+ SIFCB for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
75384782|NCT02070978|Drug|Atacicept 150 mg|Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
75384783|NCT04725630|Behavioral|Healthy food incentive|$10.50/week/household member for 12 months to purchase healthy foods in participating supermarkets.
75868822|NCT06168812|Drug|Glipizide|The therapeutic intervention in this study involves the sulfonylurea glipizide in ER formulation.
75868823|NCT06165757|Behavioral|noise stimulation|Apply non harmonic and white noise sound stimuli to the subjects, and then measure the threshold and tolerance values of pressure pain, cold pain, and electrical pain.
75868824|NCT06164626|Procedure|Extraction|extraction: in all groups, extraction will be performed
76031764|NCT03013933|Other|Pharmacokinetic Study|Correlative studies
75384784|NCT04725630|Behavioral|Healthy food prescription|A one-time healthy food prescription pamphlet
75384785|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
75384786|NCT02114268|Drug|Placebo|Participants received placebo on Day 1.
75384787|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
75384788|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
75384789|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
75384790|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
75384791|NCT02089230|Drug|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
75384792|NCT02070744|Drug|VX-661|Tablet, oral use
75384793|NCT02070744|Drug|Ivacaftor|Film coated tablet, oral use
75384794|NCT02070744|Drug|Placebo matched to VX-661|Tablet, oral use
75384795|NCT02070744|Drug|Placebo matched to Ivacaftor|Film coated tablet, oral use
75384796|NCT02113956|Behavioral|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
75384797|NCT02070588|Device|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
75384798|NCT04741698|Drug|Propranolol|Propranolol 2mg IV
75384799|NCT02111850|Biological|Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
75384800|NCT02111850|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
75384801|NCT02111850|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.
75384802|NCT02111850|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
75384803|NCT02087904|Biological|ABT-981|
75384804|NCT02087904|Other|Placebo|
75384805|NCT02087670|Other|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
75384806|NCT02087670|Other|exercise protocol no supervised|Exercise program at the community
75384807|NCT04729530|Device|Dyson Pure Cool - Active Purifier|Free standing air purifier
75384808|NCT04729530|Device|Dyson Pure Cool - Placebo purifier|Placebo air purifier
75384809|NCT02086968|Drug|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
75384810|NCT02086968|Drug|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
75705381|NCT05228860|Behavioral|Vida Sana (a Group Lifestyle Intervention)|"Vida Sana is a Group Lifestyle intervention that has been shown to be effective among patients with type 2 diabetes (T2DM). Vida Sana includes 23 group sessions with a trained health coach:~Months 1-4: 1 family-wide orientation + 12 weekly sessions~Months 5-6: 4 bimonthly group sessions~Months 7-12: 6 monthly group sessions~All regular primary care and diabetes care will remain as usual."
75384811|NCT04729218|Behavioral|movement imagery ability|Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery
75384812|NCT02086110|Dietary Supplement|Synbiotic|
75384813|NCT02086110|Dietary Supplement|Prebiotic|
75868825|NCT06164626|Radiation|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
76031765|NCT03013933|Drug|Verapamil|Given PO
76031766|NCT03013933|Drug|Verapamil Hydrochloride|Given PO
75384814|NCT02085252|Drug|Leuprorelin|Solution for injection
75705382|NCT05228860|Behavioral|Supplemental Healthy Food Deliveries|"Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)"
75868826|NCT06164626|Biological|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
75868827|NCT06164210|Behavioral|Snoezelen-Based Occupational Therapy Intervention Group|Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen-based interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
75868828|NCT06164197|Device|Lokomat|Robot Assisted Gait Training
75868829|NCT06164197|Device|Thera Trainer Balo|Virtual Reality Based Balance Training Device
75868830|NCT06164197|Other|Person-Specific Rehabilitation Program|Person-Specific Rehabilitation Program
75868831|NCT06162585|Biological|Gene Therapy product-MCO-010|Safety evaluation to monitor long term effects of previously injected MCO-010 in RP patients
75868832|NCT06161207|Procedure|Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection|Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer
75868833|NCT06161025|Drug|R-DXd|R-DXd will be administered as an intravenously (IV) infusion
75868834|NCT06161025|Drug|Gemcitabine|Gemcitabine will be administered as an IV infusion
75384815|NCT02085252|Drug|Bicalutamide|Bicalutamide tablets
75384816|NCT04417686|Procedure|arterial embolization|arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
75384817|NCT02084238|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
75868835|NCT06161025|Drug|Paclitaxel|Paclitaxel will be administered as an IV infusion
75868836|NCT06161025|Drug|Topotecan|Topotecan will be administered as an IV infusion
75868837|NCT06161025|Drug|PLD|PLD will be administered as an IV infusion
76031767|NCT04437745|Device|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
75705383|NCT05214664|Procedure|Anesthesia|"Once the anesthesia is performed by the Anesthesia practitioner either with the EZ-Block® device or by the conventional freehand technique, the surgical procedure will be performed in the same way in both arms, and for each tooth, by the Surgery practitioner:~The Surgery practitioner takes charge of the patient after a post-anesthesia time of 10 minutes and performs a new antisepsis then completes the anesthesia by anesthetizing the buccal and lingual nerve with a carpule of 1.8ml of articaine + adrenaline at 1/200000.~The Surgery practitioner starts the surgical procedure.~In the absence of pain, the practitioner Surgery carries out the surgical act in its totality (situation of success for the principal criterion of the study) then records the EVA at the end of the intervention."
75705384|NCT05214573|Drug|Glucagon like peptide 1 receptor agonist|Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication
75705385|NCT05214573|Drug|Sodium-glucose cotransporter 2 inhibitor|Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor
75705386|NCT05214573|Drug|Dipeptidyl Peptidase 4 Inhibitor|Patients in the data who filled a dipeptidyl peptidase-4 inhibitor
75868838|NCT06160999|Behavioral|Religious conferences|The conference will invite local subdistrict-level imams and other religious leaders, along with a range of community health workers, including those not traditionally trained to give vaccines. During the conference there will be some sessions with everyone, and some that are broken down by profession. The conference topics will be developed in conjunction with the religious leaders, but will focus on the importance of infant health
75384818|NCT02084082|Drug|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
75384819|NCT02084082|Drug|Linagliptin|1x Linagliptin tablet
75384820|NCT02084082|Drug|Metformin ER|2x Metformin ER tablets
75384821|NCT02083926|Drug|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
75541783|NCT02212756|Drug|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
75705387|NCT05214573|Drug|Sulfonylurea|Patients in the data who filled a sulfonylurea
75705388|NCT05211271|Device|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by visual inspection with diluted acetic acid (VIA) presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
75705389|NCT05205668|Biological|F-652|IL-22 fusion protein administered intravenously
75705390|NCT05205668|Biological|Placebo|Placebo administered intravenously
75384822|NCT02083926|Other|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
75384823|NCT02083380|Drug|Artefenomel 800mg: piperaquine 640mg|Active, loose combination
75541784|NCT02212756|Drug|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
75541785|NCT02212795|Drug|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
75541786|NCT02212795|Drug|Levofloxacin 250mg|Levofloxacin 250mg single dose
75384824|NCT02083380|Drug|Artefenomel 800mg: piperaquine 960mg|Active, loose combination
75384825|NCT02083380|Drug|Artefenomel 800mg: piperaquine 1440mg|Active, loose combination
76031768|NCT05635253|Other|Hydrogen Peroxide 35%|Group that received only bleaching treatment. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them.
75384826|NCT02109744|Drug|Decitabine|
75384827|NCT02109432|Behavioral|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
75384828|NCT02109432|Behavioral|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
76031769|NCT05635253|Other|Hydrogen Peroxide 35% + Polishing whitened teeth|Group that received only bleaching treatment followed by polishing. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them. After bleaching, the vestibular surfaces were polished for 20s on each bleached tooth, with polishing paste and felt disc (Diamond Flex, FGM, Santa Catarina, SC, Brazil) in low rotation.
76031770|NCT03069599|Procedure|irreversible electroporation (IRE)|Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
76031771|NCT05634941|Device|Active ON-tDCS|DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.
75384829|NCT02109432|Behavioral|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
75384830|NCT04723602|Biological|cAd3-Marburg|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10^11 Particle Units (PU) vaccine.
75384831|NCT04723602|Biological|cAd3-EBO-S|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10^11 Particle Units (PU) vaccine.
75384832|NCT02109042|Drug|Blosozumab|Administered subcutaneously
75384833|NCT02066922|Device|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
75384834|NCT02066922|Device|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
75384835|NCT02066922|Device|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
75384836|NCT02108262|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
75384837|NCT02108262|Biological|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
75541787|NCT02212795|Drug|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
76031772|NCT05634941|Device|Sham ON-tDCS|For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
76031773|NCT05074069|Procedure|Gynaecological reconstruction|Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
76031774|NCT04262479|Drug|recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel|3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
76031775|NCT04262479|Drug|Vitamin D|1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
76031776|NCT04275323|Genetic|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
76031777|NCT04275323|Other|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
76031778|NCT04133311|Drug|DE-130A|Latanoprost 50 microg/ml eye drops emulsion, eye drops emulsion in single-dose containers
76031779|NCT04133311|Drug|Xalatan®|Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers
76031780|NCT04237025|Other|Nordic walking exercise|Supervised Nordic Walking (NW) exercise will be conducted in a small group setting with a 2:1 participant to trainer ratio providing individualized training instruction. Training will be conducted for a total of 14 one-hour sessions over a 6-week period. Training will take place at an outdoor community track with progression tasks on hills or grassy terrain. The one-hour training sessions will include a 10-minute warm-up period, 45 minutes of individualized NW training, and a 5-minute cool down period. The target training duration goal for NW exercise will be 45 minutes of continuous walking at moderate intensity based on target heart rate and Rating of Perceived Exertion. NW exercise program will be customized and progressed for each participant by trainers with ongoing assessment of participant's gait pattern, NW technique, and exercise responses during the training sessions. Group comradery and accountability will be facilitated through training in small group training context.
76031781|NCT03217825|Drug|Rostafuroxin|This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
76031782|NCT03217825|Drug|Losartan|COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole- 5-methanol monopotassium salt.
76031783|NCT05183009|Device|eXciteOSA|eXciteOSA
75384838|NCT02107482|Device|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
75384839|NCT02107482|Device|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
75384840|NCT02066298|Drug|Mometasone 220mcg BID|Mometasone is an ICS
75384841|NCT02066298|Drug|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
75705391|NCT05204641|Biological|Fecal Microbiota Transfer provided by Human Biome Institute|Fecal Microbiota Transfer with colonoscopy
75384842|NCT02066298|Drug|Placebo|
75384843|NCT02082912|Drug|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
75384844|NCT02082912|Other|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
75705392|NCT05186974|Drug|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
75705393|NCT05186974|Drug|Pembrolizumab|Administered intravenously
75705394|NCT05186974|Drug|Carboplatin|Administered intravenously
75705395|NCT05186974|Drug|Cisplatin|Administered intravenously
75705396|NCT05182840|Drug|BI 690517|BI 690517
75705397|NCT05182840|Drug|Placebo to BI 690517|Placebo to BI 690517
75541788|NCT00261261|Behavioral|ADVANCE|
75541789|NCT00261261|Drug|Midazolam|
76031784|NCT00157963|Drug|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
75705398|NCT05182840|Drug|Empagliflozin|Empagliflozin
75705399|NCT05182840|Drug|Placebo to empagliflozin|Placebo to empagliflozin
75705400|NCT05146908|Biological|2 Blood samples from arterial and/or central venous catheters|5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
75705401|NCT05146908|Other|Echography|"In 3 steps:~before initiation of enteral nutrition~4h after initiation of enteral nutrition~After 24 hours of enteral nutrition"
76031785|NCT04014829|Diagnostic Test|Pain-Pressure Threshold|Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
75705402|NCT05146908|Other|Data collection|"At inclusion:~Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.~Within the first 24 hours, collection of:~echographic parameters at H0, H4 and H24~venous congestion parameters~biological parameters within 24 hours Constitution of a biobank (at H0 and H24)~Within the first 7 days, collection of:~the occurrence or not of the primary endpoint (and time to occurrence).~symptoms of gastrointestinal dysfunction~Within 30 days, collection of:~organ failure and replacement over the period, and mortality.~the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study."
75384845|NCT02082912|Device|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
75541790|NCT00261261|Procedure|Parental presence|
75541791|NCT00235820|Drug|adalimumab|40 mg every other week following an 80 mg dose
75541792|NCT00235820|Drug|MTX|MTX 7.5 to 25 mg once weekly
75384846|NCT02082522|Drug|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
75705403|NCT05144945|Biological|Quadrivalent Recombinant Influenza Vaccine (RIV4)|Solution for intramuscular injection
75705404|NCT05144945|Biological|Quadrivalent inactivated influenza vaccine (IIV4)|Suspension for intramuscular injection
75705405|NCT05141370|Device|cataract surgery with CATSYS|patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS
75705406|NCT05139303|Device|Orthoapnea NOA®|The efficacy of the appliance for the management of OSA will be stablished based on two criteria. Criterion I: > 50% reduction of AHI/RDI. Criterion II: AHI/RDI < 5 events/hour or <15 events/hour with a significative reduction of OSA associates symptoms as defined before. Therapeutic failure will be established when at 100% of advancement of the device, there is less than 50% of reduction of the AHI/RDI with a residual AHI/RDI >5 events/hour with OSA associates symptoms.
75705407|NCT05135767|Behavioral|Brief Motivational Interviewing with Personalized Feedback|A brief motivational interviewing (MI) intervention will target drinking. The intervention will leverage in-depth personalized feedback to identify areas of progress and barriers to change. The personalized feedback will include results of laboratory diagnostic tests, summary reports of timeline followback interviews, and graphical depictions of self-monitoring reports collected on smartphones in daily life. The brief intervention will include an initial 60-minute videoconference session, two brief, 5-10 minute phone-call check-ins completed one and two weeks after the initial intervention, and a 30-minute videoconference booster session completed three weeks after the initial intervention.
75705408|NCT05135351|Dietary Supplement|Resistant Starch|A prebiotic nutritional supplement available at commercial grocery and health food stores. Specifically, we will be using Bob's Red Mill® potato starch.
75705409|NCT05135351|Dietary Supplement|Maltodextrin|A starch commonly used as a placebo in prebiotic trials that is digested in the stomach and rapidly absorbed
75384847|NCT02082522|Procedure|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
75541793|NCT00235820|Drug|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
75705410|NCT05130996|Device|dental prothesis|5 ranges of implants can be used : IDAll, IDBio, IDCam, IDMax, ID3
75705411|NCT05126485|Device|Haptic Biofeedback from SageMotion Biofeedback System|"Haptic biofeedback units (vibrating motors) will be placed on individual body segments. The haptic biofeedback system will be configured to provide vibratory stimuli when a target minimum hip extension angle is reached during the loading response. The minimum threshold will be determined by the therapist based on the patient's current ability. Specifically, the system will target a 10-20% increase in extension angle from their current level, as identified by the therapist. A vibration stimulus will be first applied each time this minimum angle is achieved, and will continually increase in intensity in proportion to the degree with which the patient exceeds this minimum value. The stimuli will stop being applied when the extension angle drops back below the threshold. These intensity-modulated stimuli have been selected to encourage the patient to exceed the minimum threshold rather than stop extending when the stimulus is first applied"
75705412|NCT05123027|Behavioral|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|Participants will meet with the PILOT Peer consistently throughout the 6 months of study participation.
75705413|NCT05123027|Behavioral|Treatment As Usual Peer|Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.
75705414|NCT05119621|Device|TENS application|Assigned Interventions: In addition to the standard pain management applied in the clinic, TENS will be applied to children who have had surgery.
75705415|NCT05117489|Drug|Miricorilant 150 mg|Miricorilant 150 mg for oral dosing
75705416|NCT05117489|Drug|Miricorilant 100 mg|Miricorilant 100 mg for oral dosing
75705417|NCT05117489|Drug|Miricorilant 50 mg|Miricorilant 50 mg for oral dosing
75705418|NCT05117489|Drug|Miricorilant 10 mg|Miricorilant 10 mg for oral dosing.
75705419|NCT05116722|Device|Shoulder Pacemaker|Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
76031786|NCT04014829|Diagnostic Test|Mechanical Temporal Summation|"Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script."
76031787|NCT04014829|Diagnostic Test|Hospital Anxiety and Depression Scale|Standardized questionnaire to determine the level of anxiety and depression.
76031788|NCT04014829|Diagnostic Test|Pain Catastrophizing Scale|Standardized questionnaire to determine the level of pain catastrophizing.
75384848|NCT02082522|Drug|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
76031789|NCT04014829|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization.
76031790|NCT04014829|Diagnostic Test|Fear-Avoidance Component Score|Standardized questionnaire to determine the level of fear and avoidance.
76031791|NCT04014829|Diagnostic Test|EQ-5D|Standardized questionnaire to assess generic health-related quality of life.
76031792|NCT04014829|Diagnostic Test|heart rate variability|Heart rate variability will be determined from the R-to-R intervals obtained from a 5-minute ECG recording.
75384849|NCT02082210|Drug|Emibetuzumab|Administered Intravenously (IV)
75384850|NCT02082210|Drug|Ramucirumab|Administered Intravenously (IV)
75705420|NCT05101070|Drug|S-531011|Administered by intravenous infusion
75705421|NCT05101070|Drug|Pembrolizumab|Administered by intravenous infusion
75705422|NCT05087095|Behavioral|CALM Intervention|"The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy~Within one week after its completion,~3 months after the CALM intervention is complete~After each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components"
75705423|NCT05064332|Drug|PF-06650833|400 mg by mouth (PO) Once daily (QD) for 11 days
76031793|NCT04014829|Diagnostic Test|Anxiety, anticipated pain, anticipated analgesia|Preoperative anxiety (0 to 100), anticipated pain (0 to 100), and anticipated analgesia requirement (0 to 5).
76031794|NCT04014829|Diagnostic Test|State-trait anxiety inventory|Standardized questionnaire to assess anxiety.
76031795|NCT04014829|Diagnostic Test|Beck's Depression Inventory|Standardized questionnaire to assess depressive symptoms.
76031796|NCT05634629|Procedure|Anterior Lamellar Recession|ALR is a common surgical treatment that splits the skin and orbicularis oculi muscle from the tarsus and conjunctiva to recede the anterior lamella and expose the tarsus. Interlamellar separation can be accomplished via a grey line technique, an eyelid crease approach, or a combination of the two
75384851|NCT02107092|Drug|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for 11 months.
75384852|NCT02107014|Drug|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
75384853|NCT01624974|Drug|MK-1029|MK-1029 150 mg tablets taken QD
75384854|NCT01624974|Drug|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
75384855|NCT01624974|Drug|Montelukast (ML)|ML 10 mg tablets QD
75384856|NCT02065518|Device|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 21-30% of MVC during weeks 3-6 and 31-40% of MVC during weeks 6-9, 41-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
75384857|NCT02065518|Behavioral|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved. At week 7, participants will be given a weighted vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
75384858|NCT02065518|Behavioral|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
75384859|NCT01624662|Drug|Fluticasone propionate|Delivered via Optinose Exhalation Delivery System
75384860|NCT02106390|Biological|Meningococcal group B Vaccine, rMenB+OMV NZ|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
75705424|NCT05064332|Drug|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
75705425|NCT05063331|Procedure|Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)|Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.
75541794|NCT04554199|Device|Flexible partial denture|removable partial dentures (RPDs) were fabricated using thermoplastic resins (flexible RPDs). EEG and MMSE were evaluated before denture delivery and after one month of denture wear.
76031797|NCT05634629|Procedure|Bilamellar Tarsal Rotation|the full-thickness transverse blepharotomy combined with everting sutures to rotate the inferior portion of the upper lid outwards and this procedure has a low recurrence risk
75705426|NCT05063331|Procedure|Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)|The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
76031798|NCT05088031|Device|shock waves therapy|"Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)"
76031799|NCT05087953|Diagnostic Test|Head-Up Tilt table test|Autonomic response assessment in the orthostatic head up tilt test.
75868839|NCT06160999|Behavioral|Vaccine-in-a-van|For the vaccine-in-a-van concept, our community health worker will travel to different areas in the test subdistricts. These locations will be decided on in conjunction with the local health department and the research team's knowledge of the area. We will target areas which would have families with young children, particularly: schools, mosques, and sports fields. The purpose of the van will be to bring vaccines to the community, but also to put a human face (our community health worker) to vaccines outside of a clinical setting.
75868840|NCT06160973|Other|Feed the Household|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household
76031800|NCT05087953|Diagnostic Test|Heart Rate Variability|Assessment of heart rate variability on 24-hour Holter monitoring..
75868841|NCT06160973|Other|Dedicated Driver|Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
76031801|NCT05087797|Drug|nicorandil|Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
76031802|NCT05087719|Combination Product|experimental group|patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks
76031803|NCT05087719|Combination Product|conventional treatment|patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
76031804|NCT05087017|Other|Intervention group|Patients with medical condition to follow the rehabilitation program will be asked to answer questionnaires to assess their sleep quality.
75705427|NCT05057780|Other|Communication Skills Curriculum|Our novel intervention adapted curricula around effective skills used to navigate common communication challenges in clinical practice. These skills were selected after determining patterns from multiple communication sessions delivered to over 6,000 healthcare providers. Our main goal was to enhance communication with patients by helping residents gain confidence and competence using these under-utilized communication skills, regardless of the communication challenge. Over the course of three, 1-hour long sessions on communication in the 2017-2018 academic year, internal medicine residents learned three of these highly effective and often under-utilized skills; reflective listening, responding to emotion and reframing, respectively.
75705428|NCT05055141|Other|Care to Share poster|The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
75384861|NCT02106390|Biological|Meningococcal ACWY Conjugate Vaccine, MenACWY|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
75384862|NCT02064894|Drug|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
75384863|NCT02064894|Drug|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
76031805|NCT05086861|Device|Oesophageal pacing after left atrial posterior wall isolation|Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
75384864|NCT02064894|Drug|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
75384865|NCT04707768|Drug|Vadadustat|oral tablets
75384866|NCT04707768|Drug|Mircera®|intravenous administration
75384867|NCT02081586|Behavioral|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
75384868|NCT02081586|Device|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
75705429|NCT05051345|Other|Informational Intervention|Receive information on the services provided for pregnant women and smoking cessation
75384869|NCT02081586|Other|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
75384870|NCT02081196|Device|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
75384871|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
76031806|NCT05086783|Other|Video-based coaching|The coaching session will follow the Wisconsin Coaching Framework (Greenberg 2015). The surgical coaching session will last at maximum 30 minutes and will occur within 1-2 week following the procedure. The surgical coaching session will occur over Zoom. The second attempt will occur within 1 week following the coaching session.
76031807|NCT05086783|Other|Standard surgical teaching (master-apprentice model - (MAM))|Standard surgical teaching that conventionally occurs in the operating room follows a master-apprentice model (MAM).
75384872|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
75705430|NCT05051345|Other|Informational Intervention|Receive tobacco cessation self-help materials
75705431|NCT05051345|Other|Informational Intervention|Receive Smoke-Free Homes mailings
75705432|NCT05051345|Other|Media Intervention|Download and use the Wellness app
75705433|NCT05051345|Other|Questionnaire Administration|Ancillary studies
75705434|NCT05051345|Behavioral|Smoking Cessation Intervention|Receive Smoke-Free Homes kit
75705435|NCT05051345|Other|Survey Administration|Ancillary studies
75705436|NCT05051345|Behavioral|Telephone-Based Intervention|Receive telephone counseling sessions
75705437|NCT05051345|Behavioral|Telephone-Based Intervention|Receive a coaching call from a Baby Steps for Health counselor
75868842|NCT06160973|Other|Feed the Individual|Medically tailored meals will be provided for the enrolled individual
75868843|NCT06160973|Other|Commercial Shipper|Meals will be delivered by a commercial shipping organization
75868844|NCT06160414|Drug|Metformin|Participants will receive Metformin orally, after fasting.
75868845|NCT06160414|Drug|Rosuvastatin|Participants will receive Rosuvastatin orally, after fasting.
75868846|NCT06160414|Drug|ALXN2080|Participants will receive ALXN2080 orally, after fasting.
76031808|NCT05070949|Behavioral|Mindful Self-Compassion|Bi-weekly meeting will involve six lessons: What is Self-Compassion , Practicing Self-Compassion, Discovering your Compassionate Voice, Self-Compassion and Resilience , Self-Compassion and Burnout and Making it Count
76031809|NCT04011787|Dietary Supplement|bolus NGT feeding|Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes
76031810|NCT04011787|Dietary Supplement|Continuous NGT feeding|Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol
76031811|NCT04011787|Diagnostic Test|Continuous Glucose Monitoring|Both participant groups will have continuous glucose monitoring performed for 5 days while in the study
75384873|NCT02080260|Drug|regorafenib|Single agent drug therapy with regorafenib
75384874|NCT01624194|Drug|Oxytocin nasal spray|24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice daily for 4-weeks.
75384875|NCT01624194|Drug|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
75384876|NCT02079636|Drug|Abemaciclib|Administered orally
75384877|NCT02079636|Drug|Pemetrexed|Administered IV
75384878|NCT02079636|Drug|Gemcitabine|Administered IV
75384879|NCT02079636|Drug|Ramucirumab|Administered IV
75384880|NCT02079636|Drug|LY3023414|Administered orally
75384881|NCT02079636|Drug|Pembrolizumab|Administered IV
75705438|NCT05051345|Other|Tobacco Cessation Counseling|Receive telephone counseling sessions
75705439|NCT05036330|Other|Clinical Evaluation|Undergo speech and swallow evaluation
75705440|NCT05036330|Procedure|Physical Examination|Undergo examination of TEP and laryngectomy stoma
75705441|NCT05036330|Other|Quality-of-Life Assessment|Complete questionnaires
75705442|NCT05036330|Other|Questionnaire Administration|Complete questionnaires
75705443|NCT05027308|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection
75705444|NCT05022823|Device|Compression sleeve, worn during exercise|Participants wear their daytime compression sleeve during the DPRE program.
75705445|NCT05022823|Device|Adjustable Compression (AC) garment, worn during exercise|Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.
76031812|NCT04011787|Diagnostic Test|Metabolic Profile|Bloods will be taken to assess all patients metabolic profile
76031813|NCT04011787|Radiation|Chest X-ray|A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
76031814|NCT03867799|Drug|Nivolumab|Immunotherapy
76031815|NCT05085925|Behavioral|Cognitive behavioral mindfulness intervention|The group that receives mindfulness-based stress reduction at their entry into the study will have 7 sequential sessions during 3 months, and later have a booster session in month 5
76031816|NCT05085925|Behavioral|Cognitive behavioral mindfulness intervention after 3-month wait list|Wait-list control patients will get no intervention at the start of the study and instead will be contacted by study personal 7 times to care for the patient in order to control for the 7 sessions performed in the intervention group. After three months they will be offered mindfulness-based stress reduction as 8 sequential sessions.
75705446|NCT05022823|Device|Compression sleeve, daytime wear|Compression sleeve worn for at least 12 hours per day, seven days a week.
76031817|NCT05085769|Procedure|Bariatric surgery|A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
76031818|NCT05085457|Diagnostic Test|ExPreS Protocol|Prof, aqui explicamos o que é o ExPreS????? Já que ele fala para não repetir informação
76031819|NCT03726073|Device|Transcutaneous acupoint electrical acupoint stimulation(TEAS) and auricular acupressure|Bilaterally Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) will be used as the TEAS acupoints. Six acupoints (Shenmen, Point Zero, subcortex, heart, liver, and endocrine) located on ears will be used as the auricular acupressure points.
76031820|NCT03726073|Other|Usual care|Patients in this group only receive usual care developed by the study hospital
75705447|NCT05022823|Behavioral|Decongestive Progressive Resistance Exercise program|"Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually."
75705448|NCT05022823|Behavioral|Home exercise program|Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.
75705449|NCT05016531|Device|Low Intensity Focused Ultrasonic Stimulation|Brain stimulation using ultrasonic stimulation in a sequence of increasing intensity (sham, 1 W/CM2, 2 W/CM2, 4 W/CM2, 6 W/CM2, 8 W/CM2)
75541795|NCT04554355|Behavioral|School-based PA intervention|Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
75541796|NCT04554238|Device|Armeo spring|Armeo spring is an exoskeleton that allows intensive therapy aimed at upper extremity tasks, which can be regulated according to the anthropometric measurements of the child and the objective of the session. The software contains an extensive library of game-like exercises that are run in a motivating and informative virtual reality training environment, clearly showing the functional task to be performed through immediate feedback in a 3D work space.
75705450|NCT05016531|Device|Low Intensity Focused Ultrasonic Stimulation Frequency|Brain stimulation using ultrasonic stimulation of intensity level determined from intervention 1 at progressively increasing frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz)
76031821|NCT04873297|Drug|Metoclopramide 10mg|Tab. Metoclopramide 10mg TDS via NG tube
76031822|NCT04873297|Drug|Placebo|Placebo 10 ml of plain water Via NG
76031823|NCT02633501|Drug|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
76031824|NCT02633501|Drug|Gadobenate dimeglumine|Single IV bolus injection at a rate of 2 mL/second
76031825|NCT02633501|Device|MRI|
76031826|NCT05634473|Drug|Methacholine Chloride|Cholinergic agonists
75705451|NCT04997681|Behavioral|Combined Aerobic Exercise and Resistance Training (AE + RT)|AE + RT will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. AE + RT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 strength training exercises (that progressively increase in resistance intensity over time) will be completed followed by a break. Aerobic exercises that safely increase the participant's heart rate will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the AE + RT exercise session is approximately 65 minutes.
75384882|NCT02079246|Drug|Idalopirdine 60 mg|once daily, encapsulated tablets, orally
75384883|NCT02077374|Drug|IDN-6556|25 mg BID for 28 days
75384884|NCT02077374|Other|Placebo|Placebo BID for 28 Days
75384885|NCT02077140|Drug|MDT-10013|
75384886|NCT02077140|Drug|Standard of care for pain|
75384887|NCT02047110|Drug|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
75384888|NCT02047110|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
75705452|NCT04997681|Behavioral|Cognitive Training (NeuropeakTM)|NeuropeakTM is a program which will be completed by participants remotely using a tablet or computer. It consists of cognitive training including dual-task training that requires participants to maintain and prepare for many response alternatives (working memory) and to share attention between two concurrent tasks (divided attention). Difficulty of cognitive training is tailored to their individual functioning level. During each session, participants perform one of two different visuo-motor tasks, which include sets of visual stimuli (e.g., letters, numbers, animals, vehicles, fruits, celestial bodies) and respective hand-button correspondences (i.e., keys that are to be tapped on either the right or the left side of the screen). Participants are instructed to perform these tasks as fast as possible, while maintaining accuracy. Training also includes online feedback and a histogram of daily performance to encourage improvement. NeuropeakTM takes approximately 30 minutes to complete.
75705453|NCT04997681|Behavioral|Control Cognitive Training of Website Searching and Video Watching (WS+V)|During the WS + V task, participants alternate between 2 different tasks (touristic searching using internet and video watching). For the touristic searching using internet, participants are required to find 3 hotels, 3 touristic places, and 3 restaurants of their own preference in a city assigned by the instructor (a new city will be selected each session). They will also need to include the respective addresses of those places on their log sheet. For the video watching task, participants watch a National Geographic video on YouTube selected by the instructor with a different video selected for each session. They will watch the video for 20 minutes and during the remaining 5 minutes they will answer the following questions on their log sheet: 1) What is the video about? 2) What is the most important information in your opinion? 3) Create a question based on the video and answer your own question. WS + V sessions take approximately 30 minutes to complete.
75705454|NCT04997681|Behavioral|Control Balance and Toning Exercise Training (BAT)|BAT exercises will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. BAT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 balance and toning exercises will be completed followed by a break. Stretching exercises will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the BAT exercise session is approximately 65 minutes.
75705455|NCT04990349|Drug|Oxygen gas|Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
75384889|NCT02046564|Drug|ASC-01|
75384890|NCT02046564|Drug|Placebo|
75384891|NCT02046174|Biological|RENCA macrobeads|
75384892|NCT02045862|Drug|Solifenacin succinate|Participants received solifenacin 5 mg orally once a day at the same time each day.
75384893|NCT02045862|Drug|Mirabegron|Participants received mirabegron 50 mg orally once a day at the same time each day.
75384894|NCT02045862|Drug|Placebo to match solifenacin|Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
75384895|NCT02045862|Drug|Placebo to match mirabegron|Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
75384896|NCT02075658|Device|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
75384897|NCT02075658|Device|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
75384898|NCT02063880|Other|Urgent ART|Children will be started on HAART <48 hours after enrollment.
75384899|NCT02063880|Other|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
75384900|NCT02044848|Drug|Secukinumab|
75384901|NCT02044848|Drug|Placebo|Placebo
75384902|NCT02044458|Device|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
75384903|NCT04182984|Drug|Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
75384904|NCT02044302|Drug|Bupivacaine|
75384905|NCT02044302|Drug|Botulinum Toxins|
75384906|NCT02044302|Drug|Analgesics|
75541797|NCT04554238|Other|Occupational Therapy|This treatment includes passive stretching exercises, weight bearing, stimulation of protective reactions, muscle strengthening exercises and different types of motivating bimanual games, favoring reaching, grasping, exploration and manipulation.
75541798|NCT00268710|Drug|docetaxel|
75384907|NCT02062944|Drug|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
75384908|NCT02062632|Drug|Doxepin Hydrochloride|Given orally
76031827|NCT05634317|Behavioral|Smartphone delivered Behavioral activation|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 Review the present use of time and use the monitoring form~Session 2 Brain-storm pleasant events and schedule pleasant activities~Session 3 Review scheduling of events and discuss how to improve~Session 4 Review modifications and consolidate gains on scheduling~Session 5 Review present social support and explore new sources of support~Session 6 Examine communication skills and explore new options~Session 7 Review new communications and discuss how to improve~Session 8 Review modification and consolidate gains on support"
75705456|NCT04987216|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
75384909|NCT02062632|Other|Placebo|Given orally
75384910|NCT02062632|Other|Quality-of-Life Assessment|Ancillary studies
75384911|NCT02062632|Other|Questionnaire Administration|Ancillary studies
75705457|NCT04976088|Drug|Diclofenac Sodium 140 mg medicated plaster|Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
75705458|NCT04976088|Drug|Diclofenac epolamine (DIEP) 180mg medicated plaster, Flector|Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day
75705459|NCT04976088|Drug|Placebo|Placebo: Placebo plaster, topical application once a day.
75541799|NCT02212873|Other|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
75384912|NCT02062398|Device|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
75384913|NCT02061540|Drug|LUM001|LUM001 oral dose
75384914|NCT02043366|Drug|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
75384915|NCT02043366|Drug|Butorphanol|Butorphanol is intravenously administrated
75384916|NCT02043366|Drug|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
75384917|NCT02043366|Drug|Remifentanil|Remifentanil is intravenously administrated
75384918|NCT02043366|Drug|Sufentanil|Sufentanil is intravenously administrated
75384919|NCT02060370|Drug|Sunitinib|"Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
75384920|NCT02060370|Behavioral|Questionnaire|Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
75384921|NCT01622088|Drug|Dexpramipexole|Oral tablet 150 mg given twice daily (BID)
75384922|NCT01621542|Biological|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
75384923|NCT02021292|Drug|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
75705460|NCT04920318|Combination Product|tDCS + language therapy|In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
75705461|NCT04920318|Combination Product|sham TDCS + language therapy|sham control will be applied with language therapy to the same regions as active TDCS.
75705462|NCT04912323|Device|Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold|Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
75384924|NCT02021292|Drug|Placebo|Matching placebo oral tablet, to be taken once daily.
75384925|NCT02059980|Behavioral|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
75384926|NCT02059980|Behavioral|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
75541800|NCT04554082|Procedure|laparoscopic sleeve gastrectomy|bariatric surgery to loss weight
75557666|NCT00481884|Other|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
75557667|NCT00481923|Drug|rimonabant (SR141716)|
75557668|NCT00437138|Behavioral|Exposure to dilute diesel exhaust (300µg/m3) or filtered air|
75557669|NCT00481962|Drug|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
75557670|NCT00437177|Drug|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
75557671|NCT00437177|Drug|[(123)I] iodobenzamide|[(123)I] iodobenzamide 185 MBq I.V., at discharge.
75384927|NCT02043132|Drug|Tranexamic Acid|Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
75557672|NCT00482040|Device|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
75384928|NCT02043132|Drug|Placebo|Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
75384929|NCT02059434|Drug|LAS190792 Dose 1|
75384930|NCT02059434|Drug|LAS190792 Dose 2|
75384931|NCT02059434|Drug|LAS190792 Dose 3|
75384932|NCT02059434|Drug|LAS190792 Dose 4|
75384933|NCT02059434|Drug|LAS190792 Dose 5|
75384934|NCT02059434|Drug|LAS190792 Dose 6|
75384935|NCT02059434|Drug|LAS190792 Dose 1 (Part 2)|
75384936|NCT02059434|Drug|LAS190792 Dose 2 (Part 2)|
75384937|NCT02059434|Drug|Tiotropium 18 μg|
75384938|NCT02059434|Drug|Indacaterol 150 μg|
75384939|NCT02059434|Drug|Placebo|
75384940|NCT02059278|Drug|T-2345|T-2345 Ophthalmic Solution
75384941|NCT02059278|Drug|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
75384942|NCT04680780|Other|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 months
75384943|NCT04680780|Other|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
75384944|NCT04680780|Other|Control|Patients are allowed to eat ad libitum, but will be advised that low salt intake (< 5-7 g/day) and sufficient fluid intake (>3 l/day) which is considered beneficial in ADPKD.
75557673|NCT00437333|Drug|Metformin cloridrate|
75557674|NCT00482079|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
75557675|NCT00482079|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
75557676|NCT00437372|Drug|Sunitinib|"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."
75705463|NCT04874038|Drug|Lidocaine 20mg/ml|Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).
75384945|NCT02020512|Drug|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
75384946|NCT02041962|Behavioral|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
75384947|NCT02041962|Other|Educational Control|
75705464|NCT04874038|Drug|Placebo|Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
75705465|NCT04866719|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
75705466|NCT04828148|Behavioral|Survey|An online survey made by the authors was used, which is comprised of a total of 48 questions where different types of information are distinguished regarding the participant who is answering it such as age, gender, medical degree, comorbidities if during the pandemic they have been in contact with patients suspected or confirmed of COVID-19 infection if they have been infected by COVID-19 and the outcome of this infection. It also refers to whether they know doctors in the same specialty or others who have died from COVID-19 infection.
75705467|NCT04799535|Procedure|Ultrasound|Undergo breast ultrasound
75384948|NCT02041494|Device|Ventralight|
75384949|NCT02041494|Device|Strattice|
75384950|NCT04722042|Other|place-based mapping|Adjusting the electric frequency filters to align with the cochlear place frequency
75384951|NCT04722042|Other|default mapping|Default frequency filter assignments
75384952|NCT04699812|Device|ELECTROCARDIOGRAM (ECG) PATCH WEAR|ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
75384953|NCT04699266|Device|Assigned Intervention (POD F GF)|The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
75384954|NCT04698252|Radiation|Radiotherapy|Radiation therapy for oligometastatic sites
75557677|NCT00437372|Radiation|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
75705468|NCT04785352|Dietary Supplement|Nutrition Intervention|One egg per day for six months
75705469|NCT04785352|Behavioral|Grandi Byen|Multicomponent intervention on responsive parenting, nutrition, hygiene + one egg per day for 6 months
75705470|NCT04771481|Drug|Metoclopramide|Metoclopramide 10 mg + NSS 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
75557678|NCT00437411|Behavioral|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
75557679|NCT00482196|Drug|MK0493|
75384955|NCT04698252|Procedure|Surgery|Surgery for oligometastatic sites
75384956|NCT04698252|Other|Radiofrequency ablation|Radiofrequency ablation for oligometastatic sites
75384957|NCT02041104|Dietary Supplement|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
75384958|NCT02041104|Dietary Supplement|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
75384959|NCT02019420|Drug|Tedizolid phosphate|Tedizolid phosphate IV 200 mg once daily
76031828|NCT05634317|Behavioral|Smartphone delivered Mindfulness|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 The Raisin exercise (eating meditation) and12-min body scan~Session 2 Exercises on thoughts and feelings 12-min body scan~Session 3 Exercises focusing on unpleasant experiences, practicing seeing and hearing , sitting meditation, 3-min breathing space, and mindful stretching and breath meditation~Session 4 Practicing seeing and hearing, mindful communication, 3-min breathing space, and sitting meditation~Session 5 Mindful walking, 3-min breathing space, and sitting meditation~Session 6 Sitting meditation, exercises on thoughts and alternative viewpoints, and 3-min breathing space (responsive)~Session 7 Sitting meditation, activity and mood exercise, identifying habitual emotional reactions to difficulties, and 3-min breathing space (responsive)~Session 8 12-min body scan, exercise on looking forward, and exercise on preparing for the future"
75384960|NCT02019420|Drug|Linezolid|Linezolid IV 600 mg twice daily
75384961|NCT02019264|Drug|Lorcaserin hydrochloride|APD356 10 mg twice daily
75384962|NCT02019264|Drug|Placebo|Placebo twice daily
75384963|NCT02019108|Other|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
75384964|NCT02019108|Other|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
75384965|NCT02018562|Device|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
75705471|NCT04771481|Drug|Normal Saline 10 mL Injection|Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
75705472|NCT04769700|Behavioral|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale is a self-administered questionnaire made up of 10 items scored using a four-point Likert scale (0-3) designed to screen for symptoms of postpartum depression. Postpartum depression represents the end of a continuum of severity of symptoms. The present study used a cutoff point for depressive symptomatology risk of higher than 12.
75705473|NCT04769700|Behavioral|Breast Feeding Adherence|This will be addressed according to the breastfeeding initiation practices according to the WHO.
76031829|NCT05085145|Biological|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
76031830|NCT05634239|Behavioral|Health Education|"Interview, clinical examination and health education conducted by the clinic nurse.~Appointment with the physiotherapist including the assessment of physical functioning, use of assistive mobility devices, and amount of help needed in activities of daily living."
76031831|NCT04858711|Drug|ketamine-lidocaine-dexmedetomidine|In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.
76031832|NCT04858711|Drug|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
75384966|NCT02058966|Drug|Entacapone|Entacapone 200 mg oral dose
75384967|NCT02058966|Drug|Methamphetamine|Methamphetamine 20 mg oral dose
75384968|NCT02058966|Drug|Placebo|capsules compounded to be of similar appearance to the active drugs
75384969|NCT02017860|Drug|Everolimus|Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
75384970|NCT02040870|Drug|LDK378|750 mg once daily
75384971|NCT04697472|Device|LIFT System|The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
75384972|NCT04720716|Drug|IBI310|IBI310 IV d1, Q6W
75384973|NCT04720716|Drug|Sintilimab|sintilimab IV d1, Q3W
75384974|NCT04720716|Drug|Sorafenib|Sorafenib 400mg po
75384975|NCT04719624|Device|Adaptos®-Si [0.5-1 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
75557680|NCT00437450|Drug|Epoetin/Atra|
75557681|NCT00482235|Drug|MK0359|
75557682|NCT04701710|Drug|Ivermectin / Iota-Carrageenan|The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
75557683|NCT01240707|Other|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
75557684|NCT00437567|Dietary Supplement|Galacto-oligosaccharide (GOS)|Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
75557685|NCT00437567|Other|Placebo|Similar quantity of sterile water to be added to milk
76031833|NCT03138187|Behavioral|Moderate exercise|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
75384976|NCT04719624|Device|Adaptos®-Si [1-2 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
75384977|NCT04719624|Device|Geistlich Bio-Oss (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
75541801|NCT02212912|Behavioral|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
75384978|NCT04719624|Procedure|Tooth extraction without bone graft material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth and the socket is filled only by clot. Subject will be followed at 2 weeks, 5 months, and 10 months for healing.
75384979|NCT04719624|Device|Adaptos® (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
75868847|NCT06159894|Other|DAY HOSPITAL ARM|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
75868848|NCT06159894|Other|Specialist-Care arm|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
75868849|NCT06159868|Other|Structured physiotherapy and rehabilitation|Comprehensive baseline assessment of function and nutrition using indirect calorimetry to identify nutritional requirements, to create and individualised plan for followed by daily targeted mobility retraining, exercise and nutrition.
75868850|NCT06159868|Other|Standard care|Standard ward based care provided by usual care teams
75868851|NCT06159569|Device|LACRIACT|"LACRIACT is is a preservative free ophthalmic sterile medical device solution. The solution is packaged in closable vials of inert material that does not affect the contents (clear low-density polyethylene), each vial contains 0.5 ml of solution.~Eligible patients will start the treatment. Patients will receive the box of eye drops, and will be instructed on how to self-administer 1 drop in each eye 4 times a day for 30 days starting from the day following the visit."
75868852|NCT06159556|Other|Peanut intake|Participants will consume 2 ounces of peanuts/peanut butter for 12 weeks
76031834|NCT03138187|Behavioral|Vigorous exercise|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
76031835|NCT03069209|Biological|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
76031836|NCT04771819|Device|SWIS|Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
76031837|NCT03068975|Drug|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
76031838|NCT03068975|Drug|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
75384980|NCT04696068|Other|Porcelain plates|The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
75384981|NCT02016300|Device|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
75384982|NCT02016300|Device|Non-Bracing|Microfracture performed with no post-operative unloader bracing
75384983|NCT02040090|Drug|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
75384984|NCT02058498|Behavioral|Physical activity|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
75384985|NCT02039778|Radiation|Stem Cell Radiotherapy (ScRT) and Temozolomide|"Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin & the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
75384986|NCT02015754|Drug|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
75384987|NCT02015754|Device|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
75384988|NCT02015754|Procedure|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
75384989|NCT04441944|Other|Telemedicine|Use of provider-to-provider telemedicine
75384990|NCT02015676|Drug|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
75384991|NCT02015676|Drug|paclitaxel|60 mg/m^2 IV weekly; dose increased to 70 mg/m^2, and subsequently 80 mg/m^2, after 2 treatment cycles with no evidence of DLT until disease progression
75384992|NCT02015676|Drug|Myocet|40 mg/m^2 IV weekly; dose increased to 50 mg/m^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
75384993|NCT02015520|Drug|Clazakizumab|
75384994|NCT02015520|Drug|Placebo (Matching with Clazakizumab)|
75384995|NCT02058108|Drug|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
75384996|NCT02058108|Drug|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
75384997|NCT04678986|Other|ER2|No intervention, data analysis only
75384998|NCT04417374|Other|Description of groups caracteristics|Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.
76023435|NCT04203953|Other|Early mobilization program|Early mobilization will be defined as any active exercise where the patients could assist with the activity using their own muscle strength and control that occurred within the first 7 days of trauma ICU admission and will be intended to maintain or restore overall function as well as being scored using the ICU mobility scale.15 The ICU mobility scale includes rolling, bridging, sitting, standing and walking, and upper and lower limb flexion and extension. In-bed therapies will include active or active-assist range of motion, bridge exercise, quadriceps setting, straight leg raising, rolling exercises and facilitation.
76023436|NCT04196075|Drug|Andrographis Paniculata|AP as palliative treatment
75384999|NCT04678362|Drug|Talazoparib + Avelumab|Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
75385000|NCT02057874|Device|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
75385001|NCT02057874|Drug|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
75385002|NCT04678050|Drug|Ketamine/ propofol|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
75385003|NCT04678050|Drug|Dexmedetomidine|Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
75541802|NCT02212912|Behavioral|no intervention|No intervention indicated that the physicians among control hospital provide routine
75705474|NCT04769700|Behavioral|Fear of Covid-19 Scale|The Fear of Covid-19 Scale is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. It consists of seven items, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19.
75385004|NCT04677426|Drug|Hyperpolarized Xe129|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
75385005|NCT02038920|Drug|Vedolizumab|Vedolizumab IV injection
75541803|NCT00261300|Drug|Pantoprazole|Long term Pantoprozole trial
75705475|NCT04757038|Device|Intradiscal injection|The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided.
75705476|NCT04720196|Device|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
75385006|NCT02038920|Drug|Vedolizumab placebo|Vedolizumab placebo-matching IV infusion
75385007|NCT02038764|Drug|Placebo|Placebo
75385008|NCT02038764|Biological|PF-06342674 Dose A|Multiple SC Doses
75385009|NCT02038764|Biological|PF-06342674 Dose B|Multiple SC Doses
75385010|NCT02038764|Biological|PF-06342674 Dose C|Multiple SC Doses
75385011|NCT02038764|Biological|PF-06342674 Dose D|Multiple SC Doses
75705477|NCT04720196|Device|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
75705478|NCT04696198|Other|Manual Therapy Intervention|Manual Therapy Interventions to improve range of motion and decrease pain
75705479|NCT04696198|Other|Standard care|standard care
75385012|NCT04693260|Device|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
75705480|NCT04687306|Diagnostic Test|X-rays- total of 4|X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions
75705481|NCT04667312|Drug|Durvalumab|Durvalumab
75705482|NCT04651582|Behavioral|Cognitive Training|20 hours of computerized activities designed to improve processing speed and divided attention
75385013|NCT04177836|Behavioral|Mindfulness intervention|Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
75385014|NCT02014740|Drug|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
75705483|NCT04651582|Behavioral|Cognitive Stimulating Activities|20 hours of traditional computer games
75705484|NCT04650893|Drug|Intravenous Ketorolac|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
75705485|NCT04650893|Drug|Intravenous Dexamethasone|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
75705486|NCT04650893|Drug|Placebo|Control
75385015|NCT02014740|Drug|Metformin|
75385016|NCT02014584|Drug|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
75385017|NCT02014584|Drug|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
75385018|NCT02014272|Drug|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
75541804|NCT02212990|Other|Acetaminophen Arm|Blinded Therapy
75541805|NCT02212990|Other|Placebo Arm|Blinded Therapy
75541806|NCT02212990|Other|Ibuprofen Arm|Open Label Therapy
75541807|NCT00235859|Drug|adalimumab|
75541808|NCT00235859|Drug|methotrexate|
75541809|NCT02213029|Drug|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or >150mg
75705487|NCT04611152|Drug|KSI-301|Intravitreal Injection
75705488|NCT04611152|Drug|Aflibercept|Intravitreal Injection
75385019|NCT02014272|Drug|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
75705489|NCT04611152|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
75705490|NCT04604041|Diagnostic Test|1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA|All groups will not have the same intervention. Interventions are listed and numbered for each group.
75705491|NCT04603937|Drug|KSI-301|Intravitreal Injection
75705492|NCT04603937|Drug|Aflibercept|Intravitreal Injection
75385020|NCT04963452|Other|Dural puncture epidural|Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.
75385021|NCT02037984|Biological|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
75385022|NCT02037984|Biological|V114 1x:1x:1x|V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
75385023|NCT02037984|Biological|V114 2x:2x:2x|V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
75385024|NCT02037984|Biological|V114 2x:1x:2x|V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
75385025|NCT02037984|Biological|V114 1x:1x:2x|V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
75705493|NCT04603937|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
75705494|NCT04603651|Drug|Bamlanivimab|Administered intravenously (IV).
75705495|NCT04602975|Biological|Injection SF2A-TT15 10 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 10 µg)
75705496|NCT04602975|Biological|Injection SF2A-TT15 10 µg|Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)
75705497|NCT04602975|Biological|Injection Adjuvanted Placebo|Intramuscular injection of Placebo with alhydrogel
75705498|NCT04602975|Biological|Injection Placebo|Intramuscular injection of the not adjuvanted Placebo
75705499|NCT04602975|Biological|Injection SF2A-TT15 2 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
75705500|NCT04602975|Biological|Injection SF2A-TT15 2 µg|Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
75705501|NCT04600934|Device|Shockwave|Shockwave Medical, Inc. Peripheral Lithoplasty® System
75705502|NCT04600934|Device|Plain old balloon angioplasty|POBA
75541810|NCT02213029|Drug|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
75705503|NCT04595890|Device|Arthrex Angel System used to prepare injection of Bone Marrow Concentrate (BMC)|Participants will have bone marrow aspirated from their iliac crest, then processed using the Arthrex Angel System to produce autologous bone marrow concentrate (BMC). Then, BMC will be injected into the participant's knee with knee osteoarthritis (OA).
75385026|NCT02037984|Biological|V114 0.5x:0.5x:2x|V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
75385027|NCT02057406|Drug|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
75385028|NCT02057406|Drug|High EPA|
75385029|NCT02057406|Other|Placebo|
75385030|NCT02036580|Biological|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
75385031|NCT02036580|Biological|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
75385032|NCT02036580|Other|Placebo|
75385033|NCT02014116|Drug|LY3009120 capsule|Administered orally.
75385034|NCT02057250|Drug|Sarilumab|Pharmaceutical form: Solution Route of administration: Subcutaneous
75385035|NCT02057250|Device|Auto-Injector Device (AID)|
75385036|NCT02057250|Device|Pre-filled Syringe (PFS)|
76023437|NCT04142255|Biological|FMT|FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
75385037|NCT02057250|Drug|Methotrexate|Dispensed according to local practice.
75385038|NCT02057250|Drug|Sulfasalazine|Dispensed according to local practice.
75385039|NCT02057250|Drug|Leflunomide|Dispensed according to local practice.
75385040|NCT02057250|Drug|Hydroxychloroquine|Dispensed according to local practice.
75385041|NCT02036502|Biological|Pembrolizumab|Intravenous (IV) infusion
75385042|NCT02036502|Drug|Lenalidomide|Oral capsule
75385043|NCT02036502|Drug|Dexamethasone|Oral tablet IV infusion
75385044|NCT02036502|Drug|Carfilzomib|IV infusion
75385045|NCT02056626|Drug|carvedilol|
75385046|NCT02035332|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
75385047|NCT02056392|Drug|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
75385048|NCT02056392|Drug|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
75385049|NCT02056392|Drug|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
75385050|NCT04716270|Procedure|Electrophysiology Study and Ablation|Electrophysiology Study and Ablation of Supraventricular Arrhythmias
75385051|NCT02034708|Drug|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
75385052|NCT02034708|Drug|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
75541811|NCT02213029|Drug|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
75541812|NCT02213029|Drug|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson & Johnson
75541813|NCT02213146|Drug|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
75541814|NCT02213146|Drug|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
76023438|NCT03863483|Drug|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
76023439|NCT03863483|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
76023440|NCT03863483|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
75868853|NCT06159426|Other|Vojta Therapy|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
75868854|NCT06157788|Diagnostic Test|functional Magnetic Resonance Imaging and clinical assessment|"fMRI task: In the active condition, video cues were utilized (lasting 10s) depicting everyday activities that trigger shoulder apprehension. Control videos were created to match the previous content, except for the absence of cues inducing shoulder apprehension. Following each video, a visual analog scale appeared for a duration of 2.5s, and participant were asked to rate the level of perceived apprehension, using an MRI-compatible response box. The rating scale consisted of nine steps, ranging from no apprehension to high apprehension. After providing their rating, participants had a rest period during which a fixation cross was displayed visually for 17.5s. Apprehension and control videos were shown in a pseudo-randomized fashion.~General Linear Model Analysis of Task-Related Activation~TICA Analysis of Functional Connectivity~White Matter TBSS of DTI Data~Voxel-based morphometry analysis of T1 images"
75868855|NCT06155383|Drug|Capecitabine|1000 mg/m2, Bid orally, D1-14, every 3 weeks
75541815|NCT02213146|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
75868856|NCT06155383|Drug|oxaliplatin|130 mg/m2, intravenous infusion, D1, every 3 weeks
75385053|NCT02034552|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST [National Institute of Standards and Technology] update) every 4 weeks x 6 doses intravenous slow bolus
75385054|NCT02034552|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
75385055|NCT02034552|Drug|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
75385056|NCT02034552|Drug|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
75385057|NCT02034474|Drug|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
75385058|NCT02034474|Drug|Placebo|intravenously via iv drip over 60 min
75385059|NCT02011542|Drug|VSL#3|This is a probiotic mixture
75705504|NCT04595890|Other|Saline injection|Participants will have bone marrow aspirated from their iliac crest to maintain masking. Then, saline will be injected into the participant's knee with knee osteoarthritis (OA).
75385060|NCT02011542|Drug|Placebo|This is a pill with inactive ingredients.
75385061|NCT02011386|Drug|Treatment|
75868857|NCT06155383|Drug|Disitamab Vedotin|2.5 mg/kg, intravenous infusion, D1, every 2 weeks
75868858|NCT06155383|Drug|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
75868859|NCT06154772|Other|Color Therapy|Color therapy will be applied to the body chakras for 10-15 minutes with colored fabrics, color therapy with water and colored light lamp.
75385062|NCT02010684|Behavioral|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
75541816|NCT00268749|Drug|glycine|0.8 g/kg/day
75705505|NCT04564885|Device|BAGUERA®C Cervical Disc Prosthesis|surgery
75705506|NCT04564885|Device|Mobi-C Cervical Disc|surgery
75868860|NCT06153212|Procedure|Membrane placement with bone grafting|The diseased dental implant will be cleaned and the bone defect will be filled with bone graft and covered by a membrane.
76023441|NCT03863483|Drug|Placebo|0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
76023442|NCT04010045|Device|Endovascular Treatment of PAD|PAD endovascular treatment using the DABRA Laser System + other FDA cleared/ approved devices for the treatment of PAD.
76023443|NCT03871595|Drug|BI 894416|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water.
76023444|NCT03840005|Drug|Ursonorm|Ursodeoxycholic acid
76023445|NCT03780725|Drug|BI 754111|Solution for infusion
76023446|NCT03780725|Drug|[89Zr]Zr-BI 754111|Solution for infusion
76023447|NCT03780725|Drug|BI 754091|Solution for infusion
75385063|NCT02034162|Drug|Mebendazole|Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
75385064|NCT02034162|Drug|Placebo|Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
75385065|NCT02034006|Drug|Ranibizumab|All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
75385066|NCT02054910|Procedure|Celiac Plexus Block|Patients will receive celiac plexus block during endoscopy.
75385067|NCT02054910|Procedure|Sham|Patients will not receive celiac plexus block during endoscopy.
75385068|NCT04714398|Behavioral|Opt-In Recruitment|Patients in the opt-in recruitment arm will receive a letter describing the program and inviting them to participate in the remote monitoring program. Along with the letter they will receive an informational brochure and a copy of the informed consent form. Patients in this arm will then receive a recruitment phone call explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will mail a blood pressure cuff and begin the remote monitoring program for the patient 6 days later.
75385069|NCT04714398|Behavioral|Opt-Out Recruitment|Patients assigned to opt-out recruitment will receive a blood pressure cuff with instructions in the mail along with a letter describing the program and opt-out framing regarding their participation, as well as a brochure and a copy of the informed consent form. Patients in this arm will receive a recruitment phone call similar to recruitment arm A, explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will begin the remote monitoring program for the patient immediately.
75868861|NCT06153069|Drug|Short-course regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, >70kg 2000mg daily; ethambutol ≤50kg 750mg daily, >50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
75385070|NCT02033850|Behavioral|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
75385071|NCT02054130|Drug|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
75385072|NCT02054130|Drug|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
76023448|NCT03830411|Drug|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
76023449|NCT03830411|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
75385073|NCT02054130|Drug|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
75385074|NCT02054130|Drug|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
75385075|NCT04673682|Drug|D309|D309(Testosterone) 1 vial, Once, IM injection
75385076|NCT04673682|Drug|CKD-845|CKD-845(Testosterone) 1 vial, Once, IM injection
75385077|NCT02009046|Behavioral|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
75385078|NCT02009046|Behavioral|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
75385079|NCT02009046|Behavioral|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
75385080|NCT02009046|Behavioral|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
75385081|NCT02052960|Drug|CetuGEX™|60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
75385082|NCT02052960|Drug|Cetuximab|400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
75385083|NCT02052960|Drug|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
75705507|NCT04551547|Biological|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 300SU/0.5ml
75385084|NCT02008890|Biological|Secukinumab 300mg|Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
75541817|NCT04553887|Drug|Almonertinib|single agent, 110mg p.o once daily until disease progressed
75541818|NCT00235898|Drug|CoFactor|
75541819|NCT00235898|Drug|5-FU|
75541820|NCT00235898|Drug|Leucovorin|
76023450|NCT03830411|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
75541821|NCT02213185|Other|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
75541822|NCT02213224|Drug|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
75705508|NCT04551547|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 600SU/0.5ml
75705509|NCT04551547|Other|Two doses of placebo at the schedule of day 0,28|The placebo contains no active ingredient and manufactured by Sinovac Research & Development Co., Ltd.
75705510|NCT04539236|Drug|Lenalidomide|Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
75705511|NCT04539236|Drug|Luspatercept|Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
75385085|NCT02008890|Biological|Secukinumab 150mg|secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
75868862|NCT06153069|Drug|Standard regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, >70kg 2000mg daily; ethambutol ≤50kg 750mg daily, >50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
75385086|NCT02008890|Biological|Placebo|secukinumab placebo s.c. (two PFS injections of placebo) self-administered
75385087|NCT02052414|Drug|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
75385088|NCT02007954|Device|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
75385089|NCT02049450|Drug|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
75385090|NCT02031432|Drug|Cebranopadol|Film-coated tablet; strengths: 200, 400, or 600 µg
75705512|NCT04520776|Device|BAGUERA®C Cervical Disc Prosthesis|surgery
75385091|NCT02031276|Drug|risankizumab IV|risankizumab administered by IV infusion
75385092|NCT02031276|Drug|risankizumab SC|risankizumab administered by SC injection
75705513|NCT04520776|Device|Mobi-C® Cervical Disc|surgery
75705514|NCT04509102|Drug|Adderall-XR|Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
75705515|NCT04509102|Drug|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
75705516|NCT04502186|Behavioral|Raising Our Spirits Together|Raising Our Spirits Together (ROST) is an 8-session computer-assisted cognitive behavioral therapy for depression. Core CBT content, including behavioral activation, cognitive restructuring, and problem solving, are delivered via the computer-assisted platform using video and text-based elements. The computer-assisted intervention is complemented by a workbook that includes in-session exercises as well as homework/action plans. ROST is delivered weekly, either virtually or in-person at a local church, and facilitated by a local pastor.
75385093|NCT02031276|Drug|Placebo|Placebo for risankizumab administered by IV infusion
75705517|NCT04502186|Other|Enhanced Control Condition|The Enhanced Control Condition intervention consists of providing participants randomized to this condition with a self-help book for depression (The Depression Helpbook; Katon et al, 2008) that is widely used and found to be beneficial, a local resource guide, and referrals.
75868863|NCT06152263|Other|Compare color information and mucosal microvascular density|To investigate the association between the color and mucosal microvascular density of CAG and EGC using linked color imaging.
75868864|NCT06149403|Genetic|Experimental: OTL-203|Experimental: OTL-203: Autologous CD34+ enriched cell fraction that contains hematopoietic stem and progenitor cells transduced ex vivo using lentiviral vector encoding the human IDUA gene
75705518|NCT04470518|Other|diagnostic algorithm|"Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).~The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor))."
75868865|NCT06149403|Genetic|Active Comparator: Allo-HSCT|Active Comparator: Allogeneic hematopoietic stem cell transplantation
75868866|NCT06147583|Other|Simulation of an insulin pump failure|The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
76031839|NCT02034331|Drug|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
75705519|NCT04439318|Drug|Trametinib Dimethyl Sulfoxide|Given PO
75705520|NCT04428060|Other|PERSEUS CPR|Resuscitation based on patient physiology
75705521|NCT04428060|Other|Standard CPR|Resuscitation based on current guidelines
75868867|NCT06123351|Device|Denneroll cervical traction orthodontic|traction for 3 to 15 minutes once daily
76031840|NCT02034331|Drug|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
75705522|NCT04409340|Device|Magnetic Resonance Viscoelastography|Magnetic Resonance Viscoelastography
75705523|NCT04409340|Device|QUS|QUS
75705524|NCT04367922|Behavioral|Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
75868868|NCT06123351|Other|stretching and strengthening exercises|strengthening exercises with 10 repetitions twice per day 3 times per week stretching exercises with hold for 20 to 30 seconds 3 repetitions daily
75868869|NCT06123351|Device|Vacuum-formed soft occlusal splint|2 mm thick elastic rubber sheets
75868870|NCT06122870|Biological|CampETEC HBC product|Immunoglobulin from bovine milk/colostrum and challenge strain
75868871|NCT06122870|Biological|ProMilk 85|Placebo ProMilk 85
75868872|NCT06122870|Biological|C. jejuni CG8421 Challenge strain|Challenge strain C. jejuni CG8421
75868873|NCT06118333|Drug|BL-B01D1|Administration by intravenous infusion
75868874|NCT06118333|Drug|capecitabine|Oral administration
75868875|NCT06118333|Drug|gemcitabine|Administration by intravenous infusion
75868876|NCT06118333|Drug|docetaxel|Administration by intravenous infusion
75868877|NCT06113458|Behavioral|Standard and One-time Training|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
75868878|NCT06113458|Behavioral|Standard and Practice Facilitation|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
76031841|NCT02034331|Drug|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
75541823|NCT02213224|Drug|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
75385094|NCT04686864|Behavioral|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
75385095|NCT02007720|Drug|Serelaxin|Intravenous infusion
75705525|NCT04349709|Behavioral|Brief school-based DBT-A|The intervention is inspired to Dialectical Behavior Therapy for Adolescents (DBT-A) (Rathus & Miller, 2015, Mazza et al, 2016; Cappelluccio, 2019). It consists in four monthly 2-hour sessions (for a total of 8 hours) scheduled during school-time. All the sessions are conducted by two psychotherapists trained about DBT. During the sessions, the model of emotions is described through a role-play between conductors. Subsequently, teens are trained about main emotional regulation skills. Moreover, basic elements of distress tolerance, mindfulness and interpersonal efficacy are introduced too.
75385096|NCT02007720|Drug|Placebo|Intravenous infusion
75705526|NCT04325308|Procedure|Protein-enriched human milk diet|1.2 g of human-based protein will be added to each 100 ml of human milk administered
75385097|NCT02007720|Other|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
75541824|NCT02213224|Drug|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
75705527|NCT04325308|Procedure|Usual human milk diet|Human-based protein will not be added to the human milk administered.
75705528|NCT04294745|Procedure|Buccal infiltration|Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus
75705529|NCT04294745|Procedure|Inferior alveolar nerve block|Standard technique of mandibular nerve block
75385098|NCT01363440|Drug|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
75385099|NCT01363440|Procedure|Macular Laser Photocoagulation|Laser therapy
75705530|NCT04283734|Device|iFR pullback with Syncvision software (Volcano company)|iFR pullback with Syncvision software permit us to analyze the vessel completely and to predict the physiological significance of every lesion and segment, to predict the benefit of the revascularization in terms of iFR improvement, and to predict the minimum stent length necessary to achieve this improvement.
75705531|NCT04278001|Device|Dual 24-hour ABPM|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
75705532|NCT04256317|Drug|Azacitidine|Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
75705533|NCT04256317|Drug|ASTX030 (cedazuridine + azacitidine)|Tablets/Capsules for oral administration
75705534|NCT04256317|Drug|Cedazuridine|Tablets for oral administration
75385100|NCT02007252|Drug|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
75385101|NCT02007252|Drug|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
75385102|NCT02007096|Drug|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight <100kg: 50ml total; weight >100kg: 60ml total
75385103|NCT02007096|Drug|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight <100kg: 50ml; weight >100kg: 60ml
75385104|NCT02006706|Drug|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
75385105|NCT02006706|Drug|methotrexate|10 - 25 mg/week
75385106|NCT02006706|Drug|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
75385107|NCT02049138|Drug|Upadacitinib|Tablet taken orally
75385108|NCT02049138|Biological|Pneumococcal 13-valent conjugate vaccine (PCV-13)|Administered by intramuscular injection
75541825|NCT00268788|Drug|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
75541826|NCT00268788|Drug|Intravenous immunoglobulin|Individual dose and frequency
75541827|NCT00235937|Drug|Anastrozole and goserelin|
75541828|NCT02213341|Procedure|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
75541829|NCT02213341|Procedure|Blood draw|
75541830|NCT04553614|Behavioral|Home-based HIIT|Home-based HIIT uses body-weight equipment free exercises. Participants complete all exercise in their own own at a time of their choosing. This potentially removes many of the barriers preventing at risk-individuals from engaging with the current exercise referral scheme, such as cost, time or intimidating gym environment.
75541831|NCT04553614|Other|Control|Usual exercise referral scheme procedure.
75385109|NCT04686318|Diagnostic Test|Biomarkers for acute pyelonephritis|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection."
75385110|NCT02048904|Drug|Sitagliptin|Sitagliptin 100 mg/day for 3 months
75385111|NCT02048904|Drug|Placebo|Placebo 1 pill/day for 3 months
75385112|NCT02006628|Drug|Placebo|Placebo oral solution (0 milligrams [mg]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
76031842|NCT02034331|Other|Heat application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
75385113|NCT02006628|Drug|GWP42003|GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
75385114|NCT02048826|Device|FINGER I|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I
75705535|NCT04249492|Device|IOL implantation experimental (Isopure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
75705536|NCT04249492|Device|IOL implantation active comparator (Micropure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
75705537|NCT04249245|Other|Nasal Swab|All
75705538|NCT04229680|Other|High Salt|Consumption of pills containing table salt for 10 days.
75868879|NCT06113458|Behavioral|High-intensity and One-time Training|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
75868880|NCT06113458|Behavioral|High-intensity and Practice Facilitation|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
76031843|NCT03592225|Behavioral|Educational workshop|the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
76031844|NCT04166981|Procedure|Instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.
76031845|NCT04166981|Procedure|Non-instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft.
76031846|NCT03068117|Other|Regular Early Specialist Symptom Control Treatment (RESSCT)|"Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
76031847|NCT03538873|Behavioral|Physical activity|
76031848|NCT05077189|Other|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale|"4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~Demographics Survey~DC/TMD Symptom Questionnaire (SQ)~Graded Chronic Pain Scale (GCPS)~Jaw Functional Limitation Scale-20 (JFLS-20)"
75705539|NCT04229680|Other|Recommended Salt|Consumption of pills containing dextrose for 10 days.
75705540|NCT04228380|Other|No intervention|No intervention
75385115|NCT02048826|Device|FINGER II|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
75541832|NCT04553224|Other|Clinical evaluations|SCORAD and target SCORAD
75541833|NCT04553224|Other|Non-invasive instrumental measurements|TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index
75541834|NCT04553224|Other|Subject's evaluations|PO-SCORAD, target PO-SCORAD and subject's questionnaire
75541835|NCT00261339|Drug|Pantoprazole|
75385116|NCT02006472|Drug|Pridopidine|22.5 mg and 45 mg capsules
75385117|NCT02006472|Other|Placebo|Capsules matching drug
75385118|NCT02005692|Device|DynaSense sensor|
75385119|NCT02029638|Biological|anti-thymocyte globulin|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
75385120|NCT02029638|Drug|Fludarabine|Fludarabine at dose 30 mg/m^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
75541836|NCT04553653|Other|checklist|The checklist will be implemented and healthcare providers use the checklist to manage the patients.
75541837|NCT00235976|Drug|Gantacurium Chloride for Injection (AV430A)|
75541838|NCT04553380|Drug|basic insulin|"Initial dose of basic insulin: 0.2U/kg/d.~Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~Injection time: subcutaneous injection before going to bed every night."
75541839|NCT04553302|Other|This study does not contain any intervention.|This study does not contain any intervention.
75868881|NCT06109571|Device|Connections App|The Connections app was developed for patients with substance use disorders or unhealthy substance use and adapted to include HIV support. For this study, it has been modified to provide additional resources to support patients engaged in HIV care. Connections' core features include agency-specific informational resources compiled in a resource center, patient self-monitoring through weekly check-in surveys, discussion rooms, and private messaging.
75541840|NCT00236015|Drug|Gabitril|
75541841|NCT00261378|Device|Transarterialchemoembolisation (TACE)|
75541842|NCT00261378|Device|DC Bead with Doxorubicin|
75541843|NCT04555408|Device|blue light|Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
75541844|NCT04555408|Device|bright light|Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
75541845|NCT04555408|Device|dim light|Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
75541846|NCT04553458|Device|Radiofrequency ablation|Radiofrequency ablation of the tumour
75541847|NCT04553458|Drug|Trance-arterial chemoembolization|Trance-arterial chemotherapy
75541848|NCT04553458|Procedure|Liver resection|non-anatomical or anatomical liver resection
75541849|NCT04553458|Combination Product|Combined radiofrequency ablation + percutaneous ethanol injection|combined therapy
75541850|NCT04553458|Drug|Percutaneous ethanol injection|Percutaneous ethanol injection of HCC
75541851|NCT04553458|Drug|Systemic chemotherapy|Systemic chemotherapy
75541852|NCT04553458|Drug|Sorafenib|Sorafenib
75541853|NCT04553458|Dietary Supplement|Viscum|Viscum for HCC
75541854|NCT04553458|Drug|Symptomatic treatment|Symptomatic treatment
75541855|NCT00236054|Drug|Gabitril|
75541856|NCT00268827|Drug|Kaletra soft-gel capsules switched to Kaletra tablets|
75541857|NCT00268827|Device|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
75541858|NCT04552756|Diagnostic Test|Seizure Diary|"The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline.~To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present."
75385121|NCT02029638|Drug|Cyclophosphamide|"Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~High dose cyclophosphamide [50mg/kg (Ideal Body Weight)] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume."
76031849|NCT04766957|Device|Idracare|Treatment will last 3 months (12 weeks). The treatment will be applied 2 times a week, preferably at night before going to bed.
75385122|NCT02029638|Radiation|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
75541859|NCT04553029|Other|No intervention|This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
75541860|NCT04552951|Drug|Cholecalciferol|Single doe of 100.000 IU
75541861|NCT02213419|Drug|Endoscopic ultrasonography-guided double ethanol lavage|"A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes."
75541862|NCT00268866|Behavioral|Education|
75541863|NCT00236093|Drug|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
75541864|NCT04552483|Drug|Nitazoxanide|Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
75541865|NCT04552483|Drug|Placebo|Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
75541866|NCT02213536|Radiation|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
75541867|NCT00261417|Drug|Tesaglitazar|
75541868|NCT02213614|Dietary Supplement|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
76031850|NCT03068039|Other|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
75541869|NCT02213614|Dietary Supplement|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
75541870|NCT02213614|Other|natural spring water|A group will drink natural spring water for 4 months
75541871|NCT02213653|Drug|ARM A : IV iron + epoietin zeta|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
75541872|NCT02213653|Drug|ARM B: IV iron + epoietin zeta sequence|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~carboxymaltose ferric (Ferinject ®) at week 1~Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
76031851|NCT03068039|Other|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
76031852|NCT05632991|Other|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 20 ml local anesthetic each side
75385123|NCT02029638|Drug|acetaminophen|650 mg orally prior to antithymocyte globulin infusion.
75385124|NCT02029638|Drug|diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
75868882|NCT06107751|Other|Ramped position group|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
75385125|NCT02029638|Drug|methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
75541873|NCT02213653|Drug|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
75541874|NCT02213731|Other|Holter monitoring|Subjects will wear holter monitors at baseline, 6 months and 12 months.
75541875|NCT00268944|Biological|Myozyme|20 mg/kg qow
75868883|NCT06107751|Other|Sniffing position group|This position will be achieved by placing a 7 cm pillow under the occiput.
75868884|NCT06105918|Procedure|Biospecimen Collection|Undergo blood sample collection
75868885|NCT06105918|Procedure|Computed Tomography|Undergo rhPSMA-7.3 PET/CT and SPECT-CT
75868886|NCT06105918|Radiation|External Beam Radiation Therapy|Undergo EBRT
75868887|NCT06105918|Other|Flotufolastat F-18|Given IV
75868888|NCT06105918|Drug|Lutetium Lu 177 PSMA-10.1|Given IV
75385126|NCT02029638|Biological|bone marrow transplant|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
75385127|NCT02029638|Drug|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
75385128|NCT02029638|Drug|mycophenolate mofetil|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
75385129|NCT02029638|Drug|prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
75541876|NCT04721093|Device|Photobiomodulation device|In this study, PBM was applied using a machine made to be attached to the subject in the form of a probe. In this clinical trial, a low-intensity irradiation device (Color-DNA-WSF U) from Color seven was used to deliver visible light (610nm± 10nm wavelength, 3.0mW/㎠±20%) irradiation. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
75868889|NCT06105918|Procedure|Positron Emission Tomography|Undergo rhPSMA-7.3 PET/CT
75868890|NCT06105918|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT-CT scan
75868891|NCT06100588|Other|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
75868892|NCT06100588|Other|Manual therapy|Manual therapy comprises stretching of muscles, mobilizations, traction and translation of vertebrae, Sustained Natural Apophyseal Glides (SNAG), dynamic soft tissue mobilization, Muscle Energy Techniques (MET) and home-exercises.
75868893|NCT06100393|Device|Investigational Pre-Processing Algorithm|The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.
75868894|NCT06100393|Device|Cochlear Limited standard-of-care pre-processing algorithms|Automatic Gain Control, SNR-NR, Forward Focus
75868895|NCT06100237|Drug|Teclistamab|Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
75868896|NCT06100237|Drug|Talquetamab|Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
75868897|NCT06100237|Drug|Daratumumab SC|Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
75868898|NCT06099769|Drug|Enzalutamide|mouth once daily (160 mg/day)
75868899|NCT06099769|Drug|Mifepristone|mouth once daily 300-mg tablet
75868900|NCT06099769|Drug|TPC|"The treating physician must select from one of the following regimens:~Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~Carboplatin AUC 6 IV Day 1 in a 21-day cycle~Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle"
75385130|NCT02029638|Drug|filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
75385131|NCT04710654|Other|connective tissue manipulation|Individuals in CTM group, will sit on a stool with hips and knees flexed at 90° and their hands free on the thighs. The application will start from the basic area in the first session, and in the other sessions, the lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment as soon as possible according to the state of the vascular reaction. CTM will be applied three days a week, for four weeks.
75385132|NCT04710654|Other|Interferential current stimulation (100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 100 Hz frequency three days a week, for four weeks.
75385133|NCT04710654|Other|Interferential current stimulation (0-100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 0-100 Hz frequency three days a week, for four weeks.
75385134|NCT04710654|Other|behavioural therapy|"The behavioral therapy includes patient education (description of the disease, symptoms, risk factors, treatment, defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advices (diet, water consumption, fiber food, etc.), teaching effective defecation posture, timed toilet training, self-abdominal massage.~Constipation Behavioral Therapy Booklet will be prepared within the scope of behavioral therapy."
75385135|NCT04710654|Other|exercise program|"Exercise program consisting of physical activity, core stabilization exercises and pelvic floor muscle exercises.~Exercise Program Booklet will be prepared within the exercise training."
75385136|NCT02047734|Drug|Ozanimod|Oral capsule, daily for 24 months
75385137|NCT02047734|Drug|Ozanimod placebo|Oral capsule, daily for 24 months
75385138|NCT02047734|Drug|Interferon beta-1a|Intramuscular injection, 30 µg, weekly for 24 months
75385139|NCT02047734|Drug|Interferon beta-1a placebo|Intramuscular injection, weekly for 24 months
75385140|NCT02053350|Drug|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
75385141|NCT04684914|Biological|HepTcell|Intramuscular injection
75385142|NCT04684914|Drug|Placebo|Intramuscular injection
75385143|NCT04709016|Behavioral|self-questionnaire|self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
75541877|NCT04552444|Drug|Biapenem|In the course of CRKP treatment, double dose biapenem was selected.
75868901|NCT06090448|Device|EarSwitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
75868902|NCT06079593|Procedure|Gasless Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering
75385144|NCT04417140|Biological|dHACM (AmnioWrap)|Dehydrated human amnion-chorion membrane (dHACM) is a healing adjunct that has been applied in a broad range of disease, and is FDA registered for wound healing.
75868903|NCT06079593|Procedure|Standard Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
75868904|NCT06077565|Other|foot-in-the-door technique and self-determination theory|the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so. Each participant will then receive a brief (approximately 5 minutes), individual intervention with health advice about the selected health-related lifestyle practice. The whole intervention will last approximately 10 minutes, but slightly longer if necessary.
75385145|NCT01994850|Drug|brentuximab vedotin|Trade name: Adcetris
76023451|NCT03300479|Drug|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
75385146|NCT02027844|Behavioral|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
75385147|NCT02027844|Behavioral|parental presence|parental presence during inhalational induction of sevoflurane
75385148|NCT04671576|Other|Control Infant Formula|Powder, standard commercial infant formula.
75385149|NCT04671576|Other|Organic Infant Formula|Powder, organic milk-based infant formula.
75385150|NCT01994382|Drug|Cerdulatinib|Oral capsule
75385151|NCT01994382|Biological|Rituximab|IV infusion
75385152|NCT02003898|Device|Medtronic MiniMed 530G Insulin Pump|
75385153|NCT01994226|Drug|Low-dose colchicine|"Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days"
75385154|NCT01994226|Drug|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
75385155|NCT02002884|Drug|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
75385156|NCT02002884|Drug|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
76023452|NCT03300479|Drug|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
75385157|NCT02002884|Drug|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
75868905|NCT06077565|Other|Follow-up booster intervention|For the first 6 months of the study period, the research assistant will deliver WhatsApp/WeChat messages about once per week. If a participant does not own a smartphone or is unable to receive WhatsApp/WeChat messages (uncommon in Hong Kong), the research assistant will make a telephone call, instead of sending a message, as a reminder for the participants to adhere to their desirable health-related lifestyle practice. Instant messaging via mobile applications has found to be effective in enhancing treatment compliance.
75385158|NCT02002182|Biological|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
75385159|NCT01990950|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
75385160|NCT02001558|Drug|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
75385161|NCT02001558|Other|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
75385162|NCT02023866|Drug|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
75385163|NCT02023242|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
75385164|NCT02023242|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
75385165|NCT01967940|Drug|TAF|25 mg tablet administered orally once daily with food
75385166|NCT01967940|Drug|Placebo|Tablets to match TAF administered orally once daily with food
75385167|NCT01967940|Drug|E/C/F/TAF|150/150/200/10 mg STR administered orally once daily with food
75385168|NCT01967940|Drug|Current failing ARV regimen|Participants will continue taking their current ARV regimen as prescribed in Part 1.
75541878|NCT04552600|Drug|Nuvastatic|Phase 1b Interventional, multi-centered, double-masked, randomized
75541879|NCT04552600|Other|Placebo|Phase 1b Interventional, multi-centered, double-masked, randomized
75541880|NCT04552561|Behavioral|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
76031853|NCT05632991|Other|Subcostal Transversus Abdominis Plan Block Group|ultrasound guided Subcostal Transversus Abdominis Plan Block Group 20 ml local anesthetic each side
75868906|NCT06077565|Other|Control group|The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to change their health-risk behaviours and/or adopt a healthy lifestyle practice.
75385169|NCT01967940|Drug|ATV|300 mg tablet administered orally once daily.
75541881|NCT04552678|Behavioral|Healthy Eating, Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
75385170|NCT01990560|Drug|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
75385171|NCT01998984|Drug|ingenol mebutate|
75385172|NCT01998984|Other|Placebo|
75385173|NCT04416594|Other|Data collection|Only data collection
75385174|NCT01967706|Other|mTHS|Single use of Tobacco Heating System 2.2 Menthol (mTHS)
75385175|NCT01967706|Other|mCC|Single use of subject's own menthol cigarette (mCC)
75385176|NCT01967706|Other|NRT|Single administration of 2 mg gum (Nicorette® 2mg)
75385177|NCT01967628|Dietary Supplement|Vitamin D3 (cholecalciferol)|
75385178|NCT01967628|Dietary Supplement|Placebo Sugar Pill|
75385179|NCT01998906|Drug|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
75385180|NCT01998906|Drug|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
75385181|NCT01998906|Drug|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
75385182|NCT01998906|Drug|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
75385183|NCT01967550|Drug|diclofenac diethylamine, DDEA 2.32% gel|
75385184|NCT01967550|Drug|Placebo|
75385185|NCT01989546|Drug|BMN 673|Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
75557686|NCT02274129|Device|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
75557687|NCT00437606|Drug|GK Activator (2)|100mg po
75385186|NCT01989468|Biological|Secukinumab|Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
75385187|NCT01989468|Biological|Placebo|Secukinumab placebo provided in 1 mL autoinjector
75385188|NCT01989156|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
75385189|NCT01989156|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
75385190|NCT01989156|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
75385191|NCT01620762|Drug|Cat-PAD|1 dose every 4 weeks
75868907|NCT06073314|Diagnostic Test|Quantitative MRI|Patients will be asked to remain in the scanner for an additional 10 minutes while we acquire additional quantitative MR images
76031854|NCT05073601|Diagnostic Test|ELISA,DNA extraction|quantitative measurement of (Thyroid stimulating hormon (TSH), free triiodothyronine (FT3)& Free tetraiodothyronine(FT4)) measured using ELISA . Serum 25-OH vitamin D measured using ELISA. Serum 25-OH vitamin D will be classified based on 2012 American Endocrine Society guidelines into deficient (< 20ng/ml), insufficient ( 21 -30 ng/ml) and sufficient (> 30 ng/ml).vitamin D receptor polymorphisms was done in 3 steps: a) DNA extraction from whole blood using Gene Jet gene DNA Purification kits . b) PCR: three Vitamin D receptor polymorphisms were tested [Taq I (restriction enzymes according to single nucleotide polymorphism ) (rs731236), Apa I (rs7975232) and Bsm I (rs1544410)] using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genomic DNA was amplified using certain primers
76031855|NCT03068195|Procedure|microwave ablation|KY2000 microwave ablation system was used in the experimental group. A power output of 60 W for 1-3 min for 1-3 cycles to treat the renal cysts according to the cysts size and classification.Percutaneous microwave ablation will be performed under the guidance of ultrasound while the laparoscopic microwave ablation will be performed under direct vision
76031856|NCT03068195|Procedure|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts
76031857|NCT03140059|Procedure|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
76031858|NCT03140059|Procedure|Repeated application of aPDT|Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
76031859|NCT03067883|Drug|Ombitasvir, Paritaprevir and Ritonavir|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
75385192|NCT01620762|Drug|Placebo|1 dose every 4 weeks
75385193|NCT01966068|Other|MyAsthma Web Portal|Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
75385194|NCT01620528|Drug|elagolix|oral tablet
75385195|NCT01620528|Other|placebo|oral tablet
75385196|NCT01965834|Drug|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance < 50 mL/min will receive a reduced dose of 54 mg orally daily.
75385197|NCT01965600|Drug|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
75385198|NCT01965600|Drug|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
75385199|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
75385200|NCT01965600|Drug|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
75385201|NCT01965600|Drug|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
75385202|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
75385203|NCT01996332|Drug|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
75385204|NCT04669548|Device|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
75557688|NCT00437606|Drug|Ethanol|40g po
75557689|NCT00482313|Drug|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
75557690|NCT00482313|Drug|Placebo|Sugar pill
75557691|NCT00437684|Drug|LPV/r|200/50 mg 2 cpr bid monotherapy
75557692|NCT00437684|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
75557693|NCT00437684|Drug|Ribavirin|Ribavirin 1-1.2 g/day
75557694|NCT00437684|Drug|NUCS|Nucleoside Reverse Transcriptase Inhibitors
75557695|NCT00437723|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
75385205|NCT01996254|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
75385206|NCT01987986|Biological|Collagenase Clostridium Histolyticum|injectible intervention
75385207|NCT01987986|Biological|Placebo|
75385208|NCT04659018|Biological|blood collection|A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
75385209|NCT01987908|Drug|Aes-103|The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
75385210|NCT01987908|Other|Placebo|
75385211|NCT01995552|Device|External Loop Recorder|
75385212|NCT01987830|Device|MRI-PET|"[11C] temozolomide for PET scan and a contrast dye for the MRI scan~Drawing blood to assess the radioactivity of [11C] temozolomide"
75385213|NCT01987830|Device|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of [11C] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
75541882|NCT04552678|Behavioral|Healthy Eating, Active Play, Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
75541883|NCT04552678|Behavioral|Healthy Eating, Active Play, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
75868908|NCT06073314|Diagnostic Test|Reproducibility study|A subset of patients will be invited back for a repeat MRI scan (prior to any treatment for their condition) to help measure reproducibility of our Artificial Intelligence model
75385214|NCT01987596|Biological|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
75385215|NCT04658316|Behavioral|Iowa Oral Performance Instrument|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
75385216|NCT01964898|Behavioral|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
75385217|NCT01964898|Behavioral|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
75385218|NCT01964898|Drug|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
75385219|NCT01964898|Other|Printed Self-help materials for Smoking Cessation|
75385220|NCT01964352|Drug|tiotropium|fixed dose combination
75385221|NCT01964352|Drug|placebo|
75385222|NCT01964352|Drug|olodaterol|fixed dose combination
75385223|NCT01964352|Drug|tiotropium|fixed dose combination
75868909|NCT06072196|Drug|Novel hormonal therapy|As provided in real-world setting
75385224|NCT01964352|Drug|tiotropium|
75868910|NCT06067451|Behavioral|SMART GOALS Setting Tool/ Protocol|The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem. The participant will first receive the SGSG which will highlight 3 domains of SMART goals (exercise, diet, and behavior). Each domain will have 1 predetermined and unchanging primary goal which will serve as the standard for all participants to strive for.
75868911|NCT06061302|Other|Immediate yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 1-12.
75385225|NCT01964352|Drug|olodaterol|fixed dose combination
75385226|NCT01946412|Drug|Ivacaftor|
75385227|NCT01946178|Device|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
75385228|NCT01945944|Drug|Hypertonic saline (3%)|3mL of HTS given via nebulizer every 6hrs
75385229|NCT01945944|Drug|Placebo (0.9% saline)|3mL of normal saline given via nebulizer every 6hrs
75385230|NCT01945866|Drug|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
75385231|NCT01945866|Drug|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
75385232|NCT01945866|Procedure|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
75385233|NCT01986114|Drug|SM-13496|
75385234|NCT01945710|Drug|Eribulin-LF|
75385235|NCT01945242|Drug|Alogliptin|Alogliptin tablets
75385236|NCT01945086|Drug|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
75385237|NCT01945086|Drug|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
75385238|NCT01945086|Other|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
75541884|NCT04552678|Behavioral|Healthy Eating + Active Play|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
75557696|NCT00482430|Drug|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
75557697|NCT00482430|Drug|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
75557698|NCT00437762|Drug|Botulinum Toxin A Injection|Botulinum Toxin A Injection
75557699|NCT00437762|Drug|Placebo injection|Placebo Injection
75557700|NCT00482508|Drug|Omalizumab|
75385239|NCT04637802|Behavioral|CBT (SurgeryPal)|The SurgeryPal intervention is a cognitive-behavioral program for youth undergoing major surgery. SurgeryPal is delivered in two 4-week phases: the pre-operative phase, and the post-operative phase. Each phase consists of 3 separate treatment modules for youth and parents, which teach cognitive and behavioral coping skills to target known psychosocial and behavioral risk factors (i.e. anxiety/distress and sleep disturbance) for poorer postsurgical outcomes, and provide training in pain self-management skills. Pre-operative modules include: 1) Preparing for surgery, 2) Coping with stress before surgery, and 3) Getting ready for the hospital. Postoperative modules include: 1) Coping at home after surgery, 2) Return to activities and school, and 3) Long-term recovery. Modules are self-guided and interactive, and focus on phases of preparation and recovery from surgery. The goal of the program is to reduce pain and enhance quality of life following surgery in youth.
75385240|NCT04637802|Behavioral|Education|The patient education website will serve as the active comparator. The purpose is to control for time, attention, and online usage. Youth and parents will be provided access to an education website containing information about pediatric surgery at the same time interval as the active intervention; however, there will be no exposure to cognitive and behavioral coping skills. Similar to the CBT condition, the presurgery period of Education will be administered for one month prior to surgery and the postsurgery period will be administered for one month after the post-discharge assessment.
75385241|NCT01963728|Drug|Insulin, Isophane|daily dosing based on fasting morning glucose levels
75541885|NCT04552678|Behavioral|Healthy Eating, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
75868912|NCT06061302|Other|Delayed yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 13-24.
75385242|NCT01963728|Drug|insulin glargine|daily dose based on fasting morning glucose levels
75385243|NCT01963260|Drug|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
75385244|NCT01963260|Drug|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
75557701|NCT00437840|Drug|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
75557702|NCT00437840|Drug|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
75557703|NCT00482586|Other|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
76031860|NCT05631821|Procedure|differential rod bending with rod contours (MESA Spinal System)|differential rod bending with rod contours and Mesa Spinal system evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool
75705541|NCT04221594|Procedure|Invasive Cardiac Catheterization (ICA)|Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.
75868913|NCT06055556|Procedure|Partial Heart Transplantation|"Partial heart transplantation involves surgical replacement of the semilunar heart valve with a fresh donor graft. The surgical procedure (homograft valve replacement) is common and standard of care. The investigational aspect of this is using a freshly procured valve rather than a cryopreserved, cadaveric one and also the use of limited immunosuppression to help maintain the freshly procured valve as living tissue."
75868914|NCT06055556|Other|Freshly procured valve|Fresh donor graft semilunar heart valve.
75385245|NCT01962948|Drug|paclitaxel|Given IV
75385246|NCT01962948|Drug|ganetespib|Given IV
75385247|NCT01962948|Other|laboratory biomarker analysis|Correlative studies
76031861|NCT03404245|Behavioral|Education, Fitbit/self-management app, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.
76031862|NCT03404245|Behavioral|Same intervention with a 6 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
76031863|NCT05393167|Device|Echo_CT_MRI_US_x ray|Examination: General and systemic examinations of the studied neonates. Investigation will be done to the neonates according to the clinical examination including imaging studies as X-rays, U/S, echocardiography, CT and MRI studies
76031864|NCT03285763|Drug|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
75385248|NCT01985334|Drug|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
75385249|NCT01985334|Drug|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
75385250|NCT01985334|Drug|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
75385251|NCT01985334|Drug|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
75385252|NCT01985334|Drug|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
75385253|NCT01985334|Drug|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
75385254|NCT01985334|Drug|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
75385255|NCT01944774|Drug|Nemonoxacin 500 mg|IV Infusion, once daily for 7~14 days
75385256|NCT01944774|Drug|Nemonoxacin 650 mg|IV Infusion, once daily for 7~14 days
75385257|NCT01944774|Drug|Moxifloxacin 400 mg|IV Infusion, once daily for 7~14 days
75557704|NCT00482586|Other|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
75557705|NCT00482586|Procedure|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
75557706|NCT00437918|Drug|nateglinide|
75557707|NCT00437918|Drug|acarbose|
75557708|NCT00482742|Device|CiTop(TM) Guidewire|
75557709|NCT00437957|Drug|Temozolomide|75 Mg/m2/day for all Cohorts
75557710|NCT00437957|Drug|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
75385258|NCT01944462|Behavioral|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
75385259|NCT01943292|Drug|Defactinib|
75385260|NCT01961544|Drug|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
75385261|NCT01942590|Drug|Clenbuterol|
75385262|NCT01942590|Drug|Placebo|
75385263|NCT01984242|Drug|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
75385264|NCT01984242|Drug|Bevacizumab|Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
76031865|NCT03231631|Behavioral|Education plan and adherence to exercise|"Send text messages with motivational sense at any time of the day, every 3 or 4 days.~They will be given the option of performing directed exercise at the cardiac rehabilitation center.~It will be recorded in an Excel table every time that text is sent to the patient.~At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.~A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again."
75385265|NCT01984242|Drug|Sunitinib|Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
75385266|NCT01941498|Device|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
75385267|NCT01941498|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
75385268|NCT04656132|Behavioral|Physical activity assessment, promotion and monitoring in a preventive cardiology clinic|physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
75385269|NCT01960998|Behavioral|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
75385270|NCT01960998|Behavioral|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
75385271|NCT01941186|Other|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
75385272|NCT01960842|Drug|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
75385273|NCT01960842|Device|CADD-Legacy® 1400 ambulatory infusion pump|
75385274|NCT01960842|Device|PEG tube|percutaneous endoscopic gastrostomy tube
75385275|NCT01960842|Device|J-tube|jejunal tube
75385276|NCT01984164|Drug|Candesartan|blinded
75385277|NCT01984164|Drug|Lisinopril|Blinded
75385278|NCT01983930|Behavioral|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
75385279|NCT01983930|Behavioral|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
75385280|NCT04636398|Behavioral|MESSAGE - mHealth intervention|A group-based moderated six-week intervention with didactic, discussion, and text communication components.
75385281|NCT01983774|Drug|Esomeprazole|
75385282|NCT01983774|Drug|Placebo|Sugar pill
75385283|NCT01982682|Radiation|Total-Body Irradiation (TBI)|Undergo TBI
75385284|NCT01982682|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
75385285|NCT01982682|Drug|Cyclophosphamide|Given IV
75385286|NCT01982682|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo CD34+ selected allogeneic HSCT
75385287|NCT01982682|Drug|Mycophenolate mofetil|Given IV
75385288|NCT01940484|Drug|Methoxy polyethylene glycol epoetin beta|
75385289|NCT01939548|Drug|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
75385290|NCT01939548|Drug|Placebo|Placebo BID until the Week 12 visit
75385291|NCT01939548|Drug|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
75385292|NCT01960296|Drug|Clopidogrel|Continue home dose of clopidogrel into surgery
75385293|NCT01960296|Drug|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
76031866|NCT03067805|Behavioral|Sexual Infidelity Condition|
76031867|NCT03067805|Behavioral|Emotional Infidelity Condition|
76031868|NCT03067805|Behavioral|Neutral Condition|
76031869|NCT03067805|Behavioral|Player in Jealousy Condition|
75385294|NCT01982292|Drug|RLX030 (serelaxin)|RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
75385295|NCT01982292|Drug|Placebo|Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
75385296|NCT04652778|Device|Pulsed Field Ablation (PFA) using the Centauri System|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation; cavo-tricuspid isthmus (CTI) line ablation may be performed as needed
76031870|NCT03067805|Behavioral|Player in Non-Jealousy Condition|
75385297|NCT01939314|Drug|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
76031871|NCT05393011|Drug|human chorionic gonadotropin|10000 IU when at least three follicles become more than 16 mm
76031872|NCT05034835|Device|usual treatment with compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
76031873|NCT05034835|Other|usual treatment without compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
76031874|NCT03138421|Drug|ABX-1431 HCl|ABX-1431 HCl, capsules, 20 mg
75385298|NCT01939314|Drug|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
75385299|NCT01939158|Biological|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
75385300|NCT01939158|Biological|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
75385301|NCT01939002|Drug|BIIB017|
75385302|NCT01939002|Drug|naproxen|
75385303|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
75385304|NCT01938846|Drug|exemestane|exemestane once daily
75868915|NCT06050668|Dietary Supplement|Essential Amino Acid Supplementation|Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
76031875|NCT03138421|Drug|Placebo|Matching placebo
76031876|NCT03110497|Radiation|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
75385305|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
75385306|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
75385307|NCT01938846|Drug|paclitaxel|paclitaxel once weekly
75385308|NCT01960140|Drug|Baricitinib|Administered orally
75385309|NCT01960140|Drug|Simvastatin|Administered orally
75541886|NCT04552678|Behavioral|Healthy Eating + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
76031877|NCT03110731|Behavioral|Physical training|Physical training (2x / week) was performed for 12 weeks
76031878|NCT03085771|Drug|desferal|It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
76031879|NCT03085771|Drug|Isotonic saline|It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
75385310|NCT01981356|Behavioral|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
75385311|NCT01981356|Other|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
75385312|NCT01981122|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
75385313|NCT01981122|Drug|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
75385314|NCT01980888|Drug|Idelalisib|150 mg tablet administered orally twice daily
76031880|NCT05619965|Drug|sedative|dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
75868916|NCT06047041|Behavioral|EIS Only|"The EIS Only Condition includes middle schools who have elected to implement the EIS. The EIS:~Is an online tool to that enables schools to identify students in need of additional mental or behavioral health support and provides recommendations for evidence-based practices.~Asks teachers and students to report on 7 areas of student social-emotional functioning~Facilitates schools' understanding of social-emotional student needs and recommended evidence-based practices at a variety of levels (e.g., school-, grade-, and individual-level).~EIS Only Condition supports include:~Technical assistance professional development sessions to support the implementation of EIS and schoolwide practices related to identifying and supporting student mental health needs.~Individualized technical assistance for schools to support EIS implementation."
75868917|NCT06047041|Behavioral|EIS + ECHO|"EIS + ECHO supports include supports from the EIS Only condition plus:~Monthly ECHO sessions for student support teams (SSTs; e.g., interdisciplinary groups of staff tasked to support student mental health). The ECHO experience involves:~Didactic training to support EIS implementation and effective identification and support of student mental and behavioral health needs.~Case-based learning and collaborative problem-solving related to EIS implementation and effective identification and support of student mental and behavioral health needs.~Collaboration with colleagues in schools that are also implementing the EIS.~Opportunities to consult with university faculty and content experts in school mental health.~Individualized SST coaching supports to facilitate the implementation of mental and behavioral health practices and strategies discussed during ECHO sessions."
75385315|NCT01980888|Drug|Bendamustine|Administered intravenously at a starting dose of 90 mg/m^2 for up to 6 cycles. Dosing will be based on mg/m^2 of body surface area.
75385316|NCT01980888|Drug|Rituximab|Single-use vials administered intravenously weekly starting at 375 mg/m^2 on Day 1 (Week 0) and 500 mg/m^2 thereafter for a total of 6 infusions
75868918|NCT06041828|Device|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
75385317|NCT01980888|Drug|Placebo|Placebo to match idelalisib administered orally twice daily
75385318|NCT04650282|Combination Product|Lidocaine in SphenoCath device|Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.
75868919|NCT06041828|Other|Standard oral hygiene|Standard oral hygiene instructions
75868920|NCT06040268|Drug|Advair HFA|6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily
75868921|NCT06040268|Drug|Placebo|HFA134a inhaler
75868922|NCT06036212|Device|Robotic System|Robotic assisted Unicompartmental Knee replacement (UKA)
76031881|NCT05619965|Device|Awake endotracheal intubation by Glidescope videolaryngoscope|Awake endotracheal intubation by Glidescope videolaryngoscope of cervical trauma patient
75385319|NCT04650282|Combination Product|Saline Solution in SphenoCath device|Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.
75385320|NCT01937364|Drug|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
75385321|NCT01937364|Drug|Placebo|Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
75868923|NCT06036212|Device|Conventional|Unicompartmental Knee Arthroplasty (UKA) with conventional approach and conventional manual instrumentation
75868924|NCT06027320|Behavioral|Brain Health Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
76031882|NCT05619965|Device|Awake endotracheal intubation by Fiberoptic bronchoscope|Awake endotracheal intubation by Fiberoptic bronchoscope of cervical trauma patient
75385322|NCT01979952|Drug|Matching Placebo|twice daily dosing
75385323|NCT01979952|Drug|Nintedanib|gelating capsule
75385324|NCT01999218|Drug|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
76031883|NCT04659629|Drug|NL-201|NL-201 is a de novo protein therapeutic.
75705542|NCT04221594|Procedure|Coronary Computed Tomographic Angiogram (CCTA)|Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate ~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.
76031884|NCT04659629|Drug|Pembrolizumab Injection [Keytruda]|A programmed death receptor-1 (PD-1)-blocking antibody
75385325|NCT01999218|Drug|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
75385326|NCT01999218|Drug|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
75385327|NCT01999218|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
75385328|NCT01999218|Drug|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
76031885|NCT02985619|Drug|Bevacizumab Injection [Avastin] (IVB-I)|0,05ml intravitreal injection
76031886|NCT02985619|Drug|Triamcinolone Acetonide 10mg/mL (IVT-II)|0,03ml intravitreal injection
76031887|NCT02985619|Drug|Bevacizumab Injection [Avastin] (IVB-III)|0,05ml intravitreal injection
75385329|NCT01999218|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
75385330|NCT01999218|Drug|Sitagliptin|Open label, oral, once daily, rescue medication as required.
75385331|NCT01937130|Drug|IDN-6556|
75385332|NCT01937130|Other|Placebo|
75385333|NCT01936974|Drug|Gemcitabine|Patient to receive gemzar
75385334|NCT01936974|Drug|Bevacizumab|Patient to receive avastin
75385335|NCT01936974|Drug|Carboplatin|Patient to receive carboplatin
75385336|NCT01936974|Drug|Cisplatin|Patient to receive cisplatin
75385337|NCT01936974|Drug|Oxaliplatin|Patient to receive Oxaliplatin
75385338|NCT04648644|Other|Application of ERAS protocol|Application of a standardized ERAS protocol for the perioperative perioperative management of patients undergoing emergency surgery
75385339|NCT01959516|Drug|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
75385340|NCT01959516|Drug|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
75385341|NCT01959516|Drug|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
75385342|NCT01959516|Drug|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
75385343|NCT01979016|Drug|Dupilumab|
75385344|NCT01979016|Drug|Placebo|Matching placebo
75385345|NCT01979016|Other|Background treatment|Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
75385346|NCT01935336|Drug|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
75385347|NCT01978236|Drug|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
75557711|NCT00437957|Procedure|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
75557712|NCT00482781|Biological|Infanrix|
75557713|NCT00482781|Biological|Pediatrix|
75557714|NCT03270176|Drug|Debio 1143|Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
75557715|NCT03270176|Drug|Avelumab|Avelumab 10 mg/kg intravenous infusion every 2 weeks.
75557716|NCT00474279|Drug|Orally active growth hormone secretagogue (MK-677)|
76031888|NCT05587205|Biological|EO2002|Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
76031889|NCT05587205|Other|Sham injection|Sham injection
75385348|NCT01978236|Drug|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
75385349|NCT01934790|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
75705543|NCT04221594|Procedure|Dynamic Cardiac Positron Emission Tomography (dPET)|Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
75868925|NCT06027320|Behavioral|Alzheimer Disease Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
75385350|NCT01934556|Drug|Ranibizumab 0.3 mg intravitreal injection|
75385351|NCT01934556|Device|Guided Laser Photocoagulation|
75385352|NCT04415814|Procedure|Unilateral Pedicle Screw Fixation|Pedicle screws are installed unilaterally on the one side of the vertebrae and fixed with rod
76031890|NCT04958005|Diagnostic Test|ELISA|Enzim linked immunoabsorbant assay
76031891|NCT05583929|Other|GAITRite gaitway system, Bertec Balance System|GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability
76031892|NCT03110419|Other|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
76031893|NCT04123613|Drug|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
75385353|NCT04415814|Procedure|Bilateral Pedicle Screw Fixation|Pedicle screws are installed bilaterally on the both sides of the vertebrae and fixed with rods
75557717|NCT03270618|Device|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
75557718|NCT03270696|Drug|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
75557719|NCT03278600|Genetic|tissue-of-origin (ORIGIN-PanCA○R) profiling|90-gene assay to predict the primary tumor site
75557720|NCT00437996|Drug|Clonidine|
75557721|NCT00437996|Drug|Levobupivacaine|
75557722|NCT00437996|Drug|Sufentanil|
76031894|NCT03110653|Drug|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
76031895|NCT03110653|Drug|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
76031896|NCT04116593|Behavioral|Nutrition education|Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
75541887|NCT04552678|Behavioral|Healthy Eating + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
75541888|NCT04552678|Behavioral|Healthy Eating Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy.
75705544|NCT04217447|Drug|OAC + Aspirin 100mg od|Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
75705545|NCT04217447|Drug|OAC + placebo of Aspirin 100mg od|Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
75705546|NCT04210349|Biological|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
76031897|NCT05392387|Other|Standard antiviral therapy|pegylated interferon or/and nucleos(t)ide analogues
75385354|NCT04411212|Drug|Granulocyte colony-stimulating factor and platelet-rich plasma group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
75557723|NCT03270579|Drug|[18F]JNJ-64511070|An IV injection of 185 MBq [18F]JNJ-64511070 will be administered.
75557724|NCT04701125|Device|selective head-neck cooling using PolarCap system|Players receiving selective head-neck cooling after SRC
75557725|NCT00474357|Behavioral|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
75557726|NCT00474396|Behavioral|Low fat dairy diet|
75557727|NCT04701242|Drug|Ezetimibe 10mg|comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
75557728|NCT03270267|Other|Questionnaires|
76031898|NCT04583579|Device|DMV inserter (DMV® MagicTouch™) with an open end|This is a device used to help apply scleral lenses.
76031899|NCT04583579|Device|DMV inserter (DMV® MagicTouch™) with a closed end|This is a device used to help apply scleral lenses.
75385355|NCT04411212|Other|Control group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
76031900|NCT04583579|Device|Three fingers (Patient's Hand)|This is a device used to help apply scleral lenses.
76031901|NCT04583579|Device|O-ring (Hardware Store Product)|This is a device used to help apply scleral lenses.
76031902|NCT04583579|Device|Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)|This is a device used to help apply scleral lenses.
75385356|NCT01977690|Device|Clavicle Brace|
75385357|NCT04646148|Behavioral|Yoga classes|All participants are invited to attend weekly yoga classes.
75385358|NCT01934010|Drug|AM-101|AM-101 gel for intratympanic injection
75385359|NCT01620138|Drug|Pasireotide|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.~The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
75385360|NCT01620138|Drug|cabergoline|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.~The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
75385361|NCT01977612|Device|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
75385362|NCT01977612|Device|Stainless steel staples|Skin closure using stainless steel staples.
75385363|NCT01932996|Drug|nicotine patch plus nicotine gum/lozenge|12-week treatment with nicotine patch plus nicotine gum/lozenge
75385364|NCT01932996|Behavioral|Intensive Alcohol Intervention|Intensive alcohol abstinence counseling using CBT will include weekly individual sessions for 3 months followed by monthly booster group sessions for 3 months
75385365|NCT01932762|Drug|Grazoprevir|100 mg every day (QD) orally
75385366|NCT01932762|Drug|Elbasvir|50 mg QD orally
75385367|NCT01932762|Drug|Ribavirin|Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
75385368|NCT01618968|Drug|MTX|"Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)"
75541889|NCT04552678|Behavioral|Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
75385369|NCT04645524|Drug|AD182|Oral capsule administered before bed
75385370|NCT04645524|Drug|AD504|Oral capsule administered before bed
75385371|NCT04645524|Drug|Placebo|Oral capsule administered before bed
75385372|NCT04645524|Diagnostic Test|Polysomnography|for all arms
75385373|NCT04662216|Procedure|Scaling and root planing|Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes).
76031903|NCT04450199|Drug|Vitamin D2|Vitamin D tablets
76031904|NCT04450199|Other|Placebo|Over encapsulated sugar pills
76031905|NCT03067649|Behavioral|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
76031906|NCT03067649|Behavioral|Information only control|Participants are provided with a pamphlet containing referral information
76031907|NCT01884259|Drug|Docetaxel|75 mg/m² on day 1 of 21-days cycle
76031908|NCT01884259|Drug|Cisplatin|75 mg/m² on day 1 of 21-days cycle
75385374|NCT04662216|Procedure|"Scaling and root planing + Perisolv +Hyadent BG gels"|"Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes), Perisolv gel will adjectively be applied to all pockets with probing depth(PD) ≥ 5 mm, which will be inserted into periodontal pockets before and during SRP (2 times). The nozzle will be placed in the pocket mesially, lingually, distally and bucally. Afterwards, all teeth will be polished and all treated pockets will be filled with hyaluronic acid gel (Hyadent BG)."
75705547|NCT04210349|Biological|Trivalent Influenza Vaccine 1 SP Shz TIV1|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
76031909|NCT01884259|Drug|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
76031910|NCT01884259|Biological|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
76031911|NCT01884259|Biological|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
76031912|NCT01884259|Radiation|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
76031913|NCT04930549|Drug|Dapagliflozin 10Mg Tab|Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
76031914|NCT04930549|Drug|Placebo|Patients receive placebo tablets once a day during 12 weeks
76031915|NCT04930549|Procedure|impedance cardiography|impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
76031916|NCT04930549|Procedure|Applanation tonometry|Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
76031917|NCT04930549|Procedure|post-ischemic hyperemia of forearm|An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
76031918|NCT04930549|Procedure|haemodynamics parameters|haemodynamics parameters will be evaluated using automatic oscillometric recorder
76031919|NCT05392153|Other|Myofascial therapy|Running is a sport that involves repetitive movement and is particularly vulnerable to injury in the lower extremities. Myofascial release, on the other hand, is a manual method that is effective in increasing blood and oxygen permeability between tissues, renewing the tissue, protecting it from injury and increasing performance. The aim of our study is to investigate the effect of Myofascial therapy on sportive performance balance and injury risk in runners. The study will carry out on runners with a 3-month running history.
76031920|NCT03067727|Drug|Dinoprostone|The DVI contains 10 mg Dinoprostone
76031921|NCT03067727|Drug|Placebo|The placebo product is identical with the active product except that it does not contain Dinoprostone.
76031922|NCT01794793|Drug|Pasireotide|Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
76031923|NCT01794793|Drug|Cabergoline|Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
76031924|NCT01794793|Drug|Pasireotide|Long Acting Release is administered by monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
76031925|NCT03067103|Drug|Tramadol|Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
76031926|NCT03067103|Drug|Ketamine|Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
76031927|NCT03067103|Drug|Placebos|Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
76031928|NCT01398319|Behavioral|Group Brief Alcohol Intervention|The BAI contained components of effective interventions developed for young adult drinkers both in health care and educational settings and was specifically tailored to the unique needs and risk factors of Airmen. The 1-hour group intervention was administered using the principles of motivational interviewing (MI) in an interactive Socratic style to generate feedback and discussion. Open-ended questions, reflections, as well as the decisional balance scale were used to increase Airmen's motivation to remain alcohol free.
76031929|NCT01398319|Behavioral|Group Brief Alcohol Intervention Booster|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
76031930|NCT01398319|Behavioral|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
76031931|NCT03068585|Drug|Neovasculgen (Cambiogeneplasmid)|treatment
76031932|NCT01305889|Behavioral|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
75385375|NCT01931670|Other|placebo|
75385376|NCT01931670|Drug|Elagolix|
75705548|NCT04210349|Biological|Trivalent Influenza Vaccine 2 SP Shz TIV2|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
76031933|NCT01305889|Drug|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
76031934|NCT03138265|Behavioral|HIIT Device: ergometer|Supervised exercise training.
76031935|NCT05391997|Other|Modified Cervical and Shoulder Retraction exercises|11 patients will receive cervical traction and modified cervical and shoulder retraction exercises (10 to 12 repetitions). The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days.
75385377|NCT01977456|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
76031936|NCT05391997|Other|Cervical Extension Traction exercises|11 patients will receive cervical traction force for 10 seconds and extend the cervical spine. The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days
76031937|NCT03136939|Other|No intervention|No intervention
76031938|NCT03591107|Other|PTSD Care Management (PCM)|Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback
76031939|NCT03591107|Other|Minimally Enhanced Usual Care (MEU)|Education and feedback alone
76031940|NCT00223171|Drug|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
75385378|NCT01957644|Drug|Azacitidine|
75385379|NCT01957644|Drug|Volasertib|
75385380|NCT01931202|Drug|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
75385381|NCT01931202|Drug|Placebo oral tablet|Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
75385382|NCT01930890|Biological|BIIB023|
75385383|NCT01930890|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
75385384|NCT01930890|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
75385385|NCT01930188|Drug|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
75385386|NCT01930188|Drug|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
75385387|NCT01930188|Drug|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
75385388|NCT01930188|Drug|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
75385389|NCT01977222|Device|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
75385390|NCT01957488|Device|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
75541890|NCT04552678|Behavioral|Active Play + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
75705549|NCT04203901|Biological|CMN-001|Autologous Dendritic Cell Therapy
75705550|NCT04203901|Biological|Nivolumab+Ipilimumab|anti-PD-1 and anti-CTLA4 antibodies
75385391|NCT01957488|Device|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
75385392|NCT01957488|Device|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
75385393|NCT01976364|Drug|Tofacitinib|Tofacitinib 5 mg tablet twice daily
75385394|NCT01976364|Drug|Tofacitinib|Tofactinib 10 mg tablet twice daily
75385395|NCT01976364|Drug|Methotrexate|Methotrexate 7.5-20 mg weekly
75385396|NCT01976364|Drug|Placebo Methotrexate|Placebo to match active methotrexate orally once a week
75705551|NCT04203901|Drug|Lenvatinib+Everolimus|TKI+mTOR inhibitors
76031941|NCT04563481|Other|Hand Therapy via Telerehabilitation|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
75385397|NCT01956240|Procedure|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
75385398|NCT01956240|Procedure|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
76031942|NCT04563481|Other|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
75541891|NCT04552678|Behavioral|Active Play + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
75385399|NCT01929876|Drug|Cobimetinib|10 milligram (mg) (2* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2
75541892|NCT04552678|Behavioral|Active Play Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
75541893|NCT04552678|Behavioral|Self-Regulation + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
75705552|NCT04198766|Drug|INBRX-106 - Hexavalent OX40 agonist antibody|The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
75705553|NCT04198766|Drug|Pembrolizumab 200 mg|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
75705554|NCT04198766|Drug|Pembrolizumab 400 mg|Pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
76031943|NCT04497493|Device|Transcranial Direct Current Stimulation (tDCS)-active|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks
76031944|NCT04497493|Device|Transcranial Direct Current Stimulation (tDCS)-sham|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
76031945|NCT05391685|Other|Scar release techniques + therapeutic ultrasound|Control group will be treated by therapeutic ultrasound only for2 sessions per week for two weeks Study group) will be treated by various scar release techniques in addition to therapeutic ultrasound, 2 sessions per week for two weeks.
76031946|NCT03138031|Procedure|Percutaneous ethanol alcohol injection|"Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of 8 limits the procedure. Post-procedure analgesia may be required."
75705555|NCT04197648|Device|Exercise group|24 week supervised exercise program (strength and cardiovascular program).
76031947|NCT04854265|Other|Mindfulness Meditation|Mindfulness meditation will include mindfulness based stress reduction program, Qigong, Tai Chi exercise, Yoga, and Pranayama breathing exercise.
76031948|NCT04433507|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.
76031949|NCT04433507|Procedure|Hiatal Hernia repair|Hiatal hernia repair consists in a circumferential dissection of the diaphragmatic crura to achieve an intra abdominal esophageal length of 2-3 cm. The crura will then be closed anteriorly and posteriorly using nonabsorbable sutures.
76031950|NCT04363385|Biological|Biological test|Blood sample
76031951|NCT04800991|Device|Rhexium Onco Nutrition|"The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body"
76031952|NCT04790851|Biological|COVAX+IIV4; COVAX+PPV23|1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
76031953|NCT04790851|Biological|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
76031954|NCT04790851|Biological|IIV4 for the 1st dose and PPV23 for the 2nd dose|1st dose: IIV4 only; 2nd dose: PPV23 only
76031955|NCT05431283|Drug|Tofacitinib|This study aims to assess the effectiveness of TOFA
76031956|NCT05391529|Behavioral|Interview|Semi structured patient interview via telephone
75385400|NCT01929876|Drug|Itraconazole|200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
75541894|NCT04552678|Behavioral|Self-Regulation Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
75385401|NCT04630236|Diagnostic Test|Ultrasound|Using ultrasound control, the central vein catheter is injected with saline solution and the time to detect the saline bolus in the ultrasound is measured.
76031957|NCT03208985|Drug|Use Phase (Ulipristal Acetate, 30 mg)|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
75705556|NCT04196777|Behavioral|Audit-and-feedback|We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.
76031958|NCT03644953|Drug|Hydroxyurea|Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.
76031959|NCT03630835|Other|99mTc-Annexin-V-128 uptake on scintigraphy|"An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours."
76031960|NCT03067337|Device|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
75385402|NCT01929018|Behavioral|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
75385403|NCT01929018|Behavioral|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
75705557|NCT04171700|Drug|Rucaparib|Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
76031961|NCT03067337|Device|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
76031962|NCT04764097|Drug|Dapagliflozin|SGTL2 Inhibitor
76031963|NCT04764097|Drug|Placebo|Placebo
76031964|NCT02922023|Device|Ambulatory blood pressure monitor (ABPM)|"ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy."
76031965|NCT02922023|Other|Chronotherapy|Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
75385404|NCT01929018|Behavioral|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
75385405|NCT01928940|Drug|dabrafenib|150 mg twice daily
75385406|NCT01928940|Drug|trametinib|2 mg once daily
75385407|NCT01928862|Drug|Prepopik® ½ Sachet x 2 (9-12 years)|
75385408|NCT01928862|Drug|Prepopik® 1 Sachet x 2 (9-12 years)|
75385409|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
75385410|NCT01928862|Drug|Prepopik® 1 Sachet x 2 (13-16 years)|
75385411|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
75541895|NCT04552678|Behavioral|Food Literacy + Parent Education|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
76031966|NCT04761211|Device|smart bra|This is a patented infrared breast examination bra
76031967|NCT03605017|Behavioral|Virtual Reality Executive Function Training (VREFT)|
76031968|NCT05391451|Procedure|efficacy of quadratus lumborum block in post-operative analgesia in kidney transplant surgery|no premedication for anxiolytic purposes before surgery. Cimetidin 200mg can be administrated for Mendelson syndrome prevention. After general anesthesia induction, echo-guided quadratus lumborum block is performed by applying 20ml of levobupivacaine
75385412|NCT01954056|Drug|Hydrocortisone|"• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
75541896|NCT04552678|Behavioral|Food Literacy Only|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
75541897|NCT00236171|Drug|Protopic, Advantan|
75541898|NCT00236171|Procedure|Blood and Urine Test|
75541899|NCT00236171|Procedure|coherence tomography|
75541900|NCT04552639|Behavioral|Newbridge Eating disorders Activity Treatment group|A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
75541901|NCT04552639|Behavioral|Newbridge House treatment as usual|Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
75541902|NCT04552405|Dietary Supplement|Anti-inflammatory Diet|FAP individuals followed for 3 months a low-inflammatory diet
75541903|NCT00269022|Drug|SB-705498|
75541904|NCT00236210|Behavioral|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
75541905|NCT00236210|Behavioral|VIP program|Risk assessment, lifestyle counselling, exercise program
75541906|NCT04552210|Diagnostic Test|blood sample|Whole blood was collected on EDTA (1mg/ml) to prevent clotting and DNA degradation.
75385413|NCT01954056|Drug|Placebo|"7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
75385414|NCT01953354|Biological|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
75385415|NCT01953354|Biological|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
75385416|NCT01975272|Drug|Ferinject|
75385417|NCT01975272|Drug|Ferrous fumarate|
75385418|NCT01975272|Drug|Placebo for ferrous fumarate|
75385419|NCT01975272|Drug|Placebo for ferinject|
75385420|NCT04643886|Drug|GEM103|Biological
75385421|NCT01951638|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
75385422|NCT01951638|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
75385423|NCT01951638|Drug|Placebo|
75385424|NCT01928472|Biological|H7N9c low dose with adjuvant|
75385425|NCT01928472|Biological|H7N9c medium dose with adjuvant|
75541907|NCT02213848|Drug|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
75541908|NCT02213848|Drug|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
75541909|NCT00413855|Procedure|laparoscopic appendectomy or not (surgery)|
75541910|NCT04548544|Behavioral|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
75541911|NCT04548388|Other|rehabilitation|"A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
75541912|NCT00261573|Drug|galantamine hydrobromide|
75541913|NCT04548466|Device|PEP bottle|
75541914|NCT04548427|Drug|CKD-352|Eye Drop
75541915|NCT04548427|Drug|Diquafosol Sodium 3%|Eye Drop
75541916|NCT00413933|Procedure|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
75541917|NCT04548271|Drug|Camrelizumab|Anti-PD-1 targeted immunotherapy
75385426|NCT01928472|Biological|H7N9c high dose with adjuvant|
75385427|NCT01928472|Biological|H7N9c high dose without adjuvant|
75385428|NCT03563183|Other|Encoding of data collected in Zoster 006 and Zoster 022 studies|Not applicable (disease epidemiology study)
75385429|NCT03565679|Device|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
75385430|NCT03565679|Device|CO-OXIMETRY SENSORS|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
76031969|NCT05391451|Procedure|general anesthesia|general anesthesia is the current technique for kidney transplant surgery. The protocol involves the combination of several drugs: Propofol, Remifentanil, Ketamin, Atracurium or Cisatracurium. Curarization monitoring is systematic.
75385431|NCT03965039|Device|Dipotassium oxalate toothpaste|Experimental dipotassium oxalate (3%) toothpaste
75385432|NCT03965039|Drug|Stannous fluoride toothpaste|Marketed stannous fluoride (0.454%) toothpaste
75385433|NCT03965039|Drug|Potassium nitrate toothpaste|Marketed potassium nitrate (5%) toothpaste
75385434|NCT03965039|Drug|Sodium monofluorophosphate toothpaste|Marketed sodium monofluorophosphate (0.76%) toothpaste
75385435|NCT03961295|Drug|Vedolizumab SC|Vedolizumab SC liquid.
75385436|NCT00377897|Procedure|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
75385437|NCT03567005|Device|Nelfilcon A digital contact lenses|Silicone hydrogel digital contact lenses
75385438|NCT03567005|Device|Nelfilcon A contact lenses|Silicone hydrogel spherical contact lenses
75541918|NCT04548271|Drug|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
75541919|NCT04541719|Drug|Patient-controlled remifentanil analgesia|Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min
75541920|NCT04541719|Drug|Epidural analgesia|Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr
76031970|NCT03140137|Drug|Checkpoint inhibitor therapy|Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
76031971|NCT03520309|Procedure|Dental treatment|Treatment of all dental restorations of the children according to the diagnosis criteria
76031972|NCT03110341|Drug|Erythropoietin|rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
76031973|NCT03110341|Drug|Normal saline|placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
75705558|NCT04168684|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|Manualized intervention implemented in home with parent and child present focused on parental responsiveness
76031974|NCT03140215|Device|laryngeal mask insertion (Baska)|
75705559|NCT04168684|Behavioral|Developmental Education for Families (DEF)|Manualized intervention implemented in home with parent and child present focused on parental enhancement of child learning
76031975|NCT03140215|Device|laryngeal mask insertion (I-gel )|
75385439|NCT05313971|Other|Self knowledge course|The online self-knowledge and communication course, created for the purpose of this clinical trial and taught by professionals with certified training in the area by the Shalom Enneagram Institute (https://iesh.pt/), consisted of providing volunteers with mechanisms for self-knowledge using the enneagram. Three modules were carried out between October and December 2020, spaced in time to allow participants to consolidate knowledge: there was 1 month between the first and second module, and between the second and third, 3 weeks.
76031976|NCT04720729|Biological|Chemotherapy monitoring by circulating tumor DNA analysis|"During the screening step (2nd chemotherapy line, cycle 1) : at each time point (L2C1D1 & L2C1D15), 30 ml of blood will be drawn on special tubes with conservative suited for ctDNA analyses (e.g. STRECK® tubes).Then cell-free circulating DNA (cfcDNA) will be extracted from plasma following the manufacturer recommendations. cfcDNA will be quantified, and minimum 500-1000 copies will be analyzed by droplet digital PCR (ddPCR). Analyses will define if ctDNA could be detected during L2.~For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be changed."
76031977|NCT03511417|Device|over-the-counter hearing device|Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
76031978|NCT03273751|Procedure|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
76031979|NCT03273751|Procedure|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
75385440|NCT03569033|Drug|Gefapixant|Gefapixant 45 mg will be administered orally.
75385441|NCT03569033|Drug|Placebo|Placebo tablet matching gefapixant will be administered orally.
75557729|NCT03279965|Diagnostic Test|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
75557730|NCT00474435|Drug|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):~emtricitabine 200 mg~tenofovir DF 300 mg~efavirenz 600 mg"
76031980|NCT03136315|Other|INFERNAL Intervention|The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
76031981|NCT03152539|Radiation|MRI|
76031982|NCT03152539|Device|EEG|
76031983|NCT03152539|Device|NIRS|
75557731|NCT00438035|Procedure|ECG spectral|
75557732|NCT04701320|Drug|Conventional glass ionomer|Conventional glass ionomer with enhanced mechanical and esthetic proberties
75557733|NCT04701320|Drug|Nano hydroxyapatite reinforced glass ionomer|Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
76031984|NCT03136549|Other|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
76031985|NCT03136549|Other|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
75385442|NCT03955133|Other|Adverse Drug Reaction ADRe Profile for Polypharmacy|PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
76031986|NCT05377801|Behavioral|Multi-dimensional fall prevention intervention program for 12 weeks|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
75385443|NCT03991715|Behavioral|Activity Tracker|Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
75385444|NCT04002791|Device|VasoBand|Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression
75385445|NCT05314049|Procedure|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
75385446|NCT05314049|Procedure|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
76031987|NCT04537897|Drug|BI 474121|BI474121
75385447|NCT05314049|Device|inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
76031988|NCT04537897|Drug|Midazolam|Midazolam
75385448|NCT05314049|Device|Heat Therapy|superficial heating for 20 minutes
75385449|NCT03935399|Drug|Oxytocin|10 IU oxytocin (Pitocin) for intramuscular injection
75385450|NCT03935399|Drug|Saline|1.5 ml preservative free saline for intramuscular injection
75385451|NCT03571607|Biological|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
75385452|NCT03993119|Drug|Non-vitamin K antagonist oral anticoagulant|Non-vitamin K antagonist oral anticoagulant
75385453|NCT03574181|Other|Smartwatch to measure Blood Alcohol Level (BAL)|Subjects will wear a wristwatch with a sensor that measures blood alcohol level during a 1-hour period of consuming alcohol followed by a 5 hour observation period.
75385454|NCT03988049|Device|1,550 fracionated photothermolysis laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
75385455|NCT03988049|Device|755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
75385456|NCT03930641|Drug|RTH258|6 mg in prefilled syringe
75385457|NCT03910439|Biological|Avelumab|Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
75385458|NCT03910439|Radiation|External beam radiotherapy|5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
75385459|NCT03907241|Drug|Octanorm 16.5%|Human normal immunoglobulin
76031989|NCT04537897|Drug|Placebo|Placebo
76031990|NCT04543513|Other|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
76031991|NCT04421053|Behavioral|prenatal care for women with GDM|we conduct prenatal care for GDM pregnancies through both prenatal clinic and app.
76031992|NCT04405063|Device|Paclitaxel Coated PTCA Balloon Catheter|Drug coated balloon
76031993|NCT05090527|Diagnostic Test|Risk stratification|advanced penicillin challenge after risk stratification
76031994|NCT04400305|Behavioral|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
76031995|NCT04381039|Device|Insole|3D printing insole (Nylon), 3D printing insole (TPU), CNC machine insole (EVA), shoe only
76031996|NCT01672853|Biological|Simtuzumab|Subcutaneous injections weekly for a total of 96 injections
76031997|NCT01672853|Biological|Placebo|Subcutaneous injections weekly for a total of 96 injections
76031998|NCT05090449|Drug|Chlorthalidone (HIGROTON® 50)|Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
75385460|NCT03137225|Device|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
75385461|NCT03137225|Device|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
75385462|NCT03927209|Drug|BI 1467335|tablet
75385463|NCT03895307|Other|kinesio tape|two 15 cm I type kinesio tape applied longitudinally
75385464|NCT03895307|Other|local anesthetic|local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
76031999|NCT05090449|Drug|Losartan (COZZAR®)|Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
76032000|NCT05090449|Drug|A1+ A2 Co-administration of Chlorthalidone and Losartan|50mg chlorthalidone + 100 mg losartan potassium
76032001|NCT05090449|Drug|Chlorthalidone + Losartan Fixed-Dose combination|Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
75385465|NCT03895307|Other|local serum physiologic|serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
75385466|NCT01511081|Radiation|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
75385467|NCT01511081|Radiation|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
75541921|NCT04548115|Behavioral|ARTISAN Condition|Youth and senior participants will be randomly paired and engage in the 5-weekly, 3-hour ARTISAN intervention as dyads (totaling 15 hours of intervention). In the first four weeks of the ARTISAN, dyads will engage in themed museum tours facilitated by a docent (45min), guided storytelling (45 min) and professionally-led art-making (45 min). The remaining time (45 min) is allocated for session breaks, session introduction/closing, and buffer time for movement around the gallery. The final week involves an exhibition where participants share their artworks with the public and reflect on their experiences and artworks. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
75705560|NCT04128137|Drug|Fludrocortisone|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
76032002|NCT05090137|Other|Diuretics|As per group descriptions
76032003|NCT03067025|Device|Actigraphy|Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
76032004|NCT05090059|Device|Lower limb myofascial trigger points f-ESWT|3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
76032005|NCT03067415|Drug|D565H(Latanoprost 25㎍/㎖)|D565H twice daily
76032006|NCT03067415|Drug|D565(Latanoprost 50㎍/㎖)|D565 once daily
75385468|NCT03115853|Drug|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
75385469|NCT03115853|Drug|Placebo|Placebo tablet for Aliskerin
75385470|NCT03115853|Drug|HCTZ|HCTZ 25mg every day for 18 weeks
75385471|NCT03115853|Drug|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
75541922|NCT04548115|Behavioral|Intergenerational Participatory Arts Condition|Youths and senior participants in this condition will be randomly paired and engage in a 5-weekly 45-minute group-based art activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). A professional artist or art therapist will facilitate art-making sessions with the participants in a community space, utilizing the same mediums that were used in ARTISAN. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
76032007|NCT05089981|Drug|N acetyl cysteine|Intravenous use of N acetyl cysteine in prescribed doses
76032008|NCT05089981|Drug|Placebo of N acetyl cysteine|Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
75385472|NCT01498991|Device|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
75385473|NCT03895853|Other|Best Practice|Receive standard of care
75385474|NCT03895853|Dietary Supplement|early metabolic resuscitation|Given Intravenous
75385475|NCT03901313|Drug|Treatment A - 400 mg Fasting|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions
75385476|NCT03901313|Drug|Treatment B - 400 mg Fed|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
75385477|NCT03901313|Drug|Treatment C - 200 mg Fed|Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
75385478|NCT03900299|Procedure|oncoplastic breast surgery|oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
75385479|NCT03898349|Other|Annie text messaging system|Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
75705561|NCT04128137|Other|Placebo|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
75705562|NCT04112355|Other|Blood Collection|Blood draw
75705563|NCT04096066|Drug|Carfilzomib|"20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards."
75385480|NCT03898349|Other|Annie text messaging system with Usual implementation|"Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls"
76032009|NCT03349801|Other|No intervention|According to clinical practice.
76032010|NCT03066401|Procedure|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
76032011|NCT05089591|Device|Intense Pulsed Light therapy|The LacryStim System is a CE marked device for treatment of meibomian gland dysfunction. It stimulates and reactivates meibomian glands and improves the related dry eye condition. Intense pulsed light is emitted with a light spectrum from 610nm to 1200nm. Each treatment consists of short individual pulses lasting for 4ms separated by a 26ms lasting interval to hinder tissue temperature increase, thermal damage to the skin and inflammatory reaction. During this phase 8 to 12 J / cm2 are delivered. Selection of total energy levels depends on the skin type (Fitzpatrick Skin Types) as recommended by the manufacturer.
76032012|NCT05089591|Device|Sham Treatment|The fellow eye serves as the control eye. Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations). The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
76032013|NCT04206059|Radiation|MRI|A non-contrast brain MRI will be acquired for localizing EEG slow waves
75385481|NCT03898349|Other|Annie text messaging system with Augmented implementation|"Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance"
75385482|NCT03894449|Combination Product|Prebiotic + Iron Forificant|A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
75385483|NCT03888755|Drug|Icatibant|Participants will receive icatibant 30 mg SC injection in the abdominal area.
75385484|NCT00378755|Drug|velcade|
75385485|NCT00378833|Drug|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
75385486|NCT00378833|Drug|niacin|Duration of Treatment: 18 Weeks
75385487|NCT02995967|Procedure|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
75385488|NCT02995967|Drug|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
75385489|NCT03888365|Drug|Treprostinil|Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
75385490|NCT03888365|Drug|Non-Treprostinil PAH Medications|Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
75385491|NCT00377975|Drug|Ephedrine|
75385492|NCT00377975|Drug|Pioglitazone|
75385493|NCT00377975|Drug|Caffeine|
75705564|NCT04096066|Drug|Lenalidomide|- 25 mg orally on days 1-21 of each cycle.
76032014|NCT04206059|Diagnostic Test|Quantitative Sensory Testing (QST)|Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
75385494|NCT03870893|Behavioral|hippotherapy|16weeks hippotherapy program
75385495|NCT02994251|Drug|gemcitabine|1000 mg/m^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
75385496|NCT02994251|Drug|Cisplatin|25 mg/m^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
75385497|NCT02994251|Drug|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
75385498|NCT03887429|Drug|SXC-2023|SXC-2023 oral capsules
75385499|NCT03887429|Drug|Placebos|Matching Placebo oral capsules
76032015|NCT04206059|Diagnostic Test|Home sleep study|Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
76032016|NCT04206059|Other|Acoustic stimulation (65db) up-slope of EEG with QST|Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
76032017|NCT04206059|Other|Acoustic stimulation (65db) down-slope of EEG with QST|65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
76032018|NCT04206059|Other|0 db with QST|sham stimulation (0 dB volume)
75385500|NCT02978885|Radiation|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT CT
75385501|NCT02978885|Drug|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
75541923|NCT04548115|Behavioral|Intergenerational Art-space Condition|Youths and senior participants in this condition will engage in a 5-weekly 45-minute group-based curated museum tour that follow the ARTISAN themes with 15 minutes of preparation/break time, and conducted by a trained docent at the National Museum Singapore (totaling 5 hours of intervention).The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
76032019|NCT04206059|Drug|Dexmedetomidine|All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
76032020|NCT04206059|Other|Breathe-Squeeze Task|All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
76032021|NCT01038193|Other|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
76032022|NCT05377645|Other|Cyriax mobilization + traditional physiotherapy|TENS, US, exercise
76032023|NCT05430737|Radiation|stereotactic body radiotherapy|The radiation dose to the primary tumor was 40 or 45 Gy in five fractions according to the clinical determination of the radiologist. The dose to the positive lymph nodes and the prostate and seminal vesicles was 37.5Gy in five fraction. And internal iliac, external iliac, obturator, and presacral pelvic drainage regions received 25 Gy/5f, simultaneously. The treatment was delivered every other day. The volumetric modulated arc radiotherapy (VMAT) or intensity-modulated radiotherapy (IMRT) was used to complete treatment. Image-guided radiotherapy(IGRT) was performed for every treatment.
75385502|NCT02978885|Procedure|Whipple procedure|"A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care."
75385503|NCT02978885|Procedure|Major surgery|Additional surgical procedure(s) that is clinically indicated. Standard of care.
75385504|NCT02936999|Drug|Cholecalciferol|Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
76032024|NCT05431049|Procedure|Percutaneous nephrolithotomy surgery (PNL)|Percutaneous nephrolithotomy (PNL) surgery was performed in all arms of the study to remove the renal stones. This surgery was performed with 2 anesthesia methods, CSEA and GA. These formed the groups of the study.
75385505|NCT01385033|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
76032025|NCT04148573|Drug|NFX88 - 1|3 times a day
76032026|NCT04148573|Drug|NFX88 - 2|3 times a day
76032027|NCT04148573|Drug|NFX88 - 3|3 times a day
76032028|NCT04148573|Drug|PLACEBO - 4|3 times a day
76032029|NCT03136783|Other|Development of the most specific physiologically relevant experimental patient models|Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
76032030|NCT05430503|Diagnostic Test|Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise|DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
76032031|NCT03110263|Other|Multicomponent internet-based self-help|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
76032032|NCT03110263|Other|Internet-based sleep restriction|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
76032033|NCT05730023|Device|Active tDCS|Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);
76032034|NCT05730023|Behavioral|individualized language training|individualized language training
75385506|NCT02826551|Drug|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
75385507|NCT02826551|Other|Ice|
75385508|NCT02826551|Drug|Percocet|
76032035|NCT05730023|Device|Placebo tDCS|Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
76032036|NCT05089045|Biological|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
76032037|NCT04132817|Biological|Nivolumab|specified dose on specified days
76032038|NCT04132817|Biological|Ipilimumab|specified dose on specified days
76032039|NCT04132817|Drug|Nab-paclitaxel|specified dose on specified days
76032040|NCT05088811|Diagnostic Test|WRAP53, UCA-1|Diagnostic value of UCA-1 and WRAP53 in HCC
76032041|NCT03066635|Drug|Botulinum Toxin Type A 25 IU|injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
76032042|NCT03066635|Drug|Botulinum Toxin Type A 12.5 IU|injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
76032043|NCT05077267|Biological|ABNCoV2 100ug|IM injection 100ug dose
76032044|NCT05077267|Biological|ABNCoV2 50ug|IM injection 50ug dose
75385509|NCT02826551|Device|Knee Brace and Crutches|
75385510|NCT00378443|Drug|prednisone + Inhibace/Cozaar|
75385511|NCT00378443|Drug|Inhibace/Cozaar|
75385512|NCT01337609|Drug|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
75385513|NCT01337609|Other|Placebo (sugar pill)|1 pill daily for 60 days
75385514|NCT01337609|Other|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
75385515|NCT01340573|Drug|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
75385516|NCT01340573|Drug|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of <65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of >85 kg received 1200 mg of ribavirin daily.
76032045|NCT05075083|Biological|Inactivated COVID-19 vaccine|receive two doses inactivated COVID-19 vaccine with the interval of 21 days
76032046|NCT04073771|Device|Continuous renal replacement therapy with oXiris|Continuous renal replacement therapy with oXiris in patient with septic shock
76032047|NCT03136237|Drug|BCX7353|Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3
76032048|NCT03136237|Drug|Digoxin|Day 1 of Cohort 1
75385517|NCT01340885|Drug|Strattera|10-30 mg b.i.d. for 6 weeks
75385518|NCT01340885|Drug|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
75385519|NCT01340885|Other|Placebo|2-6 pills for 6 weeks
75385520|NCT01326923|Drug|Cetuximab|Single arm phase II study of chemotherapy
76032049|NCT03136237|Drug|BCX7353 + digoxin|Day 19 of Cohort 1
76032050|NCT03136237|Drug|Rosuvastatin|Day 1 of Cohort 2
76032051|NCT03136237|Drug|rosuvastatin + BCX7353|Day 15 of Cohort 1
76032052|NCT03136237|Drug|Cyclosporine + BCX7353|Day 14 of Cohort 3
75385521|NCT03855059|Drug|Placebos|This will be a saline solution of given IV or perineural.
76032053|NCT05430425|Other|respiratory safety|Which of the 3 lma selection methods is effective in ensuring respiratory safety?
75385522|NCT03855059|Drug|Dexamethasone Sodium Phosphate|This will be the active drug solution given IV or perineural.
75385523|NCT03863795|Other|Survey Administration|Respond to SurveyGizmo survey online
75385524|NCT03858335|Other|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
75385525|NCT03857243|Device|dual transcranial direct current stimulation|Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
76032054|NCT04001309|Other|Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions|Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
76032055|NCT03136081|Diagnostic Test|Candidiasis infection occurence|Candidiasis infection occurence
76032056|NCT03135925|Other|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
76032057|NCT05729789|Behavioral|Group Written Exposure Therapy|Group Written Exposure Therapy (GWET) is a brief cognitive behavioural therapy for PTSD aimed at allowing patients to process their traumatic experiences in a safe environment. GWET will consist of 6 group sessions (1 orientation session and 5 weekly group sessions). Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience. The written exposure will be followed by a guided discussion about the experience of writing the exposure. There is no homework assigned between sessions. However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
75385526|NCT01301963|Drug|plerixafor|Given SC
75385527|NCT01301963|Biological|filgrastim|Given SC
75385528|NCT05313737|Other|Automated message|Automated message via phone call (audiocare)
75385529|NCT05313737|Other|Opt-out scheduling|Scheduling via non-automated phone call
76032058|NCT04021381|Dietary Supplement|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
75385530|NCT01298921|Drug|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
76032059|NCT04021381|Dietary Supplement|Placebo|Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
75385531|NCT01298921|Drug|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
76032060|NCT04020523|Other|MRI sequence|The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
76032061|NCT04158401|Device|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
75385532|NCT05313191|Radiation|Pencil Beam Scanning Proton Therapy|Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
75385533|NCT00378521|Drug|MQX-503|
75385534|NCT03870737|Device|Active TNS|Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
75385535|NCT01269749|Radiation|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
76032062|NCT03066479|Device|Fitbit|Wearable activity & sleep tracker.
76032063|NCT03066479|Other|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
76032064|NCT03066479|Diagnostic Test|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
75385536|NCT01269749|Drug|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
75385537|NCT02757053|Device|Guardian Cap|The Guardian Cap is a third party add-on device attached to the facemask of a football helmet that covers the outside of the helmet with a soft material to reduce the initial impact severity, thus reducing the forces transmitted to the brain
76032066|NCT03066791|Dietary Supplement|Turmeric tablets|
76032067|NCT03066791|Dietary Supplement|Curcumin and Bioperine tablets|
76032068|NCT03066791|Dietary Supplement|Placebo tablets|
76032069|NCT03066869|Drug|H.P. ACTHAR GEL|H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
76032070|NCT04200131|Diagnostic Test|Biopsy of the cyst wall with the Moray™ forceps.|Tissue sample of the wall of the pancreatic cyst with micro Moray™ forceps during an ultrasound-guided puncture of a pancreatic cyst with a 19G needle.
76032071|NCT05729633|Other|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of both delivering RMIT as well as RMTT. It can provide zero, partial, or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial, or full assistance, for the patient.~Impairment oriented training will focus on the following movements:~Diagonal movement~Shoulder abduction~Shoulder adduction~Shoulder flexion~Shoulder extension~Elbow flexion~Elbow extension~Task-specific training will focus on the following activities:~Picking up a cup/glass by the side and drink~Brushing hair~Cleaning unaffected upper limb (hand to arm)~Wiping table~Wiping wall~Sliding card on table to a designated location~Clipping a clothe peg"
76032072|NCT05729555|Drug|Compound ibuprofen polyrelease tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
75385538|NCT01270919|Device|BioDuct Meniscal Repair Device|"The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear."
75385539|NCT01262339|Drug|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
75385540|NCT03861845|Device|Standard off-the-shelf pillbox|Then the participant will receive a store bought one-dose per day pillbox.
76032073|NCT05729555|Drug|reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON & JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON & JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time"
76032074|NCT01603459|Drug|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
75385541|NCT03861845|Device|Custom off-the-shelf pillbox|Then the participant will be administered an off-the-shelf pillbox that was purchased specifically for the participant's preferences, routine, medication regimen, and skills/abilities.
76032075|NCT03066245|Biological|MSC-PLGA|Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
76032076|NCT03066323|Other|Rice with tea extract|Rice with tea extract
76032077|NCT03066323|Other|Rice without tea extract|Rice without tea extract
76032078|NCT05424185|Behavioral|different type of scapular dyskinesis|rapid arm elevation to see the different of EMG rise and force development
76032079|NCT02926027|Drug|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
76032080|NCT02926027|Drug|placebo|placebo
75705565|NCT04096066|Drug|Dexamethasone|"- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle."
75541924|NCT04548115|Behavioral|Intergenerational Storytelling Condition|Youths and senior participants in this condition will be paired to engage in a 5-weekly 45 minute group-based storytelling activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). Storytelling sessions will be conducted by a trained facilitator, and conversation starters from ARTISAN intervention will be used. The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
75541925|NCT04548115|Behavioral|Control Condition|Participants in this condition will engage in a 5-weekly 45 minute group-based physical activity session conducted in the community with 15 minutes of preparation/break time (totaling 5 hours of intervention). Physical activity was selected over basic psychosocial care to test the effects of inter-generational contact independent of arts and heritage-based engagements.
75541926|NCT00414089|Drug|90Y-ibritumomab tiuxetan (Zevalin)|
76032081|NCT05037305|Other|Educational video|The brief educational video provides information about pharmacogenetic testing, the results of pharmacogenetic testing, and how to find these results in the patient portal.
76032082|NCT03136003|Drug|DDAVP|The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
75705566|NCT04085731|Procedure|Catheter ablation|Driver-guided catheter ablation of persistent atrial fibrillation
75541927|NCT00261612|Drug|bortezomib|
75541928|NCT00261612|Drug|rituximab|
75541929|NCT00261612|Drug|dexamethasone|
75541930|NCT00261612|Procedure|treatment protocol|
75541931|NCT04547764|Drug|triple antibiotic paste (TAP)|root canal treatment of pulpally involved teeth.
75541932|NCT04547764|Drug|Vitapex (calcium hydroxide/iodoform paste)|root canal treatment of pulpally involved teeth.
75541933|NCT04547647|Radiation|X- Ray|X-Ray with A-P and lateral view of the whole spine.
75541934|NCT04547608|Other|The difference of the timing of rocuronium administration after propofol injection|The difference of the timing was rocuronium was administered immediately after propofol injection or when BIS score became below 60 after propofol administration.
75541935|NCT00236249|Drug|Lidocaine|
75541936|NCT00269061|Drug|pioglitazone|
75541937|NCT02214472|Behavioral|Biofeedback|
75541938|NCT02214472|Drug|Placebo|
75541939|NCT04547452|Radiation|Stereotactic body radiation therapy|Sintilimab Combined with SBRT
75705567|NCT04057352|Device|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
76023453|NCT04718987|Radiation|Low dose rate (LDR) brachytherapy|Low dose rate (LDR) brachytherapy is a type of radiation treatment where doctor places the radioactive implants (seeds) inside patient's prostate gland and these seeds emits low dose radiation over a certain period of time. During low-dose-rate brachytherapy, a continuous low dose of radiation is released over time -from several hours to several days.
76023454|NCT04708379|Behavioral|Lifestyle intervention|Nutrition and physical activity education.
76023455|NCT03702569|Diagnostic Test|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
76023456|NCT04685447|Procedure|Expanded Hemodialysis for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks
75705568|NCT04037787|Procedure|ERAS protocol|In colorectal cancer surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting with administration of oral carbohydrates before surgery, use of intestinal preparation for selected cases only (rectal surgery), the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, preference for minimally invasive surgery, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
75385542|NCT03861845|Device|Custom designed and manufactured pillbox|Then the participant will describe any design preferences for the pillbox. The researcher will design and manufacture the pillbox using a 3D printer, publically available 3D printing object repository, and computer aided design software.
75385543|NCT03861845|Behavioral|Education & Training|The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.
75541940|NCT04547452|Drug|Anti-PD-1 antibody drug named Sintilimab|Sintilimab
75541941|NCT04547335|Drug|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
75385544|NCT03861845|Behavioral|Reflection on medication routines|The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.
75385545|NCT02708849|Drug|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
75385546|NCT02708849|Drug|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
75385547|NCT02708849|Drug|Placebo|oral dose placebo
75541942|NCT00236288|Drug|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
75541943|NCT04547296|Drug|Sodium Bicarbonate Ringer's Solution|After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH <7.2, 5% sodium bicarbonate injection was given to correct it.
75541944|NCT02214511|Behavioral|emotional facial stimuli|Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
75705569|NCT04022590|Device|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
75385548|NCT03859739|Drug|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
75385549|NCT01237613|Device|Artelon|Artelon Tissue Reinforcement
75385550|NCT01234103|Behavioral|Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits|Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
75385551|NCT01222871|Drug|Triamcinolone|Triamcinolone soaked nasopore dressing
75385552|NCT01222871|Drug|Saline soaked sponge|saline soaked sponge
75385553|NCT01219673|Other|Placebo|1 by mouth twice a day.
75385554|NCT01219673|Drug|Armodafinil|150 mg by mouth once a day.
75385555|NCT01219673|Drug|Minocycline|100 mg by mouth twice a day.
75705570|NCT04022590|Behavioral|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
75705571|NCT04018391|Behavioral|Stepped care for nonadherence and depression|"Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
75705572|NCT04018391|Other|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
75385556|NCT01219673|Drug|Bupropion|100 mg by mouth twice a day.
75385557|NCT01216631|Drug|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
75385558|NCT01216631|Drug|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
75385559|NCT01216631|Drug|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
75705573|NCT04016870|Device|Reconditioned Pacemaker|Devices from the three manufacturers below will be used.
75705574|NCT04016870|Device|New Pacemaker|Devices from the four manufacturers below will be used.
75385560|NCT02693717|Other|Laboratory Biomarker Analysis|Correlative studies
75385561|NCT02693717|Drug|Pemetrexed Disodium|Given IV
75385562|NCT03860753|Drug|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.
76023457|NCT04685447|Procedure|Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
76023458|NCT03012425|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
76023459|NCT03012425|Procedure|Acupuncture|
76023460|NCT03012425|Behavioral|questionnaires|
76023461|NCT03012425|Other|Diurnal Cortisol|saliva test
76023462|NCT03587675|Diagnostic Test|EVH test|
76023463|NCT03540875|Device|Closed loop anesthesia|"Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia."
76023464|NCT03540875|Drug|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
76023465|NCT03540875|Drug|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
76023466|NCT03536507|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
75385563|NCT03860753|Drug|Placebo|Pill capsules will look same as that of active drug.
75385564|NCT02687165|Drug|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
75385565|NCT02672033|Radiation|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
75385566|NCT02672033|Radiation|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
75385567|NCT02672033|Other|Laboratory Biomarker Analysis|Correlative studies
75385568|NCT02672033|Procedure|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
75385569|NCT02656199|Procedure|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
76032083|NCT03136003|Behavioral|Exercise|The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
76032084|NCT03798353|Combination Product|PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
75385570|NCT03845933|Procedure|Colon polypectomy|Polyp search and resection will be performed during the withdrawal phase in both groups. Insertion polypectomy will not be performed. All proximal colon polyps will be removed irrespective of their size and appearance.
75705575|NCT04010357|Drug|Abemaciclib,|Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
75705576|NCT03990610|Procedure|Mammoplasty|Undergo standard of care breast reconstructive surgery
75705577|NCT03990610|Procedure|Vascularized Lymph Node Transfer|Undergo vascularized lymph node transfer
75705578|NCT03985527|Device|Transvenous nerve stimulation|Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
75385571|NCT03817775|Other|Music therapy|"The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end."
75385572|NCT01169753|Drug|Placebo|Oral tablet every morning for 2 weeks
76032085|NCT03798353|Procedure|Surgery by sternotomy|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
76032086|NCT04962685|Other|Rapid Maxillary Expansion|"Subjects in the experimental group (with unilateral posterior crossbite) will be treated with Maxillary Rapid Expansion using a disjunctor fixed with two bands on the upper first permanent molars and a mesh cemented to the upper first premolars or upper first primary molars (depending on the eruptive stage of the patient).~The breaker screw will be activated twice a day until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with light-curing flowable resin and the patient will wear the cemented disjunctor as a retainer for a minimum of six months."
76032087|NCT05410847|Drug|Camrelizumab Nab-Paclitaxel S-1|Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
76032088|NCT04540939|Behavioral|Mindfulness-Based Cognitive Therapy|"There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
75385573|NCT01169753|Drug|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
75385574|NCT02654639|Drug|TAS-102|TAS-102 Twice a day by mouth day 1-5 and 8-12
75385575|NCT02654639|Drug|Bevacizumab|Bevacizumab by intravenous infusion once every 14 days
75385576|NCT02634827|Drug|Decitabine|Given IV
75385577|NCT02634827|Other|Laboratory Biomarker Analysis|Correlative studies
75385578|NCT02634827|Drug|Midostaurin|Given PO
75385579|NCT02506985|Drug|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
75385580|NCT02506985|Drug|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
75385581|NCT01150409|Drug|hydrocortisone|1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
75385582|NCT01150409|Drug|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
75385583|NCT01133639|Drug|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
75385584|NCT01133639|Drug|Placebo|Placebo plus standard of care
75385585|NCT01115699|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
75541945|NCT02214511|Behavioral|Cyberball game|Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
75541946|NCT00236327|Drug|fentanyl|
75541947|NCT00269139|Behavioral|Crisis resolution|
75541948|NCT02214589|Other|Oral glucose, facilitated tucking, NNS|
75541949|NCT02214589|Other|Oral glucose and NNS|
75541950|NCT02214589|Other|Facilitated tucking and NNS|
75541951|NCT04546984|Drug|HEC96719|Part 2：Mulltiple doses up to 10 days
75541952|NCT00236366|Drug|fentanyl|
75385586|NCT00378911|Drug|sunitinib malate|Given orally
75385587|NCT03819491|Dietary Supplement|COQUN ORAL FORMULATION|COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
75385588|NCT03801473|Other|robot assisted gait therapy|The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.
75385589|NCT03801473|Other|Conventional rehabilitation|Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
75385590|NCT03828149|Combination Product|Drug:OP0201|Drug: OP0201
75385591|NCT03828149|Combination Product|Drug: Placebo|Drug: Placebo
76032089|NCT04540939|Behavioral|Muscle Relaxation Therapy|Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
76032090|NCT04750291|Drug|Botulinum toxin type A|1 infiltration in the biceps muscle with botulinum toxin (100 IU)
75385592|NCT03832907|Device|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
75385593|NCT03832907|Diagnostic Test|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
75385594|NCT03831971|Drug|ANS-6637|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
75385595|NCT03823937|Other|Sniffin' Sticks test and Taste strips|"Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth."
75385596|NCT03807089|Device|Conventional Pediatric Colonoscope|
75385597|NCT03807089|Device|Short-Turn Radius Colonoscope|
75385598|NCT03822377|Drug|Ticagrelor orodispersible tablets|Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
75385599|NCT03822377|Drug|Ticagrelor standard tablets|Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
76032091|NCT04750291|Other|Placebo|1 infiltration in the biceps muscle with placebo or sterile saline
76032092|NCT04708951|Device|ENDOCUFF VISION® device|ENDOCUFF VISION® is a disposable cap placed on the tip of a standard colonoscope, intended to flatten colonic folds and assist in controlling the colonoscope's field of view and tip positioning
76032093|NCT04708951|Device|G-EYE® colonoscope|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning
76032094|NCT03726749|Drug|Tocilizumab|Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
76032095|NCT03726749|Drug|Prednisone|Prednisone is an anti-inflammatory medication
76032096|NCT04593745|Device|Intraocular pressure measurment|Intraocular pressure measurmentt using iCare devise: TONOPEN
76032097|NCT03821077|Biological|Allergen Immunotherapy (AIT)|Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation
75385600|NCT02501759|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
75541953|NCT04546789|Drug|M2951 (BTK inhibitor)|Participants will receive a single oral dose of M2951 (BTK inhibitor).
75541954|NCT00261690|Behavioral|Virtual Reality Distraction|Using virtual reality distraction during a procedure
75541955|NCT04547179|Drug|Fremanezumab-Vfrm|Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
76032098|NCT03756337|Device|Neuro 1 & Neuro 2|participant common fitting map used for tests
75385601|NCT02501759|Radiation|Gadodiamide|Given IV
75385602|NCT02501759|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
75385603|NCT02501759|Procedure|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
75385604|NCT02501759|Procedure|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
75385605|NCT03808493|Drug|TAK-438 OD|TAK-438 OD tablet
75385606|NCT03808493|Drug|TAK-438|TAK-438 tablet
75385607|NCT00378989|Behavioral|Consultation at the occupational health services|Consultation at the occupational health services
75385608|NCT02499887|Drug|beclamethasone dipropionate|Inhaler
75385609|NCT02499887|Drug|albuterol|Inhaler
75385610|NCT02499887|Drug|Prednisone|Oral corticosteroid
75385611|NCT02504099|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
75385612|NCT02504099|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
75385613|NCT02504099|Drug|ribavirin|Tablet
75385614|NCT02450591|Drug|Erlotinib|
75385615|NCT02450591|Other|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
75385616|NCT01094561|Drug|Synthetic Human Secretin|Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
75385617|NCT01094561|Procedure|Secretin-Enhanced Magnetic Resonance Cholangiopancreatography|
75385618|NCT01094561|Procedure|Secretin-Enhanced Endoscopic Ultrasound|
75541956|NCT04547179|Device|BLAfit®|Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day
75541957|NCT04547179|Other|Saline|Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
75541958|NCT04547101|Drug|AK104|AK104，6 mg/kg IV，every 2 weeks (Q2W)
75385619|NCT01074437|Drug|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
75385620|NCT01074437|Drug|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
75385621|NCT01074437|Drug|Placebo|Liquid placebo will be given during the two month treatment trial.
75385622|NCT03807245|Biological|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
75385623|NCT03807245|Biological|Placebo GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
75385624|NCT03807245|Biological|Placebo GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
75541959|NCT04546906|Biological|CD22 CAR-T|Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
76032099|NCT03756337|Device|Neuro 2 & Neuro 1|participant common fitting map used for tests
76032100|NCT03136705|Drug|Nicotinamide|Nicotinamide tablet
75385625|NCT03807245|Biological|GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
75385626|NCT02461355|Behavioral|Aphasia therapy|Aphasia therapy using a computerized scripting program
75541960|NCT00236405|Drug|epoetin alfa|
75541961|NCT00269178|Behavioral|Peer Health Education Programme|
75541962|NCT00236444|Drug|risperidone|
75541963|NCT00269217|Drug|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
76032101|NCT03136705|Drug|Lanthanum Carbonate|Lanthanum Carbonate tablet
76032102|NCT03136705|Drug|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
76032103|NCT03136705|Drug|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
76032104|NCT03066713|Other|Skin Off French Fry|Skin Off French Fries will be provided at breakfast and lunch
76032105|NCT03066713|Other|Skin On French Fry|Skin On French Fries will be provided at breakfast and lunch
76032106|NCT03066713|Other|Hash brown|Hash brown potatoes will be provided at breakfast and lunch.
76032107|NCT03066713|Other|Carbohydrate control|A pancake will be provided at breakfast, and pretzels will be provided at lunch.
76032108|NCT03066557|Procedure|TACE and Apatinib|TACE and Apatinib 250mg po qd
76032109|NCT03066557|Procedure|TACE|TACE
76032110|NCT04574401|Drug|IS-002|Intravenous injection of IS-002 Investigational Drug
76032111|NCT05729087|Behavioral|Blended intervention group|"Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session."
76032112|NCT05308667|Other|Rehabilitation (modified constraint-induced movement therapy)|Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
76032113|NCT05308667|Other|non-invasive brain stimulation (intermittent theta-burst stimulation)|Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
76032114|NCT05728931|Biological|Test of biological samples|Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title
76032115|NCT05737927|Drug|Glucose 8 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
76032116|NCT05737927|Drug|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
75385627|NCT02461355|Device|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
75385628|NCT02461355|Device|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
75385629|NCT02410577|Drug|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
75385630|NCT02410577|Device|PET/CT Scan|
75385631|NCT02410577|Device|MRI|
75385632|NCT02410577|Other|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
75385633|NCT01066637|Drug|[18F](+/-)NOS|Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis
75541964|NCT00269217|Drug|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
76032117|NCT05737927|Drug|Glucose 16 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
75385634|NCT03796013|Drug|Entrectinib Form A|Participants will receive a single oral dose of entrectinib form A under fasted conditions.
75385635|NCT03796013|Drug|Entrectinib Form C|Participants will receive a single oral dose of entrectinib form C under fasted conditions.
75385636|NCT02399111|Device|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
75385637|NCT03793751|Drug|Dexmedetomidine Injection|Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
75385638|NCT01030757|Radiation|Tomotherapy treatment|"A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~Dose will be prescribed to the isodose line which covers at least 90% of the PTV~Dose homogeneity +/- 5%"
75385639|NCT01016561|Radiation|intracavitary balloon brachytherapy|
75385640|NCT01016561|Radiation|external beam radiation therapy|
75385641|NCT01016561|Radiation|intensity-modulated radiation therapy|
75385642|NCT01016561|Radiation|radiation therapy treatment planning/simulation|
75385643|NCT01016561|Radiation|3-dimensional conformal radiation therapy|
75385644|NCT01016561|Drug|Cisplatin|
75385645|NCT01009931|Drug|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
75385646|NCT01009931|Drug|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
75385647|NCT01009931|Drug|Choline magnesium trisalicylate|"Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles."
75385648|NCT03792191|Radiation|Lumbar Spinal Ultrasonography|Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
75385649|NCT03792191|Radiation|Sham Ultrasound Procedure|Moving the ultrasound probe on the patient's back with the machine in the freeze position.
75385650|NCT03792191|Procedure|Conventional Landmark Palpation|Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
75385651|NCT03792191|Procedure|Spinal Anesthesia|Spinal anesthesia using a 25- or 22-gauge spinal needle
75541965|NCT00269217|Drug|Comparator: simvastatin|Duration of Treatment 12 Weeks
75541966|NCT04546204|Other|vaginal delivery|normal vaginal spontaneous delivery
75705579|NCT03976258|Drug|buprenorphine/naloxone|This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
75705580|NCT03976258|Drug|Methadone|This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
75705581|NCT03976258|Drug|Naltrexone Injection|This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
75705582|NCT03976258|Drug|Heroin|This is an observational study. Participants using heroin will be enrolled into this group.
75705583|NCT03953690|Other|use of e-Health service|use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation
75385652|NCT03792191|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
75705584|NCT03909165|Drug|Sugammadex 2 mg/kg|For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.
75705585|NCT03909165|Drug|Sugammadex 4 mg/kg|For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
75705586|NCT03909165|Drug|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
75705587|NCT03909165|Drug|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
76032118|NCT05737927|Drug|Glucose 12 g uncoated beads|After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
75385653|NCT03792191|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
76032119|NCT05737927|Drug|Glucose 12 g coated beads (60% w/w)|After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
75385654|NCT03791489|Device|ClariFix|The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
75385655|NCT03790865|Drug|Livoletide|Daily subcutaneous injection
75385656|NCT03790865|Drug|Placebo|Daily subcutaneous injection
75385657|NCT00986999|Drug|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
75385658|NCT02345369|Device|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
75385659|NCT02345369|Device|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
75385660|NCT03784001|Behavioral|Gratitude + No Expectations Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest
75541967|NCT04546282|Other|Description of the molecular alterations detected in blood samples of patients treated by osimertinib|Description of the molecular alterations detected in blood samples of patients treated by osimertinib. This test is usualyy performed routinely to detect conventional mutations including EGFR T790M. We performed panel of genes screeining based on next generation sequencing. Thius, iIn some cases, new mutations can be detected by this assay.
75705588|NCT03906331|Drug|Selpercatinib|Open-label expanded access
75705589|NCT03903172|Device|Abdominal binder|Abdominal binder
75705590|NCT03876808|Device|Bair Hugger™ Temperature Management Unit Model 750|Forced-air temperature management unit used for preoperative and intraoperative participant warming
75705591|NCT03876808|Device|3M™ Bair Paws™ Flex Gown|Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
75705592|NCT03858205|Other|Quality-of-Life Assessment|Ancillary studies
75385661|NCT03784001|Behavioral|Gratitude + Expectations Intervention|"Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Participants will have a statement at the top of their Google form about the benefits of gratitude. Examples of these statements are: Practicing gratitude may increase social connectedness and Cultivating gratitude was shown to improve school satisfaction in a UK sample of students. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest"
75705593|NCT03858205|Other|Questionnaire Administration|Ancillary studies
76032120|NCT05737927|Drug|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
76032121|NCT05728853|Radiation|Assessment of body composition|Assessment of body composition using BIA and DXA
76032122|NCT04152967|Device|new-designed PTFE valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
76032123|NCT04152967|Device|Bovine jugular vein valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
76032124|NCT05737771|Drug|DWC202213|DWC202213
75385662|NCT03784001|Behavioral|Events Control Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a list of up to five items about events from their day. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest.
75705594|NCT03858205|Radiation|Radiation Therapy|Receive low-dose radiation therapy
75705595|NCT03844828|Device|IOL implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
76032125|NCT05737771|Drug|DWJ1563|DWJ1563
76032126|NCT05737771|Drug|DWP16001|DWP16001
76032127|NCT05728697|Device|Endoscopic ultrasound shear wave elastography|To perform the portion of the endoscopic ultrasound exam using this device, the endoscopic ultrasound probe is placed onto the surface of the stomach with the probe facing the left liver. The probe then transmits shear waves that propagate through the tissue. The waves themselves are ultrasound waves and are harmless. This is repeated 10 times on a region of interest as guided by the endoscopic ultrasound probe. The device used in question is the linear EUS (Aloka Arietta 850, Olympus America, Center Valley, PA).
76032128|NCT04477135|Other|upper extremity pain|upper extremity pain in perinatologists due to working actively and performing ultrasonography every day
75385663|NCT03781037|Behavioral|GIVE Module|The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
75385664|NCT02319005|Drug|Revusiran (ALN-TTRSC)|
75385665|NCT02319005|Drug|Sterile Normal Saline (0.9% NaCl)|
75385666|NCT03784079|Drug|GSK3640254|GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
75385667|NCT03784079|Drug|Placebo matching GSK3640254 Mesylate salt|Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
75385668|NCT00983645|Drug|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
75385669|NCT00983645|Drug|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
75385670|NCT02308475|Device|Somatom Force CT Scanner|Dynamic CT perfusion of the heart
75385671|NCT02234687|Drug|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
75385672|NCT02234687|Drug|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
75385673|NCT02234687|Drug|Placebo|Placebo, one dose, one time
75385674|NCT00978419|Drug|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
75385675|NCT00978419|Drug|Placebo|Placebo administered every day for up to 28 days
75385676|NCT00957827|Drug|keflex|keflex 500 mg BID 5 days
75705596|NCT03826030|Device|Sham|sham group receives no active current stimulation except 15 seconds of current ramp up in the beginning and 15 seconds of current ramp up in the end of the 30-minute session to create a scalp perception to blind the subject.
75385677|NCT00957827|Drug|placebo|placebo BID for five days
75385678|NCT00962429|Drug|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
75385679|NCT00950183|Device|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
75385680|NCT00950183|Other|Ice|postoperative cold therapy
76032129|NCT04477135|Procedure|ultrasonography|ultrasonography
75385681|NCT00949403|Drug|Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate|injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism
75385682|NCT03767153|Device|Venus Viva|"The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.~Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits."
75385683|NCT03766373|Combination Product|Drug: OP0201 20mg|OP0201
75385684|NCT03766373|Combination Product|Drug: Placebo 0mg|Placebo
75385685|NCT02110277|Device|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
75385686|NCT03760913|Drug|OLP-1002 (Test): Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
75541968|NCT04546321|Other|serum L carnitine level measuring|The serum level of total L carnitine was measured for both HIE and TTN cases
75705597|NCT03826030|Device|Low dose tDCS|The low dose tDCS group receives direct current stimulation at 2 mA for 30 minutes per session
76032130|NCT05737537|Diagnostic Test|procalcitonin ,CRP and 1, 3- β -D- glucan in early diagnosis of invasive infections|using of blood biomarkers (CRP ,procalcitonin and 1, 3- β -D- glucan) in early differentiation between fungal and bacterial infections in pediatric cancer patients in comparison to blood culture.
76032131|NCT05737303|Drug|nab-paclitaxel combined with carboplatin|"Nab-Paclitaxel/carboplatin q3weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
76032132|NCT03066089|Drug|Fenfuro|
75385687|NCT03760913|Drug|OLP-1002 (Test): Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
75541969|NCT00236483|Drug|tramadol hydrochloride + acetaminophen|
75705598|NCT03826030|Device|High dose tDCS|The high dose tDCS group receives direct current stimulation at 4 mA for 30 minutes per session
75705599|NCT03826030|Behavioral|mCIMT|All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
75705600|NCT03808454|Drug|PRP|The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
75385688|NCT03760913|Other|Placebo: Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
75385689|NCT03760913|Other|Placebo: Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
75705601|NCT03808454|Other|Rehabilitation|strengthening ex, posture training,...
75385690|NCT00920309|Drug|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
75385691|NCT00920309|Other|Standard of Care-Placebo|
75705602|NCT03808454|Combination Product|PRP+Rehabilitation|combine PRP and Rehabilitation
75557734|NCT03270423|Device|PathMate2|To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services as well as sensor data integration implemented in a novel Smartphone App supported intervention have effects on stress, physical activity and weight outcomes. During the intensive phase of 6 months, patients of the intervention group (IG) are equipped with a smartphone and a specially designed chat App with game character, which encourages them through a virtual coach to achieve daily activity, healty lifestyle or relaxation challenges and earn virtual rewards, to increase adherance to the health information system.
75705603|NCT03784443|Drug|Iluvien 0.19 MG Drug Implant|Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
75705604|NCT03784443|Drug|Ranibizumab Injection [Lucentis]|Monthly PRN intravitreal injections
75705605|NCT03784443|Procedure|Sham Intravitreal Injection|Sham injection without penetrating needle and without drug delivery at baseline visit.
75705606|NCT03777709|Behavioral|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
76023467|NCT03536507|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
75385692|NCT00928499|Device|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
75385693|NCT02109809|Radiation|total nodal irradiation|Undergo TLI
75385694|NCT02109809|Other|laboratory biomarker analysis|Correlative studies
75385695|NCT02109809|Other|questionnaire administration|Ancillary studies
75385696|NCT02075411|Drug|bupivacaine|"Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block"
75385697|NCT02075411|Drug|bupivacaine|"Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block"
76032133|NCT04648501|Other|Dual-task training|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
76032134|NCT04647565|Other|interviews|interviews (human and social sciences)
76032135|NCT03066167|Other|Validation of different dysphagia scores|
75385698|NCT02075411|Device|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
75385699|NCT02075411|Device|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
75385700|NCT03753113|Drug|Topical Herbal Solution|Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.
75541970|NCT04546048|Behavioral|Strength Exercise Training|The 8-week exercise-training program consisted of two 30-min sessions a day for 5 days/week and conducted by elastic exercise bands in 2-3 sets, 6-10 repetitions, with 1-2 min rest between sets (M. Deltoideus and M. Quadriceps are trained as major muscle groups). The 8-repetition maximum(8RM) is used to determine training loads with the rated perceived exertion(RPE) lower than 5-7 on the Modified Borg scale(MBS). The program consisted functional exercises by half squat to squat and sit-to-stand chair exercises. Exercise sessions were supervised twice daily during the 1st week, the 2nd week training included one supervised and one unsupervised daily sessions. The remaining 6-week training program conducted at home individually after discharge. Patients instructed for the ongoing 8-week training program and a patient-specific schedule delivered to subjects. Phone calls are provided weekly and training load is assessed while generating 4th week evaluations.
75705607|NCT03768336|Other|Waitlist control|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. Waitlist control receives the adapted 3RP program (3RP-AYA) approximately 2 months after study enrollment.
76032136|NCT04599049|Other|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
76032137|NCT03065699|Device|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
76032138|NCT03065855|Procedure|Early removal group|Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.
76032139|NCT03065855|Procedure|Normal removal group|Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
76032140|NCT01678807|Biological|MK-8237 6 DU|
75385701|NCT03753113|Drug|Topical Minoxidil 5%|Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
75385702|NCT02084147|Device|positron emission tomography|Undergo PET
75385703|NCT02084147|Device|computed tomography|Undergo CT
75385704|NCT02084147|Device|magnetic resonance imaging|Undergo MRI
75385705|NCT02067611|Drug|X0002|Parallel Assignment
75385706|NCT02067611|Drug|Placebo|Parallel Assignment
75385707|NCT02075021|Drug|Lenalidomide|
75385708|NCT02075021|Drug|nab-paclitaxel|
75385709|NCT02057237|Drug|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
75868926|NCT06023732|Behavioral|Behavioral activation and emotion-focused interventions|Behavioral activation with emotion-focused interventions comprises two consecutive phases. In the first phase, treatment focus is behavioral activation in line with Brief behavioral activation treatment for depression - revised (BATD-R; 11) During the second phase, treatment focus shifts to address participants' emotions. Difficulties in understanding, tolerating, and labeling emotions is addressed by observing and describing emotions (12). Under the guidance of the therapist, participants are instructed to explore emotions normally avoided or ruminated on. This is conceptualized as a form of exposure to aversive emotions, thoughts and memories, to initiate emotional processing (13).
76032141|NCT01678807|Biological|MK-8237 12 DU|
76032142|NCT01678807|Biological|Placebo|
76032143|NCT05188313|Drug|Trastuzumab|Intravenous administration of study drug
75385710|NCT03752567|Other|Follow up|like group descriptions
75385711|NCT00378677|Drug|Cyclosporine A dry powder inhalation (Drug)|
75868927|NCT06021353|Device|UV fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
75868928|NCT06021353|Device|IR fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
76032144|NCT05188313|Drug|Pertuzumab|Intravenous administration of study drug
76032145|NCT05188313|Drug|Paclitaxel|Intravenous administration of study drug
76032146|NCT05188313|Drug|Carboplatin|Intravenous administration of study drug
76032147|NCT04540315|Behavioral|MobiMD|MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
76032148|NCT03065777|Device|ONE ENDO|single file rotary system
76032149|NCT03065777|Device|F6 SKYTaper|single file rotary system
75385712|NCT03748979|Drug|TAK-925|TAK-925
75541971|NCT04546165|Procedure|manipulation plus exercise|HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction
75868929|NCT06021353|Procedure|LASIK|Laser-assisted in situ keratomileusis (LASIK) surgery
75385713|NCT03748979|Drug|Placebo|TAK-925 Placebo
75385714|NCT00850421|Drug|Botulinum Toxin Type A|100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
75385715|NCT02017379|Drug|Erythromycin|
75385716|NCT02017379|Drug|Metoclopromide|
75868930|NCT06018337|Drug|DB-1303|IV
75868931|NCT06018337|Drug|Capecitabine|Oral
75868932|NCT06018337|Drug|Paclitaxel|IV
75868933|NCT06018337|Drug|Nab-paclitaxel|IV
75868934|NCT06011317|Drug|EDG-7500|EDG-7500 is administered orally once daily
76032150|NCT03065777|Device|ProTaper Universal|multi-file rotary system
76032151|NCT04310137|Behavioral|Therapist-Directed Re-loading|Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
76032152|NCT02514655|Device|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
76032153|NCT02514655|Other|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
76032154|NCT03066011|Drug|Isavuconazonium sulfate|Oral and Intravenous
76032155|NCT03066011|Drug|Voriconazole|Oral and Intravenous
76032156|NCT03066011|Drug|Posaconazole|Oral and intravenous
76032157|NCT03135769|Drug|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
76032158|NCT03781297|Other|Narrative Exposure Therapy|Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.
75385717|NCT04332263|Other|Neuromuscular Electrical Stimulation - NMES|NMES will be applied through an alternating biphasic current, with a stimulation frequency of 80 Hz and 1 ms pulse duration. Tetanic evoke forces (EF) at a 50% level of a supra-maximal single-pulse peak EF (i.e., 10-12% of a maximal voluntary isometric contraction) will be used. NMES protocol will be performed five times a week, lasting 20 minutes. Muscle fatigue will be evaluated every 5 min of the intervention, and will be used to determine the NMES protocol termination. A 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol will be used to terminate the fatigue protocol.
75385718|NCT01997567|Drug|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
75385719|NCT01997567|Drug|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
75385720|NCT03742973|Drug|Baricitinib|Administered orally.
75385721|NCT03742973|Drug|Placebo|Administered orally.
75541972|NCT04546165|Procedure|suboccipital inhibition plus exercise|Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region
75557735|NCT03270423|Device|PathMateS|Overweight or obese adolescents of the treatment as-usual group (CG) have monthly visits on site during the intensive phase. Counseling for physical activity, healthy eating and lifestyle as well as psychosocial wellbeing is provided by a pediatrician.
75868935|NCT06011317|Drug|Placebo|Placebo is administered orally once daily
75385722|NCT03742427|Diagnostic Test|ultrasonography|optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
76032159|NCT03781297|Other|Genealogical Services|At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
76032160|NCT05539313|Device|High-density mapping|Patients will undergo magnetic resonance imaging of both atria, and interventional high-density mapping of both atria.
76032161|NCT05728463|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
76032162|NCT03123211|Drug|Veliparib|Veliparib will be administered orally.
76032163|NCT05736991|Diagnostic Test|PET/CT-based Radiomics Signature|Radiomics Signature Based on PET-CT for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
76032164|NCT05527457|Drug|BAY2586116|160 μg BAY2586116 nasal spray application
75385723|NCT03741725|Other|Pay-it-forward|Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
75385724|NCT03741725|Other|Pay-what-you-want|Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
75385725|NCT00825227|Drug|Armodafinil 150 mg/day|"150 mg/day armodafinil~concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
75541973|NCT04546165|Procedure|exercise|Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
75541974|NCT04545970|Combination Product|Facial cleanser|Facial cleanser to be used by study participants
76032165|NCT05527457|Drug|Placebo|Placebo (saline) nasal spray application
76032166|NCT04096807|Other|Standard TEE exam including measurement of left upper pulmonary vein diameter and collapsibility, compared with PCWP measured continuously by a pulmonary arterial catheter|TEE takes part of the standard perioperative hemodynamic monitoring in cardiac surgery. Patients enrolled in the study are also monitored by a pulmonary arterial catheter
76032167|NCT05520749|Drug|Luspatercept|Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
76032168|NCT05092243|Device|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
75541975|NCT04545970|Combination Product|Facial moisturizer|Bland moisturizer to be used by study participants after serum in the evening.
76032169|NCT03609697|Behavioral|group-based lifestyle intervention|Involve education about pre-diabetes self-management, weight loss, behavioural modification skills, nutrition and physical activity.
75541976|NCT04545970|Combination Product|Sunscreen|Sunscreen to be applied after application of serum in the morning.
75705608|NCT03768336|Other|3RP-AYA|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.
76032170|NCT03609697|Behavioral|Minimal intervention (SMS intervention)|Text message related to general information about T2DM, pre-diabetes, and lifestyle modification.
75868936|NCT06008054|Drug|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
76032171|NCT03073525|Biological|Vigil|The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
76032172|NCT03073525|Drug|Atezolizumab|"Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters."
76032173|NCT05728307|Device|neoGuard vital signs monitor|"The neoGuard device is a 4-in-1 wearable vital signs monitor developed by Neopenda, PBC (Chicago, Illinois). The system is designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2). It contains two non-invasive sensors: an optical reflectance pulse oximeter and a digital temperature sensor. These sensors measure signals from the surface of the patient's skin, and algorithms within the device calculate the pulse rate, respiratory rate, SpO2 and temperature.~The device is made of medical grade polyetherimide plastic and can be worn on the forehead through an adjustable band. The PR, RR, temperature and SpO2 data are collected, recorded and transmitted via Bluetooth Low Energy (BLE) to a tablet which can be placed within a range of 20-30 meter distance. The neoGuard technology has received CE mark certification and is also registered with the Kenya Pharmacy and Poisons Board (KPPB)."
76032174|NCT02563015|Dietary Supplement|cholecalciferol|liquid drops
75541977|NCT04545931|Device|Posterior tibial nerve stimulation|34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
75541978|NCT04545931|Drug|Desmopressin Acetate|0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
75541979|NCT00236522|Drug|levofloxacin|
75541980|NCT00261729|Drug|Paroxetine|paroxetine 20 mg
75541981|NCT00261729|Drug|Prazosin|Prazosin
75541982|NCT00261729|Drug|placebo|placebo capsules
75541983|NCT04541836|Diagnostic Test|18F-PMPBB3|single intravenous injection 5mCi 18F-PMPBB3 per scan
75541984|NCT04541758|Procedure|surgical treatment|surgical treatment and Conservative treatment
75541985|NCT04541758|Procedure|Conservative treatment|Conservative treatment
75705609|NCT03742141|Device|Intraoperative Video Laryngoscopy|The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.
75705610|NCT03742141|Drug|Glycopyrrolate|0.004mg/kg as per routine prior to intubation
75868937|NCT06008054|Drug|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
75868938|NCT06006169|Drug|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
75868939|NCT06006169|Drug|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
75868940|NCT06005857|Other|Standard hand therapy + home digital application-based exercises|Standard post-operative hand rehabilitation and home digital application-based exercises
75868941|NCT06005857|Other|standard hand therapy + home paper-based exercises|Standard post-operative hand rehabilitation and home paper-based exercises
76023468|NCT03220685|Biological|Stool analysis|Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
76023469|NCT04765787|Drug|Combination of Paracetamol 650mg + Orphenadrine 50mg|In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
75385726|NCT00825227|Drug|Placebo,|"placebo~concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
75385727|NCT01978535|Drug|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
75385728|NCT01978535|Drug|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
75541986|NCT04541641|Procedure|New Reverse Drilling technique|a new technique of dental implant drilling that promote osseodensification by rotating the drills anti-clockwise rather than clockwise to promote bone condensation rather than bone cutting
75705611|NCT03687060|Behavioral|Knowledge assessment|Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.
75868942|NCT05999565|Other|Motor Imagery Exercises|"Lateralization Training: Individuals with cervical discogenic pain will receive lateralization training using a mobile application called Recognize Neck from the Neuro Orthopaedic Institute in Adelaide, Australia.~Kinesthetic Imagery: During this training, individuals will be asked to actively perform exercises and feel the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to imagine the positions of their bodies, the surface they are on, and the desired postures.~Visual Imagery: Individuals will be asked to actively perform exercises and visualize the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to mentally visualize their body positions, the surface they are on, and the exercises.~Mirror-Image Active Exercise: Between weeks 6 and 8 of motor imagery training, the active exercises in front of a mirror."
75868943|NCT05999565|Other|Motor Control Exercises|"Stretching Exercises: Stretching exercises will be applied to the cervical muscles, pectoral muscles, back, and shoulder muscles. Individuals will be asked to perform flexion, extension, lateral flexion, and rotational normal joint movements in the cervical region, and hold the end position for a few seconds. All stretching exercises will be performed for 15 repetitions.~Active Exercises: To strengthen the cervical muscle groups, individuals will be taught how to use a mild to moderate resistance theraband for cervical flexion, extension, and lateral flexion, without compromising the chin tuck movement. Each movement will be performed for 10 repetitions, with 5-second rest intervals between exercises.~Endurance Exercises: Before starting the endurance exercises, individuals will be taught the contraction of deep cervical flexors to gain automatic postural stabilization, and they will be instructed to maintain this movement in every exercise and activity."
76032175|NCT02563015|Dietary Supplement|Reference 400|liquid drops
76032176|NCT02382445|Device|Anesthesia depth monitor|
76032177|NCT02382445|Device|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
76032178|NCT02382445|Drug|propofol and sevoflurane|
76032179|NCT05094973|Device|Carriere Motion Appliance®|To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
76032180|NCT02875535|Behavioral|RLAS|"The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide)."
75385729|NCT00808769|Drug|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
75385730|NCT00808769|Drug|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
75385731|NCT00378131|Drug|RC-1291|
75385732|NCT00378131|Drug|placebo|
75385733|NCT01974635|Device|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
75385734|NCT00379067|Drug|Tamsulosin OCAS|Adrenoceptor antagonist
75385735|NCT00379067|Drug|Placebo|placebo
75385736|NCT01937507|Drug|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
75385737|NCT00379223|Procedure|vitrectomy with radial optic neurotomy|
75385738|NCT00378287|Drug|rabeprazole sodium|
75385739|NCT01938833|Drug|Romidepsin|
75385740|NCT01938833|Drug|Abraxane|
75385741|NCT01893359|Drug|riboflavin ophthalmic solution, 0% dextran|
75385742|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
75385743|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
75868944|NCT05993611|Procedure|Biopsy|Undergo biopsy
75385744|NCT01893359|Procedure|Laser-assisted in situ keratomileusis|
75385745|NCT05313503|Other|ketogenic diet|We propose a type of KD named MAD (Modified Atkins Diet) characterized by the following percentages of macronutrients: 65% fats, 27% proteins and 8% carbohydrates.
75385746|NCT00795665|Drug|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
75385747|NCT00795665|Drug|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
75385748|NCT00791843|Drug|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
75385749|NCT01836809|Drug|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
75385750|NCT01836809|Drug|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
75541987|NCT04541641|Procedure|osteotome technique|a technique for dental implant placement by using the osteotome to condense the bone and create an osteotome rather than cutting the bone
75541988|NCT00236561|Drug|topiramate, propranolol|
75868945|NCT05993611|Procedure|Biospecimen Collection|Undergo blood sample collection
75868946|NCT05993611|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD6-CAR Tregs IV
75868947|NCT05993611|Procedure|Computed Tomography|Undergo CT
75868948|NCT05993611|Procedure|Echocardiography|Undergo ECHO
75868949|NCT05993611|Other|Electronic Health Record Review|Ancillary studies
75868950|NCT05993611|Procedure|Leukapheresis|Undergo leukapheresis
75385751|NCT00780455|Drug|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
75541989|NCT02215330|Drug|Eplerenone|
75541990|NCT02215330|Drug|Maltodextrin|
75541991|NCT00261768|Behavioral|Digital noise reduction|
75541992|NCT02214667|Behavioral|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
75541993|NCT02214667|Behavioral|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
75541994|NCT02214667|Behavioral|Jail and community-based behavioral health services|Existing behavioral health service programs
75868951|NCT05993611|Procedure|Lumbar Puncture|Undergo lumbar puncture
75868952|NCT05993611|Procedure|Magnetic Resonance Imaging|Undergo MRI/CT
75868953|NCT05993611|Other|Quality-of-Life Assessment|Ancillary studies
75868954|NCT05993611|Biological|Tafasitamab|Given IV
75868955|NCT05993611|Procedure|X-Ray Imaging|Undergo x-ray imaging
75868956|NCT05993104|Diagnostic Test|Intrachamber ultrasound|Ultrasound left atrial geometry collecting using AcQMap.
75868957|NCT05993104|Other|Statistical shape analysis|Statistical shape analysis tools used to investigate left atrial geometry
75868958|NCT05991700|Drug|Freeze-Dried California Table Grape|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
75868959|NCT05991700|Drug|Placebo|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
75385752|NCT00780455|Drug|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
75385753|NCT00755261|Drug|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
76023116|NCT05099627|Other|"The questionnaire Cervical myelopathy treatment outcome questionnaire"|"Information gathered through clinical examination and questionnaires performed retrospectively over the phone, pre-operation and at 3- and 6-months post-operation. The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up"
75385754|NCT00755261|Drug|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
75541995|NCT02278510|Drug|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
75541996|NCT02278510|Drug|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
75385755|NCT00748085|Device|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
75385756|NCT03725033|Drug|Subetta|Oral administration.
75385757|NCT03725033|Drug|Placebo|Oral administration.
75385758|NCT03724877|Drug|Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)|(LABA-LAMA-ICS)
75385759|NCT03724877|Drug|Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)|(LABA-LAMA)
75385760|NCT03724253|Drug|[68Ga]-NeoBOMB1|[68Ga]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
76032181|NCT05736757|Drug|Tissue Plasminogen Activator|Injection of 50 ug tissue plasminogen activator into the suprachoroidal cavity or subretinal space to assist in bleeding liquefaction
76032182|NCT04483817|Device|Transcutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
76032183|NCT04483817|Device|Percutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
76032184|NCT05733481|Device|CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries|The CapBuster System is a medical device intended to facilitate the intraluminal placement of conventional guidewires beyond chronic total occlusions prior to the utilization of interventional devices. The device system, manufactured by Praxis Medical, comprises the CapBuster support catheter and CapBuster penetrating wire which are mated together with a screw thread.
76032187|NCT05732233|Device|Ultivision AI|Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas) in adult patients undergoing colorectal cancer screening and surveillance examinations.
76032188|NCT05092087|Behavioral|nutrition counseling|nutrition counseling
75705612|NCT03687060|Behavioral|Education Intervention|"Education intervention will be adapted from the the findings of these interviews and focus groups.~Clinics will be randomized to receive the education intervention and feedback implementation strategies at different times.~Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.~Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV."
75705613|NCT03687060|Behavioral|Provider Feedback|Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.
75385761|NCT05313113|Behavioral|Experimental|Pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. The training content included topics such as setting a comfortable environment and suitable position for the pregnant, when the fetus is active and asleep during the day, how to count and how to evaluate the movements. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
76023117|NCT05099627|Other|"The retrospective questionnaire CSM early diagnosis questionnaire"|To identify early clinical predictors of cervical myelopathy diagnosis based on individual patient-reported symptoms by using a questionnaire and patient characteristics as well as co-morbities, as well as clinical examination findings provided by community musculoskeletal teams.
75385762|NCT01809899|Behavioral|Enhanced consent procedure|Enhanced consent entails a more detailed consent procedure
75385763|NCT01809899|Behavioral|Consent as Usual|Routine informed consent procedures
75385764|NCT00746603|Drug|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
75385765|NCT05312957|Other|erector spinae plane block|Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
76023118|NCT05099627|Other|JOACMEQ questionnaire and mJOA|Used for prospective cohort via telephone at 3, 6 and 12-months post-operatively to assess treatment outcomes.
76023119|NCT02399683|Biological|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
76023120|NCT02407873|Other|Non|
76023121|NCT02399605|Other|Stimulation|Subcutaneous abdominal electrical stimulation
76023122|NCT05076383|Other|Study Group (Motor relearning program)|Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.
75385766|NCT04713527|Diagnostic Test|Cultivation and PCR within 24 hours|During operation for appendicitis peritoneal fluid will be extracted. This is sent to cultivation and PCR analysis to determine if there is bacteria within the peritoneal cavity.
75385767|NCT04713527|Drug|Enteral antibiotics|Patients with complicated appendicitis will receive enteral antibiotics instead of intravenous
76023123|NCT05076383|Other|Control Group (Conventional physical therapy program)|The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.
75385768|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
75385769|NCT00716807|Drug|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
75385770|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
75385771|NCT00716807|Drug|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
75385772|NCT03461705|Device|Volcano Verrata Pressure Wire|"Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature."
76023124|NCT02408029|Other|Observational study - no intervention|
75385773|NCT03461705|Device|St. Jude Medical (SJM) Aeris Pressure Wire System|The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
75385774|NCT03426137|Drug|Oxycodone|5mg Oxycodone in oral solution given every 3 hours
75385775|NCT03426137|Drug|Ketorolac|toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
75385776|NCT03426137|Other|Placebo|Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
76032189|NCT04413643|Device|Noninvasive Ventilation|The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 >45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
76032190|NCT05094583|Behavioral|Use of SmokeFree app|Intervention Arm
75385777|NCT04706351|Other|IdFAI questionnaire|The Identification of Functional Ankle Instability (IdFAI) is a newly published questionnaire that was specifically designed to detect whether individuals meet a minimum criteria necessary for inclusion in an FAI population. The IdFAI is intended to give both researchers and clinicians a simple and effective tool to determine an individual's ankle stability status
75385778|NCT05283863|Device|High-frequency stimulation|Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
76032191|NCT05091775|Drug|Asacol is used to treat and prevent mild to moderate acute fissure disease|Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
75385779|NCT05283863|Device|Sham Stimulation|Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
75385780|NCT05283863|Device|Conventional spinal cord stimulation|Patients will receive conventional spinal cord stimulation (aka 60Hz, aka tonic stimulation, aka paresthesia-based stimulation) for 2 weeks
75385781|NCT01760993|Drug|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
75385782|NCT00669461|Drug|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
75385783|NCT00673595|Drug|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
75385784|NCT00673595|Drug|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
76032192|NCT05091541|Drug|Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection|CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
75557736|NCT00438113|Drug|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
75541997|NCT02278510|Device|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
75541998|NCT04546243|Procedure|resection group|patients received VATS
75705614|NCT03663777|Other|Isometric handgrip training|Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
75705615|NCT03663777|Other|Control Group|Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
75705616|NCT03583073|Behavioral|Enhanced Referral/Linkage to Care|"The JJ worker reviews with the family psychoeducation material about the role of mental health care in emotional/behavioral problems. The JJ intake worker will contact the CSC program directly with the family for a warm hand-off. The CSC worker will speak with the parent and arrange for an intake evaluation. For families already receiving treatment, the CSC referral will be for consultation. Via phone, the CSC clinician will use a motivational interviewing style to encourage families to attend the appointment. Three and seven days after referral, the JJ worker will text the caregiver to see if the CSC appointment was kept. If not, the JJ worker will text the parent the CSC phone number and also ask permission to contact the CSC to assist the family in setting up another appointment."
75385785|NCT00670631|Combination Product|tandem autologous transplantation|"DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.~Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.~Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.~Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 & 15-18 every cycle.~Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle."
75385786|NCT03248141|Drug|Hemophilia B standard half-life|Benefix
76032193|NCT05376085|Drug|DA-5215 Tab|"single oral administration of 1 tablet of DA-5215 Tab with 150mL water"
75385787|NCT03248141|Drug|Hemophilia B extended half-life|Alprolix
75385788|NCT03248141|Drug|Hemophilia A standard half-life|Xyntha and other standard half-life agents
75385789|NCT03248141|Drug|Hemophilia A extended half-life|Eloctate and Adynovate
75385790|NCT00378365|Procedure|Arsenic trioxide|Arsenic trioxide
76032194|NCT05376085|Drug|DA-5215-R Tab|"single oral administration of 1 tablet of DA-5215-R Tab with 150mL water"
75385791|NCT00378365|Procedure|ATRA|ATRA
75385792|NCT05313425|Other|Ectohylo (R) eye drops|using Ectohylo eye drops post operative after PRK in the right eyes of the patients
76032195|NCT04821869|Drug|ProAir Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
76032196|NCT04821869|Device|Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
75385793|NCT01754987|Drug|Ascorbic Acid + Sorafenib|
75385794|NCT01754987|Drug|Sorafenib|
75385795|NCT01732211|Biological|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
75385796|NCT01732211|Other|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
75385797|NCT05600153|Procedure|implant exchange operation|To perform implant exchange via axillary incision.
75385798|NCT00652457|Drug|Memantine|10 mg BID x 3 months
75541999|NCT04546243|Radiation|radiotherapy group|patients received radiotherapy
75542000|NCT02278627|Other|manual lymphatic drainage|
75385799|NCT00645359|Procedure|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
75385800|NCT01681589|Device|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
75385801|NCT01681589|Device|Control Group|This group will receive Sham TDCS
75385802|NCT01681589|Other|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
75385803|NCT00625703|Drug|Linezolid|"Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
75542001|NCT04545892|Drug|Capsaicin|One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
75705617|NCT03583073|Behavioral|Standard Care|Referral to the Coordinated Specialty Care (CSC) clinic
75705618|NCT03531814|Behavioral|Medication Event Monitoring System (MEMS)|A computerized method of tracking the dates and times of a pill bottle being opened.
75705619|NCT03512223|Drug|Dexamethasone|Intravenous and Perineural Dexamethasone for Brachial Plexus Block
75705620|NCT03502668|Drug|ASTX727 LD|oral decitabine (LD) + cedazuridine (E7727)
75705621|NCT03502668|Drug|ASTX727 SD|oral decitabine (SD) + cedazuridine (E7727)
75705622|NCT03481075|Other|Biomechanical computer program|Fusion assisting software for image-guided intervention
75705623|NCT03474458|Drug|Doxycycline|Doxycycline
75705624|NCT03474458|Drug|Standard of care therapy|Standard of care therapy
75705625|NCT03452319|Other|Pretraining|Increased physical activity, and daily strength training and breathing exercises.
75705626|NCT03452319|Other|Usual care|Preoperative information
75705627|NCT03386500|Drug|BMX-001|BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
75705628|NCT03374332|Drug|Gemtuzumab Ozogamicin (GO)|Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
75705629|NCT03374332|Other|Donor Leukocytes|The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.
75705630|NCT03369405|Other|NO intervention, patient records review only|There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
75705631|NCT03329976|Other|measurement of visual acuity|complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
75705632|NCT03301363|Device|CRT|Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System
75705633|NCT03226418|Drug|Cytarabine|Given IV
75705634|NCT03226418|Drug|Decitabine|Given IV
75385804|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
75385805|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
75385806|NCT00616577|Drug|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
75385807|NCT00616343|Drug|Zonisamide|100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
75385808|NCT05599997|Drug|Pecavaptan (BAY1753011)|30 mg, immediate release tablet, single dose, oral
75385809|NCT05599997|Drug|Pecavaptan (BAY1753011)|15 mg, immediate release tablet, single dose, oral
75385810|NCT05599919|Drug|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
75385811|NCT05599607|Dietary Supplement|Probiotic mixture|Mixture of strains of lactobacillus and bifidobacteria
75385812|NCT05599607|Dietary Supplement|Placebo|Maltodextrin
75385813|NCT01645709|Drug|Verapamil|
75385814|NCT01645709|Drug|Placebo|
75385815|NCT05599529|Other|Differential attainment|Differential attainment related to covid, ethnicity and international graduate status
75385816|NCT05270993|Behavioral|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
75557737|NCT03270228|Other|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
75705635|NCT03226418|Drug|Idarubicin|Given IV
75557738|NCT00474474|Procedure|Virtual patient is NOT introduced|
75705636|NCT03226418|Other|Laboratory Biomarker Analysis|Correlative studies
75705637|NCT03226418|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
75705638|NCT03226418|Other|Quality-of-Life Assessment|Ancillary studies
75705639|NCT03226418|Other|Questionnaire Administration|Ancillary studies
75705640|NCT03226418|Drug|Azacitidine|Given by infusion
75557739|NCT00438152|Drug|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
75705641|NCT03226418|Drug|Venetoclax|oral tablet
76032197|NCT05091463|Device|Biostim-5/Neostim transcutaneous spinal stimulator|Transcutaneous spinal stimulation (scTS): The 5-channel stimulator capable of generating pain-free biphasic rectangular waveform of 0.3 to 1.0 ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels. Transcutaneous stimulation will be delivered in combination with activity based locomotor training in 5-10 minute bouts of stimulation at sub-motor threshold during daily sessions (5x/week) lasting for 90 minutes for a total of 60 sessions of therapy. The sessions will consist of 55-60 minutes on the treadmill for facilitated standing/stepping followed by 30 minutes of activities off the treadmill in sitting, standing, or stepping.
75557740|NCT00438152|Drug|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
76032198|NCT05091385|Biological|Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019|Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.
76032199|NCT02631551|Drug|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
76032200|NCT02631551|Drug|Olopatadine HCl NS|2 sprays in each nostril twice daily for 14 days
76032201|NCT02631551|Drug|Mometasone furoate NS|2 sprays in each nostril twice daily for 14 days
75557741|NCT03279926|Behavioral|PLAY|Activity trackers + curriculum information
75557742|NCT03279926|Behavioral|PLAY Parents|Enhanced parental engagement
75705642|NCT03226418|Drug|glasdegib|oral tablet
75705643|NCT03169010|Other|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
75705644|NCT03169010|Genetic|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
75705645|NCT03165136|Drug|Hydroxychloroquine|Hydroxychloroquine : 200 mg twice a day
75705646|NCT03165136|Drug|Placebo|placebo of hydroxychloroquine
75705647|NCT03141437|Other|Best Practice|Receive standard of care
75705648|NCT03141437|Other|Educational Intervention|Receive educational materials
75705649|NCT03141437|Other|Internet-Based Intervention|Use decision-making website
75705650|NCT03141437|Other|Questionnaire Administration|Ancillary studies
75705651|NCT03115086|Drug|Cholbam|Cholbam prescribed according to the approved label.
75705652|NCT03106701|Procedure|Ablation|Epicardial Radiofrequency ablation
75705653|NCT03089268|Procedure|Colonoscopy|A colonoscopy will be performed to all individuals.
75705654|NCT03089268|Procedure|Polypectomy or biopsy|All lesions will be removed or biopsied during the procedure
75705655|NCT03089268|Genetic|Molecular analysis|"Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion"
75705656|NCT03073785|Drug|Capecitabine|Given PO
75705657|NCT03073785|Drug|Fluorouracil|Given IV
75705658|NCT03073785|Other|Laboratory Biomarker Analysis|Correlative studies
75705659|NCT03073785|Other|Pharmacological Study|Correlative studies
75705660|NCT03073785|Radiation|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
75705661|NCT03073785|Drug|Zoledronic Acid|Given IV
76032202|NCT02631551|Drug|GSP 301 Placebo NS|2 sprays in each nostril twice daily for 14 days
75557743|NCT03279926|Behavioral|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
75868960|NCT05989581|Drug|BP <130/80mmHg|The choice of anti-HTN will be based on the patient and provider's experience and preference. First line anti-HTN recommended in pregnancy- labetalol or nifedipine- will be administered to patients. At least weekly, a study team member will review the participants' BPs and, if randomized to intervention and a higher dose is needed to maintain BPs <130/80 mmHg, the study team member will communicate with the clinical team, led by a University of Alabama Maternal Fetal Medicine Attending, in order to ensure coordination between the research and clinical care teams. Labetalol will be initiated at 200 mg twice daily and escalated in 200mg /dose daily until BP<130/80mmHg to a maximum dose of 2400mg/day. Procardia will be initiated at 30mg XL once daily and uptitrated in 30mg increments until a maximum dose of 120mg daily. Postpartum, titration will occur in similar fashion. The patient will be transitioned to her primary care provider for BP management after the 6-week postpartum visit.
76032203|NCT05094193|Procedure|Trocar-site infiltration|20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 6 mm trocar site)
75868961|NCT05980949|Drug|KarXT|KarXT 20/2 mg TID (total daily dose [TDD] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
76032204|NCT05094193|Procedure|TAP block|bilateral ultrasound-guided TAP block with 20 mL of ropivacaine 0.375% in each side
76032205|NCT05094193|Procedure|Trocar site infiltration placebo|20 mL of normal saline
76032206|NCT05094193|Procedure|TAP block placebo|bilateral ultrasound-guided TAP block with 20 mL of normal saline in each side
76032207|NCT03037255|Other|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
76032208|NCT05093725|Device|flow cytomery|take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth
75868962|NCT05978180|Device|Medical Device : HO-1|The injection will be performed at Day 1.
75868963|NCT05978180|Device|Medical Device : HS-3|The three injections will be performed at Days 1, 8 and 15.
75868964|NCT05978180|Device|Medical Device : SINOVIAL® ONE|The injection will be performed at Day 1.
75385817|NCT05270993|Behavioral|I-CREST group|A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
75385818|NCT05267483|Other|No intervention|No intervention
75385819|NCT00608465|Drug|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
75385820|NCT00608465|Drug|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
75385821|NCT00608777|Drug|Calcipotriene/betamethasone|One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
75385822|NCT00379301|Procedure|Radiofrequency ablation|Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
75385823|NCT00379379|Device|electroacupuncture|
75868965|NCT05977270|Device|Lifebloom One|LBO is made of Oxilio, an alternative to wheelchair placement for everyday use.
75868966|NCT05972889|Device|NexWave|Device subjects receive designated treatment mode twice daily for up to 8 weeks.
75868967|NCT05972889|Device|Sham|Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).
75385824|NCT00379457|Biological|dactinomycin|
75385825|NCT00379457|Drug|carboplatin|
75385826|NCT00379457|Drug|cyclophosphamide|
75385827|NCT00379457|Drug|doxorubicin hydrochloride|
75385828|NCT00379457|Drug|etoposide|
75385829|NCT00379457|Drug|ifosfamide|
75385830|NCT00379457|Drug|topotecan hydrochloride|
75385831|NCT00379457|Drug|vincristine sulfate|
75385832|NCT00379457|Drug|vinorelbine tartrate|
75385833|NCT00379457|Procedure|conventional surgery|
75705662|NCT03066648|Drug|Decitabine|Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
75705663|NCT03066648|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
75868968|NCT05971160|Behavioral|Financial education videos|Brief videos providing structured information on managing one's money
75868969|NCT05971160|Other|Microgrant|$150 stipend
75868970|NCT05971160|Behavioral|Peer mentoring|One-on-one structured mentoring sessions with a trained peer
75868971|NCT05969860|Procedure|Clinical Encounter|Receive treatment in clinic
75385834|NCT00379457|Radiation|radiation therapy|
75557744|NCT00474513|Drug|GSK239512|
75557745|NCT00438230|Drug|Warfarin|
75705664|NCT03066648|Drug|MBG453|MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
75705665|NCT03066648|Drug|Azacitidine|Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation
75868972|NCT05969860|Other|Home Health Encounter|Receive at-home treatment
75868973|NCT05969860|Other|Quality-of-Life Assessment|Ancillary studies
75868974|NCT05969860|Other|Questionnaire Administration|Ancillary studies
76032209|NCT05721911|Genetic|whole genome sequencing|Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
75385835|NCT01643525|Device|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
75385836|NCT01629329|Drug|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
75385837|NCT01629329|Drug|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
75705666|NCT02968849|Biological|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose > 10^6 cell culture infectious dose 50% (CCIDv50) and < 1 × 10^8 CCIDv50 (nominal dose of 10^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM
75705667|NCT02968849|Biological|Bivalent Subtype C gp120/MF59|Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM
75705668|NCT02968849|Biological|Placebo|Sodium Chloride for injection, 0.9% delivered IM
75705669|NCT02877394|Device|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
75705670|NCT02877394|Device|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
75868975|NCT05968859|Behavioral|Aerobic Training|Aerobic training will be conducted at 30 minutes 3 times a week using brisk walking with target heart rates goals based on percentage of peak HR reserve (HRR= peak-rest HR) during baseline exercise right heart catheterization (RHC). The target HR will progress over the study period from 50% to 70% of peak HR reserve added to resting HR using the standard Karvonen formula (Goal HR = rest HR + target % of HRR). HR will be monitored using Fitbits to guide training intensity with raw data analyzed using the Fitabase platform to monitor compliance
76032210|NCT04165811|Other|Exercise treatment|A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
76032211|NCT04165811|Other|Counselling|Only physical activity counseling will be given to the subjects in this group.
76032212|NCT05091151|Drug|Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg|Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
76032213|NCT04752917|Device|Noise Cancelling headphones|Use of headphones playing patients choice of music
75385838|NCT01606709|Drug|GnRH agonist|GnRH agonist 1mg one dose
75385839|NCT01606709|Drug|hCG|5,000 IU one dose
75385840|NCT00423059|Drug|bevacizumab|
75385841|NCT00585611|Drug|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
75385842|NCT00585611|Other|placebo|placebo
75385843|NCT00379535|Drug|potassium iodide|per os
75385844|NCT00379535|Drug|placebo|per os
75385845|NCT05596253|Procedure|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
75385846|NCT01557881|Device|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center [SCC] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
75385847|NCT00379613|Drug|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
75705671|NCT02796313|Behavioral|DASH Groceries + Weekly Sessions|Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.
76032214|NCT05377021|Behavioral|Lifestyle change|"In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention."
76032215|NCT05093257|Diagnostic Test|Laboratory investigations for control|"Complete blood picture .~Erythrocyte sedimentation rate(ESR).~Liver function tests .~Kidney function tests.~CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry"
75705672|NCT02796313|Behavioral|Groceries + Brochure|Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $35 grocery order for 8 weeks.
75868976|NCT05968859|Behavioral|Leg Training|Leg training will be performed using assigned ankle weights to perform knee extension while seated. Initial weight assignment will be guided by a protocol driven in-person exercise tolerance test using varying weights to identify the optimal initial and target training weight for each patient based on the 10 repetition maximum weight identified during this test. Leg training weight will begin at 40% of the baseline 10-repetition maximum weight for weeks 1-4 during which time patients will be required to complete 3 sets of 10 repetitions (30 repetitions total) on 3 days per week. For weeks 4-8, 55% of the initial 10-repetition maximum weight will be used for 4 sets of 10 repetitions (40 repetitions total). For weeks 8-12, 70% of the initial 10-repetition maximum weight will be used for 5 sets of 10 repetitions (50 repetitions total).
75385848|NCT00379613|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
76032216|NCT05093257|Diagnostic Test|Laboratory investigations for patients|"Complete blood picture .~Erythrocyte sedimentation rate(ESR).~Liver function tests .~Kidney function tests.~Anti-nuclear antibodies test by immunoflourescence for ITP patients.~Bone marrow aspiration (for diagnosis of ITP).~CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry."
75385849|NCT00379691|Drug|phenylephrine|
75385850|NCT01685333|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
75385851|NCT01648907|Other|Imaging exams|"Radiological examinations:~Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front~MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.~Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.~Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.~Biological tests :~Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.~Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.~Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
76032217|NCT05093179|Procedure|Deep tissue massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
75385852|NCT01556009|Drug|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
75385853|NCT01556009|Drug|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
75385854|NCT04331951|Diagnostic Test|Targeted biopsy within Sydney protocol|Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
75705673|NCT02795104|Behavioral|Educational Intervention via brochure|"Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures"
76032218|NCT05093179|Procedure|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
76032219|NCT04626167|Procedure|Concomitant Renal and Urinary Bladder Allograft Transplantation|This is a single-center, prospective, single-group unblinded phase I study that will enroll subjects with chronic kidney disease secondary to bladder dysfunction or bladder absence that is refractory to medical treatment and requires surgical intervention to prevent long-term sequelae. Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or contruction.
76032220|NCT04538989|Drug|RZ358 Sequential Group Cohort 1|IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
76032221|NCT04538989|Drug|RZ358 Sequential Group Cohort 2|IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
76032222|NCT04538989|Drug|RZ358 Sequential Group Cohort 3|IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
75705674|NCT02795104|Behavioral|Educational Intervention via DVD|Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
75705675|NCT02795104|Behavioral|Educational Intervention-DVD & Telephone Based Navigation|Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
75868977|NCT05968599|Drug|Enzalutamide|As provided in real-world setting
75385855|NCT01521143|Biological|Cvac|Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.
75705676|NCT02766465|Drug|Busulfan|"A:~Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics."
75868978|NCT05968599|Drug|Abiraterone acetate|As provided in real-world setting
76032223|NCT04538989|Drug|RZ358 Sequential Group Cohort 4|IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
76032224|NCT05704907|Other|gallbladder ultrasound|gallbladder ultrasound
75385856|NCT01521143|Biological|Placebo|"Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.~Placebo consisted of the Cvac formulation buffer (5% HSA, 10% DMSO) with 0.9% simethicone provided in 1 mL vials that had been cryopreserved and stored at the manufacturing facility."
75385857|NCT05529953|Dietary Supplement|Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)|Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects
75385858|NCT05529953|Dietary Supplement|Control commercial olive oil|Postprandial study of Oleanolic acid bioavailability in healthy subjects
76032225|NCT05093023|Genetic|Real-Time PCR|Genomic DNA was extracted from 2 ml of venous blood. ABCB1 1236 G>A and 3435 G>A were genotyped using predesigned TaqMan SNP genotyping assays on a stepOne PCR instrument in accordance with the manufacturer's protocol.
75385859|NCT00546455|Drug|Fenretinide|200 mg/day
75705677|NCT02766465|Drug|Fludarabine|"A:~Fludarabine dose will be 35 mg/m^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m^2).~C:~Fludarabine 30mg/m2 IV dose will be given on Days -8, -7, -6, -5, -4"
76032226|NCT04413175|Other|music therapy|"Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application."
75385860|NCT00546455|Drug|Placebo|2 capsules/day
75385861|NCT01525745|Radiation|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
75385862|NCT01525745|Radiation|External Beam Radiation Therapy|10 consecutive days of standard radiation
75385863|NCT05231057|Other|Pilates exercises|Mat, Pilates band or elastic bands, and Pilate's ball
75385864|NCT05231057|Other|Conventional physical therapy program|pain relief, increasing flexibility, and mobility, improving muscle strength
75385865|NCT00000737|Drug|Dronabinol|
75385866|NCT00000737|Drug|Megestrol acetate|
75385867|NCT00533351|Drug|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
75385868|NCT00533351|Drug|placebo|placebo 50 mg capsules three-times daily for 2 weeks
75557746|NCT00438269|Drug|Site-specific empiric regimens included: Meropenem|
75557747|NCT00438269|Drug|Piperacillin/tazobactam|
75385869|NCT00528437|Drug|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
75385870|NCT05480735|Behavioral|Prehabilitation|Multimodal prehabilitation program
75385871|NCT00000743|Drug|Alvircept sudotox|
75385872|NCT00000743|Drug|Zidovudine|
75385873|NCT00506909|Drug|Oxytocin|20 IU BID or 40 IU BID
75385874|NCT00506909|Drug|Placebo|20 IU BID or 40 IU BID
75385875|NCT00500045|Drug|nicotinic acid|niacin 1500 mg po qd
75385876|NCT00000749|Biological|rgp120/HIV-1 SF-2|
75385877|NCT05404685|Device|Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 7 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
75385878|NCT05404685|Device|Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 12 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
75385879|NCT05204225|Other|Tablet Application|Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions. The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation. Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks. Also, ReHand app includes a prescription and monitoring web-based system for professionals. Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.
76032227|NCT05092867|Other|Po Tra tool|Healthcare workers filled the 2 VAS of the tool but it did not impact or change the care of the patient. (observational)
75385880|NCT05204225|Other|Conventional Treatment|Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions. This intervention is the conventional approach usually delivered in their respective centres. Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
75385881|NCT00000767|Biological|TBC-3B Vaccine|
75385882|NCT00000767|Biological|Smallpox Vaccine|
75385883|NCT05383547|Drug|Bortezomib|Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
75385884|NCT00456989|Drug|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
75385885|NCT00456989|Drug|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
75385886|NCT00000773|Drug|Atovaquone|
75385887|NCT00428207|Drug|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
75557748|NCT00438269|Drug|Ciprofloxacin and cefazolin +/- metronidazole|
76032228|NCT05421689|Biological|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|The study will treat 62 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
76032229|NCT05421689|Other|Placebo|two doses of placebo will be administered and spaced 4-6 weeks apart.
76032230|NCT05411315|Other|Restricted-use of arterial catheter|The investigator will restrict the use of arterial catheters unless exclusion criteria is met.
75557749|NCT00474552|Drug|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
75385888|NCT00428207|Drug|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
75385889|NCT00000791|Drug|Glycovir|
75385890|NCT00000791|Drug|Zidovudine|
75385891|NCT00379847|Drug|conivaptan|IV
75385892|NCT05252741|Other|serum samples and punch skin biopsies|we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
75385893|NCT00374543|Drug|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
75385894|NCT00374543|Drug|Placebo|Placebo administered daily for 8 weeks
75385895|NCT00000803|Drug|Delavirdine mesylate|
75385896|NCT00000803|Drug|Zidovudine|
75385897|NCT00000803|Drug|Didanosine|
75385898|NCT00314093|Drug|RFT5pdgA|
75385899|NCT00299195|Drug|sulindac|Sulindac 150 mg po bid x 24 weeks
75385900|NCT00299195|Drug|Placebo|Placebo bid x 24 weeks
75385901|NCT01351415|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
75385902|NCT01351415|Drug|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m^2) on Day 1 every 21 days.
75385903|NCT01351415|Drug|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
75385904|NCT01351415|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 IV over 10 minutes on Day 1 every 21 days.
75385905|NCT00281879|Biological|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
75705678|NCT02766465|Drug|r-ATG|"A:~r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg)."
75385906|NCT00281879|Biological|filgrastim|"Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion."
75385907|NCT00281879|Drug|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
75385908|NCT00281879|Drug|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
75385909|NCT00281879|Drug|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
75385910|NCT00281879|Drug|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
75385911|NCT00281879|Drug|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
75705679|NCT02766465|Procedure|Hematopoietic Cell Transplant|"A,B,C:~Day 0 is the day of transplantation."
75385912|NCT00281879|Drug|etoposide|"Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.~Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload."
75557750|NCT00474591|Drug|Fondaparinux|
75557751|NCT03279848|Other||Stroke rehabilitation
75557752|NCT03279809|Drug|Aspirin|Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
75557753|NCT03279809|Drug|Placebo|Case with placebo medication for 6 months after stenting
75705680|NCT02766465|Drug|Tacrolimus|"A:~Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.~C:~Tacrolimus at therapeutic doses through Day 180, then taper per institutional guidelines"
75385913|NCT00281879|Drug|fludarabine phosphate|"Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.~Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2."
75385914|NCT00281879|Drug|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
75385915|NCT00281879|Drug|methotrexate|Administered on days +1, +3, and +7.
75385916|NCT00281879|Drug|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
75542002|NCT04541524|Device|Santen Preserflo Microshunt|The PMS is 8.5 mm long has an outer diameter of 350 μm and a lumen diameter of 70 μm. It has a fin sized 1.1 mm located 4.5 mm distally from the internal tip of the device and it consists of poly(styrene-b-isobutylene-b-styrene) SIBS. The device was implanted 1 year prior to the present study via an ab externo approach. At the beginning of the surgery, the conjunctiva was opened. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. PMS guides aqueous humor from the anterior chamber to the subconjunctival space. The forming filtering bleb absorbs aqueous humor which leads to IOP reduction.
75705681|NCT02766465|Drug|Methotrexate|"A:~Methotrexate will be administered intravenously on day+1 at 15mg/m^2, day+3 at 10mg/m^2, day+6 at 10mg/m^2, and day+11 at 10mg/m^2.~C:~Methotrexate IV 7.5 mg/m2 dose will be given on Days +1, 3, +6 following transplant"
75385917|NCT00281879|Drug|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
75385918|NCT00281879|Drug|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
75385919|NCT00281879|Procedure|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
75542003|NCT04541563|Device|Fisher Wallace Cranial Electrotherapy Stimulator Device|Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
75542004|NCT02214706|Drug|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
75542005|NCT02214706|Other|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
75542006|NCT02214706|Device|Pulsed Dye Laser|
75705682|NCT02766465|Procedure|Standard of Care|Continue to receive standard of care treatment per patient's SCD physician.
75705683|NCT02766465|Drug|Alemtuzumab|"B:~Alemtuzumab 0.03 mg/kg IV dose will be given on Day -7, Alemtuzumab 0.1 mg/kg IV dose will be given on Day -6, Alemtuzumab 0.3 mg/kg IV dose will be given on Day -5,-4,-3~C:~Alemtuzumab test dose 3 mg IV once 24 hours prior to 1st dose of Alemtuzumab Alemtuzumab 10 mg IV, 15 mg IV, 20 mg IV given on Days -22 through Day -18. Alemtuzumab doses may be administered between Days -22 and -18 but are required to be on three consecutive days."
75705684|NCT02766465|Drug|Total Body Irradiation (TBI)|Total Body Irradiation 300 cGY on Day -2
75705685|NCT02766465|Drug|Sirolimus|Sirolimus at therapeutic doses through day 180, then taper per institutional guidelines if donor CD3+ >50%
76032231|NCT05411315|Other|Standard-use of arterial catheter|The investigator will allow standard-use of arterial catheters
76032232|NCT05663333|Other|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
76032233|NCT04447469|Drug|mavrilimumab|anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G [IgG4])
76032234|NCT04447469|Other|Placebo|matching placebo
76032235|NCT04447235|Drug|Placebo|Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
76032236|NCT04447235|Drug|Ivermectin|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
76032237|NCT04447235|Drug|Losartan|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
76032238|NCT01680991|Drug|Obinutuzumab|Multiple doses of obinutuzumab.
76032239|NCT01700569|Drug|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
76032240|NCT01700569|Drug|folinic acid at pharmacological dose is the escalated drug|
76032241|NCT01700569|Radiation|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
75868979|NCT05967780|Other|Group A: Patients with FHP receiving standard cardiac rehabilitation|Consenting participants in this group will receive a standard cardiac rehabilitation protocol that includes preoperative education and post-operative exercises, chest physiotherapy, functional mobility and care. Phase 1 begins after the patient has been considered clinically compensated due to the optimization of the clinical treatment and/or the use of an interventional procedure. In this phase, a combination of low-intensity physical exercise (that includes range of motion exercises for upper & lower extremities + progressive mobilization from sitting on bedside to walking short distance and up to stair climbing), incentive spirometry exercise, percussions, breathing exercises and effective coughing exercises.
75385920|NCT00281879|Procedure|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
75385921|NCT00281879|Radiation|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
76023125|NCT05108207|Other|Prevention software|The software is installed on an Alcatel OneTouch Pixi-3 10 tablet and is delivered every day to each patient between 9:00 am and 8:00 pm, with nighttime pickup (8:00 pm to 09:00 am), so the patient can rest and to charge the device. The first day, a previously trained health professional delivers the tablet and trains the older adults in its use, taking 10 to 15 minutes. The day after the tablet is delivered, the same person goes to the patient's room to check if he or she has any doubts or problems with its use. Both groups are advised to use the tablet 3 times a day, at least 10 minutes each time.
76023126|NCT05108207|Other|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
76032242|NCT05095675|Behavioral|psychological questionnaires|Participants have to fulfill psychological questionnaires in different time points during medical oncological treatment
75385922|NCT05153057|Other|Observational study|The goal of the study is purely observational. Treatment decisions will be made by physicians according to the grading of the intraocular inflammation related to birdshot chorioretinopathy and to their consequences on visual function. These treatment decisions will be independent from the observational study.
75385923|NCT00000809|Biological|Aluminum hydroxide|
75385924|NCT00000809|Biological|QS-21|
75385925|NCT00000809|Biological|MN rsgp120/HIV-1|
76032243|NCT04442867|Other|Case management|Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.
76032244|NCT04442867|Other|Social call|Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
76032245|NCT05090761|Drug|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SAPB
76032246|NCT05090761|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
76032247|NCT05090761|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
76032248|NCT05084443|Dietary Supplement|Drink|Roselle and placebo drink for 6 months
76032249|NCT03064529|Device|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
75385927|NCT00000815|Biological|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
75542007|NCT04541485|Drug|DWRX2003|Intramuscularly injection at pre-defined injection sites
75542008|NCT04541485|Drug|Placebo|Intramuscularly injection at pre-defined injection sites
75385928|NCT00000815|Biological|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
75542009|NCT02214745|Other|Questionnaire|Questionnaire developed for this purpose by the investigators
75385929|NCT00240227|Drug|Prazosin|FDA approved medication for hypertension
75385930|NCT00240227|Drug|placebo|
75385931|NCT00205049|Drug|pentoxifylline|daily dosing
75385932|NCT00000833|Drug|Ribavirin|
75385933|NCT00000833|Drug|Didanosine|
75385934|NCT00176501|Biological|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
75542010|NCT02214784|Device|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
76023127|NCT05108207|Other|Implement a program of non-pharmacological interventions to prevent delirium|Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.
75385935|NCT00000839|Drug|Didanosine|
75385936|NCT00133679|Drug|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
75385937|NCT00133679|Drug|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
75385938|NCT00000845|Biological|P3C541b Lipopeptide|
75385939|NCT00000875|Drug|Indinavir sulfate|
75385940|NCT00000875|Drug|Diphenhydramine hydrochloride|
75385941|NCT00000875|Drug|Lymphocytes, Activated|
75385942|NCT00000875|Drug|Lamivudine|
75385943|NCT00000875|Drug|Zidovudine|
75385944|NCT00000875|Drug|Acetaminophen|
75542011|NCT02214784|Device|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
75542012|NCT02214862|Drug|[F18]-FDDNP|radiopharmaceutical tracer
75385945|NCT00000875|Drug|Aldesleukin|
75385946|NCT04941833|Drug|Desogestrel Oral Tablet|Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
75385947|NCT04890041|Drug|TPO-RA|The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10^9/L and 150×10^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10^9/L, the treatment was stopped. If the platelet count is more than 400×10^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
75385948|NCT04874909|Other|Blood sample|"Blood sample of 15ml max by subject (case, related individual, control) once time:~subject less than 5 kg : 1.8 to 4.5 ml max~subject 5 kg to 10 kg : 4.5 to 9 ml max~subject 10 kg to 15 kg : 9 to 13.5 ml~subject 15 kg to 20 kg : 13.5 to 15 ml max"
75385949|NCT04874909|Other|Urine sample|Urine sample (500 ml) once time
75385950|NCT04841369|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular
75385951|NCT04841369|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular
75385952|NCT00379925|Behavioral|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
75385953|NCT00002975|Drug|aminolevulinic acid|
75385954|NCT02221817|Procedure|Trochanter bursa injections|
75385955|NCT02221817|Device|Ultrasound|
75542013|NCT00236600|Drug|topiramate|
75542014|NCT00269295|Biological|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10^7 cfu, 5 X 10^8 cfu, and 5 X 10^9 cfu.
75542015|NCT00269295|Drug|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
75542016|NCT04541134|Drug|Pelubiprofen 45mg|Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)
75542017|NCT04541134|Drug|Placebo|Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
75542018|NCT00236639|Drug|topiramate|
75385956|NCT00521885|Drug|Arixtra (Fondaparinox) 2.5 mg SC Daily|Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
75385957|NCT00521885|Drug|Lovenox 40mg SC Daily|Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
75385958|NCT05239013|Drug|Nitroglycerin ointment|2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
75868980|NCT05967780|Other|Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises|"The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.~Therapeutic exercises will be delivered to the participant by treating physiotherapist in physical, verbal and written formats as individualized sessions on the ward 4 weeks before the surgery and keep him doing exercises under supervision while staying in the ward before surgery. A log will be provided to measure performance to ensure program compliance. After discharge from the hospital, the patient will continue exercises at home as performed and guided physically by the therapist and also in the exercises manual and flyer given to the patient. Patients will be instructed to follow therapeutic exercise for 4 weeks pre-operatively and 4 weeks postoperatively after discharge from the hospital."
75385959|NCT00000881|Drug|Cidofovir|
75385960|NCT00000881|Drug|Probenecid|
75385961|NCT00000887|Drug|Nelfinavir mesylate|
75385962|NCT00000887|Drug|Lamivudine|
75868981|NCT05967780|Other|Group C: Patients without FHP receiving standard cardiac rehabilitation|The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
75385963|NCT00000887|Drug|Zidovudine|
75385964|NCT03979079|Radiation|external beam radiation therapy|
75868982|NCT05967416|Biological|SIRPant-M|Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection
75868983|NCT05967416|Radiation|External-beam radiotherapy (XRT)|Radiotherapy given by external beam
75868984|NCT05966649|Other|Synbiotics|Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
75385965|NCT02973347|Other|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
75385966|NCT02973347|Other|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
75542019|NCT04541368|Drug|CS1 Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion
75542020|NCT00261924|Device|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
75868985|NCT05966649|Other|Placebo|Matching placebo
75868986|NCT05950113|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
76032250|NCT05608109|Behavioral|Alcohol personalized normative feedback (APNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.
75385967|NCT04618991|Other|Filling the Quebec Sleep Questionnaire|Filling the Quebec Sleep Questionnaire (QSQ) by the pre-surgery patient, then at 3 months post surgery and 1 year post surgery.
75385968|NCT00000119|Device|Heparin Surface-Modified Intraocular Lens|
75385969|NCT00000923|Drug|Indinavir sulfate|
75385970|NCT00000923|Drug|Lamivudine|
75385971|NCT00000923|Drug|Stavudine|
75385972|NCT00000923|Drug|Zidovudine|
75385973|NCT00000923|Drug|Didanosine|
75385974|NCT00000923|Drug|Aldesleukin|
75385975|NCT00000161|Drug|Aspirin|
75385976|NCT00000161|Drug|Beta-Carotene|
75385977|NCT00000161|Drug|Vitamin C|
75385978|NCT00000161|Drug|Vitamin E|
75542021|NCT04545463|Dietary Supplement|FIBRACEP|A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
75542022|NCT04545463|Dietary Supplement|INSOLUBLE|A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
75542023|NCT04545463|Dietary Supplement|SOLUBLE|A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
75542024|NCT04545697|Other|Medcorder|Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
75542025|NCT02214901|Drug|BIBW 2948 BS for oral inhalation|
75542026|NCT02214901|Drug|Placebo|
75868987|NCT05950113|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
75385979|NCT04474145|Procedure|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
75385980|NCT04474145|Procedure|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
75868988|NCT05950113|Procedure|Computed Tomography|Undergo PET/CT
76032251|NCT05608109|Behavioral|Social media personalized normative feedback (SMPNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
75385981|NCT00000929|Drug|Nonoxynol-9|
75385982|NCT00000167|Procedure|Low-Intensity Laser Treatment|Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
75385983|NCT00000935|Biological|Intravenous immune globulin (IVIG)|given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
75385984|NCT00000197|Drug|Propranolol|
75385985|NCT00000947|Drug|Azithromycin|
76032252|NCT04139057|Drug|EBV-specific TCR-T cell with anti-PD1 auto-secreted element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
75385986|NCT04251611|Other|Maintenance of physical exercise|Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.
75385987|NCT00000203|Drug|Buprenorphine|
75385988|NCT00000209|Drug|Buprenorphine|
75385989|NCT00000215|Drug|Pergolide|
75385990|NCT00000953|Drug|Sorivudine|
75385991|NCT00000953|Drug|Acyclovir|
75385992|NCT00000983|Drug|Zidovudine|
75385993|NCT00000227|Drug|Buprenorphine|
75385994|NCT00000233|Drug|Buprenorphine|
75385995|NCT00000239|Drug|Buprenorphine|
75385996|NCT00000245|Drug|Desipramine|
75385997|NCT00000263|Drug|30% Nitrous oxide|
75385998|NCT00000263|Other|0.25 g/Kg ethanol|
75385999|NCT00000263|Other|0.5 g/KG ethanol|
75386000|NCT00000263|Other|0 g/Kg ethanol|
75868989|NCT05950113|Drug|Cyclophosphamide|Receive IV
75868990|NCT05950113|Procedure|Echocardiography|Undergo ECHO
75868991|NCT05950113|Drug|Fludarabine|Receive IV
75868992|NCT05950113|Other|Fludeoxyglucose F-18|Receive IV
75868993|NCT05950113|Other|Immunotherapy|Receive CART-BCMA/CS1 cells IV
76032253|NCT04127903|Other|the Length of Right Main Stem Bronchus|The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
76032254|NCT03065309|Drug|Remifentanil|bolus dose
76032255|NCT02819479|Drug|25% Mannitol|"Route of administration:~In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery."
76032256|NCT02819479|Drug|Low-dose Intra-arterial Bevacizumab|"Route of administration:~In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery."
76032257|NCT05095285|Other|Swaddling|"Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~Common procedure steps:~Legal representatives of the infants will sign an informed consent form.~İncubator cover and nesting~Endotracheal suction(ES) was performed in the supine position.~ES was done at the time of care the baby needed.~No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~Aspiration was performed sterile at 80 mmHg pressure.~A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded."
76032258|NCT05095285|Other|Oropharyngeal colostrum|"Common procedure steps~In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue."
76032259|NCT04081025|Other|EpiWux|A cross-sectional and longitudinal study including a questionnaire and a clinical examination
75386001|NCT00000269|Drug|Pergolide|
75386002|NCT00380003|Drug|EVT 201|
75386003|NCT03967223|Drug|Letetresgene autoleucel (lete-cel, GSK3377794)|letetresgene autoleucel will be administered.
75386004|NCT03967223|Drug|Fludarabine|Fludarabine will be used as the lymphodepleting chemotherapy
75386005|NCT03967223|Drug|Cyclophosphamide|Cyclophosphamide will be used as the lymphodepleting chemotherapy.
75386006|NCT00000989|Drug|Zidovudine|
75386007|NCT00000989|Drug|Sargramostim|
75386008|NCT00000989|Drug|Ganciclovir|
75386009|NCT00000995|Drug|Zidovudine|
75386010|NCT00000995|Drug|Ganciclovir|
75386011|NCT00001019|Biological|rgp120/HIV-1 SF-2|
75386012|NCT00001019|Biological|MTP-PE/MF59|
75386013|NCT00001025|Drug|Zidovudine|
75386014|NCT00001025|Drug|Didanosine|
75386015|NCT00001031|Biological|rgp120/HIV-1MN|
75386016|NCT00001031|Biological|rgp120/HIV-1 SF-2|
75386017|NCT05440565|Diagnostic Test|Fecal immunochemical test|Fecal immunochemical test can concentrate the high-risk population.
75386018|NCT05440565|Diagnostic Test|APCS score|APCS score can concentrate the high-risk population.
75386019|NCT03118895|Device|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
75386020|NCT03055247|Drug|Ibuprofen|Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
75386021|NCT03055247|Drug|Myelostim|Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
75868994|NCT05950113|Procedure|Leukapheresis|Undergo leukapheresis
75386022|NCT03055247|Drug|Mozobil|Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are < 10 /μL) to the day of the last LP.
75386023|NCT00001049|Drug|Zidovudine|
75386024|NCT00001049|Drug|Didanosine|
75386025|NCT00001055|Biological|ALVAC-HIV MN120TMG (vCP205)|
75386026|NCT00001055|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
75386027|NCT00001055|Biological|rgp120/HIV-1 SF-2|
75386028|NCT00000275|Drug|Flupenthixol|
75386029|NCT00001061|Drug|Sevirumab|
75386030|NCT00001061|Drug|Foscarnet sodium|
75386031|NCT00001061|Drug|Ganciclovir|
75386032|NCT00000281|Behavioral|Amantadine|
75386033|NCT02788955|Behavioral|Dietary counselling|
75386034|NCT02788955|Other|Dietary Protein|
75386035|NCT00001067|Drug|Lamivudine|
75386036|NCT00001067|Drug|Stavudine|
75386037|NCT00001067|Drug|Zidovudine|
75386038|NCT02396459|Drug|Triac|Triac, individually titrated dose
75386039|NCT00001079|Drug|Testosterone enanthate|
75386040|NCT00001079|Drug|Megestrol acetate|
75386041|NCT00000293|Drug|Nefazodone|
75386042|NCT00001091|Drug|Ritonavir|
75386043|NCT00001091|Drug|Nelfinavir mesylate|
75386044|NCT00001091|Drug|Nevirapine|
75386045|NCT00001091|Drug|Lamivudine|
75386046|NCT00001091|Drug|Stavudine|
75386047|NCT00000299|Drug|Buprenorphine|
75386048|NCT00000305|Drug|Dextroamphetamine|
75542027|NCT00236678|Drug|Epoetin alfa|
75542028|NCT00269334|Drug|Using Citalopram(drug) or Paroxetine(drug)|
75542029|NCT04541251|Drug|Camrelizumab + Nab-paclitaxel + Carboplatin|The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
75868995|NCT05950113|Procedure|Magnetic Resonance Imaging|Undergo MRI
75868996|NCT05950113|Procedure|Positron Emission Tomography|Undergo PET/CT
76023128|NCT02399059|Procedure|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
75386049|NCT01771679|Biological|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
75386050|NCT00000311|Drug|Buprenorphine|Medication and Behavioral
76032260|NCT05376943|Drug|Direct Acting Antivirals|Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
75386051|NCT00000311|Drug|methadone|medication and behavioral
75386052|NCT00000317|Drug|Risperidone|Risperidone (4mg/day)
75386053|NCT00000317|Drug|Placebo|Placebo
76032261|NCT04074785|Drug|Abemaciclib|Abemaciclib 150 mg po bid
76032262|NCT04074785|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
76032263|NCT04533841|Drug|Misoprostol|Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
76032264|NCT04533841|Drug|Placebo|placebo
75386054|NCT00000317|Behavioral|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
75386055|NCT00001685|Biological|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
75386056|NCT00001115|Drug|Acyclovir|
75386057|NCT00380237|Biological|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
75386058|NCT00380315|Drug|AG1321001(drug)|
75386059|NCT00001127|Biological|Influenza virus vaccine (CAIV-T)|
75386060|NCT00001757|Drug|Voriconazole|
75386061|NCT00001133|Drug|Indinavir sulfate|
75386062|NCT00001133|Drug|Ritonavir|
75386063|NCT00000329|Drug|Opioid-Related Disorders|
75386064|NCT00000335|Drug|Morphine|
75386065|NCT00000341|Drug|Buprenorphine|
75386066|NCT00000347|Drug|Risperidone|
76032265|NCT04533841|Drug|Propranolol|Propranolol
76032266|NCT04537663|Drug|Bacille Calmette-Guérin (BCG)|Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
76032267|NCT04537663|Drug|Placebo|Intradermal injection of sterile 0.9% NaCl.
75386067|NCT00001781|Drug|CGP 77116|
75386068|NCT00001835|Drug|Oxaliplatin|
75386069|NCT00001193|Procedure|high dose melphalan and autologous bone marrow transplantation|
75386070|NCT00000353|Drug|Buprenorphine/naloxone|
75386071|NCT00000377|Drug|Nortriptyline|
75386072|NCT00001865|Drug|Daclizumab|
75386073|NCT00000389|Drug|Fluvoxamine|
75386074|NCT00001271|Drug|IgG-RFB4-SMPT-dgA|
75386075|NCT00000401|Drug|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
75386076|NCT00000407|Behavioral|Vocational counseling intervention|
76032268|NCT04536805|Drug|Metformin|Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
76032269|NCT04536805|Radiation|Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy)|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy day 0 to day 10
76032270|NCT04536805|Radiation|Stereotactic Body Radiation Therapy (SBRT) 36 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy day 0 to day 12
76032271|NCT04536805|Radiation|Stereotactic Body Radiation Therapy (SBRT) 25 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5x 5 Gy day 0 to day 10
76032272|NCT05376865|Dietary Supplement|Vitamin D supplement|The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.
76032273|NCT04064411|Combination Product|abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
75386077|NCT00000407|Behavioral|Reading materials for control participants|
75386078|NCT00000407|Behavioral|Standard of care|No education or behavioral intervention
75386079|NCT00001877|Drug|Pentoxifylline|
75386080|NCT00380939|Drug|Atorvastatin|
75386081|NCT00380939|Drug|Pravastatin|
75386082|NCT00001889|Procedure|Myocardial contrast echocardiography|
75386083|NCT00001889|Procedure|Stress echocardiography with dobutamine|
75386084|NCT00380549|Diagnostic Test|Blood ion levels|Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
75386085|NCT00001895|Drug|FDG|
75386086|NCT00001895|Drug|NH(3)|
75386087|NCT00001901|Drug|Etanercept|
75386088|NCT00000431|Drug|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
75386089|NCT00000437|Drug|Naltrexone Tablet and Nicotine Patch|
75386090|NCT00000437|Drug|Naltrexone Tablet and Placebo Patch|
75386091|NCT00000437|Drug|Placebo Tablet and Nicotine Patch|
75386092|NCT00000437|Drug|Placebo Tablet and Placebo Patch|
75386093|NCT00000443|Drug|ondansetron (Zofran)|
75386094|NCT00380783|Drug|AGN 203818|
75386095|NCT00000449|Drug|naltrexone (Revia)|
75386096|NCT00000449|Behavioral|cognitive behavioral therapy|
76032274|NCT04064411|Combination Product|abaloparatide solid microstructured transdermal system|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto a sMTS array for transdermal administration of abaloparatide.
75386097|NCT00000449|Behavioral|cue exposure treatment|
75386098|NCT00000455|Drug|naltrexone|
75386099|NCT00000473|Behavioral|dietary supplements|
76032275|NCT05086159|Behavioral|Pain Neuroscience Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1: the nervous system is like an alarm to protect.~Session 2: common ways the nervous system becomes sensitive.~Session 3: importance of gradual conditioning and neuroplasticity.~Session 4: common ways to decrease nervous system sensitivity."
75386100|NCT00000473|Drug|fatty acids, omega-3|
75386101|NCT00000473|Behavioral|diet, fat-restricted|
75386102|NCT00001919|Drug|Hypericum (LI-160)|
75386103|NCT00001925|Drug|Alcohol|
75386104|NCT00001307|Drug|Oxygen-15 Water|
75386105|NCT00001307|Drug|Capsaicin|
75386106|NCT00001931|Drug|N-0923|
75386107|NCT04713761|Drug|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with MPM received surgical treatment (PD/EPP) after neoadjuvant therapy. Patients who were unable to operate or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
75386108|NCT00380471|Device|Bath PUVA|
75386109|NCT00000509|Behavioral|diet, sodium-restricted|
75386110|NCT00000509|Behavioral|diet, potassium-supplementation|
75386111|NCT00000515|Behavioral|diet, reducing|
75386112|NCT00001937|Drug|FK463|
75386113|NCT00001937|Drug|Fluconazole|
75386114|NCT00001325|Drug|18 FDG|
75386115|NCT00000545|Behavioral|exercise|
75386116|NCT00000545|Behavioral|diet|
75386117|NCT04331327|Drug|allogenic lyophilized growth factors|Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
75386118|NCT00001955|Drug|Etanercept|
75386119|NCT00001955|Drug|Celecoxib|
75386120|NCT00000551|Behavioral|health education|
75386121|NCT04943783|Drug|Atorvastatin 20mg|One with the intervention (Atorvastatin, 20mg OD), 20 patients for this arm.
75386122|NCT00000581|Procedure|leukocyte transfusions|
75386123|NCT00000605|Drug|hormone replacement therapy|
75386124|NCT00000605|Drug|estrogens|
75386125|NCT00000605|Drug|medroxyprogesterone|
75386126|NCT00000617|Drug|azithromycin|
75386127|NCT00000623|Drug|Deferoxamine|
75386128|NCT00000623|Drug|Deferiprone|
75386129|NCT00000623|Drug|Arginine|
75386130|NCT00000623|Drug|Sildenafil|
75386131|NCT00000623|Drug|Decitabine|
75386132|NCT00001961|Procedure|MRI|
75386133|NCT00001967|Drug|HAART|
75386134|NCT00001991|Drug|Atovaquone|
75386135|NCT00001997|Drug|Interleukin-2, Polyethylene Glycolated|
75386136|NCT00001997|Drug|Zidovudine|
75386137|NCT00001997|Drug|Didanosine|
76032276|NCT05086159|Behavioral|Exercise|"The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP."
76032277|NCT05086159|Behavioral|Traditional Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1 will include a basic overview of the anatomy of the spine.~Session 2 will discuss an overview of stress symptoms to include hypervigilance, avoidance, and re-experiencing.~Session 3 will cover common recommendations delivered in stress education: the do's and don'ts of stress management.~Session 4: review and mindfulness."
76032278|NCT05085223|Other|Daily urine collection for biochemical analysis|For every patient in ICU, a daily morning urine sample will be collected from the already collected urine via catheter.
76032279|NCT05085223|Other|Subanalysis for comparison of 24hour urine collection versus spot-check measurements|For a subgroup of 30 sedated patients, 24 hour urine collection will be collected. In addition, every 2 hours a 10ml urine sample will be collected.
76032280|NCT03064997|Dietary Supplement|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
76032281|NCT03064997|Dietary Supplement|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
76032282|NCT05083663|Drug|Hyaluronidase|using hyaluronidase as an additive to bupivacaine
75386138|NCT00002003|Drug|Mitoxantrone hydrochloride|
75386139|NCT00002003|Drug|Etoposide|
75386140|NCT00002009|Drug|Sargramostim|
75386141|NCT00000629|Drug|Valproic acid|
75386142|NCT00000629|Drug|Zidovudine|
75386143|NCT00000647|Drug|CD4-IgG|
75386144|NCT00000647|Drug|Zidovudine|
75386145|NCT00000647|Drug|Interferon alfa-n1|
75386146|NCT00000647|Procedure|Peripheral lymphocyte infusion|
75386147|NCT00000647|Procedure|Bone marrow transplant|
75386148|NCT00000653|Drug|Zalcitabine|
75386149|NCT00001409|Drug|Interleukin-2|
75386150|NCT00000659|Drug|CD4 Antigens|
75386151|NCT00000659|Drug|Zidovudine|
75386152|NCT00381017|Drug|Peg interferon alpha-2b|
75386153|NCT00001439|Biological|gp100 human melanoma peptide|
75386154|NCT00002015|Drug|Ganciclovir|
75386155|NCT00002021|Drug|Foscarnet sodium|
75386156|NCT00002027|Drug|Diclazuril|
75386157|NCT00000695|Drug|Interferon beta-1b|
75386158|NCT00000695|Drug|Zidovudine|
75386159|NCT00000701|Drug|Zidovudine|
75386160|NCT00000713|Drug|Ampligen|
75386161|NCT00000725|Drug|Interferon alfa-2a|
75386162|NCT00000725|Drug|Zidovudine|
75386163|NCT00000725|Drug|Interferon alfa-n1|
75386164|NCT00002033|Drug|Zidovudine|
75386165|NCT00002033|Drug|AS-101|
75386166|NCT00002039|Drug|Foscarnet sodium|
75386167|NCT00000731|Drug|Zidovudine|
75386168|NCT00000731|Drug|Acetaminophen|
75386169|NCT00002045|Drug|Zidovudine|
75705686|NCT02766465|Drug|Melphalan|"C:~Melphalan 140 mg/m2 IV dose will be given on Day -3"
75705687|NCT02766465|Drug|G-CSF|G-CSF 5 μg/kg/day continue until neutrophil engraftment.
75868997|NCT05946837|Drug|Indocyanine green (ICG) dye|ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
75868998|NCT05946837|Device|NIRF-LI imaging|Near-infrared fluorescence lymphatic imaging (NIRF-LI) imaging will be done to assess the drainage of ICG laden lymph from ICG injection sites toward regional nodal basins for 60 minutes before, during and after the Neuroglide pad treatment
76023129|NCT02399059|Procedure|Normal saline lavage|Peritoneal irrigation with normal saline
76023130|NCT05108051|Drug|ZSP1273|ZSP1273 tablets 600mg administered orally once daily
76032283|NCT05082415|Drug|Brolucizumab|Participants received brolucizumab injection during the index period
75386170|NCT00001493|Genetic|peripheral blood progenitor cells carrying MDR1|
75386171|NCT00002051|Drug|Thymopentin|
75386172|NCT00001499|Drug|paclitaxel|
75386173|NCT00001499|Drug|cisplatin|
75386174|NCT00001499|Procedure|chest radiotherapy|
75386175|NCT00002057|Drug|Nystatin|
75386176|NCT00002297|Drug|Inosine pranobex|
75386177|NCT00001535|Drug|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
75386178|NCT00002303|Drug|Epoetin alfa|
75386179|NCT00002063|Drug|Zidovudine|
75386180|NCT00002069|Drug|Ditiocarb sodium|
75386181|NCT00001565|Drug|phenylbutyrate|
75386182|NCT00002309|Drug|Azithromycin|
75386183|NCT00002315|Drug|Netivudine|
75386184|NCT00002315|Drug|Acyclovir|
75386185|NCT00002075|Drug|Flucytosine|
75386186|NCT00002075|Drug|Fluconazole|
75386187|NCT00002075|Drug|Amphotericin B|
75386188|NCT00001577|Procedure|double isolated limb perfusion with melphalan alone|
75386189|NCT00002081|Drug|Zidovudine|
75386190|NCT00002081|Drug|Zalcitabine|
75386191|NCT00001637|Procedure|Blood cell transplantation|
75386192|NCT00002087|Drug|Alvircept sudotox|
75386193|NCT00002093|Drug|Daunorubicin (liposomal)|
75386194|NCT00002093|Drug|Bleomycin sulfate|
75386195|NCT00002093|Drug|Vincristine sulfate|
75386196|NCT00002093|Drug|Doxorubicin hydrochloride|
75386197|NCT00002099|Drug|Lentinan|
75386198|NCT00002099|Drug|Didanosine|
75386199|NCT00002321|Drug|Aldesleukin|
75386200|NCT00002327|Drug|Cidofovir|
75386201|NCT00002333|Drug|Saquinavir|
75386202|NCT00002333|Drug|Zalcitabine|
75386203|NCT00002339|Drug|Fluconazole|
75386204|NCT00002105|Drug|Doxorubicin hydrochloride (liposomal)|
75386205|NCT00002105|Drug|Bleomycin sulfate|
75386206|NCT00002105|Drug|Vincristine sulfate|
75386207|NCT00002345|Drug|Megestrol acetate|
75705688|NCT02749422|Diagnostic Test|MagStim RapidStim2|Repetitive transcranial magnetic stimulation (TMS)
75705689|NCT02743455|Drug|ISA-720|The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.
75705690|NCT02743455|Biological|MVA Smallpox Vaccine|Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.
75705691|NCT02743455|Biological|MVA-BN Yellow Fever Vaccine|Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.
76023131|NCT05108051|Drug|Oseltamivir|Oseltamivir 75mg administered orally twice daily
76023132|NCT02404909|Other|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
76023133|NCT03765359|Drug|metforminhydrochloride|metformin 500 mg tablets and insulin
76023134|NCT03765359|Drug|Placebo Oral Tablet|Placebo tablets mimic metformin 500 mg tablets and insulin
76023135|NCT02407483|Device|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
76023136|NCT02407483|Device|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
76023137|NCT02404987|Other|Nutritional Supplement|
76023138|NCT04351295|Drug|Favipiravir|Favipiravir
76023139|NCT04351295|Drug|Chloroquine|chloroquine oral tablets
75868999|NCT05946837|Device|Neuroglide pad|After injection of Indocyanine green (ICG) dye and NIRF-LI imaging the subject will lie on the Neuroglide pad for the one-hour PCT treatment session.
75869000|NCT05946590|Procedure|Frenotomy|Frenotomy in which clipping/incised of the lingual frenulum releases the tongue-tie performed by a health care professional
75869001|NCT05944419|Device|Immediate implant surgery|Placement of immediate implant and immediate provisionalization after tooth extraction
75386208|NCT00002111|Drug|Saquinavir|
75386209|NCT05752643|Other|Online follow up|The online follow up will include screening for HIV and STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Treponema pallidum (TP)) based in a self-sampling strategy
75386210|NCT00002351|Drug|Indinavir sulfate|
75386211|NCT00002357|Drug|HBY 097|
75386212|NCT00002357|Drug|Zidovudine|
75386213|NCT00002117|Drug|Zidovudine|
75386214|NCT00002117|Drug|Zalcitabine|
75386215|NCT05752565|Device|SenseWear armband device|"Device: SenseWear armband device Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life"
75386216|NCT00002123|Drug|Delavirdine mesylate|
75386217|NCT00002123|Drug|Didanosine|
75386218|NCT00381329|Behavioral|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
75869002|NCT05940129|Behavioral|Women and Child, Safety, Health and Empowerment (WC-SHE)|The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons
75869003|NCT05935241|Behavioral|mPATH|The active mPATH intervention takes 6 months including (1) The physical activity education session , (2)mHealth learning and practice; (3)Personalized physical activity training, plan, and biweekly phone calls over 24 weeks (4) mHealth strategies to encourage physical activity and facilitate intervention adherence (5) (5) mPATH during 6-12 months: mPATH will be delivered mainly in 24 weeks before the 6-month data collection. During 6-12 months, the participants will have access to study mHealth strategies, and exercise videos. No additional physical activity training by staff will be supported.
75869004|NCT05935241|Other|Attention Control|A registered nurse from the study team will provide 6 monthly home visit (approximately 55-60 minutes each) to provide physical activity education, physical activity safety at home evaluation, feedback, and social activity (meaningful or enjoyable activities as identified by the participants, such as playing cards, doing arts and crafts, listening to music, talking about life history, etc.).
76032284|NCT05050825|Other|Patient clinical management based on the CDSA strategy|The CDSA strategy is a combination of point of care tests (rapid diagnostic tests targeting malaria, dengue fever and streptococcus group a sore through) and a mHealth tool that provides patient management recommendations, including treatment, based on an algorithm integrating patient clinical signs and symptoms, history and diagnostic test results.
76032285|NCT04012931|Drug|Rilpivirine|Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
75705692|NCT02743455|Other|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
75386219|NCT00381329|Behavioral|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
75386220|NCT00002363|Drug|Peptide Construction 3, Synthetic|
75386221|NCT00381173|Drug|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
75386222|NCT00002129|Drug|Vesnarinone|
75386223|NCT00002135|Drug|Ganciclovir|
75386224|NCT00002141|Drug|Abacavir sulfate|
75386225|NCT00002369|Drug|Indinavir sulfate|
75386226|NCT00002369|Drug|Lamivudine|
75386227|NCT00002369|Drug|Stavudine|
75386228|NCT00002369|Drug|Zidovudine|
75386229|NCT00002375|Drug|Indinavir sulfate|
75386230|NCT00002375|Drug|Nelfinavir mesylate|
75705693|NCT02743455|Other|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
75869005|NCT05934890|Biological|Walvax PCV13-TT|"PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually.~The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added."
75869006|NCT05934890|Biological|Pfizer PCV13|PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
75869007|NCT05934084|Behavioral|Lifestyles Implemented-Survivorship Care Plan (LS-SCP)|Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.
75869008|NCT05924841|Drug|BL-B01D1|Administration by intravenous infusion
75869009|NCT05924841|Drug|SI-B003|Administration by intravenous infusion
75542030|NCT04540783|Device|Transcranial direct current stimulation (tDCS)|10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.
75542031|NCT04545034|Other|water aerobic exercise|The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
76032286|NCT04012931|Drug|ARV Background Regimen|The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine [AZT], abacavir [ABC], tenofovir alafenamide [TAF], or tenofovir disoproxil fumarate [TDF] in combination with emtricitabine [FTC] or lamivudine [3TC]), whichever are approved and marketed or considered local standard of care for children aged between 2 and < 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir [DTG] or raltegravir) can also be administered in combination with RPV, as appropriate.
76032287|NCT05331287|Other|Head position|Influence of different head position on nasal endotracheal intubation
76032288|NCT03063359|Drug|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
76032289|NCT03063359|Drug|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
75386231|NCT04636697|Drug|Intramuscular injection|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
75386232|NCT04636697|Biological|Intramuscular vaccine|Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
75386233|NCT00002381|Drug|Nelfinavir mesylate|
75386234|NCT00002381|Drug|Nevirapine|
75386235|NCT00002381|Drug|Stavudine|
75386236|NCT00002387|Drug|Indinavir sulfate|
75386237|NCT00002387|Drug|Efavirenz|
75542032|NCT00236717|Drug|Topiramate; Carbamazepine; Valproate|
75542033|NCT00269373|Procedure|PET-CT|no drugs included
75542034|NCT04540549|Behavioral|exercise|Jogging or cycling ≥5 days/week, 30-60 min/d
75542035|NCT04545073|Device|PanOptix|Trifocal IOL with ORA in post refractive patients
75542036|NCT00236756|Drug|topiramate|
75386238|NCT00002393|Drug|Indinavir sulfate|
75386239|NCT00002393|Drug|Efavirenz|
75386240|NCT00002399|Drug|Posaconazole|
75386241|NCT00002399|Drug|Fluconazole|
75386242|NCT00002405|Drug|Amprenavir|
75542037|NCT04545307|Biological|Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis|The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
75542038|NCT00269412|Drug|Rifaximin|
76032290|NCT02629133|Behavioral|SHE Program|The SHE program is specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It is also tailored to participants' alcohol or substance use status, and designed to reach participants across levels of motivation for change. The content of SHE is theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
76032291|NCT02660359|Biological|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
75386243|NCT00002417|Drug|Amprenavir|
75386244|NCT00381407|Behavioral|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
75386245|NCT00381407|Behavioral|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
75386246|NCT00002423|Drug|Indinavir sulfate|
75386247|NCT00002423|Drug|Abacavir sulfate|
75542039|NCT04545190|Dietary Supplement|Glucose|To investigate the effects of glucose intake during resistance training on muscle biological adaptations
75542040|NCT00236795|Drug|norelgestromin + ethinyl estradiol; triphasil.|
75557754|NCT00474825|Drug|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
75557755|NCT00474825|Drug|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
76032292|NCT02660359|Biological|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
75386248|NCT00002423|Drug|Amprenavir|
75386249|NCT00002423|Drug|Nelfinavir mesylate|
75386250|NCT00002423|Drug|Lamivudine|
75386251|NCT02973581|Drug|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
75386252|NCT02973581|Drug|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
75386253|NCT02973581|Drug|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
75705694|NCT02743455|Biological|YF Vax 17D Strain|Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos. Will be used as an active comparator.
75542041|NCT04545268|Device|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days)."
75705695|NCT02716753|Biological|seminal plasma|
75705696|NCT02716753|Biological|Physiological NaCL solution|
76032293|NCT02660359|Drug|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
75557756|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
75557757|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
75705697|NCT02675244|Procedure|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
75386254|NCT02973581|Drug|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
75386255|NCT00002435|Drug|Thymic Humoral Factor|
75705698|NCT02675244|Procedure|MVS|MVS will be performed using standard surgical techniques
76032294|NCT02660359|Drug|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
76032295|NCT03063281|Other|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
75705699|NCT02654210|Other|No Intervention|No Intervention
75705700|NCT02553447|Dietary Supplement|Cholecalciferol|Given PO
75705701|NCT02553447|Other|Laboratory Biomarker Analysis|Optional correlative studies
76032296|NCT05287373|Device|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
75386256|NCT00002435|Drug|Zidovudine|
75386257|NCT00002441|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
75386258|NCT00002447|Drug|Ritonavir|
75386259|NCT00002447|Drug|Efavirenz|
75386260|NCT00002447|Drug|Saquinavir|
75557758|NCT00438347|Behavioral|Aerobic Exercise|One hour per day three times a week for one year
75557759|NCT00438347|Behavioral|Stretching and toning|One hour per day three times a week for one year
75557760|NCT00474981|Behavioral|IMNCI|Implementation of IMNCI in the intervention sites
75386261|NCT00002453|Drug|Tenofovir disoproxil fumarate|
75386262|NCT00002459|Radiation|radiation therapy|
75386263|NCT00002465|Drug|megestrol acetate|
75386264|NCT00002471|Drug|asparaginase|
75386265|NCT00002471|Drug|cyclophosphamide|
75386266|NCT00002471|Drug|cytarabine|
75386267|NCT00002471|Drug|daunorubicin hydrochloride|
75386268|NCT00002471|Drug|dexamethasone|
75386269|NCT00002471|Drug|etoposide|
75386270|NCT00002471|Drug|leucovorin calcium|
75386271|NCT00002471|Drug|methotrexate|
75386272|NCT00002471|Drug|methylprednisolone|
75386273|NCT00002471|Drug|therapeutic hydrocortisone|
75386274|NCT00002471|Drug|thiotepa|
75386275|NCT00002471|Drug|vincristine sulfate|
75705702|NCT02424188|Other|TRIIUMPH Intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
75705703|NCT02351791|Other|Patch 1|Patch 1:standard adhesive with own feces in sleeve
75386276|NCT00002477|Drug|carboplatin|
75386277|NCT00002477|Drug|cisplatin|
76032297|NCT05287373|Other|conventional medical management|Conventional medical management
75386278|NCT00002477|Drug|cyclophosphamide|
76032298|NCT04820959|Biological|Biopsies|"Three endomyocardial intraoperative biopsies were performed on the left ventricle.~Resection of the left atrium in the event of atrial fibrillation."
76032299|NCT04820959|Biological|Blood sampling|Pre-operative blood sampling
76032300|NCT04955899|Device|Active Stimulation|The Galvani System will be implanted in eligible participants, and stimulation will be turned ON
76032301|NCT04626505|Drug|Ziltivekimab|Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
76032302|NCT04626505|Drug|Placebo (ziltivekimab)|Administered s.c. once every 4 weeks for 12 weeks
75386279|NCT00002477|Drug|doxorubicin hydrochloride|
75386280|NCT00002489|Biological|dactinomycin|
75386281|NCT00002489|Biological|filgrastim|
75386282|NCT00002489|Drug|carboplatin|
75386283|NCT00002489|Drug|cyclophosphamide|
75386284|NCT00002489|Drug|doxorubicin hydrochloride|
75705704|NCT02351791|Other|Patch 2|Patch 2:standard adhesive with own feces mixture in sleeve
75705705|NCT02351791|Other|Patch 3|Patch 3: standard adhesive with simulated feces in sleeve
75705706|NCT02351791|Other|Patch 4|Patch 4:standard adhesive with simulated feces mixture in sleeve
76032303|NCT05276609|Drug|HS-20093 (Phase Ia: Dose escalation)|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
75386285|NCT00002489|Drug|etoposide|
75386286|NCT00002489|Drug|leucovorin calcium|
75386287|NCT00002489|Drug|methotrexate|
75386288|NCT00002489|Drug|vincristine sulfate|
75386289|NCT00002489|Procedure|conventional surgery|
75386290|NCT00002495|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15
75386291|NCT00002495|Drug|vinblastine|6 mg/m^2 on days 1 and 15
75386292|NCT00002495|Radiation|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
75386293|NCT00002501|Biological|filgrastim|
75386294|NCT00002501|Drug|cyclophosphamide|
75386295|NCT00002147|Drug|Doxorubicin hydrochloride (liposomal)|
75386296|NCT00002153|Drug|A-007|
75386297|NCT00002159|Drug|Itraconazole|
75386298|NCT00002159|Drug|Amphotericin B|
75386299|NCT00002165|Drug|Nelfinavir mesylate|
75386300|NCT04713059|Genetic|FGFR2|Mutation of FGFR2
75386301|NCT00002171|Drug|Nelfinavir mesylate|
75386302|NCT00002177|Drug|Hydroxyurea|
75386303|NCT00002177|Drug|Nelfinavir mesylate|
75386304|NCT00002177|Drug|Stavudine|
75386305|NCT00002177|Drug|Didanosine|
75386306|NCT00002183|Drug|Abacavir sulfate|
75386307|NCT00002183|Drug|Amprenavir|
75386308|NCT00002183|Drug|Lamivudine|
75386309|NCT00002183|Drug|Zidovudine|
75386310|NCT00002189|Drug|Paclitaxel|
75386311|NCT00002195|Drug|Amprenavir|
75386312|NCT00002195|Drug|Lamivudine|
75386313|NCT00002195|Drug|Zidovudine|
75386314|NCT00002201|Drug|Ritonavir|
75386315|NCT00002201|Drug|Nelfinavir mesylate|
75386316|NCT00002213|Drug|Abacavir sulfate|
75386317|NCT00002213|Drug|Amprenavir|
75386318|NCT00002213|Drug|Efavirenz|
75557761|NCT00438386|Drug|Aripiprazole|
76032304|NCT05276609|Drug|HS-20093 (Phase Ib: Dose expansion)|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
76032305|NCT04909099|Other|Standard treatment|"Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness."
76032306|NCT05068297|Other|Incrediwear Germanium-Embedded Knee Brace following ACL reconstruction|Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction
76032307|NCT05068297|Other|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following ACL reconstruction
75386319|NCT04331405|Biological|Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions|"HUCBMCs samples were prepared for infusion in the specialized laboratory of Cord Blood Bank (CryoCenter Ltd) and transported to the clinic immediately within 2 hours in the Dry Shipper. All samples were chosen according to patients blood group and rhesus-factor.~All samples were examined for hemotransmissive infections and cell viability prior to the preparation.~Obtained samples were infused through the blood transfusion systems with additional filter after 3 tests for biological and individual compatibility and tolerance.~Each patient of the pilot group received 4 cell infusions (1 infusion per week) with 1 week interval during the in-hospital treatment."
75386320|NCT00381251|Drug|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
75386321|NCT00002219|Drug|Nelfinavir mesylate|
75386322|NCT00002219|Drug|Levocarnitine|
75386323|NCT00002219|Drug|Adefovir dipivoxil|
75386324|NCT00002225|Drug|Efavirenz|
75386325|NCT00002225|Drug|Stavudine|
75386326|NCT00002225|Drug|Didanosine|
75386327|NCT00002231|Biological|APL 400-003|
75386328|NCT00002237|Drug|Peldesine|
75542042|NCT04545268|Device|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
75542043|NCT04544644|Drug|AK104+anlotinib|AK 104 is given by intravenous infusion and anlotinib is given by oral.
75542044|NCT00261963|Device|ultraviolet light|
75542045|NCT04540627|Drug|Palivizumab|Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
75542046|NCT04540627|Drug|Placebo|Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
75542047|NCT04540627|Other|RSV-A Memphis 37b virus|Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
75386329|NCT00002243|Drug|Calanolide A|
75542048|NCT00236834|Drug|levofloxacin; imipenem/cilastitin|
75386330|NCT00002249|Drug|Levofloxacin|
75386331|NCT00002255|Drug|Filgrastim|
75386332|NCT00002255|Drug|Epoetin alfa|
75386333|NCT00002255|Drug|Zidovudine|
75386334|NCT05752253|Other|Counseling|Counseling is a process which, through positive orientation and the enhancement of personal resources, is aimed at promoting the improvement of the quality of life in the other.
75386335|NCT00002261|Biological|Smallpox Vaccine|
75386336|NCT00002261|Biological|HIVAC-1e|
75386337|NCT00002261|Biological|gp160 Vaccine (MicroGeneSys)|
75386338|NCT00002507|Drug|mitomycin C|
75386339|NCT00002507|Drug|porfiromycin|
75386340|NCT00002507|Radiation|brachytherapy|
75386341|NCT00002507|Radiation|radiation therapy|
75386342|NCT05752175|Drug|WPV01|WPV01 tablets
75386343|NCT05752175|Drug|Placebo|Placebo tablets
75386344|NCT00002519|Drug|chemotherapy|
75386345|NCT00002519|Drug|paclitaxel|
75542049|NCT04540393|Biological|AZD1222|Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) > 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection
75542050|NCT04544722|Behavioral|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
75542051|NCT04544722|Behavioral|lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
75542052|NCT00236873|Drug|topiramate|
75542053|NCT04544566|Device|Test product A|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
75542054|NCT04544566|Device|Test product B|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
75542055|NCT04544566|Device|Comparator|Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
75542056|NCT00269490|Behavioral|Yoga Nidra|
75542057|NCT04540510|Device|OPEP therapy|Oscillatory Positive Expiratory Pressure therapy
75386346|NCT00002519|Radiation|radiation therapy|
75386347|NCT00002267|Drug|Rifabutin|
75869010|NCT05920720|Behavioral|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
76032308|NCT05067985|Procedure|covid 19 spinal anesthesia|this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
75386348|NCT00002273|Drug|Ganciclovir|
75386349|NCT00002279|Drug|Zalcitabine|
75386350|NCT00002285|Drug|Zidovudine|
75386351|NCT00002531|Drug|asparaginase|
75386352|NCT00002531|Drug|cyclophosphamide|
75386353|NCT00002531|Drug|cytarabine|
75542058|NCT04540510|Other|Standard care|Standard pneumonia care
75386354|NCT00002531|Drug|daunorubicin hydrochloride|
75386355|NCT00002531|Drug|dexamethasone|
75386356|NCT00002531|Drug|doxorubicin hydrochloride|
75542059|NCT00236912|Drug|levofloxacin; metronidazole|
75542060|NCT00269529|Procedure|femoral nerve block|
75542061|NCT00269529|Procedure|knee infiltration and injection via catheter|
75542062|NCT04540471|Other|music|MT group receives additional music therapy
75869011|NCT05918640|Drug|Lurbinectedin|Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
75869012|NCT05911932|Other|Biosample collection.|Blood draw.
75869013|NCT05888792|Other|Variant of Defocus Incorporated Spectacle lens (DG2)|DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously
76023140|NCT05107895|Behavioral|online coping skills training|Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
76023141|NCT02407639|Other|CO2|gas
76023142|NCT02407639|Other|air|air
75386357|NCT00002531|Drug|etoposide|
75386358|NCT00002531|Drug|ifosfamide|
75386359|NCT00002531|Drug|leucovorin calcium|
75386360|NCT00002531|Drug|mercaptopurine|
75386361|NCT00002531|Drug|methotrexate|
75386362|NCT00002531|Drug|mitoxantrone hydrochloride|
75386363|NCT00002531|Drug|prednisolone|
75386364|NCT00002531|Drug|teniposide|
75386365|NCT00002531|Drug|thioguanine|
75386366|NCT00002531|Drug|vincristine sulfate|
75386367|NCT00002531|Drug|vindesine|
75386368|NCT00002531|Procedure|allogeneic bone marrow transplantation|
75386369|NCT00002531|Procedure|peripheral blood stem cell transplantation|
75386370|NCT00002531|Radiation|radiation therapy|
75386371|NCT00002537|Drug|topotecan hydrochloride|
75386372|NCT00002537|Radiation|radiation therapy|
75386373|NCT00002543|Drug|gallium nitrate|
75386374|NCT00002291|Drug|Pentamidine isethionate|
75386375|NCT00002549|Biological|filgrastim|
75386376|NCT00002549|Drug|busulfan|
75386377|NCT00002549|Drug|cyclophosphamide|
75386378|NCT00002549|Drug|cytarabine|
75386379|NCT00002549|Drug|daunorubicin hydrochloride|
75386380|NCT00002549|Drug|etoposide|
75386381|NCT00002549|Drug|idarubicin|
75386382|NCT00002549|Drug|mesna|
75386383|NCT00002549|Drug|mitoxantrone hydrochloride|
75386384|NCT00002549|Procedure|allogeneic bone marrow transplantation|
75542063|NCT04540471|Other|comprehensive in-patient education program|comprehensive in-patient education program
75557762|NCT00475059|Drug|cimetidine arrow|patients who received cimétidine
75705707|NCT02351791|Other|Patch 5|Patch 5:standard adhesive with buffer in sleeve
75705708|NCT02351791|Other|Patch 6|Patch 6:standard adhesive with buffer mixture in sleeve
76023143|NCT04344587|Other|Self-prone position recommendation|"The Qualtrics self-prone position recommendation intervention website will include the following sections:~Welcome message~Educational review of the potential benefits of prone positioning~How-To guide to safely prone in a hospital bed~A recommendation to prone while lying in bed (4 times for 1-2 hours each during the day and at night every 24 hours).~A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
75386385|NCT00002549|Procedure|autologous bone marrow transplantation|
75386386|NCT00002549|Procedure|peripheral blood stem cell transplantation|
75386387|NCT00002549|Radiation|radiation therapy|
76023144|NCT04344587|Other|Usual care|"The Qualtrics usual care website will include the following sections:~Welcome message~A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
75705709|NCT02306174|Behavioral|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|"The group sessions consists of 20 classes, each lasting approximately 90 minutes and may consist of some or all of the following:~A group agreement and a confidentiality contract~Homework assignments~Viewing informational videos about hoarding~Behavioral experiments including sorting and discarding exercises~Non-acquisition exposures~This course is based on the Manual Cognitive Rehabilitation and Exposure/Sorting Therapy for Compulsive Hoarding (Ayers et al., 2014)."
76023145|NCT02399137|Drug|MM-141|
76023146|NCT02399137|Drug|Placebo|
76023147|NCT02399137|Drug|Gemcitabine|
76023148|NCT02399137|Drug|Nab-Paclitaxel|
75542064|NCT04544605|Other|Individualized-Chinese herbal medicine|"I. Lung and spleen qi deficiency syndrome Clinical manifestations: shortness of breath, fatigue, fatigue, anorexia, nausea, fullness, weak stool, and uneasiness. The tongue is pale and greasy. Recommended prescription: French Pinellia 9g, Chenpi 10g, Codonopsis 15g, Sunburn Astragalus 30g, Stir-fried Atractylodes 10g, Poria 15g, Huoxiang 10g, Amomum villosum 6g (later), and Licorice 6g~II. Qi and Yin deficiency syndrome Clinical manifestations: fatigue, shortness of breath, dry mouth, thirst, palpitations, sweating, poor appetite, low or no lever, dry cough and little sputum; dry tongue, fine or weak pulses. Recommended prescription: North and south radix salviae 10g, 15g ophiopogonis, 6g American ginseng, 6g schisandra, 6g gypsum l5g, 10g light bamboo leaves, 10g mulberry leaves, 15g reed root, 15g salviae miltiorrhiza, 6g raw liquorice."
75386388|NCT05751785|Other|Physical Therapy|All participants may complete a PT program as standard of care (SOC) treatment addressing individual strength, mobility, and flexibility deficits in both proximal (e.g. spine and hip girdle) along with distal (thigh, leg, and foot/ankle) muscle groups. The provider may also use other modalities to address distal issues. To standardize the loading program, all participants will be given an at-home exercise program designed by Dr. Karin Sibernagel for progressive Achilles tendon loading. The participants will also follow the University of Delaware Return to Sport protocol for return to running. This will be completed alongside the standard of care PT participants will be receiving.
75386389|NCT05751785|Device|Shockwave Therapy|A medical provider will conduct SWT on study participants using the OrthoPlus Ultra 100. This Extracorporeal Pressure Activation Treatment device will be used at a radial shockwave of 3000 counts treatment settings of 15 Hz minimum 2 bars with a focus applicator head at mid-portion of Achilles using clinical focusing technique, and 3000 counts at 15 Hz minimum 2.5 bars using broad oscillator to myotendinous region and over symptomatic areas of gastrocnemius and soleus, treatment will be applied distally to proximally to facilitate lymphatic return adjusting treatment air pressure and amount of force applied by applicator head by patient comfort. The maximum setting for each treatment applicator will be 4 bars of air pressure, and the first 500 counts using each applicator will be applied at 1.5 bars to help desensitize the tissue prior to increasing energy settings. The settings used for each participant will be recorded and followed in a similar approach to treatment.
75869014|NCT05887817|Drug|Finerenone|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
75542065|NCT04540237|Diagnostic Test|Flow-cytometric analysis|Flow-cytometric analysis of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33
75542066|NCT02215447|Drug|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
75542067|NCT02215447|Drug|Carboplatin|
75542068|NCT00236990|Drug|pentosan polysulfate sodium|
75542069|NCT02215486|Other|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
75705710|NCT02020707|Biological|Bevacizumab|Given IV
76032309|NCT02672761|Behavioral|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
76032310|NCT02672761|Behavioral|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
76032311|NCT02672761|Behavioral|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
76032312|NCT02672761|Behavioral|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
75705711|NCT02020707|Other|Laboratory Biomarker Analysis|Correlative studies
75705712|NCT02020707|Drug|Nab-paclitaxel|Given IV
76032313|NCT04449913|Behavioral|10 days intensive meditation retreat|The intervention consists in a 10 days contemplative retreat, with 6 to 8 hours of sitting and walking meditation per day, and 1 or 2 hours of meditation teachings. The meditation practice will mainly train in mindfulness practice. Mindfulness meditation intends to train attention to detect and regulate afflictive cognitive and emotional patterns. Mindfulness practice requires skills involved in openness to experience, in monitoring the focus of attention and in detecting distraction, disengaging attention from the source of distraction, and flexibly (re)directing and engaging attention to the intended object. A brief introduction to loving-kindness and compassion meditation will also be present throughout the retreat.
75386390|NCT05751785|Device|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. The therapy is transmitted with a rolling glass massage ball at 10 Joules/cm^2 that is applied in a serpentine manner over the site of injury.
76032314|NCT04449913|Behavioral|Waiting for a 10 days intensive meditation retreat|At the time of measure, participants in this group are waiting to participate to the same meditation retreat as the active group. They may perform their own daily meditation practices as usual.
76032315|NCT04262869|Drug|Carboplatin|Given IV
75386391|NCT00002555|Drug|cisplatin|
76032316|NCT04262869|Biological|Durvalumab|Given IV
76032317|NCT04262869|Drug|Paclitaxel|Given IV
75386392|NCT00002555|Radiation|low-LET cobalt-60 gamma ray therapy|
75705713|NCT02020707|Other|Pharmacological Study|Correlative studies
75705714|NCT01814358|Dietary Supplement|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
76032318|NCT04262869|Drug|Pemetrexed|Given IV
76032319|NCT02628743|Drug|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
76032320|NCT05254613|Drug|ALXN1830|ALXN1830 will be administered as SC infusion(s).
75386393|NCT00002555|Radiation|low-LET electron therapy|
75386394|NCT00002555|Radiation|low-LET photon therapy|
75386395|NCT00002561|Biological|bleomycin sulfate|10 units/m2
75386396|NCT00002561|Drug|dacarbazine|375mg/m2
75386397|NCT00002561|Drug|doxorubicin hydrochloride|25mg/m2
76032321|NCT05254613|Drug|Placebo|Placebo will be administered as SC infusion(s).
75386398|NCT00002561|Drug|vinblastine|6mg/m2
75386399|NCT00002561|Radiation|radiation therapy|35Gy in 20 fractions (daily)
75386400|NCT05751707|Device|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System is a clinical device which consists in a pump which generates high frequency oscillations and connected to a jacket worn by the patient, intended to facilitate airway secretions clearance by detaching them from the bronchial wall and moving them upwards in the bronchial system.
75705715|NCT01814358|Dietary Supplement|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
75705716|NCT01714271|Behavioral|Home environs-based lifestyle counseling|Social learning theory-based behavior modification embedded in a social ecological framework is used to shape both the home environment and the lifestyle choices of the study participants to optimize their adherence to the Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans.
75386401|NCT05719649|Dietary Supplement|Lactic acid bacteria NTU 101|"One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks.~Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum."
75386402|NCT05719649|Dietary Supplement|Placebo|Maltodextrin was used as a placebo
75386403|NCT00002567|Biological|filgrastim|
75542070|NCT02215486|Other|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
75542071|NCT04540276|Drug|Inspiratory oxygen fraction|Median inspiratory oxygen fraction during general anesthesia
76032322|NCT05092165|Drug|Methylene Blue|1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
76032323|NCT05092165|Other|Control|Usual care during renal replacement therapy
75386404|NCT00002567|Drug|etoposide|
75386405|NCT00002567|Procedure|peripheral blood stem cell transplantation|
75386406|NCT00002567|Radiation|low-LET electron therapy|
75386407|NCT00002567|Radiation|low-LET photon therapy|
75386408|NCT00002579|Drug|CMF regimen|
75386409|NCT00002579|Drug|cyclophosphamide|
75386410|NCT00002579|Drug|fluorouracil|
75386411|NCT00002579|Drug|methotrexate|
75386412|NCT00002579|Drug|tamoxifen citrate|
75386413|NCT00002579|Procedure|conventional surgery|
75705717|NCT01714271|Behavioral|Cancer early detection|Conventional health education is used to increase study participant knowledge of practical strategies for detecting and treating common cancers early, before cancers have metastasized. Additional instruction is devoted to the biology and physiology of the cancer process. Although some mention will be made of the importance of maintaining a healthy weight for minimizing lifetime risk of certain cancers, most of the focus will be on episodic cancer screening, e.g., mammograms, PAP smears, colonoscopies, etc. for prevention of death from cancer.
75705718|NCT01683877|Procedure|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
76032324|NCT04682821|Other|Artificial intelligence assistant system|The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
75386414|NCT00002579|Radiation|radiation therapy|
75386415|NCT00002585|Drug|pyrazoloacridine|
75386416|NCT00382187|Biological|MF59 adjuvanted H5N1 influenza vaccine|"MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~non-adjuvanted influenza vaccine containing 15 ug of H5N1"
75386417|NCT00002609|Biological|lintuzumab|
75386418|NCT00002609|Drug|cytarabine|
75386419|NCT00002609|Drug|idarubicin|
75705719|NCT01683877|Procedure|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
75705720|NCT01632436|Drug|Pixantrone|Experimental Drug
75869015|NCT05887817|Drug|Placebo|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
75869016|NCT05886491|Drug|GDX012|GDX012 suspension for IV infusion.
75869017|NCT05886491|Drug|Chemotherapy Agents|Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
76032325|NCT03062813|Drug|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
75705721|NCT01594047|Drug|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
76032326|NCT03062813|Drug|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
75705722|NCT01594047|Drug|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
75705723|NCT01532609|Behavioral|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
75705724|NCT01519349|Biological|rAAV1.CMV.huFollistatin344|"First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"
75705725|NCT01496313|Drug|300mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
75705726|NCT01496313|Drug|150mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) [OR 300 reduced to 200mg/day if dose was increased at unblinding.] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
75705727|NCT01298323|Behavioral|Patient outreach|Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
75869018|NCT05883826|Behavioral|sexual health training|The 16-hour sexual health training will be given for 4 weeks. Case discussions using the PLISSIT Model will be held in the training content.
76032327|NCT05088577|Dietary Supplement|Whole egg|Daily consumption of two whole eggs during 8 weeks
76032328|NCT05088577|Dietary Supplement|Annatto-enriched egg|Daily consumption of two whole eggs enriched with annatto during 8 weeks
75386420|NCT05751395|Device|Central Venous Access|"Critically ill patients in severe MODS need a CVC and in some cases also a second line for e-g- blood purification techniques.~All CVCs are positioned via the ECG method with the CVC tip placed at P-max. Within 24 h a chest radiograph is obtained for assessment of the CVCs, especially their tips."
75386421|NCT00002615|Drug|cisplatin|
75386422|NCT00002615|Drug|epirubicin hydrochloride|
75705728|NCT01298323|Drug|Vandetanib|Treatment 300mg vandetanib opel label.
75869019|NCT05882110|Procedure|Cultured autologous epidermal cell membrane|The cultured autologous epidermal cell membrane is made from the patient's autologous epidermal cells by in vitro rapid expansion and culture technology, which has good biocompatibility, non-toxic, non-teratogenic, can reduce the skin area cut by traditional autologous skin grafting methods, and has high proliferative activity to promote wound repair and regeneration.
75869020|NCT05870150|Biological|Salmonella Typhimurium|Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10^3 CFU, 1-5x10^4 CFU, 1-5x10^5 CFU, 1-5x10^6 CFU)
75705729|NCT01268579|Drug|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
75869021|NCT05866419|Device|ThecaFlex DRx System|The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
75869022|NCT05860296|Drug|SLC-391|SLC-391 is an AXL inhibitor
75386423|NCT00002615|Drug|fluorouracil|
75386424|NCT00002615|Procedure|conventional surgery|
75386425|NCT05680103|Radiation|lateral cephalometry|lateral x-ray beam to capture lateral cephalometry of patients
75386426|NCT00002621|Biological|recombinant interferon alfa|
75386427|NCT00002627|Biological|filgrastim|
75386428|NCT00002627|Drug|carboplatin|
75386429|NCT00002627|Drug|cyclophosphamide|
75386430|NCT00002627|Drug|mesna|
75386431|NCT00002627|Drug|paclitaxel|
75386432|NCT00002627|Procedure|peripheral blood stem cell transplantation|
75386433|NCT00002633|Drug|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
75705730|NCT01165632|Procedure|biopsy|Correlative studies
75869023|NCT05860296|Biological|Pembrolizumab|Immunotherapy
76032329|NCT05088577|Dietary Supplement|Egg whites - Control|Daily consumption of two eggs whites during 8 weeks
75869024|NCT05859009|Procedure|EUS-Guided Therapy of Glue and Coil|This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.
75386434|NCT00002633|Drug|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
75386435|NCT00002633|Drug|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
75705731|NCT01165632|Procedure|computed tomography|Undergo computed tomography
75869025|NCT05859009|Drug|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
76032330|NCT04942327|Behavioral|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
75705732|NCT01165632|Procedure|therapeutic conventional surgery|Undergo stereotactic craniotomy
75705733|NCT01165632|Radiation|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
75386436|NCT00002633|Drug|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
75542072|NCT04544371|Device|gastric ultrasound|Focused gastric ultrasound was performed in semi-sitting position then right lateral position mindray curved transducer for examination of abdomen with low frequency (2-5 MHz) by a trained physician. The antrum of the stomach was located in the epigastrium after a sweep of the probe from left to right subcostal margins. This could be done using left lobe of liver as an anterior landmark and descending abdominal aorta as a posterior landmark
75542073|NCT04544371|Procedure|nasogastric tube insertion|Nasogastric tube (18-french) was inserted after induction of anaesthesia and endotracheal intubation. Aspiration of gastric contents was performed through gentle suction using 50 ml syringe with synchronous epigastric massage and gentle movement of nasogastric tube in and out for 10 minutes after confirmation of nasogastric tube position.
75542074|NCT00237068|Drug|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
75542075|NCT04539925|Other|Acute coronary syndrome|The effect of air pollution on acute coronary syndrome
75542076|NCT00269568|Drug|mifepristone and misoprostol|
75542077|NCT02215603|Behavioral|Breaking prolonged sitting with physical activity|
75542078|NCT04544215|Biological|Dosage 1 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (8.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
75542079|NCT04544215|Biological|Dosage 2 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (16.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
75542080|NCT04544215|Biological|No MPCs-derived exosomes|No aerosol inhalation of MPCs-derived exosomes
75869026|NCT05858008|Behavioral|Time-restricted eating|Subjects will be educated about the health benefits of time-restricted eating. Each subject will self-select a 10-hour (10hr +/- 1 hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily calories for the duration of the study.
75869027|NCT05849129|Drug|Ascorbic acid|High dose ascorbic acid delivered intravenously
75869028|NCT05849129|Other|Normal Saline|0.9% NaCl solution
75542081|NCT00237107|Procedure|Curretage|
75542082|NCT00262197|Behavioral|Customized Physician Intervention|
75542083|NCT00262197|Behavioral|Customized Patient Intervention|
75542084|NCT02215681|Device|acupuncture|
75705734|NCT01165632|Radiation|radiation therapy|Undergo radiation therapy
75705735|NCT01165632|Procedure|magnetic resonance imaging|Undergo magnetic resonance imaging
75705736|NCT01165632|Procedure|positron emission tomography|Undergo positron emission tomography
75705737|NCT01165632|Drug|fluorine F 18 fluorodopa|Given IV
75705738|NCT01056523|Drug|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
75705739|NCT01056523|Drug|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
75386437|NCT00002633|Drug|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
75386438|NCT00002633|Drug|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
75386439|NCT00002633|Procedure|orchiectomy|Optional orchiectomy
75386440|NCT00002633|Radiation|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
75386441|NCT00002639|Drug|chemotherapy|
75386442|NCT00002639|Drug|suramin|
75386443|NCT04659005|Other|Nurse-led decision counseling|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
75386444|NCT04659005|Other|Usual care|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises
75386445|NCT05751005|Dietary Supplement|Collagen Peptides vs. Placebo|Participants were randomized into one of three treatment groups.
75869029|NCT05849012|Other|Low Sulfur Diet|"Subjects will be placed on a low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
75386446|NCT00002657|Biological|bleomycin sulfate|5 mg/m^2
75869030|NCT05849012|Other|Usual Diet|"Subjects will continue on their usual diet for 8 weeks. At the end of 8 weeks, if participants are interested, they will be offered treatment with low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
75869031|NCT05848297|Device|Transcranial Doppler ultrasonography (TCD)|Portable, bedside, non-invasive diagnostic tool used for real-time assessment of cerebral hemodynamics
75386447|NCT00002657|Biological|recombinant interferon alfa|3.0 x 10^6 IU/m^2
75386448|NCT00002657|Drug|cyclophosphamide|650 mg/m^2
75386449|NCT00002657|Drug|cytarabine|300 mg/m^2
75386450|NCT00002657|Drug|doxorubicin hydrochloride|25 mg/m^2
75386451|NCT00002657|Drug|etoposide|120 mg/m^2
75386452|NCT00002657|Drug|methotrexate|120 mg/m^2
75386453|NCT00002657|Drug|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m^2.
75386454|NCT00002657|Drug|vincristine sulfate|1.4 mg/m^2
75386455|NCT00002657|Procedure|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
75386456|NCT00002657|Radiation|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
75386457|NCT05750927|Procedure|Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)|TAVI and PCI to be administered as per physician's indication and choice, in one or more stages
75386458|NCT05673785|Drug|Brentuximab Vedotin|Brentuximab vedotin IV infusion
75386459|NCT05673785|Drug|Cyclophosphamide|Cyclophosphamide IV infusion
75386460|NCT05673785|Drug|Doxorubicin|Doxorubicin IV infusion
75386461|NCT05673785|Drug|Prednisone|Prednisone tablets
75386462|NCT00381719|Drug|AGN 203818|3 mg Capsule twice daily for 4 weeks
75386463|NCT00381719|Drug|AGN 203818|20 mg Capsule twice daily for 4 weeks
76032331|NCT04601311|Behavioral|Guided self-determination|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.~A relative may take part in one session completing an analogue reflection sheet as preparation.~Participants continue usual care."
76032332|NCT04601311|Behavioral|Personal support in goal-pursuing|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.~Participants continue usual care."
76032333|NCT04582981|Drug|Fruquintinib and raltitrexed|Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
75386464|NCT00381719|Drug|AGN 203818|60 mg Capsule twice daily for 4 weeks
75386465|NCT00381719|Drug|placebo capsule|Capsule twice daily for 4 weeks
75386466|NCT05750771|Device|DES|Second-generation drug-eluting stents
75386467|NCT05750771|Device|DCB|Drug-coated balloon with paclitaxel as drug coating
75386468|NCT00381875|Biological|E1M184V peptide vaccine|
75386469|NCT00381875|Biological|incomplete Freund's adjuvant|
75386470|NCT00381875|Biological|sargramostim|
75386471|NCT00381875|Other|immunoenzyme technique|
75386472|NCT00002669|Biological|aldesleukin|
76032334|NCT04582981|Drug|Fruquintinib|Fruquintinib 5mg qd monotherapy
76032335|NCT03760627|Behavioral|Refugees Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
75386473|NCT00002669|Biological|recombinant interferon alfa|
75386474|NCT00002669|Drug|cisplatin|
75386475|NCT00002669|Drug|dacarbazine|
75386476|NCT05750693|Genetic|PIK3CA analysis|"PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations."
75386477|NCT00002675|Biological|filgrastim|
75386478|NCT00002675|Drug|carboplatin|
75386479|NCT00002675|Drug|cisplatin|
75386480|NCT00002675|Drug|cyclophosphamide|
75386481|NCT00002675|Drug|etoposide|
75386482|NCT00002675|Drug|mesna|
75386483|NCT00002675|Drug|vincristine sulfate|
75386484|NCT00002681|Biological|aldesleukin|
75386485|NCT00002681|Biological|daclizumab|
75386486|NCT02973113|Biological|EBVST Cells|EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
75386487|NCT02973113|Biological|Nivolumab|Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
75386488|NCT05665439|Radiation|radiation|radiation for patients with newly diagnosed bone metastases or patients with bone metastases after vertebroplasty
75386489|NCT05750615|Other|Uncertain what intervention will be co-created|Uncertain what intervention will be co-created
75386490|NCT00002687|Biological|aldesleukin|
75386491|NCT05750537|Behavioral|EMPACT-Us|A suite of tobacco cessation services supported by patient navigation designed in close partnership with patients, providers, and community stakeholders.
75386492|NCT00002693|Biological|filgrastim|
75386493|NCT00002693|Drug|carboplatin|
75386494|NCT00002693|Drug|topotecan hydrochloride|
75386495|NCT05750381|Other|Micrococcus luteus Blis Q24 balm|Balm formulation containing probiotic bacteria Micrococcus luteus Q24 for topical applications.
75386496|NCT05750381|Other|Placebo balm|Placebo balm formulation for topical applications.
75386497|NCT00002705|Drug|topotecan hydrochloride|
75386498|NCT00002711|Drug|chemotherapy|
75386499|NCT00002711|Drug|cisplatin|
75386500|NCT00002711|Drug|paclitaxel|
75386501|NCT00002711|Radiation|low-LET electron therapy|
75386502|NCT00002711|Radiation|low-LET photon therapy|
75386503|NCT00002717|Drug|cisplatin|
75386504|NCT00002717|Drug|paclitaxel|
75386505|NCT00002723|Drug|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
75386506|NCT00002723|Drug|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
75386507|NCT00002723|Drug|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
75386508|NCT05648123|Behavioral|Supportive Psychotherapy|Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
75869032|NCT05846659|Drug|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
75386509|NCT00002735|Drug|Induction chemotherapy|Cisplatin and 5-Fluorouracil
75386510|NCT00002735|Drug|cisplatin|Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
75386511|NCT00002735|Drug|fluorouracil|5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
75869033|NCT05846659|Drug|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
75869034|NCT05846659|Radiation|PULSAR|1st day of Cycles 1, 2 and 3.
76032336|NCT03760627|Behavioral|Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
76032337|NCT03579667|Behavioral|Diet intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
75869035|NCT05828342|Procedure|Endotracheal tube cuff inflation with the loss of resistance syringe method|The cuffs of the endotracheal tubes will be inflated with the epidural loss of resistance syringe, the syringe piston will be released, the syringe piston will be pushed back with oscillation, and then the cuff pressures will be measured and recorded with a cuff manometer (VBM Cuff Pressure Gauge) and an electronic injector that measures cuff pressure (AG Cufill). A three-way vein valve will be used when making this measurement. During the measurement, an epidural resistance loss injector will be attached to one valve, a cuff manometer attached to another valve, and an electronic injector (AG Cufill) measuring cuff pressure to the third track. With this technique, the possibility of leakage due to insertion and removal during measurements will be eliminated.
76032338|NCT03278821|Behavioral|Self Match|Video presentation of treatment option are shown to the patient whereafter the patient must choose between the five possible treatment options.
76032339|NCT03278821|Behavioral|Expert Match|Referral as usual to one of five possible treatment options. The referral is based on baseline data from the patient and by the means of an algorithm, used in daily clinical praxis.
76032340|NCT04873427|Genetic|clonal heterogeneity evaluation|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
75869036|NCT05819268|Behavioral|ReACT|ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.
75869037|NCT05819268|Behavioral|CATCH-IT|CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.
75386512|NCT00002735|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, every week for eight weeks
75386513|NCT00002747|Drug|cisplatin|
75386514|NCT00002747|Drug|fluorouracil|
75386515|NCT00002747|Procedure|conventional surgery|
75386516|NCT00002747|Radiation|low-LET cobalt-60 gamma ray therapy|
75386517|NCT00002747|Radiation|low-LET photon therapy|
75386518|NCT02973035|Drug|Amlodipine|
75386519|NCT02973035|Drug|Valsartan|
75386520|NCT05749991|Device|Dryshield|"DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)"
75386521|NCT05749991|Device|Cotton roll isolation|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
75386522|NCT00002753|Radiation|iodine I 131 monoclonal antibody 81C6|
75386523|NCT00002759|Drug|cyclosporine|
75386524|NCT00002759|Drug|irinotecan hydrochloride|
75705740|NCT00579878|Drug|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
75705741|NCT00579878|Drug|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
75705742|NCT00579878|Drug|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
75705743|NCT00554788|Procedure|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
75705744|NCT00554788|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
75705745|NCT00554788|Drug|Carboplatin|Given IV
75705746|NCT00554788|Drug|Cisplatin|Given IV
75705747|NCT00554788|Drug|Cyclophosphamide|Given IV
75705748|NCT00554788|Drug|Etoposide|Given IV
75386525|NCT00002759|Drug|phenobarbital|
75386526|NCT00002765|Biological|LMB-2 immunotoxin|
75705749|NCT00554788|Biological|Filgrastim|Given SC
75386527|NCT00002771|Biological|recombinant interferon alfa|
75386528|NCT00002771|Drug|busulfan|
75386529|NCT00002771|Drug|cytarabine|
75386530|NCT00002771|Drug|hydroxyurea|
75386531|NCT00002771|Drug|idarubicin|
75386532|NCT00002771|Procedure|allogeneic bone marrow transplantation|
75386533|NCT00002771|Procedure|autologous bone marrow transplantation|
75386534|NCT00002771|Procedure|peripheral blood stem cell transplantation|
75386535|NCT00002771|Radiation|radiation therapy|
75386536|NCT00002777|Drug|exemestane|
75386537|NCT00002777|Drug|tamoxifen citrate|
75542085|NCT00237146|Drug|Zoledronic acid|
75705750|NCT00554788|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
75705751|NCT00554788|Radiation|Radiation Therapy|Undergo radiotherapy
75705752|NCT00554788|Drug|Thiotepa|Given IV
75705753|NCT00554788|Drug|Vincristine Sulfate|Given IV
75705754|NCT00431288|Behavioral|diet high in fruits, vegetables, and dairy|
75705755|NCT00431288|Other|Routine nutrition care|
75705756|NCT00410761|Drug|ZD6474 (Vandetanib)|once daily oral tablet
75705757|NCT00138216|Drug|irinotecan hydrochloride|
75705758|NCT00138216|Drug|temozolomide|
75705759|NCT00138216|Drug|vincristine sulfate|
75705760|NCT03548103|Dietary Supplement|Green tea extract|Green tea extract 500 mg tid for 16 weeks
75869038|NCT05816590|Other|Med@HOME Mobile App|Meds@HOME is a software application designed for use on a personal mobile device. The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly). Optional push notifications can be set so that users are alerted to an upcoming routine. Only primary caregivers can create, edit, and delete routines. All caregivers can check off on routines and receive notifications. Caregivers can also post notes related to routines or events. App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
75869039|NCT05814536|Drug|AB-218 capsule|Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.
75869040|NCT05812911|Procedure|Standard oxygen|"Standard oxygen therapy administered through a Venturi mask allowing a fraction of inspired oxygen (FiO2) setting to maintain a peripheral oxygen saturation (SpO2) ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
75705761|NCT03548103|Dietary Supplement|Placebo|Placebo tid for 16 weeks
75705762|NCT03542760|Drug|Methylene Blue|Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
75705763|NCT03513653|Diagnostic Test|Echocardiography with speckle-tracking imaging|"Measurement of left ventricular ejection fraction and global longitudinal strain~Measurement of left atrial reservoir strain (peak atrial longitudinal strain)~Measurement of right ventricular global longitudinal strain"
75705764|NCT03503643|Device|Hemigland Cryoablation|Hemigland cryoablation for the treatment of prostate cancer
75705765|NCT03496792|Other|Tilt + external pressure|In Visit 1, the anti-shock trousers will be inflated to 20, 40, or 60 mmHg. BP will be measured 3 times from the brachial artery. Then the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals. The tilt table is returned to 0o and the resting supine baseline BP will be collected. Then, the anti-shock trousers will be inflated to a different pressure (20, 40, or 60 mmHg) and the head up tilt will be repeated. Repetitions at the various pressures will be performed in a random order with suitable resting intervals in between the tilting bouts.
75705766|NCT03496792|Other|Tilt + no external pressure.|In Visit 1, the anti-shock trousers will NOT be inflated. Auscultatory BP will be measured 3 times from the brachial artery. Thereafter, the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals.
75869041|NCT05812911|Procedure|HFNO|"The oxygen therapy will be administered in a semi-sitting position, with a setting of the FiO2 and the oxygen flow rate, to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
75869042|NCT05812911|Procedure|NIV|"Systematic application of NIV using two levels of pressure, pressure support (PS) + positive end-expiratory pressure (PEEP) provided using a dedicated NIV ventilator or a standard ICU ventilator with the  NIV module  through a facial mask. The FiO2 will be set to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
75386538|NCT04611035|Device|QPOP|QPOP will then be applied to establish the most efficacious drug combination for the specific organoid. Additional drugs other than those listed above may be screened depending on availability of cancer organoids. When patients progress after first-line treatment, QPOP generated second-line options will be informed to treating physicians and the physician will exercise his/her discretion to select the most suitable drug based on patient's comorbidities and organ function after a formal molecular/phenotype tumour board.
75386539|NCT00002783|Drug|cisplatin|
75386540|NCT00002783|Drug|floxuridine|
75386541|NCT00002783|Drug|fluorouracil|
75386542|NCT00002783|Drug|leucovorin calcium|
75386543|NCT00002783|Procedure|conventional surgery|
75386544|NCT05749757|Device|Acupuncture|For Shangyitang acupoint, the needle will be inserted towards the direction of nasal tip horizontally to a depth of 10-20mm without any manipulation, and a pad will be adhered afterwards. For other acupoints, the needles will be inserted through adhesive pads to 10-20mm. Needles will be lifted, thrust, and twirled for 3 times to achieve deqi sensation, and will be manipulated every ten minutes during 30-minute maintenance.
75386545|NCT05749757|Device|Sham Acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
75386546|NCT00002789|Drug|busulfan|
75386547|NCT00002789|Drug|cyclophosphamide|
75386548|NCT00002789|Drug|cyclosporine|
75386549|NCT00002789|Drug|methotrexate|
75386550|NCT00002789|Procedure|allogeneic bone marrow transplantation|
75386551|NCT00002789|Procedure|peripheral blood stem cell transplantation|
75386552|NCT00381953|Drug|Peginterferon alfa-2a|
75386553|NCT00381953|Drug|Interferon alfa-2a|
75386554|NCT00381953|Drug|Ribavirin|
75386555|NCT05749523|Behavioral|Exercise|Exercise vs non-exercise
75386556|NCT05613881|Other|Education and Telephone Follow-up|The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
75386557|NCT00382343|Drug|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
75705767|NCT03496792|Other|Limb occlusion + negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. After the cuff is inflated to 250 mmHg, the pressure in the tank will be reduced to -100mmHg for 2 minutes. The application of negative pressure creates a suction effect on the leg, and leads to an overall increase in pressure gradient across the blood vessel wall and induces vascular distension.
75386558|NCT05749445|Drug|Nirmatrelvir-Ritonavir|Nirmatrelvir-Ritonavir
75386559|NCT05749367|Drug|Ropivacaine + saline solution|SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
75705768|NCT03496792|Other|Limb occlusion + no negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. The cuff is inflated to 250 mmHg for 2 minutes, but the pressure in the tank is not changed.
75705769|NCT03487224|Device|MRI with fMRI frequency|Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
76032341|NCT04862741|Drug|NX-13 250mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
75386560|NCT05749367|Drug|Saline solution + Ropivacaine|SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
75386561|NCT05502887|Diagnostic Test|Sublingual in vivo microscopy with the Glycocheck microscope|For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
75386562|NCT05749289|Drug|Al18F-octreotide|Al18F-octreotide I was injected into the patients before the PET/CT scans
75705770|NCT03477292|Drug|Duration of antibiotic|Duration of antibiotic for treatment of VAP
75386563|NCT05501249|Behavioral|Aquatic Integrated Cognitive Motor Training|Aquatic exercise class with focus on cognitive and physical exercise
75705771|NCT03471650|Drug|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
76032342|NCT04862741|Drug|NX-13 500mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
75386564|NCT05749133|Biological|Anti-GPRC5D CAR-T Cells Injection|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10^6/kg±20%; Low dose group: 3.0×10^6/kg±20%; High dose group: 6.0×10^6/kg±20%. Dose was weight-based."
75386565|NCT04331171|Device|Web application users|questionnaire of comorbidity and symptoms completed by the patient on his smartphone
76032343|NCT04862741|Drug|NX-13 500mg MR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
75705772|NCT03465540|Drug|AMG 397|AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
75869043|NCT05807204|Dietary Supplement|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
75869044|NCT05807204|Dietary Supplement|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
76032344|NCT04862741|Drug|Placebo|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
76032345|NCT04683055|Procedure|Phacoemulsification combined with trabeculectomy|Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
75542086|NCT04544137|Behavioral|BOKS|BOKS is an evidence-based physical activity program developed by Reebok to get kids active and establish a lifelong commitment to health and fitness. It was originally developed and tested as a 12-week program offered before or after school. In the present study, BOKS will be offered four days per week for eight weeks over the summer at a public park in one low-income community. The program will run one-hour prior to lunch service by the USDA's Summer Food Service Program. The BOKS curriculum includes lesson plans for 40-45 minute classes that follow the same daily format and focus on a functional fitness skill of the week (squat, plank, push up, etc) and engage participants in team-oriented games.
76032346|NCT04683055|Procedure|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
76032347|NCT02508493|Other|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST)~Choice Reaction Time (CRT)~One-back working memory tool~Trail Making Test B (TMT-B)~Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
76032348|NCT02508493|Other|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:~Digit Symbol Substitution Test (DSST)~Trail Making Test B (TMT-B)~Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~Variant of Choice Reaction Time (CRT)~Variant of the One-back working memory tool"
76032349|NCT04613089|Other|Natural History|Natural History and Clinical Follow Up.
75542087|NCT04544059|Drug|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 [capped at 2.0 mg], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
75542088|NCT00269607|Drug|Implantation of naltrexone implants|
75542089|NCT04544176|Other|Observational|There will be no interventions in this study, it is purely observational using data already collected.
75542090|NCT04539769|Procedure|conventional BI|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.
75542091|NCT04539769|Procedure|long-limb BII|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.
75705773|NCT03465540|Drug|Dexamethasone|Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
75705774|NCT03465540|Drug|Azacitidine|Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
75705775|NCT03462316|Biological|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
75705776|NCT03437798|Other|Disease status|Women who reported periodontal disease diagnosis/condition
75386566|NCT05590481|Device|TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION|The electrodes will be surface (silicone rubber and carbonate), brand Quark®, with dimensions of 5 cm by 3 cm, coupled with conductive gel and fixed to the volunteer's skin with micropore tape. For the placement of the electrodes, the volunteer will be positioned in the horizontal supine position on the stretcher, with the knee in semiflexion and the head supported on a pillow. The electrodes will be positioned one immediately posterior to the medial malleolus of the ankle and the other approximately 10 cm above it, both fixed with micropore tape, on both legs of the patient. To ensure that the electrodes stimulate the tibial nerve, a transcutaneous electrical nerve stimulation (TENS) current with a frequency of 1 Hz will first be applied, with a gradual increase in intensity, to verify a rhythmic movement of flexion of the hallux. The following parameters will be used for TTNS: frequency 10Hz (Hertz), pulse duration 200 μs (microseconds), for 30 minutes.
75386567|NCT05590481|Behavioral|behavioral therapy protocol|submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
75705777|NCT03420404|Other|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
75705778|NCT03368547|Procedure|Computed Tomography|Undergo PET/CT scan
75386568|NCT05490017|Drug|KP104|Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
75386569|NCT05490017|Drug|Placebo|Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
75542092|NCT04539769|Procedure|long-limb RY group|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.
75542093|NCT00237224|Drug|Letrozole|
75386570|NCT05748977|Drug|SABA SAMA ICS Vs LABA LAMA ICs|Short acting agents,long acting agents ,ics
75386571|NCT02972957|Biological|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
75705779|NCT03368547|Radiation|Gallium Ga 68 Gozetotide|Given IV
75705780|NCT03368547|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75705781|NCT03338309|Other|Instantaneous wave-free ratio measurement|Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
75705782|NCT03336931|Diagnostic Test|Molecular profiling and drug testing|"Laboratory analysis including:~A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~Multi-disciplinary Tumour Board case discussion~Recommendation of personalised therapy"
75386572|NCT02972957|Drug|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
75386573|NCT05748899|Behavioral|Ujjayi pranayama|this group will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
75386574|NCT05446259|Other|Standard clinical care procedures and outcome measurements.|Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
75386575|NCT05748743|Procedure|glove changing|Surgical gloves were changed prior to abdominal closure during Cesarean section to evaluate its effectiveness in reducing wound complications after surgery
75386576|NCT05471141|Other|Cognition ECHO|Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
75705783|NCT03319407|Device|EPAD monitoring system|EPAD system will be used as part of routine care
75705784|NCT03306706|Dietary Supplement|Whole pea muffins|2 muffins containing whole peas
75705785|NCT03306706|Dietary Supplement|Split pea muffins|2 muffins containing split peas
75386577|NCT05469191|Other|Group 5 STS|"For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
75386578|NCT05469191|Other|Group 10 STS|"For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
75542094|NCT04543747|Device|HeartWare Ventricular Assist Device|The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
75542095|NCT04539847|Device|High-end hearing aid|hearing aid with premium level of technology
75542096|NCT04539847|Device|Basic hearing aid|hearing aid with basic level of technology
75542097|NCT00262236|Drug|Aliskiren|
75705786|NCT03306706|Dietary Supplement|Wheat muffins|2 muffins containing wheat
75705787|NCT03270150|Device|BTL-899|BTL-899
75705788|NCT03262155|Biological|Blood test|
75705789|NCT03217227|Other|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
75869045|NCT05803785|Drug|BBC1501|BBC1501 solution for Intravitreal injection
75869046|NCT05803018|Drug|BL-B01D1|Administration by intravenous infusion
76023149|NCT05236205|Procedure|Caries removal with a lowspeed drill|"Initial periapical and interproximal radiographs;~Prophylaxis with toothbrush and fluoride toothpaste;~Relative isolation with lip bumper, cotton roll, and aspirator;~Microbiological sampling with ear curette for standardization of volume of carious tissue;~Removal of carious dentin with carbide burs and manual instruments;~Additional microbiological sampling;~Clinical inspection of texture of remaining dentin with an exploratory probe;~Restoration with glass ionomer cement (Ketac Molar Easy Mix - 3M ESPE);~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months."
75386579|NCT04571333|Device|Mi2000 Totally Implantable Cochlear Implant|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
75386580|NCT05545319|Drug|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to <60 mL/min) every 12 hours
75386581|NCT05545319|Drug|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
75542098|NCT04539886|Device|CellFX System|CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
75542099|NCT04539886|Device|Intralesional Electrodesiccation|Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
76032350|NCT05098639|Behavioral|BASICS|In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.
75542100|NCT04543981|Diagnostic Test|Diagnostic Criteria for Tempro-mandibular Disorders(DC/TMD)|diagnostic sheet include questions to be answered by the patients and others include examinations will be done by the investigator
75542101|NCT04543864|Device|Electric intraoral welding device|welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally
75386582|NCT05545319|Drug|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to <60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
75386583|NCT05446337|Other|Open-Ended Semi-Structured Interview|Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process
75386584|NCT05536427|Biological|IPM001|IPM001 will be used against tumor cells
75386585|NCT05526287|Other|Dual-Task Training|"Dual-task training sessions include; walking on treadmill for 10-30 minutes and half of this walking period participants will perform cognitive tasks, cognitive tasks will be repeated on tandem stance position and single leg stance position other half of the session consists of motor-motor dual task activities and gait training on firm and soft surfaces.~Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week."
75542102|NCT04543864|Device|casting|casting the metal framework
75869047|NCT05798104|Behavioral|Collaborative nurse-pharmacist counseling|At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
76032351|NCT05098639|Behavioral|Deviance Regulation Theory (DRT)|The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.
76032352|NCT04469179|Biological|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
76032353|NCT04469179|Other|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
76032354|NCT04437121|Other|Online Survey about Dietary and Lifestyle Habits|"An online survey was conducted in a random sample of families. Parents self-reported their child's and their own dietary and lifestyle habits, as well as information about their sociodemographic status.~The survey consisted of 70 questions in 3 sections."
75386586|NCT05526287|Other|Home Exercise Program|Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week.
75386587|NCT05523869|Drug|Intravitreal topotecan|Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.
75386588|NCT05523869|Procedure|Pars plana vitrectomy with or without scleral buckle|Standard three-port pars plana vitrectomy with or without scleral buckle.
75542103|NCT04539613|Drug|HPFSH & HMG|. Various gonadotropin preparations
75542104|NCT00269646|Behavioral|Low-carbohydrate and high-carbohydrate diets|Each subject will consume two different ad libitum diets, each for four weeks, with a 4-week washout period inbetween each diet.
75542105|NCT04543669|Biological|Adacel®|Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
75542106|NCT00237302|Drug|topiramate|
75542107|NCT04539691|Device|Magnet|Magnet or Sham is worn by subject in close proximity to their described maximum pain site
75542108|NCT02214940|Drug|BI 11634|
75542109|NCT02214940|Drug|Placebo|
75542110|NCT00262275|Drug|Aspirin, Clopidogrel|
75542111|NCT04539652|Drug|Experimental|Experimental group are treated with TenofoBell®
75542112|NCT02214979|Drug|Telmisartan/Ramipril|fixed dose combination tablet
75542113|NCT02214979|Drug|Telmisartan|
75542114|NCT02214979|Drug|Ramipril capsule|
75542115|NCT02214979|Drug|Ramipril tablet|
75542116|NCT00237341|Drug|fentanyl|
75542117|NCT04539496|Drug|XZP-3287|a small molecular, oral potent, selective CDK4/6 inhibitor
75705790|NCT03217227|Procedure|Cardiac Catheterization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries.~If there is no significant narrowing lesions, the interventionist may perform additional flow resistance measurements of the small vessels to further investigate the cause of angina"
76032355|NCT04531579|Drug|Valproic Acid Solution|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
76032356|NCT04531579|Drug|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
76032357|NCT04362085|Drug|Therapeutic Anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
76032358|NCT04354597|Drug|HCQ & AZ|Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
75386589|NCT05523557|Behavioral|Urban Training|1) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
75386590|NCT05522465|Drug|Prednisone|Prednisone 4mg/kg.d, d1-4
75386591|NCT05522465|Drug|Dexamethasone|Dexamethasone 0.6mg/kg.d, d1-4
75386592|NCT04428047|Drug|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
75386593|NCT05248061|Other|Group A|"Wand exercises; It will be applied to increase the normal range of motion of the joint. Exercises will be performed in the directions of shoulder flexion, abduction, external and internal rotation. Objects such as a round stick, walking stick and towel can be used to assist patients during exercise.~- *Pendulum (Codman) Exercises: These exercises will be applied in 90° flexion of the waist, with the healthy hand resting on a solid place, and turning the arm back and forth, to the sides, clockwise and counterclockwise with circular movements.~*Capsule stretching: Auto stretching (by the patient) will be applied to the posterior region of the shoulder (capsule), pectoralis minor and upper trapezius muscles.~*Isometric shoulder exercises Isometric exercises will be given in the directions of shoulder extension, abduction, external rotation and internal rotation."
75542118|NCT04539301|Diagnostic Test|Estimated anticoagulant level (conversion factor x anti-Xa activity)|Estimated anticoagulant level (conversion factor x anti-Xa activity)
75542119|NCT04539535|Other|General Movements Assessment on two different surfaces in infants with DS and typically infants on the same day|Different surface
75542120|NCT00237380|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
75542121|NCT04543708|Procedure|Incision drainage|"Oropharyngeal pre-anesthesia is performed with 10% xylocaine spray, then submucosal anesthesia of the anterior pillar of the tonsil is performed with 2 ml of Rapidocaine or Rapidocaine 1 or 2% adrenaline. A scalpel incision is made with the search for the abscess pocket with a crile. If pus is present, a NaCl / Betadine rinse is performed. A syringe puncture can help locate the abscess if needed. The duration is approximately 15 minutes.~If no purulent pouch is found, the procedure is completed with tonsillectomy under general anesthesia."
75705791|NCT03217227|Other|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
76032359|NCT03839459|Drug|Denosumab|120mg of Denosumab will be administered subcutaneously once every 4 weeks
76032360|NCT04413409|Procedure|Metastasectomy for the metastatic sites|patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy
75542122|NCT04543708|Procedure|Tonsillectomy|Under general anesthesia, in dorsal decubitus, an autostatic mouth opener is placed, an incision of the anterior pillar of the tonsil allows the opening of the capsular space, along which the entire tonsil is dissected until complete extraction, hemostasis is performed, then the patient is awakened. The duration is approximately 30 minutes.
76032361|NCT05375461|Drug|TQB3616 capsules|The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
76032362|NCT05375461|Drug|TQB3616-matching placebo|The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
75542123|NCT00262353|Device|Dialysis with different artificial devices|
75705792|NCT03217227|Diagnostic Test|I123 MIBG Scintigraphy (Optional)|"The test studies the cardiac sympathetic signalling that may help to identify patients with high risks of adverse events. The scan consists of 2 acquisitions of images 3-4 hours apart.~For this study, only patients without clinically significant lesions (diagnosed via the cardiac catetherisation and have normal FFR results) will undergo this test."
75705793|NCT03216798|Other|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
76032363|NCT05375461|Drug|Fluvestrin injection|Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
76032364|NCT05097781|Drug|PD-1 blocking antibody|All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
76032365|NCT05374213|Behavioral|Mindfulness-Based Intervention|Mindfulness practices use a non-stigmatizing approach, combining secularized eastern meditative practices with western psychological advances to improve stress-management and self-care. Participants learn to generate less distress, engage more positively and fully in their lives and experiences, and respond more adaptively to challenges instead of reacting in automatic and unhelpful ways.
75542124|NCT04539145|Device|Chocolate PTA Balloon|Chocolate PTA Balloon
75542125|NCT04539145|Device|conventional balloon angioplasty|conventional bal-loon angioplasty
76032366|NCT03062969|Procedure|Cleavage stage biopsy group|"intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~Time lapse embryo culture~Cleavage stage biopsy~aCGH analysis~Fresh euploid embryo transfer"
76032367|NCT03062969|Procedure|Trophectoderm biopsy group|"ICSI-IVF~Time lapse embryo culture~Day 3 zona pellucida opening~Trophectoderm biopsy~aCGH analysis~Frozen-thawed euploid embryo transfer"
76032368|NCT04245475|Behavioral|Virtual Reality psychological pain reduction|attention distraction
75557763|NCT00438425|Dietary Supplement|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
75705794|NCT03185455|Other|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
76032369|NCT05097547|Behavioral|Contingency Management|Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.
75386594|NCT05248061|Other|Group B|"The same exercises as in Group 1 will be suitable for the participants.~PRP will be applied in the first session and 2 weeks later. Exercises will be started 2 days after PRP application.~Up to 10 cc of blood will be taken from the PRP group patients by the nurse. 25 mL of venous blood will be collected from each patient at a time, using a syringe containing 2.5 mL of the anticoagulant citrate dextrose solution. After the blood taken is transferred to the special PRP kit and centrifuged for 8 minutes at 3000 rpm, in addition to the 5-6 cc platelet-rich plasma remaining in the upper part of the kit, the entire buffy coat is injected into the syringe from the region compatible with the posterior arthroscopy portal (inferior to the acromion posterolateral bone prominence) by the physician. next, from the end point of the posterior fibers of the deltoid muscle, targeting the subacromial space) will be applied. No buffering or activating agents will be used for PRP."
75386595|NCT05233865|Behavioral|Water exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur in a pool.
75705795|NCT03182075|Behavioral|Computerized Training|OCD participants will receive 14 sessions of training via computer within 3 weeks.
75705796|NCT03179969|Other|paravalvular leak|Observational study on patients with paravalvular leak
76032370|NCT03987139|Other|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
75705797|NCT03177044|Behavioral|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
76032371|NCT03987139|Other|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
76032372|NCT03987139|Other|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
76032373|NCT01117441|Drug|PEG-L-asparaginase|see detailed protocol description
76032374|NCT01117441|Drug|cyclophosphamide|see detailed protocol description
76032375|NCT01117441|Drug|cytarabine|see detailed protocol description
75557764|NCT00438425|Dietary Supplement|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
75705798|NCT03159923|Other|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
75705799|NCT03152903|Biological|VPM1002 (Recombinant BCG Vaccine)|"VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.~VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally."
75705800|NCT03152903|Other|Placebo|Single dose of Placebo is administered intradermally.
75705801|NCT03152890|Drug|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
76032376|NCT01117441|Drug|daunorubicin hydrochloride|see detailed protocol description
76032377|NCT01117441|Drug|dexamethasone|see detailed protocol description
75386596|NCT05233865|Behavioral|Land exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur on land.
75705802|NCT03148600|Behavioral|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
75705803|NCT03148600|Other|Standard arm|Standard medical and nursing care
75705804|NCT03141255|Device|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
75705805|NCT03141255|Device|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
75705806|NCT03139162|Other|Swiss RAI-HC assessment|RAI-HC assessments done by trained nurses in clinical routine
75705807|NCT03123029|Drug|Venetoclax|Venetoclax will be administered orally.
75386597|NCT05230277|Other|the active osteopathic treatment (AOT)|The AOT will first consist of the application of a visceral technique. The patient will lie on their stomach and the osteopath will touch the patient's abdomen with a wide two-handed grip. The action will consist of following the abdominal tissues in directions where tissue mobility is allowed and occurs without restriction, from the surface to the depth of the abdomen. A change in the elasticity of the colon will then be perceived when the mobility restrictions of the tissues are dissipated. The osteopath will then use a technique on the sacrum according toik-g the procedure described by Attali et al. [8] which consists in mobilizing the sacrum between the iliac bones.
75386598|NCT05230277|Other|the sham osteopathic treatment|For SOT, the patient will lie on their stomach and the osteopath will use a wide two-handed grip on the patient's abdomen to deliberately mobilize it in an imprecise manner. Next, a technique with no apparent therapeutic effects, the light touch, first described by Licciardone et al. [13] and proposed by others to perform simulated bone manipulations [14], will be applied to the sacrum
75386599|NCT04835675|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
75386600|NCT05218187|Device|G-EO End-Effector Gait Trainer|The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.
75386601|NCT05218187|Other|Conventional Physical Therapy Treatment|Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking
75386602|NCT05217953|Device|LovedBy App|The LovedBy solution aims to leverage modern technologies such as smartphones, continuous glucose monitors (CGM), and other smart wearables to assist young sufferers managing their condition. The LovedBy platform offers a mobile application which connects to the user's smart wearables and CGM to monitor data streams that have been linked to long term risk. The mobile application is then able to deliver personally relevant educational content to the user through numerous channels including private social media message
75386603|NCT05215691|Procedure|Group I: TAPA block|Postoperative analgesia will be provided with peripheral nerve block (TAPA)
75542126|NCT04543318|Procedure|Deep temporal nerves|"Surgical procedure:~Group A Exploration on the affected side a facelift-type incision will be performed, and an anterior subcutaneous flap is then will be lifted for several centimetres. In the inferior zygomatic region, the plane of elevation is deepened into the sub-SMAS plane and a composite flap elevated for several centimetres. Following elevation in this plane, the distal facial nerve branches will be identified. The distal portion of the zygomatic nerve is usually located midway between the oral commissure and the helical root. and was confirmed by nerve stimulator.~The deep temporal fascia and temporalis muscle will be incised along the temporal fusion line and will be reflected from the skull to expose the divisions of the deep temporal nerves and the longest branch was traced and prepared for anastomosis end to end with the zygomatic branch after confirming the eyelid supply."
75542127|NCT04543318|Procedure|massteric nerve|group B The same procedure as group A except tracing the masseteric nerve related to masseter muscle and anastomosis will be the same
75386604|NCT05215691|Procedure|Group II: IV Morphine|Postoperative analgesia will be provided with opioids
75542128|NCT00237419|Drug|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
75542129|NCT04539340|Biological|GNR-055|Single intravenous administration
75542130|NCT04539106|Drug|intravitreal injection of Ranibizumab|intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
75705808|NCT03091231|Diagnostic Test|mpUS multiparametric Ultrasound|compare the mpUS to other methods
76032378|NCT01117441|Drug|doxorubicin hydrochloride|see detailed protocol description
76032379|NCT01117441|Drug|etoposide|see detailed protocol description
75386605|NCT04831073|Procedure|Surgery on the ascending aorta with or without repair of the aortic root and/or aortic arch|Surgical repair of the ascending aorta with or without surgical repair of the aortic root and/or aortic arch
75386606|NCT05204147|Drug|Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A|Given IV
75386607|NCT05204147|Procedure|Biospecimen Collection|Correlative studies
75386608|NCT04824053|Dietary Supplement|Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
75705809|NCT03088579|Device|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
75386609|NCT04824053|Dietary Supplement|Conventional milk|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
75386610|NCT04824053|Dietary Supplement|Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
75386611|NCT04824053|Dietary Supplement|Conventional yogurt|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
75386612|NCT04824053|Dietary Supplement|Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
76023150|NCT05236205|Procedure|Partial removal of carious tissue with the administration of Papacarie™|"Initial radiographs;~Relative isolation;~Microbiological sample with otoscope curette to standardize volume of carious tissue;~Application of Papacarie™ for 5 m inutes, removal of carious tissue around lateral walls of the cavity with noncutting curette and no removal of carious tissue on pulp floor;~Second microbiological sample of remaining dentin with curette;~Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~Restoration with glass ionomer cement;~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
75386613|NCT04824053|Dietary Supplement|Conventional fresh cheese|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
75386614|NCT05190653|Other|Early palliative and supportive care|The intervention itself will be predominantly the provision of education and information. It is possible that patients in the intervention arm may receive treatment recommendations to help manage symptoms.
75386615|NCT04812197|Procedure|Biospecimen Collection(Punch Biopsy)|Punch Biopsy of Skin
75386616|NCT04811339|Drug|Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable|Pepto bismol (bismuth subsalicylate)
75386617|NCT04811339|Other|Placebo oral tablet without BSS|Placebo Tablet made by P & G to contain everything except active ingredient ( BSS)
75386618|NCT04804631|Device|Enteral feeding tubes|Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
75386619|NCT05173961|Other|Internet-Based Intervention|Use oncpatient mobile application
75386620|NCT05173961|Other|Survey Administration|Complete survey
75542131|NCT04543552|Device|Bladder scan|Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
75705810|NCT03088553|Drug|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
76032380|NCT01117441|Drug|ifosfamide|see detailed protocol description
76032381|NCT01117441|Drug|mercaptopurine|see detailed protocol description
76032382|NCT01117441|Drug|methotrexate|see detailed protocol description
76032383|NCT01117441|Drug|prednisone|see detailed protocol description
76032384|NCT01117441|Drug|thioguanine|see detailed protocol description
76032385|NCT01117441|Drug|vincristine sulfate|see detailed protocol description
76032386|NCT01117441|Drug|vindesine|see detailed protocol description
76032387|NCT01117441|Drug|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
76032388|NCT01117441|Drug|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
76032389|NCT01117441|Radiation|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
76032390|NCT04829123|Drug|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen
76032391|NCT04829123|Drug|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
76032392|NCT05177705|Behavioral|Restricted access task|In the restriction period participants will have their preferred (chosen after doing a preference task, including liking) food and similar alternatives restricted by their parent for 2 weeks. In the no restricted period, participants and their parents will be given several portions of the preferred food and will consume it throughout the two-week period.
76032393|NCT05177159|Other|The regional cerebral oxygen saturation (rSO2)|Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate
76032394|NCT05177159|Other|The glial fibrillary acidic protein (GFAP)|Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
75386621|NCT04790123|Procedure|Injection of autologous freshly collected adipose tissue|injection of fresh autologous fat, previously lipoaspirates from the patient's abdomen and centrifugated, into the fistulous tract, after curettage and closure of the internal opening.
75386622|NCT04790123|Procedure|sham|curettage and closure of the internal orifice of the anal fistula and simulated intervention in the abdomen.
75386623|NCT00382577|Drug|Itopride|
75386624|NCT00382577|Drug|Placebo|
75386625|NCT05406323|Behavioral|Web-Based Fall Prevention Program|"Health education: This intervention consisted of seven health issues which are Fall among elderly, fall risk factors,  fall prevention interventions-exercise,  fall prevention interventions-healthy diet,  fall prevention interventions- drug use, fall prevention interventions- vision, fear of falling.~Exercise: This intervention is the exercise that is a combination of balance and strengthening exercises (8 exercise). Participants will do the exercises at least three days a week (along 6 week).~Safe home environment: This intervention is aimed at providing a fall-safe home environment for the participants. In this context, the participants will watch the video on creating a safe home environment for falling. Participants will also be asked to answer the Home Safety Check Form for Falls to make their home more fall-proof. In this form, according to the answers given by the participants, suggestions will be given to prevent the risks of falling in the home environment."
75386626|NCT04331093|Drug|SHR-1210+Apatinib|"Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg~Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression"
75386627|NCT05142917|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
75705811|NCT03062085|Other|Cataract|The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
75705812|NCT03055897|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
76032395|NCT05177159|Other|The brain-derived-neurotrophic factor (BDNF)|Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
76032396|NCT03939949|Behavioral|High Mindfulness|"Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt."
76032397|NCT03939949|Behavioral|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time."
76032398|NCT03939949|Behavioral|Active Control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in."
76032399|NCT04434599|Device|Fluoroscopically guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by fluoroscopy
76032400|NCT04434599|Device|Contact force guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by contact force measurement and 3D electroanatomic mapping
75386628|NCT05142917|Behavioral|Hand motor task|Various type of hand motor tasks are applied to stroke patients.
75386629|NCT04760873|Device|cryotherapy|cryotherapy is a freeze spray that will be applied to GAVE for bleeding
75386630|NCT04758767|Drug|CID-103|anti-CD38 antibody
75386631|NCT05122637|Device|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.
75386632|NCT05122637|Device|Standard of Care Aspiration Thrombectomy System|Commercially available aspiration catheter with commercially available aspiration pump
75386634|NCT05120297|Drug|AK101|Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.
75386635|NCT05120297|Drug|Placebo|Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
75705813|NCT03055832|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
75705814|NCT03055832|Device|LipiFlow Pulsation System|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
75705815|NCT03052595|Diagnostic Test|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
75705816|NCT03052595|Diagnostic Test|Testing of autonomous nervous system function|Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
75705817|NCT03052595|Diagnostic Test|Stroop test|Stroop test will be used to test cognitive function
75705818|NCT03048877|Drug|Apatinib Oral Tablet|Apatinib Mesylate Tablets
75705819|NCT03048877|Drug|Placebo Oral Tablet|Placebo Oral Tablet
75386636|NCT05106881|Device|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
75386637|NCT04740359|Other|Functional training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The functional reach (forward-lateral-cross), trunk rotation exercises were performed in the sitting positions.(25min) Facilitation of trunk extension and elongation in the prone position (10 min). Thoracic mobilization on exercise ball (10min).
75386638|NCT04740359|Other|Routine training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The strengthening exercises were applied on the mat (3x10 for the first 4 weeks and 3x15 repetition for the last 4 weeks). Eyes open-closed perturbation training was performed for trunk control in sitting and standing positions (10 min.).
75386639|NCT05104541|Other|Weight loss|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
75386640|NCT05362097|Other|The reliability and validity of the Chinese version of CC-QoL|Cc-qol, LCQ, and VCD were repeated 1-2 times before and 1-13 weeks after treatment.
75386641|NCT00382421|Drug|bisoprolol|
75386642|NCT00382421|Drug|amlodipine|
75386643|NCT00382421|Drug|molsidomine|
75386644|NCT00382421|Drug|acetylsalicylic acid|
75386645|NCT04712825|Behavioral|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions during 6 weeks of treatment
75705820|NCT03032575|Behavioral|SEARCH010/RV254|
75705821|NCT02951351|Drug|Proparacaine|Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
75705822|NCT02951351|Procedure|Conjunctival culture|Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
75705823|NCT02940925|Other|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
75705824|NCT02940925|Other|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
75705825|NCT02915705|Biological|burosumab|solution for subcutaneous (SC) injection
75705826|NCT02915705|Drug|Oral Phosphate Supplement|oral tablet; oral solution; oral powder
76032401|NCT04434599|Device|Local impedance guide ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by local impedance measurement and ultra-high density 3D electroanatomic mapping
76032402|NCT01101451|Drug|Cisplatin|Given IV
76032403|NCT01101451|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
75386646|NCT04712825|Device|HypnoVR® device|HypnoVR® sessions during 6 weeks of treatment
75386647|NCT04713215|Other|Questionnaire|A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
75386648|NCT05087849|Biological|nonavalent human papillomavirus vaccine|Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
75557765|NCT00438425|Dietary Supplement|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
75557766|NCT00475098|Drug|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
75557767|NCT00438503|Procedure|Procedure|
75386649|NCT05075837|Biological|Virus -specific T cells|The product is obtained by leukapheresis of a family donor responsive to the virus: consists of virus- specific T lymphocytes (both CD4+ and CD8+) resuspended in PBS / EDTA buffer plus 0.5% Albumin Human. The productive process lasts two consecutive days and includes two phases: a brief activation with specific viral peptide followed by immunomagnetic separation using the CliniMACS® CCS (IFNγ) capture system which allows a fast and automated separation of IFNγ secreting lymphocytes
75386650|NCT05335811|Drug|4-[18F]Fluoro-1-Naphthol|By vein (IV)
75386651|NCT05068583|Other|Blood Draw|Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
75386652|NCT05057429|Device|Procellera Bioelectric Dressing|Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.
75386653|NCT05057429|Other|Standard Gauze Dressing|Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.
75386654|NCT05314751|Behavioral|Questionnaire and interview|An online survey and an in-depth interview.
75705827|NCT02915705|Drug|active vitamin D|tablet, oral solution
76032404|NCT01101451|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
76032405|NCT01101451|Other|Laboratory Biomarker Analysis|Correlative studies
76032406|NCT01101451|Other|Quality-of-Life Assessment|Ancillary studies
76032407|NCT01101451|Other|Questionnaire Administration|Ancillary studies
75386659|NCT05043701|Drug|Personalized drug combination|A personalized drug combination will be prescribed to each patient based on the functional drug screen
75386660|NCT05040581|Behavioral|1-Day CBT-Based Workshop for Preventing PPD|The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
75386661|NCT04281719|Other|Mobile Application (working name: Bright Path)|The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
75386662|NCT05034341|Other|Multimodal Prehabilitation|"In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free."
75386663|NCT05034341|Other|Standard Pre-Surgical Clinical Care|"Education related to preoperative activity and home-based exercise program.~Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment."
75386664|NCT04615325|Drug|RO7303359|RO730359 will be administered as a single intravitreal injection.
75386665|NCT05007509|Biological|COVID-19 vaccine HIPRA 10|One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
75386666|NCT05007509|Biological|COVID-19 vaccine HIPRA 20|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
75386667|NCT05007509|Biological|COVID-19 vaccine HIPRA 40|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg
75386668|NCT05007509|Biological|Commercial COVID-19 vaccine|One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
75386669|NCT00382499|Drug|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
75542132|NCT04543474|Other|Low Lactose Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
75705828|NCT02891278|Drug|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM."
76032408|NCT03064919|Behavioral|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
76032409|NCT03656627|Drug|Nivolumab|"Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level."
75705829|NCT02891278|Drug|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
75386670|NCT04330547|Drug|Analgesic administration|"Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~Level 2: Tramadol 50mg.~Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~Increase of a prior level 3 medication :~1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)"
75705830|NCT02891278|Procedure|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
75705831|NCT02843308|Behavioral|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
75705832|NCT02807181|Drug|Cisplatin-gemcitabine|Systemic chemotherapy
75386671|NCT04330547|Drug|Placebo administration|Folavit (folic acid, 0.4 mg)
75386672|NCT00382889|Drug|beclomethasone/salbutamol combination|
76032410|NCT04773665|Biological|VBI-2902a|VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
75386673|NCT00382889|Drug|beclomethasone|
75386674|NCT00382889|Drug|salbutamol|
75386675|NCT04972799|Other|injection of autologous fat at Day 0 and injection of saline at 6 months|injection into the intersphincter space
75386676|NCT04972799|Other|injection of saline at Day 0 and injection of autologous fat at 6 months|injection into the intersphincter space
75386677|NCT05273177|Other|Chronic ankle instability|Persistent condition of ankle instability after a first ankle sprain episode.
75386678|NCT04482959|Drug|Carbetocin|(1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin
75386679|NCT04482959|Drug|Sodium chloride 0.9%|Physiological solution will be used as placebo
75386680|NCT04571879|Drug|Nebulized Lidocaine|Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
75386681|NCT04571879|Drug|Intranasal Midazolam|Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
75386682|NCT04571879|Other|Placebo|Nebulized normal saline and intranasal normal sline
75386683|NCT04563533|Biological|Low-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 12.5μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 1 μg, sodium dihydrogen phosphate: 47 μg, disodium hydrogen phosphate: 87 μg."
75705833|NCT02807181|Device|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
75705834|NCT02768870|Device|Harpoon Artificial ePTFE Chords|It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
76032411|NCT04773665|Biological|Placebo|0.9% sodium chloride
75386684|NCT04563533|Biological|High-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 25μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg."
75386685|NCT04563533|Biological|Placebo (containing aluminum)|Active ingredients: none Other ingredients: aluminum hydroxide adjuvant: 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
75386686|NCT04563533|Biological|Placebo (without aluminum)|Active ingredients: none Other ingredients: L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
75386687|NCT04330937|Dietary Supplement|dietetics|90 days of consumption
75386688|NCT04939961|Dietary Supplement|Hericium erinaceus|6 capsules per day, 3 times two after breakfast, lunch and dinner
75386689|NCT04939961|Dietary Supplement|Placebo|6 capsules per day, 3 times two after breakfast, lunch and dinner
75386690|NCT04332107|Drug|Azithromycin|Participants will be shipped a single 1.2 g dose of oral azithromycin
75542133|NCT04543474|Other|Low FODMAP Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
76032412|NCT04773665|Biological|VBI-2905a|VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
75542134|NCT00237497|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
75542135|NCT00237497|Drug|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
75542136|NCT00237497|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
75542137|NCT00416130|Drug|Vorinostat|MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
76032413|NCT03064607|Other|Fluid collection|Fluids tested for biomarker S100beta
76032414|NCT04759703|Drug|Pramipexole|0.25 mg pramipexole tablets
76032415|NCT04759703|Drug|Placebo|Matching placebo tablets
76032416|NCT03595787|Procedure|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
75386691|NCT04332107|Drug|Placebos|Participants will be shipped a dose of matching placebo
75386692|NCT04328285|Drug|Hydroxychloroquine|Hydroxychloroquine Oral Tablets
75386693|NCT04328285|Drug|Placebo of Hydroxychloroquine|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets
75386694|NCT04328285|Drug|Lopinavir and ritonavir|LPV/r Oral Tablets
76032417|NCT05087407|Procedure|Decomprssion and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
76032418|NCT05087407|Procedure|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
75386695|NCT04328285|Drug|Placebo of LPV/r Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
75386696|NCT04308473|Other|Ultra-processed Food Meal|An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.
75542138|NCT04539028|Procedure|Emergency Abdominal surgery|Emergency Abdominal surgery
75542139|NCT04543084|Behavioral|Logbook|Participants will record practice in a logbook.
75542140|NCT00416169|Drug|galantamine hydrobromide|
75542141|NCT00237536|Drug|Lonidamine|
75542142|NCT04543240|Device|Integra™ dermal regeneration template|Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
76032419|NCT05086003|Combination Product|Combined kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation
75542143|NCT02215720|Drug|Cetuximab|
75705835|NCT02750618|Biological|Burosumab|solution for subcutaneous injection
75705836|NCT02616432|Device|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
75386697|NCT04308473|Other|Whole Food Meal|A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
76032420|NCT05084131|Other|Use of an online questionnaire as follow-up after abdominal colorectal surgery|Patients were asked to complete a questionnaire via the institutional patient portal. Participants were also asked to upload a photo of their respective incisions. Participants then had an in-person follow-up visit.
76032421|NCT05026801|Drug|Azithromycin plus hydroxychloroquine|All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
76032422|NCT03063047|Other|PD21871AA|A 100s size menthol cigarette.
75386698|NCT04911881|Drug|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
75386699|NCT04906187|Other|Arm A : intraoperative ANI monitoring of nociception|For the experimental group (arm A), the sufentanil doses are adjusted to maintain an ANI between 50 and 70. Morphine doses are adjusted from 0.05 to 0.05 µg / ml. Intraoperative data will be collected for ANI, TIVA and hemodynamics.
75542144|NCT02215720|Drug|Temsirolimus|
75542145|NCT02215759|Drug|BI 44370 TA|
75542146|NCT02215759|Drug|Placebo|
75705837|NCT02552823|Other|Group1|
75705838|NCT02552823|Other|Group2|
75705839|NCT02537431|Biological|burosumab|solution for subcutaneous injection
75705840|NCT02526160|Biological|burosumab|solution for SC injection
75705841|NCT02526160|Other|Placebo|saline solution for SC injection
76032423|NCT03063047|Other|PD21872AA|A 100s size menthol cigarette.
76032424|NCT05020795|Procedure|Endovascular thrombectomy|Clot retrieval for large vessel occlusion in acute ischaemic stroke
76032425|NCT03062735|Other|Inspiratory Muscle Training|The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
75386700|NCT04906187|Other|Arm B : no specific monitoring of nociception|For the control group (arm B), adjustments to the opioid doses are made in relation to the hemodynamic reactions of the patient and the operating times. Intraoperative data will be collected for TIVA and hemodynamics.
75386701|NCT04354493|Device|Myo-electric Gaming Interface|Non-significant risk, video game controller which maps myo-electric control signals to button presses.
75386702|NCT04299269|Other|Questionnaire|Questionnaire including questions about Quality of life, symptoms and general informations
75542147|NCT00416208|Drug|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
75542148|NCT02215798|Drug|Cymbalta|
75542149|NCT02215018|Drug|BI 44370 TA solution|
76032426|NCT03062735|Other|Sham Inspiratory Muscle Training|The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
75386703|NCT04903457|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
75386704|NCT04903457|Behavioral|Motor learning|Sequential finger tapping task training is applied to stroke patients.
75386705|NCT04874519|Behavioral|Questionnaire|The questionnaire will be completed at the time of enrollment, every month, and at the end of study. Regardless of current interventions or lack of, assessments will be completed at enrollment and then monthly for a total of 18 months. In order to provide reasonable flexibility to participants, physicians, and study teams, the assessments can be completed within 30 days of the last assessment. The next month will be recalculated based on last reporting date.
76032427|NCT03818659|Other|Self-Guided M.A.P. BP Improvement Program|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
76032428|NCT03818659|Other|Full Support M.A.P. BP Improvement Program|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
76032429|NCT03789877|Other|Physical Activity|Participate in home-based walking program
76032430|NCT03789877|Other|Questionnaire Administration|Ancillary studies
76032431|NCT03789877|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
76032432|NCT03789877|Procedure|Sham Intervention|Undergo sham rTMS
75386706|NCT04869995|Other|Interview|An individual semi-structured interview per surgeon, according to an interview guide.
75386707|NCT04263779|Behavioral|Order of Options|Relevant providers who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
75542150|NCT02215018|Drug|BI 44370 TA tablet|
75542151|NCT02215018|Drug|Placebo solution|
76032435|NCT03786991|Other|No intervention|No intervention
76032436|NCT05066009|Device|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. A unique custom mold is created employing a 3D printer to capture the geometry of a patients' ear and external auditory canal with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit, and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, and head and eye movements.
76032437|NCT05066009|Device|Ellcie Healthy eyeglasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
76032438|NCT05066009|Other|Drug Holiday|Participants will not take their prescribed wakefulness promoting medication(s) for one day to complete the study assessments. Medications typically used to promote wakefulness include amphetamine salts (Adderall), armodafinil (Nuvigil), clarithromycin (Biaxin), flumazenil, methylphenidate (Ritalin), and modafinil (Provigil).
76032439|NCT03943693|Device|Double shock|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized. If the first attempt with this approach fails to terminate atrial fibrillation a second attempt will be made using the same approach. If the second attempt fails the dual shock approach will be considered to have failed and further treatment will be determined by the primary team/attending cardiologist.
76032440|NCT03943693|Device|Single shock|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only. A repeat attempt will be made using the same approach if the initial shock fails. If the second attempt fails, the single shock approach will be considered to have failed. Patients will be crossed over to dual shock therapy while under the same sedation episode. For cross-over patients, two near-simultaneous 200-Joule shocks will be delivered through the two sets of pads already in position. If this fails further treatment will be determined by the primary team/attending cardiologist.
75705842|NCT02454543|Procedure|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
76032441|NCT03493061|Drug|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
76032442|NCT03493061|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
76032443|NCT03493061|Drug|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
76032444|NCT03410017|Other|Functional Listening Index|Functional Listening Index questionnaire to assess acquisition of listening skills.
76032445|NCT04110613|Dietary Supplement|noFast: Start tube feeds within 1 hour of procedure|Earliest possible initiation of tube feeding after bedside PEG tube procedure.
75386708|NCT04263779|Behavioral|Default Option|Both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. The optional P-SNF advantage video will be included and the link to it highlighted.
75386709|NCT04437095|Other|Psychological Support Based on Positive Suggestion delivered via pre-recorded MP3 message|Daily administration of audiorecording
75386710|NCT04418297|Drug|CT-G20|oral tablet
75705843|NCT02454543|Drug|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist."
75386711|NCT04418297|Drug|Placebo|oral tablet
75386712|NCT03575195|Drug|Rifaximin|Rifaximin 550mg orally
75386713|NCT03575195|Other|Placebo|Placebo control
75542152|NCT02215018|Drug|Placebo tablet|
75705844|NCT02430740|Drug|recFSH|
76032446|NCT03516877|Behavioral|Enhanced Stress Resilience Training for Faculty Physicians|Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
76032447|NCT04800523|Device|UroMonitor System|Implantable device to wirelessly and without catheters monitor the neurogenic bladder on an ambulatory basis
75542153|NCT02215837|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
75542154|NCT02215837|Biological|Ag-D-CIK|8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
75705845|NCT02384512|Drug|Azilect®|AZILECT® 1mg Tablets
75705846|NCT02366494|Drug|Bicalutamide|ANDROGEN BLOCKADE
75705847|NCT02366494|Drug|Leuprolide|ANDROGEN BLOCKADE
75705848|NCT02366494|Drug|Goserelin|ANDROGEN BLOCKADE
75705849|NCT02366494|Drug|Triptorelin|ANDROGEN BLOCKADE
75705850|NCT02366494|Drug|Docetaxel|Chemo hormonal therapy
75705851|NCT02366494|Drug|Abiraterone|Chemo hormonal therapy
75705852|NCT02366494|Drug|Apalutamide|Nonsteroidal antiandrogen medication
75705853|NCT02366494|Drug|Enzalutamide|Nonsteroidal antiandrogen medication
75705854|NCT02333136|Device|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
75705855|NCT02257229|Procedure|Surgical|Surgery only
75705856|NCT02257229|Procedure|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
76032448|NCT04654897|Drug|[14C]-NT-814|120 mg radioactive labeled elinzanetant ([14C]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) [14C].
76032449|NCT03236077|Behavioral|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
76032450|NCT04554043|Drug|SHR7280|treatment
75542155|NCT02215057|Drug|topical anesthesia|topical anesthetic drops and Group 2
75542156|NCT02215057|Drug|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
75542157|NCT00269685|Drug|vasopressin|
75705857|NCT02257229|Procedure|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
76032451|NCT04554043|Drug|Placebo oral tablet|blank control
75705858|NCT02244788|Device|SR™ PIP|
75705859|NCT02163577|Biological|burosumab|solution for SC injection
75705860|NCT02157610|Behavioral|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
76032452|NCT04523935|Other|Placebo|Fructose powder identical with the drugs was used
76032453|NCT04523935|Drug|Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.|Drugs were used either singly or in combination guided by clinical findings and investigations.
76032454|NCT05059301|Biological|RSVPreF3 OA investigational vaccine|One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
75869048|NCT05790837|Behavioral|"Computer prompt Stand up for your Health®"|"The intervention group consists on the implementation of a desktop application Stand up for your Health® computer prompt following the model proposed by the Guide to Physical Activity at Work (34). This app works by showing reminders and asking users to pause their work activity and take an active break. Pauses can be customized and programmed according to the user's preference, allowing control of the time of each pause, between pauses, and the possibility of delaying or interrupting the pause. In this study, the Stand up for your Health® app will be scheduled to appear every 60 minutes on the workers' computers and each break will last for 2 minutes. During this resting period, the worker will see a notice or reminder on their screen with a countdown clock. The application allows you to postpone or interrupt directions."
75869049|NCT05785039|Drug|BL-B01D1|Administration by intravenous infusion
75869050|NCT05780814|Behavioral|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The CBT-I intervention is a 6-session intervention spread out over 8 weeks that combines education and behavioral techniques to reduce insomnia.
75542158|NCT04710095|Behavioral|Brief Alcohol Intervention|Brief alcohol intervention uses a motivational interviewing approach and covers the following components: giving information about the possible health risks associated with alcohol use, placing the responsibility for change on the individual, discussing the reasons for drinking and downsides of drinking, and setting a goal and change plan if the participant is receptive.
75542159|NCT04710095|Behavioral|Control Condition|The attention-matched control condition consisting of a 30-min video about astronomy.
75705861|NCT02157610|Drug|Nicotine Patch|Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke >10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke <10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
75705862|NCT02157610|Behavioral|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
75705863|NCT02157610|Procedure|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
75869051|NCT05780814|Behavioral|Sleep Education Control (EDU)|Subjects will be instructed to read and review select publications from the American Academy of Sleep Medicine
75869052|NCT05776927|Drug|QVM149|QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®
75869053|NCT05776927|Drug|Salmeterol Xinafoate / Fluticasone Propionate|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
76032455|NCT03450473|Device|SurgiMend® MP|SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
76032456|NCT01938430|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
76032457|NCT01938430|Drug|RBV|RBV tablets administered orally in a divided daily dose
76032458|NCT01937884|Drug|Parenteral Nutrition|
76032459|NCT04625530|Drug|ferric carboxymaltose|Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.
76032460|NCT04625530|Drug|tranexamic acid|Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.
76032461|NCT04625530|Drug|ferric carboxymaltose and tranexamic acid|Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
75542160|NCT02215135|Drug|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
75705864|NCT02157610|Behavioral|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
75705865|NCT02157610|Drug|Nicotine lozenge|Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
75705866|NCT02078869|Drug|Progesterone in oil|Daily administration of 50 mg of IM Progesterone
76032462|NCT01916824|Drug|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
75705867|NCT02078869|Drug|vaginal progesterone suppositories|Vaginal Promterium 200 mg , 3 times a day
75705868|NCT01946815|Drug|Atorvastatin|Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
75705869|NCT01943318|Procedure|Liver biopsy|Histologic evaluation
75705870|NCT01943318|Device|Hepatic venous pressure gradient (HVPG) measurement|Hepatic venous pressure gradient (HVPG) measurement
75705871|NCT01937156|Drug|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
75705872|NCT01937156|Drug|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
75705873|NCT01821131|Other|muffin|
75705874|NCT01805804|Drug|placebo/valsartan|
75705875|NCT01718873|Drug|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
75705876|NCT01718873|Drug|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
75705877|NCT01718873|Drug|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
76032463|NCT01915732|Drug|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
75386714|NCT04391777|Other|Fourth ventricle compression technique (CV-4)|The participant is in the supine position and the principal investigator is seated at the patient's head, with elbows resting on the table. The main investigator overlaps his hands with the thenar eminences, contacting the occipital bone squamous part, between the external occipital protuberance and the participant's occipito-mastoid suture. The technique begins with a maintained compression on the occipital squamous part during a deep thorax exhalation. Throughout the compression of the occipital bone and the participant's voluntary inspirations, the principal investigator feels a gradual pressure increase at the thenar eminences. The technique will be performed until reaching the still point, in which the mobility of the occipital bone, respiratory rate and muscle tone decrease, or until 5 minutes elapsed.
75869054|NCT05776927|Drug|Placebo to QVM149|Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®
75386715|NCT04391777|Other|Sham|The main investigator uses the technique contact but does not perform any type of tissue traction or compression, maintaining this contact for 5 minutes. At the end of the stipulated time, the contact is removed in a subtle way.
75386716|NCT03481205|Device|Ischemic conditioning device|RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.
75869055|NCT05776927|Drug|Placebo to Salmeterol Xinafoate / Fluticasone Propionate|Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
75386717|NCT04159025|Device|CoreDx Pulmonary Mini-Forceps|Manufactured by Boston Scientific
75869056|NCT05776927|Drug|Run-In Medication|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
75869057|NCT05776927|Drug|Rescue Medication|Salbutamol 100μg / Albuterol 90μg
75869058|NCT05776927|Device|Concept 1 Device|Concept1 (Breezhaler) used for QVM149 and placebo delivery
75386718|NCT00002897|Drug|cisplatin|
75386719|NCT00002897|Drug|fluorouracil|
75386720|NCT00002897|Procedure|conventional surgery|
75386721|NCT03420209|Behavioral|Group applying PNF technique|
75386722|NCT00002903|Drug|docetaxel|
75386723|NCT03375203|Drug|Placebo|Matching placebo will be administered once daily based upon dosing group.
75869059|NCT05776927|Device|Girohaler|Girohaler for Comparator and Placebo delivery.
75386724|NCT03375203|Drug|JNJ-42847922, 5 mg|JNJ-42847922 will be administered as 5 mg (2*2.5 mg capsule) oral capsules once daily.
75705878|NCT01718873|Drug|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
75869060|NCT05759039|Procedure|Medial patellofemoral ligament reconstruction|Medial patellofemoral ligament reconstruction
75386725|NCT03375203|Drug|JNJ-42847922, 10 mg|JNJ-42847922 will be administered as 10 mg oral capsule once daily.
75705879|NCT01718873|Drug|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
75705880|NCT01511250|Biological|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
75869061|NCT05747924|Drug|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
75869062|NCT05747924|Drug|Placebo|Placebo will be administered via intravenous (IV) infusion
76023151|NCT05236205|Procedure|Partial removal of carious tissue with the administration of Papacarie™ and application of Bixa Orellana extract (20%)|"Initial radiographs;~Relative isolation;~Microbiological sample with otoscope curette to standardize volume of carious tissue;~Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes, removal of carious tissue around lateral walls of the cavity with noncutting curette;~Irradiation of dental tissue for 1 minute on a single point;~Second microbiological sample of remaining dentin with curette;~Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~Restoration with glass ionomer cement;~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
76032464|NCT01915732|Drug|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
75386726|NCT03375203|Drug|JNJ-42847922, 20 mg|JNJ-42847922 will be administered as 20 mg oral capsule once daily.
75386727|NCT03375203|Drug|Zolpidem|Zolpidem will be administered as 5 mg or 10 mg (2*5mg capsule) oral capsule once daily based upon the local labeling information.
75386728|NCT00002909|Drug|chemotherapy|
75386729|NCT00002909|Drug|oral sodium phenylbutyrate|
75386730|NCT00002915|Drug|penclomedine|
75386731|NCT00002921|Drug|suramin|
75386732|NCT00002921|Drug|therapeutic hydrocortisone|
75386733|NCT00383045|Drug|Buprenorphine/Subutex|
75386734|NCT00383045|Drug|Naltrexone|
75386735|NCT00383045|Procedure|Drug counseling|
75386736|NCT00383591|Biological|Hepatitis B adjuvanted vaccine|
75386737|NCT00383591|Biological|Engerix-B|
75386738|NCT00383669|Dietary Supplement|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
75386739|NCT00383669|Dietary Supplement|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
75386740|NCT00383825|Procedure|Anterior segment indocyanine green angiography|
75386741|NCT04062461|Other|Multifaceted strategy based on sending text messages(SMS)|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
75705881|NCT01511250|Biological|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
75386742|NCT04062461|Other|Usual outpatient care|Educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
75386743|NCT04329455|Procedure|Endoscopic thyroidectomy|Endoscopic thyroidectomy in Thyroid Nodules
75386744|NCT00002933|Drug|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
75386745|NCT00002939|Drug|irinotecan hydrochloride|
75386746|NCT00002939|Drug|paclitaxel|
75386747|NCT03151967|Drug|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
75386748|NCT03151967|Drug|Placebo|vaginal applicator with medium containing no drug
75542161|NCT04543123|Device|tDCS treatment|Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
75542162|NCT04543123|Drug|Antidepressant Drug(escitalopram)|Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
75705882|NCT01424566|Drug|Nabiximols|
75705883|NCT01424566|Drug|Placebo (GA-0034)|
75705884|NCT01367561|Drug|Naloxone|
75705885|NCT01367561|Drug|IV Methylnaltrexone (MNTX)|
75705886|NCT01367561|Drug|Placebo|
75705887|NCT01361607|Drug|Nabiximols|
75705888|NCT01361607|Drug|Placebo (GA-0034)|
75705889|NCT01337089|Drug|Nabiximols|
75705890|NCT01276587|Drug|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
75386749|NCT04226027|Behavioral|T2.coach|"T2.coach is a smartphone app for low-burden capture of diet and blood glucose (BG) levels and for reviewing past records, integrated with FitBit for captured of physical activity and sleep. All captured data are sent to the computational inference engine that uses machine learning methods and expert system to formulate personalized behavioral goals. Examples of behavioral goals include the following: For high carbohydrate breakfasts, reduce your carbs to be about 1 carb choice. Examples of 1 carb choice are 1 slice of whole wheat toast, 1 cup of oatmeal, or 1 apple. The T2.coach chatbot companion uses text messages to help individuals set goals that are consistent with evidence based guidelines for diabetes self-management, inferences on data captured with T2.coach, and their own preferences, as well as send individuals goal reminders and prompts for reflection on goal achievement."
75705891|NCT01217580|Drug|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
75705892|NCT01217580|Drug|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
75705893|NCT00981396|Behavioral|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
75705894|NCT00981396|Behavioral|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
75705895|NCT00802646|Drug|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
75705896|NCT00802646|Drug|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
75705897|NCT00473707|Procedure|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
75705898|NCT00473707|Procedure|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
75386750|NCT04009967|Drug|Pembrolizumab|Pembrolizumab 200 mg every three weeks for 3 cycles only
75386751|NCT03085823|Device|Sirolimus Coated Balloon|
75386752|NCT04000217|Behavioral|Written Exposure Therapy|In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
75386753|NCT04000217|Behavioral|Imaginal Exposure Therapy|Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
75705899|NCT00473707|Drug|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
75705900|NCT00473707|Drug|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
75869063|NCT05746247|Behavioral|Testing centralized referral mechanisms for PCPs|"For patients with a Penn PCP, we are testing the two different centralized referral mechanisms to increase the number of referrals to preventive cardiology (active choice vs default/opt out referrals)~For active choice: A non-interruptive In Basket alert will be delivered to PCPs that have patients that have been screened as positive with the FIND FH tool and recommends a referral to a lipid specialist. PCPs will have the choice of either accepting the referral or declining the referral. If they do not take action on the In Basket alert, the referral will stay in their In Basket.~For default/opt out: A non-interruptive In Basket alert will be delivered to PCPs that have patients that have been screened as positive with the FIND FH tool and recommends a referral to a lipid specialist. Not interacting with the BPA or accepting the BPA will indicate that the referral to a lipid specialist should be placed."
75869064|NCT05746247|Behavioral|Testing out patient outreach methods|Testing health care system mediated outreach vs Family Heart Foundation mediated outreach to see which type of outreach might be most effective at getting patients to schedule an appointment with a lipid specialist
75869065|NCT05741944|Other|Care with the use of PERSARC|PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options
75869066|NCT05741944|Other|standard care|All patients in control condition receive usual care.
75705901|NCT00279500|Device|Argus 16 Retinal Stimulation System|The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
75705902|NCT00233675|Drug|GABITRIL (tiagabine hydrochloride; CEP-6671)|
75386754|NCT00002945|Biological|aldesleukin|IV
75386755|NCT00002945|Biological|filgrastim|IV
75386756|NCT00002945|Drug|cyclophosphamide|IV
75386757|NCT00002945|Drug|cytarabine|IV
75386758|NCT00002945|Drug|etoposide|IV
75386759|NCT00002945|Drug|idarubicin|IV
75386760|NCT00002945|Drug|melphalan|IV
75386761|NCT00002945|Procedure|peripheral blood stem cell transplantation|IV
75386762|NCT00002945|Radiation|radiation therapy|delivered to the cancer cells
75386763|NCT00002951|Drug|fluorouracil|
75386764|NCT00002951|Drug|hydroxyurea|
75386765|NCT00002951|Procedure|surgical procedure|
75386766|NCT00002951|Radiation|radiation therapy|
75386767|NCT03075839|Other|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of two weeks
75542163|NCT04539418|Drug|Vitamin K 2|Patients will be monitored during the whole protocol.
75542164|NCT00269724|Drug|OROS® oxybutynin|
75869067|NCT05729659|Dietary Supplement|Sideritis Scardica (SidTea+) extract supplementation|1500 mg of Sideritis Scardica (SidTea+) extract per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
75705903|NCT00202774|Drug|(capecitabine, oxaliplatin, 5-fluorouracil)|
75869068|NCT05729659|Dietary Supplement|Placebo supplementation|1500 mg of placebo per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
75869069|NCT05725512|Drug|Prednisolone|Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
75869070|NCT05725512|Drug|Placebo|Placebo identical to prednisolone tablets
75869071|NCT05722561|Behavioral|Telehealth Motivational Counseling|At baseline, after randomization, participants will receive their first telehealth session (20~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, and 6), 15~20 minutes each.
75869072|NCT05722561|Drug|Nicotine Replacement Product|Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.
75869073|NCT05722561|Device|National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).|Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.
75705904|NCT00114530|Biological|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
75386768|NCT03058289|Drug|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.~The drug is stored frozen and must be dosed at room temperature.~The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area"
75386769|NCT03058289|Biological|anti-PD-1 antibody|The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
75386770|NCT03058289|Biological|anti-CTLA-4 antibody|The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
75386771|NCT00002963|Drug|aminolevulinic acid hydrochloride|
75386772|NCT00002963|Procedure|conventional surgery|
75386773|NCT00002969|Drug|paclitaxel|
75386774|NCT00002987|Biological|bleomycin sulfate|
75386775|NCT00002987|Drug|cyclophosphamide|
75386776|NCT00002987|Drug|doxorubicin hydrochloride|
75386777|NCT00002987|Drug|etoposide|
75386778|NCT00002987|Drug|prednisolone|
75386779|NCT00002987|Drug|vincristine sulfate|
75386780|NCT00002987|Radiation|radiation therapy|
75386781|NCT02919683|Drug|Nivolumab|
75386782|NCT02919683|Drug|Ipilimumab|
75386783|NCT02919683|Procedure|Standard of Care Surgery|
75386784|NCT03933293|Drug|AK102|450mg, Q4W, subcutaneous injection
75386785|NCT03933293|Drug|Statins|Lipid-lowering therapies
75386786|NCT03933293|Drug|Ezetimibe|Lipid-lowering therapies
75386787|NCT03926741|Drug|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
75386788|NCT00002993|Drug|cisplatin|
75386789|NCT00002993|Drug|doxorubicin hydrochloride|
75386790|NCT00002993|Drug|mitomycin C|
75705905|NCT00114530|Drug|cyclophosphamide|An initial intravenous dose of 500 mg/m^2 was followed by 11 infusions of 750 mg/m^2 with mesna given for bladder protection.
75705906|NCT00107744|Dietary Supplement|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
75386791|NCT01928082|Drug|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
75386792|NCT01972776|Drug|QBM076|Supplied in 25 mg and 75 mg capsules
75386793|NCT01972776|Drug|Placebo|Matching placebo capsules
75869074|NCT05720507|Behavioral|Cafe Move|Participants will be offered the opportunity to choose from a number of physical function assessments and subsequently provided personalized reports of performance results.
75386794|NCT00002999|Drug|cisplatin|
75386795|NCT00002999|Drug|fluorouracil|
75386796|NCT00002999|Radiation|radiation therapy|
75542165|NCT04542928|Behavioral|nurse facilitated face care group|The experimental group is required to receive a nurse leading 50- minute face care group every two week
75386797|NCT04330469|Procedure|Periodontal therapy|"Treatment will be performed by a periodontist.~Intensive removal of subgingival and supragingival calculus and plaque biofilm by scaling, root-planing and polishing. The procedures will be carried out with the use of hand scalers and a piezoelectric ultrasonic scaler with universal tips. Disclosing solution will be used to visualize the plaque for the clinician.~One to four sessions of subgingival scaling and root planing by quadrant, under local anesthesia as may be deemed necessary during the study period.~Subgingival irrigation using an antiseptic mouth rinse (chlorhexidine 0.12%).~Polishing of the coronal and radicular surfaces of the teeth."
75386798|NCT04330469|Procedure|Oral hygiene advice|Oral hygiene advised by Periodontist
75386799|NCT00003005|Drug|Cordycepin|"Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
75386800|NCT00003005|Drug|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
75386801|NCT00003011|Drug|marimastat|10 mg PO BID
75386802|NCT00003011|Drug|Placebo|10 mg PO BID
75869075|NCT05717192|Device|InterVapor®-System|"The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life."
75386803|NCT00003017|Biological|recombinant interleukin-12|
75386804|NCT00003023|Biological|BCG vaccine|
75386805|NCT00003023|Biological|monoclonal antibody A1G4 anti-idiotype vaccine|
75386806|NCT03850067|Drug|CC-90011|CC-90011
75386807|NCT03850067|Drug|Cisplatin|Cisplatin
75386808|NCT03850067|Drug|Carboplatin|Carboplatin
75386809|NCT03850067|Drug|Etoposide|Etoposide
75386810|NCT03850067|Drug|Nivolumab|Nivolumab
75386811|NCT00383279|Other|counseling intervention|
75386812|NCT00383279|Other|study of socioeconomic and demographic variables|
75386813|NCT00003029|Drug|cisplatin|
75386814|NCT00003029|Drug|fluorouracil|
75386815|NCT00003035|Biological|filgrastim|
75386816|NCT00003035|Drug|doxorubicin hydrochloride|
75386817|NCT00003035|Drug|paclitaxel|
75869076|NCT05714345|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
75869077|NCT05714345|Drug|Fludarabine|Chemotherapy for lymphodepletion
75386818|NCT00003035|Drug|tamoxifen citrate|
75386819|NCT00003035|Procedure|surgical procedure|
75386820|NCT00003035|Radiation|radiation therapy|
75386821|NCT02579525|Other|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
75386822|NCT02579525|Other|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
75386823|NCT03837431|Diagnostic Test|Skin slit|Skin slit microscopy, RDT and PCR
75386824|NCT03837431|Diagnostic Test|Dental broach|Dental broach RDT and PCR
75386825|NCT03837431|Diagnostic Test|Tape disc|Tape disc PCR
75386826|NCT00003041|Drug|pyrazoloacridine|
75386827|NCT00383903|Biological|HRV vaccine|Two or three oral doses
75386828|NCT00003053|Drug|cisplatin|
75386829|NCT00003053|Drug|etoposide|
75386830|NCT00003053|Procedure|adjuvant therapy|
75386831|NCT04329689|Other|The Septal myectom|"The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary"
75386832|NCT04329845|Procedure|open splenectomy|open splenectomy for treatment of splenic injury
75386833|NCT04329845|Procedure|laparoscopic splenectomy for splenic injury in trauma|laparoscopy as a technique for removal of the spleen in injury
75386834|NCT00003065|Biological|filgrastim|
75386835|NCT00003065|Drug|paclitaxel|
75386836|NCT00003065|Drug|topotecan hydrochloride|
75386837|NCT04329611|Drug|Hydroxychloroquine|COVID19
75386838|NCT00383357|Drug|zolpidem|
75386839|NCT03763331|Device|Control/Sham Treatment|Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.
75386840|NCT03763331|Device|Heat Therapy|Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
75386841|NCT00003077|Dietary Supplement|omega-3 fatty acid|
76032465|NCT04635436|Other|Pathologic group|"Participants will walk on a split-belt treadmill mounted on force sensors with the belts running at the same or at different velocities. They will walk freely without hanging to any support. The test sequence will be the following:~Baseline phase. 3 minutes walking at increasing speed from 0.2 m s-1 to 0.6 m s-1, speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~Habituation phase. 30 seconds walking at 0.2 m s-1.~Adaptation phase. The velocity of the belt under the non-affected lower limb will be increased to 0.6 m s-1, while the other belt will maintain its velocity of 0.2 m s-1 for 6 minutes.~Post-adaptation phase. Belts' velocities will be restored at 0.2 m s-1 for 6 minutes.~Participants will be informed before the changes in belts' velocities with a verbal warning.~Participants will repeat the same protocol with the affected lower limb on the fast belt after one week."
75386842|NCT03759665|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
75705907|NCT00107744|Dietary Supplement|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
75705908|NCT00107744|Dietary Supplement|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
75705909|NCT00845338|Drug|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
75705910|NCT00711360|Device|Intrathoracic impedance measurement|Intrathoracic impedance measurement by cardiac resynchronization therapy (CRT) devices and implantable cardioverter defibrillators (ICDs) (Lumax 540)
76032466|NCT04634968|Behavioral|Brief Motivational Interviewing interaction|Telephone peer counselling+ Brief Motivational Interviewing interaction, and telephone-based interview after receiving all information.
76032467|NCT04634968|Behavioral|General health communication|Telephone peer counselling+ General health communication, and telephone-based interview, and telephone-based interview after receiving all information.
76032468|NCT04634266|Device|Transcatheter tricuspid valve treatment (TTVT)|Percutaneous CE-mark approved techniques for transcatheter tricuspid valve treatment (TTVT): These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II) transcatheter edge-to-edge repair (TriClip, PASCAL).
75386843|NCT00003089|Drug|amifostine trihydrate|
75386844|NCT00003089|Drug|carboplatin|
75386845|NCT00003089|Drug|paclitaxel|
75386846|NCT00003089|Radiation|radiation therapy|
75386847|NCT00003101|Biological|filgrastim|
75386848|NCT00003101|Drug|busulfan|
75705911|NCT00855634|Procedure|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
75705912|NCT00855634|Procedure|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
75705913|NCT05673174|Diagnostic Test|Non-Invasive Estimation of Left Ventricular Diastolic Pressure|Modified blood pressure cuff used to detect arterial waveforms used for the estimation of LVDP
75705914|NCT00923962|Drug|Glucagon like peptide-1|0,1 pmol/kg/min
75386849|NCT00003101|Drug|lomustine|
75386850|NCT00003101|Drug|procarbazine hydrochloride|
75386851|NCT00003101|Drug|thiotepa|
75386852|NCT00003101|Drug|vincristine sulfate|
75386853|NCT00003101|Procedure|autologous bone marrow transplantation|
75386854|NCT00003101|Procedure|peripheral blood stem cell transplantation|
75705915|NCT00923962|Drug|Adenosine|20-40 microgram/minute
75869078|NCT05714345|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
75386855|NCT03692273|Procedure|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
75386856|NCT03692273|Procedure|0.5mm punch biopsy|punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
75386857|NCT01866371|Procedure|Retinal imaging|Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
75542166|NCT04543006|Diagnostic Test|serology|blood sample of 10 ml twice (6 and 12 months after the Covid-19)
75705916|NCT00711438|Behavioral|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
75869079|NCT05714345|Genetic|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
75869080|NCT05713071|Procedure|Bariatric Endoscopic Antral Myotomy|BEAM will be performed using a standard gastric peroral endoscopic myotomy (G-POEM) technique, however with the myotomy targeting only the antrum and leaving the pyloric ring intact. G-POEM is commonly and widely employed for gastric emptying and nutritional issues and is covered by most insurance plans. This involves injecting fluid into the submucosal space, making a mucosal incision to enter the submucosal space, and tunneling along the antrum to the pylorus. A myotomy is then performed, however, in BEAM the pyloric ring is spared and the myotomy is only performed in the antrum. The incision is then closed with clips. No endoscopic suturing will be performed.
75542167|NCT04710017|Drug|Tranexamic acid|will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
75542168|NCT04710017|Drug|Medroxyprogesterone Acetate 150 MG/ML|will be given MPA at 150 mg once intramuscular injection
75705917|NCT00711438|Behavioral|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
75705918|NCT02575092|Drug|Enalapril Maleate Tablets(as the program-based antihypertension)|
75869081|NCT05700552|Behavioral|skin to skin contact|For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
75869082|NCT05687071|Drug|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 52 weeks
75386858|NCT01805609|Behavioral|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture & discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff & that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
75869083|NCT05683340|Drug|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
76032469|NCT01936948|Procedure|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
75386859|NCT01805609|Behavioral|questionnaires|
75386860|NCT00003107|Biological|recombinant interleukin-12|
75386861|NCT00383201|Device|OptiFree Multi-Purpose Disinfecting Solution|
75386862|NCT00003113|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor; G-CSF) is given subcutaneously on days 5-21 and 33-42 of each cycle.
75386863|NCT00003113|Drug|cyclophosphamide|Cyclophosphamide are given on days 22-31 of each cycle.
75386864|NCT00003113|Drug|etoposide|Etoposide is given on days 1-3.
75705919|NCT02575092|Drug|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
75705920|NCT02575092|Drug|Placebo|
75869084|NCT05683340|Drug|Placebo|placebo, tablet, once daily, for 12 weeks
75869085|NCT05676931|Drug|Domvanalimab|Administered as specified in the treatment arm
75869086|NCT05676931|Drug|Quemliclustat|Administered as specified in the treatment arm
76032470|NCT01936870|Drug|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
75386865|NCT00003113|Drug|lomustine|Lomustine is given on day 1 of cycles 1 and 3 only.
75386866|NCT00003113|Drug|procarbazine hydrochloride|Procarbazine are given on days 22-31 of each cycle.
75386867|NCT00003113|Radiation|radiation therapy|Following the third cycle of chemotherapy, if residual disease is confined to 1 or 2 nodal sites, patients receive radiation therapy.
75705921|NCT00851578|Device|WATCHMAN|WATCHMAN LAA Closure Device
75705922|NCT04097470|Drug|Decitabine|Decitabine dosage 20mg/m2 i.v.
75705923|NCT04097470|Drug|Midostaurin|Midostaurin 50 mg b.i.d.
75869087|NCT05676931|Drug|Zimberelimab|Administered as specified in the treatment arm
75869088|NCT05676931|Drug|Docetaxel|Administered as specified in the treatment arm
75869089|NCT05676931|Drug|Platinum-Based Doublet|Administered as specified in the treatment arm
75869090|NCT05663034|Behavioral|Mindfulness-based treatment for insomnia (MBTI)|A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia
75386868|NCT01545557|Device|Hyaluronic acid dermal filler gel|1 Emervel Volume injection per indication and 1 touch-up injection if necessary
75705924|NCT02575014|Drug|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
76032471|NCT01618864|Device|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
75386869|NCT00003119|Biological|filgrastim|
76032472|NCT01618708|Device|Synvisc-One (hylan G-F 20)|6-mL IA injection
76032473|NCT01618708|Device|Placebo|6 mL injection of phosphate buffered saline
76032474|NCT04434521|Behavioral|Questionnaire|Questionnaire about habits in terms of near vision activities
75386870|NCT00003119|Biological|sargramostim|
75386871|NCT00003119|Drug|carboplatin|
75386872|NCT00003119|Drug|cyclophosphamide|
75386873|NCT00003119|Drug|doxorubicin hydrochloride|
75386874|NCT00003119|Drug|etoposide|
75386875|NCT00003119|Procedure|adjuvant therapy|
75386876|NCT00003119|Procedure|conventional surgery|
75386877|NCT00003119|Radiation|radiation therapy|
75386878|NCT00003395|Drug|arsenic trioxide|
75386879|NCT00003401|Drug|carmustine|
75386880|NCT00003401|Drug|cisplatin|
75386881|NCT00003401|Drug|cyclophosphamide|
75386882|NCT00003401|Drug|dexamethasone|
75386883|NCT00003401|Drug|etoposide|
75542169|NCT04538521|Dietary Supplement|Niacin|The dose for a slow-released form of niacin will be 500-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 2 months. The intervention time with the full niacin dose is 8 months and subsequently total intervention time 10 months.
75705925|NCT04041934|Dietary Supplement|tryptophan|Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
75705926|NCT02573142|Behavioral|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
75705927|NCT02573142|Behavioral|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
76032475|NCT04434521|Other|Eye examination|"The eye examination involves the following measurements:~Distant vision phoria with Thorington method~Close vision with Thorington method~Objective eye-to-eye refraction with self-refractometer~Binocular objective refraction with autorefractometer~Monocular/biocular/binocular refraction with Nidek TS610~SiView automatic refraction~Humphriss binocular refraction~MOU Binocular refraction"
75386884|NCT00003401|Drug|gemcitabine hydrochloride|
75386885|NCT00003401|Drug|melphalan|
75386886|NCT00003401|Drug|paclitaxel|
75386887|NCT00003401|Procedure|bone marrow ablation with stem cell support|
75386888|NCT00003401|Procedure|peripheral blood stem cell transplantation|
75386889|NCT00003125|Biological|ALVAC-CEA vaccine|
75386890|NCT00003125|Biological|aldesleukin|
75386891|NCT00003125|Biological|sargramostim|
75386892|NCT00003125|Biological|vaccinia-CEA vaccine|
75386893|NCT04130555|Device|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
75386894|NCT00003131|Drug|chemotherapy|
75386895|NCT00003131|Drug|gemtuzumab ozogamicin|
75386896|NCT00384371|Drug|Botulinum Toxin A|Botulinum Toxin A
75386897|NCT00384371|Drug|Placebo|Placebo
75542170|NCT00269763|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
75542171|NCT04543630|Procedure|Sinus floor augmentation|Sinus floor augmentaion using the lateral window technique
75542172|NCT04542967|Biological|Biological|"An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.~If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out."
75542173|NCT00237575|Drug|gemcitabine|
75542174|NCT00237575|Drug|cisplatin|
75542175|NCT00237575|Drug|sargramostim|
75542176|NCT00237575|Drug|filgrastim|
75869091|NCT05663034|Behavioral|Cognitive behavioral therapy for insomnia (CBT-I)|Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.
76032476|NCT04615234|Device|Pharmacogenomics test (PGx)|"The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)"
76032477|NCT03315455|Drug|Emicizumab|Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
75386898|NCT00423215|Drug|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."
76032478|NCT03064139|Behavioral|MCG|Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
76032479|NCT03064139|Behavioral|SCG|Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
76032480|NCT02229149|Drug|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
76032481|NCT02229149|Drug|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
76032482|NCT02229149|Drug|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
76032483|NCT03259295|Device|Digiclamp (Skin tag removal initial plus follow-up)|Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
76032484|NCT04871399|Procedure|Conventional Right hemicolectomy (Non-CME)|Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.
75386899|NCT00003413|Biological|filgrastim|
75386900|NCT00003413|Drug|carmustine|
75542177|NCT04542811|Other|Acupuncture|Acupuncture is a complementary therapy modality which is used by needle inserted the specific points on the body.
75542178|NCT00269802|Drug|OROS methylphenidate HCl|
76032485|NCT04871399|Procedure|Right hemicolectomy with CME+CVL|"Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly:~The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery~The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery.~The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance."
75386901|NCT00003413|Drug|cisplatin|
75386902|NCT00003413|Drug|melphalan|
75386903|NCT00003413|Drug|paclitaxel|
75386904|NCT00003413|Procedure|peripheral blood stem cell transplantation|
75542179|NCT00269802|Drug|Ritalin|
75386905|NCT00003413|Procedure|surgical procedure|
75386906|NCT00003137|Drug|irinotecan hydrochloride|
75386907|NCT00003419|Procedure|antiviral therapy|
75386908|NCT00003425|Biological|filgrastim|
75386909|NCT00003425|Drug|amifostine trihydrate|
75386910|NCT00003425|Drug|cyclophosphamide|
75386911|NCT00003425|Drug|melphalan|
75386912|NCT00003425|Procedure|peripheral blood stem cell transplantation|
75386913|NCT00534131|Procedure|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
75542180|NCT00269802|Drug|Placebo|
75542181|NCT02215174|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
75542182|NCT00237614|Drug|intravenous and oral N-acetylcysteine|
75705928|NCT02574234|Other|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
76032486|NCT04432025|Procedure|Bariatric surgery + goal directed medical therapy|Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
76032487|NCT04432025|Procedure|Bariatric surgery|Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
76032488|NCT04867889|Device|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro X100 stimulator and a Cool-B65 A/P coil or a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The non-shielded side of the cool-B65 A/P coil is placed towards the patient, or if using the cool-B65 coil the centre of the butterfly is placed towards the patient head"
75705929|NCT02574234|Other|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
75705930|NCT02574234|Other|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
75705931|NCT02574234|Other|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
75869092|NCT05662943|Drug|Intravitreal aflibercept injection|Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
75869093|NCT05659381|Drug|Cisplatin|Cisplatin 100mg/m2 IP over 90 minutes at 42 degrees Celcius
76032489|NCT04867889|Device|Sham iTBS|"The sham iTBS is delivered with MagPro X100 stimulator and a Cool-B65 A/P coil.~The coil is placed over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. For all patients electrodes for transcutaneous electrical nerve stimulation (TENS) are applied and if the patient is randomized to sham treatment the shielded side of the coil will be pointing towards the patient's head and there will be a weak TENS current applied instead synchoronously. If the cool-B65 is used the coil is instead angled 90 degrees delivering the pulses into air instead"
75386914|NCT00534131|Procedure|APPEAR Procedure|Perineal incision to reach the distal rectum
75386915|NCT00534131|Procedure|Proctectomy|standard rectal excision which does not preserve the anal canal
75386916|NCT00330551|Drug|Oral Risperidone|Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
75386917|NCT00330551|Drug|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
75869094|NCT05659381|Other|No treatment|No treatment with Cisplatin
76032490|NCT04440371|Combination Product|Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly|Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)
76032491|NCT04440371|Combination Product|Calcipotriol/Betamethasone ointment plus NBUVB|Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
76032492|NCT04430543|Behavioral|Cognitive Bias Modification|"CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%)."
75386918|NCT00001259|Drug|Leuprolide|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
75386919|NCT00001259|Drug|Estradiol Patches|Transdermal Estradiol, 100mcg/day by skin patch
75386920|NCT00001259|Drug|Progesterone|Progesterone suppository, 200mg vaginally twice/day
75386921|NCT00001259|Drug|Placebo patch|Placebo by skin patch
75386922|NCT00001259|Drug|Placebo injection|Placebo given intramuscularly monthly
75386923|NCT00001259|Drug|Placebo suppository|Placebo vaginal suppository
75386924|NCT00003143|Drug|Amifostine|
75386925|NCT00003143|Drug|DHAP|
75386926|NCT00003431|Biological|recombinant flt3 ligand|
75386927|NCT00003149|Biological|recombinant interleukin-12|
75869095|NCT05641662|Other|Heart Farming|Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
75386928|NCT00003437|Drug|asparaginase|
75386929|NCT00003437|Drug|cyclophosphamide|
75386930|NCT00003437|Drug|cytarabine|
75386931|NCT00003437|Drug|daunorubicin hydrochloride|
75386932|NCT00003437|Drug|dexamethasone|
75386933|NCT00003437|Drug|doxorubicin hydrochloride|
75869096|NCT05632315|Drug|PMT|Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)
75386934|NCT00003437|Drug|mercaptopurine|
75386935|NCT00003437|Drug|methotrexate|
75386936|NCT00003437|Drug|pegaspargase|
75869097|NCT05620979|Behavioral|Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.|Providing financial navigation to blood cancer survivors.
75386937|NCT00003437|Drug|prednisolone|
75386938|NCT00003437|Drug|thioguanine|
75386939|NCT00003437|Drug|vincristine sulfate|
75386940|NCT00003437|Radiation|radiation therapy|
75386941|NCT00003443|Drug|bryostatin 1|
75386942|NCT00003449|Drug|dexamethasone|
75386943|NCT00003449|Drug|gemcitabine hydrochloride|
75386944|NCT00003449|Drug|paclitaxel|
75386945|NCT00002801|Drug|leucovorin calcium|
75386946|NCT00002801|Drug|tegafur-uracil|
75386947|NCT00002801|Radiation|radiation therapy|
75386948|NCT00002807|Radiation|radiation therapy|45 Gy in 25 fractions over 5 weeks
75386949|NCT04329533|Other|"Calm is a mindfulness meditation mobile app"|"Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
75386950|NCT00002813|Drug|cisplatin|
75386951|NCT00002813|Drug|vinorelbine tartrate|
75386952|NCT00002819|Drug|carboplatin|
75386953|NCT00002819|Drug|cyclophosphamide|
75386954|NCT00002819|Drug|mitoxantrone hydrochloride|
75386955|NCT00002819|Drug|paclitaxel|
75386956|NCT00002819|Procedure|autologous bone marrow transplantation|
75386957|NCT00002819|Procedure|peripheral blood stem cell transplantation|
75386958|NCT00002825|Biological|filgrastim|
75386959|NCT00002825|Drug|docetaxel|
75386960|NCT00002831|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
75386961|NCT00002831|Drug|Busulfan|Administered orally every 6 hours on consecutive days -6 through -4.
75386962|NCT00002831|Drug|Cyclophosphamide|Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
75386963|NCT00002831|Drug|Cyclosporine|Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
75386964|NCT00002831|Drug|Decitabine (DAC)|IV over 4 hours on days -8 and -7.
75386965|NCT00002831|Drug|Methotrexate|Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
75386966|NCT00002831|Drug|Methylprednisolone|Given according to clinical grade of GVHD procedures.
75386967|NCT00002831|Drug|Tacrolimus|IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
75386968|NCT00002831|Procedure|Allogeneic Bone Marrow Transplantation|Infusion of stem cells on Day 0.
75386969|NCT00002831|Procedure|Peripheral Blood Stem Cell Transplantation|Stem cell infusion on Day 0.
75386970|NCT00002837|Biological|Filgrastim (G-CSF)|
75386971|NCT00002837|Drug|Cyclophosphamide|
75386972|NCT00002837|Drug|Doxorubicin Hydrochloride|
75386973|NCT00002837|Drug|Paclitaxel|
75386974|NCT00002837|Procedure|Peripheral Blood Stem Cell Transplantation|
75386975|NCT00003455|Drug|antineoplaston A10|
75386976|NCT00003455|Drug|antineoplaston AS2-1|
75386977|NCT00003455|Procedure|alternative product therapy|
75386978|NCT00003455|Procedure|biological therapy|
75386979|NCT00003455|Procedure|biologically based therapies|
75386980|NCT00003455|Procedure|cancer prevention intervention|
75386981|NCT00003455|Procedure|complementary and alternative therapy|
75386982|NCT00003455|Procedure|differentiation therapy|
75386983|NCT00003461|Procedure|surgical procedure|
75386984|NCT00003461|Radiation|astatine At 211 monoclonal antibody 81C6|
75386985|NCT00003467|Drug|carmustine|
75386986|NCT00003467|Drug|polifeprosan 20 with carmustine implant|
75386987|NCT00003467|Procedure|surgical procedure|
75386988|NCT00003485|Drug|antineoplaston A10, antineoplaston AS2-1 (ANP)|"Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75869098|NCT05616767|Other|Training on self-screening and HPV vaccination administration|Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
76032493|NCT04430543|Behavioral|Sham Training|"Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)"
76032494|NCT02087267|Procedure|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
75386989|NCT00003491|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75386990|NCT00003497|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
75386991|NCT00003167|Biological|Ad5CMV-p53 gene|Given intravesically
75386992|NCT00003515|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
76032495|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
75386993|NCT00003521|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75386994|NCT00002849|Biological|recombinant interferon alfa|first 2 years
75386995|NCT00002849|Drug|dexamethasone|40 mg*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles*
75386996|NCT04329377|Diagnostic Test|blood test|complete blood count and platelet function
75869099|NCT05614648|Drug|Clonidine Micropellets|0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
75869100|NCT05614648|Device|Tuohy epidural needle|18-gauge Tuohy epidural needle using a custom-built injector
75869101|NCT05613413|Drug|Cabozantinib 40 MG|Cabozantinib is taken my mouth
75869102|NCT05613413|Drug|Pembrolizumab 200mg|Pembrolizumab is given intravenously
75869103|NCT05613413|Drug|Pembrolizumab 400mg|Pembrolizumab is given intravenously
75869104|NCT05610839|Behavioral|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods & Twohig, 2008).
75386997|NCT00002855|Drug|Bicalutamide|
75386998|NCT00002855|Drug|Doxorubicin hydrochloride|
75386999|NCT00002855|Drug|Estramustine Phosphate Sodium|
75387000|NCT00002855|Drug|Flutamide|
75387001|NCT00002855|Drug|Ketoconazole|
75387002|NCT00002855|Drug|Nilutamide|
75387003|NCT00002855|Drug|Therapeutic Hydrocortisone|
75387004|NCT00002855|Drug|Vinblastine|
76032496|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
76032497|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
75387005|NCT00002855|Procedure|Conventional Surgery|Surgical castration
75387006|NCT00003173|Biological|filgrastim|
75387007|NCT00003173|Drug|thiotepa|
75387008|NCT00003173|Procedure|autologous bone marrow transplantation|
75387009|NCT00003173|Procedure|peripheral blood stem cell transplantation|
75387010|NCT00003533|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75387011|NCT00003179|Drug|medroxyprogesterone|
75387012|NCT00003545|Drug|nelarabine|
75387013|NCT00003551|Drug|aminocamptothecin colloidal dispersion|
75387014|NCT00002873|Radiation|brachytherapy|
75387015|NCT00002879|Drug|cladribine|
75387016|NCT00003185|Biological|autologous tumor cell vaccine|
75387017|NCT00003185|Biological|sargramostim|
75387018|NCT00003185|Biological|tumor-draining lymph node lymphocyte therapy|
75387019|NCT00003185|Drug|cyclophosphamide|
75387020|NCT00003185|Procedure|conventional surgery|
75387021|NCT00003557|Drug|dolastatin 10|
75387022|NCT00003935|Drug|etoposide|
75387023|NCT00003935|Drug|vincristine sulfate|
75387024|NCT00003935|Radiation|radiation therapy|
75387025|NCT00003191|Drug|fenretinide|
75387026|NCT00003941|Biological|bleomycin sulfate|
75387027|NCT00003941|Biological|filgrastim|
75387028|NCT00003941|Drug|cisplatin|
75387029|NCT00003941|Drug|etoposide|
75387030|NCT00003941|Drug|ifosfamide|
75387031|NCT00003941|Procedure|bone marrow ablation with stem cell support|
75387032|NCT00003941|Procedure|peripheral blood stem cell transplantation|
75387033|NCT00384527|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
75387034|NCT00384527|Drug|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
75387035|NCT00003197|Dietary Supplement|green tea extract|
75387036|NCT00003563|Radiation|WBRT|3 GY of WBRT daily for a total of 10 days
75387037|NCT00003563|Drug|MGd|5.0 mg /kg MGd plus WBRT
75387038|NCT00003569|Drug|cisplatin|
75387039|NCT00003569|Drug|dimesna|
75387040|NCT00003569|Drug|paclitaxel|
75387041|NCT00003953|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
75387042|NCT00003953|Drug|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
75387043|NCT00003953|Drug|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
75387044|NCT00003953|Drug|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
75387045|NCT00003953|Drug|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
75387046|NCT00003953|Procedure|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
75705932|NCT02574234|Other|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
75705933|NCT00845494|Behavioral|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
75869105|NCT05608824|Device|Shear wave elastography and microvascular flow imaging.|Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
76032498|NCT04432649|Biological|4SCAR-276|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
75387047|NCT00003953|Procedure|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
75387048|NCT00003953|Radiation|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
75387049|NCT00003959|Biological|ras peptide cancer vaccine|
75387050|NCT00003959|Biological|sargramostim|
75387051|NCT02972723|Drug|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
75387052|NCT00003203|Biological|filgrastim|Given IV
75387053|NCT00003203|Drug|carboplatin|Given IV
75387054|NCT00003203|Drug|cisplatin|Given IV
75387055|NCT00003203|Drug|cyclophosphamide|Given IV
75387056|NCT00003203|Drug|vincristine sulfate|Given IV
75387057|NCT00003203|Procedure|adjuvant therapy|
75387058|NCT00003203|Radiation|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT*
75387059|NCT00003575|Biological|filgrastim|
75387060|NCT00003575|Biological|recombinant interleukin-12|
75387061|NCT00003575|Drug|etoposide|
75387062|NCT00003575|Drug|ifosfamide|
75387063|NCT00003539|Biological|trastuzumab|
75387064|NCT00003539|Drug|paclitaxel|
75387065|NCT00003209|Biological|bleomycin sulfate|
75387066|NCT00003209|Drug|cisplatin|
75387067|NCT00003209|Drug|fluorouracil|
75387068|NCT00003209|Drug|ifosfamide|
75387069|NCT00003209|Drug|methotrexate|
75387070|NCT00003209|Drug|mitomycin C|
75387071|NCT00003209|Drug|vinblastine sulfate|
75387072|NCT00003209|Drug|vindesine|
75869106|NCT05606731|Behavioral|Family-Based Childhood Obesity Intervention|The study will focus on the effectiveness of a community- and family-based intervention that will involve multiple family caregivers. The intervention will include in-person and mobile phone components focusing on Latino caregivers of young children, to support evidence-based and age appropriate dietary, media-viewing, and physical activity practices among 2- to 5-year old children.
75869107|NCT05606289|Behavioral|Crisis Intervention Team (CIT) training|Standard 40-hour CIT training given in one week.
75869108|NCT05598905|Drug|Pregabalin 150mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
75387073|NCT00003209|Radiation|radiation therapy|
75387074|NCT00003587|Drug|carboplatin|AUC=5.5 day 1 every 21 days X 3
75387075|NCT00003587|Drug|cisplatin|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3
75387076|NCT00003587|Drug|docetaxel|IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
75869109|NCT05598905|Drug|Oxycodone 10mg|one 10mg tablet
75869110|NCT05598905|Drug|Lacosamide 150 mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
75869111|NCT05595187|Device|Tricuspid repair|Tricuspid repair included suture placement and the type of prosthetic annuloplasty.
75387077|NCT00003587|Drug|gemcitabine|IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3
75387078|NCT00003587|Drug|paclitaxel|IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
75869112|NCT05588674|Dietary Supplement|Probiotic Supplement|8.5 week supplementation period. One capsule daily.
75869113|NCT05588674|Other|Placebo Capsule|8.5 week supplementation period. One capsule daily.
75869114|NCT05584553|Device|ToggleLoc 2.9 mm soft tissue device|The ToggleLoc 2.9 mm Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
75387079|NCT00003587|Drug|vinorelbine|IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3
75387080|NCT00003977|Biological|human papillomavirus 16 E7 peptide|
75387081|NCT00003977|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75869115|NCT05584553|Device|JuggerLoc soft tissue device|The JuggerLoc Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
76032499|NCT03125447|Other|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
75705934|NCT00855790|Other|evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep|Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
76032500|NCT04602923|Diagnostic Test|Corneal topography: OPD-Scan|Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
76032501|NCT04602923|Diagnostic Test|Corneal topography: Pentacam|Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
76032502|NCT04432805|Device|Performing of lung ultrasound|Performing of lung ultrasound at bedside in labor ward or in COVID unit
76032503|NCT04982939|Drug|Sintilimab|Sintilimab, 200mg IV d1 Q3W
75705935|NCT04042090|Device|Reducept, virtual reality|The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on a VR goggles. It consists of an education module and three games.
76032504|NCT04982939|Drug|S-1|S-1, 40-60mg BID d1-14 Q3W
75387082|NCT00003215|Biological|filgrastim|
75387083|NCT00003215|Drug|CHOP regimen|
76032505|NCT04982939|Drug|Oxaliplatin|Oxaliplatin，130mg/m2 d1 Q3W
76032506|NCT04982549|Drug|Durvalumab|Durvalumab (intravenous infusion)
76032507|NCT04982549|Drug|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
75387084|NCT00003215|Drug|cyclophosphamide|
75705936|NCT04069650|Procedure|Free flap|Free flap reconstruction of the oral cavity
75705937|NCT00851734|Drug|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
76032508|NCT04982549|Drug|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
76032509|NCT04982549|Drug|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
75542183|NCT04538326|Behavioral|Exercise|Participants performed stepping movements that were either cued by the investigator or interacted with a video game. There were three video game exercises that all involved stepping in either a repeated or a random pattern that was either self-paced or game paced.
75869116|NCT05581810|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy for functional memory symptoms after concussion is delivered by a psychologist over 11 individual (1:1) secure videoconference sessions. The core active ingredients are 1) Behavioural experiments, which acts by phasing out compensatory strategies in order to increase normal memory use and 2) Cognitive reappraisal, which aids in re-interpreting memory lapses in order to reduce reactivity to them.
75869117|NCT05581810|Behavioral|Cognitive Rehabilitation|Training and practice with external memory aids/compensatory strategies, adapted from Shum et al. (2011). J Rehabil Med, 43(3):216-223.
75869118|NCT05579587|Device|Transoral Incisionless Fundoplication|Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
76032510|NCT04982549|Radiation|Radiation|5 fractions/ week for ~6 weeks (±3 days) (Total 60 Gy)
75387085|NCT00003215|Drug|cytarabine|
75387086|NCT00003215|Drug|doxorubicin hydrochloride|
75387087|NCT00003215|Drug|etoposide|
75387088|NCT00003215|Drug|leucovorin calcium|
75387089|NCT00003215|Drug|melphalan|
75387090|NCT00003215|Drug|methotrexate|
75387091|NCT00003215|Drug|methylprednisolone|
75387092|NCT00003215|Drug|mitoxantrone hydrochloride|
75387093|NCT00003215|Drug|prednisone|
75387094|NCT00003215|Drug|therapeutic hydrocortisone|
75387095|NCT00003215|Drug|vincristine sulfate|
75387096|NCT00003215|Procedure|bone marrow ablation with stem cell support|
75387097|NCT00003215|Procedure|peripheral blood stem cell transplantation|
75387098|NCT00003215|Radiation|radiation therapy|
75387099|NCT00003989|Biological|ISIS 3521|
75387100|NCT00003995|Biological|trastuzumab|
75387101|NCT00003995|Drug|irinotecan hydrochloride|
75387102|NCT00003593|Drug|asparaginase|Given IV
75387103|NCT00003593|Drug|cytarabine|Given IT
75387104|NCT00003593|Drug|daunorubicin hydrochloride|Given IV
76032511|NCT04982627|Behavioral|BNI Chatbot|The BNI Chatbot is a web application that guides participants through a brief motivational intervention that motivates them to engage in treatment for opioid use disorder.
76032512|NCT04982627|Behavioral|OUD Education & Treatment Resources|The OUD Education & Treatment Resources intervention is a web application that provides OUD education and treatment resources.
76032513|NCT03064061|Device|Virtual reality|a device with virtual reality is given to the patients with a film of 18 minutes
75387105|NCT00003593|Drug|methotrexate|Given IV
75387106|NCT00003593|Drug|therapeutic hydrocortisone|Given IT
75387107|NCT00003593|Drug|thioguanine|Given IV
75387108|NCT00003599|Dietary Supplement|Vitamin E (AT)|Orally daily
75387109|NCT00003599|Drug|Isotretinoin|Orally daily
75387110|NCT00003605|Biological|rituximab|
75387111|NCT00003605|Drug|cyclophosphamide|
75387112|NCT04329299|Diagnostic Test|blood-based biomarkers analyses|Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
75387113|NCT00003611|Drug|acitretin|
75387114|NCT00003611|Other|placebo|
76032514|NCT04981691|Biological|anti-MESO CAR T cells|Autologous genetically modified anti-MESO CAR T cells
76032515|NCT03062423|Drug|Sofodelevier|1 tablet contains 400 mg sofosbuvir
75387115|NCT00003617|Drug|chlorambucil|
75387116|NCT00003617|Drug|clarithromycin|
75387117|NCT00003617|Drug|omeprazole|
75387118|NCT00003617|Drug|tinidazole|
75387119|NCT00003623|Dietary Supplement|multivitamin|
75387120|NCT00003623|Other|Placebo|
75387121|NCT00003635|Drug|nelarabine|
75869119|NCT05577364|Drug|Selinexor|"Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen."
75387122|NCT00004001|Drug|docetaxel|
75387123|NCT00004001|Drug|estramustine|
75387124|NCT00004001|Drug|mitoxantrone|
75387125|NCT00004001|Drug|prednisone|
75387126|NCT00004013|Biological|trastuzumab|
75387127|NCT00004013|Drug|paclitaxel|
75387128|NCT00004025|Biological|aldesleukin|
75387129|NCT00004025|Biological|dendritic cell-gp100-MART-1 antigen vaccine|
75387130|NCT00004037|Drug|docetaxel|
75387131|NCT00004043|Dietary Supplement|calcitriol|
75387132|NCT00004049|Drug|apomine|
75387133|NCT00004055|Biological|filgrastim|
75387134|NCT00004055|Drug|paclitaxel|
75387135|NCT00004055|Drug|topotecan hydrochloride|
75387136|NCT00004061|Biological|filgrastim|
75387137|NCT00004061|Biological|palifermin|
75387138|NCT00004061|Drug|cyclophosphamide|
75387139|NCT00004061|Drug|etoposide|
75387140|NCT00004061|Drug|ifosfamide|
75387141|NCT00004061|Procedure|peripheral blood stem cell transplantation|
75387142|NCT00004061|Procedure|quality-of-life assessment|
76032516|NCT03062423|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
76032517|NCT03062423|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
76032518|NCT00790933|Drug|Vedolizumab|Vedolizumab intravenous infusion
76032519|NCT04981457|Drug|Misoprostol and iso sorbide mononitrates|drug
75869120|NCT05577364|Drug|R-CHOP Protocol|"Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;"
75869121|NCT05568095|Drug|Domvanalimab|Intravenous (IV) Aqueous Solution
75387143|NCT00004061|Radiation|radiation therapy|
75869122|NCT05568095|Drug|Zimberelimab|IV Aqueous Solution
75869123|NCT05568095|Drug|Capecitabine|Oral Tablets
75869124|NCT05568095|Drug|Fluorouracil|IV Aqueous Solution
75869125|NCT05568095|Drug|Leucovorin|IV Aqueous Solution
75869126|NCT05568095|Drug|Oxaliplatin|IV Aqueous Solution
76032520|NCT02161211|Behavioral|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
76032521|NCT02161211|Behavioral|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
76032522|NCT02161211|Behavioral|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
76032523|NCT01676701|Drug|Tabalumab Auto-Injector|Administered SC by auto-injector
75387144|NCT00004067|Biological|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
75387145|NCT00004067|Drug|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
75387146|NCT00004067|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
75387147|NCT00004067|Drug|taxol|175 mg/m2 IV every 21 days for 4 cycles
75387148|NCT00004073|Drug|suramin|
75869127|NCT05568095|Drug|Nivolumab|IV Aqueous Solution
75869128|NCT05564663|Behavioral|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include downloading the PTSD Coach App for personal use and four, brief (<20 minutes), weekly, individual support sessions. The sessions will focus on the instruction and encouragement of App use and activities (i.e., assessments, self-management strategies, and psychoeducational readings).
76032524|NCT01676701|Drug|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
76032525|NCT04981379|Drug|Hydroxychloroquine|Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo [Favipiravir (1600 mg)], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
76032526|NCT04981379|Drug|Favipiravir|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo [Hydroxychloroquine (200 mg)], as two tablets per day for 5-day interval.
76032527|NCT04981379|Drug|Favipiravir + Hydroxychloroquine|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
76032528|NCT04981379|Drug|Placebo|Placebo [Favipiravir (1600 mg)], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
75387149|NCT00004073|Radiation|radiation therapy|
75387150|NCT00004079|Drug|SarCNU|Given PO
75387151|NCT00004079|Other|pharmacological study|Correlative studies
75387152|NCT00004079|Other|laboratory biomarker analysis|Correlative studies
75387153|NCT00004085|Biological|filgrastim|as prescribed by physician
75387154|NCT00004085|Procedure|autologous bone marrow transplantation|1-2 weeks prior to treatment
75387155|NCT00004085|Procedure|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
75387156|NCT00004085|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
75387157|NCT00004091|Other|Papanicolaou test|
75387158|NCT00004091|Other|cytology specimen collection procedure|
75387159|NCT00004091|Other|fluorescent antibody technique|
75387160|NCT00004091|Procedure|colposcopic biopsy|
75869129|NCT05564663|Behavioral|Enhanced Usual Care (EUC)|EUC will consist of one brief session (with brochure) of PTSD and AUD psychoeducation and referral information for mental health clinics that provide PTSD services, with encouragement to schedule an appointment at one of the listed clinics to discuss PTSD-related symptoms.
75869130|NCT05548452|Drug|Intestinal Microbiota Transplant (IMT) Capsules|Capsules containing freeze-dried intestinal microbiota from healthy human donors
76032529|NCT04389775|Drug|Cohort A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg."
76032530|NCT04389775|Drug|Placebo A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg."
75869131|NCT05548452|Drug|Placebo Capsules|"Capsules containing an inactive substance (sugar pill)"
75869132|NCT05548426|Drug|Group B, Linezolid 10d|Oral Linezolid 600mg, taken twice a day for 10 days
75869133|NCT05548426|Drug|Group A, Penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
75869134|NCT05546281|Other|No intervention|No intervention
75869135|NCT05544513|Drug|Ferrous sulfate|Ferrous sulfate supplementation
75869136|NCT05536141|Drug|AB521|Administered as specified in the treatment arm
75869137|NCT05534529|Drug|Rezafungin Acetate|This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.
75387161|NCT00004091|Procedure|study of high risk factors|
75387162|NCT00004097|Drug|fluorouracil|
75387163|NCT00004097|Drug|gemcitabine hydrochloride|
75387164|NCT00004097|Drug|paclitaxel|
75387165|NCT00004097|Radiation|radiation therapy|
75387166|NCT00004103|Drug|cisplatin|
75387167|NCT00004103|Drug|floxuridine|
75387168|NCT00004103|Drug|irinotecan hydrochloride|
75387169|NCT00004103|Procedure|adjuvant therapy|
75542184|NCT00269841|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
75542185|NCT00269841|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
75542186|NCT00269841|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
75869138|NCT05525676|Behavioral|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
75542187|NCT04538443|Other|functional capacity|impact of hemodialysis on functional capacity in children with CKD
75542188|NCT04538443|Other|muscle strength|impact of hemodialysis on muscle strength in children with CKD
75542189|NCT04538443|Other|Quality of life of children|impact of hemodialysis on Quality of life in children with CKD
75542190|NCT04538443|Other|Quality of life of families|impact of hemodialysis on Quality of life of families of children with CKD
75542191|NCT04538404|Procedure|Colon Surgery|Right, left colon surgery, transverse colon surgery, multiple colon surgery in open and minimally invasive surgert
75542192|NCT04538872|Behavioral|StraDiMS implicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
75705938|NCT00716040|Behavioral|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
75705939|NCT00716040|Other|Usual care|The control group will be submitted to the usual care of the health service
75705940|NCT04019028|Device|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
75705941|NCT04019028|Device|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
75705942|NCT04019028|Device|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
75387170|NCT00004103|Procedure|conventional surgery|
75705943|NCT00845572|Behavioral|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
75387171|NCT00004103|Procedure|neoadjuvant therapy|
75387172|NCT00004109|Drug|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
75869139|NCT05525676|Behavioral|Co-Located Collaborative Care (CCC)|"The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 & 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)"
75869140|NCT05521815|Other|Coma arousal therapy|early coma arousal therapy program in addition to selected physical therapy program (positioning, breathing exercise, passive movement of the four limbs).
75869141|NCT05521815|Other|Selected physiotherapy program|selected physiotherapy program only (positioning, breathing exercise, passive movement of the four limbs).
75387173|NCT00004109|Radiation|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
75869146|NCT05514197|Drug|Ascorbic acid 5000mg|Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
75869147|NCT05514197|Drug|Control Rx|Intravenous loading 100ml normal saline
75869148|NCT05513313|Biological|JYNNEOS|smallpox vaccine
75869149|NCT05511909|Drug|Buspirone|Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
75869150|NCT05511909|Drug|Lofexidine|Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
75869151|NCT05511909|Drug|Placebo|Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
75869152|NCT05496075|Drug|Orlistat|Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
75387174|NCT00003239|Biological|Recombinant Interferon Alfa|Daily by subcutaneous injection.
75387175|NCT00003239|Drug|Cytarabine|Daily by subcutaneous injection.
75387176|NCT00003239|Drug|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
75387177|NCT00004115|Radiation|yttrium Y 90 monoclonal antibody HMFG1|
75387178|NCT00003245|Drug|irinotecan hydrochloride|
75387179|NCT00004127|Drug|FOLFOX regimen|
75387180|NCT00004127|Drug|fluorouracil|
75387181|NCT00004127|Drug|leucovorin calcium|
75387182|NCT00004127|Drug|oxaliplatin|
75387183|NCT00003251|Drug|amifostine trihydrate|
75387184|NCT00003251|Drug|cisplatin|
75387185|NCT00003251|Drug|paclitaxel|
75705944|NCT00851812|Behavioral|Exercise|Standard care monitoring
75869153|NCT05496075|Drug|Orlistat placebo|Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
75387186|NCT00003251|Radiation|radiation therapy|
75387187|NCT00004139|Drug|docetaxel|
75387188|NCT00004139|Drug|gemcitabine hydrochloride|
75869154|NCT05494905|Other|VR|In this project, the investigators focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child. It consists of the Microsoft Kinect camera, a laptop, software, and TV screen. The research team will loan the system to the family. While engaged with the game, the child is immersed in a virtual world where virtual objects appear on the screen surrounding the child. Children are asked to move their arms to 'pop' as many virtual objects as possible in a certain amount of time. Playstation 2 EyeToy and EyeToy 2 games will also be used to increase children's motivation by playing a variety of different VR games.
75387189|NCT00004139|Drug|irinotecan hydrochloride|
75387190|NCT00003257|Biological|Ad5CMV-p53 gene|
75387191|NCT00004145|Biological|anti-thymocyte globulin|
75387192|NCT00004145|Drug|cyclophosphamide|
75387193|NCT00004145|Drug|fludarabine phosphate|
75387194|NCT00004145|Procedure|peripheral blood stem cell transplantation|
75387195|NCT04212923|Behavioral|Medical Dashboard based self-management intervention|Before the start of the intervention, chronic kidney disease patients and care providers will receive a face-to-face training session on the use of Medical Dashboard. To avoid contamination, Medical Dashboard will only be made accessible for participants in the intervention group via a secure password-protected registration process.
75387196|NCT00004151|Drug|acridine carboxamide|
75387197|NCT00003263|Biological|recombinant interferon alfa|vaccine
75387198|NCT00003263|Drug|cisplatin|
75387199|NCT00003263|Procedure|surgical procedure|
75705945|NCT00851812|Behavioral|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
75705946|NCT00711906|Drug|Cotrimoxazole|Cotrimoxazole
75705947|NCT00711906|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
75705948|NCT00851968|Procedure|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
75387200|NCT00003263|Radiation|radiation therapy|
75387201|NCT00004157|Biological|filgrastim|
75387202|NCT00004157|Biological|recombinant interleukin-11|
75387203|NCT00003269|Biological|sargramostim|
75387204|NCT00003269|Drug|amifostine trihydrate|
75387205|NCT00003269|Drug|cisplatin|
75387206|NCT00003269|Drug|cyclophosphamide|
75387207|NCT00003269|Drug|etoposide|
75387208|NCT00004163|Drug|Trastuzumab|
75387209|NCT00003281|Drug|paclitaxel|
75387210|NCT00003281|Drug|topotecan hydrochloride|
75387211|NCT00003281|Radiation|radiation therapy|
75387212|NCT00003287|Drug|FOLFOX regimen|
75387213|NCT00003287|Drug|fluorouracil|
75387214|NCT00003287|Drug|leucovorin calcium|
75387215|NCT00003287|Drug|oxaliplatin|
75387216|NCT00004187|Drug|capecitabine|
75387217|NCT00004187|Drug|oxaliplatin|
75387218|NCT00384137|Drug|Tacrolimus|Immunosuppression
75387219|NCT00384215|Drug|insulin glargine [rDNA origin] injection|
75387220|NCT00004193|Drug|ISIS 2503|
75387221|NCT00003293|Drug|leflunomide|
75387222|NCT00003293|Drug|procarbazine hydrochloride|
75387223|NCT00004199|Drug|cisplatin|
75387224|NCT00004199|Drug|gemcitabine hydrochloride|
75387225|NCT00004199|Drug|prinomastat|
75387226|NCT00384995|Drug|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
75387227|NCT00384995|Drug|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
75387228|NCT00003299|Drug|cisplatin|
75387229|NCT00003299|Drug|etoposide|
75387230|NCT00003299|Drug|paclitaxel|
75387231|NCT00004205|Drug|letrozole|Letrozole 2.5 mg daily oral administration.
75387232|NCT00004205|Drug|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
75387233|NCT00003305|Drug|aminopterin|
75387234|NCT00003305|Drug|leucovorin calcium|
75387235|NCT00004211|Biological|PSA RNA-pulsed dendritic cell vaccine|
75387236|NCT00003311|Biological|filgrastim|
75387237|NCT00003311|Drug|cyclophosphamide|
75387238|NCT00003311|Drug|cytarabine|
75387239|NCT00003311|Drug|dexamethasone|
75387240|NCT00003311|Drug|doxorubicin hydrochloride|
75387241|NCT00003311|Drug|methotrexate|
75387242|NCT00003311|Drug|vincristine sulfate|
75387243|NCT00003317|Drug|carboplatin|
75869155|NCT05494905|Other|FST|FST involves repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises and these exercises are designed to move the more affected arm in overhead, outward, and across midline directions. Each exercise will be embedded in a game-like activity. Children will start with no resistance and gradually add on resistance using elastic bands or weight cuffs.
76032531|NCT04389775|Drug|Cohort B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~Subject to change following SRC review of each cohort.~Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
75869156|NCT05493735|Drug|Lidocaine Hcl 2% Jelly|Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.
75387244|NCT00003317|Drug|paclitaxel|
75869157|NCT05493735|Drug|Placebo Jelly|Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
76032532|NCT04389775|Drug|Placebo B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~Subject to change following SRC review of each cohort.~Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
76032533|NCT04352569|Device|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
75387245|NCT00003317|Radiation|radiation therapy|
75387246|NCT00003317|Procedure|surgery|
75387247|NCT00004217|Biological|filgrastim|5 μg/kg/day IV or SC
75387248|NCT00004217|Biological|sargramostim|5 μg/kg/day IV or SC starting d 15
75387249|NCT00004217|Drug|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
75387250|NCT00004217|Drug|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
75705949|NCT00851968|Procedure|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
76032534|NCT05375383|Dietary Supplement|Streptococcus salivarius K12 lozenge|In this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
76032535|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
75387251|NCT00004217|Drug|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
75387252|NCT00003323|Drug|finasteride|5 mg/d PO
75387253|NCT00003323|Drug|flutamide|250 mg PO tid
75387254|NCT00003323|Other|quality-of-life assessment|Assessment survey administered at baseline, and 3 & 6 months post initiation of treatment
75387255|NCT00004229|Biological|recombinant human endostatin|
75387256|NCT00004235|Drug|docetaxel|
75387257|NCT00004235|Drug|irinotecan hydrochloride|
75387258|NCT00003335|Biological|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
75387259|NCT00003335|Drug|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
75705950|NCT00851968|Procedure|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
75387260|NCT00003335|Drug|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
75387261|NCT00003335|Drug|melphalan|melphalan IV for three days on days -4 to -2
75387262|NCT00003335|Drug|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
75705951|NCT04227184|Drug|Trospium|Drug to treat overactive bladder
75705952|NCT04227184|Drug|Placebo oral tablet|Placebo tablet containing no active drug
75387263|NCT00003335|Procedure|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
75387264|NCT00003335|Radiation|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
75387265|NCT00004241|Drug|tanespimycin|Given IV
75387266|NCT00004241|Other|pharmacological study|Correlative studies
75387267|NCT00003341|Biological|epoetin alfa|
75387268|NCT00003341|Procedure|quality-of-life assessment|
75387269|NCT00004253|Drug|carboplatin|
75387270|NCT00004253|Drug|paclitaxel|
75387271|NCT00004253|Radiation|radiation therapy|
75705953|NCT04018950|Drug|ETX2514|intravenous infusion
75705954|NCT04018950|Drug|14C-ETX2514|intravenous infusion
75705955|NCT00845806|Other|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
76032536|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
76032537|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 lozenges containing prebiotics A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
75387272|NCT00004265|Drug|paclitaxel|
75387273|NCT00003359|Drug|batabulin sodium|
75387275|NCT00003365|Dietary Supplement|curcumin|
75387276|NCT00003365|Dietary Supplement|rutin|
75387277|NCT00003365|Drug|quercetin|
75387278|NCT00003365|Drug|sulindac|
75542193|NCT04538872|Behavioral|StraDiMs explicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
76032538|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder|In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
75387279|NCT00004307|Behavioral|Protein and calorie controlled diet|
75542194|NCT00414128|Drug|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
75387280|NCT00004307|Genetic|Ornithine transcarbamylase vector|
75387281|NCT00004829|Drug|tobramycin|
75387282|NCT00004313|Drug|dehydroepiandrosterone|
75387283|NCT00004853|Biological|Filgrastim|5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC >=10,000/microliter
75387284|NCT00004853|Biological|Filgrastim-SD/01|100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
75387285|NCT00004865|Biological|cetuximab|
75387286|NCT00004865|Drug|cisplatin|
75387287|NCT00004865|Drug|fluorouracil|
75387288|NCT00004865|Drug|paclitaxel|
75869158|NCT05486585|Other|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
75542195|NCT00414128|Drug|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
76032539|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder containing prebiotic A|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
76032540|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder containing prebiotic B|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
76032541|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder containing prebiotics A and B|In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
75869159|NCT05480722|Other|Dietary Intervention|Subjects will consume a low salt diet for 1 week and a high salt diet for 1 week to determine sodium sensitivity
76032542|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 lozenges|In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
75387289|NCT00004361|Drug|calcium gluconate|
75387290|NCT00004361|Drug|sodium citrate|
75387291|NCT00004367|Procedure|Clinical vestibular tests|
75387292|NCT00004373|Drug|alprazolam|
75387293|NCT00004871|Drug|azacitidine|
75387294|NCT00004871|Drug|sodium phenylbutyrate|
75387295|NCT00004397|Drug|heme arginate|
75387296|NCT00004397|Drug|tin mesoporphyrin|
75387297|NCT00004877|Drug|BMS-214662|
75387298|NCT00004883|Biological|trastuzumab|Given IV
75542196|NCT04538677|Device|Video consultation|A two-way audio and visual connection between patients and surgeons
75542197|NCT04538365|Drug|Triclosan 0.5 % Topical Solution|Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
75542198|NCT04538365|Drug|propanolol|Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
75387299|NCT00004883|Other|laboratory biomarker analysis|Correlative studies
75542199|NCT00414245|Drug|metformin|
76032543|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
76032544|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
75542200|NCT04542772|Other|Mirror Therapy|Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.
75387300|NCT00004403|Drug|albendazole|
75387301|NCT00004403|Drug|dexamethasone|
75542201|NCT04542772|Other|Regular Rehabilitation|Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
75387302|NCT00004403|Drug|phenytoin|
75387303|NCT00004409|Drug|collagenase|
75387304|NCT00004415|Device|Medlink spinal cord electrode|
75387305|NCT00004421|Device|implanted pulse generator|
76032545|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
75387306|NCT00004889|Biological|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
75387307|NCT00385307|Drug|amibegron (SR58611A)|
75542202|NCT00269880|Drug|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
75869160|NCT05480722|Other|Hypertonic Saline|Subjects will undergo MRI with a hypertonic saline infusion with and without NKCC2 antagonism (furosemide)
75387308|NCT00004901|Drug|ethynyluracil|
75387309|NCT00004901|Drug|fluorouracil|
75387310|NCT00004901|Drug|hydroxyurea|
75387311|NCT00004901|Radiation|radiation therapy|
75387312|NCT00004433|Drug|pergolide|
75387313|NCT00004913|Drug|cisplatin|
75387314|NCT00004913|Drug|docetaxel|
75387315|NCT00004913|Drug|fluorouracil|
75387316|NCT00004913|Drug|leucovorin calcium|
75387317|NCT00004451|Drug|Glucose|
75387318|NCT00004919|Drug|cisplatin|Given IV
75387319|NCT00004919|Drug|irinotecan hydrochloride|Given IV
75387320|NCT00004919|Drug|amifostine trihydrate|Given IV
75387321|NCT00004919|Other|pharmacological study|Correlative studies
75387322|NCT00004925|Biological|trastuzumab|
75387323|NCT00004925|Drug|pegylated liposomal doxorubicin hydrochloride|
75387324|NCT00004481|Procedure|genetic testing|
75387325|NCT00004931|Drug|leucovorin calcium|Given IV
75387326|NCT00004931|Drug|fluorouracil|Given IV
75387327|NCT00004931|Drug|oxaliplatin|Given IV
75387328|NCT00004931|Other|laboratory biomarker analysis|Correlative studies
75387329|NCT00004487|Drug|chondrocyte-alginate gel suspension|
75387330|NCT00004937|Drug|acridine carboxamide|
75387331|NCT00385229|Drug|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
75387332|NCT00004979|Drug|paclitaxel|
75387333|NCT00004979|Drug|topotecan hydrochloride|
75387334|NCT00004493|Drug|sodium dichloroacetate|
75387335|NCT00004985|Drug|Capravirine|
75387336|NCT00004985|Drug|Nelfinavir mesylate|
75387337|NCT00004559|Behavioral|dietary polyunsaturated fatty acid|
75387338|NCT00004997|Drug|Leucovorin|
75387339|NCT00005009|Biological|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
75387340|NCT00004583|Drug|Lopinavir/Ritonavir|
75387341|NCT00004583|Drug|Nelfinavir mesylate|
75387342|NCT00004583|Drug|Lamivudine|
75869161|NCT05480124|Device|tACS brain stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
76032546|NCT03062501|Drug|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
76032547|NCT02987803|Other|Data|The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
76032548|NCT02102789|Drug|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
75387343|NCT00004583|Drug|Stavudine|
75387344|NCT00005015|Drug|Fluoxetine|
75387345|NCT00004637|Drug|Vitamin E|
76032549|NCT02102789|Drug|HAI|"Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump."
75387346|NCT00005021|Biological|filgrastim|
75542203|NCT00269880|Drug|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
75705956|NCT00709410|Biological|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
76032550|NCT02998879|Drug|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
76032551|NCT02926651|Drug|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
76032552|NCT02926651|Drug|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
76032553|NCT04305145|Drug|Infliximab|Infusion
76032554|NCT04305145|Drug|Methylprednisolone|Infusion
76032555|NCT04305145|Drug|Prednisone|Orally
75387347|NCT00005021|Drug|carboplatin|
75387348|NCT00005021|Drug|paclitaxel|
75387349|NCT00005021|Drug|topotecan hydrochloride|
75387350|NCT00004643|Drug|cytarabine|
75387351|NCT00005027|Drug|becatecarin|
75387352|NCT00005033|Biological|trastuzumab|
75387353|NCT00005033|Procedure|conventional surgery|
75387354|NCT00005039|Biological|recombinant fowlpox-prostate specific antigen vaccine|Given IM
75387355|NCT00005039|Biological|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
76032556|NCT04248673|Other|carbohydrate reduced bread|Consumption of carbohydrate reduced bread for three months.
75387356|NCT00005039|Other|laboratory biomarker analysis|Correlative studies
76032557|NCT04248673|Other|carbohydrate rich bread|Consumption of carbohydrate rich bread for three months.
75387357|NCT00004667|Drug|von Willebrand factor|
75542204|NCT00269880|Drug|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
75542205|NCT04542655|Other|Ergometer Cycling followed by treadmill running|The participants undergo ergometer cycling, treadmill running and rest.
75705957|NCT02545972|Drug|tacrolimus extended release|daily dosing of tacrolimus
76032558|NCT01670279|Drug|Brexpiprazole|up to 3mg oral dose once daily
76032559|NCT01670279|Drug|Placebo|
76032560|NCT04226677|Other|aerobic exercise|Treadmill training is include warming, cooling and training phase according to rating of perceived exertion for participants.
76032561|NCT04226677|Other|Video based exercise|Exergame training include virtual reality games by xbox kinect.
76032562|NCT04226677|Other|Control group|first and last evaluations will be made
75387358|NCT00004685|Drug|albuterol|
75387359|NCT00005045|Drug|carboxyamidotriazole|
75387360|NCT00005051|Drug|carboplatin|
75387361|NCT00005051|Drug|cisplatin|
75387362|NCT00005051|Drug|paclitaxel|
75387363|NCT00005051|Drug|topotecan hydrochloride|
75387364|NCT00004697|Drug|choline chloride|
75387365|NCT00004727|Drug|aspirin|
75387366|NCT00004727|Drug|ticlopidine|
75387367|NCT00004733|Drug|levodopa|
75542206|NCT04542655|Other|Treadmill Running followed by ergometer cycling|The participants undergo treadmill running, ergometer cycling and rest.
75542207|NCT04542655|Other|Rest|The participants undergo ergometer cycling, treadmill running and rest.
75542208|NCT04542538|Other|No intervention, observational study|
75705958|NCT02574780|Other|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
75705959|NCT02574780|Other|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
76032563|NCT03062579|Drug|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
76032564|NCT04188145|Drug|Fluoropyrimidine|"Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15)."
76032565|NCT04188145|Drug|Bevacizumab|"Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab"
76032566|NCT04981769|Diagnostic Test|Covid-19 test|PCR Covid-19 test
76032567|NCT04532125|Biological|ARGX-117|Subjects treated with ARGX-117
76032568|NCT04532125|Other|Placebo|Subjects treated with placebo
76032569|NCT04532125|Biological|ARGX-117 + rHuPH20|Subjects treated with ARGX-117 + rHuPH20
76032570|NCT04532125|Other|placebo + rHuPH20|Subjects treated with placebo + rHuPH20
76032571|NCT04532125|Biological|ARGX-117 PH20 SC|Subjects treated with ARGX-117 PH20 SC
76032572|NCT04532125|Other|Placebo PH20 SC|Subjects treated with placebo PH20 SC
75387368|NCT00004739|Drug|Antiretroviral therapy|
75387369|NCT00005057|Biological|adenovirus RSV-TK|
75387370|NCT00005057|Drug|ganciclovir|
75387371|NCT00004751|Procedure|Surgery|
75387372|NCT00004751|Procedure|Physical therapy|
75542209|NCT04539067|Drug|HHMG|Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
75542210|NCT00237653|Drug|Valganciclovir|
75542211|NCT00269958|Drug|epoetin alfa|
75542212|NCT04538248|Other|Combined rehabilitation during hemodialysis|Combined rehabilitation during hemodialysis
75542213|NCT04538014|Drug|Lu AF88434|Oral solution
75542214|NCT04538014|Drug|[11C]-Lu AF88434|[11C]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
75705960|NCT00852046|Drug|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
75387373|NCT00004757|Drug|acyclovir|
75387374|NCT00005069|Drug|arsenic trioxide|
75387375|NCT00004763|Drug|leuprolide|
75387376|NCT00004763|Drug|Ethinyl estradiol/norethindrone|
75387377|NCT00005075|Procedure|high-intensity focused ultrasound ablation|
75387378|NCT00004787|Drug|filgrastim|
75387379|NCT00005081|Drug|O6-benzylguanine|
75387380|NCT00005081|Drug|carmustine|
75705961|NCT02573064|Drug|Colistin|
75705962|NCT02573064|Drug|Tigecycline|
75705963|NCT02573064|Drug|Vancomycin|
75705964|NCT00845884|Drug|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|"Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days."
76032573|NCT04980989|Device|Mobile software for follow-up of early breast cancer|The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
76032574|NCT04102813|Behavioral|Functional Therapy|It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
76032575|NCT03063983|Drug|Cyclophosphamide|Continuous oral cyclophosphamide
76032576|NCT03063983|Drug|Methotrexate|Continuous oral methotrexate
75387381|NCT00005087|Biological|filgrastim|
75387382|NCT00005087|Drug|cisplatin|
75387383|NCT00005087|Drug|paclitaxel|
75387384|NCT00005087|Procedure|conventional surgery|
75869162|NCT05480124|Device|Sham stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
75387385|NCT00005087|Radiation|radiation therapy|
75387386|NCT00004799|Biological|whole-cell pertussis vaccine|
75387387|NCT00004799|Biological|diphtheria-tetanus vaccine|
75387388|NCT00004805|Behavioral|CPR instruction|
75387389|NCT00005093|Drug|gemcitabine hydrochloride|
75387390|NCT00005093|Drug|tacedinaline|
75387391|NCT00004811|Drug|itraconazole|
75387392|NCT00004817|Drug|phenytoin|
75387393|NCT00004817|Drug|valproate sodium|
75387394|NCT00005117|Drug|pravastatin|
75387395|NCT00005555|Behavioral|Exercise|
75387396|NCT02972489|Device|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
75387397|NCT02972489|Device|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
75387398|NCT00385385|Drug|Rifalazil|
75387399|NCT00005567|Behavioral|Parental knowledge and beliefs about infant sleep position|
76032577|NCT03945721|Drug|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
76032578|NCT03945721|Radiation|Radiation Therapy|radiation therapy
75542215|NCT04538209|Radiation|Abdominal computed tomography with angiography.|technique of combing a Computed Tomography scan with the injection of dye to create pictures of the portal circulation and portosystemic collaterals veins.
75869163|NCT05477901|Other|Supplemental cash transfer|Supplemental cash transfer ($40/month)
75542216|NCT02215876|Drug|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
76032579|NCT01876355|Drug|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
76032580|NCT01876355|Drug|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
76032581|NCT03943303|Radiation|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
76032582|NCT03943303|Radiation|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
76032583|NCT03062345|Other|Single-User Virtual Reality Upper Extremity Therapy|Virtual Reality games with the user as the only person required for participation
76032584|NCT03062345|Other|Multi-User Virtual Reality Upper Extremity Therapy|Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
75387400|NCT00385463|Drug|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
75387401|NCT00386165|Drug|larazotide acetate|larazotide acetate 4 mg capsules
75542217|NCT02215876|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
76032585|NCT02747407|Biological|Hepatitis A Vaccine|
76032586|NCT02747407|Other|Laboratory Biomarker Analysis|Correlative studies
76032587|NCT02747407|Biological|Tetanus Toxoid Vaccine|
76032588|NCT02747407|Biological|Trivalent Influenza Vaccine|
76032589|NCT01870193|Dietary Supplement|Glycine, cysteine (as n-acetylcysteine), alanine|"Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months"
76032590|NCT04531501|Diagnostic Test|Saliva and NPS test|N/A Our study will not impact their path of care as they will be doing an NHS test which will determine their path of care at the NHS
76032591|NCT03063905|Drug|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
76032592|NCT04432415|Device|Silver Diamine Fluoride|Annual application od Silver Diamine Fluoride
76032593|NCT04432415|Device|Soduim Fluoride Varnish|biannual apllication of Sodium Fluoride Varnish
75869164|NCT05474027|Other|Avoidance of Deliberate Hypotensive Anesthesia|The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to the patient's baseline throughout the surgery.
75869165|NCT05474027|Drug|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|1g of tranexamic acid will be given intravenously to patient undergoing orthognathic surgery as routinely performed about 5-15 minutes before first surgical incision.
76032594|NCT04432415|Device|Placebo|biannual application of artificial saliva
76032595|NCT05331937|Combination Product|repetitive transcranial magnetic stimulation (rTMS)|rTMS (real versus sham) is used as adjuvant to ERP
76032596|NCT02627495|Device|transcranial Direct Current Stimulation (tDCS): (Soterix ©)|Subjects will undergo tDCS stimulation. We will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
76032597|NCT05095753|Device|Earbud|In ear headphone with embedded infrasonic hemodynography technology
76032598|NCT04980755|Other|Body Reprogramming|An educational intervention originally designed for patients with fibromyalgia.
76032599|NCT03485053|Drug|IOP Injection / MPB-1514|Dilute with 5% Dextrose solution (D5W)
75869166|NCT05469815|Behavioral|Lost Children Society Game|36 online therapeutic role-playing sessions spread over 36 weeks, one session per week
76032600|NCT02356939|Device|intraductal removable stent custom-made segment (2 cm)|": In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 5th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1."
75869167|NCT05465239|Device|SurePace Powered Walker User|Participants will be asked to perform one baseline 5-minute trial with the lab's instrumented walker in passive mode (no powered locomotion) and two 5-minute trials with the walker in active mode (powered locomotion).
76032601|NCT02356939|Procedure|stent extraction by ERCP|stent extraction by endoscopic retrograde cholangio-pancreatography
76032602|NCT01670045|Drug|Tocilizumab|Tocilizumab in accordance with the licensed label recommendation.
76032603|NCT05102461|Dietary Supplement|Florajen Digestion Supplementation|Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
76032604|NCT05102461|Dietary Supplement|Placebo Supplementation|Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
76032605|NCT05375227|Other|Teeth brushing|The participants will be invites to brush their teeth twice a day for 3 months using either an electric toothbrush or a mannual toothbrush and low abrasivity toothpaste
76032606|NCT04980131|Device|Pointed lotus root regulator and guide template aided PPSF|20 patients in group C received PPSF with pointed lotus-style regulator
76032607|NCT04980131|Device|Flat ended lotus root regulator and guide template aided PPSF|20 patients in group B received PPSF with flat ended lotus-style regulator
75387402|NCT00423371|Device|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
75387403|NCT00423371|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
75387404|NCT00005579|Drug|dolastatin 10|
75387405|NCT00005585|Drug|cyclophosphamide|Given IV
75387406|NCT00005585|Drug|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
75387407|NCT00005585|Drug|daunorubicin hydrochloride|Given IV
75387408|NCT00005585|Drug|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
75869168|NCT05462522|Drug|RO7303509|RO7303509 will be administered as SC injection monthly, as specified in each treatment group.
76032608|NCT04974203|Device|AptameX|DNA aptamer-based test using patient's saliva
76032609|NCT05102227|Device|Left bundle branch area pacing|A dual-chamber DF-1 defibrillator is implanted. Left bundle branch area pacing is performed for cardiac resynchronization therapy.
76032610|NCT03063671|Drug|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
76032611|NCT03063827|Drug|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
76032612|NCT03063827|Diagnostic Test|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
76032613|NCT05101837|Device|Home program|Regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality
76032614|NCT04980209|Device|ultrasound evaluation|According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
75387409|NCT00005585|Drug|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
75387410|NCT00005585|Drug|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
75869169|NCT05462522|Drug|Placebo|RO7303509 matching placebo will be administered as SC injection monthly, during the MAD stage.
76032615|NCT03334201|Other|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
75387411|NCT00005585|Drug|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
75387412|NCT00005585|Drug|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
76032616|NCT03334201|Other|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
75387413|NCT00005585|Drug|thioguanine|Given orally
76032617|NCT01669421|Drug|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
76032618|NCT03210571|Device|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
75387414|NCT00005585|Drug|vincristine sulfate|Given IV
75542218|NCT02215876|Drug|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
75387415|NCT00005591|Biological|cetuximab|
75387416|NCT00005591|Drug|gemcitabine hydrochloride|
75387417|NCT00005195|Procedure|Catheter ablation|
75387418|NCT01926444|Drug|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
75387419|NCT00005597|Drug|temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
75387420|NCT00005603|Drug|asparaginase|
75387421|NCT00005603|Drug|cyclophosphamide|
75387422|NCT00005603|Drug|cytarabine|
75387423|NCT00005603|Drug|daunorubicin hydrochloride|
75387424|NCT00005603|Drug|dexamethasone|
75387425|NCT00005603|Drug|doxorubicin hydrochloride|
75387426|NCT00005603|Drug|mercaptopurine|
75387427|NCT00005603|Drug|methotrexate|
75387428|NCT00005603|Drug|prednisone|
75542219|NCT00269997|Drug|epoetin alfa|
76032619|NCT05104021|Device|game|"The game is played with a maximum of four people. Beginning points are marked with blue, red, yellow and green colors, the game progress direction is The starting color for the player is determined with the help of arrows. Dice with the biggest number The child who throws starts the game first from the starting point that belongs to him. Play ground Each child who completes a circuit around him reads from his second point. it tries to go inwards (to the world square) in the direction it points. Equivalent to card check box The next child draws one of the face down cards. the instruction written on the back of the card.~implements. Then he puts the card on the back of the other cards. Cards are reward (go forward), penalty (backward) git) cards. Coming second to the same frame during the game The child first starts the game from the starting point of the child in the square. First The child who manages to enter the world square wins the game."
76032620|NCT05103865|Behavioral|Animal-assisted therapy (AAT)|
76032621|NCT05103865|Other|usual treatment|
75542220|NCT00237731|Drug|morphine|morphine 0.05
75387429|NCT00005603|Drug|thioguanine|
75387430|NCT00005603|Drug|vincristine sulfate|
75387431|NCT00005609|Biological|rituximab|
75387432|NCT00005615|Biological|Interferon alfa|Interferon alfa as outlined in treatment arm.
75387433|NCT00005615|Radiation|Radiation therapy|Radiation therapy as outlined in treatment arm.
75387434|NCT00005627|Drug|carboplatin|
75387435|NCT00005627|Drug|docetaxel|
75387436|NCT00005627|Drug|estramustine phosphate sodium|
75869170|NCT05462288|Device|Entia Liberty|Home monitoring blood analyser
75387437|NCT00005633|Biological|OVA BiP peptide|
75387438|NCT00005633|Biological|gp209-2M antigen|
75387439|NCT00005633|Biological|recombinant 70-kD heat-shock protein|
75387440|NCT00005633|Biological|tyrosinase peptide|
75387441|NCT00005639|Drug|Azacitidine Injection|subcutaneous injection (SC)
75387442|NCT00005639|Drug|sodium phenylbutyrate|continuous intravenous (CIV)
75387443|NCT00005645|Drug|ILX-295501|
75387444|NCT00005663|Drug|Valacyclovir hydrochloride|
75387445|NCT00385775|Drug|AEG35156|weekly IV solution infused over 2 hrs
75542221|NCT00237731|Drug|morphine|morphine 0.10
76032622|NCT05103787|Procedure|deep parasternal intercostal plane block|Twenty milliliters of 0.25% bupivacaine will be placed bilaterally in the fascial plane between internal intercostal muscle and transversus thoracis muscle at intercostal space 4 or 5, lateral from sternum, with ultrasound guidance using high-frequency linear transducer.
76032623|NCT05103787|Procedure|control|Skin puncture with needle will be performed on the same location as the treatment group without administration of local anesthetics.
76032624|NCT03115021|Device|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
75542222|NCT04542226|Drug|Polyoxidonium|Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
75542223|NCT00270036|Drug|epoetin alfa|
75387446|NCT00005675|Drug|Oral bovine type I collagen|500 mcg of CI daily for 15 months
75387447|NCT00005675|Drug|Placebo|CI placebo daily for 15 months
75387448|NCT00385853|Drug|PTK787/ZK 222584|Twice daily for each 28-day cycle
75387449|NCT00385853|Drug|Temozolomide|Daily for each 28-day cycle
75387450|NCT00385853|Procedure|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
75387451|NCT00386321|Drug|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
75542224|NCT01641874|Procedure|Exercise|Directional specific exercise
76032625|NCT03115021|Device|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
75387452|NCT00005711|Behavioral|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
76032626|NCT03115021|Device|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
75705965|NCT02574936|Procedure|A new surgical technique|"Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.~A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used"
76032627|NCT03115021|Device|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
75387453|NCT00005765|Drug|nicotine|
75387454|NCT00005765|Drug|alcohol|
75387455|NCT00005771|Device|Visual utrasound feedback|
75542225|NCT01641874|Procedure|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
75542226|NCT00237848|Drug|D-serine|
75542227|NCT00237848|Behavioral|Cognitive retraining|
75542228|NCT04537975|Device|C2Rx|Hemofiltration
75705966|NCT00923806|Biological|PG13-CEA_TCR (Anti-CEA TCR PBL)|
76032628|NCT04980053|Other|massage|Intervention group Control group
76032629|NCT04973969|Other|Decapeptyl|diagnosis of predictio value
75387456|NCT00005771|Procedure|Abdominal Hollowing Exercise|
75387457|NCT00005777|Procedure|Minimal mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target (>52 mm Hg)
75387458|NCT00005777|Procedure|Routine mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target <48 mm Hg)
75542229|NCT04537975|Other|Standard of Care (SOC)|Standard of care that excludes any protocol restrictions.
75705967|NCT00923806|Drug|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
75705968|NCT00848068|Other|FID 114657|artificial tears
76032630|NCT02961205|Dietary Supplement|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
76032631|NCT04979975|Other|Placebo|PBO- placebo matching to UB-621
76032632|NCT04979975|Biological|UB-621 low-dose|fully human anti-HSV mAb
75705969|NCT00848068|Other|OPTIVE Lubricant Eye Drops|artificial tears
75705970|NCT00711984|Device|Herkulink renal artery Stent|renal artery stent
76032633|NCT04979975|Biological|UB-621 high-dose|fully human anti-HSV mAb
75542230|NCT04538131|Device|sensor-driven position-adaptive SCS|Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
75387459|NCT00005777|Drug|Dexamethasone|Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
75542231|NCT04538131|Device|conventional SCS|Conventional SCS can not change the parameter when the body position changes.
76032634|NCT02958709|Drug|High-dose: RIF, INH, PZA, EMB|high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
76032635|NCT02958709|Drug|High dose: RIF, INH, PZA, LEVO|high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
76032636|NCT02958709|Drug|Standard of care: RIF, INH, PZA, EMB|standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
75387460|NCT00005777|Drug|Placebo|The infants in the placebo groups received equal volumes of saline.
76032637|NCT04979663|Combination Product|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
76032638|NCT05307367|Behavioral|Exercise training|Patients will be enrolled in a 8 week, supervised, single-leg kicking training intervention (1h, or as long as possible, 60-70% peak workload (PWL), 2-5 days a week). Healthy age-, body weight-, gender- and activity level-matched control subjects will undertake the intervention matched to the %PWL obtained by the patients who complete the study.
75387461|NCT00005783|Drug|Recombinant-methionyl human stem cell factor|
75387462|NCT00385931|Drug|Valsartan and simvastatin|
75387463|NCT00386087|Drug|Enzastaurin Hydrochloride|
75387464|NCT00386399|Drug|Mitomycin-C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
75387465|NCT00005801|Biological|therapeutic allogeneic lymphocytes|
75387466|NCT00005801|Procedure|peripheral blood stem cell transplantation|
75387467|NCT00005801|Radiation|radiation therapy|
75387468|NCT00005807|Drug|BMS-247550|anticancer agent for the treatment of patients with malignant tumors.
75387469|NCT00005813|Biological|bispecific antibody MDX447|
75387470|NCT00005813|Biological|lymphokine-activated killer cells|
75387471|NCT00005813|Procedure|conventional surgery|
75387472|NCT00005399|Other|No interventions|No interventions
75387473|NCT04567433|Drug|Hydroxyethyl starch|Hydroxyethyl starch compared to 0.9% saline
76032639|NCT04979819|Other|Upper extremity endurance test (UULEX)|Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
76032640|NCT04979585|Drug|Camrelizumab|200mg ,IV,d1,Q3W.
76032641|NCT04979585|Drug|Anlotinib|8mg,oral, d1-14,Q3W.
76032642|NCT04979585|Drug|nab-Paclitaxel|260mg/m2,IV,d1,Q3W.
76032643|NCT05101603|Device|Air Abrasive|Applied with Nd:YAG Laser on periodontal pockets
75705971|NCT00711984|Other|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
75705972|NCT00856102|Behavioral|Exercise|Home-base walking program
75387474|NCT04567433|Drug|Hydrocortisone|Hydrocortisone compared to Placebo
75387475|NCT04567433|Procedure|Early Goal Directed Therapy|Early Goal Directed Therapy compared to Usual Care
76032644|NCT05101603|Device|Nd:YAG Laser|Applied with Air Abrasive on periodontal pockets
76032645|NCT05101603|Procedure|Non surgical periodontal therapy|The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
76032646|NCT04400513|Device|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart sounds using electronic stethoscopes
76032647|NCT02481817|Procedure|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
76032648|NCT02481817|Procedure|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
75542232|NCT00262392|Drug|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
75542233|NCT04537780|Other|Placebo|Placebo tabled every day
75542234|NCT04537780|Drug|Montelukast|Montelukast 10 mg daily at bed time.
75705973|NCT00856102|Behavioral|Control|Usual care
75705974|NCT00718536|Drug|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
75705975|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
75705976|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
75705977|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
75387476|NCT04569929|Other|(DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture|The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
75387477|NCT00003647|Drug|allovectin-7|
75387478|NCT00003647|Drug|allovectin-7/dacarbazine|
75542235|NCT00237887|Drug|adalimumab|
75542236|NCT04537858|Device|Virtual reality therapy first|First day of the protocol with Virtual Reality intervention in the morning and conventional intervention in the afternoon
75542237|NCT04537858|Device|Conventional therapy first|First day of the protocol with conventional intervention in the morning and Virtual Reality intervention in the afternoon
75542238|NCT04537819|Drug|Imupret in addition to local NAID|Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)
75542239|NCT04537819|Drug|Local NAID (Benzydamin)|(Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
75542240|NCT02215915|Procedure|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
75705978|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
75705979|NCT02572674|Other|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
75542241|NCT02215915|Procedure|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
75542242|NCT02215915|Procedure|DES implantation|
75705980|NCT02572674|Genetic|Genetic sample|Blood samples
76032649|NCT02481817|Procedure|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
75542243|NCT00262431|Procedure|Tracheostomy on day 3-5 in early group and 10-12 in late group|Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
75542244|NCT00237926|Behavioral|Exercise|aerobic or resistance training
75542245|NCT02215993|Drug|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
75542246|NCT02215993|Drug|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
75705981|NCT00856336|Drug|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
75705982|NCT00712062|Drug|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
76032650|NCT04979741|Other|No interventions|Observational study, no intervention is required
75387479|NCT00003647|Drug|dacarbazine|
75387480|NCT05895695|Procedure|levator muscle resection|resection of levator muscle in congenital unilateral ptosis
75387481|NCT05895695|Procedure|levator muscle plication|plication of levator muscle in congenital unilateral ptosis
76032651|NCT05103709|Other|MULTI-FORTIFIED|Treatment with multifortified bread for 120 days
76032652|NCT05103709|Other|FORTIFIED|Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
75705983|NCT00848146|Procedure|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
76032653|NCT04979897|Other|Intensive care unit stay during the COVID-19 pandemic|Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open [close] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
75542247|NCT04537546|Device|OBESINOV elasto-compressive belt|It is a customised medical device, using a technique for calculating the compression ratio adapted to each patient according to his morphology
75557768|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
75542248|NCT04537702|Behavioral|Streamlined Education|After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers. It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.
76032654|NCT05103553|Other|Outpatient Clinic|Follow-up in outpatient clinic
75542249|NCT04537702|Behavioral|Traditional Education|The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time. During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results. The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing. After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
76032655|NCT04979195|Other|Patients with stable normal kidney function|Covid-19 patients with stable kidney function will represent group 1.
76032656|NCT04979195|Other|Patients with unstable kidney function|Covid-19 patients with unstable kidney function will represent group 2.
76032657|NCT05101525|Procedure|Ultrasound|Ultrasound to visualize the intra tendinous marker. If this is in place, healing is effective. On the other hand, if it has migrated, there is no scarring.
76032658|NCT05103397|Drug|methyl prednisolone|Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).
76032659|NCT05103397|Drug|Methyl Prednisolonate|High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)
76032660|NCT05103397|Drug|Placebo|Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
76032661|NCT05101447|Drug|Mycophenolate Mofetil|At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care [MMFBSA: 600 mg/m2/dose; max: 3 gram/day] or pharmacokinetically-driven precision dosing [MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg*h/L].
76032662|NCT05101291|Drug|Bupivacain|Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
76032663|NCT04342169|Drug|Hydroxychloroquine|HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days
76032664|NCT04342169|Drug|Placebo oral tablet|Placebo to be taken on the same schedule as HCQ.
76032665|NCT05103163|Other|Foot Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applie
76032666|NCT04979273|Drug|Dextrose 40 % in Water|injection of adrenaline 1:20.000, followed by dextrose 40% spray
76032667|NCT04979273|Drug|Adrenaline 1 Mg/mL Solution for Injection|injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
76032668|NCT04979273|Procedure|argon plasma coagulation|Thermocoagulation
76032669|NCT04979273|Procedure|Hemoclip|Hemoclip
76032670|NCT05092555|Diagnostic Test|Nasopharyngeal swap for Reverse transcription polymerase chain reaction|Nasopharyngeal swap and Blood sample is taken for doing previous tests and CT chest is done for all patients
76032671|NCT05093881|Biological|Cellgram-LC|Patients who had administered Cellgram-LC in PMC-P-07 study
75542250|NCT04719351|Behavioral|The DIARY mobile application|The mobile application has two main functionalities. First, it will remind the user to report in regular time periods on their mental health status (e.g., sleep disturbances, stress). The assessment is done daily for four weeks. Second, some completed assessments will be combined with a behavioral prompt i.e. short message encouraging the user to engage in one of the strategies that can help coping with stress at work, e.g. remember to take short breaks, exercise in daylight, summarize a day with a colleague after a finished shift.
76032672|NCT04973423|Radiation|MRI|2 additional MRI will be done for the CALM + MRI group
76032673|NCT05073991|Procedure|Lung surgery|Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.
76032674|NCT05073991|Procedure|Open aortic surgery|Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.
76032675|NCT05073991|Procedure|TEVAR|Patients underwent TEVAR.
76032676|NCT05073991|Procedure|EVAR|Patients underwent EVAR.
76032677|NCT05099887|Biological|Procenta conformable barrier|Wound care dressing biologic allograft
76032678|NCT03061799|Dietary Supplement|HPC-03|HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
76032679|NCT03061799|Dietary Supplement|Placebo|Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
76032680|NCT05036473|Drug|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
75542251|NCT04537585|Combination Product|Tomeka®|Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms
75705984|NCT02545816|Device|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
75542252|NCT04537585|Drug|"Vernonia amygdalina"|"Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity)."
75542253|NCT00237965|Behavioral|Mole Mapping Diagram|
75542254|NCT02216110|Procedure|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
75542255|NCT02216149|Drug|S-1|S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
75542256|NCT02216149|Drug|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
76032681|NCT05036473|Drug|Placebo|placebo tablets-matching the active groups.
76032682|NCT04979351|Other|Abdominal Massage|Abdominal massage will be applied twice a day.
75542257|NCT02216149|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 D1 every 3 weeks
75542258|NCT00238004|Drug|Nicotinic acid|
75542259|NCT04537468|Other|Skin squame collection|Subjects underwent skin squame collection by scraping. The investigator gently scraped the surface of a lesional skin area for patients with psoriasis, and of a non-lesional skin area for healthy volunteers to collect superficial cells. These samples were analyzed by gene expression analyses.
75542260|NCT04537468|Other|Tape strip collection|The first subjects had up to 35 tape strips from a maximum of 4 areas (4 X 35 strippings) on the trunk or limbs (excluding the genital area). Patients with atopic dermatitis or psoriasis had tape stripping performed on lesional skin areas and the control subjects had tape stripping performed on nonlesional skin areas. The next subjects were used to determine the optimal number of tape strips required to obtain a good signal by gene expression analyses.
75705985|NCT00712140|Biological|trastuzumab|Given IV
75705986|NCT00712140|Drug|parenteral chemotherapy|per the local institutional protocols either concurrently with or sequentially to trastuzumab
75705987|NCT02546206|Dietary Supplement|Probiotic Yoghurt|Probiotic yoghurt consumption
75705988|NCT02546206|Dietary Supplement|Natural Yoghurt|Natural yoghurt consumption
75705989|NCT02545738|Drug|Liraglutide|active treatment
75705990|NCT02545738|Drug|placebo|placebo
75705991|NCT00712218|Procedure|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
76032683|NCT04985851|Drug|durvalumab + anlotinib|Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.
76032684|NCT04985851|Drug|Durvalumab|durvalumab
76032685|NCT04929769|Other|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
75542261|NCT04537468|Other|Tape strip and skin biopsy collection|Subjects had tape stripping on up to 3 different skin areas (2 areas on lesional skin and one area of nonlesional skin for patients with atopic dermatitis or psoriasis, and 2 areas of healthy skin for control subjects) using the optimal number of tape strips, as determined in the previous part. One 4-mm skin biopsy on a tape stripped area plus one 4-mm biopsy on non-tape-stripped skin (2 biopsies per subject) were also collected.
76032686|NCT04929769|Other|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
75542262|NCT00262548|Drug|Rosuvastatin; improvement of lipid profile|
75542263|NCT04537390|Diagnostic Test|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
76032687|NCT04930861|Drug|Covidir injections|administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
76032688|NCT04930861|Diagnostic Test|One Step Test|rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
76032689|NCT04930861|Diagnostic Test|IgM and IgG dosage|blood collection for dosage of Anti SARS-CoV-2 antibodies.
76032690|NCT04930861|Diagnostic Test|RT-PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
76032691|NCT04930861|Diagnostic Test|Screening blood test|complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
76032692|NCT04930861|Diagnostic Test|ECG|12-lead electrocardiogram with report.
76032693|NCT04930861|Diagnostic Test|Medical evaluation|evaluation by the principal investigator or assistant physician with a complete physical examination.
76032694|NCT04930861|Diagnostic Test|NEWS-2 score|assessment of the participant by the NEWS-2 score.
76032695|NCT04930861|Diagnostic Test|WHO score|assessment of the participant by the score of the World Health Organization.
76032696|NCT04979507|Other|Uninterrupted sleep followed by functional neuroimaging.|2 within-subject sleep conditions: uninterrupted sleep; selective REM sleep reduction, followed by functional neuroimaging with emotion reactivity and regulation tasks the following morning
76032697|NCT05099575|Drug|Syntocinon, papal, misotac|Using different drugs to prevent atonic PPH during CD in high risk group
75542264|NCT04536883|Procedure|microscopy confocal|"At this stage, the confocal microscopy procedure begins:~Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.~Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.~The fibroscopy procedure is then resumed as usual in the department, namely:"
75542265|NCT00238043|Drug|Biogeneric Epoetin|
76032698|NCT03061955|Biological|influenza vaccination|administration of influenza vaccination
76032699|NCT04979039|Other|analgesia nociception index (ANI) monitoring|The ANI monitor starts lying on the bed in the waiting area before entering the operating room, and the monitoring period should be at least 15 minutes. After entering the operating room, monitoring begins again and is maintained during the operation.
76032700|NCT04919551|Drug|vicagrel|Oral administration after fasting/high-fat meal/low-fat meal
76032701|NCT03063515|Drug|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
76032702|NCT04907773|Other|Capillary blood sampling|Each subject will have one to two capillary blood collections.
76032703|NCT04907773|Other|Venous blood sampling|Each healthy subject will also have a reference venous blood collection.
76032704|NCT04907773|Other|Arterio-venous blood sampling|Each hemodialysed subject will also have a reference arterio-venous blood collection.
76032705|NCT04973813|Behavioral|Guideline + Active Choice + action&coping planning (GA+)|Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning
76032706|NCT04973813|Behavioral|Guideline + Active Choice (GA)|Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
76032707|NCT04973813|Behavioral|Guideline + information (GI)|Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.
76032708|NCT04973813|Behavioral|Guideline (G)|Web-based information about the national physical activity guideline.
76032709|NCT04894981|Device|Immersive condition (CAVE)|Driving course with obstacles in a CAVE system
76032710|NCT04894981|Device|Immersive condition (HMD)|Driving course with obstacles with a virtual reality headset
76032711|NCT04894981|Device|Non Immersive condition (Screen alone)|Driving course with obstacles on a screen with physical simulator
76032712|NCT04894981|Device|Non Immersive condition (Screen with physical simulator)|Driving course with obstacles on a screen only
76032713|NCT04973501|Behavioral|Manual physiotherapeutic correction (MFK) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
75705992|NCT00712218|Procedure|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions [24, ].
75705993|NCT00848224|Behavioral|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
76032714|NCT04973501|Behavioral|Dynamic Neuromuscular Stabilization (DNS) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total).Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
75705994|NCT00848302|Drug|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
75705995|NCT02572596|Drug|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
75705996|NCT02572596|Drug|CTX|CTX 2.5/m2 for 2 days.
75705997|NCT02572596|Drug|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
75705998|NCT00718614|Procedure|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
75705999|NCT04069728|Other|Explanation with 3D printed fistula model|Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.
75706000|NCT04069728|Other|Standard explanation|Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
76032715|NCT04858945|Behavioral|Teach-back method|During the trial, women from teach-back group and controlled group will receive three education sessions The topics discussed at the first session included delivery mode, labor process and pain relief, newborn health and care (common health issues and care skills), perinatal die and excises, and perinatal psychological health. The topics discussed at the second session includ postpartum recovery, postpartum maternal health, perineum care (diet, oral care, perineal care, and hygiene), breastfeeding, postpartum blue and depression, neonatal care, neonatal screening tests, newborn vaccination and early child development. At two-week postpartum, the educator answers questions raised by the woman and gives advices on the challenges and difficulties in postpartum recover and caring newborn faced by the woman.
76032716|NCT04973735|Drug|LY-CovMab|single IV infusion
76032717|NCT04973579|Procedure|Simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) and cardiac surgery (CABG or surgical valve replacement / repair procedure)|"The registry enrolls patients qualified for treatment with the methods evaluated in the registry, using routinely applicable procedures and devices.~In cardiac surgery - surgical treatment systems for advanced ischemic heart disease and/or valvular disease (including - mechanical/biologic heart valves - regulatory approved for routine use and typically used at the Facility.~In the simultaneous treatment of stroke-threatening carotid artery atherosclerosis - temporary neuroprotection systems (proximal, distal, according to medical indications and local experience) - regulatory approved for routine use and typically used at the center (for over 20 years).~CGuard anti-embolic mesh stent system - a self-expanding nitinol carotid stent wrapped in MicroNet, which prevents fragments of atherosclerotic plaque from entering the lumen of the carotid artery - approved for routine use and typically used at the Center (over 5 years)."
76032718|NCT04834063|Diagnostic Test|Serum Zinc a level|Diagnostic test
76032719|NCT04834063|Diagnostic Test|serum selenium level|Diagnostic test
76032720|NCT04834063|Diagnostic Test|Fibroscan measurement|Diagnostic test
76032721|NCT04978961|Behavioral|Focused Acceptance & Commitment Therapy (FACT)|FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.
76032722|NCT04978961|Behavioral|Enhanced Treatment as Usual (ETAU)|This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
76032723|NCT04794205|Drug|Low Dose Beta-Caryophyllene|5 mg BCP
76032724|NCT04794205|Drug|Medium Dose Beta-Caryophyllene|30 mg BCP
76032725|NCT04794205|Drug|High Dose Beta-Caryophyllene|150 mg BCP
76032726|NCT04794205|Drug|Placebo|Placebo drug.
76032727|NCT04973033|Drug|Tofacitinib|patients enrolled were prescribed tofacitinib 5mg twice a day orally.
76032728|NCT04436653|Device|Tricuspid Valve Replacement System|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.
75542266|NCT04536844|Device|Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)|An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
75542267|NCT04536844|Other|Conventional prescheduled follow-up|Patients will be followed in the outpatient clinic by prescheduled follow-up
76032729|NCT02660281|Radiation|Total Body Irradiation 1200 cGy|1200 cGy TBI in 8 fractions
75387482|NCT05895682|Device|mobiCARE +Pulse (MP100W)|Volunteers were monitored using end-tidal carbon dioxide partial pressure and fraction of inspired oxygen. Each volunteer was placed in a semi-Fowler's position and connected to a breathing circuit to administer the nitrogen-air-carbon dioxide mixtures. A nose clip was applied to prevent breathing of room air. For frequent blood sampling, an arterial cannula was placed in the radial artery of each volunteer. Pulse oximeter probes were simultaneously attached to each volunteer's fingers. Each volunteer was exposed to various levels of induced hypoxia from 70~100% of SaO2. Each plateau of oxygen saturation was maintained for at least 30 s until stabilization, after which 1 ml of arterial blood was drawn into a heparinized syringe. The study period consisted of two rounds of hypoxia, and the volunteers were maintained on room air between each round. SaO2 measurements using a CO-oximeter were used as a reference for the SpO2 accuracy.
75387483|NCT05895656|Other|7 Tesla MRI|Performing an additional 7 Tesla MRI examination as part of the initial treatment pathway.
76032730|NCT02660281|Drug|Fludarabine|Fludarabine
75542268|NCT00415584|Drug|Cinacalcet HCl|
76032731|NCT02660281|Drug|Pre-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given prior to the stem cell infusion
75542269|NCT04537273|Other|Descriptive and analytical|
75542270|NCT04536922|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
76032732|NCT02660281|Drug|Pre-Stem Cell Infusion Mesna|Mesna given prior to the stem cell infusion
76032733|NCT02660281|Drug|Busulfan|Busulfan
76032734|NCT02660281|Drug|Melphalan|Melphalan
76032735|NCT02660281|Procedure|Stem Cell Infusion|Stem cell infusion
76032736|NCT02660281|Drug|Post-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given after the stem cell infusion
76032737|NCT02660281|Drug|Post-Stem Cell Infusion Mesna|Mesna given after the Stem Cell Infusion
76032738|NCT02660281|Drug|Thiotepa|Thiotepa
75542271|NCT04536922|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
75542272|NCT04536922|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
75542273|NCT04536922|Drug|Pembrolizumab (KEYTRUDA(R))|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
75542274|NCT04536922|Biological|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
75542275|NCT04536961|Drug|Reference Treatment- BMS-986165-01|Specified dose on specified days
75542276|NCT04536961|Drug|Prototype BMS-986165|Specified dose on specified days
75542277|NCT04536961|Drug|Famotidine|Specified dose on specified days
75542278|NCT04536961|Other|Alcohol|Specified quantity on specified days
75542279|NCT04537117|Other|Questionaire|Questionnaire addressing pediatric dentists behaviors and practices during the COVID-19 pandemic
75542280|NCT04542265|Combination Product|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
75542281|NCT00415662|Device|Pulsed Signal Therapy (PST)|
75542282|NCT04536610|Behavioral|Providing structured osteoporosis education|The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.
75542283|NCT04536610|Behavioral|Giving informative leaflet|Leaflets containe the same information as the OP education program
75542284|NCT00238160|Drug|cisplatin|
75542285|NCT00238160|Drug|fluorouracil|
76032739|NCT03061487|Procedure|Open Surgical Treatment of Aneurysm (Aneurysmectomy)|Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
76032740|NCT02438995|Drug|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
76032741|NCT03061409|Dietary Supplement|Pharmavite Nature Made Multi for Him 50+|To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
76032742|NCT03061409|Dietary Supplement|Placebo|served as placebo
76032743|NCT04978883|Other|No intervention|No intervention
76032744|NCT04662307|Device|Intelligent cardiopulmonary rehabilitation system (ICRS)|Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%~80% HRR determined in the pretest of cardiopulmonary exercise test.
76032745|NCT04526041|Other|Nasofibroscopy|Laryngeal exploration performed using a flexible fibrescope while singing.
76032746|NCT04526041|Other|Electroglottography|Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.
75706001|NCT00712374|Drug|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
76032747|NCT04526041|Other|Air flow measurement + acoustic signal recording|Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)
75706002|NCT02573220|Biological|Cetuximab|Given IV
75387484|NCT05895630|Behavioral|Interactive physical exercise|Interactive remote sessions of physical exercise in groups of 10 patients. The sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The intervention will last 12 weeks. The sessions will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
75387485|NCT05895630|Behavioral|Video physical exercise|Individual remote sessions of physical exercise based on pre-recorded videos. The video sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The videos will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
76032748|NCT04526041|Other|Questionnaire|Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
76032749|NCT01669811|Drug|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
75542286|NCT00238160|Procedure|adjuvant therapy|
75542287|NCT00238160|Procedure|chemotherapy|
75542288|NCT00238160|Procedure|conventional surgery|
75706003|NCT02573220|Drug|Fluorouracil|Given IV
75706004|NCT02573220|Drug|Irinotecan Hydrochloride|Given IV
76032750|NCT01669811|Drug|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
76032751|NCT05173285|Diagnostic Test|Baseline Assessment|At baseline (i.e. Pre-intervention) participants will complete several questionnaires online via Qualtrics.
75706005|NCT02573220|Drug|Leucovorin Calcium|Given IV
76032752|NCT05173285|Behavioral|Brief Online ACT Intervention|Participants will complete the 4-week online intervention via Qualtrics
76032753|NCT05173285|Diagnostic Test|Post-Intervention Assessment (i.e. between 4-6 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
76032754|NCT05173285|Diagnostic Test|Follow-up Assessment (i.e. between 8-12 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
75387486|NCT05895591|Other|Anti-aging cosmetic care product|"frequency of application: Once a day (in the morning)~modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~duration of investigational product application: 56 days (a window of + 72 hours is allowed)~quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm"
76032755|NCT04972877|Other|Treatment group protocol|"For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25*40/50 mm) will be inserted into a depth of 15~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group."
75387487|NCT05895539|Other|An automated patient-reported outcome data collection and adverse event surveillance tool|Patients received a short prompt to provide information on treatment satisfaction and side effects
75387488|NCT05895526|Procedure|Self etch dentin adhesive, Fluoride varnish|After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.
75542289|NCT00238160|Procedure|hepatic arterial infusion|
75542290|NCT00238160|Procedure|surgery|
75706006|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
75706007|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
75706008|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
75542291|NCT04536649|Radiation|Radiotherapy|Multimodal brain imaging-guided radiotherapy using different beams
76032756|NCT04972877|Other|Control group protocol|"For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18*25 mm) will be inserted superficially to a depth of < 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes."
76032757|NCT03061877|Other|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
76032758|NCT04601935|Biological|LCAR-BCX cells product|In this study, LCAR-BCX CAR+ cells will be evaluated at 5 dose levels including 0.25 × 10^6 cells/kg, 0.5 × 10^6 cells/kg, 1.0 × 10^6 cells/kg, 2.0 × 10^6 cells/kg, and 4.0 × 10^6 cells/kg, with 0.25 × 10^6 cells/kg as the starting dose, to determine RP2D for LCAR-BCX cell therapy
76032759|NCT04220723|Other|Frailty Assessment|"Liver Frailty Index measurements:~Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each."
75387489|NCT05895461|Behavioral|BWLI-College|"Behavioral modifications are based on empirically-supported principles for weight loss.~Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (~100-200 calories) that they build on over the course of the intervention.~Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant."
75387490|NCT05895448|Drug|velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .|Directly active antiviral therapy (velpatasvir 100 mg+sofobuvir 400 mg) once daily
75387491|NCT05895435|Device|radiofrequancy|"Power of device: 150 W~Duration of the session: 40 minutes~Frequency: 2 sessions per week for 8 week.~Heating temperature: According to patient tolerance."
75387492|NCT05895435|Other|aerobic exercise|The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination
75387493|NCT05895370|Biological|HPV-T|Participant will receive HPV-T iv on day 0. One time of cell infusion constitute a cycle, each participant receives up to four cycles of treatment
75387494|NCT05895370|Drug|Interleukin-2|500,000IU/m^2 SC, after each cell infusion, IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
75387495|NCT05895305|Combination Product|Paclitaxel-Coated Pulmonary Balloon Catheter|Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure
75387496|NCT05895240|Drug|Ulinastatin|Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
75387497|NCT05895227|Procedure|Oocyte retrieval|
75542292|NCT04536454|Drug|[18F]FPyGal|Radiotracer for PET-imaging
76032760|NCT04220723|Other|Functional Capacity Assessment|Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
76032761|NCT04978181|Drug|Alteplase Injection|thrombolytic therapy for acute ischemic stroke in time window
75387498|NCT05895214|Procedure|oncological relevance of the mesopancreas|Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
75387499|NCT05895188|Device|Virtual Reality Glasses|From the beginning to the end of the procedure, women will watch the selected nature video.
75387500|NCT05895175|Other|Questionnaires|Questionnaires
75542293|NCT00415701|Drug|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
75542294|NCT00415701|Drug|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
75542295|NCT00415701|Drug|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
75542296|NCT00415701|Drug|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
75542297|NCT00415701|Other|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
75542298|NCT02961998|Drug|Celecoxib|Patients from experimental group will take celecoxib, except for sorafenib
75542299|NCT02961998|Drug|Sorafenib|Each group will receive sorafenib as basic treatment.
75706009|NCT04070274|Procedure|different types of surgery platforms|58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
75387501|NCT05895149|Other|Flying buttress technique|With the volunteer in a supine position, the researcher who applied the technique positioned himself standing at the head of the massage table, supporting the patient's head. He contacted the occipital region, near the occipital-mastoid suture, with the thenar and hypothenar region of his right hand. He contacted the mastoid process of the contralateral temporal bone with the thenar and hypothenar region of his left hand. The forearms were positioned in a straight line. After a slight initial compression, the researcher applied a rhythmic pumping motion with both upper limbs in a convergent direction. The pressure applied was due to the rhythmic movement of the researcher's body. The technique was performed bilaterally and each one lasted for 2 minutes
76032762|NCT04978025|Drug|Colloidal Silver|"Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
75542300|NCT04536727|Behavioral|Fit & Strong!|The 8-week intervention will consist of the Fit & Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content
75542301|NCT04536727|Behavioral|Wait list|Participants randomized to the wait list group receive the 8-week Fit & Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
75542302|NCT04536415|Drug|Oseltamivir Phosphate 75 mg capsules|Capsules, 75 mg, single, oral dose
76032763|NCT04978025|Drug|Placebo|Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
76032764|NCT05127811|Drug|ZN-d5|BION design
76032765|NCT04978103|Drug|Gum Arabic|A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
76032766|NCT04437173|Device|Virtual Reality Headset Distraction|Patient wears a virtual reality headset during interventional pain procedure
75542303|NCT04536415|Drug|Tamiflu capsules 75 mg|Capsules, 75 mg, single, oral dose
75542304|NCT04536220|Diagnostic Test|Endoscopic Ultrasound (EUS), Fine Needle Aspiration|Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
75706010|NCT02572440|Procedure|Sorin XTRA/Sorin Group,|
75706011|NCT00718848|Procedure|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
75706012|NCT00718848|Procedure|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
76032767|NCT04154579|Behavioral|HeRe We Arts|Art Therapy interventions to promote health, resilience & well-being will discussed; & experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, & music-assisted relaxation techniques will be utilized; & discussion of use of music to elicit positive physical & emotional responses will be held. Drums Alive (drumming & movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, & Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.
76032768|NCT04154579|Behavioral|HeRe We Ed|Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
76032769|NCT04508179|Drug|7HP349 Single Ascending Dose|Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
75387502|NCT05895149|Other|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The palm of the hand rested on the acromioclavicular joint with the rest of the hand relaxed. The placebo technique was performed for 4 minutes.
75387503|NCT05895136|Drug|Human albumin|"Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01"
76032770|NCT04508179|Drug|7HP349 Multiple Ascending Dose|Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)
76032771|NCT04508179|Drug|Placebo Single Ascending Dose|Part A: Placebo Capsules, Single Ascending Dose (SAD)
76032772|NCT04508179|Drug|Placebo Multiple Ascending Dose|Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
75542305|NCT00262587|Drug|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
76032773|NCT04508179|Drug|7HP349 Food Effect|Part C: 7HP349 Capsules, Food Effect
76032774|NCT04400149|Diagnostic Test|amniocentesis|amniocentesis will be performed to the pregnant women at 16-20 weeks who had a high-risk antenatal test. Furthermore, these women also give a blood sample (at 16-20 weeks) to compare the amniotic fluid and serum progesterone levels in association with pregnancy outcomes. We perform amniocentesis to evaluate genetic disorders in pregnant women who had his risk in the antenal test.
75387504|NCT05895136|Drug|Enoxaparin|Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
75542306|NCT00262587|Drug|Placebo|Inhaled sugar powder in a placebo inhaler
75387505|NCT05895136|Drug|Standard medical treatment|SMT will be considered non-study medication and is not specified in the protocol.
76032775|NCT04437017|Drug|Olanzapine+NK-1 RA+5-HT3 RA|On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
75387506|NCT05895123|Drug|Rosuvastatin 20 mg ,40 mg|patients will receive one tablet rosuvastatin 20-40 mg every night
75542307|NCT00238199|Dietary Supplement|calcitriol|
75542308|NCT00238199|Drug|docetaxel|
75542309|NCT04536259|Behavioral|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
75706013|NCT00618982|Drug|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
75706014|NCT00716352|Behavioral|Educational intervention programme|
75706015|NCT02544880|Drug|Tadalafil|Tadalafil tablets administered by mouth. Dose will be between 10 to 20 mg adjusted depending on patient's body weight. On course 1, Tadalafil will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil will be administered daily for 14 consecutive days. No Tadalafil will be provided on Course 5.
76032776|NCT04437017|Drug|Dexamethasone+NK-1 RA+5-HT3 RA|On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
76032777|NCT03061253|Other|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
76032778|NCT03061253|Other|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
76032779|NCT03061253|Other|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
76032780|NCT04972643|Dietary Supplement|EPA|EPA 2000mg Soft capsules
76032781|NCT04972643|Dietary Supplement|DHA|DHA 2000mg Soft capsules
76032782|NCT04972643|Dietary Supplement|Placebo|Placebo Soft capsules
76032783|NCT05107141|Procedure|Ridge preservation|Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane
76032784|NCT05107141|Device|bone graft plus a collagen membrane|
76032785|NCT05107063|Drug|Pravastatin|Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
76032786|NCT04977713|Other|Acupressure|A researcher sat behind the women to comfortably access the sacral area and be in the appropriate position. The researcher then applied deep rotational pressure on the BL32 points until her nail bed colour changed to prevent any discomfort in the participants
76032787|NCT04977713|Other|Shower|During uterine contractions, these participants took a shower while standing, with a researcher on hand to assist her (average time: 20 minutes). The water's temperature was between 22°C and 26°C.
76032788|NCT05106907|Biological|ThisCART19 cells|0.2-60 x 10^6 CAR T cells per kg body weight
76032789|NCT05106829|Other|Physical therapy program with treadmill training without using of ankle weights.|The physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill without ankle weights.
75387507|NCT05895123|Drug|Atorvastatin 40mg,80mg|patients will receive one tablet Atorvastatin 20-40 mg every night
75387508|NCT05895110|Biological|Recombinant Novel Coronavirus vaccine (CHO Cells)|The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
76032790|NCT05106829|Other|Physical therapy program with treadmill training with using of ankle weights.|he physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill with ankle weights.
75387509|NCT05895097|Device|Left bundle branch pacemaker|Left bundle branch pacing (LBBP) will be the pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Final lead position will be confirmed according to ECG parameters. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory.
75387510|NCT05895097|Device|Conventional pacing|Right ventricular pacing in patients with LVEF ≥ 40% and cardiac resynchronization therapy in patients with LVEF < 40 %
75387511|NCT05895084|Behavioral|Group Yoga|Yoga is delivered as described in an earlier section in a group format. Classes are an hour in duration and occur once per week for 8 weeks, and they are led by an adaptive yoga specialist.
75387512|NCT05895071|Drug|5%potassium hydroxide|. In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks
75387513|NCT05895071|Drug|Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
75387514|NCT05895032|Other|Exercise|12-week exercise intervention
75387515|NCT05895032|Other|Usual Care|usual care
75387516|NCT05894993|Device|transient elastograghy|is a non-invasive method proposed for the assessment of hepatic fibrosis in patients with chronic liver disease by measuring liver stiffness. It can be easily performed at the bedside or in the outpatients clinic with immediate results and good reproducibility.
75387517|NCT05894980|Device|active tDCS stimulating left DLPFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
75387518|NCT05894980|Device|active tDCS stimulating right OFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
75387519|NCT05894980|Device|sham tDCS|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
75387520|NCT05894954|Dietary Supplement|Precision Medicine Approach|Precisions Medicine Approach involves a combination of medicines, dietary supplements, lifestyle changes, and diagnostics
75542310|NCT04536259|Behavioral|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
75557769|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
75387521|NCT05894954|Combination Product|Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises|"Tailored Medications and Devices to address imbalances per lab results, known to affect cognitive function:~Potential Devices: Oura Ring, Continuous Glucose Monitor, Keto-Mojo, and Heartmath Inner Balance. Few may receive Hyperbaric Oxygen Treatment, neurostimulation, neurofeedback, neurostimulation to reduce stress and relax the body), photobiomodulation (light therapy), or CPAP.~Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.~Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine Penicillin G, Methylene Blue, Nystatin, Clotrimazole, Metronidazole, Valacyclovir, Acyclovir, Famciclovir, Shingles Vaccine Vascular treatments may include: antihypertensives, Ubrelvy, aspirin, Eliquis"
75706016|NCT02544880|Biological|Anti-MUC1 Vaccine|300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
75542311|NCT04536259|Behavioral|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
75387522|NCT05894954|Behavioral|Standard-of-Care|Participate in cognitively stimulating and social activities, exercise, sleep, control risk factors, adhere to a health diet, consult physician if conditions worsen
75387523|NCT05894954|Behavioral|Lifestyle including diet, exercise, stress management|Combining a tailored diet, exercise and stress management program supported by coaching specialists
75387524|NCT05894915|Procedure|open surgery|Open surgery is a traditional surgery method.
75387525|NCT05894915|Procedure|laparoscopic surgery|Laparoscopic surgery is a newly developed minimally invasive method.
75387526|NCT05894889|Biological|Pembrolizumab 200 mg IV infusion|"Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion"
76032791|NCT04432181|Other|ophthalmic examination|ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
75387527|NCT05894863|Device|Smart flex stent|Smart flex stent will be used for femoropopliteal occlusive lesions.
75557770|NCT00438581|Drug|Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )|
75557771|NCT00438620|Behavioral|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
75706017|NCT02544880|Biological|Anti-Influenza Vaccine|300 uL Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
75706018|NCT02544880|Other|Tadalafil Placebo|Placebo tablets mimicking Tadalafil administered by mouth. On course 1, Tadalafil Placebo will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil placebo will be administered daily for 14 consecutive days. No Tadalafil Placebo will be provided on Course 5.
76032792|NCT04422613|Diagnostic Test|pulmonary anomalies 4 months after documented COVID-19 pneumonia|Characterization of pulmonary damage with a complete pulmonary assessment 4 months after COVID-19 pneumonia,
75387528|NCT05894850|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
75387529|NCT05894850|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
75387530|NCT05894850|Other|Manually remind the patients|Medical staff remind patients manually .
75542312|NCT04536064|Procedure|LVA and liposuction|"Tumescent technique in lymph-sparing fashion was adopted. Areas were infiltrated with a mix of a standard tumescent solution consisting for each liter of in 1000 ml of saline solution, 50 ml lidocaine 1%, 1 ml epinephrine 1:1000, 10 ml bicarbonate 8,4%. Infiltration volume was approximately from 0,5 to 1 liter for the upper extremities and 1-2 liters for lowers. Three to 4 mm 3 holes blunt cannulas were employed. Aspiration technique was as parallel as possible along the lymphatic network pattern and from superficial to deep layers.~Lymphatic vessels identified at ICG lymphography were spared. Volume of the aspirate was aimed to approximate 80 percent of the volume difference between the affected and non affected side.~The number and type of anastomosis were recorded as well as amount of removed lipoaspirate versus the excess limb volume."
75706019|NCT02544880|Other|Anti-MUC1 Vaccine Placebo|Placebo for Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Placebo for Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5..
75706020|NCT02544880|Other|Standard of Care Treatment|Treatment according to prescribed standard of care regimen.
76032793|NCT04971317|Behavioral|Sugar-Sweetened Beverage (SSB) Video|Participants will watch a video showing the decay of an egg in various SSBs (Coca-Cola, Sprite, Gatorade, and apple juice), followed by the evaporation of these beverages over a heat source, revealing their sugar content.
76032794|NCT04971317|Behavioral|Water Video|Participants will watch a video showing an egg maintaining its shell in water, followed by the evaporation of water.
76032795|NCT04971317|Behavioral|Control|Participants will watch a video of an egg maintaining its shell in rubbing alcohol, followed by the evaporation of rubbing alcohol.
76032796|NCT05106751|Device|Hyaluronic acid dermal filler|Hyaluronic acid dermal filler used for facial volume or wrinkle correction
75387531|NCT05894837|Drug|Serplulimab+Regorafenib|Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
75387532|NCT05894837|Drug|Hepatic Artery Bicarbonate Infusion|hepatic artery bicarbonate infusion: once every four weeks
75387533|NCT05894824|Drug|T-Dxd(Trastuzmab deruxtecan), Ramucirumab|"Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~Dosing Regimen~Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle"
75387534|NCT05894811|Diagnostic Test|oral glucose tolerance test|Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.
75387535|NCT05894811|Diagnostic Test|MRI|Using MRI to quantify of fat content in the liver and pancreas of the subjects
75387536|NCT05894746|Dietary Supplement|gluten-free|see info in arm description
75387537|NCT05894746|Dietary Supplement|probiotic|see info in arm description
75387538|NCT05894746|Dietary Supplement|gluten|see info in arm description
75387539|NCT05894733|Other|study group|Calling with phone frequently(15.th day, 1 month , 3 month, 6 month ) and face to face interwiew on first, 3 th and 6th month
76032797|NCT04383379|Behavioral|Experimental: Intervention group|The intervention NICUs (n = 6) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes toimprove the rate of breastfeeding . Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
76032798|NCT05106673|Behavioral|Optimal pathways to care|The first implementation measure focuses on optimal ways of caring for mentally ill patients who are also parents with children living in the household. The main goals of this intervention are the specific information of the referring physician, the indicated referral of mentally ill parents and the consideration of underage children living in the household in the inpatient referral. The two main components are the evaluation of the attitudes of the medical and psychotherapeutic referrers towards the target group and the intervention as well as the development and implementation of an optimal care pathway. The optimization of the allocation is organized by Silke Pawils (University Medical Center Hamburg-Eppendorf).
75387540|NCT05894733|Other|control group|first and sixth month face to face interwiew
75387541|NCT05894720|Other|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs."
75387542|NCT05894707|Drug|SCT650C|Recombinant anti-IL-17A antibody
75387543|NCT05894694|Drug|palliative care group first-line scheme+compound kushen injection|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml, at least 4 cycles of chemotherapy.
75387544|NCT05894694|Drug|palliative care group first-line scheme|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
75387545|NCT05894668|Other|ECIRS|Endoscopic Combined Intrarenal Surgery
75387546|NCT05894642|Behavioral|0|It is a case-control study, cross-sectional, so there is no intervention possible.
75387547|NCT05894629|Behavioral|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|12-week program consisting of PNE and TE
75387548|NCT05894629|Behavioral|Active Comparator: Usual treatment|12-week program consisting of home exercises, performed 3 days/week.
75387549|NCT05894551|Other|Evaluation of q angles different positions|Q angle evaluation in two different static postures (upright and supine position) and dynamic posture during the midstance phase of the gait
75387550|NCT05894551|Other|Physical examination|"With goniometric evaluations, the femoral anteversion angle will be measured. Pelvis width and thigh length will be measured with a tape measure. Quadriceps muscle strength, hamstring muscle strength, Hip abduction, adduction, internal and external rotation and extension muscle strength will be measured with hand-held dynamometer.~Joint mobility will be assessed with the Beighton score and foot posture will be evaluated with the foot posture index-6 (FPI-6)."
75387551|NCT05894551|Other|Functional mobility assessment|10-meter walking test will be conducted to understand functional mobility.
75542313|NCT04536493|Drug|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)|1 application of LET topical anesthetic gel
75387552|NCT05894486|Drug|Lutetium[177Lu] Oxodotreotide Injection|Lutetium[177Lu] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium[177Lu] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
75387553|NCT05894447|Drug|Naptumomab Estafenatox|5 or 10 µg/kg IV naptumomab estafenatox will be given on the first four days of every 21-day treatment cycle for 6 cycles
75387554|NCT05894447|Drug|Pembrolizumab|200 mg IV pembrolizumab will be given on day 2 of each 21 day cycle for up to 24 cycles
75387555|NCT05894447|Drug|Obinutuzumab|Two doses of 1,000 mg IV obinutuzumab given prior to starting pembrolizumab and naptumomab estafenatox
75387556|NCT05894434|Behavioral|Multisensory Training|The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.
75387557|NCT05894434|Behavioral|Unisensory Training|The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).
75387558|NCT05894408|Other|this is no intervention|this is no intervention
75387559|NCT05894382|Device|Double Helix Design Defocus Lens Spectacle (RACE)|Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.
75387560|NCT05894382|Device|single-vision spetacle lens|single-vision spetacle lens wearing more than 10h/day.
75706021|NCT02544880|Other|Anti-Influenza Vaccine Placebo|Placebo for Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Placebo for Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
75387561|NCT05894343|Genetic|AAV-GAD|Bilateral infusion of AAV-GAD
75387562|NCT05894278|Other|Prescription data collection|Prescription data collection
75387563|NCT05894265|Other|ActiveMatrix® Dosage A|This group will receive ActiveMatrix® (AM) product dosage A (1cc AM diluted to 3cc with saline)
75387564|NCT05894265|Other|ActiveMatrix® Dosage B|Group 2 will receive ActiveMatrix® product dosage B (2cc AM diluted to 3cc with saline)
75387565|NCT05894265|Procedure|Saline injection|Group 3 will receive saline injection
75387566|NCT05894252|Other|Walking Interventions|"Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via a questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity.~The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti watches, which will be given to them for free."
75387567|NCT05894226|Procedure|laparoscopic ventral mesh rectopexy|patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
75387568|NCT05894200|Other|Glass Ionomer cement pit and fissure sealant, Silver Diamine Fluoride|GC Fuji 7, e-SDF
75387569|NCT05894161|Other|Exercise training program|"The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.~Diaphragmatic Breathing Exercises: Diaphragmatic breathing (DBRT) or abdominal deep breathing is an expansion of the abdominal area rather than the thoracic area when breathing.~Progressive Muscle Relaxation (PMR): The physical element includes the tensing and relaxing of all muscle groups over the face, arms, trunk (abdomen & chest) and legs.~A combination of stretching, stabilization and strengthening exercises of the pelvic-lumbar region:~Walking exercise: Walking on the ground surface for 30 minutes every day."
75387570|NCT05894148|Drug|Genakumab injection|Group 1: 120mg Q4W，group 2: 200mg Q4W
75387571|NCT05894148|Drug|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
75387572|NCT05894135|Drug|BG2109 100mg|One tablet of BG2109 100mg , oral , once daily
75706022|NCT00856570|Drug|warfarin|Oral
75706023|NCT00856570|Drug|YM178|Oral
75706024|NCT04068870|Behavioral|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
75387573|NCT05894135|Drug|BG2109 200mg|One tablet of BG2109 200mg, oral , once daily.
75387574|NCT05894135|Drug|ABT(E2 1 mg / NETA 0.5 mg)|One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
75387575|NCT05894135|Drug|BG2109 100mg Placebo|One tablet of BG2109 100mg Placebo, oral , once daily.
75869171|NCT05447858|Other|SWEA|Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.
75387576|NCT05894135|Drug|BG2109 200mg Placebo|One tablet of BG2109 200mg Placebo, oral , once daily.
75387577|NCT05894135|Drug|ABT Placebo|One tablet of ABT Placebo, oral, once-daily
75387578|NCT05894044|Other|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
75387579|NCT05894044|Other|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
75387580|NCT05894044|Other|Pulsed current 500 µs phase|Pulsed current, modulated in 50 Hz, 500 µs
75387581|NCT05894044|Other|Pulsed current 200 µs phase|Pulsed current, modulated in 50 Hz, 200 µs
75387582|NCT05894031|Behavioral|Wim Hof Method|The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
75387583|NCT05893992|Device|Hearing aids (omnidirectional)|Device for hearing loss compensation with microphone sensitivity all around the listener.
75387584|NCT05893992|Device|Hearing aids (directional)|Device for hearing loss compensation with microphone sensitivity in front of the listener.
75387585|NCT05893992|Other|Unaided|Control condition
75387586|NCT05893966|Radiation|Whole breast irradiation +/- tumor bed boost|Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)
75387587|NCT05893953|Device|immediately feedback device|Sitting in a standard chair with immediate feedback device
75387588|NCT05893953|Device|Unstable chair|sitting in an unstable chair
75387589|NCT05893953|Other|Standard chair|Sitting in a standard chair
75387590|NCT05893849|Drug|Clinical probes|Inpatients taking one or more clinical probes of CYP2C19 (omeprazole, rabeprazole, pantoprazole), CYP2D6 (metoprolol, carvedilol), CYP3A4 (rivaroxaban, finasteride, amlodipine, simvastatin), OAT (meropenem), OATP1B1 (atorvastatin, rosuvastatin) and OCT (metformin) will be included in the study.
75387591|NCT05893810|Drug|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares
75542314|NCT04536493|Drug|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)|3 applications of LET topical anesthetic gel
75542315|NCT04536181|Drug|Prednisolone|12 weeks prednisolone treatment
75542316|NCT04536181|Drug|Placebo|12 weeks simulated tablets
75542317|NCT00262626|Drug|Intraocular pressure reduction|
75706025|NCT00852280|Device|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
75869172|NCT05447858|Other|Neck-specific exercise|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
75869173|NCT05445284|Behavioral|Group education sessions for parents plus usual diabetes care|≥3 in person/virtual group education sessions for parents in addition to usual diabetes care, every 3 months for 12 months
75387592|NCT05893784|Other|Use of progressive relaxation exercises education|Progressive relaxation exercises education It starts with deep breathing exercises along with music. Then stretching and relaxation exercises are performed. After the education, an 8-minute video in which the progressive relaxation exercises was explained practically to the individuals was sent to their mobile phones. The participants were asked to perform these exercises regularly for 4 weeks, each day one hour before going to bed, simultaneously with the video.
75706026|NCT00719004|Procedure|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
75706027|NCT00856648|Device|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
75706028|NCT00856804|Drug|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
76032799|NCT05106673|Behavioral|Education and training program for the professionals|The second implementation intervention concerns the improvement of the professionals' attitudes, knowledge and skills. The two main components here being the assessment of the current state in all institutions within the clinical centers and the development and implementation of an education and training program. The employees of the randomized clinical centers in the intervention group will get a three-hour training. This intervention is organized by Svenja Taubner (University Hospital Heidelberg, Germany).
76032800|NCT05106673|Behavioral|Systematic screening|The third implementation intervention includes a systematic screening process to improve detection of mentally ill parents with affected children. Employees of the clinical centers fill out two short questionnaires with the parents. This intervention project is organized by Sibylle M. Winter (Charité, Berlin, Germany).
75706029|NCT00712608|Other|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
75869174|NCT05445284|Other|Usual diabetes care|Usual diabetes care, every 3-month for 12 months
75387593|NCT05893745|Other|Supervised Exercise Program|Participants in the control group will receive a supervised exercise program that consists of three weekly sessions in addition to home exercises, over the course of four weeks. This program will include stabilization, flexing, extension, and rotation exercises for the cervical region and self-mobilization targeting the deep neck muscles. Participants will be instructed to perform the exercises at home three times a week in a manner that did not cause pain.
75706030|NCT00712608|Other|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
75706031|NCT00712608|Other|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
75869175|NCT05444517|Procedure|Interscalene Block|"Ultrasound-guided brachial plexus block injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml in the Interscalene groove.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
75706032|NCT00856882|Dietary Supplement|soy protein|
75706033|NCT00856882|Dietary Supplement|isoflavones|
75706034|NCT00856882|Dietary Supplement|milk protein|
75706035|NCT00712686|Drug|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
75706036|NCT00712686|Drug|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
75706037|NCT04041856|Drug|Povidone Ophthalmic|Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
75706038|NCT00856960|Drug|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
75706039|NCT00856960|Drug|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
75387594|NCT05893745|Other|Supervised Exercise Program plus Dermoneuromodulation Techniques|Participants in the study group will receive the same supervised exercise program as the control group, with home exercises, in addition to two dermoneuromodulation techniques for the Dorsal Cutaneous Nerve (C3-T1), which are the skin stretch technique and kitten technique. Patients in this group will receive 3 sessions/week for a total of 4 weeks.
75387595|NCT05893732|Device|High-Intensity Laser Therapy (HILT)|Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
75387596|NCT05893732|Device|Sham High-Intensity Laser Therapy (Sham HILT)|Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
75387597|NCT05893719|Device|iNedit, iNdeep, iNtercept|Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept
75387598|NCT05893693|Other|Biological|CT0594CP
76032801|NCT05106673|Other|TAU|No Intervention: Treatment as usual These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
76032802|NCT04977557|Dietary Supplement|Thiamine|Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
75706040|NCT00856960|Drug|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
76032803|NCT04316143|Drug|Zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat (BIA 5-1058)
76032804|NCT04977323|Other|TICK-B group|These interventions will use as distraction techniques.
76032805|NCT04977089|Diagnostic Test|lipid profile test .|Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
76032806|NCT05104801|Drug|sitravatinib|sitravatinib 100mg QD PO
76032807|NCT05104801|Drug|tislelizumab|tislelizumab 200mg Q3W IV
75387599|NCT05893654|Drug|Melphalan Injection|7.5mg of melphalan injected via intra-arterial catheterization of the ophthalmic artery.
75387600|NCT05893654|Radiation|Plaque brachytherapy|Brachytherapy will be performed using a 24-mm notched plaque with Ruthenium-106 seeds.
75387601|NCT05893641|Behavioral|A regular training volume|Participate will maintain their training volume of 35 h/week
75542318|NCT00262626|Procedure|Argon laser trabeculoplasty|
75706041|NCT00856960|Drug|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
76032808|NCT04977011|Other|relaxing music|30 minutes relaxing music for continuity 3 days since admission
76032809|NCT04530877|Biological|Infliximab|Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
76032810|NCT04530877|Dietary Supplement|Exclusive Enteral Nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (>110%-120% of the average requirement).
76032811|NCT04971083|Behavioral|Intervention Group|This study is designed to provide patients a tool with which they can record the nutrition related symptom burden (NRSB) they are experiencing in real time. A pre-defined algorithm then provides them with tailored nutrition information and behavioural tipps based on the severity grade of the symptom recorded. The aim is to increase the chances that such symptoms, when clinically relevant, are addressed in a timely matter and thus the nutrition status is stabilized.
76032812|NCT04971239|Drug|topical methotrexate micoemulsion|The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
75387602|NCT05893641|Behavioral|A lower exercise volume group|Participate will conduct 85% of the control group weekly training volume (i.e., 30h/week)
75387603|NCT05893641|Behavioral|A longer rest group|Participate will maintain the 35 h/week of exercise training
76032813|NCT04971239|Device|Excimer light|the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
75387605|NCT05894083|Procedure|Surgery|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
75387606|NCT05894083|Combination Product|Chemoradiation|Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV_High and PTV_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV_High in 2 Gy per fraction.
75387607|NCT05894083|Other|Observation|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
75542319|NCT00262626|Procedure|Trabeculectomy|
75542320|NCT04535869|Drug|Sofosbuvir 400 MG plus Daclatasvir 200mg|This group which receive sofosbuvir and daclatasvir for 14 days plus standard therapy
76032814|NCT04971239|Device|Narrow band ultraviolet B|the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
75387608|NCT05894083|Radiation|Post-operative radiation|Patients will receive adjuvant radiation based on pathologic features.Total radiation treatment doses and prescriptions will include 36 Gy in 18 fractions, 50 Gy in 25 fractions and 60 Gy in 30 fractions.
75387609|NCT05893615|Behavioral|Cognitive Behaviour Therapy|The CBT module was adjusted as follows: (1) Health education about paroxysmal atrial fibrillation; (2) Self-awareness training; (3) Exposure training; (4) Habitual reversal training；(5) Correcting cognitive distortion; (6) Behavioral activation (7) Specific training for anxiety; (8) Practice and feedback; (9) Relapse prevention; (10) Review.
76032815|NCT03062111|Procedure|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
75542321|NCT02216188|Biological|AFFITOPE® PD01A|s.c. injection
75542322|NCT02216188|Other|Control|Untreated control group
75542323|NCT02216227|Drug|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
75542324|NCT02216227|Drug|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
75542325|NCT02216227|Drug|Cefazolin|All patients will receive Cefazolin during surgery
75542326|NCT02216227|Drug|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
75557772|NCT00438698|Other|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
76032816|NCT03062111|Procedure|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
75557773|NCT00438698|Other|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
75387610|NCT05893602|Other|Blood sample analysis|Blood sample analysis on Cobalt and Chrome will be performed during the period under study.
75387611|NCT05893589|Other|test group|Women in the intervention group participated in face-to-face and virtual meetings based on social cognitive theory structures for 4 weeks
75387612|NCT05893550|Dietary Supplement|Smartfish Omega|Fruit juice drink containing Omega-3: the experimental condition
75542327|NCT02216227|Drug|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
75706042|NCT00856960|Drug|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
75542328|NCT00238277|Drug|temozolomide|
75542329|NCT00238277|Procedure|adjuvant therapy|
75542330|NCT00238277|Procedure|chemotherapy|
75542331|NCT00238277|Procedure|radiation therapy|
75542332|NCT00262665|Drug|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
75542333|NCT00262665|Drug|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
75542334|NCT02216266|Drug|Physostigmine|
75542335|NCT02216266|Other|Sodium Chloride solution|
75542336|NCT04535830|Device|Flash Glucose Monitoring System|During the three months experimental period,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month while people at SMBG group will receive a care visit every month.
75542337|NCT00262704|Behavioral|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
75542338|NCT00262704|Behavioral|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
75542339|NCT04535752|Drug|ANX009|Single or multiple ascending dose
75542340|NCT04535752|Drug|Placebo|Single or multiple ascending dose
75387613|NCT05893550|Dietary Supplement|Smartfish Fruit Juice Only|this is a fruit juice drink with no omega-3 added. it is the placebo condition
75387614|NCT05893524|Diagnostic Test|Timed Up-and-Go (TUG single-task)|The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
75387615|NCT05893524|Diagnostic Test|Timed Up-and-Go dual-task (TUGdt)|Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
75542341|NCT00238316|Drug|letrozole|2.5 mg PO daily for 1 year
75542342|NCT00238316|Other|Placebo|2.5 mg PO daily for one 1 year
75542343|NCT04535518|Drug|IVIG|IVIG at a single dose of 2 g/kg
75542344|NCT04535518|Drug|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
75542345|NCT04535518|Drug|Infliximab|Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
75542346|NCT02216383|Drug|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
75542347|NCT02216383|Drug|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
75706043|NCT00712764|Drug|Adenosine|
75706044|NCT00712764|Drug|Placebo|
75706045|NCT03911622|Device|MRI|medical device that is used as an imaging tool for soft tissues
75706046|NCT00848458|Other|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
75706047|NCT00848458|Other|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
75706048|NCT00578786|Drug|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
75706049|NCT00424255|Drug|Lapatinib|Dual ErbB1/2 inhibitor
75706050|NCT00424255|Radiation|Chemoradiation|Radiation plus platinum based chemotherapy
75387616|NCT05893524|Diagnostic Test|Clinical functional assessment|The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
75387617|NCT05893511|Procedure|Endoscopic ultrasound-guided gallbladder drainage|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .
75387618|NCT05893511|Drug|Antibiotics first|Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
75387619|NCT05893485|Behavioral|Music Therapy Intervention|Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
75387620|NCT05893472|Combination Product|combination of venetoclax and HAA regimen|Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
75387621|NCT05893446|Dietary Supplement|Nutrition care by RDN, medical nutrition therapy -stepped wedge cluster-randomized trial design. Everyone gets the intervention so no arms.|RDNs in the community will provide MNT and meals for three months post discharge from the hospital
75387622|NCT05892978|Other|Vascular imaging|"Experimental group - Vascular imaging device with the infrared light group: Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - Vascular access transillumination group: Before PIVC, a transilluminator will be inserted to the vein area and the procedure will be started after vein visibility is achieved"
75387623|NCT05892913|Drug|Slow dose preemptive Atropine|it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
75387624|NCT05892913|Drug|Ephedrine|For sympathetic blockade (SBP<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
75387625|NCT05891795|Drug|Clascoterone 1% Top Cream|Apply a thin layer to the affected area twice daily.
75387626|NCT05891795|Drug|Vehicle|Apply a thin layer to the affected area twice daily.
75542348|NCT02216383|Drug|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
76032817|NCT04903093|Drug|Abrocitinib tablet|Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
76032818|NCT04903093|Drug|Abrocitinib Suspension F1|Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
75387627|NCT05891522|Procedure|portable scanner|performing a portable cranial scanner on cerebro-injured intensive care patients
75387628|NCT05891522|Procedure|fixed scanner|performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
75387629|NCT05891314|Procedure|Botox Injectable Product|one group will have botox injection in the internal sphincter
75542349|NCT00262782|Drug|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
75542350|NCT00238394|Drug|cediranib maleate|Given orally
75542351|NCT00238394|Other|laboratory biomarker analysis|Correlative studies
75542352|NCT04535284|Behavioral|Coaching|"Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching."
75542353|NCT02216461|Drug|Low dose of BIBW 2948 BS for oral inhalation|
75542354|NCT02216461|Drug|Medium dose of BIBW 2948 BS for oral inhalation|
75542355|NCT02216461|Drug|High dose of BIBW 2948 BS for oral inhalation|
75542356|NCT02216461|Drug|Placebo|
75542357|NCT00238472|Drug|nateglinide|
75706051|NCT00424255|Other|Placebo|Placebo
76032819|NCT04903093|Drug|Abrocitinib Suspension F2|Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
76032820|NCT04903093|Drug|Abrocitinib Suspension F3|Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
75387630|NCT05891314|Procedure|Internal sphincterotomy|this group will have internal sphincterotomy
75387631|NCT05891028|Drug|68Ga-EB-ss-CPT|68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
75387632|NCT05891028|Drug|64Cu-EB-ss-CPT|64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
75387633|NCT05890716|Diagnostic Test|AI-powered ECG analysis to detect cardiac arrhythmic episodes|ECG recording and processing by AI platform
75387634|NCT05890690|Diagnostic Test|Urea|"Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g."
75387635|NCT05890690|Diagnostic Test|Placebo|"Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®."
75706052|NCT03910764|Other|no intervention|Investigators review patients' medical records and collect personal data, underlying diseases, indwelling catheter duration, laboratory data, diagnosis, treatment and prognosis.
75706053|NCT00852358|Drug|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
76032821|NCT04903093|Drug|Abrocitinib Suspension F4|Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
75387636|NCT05890430|Biological|Blood draw, Urine draw|Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time
76032822|NCT04903093|Drug|Abrocitinib Suspension F5|Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
75387637|NCT05890248|Procedure|Technique|Paravertebral block versus Erector spinea block versus quadratus lamborum block
75387638|NCT05887830|Drug|Nivolumab|Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.
75387639|NCT05887830|Other|Placebo|Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
76032823|NCT04903093|Drug|Abrocitinib Suspension F6|Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
75387640|NCT05885230|Procedure|pecto intercostal fascial block using bupivacaine 0.25%|patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.
75387641|NCT05885230|Drug|lidocaine infusion|1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
75387642|NCT05876000|Device|Corheart 6 Ventricular Assist System|Implantation of ventricular assist device for hemodynamic support
75387643|NCT05865028|Drug|APG-157|Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.
75387644|NCT05861258|Drug|Minocycline|Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
75387645|NCT05857800|Other|Observation|Analysis of dynamic changes of lung cancer microenvironment in neoadjuvant therapy using bio-omics information collected in clinical trials.
75387646|NCT05850598|Device|sham rTMS|The coil was held while disconnected from the stimulator, and rTMS noise was presented with computer loudspeakers with recorded sound from a real stimulation (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
75387647|NCT05850598|Device|active rTMS|Low-frequency (1 Hz) rTMS at with a stimulation intensity of 95% of the motor threshold will be delivered over the bilateral cerebellum for patients with Parkinson's disease (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
75387648|NCT05844085|Other|Non-polar lipids|The shame comparator lipid intervention product contains no polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of lipids are15g, and the total amounts of available carbohydrates are 50 g.
75706054|NCT02574156|Drug|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
76032824|NCT04903093|Drug|Famotidine|Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
76032825|NCT04970849|Other|observation|IBD doctors who perform the endoscopy perform the questionnaire
76032826|NCT04529785|Procedure|SVC only|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC alone
75387649|NCT05844085|Other|No lipids|The placebo comparator contains no added lipids. The product contains a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
76032827|NCT04529785|Procedure|SVC isolation with substrate modification and vein of Marshal ethanol infusion|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC, substrate modification and vein of Marshal ethanol infusion
75387650|NCT05844085|Dietary Supplement|Polar lipids low|The experimental intervention product contains 7,5 g plant based lipids polar lipids and 7.5 g plant based lipids non polarlipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. TThe total amounts of available carbohydrates are 50 g.
75387651|NCT05844085|Dietary Supplement|Polar lipids high|The experimental intervention product contains15 g plant based polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
75387652|NCT05824195|Other|Bread products|Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
75387653|NCT05821530|Device|HFIT|At least 1 hour daily for 4 weeks
75387654|NCT05821530|Device|TENS|At least 1 hour daily for 4 weeks
75387655|NCT05821530|Other|Control|Users will continue to use the digital MSK program as needed
75706055|NCT00848692|Drug|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
75706056|NCT00848692|Drug|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
75542358|NCT04535206|Diagnostic Test|Venous blood collecting and test and ultrasound screening|To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.
75706057|NCT00712842|Other|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
75706058|NCT00848770|Drug|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
75706059|NCT00848770|Drug|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
75706060|NCT00848770|Drug|manipulation of SAP|Esmolol or NPS or NOR
75706061|NCT04070118|Procedure|Measure niche thickness with ultrasound|in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
75706062|NCT00717704|Drug|ixabepilone|by vein once every 3 weeks
75706063|NCT00717704|Drug|Dasatinib|by mouth once daily
75387656|NCT05818787|Behavioral|Vestibular Perceptual Learning|The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a 3 second period of rest will be given. Each day of training will include three blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Noise cancelling earpieces (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
75387657|NCT05818787|Behavioral|Placebo Intervention|The placebo (or control) task will consist of oculomotor exercises that the subject will complete at home (i.e., outside of the lab). The oculomotor exercises will include saccadic eye movements performed in the horizontal and vertical planes. All movements will be completed within a limited, comfortable range of motion with the head remaining stationary. As the control intervention will be performed with the head stationary and in a seated position, no change in self-motion perception or balance is expected to result from the control (i.e., placebo) task.
75706064|NCT00713076|Other|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
75387658|NCT05784571|Other|Body Composition Assessment|Assessment of body composition using bioelectrical impedance analysis.
75387659|NCT05784571|Other|Modified Physical Performance Test|A test of physical functioning
75387660|NCT05784571|Other|Hand grip strength|A test of hand grip strength using a hand dynamometer.
75706065|NCT00713154|Drug|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
75706066|NCT00713154|Drug|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
75387661|NCT05784571|Other|6-minute walk test|Self-paced test of walking capacity.
75387662|NCT05784571|Procedure|Measurement of blood glucose and insulin|Blood will be drawn for measurement of glucose and insulin.
75387663|NCT05779943|Drug|Furosemide|Given IV
75387664|NCT05779943|Other|F18-rhPSMA-7.3|Given IV
75387665|NCT05779943|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75387666|NCT05779943|Procedure|Computed Tomography|Undergo PET/CT scan
75542359|NCT04534621|Other|Electronic survey|Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
75542360|NCT00262899|Behavioral|counseling intervention|
75542361|NCT00262899|Other|educational intervention|
75542362|NCT00262899|Procedure|psychosocial assessment and care|
75542363|NCT04534855|Drug|Treprilimab|Treprilimab 240mg Q3W until progression or unacceptable toxicity
75706067|NCT00620074|Drug|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance <50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
75706068|NCT00620074|Drug|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
75706069|NCT01033435|Other|No intervention|
75706070|NCT04069130|Drug|400 mg of BIA 5-1058|1 x 400 mg capsule Oral, Fasted
75706071|NCT04042012|Other|Eccentric exercise|soleus eccentric exercise
75706072|NCT04042012|Other|PNE|the application of galvanic current
75706073|NCT04042012|Other|Combined|soleus eccentric exercise and PNE
75706074|NCT00719238|Behavioral|Nutrition plus education|Nutritional instruction in small groups plus education
75706075|NCT00719238|Behavioral|Education only|Educational video and pamphlets
75706076|NCT02571296|Drug|micronized progesterone|Oral
75706077|NCT02571296|Drug|Placebo|Oral
75706078|NCT00857038|Drug|Doxycycline|Doxycycline tablets, 100mg daily
75706079|NCT00857038|Drug|Placebo|Placebo tablets 100mg
75706080|NCT00719316|Drug|Aliskiren|Aliskiren 300mg per day for 6 weeks
75387667|NCT05779774|Behavioral|WayToServe Plus In-service Component|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe training only [comparison control] v. WayToServe training plus WayToServe Plus in-service component [intervention]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe training and WayToServe Plus after baseline in Month 18, stratified by state and location. Remaining premises will receive WayToServe Training Only. All premises will be recruited to have servers complete WayToServe training. Servers in intervention group will be accepted into a Facebook private group after WayToServe training to receive in-service component with ~3 posts per week for 12 months. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
75387668|NCT05779774|Behavioral|WayToServe Training Only|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe Training Only [comparison control] v. WayToServe Plus In-service Component [intervention]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe Traiing Only after baseline in Month 18, stratified by state and location. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
75387669|NCT05778903|Other|Nerve block|Suprazygomatic maxillary nerve block
75387670|NCT05776797|Procedure|Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)|Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).
75387671|NCT05776797|Drug|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Optimal medication therapy according to the prescription of the physician.
75387672|NCT05768516|Other|Implementation of best practice for low back pain in primary care|"Stratified care: GPs will use a simple algorithm based on the risk of chronicity to determine the management plan. The risk level bas will be based on the Start Back Tool (SBT) and other variables that have been shown to improve the classification, such as work capacity.~Healthcare professional education: GPs will receive education to improve their knowledge about low back pain guidelines, diagnostic triage, patient education, stratified care and best practice.~Patient education: An education booklet Understanding My Low Back Pain will be used by GPs during their consultations. Second, GPs, PTs and OTs will provide similar reassuring messages and direct patients to the website www.infomaldedos.ch.~Interprofessional collaboration: A structured assessment form and a facilitated contact will be implemented between healthcare providers."
75387673|NCT05765396|Device|imPulse™ Una infrasound-to-ultrasound e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
75387674|NCT05760092|Combination Product|Institutional standard treatment for xerostomia and Long Covid|(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages . When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
75387675|NCT05760092|Radiation|Photobiomodulation Therapy|Application of Red LED in the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, 3 J/cm2, for 36 seconds, twice a week for 06 weeks.
75387676|NCT05760092|Radiation|Placebo Photobiomodulation Therapy|All parameters as the number of points, dose and place of application of the PBM will be the same as described in the item PBM therapy Intervention Group, however in the placebo PBM equipment will be turned off. The device activation noise will be recorded and used to mimic the irradiation.
75387677|NCT05752123|Biological|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
75387678|NCT05746611|Biological|Recombinant Mycobacterium tuberculosis fusion protein for injection|For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method
75387679|NCT05746611|Biological|TB-PPD was injected|For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
75542364|NCT00238511|Drug|SPM 927|
76032828|NCT04970615|Device|Three-dimensional printed model|Three-dimensional printers are able to print physical objects in real size and colours. As a respresentative of the real tumor, a personalized three-dimensional model enables visualization of the patient-specific tumor and eloquent areas.
76032829|NCT04271293|Drug|Edoxaban|Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.
75387680|NCT05727098|Drug|Bupivacaine Hydrochloride|injection of Bupivacaine 0.25% in ESPB
75387681|NCT05727098|Drug|Bupivacaine Hydrochloride and dexmedetomedine|injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
75387682|NCT05727098|Drug|Bupivacaine Hydrochloride and ketamine|injection of Bupivacaine 0.25% and ketamine in ESPB
75387683|NCT05720806|Other|Weight Bearing as tolerated (WBAT) immediately following surgery.|Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.
75387684|NCT05720806|Other|Flat foot weight bearing (FFWB) immediately following surgery|Subject will be provided standard of care physcial therapy following surgical intervention except
75387685|NCT05720182|Device|Compremium Compressibility Measurement|"CPM#1 measurements:~Step 1: Manual investigation to identify the compartment for compressibility measurements~Step 2: Marking the location for compressibility measurements~Step 3 - Examination with CPM#1~Place the probe on the target area~Identify correct landmark~Compress the compartment~Increase steadily the pressure applied by the CP probe to 80 mmHg."
75387686|NCT05720182|Procedure|Treadmill Running|"Exercise:~Step 1: Participants will walk on a treadmill with standardized walking speed (5.0 km/hour) and slope (15%) for 5 minutes.~Step 2: Immediate, one minute, and five minutes post-exercise CPM#1 measurements will be performed at one leg.~Exercise and post-exercise CPM#1 measurements will be repeated for the other leg."
75387687|NCT05720182|Other|Questionnaire|"Questionnaires NIAPS questionnaire: Baseline NIAPS questionnaire with one additional question about leg dominance.~Experience questionnaire: Scores 1-5, questioning the intensity, how painful, the nuisance, the duration of the study and the non-invasive pressure measurements."
75387688|NCT05698823|Device|Lumoral Treatment|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
75387689|NCT05694520|Other|pistachios consumption of 1.5 oz thrice per week|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for all the included participants with pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating the total nuts intake of less than 2.5 oz per week). While the women in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
75387690|NCT05692492|Drug|ZSP1601|50mg BID
75387691|NCT05692492|Drug|ZSP1601|100mg BID
75387692|NCT05692492|Drug|Placebo|Placebo
75387693|NCT05689814|Device|Paraffin based Denture Fixative|Denture fixative applied in strips to secure dentures in place
75387694|NCT05683730|Other|Intermittent caloric restriction|"Intermittente caloric restriction:~st month: restriction of 50% of the caloric intake previously determined by the dietician 1 day per week~nd month: restriction of 50% of the caloric intake 2 days per week~rd month: restriction of 60% of the caloric intake 2 days per week~th month: restriction of 75% of the caloric intake 2 days per week"
75387695|NCT05681624|Other|Maternal oxygen supplementation|Maternal oxygen supplementation 10 liters/minute via nonrebreather mask
75387696|NCT05681624|Other|Room air|Room air, no mask
75387697|NCT05680415|Biological|Mycobacterium Vaccae for Injection|The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, and a total of 6 doses were injected.
75542365|NCT04534699|Drug|KBP-5074|KBP-5074 tablet
76032830|NCT04208659|Procedure|Self-administration of auricular acupuncture without prosthesis|Participants will insert semi-permanent acupuncture needles in their ears without the guidance of a prosthesis
76032831|NCT04208659|Procedure|Self-administration of auricular acupuncture with prosthesis|The same participants who previous self-administered a standardized auricular acupuncture will be given custom-molded prostheses midway through the study to assess how much the prostheses facilitate insertion.
76032832|NCT03060239|Other|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
75387698|NCT05656352|Device|Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device|Masimo Radical-67® Pulse CO-Oximeter and rainbow® sensors.
75387699|NCT05656352|Diagnostic Test|Complete Blood Count|The test will be done using venous blood collected in EDTA tubes. Samples will be analyzed within 6 hours of collection or stored at 2 to 8C and analyzed within 24 hours. Analysis will be done using a five-part differential hematology analyzer.
75387700|NCT05649865|Diagnostic Test|Blood sample|Blood samples for analysis of circulating tumour HPVDNA
75387701|NCT05635578|Behavioral|sleep|reiki
75387702|NCT05631990|Drug|AD-209|PO, Once daily(QD), 8weeks
75387703|NCT05631990|Drug|AD-209-1A|PO, Once daily(QD), 8weeks
75387704|NCT05631990|Drug|AD-209-1B|PO, Once daily(QD), 8weeks
75387705|NCT05631990|Drug|AD-209-1C|PO, Once daily(QD), 8weeks
75387706|NCT05631990|Drug|AD-209 placebo|PO, Once daily(QD), 8weeks
75387707|NCT05631990|Drug|AD-209-1 placebo|PO, Once daily(QD), 8weeks
75542366|NCT02216539|Behavioral|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
75706081|NCT00720200|Behavioral|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
75387708|NCT05610527|Device|ENG Implant|This is an FDA approved contraceptive device
75387709|NCT05610527|Device|LNG IUD|This is an FDA approved contraceptive device
75387710|NCT05608525|Device|transcranial current stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
75387711|NCT05608525|Behavioral|GRASP|A standardized occupational therapy- GRASP will be performed daily together with tDCS over the period between the Pre Assessment and the Post Assessment. GRASP exercise will be administered concurrently with or immediately after tDCS stimulation. GRASP is a self-directed arm and hand exercise program for which is supervised by a therapist, but done independently by the participant (and with their family if possible). GRASP has been shown to improve arm and hand function and strength in stroke patients in community [22-27]. The versions of the program- Home GRASP will be used. All occupational tasks will be selected from the GRASP task pool and be progressed according to the GRASP protocol (https://neurorehab.med.ubc.ca/grasp). Each GRASP session will take about 1 hour. A total of 20 GRASP sessions will be administered.
75542367|NCT02216539|Procedure|Lung transplantation|
75706082|NCT00720200|Behavioral|Usual Care|Family Members receiving usual care/clinical interaction
76032833|NCT03059927|Procedure|Knee arthroplasty, Cruciate retaining|Legion total knee arthroplasty implant component, Smith & Nephew, Cruciate Retaining design
75387712|NCT05604053|Behavioral|Motivation Manipulation|On some trials, participants have lower motivation and on other trials participants have higher motivation.
75387713|NCT05595915|Dietary Supplement|COMP-4|COMP-4 is a novel compound that consists of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.
76032834|NCT03059927|Procedure|Knee arthroplasty, Anterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Anterior Stabilized design
76032835|NCT03059927|Procedure|Knee arthroplasty, Posterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Posterior Stabilized design
76032836|NCT03059849|Drug|Adalimumab|Dose of adalimumab will be increased by 40mg every 2 weeks.
75387714|NCT05594979|Dietary Supplement|TOTUM-070|2.5-g dose of TOTUM-070 diet supplement; Four capsules per day to consume orally in two intakes
75387715|NCT05594732|Behavioral|Weak outdoor light|Stay and stare far on the balcony or under the tree
75542368|NCT02216539|Other|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
75542369|NCT04534816|Diagnostic Test|Indocyanine Green|Perfusion assessments
75542370|NCT00262938|Behavioral|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
75542371|NCT00262938|Other|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
75706083|NCT03926988|Device|NeVa Stent Retriever|mechanical neurothrombectomy
75706084|NCT00857116|Drug|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
75706085|NCT00857116|Drug|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
75706086|NCT00717782|Procedure|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
75706087|NCT00717782|Procedure|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
75706088|NCT00719394|Drug|GSI 136|
75706089|NCT00719394|Drug|placebo|
76032837|NCT04822441|Other|data collection|Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord
76032838|NCT04976075|Other|no interventions|no interventions
76032839|NCT04796701|Other|Follow-Home-intervention|x
76032840|NCT04156165|Dietary Supplement|VLCD-Active|Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.
75387716|NCT05594732|Behavioral|Strong outdoor light|Stay and stare far in the sunlight
75387717|NCT05590468|Dietary Supplement|Nicotinamide Riboside|Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)
75387718|NCT05590468|Drug|Placebo|Looks exactly like the study drug, but it contains no active ingredient
75387719|NCT05574244|Procedure|Partial surgery preserving the prostatic apex|Partial Endoscopic resection of prostate to conserve apex
75387720|NCT05574244|Procedure|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
75387721|NCT05572658|Biological|mRNA-1345|Sterile liquid for injection
75387722|NCT05572658|Biological|Placebo|0.9% sodium chloride (normal saline) injection
75542372|NCT00262938|Other|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
75542373|NCT00262938|Other|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
76032841|NCT04156165|Other|Maintenance-Active|Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.
75542374|NCT00262938|Procedure|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
75542375|NCT04534894|Diagnostic Test|fluorescence lifetime imaging microscopy|collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
75542376|NCT00238628|Drug|Bexarotene|
75542377|NCT00238628|Drug|Iressa|
75542378|NCT02216617|Drug|Taxotere, Cisplatin, Afatinib|
75542379|NCT04534777|Other|repeated neurological, behavioral assessments and conventional, quantitative and functional brain imagery|Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
75542380|NCT00262977|Behavioral|Electronic prompt plus patient-directed intervention|
75387723|NCT05565560|Drug|Apremilast|Oral tablets
75542381|NCT00262977|Behavioral|Electronic prompt to clinician to prescribe aspirin|
76032842|NCT04156165|Dietary Supplement|VLCD-Control|Lighter life VLCD products
75542382|NCT04534504|Procedure|SG-JJB|Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
75542383|NCT00238667|Drug|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
75542384|NCT00238667|Drug|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
75542385|NCT04534426|Drug|: Arnica montana|In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
75542386|NCT04534426|Drug|Mucopolysaccharide polysulfate|In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
75387724|NCT05564325|Device|Deflectable guidewire|A deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
75387725|NCT05564325|Device|Standard of care guidewire (different models may be used)|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
75387726|NCT05563194|Device|Heating prototype (Prototype 1)|A wearable that heats and vibrates to help distract from pain. It can be wrapped around any joint with temperature and vibration settings allowing CYP to set the device to their needs.
75387727|NCT05563194|Device|Physio tool (Prototype 2)|A motivational physiotherapy tool that incrementally lights up as the CYP do their prescribed stretches, emphasising a sense of progression and making it a more engaging activity.
75387728|NCT05563194|Device|Communication tool (Prototype 3)|A wearable to help communication in the classroom between the teacher and pupil. The child can alert the teacher if they need help, through vibration, without attracting the attention of their classmates, reducing embarrassment.
75387729|NCT05527808|Drug|Tislelizumab|200 mg ,intravenous injection ,Q3W 2-4 cycles
75387730|NCT05527808|Drug|pemetrexed|500 mg/m2,intravenous injection ,Q3W 2-4 cycles
75542387|NCT04534426|Other|Control group|In Control group, only standard therapy was performed after surgery
75542388|NCT00263016|Drug|Docetaxel|
75387731|NCT05527808|Drug|cis-platemum|60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
75542389|NCT00238706|Device|Radiofrequency ablation|
75542390|NCT04534465|Drug|Polyethylene glycol (MiraLAX, BAY81-8430)|Oral solution, 17g polyethylene glycol, one time
75542391|NCT04534465|Drug|Mannitol|Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
75542392|NCT02216656|Drug|Placebo|Oral administration
75542393|NCT02216656|Drug|KHK7580 low dose|Oral administration
75542394|NCT02216656|Drug|KHK7580 middle dose|Oral administration
75542395|NCT02216656|Drug|KHK7580 high dose|Oral administration
75542396|NCT02216656|Drug|KRN1493|Oral administration
75542397|NCT00263055|Drug|oxaliplatin|
75542398|NCT00238745|Drug|Bazedoxifene|
75542399|NCT00238745|Drug|Placebo|
75542400|NCT04534348|Device|70% isopropyl alcohol-impregnated catheter caps|Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
75542401|NCT04534231|Drug|Nicotine patch|Nicotine transdermal patches as per product monograph
75387732|NCT05527808|Drug|or carboplatin|AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
75387733|NCT05516108|Behavioral|Mindfulness|The mindfulness intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific meditation techniques through didactic explanation and guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention on the intended target, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts build on the skills trained in each lesson, encouraging participants to practice brief moments of mindful awareness, mindfulness while doing daily tasks, or formal meditation.
75542402|NCT00263094|Drug|Rofecoxib|
75542403|NCT04534192|Device|JADE Balloon|Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
76032843|NCT04156165|Other|Maintenance-Control|Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
76032844|NCT04970693|Drug|Furmonertinib|The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
76032845|NCT04131751|Diagnostic Test|Next generation sequencing|we will investigate the sensitivity and specificity of next generation sequencing as a diagnostic tool in ascites infections.
75387734|NCT05516108|Behavioral|Coping|The coping intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific coping techniques through didactic explanation and guided practice. Lessons train coping skills (reflection, reappraisal, and problem solving) without encouraging focus on or acceptance of present experience (i.e., mindfulness skills). Participants are instructed to: (1) reflect and let their minds drift, (2) reframe or reappraise past and anticipated events, and (3) analyze and solve personal problems. Practice prompts build on the skills trained in each lesson, encouraging participants to take brief reflection breaks or to practice reappraisal or problem-solving skills.
75387735|NCT05496335|Drug|AGN-151586|Intramuscular Injection
75542404|NCT00238784|Drug|Budesonide/formoterol Turbuhaler|
75542405|NCT04534036|Dietary Supplement|PDS-08|PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
75542406|NCT04534036|Other|Placebo|Placebo sachets will contain potato or tapioca maltodextrin.
75542407|NCT00263133|Drug|Sertraline|
75706090|NCT00857194|Procedure|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
75706091|NCT00857194|Procedure|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
75706092|NCT03847870|Diagnostic Test|MORU in-house ELISA test followed by IFA if positive|An in-house rickettsial IgG ELISA test will be used for this study to determine previous rickettsial infections by measuring IgG levels. All specimens will be tested for IgG antibodies using ELISA tests for scrub typhus (Orientia tsutsugamushi strains Karp, Kato, Gilliam and TA716), murine typhus (Rickettsia typhi strain type Wilmington), and spotted fever rickettsiosis (Rickettsia honei and Rickettsia conorii). If the sample tests positive, it will be retested for the same antigens using the IFA test. The sample will be considered positive if both the ELISA and the IFA are positive.
76032846|NCT04918537|Dietary Supplement|Walnuts|30g of plain walnuts in addition to habitual food intakes
76032847|NCT04970303|Drug|Methylphenidate|Retina or Concerta
76032848|NCT03942835|Other|experience 1 : Competitive attention test in healthy participants|Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
76032849|NCT03942835|Other|experience 2 : Competitive attention test in patients with ADHD with no treatment|Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
75387736|NCT05496335|Drug|BOTOX|Intramuscular Injection
75387737|NCT05496335|Drug|Placebo|Intramuscular Injection
75542408|NCT04533724|Drug|Amisulpride|The amisulpride treatment group was given amisulpride tablets. The dose: the initial dose was 50 mg/d. The doctor titrated the dose to the therapeutic amount within 1 to 2 weeks according to the patient's condition. The maximum dose was 300 mg/d, taken with a single meal. Observe for 8 weeks.
75542409|NCT04533685|Behavioral|Portal Reminders for Influenza Vaccination: Direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination that include a direct scheduling link, enabling the patient to directly schedule a flu vaccination only visit
76032850|NCT03942835|Other|experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment|Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
76032851|NCT04975529|Behavioral|Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education|Two-group quasi experimental intervention with schools assigned to intervention or comparison.
75387738|NCT05480098|Drug|Brimonidine Topical|Topical brimonidine intraoperatively for hemostasis
75387739|NCT05439031|Radiation|Stereotactic Arrhythmia Radiotherapy|Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
75542410|NCT04533685|Behavioral|Portal Reminders for Influenza Vaccination: No direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination (no direct scheduling link included)
75387740|NCT05438511|Behavioral|Focus group|A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
75542411|NCT04533685|Behavioral|Pre-Commitment Prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
75542412|NCT04533685|Behavioral|Pre-Appointment flu vaccine reminders|Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine
75542413|NCT00263172|Behavioral|behavior modification for weight loss|
75542414|NCT00238901|Drug|Basiliximab|
75542415|NCT04533490|Drug|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
75706093|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
75542416|NCT00263250|Procedure|watchful waiting or tension-free hernia repair|
75542417|NCT00238940|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
75542418|NCT04533139|Drug|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens"
75542419|NCT04533256|Procedure|CytoSorb|three consecutive sessions of hemoadsorption in patients with sepsis
75542420|NCT04533217|Procedure|Vertebroplasty|Injection of cement into vertebral lesion(s)
75542421|NCT04533178|Device|soft spinal brace|Use of a soft spinal brace 16 hours per day during the 6 week treatment period.
75387741|NCT05438511|Behavioral|Organizational Readiness for Implementing Change|measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
75387742|NCT05426031|Drug|Protamine fixed dose|250 mg of protamine intravenously (IV), one time use
75542422|NCT04533178|Other|Resting from all sports activities|Resting from all sports activities
75542423|NCT00263289|Procedure|preprocedural fasting|
75542424|NCT00238979|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
75542425|NCT04533295|Device|acupuncture and IVF|Acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
75542426|NCT04533295|Device|sham acupuncture and IVF|Sham acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
75706094|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
75387743|NCT05426031|Drug|Protamine ratio dose|1mg of protamine per 100 units of heparin given intravenously (IV), one time use
75387744|NCT05424328|Procedure|ALTF (Anterolateral thigh flap) with preoperative virtual planning|In this study group, using preoperative CTs (head & neck and thigh ) to virtually plan a guide that can be used during the surgery, this guide will determine the design and dimensions of the Alt flap to be harvested and restore the defect left on the tongue due SCC resection and hemi glossectomy.
75387745|NCT05424328|Procedure|ALTF (Anterolateral thigh flap) with conventional method|ALTF (Anterolateral thigh flap) will be harvested with conventional method which depends on surgeon's own experience in determining the flap design and dimensions needed to reconstruct and restore the defect left on the tongue due SCC resection and hemi glossectomy.
75542427|NCT04532944|Diagnostic Test|imaging of energy dysfunction|7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
75542428|NCT04533061|Drug|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens"
75542429|NCT00239018|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
75542430|NCT04532905|Other|Strength Training Exercises Therapy|Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.
75542431|NCT02216734|Behavioral|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
75387746|NCT05423106|Drug|JNJ-64457744|JNJ-64457744 will be administered as oral solution.
75542432|NCT02216890|Drug|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
75542433|NCT04532983|Procedure|fixation of mesh prosthesis|in the first group mesh was fixed in position with laparoscopic tacks
75387747|NCT05423106|Drug|Placebo|Placebo will be administered as an oral formulation.
75542434|NCT04532983|Procedure|mesh placement without fixation|mesh placement in preperitoneal space without fixation
75557774|NCT00475293|Drug|Panitumumab and CPT-11|"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"
75557775|NCT00438737|Biological|bevacizumab|
75706095|NCT04068558|Device|VNI-NAVA/sNIPPV|Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
75387748|NCT05423106|Drug|Tenofovir Disoproxil Fumarate (TDF)|TDF tablet will be administered orally
75387749|NCT05423106|Drug|Tenofovir Alafenamide (TAF)|TAF tablet will be administered orally.
75387750|NCT05423106|Drug|Entecavir (ETV)|ETV tablet will be administered orally.
75387751|NCT05423106|Drug|JNJ-64457744|JNJ-64457744 will be administered as oral tablet.
75387752|NCT05415761|Behavioral|iCanQuit|iCanQuit is a smoking cessation smart phone application that uses acceptance and commitment therapy (ACT) approach, a cognitive behavioral treatment
75557776|NCT00438737|Biological|cetuximab|
75557777|NCT00438737|Drug|fluorouracil|
75557778|NCT00438737|Drug|leucovorin calcium|
76032852|NCT04902547|Behavioral|Patient Education Workshop (PEWs)|The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
76032853|NCT04902547|Procedure|Multidisciplinary Tapering Program|"The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up."
76032854|NCT04969679|Drug|E. coli Nissle 1917 (Mutaflor®)|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
76032855|NCT04969679|Drug|Placebo|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
75557779|NCT00438737|Drug|oxaliplatin|
75557780|NCT00438737|Procedure|adjuvant therapy|
75557781|NCT00438737|Procedure|conventional surgery|
75557782|NCT00438737|Procedure|neoadjuvant therapy|
76032856|NCT04969757|Device|Predigraft group|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
76032857|NCT04432259|Drug|Dexamethasone|4 mg bid for 4 days
75387753|NCT05415761|Behavioral|iCanQuit+Motiv8|iCanQuit + Motiv8 is a integrated version of iCanQuit (Cognitive Behavioral Therapy smoking cessation therapy application) with Motiv8 (a contingency management program that rewards decreased smoking determined by measuring CO levels of participant)
75387754|NCT05415761|Behavioral|Florida quit line|An evidence-based, existing smoking cessation healthcare option recommended by the U.S. clinical practice that connects active smokers to trained quit coaches via referral by their providers.
75387755|NCT05399277|Drug|Rivaroxaban|15mg oral daily for 7 days
75387756|NCT05377944|Drug|BAT2306|150 mg/1 ml/injection (2 injections/visit)
76032858|NCT04432259|Drug|Placebo|oral placebo
76032859|NCT03933085|Behavioral|Memory Support System (MSS)|A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
76032860|NCT04969523|Procedure|lobectomy|Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
76032861|NCT03578107|Behavioral|improvement of quality of stroke care|"hospital tool kits for quality improvement of reperfusion therapy ;~organizational stakeholder and opinion leader meetings;~data monitoring and feedback reports；~webinar for hospital teams"
76032862|NCT03059771|Behavioral|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
76032863|NCT03059771|Behavioral|Control|The control group will only engage in a goal-setting session.
75387757|NCT05377944|Drug|EU-approved Cosentyx|150 mg/1 ml/injection (2 injections/visit)
75387758|NCT05371145|Biological|Carnosine|Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
75387759|NCT05362409|Drug|5 Aminolevulinic Acid|5-aminolevulinic acid [5-ALA] administered orally 20 mg/kg every 4 weeks
76032864|NCT03918031|Behavioral|PFI for Smoking & Distress Tolerance|Personalized Feedback Intervention for smoking and distress tolerance.
76032865|NCT03918031|Behavioral|PFI for Smoking Only|Personalized Feedback Intervention for smoking only (no distress tolerance component)
76032866|NCT03059693|Drug|HAT1 topical cream|
76032867|NCT03059693|Drug|Vehicle cream|
75387760|NCT05362409|Device|CV01-delivered ultrasound|CV01-delivered ultrasound every 4 weeks
75387761|NCT05336071|Drug|INS068 injection|Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
75387762|NCT05336071|Drug|INS068 injection|Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
75387763|NCT05333679|Device|UTRA|Collect urine on intervention participants and screen for presence of TFV.
75387764|NCT05333679|Behavioral|UTRA feedback|Feedback will be provided to the participant based on the UTRA results on their adherence with provision of standard adherence counseling.
75387765|NCT05327244|Other|Real-world vibration feedback gait retraining|Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
75387766|NCT05325034|Behavioral|Early Intervention|"Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies."
75387767|NCT05324878|Other|Training|Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
75387768|NCT05319873|Drug|Carboplatin|Given IV
75387769|NCT05319873|Drug|Docetaxel|Given IV
75387770|NCT05319873|Drug|Fulvestrant|Given SC
75542435|NCT04532476|Device|Low level laser therapy|"Diode laser (Laser HF, Hager-Werken GmbH & Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators."
75557783|NCT00475371|Drug|MKC253 Inhalation Powder|Inhalation powder
75706096|NCT04068558|Device|sNIPPV/VNI-NAVA|Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
75387771|NCT05319873|Biological|Pertuzumab|Given IV
75387772|NCT05319873|Other|Quality-of-Life Assessment|Ancillary Studies
75387773|NCT05319873|Drug|Ribociclib|Given PO
75387774|NCT05319873|Biological|Trastuzumab|Given IV
75387775|NCT05319873|Drug|Tucatinib|Given PO
75387776|NCT05300906|Behavioral|personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
75387777|NCT05300906|Behavioral|non-personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
75387778|NCT05291884|Device|Impella BTR|Subjects will be prepared for pump insertion procedure according to clinical site standard of care. Procedural preparations for insertion of the Impella BTR are identical to the insertion of the Impella 5.0/5.5 via the axillary artery. The Impella BTR remains in situ until the patient is sufficiently recovered for removal or is transitioned to another form of support. It is expected that the Impella BTR is in situ for a maximum of 28 days.
75387779|NCT05288439|Diagnostic Test|Resting-state functional connectivity MRI|participants will undergo functional MRI
75387780|NCT05288439|Other|Neurocognitive battery with quality-of-life assessment|Cognitive and quality of life assessments performed by a trained neuropsychologist
75387781|NCT05281458|Procedure|Early drainage of peripancreatic fluid collections|Participants will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
75557784|NCT00438776|Drug|olanzapine|2.5mg to 15mg daily
75706097|NCT04068090|Other|Patient Questionnaires|FACT-Ntx, EORTC-CIPN20
75706098|NCT04068090|Other|Blood Collection|biomarker analysis
75706099|NCT00857428|Drug|oxymorphone|Tablets
75706100|NCT00857428|Drug|Oxymorphone|40 mg tablets
75706101|NCT02572778|Procedure|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
75706102|NCT04069494|Other|questionnaires|Two questionnaires in patients and another two questionnaires in carer.
75387782|NCT05264740|Behavioral|Motivational interviewing|The intervention group will receive motivational interviewing sessions with a trained study nurse plus educational material
75387783|NCT05264740|Behavioral|Educational materials|The control group will receive educational material only.
75706103|NCT04018768|Other|ibuprofen 600 mg|MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
75706104|NCT04018768|Other|Oxycodone/acetaminophen (Percocet) 5 mg/325|MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
75706105|NCT00719784|Device|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
75542436|NCT04532671|Other|Poly ether ether ketone (PEEK)|PEEK has been used in dentistry so far in certain fields as for, removable and fixed dental prostheses, implants, and implant abutments as well as orthodontic devices, whereas in literature, it is mostly mentioned in relation to prosthetics. PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks. Producing dental restorations via Additive manufacturing is still hardly widespread
75387784|NCT05260242|Other|Disparities Conversation|The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
75542437|NCT04532671|Other|CADCAM Poly ether ether ketone (PEEK)|Increased demand for long-lasting restoration's properties have led to many improvements in the production techniques of posterior restorations such as CAD/CAM systems. This technique simplifies the production of indirect restorations and make it possible to use advanced materials as PEEK
75542438|NCT04532671|Other|indirect resin composite|CADCAM resin composite blocks using milling process
75542439|NCT00239057|Drug|Enteric-Coated Mycophenolate Sodium|
75557785|NCT00438776|Drug|sugar pill|matching placebo to olanzapine
75706106|NCT00848848|Biological|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
75706107|NCT00848848|Biological|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
75706108|NCT00848848|Biological|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
75706109|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
75869176|NCT05444517|Procedure|Infraclavicular - Anterior Supraescapular Nerve Blocks|"Ultrasound-guided combined infraclavicular-anterior suprascapular block of the brachial plexus, injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an ultrasound-guided injection of 3 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml under the omohyoid muscle. If the anterior suprascapular nerve could not be identified after five minutes of insonation time, an upper trunk block will be carried out with the same amount of local anesthetic.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
75387785|NCT05249452|Other|Preconditioning with azathiprine and hydroxyurea (3 months)|Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.
76032868|NCT05090683|Behavioral|Mind-body mobile application|Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
76032869|NCT04964219|Drug|S-ketamine|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
75387786|NCT05218772|Other|Questionnaires|Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective)
75706110|NCT00848848|Biological|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
75706111|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
75869177|NCT05443178|Drug|Nivaquine ® (Chloroquine)|dose escalation and extension trial
75869178|NCT05442671|Behavioral|Exercise intervention|16-week home exercise intervention, enriched by mobile health technology
75869179|NCT05432466|Drug|ACER-002 (celiprolol) 200 mg BID|ACER-002 (celiprolol) 200 mg BID
75869180|NCT05432466|Drug|Placebo BID|placebo for ACER-002
75869181|NCT05424289|Device|videolaryngoscope|Videolaryngoscope is a high-resolution micro camera mounted on the tip of a curved blade connected to small portable digital monitor improves the view of the vocal cords
76032870|NCT04964219|Drug|Placebo|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
76032871|NCT04975451|Drug|Anlotinib|Anlotinib plus DCb
76032872|NCT04975373|Drug|Intrauterine injection of hyaluronic acid|operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
76032873|NCT04974983|Other|Observation of neurological deficits|Observation of neurological deficits
75387787|NCT05201703|Drug|Fycompa|Fycompa 4 mg daily
75387788|NCT05201703|Drug|Fycompa with a boost|Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.
75869182|NCT05405751|Drug|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.
75869183|NCT05403749|Biological|dose 1 IBI302|After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.
75706112|NCT00848848|Biological|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
75387789|NCT05200338|Drug|Engerix-B|Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.
75706113|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
75869184|NCT05403749|Drug|Aflibercept|Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month
75869185|NCT05403749|Biological|dose 2 IBI302|After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol
75869186|NCT05403580|Drug|Olanzapine|Given PO
75869187|NCT05403580|Drug|Placebo Administration|Given PO
75869188|NCT05403580|Other|Questionnaire Administration|Ancillary studies
75869189|NCT05400122|Drug|Vactosertib|Vactosertib is a highly selective, potent inhibitor of the protein serine/threonine kinase activity of transforming growth factor (TGF)-β receptor type 1 (TGFBR1; also known as activin receptor-like kinase 5 [ALK5]). Vactosertib inhibits the phosphorylation of the ALK5 substrates Smad2 and Smad3, as well as the intracellular signaling of TGF-β.
75869190|NCT05400122|Drug|Fludarabine Phosphate|Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoroara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
76032874|NCT04975061|Drug|YY-20394|YY-20394 is a small molecule inhibitor.
76032875|NCT04968977|Procedure|PCI vs. CABG|PCI vs. CABG
75706114|NCT00848848|Biological|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
75706115|NCT00848848|Biological|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
75387790|NCT05195125|Procedure|Direct Peritoneal Resuscitation|Direct peritoneal resuscitation involves the abdominal infusion and drainage of a peritoneal dialysate in high-risk liver transplant patients, for up to 24 hours after surgery.
75387791|NCT05188326|Drug|Vidaza 100 milligram (mg) injection|1st cycle 50 mg/sqm s.c. or i.v. for 7 days (5 + weekend off + 2) every 28 days and increase dosing after 1st cycle, if well tolerated, to 75 mg/ m2 for further 5 cycles, followed by cycles every 56 days for 4 years and six months post-remission.
75387792|NCT05188326|Other|Best Supportive Care|Best supportive care includes antibiotics, transfusions and fluids
75387793|NCT05182918|Other|Substance use disorder treatment|The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
75387794|NCT05180942|Drug|Atorvastatin Calcium 40Mg Tab|One tablet daily
75387795|NCT05165108|Device|Vagal Nerve Stimulator|A handheld device which consists of a battery powered portable stimulator with a digital control user interface that controls signal amplitude and two steel contact electrodes will deliver the nVNS electrical stimulation to the cervical Vagus nerve. The device has been approved by the U.S. Food and Drug Administration (FDA) for non-invasive Vagus nerve stimulator therapy for adjunctive use for the prevention and treatment of migraine and cluster headaches in adult patients.
75387796|NCT05164653|Drug|Sacubitril Valsartan Sodium Hydrate|"Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation."
75387797|NCT05164653|Drug|Standard treatment|Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
76032876|NCT04968665|Diagnostic Test|gait testing, functional MRI|diagnostic tests including the gait testing and functional MRI
75542440|NCT04532593|Procedure|autologous adipose stem cell injection|Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
75542441|NCT04532593|Procedure|saline injection|saline will be injected underneath skin graft (0.05 ml/cm2).
76032877|NCT04963829|Biological|gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration|It is a gel that was used in chronic ulcers healing
76032878|NCT04963829|Biological|Collagenase ointment|Participants who were subjected to a standardized treatment (collagenase ointment)
76032879|NCT04963829|Biological|Gel with 10% peel powder of unripe banana|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
76032880|NCT04963985|Drug|Tafamidis Pill|Oral
75542442|NCT02216968|Behavioral|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
75387798|NCT05161260|Behavioral|Yoga Breathing|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Yoga Breathing group will practice a breathing exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their breathing activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
75542443|NCT00238082|Drug|HFA-134A Beclomethasone DIpropionate (QVAR)|
75869191|NCT05400122|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity.
75869192|NCT05400122|Drug|IL-2|"Proleukin® (aldesleukin) has been shown to possess the biological activities of human native interleukin-2. In vitro studies performed on human cell lines demonstrate the immunoregulatory properties of Proleukin, including: a) enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines; b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.~The in vivo administration of Proleukin in animals and humans produces multiple immunological effects in a dose dependent manner. These effects include activation of cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and the production of cytokines including tumor necrosis factor, IL-1 and gamma interferon. In vivo experiments in murine tumor models have shown inhibition of tumor growth"
76032881|NCT04974905|Procedure|retrograde access for re-canalization of infra-inguinal arterial occlusive disease|after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
76032882|NCT01669577|Procedure|analysis of blood samples and clinical features|clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
75542444|NCT02217007|Drug|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
75706116|NCT04069364|Behavioral|TinnitusTipps|Self-helf tips for managing chronic tinnitus will be given via smartphones.
75706117|NCT02573922|Drug|oxycodone-naloxone|
75706118|NCT02573922|Drug|Oxycodone|
76032883|NCT04974827|Drug|Camrelizumab|200mg/3weeks
76032884|NCT04974827|Drug|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
75387799|NCT05161260|Behavioral|Attention Control|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Attention Control group will practice a mindfulness exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their mindfulness activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
75542445|NCT02217046|Procedure|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
75542446|NCT02217124|Other|dried apples|120 calories
75869193|NCT05400122|Drug|Natural Killer Cells|Adoptive NK cell therapy has demonstrated the potential for cancer immunotherapy in various malignancies with particular potential in hematologic malignancies including acute myeloid leukemia (AML), and colon cancer [14, 19-23]. This therapeutic approach is extremely well tolerated in patients even when massive numbers of cells are utilized (~109 NK cells/kg). In fact, studies suggest that high doses of NK cells are not only well tolerated but have potential to lead to higher levels of efficacy.
75542447|NCT02217124|Other|muffin|120 calories
75542448|NCT05897879|Biological|Nasopharyngeal swab|"For hospitalized patients :~Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril))~For ambulatory patients :~Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated."
75542449|NCT05897879|Biological|Blood samples|For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling
75542450|NCT05897814|Other|Location of the epidural analgesia catheter|Research of the location of the epidural analgesia catheter using M-mode and color Doppler (cD) ultrasonography.
75542451|NCT05897762|Behavioral|Tele rehabilitation Group|It has been determined that the telerehabilitation method applied in chronic hemiplegic patients increases daily living activities, upper extremity functionality, and spasticity levels decrease.
76032885|NCT04963595|Drug|Pyrotinib|400 mg once daily
75387800|NCT05160896|Drug|Raltitrexed|Raltitrexed 2 mg/m² iv, 15min. day 1
75387801|NCT05160896|Drug|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min. day 1
75387802|NCT05160896|Drug|Bevacizumab|Bevacizumab 5 mg/kg, iv, day 1
75387803|NCT05160896|Drug|Cetuximab|cetuximab 500 mg/ m² , iv, day 1
75387804|NCT05145881|Dietary Supplement|Low dose probiotics|Taking 1 package of low dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
75387805|NCT05145881|Dietary Supplement|Normal dose probiotics|Taking 1 package of normal dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
75387806|NCT05138939|Other|Red wine A|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
75387807|NCT05138939|Other|Red wine B|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
75387808|NCT05138939|Other|Control|8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
75387809|NCT05129670|Device|Calcite chewing gum|The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
76032886|NCT04963595|Drug|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsules on day 1 to be taken at the hospital, and on day 8 at home.
76032887|NCT04963595|Drug|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
76032888|NCT04963907|Device|Active Alpha-Stim CES|Active Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
75387810|NCT05129670|Device|Unmatched Placebo chewing gum|The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
75387811|NCT05128617|Drug|Epirubicin-cyclophosphamide|1 cycle of Epirubicin-cyclophosphamide
75387812|NCT05128617|Drug|Paclitaxel|1 cycle of Paclitaxel
75542452|NCT05897749|Other|Brucea javanica oil emulsion injection|Drug: Brucea javanica oil emulsion injection Brucea javanica oil emulsion injection: intravenous drip, 30ml each time (add 250ml sterile physiological saline),once a day, 14 consecutive days as a cycle, at least 2 cycles completed. The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
76032889|NCT04963907|Device|Sham Alpha-Stim CES|Sham Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
76032890|NCT04963361|Other|patients were exposed to fear of movement|Patients completed the questionnaires independently
76032891|NCT04963361|Other|patients were not exposed to fear of movement|Patients completed the questionnaires independently
76032892|NCT04968431|Other|2D Echocardiography|Mitral valve area will be determined by 2 D echo-Doppler methods
76032893|NCT04968431|Other|3D Echocardiography|Patients included in the study will undergo 3D Echo after being evaluated with 2D Echo. Mitral valve area will be determined by real time 3D.
76032894|NCT03061019|Procedure|Oral Myofunctional Therapy with exercices|Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
76032895|NCT03061019|Procedure|Oral Myofunctional Therapy with soft oral appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
76032896|NCT04955015|Procedure|carotid endarterectomy|patients with carotid atherosclerosis refering to CEA
75542453|NCT05897749|Other|The best supportive treatment|The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
75542454|NCT05897723|Device|Fractional Radiofrequency|Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.
75542455|NCT05897710|Other|Virtual World-Based Cardiac Rehabilitation (VWCR)|12-week virtual world technology-based program via Second Life platform. Weekly virtual visits with nurse coach and exercise physiologist, weekly education sessions, and social support group discussions within the virtual world environment.
75542456|NCT05897710|Other|Center-Based Cardiac Rehabilitation (CBCR)|Traditional 12-week in-person cardiac rehabilitation program; standard of care at participant's cardiac rehabilitation facility
76032897|NCT04963049|Other|Protocol with Mask|Look at differences in group with facemask and no mask
76032898|NCT04968041|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|The intervention using strategies from motivational interviewing and cognitive behavioral therapy to promote motivation and adherence to ketogenic nutrition in older adults at high risk for Alzheimer's disease. The program is a 6-week, group program led by a psychologist and nutrition expert.
76032899|NCT03060941|Behavioral|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
75387813|NCT05107375|Biological|Tetravalent influenza virus lysis vaccine|Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
75387814|NCT05107375|Biological|Recombinant new coronavirus vaccine (CHO cell) group|One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
75387815|NCT05065957|Drug|D07001-softgel capsules + Xeloda (or TS-1)|"D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)"
75387816|NCT05065957|Drug|mFOLFOX|intravenous infusion on Day 1 for 14-day cycle
75387817|NCT05051241|Drug|GFH018|Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen.
75387818|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg single dose
75387819|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 15mg single dose
75387820|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 20mg single dose
75869194|NCT05398250|Behavioral|Safety Planning Intervention tailored for Autistic Individuals|To develop the SPI-A, clinicians work collaboratively with patients, and when indicated, their family members, to create a list of concrete coping mechanisms to be enacted leading up to or during a crisis. This list can be depicted in writing or pictorially, depending on patient preference. As part of the intervention, patients (and family members, when appropriate) also identify warning signs that signal the need to use the safety plan, as well as a detailed plan for reducing access to lethal means. SPI-A is a stand-alone intervention without a follow-up component.
75869195|NCT05398250|Behavioral|Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts|"SPI-A+ includes SPI-A plus a structured follow-up component. The structured follow-up component of SPI-A+ includes three elements:~A brief risk assessment and mood check~Review and, if needed, revision of SPI-A~Support related to outpatient mental health treatment initiation"
75387821|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg*2 single dose
75387822|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 25mg single dose
75387823|NCT05031520|Procedure|Coronary computed tomography angiography (CCTA)|Participants will undergo CCTA. CCTA performed in this study will be technically identical to CCTA that is commonly performed in clinical practice, for which safety profiles are well defined. Guidelines implemented by the National Institutes of Health Radiation Exposure Committee will be followed. Major risks of CCTA include exposure to ionizing radiation, the requirement for intravenous catheter placement and contrast media administration, and side effects of beta-blockers and nitrates that may be used for vasodilation and heart rate control to optimize CCTA image quality.
75387824|NCT05031520|Drug|Isovue|CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).
75387825|NCT05031520|Drug|Nitroglycerin|Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality
75387826|NCT05031520|Drug|Metoprolol|Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
75387827|NCT05019950|Drug|NIM-1324|Once daily oral tablet
75387828|NCT05019950|Drug|Placebo|Once daily oral tablet
75387829|NCT05018650|Device|Route 92 Medical Reperfusion System|Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.
75387830|NCT05012813|Other|Aromatherapy with Essential Oils|Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
75387831|NCT05007431|Other|Questionnaires|Data collection will be carried out by hetero-questionnaire carried out in the presence of the questioned.
75387832|NCT05003167|Device|Expiratory Muscle Strength Training (EMST-150)|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
75387833|NCT04989829|Drug|SHR6390、Omeprazole|SHR6390 tablet single dose、Omeprazol single dose.
75387834|NCT04988035|Drug|Danicopan|Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
75387835|NCT04988035|Other|Placebo|Danicopan matching placebo tablet
75869196|NCT05395104|Drug|Midazolam|Syrup for oral administration
75869197|NCT05395104|Drug|Cefiderocol|Liquid for intravenous infusion
75387836|NCT04988035|Drug|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
75542457|NCT05897645|Other|Registration|collect clinical date, assess the morphologic characteristics of plaque
75869198|NCT05389462|Drug|ADCT-601|Intravenous (IV) infusion
75869199|NCT05389462|Drug|Gemcitabine|Intravenous (IV) infusion
75869200|NCT05380713|Drug|Cyclophosphamide|Cyclophosphamide will be applied in the neoadjuvant setting
75869201|NCT05380713|Drug|Tremelimumab|tremelimumab-durvalumab in adjuvant setting
75869202|NCT05380713|Drug|Durvalumab|tremelimumab-durvalumab in adjuvant setting
75869203|NCT05380453|Biological|Secukinumab 300 mg, s.c.|Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
75869204|NCT05380453|Drug|Placebo to match Secukinumab, s.c.|Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
76032900|NCT03060941|Behavioral|Facility access|Participants will receive at 6 month membership to a local fitness facility.
76032901|NCT03060941|Behavioral|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
76032902|NCT03060941|Behavioral|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
75387837|NCT04987138|Device|Zenflow Spring System|The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.
75387838|NCT04987138|Device|Sham Procedure|A18 Fr Foley Catheter is placed into the patient's bladder. To mimic the Treatment Arm procedure, the Foley Catheter balloon will be inflated in the bladder. Once inflated, slight tension will be applied against the subject's bladder neck. While tension is being applied the site staff will follow a script to simulate the Zenflow procedural steps. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure.
75387839|NCT04986423|Drug|ZEN003694|72 mg PO QD
75387840|NCT04986423|Drug|Enzalutamide|160 mg PO QD
75387841|NCT04939792|Drug|Vitamin D|Capsules ingested orally
75387842|NCT04939792|Drug|Placebo|Capsule ingested orally
75387843|NCT04939792|Drug|Vitamin D + L-cysteine|Capsule ingested orally
76032903|NCT03060941|Behavioral|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
76032904|NCT04962425|Drug|Trastuzumab|Trastuzumab [Herceptin] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
76032905|NCT04962269|Diagnostic Test|MRI|monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
75387844|NCT04939792|Drug|L-cysteine|Capsule ingested orally
76032906|NCT03060707|Drug|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
76032907|NCT03060863|Behavioral|2. Executive Functioning|Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).
75387845|NCT04894903|Other|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring & preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
75387846|NCT04864249|Device|SNOO|The SNOO is a commercially available device which is a responsive bassinet for neonates. The bassinet is designed to respond to the infant's cries and automatically respond by emitting engineered white noise sounds and providing a rhythmic rocking motion. The infant is also swaddled to remain securely back-down. The SNOO automatically increases the emitted sound and motion if the infant is still crying. However, if the infant does not settle within 3 minutes, the SNOO will shut off and alert the adults for additional assistance. Parents can also modify the SNOO settings to meet the baby's need for sound and/or motion.
75387847|NCT04864249|Other|Safe sleep education in the postpartum period|Comprised of education from the postpartum clinical nurse with a corresponding educational handout to take home
75387848|NCT04850495|Drug|Cyclophosphamide|Given IV
75387849|NCT04850495|Drug|Doxorubicin Hydrochloride|Given IV
75387850|NCT04850495|Drug|Prednisone|Given PO
75387851|NCT04850495|Biological|Rituximab|Given IV
75542458|NCT05897606|Combination Product|Multiviamins and minerals|The intervention group received one capsule of multivitamin and minerals supplements every day, one hour after breakfast, for 12 weeks.
76032908|NCT03060863|Behavioral|3. Food Bias|The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
75387852|NCT04850495|Drug|Vincristine Sulfate|Given IV
75387853|NCT04850495|Drug|Zanubrutinib|Given PO
75387854|NCT04847674|Drug|TEV-53275 Dose A|subcutaneous (sc) injection
76032909|NCT03060863|Behavioral|4. Emotion Regulation|Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).
76032910|NCT03060863|Behavioral|5. Future orientation|"Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present."
76032911|NCT04953533|Other|no intervention|
76032912|NCT04966949|Procedure|lateral prostate capsule sparing or neurovascular bundles sparing|When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
76032913|NCT04432103|Biological|Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.
76032914|NCT04432103|Biological|Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
76032915|NCT02658175|Drug|Volanesorsen|300 mg volanesorsen administered via SC injection.
76032916|NCT03060005|Drug|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
75387855|NCT04847674|Drug|TEV-53275 Dose B|subcutaneous (sc) injection
75387856|NCT04847674|Drug|Placebo|Matching subcutaneous (sc) placebo injection
75387857|NCT04828785|Other|MTM|weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
75387858|NCT04828785|Other|Food Subsidy|$40/month food subsidy
75387859|NCT04825613|Biological|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells
75387860|NCT04815252|Behavioral|CHIME|CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
75387861|NCT04813796|Biological|mRNA-1283|Sterile liquid for injection
75387862|NCT04813796|Biological|mRNA-1273|Sterile liquid for injection
75387863|NCT04813796|Biological|Placebo|0.9% sodium chloride (normal saline) injection
75387864|NCT04763135|Drug|Mirtazapine|"Orally disintegrating tablets of mirtazapine introduced at the dose of 15 mg and increased up to 45 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
75387865|NCT04763135|Drug|Escitalopram|"Orally disintegrating tablets of escitalopram introduced at the dose of 10 mg (or 5 mg for patients older than 65) and increased up to 20 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
75387866|NCT04762979|Drug|Alpelisib|Alpelisib 300mg, PO, days 1-28 of each cycle.
75542459|NCT05897606|Combination Product|Placebo|Placebo
75387867|NCT04762979|Drug|Fulvestrant|Fulvestrant 500mg, IM, once monthly
75706119|NCT00852436|Drug|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
75387868|NCT04762979|Drug|Aromatase inhibitor|Aromatase Inhibitor, administered per standard of care
75387869|NCT04755816|Behavioral|Sodium intervention|The sodium dietary intervention provides uses location services to determine when a participant is at home, arrives at a grocery store or arrives at a restaurant. The user receives a tailored message to assist with making dietary choices based on sodium content.
75387870|NCT04755816|Behavioral|Clinical worsening intervention|The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.
75387871|NCT04755816|Behavioral|Educational content|Standard heart failure educational information and a daily symptom survey.
75542460|NCT05897580|Behavioral|Heart Rate Variability - Biofeedback (HRV-BF)|"The HRV-BF was delivered over 30 minutes once weekly for 8 weeks by our nurse-led Community Health Worker (RN/CHW) team trained to deliver scripted material created by a trained biofeedback practitioner on our study team. The weekly sessions included the use of a tablet device to share a 10-minute video which teaches the basic techniques and breathing practices of HRV-BF and guiding the participant through a 20-minute practice, using the techniques while watching their heart rate data in real time using an HRV-BF device, the EmWave Pro (HeartMath).~Participants were also asked to complete daily practices on their own, without the HRV-BF device, for 10 minutes, twice a day, to reinforce topics and skills taught in videos. Practices logged by the participant were collected weekly by the CHW and referral to resources were provided."
75542461|NCT05897580|Behavioral|Health Promotion (HP)|The HP active control group was delivered over 30 minutes, once weekly for 8 weeks by our nurse-led Community Health Worker team, trained to deliver scripted materialized content created. In the HP program, PEH were educated on common physical chronic diseases PEH experience, including hypertension, diabetes, heart disease and arthritis, along with referrals provided based on needs expressed by PEH.
75706120|NCT00852436|Drug|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
75706121|NCT02574000|Other|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
75387872|NCT04750941|Drug|Copanlisib|Copanlisib will be infused intravenously on days 1, 8, 15 of each cycle, over 1 hour, of 28-day cycles.
75387873|NCT04750941|Other|Ketogenic Diet|"In cycle 1, patients will first start the ketogenic diet for 7 days (Day -6 to Day 0).~Only the patients who demonstrate compliance and tolerance with the ketogenic diet, as confirmed by pertinent blood and urine tests and a diary of diet, will be allowed to continue the study and start copanlisib on Day 1. The ketogenic diet will continue daily throughout the treatment days.~In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1.~The ketogenic diet will then continue daily throughout the treatment days."
75387874|NCT04723134|Combination Product|Folinic acid calcium salt|Folinic acid (2.5%) by combination with Placebo
75387875|NCT04675450|Drug|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
75542462|NCT05897567|Other|resistance training|All participants perform a four-day resistance training aimed to stimulate a hypertrophic response.
75542463|NCT05897567|Other|ketogenic diet|Subjects allocated to the ketogenic diet arm (KD group) consume less than 50 g of carbohydrates per day.
75542464|NCT05897567|Other|western diet|Subjects allocated to the western diet arm (WD group) consume a standard diet based on 55% of their daily calories from carbohydrates.
75542465|NCT05897528|Other|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
75387876|NCT04675450|Drug|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
75542466|NCT05897515|Diagnostic Test|LIAISON NES FLU A/B & COVID-19|The LIAISON® NES FLU A/B & COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
75542467|NCT05897476|Other|ultrasound|brief external ultrasound will be proceed on each patient included searching signs of aortic dissection
75542468|NCT05897424|Drug|INBRX-101|A1PI, Recombinant, Bivalent Fc Fusion Protein
76032917|NCT03060005|Drug|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
75542469|NCT05897411|Behavioral|Unmasking previous conditioning procedure|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
75542470|NCT05897411|Behavioral|No unmasking of previous conditioning|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
75542471|NCT05897398|Other|Data collection|Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.
75542472|NCT05897398|Other|Blood sampling|Blood sampling for routine care (max 15mL) and constitution of a plasma bank (28 mL)
75542473|NCT05897398|Other|Questionnaires|"Completion of questionnaires for the entire cohort:~To assess hyperphagia and eating behaviour: BES, DEBQ and Hunger Score questionnaire To assess physical activity: short IPAQ To assess sleep behaviour: MCTQ To assess quality of life: EQ5D5L To assess digestive system disorders: GIQLI To assess anxiety and depression: HAD"
75706122|NCT02574000|Other|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
76032918|NCT02774785|Device|MarginProbe|Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
76032919|NCT04953455|Other|no intervention|no intervention
75387877|NCT04666272|Drug|dabrafenib|There is no treatment allocation. Patients administered dabrafenib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
75542474|NCT05897372|Drug|ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib|Standard of care for diabetic kidney disease.
75542475|NCT05897359|Behavioral|bCBTMI|This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.
76032920|NCT03234361|Dietary Supplement|High Phosphate Phase|2 capsules of sodium phosphate with 500mg/day of phosphate.
76032921|NCT03234361|Dietary Supplement|Low Phosphate Phase|2 capsules of sodium chloride.
76032922|NCT04953299|Behavioral|Functional Imagery training|Behavioural intervention focused upon motivation and reaching achievable goals.
75706123|NCT04068350|Other|Pain questionnaire|Pain questionnaire, 3 months after surgery
75706124|NCT02573844|Drug|Proklama|
75706125|NCT02573844|Drug|Placebo|
75706126|NCT02545894|Behavioral|Cognitive therapy|"The tasks are:~visually tracking a picture as it moves across the computer screen~pressing a button every time a picture is seen on the screen~pressing a button every time a specific picture is seen on the screen~Pressing a button every time a specific sound is heard~Matching objects to a picture~Matching gestures to objects~Matching two connected objects~Sorting objects by categories~Matching sounds to objects~Complete the category and odd on out with objects~Choosing target objects by pointing~Choosing objects to complete the category by pointing"
75387878|NCT04666272|Drug|trametinib|There is no treatment allocation. Patients administered trametinib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
75387879|NCT04651998|Diagnostic Test|MMSE, MoCA, functional near-infrared spectroscopy|MMSE and MoCA are used for cognitive test before carotid artery stent implant and 6 months later. Cerebral blood oxygenation is evaluated by functional near-infrared spectroscopy under the mental task before and after revascularization within one week, 6 months later respectively.
75387880|NCT04649060|Drug|Melflufen|Powder for solution for i.v. infusion
75387881|NCT04649060|Drug|Dexamethasone|Oral tablets
75387882|NCT04649060|Drug|Daratumumab|Solution for s.c. injection
75387883|NCT04640272|Drug|RBM-007|Intravitreal injection
75387884|NCT04623008|Behavioral|Goal-Oriented Episodic Future Thinking|Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
76032923|NCT04953299|Behavioral|NHS 12 week weight loss programme|The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
76032924|NCT04210141|Biological|lyophilized BPI viper antivenom|Antivenom
76032925|NCT04962191|Diagnostic Test|Idylla EGFR Mutation Test|This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
76032926|NCT04186117|Other|Blood sample|Blood sample before any treatment
75387885|NCT04608487|Drug|Fludarabine|Intravenous infusion
75387886|NCT04608487|Drug|Cyclophosphamide|Intravenous infusion
76032927|NCT04953221|Drug|YJ001|Skin spray
75387887|NCT04608487|Biological|Axicabtagene Ciloleucel|Intravenous infusion
76032928|NCT04006951|Other|Biological collection|"Blood samples are collected at different times :~Before any treatment~After pre-operative radiochemotherapy and before surgery (if applicable)"
76032929|NCT02926417|Procedure|High Density-Electroencephalogram|
76032930|NCT04952987|Drug|Diquafosol|Diquafosol (Diquas) is a P2Y2 receptor agonist which improves mucin and tear secretion
76032931|NCT04418609|Other|further processing of health data|further processing of biological materials and health related personal data for research
76032932|NCT05106439|Behavioral|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
76032933|NCT05106439|Behavioral|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
76032934|NCT05106439|Behavioral|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
75387888|NCT04602767|Drug|Vasopressin|Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP < 65 mmHg
75387889|NCT04602767|Drug|Phenylephrine|Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP < 65 mmHg
76032935|NCT04418531|Biological|Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
75387890|NCT04590521|Biological|Gardasil®, Merck|Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).
75387891|NCT04586894|Diagnostic Test|Cardiac MRI|Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy
75387892|NCT04586894|Device|Smart cloth|A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.
75387893|NCT04586894|Other|Biobanking|Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
75387894|NCT04581447|Drug|Metformin|Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
75387895|NCT04581447|Other|Standard Care|Standard Care
75387896|NCT04581447|Dietary Supplement|Standardized meal|Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
75387897|NCT04580485|Drug|INCB106385|INCB106385 will be administered orally QD
75387898|NCT04580485|Drug|INCMGA00012|INCMGA0012 will be administered IV once every 4 weeks (Q4W)
75387899|NCT04563793|Device|Superion™ IDS|All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.
75387900|NCT04552665|Device|KODEX-EPD system|To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R&D)
75387901|NCT04520685|Drug|Oral cannabidiol 100mg/mL|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
75542476|NCT05897359|Behavioral|Control|The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
75706127|NCT00424177|Drug|eltrombopag|experimental
76032936|NCT05037019|Procedure|Radiation therapy|Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
76032937|NCT02555293|Drug|XIFAXAN® (Rifaximin)|
75387902|NCT04520685|Drug|Placebo|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
75387903|NCT04519151|Drug|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
75387904|NCT04519151|Drug|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
75706128|NCT04068116|Procedure|Primary per-cutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty & coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion & reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
75706129|NCT00716430|Behavioral|Quality Improvement Programme|Quality Improvement training programme
76032938|NCT05104255|Procedure|Spinal anesthesia|Twins delivered under under spinal anesthesia
76032939|NCT05104255|Procedure|General anesthesia|Twins delivered under general anesthesia
75706130|NCT00720512|Biological|bevacizumab|Given IV
75706131|NCT00720512|Drug|fluorouracil|Given IV
76032940|NCT05087251|Behavioral|Five Psycho-educational Session(s)|5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty
76032941|NCT05087251|Behavioral|One Psycho-educational Session(s)|1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations
76032942|NCT04436575|Device|Point-of-care ultrasound|Point-of-care ultrasound prognostic performance : echocardiography mainly
76032943|NCT03293017|Drug|Diazepam 10 MG|If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
75387905|NCT04511650|Drug|Razuprotafib Subcutaneous Solution|Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
75387906|NCT04511650|Drug|Placebo Subcutaneous Solution|Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
75387907|NCT04497012|Drug|2mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
75387908|NCT04497012|Drug|6 mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
75387909|NCT04484259|Drug|Ticagrelor monotherapy|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
75542477|NCT05897346|Other|'Learning while serving' training program|The training program will involve training workshops, hands-on sessions, and a smoker referral competition.
75706132|NCT00720512|Drug|irinotecan hydrochloride|Given IV
76032944|NCT03293017|Drug|Baclofen 30mg|Baclofen 30 mg/day given over three gifts daily
76032945|NCT03293017|Drug|Baclofen 60mg|Baclofen 60 mg/day given over three gifts daily
76032946|NCT04436809|Procedure|Sentinel Node Biopsy|"Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection)."
75706133|NCT00720512|Drug|leucovorin calcium|Given IV
75706134|NCT00720512|Drug|oxaliplatin|Given IV
75706135|NCT04069286|Drug|Oral Aroeira/ Amoxicillin/ Claritromycin|Oral Aroeira (Schinus terebinthifolius Raddi, 640mg/tablet) 1 tablet, twice day, 12/12 hours + Amoxicillin 2 tablets of 500mg, twice day, 12/12 hours, + Claritromycin, 1 tablet of 500mg, twice day, 12/12 hours, for 14 days.
75542478|NCT05897346|Other|Usual care|A 3-hour training workshops in the control group are regarded as usual care since the training workshops are also conducted regularly to other secondary or tertiary schools.
75706136|NCT04069286|Drug|Omeprazole/ Amoxicillin/ Claritromycin|Omeprazole 1 tablet of 20mg, twice day, 12/12 hours + Amoxicillin 2 tablets of 500mg, twice day, 12/12 hours, + Claritromycin, 1 tablet of 500mg, twice day, 12/12 hours, for 14 days.
76032947|NCT04436809|Procedure|Axillary Dissection|Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
75387910|NCT04484259|Drug|Ticagrelor plus aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
75387911|NCT04484259|Drug|Clopidogrel with aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
75387912|NCT04463693|Drug|Etonogestrel implant|Insertion of the contraceptive implant at an alternative insertion site located over the scapula
76032948|NCT04658251|Genetic|Blood and/or skin biopsy|Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.
76032949|NCT03198559|Drug|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
75706137|NCT00716508|Procedure|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
75387913|NCT04390529|Other|quality-of-life questionnaire: BREAST-Q|quality-of-life questionnaire: BREAST-Q
75706138|NCT00716508|Procedure|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
75706139|NCT04069442|Other|This is a non-interventional study|This is a non-interventional study
75542479|NCT05897294|Drug|Voriconazole Inhalation Powder|dry powder inhalation of voriconazole
75387914|NCT04348916|Biological|ONCR-177|Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
75542480|NCT05897255|Device|Surface EMG Biofeedback|Surface EMG activity will be recorded from the left and right abdominal muscles while the exercises will be performed in different positions. Electrical signals in the muscle are measured and displayed on the screen and are amplified into sounds that the patient can hear. This feedback increases patient effort and participation and provides the data and documentation required to measure patient outcomes and quantify progress. Electrical activity from Rectus Abdominis muscle, External Oblique muscle and Transversus Abdominis muscle will be recorded with their specific exercises. SEMG Biofeedback protocol of a series of ten second contractions, each contraction preceded by a ten second rest period will be followed. Starting with shorter work/rest periods as needed to build-up to these intervals are acceptable; for example, starting with 3-second contractions and 6-second rest periods, and then gradually increasing the duration of each.
75706140|NCT03992846|Drug|75 mg linzagolix tablet|For oral administration once daily
75542481|NCT05897203|Drug|TAZCOV|Herbal Syrup
75387915|NCT04348916|Biological|pembrolizumab|Anti-PD-1 monoclonal antibody
75387916|NCT04310163|Other|Natural history|Parent interview and video capture
75387917|NCT04299113|Drug|Vinorelbine|Given IV
75387918|NCT04299113|Drug|Mocetinostat|Given PO
75387919|NCT04295603|Other|Toucher Massage (TM) on the feet|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.
75542482|NCT05897203|Drug|Vidicine|Herbal Syrup
75387920|NCT04295603|Other|Homedics HM MP RELEX 90 device|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator."
75542483|NCT05897112|Drug|Group A received cryotherpay|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
75542484|NCT05897112|Drug|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
75542485|NCT05897060|Device|Venus Jugular O2 Saturation optical fiber|A continuous measurement of VjO2S, the usual reference measurement of the marketed devices, will be performed by implanting an optical fiber (CEVOX, PULSION Medical Systems) through an internal jugular catheter in addition to the classical catheter of the external electro-systolic drive probe. The following parameters will be recorded every 2 seconds: invasive blood pressure (systolic, mean and diastolic), heart rate, SaO2 on the pulse wave. VjO2S will be recorded continuously during the entire implantation procedure. The time of the beginning of the surgical incision, of the beginning of sinus tachycardia (overdriving) induced by external electro-systolic stimulation, of the beginning of inflation of the intravalvular aortic balloon, of the maximum occlusion of the balloon, of the end of complete deflation of the balloon, of the end of stimulation and of the end of skin closure will be recorded.
75542486|NCT05897047|Combination Product|Additional interventional telemedical management|Predefined additional telemedical management including regular telemedicine visits and automatic data transfer (e.g. vital signs, well-being, medication plan laboratory data and chat) between the patient at home and KTC through a certified smartphone application.
75542487|NCT05896982|Other|Care as usual with information support|Comprises of additional visual information in the form of two videos that show details about the procedure on both days of the MPI diagnostic procedure. Each of these two videos are approximately 5 minutes long and are made available to the patients before the first day (video 1), and in between the first and second day (video 2).
75542488|NCT05896982|Other|Care as usual with supportive coaching|Patients receive coaching from one person who is present throughout the complete diagnostic process. The coach is available for answering questions as well as comforting the patients when necessary (e.g., to reassure patients if they are anxious or stressed).
75387921|NCT04285580|Drug|Bimatoprost SR|Consists of 1 Bimatoprost SR administration in the study eye.
75542489|NCT05896982|Other|Care as usual with information support and supportive coaching|This intervention comprises additional visual information in the form of two videos and coaching throughout the diagnostic process as described above.
75542490|NCT05896956|Other|no interventions|no interventions
76032950|NCT03198559|Drug|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
75542491|NCT05896943|Drug|Ustekinumab|Patients with ulcerative colitis treated with ustekinumab
75542492|NCT05896930|Drug|Meropenem 6g IV over 6 hours|Meropenem 6g intravenously over 6 hours once daily on days 1-14.
75706141|NCT03992846|Drug|200 mg linzagolix tablet|For oral administration once daily
75706142|NCT03992846|Drug|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
75706143|NCT03992846|Drug|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
75706144|NCT03992846|Drug|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
75706145|NCT03992846|Drug|Placebo capsule to match Add-back capsule|For oral administration once daily
76032951|NCT04859491|Dietary Supplement|Carbohydrate|Participants have a one in three chance of consuming a carbohydrate beverage between two bouts of high-intensity exercise.
76032952|NCT04859491|Dietary Supplement|Carbohydrate-Protein|Participants have a one in three chance of consuming a carbohydrate-protein beverage between two bouts of high-intensity exercise.
76032953|NCT04859491|Dietary Supplement|Placebo|Participants have a one in three chance of consuming a placebo beverage between two bouts of high-intensity exercise.
75542493|NCT05896930|Drug|Ertapenem 1g IM|Ertapenem 1g intramuscularly once daily on days 1-14.
75542494|NCT05896930|Drug|Meropenem 3g IV|Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
75542495|NCT05896930|Drug|Ertapenem 1g IV|Ertapenem 1g intravenously once daily on days 1-14.
75542496|NCT05896930|Drug|Amoxicillin/CA twice daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
75542497|NCT05896930|Drug|Rifampicin 35 mg/kg|Rifampicin 35 mg/kg once daily on days 1-14.
75387922|NCT04285580|Drug|LUMIGAN|Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
75387923|NCT04259905|Behavioral|Active video game teleconference support group|12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
75387924|NCT04259905|Behavioral|Standard support group + pedometer|3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
75387925|NCT04258969|Behavioral|Pedaling|Participants will pedaling at a low-moderate intensity using a stationary pedal ergometer concurrent to their chemotherapy (FOLFOX or FOLFIRI) infusion. Participants will cycle for 30 min within the first 2 hours of their infusion.
75542498|NCT05896930|Drug|Meropenem 6g IV over 60 minutes|Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
75542499|NCT05896930|Drug|Rifafour e-275|Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
75542500|NCT05896930|Drug|Meropenem 4g IV|Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
75706146|NCT00713622|Drug|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
75706147|NCT00713622|Drug|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
75542501|NCT05896930|Drug|Amoxicillin/CA once daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
75542502|NCT05896904|Diagnostic Test|Echocardiography|Echocardiography
75542503|NCT05896852|Behavioral|physical activity|Participants will increase their physical activity through walking.
75542504|NCT05896826|Device|Magnetometer|inspection equipment for magnetocardiography
75542505|NCT05896813|Drug|CMOP+Chidamide|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
75542506|NCT05896787|Drug|AK104, nab-paclitaxel, carboplatin|AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
75869205|NCT05365776|Behavioral|Graded Exposure Therapy|Graded exposure therapy is delivered by a psychologist over 12 individual (1:1) secure videoconference sessions. The core active ingredient is graded situational exposure to foster habituation and challenge beliefs that the avoided activities are dangerous. Homework exercises involve planned exposure exercises in the home and community to support generalization.
75542507|NCT05896722|Other|Core muscle endurance|Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.
75542508|NCT05896722|Other|Upper extremity muscle strength|Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.
75542509|NCT05896722|Other|Grip strength|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
75542510|NCT05896722|Other|Pinch strength|Pinch strength will be evaluated with a pinchmeter in three positions.
76032954|NCT05106049|Diagnostic Test|serum Adiponectin|serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
76032955|NCT04523545|Device|cardiac ablation|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
75387926|NCT04254926|Behavioral|Revie ⊕|Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
75387927|NCT04245371|Drug|Lidocaine 1.8%|Topical Patch
75542511|NCT05896722|Other|Alternate hand-wall toss test|To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.
75542512|NCT05896657|Dietary Supplement|Ligilactobacillus salivarius CECT5713|Oral administration of a capsule containing 9 log10 cfu of the strain.
75387928|NCT04245371|Drug|Placebo|Matching Placebo Patch
75387929|NCT04231539|Drug|Nicotine|Vape different flavor nicotine products
75542513|NCT05896657|Dietary Supplement|Placebo|Oral administration of a capsule containing maltodextrin.
75542514|NCT05896631|Other|7.5 mg hyperbaric bupivacaine|Spinal anesthesia with 7.5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
75542515|NCT05896631|Other|5 mg hyperbaric bupivacaine|Spinal anesthesia with 5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
76032956|NCT05105815|Biological|IPM001|IPM001 will be used against tumor cells
76032957|NCT02625623|Drug|Avelumab|Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
76032958|NCT02625623|Drug|Irinotecan|Irinotecan was administered at a dose of 150 mg/m ^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
76032959|NCT02625623|Drug|Paclitaxel|Paclitaxel was administered at a dose of 80 mg/m^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
75387930|NCT04231539|Device|Vaporizer Device|Take puffs from vaporizer filled with different flavors
75387931|NCT04200248|Drug|RBM-007 Injectable Solution|RBM-007 Injectable Solution
75542516|NCT05896605|Drug|Azathioprine|Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
75542517|NCT05896553|Drug|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
75542518|NCT05896553|Drug|intranasal Placebo|Administration of intranasal Placebo
75869206|NCT05365776|Behavioral|Prescribed aerobic exercise|Participants will be asked to complete 30 minutes of aerobic exercise on 5 days/week for a 12-week period. Participants select the mode (e.g., swimming, jogging, bicycling) and location of exercise (e.g., outdoors, a gym or community centre, at home). The initial exercise intensity target will be based on the Buffalo Concussion Bike Test. The target progression will be 3-5 beats per minute every two weeks.
75869207|NCT05365776|Other|Enhanced usual care|Usual care (education about concussion from the website: concussion.vch.ca/) will be enhanced through text message support.
75869208|NCT05359445|Biological|IMA401 (Phase Ia)|Intravenous infusions in escalating dose levels
75706148|NCT00719940|Behavioral|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
75387932|NCT04200248|Drug|Aflibercept|EYLEA® (aflibercept) Injection, for Intravitreal Use
75387933|NCT04200248|Drug|Sham|Sham intravitreal injection
75869209|NCT05359445|Biological|IMA401 (Phase Ib)|Treatment at recommended dose for extension (RDE)
75387934|NCT04189432|Biological|SCM-CGH|SCM-CGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
75387935|NCT04189432|Other|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
75387936|NCT04189419|Biological|SCM-AGH|SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).
75387937|NCT04189419|Other|Placebo|Placebo will be administrated once a day for 3 days(D0, D1 and D2).
75387938|NCT04188522|Diagnostic Test|Magnetoencephalography (MEG)|Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.
75387939|NCT04179760|Biological|SCM-AGH|SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
75557786|NCT00475410|Drug|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
75706149|NCT00719940|Other|Waiting group|No intervention
75706150|NCT00718172|Procedure|Liver Biopsy|
75706151|NCT00718172|Drug|Peginterferon &amp; Ribavirin for Hepatitis C|
75706152|NCT00718172|Drug|Pre-treatment Ribavirin|
75706153|NCT00720018|Drug|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
75706154|NCT00716664|Other|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
75869210|NCT05351788|Drug|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
75869211|NCT05351788|Drug|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
75869212|NCT05351788|Drug|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
75869213|NCT05351788|Drug|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
75869214|NCT05350774|Drug|IV normal saline|IV normal saline 250ml for 5 days
76032960|NCT02625623|Other|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
76032961|NCT05105893|Other|Dates group|Seven dates to be provided to patients
76032962|NCT02749513|Drug|Itraconazole|
76032963|NCT05110339|Drug|Ropivacaine plus dexmedetomidine|Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.
75387940|NCT04179760|Other|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
75869215|NCT05350774|Drug|IV immunoglobulin|IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
76032964|NCT05110339|Drug|Ropivacaine|Erector spinae block with ropivacaine at a dose of 0.5%.
75557787|NCT00475410|Drug|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
76032965|NCT05111665|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|
76032966|NCT05111665|Behavioral|Relaxation Group Therapy (RGT)|
76032967|NCT05111665|Behavioral|Treatment as usual (TAU)|
76032968|NCT04966403|Other|Standard physical therapy|building strength, enhancing developmental skills, boosting balance, coordination, and postural control
76032969|NCT04966403|Other|trampoline-based stretch-shortening cycle exercises|muscle strength
76032970|NCT04830631|Device|Cathodal transcranial direct current stimulation (tDCS) over the contralesional motor cortex|Cathodal tDCS will be applied to the contralesional motor cortex with 2mA intesntisy for 30 mins/day. Total 10 sessions will be applied.
76032971|NCT04952831|Other|diffusion MRI (dMRI)|All participants underwent dMRI scan at baseline
75387941|NCT04178096|Other|Quality Improvement Intervention|The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
75387942|NCT04142177|Other|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
75387943|NCT04142177|Procedure|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
75542519|NCT05896540|Behavioral|ENFOCATE|ENFOCATE is a comprehensive program of sexual education for adolescents. Its design follows the guidelines of the Intervention Mapping Approach and the orientations proposed by the Framework for Gender-Transformative Health Promotion. The intervention has a participative focus, thus the activities are designed to promote processes of knowledge, understanding, application and reflection in the adolescents. The activities aim to improve the capacity for critical thinking, increase the motivation to listen and learn actively, and to improve interpersonal abilities. The execution of the intervention uses three pillars: (i) preventive sexual behavior; (ii) gender equity; and (iii) mental health. The intervention consists of ten weekly sessions, each lasting one hour. The teams that will perform the intervention will be composed of at least two professionals of the psychosocial area (mainly psychologists, social workers and/or guidance counsellors) of the schools included in the study.
75542520|NCT05896462|Other|10% povidone iodine|The apposed skin edge was covered with 10% povidone iodine-soaked gauze dressing
75542521|NCT05896449|Diagnostic Test|[68Ga]Ga-PSMA-11 PET/CT|The PET/CT image acquisition was performed from the skull to the mid-thigh (3-min per bed position, 3 iterations, 21 subsets) with a CT scan (120 kV, 170mAs reference) with dose modulation for anatomic correlation (CARE dose 4D) and attenuation correction on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) 60 min post injection of [68Ga]Ga-PSMA-11 (2 MBq per kg body weight).
75542522|NCT05896345|Device|SWL|Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone
75542523|NCT05896345|Combination Product|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
75869216|NCT05350319|Radiation|A low-dose CT scan of the shoulder|Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
75869217|NCT05350254|Other|Chiropractic maintenance care|Manual Therapy, individual exercises and lifestyle advice
75869218|NCT05350254|Other|Standard chiropractic care|Standard care based on clinician's judgement
75542524|NCT05896319|Device|Hyaluronic acid gel|"Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area."
75542525|NCT05896241|Other|non-interventional study|non-interventional study
75542526|NCT05896176|Diagnostic Test|a clinical examination and anamnesis|The investigators compare the results of the PSQ alone with the elements provided by the clinical examination regarding the referral of patients to the Otolaryngologist (ENT) consultation.
75869219|NCT05327491|Drug|Sotorasib|Oral Tablet
75869220|NCT05322239|Device|Intermittent Theta Burst Stimulation|iTBS parameters. A series of 20, 10 s trains will be presented over the course of the ~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
75542527|NCT05896137|Drug|CS0159 2mg|Oral QD
75869221|NCT05322239|Device|Continuous Theta Burst Stimulation|cTBS parameters. A single 600 pulse cTBS train will be delivered during each stimulation session. The train will consist of 50 Hz bursts, repeated at intervals of 200 ms (5 Hz) for 40 sec.
76032972|NCT04965545|Dietary Supplement|low copper diet|All patients with wilson disease should receive low copper diet
75387944|NCT04142177|Other|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
75387945|NCT04142177|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
75387946|NCT04142177|Procedure|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
75387947|NCT04142177|Procedure|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
75387948|NCT04137887|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
75387949|NCT04137887|Biological|Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
75387950|NCT04120402|Drug|EP-104IAR 25 mg|Single 5 mL intra-articular injection
75387951|NCT04120402|Drug|Vehicle|Single 5 mL intra-articular injection
75387952|NCT04096196|Behavioral|Safe City game|The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.
75387953|NCT04096196|Other|Health education|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
75542528|NCT05896137|Drug|Placebo|Oral QD
75706155|NCT00716664|Other|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
75706156|NCT00618826|Drug|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
75387954|NCT04095273|Drug|Elimusertib (BAY1895344)|Study drugs will be administered as scheduled
75542529|NCT05896124|Drug|2mg CS0159|Oral QD
75706157|NCT00618826|Drug|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
75706158|NCT00618826|Drug|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
75387955|NCT04095273|Drug|Pembrolizumab|Study drugs will be administered as scheduled
75387956|NCT04074590|Drug|LYS006|capsule for oral use
75387957|NCT04074590|Drug|Placebo|capsule for oral use
75706159|NCT02572362|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
75869222|NCT05321199|Drug|Tranexamic acid|Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.
75869223|NCT05320029|Device|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
75387958|NCT04068844|Behavioral|Exercise training|Exercise training, either whole body or isolated single leg
75387959|NCT04023487|Behavioral|Resilient, Empowered, Active Living-Telehealth (REAL-T)|REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
75387960|NCT03997773|Behavioral|Face-it Intervention|The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
75542530|NCT05896124|Drug|Placebo|Oral QD
75542531|NCT05896111|Procedure|Physical therapy exercises.|Exercises to treat hemiparetic cerebral palsy
75542532|NCT05896072|Procedure|Erector Spinae Plane Block|"Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc)."
75706160|NCT00718250|Biological|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
75706161|NCT00718250|Biological|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
75706162|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
75706163|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
75706164|NCT00720174|Biological|Cixutumumab|Given IV
75706165|NCT00720174|Drug|Doxorubicin Hydrochloride|Given IV
75706166|NCT00720174|Other|Laboratory Biomarker Analysis|Correlative studies
75706167|NCT00857740|Behavioral|Education|Education about the neurophysiology of pain
75869224|NCT05320029|Device|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
75387961|NCT03972969|Behavioral|Facility-based structured exercise|Structured exercise program in a facility with instruction and encouragement
75869225|NCT05307263|Procedure|Combination therapy of atherectomy and DCB|The target lesion in femoropopliteal artery will be treated with atherectomy folloewd by DCB. The choice of atherectomy devices (HawkOne, Jectstream, or Rotarex)and DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
75869226|NCT05307263|Procedure|DCB alone|The target lesion in femoropopliteal artery will be treated with DCB. The choice of DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
75869227|NCT05301920|Device|Elexir (trigeminal nerve electrical stimulator)|Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
75869228|NCT05300282|Drug|Atezolizumab|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice)."
75387962|NCT03972969|Behavioral|Home-based structured exercise|Structured exercise program in the home with instruction and encouragement
75387963|NCT03972969|Behavioral|Health education|Provision of general information about a variety of topics
75706168|NCT04041544|Drug|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
75387964|NCT03954366|Drug|Rucaparib|Rucaparib 600 mg BID commencing on Day 5 until Day 23.
75387965|NCT03954366|Drug|Rosuvastatin|Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
75706169|NCT04041544|Drug|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
75706170|NCT00722930|Drug|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
75706171|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
75706172|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
75387966|NCT03954366|Drug|Oral Contraceptives|Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
75387967|NCT03936569|Drug|Marketed Toothpaste|Marketed stannous fluoride (0.454%) toothpaste
75387968|NCT03936569|Drug|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
75387969|NCT03935932|Device|nasal delivery of heated and humidified air|Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
75387970|NCT03934255|Other|Constant Routine Protocol|Constant routine protocols are used in circadian research to examine underlying circadian rhythms in the absence of light, activity, and meals
75387971|NCT03912220|Drug|Nicotinamide riboside|The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.
76032973|NCT04965467|Diagnostic Test|Screening for Fabry disease|A questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.
76032974|NCT04813939|Device|IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany)|Point of care assessment of bio-adrenomedullin concentration will be performed using the IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany) on the 1,3,5-day ICU stay in COVID-19 patients. The method used is a double monoclonal sandwich immunoassay to measure the concentration of C-terminal amidated, biologically active adrenomedullin (bio-ADM) in whole blood. Additional measurement of bio-ADM will be performed as standard monitoring in patients suspected of septic complications of the course of COVID-19.
75387972|NCT03912220|Drug|Placebo Oral Tablet|Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
75387973|NCT03898167|Behavioral|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
75387974|NCT03898167|Behavioral|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
75387975|NCT03898167|Behavioral|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
75387976|NCT03872791|Biological|KN046|KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
75387977|NCT03872791|Drug|Nab-paclitaxel|Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
75387978|NCT03864042|Drug|losartan|taken orally
75387979|NCT03864042|Drug|dextromethorphan|taken orally
75387980|NCT03864042|Drug|caffeine|taken orally
75387981|NCT03864042|Drug|omeprazole|taken orally
75542533|NCT05896072|Procedure|Caudal Block|"Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances"
75542534|NCT05896059|Drug|Tislelizumab|Tislelizumab，200mg，D1, intravenous，Q3W；
75387982|NCT03864042|Drug|midazolam|taken orally
75387983|NCT03864042|Drug|rosuvastatin|taken orally
75387984|NCT03864042|Drug|bupropion immediate release (IR)|taken orally
75387985|NCT03864042|Drug|encorafenib|taken orally
75387986|NCT03864042|Drug|binimetinib|taken orally
75387987|NCT03864042|Drug|modafinil|taken orally
75387988|NCT03858361|Device|Atrial Flutter Ablation|Catheter-based electrophysiological (EP) intervention.
75387989|NCT03737604|Drug|Ropivacaine Continuous Infusion Catheter|For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
75706173|NCT00713778|Procedure|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
75706174|NCT00849004|Other|silicone gel|silicone gel
75387990|NCT03737604|Drug|Single Dose Liposomal Bupivicaine|TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
75387991|NCT03730519|Device|Baroreflex Activation Therapy with Barostim Neo|Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
75542535|NCT05896059|Drug|Anlotinib|Anlotinib，12mg，oral administration，QD.
75387992|NCT03713554|Procedure|FNIRS Observational|In addition to completing an Informed Consent and survey questions, fNIRS Imaging and Electroencephalography (EEG) will take place will take place:The fNIRS imaging is experimental technology that has not been approved by the FDA. EEG is a noninvasive way to record electrical activity of the brain. The recording device is made up of electrodes that are fixed to a snug-fitting elastic cap. An MRI and EEG will follow the fNIRS procedure. The MRI will be performed before participants undergo fNIRS or EEG. The MRI will be done to show there are no lesions in the inner ear and therefore is a recruitment clearance tool.
75542536|NCT05895994|Drug|RD13-02 cell infusion|CAR-T cells
75706175|NCT00849004|Other|silicone sheet|silicone sheet
75706176|NCT00849004|Other|paper tape|paper tape
75706177|NCT03834740|Drug|Ribociclib|Ribociclib administered orally in 5 daily doses prior to resection
75706178|NCT03834740|Drug|Everolimus|Everolimus administered orally in 5 daily doses prior to resection
75706179|NCT00849082|Drug|cyproterone acetate|
75706180|NCT00849082|Drug|goserelin acetate|
75706181|NCT00849082|Radiation|radiation therapy|
75706182|NCT00713856|Procedure|Custom PRK with iris registration|PRK
75706183|NCT00713856|Procedure|Conventional PRK|PRK
75706184|NCT02545582|Device|VITARIA System|Implantable vagus nerve stimulator
75387993|NCT03676504|Biological|CD19.CAR T Cells|Dose Level 1: 1×10^6 transduced cells/m^2; Dose Level 2: 5×10^6 transduced cells/m^2; Dose Level 3: 20×10^6 transduced cells/m^2; Dose Level 4: 5x10^7 transduced cells/m^2; Dose Level 5: 10x10^7 transduced cells/m^2; Dose Level 6: 20x10^7 transduced cells/m^2
76032975|NCT04795375|Behavioral|Physical Activity counseling|"The Physical activity counseling techniques will be based on the Self Determination Theory and Five A's (Assess, Advise, Agree, Assist, Arrange). Guidelines for physical activity will include combined aerobic and resistance exercises.~Each participant in the intervention group will receive personal exercise prescriptions in accordance the post-surgical statues and exercise recommendations after bariatric surgery. Participants will receive long term follow-up and accompaniment during the first six months after the surgery, through Personal meetings with a certified nurse, Phone-calls, motivational massages, and Exercise Videos."
76032976|NCT04961411|Procedure|operation or non-operative treatment|type of operation or if possible non-operative treatment
76032977|NCT04425785|Other|Physical Exercise Program|A structured exercise program
76032978|NCT04425785|Behavioral|Cognitive Behavioural Therapy|A structured cognitive behavioural therapy program
76032979|NCT05105659|Diagnostic Test|Wechsler IQ for Adults|IQ test that measures the cognitive functions and intelligence using a scale and consists of many subtests assessing verbal and non-verbal performance.
76032980|NCT05105659|Diagnostic Test|MAS (Memory assessment scale)|tool that uses verbal and the visual tasks to assess memory, recall and cognition. The MAS consists of 12 subtests based on the following 7 memory tasks: Verbal Span, List Learning, Prose memory, Visual Span, Visual Recognition, Visual Reproduction and Names-Faces.
75387994|NCT03676504|Drug|Fludarabine|3 days of fludarabine 30 mg/m^2/day
75387995|NCT03676504|Drug|Cyclophosphamide|3 days of cyclophosphamide 500 mg/m^2/day
75387996|NCT03637270|Dietary Supplement|Dietary supplementation|Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
76032981|NCT05105659|Diagnostic Test|Health-Related Quality of Life (HRQoL)|measures multiple aspects of the individual's life and the impact of the disease and treatment on the individual's life. It does so by assessing the individual's own views and perspective of the care and treatment they are receiving and whether consider it satisfactory or not.
76032982|NCT05105659|Diagnostic Test|Symptom check list 90|a well-known scale that is used to identify and assess psychological symptoms. It consists of a 90-item checklist having a 5-point rating scale.
75706185|NCT00713934|Biological|CD133|portal vein infusion of CD133+ cells
75387997|NCT03637270|Other|Exercise training|Including aerobic cycling training and progressive resisted exercise
75706186|NCT00713934|Biological|BM-MNC|portal vein infusion of BM-MNC
75706187|NCT00849160|Drug|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
75706188|NCT00714012|Other|observational|presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
75387998|NCT03626974|Biological|Venipuncture|Venipuncture for blood collection
76032983|NCT05105659|Diagnostic Test|Socioeconomic level|scale for measurement of socioeconomic status in health research in Egypt. The new socioeconomic status scale has 7 domains with a total score of 84. Intra-and inter-observer variability and the internal consistency of the scale were assessed.
76032984|NCT05105581|Behavioral|Quality of life scale|"To assess the quality of life of patient~To assess the degree of OCD"
75706189|NCT00857974|Other|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
75706190|NCT00720252|Device|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
75706191|NCT00720590|Drug|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
75706192|NCT00720590|Drug|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
75706193|NCT00720590|Drug|Placebo|Daily dose of placebo for 4 weeks
75706194|NCT00852514|Device|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
75706195|NCT00718406|Drug|Metoprolol|
76032985|NCT05111275|Other|Cognitive exercises|Exercises that stimulate and train memory, attention, executive functions, language and gnosis.
76032986|NCT05105347|Drug|Adalimumab plus different doses of oral glucocorticosteroid|A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
75706196|NCT00718406|Drug|metoprolol plus morphine|
75706197|NCT02572206|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner.
75706198|NCT02572206|Device|MRI scan|Structural MRI will be obtained to permit co-registration of PET images.
75706199|NCT00849238|Drug|mycophenolate mofetil|
76032987|NCT05110963|Behavioral|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence
75387999|NCT03626974|Device|Diffuser spreading odor|Diffuser will place under a Hood with an air-flow
75388000|NCT03597594|Drug|Anti-thymocyte globulin (rabbit)|given intravenously
75388001|NCT03597594|Drug|Busulfan|given intravenously
75388002|NCT03597594|Drug|Fludarabine|given intravenously
75388003|NCT03597594|Drug|Thiotepa|given intravenous infusion
75388004|NCT03597594|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
76032988|NCT05110963|Behavioral|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
75869229|NCT05300282|Combination Product|BEGEV|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I."
76032989|NCT05110963|Behavioral|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
76032990|NCT04424537|Dietary Supplement|Control diet|Meal replacement beverages made with whey protein
76032991|NCT04424537|Dietary Supplement|Low branched-chain amino acids(BCAA) diet|meal replacement beverages (MRBs) made with BCAD2 powder (lacking BCAAs).
76032992|NCT04424537|Dietary Supplement|Low protein diet|meal replacement beverages(MRBs) containing low protein
75869230|NCT05299892|Device|Phonak Audeo P or Naida P hearing aid|"Commercially available hearing aid that has access to speech enhancer feature settings off, moderate and strong"
75869231|NCT05298410|Other|Limitless|Participants will be instructed to take Limitless for 30 days.
75869232|NCT05295433|Drug|mRNA-3705|A sterile liquid for injection
76032993|NCT04965623|Device|Atrial Shunt|Transcatheter treatment of symptomatic left heart failure patients
75869233|NCT05290064|Other|Ultra-processed food, high energy density|Ultra-processed diet that is high in non-beverage energy density and low in hyperpalatable foods
75869234|NCT05290064|Other|Ultra-processed food, both low|Ultra-processed diet that is low in both non-beverage energy density and hyperpalatable foods
75388005|NCT03597594|Other|Donor Lymphocyte Infusion|given intravenous infusion
75869235|NCT05290064|Other|Ultra-processed food, both high|Ultra-processed diet that is high in both non-beverage energy density and hyperpalatable foods
75869236|NCT05290064|Other|Unprocessed food diet|Unprocessed diet that is low in both non-beverage energy density and hyperpalatable foods
75869237|NCT05281276|Drug|chidamide|During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
75869238|NCT05281276|Drug|celecoxib|During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
75388006|NCT03595657|Biological|CS1001|monoclonal antibody
75388007|NCT03591887|Biological|ABY-035|ABY-035 solution for injection
75388008|NCT03591887|Biological|Placebo|Placebo to ABY-035 solution for injection
75869239|NCT05280938|Behavioral|MAAP|Women randomized to the MAAP intervention will complete an 8 week (2hr/wk) hybrid adapted Kabat-Zinn's MBSR.(Kabat-Zinn, 1990) MAAP intervention includes activities related to spirituality, self-empowerment, interdependence, and story-telling, which are salient to AAW.(Watson-Singleton et al., 2019) Women will receive practice links and a program work book (5th grade level) containing objectives and weekly MAAP activities/. Individual weekly home practice is expected. Type and minutes of home practice will be recorded in weekly logs. Program attendance, type, amount of practice, and changes in mindfulness (Five Facet Mindfulness Questionnaire) will be included in data analysis.
75388009|NCT03563690|Other|treatment1|"Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes."
75388010|NCT03563690|Other|treatment2|"Acupoints：Needling points are the same to the above group~operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes."
76032994|NCT05105191|Diagnostic Test|Roche Cobas® Liat Influenza A/B & RSV assay|Performance of a rapid molecular assay to diagnose influenza and RSV infections
76032995|NCT04952441|Behavioral|RISE Program|Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
75388011|NCT03563690|Other|treatment3|"Acupoints：treating points are the same to the above group~Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes."
75388012|NCT03563690|Other|treatment4|"Acupoints：Needling points are the same to the above group~Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes."
75388013|NCT03563690|Other|treatment5|"points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 * 25mm single-use needle with the depth of 1-2mm."
75388014|NCT03563690|Drug|Celebrex|Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
75388015|NCT03557684|Dietary Supplement|leucine|amino acid leucine in powder
75388016|NCT03557684|Other|PO placebo|maltodextrin
75388017|NCT03557684|Biological|lipopolysaccharide (LPS)|purified bacterial wall component as an inflammatory challenge
75388018|NCT03557684|Other|IV placebo|0.9% saline
75388019|NCT03557008|Biological|Rabies Vaccine|A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
75388020|NCT03557008|Drug|Metronidazole|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
75388021|NCT03557008|Drug|Vancomycin|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
75388022|NCT03557008|Drug|Neomycin Sulfate|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
75542537|NCT05895942|Drug|Imatinib|The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib
75869240|NCT05280938|Behavioral|Educational Program|"The 8-week Educational Program will be matched in duration, frequency, delivery method, and data collection to the MAAP intervention. Like MAAP, it will be delivered using a hybrid format (virtual Zoom and in person visits).~Sessions will be given in groups by an expert perinatal clinician/educator for all cohorts. Content will be set and delivered consistently across cohorts. Sessions will be audiotaped and rated for achievement of objectives and consistency of delivery. Deviations will be promptly addressed. Subject receipt will be monitored by attendance. Sessions will not include content on stress reduction (yoga, meditation, etc.). Classes will be given in the same setting as the MAAP intervention, at the same time but on a different evening, to avoid crossover (diffusion) of effects."
75388023|NCT03556683|Device|3% Hypertonic Saline|4 mL of 3% hypertonic saline
75388024|NCT03556683|Device|7% Hypertonic Saline|4 mL of 7% hypertonic saline
75388025|NCT03543852|Behavioral|SurvivorLink|SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
75388026|NCT03520881|Other|Pediatric ASTHMA-Educator mobile application|This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
75388027|NCT03481413|Device|Ablation|Ablation therapy for cardiac arrhythmias
75542538|NCT05895916|Behavioral|High-volume road cycling|1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
75542539|NCT05895877|Drug|Goofice®|Once daily before breakfast.
75542540|NCT05895877|Drug|Goofice® Placebo|Once daily before breakfast.
75869241|NCT05280769|Other|oral nicotine pouch - 2 mg|"On brand oral nicotine pouch with 2 mg of protonated nicotine in original flavor"
75542541|NCT05895864|Drug|utidelone injection|utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone
75542542|NCT05895851|Radiation|head and neck radiation|RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
75542543|NCT05895812|Drug|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
76032996|NCT05110651|Drug|Hydroxychloroquine|Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels > 2000ng/ml
75557788|NCT00438893|Dietary Supplement|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
76032997|NCT03060785|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|
76032998|NCT05104879|Other|Biosketch Card|The experimental group received a biosketch card during rooming, pre-clinician encounter that gave an overview of the midlevel providers qualifications.
76032999|NCT04952363|Device|A vertical vibration platform PowerVibe Zen Pro 5900|Subjects received the interventions twice a week for 8 weeks. HFCWO+WBVT group received additional 30 minutes WBVT treatment. In every WBVT session, three rounds of 3 minutes of vibration (amplitude: 2 mm; frequency: 20 Hz) were provided, with a 60-second rest between rounds.
76033000|NCT04952363|Device|HFCWO|Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
76033001|NCT04961333|Behavioral|Multidisciplinary Rehabilitation|Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
75869242|NCT05280769|Other|oral nicotine pouch - 4 mg|"On brand oral nicotine pouch with 4 mg of protonated nicotine in original flavor"
76033002|NCT05110573|Procedure|pancreatoduodenectomy|Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
76033003|NCT04952207|Drug|Direct-acting antiviral agents|The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
76033004|NCT04632589|Drug|Losartan Potassium|subjects ingest 50mg losartan potassium tablet daily for 6 weeks
76033005|NCT04632589|Drug|Placebo|subjects ingest placebo tablet daily for 6 weeks
76033006|NCT05002699|Diagnostic Test|Alzheimer's disease CSF biomarkers|Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.
75388028|NCT03443323|Behavioral|Organizational Skills Training - School Based (OST-S)|OST-S is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-S and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
75557789|NCT00439010|Drug|[123I] AV 39|
75557790|NCT00475527|Drug|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
75869243|NCT05280769|Other|oral nicotine pouch - 8 mg|"On brand oral nicotine pouch with 8 mg of protonated nicotine in original flavor"
75869244|NCT05280769|Other|Smokeless tobacco|Participant's typical brand of smokeless tobacco
75869245|NCT05279040|Drug|Trikafta|Elexacaftor/Tezacaftor/Ivacaftor combination therapy
76033007|NCT04961099|Drug|HY01|low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
76033008|NCT04965233|Behavioral|DNA reports|The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
76033009|NCT04965233|Behavioral|Information reports|Reports containing general information on eczema
76033010|NCT04975009|Behavioral|Fear conditioning|Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
76033011|NCT04964999|Other|Exercise|Participants will undergo an exercise program during the 2-week bed rest period.
76033012|NCT05108701|Behavioral|Individual Psychotherapy|Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
76033013|NCT05108545|Drug|Amphotericin B liposomes|Amphotericin B liposomes for injection, 3 mg/kg, qd, IV
75388029|NCT03413254|Other|Routine follow-up|Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
75388030|NCT03413254|Procedure|Second look DLS|Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
75388031|NCT03413254|Procedure|Third look DLS|Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
75557791|NCT00475566|Device|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
76033014|NCT04951973|Diagnostic Test|Deep Learning Based Early Warning Score (DEWS)|DEWS use 4 vital signs (systolic blood pressure, HR, respiratory rate, and body temperature) to predict in-hospital cardiac arrest. Deep-learning approach facilitates learning the relationship between the vital signs and cardiac arrest to achieve the high sensitivity and low false-alarm rate of the track-and-trigger system (TTS).
75388032|NCT03367637|Other|Standard palliative care|Standard care includes regular follow-up phone calls and home visits by the RPCHO staff for all advanced cancer patients at RPCHO, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed. For after-hours emergency assistance, patients have the option of contacting the on-call palliative-care physicians for assistance.
75388033|NCT03367637|Other|Smart Phone based symptom evaluation application|In addition to the standard palliative care currently provided at the RPCHO, patients will receive biweekly reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smartphone application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly frequency, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
75388034|NCT03347617|Drug|Ferumoxytol|Given IV
75388035|NCT03347617|Other|Laboratory Biomarker Analysis|Correlative studies
75388036|NCT03347617|Procedure|Magnetic Resonance Imaging|Undergo ferumoxytol MRI
76033015|NCT05102695|Diagnostic Test|Serum CRP , ferritine and d-dimer|Correlation between the results of the tests with outcome of the patient
75388037|NCT03347617|Biological|Pembrolizumab|Given IV
75388038|NCT03328273|Drug|Ceralasertib|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
75388039|NCT03328273|Drug|Acalabrutinib|An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
76033016|NCT03060395|Dietary Supplement|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
75388040|NCT03136029|Dietary Supplement|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
75388041|NCT03136029|Dietary Supplement|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
76033017|NCT03060395|Dietary Supplement|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
76033018|NCT03060395|Dietary Supplement|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
75388042|NCT03136029|Other|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
75388043|NCT03071120|Behavioral|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
75388044|NCT03040999|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
75388045|NCT03040999|Drug|Placebo|Normal saline or dextrose solution administered as an IV infusion Q3W
75388046|NCT03040999|Drug|Cisplatin|100 mg/m^2 administered as an IV infusion Q3W
76033019|NCT03060395|Dietary Supplement|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
75388047|NCT03040999|Radiation|Accelerated Fractionation (AFX) Radiotherapy|70 Gray (Gy) given in 35 fractions over 6 weeks
75388048|NCT03040999|Radiation|Standard Fractionation (SFX) Radiotherapy|70 Gy given in 35 fractions over 7 weeks
76033020|NCT03060395|Dietary Supplement|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
76033021|NCT03060395|Dietary Supplement|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
76033022|NCT03060395|Dietary Supplement|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
75388049|NCT02848235|Other|Standard of Care + EMMA|Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
75388050|NCT02567877|Procedure|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
75388051|NCT02567877|Drug|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
75388052|NCT02366728|Biological|Unpulsed DCs|Patients in Group I will receive 1 x 10^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
75388053|NCT02366728|Biological|Td|Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
75388054|NCT02366728|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
75388055|NCT02366728|Biological|111In-labeled DCs|111In-labeled DCs are 2 x 10^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
75388056|NCT02366728|Drug|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
75388057|NCT02366728|Drug|Saline|0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
75388058|NCT02366728|Drug|Basiliximab|Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
75388059|NCT02355002|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
75388060|NCT02333370|Drug|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
75388061|NCT02333370|Drug|Letrozole|25mg
75388062|NCT02333370|Drug|Tamoxifen|20 mg
75388063|NCT02333370|Drug|Fulvestrant|500 mg
75388064|NCT02333370|Drug|goserelin|
75388065|NCT02303444|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
75388066|NCT02303444|Drug|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
75388067|NCT02267564|Procedure|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
75388068|NCT02267564|Procedure|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
75388069|NCT02246920|Drug|Fluticasone propionate|50 mcg/actuation Nasal Spray
75388070|NCT02246920|Drug|Flonase®|50 mcg/actuation Nasal Spray
75388071|NCT02246920|Drug|Placebo|Inactive Nasal Spray
76033023|NCT03060395|Dietary Supplement|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
76033024|NCT05081323|Behavioral|Self-applied treatment for phobias|The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
75706200|NCT05374070|Dietary Supplement|Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
76033025|NCT04431791|Drug|Regorafenib|oral regorafenib
76033026|NCT04431791|Drug|Fruquintinib|oral fruquintinib
75388072|NCT02129244|Other|NCM-Plus|"The NCM will follow the domains of the chronic care model by:~Assuring effective, efficient clinical care and self-management support~Promoting clinical care consistent with scientific evidence and patient preferences~Organizing data to facilitate efficient, effective care~Empowering and preparing patients to manage their health and health-care needs~Mobilizing community resources to meet the needs of patients"
75388073|NCT02086890|Device|Electro-acupuncture|
75388074|NCT02086890|Device|Laser Acupuncture|
75388075|NCT02086890|Device|Transcorneal Electrical Stimulation|
76033027|NCT05007769|Drug|Ramucirumab|Will be supplied by Lilly Oncology, free of charge to the participant
75388076|NCT02086890|Device|Sham Electro-acupuncture|
75388077|NCT02086890|Device|Sham laser acupuncture|
75388078|NCT02086890|Device|Sham transcorneal electrical stimulation|
75388079|NCT01832402|Drug|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
75388080|NCT01832402|Drug|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
75706201|NCT05374070|Dietary Supplement|Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
76033028|NCT05007769|Drug|Atezolizumab|Atezolizumab will be commercially available.
76033029|NCT05007769|Drug|N-803|Will be supplied free of charge to the participants by ImmunityBio
76033030|NCT04952051|Drug|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
76033031|NCT04952051|Drug|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
76033032|NCT04979143|Procedure|Surgical Approach|The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.
76033033|NCT04960943|Drug|Pyrotinib with or without trastuzumab|After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
75557792|NCT00475566|Device|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
75557793|NCT00439166|Drug|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
76033034|NCT03058367|Dietary Supplement|IQP-AE-103 (330mg)|High dose capsules
76033035|NCT03058367|Dietary Supplement|IQP-AE-103 (165mg)|Low dose capsules
76033036|NCT03058367|Dietary Supplement|Placebo|Placebo identical to verum capsules
75388081|NCT01832402|Other|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
75388082|NCT01832402|Behavioral|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
75388083|NCT01832402|Behavioral|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
75388084|NCT01619488|Device|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
75388085|NCT01588392|Behavioral|Short bouts of structured physical activity|Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
75869246|NCT05278234|Behavioral|STEPS|Participants will initially meet with a community health worker (CHW) for a 1-hour orientation at the participant's home, a Henry Ford Health System site or the University of Michigan Detroit Center, or virtual. The CHW will show participants how to use the web modules. Participants will be given (or mailed) a wearable activity tracker to use throughout the course of the 7-week program. Each week participants will watch a brief video on the STEPS website; they may also be asked to complete handouts in the workbook. They will have a weekly 30-minute telephone session with the CHW. CHWs will review the weekly topic, help participants practice new skills, and set a related goal. CHWs will screen for social needs and make appropriate community referrals. Participants will set walking goals each week, using step-count data from the physical activity tracker. Participants will track daily step counts.
75388086|NCT01588392|Behavioral|Unstructured physical activity|Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
75869247|NCT05269628|Drug|Cannabidiol (CBD)|Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining treatment.
75869248|NCT05269628|Drug|Tetrahydrocannabinol (THC)|The drug dose will be 2.5 mg b.i.d. during the first 7 days of active treatment, and 5 mg b.i.d. for the following treatment.
75388087|NCT01588379|Behavioral|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
75388088|NCT01588379|Behavioral|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
76033037|NCT03060317|Behavioral|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
76033038|NCT04964531|Other|speckle tracking echocardiography|before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
76033039|NCT04964687|Procedure|Liver transplantation|Liver transplantation
75388089|NCT01588379|Other|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
76033040|NCT05081167|Drug|REL-1017|REL-1017 tablet
75388090|NCT01210625|Dietary Supplement|Nutrabiotix|Fiber supplement: 9mg or 12mg
75388091|NCT01210625|Dietary Supplement|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
75388092|NCT01009190|Drug|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
75388093|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
75388094|NCT01009190|Drug|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
75388095|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
75388096|NCT00667628|Drug|TAC-101|Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
75388097|NCT00667628|Drug|Placebo|Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
75388098|NCT00597636|Behavioral|Questionaire, blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
75388099|NCT00597636|Behavioral|Questionaire, Blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
76033041|NCT05081167|Drug|Placebo|Placebo tablet
76033042|NCT03058445|Device|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
76033043|NCT03058445|Device|CVC|Injection of 5 ml of saline
76033044|NCT04431713|Drug|Exenatide Pen Injector [Bydureon]|Exenatide is a treatment licensed for use in Type 2 diabetes.
75388100|NCT00003653|Drug|bicalutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
75388101|NCT00003653|Drug|buserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
75388102|NCT00003653|Drug|cyproterone acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
75388103|NCT00003653|Drug|flutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
75557794|NCT00439166|Drug|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
75557795|NCT00439166|Drug|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
75388104|NCT00003653|Drug|goserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
75388105|NCT00003653|Drug|leuprolide acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
75388106|NCT00003653|Drug|nilutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
75388107|NCT00003665|Biological|dendritic cell-MART-1 peptide vaccine|
75388108|NCT00003665|Biological|gp100 antigen|
75388109|NCT00003665|Biological|therapeutic tumor infiltrating lymphocytes|
75388110|NCT00003665|Biological|tyrosinase peptide|
75388111|NCT00003671|Drug|asparaginase|
75388112|NCT00003671|Drug|cyclophosphamide|
75388113|NCT00003671|Drug|cytarabine|
75388114|NCT00003671|Drug|daunorubicin hydrochloride|
75388115|NCT00003671|Drug|dexamethasone|
75388116|NCT00003671|Drug|leucovorin calcium|
75388117|NCT00003671|Drug|mercaptopurine|
75706202|NCT05374070|Dietary Supplement|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)|In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
75706203|NCT05374070|Dietary Supplement|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
75706204|NCT00720408|Drug|Prograf-XL|oral
75388118|NCT00003671|Drug|methotrexate|
75388119|NCT00003671|Drug|thioguanine|
75388120|NCT00003671|Drug|vincristine sulfate|
75706205|NCT00720408|Drug|Prograf|oral
75706206|NCT00720408|Drug|MMF|oral
75706207|NCT00852670|Drug|ACT-128800|ACT-128800 administered orally once daily
75706208|NCT00852670|Drug|Placebo|Matching placebo capsules administered orally once daily
75706209|NCT00717210|Drug|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
75706210|NCT00717210|Radiation|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
75706211|NCT00723086|Drug|docetaxel (XRP6976)|combined treatment with prednisolone
75706212|NCT00720486|Behavioral|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
75706213|NCT00720486|Behavioral|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
75388121|NCT00003677|Drug|Dolastatin 10|IV bolus once every 21 days.
75388122|NCT00384605|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
75388123|NCT00384605|Drug|placebo|Placebo capsule once daily. Treatment for 52 weeks.
75869249|NCT05269628|Drug|Placebo CBD|Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
75869250|NCT05269628|Drug|Placebo THC|Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
75388124|NCT00003683|Drug|doxorubicin hydrochloride|
75388125|NCT00003683|Drug|ifosfamide|
75388126|NCT04329143|Procedure|open completion cholecystectomy|open excision of cystic duct remnant
75388127|NCT04329143|Procedure|lap completion cholecystectomy|lap excision of cystic duct stone
75388128|NCT00003695|Drug|chemotherapy|
75388129|NCT00003695|Procedure|surgical procedure|
75388130|NCT00003707|Drug|gemcitabine hydrochloride|
75388131|NCT00003707|Drug|tipifarnib|
75388132|NCT00003713|Drug|intoplicine|
75388133|NCT00003719|Drug|irinotecan hydrochloride|
75388134|NCT00003725|Drug|valrubicin|
75388135|NCT00003725|Procedure|conventional surgery|
75388136|NCT00003731|Drug|temozolomide|
75388137|NCT00003737|Drug|becatecarin|
75388138|NCT00003743|Biological|aldesleukin|
75557796|NCT00439166|Drug|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
75557797|NCT00439205|Device|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
75557798|NCT00439205|Device|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
75388139|NCT00003749|Procedure|adjuvant therapy|
75388140|NCT00003749|Procedure|conventional surgery|
75388141|NCT00003749|Radiation|brachytherapy|
75388142|NCT00003749|Radiation|radiation therapy|
75388143|NCT00003755|Drug|MKC-1|
75388144|NCT00003761|Biological|rV-DF3/MUC1|"- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~Level 1 4.76 x 106 PFU~Level 2 4.76 x 107 PFU~Level 3 4.76 x 108 PFU"
75557799|NCT00475683|Other|Mouth wash|Mouth wash with chlorehexidin, three times a day
75557800|NCT00475683|Dietary Supplement|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
75557801|NCT00439283|Drug|infliximab|
75388145|NCT00003773|Drug|oglufanide disodium|
75388146|NCT00003779|Biological|Connaught|Compare two strains of BCG
75388147|NCT00003779|Biological|Tice|Compare two strains of BCG
75388148|NCT00384917|Drug|Ketoconazole|
75388149|NCT05444153|Drug|Semaglutide|Participants will receive 1 tablet of oral semaglutide once daily.
75388150|NCT05444153|Drug|Empagliflozin|Participants will receive 1 tablet of empagliflozin once daily.
75388151|NCT00003797|Biological|trastuzumab|
75388152|NCT00003797|Drug|gemcitabine hydrochloride|
75388153|NCT00003803|Drug|cisplatin|
75388154|NCT00003803|Drug|gemcitabine hydrochloride|
75388155|NCT00003803|Radiation|radiation therapy|
75388156|NCT02972879|Procedure|Therapeutic modalities: Orthotic (Group 1)|participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness
75557802|NCT00439283|Drug|methotrexate|
75557803|NCT00475800|Drug|Lumiracoxib|
75557804|NCT00475839|Device|Tension-free Vaginal Tape|
76033045|NCT04773925|Behavioral|Mindfulness counseling|Subjects three 60-minute mindfulness counseling sessions with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The mindfulness sessions will be conducted entirely via telemedicine. The initial consultation will consist of a 60-minute individual session. The next session will be a group visit (plan for 5 subjects per group) lasting 60 minutes, which will be scheduled for 2 weeks after the initial session. The third session will be another 60-minute group session, which will be scheduled for 6 weeks after the initial session.
75706214|NCT00858286|Other|Spirometry, PEF measurements and diary cards to evaluate control of Asthma|No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
75706215|NCT04018378|Drug|varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
75388157|NCT02972879|Procedure|Therapeutic modalities: LLLT (Group 2)|"The LLLT parameters are:~LASER 904nm~P: 1.5W/cm²~30mV/cm²~Area 2 cm²~1 Joule por ponto ( in the A1 pulley)"
75388158|NCT02972879|Procedure|Therapeutic modalities: Paraffin (Group 3)|"Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:"
75388159|NCT02972879|Procedure|Corticosteroid injection (Group 4)|The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
75388160|NCT00003815|Biological|bleomycin sulfate|
76033046|NCT05104333|Biological|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
76033047|NCT05104333|Biological|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
76033048|NCT03058055|Behavioral|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
75388161|NCT00003815|Drug|carmustine|
75557805|NCT00475839|Device|Monarc sub-fascial hammock|
75557806|NCT00439361|Drug|Bortezomib|1.0 mg/m^2 by Vein Over 5 Seconds on Days 1 and 4
75557807|NCT00439361|Drug|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
75557808|NCT00439361|Drug|Etoposide|100 mg/m^2 By Vein Over 2 Hours On Days 1-3
75557809|NCT00439361|Drug|Ifosfamide|5 Gm/m^2 By Vein Continuous Infusion Over 24 Hours On Day 1
75388162|NCT00003815|Drug|cyclophosphamide|
75388163|NCT00003815|Drug|cytarabine|
75388164|NCT00003815|Drug|doxorubicin hydrochloride|
75388165|NCT00003815|Drug|etoposide|
75388166|NCT00003815|Drug|melphalan|
75388167|NCT00003815|Drug|prednisolone|
75388168|NCT00003815|Drug|vincristine sulfate|
75388169|NCT00003815|Procedure|autologous bone marrow transplantation|
75388170|NCT00003815|Radiation|radiation therapy|
75388171|NCT00003821|Drug|aminopterin|
75388172|NCT00003827|Drug|amifostine trihydrate|
75388173|NCT00003827|Drug|cytarabine|
75542544|NCT05895799|Other|Tuition from a expert clinical trainer|Each group was initially provided with an online tutorial on the complete physical examination of the cardiovascular system as performed on a standardized patient by the trainer. At the beginning of each session, the trainer performed the examination on a hybrid patient wearing the auscultation vest and provided additional teaching, explanations, and rationale. Following the demonstration, each participant was invited to perform repeated physical examinations in front of their peers with real-time one-to-one feedback from the trainer. After each performance, the participant was encouraged to critique their own performance(s), peers were invited to provide some insights, and the trainer gave some overall feedback. At the end of the session and after each participant had had the opportunity to perform the complete examination at least once, the participants were taken through a range of abnormal signs using the auscultation vest with explanations provided by the trainer.
75557810|NCT00439361|Drug|Mesna|5 mg/m^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
75557811|NCT00475917|Drug|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
75557812|NCT00475917|Drug|Gemcitabine|once-weekly 30-minute IV infusion
75869251|NCT05261490|Drug|maplirpacept (PF-07901801)|PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
75869252|NCT05261490|Drug|Pegylated Liposomal Doxorubicin (PLD)|RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
75869253|NCT05254795|Other|Molecular tumor board assisted care|Participants in this group will obtain recommendations for care from the molecular tumor board.
75869254|NCT05241210|Device|AI program for colonoscopy|Provides real-time feedback on the endoscopist moniter during colonoscopy.
76033049|NCT03058055|Behavioral|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
75388174|NCT00003827|Drug|topotecan hydrochloride|
75388175|NCT00003833|Genetic|DNA stability analysis|
76033050|NCT03058055|Behavioral|Reading|Book club that includes weekly one hour meetings and daily reading assignments
76033051|NCT04951895|Diagnostic Test|MRI|MRI of TMJ
76033052|NCT05094895|Procedure|Stretta|Radiofrequency energy delivered to the gastro-esophageal junction
76033053|NCT05094895|Procedure|Sham|Patients that have the sham condition will have a procedure using a 24Fr Savary bougie dilator over the guidewire, with the same sedation.
75388176|NCT00003833|Genetic|gene mapping|
75388177|NCT00003851|Biological|proteolytic enzymes|
75388178|NCT00003851|Drug|gemcitabine hydrochloride|
75388179|NCT00003851|Procedure|Gonzalez regimen|
75388180|NCT00003863|Genetic|comparative genomic hybridization|
75388181|NCT00003863|Genetic|cytogenetic analysis|
75388182|NCT00003863|Genetic|fluorescence in situ hybridization|
75388183|NCT00003863|Genetic|gene rearrangement analysis|
75388184|NCT00003881|Biological|trastuzumab|
75388185|NCT00003881|Drug|carboplatin|
75388186|NCT00003881|Drug|paclitaxel|
75388187|NCT00003887|Biological|peripheral blood lymphocyte therapy|
75388188|NCT00003893|Drug|CMF regimen|
75388189|NCT00003893|Drug|cyclophosphamide|
75388190|NCT00003893|Drug|doxorubicin hydrochloride|
75388191|NCT00003893|Drug|epirubicin hydrochloride|
75388192|NCT00003893|Drug|fluorouracil|
75388193|NCT00003893|Drug|methotrexate|
75388194|NCT00003893|Drug|mitomycin C|
75388195|NCT00003893|Drug|mitoxantrone hydrochloride|
75388196|NCT00003893|Procedure|adjuvant therapy|
75869255|NCT05237882|Other|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
75388197|NCT00003893|Radiation|radiation therapy|
75388198|NCT00003899|Biological|filgrastim|
75388199|NCT00003899|Drug|cyclophosphamide|
75388200|NCT00003899|Drug|melphalan|
75388201|NCT00003899|Drug|paclitaxel|
75557813|NCT00474669|Drug|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
75869256|NCT05231785|Drug|ALN-APP|ALN-APP will be administered intrathecally (IT)
75869257|NCT05231785|Drug|Placebo|Placebo will be administered IT
75869258|NCT05231668|Drug|SAR439459|Powder for solution for infusion; IV infusion
75869259|NCT05231668|Drug|Placebo|Solution for infusion; IV infusion
75869260|NCT05230537|Drug|Iptacopan (LNP023)|oral capsules
75869261|NCT05230537|Drug|Placebo|oral capsules
75869262|NCT05225623|Behavioral|BWLT|This group will attend 16 2-hour group-based weekly sessions in Small Changes BWLT in addition to their treatment at the Balfour Medical Clinic
75388202|NCT00003899|Drug|thiotepa|
75388203|NCT00003899|Procedure|autologous bone marrow transplantation|
75388204|NCT00003899|Procedure|peripheral blood stem cell transplantation|
75388205|NCT00003911|Radiation|stereotactic radiosurgery|
75388206|NCT00003917|Drug|topotecan hydrochloride|
75388207|NCT00003923|Drug|porfimer sodium|
75388208|NCT02973191|Drug|JCAR015|
75388209|NCT00003929|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
75388210|NCT00003929|Drug|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
75388211|NCT00003929|Drug|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
75388212|NCT00003929|Radiation|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
75388213|NCT02210507|Other|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
75388214|NCT02210507|Other|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
75388215|NCT02210507|Other|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
75388216|NCT02210663|Drug|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
75388217|NCT04568525|Diagnostic Test|Passive Microwave Radiometry|The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
75388218|NCT04568837|Drug|Prednisone 20 Mg|20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
75557814|NCT00439400|Drug|doxycycline|
75557815|NCT00439400|Drug|placebo|
75557816|NCT00475956|Drug|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
75542545|NCT05895760|Other|Multi-component physical exercise online intervention|"A multicomponent exercise program was implemented consisting of a combined program of endurance, strength, coordination, balance, and flexibility exercises depending on the level of functional capacity.~Three types of physical exercise programs were designed according to the physical performance level of each participant. The first type of exercise program training was performed for frail adults with an SPPB score of 4 to 6, the second was for the pre-frail adults with an SPPB score of 7 to 9 and the third for robust adults with an SPPB of 10 to 12."
75388219|NCT04568291|Other|model treatment|the treatment decisions were decided by Machine Learning （ML） model in model treatment group
75542546|NCT05895708|Other|Specific strengthening and stretching exercise|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
75388220|NCT04568291|Other|routine treatment|the treatment decisions were decided by multi-disciplinary team （MDT）
75388221|NCT04569617|Other|Resistance Training - UL endurance protocol|UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
75542547|NCT05895708|Other|General Exercise|The program will consist of regular general postural exercises such as postural awareness exercises as well as general strengthening exercises such as range of motion exercises for the upper quadrant. The program will also be repeated 4 times per week for 10 weeks, with each session lasting 30 minutes
75542548|NCT05895422|Procedure|pyeloplasty|repair of the uPJO
75557817|NCT00475956|Drug|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
75388222|NCT04569617|Other|Resistance Training - UL strength protocol|UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
76033054|NCT04819763|Other|Physical therapy|"Coordination training for lateral movement of the mandible (spatula exercise):~A wooden spatula is loosely placed between the teeth of the upper and lower jaw; the head must be aligned with the body axis; the exercise should be performed in front of a mirror.~The lower jaw moves to the left and back to the center with little contact to the spatula~The lower jaw moves to the right and back to the center under contact with the spatula~Training of the left lateral pterygoid muscle:~The left palm is placed on the left temple region~Right hand forms a fist and is placed on the tip of the right chin~Both arms are aligned parallel to the surface of the floor~The lower jaw is moved to the right against a moderate resistance of the fist = concentric muscle work~With measured force of the fist, the lower jaw is brought back to the center = eccentric muscle work (Right lateral pterygoid muscle training with opposite hands.)"
76033055|NCT04819763|Other|Appliance therapy|"Upper and lower jaw impressions are registered by using an intraoral scanner. The arbitrary hinge axis position is determined using a face bow.~The stabilization appliance with anterior canine guidance is manufactured in the Lexmann laboratory in Dresden.~The stabilization appliance is incorporated by the dentist and the static and dynamic occlusion is checked. A tension-free fit of the appliance on the lower jaw is necessary. Additionally, equal contacts in the side teeth area and incisors guidance in the case of mandibular protrusion are checked visually and by using occlusion foil. During mandibular lateral movement only the canine guidance takes place and is also registered optically and by using occlusion foil.Interference contacts should be adjusted.~The patient is instructed to wear the stabilization appliance while sleeping. The wearing rhythm is described as intermittent. (three nights - wearing the appliance, one night - not wearing the appliance)."
76033056|NCT04960631|Diagnostic Test|Double site CT guided needle biopsy|Double site CT guided needle biopsy
76033057|NCT03059615|Drug|Nerofe|Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.
75388223|NCT04569617|Other|Resistance Training - LL endurance protocol|LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).
75388224|NCT04569617|Other|Resistance Training - LL strength protocol|LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
75388225|NCT04567199|Other|Observational, retrospective|retrospective analysis of observed results, for both study groups.
75388226|NCT04569071|Device|Sinovation Laser Ablation System|In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
75388227|NCT04568057|Device|NIR Transcranial phototherapy device|1068 nm NIR helmet
75388228|NCT04568057|Device|Placebo Transcranial Device|The placebo device looks like the active device.
75388229|NCT04568135|Other|survey|survey
75388230|NCT04567901|Other|Death|Mortality group
75388231|NCT04567901|Other|Survive|Survival group
75388232|NCT04566809|Other|FES+CBA|The experimental treatment was formerly composed by 20 sessions of FES for the hand in combination with a structured cognitive therapy
75388233|NCT04566809|Other|FES|The control treatment was formerly composed by 20 sessions of FES for the hand
75542549|NCT05895331|Diagnostic Test|Thiol/Disulphide Homeostasis|An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
75388234|NCT04569305|Procedure|Negative Pressure Wound Therapy|NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.
75869263|NCT05225623|Behavioral|Waitlist Control for BWLT|This group will receive treatment as usual at the Balfour Medical Clinic and put on a waitlist for the Small Changes BWLT program
75869264|NCT05214105|Other|Biospecimen/DNA collection and analysis|Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
75869265|NCT05212272|Procedure|PET-MRI Brain Scan|Before starting radiation, participants will have a PET scan and MRI scan of the brain. After 2 to 3 weeks of radiation treatments, participants will have a repeat PET scan. Then 1 month after radiation participants will have another PET scan
75869266|NCT05212272|Diagnostic Test|Blood draw|Blood draws will be taken at baseline, one month after radiation treatment and 3 to 4 months after radiation treatment.
75869267|NCT05212272|Behavioral|Memory testing|3 sessions with simple tests to evaluate how the brain is working. These tests primarily check things like memory, attention, and thought process. The whole set of tests will take 1 hour each time.
75869268|NCT05212272|Procedure|Optional lumbar puncture for cerebrospinal fluid collection|Participants that consent for cerebrospinal fluid collection will have 6 and 20 ml of cerebrospinal collected at baseline.
75869269|NCT05209347|Device|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
75869270|NCT05183737|Dietary Supplement|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
75388235|NCT04569305|Procedure|Conventional treatment|In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
75388236|NCT04567823|Dietary Supplement|Smoothie with microalgae|Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
75869271|NCT05183035|Drug|Fludarabine|Intravenous (IV) infusion
75869272|NCT05183035|Drug|Cytarabine|Intravenous (IV) infusion
75869273|NCT05183035|Drug|Gemtuzumab Ozogamicin|Intravenous (IV) infusion
76033058|NCT03059615|Drug|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
75388237|NCT04568447|Device|IMOOVE|Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase muscle tenfold.
75388238|NCT04568915|Other|Dry Needling|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, DN
75388239|NCT04568915|Other|Maitland Mobilization|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, Maitland joint mobilization
75388240|NCT04569227|Drug|EC-18|2000 mg PO daily
75388241|NCT04569227|Drug|Placebo|PO daily
76033059|NCT04951505|Drug|cefepime-taniborbactam|IV infusion
76033060|NCT04951349|Drug|GX-03|Same dosage used in Bactroban Nasal studies.
76033061|NCT04951349|Drug|Petrolatum ointment|Viscous ointment similar in form to study drug.
76033062|NCT02658019|Drug|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
75388242|NCT02210819|Drug|Rivaroxaban (Xarelto, BAY59-7939)|"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"
75388243|NCT02210819|Drug|Recommended VTE pharmacological treatments according to international guidelines|"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."
75388244|NCT04564469|Drug|Furosemide|A number of different protocols exist in terms of the timing of furosemide injection, (F+0) protocol in which furosemide is injected at the same time of radiotracer administration &( F - 15)protocol in which furosemide is administered 15 min before tracer administration
75542550|NCT05894759|Behavioral|Psychological stress relief techniques|Psychological stress relief techniques
75869274|NCT05183035|Drug|Azacitidine|Intravenous (IV) infusion or subcutaneous injection
75869275|NCT05183035|Drug|Venetoclax|Orally via tablet or powder suspension
76033063|NCT03059303|Drug|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
76033064|NCT03059303|Drug|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
75388245|NCT04565639|Device|Powered Hand Orthosis|A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.
76033065|NCT03059303|Drug|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
75388246|NCT04564235|Genetic|genome-wide analyses|genome-wide analyses will be done in patients and parents (father, mother)
76033066|NCT03059303|Drug|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
76033067|NCT03059303|Drug|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
76033068|NCT03059303|Drug|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
76033069|NCT03059303|Drug|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
75388247|NCT04564235|Genetic|Search for de novo mutations in paternal sperm samples|Sperm analysis will be done in paternal samples
75388248|NCT04564001|Drug|Infliximab|Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A
75388249|NCT04564001|Drug|Tocilizumab|Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
75542551|NCT05894187|Other|animated video|Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
75542552|NCT05892965|Other|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
75706216|NCT04018378|Drug|varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
75542553|NCT05892640|Other|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
75388250|NCT04565873|Diagnostic Test|TSH|retrospective TSH level
75388251|NCT04565561|Device|Neovas BRS or DCB|"All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis < 30%; B. no flow limiting dissection or TIMI grade 2-3."
75388252|NCT04565405|Other|Detergent|The tracheostomy inner cannulas will be washed with detergent.
75542554|NCT05892458|Behavioral|Abdominal massage|To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
75542555|NCT05892419|Other|No intervention|There is no intervention
75557818|NCT00439439|Radiation|Beamer Ablation (Argon Plasma Coagulation)|APC-Beamerablation of heterotopic gastric mucosa
75557819|NCT00476034|Drug|lumiracoxib|
75557820|NCT00439478|Drug|Radioiodine|
75557821|NCT00476073|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
75557822|NCT00439595|Device|Hemocue 210 meter|Diagnostic device
75557823|NCT00439595|Device|Copack HBCS|
75706217|NCT05373602|Diagnostic Test|LARS questionnaire|Eligible participants were issued with LARS questionnaire (Chinese version) by E-mail, message, phone or face to face interview.
75388253|NCT04565405|Other|Sterile water|The tracheostomy inner cannulas will be washed with sterile water.
75706218|NCT05373524|Biological|Biological analysis|Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
75706219|NCT00849550|Drug|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
75706220|NCT04018976|Device|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
75706221|NCT04018976|Device|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
75388254|NCT04565093|Procedure|iPACK|"Interspace between the popliteal artery and the capsule of the posterior knee (iPACK):~This is basically ultrasound guided peripheral nerve block performed by the anesthesiologists at the posterior side of the knee to control pain after TKA."
75388255|NCT04565093|Procedure|Periarticular local infiltration analgesia (LIA)|A mixture of Bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This intervention is commonly performed by the operating orthopedic surgeon to control pain after TKA.
75706222|NCT04018976|Device|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
75388256|NCT04564937|Drug|SCT510A|SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
75388257|NCT04563689|Other|CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|rinse 15 ml during 1 min during 5 days, twice daily
75542556|NCT05891015|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
75542557|NCT05887752|Other|Standard rehabilitation|"Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~physiotherapy;~occupational therapy;~sports rehabilitation."
75542558|NCT05887752|Device|Hunova® rehabilitation|Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
75706223|NCT05373368|Behavioral|multi purpose activities|
75388258|NCT04563689|Other|placebo rinse|destilled water rinse 15 ml during 1 min during 5 days, twice daily
75388259|NCT04563221|Device|Prostatic artery embolization|Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention.
75542559|NCT05882552|Diagnostic Test|Tilted Gaze Target Tast|Tilted gaze target tast is playing a small animated video with a visual mobile device at a distance of 33 cm and 3 m, respectively, to determine the optimal angle of head position improvement and the spatial tilt angle of the screen relative to the orthostatic position.It will be conducted during the first visit. Preoperative intervention will also be conducted before surgery. Postoperative interventions will be conducted at one day, one month, and six months after surgery.
75542560|NCT05882552|Diagnostic Test|Conventional Examination Methods|The conventional examination methods include oculomotor examination, Bielschowsky head tilt test, alternate prism cover test, prism adaptation test, and monocular cover test. They will be conducted during the first visit. Preoperative intervention will also be conducted before surgery.Postoperative interventions will be conducted at one day, one month, and six months after surgery.
75706224|NCT03816488|Drug|Metformin|Metformin (usual dose) administered 2 h before surgery
75706225|NCT03816488|Drug|Salsalate|Salsalate 1.5 g administered 2 h before surgery
75557824|NCT00476112|Drug|Vernakalant Injection 20 mg/mL|
75557825|NCT00476268|Drug|beclomethasone/formoterol (100/6µg) pMDI|Two puffs b.i.d
75557826|NCT00476268|Drug|Beclometasone dipropionate 250 µg/unit dose pMDI|2 inhalations bid
75557827|NCT00476268|Drug|Formoterol powder 12 µg/unit dose|2 inhalations bid
75557828|NCT00105989|Drug|Duloxetine|
75557829|NCT00105989|Drug|placebo|
75557830|NCT00476307|Biological|Fluarix™/Influsplit SSW® 2007/2008|
75557831|NCT00476346|Dietary Supplement|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
75557832|NCT00476385|Drug|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
75557833|NCT00476424|Drug|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
75706226|NCT00858676|Drug|acarbose|50mg acarbose 3 times a day PO. duration: one year
75706227|NCT00720668|Procedure|radiofrequency ablation|radiofrequency ablation for HCC
75542561|NCT05876715|Drug|Lurbinectedin|This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
75706228|NCT00858754|Drug|methylnaltrexone|
75706229|NCT00858754|Drug|placebo|
75706230|NCT00723164|Drug|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
76033070|NCT04593199|Behavioral|Gamified Smartphone App|The primary objective was to determine the acceptability and satisfaction of the Draco app among children. Secondary objective was to evaluate if the Draco app could improve physical activity levels (steps, and moderate-to-vigorous physical activity) and intrinsic motivation for physical activity in children. The gamified smartphone app, Draco, is a virtual pet simulator where you care for a pet by exercising, walking, and answering healthy lifestyle questions.
75542562|NCT05859048|Diagnostic Test|NT-proBNP|blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory
75542563|NCT05859048|Diagnostic Test|AI echocardiogram|Artificial intelligence driven transthoracic echocardiogram
75542564|NCT05859048|Diagnostic Test|electrocardiogram|tracing of electrical cardiac activity of the heart
75542565|NCT05859048|Other|Cardiovascular physical examination|basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)
75542566|NCT05853120|Drug|Doxycycline|Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
75542567|NCT05841160|Drug|Ecopipam Hydrochloride|oral tablets
75542568|NCT05841160|Drug|Moxifloxacin|oral tablet
75542569|NCT05841160|Drug|Placebo|oral tablet
75542570|NCT05815758|Drug|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
75706231|NCT00723164|Drug|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
76033071|NCT04593199|Behavioral|Physical activity tracking app|Participants were asked to use the Fitbit app to track and sync their daily physical activity.
76033072|NCT03059225|Device|repetitive transcranial magnetic stimulation (rTMS)|undergo contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or high frequency ipsilesional rTMS for 10 daily sessions
76033073|NCT03059225|Device|Sham stimulation|2-week inhibitory non-dominate hemisphere rTMS program
75542571|NCT05815758|Drug|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
75706232|NCT00849706|Other|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
75706233|NCT00858910|Other|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
75706234|NCT00858910|Other|Control intervention|"The control intervention encloses relaxation and breathing exercises, and information about:~the disease (stroke),~therapy options,~self-help groups and their offers for support,~helping aids for independent living at home."
75706235|NCT00852826|Procedure|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
75706236|NCT00852826|Procedure|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
75706237|NCT00723242|Drug|Viraferon-peg and Rebetol|
75706238|NCT02545426|Other|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
75388260|NCT04564859|Device|Heated Humidified High-Flow Nasal Cannula|Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
75388261|NCT04563767|Procedure|Infinitome|Added sequence of rs-fMRI.
75388262|NCT04563299|Drug|Dextenza 0.4Mg Ophthalmic Insert|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
75388263|NCT04563299|Drug|Prednisolone Acetate|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
75557834|NCT00439712|Drug|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
75557835|NCT00439712|Drug|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
75706239|NCT00720824|Behavioral|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
76033074|NCT03059537|Drug|Oral chenodeoxycholic acid stimulation|oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
75388264|NCT04561895|Genetic|DNA extraction|investigation of DNA polymorphism in patients suffering from NAFLD
75388265|NCT04561583|Device|LED light source system for endoscope|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
75388266|NCT04561583|Device|Pinpoint Endoscopic Fluorescence Imaging System|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
75388267|NCT04561505|Procedure|Holmium laser enucleation of prostate|surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation
75388268|NCT04561505|Procedure|monopolar transurethral resection of prostate|surgical management of BPH by monopolar TURP using distilled water for irrigation
75388269|NCT04561817|Drug|Ipatasertib|400mg PO daily: day 1-21 of 28 day cycle
75388270|NCT04561817|Drug|Paclitaxel|80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
75557836|NCT00476463|Drug|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
75388271|NCT04561349|Other|Task oriented training|Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan
75706240|NCT00720824|Behavioral|Office routine|Standard vaccine administration
75869276|NCT05180799|Biological|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
75388272|NCT04561349|Other|Conventional rehabilitation treatment|"Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised."
75388273|NCT04561271|Other|foot reflexology|Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.
75542572|NCT05813613|Other|Squatting with the aid of Kynapsis Virtual Training apparatus.|Squatting exercise was performed using a virtual reality (VR) machine (kynapsis) for guidance in both groups. Squats were performed while the hands were kept in front of the bodies and the knees flexed to 90 degrees following a rhythm of two seconds for descent, two second ascent mimicking the movement done on the VR machine.
75542574|NCT05788978|Other|Scale development|Scale development
75869277|NCT05180799|Biological|Nivolumab|Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1
76033075|NCT04416685|Procedure|primary repair|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
75706241|NCT05373290|Other|there is no intervention in the study|there is no intervention in the study
75706242|NCT05373134|Drug|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
75706243|NCT05373134|Other|Placebo|Placebo
75706244|NCT00723320|Drug|Atorvastatin|atorvastatin 10mg/d
75706245|NCT00723320|Behavioral|Aggressive lifestyle intervention|aggressive lifestyle intervention
75706246|NCT00578448|Drug|Belatacept|IV infusion
75869278|NCT05180799|Biological|Pembrolizumab|Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor
75869279|NCT05178784|Device|External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation|Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
75869280|NCT05176626|Behavioral|Online Lifestyle Behavioral Therapy|Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
75869281|NCT05176626|Drug|Phentermine Hydrochloride 8 MG|At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
76033076|NCT04416685|Procedure|segmental resection|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
76033077|NCT04416685|Procedure|graft reconstruction|Regarding Level III tumors, complete resection of the tumor was done either by tangential excision or by partial venous excision and subsequent reconstruction. To maintain a secure anastomosis, the mesenteric root was mobilized completely or/and splenic vein was divided.
75869282|NCT05176210|Drug|PS1|PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient
75388274|NCT04561271|Other|toucher massage|one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
75869283|NCT05176210|Drug|Placebo|Placebo
75388275|NCT02211833|Drug|BI 2536|
75388276|NCT02211833|Drug|Pemetrexed|
75869284|NCT05172245|Procedure|Biopsy|Undergo tumor biopsy
76033078|NCT04944407|Procedure|LHP|A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
75706247|NCT05373056|Behavioral|Scapular program|the patient will be in prone. With the elbow extended, begin by raising the shoulder above the head, keeping the upper extremity in line with the fibers of the lower trapezius. The participant will then remain pronated with the elbow flexed at 90 degrees and the shoulder abducted and externally rotated. Starting from this position, you should exert the force towards external rotation and then return to internal rotation. For the last exercise, the subject will be placed in a standing position holding the elastic band with one hand while the other end will fix it to the ground, while stepping on it with the foot. You will start the movement with a shoulder elevation in the plane of the scapula above 120 degrees and then perform the eccentric returning to the starting position.
76033079|NCT04944407|Procedure|MM|The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
76033080|NCT04428775|Drug|ALZT-OP1a (cromolyn)|"Mast cell stabilizer~Neuroinflammatory microglial modulator~anti-inflammatory"
76033081|NCT04944329|Procedure|Hip fracture surgery|Hip fracture surgery
75706248|NCT05373056|Behavioral|Conventional program|They will be performing a combination of concentric-eccentric type contractions adding an isometric contraction
76033082|NCT04436263|Behavioral|Supplement|A sufficient quantity of the winery by-products will be extracted on an industrial scale and capsules will be produced, each one containing 110mg of phenolic compounds (gallic acid equivalents).Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
75542575|NCT05782179|Biological|GBS-NN/NN2|GBS-NN/NN2 bound to alhydrogel as an adjuvant
75869285|NCT05172245|Procedure|Biospecimen Collection|Undergo blood sample collection
75869286|NCT05172245|Drug|Cisplatin|Given IV
75542576|NCT05782179|Biological|Placebo|Normal Saline 0.9 %
76033083|NCT04436263|Behavioral|Placebo|A look-alike placebo containing maltodextrin will be prepared.Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
75706249|NCT05372978|Behavioral|Cash transfer|Participants will receive a one-time unconditional cash transfer of $8,500.
75388277|NCT04562909|Device|Neurocom balance master device|With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.
75388278|NCT04562675|Behavioral|LHA intervention|For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.
75542577|NCT05755373|Other|No treatment given|No treatment given
75706250|NCT02571764|Other|Nutritional Oats Cookie|
76033084|NCT04951271|Behavioral|Solution focused approach|The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
76033085|NCT04272619|Behavioral|LIVE-R Life Education|A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
75706251|NCT02572128|Other|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
75542578|NCT05740241|Other|Elderly|A group of participants with physical activity (protocolized)
75706252|NCT03786926|Drug|HMPL-689|HMPL-689 is a PI3Kδ inhibitor
75706253|NCT02572050|Procedure|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
75706254|NCT00720564|Drug|arsenic trioxide|
75706255|NCT00720564|Drug|temozolomide|
75706256|NCT00720564|Procedure|adjuvant therapy|
75706257|NCT00720564|Radiation|intensity-modulated radiation therapy|
75706258|NCT00720564|Radiation|radiation therapy|
75869287|NCT05172245|Procedure|Computed Tomography|Undergo CT or PET/CT
75869288|NCT05172245|Drug|Ipatasertib|Given PO
75869289|NCT05172245|Procedure|Magnetic Resonance Imaging|Undergo MRI
76033086|NCT04950569|Drug|levosimendan|On the basis of standard conventional anti-heart failure treatment, levosimendan was used for 24 hours. The first load was 12 μg/kg, intravenous injection for 10 minutes, followed by intravenous infusion of 0.1 μg/Kg/min for 24 hours.
76033087|NCT04944251|Behavioral|Regular Exercise|the third month, for 30 minutes or 1 hour, 3 days a week
76033088|NCT04411043|Behavioral|Molecular caracterization|Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T
76033089|NCT04944641|Behavioral|education on epilepsy|education on epilepsy, including epilepsy diary, pamphlet，discussion between patients and phone visits and so on
76033090|NCT04944641|Drug|routine and proper antiepileptic drugs|routine and proper antiepileptic drugs
75706259|NCT04070430|Other|2 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
75869290|NCT05172245|Procedure|Positron Emission Tomography|Undergo PET/CT
75869291|NCT05172245|Radiation|Radiation Therapy|Undergo radiation therapy
75869292|NCT05172180|Drug|Reamberin|the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)
76033091|NCT04436419|Dietary Supplement|Alpha lipoic acid (plus full hospitalization)|"Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1*04-03/06 polymorphisms; recent hospitalization (<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals."
76033092|NCT04436419|Dietary Supplement|Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)|Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
76033093|NCT02624687|Behavioral|Intervention|Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
76033094|NCT02624687|Other|No intervention|No contact control
75388279|NCT04562675|Other|brochure-only|brochure-only for control group (CG)
75388280|NCT02211443|Biological|Recombinant full human Anti-EGFR Monoclonal Antibody|
75388281|NCT04562753|Procedure|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
75388282|NCT04562753|Procedure|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
75388283|NCT04562519|Device|TENS|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
75869293|NCT05172180|Drug|Ringer's solution|Ringer's solution at an average daily dose of 8.1 ml/kg/day
75706260|NCT04070430|Other|4 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
76033095|NCT04943705|Device|Yin and Yang Regulating Moxibustion|Before making Wenyang Yishen moxibustion, the width and length of the patient's moxibustion site were evaluated by the same body measurement method. Take about 700g of fresh ground ginger with moderate dryness and wetness, and place it on the treatment towel to make a round cake with a diameter of about 20cm and a thickness of about 2.5cm. Spread 25g of moxa moxa with a diameter of about 18cm on top of ginger and light it. When the bottom temperature reaches about 37 degrees, the door can be placed on the patient's waist for treatment. According to the patient's tolerance, the temperature should be controlled at 43-45 degrees. It is better to replace the moxa biscuit every time when the moxa biscuit is burned for about 10 minutes. The patient's local skin has a slight redness and burning. The moxibustion time is 60 minutes. Peiyuan Guben moxibustion is centered on Shenque, and the operation is the same as that of WenYang and Yishen moxibustion.
75869294|NCT05167201|Device|Nasal High Flow|High flow nasal cannula (NHF) is a device that delivers warmed and humid air through a high air flow rate, through the nose. It is used as a non-invasive ventilatory approach, which is relatively comfortable, in the management of respiratory failure and has been investigated in several studies evaluating the outcomes as domiciliary treatment in patients with COPD.
75388284|NCT02211521|Biological|PRP|3ml of PRP
75388285|NCT02211521|Drug|Hyaluronic acid|3ml hyaluronic acid
75706261|NCT00578318|Behavioral|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
75388286|NCT01597908|Drug|Dabrafenib|Dabrafenib 150 mg twice daily orally
75388287|NCT01597908|Drug|Vemurafenib|Vemurafenib 960 mg twice daily orally
75388288|NCT01597908|Drug|Trametinib|Trametinib 2 mg once daily orally
75388289|NCT04415970|Other|Flotation therapy sensory deprivation tank|Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
75388290|NCT04415970|Other|Sleep Pod|Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
75869295|NCT05165498|Procedure|Real-time ultrasound guidance for thoracic epidural catheter placement.|With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.
75706262|NCT00714090|Other|active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|"active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.~active rTMS : 5 sessions per week for 2 to 6 weeks"
75869296|NCT05156112|Device|Positive Airway Pressure Device|Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
75869297|NCT05154487|Drug|Alpelisib Pill|Kinase inhibitor
75869298|NCT05154487|Drug|Fulvestrant injection|estrogen receptor agonist
75869299|NCT05140122|Drug|Multiple|We will collect information on all medications taken by the caregiver and the person they care for.
75388291|NCT01951170|Drug|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
75706263|NCT00714090|Other|active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
75869300|NCT05140122|Other|Multiple|We will collect information on all forms of therapy or medical intervention taken by the caregiver and the person they care for.
75869301|NCT05103332|Drug|Olmesartan|Olmesartan administered orally
75869302|NCT05103332|Drug|Amlodipine|Amlodipine administered orally
75869303|NCT05103332|Drug|Indapamide|Indapamide administered orally
76033096|NCT04950491|Other|Modified Dental Anxiety Score (MDAS) questionnaire|MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, &Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
76033097|NCT04950491|Other|Pain questionnaire|Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
75388292|NCT01951092|Other|Text messaging|
75869304|NCT05103332|Drug|Placebo|Placebo administered by subcutaneous (SC) injection
75869305|NCT05103332|Drug|Zilebesiran|Zilebesiran administered by SC injection
75869306|NCT05099822|Drug|CC-97489|Specified dose on specified days
75869307|NCT05099822|Other|Placebo|Specified dose on specified days
75869308|NCT05086393|Drug|Duloxetine|Patients will be randomized to receive Duloxetine or a placebo.
75869309|NCT05086393|Drug|Placebos|Patients will be randomized to receive Duloxetine or a placebo.
75869310|NCT05079568|Device|Oculus Go VR headset|Virtual reality programs consisting of interactive games, meditation and deep breathing exercises, and passive virtual reality experiences designed to facilitate relaxation.
75869311|NCT05079568|Device|Sham Oculus Go VR headset|Virtual reality program with two-dimensional nature video
75869312|NCT05077033|Drug|phIL12 GET|intratumoral phIL12 gene electrotransfer
75869313|NCT05072080|Biological|CHIKV VLP/adjuvant|PXVX0317 vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%
75869314|NCT05072080|Biological|Placebo|Placebo is comprised of formulation buffer
75869315|NCT05068791|Drug|Psilocybin|0.36 mg/kg will be administered orally to participants
75869316|NCT05068791|Drug|Dextromethorphan|2.6 mg/kg of active placebo will be administered orally to participants
75869317|NCT05063929|Other|Fruit (2 cup eq)|participants will receive 2 cup eq fruits
75869318|NCT05063929|Other|Fruit restriction (1/2 cup eq)|participants will receive 1/2 cups eq fruits
75869319|NCT05059639|Other|Almond|Consume 2 ounces of almond daily for 8 weeks
75869320|NCT05059639|Other|Pretzel|Consume comparative amount of pretzel daily for 8 weeks
75388293|NCT04640922|Device|Gedea Pessary pHyph|Vaginal tablet
75388294|NCT04640922|Device|Placebo|Vaginal tablet
75388295|NCT01949532|Drug|Carfilzomib|Carfilzomib was administered by IV injection.
75388296|NCT01949142|Drug|OTO-201|Single, intratympanic injection
75388297|NCT01949142|Drug|Sham|Simulated single, intratympanic injection
75388298|NCT01948908|Drug|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
75388299|NCT01925274|Drug|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
75869321|NCT05047523|Drug|ALXN1840|Administered as an oral tablet.
75869322|NCT05047523|Drug|Standard of Care|Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
75869323|NCT05044065|Other|Physical exercise|The intervention group will receive an exercise program consisting of a combination of supervised and home-based exercise with a focus to induce metabolic stress (blood flow restriction exercise) during both a pre- and postoperative period consisting of a total of 5-6 weeks. Protein supplementation will be given to exclude insufficient intake.
75869324|NCT05042362|Drug|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
75869325|NCT05042362|Drug|Placebo|Matching placebo orally once daily
75869326|NCT05006196|Diagnostic Test|Outpatient MRI|"Participation in the study includes up to a maximum of 2 study visits. The visits will include clinical measurements (height, weight, blood pressure), blood tests, MRI scan and patient symptoms and experience questionnaires.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications. These will be managed by the routine clinical care team as part of standard care."
75869327|NCT05003986|Drug|Sparsentan|Population 1: 800 mg Sparsentan
75869328|NCT05003986|Drug|Sparsentan|Population 2: 400 mg Sparsentan
75388300|NCT01925274|Drug|irinotecan|90 minutes IV infusion of irinotecan 180mg/m^2 on days 1 and 15 of each cycle
75388301|NCT01925274|Drug|Cetuximab|120 minute IV infusion of cetuximab 400mg/m^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
75388302|NCT01925274|Drug|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m^2 on days 1 and 15 of each cycle
75706264|NCT00714090|Other|sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine|sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
75706265|NCT04067024|Procedure|Local anesthesia made by surgeon|infiltration with local anesthetics
75706266|NCT04067024|Procedure|Regional anesthesia group|Pecs block I and Supraclavicular nerf block
75706267|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors"
75706268|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors"
75706269|NCT05364710|Dietary Supplement|Transfer factor from colostrum ultrafiltrate|Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
75706270|NCT00618748|Drug|Olanzapine|5-20 mg/day, oral, daily
75706271|NCT04067544|Device|Acupuncture|"The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion."
75706272|NCT00723476|Behavioral|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
75706273|NCT00723476|Behavioral|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
75706274|NCT02570906|Device|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
75869329|NCT04983940|Drug|Jatenzo|237 mg soft gel capsule taken twice a day by mouth with food.
75706275|NCT00717600|Dietary Supplement|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
75542579|NCT05729997|Other|Listening to live classical music|The group of musicians perform music in the hemodialysis room while patients receive treatment.
75542580|NCT05726604|Other|Respiratory gating|10 minutes breathing motion monitoring during an additional CT scan to establish a more accurate cardiac and LAD dosimetry compared to reality
75706276|NCT00721058|Other|CT-scan|A pre-operative CT-scan will be made
75869330|NCT04981730|Behavioral|Web-based intervention|The web-based intervention participants will follow the website's orientation, the curriculum of modules, and professional feedback to complete the intervention.
76033098|NCT04950491|Other|Oral Health-Related Quality of Life (OHRQoL) questionnaire|The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, & Chaushu, 2004). Patients answered using a 5-category Likert scale.
76033099|NCT04950335|Procedure|AOPT|The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
75869331|NCT04980248|Biological|ALXN1850|ALXN1850 will be administered as an IV infusion and via the SC route.
75869332|NCT04979806|Drug|Cefepime-zidebactam (FEP-ZID)|3 g (2 g FEP + 1 g ZID) IV q8h
75869333|NCT04979806|Drug|Meropenem|1 g IV q8h
75869334|NCT04967807|Diagnostic Test|Cardiac PET/MRI|An imaging technique that combines the strengths of both MRI and PET into one comprehensive study. This technique allows for detailed myocardial tissue characterization with MRI (including assessment of myocardial edema and fibrosis) and metabolic changes (including myocardial inflammation).
76033100|NCT04950335|Procedure|AOCT|Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
76033101|NCT04950179|Other|PDRI patients|The study was conducted by retrospective data collection from medical records of 135 continuous ambulatory peritoneal dialysis (CAPD) patients at Phramongkutklao Hospital from January 1, 2016 to December 31, 2020.
75706277|NCT00850018|Procedure|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
75869335|NCT04967807|Diagnostic Test|Blood Biomarkers|Markers of cardiac damage, inflammation, circulating microRNA profiles, and COVID antibody levels will be evaluated in patients after COVID-19 vaccination.
75388303|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
75706278|NCT00850018|Behavioral|Usual care|Participants will receive usual care for the treatment of SCD.
75706279|NCT00721370|Device|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
75706280|NCT03566160|Device|Cryobiopsy probe, administered to study participants|Cryobiopsy probe as a tool for gastrointestinal biopsy
75869336|NCT04966910|Behavioral|Stay Connected|Stay Connected is a menu-driven set of strategies to combat loneliness, anxiety and depression in older adults based on behavioral activation principles.
75869337|NCT04966910|Behavioral|Treatment as usual|Regular check-ins, resource/referral provision
75869338|NCT04958122|Drug|Cefixime 400mg|Oral cefixime 400 mg, one capsule, twice a day for 10 days
75869339|NCT04958122|Drug|benzathine penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
76033102|NCT04960319|Device|Intravascular Lithotripsy|Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.
76033103|NCT04950647|Drug|Nitrofurazone Group 1|Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.
76033104|NCT04950647|Drug|Nitroketazine Group 2|Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
76033105|NCT04950647|Drug|placebo group|Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
76033106|NCT01675765|Biological|Immunotherapy plus chemotherapy|live attenuated double deleted Lm
76033107|NCT01675765|Biological|Immunotherapy with cyclophosphamide plus chemotherapy|live attenuated double deleted Lm
75869340|NCT04951492|Drug|Olaparib|Given PO
75869341|NCT04948112|Device|real time continuous glucose monitor|CGM sensor will read blood glucose every 10 minutes
75869342|NCT04948112|Device|blinded continuous glucose monitor|CGM that records blood glucose but not visible to patient
75869343|NCT04927975|Drug|Upadacitinib|Oral tablets
75869344|NCT04927975|Drug|Placebo|Oral tablets
76033108|NCT04960163|Other|No intervention|No intervention
76033109|NCT04960085|Device|echocardiography|philips IE33
75388304|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
75388305|NCT01972464|Drug|Progesterone|oral micronized progesterone
75388306|NCT01972464|Drug|Placebo|
75388307|NCT01948050|Device|non-invasive transcranial direct current stimulation (tDCS)|
75388308|NCT01947894|Other|Non Interventional Study|Non Interventional Study
75388309|NCT01947582|Device|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
76033110|NCT04522453|Other|paper-based version of mental health Gap Action Program-Intervention Guide|A paper-based guide for diagnosis and management of mental disorders in primary care.
76033111|NCT04522453|Other|digital version of the mental health Gap Action Program-Intervention Guide|A digital guide and client data entry tool for diagnosis and management of mental disorders in primary care.
76033112|NCT04943237|Drug|Anti-TNF agents|Group of patients using anti-TNF for the last 5 years.
76033113|NCT04943237|Drug|Conventional therapy users for the last 5 years|Group of patients not using anti-TNF. Group of patients using conventional therapy (non -steroid anti-inflammatory drugs and/or salazopyrin) for the last 5 years
76033114|NCT05011435|Device|web-application for burnout|Use of burnout advisor web-application for detection of professional burnout
75388310|NCT01924806|Device|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
75706281|NCT04067102|Drug|Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
75706282|NCT04067102|Drug|paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
75388311|NCT01924806|Device|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
75388312|NCT01924182|Device|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
75388313|NCT01924182|Other|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
75869345|NCT04927247|Drug|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
75869346|NCT04927247|Drug|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
76033115|NCT04950413|Other|Conventional physical therapy program|Infrared, Exercises, Stretching exercise of Suboccepital muscle
75869347|NCT04926831|Drug|capmatinib|150 mg and 200 mg tablets for oral administration
75869348|NCT04922463|Device|PLASOMA|Treatment with cold plasma device
75869349|NCT04915846|Drug|ApoTamox 10mg|All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).
75869350|NCT04915846|Drug|Placebo|placebo comparator
75869351|NCT04900532|Dietary Supplement|Tocotrienol rich fraction|Supplementation with a Vitamin E compound.
76033116|NCT04950413|Other|IASTM by M2t blade|A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2t blade will be cleaned with an alcohol pad. First, the M2T blade will used to ﬁnd the exact areas of restriction in affected muscles. Then the M2T blade will use at an angle of 45 to apply slow strokes along the muscle. Changes in soft tissue consistency will detected by the clinician through vibrations of the instrument when it slides on areas of irregular fibrosis of the underneath connective tissue. Once an adhesion is discovered, strokes are repeated for 5 min.
75388314|NCT01972308|Behavioral|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
75388315|NCT01972308|Behavioral|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
75706283|NCT00859144|Behavioral|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
75388316|NCT01946880|Drug|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
75388317|NCT01946880|Drug|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
75388318|NCT01946880|Drug|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
75388319|NCT01972152|Drug|G-Pen(TM) 1 mg|
75388320|NCT01972152|Drug|Lilly Glucagon(TM) 1 mg|
75706284|NCT00859144|Behavioral|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
75869352|NCT04900038|Drug|GSK3640254|GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
75388321|NCT01972152|Drug|G-Pen(TM) 0.5 mg|
75388322|NCT01972074|Drug|Memantine|Capsule
75388323|NCT01972074|Other|Placebo|Capsule
75388324|NCT01970982|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
75388325|NCT01970982|Other|Smoking abstinence (SA)|SA for 5 days in confinement
75388326|NCT01970982|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
75388327|NCT01946802|Device|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
75388328|NCT01618266|Drug|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
75388329|NCT01919112|Device|tDCS|Anodal tDCS will be administered with swallowing exercises
75388330|NCT01918332|Drug|Valsartan 160mg|
75388331|NCT01918332|Drug|Rosuvastatin 20mg|
75388332|NCT01918332|Drug|Valsartan 160mg placebo|
75388333|NCT01918332|Drug|Rosuvastatin 20mg placebo|
75869353|NCT04900038|Drug|Dolutegravir|DTG was available as 50 mg tablets administered orally.
75388334|NCT04628832|Behavioral|PMP Use Mandate Letter|A letter with reminders about the mandate to check the PMP when prescribing opioids.
75706285|NCT00859144|Behavioral|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
75706286|NCT04067154|Diagnostic Test|ALPE|Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
75388335|NCT04628832|Behavioral|Prescribing Information Letter|A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
75388336|NCT04628832|Behavioral|Prescribing Information + PMP Use Mandate Letter|A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
75388337|NCT01922934|Behavioral|Commercial weight loss program|vouchers for Weight Watchers
75388338|NCT01922934|Behavioral|Colorado Weigh|Group behavioral weight loss program
75388339|NCT01922934|Dietary Supplement|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
75706287|NCT05311202|Behavioral|low-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 20 minutes of two sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
75706288|NCT05311202|Behavioral|moderate-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 30 minutes of three sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
75706289|NCT05311202|Behavioral|high-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 40 minutes of four sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
76033117|NCT04950413|Device|Phonophoresis|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2 and. A 5 cm2 crystal head with an effective radiating area of 4.0 cm2 ±1.0 wills utilized for 5 Min for each trigger point of neck. lidocine gelwill applied instead of coupling US gel used for transmission.
76033118|NCT04285255|Drug|Fentanyl|opioids anaesthesia
76033119|NCT04285255|Drug|Ketamine|ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia
76033120|NCT04285255|Drug|Dexmedetomidine Injection [Precedex]|alpha 2 agonist with sedative, analgesic effect
76033121|NCT04285255|Procedure|Oblique subcostal transversus abdominis plane block|Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane
75388340|NCT01922934|Drug|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
75388341|NCT01922934|Behavioral|Recreation center passes|1 year pass to a Denver recreation center
75388342|NCT01970592|Behavioral|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
75388343|NCT01921140|Drug|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
75388344|NCT01921140|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
76033122|NCT04285255|Drug|Lidocaine|infusion of lidocaine 2%(1mg/kg/h)
75388345|NCT01921140|Other|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
75388346|NCT01921140|Other|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
75388347|NCT01920594|Drug|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
75388348|NCT01920594|Drug|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
75388349|NCT01917084|Other|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
75388350|NCT01917006|Drug|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
75388351|NCT01917006|Drug|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
75869354|NCT04900038|Drug|Lamivudine capsules|3TC was available as 300 mg capsules administered orally as a blinded treatment.
76033123|NCT04943003|Device|Transcranial Direct Current Stimulation (tDCS)|"Initially, a measuring tape will be used to make the markings and measurements necessary for placing the electrodes.~Regarding neurostimulation, the tDCS device is simple and portable, consisting of four main components: two electrodes (anode and cathode), an ammeter (electric current intensity meter), a potentiometer (voltage controller between electrodes) and a set of batteries. We will use the TCT-Research Neurostimulator, developed by Trans Cranial Technologies (Hong Kong, China), Regarding the protocols, the Active tDCS group will receive active tDCS for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area. The 10-20 International EEG system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (NMR) to estimate and individualize the dose to be administered."
75542581|NCT05726058|Device|XyCAM with oxygen|After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.
75542582|NCT05723913|Dietary Supplement|Dietary Supplement: A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
75542583|NCT05709743|Behavioral|Experimental: Within-Subjects Attentional Information|Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
75706290|NCT05311202|Behavioral|moderate-volume low-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 35 minutes of four sets of low intensity resistance exercise with 20 repetitions; (3) 5 minutes of cool down
75869355|NCT04900038|Drug|Lamivudine tablets|3TC was available as 300 mg tablets administered orally as an unblinded treatment.
75869356|NCT04880642|Drug|C21|C21
75869357|NCT04880642|Drug|Placebo|Placebo
76033124|NCT04963543|Other|FID123238|Lubricant applied to the ocular surface
76033125|NCT04943081|Procedure|Percutaneous nephrolithotomy|Percutaneous nephrolithotomy (PCNL) is a technique used to remove complex renal stones, or stones resistant to shockwave lithotripsy. A tube is placed through the incision in the kidney, under X-ray guidance, and renal stones are extracted by using nephroscope
76033126|NCT04942691|Other|physical activity|training with trampoline. Each session lasted sixty minutes. Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
75542584|NCT05694533|Drug|INDV-2000|Capsules administered orally twice a day
75542585|NCT05694533|Drug|Midazolam|Midazolam syrup administered orally on Days 1 and 15
75542586|NCT05681390|Drug|Tislelizumab|Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
75542587|NCT05669547|Device|dual hormone fully closed loop (DHFCL)|dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.
75542588|NCT05669261|Procedure|Adipose Tissue Harvest|"Local Anesthesia will be administered. A Stab wound will be created at the harvest site through which a 3.0 or 2.5 mm cannula will be inserted to suction fat using the syringe (i.e. manual) technique. A total of 100 cc of lipoaspirate will be collected by manual draw of the adipose tissue into syringes."
75542589|NCT05669261|Biological|ATCell|Infusion of the study medication at the rate of 575 mL/HR (500ml of LRD5 plus 75ml of ATCell suspended in LRD5) and continue until all received trial medication has been delivered.
75542590|NCT05669079|Drug|decitabine|15 mg/m2 daily intravenously for consecutive 3 days
75542591|NCT05669079|Biological|umbilical cord blood|MNC ≥ 3*108 cells; HLA compatibility ≥ 5/6
75542592|NCT05669079|Drug|Granulocyte-colony stimulating factor|Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
75542593|NCT05669079|Drug|Recombinant human thrombopoietin / thrombopoietin receptor agonist|Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
75869358|NCT04880434|Drug|Fludarabine|Administered intravenously
75869359|NCT04880434|Drug|Cyclophosphamide|Administered intravenously
75869360|NCT04880434|Biological|Brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
75869361|NCT04877535|Device|ML-based report card|PACU and ward providers caring for participants will be notified by Anesthesia Control Tower clinicians before arrival if the patient's report card. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.The ML risk profile generated for each patient will include risk of 30 day mortality, risk of respiratory failure, risk of acute kidney injury, and risk of postoperative delirium
75869362|NCT04873856|Dietary Supplement|Intervention|"The four dimensions of MINDNUT are described below:~Nutritional plan: is conducted in collaboration with the participant based on nutritional registration and information about routines and habits to reach a daily protein target of 1.5 g/kg/day. The nutritional plan is adjusted at the regular contact, and nutritional supplementation will be handed out to the participant.~Friendly reminder/informal caregiver: is a friendly reminder that encourage the participant to follow the nutritional plan and to ask for support (a note to hang on the refrigerator). The informal caregiver is a person with close contact to the participant.~Regular contacts: The participant will be contacted on regular basis (with an interval of 7-14 days) via phone and besides nutritional plan, this conversation will be used to talk about well-being, compliance and potential side-effects.~Weight diary: participants is instructed in keeping a weight diary which include registration of a daily weight."
75542594|NCT05669079|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
76033127|NCT04942847|Device|Sucking trainer|Repeated sucking for tongue flexibility training can improve the tongue muscle's ability to control and transmit food, and improve the swallowing function.
75542596|NCT05630625|Behavioral|Drinking Dashboard|Day-level feedback on alcohol use and consequences
75706291|NCT05311202|Behavioral|Control group|Reading a book related to cognitive function & exercise for 40 minutes
75869363|NCT04865588|Procedure|rotational atherectomy|angioplasty with rotational atherectomy - a rotating instrument used to break up the calcification
75869364|NCT04865588|Device|cutting balloon|a balloon with microsurgical blades on its outer surface which make longitudinal incisions in the calcified area in order to open resistant clogs
75869365|NCT04865588|Device|plain old balloon|current standard treatment of stent placement
76033128|NCT04942847|Device|Cognitive card|To measure the patient's ability to focus, to calculate, to remember and to judge
76033129|NCT04121299|Drug|Carvedilol|Carvedilol 40mg Extended Release Once Daily
76033130|NCT04121299|Drug|Amlodipine|Amlodipine 10mg Once Daily
76033131|NCT04942769|Drug|Selenium|selenium 100ug ，take it orally twice daily
75542597|NCT05628350|Other|No UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
75706292|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
75706293|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
75388352|NCT04625790|Device|Repetitive transcranial magnetic stimulation|"Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe."
75388353|NCT04625790|Other|Speech therapy|Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
75388354|NCT01916304|Drug|Levothyroxine sodium new formulation|Levothyroxine tablets
75388355|NCT01916226|Drug|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
75388356|NCT01916226|Drug|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
75388357|NCT01916226|Drug|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
75388358|NCT01916226|Drug|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
75869366|NCT04850599|Drug|Carfilzomib|Given IV
75388359|NCT01969500|Behavioral|Mobile Application|
76033132|NCT04253665|Behavioral|Nursing discharge teaching|Nurses will provide multimorbid seniors inpatients with teaching related to self-management to prepare them to be discharged home. The teaching delivery will be tailored to patients' activation level and priorities. The intervention begins by determining the level of activation at which patients are and identifying priorities to address related to patients' life situation. A Discharge Teaching Guide will be used by nurses to deliver the teaching and includes six domains of self-management. For each domain, nurses first report whether a priority has been identified and what intervention they have proposed to address it. Then for each domain, teaching objectives are described and differ according to the level of patient activation. These six domains of self-management are found in the patient-oriented discharge summary, which is a document for the patient that summarizes what has been addressed in discharge teaching.
76033133|NCT04942301|Drug|Endostar|This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed
76033134|NCT04942301|Device|use the vein pump to pump drugs|During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.
76033135|NCT04942301|Combination Product|combination therapy|Combination therapy with chemotherapy drugs was used
75388360|NCT01969500|Behavioral|Treatment as Usual (TAU)|
75388361|NCT05120154|Other|Online educational materials|The CAPACITI program is comprised of three independent modules, taken separately (each constituting an intervention): (1) Identify and Assess; (2) Enhance Communication Skills; (3) Enhance Skills for Ongoing Care (including involvement of family and specialists). Each module addresses a critical component of implementing a palliative care approach into primary care practice. The CAPACITI program emphasizes practice supports in each module, integrating two components: 1) clinical education in the form of expert advice and tips, and 2) evidence-based tools with action steps.
75869367|NCT04850599|Biological|Isatuximab|Given IV
76033136|NCT04959539|Procedure|endoscopic transcanal tympanoplasty with attico-antrostomy|Transcanal approach followed by atticotomy to remove the attic cholesteatoma sac
75388362|NCT05120154|Behavioral|Facilitated online webinars|Intervention participants will be invited to participate in facilitated online discussions. These discussions review the online materials and share strategies for problem-solving.
75557837|NCT00439751|Drug|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
75557838|NCT00439790|Procedure|Microneurography|Microneurography
75557839|NCT00438243|Drug|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
75557840|NCT00438243|Drug|Refresh Plus|1 drop in the affected eye twice daily
75869368|NCT04850599|Drug|Pomalidomide|Given PO
75869369|NCT04847739|Procedure|Seton Placement|This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.
75388363|NCT01915914|Drug|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
76033137|NCT04959539|Procedure|endoscopic assisted canal wall up mastoidectomy|traditional canal wall up mastoidectomy followed by endoscopic evaluation of the attic to exclude any remnant cholesteatoma
75388364|NCT01919970|Other|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
76033138|NCT04184479|Behavioral|LEVAmethod by Bertz et al|Ordinary treatment
76033139|NCT04959227|Other|Sema activity|sema activity 3 days a week for at least a year
76033140|NCT04725175|Drug|PIPE-307|Single and multiple ascending oral doses of PIPE-307 tablets
76033141|NCT04725175|Drug|Placebo oral tablet|Single and multiple ascending oral doses of matching Placebo tablets
75388365|NCT01919970|Other|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
75388366|NCT01919814|Dietary Supplement|Appethyl™|Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
75388367|NCT01919814|Other|Placebo|Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
75388368|NCT01968954|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
75388369|NCT01968954|Other|Placebo|subcutaneous injection, every 2 weeks for 12 months
75388370|NCT01919190|Drug|EXPAREL|TAP with EXPAREL
75388371|NCT01919190|Drug|Placebo|Placebo
75706294|NCT05659290|Drug|Fruquintinib alternating with Bevacizumab plus Capecitabine|Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
76033142|NCT02625233|Device|senofilcon C|
76033143|NCT02625233|Device|comfilcon A|
76033144|NCT04704349|Radiation|Scintigraphy|The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.
76033145|NCT03059069|Drug|Chonline Alphoscerate|Patients treated with Chonline Alphoscerate as add on therapy to their medication
76033146|NCT03059069|Drug|Placebo Oral Tablet|Patients maintain their medication with either Gliatamin or placebo for 6 months.
75388372|NCT01620060|Drug|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
75388373|NCT04615182|Device|Transplant|To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
75388374|NCT01914666|Drug|Duloxetine|Administered orally
75388375|NCT01913340|Drug|Erythropoietin|1000 U/kg/dose IV x 5 doses
75388376|NCT01913340|Drug|Normal saline|placebo: NS IV x 5 doses
76033147|NCT04942223|Device|guided bone regeneration|After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
75388377|NCT01864200|Biological|Crotalidae polyvalent immune fab (ovine)|crotalidae antivenom
76033148|NCT03710785|Behavioral|cervical spine extension exercise|cervical spine extension exercise for 4 weeks
75388378|NCT01864200|Biological|Placebo|Saline placebo
75869370|NCT04847739|Drug|AVB-114|AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
76033149|NCT04949945|Behavioral|Self Help Culturally Cognitive Behavioral Therapy|Experimental group (CHF patients)will be screened on PHQ9 questionnaire for depression after receiving guided self help culturally adapted cognitive therapy they will be reassessed for their depression,improvement in functional disability ,improvement in classification of NYHA,reduction in hospital admission as compare to control group.
75388379|NCT01912872|Drug|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
75388380|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
75388381|NCT01912872|Drug|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
75388382|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
75388383|NCT01912872|Drug|Formoterol|Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
75388384|NCT01912404|Drug|IDN-6556|25 mg BID for 28 days
75869371|NCT04831580|Device|da Vinci|Minimally invasive robotic-assisted surgical device
76033150|NCT04563715|Diagnostic Test|HIV counseling and testing|Receive HIV testing risk assessment and advice about risk reduction and future testing.
76033151|NCT04563715|Behavioral|Network intervention|Key individuals are trained to provide advice about regular testing and risk reduction.
75869372|NCT04831580|Other|open surgery|open radical hysterectomy
75869373|NCT04826640|Other|Observational|Observational
75869374|NCT04826003|Drug|RO7122290|RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).
76033152|NCT04941677|Other|no intervention|no intervention in this study
76033153|NCT03057899|Drug|TFG capsules (200 mg /capsule)|TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
76033154|NCT03057899|Drug|Placebo oral capsule|During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
75869375|NCT04826003|Drug|Cibisatamab|Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).
76033155|NCT03284827|Drug|NOAC|edoxaban (60 mg once daily [OD]) for at least 6 months
76033156|NCT03284827|Drug|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
76033157|NCT04959071|Procedure|Vacuum assisted closure VAC vs conventional dressing|"In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily."
76033158|NCT04949321|Other|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
76033159|NCT04434001|Drug|Fibrinogen Concentrate Human|Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.
76033160|NCT04434001|Drug|Prothrombin Complex Concentrate|Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.
76033161|NCT04434001|Biological|Fresh Frozen Plasma|Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
76033162|NCT04958993|Drug|Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy|radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
75388385|NCT01912404|Drug|Placebo|Placebo controlled
75388386|NCT01911780|Drug|placebo|placebo matching amlodipine capsule
75388387|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
75869376|NCT04826003|Drug|Obinutuzumab|"Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab"
75869377|NCT04824638|Biological|3 doses of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 D29 and M8, intramuscularly (participants without antecedent of SARS-CoV-2 infection)
76033163|NCT04683913|Behavioral|Foot rotation modification|"The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable."
75542598|NCT05628350|Other|Standard UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet maintaining usual UPF intake (59% energy). Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
75542599|NCT05611905|Combination Product|11C-para-aminobenzoic acid PET/CT|A bolus of 20 mCi of 11C-PABA followed by PET/CT
76033164|NCT04683913|Other|Waiting Period - Delayed Group|Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
75706295|NCT05659290|Drug|Bevacizumab plus Capecitabine|Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
75706296|NCT00852982|Behavioral|Exercise|Nordic walking, with walking poles, five hours per week during four months
75706297|NCT02571504|Behavioral|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
75869378|NCT04824638|Biological|2 dose of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 and M8, intramuscularly (participants with antecedent of SARS-CoV-2 infection)
75869379|NCT04820023|Drug|BBT-176|BBT-176 given orally alone
76033165|NCT03603925|Diagnostic Test|Positron Emission Test / Magnetic Resonance (PET/MR)|The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.
75869380|NCT04817891|Device|HD-tDCS|Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
75869381|NCT04809805|Drug|BAY2666605|One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
75869382|NCT04803604|Behavioral|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, lay coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training as well as monthly follow-up.
76033166|NCT03603925|Diagnostic Test|Positron Emission Test / Computed Tomography (PET/CT)|Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
76033167|NCT04958603|Procedure|"L type release surgery"|Lateral release of the lateral support belt
76033168|NCT03540901|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
76033169|NCT03540901|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
76033170|NCT03517735|Device|EasyTiva (algorithm is the property of Medsteer SAS)|Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
76033171|NCT03517735|Drug|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
76033172|NCT03517735|Drug|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
76033173|NCT04958915|Diagnostic Test|Knee joint 30° flexion scan|The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
75542600|NCT05611905|Drug|Probenecid|Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.
75542601|NCT05607173|Drug|Fexinidazole (HOE239)|Route of administration: oral; pharmaceutical form: tablet
75542602|NCT05586373|Drug|medication 1|Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days
75706298|NCT05304494|Other|Biomarker tests for participant profiling|Combination of digital and physical tests to objectify measures relevant for breathlessness
75706299|NCT00859378|Device|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith & Nephew)
75869383|NCT04784052|Drug|JSP191|Participants will receive a single IV dose at start of conditioning
75706300|NCT00859378|Device|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
75706301|NCT00717678|Drug|Prograf-XL|oral
75706302|NCT00717678|Drug|Prograf|oral
75706303|NCT00717678|Drug|MMF|oral
75706304|NCT00859534|Drug|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
75869384|NCT04784052|Device|CliniMACS Prodigy System|The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
75706305|NCT05050682|Drug|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
75706306|NCT00853138|Behavioral|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week."
75706307|NCT04067466|Dietary Supplement|Fiber product|Fiber product with inulin, maltodextrin, gum guar and plum powder.
75706308|NCT04067466|Dietary Supplement|Control product|Placebo product with maltodextrin and plum powder
75706309|NCT02571842|Drug|Intravenous Rituximab|- 375 mg/m2 rituximab be prescribed 4 consecutive monthly
75869385|NCT04784052|Biological|Depleted Stem Cell Transplant|TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
75869386|NCT04784052|Biological|Rabbit Anti-Thymoglobulin (rATG)|3 consecutive daily doses of rATG will be given by IV during conditioning
75869387|NCT04784052|Drug|Cyclophosphamide|4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
75869388|NCT04784052|Drug|Fludarabine|4 consecutive daily doses of fludarabine will be given by IV during conditioning
75869389|NCT04784052|Drug|Rituximab|1 dose of rituximab will be given at the end of conditioning
75869390|NCT04781153|Procedure|Periodontal treatment|Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use
75542603|NCT05586373|Drug|medication 2|Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days
75542604|NCT05549401|Drug|CKD-348(4) F1|QD, PQ
75542605|NCT05549401|Drug|CKD-348(4) F2|QD, PQ
75542606|NCT05549401|Drug|CKD-828, D097, D337|QD, PQ
75542607|NCT05491668|Diagnostic Test|Non-hyperemic pressure ratio assessment pre and post PCI|Pre and post PCI invasive physiologic assessment
75706310|NCT02571842|Drug|ACEI/ARB and corticosteroids|"ACEI or ARB will be prescribed as high as tolerable dose.~Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks"
75706311|NCT02546284|Drug|lenzilumab|
75706312|NCT02572830|Behavioral|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
75706313|NCT02572830|Behavioral|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
75706314|NCT00721448|Drug|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
76033174|NCT03489811|Other|Test Essential Oil Blend|The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
76033175|NCT03489811|Other|Active Essential Oil Blend|The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
75542608|NCT05472519|Biological|blood samples|"Only one visit for each participant: A large majority of visits will be part of patients' usual care.~Medical examination : weight, gender, blood pressure, medical history~Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
75869391|NCT04777201|Drug|Faricimab|Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
76033176|NCT03489811|Other|Control Blend|The control blend consists of inert vegetable oils which are produced from plant matter.
76033177|NCT04941131|Drug|Chlorhexidine digluconate, povidone iodine|This is a mouth wash that can be used over the counter.
76033178|NCT03400501|Drug|Insulin Degludec|Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose
76033179|NCT03400501|Drug|Insulin Glargine|Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose
75388388|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
75388389|NCT01911780|Drug|amlodipine|capsule
75542609|NCT05472519|Biological|blood samples|"Only one visit for each participant:~Medical examination : weight, gender, blood pressure, medical history~Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
75542610|NCT05434546|Drug|Sepranolone|Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
75706315|NCT00721448|Drug|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
75869392|NCT04777201|Other|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.
75869393|NCT04770779|Drug|Placebo Matching Mitapivat|Tablets
75869394|NCT04770779|Drug|Mitapivat|Tablets
75869395|NCT04770259|Other|Timely pre-surgical conditioning|Timely pre-surgical conditioning seeks to prepare frail, pre-frail and / or dependent older patients for the surgery process. For which a work plan has been designed according to your needs and health conditions.
75869396|NCT04765202|Procedure|AG Tx|The control treatment is meshed autograft applied to a FT burn area
75869397|NCT04765202|Biological|SOMA Tx|The experimental treatment is more widely meshed autograft than the AG Tx site applied to a FT burn area and covered with SOMA
76033180|NCT04940975|Behavioral|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
75388390|NCT01911546|Drug|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
75388391|NCT01910298|Procedure|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|
75388392|NCT01910298|Procedure|Two Stage Breast Reconstruction|
75388393|NCT01909674|Device|Switch CPAP mask type|
75388394|NCT05114694|Procedure|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
75388395|NCT05114694|Procedure|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
75388396|NCT01908816|Drug|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
75388397|NCT01908582|Drug|Evacetrapib|Administered orally
75388398|NCT01908582|Drug|Rifampin|Administered orally
75388399|NCT01908426|Drug|Cabozantinib tablets|
75388400|NCT01908426|Drug|Placebo tablets|
75388401|NCT01907100|Drug|Nintedanib|triple kinase inhibitor; 200mg starting dose
75388402|NCT01907100|Drug|Pemetrexed|backbone chemo
75388403|NCT01907100|Drug|Cisplatin|backbone chemo
75388404|NCT01907100|Drug|Cisplatin|backbone chemo
75388405|NCT01907100|Drug|Pemetrexed|backbone chemo
75388406|NCT01907100|Drug|Placebo|Nintedanib matching placebo
75388407|NCT01889862|Drug|BMN165 20mg/day|BMN165 20mg/day self-administered daily
75388408|NCT01889862|Drug|BMN165 40mg/day|BMN165 40mg/day self-administered daily
76033181|NCT04940975|Behavioral|Insomnia Education Program at Integrated Mental Health Clinic (IMHC)|A program composed of four educational sessions on sleep and insomnia, plus relaxation training, plus two individual review sessions on sleep hygiene with participant.
75388409|NCT01889862|Drug|Placebo|Non-drug placebo, self-administered daily
75388410|NCT01887912|Biological|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
75388411|NCT01887912|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
75388412|NCT04415346|Biological|HU-014 Inj|Clostridium botulinum type A
75388413|NCT01887678|Drug|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
75388414|NCT01887678|Drug|Placebo|Placebo is an injection of Saline
75388415|NCT01887600|Drug|Roxadustat|Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
75706316|NCT00720954|Procedure|Ct-guided pleural needle biopsy|Biopsy of pleura
75706317|NCT00720954|Procedure|Thoracoscopy|Biopsy of pleura
76033182|NCT04383847|Behavioral|Sumadhur Aarambha|Group intervention for newly married women, their husbands, and mothers-in-law with information mainly about nutrition, but also pre-pregnancy health, reproductive/pregnancy health and gender equality.
76033183|NCT03231475|Drug|SPH1188-11|qd.po
76033184|NCT04415957|Other|Elastic Tape|The subject's trunk was passively extended for ET placement. The ET was placed on the chest wall and abdomen, considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. The intervention lasted 14 days, therefore, the participants remained with the tapes for two consecutive weeks. Due to the adhesive durability of ETs (6 weeks on average), the participants were asked to return to change the ET after seven days.
75388416|NCT01887600|Drug|Placebo|Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
75388417|NCT01887288|Drug|Capecitabine|650 mg/m^2 PO b.i.d.
75388418|NCT01887288|Drug|Digoxin|0.25 mg once daily
75388419|NCT01887210|Behavioral|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
75388420|NCT01887210|Behavioral|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
75388421|NCT03405714|Drug|Brivaracetam|"Pharmaceutical form: Solution for iv injection~Route of administration: intravenous use~Concentration: 10 mg/ml"
75388422|NCT01885182|Drug|Oxycodone/Naloxone|
75388423|NCT01885182|Drug|Oxycodone|
75706318|NCT02570828|Device|Thermal Imaging|FLIR ONE attachment to an iPhone
76033185|NCT04958681|Other|exercise|The participants were subsequently asked whether the pandemic had altered their physical activity status and rate the severity of reduction in mobility level compared to the period before the Covid-19 with the following options: none, 0; mild, 1; moderate, 2; severe, 3. Then, the participants were also asked whether they perform a physical exercise in a home setting. We recorded regular outdoor physical activity and home-based exercises (only after the pandemic) as a dichotomous variable (yes or no). The number of physical activity days per week was also obtained.
76033186|NCT04949009|Drug|Avatrombopag|Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
76033187|NCT04948541|Combination Product|osa treatment|different treatments can be included
76033188|NCT04948541|Other|no treatment|no treatment was undergone
75869398|NCT04760405|Other|Tai Chi Easy|Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
75869399|NCT04754139|Other|WeChat mobile mini-application|Sexual health education and the role of PrEP
75542611|NCT05433090|Behavioral|Inpatient serious illness care program|Inpatient advance care planning intervention that will be delivered by advanced care practitioners or hematology/oncology fellow physicians. The intervention will be an adapted version of the serious illness care program.
75869400|NCT04753749|Drug|Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)|Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months
76033189|NCT04948229|Other|Blood serum samples|Blood serum samples will be taken.
76033190|NCT04940819|Behavioral|Mobile Application for Dietary Management|A mobile application developed by a multi-disciplinary team will be used in the dietary management of CKD patients. The application is patient orientated. It has 4 core features including food searching, dietary logging, personalized key nutrient intake feedback and patient-caregiver interaction.
75388424|NCT01885104|Drug|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
75388425|NCT01885104|Drug|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
75388426|NCT01885104|Drug|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
75869401|NCT04753749|Drug|Standard DAPT|Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
75869402|NCT04749888|Behavioral|Targeted nurse-led home visiting|The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
76033191|NCT03058211|Diagnostic Test|Echocardiography|Standard protocols
76033192|NCT03058211|Diagnostic Test|Cardiac Magnetic resonance|MRI with late gadolinium increase and T1 mapping
76033193|NCT04940429|Device|Neurofit|This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.
75706319|NCT00853216|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
75388427|NCT04613232|Device|Wearable sensor|The patients will be asked to wear an Apple Watch during their treatment course. The watch will pasively collect sensor data (heart rate and physical activity)
75388428|NCT04612374|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
75388429|NCT04612374|Behavioral|Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
75388430|NCT01881750|Behavioral|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
75388431|NCT01881750|Behavioral|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
75388432|NCT01906008|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
75388433|NCT01906008|Drug|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
75388434|NCT01906008|Behavioral|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
75388435|NCT01906008|Behavioral|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
75388436|NCT01863732|Biological|Secukinumab|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
75388437|NCT01863732|Other|Placebo (Pbo)|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
75388438|NCT01905540|Drug|SSP-004184AQ|Magnesium salt
75388439|NCT01905540|Drug|SSP-004184SS|Disodium salt
75869403|NCT04749524|Diagnostic Test|Measurement of Otoacoustic Emissions with and without suppression noise|Otoacoustic emissions will be recorded using an ear probe with and without a suppression noise.
75869404|NCT04740918|Drug|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
75869405|NCT04740918|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion
75869406|NCT04740918|Other|Placebo|Placebo matched to atezolizumab
75869407|NCT04736173|Drug|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
75869408|NCT04736173|Drug|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
75388440|NCT01904760|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
75388441|NCT01904760|Drug|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
75388442|NCT01904604|Biological|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
75388443|NCT01904604|Biological|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
75388444|NCT01904604|Biological|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
75388445|NCT01904058|Drug|LUM001|
75388446|NCT01904058|Drug|Placebo|
75388447|NCT01904058|Drug|Ursodeoxycholic Acid|
75388448|NCT01881126|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
75869409|NCT04736173|Drug|Carboplatin|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
75869410|NCT04736173|Drug|Paclitaxel|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
75869411|NCT04736173|Drug|Pemetrexed|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
75869412|NCT04736173|Drug|Pembrolizumab|Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor
75869413|NCT04715048|Drug|PrabotulinumtoxinA|Glabellar line correction
75869414|NCT04715048|Drug|Onabotulinum toxin A|Glabellar line correction
75869415|NCT04703075|Drug|Rifapentine 600 mg and INH 300 mg|Participants will receive Rifapentine 600 mg and INH 300 mg
75869416|NCT04703075|Drug|Rifapentine 900 mg and INH 900 mg|Participants will receive Rifapentine 900 mg and INH 900mg
75869417|NCT04701151|Drug|Bacillus Calmette Guerin|The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
75869418|NCT04699786|Other|Arm A , Arm B, Arm C, & Arm D|All arms will receive the same intervention, but at different time points. All arms will be offered the option to learn their research results in personalized five-year risk estimate of getting Alzheimer disease dementia. Arms A & C participants will receive their risk estimate about two weeks after consent is signed and Arms B& D will receive their risk estimate about one year after consent is signed. The risk estimate returned to participants is based on research results from individual genotyping results, imaging or plasma amyloid testing & demographic characteristics. All arms will complete psychosocial and cognitive testing. Also, surveys used in this study will ask about participants' experiences and feelings after learning their risk estimate. All arms will receive follow up calls at one week post disclosure of the risk estimate and surveys two, six, and twelve months post disclosure. Arms A & C will have extra surveys at twenty-four months post disclosure.
75388449|NCT01881126|Drug|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
75388450|NCT01881126|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
75388451|NCT01881126|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
75388452|NCT03357588|Other|Intensified monitoring|Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
75388453|NCT03357588|Other|Standard of care monitoring|Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
75388454|NCT01614600|Device|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
75388455|NCT04611672|Diagnostic Test|Assessment of CA|As part of our routine stroke work up, each patient receives an initial CT scan with CT perfusion to indicate thrombolysis therapy (intravenous, mechanical, or both, depending on the time since first stroke symptoms and perfusion-mismatch), an MRI within 2 days, extracranial and transcranial Duplex ultrasound, echocardiography, continuous Monitoring of BP, O2, body temperature, NIHSS and Glagow Coma Scale (GCS) every 6 hours. Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
75388456|NCT04611672|Diagnostic Test|Assesment of CA only|Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
75388457|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
75388458|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
75542612|NCT05419622|Biological|bronchial biopsies|This fibroscopy will make it possible to perform 4 bronchial biopsies at the level of the 4th bronchial generation (subsegmental bronchi), using suitable pediatric forceps.
75706320|NCT00853216|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
75388459|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
75388460|NCT01880424|Drug|Placebo|matching Placebo Capsules, Oral, once daily
75869419|NCT04685590|Drug|Dasatinib + Quercetin|D+Q will be administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
75388461|NCT01880424|Drug|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
75388462|NCT01862874|Biological|V501|Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
75388463|NCT01862874|Biological|Placebo|Formulated with AAHS adjuvant
75869420|NCT04685590|Other|Placebo Capsules|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
75388464|NCT01879722|Drug|TAK-063|TAK-063 tablets
75388465|NCT01879722|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
75542613|NCT05405998|Other|Proactive care pathway|"Patient participation in a specific therapeutic education program, as soon as the therapeutic decision is made.~The reinforced cooperation of the expert centers with the homecare providers on 2 different times:~before the installation of the pump, i.e. before the episode of hospitalization dedicated to the starting of the treatment;~after the installation of the pump following the above mentioned hospitalization."
75706321|NCT02571062|Drug|Fexinidazole|
75706322|NCT00859768|Other|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
75869421|NCT04675710|Procedure|Conventional Surgery|Undergo surgery
75388466|NCT01879410|Drug|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
75388467|NCT01879410|Drug|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
75388468|NCT01879410|Drug|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
75542614|NCT05376917|Device|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50D on the dominated eye
75869422|NCT04675710|Drug|Dabrafenib|Given PO
75542615|NCT05376917|Device|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
75388469|NCT01879410|Drug|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
75706323|NCT04961528|Drug|Tranexamic Acid 500 MG|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 5 days"
75869423|NCT04675710|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75869424|NCT04675710|Biological|Pembrolizumab|Given IV
75869425|NCT04675710|Other|Quality-of-Life Assessment|Ancillary studies
75869426|NCT04675710|Drug|Trametinib|Given PO
75388470|NCT05114148|Device|Holmium-166 radioembolization|Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
75388471|NCT01903434|Drug|Evacetrapib|Administered orally
75388472|NCT01903356|Drug|Trajenta duo|Linagliptin and Metformin
75388473|NCT01862796|Behavioral|Underfeeding diet|Heart healthy diet with 35% reduced calories
75388474|NCT01862796|Behavioral|Weight maintaining diet|Heart healthy weight-maintaining diet
75388475|NCT01878084|Other|bioactive glass (sol-gel)|Extraction sockets will be augmented using bioactive glass (sol-gel)
75388476|NCT01878084|Other|empty extraction socket|Extraction socket will be left empty
75388477|NCT01862640|Drug|Brexpiprazole, OPC-34712|Once-daily, tablets
75388478|NCT01862640|Drug|Placebo Oral Tablet|Once-daily, tablets
75388479|NCT01902966|Drug|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
75388480|NCT01902966|Behavioral|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
75388481|NCT01902966|Behavioral|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
75388482|NCT01902966|Behavioral|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
75388483|NCT01862484|Dietary Supplement|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
75388484|NCT01862484|Dietary Supplement|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
75388485|NCT01902888|Device|GORE® VIABAHN® Endoprosthesis|
75388486|NCT01862328|Drug|MLN4924|"MLN4924 (intravenously [IV]) in participants in a 21-day cycle:~MLN4924 on Days 1,3,5 of each cycle"
75388487|NCT01862328|Drug|Paclitaxel|"Paclitaxel (IV) in a 21-day cycle:~Paclitaxel on Day 1 of each cycle"
75388488|NCT01862328|Drug|Gemcitabine|"Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle"
75388489|NCT01862328|Drug|Docetaxel|"Docetaxel (IV) in participants in a 21-day cycle:~- Docetaxel on Day 1 of each cycle"
75542616|NCT05376917|Device|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
75388490|NCT01862328|Drug|Carboplatin|"Carboplatin (IV) in participants in a 21-day cycle:~- Carboplatin on Day 1 of each cycle"
75388491|NCT01862250|Drug|Clonidine (Duraclon®)|"Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~HR ≤70/min, sustained for ≥30 min after administration"
75388492|NCT01901874|Device|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
75388493|NCT01860534|Behavioral|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
75388494|NCT01901328|Drug|CB-5945|
75388495|NCT01901328|Drug|Placebo|
75542617|NCT05376917|Device|Zeiss AT Lara / Zeiss AT Lara|Micromonovision with refractive target of -0.75D on the non-dominant eye
75388496|NCT01859988|Drug|Dupilumab|
75388497|NCT01859988|Drug|Placebo|
75388498|NCT01876446|Other|Laboratory Biomarker Analysis|Correlative studies
75388499|NCT01876446|Drug|Pegylated Irinotecan|Given IV
75388500|NCT01876446|Other|Pharmacological Study|Correlative studies
75542618|NCT05372055|Other|Semi-structure interviews|Semi-structured interview focusing on psychosocial impact of living with an IPC to be performed at 2 weeks and 6-8 weeks post IPC insertion
75542619|NCT05367778|Drug|HS-10370|HS-10370 will be administered orally once daily in a continuous regimen
75388501|NCT04599660|Other|Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
75388502|NCT01900626|Drug|epidural catheter|epidural catheter with 0.3% ropivacaine
75388503|NCT04414800|Drug|Placebo|Distilled water
75542620|NCT05362981|Other|CAT|2 group programs, led by trained speakers, addressing specific ED topics through written, verbal and/or behavioral exercises,
76033194|NCT04940429|Diagnostic Test|Psychometric hepatic encephalopathy score|During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
76033195|NCT02656693|Behavioral|Online weight management program|Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.
76033196|NCT02656693|Behavioral|Population health management support|Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
76033197|NCT04940273|Drug|Remifentanil Injection [Ultiva]|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
75388504|NCT04414800|Drug|Ketamine|1 mg/kg intranasal ketamine
75388505|NCT04414800|Drug|Fentanyl|1μg/kg intranasal fentanyl
75388506|NCT01900314|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
75869427|NCT04648202|Drug|FS120|Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
75388507|NCT01899768|Drug|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
75388508|NCT01899768|Drug|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
75869428|NCT04647253|Device|AGENT DCB|Drug coated PTCA balloon catheter
75869429|NCT04647253|Device|PTCA balloon catheter|PTCA balloon catheter
75388509|NCT01898598|Drug|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
75388510|NCT01898598|Drug|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
75388511|NCT01898442|Drug|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
75388512|NCT01898442|Drug|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
75388513|NCT01898442|Drug|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
75388514|NCT01898286|Drug|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
75388515|NCT01898208|Device|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
75388516|NCT01898208|Behavioral|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
75388517|NCT01898208|Other|Bacterial culture|This test identifies the pathogen responsible for an infection.
75388518|NCT01898208|Other|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
75388519|NCT01898130|Biological|bevacizumab|Given IV
75388520|NCT01898130|Procedure|quality-of-life assessment|Ancillary studies
75388521|NCT01876368|Drug|LCZ696|
75388522|NCT01876368|Drug|Olmesartan|
75388523|NCT01876368|Drug|Placebo of LCZ696|
75388524|NCT01876368|Drug|Placebo of Olmesartan|
75706324|NCT04961528|Drug|Terlipressin|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 5 days"
75388525|NCT01874340|Drug|Placebo|Placebo will be administered at predefined visits over the 6-month treatment phase.
75388526|NCT01874340|Drug|AIN457|AIN457 will be administered at predefined visits over the 6-month treatment phase.
75388527|NCT04597242|Drug|Exebacase|Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.
75388528|NCT01897896|Drug|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
75388529|NCT01858194|Device|Renal sympathetic denervation|"The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
75388530|NCT01858194|Device|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
75388531|NCT01873950|Drug|Ranolazine|
75388532|NCT01873950|Drug|Dofetilide|
75388533|NCT01873950|Drug|Verapamil|
75388534|NCT01873950|Drug|Quinidine sulfate|
75388535|NCT01873950|Drug|Placebo|
75388536|NCT01857102|Device|etafilcon A|Soft contact lens to be worn in a daily wear, daily disposable modality for one week
75388537|NCT01857102|Device|etafilcon A for Astigmatism|Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
75388538|NCT01872078|Drug|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
75388539|NCT01872078|Drug|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
75388540|NCT04618458|Behavioral|Power to Prevent|Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
75388541|NCT01896726|Drug|Baricitinib|Administered orally
75388542|NCT01896726|Drug|Microgynon|Administered orally
75388543|NCT01856790|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
75388544|NCT01856790|Drug|liraglutide|Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
75388545|NCT01856322|Drug|Sulindac|one tablet 150mg twice daily
75388546|NCT01856322|Drug|Placebo|One tablet twice daily
75388547|NCT01856322|Other|Validate assays and shipping methods|
75388548|NCT01896102|Genetic|Lenti-D Drug Product (eli-cel)|Participants received a single IV infusion of Lenti-D Drug Product.
75388549|NCT01871532|Drug|Gonal-f®|
75388550|NCT04606992|Procedure|CELS|CELS resection for early colon cancer is a compromised resection performed in frail patients
75388551|NCT01855074|Drug|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
75388552|NCT01871142|Drug|Placebo|100 mL
75388553|NCT01871142|Drug|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
75388554|NCT01871142|Drug|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
76033198|NCT04958525|Procedure|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal in basal ganglia region:According to the brain CT scan and reconstruct the operation plan, choose a side by 2 cm before the coronal suture line 4 cm and 3 cm center longitudinal incision formation of 2 cm bone drilling the hole, ultrasonic measurement and the size of hematoma puncture depth, and guide the puncture direction, the transparent channel under endoscopic direct placement hematoma backend, after entering the hematoma cavity, under the neural endoscopic removal of hematoma,Wash the hematoma cavity with warm salt water.Bipolar electrocoagulation hemostasis for active bleeding.An indwelling drainage tube was placed in the hematoma cavity, and ultrasonography determined that the hematoma was cleared satisfily without active bleeding.
75388555|NCT04606290|Device|O2matic HOT|Automated oxygen titration with O2matic HOT
75388556|NCT04606290|Device|Oxygen concentrator|Fixed dose oxygen flow from concentrator
75388557|NCT04411056|Other|Barrier box|Placement of barrier box ( a plastic box for shielding)
75388558|NCT01895322|Drug|OPC-41061|
75388559|NCT01894776|Drug|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
75388560|NCT01894776|Drug|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
75388561|NCT01894620|Device|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
75388562|NCT01894620|Device|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
75388563|NCT01854918|Biological|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
75388564|NCT01854918|Drug|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
75388565|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization
75388566|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
75388567|NCT01894230|Genetic|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1*5 allele
75388568|NCT01894152|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
75388569|NCT04596930|Procedure|Laser ablation thermal therapy|The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance
75388570|NCT01854528|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
75388571|NCT01854528|Drug|Ribavirin|Tablet
75869430|NCT04644172|Behavioral|Speed of Processing Training|"Testing involves trainer-guided practice of computerbased video games. The games require the player to identify targets that are presented very briefly. In the first level, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. SOPT is aimed at improving the fluidity of mental processing speed (not psychomotor reaction time) so that trainees can process more complex information over briefer periods of time. The training involves practice with feedback. The trainer teaches some task-specific strategies, offer suggestions, encouragement, and personalized modification of difficulty for enhancing performance. Speed and task difficulty level are tailored to trainee ability, trainees practice blocks of 16 trials with a goal of achieving performance of 10 to 12 correct trials for each training block."
75388572|NCT01854528|Drug|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
75388573|NCT01854528|Drug|Telaprevir|Film-coated tablet
75542621|NCT05359939|Diagnostic Test|18F-FDGal PET/CT versus 18F-choline PET/CT|Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
75542622|NCT05354934|Other|quetionnaire|"The questionnaire includes the following modules~Demography and socio-economic conditions~Screening and modalities of discovery and announcement of HIV infection~Time and modalities of introduction of antiretroviral drugs after diagnosis~Knowledge of HIV infection~The perception of follow-up in the health care service~Experiences of stigma~Barriers to accessing care~Periods of loss of sight and reasons for this~Perceived health status, mental health (PHQ4), chronic illness, functional limitations~Addictions~Social network and support~Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
75388574|NCT01853982|Drug|Ceftolozane/Tazobactam|
75388575|NCT01853982|Drug|Piperacillin/Tazobactam|
75388576|NCT01853280|Drug|L-methylfolate|15mg/day L-methylfolate.
75388577|NCT01853280|Drug|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
75388578|NCT01853280|Drug|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
75388579|NCT04415736|Other|No intervention, observational study|
75388580|NCT01892436|Drug|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
75388581|NCT01892436|Drug|Placebo|Placebo
75388582|NCT04415580|Other|Vestibular Rehabilitation (VR)|"VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right)."
75388583|NCT04415580|Other|Conventional Neurorehabilitation|muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
75388584|NCT01853046|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
75388585|NCT01891890|Drug|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
75388586|NCT01891890|Drug|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
75542623|NCT05338151|Behavioral|Brief Negotiated Interview (BNI)|Brief Negotiated Interview (with referral and telephone booster) alone
75706325|NCT04961528|Drug|Placebo|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 5 days."
75388587|NCT01891890|Drug|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
75388588|NCT01852812|Drug|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
75388589|NCT01852812|Drug|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
75388590|NCT04602624|Drug|SAGE-718|SAGE-718 oral tablets.
75388591|NCT01869348|Behavioral|Monitor intervention|"Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior."
75388592|NCT01869192|Drug|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
75388593|NCT01869192|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
75388594|NCT01869192|Drug|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
75388595|NCT01869192|Drug|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
75542624|NCT05338151|Behavioral|BNI+facilitated provision of MAUD|Brief Negotiated Interview (BNI)+ Medication for Alcohol Use Disorder (MAUD)
75706326|NCT00721032|Procedure|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
75706327|NCT00721032|Drug|Increased dose of amiodarone|"Increase the dose of amiodarone according to the following scheme:~current dose -> new dose 100 once daily (QD) -> 200 QD; 200 QD -> 400 QD; 300 QD -> 600 QD; 400 QD -> 600 QD"
75542625|NCT05338151|Behavioral|Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT|Brief Negotiated Interview (BNI)+Medication for Alcohol Use Disorder (MAUD)+Computer Based Treatment for Cognitive Behavioral Treatment (CBT4CBT)
75388596|NCT01869192|Radiation|Radiation Therapy|Standard dosing, fields depending on clinical findings
75388597|NCT04415190|Other|early palliative care|early palliative care
75388598|NCT04615884|Dietary Supplement|Chinese herbs formula: Shu Yu Wan|Shu Yu Wan Formula is a combination of 23 natural chinese herbs.This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.
75388599|NCT04615884|Other|Placebo capsules|Placebo
75542626|NCT05335044|Drug|CKD-331|QD, PO
75542627|NCT05335044|Drug|EX5619|QD, PO
75388600|NCT01868646|Drug|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
75542628|NCT05332275|Behavioral|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
75542629|NCT05332275|Behavioral|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and followup to address potential contamination effects across study arms.
75542630|NCT05312047|Procedure|Pelvic organ prolapse surgery|Vaginal surgery of any compartment for pelvic organ prolapse
75706328|NCT00859846|Procedure|Arterial line placement|"The following measures will be collected and compared.~Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~number of attempts, defined as forward advancements of needle, required to cannulate the artery.~number of separate skin punctures.~number of arteries into which entry is attempted."
75388601|NCT01868646|Drug|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
75388602|NCT01852110|Drug|MK-7622|MK-7622 capsule
75388603|NCT01852110|Drug|Placebo|Matching placebo to MK-7622 capsule
75388604|NCT01852110|Drug|AChEI|"One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally"
75388605|NCT01851720|Drug|Low dose fentanyl PCA|
75388606|NCT01851720|Drug|Standard IV fentanyl bolus|
75388607|NCT01851330|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
75388608|NCT01851330|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75388609|NCT01868022|Drug|GSK3052230|A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
75388610|NCT01868022|Drug|paclitaxel|paclitaxel will be from commercial stock.
75388611|NCT01868022|Drug|carboplatin|carboplatin will be from commercial stock.
75706329|NCT00723866|Other|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
75706330|NCT00723866|Other|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
75388612|NCT01868022|Drug|docetaxel|docetaxel will be from commercial stock.
75388613|NCT01868022|Drug|pemetrexed|pemetrexed will be from commercial stock
75388614|NCT01868022|Drug|cisplatin|cisplatin will be from commercial stock
75388615|NCT01850004|Drug|Dasatinib|
75388616|NCT01867710|Drug|Abiraterone Acetate|Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
75388617|NCT01867710|Drug|Prednisone 5 mg twice daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
75388618|NCT01867710|Drug|Prednisone 5 mg once daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
75388619|NCT01867710|Drug|Prednisone 2.5 mg twice daily|type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
75388620|NCT01867710|Drug|Dexamethasone 0.5 mg once daily|type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
75388621|NCT01849848|Drug|SyB L-0501|The administration of SyB L-0501 at 90 mg/m^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
75388622|NCT01849458|Device|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
75388623|NCT04415034|Other|VAS and 5-D itch pruritus assessment|All subjects were evaluated for presence of pruritus using VAS and 5-D itch scale
75388624|NCT01832766|Drug|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
75388625|NCT01832766|Other|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
75388626|NCT01832532|Drug|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
75388627|NCT04414956|Diagnostic Test|AFP-L3|AFP-L3 will be tested using serum sample every 6 months.
75388628|NCT04414956|Diagnostic Test|AFP|AFP will be tested using serum sample every 6 months.
75388629|NCT04414956|Diagnostic Test|PIVKA-II|PIVKA-II will be tested using serum sample every 6 months.
75388630|NCT04414956|Diagnostic Test|Sonography|Sonography will be tested by experts every 6 months.
75388631|NCT04414956|Diagnostic Test|CT|Contrast-enhanced CT will be tested annually.
75706331|NCT04069182|Behavioral|Behavioral Activation Therapy|Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.
75706332|NCT00850252|Device|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
75388632|NCT04589910|Diagnostic Test|diaphragm thickness and thickening fraction|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
75388633|NCT04415112|Behavioral|Mediterranean Diet|A list of foods high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, moderate consumption of fish and poultry and low consumption of full fat dairies, red meat and its products and homemade sweets.
75706333|NCT00853294|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
75388634|NCT04415112|Behavioral|Low Fat Diet|These children are forbidden to eat high-fat foods such as fried foods, butter, cream cheese, while foods such as fruits, vegetables (starchy and non-starch), cereals, poultry, lean meat and low-fat dairy products are allowed.
75388635|NCT01848990|Drug|Commercial Hylenex® recombinant (hyaluronidase human injection)|
75869431|NCT04644172|Behavioral|Instrumental Activities of Daily Living Shaping|In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
75388636|NCT01848990|Drug|Precommercial Hylenex recombinant (hyaluronidase human injection)|
75388637|NCT01848990|Drug|Insulin lispro|
75388638|NCT01848990|Drug|Insulin aspart|
75388639|NCT01848990|Drug|Insulin glulisine|
75388640|NCT01867086|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
75388641|NCT01867086|Drug|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
75706334|NCT00853294|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
75388642|NCT01867086|Drug|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
76033199|NCT04958525|Procedure|Small bone window craniotomy for hematoma removal under microscope|Small bone window craniotomy for hematoma removal under microscope:Small bone window craniotomy in frontotemporal region, no blood vessels and non-functional areas of the hematoma nearest to the cortex was cut open, the hematoma was removed under the microscope and the cavity of the hematoma was washed with warm saline, and bipolar electrocoagulation hemostasis was performed for active bleeding.An indwelling drainage tube was placed in the hematoma cavity and the operation was completed without active bleeding.
75706335|NCT00717834|Biological|Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant|Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
75388643|NCT01831596|Device|ciSNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
75388644|NCT01848834|Biological|Pembrolizumab|IV infusion
75388645|NCT01867008|Device|Nucleus CI422 Cochlear Implant with N6 Sound Processor|
75388646|NCT01848756|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
75388647|NCT04594434|Other|Scale SUD|Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
75388648|NCT04594434|Other|VOC scale|The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
75388649|NCT04594434|Other|DES II scale|The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
75388650|NCT01830972|Drug|SA-ER 500 mg|oral tablets
75388651|NCT01830972|Drug|SA-IR 500 mg|oral capsules
75542631|NCT05286177|Procedure|Volume-based EN|Bedside nurses will receive a total daily feed volume prescription to be administered to the participant over a 24-hour period. The bedside nurse will calculate the initial hourly rate by dividing the total daily feed goal by 24 hours at approximately 0700 hours. In this intervention group, they will be instructed to titrate the rate of feeds to accommodate for any feeding interruptions as follows: When feeds are held for > 1 hour, the remaining daily feed volume will be divided by the remaining number of hours. A maximum infusion rate will be set at 2 times the patient's baseline 24-hour feed rate to ensure that a large bolus volume of feed is not administered over a too short period of time.
75542632|NCT05286177|Procedure|Rate-based EN|Bedside nurses will receive an hourly feed rate prescription to administer the tube feedings over a 24-hour period. If feeds are held, they will be restarted at the same consistent hourly rate that was previously ordered. Nurses will not adjust feed rates to compensate for feed interruptions
75542633|NCT05250947|Device|Angel® Concentrated Platelet Rich Plasma System|Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.
75706336|NCT00658359|Drug|Cyclosporine|Standard of care
76033200|NCT02642107|Radiation|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
75706337|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
75706338|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
76033201|NCT02642107|Radiation|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
76033202|NCT04948385|Drug|Propofol|deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
76033203|NCT04948385|Procedure|No sedation|No sedation
76033204|NCT03057821|Other|3% hydrogen peroxide|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
75388652|NCT01848288|Device|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
75388653|NCT01848288|Device|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
75388654|NCT01848210|Drug|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
75388655|NCT01848210|Drug|Placebo|Coumarin + troxerutin placebo-matching tablets
76033205|NCT04947761|Drug|modified Tian Wang Bu Xin Dan hydrogel patch|modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
76033206|NCT04947761|Other|placebo patch|placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
75388656|NCT01830816|Drug|Ixazomib|Ixazomib capsules
75388657|NCT01846416|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
75388658|NCT01865448|Dietary Supplement|Omega-3 DHA|Patients take daily 2 tablets of Docosahexaenoic Acid
75388659|NCT01865448|Other|Placebo|Patients in control group take daily 2 placebo capsule
75388660|NCT04414878|Device|VitaFlow™ II Transcatheter Aortic Valve System|VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
75388661|NCT01846104|Biological|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
75388662|NCT01803282|Drug|Andecaliximab|Administered intravenous infusion
75388663|NCT01803282|Drug|Gemcitabine|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
76033207|NCT04958213|Drug|Dextrose prolotherapy injection|15% dextrose prolotherapy injection into the knee and 15% dextrose prolotherapy injection will be applied to the painful adhesions of the ligaments around the knee.
76033208|NCT04958213|Combination Product|conventional physical therapy|4 weeks (20 sessions) physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises).
76033209|NCT04958135|Drug|Acoramidis|Film-coated immediate release oral tablet.
76033210|NCT04948151|Drug|Sildenafil|Patients will apply 2-gram applications up to 9 times per month.
76033211|NCT04948151|Drug|Placebo|Patients will apply 2-gram applications up to 9 times per month
76033212|NCT04939493|Other|Rhythmic Auditory Cueing|"Patients will perform the same movement sequence in time with the metronome beat. The frequency of the rhythmic auditory stimulation will be matched to the participants preferred movement speed, which will be assessed prior to the start of the trial, and participants typically started moving after they had heard the metronome beat two to three times. Participants will be given sufficient practice trials to ensure full understanding before the actual recording of data, and will be given 3-minutes break between trials.~On the 3rd and 5th week, the rhythm frequency was increased by 5%."
76033213|NCT04939493|Other|Bilateral arm training|Training will consist of 20 minutes of bilateral arm training In each session, patients will be seated comfortably at a table in the following limb positions: ankles in neutral dorsiflexion, knees and hips placed at 90°, shoulders in 0° flexion, elbows in 60° flexion, and wrists in neutral position of flexion/extension
76033214|NCT04939493|Other|Conventional physical therapy program|Scapular mobilization. Thoracic spine mobilization. Mechanical assisted (active and passive) exercises. Therapeutic positioning as weight bearing on the paretic arm. Opening and closing closed fist. Strengthening exercise. Stretching of spastic muscles.
76033215|NCT04947995|Device|ctDNA multi-omics test|The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.
76033216|NCT04939337|Drug|TH-SC01|Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
75388664|NCT01803282|Drug|Nab-paclitaxel|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
75388665|NCT01803282|Drug|Carboplatin|Administered intravenously on Day 1 of each 21-day treatment cycle
75388666|NCT01803282|Drug|Pemetrexed|Administered intravenously on Day 1 of each 21-day treatment cycle
75388667|NCT01803282|Drug|Leucovorin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
75388668|NCT01803282|Drug|Oxaliplatin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
75388669|NCT01803282|Drug|5-FU|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
75388670|NCT01803282|Drug|Bevacizumab|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
75388671|NCT01803282|Drug|Irinotecan|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
75388672|NCT01803282|Drug|Paclitaxel|Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
75869432|NCT04644172|Behavioral|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
75388673|NCT01844778|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
75388674|NCT01844778|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
75388675|NCT01844778|Drug|Colistimethate|Colistimethate was administered via nebuliser.
75388676|NCT01802580|Behavioral|Internet Survey|
75388677|NCT01802580|Drug|fluocinonide 0.05% ointment|
75388678|NCT01802346|Dietary Supplement|dietary intervention|Consume a low-calorie diet
75388679|NCT01802346|Procedure|nutritional support|Receive dietary advice
75388680|NCT01802346|Other|laboratory biomarker analysis|Correlative studies
75388681|NCT01611090|Drug|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
75388682|NCT01611090|Drug|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
75388683|NCT01611090|Drug|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
75542634|NCT05250791|Drug|Lidocaine hydrochloride 2% for injection|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
75869433|NCT04644172|Other|Usual Care|Healthcare that is available for adults with cognitive impairment subsequent to COVID-19 in the community on a clinical basis. This includes commercially available, gamified, computerized cognitive training programs.
75388684|NCT01611090|Drug|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
75388685|NCT01844700|Drug|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
75388686|NCT01844700|Drug|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
75388687|NCT01844076|Drug|Quinacrine and Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
75542635|NCT05250791|Drug|0.9% sterile Sodium Chloride solution for injection|Administered as lidocaine
75542636|NCT05230342|Dietary Supplement|A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.
75542637|NCT05230342|Other|Placebo ingredient group|The control group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
75706339|NCT00721266|Drug|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
75706340|NCT00853450|Drug|AZD6482|Single intravenous infusion during a maximum of 5 hours
75706341|NCT00853450|Drug|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
75706342|NCT00853450|Drug|ASA|75 mg orally once daily during 7 days in each treatment arm
75706343|NCT04066790|Drug|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
75869434|NCT04634240|Procedure|Percutaneous Coronary Intervention (PCI)|PCI of all qualifying lesions.
75869435|NCT04631484|Drug|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.
75869436|NCT04631484|Drug|Placebo|20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days
75388688|NCT01826604|Device|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
75388689|NCT01826604|Other|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
75388690|NCT01843842|Drug|Ergoferon|Safety and Efficiency of liquid dosage form
75869437|NCT04630418|Other|NanoSilk Cosmo|Participant will receive 30 mL of NanoSilk Cosmo jar.
75388691|NCT01843842|Drug|Placebo|Safety and Efficiency of liquid dosage form
75388692|NCT01826448|Drug|PLX3397|
75388693|NCT01826448|Drug|vemurafenib|
75869438|NCT04608903|Dietary Supplement|L-sulforaphane 1%|Administration of 4g L-Sulforaphane per day, for 2 months
75869439|NCT04608903|Dietary Supplement|Placebo Group|Administration of 4g corn starch colored with chlorophyll, per day, for 2 months
75869440|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
75869441|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
75869442|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
75869443|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
75869444|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
75388694|NCT01826370|Drug|Linagliptin|tablet
75388695|NCT01826214|Drug|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
75388696|NCT04582344|Biological|CoronaVac|Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
75388697|NCT04582344|Biological|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
75388698|NCT01843062|Drug|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
75388699|NCT01843062|Drug|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
75706344|NCT04066790|Drug|nab-Paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
75869445|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
75388700|NCT01843062|Drug|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
75388701|NCT01842438|Behavioral|Behavioral: psychosexual intervention|6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
75542638|NCT05200520|Behavioral|Appetite Self-Regulation Intervention|The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
75542639|NCT05197322|Drug|Pembrolizumab|Dose: 200mg by IV infusion on Day 1 of each treatment cycle
75542640|NCT05192356|Drug|CKD-348(3)|QD, PO
75542641|NCT05192356|Drug|CKD-828, D097, D337|QD, PO
75557841|NCT00439829|Drug|Gonal F|"450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
75869446|NCT04577573|Device|Cognition glove|The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
75388702|NCT01799226|Other|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
75388703|NCT01799226|Other|Triclosan|this intervention will use Colgate Total which contains triclosan
75388704|NCT01825200|Biological|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
75388705|NCT01825200|Biological|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
75388706|NCT01824576|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
75388707|NCT01824498|Other|Low Fat diet|Low fat diet = 20% fat
75388708|NCT01824498|Other|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
75388709|NCT01824498|Other|High Fat Diet|High Fat Diet = 40% fat
75706345|NCT04066790|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
75388710|NCT01798134|Device|TANDEM™|
75388711|NCT01798056|Biological|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
75869447|NCT04577573|Device|Sensory brace|"A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns"
75388712|NCT01798056|Drug|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
75388713|NCT01824342|Biological|Denosumab|Administered by subcutaneous injection
75388714|NCT01841970|Device|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
75706346|NCT04066790|Drug|EC chemotherapy|epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
75706347|NCT04066790|Procedure|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
76033217|NCT04939025|Procedure|Multi-interventional program|"Preoperative oral antibiotics and antibiotic enema of the rectal stump prior to the surgery~Routine and tailored lengthening measures of the mesentery~Intraoperative control of pouch vascularization using ICG~Early diagnosis and active assessment of the integrity of the anastomosis.~Routine CRP-measurements at day 4 and 6 (after removal pouch catheter) in the non-diverted pouches with CT-scan with rectal contrast if any suspicion on a leak (elevated or rise in CRP. symptoms).~Routine CRP-measurements at day 4 in the diverted pouches with endoscopy 10-14 days after pouch creation.~Endosponge vacuum assisted closure (EVAC) of the anastomotic defect aiming to close the defect within 10-14 days after diagnosis.~MRI assessment of the pouch after stoma closure preferably at one year to rule out chronic sepsis mimicking pouchitis or Crohn's disease."
75388715|NCT01823328|Drug|Ketamine|Subjects will receive ketamine for sedation prior to rapid sequence intubation.
75388716|NCT01823328|Drug|Etomidate|Subjects will receive etomidate for sedation prior to rapid sequence intubation.
75388717|NCT01840410|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
75388718|NCT01840410|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
75388719|NCT01797432|Drug|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
75388720|NCT01797432|Device|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
75388721|NCT01797120|Drug|Fulvestrant|"Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
75388722|NCT01797120|Drug|Everolimus|"Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
75388723|NCT01797120|Drug|Placebo|Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
75706348|NCT03477552|Device|Accuvein V400 device|Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network
75869448|NCT04574362|Drug|Rimegepant|One 75mg orally disintegrating tablet
75869449|NCT04574362|Drug|Placebo|Matching placebo
75869450|NCT04570956|Drug|Tamoxifen|Oral Tamoxifen 10 mg/day
76033218|NCT04947371|Drug|Anlotinib Hydrochloride|Oral anlotinib hydrochloride 12 mg/d
76033219|NCT04957121|Other|on-hours|"If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours."
75388724|NCT01796964|Drug|ESBA1008 solution|For intravitreal (IVT) injection
75388725|NCT01796964|Drug|Aflibercept|For intravitreal (IVT) injection
75542642|NCT05187000|Device|individualized repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 10 consecutive sessions (one session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
75869451|NCT04570956|Drug|Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
75869452|NCT04570956|Drug|Placebo|placebo pill or placebo gel
75388726|NCT01838694|Biological|Ala-Cpn10|
75388727|NCT01838694|Drug|Placebo|
75869453|NCT04566887|Drug|Acalabrutinib|Administered as 100mg tablets.
75869454|NCT04566887|Drug|R-CHOP chemotherapy|R-CHOP chemotherapy
75869455|NCT04564027|Drug|Ceralasertib|Tablets will be administered orally
75869456|NCT04562896|Device|Custom Carbon Fiber Dynamic Orthosis (CDO)|The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
75388728|NCT01795638|Drug|Sodium chloride|
75388729|NCT01795638|Drug|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
75388730|NCT01794780|Drug|LABA based treatment: indacaterol|LABA based treatment: indacaterol
75388731|NCT01794780|Drug|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
75388732|NCT01794780|Drug|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
75388733|NCT01794780|Drug|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
76033220|NCT04957121|Other|off-hours|"If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours."
76033221|NCT02633293|Drug|Inhaled Treprostinil|Inhaled treprostinil up to 15 breaths (90 mcg) four times daily
76033222|NCT04938713|Drug|Ketamine 50 MG/ML|Intravenous Ketalar® 0,30 mg/kg in 1 hour.
76033223|NCT04938713|Drug|Esketamine 25 MG/ML|Intravenous Vesierra® 0,15mg/kg in 1 hour.
76033224|NCT04938401|Other||
76033225|NCT04938011|Drug|progesterone|the transfer of day 6 blastocyst on the 6th day of progesterone supplementation
76033226|NCT04938011|Drug|progesterone|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
76033227|NCT04296019|Drug|Fruquintinib|Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
76033228|NCT04947215|Diagnostic Test|stress biomarkers|used to estimate the reference values of putative biomarkers of birth stress such asCTnT, CTnI, copeptin, NT-proBNP and hs-CRP in the cord blood of full term neonates
76033229|NCT05115565|Device|TENS (Transcutaneous Electrical Nerve Stimulation) Application|Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
75388734|NCT01794780|Drug|theophylline based treatment|theophylline based treatment
75706349|NCT03477552|Other|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
75706350|NCT00860080|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
75706351|NCT00860080|Drug|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
76033230|NCT03057665|Device|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
75388735|NCT01794780|Drug|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
75388736|NCT04587726|Behavioral|Girl's room video|"Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~Appearance comparison~Body appreciation~Body talk~Body functionality~Appearance teasing & bullying~Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020."
76033231|NCT04677907|Device|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
76033232|NCT04677907|Device|Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
75388737|NCT04587726|Other|Control video - Chicken Girls|Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
75388738|NCT01838616|Drug|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
76033233|NCT03057509|Drug|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
76033234|NCT03057509|Device|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
76033235|NCT03057509|Other|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
75388739|NCT01838616|Drug|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
75542643|NCT05187000|Device|Sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.
75706352|NCT00721604|Drug|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
75706353|NCT00850330|Other|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
75706354|NCT02571192|Drug|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
75706355|NCT02571192|Radiation|5.95 μCi RAD|
76033236|NCT03057509|Drug|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
75706356|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
75706357|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
75706358|NCT00724022|Drug|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
76033237|NCT05115487|Diagnostic Test|digital dynamometer|Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
75542644|NCT05160012|Behavioral|Peer Comparison Message|"In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~If HTN control rate <50th percentile, PCP is told they are below median~If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~If HTN control rate is between 90-100th percentile, PCP is told they are a high performer"
76033238|NCT04957199|Other||
75542645|NCT05148065|Device|BIS|Bispectral index monitoring
75542646|NCT05148065|Device|PSi|Patient state index monitoring
75706359|NCT00850408|Procedure|Repetitive Transcranial Magnetic Stimulation|For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
75706360|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
76033239|NCT04436887|Procedure|positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia|Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies >20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
75542647|NCT05145764|Drug|Suvorexant|Encapsulated suvorexant (matched for color, weight, and size)
75542648|NCT05145764|Drug|Placebo|Encapsulated placebo (matched for color, weight, and size)
75542649|NCT05142826|Behavioral|Relative Age Effect Intervention|School-based consultation to establish a developmentally appropriate daily behavior report; teacher education regarding developmentally appropriate behaviors; teacher consultation to promote positive behavior supports.
75542650|NCT05142826|Other|School as Usual|Interventions and supports as provided through usual care
75542651|NCT05128812|Dietary Supplement|PLX|Intake of natural food supplement of vegetable origin based on lemon verbena extract (Lippia citriodora). To study the anxiolytic effects in subjects with high perceived stress levels and low sleep quality.
75542652|NCT05123235|Behavioral|Physical Activity|the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.
75542653|NCT05113693|Drug|CKD-393|QD, PO
75542654|NCT05113693|Drug|CKD-501, D759, H053|QD, PO
75706361|NCT00721344|Drug|Moxifloxacin|Tablets 400mg
75706362|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
75706363|NCT00721344|Drug|Placebo|Placebo cartridges
75542655|NCT05087342|Drug|Semaglutide 2.4mg|The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
76033240|NCT05115175|Behavioral|Mindfulness-Based Stress Reduction|Participants engaged in meditation and self-led exercises to help them understand and cope with stress.
75542656|NCT05087342|Drug|Placebo|A placebo will be given to the control group per the schedule outlined in the armed description.
75542657|NCT05086432|Other|Sputum-guided management|As previously described.
75542658|NCT05086432|Other|Standard of Care|As previously described.
75542659|NCT05085496|Biological|Atezolizumab|Given IV
75542660|NCT05085496|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75542661|NCT05078476|Other|Manchester Short Splint|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
75706364|NCT00717990|Drug|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
75542662|NCT05078476|Other|Relative Motion Flexion|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
75542663|NCT05060146|Other|Structured medico-pharmaceutical collaboration|Reconciliation of drug treatments; Writing of the prescription for discharge from hospital for the pneumococcal vaccine; Pharmaceutical interview at discharge; Drafting of the discharge letter and transmission to the attending physician; Writing of the pharmaceutical discharge letter and transmission to the pharmacist; Pharmaceutical dispensing in the pharmacy; Administration of the vaccine by the attending physician or a nurse at home.
75542664|NCT05044715|Behavioral|Treatment as Usual|"Treatment as usual-TAU groups include:~Mood Groups - General Process Groups~Anxiety Groups - Cognitive Behavioral Therapy~Body Image and Eating Concerns Groups~Reconciling Faith and Sexuality Groups"
75706365|NCT00717990|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
75706366|NCT00717990|Drug|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
75706367|NCT00853528|Other|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
75706368|NCT00853528|Procedure|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
76033241|NCT03800329|Device|Snap40 Monitor|Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
76033242|NCT03800329|Other|No Monitor|Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
76033243|NCT04946513|Other|Muscle volumes were measured on pre- and postoperative MRI scans.|Muscle volumes were measured on pre- and postoperative MRI scans.
76033244|NCT03058133|Other|fMRI study|Functional brain activations of face-voice processing during a gender task
75869457|NCT04562688|Other|CICADAS and then PEERS|Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. After 16 weeks, participants will then crossover to PEERS, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians.
76033245|NCT04798495|Other|Multimodal interdisciplinary rehabilitation programme (HAPPY)|A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
75542665|NCT05044715|Behavioral|Compassion-Focused Therapy (CFT)|The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
76033246|NCT05114707|Drug|camrelizumab|Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.
76033247|NCT04937621|Diagnostic Test|ECG data analysis|Baseline ECG as well as follow-up ECG are analysed
76033248|NCT04937621|Drug|Treatment data collect|Baseline treatment data as well as follow-up treatment data are collected
76033249|NCT04937621|Biological|Biological check-up data collect|Baseline Biological check-up data as well as follow-up data are collected
76033250|NCT04937621|Other|Collection of clinical events of interest|Clinical events of interest at the baseline as well as follow-up clinical events are collected
76033251|NCT04937855|Other|no intervention|no intervention
75542666|NCT05035095|Drug|Oral semaglutide|Participants will receive a daily dose of oral semaglutide.
75542667|NCT05035095|Drug|Placebo (semaglutide)|Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
75542668|NCT04983836|Procedure|Serratus anesthesia technique|locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml
75706369|NCT00853528|Procedure|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
75706370|NCT00853528|Radiation|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
76033252|NCT03572413|Procedure|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
76033253|NCT03572413|Drug|Rocuronium bromide|Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
76033254|NCT04946747|Device|Modern microelectrical mechanical systems (MEMS) head-impact sensors|Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.
75706371|NCT00853528|Radiation|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
75706372|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
75706373|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
75706374|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
75706375|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
76033255|NCT04946747|Other|Virtual Reality (VR) Goggle Use with consistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
76033256|NCT04946747|Other|Virtual Reality (VR) Goggle Use with inconsistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Control group will also receive the same CS and the same US as trained group, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge.
76033257|NCT04937933|Drug|Coolant spray (Cryos ®Spray, Phyto Performance, Italy)|The coolant spray treatment method is a cryotherapy non-pharmacological treatment choice.
76033258|NCT04937933|Drug|Saline solution|saline solution
76033259|NCT04956419|Drug|SHR8008 capsule|once daily for 2 days(Day 1 and Day 2),oral
76033260|NCT04956419|Drug|Fluconazole capsule|once daily for 2 days(Every 72 hours) ,oral
75542669|NCT04983836|Procedure|Paravertebral anesthesia technique|Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
75542670|NCT04971967|Combination Product|Crowdsourced partner services intervention|The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
75542671|NCT04950985|Other|Observational Study|Observational study
75542672|NCT04933383|Drug|AQ001S 0.125 mg/ml|administered by nebulization once daily
75542673|NCT04933383|Drug|Budesonide 0.125 mg/ml inhalation suspension|administered by nebulization once daily
75542674|NCT04923906|Drug|Aumolertinib|"Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4~6 cycles, followed by Aumolertinib daily with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity."
75542675|NCT04923906|Drug|Placebo Aumolertinib|Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
75542676|NCT04923776|Drug|Carboplatin|The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
75542677|NCT04923776|Drug|Etoposide|The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
75706376|NCT04878302|Behavioral|Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training)|Families assigned to the immediate treatment group will receive the telehealth-based Taming Tics Together protocol(created using well-established, evidence-based treatment protocols), which includes group (parent/caregiver-only, child/teen-only) and individualized one-to-one sessions to address tics and co-occurring diagnoses.
75706377|NCT00850486|Device|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
76033261|NCT04956653|Other|Without additional intervention|Only patients' information was collected
75706378|NCT02572986|Drug|Permethrin|
75542678|NCT04923776|Drug|Atezolizumab|The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
76033262|NCT04615429|Biological|Mesenchymal stromal cells|Administration of one single dose of allogenic Mesenchymal stromal cells
76033263|NCT04615429|Other|Placebo|Administration of placebo (solution identical to experimental treatment, without the MSC)
75869458|NCT04562688|Other|PEERS + CICADAS and then no-contact|Participants will complete both PEERS and CICADAS study activities. Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
76033264|NCT04956965|Radiation|Cardiac electro-mapping|Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
76033265|NCT05114395|Other|Pelvic Floor Telerehabilitation Program|See experimental and active comparator arms.
76033266|NCT05114395|Other|Pelvic Floor Face-to-Face Program|See experimental and active comparator arms.
76033267|NCT04946669|Drug|Abatacept|Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
76033268|NCT04956497|Device|extracorporeal membrane oxygenation (ECMO)|ECMO under ongoing cardiopulmonary resuscitation (eCPR) in patients with refractory cardiac arrest
76033269|NCT03219775|Biological|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)*~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~since June 5, 2019, the treatment in all four boost cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)"
76033270|NCT04409015|Device|ROTEM - rotation thromboelastometry testing|The ROTEM® is a simple blood test that provides information about specific components involved in blood clotting and stopping hemorrhage.
75542679|NCT04923776|Radiation|Stereotactic Body Radiation Therapy (SBRT)|This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
75542680|NCT04903691|Behavioral|Cardiac Exercise Program|Participants who enrolled in cardiac exercise program
75706379|NCT00853684|Drug|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
75706380|NCT00853684|Drug|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
76033271|NCT04946045|Other|Sensorimotor Interventions (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking)|"Sensorimotor interventions were applied to in preterm infants between 30-33 weeks of age for 10 days. After that, preterms were included in the Six-phase feeding progression protocol."
75706381|NCT00853918|Other|$20 cash|$20 cash incentive mailed with survey
76033272|NCT03057587|Device|NIRS Monitoring|NIRS data will be collected throughout the surgery
76033273|NCT03100045|Drug|Artesunate Suppositories|Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
76033274|NCT04946123|Dietary Supplement|L-carnitine+Selenium|Supplementation with L-carnitine and Selenium
76033275|NCT04945889|Diagnostic Test|Quick Sequential Organ Failure Assessment (qSOFA)|Clinical bedside tool that evaluates three vital parameters, scoring one point each if altered: respiratory rate (RR) ≥22 breaths/minute, systolic blood pressure (SBP) ≤100 mmHg and altered mental status (defined in our study as either Glasgow Coma Scale (GCS) score <15 or any worsening in the Italian Oriented, Disoriented, Agitated, Sleepy scale). A qSOFA score ≥2 points is considered indicative of sepsis.
76033276|NCT04945889|Diagnostic Test|Modified Early Warning Score (MEWS)|Clinical bedside tool that evaluates five vital parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), body temperature (0-2 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A MEWS score ≥5 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
76033277|NCT04945889|Diagnostic Test|National Early Warning Score (NEWS)|Clinical bedside tool that evaluates seven parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), oxygen saturation (0-3 points), need for any supplemental oxygen (0-2 points), body temperature (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A NEWS score ≥7 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
76033278|NCT04945811|Diagnostic Test|Interlukein 6 and procalcitonin serum levels|Blood tests
76033279|NCT04955561|Other|Oxygen therapy|Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
76033280|NCT04955561|Other|Medical Air|Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
75706382|NCT00853918|Other|$50 cash|$50 cash incentive mailed with survey
75706383|NCT00853918|Other|$50 check|$50 check incentive mailed with survey
75706384|NCT00853918|Other|$100 check|$100 check incentive mailed with survey
75706385|NCT02570360|Behavioral|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
75706386|NCT02570360|Behavioral|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
75706387|NCT00723060|Drug|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
76033281|NCT04955561|Other|10L/min O2|Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
76033282|NCT04945577|Diagnostic Test|Inflammatory Parameters|Laboratory measurement of patient's inflammatory status in unit of % and mg/dl
76033283|NCT04945577|Other|25 OH Vitamin D Level|Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
76033284|NCT04945343|Procedure|Growing Rods|Growing Rods(GR), are implants used to correct pediatric scoliosis deformity. They attempt to allow the growth of the spine and thorax while controlling curve progression to preserve normal lung volume.
76033285|NCT02623829|Drug|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
76033286|NCT02623829|Drug|Saline|1ml of normal saline will be administered
76033287|NCT04945499|Drug|d-glucose|using d-glucose as an contrast agent on CEST MR Imaging
76033288|NCT04944875|Procedure|Group headphone|The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
76033289|NCT04944875|Procedure|Group music|The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
76033290|NCT04944875|Procedure|Group maternal voice|The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
76033291|NCT02655679|Drug|VTP-38543|VTP-38543 topical cream
76033292|NCT02655679|Other|Vehicle with Transcutol®P|Vehicle matching VTP-38543 cream with Transcutol®P
76033293|NCT02655679|Other|Vehicle without Transcutol®P|Vehicle matching VTP-38543 cream without Transcutol®P
76033294|NCT04936295|Drug|Fulvestrant plus Anlotinib|Each patient receives Fulvestrant (500mg delivered by intramuscular injection every 4 weeks) plus Anlotinib(20mg taken orally for 14 days and stop for 7 days in one cycle)
76033295|NCT04955873|Device|Treatment of the dental extraction socket using newly-released biomaterials|Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.
75706388|NCT00860236|Other|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
76033296|NCT04955873|Device|Treatment of the dental extraction socket using well-known biomaterials|Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane
76033297|NCT05114239|Drug|Timolol 0.25% Ophthalmic Solution|Applied to treatment side prior to standard wound care
76033298|NCT05114239|Other|Standard Wound Care|Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
76033299|NCT05114083|Other|symptom assessment|symptom assessment
76033300|NCT04945031|Other|cannabis|This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
76033301|NCT05113849|Biological|IN-B009 (Low-dose)|Two doses, intramuscular injection
75542681|NCT04902521|Device|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (TMS) is a safe non-invasive technique that stimulates the brain using repetitive magnetic pulses to enhance neuroplasticity. TMS has been shown to produce lasting modulation of cortical activity and improve clinical symptoms of children with neurodevelopmental disorders including CP
75542682|NCT04902521|Device|Sham Transcranial Magnetic stimulation|Sham Transcranial Magnetic stimulation will be given to the control group. During the Sham procedure patients will sit near the TMS but will not receive any magnetic pulses.
76033302|NCT05113849|Biological|IN-B009 (High-dose)|Two doses, intramuscular injection
76033303|NCT04935827|Other|Season of Year|"We stratify patients into 4 groups based on the season of the year (between 12/1/2007-11/30/2017)~Winter: December, January, February~Spring: March, April, May~Summer: June, July, August~Fall: September, October, November"
76033304|NCT04935827|Other|Hospitalized 14 days prior to dialysis|"We further stratify patients into 3 groups based on whether they were hospitalized within 14 days prior to dialysis~Group 1: No hospitalization prior to dialysis~Group 2: Hospitalized within 14 days prior to dialysis for an acute infectious respiratory condition or one of the following acute cardiac conditions (arrhythmia, myocardial infarction, stroke, or fluid overload)~Group 3: Hospitalized within 14 days prior to dialysis for a condition not in Group 2"
76033305|NCT04944719|Diagnostic Test|nasopharyngeal aspirate|nasopharyngeal aspirate to determinate colonization by streptococcus pneumoniae
76033306|NCT04469725|Drug|KN046|KN046 5 milligram per kilogram, every 2 weeks
75388740|NCT01611792|Other|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
75388741|NCT01611792|Other|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
76033307|NCT04418999|Drug|dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use|Experimental
76033308|NCT04418999|Drug|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Active Comparator
76033309|NCT04427527|Behavioral|Multi-level intervention to increase CRC screening|Intervention for the community, providers, patients, clinics and systems
75388742|NCT01820364|Drug|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
76033310|NCT02623361|Drug|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
76033311|NCT02623361|Drug|Sham Block|Sham Block by saline injection
76033312|NCT05113459|Drug|Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy|disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
75388743|NCT01819506|Behavioral|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
76033313|NCT04944485|Other|(FIT SA F03, SHOFU, USA)|Self adhesive giomer containing nanohybrid flowable composite
76033314|NCT04944485|Other|(Neo Spectra™ ST, Dentsply, Sirona, USA)|Conventional technique using putty nanohybrid resin composite
75388744|NCT01794000|Drug|Prasugrel|Administered orally
75388745|NCT01794000|Drug|Placebo|Administered orally
75388746|NCT01609296|Device|IN.PACT Admiral™ Drug Eluting Balloon|IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
75388747|NCT01609218|Drug|LY2140023|
75542683|NCT04902144|Other|Electronic Health Record Review|Medical data collected
75542684|NCT04902144|Other|Questionnaire Administration|Complete questionnaires
75542685|NCT04902144|Behavioral|Behavioral Intervention|Receive coaching
75706389|NCT00860236|Behavioral|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
75388748|NCT01609218|Drug|Aqueous activated charcoal|
75388749|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
75388750|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
75388751|NCT04580472|Drug|Cephalexin|If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
75388752|NCT04580472|Other|Placebo capsules|Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.
75388753|NCT01819272|Drug|Met DR|metformin delayed-release tablets
75388754|NCT01819272|Drug|Met XR|metformin extended-release tablets
75388755|NCT01819272|Drug|Placebo|placebo delayed-release tablets
75388756|NCT01819194|Device|senofilcon A|
75388757|NCT01611558|Biological|Ipilimumab|
75388758|NCT04579926|Other|Pinpoint app|Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.
75542686|NCT04871542|Procedure|Biospecimen Collection|Undergo collection of blood sample
76033315|NCT04935983|Other|High CHO|Diet with high carbohydrate content
76033316|NCT04935983|Other|Low CHO|Diet with low carbohydrate content
76033317|NCT04935749|Device|Ultra wide-field retinal imaging|Diabetic patients will be imaged with an ultra wide-field retinal imaging device (Optos, California). Patients will be imaged either with or without mydriasis.
76033318|NCT05113147|Other|In-depth individual interviews|In-depth individual interviews were based on a semistructured script designed to investigate the perceptions of the participants about the activity they performed, the ideal working conditions, the presence of disruptive behaviors, and their management.
76033319|NCT04955483|Diagnostic Test|Virtual single energy combined with MAR reconstruction group|combined with MAR reconstruction group
76033320|NCT04447963|Device|Non-invasive treatment of facial wrinkles|Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
76033321|NCT04933019|Genetic|Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|Detection of Clindamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
76033322|NCT04955093|Device|Biofeedback|Technology to provide Heart Rate Variability Biofeedback
76033323|NCT04935281|Other|percutaneous repair with an intraoperative assisted ultrasound|Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .
75388759|NCT04579068|Behavioral|Screening and Brief Intervention of Problematic Alcohol Use|Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
75388760|NCT04577976|Device|SMBG|Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months.
75388761|NCT01818726|Drug|ICL670|ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
75388762|NCT01818726|Drug|Chelation|Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
75388763|NCT01818726|Drug|No chelation|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
75388764|NCT01818336|Drug|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
75542687|NCT04871542|Other|Questionnaire Administration|Complete questionnaires
75557842|NCT00439829|Drug|Luveris|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~leading follicle is > 13 mm in diameter~if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~Dosing to continue until administration of hCG (see below)."
75557843|NCT00439829|Drug|Cetrotide|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~leading follicle is > 13 mm in diameter~if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~Dosing to continue until administration of hCG (see below)."
75557844|NCT00439829|Drug|hCG|"- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o > 3 follicles are > 17 mm in diameter"
75557845|NCT03278769|Procedure|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
75557846|NCT00439868|Drug|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
75542688|NCT04826718|Other|Questionaire|"A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.~Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).~Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls)."
75542689|NCT04822311|Behavioral|Experimental: Investigate the effects of an exercise intervention on retired APF players|Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
75388765|NCT04592640|Other|Human amniotic mesenchymal stem cells|"Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).~Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance)."
75542690|NCT04815824|Behavioral|Exercise Mode|Stationary cycling or treadmill walking
75542691|NCT04791215|Other|Observational|All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
75542692|NCT04744051|Drug|50 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
75542693|NCT04744051|Drug|150 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
75542694|NCT04744051|Drug|300 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
75869459|NCT04562688|Other|PEERS + Active Comparator and then no-contact|Participants will complete both PEERS and Active Comparator study activities. Participants will engage in computerized, casual video games for a total of 40 hours. Participants will also complete the 10 sensory processing abnormalities (SPA) computerized assessments. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
75869460|NCT04551521|Drug|Vemurafenib|960 mg twice daily during run-in Phase, followed by 720 mg twice daily
75869461|NCT04551521|Drug|Cobimetinib|60 mg once daily
75869462|NCT04551521|Drug|Atezolizumab|840 mg every 2 weeks
75869463|NCT04551521|Drug|Trastuzumab|8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
75869464|NCT04551521|Drug|Pertuzumab|840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
75388766|NCT01818258|Drug|ZDV+3TC+LPV/r|
75542695|NCT04744051|Drug|Placebo Infusion|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
75869465|NCT04551521|Drug|Alectinib|600 mg twice daily
75869466|NCT04551521|Drug|Ipatasertib|400 mg once daily
75388767|NCT01817790|Drug|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
75869467|NCT04551521|Drug|Atezolizumab|1200 mg every 3 weeks
75869468|NCT04551521|Drug|Atezolizumab|1200 mg in the first cycle, followed by 840 mg every 3 weeks
75869469|NCT04551521|Drug|Atezolizumab|1,200 mg every 3 weeks
75388768|NCT01817790|Drug|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
75869470|NCT04551521|Drug|Inavolisib|9 mg once daily
75869471|NCT04545762|Drug|Fludarabine|Given intravenously (IV)
75869472|NCT04545762|Drug|Cyclophosphamide|Given intravenously (IV)
75869473|NCT04545762|Biological|anti-CD19 CAR-T cells|Single infusion
75388769|NCT01793688|Drug|Sulbactam Sodium/Ampicillin Sodium|"Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency))."
75388770|NCT01793142|Drug|Viviant|Viviant (Bazedoxifene) 20mg once daily
75869474|NCT04536584|Other|Personalized Coaching (Arm A)|Patients will receive personalized physical activity coaching with an online digital platform to take online educational workshops and interact with other peers of the cohort with a online private forum. They will also have a connected watch that will measure several physical activity metrics.
75869475|NCT04536584|Other|Standard supportive approach (Arm B)|Patients will receive the standard recommendations during their visits with the oncologist. The exercise recommendations include strength training and aerobic activities.
75388771|NCT01792830|Drug|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c < 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
75388772|NCT01792830|Drug|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c > 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
75388773|NCT01792830|Drug|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
75388774|NCT01792518|Drug|Placebo|
75388775|NCT01792518|Drug|Linagliptin 5mg|
75388776|NCT01792284|Drug|LY2605541|
75388777|NCT01792284|Drug|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
75388778|NCT04414566|Drug|gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil|Patients receive GP gemcitabine (1000 mg/m^2 d1,8) and cisplatin (80mg/m^2 d1) or TPF docetaxel (60mg/m^2 on day 1), cisplatin (60mg/m^2 on day 1) and fluorouracil (600mg/m^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
75388779|NCT04414566|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
75542696|NCT04743856|Behavioral|ActiveGOALSv2|13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
75542697|NCT04743856|Behavioral|PAT|Participants will receive a physical activity tracker and encouragement to increase activity.
75869476|NCT04526782|Drug|Encorafenib 75 MG|450 mg (6 × 75 mg capsule) per day
75542698|NCT04716881|Drug|Naltrexone 380 MG|Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days
75557847|NCT00439868|Drug|placebo|Matching placebo tablets to WELLBUTRIN XL.
75869477|NCT04526782|Drug|Binimetinib 15 MG|45 mg (3 × 15 mg tablet) twice daily
75869478|NCT04522973|Other|Beverage with ethanol and E-cigarette liquid with ethanol|Beverage with ethanol and E-cigarette liquid with ethanol
75869479|NCT04522973|Other|Beverage with ethanol and E-cigarette liquid without ethanol|Beverage with ethanol and E-cigarette liquid without ethanol
75388780|NCT04414566|Radiation|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m^2 every 3 weeks for 3 cycles.
75388781|NCT01837914|Procedure|Maxillary expansion|
75388782|NCT01837914|Procedure|Adenotonsillectomy|
75388783|NCT01791894|Drug|arsenic trioxide|Given IV
75388784|NCT04592016|Drug|Voltaren - Diclofenac sodium gel 1% (GSK, USA)|Topical application in dermal-sampling visit
75388785|NCT04592016|Drug|Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)|Topical application in dermal-sampling visit
75388786|NCT04592016|Drug|Diclofenac sodium gel 1% (Perrigo, USA)|Topical application in dermal-sampling visit
75388787|NCT04592016|Device|Dermal open flow microperfusion - Pilot|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 24 hours post-dose.
75388788|NCT04592016|Device|Dermal open flow microperfusion - Pivotal|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose.
75388789|NCT04592016|Procedure|Blood sampling - Pilot|1 sample is taken pre-dose and 24 samples are taken post-dose.
75869480|NCT04522973|Other|Beverage without ethanol and E-cigarette liquid with ethanol|Beverage without ethanol and E-cigarette liquid with ethanol
75388790|NCT04592016|Procedure|Blood sampling - Pivotal|1 sample is taken pre-dose and 12 samples are taken post-dose.
75388791|NCT01837680|Drug|Insulin|
75388792|NCT01836276|Drug|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
75869481|NCT04522973|Other|Beverage without ethanol and E-cigarette liquid without ethanol|Beverage without ethanol and E-cigarette liquid without ethanol
75388793|NCT01790568|Drug|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
75388794|NCT01790568|Drug|Tacrolimus|
75869482|NCT04521608|Behavioral|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
75869483|NCT04484077|Biological|hCT-MSC|2x10^6 hCT-MSC/kg suspended in plasmalyte-A, 5% HSA, and residual DMSO/dextran administered intravenously over 30-60 minutes via syringe pump
75388795|NCT01790568|Drug|Methotrexate|
75388796|NCT01610076|Other|Code Status Video|"10 minute video about Code Status"
75388797|NCT01836198|Drug|LY2409021|
75388798|NCT01836198|Drug|Gemfibrozil|
75388799|NCT01836198|Drug|Ketoconazole|
75388800|NCT01836198|Drug|Clarithromycin|
75542699|NCT04715074|Behavioral|Interviews|We will understand the impact psychosocial, lifestyle, and familial aspects play on an EOCRC diagnosis through 20 one-hour interviews with EOCRC patients and survivors.
75869484|NCT04470908|Drug|Zanubrutinib|Single oral dose of 320 mg
75869485|NCT04470908|Drug|Rifabutin|Oral dose of 300 mg once daily
75388801|NCT04590846|Behavioral|Constipation Health Education Intervention Course|"The 4-weeks health education includes three dimensions. The first is Causes and Hazards of Constipation. The second is Constipation Symptoms and Criteria. The third is Constipation Treatment Strategies and Prevention.~Health education leaflets with 3 to 5 test questions in the weekly are distributed once a week, students will bring them back to parents, and parents need to complete the answers and sign after reading them."
75388802|NCT04590846|Behavioral|General Health Course|General courses about health issues according to the curriculum of each primary school.
76033324|NCT04935281|Other|percutaneous repair without an intraoperative assisted ultrasound|For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
75388803|NCT01816074|Drug|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
75388804|NCT01816074|Behavioral|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
76033325|NCT04935515|Drug|Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
75542700|NCT04715074|Behavioral|Pilot|Utilizing the Behaviour Change Wheel in conjunction with results gathered from Aims 1 and 2 we will develop a theory-driven, multi-media campaign intervention to increase awareness of EOCRC, risk factors, and early detection benefit.
76033326|NCT04935515|Drug|Oral low dose steroid|Low dose oral methyl prednisolone was added.
76033327|NCT04935515|Drug|Intravenous Antibiotics with Low dose steroid.|Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
76033328|NCT04935515|Drug|Oral anti-coagulant|Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
76033329|NCT04447729|Drug|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
76033330|NCT04090645|Device|TheraSphere|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
76033331|NCT04932551|Other|Questionnaire|physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.
76033332|NCT05110885|Other|Questionnaire|A questionnaire prepared by the researchers will be presented to the group.
75388805|NCT01815918|Drug|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
75388806|NCT01815918|Drug|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
75388807|NCT01789476|Drug|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
75388808|NCT01789476|Drug|Placebo|Matching placebo administered using same dosing algorithm as the active arm
75557848|NCT03279653|Procedure|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
75557849|NCT03277248|Biological|Ublituximab|Administered as an IV infusion.
75557850|NCT03277248|Drug|Teriflunomide|Film coated tablets administered orally.
75388809|NCT01789320|Drug|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
75388810|NCT01815840|Drug|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
75388811|NCT01815840|Drug|Placebo|Vismodegib placebo orally once daily
75388812|NCT01774110|Other|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
75388813|NCT01788228|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
75557851|NCT03277248|Drug|Oral Placebo|Administered orally.
75557852|NCT03277248|Drug|IV Placebo|Administered as an IV Infusion.
76033333|NCT05104177|Procedure|conservative tecchniques in management of PAS|"Meticulous complete dissection of the urinary bladder from the lower uterine segment.~Transverse uterine incision above the visible vascular bulge if visible in cases with anterior PAS, otherwise a transverse lower uterine segment incision is performed in the same site of previous CS scar.~Delivery of the baby, clamping of the cord and administration IV 10 IU oxytocin.~Bilateral uterine artery ligation at one or two levels below the lowermost part of the placenta.~Removal of the separable part of the placenta from above downwards, until the adherent part is encountered.~A decision is taken to either resect a wedge of the myometrium above the adherent placenta (in case the adherent area is small and anterior), or removing all the adherent placenta then inserting a rubber or plastic catheter inside the cervical canal then identifying and closing the placental pouch. Care is given to rapidly perform this step to decrease the blood loss after removing the placenta"
76033334|NCT03951883|Other|Increased Egg Consumption|Subjects will be instructed to use a weekly food purchase supplement for inclusion of 2 additional eggs per day to be added to subject's typical daily diet.
76033335|NCT03951883|Other|Typical diet|Subjects will be instructed to maintain their current dietary patterns.
76033336|NCT04376281|Drug|Noradrenaline|Noradrenaline infusion for patients undergoing liver transplantaion from living donor .
75869486|NCT04458038|Other|driving simulator|For this study a driving simulator is being used which is an internationally approved method. Besides the driving simulator following tests are done: COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), a clock drawing test and a continuous reaction time test (CRT). A CardioRespiratory Monitor (CRM), NOX T3TM, is used to measure if the patients have moderate to severe OSA. Furthermore, following tests are done: Epworth Sleepiness Scale (ESS).
75388814|NCT01607346|Drug|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
75388815|NCT01787838|Other|Focused Health Education|"A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.~The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it."
75388816|NCT01787760|Device|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
75869487|NCT04451044|Device|Philips SyncVision system with Philips pressure wires|Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
75869488|NCT04451044|Procedure|standard of care angiographically-guided PCI|Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
75869489|NCT04439292|Drug|Dabrafenib Mesylate|Given PO
75869490|NCT04439292|Drug|Trametinib Dimethyl Sulfoxide|Given PO
75869491|NCT04439188|Drug|PI3K-beta Inhibitor GSK2636771|Given PO
75869492|NCT04439149|Drug|PI3K-beta Inhibitor GSK2636771|Given PO
76033337|NCT04932629|Biological|Ex-vivo cultivated Allogeneic limbal stromal stem cells|n this prospective intervention study patients with unilateral superficial corneal scars will undergo a surgical procedure and in the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x10*6 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery
76033338|NCT04332445|Other|Hyaluronic Acid Gel|Health care product - to be apllied on the subject's skin
76033339|NCT04954703|Other|Muscle energy technique of gluteus maximus and tensor fascia lata|it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.
76033340|NCT04954703|Other|Myofascial release of iliotibial band syndrome|Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
75542701|NCT04655937|Other|Acceptance and Commitment Therapy|none two hour remote sessions (50 minutes activity + 20 minute break + 50 minutes activity). Acceptance and Commitment Therapy (ACT) is a third wave transdiagnostic cognitive-behavioural therapy that supports clients to adjust to current experiences and 'commit' to behaviours that are congruent with their personal values, in order to promote psychological well-being and prevent future mental health crisis. ACT uses a variety of experiential techniques to support this process including: mindfulness practices; exercises to identify personal values; commitment to goals for valued living.
76033341|NCT04932863|Biological|BNT162b2 mRNA Covid-19 Vaccine|Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.
75706390|NCT00724100|Drug|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
75706391|NCT04069416|Procedure|living donor liver transplantation|liver graft from a living donor
75388817|NCT01787760|Device|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
75388818|NCT01787760|Device|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
75869493|NCT04419766|Other|IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester) house spraying|The spraying will be performed monthly during the first 3 months, bimonthly during the next 6 months and then quarterly thereafter. The spraying will be carried out inside and outside the houses during the morning.
75869494|NCT04417530|Drug|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
75388819|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
75388820|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
75388821|NCT01606800|Drug|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
75388822|NCT01606800|Drug|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
75542702|NCT04652479|Drug|Avexitide|Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
75542703|NCT04642599|Device|Bimanual motor skill learning with the REAplan® rehabilitation robot|REAplan® rehabilitation robot: training to perform complex, coordinated, bimanual movements
75869495|NCT04417530|Device|Suprachoroidal Microinjector|Suprachoroidal Injection Device
75869496|NCT04417530|Device|PDT Laser|Laser Administration
75869497|NCT04416633|Drug|Durvalumab|500-mg/120-mg IV
75869498|NCT04413266|Dietary Supplement|Curcumin supplementation|The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks
75542704|NCT04634617|Other|Questionnaire Administration|Complete questionnaires
75557853|NCT03279614|Drug|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
76033342|NCT04278313|Procedure|PRP - Platelet Rich Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube to leave 2.5 ml of Platelet Rich Plasma in the tube. The tube is inverted several times to suspend the platelet pellet. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
76033343|NCT04278313|Procedure|PPP - Platelet Poor Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube. The prepared plasma will be transported to the procedure room. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
76033344|NCT04934735|Procedure|Rehabilitation program group|"The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~Intake by a case manager~Referral to an occupational physician was within one week of the intake.~Charting an occupational rehabilitation program and timing the RTW date~Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~Provision of a guidance booklet for employers on the RTW of cardiac patients.~The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned."
76033345|NCT04232839|Drug|BI 894416 - Formulation A2|Tablet
76033346|NCT04232839|Drug|BI 894416 - Formulation C2|Tablet
75388823|NCT04414488|Procedure|Thoracic paravertebral block (ThPVB)|Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
75388824|NCT01772550|Device|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
75706392|NCT00860392|Drug|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
76033347|NCT04232839|Drug|BI 894416 - Formulation D2|Capsule
76033348|NCT04232839|Drug|BI 894416 - Formulation F2|Capsule
76033349|NCT04232839|Drug|BI 894416 - Reference Formulation 1|Tablet
76033350|NCT04934813|Other|Alveolar ridge preservation|application of different bone graft and sealing means after tooth extraction
76033351|NCT04934423|Device|Direct Current Transcranial Stimulation - tDCS|Active intervention
76033352|NCT04934423|Device|Sham Intervention|Direct Current Transcranial Stimulation - Sham intervention
76033353|NCT03890887|Drug|BI 1291583|Tablet
76033354|NCT03890887|Drug|Itraconazole|Oral solution
76033355|NCT05098951|Device|Acupuncture|Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
76033356|NCT04934501|Diagnostic Test|High-frame-rate contrast-enhanced ultrasound measurements (echoPIV)|Patients will undergo high-frame-rate contrast-enhanced ultrasound measurements, within 6 to 8 weeks after the endovascular procedure, at the vascular center of Rijnstate hospital. Prior to these measurements a venous cannula will be placed to ensure venous access for the contrast administration.
76033357|NCT04934501|Diagnostic Test|Computed tomography angiography (CTA) scan|Patients will undergo a CTA scan of the lower extremities at the Radiology dept. of Rijnstate hospital the same day as the echoPIV measurements. This CTA scan serves as a reference for the vessel geometry and stent location.
75388825|NCT01772550|Device|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
75557854|NCT00439907|Procedure|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
75706393|NCT02571816|Drug|ASP2215|oral
75388826|NCT01787292|Behavioral|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
75869499|NCT04399876|Combination Product|Microdevice|"Surgery Cohort: Placement of 1-6 microdevices: Drugs chosen have all been FDA approved for the treatment of cancer (so therefore safe) and there are phase 2 or 3 data that the drug has efficacy in prostate cancer. Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations~Ex vivo Cohort: Placement of multiple microdevices with miniature drug reservoirs but no drug is loaded into the removed prostate"
76033358|NCT04111861|Other|Singing|To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
76033359|NCT04932161|Procedure|Titanium Granules|After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.
75869500|NCT04399837|Drug|Spesolimab|Solution for injection
76033360|NCT04932161|Procedure|Hydroxyapatite|After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
75388827|NCT01787292|Behavioral|Aerobic Exercise Intervention|Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
75388828|NCT01787292|Behavioral|Self Monitoring|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
76033361|NCT05073523|Other|Diet|All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
75388829|NCT04414644|Behavioral|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
75388830|NCT01814748|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly
75388831|NCT01814748|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
75388832|NCT01814748|Drug|Metformin|Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
75388833|NCT01814670|Biological|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
75869501|NCT04399837|Drug|Placebo|Solution for injection
75869502|NCT04391803|Device|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
75388834|NCT01814046|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
75706394|NCT00850798|Drug|Intensive glycemic control|Intensive glycemic control
75706395|NCT00850798|Drug|Conservative glycemic control|OADs and insulin
75706396|NCT02572908|Other|Sourdough wheat bread|
75706397|NCT02572908|Other|Regular yeast baked toast bread|
75706398|NCT02572908|Other|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
75388835|NCT01814046|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
75706399|NCT02571140|Drug|Teriparatide|subcutaneous standard injection
75706400|NCT02571140|Drug|Oral PTH (1-34)|Different optimization of API
75388836|NCT01814046|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
75388837|NCT01814046|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
75706401|NCT00854074|Device|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
75388838|NCT01813890|Drug|Tapentadol IR 50 mg|Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
76033362|NCT04934345|Diagnostic Test|Fluid challenge|The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
75388839|NCT01813890|Drug|Tapentadol IR 75 mg|Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
75388840|NCT01813890|Drug|Placebo|Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
75388841|NCT01772316|Drug|tocilizumab|162 mg subcutaneously weekly or every two weeks, 96 weeks
76033363|NCT04922177|Procedure|Indirect ceramic restoration|Indirect ceramic restoration using an optical impression.
76033364|NCT04922177|Procedure|Direct restoration|Restoration using a Glass Ionomer Cement
76033365|NCT03817957|Drug|Polyglucoferron|intravenous administration
75388842|NCT01813422|Biological|Evolocumab|Administered by subcutaneous injection
75388843|NCT01813422|Drug|Placebo|Administered by subcutaneous injection
75542705|NCT04599088|Other|Brain functional MRI with simplified urodynamics|"Structural:~MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.~Functional:~With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image."
75869503|NCT04388930|Other|Pre-operative assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing"
75388844|NCT01786668|Drug|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
75388845|NCT01786668|Drug|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
75388846|NCT01786668|Drug|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
75388847|NCT01786668|Drug|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
75388848|NCT01786512|Drug|Omecamtiv Mecarbil Matrix F1 Formulation|Modified release tablets for oral administration
75388849|NCT01786512|Drug|Omecamtiv Mecarbil Matrix F2 Formulation|Modified release tablets for oral administration
75388850|NCT01786512|Drug|Placebo|Modified release tablets matching to omecamtiv mecarbil
75388851|NCT01786512|Drug|Omecamtiv Mecarbil Swellable Core Technology F2|Modified release tablets for oral administration
75869504|NCT04388930|Other|Post-operative day 3 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
76033366|NCT03817957|Drug|Ferric carboxymaltose|intravenous administration
76033367|NCT03817957|Drug|Ferrous Sulfate|oral administration
76033368|NCT04922489|Procedure|Dental implant placement|Dental implant placemente on edentulous jaw.
76033369|NCT04955171|Drug|BEOVU intravitreal injection|BEOVU intravitreal injection
76033370|NCT05015335|Drug|Adalimumab|ADA 40mg q2w
76033371|NCT05015335|Drug|Methotrexate|MTX 10mg qw
76033372|NCT03805243|Device|test of sensors for somnonaute device|test of sensors
76033373|NCT03805243|Device|test of sensors for uronaute device|test of sensors
76033374|NCT03805243|Device|test of sensors for toconaute device|test of sensors
76033375|NCT03805243|Device|test of sensors for neuronaute device|test of sensors
76033376|NCT03805243|Device|test of sensors for cardioskin device|test of sensors
76033377|NCT03056261|Procedure|Combined general and epidural|Combined general and epidural anaesthesia
76033378|NCT03056261|Procedure|General anaesthesia|General anaesthesia
76033379|NCT04922099|Device|glycemic gap|"Measurements of HbA1c-based adjusted glycemic gap:~The estimated chronic average glucose levels (eAG) over the past 3 months will calculate from the equation AG = 28.7 × HbA1c - 46.7 Glycemic gap was calculated as the ADAG level subtracted from the admission glucose level."
76033380|NCT03534817|Behavioral|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
75388852|NCT04414254|Drug|Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)|"Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
75869505|NCT04388930|Other|Post-operative week 4-6 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
75869506|NCT04388930|Other|Post-operative 3 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
75388853|NCT01772160|Other|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
75388854|NCT01770912|Drug|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
75388855|NCT01770912|Drug|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
75388856|NCT01811706|Drug|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
75869507|NCT04388930|Other|Pre-operative 6 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
75869508|NCT04388930|Other|Post-operative month 12 recipient assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
76033381|NCT04933799|Drug|PF-06650833|"PF-06650833 is an investigational, highly potent and selective, reversible inhibitor of IRAK4. IRAK4 is a serine, threonine kinase that is a key intracellular signaling node downstream of the myddosome-associated Toll-Like Receptors (TLR) 1, 2, 4, 5, 6, 7, 8, 9 and 10, and the interleukin (IL)-1 family receptors (IL-1R, IL-18R and IL-33R) that mediate much of the innate immune signaling.~As an inhibitor of TLR signaling, PF-06650833 targets a different part of the immune system from the Janus kinase (JAK) inhibitors. Given the partial redundancy of innate immune signaling through IRAK4-independent TLR pathways and the lack of direct suppression of T- and B-cell signaling, PF-06650833 is unlikely to lead to exaggerated immunosuppression."
76033382|NCT04933799|Drug|Matching Placebo|Placebo will match the study drug in dose, formulation, route and frequency.
76033383|NCT03921619|Device|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
75388857|NCT01811706|Drug|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
75388858|NCT01811472|Drug|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
76033384|NCT04985383|Device|AKST1210 S-15 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 250mL/min
76033385|NCT04985383|Device|AKST1210 S-15 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 450mL/min
75388859|NCT01811472|Drug|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
75869509|NCT04374630|Drug|Paclitaxel|Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.
76033386|NCT04985383|Device|AKST1210 S-25 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 250mL/min
76033387|NCT04985383|Device|AKST1210 S-25 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 450mL/min
75388860|NCT01811238|Drug|Oxycodone/naloxone|Targin 5mg, 10mg, 20mg up to 40mg b.i.d
75869510|NCT04374630|Drug|Afuresertib|"Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)"
75869511|NCT04368013|Procedure|Extended sampling and procedures|The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
75869512|NCT04365413|Device|MSOT Device|The MSOT Device will be used to take images of the tumor and/or lymph nodes of patients with solid tumors before and after surgery to measure the margins of the tumor and/or positive lymph node.
75869513|NCT04365413|Procedure|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
75869514|NCT04364269|Drug|VIT-2763 once a day (QD)|Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
75869515|NCT04364269|Drug|VIT-2763 twice a day (BID)|Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
75869516|NCT04364269|Drug|Placebo|Participants will receive hard capsules of Placebo, twice a day.
75869517|NCT04358874|Other|Medication reconciliation|Medicines currently being taken will be reviewed and compared to the medicines that were prescribed at discharge.
75869518|NCT04358874|Other|Blood Pressure Management|Blood pressure will be checked at follow-up visits and medicines will be adjusted if blood pressure is above target range (>160/100)
75869519|NCT04337970|Drug|Talazoparib|"Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined."
75869520|NCT04337970|Drug|Axitinib|5 mg PO BID
75869521|NCT04321031|Drug|Placebo|Tablet
75869522|NCT04321031|Drug|PF-06865571|Tablet
75869523|NCT04321031|Drug|PF-05221304|Tablet
76033388|NCT04985383|Device|AKST1210 S-35 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 250mL/min
76033389|NCT04985383|Device|AKST1210 S-35 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 450mL/min
76033390|NCT03533257|Drug|AMX0035|Combination Therapy of TUDCA and Sodium Phenylbutyrate
76033391|NCT03533257|Drug|Placebo|Placebo
76033392|NCT04933409|Procedure|3D printed replica of the donor tooth|3D printed replica of the donor tooth.
76033393|NCT04933409|Procedure|Conventional Autotransplantation of tooth|Conventional Autotransplantation of tooth without using the 3D printed guide
75388861|NCT01769508|Drug|5-Fluorouracil|5-FU, 225 mg/m2 IVCI, during XRT.
75388862|NCT01769508|Drug|Oxaliplatin|Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
75388863|NCT01769508|Drug|Lapatinib|Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
75388864|NCT01769508|Radiation|Radiation Therapy|Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
76033394|NCT04574479|Procedure|Supra-inguinal fascia iliaca compartment block|"Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.~Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump"
75388865|NCT04576260|Behavioral|Cognitive Behavioural Therapy for Insomnia|Weekly CBTI training
75388866|NCT01810380|Drug|Placebo|Once daily as tablets and capsules, orally
76033395|NCT04574479|Drug|Multimodal analgesia and PCA morphine pump|Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
75542706|NCT04582266|Drug|Remdesivir|RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
75542707|NCT04535648|Other|Non-invasive detection method: CRISPR techonology|This study was a laboratory diagnostic study without any intervention.
75869524|NCT04318080|Drug|Tislelizumab|200 mg intravenously (IV) every 3 weeks (Q3W)
75388867|NCT01810380|Drug|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
75388868|NCT01810380|Drug|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
75388869|NCT01769196|Drug|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
75388870|NCT01769196|Drug|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
75388871|NCT01810302|Drug|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
75388872|NCT01810302|Drug|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
75388873|NCT01783938|Biological|Nivolumab|
75542708|NCT04528134|Device|Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish|This is a light-cured, durable coating that forms an immediate layer of protection that releases fluoride, calcium and phosphate and can be recharged with fluoride by using fluoride-containing products over the 6-month life of the product.
75388874|NCT01783938|Biological|Ipilimumab|
75869525|NCT04316962|Other|Complex cancer rehabilitation|"The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~Individual goal-setting~Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~Peer support."
75388875|NCT01768572|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
75388876|NCT01768572|Drug|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
75388877|NCT01768572|Drug|hydroxychloroquine|Dispensed according to local practice.
75388878|NCT01768572|Drug|methotrexate|Dispensed according to local practice.
75388879|NCT01768572|Drug|sulfasalazine|Dispensed according to local practice.
76033396|NCT04933487|Device|IOL implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
75388880|NCT01768572|Drug|leflunomide|Dispensed according to local practice.
75388881|NCT01768572|Drug|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
75388882|NCT01768572|Drug|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
75388883|NCT01783548|Drug|BDP Nasal Aerosol|
75542709|NCT04528134|Device|5% Sodium Fluoride Varnish|This is a 5% Sodium Fluoride varnish that hardens on the teeth upon contact with saliva.
75542710|NCT04521920|Drug|Suboxone|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
75388884|NCT01783548|Drug|Placebo|
75388885|NCT01809210|Drug|selumetinib|2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
75388886|NCT01809210|Drug|gemcitabine|1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
75388887|NCT01809210|Drug|cisplatin|75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
75388888|NCT01809210|Drug|carboplatin|If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
75388889|NCT01809210|Drug|pemetrexed|Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
75388890|NCT01809132|Drug|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
75388891|NCT01809132|Drug|Pentoxifylline|Pentoxifylline, generic
75388892|NCT01809132|Drug|Zinc Sulfate|Zinc Sulfate, nutritional supplement
75542711|NCT04521920|Drug|PrEP|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
75388893|NCT01809132|Drug|Methylprednisolone|Methylprednisolone, corticosteroid
75388894|NCT01808508|Device|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
75388895|NCT01808508|Device|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
75388896|NCT01766778|Drug|LAF237 (vildagliptin)|Vildagliptin 50mg capsule
75388897|NCT01766778|Drug|Metformin|Metformin maximum tolerance dose
75388898|NCT01808196|Drug|Losartan Potassium|The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
75388899|NCT01808118|Biological|adalimumab|40 mg every other week
75388900|NCT01808118|Biological|Placebo|every other week
75388901|NCT01807650|Drug|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
75388902|NCT01807650|Device|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
75557855|NCT00439907|Procedure|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
75557856|NCT03279822|Other|not any intervention|not any intervention
75706402|NCT04068324|Dietary Supplement|New Care No Nil Per Os|"The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant."
75706403|NCT02570204|Behavioral|Self-assessment|Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
75706404|NCT00721656|Drug|Placebo|
75706405|NCT00721656|Drug|KLS-0611|
75706406|NCT04066712|Drug|LC350189 200 mg|Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
75388903|NCT01782690|Drug|erlotinib|Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
75388904|NCT01782690|Drug|gemcitabine|Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
75388905|NCT01782378|Device|Real LED Treatment|"PhotoMedex Helmet: 12 Pods, 4.5 x 4.8cm (21.6 cm2); 20 diodes; 830nm; Power Output (PO) 665.3 mW; Power Density (PD)/LED 30.8 mW/cm2; CW; Time/session 28m 10s*; Dose: Energy Density 26 J/cm2.~MedX Device: 1 Cluster Head/ear, 2 inch diameter (22.48 cm2); 870nm; PO 90 mW; PD/LED 4 mW/cm2; CW; Time/session 4m; Energy Density 4 J/cm2; 2 Vielight Intranasal Devices: Red, 633nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; CW; Time/session 25m; Energy Density 11.4 J/cm2 and NIR, 810nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; Pulse frequency 10Hz; Duty Cycle 50%; Time/session 25m; Energy Density 11.4 J/cm2 Thor Photomedicine Helmet: 10 Pods, 6cm diameter (28.3 cm2); 35 diodes; Wavelength 850nm; PO 1050 mW; PD/LED 50 mW/cm2; CW; Time/session 23m, 24s; Energy Density 26 J/cm2 2 Placement sets: 1) midline, 6 cluster heads; 2) L&R side of head 12 cluster heads (14m, 5s, each set); 1) midline, 5 cluster heads; 2) L&R side of head 10 cluster heads (11m, 42s, each set) CW, Continuous Wave"
75388906|NCT01782378|Device|Sham LED Treatment|Intervention for Real and Sham are Identical, but sham has power output of 0, no photons emitted.
75388907|NCT01766310|Drug|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
75388908|NCT01766310|Drug|placebo|sugar tablet manufactured to mimic folic acid tablet
75388909|NCT01765920|Drug|Ergoferon|5 ml 3 times a day
75557857|NCT00439985|Behavioral|Cognitive Behavioral Therapy|The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
75388910|NCT01765920|Drug|Placebo|5 ml 3 times a day
75706407|NCT02571686|Device|Surveyor S4|
75706408|NCT00723216|Drug|enoxaparin|20 mg twice a day
75706409|NCT00723216|Other|Physical prophylaxis|
75706410|NCT00619918|Drug|Nebulized 3% saline|4 ml inhaled q8h
75706411|NCT00619918|Drug|Placebo|normal saline
75706412|NCT00724178|Dietary Supplement|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
75706413|NCT02571270|Other|Combined aerobic and resistance physical training program|
76033397|NCT03338257|Behavioral|Husky Reads Intervention|The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
76033398|NCT04933955|Procedure|vital pulp therapy|pulpotomy
76033399|NCT02925013|Procedure|Blood sampling|Blood sampling for lipid profile
76033400|NCT02925013|Other|Dietary- Normal western diet|Normal western diet
75388911|NCT01782222|Drug|Rotigotine|"Rotigotine, transdermal patches:~10 cm^2 (2 mg / 24 hours); 20 cm^2 (4 mg / 24 hours); 30 cm^2 (6 mg / 24 hours); 40 cm^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
75388912|NCT01782222|Other|Placebo|"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
75388913|NCT04414098|Drug|INC424 / Ruxolitinib|"Ruxolitinib 5 mg orally every 12 hours during 14 days.~Total Follow-up time will be of 45 days.~The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.~During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45~During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.~After discharge, monitoring of adverse events will continue during the outpatient follow-up.~Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)~Ruxolitinib will be associated to the standard of care for COVID-19 of each center.~In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended."
76033401|NCT04933175|Drug|Fluzoparil|Fluzoparil: 150 mg, P.O, BID, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
76033402|NCT04933175|Drug|Anlotinib|Anlotinib: 8mg, P.O, qd, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
76033403|NCT02370901|Device|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
75388914|NCT01781832|Device|ARFI-Derived Shear Wave Velocities|An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
75388915|NCT01807182|Biological|Aldesleukin|Given IV
75388916|NCT01807182|Drug|Cyclophosphamide|Given IV
76033404|NCT02370901|Behavioral|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
75388917|NCT01807182|Drug|Fludarabine Phosphate|Given IV
75706414|NCT04800536|Other|Rapidly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
75706415|NCT04800536|Other|Slowly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
75706416|NCT02546050|Drug|Metformin|
75706417|NCT00721812|Drug|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
75706418|NCT04800224|Drug|Standardized Brazilian Green Propolis Extract|900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
75388918|NCT01807182|Other|Laboratory Biomarker Analysis|Correlative studies
75388919|NCT01807182|Biological|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
75388920|NCT04584762|Device|Automated Variable Pressure Insufflation|Acute migraine treatment
75388921|NCT01806714|Other|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
76033405|NCT04431167|Behavioral|Living well with Lupus|The lifestyle change intervention will involve two constructs: increasing the level of physical activity and improving eating habits, each with its own specific domains and goals. It will be based on a structured program of physical exercises and selection of individualized goals in the domains of transportation, leisure and work to reduce sedentary behavior with the aim of increasing the level of physical activity, as well as establishing changes in dietary aspects, involving consumption domains, structure, behavior and eating attitude using nutritional counseling techniques.
75706419|NCT04800224|Drug|Placebo|900mg/day of Placebo for 10 days.
75706420|NCT00860548|Drug|currently available therapy in the community|Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
75706421|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
75706422|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
76033406|NCT04921709|Other|Medical tests|Blood tests
76033407|NCT04930835|Procedure|Implant supported dentures|Placement of dental implants with different loading protocols for supporting full arch dentures.
76033408|NCT04976725|Other|Osteopathic Manipulative Therapy|"75 individuals will be included in our study, including 3 groups: control group (N= 25), osteopathic manipulative technique (n= 25), myofascial relaxation group (n=25). Which group of individuals will be determined by randomizing them with closed envelope method.~Osteopathic Manipulative Therapy and myofascial relaxation treatment applications will be applied 2 days a week, for periods of 30 min for 4 weeks."
75706423|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
76033409|NCT04921553|Other|Data collection and quality of life questionnaire|"Data collection from the medical file~Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months"
76033410|NCT02195947|Drug|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
76033411|NCT04913207|Procedure|method of device size selection|device size selection based on 3D-CTA
76033412|NCT01698307|Other|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
76033413|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
76033414|NCT03054545|Drug|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
76033415|NCT04111757|Device|Technolas® TENEO 317 Model 2|LASIK eye surgery
76033416|NCT05119153|Dietary Supplement|Placebo Comparator|Placebo designed to mimic coffee color.
76033417|NCT05119153|Dietary Supplement|Light Roasted Coffee|12 oz light roast coffee
75388922|NCT01806714|Other|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
75388923|NCT01765764|Drug|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
75706424|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
76033418|NCT05119153|Dietary Supplement|Medium Roasted Coffee|12 oz medium roast coffee
75388924|NCT01765764|Drug|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
75388925|NCT01806168|Device|rTMS|Magstim Super Rapid-2
76033419|NCT05119153|Dietary Supplement|Dark Roasted Coffee|12 oz dark roast coffee
76033420|NCT04930913|Diagnostic Test|Three-dimensional Ultrasound|women suspected of having adhesions will perform 3D US
76033421|NCT04954339|Drug|Aatezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
75542712|NCT04521894|Device|Positron emission tomography/computerized tomography (PET/CT)|"Genetic factors and age:~Epidemiological studies have shown that if an immediate family member (brother or father) suffers from prostate cancer, the risk of prostate cancer will be more than doubled. Age is a relatively strong risk factor for PCa.~Prostatitis: Prostatitis is related to PCa. Cancer is usually found in the tissues where inflammation is found.~Obesity: Research has found that obese patients have a low grade of PCa, but their risk of developing aggressive cancer is higher.~Infection:~Exercise: Most studies have found that exercise does not reduce the risk of prostate cancer, but some studies have shown that.~Daily diet: The corrective mechanism of diet in PCa is not very clear.~Drinking history:"
75542713|NCT04475510|Other|Antiplatelet treatment discontinuation|All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
75542714|NCT04459338|Biological|Exendin-9,39|Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor
75388926|NCT01804842|Drug|Met DR|metformin delayed-release tablets
75388927|NCT01781286|Behavioral|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
76033422|NCT04930523|Other|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"Pre physiotherapy treatment~Gym (treadmill ,cycling,vibrator) according to ability and condition of patient Shortwave diathermy SWD for atleast 10 mins Decompression treatment i.e. Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes.~Post physiotherapy treatment~Conventional Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension,by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~No exercises or walk were guided for home (till 24 hrs) Low back exs guided i.e knee to chest, pelvic rolling, bridging, SLR, pirformis exs is guided for home plan along with precautions.~No exertion ,drive carefully Avoid stairs climbing ,twisting ,bending ,weight lifting"
75388928|NCT01781286|Behavioral|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
75388929|NCT01780974|Drug|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
75388930|NCT01780974|Drug|Placebo|placebo capsules
75388931|NCT01780662|Drug|Brentuximab Vedotin|Given IV
75542715|NCT04459338|Other|Saline|Placebo comparator
75542716|NCT04457687|Drug|Lorcaserin|Lorcaserin 10 milligram (mg) tablets orally.
75542717|NCT04381143|Drug|Aspirin 100 mg Oral Tablet|Aspirin 100 mg tablets daily
75542718|NCT04370093|Drug|Pioglitazone 45 mg|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
75542719|NCT04370093|Behavioral|Weight Loss|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
75388932|NCT01780662|Drug|Gemcitabine Hydrochloride|Given IV
75388933|NCT01780584|Drug|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
75388934|NCT01780584|Drug|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
75388935|NCT01780584|Drug|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
75388936|NCT01780506|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
75542720|NCT04370093|Other|Pioglitazone + Weight Loss|Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
75542721|NCT04298229|Drug|Dapagliflozin 10 MG|SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
75869526|NCT04309721|Drug|Perampanel|Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
75869527|NCT04309721|Drug|Placebo|Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
75869528|NCT04299945|Dietary Supplement|concentrated beetroot juice (400mg of nitrate per serving)|Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
75869529|NCT04299945|Dietary Supplement|concentrated beetroot juice (trace amounts of nitrate per serving)|Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
75869530|NCT04299048|Drug|PF-06946860|subcutaneous injection
75869531|NCT04258943|Drug|Bosutinib|"Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)"
75388937|NCT01780506|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
75388938|NCT01780506|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
75388939|NCT01780506|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
75388940|NCT01779648|Device|DVT-3000|
75388941|NCT01779648|Device|SCD Express|
75542722|NCT04298229|Other|Protocolized Diuretic Therapy|Structured usual care arm with protocolized diuretic therapy based on urine output.
75388942|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg|Active, 50/250mcg, Twice daily (morning and evening)
75388943|NCT01762800|Drug|fluticasone propionate/salmeterol placebo|Placebo, Twice daily (morning and evening)
76033423|NCT04930523|Other|Decompression|"Pre physiotherapy treatment~Gym (treadmill ,cycling, vibrator) according to ability and condition of patient Shortwave diathermy SWD for at least 10 minutes. ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precautions.~Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes. Post physiotherapy treatment Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension, by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~ELDOA exercises(positions)are guided for home plan after session (after 24 hrs) No exertion ,drive carefully Avoid stairs climbing, twisting bending, weight lifting"
75557858|NCT03279783|Device|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
76033424|NCT04304833|Other|Provider-Based Care Model Arm|The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.
76033425|NCT04304833|Behavioral|mHealth Model Arm|The PI will provide each patient with weight scale, blood pressure cuff, & pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
75388944|NCT01762800|Drug|tiotropium bromide 18mcg|Active, 18mcg, Once daily(morning)
75388945|NCT01762800|Drug|tiotropium bromide placebo|Placebo, Once daily(morning)
75557859|NCT00440024|Drug|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
75869532|NCT04254549|Drug|Rifaximin|550 mg by mouth three times daily for 14 days
76033426|NCT04912661|Dietary Supplement|Ferinject|intravenous iron carboxymaltose
76033427|NCT04391959|Drug|AZR-MD-001 Active|AZR-MD-001 is an active ophthalmic ointment
76033428|NCT04391959|Drug|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
75388946|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg|Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
75388947|NCT01597596|Biological|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
75869533|NCT04254549|Drug|Placebo|By mouth three times daily for 14 days
76033429|NCT03429985|Behavioral|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
75388948|NCT01597596|Biological|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
75542723|NCT04298086|Other|Exercise Treatment|Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.
75542724|NCT04298086|Other|Plant-Based Diet|Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
75869534|NCT04227288|Drug|Enstilar Foam|Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
76033430|NCT04921319|Diagnostic Test|VExUS score|"The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~VExUS 0: The patient will likely tolerate more fluid if clinically needed.~VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
75388949|NCT01778556|Biological|Metreleptin|Recombinant analog of the human hormone, leptin
75388950|NCT04562376|Other|High-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes twice a week (group A) during 12 weeks
75388951|NCT04562376|Other|Low frequency of high-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes once a week (group B) during 12 week
76033431|NCT04939831|Other|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
76033432|NCT04939831|Other|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
75388952|NCT04562298|Biological|LCAR-M23 cells|Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
75542725|NCT04298086|Other|Physical activity|Treadmills and low-calorie recipes will be provided to patients in the counseling arm.
75869535|NCT04210206|Other|PHE-diet|phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
76033433|NCT04921085|Other|Cross-sectional obeservational survey|Cross-sectional obeservational survey
76033434|NCT03357523|Device|Omnilux new-U (Red LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Red LED) light source, while the right wrist will not be illuminated
76033435|NCT03357523|Device|Omnilux new-U (Near infrared LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Near infrared LED) light source, while the right wrist will not be illuminated
75388953|NCT04562064|Device|corneal tomography scans|corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
75388954|NCT01761162|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
75869536|NCT04203069|Device|Control group : Day-time compression sleeve|"In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
75388955|NCT01761162|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
75388956|NCT01778010|Drug|Modafinil 0 mg|Modafinil (0 mg/day)
75388957|NCT01778010|Drug|Modafinil 200 mg|Modafinil (200 mg/day)
75388958|NCT01778010|Drug|Modafinil 400 mg|Modafinil (400 mg/day)
75388959|NCT01778010|Drug|Cocaine 0 mg|Cocaine (0 mg/day)
76033436|NCT03357523|Device|RESPeRATE|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm
76033437|NCT03357523|Device|Heating bag|Applying a standard 10X13 [cm] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
76033438|NCT04912349|Procedure|TUSP|Patients received the transurethral split of the prostate(TUSP) treatment.
76033439|NCT04912349|Procedure|TURP|Patients received the transurethral resection of the prostate(TURP) treatment.
76033440|NCT04406207|Other|Demonstration of T cell responses|"Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest."
75388960|NCT01778010|Drug|Cocaine 12 mg|Cocaine (12 mg/day)
75388961|NCT01778010|Drug|Cocaine 25 mg|Cocaine (25 mg/day)
75388962|NCT01778010|Drug|Cocaine 50 mg|Cocaine (50 mg/day)
75388963|NCT04568928|Device|OLTP/PE + FES|12 sessions OLTP/PE + FES
75388964|NCT01777854|Drug|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients >20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
75557860|NCT00440024|Drug|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
75869537|NCT04203069|Device|Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit|"In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
75388965|NCT01777776|Drug|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
75388966|NCT01777776|Drug|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
75869538|NCT04182204|Drug|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle IV on Day 1 of each 21-day cycle for up to 8 cycles.
75542726|NCT04298086|Other|Nutrition counseling|Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).
75869539|NCT04182204|Drug|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.
75388967|NCT01777620|Biological|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
75388968|NCT01777620|Drug|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
75388969|NCT01777542|Drug|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
75388970|NCT01777542|Drug|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
75542727|NCT04298086|Other|Replication Exercise Test|Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
75542728|NCT04278118|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
75542729|NCT04278118|Radiation|Photon Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
75542730|NCT04278118|Radiation|Proton Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
75542731|NCT04278118|Other|Quality-of-Life Assessment|Ancillary studies
75542732|NCT04278118|Other|Questionnaire Administration|Ancillary studies
75542733|NCT04273269|Genetic|LYS-GM101|LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection
75542734|NCT04241666|Diagnostic Test|renal scintigraphy|Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys
75542735|NCT04241666|Diagnostic Test|renal doppler sonography|doppler ultrasound of both kidneys
75388971|NCT01736124|Other|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
75869540|NCT04182204|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.
75869541|NCT04182204|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.
75388972|NCT01736124|Other|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
75557861|NCT00440024|Drug|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
75869542|NCT04179981|Device|Positive airway pressure|Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.
75869543|NCT04179981|Other|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
75869544|NCT04172532|Procedure|Biopsy|Undergo tissue collection
75557862|NCT00476502|Genetic|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
75869545|NCT04172532|Procedure|Biospecimen Collection|Undergo blood sample collection
75869546|NCT04172532|Procedure|Computed Tomography|Undergo CT
75388973|NCT01759446|Drug|Placebo taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
75388974|NCT01759446|Drug|Generic H/A taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
75388975|NCT01759446|Drug|Vycavert taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
75388976|NCT01759446|Drug|Generic H/A plus i taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
75869547|NCT04172532|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75869548|NCT04172532|Procedure|Magnetic Resonance Imaging|Undergo MRI
75869549|NCT04172532|Drug|Peposertib|Given PO
75388977|NCT01759446|Drug|Generic H/A plus p taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
75388978|NCT01777308|Biological|Meningococcal conjugate vaccine GSK134612|Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
75388979|NCT01759368|Device|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
75388980|NCT01777152|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
75388981|NCT01777152|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
75388982|NCT01777152|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
75388983|NCT01777152|Drug|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
75388984|NCT01777152|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
75388985|NCT01759290|Device|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
75388986|NCT01758900|Device|CO2 insufflation regulator|The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
75388987|NCT01758900|Device|Air insufflation|The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
75388988|NCT01757184|Drug|Sebelipase Alfa|IV infusions of sebelipase alfa
75388989|NCT01757184|Drug|Placebo|IV infusions of matched placebo
75388990|NCT01775904|Drug|LY2886721 in a Capsule|Administered orally.
75388991|NCT01775904|Drug|LY2886721 in an orally disintegrating tablet (ODT)|Administered orally.
75388992|NCT01775670|Device|Off-the-shelf splint|Subjects will use an off-the-shelf splint
75542736|NCT04234646|Behavioral|Patient Navigation (PN) 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
75388993|NCT01775670|Device|OT Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
75388994|NCT01775124|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
75388995|NCT01733316|Drug|RP103|
75388996|NCT01733316|Drug|Cystagon®|
75388997|NCT01732926|Drug|Idelalisib|150 mg tablet administered orally twice daily
75388998|NCT01732926|Drug|Rituximab|375 mg/m^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
75557863|NCT00440063|Drug|epoetin beta [NeoRecormon]|
75557864|NCT00438282|Behavioral|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
75557865|NCT00440102|Drug|Ketamine|Ketamine
75557866|NCT00440102|Drug|Etomidate|Etomidate
75557867|NCT00476541|Drug|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
75869550|NCT04172532|Other|Placebo Administration|Given PO
75388999|NCT01732926|Drug|Bendamustine|90 mg/m^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
75389000|NCT01732926|Drug|Placebo|Tablet administered orally twice daily
75389001|NCT01755858|Drug|Bendavia|
75389002|NCT01755858|Drug|Placebo|
75389003|NCT01732770|Biological|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
75389004|NCT01732770|Drug|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
75389005|NCT01732770|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
75542737|NCT04234646|Behavioral|One-on-one Patient Navigation (PN)|The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
75542738|NCT04202445|Drug|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
75542739|NCT04177433|Drug|Depo-Medrol Injectable Product|Corticosteroid
75542740|NCT04177433|Drug|Saline|Placebo
75542741|NCT04141748|Device|Symphonie Aqua SystemTM|a water filled cylinder that can be pressurized around the residual limb to support body weight
75389006|NCT01732770|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
75389007|NCT01732692|Drug|MOVIPREP|MOVIPREP solution
75542742|NCT04141748|Procedure|Hand Casting|plaster of Paris or fiberglass bandages are wrapped around the residual limb
75389008|NCT01774968|Drug|Human Regular U-500 Insulin|
75389009|NCT01774344|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib, 40 mg tablets
75389010|NCT01774344|Drug|Placebo|Placebo tablets matching in appearance
75389011|NCT01732536|Drug|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
75389012|NCT01732536|Procedure|Sham procedure|In-office bilateral sham procedure
75389013|NCT01732536|Drug|Mometasone furoate nasal spray|Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
75389014|NCT01755702|Drug|Placebo|Placebo
75389015|NCT01755702|Drug|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
75389016|NCT01755702|Drug|ibuprofen marketed formulation|ibuprofen marketed formulation
75542743|NCT04132895|Other|observational only, no interventions are prescribed in protocol.|"Treatment will be given as per usual standard of care.~No treatments are specified by this protocol."
75542744|NCT04131842|Other|External focus of attention visual feedback|Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
75542745|NCT04131842|Other|External focus of attention auditory feedback|Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
75542746|NCT04131842|Other|Internal focus of attention video feedback|Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
75542747|NCT04131842|Other|No feedback|Patients will receive no feedback during the impairment-based rehabilitation program.
75389017|NCT01755702|Drug|Paracetamol marketed formulation|Paracetamol marketed formulation
75389018|NCT01732458|Drug|Aprepitant|Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.
75389019|NCT01732458|Drug|Placebo to Aprepitant|
75389020|NCT01732458|Drug|Ondansetron|Administered IV at a dose of 4 mg for participants >40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants <1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.
75389021|NCT01732458|Drug|Placebo to match ondansetron|Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
75389022|NCT01731990|Drug|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
75389023|NCT01731990|Drug|Placebo|Matching placebo of Canakinumab
75389024|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
75389025|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
76033441|NCT04509739|Behavioral|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
76033442|NCT01966263|Procedure|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
76033443|NCT01966263|Procedure|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
76033444|NCT01966263|Procedure|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
75389026|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
75557868|NCT00476580|Behavioral|Questionnaire|Questions to collect health information specific to Sri Lankans.
75869551|NCT04156919|Behavioral|fooya!™|fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.
76033445|NCT01966263|Procedure|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
75557869|NCT00440141|Drug|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
75557870|NCT00440141|Drug|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
75389027|NCT01708902|Drug|Metformin 500mg|Metformin 500mg BID
75389028|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
75389029|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
75389030|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
75389031|NCT01708902|Drug|Metformin 1000mg|Metformin 1000mg BID
75389032|NCT01755546|Drug|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
75557871|NCT00475449|Procedure|percutaneous coronary intervention|
75557872|NCT00475449|Procedure|coronary artery bypass grafting|
75557873|NCT03279575|Behavioral|Night Shift|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.
75557874|NCT03279575|Behavioral|Graveyard Shift|Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.
75557875|NCT03279575|Behavioral|Educational program|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.
75557876|NCT03279575|Behavioral|Control|Physicians in this arm will serve as a no-contact control group.
75389033|NCT04413864|Other|Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration|"Assigned Interventions:~Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)"
75389034|NCT04560504|Other|Control Group|Leisure activities
75389035|NCT04560504|Other|Oculomotor Training Group|Eye movement training
75389036|NCT01755234|Drug|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
75542748|NCT04130711|Other|Visual virtual Conditions|"The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background."
75869552|NCT04156919|Other|WordSearch|We will have an active control group that will play a WordSearch game. The intention is to have the children play a familiar video game through the same modality (IPAD) that is unrelated to diet or lifestyle choices.
75869553|NCT04152200|Drug|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
75389037|NCT01755234|Drug|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
75389038|NCT01731912|Drug|Degarelix|Given SC
76033446|NCT04930679|Drug|Andiabet|Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
75389039|NCT01731912|Radiation|External Beam Radiation Therapy|Undergo standard EBRT
75389040|NCT01731912|Other|Laboratory Biomarker Analysis|Correlative studies
75869554|NCT04144023|Biological|Granulocyte-Macrophage Colony-Stimulating Factor|Given intradermally
75389041|NCT01731678|Procedure|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
75557877|NCT00438321|Drug|Zoladex|
75557878|NCT00438321|Drug|Testosterone gel|
75557879|NCT00438321|Drug|Anastrozole Pill|
75557880|NCT00438321|Other|Placebo|
75557881|NCT00476619|Drug|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
75869555|NCT04144023|Biological|Multi-epitope HER2 Peptide Vaccine H2NVAC|Given intradermally
75869556|NCT04144023|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
75869557|NCT04144023|Procedure|Echocardiography|Undergo ECHO
75389042|NCT01731600|Drug|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
75869558|NCT04144023|Procedure|Biospecimen Collection|Undergo collection of blood samples
75869559|NCT04144023|Procedure|Biopsy|Undergo biopsy
76033447|NCT04436185|Behavioral|Comparisons of procedural pain|This randomized experimental study with placebo and control groups
76033448|NCT04400201|Drug|Remimazolam Tosilate|Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
76033449|NCT04400201|Drug|Propofol|Intravenous injection at a dose of 1.5~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0~12 mg/kg/h for sedation maintenance
76033450|NCT05434845|Other|Blood draw|An additional 8 mL of blood will be drawn during routine lab collection
75389043|NCT01730586|Drug|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
75389044|NCT04413942|Biological|FB825|Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
75389045|NCT04413942|Other|Placebo|Formulation buffer
75389046|NCT01707030|Other|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
75389047|NCT01707030|Other|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
75389048|NCT01755156|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
75869560|NCT04134091|Drug|LPCN 1144 Formulation A|Oral LPCN 1144 Formulation A capsule, total daily dose of 450 mg testosterone undecanoate administered as 225 mg testosterone undecanoate twice daily (BID).
75389049|NCT01755156|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
75389050|NCT01755156|Drug|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
75389051|NCT01755156|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
75869561|NCT04134091|Drug|LPCN 1144 Formulation B|Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg d-alpha tocopherol BID
75869562|NCT04134091|Drug|Placebo|Oral matching placebo capsule administered as BID
75389052|NCT01755156|Drug|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
75389053|NCT01755156|Drug|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (>= 1500 mg daily) throughout the study.
75869563|NCT04115644|Drug|Ketorolac|Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
75869564|NCT04115644|Drug|Marcaine (placebo)|Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
75389054|NCT01754766|Drug|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
75389055|NCT01754766|Other|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
75389056|NCT01754376|Drug|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
75557882|NCT03279536|Combination Product|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
75869565|NCT04115644|Drug|Kenalog|Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
75869566|NCT04113382|Drug|CLENPIQ|"CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL."
75869567|NCT04113382|Drug|MIRALAX|MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol [PEG] 3350).
75869568|NCT04108026|Drug|Durvalumab|1500 mg IV every 4 weeks
75557883|NCT03279536|Combination Product|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
75389057|NCT01754376|Drug|Vemurafenib|Tablets given twice daily.
75389058|NCT01605396|Drug|Ridaforolimus|Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, & 22-26 of 28-day cycle.
75389059|NCT01605396|Drug|Dalotuzumab|Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
75389060|NCT01605396|Drug|Exemestane|Exemestane 25 mg tablet administered PO QD.
75389061|NCT01730118|Biological|Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine|autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
76033451|NCT04920773|Other|Guduchi Ghanvati|500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
75389062|NCT01730040|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
75389063|NCT01730040|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
75389064|NCT01730040|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
75389065|NCT01730040|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
75389066|NCT01730040|Drug|Placebo|Placebo for alirocumab and ezetimibe.
75542749|NCT04130711|Other|Standard EEG|Twenty healthy volunteers test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order.
75557884|NCT03279497|Behavioral|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
75869569|NCT04099823|Other|MRI screening form|Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
75869570|NCT04099823|Diagnostic Test|Urine pregnancy test|Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
76033452|NCT04920773|Other|Standard guidelines|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
75557885|NCT03279497|Behavioral|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
76033453|NCT04423107|Drug|Acetaminophen, Ibuprofen|Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
76033454|NCT04423107|Drug|Acetaminophen, Ibuprofen, Oxycodone|Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
76033455|NCT01675531|Drug|Targin|Single arm for Targin
76033456|NCT04920851|Device|cytokine hemadsorption|to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
76033457|NCT05406999|Drug|ADT|The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
76033458|NCT05406999|Drug|Abiraterone Acetate|1000 mg (250 mg×4 tablets) once daily, orally
76033459|NCT05406999|Drug|Prednisolone tablets|5 mg once daily, orally.
76033460|NCT05406999|Drug|Enzalutamide|160 mg (40 mg× 4 tablets) once daily, orally.
75389067|NCT01706328|Drug|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
75389068|NCT01706328|Drug|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
75389069|NCT01706328|Drug|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
75389070|NCT01706328|Drug|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
75542750|NCT04130711|Other|Neurofeedback Training Stroke Patients|The post-stroke subject is evaluated on clinical tests (FMA, ARAT, MAL, NHPT, Finger Tapping test) during the first visit. Then, he performs 12 sessions of NFB (on his deficit member) lasting 45 minutes, spread over 6 weeks, depending on the feedback modality that has been drawn randomly (visual or visuo-vibratory). A second visit after the first NFB session and a third visit after the last NFB session evaluates the motor skills of the trained upper limb (FMA, ARAT, MAL, NHPT, Finger Tapping test) and a satisfaction questionnaire is given to the subject for evaluate tolerance and satisfaction with the feedback modality assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
75542751|NCT04120285|Behavioral|remote internet-based cognitive behavior therapy (eCBT)|Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
75542752|NCT04108897|Drug|Doxycycline|The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.
75542753|NCT04108897|Drug|Ivermectin Topical|1% topical ivermectin.
75542754|NCT04101877|Drug|Bevacizumab Injection|25 mg/ml
75542755|NCT04101877|Drug|Aflibercept Injection|40 mg/ml
75542756|NCT04101838|Drug|Fluzone|inactivated seasonal influenza vaccine
75869571|NCT04099823|Diagnostic Test|MR brain|"You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging."
76033461|NCT05406999|Drug|Apalutamide|240 mg (60 mg×4 tablets) once daily, orally.
76033462|NCT05406999|Drug|Darotamide|600 mg (300 mg × 2 tablets) twice daily, orally.
75542757|NCT04101838|Drug|Flucelvax|inactivated seasonal influenza vaccine
75542758|NCT04101838|Drug|Fluzone High-Dose|inactivated seasonal influenza vaccine
75542759|NCT04101838|Drug|Fluad|inactivated seasonal influenza vaccine
75542760|NCT04061044|Drug|Ophthalmic Insert|Travoprost, 0.32 mg
75542761|NCT04054648|Other|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
75542762|NCT04026958|Drug|Clarithromycin|Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
75542763|NCT04026958|Drug|Placebo|A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
75542764|NCT04024254|Drug|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
75542765|NCT04016376|Drug|PVB Protocol|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
75542766|NCT04016376|Drug|PECS-1|For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
75542767|NCT04016376|Drug|Serratus|For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
75542768|NCT03939481|Drug|Chemotherapy|Given chemotherapy regimen
75542769|NCT03939481|Other|Functional Assessment|Functional and sensory clinician assessments
75542770|NCT03939481|Other|Questionnaire Administration|Patient and physician reported responses
75869572|NCT04098666|Drug|Placebo oral tablet|Placebo tablet identical to metformin, up to 4 tablets a day
75389071|NCT01706328|Drug|Salbutamol as needed|Salbutamol inhalation powder
75389072|NCT01753518|Device|Subcuticular suture|subcuticular Monocryl suture closure
75389073|NCT01753518|Device|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
75389074|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
75389075|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
75389076|NCT01706250|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
75389077|NCT01706250|Other|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
75542771|NCT03939182|Drug|Abexinostat|Two doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.
75389078|NCT01706250|Other|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
75389079|NCT01706250|Other|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
75389080|NCT01729728|Drug|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
75542772|NCT03939182|Drug|Ibrutinib|Ibrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.
75542773|NCT03935633|Drug|CN128 Tablets|Iron chelator， oral tablets
75542774|NCT03901807|Device|Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge|TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
75542775|NCT03887702|Other|Best Practice|Receive best practice
75542776|NCT03887702|Drug|Entecavir|Given PO
75706425|NCT00860626|Drug|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
75542777|NCT03887702|Drug|Tenofovir Alafenamide|Given PO
75542778|NCT03887702|Drug|Tenofovir Disoproxil Fumarate|Given PO
75542779|NCT03878589|Drug|Oxytocin (OT)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
75542780|NCT03878589|Drug|Placebo (P)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
75542781|NCT03875326|Device|1 mA HD-tDCS|Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
75542782|NCT03875326|Device|2 mA HD-tDCS|Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
75389081|NCT01729026|Other|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
75389082|NCT01728792|Biological|TDV|TDV IM or SC injection
75389083|NCT01752036|Radiation|Post-operative, Stereotactic Body Radiation Therapy (SBRT)|All participants received SBRT at 600 cGy x 5 fractions
75389084|NCT01728324|Drug|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
75389085|NCT01728324|Drug|Ribavirin: 24-week treatment|24 weeks of active treatment
75389086|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
75389087|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
75389088|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
75389089|NCT01728324|Drug|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
75542783|NCT03875326|Device|3 mA HD-tDCS|Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
75542784|NCT03875326|Device|Sham|Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
75542785|NCT03843190|Behavioral|Take of Pounds Sensibly (TOPS)|Experimental arm: Dietician-facilitated Wait-list control arm: Peer-led
75542786|NCT03833206|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
75542787|NCT03832829|Device|Indirect composite restoration|Restoration of tooth with extensive substance loss
75542788|NCT03827850|Drug|ERDAFITINIB|Daily in a range from 3 mg to 9 mg
75706426|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
75706427|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
75706428|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
75389090|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
75389091|NCT01728324|Drug|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
75389092|NCT01728324|Drug|Faldaprevir: 16-week treatment|16 weeks of active treatment
75389093|NCT01728324|Drug|Ribavirin: 16-week treatment|16 weeks of active treatment
75389094|NCT01728324|Drug|RBV: 24-week treatment|24 weeks of active treatment
75389095|NCT01728324|Drug|BI 207127: 16-week treatment|16 weeks of active treatment
75389096|NCT01728246|Drug|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
75542789|NCT03813836|Drug|Pembrolizumab|Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
76033463|NCT05406999|Drug|Rezvilutamide|240 mg (80 mg × 3 tablets) once daily orally
75389097|NCT01728246|Drug|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
75706429|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
75869573|NCT04098666|Drug|extended release metformin|Metformin extended release 500 mg tablets, up to 4 tablets a day
75869574|NCT04089579|Biological|Cord Tissue Mesenchymal Stromal Cells|Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.
76033464|NCT05406999|Drug|PARP inhibitor|The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
75389098|NCT04414020|Drug|Progesteron|intramusculer progesterone
75542790|NCT03801330|Other|Usual Care Pulmonary Rehabilitation Program|Participants in the Usual Care Pulmonary Rehabilitation Program group will complete an 8 week clinic based Pulmonary Rehabilitation Program (usual care).
75706430|NCT04041466|Diagnostic Test|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
75389099|NCT04559178|Other|Fluid challenge|fluid challenge administration when patient is in the gray zone
75706431|NCT04067934|Behavioral|Jumping Exercise programme|Four weeks of three jumping-based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
75869575|NCT04089579|Other|Placebo Infusion|Placebo comparative infusion
75869576|NCT04078568|Drug|IVIG|IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
75869577|NCT04078568|Drug|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
75389100|NCT04559022|Procedure|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
75389101|NCT01705236|Drug|Fingolimod|All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
75389102|NCT01705080|Device|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
75389103|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
75389104|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
76033465|NCT05406999|Procedure|Robot-assisted radical prostatectomy|Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
76033466|NCT05118607|Device|IG1|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
75389105|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
75542791|NCT03801330|Other|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete an 8-week home-based Pulmonary Rehabilitation Program using a software app (software)
75542792|NCT03796988|Device|Autologous Regeneration of Tissue (ART) device|This device will harvest hundreds of full-thickness columns of skin tissue (500 micrometer diameter) using single-needle, fluid-assisted harvesting technology.
75542793|NCT03740048|Other|Hemodialysis|Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
75542794|NCT03740048|Drug|Patiromer Oral Product|Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
75542795|NCT03733951|Drug|KN046|"Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia."
75542796|NCT03730649|Drug|Sulforaphane (broccoli sprout extract)|Participants will topically apply Sulforaphane for a period of time
75389106|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
75542797|NCT03730649|Radiation|UV or visible light|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
75542798|NCT03683355|Radiation|18F-FDG PET/CT|18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
75869578|NCT04078568|Drug|Prednisolone|Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
75389107|NCT01751802|Drug|Ecopipam|Antagonist of the dopamine D1 receptor
75389108|NCT01751802|Drug|Placebo|Placebo for Ecopipam
75389109|NCT01704456|Behavioral|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
75389110|NCT01704456|Behavioral|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
75389111|NCT04166526|Device|FDNIRS-DCS|FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
75389112|NCT04166526|Device|MRI|Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
75389113|NCT01703988|Drug|Nusinersen|Single IT injection for each dose
75389114|NCT01703832|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
75389115|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
75389116|NCT01703286|Drug|Linagliptin|given once daily for 28 days
75542799|NCT03645031|Other|Acute Intermittent Hypoxia|AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
75542800|NCT03645031|Other|Sham Acute Intermittent Hypoxia|Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
75542801|NCT03612596|Behavioral|Narrative visualization|Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior
75542802|NCT03612596|Behavioral|Standard self-regulation|Participants self-monitor steps using a wearable device, app, and a hand-written step log
75706432|NCT00860704|Drug|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
76033467|NCT04930211|Drug|Dexamethasone-Lidocaine|Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
75542803|NCT03598426|Drug|Dexamethasone|Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
75542804|NCT03561805|Device|ECG monitoring|Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
75542805|NCT03558204|Procedure|Denervation of the thumb CMC joint|Removal/disconnection of the nerve branches to the joint from their attachments to the joint
75542806|NCT03558204|Procedure|trapeziectomy with ligament reconstruction (LRTI)|excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
75706433|NCT04742660|Drug|Ammonium Glycyrrhizinate|In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.
75706434|NCT00860782|Behavioral|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
75542807|NCT03521037|Drug|Rucaparib camsylate|In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
75542808|NCT03507777|Device|Coronary PCI guided by OCT|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using OCT guidance
75706435|NCT04069260|Drug|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
76033468|NCT03177265|Behavioral|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
75706436|NCT04734938|Dietary Supplement|Huel Powder|Huel is made of an ultra-fine blend of sustainable ingredients. Oats, rice, peas, coconut, flaxseed, and our unique mix of vitamins and nutrients to provide you a meal with all the carbohydrates, protein, essential fats, fibre, and all the 26 essential vitamins and minerals your body needs to thrive. Volunteers will consume only Huel as their food source for the final four weeks of the study.
75706437|NCT00860860|Drug|TF2|TF2: 75-300 mg
75706438|NCT00860860|Drug|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
75706439|NCT02571894|Other|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
75706440|NCT01089296|Other|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant's condition allows it. The length of each treatment session will be adjusted dependent on the infant's response and condition. Maximum treatment time is 10 minutes.
75706441|NCT04041388|Other|Conebeam CT|medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
75389117|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
75389118|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
75389119|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
75389120|NCT01703286|Drug|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
75706442|NCT00854152|Drug|GDC-0980|Escalating repeating dose
75706443|NCT00721890|Dietary Supplement|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
75706444|NCT01005914|Drug|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
75389121|NCT04166448|Other|Fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
75389122|NCT01703208|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
75389123|NCT01703208|Drug|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
75542809|NCT03507777|Device|Coronary PCI guided by Angiography|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using angiography guidance
75706445|NCT01005914|Drug|cytarabine|Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4
75706446|NCT01005914|Drug|dexamethasone|Day 1-4; 11-14: 40 mg daily
75706447|NCT01005914|Drug|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
75706448|NCT01005914|Drug|imatinib mesylate|600 mg/day
75706449|NCT01005914|Drug|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
75706450|NCT01005914|Drug|methylprednisolone|Day 1-3: 50mg IV BID
75706451|NCT01005914|Drug|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
75706452|NCT01005914|Drug|vincristine sulfate|Day 4 & 11: 2 mg IV
75389124|NCT01727700|Drug|Aripiprazole|Once-daily, tablet
75389125|NCT01727700|Drug|Placebo|
75389126|NCT01727154|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
75706453|NCT00854230|Drug|Naltrexone|Naltrexone dose 25-100mg
75706454|NCT04067076|Other|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
75542810|NCT03499444|Drug|Rucaparib|Rucaparib will be administered twice daily
75389127|NCT01725750|Device|Bright White Light (BWL)|"Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
75389128|NCT01725750|Device|Dim Red Light (DRL)|"A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
75542811|NCT03494322|Drug|Avelumab|Avelumab 10 mg/kg given IV
75542812|NCT03494322|Drug|Cetuximab|"Cetuximab 500* mg/m2 given IV~*Cetuximab dose will be dependent on outcome of safety run-in."
75542813|NCT03459079|Drug|Lanifibranor|The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
76033469|NCT03177265|Behavioral|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
75542814|NCT03459079|Other|Placebo|Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
76033470|NCT03177265|Behavioral|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
75542815|NCT03441633|Drug|apixaban|current or new medication
75542816|NCT03441633|Drug|dabigatran|current or new medication
75542817|NCT03441633|Drug|VKA|current or new medication
75706455|NCT00861016|Drug|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
75706456|NCT04018144|Diagnostic Test|Gingiva Biopsy Sampling|Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.
76033471|NCT03177265|Behavioral|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
76033472|NCT03054311|Behavioral|Lifestyle Matters|
76033473|NCT04912271|Drug|Granisetron transdermal patch|Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting.
76033474|NCT04912271|Drug|Palonosetron|Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV).
76033475|NCT04912271|Drug|Aprepitant|Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.
76033476|NCT04912271|Drug|Fosaprepitant|Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.
76033477|NCT04912271|Drug|Dexamethasone|Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.
76033478|NCT02807779|Drug|Dexamethasone infusion|Participants will receive dexamethasone infusion following plain balloon angioplasty
76033479|NCT02807779|Device|Drug coated balloon|Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
75389129|NCT01725282|Drug|quetiapine extended release (XR)|Extended release tablets
75389130|NCT01725282|Drug|Placebo|matching tablets
75389131|NCT01725126|Drug|GSK2890457|Provided as powder and capsule.
75542818|NCT03441633|Drug|rivaroxaban|current or new medication
75542819|NCT03397394|Drug|Rucaparib|Rucaparib will be administered daily.
75542820|NCT03373760|Biological|Durvalumab|Given IV
75542821|NCT03373760|Other|Laboratory Biomarker Analysis|Correlative studies
76033480|NCT02807779|Device|Plain balloon angioplasty|Participants will receive plain balloon angioplasty only
76033481|NCT03057197|Procedure|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
75542822|NCT03373760|Biological|Tremelimumab|Given IV
75542823|NCT03324880|Biological|rhPTH (1-84)|rhPTH (1-84) SC injection.
75542824|NCT03324880|Biological|Placebo|Placebo QD SC injection.
75542825|NCT03290794|Drug|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
75542826|NCT03107897|Other|Pre-habilitation|Eight - Twelve visits to physical therapy prior to their TAVR procedure.
75542827|NCT03059342|Procedure|single event multilevel surgery|
76033482|NCT02769091|Drug|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
76033483|NCT02769091|Drug|Placebo|
76033484|NCT04912193|Drug|Antithrombin III|In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.
76033485|NCT02680561|Drug|Fluticasone Propionate MDPI|
76033486|NCT02680561|Drug|Fluticasone Propionate/Salmeterol MDPI|
76033487|NCT02680561|Drug|Fluticasone propionate/salmeterol|
76033488|NCT02532543|Biological|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
76033489|NCT02532543|Biological|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
76033490|NCT02532543|Biological|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
76033491|NCT02532543|Biological|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
76033492|NCT03057353|Device|lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
76033493|NCT03054389|Other|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
76033494|NCT03054389|Other|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
76033495|NCT05118373|Behavioral|BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA|The intervention is a mass media campaign using TV, radio, billboard and posters to disseminate the message. The content are well-produced videos and pictures emphasising the need to wash hands, wear a mask, maintain social distance and clean surfaces. The English version of the video can be viewed at this link: https://youtu.be/tcjaLAxy4Ms.
76033496|NCT03057275|Device|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
76033497|NCT05116111|Drug|SYHA1402 tablets|SYHA1402 tablets, oral, twice daily
76033498|NCT05116111|Drug|Placebo|Placebo, oral, twice daily
76033499|NCT04929977|Device|Wearable device with smart mobile phone|The wearable device will act as a sensor designed to identify critical parameters such as Kangaroo Mother Care adherence and temperature of the infant 24/7 and of the mother-infant pairs during these sessions.
75542828|NCT03053440|Drug|BGB-3111|160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
75542829|NCT03053440|Drug|Ibrutinib|420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
76033500|NCT05095051|Device|Paxman Cryocompression System (PCCS)|"Establishing optimal temperature and pressure for limb cryocompression therapy. Healthy subjects will undergo 3 hours of limb cryocompression.~The cryocompression device used in this study consists of a control unit, and limb wraps. The control unit contains the coolant reservoir and pump to circulate the coolant and air for compression. It is able to thermoregulate (control the temperature of the circulating coolant) and offer cyclic air pressure in the wraps. The wraps cover the limbs from the elbow/knee to the fingers/toes."
75542830|NCT02986100|Drug|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and [14C]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of [14C]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of [14C]-rucaparib
75542831|NCT02986100|Drug|Rucaparib|200 & 300 mg tablet
75542832|NCT02985684|Device|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
75542833|NCT02965027|Drug|Prazosin|
75542834|NCT02965027|Drug|Placebos|
76033501|NCT05095051|Device|Paxman Cryocompression System (PCCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Limb cryocompression sessions comprised of a pre-cooling period (up to one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, limb cryocompression will be administered for no longer than four hours."
76033502|NCT05597631|Device|G-IVF PLUS|Experimental
76033503|NCT04912037|Device|artificial intelligence assistance system|the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
75557886|NCT00438438|Behavioral|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
75557887|NCT00476697|Device|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
75557888|NCT00440219|Drug|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
75557889|NCT00440219|Drug|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
75557890|NCT00438477|Drug|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
75389132|NCT01725126|Drug|Metformin|"Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study"
75389133|NCT01725126|Drug|Placebo|Provided as powder and Capsule.
75542835|NCT02959450|Dietary Supplement|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
75542836|NCT02952534|Drug|Rucaparib|Rucaparib will be administered daily
75542837|NCT02949934|Drug|Tolcapone|
75542838|NCT02949934|Drug|Placebo|
75389134|NCT01725126|Drug|Liraglutide|"Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg~Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only"
75389135|NCT01751724|Drug|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
75542839|NCT02935634|Biological|Nivolumab|Specified dose on specified days
75542840|NCT02935634|Biological|Ipilimumab|Specified dose on specified days
75542841|NCT02935634|Biological|Relatlimab|Specified dose on specified days
75706457|NCT04697966|Behavioral|Mindfulness (Headspace) App|"The Headspace app consists of guided mindfulness meditations and is available for both Apple iOS and Android devices. For the proposed study, participants will be instructed to complete the app's most popular introductory program which consists of three levels (Basics 1-3), with each level comprising 10 sessions (30 in total) over 30 days. The program is intended to introduce the key principles and techniques of mindfulness (including focused meditation on the breath, body scanning, and noting), and strategies for applying mindfulness to daily life."
75706458|NCT04697966|Behavioral|"Active Control Condition (Recharge condition delivered in Headspace app)"|"The majority of prior research on mindfulness interventions has relied on single-arm designs or wait-list controls conditions, rather than active control conditions. Accordingly, we will include a structurally-equivalent active control condition, delivered via the same Headspace app. Specifically, the control condition will consist of 30 guided Recharge sessions led by Andy Puddicombe (i.e., structurally equivalent to the Mindfulness app). The sessions are the same length as the interventions (Basics) sessions and also delivered via the Headspace app, thus closely matching the mindfulness intervention across key attributes. Specifically, user flow through the app is identical in both the mindfulness and control conditions, differing only in session content. The Recharge sessions include guide reflections, guided positive imagery, problem solving and daily planning. The chosen excerpts exclude any content which feature guided mindfulness exercises."
75389136|NCT01751724|Other|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
75389137|NCT01751646|Dietary Supplement|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
75389138|NCT01751646|Dietary Supplement|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
75389139|NCT01751568|Drug|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
75389140|NCT01751412|Radiation|Proton Radiation|
75389141|NCT04556682|Device|Rotational atherectomy|Device used for severely calcified coronary lesion preparation before stent implantation.
75389142|NCT04556682|Device|Intravascular lithotripsy|Device used for severely calcified coronary lesion preparation before stent implantation.
75542842|NCT02935634|Biological|BMS-986205|Specified dose on specified days
75542843|NCT02935634|Drug|Rucaparib|Specified dose on specified days
75542844|NCT02864992|Drug|Tepotinib|Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
75542845|NCT02740712|Drug|Caffeine|200 mg (4 x 50mg) Tablet
75542846|NCT02740712|Drug|Warfarin|10 mg (2 x 5mg) Tablet
75542847|NCT02740712|Drug|Omeprazole|40 mg Tablet
75542848|NCT02740712|Drug|Midazolam|5 mg/mL
75542849|NCT02740712|Drug|digoxin|.25 mg Tablet
76033504|NCT05406297|Procedure|pressure-temperature sensor guidewire-based measurement|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire was first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
75389143|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
75389144|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
75542850|NCT02740712|Drug|Vitamin K|10 mg Tablet
75542851|NCT02740712|Drug|Rucaparib|200 & 300 mg tablet
75542852|NCT02684578|Drug|Metformin|
75542853|NCT02612129|Drug|arimoclomol|
75542854|NCT02612129|Drug|Placebo|
75542855|NCT02580305|Drug|SUVN-502|Once-daily, tablets, orally
75542856|NCT02580305|Drug|Placebo|Once-daily, tablets, orally
75706459|NCT00718380|Drug|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
76033505|NCT04824469|Other|intervention group|web based training: By establishing a website, training on drug use, symptom management and quality of life will be provided.
76033506|NCT04258059|Device|Active household UV water treatment device|This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
76033507|NCT04258059|Device|Inactive household UV water treatment device|This sham device will use a lamp not emitting germicidal UV.
75389145|NCT01606254|Drug|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
75542857|NCT02580305|Drug|Donepezil|Donepezil HCl (10 mg, once a day)
75542858|NCT02580305|Drug|Memantine|Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
75542859|NCT02279394|Drug|Elotuzumab|10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8
75542860|NCT02279394|Drug|Lenalidomide|25 mg Oral; Days 1-21 days Cycles 1-24
75542861|NCT02279394|Drug|Dexamethasone|40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
75542862|NCT02229578|Drug|Lidocaine|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
75557891|NCT00438477|Procedure|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
75389146|NCT01750242|Device|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
75706460|NCT02553291|Behavioral|SystemCHANGE|
75706461|NCT02553291|Behavioral|Control|
75706462|NCT04683068|Behavioral|Message comparison|Message comparison
75389147|NCT01723254|Biological|IGE-1|Intramuscular, multiple dose
75389148|NCT01723254|Biological|IGE-2|Intramuscular, multiple dose
75557892|NCT00438477|Radiation|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection."
75557893|NCT00440258|Drug|Cabergoline|
75557894|NCT00440258|Procedure|MR|
75557895|NCT00440258|Procedure|Ultrasound|
75557896|NCT00440258|Procedure|Blood Analysis|
75706463|NCT00851032|Other|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
75869579|NCT04064723|Device|Randomization between prosthetic components|Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
75869580|NCT04064528|Dietary Supplement|Amino Acids|10 g bolus of essential amino acids
76033508|NCT05406063|Radiation|SBRT|Stereotactic multiple fraction radiotherapy
75389149|NCT01723254|Biological|Saline|Saline (0.9% sodium chloride)
75389150|NCT01722162|Drug|Bevacizumab|
75389151|NCT01722162|Drug|Capecitabine|
75389152|NCT01722162|Drug|Levocetirizine|
75389153|NCT01721772|Biological|BMS-936558 (Nivolumab)|
75389154|NCT01721772|Biological|Placebo matching BMS-936558 (Nivolumab)|
75706464|NCT05632250|Device|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
75706465|NCT00807105|Device|H-coil dTMS|treatment with deep TMS stimulation.
76033509|NCT05037097|Biological|ARCT-165|Dose 3
75389155|NCT01721772|Drug|Dacarbazine|
75389156|NCT01721772|Drug|Placebo matching Dacarbazine|
75542863|NCT02229578|Drug|Placebo|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
75542864|NCT02151513|Device|Intrathecal Pump Placement|
75542865|NCT02054741|Other|Comprehensive Geriatric Assessment|Complete geriatric assessment
75542866|NCT02054741|Other|Quality-of-Life Assessment|Ancillary studies
75542867|NCT02054741|Other|Survey Administration|Ancillary studies
75542868|NCT01821781|Drug|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
76033510|NCT05037097|Biological|ARCT-154|Dose 2
76033511|NCT05037097|Biological|ARCT-021|Dose 1
75389157|NCT01702428|Biological|Priorix|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
75389158|NCT01702428|Biological|M-M-R II|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
75389159|NCT01702428|Biological|Varivax|Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
75389160|NCT01702428|Biological|Havrix|Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
75389161|NCT01702428|Biological|Prevnar 13|US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
75389162|NCT01701258|Drug|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
75389163|NCT01701258|Drug|Placebo|single-dose placebo capsule during the fMRI session only
75389164|NCT01700946|Drug|dexamethasone|given intravenously or orally
75542869|NCT01555463|Drug|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
75542870|NCT01555463|Drug|Vehicle foam|twice daily topical application
75557897|NCT00438516|Behavioral|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
75557898|NCT00440336|Drug|Cosopt|
75557899|NCT00440336|Drug|Xalatan|
75557900|NCT03276780|Behavioral|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
75389165|NCT01700946|Drug|vincristine sulfate|given intravenously
75389166|NCT01700946|Biological|rituximab|given intravenously
75557901|NCT03276780|Drug|combination NRT|Both groups will receive combination NRT to help with smoking cessation
75557902|NCT00440375|Drug|Rosiglitazone|
76033512|NCT05025163|Drug|1.23% fluoride foam application|topical application of fluoride foam every 6 months
75389167|NCT01700946|Drug|clofarabine|given intravenously
75389168|NCT01700946|Drug|cyclophosphamide|given intravenously
75389169|NCT01700946|Drug|etoposide|given intravenously
75389170|NCT01700946|Biological|aldesleukin|given subcutaneously
75389171|NCT01700946|Drug|pegaspargase|given intravenously
75389172|NCT01700946|Drug|methotrexate|given intrathecally or intravenously
76033513|NCT05025163|Drug|2.26% fluoride varnish application|topical application of fluoride varnish every 6 months
76033514|NCT02674321|Drug|SD-809|
75389173|NCT01700946|Drug|mercaptopurine|given orally
75389174|NCT01700946|Drug|cytarabine|given intrathecally or intravenously
75389175|NCT01700946|Drug|mitoxantrone|given intravenously
75389176|NCT01700946|Drug|teniposide|given intravenously
75389177|NCT01700946|Drug|vinblastine|given intravenously
75389178|NCT01700946|Biological|natural killer cell infusion|undergo allogeneic natural killer cell infusion
75389179|NCT01700946|Other|laboratory biomarker analysis|correlative studies
75389180|NCT01700946|Drug|therapeutic hydrocortisone|given intrathecally
75389181|NCT01700946|Procedure|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
75389182|NCT01700946|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
75389183|NCT04565886|Device|Diode laser application|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Adjunctive diode laser (settings: 810 nm, 2.5 W, 50 Hz, 10 ms) will be applied 3x for 30 s (i.e., 90 s per appointment) using a 400-lm thick fiber (WhiteStar, Orcos Medical AG, Küsnacht, Switzerland) in the test group. In the control group, non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way. The laser tip will be checked after 4-5 s for coagulation to prevent hotspots in the soft tissues.
75389184|NCT04565886|Device|Sham Diode laser|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way.
75389185|NCT04548804|Diagnostic Test|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan
75389186|NCT01748994|Drug|Pioglitazone|30mg per day for four months
75389187|NCT01748994|Drug|Placebo|
75389188|NCT01721070|Drug|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
75389189|NCT01721070|Drug|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
75706466|NCT00854386|Drug|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
76033515|NCT05070637|Procedure|No-touch laparoscopic radical nephrectomy|We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.
75389190|NCT01748760|Behavioral|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
75389191|NCT01748760|Other|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
75389192|NCT01748292|Drug|0.5 mg ranibizumab|Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
75706467|NCT00854386|Drug|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
75389193|NCT01720602|Drug|vorinostat|Given PO
75389194|NCT01720602|Drug|anastrozole|Given PO
75706468|NCT00804219|Biological|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
75389195|NCT01720602|Drug|letrozole|Given PO
75389196|NCT01720602|Drug|exemestane|Given PO
75389197|NCT01720602|Procedure|positron emission tomography|Correlative studies
75389198|NCT01720602|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
75389199|NCT01720602|Radiation|fludeoxyglucose F 18|Correlative studies
75389200|NCT01720602|Other|laboratory biomarker analysis|Correlative studies
75389201|NCT01746732|Drug|Ortho-Cyclen|Oral administration
75389202|NCT01746732|Drug|Evacetrapib|Oral administration
75869581|NCT04057456|Other|Placebo diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
76033516|NCT05070637|Procedure|Conventional laparoscopic radical nephrectomy|Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
76033517|NCT05070637|Procedure|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
75389203|NCT01720524|Drug|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
76033518|NCT02532465|Device|Air-Q|
76033519|NCT02532465|Device|i-gel|
75389204|NCT01720524|Drug|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
75557903|NCT04700930|Other|CBD-Cigarettes|CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
76033520|NCT02665507|Device|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
75557904|NCT00438555|Behavioral|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
75557905|NCT00438555|Behavioral|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
76033521|NCT02665507|Device|Sham|Hand held laser that emits no LLLI
76033522|NCT02528331|Device|Transcranial magnetic stimulation|
76033523|NCT02528331|Behavioral|Cognitive behavioral therapy|
76033524|NCT02919241|Behavioral|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
75706469|NCT00723684|Other|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
76033525|NCT02919241|Behavioral|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
76033526|NCT02592031|Drug|XM17|300 IU corresponds to an injection volume of 0.5 mL.
76033527|NCT02592031|Drug|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
75389205|NCT01720446|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
75389206|NCT01720446|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
75389207|NCT01720446|Drug|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
75389208|NCT01746108|Biological|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
75389209|NCT01717638|Biological|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
75389210|NCT01717638|Biological|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
75389211|NCT01745094|Drug|mirabegron|oral
75389212|NCT01745094|Drug|solifenacin|oral
76033528|NCT02592031|Drug|Zoladex®|3.6 mg
75389213|NCT01697748|Device|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
75389214|NCT01697748|Device|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
75389215|NCT01717326|Drug|Grazoprevir|100 mg tablet orally QD
75389216|NCT01717326|Drug|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
76033529|NCT05002231|Drug|Losmapimod 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fasted conditions.
76033530|NCT05002231|Drug|Losmapimod two 7.5 mg oral tablets|Subjects will receive two losmapimod 7.5 mg tablets by mouth under fasted conditions.
76033531|NCT05002231|Drug|Losmapimod one 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fed conditions.
76033532|NCT04423263|Procedure|Bilateral internal iliac artery balloon occlusion|Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol
76033533|NCT04423263|Procedure|Control|Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion
76033534|NCT02857543|Other|Plant-Based Diet|
76033535|NCT02857543|Other|American Heart Association Diet|
76033536|NCT02857543|Other|Mediterranean Diet|
75389217|NCT01717326|Drug|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
75389218|NCT01717326|Drug|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
75389219|NCT01697592|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
76033537|NCT05377671|Diagnostic Test|IRM multimodale a ultra-haute camp|The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
76033538|NCT04784299|Device|YVOIRE volume plus|Hyaluronic acid dermal filler
76033539|NCT04784299|Device|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
75389220|NCT01697592|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
76033540|NCT02765659|Behavioral|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
76033541|NCT02765659|Behavioral|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
75706470|NCT00723684|Other|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
75389221|NCT01744782|Drug|RP103|Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was <1 nmol ½ cystine/mg protein.
75706471|NCT00851110|Procedure|stem cell reinfusion|hematopoietic stem cell reinfusion
75389222|NCT01744392|Behavioral|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
75389223|NCT01604850|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
75389224|NCT01604850|Drug|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
75389225|NCT01604850|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
75869582|NCT04057456|Other|Anti-inflammatory diet|"Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes. Occasional cheat foods are built into the anti-inflammatory diet (e.g. two bottles of beer per week)"
76033542|NCT02765659|Behavioral|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
75389226|NCT01604850|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
75389227|NCT01742286|Drug|Ceritinib|"LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat."
75389228|NCT01697358|Device|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
75706472|NCT00851110|Drug|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
75706473|NCT00798291|Other|Ad lib diet and Control placebo|one packet with water two times a day
75706474|NCT00798291|Other|Ad lib diet and An 777|one packet with water two times a day
75706475|NCT00798291|Other|Ad lib diet/ placebo/ exercise|one packet with water two times a day; resistance training three times a week
75869583|NCT04057456|Drug|Nabilone Capsules|Capsules will be 0.5mg nabilone. Participants will undergo a 5-week titration period by taking 1 (0.5mg) nabilone capsule per day for a three-day period. The dose will be increased on a fixed schedule by 1 (0.5mg) capsule every three days to a maximum of 8 capsules/day (4mg). Dosage will be maintained if higher doses are not tolerated or if sufficient relief is obtained (at least a 2-point change on the NRS). Once the appropriate nabilone (or placebo) dosage for each participant is determined, participants will begin their respective interventions over the course of the 4-week treatment period.
76033543|NCT02333149|Dietary Supplement|Melatonin|"Children <40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
76033544|NCT02333149|Drug|Placebo|Placebo frequency and volume are identical to the experimental arm
75389229|NCT01697358|Drug|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
75389230|NCT01716234|Drug|Posaconazole 12 mg/kg/day BID|Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
75389231|NCT01716234|Drug|Posaconazole 18 mg/kg/day BID|Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
75389232|NCT01716234|Drug|Posaconazole 18 mg/kg/day TID|Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
75389233|NCT01716234|Drug|Posaconazole 12 mg/kg/day TID|Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
75389234|NCT01716156|Drug|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
75389235|NCT01716156|Drug|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
75389236|NCT04555512|Other|Progressive High Intensity Interval Training (PRO-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves progression of training of 3 stages: 1) six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min; 2) three high-intensity intervals of 2-min separated by two low-intensity intervals of 4-min, and a further 2-min of low intensity following the last interval before cool-down; and 3) three high-intensity intervals of 3-min separated by two low-intensity intervals of 3-min, and a further 1-min of low intensity following last interval before cool-down.
75389237|NCT04555512|Other|Constant High Intensity Interval Training (CON-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves a constant protocol of training, including six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min.
75389238|NCT01739790|Drug|N-Acetylcysteine|1800 mg twice daily for 8 weeks
75389239|NCT01739790|Drug|Placebo|Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
75389240|NCT01696032|Drug|SGI-110|
75389241|NCT01696032|Drug|Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)|Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
75706476|NCT00798291|Other|Ad lib diet; AN 777; exercise|one packet with water two times a day; resistance training three times a week
75389242|NCT01696032|Drug|Carboplatin|
75389243|NCT01695954|Drug|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
75389244|NCT01695954|Drug|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
75389245|NCT01695954|Drug|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
75557906|NCT00440414|Drug|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
75869584|NCT04057456|Other|Placebo capsules|Placebo capsules contain no active ingredient. Participants on placebo capsules will undergo the same 5-week titration period and intervention period as those on active treatment.
75869585|NCT04030442|Drug|Immediate-release Oral Morphine Sulfate Tablets|0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions
75389246|NCT01695954|Drug|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
75389247|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
75389248|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
75389249|NCT01694706|Drug|omeprazole|medium dose of omeprazole
75389250|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
75389251|NCT01693692|Drug|TD-9855 Group 1|
75389252|NCT01693692|Drug|TD-9855 Group 2|
75389253|NCT01693692|Drug|Placebo|
75389254|NCT01693614|Drug|Buparlisib|100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
75869586|NCT04030442|Other|Thermal and Pressure Nociceptive Sensitivity|Primary outcome measures of pain threshold and tolerance.
76033545|NCT02315131|Drug|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
76033546|NCT02315131|Drug|Placebo|Placebo Comparator
75389255|NCT01715298|Drug|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
75389256|NCT01715298|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
76033547|NCT02029963|Device|Transcranial Magnetic Stimulation (rTMS)|A non-invasive method for brain stimulation
75389257|NCT01713582|Drug|OTX015/Birabresib|OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
75389258|NCT01739400|Drug|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
75389259|NCT01713348|Device|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
75389260|NCT01713348|Device|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
75389261|NCT01737996|Drug|BI 207127 + faldaprevir|fixed dose combination
75557907|NCT00440414|Drug|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
75557908|NCT00476736|Drug|Effect on small airways (N-Acetylcystein)|
75557909|NCT00440453|Other|Nutritional therapy|Nutritional therapy by dietician
75557910|NCT00438594|Behavioral|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
75557911|NCT00440492|Drug|PLA-695|
75557912|NCT00476775|Behavioral|after school ethnic dance program - ballet folklorica|
75557913|NCT00476775|Behavioral|culturally-tailored, home-based screen time reduction|
76033548|NCT02029963|Behavioral|Treatment as Usual|An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
76033549|NCT04514965|Other|Blood sampling|Blood sampling
76033550|NCT04514965|Device|Fibroscan|Measurement of liver stiffness
76033551|NCT04514965|Other|Question|Question about pruritus
75557914|NCT00476775|Behavioral|culturally-tailored health and nutrition education|
76033552|NCT05122429|Behavioral|e-Health Treatment|Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
76033553|NCT05122273|Device|Stella BIO|Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
76033554|NCT01794715|Procedure|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
76033555|NCT05118217|Other|This is a non-interventional study|This is a non-interventional study
76033556|NCT02654977|Drug|Metreleptin|MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
76033557|NCT05117983|Device|Repetitive transcranial magnetic stimulation (rTMS)|Real-time MRI-guided neuronavigation with a Visor neuronavigation system (ANT Neuro, Enschede, Netherlands) will be used for coil positioning. Left dorsolateral prefrontal cortex target is located in each participant.
76033558|NCT05117671|Other|data collection to classify infection status|Review of medical records of all selected cases (TKA/THA patients) to classify infection status according to different classifications (EBJIS, MSIS/ICM 2013, ICM 2018).
76033559|NCT05117437|Other|Physiological test|This test was conducted to determine the endurance levels of the participants.
75557915|NCT00440570|Device|Low levels of amplitude-modulated electromagnetic fields|
75557916|NCT00440570|Device|Emitter of low levels of amplitude-modulated electromagnetic fields|
75557917|NCT03270462|Drug|Envarsus XR|Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
75869587|NCT04026386|Behavioral|Center Based or In Home Early Intervention Program|This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
76033560|NCT05117437|Other|Physical test|Height, weight, and BMI were determined
76033561|NCT05117437|Other|Biochemical tests|BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
76033562|NCT05117359|Device|transcatheter paravalvular leak closure|transcatheter paravalvular leak closure on cardiac valve
76033563|NCT03807817|Other|Alcohol administration|Amount of alcohol to be administered.
76033564|NCT03807817|Other|Placebo|Placebo Alcohol
76033565|NCT03807817|Other|No Alcohol|No Alcohol
76033566|NCT03508297|Diagnostic Test|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
75542871|NCT01534104|Procedure|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI & DSI, neurological/physical testing & brain MRI showing tumor &/or edema located in or near (<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), &/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately <48 hours before surgery*) fMRI to localize gray matter DTI, DSI & tractography to localize white matter, DSI & updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray &/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (<48 hours after surgery)
75542872|NCT01482715|Drug|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
75389262|NCT01713036|Drug|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) [14C] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries [mcgCi]) of [14C] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
75389263|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
75542873|NCT01378871|Drug|IMTOX-25|"This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7."
75869588|NCT04010539|Drug|Gepotidacin|Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
75869589|NCT04010539|Drug|Ceftriaxone|Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
75389264|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
75389265|NCT01712256|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
75869590|NCT04010539|Drug|Azithromycin|Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
76033567|NCT02871115|Other|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
76033568|NCT02871115|Other|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
75389266|NCT01712178|Biological|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
75389267|NCT01712178|Biological|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
76033569|NCT02078947|Behavioral|High Intensity Exercise|
76033570|NCT02078947|Behavioral|Moderate Continuous Exercise|
76033571|NCT02078947|Behavioral|Usual Care|
75706477|NCT03650088|Behavioral|Behavioral weight loss with digital tools|Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
75389268|NCT01693068|Drug|Pimasertib|Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
75389269|NCT01693068|Drug|Dacarbazine|Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
75542874|NCT01360606|Radiation|Stereotactic Body Radiation Therapy|"SBRT:~Patients will receive one of the following radiation regimens:~50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
75389270|NCT01691898|Drug|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
75389271|NCT01691898|Drug|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
75542875|NCT01257919|Drug|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
75389272|NCT01691898|Drug|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
75542876|NCT01257919|Drug|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
75389273|NCT01691898|Drug|Rituximab|RTX 375 mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle.
75389274|NCT01691820|Procedure|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
75389275|NCT01691820|Procedure|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
75542877|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
75542878|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
76033572|NCT05122117|Device|Methylene blue mediated Photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
76033573|NCT05122117|Procedure|Non-surgical periodontal therapy|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
76033574|NCT05117047|Procedure|liver resection|After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
75542879|NCT00239096|Drug|losartan (drug)|
75706478|NCT00721916|Drug|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
75389276|NCT01691820|Procedure|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
75869591|NCT03999333|Device|Virtual Reality (Oculus Go)|Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
75389277|NCT04547400|Other|assessment|Assessments of balance, gait, lower extremity position sense, and foot sole sense
75389278|NCT04167930|Other|electronic medical record(EMR) Data and patient survey|"Retrospective Data Collection (1) Neck Disability Index (NDI), Oswestry Low Back Disability Index(ODI), euroqol-5 dimension(EQ-5D) scores during hospitalization (2) symptom onset date, symptom onset motive, past history, accident occurrence date, accident treatmen termination agreement date, etc.~Question items (consistent with the case record) according to the purpose of the investigation (1) General: Demographic sociological characteristics (gender, age, occupation, income, etc.) (2) Matters concerning the correlation between traffic accident agreements and symptoms"
75389279|NCT01711866|Drug|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
75389280|NCT01737762|Biological|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
75389281|NCT01737762|Biological|Vehicle|
75706479|NCT00721916|Drug|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
75869592|NCT03977194|Drug|Carboplatin|AUC 6 every 4 weeks
75869593|NCT03977194|Drug|Paclitaxel|90 mg/m² D1, 8, 15, every 4 weeks
76033575|NCT05116969|Drug|PTX-35|PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
76033576|NCT00232999|Drug|Nebulized IVX-0142|
75389282|NCT01691508|Drug|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
75389283|NCT01691508|Drug|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
75389284|NCT01691508|Drug|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
75389285|NCT01682460|Drug|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
75389286|NCT01691430|Dietary Supplement|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
75389287|NCT01691430|Dietary Supplement|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
75706480|NCT02552901|Drug|0.1 mg/kg ICG Dose|least efficacious dose
75706481|NCT02552901|Drug|0.5 mg/kg ICG dose|per package insert
75869594|NCT03977194|Drug|Atezolizumab|1200 mg every 3 weeks
75869595|NCT03962959|Device|TBS|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
75869596|NCT03950232|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
76033577|NCT05116657|Diagnostic Test|Nasal Lavage and Oral Wash|"Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing."
76033578|NCT05116501|Diagnostic Test|Whole-exome sequencing|Whole Exome Sequencing (WES), as a comprehensive genetic test, will be used to identify changes in a patient's DNA that are causative or related to patient's low VWF levels.
76033579|NCT05116345|Drug|DEXTENZA|Intracanalicular Dexamethasone ophthalmic insert (0.4mg)
76033580|NCT05116345|Drug|Topical Dexamethasone|topical dexamethasone drops
76033581|NCT05120401|Device|presbyopia glasses|fogging for glasses for far and intermediate
76033582|NCT05121181|Other|delphi project|delphy study
76033583|NCT05096689|Other|MRI|Magnetic Resonance Imaging
76033584|NCT05076097|Drug|Orelabrutinib in in combination of rituximab and lenalidomide(OLR)|Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
76033585|NCT04413019|Other|Clinical follow up|"Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~Penicillin may be used in patients who can't tolerate erythromycin~In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection."
75542880|NCT04532398|Other|Gugging swallowing screen - ICU (GUSS-ICU) index test|"Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food)."
75389288|NCT04413708|Behavioral|P3-T PrEP Adherence App|"P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar."
75389289|NCT01709838|Drug|deferasirox|Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
75542881|NCT04532398|Other|Flexible Endoscopic Evaluation of Swallowing (FEES) reference test|"Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test."
75542882|NCT04532554|Drug|Growth Hormone|Recombinant growth hormone will be used
75542883|NCT04532554|Drug|Placebo|Saline injection with the same amount
75542884|NCT04532281|Drug|Murine CD19 CAR-T cells|Each subject receive murine CD19 CAR T-cells by intravenous infusion
75542885|NCT00239135|Drug|PEP005|
75542886|NCT04532086|Diagnostic Test|Uterocervical angle|Transvaginal ultrasound examination will be performed at 18-28 weeks gestation in (197) pregnant women with live singleton fetuses, attending routine prenatal care services. Measuring length of uterine cervix at (18-28) weeks & evaluation of dilatation of internal os & measurement of uterocervical angle between(18-28)weeks gestational age.
75542887|NCT04532203|Drug|CAR-T cells|Each subject receive CAR T-cells by intravenous infusion
75542888|NCT04532203|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
75542889|NCT02217163|Drug|Carfilzomib, , Cyclophosphamide, Dexamethasone|Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
75542890|NCT02217202|Device|Aquacel Ag dressing|Participants will have their knee arthroplasty wound dressed using the Aquacel Ag dressing instead of the standard Aquacel dressing.
75542891|NCT00239174|Drug|SR147778|
75869597|NCT03942887|Drug|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
75389290|NCT01682226|Device|CliniMACS Fractionation system (Arm A)|"7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)~1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
75389291|NCT01682226|Device|CliniMACS Fractionation system (Arm B)|"8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3~1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood~1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
75389292|NCT01682226|Biological|Haploidentical donor CD34+ cells|CB grafts will consist of two CB units 4-6/6 HLA-matched to the patient to augment graft cell dose and additional T-cell depleted PBSC from a haplo-identical donor.
75389293|NCT04167618|Drug|177Lu-DTPA-omburtamab|Biological, radiolabeled DPTA-omburtamab
75389294|NCT01688466|Drug|Pomalidomide|0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
75389295|NCT01682148|Biological|Botulinum toxin type A|
75389296|NCT01681992|Biological|Priorix|Subjects receive one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
75869598|NCT03942887|Drug|endoxan|Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
75869599|NCT03942887|Drug|Methylprednisolone|Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
75869600|NCT03942887|Drug|Prednisolone|after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
75869601|NCT03924830|Procedure|Bulk without surface sealant|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds.
75389297|NCT01681992|Biological|M-M-R II|Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
75389298|NCT01681992|Biological|Varivax|Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
75389299|NCT01681992|Biological|Havrix|Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
75389300|NCT01681992|Biological|Prevnar 13|US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
75389301|NCT01737840|Drug|Pantoprazole|33 patients
75389302|NCT01737840|Drug|Ranitidine|33 patients
75389303|NCT01687998|Drug|Evacetrapib|Administered Orally
75389304|NCT01687998|Drug|Placebo|Administered Orally
75389305|NCT01681836|Drug|15Nitrogen(15N)-labeled sodium nitrite|15Nitrogen(15N)-labeled sodium nitrite 20 mg once
75389306|NCT01681836|Drug|15Nitrogen(15N)-labeled sodium nitrate|15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
75389307|NCT01681368|Drug|Birinapant (TL32711)|47mg/m^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
75389308|NCT01681212|Drug|Ipilimumab|
75389309|NCT01681212|Drug|Dacarbazine|
75389310|NCT01687296|Drug|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
75389311|NCT01687296|Drug|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
75389312|NCT01687296|Drug|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
75389313|NCT01687296|Drug|placebo tablet|placebo soluble tablet, oral ,once daily
75389314|NCT01687296|Drug|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
75389315|NCT04410432|Biological|Blood sample collection|"Additional blood volumes taken during a routine care blood test:~1 dry tube 5 mL for isolation and freezing of serum~1 x 5 mL EDTA tube to isolate and freeze plasma~8 heparinized 6 mL tubes for flow cytometry study"
76033586|NCT05119933|Drug|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
75389316|NCT02071914|Drug|CT-P27|Influenza A treatment drug.
75389317|NCT02071914|Drug|Placebo|Placebo.
75389318|NCT01568892|Drug|Dolutegravir 50 mg twice daily|Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
75389319|NCT01568892|Drug|Dolutegravir placebo twice daily|Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
75389320|NCT01568112|Drug|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
76033587|NCT05085847|Other|Mindfulness meditation training|Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (> 5 years each) experiences.
75389321|NCT01568112|Drug|BG00012 placebo|Placebo matching BG00012
75389322|NCT01568112|Drug|ASA|325 mg microcoated aspirin (ASA)
75389323|NCT01568112|Drug|ASA placebo|Placebo matching aspirin
75389324|NCT04116840|Drug|MT1002 for injection|Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
75389325|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 25 mg single-dose
76033588|NCT05085847|Other|Active control|Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
76033589|NCT04932577|Biological|Faecal microbiota transplantation|All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
75389326|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 50 mg single-dose
75869602|NCT03924830|Procedure|Bulk with Biscover|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, biscover surface sealant will be applied according to the manufacturer's instructions.
75389327|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 100 mg single-dose
75389328|NCT01568034|Drug|Placebo|single-dose
75389329|NCT01568034|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
75389330|NCT01568034|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
75389331|NCT01687218|Drug|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
75389332|NCT01687218|Drug|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
75389333|NCT01687218|Drug|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
75389334|NCT01686828|Drug|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
75389335|NCT01686828|Drug|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
75389336|NCT01686828|Drug|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
75389337|NCT01686828|Drug|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
75389338|NCT01686828|Drug|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
75389339|NCT01686438|Behavioral|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
75389340|NCT01593696|Biological|Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)|Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
75389341|NCT01592760|Device|air-Q SP|air-Q SP placement for airway maintenance.
75389342|NCT01592760|Device|air-Q|air-Q placement for airway maintenance.
75389343|NCT01592760|Device|i-gel|i-gel placement for airway maintenance.
75389344|NCT03901014|Other|Standard American diet|Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.
75706482|NCT00861172|Procedure|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
75706483|NCT00721994|Device|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
75389345|NCT03901014|Other|Very low carbohydrate diet|Ketogenic diet with <50g carbohydrate, 60-75% energy from fat, and 20% from protein
75389346|NCT01696188|Device|interscalene nerve catheter|
75389347|NCT02985762|Drug|EXPAREL|
75389348|NCT04768374|Other|Virtual Reality with Kinect|"In the study it was conducted a 12 week-intensive VR intervention (twice a week, 45 minutes each) and compared the results in the 12th week to investigate the effects of rehabilitation and follow-up assessments were made in the 16th and 24th weeks. From the beginning of the VR intervention, each game was played in equal durations by each participant. However, the difficulty of the games varied depending on the child's performance.~Microsoft Kinect Games-Carnival Games was used as VR intervention. In meeting held with the authors to determine which games would be used in the VR program, 5 games were chosen and the remaining games were removed from the program because of their similar contents."
75706484|NCT04068714|Procedure|Type of aneurysm repair|In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
76033590|NCT04932577|Biological|Placebo|Placebo
75389349|NCT04768374|Other|Conventional Occupational Therapy (COT)|"The COT based on neurodevelopmental treatment was carried out by the same occupational therapist. The treatment goals aimed at increasing the use of participant's extremities and improving the independence in ADL. The activities in the treatment were chosen in view of children's motor skills and daily living activities such as getting dressed, solving puzzles, and writing etc.~Both groups received COT while the control group received COT only for 12 weeks."
75389350|NCT01603602|Biological|botulinum toxin Type A|Intramuscular injections of botulinum toxin Type A into specified muscles of the upper limb on Day 1.
75389351|NCT01603602|Drug|Normal Saline (Placebo)|Intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1.
75706485|NCT00861250|Drug|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
75706486|NCT00807183|Other|woodstove|installation of new EPA-certified woodstove
75706487|NCT00807183|Other|inactive air filter|air filter units without filter in place
75706488|NCT00807183|Other|Active air filter|air filter units correctly operating
75706489|NCT00722150|Drug|Artesunate|2 mg/kg/day x 7 days
75706490|NCT00722150|Drug|Artesunate|4 mg/kg/day x 7 days
75706491|NCT00722150|Drug|Artesunate|6 mg/kg/day x 7 days
75706492|NCT02571738|Biological|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
75706493|NCT02571738|Other|Control|Standard of Care
75706494|NCT00861094|Drug|cisplatin|
75706495|NCT00861094|Drug|5-FU|
75706496|NCT00861094|Drug|oxaliplatin|
75389352|NCT01684878|Drug|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
75542892|NCT04531852|Other|CALSTI - Complex Active Lifestyle Intervention|"A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance)."
75542893|NCT04531852|Behavioral|SEMAI - Self-Management Intervention|A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
75706497|NCT00861094|Radiation|radiation therapy|
75706498|NCT00861094|Drug|Folinic Acid|
75706499|NCT02554149|Radiation|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
75706500|NCT00722228|Biological|Autologous or Allogeneic tumor cells|Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
75389353|NCT01684878|Drug|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
75389354|NCT01684878|Drug|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
75389355|NCT01684878|Drug|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
75869603|NCT03924830|Procedure|Bulk with Permaseal|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, Permaseal surface sealant will be applied according to the manufacturer's instructions.
75869604|NCT03905694|Drug|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
75389356|NCT01684878|Drug|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
75389357|NCT01684722|Dietary Supplement|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
75389358|NCT01684722|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
75389359|NCT01684722|Dietary Supplement|Vitamin D placebo|Vitamin D3 placebo
75389360|NCT01684722|Dietary Supplement|Fish oil placebo|Fish oil placebo
75389361|NCT01592292|Drug|Rituximab|Rituximab as per physician's discretion.
75389362|NCT01592292|Drug|Adalimumab|Adalimumab as per physician's discretion.
75389363|NCT01592292|Drug|Etanercept|Etanercept as per physician's discretion.
75389364|NCT01592292|Drug|Infliximab|Infliximab as per physician's discretion.
75389365|NCT01590888|Drug|PBT2|250mg capsules administered orally once per day for 26 weeks
75389366|NCT01590888|Drug|PBT2|100mg capsules administered orally once per day for 26 weeks
75706501|NCT00807261|Drug|Gemcitabine and Docetaxel|"Drug and schedule~Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)~Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days~Dose modification~Treatment should be delayed if the ANC<1,500/ mm3, or if the platelet count <75,000/mm3 on the first day of the next cycle.~Gemcitabine & docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.~Patients with response or no change will receive 2 additional cycles."
75389367|NCT01590888|Drug|Placebo|Matching capsules administered orally once per day for 26 weeks
75389368|NCT01565928|Drug|MDV3100|4 x 40 mg capsules, orally, once per day
75389369|NCT01565850|Drug|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
75389370|NCT01565850|Drug|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
75389371|NCT01565850|Drug|COBI|COBI 150 mg tablet administered orally once daily
75389372|NCT01565850|Drug|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
75389373|NCT01565850|Drug|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
75389374|NCT01565850|Drug|DRV Placebo|DRV placebo tablet administered orally once daily
75389375|NCT01565850|Drug|COBI Placebo|COBI placebo tablet administered orally once daily
75389376|NCT01565850|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
75389377|NCT01565694|Drug|Solifenacin succinate|Oral suspension administered once a day via syringe.
75389378|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
75706502|NCT04019106|Drug|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
75706503|NCT02571608|Drug|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
75706504|NCT02571608|Drug|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
75706505|NCT00865072|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
75706506|NCT00865072|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
75706507|NCT00798447|Drug|MLF 541|22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
75706508|NCT00798447|Drug|Lipofundin MCT|22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
75389379|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
75389380|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
75389381|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
75389382|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
75389383|NCT01590810|Drug|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
75706509|NCT02571660|Drug|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
75706510|NCT02571660|Drug|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
75389384|NCT01590810|Drug|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
75389385|NCT01590810|Drug|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
75389386|NCT01590810|Drug|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
75706511|NCT00722306|Drug|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
75706512|NCT00804297|Drug|Octreotide (drug)|
75706513|NCT00722384|Drug|bevasiranib|
75706514|NCT00722384|Drug|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
75706515|NCT00804375|Drug|2PX|cutaneous solution to be applied twice daily for 84 days
75706516|NCT00804375|Drug|Placebo|cutaneous solution to be applied twice daily for 84 days
75706517|NCT04067700|Procedure|Invasive coronary treatment|Coronary artery bypass surgery or percutaneous coronary intervention.
75706518|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
75389387|NCT01590810|Drug|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
75389388|NCT01590810|Drug|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
75389389|NCT01590810|Drug|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
75706519|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.
76033591|NCT04882111|Behavioral|ALIGN|The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers. The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams. Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies). The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
76033592|NCT05230069|Other|Interview|Patients will be interviewed post an emergency call and evaluation.
75389390|NCT01590810|Drug|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
75706520|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.
75706521|NCT00865228|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
76033593|NCT04513639|Drug|Early treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at MRD reapperance
75706522|NCT00724412|Other|Systane|Dry Eye relief eye drops
75706523|NCT00724412|Other|Optive|Dry Eye relief eye drops
75706524|NCT00722202|Drug|ERB-257|
75706525|NCT00722202|Other|placebo|
76033594|NCT04513639|Drug|Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at progressive disease
76033595|NCT04765735|Device|Open-loop testing, Closed-loop testing - External Spinal Cord Stimulator (SCS)|SCS therapy with an external neurostimulator using either open-loop or closed loop algorithm
75706526|NCT00724490|Procedure|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
75389391|NCT01590810|Drug|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
75389392|NCT01590810|Drug|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
75389393|NCT01590810|Drug|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
75389394|NCT01590810|Drug|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
75389395|NCT01590810|Drug|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
75389396|NCT01590810|Drug|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
75389397|NCT01590810|Drug|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
75389398|NCT01590810|Drug|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
75389399|NCT01590810|Drug|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
75389400|NCT01590810|Drug|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
75389401|NCT01590810|Drug|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
75706527|NCT00723762|Procedure|Specimen collection|A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
75869605|NCT03900689|Other|Part 1 Survey Group|At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.
75389402|NCT01542528|Behavioral|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
75706528|NCT00861328|Drug|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
76033596|NCT04746001|Diagnostic Test|Genomic sequencing|Sequencing data
75389403|NCT01565148|Drug|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
75389404|NCT01565148|Drug|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
75389405|NCT01565148|Drug|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
75869606|NCT03900689|Other|Part 2 Focus Group|If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
76033597|NCT04746001|Diagnostic Test|Histological examination|Images for deep learning
76033598|NCT04696549|Behavioral|Virtual visual art experience guided by Visual Thinking Strategies|All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
76033599|NCT05119543|Other|outdoor time|This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
76033600|NCT05229913|Drug|Esketamine is not added|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg
76033601|NCT05229913|Drug|Esketamine 0.2mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
75389406|NCT01565148|Drug|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
75389407|NCT04410354|Drug|Merimepodib|400 mg (total daily dose of 1200 mg) for 10 days
75389408|NCT04410354|Drug|Matching Placebo|0 mg (total daily dose of 0 mg) for 10 days
75389409|NCT04410354|Drug|Remdesivir|200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
75869607|NCT03866460|Diagnostic Test|Distortion product otoacoustic emission measurement (DPOAE)|Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
75389410|NCT01564758|Drug|Linezolid|"Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"
75706529|NCT00861328|Drug|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
75706530|NCT00722462|Procedure|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
75706531|NCT00722462|Procedure|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
75706532|NCT02570880|Other|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
76033602|NCT05229913|Drug|Esketamine 0.4mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.
76033603|NCT05229913|Drug|Esketamine 0.6mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
76033604|NCT05229913|Drug|Esketamine 0.8mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
76033605|NCT04667923|Diagnostic Test|Respiratory monitoring|Measurement of the tidal volume, peak inspiratory flow, inspiratory time, respiratory rate and the pressure gap during triggering on NIV and plateau pressure on mechanical ventilation
76033606|NCT04667923|Diagnostic Test|Respiratory muscles ultrasound|Measurement of the diaphragm thickening fraction, assessment of the contraction of scalene and sternocleidomastoid muscles
76033607|NCT04667923|Diagnostic Test|Electro impedance tomography|Measurement of the lung impedance changes in 4 quadrants, measurement of regional ventilation delay in 4 quadrants
76033608|NCT04667923|Diagnostic Test|Capnography|Measurement of end-tidal carbon dioxide tension
75389411|NCT01541826|Dietary Supplement|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
75389412|NCT01541826|Dietary Supplement|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
75706533|NCT00724646|Other|Survey|3 individual surveys
75706534|NCT00724646|Other|Focus group|Focus group discussions facilitated by a psychologist
75706535|NCT00618514|Device|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
75706536|NCT00618514|Device|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
75389413|NCT01541826|Dietary Supplement|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
75389414|NCT01541748|Other|Axis|Coloplast's Axis™ Allograft Dermis is used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.
75389415|NCT01589094|Drug|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
75389416|NCT01563978|Drug|fostamatinib|fostamatinib 100 mg twice daily
76033609|NCT04667923|Diagnostic Test|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
76033610|NCT04667923|Diagnostic Test|Quasistatic pressure-volume curve|Quasistatic pressure-volume curve
75389417|NCT01563978|Drug|placebo|placebo
75389418|NCT04114344|Procedure|TAPP|Trans Abdominal Pre Peritoneal approach
75389419|NCT04114344|Procedure|TEP|Total Extra Peritoneal approach
75389420|NCT01563354|Drug|Pasireotide LAR|60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
75389421|NCT01563354|Drug|Everolimus|10 mg tables administered orally once a day
75389422|NCT01563354|Drug|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
75389423|NCT01588548|Drug|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
75389424|NCT01587924|Drug|GSK1278863|tablet
75389425|NCT01587924|Drug|rhEPO|injection
75389426|NCT03028038|Drug|Platelet Rich Plasma|"Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
75389427|NCT03028038|Drug|No Platelet Rich Plasma|"No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
75389428|NCT03027960|Drug|Empagliflozin|10mg empagliflozin for a 2-week period
76033611|NCT05229757|Other|Physiotherapy and rehabilitation treatment in a special education and rehabilitation center.|Routine physiotherapy and rehabilitation practice was performed 2 days a week for 8 weeks in the special education and rehabilitation center.
75869608|NCT03831503|Biological|INO-A002|Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
76033612|NCT05229757|Other|Family-based home exercise.|Home exercise was applied by the families every day of the week for 8 weeks.
76033613|NCT05229289|Other|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
76033614|NCT05229289|Other|Fecal Microbiota Transplant|Fecal Microbiota Transplant
76033615|NCT01362517|Biological|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age"
75389429|NCT03027960|Drug|Placebo Oral Capsule|10 mg placebo for a 2-week period
75389430|NCT03028194|Procedure|Curettage|Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
75389431|NCT03028194|Procedure|Placebo|No procedure after delivery of the placenta
75389432|NCT03027882|Other|No Intervention|This is a reliability/validity study of a functional clinical test. There is no intervention
75389433|NCT01539642|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
75389434|NCT01539642|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
75389435|NCT01586364|Drug|Ospemifene 60Mg Oral Tablet|
75389436|NCT01538628|Device|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
75389437|NCT01538472|Drug|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
75389438|NCT01538472|Drug|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
75389439|NCT01538472|Drug|Rituxan|"250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8."
75869609|NCT03831503|Device|CELLECTRA® 2000|Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
76033616|NCT05229133|Device|CLEAR|FEMTO LDV Z8 Surgical Laser is intended for use in Corneal Lenticule Extraction for Advanced Refractive correction (CLEAR), also called Curved Lamellar Resection (CLR), for the reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude.
75389440|NCT01538472|Drug|BCNU|300 mg/m2 by vein on Day -6.
75389441|NCT01538472|Drug|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
76033617|NCT04330261|Other|Exposure (not intervention) - SARS-CoV-2 infection|Exposure is infection with the virus. There is no intervention
76033618|NCT05108155|Procedure|Cemented THA|THA with cement fixation
76033619|NCT05108155|Procedure|Unemented THA|THA with uncemented / pressfit fixation
76033620|NCT04375735|Drug|Bovine Lipid Extract Surfactant|BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
76033621|NCT01362439|Drug|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
75706537|NCT04067804|Behavioral|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
75869610|NCT03831503|Device|Dengue Fever Antibodies (IgG)|To determine if the subject is Dengue seronegative at baseline
75869611|NCT03800017|Biological|Hyperoxia|Participants breathe 60% oxygen during exercise
75869612|NCT03785405|Drug|sacubitril/valsartan|"Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules [12.5 mg (4 granules), 31.25 mg (10 granules), in capsules] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)"
75869613|NCT03774641|Drug|Lamictal|Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
76033622|NCT05228743|Procedure|Comparing Hyperthermic Intraperitoneal Chemotherapy|After laparoscopic exploration, HIPEC was started immediately: the temperature was 43 ℃ and the duration was 60 min. paclitaxel (PTX) was used with a dose of 50mg / m2. The second HIPEC was completed 24-48 hrs after the first HIPEC, and at least 4 HIPEC was completed.
76033623|NCT05228743|Drug|Paclitaxel|A natural anticancer drug that has been widely used in the treatment of breast, ovarian and some head and neck and lung cancers.Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
76033624|NCT05228743|Drug|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
76033625|NCT05228665|Behavioral|Heart Rate Variability Biofeedback (HRV-B)|Breathing technique twice every day (10 min each) to increase HRV
76033626|NCT05228587|Drug|Indocyanine green|Indocyanine green will be injected in all donor
76033627|NCT03307915|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5*10^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
76033628|NCT03307915|Biological|MVA-Mosaic|Participants will receive MVA-Mosaic 10^8 pfu as IM injection at Weeks 24 and 36.
76033629|NCT03307915|Biological|Clade C gp140 + Mosaic gp140|Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.
76033630|NCT03307915|Drug|Placebo|Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
75389442|NCT01538472|Drug|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
75389443|NCT01538472|Drug|Melphalan|140 mg/m2 by vein on Day -1.
75389444|NCT01538472|Procedure|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
75389445|NCT01538472|Drug|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
75706538|NCT00854542|Behavioral|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
76033631|NCT04154059|Other|Intervention Group|Patients will receive a physical therapy intervention for strengthening, stretching and functional training of ankle and foot.
76033632|NCT05227963|Other|soft tissue mobilization|In this group, each participants received 45-minutes long session that includes 25-minutes of soft tissue mobilization and 20-minutes of neck isometric strengthening exercises. In each session, patient was seated on chair and sustained pressure, direct oscillation, perpendicular mobilization, parallel mobilization, and friction massage was applied on the neck musculature for a minute followed by a release for 30 seconds. This protocol was repeated three times in each session. Each session was repeated four-times a week for two-weeks (a total eight sessions).
75706539|NCT00722540|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
75706540|NCT00722540|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
75706541|NCT00722540|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
75706542|NCT00722540|Drug|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
75706543|NCT00722540|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
76033633|NCT05227963|Other|neck isometric strengthening exercises|In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
76033634|NCT05010343|Radiation|carbon ion irradation|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
75389446|NCT01562028|Drug|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
75389447|NCT01562028|Drug|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
75706544|NCT00722540|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
75706545|NCT00722540|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
75706546|NCT00722540|Drug|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
75706547|NCT00722540|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
75706548|NCT00722540|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
75706549|NCT00861406|Drug|Pegylated Interferon-Alfa 2b (PEG Intron)|"Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks."
75706550|NCT00861406|Drug|GP-100 Peptide Vaccine|Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
75706551|NCT00861484|Drug|GSK958108|Coated Tablets 1 mg
75706552|NCT00861484|Drug|Placebo|Coated tablets
75389448|NCT03028662|Behavioral|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
75389449|NCT04767828|Drug|PYRROTINI|CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .
75389450|NCT04767828|Radiation|Brain radiation therapy|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.
75389451|NCT01585584|Drug|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
75389452|NCT01561560|Device|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
75389453|NCT01561560|Device|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
75389454|NCT01537068|Drug|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
75389455|NCT01537068|Drug|Placebo|Matching placebo pills
75389456|NCT01585428|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
76033635|NCT05010343|Radiation|Carbon Ion Irradiation With SIB|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
75389457|NCT01585428|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
76033636|NCT04990921|Combination Product|Palliative Radiation and Pembrolizumab|Stereotactic radiation therapy will be administered as clinically indicated.
76033637|NCT02824237|Device|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
75389458|NCT01585428|Biological|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
75389459|NCT01585428|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
75389460|NCT01585272|Drug|ENA713|
76033638|NCT02673385|Other|Brazelton scale|
75389461|NCT03028116|Biological|influenza vaccine|"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."
76033639|NCT02628535|Biological|MGD009|B7-H3 x CD3 DART protein
76033640|NCT04984603|Procedure|PLR in patients under VA-ECMO|After securing the VA-ECMO tubing, PLR is realized using an automatic bed elevation technique. The lower limbs are raised to a 45° angle while the patient's trunk is lowered in supine position
75706553|NCT04018742|Other|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
75389462|NCT03028116|Biological|Placebo|water for injection
75389463|NCT01560780|Drug|Prasugrel|one 10 mg tablet by mouth daily
75389464|NCT01560780|Drug|Placebo|placebo similar in appearance to prasugrel
75389465|NCT01585038|Drug|Efavirenz|600mg orally every evening
75389466|NCT01585038|Drug|Rilpivirine|25mg orally once daily
76033641|NCT04853407|Drug|LY03005 extended-release tablet|orally once a day
76033642|NCT04853407|Drug|Placebo|orally once a day
76033643|NCT02653495|Biological|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
76033644|NCT04218487|Drug|Xuefu-Zhuyu Capsule|treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
76033645|NCT04218487|Drug|placebo|treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
76033646|NCT04218487|Other|conventional therapy|conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
76033647|NCT04507477|Biological|Rituximab|For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
76033648|NCT02472925|Behavioral|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
75389467|NCT01560234|Drug|AZD8848|Single dose, oral inhalation (nebuliser solution)
75389468|NCT01560234|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
75389469|NCT04124328|Procedure|ALINE + VoM infusion|In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.
75389470|NCT04124328|Procedure|ALINE only|In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
75389471|NCT01559844|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
75706554|NCT00865384|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
76033649|NCT01391143|Biological|MGA271|"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
75389472|NCT01559844|Drug|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
75389473|NCT01584648|Drug|Dabrafenib|Dabrafenib 150 mg twice daily
75706555|NCT00865384|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
75706556|NCT00724724|Drug|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
76033650|NCT01675141|Drug|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
76033651|NCT04505293|Device|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
76033652|NCT03915223|Procedure|leg fracture|Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
76033653|NCT05102149|Drug|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively;
76033654|NCT05102149|Drug|Vildagliptin|Vildagliptin: 50 mg each time, orally in the morning and evening respectively;
75706557|NCT00724724|Drug|Aspirin|Aspirin 100mg Qd for 1 year
75706558|NCT00865462|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
75389474|NCT01584648|Drug|Trametinib|Trametinib 2 mg once daily
75389475|NCT01584648|Drug|Trametinib placebo|Dabrafenib 150 mg twice daily and trametinib placebo
75389476|NCT01559454|Drug|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
75706559|NCT00865462|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
75706560|NCT04130204|Drug|DYV700|Proprietary transdermal delivery platform
75706561|NCT04130204|Drug|Placebo|Vehicle transdermal delivery platform
75706562|NCT04130204|Drug|Colchicine 0.6 mg|Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
75706563|NCT00723918|Drug|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
75706564|NCT00723918|Drug|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
75706565|NCT00723918|Drug|SAB placebo|an inactive substance
75389477|NCT01559454|Drug|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
75389478|NCT03028584|Behavioral|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
75706566|NCT00723918|Drug|Methadone placebo|Methadone placebo
75706567|NCT00722618|Behavioral|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
75706568|NCT00722618|Other|Written materials|2 written materials available on public website
76033655|NCT05102149|Drug|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
75389479|NCT01584024|Device|Resin infiltration|"Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062"
75389480|NCT01584024|Device|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
75389481|NCT01583166|Drug|Bupivacaine|10ml 0.5% bupivacaine
75389482|NCT01583166|Drug|Saline|10ml 0.9% sodium chloride
75389483|NCT01583166|Drug|Epinephrine|1:200,000 epinephrine
75706569|NCT05373888|Device|Flexima®/Softima® stoma bags|"One piece stoma bags for enterostomates available as:~Closed (flat and convex)~Drainable with Roll'Up (flat and convex)~High flow with tape outlet (flat)"
75706570|NCT00865540|Drug|prednisolone acetate 1%|1 drop every 8h two days before surgery
75706571|NCT00865540|Drug|ketorolac tromethamine 0.4%|1 drop every 8h two days before surgery
76033656|NCT05102149|Drug|Vildagliptin matched placebo|One tablet each time, orally in the morning and evening respectively;
76033657|NCT04019431|Dietary Supplement|Whey protein, vegetable protein or animal protein|meal replacements or animal protein
75389484|NCT01535274|Other|Inspired oxygen fraction / end tidal carbon dioxide|"Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~FIO2 100%, PETCO2 30mmHg - beach chair position.~FIO2 100%, PETCO2 45mmHg - beach chair position.~FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position."
76033658|NCT04922749|Behavioral|MULTI+|MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
75706572|NCT00865540|Drug|nepafenac 0.1%|1 drop every 8h two days before surgery
75706573|NCT00865540|Drug|methylcellulose 0.5%|1 drop every 8h two days before surgery
75706574|NCT00723996|Behavioral|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
75389485|NCT01558752|Device|Total hip replacement with titanium shell and CORAIL stem|Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
75542894|NCT04531774|Behavioral|RECHARGE|"RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches."
75706575|NCT04066556|Other|Brain CT imaging|"The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~Cut-off values in areas of irreversible changes according to non-contrast CT images~Cut-off values in occlusion sites and collateral scores according to CT angiographies~Cut-off values of consolidated CT imaging index including clot, core, and collateral score~Cut-off values of comorbidity index~Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments."
75706576|NCT00865618|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
75706577|NCT00865618|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
75706578|NCT02570594|Other|questionary|
75706579|NCT00722280|Procedure|Hand Transplantation|"This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants."
75389486|NCT01558752|Device|Total hip replacement with Modular Titanium Femoral Stem|Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
75389487|NCT01582854|Drug|Actovegin|Actovegin solution for infusion and Actovegin tablets
75389488|NCT01582854|Drug|Placebo|Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
75542895|NCT04531774|Behavioral|Self Study|HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
75542896|NCT00239213|Drug|catechin extracts (health food)|
75542897|NCT04531930|Procedure|surgery|Colorectal surgery, mainly total proctocolectomy.
75706580|NCT00655629|Drug|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
75389489|NCT03884400|Procedure|Specimens obtained from surgical, phlebotomy or other non-invasive procedure|Biospecimen Collection
75389490|NCT04102644|Other|Observation|Documentation of course and outcome of hospitalization, labor, delivery, and postpartum period
75389491|NCT01582308|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
75389492|NCT01582308|Drug|Saxagliptin 5 mg|Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
75389493|NCT01582308|Drug|Vildagliptin 50 mg|Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
75389494|NCT01582308|Drug|Vildagliptin 50 mg BID|Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
75706581|NCT00655629|Drug|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
75706582|NCT00865696|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
75389495|NCT01582308|Drug|Placebo|Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
75389496|NCT01558674|Drug|MK-7145|
75389497|NCT01558674|Drug|Furosemide|
75389498|NCT01558674|Drug|Torsemide|
75389499|NCT01558596|Procedure|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
75389500|NCT01558596|Procedure|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
75389501|NCT01535040|Drug|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
75389502|NCT01535040|Drug|placebo|Placebo by mouth through completion of 12 weeks.
75389503|NCT04410510|Drug|P2Et (Caesalpinia spinosa extract)|P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
75389504|NCT04410510|Other|Placebo|Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
75389505|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
75542898|NCT04531930|Procedure|enhanced colonoscopy|Colonoscopic treatment and surveillance in every 3 months.
75542899|NCT04531930|Other|self choosed methods|A patient chooses a method for himself other than surgery.
75542900|NCT04532008|Behavioral|Group based treatment|12 sessions of group based therapy that included cognitive restructuring, behavioral activation, and interpersonal therapy
75542901|NCT00263367|Other|Hyperbaric Oxygen|Hyperbaric Oxygen at 1.3 ATA for one hour
75542902|NCT04531423|Drug|SSRI + golimumab|Golimumab will be administered at the dose of 50mg every month during the acute phase.
75542903|NCT04531423|Other|SSRI + placebo|placebo
75542904|NCT04531657|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
75706583|NCT00865696|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
75706584|NCT00724802|Dietary Supplement|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
75706585|NCT00724802|Drug|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
75706586|NCT05373732|Behavioral|meditation|meditation practice 20 minutes twice a day at home and attending classes at the clinic.
75706587|NCT05373732|Behavioral|Health education control|didactic based classes in CVD risk factor reduction and prevention
75706588|NCT02545114|Drug|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
75706589|NCT00722696|Other|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
75389506|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
75389507|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
75389508|NCT01534962|Drug|Placebo|Oral administration, BID; for a maximum of 112 days.
75706590|NCT02570568|Device|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
76033659|NCT04412395|Dietary Supplement|Lactoferrin (Apolactoferrin)|Apolactoferrin is an iron-free Lactoferrin (with very low iron saturation). Lactoferrin (Lf) is a natural glycoprotein that is found predominantly in milk. Lf represents a known component of the innate immune system present in neutrophil-specific granules and broadly distributed within the body fluids and exocrine secretions.
76033660|NCT04412395|Drug|Placebo of excipient(s) will be administered|Placebo of the equivalent excipient will be administered to placebo group
76033661|NCT04016935|Other|Observational|Observational
75389509|NCT04758234|Drug|LY3549492|Administered orally.
76033662|NCT04754269|Behavioral|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
76033663|NCT04754269|Behavioral|Reading Intervention|Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
76033664|NCT04987099|Dietary Supplement|550 mg/day Choline|Choline chloride (550 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
76033665|NCT04987099|Dietary Supplement|25 mg/day Choline|Choline chloride (25 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
76033666|NCT03906721|Drug|Placebo|Sugar pill used to condition patients.
76033667|NCT03906721|Drug|Oxycodone|An opioid used for analgesia.
76033668|NCT03906721|Other|Essential Oil|An aromatic oil used for conditioning.
76033669|NCT04668001|Device|Near-Infrared Transcranial Photobiomodulation|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
76033670|NCT04668001|Device|Sham Transcranial Photobiomodulation|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
76033671|NCT03994081|Device|tACS|XCSITE100
76033672|NCT03994081|Device|Sham tACS|XCSITE100
75389510|NCT04758234|Drug|Placebo|Administered orally.
75389511|NCT01582152|Drug|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
75389512|NCT01582152|Drug|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
75389513|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
75389514|NCT01581684|Drug|Placebo|Solution for oral administration
75389515|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
75389516|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
75389517|NCT01581684|Drug|BI 411034|High dose solution for oral administration
75389518|NCT01581684|Drug|BI 411034|High dose solution for oral administration
75389519|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
75706591|NCT02570568|Device|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
75389520|NCT01581684|Drug|BI 411034|High dose solution for oral administration
75389521|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
75389522|NCT01557582|Device|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
75389523|NCT01557504|Drug|Sitagliptin/metformin XR|Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).
75389524|NCT01557504|Drug|Placebo|Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
75389525|NCT01557504|Drug|Metformin|Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
75706592|NCT02570568|Procedure|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
75389526|NCT01557504|Drug|Thyroid hormone|Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
76033673|NCT04663711|Behavioral|degree of adherence of pre-anesthetic tests at kasr Alaini hospital to the NICE-Uk guidelines|"The anesthesiologist, whom is in charge of preoperative assessment at each unit, will assess patients who are scheduled for elective surgery, and will inform senior anesthesiologists with a minimum 3 years of experience.~preoperative investigations will be divided into: First part will be on patient's gender, ASA classification, medical history and examination.~Second part will be on Grade of surgery - Minor/ Intermediate/ Major or complex.~Third part is requested investigation(s), its rationale, the hierarchy of anesthesiologist requested, and the planned date for surgery.~Fourth part is about whether that investigation(s) is adherent with NICE-UK guidelines or not."
76033674|NCT04096573|Drug|LC51-0255|LC51-0255
76033675|NCT04096573|Drug|Placebo|Placebo
75706593|NCT00861562|Drug|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
75542905|NCT00239252|Drug|Interferon alfacon-1|
75542906|NCT04531306|Other|Kinesio® Tape|Fascial taping technique for myofascial trigger points on the iliotibial band
75706594|NCT00861562|Drug|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
75706595|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
75706596|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
75389527|NCT01580670|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
75389528|NCT04748484|Device|KCC Active or inactive|Depending of the randomization, the KCC will be active or inactive, and will provide heat when active, but the patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
75389529|NCT01534260|Drug|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
75389530|NCT01534182|Drug|Fingolimod|0.5 mg orally once a day
75389531|NCT01534182|Drug|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
75389532|NCT01534182|Drug|Glatiramer acetate (GA)|20 mg subcutaneously once a day
75389533|NCT01579812|Drug|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
76033676|NCT04919083|Other|Program of Therapeutic Exercise and Functional Recovery|"Specific hip fracture recovery programme,restoring the mobility, strength and balance of the operated patient, in order to facilitate the return to a functional state as close as possible to the state prior to surgery and in the shortest possible time, as detailed in Annex VIII. This programme is part of the standard treatment protocol implemented since January 2021 by the Orthogeriatrics Unit of the San Juan de Dios Hospital.~This programme is divided into 5 phases, each of these phases coincides with a level of the gait assessment scale. Each individual will start at the level assigned by the doctor and will only have access to the videos of the indicated level and the levels below it. As the patient meets the recovery goals, the physician will provide access to the higher level videos.The functional recovery plan begins the day after the hip fracture and continues after the patient has been discharged for a total of 16 weeks."
76033677|NCT04919083|Other|Standardised nursing care plan|Consisting of postural changes described in the standardised nursing care plan. Within this plan, the patient was moved to a sitting position prematurely (within the first 24 hours) and started to ambulate within the following 48 hours, provided that the patient's general condition allowed it. This group did not receive any specific functional recovery plan.
75706597|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
75706598|NCT02571348|Procedure|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
76033678|NCT04529863|Drug|Tocilizumab|Tocilizumab claim is used as the reference group.
75706599|NCT00854698|Other|exercise training|subjects are asked to exercise 20 or 30 minutes.
76033679|NCT04529863|Drug|Abatacept|Abatacept claim is used as the exposure group.
75389534|NCT01533714|Biological|CDP6038 (olokizumab)|Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection
75706600|NCT00854698|Other|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
75706601|NCT00804453|Device|Cartridge blood set|Once a week
75389535|NCT01533246|Drug|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
75389536|NCT01533246|Other|laboratory biomarker analysis|Correlative studies
75389537|NCT01579578|Drug|AZD8931|40 mg, oral dose twice daily
75389538|NCT01579578|Drug|Placebo|Placebo, oral dose twice daily
75389539|NCT01579578|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off.
75389540|NCT01578486|Drug|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
75706602|NCT00804453|Device|Standard blood line|Once a week
75389541|NCT01532934|Behavioral|motivational enhancement therapy|Four 45-minute MET sessions
75389542|NCT01532934|Other|standard care|
75542907|NCT00263406|Drug|Administration of an ACE-inhibitor or not|
75706603|NCT00724074|Device|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
75706604|NCT00724074|Device|Usual Care|Usual Care
75706605|NCT00854776|Drug|lansoprazole|30 mg once daily
75706606|NCT00854776|Drug|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
75706607|NCT00798525|Drug|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of > 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
75389543|NCT01555164|Drug|Ranolazine|Ranolazine tablet(s) administered orally
75389544|NCT01555164|Drug|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
75389545|NCT01555164|Drug|Metformin|Metformin tablet(s) administered orally once daily
75389546|NCT01555164|Drug|Placebo to match metformin|Placebo to match metformin for the duration of the study
76033680|NCT04456933|Procedure|Extracorporeal left hemicolectomy anastomosis|"Standard surgical technique protocolized in the unit for laparoscopic surgery of the left colon, sigma and high rectum for the last 10 years.~After sectioning the distal colon using a mechanical stapler (60mm blue load), a pfannestiel-type suprapubic accessory incision is made, with externalization of the tumor under wound protection with a ringed retraction device. Both the resection of the left mesocolon or mesosigma, and the placement of the head of the circular stapler are performed extracorporeally by proximal section of the colon with a pursetring® self-suturing device, removal of the piece, placement of the head, and reconnection of the pneumoperitoneum for colorectal anastomosis with Circular Stapler Curved B. Braun®"
75542908|NCT04531267|Dietary Supplement|Individualized dosage of calcium and magnesium|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
75389547|NCT01555164|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
75389548|NCT01555164|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
75389549|NCT03028428|Biological|Placenta Derived Mesenchymal Stem Cell|1ml 1*10^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
75389550|NCT03028428|Drug|Sodium Hyaluronate|Sodium hyaluronate administered into the knee joint once
75389551|NCT01578330|Drug|Fingolimod|Fingolimod 0.5mg orally once a day without food.
75389552|NCT01577160|Drug|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
75389553|NCT01554618|Drug|Exenatide Once Weekly|2 mg exenatide once weekly
75389554|NCT01554618|Drug|Placebo|Placebo
75706608|NCT00798525|Drug|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine < 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
75706609|NCT02571374|Dietary Supplement|symbiotic group|this group received sachets of symbiotic
75706610|NCT02571374|Dietary Supplement|placebo group|this group received placebo
75389555|NCT04108728|Diagnostic Test|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
75389556|NCT01531998|Drug|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
75389557|NCT01531998|Drug|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
75389558|NCT01531998|Drug|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
75389559|NCT01531998|Drug|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
75542909|NCT04531228|Procedure|TACE-HAIC plus lenvatinib|chemo-lipiodolization with EADM (30mg/m2), followed by FOLFOX-based chemotherapy artery infusion (Oxa 85mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2). Lenvatinib was administrated two or four days after TACE-HAIC, with 8mg for patients weight <60kg, or 12mg for patients weight more than 60Kg.
75542910|NCT04531150|Drug|INV-101|Subjects will be randomized to receive INV-101 tablets
75706611|NCT00861640|Drug|Intravenous Omeprazole|Intravenous Omeprazole 1amp qd (every day)
75389560|NCT01531998|Behavioral|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
75389561|NCT01576146|Drug|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
75389562|NCT01553916|Drug|Lithium Carbonate|
75389563|NCT01553916|Radiation|Prophylactic cranial irradiation|
75706612|NCT00861640|Drug|Oral Rabeprazole|Oral Rabeprazole 1 bid
75706613|NCT00724230|Drug|PegIntron (peginterferon alfa-2b; SCH 54031)|"PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks."
75706614|NCT00724230|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
75706615|NCT04066322|Procedure|system treatment and surgery|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
75706616|NCT04066322|Other|system treatment|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.
75706617|NCT00861718|Drug|AZD7268|Capsule, Oral, QD
75706618|NCT00861718|Drug|AZD7268|Capsule, Oral, BID
75706619|NCT00861718|Drug|Placebo|Capsule, Oral BID
75706620|NCT00725036|Drug|inhaled human insulin|
75706621|NCT00725036|Drug|insulin aspart|
75706622|NCT00725036|Drug|insulin NPH|
75706623|NCT00865774|Behavioral|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
75389564|NCT01553136|Drug|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
75389565|NCT03028506|Other|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
75389566|NCT04836468|Diagnostic Test|Tape application|Magnetic Tape or Kinesiology tape will be applied randomly with both the examiner and the subjects blinded.
75389567|NCT01552902|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
75389568|NCT01552902|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
75389569|NCT01552902|Drug|Placebo|Daily oral dosing in the AM for 6 weeks
75389570|NCT03923790|Behavioral|Educational Packet|The patient will receive an educational packet.
75389571|NCT03923790|Behavioral|Phone call at 72 hours by discharge nurse navigator|Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
75389572|NCT03923790|Behavioral|Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge|A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
75389573|NCT03923790|Behavioral|Educational messages every other week|The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence
75706624|NCT00865774|Behavioral|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
75706625|NCT00724386|Drug|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
75706626|NCT00724386|Drug|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
75706627|NCT00724386|Drug|Filgrastim|"daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).~For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject"
75706628|NCT00724386|Radiation|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
75706629|NCT00865852|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
75706630|NCT00865852|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
75706631|NCT02571114|Dietary Supplement|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
75706632|NCT02571114|Dietary Supplement|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
75706633|NCT02571114|Dietary Supplement|Control 1|White bread (serving size = 25 g available carbohydrate)
75706634|NCT02571114|Dietary Supplement|Control 2|White bread (serving size = 25 g available carbohydrate)
75389574|NCT03923790|Diagnostic Test|BP monitoring by QardioARM with periodic transmission of BP data|Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is < 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
75389575|NCT04102254|Procedure|ANT recording and stimulation|In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
75389576|NCT02072928|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
75389577|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
75389578|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
75389579|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
75706635|NCT00725114|Biological|Tetrodotoxin|30 µg twice daily for 4 days
75389580|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
75706636|NCT00725114|Biological|Placebo|2 mL subcutaneous injection twice daily for 4 days
75706637|NCT02545192|Device|Low Field Magnetic Stimulation|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
75706638|NCT00724542|Drug|Voglibose tablets|0.2mg Tid
75706639|NCT00724620|Biological|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
75706640|NCT00724620|Drug|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
75706641|NCT00866008|Drug|Ovarian stimulation|"Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
75389581|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
75389582|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
75389583|NCT01529346|Drug|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
75542911|NCT04531150|Drug|Placebo|Subjects will be randomized to receive placebo tablets
75706642|NCT00722514|Behavioral|patient education|"complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~Patient education 6 x 90 Minutes"
75706643|NCT00722514|Behavioral|Standard Care|"complex individual antiinflammatory rehabilitation program during inpatient~complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
75706644|NCT00866086|Other|questionnaire administration|
75706645|NCT00866086|Procedure|computed tomography|
75706646|NCT00866086|Radiation|radiation therapy treatment planning/simulation|
75706647|NCT02571426|Drug|Sevoflurane|anesthetic agent
75706648|NCT02571426|Drug|propofol|anesthetic agent
75706649|NCT00861796|Drug|CYR-101|Experimental arm
75706650|NCT00861796|Drug|Placebo|Placebo comparator
75706651|NCT00722670|Behavioral|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
75389584|NCT01529346|Other|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
75389585|NCT01529346|Other|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
76033681|NCT04456933|Procedure|Intracorporeal left hemicolectomy anastomosis|"o Intracorporeal resection of the left mesocolon~The mesocolon resection will be performed totally intracorporeally to its proximal end. The distal colon section will be performed using a mechanical stapler (blue charge 60mm)~o Preparation of Intracorporeal Anastomosis~The anastomosis will be performed in a mechanical end-to-end manner using a Circular Stapler Curved B. Braun®.~The Insertion of the stapler head into the proximal colon will be placed intracorporeally with an incision distal to the staple section. Once the head has been exteriorized at the terminal end of the proximal colon, a circular purse-type suture with prolene 2.0 will be made.~Once the mechanical colorectal anastomosis is performed, 4-6 stitches of anastomotic reinforcement with silk 2.0 will be placed.~The extraction of the piece will be carried out with endobag protection and with an accessory incision (pfannestiel or other location depending on the patient)"
75389586|NCT01529346|Other|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
75389587|NCT02073162|Procedure|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
75389588|NCT01529268|Drug|DR cysteamine bitartrate capsule|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
75542912|NCT00414284|Drug|Increased dose of Kaletra|
75542913|NCT04531345|Diagnostic Test|Flow cytometric analysis|IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
75542914|NCT04531072|Drug|Artemether-lumefantrine|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
75542915|NCT04531072|Drug|Atazanavir-ritonavir 300/100 mg|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
75542916|NCT04530955|Device|Prometra II Programmable Pump - Flowonix Medical|The valve gated Prometra II Programmable Pump will be replacing the prior peristaltic Synchromed II pump and a 20% dose decrease will be performed at the time of the replacement.
75706652|NCT00722670|Behavioral|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
76033682|NCT04441957|Device|Endovenous Mechano- Chemical Ablation|The Flebogrif™ catheter (Balton® Sp. z o.o., Warsaw, Poland) represents endoluminal Non Thermal Non Tumescent devices designed to cause occlusion (fibrosis) of the target vein through the combined mechanical and chemical damage to its endothelial lining with retractable cutters and foamed sclerosant.
75389589|NCT01529268|Other|DR cysteamine bitartrate placebo|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
75389590|NCT01529112|Drug|Lenvatinib|
75389591|NCT01529112|Drug|Lenvatinib matched placebo|
75389592|NCT01529112|Drug|BSC|
75389593|NCT01551420|Device|Advanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic IMU controlled
75389594|NCT01551420|Device|Advanced upper limb prosthetic EMG-PR controlled|Advanced upper limb prosthetic EMG-PR controlled
75542917|NCT00414323|Drug|Duloxetine|
75542918|NCT00414323|Drug|Escitalopram|
75542919|NCT00414323|Drug|Placebo|
75542920|NCT00263484|Drug|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
75542921|NCT00263484|Drug|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
75542922|NCT00263484|Drug|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
75542923|NCT04531033|Dietary Supplement|Lactobacillus acidophilus MPH734|After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.
76033683|NCT04432441|Other|Therapeutic physical exercise program for scapulo-humeral stabilitation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation during a month
75389595|NCT01575054|Biological|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
75389596|NCT01575054|Drug|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
75389597|NCT04748328|Procedure|ACL Reconstruction surgery and Rehabilitation Treatment|ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
75706653|NCT00854854|Biological|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
76033684|NCT04432441|Other|Therapeutic physical exercise program for scapulo-humeral stabilitation + electrostimulation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation added electrostimulation during a month
76033685|NCT03883945|Drug|AIV001|intradermal injection
76033686|NCT03883945|Drug|Vehicle|intradermal injection
75706654|NCT05373030|Biological|Recombinant adenovirus type-5-vectored COVID-19 vaccine|One dose COVID-19 vaccine
75706655|NCT00854932|Other|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
76033687|NCT04582591|Drug|Cannabidiol 100 MG/ML|Patients receive cannabidiol before and after treatment with chemotherapy
76033688|NCT04217239|Procedure|MIE Ivor- Lewis|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
76033689|NCT04217239|Procedure|MIE McKeown|minimally invasive esophagectomy (MIE) with cervical anastomosis
76033690|NCT04212481|Procedure|uniport video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using single port or two ports or three ports
76033691|NCT04212481|Procedure|two ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using two ports
76033692|NCT04212481|Procedure|three ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using three ports
76033693|NCT04007575|Diagnostic Test|Magnetic Resonance CholangioPancreatography|The imaging data will be collected from the hospital records and image archiving system of the radiology departments of the University Hospitals
75389598|NCT01528254|Drug|Placebo of vildagliptin|
75706656|NCT02570802|Procedure|Ultrasonographic examination|
75706657|NCT00578292|Drug|Busulfan|"4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6"
75706658|NCT00578292|Drug|Fludarabine|30mg/m2 Day -5 through Day -2
75706659|NCT00578292|Drug|Campath 1H|Per institutional guidelines Days -5 through -2
76033694|NCT03997669|Other|Collection of pleural effusion|Detection of pleural effusion
75389599|NCT01528254|Drug|vildagliptin|One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
75389600|NCT01528254|Drug|Metformin|Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
75706660|NCT00578292|Drug|Cyclophosphamide|50 mg/kg Days -5 through -2
75706661|NCT00578292|Drug|MESNA|10 mg/kg x 5 Days -5 through -2
75706662|NCT00861874|Drug|Decitabine|20 mg/m2 IV, Days 1-5
76033695|NCT04497883|Drug|Maribavir (400 mg)|Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
76033696|NCT04497883|Drug|Maribavir (200 mg)|Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
76033697|NCT04497883|Drug|Maribavir (800 mg)|Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
76033698|NCT03756103|Drug|SPH3127 tablet Dose 1|Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
76033699|NCT03756103|Drug|SPH3127 tablet Dose 2|Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
76033700|NCT03756103|Drug|SPH3127 tablet Dose 3|Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
76033701|NCT03756103|Drug|SPH3127 tablet Placebo|Oral SPH3127 tablet placebo, once daily for 8 weeks.
76033702|NCT04347655|Procedure|handgrip test|The patient will be supine for at least 5 minutes to collect baseline data before being handed a dynamometer device. The subject will then be asked to squeeze the dynamometer with maximum force for a minimum of 2 minutes while only engaging their forearm and remaining relaxed in the rest of their body. The subject will then release the dynamometer and remain supine, in recovery, for a minimum of 5 minutes.
76033703|NCT03688633|Drug|Candesartan|Candesartan treatment with dose adjustments (8-16mg/day) during 6 months in accordance with adverse effects
76033704|NCT03688633|Other|Usual care|patients will be followed as usual
76033705|NCT04436029|Biological|Descartes 11|Car T-cells
76033706|NCT03743935|Other|Gadolinium-enhanced cardiac MRI|Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
75389601|NCT01574352|Behavioral|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
75389602|NCT01574352|Behavioral|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
75706663|NCT00861874|Drug|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
76033707|NCT03963895|Drug|AB002 Dose 1|AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
76033708|NCT03963895|Drug|AB002 Dose 2|AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
76033709|NCT03963895|Drug|placebo|placebo administered on Day 1 as a single intravenous infusion
76033710|NCT03736759|Behavioral|Exercise|10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
75389603|NCT01527006|Drug|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
76033711|NCT03662815|Biological|iNeo-Vac-P01|Neoantigen peptides
75542924|NCT04531033|Dietary Supplement|Placebo|placebo made to match dietary supplement being tested.
75706664|NCT03765242|Other|Non-Interventional|Non-Interventional
75706665|NCT05372874|Drug|Direct Acting Antivirals|hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
75706666|NCT02544646|Other|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
75706667|NCT00725192|Behavioral|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
75706668|NCT00725192|Behavioral|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
76033712|NCT03662815|Other|GM-CSF|immune adjuvant
76033713|NCT03490903|Device|Virtual Reality|Subjects undergoing the Virtual Reality Intervention will be fitted with a VR headset and headphones, and undergo an immersive meditation experience provided by AppliedVR, Inc. The headphones will not be noise-cancelling, and the subject will be able to communicate with the physician or circulating nurse if needed.
76033714|NCT03490903|Drug|Fentanyl Injection|Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
76033715|NCT03490903|Drug|Midazolam injection|Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.
76033716|NCT03438721|Behavioral|Infant obesity prevention|Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
76033717|NCT03438721|Behavioral|Financial coaching|Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
76033718|NCT04435951|Other|Evaluation|No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
76033719|NCT04253509|Diagnostic Test|Circulating Tumor DNA Methylation Sequencing|Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
75389604|NCT01526928|Drug|Rociletinib|Phase 1: Rociletinib <900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
75389605|NCT01526928|Drug|Rociletinib|Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
75389606|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
75706669|NCT04067856|Drug|Bevacizumab Injection|Intravitreal injection
75706670|NCT00866164|Device|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
75389607|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
75389608|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
75389609|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
75389610|NCT01549860|Device|MIST Therapy|Non-contact low frequency ultrasound therapy
75389611|NCT01549392|Device|DECT|DECT at tumor progression and 3 months later
75389612|NCT01549392|Device|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
75389613|NCT01526148|Drug|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels > 0.6mEq/L.
75389614|NCT01526148|Drug|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
76033720|NCT03712579|Dietary Supplement|SFA-Rich Meal|Saturated fatty acid-rich test meal, containing 75g test fat
76033721|NCT03712579|Dietary Supplement|MUFA-Rich Meal|Monounsaturated fatty acid-rich test meal, containing 75g test fat
75389615|NCT01572948|Drug|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
75389616|NCT01572948|Drug|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
75706671|NCT00570063|Drug|PF-02545920|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
75389617|NCT01525602|Drug|PLX3397|PLX3397 tablets, 200mg
75389618|NCT01525602|Drug|Paclitaxel|Paclitaxel IV
75389619|NCT04749966|Other|This is an observational study, there are no interventions|This is an observational study, there are no interventions
76033722|NCT04248985|Other|Pre-Imaging - an ultrasound technique of acquiring images|Technique involves finding low quality images of the heart during CPR prior to pausing CPR to acquire high quality images once CPR is paused.
76033723|NCT03954613|Combination Product|Ebicomb|Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
75706672|NCT00570063|Drug|Placebo|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
75389620|NCT01549002|Drug|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
75389621|NCT01549002|Drug|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
75706673|NCT05372796|Other|IASTM|instrument-assisted soft tissue mobilization
75706674|NCT05372796|Other|home exercise|home exercise
75706675|NCT05372796|Device|Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom)|OTES (Occipital Transcutenous Electric Stimulation)
75706676|NCT04042714|Drug|All patients- TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
75706677|NCT03401918|Diagnostic Test|Uterine ERA and microbiome testing|Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.
75706678|NCT03401918|Drug|Oral antibiotics and vaginal probiotics|For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
76033724|NCT04504201|Other|Focus Group|Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
75389622|NCT01548768|Drug|TNF inhibitors|"TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi."
75389623|NCT01548768|Drug|DMARDs|Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
75389624|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
75389625|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
75706679|NCT05227378|Biological|neoantigen tumor vaccine with or without PD-1/L1|personalized neoantigen tumor vaccine with or without PD-1/L1
75389626|NCT01572792|Drug|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day
75389627|NCT01572792|Drug|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day
75389628|NCT01572792|Drug|Placebo|Inhaled dose-matched placebo, twice per day
75389629|NCT03028272|Other|Skye Barrier|Substrate derived from amniotic tissue that is FDA-approved for human implantation
75389630|NCT03028272|Other|Fascia|Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
75389631|NCT01547598|Drug|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
75389632|NCT01547598|Drug|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
75706680|NCT02570646|Behavioral|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
75389633|NCT01547598|Drug|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
75389634|NCT01547286|Biological|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is < 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
75389635|NCT01547286|Radiation|Computed Tomography imaging, functional Positron Emission Tomography imaging|Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
75389636|NCT01547286|Drug|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
75706681|NCT00725348|Drug|Talarozole|1.0 mg oral dose per day
75706682|NCT02545348|Procedure|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
75706683|NCT00724776|Biological|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
75706684|NCT05325216|Procedure|POPRC+OIN|Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
75706685|NCT05325216|Procedure|SRC+OIN|Standard radical cystectomy with orthotopic ileal neobladder
75706686|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
76033725|NCT04052893|Procedure|Expanded Mckissock surgery|Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
76033726|NCT04052893|Procedure|Modified radical mastectomy|The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
75389637|NCT01547130|Drug|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
75389638|NCT01547130|Drug|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
75389639|NCT01524978|Drug|cetuximab|Escalating doses administered on Day 1 and then once weekly by intravenous infusion.
75389640|NCT01524978|Drug|vemurafenib|Escalating doses given orally twice a day starting on Day 2
75389641|NCT01524978|Drug|vemurafenib|960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.
76033727|NCT03367819|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
76033728|NCT03367819|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
76033729|NCT04051333|Device|ALS Nutrition App (MyDataHelps platform)|We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.
75389642|NCT04410120|Other|Interview|Semi-structured 45 minute interviews regarding impact of asthma attacks
75389643|NCT01524198|Drug|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
75389644|NCT01524198|Drug|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
75389645|NCT01523886|Drug|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
75389646|NCT01523886|Drug|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
75389647|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
75389648|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
75389649|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
75389650|NCT01546038|Drug|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
75389651|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
75389652|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
75389653|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
75389654|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
76033730|NCT03044509|Diagnostic Test|Secreted cytokine assay|Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
75389655|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
75542925|NCT04530721|Other|no intervention|we don't do any intervention
76033731|NCT03044509|Diagnostic Test|Intracellular cytokine assay|Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
75389656|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
75389657|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
75389658|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
75389659|NCT01571232|Drug|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
76033732|NCT04875871|Radiation|Particle radiotherapy|Partial radiotherapy targeting the hypoxic tumor segment
76033733|NCT04875871|Diagnostic Test|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
76033734|NCT04875871|Diagnostic Test|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
75542926|NCT00263523|Drug|[11C] (-)-RWAY|
75542927|NCT04530370|Biological|recovered covid 19 patients plasma|we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
76033735|NCT04875871|Diagnostic Test|Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|For the definition of the hypoxic tumor segment in treatment planning.
76033736|NCT04875871|Diagnostic Test|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For follow-up radiological tumor assessment.
76033737|NCT04875871|Diagnostic Test|Blood sampling|Evaluation before treatment-start, during treatment and follow-up period.
75389660|NCT01571232|Drug|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
75389661|NCT01544478|Biological|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
75389662|NCT02985528|Other|further diagnostic|further diagnostic procedures - mainly CHEST CT -
75389663|NCT01522950|Drug|Nebivolol|5 mg daily or 10 mg daily
75389664|NCT01522950|Drug|atenolol|25 mg daily or 50 mg daily
75389665|NCT01522950|Drug|placebo|one tablet daily
75389666|NCT01522404|Drug|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
75389667|NCT01522404|Drug|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
75389668|NCT01570686|Drug|Aliskiren|Aliskiren 300 mg once daily
75389669|NCT01522248|Biological|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
75542928|NCT00414401|Behavioral|Clinical Reminder|
75542929|NCT04530331|Behavioral|Nutrition education|Dietitians visited the worksites of the intervention group once a week to deliver a nutrition education session and provide dietary advice for each participant.
75542930|NCT02217319|Drug|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
75542931|NCT02217319|Drug|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
75542932|NCT00263601|Biological|Allergovit 6-grasses|Subcutaneous injections
75542933|NCT00263601|Other|Placebo|Subcutaneous injections
75542934|NCT02217397|Device|OA, CPAP, combination therapy|
75542935|NCT00414479|Drug|praziquantl, iron, ACT|
75542936|NCT02217514|Drug|Midazolam|
75542937|NCT02217514|Drug|BI 44370 low dose|
75542938|NCT02217514|Drug|BI 44370 medium dose|
75542939|NCT02217514|Drug|BI 44370 high dose|
75542940|NCT02217553|Drug|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
76033738|NCT03598387|Other|Automated peritoneal dialysis|"The prescription of automated peritoneal dialysis:~The first 48-72 hours dose: 0.8-2.0 liter exchange with 1-2 hour-cycle (8-36 liters per day); After initial 48-72 hours, 1.0-2.5L exchange with 2-6 hour-cycle (at least 8 liters per day), if the acidosis, hyperkalemia and pulmonary edema are corrected.~The minimal target weekly Kt/V is 2.1-3.5/W."
76033739|NCT03598387|Other|Intermittent hemodialysis|Intermittent hemodialysis will be performed 3-4h of each session and 2-5 times per week. The prescription will be adjusted based on patients' conditions to ensure spKT/V≥1.3.
75389670|NCT04120584|Device|Forma Eye Applicator|"Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment."
75389671|NCT01543776|Drug|abiraterone acetate|Given PO
75389672|NCT01518192|Drug|doxycycline|100 mg bid; 15 days
76033740|NCT04781725|Drug|INT230-6|INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
76033741|NCT04781725|Other|Saline injection|Standard 0.9 % NaCl Normal Saline
76033742|NCT04761835|Biological|Peanut powder or peanut butter|Commercially available peanut powder or peanut butter.
75389673|NCT01518192|Drug|cefuroxime axetil|500 mg bid; 15 days
75542941|NCT04719312|Procedure|Y modification of transconjunctival approach|"Section of the orbital septum is done at the Arcus Marginalis and subperiosteal dissection done to expose the infraorbital rim and orbital floor.~Subsequently, canthotomy of the superficial limb of the lateral canthal ligament is performed and subperiosteal dissection is carried out to expose the fracture at the frontozygomatic region.~The cutaneous Y will transform into a box when retracting its corners, increasing the working area and allowing access of the frontozygomatic (FZ) suture, lateral orbital wall, body of the zygoma, infraorbital rim, and floor of the orbit with a single approach.~A small upper vestibular incision is placed to expose the fracture at the zygomatic buttress. Reduction and fixation of fractures in a regular fashion are accomplished."
75542942|NCT02217631|Drug|BI 653048 BS H3PO4|
75706687|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
75706688|NCT00577772|Drug|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
76033743|NCT02550769|Procedure|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
75706689|NCT00577772|Device|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
75389674|NCT04099056|Device|Neurostimulation|"Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI).~TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.~TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates."
76033744|NCT02550769|Procedure|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
75389675|NCT01517802|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
75542943|NCT02217631|Drug|Prednisolone low dose|
76033745|NCT02320279|Device|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
75706690|NCT00577772|Procedure|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
75542944|NCT02217631|Drug|Prednisolone high dose|
76033746|NCT03554707|Genetic|SGT-53|2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly
75542945|NCT02217631|Drug|Placebo|
75706691|NCT00578136|Drug|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
75706692|NCT00861952|Other|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
75706693|NCT00861952|Other|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
75706694|NCT04065698|Drug|RV521|Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
75706695|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
75706696|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
75706697|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
76033747|NCT03554707|Radiation|Radiation|Standard radiation plan
75389676|NCT01517802|Drug|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
75389677|NCT04714710|Drug|IV Potassium Canrenoate|"Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room"
75389678|NCT04714710|Drug|IV Sodium Chloride 0.9 %|"Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room."
75542946|NCT04530292|Behavioral|Intervention by a pediatric nurse at the child's home|"The intervention will consist of a coordinated intervention by a pediatric nurse at the child's home to support the parents in the implementation of the theoretical knowledge acquired at the hospital.~Three home visits will be set up by a nurse during the first six months of the discovery of diabetes in the child. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit may be set up according to the needs of families."
75706698|NCT00855088|Drug|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
75706699|NCT00855088|Drug|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
75706700|NCT00855088|Drug|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
75389679|NCT01520922|Biological|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
75389680|NCT01520922|Drug|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
75389681|NCT01569438|Drug|Gefapixant|50 or 300 mg tablets for a total daily dose of 50, 100, 150, 200, 250 or 300 mg BID, orally with food for 4 weeks
75389682|NCT01569438|Drug|Placebo|Dose matched placebo tablets, BID, orally, with food for 4 weeks
75389683|NCT01517412|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
75389684|NCT01517412|Device|Self-injector pen device (OptiClik®)|
75389685|NCT01517412|Drug|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
75389686|NCT01517178|Device|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
75542947|NCT02217670|Drug|Metformin 1000 mg granules|
75542948|NCT02217670|Drug|Metformin 1000 mg film-coated tablets|
75542949|NCT00239291|Drug|Gefitinib, radiotherapy|
75542950|NCT02217748|Other|Survey questionnaire|
75542951|NCT00263640|Biological|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
75706701|NCT00725426|Drug|Bosutinib|
75706702|NCT02553603|Drug|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
75706703|NCT02553603|Drug|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
75706704|NCT00730184|Dietary Supplement|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
75706705|NCT00730184|Dietary Supplement|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
75706706|NCT03846622|Other|Calculation of scoring systems for bleeding|
75706707|NCT00807339|Radiation|Stereotactic radiation|Dose escalation three consecutive treatments
75706708|NCT00807339|Device|CyberKnife Robotic Radiosurgery System|
75706709|NCT03314766|Device|IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
75706710|NCT00730262|Drug|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
75706711|NCT00862030|Procedure|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
76033748|NCT03554707|Drug|Irinotecan|50mg/m2/dose IV daily for five days in a 4-week cycle
75389687|NCT01517178|Device|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
76033749|NCT03554707|Drug|Temozolomide|100mg/m2 PO daily for five days in a 4-week cycle
76033750|NCT03554707|Drug|Bevacizumab|10mg/kg IV every two weeks in a 4-week cycle
76033751|NCT02179333|Other|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
76033752|NCT03502759|Behavioral|CHICA SUDEP module|CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
76033753|NCT04349605|Behavioral|Meditation|Meditation involves guided breathing and mindfulness training.
76033754|NCT04349605|Behavioral|Kundalini Yoga|Kundalini Yoga involves stretching, guided breathing and meditation
76033755|NCT04299451|Other|Open dialogue about CAM|1-hour dialogue about CAM with a nurse specialist as an integrated part of conventional oncology care
76033756|NCT04264663|Drug|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
76033757|NCT04264663|Drug|Tinidazole|tinidazole-tetracycline-containing quadruple regimens
76033758|NCT04264585|Behavioral|Internet-delivered cognitive behaviour therapy|All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend ~15 mins. per week/per client.
75706712|NCT00804531|Drug|Visipaque - Hydrocortancyl|Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
76033759|NCT04264585|Behavioral|Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive access to the Planning for Change lesson before accessing Lesson 1. They will be presented with five interactive online exercises based on motivational interviewing principles (i.e. values clarification, importance ruler, looking back, confidence ruler, and looking forward). As clients complete the exercises, they are prompted to answer open-ended questions and are provided with written feedback.
76033760|NCT04264585|Behavioral|Booster Session|"Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered)."
76033761|NCT02827045|Device|Vestibular test|
76033762|NCT02765737|Other|Dehydrated Human Amnion/Chorion Membrane|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
76033763|NCT02765737|Device|Mepilex Ag|
76033764|NCT04599751|Device|Hair removal treatment|Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
76033765|NCT04563559|Drug|Dextenza 0.4Mg Ophthalmic Insert|The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
75389688|NCT01489956|Biological|Immucothel Alone (Part A)|100 ug at day 0 (priming dose) and day 9(booster dose)
75389689|NCT01489956|Biological|Immucothel+Montanide (Part A)|100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
75389690|NCT01489956|Biological|Immucothel Alone or Immucothel+Montanide (Part B)|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
76033766|NCT04563559|Drug|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
76033767|NCT02124187|Device|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
76033768|NCT02124187|Device|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
76033769|NCT02124187|Device|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
76033770|NCT05403073|Procedure|Ultrasound guided Suprainguinal Iliac Fascia Nerve Block.|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
76033771|NCT02002819|Drug|levetiracetam|
75389691|NCT03027726|Behavioral|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
75389692|NCT03027726|Other|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
75542952|NCT00263640|Drug|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
75706713|NCT00804531|Drug|Placebo comparator|Visipaque - 320 mg I/ml - 1 ml in intra-discal route
75389693|NCT01516008|Drug|Tapentadol IR 50 mg|Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
75389694|NCT01516008|Drug|Tapentadol IR 75 mg|Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
75389695|NCT01516008|Drug|Placebo|Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
75389696|NCT01489254|Drug|Glatiramer Acetate (GTR)|Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
75389697|NCT01489254|Drug|Glatiramer Acetate (Copaxone®)|Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
75542953|NCT02217826|Drug|DG3173|
75542954|NCT02217826|Drug|Saline|
75542955|NCT02217826|Drug|Octreotide|
75542956|NCT00239330|Drug|Rosuvastatin|
75542957|NCT00239330|Drug|Atorvastatin|
75542958|NCT04530097|Procedure|RFA|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
75542959|NCT02218021|Drug|Samidorphan|
75542960|NCT02218021|Drug|Placebo|
75706714|NCT00725088|Behavioral|Exercise training|Exercise training
75706715|NCT00866710|Other|Exercise-based behavioral therapy|Participants will be taught pelvic floor muscle exercises as well as urge suppression strategies to overcome the urge to void. In the first 20 participants, computer-assisted biofeedback will also be utilized to help participants identify the pelvic floor muscles and contract and relax these muscles while keeping the abdominal muscles relaxed
75706716|NCT00807729|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
75389698|NCT01489254|Drug|Placebo|Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
75389699|NCT01489020|Biological|subcutaneous immunotherapy with DPT extract|Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
75389700|NCT01489020|Biological|Subcutaneous depot placebo|Increasing doses of subcutaneous depot placebo in three different scales
75389701|NCT03027024|Device|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
75389702|NCT01514760|Other|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
75389703|NCT01514682|Drug|Anti-inflammatory Combination Therapy|"salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~fluvastatin: target dose 40 mg/day, administered in a single evening dose~combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"
75389704|NCT01514682|Drug|Placebo|Non-medication pills; To be taken in morning and evening intervals.
76033772|NCT05399017|Device|EZVent|EZVent Ventilator System is designed for respiratory support in hospitalized mechanical ventilated patients. The Ventilator is designed to be used for adults patients. It is designed to be a stationary product suitable for service in hospitals, critical care situations to provide continuous positive pres- sure respiratory support to the patient. The ventilator met EDA, ISO 80601-2-12 requirements on essential performance of critical care ventilator and other applicable international standards.
75389705|NCT01514448|Drug|Everolimus (RAD001)|Everolimus was used as commercially available formulated tablets of 10 mg strength
75542961|NCT02218021|Drug|Oxycodone|
75542962|NCT04719234|Device|lung ultrasonography|Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
75542963|NCT02218060|Procedure|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
75542964|NCT02218060|Procedure|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
75542965|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 25 mg|
75542966|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg|
75542967|NCT04529746|Behavioral|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
75542968|NCT04529668|Drug|vitamin D supplementation|vitamin D supplementation
75542969|NCT04529668|Drug|usual therapy for nasal polyposis|steroids ( systemic and local )
75542970|NCT00263679|Biological|Prophylaxis: Diphtheria, tetanus and pertussis|
75542971|NCT02218099|Drug|ASP8232|Oral
75542972|NCT02218099|Drug|Placebo|Oral
75542973|NCT00239408|Device|Pulmonary function Testing|
75542974|NCT00239408|Drug|tiotropium bromide|
75542975|NCT02218138|Behavioral|Learning 2 BREATHE|Mindfulness-based group program
76033773|NCT05123833|Procedure|Hypospadias repair|surgical repair of hypospadias
75389706|NCT01514370|Drug|IFN beta 1a 44 mcg TIW|Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
75389707|NCT01514370|Drug|Curcumin|Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
76033774|NCT05123677|Diagnostic Test|Non-invasive haemodynamic assessment|Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded
75389708|NCT01514370|Drug|Placebo|Subjects received placebo matched to curcumin orally twice a day for 24 months.
75389709|NCT04705974|Procedure|Fascia iliaca block|Fascia iliaca block will be performed under ultrasound guidenance.
75389710|NCT04705974|Procedure|Femoral nerve block|Femoral nerve block will be performed under ultrasound guidenance.
75389711|NCT04705974|Procedure|Pericapsular nerve group block (PENG block)|Pericapsular nerve group block (PENG block) will be performed under ultrasound guidenance.
75389712|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
75389713|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
75389714|NCT01519674|Drug|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
75389715|NCT01519674|Drug|metformin|Subjects will continue on their pre-trial metformin treatment.
75389716|NCT01519518|Drug|unfractionated heparin|70 units/kg body weight intravenous
75389717|NCT01519518|Drug|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
75389718|NCT01519206|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
75389719|NCT01518972|Drug|Prazosin|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
76033775|NCT05123677|Diagnostic Test|Maternal ophthalmic artery doppler|Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
75706717|NCT00807729|Procedure|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
75706718|NCT00866866|Drug|N-Acetyl Cysteine|600 mg PO BID
76033776|NCT05123521|Diagnostic Test|urine analysis|Urine was then tested for evidence of substance abuse using the multi-drug screen panel dip steak ABONtm (Abon Biopharm (Hangzhou) CO., Ltd) which is a lateral flow chromatographic immunoassay . It allowed for qualitative detection of multiple drugs in a single run. This kit was chosen for its ability to detect the most commonly abused substances in Egypt, namely: opioids, benzodiazepines, hashish, and tramadol. A single coloured line at region C for of a specific drug indicated a positive result, whilst two coloured lines at both regions C and T indicated a negative result. The absence of coloured lines was an indication of the invalidity of the particular kit, and the kit was discarded.
76033777|NCT05123443|Biological|Blood sample provided|Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.
75389720|NCT01518972|Drug|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
75706719|NCT00866866|Drug|Placebo|1 tab PO BID
76033778|NCT05123443|Diagnostic Test|7-T MRI scan|Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
75706720|NCT00804765|Other|Therapeutic education|Intensive training individual and collective teaching
75706721|NCT00804765|Other|Follow-up|classical follow-up with two individual consultations
75706722|NCT00855244|Other|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
76033779|NCT01597193|Drug|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
76033780|NCT01597193|Drug|anastrozole|1 mg/day
76033781|NCT01597193|Drug|exemestane|The exemestane dose is 25mg daily.
76033782|NCT01597193|Drug|fulvestrant|500 mg every 28 days
75389721|NCT01514136|Device|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
75706723|NCT00312728|Drug|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be < 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
75706724|NCT00312728|Drug|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
76033783|NCT01597193|Drug|enzalutamide|160 mg (4 capsules) taken orally daily.
76033784|NCT01597193|Drug|exemestane|The exemestane dose is 50 mg daily.
76033785|NCT04920461|Device|Additional MRI sequences|Additional MRI sequences (3D T2 SPACE sequence, 4/5 minutes approximatively)
75389722|NCT01513590|Drug|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
75389723|NCT03027570|Behavioral|Control|Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.
75542976|NCT02218138|Behavioral|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
75706725|NCT00312728|Drug|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
75389724|NCT03027570|Behavioral|Exergame activity_EXG|"In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app."
75389725|NCT03027570|Other|Application activity|"The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity."
75706726|NCT00804921|Drug|bevacizumab|
75389726|NCT04672512|Drug|CORT125329 lipid capsule formulation|CORT125329 lipid capsule formulation 1 or 2 for oral administration
75389727|NCT04672512|Drug|Placebo|Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
75389728|NCT04672512|Drug|Prednisone|Prednisone tablet for oral administration
75389729|NCT01512264|Device|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
75706727|NCT00804921|Procedure|anterior chamber paracentesis|
75706728|NCT00804921|Drug|acetazolamide|
76033786|NCT04920461|Other|Neuropsychological assessment|Neurovisual function assessed with neuropsychological tests
75389730|NCT01512108|Drug|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
75389731|NCT01512108|Drug|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
75389732|NCT01486758|Drug|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
75389733|NCT01486758|Drug|Placebo|
75389734|NCT01463982|Drug|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
75389735|NCT01486446|Drug|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
75706729|NCT00804921|Drug|brimonidine|
75706730|NCT00866944|Drug|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
75706731|NCT00866944|Drug|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
75706732|NCT00866944|Drug|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
76033787|NCT04920305|Dietary Supplement|Phosphatidylserine|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
76033788|NCT04920305|Dietary Supplement|Bean powder|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).
75389736|NCT01486446|Drug|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
75389737|NCT03027180|Device|Noninvasive positive airway pressure with different levels|
75389738|NCT04655352|Dietary Supplement|Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days
75389739|NCT01485354|Device|Armeo Spring training|Upper-limb training using the Armeo system for a period of 6 weeks
75389740|NCT01510158|Drug|Lesinurad|Tablets, 200 mg once daily (qd)
75542977|NCT02218177|Drug|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
75542978|NCT02218177|Drug|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
75542979|NCT02218177|Procedure|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
75542980|NCT00263718|Drug|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
75542981|NCT02218255|Device|Eeva™ results|
75542982|NCT02218294|Drug|BCX4161|
75542983|NCT02218333|Dietary Supplement|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
75542984|NCT02218333|Dietary Supplement|Placebo|
75706733|NCT00922155|Device|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
75706734|NCT00798681|Dietary Supplement|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
75706735|NCT00798681|Other|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
75706736|NCT00798681|Other|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
75389741|NCT01510158|Drug|Lesinurad|Tablets, 400 mg qd
75389742|NCT01510158|Drug|Placebo|Tablets, Placebo qd
75389743|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
75389744|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
75389745|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
75389746|NCT04080882|Biological|AbobotulinumtoxinA dose 1|Treatment of platysmal bands
75542985|NCT02218528|Dietary Supplement|Plant-based ingredient|
75389747|NCT04080882|Other|Placebo|Treatment of platysmal bands
75389748|NCT04080882|Biological|AbobotulinumtoxinA dose 2|Treatment of platysmal bands
75389749|NCT04080882|Biological|AbobotulinumtoxinA dose 3|Treatment of platysmal bands
75389750|NCT03027336|Dietary Supplement|Coleosoma|patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
75389751|NCT03027336|Dietary Supplement|Placebo|patients will take one tablet daily for 12 weeks.
75542986|NCT02218528|Dietary Supplement|No Plant-based ingredient|
75542987|NCT02218567|Behavioral|questionnaire qualilty of life|
75542988|NCT02218567|Behavioral|psychological interview|
75542989|NCT02218567|Behavioral|psychological tests|
75542990|NCT02218567|Other|Motor evaluation|
75542991|NCT02218567|Behavioral|Behavioral evaluation|
75542992|NCT02218567|Behavioral|cognitive tests|
75542993|NCT02218645|Drug|WE 941 OD tablets|
75542994|NCT02218645|Drug|Brotizolam|
75542995|NCT02218684|Drug|Telmisartan|
75542996|NCT02218684|Drug|Lacidipine|
75542997|NCT02218684|Drug|Placebo|
75542998|NCT02278822|Other|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
75706737|NCT00577824|Drug|exenatide|subcutaneous injection, 5mcg, twice a day
75706738|NCT00577824|Drug|exenatide|subcutaneous injection, 10mcg, twice a day
75706739|NCT00577824|Drug|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
75706740|NCT04046289|Dietary Supplement|Low Calcium Milk|50 mg calcium/day
75706741|NCT04046289|Dietary Supplement|Regular Calcium Milk|400 mg/day
75706742|NCT04046289|Dietary Supplement|Probiotic 1|regular calcium milk + probiotic
75706743|NCT04046289|Dietary Supplement|Probiotic 2|regular calcium milk + probiotic
75389752|NCT01485120|Device|BP monitoring using two methods|BP readings from participant using invasive radial arterial line, Non-invasive cuff with SuperSTAT NIBP algorithm, and Non-invasive cuff with Classic NIBP algorithm.
75389753|NCT03027258|Other|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
75389754|NCT01484496|Biological|Placebo|Placebo
75389755|NCT01484496|Biological|Belimumab 200 mg SC|Belimumab 200 mg SC
75389756|NCT01484496|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
75542999|NCT02278822|Other|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
75543000|NCT02278861|Drug|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
75543001|NCT02278861|Drug|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
75543002|NCT02278861|Drug|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
75543003|NCT02278900|Other|Communication aids|Question Prompt list Audiofile
75543004|NCT01641913|Other|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
75389757|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^8 vp/mL administered on Day 0
75389758|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^9 vp/mL administered on Days 0, 28, and 56
75389759|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^10 vp/mL administered on Days 0, 28, and 56
75389760|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^11 vp/mL administered on Days 0, 28, and 56
75389761|NCT01509846|Biological|Placebo: 1-3 doses|Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
75389762|NCT01462344|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
75543005|NCT01642030|Drug|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
75543006|NCT01642030|Drug|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
75543007|NCT01642030|Drug|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
75543008|NCT01642069|Other|laboratory biomarker analysis|Correlative studies
75543009|NCT00263796|Drug|Oxytocin|10 international units = 1 cc, IV over 4 hours
75543010|NCT00263796|Drug|Placebo|Normal Saline, IV over 4 hours
75543011|NCT01642108|Drug|Sitagliptin|50 mg once per day
75543012|NCT01642264|Behavioral|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
75543013|NCT01642303|Other|vodcasting|listening to downloaded vodcasting files
75543014|NCT01642303|Other|no intervension|Listen to student book listening files
75869614|NCT03773523|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
75389763|NCT01462344|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
75389764|NCT01462344|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
75389765|NCT01462344|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
75389766|NCT01484028|Device|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
75389767|NCT01484028|Device|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
75543015|NCT00250185|Drug|Sodium Nitrate|
75543016|NCT00250185|Drug|Acetylcholine|
75869615|NCT03699241|Biological|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 30ug, Intramuscular administration
75389768|NCT01484028|Device|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
75389769|NCT01462266|Drug|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
75389770|NCT01462266|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
75543017|NCT01642381|Behavioral|"Full Motivational Interviewing (FMI)"|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
75543018|NCT01642381|Behavioral|"Spirit Only Motivational Interviewing (SOMI)"|Empathic and non-directive counselling based on Rogerian psychotherapy model.
75543019|NCT00239486|Drug|Pramipexole|
75543020|NCT01642459|Other|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
75543021|NCT01642459|Other|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
75543022|NCT01642498|Device|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
75543023|NCT01642537|Device|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
75389771|NCT01462266|Biological|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
75389772|NCT01462266|Drug|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
75389773|NCT01508910|Biological|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
75389774|NCT01508910|Biological|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
75389775|NCT01508910|Other|Standard of care|Standard of care for refractory angina
75389776|NCT01462110|Device|19416-154-1|0.15% ethyl lauroyl arginate HCl-containing mouthrinse
75389777|NCT01462110|Device|W002194-0221P|5% hydroalcohol mouthrinse
75389778|NCT04087590|Drug|Formoterol-glycopyrronium co suspension (PT003)|Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
75389779|NCT01508676|Drug|Pennsaid|
75389780|NCT01508676|Drug|Placebo (2.3% DMSO solution)|
75543024|NCT00263835|Behavioral|Empowerment|
75543025|NCT00239525|Device|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
75389781|NCT04095546|Other|routine psychotherapy for Borderline Personality Disorder (BPD)|Routine psychotherapy as treatment for patients with Borderline Personality Disorder
75389782|NCT02985372|Drug|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
75389783|NCT02985372|Drug|Cytarabine|
75389784|NCT04087512|Other|Training on perturbation treadmill|Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.
75389785|NCT04087512|Other|Exercises of dynamic stability under unstable conditions|The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
75389786|NCT02985216|Drug|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO"
75389787|NCT02985216|Drug|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
75706744|NCT02554071|Other|Pharmacist - Smoking Cessation Support|Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
75389788|NCT01482312|Device|lotrafilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
75706745|NCT00855322|Other|Gym exercise group intervention|Gym based circuit class
75706746|NCT00855322|Other|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
75389789|NCT01482312|Device|comfilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
75706747|NCT00855322|Other|Control group|No intervention
75706748|NCT00807807|Dietary Supplement|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
75706749|NCT00807807|Drug|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
75389790|NCT01482312|Other|Glasses|Glasses per habitual prescription
75389791|NCT01461096|Biological|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
75389792|NCT01461096|Biological|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
75706750|NCT05333406|Drug|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10^5 cells/kg"
75706751|NCT05333406|Drug|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10^6 cells/kg"
75706752|NCT00867256|Device|Large Diameter Metal on Metal|
75706753|NCT00805077|Procedure|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
75706754|NCT00805077|Other|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
75706758|NCT00870298|Drug|Trimethoprim/Sulfamethoxazole and Warfarin|
75706759|NCT00730340|Procedure|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
75706760|NCT00730340|Procedure|Tonsillectomy with open fossa|SOP for a tonsillectomy.
75389793|NCT01461096|Biological|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
75389794|NCT04077294|Other|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
75389795|NCT04077294|Other|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
75389796|NCT01507896|Biological|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
75389797|NCT01507662|Behavioral|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
75389798|NCT01506960|Device|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
76033789|NCT04930133|Drug|Gilotrif|This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
76033790|NCT02649439|Biological|PROSTVAC -V|Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus
76033791|NCT02649439|Biological|PROSTVAC-F|Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
76033792|NCT04911647|Device|ERCP using plastic stent|Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
75389799|NCT01480674|Drug|Trastuzumab|
76033793|NCT04911647|Device|ERCP using metal stent|Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
76033794|NCT03057041|Drug|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
76033795|NCT03057041|Drug|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
75389800|NCT01506882|Drug|Levetiracetam (LEV)|"Active Substance: Levetiracetam~Pharmaceutical Form: Film-coated tablet~Concentration: LEV 250 mg, LEV 500 mg~Frequency: Twice daily~Route of Administration: Oral use"
75389801|NCT01506726|Drug|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
75389802|NCT01506726|Drug|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
75389803|NCT01505868|Drug|Cabazitaxel|Given IV
75389804|NCT01505868|Drug|Carboplatin|Given IV
75389805|NCT01505868|Other|Laboratory Biomarker Analysis|Correlative studies
75869616|NCT03699241|Biological|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 100ug, Intramuscular administration
75389806|NCT01505634|Drug|Relebactam 250 mg|Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
75389807|NCT01505634|Drug|Relebactam 125 mg|Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
75389808|NCT01505634|Drug|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
75389809|NCT01505634|Drug|Placebo to relebactam|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
75389810|NCT01505634|Drug|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
75389811|NCT04409730|Other|Photographic Posture Analysis|Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
75389812|NCT01460628|Drug|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
75543026|NCT00239525|Drug|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
75389813|NCT01480596|Biological|Belimumab|10mg/kg IV infusion
75389814|NCT01480596|Other|Placebo|placebo IV infusion
75543027|NCT01642576|Behavioral|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
75706761|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
75706762|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
75706763|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
75706764|NCT04016350|Behavioral|Exercise training with Inulin Propionate Ester|Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
75706765|NCT04016350|Behavioral|Exercise training with placebo|Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
75389815|NCT01480284|Drug|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
75389816|NCT01480284|Drug|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
75389817|NCT04409028|Procedure|Coronal restoration|A restorative material like composite resin is condensed into the cavity of teeth.
75389818|NCT01459614|Drug|Gemcitabine|IV on Days 4 and 11
75389819|NCT01459614|Drug|Taxotere|IV on Days 4 and 11
75706766|NCT00725166|Other|Skeletal muscle aging|"W1 - Blood test~Maximal voluntary contraction of quadriceps~Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy"
75706767|NCT02575742|Device|3D-Transit system|
75706768|NCT00807963|Drug|rHuPH20|recombinant human hyaluronidase PH20 injection
75706769|NCT00807963|Drug|zoledronic acid|subcutaneous injection
75706770|NCT05227066|Other|adding lower extremity weights|All children in the two groups received physical therapy protocol for 30 minutes in addition to half kg of sandbags weights attached for each leg
75706771|NCT05227066|Other|traditional physical therapy group|traditional physical therapy group
75706772|NCT05210634|Dietary Supplement|THCv|THCv in MCT oil
75389820|NCT01459614|Drug|Xeloda|orally, twice a day Days 1-14
75706773|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
75389821|NCT01459614|Drug|Cisplatin|IV Days 4 and 11
75389822|NCT01458522|Drug|fPHT|"If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
75389823|NCT01458522|Drug|LCM|"If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
75389824|NCT01505010|Procedure|Renal denervation|Renal denervation in the intervention group
75389825|NCT03026946|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
76033796|NCT05123287|Drug|PD-1 immune checkpoint blockades|intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
76033797|NCT04911569|Device|Cryoneurolysis|Cryoneurolysis
75389826|NCT03026946|Drug|cyclosporin A|Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
75389827|NCT01458210|Drug|Ortho-Cyclen|Administered orally
75389828|NCT01458210|Biological|Dulaglutide|Administered subcutaneously
75389829|NCT01478958|Dietary Supplement|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
75543028|NCT01642654|Other|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
75543029|NCT01642654|Other|Educational lectures|Educational lectures
75543030|NCT01642693|Radiation|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
75543031|NCT01642693|Other|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
75543032|NCT01642810|Behavioral|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
75543033|NCT01642810|Other|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
75543034|NCT00239564|Drug|IPX054 100 mg|IPX054 containing 25 mg carbidopa and 100 mg levodopa
75543035|NCT00239564|Drug|IPX054 150 mg|IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
75706774|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
76033798|NCT05123209|Biological|IM83 CAR-T cells|3×10^9 CAR-T cells
76033799|NCT05123209|Combination Product|The second-line treatment of liver cancer|approved by NMPA
76033800|NCT03056807|Other|25° head-up position|Angle person is positioned for procedure.
76033801|NCT03056807|Other|55° head-up position|Angle person is positioned for procedure.
75706775|NCT00805233|Drug|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
76033802|NCT04377685|Other|CT-Scan|Chest CT scan on admission to the hospital
75543036|NCT00239564|Drug|IPX054 200 mg|CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
75543037|NCT00239564|Drug|IPX054 250 mg|CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
76033803|NCT03056885|Other|Conventional One-Lung Ventilation|Vt 10 ml/kg
76033804|NCT03056885|Other|Protective One-lung ventilation|Vt 5 ml/kg
75389830|NCT01478958|Dietary Supplement|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
75389831|NCT01478958|Dietary Supplement|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
75389832|NCT06175442|Device|Intraoperative intestinal decompression|Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction
75389833|NCT06175429|Diagnostic Test|Physical performance testing|Assessment of physical performance using established clinical tests and scoring systems
75389834|NCT06175429|Diagnostic Test|Breath sampling and VOC analysis|Sampling of exhaled breath and using Proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF) for VOC quantification.
75389835|NCT06175429|Diagnostic Test|Muscle ultrasound|Quantitative and qualitative assessment of different limb skeletal muscles using non-invasive ultrasound.
75706776|NCT00805233|Drug|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
75706777|NCT00725244|Device|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
75869617|NCT03699241|Biological|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 300ug, Intramuscular administration
75869618|NCT03699241|Biological|Placebo|Tris-NaCl Diluent
75389836|NCT06175429|Diagnostic Test|Blood-based biomarker analysis|Blood sampling and assessment of different blood-based biomarkers of muscle integrity using Enzyme-linked Immunosorbent Assay (ELISA) and Electrochemiluminescence Immunoassay (ECLIA)
75389837|NCT06175403|Drug|Niacin|Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion
75389838|NCT06175377|Procedure|Percutaneous coronary intervention|A percutaneous coronary intervention for chronic total occlusion lesion with at least one implanted coronary stent will be performed as part of routine care.
75869619|NCT03681184|Drug|Placebo|Placebo by SC injection
75389839|NCT06175377|Drug|Short dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 1 month.
75389840|NCT06175377|Other|Long dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 6 to 12 months.
75389841|NCT06175377|Other|Follow-up visit at 1 month|At 1 month following the inclusion a visit or a phone call with the referring cardiologist will be organized.
75389842|NCT06175377|Other|Follow-up visit at 6 months|At 6 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
75389843|NCT06175377|Other|Follow-up visit at 12 months|At 12 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
75389844|NCT06175351|Drug|9MW1911|Participants will receive IV 9MW1911 every 4 weeks.
75389845|NCT06175351|Drug|Placebo|Participants will receive IV placebo every 4 weeks.
75389846|NCT06175338|Drug|Rituximab|Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
75389847|NCT06175338|Drug|MabThera®|MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
75543038|NCT00239564|Drug|IPX054 300 mg|CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
75543039|NCT02961036|Other|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
75869620|NCT03681184|Drug|Lumasiran|Lumasiran by SC injection
75389848|NCT06175325|Procedure|Trans-radial embolisation of haemorrhoids|"Once patients have provided informed consent to participate, an assessment of symptom severity will be obtained during the initial visit using the a standardised set of 4 validated scoring systems used in research of haemorrhoidal disease. These include the French bleeding score (FBS), Goligher classification of internal haemorrhoids (GS), quality of life score (QoL) and Visual analogue score for pain (VAS). Routine blood tests will be taken. During the procedure, routine observations will be recorded on the paper CRF. The data collected on the paper CRF will be entered onto the electronic CRF.~The Transarterial fluroscopically guided superior rectal artery embolization procedure will be performed on all participants. It is a day case procedure performed under local anaesthetic."
75389849|NCT06175312|Other|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
75389850|NCT06175312|Other|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
75706778|NCT00725244|Device|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
75389851|NCT06175299|Behavioral|Adherence Promotion With Person-centered Technology (APPT) System with Social Functions|The system has seven games for cognitive training and two social interactions functions: a chat function and a leaderboard function.
75389852|NCT06175286|Other|POWERBreath Plus Medium Resistance training device|30 inspirations with the POWERBreath Plus Medium Resistance training device, twice per day for 5 weeks
75389853|NCT06175273|Dietary Supplement|Oral Nutrition Supplement|8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL
75543040|NCT02961036|Other|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
75543041|NCT02961036|Other|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
75543042|NCT02961036|Other|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
75706779|NCT02569502|Drug|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
75869621|NCT03673462|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution. Route of administration: Intramuscular
75543043|NCT02961036|Other|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
75543044|NCT02961036|Other|Group A Reminder|One survey reminder at 14 days
75543045|NCT02961036|Other|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
75543046|NCT01642849|Dietary Supplement|high protein diet|6 months on HP diet
75543047|NCT01642849|Dietary Supplement|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
75543048|NCT01642888|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
75389854|NCT06175273|Dietary Supplement|Tube Feed|EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs
75389855|NCT06175273|Drug|Cyproheptadine|0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
75389856|NCT06175273|Drug|Dronabinol|5mg BID (before breakfast and lunch). May titrate by 2.5mg increments to max of 20mg/day
75706780|NCT00798837|Radiation|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~The prescription dose will be 73.7 Gy in 28 fractions~A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
75543049|NCT01642888|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
75543050|NCT00239603|Device|OV-Watch|
75543051|NCT01642966|Drug|Prasugrel|Prasugrel 10mg/day for 15 days
75543052|NCT01642966|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
75543053|NCT01643005|Behavioral|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
75543054|NCT01643005|Behavioral|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
75543055|NCT04529317|Dietary Supplement|Quinoa and quinoa-based food|"Products created replaced grains, legumes, tubers, also farinaceous commonly consumed by the participants and only the cereal fraction was modified, similar products based on quinoa flour were created.~Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche, sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of the recipe. Each subject received the equivalent of what they consumed according to their regular diet dietary records."
75543056|NCT01643083|Drug|Rifaximin|Rifaximin 400mg tid for 2 wk
75706781|NCT02569580|Device|Topically|"use the No More medical device as anti lice treatment"
75869622|NCT03673462|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)|Pharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular
75869623|NCT03673462|Biological|Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine|Pharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
75389857|NCT06175273|Other|Standard of Care|Diet education on high protein, high calorie food consumption
75389858|NCT06175260|Diagnostic Test|oral carnitine challenge test|Urine samples will be collected to quantify trimethylamine N-oxide (TMAO) levels at four time points: before, and 24, 48, and 72 hours after the oral administration of 1500 mg of L-carnitine.
75389859|NCT06175247|Other|Low Glycemic Index Diet|A low glycemic diet will be initiated with dietician support and guidance.
75389860|NCT06175234|Device|Ablation Treatment|For subjects with paroxysmal AF, Pulmonary Vein Isolation will be performed with the FARAWAVE NAV catheter. For subjects with persistent AF, left atrial posterior wall isolation (PWI) may also be performed at the discretion of the investigator, with the FARAWAVE NAV PFA catheter.
75389861|NCT06175208|Behavioral|Emotional Freedom Techniques|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
75543057|NCT01643083|Drug|Placebo|Placebo for 2 week
75706782|NCT00725400|Other|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
76033805|NCT03056105|Other|Residential Insight Meditation Retreat|"Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence-refraining from eye contact as well as verbal and written communication-except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet."
75389862|NCT06175208|Behavioral|Mindfulness Meditation|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
75706783|NCT00725400|Procedure|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
75706784|NCT00798915|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
75389863|NCT06175195|Behavioral|Psychoeducational Inervention|Psychoeducational Program would be used as an intervention stratégie for cancer patients to provide understanding and insight to the patients about the problems. Further, this program would address treatment refusal and illness denial, depressive symptoms, and treatment related irrational fears and anxiety. Moreover, this program will improve patients' motivation and attitude toward changing health, and quality of life.
76033806|NCT03949777|Device|Aer-O-Scope Colonoscopy|resection or biopsy of colonic abnormalities for histopathalogical evaluation
75389864|NCT06175169|Device|Information of Appendix (IA) model|Deep learning model
75389865|NCT06175156|Procedure|Controlled analgesia/sedation|During the pre anesthesia assessment, explain in detail to the patient the usage of the self-control pump and confirm that each patient can master it. Firstly, connect the self-control analgesic pump with a loading dose of 3 ml. Then, continuously pump in a mixture of propofol and remifentanil at a speed of 0.1 ml/kg/h. After the loading dose is completed, the examination can begin. During the operation, press the self-control handle according to the patient's sensation. Each press can quickly push 1ml of the medication, with a locking time of 1 minute
75389866|NCT06175156|Procedure|Intravenous combined anesthesia|Intravenous slow infusion of fentanyl 1 μ G/kg, midazolam 0.02mg/kg, slowly administer propofol 0.8-1mg/kg after 2 minutes (time greater than 60 seconds), and start the examination when the patient's consciousness disappears and they do not respond. During the surgery, propofol is interrupted to maintain the auditory evoked potential index (AAI) between 30-40.
75389867|NCT06175143|Biological|GR2002 injection|TSLP monoclonal antibody
76033807|NCT03056963|Behavioral|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
75389868|NCT06175117|Drug|compound E Jiao Jiang(cEJJ)|compound E Jiao Jiang(cEJJ)：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
75389869|NCT06175117|Drug|compound E Jiao Jiang(cEJJ) placebo|"compound E Jiao Jiang(cEJJ) placebo：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.~ferrous succinate tablet：1 tablet at a time, 2 times a day, should be taken in the morning, after dinner or during meals."
75389870|NCT06175104|Behavioral|HeartGPS|"HeartGPS includes three key components:~Sessions with a psychologist trained to deliver the intervention using attachment-based and trauma-informed therapy techniques, coupled with mind-body skills. The intervention can be delivered in-person or via telehealth, in accordance with participants' preferences.~Educational resources, including a series of modules to complement the sessions and evidence-based tools to support psychological adjustment and coping, parent-infant bonding and attachment, and parent-clinician communication.~A personalized care plan, charting mental health care needs, goals, and preferences, with evidence-based strategies to support longer-term wellbeing."
75389871|NCT06175091|Device|alarm management left to the discretion of the nurse|alarm management left to the discretion of the nurse in charge of the patient
76033808|NCT03056963|Behavioral|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
75389872|NCT06175091|Device|restrictive alarm use strategy|more restrictive protocol for the use of alarms
75389873|NCT06175039|Other|Telerehabilitation exercise program|TRGr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone.
75389874|NCT06175039|Other|Control program|KGr will be a pulmonary rehabilitation information brochure will be given after the initial evaluation. They will be asked to do the exercises on the brochure.
75389875|NCT06175013|Device|Sérum PURIFIANT|Application of Sérum PURIFIANT only, twice daily during 112 days
75543058|NCT01643122|Other|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
76033809|NCT04184323|Drug|EX-527 (Selisistat)|EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1). It is being given to reverse the effects of endometriosis, namely progesterone resistance, that is thought to interfere with the establishment of pregnancy in women with endometriosis
75389876|NCT06175013|Device|Sérum PURIFIANT in association Sérum BOOSTER|Application of Sérum PURIFIANT twice daily during 112 days AND Application of Sérum BOOSTER 5 minutes before the Serum PURIFIANT, twice weekly
75389877|NCT06175000|Procedure|Cognitive Assessment|Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.
75543059|NCT01643122|Other|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
75543060|NCT01643161|Behavioral|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
75543061|NCT01643161|Behavioral|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
75389878|NCT06175000|Biological|Obinutuzumab|Given IV
75389879|NCT06175000|Other|Quality of Life Assessment|Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.
75543062|NCT01643239|Other|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
75706785|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
76033810|NCT04184323|Drug|Placebo|We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
75389880|NCT06174987|Drug|T-DXd|T-DXd (DS8201a) will be administered as an intravenous (IV) infusion, on Day 1 of each 21-day cycle according to the dosage regimens
75543063|NCT01643239|Other|Hospital-based mCIT|the mCIT group with individualized intervention
75543064|NCT01643239|Other|Hospital-based TR|OT or PT or therapist-based training
75706786|NCT00798915|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
75706787|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
76033811|NCT03056027|Diagnostic Test|Ecocolordoppler ultrasound testicular evaluation|Ecocolordoppler ultrasound testicular evaluation
75389881|NCT06174974|Other|Education|The education was designed to cover the environmental stressors of the intensive care unit and the practices performed to reduce these stressors. The education content was created according to the Activities of Daily Living (ADL) Theory based on the institution's cardiovascular surgical intensive care unit protocols (Cardiovascular surgical intensive care unit visitor entry-exit rules information form) and the literature (included at the end of the presentation). Expert (intensive care nurses, ward nurses, cardiovascular surgeons and academic nurses) opinions were obtained. Patient-friendly and simple language was used to ensure that the content of the information presentation was acceptable and interesting.
75543065|NCT01643278|Drug|Dasatinib|Given PO
75543066|NCT01643278|Biological|Ipilimumab|Given IV
75543067|NCT01643278|Other|Laboratory Biomarker Analysis|Correlative studies
75543068|NCT01643278|Other|Pharmacological Study|Correlative studies
75543069|NCT01643356|Behavioral|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
75389882|NCT06174948|Device|CUE1 non-invasive device|This is a 9-week feasibility study which will involve wearing the CUE1 device on a daily basis at participants' homes while they continue their usual activities of daily living (ADL). The CUE1 is a non-invasive medical device which delivers low frequency metronomes like tactile cueing and high frequency focused vibrotactile stimulation. All participants will be using the same pre-programmed settings for the CUE1 device which are: vibration strength delivered at 80%, pulse length 800 milliseconds (ms), and rest length 800ms as set at baseline and will not change. The CUE1 device is attached to the skin via an adhesive patch which has been dermatologically tested and approved. Participants will be provided with the adhesive patches and shown how to use them and the CUE1 device by the research team.
75706788|NCT00730496|Procedure|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
75706789|NCT00798993|Other|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
75543070|NCT01643395|Other|vertebroplasty|Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
75389883|NCT06174935|Drug|0.01% atropine ophthalmic drop|0.01% atropine ophthalmic drop will be applied daily to the affected eye
75389884|NCT06174922|Drug|Prednisolone|Prednisolone for 4 months
75389885|NCT06174922|Drug|Itraconazole|SUBA-itraconazole for 4 months
75543071|NCT01643395|Other|conservative therapy|The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
75543072|NCT01643590|Biological|JVS-100 15 mg dose Injection|Intramyocardial Injection
75543073|NCT01643590|Biological|Placebo Injection|Intramyocardial Injection
75543074|NCT01643590|Biological|JVS-100 30 mg dose injection|Intramyocardial Injection
75543075|NCT01643629|Biological|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
75543076|NCT01643629|Other|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
75543077|NCT01643746|Device|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
75543078|NCT01643746|Device|Life Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
75543079|NCT04529200|Other|electrotherapy treatment|physical therapy management like EMS IFT
75543080|NCT01643785|Drug|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
75706790|NCT00798993|Drug|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
75706791|NCT00798993|Other|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
75706792|NCT00725582|Drug|IMA-026|
75706793|NCT00725582|Other|Placebo|
75706794|NCT00862108|Drug|Methylphenidate|mg/kg dose: 0.7~1.2mg/kg PO daily morning intake 8 weeks
75706795|NCT04041154|Behavioral|Cognitive Fatigue|Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.
75543081|NCT01643824|Radiation|Proton Beam Therapy|"- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%~- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
75543082|NCT04529161|Dietary Supplement|Fasting Mimicking Diet (FMD)|The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.
75706796|NCT04041154|Behavioral|Physical Fatigue|Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
75706797|NCT04041154|Behavioral|Rewarding Stimuli|Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
75706798|NCT00862264|Drug|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
75706799|NCT02569424|Behavioral|Patient's position|Supine or Trendelenburg strict -20°)
75706800|NCT00870376|Other|biomarkers|To define a biomarker or combination of overactive bladder syndrome
75389886|NCT06174909|Drug|Calcium Hydroxide|After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
75543083|NCT04529161|Dietary Supplement|Routinary diet habits|Subjects will follow their routinary eating habits for 6 consecutive months
75543084|NCT04528966|Other|Whole-Body Vibration|Whole-Body Vibration Treatment for 3 sessions in a week for 8 weeks. Each sessions takes 15 minutes.
75706801|NCT02844660|Biological|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
75706802|NCT02844660|Other|Standard of Care|moist wound therapy and offloading
75706803|NCT00730574|Dietary Supplement|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
75706804|NCT02570048|Device|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
75389887|NCT06174909|Drug|Triple Antibiotic paste|After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
75389888|NCT06174896|Procedure|Group 1|The LMA Proseal will be inserted directly by hand, without the use of any laryngoscope, as recommended in the instruction manual. The cuff will be gently guided along the hard palate where it is pushed into the hypopharynx and increased resistance is felt, and the cuff will be placed towards the hypopharynx.
75706805|NCT00870532|Drug|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
75706806|NCT00870532|Drug|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
75706807|NCT02771496|Other|Other: observational only- no intervention|Other: observational only- no intervention
75706808|NCT05121402|Drug|TLL018|a TYK2/JAK1 inhibitor
75706809|NCT05121402|Other|Placebo|a TLL018 Placebo
75706810|NCT00867724|Device|Aer-O-Scope Colonoscopy|Screening Colonoscopy
75543085|NCT04528966|Other|Conventional Physiotherapy|conventional physiotherapy for 2 sessions in a week for 8 weeks. Each sessions takes 45 minutes.
75543086|NCT01644019|Procedure|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
75543087|NCT01644097|Dietary Supplement|Lactobacillus plantarum strain 299v|Given PO
75543088|NCT01644097|Dietary Supplement|Lactobacillus acidophilus probiotic|Given PO
75543089|NCT01644097|Dietary Supplement|placebo|Given PO
75543090|NCT01644097|Other|laboratory biomarker analysis|Correlative studies
75543091|NCT01644097|Other|questionnaire administration|Ancillary studies
75543092|NCT01644097|Procedure|quality-of-life assessment|Ancillary studies
75706811|NCT02570516|Procedure|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
75706812|NCT00725478|Drug|Piribedil|
75706813|NCT00730652|Biological|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
75706814|NCT01951274|Drug|VPD-737|NK1 Receptor Antagonist
75706815|NCT01951274|Drug|Placebo|
75706816|NCT00725556|Other|Speech Therapy|Speech Therapy
75706817|NCT03355794|Drug|ribociclib|Oral capsule or liquid formula
75389889|NCT06174896|Procedure|Group 2|Appropriately sized laryngoscope blade will be used and after the location of the epiglottis is determined, the tongue and epiglottis will be lifted forward. Then, LMA Proseal will be placed at the point where resistance is felt at a level where the proximal edge of the mask can be seen.
75389890|NCT06174896|Procedure|Group 3|After the video laryngoscope is placed with an appropriately sized blade, the location of the epiglottis and vocal cords will be determined and the LMA Proseal will be placed at the point where slight resistance is encountered after the epiglottis is lifted. proximal aspect of LMA
75389891|NCT06174870|Other|Inspiratory muscle training|Inhale against 60% of Maximal inspiratory pressure 30breaths/day 5days/week for 6 weeks
75389892|NCT06174844|Other|No intervention applied|No intervention applied: data will only be collected in the indicated sampling periods from patients admitted to the participating hospitals.
75389893|NCT06174818|Procedure|PRF|Pulsed Radiofrequency Current of the Gasserian Ganglion
75706818|NCT03355794|Drug|Everolimus|Oral tablets or dispersible tablets
75706819|NCT01487174|Drug|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
75706820|NCT01487174|Drug|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
75389895|NCT06174792|Drug|Drospirenone 4 MG|Patients who met all inclusion criteria and had no exclusion criteria would receive one tablet of Drospirenone 4mg daily for 20 weeks, starting from day 2 to day 5 of their menstrual cycle.
75389896|NCT06174779|Drug|HM11260C|Test drug
75389897|NCT06174779|Drug|Placebo|Placebo drug
75389898|NCT06174766|Drug|HGP2102-1|Test drug
75389899|NCT06174766|Drug|HGP2102-2|Test drug
75389900|NCT06174766|Drug|RLD2209-1|Control drug
75389901|NCT06174766|Drug|RLD2209-2|Control drug
75389902|NCT06174753|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg daily X 7 days
75389903|NCT06174753|Diagnostic Test|CMR|CMR 3-5 days post randomization
75389904|NCT06174740|Behavioral|Music-cued audiovisual motor training|In addition to visual cues, music stimuli guide finger sequence movement both rhythmically (temporal component) and sonically (pitch-finger alignment).
75389905|NCT06174740|Behavioral|Visually-cued motor training|Visual cues guide finger sequence movement by indicating which finger to move in alignment with the position and of the visual cue.
75389906|NCT06174714|Behavioral|Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)|4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.
75389907|NCT06174701|Behavioral|Problem Solving Therapy (PST)|PST intervention in the form of one-on-one coaching in preparation for surgery and post-operative care. This coaching consists of educating and guiding the patient in developing problem-solving skills.
75543093|NCT01644097|Dietary Supplement|Bifidobacterium lactis probiotic supplement|Given PO
75543094|NCT01644136|Procedure|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
75706821|NCT00725634|Biological|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
75706822|NCT00725634|Biological|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
75543095|NCT01644136|Procedure|regional lymph node dissection|Undergo pelvic lymph node dissection
75543096|NCT01644136|Device|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
75706823|NCT01248806|Radiation|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
75543097|NCT01644253|Biological|20 mg/kg TRU-016 + Rituximab|"TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses"
75706824|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine , 5555 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
75706825|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine , 5553 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
76033812|NCT03055949|Behavioral|Early rehabilitation program|The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
75543098|NCT01644253|Biological|10 mg/kg TRU-016 + Rituximab|"TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule"
75543099|NCT01644253|Biological|TRU-016 20 mg/kg + Obinutuzumab|"TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months~Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months"
75543100|NCT01644253|Biological|TRU-016 6-20 mg/kg + idelalisib + rituximab|TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
75706826|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine, 4444 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
75706827|NCT02570724|Drug|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
75543101|NCT01644253|Biological|TRU-016 10-20 mg/kg + ibrutinib|TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
75543102|NCT01644253|Biological|TRU-016 10-20 mg/kg + bendamustine|TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days). Bendamustine (90 mg/m2 on days 2 and 3 of cycle 1 and then days 1 and 2 of cycles 2 to 6) will be infused after completion of TRU-016. If a patient is benefiting with stable disease or better, then TRU-016 may continue to be dosed every 3 weeks after the first 6 cycles; bendamustine will not be dosed beyond 6 cycles.
75706828|NCT02570724|Biological|blood patch|
75706829|NCT00725738|Genetic|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
75706830|NCT00862342|Drug|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
75706831|NCT00870610|Procedure|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
75706832|NCT00730808|Dietary Supplement|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
75706833|NCT02544724|Biological|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
75706834|NCT00867880|Drug|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
75543103|NCT01644370|Drug|HAART|as per Thai HIV Treatment guidelines
75543104|NCT01644448|Other|Autologous Human Platelet Lysate|Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
75543105|NCT01644448|Other|Standard Therapy|Topical Applications as directed by the investigator
75706835|NCT04040374|Diagnostic Test|AI-based diagnosis|AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
75706836|NCT04040374|Diagnostic Test|The expert endoscopists-based diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
75706837|NCT00862420|Drug|clopidogrel (SR25990)|oral administration (tablets)
75706838|NCT00862420|Drug|ticlopidine|oral administration (tablets)
75706839|NCT00321698|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
76033813|NCT04202107|Other|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
76033814|NCT04202107|Other|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours
75389908|NCT06174675|Procedure|combined bilateral infraorbital and infratrochlear nerve blocks|"Filling the block labelled syringe with 8 mL of bupivacaine 0.25%. Starting with Infraorbital nerve block using an extraoral approach.Inserting a 25-gauge needle laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. Positioning of the index finger of the non-dominant hand above the infraorbital foramen and advancing the needle feeling it beneath the finger to avoid globe penetration injury. Injecting 3 mL of the study solution slowly after confirming negative aspiration of blood and taking care not to inject into the foramen itself.~Shifting to infratrochlear nerve block by inserting the needle 1 cm above the inner canthus targeting the junction of the orbit and the nasal bone. Injecting 1mL of the study solution after confirming negative aspiration of blood.~Performing contralateral nerve block in the same manner. Applying pressure to four injection points for one minute to prevent hematoma."
75389909|NCT06174662|Device|Music|The patient can decide the music genre (a standard playlist) and receives a noise-cancelling headphone playing the chosen music during mobilization.
75389910|NCT06174636|Procedure|Application of abdominal weight|Application of variable weight on the abdomen to reach a 5 mmHg increase in IAP
75389911|NCT06174623|Device|ModulHeart Support|The ModulHeart device will be implanted in the descending abdominal aorta.
75389912|NCT06174597|Procedure|UCA-PSCs/bFGF or bFGF Intramuscular injection|After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
75543106|NCT01644487|Device|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
75543107|NCT01644487|Device|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
75543108|NCT01644526|Device|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
75706840|NCT00321698|Drug|Docetaxel+IMRT|"Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
76033815|NCT04911413|Drug|Tranexamic acid|The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
76033816|NCT04911725|Device|Elastic Compression Prototype|Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
76033817|NCT04929665|Procedure|Two different block and combination of these two blocks|Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
75389913|NCT06174584|Drug|Hypertonic saline|Hypertonic saline
75389914|NCT06174584|Other|Cow Milk|Cow Milk
75389915|NCT06174545|Drug|Pigment Solution Program|adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.
75706841|NCT02569944|Procedure|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients."
75706842|NCT02569944|Procedure|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
75706843|NCT00725894|Device|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
75869624|NCT03673462|Biological|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75869625|NCT03673462|Biological|Rotavirus Vaccine|Pharmaceutical form: Oral solution Route of administration: Oral
75543109|NCT01644604|Device|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
75543110|NCT01644682|Other|IWFPL|Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
75869626|NCT03673462|Biological|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75389917|NCT06174467|Behavioral|SEELearning Training|"This group will receive the Learning Training for Hearts and Minds and will be submitted to assessments and questionnaires that measure the improvement of well-being, reduction of stress and literacy in the contents and human values taught in the training.~The program aims to increase participants' awareness, compassion and engagement. Compassion refers to cultivating a way of relating to oneself, others and humanity through kindness, empathy and genuine care for the happiness and suffering of these individuals. Awareness refers to cultivating a detailed, first-person understanding of thoughts, feelings, and emotions."
75389918|NCT06174467|Behavioral|Waiting list group of the intervention|The group will remain on a waiting list and will respond to questionnaires about well-being and other items before receiving the training and, in the second semester, during the period in which it will receive the training
75389919|NCT06174454|Other|Respiratory Pediatric Physiotherapy|Prolonged slow expiration Tracheal pumping Controlled expiratory flow exercises Forced expiration technique
75389920|NCT06174454|Other|Control Group|Will be subject to muscle compressions of the upper limbs. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
75389921|NCT06174428|Device|Oral/Throat cancer test|The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
75869627|NCT03673462|Biological|Measles, Mumps, and Rubella Virus Vaccine|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous
75869628|NCT03673462|Biological|Varicella Virus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Subcutaneous
75869629|NCT03611725|Procedure|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
76033818|NCT04911179|Other|Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.|"The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant."
76033819|NCT04095559|Diagnostic Test|multipolar mapping catheter|mapping of the left atrium will be performed in sinus rhythm using the IntellaMap Orion multipolar mapping catheter (Boston Scientific).
76033820|NCT04095559|Diagnostic Test|multielectrode circular catheter|mapping of the left atrium will be performed using the multielectrode circular catheter (Lasso, spacing 2-6-2 mm, Biosense Webster)
76033821|NCT04095559|Diagnostic Test|irrigated ablation catheter|mapping of the left atrium will be performed using the irrigated ablation catheter (IntellaNav Mifi OI)
76033822|NCT04919915|Device|HEPA air cleaner|Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.
76033823|NCT03830203|Drug|BAT1806|8 mg/kg
76033824|NCT03830203|Drug|Actemra(EU-licensed)|8 mg/kg
75543111|NCT01644682|Other|IDWL|Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
75543112|NCT01644682|Other|ITN|Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
75869630|NCT03611725|Procedure|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
75869631|NCT03590327|Device|Transcranial Magnetic Stimulation|rTMS
75869632|NCT03583684|Behavioral|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
76033825|NCT03668587|Other|Troponin Protocol|Feasibility and security of a rapid rule-out and rule-in troponin protocol in the management of NSTEMI in an Emergency Departement.
75389922|NCT06174415|Device|Perceptual Learning|Perceptual training is carried out at home once a day, and the viewing distance of the patients from the display screen is uniformly 1.5m, 30 minutes each time, for three months, and they return to the hospital for re-examination of ophthalmology at the 3rd months after the training. When using the perceptual training program for the first time, the training program will adjust the size of the Gabor spot according to the size of the user's computer, and prompt the patient to adjust the brightness of the computer screen to unify the Gabor spot parameters of each user and ensure the consistency of the spot stimulation information received by each user.
75389923|NCT06174389|Behavioral|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.
75389924|NCT06174376|Device|GORE Synthetic Cornea Device|Treatment with GORE Synthetic Cornea Device
75389925|NCT06174350|Behavioral|Cognitive behavioral therapy|Earthquake is a process that affects the lives of many people. It is very important to evaluate the psychological state of individuals after the earthquake and take appropriate action. When studies conducted after the earthquake were examined, no study was found that evaluated the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes. For this reason, this thesis was conducted to evaluate the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes.
75389926|NCT06174350|Other|Placebo|Intervention Description not
75389927|NCT06174337|Behavioral|Use of Video Connection with Family via Robot|A remote family member is able to connect via video with a nursing home resident.
75389928|NCT06174324|Device|PreserFlo Microshunt|The PreserFlo MicroShunt was invented to create a minimally invasive glaucoma drainage device, that comes close to the eye pressure reduction and safety profile of the current gold standard, the trabeculectomy. Reference: Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, Palmberg P, Parrish RK 2nd, Weber BA, Kwon Y, Parel JM. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017 Jan;105(1):211-221. doi: 10.1002/jbm.b.33525. Epub 2015 Sep 18. PMID: 26380916; PMCID: PMC5215625.
75543113|NCT01644760|Procedure|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
75543114|NCT01644799|Drug|idelalisib|oral
75543115|NCT01644799|Drug|lenalidomide|oral
75543116|NCT01644838|Drug|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
75869633|NCT03574207|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
75543117|NCT01644838|Drug|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
76033826|NCT02622113|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
76033827|NCT02622113|Drug|Insulin|
76033828|NCT04920227|Procedure|phacoemulsification;|Group A: class combined with phacoemulsification
75543118|NCT01644877|Drug|DAS181 dry powder, formulation F02|
75543119|NCT01644877|Drug|Lactose Placebo|
75543120|NCT01644955|Drug|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
75543121|NCT01644955|Procedure|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
76033829|NCT03860155|Biological|allo-APZ2-ACLF|Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.
76033830|NCT04430777|Drug|Tranexamic acid|Administration of tranexamic acid 1 gr either intravenously or subcutaneously
75543122|NCT01644994|Combination Product|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
75543123|NCT00263874|Drug|UK-500,001|
75389929|NCT06174311|Behavioral|Active Cognitive Bias Modification|The intervention comprises three sessions and is provided online. Each session consists of two different tasks. To prevent order effects, these tasks will be presented to each participant in a random sequence. One of the tasks involves uncertain scenarios based on a scenario paradigm. At the end of these scenarios, participants will be asked to complete a missing letter in a word that in the scenario, followed by a comprehension question related to the scenario interpretation. Following each question, feedback will be provided regarding the correctness of the response. The other task is a word-sentence pair paradigm, where participants will be asked to assess whether these pairs are related, and feedback will also be provided.
75543124|NCT01645033|Other|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
75543125|NCT01645033|Other|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~Teaching about the treatment program~Teaching important ideas about sexual behaviors risks~Increasing knowledge about specific sexually transmitted diseases~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
75543126|NCT01645150|Behavioral|Progressive strength training|12 weeks of supervised progressive strength training
75869634|NCT03570229|Other|Hyperbaric oxygen treatment|"Participants in this study will receive hyperbaric oxygen treatment (HBOT) but the investigators do not assign this specific intervention to the study participants. Thus, the patients in this study will receive HBOT as part of routine medical care. Consequently, we regard this as an observational study because the patients will get HBOT independently of the study and they are NOT assigned prospectively to HBOT according to a protocol to evaluate the effects.~HBOT for pelvic radiation injury typically involves a treatment pressure of 2.4 ATA (Atmospheres Absolute) breathing oxygen for 90 minutes. The treatment is delivered as series treatment, usually daily treatment up to 30 dives."
75869635|NCT03547739|Behavioral|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
75869636|NCT03547739|Behavioral|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
75543127|NCT01645189|Biological|Hunterase|once weekly, 0.5mg/kg IV infusion
75869637|NCT03522831|Drug|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
76033831|NCT04929587|Other|This is a observational research, there is no intervention|This is a observational research, there is no intervention
76033832|NCT04910789|Procedure|transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach
75543128|NCT04528888|Drug|Enoxaparin|Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
75543129|NCT04528888|Drug|Methylprednisolone|Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
75869638|NCT03522831|Drug|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
75389930|NCT06174298|Drug|Granulocyte Colony-Stimulating Factor (Filgrastim)|"Intervention Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
75543130|NCT04528888|Drug|unfractionated heparin|Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
75543131|NCT00250224|Device|Radiotherapy stent|
75543132|NCT04528615|Behavioral|CCK In-Person Sessions|This group attended eight weeks of nutrition education-focused experiential learning.
75543133|NCT04528615|Behavioral|CCK Printed Materials|This group did not attend any in-person sessions and was only provided with select CCK written materials.
76033833|NCT04910789|Procedure|thoracoabdominal approach|Radical surgery should be finished via thoracoabdominal approach
75543134|NCT01645267|Procedure|Hydroxyapatite|Use of artifical bonegraft material
75543135|NCT01645345|Device|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
75543136|NCT00263952|Biological|bee venom|
76033834|NCT02651467|Other|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
75543137|NCT01645384|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
75543138|NCT00239798|Drug|FTY720|
76033835|NCT02651467|Other|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
76033836|NCT02651467|Other|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
76033837|NCT04910477|Drug|Dexmedetomidine|ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
76033838|NCT04910477|Drug|Neostigmine/atropine|nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
76033839|NCT04910477|Other|Saline placebo|nebulization of saline placebo in 4 ml) twice daily for three days.
76033840|NCT03487705|Other|electromyographic essential tremor|"Making a recording electromyographic recording of the essential tremors in each child included at prospective.~Collect an electromyographic recording of essential tremors already made in each child included at retrospective."
76033841|NCT04431089|Drug|SHC014748M|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
75543139|NCT01645423|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
75543140|NCT01645774|Procedure|10s injections duration|10s injections duration
75543141|NCT01645774|Procedure|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
75543142|NCT01645774|Procedure|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
75543143|NCT01645774|Procedure|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
75543144|NCT00263991|Device|EEC-techniques|
75543145|NCT01645852|Dietary Supplement|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
75543146|NCT00239876|Drug|FTY720|
76033842|NCT02468245|Behavioral|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
76033843|NCT02468245|Behavioral|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
75543147|NCT01646008|Other|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
75543148|NCT01646008|Other|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
76033844|NCT04910555|Other|strong desire to void - cognitive task|Strong desire to void - cognitive task (verbal fluency)
76033845|NCT04910633|Other|COCA is an observational study based on retrospective data issued from patient medial file.|"The following parameters will be collected from the medical files of the patients involved in this study:~Age~Gender~Cancer type~Cancer Stage~Cancer Treatment~COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%)~Living Status~Attribution of Mortality to COVID status~Comorbidities"
76033846|NCT05099419|Device|Repetitive Transcranial Magnetic Stimulation|"rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles."
76033847|NCT04919603|Behavioral|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
76033848|NCT04919603|Behavioral|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)
76033849|NCT05092633|Device|Miniscrew|Application of laser on miniscrew
76033850|NCT04929353|Other|Systematic symptom assessment|"Systematic symptom assessment~Conventional symptom assessment"
76033851|NCT03843151|Drug|BI 1358894|tablet
76033852|NCT03843151|Drug|Itraconazole|oral solution
76033853|NCT04919759|Behavioral|R-Basic|Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
75389931|NCT06174298|Other|Standard Embryo Transfer Media|"Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
75389932|NCT06174285|Other|Therapeutic Intervention with Psychedelic Virtual Reality|A 55-minute immersive psychedelic virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
75389933|NCT06174285|Other|Therapeutic Intervention with Non-Psychedelic Virtual Reality|A 55-minute immersive virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
75389934|NCT06174194|Dietary Supplement|Tulsi Gum|"The intervention involves participants chewing a specially formulated gum known as Tulsi Gum for 5 minutes. Tulsi Gum contains Tulsi extract, a natural substance derived from the Tulsi plant. This extract is recognized for its potential antimicrobial properties. Participants are then required to discard the gum. The study aims to assess the effect of Tulsi Gum on salivary Streptococcus mutans count in children aged 4 to 11 years. This assessment contributes to understanding the potential of Tulsi Gum in preventing dental caries in children."
75389935|NCT06174181|Device|Preservative-free ophtalmic lubricant emulsion|Use of a preservative-free ophtalmic lubricant emulsion continous during 6 months
75389936|NCT06174181|Other|Routine treatment|Use of a preservative-free ophtalmic lubricant emulsion after each intravitreal injection during few days
75389937|NCT06174142|Device|High-Frequency ESWT|Participants will receive extracorporeal shock wave therapy at a frequency of 15 Hz and intensity/pressure level 3, with a total of 1800 impulses per session. This intervention will be conducted once per week for six weeks, alongside a standard physical therapy regimen
75389938|NCT06174142|Device|Low-Frequency ESWT Group|"Participants will be treated with extracorporeal shock wave therapy at a frequency of 10 Hz and intensity/pressure level 4, also with a total of 1800 impulses per session. This protocol will be delivered weekly for six sessions, accompanied by standardized physical therapy exercises."
75389939|NCT06174142|Device|Sham ESWT Control Group|"Participants in this control group will undergo a sham ESWT procedure that mimics the treatment experience without actual therapeutic effects, ensuring the blinding of participants. This sham therapy will be scheduled once a week for six weeks, in conjunction with the same physical therapy program as the other groups."
76033854|NCT04919759|Behavioral|R-Enhanced|The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
75389940|NCT06174129|Other|Routine examinations|Electrocardiography and clinical parameters examinations, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications
75869639|NCT03517787|Other|FES+TE|Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).
75869640|NCT03517787|Other|TE|Group perform only therapeutic exercise. Exercises are the same between all 4 groups.
75869641|NCT03517787|Other|REF-FES+TE|Group perform FES+TE, but only participate in 1 session to collect reference data.
75869642|NCT03517787|Other|REF-TE|Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
75869643|NCT03513783|Other|measurement of human movement|"The objective measurement of human movement through the use of kinematic markers and electromyography is a clinical exam commonly performed to analyze the movements of patients with motor control disorders. The different steps are the following:~A clinical exam is performed by the Physical Medicine & Rehabilitation clinician (passive range of motion , spasticity, muscular force, etc.).~Intramuscular and surface electromyography and kinematic markers are placed on the upper limb of the participant. A maximum of two intramuscular electrodes will be inserted with guiding of an echography system.~The participant will be asked to perform several upper limb movements: specifically, he will be asked to perform consecutive cycles of elbow extension-flexions with the shoulder at different levels of abduction. Times of rest will be given to the participants.~Time of the procedure is estimated to 1h, with only about 2 minutes of active effortless movements from the participants."
76033855|NCT03711019|Device|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
75706844|NCT02544568|Other|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
75389941|NCT06174103|Device|BiVACOR TAH System|The BiVACOR pump is an implantable rotary biventricular blood pump that uses magnetic levitation technology for increased durability to replace both ventricles of a failing heart. The device is intended to replace the diseased heart in patients suffering from heart failure to bridge the time to heart transplant.
75389942|NCT06174090|Other|Coronary bypass graft surgery video education|It includes information about surgical process and handling issues within the first few days of surgery.
75706845|NCT03317964|Other|Saliva sample|Extract sample of saliva only once
75706846|NCT02569970|Drug|fluoxetine 20 mg|"Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
75869644|NCT03464292|Drug|Capsaicin Patch 8% or 0.1% Capsaicin Cream|0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream
75869645|NCT03464292|Other|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin.
75389943|NCT06174064|Device|Broadband Light treatment|While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.
75869646|NCT03452137|Drug|Atezolizumab|Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
75869647|NCT03452137|Drug|Placebo|Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
75869650|NCT03434717|Other|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
75869651|NCT03434717|Other|Care as usual|Patients will get care as usual
75869652|NCT03432364|Genetic|ST-400 Investigational product|Single dose of ST-400 following chemotherapy conditioning with busulfan
75869653|NCT03421353|Drug|AZD9150|"AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
75869654|NCT03421353|Drug|Durvalumab|"Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
76033856|NCT03711019|Device|RUL-UB ECT|"In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
75869655|NCT03421353|Drug|Cisplatin|Cisplatin will be infused over 30-60 minutes on Day 1.
75869656|NCT03421353|Drug|5-Flourouracil|5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
75389944|NCT06174064|Device|Sham broadband light treatment|The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.
75543149|NCT01646047|Dietary Supplement|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
75543150|NCT01646047|Dietary Supplement|multi-component dietary supplement|placebo capsules
75543151|NCT00264030|Device|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
75869657|NCT03421353|Drug|Carboplatin|Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
75543152|NCT00264030|Other|PTCA|PTCA
76033857|NCT03711019|Device|Bitemporal ECT|"Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
76033858|NCT04919837|Other|Low vision aids|the assisting devices fitting for low-vision patients
76033859|NCT02918305|Device|PRDS-001 Renal Denervation Ultrasound System|
76033860|NCT02918305|Procedure|Sham Procedure|
76033861|NCT04929509|Other|self-assembling peptide|each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators
76033862|NCT04929509|Other|nanosilver fluoride varnish|The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
75869658|NCT03421353|Drug|Gemcitabine|Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
75543153|NCT01646086|Behavioral|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
75543154|NCT04709510|Diagnostic Test|Duplex Ultrasound|Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
75543155|NCT01646242|Procedure|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
75543156|NCT01646242|Procedure|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
75543157|NCT02961075|Other|local surface anesthesia|Airway anesthesia for Bronchoscopy
75543158|NCT02961075|Device|Laryngeal tube|
75543159|NCT01646281|Drug|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
75543160|NCT01646281|Drug|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
76033863|NCT04929509|Other|sodium fluoride varnish|5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
76033864|NCT02798107|Drug|idarucizumab|drug
75706847|NCT02569970|Drug|placebo 20 mg|"Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
75706848|NCT00867958|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
75869659|NCT03421353|Drug|Nab-paclitaxel|Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
75869660|NCT03408665|Radiation|SBRT|3 sessions at least, up to 6. Neither specifc device is imposed.
75706849|NCT04066998|Other|Tears sampling|Tears sampling
76033865|NCT04403867|Procedure|Sentinel lymph node (SLN) biosy +/- lymphadenectomy|Evaluation of type and volume of lymph nodal disease
75706850|NCT04066998|Other|Lashes sampling|Lashes sampling
75706851|NCT00868036|Procedure|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
75706852|NCT00725972|Other|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
75706853|NCT00725972|Procedure|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
75869661|NCT03406624|Procedure|Biopsy|Biopsies will be taken from disc and / or endplates during elective lumbar fusion surgery or disc herniation surgery (endplate biopsy is omitted in disc herniation surgery)
75869662|NCT03372733|Drug|control olive oil (COO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
75869663|NCT03372733|Drug|palmitoleate-rich oil (PLO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
75869664|NCT03348969|Drug|Mitomycin c|Neoadjuvant Mitomycin C
76033866|NCT01865539|Device|Custom Foot Orthotic|Custom foot orthotic with custom design pads
76033867|NCT01865539|Device|Sham Orthotic|Leather insert without the custom design pads
76033868|NCT03054467|Drug|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
76033869|NCT03054467|Drug|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
76033870|NCT05009485|Device|Current Health platform|A remote patient monitoring system which includes a small footprint device and tablet, combined with an AI-powered, cloud-based system driving advanced real-time and predictive analytics related to a patient's clinical condition. The wearable records heart rate, respiratory rate, oxygen saturation, skin temperature and step count.
76033871|NCT04910165|Drug|Exparel|Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
76033872|NCT04910165|Drug|Ropivacaine|Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
76033873|NCT02730325|Other|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
76033874|NCT02730325|Other|Placebo|
76033875|NCT03054233|Procedure|Crossed leg sitting position|Spinal anesthesia done in crossed leg sitting position
76033876|NCT04928495|Drug|Vitamin C|Vitamin C 500 mg / day for ten days
76033877|NCT04928495|Drug|N-acetylcysteine (NAC)|N-acetylcysteine 1800 mg / day for ten days.
75389945|NCT06174038|Device|Hearing Intervention|"The hearing intervention includes an auditory needs assessment, hearing aid fitting, establishing Bluetooth connectivity from hearing aids to devices such as smartphones and computers, systematic orientation and instruction in device use, and provision and discussion of hearing toolkit materials for self-management and communication strategies. The hearing intervention is person-centered, focusing on identification of individual needs, setting of specific goals, engagement in shared-informed decision-making, and development of self-management abilities. Intervention-centric outcomes (e.g., hearing aid data logging, real ear measures) to verify the best-practices intervention will be gathered at all 5 intervention sessions as well as weeks 16 and 52. Additional visits to troubleshoot hearing aids or address concerns will be scheduled as needed."
75389946|NCT06174038|Behavioral|Health Education Intervention|"The evidence-based interactive health education program is designed for older adults and addresses chronic disease and disability prevention. Session content will be individualized for each participant based on a key, depending on his/her goals/interests. The curriculum includes didactics, activities, and goal setting led by staff trained/certified to deliver the intervention."
75389947|NCT06174012|Drug|Sodium Fluoride|Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
75389948|NCT06173999|Drug|SHR2554/CHOP|SHR2554 with CHOP
76033878|NCT04928495|Drug|NAC + Bromhexine (BMX)|NAC + Bromhexine (BMX) 32 mg / day for ten days.
76033879|NCT03053921|Procedure|recession coverage|recession coverage done using Zuchellis technique
76033880|NCT03053921|Procedure|recession coverage and membrane|recession coverage done using Zuchellis technique with placental membrane
75389949|NCT06173999|Drug|SHR2554/CHOEP|SHR2554 with CHOEP
75389950|NCT06173986|Drug|PD-1inhibitor|PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
75389951|NCT06173986|Drug|nab-paclitaxel + cisplatin|Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
76033881|NCT05015413|Device|Shockwave|Shock wave master 500 Germany
75389952|NCT06173986|Radiation|Radiotherapy|Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle
75389953|NCT06173973|Dietary Supplement|Kenetik; Ketone Concentrate|Ketone Supplement
75389954|NCT06173973|Dietary Supplement|Isocaloric dextrose placebo|Drink that is taste and visually matched to Ketone supplement
75543161|NCT01646359|Device|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
75543162|NCT01646359|Device|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
75706854|NCT00725790|Drug|Vardenafil|"10 mg vardenafil on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period."
76033882|NCT01573429|Other|deuterated-Bisphenol A (d-BPA)|The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
75389955|NCT06173960|Device|atherectomy|Jetstream atherectomy in combination with Ranger paclitaxel elution balloon (Drug Coated Balloon (DCB))
75389956|NCT06173947|Device|FibroScan® Expert 630|The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.
75389957|NCT06173934|Drug|insulin injection 15 minutes before meals|Adjust insulin injection time to observe blood glucose spectrum
75389958|NCT06173934|Drug|Insulin injection 15 minutes after eating|Adjust insulin injection time to observe blood glucose spectrum
75543163|NCT00239915|Drug|Pagoclone|
75389959|NCT06173921|Procedure|robotic system|Implant placement will be navigated by robotic system based on a digital plan
75389960|NCT06173921|Procedure|Static navigation system|Implant placement will be navigated by static navigation system based on a digital plan
75706855|NCT00725790|Drug|Placebo|"10 mg placebo on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period."
75706856|NCT00862498|Other|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
75389961|NCT06173908|Procedure|cell treatment|Autologous epidermal basal cells were used to repair nonhealing postoperative wound
75706857|NCT00731276|Drug|irinotecan hydrochloride|
75706858|NCT00731276|Other|pharmacogenomic studies|
75389962|NCT06173908|Procedure|control treatment|anyother treatments except autologous epidermal basal cells were used to repair nonhealing postoperative wound
75706859|NCT00731276|Other|pharmacological study|
75706860|NCT00725868|Other|Data private hospitals, angioplasty, sampling of blood|"Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency~coronary angioplasty~Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made"
75389963|NCT06173882|Behavioral|Ordinary moxibustion volume group|Moxibustion for 10 minutes per acupoint
75389964|NCT06173882|Behavioral|First group of heavy moxibustion|Moxibustion for 20 minutes per acupoint
75706861|NCT00868114|Biological|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
75706862|NCT00731354|Device|Suction-assisted Lipoplasty|Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
75706863|NCT00731354|Device|VASER-assisted lipoplasty|VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
75706864|NCT00725946|Drug|Iodine-124|
75389965|NCT06173882|Behavioral|Second groups of heavy moxibustion|Moxibustion for 30 minutes per acupoint
75389966|NCT06173856|Other|LED phototherapy|LED phototherapy (430-470nm) alone will be applied.
75706865|NCT00725946|Radiation|PET/CT with Iodine-124|
75706866|NCT02569346|Drug|Triumeq|Single-dose Triumeq as a whole tablet
75706867|NCT02569346|Drug|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
76033883|NCT03055559|Dietary Supplement|Globifer Forte|
75706868|NCT02569346|Drug|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
76033884|NCT04910009|Other|Four sessions of practical privacy education|Two sessions of theoretical, four sessions of practical privacy education
75706869|NCT04066842|Other|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
75389967|NCT06173843|Other|PFAS / heavy metal testing, exposures|PFAS / heavy metal concentrations, exposure survey
75389968|NCT06173830|Other|radiofrequency ablation|34 patients with chronic knee osteoarthritis meeting the criteria will undergo ultrasound-guided radiofrequency ablation of the genicular nerve.
75543164|NCT01646476|Device|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
75706870|NCT00731432|Drug|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
75706871|NCT00731432|Drug|Placebo Patch|Identical in shape and texture to treatment patch
75706872|NCT00726102|Other|Meat|2 0z of locally available meat per day
75706873|NCT00726102|Other|Cereal|Daily provision of cereal to infants from 6-18 mos
76033885|NCT01518673|Procedure|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
76033886|NCT04909931|Drug|Vitamin D 2|Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
76033887|NCT04909931|Drug|Placebo|Second arm : add on placebo for 12 weeks
76033888|NCT02360839|Device|EUS-guided fine needle biopsy sampling (EUS-FNB)|Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
76033889|NCT04919291|Device|Topoguided LASIK|Topoguided ablation profile on dominant eye
76033890|NCT04919291|Device|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
76033891|NCT04918589|Drug|Tranexamic acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
76033892|NCT04918589|Drug|Normal Saline|40 mL topical of 0.9% normal saline
76033893|NCT05128981|Behavioral|MI-CBT|Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
75389969|NCT06173830|Other|physical therapy|34 patients with chronic knee osteoarthritis meeting the criteria will undergo 10 sessions of physical therapy.
75389970|NCT06173817|Device|isocapnic hyperventilation|isocapnic hyperventilation (iHV) increases the elimination of methanol to the extent that it could replace haemodialysis for elimination purposes when haemodialysis is not required for the correction of acidosis, and alcohol dehydrogenase (ADH) is completely blocked by an antidote.
75389971|NCT06173791|Device|DFDBA fibers|Bone Allograft fibers used in dental sinus reconstruction surgery
75389972|NCT06173791|Device|DFDBA particles|Bone Allograft particles used in dental sinus reconstruction surgery
75706874|NCT00726102|Other|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
75706875|NCT00731510|Dietary Supplement|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
75706876|NCT00731510|Dietary Supplement|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
75706877|NCT00726804|Drug|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
75706878|NCT00726908|Dietary Supplement|Low carbohydrate|43% CHO
75706879|NCT00726960|Drug|aprepitant|Oral, 125 mg once daily for one week
76033894|NCT04101643|Drug|evolocumab|Eligible patients receive subcutaneous injections of evolocumab 420 mg
76033895|NCT02620787|Drug|Tedizolid|
75389973|NCT06173791|Device|DBBM|DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.
75389974|NCT06173778|Drug|semaglutide 2.4mg|Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
75706880|NCT00726960|Drug|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
75706881|NCT00726128|Device|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
75869665|NCT03343184|Procedure|SEE Strategy and Incremental Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
75389975|NCT06173778|Drug|Placebo|Non-active medication, self-administered
75389976|NCT06173778|Drug|Nicotine Replacement Therapy (NRT, nicotine patch)|Participants who smoke >10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
75389977|NCT06173778|Behavioral|Brief Smoking Cessation Counseling|Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
75389978|NCT06173765|Other|freeze-dried whole strawberry powder 36 g powder|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 3 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (36 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
75389979|NCT06173765|Other|freeze-dried whole strawberry powder 12 g|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 1 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (12 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
75557918|NCT00440609|Drug|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
75389980|NCT06173765|Other|freeze-dried control powder 0 g strawberry|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 0 cup FW equivalent of strawberries. The freeze-dried powder is used as a control.~All drinks will be standardized to 41 g powder to match USDA Control arm."
75389981|NCT06173752|Behavioral|Exposure therapy|Participants will complete exposure therapy for up to 12 weeks, and coached exposure session will be approximately 50 minutes.
75389982|NCT06173739|Procedure|Non-surgical mechanical treatment|"Nonsurgical mechanical therapy (NSMT) aims to control infection and minimize bacterial burden through debridement of the implant surface. It is the gold standard treatment method for both peri-implantitis and peri-implant mucositis.~Non-surgical mechanical treatment will be applied to patients with the purpose of surface debridement and reducing bacterial flora in implants with peri-implant disease for which clinical examination has been completed and the diagnosis has been confirmed. All intraoral implants of the patients will be evaluated and all implants that do not meet the clinical definition of health will be intervened. Each implant surface will be treated with a titanium curette. In all groups, mechanical debridement was performed on the surfaces by the same clinician.~The procedure will continue gently until it is felt that it has been adequately debrided. Subgingival irrigation will be performed with physiological saline. Post NSMT No medication will be administered."
75389983|NCT06173726|Biological|BST02 Injection|"The TIL used for tumor tissue surgical sampling of qualified subjects was used to prepare BST02 injection, and the subjects who successfully received the surgical sampling were considered to be enrolled.~In the study process, cell transfusions were recorded as day 0 of the study. On the 3rd day (D-3) before infusion of BST02 injection, it is necessary to receive eluvial pretreatment. Considering that this product is unmodified autologous T lymphocytes, previous studies have shown that low-intensity cyclophosphamide can stimulate their proliferation in vivo. Therefore, the cyclophosphamide (Cy) single-drug regimen is recommended: Cy 250mg~1.5g/m2, a single intravenous infusion"
75389984|NCT06173713|Device|Emphasys Hip Solutions|Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
75869666|NCT03343184|Procedure|SEE Strategy and Bulk Fill Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
75543165|NCT01646476|Device|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
75543166|NCT01646554|Drug|Modified FOLFOX6|
75543167|NCT01646554|Biological|Aflibercept|Targeted therapy
75543168|NCT01646554|Procedure|Surgery|
75557919|NCT00440648|Drug|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
75557920|NCT00440648|Drug|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
75557921|NCT00440687|Drug|Fluticasone 500mcg BD via accuhaler or identical placebo|
75389985|NCT06173700|Behavioral|web-based group problem solving and coping training|"The group included one-hour, weekly Zoom sessions, that were facilitated by an occupational therapy doctoral candidate (first author) for 7 consecutive weeks. During the first session, the candidate explained adaptive and maladaptive coping strategies and asked each participant to identify one adaptive coping strategy that they currently use and will continue to use in the future. The candidate then explained the FOCUS problem-solving approach. For each session afterward, the candidate presented a topic-related scenario for parents to identify an effective solution using the FOCUS steps (APA, 2011). Parent-chosen topics included recreation, assistive technology, motivating and advocating, physical activity, skin integrity, and adaptive fashion. The general process of the meetings is presented in Figure 1. After every meeting the candidate sent out a summary of resources that were discussed during the meeting, ultimately putting them all together in an Empowering Caregiver Guide."
75389986|NCT06173674|Other|Music intervention|"The music intervention will consist of three components including:~Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital."
75389987|NCT06173635|Device|Maxi Move 5|4 comparative devices will be used to evaluate the MM5 device
75389988|NCT06173622|Behavioral|Fetal Positioning|In the study, venipuncture was applied to the intervention and control groups. While the procedure was performed by an experienced neonatal nurse, the neonates' pain score, crying duration and physiological parameters were monitored by another researcher (observer).
75389989|NCT06171750|Drug|ANK-101|IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.
75389990|NCT06167954|Device|EXPLORER|8 sessions of use of the device in the home and the community of the participants
75389991|NCT06167733|Device|VERTICA Active device|VERTICA device with a therapeutic RF energy level
75389992|NCT06167733|Device|VERTICA Sham device|VERTICA device with a low, non-therapeutic RF energy level
75389993|NCT06167551|Other|mother lullaby group|mother's lullaby: the mother will be made to sing her own lullaby 5 minutes before the heel prick.
75389994|NCT06167551|Other|white noise group|white noise: 5 minutes before taking heel prick blood, white noise will be started to be played on an MP3 player with white noise. The MP3 player will be placed in the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
75389995|NCT06167551|Other|classical music group|classical music: 5 minutes before heel prick, classical music will be started to be played from the MP3 player with white noise. The MP3 will be placed inside the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
75389996|NCT06167551|Other|Contol Group|No intervation
75557922|NCT03271047|Drug|binimetinib|Orally, twice daily.
75557923|NCT03271047|Drug|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
75557924|NCT03271047|Drug|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
75557925|NCT00440765|Drug|bortezomib|dose as determined (observational study) by treating physician
75557926|NCT00440804|Drug|ibuprofen l-lysine iv solution (NeoProfen (R) )|
75557927|NCT03276936|Drug|FMX103 1.5%|FMX103 1.5% minocycline foam
75557928|NCT00440843|Drug|Olanzapine (Zyprexa)|OLZ
75557929|NCT00440843|Drug|Typicals|Stay on typicals regimen
75706882|NCT02570958|Drug|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
75706883|NCT00731744|Procedure|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
75706884|NCT02570412|Drug|aldoxorubicin|aldoxorubicin administered at 350 mg/m2
75706885|NCT00726206|Other|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
76033896|NCT02620787|Procedure|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
76033897|NCT04082455|Radiation|carbon ion radiotherapy|carbon ion radiotherapy
75706886|NCT02202590|Device|SECM Capsule|Imaging of the esophagus using the SECM capsule and system
75706887|NCT00727038|Drug|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
76033898|NCT04062799|Other|no intervention|It is an observationa study. There is no intervention.
76033899|NCT04909619|Procedure|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|The maxillary nerve, V2, is purely a sensory branch of the trigeminal nerve. V2 exits the skull through the foramen rotundum and courses through the pterygopalatine fossa, a small pyramid-shaped depression located posterior to the maxilla. As the maxillary nerve exits the pterygopalatine fossa, it divides into numerous branches that supply sensation to the posterior nasal cavity, palate, sinuses, and maxilla. It is within the pterygopalatine fossa that the maxillary nerve is targeted and anesthetized during the block. With the patient in the supine position after nasotracheal intubation, a needle is inserted perpendicularly between the upper border of the zygomatic arch and posterior orbital rim until it reaches the greater wing of the sphenoid, where the needle is then retracted by a few millimeters and redirected toward the nasolabial fold until it hits the pterygopalatine fossa.
76033900|NCT04909619|Procedure|Local anesthetic infiltration of the palate|Local anesthetic infiltration of the palate during cleft palate repair is universally practiced. The benefits of local anesthetic infiltration are twofold: to provide anesthesia to the terminal branches of the nasopalatine and greater palatine nerves that are in the immediate area of the injection sites and to achieve hemostasis during closure when the medication is mixed with epinephrine. To administer local anesthetic infiltration of the palate, a 25 gauge needle is inserted next to the incision into the soft tissue. The tissue is first aspirated to determine safety of injection at that site. The medication is then injected parallel to the incision on both sides.
76033901|NCT05128747|Other|DASH diet|it will be face to face about the role of nutritional program to control dyslipidemia
76033902|NCT03056729|Drug|BIIB076|Administered as single intravenous (IV) infusion
76033903|NCT03056729|Drug|Placebo|Administered as single IV infusion
75543169|NCT00250263|Drug|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily"
76033904|NCT03053999|Other|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
76033905|NCT03053999|Other|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
75389997|NCT06167499|Other|Diabetes Therapeutic Education conducted by nurses|"Individual consultations with the therapeutic education IDE, who will help the patient to achieve the therapeutic objectives set before the medical consultation.~Once the objectives have been set, the IDE will set up individual workshops and subsequently assess the patient's learning and its impact on his or her care. These workshops can include equipment demonstrations and practical exercises, explanations of treatment adaptation protocols, and dietary or sexual advice."
75389998|NCT06167200|Other|No intervention, study is observational|No intervention, study is observational
75389999|NCT06167161|Device|Hearing aid|The hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and through a dedicated smartphone application
75390000|NCT06167096|Other|Lavender essential oil|Lavender Oil; blend of two (2) pure lavender oil - Lavandula angustifolia from Bulgaria and Lavandula hybrida from France
75390001|NCT06167096|Other|Water|Water
75557930|NCT00438789|Drug|eculizumab|600mg IV every week and 900mg IV every 2 weeks
75557931|NCT00440921|Drug|Single donor Allogenous Fibrin Sealant|
76033906|NCT03843073|Device|Connected Urinary Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
76033907|NCT03053843|Dietary Supplement|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
76033908|NCT05128435|Diagnostic Test|Blood sample|Blood sample taken 3 to 5 months after the infection
76033909|NCT03055637|Procedure|Furlow double opposing z-plasty|* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions
76033910|NCT03055637|Procedure|Two flap palatoplasty|design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
76033911|NCT03559855|Behavioral|Real Essentials|The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
76033912|NCT04918901|Combination Product|NO Severe COVID-19|Non-severe and critically ill patients with COVID-19
75557932|NCT00440960|Drug|propofol|
75557933|NCT00440960|Drug|midazolam|
75557934|NCT00440960|Drug|alfentanil|
76033913|NCT03520231|Drug|Denosumab|RANK Ligand Inhibitor
76033914|NCT03520231|Other|Denosumab Placebo|Placebo
76033915|NCT03520231|Drug|Gemcitabine|Antineoplastic Agent
76033916|NCT03520231|Drug|Carboplatin|Antineoplastic Agent
76033917|NCT03520231|Drug|Cisplatin|Antineoplastic Agent
75543170|NCT00250263|Drug|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily"
76033918|NCT03520231|Dietary Supplement|Calcium|Calcium Supplement
76033919|NCT03520231|Dietary Supplement|Vitamin D|Vitamin D Supplement
75543171|NCT02279368|Behavioral|Family Counselling and safeguarding|
75543172|NCT02279446|Other|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
75543173|NCT02279485|Drug|Perampanel|
75543174|NCT01646593|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
75557935|NCT00440960|Drug|lidocaine|
76033920|NCT04927481|Drug|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
76033921|NCT05128357|Other|the study is observational, no intervention foreseen|the study does not foresees any intervention, since it is a multi step observational study.
76033922|NCT05117749|Drug|Saffron 100|to Mild and Moderate UC patients
76033923|NCT05117749|Drug|Saffron 50|to Mild and Moderate UC patients
75390002|NCT06166862|Other|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
75390003|NCT06166862|Other|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
75390004|NCT06166654|Drug|Acetazolamide|1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
75390005|NCT06166654|Drug|Metolazone 2.5 MG|2. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
75390006|NCT06166654|Other|Double-placebo|This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
75390007|NCT06166420|Other|Experimental|Counseling on cervical cancer screening followed by home-based HPV self-sampling test proposal.
75543175|NCT00264069|Drug|antipsychotic|as prescribed
75390008|NCT06166420|Other|Active comparator|Counseling on cervical cancer screening followed invitation to screen at Dschang District Hospital.
75390009|NCT06166251|Behavioral|low ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.
75390010|NCT06166251|Behavioral|moderate ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
75390011|NCT06165328|Diagnostic Test|CT and colonoscopy|All patients were admitted and worked up as inpatient cases. A blood test was obtained and a CT whole abdomen was performed for all patients in the evening. On the next day, all patients were prescribed for bowel preparation in the morning, then subsequently underwent colonoscopy in the afternoon.
75543176|NCT00264069|Drug|antidepressants|as prescribed
75543177|NCT01646632|Behavioral|Physical exercise intervention|the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
76033924|NCT05117749|Drug|Placebo|to Mild and Moderate UC patients
76033925|NCT04918667|Combination Product|Berberine incorporated in gamma cyclodextrin|Experimental modified product. One capsule contains 250 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract incorporated in gamma-cyclodextrin
75543178|NCT01646632|Behavioral|Lifestyle counseling|the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
75543179|NCT01646710|Behavioral|Pretesting food based recommendations|
75543180|NCT01646788|Device|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
75543181|NCT01647178|Procedure|TORQ assisted sternal closure|
76033926|NCT04918667|Dietary Supplement|Berberine|Active comparator. One capsule contains 500 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract
75543182|NCT01647178|Procedure|Conventional closure|
75543183|NCT02961699|Device|Transpose ® RT System|adipose-derived stem cell therapy
75543184|NCT02961699|Other|debridement/dressing of wound|standard of care debridement and wound dressing
75543185|NCT01647256|Drug|Nikkomycin Z|Capsule, 500 mg, single-dose
75543186|NCT00239954|Drug|Escitalopram|
75390012|NCT06165055|Diagnostic Test|DNA Sample Collection + DNA genotyping|Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.
75706888|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
75706889|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
75706890|NCT04018586|Device|AVACEN 100|AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
75543187|NCT04528927|Drug|HCQ|600 mg on the 1st day as a starting dose then 200 mg * 2 /D for 9 days
75543188|NCT04528927|Drug|Azithromycin|500 mg (1st day) then 250 mg / D for 4 days
75543189|NCT04528927|Drug|Doxycycline|200 mg per day for 10 days
75706891|NCT04018586|Device|AVACEN 100 Heat Only|AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
76033927|NCT03456193|Procedure|LA transplant|"The proposed study treatment will include three central components:~Harvest of the left atrium and pulmonary veins from a suitable donor~Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis~Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient."
75543190|NCT04528927|Dietary Supplement|Zinc|220 mg per day for 10 days
76033928|NCT03056495|Drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
75543191|NCT04720287|Drug|bupivacaine/ neostigmine.|will receive bilateral ultrasound guided QLB
75543192|NCT04720287|Drug|bupivacaine/ neostigmine.|will receive ultrasound guided CB.
75543193|NCT04528654|Other|Mobile Health Application|The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
75543194|NCT00239993|Drug|glatiramer acetate|
75543195|NCT00239993|Procedure|Warm compress prior to injection of glatiramer acetate|
75543196|NCT01647334|Radiation|Adaptive radiotherapy|
75543197|NCT00264108|Drug|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
75390014|NCT06163495|Behavioral|School-based extracurricular intervention focusing on time spent with friends and screen media use|"The intervention includes the following components:~For each participating class, children and parents will engage in two family workshops. The purpose of these events is to support the class and families in establishing and maintaining a leisure time behavior among children with less solitary screen usage and more face-to-face interaction with peers.~In the beginning of 4th grade, parents will engage in a short exercise focusing on screen media dilemmas.~Children will engage in school hour workshops focusing on the class culture related to screen media use and face-to-face interaction with peers.~Afterschool club personal will engage in a training program consisting of three workshops aimed to increase participation rate in the afterschool club.~Local stakeholders relevant to children's leisure time will engage in two workshops to develop local actions focusing on children's engagement in face-to-face interactions with peers."
75390015|NCT06163105|Procedure|Meibomian gland expression (MGX)|"The MGX procedure has a standardized protocol in lid spa at Chula's Refractive Surgery Center every 2 weeks (totally 6 sessions). During the study, all MGX procedures will be conducted by the same nurse following these steps:~Topical anesthesia by Tetracaine 0.5%~Clean the eyelids by gauzes with commercial available foam~Warm the eyelids by Blephasteam machine for 10 minutes~Instill Tetracaine 0.5% again~Use Mastrota paddle and Q-tip to squeeze the gland~Clean the lid margin by commercial available foam~Use Moxifloxacin 0.5% eyedrop"
75543198|NCT00264108|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length.
75706892|NCT04018586|Device|AVACEN Sham|AVACEN 100 neither heats nor pulls a vacuum to hand
75706893|NCT00726258|Drug|ketamine|ketamine with various concentrations
75706894|NCT00726258|Drug|placebo|physiological serum
75706895|NCT00727142|Procedure|Surgical treatment|Insertion of a functioning shunt
75543199|NCT01647412|Drug|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
75543200|NCT01647412|Dietary Supplement|Nutraceutical Combination|
75543201|NCT01647412|Other|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
75543202|NCT01647412|Other|Placebo Growth Hormone|
75706896|NCT04793802|Other|PHYSIO|session of physiotherapy
75706897|NCT02569814|Drug|Fimasartan/Amlodipine/Rosuvastatin|
75706898|NCT02569814|Drug|Fimasartan/Amlodipine|
75706899|NCT02569814|Drug|Rosuvastatin|
75706900|NCT00726492|Other|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
75706901|NCT00726492|Other|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
75706902|NCT00726570|Device|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
75706903|NCT00726570|Drug|Dalteparin|"2500 UI qd if ≤ 50 kg body weight~5000 UI qd if > 50 kg"
75390016|NCT06162871|Behavioral|Presentations and interactive debate sessions, with intergenerational exchange|Intervention will consist of 12 sessions, each lasting about two hours, conducted on a weekly basis and delivered both in-person and remotely. The sessions will include presentations and interactive debate sessions, with a central focus on intergenerational exchange covering cultural, historical, and health-related topics. A key aspect is the active involvement of beneficiaries, individuals over sixty-five, who will be asked to prepare presentations with the support of project-provided facilitators. Simultaneously, the project will promote and enhance skills, organizational capabilities, and computer literacy.
75543203|NCT01647529|Drug|Ganciclovir|Treatment with topical ganciclovir ointment
75543204|NCT00240032|Drug|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
75543205|NCT00240032|Drug|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
75543206|NCT01647607|Behavioral|Young Women's Intervention (YWI)|This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
75543207|NCT01647607|Behavioral|Physical Activity Intervention (PAI)|This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
76033929|NCT03171805|Drug|Propranolol|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
75543208|NCT00250302|Procedure|autologous mesenchymal stem cells implantation|
76033930|NCT03098329|Other|Ct/GC screening|Men aged 15-26 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
75543209|NCT04528849|Drug|Gonadotropin dose increment timing|Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
75543210|NCT00240149|Drug|Regular Insulin via Insulin-Glucose Algorithm|
75543211|NCT01647646|Drug|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
75543212|NCT01647685|Drug|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
75543213|NCT01647685|Drug|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
75706904|NCT00726570|Procedure|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~Patient admission (before SCD start)~40-60 min after admission~Morning after surgery"
76033931|NCT03053531|Device|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
76033932|NCT05117593|Drug|FBL-MTX|FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
76033933|NCT05117593|Drug|Placebo|Placebo will consist of sterile saline 0.9% NaCl solution.
75543214|NCT01647685|Drug|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
75543215|NCT00240188|Procedure|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
75543216|NCT00240188|Procedure|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
75543217|NCT01647802|Device|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
75557936|NCT00438828|Drug|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
75557937|NCT00441038|Behavioral|The Back Guide|Education on postural hygiene and handout of The Back Guide
75557938|NCT00441038|Behavioral|The Back Book|Education on active management and Handout of The Back Book
75557939|NCT00441038|Behavioral|Cardiovascular and general health|Education on cardiovascular and general health
75557940|NCT00438867|Genetic|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
75390017|NCT06162312|Other|Antenatal perineal massage|Participants at 34-35 weeks of gestation were received training in self-perineal massage and performed a daily 5-minute massage using water-based jelly until delivery to compare with standard obstetric care on postpartum morbidities
75706905|NCT00726726|Drug|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
75706906|NCT00726726|Drug|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
75869667|NCT03343184|Procedure|SET Strategy and Incremental Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
76033934|NCT04927013|Behavioral|Message-based Outreach Intervention for Survivors|The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.
76033935|NCT04927013|Behavioral|Standard Outreach for Survivors|The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log-in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.
75390018|NCT06161649|Behavioral|accepting the operation process of automated intelligent education software system|"Execute registration and qualification review~Automated smart education interaction"
75390020|NCT06155331|Drug|Fenofibrate|It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).
75390021|NCT06155331|Other|Placebo|Placebo is made to look exactly like a real drug but is made of an inactive substance.
75390022|NCT06155331|Drug|Doxorubicin|Anthracycline derived chemotherapy used in treatment of breast cancer
75543218|NCT01647802|Device|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
75543219|NCT01647802|Device|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
75557941|NCT00438867|Genetic|Placebo|Control group
75557942|NCT00441077|Behavioral|Education|
75557943|NCT00441155|Drug|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
75557944|NCT00106002|Drug|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
75557945|NCT00441194|Device|Visual Field (Octopus 311 and the HFA 700 series)|
75557946|NCT00476853|Drug|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
75390023|NCT06155331|Drug|Cyclophosphamide|Alkylating agent used in treatment of breast cancer
75390024|NCT06153810|Device|Biofeedback stimulation|Delivery of the vibratory biofeedback stimulus
75390025|NCT06152718|Other|Karisma|Use of regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen
75557947|NCT00441233|Device|Silicone hydrogel contact lens|
75390026|NCT06152601|Procedure|anticipated bipedal standing position in the immediate post-operative phase|"Realization of a first stand-up within 6 hours after entry into PACU or extubation for admitted patients intubated, in PACU or on admission to ICU by a state-certified physiotherapist.~Immediately postoperatively, during his stay in a Intensive Care Unit, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position."
75390027|NCT06145477|Behavioral|Chicago Parent Program - individualized for families (CPPi)|CPPi is a 8-12 session individual- based parenting skills program
75390028|NCT06142526|Device|DividPro film|DividPro Film is a sterile biodegradable translucent film that served as a physical barrier for preventing the adhesion between two adjacent layers of tissue in wound healing process.
75706907|NCT00726726|Drug|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
75706908|NCT00731978|Procedure|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
75706909|NCT00727350|Radiation|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
75706910|NCT00732056|Drug|GRN163L|25% dose escalation infused over 2 hours weekly
75390029|NCT06142357|Other|Secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled
75706911|NCT00654381|Drug|BI 1356|5 mg/daily
75706912|NCT00654381|Drug|BI 1356|10 mg/daily
75706913|NCT00654381|Drug|voglibose placebo|three times daily
75706914|NCT00654381|Drug|BI 1356 placebo|once daily
75706915|NCT00654381|Drug|voglibose|0.6 mg/daily
75706916|NCT00727428|Biological|FluLaval® TF|One IM injection.
75706917|NCT02089880|Device|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
75706918|NCT02089880|Device|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
75390030|NCT06140667|Device|LarysealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr.
75543220|NCT01647919|Dietary Supplement|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
75543221|NCT01647919|Dietary Supplement|Placebo|4 capsules of placebo identical to cogniVida™ once a day
75543222|NCT00240266|Drug|Rosuvastatin|
75706919|NCT00727584|Radiation|radiation therapy|Patients undergo external beam radiotherapy
75706920|NCT04018482|Other|Povidone Iodine|FDA-approved disinfectant for intravitreal injections
75706921|NCT04018482|Other|Hypochlorous Acid|FDA-approved disinfectant for intravitreal injections
75706922|NCT00808041|Device|Dedicated breast computed tomography imaging|Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
75390031|NCT06140667|Device|Ambu Aura Gain|The AuraGain is Ambu ꞌs 3rd generation disposable laryngeal mask, satisfying 3 fundamental airway management needs by integrating gastric access channel for managing gastric content and intubation capability using standard ET-tubes in an anatomically curved single-use device that facilitates rapid establishment of a safe airway through integrated bite absorption area that could prevent airway occlusion. Other characters include pilot balloon that identifies mask size and provides tactile indication of degree of inflation, navigation marks for guiding flexible scope and is made of phthalate-free material. Its thin and soft cuff is designed to deliver high seal pressure up to 40 cmH2O. It was presented in the clinical market in sizes 3, 4, 5 and 6 (according to the body weight; size 3: 30-50 kg, size 4: 50-70 kg, size 5: 70-100 kg, and size 6: >100 kg) with maximum suction catheter size of 16 Fr.
75706923|NCT00727454|Device|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
75390032|NCT06139718|Behavioral|ACT Guide Lite|ACT Guide Lite is a single session online mental health program that is designed to take 30-45 minutes to complete. The single session self-guided intervention includes a series of sections that teach key ACT skills.
75543223|NCT01648036|Drug|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
75390033|NCT06138691|Combination Product|Ketamine Infusion plus RO DBT|The participant will receive 4 weeks of 0.5mg/kg intravenous ketamine given over 40 minutes, as is routinely done in ketamine treatment and four months of RO DBT treatment.
75390034|NCT06134544|Dietary Supplement|Isomaltooligosaccharides (IMO)|Patients will still receive standard treatment, including medicine and other invasive treatment.
75543224|NCT01648036|Drug|Dalteparin|Dose 5000 IU, subcutaneous, daily
75390035|NCT06132984|Diagnostic Test|Cardiac magnetic resonance|Cardiac magnetic resonance protocols include cine, non-contrast T1-mapping and T2-mapping.
75390036|NCT06131905|Drug|Magnesium Sulfate|40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
75543225|NCT01648075|Dietary Supplement|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
75543226|NCT01648114|Other|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
75543227|NCT04528537|Other|questionnaire|16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU)
75706924|NCT00727454|Device|No treatment|No treatment
75706925|NCT00727662|Other|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
75390037|NCT06131905|Drug|Propofol|An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
75390038|NCT06128655|Other|Participation in PFCC-IR|PFCC-IR with the critical care team is standard practice in ICU but it doesn't usually include family members. The intervention for this study is interdisciplinary patient care rounds that include one family member of the patient.
75390039|NCT06127719|Other|questionnaires|before surgery, patients are asked to fill out the questionnaires as stated in the outcome measures paragraph
75390040|NCT06127394|Procedure|Sacral ESP Block|Sacral ESPB median approach, 40 ml %0,25 Bupivacaine
75390041|NCT06127394|Procedure|Pudendal Block|Bilateral pudendal block, 10 ml %0,25 bupivacaine
75390042|NCT06127030|Behavioral|Brief behavioral teacher training|A brief behavioral teacher training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of two hours and a third session of one hour in which the training will be evaluated and maintenance training will be provided.
75390043|NCT06127030|Behavioral|Practice as usual only (PAU)|PAU may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. PAU can also imply that there is no support or treatment.
75390044|NCT06122363|Device|hysteroscopy|uterine hysteroscopy right after Novasure endometrial ablation
75390045|NCT06120257|Procedure|lithotripsy using Flexible ureteroscope|using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate
75543228|NCT00240305|Drug|Rosuvastatin|
75390046|NCT06120257|Procedure|extracorporeal shock wave lithotripsy (ESWL)|using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate
75706926|NCT00727662|Other|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
75390047|NCT06120257|Procedure|holmium laser lithotripsy using Karl® Storz MIP set|using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate
75390048|NCT06117163|Behavioral|Collaborative Care Model|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
75390049|NCT06111807|Diagnostic Test|ctDNA|ctDNA will be tested retrospectively, no treatment decisions will be made prospectively
75390050|NCT06108219|Drug|Miricorilant|Miricorilant 100 mg for oral dosing
75390051|NCT06108219|Drug|Placebo|Matching placebo for oral dosing
75390052|NCT06106022|Drug|Vonoprazan|Administered orally
75543229|NCT01648192|Drug|Losmapimod for single dose|Film coated white tablet
75543230|NCT01648192|Drug|Losmapimod for repeat dose|Film coated white tablet
75706927|NCT00805311|Procedure|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
75706928|NCT00805311|Drug|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
75706929|NCT00726440|Device|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
75706930|NCT00726440|Device|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
75706931|NCT00726440|Device|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
75706932|NCT04474314|Drug|IMR-687|Oral administration of once daily IMR-687
75543231|NCT01648231|Drug|Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
75543232|NCT01648231|Drug|Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
75543233|NCT01648231|Drug|Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
75706933|NCT04474314|Drug|Placebo|Oral administration of once daily Placebo
75706934|NCT00808119|Drug|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
75390053|NCT06099457|Behavioral|SIB-Time web-application tool|Parent-child dyads will use the SIBTime app in an 8-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
75390054|NCT06098339|Device|Lens A (fanfilcon A)|Daily wear for one month
75390055|NCT06098339|Device|Lens B (lotrafilcon B)|Daily wear for one month
75390056|NCT06094270|Device|EndoMind|Withdrawal time is calculated and an image report is generated using the EndoMind system.
75390057|NCT06092554|Dietary Supplement|LactoLevure|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The probiotic capsules look identical to the placebo capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
75543234|NCT01648309|Other|Neuropsychological testing|This is an observational study
75543235|NCT01648504|Other|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
75543236|NCT01648543|Procedure|lumbar sympathetic ganglion block|
75543237|NCT01648660|Dietary Supplement|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
75390058|NCT06092554|Other|Placebo|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The placebo capsules contain a powdered glucose polymer that is unharmful for the patient and will be provided by the sponsor. The placebo capsules look identical to the probiotic capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
75390059|NCT06088901|Procedure|Autologous Blood Patch|2 ml/kg of whole blood (max 100 ml) is obtained via venipuncture. This blood is then injected via the chest tube which will then be clamped for 180 minutes, before being returned to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
75543238|NCT00264186|Drug|LPS 2 ng/kg intravenous (IV) bolus|
75543239|NCT00264186|Drug|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
75543240|NCT00264186|Drug|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
75543241|NCT00264186|Drug|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
75543242|NCT00264186|Drug|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
75706935|NCT00732290|Drug|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
75706936|NCT00732290|Drug|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
75706937|NCT02569788|Radiation|Carbon ion radiotherapy (CIRT)|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3~5mm.
75869668|NCT03343184|Procedure|SET Strategy and Bulk Fill Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
75543243|NCT01648738|Other|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
75543244|NCT01648738|Other|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
75706938|NCT03906344|Drug|INCB052793|
75869669|NCT03307785|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
75543245|NCT01648855|Other|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
75543246|NCT01648933|Radiation|Rubidium PET|Myocardial Perfusion Imaging
75390060|NCT06087770|Drug|SM3321|Intravenous infusion, once a week, 28 days for a dosing cycle
75390061|NCT06087328|Drug|Regular Nicotine patch and lozenge dose|1mg patch, qd + 4mg lozenge prn [minimum of 5 & up to 20 per day]
75390062|NCT06087328|Drug|Augmented Nicotine patch and lozenge dose|21mg patch + 14mg patch qd + 4mg lozenge prn [minimum of 5 & up to 30 per day] OR 2 x 21mg patches qd + 4mg lozenges prn [minimum of 5 & up to 40 per day]
75390063|NCT06078904|Drug|Colchicine 0.5 MG|Colchicine 0.5 MG, one pill a day, oral intake
75390064|NCT06078904|Drug|Colchicine 0.375 MG|Colchicine 0.375 MG, one pill a day, oral intake
75390065|NCT06078904|Drug|Colchicine 0.25 MG|Colchicine 0.25 MG, one pill a day, oral intake
75390066|NCT06078904|Drug|Placebo|Placebo, one pill a day, oral intake
75543247|NCT01648972|Drug|Gastrografin|
75390067|NCT06078748|Behavioral|EX|"EX involves 2.5hrs of moderate intensity aerobic and resistance exercise per week. EX will be instructed by a clinical exercise physiologist (CEP) or registered kinesiologist (RKIN). The EX session will include a 5min warm-up, 20-30min of moderate intensity aerobic exercise, 20-30min of moderate intensity resistance training, and a 5min cool down. The virtual video session will be pre-recorded, have similar composition, and will be led by the same instructor as the group sessions. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on exercise in order to overcome barriers and increase maintenance of lifestyle changes."
75390068|NCT06078748|Behavioral|DIET|"DIET involves one session per week of diet education delivered by a Registered Dietitian. The DIET session will be 90 minutes during months 1-4, and 30 minutes in months 5 and 6. DIET was developed by our team, emphasizing foods identified as supporting executive function, memory, and other cognitive abilities. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on diet in order to overcome barriers and increase maintenance of lifestyle changes."
75543248|NCT01648972|Drug|Placebo|
75543249|NCT00240422|Drug|Telmisartan|
75543250|NCT00240422|Drug|Ramipril|
75543251|NCT00264225|Drug|Lamaline® , 3 different doses, Dafalgan codeine|
75543252|NCT01649011|Behavioral|Application of the initial evaluation|Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
75543253|NCT01649011|Behavioral|Final application of scales|Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
75543254|NCT01649050|Drug|BGG492|
75543255|NCT01649050|Drug|Placebo|
75557948|NCT00438906|Procedure|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
75390069|NCT06078748|Behavioral|STRETCH|STRETCH sessions will be time/frequency-matched to EX sessions (2.5hrs/week: 1.5hr in virtual group sessions; 1hr virtual video session) to control for social aspects and placebo effects of EX.Each STRETCH session will include a 5min warm-up, 5min of balance exercises, and 50min of stretching. Difficulty will not be progressed. STRETCH sessions will also be led by a CEP/RKIN instructor and video sessions will be pre-recorded by the same instructor.
75706939|NCT00730002|Procedure|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
76033936|NCT04927013|Behavioral|Message-based Outreach Intervention for Close Relatives|Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.
76033937|NCT04927013|Behavioral|Standard Outreach for Close Relatives|The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
76033938|NCT02787187|Procedure|Pancreaticoduodenectomy with Standard lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
76033939|NCT02787187|Procedure|Pancreaticoduodenectomy with Extended lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
75390070|NCT06078748|Behavioral|ED|ED sessions designed to be of equal intensity and social engagement to the DIET intervention. Participants will engage in group discussion and receive information on the brain and cognitive processes, the effect of age on cognition, and tips to promote healthy aging. This will include lectures, watching documentaries and participating in various games.
76033940|NCT03053375|Device|MDCure|Battery powered portable pulsed electromagnetic therapy device
76033941|NCT05405023|Other|Concentric exercises with wrist mobilization|Participants will receive concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements.
76033942|NCT05405023|Other|Concentric exercises without wrist mobilization|Participants will receive concentric exercises only.
76033943|NCT04918277|Device|Assessment of gastric volume|Measuring the cross-sectional area of stomach in supine and right lateral decubitus
76033944|NCT04918433|Procedure|Regional anaesthesia|Regional anaesthesia for sternotomy incision for congenital cardiac surgery
75390071|NCT06076018|Drug|intrathecal morphine|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally, and 120 mcg intrathecal morphine (ITM) will be administered to the morphine group. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
76033945|NCT05093803|Behavioral|CONTROL GROUP|Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.
76033946|NCT05093803|Behavioral|HEALTH APP GROUP|"Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators."
75390072|NCT06076018|Drug|intrathecal fentanyl|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
75543256|NCT02279563|Drug|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
75543257|NCT02279563|Drug|Dymista™ Nasal Spray|
75706940|NCT00730002|Procedure|Magnetic resonance imaging|MR spectroscopy
75706941|NCT00730002|Procedure|MRA|MRA of the brain
75706942|NCT00730002|Procedure|MRA|
76033947|NCT04926467|Drug|Anakinra|"Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.~Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8."
76033948|NCT02302105|Radiation|IGRT|Image Guided RT to the prostate
75706943|NCT00730002|Procedure|diffusion Imaging|MRA of the Brain
75706944|NCT00730002|Procedure|perfusion imaging.|MRA of the brain
76033949|NCT05128045|Behavioral|NEW-R|Eight session class on nutrition, physical activity, diet, and weight management
76033950|NCT03053297|Other|Patient Reported Outcomes|"HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete"
75706945|NCT04460664|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
75869670|NCT03307785|Drug|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
75543258|NCT02279563|Drug|Placebo|
75543259|NCT00240461|Dietary Supplement|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
75543260|NCT00240461|Dietary Supplement|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
76033951|NCT05127889|Drug|curodont|"To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~The varnish will be mixed with the brush to avoid separation of the material during storage~However, to guarantee the best results suction will be used during application of the varnish.~A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs."
76033952|NCT05127655|Procedure|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
75390073|NCT06072807|Diagnostic Test|Brain Imaging with 18F-FES|Using 18F-FES radiotracer in PET/CT scan to evaluate brain metastases in ER positive breast cancer patients.
75390076|NCT06067659|Other|Extracorporeal shock wave therapy|ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
75390077|NCT06067659|Other|Kinesiology taping|The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
75390078|NCT06067659|Other|Extracorporeal shock wave therapy+Kinesiology taping|Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
75390079|NCT06067568|Drug|Lutikizumab Dose A|Injection; subcutaneous (SC)
75390080|NCT06067568|Drug|Lutikizumab Dose B|Injection; subcutaneous (SC)
75543261|NCT00240461|Other|Placebo|crystalline substance 200 mg twice daily for 6 months
75543262|NCT02279680|Device|Electroencephalography|
75543263|NCT02279680|Behavioral|Neuropsychological assesments|
75543264|NCT02279758|Drug|Metformin|
75543265|NCT00264264|Procedure|Closure Device|
75543266|NCT00264264|Procedure|Direct Compression|
75543267|NCT01649206|Procedure|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
75543268|NCT01649245|Drug|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
75543269|NCT04721210|Other|Transcranial magnetic stimulation|"The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv."
75543270|NCT01649284|Drug|afatinib|40, 30, and 20 mg film-coated tablets
75390081|NCT06061926|Drug|Celery Seed|Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
75390082|NCT06061926|Drug|Placebo|Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
75390083|NCT06061809|Drug|Bevacizumab|Participants will receive 10mg/kg of Bevacizumab intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
76033953|NCT04926935|Diagnostic Test|Microbiological analysis of blood samples.|Microbiological analysis of blood samples collected from the patients with clinically suspected infection.
75706946|NCT02570334|Other|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
75390084|NCT06061809|Drug|PD-L1 t-haNK|Participants will receive PD-L1 t-haNK (~2 × 109 cells/infusion) intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
75390085|NCT06061809|Drug|N-803|Participants will receive 1mg subcutaneously (SC) on Day 1 and Day 15 of each repeated cycle of treatment.
75706947|NCT00732446|Drug|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
76033954|NCT03053219|Drug|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
75390086|NCT06055621|Drug|Dasatinib|Daily orally administration of DASATINIB
75390087|NCT06045962|Device|Ureteral stent|Used to open the ureter and help the kidney drain
75390088|NCT06041087|Behavioral|High-Intensity Exercise|A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
75390089|NCT06041087|Dietary Supplement|Carbohydrate (Maltodextrin powder mixed with water)|50g consumed immediately after exercise and 1h after exercise.
76033955|NCT04764019|Diagnostic Test|High resolution intestinal manometry|Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
76033956|NCT03055793|Other|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
76033957|NCT04583761|Behavioral|questionnaire|Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
75390090|NCT06041087|Dietary Supplement|Skim Milk|500ml consumed immediately after exercise and 1h after exercise.
75390091|NCT06041087|Dietary Supplement|Greek yogurt|200g consumed immediately after exercise and 1h after exercise.
75390092|NCT06041087|Dietary Supplement|Water|500ml consumed immediately after exercise and 1h after exercise.
75390093|NCT06040541|Drug|RMC-9805|Oral Tablets
75390094|NCT06039761|Procedure|Digestive or gynecological surgery by laparoscopy|Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
75543271|NCT00250419|Biological|V930|
75706948|NCT00732446|Drug|Moxifloxacin|moxifloxacin 0,5% qid and
76033958|NCT04531891|Other|Fatigue protocol|During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
76033959|NCT04926389|Other|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|one side of the maxillary arch will randomly receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter and the contralateral side will serve as the controls.
76033960|NCT04926389|Other|low-level laser therapy applied every 3 weeks|one side will also be randomly chosen to receive LLLT every 3 weeks and the contralateral side will serve as the controls.
76033961|NCT04926155|Drug|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
76033962|NCT05133583|Other|Laughter yoga|"The experimental group was interviewed in an online meeting prepared by a certified LY trainer.~She received LY exercises once a week (40 minutes per session) for 6 weeks (6 sessions). Each The meeting was organized with a maximum of 12 people."
75390095|NCT06035965|Other|Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19)|19 items assessing post-surgery satisfaction.
75390096|NCT06035965|Other|Quality of Life in Epilepsy Inventory (QOLIE-31)|31 items to assess different dimensions of quality of life
75390097|NCT06035965|Other|Generalized Anxiety Disorder 7 (GAD7)|7 items, rated from 0 to 3, to detect anxiety disorders.
75390098|NCT06035965|Other|Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)|to screen for depressive disorders
75390099|NCT06035965|Other|Evaluation of Changes in Daily Life after Epilepsy Surgery (EVOCQUE)|self-questionnaire developed by the Toulouse epileptology team in 2023 for patients who have undergone epilepsy surgery. It aims to collect the feelings of patients concerning the changes induced by surgery in their daily life according to a 7-point Likert scale.
75543272|NCT01649401|Device|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
76033963|NCT04917965|Other|Laboratory clotting studies|Cord blood will be utilized to perform lab test including PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s
75706949|NCT00732446|Drug|Dexamethasone|dexamethasone 0,1% qid
76033964|NCT04909775|Drug|Tislelizumab|200 mg per cycle, IV on day 1 of 3-week
76033965|NCT04909775|Drug|Cisplatin|70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
76033966|NCT04909775|Drug|Gemcitabine|1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
75390100|NCT06035731|Other|SOCIO-AESTHETICS care|SOCIO-AESTHETICS well being care performed by qualify person
76033967|NCT05133349|Drug|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
76033968|NCT04925141|Drug|Dasatinib Tablets|Tyrosine Kinase Inhibitor (TKI)
75390101|NCT06034743|Drug|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths:~1 mg per tablet for 1 mg baxdrostat Arm;~2 mg per tablet for 2 mg baxdrostat Arm."
75390102|NCT06034743|Drug|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
75390103|NCT06034314|Drug|Dronabinol Capsules|Two 10 mg Dronabinol capsules will be administered orally, for a total of 20mg, on test day.
75390104|NCT06021457|Drug|RBT-1|Intravenous administration
75390105|NCT06021457|Drug|Placebo|Intravenous administration
75543273|NCT01649401|Device|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
75543274|NCT00415740|Drug|ELC200 (carbidopa+levodopa+entacapone)|
75543275|NCT01649479|Biological|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
75543276|NCT01649479|Biological|Thrombophilia bloodwork|"Bloodwork will be drawn up for:~antithrombin, protein C, protein S~Factor V Leiden polymorphisms (F5 1691A)~prothrombin 20210A gene polymorphism (F2 20210A)~JAK2 617F Mutation~Homocysteine~Factor VIII"
75557949|NCT00438906|Drug|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
75557950|NCT00441311|Behavioral|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
75557951|NCT00438945|Drug|Eprosartan|
75557952|NCT00476892|Procedure|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
76033969|NCT04209517|Other|Filming|Behavioural markers selection from video-recordings of the interview
76033970|NCT04908917|Device|Portable Air Cleaner with a HEPA Filter|A novel intervention using a portable air cleaner with HEPA filter to treat mildly high BP to potentially reduce the cardiovascular effects of PM2.5. Leave the PAC running with the HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
76033971|NCT04908917|Device|Portable Air Cleaner without a HEPA Filter|Leave the PAC running without a HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
75390106|NCT06019442|Behavioral|Brief alcohol intervention (Health4Her-Automated)|"Embedded within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive a brief alcohol intervention. The brief alcohol intervention will comprise information and behaviour-change content regarding alcohol consumption, including: messaging around alcohol risks/harms (with a focus on alcohol use and breast cancer risk), positive-framed messaging on the health benefits of reducing alcohol intake, and alcohol harm-reduction / behaviour change strategies (e.g. drink counting, goal setting, behaviour substitution, problem solving).~Post-session information will be provided via email (i.e. electronic brochure summarising brief alcohol intervention content)."
75390107|NCT06019442|Behavioral|Lifestyle health promotion|"Lifestyle health promotion, focused on physical activity and maintaining a healthy weight for reducing breast cancer risk, will be provided.~Post-session information will be provided via email (i.e. electronic brochure summarising nutrition for maintaining a healthy weight)."
75390108|NCT06018558|Genetic|OCU410|Subretinal administration of OCU410
75706950|NCT04065672|Drug|Low-dose IL-2|One million units of rhIL-2 was administered subcutaneously five days every week for 4 weeks and then twice a week for 8 weeks. All patients were followed up for 3 months after treatment.
76033972|NCT04908995|Drug|EC5026 oral tablet|"12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2."
75543277|NCT01649479|Other|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
75543278|NCT01649635|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
75706951|NCT00732524|Drug|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
75706952|NCT00732524|Drug|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
76033973|NCT04908995|Other|Placebo oral tablet|"6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period."
76033974|NCT02651155|Drug|Lubiprostone|Lubiprostone capsules
75706953|NCT00657267|Drug|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
75706954|NCT00733850|Drug|Kanglaite Injection plus gemcitabine|Intravenous repeating dose
75706955|NCT00733850|Drug|Gemcitabine|Intravenous repeating dose
75706956|NCT00727818|Device|guided bone regeneration|
76033975|NCT02651155|Drug|Placebo|Lubiprostone placebo-matching capsules
76033976|NCT04925063|Drug|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
75706957|NCT04016961|Other|AAT - Dog|therapy dog added to inpatient PT and OT session
75390109|NCT06005623|Device|SENS Motion + Motivational Feedback|"To weeks prior to surgery and in a 12-week period following discharge after TKA/UKA patients will be equipped with a discrete patch and built-in accelerometer (SENS Motion, Denmark, Copenhagen) attached on the thigh of the leg not undergoing surgery.~Following discharge after TKA/UKA patients randomized to the intervention-group will receive the app (SENS motion). On their provided app, patients will be able to choose between two tabs. Tab 1 will allow patients to view predefined goals, all of which are locations in a self-selected city. The sensor will measure the physical activity and daily rhythm of the patient, and accelerometer counts will be converted into daily steps, which will be visible to the patients. In Tab 2, patients will be able to see graphical representations of their daily activity as well as their history during the period in which they have worn the accelerometer. The graphical representations include: Daily steps, physical active minutes, and type of activity."
75390110|NCT06002217|Drug|Levobupivacaine|Patients in the tap block arm will receive an injection of levobupivacaine 2.5mg/ml
75543279|NCT01649635|Drug|Prednisone|Pharmaceutical form: tablet Route of administration: oral
75706958|NCT04016961|Other|TAU - No Dog|PT and OT as usual without the addition of therapy dog
75706959|NCT00732602|Other|GIP-infusion|
75706960|NCT00732602|Other|Sodium-chloride|
75543280|NCT01649635|Drug|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
75557953|NCT00441428|Drug|solifenacin|
75557954|NCT00438984|Drug|cyclophosphamide|Given IV
75557955|NCT00438984|Biological|therapeutic autologous lymphocytes|Given IV
75557956|NCT00438984|Biological|aldesleukin|Given IV or SC
75706961|NCT00732602|Other|GLP-2 infusion|
75706962|NCT00808197|Procedure|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
75706963|NCT00727896|Behavioral|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
75706964|NCT00727896|Drug|Diabetes Treatment|Life style modification and drug therapy
75706965|NCT00727766|Drug|Clofarabine|
75706966|NCT00799071|Drug|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
75706967|NCT00730080|Drug|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
75706968|NCT02569268|Other|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
76033977|NCT04909151|Device|Robot-assisted gait training (walking speed: 0.5km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
76033978|NCT04909151|Device|Robot-assisted gait training (walking speed: 0.8km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
75390111|NCT06002217|Other|Placebo Tap block|Patients in the placebo arm will receive an injection of salin solution 2.5mg/ml , in the same way as tap block
75543281|NCT01649635|Drug|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
75706969|NCT04066920|Drug|IBER salvage chemotherapy followed by ibrutinib maintenance therapy|Induction therapy with IBER (up to 6 cycles) [ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 ], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
76033979|NCT04909151|Device|Robot-assisted gait training (walking speed: 1.1km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
76033980|NCT05127343|Procedure|Sealing deep pits and fissures|Application of the pit and fissure sealant
76033981|NCT05132959|Diagnostic Test|magnetic resonance imaging|The MRI images of patients who had undergone to shoulder magnetic resonance imaging because of shoulder pain or another pathology were studied
76033982|NCT04925297|Other|No intervention|No intervention will be given
76033983|NCT04495777|Other|Fonseca Anamnestic Index|"Fonseca Anamnestic Index was developed to assess the severity of temporomandibular disorders, based on its signs and symptoms. It has been proposed as a low cost and easy to apply alternative and has been used in screening for TMD in a non-patient population5. It was created with 10 items with 3 options of answers (specific scores): yes (10 points), sometimes (5 points) and no (0 points). The final score of the instrument is determined by the sum of the scores of all items, allowing the following classifications: the absence of signs and symptoms of TMD (0-15 points), mild TMD (20-45 points), moderate TMD (50-65 points), and severe TMD (70-100 points) (19)."
76033984|NCT03055169|Genetic|genetic analysis|
76033985|NCT03055169|Biological|blood and stools samples|
76033986|NCT05132725|Behavioral|diet therapy|Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
76033987|NCT04908527|Behavioral|Walking to OR|Patients, after being prepared for the OR, walk to the operating room
75543282|NCT00250536|Drug|nandrolone decanoate|
75543283|NCT00250536|Behavioral|resistance exercise training|
75543284|NCT00240617|Drug|sumatriptan succinate/naproxen sodium|comparator
76033988|NCT04924829|Drug|Tocilizumab|Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.
76033989|NCT05132413|Drug|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
76033990|NCT05132413|Drug|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
76033991|NCT05132413|Drug|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
76033992|NCT04924751|Diagnostic Test|Endoscopic ultrasound-guided fine needle biopsy|Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.
76033993|NCT05126953|Device|samfilcon A Lenses with EPG01 Packaging Solution|samfilcon A Lenses with EPG01 Packaging Solution
76033994|NCT05126953|Device|B+L Ultra Lenses|Commercially available Biotrue ONEday lenses
76033995|NCT03052829|Behavioral|Physical activity counseling|Subjects in this arm will receive counseling on how to increase their physical activity level.
76033996|NCT03052829|Behavioral|Usual care|Subjects will undergo their usual care without intervention
76033997|NCT04924595|Behavioral|Personalised exercise|Personalised exercise intervention including aerobic and resistance training
75390112|NCT05988944|Other|TT+CIMT+VR|TT: Traditional Techniques CIMT: constraint-induced movement therapy VR: virtual reality
75390113|NCT05988944|Other|TT+CIMT|TT: Traditional Techniques CIMT: constraint-induced movement therapy
75390114|NCT05988944|Other|TT|TT: Traditional Techniques
75390115|NCT05985057|Other|Artificial intelligence|Prediction of carbapenem resistance via deep machine learning model
75543285|NCT00240617|Drug|placebo|placebo to match
75543286|NCT01649713|Drug|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
75543287|NCT01649752|Biological|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
76033998|NCT03052907|Behavioral|BSPAN|"Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach & Health Promotion and Delivery & Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach & Health Promotion component (Medium Capacity).~Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
75390116|NCT05983211|Device|Repetitive Transcranial Magnetic Stimulation|Accelerated rTMS using continuous theta burst stimulation inhibitory paradigms over bilateral M1 hand region outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600 pulses over 40 seconds. ALS patients will receive rTMS bilaterally at a regimen of cTBS for 40 seconds per treatment, for up to 8 treatment sessions per day, delivered one per hour, over 5 days.
75390117|NCT05978089|Drug|Yangxinshi tablet|The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
75390118|NCT05978089|Drug|Yangxinshi tablet simulants|The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
75869671|NCT03307785|Drug|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer [NSCLC], ovarian cancer, endometrial cancer, and head and neck cancer.
75390119|NCT05977621|Other|Transrectal ultrasound (TRUS)|Transrectal ultrasound (TRUS) images of the female pelvis
75390120|NCT05963698|Device|WATCHMAN device|Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
75390121|NCT05958082|Behavioral|Educational video|The educational intervention will occur with a clinical research coordinator who will be trained to educate on germline testing in prostate cancer.
75390122|NCT05956626|Genetic|OCU410ST|Subretinal Administration of OCU410ST
75869672|NCT03307785|Drug|Bevacizumab|Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
75390123|NCT05955638|Device|MiSight contact lenses|Contact lens for myopia management.
75390124|NCT05955638|Device|Proclear contact lenses|Single vision contact lens as control
75390125|NCT05955300|Other|Training program|The GLAD training program consists of neuromuscular exercises for the core, the knee and the hip muscles and patient education. The New Nordic Diet is a plant-based nutrition thats aims to reduce systematic low-grad inflammation.
75390126|NCT05955300|Other|Nutrition therapy|Nutrition therapy based on the New Nordic Diet
75390127|NCT05949138|Device|ECG-Less Cardiac CT using SmartPhase|"Administration of medications and biologic products (such as contrast agent administration, and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational workflow on an existing CT device that has regulatory clearance. The investigational workflow includes preforming the CT acquisition according to the hospital's usual care with the exception that the ECG signal which triggers the scan will be coming from an ECG simulator based on an estimate of the patient's heart rate, rather than through ECG leads connected to the subject. Clinically-indicated Cardiac CTs take approximately 30-60 minutes. No additional imaging is needed as part of the study."
75390128|NCT05936593|Device|Condylar Stabilizing (CS) insert|During TKA surgery a Condylar Stabilizing (CS) insert is implanted and tantalum beads are placed around the prosthesis.
75390129|NCT05936593|Device|Cruciate Retaining (CR) insert|During TKA surgery a Cruciate Retaining (CR) insert is implanted and tantalum beads are placed around the prosthesis.
75390130|NCT05926856|Drug|Indocyanine green|Indocyanine Green 25mg kit for injection
75390131|NCT05926388|Other|Video-assisted training|Patients will be given training on insulin therapy and management using lecture, question-answer, video and demonstration methods.
75390132|NCT05919680|Drug|NST-6179 Part A|Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
75869673|NCT03307785|Drug|TSR-022|"TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth."
75869674|NCT03307785|Drug|Carboplatin-Pemetrexed|Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
76033999|NCT04133935|Procedure|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
76034000|NCT04133935|Procedure|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
76034001|NCT04924049|Other|Video-assisted education|Prior the study, the content and comprehensibility of the VE were evaluated by an orthopedic surgeon, two orthopedic nurses, and a physiotherapist who were not involved in the study and relevant amendments were made based on their suggestions. The preview of the final version of the VE was shown to four patients (10% of the sample) and these patients were excluded from the study. The patients were interviewed by phone calls on a weekly basis and watching VE at home, the frequency of watching VE, and doing home-based exercises were questioned.
75390133|NCT05919680|Drug|NST-6179 Part B|Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
75390134|NCT05919680|Other|Matched Placebo|Matched placebo for administration in Part A or Part B
75390135|NCT05917639|Device|Vitruvian plot|Visual (magnitude, uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
75390136|NCT05917639|Device|Kilim plot|Visual (uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
75390137|NCT05917639|Device|Summary of findings table|Written (magnitude, uncertainty) communication tool / interventional decision-making aid tool
75390138|NCT05912270|Behavioral|Orchestra in Class|See arm/group descriptions
75390139|NCT05909709|Drug|Alocyte low dose|"Low dose containing 0.2 - 1.0 x 10^11 particles and 3-10x10^6 cell in 2mL which will be administered intra-facet into a single facet joint.~Preparation of low dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 2ml of the diluted product will be used."
75390140|NCT05909709|Drug|Alocyte medium dose|"Medium dose containing 0.6 - 3.0 x 10^11 particles and 9-30x10^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used."
75390141|NCT05909709|Drug|Alocyte high dose|"High dose containing 1.0 - 5.0 x 10^11 particles and 15-50x10^6 cell in 10mL which will be administered intra-facet into five facet joints delivering 2ml/facet joint.~Preparation of high dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, 10ml of diluted product will be used."
75543288|NCT01649752|Biological|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
75543289|NCT01649830|Radiation|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
75557957|NCT00438984|Other|immunohistochemistry staining method|Correlative studies
75706970|NCT00732836|Drug|HAI Abraxane|Escalating doses (beginning dose 180 mg/m^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
76034002|NCT04435717|Drug|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Tocilizumab 20 MG/ML Intravenous (one dose)
75390142|NCT05897801|Diagnostic Test|MeMed BV®|One blood sampling of 3ml will be drawn on the first day for the performance of the MeMed BV® test. Two rectal swabs will be taken for determining the MDRO gut colonization. Patient information regarding the specific respiratory tract infection and the treatment regimen being prescribed will be recorded in the eCRF made specifically for this trial.
75390143|NCT05896527|Drug|DC-806|DC-806 will be supplied as tablets to be administered orally.
75390144|NCT05896527|Other|Placebo|Matching placebo will be supplied as tablets to be administered orally.
75390145|NCT05896163|Drug|maplirpacept (PF-07901801)|Intravenous infusion
75543290|NCT01649830|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
75543291|NCT04708743|Diagnostic Test|Automatic Tongue Diagnosis System|tongue image capture tongue images by Automatic Tongue Diagnosis System
75543292|NCT01649986|Behavioral|Non-pharmacologic intervention|Diet and physical exercise
76034003|NCT04435717|Drug|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)|Tocilizumab 20 MG/ML Intravenous ( two doses)
76034004|NCT04907981|Diagnostic Test|Novel coronavirus infection|Using eye examination to judge whether novel coronavirus is infected or not.
75543293|NCT01649986|Drug|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
76034005|NCT05124223|Diagnostic Test|Cardiac MRI|Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
76034006|NCT04075981|Drug|Botulinum Toxin Type A Injection [Xeomin]|Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
75390146|NCT05896163|Drug|Glofitamab|Intravenous infusion
75390147|NCT05896163|Drug|Obinutuzumab|Intravenous infusion
75390148|NCT05894603|Drug|Nirmatrelvir/ritonavir|Nirmatrelvir/ritonavir
75390149|NCT05894603|Drug|Molnupiravir|Molnupiravir
75390150|NCT05893355|Behavioral|Acupressure group|"Application to Acupressure Group~Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~Participant Information Form will be filled in by the researcher by face-to-face interview.~The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~The VAS Evaluating Back Pain after the application will be filled in by the participant.~The participant will be informed that the study has been completed."
75390151|NCT05890963|Drug|ART|ART is a combination of three or more drugs from different classes of antiretroviral medication.
75390152|NCT05890963|Drug|10E8.4/iMab|10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
75390153|NCT05890963|Drug|VRC07-523LS|VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
75390154|NCT05889156|Drug|NST-1024|400 mg BID
75390155|NCT05889156|Other|Placebo|matched placebo to active arm
75390156|NCT05884554|Drug|PF-07817883|Experimental
75543294|NCT00240656|Drug|spironolactone captopril carvedilol|
75543295|NCT01645696|Device|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
75543296|NCT01645696|Device|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
75543297|NCT01645696|Device|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
75543298|NCT01647451|Drug|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
75706971|NCT00732836|Procedure|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
75706972|NCT00732836|Drug|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
75543299|NCT01647451|Drug|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
75390157|NCT05881005|Diagnostic Test|hepatic MRI|Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
75390158|NCT05879913|Device|Coronary CT Angiography (CCTA)|Coronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
75543300|NCT00250575|Drug|Clozapine|
75390159|NCT05877430|Drug|CJRB-101|In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
75390160|NCT05877430|Drug|Pembrolizumab injection|200 mg given by intravenous (IV) infusion once every 3 weeks
75390161|NCT05874141|Diagnostic Test|HBA1C|blood sample on EDTA
75390162|NCT05874141|Diagnostic Test|Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides|serum sample
75390163|NCT05874141|Diagnostic Test|Urine analysis and urinary albumin-to-creatinine ratio|Morning urine sample
75543301|NCT01640899|Device|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
75543302|NCT00240695|Drug|galantamine hydrobromide|
75543303|NCT04528381|Procedure|Laparoscopy|Laparoscopic orchiopexy
75543304|NCT00250614|Drug|Saredutant succinate (SR48968C)|
75390164|NCT05874141|Diagnostic Test|Serum creatinine and estimated glomerular filtration rate|serum sample
75543305|NCT04528186|Diagnostic Test|Maternal thyroid volume|Maternal thyroid volume measurement
75390165|NCT05874141|Diagnostic Test|Complete blood count|blood sample on EDTA
75390166|NCT05874141|Diagnostic Test|Thyroid-stimulating hormone|serum sample
75543306|NCT00240734|Drug|Epoetin alfa|
75543307|NCT01645072|Other|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI >55) will be eliminated from the diet and only food items with low glycemic index (GI <55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
75543308|NCT01645072|Other|Control group|The ongoing anti epileptic drug treatment will be continued without change.
75543309|NCT01645891|Device|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
75543310|NCT01645891|Device|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
75543311|NCT04720248|Drug|Metamizole|Patients will receive metamizole intraoperatively and throughout 48h postoperatively.
75543312|NCT01646515|Drug|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
76034007|NCT04075981|Other|Drug placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
75543313|NCT01646515|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
75543314|NCT00240773|Drug|acetaminophen|4 grams daily for six months
75543315|NCT00240773|Drug|naproxen|750 mg daily for 12 months
75543316|NCT00240773|Drug|acetaminophen|4 grams daily for 12 months
75543317|NCT00240773|Drug|naproxen|750 mg daily for six months
75543318|NCT02279797|Behavioral|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
75557958|NCT00438984|Procedure|biopsy|Optional correlative studies
75390167|NCT05874141|Diagnostic Test|Serum iron, TIBC, Transferrin saturation and serum ferritin if needed|serum sample
75390168|NCT05874141|Procedure|Electrocardiography (ECG)|by electrocardiogram
75390169|NCT05874141|Procedure|Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound|imaging
75390170|NCT05874141|Procedure|Arterial duplex ultrasound of both lower limbs|imaging
75390171|NCT05874141|Diagnostic Test|Random blood glucose|serum sample
75390172|NCT05874141|Diagnostic Test|AST, ALT, albumin|serum sample
75390173|NCT05872295|Drug|IKS014|IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
75390174|NCT05865041|Drug|Farudodstat|Farudodstat tablets administered orally
75390175|NCT05865041|Drug|Placebo|Placebo tablets administered orally
75390176|NCT05859997|Biological|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
75390177|NCT05859035|Device|KIOS Informational App|"The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
75390178|NCT05852431|Drug|Pegozafermin|Subcutaneous injection
75390179|NCT05852431|Drug|Placebo|Subcutaneous injection
75390180|NCT05846841|Behavioral|Precision Treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.
75390181|NCT05846841|Behavioral|Usual Care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
75390182|NCT05846724|Drug|Pembrolizumab + Lenvatinib|single-arm study of pembrolizumab plus lenvatinib
75390183|NCT05845554|Diagnostic Test|The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.|The extracted gDNA from bile sample will be analyzed by BileCAD to determine the level of CINs.
75390184|NCT05838729|Drug|RiMO-301|"A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions."
75390185|NCT05837351|Behavioral|Exercise -Running|"At baseline participants will wear a Fitbit for one week and attend the Runner's Assessment. After this the participant will begin to run 3 times per week for eight weeks. Every week, participation in a virtual support group with the physical therapist, research coordinator, and other research staff will be expected. Rest-activity cycles' data will be monitored; if at any point the runner is not able to complete 3 runs per week, participants will be encouraged to contact research staff the issues for this (such as medical problem or scheduling difficulty) and formulate plans to remediate the situation. Participants that would like to continue the treatment for an additional eight weeks will have additional data collected.~Participants will also wear the Fitbit through-out the study and complete surveys during the study and have blood drawn."
75543319|NCT01688401|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
76034008|NCT05122195|Other|Compression therapy|Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
75543320|NCT04708821|Drug|Dexamethasone ophthalmic insert 0.4Mg|Dextenza 0.4Mg Ophthalmic Insert
75543321|NCT04708821|Drug|0.2% loteprednol etabonate ophthalmic suspension|0.2% loteprednol etabonate ophthalmic suspension
75543322|NCT04708821|Drug|olopatadine hydrochloride ophthalmic solution 0.7%|olopatadine hydrochloride ophthalmic solution 0.7%
75543323|NCT01688440|Other|#1 Respiratory Care Solution|Respiratory care solution.
75543324|NCT00240812|Drug|ibuprofen; pseudoephedrine HCl|
75543325|NCT01688479|Drug|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
75543326|NCT01688479|Drug|Essex® cream (Schering-Plough), aqueous cream without parabens|
75543327|NCT01688518|Drug|Heated Lidocaine/Tetracaine Patch|
75543328|NCT01688518|Drug|5% Lidocaine Patch|
75543329|NCT00250653|Drug|Saredutant succinate (SR48968C)|
75543330|NCT05140681|Procedure|FibReORS with apically positioned flap (apical position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at 2 mm subcrestal position
75543331|NCT05140681|Procedure|FibReORS with apically positioned flap (crestal position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at either a crestal position
75543332|NCT00240851|Drug|acetaminophen extended release|
75557959|NCT00438984|Other|laboratory biomarker analysis|Correlative studies
75557960|NCT00438984|Other|immunologic technique|Correlative studies
75557961|NCT00438984|Genetic|polymerase chain reaction|Correlative studies
75557962|NCT00441506|Drug|daily interruption of sedatives|
75557963|NCT04700852|Device|Puressentiel protective nasal spray|provocative nasal test with grass pollen and nasal lavage
75557964|NCT00439023|Procedure|dialysis with glucose in dialysis water|
75557965|NCT00441623|Behavioral|observational|effect of protein-bound uremic retention solutes
75390186|NCT05837104|Drug|Magnesium vitamin B6|Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
75390187|NCT05837104|Drug|Placebo|Placebo tablet, three times daily for four weeks.
75543333|NCT01688557|Device|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
75390188|NCT05835505|Drug|BRS201|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
75706973|NCT00799149|Drug|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
75390189|NCT05835505|Drug|Placebo|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
75390190|NCT05834777|Drug|Icatibant|Icatibant will be administered with an infusion rate of 100µg/kg/h for 15 minutes before their hemodialysis session (pre-infusion) and 50µg/kg/h during their routine hemodialysis session (maintenance infusion).
75390191|NCT05834777|Drug|Placebo|0.9% sodium chloride will be administered as the same rate as icatibant
75390192|NCT05825404|Device|Smart Ambient Bright Light (SABL)|The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers. The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night
75390193|NCT05825404|Other|Control|Usual light.
75390194|NCT05824806|Biological|PRP Protocol A|Platelet rich plasma protocol A
75706974|NCT00733928|Device|PFC Sigma knee with all-poly tibial component|Orthopaedic implant for total knee replacement with an all-polyethylene tibial component
75543334|NCT01688557|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
75706975|NCT00733928|Device|PFC Sigma knee with metal backed tibia|Orthopaedic implant for total knee replacement with a metal-backed tibial component
75543335|NCT01688674|Drug|10% dextrose|
75543336|NCT04708977|Procedure|One-level lateral lumbar interbody fusion with Indirect Decompression|One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.
75557966|NCT00476970|Behavioral|Patient Navigation|Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
75557967|NCT00441662|Drug|Sub-Tenon triamcinolone 40mg|
75557968|NCT00439062|Drug|Roxithromycin|
75706976|NCT00805623|Dietary Supplement|sucrose|1 cc of sucrose 33.5% with or without pacifier
75706977|NCT04280172|Other|Cultural Competence Education|Cultural competence education for participants in the intervention group comprises of completion of an online learning module and participation in an eight-hour training day. The educational content includes various topics related to cultural and linguistic diversity and cultural competence in mentoring.
75706978|NCT04280172|Other|Standard Mentoring Education|Participants in the control group will not receive the educational intervention but will participate in standard mentoring education. This education is offered in an online learning environment and participants can complete the education at their own pace. The educational content focuses on general issues related to mentoring and does not contain topics specific to cultural competence in mentoring.
75706979|NCT00732914|Drug|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
75390195|NCT05824806|Biological|PRP Protocol B|Platelet rich plasma protocol B
75390196|NCT05824806|Device|Hyaluronic acid|Hyaluronic acid
75390198|NCT05800964|Drug|AMG 305|Short-term intravenous (IV) infusion
75390199|NCT05789862|Behavioral|Counseling Sessions|Virtual sessions
75390200|NCT05789862|Behavioral|Quality of Life Questionnaires|Self administered questionnaires
75390201|NCT05789225|Behavioral|Fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program is group-based with 8 participants in each group, led by a facilitator, and performed online. It comprises seven two-hour sessions held once a week, and a booster session held four weeks after the seventh session. In addition participants will receive a brochure about falls and fall risk factors.
75390202|NCT05789225|Other|Brochure|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
76034009|NCT04917497|Drug|Levosimendan|Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
75390203|NCT05786365|Drug|Ketalar 50 MG/ML Injectable Solution|Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
75390204|NCT05773846|Drug|Ropivacaine|A long acting formulation of ropivacaine
75390205|NCT05769114|Procedure|Surgical stabilization|Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
75390206|NCT05763953|Drug|Etripamil NS|"Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A."
75390207|NCT05757609|Device|Anodal tDCS combined with active physiotherapy|anodal tDCS over prefrontal cortex combined with active physiotherapy
75390208|NCT05757609|Device|Sham anodal tDCS combined with active physiotherapy|Sham anodal tDCS over prefrontal cortex combined with active physiotherapy
75390209|NCT05757570|Drug|povetacicept|Administered by subcutaneous injection every 4 weeks
75390210|NCT05757362|Other|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation (cq-HEPT)|An online application of the developed questionnaire form
75390211|NCT05757063|Other|Sedation with propofol|After spinal anesthesia, patients will be sedated with propofol.
75390212|NCT05757063|Other|sedation with dexmedetomidine|After spinal anesthesia, patients will be sedated with dexmedetomidine.
76034010|NCT03933007|Drug|Colchicine,|"the day of phenotyping assay~Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)"
76034011|NCT03933007|Drug|midazolam,|Midazolam 1 mg
76034012|NCT03933007|Drug|fexofenadine|Fexofenadine 120 mg
76034013|NCT04924439|Other|foot reflexology|Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
76034014|NCT05126875|Radiation|Repeated stereotactic radiosurgery|Repeated stereotactic radiosurgery to recurring brain metastases
76034015|NCT03056651|Other|treatment in day-care heart failure unit|
75390213|NCT05755035|Biological|TAK-881|Participants will receive SC infusion of TAK-881.
75390214|NCT05755035|Biological|HYQVIA|Participants will receive SC infusion of HYQVIA.
75390215|NCT05753176|Behavioral|Online 1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained facilitators (i.e., psychotherapists, social workers, nurses, and/or a psychiatrist) consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. Participants are also given a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
75390216|NCT05751278|Device|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
75390217|NCT05751278|Device|Radial Jaw 4 Pulmonary Biopsy Forceps|Radial Jaw 4 Pulmonary Biopsy Forceps Standard Capacity for 2mm endoscope
75390218|NCT05736432|Dietary Supplement|Blueberries|Experimental condition
75390219|NCT05736432|Dietary Supplement|Placebo|Placebo condition
75390220|NCT05733767|Other|Enhanced Usual Care (EUC)|Patients randomized to arm 1, enhanced care (EC), will receive the following intervention: 1) referral to the state quitline, 1-800-QUIT-NOW, 2) primary care physician notification of an ongoing quit attempt, and 3) enrolled in an assessment-only text message system. This text message system will assess medication use and self-reported smoking cessation outcomes, but will not provide any counseling, advice, or feedback. Participants in arm 1 will receive a text message at discharge, and then they will receive 1 text assessment at the following time points: day 7, month 1, and month 3.
75390221|NCT05733767|Other|Nurse Practitioner Tobacco Treatment Team (NPT3)|Patients randomized to arm 2, personalized care (PC), will receive a multi-component, multi-disciplinary smoking cessation intervention in addition to usual care. This intervention will include three main interventions. First, a nurse practitioner will assess all patients and then prescribe tailored medications for smoking cessation based on patient preferences. Patients will also then receive a sample ad-lib nicotine replacement therapy (NRT) packet for use as needed to their prescribed medications. Second, a Tobacco Treatment Counselor (TTC) will provide personalized advice, education, and coaching to the patient and encourage medication adherence. Third, patients will be enrolled in a smoking cessation text messaging program designed to maintain motivation, encourage medication adherence, and allow communication with the team. The text message program will last for 6 months and will include assessment at the following time points: day 7, month 1, and month 3.
75390222|NCT05731895|Drug|BI 425809 (iclepertin)|BI 425809 (iclepertin)
75390223|NCT05707806|Device|MRI|Enables the use of custom pulse sequence
75390224|NCT05698732|Device|Coroflex® ISAR NEO coronary stent system|Patients in whom treatment with Coroflex® ISAR NEO coronary stent system has been attempted
75390225|NCT05684887|Other|Digital based contact tracing|"Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~Immediate access to the contact list in Mamal Pro once validated by the health care worker.~Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~Contacts will be invited to go to the nearest testing facilities/units to get tested.~Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module."
75390226|NCT05676047|Behavioral|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
75390227|NCT05676047|Other|Education|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
75390228|NCT05667493|Drug|Eplontersen|Eplontersen will be administered by SC injection.
75390229|NCT05660213|Drug|Huaier granule|Treatment period: Huaier Granule, oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and patient together.
75543337|NCT04708977|Procedure|One-level lateral lumbar interbody fusion with Direct Decompression|"One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access instruments. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.~Additionally, direct decompression through midline or parasagittal approach will be utilized. A unilateral laminotomy or complete bilateral laminectomy may be performed."
75706980|NCT00732914|Drug|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
75706981|NCT00728052|Drug|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
75706982|NCT00728052|Drug|Placebo|Placebo capsules will be administered orally with water.
75706983|NCT00808275|Dietary Supplement|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
76034016|NCT04917263|Diagnostic Test|Immunohistochemistry, Flow citometry, Trascriptome analysis|we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling
75869675|NCT03307785|Drug|Carboplatin-Nab-Paclitaxel|Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
76034017|NCT04907435|Procedure|simultaneous operations|simultaneous operations
76034018|NCT05404399|Behavioral|"Free From Pain Exercise Book"|"Participants in Group 1 will be provided with the Free From Pain Exercise Book."
76034019|NCT05404399|Behavioral|Physiotherapy|Participants in Group 2 would be referred to Physiotherapy (usual care)
76034020|NCT04923503|Behavioral|diurnal fasting|subject conduct fasting in Ramadan for 30 days
75706984|NCT00727922|Drug|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
76034021|NCT03862729|Procedure|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
75390230|NCT05660213|Drug|Atezolizumab + Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
76034022|NCT03862729|Procedure|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
75543338|NCT05140486|Procedure|Rehabilitation: shortwave diathermy and perceptual training|All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
75706985|NCT00809289|Drug|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
75706986|NCT00809289|Drug|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
75706987|NCT00809289|Drug|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
75869676|NCT03292484|Biological|AR101|AR101
76034023|NCT04907747|Drug|Vonoprazan|Potassium-competitive acid blocker
76034024|NCT04907747|Drug|Esomeprazole|Proton pump inhibitor
75390231|NCT05660213|Drug|Camrelizumab+Apatinib|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
76034025|NCT04907747|Drug|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
75390232|NCT05660213|Drug|Sintilimab+Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
75390233|NCT05658562|Drug|MT-2111|i.v. infusion
75390234|NCT05657691|Drug|Xanamem™|Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
75543339|NCT00240929|Drug|MEDI-493|Active Comparator
75543340|NCT05140447|Other|preheating of resin composite|evaluate the effect of preheating BIS-GMA free resin composite at different temperatures on temperature change of the pulpal floor and restorations and compare it with BIS-GMA containing resin composite.
75543341|NCT01688713|Drug|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
75543342|NCT00250692|Drug|Nitrous Oxide|
75543343|NCT01688791|Drug|Vintafolide|
76034026|NCT04907747|Drug|Amoxicillin|Antibiotic for H. pylori eradication
75390235|NCT05657691|Drug|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
75390236|NCT05648110|Biological|AZD5156 (Parent study Sentinel Safety Cohort)|600 mg single dose of AZD5156 IM (300 mg of AZD1061 and 300 mg of AZD3152) on Visit 1 Day 1
75390237|NCT05648110|Biological|Placebo (Parent study Sentinel Safety Cohort)|single dose of Placebo IM
75390238|NCT05648110|Biological|EVUSHELD™ (Parent study Main Cohort)|600 mg single doses of EVUSHELD™ IM on Visit 1 Day 1 and on Visit 5 Day 181
76034027|NCT04907747|Drug|Furazolidone|Antibiotic for H. pylori eradication
75390239|NCT05648110|Biological|AZD3152 (Parent study Main Cohort)|300 mg single doses of AZD3152 IM on Visit 1 Day 1 and on Visit 5 Day 181
75706988|NCT02570256|Behavioral|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
75869677|NCT03267381|Other|Blood draw (before surgery)|Blood will be drawn before surgery
75869678|NCT03267381|Other|Blood draw (every 3 months)|Blood will be drawn every 3 months
75390240|NCT05648110|Biological|Placebo (Parent study Main Cohort)|Single doses of 0.9% sodium chloride IM for injection on Visit 1 Day 1 and Visit 5 Day 181
75390241|NCT05648110|Biological|AZD3152 (Sub-study)|Single dose of 1200 mg IV at Visit 1 Day 1
75390242|NCT05648110|Biological|AZD7442 - EVUSHELD™ (Sub-study)|Single dose 300 mg IM administered on Visit 1 Day 1
75390243|NCT05648110|Biological|AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152|Single dose of AZD7442 (EVUSHELD™) 300 mg IM
75543344|NCT01688791|Drug|Carboplatin|
75543345|NCT01688791|Drug|Paclitaxel|
75869679|NCT03267381|Other|Blood draw (at diagnosis)|Blood will be drawn at time of diagnosis
75390244|NCT05646589|Behavioral|Person-centred care transition support|Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.for persons who are to be discharged from hospitals after stroke or TIA
75390245|NCT05646589|Behavioral|Regular care transition|Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
75390246|NCT05644873|Drug|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) <90mmHg or <20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR < 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
75390247|NCT05644873|Drug|control group saline|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) <90mmHg or <20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR < 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
75390248|NCT05643794|Drug|rozanolixizumab|Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
75390249|NCT05643794|Other|Placebo|Study participants will receive Placebo during the dosing periods as pre-defined.
75390250|NCT05639751|Drug|PRT3789|PRT3789 will be administered by intravenous infusion
75390251|NCT05628363|Device|Ethos Varian treatment system|Device that will be used to administer radiotherapy
75706989|NCT02570256|Behavioral|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
75706990|NCT02570256|Behavioral|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
75869680|NCT03267134|Device|Hydrus Microstent|Device implanted into the Schlemm's canal of the eye for the purpose of providing a natural outflow pathway for aqueous humor. The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
75869681|NCT03267134|Procedure|Ophthalmic surgery|Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
75390252|NCT05628363|Radiation|Adaptive stereotactic body radiotherapy|Radiotherapy interruptions are acceptable as long as treatments are no more than 16 days apart.
75390253|NCT05628363|Drug|Androgen deprivation therapy|"Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference.~Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling."
75390254|NCT05626322|Drug|Maplirpacept|Intravenous infusion
75390255|NCT05626322|Drug|Tafasitamab|Intravenous infusion
75390256|NCT05626322|Drug|Lenalidomide|Oral (by mouth)
75390257|NCT05617599|Device|SUPRAFLEX CRUZ|Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
76034028|NCT03812263|Biological|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
75390258|NCT05615922|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
75390259|NCT05615922|Behavioral|Word-Naming Activity|During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.
75390260|NCT05608915|Other|No Cue|There will be no visual cues at all. Will be tested off-medication (after holding morning dopaminergic medications).
75390261|NCT05608915|Other|Conventional Cue|Physical lines taped to floor at regular intervals. Will be tested off-medication (after holding morning dopaminergic medications).
75869682|NCT03260881|Drug|Liraglutide Pen Injector [Victoza]|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
75869683|NCT03260881|Drug|matching liraglutide-placebo pre-filled pens|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
75390262|NCT05608915|Other|Constant Cue|The augmented-reality visual cue will always be turned on. Will be tested off-medication (after holding morning dopaminergic medications).
75390263|NCT05608915|Other|Patient hand-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient clicks a handheld button. Will be tested off-medication (after holding morning dopaminergic medications).
75390264|NCT05608915|Other|Patient eye-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient looks down at the floor near their feet. Will be tested off-medication (after holding morning dopaminergic medications).
75390265|NCT05608915|Other|Examiner-triggered|The augmented-reality visual cue will be turned on, intermittently, by an examiner, whenever they feel the patient is having a freezing episode or at risk of having a freezing episode. Will be tested off-medication (after holding morning dopaminergic medications).
76034029|NCT03052673|Drug|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
76034030|NCT03052673|Drug|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
75390266|NCT05603650|Other|Lumineux Oral Essentials rinse|mouthrinse
75390267|NCT05603650|Other|Listerine rinse|mouthrinse
76034031|NCT04907123|Other|Intensive sodiuria-guided diuretic treatment|Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment
76034032|NCT04907123|Other|Standard diuretic treatment|Stepwise diuretic therapy based on diuresis assessment
76034033|NCT05030857|Drug|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
76034034|NCT05030857|Drug|Midazolam|On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
75390272|NCT05597371|Other|the use of the platform|the use of the platform
75706991|NCT02569034|Other|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
75390273|NCT05590325|Drug|Dolutegravir|"Single dose of the DTG-DT in two sequential cohorts and multiple-doses of the DTG-DT or DTG-ODF in a two cohorts.~Qualitative Acceptability will be collected from mothers and health workers in structured discussion guides."
75390274|NCT05585918|Behavioral|SEL + Equity|For the SEL + Equity (experimental) condition schools, activities include those in the SEL Only condition, as well as equity lessons designed by the project team, as well as training and individualized support for implementing classroom equity lessons, five 45-minute equity professional development sessions, and one-on-one coaching to support equitable practices and the implementation of the 6 classroom equity lessons.
75390275|NCT05585918|Behavioral|SEL Only|For the SEL Only (active comparator) condition schools, activities involve school-wide technical assistance and implementation support for SEL curriculum implementation, as well as individualized technical assistance for the SEL curriculum. In the year following participation, SEL Only condition schools are offered access to and training and technical support for the classroom equity lessons.
75543346|NCT01688908|Procedure|Endoscopic Screening|"Upper G.I. endoscopic examination with Lugols Iodine in esophagus~Biopsy at the visually abnormal sites~Pathologic examination of all biopsy tissue specimens~Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
75543347|NCT00240968|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
75390276|NCT05583838|Drug|rhTPO|initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 ~ 600U/kg every other day depends on platelet count.
75390277|NCT05583838|Drug|Eltrombopag|initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 ~ 75mg daily or every other day depends on platelet count.
75543348|NCT01688947|Drug|V116517 50-mg tablets|Taken orally twice daily
75543349|NCT01688947|Drug|V116517 30-mg tablets|Taken orally twice daily
75543350|NCT01688947|Drug|Pregabalin capsules|1-2 capsules taken orally twice daily
75543351|NCT01688947|Drug|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
75543352|NCT00250731|Behavioral|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
75706992|NCT02569034|Other|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
75543353|NCT00250731|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
75390278|NCT05583448|Device|ExploR Radial Head|Patient must have undergone primary or revision elbow arthroplasty with the ExploR Radial Head System according to a cleared indication.
75390279|NCT05580185|Device|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
75543354|NCT00241007|Drug|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
75543355|NCT01689025|Drug|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
75543356|NCT01689025|Drug|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
75543357|NCT01689142|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
75390280|NCT05578235|Procedure|stapled side-to-side anastomosis|Standard procedure for CD
75390281|NCT05578235|Procedure|Handsewn anastomosis|handsewn end-to-end or Kono-s anastomosis
75390282|NCT05559476|Biological|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
75390283|NCT05559476|Biological|FLU HD vaccine|FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).
75390284|NCT05546879|Drug|NP137|NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
75543358|NCT01689142|Drug|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
75543359|NCT00241046|Drug|Letrozole|
75543360|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
75543361|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
75390285|NCT05546879|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
75390286|NCT05546879|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
75706993|NCT05623722|Procedure|Erector spinae plane block|Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.
75706994|NCT02552667|Drug|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
75706995|NCT02552667|Drug|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
75706996|NCT00728000|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
75390287|NCT05546853|Drug|NP137|NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
75390288|NCT05546853|Drug|Oxaliplatin|Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
75706997|NCT00728000|Drug|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
75706998|NCT00728000|Drug|Erlotinib|100mg/day PO on days 1-14 and 15-28
75390289|NCT05546853|Drug|Irinotecan|Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
75390290|NCT05546853|Drug|Calcium levofolinate|Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
75390291|NCT05546853|Drug|5 FU|5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
75390292|NCT05541029|Behavioral|Live music|Live Music. A board-certified music therapist will provide live music (singing with instrument accompaniment) of child preferred songs, per caregiver report, with the tempo entrained to the child's respiratory rate at intervention start and decreased as needed to facilitate relaxation, with a target tempo of 60-80 beats per minute (BPM). Song choices will be based on patient preferences, per caregiver report, and performed with relaxing characteristics (steady rhythm and volume)
75390293|NCT05541029|Behavioral|Recorded music|Recorded Music. MP3 players will be loaded with a recorded music playlist of the child's preferred songs, per caregiver report, and connected to two small speakers that are to be placed at either side of the head of the bed. Speakers will be tested with sound level meter and volume control set at 50-60 decibels. A member of the study team will stay at bedside throughout the recorded music condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
75543362|NCT01689259|Drug|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
75706999|NCT04066530|Drug|AD-203|AD-203 administered two times daily for two weeks
75707000|NCT04066530|Drug|Mucosta tab.|Mucosta tab. administered three times daily for two weeks
75707001|NCT00808431|Behavioral|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
75707002|NCT02569190|Device|Walkbot|Robot assisted gait training
75707003|NCT04235556|Behavioral|Care pathway unit|Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
75707004|NCT00809367|Other|Collection of Leukemia Cells|Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
75707005|NCT00728208|Drug|GSK372475|1.5mg for 28 days
75707006|NCT02552433|Dietary Supplement|protein intake assessment and optimisation|
75707007|NCT00733070|Device|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
75390294|NCT05541029|Other|Usual care|Usual Care. A pharmacologic approach to ameliorating stress and pain in MV children is standard of care in CHP's PICU. CHP provides weight-based guidelines to aid clinical decisions on medications for sedation and analgesia. Bedside nurses assess the child's sedation and pain scores once an hour and administered PRN medications as needed, based on clinical judgement, using CHP's PICU weight-based guidelines. For example, if a child has a pain score of >1-2 above goal, guidelines suggest providing a fentanyl dose of 0.5 mcg/kg and assessing again in 1 hour. We will include usual care as a third condition to explore how our selected biomarkers vary over 20 min. without the addition of any musical stimuli. A member of the study team will stay at bedside throughout the usual care condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
75543363|NCT01689259|Drug|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
75543364|NCT01689259|Drug|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
75543365|NCT01689259|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
76034035|NCT04917341|Diagnostic Test|re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital|The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.
76034036|NCT03810859|Biological|Blood sample|Adults : 7 to 10 mL Childs : 2 to 4 mL
75390295|NCT05530291|Other|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
75543366|NCT01689298|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
75543367|NCT01689298|Drug|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
75543368|NCT00241085|Drug|valsartan|
75543369|NCT01689376|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
75543370|NCT02272075|Device|Mobile OCT M3 scope|
75543371|NCT00241124|Drug|valsartan|
75543372|NCT00241124|Drug|lisinopril|
75543373|NCT00241163|Procedure|Fibrinogen (human) + thrombin (human) (TachoSil)|
75543374|NCT00241202|Behavioral|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
75543375|NCT02277106|Drug|SAGE-547|
75543376|NCT02277106|Drug|Placebo|
75543377|NCT00241241|Drug|pegylated interferon-alfa 2a|
75390296|NCT05530070|Other|Dietary intervention|Patients will participate in a structured, group-based dietary counseling. Consultations will be organized online (Zoom meeting) lasting approximately 60 min/occasion. The intervention will include 6 sessions for 1 year (monthly for 5 months and finally at month 9). The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.
75869684|NCT03244124|Other|Self-Etching Application Strategy|In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
75869685|NCT03244124|Other|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
75390297|NCT05530070|Other|Standard of care|Patients will receive standard of care and baseline dietary education.
75543378|NCT00241319|Drug|R89674 (generic name not yet established)|
75543379|NCT00414804|Device|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
75543380|NCT00414804|Procedure|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
75543381|NCT02279602|Drug|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
75543382|NCT02276209|Drug|Dasotraline|Dasotraline 4 mg once daily
75543383|NCT02276209|Drug|Dasotraline|Dasotraline 6 mg once daily
75543384|NCT02276209|Other|Placebo|Placebo once daily
75869686|NCT03244124|Other|Etch&Rinse Dry Application Strategy|In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
75869687|NCT03244124|Other|Etch&Rinse Wet Application Strategy|In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
75390298|NCT05530070|Diagnostic Test|Cardiovascular risk-related parameters|Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
75390299|NCT05519878|Other|Best Practice|Undergo routine treatment and usual follow up care
75390300|NCT05519878|Device|Bright White Light Therapy|Undergo bright white therapy
75390301|NCT05519878|Behavioral|Occupational Therapy|Undergo occupational therapy
75390302|NCT05519878|Other|Questionnaire Administration|Complete questionnaires
75543385|NCT01689493|Behavioral|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
75543386|NCT01689571|Drug|CHF6001|
75543387|NCT01689571|Drug|Placebo|
75543388|NCT00241436|Drug|Anastrozole (ARIMIDEX™)|
75390303|NCT05519228|Device|ToggleLoc 2.9 mm Soft Tissue System|The ToggleLoc 2.9 mm Soft Tissue System consist of non-resorbable device intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation
75390304|NCT05517811|Diagnostic Test|TEG indices|Blood samples
75390305|NCT05514444|Biological|MK-4464|MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.
75390306|NCT05514444|Biological|Pembrolizumab|Pembrolizumab 200 mg administered as an IV infusion every three weeks.
75390307|NCT05514444|Drug|89Zr-MK-4464|89ZR-MK-4464 administered as an IV infusion on C1D1.
75390309|NCT05510245|Drug|PF-07081532|One PF-07081532 20 mg tablet, administered orally
75390310|NCT05510128|Other|Pharmacist management|"When a patient comes to the pharmacy with signs of urinary burning, the following will follow:~Completion of the acute cystitis symptoms score (ACSS) questionnaire.~Measure the temperature.~Perform a urine dipstick.~If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made."
75390311|NCT05507164|Drug|Temporomasseteric Nerve Block|The TMNB injection is a local anesthetic injection technique that targets the anterior deep temporal and masseteric branches of the mandibular division of the Trigeminal Nerve. The surface landmark for the twin block injection site is located by palpating for the depression created by the greater wing of the sphenoid bone at the superior border of the zygomatic process and approximately 1 cm posterior to the posterior border of the frontal process of the zygomatic bone. This site is first disinfected with alcohol wipes prior to inserting a 27- or 25-gauge long dental needle (32 mm). Angled 35-45° away from the calvarium (skull) and perpendicular to the zygomatic arch (along the coronal plane), the needle is advanced to its length before injecting 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
75390312|NCT05500690|Dietary Supplement|Folic Acid Tablet|5 mg folic acid supplement
75390313|NCT05484804|Other|Data Accountability and Transparency|Collaboration with Practice Facilitators; Maternal Early Warning System; Disparities Dashboard; Racial Equity Training
75390314|NCT05484804|Other|Community-Based Doula (CBD) Support|Community-Based Doula support for high-risk patients; Racial Equity Training
75390315|NCT05470023|Other|OTC Toothpastes or Mouthrinses|OTC Toothpastes or mouthrinses used according to standard of care
75390316|NCT05427253|Drug|C106 solution|selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
75390317|NCT05427253|Drug|Placebo|Placebo for C106 solution
75390318|NCT05416814|Dietary Supplement|Kefir|Oral route (via feeding tube in intubated patients). Serving size 240mL to be given in an ascending dosing regimen if tolerated starting at 60 mL/day, 120 mL/day until single 240 mL/day; if evidence of intolerance, dose will be reduced to previously tolerated dose.
75390319|NCT05414500|Drug|Mogamulizumab|Administered IV
75390320|NCT05414500|Drug|Brentuximab vedotin|Administered IV
75390321|NCT05409924|Drug|ATR-258|Single Ascending Dose
75390322|NCT05409924|Drug|ATR-258|Multiple Ascending Dose
75390323|NCT05409924|Drug|ATR-258|Repeat Dose
75390324|NCT05406570|Procedure|Standardized ventilation|Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group
75390325|NCT05406570|Procedure|Personalized ventilation|Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
75390326|NCT05402345|Drug|GlcNAc-GlcN|GlcNAc eye drops
75390327|NCT05402345|Other|Placebo|Placebo eye drops
75390328|NCT05402332|Drug|AVTX-801|D-Galactose medical grade supplement
75390329|NCT05385471|Biological|Matrix M with R78C and/or RH5.1|50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints
75390330|NCT05382325|Biological|MK-1484|Subcutaneous (SC) injection
75390331|NCT05382325|Biological|Pembrolizumab|Intravenous (IV) infusion
75390332|NCT05367960|Drug|Zatolmilast/ BPN14770|25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents <43 kg)
75390333|NCT05366790|Behavioral|CEASE and CEASE-A|CEASE (for parents) and CEASE-A (for adolescents) are evidence-based tobacco and vaping cessation interventions delivered in pediatric practices.
75390334|NCT05363683|Procedure|Squat Biofeedback|The intervention group will complete bilateral squats with each limb on a separate portable force plate. They will receive real-time visual feedback on a 32-inch screen during all squats. Biofeedback conditions will be progressed from simplest (ground reaction force only) to most complex (ground reaction force plus center of pressure). This intervention will be included in additional to standard care post-operative physical therapy.
75390335|NCT05363683|Procedure|Standard Care|Standard care post-operative physical therapy
75390336|NCT05360901|Behavioral|IntelliCare with automated motivational messaging|Digital mental health intervention with automated motivational messaging
75390337|NCT05360082|Other|[11C]UCB-J|11C-labeled SV2A binding PET radioligand
75390338|NCT05360082|Other|[18F]SynVest-1|18F-labeled SV2A binding PET radioligand
75390339|NCT05346692|Other|Survey Administration|Complete Survey
75390340|NCT05346692|Other|Interview|Complete Interview
75390341|NCT05346692|Other|Text Message-Based Navigation Intervention|Complete mindfulness intervention
75390342|NCT05346692|Other|Interview|Complete interview
75390343|NCT05336253|Behavioral|EVERYbody Project-Connect|3-week dissonance-based, group, online body image program (4.5 hours total)
75543389|NCT00264420|Drug|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
75543390|NCT00241475|Drug|Gefitinib|
76034037|NCT04917185|Other|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
76034038|NCT03319459|Drug|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
75390344|NCT05336253|Behavioral|Self-Help Workbook|Time-matched 3-week passive, individual workbook condition (4.5 hours total)
75390345|NCT05333523|Radiation|Sentinel lymph node biopsy guided selective elective neck irradiation|"Patients will undergo sentinel lymph node biopsy. Based on the histopathologic status of the sentinel lymph node(s), selective elective neck irradiation is performed with standard radiation treatment of the primary tumor.~There are 3 possible treatment scenarios.~Bilateral elective neck irradiation is indicated when sentinel lymph nodes at both sides of the neck contain metastases or when sentinel lymph node detection fails.~Unilateral elective neck irradiation is indicated when sentinel lymph node(s) at one side of the neck contain metastases.~Full omission of elective neck irradiation is indicated when all sentinel lymph nodes are free of metastases."
75543391|NCT01689844|Behavioral|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
75543392|NCT01689844|Behavioral|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
75543393|NCT01689883|Device|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
75543394|NCT01689922|Other|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
75557969|NCT00477009|Device|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
75557970|NCT02957162|Drug|Atorvastatin|
75557971|NCT02957162|Other|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
75557972|NCT00439101|Drug|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
75557973|NCT00439101|Other|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
75557974|NCT00441740|Drug|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
75557975|NCT00441740|Drug|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
75557976|NCT00441740|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
75557977|NCT00441740|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
75390346|NCT05333523|Radiation|Standard elective neck irradiation|Patients randomized to the control arm will receive the standard of care, according to (inter)national clinical practice guidelines. This will consist of (chemo)radiotherapy to the primary tumor with standard elective neck irradiation in all patients. No sentinel lymph node biopsy will be performed.
75390347|NCT05330884|Biological|BCG vaccine|0.1ml BCg vaccine to be given intradermally
75390348|NCT05330884|Drug|Oral Chemoprophylaxis|Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
75543395|NCT01689961|Behavioral|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
75543396|NCT01686061|Other|No intervention- only one time survey|
75707008|NCT04065620|Diagnostic Test|ambulatory blood pressure measurement|24-hour ABPM will be made using validated devices, following ABPM device should be programmed to take measurements every 30 minutes . Patients will be instructed in their use. Periods of activity and rest will be pre-determined in short windows: for Asian and European Countries daytime period will be defined between 10:00 and 8:00 pm; and night-time period between 00:00 am and 6:00 am. For Latin American Countries daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 00:00 am and 6:00 am. For Africa daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 11 PM and 5 AM In addition, the duration of ABPM (hours), the percentage of valid readings, and the mean SBP/DBP values during periods of activity, rest and in 24 hours will be recorded. Records with a duration <24 hours, those without one good reading per hour and those with <70% of satisfactory readings will be excluded
76034039|NCT03319459|Drug|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
75390349|NCT05327959|Device|Clavicle open reduction and internal fixation|Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
75390350|NCT05325788|Other|e-Covery|Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.
75543397|NCT01685359|Drug|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
75543398|NCT01682824|Other|Nutritional Assessment|Complete dietary intake assessment
75543399|NCT01682824|Other|Questionnaire Administration|Complete TFEQ-R18v2 questionnaire
75543400|NCT01682824|Other|Questionnaire Administration|Complete EQ-EMA questionnaire
75707009|NCT00730314|Procedure|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
75707010|NCT02553993|Device|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
76034040|NCT03319459|Drug|Trastuzumab|HER2/neu receptor inhibitor
75390351|NCT05325788|Other|Comparator Condition|Through the e-Covery app, participants will receive a single general message sent daily in the morning.
75390352|NCT05307237|Device|Dexcom G6 Continous Glucose Monitoring Management|CGM data will be transmitted from the bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by the remote monitoring team) and (2) Clinical Optimization (via CLARITY, by which a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub.
75543401|NCT01687738|Other|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
75543402|NCT01687738|Other|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
76034041|NCT04998799|Behavioral|Current clinical practices of participating physicians|Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge
76034042|NCT04430933|Drug|NC318|NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
76034043|NCT04430933|Drug|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
75390353|NCT05307237|Device|Usual Care - Blinded Continuous Glucose Monitoring Management|CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring.
75390354|NCT05298358|Biological|RIC alloBMT w PTCy in refractory SSc|"The preparative regimen:~Thymoglobulin 0.5 mg/kg IV day -9~Thymoglobulin 2 mg/kg IV Days -8, -7~Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5~Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2~Total body irradiation (TBI) 400cGy~Day 0- infusion of unmanipulated bone marrow~The GVHD prophylaxis regimen:~Cy 50 mg/kg IV Days 3, 4~Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus.~Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35~Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.~Supportive care:~Mesna- 10 mg/kg/ IV Day 3, 4~Patients will receive infection prophylaxis and treatment according to institutional guidelines."
75543403|NCT02278978|Drug|BIBF1120|BIBF1120 200 mg two times per day orally
75543404|NCT02218723|Drug|FF UD-DPI|A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
75707011|NCT02553993|Device|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
75543405|NCT02218723|Drug|FF ELLIPTA DPI|A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
75543406|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
75390355|NCT05289349|Drug|Propofol|Propofol (2 mg/kg) for induction of anesthesia , and ( 6 mg/kg/h) for maintenance of anesthesia
75543407|NCT02218762|Drug|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
75390356|NCT05289349|Drug|Sevoflurane|Sevoflurane 1.0-1.5 minimum alveolar concentration (MAC)
75707012|NCT02553993|Other|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
75707013|NCT04065230|Drug|Tenofovir Alafenamide Fumarate tablets|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
75543408|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
75543409|NCT02218762|Drug|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
75543410|NCT00264459|Biological|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
75707014|NCT00728078|Drug|thalidomide|thalidomide 50mg tid for 6 months
75707015|NCT00653991|Behavioral|SOLVE-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
75707016|NCT02561988|Drug|Avapritinib|
75707017|NCT04066088|Other|Placebo|Placebo will be administered same times as GXR
76034044|NCT04430933|Drug|Nab paclitaxel/Carboplatin|Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
75543411|NCT00264459|Other|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
75390357|NCT05278000|Other|Presence of scarcity mindset|"This observational study will examine whether~Individuals exhibiting a scarcity mindset have lower adherence to asthma controller medication~Individuals with higher rates of future discounting have lower adherence to controller medication~Individuals with unmet social needs are more likely to experience scarcity and have higher rates of future discounting, and whether these relationships mediate adherence to asthma controller medication"
75390358|NCT05275998|Drug|TMB-365/TMB-380|Monoclonal antibodies to be given intravenously
75390359|NCT05267626|Drug|AU-007|Monoclonal Antibody Targeting IL-2
75543412|NCT00241514|Drug|Esomeprazole|
76034045|NCT04430933|Drug|Docetaxel|Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
75390360|NCT05267626|Drug|Aldesleukin|IL-2
75390361|NCT05263011|Other|Avocado|1 avocado as evening snack
75390362|NCT05263011|Other|low fat yogurt|1 serving of low fat yogurt matching calories of 1 avocado
75390363|NCT05263011|Other|low fat yogurt + fiber +fat|low fat yogurt mixed with ultra processed olive oil + fiber supplement, equivalent to fat and fiber content in 1 avocado
75543413|NCT02218879|Drug|Tecfidera|Oral Tecfidera 240 mg bid
75543414|NCT02218918|Behavioral|Ground walk training|3 times a week and 6 weeks
75543415|NCT02218918|Behavioral|Supervised Treadmill Walk training|3 times a week and 6 weeks
75543416|NCT02218957|Procedure|Extended Pouch RYGB|
75543417|NCT02218957|Procedure|Standard RYGB|
75543418|NCT00241553|Drug|Esomeprazole|
75543419|NCT02219074|Device|Sebacia microparticle and laser treatment|
75543420|NCT02219074|Device|Vehicle and laser treatment|
75543421|NCT00250887|Drug|Gefitnib|
75543422|NCT02219113|Procedure|Arthroscopic surgery|
75390364|NCT05248997|Drug|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
75543423|NCT02219113|Procedure|Liposuction|
75543424|NCT02219113|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
75543425|NCT02219113|Other|Intraarticular administration of autologous ADRC|
75543426|NCT02279017|Behavioral|mHealth Texting for Weight Loss|
75543427|NCT02219152|Drug|tranexamic acid|
75543428|NCT02219152|Drug|saline|
76034046|NCT04839133|Device|MyoSuitFeasibility|Participants will absolve feasibility tests with and without wearing a MyoSuit.
75543429|NCT00264615|Drug|lamotrigine extended-release|
75543430|NCT02219191|Drug|puerarin tablet 50 mg|
75543431|NCT02219191|Drug|Atorvastatin tablet 20 mg|Approval No.: H19990258
76034047|NCT03056417|Behavioral|The Complete Health Improvement Program|The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
76034048|NCT04815343|Device|Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)|Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
76034049|NCT04906733|Procedure|Tumor biopsy|Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
76034050|NCT03176095|Dietary Supplement|Probiotic|
76034051|NCT03176095|Dietary Supplement|Placebo|
75390365|NCT05248997|Drug|Matching placebo|One dose of matching placebo
76034052|NCT04906655|Drug|Glycopyrronium 2.4 % Medicated Cloth|The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.
76034053|NCT03130699|Behavioral|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
76034054|NCT03130699|Behavioral|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
75390366|NCT05241223|Other|Behavior change intervention|This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
75390367|NCT05241223|Other|Educational program|The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.
75390368|NCT05228158|Drug|Tazemetostat|Tazemetostat oral tablets.
75390369|NCT05220254|Behavioral|MindCotine's VR app|The MindCotine program would be a 6-week intervention to help users utilize mindfulness based skills, and involves virtual exposure therapy.
75543432|NCT02219347|Drug|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
75557978|NCT02274012|Drug|Afatinib|Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
75557979|NCT02274012|Drug|Paclitaxel|On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
75557980|NCT00477048|Drug|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
75557981|NCT00441818|Drug|TNX-650|
75557982|NCT00477126|Drug|GPO ritonavir versus Norvir|RTV generic compared to reference drugs (Norvir, Abbott)
75557983|NCT03279419|Diagnostic Test|Thermal imaging|Use of thermal imaging camera to capture images of peripheral vasculature (hands).
75390370|NCT05220098|Drug|TAK-280|Participants will receive TAK-280 as IV infusion.
75390371|NCT05217927|Drug|Rimegepant 75mg daily dosing|Daily
76034055|NCT03130699|Behavioral|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
75390372|NCT05217927|Drug|Rimegepant 75mg every other day dosing|Every other day
75390373|NCT05217927|Drug|Placebo comparator dosing|Placebo comparator
75390374|NCT05217888|Device|Sentinel|cerebral protection devices during transfemoral transcatheter aortic valve replacement
75390375|NCT05216250|Biological|BOTOX|Intramuscular injection
75390376|NCT05216250|Drug|Placebo for BOTOX|Intramuscular injection
75543433|NCT04529512|Drug|DEXTENZA®|DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.
75543434|NCT00241592|Drug|Cannabis|
75557984|NCT03279380|Other|SNP|Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
75390377|NCT05215288|Biological|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
75390378|NCT05205850|Drug|RC118-ADC|RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
75390379|NCT05201456|Device|LithoVue Elite System|The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
75390380|NCT05199584|Drug|ENV-101 (taladegib)|tablets dosed once-daily
75390381|NCT05199272|Drug|23ME-00610|23ME-00610 given by IV infusion
76034056|NCT03056183|Behavioral|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
76034057|NCT03055091|Other|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
75390382|NCT05194293|Biological|Durvalumab|Given IV
75390383|NCT05194293|Drug|Regorafenib|Given PO
75390384|NCT05188664|Drug|LM-302|LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。
75390385|NCT05188664|Drug|Toripalimab|Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
75390386|NCT05188183|Device|M1 anodal home-based tDCS|During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10 mA.
75390387|NCT05188183|Behavioral|Somatosensory Training|The somatosensory training will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks. Sessions will start with relaxation exercises using a body scan technique, whereby subjects in a relaxed state will be instructed to sequentially interchange their mind to different regions of the body while perceiving it and establishing contact with the body part. Subjects will be asked to concentrate on any feeling (kinetic, kinesthetic or exteroceptive) related to each body part. Phantom exercises will involve the use of imagined movements of the phantom limb. Therefore, patients will be asked to perform general exercises with their phantom limb. Exercises will include hip, knee, ankle, and toe movements.
75390388|NCT05188183|Other|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
75390389|NCT05183048|Drug|[89Zr]Panitumumab Tracer|All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.
75390390|NCT05179187|Behavioral|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
75390391|NCT05178121|Behavioral|eLearning Training in Suicide Safety Planning|The training includes a web-based didactic in suicide safety planning, interactive practice in counseling microskills with a chat bot, role-playing safety planning with a standardized patient, and reviewing automated feedback on safety planning counseling skills generated from a computer coding system.
75390392|NCT05177835|Drug|ABX464|All subjects will receive ABX464 given at 25 mg QD.
75390393|NCT05174052|Drug|Dapagliflozin 10Mg Tab|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.
76034058|NCT03055091|Other|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
76034059|NCT02648581|Drug|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
76034060|NCT04916717|Other|Counseling|Face-to-face and telephone counseling were applied to individuals in the intervention group.
76034061|NCT02609815|Drug|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
75390394|NCT05174052|Drug|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
75390395|NCT05171764|Device|Additional Gemstone Spectral Imaging (GSI) cardiac scan|After the subject undergoes the clinically prescribed cardiac Computed Tomography (CT) scan for their diagnostic purposes, the investigational Gemstone Spectral Imaging (GSI) scan will be conducted following the diagnostic CT scan utilizing the same contrast administration.
75390396|NCT05169047|Other|Best Medical Treatment|For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.
75390397|NCT05169047|Other|Subthreshold Spinal Cord Stimulation|SCS will be programmed at subthreshold stimulation.
76034062|NCT02609815|Drug|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
76034063|NCT01315639|Biological|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
75390398|NCT05163821|Diagnostic Test|Manchester Somali Cognitive Assessment Tool|Cognitive screen for dementia
75390399|NCT05163821|Diagnostic Test|ACE-III Somali Translation|Cognitive screen for dementia
76034064|NCT04662463|Behavioral|Cognitive Bias Modification for Interpretation (CBM-I)|Patients will receive CBM-I training by reading and imaging themselves in a series of emotionally ambiguous scenarios. Each scenario ends with an incomplete final word. Patients need to complete the final word to resolve the scenario in a positive direction.
75390400|NCT05162365|Biological|IBI314|Low/medium/high dose, intravenously, once, on Day 1
75390401|NCT05162365|Other|Placebo|Placebo, intravenously, once, on Day 1
75543438|NCT02219386|Other|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
75543439|NCT02219386|Other|group 2. Passive analitical stretch (performed in both groups)|
75543440|NCT02219425|Procedure|endometrial biopsy|
75543441|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
75707018|NCT04066088|Drug|Guanfacine extended release (GXR)|The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
75707019|NCT00799461|Other|internet-based intervention|Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
75707020|NCT00799461|Other|questionnaire administration|Completion of questions in an online format
75390402|NCT05150938|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
75390403|NCT05150938|Drug|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
75390404|NCT05150938|Drug|vitamin K antagonist (VKA)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
75390405|NCT05150938|Drug|other NOACs|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
75543442|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
75543443|NCT02219620|Behavioral|Music, Imagery, Movement|Implementation of music, art and imagery activation, and movement in group modality
75543444|NCT02219620|Behavioral|Social Control|social conversational group facilitated by care counselor
75543445|NCT00241670|Drug|5-aminolevulinic acid (5-ALA)|1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
75543446|NCT02219737|Drug|Carboplatin|Given IVPB
75543447|NCT02219737|Drug|Etoposide|Given IVPB
75543448|NCT02219737|Drug|Ibrutinib|Given PO
75543449|NCT02219737|Drug|Ifosfamide|Given IV
75543450|NCT02219737|Other|Laboratory Biomarker Analysis|Correlative studies
75543451|NCT02219737|Other|Pharmacological Study|Correlative studies
75543452|NCT02219737|Biological|Rituximab|Given IV
75543453|NCT02219854|Procedure|Laparoscopic gastrectomy|
75543454|NCT02219854|Procedure|Open gastrectomy|
75543455|NCT02219893|Drug|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
75543456|NCT02219971|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
75543457|NCT04720170|Procedure|Revascularization|Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
75543458|NCT02218801|Other|Evaluation of treatment for liver metastasis|
75543459|NCT02217865|Behavioral|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
75543460|NCT02217865|Behavioral|Questionnaire|Questionnaire completion asking general health and demographic questions.
75543461|NCT02217865|Behavioral|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
75707021|NCT00799461|Procedure|psychosocial assessment and care|Assessment and care of psychosocial aspects
75707022|NCT00799461|Procedure|assessment of therapy complications|Evaluation of complications of treatment
75390406|NCT05146453|Procedure|Pectointercostal fascia blocks|PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.
75390407|NCT05146453|Other|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
75707023|NCT00799461|Procedure|management of therapy complications|Managing therapy complications
75707024|NCT00799461|Procedure|fatigue assessment and management|Assessing and managing fatigue
75707025|NCT00799461|Other|counseling intervention|Counseling provided via telephone
75707026|NCT02570178|Other|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
75707027|NCT00733148|Drug|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
75390408|NCT05137158|Device|Intermittent theta burst stimulation|Intermittent theta burst stimulation(iTBS) on the left DLPFC, the left DLPFC will be targeted utilizing the localite neuronavigation system. The stimulation intensity is set at 80% of resting motor threshold(RMT), and the other parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 600 pulses per session, total duration of 3 minutes and 20 seconds.
75390409|NCT05137158|Device|Sham stimulation|The same procedure will be performed in sham group including the RMT assessment and the neuronavigation system for target localization, but the sham coil will vertical to the brain surface and deliver a very slight magnetic field, which have the same appearance and sound, and provide the same tactile sensations as the active coils.
75390410|NCT05130073|Procedure|Computed Tomography|Undergo PET/CT
75390411|NCT05130073|Other|Electronic Health Record Review|Review of medical records
75390412|NCT05130073|Procedure|Follow-Up|Undergo follow-up
75390413|NCT05130073|Procedure|Positron Emission Tomography|Undergo PET/CT
75543462|NCT02217865|Behavioral|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
75707028|NCT00730392|Drug|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
76034065|NCT04662463|Behavioral|Placebo|Patients will receive placebo task which uses neutral rather than emotional material.
75390414|NCT05110690|Behavioral|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
75390415|NCT05110690|Other|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
75543463|NCT02210650|Procedure|Symptomatic stone removal|Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy
75543464|NCT02210650|Procedure|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
75543465|NCT04720014|Behavioral|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~an understanding of stress physiology and the physiology of the relaxation response;~a regular practice of eliciting the relaxation response; and~cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
75543466|NCT02212951|Drug|BIOD-531|
75543467|NCT02212951|Drug|Humalog Mix 75/25|
75543468|NCT02212951|Drug|Humulin R U-500|
75543469|NCT02211508|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
76034066|NCT04916561|Diagnostic Test|RT-PCR|Detection of Covid-19 in bone, articular fluid and muscle samples using RT-PCR
76034067|NCT04906967|Procedure|flaps|coverage of soft tissue defect around ankle
76034068|NCT01118767|Other|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
75390416|NCT05110001|Drug|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
75390417|NCT05110001|Drug|Chlorhexidine Gluconate|Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.
75390418|NCT05110001|Drug|Natamycin|Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
75543470|NCT00250965|Drug|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
75707029|NCT00730392|Drug|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
75869688|NCT03235804|Dietary Supplement|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
75390419|NCT05110001|Drug|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
75390420|NCT05110001|Other|Placebo|Study participants receive sham RB-PDT within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.
75707030|NCT00809601|Device|Insertion of a specific type of ventilation tube through the tympanic membrane|"The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.~The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.~The first combination will test:~Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)~The second combination will test:~Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)~The third combination will test:~Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)~The fourth combination will test:~Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)"
75390421|NCT05107544|Other|HIGH INTENSITY INTERVAL TRAINING|Will be prescribed HIIT through online modality to a group of adolescents with type 1 diabetes 3 times a week for 3 months. The training is going to have 2 phases, the initial phase and improvement phase, which are going to be differentiated according to work intensity following the recommendations of the American College of Sports Medicine. During the initial phase (first 4 weeks) the intensity is going to be 60-75% of the VO2 max. During the improvement phase the intensity is going to increase to a 75-85% of the VO2 max for 8 week.
75869689|NCT03217188|Radiation|conventionally fractionated full dose re-irradiation|re-irradiation [60-70 Gy (RBE) in 2 Gy (RBE) fractions
75390422|NCT05091632|Procedure|Electroencephalography|Undergo EEG
75390423|NCT05091632|Other|Questionnaire Administration|Complete questionnaires
75390424|NCT05084196|Drug|Melatonin|Melatonin 5 mg capsule by mouth at bedtime
75390425|NCT05084196|Other|Placebo Capsule|Placebo capsule by mouth at bedtime
75390426|NCT05079347|Diagnostic Test|HIV rapid test|Using a rapid test to assess a patient's HIV status
75390427|NCT05067088|Other|CPAP (all patients receive CPAP as part of routine clinical care)|Continuous positive airway pressure
75869690|NCT03217188|Radiation|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break [+/- 2 weeks], repeated up to 4 cycles)."
75390428|NCT05060315|Combination Product|Remunity Pump for Remodulin|Participants on the study will receive Remodulin via the Remunity Pump with dosing and titration managed at the discretion of the prescribing healthcare professional. Dosing and titration of Remodulin will in no way be influenced by the participation in this study or this protocol.
75390429|NCT05035212|Biological|RSVpreF|RSV vaccine (RSVpreF)
75390430|NCT05035212|Biological|Placebo|Placebo
75390431|NCT05031234|Drug|anaesthesia without opiates|Anaesthesia without opiates for patients undergoing laparoscopic colectomy
75390432|NCT05031234|Drug|anaesthesia with morphine|anaesthesia with morphine for patients undergoing laparoscopic colectomy
75543471|NCT00241826|Procedure|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
75543472|NCT00241826|Procedure|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
75543473|NCT02210806|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
75543474|NCT02210806|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
75543475|NCT02210806|Other|Placebo DPI|Placebo, 1 inhalation
75543476|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
75543477|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
75543478|NCT02210026|Device|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
75543479|NCT00264654|Drug|BRL29060A|
75543480|NCT00264654|Drug|paroxetine hydrochloride hydrate|
75869691|NCT03199040|Drug|Durvalumab|-Human monoclonal antibody
75869692|NCT03199040|Biological|Neoantigen DNA vaccine|-The vaccine will be given by the TDS-IM system
75543481|NCT00241943|Procedure|Hepatitis C educational video|
75543482|NCT02219230|Device|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
75543483|NCT02219230|Device|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
75390433|NCT05030051|Device|SkinPen Precision System|Microneedling is a relatively new, minimally invasive technique originally developed for skin rejuvenation. Controlled micro-injury to the dermis via the application of several small needles connected to a motorized device stimulates the wound healing process, resulting in the formation of new tissue and blood vessels. The SkinPen by Crown Laboratories is an FDA-cleared microneedling device proven to improve the appearance of acne scars This study evaluates the clinical performance of the SkinPen device for the treatment of signs of aging on the back of the hand. We hypothesize that the SkinPen device will produce a significant improvement in dorsal hand appearance at 3 month post treatment visit, when compared with baseline scores. The assessments will be based on the Clinician's Global Aesthetic Improvement Scale, and the Subject's Global Aesthetic Improvement Scale at the 3 month post treatment visit.
75390434|NCT05029739|Device|A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease|See description of the e-intervention group as above.
75390437|NCT05015816|Diagnostic Test|Total body photography|3 monthly TBP imaging
76034069|NCT04922879|Behavioral|Individualized lung rehabilitation|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
75707031|NCT00730470|Drug|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
75390438|NCT05005260|Drug|Bupivacaine HCl|Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.
75390439|NCT05005260|Drug|Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj|Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
75390440|NCT04968587|Procedure|Sustained Low-Efficiency Dialysis|All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate
75543484|NCT02219230|Device|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
75707032|NCT00734084|Device|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
75707033|NCT01528046|Drug|Vincristine|Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
76034070|NCT04906343|Procedure|Colonoscopy|Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
76034071|NCT05132023|Drug|Empagliflozin & Metformin (Test)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
76034072|NCT05132023|Drug|Empagliflozin & Metformin (Reference)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
76034073|NCT04916405|Other|Standardized management of pregnancy weight of twin pregnancy|Standardized management of pregnancy weight of twin pregnancy
75707034|NCT01528046|Drug|Irinotecan|Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes
75707035|NCT01528046|Drug|Temozolomide|Temozolomide (TEM) = 50 mg/m^2/day by mouth (PO) Days 1-5
75707036|NCT01528046|Drug|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
75707037|NCT00652899|Biological|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
75707038|NCT00652899|Drug|Cyclophosphamide|60 mg/m^2 on Days 4 and 5 preceding natural killer cell infusion.
75707039|NCT00652899|Drug|Fludarabine phosphate|25 mg/m^2 on Days 6 through 2 preceding natural killer cell infusion.
75707040|NCT00652899|Radiation|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
75707041|NCT00652899|Biological|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 * 10^7/kg
75869693|NCT03199040|Device|TDS-IM system (Inchor Medical Systems)|-At each vaccination time point, patients will receive two injections at separate sites.
76034074|NCT05404087|Device|Dedicated breast CT|Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor
75390441|NCT04967170|Biological|Autologous Platelet-Rich Plasma (PRP)|Two intralesional injections of approximately 5-6mL given approximately 6 weeks apart
75390442|NCT04967170|Other|Sham Procedure|Intralesional needle insertion without any injectate.
75390443|NCT04965519|Drug|RC48-ADC|2.0mg/kg IV every 2 weeks
75707042|NCT00652899|Biological|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
76034075|NCT04904159|Procedure|Thyroidectomy|total thyroidectomy
76034076|NCT04904159|Procedure|Lobectomy|Lobectomy
75543485|NCT02219659|Drug|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
75543486|NCT02219659|Drug|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
75543487|NCT02219659|Drug|Fentanyl Push First|Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
75543488|NCT00241982|Drug|long-circulating liposomal prednisolone|
75543489|NCT02212015|Drug|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
75543490|NCT04720859|Drug|Canagliflozin 300 MG Oral Tablet|Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
75543491|NCT00272727|Behavioral|Dialog tool for caregivers|
75869694|NCT03199040|Procedure|Peripheral blood draw|-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
75869695|NCT03198702|Drug|Botulinum toxin type A injection|A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.
75869696|NCT03198702|Other|Sham|The injection is mimed, the procedure is the same as the botulinum toxin injection.
75869697|NCT03198650|Drug|Acalabrutinib|Acalabrutinib
75869698|NCT03198650|Drug|Obinutuzumab|Obinutuzumab
75869699|NCT03192956|Other|No active intervention|No active intervention is performed
75869700|NCT03161353|Drug|Perjeta|All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
75869701|NCT03161353|Drug|Herceptin|All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
75869702|NCT03161353|Drug|Docetaxel|Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
75543492|NCT02279056|Behavioral|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
75390444|NCT04965298|Drug|Lansoprazole|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
75543493|NCT02279056|Behavioral|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
75543494|NCT00272766|Drug|pegaptanib sodium|
75869703|NCT03161353|Drug|Carboplatin|Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
76034077|NCT04498663|Behavioral|Emotion- and Relationship-Focused Therapeutic Interview|In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.
75390445|NCT04965298|Other|Matched placebo|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
75543495|NCT00242060|Procedure|MRI|
75543496|NCT02961842|Drug|500 mL Colloid Preload|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
76034078|NCT04916483|Other|group cognitive stimulation therapy|The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
76034079|NCT04916483|Other|usual care|The control group maintains the unit routine treatment.
76034080|NCT05131711|Combination Product|Combined stereotactic radiosurgery and enhanced immunotherapy|Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
76034081|NCT02619617|Drug|SOM230|The study evaluated SOM230 vs Placebo
76034082|NCT02619617|Drug|Placebo|The study evaluated SOM230 vs Placebo
75390446|NCT04964947|Drug|Tobramycin Injection|80 milligrams of tobramycin diluted in 40 milliliters of normal saline
75390447|NCT04964466|Biological|Amount of PDGF-BB in PRF preparation vs. GEM21|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
75543497|NCT02961842|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
75543498|NCT02961842|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
75543499|NCT02961842|Drug|Intrathecal Fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space
75543500|NCT02961842|Drug|500 mL Crystalloid Coload|Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
75543501|NCT02961842|Drug|1000 mL Crystalloid Coload|Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
75543502|NCT02961842|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
75543503|NCT02961842|Radiation|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
75543504|NCT02961842|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
75543505|NCT00272805|Drug|carvedilol|
75869704|NCT03161353|Drug|Letrozole|Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
75869705|NCT03161353|Drug|Tamoxifen|"Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.~Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy."
75543506|NCT00242099|Procedure|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
76034083|NCT04012957|Drug|Desidustat Oral Tablet|Desidustat tablet
76034084|NCT04012957|Drug|Darbepoetin Alfa|Darbepoetin injection
76034085|NCT05125705|Biological|Platelet rich plasma injection|The PRP is prepared by RegenLab's RegenKit-THT, in accordance with operating instructions supplied with the kit. The device allows automated blood collection (8 mL) and blood component separation in closed circuit. After centrifugation at room temperature for 9 minutes at centrifugal force of 1500g, the RegenTHT tube is then inverted several times before re-suspension, allowing 4mL of PRP to be obtained for each tube. 2.5mL will be injected into patients
75543507|NCT00242138|Behavioral|Erectile Dysfunction|
75543508|NCT00242177|Drug|ACTOS (Pioglitazone)|
75543509|NCT00264888|Drug|PTC124|
75543510|NCT00416481|Behavioral|quality of life questionnaires|
75543511|NCT00264927|Drug|SR121463B|
75543512|NCT00242294|Drug|Roflumilast|
75543513|NCT00242333|Drug|AD 237|
75543514|NCT00416559|Other|clinical observation|
75543515|NCT00264966|Drug|ASM8|
75543516|NCT00242372|Drug|Tesaglitazar 0.5|
75543517|NCT00242372|Drug|Insulin at least 30 units/day|
76034086|NCT05125705|Other|Saline injection|Saline injection
75390448|NCT04964466|Biological|Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
76034087|NCT04906031|Drug|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
75390449|NCT04964466|Biological|Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
75390450|NCT04964466|Biological|Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
75543518|NCT00265005|Drug|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
75543519|NCT00242411|Drug|Budesonide/Formoterol Turbuhaler|
75543520|NCT00242411|Drug|Conventional Best Asthma Therapy|
75543521|NCT00272922|Device|hernia repair|
76034088|NCT05131243|Procedure|Chemotherapy time|6 months of chemotherapy
76034089|NCT05131243|Procedure|Chemotherapy time|3 months of chemotherapy
75543522|NCT00265044|Behavioral|Provider Education|
75543523|NCT00265044|Behavioral|Hypertension Alert|
76034090|NCT05125627|Drug|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
76034091|NCT05125627|Drug|Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
76034092|NCT04399265|Dietary Supplement|Trehalose|A disaccharide sugar usually used as food preservative, but for this study it is given at a higher dose
75390451|NCT04956549|Behavioral|Physical activity program|Supervised group sessions will be held twice per week for approximately 52 weeks. Each physical activity session will last slightly approximately 80 minutes and will consist of aerobic, strength, flexibility, and balance training. The 80 minutes of activity consists of a 5 minute warm-up, 45 minutes of aerobic training, 15 minutes of strength training, 10 minutes of balance training, and a 5 minute cool-down. The physical activity group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations.
75390452|NCT04956549|Behavioral|Successful Aging|The successful aging group will be based on a low-intensity activity program and a healthy aging educational component. Sessions will be approximately 60 minutes in duration and will occur once per week for the first 6 months and then every other week for the remainder 6 months of the study. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
75390453|NCT04938557|Device|Automated closed-loop insulin delivery (AiD)|Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.
75390454|NCT04938557|Device|A standard insulin delivery system|Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.
75707043|NCT04147962|Device|intense pulsed light (usual practice)|collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
75543524|NCT00265044|Behavioral|Patient Education|
75390455|NCT04937881|Drug|Tenofovir alafenamide|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)
75543525|NCT02962037|Other|Melatonin and light therapy|
75707044|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, single dose
75707045|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
75707046|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, single dose
75707047|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
75707048|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
75707049|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, single dose
75707050|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, single dose
75390456|NCT04937881|Drug|Tenofovir Disoproxil Fumarate|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)
75543526|NCT00273000|Drug|GLP-2|
75543527|NCT04720586|Procedure|lower eyelid blepharoplasty , retractor plication and wedge resection|combined lower eyelid blepharoplasty , retractor plication and wedge resection
75543528|NCT04720586|Procedure|lower eyelid blepharoplasty and retractor plication|combined lower eyelid blepharoplasty and retractor plication procedures
75707051|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, single dose
75707052|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, single-dose
75543529|NCT00282399|Drug|Subcutaneous Decitabine|
75543530|NCT00242450|Drug|Metoclopramide|
75543531|NCT00273039|Drug|paroxetine|
75543532|NCT00242528|Drug|Zoledronic acid|
75543533|NCT00273117|Procedure|transnasal gastroscopy|
75543534|NCT00273156|Behavioral|Telephone quitline|
75543535|NCT00242606|Drug|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
75543536|NCT00242606|Drug|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
75543537|NCT00242645|Behavioral|Health Information|
75707053|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
75707054|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
75707055|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
75707056|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
75707057|NCT00734240|Drug|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
75707058|NCT00734240|Drug|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
75707059|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
76034093|NCT04399265|Dietary Supplement|Maltose|Maltose power
75390457|NCT04911452|Device|Calmer|Once randomized, infants in the Calmer group will receive treatment for a minimum cumulative total of 3 hours/day during periods when the infant may be too ill to be held or when parents do not wish to hold their infant or are not present. Calmer does not replicate a parent's contact and so the minimum exposure has been tripled. No upper limit of Calmer use will be set. Each day, the research and/or bedside nurse will record the heart and respiratory rates for a two-minute period. The one-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The Neonatal Intensive Care Unit (NICU) research nurse will also train the parents/caregivers to self-measure their resting heart and breathing rates so that if they are away from the NICU for more than one day, these values can be sent to the research/ bedside nurse by phone.
75707060|NCT04066452|Diagnostic Test|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP).|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees.
75707061|NCT04066452|Diagnostic Test|Proteinogram and serum immunoglobulins. Light chains free in serum -Freelite-. Immunofixation in serum and urine|Analysis to rule out the presence of monoclonal protein in blood and urine.
75707062|NCT00733382|Drug|dexamethazone|injection form, 8 miligram, injected once
76034094|NCT05125549|Drug|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
75869706|NCT03159897|Drug|Doxorubicin|Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
76034095|NCT05125549|Drug|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
76034096|NCT04906577|Other|photography+odour|Daily from D0 to D5: a square of cotton cloth will be placed against the child's scalp by the childcare worker in charge of the child, then removed and placed in a sealed box containing a photograph of the child, which will then be given to the mother.
76034097|NCT04906577|Other|photography|A neutral smelling cloth will be placed with the child's photograph which will then be given to the mother.
75543538|NCT00242645|Behavioral|Preventive Services|
76034098|NCT04903847|Drug|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Two-drug therapy
75543539|NCT00242645|Behavioral|Computer tailored information|
75543540|NCT00273195|Device|Implantable Cardioverter Defibrillator|
75543541|NCT00242762|Drug|ZD1839 (IRESSA™)|
75543542|NCT00242762|Drug|Docetaxel|
75543543|NCT00242762|Drug|Cisplatin|
75543544|NCT00282516|Procedure|In-home telemonitoring of pediatric patients with persistent asthma|
75543545|NCT00242801|Drug|Gefitinib|
75543546|NCT00273234|Procedure|Autologous Platelet Gel (APG)|
75543547|NCT00282555|Drug|S-Tenatoprazole-Na (STU-Na)|
75543548|NCT00242840|Drug|No intervention; Observational study|
76034099|NCT04903847|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Three-drug therapy
76034100|NCT05130697|Other|eMPowEr App|A mobile app to support participants in the management of malignant pleural effusions at home
76034101|NCT04905953|Drug|Neostigmine|Intrathecal injection of two doses of neostigmine (10 & 20 mic) during spinal anesthesia for cesarean section.
76034102|NCT03647917|Biological|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
75390458|NCT04875052|Device|Experimental: Whole Body Vibration|Whole body vibration will be delivered using a commercially available device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
75390459|NCT04875052|Device|Experimental: Local Muscle Vibration|Local muscle vibration will be delivered using a prototype device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
75390460|NCT04875052|Other|Standard ACL Rehabilitation|Patients will complete a standard of care rehabilitation emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control.
76034103|NCT03647917|Biological|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
75707063|NCT00728442|Device|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
76034104|NCT04905875|Procedure|Prone Position|Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
76034105|NCT03637309|Behavioral|BeReady2Smile Video and App|BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
76034106|NCT04905719|Diagnostic Test|Ultrasound|Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.
76034107|NCT03619681|Drug|KN026|Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
76034108|NCT04905641|Procedure|Bilateral intermediate cervical plexus block|Bilateral intermediate cervical plexus block was performed under ultrasound guidance.
75390461|NCT04862572|Other|MRI scanning|"In the audiological assessment, participants will undergo various audiometric test, such as pure tone audiometry with extended high-frequency range, speech audiometry, tympanometry, and auditory reflex threshold. These tests are all noninvasive and aim to assess participants hearing threshold, speech-in-noise difficulty, whether or not they have conductive hearing loss, and test efferent auditory function. The appointment will take around 60-90 minutes. An experienced audiologist on-site will be in charge of this procedure.~In the MRI appointment, participant will undergo MRI scanning. Before the MRI scan, a researcher with experienced radiographer will re-check that the participant is safe to be scanned, with the standard University of Nottingham safety questionnaire. This rechecking step is necessary to make sure that participants are still eligible for the scanning. An experience radiographer will be in charge of this procedure."
75543549|NCT00273273|Procedure|blood draw|
75543550|NCT00242879|Drug|Physician determined comparator PI + ritonavir|
75543551|NCT00242879|Drug|GW640385 + ritonavir|
75543552|NCT00282594|Drug|Novolin R (human recombinant Insulin)|
75543553|NCT00242918|Drug|docetaxel|
75543554|NCT00242918|Drug|ZD1839|
75543555|NCT00282633|Device|Dermabond|
75543556|NCT00242957|Behavioral|Intervention with Microfinance for AIDS and Gender Equity|
75543557|NCT00273312|Drug|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
75543558|NCT00242996|Biological|filgrastim|
75543559|NCT00242996|Biological|rituximab|
75707064|NCT00733460|Drug|BFPET|
75707065|NCT00728520|Drug|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
75869707|NCT03159897|Drug|Bleomycin|Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
75390462|NCT04861571|Dietary Supplement|Dietary intervention with very low calorie diet (VLCD)|The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.
75390463|NCT04861571|Other|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
75707066|NCT04065308|Drug|Drug Combinations|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response <CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~dexamethasone :40mg/day D1-4, intravenous~cyclophosphamide: 400mg/m2 D1-4, intravenous~etoposide: 40mg/m2 D1-4, intravenous~cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
75390464|NCT04846517|Device|Transcranial Magnetic Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC~LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
75707067|NCT00733538|Drug|zometa|patients receiving treatment during their follow-up
75869708|NCT03159897|Drug|Vinblastine|Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
75543560|NCT00242996|Biological|sargramostim|
75390465|NCT04842604|Drug|Glasdegib|25 mg or 100 mg tablet
75390466|NCT04842604|Drug|Azacitidine|100 mg/vial powder for 25 mg/mL suspension for injection
75390467|NCT04827576|Drug|Magrolimab|Administered intravenously
75390468|NCT04827576|Drug|Docetaxel|Administered intravenously, 75 mg/m^2 on Day 1 of each cycle
75390469|NCT04817774|Biological|TX200-TR101|TX200-TR101 is an autologous gene therapy medicinal product composed of Treg cells (CD4+/CD45RA+/CD25+/CD127low/neg) that have been ex vivo expanded and transduced with a lentiviral vector encoding for a CAR to recognize HLA-A*02. Treatment will be given via an IV infusion at a pre-defined timepoint several weeks after transplant. Four, single ascending dose cohorts of TX200-TR101 are planned and an additional expansion cohort.
75543561|NCT00242996|Drug|carmustine|
75869709|NCT03159897|Drug|Dacarbazine|Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
75869710|NCT03113981|Device|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
75869711|NCT03102866|Other|Best Practice|Receive usual care
75869712|NCT03102866|Behavioral|Exercise Intervention|Undergo aerobic and strength training exercise
75869713|NCT03102866|Other|Quality-of-Life Assessment|Ancillary studies
75869714|NCT03102866|Other|Questionnaire Administration|Ancillary studies
75390470|NCT04801160|Procedure|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
75390471|NCT04801160|Procedure|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
75543562|NCT00242996|Drug|cyclophosphamide|
75543563|NCT00242996|Drug|etoposide|
75543564|NCT00242996|Procedure|adjuvant therapy|
75543565|NCT00242996|Procedure|bone marrow ablation with stem cell support|
75543566|NCT00242996|Procedure|peripheral blood stem cell transplantation|
75707068|NCT00730548|Behavioral|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
75707069|NCT00728156|Drug|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
76034109|NCT03609073|Device|Endomina|Suturing system then cutting the bridge between the diverticulum and the esophagus.
75707070|NCT00728156|Drug|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
75707071|NCT02569554|Drug|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
75869715|NCT03096886|Behavioral|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
75707072|NCT02569554|Drug|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
75707073|NCT00728234|Device|aEEG recording|weekly recordings with aEEG
75707074|NCT00734318|Drug|Flutiform 250/10 micrograms|
75707075|NCT00734318|Drug|Flutiform 50/5 micrograms|
75707076|NCT00734318|Drug|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
75707077|NCT00734318|Drug|Flixotide pMDI 250 micrograms|
75869716|NCT03079999|Drug|Aspirin|Twice daily aspirin
75869717|NCT03079999|Drug|Placebo|Twice daily placebo
75869718|NCT03078010|Drug|Piperacillin-tazobactam|piperacillin-tazobactam (4.5 gm IV q 6 hrs)
75869719|NCT03078010|Drug|cefepime|(2 gm IV q 8 hrs)
75869720|NCT03072238|Drug|Ipatasertib|Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
75869721|NCT03072238|Drug|Abiraterone|Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
76034110|NCT04916093|Drug|Vildagliptin 50 MG|Galvus 50 mg oral tablets
75390472|NCT04789668|Drug|Bintrafusp Alfa|Given IV
75543567|NCT00273390|Drug|Remicade (infliximab)|
75543568|NCT00243035|Drug|bortezomib|Given IV
75543569|NCT00243035|Drug|tipifarnib|Given orally
76034111|NCT04916093|Drug|Sitagliptin 100mg|Januvia 100mg oral tablets
75543570|NCT00243035|Other|laboratory biomarker analysis|Correlative studies
75707078|NCT04052412|Drug|18F-AraG|All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
76034112|NCT04916093|Drug|MetFORMIN 1000 Mg Oral Tablet|Glucophage 1000 mg oral tablets
76034113|NCT03052205|Drug|IMO-2125|IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
75543571|NCT00243113|Drug|docetaxel|
75543572|NCT00243113|Radiation|radiation therapy|
75543573|NCT00273429|Drug|timolol maleate 0.5%|
75707079|NCT00733616|Drug|DOX: Docetaxel, oxaliplatin, Capecitabine|"Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~Capecitabine 625 mg/m2, bid, oral, continuous~6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"
75707080|NCT00728832|Drug|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
75543574|NCT00273429|Drug|dorzolamide/timolol maleate fixed combination|
75543575|NCT00273429|Drug|latanoprost 0.005%|
75707081|NCT00734396|Procedure|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
75707082|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
76034114|NCT03512119|Drug|Lumacaftor-Ivacaftor treatment|Lumacaftor-Ivacaftor treatment during one year
75543576|NCT00273429|Drug|placebo|
75543577|NCT00243308|Drug|Serine proteinase-1 (Serp-1)|
75543578|NCT00273468|Drug|Granisetron|
75543579|NCT00243425|Procedure|Standard Quality Improvement|
75543580|NCT00243425|Procedure|Patient-centered Intervention|
75543581|NCT00282750|Device|Bar coded sponge and scanner|
76034115|NCT04903769|Behavioral|Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)|SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
75543582|NCT00243464|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
75543583|NCT00282789|Device|bilevel positive airway pressure|
75707083|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
75707084|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
75707085|NCT00733694|Device|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
75707086|NCT00733772|Dietary Supplement|flaxseed|30 grams/day of flaxseed for 12 weeks
75707087|NCT00733772|Behavioral|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
76034116|NCT05130541|Behavioral|Proning|Rotating on long axis 90 degrees every 30 minutes
76034117|NCT05130541|Other|Supportive Care|Usual Care
76034118|NCT04903613|Drug|Ligelizumab|Ligelizumab 120 mg s.c every 4 weeks
75543584|NCT00282789|Device|bilevel positive airway pressure (Device)|
75543585|NCT00243542|Drug|ACZONE Gel, 5%|
75543586|NCT00243542|Drug|Vehicle|
75543587|NCT00282906|Device|hybrid PET-CT imaging system|15 mCi of FDG
75543588|NCT00243581|Behavioral|Dean Ornish Heart Disease Reversing Program|
75543589|NCT00273507|Drug|Carboplatin and Paclitaxel|
75543590|NCT02962154|Radiation|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
75707088|NCT00728312|Drug|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
75707089|NCT00728312|Drug|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
76034119|NCT04905485|Behavioral|VIOME Precision Nutrition Program|Precision diet and supplement recommendations based on participants' microbiome results.
76034120|NCT03052439|Other|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
76034121|NCT04905329|Drug|Empegfilgrastim|Extimia®
76034122|NCT02767921|Other|Cytology Specimen Collection Procedure|Correlative studies
75707090|NCT00728390|Drug|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
75707091|NCT00734552|Dietary Supplement|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d."
75390473|NCT04789668|Drug|Pimasertib|Given PO
75390474|NCT04789668|Other|Quality-of-Life Assessment|Ancillary studies
75390475|NCT04785131|Other|Prune|daily consumption of 50 grams prune.
75390476|NCT04782115|Biological|intravitreal injection of RC28-E|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
75390477|NCT04782115|Biological|Conbercept|KH902(Conbercept）
75390478|NCT04778514|Drug|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
75390479|NCT04778514|Drug|PrEP and combined oral contraceptive (COC) as two separate tablets|PrEP tablet and a COC as two separate tablets
75390480|NCT04778475|Other|Intensive therapy|PT services twice a day for 3-5 days and then daily for the remainder of hospital stay
75390481|NCT04778475|Other|Standard of care therapy|PT services 3-5 times a week for 15 to 30 minutes
75707092|NCT00734552|Dietary Supplement|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
75707093|NCT00728546|Drug|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
75707094|NCT02568722|Other|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI > 72 hours following the time of randomization."
75390482|NCT04776109|Procedure|erector spinae block|"Bilateral erector spinae catheters will be placed at T8 level. an ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles and the transverse Processes. Next, 2-3 ml of 2% lidocaine will be infiltrated .~A 16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the ultrasound beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle, 10 ml of saline 0.9% will be injected lifting the muscle of the transverse process. A catheter will be inserted into the newly formed space underneath the ES muscle and secured. The procedure will be repeated on the contralateral side. bupivacaine (20 ml of bupivacaine 0.25%) solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours."
75390483|NCT04756401|Drug|Carfilzomib|Given IV
75390484|NCT04756401|Biological|Daratumumab|Given IV
75543591|NCT02962154|Other|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
75707095|NCT02568722|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
75707096|NCT00738686|Device|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
75390485|NCT04756401|Drug|Dexamethasone|Given PO
75390486|NCT04756401|Other|Quality-of-Life Assessment|Ancillary studies
75390487|NCT04756401|Drug|Selinexor|Given PO
75390488|NCT04741776|Behavioral|Resilience Enhancement Skills Training|Family therapy
75390489|NCT04741776|Behavioral|Problem-Solving Individual Therapy|Individual therapy
75390490|NCT04726293|Dietary Supplement|Mango|Mango beverage -1 cup fresh mango equivalent, twice a day for 4 weeks
75390491|NCT04726293|Dietary Supplement|Control|control beverage 1 cup, twice a day for 4 weeks
75390492|NCT04716634|Drug|Tislelizumab|Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
75390493|NCT04716634|Drug|Fruquintinib|Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
75390494|NCT04708041|Biological|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
75390495|NCT04701385|Diagnostic Test|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) can undertake detailed characterisation of plaque morphology in patients with myocardial infarction at the time of percutaneous treatment. This allows plaque rupture, erosion and other mechanisms of myocardial infarction to be differentiated
75390496|NCT04696263|Device|Da Vinci ® Xi system - MP Robotic Radical Prostatectomy|After pneumoperitoneum is established, four 8mm, one 12 mm, and one 5 mm trocars are placed for instrumentation. After the robot is docked, radical prostatectomy is performed with the SOC approach.
75390497|NCT04696263|Device|Da Vinci ® SP system - SP Robotic Radical Prostatectomy|After induction of general anesthesia and supine participant positioning, a 3.5 cm infraumbilical incision will be made for single-port access into the space of Retzius. Radical prostatectomy is then performed with the SOC approach
75390498|NCT04690738|Diagnostic Test|Fecal Elastase Concentration|Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
75543592|NCT02962154|Other|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
75707097|NCT04064216|Procedure|Laparoscopic surgery|Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis
75707098|NCT00617890|Biological|robatumumab|Robatumumab IV every two weeks until disease progression.
75707099|NCT04066010|Other|Mobile application (BP-n-Me)|"The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys."
75707100|NCT00730626|Dietary Supplement|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
75869722|NCT03072238|Drug|Placebo|Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
75869723|NCT03072238|Drug|Prednisone/Prednisolone|Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
75869724|NCT03017755|Other|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
75543593|NCT02962154|Other|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
75869725|NCT02977403|Behavioral|Attention Bias Retraining|Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
75543594|NCT02962154|Other|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
75707101|NCT00730626|Dietary Supplement|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
75707102|NCT00730626|Dietary Supplement|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
75707103|NCT00870766|Procedure|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
75707104|NCT00728780|Drug|ABT-143|once
75707105|NCT00728780|Drug|ABT-335 and rosuvastatin|once
75707106|NCT00870844|Drug|Lu AA24493 (CEPO)|0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
75707107|NCT00870844|Drug|Placebo|Vials with solution for IV infusion
75707108|NCT00734708|Drug|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
75707109|NCT00734708|Drug|Placebo|Control
75707110|NCT04066296|Drug|Liposomal bupivacaine|Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
75707111|NCT02341014|Drug|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient regardless of dose level must be 20mg/m2 . All subsequent doses of carfilzomib will be based on the patient's dose level.
75707112|NCT02341014|Drug|Romidepsin|
75707113|NCT02341014|Drug|Lenalidomide|
75707114|NCT00738764|Biological|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
75707115|NCT00730782|Biological|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
75707116|NCT00868426|Drug|Budesonide/Formoterol Batch 1|Single, inhaled dose
75707117|NCT00868426|Drug|Budesonide/Formoterol Batch 2|Single, inhaled dose
75707118|NCT00868426|Drug|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
75869726|NCT02977403|Behavioral|Booster Attention Retraining|All subjects can opt to undergo attention bias training after the randomized phase of the study is complete
75869727|NCT02970318|Drug|Acalabrutinib (ACP-196)|Acalabrutinib monotherapy
75869728|NCT02970318|Drug|Rituximab|Rituximab in combination with idelalisib or bendamustine
75390499|NCT04678882|Drug|Placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous (SC)
75390500|NCT04678882|Drug|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous (SC)
75390501|NCT04672304|Other|Al-Husban University Naser|filling a questionnaire
75390502|NCT04670965|Biological|E-PRF/rhBMP-2 (similar ratios)|During its preparation, 1.5 mg/ml rhBMP-2 will be incorporated into standardized samples to assure similar E-PRF to rhBMP-2 ratios. To allow for consistency across all samples, standardized E-PRF volume will be established using formation templates. Following its preparation, the E-PRF/rhBMP2 scaffold will undergo a standard in vitro assay to investigate growth factor release over time (ELISA quantification assay). Briefly, the e-PRF/rhBMP2 scaffold will be placed in a shaking incubator at 37 degree Celsius and assessed for growth factor release of rhBMP-2 over time.
75707119|NCT03872856|Device|BP-ICAN|"One of two home blood pressure monitor devices will be used.~Omron 7 Series Wrist cuff~Omron 10 Series Upper Arm cuff"
75390503|NCT04670965|Biological|E-PRF/ACS/rhBMP-2|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. After the addition of the rhBMP-2, the ACS will be cut into 2mm x 2mm pieces and incorporated into the E-PRF membrane. Following its preparation, rhBMP-2 release from the E-PRF/ACS/rhBMP2 scaffold will be quantified using the ELISA quantification assay as described above.
75390504|NCT04670965|Biological|rhBMP-2/E-PRF|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. Rh-BMP2 release will be quantified using the ELISA quantification assay as described above
75390505|NCT04670965|Biological|E-PRF only|E-PRF will be prepared and standardized, but no rhBMP-2 will be added to the material. After preparation, the E-PRF scaffold assayed via ELISA quantification assay as described above to determine the release (if any) of intrinsic BMP-2 from the platelet concentrate scaffold.
75390506|NCT04661020|Drug|CD19 CAR-T cells|Each subject receive CD19 CAR T-cells by intravenous infusion
75390507|NCT04642391|Drug|Cosyntropin|Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
75707120|NCT00870922|Procedure|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
75869729|NCT02970318|Drug|Idelalisib|Idelalisib in combination with rituximab
75707121|NCT00868504|Other|no intervention|no intervention
75390508|NCT04628416|Device|PICO dressing|Use of a portative miniature negative pressure dressing system named PICO® on the split-thickness skin graft of fibula free flap donor sites
75390509|NCT04628416|Device|Conventional dressing|use of a conventional dressing (parrafin gauze) on the split-thickness skin graft of fibula free flap donor sites
75390510|NCT04613518|Drug|BMS-986165|Specified Dose on Specified Days
75707122|NCT03853746|Drug|Ocrelizumab|Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
75869730|NCT02970318|Drug|Bendamustine|Bendamustine in combination with rituximab
75869731|NCT02949726|Drug|Indocyanine Green (ICG)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
75869732|NCT02949726|Device|Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
75390511|NCT04613518|Other|Placebo Comparator|Specified Dose on Specified Days
75390512|NCT04610372|Radiation|Hypofractionated external beam radiotherapy|5500 cGy/20 fractions delivered 5 days per week over 4 weeks
75390513|NCT04610372|Radiation|High dose rate brachytherapy|A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance
75390514|NCT04610372|Radiation|Permanent seed implant|Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance
75390515|NCT04610372|Radiation|Stereotactic body radiotherapy|External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.
75543595|NCT02962154|Other|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
75707123|NCT00868582|Other|PET scanning in cancer|Collection of institutional practice PET imaging data
75707124|NCT03037242|Procedure|Transtibial pullout technique|Evaluating radographs
75707125|NCT00868660|Drug|ZP1848|sc. bolus
75707126|NCT00712166|Drug|AZLI 75 mg three times daily (TID)|
75707127|NCT00712166|Drug|Placebo three times daily (TID)|
75707128|NCT00868738|Dietary Supplement|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
75707129|NCT00652743|Biological|Pandemic influenza vaccine GSK1562902A|IM administration
76034123|NCT02767921|Other|Laboratory Biomarker Analysis|Correlative studies
75707130|NCT00730860|Procedure|radiofrequency ablation associated with TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
75707131|NCT00730860|Procedure|radiofrequency ablation only|treatment of hepatocellular carcinoma by radiofrequency ablation only
75707132|NCT00868816|Drug|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
75707133|NCT00868816|Drug|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
75390516|NCT04592614|Behavioral|Choose to Move - Next Steps|Choose to Move - Next Steps consists of a series of group meetings delivered virtually for 2 years. Group meetings (1-hr each) of 6-11 older adults will be facilitated by a trained Activity Coach and delivered remotely via the Zoom or GoToMeeting platform (password protected; access through phone or internet). Each group meeting will provide information on a health-related topic of interest and will include time for goal setting, discussion and sharing among participants. Older adults will have the option to sign up for a bi-weekly CTM electronic newsletter containing health information and ideas and resources for older adults to be physically active and socially connected at home (and elsewhere as local restrictions permit). Activity Coaches will also facilitate social connections between participants to encourage contact (by phone or online) outside of group sessions (for interested participants only).
75869733|NCT02948686|Other|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
76034124|NCT02767921|Procedure|Radical Cystectomy|Undergo robotic-assisted radical cystectomy
76034125|NCT02767921|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
76034126|NCT02767921|Procedure|Therapeutic Conventional Surgery|Undergo robotic-assisted radical or partial nephrectomy
76034127|NCT04903379|Other|Education|An explanation of contemporary pain science and a description of effective treatment strategies used by people with a history of persistent pain.
76034128|NCT02642809|Drug|Pembrolizumab|
75390517|NCT04590599|Drug|IBI310|IBI310 3 mg/kg,Q3W, for a total of 4 cycles
75390518|NCT04590599|Drug|Placebo|Placebo Q3W, for a total of 4 cycles
75390519|NCT04590599|Drug|Sintilimab|Sintilimab 200mg,Q3W
75390520|NCT04588727|Drug|AZD3366|In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort[s]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
75707134|NCT02569866|Drug|Cephalexin|Capsules containing cephalexin/500mg
76034129|NCT02642809|Radiation|Brachytherapy|
76034130|NCT02642809|Procedure|Endoscopic biopsy|
76034131|NCT02642809|Procedure|Computed tomography-guided biopsy|
76034132|NCT02642809|Procedure|Peripheral blood collection|
76034133|NCT03052361|Drug|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
76034134|NCT03052361|Drug|Placebos|similar looking and tasting liquid placebo
75390521|NCT04588727|Drug|Placebo|In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
75390522|NCT04588727|Drug|Ticagrelor|In Part B, subjects will receive oral ticagrelor tablets.
75390523|NCT04588727|Drug|acetylsalicylic acid (ASA)|In Part B, subjects will receive oral ASA chewable tablets.
75390524|NCT04582565|Combination Product|Decongestive lymphatic therapy (DLT)|Manual lymphatic drainage
75390525|NCT04582565|Other|Standard Care|
75707135|NCT02569866|Drug|Placebo|Capsules containing placebo/500mg
75707136|NCT00868894|Drug|DE-104 medium concentration|Topical ocular application
75707137|NCT00868894|Drug|DE-104 high concentration|Topical ocular application
75707138|NCT00868894|Drug|Placebo|Topical ocular application
75707139|NCT00868894|Drug|0.005% latanoprost|Topical ocular application
75707140|NCT00730938|Drug|cefuroxime|intracameral cefuroxime 0.1 ml
75707141|NCT00730938|Drug|Saline placebo|0.1 ml of Ringers lactate
75390532|NCT04564547|Drug|Islatravir|ISL capsule taken by mouth.
75390533|NCT04564547|Drug|Ulonivirine|Ulonivirine tablet taken by mouth.
75390534|NCT04564547|Drug|BIC/FTC/TAF|BIC/FTC/TAF tablet taken by mouth.
75390535|NCT04564547|Drug|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
75390536|NCT04564547|Drug|Placebo to Ulonivirine|Placebo tablet matched to ulonivirine taken by mouth.
75390537|NCT04564547|Drug|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
75390538|NCT04559607|Drug|Camrelizumab|Camrelizumab: 200mg, iv, Q3W
75390539|NCT04559607|Device|TACE|TACE if necessary
75390540|NCT04559607|Drug|Apatinib|Apatinib: 250m, po, QD
75390541|NCT04515329|Drug|Cyclosporine|Eye drops taken twice daily.
75390542|NCT04515329|Drug|Artificial tear|Preservative-free artificial tear drops 4 times a day.
75390543|NCT04508621|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
75390544|NCT04508621|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
75707142|NCT00712010|Other|Whey protein native|Whey protein native against the 6 other arms
75707143|NCT00712010|Other|Whey protein microgels|Whey protein microgels versus the six other arms
75707144|NCT00712010|Other|Hydrolyzed whey protein|versus the six other arms
75707145|NCT00712010|Other|Casein native|versus the six other arms
75707146|NCT00712010|Other|Hydrolyzed casein|versus the six other arms
75707147|NCT00712010|Other|Total milk protein native|versus the six other arms
75707148|NCT00712010|Other|Hydrolyzed milk protein|versus the six other arms
75390545|NCT04506684|Device|Investigational RAMware downloaded onto Reveal LINQ device|The study is utilizing an investigational RAMware, either LINQ HF or ALLEVIATE-HF, that will be downloaded onto the subject's market-released Medtronic Reveal LINQ ICM. The investigational RAMware enables the hardware to record and store additional sensor data from which a respiratory rate will be derived.
75390546|NCT04506554|Drug|AMVAC + Nivolumab|Nivolumab 240mg will be administered intravenously for 3 doses - on days 1, 15 and 29. AMVAC will be dosed intravenously every 2 weeks for 3 doses on days 1, 15 and 29 with Neulasta or equivalent. Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.
75390547|NCT04504669|Drug|AZD8701|FOXP3 antisense oligonucleotide
75390548|NCT04504669|Biological|Durvalumab|anti PDL-1 monoclonal antibody
75390549|NCT04498117|Biological|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
75390550|NCT04498117|Drug|Paclitaxel|175 mg/m^2, every 3 weeks
75390551|NCT04498117|Drug|Carboplatin|AUC 6 IV Day 1 x 6 cycles (every 21 days)
75390552|NCT04498117|Biological|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
76034135|NCT05125393|Procedure|Laparoscopic linear stapler|The ileocecal or ascending colon tumors were resected using a combined cephalic caudal approach. When the accessory right colonic vein is separated from the head and then turned to the caudal side for upward dissociation. After no metastasis of 203 groups of lymph nodes is confirmed according to ICG development during the operation, the Henle stem and its root tissue were resected with a linear stapler.
75390553|NCT04498117|Drug|Carboplatin|AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
75390554|NCT04482972|Procedure|DCB|Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.
75543596|NCT02962154|Other|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
75543597|NCT00282945|Drug|Rosiglitazone|
76034136|NCT04905095|Diagnostic Test|EWS|Early Warning Score will be implemented in the computer system of the nursing station. When the nurses enter the vital signs of the patients into the system, the EWS will be automatically calculated and an alarm will be displayed if an intervention is necessary, which is protocolized.
75543598|NCT00282945|Drug|Metformin|
75543599|NCT00243620|Device|Vacuum therapy (device)|
75707149|NCT00731016|Drug|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~injection 1, S1: 0.0125 mg/kg of zoledronic acid~injection 2, S6: 0.025 mg/kg of zoledronic acid~injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
76034137|NCT05125159|Procedure|angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture|"Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical)."
76034138|NCT02532127|Other|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
75543600|NCT00273546|Drug|XRP6976 (Docetaxel/Taxotere)|
75543601|NCT00273585|Device|Personally-tailored educational software program|
75707150|NCT00868972|Procedure|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
75707151|NCT00868972|Device|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
75390555|NCT04482972|Procedure|DES|Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
75390556|NCT04465448|Other|MRI|Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement
75390557|NCT04459650|Procedure|Platelet Rich Plasma system|Participants will receive PRP obtained with PRP harvesting kits on one side of the scalp and no injections on the other side of the scalp (split-scalp technique). The entire half of the intended scalp will receive inter-follicular injections of PRP under aseptic conditions at the amount of 0.05-0.1 ml/cm2 in a retrograde fashion from deep to superficial, at every centimeter throughout the treated site. For study purposes, Study Day 0 is defined as the first day of injection. Subsequently the patient will continue therapy every 4 weeks for a total of 3 injections (12 weeks).
75390558|NCT04451525|Device|MicroVention Mechanical Thrombectomy Devices as first-line treatment|Patient will be treated with mechanical thrombectomy at the direction of the treating physician
75390559|NCT04416204|Other|glycogen loading|Subjects will consume an isocaloric diet [60% carbs, 20% protein, 20% fat (33 kcal/kg/day)] for 3 days prior to the overnight study.
75390560|NCT04416204|Other|No Glycogen Loading|Subjects will consume an isocaloric diet [40% carbs, 20% protein, 40% fat (33 kcal/kg/day)] for 3 days prior to the overnight study.
75390561|NCT04414514|Drug|Ruxolitinib 1.5% Cream|Topical Ruxolitinib 1.5% Cream
75390562|NCT04409236|Behavioral|Quit2Heal|Use Quit2Heal app
75390563|NCT04409236|Behavioral|QuitGuide|Use QuitGuide app
75390564|NCT04409236|Other|Survey Administration|Ancillary studies
75390565|NCT04394858|Procedure|Biospecimen Collection|Undergo collection of blood samples
75707152|NCT00799539|Drug|bortezomib|From cycles 1-4, 1.3mg/m^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
75707153|NCT00799539|Drug|bortezomib|From cycles 5-9, 1.3mg/m^2 on days 1, 8, 22, and 29 of each 6-week cycle
75543602|NCT00283023|Procedure|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
75543603|NCT00283101|Drug|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
75707154|NCT00799539|Drug|melphalan|9 mg/m^2 once daily on days 1-4 of each 6-week cycle
75390566|NCT04394858|Procedure|Computed Tomography with Contrast|Undergo CT with contrast
75390567|NCT04394858|Procedure|Magnetic Resonance Imaging|Undergo MRI
75390568|NCT04394858|Drug|Olaparib|Given PO
75390569|NCT04394858|Other|Quality-of-Life Assessment|Ancillary studies
75543604|NCT00243698|Drug|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
75543605|NCT00273663|Device|TCES|
75543606|NCT00243737|Drug|Artesunate-Mefloquine|
75543607|NCT00273702|Drug|N-Acetyl Cysteine|
75543608|NCT00243815|Drug|ibuprofen|
75543609|NCT00283179|Drug|Aripiprazole|
75543610|NCT00283179|Drug|Risperidone|
75707155|NCT00799539|Drug|prednisone|60 mg/m^2 once daily on days 1-4 of each 6-week cycle
75707156|NCT00731172|Drug|glatiramer acetate|20 mg daily subcutaneous injection through week 12
75543611|NCT00243854|Drug|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
75543612|NCT00273741|Drug|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
75543613|NCT00273741|Drug|placebo comparator|placebo capsules
75707157|NCT00731172|Drug|placebo|subcutaneous daiky injection through week 12
75707158|NCT00799695|Behavioral|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
75707159|NCT00869284|Drug|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
75390570|NCT04394858|Drug|Temozolomide|Given PO
75390571|NCT04373642|Drug|Pebrolizumab + QUADSHOT Radiotherapy|"Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab."
75390572|NCT04370444|Device|Phallus Length Reducer|Phallus Length Reducer
75390573|NCT04370444|Other|Self-assessment of dyspareunia|Use of a vaginal insert to self assess dyspareunia
75390574|NCT04359017|Drug|Lidocaine 1% Injectable Solution|The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
75390575|NCT04358705|Other|Aim 1: Online survey|"This survey will evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users. This survey will be used to inform survey design for further aims.~As a proxy for biological verification of tobacco use status, data on brand, frequency, and pricing will be collected to confirm user status~Participants will rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions. Participants will also complete purchase and substitution tasks."
75390576|NCT04358705|Behavioral|Eye Tracking Activity|The eye tracking activity consists of a single in-person eye tracking activity that will take place in a private office where the participant will be seated in a chair within a typical viewing distance from a computer monitor equipped with an infrared camera on the monitor to capture precise eye movements. Participants will have their gaze monitored continuously by the camera on the computer monitor while a randomized set of stimuli (product advertisements) are viewed (n=30) for 10 seconds per image. Following each advertisement, an on-screen closed response question will re-center the participant's gaze for standardization prior to the next image
75390577|NCT04358705|Other|Eye tracking survey|Participants will complete a survey using Qualtrics immediately after the eye tracking activity and one week following completion of the activity via email to measure recall of brand name, product flavors, perceptions of cigarillo harm, and tobacco use behaviors and intentions.
76034139|NCT04915547|Other|Group-Based Exercise|"Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor."
76034140|NCT05079607|Other|Mitopure Topical Formula 1|topical skin cream containing the low dose mitophagy activator Mitopure
76034141|NCT05079607|Other|Mitopure Topical Formula 2|topical skin cream containing the high dose mitophagy activator Mitopure
76034142|NCT02370589|Biological|Base Dose EBOV GP Vaccine|
75543614|NCT02279134|Radiation|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
75707160|NCT00869284|Procedure|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|"The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.~The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8."
75707161|NCT00738842|Drug|AZD6140|Oral tablets taken bid for 5 days
75707162|NCT00738842|Drug|Placebo to match AZD6140|Oral tablets taken bid for 5 days
75707163|NCT00809913|Drug|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
75707164|NCT00729222|Drug|Comparator: Placebo|rolofylline placebo IV infusion over 4 hours.
75707165|NCT00729222|Drug|rolofylline|rolofylline 30 mg IV infusion over 4 hours.
76034143|NCT02370589|Biological|2x Base Dose EBOV GP Vaccine|
76034144|NCT02370589|Biological|4x Base Dose EBOV GP Vaccine|
75707166|NCT03896386|Other|Use of seizure diary|"The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end"
75707167|NCT00734786|Other|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
75390578|NCT04358705|Behavioral|Online Experimental Marketplace (ETM)|"Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes."
75390579|NCT04358705|Other|Aim 3 survey|"Consists of:~A screener and demographic data collection.~A tobacco product withdrawal scale~Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~The tobacco product withdrawal scale again~Measurements of nicotine dependence and flavor preferences"
75543615|NCT02279134|Radiation|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
75707168|NCT00808743|Drug|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
75707169|NCT00808743|Drug|Ursodeoxycholic acid|"Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
75707170|NCT00808743|Drug|Placebo|"Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
75707171|NCT00869596|Drug|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
75707172|NCT00869596|Drug|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
75707173|NCT00869596|Drug|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
75707174|NCT00869596|Drug|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
75707175|NCT03743376|Biological|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
75707176|NCT03743376|Biological|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
76034145|NCT02370589|Biological|8x Base Dose EBOV GP Vaccine|
76034146|NCT02370589|Biological|Placebo|
76034147|NCT02370589|Biological|Matrix-M Adjuvant|
76034148|NCT04903145|Diagnostic Test|REOM|To compare data generated by the REOM device with data from the tremoflo C-100 device
76034149|NCT04904939|Procedure|Bronchoscopic mucosal biopsy|Endobronchial forceps biopsy using flexible bronchoscope
75390580|NCT04358705|Other|Cognitive Interviews|Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.
75390581|NCT04345250|Other|Energy restriction|A 25% reduction in total caloric intake, as calculated through the app. Therefore, during the control period, participants will input what they consume into the Eat This Much app, then the app will calculate the 25% reduction in calories to present participants with how much to consume of the same foods. By doing this their diet will not be altered in terms of macronutrients or micronutrients, but solely on calories.
76034150|NCT05067673|Other|Dry needling|The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.
75390582|NCT04328740|Drug|TP-1454 monotherapy|Flat dose once or twice daily, alone
75390583|NCT04317716|Behavioral|fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program will be group-based with 6-8 participants, led by a facilitator, and performed online. It comprises six two-hour sessions held once a week, and a booster session held eight weeks after the sixth session. In addition they will receive a brochure about falls and fall risk factors.
75390584|NCT04317716|Other|Brochure about falls and fall risk factors|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
75390585|NCT04311034|Drug|RC48|Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
75543616|NCT02279134|Drug|Paclitaxel|135-150mg/m2 (D1 and D29)
75543617|NCT02279134|Drug|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
75543618|NCT00243893|Drug|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
75543619|NCT00243893|Drug|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
75543620|NCT00243971|Drug|SPM 962|
75543621|NCT00283218|Drug|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
75543622|NCT00244049|Behavioral|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
76034151|NCT05067673|Other|Placebo dry needling|Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
76034152|NCT05049265|Biological|JS007|JS007 only
76034153|NCT04902989|Other|pollutants and pollen|Pollutants (ozone, SO3, NO3, PM2.5, diesel exhaust particles)
75390586|NCT04303676|Other|Virtual Practice Facilitation with e-Learning|"Virtual practice facilitation intervention using e-learning modules to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (combination of virtual academic detailing plus online training resource) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist.~c. Resources largely included as part of the e-learning module, but supplemented by online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
75707177|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
75390587|NCT04303676|Other|Virtual Practice Facilitation without e-Learning|"Virtual practice facilitation intervention without e-learning to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (virtual academic detailing) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist c. Online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
75707178|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
75707179|NCT00869674|Procedure|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
75707180|NCT03728478|Drug|Etanercept|Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
76034154|NCT05013619|Other|Circumstances of pain|It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.
76034155|NCT05013619|Other|Pain Questionnaire|"Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain."
75707181|NCT03728478|Drug|Methotrexate|Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
75707182|NCT03728478|Drug|Intra-articular corticosteroid injections|Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
75707183|NCT00738998|Behavioral|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
75707184|NCT00738998|Other|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
75390588|NCT04294199|Other|Early Range of MOtion|Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
75390589|NCT04277117|Behavioral|Waitlist|"Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes."
75390590|NCT04277117|Behavioral|Medically tailored meals - Daily delivery with human interaction|"Phase 1 (6 months)~Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~Food: 10 MTM a week: mix of hot and frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~Delivery: 3 to 5x per week. Each delivery day, one meal is warm, the other is frozen. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off & visual check) with the participant."
75707185|NCT00653523|Drug|Ezetimibe|Ezetimibe 10 mg once daily
75390591|NCT04277117|Behavioral|Medically tailored meals - Weekly delivery with no human interaction|"Phase 1 (6 months)~Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~Delivery: 1x per week shipment.~Engagement: Meals are shipped to the participant's home. No human engagement."
75390592|NCT04277117|Behavioral|Medically tailored meals - Standard MOWCTX delivery with human interaction|"Phase 2 (6 months)~Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care)."
75543623|NCT00244049|Other|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
75543624|NCT00273780|Behavioral|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
75543625|NCT00273780|Device|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
75543626|NCT00244127|Drug|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
75543627|NCT00273819|Procedure|CT angiography|
75543628|NCT00414557|Procedure|Quadriceps strengthening|
75543629|NCT00273897|Device|Phoresor II|
75543630|NCT00244166|Drug|prednisolone|
75543631|NCT00273936|Drug|AVN-944 capsules for oral administration|
75543632|NCT00244205|Procedure|Identifying genes methylated in urine|
75707186|NCT00653523|Drug|Simvastatin|Simvastatin 20 mg daily
75707187|NCT00739076|Behavioral|Virtual Reality|Using Virtual Reality for pain control
75543633|NCT00283257|Behavioral|Patients and caregivers are taught problem solving skills|
75543634|NCT00244244|Drug|arimoclomol|
75543635|NCT00273975|Drug|Nevirapine|
75707188|NCT00869830|Other|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
75707189|NCT00799851|Device|Variceal band ligation|
75390593|NCT04273776|Drug|Suvorexant 10 mg|10 mg of suvorexant
75390594|NCT04273776|Drug|Zolpidem|5 mg of zolpidem
75707190|NCT00799851|Drug|cyanoacrylate injection|cyanoacrylate injection
75707191|NCT02544412|Behavioral|novel mindfulness-based well-being training|
75707192|NCT02717442|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
75707193|NCT02717442|Drug|Placebo|Single intratympanic injection of placebo
75707194|NCT00799929|Other|in vitro fertilization (IVF/ICSI)|
75707195|NCT00734942|Other|support service|"professional partners for communication~befriending with other families concerned~information and education (about illness, symptoms, first aid, caring)~free-time activities and time out~homework assistance~administrative advise~support for everyday life"
75707196|NCT00862732|Behavioral|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
75707197|NCT00862732|Other|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
75707198|NCT00808977|Drug|Dersalazine sodium|Dersalazine sodium 2400 mg daily
75707199|NCT00808977|Drug|Mesalazine|Mesalazine 2400 mg daily
75707200|NCT00808977|Drug|Placebo|Placebo matching active and experimental treatments
75707201|NCT04065854|Behavioral|Intervention|Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
75707202|NCT02544334|Procedure|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
75707203|NCT02544334|Other|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
75707204|NCT02544334|Other|Saliva Collection|All participants will have a saliva collection.
75707205|NCT00800007|Drug|ANZ-521|3x10^7 cfu or 3x10^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
75707206|NCT00800007|Drug|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
75390595|NCT04273776|Drug|Placebos|Avicel
75390596|NCT04272944|Drug|10 mg/kg Q2W|10 mg/kg MSB2311 every two weeks
75390597|NCT04272944|Drug|20 mg/kg Q3W|20 mg/kg MSB2311 every three weeks.
75390598|NCT04264143|Drug|Infusate with MTX110 and gadolinium|Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
75390599|NCT04264143|Device|Convection-Enhanced Delivery (CED)|CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
75390600|NCT04258488|Drug|Rivaroxaban Oral Tablet|For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects_creatinine clearance 15-49 mL/min, 15mg once daily
75390601|NCT04258488|Drug|Vitamin K antagonist(warfarin)|For 12months, keep the international normalized ratio (INR) 1.7-3.0
75390602|NCT04255875|Biological|Placebo|Participants will receive matching placebo
75390603|NCT04255875|Biological|PF-07209326|Participants will receive SC or IV single ascending doses
75707207|NCT00739232|Drug|HSD-016|
75390604|NCT04255875|Biological|PF-07209326|SCD participants will receive a multiple dose of subcutaneous PF-07209326
75390605|NCT04253548|Behavioral|iPeer2Peer Support Mentorship Program|iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
75707208|NCT00739232|Other|placebo|
75707209|NCT02569008|Drug|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
75707210|NCT00735020|Biological|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
75390606|NCT04246281|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
75390607|NCT04246281|Procedure|Standard interventional management of low back pain|Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
75390608|NCT04243668|Procedure|ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)|"In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry,reflux questionnaire."
75543636|NCT00273975|Drug|Lamivudine|
75543637|NCT00273975|Drug|Zidovudine|
75543638|NCT00244283|Drug|Sevoflurane|
75543639|NCT00244283|Procedure|High thoracic epidural analgesia|
75543640|NCT00283335|Drug|gemfibrozil|
75543641|NCT00283335|Other|Placebo|Matching placebo tablets taken once per day
75390609|NCT04228965|Drug|Varenicline|Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
75390610|NCT04228965|Behavioral|Contingency Management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
75390611|NCT04228965|Behavioral|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
75869734|NCT02948686|Other|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
75390612|NCT04228367|Device|JuggerStitch Meniscal Repair Device|Treatment of torn meniscus with JuggerStitch.
75707211|NCT00735020|Biological|Influenza Vaccine|1 dose of Influenza Vaccine
75707212|NCT03869151|Diagnostic Test|CBC|lymphocyte and monocyte count
76034156|NCT05013619|Other|Gross Motor Functional Classification System|Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent
76034157|NCT05013619|Other|The subtypes of Cerebral palsy|The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
76034158|NCT04904783|Radiation|Low dose radiotherapy|Patients in study group will receive LDRT to both lungs by two parallel opposed fields, antero-posterior (AP) and postero-anterior (PA) to deliver a midplane dose of 0.5 Gy in a single fraction. As this dose is very less, doses to the critical structures including heart and lungs would be very low. All the patients will be treated on Telecobalt unit (Theratronics Phoenix, Canada) and not on the linear accelerator to avoid risks to cancer patients on treatment with linear accelerator. CT based plan will not be undertaken for logistic issues and is also not felt to be mandatory for this LDRT. Dose computation would be carried out by manual dose calculation for the Telecobalt unit.
75390613|NCT04218526|Device|Vercise DBS System|Vercise Deep Brain Stimulation (DBS) System that consists of two bilateral directional DBS Cartesia electrodes implanted in the cuneiform nucleus and a Gevia generator implanted in the upper chest area just below the clavicle.
75390614|NCT04197687|Biological|Multi-epitope HER2 Peptide Vaccine TPIV100|Given ID
75390615|NCT04197687|Biological|Pertuzumab|permitted at physician's discretion
75543642|NCT00244322|Drug|LY450139 dihydrate|
75543643|NCT00244322|Drug|placebo|
76034159|NCT05136079|Procedure|Prophylactic lymphaticonvenous anastomosis|Prophylactic lymphaticovenous anastomosis is an immediate prophylactic approach whereby the lymphaticovenous anastomosis is performed at the time of nodal dissection utilizing fluorescing indocynanine green (ICG) and an operating microscope.
75390616|NCT04197687|Other|Placebo Administration|Given ID
76034160|NCT04915469|Other|Standardized enhanced adherence counseling package|A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
76034161|NCT04959877|Behavioral|health education|data collect / Telemedicine
76034162|NCT04915235|Behavioral|Algorithm|Algorithm
75390617|NCT04197687|Biological|Sargramostim|Given ID
75390618|NCT04197687|Biological|Trastuzumab|therapy are at the discretion of the treating physicians
75543644|NCT00283374|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
75707213|NCT04065906|Behavioral|NIRS neurofeedback|Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
75707214|NCT04065906|Drug|Methylphenidate or Tomoxetine|Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
75707215|NCT02544256|Procedure|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
75707216|NCT00739388|Drug|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
75707217|NCT00809211|Drug|nilotinib|
75707218|NCT00809211|Genetic|cytogenetic analysis|
75707219|NCT00809211|Genetic|mutation analysis|
75707220|NCT00809211|Genetic|polymerase chain reaction|
75707221|NCT00809211|Other|pharmacological study|
76034163|NCT05124145|Other|No intervention (surveillance system)|The surveillance network will collect data on all consecutive COVID-19 cases
75390619|NCT04197687|Biological|Trastuzumab Emtansine|at the discretion of the treating physicians.
75390620|NCT04186494|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|GLP-1 analogue treatment in combination with advice on diet and physical exercise
75390621|NCT04186494|Device|Continuous positive airway pressure treatment|Gold standard treatment for obstructive sleep apnea
75390622|NCT04186494|Combination Product|Liraglutide and CPAP|Combination of both treatments
75390623|NCT04185883|Drug|Sotorasib|Sotorasib administered orally as a tablet.
75390624|NCT04185883|Drug|trametinib|trametinib administered orally as a tablet.
75390625|NCT04185883|Drug|RMC-4630|RMC-4630 administered orally as a capsule.
75390626|NCT04185883|Drug|afatinib|afatinib administered orally as a tablet.
75390627|NCT04185883|Drug|pembrolizumab|pembrolizumab administered as an intravenous (IV) infusion.
75390628|NCT04185883|Drug|panitumumab|panitumumab administered as an intravenous (IV) infusion.
75543645|NCT00244361|Drug|rituximab|
75543646|NCT00274014|Drug|Tiotropium|
75543647|NCT00244439|Drug|MALG|30 minute application
75543648|NCT00244439|Drug|Ovide (malathion) lotion 0.05%|8-12 hour application
75543649|NCT00244439|Drug|Permethrin 1%|10 minute application
75543650|NCT00417144|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
75543651|NCT00417144|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
75390629|NCT04185883|Drug|carboplatin, pemetrexed, docetaxel, paclitaxel|carboplatin, pemetrexed, docetaxel administered as an intravenous (IV) infusion.
75707222|NCT00862888|Drug|PF-00446687|Single 200mg dose as an oral solution
75390630|NCT04185883|Drug|atezolizumab|atezolizumab administered as an intravenous (IV) injection.
75543652|NCT00244478|Dietary Supplement|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
75707223|NCT00862888|Drug|Placebo|Placebo for oral solution
75707224|NCT00862888|Drug|Placebo|Placebo for tablet
75543653|NCT00244478|Dietary Supplement|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
75543654|NCT00274053|Drug|tiotropium|
75543655|NCT04709588|Dietary Supplement|placebo group|subjects drank 50 ml every night for 14, 28 days
75543656|NCT04709588|Dietary Supplement|collagen drinkss|subjects drank 50 ml every night for 14, 28 days
75707225|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
75707226|NCT00862888|Drug|PF-00446687|Single 125 mg dose as an oral solution
75707227|NCT00862888|Drug|PF-00446687|Single 175 mg dose as an oral solution
75707228|NCT00862888|Drug|PF-00446687|Single 20 mg dose as an oral solution
75707229|NCT00862888|Drug|Placebo|Placebo for oral solution
75707230|NCT00862888|Drug|Placebo|Placebo for tablet
75707231|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
75707232|NCT00729456|Other|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
75707233|NCT00800085|Drug|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
75390631|NCT04185883|Drug|palbociclib|palbociclib administered orally as a tablet.
75390632|NCT04185883|Drug|MVASI® (bevacizumab-awwb)|MVASI® (bevacizumab-awwb) administered as an intravenous (IV) infusion.
75543657|NCT00417183|Drug|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
75543658|NCT00417183|Drug|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
75543659|NCT00244517|Drug|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
75543660|NCT00244517|Drug|Sevoflurane, Isoflurane, Desflurane|1 MAC
75543661|NCT00274092|Drug|tiotropium inhalation capsules (18 mcg once daily)|
75543662|NCT00274092|Drug|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
75543663|NCT00244556|Drug|Methotrexate plus ENBREL or ENBREL alone|
75707234|NCT00731250|Drug|SB-705498|Subjects will be administered a single dose of 400 mg SB-705498
75707235|NCT00731250|Drug|Placebo|Subjects will be administered SB-705498 matching placebo tablets
75707236|NCT00731250|Other|Caspaicin|Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose
75707237|NCT04041076|Procedure|Major surgical operation|Surgical operation with magnitude defined as major or ultra-major
75390633|NCT04185883|Drug|TNO155|TNO155 administered orally as a capsule.
75390634|NCT04185883|Drug|FOLFIRI|FOLFIRI chemotherapy combination of leucovorin administered as an intravenous (IV) injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.
75543664|NCT00283413|Device|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
75390635|NCT04185883|Drug|FOLFOX|FOLFOX chemotherapy combination of leucovorin administered as intravenous (IV) injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.
75390636|NCT04185883|Drug|BI 1701963|BI 1701963 administered orally
75390637|NCT04185883|Drug|AMG 404|AMG 404 administered as an intravenous (IV) infusion.
75390638|NCT04185883|Drug|everolimus|everolimus administered orally.
75543665|NCT00283413|Device|Bare metal stent|Any commercially available bare metal stent for coronary indication
75543666|NCT00244595|Drug|candsartan cilexetil|
75390639|NCT04179448|Procedure|SAMRI|Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
75390640|NCT04179448|Procedure|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
75390641|NCT04158648|Drug|Emicizumab|Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
75390642|NCT04155541|Drug|dacomitinib hydrate|The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.
75390643|NCT04123821|Device|Nasopharyngeal airway|A disposable nasopharyngeal airway of appropriate size will be selected for patients allocated to the intervention group with 5L/min oxygen through nasal cannula
75390644|NCT04117945|Biological|Cetuximab|Given IV
75543667|NCT00274131|Drug|Pramipexole 0.125 mg tablets|
75543668|NCT00274131|Drug|Pramipexole 0.5 mg tablets|
75543669|NCT00244634|Drug|candsartan cilexetil|
75543670|NCT00274170|Drug|Octreotide|
75543671|NCT00244673|Biological|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
75543672|NCT00244790|Behavioral|Diet|crossover low vs high protein diet before and after weight loss
75543673|NCT00283452|Behavioral|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
75707238|NCT00735098|Other|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
75543674|NCT02961530|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
75543675|NCT02961530|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
75543676|NCT00283491|Behavioral|Active Lactobacillus plantarum 299v|10^11 cfu/meal in 2 meals on 2 consecutive days
75543677|NCT00283491|Dietary Supplement|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
75543678|NCT00244829|Drug|imatinib mesylate|
75543679|NCT00244829|Procedure|adjuvant therapy|
75543680|NCT00283530|Procedure|Tumor biopsy|
75707239|NCT00735098|Other|strength training exercise|strength training exercise, 3 times per week for 8 weeks
75390645|NCT04117945|Drug|Irinotecan|Given IV
75390646|NCT04117945|Biological|Panitumumab|Given IV
75390647|NCT04117945|Drug|Regorafenib|Given PO
75390648|NCT04115319|Drug|SEP363856|SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
75390649|NCT04115319|Drug|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
75390650|NCT04110132|Procedure|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative."
75390651|NCT04110132|Procedure|Ganglion impar block with normal saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
75390652|NCT04107935|Behavioral|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
75543681|NCT00244868|Other|counseling intervention|
75543682|NCT00244868|Other|educational intervention|
75707240|NCT00735098|Other|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
75707241|NCT00735098|Other|Control group|8 week control group
76034164|NCT04902755|Other|Questionnaire|validation of the French linguistic version and the cross-cultural adaptation of the NBSS-SF.
76034165|NCT05136625|Drug|Sphenopalatine ganglion block|A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
76034166|NCT05136625|Drug|Standard Preparation|Troncular scalp blockade. Local site infiltration
76034167|NCT04402697|Other|Dietary and physical activity intervention|"OW-OB group: 6-month program of weight loss consisting in a low-calorie food plan (30% reduction in the individual energy requirements) with dietary sessions and exercise counselling.~MONW group: 6-month program to improve eating habits (Mediterranean diet) with dietary sessions and exercise counselling."
76034168|NCT05124847|Behavioral|Standard Care|Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.
76034169|NCT05124847|Behavioral|Time restricted eating|A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.
76034170|NCT04402619|Behavioral|Cognitive behavior therapy|"The ten modules cover:~Psychoeducation about sleep, sleep problems, and associations with alcohol~How to keep and use a sleep diary~Sleep hygiene~Sleep compression~Cognitive restructuring~Emotional regulation~Preparing for the future"
75543683|NCT00274209|Procedure|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
75543684|NCT00244907|Dietary Supplement|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
75869735|NCT02948686|Other|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
76034171|NCT04902001|Behavioral|Multidisciplinary weight loss|The adolescents will follow a 12-week intervention combining nutritional education, physical activity 3 times per week and psychological supports.
76034172|NCT04904315|Other|Mindera Kit|The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.
76034173|NCT05124613|Other|Survey|"Information collected and stored in Survey:~Type of knee surgery the patient is waitlisted for~Demographics: age, sex, recent weight gain~Validated and bespoke questions:~EQ-5D survey (a validated questionnaire on health)~Bespoke questions on knee pain today~Bespoke questions on knee function today~Bespoke questions on change in knee pain since being waitlisted for surgery~Bespoke questions on change in knee function since being waitlisted for surgery~Bespoke questions on coping mechanisms patients use to manage symptoms~Bespoke questions on what support they would find beneficial whilst they wait for their surgery~Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)"
76034174|NCT04904393|Device|Implant of the device for Cardiac Contractility Modulation (CCM) Therapy|The intervention is an implant of CCM therapy devices and it is similar to conventional dual chamber cardiac devices with only difference of to insert n 2 leads fixed in right ventricular septum
76034175|NCT04904237|Drug|Aza-Ven-allo-HSCT|aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
75707242|NCT00800163|Other|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
76034176|NCT05136469|Other|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
76034177|NCT05136469|Other|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
76034178|NCT04894487|Behavioral|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABY|Using of baby mobile and listening Brahms Lullaby during sternum dressing process
76034179|NCT05136235|Diagnostic Test|Echocardiography|There will be screened for pulmonary hypertension by means of serial echocardiographies during the study period
76034180|NCT05136235|Diagnostic Test|NT-proBNP|At 36 weeks postmenstrual age there will be screened for pulmonary hypertension by means of an NT-proBNP measurement in a blood sample
75390653|NCT04107935|Behavioral|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
75390654|NCT04105270|Drug|Oral Restorative Microbiota Therapy (RMT) Capsules|Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
75543685|NCT00283569|Other|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
75543686|NCT00274248|Drug|MLN518|
75543687|NCT00244946|Biological|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
75543688|NCT00244946|Drug|carmustine|
75543689|NCT00244946|Drug|cytarabine|
75707243|NCT00731328|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
75390655|NCT04105270|Drug|Durvalumab 1500 mg IV|Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab
75707244|NCT00729170|Dietary Supplement|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
75707245|NCT00871078|Device|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
75543690|NCT00244946|Drug|etoposide|
76034181|NCT04902209|Procedure|postural stability measurements|"Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment"
75390656|NCT04105270|Drug|Cisplatin/pemetrexed or Carboplatin/pemetrexed|Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W
75543691|NCT00244946|Drug|melphalan|
76034182|NCT04894409|Device|Mouthwash and nose rinse with the AgNPs solution|"The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers"
76034183|NCT04894409|Device|Mouthwashes and nose rinse in a conventional way|The control group was instructed to do mouthwashes and nose rinse in a conventional way
76034184|NCT04949113|Drug|Neoadjuvant ipilimumab + nivolumab|2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
76034185|NCT04949113|Drug|Adjuvant nivolumab|Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
75390657|NCT04105270|Other|Placebo|Sixteen doses of oral placebo capsules given weekly
75390658|NCT04100200|Dietary Supplement|Mixed berries|Strawberry and red raspberry
75390659|NCT04100200|Dietary Supplement|FOS|Fructo-oligosaccharide
75390660|NCT04100200|Dietary Supplement|Control|Placebo similar in color to mixed berry supplement without any polyphenols
75390661|NCT04100200|Dietary Supplement|Combination|Mixed berry composite + FOS
75390662|NCT04099472|Behavioral|Delirium Education, Prevention, and Management|"Patients and families will have a choice of either watching a 6-minute video or reading an educational booklet with a competent research assistant on the signs of delirium, risk factors, and prevention and management strategies.~Caregivers will practice identifying delirium with the Sour Seven questionnaire, using previously validated case vignettes of hypothetical ICU patients. Family members will also complete a daily checklist of non-pharmacological interventions (ie. orientation, mobility, and environmental cues).~Delirium detection by family caregivers will be assessed by the Sour Seven Questionnaire and communicated to the bedside nurse."
75543692|NCT00244946|Procedure|peripheral blood stem cell transplantation (PBSCT)|
75543693|NCT00283608|Genetic|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
75543694|NCT00283608|Other|high performance liquid chromatography|analysis of plasma concentrations of drugs
76034186|NCT04901897|Device|kalifilcon A|kalifilcon A daily disposable contact lens
76034187|NCT04901897|Device|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
76034188|NCT04901897|Device|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
76034189|NCT04895371|Other|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
76034190|NCT04895371|Other|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
75390663|NCT04099472|Behavioral|Standard Care|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission.
75390664|NCT04097795|Other|Prehabilitation|According to our definition, prehabilitation consists of exercise therapy during at least 2 weeks. This is combined with optimalisation of the patients' nutritional status at least 2 weeks before surgery.
75543695|NCT00283608|Other|measurements by DXA|determine bone mineral density (BMD)
75543696|NCT00283608|Other|questionnaire administration|determine attitude changes
75543697|NCT00245024|Drug|sulindac|
75543698|NCT00245024|Other|laboratory biomarker analysis|
75543699|NCT00274326|Drug|SR121463B|
75543700|NCT00245141|Biological|dactinomycin|
75543701|NCT00245141|Drug|cyclophosphamide|
75543702|NCT00245141|Drug|vincristine sulfate|
75869736|NCT02948686|Other|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
76034191|NCT05135221|Biological|dual biological therapy|Simultaneous use of two biologicals.
76034192|NCT05135065|Other|Artificial Intelligence-Assisted Supervision Protocol|Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
76034193|NCT04894331|Other|Dietary intervention|"Each patient receives one of 5 dietary plans, different only for energy intake (1400-1600-1800-2000-2100 Kcal/day). The choice depends on the personalized energy needs. The energy requirement is calculated on basal metabolic rate (BMR) of the patient according to Harris & Benedict's and Schofield's formulas.~All dietary plans include foods with low-Ni content. Finally, each patient completes 30-day personalized diet."
76034194|NCT04894331|Other|Video call|Each patient receives a follow-up remote visit through video call 15 and 30 days after the start of the dietary intervention.
76034195|NCT05134909|Device|Customized contact lens|The customized lenses are designed to correct the eye's optical aberrations.
76034196|NCT04893941|Drug|CM310|IL-4Rα monoclonal antibody
76034197|NCT04893941|Drug|Placebo|Placebo
75543703|NCT00245141|Radiation|radiation therapy|
75543704|NCT00245180|Behavioral|Diet|
76034198|NCT05057845|Drug|Tislelizumab|Tislelizumab will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks
76034199|NCT05057845|Drug|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
76034200|NCT05057845|Combination Product|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
75707246|NCT00871078|Device|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
75543705|NCT00245180|Behavioral|Exercise|
75543706|NCT00416637|Biological|Bevacizumab (Avastin)|
75543707|NCT00245258|Drug|Sildenafil Citrate|
75543708|NCT00283725|Other|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor [AChEI] nor memantine).
75543709|NCT02961803|Drug|MD1003 100 mg capsule|
75543710|NCT02961803|Drug|Placebo|
75543711|NCT00274365|Procedure|videoconference|
75543712|NCT00245297|Drug|Kogenate FS, reconstituted in a suspension of liposomes|
75707247|NCT04065594|Procedure|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
76034201|NCT04901585|Procedure|Totally intracorporeal distal gastrectomy|Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
75543713|NCT00274404|Drug|valacyclovir|
75543714|NCT00283764|Drug|Xalatan|
75543715|NCT00245336|Biological|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
75543716|NCT00245336|Drug|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
75543717|NCT00274443|Drug|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
75543718|NCT00245375|Drug|Tylenol #3|
75543719|NCT00245375|Drug|Combination Tylenol and Ibuprofen|
75543720|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 48 weeks
75543721|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 24 weeks
75543722|NCT00274521|Drug|Tiotropium|
75543723|NCT00245453|Drug|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
75707248|NCT04065594|Procedure|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
75707249|NCT00735176|Procedure|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
75707250|NCT00735176|Procedure|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
75543724|NCT00245453|Drug|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
75390665|NCT04084561|Behavioral|HRHA|participants will be asked to consider a hypothetical scenario in which genetic test results reveal that: 1) they carry genotypes that place African American smokers at a particularly high (~50%-80%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly high concordance with African heritage (~90%).
75543725|NCT00245453|Drug|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
75543726|NCT00245492|Procedure|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
75543727|NCT00283920|Drug|[(11)C] PBR28|
75543728|NCT00245609|Drug|Pregabalin|
75390666|NCT04084561|Behavioral|LRLA|participants will be asked to consider a scenario in which genetic test results reveal that: 1) they are at normal (~7%-10%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly low concordance with African heritage (~10%).
75543729|NCT00245609|Drug|Alprazolam|
75543730|NCT00245609|Drug|Placebo|
75707251|NCT00862966|Other|citrate|comparison of different catheter lock solutions
75543731|NCT00283998|Procedure|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
75390667|NCT04084561|Behavioral|HRLA|"participants will receive High Risk, Low Ancestry (HRLA) hypothetical"
75543732|NCT00245648|Drug|fibrinolytic therapy or combination reduced fibrinolytic therapy|
75543733|NCT00245687|Device|Tiger Tube|
75707252|NCT00862966|Other|heparin|comparison of different lock solutions
75707253|NCT02569320|Drug|Dexamethasone|Given PO
75707254|NCT02569320|Drug|HDAC Inhibitor AR-42|Given PO
75543734|NCT00245726|Device|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
75543735|NCT00245726|Device|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
75543736|NCT00245726|Device|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
75543737|NCT00274638|Drug|Telmisartan & Hydrochlorothiazide|
75543738|NCT00274638|Drug|Losartan & Hydrochlorothiazide|
75543739|NCT00274638|Procedure|ABPM|
75707255|NCT02569320|Other|Laboratory Biomarker Analysis|Correlative studies
75707256|NCT02569320|Drug|Pomalidomide|Given PO
75707257|NCT00739466|Drug|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
75707258|NCT00739466|Drug|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
75707259|NCT00739466|Drug|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
75707260|NCT02544178|Radiation|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
75707261|NCT00863044|Procedure|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
76034202|NCT05109949|Drug|Dapagliflozin 10Mg Tab|Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
75390668|NCT04084561|Behavioral|LRHA|"participants will receive Low Risk, High Ancestry (HRLA) hypothetical"
75390669|NCT04073602|Drug|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
75543740|NCT02961569|Procedure|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
75543741|NCT00274677|Drug|Placebo|Experimental treatment arm
75543742|NCT00274677|Drug|lamotrigine|Experimental treatment
75543743|NCT00245843|Behavioral|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
75543744|NCT00284037|Device|continuous positive airway pressure therapy|
75543745|NCT00245882|Behavioral|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
75543746|NCT00245882|Behavioral|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
75543747|NCT00274755|Drug|chemotherapy|
75543748|NCT00274755|Procedure|conventional surgery|
75543749|NCT00274755|Procedure|magnetic resonance imaging|
75543750|NCT00274755|Procedure|magnetic resonance spectroscopic imaging|
75543751|NCT00274755|Radiation|radiation therapy|
75543752|NCT00245921|Drug|Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg|
75543753|NCT00284076|Drug|L-arginine|
75543754|NCT00246038|Device|Boston Scientific ENOVUS AAA Endograft|
75543755|NCT00274794|Biological|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
75543756|NCT00274794|Biological|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
75543757|NCT00246155|Biological|Botulinum toxin type A|
75543758|NCT00284193|Drug|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
75543759|NCT00284193|Drug|FEIBA- Activated Prothrombin Complexes|
75390670|NCT04060355|Behavioral|Savvy program|Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.
75543760|NCT00246194|Drug|risperidone (RISPERDAL CONSTA)|Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
75543761|NCT00284232|Behavioral|Use and interpretation of blood glucose results|
75543762|NCT00284232|Drug|Insulin dosing based on SMBG chart and education|
75543763|NCT00246233|Drug|methylphenidate|
75543764|NCT00274833|Drug|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
75707262|NCT00863044|Procedure|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
75707263|NCT00739544|Other|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
75707264|NCT00735332|Drug|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
75707265|NCT00869908|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75390671|NCT04060355|Behavioral|Semi-structured video interviews|Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
75390672|NCT04060277|Drug|Letermovir|Given as SOC
75543765|NCT00274833|Drug|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
75543766|NCT00274833|Radiation|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
75543767|NCT04709666|Procedure|Endsocopic Retrograde ColangioPancreatography (ERCP)|
75543768|NCT00274872|Drug|fluorouracil|
75543769|NCT00274872|Drug|leucovorin calcium|
75543770|NCT00274872|Drug|oxaliplatin|
75543771|NCT00246272|Drug|risperidone|
75543772|NCT00284271|Drug|Cyclophosphamide|
75543773|NCT00284271|Drug|Adramycin|
75543774|NCT00284271|Drug|Procarbacine|
75543775|NCT00284271|Drug|Prednisone|
75543776|NCT00284271|Drug|Vincristine|
75543777|NCT00284271|Drug|Bleomycin|
75543778|NCT00284271|Drug|Erythropoietin beta|
75707266|NCT00869908|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75707267|NCT00869908|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75543779|NCT00284115|Device|Gait trainer|Mechanical gait repetitive training
75543780|NCT00284115|Device|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
75543781|NCT00246350|Procedure|massage|8 light massage treatments and hot pack
75543782|NCT00246350|Procedure|massage|16 light massage treatments and hot packs
75543783|NCT00246350|Procedure|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
75543784|NCT00246350|Procedure|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
75543785|NCT00246389|Drug|cyclobenzaprine hydrochloride|
75543786|NCT00274911|Drug|cisplatin|
75390673|NCT04060277|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
75543787|NCT00274911|Drug|lomustine|
75543788|NCT00274911|Drug|vincristine sulfate|
75543789|NCT00274911|Procedure|adjuvant therapy|
75543790|NCT00274911|Radiation|radiation therapy|
76034203|NCT05109949|Drug|Empagliflozin 25 MG|Daily morning dose per oral of Empagliflozine 25 mg for 7 days
76034204|NCT05109949|Other|Placebo|Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
76034205|NCT04893473|Device|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.
76034206|NCT04901429|Procedure|Truncal vagotomy|Truncal vagotomy will be performed in 50% of patients during other routine procedure.
75390674|NCT04060277|Other|Placebo Administration|Given IM
75390675|NCT04043520|Drug|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
75543791|NCT00246428|Behavioral|Motivational Interviewing|Experimental manipulations will be evaluated 6, 9, and 12 months
75543792|NCT00284349|Device|Use of a rehabilitation brace instead of a plaster|
75543793|NCT00246467|Biological|Alhydrogel|
75543794|NCT00246467|Biological|rF1 and rV protein antigens|
75543795|NCT00277173|Behavioral|Adoption of Crew Resource Management approach|
75543796|NCT00246506|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
75543797|NCT00246506|Procedure|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
75869739|NCT02904577|Other|Any treatment, watch and wait policy included|"Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes."
75869740|NCT02879409|Drug|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
76034207|NCT04926259|Drug|18F-T807|Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
75390676|NCT04043520|Drug|Estrogen Product|Estrogen patches will be worn by those randomized to the Estradiol arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
75390677|NCT04043520|Drug|Placebo estradiol|Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
75543798|NCT00246545|Behavioral|exercise|
76034208|NCT04901663|Drug|Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG|Orally twice daily for 2 weeks
76034209|NCT04901663|Drug|Vonoprazan 20 MG; Amoxicillin 1000 MG|Orally twice daily for 2 weeks
75543799|NCT00277251|Drug|Alendronate|
75543800|NCT00246584|Drug|SPP100|
75543801|NCT00416676|Drug|carboplatin|
75543802|NCT00416676|Drug|cisplatin|
75543803|NCT00416676|Drug|cyclophosphamide|
75543804|NCT00416676|Drug|etoposide|
75390678|NCT04043520|Drug|Placebo GnRH antagonist|Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
76034210|NCT05134597|Genetic|Genetic assessment|Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.
76034211|NCT05134519|Drug|Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)|Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles
76034212|NCT04394663|Drug|High-dose oral omeprazole|Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.
75707268|NCT00734058|Device|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
76034213|NCT04394663|Drug|Standard IV PPI|Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
76034214|NCT05133193|Drug|three kinds of antibiotics|All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
76034215|NCT04901117|Drug|Amoxicillin|Use according to the drug combination options selected by each center.
76034216|NCT04901117|Drug|Clarithromycin|Use according to the drug combination options selected by each center.
76034217|NCT04901117|Drug|Tetracycline|Use according to the drug combination options selected by each center.
76034218|NCT04901117|Drug|Metronidazole|Use according to the drug combination options selected by each center.
76034219|NCT04901117|Drug|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
76034220|NCT04901117|Drug|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
75390679|NCT04038294|Dietary Supplement|ISOlution protein supplement|EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
75390680|NCT04038294|Dietary Supplement|Placebo Supplement|PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
75390681|NCT04034056|Drug|Obinutuzumab|Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
75390682|NCT04028687|Device|Taperloc Complete Stem|Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
75390683|NCT04004494|Other|3D reconstruction|3-dimensional computed tomography reconstruction guided VATS segmentectomy
75543805|NCT00416676|Drug|vincristine sulfate|
75707269|NCT00739622|Drug|TMC278|
75707270|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
76034221|NCT04901117|Drug|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
76034222|NCT05121571|Procedure|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
76034223|NCT05121571|Drug|Sorafenib|sorafenib 400mg bid
76034224|NCT03051269|Drug|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
76034225|NCT03051269|Device|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
76034226|NCT05088733|Drug|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
76034227|NCT05088733|Other|Routine medical care|Routine medical care
76034228|NCT04924777|Other|Brisk Walk|1-Brisk walk for 30 minutes 2-5 days a week 3-3months
76034229|NCT04924777|Other|Strength training|1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
76034230|NCT04924777|Other|Aerobic Exercises|1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
76034231|NCT04861285|Device|RACESTYPTINE Solution with cord|The dentist inserts a non-medicated gingival retraction cord into the sulcus and then impregnates the cord in situ with a few drops of RACESTYPTINE Solution. The impregnated cord is left in place a few minutes and then removed. The gingival sulcus is washed and gently air-dried before taking impression.
75707271|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
75707272|NCT00870064|Procedure|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
75390684|NCT04003311|Device|Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
75707273|NCT00870064|Procedure|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
75390685|NCT04003311|Device|Comprehensive Anatomic Versa-Dial Titanium Humeral Head|Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.
75390686|NCT03981055|Device|Active Comparator: Active tDCS and Active TUS|"Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
75543806|NCT00416676|Procedure|adjuvant therapy|
75543807|NCT00416676|Procedure|conventional surgery|
75543808|NCT00416676|Procedure|neoadjuvant therapy|
75707274|NCT00734136|Procedure|Blood Draws and a hepatectomy specimen|"Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).~Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.~Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)"
75707275|NCT00734136|Procedure|Blood draw - pre operative standard of care|Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
75543809|NCT00416676|Radiation|radiation therapy|
75543810|NCT00284388|Procedure|Simultaneous controlled power measurement|
75543811|NCT00284388|Procedure|Surface EMG measurement|
75707276|NCT00739778|Other|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
75543812|NCT00246623|Drug|Exubera (inhaled insulin)|
75707277|NCT00739778|Other|food vehicle blank|water blank
75707278|NCT00739778|Other|food - sweetener, positive control|4.7% sucrose in water
75707279|NCT00739778|Other|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
75707280|NCT00731718|Device|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
75543813|NCT00246623|Procedure|8-point glucose diary (to assess pre- and post prandial glucoses)|
75543814|NCT00246623|Procedure|Meal Tolerance Test|
75707281|NCT04695392|Other|R2 Bundle|"During the intervention phase subjects will receive R2.~Focused effort to replicate the child's pre-hospitalization daily routine (bedtime/wake time, bedtime/arousal routine, nap time, feeding schedule, active periods),~Cycled day-night lighting and modulation of sound to match the child's routine,~Minimal yet effective sedation using a nurse-implemented goal-directed sedation plan (RESTORE),~Night fasting with bolus enteral daytime feedings,~Early, developmentally-appropriate, progressive exercise and mobility (PICU Up!),~Continuity in nursing care, and~Parent diaries."
75707282|NCT00870142|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
75707283|NCT00870142|Drug|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
75707284|NCT00731796|Device|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
76034232|NCT04861285|Device|RACEGEL with cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth, and then inserts a non-medicated gingival retraction cord into the sulcus. The impregnated cord is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
76034233|NCT04861285|Device|RACEGEL without cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth. The gel is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
75707285|NCT00870220|Drug|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
75707286|NCT00735410|Biological|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
75707287|NCT00729768|Drug|basiliximab|2 intravenous doses
75707288|NCT00729768|Drug|efalizumab|Subcutaneous repeating dose
75707289|NCT00729768|Drug|mycophenolate mofetil|Oral repeating dose
75707290|NCT00729768|Drug|corticosteroids|Repeating doses
75707291|NCT00729768|Drug|cyclosporine|Oral repeating dose
76034234|NCT04725955|Other|Enriched wheat bread|Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).
75543815|NCT00246623|Procedure|24-hour continuous glucose monitoring (at select sites)|
75543816|NCT00246623|Procedure|Pulmonary Function Testing|
75543817|NCT00246623|Procedure|Hypoglycemic Event Monitoring|
75543818|NCT00246623|Procedure|Laboratory Assessments|
75543819|NCT00246623|Behavioral|Nutritional Counseling and Diabetes Education|
75543820|NCT00284427|Drug|vitamin C|IV Vitamin C given 2-3 times a week
75390687|NCT03981055|Device|Sham Comparator: Sham TDCS and Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
75390688|NCT03981055|Other|Physical Therapy|All subjects will enroll in a conventional PT balance and gait focused training program, and will receive PT 3x/week over the two weeks of stimulation for 45 minutes following the stimulation sessions when applicable. (And during the biweekly sessions for Phase II)
75390689|NCT03943537|Drug|Intranasal Insulin|40 units Novolin R administered intranasally using ViaNase device.
76034235|NCT04674007|Other|3D analysis of landing task|Landing tasks (anticipated, unanticipated and cognitive dual task) are investigated with 3D analysis by using an opto-electronic system
75543821|NCT00246662|Drug|Vosaroxin|All patients receive vosaroxin Injection
75707292|NCT00739856|Procedure|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
76034236|NCT05005585|Procedure|immediate implant|immediate implant placement with VST technique versus early implant placement with contour augmentation technique
75390690|NCT03935256|Drug|Carboplatin and Paclitaxel|Regimen I: Carboplatin AUC 6 & Paclitaxel 175mg/m2 given intravenously for 4 cycles during weeks 1, 10, 13, 16 Regimen II: Carboplatin AUC 2 & Paclitaxel 45mg/m2 given intravenously for 2 cycles during weeks 4 & 7 concurrent with radiotherapy
76034237|NCT04646239|Diagnostic Test|Heterologous stimuli|In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli
76034238|NCT04646239|Diagnostic Test|Neutralization assay|In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2
75390691|NCT03935256|Radiation|Radiation Therapy|"An external beam radiation dose of 45 Gy in 25 fractions is routinely prescribed to the Planning Target Volume (PTV) for postoperative radiotherapy.~The Vaginal Brachytherapy (VBT) Boost will be delivered after the external beam radiation. Doses of 12-18 Gy in 2-3 fractions are often prescribed to the surface of the vagina to a treatment length of 3-5 cm. There is no standard dose or fractionation schedule, so this dose, fractionation, location of dose specification , and length of vagina treated will be individualized for the patient and will be at the discretion of the treating radiation oncologist."
75543822|NCT00277290|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
75543823|NCT00246701|Drug|Simvastatin|Simvastatin
75543824|NCT00246701|Drug|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
75543825|NCT00284466|Procedure|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
75543826|NCT00246779|Procedure|Modified ultrafiltration|
75543827|NCT00277329|Drug|XL999|• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
75543828|NCT00246818|Procedure|Tai Chi Chuan|
75543829|NCT00277368|Other|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
75869741|NCT02879409|Drug|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
75869742|NCT02879409|Drug|Sitagliptin|Oral: 100 mg once daily
75390692|NCT03930914|Device|Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device|Daily use of Parasym (TM) device on tragus or ear lobe, as assigned treatment arm
75390693|NCT03928717|Behavioral|Text-Based Adherence Game|A mobile health intervention facilitated by a cloud-hosted web application and designed to promote adherence to HIV care through text message-delivered gamification strategies including peer comparison, point reinforcement, feedback on adherence outcomes, facilitation of social support, and use of an engaging and culturally-relevant story-line.
75543830|NCT00246896|Behavioral|care management|
75543831|NCT00284505|Drug|thalidomide|
75543832|NCT00246935|Drug|Roflumilast|
75390694|NCT03928717|Behavioral|Standard of Care (SOC)|A 10- to 20-minute in-person intervention led by a trained HIV treatment adherence counselor focused on providing basic knowledge of HIV and HIV treatment, motivating participants to engage in HIV treatment, and problem-solving barriers to adherence.
75390695|NCT03923491|Behavioral|Healthy Feeding, Healthy Eating|Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
75390696|NCT03923491|Behavioral|Reading Readiness|Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
75390697|NCT03923426|Other|Zavicefta Treatment|Non-interventional - Retrospective Chart Review
75390698|NCT03896152|Drug|LNP023|approximately 2 year of Treatment with LNP023
75390699|NCT03876951|Diagnostic Test|Vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery.
75543833|NCT00277407|Procedure|NAET with acupressure and/or chiropractic procedures|
75543834|NCT00246974|Drug|Gemcitabine|intravenous
75543835|NCT00246974|Drug|Cisplatin|intravenous
75707293|NCT00734370|Behavioral|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~Psycho-education, breathing training and cognitive restructuring~Virtual reality Exposure to agoraphobic situations and interoceptive exposure~Relapse prevention"
75869743|NCT02879409|Drug|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
75543836|NCT00246974|Drug|Gefitinib|oral
75543837|NCT00284583|Drug|Injection of Steroid into Foot|
75543838|NCT00284583|Drug|Injection of Alcohol into Foot|
75543839|NCT00284583|Drug|Injection of Lidocaine into Foot|
75869744|NCT02879409|Drug|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
75869745|NCT02879409|Drug|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
75543840|NCT00247013|Behavioral|Breast Cancer Screening Compliance|
76034239|NCT04934527|Drug|Cytotect|"The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12."
76034240|NCT05288647|Procedure|TMJ injection|four sodium hyaluronate injections in superior TMJ space
75869746|NCT02879409|Drug|human insulin|insulin dosage and administration according to physician
76034241|NCT05287009|Procedure|ILM nonpeeling|ILM is not peeled after ERM removal
76034242|NCT05287009|Procedure|ILM peeling|ILM is peeled after ERM removal
76034243|NCT04584619|Device|Spine fusion surgery with Clariance Idys TLIF 3DTi|Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).
76034244|NCT04576663|Drug|Normal saline|Normal saline infusion simultaneous with subarachnoid block
75390700|NCT03875963|Other|Antibiotic loaded bone filler|Defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin].
76034245|NCT04576663|Drug|Phenylephrine|Different infusion dose of phenylephrine simultaneous with subarachnoid block
76034246|NCT04789369|Behavioral|Questionnaires|Assessing the behavioral metrics (quality of life, functionality and fear of movement) with appropriate measurement tools
76034247|NCT04905199|Procedure|Temporary transvenous cardiac pacing|Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
75390701|NCT03863288|Procedure|Functional MRI (fMRI)|Functional MRI (fMRI) scan with affective/cognitive tasks
75390702|NCT03863288|Drug|Oxytocin Intranasal Spray 8 International Unit (8IU)|Oxytocin intranasal spray liquid administration
76034248|NCT04763005|Behavioral|HIIT exercise intervention|The exercise intervention will be eight weeks of high-intensity interval training (HIIT) started by one warm-up week with an intensity of 75% maximum heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and with a total duration of 45 minutes per session: warm-up for 10 minutes at 60-70% HRmax followed by a high-intensity interval consisting of 4x4 minutes at 80-90% HRmax with 3 minutes of active recovery at 60-70% HRmax and a 10 minutes cool-down at 60-70% HRmax. HR will be monitored during training by Polar® H7 heart rate sensors combined with Polar® M400 watches.
75390703|NCT03863288|Drug|Oxytocin intranasal spray 24 International Unit (24IU)|Oxytocin intranasal spray liquid administration
75390704|NCT03863288|Drug|Oxytocin intranasal spray 48 International Unit (48IU)|Oxytocin intranasal spray liquid administration
75390705|NCT03863288|Drug|Oxytocin intranasal spray 80 International Unit (80IU)|Oxytocin intranasal spray liquid administration
75390706|NCT03863288|Drug|Placebo|Placebo intranasal spray liquid administration
75390707|NCT03837353|Drug|DKN-01|DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.
75390708|NCT03837353|Drug|Docetaxel|Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
75390709|NCT03832010|Drug|Crisaborole|Participants will be instructed to apply crisaborole to affected areas with eczema.
75390710|NCT03832010|Drug|Hydrocortisone Ointment|Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
75390711|NCT03832010|Drug|Triamcinolone ointment|Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.
75390712|NCT03832010|Drug|Aquaphor|Participants will be instructed to moisturize all over the body with Aquaphor.
75543841|NCT00277563|Device|reduction of pain scores by magnetic energy|
75543842|NCT00247052|Drug|diclofenac|diclofenac 50 mg bid versus placebo bid
75543843|NCT00247052|Drug|diclofenac|diclofenac 100 mg per day for 14 days
75869747|NCT02840149|Drug|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
75390713|NCT03825835|Drug|30% oxygen group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
75543844|NCT00247052|Drug|matching placebo|
75543845|NCT00284622|Procedure|Arthroscopy|HTO with pre-scope
75543846|NCT00247091|Biological|standard-titer measles vaccine|
75543847|NCT00277602|Drug|Riluzole|
76034249|NCT04763005|Behavioral|Physical activity recommendations|The control group will get physical activity recommendations based on actual guidelines from the European Association of Preventive Cardiology.
75390714|NCT03825835|Drug|60% oxygen group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
75543848|NCT00277641|Drug|Lamotrigine|25 mg or 100 mg
75543849|NCT00277641|Drug|placebo|identical tablets to study drug
75543850|NCT00284661|Procedure|FAST FIX|Fast fix repair of a meniscal tear
75707294|NCT00734370|Behavioral|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~Psycho-education, breathing training and cognitive restructuring~Standard exposure in vivo to agoraphobic situations and interoceptive exposure~Relapse prevention (according to the protocol of Craske & Barlow)"
75707295|NCT00871156|Drug|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
76034250|NCT05281549|Drug|Alteplase|Alteplase 0.9mg/kg are being used.
76034251|NCT05281549|Drug|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
75390715|NCT03812393|Drug|Neratinib|For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.
75543851|NCT00284661|Procedure|Meniscal suturing|standard suturing of meniscal tear
75543852|NCT00247130|Drug|Omeprazole|
75707296|NCT00871156|Drug|Placebo|Placebo
75707297|NCT00734448|Dietary Supplement|myo-inositol|2 g twice a day until delivery
75707298|NCT00735488|Other|Observational|Summary of data
75707299|NCT04039906|Device|Removal of needle with using ANDYs|"ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~Identify the number of syringes processed by ANDY.~After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary."
75707300|NCT02128152|Device|Ekso exoskeleton|
76034252|NCT05281549|Drug|Tenecteplase|Tenecteplase 0.4mg/kg are being used.
76034253|NCT05276479|Other|Anonymous online survey on dietary habits and mental health|Assessment of regular feeding behavior and mental health
75543853|NCT00247130|Drug|Ranitidine|
75543854|NCT00277680|Procedure|Laparoscopic bilateral occlusion of uterine artery|
76034254|NCT04284475|Diagnostic Test|Quadriceps strength|Using a handheld dynamometer, in supine position in a standardized position of the dominant leg Measurement of the maximal isometric voluntary quadriceps contraction Measure expressed as Newton and Newton/kg
76034255|NCT04284475|Diagnostic Test|Grip strength|Testing of dominant hand using a handgrip Measurement of the maximal isometric voluntary grip contraction Measure is expressed as kg
76034256|NCT04284475|Diagnostic Test|ICU mobility scale|Scoring the physical capacity of the patient on a 10-points validated scale: the ICU mobility scale
76034257|NCT05255809|Other|Alexander Technique + Routine Physical Therapy|Verbal Instructions in Trunk stabilizing exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
76034258|NCT05255809|Other|Routine Physical Therapy|Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
75543855|NCT00277680|Procedure|Radiological embolization (UFE)|
75543856|NCT00247169|Drug|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
75543857|NCT00247208|Device|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
75390716|NCT03806439|Other|Radical cystectomy.|Adult patients undergoing radical cystectomy.
75390717|NCT03806413|Other|Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
75543858|NCT00247208|Device|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
75543859|NCT00284778|Drug|Alimta®|
75707301|NCT04064372|Behavioral|Mindful response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
75707302|NCT04064372|Behavioral|Strengths-based response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
76034259|NCT05239351|Device|Jalucomplex|Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
76034260|NCT05230147|Procedure|Spinal cord stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.
76034261|NCT05230147|Procedure|Sham stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
76034262|NCT04227301|Other|blood sampling|blood sampling for measurement of bone markers after a fasting period of at least 6 hours
76034263|NCT05214547|Device|Radial Extracorporeal Shock-wave Therapy|Radial Extracorporeal Shock Wave Therapy, also called radial pulse therapy. In contrast to regular focused shock wave therapy,Radial Extracorporeal Shock Wave Therapy creates a diverging pressure field, which reaches a maximal pressure already at the source, and therefore has a more superficial, but broader, effect than focused shock wave therapy. This treatment is increasingly used for calcific and non-calcific tendinopathy, probably because it is easier to apply and more affordable than focused shock wave therapy. The proposed mechanisms for the effect of Radial Extracorporeal Shock Wave Therapy include pain relief, tissue regeneration and destruction of calcification.
76034264|NCT03965611|Procedure|Oropharyngeal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
75390720|NCT03794583|Drug|Inhaled treprostinil solution|Inhaled treprostinil solution per dose and schedule specified in the arm
75390721|NCT03781011|Behavioral|Vegetarian diet intervention|Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.
75390722|NCT03774732|Radiation|Radiotherapy|Irradiation technique (3D-CRT or SABR) will be at physician discretion.
75390723|NCT03774732|Drug|Pembrolizumab|pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity
75543860|NCT00284778|Drug|Taxotere®|
75543861|NCT00247247|Drug|Comtess®|
75543862|NCT00277758|Biological|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
75543863|NCT00277758|Drug|Ribavirin|Ribavirin @ 800 mg daily (< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (> 85 kg)
75543864|NCT00277758|Biological|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
75543865|NCT00277758|Biological|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
75707303|NCT00734526|Drug|Temozolomide|"Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
75707304|NCT00734526|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
75707305|NCT00734526|Drug|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
75707306|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
75390724|NCT03774732|Drug|Chemotherapy|for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
75390725|NCT03759379|Drug|Patisiran|Patisiran will be administered by IV infusion.
75390726|NCT03759379|Drug|Vutrisiran|Vutrisiran will be administered by SC injection.
75390727|NCT03759366|Drug|Eculizumab|Eculizumab will be administered by IV infusion.
75390728|NCT03741374|Procedure|Minimally-invasive non-surgical therapy (MINST)|A non-surgical minimally-invasive treatment protocol, named MINST, has been proposed (Ribeiro et al. 2011) for the treatment of periodontitis, in order to minimise patient discomfort and maximise the healing potential. This technique usually involve the use of magnification lenses or microscopes and small instruments which would reduce the risk of tissue trauma compared with traditional instruments.
75390729|NCT03740997|Drug|Optison|Optison is administered intravenously
75390730|NCT03738904|Combination Product|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
75543866|NCT00277758|Drug|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight <65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight >85 kg.
75543867|NCT00247286|Behavioral|weighted vaginal cones|
75543868|NCT00247286|Behavioral|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
75543869|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
75390731|NCT03738904|Combination Product|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
75390732|NCT03725059|Biological|Pembrolizumab (K)|IV infusion Q3W
75390733|NCT03725059|Drug|Placebo (P)|Normal saline or dextrose IV infusion Q3W
75543870|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
75707307|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
75390734|NCT03725059|Drug|Paclitaxel (X)|IV infusion QW
75390735|NCT03725059|Drug|Doxorubicin (A)|IV infusion either in Q2W or Q3W
75390736|NCT03725059|Drug|Epirubicin (E)|IV infusion either in Q2W or Q3W
75390737|NCT03725059|Drug|Cyclophosphamide (C)|IV infusion either in Q2W or Q3W
75390738|NCT03725059|Drug|Endocrine therapy|Variable endocrine therapy for up 10 years
75707308|NCT00876304|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
75390739|NCT03725059|Radiation|Radiation therapy|Variable radiation therapy per local standard of care
75543871|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
75543872|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
75543873|NCT00284817|Drug|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
75543874|NCT00247325|Drug|Iodixanol(Drug)|
75707309|NCT00876304|Drug|Placebo|Placebo capsules every 12 hours for 10 days
75390740|NCT03725059|Procedure|Surgery|Surgery for breast cancer
75390741|NCT03705676|Behavioral|Rapid Arm Movements|240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
75543875|NCT00277797|Device|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
75543876|NCT00277797|Device|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
75707310|NCT00735722|Device|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
75707311|NCT00731952|Drug|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
75707312|NCT04065932|Drug|BMS-986165-01|Participants will receive BMS- 986165 -01 in prototype formulation
75707313|NCT04065932|Drug|BMS-986165 Tablet|Participants will receive BMS-986165 in tablet form.
75390742|NCT03705676|Device|Unpleasant stimulus|An unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization).
75390743|NCT03705676|Device|Vibrotactile stimulus|In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
75390744|NCT03695237|Drug|Leuprolide Acetate (LA)|Administered intramuscularly as an injection
75390745|NCT03665597|Biological|Pembrolizumab Dose C|SC injection
75390746|NCT03665597|Biological|Pembrolizumab Dose A|SC injection
75390747|NCT03665597|Biological|Pembrolizumab Dose B|IV infusion
75390748|NCT03665597|Biological|Pembrolizumab Dose D|IV infusion once every 6 weeks
75390749|NCT03654573|Device|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
75390750|NCT03633708|Drug|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
75390751|NCT03631693|Procedure|Simplified papilla preservation flap|The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
75390752|NCT03631693|Procedure|Resective periodontal flap with osseous recontouring|The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
75390753|NCT03607656|Drug|Oxaliplatin|Oxaliplatin powder injection
75390754|NCT03607656|Drug|Capecitabine|Capecitabine tablet
75390755|NCT03607656|Other|TCM|TCM decoction orally taken twice a day for at least 3 months
75390756|NCT03607656|Drug|S-1|S-1 capsule
75543877|NCT00247364|Drug|Levetiracetam (Keppra)|
75543878|NCT00247403|Drug|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
75543879|NCT00277836|Drug|MST-997|
75543880|NCT00247442|Behavioral|Decision aid|
75543881|NCT00277875|Drug|ALT-711 (alagebrium chloride)|
75707314|NCT04065932|Drug|Famotidine|Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
75543882|NCT00424814|Drug|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
75543883|NCT00424814|Drug|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
75543884|NCT00284973|Biological|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
75543885|NCT00247481|Drug|Gefitinib|
75543886|NCT00247481|Drug|Docetaxel|
76034265|NCT03965611|Procedure|Rectal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
75543887|NCT00277914|Drug|Flibanserin|flibanserin flexible dosing
75543888|NCT00247520|Drug|topical nasal rEV131|
76034266|NCT03965611|Procedure|Disability rating scale (DRS-F)|Will be assessed at day 90 +/- 7 days.
76034267|NCT05191225|Drug|RiTUXimab Injection [Truxima]|375 (mg/m2) / 60 minutes
76034268|NCT05191225|Drug|RiTUXimab Injection [Truxima]|375 (mg/m2) / 30 minutes
76034269|NCT05187325|Other|no intervention|there is no intervention
76034270|NCT05185921|Behavioral|Trial-based Cognitive therapy|The virtual CBT will be provided by 02 psychotherapists, who will follow a protocol developed for this study. The number of sessions will be eight, which will be held weekly, projecting an intervention time of 2 to 3 months considering the possibility of rescheduling any of the sessions for reasons derived from the participant People with relevant cognitive impairment that prevents them from answering the questionnaire questions or providing informed consent are excluded.
75390757|NCT03607656|Drug|Docetaxel|Docetaxel injection
75390758|NCT03607656|Drug|5-FU|5-FU injection
75390759|NCT03603600|Device|enVista MX60E|enVista MX60E monofocal IOL
75390760|NCT03603600|Device|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
75390761|NCT03586609|Drug|Azacitidine|Given SC or IV
75390762|NCT03586609|Drug|Cladribine|Given IV
75390763|NCT03586609|Drug|Cytarabine|Given SC
75390764|NCT03586609|Drug|Venetoclax|Given PO
75390765|NCT03584815|Procedure|Surgery/Fasciotomy|Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks
75390766|NCT03584815|Other|Physiotherapy|Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
75390767|NCT03584373|Drug|Ketorolac Oral Tablet [Toradol]|Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
75390768|NCT03584373|Drug|Acetaminophen|Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
75390769|NCT03584373|Drug|Oxycodone Acetaminophen|Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
75390770|NCT03582124|Procedure|Near-Infrared Fluorescence Imaging|Undergo imaging
75390771|NCT03582124|Drug|Panitumumab-IRDye800|Given IV
75543889|NCT04719039|Behavioral|Restorative Yoga Internvention|Participants in the intervention group will receive links to two 60-min videos per week for 8 consecutive weeks. Each video will include a yoga practice guided by a certified yoga instructor. The intervention group is required to perform the yoga practice at least two times per week. If preferred, they can do additional sessions with the videos and record their total hours of self-practice.
76034271|NCT03914833|Other|Inclusion Questionnaires|During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
76034272|NCT03914833|Other|Questionnaires at inclusion, M1 and M3|During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
75390772|NCT03582124|Other|Pharmacokinetic Study|Correlative studies
75390773|NCT03582124|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75390774|NCT03576391|Behavioral|Control condition|45 minute rest while seated. Watching an animated movie, sleeping was not allowed.
75390775|NCT03576391|Behavioral|Rapid Arm Movements|2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
75390776|NCT03576391|Behavioral|Physical fatigue condition|40 minutes rest while seated followed by static endurance tasks, i.e. modified Biering-Sörensen task and static abdominal curl task.
75390777|NCT03576391|Behavioral|Cognitive fatigue condition|45 minutes of a cognitively fatiguing condition consisting of a modified incongruent Stroop color-word task.
75390778|NCT03570333|Diagnostic Test|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
75390779|NCT03569839|Drug|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
75390780|NCT03558789|Biological|bovine lactoferrin|mouthwash
75543890|NCT00247559|Biological|Botulinum toxin type A|
75390781|NCT03545490|Dietary Supplement|Early nutritional intervention|Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
76034273|NCT03909217|Procedure|TECAS Procedure|"Location:~Cranial electrical stimulation acupoints: Baihui (DU20) and Yintang (DU29).~Auricular electrical stimulation zone: the distribution area of auricular branch of the vagus nerve.~Two electrodes electric stimulation at a frequency of 4/20 Hz will be employed on the cranial acupoints and the auricular zone respectively. The TECAS treatment will consistent of two sessions per day (30 minutes) for 8 consecutive weeks."
76034274|NCT03909217|Drug|Escitalopram|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
75390782|NCT03527589|Device|Prostate artery embolization|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.
75390783|NCT03523858|Drug|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
75390784|NCT03479567|Other|Gait accelerometry|accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)
75390785|NCT03479567|Other|balance accelerometry|accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
75390786|NCT03479567|Other|Fine motor skill test|assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
75390787|NCT03479567|Diagnostic Test|Paratonia Assessment Instrument (PAI)|diagnosis of paratonia based on passive movement of the four limbs
75390788|NCT03479567|Other|myotonometric measurement of muscle tone|MyotonPRO measurement of muscle tone
75707315|NCT06147674|Device|VQm Pulmonary Health Monitor™|"The VQm Pulmonary Health Monitor™ (may be referred to as the VQm PHM™) is a a Class IIa, Health Canada approved medical device used as an adjunct monitor and is non-life supporting, providing clinicians with measurements of pulmonary function parameters of mechanically ventilated adult patients. The measurements provided are:~Pulmonary Blood Flow (PBF)~Shunt Fraction (Qsi)~Dead space (VD):~Functional Residual Capacity (FRC)"
75707316|NCT06147648|Drug|Tacrolimus Sustained-release Capsules|Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
75707317|NCT06147635|Dietary Supplement|Micro-encapsulated granules of tributyrin (intervention)|Three times daily 4 grams of micro-encapsulated granules of tributyrin, for a maximum of 14 days
76034275|NCT03909217|Drug|Insomnia medication|For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
76034276|NCT04914533|Device|Luminance RED Low Level Laser Therapy Device|Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
75390789|NCT03463473|Drug|3 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 3 mg/kg (Q3W)
75390790|NCT03463473|Drug|10 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q3W)
75390791|NCT03463473|Drug|20 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 20 mg/kg (Q3W)
75390792|NCT03463473|Drug|10 mg/kg Q2W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q2W)
75390793|NCT03453567|Procedure|Valve Replacement|Aortic valve replacement
75543891|NCT00285051|Drug|inhaled delta-8-THC 300mcg or 600mcg per dose|"drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC"
75543892|NCT02961725|Biological|UCMSC|UCMSC: umbilical cord mesenchymal stem cells 3-5*10^7/5 ml
75543893|NCT00247715|Drug|algeldrate/magnesium oxide|
75543894|NCT00247715|Drug|ranitidine|
75869748|NCT02754037|Radiation|Fluorodeoxyglucose (FDG) positron emission tomography (PET)|This imaging method uses radiotracers for functional analysis of liver inflammation. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
75390794|NCT03449498|Other|Qualitative functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Six functional activities focusing on lower limbs and trunk are performed: walking, stair climbing, balance, transfers, trunk control, and Wii (combination of functional activities in sitting and/or standing). A group of clinical experts composes a set of exercises for each of these activities, however individual adaptations according to the needs and abilities of the child can be still be done. Quality of movement (alignment, weightshift, dissociation, coordination and stability) is hereby very important. The theme 'circus' is used to enhance the motivation of the children.
75390795|NCT03449498|Other|Functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Goals are set with the parents and the children. During the camp children work on obtaining these goals in a exclusively functional way.
75543895|NCT00247715|Drug|pantoprazole|
75543896|NCT00247754|Behavioral|Cognitive Behaviour Treatment|
75869749|NCT02754037|Other|Magnetic resonance imaging (MRI)|Novel non-invasive MRI based tools to assess liver fat and fibrosis. Potential risks include a sensation of claustrophobia. No contrast dye is used and thus no risk of contrast allergy. Inflammation of the liver may be assessed by MRI software after processing of images and does not require additional patient involvement or change in MRI protocol.
75707318|NCT06147635|Dietary Supplement|Micro-encapsulated granules of sunflower oil (placebo)|Three times daily 4 grams of micro-encapsulated granules of sunflower oil, for a maximum of 14 days
75707320|NCT06147570|Drug|HS-10365 capsules|HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.
75390799|NCT03439345|Drug|Fenofibrate 145 mg|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
75390800|NCT03439345|Drug|Placebo Oral Tablet|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
75390801|NCT03409718|Device|Biomet Comprehensive Shoulder System|Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform
75390802|NCT03404778|Device|Biomet Comprehensive Reverse Shoulder|Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
75707321|NCT06147557|Procedure|Heat therapy|14 heat sessions, during each session subjects were fully immersed in a 45°C water bath for 5 minutes.
75390803|NCT03386929|Drug|Avelumab|A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
75390804|NCT03386929|Drug|Axitinib|A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
75543897|NCT00285090|Dietary Supplement|Calcium, Vitamin D|
75543898|NCT00285090|Dietary Supplement|Calcium,Vitamin D|
75543899|NCT00285090|Dietary Supplement|Calcium, VitaminD|
75543900|NCT00285090|Other|Sugar Pill|
75543901|NCT00247793|Drug|Oral Impact (preoperative enteral nutritional supplement)|
75543902|NCT00417222|Drug|olmesartan medoxomil|5 to 40mg P.O. daily until the end of the study
75543903|NCT00247832|Behavioral|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
75707322|NCT06147544|Drug|PB-718|Administered subcutaneously once a week
75390805|NCT03386929|Drug|Palbociclib|A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
75390806|NCT03358303|Device|Medly|Medly will enable patients with HF to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
75543904|NCT00247832|Behavioral|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
75543905|NCT00278070|Drug|vinorelbine oral formulation|Patients will take three times a week [Monday, Wednesday and Friday] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
75543906|NCT00417261|Drug|ATF936|
75543907|NCT00417261|Drug|AXT914|
75543908|NCT00424983|Drug|Zoledronic acid|
75707323|NCT06147544|Drug|Placebo|Administered subcutaneously once a week
75390807|NCT03340454|Other|Test-and-treat EHR-CHW intervention|a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies
75390808|NCT03340454|Other|Usual care of EHR-only intervention|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability.
75390809|NCT03335839|Drug|tissue plasminogen activator|Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
75390810|NCT03335839|Other|Saline|Placebo
75390811|NCT03318640|Behavioral|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
75390812|NCT03246802|Radiation|HDR partial prostate brachytherapy|temporary radioactive implant
75390813|NCT03245658|Drug|THC and CBD Mixture|Individually titrated doses on daily basis
75543909|NCT00247910|Drug|Hydrochlorothiazide|Not recorded in detailed description.
75543910|NCT00278187|Biological|volociximab|
75543911|NCT00278187|Drug|erlotinib hydrochloride|
75543912|NCT04718610|Other|Osteopathic intervention|Nerve vagus stimulation
75543913|NCT04718610|Biological|CRP assessment|Blood CRP will be assessed during trial
75543914|NCT04718610|Behavioral|QLQ-C30 questionnaire|Completion of QLQ-C30
75543915|NCT00247988|Drug|Weekly Taxotere with weekly carboplatin|
75543916|NCT00425022|Procedure|thoracoscopy|
75543917|NCT00248066|Drug|RESTEN-MP|
75543918|NCT00285129|Device|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
75390814|NCT03241134|Other|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
75390815|NCT03241134|Other|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
75390816|NCT03236129|Procedure|T-reg depleted DLI|The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
75390817|NCT03236129|Procedure|Standard DLI|The patients in this arm benefit of a standard DLI.
75390818|NCT03223220|Drug|Ketamine|IV infusion
75390819|NCT03223220|Other|Normal Saline|IV infusion
75390820|NCT03223220|Drug|Midazolam injection|Injection
75390821|NCT03194256|Behavioral|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
75390822|NCT03148327|Drug|Durvalumab (MEDI 4736)|Early studies has shown to possibly reduce the growth of certain types of lung cancer
75390823|NCT03148327|Radiation|Radiotherapy|Stereotactic Body Radiation Therapy (SABR)
75390824|NCT03143322|Radiation|SBRT|SBRT will be added to systemic (standard) treatment of bone metastases.
75390825|NCT03133559|Other|Observational|We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.
75390826|NCT03133377|Behavioral|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
75390827|NCT03084146|Other|12-week elimination diet|individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
75390828|NCT03052634|Drug|RC48-ADC 1.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
75543919|NCT00248105|Behavioral|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
75543920|NCT00278226|Behavioral|smoking cessation intervention|
75543921|NCT00278226|Other|educational intervention|
75543922|NCT00248144|Drug|Famciclovir|
75543923|NCT00278265|Drug|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
75543924|NCT00248183|Drug|PRX-00023|
75543925|NCT00278304|Radiation|brachytherapy|
75543926|NCT00278304|Radiation|radiation therapy|
75543927|NCT00248222|Behavioral|Supervised aerobic training|
75390829|NCT03052634|Drug|RC48-ADC 2.0 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
75390830|NCT03052634|Drug|RC48-ADC 2.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
75390831|NCT03052634|Drug|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
75390832|NCT03023930|Other|Standard Dissemination Practice|Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.
75543928|NCT00278343|Drug|cediranib maleate|30mg given PO, daily
75543929|NCT00278343|Other|laboratory biomarker analysis|Correlative studies
75543930|NCT00248261|Drug|ziprasidone, sertraline|
75543931|NCT00285168|Behavioral|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
75543932|NCT00248300|Other|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
75543933|NCT00278382|Drug|sorafenib tosylate|Given orally
75543934|NCT00278382|Other|laboratory biomarker analysis|Correlative studies
75390833|NCT03023930|Other|Implementation Facilitation (IF)|"IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback."
75390834|NCT02969083|Procedure|RNU|Radical surgical removal by open or laparoscopic access
75390835|NCT02969083|Drug|Gemcitabine/Cisplatin|Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
75707324|NCT06147531|Biological|Delayed Cold-Stored Buffy Coat Platelets|To prepare cold-stored platelets, blood banks will transition conventional room temperature platelets up to 4 days after collection (with agitation) to cold-storage (at 1-6 C without agitation) for a minimum of 1 day (24 hours) and a maximum of 10 days after collection (for a total shelf life of ≤ 14 days after collection). Thus, cold-stored platelets will be produced and stored the same way as room temperature platelets up until their transition to cold-storage, ensuring similar products differing only in storage conditions and expiration date (as cold-stored platelets will have an expiration date beyond the current 5 days for pathogen inactivated platelets or 7 days for bacterially cultured platelets). Pathogen reduced platelets will be used for the pilot study (Canada is transitioning in 2022-23 to pathogen-reduced platelets and one site has already transitioned).
75869750|NCT02754037|Radiation|PET Explorer|Similar to the regular PET-Scan, this imaging method uses radiotracers to scan multiple organs of the body. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
76034277|NCT04914065|Other|Regular care in the surgery intensive care unit|"Part 1: Two arms(muscle thickness observation):~Inspiratory muscles: diaphragm~Anti-gravity muscles: rectus femoris and the vastus intermedius~Part 2: Predictors of short-term and long-term goals in the ICU~Short-term goal: successful ventilator weaning in the ICU- pass weaning profile without re-intubation in the hospital~Long-term goal- Quality of life after hospital discharge: SF-36 (Taiwan version)"
76034278|NCT02650921|Device|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
76034279|NCT04914143|Other|broken Ganoderma lucidum spore powder|The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
76034280|NCT04914143|Other|placebo|the control group was treated with placebo after chemotherapy
76034281|NCT04913987|Device|Stryker Triathlon total knee replacement|Knee arthroplasty using a standard care total knee.
76034282|NCT04913987|Device|Zimmer Biomet Persona Partial Knee unicondylar knee replacement|Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
75390836|NCT02969083|Drug|M-VAC Protocol|Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
75390837|NCT02943590|Drug|Placebo|A pill taken once a day
75390838|NCT02943590|Drug|Atorvastatin|A pill taken once a day
75390839|NCT02925871|Behavioral|Co-designed person-centred care transitions|The intervention consists of several elements that aim to meet patients', significant others', and professionals' needs for shared understanding, patient preparedness for homecoming, and coordination.
76034283|NCT03054935|Other|Indirect Calorimetry|Measurement of resting energy expenditure
75390840|NCT02925871|Behavioral|Current care transitions|Control group participants will receive current care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
75390841|NCT02916472|Behavioral|CyberCycling|All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Participants in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the participants' tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.
75390842|NCT02916472|Behavioral|Stretching|Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Participants will be provided with two different colored resistance bands (lighter colored - easier resistance; darker colored - harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participant by the exercise physiologist before the 12 week program begins.
75543935|NCT00248339|Drug|Peginterferon-alpha-2b (PEG-Intron)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
76034284|NCT04914299|Behavioral|"App-based positive intelligence intervention"|"A 6 weeks App-guided and support-group based positive intelligence cognitive behavioral intervention in addition to standard prenatal and postnatal care"
76034285|NCT04914299|Behavioral|Standard of care|Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
76034286|NCT03801109|Other|Hyperbaric group|Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
75543936|NCT00248339|Drug|Ribavirin|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
76034287|NCT03801109|Other|Magnetic group|There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
76034288|NCT03801109|Other|Physical group|A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
76034289|NCT03801109|Other|Baseline group|This group will be the control group that did not take any action, perform the activities of daily life
76034290|NCT04914221|Drug|JLP-2002|administration of JLP-2002
76034291|NCT04914221|Drug|Comparator|administration of comparator
76034292|NCT04739449|Behavioral|Coaching, Cleaning, Communication, Collaboration|"Coaching staff~Cleaning protocols, standardized~Communication with staff and leadership~Collaboration with local expertise"
76034293|NCT03711877|Device|Scalp cooling system|Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
76034294|NCT03711877|Device|Cold cap|The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
76034295|NCT03054701|Other|Hip specific resistance exercise|Hip specific resistance exercise
76034296|NCT03054701|Other|Knee specific resistance exercise|Knee specific resistance exercise
76034297|NCT05124379|Device|Hemoclin Gel|Non sterile gel for intra-rectal use
76034298|NCT03344263|Diagnostic Test|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
76034299|NCT04892615|Device|drainage tube was removed on 5th days after surgery.|drainage tube was removed on 5th days after surgery.
76034300|NCT04892615|Device|drainage tube was removed on 7th days after surgery.|drainage tube was removed on 7th days after surgery.
75390843|NCT02916472|Behavioral|Resistance Bands|"Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks.~The resistance band program will include upper body and lower body exercises and will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participants by the exercise physiologist before the 12 week program begins."
75390844|NCT02914561|Drug|Filgotinib|Filgotinib tablets administered orally once daily.
75390845|NCT02914561|Other|Placebo|Placebo administered orally once daily.
75390846|NCT02840799|Drug|Potassium Nitrate (KNO3)|The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
75390847|NCT02840799|Drug|Potassium Chloride (KCl)|Potassium Chloride (KCl) is the matching placebo control drug in this trial.
75390848|NCT02838732|Dietary Supplement|L-carnitine supplementation (500 mg per tablet per day, purchased from GNC company)|
75390849|NCT02798666|Other|High intensity exercise training|Exercise training using sprint interval exercise
75390850|NCT02798666|Other|Continuous exercise training|Exercise training using continuous exercise at constant heart rate
75390851|NCT02773238|Procedure|Computed Tomography|Undergo FDG PET/CT
75390852|NCT02773238|Procedure|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
75707325|NCT06147531|Biological|Room Temperature Buffy Coat Platelets|Room temperature stored platelets are prepared from donor whole blood, which is centrifuged to collect the buffy coat layer containing platelets. Seven ABO matched buffy coats from male and/or female donors are pooled in 280 ml of platelet additive solution and split into a single dose after pathogen inactivation, resulting in a product with a final platelet count of approximately 1300 x 109. Pathogen inactivated platelets (shelf-life of 5 days, with recent Health Canada approval for an extension of the shelf-life to 7 days), will be used as Canada is transitioning in 2022-23 to pathogen-inactivated platelets and one site has already transitioned.
75707326|NCT06147505|Biological|XS005 Cell Injection|"Treatment on this study includes eight XS005 cell infusions over an 16 week period.~Phase 1： dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D)."
75707327|NCT06147505|Drug|Temozolomide（TMZ）|Patients were given temozolomide on day 1 to day 5 of each cycle, 28 days per cycle, for a total of 4 cycles.
75707328|NCT06147492|Procedure|transanal total mesorectal excision|a transanal bottom-up approach was employed for the TME procedure
75707329|NCT06147492|Procedure|Laparoscopic Total Mesorectal Excision|Laparoscopic Total Mesorectal Excision
75707330|NCT06147466|Device|Dexcom Continuous Glucose Monitoring|A continuous glucose monitor (CGM) is a wearable device that tracks blood glucose (sugar) every few minutes, throughout the day and night. The readings are relayed in real time to a device which can be read by the patient, caregiver or health-care provider, even remotely
75707331|NCT06147453|Device|Aerobika OPEP device|16 week twice daily use of the Aerobika OPEP device
76034301|NCT04892381|Diagnostic Test|Skin Biopsy|"Skin biopsy will be taken under local anesthesia :~From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~The level of PD1 and PD-L1 will be detected using ELISA technique.~The lesional biopsy will be assessed by routine hematoxylin and eosin (H&E) to confirm the diagnosis of LP"
75390853|NCT02773238|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
75390854|NCT02773238|Other|Laboratory Biomarker Analysis|Correlative studies
75390855|NCT02773238|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
75390856|NCT02773238|Radiation|Radiation Therapy|Undergo functional avoidance radiation therapy
75707332|NCT06147440|Other|Dietary intervention|Participants receive diets following different dietary patterns for 1 week.
75707333|NCT06147401|Procedure|PENG plus LFCN block|"The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine."
75707334|NCT06147401|Procedure|FIC Block|"The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment."
75707335|NCT06147388|Diagnostic Test|Colposcopy|No surgery, observation
76034302|NCT05100121|Device|Interactive app|In the app, the patients will report frequency and distress on commons concerns regarding urine dysfunction, bowel dysfunction, emotional distress, sleep, pain, loss of appetite, hot flashes/sweating, edema, and sexual dysfunction. Free text comments will also be possible to make to cover the patients' other potential needs. Questions regarding symptoms of acute character that might need to be treated quickly like severe pain, blood in stool and urine, and involuntary weight loss will also be asked for to timely detect and treat signs of for example cancer relapse. Information about the concerns will be included in the app containing; a) general information of why they have the side effect and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents and web pages.
75390857|NCT02773238|Procedure|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
75390858|NCT02773238|Radiation|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
75390859|NCT02773238|Radiation|Technetium Tc-99m Sulfur Colloid|Undergo Tc-99m sulfur colloid
75707336|NCT06147375|Drug|Tacrolimus or Cyclosporine A|The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
75390860|NCT02743858|Other|Bilateral arm measurements|Pts treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder & the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed before surgery, post-operatively & at timepoints of 6,12,18, & 24 months after surgery for 2 years will be obtained using the Perometer (Model 350 NT Perometer, Per-System) for bioimpedance measurements. Pts who have not yet developed lymphedema by 2 years, an additional measurement at approx 3 years post-surgery will be performed. If pt is diag with lymphedema at the 3-year visit, she will be asked to continue on study for an additional year. Pts treated with SLNB alone, following re-consent, a long-term follow-up volumetric arm measurement will be obtained using the perometer & circumferential arm measurements at a minimum of 2 years post-surgery.
75543937|NCT00248339|Drug|Epoetin-alpha (Procrit)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
75543938|NCT00278421|Biological|rituximab|
75543939|NCT00278421|Drug|cyclophosphamide|
75707337|NCT06147362|Drug|68Ga-NOTA-PEG2-RM26|Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before the PET/CT scans.
75707338|NCT06147349|Procedure|Radical or partial nephrectomy|Removal of neoplastic mass either by full kidney excision or by targeted cancer removal
75543940|NCT00278421|Drug|doxorubicin hydrochloride|
75543941|NCT00278421|Drug|prednisone|
75390861|NCT02743858|Other|Body mass index (BMI)|Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.
75390862|NCT02743858|Behavioral|Quality of Life Questionnaire|
75543942|NCT00278421|Drug|vincristine sulfate|
75390863|NCT02743858|Other|Blood draw|Patients enrolled in the translational study (Cohort 3) will undergo blood draws for serum collection preoperatively and 12-24 months postoperatively to test for FGF2, IL4, IL10, TGFB, Leptin, IL6, and CRP. At both timepoints, up to 20 mL of blood will be collected.
75543943|NCT00248378|Drug|Smoked Cannabis|
75869751|NCT02713438|Behavioral|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
75390864|NCT02719106|Device|Ultimaster stent|
75390865|NCT02708615|Other|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
75390866|NCT02703506|Other|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
75390867|NCT02703506|Other|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
75390868|NCT02683889|Drug|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
75390869|NCT02678091|Device|Ultrasound exam with Doppler|Ultrasound exam of the orbit
75390870|NCT02670174|Other|Traditional training|
75390871|NCT02670174|Other|Separate kinetic chain training|
75543944|NCT00248456|Drug|Calcipotriol plus betamethasone dipropionate ointment|
75543945|NCT00285285|Device|Point of Care Device; i-Stat Analyzer|
75543946|NCT00248690|Device|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
75543947|NCT00278460|Drug|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
75543948|NCT00278460|Drug|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
75543949|NCT00248729|Drug|Etomidate (20mg) or Midazolam (7mg)|
75543950|NCT00248768|Device|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
75543951|NCT00278499|Behavioral|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
75543952|NCT00278499|Behavioral|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
75707339|NCT06147297|Behavioral|Tuned In|The Tuned In programme is based on Russell's (1980) circumplex model of emotion, which categories emotions along the two dimensions of valence and arousal. Through psychoeducation and group discussions, participants in the programme first learn how to categorise their emotions in terms of intensity (i.e., arousal level) and positivity (i.e., valence). They then reflect on and develop a list of songs that they relate to personally and use them to increase or decrease the intensity and positivity of their emotions. In other words, the participants practise monitoring their emotional state and use music to help them modify how they feel. The programme will be conducted by a facilitator with a psychology background, and a registered music therapist.
75707340|NCT06147271|Drug|SGLT2i|A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
75707341|NCT06147232|Drug|Sotagliflozin|Sodium-glucose-co-transporter 1 and 2 inhibitor
75707342|NCT06147232|Drug|Placebo|Placebo tablet
75707343|NCT06147219|Procedure|interlocking intramedullary tibial nail|primary dynamization versus standard interlocking intramedullary tibial nail
75390872|NCT02670174|Other|Integrated kinetic chain training|
75390873|NCT02630628|Drug|Tacrolimus|Dosage: start at 2mg twice a day, then taper as per protocol
75390874|NCT02630628|Drug|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
75390875|NCT02625961|Biological|Pembrolizumab|Participants receive pembrolizumab 200mg via IV infusion once every 3 weeks for up to 35 administrations
75390876|NCT02625961|Biological|Pembrolizumab/vibostolimab coformulation|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion once every 3 weeks for up to 35 administrations
75390877|NCT02625961|Biological|Favezelimab/pembrolizumab coformulation|Participants receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion once every 3 weeks for up to 35 administrations
75543953|NCT00248846|Behavioral|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
75543954|NCT00278577|Biological|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
75543955|NCT00248885|Procedure|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
75390878|NCT02619253|Drug|Pembrolizumab|
75390879|NCT02619253|Drug|Vorinostat|
75390880|NCT02598661|Drug|Imetelstat|Intravenous injection.
75543956|NCT00285402|Drug|AST-726 Low dose|
75543957|NCT00285402|Drug|AST-726 High dose|
75543958|NCT00285402|Drug|AST-726 Placebo|
75543959|NCT00248924|Behavioral|Social Services|
75543960|NCT00278616|Biological|Stem Cell Transplantation|Autologous Stem Cell Transplantation
75543961|NCT00278694|Drug|Oxaliplatin|
75390881|NCT02598661|Drug|Placebo|Matching Placebo to Imetelstat will be administered.
75543962|NCT00278694|Drug|Chemoradiation|
75543963|NCT00278694|Drug|5-FU|
75543964|NCT00278694|Radiation|Preoperative chemoradiation|
75543965|NCT00278694|Procedure|Pelvic surgery|
75543966|NCT00278694|Drug|Neoadjuvant oxaliplatin|
75543967|NCT00248963|Drug|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
75543968|NCT00278733|Behavioral|Brief intervention (physician advice)|
75543969|NCT04720508|Diagnostic Test|blood sample collection.|venipuncture procedure
75543970|NCT00249041|Drug|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
75543971|NCT00249041|Drug|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
75543972|NCT00285519|Drug|Doxazosin (drug)|
75390882|NCT02549820|Device|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
75390883|NCT02544815|Drug|Digoxin|Digoxin 0.25 mg pills
75543973|NCT00278772|Drug|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
75390884|NCT02544815|Drug|Placebo|Placebo pills
75390885|NCT02517034|Other|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
75390886|NCT02517034|Other|Quality-of-Life Assessment|Ancillary studies
75390887|NCT02517034|Other|Questionnaire Administration|Ancillary studies
75390888|NCT02517034|Other|Survey Administration|Ancillary studies
75390889|NCT02503579|Behavioral|physical training|physical activity program, 30 minutes
75390890|NCT02481414|Biological|PepCan|50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities
75543974|NCT00278772|Other|Placebo|oral dose, placebo
75390891|NCT02481414|Biological|Candin®|0.3 mL Candin® per dose administered intradermally in the extremities
75390892|NCT02476786|Behavioral|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
75390893|NCT02476786|Drug|Goserelin|
75390894|NCT02476786|Drug|Anastrozole|
75390895|NCT02476786|Drug|Exemestane|
75390896|NCT02476786|Drug|Fulvestrant|
75390897|NCT02476786|Drug|Tamoxifen|
75390898|NCT02476786|Other|Archived tissue collection|
75390899|NCT02400255|Drug|Crenolanib besylate|
75543975|NCT00249119|Drug|risperidone|
75543976|NCT00278811|Procedure|mobile crisis team|
75543977|NCT00285558|Behavioral|CBT with peer-enhanced activities|
75543978|NCT00285558|Behavioral|CBT with supervised aerobic exercise|
75543979|NCT00414713|Procedure|red blood cell transfusion|red blood cell transfusion
75543980|NCT00278850|Behavioral|Educational|three 1 hour long educational seminars
75390900|NCT02301468|Other|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
75390901|NCT02301468|Other|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
75390902|NCT02263729|Drug|Losartan|
75390903|NCT02263729|Drug|placebo|
75390904|NCT02161783|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
75390905|NCT02161783|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
75390906|NCT02161783|Radiation|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
75390907|NCT02161783|Biological|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
75390908|NCT02042300|Device|XIENCE Xpedition/Alpine/Sierra|
75390909|NCT02039752|Other|Treatment|
75390910|NCT01997710|Device|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
75390911|NCT01997710|Device|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
75543981|NCT00414752|Drug|AFQ065|
75543982|NCT00285597|Drug|Ursodeoxycholic Acid|
75543983|NCT00249158|Drug|Risperidone|
75543984|NCT00278928|Drug|Liposyn III 20% (lipid infusion)|
75543985|NCT00278928|Drug|Intralipid 20% (lipid infusion)|
75543986|NCT00249197|Drug|levofloxacin|
75543987|NCT00278967|Drug|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
75543988|NCT00278967|Drug|HalfLytely - Reformulation|
75543989|NCT00249236|Drug|Risperidone, oral tablets|
75390912|NCT01868438|Drug|Pyronaridine-artesunate granules|
75390913|NCT01868438|Drug|Pyronaridine-artesunate tablets|
75390914|NCT01585805|Procedure|Biopsy|Undergo biopsy
75543990|NCT00249275|Device|spectacles|
75390915|NCT01585805|Procedure|Biospecimen Collection|Undergo tumor tissue and blood sample collection
75390916|NCT01585805|Drug|Cisplatin|Given IV
76034303|NCT05100121|Other|Survivor-ship care|At coaching session with the district nurse, patient reported assessments will be used to discuss the individual's current situation and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in a survivorship care plan which contain e.g., risk of symptoms, late effects, healthy lifestyle information, prevention tips and support of psychosocial concerns. The intervention incorporates coaching encounters using motivational interviewing techniques to engage patients in the patient-owned survivor-ship care plan that include health goals and strategies related to cancer follow-up, surveillance, symptom management, and health behavior.
75390917|NCT01585805|Procedure|Computed Tomography|Undergo CT
75390918|NCT01585805|Drug|Gemcitabine|Given IV
75390919|NCT01585805|Drug|Gemcitabine Hydrochloride|Given IV
75390920|NCT01585805|Procedure|Magnetic Resonance Imaging|Undergo MRI
75390921|NCT01585805|Drug|Veliparib|Given PO
75543991|NCT00279006|Procedure|Percutaneous coronary intervention|
75543992|NCT00285675|Drug|DN-101 (calcitriol) - Drug|
75543993|NCT02215096|Drug|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
75543994|NCT02215096|Drug|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
75390922|NCT01554046|Drug|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~Ages 6-12, up to 25Kg - 35mg maximum per day.~Ages 6-12, above 25Kg - 50mg maximum per day.~Ages 12-65, above 25Kg - 80mg maximum per day."
75390923|NCT01208662|Drug|Lenalidomide|oral administration
75390924|NCT01208662|Drug|Bortezomib|intravenous or, following protocol amendment, subcutaneous administration
75390925|NCT01208662|Drug|Dexamethasone|"oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
75390926|NCT01208662|Procedure|Autologous Stem Cell Transplant|Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
75390927|NCT00929045|Drug|Growth Hormone Replacement|
75390928|NCT00683631|Other|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
75390929|NCT00636519|Biological|Botulism Antitoxin Bivalent (Equine) Types A and B|One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
75390930|NCT00636519|Biological|Botulism Antitoxin Heptavalent (Equine) Types A-G|One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
75390931|NCT00540774|Device|detection of oral pathology|detection of oral pathology
75543995|NCT02961647|Procedure|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
75543996|NCT00279045|Drug|Rosiglitazone|
75543997|NCT00279045|Drug|glyburide|
75543998|NCT00279045|Drug|metformin|
76034304|NCT04900961|Other|Resistance Exercise|The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
75390937|NCT01457352|Drug|SPARC0921|
75390938|NCT01457352|Drug|Placebo0921|
75390939|NCT01457118|Drug|NKTR-102 145 mg/m2|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
75869752|NCT02713438|Behavioral|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads)."
75543999|NCT00249353|Drug|methylphenidate hydrochloride|
75544000|NCT02215408|Behavioral|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
75544001|NCT02216032|Other|TMW Curriculum|
75544002|NCT02216032|Other|Nutrition Curriculum|
75390940|NCT01457118|Drug|NKTR-102 120 mg/m2|A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
75390941|NCT01457118|Drug|NKTR-102 95 mg/m2|A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
75390942|NCT01457118|Drug|NKTR-102 50 mg/m2|A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
75390943|NCT01501110|Drug|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
75390944|NCT01500720|Drug|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
75390945|NCT01500720|Drug|Topotecan|Topotecan 1.5 mg/m^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
75390946|NCT04408872|Diagnostic Test|Esophago-gastro-duodenoscopy (EGD)|EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.
75390947|NCT04408872|Diagnostic Test|Endoscopic ultrasound (EUS)|EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
75390948|NCT01500252|Device|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
75390949|NCT01500252|Device|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
75390950|NCT01476696|Drug|Prasugrel|Administered orally
75390951|NCT01500096|Drug|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
75390952|NCT01500096|Dietary Supplement|Placebo for American ginseng|"Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day"
75869753|NCT02713438|Behavioral|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity."
75869754|NCT02713438|Behavioral|Education|"CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.~The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners."
75869755|NCT02700620|Behavioral|Internet-delivered CBT|Guided internet treatment
75869756|NCT02664753|Drug|56 days of weight-adjusted L-Carnitine treatment|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~< à 60kg : 2g/day > 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization"
75390953|NCT04767438|Other|Pregnant women|All pregnant women that present to the 12-week scan in the Obstetrics Unit
75390954|NCT01455012|Drug|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
75390955|NCT01455012|Drug|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
75390956|NCT01454778|Drug|Paclitaxel|"Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon* Popliteal: 1.8 mg/inflation of balloon* Tibial: 1.4 mg/inflation of balloon*~not to exceed 10mg total dose"
75544003|NCT00249431|Drug|Sertraline|Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
75707344|NCT06147141|Behavioral|Online Peer Companion Intervention|Ordinary children would be paired with ASD children before the interventions. Dyads in the OPCI would have a total of 12 sessions within two months, each lasting 30-60 minutes. The longest interval between two sessions couldn't exceed two weeks. Researchers would recommend a series of companion themes for children to choose from (e.g., daily sharing and drawing). Ordinary children and ASD children need to discuss activities that are of mutual interest before each session. A researcher assistant would be online to ensure the normal development of the interventions and be responsible for video recording of the exchanges at the beginning of each session. Except for extreme circumstances, he or she would turn off the video and sound throughout the process and withdraw soon. During the interventions, parents would play a supporting role when children express needs without over-involvement.
75707345|NCT06147141|Behavioral|Wait-List|Dyads in the WLG would only participate in preliminary training and measurement during the implementation of the intervention. After completing the post-test, this study will implement the same online peer companionship intervention.
75707346|NCT06147115|Other|Assessment tool to determine severity of GI bleeding|The Rockall score is a validated mortality risk assessment for patients admitted with upper GI bleeding.
75707347|NCT06147089|Behavioral|Sleep Intervention|Participants in the sleep intervention receive advice on: sleep hygiene/environment, sleep timing, naps, and exposure to light. These advices will be tailored to the personal situation of the participant, as measured during the run-in period.
75390957|NCT04408404|Procedure|Acute aortic dissection|Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)
75390958|NCT01454076|Drug|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
75390959|NCT01454076|Drug|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
75390960|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
75390961|NCT01454076|Drug|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
75390962|NCT01454076|Drug|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
75390963|NCT01454076|Drug|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
75390964|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
75390965|NCT01453998|Biological|Infanrix hexa|Single dose, licensed formulation, intramuscular into right thigh
75544004|NCT00249431|Behavioral|Relapse Prevention Therapy|Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
75544005|NCT00285714|Procedure|3D stereophotogrammetric imaging|
75544006|NCT00285714|Procedure|3D CT-imaging with cone-beam CT|
75544007|NCT00285714|Procedure|Case report form|
75544008|NCT00249509|Drug|Nefazodone|
75544009|NCT00249509|Drug|Bupropion|
75390966|NCT01453998|Biological|Prevenar 13|Single co-administered dose, intramuscular into left thigh
75390967|NCT01453998|Biological|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
75390968|NCT01453374|Drug|VIVITROL 380mg|380 mg IM injection given once monthly
75390969|NCT01453296|Drug|GW642444|GW642444 25 μg; Novel dry powder inhaler
75390970|NCT01453296|Drug|Placebo|Matching placebo; Novel dry powder inhaler
75390971|NCT01453140|Drug|Cyclophosphamide and Sirolimus|"On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are >40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily."
75544010|NCT00279084|Drug|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
75707348|NCT06147089|Behavioral|Nutritional intervention|Participants in the nutritional intervention receive personalised advice on the distribution of calories and nutrients over 24 hrs, and on specific food products based on the outcomes of the continuous glucose measurements (CGM) during the run-in period. The guidelines will include room for personal dietary preferences.
75707349|NCT06147050|Drug|Metformin|Metformin is an FDA-approved antidiabetic agent that manages high blood sugar levels in type 2 diabetes patients. However, emerging evidence may suggest a benefit to COVID recovery.
76034305|NCT03054623|Procedure|DRIL procedure|The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
76034306|NCT04892225|Behavioral|Technology-supported behavioral intervention (text message)|A simple text message regarding the salt and fluid restriction in order to reduce the inter-dialytic weight gain will be send on daily basis to all the individuals in the intervention group.
75390972|NCT01453140|Drug|Low dose IL-2 with Cytoxan + Sirolimus|"Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide."
75390973|NCT01453140|Drug|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|"Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off."
75390974|NCT01453140|Drug|Cyclophosphamide and Sirolimus|Day 1: Cyclophosphamide Day 2: Sirolimus
75390975|NCT01453140|Drug|Low dose IL-2 with Cytoxan + Sirolimus|treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus
75544011|NCT00279084|Drug|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
75544012|NCT00249548|Behavioral|Contingency management|
76034307|NCT04900649|Other|chest resistance exercise|lung function.
75390976|NCT01453140|Drug|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
75390977|NCT01499940|Drug|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
75390978|NCT01499160|Drug|letrozole|Drug is are to be taken orally. 2.5 mg once daily
75390979|NCT01499160|Drug|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
75390980|NCT01499160|Drug|everolimus|Drug is to be taken orally. 5 mg once daily.
75390981|NCT01498692|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
75707350|NCT06147050|Other|Placebo|Patients will receive matching placebo control twice daily.
75707351|NCT06147024|Other|historical control|Received a conventional preoperative assessment
75707352|NCT06147024|Other|3D printed lesion model|Received 3D printed lesion models for preoperative planning
75707353|NCT06146998|Other|3D health education model|explanation combined with 3D health education model
75707354|NCT06146998|Other|Verbal explanation|Regular explanation
75544013|NCT00285753|Behavioral|support groups|cognitive behavioral intervention with psychoeducation
75544014|NCT00249587|Drug|Methadone|dosed to effect, every six hours
75707355|NCT06146972|Drug|Iguratimod|Iguratimod 25mg bid + tofacitinib 5mg bid
75707356|NCT06146959|Device|Corrective Kinesiology taping|corrective kinesiology tape is a form of biomechanical tape that is used with specific tension to get a corrective effect
75544015|NCT00279123|Drug|pantoprazole infusion|
75544016|NCT00279123|Drug|pantoprazole bolus|
75544017|NCT00279123|Drug|no treatment|
75544018|NCT00249626|Behavioral|Contingency management|Rewards (prizes) for abstinence
75707357|NCT06146959|Device|Non corrective kinesiology tape|Non-corrective kinesiology tape is a form of biomechanical tape that is used without any tension
75707358|NCT06146959|Other|Home exercise program|Intrinsic foot strengthening and stretching exercises
75869757|NCT02664753|Drug|10 days of intravenous placebo (isotonic saline)|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening."
76034308|NCT04900649|Other|chest expansion exercises|thoracic excursion
75390982|NCT01498068|Drug|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
75544019|NCT00279162|Drug|Calcipotriene/betamethasone gel and ointment|
75544020|NCT04720352|Device|Active treatment|Active treatment delivers radiofrequency and cryogen
75544021|NCT04720352|Device|Sham|Sham delivers non therapeutic levels of radiofrequency and cryogen
75544022|NCT00285792|Behavioral|Physical Activity|
75707359|NCT06146933|Diagnostic Test|Glucometer Test|blood glucose measurement using finger tip capillary blood using BGM
75707360|NCT06146933|Diagnostic Test|Refernce Measurement|blood glucose measurement using finger tip capillary blood using reference method
75707361|NCT06146920|Other|Evaluation of ctDNA using the F1T after 1 year of immunotherapy|"Patients with evidence of disease control after at least 10months of an ICI-based therapy will initially undergo a pre-screen. In patients with successful F1CDx baseline tissue testing whole blood will be collected and evaluated for plasma ctDNA measurement. If there is detectable ctDNA during the pre-screening period, patients will be excluded from enrollment. If there is no detectable ctDNA, patients will be eligible to screen and enroll in the main study.~If enrolled, patients will stop ICI- based treatment and continue with serial ctDNA at pre-specified timepoints. The treating physician will not be blinded to the serial ctDNA results There will be no proscriptive therapeutic measures outlined if ctDNA becomes detectable while on study."
75390983|NCT01498068|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
75390984|NCT01498068|Drug|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is < 75kg) or 1200mg (if participant's weight is >= 75kg) per day for 24 or 48 weeks.
75390985|NCT01497366|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
75390986|NCT01497366|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
75390987|NCT01497366|Drug|RBV|"Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~Dose of sofosbuvir+RBV group based on baseline weight: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg~Dose of PEG+RBV group: 800 mg"
75390988|NCT01475838|Drug|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
75869758|NCT02621398|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
75390989|NCT01475838|Drug|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
75390990|NCT01475838|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
75544023|NCT00249704|Drug|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
75544024|NCT00249704|Procedure|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
75544025|NCT00249704|Procedure|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
75544026|NCT00249704|Drug|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
75544027|NCT00249743|Device|FallSaver (formerly called NOCwatch)|
75544028|NCT00249782|Drug|Vehicle control, 2x/day|
75869759|NCT02621398|Drug|Carboplatin|Given IV
75869760|NCT02621398|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
75869761|NCT02621398|Other|Laboratory Biomarker Analysis|Correlative studies
75869762|NCT02621398|Drug|Paclitaxel|Given IV
75869763|NCT02621398|Biological|Pembrolizumab|Given IV
75390991|NCT01475838|Drug|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
75390992|NCT01451814|Behavioral|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
75390993|NCT01451814|Drug|Nicotine polacrilex|8 weeks of nicotine patch
75390994|NCT01451814|Behavioral|Relaxation training|Instructions in progressive muscle relaxation
75544029|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 2x/day|
75544030|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day|
75544031|NCT00249782|Drug|MetroGel® (metronidazole gel), 1.0% 1x/day|
75544032|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
75544033|NCT00279240|Drug|Metformin|
75544034|NCT00249860|Drug|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
75544035|NCT00249860|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
75544036|NCT00249860|Drug|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
75544037|NCT00249899|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
75544038|NCT00249899|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
75544039|NCT00249938|Drug|Minute Maid Heart Wise orange juice|
75544040|NCT00249938|Drug|Welchol|
75544041|NCT00279279|Device|Implanted Device|
75544042|NCT00249977|Drug|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
75390995|NCT01451814|Behavioral|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
75390996|NCT01475370|Drug|OCV-501|"Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
75390997|NCT01496430|Drug|Placebo|
75390998|NCT01496430|Drug|Azilsartan medoxomil|
75390999|NCT01496430|Drug|Azilsartan medoxomil|
75544043|NCT00285909|Behavioral|Alcohol: 25 gday (white wine)|
75544044|NCT00285948|Device|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
75544045|NCT00279357|Procedure|Narrow Band Imaging|
75544046|NCT00250094|Drug|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is >1,500 and platelets > 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
75544047|NCT00285987|Procedure|Reconstruction of the cruciate ligament|
75544048|NCT00250133|Procedure|Blood draws|
75544049|NCT00279435|Drug|visilizumab|
75544050|NCT00286026|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
75544051|NCT00250172|Drug|[C-11](R)-rolipram|
75544052|NCT00279474|Behavioral|cognitive-behavior groups|
75544053|NCT00286065|Drug|AeroLEF|
76034309|NCT04913909|Dietary Supplement|Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients|"The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse."
76034310|NCT04891601|Procedure|polypropelene mesh|compare use mesh alone or combined mesh and darn repair
76034311|NCT01596335|Drug|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
75544054|NCT00250211|Procedure|Functional MRI imaging and tomotherapy|
75544055|NCT00279513|Drug|Traumeel S|
75544056|NCT00250250|Drug|ZOMACTON|
75544057|NCT00279552|Drug|Recombinant human intrinsic factor|
75544058|NCT02961608|Drug|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
75544059|NCT00286104|Device|Antibiotics-impregnated ventricular catheter (Bactiseal®)|Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
75544060|NCT00286104|Device|Plain ventricular catheter (Codman EDS II/III)|Plain ventricular catheter
75544061|NCT00250289|Device|a mucosal sticker with herbal formula|
75544062|NCT00286143|Drug|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
75544063|NCT00250328|Device|LapCAC Laparoscopic Compression Anastomosis Clip|
75544064|NCT00286260|Drug|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
75544065|NCT00250367|Drug|risperidone|
75544066|NCT00279630|Procedure|Orthoses and Exercise|orthrose and exercise - daily
75544067|NCT00250406|Device|Ureteral Stent|triclosan-eluting ureteral stent
75544068|NCT00250406|Device|Ureteral Stent|Percuflex Plus Stent as the control
75544069|NCT02960841|Other|Intracavitary Manual Lymphatic Drainage|
75544070|NCT02960841|Other|Conventional treatment|
75544071|NCT04720235|Device|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
76034312|NCT01596335|Drug|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
75391000|NCT04408326|Drug|Angiotensin II|Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
75544072|NCT00279669|Procedure|Ultrasound examination|contact ultrasound examination
75544073|NCT02960724|Other|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
75391001|NCT04408326|Drug|Interleukin-1 receptor antagonist|Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
75391002|NCT01451424|Drug|Proellex|vaginal suppository, daily, for 12 weeks
75391003|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
75391004|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
75391005|NCT01475214|Other|Inactive placebo capsule|microcrystalline cellulose
75544074|NCT00250562|Drug|valsartan plus hydrochlorothiazide|
75707362|NCT06146907|Other|cognitive motor dual task exercises|exercise program that combined motor tasks such as walking and juggling with cognitive task such as naming fruits or colors in the room.
75707363|NCT06146907|Other|exergaming|Nintendo switch games that involve physical activity by participants to complete
75707364|NCT06146881|Drug|Diquafosol sodium 3%|Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
75707365|NCT06146881|Drug|Sodium hyaluronate 0.1%|Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
75707366|NCT06146842|Drug|Bupivacaine Hydrochloride|Each subject will receive allocated dose of bupivacaine
75869765|NCT02609750|Other|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
75707367|NCT06146829|Other|no intervention|no intervention
75707368|NCT06146751|Drug|Superparamagnetic Iron Oxide Nanoparticles|Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
75707369|NCT06146738|Behavioral|Palliative Care|Best supportive care without surgical intervention
75707370|NCT06146738|Procedure|Tumor biopsy|Tumor biopsy
75707371|NCT06146738|Procedure|Tumor resection|Maximal safe resection of the tumor
75707372|NCT06146725|Procedure|Tumor resection|Maximal safe resection of the tumor
75707373|NCT06146725|Procedure|Tumor biopsy|Biopsy of the tumor
75707374|NCT06146712|Other|Asutra's 'Dream the night away' nighttime lotion|Product contains Water (Aqua), Magnesium Chloride, Dimethyl Sulfone (MSM), Prunus Amygdalus Dulcis (Sweet Almond) Oil, Butyrospermum Parkii (Shea Butter), Sodium Lactate, Cetearyl Alcohol, Glyceryl Stearate Citrate, Glycerin, Undecane, Cetyl Palmitate, Polyglyceryl-3 Diisostearate, Pentylene Glycol, Glyceryl Stearate, Magnesium Sulfate, Melatonin, Tridecane, Potassium Chloride, Sodium Chloride, Calcium Chloride, Tocopheryl Acetate, Xanthan Gum, Hydroxyacetophenone, Sodium Hydroxide, Cymbopogon Flexuosus (East-Indian Lemongrass) Oil, Citral, Geraniol, Linalool
75707375|NCT06146686|Device|Fanta AF blue rotary files 20 taper 4|single rotary file Fanta AF blue rotary files 20 taper 4
75707376|NCT06146686|Device|Fanta AF baby rotary files 20 , 25 , 30 taper 4|multiple rotary files system Fanta AF baby rotary files 20 , 25 , 30 taper 4
75707377|NCT06146660|Drug|Mavacamten|According to approved product label
75869766|NCT02609750|Other|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
76034313|NCT04891679|Drug|Oral misoprostol solution (OMS)|"Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~hour= 20ml~hour= 30ml~hour= 30ml~hour= 30ml~hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity."
76034314|NCT04913831|Drug|Cerebrolysin|Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration
76034315|NCT04913831|Drug|Placebo|physiological saline 100ml, 8-35 days, once/day, intravenous administration
75391006|NCT01496274|Biological|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
76034316|NCT04900415|Drug|Vitamin A|Metabolic supplement for neurogenesis at the olfactory apparatus
76034317|NCT04900415|Device|Electronic portable aromatic rehabilitation (EPAR) diffuser|Handheld essential oil ultrasonication diffuser technology
75544075|NCT00286299|Other|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
75391007|NCT01475136|Drug|LY2140023|
75391008|NCT01474746|Drug|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
75544076|NCT00286299|Other|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
76034318|NCT03051035|Drug|KO-947|Intravenous administration
76034319|NCT04900571|Drug|Nitrofurantoin 100 MG|Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide
75391009|NCT01474746|Drug|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
75391010|NCT01450800|Drug|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
75391011|NCT01450800|Drug|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
75544077|NCT00286299|Other|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
76034320|NCT04900337|Drug|AMOR 18 Powder & Inhalation|AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
76034321|NCT04900337|Drug|Placebo|Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
76034322|NCT04900727|Other|No intervention|No intervention
75544078|NCT02960880|Drug|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
75544079|NCT02960880|Drug|Phenprocoumon (branded and generics)|Individually adjusted dose
75544080|NCT00279747|Drug|meloxicam 0.25 mg/kg|
75544081|NCT00279747|Drug|meloxicam 0.125 mg/kg|
75544082|NCT00279747|Drug|naproxen 10 mg/kg|
75544083|NCT00250601|Drug|Saredutant succinate (SR48968C)|
75544084|NCT00286377|Drug|prosaptide|
75544085|NCT02961686|Radiation|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
76034323|NCT04900181|Procedure|the same-day discharge surgery|the same-day discharge surgery is the procedure in which the patient is admitted, operated and discharged within 24 hours.
76034324|NCT04891211|Dietary Supplement|Vitamin D deficiency|Ocular significance of vitamin D deficiency in pediatric cases
76034325|NCT03050957|Dietary Supplement|menthol|Alimentary bolus supplemented with menthol
76034326|NCT04885049|Drug|Racecadotril|Anti secretary
75391012|NCT03026634|Behavioral|Sleep-disordered breathing|Prevalence and dynamic of sleep-disordered breathing after heart transplantation
75391013|NCT01474512|Drug|80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Administered SC
75391014|NCT01474512|Drug|Placebo|Administered SC
75391015|NCT01474434|Drug|pradigastat (LCQ908)|pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
75391016|NCT01474434|Drug|Placebo|matching placebo tablets
75869767|NCT02525029|Drug|Pregnyl®|"Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic. Study will use Continual Reassessment Method (CRM) to establish a maximum tolerated dose (MTD).~Step -2: 125 USP hCG/875 pg EGF/m2 Step -1: 250 USP hCG/1,750 pg EGF/m2 Step 1 (start): 500 USP hCG/3,500 pg EGF/m2 Step 2: 1,000 USP hCG/7,000 pg EGF/m2 Step 3: 2,000 USP hCG/14,000 pg EGF/m2 Step 4 (Arm 2b only): 3,500 USP hCG/24,500 pg EGF/m2 Step 5 (Arm 2b only): 5,000 USP hCG/35,000 pg EGF/m~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
75869768|NCT02455479|Biological|dAd5GNE Vaccine|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
75869769|NCT02455479|Biological|Placebo|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
75869770|NCT02427620|Drug|Cyclophosphamide|Given IV
75869771|NCT02427620|Drug|Cytarabine|Given IV
75869772|NCT02427620|Drug|Dexamethasone|Given PO or IV
75869773|NCT02427620|Drug|Doxorubicin|Given IV
75869774|NCT02427620|Drug|Doxorubicin Hydrochloride|Given IV
75869775|NCT02427620|Drug|Ibrutinib|Given PO
76034327|NCT04885049|Drug|DiaResQ Children's Powder for Suspension|oral immunoglobulins
76034328|NCT04884581|Device|GI Genius CADx device|GI Genius System is an Intelligent Endoscopy Module designed to be an adjunct to video colonoscopy with the purpose of supporting the operating physician with artificial intelligence during colonoscopy. GI Genius CADx is the AI software that provides a histology prediction of framed polyps during real-time colonoscopy, with each polyp being classified as adenoma or non-adenoma.
76034329|NCT04056533|Biological|CMV CTLs|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when their donors are sero-positive for CMV-DNA 21 days after transplant. The CMV-DNA levels will be monitored weekly for at least 100 days after the HAPLO. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive a CMV specific antiviral drug.
75391017|NCT02985606|Other|Caffeine powder -60|
75391018|NCT02985606|Other|Caffeine powder -30|
75391019|NCT02985606|Other|Caffeine powder 0|
75391020|NCT02985606|Other|Placebo powder -60|
75391021|NCT02985606|Other|Placebo powder -30|
75391022|NCT02985606|Other|Placebo powder 0|
75391023|NCT01473732|Drug|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
75391024|NCT01473732|Drug|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml.
75391025|NCT01473732|Drug|Mycophenolic acid|Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
75391026|NCT01450098|Drug|LY2484595 Reference Formulation (RF)|Administered orally
75391027|NCT01450098|Drug|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
75391028|NCT01449708|Drug|TIVA NoNarc|"patients in both groups receive antiemetic prophylaxis~patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively~postop management in both groups is similar in both groups"
75391029|NCT01449630|Drug|LY3031207|Administered orally
75391030|NCT01449630|Drug|Placebo|Administered orally
75391031|NCT01449630|Drug|Celecoxib|Administered orally
75391032|NCT01493778|Drug|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
75391033|NCT01473420|Biological|Epoetin Hospira|Variable dose
75391034|NCT01473420|Biological|Epogen Amgen|Variable dose
75391035|NCT04674774|Drug|Tegoprazan|oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days
75391036|NCT04674774|Drug|Lansoprazole|oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day
75391037|NCT01492686|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
75544086|NCT00250640|Drug|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
75544087|NCT00250796|Drug|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
75544088|NCT00250796|Drug|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
75544089|NCT00286416|Drug|omalizumab (Xolair)|
75707378|NCT06146569|Device|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.
75544090|NCT00250874|Drug|Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab|
75544091|NCT00279825|Drug|IPX054 200 mg|IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
75544092|NCT00279825|Drug|IPX054 250 mg|IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
75544093|NCT00279825|Drug|CD-LD IR|Active comparator containing 25 mg carbidopa and 100 mg levodopa
75544094|NCT00279825|Drug|CD-LD CR|Active comparator containing 50 mg carbidopa and 200 mg levodopa
75544095|NCT00279825|Drug|IPX054 200 mg Placebo|Placebo to match IPX054 200 mg
75544096|NCT00279825|Drug|IPX054 250 mg Placebo|Placebo to match IPX054 250 mg
75707379|NCT06146569|Device|Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
75707380|NCT06146556|Procedure|catheter based ablation|electrophysiological catheter based ablation of ventricular arrhythmia
75544097|NCT00279825|Drug|CD-LD IR Placebo|Placebo to match CD-LD IR
75707381|NCT06146543|Other|Stress ball|Before the procedure begins, the patient's free hand will be given an elastic ball that is large enough to hold in the palm of the hand and squeeze easily. He/she will be asked to squeeze this ball slowly throughout the process. At the end of the procedure, the ball will be removed from his hand and the patient will be relieved.
75707382|NCT06146517|Other|Clevr Sleeptime|Participants will trial Clevr Blends Sleeptime during weeks 1-4.
75544098|NCT00279825|Drug|CD-LD CR Placebo|Placebo to match CD-LD CR
75544099|NCT00250913|Behavioral|Telephone-based physical activity counseling program|
75544100|NCT00250952|Drug|Botox Cosmetic™|
75544101|NCT00250991|Drug|activase|
75544102|NCT00250991|Drug|integrilin|
75544103|NCT00416754|Other|counseling intervention|subjects will receive genetic counseling
75707383|NCT06146517|Other|Clevr Matcha|Participants will trial Clevr Matcha during weeks 5-8.
75707384|NCT06146517|Other|Clevr Chai|Participants will trial Clevr Chai during weeks 9-12.
75707385|NCT06146504|Dietary Supplement|CanXida Remove (Formula RMV)|Supplement composed of a 12 ingredient anti-fungal, anti-bacterial & anti-parasite formula.
75544104|NCT00286611|Procedure|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
75544105|NCT04719962|Procedure|Targeted proteomics in skin +/- cerebrospinal or synovial fluid to diagnose disseminated Lyme disease|"Following a 2-days course of local daily clobetasol propionate 0,05% cream application, a skin biopsy (3 mm punch-biopsy ) of healthy-looking skin of the upper part of the thigh will be performed in all patients,.~Arthrocentesis (in patients with Lyme arthritis only) and lumbar puncture to collect cerebrospinal fluid (in patients with neuroborreliosis only) will be performed in the usual care setting as appropriated.~All biological samples will be subject to Borrelia culture, PCR and SRM-MS proteomics."
75544106|NCT00416832|Drug|cyclophosphamide|
75544107|NCT00416832|Drug|dacarbazine|
75544108|NCT00416832|Drug|doxorubicin hydrochloride|
75544109|NCT00416832|Drug|etoposide|
75544110|NCT00416832|Drug|prednisone|
75544111|NCT00416832|Drug|procarbazine hydrochloride|
75544112|NCT00416832|Drug|vincristine sulfate|
75544113|NCT00416832|Radiation|radiation therapy|
75707386|NCT06146504|Other|Placebo|Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
75707387|NCT06146491|Drug|Oral tablet and transdermal patch|oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.
75544114|NCT00251030|Drug|Nelfinavir and Omeprazole|
75544115|NCT00286650|Procedure|3rd molar teeth extraction|
75544116|NCT00251069|Drug|Glucosamine sulphate|
75544117|NCT00286689|Drug|Growth Hormone|
75544118|NCT00286689|Procedure|Whole body Protein turnover|
75544119|NCT00286689|Procedure|DEXA scan|
75544120|NCT02961491|Drug|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
75544121|NCT01640002|Drug|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
75544122|NCT01640002|Drug|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
75544123|NCT01640041|Device|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
75544124|NCT00279903|Drug|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
75544125|NCT00279903|Drug|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
75391038|NCT01492686|Drug|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
75391039|NCT01492686|Drug|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
75391040|NCT04409496|Behavioral|Chat-based instant messaging support|"Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered."
76034330|NCT04890899|Procedure|Cystic enculation of spleen hydatid|Preoperative preparation did according to the general condition of the patient and fitness for anaesthesia. Laparotomy did under general anaesthesia, supine position, the abdomen opened either by midline or left subcostal incision. Identification of splenic hydatid cyst. Exploration of the peritoneal cavity for undetected hepatic or peritoneal hydatid preoperatively. Isolation of operative field by packs socked with hypertonic solution (20 -30 % hypertonic saline). Aspiration of the cyst fluid. Injection of suitable amount about 5 ml of (1 % of cetramid) solution and waiting for at least 5 minutes and then re-aspiration. The spleen is not needed to mobilize. Extraction of the endocyst and washing of the cavity with normal saline. Occupying the cystic cavity intracystic drain. Perioperative and postoperative close observation of the patient for an anaphylactic reaction or any other complication. Follow-up of the patient until discharge from hospital on (3th - 5th) days.
75391041|NCT04409496|Behavioral|SMS message support|Subjects will receive regular SMS on generic smoking cessation for 3 months.
75391042|NCT04409496|Behavioral|Self-help booklet|Subjects will receive a standard self-help booklet on smoking relapse prevention.
75391043|NCT01449006|Drug|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
75391044|NCT01448850|Biological|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
75391045|NCT01448850|Other|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
75391046|NCT04748406|Device|Extracorporeal Shock Wave Therapy(ESWT)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied.
76034331|NCT04890587|Drug|AL8326 tablets|Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
76034332|NCT04890665|Behavioral|Online psychological intervention for healthcare workers|"The intervention is based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, Acceptance and Commitment Therapy and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of anxiety, depression, burnout, fatigue compassion, posttraumatic stress disorder, and affectations in sleep quality and perception of life quality in healthcare workers.~And 3 complementary modules that according to the scientific literature could affect the mental health of healthcare workers related to how to deliver bad health news, Psychological first aid and how beliefs could influence physical and emotional self-care in the face of the COVID-19 pandemic."
75391047|NCT04748406|Other|Peloid therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week
76034333|NCT04899713|Other|Survival survey|To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.
76034334|NCT04430621|Drug|Follicle Stimulating Hormone|FSH will be administered s.c. in the morning to male healthy subjects
75391048|NCT04748406|Other|Home Workout Program|Patients will be given a home exercise program consisting of eccentric strengthening exercises and stretching exercises, which are planned to increase resistance every week. The patients will be taught strengthening exercises for forearm pronation-supination with wrist extensors and a home exercise program will be started 3 sets of 10 repetitions per day.
75391049|NCT04748406|Other|Cold application|At the beginning of each treatment, gel ice packs are wrapped with a moist towel and placed around the elbow joint for 15 minutes. will be applied.
75391050|NCT01491672|Drug|RAD001|Study drug was supplied as 5 mg tablets in blister packs.
75544126|NCT02961452|Other|Cross reaction detection|
75391051|NCT01447446|Drug|Peg-IFN Alfa-2a|Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
75391052|NCT01447446|Drug|Peg-IFN Alfa-2b|Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
75391053|NCT01447446|Drug|Ribavirin|Ribavirin according to standard of care and in line with local labeling.
75391054|NCT01447446|Drug|Boceprevir|Boceprevir according to standard of care and in line with local labeling.
75391055|NCT01447446|Drug|Telaprevir|Telaprevir according to standard of care and in line with local labeling.
75391056|NCT01490814|Procedure|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
75391057|NCT01490814|Procedure|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
75391058|NCT01471782|Biological|Blinatumomab|Administered by continuous intravenous infusion
75391059|NCT01490580|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
76034335|NCT04393649|Other|ESOGER|Questionnaire
75707388|NCT06146478|Drug|Thalidomide|Thalidomide given at an average dose of 1.5mg/kg/day
75707389|NCT06146426|Dietary Supplement|Early diet resumption|Resuming oral diet at pace started from 2 hours after extubation from ventilator.
75707390|NCT06146387|Dietary Supplement|Investigational Formula|Participants in this arm will receive stage 1 and stage 2 investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
76034336|NCT04900259|Behavioral|COVID-19 pandemic|Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
76034337|NCT04884503|Drug|Clonazepam tablets|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
76034338|NCT04884503|Device|tongue pads|wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
76034339|NCT04884425|Device|Pulsed Electromagnetic Frequency Device (Energy5)|A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
76034340|NCT03051893|Drug|Chronocort|Modified formulation of hydrocortisone
76034341|NCT04890197|Dietary Supplement|tahini|48 grams tahini
75391060|NCT01490580|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
75391061|NCT01490190|Drug|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
75391062|NCT01446042|Drug|Testosterone|Intranasal testosterone
75391063|NCT01446042|Drug|Testosterone|Intranasal testosterone
75544127|NCT01640275|Drug|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
75869776|NCT02427620|Other|Laboratory Biomarker Analysis|Correlative studies
75707391|NCT06146387|Dietary Supplement|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
76034342|NCT04890197|Other|control|no intervention
76034343|NCT04889963|Biological|adypose mesenchymal conditioned medium and ligament derived conditioned medium|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
76034344|NCT04412213|Other|Stuttering severity instrument for school-age children (SSI-3 Arabic version)|Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
76034345|NCT04889885|Device|High-intensity laser therapy (HILT)|"HILT was done by Multiwave Locked System (MLS) laser therapy combining 2 laser wavelengths (808 and 905 nm) in order to strengthen the effects of HILT. The laser was applied on medial, lateral and posterior parts around the knee joint. The total energy per session was 562.5 Joules (J) which was done 2-3 times a week for a total of 10 sessions.~Additionally, the participants received conservative treatment for knee OA such as education about the disease, proper activities, and exercise."
75707392|NCT06146387|Dietary Supplement|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
75707393|NCT06146374|Other|Placebo for SLV213|Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
75707394|NCT06146374|Drug|SLV213|SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
75869777|NCT02427620|Drug|Methotrexate|Given IV
75869778|NCT02427620|Biological|Rituximab|Given IV
75869779|NCT02427620|Drug|Vincristine|Given IV
75869780|NCT02427620|Drug|Vincristine Sulfate|Given IV
75869781|NCT02408549|Drug|Lacosamide Tablet|"Active substance: Lacosamide~Pharmaceutical form: Tablet~Concentration: 50 mg and 100 mg~Route of Administration: Oral administration"
75869782|NCT02408549|Drug|Lacosamide Oral Solution|"Active substance: Lacosamide~Pharmaceutical form: Oral solution~Concentration: 10 mg/ml~Route of Administration: Oral administration"
76034346|NCT04889885|Device|Sham laser|The control group received a sham laser (2-3 times a week for a total of 10 sessions) plus conservative treatment as in the intervention group. The laser machine was the same as in the intervention group; however, the laser was applied without releasing laser energy to the knee joint.
75391064|NCT01445886|Drug|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
75391065|NCT01445886|Drug|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
75391066|NCT01470612|Drug|CP-690,550|5 mg tablets, BID, for at least 12 months
75391067|NCT01470612|Drug|CP-690,550|10 mg tablets, BID, for at least 12 months
75869783|NCT02378558|Device|MagneMarker|The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
76034347|NCT04899401|Dietary Supplement|Standard of care + PediaFlù®|Standard of care: Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. PediaFlù®: During the 6 days of the clinical investigation, the subjects will administer PediaFlù® 5ml x3 times per day for children below 6 years and 10mlx3 times per day for children above 6 years.
75707395|NCT06146361|Behavioral|COVID-19 Group Problem Solving|"This group will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a plan of action to reduce their and their peers' risk for COVID-19 transmission. Navigation Component will consist of providing information and linking LDLs with social service providers that can help buffer some of the social and economic effects of the COVID-19 pandemic and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support, defined as encouraging social networks to provide informational, emotional, appraisal, and instrumental support as cited in the Taxonomy of Behavior Change Methods."
75544128|NCT01640275|Drug|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
75544129|NCT01640392|Behavioral|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
75707396|NCT06146361|Behavioral|Standard of Care|This group will receive a COVID-19 prevention flyer and social resources list only
75707397|NCT06146361|Behavioral|Booster session|"Participants will have a 10 - 15 minute booster' session about a week after engaging in the small group intervention. They will be contacted by phone and the booster will consist of brief prompts to engage participants in a discussion to encourage them to act on their personal commitments to protect themselves and others against COVID. They will also be encouraged to seek COVID related resources based on the information provided during the small group intervention."
75869784|NCT02265601|Other|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
75869785|NCT02265601|Other|standard care|paper/pencil living will form
75869786|NCT02242942|Drug|Chlorambucil|Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.
75544130|NCT01640470|Device|Assistive Technology Provision and Tune-Up Intervention|"The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.~The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist."
75544131|NCT01640470|Device|Customary Care|Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
75544132|NCT01640509|Radiation|treated by synchrotron radiation|treated by synchrotron radiation
75707398|NCT06146348|Behavioral|adapted DRAUP strategy bundle|DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.
75391068|NCT01445730|Dietary Supplement|Fructose|3 month fructose diet 75 g/day
75544133|NCT04719923|Behavioral|Children with autism spectrum disorders|Subjects affected by autism spectrum disorders
75544134|NCT04529356|Device|Transcranial magnetic stimulation|By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
75544135|NCT04529356|Drug|Acetaminophen|Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
75544136|NCT04529083|Device|Mr. MAPP|Mixed reality device to provide virtual mirror therapy to patients with phantom pain
75544137|NCT01640626|Other|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
75391069|NCT01445652|Device|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
75391070|NCT01445652|Other|Spectacles|Spectacles per current prescription
75391071|NCT04073316|Drug|Rivaroxaban 20 MG|Rivaroxaban intake, 20mg/day
75391072|NCT04073316|Drug|Warfarin|Warfarin intake, with target INR range between 2 and 3
75391073|NCT04089852|Drug|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
75707401|NCT06146322|Other|WR|Unsweetened preload condition: 240 mL white glutinous rice, 250 kcal, 0 g β-glucan
75707402|NCT06146322|Other|LB|Unsweetened preload condition: 240 mL low β-glucan barley, 250 kcal, ~4 g β-glucan
75391074|NCT04089852|Drug|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
75869787|NCT02242942|Drug|Venetoclax|Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.
75869788|NCT02242942|Drug|Obinutuzumab|Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
75869789|NCT02168140|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
75869790|NCT02168140|Drug|bendamustine hydrochloride|Given IV
75707403|NCT06146322|Other|MB|Unsweetened preload condition: 240 mL medium β-glucan barley, 250 kcal, ~5 g β-glucan
75391075|NCT03026244|Dietary Supplement|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
75391076|NCT03026244|Dietary Supplement|Placebo product|3 periods of 3 weeks placebo product
75391077|NCT03026322|Other|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
75391078|NCT03026322|Other|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
75391079|NCT01470144|Drug|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
75391080|NCT01443858|Drug|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
75391081|NCT01443858|Drug|Nicotine Patch|"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."
75391082|NCT01443858|Drug|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
75391083|NCT01443078|Drug|pemetrexed|
75391084|NCT01443078|Drug|cisplatin|
75391085|NCT01443078|Drug|Carboplatin|
75391086|NCT01443078|Drug|Gemcitabine Hydrochloride|
75391087|NCT01443078|Drug|Vinorelbine Tartrate|
75391088|NCT01443078|Drug|Docetaxel|
75391089|NCT01439880|Biological|Evolocumab|Administered by subcutaneous injection
75391090|NCT01439880|Other|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
75391091|NCT01469364|Drug|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
75391092|NCT01469364|Procedure|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
75391093|NCT01439724|Device|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
75391094|NCT01439724|Device|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
75391095|NCT01439568|Drug|LY2510924|Administered subcutaneous injection
75391096|NCT01439568|Drug|Carboplatin|Administered intravenously
75391097|NCT01439568|Drug|Etoposide|Administered intravenously
75391098|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
75544138|NCT00279942|Dietary Supplement|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
75391099|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
75391100|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
75391101|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
75391102|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
75544139|NCT00279942|Other|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
75544140|NCT01640665|Drug|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
76034348|NCT04899401|Other|Standard of care|Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. Standard of care Nasopharyngeal liberation through hydration with drinking fluids to support body fluid excretion, aspiration of secretions, NaCl solution for nasal irrigation, Nasal sprays with sea water, nasal spray with active compound (to be used only at special indication of the medical doctor) Throat spray with Benzydamine hydrochloride (Tantum Verde®), Pediatric use: children over 6 and below 12: 4 sprays 2 - 6 times a day. Children (under 6 years): 1 spray per 4 kg of body weight, a maximum of 4 sprays at once, 2-6 times a day according to the leaflet. Each spray equals 0.17 ml of solution. Acetaminophen (Paracetamol) per os: at need, as antipyretic (>38,5C), 10 mg/kg/dose, per need every 6-8 hours or according to the leaflet, maximum dosage 80 mg / kg / day. A dosage of over 30 mg/Kg/dose will result in an IP failure;
76034349|NCT04889651|Drug|BR9004|BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
76034350|NCT04889651|Drug|BR9004-1|BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
76034351|NCT04898933|Procedure|eyelid lesion excision|eyelid lesion excision was done under local anesthesia
75391103|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
75391104|NCT01468818|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
76034352|NCT04898777|Procedure|Biliary drainage|Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
75391105|NCT01468818|Drug|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
75544141|NCT01640665|Drug|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
75544142|NCT00251108|Procedure|Cardiorespiratory fitness training|
75544143|NCT01640704|Behavioral|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
75707404|NCT06146322|Other|HB|Unsweetened preload condition: 240 mL high β-glucan barley, 250 kcal, ~6 g β-glucan
75707405|NCT06146322|Other|WR+50g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL white glutinous rice + 50g HFCS, 391 kcal, 0 g β-glucan
75869791|NCT02119611|Device|Deep Brain Stimulation management|The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.
76034353|NCT04889339|Device|Test brace versus control brace: Immediate correction|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
75869792|NCT01837277|Drug|Dolutegravir 50 mg|Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
75869793|NCT01837277|Drug|Efavirenz-based regimens|Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
76034354|NCT04889339|Device|Test brace versus control brace: Long-term correction|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
76034355|NCT04884347|Dietary Supplement|Alline proMEN|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
76034356|NCT04884347|Dietary Supplement|Placebo|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
76034357|NCT04883723|Device|Shotblocker|Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain
76034358|NCT04883723|Other|Manual Pressure|The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
75707406|NCT06146322|Other|LB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL low β-glucan barley + 50 g HFCS, 391 kcal, ~4 g β-glucan
75707407|NCT06146322|Other|MB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL medium β-glucan barley + 50 g HFCS, 391 kcal, ~5 g β-glucan
75869794|NCT01827605|Other|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
75544144|NCT01640782|Drug|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|"Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles."
75707408|NCT06146322|Other|HB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL high β-glucan barley + 50 g HFCS, 391 kcal, ~6 g β-glucan
76034359|NCT04898699|Device|UrSure Rapid Urine Tenofovir Test|A point of care urine immunoassay to measure PrEP drug levels for adherence in participant urine samples over the preceding seven days will be done at all follow-up visits. At enrollment, study staff will explain the use of this experimental measurement of PrEP drug level in urine samples. Participants will receive results of the test at the same study visit during which it is performed.
75391106|NCT01468818|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
75869795|NCT01827605|Drug|BEAM|"BEAM REGIMEN day -6 Carmustine* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~Patient collecting ≥6x106 CD34+ cells/kg use >4x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~Patient collecting 4-6x106 CD34+ cells/kg use >2x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC > 1500/mmc"
75391107|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
75391108|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
75391109|NCT01442376|Drug|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
75391110|NCT01442376|Drug|Placebo to Ondansetron|
75391111|NCT01442376|Drug|Placebo to Ondansetron|
75391112|NCT01442376|Drug|Placebo to Palonosetron|
75391113|NCT01442064|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
75391114|NCT03026868|Procedure|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
75391115|NCT01441596|Drug|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
75391116|NCT01441596|Drug|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
75391117|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
75391118|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
75391119|NCT01441440|Drug|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
75869796|NCT01778647|Dietary Supplement|Stimulants plus Lovaza|Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit
75869797|NCT01778647|Drug|Stimulants plus placebo|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
75869798|NCT01658878|Biological|Nivolumab|
75869799|NCT01658878|Drug|Sorafenib|
75869800|NCT01658878|Drug|Ipilimumab|
75391120|NCT01441440|Drug|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
75869801|NCT01658878|Drug|Cabozantinib|
75391121|NCT01441440|Drug|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
75391122|NCT03026400|Procedure|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
75869802|NCT01628406|Procedure|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
75391123|NCT03026400|Procedure|Subumbilical incision|Considered here as the ''control'' intervention.
75391124|NCT01438476|Procedure|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
75391125|NCT01438476|Procedure|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
75391126|NCT01438476|Behavioral|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
75391127|NCT01438476|Behavioral|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
75391128|NCT03026478|Drug|Betamethasone Dipropionate|
75391129|NCT03026478|Drug|Clobetasol Propionate|
75391130|NCT01467570|Dietary Supplement|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:~fast oral rehydration in 3-4 hours by mouth~ORS given for ongoing losses until diarrhea stops (maintenance phase)"
75391131|NCT01467570|Dietary Supplement|ESPGHAN ORS|"Volume of the solution calculated by weight:~fast oral rehydration in 3-4 hours by mouth~ORS given for ongoing losses until diarrhea stops (maintenance phase)"
75391132|NCT04066764|Drug|Rivaroxaban|15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
75391133|NCT04066764|Drug|Warfarin|3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
75544145|NCT01640782|Drug|Leucovorin, 5-Fluorouracil|"Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations."
75869803|NCT01624285|Drug|sorafenib tosylate|Given PO
75869804|NCT01624285|Other|placebo|Given PO
75869805|NCT01624285|Other|laboratory biomarker analysis|Correlative studies
75869806|NCT01523002|Drug|Metoprolol and pyronaridine-artesunate|"On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period."
75869807|NCT01523002|Drug|pyronaridine-artesunate|"On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period."
75391134|NCT04066764|Drug|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
75391135|NCT01437540|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
75391136|NCT01437540|Drug|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
75391137|NCT01440972|Other|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
75869808|NCT01491269|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
75869809|NCT01471106|Drug|Dasatinib|"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."
75869810|NCT01431807|Drug|SYR-472|oral, for up to 52 weeks.
75391138|NCT01440972|Other|low intensity resistance training|low intensity resistance training without partial blood flow restriction
75544146|NCT00279981|Device|Diagnostic|
75869811|NCT01402258|Behavioral|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
75869812|NCT00493792|Device|Stryker X3 crosslink|Radiographs, questionnaires and an exam will be obtained at key post-surgical follow up dates. 3months, 2years, 5 years, 7 years and 10 years.
75869813|NCT00489307|Drug|Dexamethasone|4 mg PO (by mouth) twice daily x 14 days
76034360|NCT04898699|Device|OraQuick Rapid HIV Self-test kit|Participants will be provided with HIV self-testing kits to use at their discretion and, in case of multi-month dispensing, prior to start of new bottle of PrEP medication, in between study visits. HIV self-testing kits will be provided to confirm their HIV-negative status and make a connection between PrEP use and protection against HIV. Participants will receive detailed, interactive training on HIVST with pictorial elements, including instructions to contact study staff immediately in event of a reactive test for confirmation as per Kenya guidelines.
75869814|NCT00489307|Drug|Placebo|Placebo PO twice daily x 14 days
75869815|NCT00349310|Drug|Pramipexole|
75869816|NCT00267917|Device|Berodual Respimat|
75869817|NCT00267917|Device|Berodual HFA-MDI|
75869818|NCT00171002|Drug|valsartan/amlodipine|
75869819|NCT00154323|Drug|Oxcarbazepine|
75391139|NCT01420536|Procedure|Occlusal scheme|"Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts."
75391140|NCT01420068|Drug|SPP100|
75391141|NCT01467492|Drug|Telaprevir|Tablet
75391142|NCT01467492|Drug|Ribavirin|Tablet
75391143|NCT01467492|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
75391144|NCT01466790|Drug|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
75707409|NCT06146309|Drug|aflibercept (2mg/0.05ml)|Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
75707410|NCT06146296|Biological|Local Vitamin C injection|An injection of 1-1.5 ml of L-ascorbic acid, locally introduced in relation to the keratinized gingival tissues, with extension to the whole target region successively. The injected area will be massaged for equal distribution of the injected vitamin. Injections will be performed on the first day of retainer delivery (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3). Hence, a total of 4 local Vit-C injections will be performed over the study period.
75391145|NCT01466790|Drug|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
75391146|NCT01466790|Drug|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
75391147|NCT01418352|Drug|Aripiprazole|Aripiprazole tablets once weekly for 8 weeks.
75391148|NCT01418352|Drug|Placebo|Aripiprazole matching-placebo once-weekly for 8 weeks.
75707411|NCT06146296|Biological|Oral Vitamin C supplement|Patients will be prescribed a daily oral (systemic) Vit-C supplement to be taken over the follow up period.
75391149|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose [60 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
75391150|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® [15 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
75391151|NCT01465464|Drug|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
75391152|NCT01465464|Drug|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
75391153|NCT03026010|Procedure|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
75391154|NCT01417104|Drug|Aliskiren|150 mg/300mg
75391155|NCT01417104|Drug|Placebo|150mg/300mg
75391156|NCT01465386|Drug|bortezomib|Given SC
75391157|NCT01465230|Drug|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
75391158|NCT04767516|Other|no intervention|no intervention
75391159|NCT04500132|Drug|EC-18|EC-18 QD
75391160|NCT04500132|Drug|Placebo EC-18|Placebo EC-18 QD
75391161|NCT01435356|Biological|recMAGE-A3 + AS15 ASCI|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
75707412|NCT06146283|Combination Product|Jamar Hydraulic Hand Dynamometer|"This device measures hand grip strength. The individual should be in an upright sitting position. There should be no arm support on the sitting surface. ...~The knee angle should be 90 degrees. Elbow angle should be 90 degrees. The wrist should be held without deviation. The measurement should be performed 3 times with an interval of 10 seconds."
76034361|NCT04898699|Drug|Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®]|Information will be provided regarding dosing of PrEP medications, importance of daily adherence, importance of frequent HIV testing, and signs and symptoms of drug toxicity, acute HIV infection and STIs. An initial one-month supply (30 pills) of FTC/TDF will be given to all PrEP study participants. At the one-month study assessment, a two-month supply of daily oral FTC/TDF will be given to each participant, after HIV testing, assessment for acute HIV infection and review of side effects and adherence, following national guidelines and procedures for PrEP services. At Month 3 assessment, a three-month supply of oral FTC/TDF will be given.
75391162|NCT01435356|Biological|Placebo|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
75391163|NCT01435122|Drug|Axitinib|Axitinib Administration as outlined in Arm description
75391164|NCT04048122|Behavioral|MultiContext for PD Strategy Training|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
75391165|NCT04048122|Behavioral|Standard of Care|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
75391166|NCT01434810|Device|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
75391167|NCT01434810|Device|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
75391168|NCT01393626|Drug|Placebo|oral tablets twice daily
75391169|NCT01393626|Drug|CP-690,550|oral tablets twice daily
75391170|NCT01393626|Drug|CP-690,550|oral tablets twice daily
75707413|NCT06146244|Procedure|sinus lift|Implant placement on grafted sinus vs antral autogenous bone
75391171|NCT04059666|Other|Investigational|Cow's milk-based Infant Formula with whey protein-lipid concentrate
75391172|NCT04059666|Other|Control|Cow's milk-based Infant Formula
75391173|NCT04059276|Diagnostic Test|MRI|We will examine chronic (>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
75544147|NCT00251147|Procedure|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
75391174|NCT04059276|Diagnostic Test|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
75869820|NCT03521141|Drug|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
75869821|NCT03521141|Drug|Varenicline|FDA-approved smoking cessation pharmacotherapy
75869822|NCT03521141|Genetic|Nicotine metabolism|Information on nicotine metabolism will be used to inform selection of medication.
75391175|NCT01393158|Drug|Apremilast|20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.
75391176|NCT01413360|Drug|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
75391177|NCT01413204|Drug|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
75391178|NCT01413204|Drug|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
75391179|NCT01413204|Drug|Placebo|The patients will receive Placebo orally for 24 weeks.
75391180|NCT03815448|Drug|Methotrexate|Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
75391181|NCT03815448|Other|Placebo|Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
75391182|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75391183|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75391184|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
75391185|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75707414|NCT06146244|Device|resonance frequency analysis|analysis of the ISQ evolution and its changes after 3 months of placing the implant in native or regenerated bone, always in the antral area
75707415|NCT06146205|Procedure|Direct lateral approach|The hip joint is approached from laterally, and parts of the gluteus medius tendon is released from the greater trochanter before the hip joint is entered from the anterior side.
75707416|NCT06146205|Procedure|SPAIRE|The hip joint is entered from posterior, and the approach preserves the external rotators of the hip joint.
75391186|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75391187|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
75391188|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75391189|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75391190|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
75707417|NCT06146192|Drug|Colchicine|colchicine 1-2 mg/day
75707418|NCT06146166|Dietary Supplement|Oral herbal supplement|Oral supplement containing an oral blend taken once daily
75707419|NCT06146166|Dietary Supplement|Oral placebo supplement|Oral placebo supplement taken once daily
75707420|NCT06146140|Dietary Supplement|Oral herbal supplement|Take one capsule daily
75707421|NCT06146140|Dietary Supplement|Oral placebo supplement|Take one capsule daily
75869823|NCT03521141|Genetic|Genetically-informed lung cancer risk score|This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
75391191|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75391192|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75391193|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
75391194|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75707422|NCT06146127|Other|phenotyping|Large scale molecular phenotyping
75544148|NCT00251147|Procedure|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
75544149|NCT01640821|Behavioral|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
75391195|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
75391196|NCT01412424|Drug|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
75391197|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
75391198|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
75391199|NCT01433172|Biological|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
75544150|NCT01640977|Procedure|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
75544151|NCT01640977|Procedure|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
75707423|NCT06146114|Diagnostic Test|Collect HER2 expression in prostate cancer patients|HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
75707424|NCT06146062|Drug|Mesenchymal Stromal Cells (MSC)|3 injections one week apart
75707425|NCT06146062|Drug|placebo|3 injections one week apart
75707426|NCT06146036|Behavioral|HIIT snacks|Cycling Exercise. 3 times per day 6 x 1 min at approximately 85-95% of HRmax
75391200|NCT01433172|Biological|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10^6 irradiated H1944 tumor cells, 7.5 X 10^6 irradiated H2122 cells, and containing 15 X 10^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
75544152|NCT00251186|Drug|Capecitabine and Cetuximab|
75707427|NCT06146036|Behavioral|Sprint snacks|Cycling Exercise. 3 times per day one ''all out'' sprint
75707428|NCT06146036|Other|Control|No exercise, sedentary.
75707429|NCT06146023|Device|Robotic anastomosis (Symani surgical system and RoboticScope)|Robot-assisted microvascular anastomosis on 1.0-mm-diameter silicone vessels using the Symani surgical system and RoboticScope
75707430|NCT06146023|Procedure|Conventional anastomosis|Conventional microvascular anastomosis on 1.0-mm-diameter silicone vessels using conventional microsurgical instruments and conventional surgical microscope
76034362|NCT04898699|Behavioral|2-way text message reminders|"All participants will receive weekly SMS visit reminders to support PrEP adherence. Participants will be asked at study enrollment for a primary contact telephone number and an alternate number for contact. Participants without cell phones will be provided an inexpensive cell phone (although cell phone ownership is very high in Kenya). Participants will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, use of HIV self-test kit, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with any questions, concerns or messages that they have for the study staff."
76034363|NCT04898699|Behavioral|HIV risk-reduction counseling|All study participants will be provided with brief interactive counseling at each study visit, tailored to the results of their urine assay.
76034364|NCT04883801|Diagnostic Test|Reviewed clinical records and laboratory results|Retrospectively reviewed clinical records and laboratory results
76034365|NCT02618759|Drug|DSXS|active treatment
76034366|NCT02618759|Drug|Placebo|placebo treatment
75544153|NCT01641172|Procedure|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
75544154|NCT01641172|Procedure|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
75544155|NCT01641172|Procedure|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
75707431|NCT06146010|Other|No intervention|Once the patient or their legal guardian has given their written consent, a patient is included in the leptomeningeal disease register. Due to the rapid course of the disease and potential rapid deterioration, the documentation of the course of the disease of the individual patients is to be carried out retrospectively from the data recorded during the course of the clinical routine for the entire duration of the study or until the death of the participating patients after the written consent of the patients. The registry's data sources are the diagnostic findings made at the center and doctors' letters from routine clinical practice. The participating centers carry out the assessment of the participants' performance status so that the patients do not have to complete any study-related questionnaires.
75544156|NCT01641172|Procedure|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
75869824|NCT03521141|Behavioral|"NCI Clearing the Air"|A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
76034367|NCT04899011|Other|Questionnaire|"Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life."
76034368|NCT04888715|Drug|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
76034369|NCT04888715|Drug|Pirfenidone|Pirfenidone
76034370|NCT04888715|Drug|Nintedanib|Nintedanib
76034371|NCT04888559|Other|Breakfast product: Whole grain|This intervention is a whole grain-based breakfast product containing oats and barley.
76034372|NCT04888559|Other|Breakfast product: Reference|This intervention is a rice-based breakfast product.
76034373|NCT04897997|Procedure|coronarography and angioplasty|selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
76034374|NCT04888325|Other|Oral glucose|Oral glucose consumption (1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours). During the 6-hour observation period infusion of normal saline (NaCL 0,9%) at a rate of 0.83 plus Heparin, 800 IU/h with a priming dose of 1000 IU.
76034375|NCT04888325|Other|Intravenous glucose|10% intravenous glucose infusion at a rate of 3.6 ml/kg/h plus Heparin 800 IU/h with a priming dose of 1000 IU will be administrated for 6 hours. Consumption of 300 ml of water at 0 and 3 hours
76034376|NCT04888091|Procedure|Cotton swab|Removal of the cervical mucus with a cotton swab before embryo transfer.
76034377|NCT04888091|Procedure|Cannula|Removal of the cervical mucus with a cannula before embryo transfer.
76034378|NCT03050723|Device|Princess® FILLER|Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
75869825|NCT03728621|Behavioral|Normocaloric and balanced diet, physical activity|Promotion of normocaloric & balanced diet and physical activity
76034379|NCT04888403|Drug|Toripalimab+Nedaplatin+Albumin Paclitaxel|"Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel"
76034380|NCT04883567|Diagnostic Test|The use of artificial intelligence system Cerebro|The artificial intelligence system Cerebro would be used during OGD
75391201|NCT01433172|Biological|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
75391202|NCT01432938|Biological|dulaglutide|Administered subcutaneously
75391203|NCT01432938|Drug|Warfarin|Administered orally
75391204|NCT03025230|Other|Dry needling and electric stimulation|Dry needling technique and the application of electric stimulation of levator scapulae PG
75391205|NCT03025230|Other|Dry needling|Treatment of PG with a filiform needle in levator scapulae muscle
75391206|NCT01392300|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
75391207|NCT01392300|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
75544157|NCT01641172|Dietary Supplement|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
75544158|NCT01641172|Behavioral|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
75391208|NCT04767204|Behavioral|peer co-delivered vocational rehabilitation service|The services provided by the trained peers in the work training or problem-solving group, which integrates into a supported employment services
75391209|NCT01432626|Drug|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
75869826|NCT03722147|Biological|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
75869827|NCT03722069|Other|Low sodium diet|Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
76034381|NCT03050177|Drug|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
76034382|NCT03050177|Drug|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
76034383|NCT04882787|Device|BTE hearing aid|Amplification
76034384|NCT03051581|Device|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
75391210|NCT02985294|Other|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
75391211|NCT03025776|Behavioral|Reaching|sitting reaching under various task conditions (size, speed, location)
75391212|NCT03025776|Behavioral|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many & which hand to use, kinematic data collected
75391213|NCT01410474|Biological|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
75391214|NCT04037592|Device|Active standardized iTBS-DMPFC|Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
75391215|NCT04037592|Device|Active high-dosage iTBS-DMPFC|Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
75391216|NCT04037592|Device|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
76034385|NCT04882865|Device|assist|A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
75391217|NCT01391130|Drug|LY2510924|Administered subcutaneously
75391218|NCT01391130|Drug|Sunitinib|Administered orally
75391219|NCT04046094|Drug|Ascorbic Acid|Ascorbic Acid Intravenous
75391220|NCT01410240|Procedure|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
75391221|NCT01410240|Drug|FLOSEAL Hemostatic Matrix + Standard of care|"FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used"
75391222|NCT01409928|Device|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
75391223|NCT04037124|Procedure|Cervical procedure|simple hysterectomy, radical hysterectomy or fertility sparing surgery
75391224|NCT01431534|Drug|Ridaforolimus|Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m^2, 28 mg/m^2, or 33 mg/m^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
75869828|NCT03722069|Other|Normal sodium diet|Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
75391225|NCT01409382|Behavioral|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
75391226|NCT01408914|Drug|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
75391227|NCT04044846|Behavioral|Physical activity program for homebound older adults faciliated by Personal Support Workers|The intervention is an evidence- informed, theory-driven mobility intervention for community-dwelling OAs who are moderately and severely frail according to the clinical frailty scale (Rockwood et al., 2005). The intervention, entitled Promoting Movement in OAs (ProMO), will be implementable with frail OAs in partnership with any care provider in the home. Investigators will focus the study on the two main providers of care- personal support workers (PSWs) and family caregivers. OAs, PSWs, and caregivers will co-create ProMO with us. ProMO will be distinct from existing home-based exercise programs (Johnson et al., 2003) (Giangregorio et al., 2018) because it will optimize natural opportunities for mobilization during care (e.g., bathing and dressing) and will be embedded in facilitated activities of daily living.
75391228|NCT04044222|Biological|Sintilimab|IV
75391229|NCT04044222|Drug|Carboplatin|IV
75391230|NCT04044222|Drug|Etoposide|IV
75391231|NCT04044222|Drug|Ifosfamide|IV
75391232|NCT04044222|Drug|Placebo|IV
75391233|NCT04044222|Drug|Carboplatin|IV
75391234|NCT04044222|Drug|Etoposide|IV
75391235|NCT04044222|Drug|Ifosfamide|IV
75391236|NCT01431144|Procedure|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
75391237|NCT01431144|Procedure|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
75391238|NCT01430754|Drug|tasimelteon|20 mg tasimelteon capsules, daily
75391239|NCT01430754|Drug|Placebo|Placebo capsules, daily
75391240|NCT01390428|Drug|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
75544159|NCT01641172|Behavioral|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
75391241|NCT01430130|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
75391242|NCT04052256|Diagnostic Test|Coronary computed tomography angiography|Computational fluid dynamic model information derived from CT
75391243|NCT01407354|Device|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
75391244|NCT01407354|Other|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
75391245|NCT01407276|Drug|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
75391246|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
75391247|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
75391248|NCT01390272|Behavioral|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
75391249|NCT01390272|Behavioral|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
75391250|NCT01429584|Drug|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
75391251|NCT01429584|Drug|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
75391252|NCT01406652|Procedure|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
75869829|NCT03725267|Drug|Melatonin Pill|Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
75391253|NCT01406574|Drug|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
75391254|NCT01406574|Drug|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
75391255|NCT01405950|Drug|Zanaflex Capsules|0.025 mg/kg
75391256|NCT01405950|Drug|Zanaflex Capsules|0.05 mg/kg
75391257|NCT01405950|Drug|Zanaflex Capsules|0.075 mg/kg
75544160|NCT00286845|Drug|Standard Chemotherapy|physician determined
75544161|NCT01641211|Behavioral|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
75544162|NCT01641211|Other|Nutrition video|Children in this group will watch a 2-minute nutrition video.
75544163|NCT01641250|Drug|RO5429083|Multiple escalating doses
75544164|NCT01641250|Drug|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
75869830|NCT03725267|Drug|Placebo oral capsule|Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
75869831|NCT02997176|Drug|Talazoparib|Daily oral doses of talazoparib 0.5 mg
75869832|NCT03000452|Drug|DARATUMUMAB|DARATUMUMAB
75869833|NCT03000452|Drug|DURVALUMAB|DURVALUMAB
75869834|NCT03664856|Other|interview|The patient will be asked to answer the questions that the interviewer will ask him.
76034386|NCT04883021|Device|Dual Target Theta Burst Stimulation|"TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold."
76034387|NCT04897685|Behavioral|Flow with Nature|Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
76034388|NCT03050411|Drug|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
75391258|NCT01405950|Drug|Zanaflex Capsules|0.1 mg/kg
75391259|NCT01405560|Drug|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
75391260|NCT01405560|Biological|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
75391261|NCT01405560|Drug|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
75391262|NCT01428882|Drug|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
75391263|NCT01428882|Drug|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
75869835|NCT03664388|Drug|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
75869836|NCT03664310|Other|FSET Anxiety and Sleep Treatment|Computerized anxiety and insomnia intervention.
75391264|NCT01428258|Other|GMP Diet/GMP Medical Foods|The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
75391265|NCT01428258|Other|AA Diet/AA Medical Foods|The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
75869837|NCT03664310|Other|Control|Physical health control
75869838|NCT04056416|Device|MedBIKE|A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
75869839|NCT03663686|Drug|Litapiprant Tablet|Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
75869840|NCT01373164|Drug|Galunisertib|Administered orally
75869841|NCT01373164|Drug|Gemcitabine|Administered intravenously
75869842|NCT01373164|Drug|Placebo|Administered orally
75869843|NCT04349332|Device|Helmet non-invasive ventilation (NIV)|After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate <30breaths/min and PaO2 >75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.
75869844|NCT02999984|Genetic|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
75869845|NCT02999984|Drug|busulfan|Busulfan is used for non-myeloablative conditioning
75869846|NCT02999984|Drug|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
76034389|NCT03050411|Drug|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
75391266|NCT01389882|Procedure|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
75391267|NCT01442688|Drug|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
75391268|NCT01442688|Drug|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
75391269|NCT01466166|Biological|Pegloticase|Pegloticase 8 mg intravenous every 2 weeks
75707432|NCT06145984|Behavioral|Mindfulness|Participants receive a two-hour professional training to get familiar with the basic techniques of mindfulness. The training is given by a mindfulness professional and consists of psycho-education, instructions for mindfulness and guided practice. It focuses mainly on attending to stimuli such as breathing, external sounds or bodily sensations and becoming aware of where one's attention is. After the professional training, participants receive instructions about the audio application with which participants continue performing short exercises using the learned technique every day guided by an application on their smartphone customized for this research. Specifically, participants perform one short exercise (10 min) per day for in total six days. The exercises that are being performed are: attention to breathing part 1, attention to breathing part 2, attention to sounds, attention to bodily sensations, attention to thoughts, attention to emotions and feelings.
75391270|NCT03814200|Drug|Saline|Single i.v. infusion of 100 mL saline 0.9% for 30 min
75869847|NCT03664154|Behavioral|Stress and Feeding (SAFE)|"The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls."
75869848|NCT03664700|Device|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
75869849|NCT03550313|Biological|Multivalent|Pneumococcal conjugate vaccine
75391271|NCT03814200|Drug|ACT-246475|Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
75869850|NCT03550313|Biological|Prevnar 13|Pneumococcal conjugate vaccine
75869851|NCT03312907|Drug|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
75869852|NCT03312907|Drug|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
75391272|NCT03814200|Drug|Rifampicin|Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
75391273|NCT01426854|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
75869853|NCT03312907|Drug|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
75869854|NCT03312907|Drug|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
75869855|NCT03312907|Drug|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to <= 5 mg/day will administered through Week 104.
75869856|NCT03312907|Drug|Steroid Taper|Steroid taper will include prednisone doses equivalent to =< 5 mg/day in all Arms through Week 104.
75869857|NCT02999672|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
75391274|NCT01426854|Other|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
75391275|NCT04050774|Device|Balance boards|The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
75391276|NCT01426386|Drug|FE 999049|
75869858|NCT03664076|Diagnostic Test|COMISS score|cow's milk protein symptoms score awareness tool to select cow's milk protein allergy in infants
75391277|NCT01426386|Drug|Gonal - F|
75544165|NCT00251264|Procedure|Open stabilization|"Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy."
75707433|NCT06145984|Behavioral|Positive Fantasizing|"In a two-hour training session by a professional trainer, participants get familiar with the positive fantasizing technique. Participants receive psycho-education about the role of dysfunctional beliefs. The positive fantasizing technique starts with identifying dysfunctional beliefs and schema and subsequently fantasize about a positive fantasy belief. Participants are guided by the professional using imagery and experiencing thoughts and feelings that would be elicited when using their fantasy belief as if in an ideal world. After using imagery techniques, participants are asked, with help of the professional, to reflect on their experience during the fantasizing exercise and to think of how they could implement this fantasy belief more in their daily life, by adapting their fantasy belief into a more practical belief. After the training, participants are asked to perform one exercise per day using the fantasizing technique using a mobile application for six days in total."
75707434|NCT06145971|Behavioral|brief Cognitive Behavioural Therapy for Insomnia (bCBTi)|Two sessions of Cognitive Behavioural Therapy for Insomnia, encompassing a cognitive therapy technique and a behavioural technique as a minimum.
75707435|NCT06145958|Drug|Luteinising Hormone-Releasing Factor Analogue|Androgen Deprivation Therapy
75707436|NCT06145932|Device|real rTMS|treated with 1HZ rTMS 1800 pulses / day,for 10 days
75707437|NCT06145932|Device|sham rTMS|treated with sham rTMS 1800 pulses / day,for 10 days
75869859|NCT03664622|Drug|Ketamine|Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
75869860|NCT03664622|Drug|Morphine|a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
75869861|NCT05276869|Other|WeeFIM instrument|In a formative setting, the WeeFIM tool examines functional independence in kids aged 6 months to 7 years old. It can also be used with children over the age of 7 who show functional ability. The instrument may be controlled by observational data or a meeting, and it takes 15 to 20 minutes to create [10].
75869862|NCT01911676|Drug|PF-03463275|
75869863|NCT01911676|Drug|Placebo|
75869864|NCT03663998|Biological|CN54ENV DNA|"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."
75869865|NCT03663998|Biological|GENEVAX® IL-12 DNA|"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."
75869866|NCT01793233|Other|Laboratory Biomarker Analysis|Correlative studies
75869867|NCT01793233|Other|Questionnaire Administration|Ancillary studies
75391278|NCT01404234|Drug|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
75391279|NCT01403610|Drug|TH-302 preoperative|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
75391280|NCT01403610|Drug|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
75391281|NCT01403610|Drug|TH-302 (escalating) with bevacizumab 10mg/kg|Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
75391282|NCT01403064|Biological|ALD518|IV
75391283|NCT01403064|Drug|0.9% saline|IV Infusion
75391284|NCT04408014|Diagnostic Test|Serological test|IgM and IgG for SARS-CoV-2
75391285|NCT04408014|Diagnostic Test|Nasopharyngeal Swab|PCR for SARS-CoV-2
75391286|NCT04408014|Diagnostic Test|Oropharyngeal Swab|PCR for SARS-CoV-2
75391287|NCT01402986|Other|Placebo Q2W|Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
75391288|NCT01402986|Biological|Tralokinumab 300 mg, Q2W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
75391289|NCT01402986|Other|Placebo, Q2/4W|Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
75391290|NCT01402986|Biological|Tralokinumab 300 mg, Q2/4W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
75391291|NCT01402908|Drug|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
75391292|NCT01402908|Other|Placebo|Lactose lyophilized powder
75391293|NCT01389258|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
75391294|NCT01389102|Drug|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
75391295|NCT01389102|Drug|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
75391296|NCT01389102|Drug|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
75544166|NCT00251264|Procedure|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
75391297|NCT01389102|Drug|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
75391298|NCT01389102|Drug|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
75391299|NCT01389102|Drug|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
75391300|NCT01402284|Drug|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
75391301|NCT01402284|Drug|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
75391302|NCT01402284|Drug|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
75707438|NCT06145880|Diagnostic Test|Artificial intelligence tool for transthoracic echocardiography|Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.
75707439|NCT06145854|Drug|Cabotegravir Injection [Apretude]|Apretude for PrEP
75707440|NCT06145841|Diagnostic Test|Pathogen metagenomic next-generation sequencing|In diagnosing patients with AIDS combined with severe pneumonia and/or sepsis, use pathogen metagenomics technology to detect peripheral blood specimens
75544167|NCT01641289|Drug|Paracetamol|>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate <50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
75544168|NCT01641289|Drug|No Paracetamol|"No paracetamol + Intravenous Artesunate~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
75391303|NCT01402284|Drug|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
75391304|NCT01402284|Drug|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
75707441|NCT06145828|Device|Cytokine Adsorption|During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
76034390|NCT03050567|Diagnostic Test|Transcranial Doppler Ultrasound|Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
76034391|NCT04882943|Other|questionnaires|Quality of life questionnaires
76034392|NCT04887545|Diagnostic Test|Proteomics analysis of pleural effusion|Pleural effusion removed as part of standard care is fractionized and analyzed by mass spectrometry
75391305|NCT01388790|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
75391306|NCT01388790|Drug|Cisplatin|Cisplatin 60 mg/m^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
75391307|NCT01388790|Drug|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
75544169|NCT01641328|Behavioral|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
75544170|NCT01641328|Behavioral|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
75544171|NCT00280020|Behavioral|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
75544172|NCT00280020|Behavioral|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
75707442|NCT06145802|Biological|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
75707443|NCT06145737|Behavioral|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)|"One on one virtual self-management program for cognitive dysfunction associated with Multiple Sclerosis (MS).~HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-MS is an adaptation of the HOBSCOTCH program for people with MS and incorporates education about multiple sclerosis and cognition into the education module."
76034393|NCT03049943|Device|low level laser|
76034394|NCT04896905|Other|Rehabilitation|Rehabilitative procedures in isolation ward
76034395|NCT04887233|Other|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
76034396|NCT04887233|Other|Placebo|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
76034397|NCT04887311|Drug|MBM-01|Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
76034398|NCT03050255|Other|Medical air|
76034399|NCT03050255|Other|Oxygen (2Liter/min)|
76034400|NCT03050255|Other|Oxygen (4Liter/min)|
75544173|NCT00280020|Behavioral|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
75707444|NCT06145724|Behavioral|Maternal Sepsis Safety Bundle|Maternal sepsis safety bundle implemented at Columbia, Lincoln, Harlem, and Allen hospitals.
75707445|NCT06145711|Other|hiPSC-DAP|Using hiPSC-DAP for the treatment of the patients of Parkinson's diease
75707446|NCT06145685|Procedure|Minimally invasive non-surgical periodontal therapy|Minimally invasive non-surgical periodontal therapy
75707447|NCT06145685|Procedure|Conventional non-surgical periodontal therapy|Conventional non-surgical periodontal therapy
75869868|NCT03113734|Other|Construction and validation of a functional score|"All patients will be treated at the same way:~Completion of questionnaire by the physician with him. Once the consultation has been completed, the physician will issue prescriptions for the usual medical treatment, laximetry prescription (GNRB) to be performed when the knee is indolent and the prescription of the MRI to be performed .The physician will inform the patient that they should consult with the investigator's orthopedic surgeon once the results of GNRB and MRI are available.The study will end there for the patient. The surgeon will then follow his usual diagnostic procedure to decide on the future care of the patient."
75544174|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
75707448|NCT06145672|Procedure|follicular unit extraction and implantaion|extract hair follicles as grafts from donor area and implant them in recipient area
76034401|NCT04886921|Behavioral|Abdominal muscle training|Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
76034402|NCT04886843|Other|Cold pack|Five minutes cold pack was applied on the affected side dorsiflexor muscle skin, a five-minute break was given and a further 5-minute cold application was repeated
76034403|NCT04886843|Device|NMES|NMES was applied to the nonaffected side ankle dorsiflexors
75707449|NCT06145659|Behavioral|Preschool and Me|Utilizes patient navigation services and a medical-educational care plan to support linkages between medical and educational systems
75707450|NCT06145633|Procedure|Biopsy|Undergo biopsy
75707451|NCT06145633|Procedure|Biospecimen Collection|Undergo blood sample colleciton
75707452|NCT06145633|Procedure|Bone Scan|Undergo bone scan
75707453|NCT06145633|Procedure|Computed Tomography|Undergo CT, SPECT/CT, PET/CT
75707454|NCT06145633|Other|Fludeoxyglucose F-18|Undergo FDG PET/CT
75707455|NCT06145633|Other|Gallium Ga 68 Gozetotide|Given IV
75707456|NCT06145633|Drug|Lutetium Lu 177 Vipivotide Tetraxetan|Given 177Lu-PSMA-617
75707457|NCT06145633|Procedure|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET
75707458|NCT06145633|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
75707459|NCT06145633|Drug|Vorinostat|Given IV
75391308|NCT01388478|Drug|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
75391309|NCT04029714|Procedure|Active Surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
75707460|NCT06145568|Other|Pregnant Women|We want to quantify Minority Americans at risk of pregnancy complications
75707461|NCT06145542|Behavioral|AR group: aerobic training before resistance training|"Exercise are performed 3 times/wk for 8 wks.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve (HRR). Real-time heart rate monitors are worn by each participant during the session. Aerobic training session lasts for 30 minutes, with an additional 5-minute warm-up and 5-min relaxation training before and after the session, respectively.~Participants perform resistance exercise on a set of strength training equipment. Load of resistance exercise is between 60-80% of repetition maximum (RM) in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 seconds. Between each two sets, there are 60 s of rest time."
75869869|NCT04051658|Device|Transcranial direct current stimulation|tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
76034404|NCT03049631|Dietary Supplement|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
76034405|NCT03049631|Dietary Supplement|Raspberry|Red raspberries (1 cup equivalent)
75391310|NCT01424670|Drug|Delamanid + OBR|The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
75707462|NCT06145542|Behavioral|RA group: resistance exercise before aerobic exercise|"Exercise are performed 3 times/wk for 8 wks.~Following a 5-min warm-up exercise, the participants perform resistance training on a set of equipment. Load of resistance exercise is set between 60-80% of repetition maximum in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 s. Between each two sets, there are 60 seconds of rest time.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve. Real-time heart rate monitors are worn during the entire session. Each aerobic training session lasts for 30 minutes, with an 5-minute relaxation training after the session."
76034406|NCT04886765|Drug|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
75391311|NCT01424670|Drug|Placebo + OBR|Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
75391312|NCT01424514|Drug|SB-705498|12mg intra nasal
75391313|NCT01424514|Drug|Placebo|Placebo intra nasal
75391314|NCT01400958|Drug|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
75391315|NCT01400958|Drug|Placebo|Placebo x 42 days; THEN, No More Placebo
75391316|NCT01388166|Procedure|Education|Education
75544175|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|"Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX."
75391317|NCT01400412|Drug|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
75391318|NCT01400412|Drug|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
75391319|NCT01400412|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
75391320|NCT01400412|Drug|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
75391321|NCT01400412|Drug|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
75391322|NCT01400412|Drug|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
75391323|NCT01400412|Drug|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
75391324|NCT01422876|Drug|high dose FDC|once daily
75391325|NCT01422876|Drug|BI 10773 high dose|once daily
75391326|NCT01422876|Drug|high dose FDC placebo|once daily
75544176|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is >5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is <5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
76034407|NCT04896671|Behavioral|Physical exercise (running on a treadmill)|Participants in the intervention group join a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes. In each session, every participant will be trained to run for 30 minutes on a treadmill. According to Exercise and Sports Science Australia (ESSA) exercise intensity guidelines, the intensity of running is suggested to be moderate and vigorous (alternating between the two) in this study.
75391327|NCT01422876|Drug|low dose FDC placebo|once daily
76034408|NCT04396847|Drug|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
75391328|NCT01422876|Drug|high dose FDC placebo|once daily
75391329|NCT01422876|Drug|high dose FDC placebo|once daily
75391330|NCT01422876|Drug|low dose FDC placebo|once daily
75391331|NCT01422876|Drug|low dose FDC placebo|once daily
75391332|NCT01422876|Drug|high dose BI 10773 placebo|once daily
75391333|NCT01422876|Drug|low dose FDC|once daily
75391334|NCT01422876|Drug|high dose FDC placebo|once daily
75391335|NCT01422876|Drug|BI 10773 low dose|low dose once daily
75391336|NCT01422876|Drug|high dose BI 10773 placebo|once daily
75391337|NCT01422876|Drug|high dose BI 10773 placebo|once daily
75391338|NCT01422876|Drug|linagliptin|once daily
75391339|NCT01422876|Drug|low dose FDC placebo|once daily
75391340|NCT01422876|Drug|linagliptin placebo|once daily
75391341|NCT01422876|Drug|BI 10773 low dose placebo|once daily
75391342|NCT01422876|Drug|linagliptin placebo|once daily
75391343|NCT01422876|Drug|low dose BI 10773 placebo|once daily
75391344|NCT01422876|Drug|linagliptin placebo|once daily
75391345|NCT01422876|Drug|high dose BI 10773 placebo|once daily
75391346|NCT01422876|Drug|BI 10773 low dose placebo|once daily
75391347|NCT01422876|Drug|low dose BI 10773 placebo|once daily
75391348|NCT01422876|Drug|linagliptin placebo|once daily
75391349|NCT01422720|Drug|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
75391350|NCT01387932|Device|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
75391351|NCT01387932|Procedure|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
75391352|NCT04413786|Drug|oxytocin treatment|intranasal administration of oxytocin (24IU)
75391353|NCT04413786|Drug|placebo treatment|intranasal administration of placebo (24IU)
75707463|NCT06145529|Other|RT Functional HIIT circuit program (15 minutes) with or without gamification approach|"EG1 (RT Functional HIIT circuit program): This intervention involves a 15-minute Resistance Training (RT) Functional High-Intensity Interval Training (HIIT) circuit program. The focus is on functional movements performed at a high intensity within intervals.~EG2 (RT Functional HIIT circuit program with gamification): This intervention replicates the RT Functional HIIT circuit program from EG1 but incorporates gamification strategies. Gamification involves the application of game-like elements, such as points, rewards, and competition, to make the exercise routine more engaging and enjoyable for the participants.~Control Group (CG): Children in the control group continue with their regular Physical Education (PE) sessions, maintaining their usual routine"
75707464|NCT06145516|Behavioral|Cognitive behavioral therapy for insomnia (CBT-I)|Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)
75707465|NCT06145516|Behavioral|Sleep education therapy (SET)|Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
75707466|NCT06145490|Dietary Supplement|Caffeine|Caffeine capsule 250 mg, oral intake
75707467|NCT06145490|Drug|Placebo|Placebo capsule, oral intake
76034409|NCT04396847|Drug|Placebo oral tablet|Placebo Oral Tablet (BID)
76034410|NCT03051503|Drug|The Transdermal Therapeutic System-Fentanyl (TTS-F)|(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
75707468|NCT06145451|Behavioral|Family Success Network|The Family Success Network (FSN) is a community-based maltreatment prevention program that is being piloted to serve caregivers of children aged between 0-18 in the Trumbull, Mahoning, and Columbiana Counties in Ohio. FSN is a comprehensive multi-tier program providing information and referrals to community resources at Tier I (i.e., the initial contact stage), caregiver education, and financial literacy program along with concrete support at Tier II (i.e., enrollment in family coaching services in FSN), and a life skills program and monthly home visits for families with more intensive needs at tier III (most intensive level of FSN services).
75707469|NCT06145438|Drug|Dienogest|Drug is administered orally at the same time every day
75707470|NCT06145438|Drug|Depo Medroxyprogesterone acetate|Drug is injected intramuscularly on the buttock
75707471|NCT06145438|Drug|Leuprolide (as Leuprolide Acetate)|Drug is injected intramuscularly on the buttock
76034411|NCT03051503|Device|Intravenous patient-controlled analgesia (PCA) morphine|IV PCA morphine for pain in the postoperative period.
76034412|NCT04896437|Procedure|non-centrifuge fat graft application to the wounds|Autologous fat grafts were harvested from abdominal or gluteal regions of the patients and injected into the wound bed and wound environment. Clinical observation and photograph records were used to follow the wounds.
76034413|NCT04886687|Procedure|mechanical thrombectomy|mechanical thrombectomy
76034414|NCT04886375|Procedure|erector spina plane block|The investigators performed erector spina plane block to that patient group for postoperative analgesia
76034415|NCT04886375|Procedure|modified pectoral nerve block|The investigators performed modified pectoral block to that patient group for postoperative analgesia
76034416|NCT04882709|Device|Receiver-in-canal hearing aid 1 default|A receiver-in-canal hearing aid developed by the Study Sponsor used with the default settings as specified in the Study Sponsor's fitting software.
75391354|NCT01422408|Drug|Fluocinonide Cream|Given topically
75391355|NCT01422408|Procedure|Management of Therapy Complications|Receive fluocinonide cream
75391356|NCT01422408|Other|Questionnaire Administration|Ancillary studies
75391357|NCT01399788|Drug|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
75391358|NCT01399788|Drug|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
75391359|NCT01387542|Drug|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
75391360|NCT01387230|Drug|GSK573719|62.5 mcg
75391361|NCT01387230|Drug|GSK573719|125mcg
75391362|NCT01387230|Other|Placebo|Placebo
75391363|NCT01387074|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
75391364|NCT01386606|Drug|Androxal (enclomiphene citrate)|"capsule oral~1X a day 6 weeks"
76034417|NCT04882709|Device|Receiver-in-canal hearing aid 2|A receiver-in-canal hearing aid developed by another hearing aid manufacturer used with the default settings as specified in the manufacturer's fitting software.
76034418|NCT04882709|Device|Receiver-in-canal hearing aid 1 strategy 1|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
76034419|NCT04882709|Device|Receiver-in-canal hearing aid 1 strategy 2|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
76034420|NCT04896359|Dietary Supplement|Vitamin C|12.5 grams of ascorbic acid
76034421|NCT04896359|Other|Placebo|vehicle
75391365|NCT01386606|Drug|Testosterone|"topical gel~1X a day 6 weeks"
75391366|NCT01385748|Drug|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablet once day every day up to 8 weeks
75391367|NCT01385748|Drug|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
75391368|NCT01385748|Drug|Placebo Lauriad®|placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
76034422|NCT04886609|Device|ORISE gel|To establish if ORISE Gel an effective and feasible submucosal injecting solution during endoscopic resection of large colorectal polyps
76034423|NCT04896203|Procedure|rotational thromboelastometry|Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
76034424|NCT04895891|Device|EOS hand imaging|For each patient, EOS images are compared with CT images
75544177|NCT01641484|Procedure|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
76034425|NCT04896125|Drug|Lumigan PF; Xalatan|Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.
75544178|NCT01641523|Device|CustomBone Service|customized hydroxyapatite cranial prosthesis
75544179|NCT00417339|Procedure|hemodialysis|individualised
75544180|NCT00251342|Procedure|Edinburgh Postnatal Depression Scale|
75544181|NCT01641796|Drug|Paromomycin|Paromomycin Topical Cream applied to all lesions once a day for 20 days
75544182|NCT00280098|Drug|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
75544183|NCT01681147|Behavioral|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
75544184|NCT01681147|Behavioral|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
75544185|NCT00251381|Drug|Cetuximab|
75544186|NCT01685827|Drug|Fexinidazole|
75544187|NCT01685827|Drug|Nifurtimox|
75544188|NCT01685827|Drug|Eflornithine|
76034426|NCT03049319|Device|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
76034427|NCT03049319|Device|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
76034428|NCT03049319|Device|Psoriashield|The psoriashield will be applied to patient's back.
75544189|NCT00251420|Procedure|writing about disease|writing about physical or emotional consequences of pulmonary disease
76034429|NCT03049319|Device|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
75391369|NCT01397448|Drug|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
75391370|NCT01397448|Drug|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
75391371|NCT01397448|Drug|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
75391372|NCT01385202|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
75391373|NCT05365932|Device|Intra auricular device (IAD)|The Intra Auricular Device (IADs) are a pair of inconspicuous, custom fit auricular prosthetic devices.The ear inserts are manufactured using computer-aided design/computer-aided manufacturing (CAD/CAM) technology and are made from a liquid, photo-reactive acrylate (EShell 300), used in hearing aid shells and otoplastics for the last 10 years. They are designed to be placed into the outer third of the ear canals, and they have a small retraction post used to facilitate removal . A red or blue dot, respectively, indicates the right and the left side. The device do not interfere with hearing or speech
75391374|NCT01384734|Drug|BMS-663068 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
75391375|NCT01384734|Drug|BMS-663068 800 mg|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
75391376|NCT01384734|Drug|BMS-663068 600 mg|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
75391377|NCT01384734|Drug|BMS-663068 1200 mg|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
75391378|NCT01384734|Drug|Raltegravir 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
75391379|NCT01384734|Drug|Tenofovir 300 mg|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
76034430|NCT03049319|Device|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
75391380|NCT01384734|Drug|Ritonavir 100 mg|Tablets, Oral, 100 mg, Once daily, 96 weeks
75391381|NCT01384734|Drug|Atazanavir 300 mg|Capsules, Oral, 300 mg, Once daily, 96 weeks
75391382|NCT01396512|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous
75391383|NCT01396512|Biological|Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)|0.5 mL, Subcutaneous
75391384|NCT01396434|Biological|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
75391385|NCT01383954|Drug|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
75391386|NCT05365464|Drug|Progesterone Pill|Orally active progesterone
75544190|NCT05108584|Procedure|PPE Level 3 and Video Laryngoscope|The operator used level 3 PPE and video laryngoscope for the intubation process
75391387|NCT05365464|Drug|hCG|Given by subcutaneous injection
75391388|NCT01383486|Drug|Naproxen sodium ER (BAYH6689)|Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
75391389|NCT01383486|Drug|Advil|Commercially available Advil; oral caplet upon incidence of pain
75391390|NCT04407780|Other|No interventions are planned|Non applicable
75391391|NCT04766736|Procedure|Quantification of netrin-1 signals by antibody-based approaches|Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
75391392|NCT01383174|Behavioral|Peer Support Program|"Work with a trained counselor who is a breast cancer survivor~Meet 8 times in-person over the 8 week program with the counselor~Counselor helps participant develop a personalized support program to help her improve her quality of life~Receives information on breast cancer, its treatments, and stress management"
75391393|NCT01396278|Drug|Placebo|Placebo matching fluticasone propionate HFA MDI
75391394|NCT01396278|Drug|Fluticasone propionate|Fluticasone propionate HFA MDI
75391395|NCT01396278|Drug|BI 54903|BI 54903 via Respimat inhaler
75391396|NCT05365152|Dietary Supplement|Meal Replacement|Meal Replacement
75544191|NCT05108584|Procedure|PPE Level 3 and Direct Laryngoscope|The operator used level 3 PPE and direct laryngoscope for the intubation process
75544192|NCT05108584|Procedure|PPE Level 2 and Direct Laryngoscope|The operator used level 2 PPE and direct laryngoscope for the intubation process
76034431|NCT03049319|Device|Xtrac laser|The Xtrac laser will be applied to patient's back.
76034432|NCT04895657|Drug|Piperacillin/Tazobactam Continuous infusion|Continuous infusion
76034433|NCT04895657|Drug|Piperacillin/Tazobactam Intermittent infusion|Intermittent infusion
76034434|NCT04885673|Device|Vapotherm|flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
76034435|NCT04885673|Device|Apneic oxygenation|Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
76034436|NCT04895423|Drug|Methotrexate therapy|Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
76034437|NCT04895423|Drug|Mycophenolate mofetil therapy|Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
75391397|NCT05365074|Drug|Chloroprocaine Injection|Spinal anesthesia with 50 mg of 1% Chloroprocaine
75544193|NCT01686841|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
75544194|NCT00417378|Device|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
75707472|NCT06145438|Drug|Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)|Drug is administered orally at the same time every day
75869870|NCT04054778|Behavioral|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
76034438|NCT04895423|Drug|Cyclosporine therapy|Cyclosporine per os 3 mg/m2 2 times a day within 12 months
75391398|NCT01383096|Drug|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
75544195|NCT00417378|Device|Intraaortic Balloon Pump|Counterpulsation
75391399|NCT01383096|Drug|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
75391400|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
75391401|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
75391402|NCT04040244|Other|Exhaled Breath Collection|Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
75391403|NCT04040244|Other|Blood sample|Blood samples collected simultaneously with routine standard of care blood draws.
75391404|NCT01383018|Device|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
75391405|NCT01382940|Drug|rituximab|1000 mg in 250 mL intravenous infusion
75391406|NCT01382940|Drug|methotrexate|10 to 25 mg/week (oral or parenteral)
75544196|NCT05140096|Drug|Acalabrutinib|"Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C)."
75544197|NCT05140096|Drug|Fluconazole|Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).
75707473|NCT06145425|Other|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based mindfulness training (audio files).
75707474|NCT06145412|Drug|Xevinapan|Xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles)
75391407|NCT01382940|Drug|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
75391408|NCT01382940|Drug|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
75544198|NCT05140096|Drug|Isavuconazole|Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
75391409|NCT01382940|Drug|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
75391410|NCT01381926|Drug|exenatide|exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
75544199|NCT00251459|Drug|rhuFab V2 (ranibizumab)|
75544200|NCT04823065|Drug|Loperamide Pill|4 mg Imodium, per os
75544201|NCT04823065|Drug|hyoscine-n-butylbromide|3 X 20 mg Buscopan, intravenous
75544202|NCT00280176|Drug|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
75391411|NCT01381926|Drug|Saline|Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
75544203|NCT00280176|Drug|fluorouracil|225mg/m2 given weekly, up to 6 weeks
75544204|NCT00280176|Radiation|radiation therapy|180 cGy, every 5 days, up to six weeks
75391412|NCT01395888|Drug|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
76034439|NCT04895423|Drug|Dupilumab therapy|Patients weighing <30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to <60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
75391413|NCT01395888|Drug|Tiotropium|• Tiotropium (18 mcg) administered QD via a HandiHaler
75544205|NCT02961179|Behavioral|Increased dairy product|
75544206|NCT02961179|Behavioral|Dietary counselling|
76034440|NCT03051425|Dietary Supplement|Probiotic yogurt|120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
75391414|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
75544207|NCT04829305|Drug|SHR2285|SHR2285 is a selective inhibition of human FXIa small molecule compound.
75544208|NCT00280215|Drug|ACEI / Angiotensin converting enzyme inhibitor|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
75544209|NCT00280215|Drug|ARB /Angiotensin Receptor Blocker|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
75544210|NCT00280215|Drug|Placebo|Patients will receive placebo for 24 months
75544211|NCT04720118|Other|No Intervention|There is no intervention for this study.
75544212|NCT04826029|Other|Standard strategy|In the standard arm, patients will complete CA 125 (+/- HE4) at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days), complete the HAD and EQ5D self-questionnaires, and be managed according to INCa 2018 recommendations. If clinical symptoms, marker elevation, and/or imaging workup occur, the patient will be referred to the multidisciplinary consultation meeting (MDC) for management according to INCa 2018.
75707475|NCT06145412|Drug|Cisplatin|Cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks)
75707476|NCT06145412|Radiation|External beam|60 - 66 Gy in 2 Gy fractions for patients without gross disease and 70 Gy for patients with early recurrence) with concurrent cisplatin (40 mg/m2 once weekly)
75707477|NCT06145399|Diagnostic Test|18F-FDG PET/CT|Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners
76034441|NCT03051425|Dietary Supplement|Placebo|120 mL of low-fat milk
76034442|NCT03050099|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
76034443|NCT04882163|Drug|CC-220|CC-220
76034444|NCT04882163|Drug|Polatuzumab vedotin|Polatuzumab vedotin
76034445|NCT04882163|Drug|Rituximab|Rituximab
76034446|NCT04882163|Drug|Tafasitamab|Tafasitamab
76034447|NCT04882163|Drug|Gemcitabine|Gemcitabine
76034448|NCT04882163|Drug|Cisplatin|Cisplatin
75391415|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
75544213|NCT04826029|Other|Follow-up strategy|In the interventional arm, patients will perform at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days) a CA125 assay (+/- HE4 assay), a thoracoabdominal CT scan after contrast injection and a whole body MRI (T2, DW and T1 sequences after fat saturation before and after gadolinium injection) with a maximum delay of 15 days between the two examinations, and will complete the HAD and EQ5D self-questionnaires. A senior radiologist from each center will perform a prospective reading of each of the images. For any suspicious anomaly identified, the following criteria will be analyzed: Size, location, number, evolution, contrast after injection, MRI signal (T2, Diffusion, Dynamic Enhancement Curve). The RECIST criteria (version 1.1) will be applied.
75391416|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
75391417|NCT01381692|Drug|Bortezomib|Given IV or SC
76034449|NCT04882163|Drug|Dexamethasone|Dexamethasone
75391418|NCT01381692|Drug|Dexamethasone|Given PO
75544214|NCT00251498|Drug|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
75544215|NCT00417456|Other|Evisit|Asynchronous,remote care delivery via a secure web platform
75544216|NCT00417456|Other|Office visit|Conventional office-based care
76034450|NCT04882163|Drug|Bendamustine|Bendamustine
75544217|NCT00280254|Procedure|Hemodynamically Oriented Echocardiography-based Strategy|
75544218|NCT02275351|Drug|SM04554|Topical solution, applied once a day
75391419|NCT01381692|Other|Laboratory Biomarker Analysis|Correlative studies
75391420|NCT01381692|Other|Quality-of-Life Assessment|Ancillary studies
75391421|NCT01381692|Biological|Rituximab|Given IV
75391422|NCT01381692|Drug|Temsirolimus|Given IV
75391423|NCT01395030|Diagnostic Test|Computed Tomography|Undergo FCH PET/CT
75544219|NCT02275351|Drug|Vehicle|Topical solution, applied once a day
75544220|NCT04720040|Device|Mind STIM|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
75544221|NCT00417495|Behavioral|Sentinel Lymph Node Technique|
75544222|NCT05140057|Combination Product|Moviprep|Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
75544223|NCT00251537|Drug|LTB4|
76034451|NCT04882163|Drug|Lenalidomide|Lenalidomide
76034452|NCT04882007|Drug|OSE-127|mAb antagonist to CD127 receptor (or IL-7Rα)
76034453|NCT04882007|Drug|Placebo|Normal saline
76034454|NCT04885751|Drug|Eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
75391424|NCT01395030|Drug|18F-fluoromethylcholine|Undergo FCH PET/CT
75391425|NCT01395030|Diagnostic Test|Positron Emission Tomography|Undergo FCH PET/CT
75391426|NCT01381068|Device|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
75391427|NCT01394952|Drug|Dulaglutide|Administered subcutaneously
75391428|NCT01394952|Drug|Placebo|Administered subcutaneously
75544224|NCT02271334|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
75544225|NCT02271334|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
75544226|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
75544227|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
76034455|NCT04885751|Drug|Rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
76034456|NCT03051347|Other|Itch Questionnaire and Interview|
76034457|NCT03051347|Other|Stigma Questionnaire and Interview|
76034458|NCT03051347|Other|Cognitive Interview and PROMIS Itch Questionnaire|
76034459|NCT04885517|Device|Esophageal catheter|Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
76034460|NCT03051191|Diagnostic Test|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
76034461|NCT04895345|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
76034462|NCT04895345|Radiation|Intensity modulated radiotherapy|Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
75544228|NCT00280332|Procedure|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
75544229|NCT02276755|Dietary Supplement|Cholecalciferol (vitamin D3)|14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
75544230|NCT02276755|Other|Placebo|Placebo group will receive placebo (Tishcon, USA) weekly.
75544231|NCT02278198|Drug|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
75544232|NCT00286884|Procedure|Monitoring of heart rate variability|
75869871|NCT04054778|Behavioral|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
75869872|NCT05276713|Drug|Tucidinostat|Tucidinostat in combination with endocrine drugs
75869873|NCT05276635|Behavioral|The Sleep Hygiene Education (SHE)|Patients were randomized into two equal groups of 30 participants each. One group received a Sleep Hygiene Education (SHE) intervention
75391429|NCT01394718|Drug|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
75391430|NCT01394718|Other|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
75391431|NCT01394250|Device|Buzzy|Cold, Vibrational Device
75391432|NCT01394250|Drug|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
75391433|NCT01380990|Genetic|Infusion of autologous EFS-ADA LV CD34+ cells|Autologous EFS-ADA LV CD34+ cells (OTL-101*) are infused intravenously
75391434|NCT01380990|Other|Haematopoietic Stem Cell Transplantation (HSCT)|Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from GOSH will be collected as comparator group.
75391435|NCT01380990|Drug|Busulfan|Busulfan is used for non-myeloablative conditioning
75544233|NCT02279290|Behavioral|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
75544234|NCT02279290|Behavioral|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
75544235|NCT04826419|Other|ozone therapy|The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
75544236|NCT00280371|Drug|Formoterol Fumarate|
75544237|NCT04822480|Behavioral|Diabetes Prevention Program (DPP)|Individuals with prediabetes can mitigate the risks and costs of diabetes by taking preventative action, such as participation in a National Diabetes Prevention Program (DPP). The DPP began as a multisite randomized controlled trial demonstrating the effectiveness and cost-benefit of a 12-month intensive lifestyle intervention over pharmaceutical treatment for preventing or delaying diabetes among prediabetic participants. In 2010, Congress authorized the Centers for Disease Control and Prevention to lead the dissemination of the DPP as a targeted approach (high risk populations) and population-based strategy to reduce the incidence of diabetes and diabetes-related healthcare costs. The goal is to achieve modest weight loss (7%) by developing and implementing behavior change skills resulting in lifestyle modifications such as physical activity (150 minutes per week) and dietary and nutritional practices.
75707478|NCT06145399|Diagnostic Test|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
75707479|NCT06145399|Drug|18F-FDHT|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
75707480|NCT06145321|Device|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
75707481|NCT06145321|Drug|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
75391436|NCT01380990|Drug|Peg-Ada|Peg-Ada enzyme replacement therapy is discontinued at Day +3- (-3/+15 days) after successful engraftment
75869874|NCT05276635|Behavioral|Emotional Freedom Techniques (EFT)|30 participants had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I).
75869875|NCT04056182|Drug|Lofexidine 0.18 MG|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
75544238|NCT04826926|Procedure|Procedure/Surgery: Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
76034463|NCT04885361|Biological|CoVepiT (OSE13E)|Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
75544239|NCT00280410|Drug|E7337|
76034464|NCT03049163|Drug|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
76034465|NCT04894955|Device|MARIA|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to ascertain their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® participant bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts and array are brought into contact with the breast. A scan sequence comprising of two complete scan rotations will then be performed, which takes around 5 minutes. The participant will then be assisted to adjust their positioning, and the scan sequence performed on the other breast.
76034466|NCT04881695|Other|Questionary patients|"The patients will answer 1 questionnaire consisting of 5 parts :~General (demographic information)~Desire for a child~Hospital Anxiety and Depression scale~Sexual life~Additional questions regarding medical care"
76034467|NCT04881695|Other|Questionary controls|"Witnesses will complete 1 survey containing 4 parts:~General (demographic information)~Desire to have a child~Hospital Anxiety and Depression scale~Sexual life"
76034468|NCT04885439|Behavioral|NextSteps|Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.
76034469|NCT04410809|Biological|TA-46|Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion
76034470|NCT04410809|Other|Placebo|The same composition as the active medication but without the active substance TA-46
75391437|NCT01380834|Drug|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
76034471|NCT04894565|Procedure|rehabilitation|physical therapy 24 hrs after surgery
76034472|NCT04881851|Dietary Supplement|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
75544240|NCT04900246|Procedure|Visual Inspection|"The examiners will evaluate the surfaces included in the study independently and without knowledge of the results of the other examiner, after prophylaxis, using a mouth mirror and a WHO probe or Ball point. The evaluations will be carried out in a dental chair with the aid of a reflector. The teeth will be examined moist, and afterwards, they will be dried for 5 seconds with the use of a triple syringe.~For visual inspection, the International Caries Detection and Assessment System (ICDAS) evaluation system will be used. Complete ICDAS has seven categories, the first for healthy teeth (code 0) and the next two for limited enamel caries, white/brown stain (codes 1 and 2). The following two categories (codes 3 and 4) are considered to be caries that extend to the enamel without exposed dentin. And the two remaining categories (codes 5 and 6), are considered caries with exposed dentin."
75544241|NCT04900246|Radiation|BWX Radiographic Assessment|Participants will be radiographed with a digital X-ray device (DIOX-602, Micro Imagem, Indaiatuba, Brazil) with a regulation of 60 kV and 2 mA and exposure time of 0.10s. The technique used will be the interproximal/bitewing (BWX), with the FIT T1 Digital Sensor (external dimensions: 36.7mm x 24.3mm/sensitive area dimensions: 30.0mm x 20.0mm - 600mm²) and the sockets will be standardized with use of Han-Shin radiographic positioners (Jon, São Paulo, Brazil).
75391438|NCT01380834|Drug|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
75391439|NCT04407702|Other|Hygiene Instructions|Two weeks prior to the onset of the study, the volunteers will undergo a wash-out period, in which they will only use oral hygiene products donated by the researchers. These products will be used through to the end of the study. The oral hygiene kit will contain a soft-bristle toothbrush (Professional Lab Series, Colgate Palmolive), fluoride toothpaste with no desensitizing agent (Elmex) and dental floss (Colgate). The participants will be extensively trained with regards to all procedures involved in the experiment.
75391440|NCT04407702|Procedure|Sealant application|The teeth to be sealed will be isolated and 35% phosphoric acid will be applied for 20 seconds, followed by rinsing and drying the dental surfaces. A thin layer of PermaSeal will be applied to the tooth surface for 5 seconds and photopolymerized for 20 seconds. The occlusion will then be evaluated.
75707482|NCT06145308|Drug|Vedolizumab|Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (HER2 expression group) : Vedicetumab (2.5mg/kg, Q2w) alone or combined with platinum-based chemotherapy drugs (carboplatin 200-250mg/m2, Q2w or cisplatin 50mg/m2, Q2w) Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (HER2 expression group) : Vedicetumab monotherapy (2mg/kg, IV, Q2w) or vedicetumab (2mg/kg, IV, Q2w) combined with immune checkpoint inhibitors (triprilizumab 3mg/kg, IV, Q2w, etc.) or vedicetumab (2mg/kg, IV, Q2W, etc.) Q2w) in combination with oral HER2 TKI (pyrrotinib 400mg po qd and other drugs) or Vedicetsol in combination with platinum-based chemotherapy drugs of the doctor's choice (carboplatin 200-250mg/m2, intravenous drip, Q2w or cisplatin 50mg/m2, intravenous drip, Q2w).
76034473|NCT04881851|Dietary Supplement|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
76034474|NCT04881851|Dietary Supplement|Folic acid (placebo comparator)|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
75391441|NCT04407702|Radiation|Low-level Laser|Irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation. The power will be set to 100 mW; energy density will be 35 J/cm2 (considering a spot size of 0.028 cm2 of the equipment) and the dose will be 1 J per point. Irradiation will be performed on a cervical point, an apical point and a point precisely over the lesion, totaling a dose of 3 J. Treatment will be performed in three sessions with a 72-hour interval between sessions.
75391442|NCT04766658|Other|Gargle Phonation|Subjects will gargle water while making sound
75391443|NCT04766658|Other|Water swallow|Subjects will hold water in their mouth for 5 seconds and swallow
75391444|NCT05360940|Diagnostic Test|H.pylori stool antigen rapid test and stool parasitological examination|200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done
75391445|NCT04407468|Procedure|Prone position|Position of the patient in which he is face down, for an improvement in oxygenation
75391446|NCT04009746|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass
75391447|NCT05368740|Device|integrated pulmonary index monitor|Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention [2].
75391448|NCT05361330|Drug|Shuganjieyu capsule|2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
75707483|NCT06145308|Drug|larotinib or enttraitinib|Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po;
75707484|NCT06145308|Drug|antiandrogen drug treatment|Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po or antiandrogen drug treatment; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po or antiandrogen drug treatment;
75707485|NCT06145308|Drug|SHR-A1921|"Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(TROP-2 positive group) : Goxatuzumab 10mg/kg, D1 and D8, Q3w or SHR-A1921 anti-TROP-2 therapy.~Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(TROP-2 positive group) : Goxatuzumab 10mg/kg, D1 and D8, Q3w or SHR-A1921 anti-TROP-2 therapy."
75869876|NCT03573323|Drug|Ixekizumab|Administered SC
75869877|NCT03573323|Drug|Guselkumab|Administered SC
75391449|NCT05361330|Drug|Fluoxetine|Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
75391450|NCT05364060|Other|Questionnaires|Different questionnaires detailed in the objectives part
75391451|NCT00214968|Drug|Modafinil|maximum dosage 400 mg/day (4 tablets)
75544242|NCT04900246|Device|Assessment of the iTero Element 5D scan|For scanning, the iTero 5D (Align Technology) equipment featuring NIRI Technology will be used. The Infrared Imaging Technology (NIRI) is a diagnostic tool that allows the detection of interproximal and occlusal caries in several stages, from the initial enamel caries to lesions in the amelo-dentin junction, without the use of ionizing radiation. Infrared is the region of the electromagnetic spectrum between 0.7 and 2.0 micrometers (µm). The iTero Element 5D imaging system uses wavelength light (= 850 nm) in an electromagnetic spectrum that, in interaction with the hard tooth tissue, provides additional data on its structure.
75544243|NCT00280449|Behavioral|strengths-based case managed proactive service model|
75544244|NCT00251654|Procedure|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
75544245|NCT04335019|Other|Pulmonary ultrasound|Pulmonary ultrasound results: quotation in 8 fields (right antero-superior, left antero-superior, right antero-inferior, left antero-inferior, right postero-superior, left postero-superior, right postero-inferior and postero-upper left).
75544246|NCT00286923|Drug|Topiramate|
75544247|NCT04822168|Other|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
75544248|NCT04822168|Other|Standard Care|Standard Care through office-based opioid treatment with B/N dosing, on-site counseling and regular urine toxicology screening
75544249|NCT00251732|Drug|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
75869878|NCT03573323|Drug|Placebo|Administered SC
75869879|NCT01895842|Drug|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."
75391452|NCT00210522|Drug|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
75391453|NCT00214422|Radiation|Radiation|Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
75391454|NCT03592212|Drug|Salbutamol|Measurement of bronchodilator response (BDR)
75544250|NCT00251732|Drug|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
75544251|NCT00251732|Drug|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
76034475|NCT04872335|Other|Gong's Mobilization|Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.
75391455|NCT03024450|Drug|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
75391456|NCT03997422|Procedure|Vertical Sleeve Gastrectomy (VSG)|Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
75544252|NCT04088539|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date)
75544253|NCT04088539|Behavioral|Video-based health education|Educational videos on smoking and health will be developed to improve the knowledge of CSD smokers. The videos aim to raise their awareness on these important health topics and acquire effective cessation methods. The effectiveness of the educational videos will be evaluated by pre- and post-tests through a self-administered survey that assess the changes in knowledge related to smoking hazards, benefits of quitting, and methods to quit smoking.
75544254|NCT04042792|Other|pharmacokinetics (PK) measurement|two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
75544255|NCT00286962|Device|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
75544256|NCT00286962|Device|continuous subcutaneous insulin infusion (CSII) or MDI|
75544257|NCT04011826|Device|Device: Trial nasal mask (F&P)|This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
75544258|NCT04006756|Behavioral|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
75544259|NCT04006756|Behavioral|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
75869880|NCT04058054|Device|KeraStat® Cream|Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
75869881|NCT04058054|Device|KeraStat Gel|Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
75869882|NCT04058054|Device|Biafine|Administered 0.025 gm of Biafine per subject on day 1 of the study.
75869883|NCT04058054|Drug|Histamine|Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
75391457|NCT04263090|Drug|Rigosertib|Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).
75391458|NCT04263090|Drug|Nivolumab|Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).
75391459|NCT03832764|Device|ANSPEC-PRO|Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU
75391460|NCT05368272|Other|Processed electroencephalography|Acquisition of raw EEG data from processed EEG monitor. Analysis of data acquired for prespecified bandwidth properties
75869884|NCT04058054|Drug|Saline (0.9% NaCl)|Administered 1 drop of saline per subject on day 1 of the study.
75391461|NCT05368272|Other|Postoperative delirium assessment|Twice daily assessment for the incidence of postoperative delirium using validated tool (questionnaire)
75391462|NCT05630508|Behavioral|interactive Mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
75544260|NCT00251771|Procedure|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
75869885|NCT03306043|Drug|Mepolizumab|Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
75391463|NCT05630508|Other|Sham|Receiving standard care, LIVEN educational material and access to the application
75391464|NCT05368818|Other|Secukinumab|Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source
75391465|NCT05630274|Drug|Selpercatinib|Administered orally
75391466|NCT05630274|Drug|Moxifloxacin|Administered orally
75391467|NCT05630274|Drug|Placebo|Administered orally.
75544261|NCT03946462|Drug|NO gas delivered during cardiac surgery|intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
76034476|NCT04872335|Other|Gradually Graded Exercise Therapy|"The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug."
75391468|NCT04407624|Other|Intermittent Exercise|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.
75544262|NCT03946462|Other|placebo gas delivered during cardiac surgery|placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
75391469|NCT04407624|Other|Control|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
75544263|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
75544264|NCT00280488|Behavioral|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
75544265|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
75544266|NCT03658486|Other|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
76034477|NCT03048929|Biological|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
75869886|NCT01728220|Combination Product|Inhaled NO delivered via INOpulse DS-C Device|Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.
75869887|NCT01728220|Combination Product|Placebo delivered via INOpulse DS-C Device|Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
75869888|NCT04057430|Device|GumChucks|GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
75869889|NCT04057430|Device|String floss|Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
75869890|NCT04498286|Diagnostic Test|Testing of SARS-CoV-2 antibodies|Sars-CoV-2 RBD total antibody test developed by Sanquin
76034478|NCT03048929|Biological|Placebo|The placebo injection will consist of 0.5mL of saline.
76034479|NCT04871789|Diagnostic Test|Laboratory and instrumental examination|All patients will undergo a comprehensive examination to identify the consequences of COVID-19
75869891|NCT01313533|Drug|Polyarginine|Vein soak treated with polyarginine
75869892|NCT01313533|Drug|Vein soak treated with Lactated Ringers Solution|Vein soak
75869893|NCT03663842|Other|Physical therapy treatment|All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
75391470|NCT05632692|Other|Menthol solution|Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
75391471|NCT03594162|Drug|iC9-CAR19 cells|One of two dose levels will be given: 1 x 10^5 or 5 x 10^5
75869894|NCT03725189|Device|PPG during exercise|PPG use for pulse waveform evaluation of healthy exercise group
75391472|NCT03594162|Drug|AP1903|Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
75869895|NCT04479904|Drug|Famitinib|po
75869896|NCT03725111|Device|venous compression|venous compression
75869897|NCT01069172|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
75391473|NCT03594162|Drug|Cyclophosphamide|900 mg/m^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
75391474|NCT03594162|Drug|Fludarabine|25 mg/m^2/day IV over 30 minutes administered for 3 consecutive days.
75391475|NCT04407312|Drug|Cilostazol Tablets|Cilostazol-SR, capsule, 200mg, once daily, 30 days.
75391476|NCT04407312|Drug|placebo|Placebo, tablet, 200mg, once daily, 30 days.
75391477|NCT04407312|Drug|Aspirin|Astrix, capsule,100mg, once daily, 30 days.
75391478|NCT04407312|Drug|Clopidogrel|Plavix, tablet, 75mg, once daily, 30 days.
75391479|NCT03993444|Behavioral|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
75391480|NCT03993444|Behavioral|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
75391481|NCT04326738|Drug|Midazolam|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
75391482|NCT04326738|Drug|normal saline|N group received corresponding intravenous normal saline of1ml·kg-1 .
75869898|NCT01069172|Procedure|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
75869899|NCT03724955|Drug|Estradiol 2 mg|Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
75869900|NCT03724955|Other|Placebo|The placebo group will receive placebo oral daily for 6 months
75869901|NCT04220008|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
75391483|NCT03597126|Device|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1&2)
75391484|NCT03597126|Device|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1&2)
75391485|NCT04347486|Drug|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
75391486|NCT04347486|Drug|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
75391487|NCT04347486|Drug|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
75869902|NCT04220008|Drug|Busulfan|Given IV
75869903|NCT04220008|Drug|Clofarabine|Given IV
75869904|NCT04220008|Drug|Cyclophosphamide|Given IV
75391488|NCT04347486|Drug|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
75391489|NCT03025152|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
75391490|NCT03025152|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
75869905|NCT04220008|Drug|Gemcitabine|Given IV
75869906|NCT04220008|Drug|Mycophenolate Mofetil|Given IV
75391491|NCT05632458|Device|Thrombectomy|Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.
75391492|NCT05632224|Drug|Aprepitant|The drug is given 1 hour before the start of the surgery
75391493|NCT05632224|Drug|Granisetron|The drug is given 10 minutes before the patients's extubation
75391494|NCT05632146|Procedure|Continuous suturing|In continuous closure, each bite will be taken 2 cm from the cut edge of linea alba and successive bites taken 1 cm from each other in continuous fashion followed by gentle approximation of the wound
75391495|NCT05632146|Procedure|Interrupted X suturing|In interrupted X closure, large bite will be taken outside-in, 2 cm from the cut edge of linea alba and the needle emerged on the other side from inside out diagonally 2 cm from the edge and 4 cm below the first bite and this strand will be crossed and continued outside-in, diagonally at 90 degree to the first diagonal. The two ends will be tied just tight enough to approximate the edges of linea alba.
75391496|NCT03024840|Drug|Sevoflurane|Sevoflurane: 1%~2%
75544267|NCT00251810|Device|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
75544268|NCT03531580|Device|Magnetic Resonance Imaging|Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
75544269|NCT03488641|Diagnostic Test|ex-vivo drug response assay|drug sensitivity testing of primary patient derived cancer cells
75544270|NCT00287001|Device|Cold air cooling|
75544271|NCT03439930|Other|Balance training|6 weeks lasting balance training program
75544272|NCT04719650|Drug|Zoledronic Acid Injection|Infusion 1mg zoledronic acid once.
75544273|NCT04719650|Drug|Zoledronic Acid Injection|Infusion 2.5mg zoledronic acid once.
75544274|NCT04719650|Drug|Zoledronic Acid Injection|Infusion 5mg zoledronic acid once.
75544275|NCT04719650|Drug|Placebo|Infusion normal saline once.
75544276|NCT03406312|Diagnostic Test|Post Prandial Hypoglycemia test|three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
75544277|NCT03218605|Other|physical activity|Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
75544278|NCT00251849|Drug|Rifalazil|
75869907|NCT04220008|Biological|Rituximab|Given IV
75869908|NCT04220008|Drug|Tacrolimus|Given IV
75869909|NCT04220008|Drug|Vorinostat|Given PO
75391497|NCT03024840|Drug|Propofol|Propofol: 9-15 mg/kg/h
75391498|NCT05366088|Behavioral|Mindfulness-Based Cognitive Therapy|"MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse."
75391499|NCT05366088|Behavioral|Health Enhancement Program|HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
75391500|NCT03595644|Radiation|SBRT+TKI|Received SBRT after three months after EGFR-TKI treatment
75391501|NCT03595644|Drug|TKI|Received EGFR-TKI treatment
75391502|NCT05631678|Drug|Rifampicin; ASK120067|Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
75391503|NCT05631678|Drug|ASK120067;itraconazole|Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
75544279|NCT03189862|Behavioral|Motor Skills Intervention|"The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time."
75544280|NCT02960802|Procedure|kidney transplantation|
75544281|NCT00251888|Drug|campto (irinotecan)|
75544282|NCT00251888|Drug|cisplatin (cisplatyl)|
75544283|NCT04823221|Device|Rezūm System|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
75391504|NCT05631600|Biological|Manuka honey|The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
75391505|NCT05631522|Other|foot reflexology|"Warm-Up Phase:~Pre-reflexology foot massage and all-over foot squeeze will be performed for two minutes.~Mini-Reflexology Session:~Specific reflexology will be performed with special attention to two important foot reflex areas that include:~Diaphragm and Solar Plexus Reflex Areas are located in the distance between the upper and middle third of the sole.~The Heart and Lung Reflex Areas are located below the chest of the foot. The heart pumps the oxygen-rich blood around the body"
75391506|NCT05631444|Biological|Cell-based therapy|One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
75391507|NCT03599778|Drug|Apatinib|XELOX + apatinib's MTD
75391508|NCT03990012|Procedure|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
75544284|NCT01600027|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
75544285|NCT01600027|Procedure|Fascia iliaca block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
75544286|NCT00251966|Drug|Esomeprazole|
75544287|NCT02699086|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
75544288|NCT00252044|Drug|Pergolide|
75544289|NCT01805284|Drug|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
75391509|NCT03990012|Procedure|3D Scanning|Subjects will undergo 3D scanning of the breasts.
75391510|NCT03980418|Procedure|DaTSCAN SPECT/CT in VERITON-CT camera|the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
75391511|NCT03979404|Device|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
75391512|NCT03599700|Diagnostic Test|myeloproliferative neoplasms|BLOOD SAMPLING
75391513|NCT04008264|Drug|Scopolamine Patch (Transderm V)|During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
75544290|NCT01337128|Procedure|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
75544291|NCT01337128|Procedure|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
75544292|NCT01337128|Procedure|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
75544293|NCT01337128|Procedure|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
75544294|NCT01337128|Procedure|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
75707486|NCT06145308|Drug|small molecule multi-target tyrosine kinase inhibitors|"Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(ACC group): Adenoid cystadenocarcinoma given acitinib (5mg bid po) or apatinib (500mg qd po) or Renvastinib (24mg qd po) or sorafenib (400mg bid po) or anrotinib (12mg qd) po) or other small molecule multi-target tyrosine kinase inhibitors.~Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(ACC group): Adenoid cystadenocarcinoma given acitinib (5mg bid po) or apatinib (500mg qd po) or Renvastinib (24mg qd po) or sorafenib (400mg bid po) or anrotinib (12mg qd) po) or other small molecule multi-target tyrosine kinase inhibitors."
75869910|NCT03721991|Dietary Supplement|Gama amino butyric acid (GABA)|food supplement Gama amino butyric acid (GABA) as capsules
75869911|NCT03721991|Dietary Supplement|placebo|matching placebo
75391514|NCT05631288|Genetic|Sampe collection|Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
75391515|NCT03595410|Other|Recurrence laryngeal cancer|Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
75391516|NCT03595254|Behavioral|Thrive|Computerized Cognitive Behavior Therapy program
75391517|NCT05631210|Other|Privacy agreements with pictograms|The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
75544295|NCT01337128|Procedure|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
75544296|NCT04719884|Procedure|Perioperative fluid optimisation|"In case of stroke volume variation (SVV) >10% and SI and CI >10% below the starting value, fluid challenge was performed with approximately 2 ml/kg of colloid over maximum of 5 minutes. The response was monitored.~If there was a fall in SVV and an increase in SI of >10% and the SVV still >10%, the second fluid challenge was performed.~If there was still a reduction in SVV after the second fluid challenge, but an increase in nSI <10% and decrease in systemic vascular resistance (SVR), no additional fluids were given. Vasoactive drugs were used instead."
75544297|NCT01191073|Device|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
75544298|NCT01191073|Device|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
75707487|NCT06145308|Drug|albumin paclitaxel with platinum|Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(no target and other groups) : albumin paclitaxel 160mg/m2 combined with platinum-based chemotherapy drugs of the doctor's choice (carboplatin 200-250mg/m2, intravenous drip, Q2w or cisplatin 50mg/m2, intravenous drip, Q2w); Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(no target and other groups) : albumin paclitaxel 160mg/m2 combined with platinum-based chemotherapy drugs of the doctor's choice (carboplatin 200-250mg/m2, intravenous drip, Q2w or cisplatin 50mg/m2, intravenous drip, Q2w);
75869912|NCT02911688|Drug|gamma tocopherol|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
75544299|NCT00280605|Drug|Alfuzosin|
75707488|NCT06145295|Behavioral|mobile online support group (experiment group)|The experimental group engaged with the mobile application use for four weeks, with specific tasks including completing the four mandatory courses within one month and submitting at least two health records and online posts every week.
75707489|NCT06145295|Behavioral|offline support group (control group)|The control group participates in the offline group intervention that last for four weeks. Participants in the control group will participant in four weekly workshop that last between 1 hour to 1.5 hours.
75869913|NCT02911688|Drug|Placebo|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
75869914|NCT05580250|Drug|LY3526318|Administered orally.
75544300|NCT01134601|Procedure|Radiation Therapy|
75544301|NCT01134601|Drug|Capecitabine|
75544302|NCT01134601|Drug|AZD6244|
75544303|NCT00252083|Behavioral|Popular Opinion Leader|
75544304|NCT00287040|Behavioral|Tailored, interactive intervention for mammography screening|Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
75707490|NCT06145269|Drug|New oral anticoagulant (rivaroxaban) and Marevan (warfarin)|comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)
75707491|NCT06145243|Other|Home based exercise|Patients will be given a visual brochure with pictures explaining the exercises. Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the home exercise group will be checked by phone every week.
75707492|NCT06145243|Other|Video-based resistive exercise|A video recording of the exercises will be taken and given to the patients as a video recording.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the video-based exercise group will be checked by phone every week.
75707493|NCT06145243|Other|Supervised resistive exercise|Patients will perform their exercises under the supervision of a physiotherapist.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.
75707494|NCT06145230|Other||
75707495|NCT06145217|Drug|SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg|To evaluate the drug-drug interaction between SPRYCEL® 100 mg and Omeprazole under fasted conditions in healthy, adult, human subjects.
75707496|NCT06145204|Other|questionnaire|anamnesis, OMSPQ, DN4, Brief Pain Inventory-short form, lymph-ICF-LL
75707497|NCT06145178|Biological|SPYVAC01|Novel vaccine SPYVLP01
75707498|NCT06145165|Other|Nerve block with ropivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
75391518|NCT03599466|Drug|BF-Lisinopril Tablets 20mg|BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
75391519|NCT03599466|Drug|Zestril Tab 20mg|Zestril Tab 20mg will be used as a reference drug in this study
75391520|NCT03599388|Behavioral|Self- management for adequate sleep intervention (SASI)|Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains >90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
75391521|NCT03599310|Behavioral|Advance care planning|The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.
75869915|NCT05580250|Drug|Placebo|Administered orally.
75869916|NCT05580250|Drug|Iohexol|Administered intravenously (IV).
75869917|NCT05580250|Drug|Simvastatin|Administered orally.
75869918|NCT05580250|Drug|Metformin|Administered orally.
75869919|NCT03663374|Drug|Odelepan|Tablets, 125 mg
75391522|NCT03599310|Behavioral|Usual care|In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
75391523|NCT03987672|Dietary Supplement|Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula|Kate Farm Peptide 1.5 nutritional Formula
75707499|NCT06145165|Combination Product|Nerve block with liposomal bupivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
75391524|NCT03987360|Other|Observational|Participants who attended different educational and cultural activities either in a community centers or public institutions like arts museums or universities.
75391525|NCT03986970|Drug|Tenofovir|Pre-exposure prophylaxis
75391526|NCT03594942|Diagnostic Test|procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.
75391527|NCT03594864|Procedure|Liver transplantation with hyper-reduced grafts|Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
75391528|NCT03594786|Device|endovascular aneurysm repair (EVAR)|Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
75391529|NCT03599232|Other|Formative objective structured clinical examination (OSCE)|
75391530|NCT03978546|Diagnostic Test|Humphrey Visual Field Test|SITA Standard and 24-2 and 10-2 visual field tests
75391531|NCT03978546|Diagnostic Test|Optical Coherence Tomography (OCT) Scan|Circle and Wide Angle Scans
75391532|NCT03978546|Diagnostic Test|Smart Perimetry - Henson 9000|24+10-2 Smart Supra test
75391533|NCT03594396|Drug|Olaparib|Olaparib 300mg bid will be given on days 1-28 days without rest.
75391534|NCT03594396|Drug|Durvalumab|A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
75391535|NCT03599076|Other|HD Wear|Wearable sensor system for monitoring Huntington's chorea during activities of daily living
75707500|NCT06145165|Other|Intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
75391536|NCT03598764|Procedure|Classic head extraction during Cesarean section|by putting the fingers of the right inside the lower uterine segment to deliver the head
75391537|NCT03598764|Procedure|External pop out technique|The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
75391538|NCT03594240|Drug|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily
75391539|NCT03594240|Dietary Supplement|Placebo|Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.
75391540|NCT03976908|Device|Deep Brain Stimulation|High frequency deep brain stimulation in the medial geniculate body of the thalamus.
75391541|NCT03594006|Behavioral|CCI; cancer care coordination instrument|Designed to assess cancer patients' perceptions of care coordination
75391542|NCT03593850|Behavioral|Music group|The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).
75391543|NCT03593850|Behavioral|Silence Group|Audio file that contained no sounds.
75391544|NCT03024762|Procedure|targeted Provider-Initiated-Testing and Counseling (tPITC)|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
75391545|NCT03976362|Biological|Pembrolizumab|IV infusion
75391546|NCT03976362|Drug|Carboplatin|IV infusion
75391547|NCT03976362|Drug|Paclitaxel|IV infusion
75391548|NCT03976362|Drug|Nab-paclitaxel|IV infusion
75391549|NCT03976362|Drug|Olaparib|Tablets
75391550|NCT03976362|Drug|Placebo|Placebo to olaparib, tablets
75391551|NCT05633004|Device|Vivio|Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)
75391552|NCT04747782|Other|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
75391553|NCT03593694|Behavioral|TECH DM-BAT|Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
75391554|NCT03593694|Behavioral|TECH DMBAT Active Comparator|Technology delivered diabetes education and home tele monitoring
75391555|NCT03593694|Behavioral|TECH DMBAT Other|Technology delivered diabetes education
75391556|NCT03593616|Procedure|Phacoemulsification|insertion of intra-ocular lens after emulsification of catractous lens
75869920|NCT03663374|Drug|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
75391557|NCT05632848|Drug|Chidamide combined with Zimberelimab|Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
75391558|NCT03598374|Dietary Supplement|Inositol + Folic acid|"Daily oral supplementation of for 6 months or until pregnancy conception:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
75391559|NCT03598374|Dietary Supplement|Folic acid|"Daily oral supplementation of for 6 months:~Folic acid: 400 mcg"
75391560|NCT03598374|Behavioral|Regular intercourses|Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
75391561|NCT03593460|Drug|Synthetic PreImplantation Factor|peptide
75391562|NCT03024294|Other|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
75391563|NCT04407078|Drug|Sugammadex Injectable Product|Sugammadex of 2 mg/kg is injected.
75869921|NCT03431948|Drug|Nivolumab|Nivolumab 240 mg given by intravenous infusion every 2 weeks
75869922|NCT03431948|Drug|Cabiralizumab|Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
75707501|NCT06144216|Other|CLOE Outreach Intervention|The CLOE outreach intervention is a community-led, strengths-based, and trauma-informed program to support self-identifying women and youth who experience interpersonal and structural gender-based violence. Outreach services are designed to mitigate the effects of gender-based violence, build trusting relationships with service providers, and improve safety, well-being and engagement with health and social care.
75869923|NCT03431948|Drug|Urelumab|Urelumab 8 mg given by intravenous infusion every 4 weeks
75707502|NCT06144021|Dietary Supplement|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
75707503|NCT06144021|Dietary Supplement|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
75869924|NCT03431948|Radiation|Stereotactic Body Radiation Therapy|Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
75869925|NCT02670928|Behavioral|Lifestyle intervention|Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
75391564|NCT04407078|Drug|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
75391565|NCT04003116|Drug|Oxygen gas|Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
75391566|NCT00218634|Behavioral|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
75391567|NCT00218634|Behavioral|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
75707504|NCT06143566|Drug|Polypill|A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
75869926|NCT03662516|Drug|PF-04965842|Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
75391568|NCT00217620|Drug|sorafenib|800 mg per day, daily until progression
75391569|NCT00217464|Drug|fulvestrant|intramuscularly
75391570|NCT00214500|Drug|migalastat HCl|
75391571|NCT04002726|Other|Inter-grader agreement (IGA) app|A smartphone-based app with images of conjunctivae for trachoma grading training purposes.
75869927|NCT03662516|Drug|Ethinyl estradiol (EE) and levonorgestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
75391572|NCT03597984|Radiation|Simultaneous Integrated Boost-SIB on macroscopic metastases|"Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
75391573|NCT03597906|Procedure|topography guided ablation|using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
75707505|NCT06143358|Drug|Qingkepingchuan Granules|Qingkepingchuan Granules,Take it three times a day with water after meals.
76034480|NCT04881305|Diagnostic Test|questionnaires and neuropsychological assessment|Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
76034481|NCT04871633|Drug|Remdesivir|Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days
76034482|NCT04871633|Drug|Conventional|IV Steroids Antibiotics
76034483|NCT04881071|Device|Scarf|Scarf specifically designed to facilitate mother-neonate skin-to-skin contact
75391574|NCT03597906|Procedure|manifest refraction|using for ablation the exact manifest refraction
75391575|NCT03597906|Procedure|full topography modified refraction|full topography modified refraction means changing both sphere and cylinder power in the ablation profile
75391576|NCT03597906|Procedure|partial topography modified refraction|partial topography modified refraction means changing only cylinder power and axis in the ablation profile
75391577|NCT03597516|Drug|RP-G28|powder for reconstitution for oral administration
75391578|NCT03597516|Drug|Placebos|powder for reconstitution for oral administration
75391579|NCT03597282|Biological|NEO-PV-01|Personal Cancer Vaccine
75391580|NCT03597282|Biological|Nivolumab|monoclonal antibody against PD-1
75707506|NCT06143358|Other|conventional treatment|Oxygen intake, selection of appropriate antibiotics based on lab results, and other treatments
75391581|NCT03597282|Other|Adjuvant|immune adjuvant
75391582|NCT03597282|Biological|APX005M|monoclonal agonist antibody against CD40
75707507|NCT06142942|Other|Exercise Intervention|Participants will complete an exercise intervention where they will exercise 2, 3, or 4 days per week for 4 weeks.
76034484|NCT04880915|Other|surgical smoke affects|The study, experimental type, was conducted to investigate the effects of five different methods on surgical smoke protection.
76034485|NCT04880993|Drug|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd
76034486|NCT04880993|Drug|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
76034487|NCT05183243|Drug|GH21 Capsule|GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
76034488|NCT04871555|Other|MRI|structural imaging
75391583|NCT03597282|Biological|ipilimumab|monoclonal antibody against CTLA4
75391584|NCT03597204|Diagnostic Test|Fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
75391585|NCT03593304|Drug|Injection Mecobalamin|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
75391586|NCT03593304|Drug|Tablet Pyridoxine hydrochlorid|Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
75391587|NCT03593304|Drug|Normal saline|Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
75391588|NCT03593304|Drug|Oral Placebo|Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
75391589|NCT00211536|Drug|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
75391590|NCT00211536|Device|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
75391591|NCT00211536|Drug|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
75391592|NCT04001088|Dietary Supplement|Probiotic|Dosing regimen of one capsule daily for a maximum of 48 weeks.
75707508|NCT06142110|Other|Funcional movement screen|FMS is a biomechanical screening and evaluation method to reveal the limitations and asymmetries on the 7 basic movement patterns, which are the determinants of functional movement quality.
75707509|NCT06142110|Diagnostic Test|Respiratory muscle strength|Respiratory muscle strength was assessed with an additional mouthpiece attached to the portable spirometer as maximum inspiratory pressure and maximum expiratory pressure.
75707510|NCT06141681|Other|photoplethysmography|Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.
76034489|NCT04430231|Other|Wait list time|
76034490|NCT04936997|Biological|SARS-COV2 Pfizer Vaccine|Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
75707511|NCT06141512|Behavioral|Reduced-exertion high-intensity interval training (REHIT)|Description same as Arm description.
76034491|NCT04880525|Other|Dietary intervention|In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
75391593|NCT04001088|Other|Placebo|Dosing regimen of one capsule daily for a maximum of 48 weeks.
75391594|NCT03976128|Behavioral|Nordic Walking Training|The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
75391595|NCT03976128|Behavioral|Conventional endurance training|15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
75391596|NCT03596970|Drug|TAC withdrawal|Everolimus (RAD001) with MMF and Steroids
75391597|NCT03596970|Drug|Everolimus with reduced TAC|Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
75391598|NCT03596892|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
75391599|NCT03596892|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
75391600|NCT03596892|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
75391601|NCT03596814|Other|No Interventional study|Retrospective data
75544305|NCT00252122|Drug|Ketamine|Ketamine. 0.2 mg/kg, intravenously
75391602|NCT04199286|Procedure|symmetrical and asymmetrical horizontal strabismus surgery|surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye
75391603|NCT04198896|Other|incidece of cancers|With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
75391604|NCT03592836|Drug|Loop Diuretics|intravenous administration of diuretics
75391605|NCT03596502|Drug|Direct oral anticoagulants (DOACs)|Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
75391606|NCT03596502|Drug|Warfarin|Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
75391607|NCT03592680|Dietary Supplement|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
75391608|NCT03592680|Other|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
75391609|NCT04198194|Diagnostic Test|Predictors of events|Apple Heart & Movement Study in Apple Research app
76034492|NCT04880369|Dietary Supplement|Soy isoflavones|Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).
76034493|NCT04880369|Dietary Supplement|Lignans|Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)
75391610|NCT03592524|Behavioral|Fasting Ramadan|Muslims recipients refrain from eating and drinking anything from dawn until sunset(14-15 hours)
75391611|NCT04198038|Behavioral|Songwriting with licensed music therapist|Song selected by parent-child dyad with recordings of physiologic components (i.e. heartbeat, breathing)
75391612|NCT03596346|Other|Rapeseed ingredient (RI)|2 snack bars daily containing 10 g of RI each.
75391613|NCT03596346|Other|Control product without added RI|2 snack bars daily containing 0 g of RI.
75391614|NCT03596190|Diagnostic Test|ultrasonographic diaphragmatic assessment|"Diaphragmatic dysfunction will be determined by intercostal diaphragm thickening. The available image will be saved.~Diaphragmatic motion assessments will be conducted on the side to be blocked both at baseline, and then every 5 minutes until patient leaves for operating room or 30 minutes (whatever is earlier)."
75707512|NCT06140823|Other|Liver Risk Computation Model (LIRIC)|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the general population
76034494|NCT04880369|Dietary Supplement|Placebo|The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.
76034495|NCT04870931|Procedure|TEM / TEM-ESD|Transanal local excision of a rectal tumour as a conventional, full-thickness TEM or submucosal dissection as TEM-ESD
76034496|NCT04879901|Diagnostic Test|surface EMG|surface EMG estimation with Carrying backpacks forward or backward
76034497|NCT04738175|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
76034498|NCT04738175|Drug|Placebo|Diluent solution
75391615|NCT03592446|Device|Transcutaneous electrical vagus nerve stimulation|All subjects receive electrical VNS stimulation at cymba conchae.
75391616|NCT03592446|Device|Sham vagus nerve stimulation|All subjects receive electrical stimulation at earlobe.
75391617|NCT03596112|Other|application of a polyacrylate wound pad|A sterile polyacrylate wound pad with activated carbon cloth treatment will be applied to chronic wounds in an outpatient clinic from a specialist nurse
75391618|NCT03596112|Other|Hydrocellular foam|Active Comparator: hydrocellular foam pad serile hydrocellular standard foam pad will be applied to chronic wounds in an outpatient clinic from a specialist nurse
75391619|NCT04197570|Drug|Opioid Anesthetics|see arm/group description
76034499|NCT03046979|Drug|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
76034500|NCT04711187|Drug|AT-527 Formulation 1|AT-527 Formulation 1 (R07496998)
76034501|NCT04711187|Other|Placebo Comparator|Placebo Comparator
75391620|NCT04197570|Drug|Non Opioid Analgesics|see arm/group description
75391621|NCT04197882|Biological|OrienX010 Combination with Toripalimab injection|OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
75391622|NCT03591978|Diagnostic Test|Isolation of Circulating Pulmonary Cells in peripheral blood|Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
75391623|NCT04197024|Device|Exercise capacity test|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.
75391624|NCT04197024|Device|Exercise capacity test in virtual reality|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
75391625|NCT03024060|Drug|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
75391626|NCT03024060|Drug|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
75391627|NCT03024060|Device|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
75707513|NCT06140823|Other|Liver Risk Computation Model (LIRIC)_cirrhosis|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population with liver cirrhosis
75707514|NCT06140823|Other|Liver Risk Computation Model (LIRIC)_no_cirrhosis|neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population without liver cirrhosis
76034502|NCT04711187|Drug|AT-527 Formulation 2|AT-527 Formulation 2 (R07496998)
76034503|NCT04676399|Drug|Hydrochlorothiazide 12.5mg|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
76034504|NCT04676399|Drug|Placebo|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
76034505|NCT04880213|Drug|M5049|Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
76034506|NCT04880213|Drug|M5049|Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
76034507|NCT04880213|Drug|M5049|Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
75707515|NCT06140602|Other|Intervention shake|The pecan shake contains 69g of pecans
75869928|NCT04978168|Behavioral|Core Intervention|Staff are provided with a core set of implementation strategies to facilitate interorganizational linkages between probation agencies and local community treatment providers.
76034508|NCT03047057|Drug|Lidocaine|IV Lidocaine infusion
76034509|NCT03047057|Drug|IV normal saline|IV normal saline infusion
76034510|NCT04630847|Biological|Fecal Microbiota Transplant|FMT utilizing stool from first degree relatives
76034511|NCT04430309|Behavioral|Baduanjin exercise program|The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
76034512|NCT04430309|Behavioral|Brisk walking program|The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
75391628|NCT03024060|Device|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
75544306|NCT00287157|Drug|Sublingual Tizanidine HCl|
75544307|NCT00252161|Procedure|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
75544308|NCT00252161|Drug|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
75544309|NCT00280644|Drug|Leflunomide|
76034513|NCT04880135|Other|Supervised stretching and strengthening exercise|The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
76034514|NCT04880135|Other|Home-based stretching and strengthening exercise|The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
75391629|NCT03024138|Radiation|Repeat CT scan|
75391630|NCT03024216|Drug|Atezolizumab1200 mg IV|Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
75707516|NCT06140342|Behavioral|Feasibility study of music-based mobile app|To determine the performance and usability of the app, 20 dyads will be recruited to test it for 2 weeks. The investigators will collect physiological measures based on the application's demonstration to auto-play music according to movement or sedentary states.
75707517|NCT06139432|Device|Active tDCS|"Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~Cathode opposite the left temporoparietal junction (between T3 and P3).~The stimulation level is 2mA for 20 minutes.~Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
75544310|NCT00252200|Drug|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
75544311|NCT00280722|Behavioral|patient information leaflet|
75544312|NCT00252278|Drug|atomoxetine|
75544313|NCT00287196|Radiation|Radiotherapy|48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
75544314|NCT00252317|Drug|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
75544315|NCT00252317|Drug|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
75544316|NCT01118026|Drug|ABVD|doxorubicin 25 mg/m^2 IV bleomycin 10 units/m^2 IV vinblastine 6 mg/m^2 IV dacarbazine 375 mg/m^2 IV
75391631|NCT03024216|Drug|Sipuleucel-T|Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
75391632|NCT03596034|Other|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
75391633|NCT03595956|Other|Medical gender affirmation|The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).
75391634|NCT03981744|Drug|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
75391635|NCT03981744|Drug|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
75391636|NCT03981744|Drug|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
75391637|NCT03981744|Drug|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
75544317|NCT01118026|Drug|BEACOPP|bleomycin 10 units/m^2 IV on Day 8 etoposide 200 mg/m^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m^2 IV on Day 1 cyclophosphamide 1250 mg/m^2 IV on Day 1 vincristine 1.4 mg/m^2 IV on Day 8 procarbazine 100 mg/m^2 orally on Days 1-7 prednisone 40 mg/m^2 orally on Days 1-14
75391638|NCT03591900|Device|insulin pump/CGMS|"A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009)."
75391639|NCT03591744|Drug|Bortezomib|Given SC
75391640|NCT03591744|Biological|Daratumumab|Given IV
75391641|NCT03591744|Drug|Dexamethasone|Given IV and PO
75391642|NCT03591744|Drug|Lenalidomide|Given PO
75391643|NCT03591744|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75391644|NCT03595800|Procedure|Hematopoietic stem cells transplantation|Allogeneic Hematopoietic stem cells transplantation
75391645|NCT03023670|Procedure|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
75391646|NCT03023670|Procedure|cardiopulmonary bypass|Low rate (4\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
75391647|NCT03023592|Drug|Iguratimod|Iguratimod 25 mg orally twice a day for 24 weeks
75391648|NCT03591666|Drug|Anlotinib|Anlotinib p.o. qd
75391649|NCT04196946|Drug|25 mcg fentanyl|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
75391650|NCT04196946|Drug|250 mcg alfentanil|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
75544318|NCT01118026|Radiation|radiation therapy|
75391651|NCT04199208|Other|Prehabilitation and Immunonutrition|See study synopsis
75391652|NCT04199208|Other|Standard Care Arm|Standard care as per the daily routines of the Hospital at which the study takes place
75391653|NCT03591588|Other|diet|The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
75391654|NCT04194918|Behavioral|Computer-Assisted Smoking Cessation Intervention|Use the Flexiquit+ program
75391655|NCT04194918|Other|Text Message|Receive text messages
75544319|NCT00280800|Device|constant CPAP devices|different CPAP mode
75544320|NCT00280800|Device|automatic CPAP devices|different CPAP mode
75391656|NCT04194918|Other|Handout|Receive handouts via email
75391657|NCT04194918|Other|Questionnaire Administration|Ancillary studies
75391658|NCT04194918|Other|Quality-of-Life Assessment|Ancillary studies
75391659|NCT04194918|Other|Survey Administration|Ancillary studies
75544321|NCT00252356|Drug|SR58611A|
76034515|NCT04879667|Procedure|endoscopic management of gastrocutaneous fistula after laparoscopic sleeve gastrectomy|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral & I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral & I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
76034516|NCT04550195|Drug|BMS-986337|Specified Dose on Specified Days
76034517|NCT04550195|Other|BMS-986337 Placebo|Specified Dose on Specified Days
76034518|NCT04550195|Biological|Famotidine|Specified Dose on Specified Days
76034519|NCT04525391|Drug|Durvalumab+AZD2811 to SCLC patients|AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
76034520|NCT04870697|Behavioral|ACT intervention|"The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer."
76034521|NCT04870697|Other|Usual care|Usual care in this study setting includes providing general information, education, psychological support, and consultation.
75391660|NCT04747938|Device|Energy accumulator|All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
75391661|NCT04747938|Behavioral|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
75391662|NCT03023904|Biological|Nivolumab|Given IV
75391663|NCT03023904|Other|Laboratory Biomarker Analysis|Correlative studies
75391664|NCT03967002|Procedure|Test group with corticotomy surgery|"The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~the second premolars and first premolars,~the first lower premolars and canines,~the canines and lateral incisors,~the lateral incisors and central incisors, and,~the two lower central incisors."
75391665|NCT03966768|Device|Duramesh suturable mesh for laparotomy closure|Patients undergoing laparotomy will be closed with Duramesh suturable mesh
76034522|NCT04505423|Procedure|Blind CSF Drain Placement|CSF Drain placement without fluoroscopic image guidance.
76034523|NCT04505423|Procedure|Fluoroscopy-guided Drain Placement|CSF Drain placement utilizing fluoroscopic image guidance.
76034524|NCT04879511|Drug|metformin|Oral hypoglycemic drug metformin
76034525|NCT04879511|Drug|Basal/bolus insulin|Basal/bolus insulin
76034526|NCT03048695|Behavioral|GMT|Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
76034527|NCT03046901|Drug|Vancomycin|Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
76034528|NCT03048539|Procedure|Transoral endoscopic thyroidectomy|This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
76034529|NCT04181801|Procedure|Subtotal cholecystectomy|a surgical procedure in which more than the top half of the gallbladder is removed
76034530|NCT04879277|Biological|Blood samples|Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.
76034531|NCT03046667|Dietary Supplement|Barley β-glucan|The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
75391666|NCT03966768|Device|Conventional suture for laparotomy closure|Patients undergoing laparotomy will be closed with conventional polydiaxonone suture
75544322|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
75544323|NCT01648153|Other|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
75391667|NCT04406922|Procedure|Personalized cooling protocol|As an intervention, a personalized cooling protocol will be used in order to activate BAT and induce non-shivering thermogenesis. During the cooling procedure, subjects will be exposed to mild cold (approx. 14°C) for 150 min. Since the onset temperature of shivering shows a high interindividual variation, we will use a personal cooling protocol to ensure maximum non-shivering EE (and thus an equal maximum activation of BAT). The right temperature will be determined via a subjective method, e.g. to ask the subject if he or she experiences shivering. The time needed to achieve the right temperature is approximately 30-60 minutes. Then, the stable cooling period of 90 min is started. During this time the subject will be asked every 15 minutes whether he is experiencing shivering. If so, temperature will be increased with 2-3°C so that shivering just stops.
75544324|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
76034532|NCT03046667|Dietary Supplement|Control|The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
76034533|NCT03046589|Drug|DP13|dose escalation
76034534|NCT03046589|Drug|placebo|control to dose-escalation
76034535|NCT04037813|Procedure|Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx|"For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut."
75391668|NCT03591198|Behavioral|Qigong Training|Eight-Section Brocades
75391669|NCT03591198|Behavioral|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
75391670|NCT04196400|Drug|steroid betamethasone|The steroid is injected using insulin needle in the subcutaneous tissue after finishing the repair
75391671|NCT04021758|Behavioral|Peer to peer program intervention|Peer to peer suicide prevention program aimed at reducing suicide in a military population.
75391672|NCT04196322|Other|observational study|observational study
75544325|NCT02753998|Combination Product|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
75544326|NCT02753998|Combination Product|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
75544327|NCT02753998|Procedure|Conventional angioplasty|
75544328|NCT02279836|Device|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
75544329|NCT00287235|Device|MARS|
75544330|NCT00287235|Drug|Standard Medical Therapy|
75544331|NCT00252395|Device|PDA-based Electronic Prescribing Software|
75544332|NCT02753452|Behavioral|Residential Immersive Life Skills programming|
75544333|NCT02753452|Behavioral|Non-residential life skills programming|
75544334|NCT02754154|Drug|Warfarin|
75544335|NCT02754154|Drug|Apixaban|
75544336|NCT02754154|Drug|Dabigatran|
75544337|NCT02754154|Drug|Rivaroxaban|
76034536|NCT02614079|Device|DSSEP|Collision testing after the placement of SCS leads
76034537|NCT03871049|Drug|Bupivacaine with dexamethasone|bupivacaine with dexamethasone
76034538|NCT03871049|Drug|Bupivacaine|bupivacaine
76034539|NCT04878809|Other|Escola L'Horitzó|Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
76034540|NCT04878809|Other|Escola John Talabot|John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
76034541|NCT04430465|Dietary Supplement|Grain products high in wholegrains from oat and rye|A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products
75391673|NCT04196088|Device|Ultivision Artificial Intelligence Software|Screening Colonoscopy
75544338|NCT00252434|Behavioral|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
75391674|NCT04196088|Device|No Artificial Intelligence Software enhancement|Screening Colonoscopy
75869929|NCT04978168|Behavioral|Peer Support Specialists (PSS)|Participants randomized to PSS will meet with a PSS for 12 months. Contact scheduled is flexible and based on the participant's needs and wants, plus written guidance for PSS-participant interactions.
75391675|NCT04196166|Other|preoperative blood tests|
75391676|NCT03591042|Diagnostic Test|cervical length screening|transvaginal ultrasound cervical length
75391677|NCT04195932|Other|Exercise training|
75391678|NCT03590886|Other|total response Group|biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
75391679|NCT03972774|Diagnostic Test|PET Stress Test|Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management
75391680|NCT03972774|Other|Non-PET Medical Management|Appropriate medical management without cardiac PET stress-imaging
75391681|NCT03023436|Procedure|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
75391682|NCT03023436|Procedure|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
75544339|NCT00280839|Drug|Topiramate|
75544340|NCT00280839|Drug|Placebo|
75391683|NCT03023436|Drug|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
75544341|NCT04719728|Diagnostic Test|Aided pure tone audiometry|aided response, speech, evoked potential
75544342|NCT00287274|Device|computerized physician order entry|
75544343|NCT00414869|Drug|NCX-1000|500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days
75544344|NCT00414869|Drug|Placebo|Inactive powder matching NCX-1000
75544345|NCT00280878|Drug|gemcitabine|
75544346|NCT00280878|Drug|vinorelbine|
75544347|NCT00280878|Drug|ifosfamide|
75544348|NCT00280878|Drug|rituximab|
75544349|NCT00252473|Device|MedTec S-frame Immobilization Masks|
75544350|NCT00287313|Drug|Vitamin K|
75544351|NCT01680133|Other|Hyperinsulinemic euglycemic clamp|
75544352|NCT01680211|Dietary Supplement|Salacia bark extract|
75544353|NCT01680211|Dietary Supplement|Salacia leaf extract|
75544354|NCT01680211|Dietary Supplement|Sesame seed extract|
75544355|NCT01680211|Behavioral|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
75544356|NCT01680211|Other|Placebo|
75869930|NCT04978168|Behavioral|Treatment as Usual (TAU)|Participants randomized to TAU will receive the services that will be offered at the time the Core Implementation intervention is completed.
75869931|NCT04057508|Other|Modulation of muscle sympathetic nerve activity|Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
75869932|NCT04887077|Device|Kiplin|"The Kiplin intervention will be composed of four components within a smartphone application: a) a gamification of Physical Activity through multiple games called animations, b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool."
75391684|NCT03023436|Drug|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
75391685|NCT04020042|Other|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
75391686|NCT04020042|Other|Landmark palpation|Epidural landmarks will be determined with palpation
75391687|NCT04026594|Other|Mindfulness Based Stress Reduction|"MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
75391688|NCT04026594|Other|Relaxation group|control group
75391689|NCT04025424|Genetic|Genetic tests of the available tumor and plasma samples|Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
75391690|NCT04023396|Drug|ABX464|"ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks."
75391691|NCT04195464|Other|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
75391692|NCT04195464|Other|Sham dry needling|Sham Dry needling use a non-penetrating acupuncture needle
75391693|NCT04195386|Procedure|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
75391694|NCT04195386|Procedure|Dental Restoration with Resin-Modified Glass ionomer Cement|Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
75391695|NCT04195152|Other|Observational|No intervention
75391696|NCT04195074|Drug|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
75869933|NCT04887077|Behavioral|face-to-face|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
75391697|NCT04195074|Drug|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
75391698|NCT04195074|Drug|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
75391699|NCT04194762|Other|Non pharmacological therapy|treadmill training and cycling training in equal intensity exercise.
75391700|NCT03971838|Behavioral|Positive Outcomes for Women|"Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight."
75391701|NCT04029792|Combination Product|Combination of plant extracts (BSL_EP028)|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
75391702|NCT04029792|Combination Product|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
75544357|NCT01680250|Drug|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
75869934|NCT03663062|Diagnostic Test|Colonoscopy|All patients would undergo colonoscopy as part of standard care. Patients recruited for this study would have their past medical history, family history, medication history, as well as waist circumference, BMI and blood pressure recorded. All patients would also have blood tests (described earlier) and a subset will undergo Fibroscan.
75544358|NCT00280956|Drug|natalizumab|
75544359|NCT02279875|Drug|Linezolid|
75707518|NCT06139432|Device|Sham tDCS|"Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~Cathode opposite the left temporoparietal junction (between T3 and P3).~Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation.~Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
75707519|NCT06137963|Other|Transform10 Diabetes Prevention Program|"The Transform10 app includes a Centers for Disease Control (CDC)-approved diabetes prevention program.~The self-paced curriculum and optional video content covers:~Strategies to overcome emotional eating using cognitive behavioral therapy principles.~Improving cardiovascular function with capacity-matched training programs using participants' estimated cardio scores.~An introductory-level course for increasing muscle and bone density foundation via strength training.~Education regarding physical therapy and expectations for patients.~The Transform10 app also provides access to lifestyle coaches who discuss evidence-based information regarding hunger and insulin, macronutrient strategies, time-restricted intermittent fasting, and inflammation."
75707520|NCT06137131|Behavioral|Straw phonation in air|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in air
75707521|NCT06137131|Behavioral|straw phonation in water|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in 2 cm or 5 cm water
75391703|NCT04029948|Procedure|Laser En Bloc Resection Of bladder Tumor|Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
75391704|NCT04029948|Procedure|Electro-surgical En Bloc Resection Of bladder Tumor|Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
75391705|NCT03590262|Drug|Metformin|take the metformin 500mg twice or three times a day
75391706|NCT04029636|Other|Inhaled Hyperpolarized Xenon-129|How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
75391707|NCT04029402|Other|RNA sequencing|Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
75707522|NCT06137131|Behavioral|/u/ phonation|/u/ phonation without a straw, control condition
76034542|NCT04430465|Dietary Supplement|Grain products low in wholegrains|A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products
75391708|NCT04029558|Dietary Supplement|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
75391709|NCT04029558|Dietary Supplement|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
75707523|NCT06135259|Drug|erythropoietin|erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan(5%) and glycerophosphate (20%).
76034543|NCT04878653|Device|BACtrack S80 Breathalyzer|The breathalyzer, BACtrack S80 Breathalyzer, will be calibrated per manufacturer's recommendations before each reading will be taken. Participants will administer the breathalyzer test on themselves. They will be instructed on how to hold and blow into the breathalyzer machine.
75544360|NCT02279875|Drug|HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)|isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
75544361|NCT04824508|Behavioral|position|teamleaders are instructed to allocated position
75544362|NCT00252551|Procedure|Osteosynthesis|
75544363|NCT00252551|Procedure|Simple surgery|Surgery without device
75544364|NCT00280995|Drug|ISIS 301012|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
75544365|NCT00280995|Drug|ISIS 301012|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
75544366|NCT00280995|Drug|ISIS 301012|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
75544367|NCT00280995|Drug|ISIS 301012|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
75707524|NCT06135259|Drug|Triamcinolone acetonide|Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
75544368|NCT04822675|Procedure|Percutaneous mitral valve repair|Percutaneous mitral repair will be performed using the MitraClip system.
75544369|NCT04822675|Procedure|Surgical mitral valve repair/replacement|All mitral valve surgeries will be performed either via sternotomy or right thoracotomy, and with cardioplegic arrest and cardiopulmonary bypass. Mitral valve repair may include annuloplasty and adjunctive procedures as determined by the operating surgeon. For mitral valve replacement, the choice of mitral valve prosthesis will be left at the surgeon's discretion.
75544370|NCT04821349|Device|Capsule endoscopy|"A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.~Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient."
75707525|NCT06134362|Drug|CAB LA|Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
75544371|NCT05139667|Drug|Corticosteroid Topical|topical tacrolimus and corticosteroids
75707526|NCT06134167|Device|Transdermal Compress Device|Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.
75707527|NCT06132841|Drug|AZD6234|Participants will receive repeated doses of AZD6234 as a solution via SC
75707528|NCT06132841|Drug|Placebo|Participants will receive matching volumes of the placebo as a solution via SC
75707529|NCT06132698|Drug|Tislelizumab, pemetrexed|Drug 1: Tislelizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy
75707530|NCT06129643|Drug|Conventional group|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
76034544|NCT04870541|Drug|Ondansetron 8mg|Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
75707531|NCT06129643|Device|Dual laser group|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
75707532|NCT06129643|Combination Product|Combined group|17% EDTA was used to remove smear layer followed by diode laser for disinfection
76034545|NCT04870541|Drug|Nefopam Injectable Solution|Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
76034546|NCT04870385|Behavioral|5-week prevention program|Online modular psychological prevention program featuring integrated elements of Islamic spirituality and Acceptance and Commitment Therapy (ACT).
75707533|NCT06128096|Drug|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|"Patients (180 diabetic patients with CAD that are using SGLT-2 inhibitors and 180 diabetic patients with CAD that are not using SGLT-2 inhibitors) who fulfil the inclusion and exclusion criteria will be recruited from the following sources:~UMMC Cardiology and Diabetes out-patient clinics UMMC Cardiology and Endocrinology in-patients (wards)~During the recruitment, patients will do baseline echocardiography in which includes epicardial adipose tissue and cardiac function. The same procedure will be repeated 6 months post intervention."
76034547|NCT04870385|Behavioral|Control|Control group waitlisted to receive prevention program after completion of final data collection.
75544372|NCT02271061|Device|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
75544373|NCT02271061|Device|Control tape|Apply tape in same technique without tension.
75544374|NCT00287352|Drug|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
75544375|NCT00287352|Drug|Olanzapine and placebo|Olanzapine continuing as clinically indicated
75391710|NCT04194684|Drug|nab-paclitaxel|nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
75391711|NCT03590106|Behavioral|Peer Recovery Support Program|See above
75391712|NCT04194294|Drug|Lidocaine|Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.
75544376|NCT04823962|Drug|rhGM-CSF + hydrogel|The active substance: molgramostim (rhGM-CSF)
75544377|NCT04823962|Drug|Placebo hydrogel|Placebo hydrogel
75544378|NCT04823962|Other|Standard care|Compression therapy and neutral dressings
75544379|NCT00252668|Drug|Etanercept|
76034548|NCT04870073|Procedure|Retrograde autologous priming|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
76034549|NCT04870073|Drug|Mannitol|Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
75391713|NCT04194294|Other|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
75391714|NCT04029324|Procedure|tooth extraction|Under local anesthesia, tooth will be extracted atraumatically.
75544380|NCT00252668|Drug|Methotrexate|
75707534|NCT06127017|Procedure|splinting dental implants with titanium bar|splinting of dental implants will be done in the placebo comparator group by welding a titanium bar intraorally to the temporary sleeves attached to the implants.
75707535|NCT06127017|Procedure|splinting dental implants with PEEK bar|in the active comparator group ,the PEEK bar will be attached to the temporary sleeves using flowable composite resin material.
75391715|NCT04029324|Procedure|Implant placement|Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
75544381|NCT02271997|Drug|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
75544382|NCT02271997|Drug|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
75707536|NCT06125210|Behavioral|early bedside rehabilitation|① electrical diaphragm stimulation, ② electrical muscle stimulation, ③ passive limb movement, ④ respiratory rehabilitation.
75707537|NCT06125210|Dietary Supplement|nutrition program|(1) nutrition department consultation, (2) MDT to develop individualized nutritional pathways, nutrient formulations and use methods, and achieve the target nutritional level within 2 weeks
76034550|NCT04870073|Procedure|Conventional Priming|The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.
76034551|NCT04869839|Other|oral examination|examination done by dentist
76034552|NCT02616029|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
75391716|NCT04029324|Procedure|Bone augmentation|Bone substitute will be used to augment or maintain the bone contour.
75391717|NCT04029324|Procedure|Coronally repositioned flap|After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
75391718|NCT04029090|Drug|MCI-186|A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
75391719|NCT04029090|Drug|MCI-186|A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
75391720|NCT04029090|Drug|Placebo|A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
75391721|NCT04193982|Drug|Saroglitazar|Patient receives Saraglitazar 4mg once daily
75391722|NCT04193982|Drug|Vitamin E|Patient receive Vitamin E 400mg twice daily after food for 6 months
75391723|NCT04193982|Drug|Combination drug|Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
75391724|NCT04193982|Behavioral|Lifestyle Changes|Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
75391725|NCT04028778|Drug|Gefitinib|Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
75391726|NCT04028778|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
76034553|NCT04878341|Other|Erector Spinae Plane Block|The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
76034554|NCT04878497|Drug|Warfarin|Initiation of warfarin, identified using prescription fill in pharmacy claims
76034555|NCT04878497|Drug|Dabigatran|Initiation of dabigatran, identified using prescription fill in pharmacy claims
75391727|NCT04028778|Other|Placebo|Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
75707538|NCT06125210|Procedure|tracheotomy|early tracheotomy for special diseases (e.g central nervous system diseases) receiving mechanical ventilation 14-21 days recommended tracheotomy
75391728|NCT04028856|Drug|interferon|Chronic hepatitis B patients were treated with interferon for 48 weeks
75391729|NCT03594474|Other|Intravenous lipid emulsion|using higher dose of IV lipids after birth
75391730|NCT04028544|Drug|Qishenyiqi dropping pills|on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
75707539|NCT06122064|Other|Best Practice|Receive standard of care
76034556|NCT04878497|Drug|Rivaroxaban|Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
76034557|NCT04878497|Drug|Apixaban|Initiation of apixaban, identified using prescription fill in pharmacy claims
76034558|NCT04878497|Drug|Edoxaban|Initiation of edoxaban, identified using prescription fill in pharmacy claims
76034559|NCT03277703|Biological|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
75391731|NCT04028544|Drug|Placebo|on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
75391732|NCT04406220|Other|Small clog size|Participants will be randomized to run in small clogs
75391733|NCT04406220|Other|Large clog size|Participants will be randomized to run in large clogs
75391734|NCT04193592|Drug|Pirfenidone|Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
75391735|NCT03964272|Device|Exablate Bilateral Subthalamotomy|Exablate bilateral treatment for Parkinson's Disease Motor Features
75391736|NCT03963102|Drug|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
75707540|NCT06122064|Other|Communication Intervention|Use shared decision-making conversation tool
75707541|NCT06122064|Other|Electronic Health Record Review|Ancillary studies
75707542|NCT06122064|Other|Survey Administration|Ancillary studies
76034560|NCT03257033|Drug|Gemcitabine|Chemotherapy
76034561|NCT03257033|Drug|nab-paclitaxel|Chemotherapy
76034562|NCT03257033|Device|RenovoCath|Intra-arterial catheter
75391737|NCT03599856|Other|TraceBook|TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
75391738|NCT04193358|Dietary Supplement|FERTILIS HOMME®|L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
75391739|NCT04193358|Other|PLACEBO|Sugar pills
75391740|NCT04193436|Drug|PF-06835919 25 mg|PF-06835919 in 25 mg oral tablet will be administered on Day 1
75391741|NCT04193748|Drug|Topical pomegranate seeds and peel extracts|Topical pomegranate seeds and peel extracts in the form of gel
75391742|NCT04028154|Procedure|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
75391743|NCT04028154|Procedure|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
75707543|NCT06122064|Other|Video Recording|Ancillary studies
75707544|NCT06117839|Procedure|using antibiotic loaded cement and regular cement after total knee arthroplasty in primary knee osteoarthritis.|-There are 2 groups ,first group is patients will betreated with regular bone cement ,the second one is patient will be treated with antibiotic loaded bone cement, commonly used antibiotics include Gentamycin powder .
75707545|NCT06116409|Drug|Bupivacain|Bupivacaine was used for postoperative analgesia block.
76034563|NCT03250169|Drug|Alemtuzumab|Licensed dose
76034564|NCT04429841|Procedure|Radical gastrectomy with D1 lymphadenectomy|
76034565|NCT04429841|Procedure|Radical gastrectomy with D2 lymphadenectomy|
75391744|NCT04028076|Behavioral|Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence|An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
76034566|NCT02614859|Drug|Observation and Bicalutamide|Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).
76034567|NCT02614859|Drug|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
75391745|NCT04027764|Drug|Toripalimab Combined With S1 and Albumin Paclitaxel|Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \8
75391746|NCT04027842|Device|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
76034568|NCT04384445|Biological|Zofin|Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
75391747|NCT04192890|Device|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
75391748|NCT03592602|Procedure|arm abduction and adduction|All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
75391749|NCT04027530|Drug|Ertugliflozin 15 mg|Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
75391750|NCT03023358|Drug|chidamide|30mg po twice a week
75391751|NCT03023358|Drug|cyclophosphamide|750mg/m2 iv on day 1
75391752|NCT03023358|Drug|liposomal doxorubicin|30mg/m2 iv on day 1
75391753|NCT03023358|Drug|vincristine|1.4mg/m2 iv on day 1
75391754|NCT03023358|Drug|prednisone|100mg/d po on day 1-5
75391755|NCT03023280|Procedure|Radiofrequency ablation|
75391756|NCT04192812|Drug|PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
75391757|NCT04192812|Drug|NO GnRHa|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
75391758|NCT04192578|Device|remote ischemic conditioning|RIC is induced by short-term insulting blood-flow of nonvital distant organs intermittently.
75391759|NCT04407000|Drug|Test: Favipiravir 200 mg (LOQULAR)|Test Drug
75391760|NCT04407000|Drug|Reference: Favipiravir 200 mg (Avigan)|Reference Drug
75391761|NCT04192422|Other|no intervention|This is a cohort study no intervention
75391762|NCT04192656|Device|non-invasive positive airway pressure|non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea
76034569|NCT04384445|Other|Placebo|Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
75391763|NCT04192656|Drug|Methylprednisolone Hemisuccinate|Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
75391764|NCT04192656|Drug|Ginaton|ginnaton is ginkgo biloba extract
75391765|NCT04191954|Drug|Fasudil eye drops (concentration 0.5 percent)|receive Fasudil eye drops (concentration 0.5 percent) twice daily
75391766|NCT04191954|Drug|receive artificial tears drop|receive artificial tears drop with the same frequency
75391767|NCT04192032|Other|Preferred Juul pod flavor (5% nicotine)|Preferred Juul pod flavor (5% nicotine)
75391768|NCT04192032|Other|Classic Tobacco Juul pod flavor (5% nicotine)|Classic Tobacco Juul pod flavor (5% nicotine)
75391769|NCT04192032|Other|Preferred flavor with HWL|Preferred flavor (5% nicotine) with HWL
75391770|NCT04192032|Other|Preferred flavor, 3% nicotine|Preferred flavor, 3% nicotine
75391771|NCT04192032|Other|Preferred flavor, 0% nicotine|Preferred flavor, 0% nicotine
75391772|NCT04027062|Behavioral|Diabetes Continuing Education Intervention|"The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians."
75391773|NCT04026828|Genetic|Periodontitis Group|Periodontitis group consists of both chronic and aggressive periodontitis patients
75391774|NCT04191408|Procedure|PEEP increase|PEEP increase +5 to +15 cmH2O. PLR at 30 degrees.
75391775|NCT04191564|Procedure|low perfusion state|reduce SAP below 100 mmHg
75707546|NCT06113029|Diagnostic Test|The Hamilton Rating Scale for Anxiety|The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety).
75707547|NCT06113029|Diagnostic Test|The Beck Depression inventory|one of the most widely used instruments for measuring the severity of depression
76034570|NCT04877795|Diagnostic Test|Blood sampling|Blood will be sampled from enrolled patients and analyzed for levels of troponin, copeptin and heart-type fatty acid binding protein (HFABP).
75391776|NCT04191564|Procedure|normal perfusion state|maintain SAP above 100 mmHg
75391777|NCT04195620|Other|High self-disclosure|"The high self-disclosure condition involves individuals asking and answering a series of questions that are more personal in nature and involve sharing or receiving information that is likely to be emotionally laden and information that is not readily shared in typical conversations. An example of a question from this condition includes If you were to die today without the chance to speak with anyone, what would you most regret not having said to someone? Why haven't you said it yet?"
75391778|NCT04195620|Other|Low self-disclosure|"The low self-disclosure condition involves individuals asking and answering a series of questions that are not personal in nature and involve sharing or receiving information that is shared in very casual conversations. An example of a question from this condition includes What did you do to celebrate Halloween last year?"
75707548|NCT06113029|Diagnostic Test|Rand SF-36 Questionnaire|The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). Component analyses showed that there are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS). All scales do contribute in different proportions to the scoring of both PCS and MCS measures
75707549|NCT06107621|Behavioral|iCBT for Gambling Disorder and psychiatric comorbidities|The iCBT, is based on the gambling pathways model. As a clinical conceptualization, the treatment build on loss of control, but also include additional interventions (e.g., emotion regulation and impulse control) targeting the etiological co-morbidity factors in the pathways model for emotionally vulnerable and impulsive gamblers (pathways subtypes 2 and 3).
75707550|NCT06105983|Drug|Sisunatovir|Single Dose
75707551|NCT06105983|Drug|Rabeprazole|Tablets once daily for 7 days
75707552|NCT06105697|Device|Blood flow restriction Running on Treadmill|Soccer players included in experimental group I will carry out this program for 6 weeks, setting the blood pressure to ~ 60% of limb occlusion pressure (AOP). They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
76034571|NCT03046355|Procedure|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
75391779|NCT04191018|Diagnostic Test|Liver elastography|Liver stiffness measurement
75391780|NCT04191018|Diagnostic Test|Splenic elastography|Splenic stiffness measurement
75391781|NCT04191018|Diagnostic Test|Gastrointestinal endoscopy|Gastrointestinal endoscopy
75391782|NCT03023982|Drug|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
75391783|NCT03023982|Device|Ultrasound|All blocks will be done under ultrasound
75391784|NCT03023982|Procedure|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
75391785|NCT03023982|Drug|Opioids|standard pain control with opioids
75391786|NCT03023982|Drug|NSAID|standard pain control with NSAIDs
75391787|NCT04191252|Diagnostic Test|A multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
75544383|NCT02271997|Drug|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
75391788|NCT03951870|Behavioral|Neuromodulation via fMRI Neurofeedback task|Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
75391789|NCT03951870|Biological|Hepatitis B vaccination|Subjects will be vaccinated against Hepatitis B
75391790|NCT04026360|Other|no intervention|
75391791|NCT04192110|Drug|Diuretic initiation or augmentation|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
76034572|NCT03046355|Procedure|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
75391792|NCT04025736|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
75391793|NCT04025736|Drug|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
75391794|NCT04766112|Other|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training
75391795|NCT04766112|Other|Group II|Group II will receive yang style Tai chi exercise which consist of 10 positions.
75391796|NCT04190940|Behavioral|Behavioral Assessment|"Patients will be asked to complete the behavioral assessment before and after their HIFU treatment or on and off their DBS treatment."
75391797|NCT04195230|Behavioral|Multi-tasking Training|Participants will undergo training protocol where they will have, concomitantly, to cook different meals and set the table under different instructions, rules and difficulty level.
75391798|NCT04199598|Drug|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
75391799|NCT04199598|Drug|Abediterol (4.8 μg)|4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
76034573|NCT04877717|Drug|SHR-A1904|SHR-A1904
76034574|NCT04877951|Behavioral|LSVT BIG|LSVT BIG is a 4-week program that focuses on movement recalibration for people with a diagnosis of Parkinson's disease.
76034575|NCT04877171|Other|telemedicine neurology consultation|consultations via phone-only at 12-14-day post-discharge. Consultations via phone both audio and video at 1, 3 and 6 months
75391800|NCT04199598|Drug|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
75391801|NCT04199598|Drug|Abediterol (2.5 μg)|2.5 μg (nominal dose) abediterol via DPI, reference
75391802|NCT04190784|Other|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
75391803|NCT04190784|Other|Placebo stretching|The therapist maintains the same manual contact without stretching force.
75391804|NCT03023748|Drug|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
75391805|NCT04190316|Other|Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
75391806|NCT04190160|Drug|IDegLira|A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
75391807|NCT04190004|Drug|Vasopressins|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
75391808|NCT04190004|Drug|Placebo|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
76034576|NCT04877171|Other|in-person neurology consultation|consultation in-person at Hospital Internacional de Colombia
75391809|NCT03961620|Device|The SpotOn system that encompasses the registration unit (3M SpotOn Control Unit), disposable sensor (3M SpotOn Control Sensor) along with the cords and electric power unit.|Patients submitted to major surgical procedure will be assessed for core body temperature by employing SpotOn sensor device, before, during and after surgical procedure.
75391810|NCT04406298|Procedure|small quantity paracentesis|Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days
75391811|NCT04406298|Procedure|Large Volume Paracentesis|Large Volume Paracentesis > 5litres
75391812|NCT04025892|Behavioral|Daily weighing|Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
75391813|NCT04406376|Drug|Prednisone tablet|Treatment of Bell's Palsy with prednisone, with or without tapering down.
75707553|NCT06105697|Other|Running on Treadmill|Soccer players included in experimental group II will carry out the program for 6 weeks without occlude the blood pressure. They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
75707554|NCT06104904|Behavioral|MAPP|Behavioral intervention based on exposure therapy strategies.
75707555|NCT06104293|Other|Grass Pollen Allergen Exposure|"After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations."
75707556|NCT06102057|Radiation|standard Radiotherapy|standard FDG-PET-based radiotherapy
75391814|NCT04025268|Behavioral|Group Prenatal Care (GPNC)|GPNC participants will attend 11 group sessions total: 10 during pregnancy and one postpartum. Each session will be 90-100 minutes long. Groups will collectively identify the preferred time of day for these sessions. Groups of 10 women will be led by a locally trained, Samoan nurse-midwife with the study Project Director as a co-facilitator. At each of the visits participants will engage in self-assessments of weight and blood pressure, including learning to take their blood pressure with a digital cuff, calculating BMI, and plotting their weight gain on a graph), receive short individual clinical examinations from a midwife, and participate in group discussions about prenatal care, childbirth preparation, and their postpartum care. The session at 6-weeks postpartum will allow women to introduce their babies to the group and share childbirth stories.
75391815|NCT04025268|Behavioral|Standard of Care|Standard of prenatal care
75391816|NCT04025346|Other|Capsimax|1 capsule to be taken before breakfast.
75707557|NCT06102057|Drug|Chemotherapy|concurrent standard of care chemotherapy
75707558|NCT06102057|Drug|Immunotherapy|standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
75707559|NCT06102057|Radiation|Experimental Radiotherapy|FDG-PET-based small volume accelerated radiotherapy
75707560|NCT06101498|Diagnostic Test|Akut kidnet injury(AKI)|postoperative 24 hours
75707561|NCT06100198|Other|nutrition and exercise program|Nutrition courses include understanding malnutrition and sarcopenia; understanding the six major food categories and their requirements; and understanding protein-rich food sources. Exercise courses include understanding exercise types, flexibility exercises, and muscle strength training exercises.
75707562|NCT06091904|Drug|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
76034577|NCT03046277|Other|No intervention|No intervention
76034578|NCT04876859|Procedure|CRF of anterior sensitive branches to the hip|Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.
76034579|NCT04876859|Procedure|Anesthetic block with steroid injection of anterior sensitive branches to the hip|Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
76034580|NCT03049241|Other|neuromuscular fatigue|The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
76034581|NCT03046043|Procedure|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
75391817|NCT04025346|Other|Micro Crystalline Cellulose|1 capsule to be taken before breakfast.
76034582|NCT03046043|Procedure|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
76034583|NCT05257889|Diagnostic Test|blood and CSF studies + neuroimaging studies|blood and CSF studies + neuroimaging studies
75391818|NCT04025034|Procedure|Orbital decompression with ultrasonic bone removal|Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
75391819|NCT04025112|Device|Armeo®Power|Randomized patients will be offered rehabilitation robotic using Armeo®Power from Hocoma, the first robotic arm exoskeleton for integrated arm and hand therapy, during one month, three times a week, totalizing 12 sessions of 45 minutes.
75391820|NCT04025112|Other|Conventional rehabilitation protocol|Randomized patients will be offered the conventional rehabilitation protocol from Barretos Cancer Hospital during one month, three times a week, totalizing 12 sessions of 45 minutes.
75391821|NCT04024722|Procedure|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
75391822|NCT04024800|Biological|AE37 Peptide vaccine|"Starting dose: AE37 vaccine 1000 micrograms split into 2 doses given as intradermal injection on day 1 of every 3 week cycle (21 day cycle) for 5 cycles.~Should ≥ grade 3 systemic toxicities (DLT) occur in > 25% (4) of the first 13 patients (4 or more) the study therapy vaccine dose will be de-escalated to 500 micrograms (dose level -1)."
75391823|NCT04024800|Biological|Pembrolizumab|Pembrolizumab 200 mg IV on day 1 of every 3 week cycle (21 day cycle) for 2 years (35 cycles)
76034584|NCT03047915|Other|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
76034585|NCT04876313|Drug|Nivolumab + Nab-paclitaxel|4x3 weekly cycles of 360 mg nivolumab + 125 mg/m^2 nab-paclitaxel IV on days 1 and 8
76034586|NCT04876313|Drug|Nivolumab|360 mg IV Q3W x 13 cycles
76034587|NCT04876469|Procedure|Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion|Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion
76034588|NCT02615249|Biological|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
75391824|NCT04195854|Device|P4HB product|Retrospective use of P4HB in various anatomies
75391825|NCT04199520|Combination Product|surgery combined with systemic therapy|surgery combined with systemic therapy
75391826|NCT04199520|Other|systemic therapy|systemic therapy
75391827|NCT04406610|Biological|GD2 CAR-T immunotherapy|Antigen-specific T cell therapy
75391828|NCT04024176|Other|Gait analysis|The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
75391829|NCT04024332|Drug|ACT-541468|ACT-541468 25 mg; administered orally
75391830|NCT04023864|Dietary Supplement|Platycodon Grandiflorus Extract(GCWB107)|Once-daily, once a tablet, after meals, for 12 week
75391831|NCT04023864|Dietary Supplement|Placebo|Placebo for 12 week
75707563|NCT06091904|Drug|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
75707564|NCT06090305|Behavioral|levidex|Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).
75707565|NCT06090305|Behavioral|Control|Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).
75707566|NCT06090305|Other|treatment as usual (TAU)|treatment as usual (TAU)
75707567|NCT06090175|Other|Projector colleyscope group|Projector kaleidoscope will be used in children aged 3-6 who are administered inhaler medication.
75707568|NCT06090175|Other|Matching card group|Matching card will be used in children aged 3-6 who are administered inhaler medication.
75869935|NCT03728543|Drug|Sugammadex|"Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection"
75707569|NCT06088992|Genetic|HG004|Method of Administration: Once unilateralsubretinal injection; The duration of the study isabout 60 weeks for each subject including a 8-weekscreening period, enrollment/baseline visit,treatment visit, and 52 weeks follow-up period.
75544384|NCT04821076|Other|Diet intervention - caloric restriction|Energy restriction is set to 25 kcal / kg fat-free mass
75544385|NCT04821076|Other|Exercise intervention|Exercise will consist of supervised resistance training, interval training and moderate intensity cycling
75707570|NCT06087757|Drug|Open Label Clemastine with a blinded randomize withdrawal|Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.
75707571|NCT06086795|Other|Whole eggs|3 large whole eggs per day for 4 weeks
75544386|NCT04821076|Other|Diet intervention - Energy balance|Energy balance is set to 50 kcal / kg fat-free mass
75544387|NCT05139394|Procedure|emergency pancreaticoduodenectomy|Emergency pancreaticoduodenectomy (EPD) is a complex surgical procedure, that can be performed for complex pancreaticoduodenal injuries, that cannot be controlled through less invasive procedures. EPD can be performed either as a classical Whipple procedure, or as a pylorus-preserving procedure. A one stage procedure implies the reconstruction step being done in the same surgical intervention, while a two step procedure implies the reconstruction being done in a later stage, through a second surgical intervention.
75707572|NCT06086795|Other|Egg yolks|3 large egg equivalent of egg yolks per day for 4 weeks
75707573|NCT06086795|Other|Egg whites|3 large egg equivalent of egg whites per day for 4 weeks
75391832|NCT03022890|Behavioral|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
75707574|NCT06083012|Device|Cardiac mapping|"All patients enrolled are treated for their atrial fibrillation/tachycardia via a catheter ablation procedure using VX1 software (used in accordance with its approved indication as per of its IFU) during the mapping phase to identify areas of interest specific to the patient.~The ablation approach is free and chosen by the operator according to his standard practice. The two main phases of the ablation procedure are:~3D mapping of the atria and location of areas of interest;~Catheter ablation at the operator's discretion."
75391833|NCT03022890|Behavioral|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
75391834|NCT04021056|Other|No intervention|
75707575|NCT06080191|Drug|CD19-CAR_Lenti_ALLO|"Biological/Vaccine: CD19-CAR_Lenti_ALLO~A single infusion of CD19-CAR_Lenti_ALLO on Day 0"
75707576|NCT06079060|Device|Synthetic Nitrile Condom (61mm)|61mm width Synthetic Nitrile Condoms
75707577|NCT06079060|Device|Control Latex Condom|61mm width Natural Rubber Latex Condom
75869936|NCT03728465|Biological|Nivolumab|In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
76034589|NCT02615171|Behavioral|Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
76034590|NCT02615171|Behavioral|Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity|Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
75391835|NCT04023786|Procedure|PEEP-TEST|The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
75391836|NCT04023630|Drug|Rivaroxaban 15 MG Oral Tablet|One 15 mg tablet once daily for up to twelve months
75869937|NCT03728465|Biological|Ipilimumab|In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
75391837|NCT04023630|Drug|Clopidogrel 75 Mg Oral Tablet|One 75 mg tablet once daily for up to twelve months
75391838|NCT04023630|Drug|Ticagrelor 90 MG Oral Tablet|One 90 mg tablet twice daily for up to twelve months
75391839|NCT04199754|Drug|Omnipaque 300mg/mL Solution for Injection|Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
75391840|NCT04199754|Radiation|Cone Beam CT|60 seconds after contrast administration, a Cone Beam CT will be performed.
75391841|NCT04199754|Radiation|Radiation Therapy|Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.
75391842|NCT04199754|Drug|0.9% Saline|50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
75391843|NCT04023474|Procedure|Platelet Rich Fibrin (PRF) Application|Platelet Rich Fibrin application to flap defect.
75391844|NCT04023006|Device|Removable prostheses|Full dentures created by Additive manufacturing (Carbon Printers)
75391845|NCT04022928|Other|PRP|, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
75391846|NCT04147104|Device|Low flow ECCO2R|"Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as sweep gas containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal."
75391847|NCT04147104|Device|Invasive mechanical ventilation|Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.
75391848|NCT04147182|Drug|Hypertonic Saline 3%|3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
75391849|NCT04146792|Behavioral|body acceptance program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
75391850|NCT04146792|Behavioral|writing creatively program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
75707578|NCT06078813|Radiation|Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)|Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume_1 (PTV_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV_2 will remain the same through all dose levels. All doses are prescribed to the target volume.
75707579|NCT06075836|Other|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~- Review 500 chest X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period of 2 weeks.~Phase 2 - Time allowed: 2 weeks~- Review 500 chest X-rays together with an AI report for each case and express your clinical opinion through the same structured reporting template used in Phase A."
75391851|NCT04146948|Other|no intervention|no intervention in this study
75391852|NCT04022304|Biological|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
75869938|NCT03728387|Other|Clinical Pilates Exercise|All evaluations of the individuals included in the study will be done by the physiotherapist.. For the second evaluation the same individuals will be visited by the same physiotherapist at least 7 days after the first evaluation and only the FAB-T scale will be applied. 34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section. Various exercise methods (clinical pilates exercises) and tools will be utilized to improve balance and mobility. Third assessment of FAB-T will be applied only to individuals participating in the 6-week exercise training program.
75707580|NCT06075836|Other|Ground truthing|Two consultant thoracic radiologists will independently review the images to establish the 'ground truth' findings on the CXRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior thoracic radiologist's opinion (>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
75707581|NCT06075511|Diagnostic Test|6 minutes walk distance|Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded
75707582|NCT06075511|Behavioral|Activity Monitor|Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.
76034591|NCT03049085|Drug|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
76034592|NCT03049085|Drug|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
76034593|NCT04876547|Procedure|appendectomy|appendectomy performance
75391853|NCT04022304|Biological|Humulin® N|Humulin® N (human insulin [recombinant deoxyribonucleic acid origin] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
75544388|NCT05139082|Drug|TQB3616 capsules＋ TQB2450 injection|"TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
75707583|NCT06075511|Behavioral|Continuous Glucose Monitor|Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.
75707584|NCT06075511|Behavioral|Blood Pressure Monitoring|Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day
75707585|NCT06075511|Diagnostic Test|Blood Pressure Monitoring|24-hour ambulatory blood pressure monitoring
75707586|NCT06075511|Diagnostic Test|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
75707587|NCT06075511|Diagnostic Test|Mixed meal testing|Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min
75707588|NCT06075511|Diagnostic Test|Quality of Life|Subject will complete Quality of Life Questionnaire
75707589|NCT06066736|Other|observational|No intervention, observational group
76034594|NCT04876001|Behavioral|Brief Behavior Therapy for Insomnia|"The BBTI consists of two in-person sessions on week 1 and 3 and two sessions on week 2 and 4 as the booster delivered by phone call."
75707590|NCT06066203|Drug|GNC-035|GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
75707591|NCT06066099|Drug|AP31969|Oral tablets
75707592|NCT06066099|Drug|Placebo|Oral tablets
75707593|NCT06065475|Behavioral|Ultrasound-guided bilateral Thyroid Cartilage Plane Block|Use a SonoSite high-frequency linear array transducer (5-13 MHz, SonoSite, USA). Place the transducer parallel to the spine on one side of the neck, ensuring clear visualization of the thyroid cartilage plate under ultrasound. Employ ultrasound-guided in-plane or out-of-plane techniques to display the needle insertion path and tip. Once the needle tip contacts the upper half of the thyroid cartilage plate, inject 3ml of 2% lidocaine on the surface of the thyroid cartilage plate.
76034595|NCT04875845|Behavioral|Fasting for elective surgery|6-hours and 8-hours fasting before elective surgery
76034596|NCT04869293|Device|Hypnosis 3D virtual reality headset|3D experience to journey through a natural and therapeutic environment. Immersion is amplified by the realism of 3D environment, a soothing sound atmosphere and specific medical hypnosis.
75391854|NCT04022382|Device|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.
75391855|NCT04021446|Other|Exercise|personalized exercise prescription
75391856|NCT04022460|Diagnostic Test|Video clip assessment|Parents will take short video clips of their child sleeping at night. They will be asked to review the video clips and rate whether they think their child has obstructive sleep apnea (OSA), and if so, how severe it is. Two clinicians will review the video clips on a separate night.
75391857|NCT04022460|Diagnostic Test|Polysomnography (sleep study)|Children will undergo a polysomnography as the gold standard test to assess for OSA.
75707594|NCT06065189|Biological|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
75391858|NCT04022460|Other|Educational webinar|After evaluating the video clips of their child sleeping, parents will watch an educational webinar on OSA in children with Down syndrome and how to recognize symptoms.
75707595|NCT06064903|Biological|CD7-CART01|A single IV infusion of CD7-CART01 on Day 0
76034597|NCT04875611|Drug|Opdivo|Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).
76034598|NCT04875689|Other|Group A (Experimental|"Laser therapy is performed on patients in supine lying position. Treatments will be delivered with a diode laser (wavelength 830 nm, continuous wave, power 50 mW) in skin contact at a dose of 6 J/point. Treatment times per point are in the range of 30 seconds to 1 minute. eight points were irradiated per session.~Conventional therapy will include:~TENS for 15 minutes~Hot pack for 15 minutes~Hamstrings muscle stretching and calf muscle stretching. Strengthening exercises ,straight leg raising exercise in crook lying position~Joint mobilizations"
75391859|NCT03930654|Behavioral|iPrEP|"iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV.~Women will receive the iPrEP intervention on an iPAD Air tablet device~iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~iPrEP uses qualitative themes~iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~Scales were modified (in some cases) for cultural competency and tailoring to women"
75391860|NCT03930654|Behavioral|Usual Care|"Women will receive usual care~Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~Social worker will offer a list of substance abuse treatment referral agencies"
75391861|NCT04020900|Other|Respiratory management|Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
75391862|NCT04020666|Drug|Urinary Kallidinogenase|
75391863|NCT04405986|Procedure|Auditory Evoked Potentials (AEP)|Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).
75391864|NCT04405986|Procedure|Blink and Masseter Inhibitory Reflex|Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
76034599|NCT04875689|Diagnostic Test|Group B (Control)|"1. Participants of this group will receive only conventional therapy which will include;~TENS for 15 minutes~Hot pack for 15 minutes~Hamstrings muscle stretching and calf muscle stretching.Each stretch was sustained for 30 seconds, with 10-second rest intervals.~Strengthening exercises include quadricep drills(full knee extension maintained for 5 seconds, followed by a 5-second rest) 20 repetitions per session,straight leg raising exercise in crook lying position(the patients were asked to tense the quadriceps muscle, elevate the limb to 45° and maintain it for 6 seconds, and lower the limb slowly and then relax for 6 seconds; the exercise was performed for three sets of 10 repetitions per session).~Joint mobilizations (tibiofemoral extension and flexion; patellofemoral medial-lateral and inferior glide)."
75707596|NCT06061510|Dietary Supplement|omega-3 polyunsaturated fatty acids|Participants in the intervention group took fish oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
75391865|NCT04021992|Drug|gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab|All patients enrolled in the study will accept gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab as their salvage chemotherapy.
75391866|NCT04022070|Other|Dynamic Tape® (Tape)|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage affected by plantar fasciitis during a week the Outcome Measure, pain is evaluate with a VAS (visual pain scale).
75391867|NCT03593148|Other|Lifestyle|Lifestyle treatment
75391868|NCT03022734|Drug|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
75391869|NCT03022734|Radiation|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
75544389|NCT04719767|Device|visual laryngeal mask|After anesthesia induction, visual laryngeal mask airway was placed in the visual group and tracheal intubation was guided under visual conditions. In the non-visual group, laryngeal mask airway was inserted, after clinical judgment of good counterpoint of the laryngeal mask, endotracheal intubation was inserted blindly through LMA. Selection of laryngeal mask airway (LMA) model: the ideal body weight of the patient was calculated.
75544390|NCT05138926|Other|Cervical Manipulation|high speed, low amplitude cervical manipulation
75707597|NCT06061510|Dietary Supplement|corn oil|Participants in the placebo group took corn oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
75544391|NCT05138926|Other|Sham Cervical Manipulation|Cervical mobilization without performing spinal manipulation
75544392|NCT00287391|Drug|Rabeprazole|
75391870|NCT04406532|Behavioral|PT-Pal|"Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
75391871|NCT04406532|Behavioral|Self-guided exercises|"Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
75391872|NCT04021836|Other|3d evaluation of nasolabial change|Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
75391873|NCT04020588|Drug|Celecoxib 200mg|Will be administered for 6 weeks
75391874|NCT04020588|Drug|Placebo oral capsule|Will be administered for 6 weeks
75391875|NCT04020588|Drug|Minocycline 100mg|Will be administered for 6 weeks
75391876|NCT04146402|Drug|SCT-I10A+chemo|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
75391877|NCT04146402|Drug|Placebos+chemo|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
75391878|NCT04146168|Diagnostic Test|Ultrasound|Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
75391879|NCT04146480|Diagnostic Test|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5. Upon completion of the scan, will be released without any restrictions."
75391880|NCT03021798|Other|No Drug and no aspecific intervention|No intervention
75391881|NCT03021876|Drug|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
75391882|NCT03021876|Other|usual intake|baseliner
75707598|NCT06060509|Dietary Supplement|Phytosterol-rich Wheat and Corn Germ Blended Oil|Blending of corn germ oil and wheat germ oil supplied by Yihai Kerry to obtain germ blended oil with high phytosterol content.
76034600|NCT04369625|Behavioral|CHIMPS-T|CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
75391883|NCT03948438|Procedure|Endoscopic septotomy|Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)
75391884|NCT04020354|Behavioral|HABIT-ILE|Early Hand and arm bimanual intensive therapy including lower extremities
75391885|NCT04020354|Behavioral|Usual Care|Usual customary care
75391886|NCT03907410|Other|Nominal Financial Incentives|The nominal financial incentives will consist of fixed-ratio incentives for each inhaled corticosteroids (ICS) actuation (25 cents for children on 4 daily ICS doses and 50 cents for children on 2 daily doses), with a maximum of $1 per day.
75391887|NCT03907410|Other|Daily Adherence Reminders/Adherence Performance Feedback|Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
75544393|NCT05138536|Procedure|Pan-Computer Tomography|trauma centers use the pan-computed tomography (CT) scan (head, neck, chest, and abdomen/pelvis) for the evaluation of blunt trauma.
75544394|NCT00252707|Drug|Gefitinib or Docetaxel|
75391888|NCT04145544|Device|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~Cut the ArtiFascia® to the required shape under aseptic conditions~Apply ArtiFascia® to the damaged area~Suture the ArtiFascia® in place~Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
75707599|NCT06060509|Dietary Supplement|Peanut oil|Participants in the control group consumed peanut oil daily for cooking.
75391889|NCT04145544|Device|Implantation of other commercial suturable dural substitute|Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
75544395|NCT01680367|Procedure|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
75707600|NCT06060210|Drug|normal Saline|50-ml Saline
75707601|NCT06060210|Drug|Ketamine|50-ml volumes, and the ketamine concentration is 1 mg/ml
75707602|NCT06059586|Behavioral|Pelvic health therapy|Female Sexual Function Index (FSFI) and VAS Pain Scale Questionnaires, Physical Therapy Evaluation including Pelvic Floor Muscle Examination, Dilator Education
75391890|NCT04146558|Drug|Individualized internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
75544396|NCT01680367|Procedure|wound care management|Receive native collagen wound dressing
75544397|NCT01680367|Other|questionnaire administration|Ancillary studies
75707603|NCT06059586|Device|Dilator feasability|Patient Adherence to Vaginal Dilation Questionnaire
75391891|NCT04146558|Other|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
75391892|NCT03619044|Other|2 FES-PET Imaging will be performed:|"before treatment initiation~before treatment cycle 3 initiation"
75391893|NCT04146246|Diagnostic Test|G6PD assay|A test for G6PD deficiency.
75544398|NCT00281073|Device|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
75544399|NCT00281073|Device|Intracardiac Echo|Intracardiac Echo Viewmate
75544400|NCT00281073|Device|ICE|ICE or TEE
75544401|NCT01680406|Drug|Artemether-lumefantrine combination|
75544402|NCT01680406|Drug|Primaquine|
75707604|NCT06056479|Procedure|external oblique intercostal block|20 ml of bupivacaine 0.25% will be administered by US into external oblique intercostal plane at the level of sixth rib space .
75391894|NCT04020120|Other|questionnaires|answer questionnaires
75391895|NCT04145856|Dietary Supplement|I31 probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
76034601|NCT04369625|Behavioral|CHIMPS-P|CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention.
75391896|NCT04145856|Combination Product|I31 probiotic combined to Alverine/Simethicone|"I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)"
75391897|NCT04145856|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
75391898|NCT04146090|Other|Low-pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 10 mmHg
75391899|NCT04146090|Other|Standard pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 14 mmHg
75391900|NCT04140786|Drug|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
75391901|NCT04144998|Diagnostic Test|central sensitization inventory (questionnaire)|T.G. Mayer, R. Neblett, H. Cohen, et al. The development and psychometric validation of the central sensitization inventory Pain Pract, 12 (2012), pp. 276-285
75391902|NCT04147650|Drug|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
75391903|NCT04147650|Drug|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
75391904|NCT04147650|Drug|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
75391905|NCT04147650|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
75391906|NCT04023942|Behavioral|Weight maintenance intervention|Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
75391907|NCT04022226|Drug|Ketamine|Induction agent that suppresses infra-slow waves
75391908|NCT04022226|Drug|Methohexital|Induction agent that does not suppress infra-slow waves
75391909|NCT04029012|Drug|Methoxyflurane|Methoxyflurane inhaler before Rezum procedure
75391910|NCT04025658|Drug|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
75391911|NCT03605706|Drug|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
75391912|NCT03605706|Drug|FOLFOX4|Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
75391913|NCT03605706|Drug|Placebo|Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
75391914|NCT03924180|Dietary Supplement|Dietary Supplement for PKU patients|For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
75391915|NCT05581680|Other|dental impressions|dental impressions
75391916|NCT05581680|Other|Simultaneous MoCap and EMG acquisition|Simultaneous MoCap and EMG acquisition
75391917|NCT05581680|Other|Eye-tracking acquisition for pathological subjects|Eye-tracking acquisition for pathological subjects
75544403|NCT01680406|Drug|Chloroquine|
75391918|NCT05581680|Other|Follow-up visit for pathological subjects|Follow-up visit for pathological subjects
75391919|NCT04023240|Drug|68Ga-FAPI|"68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)"
75391920|NCT04023240|Procedure|Computed Tomography (CT) scan|Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
75391921|NCT04023240|Procedure|Positron Emission Tomography (PET) scan|PET images will be acquired.
75391922|NCT05586438|Drug|Colistin Sulfomethate|The patients receive colistin 150 mg intravenous once daily on non-dialysis day and receive colistin 150 mg intravenous every 12 hours on dialysis day
75391923|NCT05581524|Device|VASC|At day 0 the patient will undergo the VASC treatment procedure with VelexTM device. VelexTM venous catheter is inserted in the introducer and pushed in the desired position under echo guidance. At 7 days, 1, 3 and 6 months after the procedure, the patients will undergo a clinical examination and an echo-color doppler assessment.
75391924|NCT04765878|Device|RespirAq Humidification|Humidifier
75391925|NCT04024566|Device|Vivio System|Optical/sensor tonometer applied to the neck over the carotid pulse (bilateral)
75391926|NCT05581446|Diagnostic Test|Visual Analogue Scale|pain type severity determination and quality of life assessment
75391927|NCT03921294|Drug|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
75391928|NCT04145232|Biological|Collection of biopsy (FFPE), blood (PBMC) and stool|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
75544404|NCT00252746|Drug|ZD6474 (vandetanib) 100mg|once daily oral dose
75544405|NCT00252746|Drug|ZD6474 (vandetanib) 200mg|once daily oral dose
75544406|NCT00252746|Drug|ZD6474 (vandetanib) 300mg|once daily oral dose
75544407|NCT01680484|Dietary Supplement|Bitter chocolate|
76034602|NCT04369625|Behavioral|CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.
76034603|NCT04369625|Behavioral|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
75544408|NCT01680484|Dietary Supplement|Orange juice|
75544409|NCT01680523|Procedure|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
76034604|NCT04366895|Other|conventional single implant overdenture|conventional manufactured implant overdenture
76034605|NCT04366895|Other|3d printed single implant overdenture|CAD-CAM manufactured implant overdenture.
76034606|NCT04429763|Biological|Umbilical cord derived mesenchymal stem cells|One dosis of 1*10^6 cells/Kg
76034607|NCT04429763|Biological|Placebo|Placebo
76034608|NCT05257031|Drug|SmofKabiven extra Nitrogen|SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.
76034609|NCT05256953|Procedure|Erector spina plane block + general anesthesia|"Bilateral-injection ultrasound-guided bilateral erector spinae plane block~Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally.~Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score >3, (max doses 300 mg/day)."
75707606|NCT06051396|Procedure|Right sided heart catheterization|Hemodynamic evaluation was performed in the supine position. RHC was performed using the modified Seldinger technique with an 8F sheath inserted in the jugular, basilic or cephalic vein . The Swan-Ganz catheter was a 7F, two-lumen, fluid filled, and pressure-measuring tipped catheter (Corodyn TD; Braun Medical, Bethlehem, PA, USA). The zero-level reference was determined at midthoracic line.(9)
75391929|NCT04144764|Other|Workplace-based exercise|Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
75391930|NCT04144764|Other|Ergonomic advice and education|Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
75391931|NCT04029246|Behavioral|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
75391932|NCT04029246|Behavioral|Incentive|Offer of a shopping voucher if patient attends for appointment
75391933|NCT04144920|Behavioral|CS: Continuous sitting|Participants were asked to sit continuously throughout the duration of the lab visit.
76034610|NCT05256953|Procedure|Only general anesthesia|"Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score >3, (max doses 300 mg/day)."
75391934|NCT04144920|Behavioral|HFLD: HIgh frequency, low duration standing breaks|Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
75391935|NCT04144920|Behavioral|LFHD: Low frequency, high duration standing breaks|Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
75391936|NCT04027452|Behavioral|Traumatic memory reactivation|"125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
75391937|NCT04027452|Behavioral|Neutral memory reactivation|"125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
76034611|NCT04875299|Other|The study is observational|The study is observational
76034612|NCT04875143|Dietary Supplement|Citrus aurantium L.|In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
76034613|NCT04874753|Other|change in kidney function and proteinuria|change in eGFR nad proteinuria in patients with chronic kidney disease
75707607|NCT06049654|Device|NVT ALLEGRA TAVI System TF|Transcatheter aortic valve implantation of a NVT ALLEGRA TAVI System TF in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
75707608|NCT06049654|Device|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM|Transcatheter aortic valve implantation of an EDWARDS SAPIEN 3 SYSTEM in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
76034614|NCT05256485|Behavioral|cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy|"In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life."
75707609|NCT06049043|Other|Intervention to Help Orient Men to Excel (IN-HOME)|A multi module online training
76034615|NCT04874987|Other|Simulation based learning with Advocacy inquiry and ladder of influence|Simulation scenarios based on identified gender and equity gaps. We will explore experiences of male and female participants, and inter-professional simulation participants (e.g nurses and doctors, medical and nursing students) post intervention exposure on their role and experiences in simulated sessions and clinical care experiences
76034616|NCT04874675|Drug|diclofenac / acetaminophen /codeine|routine pain medication used post extraction of third molars
76034617|NCT04874675|Drug|ibuprofen/acetaminophen/codeine|routine pain medication used post extraction of third molars
76034618|NCT04874363|Other|no intervention|no intervention
75391938|NCT04144452|Other|Patient Education Session|The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.
75391939|NCT04144452|Other|Therapeutic Exercise plus educational session|Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.
75391940|NCT03947190|Biological|R21/Matrix-M|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
75391941|NCT03947190|Biological|ChAd63/MVA ME-TRAP|ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.
75707610|NCT06049043|Other|"AARP's English Care at Home resource webpage"|Caregiver information from the American Association of Retired Persons
75544410|NCT01680523|Radiation|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
75707611|NCT06047470|Behavioral|Kangaroo Care|Lactating parents will participate in kangaroo care (holding an infant upright, directly on the chest with skin-to-skin contact) prior to expressing a breast milk sample.
75869939|NCT03662984|Drug|Ciprofibrate 100Mg Tablet|Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
75391942|NCT03947190|Biological|intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge|PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
75391943|NCT04144374|Drug|Omadacycline|Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.
75707612|NCT06047470|Behavioral|No Kangaroo Care|Lactating parents will provide a breast milk sample after having no contact with their infant for at least 6 hours.
75707613|NCT06046170|Behavioral|Cognitive Behavioral Therapy|Participants will receive cognitive behavioral therapy with elements of exposure in order to target anxious behaviors.
75544411|NCT01680523|Radiation|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
75707614|NCT06046170|Other|Treatment as Usual|Participants will receive treatment as usual at a community mental health center, including receiving skills training.
75707615|NCT06043700|Other|No Intervention|No treatment intervention will be administered.
75707616|NCT06041880|Device|Passive calf muscle stretching device|Modified night splints will be used to passive stretch the calf muscle.
75707617|NCT06039852|Other|Novel Postural Management Night-time Intervention|"Essential elements and components of PMN-TI:~Safe and comfortable position to enable sleep~Positioning to enable UAD overnight~Quiet breathing unobstructed by base of tongue (i.e. stertor), vocal cords (i.e. stridor) or pooled secretions~Postural support in lying to achieve comfort, promote symmetry of posture and maximum loadbearing~Stomach contents reduced or emptied overnight to minimize reflux and associated aspiration risk."
76034619|NCT04868669|Behavioral|In-home, intensive nutrition counseling|"Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)~The messages to be provided through the counseling will be contextualized~Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation~Counseling sessions will be conducted at the participant's place~Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women~Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session~Sessions will be tailored according to each participant's need and progress"
76034620|NCT03048851|Device|Low dosage SES group|The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
75707620|NCT06038331|Biological|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the STT joint
75707621|NCT06034262|Biological|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the PIPJ
75707622|NCT06033027|Device|Carbonhand|During this phase, participants use the Carbonhand soft-robotic glove system in daily life for 6 weeks to support the performance of daily activities with their affected hand in the home environment. The participants are free to choose for which activities, when and for how long they use the Carbonhand. However, it is recommended to use the Carbonhand at least 180 minutes a week during the most common ADL, such as household activities, dressing/undressing, eating/drinking/cooking, and/or leisure activities.
75869940|NCT03662984|Drug|Placebo Oral Tablet|To compare ciprofibrate
75544412|NCT00287430|Drug|Growth Hormone|
75544413|NCT00287430|Procedure|Whole body Protein Turnover Study|
75544414|NCT00287430|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
76034621|NCT03048851|Device|High dosage SES group|The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
76034622|NCT03048851|Device|VRCIT group|The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
75391944|NCT04144374|Procedure|Microdialysis Catheter Insertion|A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
76034623|NCT03048851|Device|VRCIT+SES group|The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
76034624|NCT03048851|Procedure|traditional rehabilitation program|The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
75391945|NCT04026282|Procedure|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
75391946|NCT04026282|Procedure|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
75391947|NCT04144296|Diagnostic Test|Study procedure|"Measurement of the flow rate of supplemental oxygen~Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~Taking of an ABG sample (ABG1) from the arterial line~Taking of capillary blood gas analysis from the earlobe and from the finger tip~Taking of an a second ABG (ABG2) from the arterial line"
75391948|NCT04144218|Drug|Lacosamide|The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
75391949|NCT04144218|Drug|Placebo oral tablet|The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
75391950|NCT05580900|Other|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment.
75707623|NCT06030999|Dietary Supplement|Study product A (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
75391951|NCT05580900|Other|Live Modality (control)|For this evaluation, the live or in-person modality is considered the control group.
75391952|NCT04021602|Behavioral|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
75707624|NCT06030999|Dietary Supplement|Study product B (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
75707625|NCT06030999|Dietary Supplement|Study product C (placebo)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
75869941|NCT03724799|Device|Intravascular laser irradiation of blood for the patients with cerebral infarction|Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.
75869942|NCT03728231|Other|Complete blood count|taking blood sample from venous blood
76034625|NCT04868513|Drug|Pregnant women to whom applied silane fluoride|Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
75391953|NCT04021602|Behavioral|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
75391954|NCT04021602|Behavioral|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
75391955|NCT05580822|Drug|Tenecteplase for Injection|intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
75391956|NCT05580822|Drug|Saline|intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
75391957|NCT04026126|Behavioral|Heat Therapy Treatment|Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
75391958|NCT05580354|Drug|BCG combined with Tislelizumab|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
75391959|NCT04144062|Other|CAD/CAM crowns|CAD/CAM crowns
75391960|NCT04143906|Drug|Vinorelbine|injection
76034626|NCT04868513|Drug|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
76034627|NCT05256407|Other|Intervention, digital support|Internet based support of parents in child health care. Various options and choices includes parental education, digital meetings with child health nurse and peer groups
75391961|NCT04143906|Drug|Gemcitabine|injection
76034628|NCT04873973|Other|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
76034629|NCT04874129|Drug|YYC506-T and YYC506-A (phase 1)|Comparator
76034630|NCT04874129|Drug|YYC506 (phase 1)|Test
76034631|NCT04874129|Drug|YYC506-T and YYC506-A (phase 2)|Comparator
76034632|NCT04874129|Drug|YYC506 (phase 2)|Test
75391962|NCT04143906|Drug|Carboplatin|injection
75391963|NCT04143750|Drug|[14C]Vicagrel|Take a suspension of 20 mg vicagrel ,containing about 120 μCi [14C]Vicagrel, in fasting within 5 minutes
75391964|NCT03022110|Device|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
75869943|NCT03724721|Procedure|vacuum bottle|using vacuum bottle plus catheter for drainage of pneumothorax
75869944|NCT03305809|Drug|LY3154207|Administered orally.
75869945|NCT03305809|Drug|Placebo|Administered orally.
76034633|NCT03047837|Drug|Aspirin (ASA) + Metformin (MET)|Arm D (experimental arm) Treatment: active ASA + active MET Dose: 100 mg, 1 tablet daily + 850 mg,1 tablet twice a day (BID) Duration: 12 months
76034634|NCT03047837|Drug|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
76034635|NCT03047837|Drug|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
75544415|NCT01680562|Other|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
75391965|NCT02708004|Drug|Aprocitentan|Formulated in capsules in 2 different strengths; 2 capsules per day
75391966|NCT02708004|Other|Placebo|Matching active drug
75391967|NCT03021720|Procedure|Arterial access|Location of arterial puncture
75391968|NCT02708706|Drug|hyaluronic acid (hyruan)|2cc hyaluronic acid
75391969|NCT02708706|Other|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
75391970|NCT04143672|Device|Electronic digital pressure algometer|"Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer."
75391971|NCT04143672|Diagnostic Test|Pain sensitivity questionnaire|Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
76034636|NCT03047837|Drug|Placebos|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
76034637|NCT05256173|Other|Melatonin Tablets|Melatonin Tablets was given 3 tablets (6.21mg) daily at the beginning of bedtime at night for a total of 4 weeks.
76034638|NCT05256173|Other|Lactasin Tablets|The placebo group was given at the beginning of bedtime at night for a total of 4 weeks.
75391972|NCT04143828|Behavioral|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
75391973|NCT05587608|Procedure|combined thoracic segmental spinal epidural anesthesia|ultrasound guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space , patients will be in sitting position, spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle.
75391974|NCT02703714|Drug|Pembrolizumab|200 mg given intravenously (IV)
75391975|NCT02703714|Drug|Sargramostim|250 µg given subcutaneously (SC)
75544416|NCT04528147|Behavioral|Yi Jin Jing Tiger Roaring Speech Rehabilitation|A traditional Chinese medicine treatment
75544417|NCT04528147|Behavioral|Conventional Speech Rehabilitation|A active speech rehabilitation method recommended by the Parkinson's Foundation of America
75544418|NCT01680601|Procedure|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
75544419|NCT01680601|Procedure|Placebo|
76034639|NCT05256173|Device|transcutaneous vagus nerve stimulation|transcutaneous vagus nerve stimulation treatment, frequency 10Hz, stimulation site is the anterior wall of the left external auditory canal (tragus), used twice a day, each treatment for 30 minutes, a total of 4 weeks.
76034640|NCT05256173|Device|sham transcutaneous vagus nerve stimulation|In the sham stimulation group, the stimulation site was the left earlobe with a frequency of 10Hz, which was used twice a day for 30 minutes for a total of 4 weeks.
76034641|NCT03048071|Other|Data collection within medical files|Data collection within medical files
75391976|NCT03919578|Biological|Recombinant Hepatitis B vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.
75544420|NCT01680679|Biological|Inactivated Trivalent Influenza Vaccine (TIV)|
75544421|NCT01680679|Biological|Inactivated poliovirus vaccine (IPV), trivalent|
75544422|NCT01680718|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
75544423|NCT01680718|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
75544424|NCT01680718|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
75391977|NCT03919578|Biological|Recombinant Hepatitis B (Bio Farma)|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.
75391978|NCT03945864|Device|antimicrobial synthetic bone graft|It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
75391979|NCT03945864|Device|parentaral antimicrobials and pure bone grafts|Historical data of the department will be used for comparison of the results
75391980|NCT04143048|Other|DNA extraction of tumer tissue samples and high-throughput sequencing of small panels|DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed
75391981|NCT04143048|Other|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
75391982|NCT04143048|Other|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
75391983|NCT03904446|Drug|Methylergonovine|0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
75391984|NCT03904446|Drug|Normal Saline (placebo)|1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
75391985|NCT04143984|Drug|Induction chemotherapy|Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.
75391986|NCT04143984|Radiation|Carbon-ion radiotherapy|Accelerated carbon-ion beam with pencil beam scanning technique.
75391987|NCT04143984|Drug|Camrelizumab|An anti-PD-1 antibody.
75391988|NCT05583318|Other|Data collection|Data from hematological malignancy registries
75391989|NCT05583318|Other|Questionnaires|"9 questionnaires were sent out:~QLQ-C30 and SF-12 Quality of Life Questionnaire.~Oral quality of life questionnaire QLQ-OH15~Sexuality questionnaire SHQ-C22~Anxiety and depression questionnaire HADS,~Rosenberg Self-Esteem Questionnaire~RNLI Reintegration to Normal Life Questionnaire~Social Support Questionnaire SSQ6,~Socio-economic status questionnaire EPICES,~Complementary questionnaire collecting data on socio-professional status."
75544425|NCT01680757|Device|LARIAT Suture Delivery Device and Accessories|
75544426|NCT01680796|Drug|Dovitinib|"Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily"
75544427|NCT01680796|Drug|Bortezomib|"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"
75544428|NCT01680796|Drug|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
75544429|NCT00252785|Drug|Budesonide/Formoterol|
75544430|NCT00252785|Drug|Budesonide|
75544431|NCT00252785|Drug|Theophylline|
75544432|NCT01680874|Dietary Supplement|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
75869946|NCT02994056|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
76034642|NCT04868825|Device|Ivory Dentin Graft|Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 900 μm porous particles or granules of hydroxyapatite and collagen which retain the natural form of the source porcine dentin and protein matrix. (Packed Vial: 1.00 gr; Packed Syringe: 1.0 gr)
75391990|NCT05582772|Other|GA+M Intervention|Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.
75544433|NCT01680874|Dietary Supplement|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
75544434|NCT01680913|Procedure|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
75391991|NCT05582772|Other|RSM intervention|Telephone-based, symptom management of patients with cancer
75707626|NCT06030882|Other|Biologic Care Pathway|Receiving care administered through a biologic care pathway.The central biologic intake nurse will touch base with the IBD program nurse navigator at preselected time points as per the pathway in order to coordinate the baseline pre- biologic work-up, clinical and biomarker assessments, and clinical assessments. Clinical management decisions will be informed by a combination of data points including clinical risk factors, TDM, fecal calprotectin concentrations, endoscopic and clinical disease activity indices as well as drug tolerance and adverse events. Within the care pathway, time- bound clinical and biomarker data will be provided to the treating clinician to help inform their clinical decisions.
75707627|NCT06025136|Other|Using a gel pillow|Within the scope of the study, gel pillows with a cold surface were used in the patients in the study group. It is produced by combining the obtained special liquid with elastic material with NASA approved molecule exchange technology and is made of OEKO-TEX CLASS 1 certified material.Thanks to the gel material on the pillow surface, the surface temperature is reduced from 37°C to 24°C in about 10 seconds. It gives a feeling of coolness with its thermal conductivity feature.
75869947|NCT02994056|Drug|RBV|Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
76034643|NCT04868825|Device|OsteoBiol Gen-Os|Comparator control device A natural porcine origin cortico-cancellous heterologous bone mix consists of sterile 250 - 1000 μm porous particles of hydroxyapatite and collagen (Packed Vial: 1.0 gr)
76034644|NCT03048773|Device|shockwave therapy|Intervention with shockwave therapy
76034645|NCT03048773|Other|PT|Physical therapy 3 times per week for 3 weeks
76034646|NCT03048773|Other|placebo|sham shockwave therapy
76034647|NCT04868201|Device|0-anxiety|0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
76034648|NCT04429997|Procedure|Removal of fibrosynovial tissue|Remove of fibrosynovial tissue at the superior border of patella
76034649|NCT04429997|Procedure|Non-removal of fibrosynovial tissue|Do not remove of fibrosynovial tissue at the superior border of patella
76034650|NCT05255939|Procedure|distal TRA group|dTRA for PCI procedure to ACS patients.
76034651|NCT05255939|Procedure|conventional TRA group|Conventional TRA for PCI procedure to ACS patients
76034652|NCT02648347|Drug|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
75391992|NCT05582772|Other|GA+RSM intervention|Combining a geriatric assessment and remote symptom control
75391993|NCT03902652|Procedure|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
75391994|NCT03902652|Procedure|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
75391995|NCT03916692|Dietary Supplement|Carbohydrate drink|Meal replacement drink containing 200 kcal
75544435|NCT01680913|Procedure|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
76034653|NCT02648347|Drug|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
75544436|NCT01680913|Procedure|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
75544437|NCT00287508|Device|Carotid artery stenting with filter (interventional)|
75544438|NCT01680952|Drug|A) TEST|"Extended Release Tacrolimus (Advagraf®)~① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level."
75544439|NCT01680952|Drug|B) CONTROL|"Extended Release Tacrolimus (Advagraf®)~: Same as above.~Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid"
75544440|NCT01681108|Behavioral|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
75544441|NCT01681303|Drug|AST-120|
76034654|NCT05255783|Device|subcutaneous continuous glucose sensor|Dexcom G6 continuous glucose monitoring system
76034655|NCT02614703|Drug|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
76034656|NCT02614703|Other|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
76034657|NCT03047525|Biological|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
76034658|NCT04867967|Behavioral|Iyengar Yoga|Classical Iyengar Yoga intervention, especially designed for headache patients. Note: First administered face-to-face, due to Covid-restrictions changed to online classes
75391996|NCT03916692|Dietary Supplement|Energy smart Carbohydrate blend|Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
75391997|NCT03916692|Dietary Supplement|Liquid Dextrose|Liquid Dextrose drink of 200 kcal
75391998|NCT04142970|Drug|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
75391999|NCT04765332|Other|DLQI and PSO-TARGET QoL grid|At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid
75392000|NCT03022344|Radiation|Cardiac CT|
75392001|NCT04142346|Behavioral|Sitting + moderate intensity breaks|Participants will be followed in a randomized crossover trial undertaken at Faculty of Human Kinetics between April and August 2019. Participants will attend to the laboratory on twelve separate occasions: visit 1 (day 1), baseline assessments for body composition; visit 2 (day 2), cardiorespiratory fitness assessment; visit 3 (day 3), OGTT and the first randomized experimental protocol; visit 4 (day 4), follow-up OGTT; visit 5 (4-6 days after the first experimental protocol), OGTT and the remaining experimental protocol; visit 6 (day following the previous experimental protocol), follow-up OGTT. An additional 6 visits will be performed following the same rational, after a 2-week period of detraining, where participants will be instructed to refrain from structured exercise. The follow-up assessments for body composition and cardiorespiratory fitness will be accomplished after the protocols.
75392002|NCT04142112|Device|Ohana IVF Sperm Preparation Kit (OHB035)|The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
75392003|NCT04142112|Device|Standard IVF Preparation Kit (OHB037)|The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
75392004|NCT04143282|Drug|Metformin plus chemotherapy|determine the effect of metformin along with standard chemotherapy
75392005|NCT04143282|Drug|Chemotherapy|standard chemotherapy
75392006|NCT04142190|Drug|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
75392007|NCT04142190|Drug|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
75544442|NCT00252824|Drug|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
75392008|NCT05582148|Device|Hearing aids fitting|Fitting hearing aids and evaluating the results at 6 months
75392009|NCT04149678|Drug|Ozanimod|Ozanimod
75392010|NCT04149678|Drug|Cyclosporine|Cyclosporine
75869948|NCT03728153|Drug|Fluoxetine 20 MG Oral Tablet|Once-daily dosing for 90 days
76034659|NCT04867967|Behavioral|Mindfulness-based stress reduction|Standardazied Mindfulness-based stress reduction intervention Note: First administered face-to-face, due to Covid-restrictions changed to online classes
76034660|NCT05218265|Diagnostic Test|routine laboratory tests|Complete blood count (CBC), coagulation profile, serum biochemical tests (including renal and liver function, and electrolytes), laboratory investigation to assess severity of COVID-19: lactate dehydrogenase (LDH), myocardial enzymes (CPK-MB), serum ferritin, D dimer and arterial blood gases analysis
76034661|NCT01669343|Drug|Letrozole|Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
76034662|NCT04867811|Other|conventional therapy|conventional therapy
75392011|NCT05582070|Other|actigraphy|Actigraphy examination will be performed during 2 periods of 7 days before and after nose nasal desobstruction surgery (septoplasty, septorhinoplasty or total ethmoidectomy). Respectively 2 months before surgery (inclusion) and 4 months after surgery.
75392012|NCT05581992|Drug|AMG 510|Oral Tablet
75544443|NCT04528420|Other|optimised management|"At the inclusion , the patient will benefit from an early consultation with a nutritionist, a pain doctor and a social worker.~During the preparation phase for radiotherapy the patient will benefit from weekly consultations with a pain nurse and a dietician.~During the radiotherapy the patient will be weighed daily and have an assessment of their nutritional needs and a weekly consultation with a pain nurse and dietician and then twice a month until three months post-radiotherapy."
75544444|NCT01681381|Device|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
75544445|NCT01681381|Device|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
75544446|NCT01681420|Behavioral|HIV Counseling and Testing|HIV counseling and testing in lieu of blood donation.
75544447|NCT01681420|Behavioral|Blood Donation|Blood donation without HIV counseling
76034663|NCT04867811|Other|cupping therapy|cupping therapy
76034664|NCT04867811|Device|TENS|transcutaneous electrical nerve stimulation
76034665|NCT04867811|Other|TENS and cupping therapy|TENS and cupping therapy
76034666|NCT05403619|Diagnostic Test|Diagnostic test|Cardiac Ultrasound in order to explore the causes of shortness of breath
76034667|NCT04678765|Procedure|Ultrasound-guided distal peripheral nerve block|"To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease."
75392013|NCT05581992|Drug|Omeprazole|Capsule
75392014|NCT03021174|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
76034668|NCT04678765|Procedure|Ultrasound-guided quadruple-injection axillary nerve block|"The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited."
76034669|NCT03126643|Biological|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
76034670|NCT02675179|Device|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
76034671|NCT02675179|Device|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
76034672|NCT04617067|Drug|Paricalcitol|Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.
76034673|NCT04617067|Drug|Gemcitabine (GEM) and Nab-paclitaxel|GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
75392015|NCT03021174|Behavioral|Nutrition Education Control|12 weeks of implementing eating tips
75392016|NCT03020940|Drug|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
76034674|NCT04600531|Device|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
75392017|NCT03020628|Biological|NBP607-QIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
75392018|NCT03020628|Biological|NBP607-TIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
75392019|NCT05581914|Other|MY LIFE treatment|"The MY LIFE is a group treatment consisting of 5 workshops, for adolescents with a low motivation for mental health treatment. It aims to increase self- worth, hope for the future and seeking social support through exercises by using music and lyrics and other creative exercises to engage adolescents. The MY LIFE treatment also uses methods that stem from psychodynamic, cognitive behavioral, and solution focused theories. The therapeutic attitude is based on client-centered therapy of Rogers, which includes a genuine, positive regard and empathic understanding, focusing on the inner strength and growth potential of a person. Adolescents are never forced to participate during the workshops, merely encouraged.~The core of the treatment is: the adolescent decides"
75392020|NCT05581914|Other|Care as Usual|The care as usual the adolescents receives
75392021|NCT05580198|Diagnostic Test|Transcranial sonography.|Transcranial sonography examination to determine the brainstem raphe echogenicity.
75392022|NCT04141956|Other|High-Flow Nasal Cannula|Incidence of nasal High Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care.
75392023|NCT03645564|Other|Specialized nurse consultation|The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
75392024|NCT03645408|Drug|Exenatide|Subject received an injection of 5 mcg of immediate release exenatide.
75392025|NCT03645408|Other|Sham injection|Subjects received a sham injection with no study drug.
75544448|NCT00281190|Procedure|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
75544449|NCT00281190|Procedure|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
75544450|NCT00252863|Drug|Symbicort, used twice daily (b.i.d) and as needed (prn)|
75392026|NCT04141722|Behavioral|Overnight sleep|Participant sent home to sleep overnight wearing PSG.
75392027|NCT04141722|Behavioral|Wake|Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
75392028|NCT04141410|Drug|Levosimendan|Use of Levosimendan in cardiogenic shock during sepsis
75544451|NCT00252863|Drug|Budesonide Turbuhaler 200 µg|
75544452|NCT00252863|Drug|Fluticasone Discus 250 µg|
75544453|NCT00252863|Drug|Formoterol Turbuhaler 4.5 µg|
75392029|NCT04141410|Device|Echocardiography|Use of global longitudinal strain in cardiogenic shock during sepsis
75392030|NCT04141488|Other|experimantal group|Control Group
75392031|NCT04141254|Other|Debriefing and educative components|The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
75392032|NCT04141254|Other|Without debriefing and educative components|Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
75392033|NCT03914976|Procedure|patient having to undergo a high risk programmed digestive surgery|The objective is to determine if there is an association between the mean intraoperative values and within 24 hours postoperative ΔPCO2 and the occurrence of major post-operative complications at day 28 in high-risk surgery (major hepatectomy, esophagectomy or duodeno- cephalic pancreatectomy)
75544454|NCT00252863|Drug|Terbutaline Turbuhaler 0.5 mg|
75544455|NCT00252863|Drug|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
75544456|NCT00252863|Drug|Salmeterol Discus 50 µg|
75544457|NCT00252863|Drug|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
75392034|NCT04149756|Other|observation of weight after 6months|"This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. ."
75544458|NCT00252863|Drug|Fluticasone/Salmeterol Discus 250/50 µg|
75544459|NCT00252863|Drug|Fluticasone/Salmeterol Discus 500/50 µg|
75544460|NCT00252863|Drug|Theophylline 200 mg|
75544461|NCT00252863|Drug|Theophylline 300 mg|
75544462|NCT00252863|Drug|Singulair 10 mg|
75544463|NCT01681537|Drug|Lenalidomide|
75544464|NCT01681537|Drug|Mitoxantrone|
75544465|NCT01681537|Drug|Etoposide|
75544466|NCT01681537|Drug|Cytarabine|
75544467|NCT00287625|Procedure|Pulmonary rehabilitation|Pulmonary rehabilitation
75392035|NCT04141098|Device|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
75392036|NCT05586204|Behavioral|Eligibility reminder|Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
75392037|NCT05586204|Behavioral|Link to a narrow set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
75707628|NCT06019988|Other|Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening|All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)
75707629|NCT06019767|Behavioral|Cognitive Processing Therapy|CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
75707630|NCT06019559|Drug|K-757 and K-833|Both administered orally
75392038|NCT05586204|Behavioral|Link to a broad set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
75392039|NCT05586204|Behavioral|Doctors' recommendation and value of vaccine|The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
75392040|NCT04149834|Procedure|Group A (Test): Patients will receive NIPSA|patients received Non- incised papilla surgical approache
75392041|NCT04149834|Procedure|Group B (Control): Patients will receive M-MIST|patients received Modified Minimally Invasive Surgical Technique
75392042|NCT04140474|Device|Archimedes procedure|All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
75392043|NCT04149444|Drug|Trifluridine/Tipiracil|Oral medication
75544468|NCT01681654|Behavioral|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
75707631|NCT06019559|Drug|K-757 and matching placebo to K-833|Both Administered orally
75707632|NCT06019559|Drug|Matching placebo to K-757 and matching placebo to K-833|Both administered orally
75707633|NCT06018935|Other|No intervention|No intervention
75392044|NCT03020706|Drug|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
75392045|NCT04149366|Device|Retainer|Orthodontic retainer
75392046|NCT04148976|Dietary Supplement|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
75392047|NCT04148976|Dietary Supplement|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
75392048|NCT05583084|Other|Investigation|
75392049|NCT04140630|Other|No intervention|No intervention; 1 week observational study
75392050|NCT03900624|Drug|Dexamethasone|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus
75392051|NCT04149132|Device|pulse photoplethysmography (PPG)|PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
75392052|NCT04149132|Diagnostic Test|Measurements of nitric oxide (NO) and malondialdehyde (MDA)|On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
75392053|NCT03908892|Drug|zanthoxylum nitidum tincture|Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
75392054|NCT03908892|Drug|tetracycline ointment|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
75392055|NCT04140318|Drug|sintilimab|Sintilimab 200mg, iv, 30-60min, q3w;
75392056|NCT04140318|Drug|nab-paclitaxel|Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
75392057|NCT03021408|Other|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
75392058|NCT03021408|Other|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
75392059|NCT03021408|Other|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
75392060|NCT04140006|Drug|ALN Gel|Flapped surgery for insertion of dental implant with topical application of ALN gel
75392061|NCT04140006|Drug|BMP Gel|Flapped surgery for insertion of dental implant with topical application of BMP gel
75392062|NCT04140006|Drug|Mixed Gel|Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP
75392063|NCT04140006|Drug|Control|Flapped surgery for insertion of dental implant without topical application of any gel
75392064|NCT04140084|Device|Real-life clinical meetings|Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
75392065|NCT04140240|Behavioral|intervention group|Parallel Assignment a experimental design with pre test and post test
75392066|NCT04146324|Drug|nivolumab|Administered as adjuvant therapy as per the market authorization in Australia
75392067|NCT03588936|Drug|Nivolumab (.25 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
75392068|NCT03588936|Drug|Tocilizumab|Participants will receive 2 doses of tocilizumab
75392069|NCT03588936|Drug|Nivolumab (.5 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
75392070|NCT03588858|Other|structured interview questionnaires|"Module (1): Socio-demographic characteristics~Module (2) :Occupational history~Module (3): Presence of work related injuries and diseases by history and observation.~Module (4): Food frequency questionnaires (FFQ) during the past week.~Module (5): Mental health screening: Self-reporting questionnaire 20 questions for assessment of mental health status of children."
75707634|NCT06017284|Drug|Thalidomide|Thalidomide 100 mg/day, once a day, orally intake at night.
75707635|NCT06017284|Drug|Nab paclitaxel|nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.
75707636|NCT06017284|Drug|Gemcitabine|gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
75392071|NCT03588624|Device|TearCare|The TearCare procedure includes the delivery of thermal energy to the external surface of the eyelids for 15 minutes, immediately followed by manual expression of each eyelid.
75707637|NCT06017284|Drug|Placebo|Placebo, 100 mg/day, once a day, orally intake at night.
75707638|NCT06016439|Procedure|Arthroscopic rotator cuff partial repair with superior capsular augmentation with LHBBT|Residual rotator cuff defect will be reconstructed using LHBBT.
75707639|NCT06016439|Procedure|Arthroscopic rotator cuff partial repair|Rotator cuff will be repaired with remaining residual defect.
75392072|NCT03585582|Other|Prospective follow-up|This is a prospective follow-up study to assess of outcomes at 1 year following the discharge from the hospitalization during which PARDS was diagnosed
75392073|NCT03020862|Dietary Supplement|Dietary beetroot juice|Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.
75544469|NCT01681654|Behavioral|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
75544470|NCT01681693|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
75707640|NCT06016439|Procedure|Arthroscopic complete rotator cuff repair|Arthroscopic complete repair as a standard procedure.
76034675|NCT04600531|Device|4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)|"HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS)."
75544471|NCT01681732|Other|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
75544472|NCT01681732|Other|Control Standard Care|This is the standard care arm
75544473|NCT01681888|Device|Sanger EMG Biofeedback Device|
75544474|NCT00252902|Behavioral|Behavior change counseling|
75707641|NCT06016439|Device|Suture anchor(s)|Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
75392074|NCT03586128|Drug|PrEP|PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.
75392075|NCT03586128|Drug|ART|ART medication will be provided according to Uganda national guidelines for persons living with HIV.
75392076|NCT03582462|Drug|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection
75392077|NCT03582462|Drug|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
75544475|NCT04528264|Device|Intraoperative ultrasound guided|Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.
75544476|NCT04528264|Other|Conventional blind reduction technique|Conventional blind reduction technique
75544477|NCT01681966|Drug|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
75707642|NCT06014515|Drug|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
75707643|NCT06014515|Drug|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
75392078|NCT03580278|Biological|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
75392079|NCT03589950|Drug|anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
75392080|NCT03589950|Drug|chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
75544478|NCT01682161|Drug|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
75544479|NCT01682200|Drug|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
75544480|NCT01682395|Procedure|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
75544481|NCT01682395|Procedure|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
75544482|NCT01682395|Procedure|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
75544483|NCT01682434|Procedure|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
75544484|NCT01682473|Drug|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
75544485|NCT00252941|Device|Memokath 028SW Urethral Stent|
75544486|NCT01682551|Drug|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
75544487|NCT01682551|Drug|Acetalozamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
75544488|NCT00281268|Procedure|pulmonary artery catheter|
75544489|NCT00281268|Procedure|central venous catheter|
75544490|NCT00281268|Procedure|fluid management|
75544491|NCT02279914|Drug|Misoprostol 400 mcg 3 hours prior to procedure|Misoprostol 400 mcg 3 hours prior to D&E procedure
75544492|NCT02279914|Drug|Misoprostol 600 mcg 90 minutes prior to procedure|Misoprostol 600 mcg 90 minutes prior to D&E procedure
75544493|NCT01682590|Procedure|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output > 1000ml/24 hr or >2000ml/24hr with diuretics), RRT is not mandatory."
75544494|NCT00281307|Drug|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
75557985|NCT03279380|Other|High Intensity Interval Training (HIIT)|The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
75392081|NCT03589872|Diagnostic Test|Fine motor dexterity test, nine hole peg test|The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
75544495|NCT01682629|Other|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
75544496|NCT01682629|Other|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
75392082|NCT03589716|Other|Vital Moto Mod|All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.
75392083|NCT03589716|Other|Welch Allyn Connex Spot Vital Signs Monitor|This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
75392084|NCT03589716|Other|Capnostream 20 Portable Bedside Capnograph|This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.
75392085|NCT03589716|Other|Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope|These reference devices will be used together for blood pressure measurements.
75544497|NCT01682746|Drug|Photofrin (porfimer sodium) & photodynamic therapy.|"Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity & light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."
75544498|NCT00287664|Drug|terlipressin|
75544499|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
75392086|NCT03589716|Other|Scifit 1000R cycle ergometer|This is the device that will be used for exercise testing
75392087|NCT03589638|Device|Direct laryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
75392088|NCT03589638|Device|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
75392089|NCT03589638|Device|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
75392090|NCT03022500|Drug|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
75544500|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
75544501|NCT01682902|Drug|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
75707644|NCT06014424|Drug|JZP541|Participants in this arm will receive ZP541 for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
76034676|NCT05023057|Behavioral|Multidomain intervention|For 24 weeks, participants will receive cognitive training using the tablet PC application twice a week, exercise 3 times a week, nutrition education 12 times, anthropometric measurements and alcohol and smoking monitoring every 4 weeks, motivation reinforcement training 4 times.
76034677|NCT04669015|Biological|Novaferon|a novel recombinant antiviral protein drug
75544502|NCT01683097|Other|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
75544503|NCT01683136|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
75544504|NCT01683175|Drug|Erlotinib|
75544505|NCT01683175|Drug|cis-platinum|
75544506|NCT01683175|Drug|Vinorelbine|
75544507|NCT00252980|Behavioral|Psychotherapy|
75392091|NCT04148742|Drug|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
75544508|NCT00281346|Procedure|Doppler echocardiography|Echocardiography
75544509|NCT01683253|Drug|Levodopa/Carbidopa(200mg/50mg)|
76034678|NCT04669015|Biological|Placebo|Formulation vehicle
75544510|NCT01683253|Drug|Dopaminergic Agonists|Treated for at least 6 months after diagnosis of Parkinson's Disease.
75544511|NCT01683292|Drug|Inhaled VR040|
75544512|NCT01683292|Drug|Placebo for VR040|Placebo arm
75544513|NCT00253058|Drug|Cetirizine Dry Syrup|
75544514|NCT00281385|Behavioral|traditional vs. lifestyle exercise|
75544515|NCT01683487|Procedure|Observation|Observational study only, no intervention.
76034679|NCT02590783|Procedure|experimental intervention surgery|Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).
75392092|NCT03589560|Drug|Biodentine|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
75392093|NCT03589560|Drug|Mineral Trioxide Aggregate|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
75392094|NCT03588390|Drug|BI 1323495|Low strength tablet
75392095|NCT03588390|Drug|BI 1323495|Middle strength tablet
75392096|NCT03588390|Drug|BI 1323495|High strength tablet
75392097|NCT03588390|Drug|Placebo|Placebo to low strength tablet
75392098|NCT03588390|Drug|Placebo|Placebo to middle strength tablet
75392099|NCT03588390|Drug|Placebo|Placebo to high strength tablet
75392100|NCT04148898|Drug|Osimertinib|Treatment of LM With osimertinb
75392101|NCT04148898|Drug|Bevacizumab|Treatment of LM With osimertinb combined with bevacizumab
75392102|NCT04148820|Drug|Aspirin, Atorvastatin, Perindopril|Cardiovascular drugs will be administered all together every day at the same time
75392103|NCT03588312|Procedure|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
75392104|NCT03589404|Device|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
75544516|NCT01683682|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
75544517|NCT01683682|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
75707645|NCT06014424|Other|Placebo|Participants in this arm will receive placebo for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
75707646|NCT06011031|Device|Novaloc attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
75707647|NCT06011031|Device|Locator attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
75707648|NCT06009926|Procedure|Biospecimen Collection|Undergo urine sample collection
75707649|NCT06009926|Dietary Supplement|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
75392105|NCT04148586|Other|Whole Breast Irradiation|Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
75392106|NCT03589248|Diagnostic Test|GIF score|assessment by GIF score
75544518|NCT01683682|Drug|Carboplatin|AUC 5 i.v. on day 1 (three-week cycle)
75544519|NCT00287703|Device|Pulsating Electro-Magnetic Fields|5 days a week for 5 weeks 30 minutes
75544520|NCT00287703|Device|Pulsating Electro-Magnetic Fields sham|sham PEMF
75707650|NCT06009926|Drug|Placebo Administration|Given PO
75707651|NCT06009926|Other|Questionnaire Administration|Ancillary studies
75707652|NCT06009926|Other|Training|Undergo flashover training
75392107|NCT03589248|Diagnostic Test|US score|assessment by ultrasonography score
75392108|NCT03588156|Drug|Benapenem|Dose-escalation For 11 level dose groups A1 ~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
75392109|NCT03588156|Drug|Placebo|Placebo
75392110|NCT03588000|Other|Strengthen self-monitoring of blood glucose|Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
75392111|NCT03941808|Drug|Glisodin tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
75392112|NCT03941808|Drug|Placebo tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
75707653|NCT06008236|Behavioral|Progressive Muscle Relaxation and Breathing Exercises|Progressive relaxation exercise is a method that provides relaxation in the whole body by voluntary, regular relaxation of large muscle groups in the human body. Exercise helps individuals to be able to feel the difference between tension in the muscles and relaxation, and to learn to relax on their own in case of tension. Deep breathing exercise supports the maximum ventilation of the lung by correct breathing using the diaphragm.
76034680|NCT02590783|Procedure|control intervention|Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
75392113|NCT03587610|Biological|Remedial vaccination|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
75392114|NCT03589092|Genetic|Next generation sequencing (NGS)|NGS Panel, Whole exome/genome sequencing
75707654|NCT06007209|Other|Manual Pressure Point|Compression of the subclavian artery against the 1st rib and of the common femoral artery against the pelvis.
75392115|NCT03941496|Drug|Azacitidine Injection|"In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~5 mg/m^2~15 mg/m^2~30 mg/m^2~50 mg/m^2~75 mg/m^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~an increase in TNF and IFN-γ signaling pathways~an increase in ex vivo mycobacterial growth inhibition assay"
75707655|NCT06005428|Drug|CRD-4730|Oral CRD-4730 in capsule form
75707656|NCT06005428|Drug|Placebo|Placebo to match CRD-4730 in capsule form
76034681|NCT01594931|Drug|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.
75392116|NCT03895476|Diagnostic Test|palatal wound will not cover|after harvesting the graft from the palate the wound will be left uncovered with secondary healing intention
75392117|NCT03895476|Diagnostic Test|palatal wound covered with platelet rich fibrin|after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
75392118|NCT03895476|Diagnostic Test|palatal wound covered with a collagen sponge and cyanoacrylate|after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
75392119|NCT03895476|Diagnostic Test|palatal wound covered with a stent|after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
75392120|NCT04406064|Biological|Viral Specific T-cells (VSTs)|VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.
75392121|NCT04405752|Device|12-mm metallic biliary stent|Metallic biliary stent, covered or uncovered,KEBOMED HILZO 12mm in diameter (length 4 or 6 cm).
75392122|NCT04405752|Device|10-mm metallic biliary stent|Biliary, metallic, covered or uncovered stent, COOK EVOLUTION 10mm in diameter (length 4 or 6 cm)
75392123|NCT03894150|Drug|F0002-ADC|Every 21 days for 1 cycle, continue treatment until a maximum 16 cycles. Dose Escalating: 0.3 - 4.8 mg/kg
75392124|NCT05702892|Diagnostic Test|ELISA|ELISA(enzyme-linked immunosorbent assay)
75392125|NCT03255564|Other|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
75392126|NCT04765410|Diagnostic Test|EUS FNA (endoscopic ultrasound fine needle aspiration)|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).
75392127|NCT04765254|Other|no intervention as it is an observational study|both groups will be monitored for the disease progress or deterioration and mortality rate
75392128|NCT03581058|Drug|Cannabis|Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
75392129|NCT03580980|Drug|Paracetamol and ketamine|intravenous paracetamol and ketamine followed by ketorolac
75392130|NCT03580980|Procedure|Caudal levobupivacaine|an epidural injection of morphine and levobupivacaine through the caudal space
75392131|NCT03580980|Drug|Morphine|patient controlled analgesia by morphine
75392132|NCT04405440|Behavioral|Behavioral avoidance task|Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
75392133|NCT02985060|Device|Arctic Sun|"Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~Recovery phase:Rewarming velocity: 0.05~0.1℃ (within 30 hours)"
75392134|NCT02985060|Other|Standard treatment|"All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
75392135|NCT02985060|Drug|Saline|
76034682|NCT04981171|Procedure|Electro-thumbtack Needle Therapy|Each treatment session starts with sterilizing acupoints. Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) have been selected in accordance with the principle of acupuncture prescription making and the consensus of experts on treating neck pain. Electro-thumbtack needles (0.25×2 mm) will be held by the acupuncturist between thumb and forefinger, vertically inserted into skin instantly and taped well on skin. Then assemble the gel electrodes to the surface of the conductive adhesive tape, also assemble the portable stimulation devices, adjust the current intensity from level 1 to a proper level that the participant can tolerate. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
76034683|NCT04981171|Procedure|Sham electro-thumbtack needle therapy|Each treatment session starts with sterilizing acupoints. Sham electro-thumbtack needles (0.25×0.2 mm) will be held by the acupuncturist between thumb and forefinger, taped well on skin without penetration. The adhesive tape of needles are also produced with conductive material, after assembling the gel electrodes and the portable stimulation devices, adjust the current intensity to level 1 for a minimal stimulus which will last for only 30 seconds. By this time the acupuncturist will turn the device off to cut the current. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
75392136|NCT03587454|Diagnostic Test|Teleglaucoma|Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
75392137|NCT03587376|Drug|Atabecestat|Blood samples will be collected from participants previously treated with atabecestat.
75869949|NCT04934488|Behavioral|Online Peer-Delivered 1-Day CBT-Based Workshop|It is a day-long intervention delivered in 4 modules. Each participant is given a professionally designed manual to facilitate learning. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays.
75869950|NCT04056806|Drug|Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial|efficacy comparison between 2 days and 5 days
75869951|NCT03724643|Other|Protocolized wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
75869952|NCT04056884|Behavioral|SIBS intervention|SIBS is a manual-based group intervention for siblings and parents of children with chronic illness
75869953|NCT04057118|Drug|SKI-O-703|Oral administration, twice per day
75869954|NCT04057118|Drug|Placebo|Oral administration, twice per day
75869955|NCT03548051|Procedure|Fecal Microbiota Transplantation (FMT)|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema
75869956|NCT03548051|Drug|Saline|250 ml of saline delivered by retention enema
75869957|NCT03728075|Device|Neuromuscular electrical stimulation (NMES)|NMES was placed on the quadriceps muscle of both legs
75869958|NCT03305731|Behavioral|Activating Behavior for Lasting Engagement|Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
75392138|NCT03587298|Procedure|Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)|"The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the hardest appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded."
75544521|NCT00253097|Behavioral|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
75544522|NCT01683799|Behavioral|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
75869959|NCT03305575|Drug|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
75392139|NCT04148196|Other|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
75392140|NCT03587220|Drug|Capsaicin Topical|Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.
75869960|NCT03305575|Drug|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
75869961|NCT04916782|Other|Quality of life Questionnaire|Quality of life questionnaire
75869962|NCT02993822|Drug|Orvepitant Maleate|Tablet, once daily, oral
75869963|NCT02993822|Drug|Placebo|Tablet, once daily, oral
75544523|NCT00287742|Drug|risperidone|
75392141|NCT03587220|Radiation|Ultraviolet-B (UVB) irradiation|Two circular areas (Ø 2 cm) on the forearm are irradiated with 2 x MED (Minimal Erythema Dose) dose of UVB using a calibrated UVB machine (290-320nm wavelength), Saal Mann Multi Tester (Mann Saal, LT SBC 400 Herford, Germany).
75557986|NCT03279380|Other|Low Intensity Continuous Training|The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
75392142|NCT03587220|Other|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
75392143|NCT03587220|Drug|Lidocaine|Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
75392144|NCT04148274|Other|No intervention|There is no intervention for this study.
75392145|NCT04148040|Procedure|G-POEM|Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
75392146|NCT03586908|Drug|PHP-201 0.5% ophthalmic solution (topical eye drop)|D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2~D6: PHP-201 0.5% topical eye drop OU TID
75392147|NCT03580746|Procedure|Taping and posteromedial release|
75544524|NCT04527640|Dietary Supplement|Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of synbiotics per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same synbiotics per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
75544525|NCT04527640|Other|Placebo|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of placebo per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same placebo per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
75392148|NCT03580746|Procedure|Ponseti|
75392149|NCT04147572|Drug|Placebo Tiotropium inhalation powder type A|Placebo inhalation from inhaler A
75392150|NCT04147572|Drug|Placebo Spiriva capsule|Placebo inhalation from HandiHaler
75544526|NCT04527562|Drug|Colchicine|Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
76034684|NCT04978831|Device|PEP Device|The breathing exercise device is a device that simulates pursed-lip breathing by creating positive expiratory pressure (PEP). Before starting to use the device, it will be explained that they need to put the mouthpiece on the device and put the nose clip on their nose, and the participants will be shown how it is done. The device will be used at 5 cmH2O pressure. A single exercise session consists of 3 exercise cycles, and a single exercise cycle consists of 15 breathing-exhalation activities. Participants will complete 3 cycles (a total of 45 inhales and exhales) in a single session. 1 loop lying on the left side, 1 loop lying on the right side, and 1 loop in sitting upright position. Participants held these sessions in the morning, afternoon, and evening. After completing each cycle, the participants will remove their nose clips and cough 2-3 times. Each participant will perform a total of 135 breathing exercises in one day.
76034685|NCT04978831|Other|Reading Aloud|"The patients in this group were given a book that they chose from among the book types within the scope of the study, according to their wishes. For the selection of books, opinions were taken from the experts in the education faculty of the same university and it was stated that any book separation was not important. The books that the participants wanted to read were provided by the researcher. They were asked to read this book aloud during the day, sitting upright on a chair or sofa, for 15 minutes, three times a day.~They were able to stop reading when the participant was tired or felt too short of breath to continue reading."
76034686|NCT04872725|Behavioral|Time management & participation & the leisure time activity|evaluated in terms of leisure time activities, time management and participation
75392151|NCT04147572|Drug|Placebo Tiotropium inhalation powder type B|Placebo inhalation from inhaler B
75392152|NCT04147572|Device|Substudy Placebo Tiotropium Easyhaler|Substudy placebo inhalation
75392153|NCT04147572|Device|Substudy Placebo Spiriva® via HandiHaler|Substudy placebo inhalation
75392154|NCT05702580|Procedure|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
75392155|NCT03580590|Drug|oral Diltiazem|Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
75392156|NCT03580590|Drug|IV Tranexamic Acid|Tranexamic acid inhibits fibrinolysis, which reduces blood loss
75392157|NCT03580590|Drug|Placebo Oral Tablet|Placebo Oral Tablet
75392158|NCT03934944|Device|Phone application|Weekly foot alerts and educational video
75392159|NCT03934944|Other|Usual care|Usual routine of diabetic foot education
75392160|NCT03192462|Biological|multiTAA specific T cells|Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.
75707657|NCT06000436|Other|Cardiovascular disease risk assessment|"Cardiovascular disease risk assessment~Training and Consultancy Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. By using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the working hours of the participants.~Mobile Application To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Monitoring Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application."
75707658|NCT06000436|Other|Training and Consultancy|Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. Using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the participants' working hours.
75707659|NCT06000436|Other|Mobile Application|"To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Text Messages Week 2 Tobacco use causes 6 million deaths in the world. The risk of death is reduced by 90% in those who stop using tobacco. Alcohol use causes damage to the heart muscle, arrhythmia, and stroke. For a healthy life, you should stay away from smoking and alcohol. ' Week 4 '' Inadequate physical activity increases the risk of death from all causes. Physical activity reduces the risk of hypertension, stroke, and depression. 30 minutes of moderate-intensity physical activity daily is recommended.~Week 6 Adequate consumption of vegetables and fruits reduces the risk of cardiovascular disease. Saturated and trans fats increase the risk of cardiovascular disease. It is recommended to consume <5 g less per day to prevent cardiovascular diseases."
75707660|NCT06000436|Other|Monitoring|Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
75392161|NCT03586752|Other|On-line program|18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
75557987|NCT03277521|Other|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
75557988|NCT03279341|Drug|polyethylene glycol|osmotic laxative
75557989|NCT03279341|Drug|Bisacodyl|stimulant laxative
75557990|NCT03279341|Drug|Prucalopride|prokinetic
75557991|NCT00441857|Behavioral|plant stanol consumption|
75544527|NCT04527562|Drug|Placebo|Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
75544528|NCT00281424|Device|pedometer|gave pedometer and info
75544529|NCT01684072|Biological|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
75544530|NCT01684072|Biological|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
75544531|NCT01684111|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
75544532|NCT01684111|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
75544533|NCT01684189|Other|Patient registry|Patient registry without study intervention
75544534|NCT00253136|Drug|risperidone|
75544535|NCT02960529|Procedure|extra-peritoneal high ligation of hernia|
75707661|NCT05997680|Behavioral|Parent-child yoga|The 45-minute yoga sessions are structured to include an opening and a closing ritual that remain the same throughout the 8 weeks, between which an active and a calming parts are scheduled. The active and calming parts are embedded in stories that align with the developmental level and interests typical of 4-to-6-year-olds. Each session is clearly structured with each exercise and transition well described in the Yoga for Little Hearts Yoga Program Manual. In addition to the yoga sessions, at-home exercises (5 min) including breathing, meditation and mindfulness activities will be explained to participants. We will ask them to practice them at home at least 3 times every week, for the 8-week duration of the intervention. Including the yoga session and home exercises, the 8-week intervention thus includes at least 60 minutes of yoga per week. Parents will be encouraged to pursue the at-home exercises after the end of the 8-week yoga program, up to the 6-month follow-up.
76034687|NCT03045185|Procedure|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
76034688|NCT03045497|Drug|Perflutren Lipid Microspheres|Given IV
76034689|NCT03045497|Device|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
76034690|NCT03045497|Device|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
76034691|NCT03047759|Device|water flosser|Powered
75544536|NCT02960529|Procedure|intraabdominal high ligation of hernia|
75544537|NCT01684267|Device|Robotic Gait Rehabilitation (RGR) Trainer|
75392162|NCT03586752|Other|Standard program|60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
75392163|NCT03891576|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
75392164|NCT03586674|Drug|Lipanthyl|Tablet
75392165|NCT03586674|Drug|Ursogal|suspension
75392166|NCT05702346|Behavioral|Enhance Physical Activity (EPA)|EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.
75707663|NCT05996809|Device|Coseal|Adhesion reduction
75707664|NCT05992168|Device|Stent-Retriever|all the participants in this group will be performed with Stent-Retriever
75707665|NCT05991453|Other|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
76034692|NCT03047759|Device|air floss|Powered
76034693|NCT04435639|Other|Manual lymph drainage.|"Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period."
76034694|NCT04435639|Procedure|Coban compression bandage..|Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
75392167|NCT03156348|Other|Clinical Pharmacist Care|"During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations."
75392168|NCT03580200|Other|Trigger Point Dry Needling|For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
75392169|NCT03580122|Drug|Arginine Aspartate|Asparten
75392170|NCT03346668|Drug|Topical gabapentin|topical gabapentin 6% solution
76034695|NCT04435639|Device|Adjustable Compression Sleeve|Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
75392171|NCT03156426|Other|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
75392172|NCT03585738|Dietary Supplement|Inositol + Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
75392173|NCT03585738|Dietary Supplement|Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Folic acid: 400 mcg"
75392174|NCT03583164|Drug|F901318|30mg tablets with a maximum daily dose of 300mg with dose adjustments according to plasma levels of F901318 and concomitant treatment with CYP inducers or inhibitors
75392175|NCT03589326|Drug|Ponatinib|Ponatinib Tablets.
75392176|NCT03589326|Drug|Imatinib|Imatinib Tablets.
75392177|NCT03589326|Drug|Vincristine|Vincristine IV injection.
75392178|NCT03589326|Drug|Dexamethasone|Dexamethasone Tablets.
76034696|NCT04969237|Diagnostic Test|Vitamine D in blood samples|vitamine D values
76034697|NCT05138185|Device|Exoskeleton assisted gait on a treadmill|Subjects were instructed to walk on a treadmill at a constant speed during trials of 5 minutes. All subjects carried out four trials: (1) NoExo: subjects only wore the sensors to acquire their basal motion; (2) Free: subjects wore the exoskeleton although the actuator was mechanically decoupled, so it enabled the free movement of the knee; (3) Echo: the device provided gait assistance following the Echo-control strategy; and (4) Pattern: the device provided gait assistance following the Pattern strategy. During trials, patients wore a safety harness that did not support any weight. Previously to the execution of the trials, the gait velocity was self-selected by the subjects to a comfortable level. Subjects rested between trials for five minutes. Healthy subjects also performed a previous trial under variable gait speed. They walked over the treadmill as in the NoExo condition, although the gait speed randomly varies from 1km/h to 3km/h in 0.2km/h steps for 15 seconds at least.
76034698|NCT03045419|Procedure|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
75392179|NCT03589326|Drug|Cytarabine|Cytarabine IV infusion.
75392180|NCT03589326|Drug|Methotrexate|Methotrexate IV infusion.
75392181|NCT03589326|Drug|Prednisone|Prednisone Tablets.
75392182|NCT05684640|Drug|Rodatristat Ethyl|Tablets, Oral, 600mg, QD
75392183|NCT05684640|Drug|Placebo|Tablets, Oral, 0mg, BID
76034699|NCT05048251|Device|cTBS|continuous theta burst stimulation
75707666|NCT05991453|Other|Anesthetic technique inhaled agent|Must administer inhaled agent.
75707667|NCT05990166|Other|Mineral-enriched powder|Mineral-enriched powder Mineral-enriched powder to allow for at-home fortification of beverages with 5 mg of ferrous iron and 10 mg of zinc sulfate monohydrate
76034700|NCT05048251|Device|iTBS|intermittent theta burst stimulation
76034701|NCT05048251|Device|sham|sham stimulation
76034702|NCT01594853|Behavioral|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
76034703|NCT03047681|Diagnostic Test|venous blood withdrawl|patients will be asked for a venous blood sample
76034704|NCT05137561|Procedure|PSMA PET guided prostate biopsy|PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.
75392184|NCT03583866|Drug|Candesartan|7 days of Candesartan (16mg/day)
75392185|NCT03583866|Drug|Placebo|7 days of Placebo
75392186|NCT05701878|Behavioral|SMARTest mobile app for COVID-19 self-testing|The mobile app has self-testing features and information with regard to self-testing and COVID-19.
75392187|NCT03585192|Other|Skin Group|"If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life."
75392188|NCT03585192|Other|Warmer Group|"Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life."
75707668|NCT05990166|Other|Placebo powder|Placebo powder which is identical to the mineral- enriched powder, but does not contain the active ingredients (ferrous iron and zinc sulfate monohydrate)
75707669|NCT05989672|Biological|HSVTI Formulation 1|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F1 Group.
76034705|NCT05137561|Procedure|MRI directed TRUS guided prostate biopsy|TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring
76034706|NCT04341467|Drug|Amisulpride|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
75392189|NCT03585426|Drug|Vancomycin|Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
75392190|NCT03585036|Drug|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
76034707|NCT04341467|Drug|Olanzapine|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
76034708|NCT04933591|Drug|Diosmin / Hesperidin|Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
76034709|NCT04872881|Procedure|Endotracheal Tube Insertion|ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)
75392191|NCT03585036|Drug|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
75392192|NCT03585036|Drug|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
75392193|NCT03584880|Device|Diode laser disinfection|Root canal disinfection using a 940 nm dental laser after the removal of root canal filling of failed endodontic cases.
75707670|NCT05989672|Biological|HSVTI Formulation 2|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F2 Group.
75707671|NCT05989672|Biological|Placebo|This intervention will be administered intramuscular as 2 doses to Placebo group.
76034710|NCT04872881|Procedure|Laryngeal Mask Insertion|After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.
75392194|NCT03584880|Device|Pseudo diode laser disinfection|Without activating laser energy, same procedure as experimental group was performed (Sham laser application)
75392195|NCT03155568|Procedure|sciatic nerve block|sciatic nerve block at popliteal fossa
75392196|NCT03155568|Procedure|ankle block|block of major nerves supplying the foot at the level of the ankle
75392197|NCT03155568|Drug|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
75392198|NCT03584802|Other|Therapeutic plasma exchanges|The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
75392199|NCT03584802|Other|Conventional treatment of AE-IPF|Conventional treatment of AE-IPF
75392200|NCT03584568|Behavioral|Perspective Taking Reappraisal|Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.
75392201|NCT03584568|Other|Basic Skill Building|These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
75392202|NCT03020238|Procedure|BiClamp group|electric energy
75707672|NCT05988996|Behavioral|Participant guided peer support gathering|This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.
75392203|NCT03020238|Procedure|water jet group|water jet energy
75392204|NCT04405128|Diagnostic Test|Transcranial Tissue Doppler (TCTD)|"Doppler ultrasound technique called 'Brain Tissue Velocimetry (Brain TV), to investigate brain tissue motion over the cardiac cycle."
75392205|NCT04405128|Diagnostic Test|Brain MRI|Brain MRI for investigation of brain tIssue motion in the presence of acute acquired brain injury.
75707673|NCT05988541|Diagnostic Test|Ultrasonography imaging|Ultrasonography: rotator cuff tendons (supraspinatus, infraspinatus, subscapularis) integrity, long head of the biceps tendon integrity and location, SASD (subacromial-subdeltoid) bursitis, synovitis and muscle atrophy.
75392206|NCT03584412|Behavioral|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
75544538|NCT01684306|Drug|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
76034711|NCT04872881|Procedure|Fiberoptic Bronchoscopy|"After the patients' airway is established, the trachea and the process area will be displayed by the physician.~The success rate will be increased by performing the procedure with fiberoptic bronchoscopy."
75544539|NCT01684306|Drug|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
76034712|NCT04872881|Procedure|Radial Artery Monitoring|The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.
76034713|NCT04872881|Diagnostic Test|Anteroposterior chest x-ray|When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.
76034714|NCT04872881|Diagnostic Test|Arterial Blood Gas Analyses|Hypoxia, acidosis and carbon dioxide increase will be followed
76034715|NCT04872881|Drug|Propofol Fresenius|2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.
76034716|NCT04872881|Drug|Rocuronium|0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.
76034717|NCT04872881|Drug|Fentanyl|1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.
76034718|NCT05137483|Other|Functional tests|We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
76034719|NCT04872647|Behavioral|Phone-Based Health Coaching Utilizing Lifestyle Action Plans|Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
75392207|NCT03584412|Other|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
75544540|NCT01684345|Drug|Placebo|Solution for subcutaneous injection
75544541|NCT01684345|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
75707674|NCT05988541|Diagnostic Test|American Shoulder and Elbow Surgeons (ASES) Score|"The patient self-assessment (pASES) includes 6 pain items and 10 functional items that are shoulder specific (Angst, 2008).~The pASES form has 3 sections: pain, instability, ADLs (Goldhahn, 2008).~Pain section: 4 questions with yes/no responses, 1 question covering number of pain tablets per day, and a VAS (visual analogue scale) from 0 (no pain) to 10 (worst pain).~Instability section: 2 questions (1. Response yes/no about feelings of instability, 2. Quantify instability from 0 (stable) to 10 (very unstable)).~Activities of daily living (ADLs): Each shoulder is included (affected/non affected), 10 items, with a 4 point ordinal scale, range: 0 (unable to perform activity) to 3 (no difficulty in doing activity) (Goldhahn 2008)."
75544542|NCT01684345|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
75544543|NCT00287781|Drug|Lidocaine|
75544544|NCT01684384|Radiation|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
75544545|NCT01684462|Biological|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4~8h, commencing within 12 hours of stroke onset
75392208|NCT03155646|Drug|Dexmedetomidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
75392209|NCT03155646|Drug|Clonidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
75392210|NCT03155646|Drug|Levobupivacaine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
75392211|NCT03584178|Device|Budesonide via MAD device|Delivery through Mucosal Atomization Device
75392212|NCT03584178|Device|Budesonide via intranasals Saline Irrigation|delivery via nasal irrigation bottle
75544546|NCT01684462|Drug|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4~8h, commencing within 12 hours of stroke onset
75707675|NCT05988541|Diagnostic Test|The Constant-Murley score (CMS)|The test is divided into four subscales: pain (15 points), activities of daily living (ADL) (20 points), strength (25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (40 points).
75707676|NCT05988541|Diagnostic Test|The Disabilities of the Arm, Shoulder and Hand (DASH)|"30-item self-report questionnaire designed to assess symptoms and function of the entire upper extremity.~Total scores range from 0 (minimum) to (100) maximum."
75392213|NCT04405206|Drug|Oxaliplatin|OXA 130mg/m2
75392214|NCT04405206|Drug|Capecitabine|Cape 1000mg/m2
75544547|NCT00416871|Biological|aldesleukin|
75544548|NCT00416871|Biological|recombinant interferon alfa|
75392215|NCT04405206|Radiation|intensity modulated radiotherapy|IMRT 50.4Gy/22f
75392216|NCT04405206|Procedure|DRE-Endoscopy-MRI-CEA|examination process in follow up
75392217|NCT04405206|Procedure|Nonoperative Management|Watch and Wait
75392218|NCT04405206|Procedure|Local excision|For ymriT1N0 and near-cCR patients，LE is optional.
75392219|NCT04405206|Procedure|Total Mesorectal Excision|Standard TME surgery openly or laporoscopically
75392220|NCT04405206|Behavioral|Quality of Life Questionnaires|QLQ C30 and QLQ CR29
75392221|NCT03101046|Drug|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m² every 3 weeks up to 10 cycles.
75392222|NCT03101046|Drug|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
75392223|NCT03152448|Behavioral|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
75544549|NCT01684540|Other|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
75544550|NCT01684540|Drug|Sinupret forte|
76034720|NCT04591249|Behavioral|Physical activity intervention|Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is <8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
76034721|NCT04591249|Other|Usual care|Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
75392224|NCT03159936|Biological|Tofacitinib citrate|10 mg daily by mouth
75392225|NCT03027414|Drug|Transcranial Magnetic Stimulation Sham|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
75392226|NCT03027414|Device|Transcranial Magnetic Stimulation|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
75392227|NCT03156816|Drug|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
76034722|NCT03044873|Drug|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
76034723|NCT03044873|Drug|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
75707677|NCT05987657|Diagnostic Test|Salivary and blood progesterone dosage|"Salivary dosage: patient will chew a dry swab for 2 minutes; when the swab is soaked it is put back in its small case and sent to the laboratory for analysis.~In parallel, the same patients will have a blood sample of 4 ml to dose blood progesterone on an EDTA tube. It will be also sent to the laboratory for analysis.~Both analyses will be done only once on triggering day meaning 36 hours before oocyte retrieval."
76034724|NCT03044951|Procedure|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
76034725|NCT03044951|Procedure|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
76034726|NCT05137405|Procedure|Sleeve gastrectomy|An online survey format was administered to all obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences to obtain information about the COVID- 19 pandemic's impact on patients with obesity starting March 09, 2020 until May 18, 2020.
76034727|NCT03044795|Drug|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
76034728|NCT04587583|Behavioral|WeCareAdvisor|Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.
76034729|NCT04581811|Other|Prolonged Proned Positioning|Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period
76034730|NCT04581811|Other|Traditional Proning Arm|Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
76034731|NCT03047603|Diagnostic Test|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
76034732|NCT04430153|Other|"Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer"|Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
75392228|NCT03156816|Drug|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
75392229|NCT03583944|Drug|Eribulin Mesylate|Eribulin mesylate IV infusion.
75392230|NCT02841696|Device|Cardiac echography|The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
75392231|NCT04764786|Other|EVOO+POLY|a test meal seasoned with extra virgin olive oil rich in polyphenols
75392232|NCT04764786|Other|OO-POLY|a test meal seasoned with olive oil poor in polyphenols
75707678|NCT05986487|Device|CPAP or usual practice|CPAP (continuous positive airway pressure) is a machine that uses mild air pressure to keep breathing airways open while you sleep.
75544551|NCT01684579|Behavioral|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
75707679|NCT05986487|Device|Monitoring and intervention in follow-up|Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.
75707680|NCT05983588|Drug|RAVICTI 1.1 g/ml|"Duration of Treatment: 26 weeks, twice daily~Dosage:~weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
75707681|NCT05983588|Drug|Placebo|"Duration of Treatment: 26 weeks, twice daily~Dosage:~weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
75707682|NCT05983380|Other|Hand Mobility and Grip Strengthening Exercises|Addition of hand mobility and grip strengthening exercises to the usual care for breast cancer-related lymphedema to assess changes in limb volume, quality of life, and hand function.
76034733|NCT03047291|Drug|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
75707683|NCT05983380|Other|Usual Care|Manual lymphatic drainage, compression, exercise, skin hygiene.
76034734|NCT03047291|Device|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
75392233|NCT03159546|Device|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
75707684|NCT05981664|Device|One Handed Video Game Controller Adapter|The one handed video game controller adapter was designed and 3D printed at Rehabilitation Centre for Children. It is a simple model that snaps onto an XBox One controller and uses a series of levers to allow access to almost all buttons of the controller from one side. There is both left and right sided versions
75707685|NCT05979506|Procedure|Cutaneous wraps|"The topical treatment that will be used in this study are:~For the body, an emollient cream with a high lipid content: Cold cream~For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage~Each of the 3 treatments (body, scalp and feet) will be carried out as follows:~Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes~Occlusion by wrapping the patient in a plastic film, then covering with a blanket~After 1 hour, the unabsorbed excess cream is removed with a towel"
75707686|NCT05977673|Drug|Tislelizumab|Tislelizumab 200mg IV day1
75392234|NCT03159858|Device|Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System|The Compassionate Use Request is for the use of the Cook Zenith Fenestrated Endovascular Graft (4 branches) for the treatment of a 70-year-old male patient considered unfit for open surgical repair of his 6cm paravisceral abdominal aortic aneurism (AAA).
75707687|NCT05977465|Drug|Empagliflozin 25 MG|treatment
75707688|NCT05975554|Drug|Interleukin-2 [IL-2]|5 sequential days of treatment (1.5MIU/day subcutaneously)
76034735|NCT04487899|Device|Analysis of heart rate variability|The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
75707689|NCT05975554|Procedure|Standard care - Carotid Endarterectomy|Standard care for patients with carotid stenosis undergoing carotid endarterectomy
75707690|NCT05972993|Biological|mRNA-CR-04 vaccine 10μg|mRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
75707691|NCT05972993|Biological|mRNA-CR-04 vaccine 30μg|mRNA CR-04 vaccine, 30 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
75707692|NCT05972993|Biological|mRNA-CR-04 vaccine 100μg|mRNA CR-04 vaccine, 100 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
75707693|NCT05972993|Drug|Placebo|Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
75707694|NCT05969574|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation
75707695|NCT05969574|Diagnostic Test|Blood test AMH|Measurement of AMH performed on the day of first consultation
76034736|NCT04865705|Drug|tislelizumab|Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
76034737|NCT04375111|Procedure|Serratus anterior plane block|•Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.
75392235|NCT03583632|Other|visual acuity testing|testing of visual ycuity by ETDRS charts
75392236|NCT03583632|Device|optical coherence tomography|optical coherence tomography generates sectional slides of the retinal tomography with light
75392237|NCT03583476|Drug|Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole|Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
75392238|NCT03583398|Procedure|transcatheter aortic valve implantation, surgical aortic valve replacement|Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
76034738|NCT04375111|Procedure|Transversus thoracic plane block|•Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of isobaric bupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
76034739|NCT03044717|Other|Nutrition survey|Survey will be done prior to the initiation of the education
76034740|NCT03044717|Other|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
75544552|NCT01684579|Behavioral|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
75707696|NCT05968274|Device|Rebox-Physio 4 (real stimulation)|Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.
76034741|NCT03044717|Other|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
76034742|NCT04898179|Other|Telecare Group|"Home-based telehealth program: telenursing and specialist teleconsultation~Telemonitoring with a new pulse oximeter and specific App~E-health platform~Videoconference"
76034743|NCT04898179|Other|Control group|Usual care
76034744|NCT04867577|Diagnostic Test|CT scan of lung and spine|Dual energy CT scan of thorax and spine
76034745|NCT05137171|Drug|AK105 and anlotinib|AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
76034746|NCT04384679|Device|Hydrophilic polymer and potassium ferrate powder|Application with pressure until hemostasis is achieved
75707697|NCT05968274|Device|Rebox-Physio 4 (sham stimulation)|"In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded."
75707698|NCT05965167|Drug|EBP05|Oral tablets
75707699|NCT05965167|Drug|Forteo 20 mg|Subcutaneous injection
76034747|NCT04866875|Behavioral|dieting|The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
75392239|NCT03583320|Diagnostic Test|Cardiac CT angiogram|To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
75707700|NCT05965167|Drug|EBP11|Oral tablets
75707701|NCT05965167|Drug|EBP22|Oral tablets
75707702|NCT05964998|Device|transcranial direct current stimulation|Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes
75707703|NCT05964998|Device|Sham transcranial direct current stimulation|Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
76034748|NCT04858997|Drug|Palbociclib|Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
76034749|NCT04858997|Drug|AI|AI, orally once daily (continuously)
75392240|NCT03583242|Drug|Antiangiogenic Agents|3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
75544553|NCT01684579|Behavioral|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
75707704|NCT05964725|Device|Receive traditional medical therapy and transcranial direct current stimulation|Equipment used: Bricon tDCS stimulator, high-precision electrode stimulation method Stimulant dose: 1.5mA Stimulation time: 20 minutes/time, continuous treatment for 5 days Stimulation course: 5 days/course Stimulation target: left auditory cortex area, i.e., under system 10-20, left T3 position.
76034750|NCT05135143|Combination Product|Antioxidant formula|Administration of antioxidant formula 3 times a day and once daily.
76034751|NCT04865549|Procedure|SNB + TAD + Lymphadenectomy|Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
76034752|NCT04867265|Procedure|Mout-to-mouth ventilation|we will record the visibility of chest rising
76034753|NCT04867265|Procedure|Mout-to-mouth ventilation with quantitative analysis|we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
76034754|NCT04865653|Drug|Lysergic Acid Diethylamide Base oral drinking solution|A moderate dose of 0.1 mg LSD will be administered.
76034755|NCT04865653|Drug|Lysergic Acid Diethylamide Base solid orodispersible film|A moderate dose of 0.1 mg LSD will be administered.
76034756|NCT04865653|Drug|Lysergic Acid Diethylamide Tartrate oral drinking solution|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
76034757|NCT04865653|Drug|Lysergic Acid Diethylamide Tartrate intravenous administration|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
76034758|NCT04865653|Other|LSD Placebo|Placebo for each formulation containing only the solvent or gel but no LSD.
76034759|NCT04858763|Other|No Intervention|There will be no intervention during this study.
75392241|NCT03583242|Drug|Corticosteroid|1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
76034760|NCT04863469|Behavioral|B-POC high load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
75392242|NCT03078426|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
75392243|NCT03078426|Other|Thoracic HRCT (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
75544554|NCT01684618|Procedure|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
75544555|NCT01684657|Drug|Asenapine|This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
75544556|NCT00416910|Biological|Filgrastim|
75544557|NCT00416910|Drug|Fludarabine|
75544558|NCT00416910|Drug|Cyclophosphamide|
75544559|NCT00416910|Drug|Mitoxantrone|
75392244|NCT03159312|Behavioral|Physical activity based on a moderate exercise program|Physical exercise program begins with a 2-week adaptation stage, climbs onto the treadmill (HP Cosmos®). The programming of the tape will be done initially with an intensity of 40% of its FCdRes obtained from the formula of Karvonen after performing the 6-minute walk test, you will have to maintain that intensity for 15 min, the patient is evaluated with the Borg scale and oxygen saturation permanently.After two weeks of adaptation, the HRdRes becomes to be calculated, 59% of said frequency will be modified until the exercise program is completed.The training is 30 minutes in the tradmill machine.The work of muscle strengthening of biceps, triceps, deltoids and pectorals, will be progressive in intensity and number of repetitions, determined by the evaluation of 1 Rmax. The start of work with weights is 40% of the Rmax, it will be modified monthly from 40% to 75%. Cycloergometer training (Monark ®) is without load for 15 minutes.
75544560|NCT01684696|Behavioral|Virtual experience|
75544561|NCT01684696|Behavioral|Videos|
75544562|NCT01684774|Drug|Bupivacaine|
75544563|NCT02279992|Drug|Vardenafil|
76034761|NCT04863469|Behavioral|B-POC low load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
76034762|NCT04867109|Other|Patients with Post menopausal bleeding|"Any patient presenting post-menopausal bleeding who is to undergo hysteroscopy or hysterectomy will have an additional blood tube taken during her pre-operative blood work-up for the determination of the serum markers HE4 and CA125, after having obtained her non-opposition to participate in the study.~The blood tube collected for the research will be sent to the biochemistry laboratory of the Nantes University Hospital for a centralized analysis.~This analysis will be done sequentially and the results will not be transmitted to the investigator.~At D0, the day of surgery, the operative report will be retrieved as well as the quality of life questionnaires SF12 and PGI-I and the acceptability questionnaire completed before surgery.~At 1 month after surgery, the anatomopathological results will be retrieved as well as the value of the tumour markers CA125 and HE4."
75544564|NCT02279992|Drug|Carboplatin|
75544565|NCT00253175|Drug|topiramate|
75544566|NCT00287820|Drug|Olanzapine|olanzapine 5-40 mg/day
75707705|NCT05964725|Device|Receive traditional medical therapy and sham stimulation|By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
75707706|NCT05960032|Drug|Zavegepant|Participants receiving single dose of Zavegepant 10 mg
75392245|NCT05701410|Diagnostic Test|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin amyloidosis.
75392246|NCT03583008|Behavioral|Anticoagulation (AC) Intervention--Academic Detailing|One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.
75544567|NCT00287820|Drug|olanzapine|olanzapine 5-40 ,mg/day
75544568|NCT00287820|Drug|risperidone|risperidone 1-12 mg/day
75544569|NCT02272348|Other|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
75544570|NCT02272348|Other|Usual diabetes management.|
75544571|NCT02279095|Drug|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
75544572|NCT02279095|Drug|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
75544573|NCT02279095|Drug|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
75544574|NCT02279095|Drug|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
75544575|NCT01684852|Other|Medical device, drug-like|
75544576|NCT00253214|Drug|galantamine hydrobromide|
75544577|NCT00287859|Drug|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
75544578|NCT01684891|Drug|RG1662|multiple doses of RG1662
75544579|NCT01684969|Drug|Haloperidol|0.5 mg iv x one dose
75544580|NCT01684969|Drug|Placebo|0.5 mg iv , one dose
75544581|NCT01685125|Drug|abiraterone acetate|Given PO
75544582|NCT01685125|Drug|dasatinib|Given PO
75544583|NCT01685125|Drug|prednisone|Given PO
75544584|NCT00416988|Other|educational intervention|
76034763|NCT04867109|Diagnostic Test|CA125 and HE4 assays|Blood was collected in a standard heparinized vial. Samples were sent to a central laboratory unit (biochemistry laboratory at the Nantes university hospital), centrifuged and plasmas were stored at -20°C until analysis. Plasma CA125 and HE4 concentrations were determined by run in single measurements using an electrochemiluminescence Elecsys immunoassay (ECLIA) on a Roche Diagnostics Cobas 8000® e602 analyser (Roche Diagnostics, Mannheim, Germany).
75707707|NCT05957952|Procedure|Motor control exercise with dynamic taping|Subjects will learn how to control their scapula during motor control exercise with application of dynamic tape
75707708|NCT05957952|Procedure|Motor control exercise|Subjects will learn how to control their scapula during motor control exercise without taping
75392247|NCT03583008|Behavioral|Anticoagulation (AC) Intervention--Prescribing Practices|Education and support related to anticoagulant prescribing practices.
75392248|NCT05703126|Diagnostic Test|History taking|Careful history taking, including using questionnaires, to identify risk factors for the development of cardiovascular diseases using the SCORE scale.
75392249|NCT05703126|Diagnostic Test|Anthropometry|Anthropometry: measurement of body weight and height. Calculation of body surface area using the Du Bois formula.
75392250|NCT05703126|Diagnostic Test|Complete blood count|Before and after each course of chemotherapy: Complete blood count with counting the number of erythrocytes, leukocytes, leukocyte formula, platelets, erythrocyte sedimentation rate.
75392251|NCT05703126|Diagnostic Test|Biochemical blood test|Before and after each course of chemotherapy: Biochemical blood test with the determination of the amount of total protein, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, urea, AlAT, AsAT, LDH, glucose, C-reactive protein, troponin T, proBNP.
75392252|NCT05703126|Diagnostic Test|Coagulogram|Before and after each course of chemotherapy: Coagulogram parameters (fibrinogen, APTT, INR).
75392253|NCT05703126|Diagnostic Test|Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine|Before the start of the treatment and after each course of chemotherapy: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine.
75707709|NCT05953688|Drug|ESK-001|Oral tablet
75392254|NCT05703126|Diagnostic Test|Stress echocardiography with the definition of global longitudinal deformation of the myocardium|Before the start of the treatment and after each course of chemotherapy: Stress echocardiography with the definition of global longitudinal deformation of the myocardium.
75392255|NCT05703126|Diagnostic Test|Triplex scanning of neck vessels|Before the start of the treatment and after each course of chemotherapy: Triplex scanning of neck vessels.
75392256|NCT05703126|Diagnostic Test|Electrocardiography|Before and after each course of chemotherapy: Electrocardiography.
75392257|NCT05703126|Diagnostic Test|Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes|Before the start of the treatment and after each course of chemotherapy: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes.
75392258|NCT05703126|Diagnostic Test|Cytogenetic examination of the bone marrow to determine genetic abnormalities.|Before the start of the treatment: Cytogenetic examination of the bone marrow to determine genetic abnormalities.
75392259|NCT05703126|Diagnostic Test|Cytological examination of bone marrow cells with cytochemical examination|Before the start of the treatment and after each course of chemotherapy: Cytological examination of bone marrow cells with cytochemical examination.
75392260|NCT05703126|Diagnostic Test|Immunophenotypic examination of the bone marrow by flow cytometry|Before the start of the treatment: Immunophenotypic examination of the bone marrow by flow cytometry.
75392261|NCT05703126|Diagnostic Test|Determination of the presence of a FLT3 mutation using the PCR Method|Before the start of the treatment: Determination of the presence of a FLT3 mutation using the PCR Method.
75392262|NCT05703126|Diagnostic Test|laser Doppler flowmetry|Before the start of the treatment and after each course of chemotherapy: Examination of microcirculation by laser Doppler flowmetry using the LAKK-OP apparatus (NPP Lazma, Moscow, 2011) with respiratory and occlusion tests.
75392263|NCT03155334|Other|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~individual reading of the text;~individual questionnaire for a quantitative and qualitative evaluation;~a brief semi-structured interview to each participant;~a text revision to address any problems identified from participant feedback."
75869964|NCT04846972|Behavioral|FASTRACS intervention|"Intervention (4 steps) :~Penultimate to last chemotherapy : patient will receive tools of the intervention~1 month after the end of oncological treatment (OT): patient will attend a general medicine consultation with the GP RTW checklist~2 months after OT: patient will attend a pre RTW visit with the OP RTW checklist~5 months after the end of OT: if the patient has not returned to work 10 months after inclusion, they will have a visit with an OP-RTW to work coordinator~Self-questionnaires will evaluate quality of life (EORTC QLQC30, BR23, Euroqol (EQ-5D-5L)), anxiety and depression (HAD), employment status, self-efficacy to return to work (RTW-SE11), pre-RTW and RTW visit with the OP, social support, care consumption, physical activity (short IPAQ), perceived performance (WRF), work conditions. The implementation and use of the intervention tools will also be assessed: the patient guide, the employer guide, RTW checklists for the GP and the OP."
75869965|NCT02391844|Drug|Oxycodone|Oxycodone with Acetaminophen Extended Release
75392264|NCT03582696|Behavioral|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
75392265|NCT03159390|Other|phenylacetate salt of ornithine|
75392266|NCT03159156|Behavioral|Applied Tension|Described above.
75869966|NCT05675332|Behavioral|Task-based behavioral intervention|Brief behavioral intervention is absent of stressors.
75392267|NCT03159156|Behavioral|Respiration Control|Described above.
75392268|NCT03159156|Behavioral|Applied Tension/Respiration Control|Described above.
75392269|NCT03582306|Behavioral|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
75392270|NCT03582306|Behavioral|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
75392271|NCT05629182|Other|No intervention applied - Observational study only|Observational study only. Video footage is used to review all 64 matches in the football tournament.
75544585|NCT04527679|Drug|GC combined Lenvatinib|"GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~Lenvatinib (<60kg: 8mg /d; ≥60kg, 12mg)."
75392272|NCT03582228|Behavioral|Virtual Envrionment for Social Communication|"Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~15 minutes- Social support group (guided discussion of experiences related to weekly topic)~20 minutes- Didactic instruction~15 minutes- Role playing~10 minutes- Debriefing and group feedback"
76034764|NCT05306119|Other|Rehabilitation method|Application of techniques of kinesiotherapy, electrotherapy, massage in comorbid patients and patients with low back pain who had undergone myocardial revascularization surgery in main group.
75392273|NCT03159234|Radiation|fetal lung volume|the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia
75392274|NCT03159234|Radiation|pulmonary artery resistance index|Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
75392275|NCT03159234|Radiation|Fetal adrenal gland volume:|the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
76034765|NCT05305729|Other|No intervention|No intervention
75392276|NCT03020316|Behavioral|Peer Mentor|A volunteer with a similar disease as the subject
76034766|NCT04488679|Other|direct pulp capping|teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
75392277|NCT03020316|Behavioral|Transcendental Meditation|A meditation technique
75392278|NCT03158844|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
76034767|NCT05305417|Procedure|Autologous Regenerative Endodontic Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an autologous biological scaffold and bioactive biomaterials to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
76034768|NCT05305417|Procedure|Conventional Root Canal Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an inert biomaterial to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
76034769|NCT05305339|Other|Placental and Umbilical cord biopsy|After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
76034770|NCT04794283|Other|Breast milk|Milk substitute given during the first 24h
76034771|NCT05305183|Drug|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|all subjects will receive Calcium Carbonate and Vitamin D3 Tablets as basic medication.
76034772|NCT04782271|Drug|SYL18001 sodium Low dose q.d|1 drop in the randomized eye once daily
76034773|NCT04782271|Drug|SYL18001 sodium Middle dose q.d|1 drop in the randomized eye once daily
75392279|NCT05628246|Other|Telemedicine|Telemedicine
75392280|NCT05628246|Other|In-person|In-person
76034774|NCT04782271|Drug|SYL18001 sodium High dose q.d|1 drop in the randomized eye once daily
76034775|NCT04782271|Drug|SYL18001 sodium High dose b.i.d|1 drop in the randomized eye twice daily
76034776|NCT04781179|Behavioral|CM-II|It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique
76034777|NCT04781179|Behavioral|Psychoeducation|It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation
76034778|NCT01668797|Drug|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
76034779|NCT01668797|Drug|Placebo|Placebo comparator for 52 weeks
76034780|NCT05305027|Behavioral|Prompt diagnois pregnancy outcome|
76034781|NCT04759027|Other|subacromial distance measurement|distance between acromion and humerus
76034782|NCT05304637|Device|iTEAR100 treatment|Vibratory energy to the external nasal nerve
76034783|NCT04511767|Other|Do not take any interventions|Do not take any interventions
75707710|NCT05950646|Drug|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.01 ml/ kg/h (0.02 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
75544586|NCT01685164|Other|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
75707711|NCT05950646|Drug|Esketamine|Esketamine will be infused at a rate of 0.01 ml/ kg/h (5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
75392281|NCT05701332|Biological|Bacillus Calmette Guerin|effect of local B.C.G and Gemcitabine on semen parametes and testicular volume
75392282|NCT03582072|Behavioral|letter from the CMO|informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.*
75707712|NCT05950646|Drug|Normal saline|Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
75707713|NCT05949008|Drug|Metformin Extended Release (ER) Oral Tablet|Metformin ER will be provided as 1000 mg capsules by Qingdao Baheal Pharmaceutical Co., Ltd. In addition to the active ingredient metformin HCl,each tablet contains the following inactive ingredients: Povidone, Sodium Lauryl Sulfate, Magnesium Stearate, Cellulose Acetate, Polyethylene Glycol (PEG 400, PEG 8000), Triacetin, Hypromellose, Titanium Dioxide, Polysorbate 80, Ferrosoferric Oxide, Shellac.
75869967|NCT05675332|Behavioral|Task-based behavioral intervention|Brief behavioral intervention involves interacting with common everyday types of stress.
76034784|NCT05304559|Drug|S-Ketamine|S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
76034785|NCT05304559|Device|Continuous iliac fascia space block|After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
75392283|NCT03581994|Diagnostic Test|DDI Test Report|Test results of simulated patients
75392284|NCT03581916|Drug|18F-JNJ-64326067|18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
75392285|NCT03154866|Dietary Supplement|Lactobacillus kefiri LKF01 DSM32079|Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
75544587|NCT01685281|Drug|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
75544588|NCT01685281|Drug|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
75869968|NCT03663296|Other|Airway Ex App|30 minutes of self-directed learning and practice using the mobile application
75544589|NCT00417066|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
75544590|NCT00417066|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
75544591|NCT04527952|Behavioral|Online handouts describing how to follow each diet for 1 week each|Participants will receive handouts via email about how to follow each diet
75392286|NCT03154866|Dietary Supplement|Placebo|Placebo in drop formulation. 5 drop/daily for 21 days
75392287|NCT03581838|Behavioral|Observed eating session|Eating a Jimmy Johns turkey or vegetarian sandwich
75392288|NCT03581682|Other|Tele-Clinic Visits Using Parent-Acquired Echos|"Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other."
75707714|NCT05949008|Drug|Placebo|Matching placebo will be provided as 1000 mg capsules
75392289|NCT03157986|Other|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
76034786|NCT05304559|Drug|Normal saline|Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
75392290|NCT03157986|Other|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
75707715|NCT05944926|Behavioral|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
75707716|NCT05944926|Drug|Antidepressant medication (fluoxetine)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit.
76034787|NCT03045263|Behavioral|Pivotal Response Treatment|Behavioral intervention for autism
75392291|NCT03158142|Drug|Atropine Sulfate 1% Oph Soln|Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
75544592|NCT01682005|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
75707717|NCT05944562|Drug|Tulmimetostat|Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.
75392292|NCT05701176|Diagnostic Test|[18F]F-AraG PET scan|[18F]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
75392293|NCT03154944|Device|Ostomy device 1|This device consists of a known adhesive and a new top film
75707718|NCT05942911|Drug|IHL-675A|Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.
75392294|NCT03154944|Device|Ostomy device 2|This device consists of a new adhesive and a known top film
76034788|NCT04478851|Behavioral|Group Exercise Classes|The exercise program to be implemented for rural cancer survivors will combine aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for a 12-week period. If public health restrictions require closure of fitness facilities due to COVID-19, the program will be delivered online. If facilities are open, the sessions will be integrated in the community, delivered in-person. Whether delivered in-class or remotely, the program follows exercise progression principles (ie, frequency, intensity, time, type, overload and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
76034789|NCT04866797|Other|cyclic merocyanine|long-UVA absorber
76034790|NCT04866797|Other|Placebo|Placebo
76034791|NCT04476355|Other|Select and Tailor implementation interventions|Based on previously adapted guidelines and the assessment of innovation, adopters and practice environment for barriers and supports, the interventions mainly include patients education, practioners education and system changes.
75392295|NCT03154944|Device|Ostomy device 3|This device consists of a known adhesive and a new top film
75707719|NCT05942911|Drug|Cannabidiol|Formulated using UniGel™ technology by ProCaps®. The CBD soft gel capsules contain 75 mg CBD oil solution. These capsules look identical to the IHL-675A UniGel™ capsules, to aid double-blinding
75392296|NCT03028740|Drug|Placebo|Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
76034792|NCT04865471|Procedure|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
76034793|NCT04117711|Drug|AT-007|AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
75392297|NCT03028740|Drug|Cenicriviroc|Cenicriviroc, 150 mg, tablet, orally, once daily for up to approximately 40 months.
75392298|NCT03157596|Other|Oral Health Educational Program for Caregivers of Children with developmental disabilities|Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD & methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
75392299|NCT03154632|Device|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
75392300|NCT03154632|Device|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
75392301|NCT03027648|Procedure|Placement of levonorgestrel-releasing intrauterine system|All the patients accepted treatment of levonorgestrel-releasing intrauterine system
75392302|NCT05252520|Drug|JNJ-77474462|JNJ-77474462 will be administered subcutaneously.
75707720|NCT05942911|Drug|Hydroxychloroquine|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules each contain a 100 mg HCQ tablet. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
75707721|NCT05942911|Drug|Placebo|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
76034794|NCT04117711|Drug|placebo|Matching placebo will be administered once in the morning before breakfast
76034795|NCT02613221|Drug|Panitumumab + TAS-102|panitumumab + TAS-102 combination therapy
76034796|NCT05304325|Procedure|Bariatric surgery|Sleeve gastrectomy
75392303|NCT03886584|Other|Monitoring source test|Internal- and external-monitoring correct responses and inversions
75392304|NCT01670448|Procedure|PECBLOCK under echoguidance|Performance of block under echography
75392305|NCT01670682|Procedure|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
75392306|NCT01670682|Procedure|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
76034797|NCT05304325|Other|Blood sampling|Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants
75544593|NCT01685398|Drug|0.5% timolol maleate eye drop|
75392307|NCT01670682|Device|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
75707722|NCT05942716|Drug|Administration of a PET radiotracer|"A highly selective 5-HT2A receptor ligand ([18F]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic."
75707723|NCT05942105|Procedure|Breast conservative surgery|Breast conservative surgery after non-palpable lesion localization
76034798|NCT05304325|Other|Blood pressure|Systolic and diastolic blood pressure will be measured.
76034799|NCT05304325|Other|Anthropometric measurements|Body weight, height and waist circumference will be measured.
76034800|NCT05304325|Other|Body composition|Body composition will be evaluated by dual-energy X-ray absorptiometry.
75392308|NCT01670994|Biological|ALT-801|Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
75392309|NCT03157752|Behavioral|Quality of life questionnaire|Quality of life questionnaire
76034801|NCT05304325|Other|Resting metabolic rate|Resting metabolic rate will be measured by indirect calorimetry.
76034802|NCT05304325|Other|Food intake|Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.
76034803|NCT05304325|Procedure|Adipose tissue biopsy|A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
76034804|NCT05304169|Drug|Leuprorelin Acetate (Eligard® 45 mg).|Semiannually Leuprorelin Acetate (Eligard® 45 mg).
76034805|NCT04867031|Dietary Supplement|Milk|One portion of semi-skimmed cow's milk (approx. 450mL), providing ~140µg of iodine.
76034806|NCT04867031|Dietary Supplement|Fish|One portion of cod (approx. 130g), providing ~140µg of iodine.
76034807|NCT04867031|Dietary Supplement|Seaweed|One portion of dried seaweed sheets (approx. 6g), providing ~140µg of iodine.
76034808|NCT03045107|Procedure|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
76034809|NCT03045107|Procedure|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
76034810|NCT05304091|Other|Questionnaire on a smartphone application|Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.
76034811|NCT04865081|Device|VACCIN box|The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
76034812|NCT04865003|Other|treatment of infection|
75544594|NCT01685398|Drug|Normal saline|
75544595|NCT01685476|Device|Echodia® hand-held equipment|
75544596|NCT01685515|Drug|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
75544597|NCT01685515|Drug|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
75544598|NCT00281502|Drug|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
75544599|NCT00253331|Drug|topical organogel with nitroglycerin|
75544600|NCT04527250|Drug|ASC41|ASC41,1mg/table;5mg/table
76034813|NCT04730011|Behavioral|Short and Intensive Treatment|Intensive Treatment Week with behavioural psychotherapy
76034814|NCT04864769|Dietary Supplement|Krill protein hydrolysate|Ingestion of 35 g Krill protein hydrolysate
76034815|NCT04864769|Dietary Supplement|Soy protein isolate|Ingestion of 35 g Soy protein isolate
76034816|NCT04864769|Dietary Supplement|Whey protein isolate|Ingestion of 35 g Whey protein isolate
76034817|NCT04864769|Dietary Supplement|Water|Ingestion of water (control)
75544601|NCT04527250|Drug|ASC41 placebo|ASC41 placebo,1mg/table;5mg/table
75392310|NCT03157908|Device|CareConekta|CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
75392311|NCT03028896|Procedure|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
76034818|NCT03042455|Device|Armeo and rTMS|"The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks."
76034819|NCT03042455|Device|Armeo|The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
76034820|NCT03042455|Other|Control group|The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
75392312|NCT03157440|Diagnostic Test|Ring oxymetry|a new type oxymetry wear on index finger like a ring
75392313|NCT03157050|Other|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
75544602|NCT04527484|Drug|SHR-1314|each group subjects will be given different formulations of SHR-1314
75544603|NCT04527835|Diagnostic Test|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
75544604|NCT01685554|Device|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
76034821|NCT04451785|Biological|blood sample|6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).
75544605|NCT01685554|Device|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
75544606|NCT01685593|Device|abdominal binder|
75544607|NCT01685593|Other|no binder|
75544608|NCT00253409|Drug|chemotherapy|
75544609|NCT00253409|Procedure|adjuvant therapy|
75544610|NCT00253409|Procedure|conventional surgery|
75544611|NCT00253409|Procedure|neoadjuvant therapy|
75544612|NCT00253409|Radiation|radiation therapy|
75707724|NCT05942092|Procedure|Breast conserving surgery|Breast conserving surgery after lesion's localization with ROLL or magnetic seed
75392314|NCT03156972|Procedure|Replacment of mitral valve|Mitral valve replacment by prothsis
75707725|NCT05940896|Drug|Disitamab vedotin|Disitamab Vedotin intravenously combined with radiotherapy (concurrent)
75707726|NCT05939648|Biological|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
75707727|NCT05939648|Other|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
76034822|NCT04451785|Diagnostic Test|Pulse wave velocity|Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.
76034823|NCT03042065|Device|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
76034824|NCT03042065|Device|jet nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
75707728|NCT05939063|Procedure|LRAMPS|For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
75707729|NCT05939063|Procedure|LDP|For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
75869969|NCT03285854|Diagnostic Test|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
75392315|NCT01671072|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
75392316|NCT01671072|Drug|Normal Saline|Sodium chloride 0.9%, 3.5ml
75707730|NCT05937165|Other|Freeze-dried Blueberry Powder|Three day consumption of two doses of freeze-dried blueberry powder
75707731|NCT05936736|Radiation|prostate SBRT|Patients with prostate cancer will be treated with high-dose SBRT to prostate and seminal vesicles, delivered in one fraction, sparing the urethra and generating a dose distribution similar to HDR brachytherapy
75707732|NCT05933187|Drug|Treatment A: Emraclidine 30mg IR tablets (reference)|IR oral tablets
75707733|NCT05933187|Drug|Treatment B: Emraclidine 30mg IR test tablets 1|IR oral tablets
75707734|NCT05933187|Drug|Treatment C: Emraclidine 30mg IR test tablets 2|IR oral tablets
75392317|NCT01671150|Drug|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
75392318|NCT03156738|Drug|MT-2990|Subjects will receive a single IV dose of MT-2990
75392319|NCT03156738|Drug|Placebo|Subjects will receive a single IV dose of placebo
75392320|NCT01671228|Other|Decision Aid|The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
75392321|NCT01671228|Other|Decision aid + patient stories|The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
75869970|NCT03663140|Diagnostic Test|gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection|GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
75869971|NCT02391922|Behavioral|First aid course|
75869972|NCT02391922|Behavioral|First aid instructions by mobile phone|
75869973|NCT04056728|Biological|Eupenta Inj.|fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [recombinant-deoxyribonucleic acid])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
76034825|NCT04858685|Other|early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.
75392322|NCT01671228|Other|Decision Aid + values task|The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
75544613|NCT01685632|Procedure|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
76034826|NCT04709107|Other|Quality of life assessment - elective|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. To assess reliability and systematic shift and variation between the two assessments, elective patients will be asked to fill the VascuQoL-6 again at the admission to hospital, as well as 1 week after the 30-days follow-up vie an e-mail link for a test-retest assessment. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
76034827|NCT04709107|Other|Quality of life assessment - emergent|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
76034828|NCT04858919|Diagnostic Test|3D transabdominal ultrasound|Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).
76034829|NCT04858919|Diagnostic Test|transrectal ultrasound|The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.
75392323|NCT01671384|Drug|Valproate, Levocarnitine|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
75392324|NCT01671384|Drug|Placebo|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
75707735|NCT05933187|Drug|Treatment D: Emraclidine 30mg IR test tablets 3|IR oral tablets
75869974|NCT04056338|Other|No intervention|No intervention.
76034830|NCT04858919|Diagnostic Test|vaginoscopy|It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.
76034831|NCT05303389|Procedure|Fixation of 2,3 or 4 column pilon fracture of the tibia|anterior to posterior screws in classic arm and posterolateral approach in new arm group
75392325|NCT03154164|Device|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
75392326|NCT01671540|Device|intrapulmonary percussive ventilation|
76034832|NCT04858841|Drug|Levetiracetam Oral Product|Administer levetiracetam powder once a day in eligible patients
75544614|NCT01685632|Procedure|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
76034833|NCT04858841|Drug|Perampanel Oral Product|Administer perampanel powder once a day in eligible patients
76034834|NCT04858841|Drug|Placebo|Administer placebo powder once a day in eligible patients
75392327|NCT01671540|Other|standard treatment|breathing control exercises
75392328|NCT01671774|Drug|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
75392329|NCT01671774|Drug|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
75392330|NCT01671774|Drug|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
75392331|NCT01671774|Drug|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
75392332|NCT01671852|Drug|Mometasone furoate nasal spray|"Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks."
75544615|NCT00281541|Drug|YM155|
75544616|NCT01685671|Drug|NESP 60μg|Administrated NESP 60μg once subcutaneously
75544617|NCT01685671|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
75544618|NCT01685710|Drug|GTN patch|
76034835|NCT04866407|Other|Mentha x piperita|2% solution of Mentha x piperita diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Mentha x piperita' group.
75544619|NCT01685710|Drug|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
75544620|NCT00253487|Drug|O6-benzylguanine|
76034836|NCT04866407|Other|Eucalyptus globulus|2% solution of Eucalyptus globulus diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Eucalyptus globulus' group.
76034837|NCT03997747|Other|cytology specimen|Biopsy and Genetic: DNA analysis;Genetic: RNA analysis;Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymorphism analysis
76034838|NCT03970915|Device|Body warmer|The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.
76034839|NCT03970915|Device|Standard warming procedure|Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
75392333|NCT01671852|Drug|Placebo|
75392334|NCT01672086|Device|Stelkast Surpass Acetabular System implant|
75392335|NCT03153930|Behavioral|Walking breaks|In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes
75392336|NCT03153930|Behavioral|Sitting only|In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
75544621|NCT00253487|Drug|busulfan|
75544622|NCT00253487|Drug|temozolomide|
75869975|NCT02391766|Behavioral|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
75392337|NCT05547750|Drug|Vitamin K2|Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
75869976|NCT02391766|Behavioral|usual care|
75869977|NCT04056260|Procedure|ICG-NIR guided surgery|ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy
75392338|NCT05547750|Drug|Placebo|Similar-looking placebo tablets
75544623|NCT00253487|Procedure|adjuvant therapy|
75869978|NCT05675020|Behavioral|Zoom Intervention|"This educational program will be delivered via a 45-minute presentation via Zoom.~The educational presentation will be recorded and emailed to participants within 1 week of intervention to re-watch/review.~The educational program will promote a healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines.~We will compare the effects of an educational program on healthy lifestyle knowledge and behaviors pre-and post-program (after one month) via a REDCap survey for the adolescent and their parent/legal guardian."
75869979|NCT05674864|Drug|Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus|Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
75869980|NCT02391688|Drug|Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam|
75869981|NCT02391688|Drug|Bupropion|
75392339|NCT04370106|Other|Social leg program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
75392340|NCT04321200|Diagnostic Test|PANDA Gym|Infants will lie supine on a flat surface and will be placed in the PANDA gym where they either move by themselves or will interact with an instrumented toy. We will collect video, mat, and toy data from PANDA gym under two conditions: 1) infants playing supine without a toy and 2) infants reach, grasp and kick of the new PANDA toy. A test session will proceed as follows: The infant will be placed on his or her back at a predetermined position on the gym mat for the 2-minute no toy condition. Next, the toy will be given to the baby and adjusted for the infant to reach or kick. A caregiver will be seated at the head of the baby (out of a baby's sight) to provide comfort if needed. Testing will be done in NICU or at daycare or the rehabilitation robotics lab at University of Pennsylvania.
75544624|NCT00253487|Procedure|autologous bone marrow transplantation|
75544625|NCT00253487|Procedure|conventional surgery|
75544626|NCT00253487|Procedure|peripheral blood stem cell transplantation|
75544627|NCT00253487|Radiation|radiation therapy|
75544628|NCT01685788|Other|No intervention|
75544629|NCT00281619|Drug|CellCept (mycophenolate mofetil)|
75869982|NCT02391688|Drug|Fexofenadine|
75869983|NCT04117360|Other|Orthognathic surgery and Orthodontics|This study is observational. All subjects identified to participate will be undergoing orthognathic jaw surgery and orthodontic treatment.
76034840|NCT05303155|Diagnostic Test|16S rRNA sequencing|Fecal microbiome analysis using 16S rRNA sequencing
76034841|NCT04379089|Other|Observational study only|No Intervention
76034842|NCT04363177|Behavioral|Web-based psychosocial peer-to-peer support|"The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting."
75544630|NCT00281619|Behavioral|Dietary Monitoring|
75544631|NCT00281619|Behavioral|Drug Diary|
75544632|NCT00281619|Procedure|Blood Sampling|
75544633|NCT04527211|Drug|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
75544634|NCT01685866|Device|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
75544635|NCT00253526|Drug|bevacizumab|
75869984|NCT02391454|Device|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
75544636|NCT00253526|Drug|gemcitabine hydrochloride|
75544637|NCT00253526|Procedure|adjuvant therapy|
75544638|NCT00253526|Procedure|anti-cytokine therapy|
75544639|NCT00253526|Procedure|antiangiogenesis therapy|
75544640|NCT00253526|Procedure|antibody therapy|
75544641|NCT00253526|Procedure|biological therapy|
75544642|NCT00253526|Procedure|chemotherapy|
75544643|NCT00253526|Procedure|conventional surgery|
75544644|NCT00253526|Procedure|growth factor antagonist therapy|
75869985|NCT02391454|Other|Usual care|
75544645|NCT00253526|Procedure|monoclonal antibody therapy|
75869986|NCT01068860|Drug|Canakinumab 150 mg|Single subcutaneous injection of Canakinumab 150 mg.
75869987|NCT01068860|Drug|Placebo to Canakinumab|Single subcutaneous injection of Placebo to Canakinumab.
76034843|NCT05302843|Drug|BPI-28592|Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
76034844|NCT05302219|Other|Respiratory rate|The participant alternates respiratory rates of 30, 15 and 7.5 breaths/min. Breathe each frequency for 2 minutes with a one-minute break.
76034845|NCT05302219|Other|Tidal volume|The participant alternates tidal volumes of approx. 2, 1 and 0.5 litres. Breathe each tidal volume for 2 minutes with a one-minute break.
76034846|NCT05302219|Other|Apnea|The participant simulates three apneic pauses lasting 1 minute with a two-minute break.
75544646|NCT00253526|Procedure|surgery|
75544647|NCT01685944|Dietary Supplement|Live Pediococcus pentosaceus LP28|
75392341|NCT04321200|Other|Mobile App|"The parent or legal guardian will be consented first via the virtual rounding mobile app. They will also be asked to fill out general surveys including, a demographic survey, and a case report form, and a user feedback survey that provides relevant information, on both the family's and infant's medical history and experience. (see the flow-chart for the app). Within the caregiver survey, we will request the pediatrician (or primary care physician) name. We believe that with the baby name, caregiver name, zip code, and physician name, we will be able to locate the physician if needed.~Parents or legal guardians or the research will be asked to collect video via the MOBILE app. They will be instructed to ensure that the infant lies supine in no more than one-layer of tight-fitting clothing (i.e. infant onesie) while calm and awake. In all cases, we will have video recordings of the baby. They will be asked to upload the video to the app."
75392342|NCT04317612|Other|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
75392343|NCT04317612|Other|Reference product|Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
76034847|NCT04690465|Behavioral|Resistance training|"Participants will receive a 16-week resistance training program, with 3 times a week (a total of 48 training sessions) and 60 minutes per session intervention, which is adopted from the 12-week resistance training program introduced in the book Growing Stronger: Strength Training for Older Adults (Seguin et al., 2002), with minor modifications under the advice of Physical Fitness Association of Hong Kong, China (PFA)."
75707736|NCT05930535|Behavioral|Parenting for Lifelong Health for Parents and Teens|"PLH will be delivered over 6 sessions as a group-based family program with both adolescents and caregivers attending, with joint and separate core sessions framed by joint introductions and endings. It will include activities such as: building positive parent-child relationships; developing problem-solving skills; stress-management and stress-reduction skills; improving effective limit-setting and discipline by parents; talking about feelings and regulating emotions.~The PLH program will also include a peer support component and incentive boosters. The Helping Adolescents Thrive comic chapters will be provided as homework activities. The comics, developed by UNICEF, cover adaptation to new situations, stress management, problem-solving, communication skills, risky choices and being there for each other."
75544648|NCT01685944|Dietary Supplement|Heat-killed Pediococcus pentosaceus LP28|
75544649|NCT01685944|Dietary Supplement|Placebo|
76034848|NCT04690465|Behavioral|Eight-form Yang-style Tai Chi program|The active concurrent control group will receive Eight-form Yang-style Tai Chi program which has been confirmed feasible and will be taught by the qualified coach.
75544650|NCT01686022|Other|Immunoblot|serum specific IgE binds to grass extract by immunoblot
75544651|NCT01686217|Drug|ASP015K ER|oral extended release (ER) at three dosing levels
75544652|NCT01686217|Drug|ASP015K IR|oral immediate release (IR)
76034849|NCT04682743|Drug|paracetamol|received intravenous one gram of paracetamol over a 15-minute period,
75544653|NCT04719572|Other|Basic treatment group|A total of 60 subjects were recruited in the group.
75544654|NCT04719572|Other|Basic treatment+ anti-osteoporosis drug group|A total of 60 subjects were recruited in the group.
75544655|NCT04719572|Other|Basic treatment + non-drug treatment group|A total of 60 subjects were recruited in the group.
75707737|NCT05930210|Drug|ENERGI-F703 GEL|Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
75707738|NCT05930210|Drug|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
75544656|NCT01686295|Device|iRestore Hair Rejuvenation System|This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
75707739|NCT05927012|Drug|KER-047|Oral tablet, daily (or every other day) administration
76034850|NCT04682743|Drug|ondansetron|received intravenous 8 mg of ondansetron over a 15-minute period.
76034851|NCT04682743|Drug|normal saline|received intravenous 0.9% normal saline over a 15-minute period.
76034852|NCT03472573|Drug|Palbociclib|Given PO
76034853|NCT03472573|Drug|Dexamethasone|Given PO
75392344|NCT04244682|Device|Repetitive transcranial magnetic stimulation (rTMS)|In the rTMS procedure a small plastic coil will be placed next to the participant's head. The position of the coil will be guided by neuro-navigational software utilizing the individual's MRI scan. The coil will be placed over the relevant brain region using the Brainsight TMS-MRI co-registration system for visualizing the coil position with respect to the participant's individual MRI scan. The coil will then generate a series of repetitive magnetic pulses, and stimulation will occur, disrupting typical function of the targeted brain region.
75392345|NCT04200768|Other|Prospective data and sample collection|Performance of measurements of adiposity, extra collection of blood samples
75392346|NCT04404816|Drug|heliox|NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.
75869988|NCT03661736|Other|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
76034854|NCT04357717|Diagnostic Test|ExoDx Prostate|Urine-based biomarker tool to support decision to biopsy in patients with PSA between 2-10ng/ml
76034855|NCT05301985|Dietary Supplement|preoperative nutrition|The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
75392347|NCT04077372|Behavioral|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
75544657|NCT01686295|Device|sham device|This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
76034856|NCT04331509|Other|No Intervention|No Intervention
76034857|NCT04672915|Diagnostic Test|test of HBV DNA|Real time PCR or nested PCR to check
76034858|NCT04649593|Dietary Supplement|Samarin|Half of the group with a high AFL value will have a glass of Samarin to drink
76034859|NCT04636333|Biological|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
75392348|NCT04077372|Behavioral|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
75392349|NCT04348968|Device|Total hip arthroplasty|"The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol."
75392350|NCT01672398|Other|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
75392351|NCT01672476|Drug|Placebo|Placebo
75392352|NCT01672476|Drug|Valsartan|Valsartan 80mg
75544658|NCT04528030|Device|WAVE device|WAVE applies a transcutaneous vibration to the soles of the foot and palms of the hand to elicit nerve signalling from pressure and other limb proprioceptor sensors to pontine, cerebellar, and medullary brain areas that coordinate limb movement and reflexively activate brain areas controlling breathing. The WAVE device is a battery-operated product to reduce the episodes of Apnoea of Prematurity by vibratory stimulation to the hand and foot.
75544659|NCT01686412|Device|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
75544660|NCT01686490|Behavioral|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
76034860|NCT04636333|Biological|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
76034861|NCT04636333|Biological|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
76034862|NCT04636333|Biological|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
76034863|NCT04636333|Biological|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
76034864|NCT04636333|Biological|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
76034865|NCT04636333|Biological|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
75707740|NCT05925712|Device|AeroFit Seal-In Liner / Socket|Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.
76034866|NCT04636333|Biological|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
75392353|NCT01672476|Drug|Fimasartan|Fimasartan 30mg
76034867|NCT01362049|Other|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
76034868|NCT01362049|Other|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
75392354|NCT01672554|Drug|Quetiapine XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
75392355|NCT03153696|Behavioral|Cellie Coping Kit Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
75392356|NCT03153540|Device|Active iTBS|Intermittent theta burst transcranial magnetic stimulation
75707741|NCT05925712|Device|Seal-In Silicone Liner|Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
76034869|NCT04435561|Other|Standard physiotherapy rehabilitation and dry needling|The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.
75392357|NCT03153540|Device|Sham iTBS|Sham intervention
75392358|NCT05033808|Drug|Epirubicin|Epirubicin is given once over 15 Minutes via a central line
75392359|NCT05033808|Drug|Placebo|NaCl is given once over 15 Minutes via a central line
75392360|NCT05027256|Device|Entia Liberty|Home Monitoring solution
75392361|NCT01672632|Other|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
75392362|NCT04026984|Drug|Rifamycin SV-MMX|2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
75707745|NCT05915546|Drug|Emraclidine|Tablets
75392363|NCT04026984|Drug|Placebo|Matching Placebo tablets
75392364|NCT04019340|Other|Education|Usual care as described for the CG will also be provided to the IG. Wound size measurement, wound care, and questionnaires will be provided by the institute's nurses. Usual care will be enhanced by a pluridisciplinary educational program
75392365|NCT03153618|Other|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
75392366|NCT03833934|Diagnostic Test|Plasma Next Generation Sequencing (NGS)|Liquid biospys
75392367|NCT04275882|Diagnostic Test|Electrocardiogram|There will be no new intervention performed for the patients.
75544661|NCT01686490|Behavioral|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
75544662|NCT00281736|Drug|HPPH|Given IV
75544663|NCT00253565|Drug|capecitabine|
75544664|NCT00253565|Drug|imatinib mesylate|
75544665|NCT01686529|Procedure|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
75544666|NCT01686529|Drug|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
75544667|NCT01686607|Drug|Parenteral micafungin application|Parenteral
75544668|NCT01686607|Drug|Other parenteral antifungal drugs|Parenteral
75544669|NCT05140720|Biological|PNEUMOSIL®|"Study subjects will be vaccinated PNEUMOSIL® with the primary doses as described below:~Group 1: 3 doses, 4 to 8 week interval Group 2: 2 doses, dose interval > 1 month Group 3: 2 doses, dose interval > 2 months"
75707747|NCT05912283|Device|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
75707748|NCT05912283|Device|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
76034870|NCT04435561|Other|Standard physiotherapy rehabilitation|This group receives their traditional intervention, without dry needling.
76034871|NCT04481737|Behavioral|Peer-delivered and Technology Support Integrated Illness Management and Recovery|PDTA-IIMR is delivered by a peer support specialist with the use of guided IIMR eModules and a smartphone application designed to complement in-person eModule sessions. The eModules are designed to be reviewed with a peer support specialist and consumer during one-hour, weekly, telephonic sessions in a community setting. Each eModule includes videos and experiential learning tasks on psychoeducation and coping skills training.
76034872|NCT04481737|Behavioral|Peer support|Peer support is a non-manualized form of social support, frequently coupled with instrumental support, that is mutually offered or provided by persons having a mental health condition to others sharing a similar mental health condition to bring about a desired social or personal change. Peer support specialists are provided with 1-hour of supervision each week
76034873|NCT03103009|Drug|Pasireotide|Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
75392368|NCT04404348|Behavioral|Cognitive Training|Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.
75544670|NCT00281814|Procedure|psychosocial assessment and care|psychosocial assessment and care
76034874|NCT02839291|Other|quality of life questionaries|
75707749|NCT05912283|Device|Control Latex Condom|Commercial natural rubber latex condom
76034875|NCT02839291|Drug|intravenous or oral bone antiresorptive treatments|
76034876|NCT04485481|Drug|ADX-914|Single dose from 0.1mg/kg to TBD
75392369|NCT04404348|Behavioral|Placebo Control|Games are drawn from the set of research control games provided by Posit Science-Brain HQ.
75392370|NCT01672944|Other|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
75392371|NCT01672944|Other|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
76034877|NCT04485481|Drug|Placebo|Matching single dose placebo
76034878|NCT04485481|Drug|ADX-914|Multiple dose from TBD to TBD
76034879|NCT04485481|Drug|Placebo|Matching multiple dose placebo
76034880|NCT03852511|Biological|NG-350A|NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
76034881|NCT03787381|Device|Ultrasound|Vaginal ultrasound examination
75392372|NCT03152994|Other|Checking fasting blood glucose(FBG)|This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
75392373|NCT02653248|Radiation|Stereotactic Body Radiation Therapy|Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
75707750|NCT05905705|Diagnostic Test|Electroencephalography (EEG)|High-density EEG will be acquired during resting wakefulness before each ECT session.
75707751|NCT05905705|Diagnostic Test|Quantitative Measurements of Sleep Microstructure|Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
75707752|NCT05900752|Dietary Supplement|QiMeiYan Probiotics|consume one sachet of the assigned product, once a day after meals.
76034882|NCT03153787|Other|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
76034883|NCT04196335|Device|intra-procedural intracardiac echocardiography|use of intra-procedural intracardiac echocardiography during Watchman FLX devices
76034884|NCT03357367|Device|TiVi system|"Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
76034885|NCT04183699|Diagnostic Test|Prostate biopsy|MRI-targeted + systematic random prostate biopsy
76034886|NCT04173013|Biological|Uromune|2 sprays of solution once daily for a total of 3 months.
76034887|NCT03020875|Drug|Ofirmev|Intravenously administered acetaminophen.
76034888|NCT03020875|Drug|Per Os Acetaminophen|Orally administered acetaminophen.
76034889|NCT03102931|Other|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
75707753|NCT05900752|Dietary Supplement|Placebo product|consume one sachet of the assigned product, once a day after meals.
75707754|NCT05900362|Device|VitalCare Platform|All participants will receive an VitalCare platform with tablet, Eko Duo with capability to record heart/lung sounds, blood pressure cuff, pulse oximetry and digital scale
76034890|NCT03102931|Other|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
76034891|NCT02996305|Drug|OV101 Regimen 1|
76034892|NCT02996305|Drug|OV101 regimen 2|
76034893|NCT02996305|Other|Placebo|
76034894|NCT02612909|Biological|IVACFLU-A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
76034895|NCT02612909|Biological|Placebo|Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
76034896|NCT02975479|Drug|ALK Diluent|
76034897|NCT02975479|Drug|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
76034898|NCT03102853|Other|Nordic diet|
76034899|NCT03102853|Other|Control diet|
76034900|NCT04866485|Drug|HBM4003 and pembrolizumab|Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
76034901|NCT04858373|Other|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
76034902|NCT04858373|Other|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Greek emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
75707755|NCT05896033|Behavioral|Non-Menthol Cigarettes|Ppts will be randomly assigned to a group that receives non-menthol cigarettes
76034903|NCT04858373|Other|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Italian emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
75707756|NCT05896033|Behavioral|Tobacco Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives tobacco flavored e-cigarettes
75707757|NCT05896033|Behavioral|Menthol Cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored cigarettes
75707758|NCT05896033|Behavioral|Menthol Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored e-cigarettes
75707759|NCT05895773|Drug|Povidone-Iodine|Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.
75707760|NCT05895773|Drug|Saline spray|Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
75707761|NCT05894785|Procedure|External cephalic version|An ECV attempt is made on the study group
76034904|NCT04858373|Other|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from whole wheat commercial bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
76034905|NCT02888041|Drug|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
76034906|NCT02888041|Drug|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
76034907|NCT04858139|Drug|Lactate|Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,
75707762|NCT05894005|Other|Immersive 360 (3D) video|"Group A VR - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of Route 1.~Traditional - Route 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Group B Traditional - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1. Then the students will be assessed with an observed walkthrough of Route 1.~VR - Route 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2."
76034908|NCT04858139|Drug|Placebo|Intravenous injection (20 min)
76034909|NCT01688167|Behavioral|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
76034910|NCT04864691|Biological|endovascular recanalization|to recanalize the occlusion cerebral artery with intravascular intervention
76034911|NCT02838745|Drug|Pemetrexed|
76034912|NCT02838745|Drug|Cisplatin|
76034913|NCT03102541|Other|None intervention|
76034914|NCT04143919|Diagnostic Test|NYHA assessment|The New York Heart Association (NYHA) functional classification of HF
75392374|NCT04764240|Procedure|R0 resection with lymphadenectomy|Patients received a surgical R0 resection; patients who received an R1 or R2 resection were excluded.
75392375|NCT03024528|Behavioral|CPOT assessment|Polish version of Critical care pain observation tool validation.
76034915|NCT04143919|Procedure|Serum NT-proBNP concentration|Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
75392377|NCT03153072|Biological|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
76034916|NCT04143919|Diagnostic Test|Transthoracic Ecocardiogram|Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
76034917|NCT00136435|Drug|prednisone|Induction Phase: Given orally on days 1-28
76034918|NCT00136435|Drug|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
76034919|NCT00136435|Drug|vincristine|"Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.~CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle"
76034920|NCT00136435|Drug|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
76034921|NCT00136435|Drug|asparaginase|Induction: Given into the muscle on day 5
76034922|NCT00136435|Drug|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
76034923|NCT00136435|Radiation|cranial radiation|Given in 10 daily treatments during CNS therapy phase
76034924|NCT00136435|Drug|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
76034925|NCT00136435|Drug|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
76034926|NCT00136435|Drug|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
76034927|NCT00136435|Drug|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
76034928|NCT00136435|Drug|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
76034929|NCT04857749|Other|Standard care|As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.
76034930|NCT04857749|Other|Navigation Nursing|With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
76034931|NCT05045209|Other|Virtual rehabilitation|Patient who are assigned to this group will receive virtual rehabilitation
75392378|NCT01673334|Device|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
75392379|NCT03609372|Behavioral|The STOP-HPV Trial 6: Maintenance|In this period, study team support will be withdrawn after previous bundled intervention (including HPV vaccine communication, performance feedback and provider prompts) was given to reduce MOs and increase HPV vaccination rates.
75392380|NCT05394948|Dietary Supplement|Dietary recommendations including experimental nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the experimental nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
76034932|NCT02612285|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
75392381|NCT05394948|Dietary Supplement|Dietary recommendations including control nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the control nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
75392382|NCT03504228|Device|Roadsaver|Dual layer micromesh Roadsaver carotid stent
75392383|NCT04843332|Behavioral|Community Health Worker Support|For those in the experimental group, a community health worker will provide health education and support as described in the Community Health Worker Intervention arm.
75392384|NCT01673412|Other|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
76034933|NCT02737579|Procedure|XFM guidance|X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
76034934|NCT02642185|Procedure|Microwave ablation|CT-guided percutaneous ablation of 1-5, <31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
76034935|NCT02642185|Procedure|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
75392385|NCT03153306|Drug|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
76034936|NCT02609633|Device|Accu-Chek® CONNECT DMS|SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.
76034937|NCT02609633|Device|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
76034938|NCT04053907|Other|Community Case Management|Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.
76034939|NCT04053907|Other|Weekly fever screening and treatment|Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.
76034940|NCT04053907|Other|Monthly malaria screening|CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).
76034941|NCT04053907|Other|MDA|CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
76034942|NCT04857125|Other|Patient interventions|"The multicomponent intervention consists of several elements regarding avoidance of specific pre-medications and optimising the patients condition before surgery (reducing fasting and fluid-fasting time).~Per-operative focus on using bispectral index (BIS) guided anaesthesia, Total intravenous anaesthesia (TIVA) as first choice, pain-and PONV (postoperative nausea and vomiting) prophylaxis and treatment.~Postoperative focus on: Reducing indwelling catheters, Fluid (p.o. or IV), Nutrition, Mobilisation, Sleep, Non-pharmacological interventions (Shielding, involving of relatives, orientation, optimizing of senses)"
75392386|NCT03152916|Device|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
75392387|NCT01673724|Drug|pramipexole|pramipexole
75392388|NCT01673724|Drug|Bromocriptine|bromocriptine
75392389|NCT04765098|Drug|Tamoxifen|Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
75544671|NCT01686724|Behavioral|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
75544672|NCT01686724|Other|Business As Usual|
76034943|NCT04857125|Other|Staff education|Staff will be educated for at least 1-2 hours. Anaesthesiologist and nurse anaesthetists will receive a brush up on the use of bispectral index (BIS) and the intervention elements that are implemented and monitored. Staff in the PACU, as well as staff in the surgery wards, will be educated in postoperative delirium, learning to identify symptoms of delirium and how to use the screening tool CAM.
76034944|NCT04864379|Biological|iNeo-Vac-P01|iNeo-Vac-P01: 300 mcg per peptide
76034945|NCT04864379|Other|GM-CSF|GM-CSF: 40 mcg
76034946|NCT04864379|Drug|PD-1|PD-1: 200mg administered by intravenous infusion every 2 weeks.
76034947|NCT04864379|Procedure|RFA|Radiofrequency ablation surgery
76034948|NCT04849559|Drug|Tradipitant|Tradipitant Capsule
76034949|NCT04849559|Drug|Placebo|Placebo Capsule
76034950|NCT03044561|Drug|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
76034951|NCT03044561|Drug|matching placebo|orally, 4 times per day for 21 days
76034952|NCT02494063|Procedure|Sentinel lymph node biopsy|Bilateral sentinel lymph node biopsy, pathologic ultrastaging
75392390|NCT04765098|Drug|Etoposide|etoposide 50mg/m2 daily
75392391|NCT01673880|Drug|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
75392392|NCT01673958|Other|Exercise|Comparison between stair descending and stair ascending training
75544673|NCT01686802|Drug|oral morphine|
75544674|NCT01686802|Drug|Ibuprofen|
75544675|NCT00281853|Procedure|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
76034953|NCT02494063|Procedure|At least unilateral systematic pelvic lymph node dissection|
76034954|NCT03044405|Diagnostic Test|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
76034955|NCT03044405|Diagnostic Test|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
75392393|NCT01674036|Drug|Genz-682452|Capsules for oral administration.
75392394|NCT01674036|Drug|Placebo|Placebo to Genz-682452
76034956|NCT02455141|Drug|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
76034957|NCT02455141|Drug|Taxanes|Paclitaxel: 80mg/m2, d1, qw*12 or Docetaxel: 80-100mg/m2,d1,q3w*4
76034958|NCT02455141|Drug|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w*4 Carboplatin AUC=2, d1,d8,d15, q4w*4 or Docetaxel: 75mg/m2,d1,q3w*4 plus Carboplatin AUC=5-6, d1, q3w*4
76034959|NCT03044639|Drug|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
75392395|NCT04348578|Other|QMix 2in1|In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
75392396|NCT03378102|Biological|IFN-gamma-secreting HAdV antigen specific T cells|Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
75392397|NCT01775046|Device|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
75392398|NCT03032328|Dietary Supplement|vitamin D supplement|Patients will be given a dose of vitamin D for at least 2 months
75544676|NCT01686880|Device|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
76034960|NCT04864301|Procedure|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
75544677|NCT00253721|Drug|Melphalan|"All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days"
75707763|NCT05891743|Diagnostic Test|Patch Test|The Patch Test will include the European baseline series, as well as the epoxy and isocyanate series. Additionally, specific products commonly used in the workplace, such as glues, resins, and paints, will be prepared and included in the testing.
76034961|NCT02439385|Drug|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
76034962|NCT02439385|Dietary Supplement|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
76034963|NCT04429529|Biological|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)
75707764|NCT05891470|Device|MonaLisa Touch device|sessions with intra-vaginal CO2 laster system
76034964|NCT04429529|Other|0.9% Saline|Placebo
76034965|NCT03104959|Dietary Supplement|N-acetyl cysteine|
76034966|NCT03104959|Other|placebo|
75544678|NCT01686919|Dietary Supplement|milk-free|milk-free diet during 8 preoperative weeks
75544679|NCT01686997|Procedure|Roux-en-Y Gastric Bypass|
75544680|NCT01687075|Device|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
75707765|NCT05891470|Device|Vaginal dilatators|Home use of vaginal dilatators (at least twice a week for minimum 5 minutes)
76034967|NCT04006015|Other|No intervention being delivered.|No interventions are being delivered.
76034968|NCT03044171|Device|Low Level Laser Therapy|Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
76034969|NCT03044171|Drug|1.1% Sodium Fluoride|Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
76034970|NCT03044171|Drug|In-office dental bleaching|Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
76034971|NCT03102463|Dietary Supplement|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
75392399|NCT03025464|Device|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
75392400|NCT02998164|Behavioral|augmentative and alternative communication technology|
75392401|NCT02998164|Behavioral|Usual Care|No change to the therapy care received
75392402|NCT02980692|Drug|SUNPG1623 I|injection
75392403|NCT02980692|Drug|SUNPG1623 II|injection
75392404|NCT02980692|Drug|SUNPG1623 III|injection
76034972|NCT03102463|Dietary Supplement|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
75392405|NCT02980692|Drug|SUNPG1623 IV|injection
76034973|NCT03102463|Dietary Supplement|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
75392406|NCT02980692|Drug|PLACEBO|injection
75392407|NCT04747392|Biological|SAL001|administrated once by subcutaneous injection
75544681|NCT00253760|Drug|dietary amino acids; cysteine and methionine|
75544682|NCT00281892|Biological|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
75544683|NCT00281892|Drug|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
75544684|NCT02274571|Drug|TSEC (Tissue-selective estrogen complexes)|Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
76034974|NCT03102463|Other|Lipid Load|100mL oral lipid load
76034975|NCT04863989|Procedure|tube thoracostomy|insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
76034976|NCT03102385|Behavioral|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
76034977|NCT03102385|Behavioral|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
76034978|NCT04863755|Behavioral|DASH|Patients receive DASH diet orientation and recommended to maintain their usual physical activity
76034979|NCT04863755|Behavioral|DASHPED|Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
76034980|NCT03102229|Other|Enhanced Supportive Care - Status Checks|Would occur everyday during treatment when a patient is deemed high-risk.
76034981|NCT03102229|Other|Enhanced Supportive Care - Referrals|On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
75392408|NCT04747392|Biological|FORSTEO|administrated once by subcutaneous injection
75392409|NCT03728712|Diagnostic Test|SPECT/CT|"Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation."
75392410|NCT01674192|Drug|prucalopride|single dose of 2 mg prucalopride
75392411|NCT01674270|Drug|Degarelix|
75392412|NCT01674270|Drug|Casodex|
75392413|NCT01674270|Drug|LHRH Agonist|
75392414|NCT01674348|Drug|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
75392415|NCT01674348|Drug|Placebo|Placebo
75392416|NCT01674504|Drug|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
75544685|NCT02274571|Other|Placebo|non active
75544686|NCT00253799|Device|Hylan GF-20|
75392417|NCT02431104|Device|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
75869989|NCT03662594|Other|ECMO|In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
75869990|NCT04056572|Drug|TQ-B3139|TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
76034982|NCT04108429|Behavioral|IntelliCare for College Students|Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
76034983|NCT04857515|Device|Clickotine®|Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
75392418|NCT02326116|Other|Trachael Preparation Education|
75544687|NCT01687231|Other|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
76034984|NCT04857047|Drug|BR9003 2mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
76034985|NCT04857047|Drug|BR9003A 1mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
76034986|NCT04856969|Drug|Olmesartan|First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
75392419|NCT01674582|Other|MRI, neuropsychological evaluation, blood sampling|"MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years."
75392420|NCT05353062|Procedure|Hemostatic therapy|Bipolar hemostatic forceps
75392421|NCT05353062|Procedure|Endoscopic therapy with hemoclip +/- injection of epinephrine solution|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
75544688|NCT00281931|Biological|rituximab|
75544689|NCT00281931|Drug|cyclophosphamide|
75869991|NCT04056650|Drug|L-theanine|up to 250 mg
75869992|NCT04056650|Dietary Supplement|Caffeine supplement|50-400mg
75392422|NCT03152370|Drug|E7046|oral administration
75392423|NCT03152370|Radiation|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
75392424|NCT03152370|Radiation|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
75392425|NCT03152370|Drug|capecitabine|chemotherapy
75392426|NCT03152370|Drug|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
75544690|NCT00281931|Drug|fludarabine phosphate|
75544691|NCT01687309|Drug|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
75544692|NCT01687309|Drug|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
75544693|NCT01687309|Other|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
75544694|NCT01687309|Other|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
75544695|NCT01687348|Drug|lidocaine aguettant|
75392427|NCT02187120|Drug|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
75392428|NCT02187120|Drug|Placebo|
75392429|NCT02335710|Device|Journey II BCS TKA|
75392430|NCT01674738|Drug|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
76034987|NCT04856969|Drug|Dapagliflozin|First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
75392431|NCT01674738|Drug|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
75544696|NCT01687426|Drug|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
76034988|NCT04856735|Other|Intraperİtoneal local anaesthesİc İn cesarean sectİon|After the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon area.
75869993|NCT04056650|Device|N1 app|N1 App on mobile device
76034989|NCT04856735|Other|Local wound infiltrasyon|A solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed
75869994|NCT03662438|Other|Home-based physiotherapy program|The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
76034990|NCT04856735|Other|Control group|One of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
75392432|NCT01674738|Drug|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
75392433|NCT01674972|Other|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
75392434|NCT01675206|Dietary Supplement|Vitamin K2 supplementation|
75869995|NCT03662438|Device|Prescription of a Portable Oxygen Concentrator (POC) device|Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device [Philips SimplyGo Mini] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
75392435|NCT01537458|Procedure|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
75392436|NCT03150576|Drug|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
75544697|NCT01687426|Drug|Vehicle|1 drop in each eye daily four times a day for 14 days
75707766|NCT05888727|Behavioral|"Seated Physical activity INtervention for persons with MS, SPIN program- Intervention Condition"|"The proposed exercise training program is based on Social Cognitive Theory (SCT) for promoting aerobic and strength training in wheelchair users with MS. The 16-week program includes one-on-one video chats with a behavioral coach and various tracks for progressive increases in both strength and aerobic training. The proposed strength training includes 15 exercises with step-by-step instructions using resistance bands and/or wrist weights that were adapted for seated body-position that can be executed in a wheelchair. The proposed aerobic training is arm cycle ergometry; this is a low-cost and modifiable option that fits the needs of both power and manual wheelchair users. Other proposed equipment includes a comprehensive Training Manual, fitness tracker for use during exercise training sessions, and Rate of Perceived Exertion (RPE) scale for guiding individualized exercise intensity. The research team created 12 Newsletters that align with 12 proposed coaching calls."
75869996|NCT03661658|Procedure|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
75869997|NCT03661658|Procedure|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
76034991|NCT04856501|Behavioral|PALS intervention condition|The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.
75392437|NCT03150576|Drug|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 & 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
75392438|NCT04747080|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
75392439|NCT04747080|Drug|Tacrolimus|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
75392440|NCT01675284|Biological|AT-301|Inactivated H5N1 Influenza Virion Vaccine
76034992|NCT04856501|Behavioral|Control condition|Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
76034993|NCT04856579|Procedure|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
76034994|NCT03104803|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
75392441|NCT01675362|Drug|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
75392442|NCT01675362|Drug|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
75392443|NCT01675362|Drug|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
75392444|NCT01675362|Drug|Placebo|They will receive placebo
75392445|NCT01675518|Drug|ASP7991|oral
75392446|NCT01675518|Drug|Placebo|oral
75392447|NCT03158532|Drug|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
75392448|NCT03158532|Drug|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
75392449|NCT03158532|Drug|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
75392450|NCT03158532|Drug|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
75869998|NCT03661580|Behavioral|Behavioural Activation|The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.
75392451|NCT04404738|Procedure|MicroPort® robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System
75392452|NCT04404738|Procedure|da Vinci robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
75392453|NCT03879876|Drug|Human T Lymphoid Progenitor (HTLP) injection|Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
76034995|NCT03041519|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
76034996|NCT03041519|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
76034997|NCT03938311|Other|early rehabilitation|"The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed."
75392454|NCT01675986|Drug|hydroxyzine|75 mg
75392455|NCT01675986|Drug|Pregabalin|150 mg
75392456|NCT01675986|Drug|Lactose|4 g
75392457|NCT03155490|Behavioral|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
75544698|NCT04719689|Other|Dry needling|Experimental group 1 got this intervention containing Dry needling for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus lumborum
76034998|NCT03041597|Procedure|placement of implants|surgical procedure and placement of implants
76034999|NCT03041597|Procedure|immediate loading|cone-anchored implant supported removable dental prostheses placement
76035000|NCT03041597|Procedure|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
76035001|NCT03041597|Device|Ankylos implant|
76035002|NCT04435171|Procedure|Renal transplantation|Open or robot assisted renal transplantation
75392458|NCT03150186|Other|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
75392459|NCT03150186|Other|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
75392460|NCT03150186|Other|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
75392461|NCT03875664|Drug|Liposomal bupivacaine|Extended-release local anesthetic
75392462|NCT03875664|Drug|Placebo - injection|Injectable normal saline solution
75392463|NCT01676064|Drug|ringer lactate solution|
75392464|NCT01676064|Other|restrictive fluid regime|
75392465|NCT01670136|Drug|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
76035003|NCT04856345|Other|Walking with music with synchronisation|Walking with music than one can synch to
76035004|NCT04856345|Other|Walking with music without synchronisation|Walking with music than one cannot synch to
76035005|NCT04856345|Other|walking without music|Walking without music
75392466|NCT01670214|Procedure|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
75707767|NCT05888727|Behavioral|WEllness for Longevity Living with MS (WELL)- Control Condition|The attention/contact wellness control condition will mirror the exercise training intervention condition, but focuses on implementing health behaviors other than physical activity (e.g., diet and emotional wellbeing). This program is an adapted version of the WellMS program from Prof. Motl's Phase III clinical trial (NCT03490240). The program is based on SCT principles of behavior change and integrates wellness resources from the National MS Society (NMSS). The research team has created 12 Newsletters that will be delivered on the same chat schedule as the exercise training intervention. All coaching chats and newsletters will occur with the same frequency as in the exercise training intervention condition. Participants will be provided with a participant manual, logbook, and calendar. Participants will work with their behavioral coach on goal setting specific to wellness behaviors.
75544699|NCT04719689|Other|Dry cupping|Experimental group 2 got this intervention containing Dry cupping for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum
75869999|NCT03661580|Behavioral|Treatment as Usual|The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
76035006|NCT04856267|Device|"LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)"|Implantation of an implantable cardiac monitor device (brand name LINQ device, Medtronic) will be performed under local anaesthetic using an aseptic sterile technique. They will undergo frequent follow-up and monitoring for arrhythmias through remote monitoring of the device
76035007|NCT03919045|Drug|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
76035008|NCT03919045|Procedure|Placebo|Half of the group will be treated with needle stings without injections
75392467|NCT04747002|Drug|DSP-7888|Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides
75392468|NCT03873480|Procedure|Administration of Marcaine without Epinephrine prior to the start of surgery|The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
75544700|NCT01687543|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
75544701|NCT01687543|Other|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
75544702|NCT00287898|Behavioral|Telephone Genetic Counseling|Participants will receive all genetic counseling via telephone
75707768|NCT05884580|Device|Neuflo BPH Treatment System|The Neuflo BPH Treatment System is designed to treat patients with lower urinary tract symptoms (LUTS) associated with BPH. It is an outpatient-based, minimally invasive treatment option and uses hydrolysis to reduce prostatic tissue in the lateral lobes of the prostate. Reduced pressure and constriction of the urethra alleviates urinary and other symptoms of BPH.
75870000|NCT03661502|Device|VVV|ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
75870001|NCT03661502|Device|PCV|ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
76035009|NCT04856111|Drug|Pirfenidone|Same as arm description
76035010|NCT04856111|Drug|Nintedanib|Same as arm description
76035011|NCT02053051|Device|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
76035012|NCT02053051|Drug|Novorapid|Multiple daily injections(MDI) of insulin
76035013|NCT04856423|Diagnostic Test|The us-qFIT and colonoscopy with pathological examination|Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
76035014|NCT03881683|Diagnostic Test|HRD and BRCA mutations|Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
76035015|NCT04856033|Behavioral|TM|Transcendental Meditation instruction, 12-sessions over 3-4 months with monthly follow-up
76035016|NCT04856033|Behavioral|PCT|Present Centered Therapy, 12-sessions over 3-4 months with monthly follow-up
76035017|NCT04077541|Behavioral|internet platform|The trauma care bundles combined with the internet platform.
76035018|NCT04855565|Drug|ALY688-SR|single dose subcutaneous injection
75392469|NCT03872310|Device|STARSTIM|Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
75392470|NCT04404426|Dietary Supplement|L-citrulline|Administration of citrulline enterally for 7 days.
75392471|NCT04404426|Other|Placebo|Administration of placebo (water) enterally for 7 days
75392472|NCT04764084|Drug|Niraparib|Niraparib 100mg or 200mg, PO, qd，d1-d21
75392473|NCT04764084|Drug|Anlotinib|Anlotinib 12mg, PO, qd，d1-d14
75392474|NCT03860922|Device|Magnetic Resonance Imaging|all patient will undergo Magnetic resonance imaging and magnetic imaging arthrography of the ankle joint.
75392475|NCT02984904|Other|survey|survey
75544703|NCT00287898|Behavioral|Usual Care|subjects will receive standard in-person genetic counseling
75544704|NCT01687582|Drug|GLP-1 analog|GLP-1 analog treatment
75544705|NCT01687621|Procedure|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
75544706|NCT01687660|Other|acupuncture|apply acupuncture to prevent the migraine attack
75544707|NCT01687699|Drug|Spironolactone|
75870002|NCT02989610|Device|Omnidirectional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.
75870003|NCT02989610|Device|Directional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
75870004|NCT01372774|Radiation|stereotactic radiosurgery|Undergo RT
75544708|NCT00287937|Drug|vorinostat|Given orally
75544709|NCT00287937|Drug|paclitaxel|Given IV
75870005|NCT01372774|Radiation|whole-brain radiation therapy|Undergo radiotherapy (RT)
75870006|NCT04055402|Other|Ecological momentary assessments|The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.
75870007|NCT04055402|Other|Control|Completion of a baseline questionnaire and a 1-month follow-up survey.
75870008|NCT04055480|Device|Closed-loop using standard rapid-acting insulin|Closed-loop using standard rapid-acting insulin
75392476|NCT03871530|Other|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
75392477|NCT03871530|Other|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
75392478|NCT03871530|Other|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
75870009|NCT04055480|Device|Closed-loop using faster insulin aspart|Closed-loop using faster insulin aspart
75870010|NCT03660800|Drug|CTAP101 Capsules|Calcifediol Extended-Release Capsules
76035019|NCT03864289|Behavioral|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
75392479|NCT03871530|Other|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
75544710|NCT00287937|Drug|carboplatin|Given IV
75544711|NCT00287937|Other|laboratory biomarker analysis|Correlative studies
75870011|NCT03158090|Procedure|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
75870012|NCT03158090|Drug|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
75544712|NCT00287937|Other|pharmacological study|Correlative studies
75392480|NCT03871530|Other|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
75392481|NCT03871530|Other|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
75392482|NCT03871530|Other|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
76035020|NCT04863911|Radiation|combined CT and MRI|"1 mL of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) will be diluted with 100 mL of saline; 8 mL of this will be mixed with 7 mL of iodine solution (340 mg/cc) and 3 mL of lidocaine 2% and injected under ultrasonographic guidance.~The fixed US-guided technique, the needle will be inserted into the needle guide hole and directed toward the hip joint, targeting the femoral head-neck junction. The volume injected varies from 10 to 20 mL, with a mean of 15 mL.~Ideally CT should be performed immediately after the injection and MR should be performed within 90 minutes after the initial injection."
76035021|NCT04855877|Drug|Oral tablet|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
75392483|NCT03871530|Other|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
75392484|NCT03871530|Other|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
75707769|NCT05884359|Diagnostic Test|3D Electroanatomical Mapping (NavX)|To utilize 3D mapping as a tool to explore electro-anatomical and electrocardiographic characteristics of the Left Bundle Branch Area. Patients will undergo placement of standard Left Bundle Area pacing leads for routine indications, during the implantation procedure electro-anatomical map of the target area and neighboring tissues will be created. Map characteristics will be analyzed and used intra-operatively to assist with lead placement along with standard pacing metrics and standard X-ray criteria. We plan on prospectively reviewing the data found from 3D mapping the left bundle branch implantation cases.
75392485|NCT03871530|Other|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
75392486|NCT03871530|Other|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
76035022|NCT04855877|Drug|Placebo|Oral administration of lactose tablet (placebo)
75392487|NCT03871530|Other|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
75707770|NCT05878665|Diagnostic Test|Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT|The investigators are aiming for a 10% reduction in iodine dosage at 10 kVp reduction in CT radiation. Routine iodine dosing is 0.521 g I/kg at 120 kVp. Therefore, at 90 kVp, a 30% reduction in iodine dosing is expected, which is 0.365 g I/kg. At 100 kVp, the iodine dosage is reduced to 0.417 g I/kg, which is a 20% reduction. The kVp value is automatically selected by the CT device according to the body habitus, which is a clinical routine.
75707771|NCT05871060|Dietary Supplement|Whey Protein Concentrate|Whey protein concentrate consumed 30 minutes prior to breakfast and lunch meals
75707772|NCT05871060|Dietary Supplement|Placebo|Flavoured water consumed 30 minutes prior to breakfast and lunch meals
75707773|NCT05871060|Dietary Supplement|Whey hydrolysate|Whey hydrolysate consumed 30 minutes prior to breakfast and lunch meals
76035023|NCT03102073|Diagnostic Test|Radner test|"The A5 reading booklet is held by the subject~The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~Stop criterion: reading time longer than 20 seconds or severe errors."
75392488|NCT03871530|Other|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
75392489|NCT03871530|Other|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
75392490|NCT02984826|Other|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
75392491|NCT02984826|Other|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
75392492|NCT03870048|Device|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
75392493|NCT03866538|Drug|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
75392494|NCT03861624|Procedure|Intramedullary nailing with standard SIGN nail|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the standard SIGN nail (SIGN Fracture Care International, Richland, WA). The number of interlocking screws is at the discretion of the treating surgeon, who also has the option to use an external fixator for damage control, and later conversion to IMN when clinically appropriate. The experimental group procedure is less common in the study setting, and thus, viewed as the experimental group.
75707774|NCT05866354|Drug|Tisotumab Vedotin|Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.
75392495|NCT03861624|Procedure|External Fixation with uniplanar Dispofix external fixator|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the uniplanar Dispofix external fixator with two Shanz screws placed proximally and two Schanz screws placed distally to fracture site with a single stainless steel bar.The active comparator group procedure is more common in the study setting, and thus, viewed as the comparator group.
75392496|NCT01677390|Drug|SGN-75|1-2 mg/kg IV every 21 days
75392497|NCT01677390|Drug|everolimus|10 mg PO daily
75392498|NCT03661086|Device|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
75870013|NCT03158090|Radiation|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
75870014|NCT02670538|Drug|Cariprazine|Cariprazine capsule one per day orally.
75870015|NCT02670538|Drug|Placebo|Matching placebo capsule one per day orally.
76035024|NCT03041675|Device|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
75392499|NCT03750864|Behavioral|ACT-LCS Therapy|All participants in Stage 1, and those randomized to the intervention condition in Stage 2, will receive the Acceptance & Commitment Therapy for Lung Cancer Stigma (ACT-LCS) intervention. The ACT-LC intervention is designed to be delivered as 6 sessions of individual psychotherapy with a trained psychotherapist at a weekly or bimonthly rate, delivered either in person or over the phone. The treatment manual is based in Acceptance and Commitment Therapy (ACT). Therapists are instructed to begin treatment with Module 1. Modules 2-5 can then be administered in any order at the discretion of the therapist, based upon what the therapist thinks is most likely to be helpful to the patient. Module 6 is the final session of treatment.
75707775|NCT05865457|Device|BUFY02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
75707776|NCT05865457|Device|TRB02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
75707777|NCT05865405|Behavioral|MS CATCH|Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
75707778|NCT05865379|Device|BUFY01 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
75707779|NCT05865379|Device|SVS20 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
75707780|NCT05863442|Drug|Soliris 300 MG in 30 ML Injection|Active Comparator
75707781|NCT05863442|Drug|TUR03 300 MG in 30 ML Injection|Investigational medicinal Product, eculizumab - Turgut
75707782|NCT05858541|Behavioral|Music Listening|The LUCID AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener
75870016|NCT03131414|Other|Diet|Dietary intake
75870017|NCT03131414|Other|Gastrointestinal microbiome|Genomic sequencing of stool for gut bacteria
75870018|NCT03114592|Other|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
76035025|NCT03041675|Device|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
76035026|NCT04849247|Drug|68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI|PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
75870019|NCT03547583|Drug|Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
75870020|NCT03547583|Drug|Placebo|Placebo and sham up-titration at weeks 2, 4, and 6
75392500|NCT03749070|Dietary Supplement|Silymarin|It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
75707783|NCT05858541|Behavioral|Listening to Audiobooks|A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
75707784|NCT05858112|Diagnostic Test|SuperTROPO novel assay to measure the long forms of cTnT|SuperTROPO novel assay to measure the long forms of cTnT
75707785|NCT05855746|Drug|Colchicine Pill|"Participant receive, in addition to standard of care therapy, six months of colchicine (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization. The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF < 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.~During the six months of the treatment administration, in case of severe adverse reaction (such as nausea and/or diarrhea during five days), a dose reduction could be considered by the investigator: half of the study protocol dose could be accepted (0.5 mg per day in the morning). In case of remaining adverse reactions, the study drug should be stopped."
76035027|NCT02845453|Drug|Quetiapine|Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
76035028|NCT02845453|Other|Placebo|Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
76035029|NCT01799629|Drug|Glycerin suppositories|
76035030|NCT04849403|Procedure|CTSP|In all patients Carter Thomasson Suture Passer (CTSP) were used for closing fascial defect peroperatively
75392501|NCT03748602|Procedure|Thoracic outlet decompression|TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
76035031|NCT04848701|Other|latent phase duration|latent phase duration in post term pregnancies
76035032|NCT04848701|Other|uterocervical angle (UCA)|uterocervical angle is the angle between lower segment of uterus and cervix
76035033|NCT04428827|Procedure|Unilateral adrenalectomy in patients with unilateral disease|Unilateral adrenalectomy in patients with unilateral disease
76035034|NCT03041129|Diagnostic Test|oral glucose tolerance test|6 hours OGTT
76035035|NCT03041129|Diagnostic Test|MRI of liver|MRI of the liver and use of DIXON method
75707786|NCT05855746|Drug|Placebo|"Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF < 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision."
75392502|NCT01345656|Drug|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
75392503|NCT01345656|Drug|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
75707787|NCT05855447|Other|NIRS device usage during 6MWT|It will be performed by placing a traffic cone as the sign of the turning point in a straight 30 meter long corridor, after patients have rested for a sufficient time (> 30 minutes) by sitting in a chair. Participants will be asked to walk as fast as possible but without running along the corridor within 6 minutes. Before and after the test, the patient's fatigue and dyspnea conditions will be questioned using the Modified Borg Scale and blood pressure using a digital sphygmomanometer, and saturation and pulse measurement will be evaluated using finger pulse oximetry before, during and after the test. During the 6-minute walk test, the muscle oxygenation of the patients and the amount of muscle oxygen will be measured using Moxy (Fortiori Design LLC, Minnesota, USA) brand NIRS technology. During the walking test, the change in intramuscular oxygenation will be monitored and recorded with the company's software program.
75707788|NCT05855447|Other|Peripheral Muscle Strength Measurement|The muscle strength of shoulder flexors, abductors, elbow flexors, hip flexors, abductors, and knee extensors will be evaluated using a Lafayette® 01165 model electronic hand dynamometer. The force measurement will be repeated 3 times and it will be requested to maintain muscle strength against the dynamometer for at least 5 seconds in each trial. The best value out of 3 test results will be recorded
75707789|NCT05855447|Other|Pulmonary Function Test|Pulmonary Function Test (PFT) with desktop type spirometry for FVC (Forced Vital Capacity), Forced expiratory flow rate (FEV1), FEV1/FVC.
75870021|NCT04040296|Other|Kidney Action Team Recommendations|Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 30 minutes of AKI development. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
75870022|NCT02391298|Behavioral|Mindfulness Meditation|
76035036|NCT01597375|Drug|Placebo Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
76035037|NCT01597375|Drug|Prasugrel Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
76035038|NCT03044093|Drug|Mifepristone|The group that will get in addition to Misoprostol also Mifepristone
75870023|NCT02391532|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
75870024|NCT02391532|Dietary Supplement|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
76035039|NCT03044093|Drug|Placebo|The group that will only get Misoprostol
76035040|NCT03044093|Drug|Misoprostol|Both groups will get think drug
76035041|NCT04848545|Other|Observational|Prenatal maternal exposure to endocrine disrupting chemicals
76035042|NCT01553071|Drug|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
76035043|NCT03044327|Procedure|LPS challenge|LPS inhalation and bronchial instillation
76035044|NCT01506973|Drug|Hydroxychloroquine (HCQ)|
76035045|NCT01506973|Drug|Gemcitabine|
75392504|NCT01345656|Drug|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
75392505|NCT01345656|Drug|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
75392506|NCT01345656|Drug|Placebo|Placebo tablets for duration of 4 weeks
75392507|NCT01345656|Drug|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
75392508|NCT03744624|Procedure|Laparoscopic liver resection|Laparoscopic liver resection for oncological purposes
75392509|NCT03744624|Device|3D printing model|Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
75392510|NCT03743064|Drug|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
76035046|NCT01506973|Drug|Abraxane|
76035047|NCT03041207|Behavioral|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
75544713|NCT01687855|Device|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
76035048|NCT04848467|Biological|SARS-CoV-2 mRNA Vaccine (CVnCoV)|Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
76035049|NCT04848467|Biological|Quadrivalent influenza vaccine (QIV)|One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
76035050|NCT04848467|Other|Placebo|One intramuscular injection as normal saline [0.9% NaCl].
76035051|NCT03102307|Other|Not suitable for TAD|Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done
75392511|NCT03743064|Drug|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
75392512|NCT01196832|Procedure|blood sample|blood sample for fibrocytes analysis
75392513|NCT01196832|Procedure|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
76035052|NCT03102307|Procedure|Suitable for TAD|Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
76035053|NCT02527161|Device|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
76035054|NCT04848311|Procedure|lymph nodes dissection at 253 station assisted by ICG|In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
75392514|NCT03737916|Other|5 cc 5% Dextrose solution|Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
75392515|NCT03737916|Other|5 cc salin|Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
75707790|NCT05850884|Diagnostic Test|stool examination|Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
76035055|NCT05431231|Diagnostic Test|Outcome Questionnaire-45|a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
75392516|NCT04763460|Device|Programming of CRT device settings|Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.
75392517|NCT04763616|Drug|Isatuximab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
75392518|NCT04763616|Drug|Cemiplimab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
75392519|NCT04747158|Biological|Convalescent plasma|COVID-19 convalescent plasma at admission, after confirmation of eligibility, 200 ml on day 1 and 2
75707791|NCT05845307|Drug|Control Group|Given by PO
75392520|NCT03652974|Drug|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
75707792|NCT05845307|Drug|TTI-101|Given by PO
76035056|NCT05431231|Diagnostic Test|Hopkins symptoms checklist - short form|a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
75392521|NCT03652974|Device|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
75392522|NCT03652974|Drug|amisulpride with Clozapine|amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
76035057|NCT05431231|Diagnostic Test|Prodromal Questionnaire - Brief Version|a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
75392523|NCT03652974|Drug|placebo with Clozapine|placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
75392524|NCT03650244|Device|REMEEX implantation|Device implantation
75392525|NCT03649152|Drug|Propagermanium|Immediate release capsule
75392526|NCT03649152|Drug|Placebo|Placebo capsule
75544714|NCT00253838|Procedure|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
75544715|NCT00253838|Procedure|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
75707793|NCT05845073|Dietary Supplement|Probiotic|Participants in this arm will receive a daily dose of 2x10^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules twice daily, for the duration of antibiotic therapy, and 14 days thereafter.
75392527|NCT02082288|Other|Edessy ICSI Outcome Embryo Score|"EIOS:~Age (ys) >35 (0) 30-35 (1) <30 (2) No of retrived oocyte <5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos <2 (0) 2-4 (1) >4 (2) No of good quality embryos <3 (0) 3-5 (1) >5 (2) No of embryos transferred -------- (0) ≤2 (1) >2 (2)"
75392528|NCT03646188|Drug|Placebo-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
75392529|NCT03646188|Drug|25 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
75392530|NCT03646188|Drug|50 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
75392531|NCT03646188|Drug|100 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
75392532|NCT03646188|Drug|200 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
75392533|NCT03849456|Drug|GWP42006|Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
75392534|NCT03645720|Device|Plastic cannula|puncture using plastic cannula
75392535|NCT03645096|Drug|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
75392536|NCT03645096|Drug|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
75392537|NCT03645096|Drug|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
75544716|NCT01687894|Drug|Vasopressins|Vasopressins propofol vasopressins sevoflurane
75544717|NCT01687894|Drug|Placebo|Placebo propofol & placebo sevoflurane
75392538|NCT03734172|Diagnostic Test|Sample collection|Specimen collection
76035058|NCT05431231|Diagnostic Test|Manchester Short Assessment of Quality|a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
75392539|NCT03732300|Other|ASSIP|Three PSychotherapy Sessions plus after 3/6/9/12 months individualized letters
75392540|NCT04762524|Other|CVVH vs CVVHD|Patients are initiated on CRRT in either the CVVH or CVVHD modality
75392541|NCT03642678|Dietary Supplement|ONS|High-risk patients identified by prediction model in study group are intervened by pre-defined intervention protocol, which include oral nutrition supply, infection prevention, bp control and improving of dialysis therapy options and so on.
76035059|NCT05431231|Diagnostic Test|Self-Stigma of Mental Illness Scale|a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
76035060|NCT05431231|Diagnostic Test|Session Alliance Inventory - for patient|this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
76035061|NCT05431231|Other|Quality of service/satisfaction questionnaire|measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
75707794|NCT05845073|Dietary Supplement|Placebo|Participants in this arm will receive an equivalent placebo for for the duration of antibiotic therapy, and 14 day thereafter.
75392542|NCT03642210|Combination Product|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system
75392543|NCT03844386|Biological|MVA.tHIVconsv3|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
75392544|NCT03844386|Biological|MVA.tHIVconsv4|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
75392545|NCT03844386|Other|Placebo|The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
75392546|NCT02082678|Drug|Ondansetron|Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
75392547|NCT02082678|Drug|Placebo|Inactive ingredient matching the active medication in appearance
75392548|NCT03836430|Behavioral|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
75392549|NCT04403958|Procedure|PRC|Total wrist arthrodesis with dorsal plate using proximal row of the wrist as bone graft
75392550|NCT04403958|Procedure|TWA|Total wrist arthrodesis with dorsal plate using iliac crest as bone graft
75392551|NCT04763850|Other|Decline Walking with real-time Feedback|Participants are walking decline with self-paced speed on an instrumented treadmill with virtual reality projection under three conditions: without instruction, with instruction for an internal focus of attention and with real-time feedback of their frontal knee alignment
75544718|NCT01687894|Drug|propofol|vasopressin propofol & placebo propofol
75707795|NCT05838404|Behavioral|M-O-M-S on the Bayou|Peer and mentor support and meetings across pregnancy
75707796|NCT05838170|Drug|Lotilaner Gel, 2.0%|Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).
75707797|NCT05838170|Other|Vehicle control gel|Aqueous gel
75707798|NCT05837325|Procedure|Oocyte Pick Up - Out of Study|Aspiration of follicles. search for the oocyte(s) All oocytes are grouped in one dish.
75707799|NCT05837325|Procedure|Denudation - Out of Study|All oocytes are denuded together. Maturational stages are recorded.
75707800|NCT05837325|Procedure|ICSI|One oocyte injected at a time.
75707801|NCT05837325|Procedure|Culture|One embryo per culture drop. Individual follow-up of the embryo development.
76035062|NCT05431231|Diagnostic Test|Clinical decision-making style|a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, & Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
76035063|NCT05431231|Diagnostic Test|Global Assessment of Functioning Scale|a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, & Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
75707802|NCT05837325|Genetic|Biopsy|One embryo per culture drop.
75707803|NCT05837325|Procedure|Vitrification|One embryo per vitrification straw.
75707804|NCT05837325|Procedure|OPU - Study Group|Measure the size of the follicle and aspirate only one follicle and flush. The needle before moving to the second ovary. Oocyte included in the study will be cultured separately (each ovary separately too).
75544719|NCT01687894|Drug|sevoflurane|vasopressins sevoflurane placebo sevoflurane
76035064|NCT05431231|Diagnostic Test|Session Alliance Inventory - for therapist|a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, & Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
76035065|NCT03040583|Other|No intervention|Patients data will be collected during their disease follow-up
76035066|NCT03104335|Drug|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
76035067|NCT04863365|Drug|Placebo ophthalmic solution|A matching placebo ophthalmic solution, 3 drops daily, 28 days
76035068|NCT04863365|Drug|PHP-201 ophthalmic solution|PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
76035069|NCT04847765|Device|VIPUN Gastric Monitoring System prototype|"The VIPUN Balloon Catheter prototype is a nasogastric feeding tube with integrated balloon that can be inflated with a preset volume of air. Intraballoon pressure changes are recorded outside the body. Gastric contractions can be detected in the pressure profile.~The recording lasts 30 minutes and is combined with simultaneous cine magnetic resonance imaging."
76035070|NCT03104179|Device|Cytosorb Adsorber|Cytokine adsorption during CPB
75392552|NCT03624114|Procedure|comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery|A comparison of MRI with CT of the skull base or paranasal sinuses and intraoperative Video documentation of the anatomical site will be used.
75392553|NCT01677468|Procedure|Intermediate embolization|TACE with substasis using gelfoam
75544720|NCT00287976|Drug|irinotecan hydrochloride|
75544721|NCT01687933|Device|three-dimensional glasses(manufactor Vuzix,wrap 920)|The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.
75544722|NCT01687933|Other|usual care|Women in Control group did not use the glasses.
76035071|NCT04855175|Device|Synthetic Bone Allograft (ClearFit)|Patients in this arm will receive ClearFit (synthetic bone allograft)
76035072|NCT04855175|Other|Autograft|Patients in this arm will use patient's own bone
75392554|NCT01677468|Procedure|Complete embolization|TACE with complete embolization using gelfoam
75392555|NCT00003816|Biological|anti-thymocyte globulin|Given IV
75392556|NCT00003816|Drug|busulfan|Given IV
75392557|NCT00003816|Drug|carboplatin|Given IV
75392558|NCT00003816|Drug|cyclophosphamide|Given IV
75544723|NCT01688089|Drug|ODM103|
75544724|NCT01688089|Drug|Placebo|
75544725|NCT01688089|Drug|Entacapone|
75544726|NCT01688089|Drug|Levodopa/carbidopa|
75392559|NCT00003816|Drug|etoposide|Given IV
75392560|NCT00003816|Drug|fludarabine phosphate|Given IV
75544727|NCT00253877|Other|Complication rate|All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
75544728|NCT01688128|Device|Phase I U-SMART (4 wks)|Intervention_Control Group, 4-weeks U-SMART(2 session/week); Control_Intervention Group, no intervention
75392561|NCT00003816|Drug|melphalan|Given IV
75392562|NCT00003816|Drug|thiotepa|Given IV
76035073|NCT05430997|Device|IOB Warming Unit (WU505) + Inflatable Warming Blanket|The inflatable warming method (Inflatable Warming Unit (IOB Warming Unit, WU505) + Inflatable Warming Blanket (IOB Warming Blanket)) is a common clinical warming technique in anesthesiology, which is well tolerated by patients and safe and effective. The anesthesiology department has established standard operating procedures for the above-mentioned non-invasive operations.
75392563|NCT00003816|Radiation|total-body irradiation|Given twice daily for 3 days
75392564|NCT03618654|Drug|Metformin|Given PO
75392565|NCT03618654|Biological|Durvalumab|Given IV
76035074|NCT05430997|Device|cover with a quilt from the neck to both feet|The patient was covered with a quilt from the neck to both feet after entering the operating room.
76035075|NCT05376423|Biological|OBI-833/OBI-821|OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.
76035076|NCT00484471|Drug|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
75392566|NCT03617874|Other|PC4PrEP- Intervention Clinics|PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.
75392567|NCT03617874|Other|Standard of Care Clinics|The standard of care model is the model approved by the health system for their health care clinics.
75392568|NCT03614910|Device|Nanoknife Irreversible Electroporation|Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor
75392569|NCT03718104|Other|Pharmacokinetic analysis|Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
75392570|NCT03718104|Other|Safety and Efficacy|Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).
75544729|NCT01688128|Other|Washout (2 wks)|2-weeks wash out period in both arms
75392571|NCT03718104|Genetic|Genetic and epigenetic analysis|Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.
75392572|NCT03718104|Other|Breast milk analysis|Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
75392573|NCT03714750|Procedure|DK crush|revascularization of true coronary bifurcation stenosis in DK crush technique
75544730|NCT01688128|Device|Phase II U-SMART (4 wks)|Intervention_Control Group, no intervention; Control_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
75544731|NCT01688206|Biological|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
75544732|NCT01688206|Biological|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram [mg] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
75707805|NCT05837325|Procedure|Denudation - Study Group|Oocyte included in the study will be denuded separately. Maturational stages are recorded per follicle.
76035077|NCT00484471|Drug|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
75392574|NCT03714750|Procedure|Reverse TAP|revascularization of true coronary bifurcation stenosis in Reverse TAP technique
76035078|NCT00484471|Drug|placebo|placebo to aripiprazole, 22 weeks
76035079|NCT03041051|Biological|PCV13|
76035080|NCT03041051|Biological|PPV23|
75392575|NCT01677078|Device|Neuronavigation system|Neuronavigation
75392576|NCT01677078|Device|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
75707806|NCT05836064|Device|GastroBot|An artificial intelligence-developed and WhatsApp-based software bot. It will send the instructions to the patient through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results.
75392577|NCT04763070|Drug|Ciprofloxacin Oral Product|The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
75392578|NCT04763694|Device|Multifocal soft contact lenses|Myopic subjects wore multifocal soft contact lenses for 12 months
75392579|NCT04762914|Other|Prehabilitation|Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
75544733|NCT01688245|Behavioral|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
75544734|NCT01688245|Behavioral|SMS Assessments|Weekly post-weekend drinking outcome assessments
75544735|NCT01688284|Device|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
75707807|NCT05836064|Other|Conventional explanation|Patients will receive in writing detailed explanation about bowel preparation with polyethylene glycol
75707808|NCT05835375|Other|EQ-778|"capsule daily after breakfast (in case of no URTI episode);~capsules after breakfast (in case of URTI episode)"
76035081|NCT03835273|Other|3D motion capture system|Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
76035082|NCT03835273|Other|Incentive spirometry|Incentive spirometry is a non-invasive device for assessment of pulmonary function.
75392580|NCT03828318|Other|Patient Activation Booklet and nursing support for patients with LARS|The LARS Patient-Centered Program will consist of an educational booklet and nursing support made available only to patients randomized to the intervention group.
75392581|NCT03609060|Drug|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
75392582|NCT03706794|Behavioral|Clinical Decision Support Tool|Tailored education provided via a smartphone application.
75392583|NCT03706794|Behavioral|Headache Education|Non-tailored education provided via a smartphone application.
75392584|NCT03705234|Drug|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
75392585|NCT03705234|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
75392586|NCT03704766|Diagnostic Test|Synovial Alpha-defensin assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
76035083|NCT03835273|Other|Questionnaires|Two validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and one non-validated satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system [7,8]
76035084|NCT03103945|Device|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
76035085|NCT05591547|Radiation|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
76035086|NCT04847999|Dietary Supplement|Dark chocolate|Dark chocolate
76035087|NCT05430841|Diagnostic Test|18F-FDG, 18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
75392587|NCT03704766|Diagnostic Test|Synovial Neutrophil elastase assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
75392588|NCT03704766|Diagnostic Test|Synovial lactate assay|Synovial Fluid (joint fluid) will be sent out to CD Diagnostics for this test.
75392589|NCT03704766|Diagnostic Test|Synovial C-reactive Protein (CRP)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
75392590|NCT03704766|Diagnostic Test|Synovial Staphylococcus spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
75392591|NCT03704766|Diagnostic Test|Synovial Candida spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
75392592|NCT03704766|Diagnostic Test|Synovial Enterococcus faecalis assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
75392593|NCT03704766|Diagnostic Test|Synovial bacterial culture by BacT/Alert|The synovial fluid (joint fluid) sent to CD Diagnostics for testing will also be cultured to see if any organisms grow.
75392594|NCT03704766|Diagnostic Test|Synovial Cell count + differential (CBC)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
75544736|NCT01688323|Other|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
76035088|NCT05375721|Procedure|ST36 acupoint injection|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
76035089|NCT04863053|Other|Blood samples will be taken to assess platelet function. There is no change in treatment.|
75707809|NCT05835375|Other|Placebo|"capsule daily after breakfast (in case of no URTI episode);~capsules after breakfast (in case of URTI episode)"
76035090|NCT03104101|Combination Product|TPTNS+Drug|one tablet Trospium Chloride 20 mg once daily Plus TPTNS
76035091|NCT03104101|Device|TPTNS|Surface adhesive electrodes placed on the skin above medial malleolus
75392595|NCT03704766|Diagnostic Test|Synovial Gram Stain|This will be performed by CD Diagnostics if any organisms are present in the synovial fluid.
75392596|NCT03704766|Diagnostic Test|Synovial Leukocyte Esterase Test Strips|These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.
75392597|NCT03704766|Diagnostic Test|Synovial PCR for Kingella kingae|In participants < 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.
75392598|NCT03704766|Diagnostic Test|Serum Cell count + differential (CBC)|A blood test performed at the hospital.
75392599|NCT03704766|Diagnostic Test|Serum erythrocyte sedimentation rate (ESR)|A blood test performed at the hospital.
76035092|NCT05400525|Dietary Supplement|YMETA|1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)
76035093|NCT05400525|Other|Placebo control|3g Maltodextrin (i.e. DE 10) daily
75392600|NCT03704766|Diagnostic Test|Serum C-reactive Protein (CRP)|A blood test performed at the hospital.
75392601|NCT03704766|Diagnostic Test|Serum D-dimer|A blood test performed at the hospital.
75392602|NCT03704766|Diagnostic Test|Serum Procalcitonin|A blood test performed at the hospital.
75392603|NCT03704766|Diagnostic Test|Blood Cultures|Blood will be cultured at the hospital to see if any organisms grow.
75392604|NCT03704766|Diagnostic Test|Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )|In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.
75392605|NCT03826992|Drug|Vyxeos|Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
75392606|NCT03826992|Drug|Venetoclax|"Venetoclax Dose:~Dose Level 0 - weight based daily dosing for 21 days~Dose Level -1 - weight based daily dosing for 14 days~Dose Level -2- weight based daily dosing for 10 days~Dose Level -3- weight based daily dosing for 7 days"
75392607|NCT00004092|Biological|filgrastim|Given IV or subcutaneously
75392608|NCT00004092|Drug|carboplatin|Given IV
75392609|NCT00004092|Drug|cyclophosphamide|Given IV
76035094|NCT03104023|Procedure|Staple line inversion|A staple line inversion will be performed with a running suture of Polypropylene 2/0
76035095|NCT03104023|Combination Product|Staple line buttressing|The gastric section will be performed with a stapler with preloaded buttress material
76035096|NCT04847687|Drug|methylprednisolone|Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
75392610|NCT00004092|Drug|doxorubicin hydrochloride|Given IV
75392611|NCT00004092|Drug|paclitaxel|Given IV
75707810|NCT05830578|Device|ASUS Blood Pressure Monitor/Oximeter/ECG Monitor|"The ASUS Blood Pressure Monitor/Oximeter/ECG Monitor analyzes data collected by the integrated electrical sensors on a ASUS Vivowatch to generate an ECG waveform similar to a Lead I, calculate average heart rate, and provide a rhythm classification to the user for a given 30 second session. When a user opens the ECG App while wearing the ASUS VivoWatch on one wrist and places the finger of the opposite hand on the digital crown, they are completing the circuit across the heart which begins a recording session.~Once the recording session is complete, the ECG App performs signal processing, feature extraction and rhythm classification to generate a session result."
75392612|NCT00004092|Drug|thiotepa|Given IV
75392613|NCT00004092|Procedure|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
75392614|NCT00004146|Radiation|radiation therapy|Undergo radiotherapy
75392615|NCT00004146|Drug|carboxyamidotriazole|Given orally
76035097|NCT05430685|Dietary Supplement|Ashwagandha|Intervention and placebo group each received a bottle of 60 capsules. Subjects were instructed to take one capsule in the morning and 1 capsule in the evening. Intervention group was getting 350 mg ashwagandha root extract per capsule (or 700 mg per day). Each intervention capsule delivered 2.5 mg withanolides with equivalence of 2,700 mg dry herb.
76035098|NCT05430685|Other|Placebo|The Placebo group received the same type of bottle with similar looking capsules. Each person in the placebo group was instructed to take 1 capsule twice a day (2 capsules total). Capsules were filled with glycerin to the same weight as ashwagandha. Capsules were indistinguishable from each other.
76035099|NCT01729455|Biological|BENLYSTA|"As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
75392616|NCT00004146|Other|pharmacological study|Correlative studies
75392617|NCT00004500|Drug|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
75544737|NCT00288093|Radiation|3-Dimensional Conformal Radiation Therapy|
75544738|NCT00288093|Drug|Triapine|
76035100|NCT01729455|Other|SLE treatment|"As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
75707811|NCT05830526|Other|Escape Room|"The next day, 56 students, who agreed to participate in the study, were divided into groups of 5, and they had to fill out a 10-question test, which includes the stages of the ERAS Protocol preoperative period, within the scope of the pre-test. A simulation room for students has been set up as an escape room. At the briefing on the theme of the escape room, it was explained that they would have 10 minutes to complete six missions using the clues given to them.~The 6 stations created in the room were numerically numbered from 1 to 6. There were question/answer cards at each station and a clue on the back of the correct answer card to reach the next station. The first clue was given by the observer who made the information in the information room.The student who could not get out of the room within 10 minutes was considered as unable to leave the escape room."
76035101|NCT04854473|Device|Exero Medical Leak Detection System|"the Exero Leak Detection System components used in this study are:~Smart drain - a surgical drain with added sensing electrodes~Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes."
76035102|NCT03101839|Drug|AZD4785|KRAS Antisense Oligonucleotide
76035103|NCT04428983|Dietary Supplement|Hericium erinaceus mycelium|Hericium erinaceus capsules 3 tables per day for 24 months
76035104|NCT03103867|Device|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
76035105|NCT03103867|Device|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
76035106|NCT04847375|Drug|exogenous surfactant|Nebulized Surfactant would be administered by face mask which has a nebulizer
76035107|NCT03103711|Behavioral|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
76035108|NCT03044015|Behavioral|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
76035109|NCT03044015|Behavioral|as usual|
76035110|NCT05430607|Behavioral|Running therapy|A 9-week running program.
76035111|NCT04847219|Device|Professional flash glucose mornitoring|Subjects will use Professional flash glucose mornitoring once a month for 3 months.
76035112|NCT04847219|Device|Personal flash glucose mornitoring|Subjects will use Personal flash glucose mornitoring once a month for 3 months.
76035113|NCT03799861|Other|Epoch 2: HBB with NeoBeat|At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.
76035114|NCT03799861|Other|Epoch 3: HR-guided HBB|At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
75544739|NCT04525339|Procedure|TAVI and Off pump CABG|Concomitant Transcatheter aortic valve implanatation and off pump coronary artery bypass grafting
76035115|NCT04847297|Procedure|Preoperative drainage and pancreatoduodenectomy|Preoperative biliary drainage before surgical removal of the tumor
76035116|NCT04847297|Procedure|Pancreatoduodenectomy|Pancreatic tumor resection without previous preoperative biliary drainage
76035117|NCT04737343|Drug|Leflunomide|Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months
75544740|NCT00288132|Behavioral|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
75544741|NCT00288132|Behavioral|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
75544742|NCT04519840|Other|nill|nill
75544743|NCT04519372|Diagnostic Test|Testing for SARS-CoV-2|All Patients admitted to the hospital were routinely tested for SARS-CoV-2 within 72 hours of admission by nasopharyngeal swabs.
75544744|NCT00253916|Behavioral|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
75544745|NCT00253916|Behavioral|Resistance Exercise Program|Resistance Exercise Program
75544746|NCT00288171|Drug|Placebo|placebo capsule twice daily for one month
75392618|NCT00004500|Other|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
75392619|NCT03606330|Diagnostic Test|Cardiac imaging tests|"2D transthoracic echocardiography~128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~Shear stress evaluation via computational fluid dynamics.~Intracoronary imaging techniques: IVUS and OCT."
75392620|NCT03606330|Diagnostic Test|Venous blood sample collection|Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
75392621|NCT03605628|Other|measuring tape|measurement of change in abdominal wall length [cm] during neuromuscular block with a measuring tape.
75544747|NCT00288171|Drug|Allopurinol|Allopurinol 200mg twice daily for one month
75544748|NCT00253955|Drug|Levofloxacin|
75544749|NCT00253955|Drug|Piperacillin/Tazobactam|
75544750|NCT00288210|Procedure|Primary angioplasty in acute myocardial infarction|
75870025|NCT03114202|Other|intensive nutritional counseling|Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.
75870026|NCT03114202|Other|Standard care|Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
75870027|NCT02391610|Other|No intervention|
75544751|NCT00253994|Procedure|Acupuncture|
75544752|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
75544753|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
75544754|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
75544755|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
75544756|NCT00254033|Drug|Dextroamphetamine|
75544757|NCT00254033|Drug|Methylphenidate|
75544758|NCT01600573|Drug|pazopanib in combination with weekly topotecan|"Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
75544759|NCT01600612|Drug|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
75544760|NCT01600612|Drug|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
75544761|NCT01600612|Drug|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
75544762|NCT01600651|Other|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
75544763|NCT01600651|Other|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
75544764|NCT00288288|Procedure|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
75544765|NCT00288288|Procedure|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
75544766|NCT00254111|Device|Ultra Probe Laser System|
75870028|NCT03727763|Drug|Vemurafenib|960mg po bid
76035118|NCT04737343|Drug|Azathioprine Tablets|Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
75870029|NCT03727763|Drug|Cetuximab|500mg/m2 iv gtt (14 days per course)
75870030|NCT02391220|Other|LCA symbiotic fermented milk|LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
75707812|NCT05827952|Behavioral|behavior modification-Atomic Habit by hybrid|Atomic Habits (20-minute audiobook format), a role structure, and a game structure, online schedule reminders more than twice a week, and individual counseling sessions (online and physical) with one to two total interventions. The content of the online schedule reminders consisted of a total of four concepts for each of the four major habits, and a total of 16 sessions of the online audiobook interventions were adapted for the caregivers' relationship-building habits with the children.
76035119|NCT04480723|Other|Blood Sample|Blood samples will be taken and analyzed to evaluate the presence of PH.
75392622|NCT03605628|Other|neuromuscular block|Measurement of the time course of the neuromuscular block: neuromuscular transmission is measured by assessment of the post tetanic count and the train of four ratio using acceleromyography (TOF Watch SX™, Essex Pharma GmbH, Munich, Germany) at the right adductor pollicis muscle with transcutaneous Ag/AgCl electrodes (electrocardiogram electrodes; Ambu Inc., MD 21060 USA);
75392623|NCT03605628|Other|Surgical rating score|"assessment of operating conditions by means of a standardized score: surgical rating score:~extremely poor conditions~poor conditions~acceptable conditions~good conditions~optimal conditions"
75392624|NCT03701724|Device|Systematic maintenance rTMS|Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
75544767|NCT01600690|Other|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
75392625|NCT03701724|Device|rTMS course in case of relapse|Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
75392626|NCT03701724|Device|sham rTMS|The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
75544768|NCT01600768|Drug|Beta-Lactams|infusion time: 30 mins or 1 hr
75544769|NCT01600768|Drug|Beta-Lactams|infusion time 4 hrs
75544770|NCT00288327|Behavioral|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
75544771|NCT00288327|Behavioral|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
75544772|NCT04467112|Device|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
75707813|NCT05827068|Biological|mRNA-1011.1|Sterile liquid for injection
75707814|NCT05827068|Biological|mRNA-1011.2|Sterile liquid for injection
75707815|NCT05827068|Biological|mRNA-1012.1|Sterile liquid for injection
75707816|NCT05827068|Biological|mRNA-1010|Sterile liquid for injection
75707817|NCT05827068|Biological|mRNA-1010.2|Sterile liquid for injection
75707818|NCT05827068|Biological|mRNA-1010.3|Sterile liquid for injection
76035120|NCT04480723|Diagnostic Test|Cardiac MRI|Cardiac MRI will be performed to evaluate the presence of PH.
75707819|NCT05825261|Other|voice sampling|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
76035121|NCT04862819|Drug|new local drug delivery|In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
76035122|NCT04862819|Procedure|scaling root planing|In the second group, on one side of the dental arch srp will be performed
75544773|NCT00414947|Drug|Vildagliptin (LAF237)|
75544774|NCT04465747|Other|Publications|Reviewing published evidence
75544775|NCT04464772|Device|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
75707820|NCT05825261|Other|capnometry|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
75707821|NCT05822557|Other|Bolus Pouch Feed|Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management
75870031|NCT02391220|Other|heat-treated fermented milk|heat-treated fermented milk without probiotic cultures and dietary fibres
75870032|NCT03724565|Procedure|Method of endoscopic procedure|Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
75870033|NCT02670382|Dietary Supplement|EPA|10 week supplementation
75544776|NCT00288405|Device|Cordis Self Expanding Stent|
75544777|NCT04462744|Other|educational program|an oral health educational program regarding the emergency management of traumatic dental injuries.
75544778|NCT00414986|Behavioral|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
75544779|NCT00414986|Behavioral|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
75870034|NCT02670382|Dietary Supplement|DHA|10 week supplementation
75870035|NCT02670382|Dietary Supplement|sunflower oil|4-week lead-in
75870036|NCT01310621|Drug|Bovine surfactant|"Dose of diluted surfactant : 20ml/kg~Type :Bovine surfactant~Phospholipid concentration: 5 mg/ml~Number of lavages to be given: 2 (10ml/kg each)"
75870037|NCT02991482|Drug|Pembrolizumab|Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
75870038|NCT02991482|Drug|Gemcitabine|"Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide)."
76035123|NCT03776149|Dietary Supplement|Beetroot juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
75392627|NCT00745992|Other|Blood drawn (lab data)|"Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
75707822|NCT05822128|Other|Test of an alternative Epworth Sleepiness Scale ESS-ALT in French|Seniors recruited into the study will test the Epworth Alternate Sleepiness Scale -ALT
75707823|NCT05821933|Drug|RC108|RC108 plus Furmonertinib and/or Toripalimab
75392629|NCT03825198|Procedure|Erector spinae plane block|Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
75392630|NCT03825198|Drug|Levobupivacaine 0,25%|20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
75392631|NCT03825198|Procedure|spine fusion|fusion of lumbar vertebral body on 1 or two levels
75392632|NCT03825198|Drug|NaCL 0,9%|20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
75392633|NCT03825198|Drug|Sufentanil|opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
75544780|NCT00414986|Behavioral|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
75544781|NCT00288444|Drug|Lonafarnib|
76035124|NCT03776149|Dietary Supplement|Black currant juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
76035125|NCT04854239|Procedure|Half-guided implant placement|The surgery was performed under local anaesthesia in both groups, half-guided implant placement was carried out based on randomization.
76035126|NCT05578911|Other|"medical students group"|medical student in general practice or in specialty medicine
76035127|NCT02724631|Device|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
75544782|NCT00288444|Drug|Docetaxel|
75544783|NCT04460716|Procedure|Major noncardiac surgery|Vascular, thoracic, visceral, orthopedic, gynecologic, urologic, ENT, maxillo-facial, plastic and reconstructive surgery
75707824|NCT05819853|Drug|Wegovy Injectable Product|10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
75707825|NCT05819853|Drug|Metformin and Wegovy|Participants already on Metformin as part of their clinical care, and still having irregular periods will be enrolled in the Metformin and Semaglutide arm. Semaglutide will be added in addition to the Metformin they are currently taking. 10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
76035128|NCT03760783|Other|Parabolic flight|Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
76035129|NCT03754231|Other|Heart rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
75392634|NCT03825198|Drug|propofol|induction agent for general anaesthesia ( 2-3 mg/kg)
75392635|NCT03825198|Drug|Rocuronium Bromide|muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
75707826|NCT05819541|Drug|Montelukast Oral Granules|Oral montelukast granules, USP powder, or crushed tablets at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.
75707827|NCT05819541|Drug|Albuterol|Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
75392636|NCT03825198|Drug|sevoflurane|inhalation aesthetic used for the maintenance of general anaesthesia
75392637|NCT03825198|Drug|paracetamol|postoperative drug for analgesia ( 1 gram 4/day)
75392638|NCT03825198|Drug|Ketorolac|non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
75392639|NCT03825198|Drug|morphine pca|postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
75392640|NCT03825198|Drug|Dexamethasone|drug given during general anaesthesia to prevent postoperative nausea
75392641|NCT03825198|Drug|Morphine|loading dose morhine 0,1 mg/kg at the end of surgery
75392642|NCT03596658|Drug|SHR9549|If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
75392643|NCT03690648|Other|Quality of life survey|Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
75392644|NCT03690648|Genetic|Saliva collection|Collection of 20 ml of saliva with a kit of saliva collection
75392645|NCT03690648|Genetic|Blood collection|Collection of 20 ml of blood with kit of blood collection
75392646|NCT01677156|Diagnostic Test|CORUS CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
75544784|NCT00415025|Procedure|adjuvant therapy|
75544785|NCT00415025|Procedure|management of therapy complications|
75544786|NCT00415025|Procedure|quality-of-life assessment|
75544787|NCT00415025|Radiation|intensity-modulated radiation therapy|
75544788|NCT04460404|Behavioral|Lifestyle consultation|"Collect relevant data of patients included in the study through outpatient consultation, telephone follow-up, questionnaire follow-up, etc., including:~Basic information~Digestive tract symptoms:~A constipation-related symptoms B abnormal symptoms~Fecal traits~Lifestyle habits~Others"
75392647|NCT03689166|Dietary Supplement|Probiotic|Reduce preterm birth with this dietary supplement
75707828|NCT05819541|Drug|Corticosteroid|Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
75392648|NCT03689166|Other|Placebo|Placebo
75392649|NCT03684408|Device|RFID Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
75392650|NCT03684408|Device|Wire Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
75392651|NCT03684408|Device|RFID and Wire Localization|Both RFID and the standard of care wire localization will be performed for physician training.
75392652|NCT03817320|Drug|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
75707829|NCT05819359|Drug|BIA 28-6156 10 mg|BIA 28-6156 10 mg, once daily, oral administration.
75707830|NCT05819359|Drug|BIA 28-6156 60 mg|BIA 28-6156 60 mg, once daily, oral administration.
76035130|NCT03754231|Other|Respiratory rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
75392653|NCT03817320|Drug|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and < 1 year: 1.2mg/m2/dose~< 6 months: 1mg/m2/dose"
75544789|NCT04459819|Other|Respiratory physiotherapy|"Respiratory physiotherapy consists of:~early mobilization (passive and active mobilization, muscle-strengthening exercises, mobilization out of bed, standing, walking, ADL)~patients positioning~non-invasive mechanical ventilation / CPAP~tracheostomy management~invasive mechanical ventilation weaning~airway clearance~oxygen titration"
75707831|NCT05819359|Drug|Placebo|Placebo, once daily, oral administration.
75707832|NCT05818332|Other|Observational study|No intervention, observational only
75392654|NCT03817320|Drug|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and < 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
75392655|NCT03817320|Drug|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and < 1 year: 2,000 IU/m2/dose~< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~1 year: 25,000 IU/m2/dose~6 months and < 1 year: 20,000 IU/m2/dose~< 6 months: 17,500 IU/m2/dose"
75392656|NCT03817320|Drug|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and < 1 year: 48 mg/m2/dose~< 6 months: 42mg/m2/dose"
75392657|NCT03817320|Drug|Methotrexate (IT)|For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
75392658|NCT03817320|Drug|Triple IT (Methotrexate, Hydrocortisone, Cytarabine)|For patients with CNS 3, on Days 1, 8, 15, 22, and 29
75392659|NCT03817320|Drug|Leucovorin|For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
75392660|NCT03681366|Device|DISC3.5 plus|The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
75707833|NCT05817825|Behavioral|Smart IOP Intervention|Smart IOP is a remotely delivered IOP program in operation since 2016, allowing patients to complete addiction treatment entirely online. The original program, consisting of 72 video modules across 8 different topics, will be adapted and tailored to hospitalized patients with serious infections from injection drug use. Participants will watch video content asynchronously, and will be required to correctly answer knowledge questions to proceed to the next module. The whole treatment program will require approximately 4 weeks to complete. Participants are also asked to answer questions about how to apply the knowledge to their own personal circumstances. The answers to these are reviewed by the peer recovery coach during weekly encounters. Videos can be viewed at a time that is most convenient to the participants. T
75707834|NCT05817825|Behavioral|Peer Recovery Coach|Peer recovery coach, an individual in sustained recovery (>5 years) and certified to be a coach, will meet weekly with the participant to review progress, answer questions about the videos, review answers to questions, and encourage continuation of treatment after discharge. These meetings will occur in-person or remotely.
76035131|NCT05400213|Device|Vallos|Demineralized freeze-dried bone allograft (DFBA) in a small particle form
75392661|NCT03593226|Drug|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
75392662|NCT03591354|Device|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology & Dexcom G6 CGM for 3 months.
75392663|NCT03591354|Device|t:slim X2 with Basal-IQ & Dexcom G6 CGM|Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
75392664|NCT03582852|Procedure|Surgical treatment of genital prolapse|Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
75392665|NCT00006156|Other|Control|No injection of FSH
75544790|NCT00417573|Drug|IV Gamunex 10%|
75544791|NCT00415064|Drug|Perifosine|Perifosine given in either 50 mg or 100 mg / day
75544792|NCT00415064|Drug|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
75544793|NCT00415064|Drug|Dexamethasone|Dexamethasone given in 20 mg / day
76035132|NCT05400213|Device|Vallomix|A combination of cow-derived xenograft and human-derived DFDBA particulate
76035133|NCT05400213|Device|Vallos-F|Demineralized freeze-dried bone allograft (DFDBA) in a fiber form
75707835|NCT05815264|Biological|23-valent pneumococcal polysaccharide vaccine|This vaccine（0.5ml） is produced by Ab&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.
75870039|NCT02991482|Drug|Vinorelbine|Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
75392666|NCT00006156|Drug|Drug: FSH|FSH Stimulation Test
75392667|NCT03677778|Procedure|Normal saline injected via interscalene nerve catheter|With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (30cc 0.9% NS) via their interscalene nerve block catheter.
75392668|NCT03677778|Other|Placebo|With the catheter covered, placebo group patients will go through the same steps as the treatment group, but no solution will be injected into the interscalene nerve block catheter.
75707836|NCT05815264|Biological|pneumococcal vaccine polyvalent|This vaccine（0.5ml） is produced by Merck Sharp & Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
75707837|NCT05813834|Procedure|Genicular Nerves Block|US guided genicular nerves block
75707838|NCT05812963|Diagnostic Test|IVUS-guided PCI group|In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
75870040|NCT04743466|Other|Electronic Health Record Review|Biobank records are reviewed
75392669|NCT03810534|Behavioral|Connect-Home|Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
75392670|NCT05347836|Diagnostic Test|ELISA|Determination of serum levels of sCD14 and sCD163 using ELISA
75392671|NCT05347758|Drug|HRS-7535|Drug: HRS-7535
75392672|NCT05347758|Drug|Placebo|Drug: Placebo
75707839|NCT05812963|Diagnostic Test|FFR-guided PCI group|In FFR-guided PCI group, FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis >90%, we will judge FFR value of ≤0.80.
75707840|NCT05808413|Behavioral|Informational Video|This video emphasizes that vaccination against COVID-19 continues to be important, highlights the importance of seeking accurate information, and provides statistics about the estimated number of lives saved by vaccination and reported adverse events following vaccination in Canada.
75707841|NCT05808413|Behavioral|Altruistic Video|This video presents a vignette about a young adult woman who has many social interactions during her daily life. It shows that her decision to stay up-to-date on COVID-19 vaccination could help to protect those people she comes into contact with, who may be at greater risk from COVID-19 infection. Statistics are used to show that up to one-in-four people in Canada have underlying conditions that make them more vulnerable to COVID-19, and to quantify the number of surgeries that were delayed by pandemic-related disruptions.
75707842|NCT05808413|Behavioral|Individualistic Video|This video presents a vignette about a young adult man who is very health-conscious. He is unsure about staying up-to-date on COVID-19 vaccination until he learns that COVID-19 infection can have serious and disruptive consequences even if someone is younger. Statistics are used to quantify the increased risk of severe symptoms in young adults who are not up-to-date on vaccination.
75707843|NCT05807841|Procedure|percutaneous coronary intervention|IVUS-guided stent implantation
76035134|NCT05400213|Device|Vallomix-F|A combination of cow-derived xenograft and human-derived DFDBA fibers
75707844|NCT05803694|Device|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
75392673|NCT05347680|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
75707845|NCT05792475|Diagnostic Test|Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software|TaiHao Breast Cancer Diagnostic Software independently define standard of truth (SOT) about108 cases.
75392674|NCT05347680|Device|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
75707846|NCT05788458|Drug|Bupivacain|"The blocks will be performed in supine position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) will be initially placed in a transverse plane over the anterior superior iliac spine (ASIS) and then alignes to identify the following landmarks: Anterior inferior iliac spine, ilio-pubic eminence, iliopsoas muscle and tendon, the femoral artery, and Pectineus muscle. Point of injection will be musculo-fascial plane between the psoas tendon and ilio-pubic eminence."
76035135|NCT02609399|Drug|Oseltamivir|Oral
75392675|NCT03580434|Device|V-STRUT|Minimally invasive implantation of V-STRUT
75392676|NCT03580356|Biological|Ligelizumab|Liquid in vial
75392677|NCT03580356|Biological|Omalizumab|Lyophilized powder for solution in vial
75392678|NCT03580356|Other|Placebo|Liquid in vial
75392679|NCT06125938|Procedure|tent pole technique|The screw tent-pole method is an effective technique to achieve initial reconstruction of alveolar bone deficiencies
75392680|NCT06125938|Procedure|Autogenous bone block technique|Bone block graft has been the gold standard for restoring deficient regions.
75392681|NCT06125912|Other|Dime Beauty TBT Cream|Test product contains: Water, Ammonium Acryloyldimethyltaurate/VP Copolymer, Behenyl Alcohol, Dimethicone, Caprylic/Capric Tiglyceride, Cetearyl Alcohol, Dimethicone Crosspolymer, Glycerin, Glyceryl Stearate, Pentylene Glycol, 1,2-Hexanediol, Isododecane, Linoleic Acid, Caprylic/Capric/Succinic Triglyceride, Octadecene, Olea Europaea (Olive) Oil Unsaponifiables, Orobanche Rapum Extract, Phospholipids, Phytosterols, Polyglyceryl-6 Behenate, Polyglyceryl-6 Stearate, Propanediol, Pyrus Malus (Apple) Fruit Extract, Caprylic/Capric/Myristic/Stearic Triglyceride, Stearyl Dimethicone, Hydroxyacetophenone, Bakuchiol, Cetyl Ricinoleate, Tetrasodium Glutamate Diacetate, Tocopherol, Xanthan Gum.
75392682|NCT06125912|Other|Positive Control|Water, Glycerin, Caprylic/Capric Triglyceride, Helianthus Annuus (Sunflower) Seed Oil, Pentylene Glycol, 1,2-Hexanediol, Cetearyl, Alcohol, Glyceryl Stearate, PEG-100 Stearate, Dimethicone, Hydroxyacetophenone, Sodium Ascorbate, Tocopherol, Carbomer, Xanthan Gum, Retinol, PEG-40 Hydrogenated Castor Oil.
75392683|NCT06125899|Behavioral|emhGAP-Age|"Adapted emhGAP-IG;~Adapted Problem-Solving Therapy (PST-PC)~Support/supervision of lay providers~Links to social support resources."
75707847|NCT05788237|Biological|RSVpreF+qIRV|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
76035136|NCT02609399|Drug|Peramivir|"IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician."
76035137|NCT05430217|Drug|Buspirone|1 tablet (15 mg) once per day for 28 days
75392684|NCT06125886|Diagnostic Test|transvaginal ultrasound and microscale endometrial sampling biopsy|Transvaginal ultrasound and endometrial micro tissue pathology examination are used concurrently for endometrial cancer screening in high-risk populations. The specificity, sensitivity, and optimal combination of the two screening methods are clarified, and a cost-effectiveness analysis is conducted on different screening strategy.
75544794|NCT04456465|Other|Pain diabetic peripheral neuropathy|Neuropathic pain is the focus of current clinical research, clinical identification, and treatment. It is unique from nociceptive pain and requires evaluation of the relevance and utility of common pain measures created for other painful conditions.
75544795|NCT04455685|Other|anonymised data collection|The population of the present study corresponds to a sample of previous market research. Data from participants from the five main regions of Brazil (North, Northeast, Midwest, South, Southeast) will be selected at random and according to the sample size calculation.
75707848|NCT05788237|Biological|qIRV|Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
75707849|NCT05788237|Biological|RSVpreF|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B
75707850|NCT05788237|Drug|Placebo|0.9% saline for injection
76035138|NCT05430217|Drug|Placebo|1 placebo tablet once per day for 28 days
76035139|NCT05430061|Dietary Supplement|slowly digestible carbohydrate|carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
76035140|NCT04853927|Drug|Proxalutamide|Proxalutamide 300mg q.d suspension
76035141|NCT04853927|Drug|Placebo|Proxalutamide 300mg q.d placebo
76035142|NCT03103555|Drug|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
75392685|NCT06125873|Drug|Metformin|Moringa + Metformin - Moringa 1 gm and Metformin 500 mg
75392686|NCT06125860|Dietary Supplement|Targeted BEP based on baseline nutritional status|In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.
76035143|NCT03103555|Drug|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
75544796|NCT04455217|Other|data collection from patients with FAI (occuring January 2000 until December 2019)|data collection from patient files (data regarding surgery, adverse events, infections, demographic data)
75544797|NCT00415103|Drug|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
75707851|NCT05788237|Biological|RSVpreF + qIRV 1.0 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection
75707852|NCT05788237|Biological|RSVpreF + qIRV 0.5 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
75707853|NCT05779761|Behavioral|Online, Self-Directed Attention Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
75870041|NCT03660644|Behavioral|WhatsApp, Pedometer and Step Diary|"Participants will be provided with a daily step diary and added to a group chat on WhatsApp. The group chat will be populated by other members of pulmonary rehabilitation programme (cluster) and the WhatsApp group leader will encourage participants to keep active. Participants will be encouraged to record the number of steps walked in a paper diary at the end of each day (i.e. prior to bedtime). This diary will simply have three columns: day of the week; number of steps; comments (optional).~The intervention will last 52 weeks."
75870042|NCT02674750|Drug|CUDC-907|
76035144|NCT04846751|Behavioral|TYPE OF EXERCISE (OR REST)|continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
75392687|NCT06125860|Dietary Supplement|Targeted BEP based on baseline nutritional status and monthly GWG monitoring|In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.
75544798|NCT00415103|Drug|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
75544799|NCT00415103|Drug|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
75544800|NCT00417690|Drug|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
75392688|NCT06125860|Dietary Supplement|Universal BEP|In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.
75392689|NCT06125847|Genetic|NGGT006|Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).
75392690|NCT06125834|Drug|Trastuzumab Emtansine (T-DM1)|Enrolled patients will receive Trastuzumab Emtansine (T-DM1) treatment (3.6mg/kg, d1/21, IVD) until progressive diseases or intolerable adverse effects occurs.
75392691|NCT06125808|Drug|HRO350|Active substance phospholipid esters from herring roe oil (PEHeRo)
75392692|NCT06125808|Drug|Placebo|Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.
75544801|NCT00417690|Drug|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
75544802|NCT04454320|Other|INTUSSUSCEPTION IN CHILDREN|the seasonal variation and management outcomes of childhood intussusception.
75544803|NCT04453540|Diagnostic Test|FilmArray PCR on respiratory samples|Molecular test performed on respiratory samples realized for microbiological routine testing as part of the care
75870043|NCT03998566|Device|TraceIT Tissue Spacer implantation|The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
75544804|NCT00254150|Procedure|Increase oxygen extraction rate|
75544805|NCT04452994|Drug|JNJ-68284528|JNJ-68284528 will be administered as a single intravenous (IV). The target dose will be the recommended Phase 2 dose (RP2D) of 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg) (range: 0.5 to 1.0*10^6 CAR-positive viable T cells/kg).
75544806|NCT00417729|Drug|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
75544807|NCT00254189|Drug|Levonorgestrel|
75544808|NCT00254189|Drug|Ethinyl Estradiol|
76035145|NCT05417685|Device|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
75544809|NCT01600807|Drug|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
75544810|NCT01600807|Drug|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
75544811|NCT00288483|Drug|Policosanol|
75544812|NCT00254228|Device|Electrotactile sensory substitution|
75544813|NCT01600963|Drug|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
75544814|NCT01600963|Drug|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
75544815|NCT01600963|Drug|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
75544816|NCT01600963|Drug|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
75544817|NCT01606969|Drug|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
75870044|NCT02389192|Drug|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
75870045|NCT05672758|Behavioral|Sprint training|One-year cycle including specific sprint-oriented athletic training
75870046|NCT05672758|Behavioral|Endurance training|One-year cycle including specific endurance-oriented athletic training
75870047|NCT05672758|Behavioral|Recreational Training|One year of nonspecific recreational training
76035146|NCT05417685|Device|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
76035147|NCT05417685|Device|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
76035148|NCT04853771|Behavioral|progressive muscle relaxation exercise training|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
75392693|NCT06125782|Drug|Omega 3 fatty acid|Omega 3 fatty acid 1 gm softgel capsule- 1 for children at or below 25 kg and two for above 25 kg.
75392694|NCT06125782|Drug|Placebo of Omega-3 fatty acid softgel capsule|Placebo of Omega-3 fatty acid softgel capsule- colour and shape almost similar to the original drug- 1 for children at or below 25 kg and 2 for above 25 kg.
75392695|NCT06125756|Drug|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10^12 vg/kg.
75392696|NCT06125756|Drug|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10^12 vg/kg.
75392697|NCT06125756|Drug|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10^13 vg/kg.
75392698|NCT06125730|Other|DIME Beauty Eyelash Boost Serum|The test product contains Water, Glycerin, Amino Acids (Sodium PCA, Sodium Lactate, Arginine, Aspartic Acid, PCA, Glycine, Alanine, Serine, Valine, Proline, Threonine, Isoleucine, Histidine, Phenylalanine), Hyaluronic Acid, Panthenol, Aloe Leaf Extract, Niacinamide, Purslane, Chebulic Fruit Extract, Apple Fruit Extract, Tocopherol, Phenoxyethanol, Hexanediol, Ethylhexylglycerin, Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-4.
75392699|NCT06125717|Biological|H1 influenza antigen|Either 7.5 μg or 15 μg of the H1 influenza antigen
75707854|NCT05779761|Behavioral|Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
76035149|NCT02720185|Drug|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
76035150|NCT02720185|Procedure|Conventional Surgery|Undergo surgery
76035151|NCT02720185|Other|Laboratory Biomarker Analysis|Correlative studies
75707855|NCT05779761|Behavioral|Online, Self-Directed Health & Wellness Education Training with Coaching Support|The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
75707856|NCT05778279|Diagnostic Test|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
76035152|NCT04846673|Drug|Pregabalin 150mg + Alpha-lipoic acid 480mg|Pregabalin qd + alpha-lipoic acid qd
76035153|NCT04846673|Drug|Pregabalin 150mg|pregabalin qd
76035154|NCT04846673|Drug|Alpha-Lipoic Acid 480mg|alpha-lipoic acid qd
75392700|NCT06125691|Biological|ARCT-2138|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
75392701|NCT06125691|Biological|Licensed Quadrivalent Vaccine for younger adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
75392702|NCT06125691|Biological|Licensed Quadrivalent Vaccine for older adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
75392703|NCT06125652|Drug|anti Tim-3/CD123 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
76035155|NCT04846283|Procedure|Elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure|We considered all the procedures that required an intestinal anastomosis in colo-rectal surgery
75392704|NCT06125639|Behavioral|Sauna Bathing|Participants will take part in 9 evening sauna bathing session over the course of 3 weeks
75392705|NCT06125600|Other|Clustering of people living with obesity using behavioural questionnaires|In a cross-sectional analysis using the online Aviitam® platform, a cluster analysis was carried out in overweight/obese adults. The following questionnaires were studied: Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Epworth Sleepiness Scale, Morin's Insomnia Scale, Intuitive Eating Scale-2 (IES-2), Binge Eating Scale (BES), Ricci/Gagnon Physical Activity questionnaire and EQ-5D Quality-of-Life questionnaire.
75544818|NCT01606969|Drug|scalp infiltration solution|1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
76035156|NCT05398497|Device|Cryoablation|Cryoablation will be performed under ultrasound guidance.
76035157|NCT03040739|Other|use of O'ARM imaging system|use of O'ARM imaging system
75392706|NCT06125587|Drug|Chiglitazar|Chiglitazar is a novel PPAR agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
75392707|NCT06125587|Drug|Metformin|Metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome.
75392708|NCT06125561|Other|Probing depth and Clinical attachment loss|CPTIN probe will be used for the clinical examination
75392711|NCT06125496|Other|Pain management|Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP
75544819|NCT00288522|Drug|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
75544820|NCT00254267|Drug|AMG 706|AMG 706 125mg, oral, once a day
76035158|NCT04498273|Drug|Apixaban 2.5 MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
75392712|NCT06125483|Procedure|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, TBI/Flu/Bu/Mel combined with UCBT is safe and feasible for the treatment of patients with malignant hematological diseases who experienced post-transplant relapse, which has enormous potential to improve patient outcomes.
75392713|NCT06125470|Behavioral|Uptake of quality Reproductive health and Family planning products, information and Services|Strengthening capacity of health facilities and outreach to deliver quality reproductive and family planning services and address demand side barriers to the uptake of the services
75544821|NCT01601002|Drug|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
75544822|NCT00288561|Drug|ranibizumab|
75544823|NCT01607086|Drug|Cherry lamotrigine ODT|25mg, taken orally on one study visit
75707857|NCT05777720|Device|Filtration Fan|Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
75544824|NCT01607086|Drug|Cherry Placebo|Taken orally on one study visit
75544825|NCT01607125|Drug|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
75544826|NCT01607125|Drug|Placebo|capsules, orally, once daily for 13 to 14 days
75544827|NCT00288678|Procedure|Health Education|
75544828|NCT00254345|Procedure|coating a dental restoration material ,polymethylmethacrylate, with liquid polish resin|
75544829|NCT01607164|Behavioral|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
75544830|NCT01601041|Other|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
75707858|NCT05777720|Behavioral|Safe-home pamphlet|The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
75707859|NCT05777720|Behavioral|Mid-week phone call|On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
75707860|NCT05775341|Other|No Intervention|This is purely an observational study.
75707861|NCT05771922|Diagnostic Test|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
75870048|NCT02391376|Other|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
75392714|NCT06125470|Behavioral|Capacity building of facility based and community based healthcare providers (public and private sector) on FP /SRH|"Training sessions on FP / SRH including FP Methods - LARC, PPIUD - Task Sharing & Shifting for facility based healthcare providers at provincial level for Master Trainers with trickle down sessions at district level.~Training on Sayana Press, ECP, Balance Counselling Strategy and Life Skills Based Education for community-based healthcare providers including LHWs at district level."
75392715|NCT06125470|Behavioral|Adolescent Engagement|Identification of adolescent-friendly spaces through community based platforms including LHW health houses for girls and village health committees for boys with context-appropriate arrangements for LSBE and SRH counselling.
75870049|NCT02391376|Other|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
75392716|NCT06125470|Behavioral|Renovation and Refurbishment of selected healthcare facilities|Identification and improvement/ renovation of public and private healthcare facilities to strengthen the quality, provision and delivery of FP/SRH services, especially counselling, to catchment population
75392717|NCT06125470|Behavioral|Use of Data for Effective Decision-making|Improvement in data recording at the source level with reporting at existing platforms i.e. DHIS and LHW-MIS and use of this data for local decision making
75392718|NCT06125470|Behavioral|Procurement of FP/SRH medical supplies and equipment|Provision of commodities / supplies for shortest-time possible in facilities having stock-outs
75870050|NCT02391376|Other|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
75870051|NCT02391142|Drug|Lidocaine|0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
75870052|NCT02388334|Other|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).~The development of this standardized tool will also :~identify the specific support needs of the caregivers~study the links between the quality of care as perceived by the professionals, patients and caregivers~identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
75870053|NCT02391064|Behavioral|Cognitive evaluation|"Questionnaires for assessment of confounding factors~Cognitive evaluation~Walking tests and 9 Hole Peg Test"
75392719|NCT06125418|Procedure|customized healing abutment|patients will undergoes one-stage implant placement with customized healing abutments with different macrogeometry and emergence angle made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
75707862|NCT05768620|Other|CAVE|The training is designed to train spatial navigation and memory and in particular egocentric and allocentric processes
75707863|NCT05768620|Other|TAU|This is the usual care used to train visuospatial processes
75392720|NCT06125418|Procedure|standard healing abutment|patients will undergoes one-stage implant placement with standard titanium healing abutment made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
75392721|NCT06125405|Drug|Telitacicept|The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
75707864|NCT05764616|Procedure|PARASTERNAL BLOCK|After induction of general anesthesia, an ultrasound-guided Parasternal Block will be performed with 20 mL of ropivacaine 0.5 % per side.
75707865|NCT05764616|Procedure|LOCAL INFILTRATION OF DRAINAGE EXIT SITES|At the end of surgery, a local infiltration of drainage exit sites will be performed with 10 mL of ropivacaine 0.25% per side
75707866|NCT05764616|Procedure|RECTUS SHEATH BLOCK|At the end of surgery, a rectus sheath block will be performed with 10 mL of ropivacaine 0.25% per side.
75707867|NCT05764343|Other|Immediate smoking cessation support|Smoker patients with chronic airway diseases (asthma and/or COPD and/or bronchiectasis) will be evaluated for the inclusion criteria. Afterwards they will be randomized as routine support arm (as the current procedure of the care) and immediate support arm (intensive brief cessation advices following by the immediate arrangement of the appointment from the same clinic's smoking cessation service). Both arms will be followed remotely at first week and third months of the randomization regarding their quit status as well as their use of evidence based cessation treatments.
75870054|NCT02391064|Behavioral|Expanded Disability Status Scale (EDSS) score|- EDSS score
75870055|NCT02390986|Drug|LON002|Extension study to provide continuing access to LON002 medication.
75870056|NCT02987972|Biological|V114 Lot 1|Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
75392722|NCT06125392|Diagnostic Test|Coronary physiology assessment|Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and papaverin or adenosine, Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and acetylcholine.
75870057|NCT02987972|Biological|V114 Lot 2|Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
75870058|NCT02987972|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
75870059|NCT04479202|Drug|Berberine|Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.
75707868|NCT05756569|Procedure|Biospecimen Collection|Undergo collection of blood
75707869|NCT05756569|Procedure|Computed Tomography|Undergo CT
75392723|NCT06125366|Drug|BAY1747846|Single dose; IV injection.
75707870|NCT05756569|Drug|Enfortumab Vedotin|Given IV
75707871|NCT05756569|Procedure|Magnetic Resonance Imaging|Undergo MRI
75707872|NCT05756569|Biological|Pembrolizumab|Given IV
75707873|NCT05756569|Other|Questionnaire Administration|Ancillary studies
75707874|NCT05753215|Drug|Omadacycline Pill|Omadacycline will be administered 300 mg orally daily without the loading dose.
75707875|NCT05753215|Drug|Standard of Care|Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
75870060|NCT04479202|Drug|Montmorrillonite|Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
75870061|NCT02388256|Device|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
75392724|NCT06125366|Drug|Matching placebo|Single dose; IV injection.
75392725|NCT06125353|Dietary Supplement|Melatonin|Patients of the Intervention group (melatonin group) received a personalized dietary plan based on the Mediterranean Diet, together with a booklet of lifestyle guidelines (nutritional and physical activity), all generated by a Clinical Decision Support System (CDSS). Moreover, participants in the Intervention group consumed one melatonin tablet per day, containing 1 mg of melatonin, together with water for a total of three months.
75392726|NCT06125327|Drug|SC1011|Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
75870062|NCT02388256|Other|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
76035159|NCT04498273|Drug|Apixaban 5MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
75544831|NCT00254618|Drug|mesalamine|oral tablet, 30 mg mesalamine/day for 28 days
75392727|NCT06125327|Drug|Placebo comparator|Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
75544832|NCT00254618|Drug|mesalamine|oral tablet, 60 mg mesalamine/day for 28 days
75707876|NCT05751993|Behavioral|ADAPT|The intervention is testing the feasibility of a reinforcement learning tool to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (early morning, morning, midday, and evening on a daily basis), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability).
75707877|NCT05750342|Dietary Supplement|Experimental Product Caqui|Supplement extracted from persimmon
75870063|NCT02388100|Procedure|Capillary HbA1c collection|
75870064|NCT01372618|Drug|SOM 230 / Pasireotide|SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
75392728|NCT06125301|Device|MS Sherpa|MS sherpa® is a medical device, intended to support monitoring of persons with MS in order to give patients and their professional healthcare team(s) insight into the presence and progress of symptoms related to MS. MS sherpa® is a system consisting of a smartphone app for data collection and data presentation, a cloud service for data storage, analysis algorithms, and a clinician or research dashboard for user management and data visualization. The device measures the course of symptoms related to MS with respect to walking speed (average walking speed derived from the distance walked during a 2-minute walk), cognitive processing speed, number of correct answers on a smartphone variant of the symbol digit modalities test (SDMT) and patient reported outcomes, through predefined questionnaires regarding fatigue, amongst others. MS sherpa® measures changes in these parameters over time and shows these on an insights screen in the app and on the clinician dashboard.
75392729|NCT06125197|Biological|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
75392730|NCT06125197|Biological|Pembrolizumab|Pembrolizumab, a monoclonal antibody binding PD-1
76035160|NCT04498273|Drug|Aspirin|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
76035161|NCT04498273|Drug|Placebo|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
75392731|NCT06125184|Drug|Vasopressor test|Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.
75392732|NCT06125171|Drug|Tucidinostat, Apatinib|"Tucidinostat:~age≥18years, 30mg, po., biw, q4w; age≥10years，<18years，0.5mg/kg, biw, q4w~Apatinib:~BSA≥1.2m^2, 500mg, qd, q4w BSA<1.2m^2, 250mg, qd, q4w"
75392733|NCT06125158|Procedure|Conventional ankle training|The program included ankle elastic band resistance training and balance training, in which the elastic band resistance training required subjects to complete resistance training in ankle plantarflexion, dorsiflexion, inversion and eversion directions with the help of elastic bands; and the balance training required subjects to complete the movements of standing with eyes open, standing with eyes closed, and throwing and catching the ball on flat ground and BOSU ball.
75392734|NCT06125158|Procedure|Hip strength training|Hip strength training required subjects to complete resistance training in hip abduction and posterior extension, anterior step-up and lateral step-up exercises with the help of elastic bands.
75544833|NCT00254618|Drug|mesalamine|oral tablet, 90 mg mesalamine/day for 28 days
75392735|NCT06125158|Procedure|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation of the gluteus mediums and gluteus maximus muscles of the affected side was carried out using the TB6807 low-frequency therapeutic instrument (with prescription for neuromuscular electrical stimulation) manufactured by China Tangbang Science and Technology Company.
75544834|NCT00288717|Drug|Candesartan|
75544835|NCT00288717|Drug|Telmisartan|
75544836|NCT01601119|Drug|Rebif|The subjects will receive Rebif as per the current practices or as directed by the physician.
75544837|NCT01601119|Other|Other: Disease modifying therapies (DMT)|The subjects will receive other DMTs as per the current practices or as directed by the physician.
75544838|NCT01601158|Biological|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
75544839|NCT01601158|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
75707878|NCT05750342|Dietary Supplement|Control product placebo|Product with identical characteristics to the experimental product.
76035162|NCT04853615|Drug|Empagliflozin 25 MG|PAtient will receive empagliflozin 25 mg daily
75392736|NCT06125145|Behavioral|Geriatric Assessment and Promotora Coaching|In Visit 1 the community health worker/promotora will assess frailty, cognition, polypharmacy, depression, symptom burden, and social support. In Visits 2 and 3 the community health worker will deliver interpersonal communication techniques to deliver the problem solving coaching format, leverage cultural congruence with clients, and provide social support to assist in adopting healthy behaviors.
75392737|NCT06125106|Drug|Blinatumomab|Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
75707879|NCT05749055|Drug|ENX-102|Selective GABA-A alpha2,3,5 positive allosteric modulator
75707880|NCT05749055|Drug|Placebo|Placebo
75870065|NCT03304873|Drug|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
76035163|NCT04853537|Dietary Supplement|intermittent fasting diet|intermittent fasting diet to obese pregnant women >30 BMI and incidence of gestational diabetes
76035164|NCT02526693|Diagnostic Test|Pupillometer|The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.
75392738|NCT06125093|Behavioral|Incredible Years Autism Spectrum and Language Delays Parent Program (IY-ASLD®)|"The IY-ASLD® program is a weekly group-based intervention for parents of children presenting neurodevelopmental problems (ASD symptoms, communication or language difficulties). The group is formed by 6-10 parents, and it is led by a group leader and a co-therapist, trained in the model.~The intervention is manualized. It includes video modelling and emphasizes the importance of practice-based learning through role-playing. The IY-ASLD® program takes into consideration the different developmental levels of each child and pairs parents according to this variable in role-play and other one-to-one discussions. Weekly home tasks will be assigned to parents, and families will be phoned each week to encourage home-based practice.~The intervention will be conducted online. Even though the IY-ASLD® original intervention comprises 14 sessions, the online format requires 22 weekly sessions.~Fidelity to the intervention will be assessed in accordance with the regulations of the program."
75392739|NCT06125080|Drug|Utidelone|Utidelone (30 mg/m2, days 1-5, every 3 weeks)
75707881|NCT05748028|Other|Rehabilitation|All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.
75392740|NCT06125080|Drug|Tirelizumab|Tirelizumab（200mg, day1, every 3 weeks）
75870066|NCT03304873|Drug|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
75870067|NCT02669758|Drug|ALKS 3831|Tablets were administered for daily dosing
75544840|NCT01601197|Behavioral|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
75544841|NCT01601314|Drug|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
75544842|NCT01601314|Other|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
76035165|NCT04440475|Procedure|TAP block|"Tap block description:~The skin is prepped and draped in a sterile fashion for a lateral to posterior/lateral approach to the Transverse Abdominis Plane (TAP). The Anesthesiologists use ultrasound guidance for all TAP blocks and pre mix 60cc of 0.2% ropivicaine with 10mg of preservative free dexamethasone. After the plane is identified in approximately the mid axillary line, a 17g Tuohy needle is used under ultrasound guidance to enter the potential space from an anterior approach. The needle is visualized in-plane with the ultrasound probe, traversing the exterior and interior oblique muscles and penetrating through the posterior fascia of internal oblique into the transverse abdominal plane. Once the Tuohy is in place, the needle is aspirated and the plane is hydro-dissected using 0.2% Ropivicaine with 10mg of dexamethasone. The anesthesiologist will use 30ml of 0.2% Ropivicaine on each side."
76035166|NCT05573607|Dietary Supplement|Placebo|Maltodextrin tablet
75870068|NCT02987660|Procedure|Topography Guided LASIK|Corneal surgery for refractive error correction
75870069|NCT02987660|Procedure|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
75870070|NCT02987660|Device|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
75392741|NCT06125080|Drug|Bevacizumab|Bevacizumab(7.5mg/kg, day1, every 3 weeks)
75392742|NCT06125041|Drug|Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy|Eligible patients will receive the following treatment schemes: adebelizumab+carboplatin+etoposide, with one treatment cycle every three weeks. After 4-6 cycles, adebelizumab maintenance therapy combined with concurrent radiotherapy will be given, and conventional radiotherapy will be given to chest lesions (2Gy*(20-30)f), brain (3Gy*10f)/ bone (3Gy*10f)/ adrenal gland. Immunotherapy is suspended during radiotherapy for chest lesions and lymph nodes in mediastinum, and immunotherapy is given 1-2 weeks after radiotherapy. Radiotherapy for other metastatic lesions can be carried out simultaneously with immunotherapy.
75392743|NCT06125028|Drug|[68Ga]Ga-PentixaFor|[68Ga]Ga-PTF i.v. injection
75870071|NCT02987660|Device|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
75707882|NCT05748028|Other|Administration of Clinical scales|All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.
75392744|NCT06125028|Drug|[18F]Fluorodeoxyglucose|[18F]FDG i.v. injection.
75544843|NCT00254657|Drug|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
75544844|NCT00254657|Drug|Placebo|
75707883|NCT05742802|Combination Product|Tozorakimab|Participants previously randomised to Tozorakimab in one of the predecessor studies will be assigned to the same Tozorakimab dose and regimen in the PROSPERO study.
75707884|NCT05742802|Combination Product|Tozorakimab|Participants previously randomised to Tozorakimab in one of the predecessor studies will be assigned to the same Tozorakimab dose and regimen in the PROSPERO study.
76035167|NCT05573607|Dietary Supplement|Chromium|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
75544845|NCT00288756|Procedure|lv injection of contrast|
75544846|NCT01607515|Other|Impedance cardiography|noninvasive measure of cardiac index by impedance cardiography.
75544847|NCT02482753|Drug|Chidamide|30 mg, administered orally twice per week (BIW)
75707885|NCT05742802|Combination Product|Placebo|Participants previously randomised to placebo in one of the predecessor studies will be reassigned to one of the active doses of Tozorakimab or placebo in a 1:1:2 ratio.
75707886|NCT05739435|Drug|ESK-001|Oral tablet
76035168|NCT04435483|Drug|Acalabrutinib Treatment A|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
76035169|NCT04435483|Drug|Acalabrutinib Treatment B|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
76035170|NCT04435483|Drug|Acalabrutinib Treatment C|Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
75392745|NCT06125015|Diagnostic Test|Hearing Thresholds Assessments|Auditory Neuropathy Spectrum Disorder (ANSD) is a type of hearing disorder that affects the transmission of sound signals from the inner ear to the brain. In individuals with ANSD, the outer hair cells in the cochlea, which are responsible for amplifying sound, typically function properly. However, there is a disruption in the transmission of auditory information from the cochlea to the auditory nerve and then to the brain. It is characterized by a mismatch between the results of objective hearing tests, such as Auditory Brainstem Response (ABR), and subjective hearing experiences. In ABR tests, the responses of the auditory nerve to sounds may be abnormal, while the individual perceives their hearing to be better than suggested by the test results. In this study we showed ANSD patients with abnormal ABR results by using ABR, Otoacoustic Emissions, Tympanometry and behavioral test batteries.
75392746|NCT06125002|Drug|Diosmin750|The ingestion will occur orally, under monitoring by the responsible investigator.
75392747|NCT06125002|Drug|Placebo|The ingestion will occur orally, under monitoring by the responsible investigator.
75544848|NCT02482753|Drug|exemestane|25 mg, PO daily
75544849|NCT02482753|Drug|placebo|Administered orally twice per week (BIW)
75544850|NCT00254696|Drug|Extended-Spectrum-Lactamases (ESBLs)|
75707887|NCT05737940|Drug|AZD3427|The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
75707888|NCT05737940|Drug|Placebo|The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
75392748|NCT06124989|Diagnostic Test|MINERVA Machine Learning model|The MINERVA score for the prediction of the risk of relapse of acute pancreatitis in patients who did not undergo early cholecystectomy after the first episode of acute biliary pancreatitis will be grounded upon a Machine Learning model that takes into account patients' demographic, clinical, and laboratory variables that can be easily collected and recorded at index patient admission.
75392749|NCT06124976|Drug|ST-02|ST-02 drug instillation into the upper urinary tract (renal pelvis)
75392750|NCT06124963|Drug|WX390|WX390 tablet, 0.9 mg once a day
75392751|NCT06124963|Drug|Toripalimab|240 mg, Day 1, every 3 weeks
75392752|NCT06124924|Drug|SGLT2 inhibitor|a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
75392753|NCT06124911|Other|Leg Press Resistance Training (3x5)|Leg Press resistance training at 60% one-rep-max for three sets of five repetitions
75392754|NCT06124911|Other|Leg Press Resistance Training (5x5)|Leg Press resistance training at 60% one-rep-max for five sets of five repetitions
75544851|NCT00288795|Other|Massage Therapy|Therapeutic Touch
75392755|NCT06124885|Diagnostic Test|AKI risk screening using RenaFAST POCT test kits|"Based on the type and duration of drug therapy, a maximum of 5 time-point urine samples will be collected and real-time biomarker measurement will be done using the RenaFAST POCT kits. Additionally, Trefoil factor 3 (TFF3) biomarker levels will also be quantified using developed POCT kits.~Patients with all 3 biomarker (Clusterin, MCP1 and ß2MG) levels higher than the study cut-off will be identified as high-risk for AKI. The nephrology consultants within the research team will perform a medical chart and physical review (where required) of these patients, detailing potential actions to be taken in research data collection forms. No actual intervention (other than a patient review) will be performed."
75392756|NCT06124872|Other|Survey questionnaire|Household screening questionnaire Snakebite details questionnaire where a history of snakebite is reported
75392757|NCT06124872|Other|Key informant interview|Semi-structured interview with selected key informants
76035171|NCT05372445|Behavioral|Non-intensive intervention|"After an evaluation of 7 day initial food-recall, subjects will receive counseling in order to improve their dietary habits, according to the American Diabetes Association 2019 Guidelines. The goals of this intervention are (i) achieve a caloric restriction of 500 kcal from their habitual energy intake, (ii) prioritize natural, minimally processed foods with a low glycemic index and glycemic load, (iii) eat lean protein sources, both from plant and animal origin and (iv) gradual increments of fiber intake, to achieve at least the minimum recommendations for the general population.~The frequency of the follow-up appointments will be every 4 weeks, alternating between a clinical control and nutritional one. Therefore, the planned nutritional follow-up frequency will be every 2 months. In these appointments, the objective will be to achieve the mentioned energy intake reduction of 500 kcal, aiming to the nutritional goals previously mentioned, with the aid of the food-recalls."
76035172|NCT05372445|Behavioral|Intensive intervention|"People will have virtual education with food and nutrition coaching workshops, as well as weekly meetings in small groups as a support and follow-up groups. The frequency of the face-to-face follow-up appointments will be every 3 weeks.~The nutritional intervention will emphasize the consumption of mainly minimally processed food from plant origin. A vitamin b12 supplement per week will be provided. This intervention group will have 2 stages. First stage will have a duration of 3 months setting the nutritional bases going to a plant-based diet with basic considerations regarding fiber intake reducing meat consumption, and incorporating protein from vegetable sources, among other considerations. Second stage will progress to higher levels of fiber and others nutritional requeriments in order to intensify the nutritional plant-based intervention."
76035173|NCT05425849|Other|rose oil aromatherapy|Aromatherapy refers to the medicinal or therapeutic use of essential oils absorbed through the skin or the olfactory system. The positive effects of social support, such as hand-holding, on anxiety and pain have been described
76035174|NCT04846205|Diagnostic Test|systematic etiological|"Theses following tests are made as usual practice :~Ventilator polygraphy, or polysomnography between 1 month and 1 year after cryptogenic ischemic stroke.~Transoesophageal ultrasound"
75544852|NCT00288795|Other|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
75392758|NCT06124859|Other|Functional capacity tests|"Maximal effort test on cycloergometer (1st visit)~Maximal effort test, 6-minute stepper test, 6-minute walk test, 5-times sit to stand test. A minimum rest period of 15 minutes must be observed between these tests (2nd Visit)"
75392759|NCT06124846|Behavioral|CB-Abst|incentivized, biochemically verified abstinence via contingency management
75707889|NCT05736406|Combination Product|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 200 J/cm^2.
76035175|NCT03103633|Procedure|mean artery pressure|mean artery pressure declined with less than 20% of baseline
75392760|NCT06124846|Behavioral|CB-Mon|monitoring with no required abstinence
75392761|NCT06124820|Device|Deka SmartXide Touch C60 (MonaLisa Touch)|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)
75392762|NCT06124820|Device|Sham|Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
75392763|NCT06124781|Procedure|Blood sample|A blood sample (48 ml) will be collected from each patient before performing the ROAT tests. This sample will be used to perform in vitro lymphocyte proliferation test, and cytokine measurements.
75544853|NCT01607632|Behavioral|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
75544854|NCT00254735|Drug|quetiapine fumarate|
75544855|NCT00254735|Drug|SSRI/Clomipramine|
75544856|NCT00288834|Behavioral|dysphagia rehabilitation|
75707890|NCT05736406|Combination Product|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 400 J/cm^2.
76035176|NCT03103633|Procedure|bispectral index|BIS 45-60 before and after CPB; and BIS 40-45 during CPB
76035177|NCT03103633|Procedure|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
76035178|NCT03103633|Other|Controlled|receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
76035179|NCT04862039|Device|Virtual Reality (VR) devices|Virtual Reality (VR) devices. Subjects receiving the experimental treatment will be given a VR headset, headphones and wristband and the Philips wireless fetal-maternal monitoring system, after the necessary preparation of the abdominal skin.
75392764|NCT06124781|Procedure|Skin biopsies|2 skin biopsies will be performed at the inclusion: one from positive/doubtful patch test reaction and one from control patch test. In case of positive ROAT test, 2 additional biopsies will be collected: one from positive ROAT test reaction and one from control area. Molecular analysis will be performed.
75392765|NCT06124781|Procedure|ROAT test|ROAT test (repeated open application test) is a use test used to establish the clinical relevance of patch tests. Patients will be exposed to 3 solutions of increasing concentration containing the culprit allergen (nickel, limonene hydroperoxide or linalool hydroperoxide), as well as a solution containing the vehicle alone (control solution), 2 times a day for up to 21 days, in the absence of a reaction.
75870072|NCT04528069|Device|ACRYSOF® IQ PanOptix® Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.
76035180|NCT04862117|Device|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
76035181|NCT03691909|Biological|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
75392766|NCT06124768|Procedure|Percutaneous mechanical thrombectomy (PMT) by the modified approach|The modified approach includes the ipsilateral calf venous access and the contralateral femoral venous access. Through contralateral femoral venous access, a hydrophilic guide wire and a catheter will be crossover through the thrombus side to the distal calf vein. The ipsilateral calf venous access will be punctured under the guidance of ascending venography. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is >50% stenosis of the diameter of the iliac vein.
75392767|NCT06124768|Procedure|Percutaneous mechanical thrombectomy (PMT) by the traditional approach|The traditional approach will be punctured from the ipsilateral popliteal vein under ultrasound guidance. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is >50% stenosis of the diameter of the iliac vein.
75870073|NCT04528069|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
76035182|NCT04861649|Biological|fecal microbiota transplantation|"The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
75870074|NCT03661268|Other|fluid chanllenge|A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
75392768|NCT06124755|Device|Viabahn endoprosthesis group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
75392769|NCT06124755|Device|Drug-coated balloon group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
75392770|NCT06124742|Device|clear aligners|taste perception will be evaluated before and after using clear aligners.
75392771|NCT06124729|Drug|Bevacizumab Combined With PD-1 Monoclonal Antibody|Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS colorectal cancer with liver metastases
75392772|NCT06124716|Other|Enhanced COACH CDS Tool|CDS tool with features to promote high blood pressure management
75392773|NCT06124716|Other|Usual Care COACH CDS Tool|CDS tool with limited features to promote high blood pressure management
75707891|NCT05734287|Diagnostic Test|clinical, biophysical and biochemical assessment of young females with clinical hyperandrogenism|To assess clinical, biophysical and biochemical criteria of young females with clinical hyperandrogenism as a search for PCOS
75707892|NCT05732883|Drug|Dexamethasone|Dexamethasone injection
75392774|NCT06124690|Device|Catheter ablation|Pulmonary vein isolation and ablation of low voltage areas.
75392775|NCT06124664|Diagnostic Test|Radionuclide venography|With the patient in an upright position, 370 MBq of 99mTc pertechnetate is injected into one of the dorsal veins of the foot after applying a tourniquet in the area of the ankle joint. Then, with the help of a gamma camera detector, the movement of the radiopharmaceutical is monitored in the following segments: tibial (muscular-venous pump of the lower leg), popliteal, femoral and iliocaval. To study the evacuation function of the muscular-venous pump (MVP) of the leg, using an analytical computer program, areas of interest are identified in the tendon, muscle parts of the veins of the leg and the popliteal vein. The time of evacuation of the radiopharmaceutical from the MVP of the leg is estimated - the average transport time of the isotope.
75707893|NCT05732883|Drug|Normal saline|Placebo
75707894|NCT05729958|Diagnostic Test|CT scan|CT scan of the involved ankle
75707895|NCT05727735|Device|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
75392776|NCT06124664|Diagnostic Test|single-photon emission computed tomography|"SPECT of the pelvic veins with in vivo-labelled red blood cells (RBCs). For radionuclide assessment of the state of the pelvic veins, 2 ml of Perfotech solution is injected into the cubital vein for subsequent labeling of red blood cells in vivo. In 20 minutes. 370 MBq of 99mTc-pertechnetate is injected into one of the veins of the dorsum of the foot and radionuclide venoscintigraphy is performed according to the method presented above. 20 minutes after the administration of the radiopharmaceutical and the venography, SPECT of the pelvic veins is performed. Tomography of the distribution of labeled erythrocytes in the pelvic veins is carried out in a circular orbit with the gamma camera detector rotated 360°. The analysis of the obtained information is carried out using the standard ECT Protocol software package, which allows obtaining sections in 3 projections (sagittal, transversal and coronal) with a slice step of 8 mm."
75392777|NCT06124651|Procedure|Total knee replacement with cruciate retaining femoral component|To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate a metallic implants. Implants are fixed to patients' bone with bone cements. Many designs for femoral component designs are available. In the present study, two types of implants, one CR(cruciate retaining), where the posterior cruciate ligaments are retained, and one PS(Posterior cruciate substituting), where the posterior cruciate ligaments are resected, will be compared. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component design remains the same and the tibial component remains the same. Only the cruciate ligament parts are different. For this arm of intervention, CR knee will be used, so posterior cruciate will remain intact after the surgery and still function to aid in the knee stability.
75392778|NCT06124651|Procedure|Total knee replacement with cruciate substituting femoral component|"To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate metallic implants that has similar contours of a native knee. Implants are fixed to patients' bone with bone cements. This procedure will use the femoral component that sacrifice the posterior cruciate ligament and having a box area with a post, so that cam-post mechanism of implants can mimic the function of the posterior cruciate ligament. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component remains the same. The tibial component will remain the same design. Therefore, only the cruciate ligament parts will be different."
75392779|NCT06124612|Diagnostic Test|Thrombotic assessment|"GTT~The Global Thrombosis Test (GTT) (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~TEG Thromboelastography (TEG, Haemonetics Corporation, USA) is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Citrated plasma will be stored for subsequent evaluation of thrombosis and fibrinolysis markers (including but not restricted to D-dimer, PAI-1, hs-CRP, NETs)"
75392780|NCT06124599|Other|Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other
75707896|NCT05727735|Drug|Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
75707897|NCT05727189|Drug|TR-01-XRR (1)|Extended-release form
75707898|NCT05727189|Drug|TR-01-XRR (2)|Extended-release form
75707899|NCT05727189|Drug|TR-01-XRR (3)|Extended-release form
75707900|NCT05727189|Drug|TR-01-XRS|Extended-release form
76035183|NCT03040817|Procedure|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
76035184|NCT03040817|Drug|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
75707901|NCT05727189|Drug|TR-01-XR|Extended-release form
75707902|NCT05727189|Drug|TR-01-IR|Active comparator
75707903|NCT05727189|Drug|Placebo|Placebo comparator
75707904|NCT05725226|Device|Double J Stent 6Fr x 26cms|Surgery will be performed by expert Urologist.
75870075|NCT03660566|Procedure|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
76035185|NCT05416749|Drug|8MW2311|All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
75392781|NCT06124599|Other|Identification of symptoms of menstrual in control patient in the last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other...
75870076|NCT03660566|Procedure|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
75392782|NCT06124586|Procedure|percutaneous transluminal angioplasty|percutaneous transluminal angioplasty
75392783|NCT06124573|Drug|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
75392784|NCT06124560|Drug|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
75392785|NCT06124547|Drug|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
75392786|NCT06124495|Drug|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
75392787|NCT06124482|Device|Total Knee arthroplasty|The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.
75392788|NCT06124469|Diagnostic Test|US-guided fine needle aspiration (FNA)|This study enrolled consecutive patients in follow-up for DTC history who underwent US-guided fine needle aspiration (FNA) of the LNs for suspicious metastatic cervical
75707905|NCT05725226|Device|Double J Stent 4Fr x26cms|Surgery will be performed by expert Urologist.
75707906|NCT05710172|Device|Auditory Mirror Therapy|21 days, up to 3 hours per day intervention
75707907|NCT05710055|Dietary Supplement|Study product A (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
75707908|NCT05710055|Dietary Supplement|Study product B (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
75870077|NCT04526509|Drug|GSK3901961|GSK3901961 as an IV infusion.
75870078|NCT04526509|Drug|GSK3845097|GSK3845097 as an IV infusion.
75870079|NCT04526509|Drug|GSK4427296|GSK4427296 as an IV infusion.
75870080|NCT04526509|Drug|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
75870081|NCT04526509|Drug|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
75870082|NCT03660410|Other|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
75392789|NCT06124430|Other|ECOX box|For the ECOX approach, they will have the various ECOX grids and a stopwatch at their disposal in the 2 units of the emergency department. There will be around thirty evaluation grids at their disposal. Students will choose the ECOX grid corresponding to a starting situation. Once the time limit has elapsed, they must compare their answers with the grid's expectations. Each completed grid will be returned to a drawer in the box, to assess adherence to the tool and suggestions for grid modifications, as well as any comments. Students will be able to use them as many times as they wish during the course and before the service ECOS.
75392790|NCT06124417|Drug|Sertraline|The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication.
75392791|NCT06124404|Drug|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
75392792|NCT06124404|Drug|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given
75392793|NCT06124404|Drug|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
75544857|NCT01607827|Procedure|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
75392794|NCT06124365|Other|Shock wave therapy and core stability exercises|20 post-partum women with SIJP will be treated by ESWT once weekly combined with core stability exercises 3 times per week for 6 weeks.
75392795|NCT06124365|Other|core stability exercises only|20 post-partum women with SIJP will be treated by core stability exercises 3 times per week for 6 weeks.
75392796|NCT06124352|Diagnostic Test|Gross Motor Function Measurement - 66 (GMFM- 66)|GMFM-66 was performed for participants established on self-independent motion, with importance on allocations, and motion. The emphasis is to detect the grade that greatest reveals the current skills and disabilities of the child regarding motor functions. The new Gross Motor Ability Estimator (GMAE) scoring method for test-retest reliability data showed a high level of stability of the GMFM-66 over time (ICC=0.9932) that did not differ since the original GMFM 88-item test-retest reliability
75392797|NCT06124352|Diagnostic Test|Bruininks- Oseretsky Motor Proficiency|The BOT-2 are scale used to evaluate fine and gross motion skill development. It's used to classify children with movement control limitation. The test is appropriate for those aged 4 to 21 years. The interrater reliability ranging from 0.92 to 0.99 and construct validity. r = 0.78 (0.56 - 0.86) (test grades / chronological age)
75392798|NCT06124352|Diagnostic Test|the Peabody Developmental Motor Scale - Second Edition (PDMS-2|The PDMS-2 is a consistent test that evaluates a child's movement skills. It is norm-referenced and consists of three composites: Fine Motor (FM), Gross Motor (GM), and Total movement composites (TM). GM composite incorporates 151 points from four sub-tests: reflexes, stationary, locomotion, and object manipulation. A 3-point scale scored for each item, with 2 being the highest score. Definite criterion for score of 2 is given when the child achieves the item, 1 is given when the behavior is emerging but not fully met, and 0 is given when the child cannot achieve the point. The highest raw scores of the sub-tests range from 16 to 198. The test-retest reliability of PDMS-2 was found to be r = 0.85 [24, 25].
75392799|NCT06124339|Behavioral|Physical Activity|There will be three sessions a week over the course of 16 weeks.
75392800|NCT06124339|Behavioral|Cognitive Activity (VR)|There will be three sessions a week over the course of 16 weeks.
75392801|NCT06124339|Behavioral|Physical and Cognitive Activity|There will be three sessions a week over the course of 16 weeks.
75392802|NCT06124326|Dietary Supplement|Premenstrual Syndrome Supplement|Ginger, Curcumin, Organic Turmeric, Black Pepper, Magnesium, Zinc, Vitamin B6, Vitamin D.
75392803|NCT06124300|Dietary Supplement|Female Hormone Balance Supplement|The product contains: Myo-Inositol D-Chiro Inositol Folic Acid Vitamin D Vitamin B12
75544858|NCT01607827|Procedure|Polyp removal upon withdrawal only|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
75544859|NCT01607866|Procedure|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
75544860|NCT01607866|Procedure|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
75544861|NCT00288873|Drug|Ergocalciferol|
75544862|NCT00288873|Drug|Cholecalciferol|
75544863|NCT01608022|Drug|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
75707909|NCT05710055|Dietary Supplement|Study product C (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
75870083|NCT03660410|Other|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
75707910|NCT05710055|Dietary Supplement|Study product D|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
75707911|NCT05709873|Behavioral|Imagery rehearsal therapy|Therapy to reduce nightmares, delivered via videoconference sessions
75707912|NCT05709873|Behavioral|Targeted dream control|Therapy to reduce nightmares, delivered in videoconference sessions and lab session. Lab session will involve a sleep study during a daytime nap.
75707913|NCT05709288|Drug|BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
75707914|NCT05704036|Drug|Transdermal estrogen|Transdermal estradiol 0.1 mg/day, applied once weekly
75707915|NCT05704036|Drug|Progesterone|Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
75707916|NCT05703048|Drug|Esmolol Esterase|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
75870084|NCT03660332|Procedure|Infusion of a liquid meal intraduodenally|Infusion of IL-6/NaCL before a liquid meal intraduodenally
75870085|NCT03303469|Drug|FMISO|FMISO PET/CT imaging at baseline
75870086|NCT03303469|Drug|FMISO|FMISO PET/CT post TACE
75707917|NCT05703048|Drug|Dexmedetomidine|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
75707918|NCT05700721|Drug|Niraparib|Given by PO
75707919|NCT05700721|Drug|Dostarlimab|Given by IV (vein)
75707920|NCT05697848|Other|Physiotherapy combined with Pain Education|Patients with chronic low back pain receive manual therapy treatment combined with Pain Education sessions.
75707921|NCT05697848|Other|Physiotherapy|Patients with chronic low back pain receive manual therapy treatment
75870087|NCT03303469|Drug|FMISO|FMISO PET/CT post SBRT
76035186|NCT05423431|Other|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
76035187|NCT04853303|Device|Hypnosis VR|Children will be required to wear a VR gadget for hypnosis when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain. The duration is 15 minutes.
75707922|NCT05697601|Diagnostic Test|Artificial-Intelligence Based Screening Tools|Artificial-Intelligence Based Screening Tools build on machine learning models
75707923|NCT05697601|Diagnostic Test|Pathology analysis|Pathology assessment of cells and tissues from respective organs
76035188|NCT05412355|Procedure|ERAS protocol|ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
76035189|NCT04853069|Drug|Transdermal estradiol gel|Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
75707924|NCT05696938|Dietary Supplement|Wonderlab Nicotinamide Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
75707925|NCT05696938|Dietary Supplement|Ordinary Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
75707926|NCT05690464|Dietary Supplement|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
76035190|NCT04259853|Procedure|PCI|Revascularization on non culprit vessel
75707927|NCT05690464|Dietary Supplement|placebo|placebo
75707928|NCT05690243|Behavioral|Group psychotherapy delivered via video telehealth|Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.
75870088|NCT02990000|Behavioral|Scientific Match|We have developed an innovative, personalized Match System based on provider track records determined with a multidimensional outcomes tool - the Treatment Outcome Package (TOP). Specifically, patients are assigned to therapists with previously established strengths (i.e., being historically effective) in treating their primary problems (e.g., depression, anxiety).
75392804|NCT06124274|Behavioral|Protein tracer drink|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with [13 Carbon(13C)]-leucine.
75392805|NCT06124222|Procedure|Prosthetic oral rehabilitation|Prosthetic rehabilitation with fixed and/or removable prosthesis.
75392806|NCT06124209|Drug|TachoSil|TachoSil used in Vena Cava Inferior anastomosis during liver transplantation.
75392807|NCT06124170|Procedure|Preoperative pain managment|propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery
75392808|NCT06124170|Procedure|Intraoperative pain managment|Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;
75392809|NCT06124170|Procedure|Postoperative pain managment|The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡
75392810|NCT06124157|Procedure|Biospecimen Collection|Undergo blood and CSF sample collection
75392811|NCT06124157|Biological|Blinatumomab|Receive IV
75392812|NCT06124157|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75392813|NCT06124157|Drug|Calaspargase Pegol|Receive IV
75392814|NCT06124157|Drug|Cyclophosphamide|Receive IV
75544864|NCT04719494|Other|Dynamic balance walking training|Participants in the training group will walk on an elevated treadmill that will move side-to-side in a pseudorandom manner, thereby increasing the difficulty to their balance. Participants are asked to walk independently for 30-minutes per session, for 12 days over 4 weeks.
75544865|NCT01608139|Drug|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
75870089|NCT04521127|Other|Kinesio Taping|Taping will be performed on sitting position with contralateral lateral flexion and flexion of the neck, using muscle technique with I strip and stretching the head at the maximum level in order to benefit from the muscle release effect. Kinesio tape was applied directly on muscle with 0% stretching.
76035191|NCT05245279|Diagnostic Test|3 dimensional ultrasound investigation|Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.
75392815|NCT06124157|Drug|Cytarabine|Receive IV
75544866|NCT01608139|Drug|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
75392816|NCT06124157|Drug|Dasatinib|Receive PO or NG
75544867|NCT01608139|Drug|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
76035192|NCT05245279|Diagnostic Test|2 dimensional ultrasound investigation|The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
76035193|NCT04852913|Other|Bowen's Technique|The thumb of the therapist was placed on the top of the targeted muscle (upper trapezius, levator scapulae, tight pectoralis and sternocleidomastoid, longissimus capitis, splenius capitis cervical multifidus). The skin was carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb was flattened in the medial direction, when this happened the muscle would plop or 15 respond in some way. Heating pad + TENS will be given The session lasted for 20 minutes 3sessions/week for 6th week
76035194|NCT04852913|Other|Convention Physical Therapy|"Myofascial Release + Active Range of Motion Deep transverse friction was given for 10 minutes followed by myofascial stretching of muscle for 3 times, each holding for 90 seconds. Then myofascial release was given using ulnar border of both palms of the therapist.~Active range of motion exercises will be given 10 reps with 5 seconds hold. Heating pad + Transcutaneous Electrical Nerve Stimulator (TENS) will be given The session lasted for 20 minutes 3sessions/week for 6th week"
75392817|NCT06124157|Drug|Daunorubicin|Receive IV
75392818|NCT06124157|Drug|Doxorubicin|Receive IV
75392819|NCT06124157|Procedure|Echocardiography|Undergo ECHO
75392820|NCT06124157|Drug|Leucovorin|Receive PO or IV
75392821|NCT06124157|Drug|Mercaptopurine|Receive PO
75392822|NCT06124157|Drug|Methotrexate|Receive IT or IV
75392823|NCT06124157|Procedure|Multigated Acquisition Scan|Undergo MUGA
75392824|NCT06124157|Drug|Pegaspargase|Receive IV
75392825|NCT06124157|Drug|Prednisolone|Receive PO
75392826|NCT06124157|Drug|Prednisone|Receive PO
75392827|NCT06124157|Radiation|Radiation Therapy|Undergo radiation therapy
75392828|NCT06124157|Drug|Thioguanine|Receive PO
75392829|NCT06124157|Drug|Vincristine|Receive IV
75544868|NCT01607671|Drug|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
75544869|NCT00288951|Drug|Travoprost 0.004% with and without BAK|
75544870|NCT00254774|Drug|quetiapine fumarate or valproate|
75544871|NCT01608334|Drug|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
75392830|NCT06124092|Other|neurocognitive tests|Cohort study: all parents and participants will have questionnaires to complete, based on participant's age.
75392831|NCT06124079|Other|OPY interactive messaging service|3 specific versions of OPY. information. Each version will deliver the same instructions and information about pain management recommendations, and collect the same information about patient pain experience and side effects. The three versions differ in the motivational techniques interspersed throughout the OPY experience.
75392832|NCT06124079|Other|Standard care|Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
76035195|NCT05397561|Other|Turkish Translation of Physical Activity Barriers and Facilitators Scale|Participants to be included in the study will be listed under a special code (traffic code of their city of birth, date of birth and order of participation). The socio-demographic characteristics, age, gender, body weight, height and Body Mass Index (BMI) of the participants will be evaluated and recorded with a specially prepared evaluation form. All participants in the study will complete the Turkish version of the PABFS, the Physical Activity Disability Scale (PADS), the Motivation for Participation in Physical Activity Scale (MPPAS), and the International Physical Activity Questionnaire (IPAQ) at their first visit. Participants will complete the BFYPA again after 7 days.
75392833|NCT06124040|Behavioral|psychological assessment evaluation|"A prospective data collection will be performed with self-administered psychological measures, with the aim to compare two different groups of patients with cervical cancer neo diagnosis, candidates for non conservative surgery or radio-chemotherapy treatment, based on FIGO Gynecologic Oncology Committee Guidelines.~Test will be repeated at Time 0 (firs access in radiotherapy Day Hospital, or first access in hospital ward for surgery), and Time 1 (after 6 months)."
75544872|NCT01608334|Drug|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
75392834|NCT06124027|Device|Monitoring tcPCO2 and mitoPO2|Monitoring tcPCO2 using SenTec and mitoPO2 using COMET
75392835|NCT06123975|Other|Venous blood collection|Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
75544873|NCT01608373|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
76035196|NCT04846049|Other|Comprehensive Care|"Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~Care Planning with Interdisciplinary Team~Care coordination~Co-management with Primary care~Social work needs assessment~Patient-centered telehealth using phone, home telehealth, patient portal, Video~Transportation provided for all visits~Referral to Geriatric primary care clinic and mental health per Veteran need~Goals of Care and Veteran preferences conversation~Educate primary care providers about HNHR population, home and community based services, collaboration"
75544874|NCT01608373|Drug|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
75544875|NCT01608373|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
75544876|NCT01608412|Drug|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
76035197|NCT04846049|Other|Standard Care|No intervention or treatment will be provided.
75544877|NCT01608412|Drug|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
75544878|NCT00254813|Drug|Quetiapine|
75544879|NCT01608529|Device|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
75544880|NCT04718454|Device|dental attachment|This research aimed to evaluate the retentive power and wear of the smart box attachment use with tilted two implant assisted mandibular overdenture
75544881|NCT01608568|Device|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
75707929|NCT05689307|Device|SIVA-MVP|Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.
75707930|NCT05683171|Drug|Rituximab|Given by IV (vein)
75707931|NCT05683171|Drug|Lenalidomide|Given by PO
75707932|NCT05683171|Drug|Valemetostat|Given by PO
75707933|NCT05682157|Other|Paula Method of muscle exercises|12 weekly sessions of Paula Method of excercise
75707934|NCT05675579|Drug|Sacituzumab Govitecan|Given by IV (vein)
75707935|NCT05675579|Drug|Pembrolizumab|Given by IV (vein)
75707937|NCT05671991|Drug|Empagliflozin 25 mg vs Placebo|Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
75392836|NCT06123962|Procedure|Collect peripheral blood and bronchoalveolar lavage fluid|"Peripheral venous blood will be collected and stored from the study participants at a total of five time points: Day 0, Day 1, Day 2, Day 3 after admission to the ICU, and the day of ICU discharge/death. The collection will be conducted after assessing the patients' eligibility for ARDS diagnosis. Each time point will involve the collection of one tube of peripheral venous blood, totaling 5 mL per sample.~Within 24 hours after patients' admission to the ICU and meeting the assessment criteria for ARDS diagnosis, bronchoalveolar lavage fluid (BALF) will be collected and retained, totaling 10 mL."
75392837|NCT06123923|Other|no intervention|no intervention, just retrospective observation
75392838|NCT06123910|Dietary Supplement|Colostrum bovine|Colostrum bovine supplements, 25 kcal per portion, containing 0.25 g fats, 2.0 g CHO and 3 g protein. Lactose reduced.
75392839|NCT06123910|Other|Placebo|Dairy comercial product. 25 kcal per portion, 1.3 g fats, 1.95 CHO and 1.3 protein. Lactose based.
75544882|NCT01608646|Drug|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
75544883|NCT00254852|Procedure|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
75544884|NCT00254852|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
75707938|NCT05671991|Drug|Empagliflozin 10 MG|Chronic Study- Empagliflozin 10 mg for 8 weeks
75707939|NCT05656040|Biological|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
75707940|NCT05656040|Drug|Placebo|Normal saline administered subcutaneously
75707941|NCT05651282|Drug|Provera|Progesterone Challenge Test
75870090|NCT04521127|Other|Dry needling|The trigger point on the taut band will be held with the thumb and forefinger from below and above. In the needling technique, a 0.25 * 25-mm with nickel handle, disposable sterile steel acupuncture needle will be used. The needle tip will be inserted perpendicularly into the subcutaneous tissue and inserted into the muscle until the trigger point in the taut band was found. The same point will be pinned 8-10 times with fast needle movements inside and out. Then the needle tip will pulled back so that it did not come out of the skin, and the bottom, top and sides of the first entered point were also pinned. This procedure was applied to all trigger points in the trapeze muscle.
75870091|NCT03660254|Behavioral|tai chi|tai chi exercise intervention，two times a week and each time cost one hour
75870092|NCT03660176|Drug|butyrate enemas + routine management|10ml/kg volume of butyrate enemas in addition to the colonic irrigations
75870093|NCT03660176|Other|routine management|the colonic irrigations
75870094|NCT04056026|Biological|Fecal Microbiota Transplant|Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
75870095|NCT03661190|Other|Grammatical Reasoning|START measures the ability to determine the relationships among different shape combinations which are assigned to grammatical statements about them which can be either correct or incorrect. It is a measure of attention, working memory and executive control.
75870096|NCT03661190|Other|Card Pairs|A basic picture-matching task.
75392840|NCT06123884|Drug|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
75392841|NCT06123884|Drug|Cisplatin|the usage and dosage should be determined by the investigator
75392842|NCT06123884|Drug|Bevacizumab Injection|Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
75544885|NCT00254852|Procedure|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
75870097|NCT03660020|Drug|Local anesthetic|ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
75392843|NCT06123884|Drug|carboplatin|the usage and dosage should be determined by the investigator
75392844|NCT06123884|Drug|Paclitaxel for Injection|the usage and dosage should be determined by the investigator
75544886|NCT00254852|Procedure|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
75544887|NCT00254852|Procedure|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
75544888|NCT01608763|Behavioral|Check Your Drinking (CYD) personalized feedback intervention|The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
75544889|NCT01608802|Other|Palliative care|Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
75544890|NCT01608802|Other|Standard care|Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
75544891|NCT01608841|Drug|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
75707942|NCT05650008|Drug|Intrathecal local anesthesia|Administration of local anesthetic into intrathecal space to achieve surgical anesthesia
75707943|NCT05646719|Drug|Phentolamine Opthalmic Solution 0.75%|phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
75707944|NCT05646719|Other|Placebo|Vehicle for Phentolamine Ophthalmic Solution
75707945|NCT05646719|Drug|Low dose pilocarpine|Pilocarpine hydrochloride ophthalmic solution 0.4%
75707946|NCT05646719|Other|Low dose pilocarpine vehicle|Vehicle for low dose pilocarpine
75870098|NCT03660020|Drug|Hyaluronidase|hyaluronidase will be added to ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy
75544892|NCT00254930|Drug|risperidone|
75544893|NCT01608919|Other|blood tests|thromboelastogram platelet mapping
75544894|NCT00289029|Drug|Iopamidol 370 mgI/mL|
76035198|NCT03685045|Procedure|Campaign days|Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
76035199|NCT04845971|Dietary Supplement|Saisei Maf capsules|Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan
76035200|NCT05245045|Procedure|Shengtaibufen Photodynamic Therapy(STBF-PDT)|Shengtaibufen Photodynamic Therapy(STBF-PDT)
76035201|NCT05245045|Procedure|Red light|Red light
75870099|NCT03659942|Other|CAST questionnaire|the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
75392845|NCT06123819|Device|elastography|. First, strain elastography (it is based upon the fact that hard tissue is more difficulty compressed than soft tissue. SE is a technique that measures the tissue deformation generated by compression, which may be applied with a probe on the body surface for static imaging) will be performed. The elastogram image of the detected lesion, will be evaluated Using color coding ranging from blue, through green and red. All lesions will be scored on elastogram in terms of their Stiffness compared to normal parenchyma. Second, shear wave elastography (is a method to generate shear waves and measure SWV ,based on the principle of fast propagation of shear wave speed in hard tissue and slow propagation in soft tissue , the hardness of tissue is indirectly reflected by measuring shear wave speed ) , will also be calculated individually.
75392846|NCT06123754|Drug|Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection|The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.
75392847|NCT06123754|Drug|placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection|The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
75392848|NCT06123715|Drug|Vitamin C|Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.
75544895|NCT00254969|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
75870100|NCT03659864|Other|diesel exhaust particulate|aerosolised diesel exhaust particulate
75870101|NCT03659864|Other|carbon nanoparticles|aerosolised 'clean' carbon nanoparticles
75870102|NCT03659864|Other|small graphene oxide|aerosolised 'small' graphene oxide
76035202|NCT03663595|Other|Model 1|Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
75870103|NCT03659864|Other|ultrasmall graphene oxide|aerosolised 'ultrasmall' graphene oxide
76035203|NCT03663595|Other|Model 2|Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
76035204|NCT04846361|Other|Vaginal hygiene wash|vaginal hygiene wash containing Propylene Glycol, Ethylhexylglycerin, Lactic Acid, Sodium Pyrrolidone Carboxylic Acid, Alpha-Glucan Oligosaccharide, Lactococcus Ferment Lysate, Octenidine Hydrochloride plus all other ingredients in placebo wash
75870104|NCT03659864|Other|filtered air|control: filtered air
75544896|NCT02273440|Drug|BIIL 284 BS|
75544897|NCT02273440|Drug|Theophylline|
75392849|NCT06123715|Drug|Placebo|Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
75392850|NCT06123702|Behavioral|Fear extinction|Extinction of conditioned fear response
75392851|NCT06123702|Drug|Cannabidiol Cap/Tab|6 100-mg capsules
75392852|NCT06123702|Drug|Placebo|6 placebo capsules
76035205|NCT04846361|Other|placebo wash|placebo wash containing water, disodium cocoamphodiacetate, sodium chloride, sodium glycolate, acrylates copolymer, potassium laureate phosphate, tripotassium phosphate, laurel glucoside, lauramidopropyl hydroxysultaine, disulfonate de sodium, Polyethylene glycol (PEG)-120 Methyl Glucose Trioleate, Propanediol, Glycol distearate, Laureth-4, Cocamidopropyl betaine, Potassium Lactate, Caprylyl Glycol, Disodium ethylenediaminetetraacetic acid (EDTA), Potassium Hydroxide, and Perfume
76035206|NCT04429373|Procedure|Implant installation with PRF membrane|Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation
75392853|NCT06123676|Device|Y90-PET-CT scan|40 min extra PET-CT scan - no extra injection of radiotracer. We image the Y90-microspheres administered to these patients during the therapy
75544898|NCT02273440|Drug|Placebo|
75544899|NCT01588678|Drug|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
75707947|NCT05644522|Device|Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)|The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
76035207|NCT04429373|Procedure|Implant installation without PRF membrane|Implant installation contralateral to the experimental side without PRF membrane
76035208|NCT05371977|Procedure|Trabeculectomy|trabeculectomy glaucoma surgery
76035209|NCT05371977|Procedure|Deep Sclerectomy|deep sclerectomy glaucoma surgery
76035210|NCT05244811|Drug|Combined Oral Contraceptive|effect of cocs in treatment of ovarian cysts
76035211|NCT05244811|Drug|Progestin|effect of progestin in treatment of ovarian cystn
76035212|NCT04845659|Drug|Doptelet Pill|40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
75392854|NCT06123650|Device|Repetitve transcranial magnetic stimulation|"The Magstim Rapid2 magnetic stimulator system (Model P/N 3576-23-09, Magstim Company, Whitland, UK) was used to deliver rTMS electrical currents via a figure of 8 coil applied to the scalp against the targeted contralesional motor  Hot spot , at a depth of approximately 1 cm . The inhibitory rTMS will be applied to the intact cerebral hemisphere at 1 Hz with a train of 1200 for 5 consecutive days."
75392855|NCT06123650|Device|Sham transcranial magnetic stimulation|Repetitive TMS via a sham Magstim coil (identical appearance and noise, but no active stimulation). Identical stimulation schedules as patients in study group.
75392856|NCT06123637|Behavioral|Analgesia nociception index-guided anesthesia|Maintaining the blood pressure based on analgesia nociception index of >50 value
75392857|NCT06123637|Behavioral|Standard anesthesia|Maintaining the blood pressure based on anesthesiologist's decision
75392858|NCT06123624|Drug|Desflurane Inhalation Solution|Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration
75392859|NCT06123624|Drug|Sevoflurane Inhalation Solution|Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration
75392860|NCT06123585|Other|Invisalign® SmileView™|Pretreatment smiles were captured using the Invisalign® SmileView™ to simulate their new smiles before treatment was started.
75392861|NCT06123585|Other|Invisalign aligners|Patients were then treated using upper and lower Invisalign aligners with average treatment time of 12±3 months.
75707948|NCT05642442|Drug|Placebo|Matching placebo capsule(s) administered every day (QD) orally. Titration may proceed at a rate of 1 matching placebo capsule per day every 7 days as required for optimal efficacy and tolerability up to a maximum number of 3 matching placebo capsules per day.
75392862|NCT06123364|Drug|mirabegron 50 mg daily|Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
75707949|NCT05642442|Drug|Suvecaltamide|Suvecaltamide capsule administered every day (QD) orally. Titration may proceed at a rate of 10 mg suvecaltamide per day every 7 days as required for optimal efficacy and tolerability up to a maximum dose of 30 mg suvecaltamide per day.
75870105|NCT04055714|Device|Balloon dilation of the Eustachian tubes|Use the Aera Balloon through the nose to dilate the Eustachian tubes
75392863|NCT06123364|Device|Extracorporeal magnetic innervation (active treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive sham stimulation.
75392864|NCT06123364|Device|Extracorporeal magnetic innervation (sham treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.
75392865|NCT06122948|Drug|The midazolam group|The midazolam group will receive intranasal midazolam (0.1 mg/kg)
75392866|NCT06122948|Drug|The midazolam ketamine group|the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
75707950|NCT05641922|Device|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
75707951|NCT05632809|Drug|NKTR-255|Given by IV (vein)
75707952|NCT05632809|Drug|Durvalumab|Given by IV (vein)
75870106|NCT03661034|Device|GammaSense Stimulation System (non-invasive, non-significant risk)|Non-invasive, non-significant risk audio-visual sensory stimulation device
75870107|NCT03659786|Other|CC-Test|Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
75870108|NCT03659708|Procedure|Lyon-VTE score|follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
75392867|NCT06122142|Device|Transfluthrin - delivery by paid study personnel|Passive emanator with formulated transfluthrin, SR product will be delivered by paid study personnel
76035213|NCT03614611|Device|Contiform pessary|"Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"
76035214|NCT04845581|Procedure|Diagnostic tests: Determination of the gingival phenotype, measure gingival thickness and width of keratinized tissue|Gingival thickness was measured using UGTM method and CBCT/ CAD with PDIP technology at upper incisors and canines in three points localized midbucally : Free gingival thickness (FGT), supracrestal ( SGT) and crestal (CGT). Width of keratinized tissue was measured using periodontal probe calibrated for 1 mm. The gingival phenotype was determined by both methods according to the following criteria: GT ≤ 0,7 mm - thin gingival phenotype, GT &gt; 0,7 mm ≤ 1,0 mm - medium gingival phenotype, GT &gt; 1,0 mm - thick gingival phenotype. Toincrease the repeatability of the results, two researchers tested the same values twice on 2days interval between sessions.
76035215|NCT05404555|Other|two-dimensional speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography is used to assess cardiac function in all enrolled patients
75392868|NCT06122142|Device|Transfluthrin - delivery by voucher system|Passive emanator with formulated transfluthrin, voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
75392869|NCT06122142|Device|Transfluthrin - delivery by village health teams|Passive emanator with formulated transfluthrin, village health teams will distribute SR products.
75392870|NCT06122129|Procedure|Flexible ureteroscope with ureteral access sheath|The flexible ureteroscope either directly or via an access sheath, depending on the size of the ureter, a 9.5/11.5 Fr or a 12 Fr access sheath will be used.
75392871|NCT06122129|Procedure|Flexible ureteroscope without ureteral access sheath|Ureteroscopy will be carried out without a ureteral access sheath
75392872|NCT06121713|Dietary Supplement|GCE + Low ALA|Participants will consume a pill containing 200mg green coffee extract and 200mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
75392873|NCT06121713|Dietary Supplement|GCE + High ALA|Participants will consume a pill containing 200mg green coffee extract and 400mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
75392874|NCT06121713|Dietary Supplement|Placebo|Participants will consume a placebo pill (500mg insoluble microcrystalline cellulose, 5mg magnesium stearate, 5mg silicon dioxide) prior to a 75g oral glucose tolerance test
75707953|NCT05630781|Drug|Belsomra|randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional ~7 days and then scanned a final time.
75707954|NCT05630781|Drug|Placebo|comparator taken for ~10 days
75392875|NCT06121466|Drug|Abdominal wall injections with lidocaine 2%|Injections will be administered for patient who are identified as having abdominal wall pain.
75392876|NCT06121193|Behavioral|PREVENT tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
75392877|NCT06121193|Behavioral|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
75870109|NCT03659708|Procedure|recommendations currently available|follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
75392878|NCT06121167|Diagnostic Test|urinary partial oxygen pressure|arterial blood gas
75392879|NCT06120751|Biological|TTVA|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
75392880|NCT06120751|Biological|TT|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
75870110|NCT03659630|Behavioral|MyCompass|Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.
75870111|NCT03659630|Behavioral|Comparison group|An email containing a brief text on general tips regarding mental health was sent out once a week.
75707955|NCT05630781|Drug|Methylphenidate|Control Arm: Baseline visit with 2 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
75707956|NCT05629754|Diagnostic Test|MRI, radiological assessment|MRI and radiological assessment of the involved knee
75707957|NCT05624268|Drug|Psilocybin|COMP360 Psilocybin administered under supportive conditions
75392881|NCT06120712|Biological|GC101 TIL|"Patients with advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment such as PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed) and are ineligible for resection."
75392882|NCT06120101|Behavioral|Reflexology Massage|The researcher washed his hands with an antibacterial soap before cleaning the patient's feet. The feet were cleaned according to the patient's preference; To wash feet with water or use disposable wet cloth. The patients were placed in a supine position on the bed in the room and their joint points were supported. The researcher stood at the end of the patient's bed during treatment. Unscented sesame oil at room temperature was used to provide lubrication during reflexology. The application started with the patient's right foot. The foot was first relaxed by applying effleurage, shaking, rotation and stretching methods. During the application, the researcher used the fingers of the other hand while supporting the patient's foot with one hand, and the thumb and caterpillar technique was mostly used. In other applications, the index finger and other fingers were used. The training ended by applying solar plexus pressure to both feet.
75392883|NCT06119893|Drug|submucosal 8 mg (2 mL) dexamethasone application|The mucoperiosteal flap was applied. After operation, submucosal dexamethasone 8 mg (2 mL) was applied to the operation area as a test group.
75392884|NCT06119893|Drug|submucosal 2 mL 0.9% isotonic sodium chloride application|The mucoperiosteal flap was applied. After operation, 2 mL 0.9% isotonic sodium chloride was applied to the operation area as a control group
75544900|NCT04719455|Behavioral|Adherence Improving self-Management Strategy|An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.
75392885|NCT06118619|Drug|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
75544901|NCT04719455|Other|Regular care|Treatment as usual (appointments with nurse/nurse practioner with regular content)
75544902|NCT01588717|Drug|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
75544903|NCT00270075|Drug|epoetin alfa|
75707958|NCT05621460|Other|500mL carbonated water|Drink 500mL carbonated water immediately prior to head-up tilt test
75707959|NCT05621460|Other|500mL still water|Drink 500mL still water immediately prior to head-up tilt test
75707960|NCT05621460|Other|50mL still water|Drink 50mL still water immediately prior to head-up tilt test
75707961|NCT05621252|Drug|PLN-74809|160 mg PLN-74809
75707962|NCT05621252|Drug|Placebo|Matching placebo
75707963|NCT05613322|Diagnostic Test|Resistell Phenotech|Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.
75392886|NCT06118463|Diagnostic Test|Detection of serum AUNIP expression|The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
76035216|NCT03043859|Behavioral|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
75392887|NCT06118164|Behavioral|pursing- lip breathing combined with aerobic walking exercise|pursing- lip breathing combined with aerobic walking exercise
75392888|NCT06118164|Behavioral|pursing- lip breathing|pursing- lip breathing
75392889|NCT06118164|Behavioral|aerobic walking exercise|aerobic walking exercise
75392890|NCT06117592|Other|Education, training and assessment intervention|Staff competence assessment documents for acute oncology knowledge and skills
75392891|NCT06116942|Device|Active rTMS|"The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil.~In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas."
75544904|NCT01588756|Drug|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
75544905|NCT01588756|Drug|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
75870112|NCT03659552|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
75870113|NCT03659474|Other|compression|compression by Game Ready
76035218|NCT02710669|Drug|(R)-propafenone|
76035219|NCT02710669|Drug|(S)-Propafenone|
76035220|NCT02710669|Drug|Placebo|
76035221|NCT01649661|Behavioral|questionnaire|
75392892|NCT06116942|Device|Sham rTMS|To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.
75392893|NCT06114667|Device|Ventilatory support via nasal high flow|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
75392894|NCT06114667|Device|Ventilatory support via NIV|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
75392895|NCT06113640|Drug|levodopa-carbidopa|Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
75392896|NCT06113640|Drug|Montelukast|Montelukast and other CysLT1 antagonists are currently used as an adjuvant therapy for children and adults suffering from asthma. Other indications have been proposed and most evidence exists for the use of montelukast to treat allergic rhinitis, but its use in other inflammatory conditions, such as atherosclerosis and chronic obstructive pulmonary disease, have also been suggested.
75392897|NCT06112730|Other|Standard pulmonnary rehabilitation|Undergo routine pulmonary rehabilitation without dietary intervention
75544906|NCT04719104|Device|Transcutaneous Bilirubin Meter - 'Bilimeter'|Taking a transcutaneous (TcB) measurement will involve using a 'biliflash'. This is a non-invasive measurement that involves flashing a light against the helix of the infant's ear and can be done at the cotside. This process takes approximately 1-2 minutes and does not cause the baby discomfort. The meter gives an immediate bilirubin level.
75544907|NCT01588795|Procedure|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
75707964|NCT05611125|Other|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in our study.
75870114|NCT03659474|Other|ice pack|cryotherapy for ice pack
75870115|NCT03659474|Other|immersion|immersion therapy
75870116|NCT03659396|Other|individualized Tai Chi|individualized Tai Chi training exercise
75870117|NCT03659396|Other|Entire Tai Chi|the classical Yang style Tai Chi program
75870118|NCT03659396|Other|home-based program|Home-based exercise
76035222|NCT04844645|Other|mini program|To design, construct, and test the mini program in patients managing cancer pain
75870119|NCT03662048|Behavioral|Safe|Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
75870120|NCT04055870|Procedure|EUS-guided liver biopsy at MDMC|Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
75707965|NCT05610319|Drug|Faricimab|Faricimab will be administered via intravitreal injection.
76035223|NCT04844645|Other|conventional pharmaceutical care|conventional pharmaceutical care
75707966|NCT05607758|Behavioral|StressProffen©™|An app-based program for stress management consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
75870121|NCT03660956|Behavioral|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
75870122|NCT03660956|Behavioral|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
75392898|NCT06112730|Other|Nutritional supplementation intervention|Receive personalized dietary guidelines based on indirect calorimetry assessment
75392899|NCT06112249|Behavioral|SAFE Employment Training|The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
75392900|NCT06110143|Other|Periodontal treatment|Periodontal treatment
75392901|NCT06108323|Behavioral|Theapeutic exercise plus action observation training|Participants make an observation of actions related to the training they are going to perform. Subsequently, they perform the therapeutic exercise session.
75392902|NCT06108323|Behavioral|Therapeutic exercise plus sham observation training|Participants make a sham observation. Subsequently, they perform the therapeutic exercise session.
75392903|NCT06105957|Behavioral|Core|The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals. Weekly tips and discussion board postings invite participants to apply skills introduced in the modules and prompt interaction and social support within the closed group which starts the program simultaneously.
75392904|NCT06105957|Behavioral|Facilitated Weekly Group Sessions|Participants will receive 24 facilitated online video-conference-based weekly group sessions. These groups will be 60 minutes long and will be facilitated by a trained professional, who reinforces the information and behavioral strategies introduced in the weekly modules, elicits the experiences of participants in applying behavioral skills to establish new diet and exercise habits, and guides problem solving. Group cohesion to offer social support is promoted.
75392905|NCT06105957|Behavioral|Counselor Crafted Feedback|Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message. The emailed feedback will provide positive reinforcement for successful goal achievement, identify possible areas for improvement, and suggest possible strategies for identified challenges.
75392906|NCT06105957|Behavioral|Individual Coaching Calls|Participants will receive 3 online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss. The first call will emphasize amplifying motivation and promoting early treatment engagement by establishing rapport, exploring personal reasons for weight loss and lifestyle change, and reinforcing and expanding change talk, and it will occur prior to starting the core program. Subsequent calls will use a motivational interviewing-informed approach to problem solve barriers to self-monitoring, particularly dietary self-monitoring because of the strong role it plays in promoting better weight loss and will occur during the first half of the program, reflecting the critical role of early engagement in the treatment program on long term weight loss success. Coaching calls will be of approximately 30 min duration and will follow a semi-structured interview format.
75392907|NCT06105957|Behavioral|Pre-Scripted Feedback|Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring within each of the following domains: dietary monitoring, physical activity monitoring, and self-weighing, as well as on weekly module completion. Feedback is automatically generated based on decision algorithms and will be sent from program staff.
75392908|NCT06104280|Other|Post-Illumination Pupillary Response (PIPR)|The PIPR is measured in six, 80-s test periods in which the stimulus, either Blue (470 nm) or Red (623 nm), is presented to the dilated eye while the pupil response of the un-dilated eye is measured (consensual pupil response
75544908|NCT01588795|Drug|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
75544909|NCT01588834|Procedure|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
75544910|NCT00107614|Drug|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with < 50% response to induction) OR MEL-DT PACE (Patients with > 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
75870123|NCT03659318|Procedure|Robotic-assisted TKA|Total knee arthroplasty is carried out with help of robotic surgery system, using a Robodoc system. CT-based preoperative planning using ORTHODOC (Integrated Surgical Technology Corp) performed in the first step before the day of surgery, and the robotic-assisted surgery using the ROBODOC surgical assistance in the second step. The bone markers are registered to the computer, and the computer arm does all the cutting and preparation of bones. This is in contrast to conventional jigs and cutting blocks. Actual implantation of the implants is done by a surgeon. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
75707967|NCT05605912|Other|Control|Participants perform five one-hour conventional training sessions at the Sint Maartenskliniek in which they perform functional exercises. After the conventional training program, the control group will receive a recommendation for physical activity at home for six weeks.
75392909|NCT06104280|Other|Polysomnography|Measure electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), electrocardiography (ECG), respiratory channels (effort and nasal pressure), and oxygen saturation.
75392910|NCT06104280|Other|Multiple Sleep Latency Test|Assist in the diagnosis of disorders of hypersomnolence,63 it is also used in research to quantify daytime sleepiness and serves as a more objective measure of daytime sleepiness than self-report questionnaires
75392911|NCT06104280|Behavioral|Ecological Momentary Assessments|Morning after overnight Visit 2, participants will complete ecological momentary assessments (EMAs) over a 10-day assessment period. Using EMA through the InsightTM mHealth platform to capture momentary craving, withdrawal and mood states across 10 days among persons who smoke and nonsmokers prior to an overnight procedures. Participants will complete morning and evening sleep diaries via the EMA InsightTM mHealth platform self-reported sleep and wake information, fatigue, naps, opioid craving and withdrawal.
75392912|NCT06104280|Device|Actigraphy|7-day actigraphy period will be used to determine the habitual sleep start and wake times. The CamNTech MotionWatch8 (Cambridge, UK) is a solid-state piezo-electric accelerometer that collects data on activity (i.e., arm motion) and ambient light.Actigraphy data are downloaded from the MotionWatch8 into the software (MotionWare) for analysis, management, and exportation. Bed and wake times will be entered by the subjects via a REDCap link and this information coupled with the sleep diary reports will be entered to determine sleep intervals. Algorithms in the Motion Watch 8 software will determine sleep start, sleep end, total sleep time (duration), sleep quality, sleep efficiency, wake after sleep onset, and sleep fragmentation
75392913|NCT06104280|Other|DLMO|Participants will be given an evening meal and then be accompanied to the UAB Highlands Hospital Sleep Unit by 5:30pm. The sleep unit allows for strict control of light exposure (< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels.Participants will be allowed to sleep in darkness until 8:00am, at which time they will be provided transportation.We will also bank frozen samples taken prior to the light exposure for later calculation of the Dim Light Melatonin Onset (DLMO), a circadian phase estimate.
75392914|NCT06104280|Other|Melatonin Suppression Test|The sleep unit allows for strict control of light exposure (< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels. Participants will be asked to refrain from caffeine consumption 12 hours before reporting to the sleep unit and will provide 2-3 ml of saliva every 30 minutes starting at 6:00pm and ending after the light exposure. For melatonin suppression, 2-hours light exposure will begin 2 hours before the calculated mid-sleep time. Collection saliva samples 1-h, 30-min, and immediately before the light exposure and every 30 min throughout exposure. Samples will be centrifuged and frozen/stored at -20ºC until assay and remaining samples stored at -80ºC. Melatonin levels will be assayed via the Buhlmann Direct Saliva Melatonin. Melatonin suppression will be calculated as the percent decrease from the sample taken immediately prior to the light exposure
75392915|NCT06096597|Drug|Clarix Flo|100 mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride
75392916|NCT06096597|Drug|Placebo|10 mL of 0.9% preservative-free sodium chloride
75392917|NCT06095154|Radiation|New-mode reduce-volume target IMRT|The CTVp was defined as a subclinical disease consisting of 10 mm margin surrounding GTVnx (not including all nasopharyngeal mucosa)
75392918|NCT06095011|Device|UpRight Go|The UpRight Go posture trainer is a commercially available biofeedback sensor that externally attaches to the wearer via a necklace or silicon adhesive. It vibrates when it senses that the wearer is slouching and connects to a smartphone application which sets daily goals, tracks usage, and provides assistance and support. It complies with International Electrotechnical Commission (IEC) standards.
75392919|NCT06094218|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
75392920|NCT06094218|Behavioral|Treatment as usual (TAU)|Behavioral health treatment as it is typically provided at the treatment site.
75392921|NCT06093321|Device|SYB PDO Thread|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
75392922|NCT06093321|Device|MINT lift®|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
75544911|NCT00255242|Drug|Simvastatin treatment for 28 days|40 mg / day
75392923|NCT06087276|Drug|60 mg ulixacaltamide|Once daily oral treatment with titration
75392924|NCT06087276|Drug|Placebo|Once daily oral treatment
75544912|NCT00270114|Drug|epoetin alfa|
75544913|NCT00255281|Drug|AZD7009, no generic name available|
75544914|NCT00107380|Biological|rituximab|
75544915|NCT00107380|Drug|cyclophosphamide|
75544916|NCT00107380|Drug|doxorubicin hydrochloride|
75870124|NCT03659318|Procedure|Conventional TKA|Total knee arthroplasty is carried out with classical, conventional, manual method. A surgeon measures the angle, length of the cuts with bone landmarks and specialized surgical instruments. After all the cuts actual implantation is done. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
75544917|NCT00107380|Drug|prednisone|
75544918|NCT00107380|Drug|vincristine sulfate|
75544919|NCT00107380|Radiation|tositumomab and iodine I 131 tositumomab|
75544920|NCT00270153|Drug|enalapril|5mg enalapril daily for 6 months
75544921|NCT00270153|Drug|Placebo|5mg enalapril-matching placebo daily for 6 months
75544922|NCT00255320|Drug|VIP|
75707968|NCT05605912|Device|Myosuit|Participants perform five one-hour Myosuit training sessions at the Sint Maartenskliniek in which they perform functional exercises and learn to don, doff and use the device for standing, walking, climbing the stairs and sit-to-stand transitions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home and a recommendation for physical activity at home for six weeks.
75707969|NCT05604833|Behavioral|Progressive Muscle Relaxation Exercises|"In the research, data will be collected with the Descriptive Information Form and Pittsburgh Sleep Quality Index (PUKI). Statistical analysis of the data obtained as a result of the research will be made in the IBM SPSS25 program. This study was planned because it is thought that making progressive muscle relaxation exercises (PKGE) in patients with poor sleep quality who receive hemodialysis treatment will be effective in increasing sleep quality, since it is easy to learn, can be done anywhere, and has no side effects."
75707970|NCT05604807|Other|Dementia course with virtual reality|dementia virtual reality activity, intergenerational learning, world café teaching method and community practice
75392925|NCT06086340|Drug|Palbociclib|Palbociclib with an aromatase inhibitor therapy
75392926|NCT06086340|Drug|Aromatase Inhibitor|Aromatase Inhibitor Therapy
75392927|NCT06085326|Other|Smart Checklist|The digitized Smart Checklist includes three new features that currently do not exist on a paper checklist: 1) decision support prompts based on patient-provider dyad characteristics, 2) real time display of patient pertinent airway information from the EHR, and 3) high-risk warning alerts based on predictive analytics with potential explanatory factors from the model.
75392928|NCT06083883|Drug|Fludarabine phosphate|Given by IV (vein)
75392929|NCT06083883|Drug|NY-ESO-1 TCR/IL-15 NK|Given by IV (vein)
75392930|NCT06083883|Drug|Cyclophosphamide|Given by IV (vein)
75544923|NCT00289224|Biological|bivalent killed whole cell oral cholera vaccine|"Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
75544924|NCT00289224|Biological|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
75544925|NCT00255359|Drug|XTL-2125|
75707971|NCT05604807|Other|Dementia course with no virtual reality|dementia course, intergenerational learning, world café teaching method and community practice
75707972|NCT05603442|Procedure|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
75870125|NCT03661892|Drug|Syndros|"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"
75544926|NCT04054843|Diagnostic Test|Afamin|Plasma maternal afamin levels
75544927|NCT04055038|Drug|Platinum-Based Drug|Reintroduction of platinum-based chemotherapy
75544928|NCT04055038|Drug|Conventional chemotherapy|Conventional chemotherapy
75544929|NCT00270192|Behavioral|individual lactation counseling and educational material|
75544930|NCT00270192|Behavioral|educational material alone|
75707973|NCT05601232|Radiation|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
75392931|NCT06082518|Device|Monoplace Hyperbaric Chamber (Class III medical device).|"40 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2 atmospheres (ATM) per treatment), scheduled daily from Monday to Friday (i.e., 5 treatments per week) until treatments are completed (approximately 8 weeks). Treatments will be delivered in a medical grade, Health Canada-approved monoplace hyperbaric chamber and overseen by specialist hyperbaric physicians and a Certified Hyperbaric Technologist.~Device is being used in manner consistent with approved usage in Canada."
75707974|NCT05601206|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
75707975|NCT05601206|Behavioral|Enhanced Usual Care|Usual care from health providers
75707976|NCT05601102|Behavioral|danceSing Care|- Physical activity interventions, including multi-component (chair-based) exercises or dancing, and music therapies have been shown to improve multidimensional health markers in older adults.
75707977|NCT05600803|Procedure|Single-operator cholangioscopy|SpyGlass (Boston Scientific Co, Marlborough, USA) which enabled the direct visualization of the pancreaticobiliary system for the evaluation of intraductal lesions
75707978|NCT05597189|Dietary Supplement|Experimental product|Botanical extract
75707979|NCT05597189|Other|Control product consumption|Product with identical characteristics to the experimental product.
75707980|NCT05592249|Other|Dual Task MC|Dual Task MC group will receive 60 minutes motor - cognitive dual task intervention 5 day per week for 4 weeks in clinic.
75707981|NCT05592249|Other|Dual Task MM|Dual Task MM group will receive 60 minutes motor - motor dual task intervention 5 day per week for 4 weeks in clinic.
75392932|NCT06080061|Radiation|Hypofractionated accelerated radiation therapy|Hypofractionated accelerated radiation therapy
75392933|NCT06075979|Other|Lumbar disc herniation|Patients undergoing surgery for lumbar disc herniation
75392934|NCT06075979|Other|Lumbar spinal stenosis|Patients undergoing surgery for lumbar spinal stenosis
75392935|NCT06075966|Other|Non-fusion group|Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
75392936|NCT06075966|Other|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University
75392937|NCT06067438|Drug|Amiodarone Hydrochloride|Given IV and via feeding tube
75392938|NCT06067438|Other|Saline|Given IV
75544931|NCT00270192|Behavioral|routine antenatal care without educational intervention|
75707982|NCT05589896|Drug|Busulfan|pre-transplant conditioning treatment
75707983|NCT05589896|Drug|Fludarabine|pre-transplant conditioning treatment
75870126|NCT03658850|Drug|Hydrochlorothiazide 50Mg|for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
75392939|NCT06065501|Behavioral|PACE intervention|"The PACE intervention involves using Line (technological devices) to establish a collaborative group with patients. The researchers will regularly provide reminders to chronic kidney disease patients regarding the importance of nutrition and exercise. They will also provide information on how to adhere to nutritional and exercise regimens, offering praise for consistent performance."
75392940|NCT06065501|Behavioral|Usual care|Nurses provide routine education and consultation
75392941|NCT06057974|Other|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational model for healthcare staff working in NICUs. It aims to improve the ability of the members of the NICU healthcare team to I) observe the infants' individual behaviors and needs, II) support parents to take the initiative and share their observations and understanding of their infant's behaviors and to collaboratively plan the infant's care with the healthcare staff, III) understand the individual story of the family regarding parenthood through a dialogue with parents, and IV) involve parents in the decision-making about the care of their baby from an early stage of care through to the preparation for discharge. The final goal is to improve the care culture in the NICUs by changing the attitudes of the healthcare staff and the care practices of the unit to be more in line with family-centered care principles.~It usually takes 1.5 years for each NICU to complete the intervention."
75544932|NCT04054609|Diagnostic Test|FAZA PET/MRI scan|PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
75392942|NCT06057753|Behavioral|MyStroke|Personalized video-based stroke education platform
75392943|NCT06050954|Drug|Pembrolizumab (200mg)|200mg Pembrolizumab every six weeks via IV infusion.
75392944|NCT06050954|Drug|Pembrolizumab (400mg)|400mg Pembrolizumab every six weeks via IV infusion.
75392945|NCT06050954|Diagnostic Test|Monitoring|active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.
75392946|NCT06050369|Device|EEG|Recording, from the scalp, the electrophysiological activity of the brain.
75392947|NCT06050369|Device|MRI|Get the anatomical shape of the brain.
75392948|NCT06050135|Other|Roadmap to Parenthood|web-based decision support
75544933|NCT04054531|Biological|KN046|IV infusion
75544934|NCT04054531|Drug|Paclitaxel|IV infusion
75544935|NCT04054531|Drug|Pemetrexed|IV infusion
75392949|NCT06050135|Other|Informational Booklet|web-based informational booklet about young adult cancer survivorship
75544936|NCT04054531|Drug|Carboplatin|IV infusion
75544937|NCT00289263|Drug|Paclitaxel|
75544938|NCT04054336|Behavioral|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
75544939|NCT04054336|Behavioral|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
76035224|NCT04259229|Other|Mediterranean Diet -- Mushrooms|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The mushroom group will consume 0.5 cups/day of cooked mushrooms (white button mushrooms and yellow oyster mushrooms on 4 and 3 days/week, respectively). All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
76035225|NCT04259229|Other|Mediterranean Diet -- Control|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The control group will not consume mushrooms at any point. All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
75392950|NCT06048185|Biological|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
75392951|NCT06038175|Device|Video Head Impulse Testing|During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. (Interacoustics EyeSeeCam vHIT 3rd Generation Tests: VOR of lateral, RALP, & LARP canals. SW: 3rd generation VE525 software. HW: laptop PC, lightweight monocular video goggles). Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side (10-20° angle, duration 150-200 ms, peak velocity of >150°/s) in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is <0.8 in the presence of refixation saccades .
75544940|NCT04054336|Behavioral|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
75392952|NCT06038175|Other|Standard of care neurologic evaluation|A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
76035226|NCT02693041|Drug|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
75544941|NCT00289302|Device|Cardiac resynchronization therapy device|
76035227|NCT02693041|Drug|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
75870127|NCT03658850|Drug|Placebos|for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
75392957|NCT06031428|Behavioral|MANAGe-DM - novel nurse case management|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
75870128|NCT03659162|Drug|Azole Antifungal|oral gel & injections
75392958|NCT06031428|Behavioral|Monthly Educational Mailing|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
75544942|NCT04516486|Other|retrospective metagenomics on clinical samples collected during hospitalization|Massive sequencing of respiratory samples (restrospective)
75870129|NCT03659084|Drug|EXJADE|The patient having given his consent, will begin the Exjade at 10 mg / kg per day if the ferritin level reached 1000 ng / ml at 6 months after allograft, for a minimum duration of three months and up to 6 months. The iron parameters will be evaluated at 3, 6, 9, 12, 18 and 24 months after the beginning of the exjade treatment. The evaluation of the disease will be carried out according to the practices of the center. It is recommended to have a washout period of one week between stopping the ciclosporin and the beginning of treatment by exjade.
75870130|NCT01068626|Drug|Rosuvastatin|10 mg once daily
75870131|NCT01068626|Drug|Placebo for rosuvastatin|once daily
75870132|NCT03060668|Other|Peptamen intense|Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
75870133|NCT03060668|Other|Novasource senior|Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
75392959|NCT06027723|Drug|Nicotine|Nicotine delivered through a vape
75544943|NCT04516525|Device|cardiac resynchronisation therapy (CRT) implantation|In a group of 100 patients with chronic cardio-renal syndrome, the blood and urine biomarkers are tested before CRT implantation and after 48 hours, 3 months and 1 year of follow-up.
75544944|NCT00255437|Drug|ferumoxytol or oral iron|
75544945|NCT04515940|Dietary Supplement|acceptability, tolerance and palatability study|prospective acceptability study
75544946|NCT00255476|Drug|gefitinib|
75392960|NCT06027723|Other|Placebo|Placebo nicotine-free vaping liquid delivered through a vape
75392961|NCT06024512|Device|Burn|This study is being done to collect pictures of burns using an investigational device called the Spectral MD Deep View Snapshot Handheld (DV-H), similar to a camera. The data collected will be used to assess the performance of the DV-H device, and to determine the device's ability to differentiate healing versus non-healing burn tissue. This device, if approved, is expected to give caregivers a better understanding of what parts of burn wounds will likely not heal on their own and as a tool used by the military in the field. This current study involves the collection of images over the course of your clinical treatment and follow-up according to your routine standard of care. The device will not be used to diagnose or prescribe treatment for your burn.
75392962|NCT06019338|Other|Pain Diary use|Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia
75544947|NCT00255476|Drug|cisplatin|
75544948|NCT00255476|Drug|5-flourouracil|
75544949|NCT04513249|Diagnostic Test|dynamics of coagulation parameters|the effects of fresh frozen plasma administered during a plasma exchange therapy on viscoelastic tests
75544950|NCT00270270|Drug|epoetin alfa|
75544951|NCT04512118|Diagnostic Test|PET-CT of 18F-FDG|Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)
75544952|NCT04511143|Other|muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.
75544953|NCT00255515|Drug|Quetiapine fumarate|oral
75707984|NCT05589896|Radiation|Total Body Irradiation|pre-transplant conditioning treatment
75392963|NCT06014086|Drug|PH-762|PH-762 is a potent RNAi molecule targeting PD-1.
75544954|NCT00255515|Drug|conventional treatment for schizophrenia|various standard therapies
75544955|NCT00270309|Behavioral|Self-management|
75544956|NCT00289419|Drug|Epidural Ropivacaine, morphine|Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
75392964|NCT06013579|Behavioral|Phase 1 Gym Exercise HIIT|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
75544957|NCT00289419|Drug|Ropivacaine, Ketorolac and Adrenaline|Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
75544958|NCT01600144|Other|digital mammography|data collection
75544959|NCT00255554|Behavioral|Dialectical Behavioral Therapy|
75544960|NCT00255554|Drug|Escitalopram|
75544961|NCT00270348|Drug|ciclesonide|
75544962|NCT00255593|Drug|rituximab|
75544963|NCT00289497|Device|TempTouch®|
75707985|NCT05589896|Drug|Cyclophosphamide|pre-transplant conditioning treatment
75707986|NCT05589896|Drug|Mesna|given with Cyclophosphamide
75707987|NCT05589896|Procedure|Bone Marrow Transplant|Bone marrow transplant with Ossium HPC, product
75707988|NCT05589896|Drug|Cyclophosphamide|post-transplant treatment
75707989|NCT05589896|Drug|Tacrolimus|post-transplant treatment
75392965|NCT06013579|Behavioral|Phase 1 Gym Exercise CME|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
75392966|NCT06013579|Behavioral|Phase 2 Home Exercise Coaching Text Messages|The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.
75392967|NCT06013579|Behavioral|Phase 2 Home Exercise Control Text Messages|"The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group."
75392968|NCT06004492|Behavioral|blended learning program|8 hours of workshops and four months of practical learning on technology platforms
75392969|NCT06002347|Behavioral|STAC Parent Module for Middle School|"The STAC Parent Module is a 30-minute pre-recorded online presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies parents can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
75392970|NCT06001112|Other|cheek acupuncture|Based on the theory of holography and the theory of the Great Sanjiao, the acupoints were chosen under the guidance of the foundation of cheek acupuncture, selecting bilateral Sanjiao acupoints, bilateral head acupoints, foot and ankle acupoints on the affected side, and matching acupuncture points for local strengthening of the foot and ankle acupuncture points, using the triangular needle strengthening method. The treatment was performed with the patient lying on his back in a comfortable position, with routine local disinfection, rapid transdermal needle entry to the acupuncture points, and needle discharge after 30 minutes of needle retention, after which the needle hole was compressed with a cotton ball for a few moments.
75392971|NCT06001112|Drug|Etoricoxib|etoricoxib 120mg
75392972|NCT05994235|Drug|Mosunetuzumab|"Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks."
75707990|NCT05589896|Drug|Mycophenolate Mofetil|post-transplant treatment
75392973|NCT05994235|Drug|Tazemetostat Pill|Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
75544964|NCT04497337|Procedure|Complete excision to superficial lesions around the ear|Complete excision of these lesions and histopathology
75544965|NCT04496869|Other|Online questionnaire|the investigators sent by email a Googleform online questionnaires to women followed in ART center of HFME (Hospital Femme-Mère-Enfant) . Questions are about demographic characteristics, ART history, feeling during the lockdown. To evaluate psychological impact, the investigators use PSS10 and HADS scales. Both scales are worldwide validated and used in recent COVID19's research. the investigators add some quantitative questions about de feeling during the look down, ART interruption, pregnancy desire.
75707991|NCT05589896|Drug|Filgrastim|post-transplant treatment
75707992|NCT05588219|Drug|Tislelizumab|Tislelizumab injection[10ml:100mg] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
75707993|NCT05588219|Drug|DDP synchronous with radiotherapy|DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.
75707994|NCT05585346|Device|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
75707995|NCT05585346|Drug|Oral vitamin B1|Oral vitamin B1 10mg, times/day
75870134|NCT02921750|Device|Exufiber Gelling Fibre Dressing|Gelling fibre dressing
75392974|NCT05991544|Behavioral|Training and Follow-up According to the Neuman Systems Model|Neuman Systems Model (NSM) it presents a holistic approach to patients by including physiological, spiritual, sociocultural and five major developmental variables
75392975|NCT05991427|Biological|Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
75392976|NCT05991427|Biological|Zoster Vaccine Recombinant, Adjuvanted (Shingrix)|2 doses of Shingrix vaccine on Day 0 and Month 4
75392977|NCT05991427|Biological|ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
75392978|NCT05991427|Biological|Shingrix|2 doses of Shingrix vaccine on Day 0 and Month 4
75544966|NCT00255671|Other|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
75544967|NCT04496206|Other|No intervention|No intervention, it is retrospective study.
75392979|NCT05991427|Biological|IH ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
75392980|NCT05991427|Biological|IH saline|2 doses of saline on Day 0 and Month 4
75392981|NCT05991232|Drug|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
76035228|NCT04851743|Other|Dry needling|The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
75392982|NCT05990569|Other|Ultrasound guided Pudendal nerve block|Ultrasound guided bilateral pudendal nerve block
76035229|NCT05392959|Drug|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg per day
75392983|NCT05990192|Drug|Niraparib oral capsule|Niraparib used following SBRT treatment until disease progression
75392984|NCT05990192|Radiation|SBRT|SBRT may be delivered using a specialist SBRT platform, such as CyberKnife or with a linear accelerator with SBRT capabilities.
75392985|NCT05987020|Other|Aromatherapy|"The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil."
75392986|NCT05982158|Behavioral|Avatar therapy|Seven 50-minute therapy sessions conducted by videoconferencing.
75392987|NCT05982158|Behavioral|Cognitive behavioural therapy (CBT)|Seven 50-minute therapy sessions conducted by videoconferencing.
75544968|NCT00270387|Drug|Natrecor (nesiritide)|
75392988|NCT05979688|Behavioral|yogic breathing exercise|A typical session will begin with the yoga instructor demonstrating a breathing exercise technique. The participants will learn and practice each technique.
75392989|NCT05977049|Behavioral|Takotsubo Support Group|Participants will undergo virtual group therapy/education. Participants will meet once every other week (at minimum), for 1 - 1.5 hours (on average). The frequency and/or length of the support group sessions may be adjusted according to participants' needs.
75544969|NCT00255710|Biological|filgrastim|
76035230|NCT05392959|Drug|Placebo|Placebo for dapagliflozin film-coated tablets 10 mg
76035231|NCT04851977|Biological|Respiratory Syncytial Vaccine|BARS13 low dose (one dose of 10 μg rRSV-G protein/10 μg CsA by IM injection to the deltoid region of one arm, and one dose of placebo [saline/mannitol] by IM injection to the deltoid region of the other arm, given sequentially).
75392990|NCT05972512|Other|Placebo|Mode of usage: Two times a day Route of administration: Oral
75392991|NCT05972512|Dietary Supplement|Botanical extract of standardized biotin|Mode of usage: Two times a day Route of administration: Oral
75392992|NCT05972512|Dietary Supplement|Botanical extract of standardised biotin with silica|Mode of usage: Two times a day Route of administration: Oral
75544970|NCT00255710|Drug|cyclophosphamide|
75544971|NCT00255710|Drug|fludarabine phosphate|
75544972|NCT00255710|Drug|mycophenolate mofetil|
75544973|NCT00255710|Drug|tacrolimus|
75544974|NCT00255710|Procedure|allogeneic bone marrow transplantation|
75544975|NCT00255710|Procedure|peripheral blood stem cell transplantation|
75544976|NCT00255710|Radiation|radiation therapy|
75870135|NCT02921750|Device|Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre|Hydrofiber® Dressing with Strengthening Fibre
76035232|NCT04851977|Biological|Respiratory Syncytial Vaccine|BARS13 high dose (IM injection of 10 μg rRSV-G protein/10 μg CsA administered to the deltoid region of each arm [one injection of 10 μg rRSV-G protein/10 μg CsA per arm], given sequentially). The high dose is twice the strength of the low dose.
76035233|NCT04851977|Biological|Placebo|Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm [one injection per arm], given sequentially).
76035234|NCT04851431|Behavioral|one-to-one peer mentoring|Weekly meetings with a peer family caregiver
75707996|NCT05585021|Dietary Supplement|Wonderlab Kids instant probiotics|"During study intervention, subjects are required to take the randomly assigned product based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period."
75392993|NCT05970796|Behavioral|Pelvic floor muscle training|"The pelvic floor muscle training program will be provided via an intra-vaginal biofeedback device - Smart Kegel Trainer, which will be connected to the product application installed on the mobile phone or tablet so the participants can monitor their pelvic floor contractions in real time and directly in the application. Participants will be asked to complete three sets of 8 to 12 maximal pelvic floor muscle contractions and three to ten fast contractions per training session. The home program will be tailored to each participant and include pelvic floor safe exercises recommended by the Continence Foundation of Australia."
76035235|NCT04851665|Other|No Intervention - this was a qualitative analysis|No Intervention - this was a qualitative analysis
75392994|NCT05970718|Drug|REGN7544|Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
75392995|NCT05970718|Drug|Matching Placebo|Solution for single ascending IV or SC administration per the protocol
76035236|NCT05370417|Other|Use of fluoride toothpaste|All participants will receive brushing instruction and will be provided with toothpaste with a concentration equal to or greater than 1000ppm of fluoride, indicating three daily brushings. With this generalized measure, all of them receive basic treatment for hypersensitivity.
76035237|NCT05370417|Radiation|Laser Therapy|"For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Applied in three perpendicular points and in contact with the surface. One in the vestibular, mesial and distal cervical third and the third in the center of the lesion. (6) Applied 10 seconds per point with an energy of 1 J."
75392996|NCT05949957|Behavioral|LvL UP App|LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).
75707997|NCT05585021|Dietary Supplement|Instant probiotic placebo|"Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.~1 bottle a day. Lasting for 24 weeks intervention period."
75707998|NCT05584098|Other|qSOFA and MEWS|qSOFA and MEWS used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
76035238|NCT05370417|Procedure|Simulated Laser Therapy|The same application described in the laser therapy group will be simulated, with the device turned off.
76035239|NCT05370417|Procedure|Sealant application|A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
76035240|NCT03043781|Other|Continuous epidural infusion|Continuous infusion, 5 ml/h
76035241|NCT03043781|Other|Intermittent epidural bolus|Intermittent bolus 5 ml every hour
76035242|NCT03043937|Other|registry|
75870136|NCT03659006|Biological|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
75707999|NCT05575908|Procedure|Digital expert team|A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
75708000|NCT05575102|Other|Walking Football|"Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games."
75708001|NCT05574296|Drug|Hydrogen|Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane. Oxygen concentration titrated per clinical team.
75392997|NCT05949957|Behavioral|HAPPY App|HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.
75392998|NCT05949957|Behavioral|Oura Ring And Oura App|Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App
75708002|NCT05574296|Other|Usual care|Usual care post-ECPR event, including targeted temperature management.
75870137|NCT03657836|Dietary Supplement|Sublimated mare milk supplement|The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
75870138|NCT03657836|Drug|Standard antibiotic therapy|Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
75392999|NCT05949710|Behavioral|aerobic exercise(AE)|The participants in Groups A and C will receive AE three times per week, and those in Group D will receive AE five times per week (the same supervised AE protocol three times a week with additional home-based AE training with an instructional video two times a week). The exercise movements in the instructional video will be identical to those of the supervised exercise to enable the participants to easily perform the exercise at home. The participants in the two control groups (Groups B and E) will maintain their original lifestyle without any exercise intervention during the 16 weeks.
75393000|NCT05947955|Drug|Rhu-pGSN|Intravenous administration based on actual body weight
75393001|NCT05947955|Drug|normal saline|intravenous administration in the same volume as the active therapy
75393002|NCT05944302|Behavioral|EMDR group|Eye Movement Desensitization and Reprocessing
75393003|NCT05941793|Drug|MBS-COV|MBS-COV for inhalation
75393004|NCT05941793|Drug|Placebo|Placebo for inhalation
75393005|NCT05933174|Other|Prompt-sheet|Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
75544977|NCT04493866|Other|Messages to departmental employees to improve quality of consent form completion|All interventions directed to members of the plastic surgery department: Intervention 1: Poster illustration common mistakes on consent forms. Intervention 2: Group message explaining Quality Improvement Project to the department. Intervention 3: Email from Consultant lead in support of project. Intervention 4: Further group message illustrating gains and ongoing goals of the project.
75544978|NCT00270426|Drug|Benazepril|
75544979|NCT00255749|Biological|epoetin alfa|
75544980|NCT04491214|Other|quality of live assessment|quality of live assessment 3 moth and 6 moth after ointensive care hospitalisation using SF36.
75544981|NCT04491448|Behavioral|Social needs screening|Interview and referral for non-medical health-related social needs
75544982|NCT00289575|Device|MBCP|
75544983|NCT01600183|Device|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
75544984|NCT01600183|Procedure|cast|casting of the infant legs
75544985|NCT04489030|Other|Magnifying narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
75393006|NCT05933174|Other|Usual education|Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
75393007|NCT05921565|Behavioral|Interventional Behavioral Arm|All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
75393008|NCT05917522|Biological|Abatacept|Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector
75544986|NCT00270465|Drug|VRC-HIVDNA016-00-VP|
75544987|NCT00270465|Drug|VRC-HIVADV014-00-VP|
75708003|NCT05573906|Combination Product|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
75708004|NCT05573906|Combination Product|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
76035243|NCT05369949|Drug|DEX group|Participants will receive a dexmedetomidine infusion in addition to low dose sevoflurane anesthesia.
75393009|NCT05917522|Procedure|Standard of Care at US Transplant Centers|Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))
75708005|NCT05567406|Drug|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
75870139|NCT03622502|Drug|Dexmedetomidine|Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery
75870140|NCT03622502|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
75870141|NCT03622502|Drug|Normal saline|Normal saline was infused over 10 min before end of the surgery
75870142|NCT03658460|Other|DNA sequencing|Targeted next generation sequencing and gene expression analysis with focus on immuno-oncology signatures
75870143|NCT03658382|Other|Virtual Visit|Patients will receive the results of their genetic testing via a virtual visit.
76035244|NCT05369949|Other|Control group|Participants will receive general anesthesia based on institutional's practice with commonly used doses of sevoflurane.
75393010|NCT05913791|Dietary Supplement|Nutrients-fortified egg|Consumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed)
75393011|NCT05913791|Other|Regular egg|Consumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison.
75393012|NCT05908695|Drug|GV-971|Administered PO
75393013|NCT05908695|Drug|Placebo|Administered PO
75393014|NCT05895266|Drug|ABBV-903|Oral Tablet
75393015|NCT05895266|Drug|Midazolam|Oral Liquid
75393016|NCT05894421|Drug|TQB2223 injection+ Penpulimab Injection|TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
75544988|NCT04486807|Diagnostic Test|Elite badminton players|The population was all the elite badminton players followed in a University Hospital Centre and the National Institute of Sport, Expertise, and Performance. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed during the badminton season (Nineteen elite badminton players and followed over the badminton season (from september 2018 to may 2019 or from september 2019 to may 2020)
76035245|NCT03043703|Device|AirSense 10 AutoSet for Her|Positive airway pressure
75393017|NCT05894070|Other|Voice recording, ENT (Ear, Nose and Throat) examination including transnasal fiberendoscopy, and VHI-30-questionnaire|"The following speech samples will be recorded from the study participants:~Standardized, phonetically balanced text~Sustained, modulated production of five vowels~Picture description~Diadochokinetic exercise.~Before starting speech recording, the participant fills in a questionnaire consisting of:~Health barometer~Self-rating in terms of stress/fatigue/emotional status.~An Ear, Nose and Throat examination incl. transnasal fiberendoscopy is performed at each visit. The investigators will assess the vocal folds/aryepiglottic folds for the presence of paralysis or reduced mobility, as well as the presence of scar/synechia, edema, erythro-/leukoplakia, or a cancer-suspicious lesion/mass in the larynx/hypopharynx or a chondroradionecrosis in the larynx.~Additionally, it will be assessed, if a tracheotomy canula or a nasogastric tube is in place or was used since the last visit.~Furthermore, the investigators will ask the patients to fill out the VHI-30."
75393018|NCT05889845|Drug|Candin, Intradermal Solution|Injection at the base of the selected wart
75393019|NCT05889845|Drug|Placebo|Injection at the base of the selected wart
75393020|NCT05883319|Other|manuel therapy|approaches will be applied for 3 days / week for 6 weeks.
75544989|NCT00255827|Biological|HyperAcute-Pancreatic Cancer Vaccine|
75708006|NCT05555771|Behavioral|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
75393021|NCT05883319|Other|exercises|approaches will be applied for 3 days / week for 6 weeks.
75393022|NCT05880485|Radiation|online adaptive radiotherapy|PTV with 5-10 margins covers CTV
75544990|NCT00270504|Device|Memokath stenting|Urethral Stenting
75544991|NCT00255866|Behavioral|Skills training for the care of dementia patients|
75544992|NCT00289614|Drug|Iopamidol 370 mgI/dL|
75544993|NCT04482361|Diagnostic Test|Presence of specific anti-SARS-CoV-2 antibodies|Presence of specific anti-SARS-CoV-2 antibodies
75544994|NCT00255905|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|
75544995|NCT00255905|Behavioral|Clinician monitoring|
75544996|NCT00270543|Drug|Taxotere, Fluorouracil, Leucovorin|
75544997|NCT04480684|Diagnostic Test|Three-dimensional Endoanal Ultrasound|"Three-dimensional endoanal ultrasound is the gold standard diagnostic tool in the assessment of obstetric anal sphincter injury. The anorectal transducer is inserted directly into the anal canal which allows assessment of the anal sphincter complex.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
76035246|NCT03043625|Other|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
75544998|NCT04480684|Diagnostic Test|Transperineal Ultrasound(multiplanar)|"If endoanal ultrasound is declined or not tolerated, the anal sphincter will also be assessed using three-/four-dimensional (3D/4D) transperineal ultrasound with the probe placed externally on the area of the fourchette.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
75708007|NCT05555771|Behavioral|Usual Care|Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
75708008|NCT05555758|Drug|Adamgammadex Sodium|Aom0319 will be administered intravenously with water for injection.
76035247|NCT03043625|Other|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
76035248|NCT04423185|Drug|Almonertinib 110 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
76035249|NCT04423185|Drug|Dacomitinib 45 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
76035250|NCT04423185|Drug|Alectinib 150 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
76035251|NCT04423185|Drug|Crizotinib 250 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
75393024|NCT05876390|Procedure|Breast surgery|Breast surgery
75393025|NCT05876390|Drug|analgesia|Multimodal analgesia
75393026|NCT05866757|Other|Discontinuation of maintenance treatment|The discontinuation of maintenance treatment in multiple myeloma. Classed as interventional due to treatment being taken away.
75544999|NCT04480684|Diagnostic Test|The MolecuLight i:X: Bacterial autofluorescence camera|"The bacterial load of the perineal wound will be measured every week using the MolecuLight i:X. This is a system, which uses fluorescent illumination to capture and document the presence of bacteria.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed.~These findings will be supported by microbiological analysis of the wound fluid with swab culture and sensitivity."
75708009|NCT05555758|Drug|0.9% Sodium Chloride Injection|0.9% Sodium Chloride will be administered intravenously.
75708010|NCT05555706|Drug|B013+Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
75708011|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359.
75708012|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359.
75708013|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359.
75708014|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359.
76035252|NCT04423185|Drug|Pyrotinib 160/80 MG|Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
75393027|NCT05865158|Other|Home-based exercises|Home-based exercises proposed through the CardioSafe+ platform, guided by therapists specialized in cardiovascular disorders, who will try to adapt the sessions to each participant.
75393028|NCT05861284|Device|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method that can induce long-term changes in connections between neuronal networks.
75393029|NCT05854745|Behavioral|HBB Virtual Training|HBB Virtual Training (Intervention): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day virtual training will be delivered remotely to participants via Zoom. Facilitators and training materials will be the same in both the control and intervention arms.
75393030|NCT05854745|Behavioral|HBB In-person Training|HBB In-Person Training (Control): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day in-person training will be delivered in person. Facilitators and training materials will be the same in both the control and intervention arms.
75393031|NCT05849181|Device|Moona Device|Moona Device pillow pad
75393032|NCT05849181|Device|Inactive Moona Device|Inactive Moona Device pillow pad
76035253|NCT04423185|Drug|Imatinib 400 MG|Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
75393033|NCT05845021|Combination Product|Surgeon-Initiated Bone Health Referral Pathway|Described in arm description
75393034|NCT05836779|Drug|CBL-514 injection|CBL-514 will be administered at the raised area of cellulite.
75393035|NCT05834309|Other|Physical exercise|The intervention protocol consists of a 10-minute warm-up doing joint mobility exercises and adaptation exercises to the core exercises of the training session. The exercises will be performed at low intensity in the warm-up. During the main part of the training session, exercises will be performed on a stationary bike at a higher intensity than in the warm-up and strengthening exercises using weights and body weight exercises such as jumping jacks and squats will also be performed. All movements will be performed at 100% of the maximum speed reached in the propulsive phase (understood as executing the movement as fast as possible according to your muscular and functional capacity). The rests between sets will be between 1 and 2 minutes. At the end of the session, there will be a 5-minute return to calm by stretching.
76035254|NCT04423185|Drug|Niraparib 200/300 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.
76035255|NCT04423185|Drug|Palbociclib 125mg|Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
76035256|NCT04423185|Drug|Vemurafenib 240 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
75393036|NCT05819827|Other|Blood and Tissue|"Patients will collect stool for microbiome analysis at baseline (i.e., 3 +2 days prior to chemotherapy) and again 5-7 days following initiation of chemotherapy.~Blood samples will be collected prior to their first chemotherapy treatment, and in the second week after chemotherapy."
76035257|NCT04423185|Drug|Sintilimab 100MG|Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
75393037|NCT05816473|Other|LLM|Use of a Large Language Model (LLM) chatbot interface to Interact with the Machine Learning Algorithm and interpretability dashboard.
75393038|NCT05814159|Drug|Anakinra|sub cutaneous daily injection
76035258|NCT04423185|Drug|Atezolizumab 1680 MG|Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
76035259|NCT04851275|Behavioral|Physicians trained in shared decision making|Physicians in this group were trained in shared decision making
76035260|NCT04851275|Behavioral|Physicians were not trained in shared decision making|Physicians did not receive training in shared decision making
75393039|NCT05814159|Drug|Placebo|sub cutaneous daily injection
76035261|NCT04851041|Other|Potato|Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
75393040|NCT05811364|Device|Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
75393041|NCT05811364|Device|Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent|Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.
76035262|NCT04851041|Other|Pasta/rice|Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
75393042|NCT05806138|Drug|Vericiguat|A starting dose of vericiguat 2.5 mg will be administered in-clinic at the Day 1 visit. Titration visits will occur on Days 14 and 28, with dose escalation to 5 mg and 10 mg.
75393043|NCT05806138|Other|Optimal medical therapy|All subjects will be followed by a cardiologist throughout the study period and will receive optimal medical therapy for cardiomyopathy/heart failure following the ACCF/AHA and ESC Guidelines for the Management of Heart Failure recommendations, applied individually at the discretion of the treating investigator and in line with individual tolerability. This includes medications such as ßblockers, angiotensin converting enzyme inhibitors(ACEI), angiotensin receptor/neprilysin inhibitor (ARNI), angiotensin receptor blockers (ARB), and mineralocorticoid antagonists
75393044|NCT05789368|Dietary Supplement|Placebo sachet|consume 1 sachet per day
75393045|NCT05789368|Dietary Supplement|VeCollal sachet|consume 1 sachet per day
75393046|NCT05789368|Dietary Supplement|Collagen sachet|consume 1 sachet per day
75393047|NCT05788692|Device|electric tootbrush|Participants will brush twice per day with an electric toothbrush
75545000|NCT04480684|Device|Silhouette® 3D camera: Three-dimensional wound measuring camera|For wound that have superficially dehisced, the wound surface area, depth, volume and healing progress will be precisely measured using the Silhouette® 3D camera. This is a system that uses 3D laser technology to track wound healing progression.
75708017|NCT05545514|Drug|One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,|To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
75393048|NCT05788692|Device|manual toothbrush|Participants will brush twice per day with a manual toothbrush
75393049|NCT05788692|Device|toothbrushing assisting application|Participants will brush twice per day with toothbrushing assisting application
75393050|NCT05786768|Drug|single infusion of Rituximab|single infusion of Rituximab 375 mg/m2
75393051|NCT05786768|Drug|single infusion of Obinutuzumab|single infusion of Obinutuzumab 300mg/1.73 m2
75393052|NCT05777343|Other|Experimental|Cognitive training combined with the recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
75393053|NCT05777343|Other|Exercise and PNE|Recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
75393054|NCT05777343|Other|Cognitive training|Online sessions of cognitive training.
75393055|NCT05765084|Biological|Dendritic cell vaccination|WT1/DC vaccines (8-10 x 10^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered on day 14 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Additional WT1/DC vaccinations after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week).
75393056|NCT05765084|Drug|Atezolizumab|Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.
75393057|NCT05765084|Drug|Platinum/pemetrexed based chemotherapy|On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
75393058|NCT05763056|Procedure|McGrath videolaryngoscopy|The McGrath video laryngoscope has a thin, disposable, clear, regularly shaped blade similar to a Macintosh blade and a large LCD display attached to the arm. It is lighter in weight and the Mc VL has a small camera at the tip, with a more compact screen and handle that can make tracheal intubation easier and faster in normal or difficult airway. The smaller volume, thinner and portrait screen helps reduce blind spots
75708018|NCT05545384|Drug|Immediate Azathioprine (1st attack)|"Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
76035263|NCT04851197|Other|Flipped Learning Model|Students in the intervention group will be given training on testicular cancer and testicular self-examination in accordance with the Flipped Learning Model. The students in the control group will receive the same training with the traditional method. It was aimed to examine the effect of the training given with the Flipped Learning Model on the students' knowledge levels and health beliefs about testicular cancer and self-testicular examination.
76035264|NCT03040271|Other|Health-E-PALS-|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
75393059|NCT05763056|Procedure|C-MAC videolaryngoscopy|The Macintosh blade is attached to the handle and the light beam is passed through the blade tip into a small metal guide tube indented 40 mm. The camera cable is connected to the control unit and the optical cable is connected to the light source. The video macintosh system is installed in a small trolley for easy portability of the device. The trolley supports an 8-inch monitor mounted on a rotating arm on the patient's left side. C-MAC VL devices can create continuous video recordings or static images on a secure removable digital card. The electronic module includes 2 buttons for photo and video shooting. In addition, the image of the C-MAC VL device can be viewed on other devices or recorded via a standard video output port. 3 C-MAC VL reusable metal macintosh blades (sizes 2 to 4) can be used for adult patients. These non-disposable knives have a closed design without gaps in terms of hygiene and have beveled edges to prevent tissue damage.
75545001|NCT00255983|Drug|Faropenem medoxomil|600 mg BID for 5 days
75545002|NCT00255983|Drug|placebo|placebo tablets BID for 5 days
75545003|NCT04480060|Diagnostic Test|COVID-19 diagnostic PCR|Nasopharyngeal swab samples will be analyzed by PCR for COVID-19 DNA existence.
75708019|NCT05545384|Drug|Immediate Rituximab (1st attack)|"Patients randomized in Immediate Rituximab group will benefit from immediate treatment with rituximab. Rituximab 375mg/m2 IV will be given at D1 and D15 and repeat every 6 months for 2 years.~Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
75708020|NCT05545384|Drug|Standard of care|Patients in this group will be treated according to standard care
75708021|NCT05540054|Other|Inspiratory muscle training|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device.
75708022|NCT05540054|Other|Standard pulmonary rehabilitation programme|The standard PR consisted of breathing exercises, peripheral muscle strengthening and self walking training.
75393060|NCT05763056|Device|Direct laryngoscopy|During intubation with a direct laryngoscope (DL), the laryngoscope is inserted into the oral cavity from the right side of the mouth, the tongue is pushed to the left, and after advancing up to the vallecula, it hangs up and forward. In this way, the floor of the mouth and the epiglottis structure are removed from the field of view. If a straight blade laryngoscope is to be used, it is advanced so that the epiglottis remains under the blade after viewing the epiglottis (1). In DL, manipulations such as head extension, sniffing position, and compression of the cricoid cartilage may be required to facilitate visualization of the vocal folds. In 10-15% of the complications experienced during intubation with DL, there are problems related to the angle of view.
75393061|NCT05754125|Dietary Supplement|Di-Leucine Supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
75393062|NCT05754125|Dietary Supplement|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
75393063|NCT05754125|Dietary Supplement|Collagen Supplement|Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
75393064|NCT05750667|Behavioral|Cascade screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
75393065|NCT05747274|Device|SRDK0921|SRDK0921 is an IVD composed of IVD kit for qPCR (SRDK0921KIT) and a cloud-based software (SRDK0921SOFT). It is a class C, rule 3k, IVD according to Regulation (EU) 2017/746.
75545004|NCT02960919|Drug|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
75708023|NCT05538715|Procedure|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
75708024|NCT05538715|Procedure|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
75545005|NCT02960919|Drug|parenteral ampicillin/ penicillin|
75545006|NCT02960919|Drug|gentamicin|
75708025|NCT05538702|Device|IQOS 3.0 DOU with bland taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
75393066|NCT05745350|Drug|Pembrolizumab, Plinabulin plus Etoposide and Platinum|Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.
75393067|NCT05735366|Drug|SAIL66|SAIL66 as a IV infusion
75393068|NCT05735366|Drug|Tocilizumab|Tocilizumab as a IV infusion
75393069|NCT05735340|Behavioral|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
75545007|NCT04479124|Diagnostic Test|COVID-19 PCR|Nasopharyngeal samples were analyzed by PCR for the detection of Novel Coronavirus 2019 DNA
75545008|NCT04478383|Procedure|a new transosseous suture technique|a new technique using the spur base on the insertional site to drill the suture tunnel to repair Achilles sleeve avulsion.
75545009|NCT00415220|Procedure|Spinal Manipulation, Microdiscectomy|
75545010|NCT00270582|Drug|Taxotere, Cisplatin, Gemcitabine|
75393070|NCT05735340|Behavioral|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
75393071|NCT05734508|Biological|MVA-BN vaccine|A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
75393072|NCT05731193|Other|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.|After 3 days students will take 3 tests with different levels of white noise pollution added ( signal-to-noise ratio (SNR) 20, 40 and none added)
75393073|NCT05717387|Behavioral|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
75393074|NCT05717387|Behavioral|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
75393075|NCT05717075|Behavioral|Parents Round|The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.
75708026|NCT05538702|Device|IQOS 3.0 DUO with menthol taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
75393076|NCT05711134|Behavioral|Audit and Feedback on Individual Practice Patterns|Providers are given feedback on their practice patterns of ordering computed tomography of the cervical spine.
75393077|NCT05706376|Behavioral|Promoting Positive Family Futures|Promoting Positive Family Futures is a group-based program that aims to help parents and their adolescent children (13-16 yrs) cope with chronic violence by developing emotional and cognitive awareness, learning constructive conflict resolution strategies, and developing family-wide emotional security and positive family relationships. Emotional Security Theory is the foundational conceptual model for the program, and as such, the PPFF focuses on promoting family-wide communication and establishing emotional security in both the family and community across multiple sessions.Firmly grounded the cultural context of Palestine, the intervention also incorporates intervention elements derived from social ecological theories of resilience, and cognitive behavioral approaches to coping. In total, the program includes 8 sessions lasting approximately 1.5 hours each.
75393078|NCT05706376|Behavioral|Treatment as Usual|Families assigned to the TAU condition will participate in a common service offered by both PCC and CRS - a weekly adolescent-only support group. Both CRS and PCC conduct extended group programs for children and adolescents (24 sessions at PCC; 25 sessions at CRS).
75393079|NCT05701150|Other|Minimal documentation|Minimal data documentation only of patients without targeted therapy based on NGS results
75393080|NCT05701150|Other|Extended documentation|Extended data documentation of patients with targeted therapy based on NGS results
75393081|NCT05700448|Biological|Sugemalimab|IV infusion
75393082|NCT05700448|Drug|Placebo|IV infusion
75393083|NCT05700448|Drug|Pegaspargase|Intramuscular injection
75393084|NCT05700448|Drug|Gemcitabine|IV infusion
75393085|NCT05700448|Drug|Oxaliplatin|IV infusion
75545011|NCT04476823|Other|Activity|The questionnaire had requested information on the biosafety organization, impact of the COVID-19 crisis on the clinical and molecular pathology and the biobanking activity in thoracic pathology, on the research activity associated with the COVID-19, and on the educational and training organization. It requested the different needs planned by the different laboratories following the COVID-19 crisis and finally the consequence of this latter on the health and virological status of the staff members.
75545012|NCT00415259|Device|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
75545013|NCT00415259|Device|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
75708027|NCT05538702|Device|Marlboro Gold (Conventional cigarette)|Conventional cigarette
75708028|NCT05538702|Device|IQOS 3.0 DUO turned off with a bland taste unit|Placebo device
75708029|NCT05529732|Other|e-Mobile Application Patient Education for Patients with Thyroidectomy|"Its mobile application is prepared according to the Android Operating System and can be downloaded free of charge from the Google Play Store, it is an application that provides training and consultancy services for patients who have had thyroidectomy surgery."
75708030|NCT05525871|Dietary Supplement|Nitrates and Citrulline Malate|"Female soccer players should consume the experimental product for 30 days to evaluate the efficacy of a sports supplement high in nitrates combined with citrulline malate in the improvement of performance in high-intensity intermittent exercise.~high intensity"
75545014|NCT00270621|Behavioral|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
75708031|NCT05525871|Dietary Supplement|Control product|Fruit puree
76035265|NCT04423419|Procedure|PENG block|The US probe placed in a transverse plane over the AIIS . the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic drug was injected while observing for adequate fluid spread for a total volume of 20 mL of Bupivacain 0.25%
76035266|NCT04423419|Procedure|fascia iliaca block|ultrasound guidance landmarks are the anterior superior iliac spine and the pubic tubercle (inguinal ligament). The injection site along the lateral one-third of aline joining the anterior superior iliac spine (ASIS) and pubic tubercle (PT) targeting the compartment between fascia iliaca and fascia lata ,the total volume of injection is 20ml of Bupivacain 0.25%
75545015|NCT01600300|Device|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
76035267|NCT04423419|Other|IV analgesia|IV analgesia
75708032|NCT05525429|Behavioral|Nutrition Education|Multidimensional nutrition education will be provided.
75545016|NCT01600300|Device|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
75545017|NCT01600339|Drug|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
75708033|NCT05520203|Other|Care provided by the Nurse Practitioner|Introduction of a Nurse Practitioner in the interdisciplinary care team
75708034|NCT05519800|Dietary Supplement|Isomaltulose|Diet will be supplemented with a beverage containing Isomaltulose as a carbohydrate source.
75708035|NCT05519800|Dietary Supplement|Maltodextrin|Diet will be supplemented using a beverage containing Maltodextrin.
75708036|NCT05514873|Drug|zilucoplan (RA101495)|Subcutaneous injection
75545018|NCT00256022|Drug|Lactobacillus Probiotic|
75708037|NCT05503810|Behavioral|Social support|Contact ones a week with Informal caregiver or peer support
75708038|NCT05501132|Device|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days
75708039|NCT05499780|Device|Sentinox|The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
75708040|NCT05498155|Drug|Neoadjuvant Olaparib monotherapy group|Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.
75708041|NCT05498155|Combination Product|Neoadjuvant combination therapy with olaparib plus durvalumab|Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.
75708042|NCT05495230|Behavioral|Person-centred integrated care intervention|See arm description.
75708043|NCT05495230|Other|Usual care|See arm description.
75708044|NCT05490290|Other|Active|In the active intervention condition, decision support is provided during the referral procedure of medical imaging exams.
75708045|NCT05488808|Device|repetitive Transcranial Magnetic Stimulation|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.
76035268|NCT04850885|Drug|inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml|The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
76035269|NCT04851353|Behavioral|GT+VC|Gentle touch and verbal comfort,
76035270|NCT04851353|Behavioral|Smell|Smell breast milk
76035271|NCT04851353|Behavioral|Taste|Taste breast milk
75545019|NCT00256022|Other|Lactose Powder|
75545020|NCT00270660|Behavioral|biopsy, audiometry, ET function test, ear swab culture, DNE|
75545021|NCT01600456|Behavioral|Prolonged exposure (PE)|PE will include 10 weekly sessions of individual cognitive behavioral therapy.
75545022|NCT01600456|Other|PE plus Sertraline|PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
75545023|NCT00289809|Drug|combination of TLC D-99 and Ifosfamide|"TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
75708046|NCT05488054|Procedure|Physical Therapy|Patients will undergo physical therapy following surgical intervention
75708047|NCT05488054|Procedure|Monitored Work-out|Healthy volunteers will undergo a monitored workout for comparison of data
75708048|NCT05488054|Device|Moxy Oxygen Sensor Device|Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles
75708049|NCT05485584|Drug|rSIFN-co Nasal Spray|8 million IU (16 μg)/day; Once daily
75708050|NCT05485584|Drug|rSIFN-co Nasal Spray|16 million IU (32 μg)/day; Twice daily
75708051|NCT05485584|Drug|Placebo Nasal Spray|Once daily
75708052|NCT05485584|Drug|Placebo Nasal Spray|Twice daily
75708053|NCT05482048|Other|Exercise as Airway Clearance Therapy (ExACT)|"Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET). The undertaking of ExACT at least once per day is expected.~Written and verbal instruction will be provided on the type, duration, frequency and intensity of exercise that is considered adequate replacement for routine chest physiotherapy. A compendium of allowable activity types, and the required times at different intensities that are considered to replace chest physiotherapy for ACT The research team will support exercise advice in line with standard care if subjects request this. The trial has no other changes to CF care. All medications, nutritional support and other treatments continue."
75708054|NCT05477784|Other|Educational Intervention|Receive EC-PC program
75708055|NCT05477784|Other|Informational Intervention|Receive education booklet
75708056|NCT05477784|Other|Questionnaire Administration|Ancillary studies
75708057|NCT05477199|Other|Cognitive behavioral principles-based treatment program|The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.
75393086|NCT05700084|Drug|Utidelone Capsule (Part 1)|"At least 3 dose cohorts are planned, and 14-26 cases are expected. Cohort 1: 2 cases are planned, and the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days, in a 21-day cycle respectively."
75708058|NCT05477199|Other|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
75708059|NCT05468372|Drug|Posaconazole 600 mg followed by posaconazole 300 mg once daily|Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.
75870144|NCT04401566|Other|Internal myofascial release|Internal myofascial trigger point release therapy consist of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial relase techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point
75870145|NCT04401566|Other|External myofascial release|Eksternal myofascial trigger point release therapy consist 30 minutes massage to the abdominal wall, gluteal area and adductors and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and lower extremity of the muscle.
75545024|NCT00256100|Drug|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
75545025|NCT01600534|Behavioral|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
75708060|NCT05468372|Drug|Liposomal Amphotericin B|"All study subjects will be administered intravenous liposomal amphotericin B [5 mg/kg/day infusion in 5% dextrose solution] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment."
75870146|NCT04401566|Other|Control Group|The Control group will have a paper about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breating, pelvic floor muscle stretching and releasing.
75393087|NCT05700084|Drug|Drug A Utidelone Capsule (Part 2: Group A-B)|"Utidelone Capsule at Part 2 in Group A-B will be administered at 60 mg/m2/d.~At Cycle 0, on day 1, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration).~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration). Subjects will receive the drug on day 1-5 with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
75870147|NCT04397354|Drug|Intracochlear Dexamethasone|intracochlear injection of dexamethasone with cochlear implantation
75870148|NCT04397354|Drug|Intratympanic Dexamethasone|intratympanic injection of dexamethasone with cochlear implantation
75393088|NCT05700084|Drug|Drug A Utidelone Capsule (Part 2: Group B-A)|"Utidelone Capsule at Part 2 in Group B-A will be administered at 60 mg/m2/d.~At Cycle 1, on day 1-5, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration), with 21 days as a cycle.~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration), with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
75545026|NCT00289926|Drug|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
75708061|NCT05468281|Other|Checklist implementation|. Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
75708062|NCT05465083|Device|Lungpacer AeroPace Protect System|AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
75708063|NCT05462873|Biological|QEQ278|Intravenous dosing of QEQ278
75708064|NCT05461859|Procedure|Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)|CNA of RAGP
75708065|NCT05453682|Radiation|hypo-IMRT|Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume.
75708066|NCT05453084|Behavioral|Exercise Program|The intervention includes an individualized exercise program in terms of Frequency, Intensity, Time, Type, Volume and Progression (FITT-VP).
75870149|NCT04397354|Drug|No additional drugs(control Group)|Control group: No drugs will be injected middle ear with cochlear implantation
75870150|NCT02970344|Behavioral|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
75870151|NCT03658226|Behavioral|Psychodynamic Interpersonal Therapy (PIT)|PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
75708067|NCT05452720|Device|Surgical Right Ventricular Outflow Tract Reconstruction|Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)
75870152|NCT04387916|Drug|KC1036|Part 1: Dose-escalation phase , KC1036 10mg~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
75393089|NCT05700084|Drug|Drug B Utidelone Injection (Part 2: Group A-B)|"Utidelone Injection at Part 2 in Group A-B will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 1, subjects will be administered Utidelone Injection on day 1-5 with 21 days as a cycle."
75393090|NCT05700084|Drug|Drug B Utidelone Injection (Part 2: Group B-A)|"Utidelone Injection at Part 2 in Group B-A will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 0, all patients will be administered Utidelone Injection on day 1, with 21 days as a cycle."
75393091|NCT05692596|Other|Data collection|Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.
75393092|NCT05691231|Device|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
75393093|NCT05689164|Biological|fordadistrogene movaparvovec|gene therapy administered in a previous study.
75708068|NCT05451784|Drug|PD1+ TILs (NUMARZU-001) product infusion|"The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute.~Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following:~Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion.~Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist.~Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction)."
75870153|NCT03657758|Drug|EPA and rosuvastatin|To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
75393094|NCT05689151|Drug|Abrocitinib|Study Drug for Observational Data Collection
75393095|NCT05688540|Other|e book|e book
75393096|NCT05688540|Other|traditional education booklet|traditional education booklet
75545027|NCT00289926|Drug|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
75870154|NCT03657758|Drug|High dose rosuvastatin|To take high dose rosuvastatin (10mg/day) for ９ months.
75870155|NCT02920970|Device|narafilcon A|contact lens
75545028|NCT01609192|Drug|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
75393097|NCT05681000|Drug|Utidelone Capsule|"At least 4 dose cohorts are planned, and 16-28 cases are expected.~Cohort 1 and 2: 2 cases are planned for each. In cohort 1, the subjects will receive Utidelone Capsule at a dose of 25 mg/m2/d for 5 days, in a 21-day cycle. In cohort 2, the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days, in a 21-day cycle.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days in a 21-day cycle respectively."
75393098|NCT05679154|Behavioral|Team-focused Implementation|CACs randomized to the experimental condition (n = 2) will participate in team-focused implementation. They will receive team development interventions (e.g., goal-setting exercise, training in communication skills) integrated with standard CPM-PTS training and technical assistance strategies.
75393099|NCT05679154|Behavioral|Standard Implementation|CACs randomized to the comparison condition (n = 2) will receive standard training and technical assistance strategies to support CPM-PTS implementation. They will receive CPM-PTS materials (e.g., manual, REDCap surveys, referral protocols), an interactive training, and six months of technical assistance.
75393100|NCT05668585|Drug|CFT1946|Specified oral dose on specified day
75393101|NCT05668585|Drug|Trametinib|Specified oral dose on specified day
75393102|NCT05666102|Behavioral|Transgender men's perspectives on HIV risk and HIV prevention interventions|Investigators will enroll 30 TMSM in 5 focus groups where they will examine the unique contexts in which risk for HIV acquisition occurs for TMSM, and explore participant preferences for HIV prevention services. Focus group questions will focus on five areas: 1) Gathering information related to partner selection and sorting among TMSM; 2) assessing TMSM's perceptions of HIV risk in their lived experiences; 3) exploring the various types of sexual behavior TMSM are engaging in; 4) understanding the various HIV prevention strategies currently being deployed by TMSM; and 5) examine the preferences TMSM have for receiving information related to sexual health and HIV prevention information.
75870156|NCT02920970|Device|stenfilcon A|contact lens
75393103|NCT05662865|Drug|SGLT2 inhibitor|SGTL2i (15 mg) once daily
75393104|NCT05662865|Other|Controlled, Adaptive Study Diet|An adaptive study diet combined with SGLT2i, which consists of four sequential, 7-day long phases in which dietary carbohydrates are gradually reduced (50% carbs, 30% carbs, 20% carbs, and 10% carbs) based on safety and tolerability to achieve moderate ketosis. All diet phases are isocaloric. All meals are provided on an inpatient unit.
75393105|NCT05630365|Diagnostic Test|Panbio™|The Panbio™ COVID-19/Flu A&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs
75393106|NCT05629533|Device|SimpleSense|The study is observational only. No interventions will be triggered by the SimpleSense device
75393107|NCT05622071|Drug|Tislelizumab|Tislelizumab 200 mg will be administered every 3 weeks IV for a maximum of 2 years
75393108|NCT05618054|Behavioral|Looming task|Participants will be asked to look at some pictures during an fMRI scan. Participants will press a button as soon as they see the image appear.
75393109|NCT05615844|Drug|Antibiotic Cement Bead Pouch|The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and tobramycin powder.
75393110|NCT05615844|Device|Negative Pressure Wound Therapy|Standard application of negative pressure wound therapy
75870157|NCT03658148|Procedure|Cardiac Surgery with Cardiopulmonary Bypass|Cardiac Surgery with Cardiopulmonary Bypass
75870158|NCT01068158|Drug|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
75870159|NCT01068158|Drug|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
75870160|NCT03303079|Drug|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
75870161|NCT03303079|Drug|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
75870162|NCT03303079|Drug|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
75870163|NCT01067846|Drug|Seromycin (D-cycloserine, DCS)|250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
75870164|NCT01067846|Drug|Placebo|Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
75870165|NCT01067846|Behavioral|Computerized Cognitive Behavioral Therapy|All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
75870166|NCT03657680|Other|Evaluation|The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
75393111|NCT05613036|Drug|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)
75393112|NCT05613036|Drug|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)
75393113|NCT05613036|Drug|BI 907828|BI 907828
75393114|NCT05606575|Device|Nelli|Nelli is a non-EEG physiological signal-based seizure detection and quantification device that is indicated for use as an adjunct to seizure monitoring during periods of rest. The device utilizes automated analysis of audio and video (media) data collected via the personal recording unit (PRU) hardware accessory to identify epileptic and non-epileptic seizure events with a positive motor component.
75393115|NCT05606146|Device|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
75393116|NCT05601219|Drug|ADA-011|ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.
75393117|NCT05601219|Drug|PD(L)-1 inhibitor|PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
75393118|NCT05591352|Dietary Supplement|Chenopodium formosanum extracts sachet|consume 1 sachet per day
75393119|NCT05591352|Dietary Supplement|Placebo sachet|consume 1 sachet per day
75393120|NCT05589883|Behavioral|EMPOWER-Latinx|EMPOWER-Latinx will be delivered in Spanish by videoconferencing (i.e., Zoom, WebEx) with a trained study interventionist. Intervention modules will be audio- and video-recorded (videorecording optional).
75393121|NCT05584696|Other|Green light exposure|The experimental group wears green color glasses ten minutes before surgery until it ends.
75393122|NCT05584696|Other|Normal light exposure|The control group wears green color glasses ten minutes before surgery until it ends.
75393123|NCT05584618|Other|Education|education
75708069|NCT05444270|Other|Standard salvage therapy|Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
75393124|NCT05582681|Diagnostic Test|Cepheid POC HCV Viremia (RNA) test|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
75393125|NCT05582681|Other|HCV education from a health care provider|HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
75393126|NCT05582681|Drug|Glecaprevir and Pibrentasvir|G/P will be provided for 8 weeks.
75393127|NCT05566054|Drug|Chidamide|Chidamide 10mg orally daily for 7 days (d1-d7)
75708070|NCT05444270|Radiation|Standard salvage therapy + SABR|Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
75708071|NCT05443529|Other|Adaptive sports|Participation in community adaptive sports programs
75393128|NCT05566054|Drug|Azacitidine|azacytidine 75mg/m2 daily for 7 days (d1-d7)
75393129|NCT05566054|Drug|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
75393130|NCT05560932|Behavioral|IMB-motivational interviewing (MI) techniques (IMB-MI)|The clinical pharmacist will employ MI in informational, participant-centered discussions in which the clinical pharmacist and participant collaboratively discuss the harms of drinking and polypharmacy (specifically alcohol interactive medications), symptoms associated with alcohol and specific medications, and how to mitigate these harms. Motivational elements include messages highlighting the participant's personal risk of bothersome symptoms from their use of alcohol and level of polypharmacy, attitude change elements to improve attitudes toward the intended behavior change, social normative support for the intended behavior change including identification of people who can support the participant in this process, and a menu of options for referrals for skill building (e.g. Social Work, meeting with the clinical pharmacist at their clinic, follow-up with the HIV clinician, alcohol-reduction programs, based on what is locally available as part of VA-based care).
75393131|NCT05557760|Behavioral|Cognitive Control Training (CCT)|"The CCT training group without booster sessions will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). The aPASAT is a Cognitive Control Training where participants need to click on the sum of the last two heard digits.~Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control."
75708072|NCT05443061|Drug|Nitroglycerin|Subcutaneous nitroglycerin injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
75393132|NCT05557760|Behavioral|Cognitive Control Training (CCT) + Booster Sessions|The CCT with booster sessions group will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). After these training sessions, participants in this condition will be asked to complete additional CCT sessions after reporting two consecutive assessments of increased depressive symptoms during the monitoring period (PHQ-9 scores equal or greater to 9). Specifically, they will then be instructed to perform three additional sessions within one week. This may be repeated when the participant reports multiple consecutive assessments of increased depressive symptoms during the post-training phase, with a minimum of 3 weeks between the booster sessions and a maximum of 9 boosters (3 x 3 sessions) in total.
75545029|NCT01609270|Device|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
75545030|NCT00256139|Drug|Raptiva|
75545031|NCT00270699|Biological|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
75545032|NCT00270699|Biological|Placebo|Placebo for rDEN4delta30-200,201
75545033|NCT01609387|Dietary Supplement|Fit For me|
75545034|NCT01609387|Dietary Supplement|Davitamon|
75545035|NCT01609426|Genetic|DNA chip dedicated to the pharmacogenetic of steroids|direct DNA extraction from peripheral blood cells
75545036|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
75708073|NCT05443061|Drug|Normal saline|Subcutaneous normal saline injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
75708074|NCT05440149|Radiation|No PMRT for mastectomy / No regional RT for BCS|"Regional RT includes high-tangent field, and can include undissected axilla.~The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
75545037|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
75545038|NCT00256178|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
75545039|NCT00270738|Procedure|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
75545040|NCT00270738|Procedure|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
75545041|NCT00270738|Procedure|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
75870167|NCT03658070|Drug|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
75393133|NCT05552001|Drug|Sacituzumab govitecan|Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
75393134|NCT05544708|Behavioral|Wellness Engagement Intervention|Train for, recruit participants into, and lead a 12-week lifestyle intervention delivered via weekly group meetings
75708075|NCT05440149|Radiation|PMRT for mastectomy / WBI + Regional RT for BCS|"Regional RT includes high-tangent field, and can include undissected axilla.~The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
75708076|NCT05439564|Drug|Dexmedetomidine|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
75393135|NCT05540288|Drug|Nalmefene|"Week 1: 18 mg/d~Week 2:~In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d~In the presence of grade 3 ARs, 18 mg/d~In the presence of grade 4 ARs, treatment will be stopped immediately.~Week 3 to week 5:~In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage~In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped.~In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage~In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d~Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
75708077|NCT05439564|Drug|Morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
75708078|NCT05439564|Drug|Dexmedetomidine|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
75708079|NCT05438875|Drug|all-trans retinoic acid|ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.
75545042|NCT01609504|Procedure|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
75545043|NCT01609504|Procedure|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
75708080|NCT05438875|Drug|Eltrombopag|The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
75393136|NCT05540288|Drug|Placebo|"Week 1: 1 tablet/d~Week 2:~In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d~In the presence of grade 3 ARs, 1 tablet/d~In the presence of grade 4 ARs, the treatment will be stopped immediately.~Week 3 to week 5:~In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage~In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.~In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage~In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d~Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
75393137|NCT05537285|Device|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|active side magnetic coil stimulation applied to individualized target in the left dorsal lateral prefrontal cortex.
75393138|NCT05537285|Device|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|active side magnetic coil stimulation applied to standardized target in the left dorsal lateral prefrontal cortex.
75393139|NCT05537285|Device|Sham Accelerated Intermittent Theta Burst Stimulation (Sham)|sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
75708081|NCT05435833|Procedure|bilateral ultrasound guided GPN block|a linear high frequency ultrasound probe will be initially positioned over the hyoid bone in the transverse plane, then the probe will be rotated to keep in line with the mandibular angle and the pharyngeal wall is identified by US. Using an in plane approach, a 22 G ,5 cm needle will be advanced till it reaches just superficial to the pharyngeal wall and 2.2 ml of 0.25% bupivacaine will be injected.
75708082|NCT05427123|Other|Medication or psychosocial treatment|Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
75708083|NCT05425485|Behavioral|Multi-component intervention|Web-based strategy with processes, materials, and patient and doctor education formats.
75708084|NCT05424237|Behavioral|App intervention|usual care plus app ussage with the aim of promote healthy behaviors (diet, physical activity and weight)
75708085|NCT05422820|Diagnostic Test|Diagnostic high-definition white-light (HDWL) colonoscopy|All participants will undergo to colonoscopy examination performed by competent/junior or expert/senior endoscopists (>150-400 or >400 previous colonoscopies, respectively). Bowel preparation was performed using different solutions, according to the clinical discretion of the attending, who indicated colonoscopy. After deep sedation by intravenous propofol with or without fentanyl or midazolam administration, a water-assisted colonoscopy was performed using a high-definition (HD) scope with white light (WL). Colonoscope trademark differs among participant centres.
75708086|NCT05421858|Drug|PF-07842805|PF-07842805 (IV infusion)
75870168|NCT03657914|Procedure|Single-hole inflatable mediastinal mirror|The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
75870169|NCT03657524|Other|echocardiography|Speckle tracking echocardiography
75393140|NCT05536440|Drug|PF-07261271|IV or SC
75708087|NCT05421858|Drug|Caspofungin|Caspofungin (IV infusion)
75870170|NCT03311659|Biological|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
75870171|NCT03874234|Drug|GSK3186899|GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
75870172|NCT03874234|Drug|Placebo|Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
75870173|NCT03657446|Drug|Clazosentan|Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
75870174|NCT03657446|Drug|Placebo|Matching placebo infusion
75870175|NCT03657446|Drug|Moxifloxacin|Film-coated tablet containing 400 mg moxifloxacin
75870176|NCT05276323|Drug|Medihoney Derma Cream|applied topically, twice a day, on all affected areas in the body for two weeks.
75870177|NCT05276323|Drug|Hydrocortisone 1% cream|applied topically, twice a day, on all affected areas in the body for two weeks.
75870178|NCT02727452|Other|Skin-to-skin contact|
75393141|NCT05536440|Drug|Placebo|IV or SC
75393142|NCT05523440|Drug|Bevacizumab|Bevacizumab infusion.
75393143|NCT05523440|Drug|Niraparib|Niraparib oral capsule.
75393144|NCT05522972|Behavioral|Video Game Vision Training|A new approach for improving amblyopic vision using video games
75393145|NCT05522972|Behavioral|Perceptual Learning|A new approach for improving amblyopic vision with perceptual learning
75393146|NCT05522972|Behavioral|Occlusion Therapy|Conventional treatment for amblyopia
75393147|NCT05518539|Device|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
75393148|NCT05512806|Drug|AZD5462|Participants will receive AZD5462 orally.
75393149|NCT05503927|Other|No Intervention|This is a non-interventional study, therefore no intervention is used.
75393150|NCT05494034|Device|Reveal LINQTM|"implantable cardiac monitoring device (Reveal LINQTM)"
75545044|NCT01609621|Device|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
75545045|NCT02488408|Drug|Bemcentinib|
75545046|NCT02488408|Drug|Cytarabine|
75545047|NCT02488408|Drug|Decitabine|
75545048|NCT00270777|Drug|adrenaline, promethazine, hydrocortisone|
75545049|NCT00256256|Drug|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
75545050|NCT01580176|Device|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
75545051|NCT01609660|Dietary Supplement|Saccharomyces boulardii|100mg daily for seven days prior to surgery
75708088|NCT05421858|Drug|PF-07842805|PF-07842805 oral tablet
75708089|NCT05421858|Drug|Fluconazole|Fluconazole oral capsule
75708090|NCT05421858|Drug|Placebo|Matching placebo (IV infusion)
75708091|NCT05421858|Drug|Placebo|Matching placebo (tablet or capsule)
75708092|NCT05421611|Biological|STAMARIL|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent."
75393151|NCT05483075|Behavioral|HCP-Guided Exercise Training Program|"Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).~Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.~The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR)."
75708093|NCT05421611|Biological|SII-YFV|"SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine. The SII-YFV is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF working seed virus.~SII-YFV will be provided in vial presentation for the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with sterile water for injection."
75708094|NCT05418816|Device|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during the normal arteriovenous fistula (AVF) creation procedure. It provides mechanical support to the vein and induces outward remodeling to improve maturation and patency of AVFs.
75393152|NCT05482542|Other|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
75393153|NCT05482542|Drug|Cyclophosphamide/ATG|Cyclophosphamide/ATG
75393154|NCT05482542|Drug|Cyclophosphamide/Rituximab|Cyclophosphamide/Rituximab
75393155|NCT05471518|Other|No intervention|No intervention
75545052|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
75708095|NCT05417711|Device|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
75708096|NCT05417711|Device|Tailor-made Notched Music Training|Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.
75393156|NCT05470777|Combination Product|"CD22/CD19 CAR T and auto-HSCT sandwich strategy"|The patients received sequential infusion of CD22 and CD19 CAR-T cells (co-stimulatory molecule was 4-1BB and infusion dose was 5*10^6/kg respectively) after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after CAR-T infusion. Standard BuCy as conditioning regimen for Auto-HSCT was used 4 weeks after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after Auto-HSCT. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
75393157|NCT05458960|Behavioral|Social needs navigator program|4 months of assistance tailored to the needs of the participant
75393158|NCT05458960|Behavioral|Enhanced usual care|Referral to United Way 2-1-1
75393159|NCT05456295|Device|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.
75393160|NCT05454410|Drug|MIJ821 Subcutaneous Injection - low dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
75393161|NCT05454410|Drug|MIJ821 Subcutaneous Injection - medium dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
75393162|NCT05454410|Drug|MIJ821 Subcutaneous Injection - high dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
75393163|NCT05454410|Drug|Placebo Subcutaneous Injection|0.9% sodium chloride solution to be administered as a single subcutaneous injection on Day 1
75393164|NCT05453617|Behavioral|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
75393165|NCT05453617|Behavioral|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
75708097|NCT05417360|Dietary Supplement|Akkermansia muciniphila|"During the weight management period (weeks 8 to 32), the pasteurized A. muciniphila product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks) capsules. It appears as a white homogenous powder.~."
75545053|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
76035272|NCT03043391|Biological|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
75545054|NCT00289965|Behavioral|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
75545055|NCT00289965|Behavioral|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
75545056|NCT00289965|Behavioral|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
75545057|NCT01609738|Device|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
75545058|NCT00256334|Drug|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
75545059|NCT01609777|Procedure|SBAR|situation, background, assessment, recommendation
75545060|NCT01609855|Drug|Hyoscine Butyl Bromide 20mg/2 ml i.v.|Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
75545061|NCT01609855|Drug|Saline 2 ml i.v.|Administration of Saline 2 ml at time of caecal intubation
75545062|NCT00256373|Procedure|Mod. functional restoration-Individ. dynamic back-muscle|
75545063|NCT00270816|Drug|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
75545064|NCT00270816|Drug|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
75545065|NCT01609972|Device|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
75545066|NCT00256412|Drug|Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
75708098|NCT05417360|Dietary Supplement|Placebo|During the weight management period (weeks 8 to 32), the placebo product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks). It appears as a white homogenous powder.
75545067|NCT00256412|Drug|Placebo|4 capsules of placebo each day
75545068|NCT01602367|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 12 weeks
75545069|NCT01602367|Drug|BMS-823778|Capsules, Oral, 6 mg, Once daily, 12 weeks
75545070|NCT01602367|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 12 weeks
75545071|NCT01602367|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 12 weeks
75545072|NCT00290004|Drug|motexafin gadolinium|
75545073|NCT01606891|Behavioral|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
75545074|NCT00256490|Procedure|PET/CT 20 days after the first cycle of chemotherapy|
75545075|NCT01609816|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
76035273|NCT04844177|Other|conditioning with TLI|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~Cyclophosphamide 120 mg/kg (days -5, -4, -3)~Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~Melphalan 180 mg/m2 (day -2)~Rituximab 100 mg/m2 (day -1)~Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
76035274|NCT04844255|Dietary Supplement|dietary salt|2 grams of dietary salt
76035275|NCT04843865|Dietary Supplement|Chinese Herbs|Chinese Herbs
76035276|NCT02610725|Other|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
75393166|NCT05448209|Behavioral|walking exercise|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
75545076|NCT00256529|Procedure|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
75545077|NCT00290043|Drug|Insulin glulisine|
75545078|NCT01606930|Behavioral|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
75545079|NCT00256568|Behavioral|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
76035277|NCT04850417|Drug|Beta blocker, aspirin, clopidogrel|Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy
76035278|NCT04843943|Drug|Sintilimab|Sintilimab: 200mg IV Q3W D1
76035279|NCT04843943|Drug|Bevacizumab Biosimilar|Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
76035280|NCT04850261|Drug|hCG Injection|Ovulation will be induced by subcutaneous hCG injection
76035281|NCT04850261|Drug|Nafarelin nasal spray|Ovulation will be induced by nasal application of Nafarelin
75545080|NCT02270047|Dietary Supplement|Orange nectar|Orange nectar
75545081|NCT02270047|Dietary Supplement|Orange Nectar with fibre|
75545082|NCT02960607|Drug|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
75545083|NCT02270125|Procedure|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
75545084|NCT02270164|Dietary Supplement|Artichoke Leaf Extract|Capsule
75708099|NCT05416385|Other|Carotid Contrast Enhanced Ultrasound|Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
75708100|NCT05403944|Behavioral|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
76035282|NCT04850027|Procedure|TME+Lateral lymph node dissection.|TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
76035283|NCT04850183|Behavioral|Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis|The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
75545085|NCT02270164|Other|Placebo|Capsule
75545086|NCT00290082|Drug|loxapine, midazolam|agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
75545087|NCT00290082|Biological|blood sample|was evaluated in patients sedated, alcohol level, blood sugar
75708101|NCT05403944|Behavioral|Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)|6 weeks of STRIPE rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
76035284|NCT04849949|Other|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
76035285|NCT04849949|Other|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
76035286|NCT04849949|Other|English walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
76035287|NCT04843553|Drug|Oral Nicotinamide|
76035288|NCT02684461|Drug|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
75393167|NCT05432778|Drug|Letermovir Pill|Patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available). n all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay.
75393168|NCT05429736|Behavioral|Motor Skill Training (MST)|During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
75545088|NCT00290082|Other|patient monitoring|Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
75708102|NCT05400603|Combination Product|Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate|"The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10^7 and then 3 x 10^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels."
76035289|NCT04843475|Diagnostic Test|Echocardiography|Trans-thoracic Echocardiography
76035290|NCT03040193|Drug|Lignocaine Nebulization|4% Lignocaine delivered via Nebulization
76035291|NCT03040193|Drug|Saline Nebulization|Normal Saline Delivered via Nebulization
76035292|NCT03039101|Procedure|Nasal lavage|determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry
76035293|NCT03039101|Procedure|Nasal allergen challenge|A small amount of allergen extract will be applied to one naris.
76035294|NCT03039101|Procedure|Epicutaneous skin testing|Skin testing (prick) to determine allergies.
76035295|NCT03039101|Procedure|Peripheral blood|Peripheral blood draw
76035296|NCT03039101|Drug|Montelukast 10Mg Tablet|one pill orally, daily, for 1 week
76035297|NCT03039101|Drug|Placebo Oral Tablet|one pill orally, daily, for 1 week
76035298|NCT03604393|Behavioral|Practice facilitation|For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
76035299|NCT03043469|Other|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
76035300|NCT03043469|Other|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
76035301|NCT03043469|Other|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
76035302|NCT03043469|Other|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
75393169|NCT05429736|Device|Transcutaneous Spinal Stimulation (TSS)|TSS will be delivered using a commercially available neuromuscular electrical stimulator. The active electrode will be positioned directly over the spine at the T11/T12 spinous interspace, and the reference electrode will be positioned over the umbilicus. Stimulation intensity will be gradually increased until paresthesia of the lower legs and feet is achieved or to the highest level each participant can tolerate. Stimulation will be delivered for a total duration of 30 min after paresthesia/ maximum tolerability is reached.
76035303|NCT03043469|Other|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
75393170|NCT05421832|Device|Digital Speech Application|A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.
76035304|NCT03043469|Other|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
75545089|NCT00290082|Drug|Loxapine|Loxapine 1 mL / 10 kg
75545090|NCT00290082|Drug|Midazolam|Midazolam 1 mL / 10 Kg
75545091|NCT02270203|Radiation|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
75393171|NCT05421780|Dietary Supplement|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits as breakfast.
75393172|NCT05421780|Dietary Supplement|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits as breakfast.
75393173|NCT05421780|Dietary Supplement|control biscuits|Consumption of plain biscuits as breakfast.
75393174|NCT05417126|Biological|Gene Therapy-vMCO-010|The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
75393175|NCT05394051|Behavioral|Positive Affect Regulation sKills (PARK)|"The goal of the PARK program is to reduce feelings of anxiety, depression, and social isolation, as well as increase well-being and a sense of meaning and purpose through the practice of positive emotion skills via a self-guided online platform.~The total time involved from the beginning to the end of the intervention portion of the study is approximately 6 months (includes 6-week PARK course, baseline and follow-up assessments. Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up."
75393176|NCT05391828|Device|Zimmer-Biomet Persona Medial Congruent (MC) Bearing Design|TKA will be performed using the MC Bearing Design. The MC bearing provides medial stability and lateral mobility to facilitate more natural motion.
75393177|NCT05391828|Device|Zimmer-Biomet Persona Posterior-Stabilized (PS) Bearing Design|TKA will be performed using the PS Bearing Design. The PS bearings are designed to provide ±1.5 degrees varus/valgus constraint and ± 5.5 degrees internal/external rotation constraint.
75393178|NCT05390736|Behavioral|Gait and balance assessment|Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).
75393179|NCT05390736|Behavioral|Medication review|Patients' medication history in the EHR is assessed for polypharmacy (using 5 or more medications concurrently) and use of medication in the following classes: tricyclic antidepressants, antihistamines, antiemetics, antipsychotics, antispasmotics, muscle relaxants, benzodiazepines, hypnotics, and opioids. The CRN confirms prescriptions with the patient. The CRN reports the medication risk in her provider report and provides medication management educational materials to the patient. At the patient's upcoming primary care visit, providers evaluated whether the medications associated with increased fall risk could be adjusted.
75393180|NCT05390736|Behavioral|Comorbidity review|The clinical research nurse reviews the patient's EHR problem list for diagnoses of comorbidities associated with increased fall risk including: cognition problems, Parkinson's disease, cardiac issues, depression, or incontinence. Comorbidities are shared with providers in the recommendation statement.
75393181|NCT05390736|Behavioral|Fall history|The CRN asks how many times the patient had fallen in the past 12 months, whether those with falls sought medical attention, and if they experienced blackouts, loss of consciousness, or a broken/fractured bone(s) resulting from a fall. Fall history information is added to the provider report to increase the salience of fall prevention information.
75708103|NCT05399485|Drug|Rimegepant|Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12
75708104|NCT05399485|Drug|Placebo|Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
75708105|NCT05397496|Biological|PIT565|Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
75545092|NCT02270320|Behavioral|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
75708106|NCT05391841|Drug|NOVOCART Inject|Autologous Chondrocyte Implantation
75708107|NCT05389553|Other|Ultrasound exam|We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth
75393182|NCT05390736|Behavioral|Assessment of feet/footwear|The CRN observes or asks about the patient's current footwear, asks about foot pain or loss of sensation, and notes a diabetes diagnosis when applicable. Patient reports of foot pain, loss of sensation or diabetes result in a CRN note to the provider to examine the patient's feet and the potential need for a referral to podiatry. The CRN also reviewed a safe footwear handout with all patients regardless of their responses and emailed it to patients with other patient information following the call.
75393183|NCT05390736|Behavioral|Assessment of visual acuity|The CRN projects a Banner eye chart on Zoom for the patient to read with their contacts or glasses from five feet away for both eyes together and each eye individually. Phone patients are asked to self-report any vision problems. If either the video screening or patient self-report indicated any vision problems, the CRN notes the result and recommendation for eye care referral for the patient's provider to review and order.
75393184|NCT05390736|Behavioral|Home safety risk assessment|"The CRN reviews the CDC brochure Check for Safety: A Home Fall Prevention Checklist for Older Adults with each patient. Check for Safety asks 17 questions about the home's floors, stairs and steps, kitchen, bathrooms, and bedrooms and suggests ideas for removing or reducing fall hazards. The CRN communicates home safety risks and a recommendation for occupational therapy to the provider for indicated patients."
75393185|NCT05390736|Behavioral|Vitamin D Deficiency|The CRN asks the patient if they usually take a Vitamin D supplement with their other medications. If the patient does not take a Vitamin D supplement, the CRN recommends the provider check Vitamin D levels and consider supplementation if Vitamin D levels are less than 20 ng/mL.
76035305|NCT03043469|Other|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
76035306|NCT03043469|Other|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
75393186|NCT05380856|Device|Turning ON the neuromodulator|IPG on
75393187|NCT05380856|Device|Turning OFF the neuromodulator|IPG OFF
75393188|NCT05371028|Other|Non-interventional Study|This is non-interventional study.
76035307|NCT03043469|Other|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
75393189|NCT05369052|Drug|contezolid acefosamil (IV)/contezolid (PO)|Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
75393190|NCT05369052|Drug|Linezolid (IV and PO)|Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
75393191|NCT05359822|Other|Image-Based Report|Participants will receive the new coronary artery calcium score risk report plus the old report
75393192|NCT05355870|Behavioral|Cognitive Training Intervention|Participants in the intervention group will complete a series of cognitive training exercises adapted from the BrainHQ. Results from the intervention development activities will be used to finalize the dose, frequency, and duration of the training. Each session will include 2 training exercises that target different cognitive domains. As participants progress, the difficulty level will be automatically adapted based on participants' performance.
75393193|NCT05354115|Diagnostic Test|Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel|Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
75393194|NCT05353751|Behavioral|Kind Minds Program|"The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude."
75545093|NCT02270398|Behavioral|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
75545094|NCT02270398|Behavioral|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
76035308|NCT03043469|Other|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
75393195|NCT05353452|Behavioral|Neurology Based Collaborative Care|Twenty-four week, evidence-based remote collaborative care model initiated around the time of a neurology visit. The collaborative care team roles include the care manager, psychiatrist, and psychologist/social worker who interact with the patient participant and the patient's neurologist.
75545095|NCT02270398|Behavioral|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
75708108|NCT05381441|Behavioral|Safety Action Feedback and Engagement (SAFE) Loop|Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
76035309|NCT03043469|Diagnostic Test|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
75393196|NCT05353452|Behavioral|SOC Neurological care|Usual neurology care means ongoing, epilepsy provider-recommended clinic visits, prescriptions, testing and referrals from their epilepsy provider. Mental health referrals or prescribing of antidepressants may potentially occur in this group; these types of interventions will be tracked at outcome assessments.
75393197|NCT05353283|Behavioral|Motivational Interviewing Counselling|Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test
75393198|NCT05353283|Device|Point-of-care Urine Tenofovir Measurement|Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.
75545096|NCT00256646|Drug|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
75708109|NCT05379725|Other|Mediterranean Dietary Pattern|The Mediterranean dietary pattern includes whole or minimally processed foods with a high intake of vegetables, fruits, whole grains, fish, and olive oil.
76035310|NCT03043469|Other|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
76035311|NCT03043469|Other|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
76035312|NCT03043469|Other|Breath-hold test|Holding the breath a few times for as long as possible.
76035313|NCT03043469|Other|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
76035314|NCT03043469|Other|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
75393199|NCT05352009|Other|Sling exercise training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of sling exercise training and 10 min treadmill training.
75393200|NCT05352009|Other|Conventional balance training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of balance exercise training and 10 min treadmill training.
75393201|NCT05344209|Biological|UV1|UV1 vaccine
75393202|NCT05344209|Drug|Sagramostim|for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
75545097|NCT02270437|Drug|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
75545098|NCT02270554|Device|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
75545099|NCT02270749|Drug|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
76035315|NCT03103399|Drug|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
76035316|NCT03103399|Drug|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
76035317|NCT03103399|Drug|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
75545100|NCT02270749|Drug|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
75545101|NCT00256685|Drug|DVS-233 SR|
75545102|NCT02270788|Drug|Crenolanib|"Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.~All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old."
75708110|NCT05379725|Other|High Fermented Food Dietary Pattern|Fermented foods such as yogurt, kefir, fermented cottage cheese, fermented vegetables, vegetable brine drinks, kombucha, other fermented non-alcoholic drinks, and other foods will be recommended.
76035318|NCT03103399|Drug|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
76035319|NCT03040115|Other|Non-Interventional Study|
76035320|NCT03038945|Other|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
76035321|NCT03038945|Other|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
75393203|NCT05344209|Drug|Anti-PD-1/PD-L1 treatment|either pembrolizumab, atezolizumab or cemiplimab
75393204|NCT05335148|Drug|oral colchicine(0.6 mg) once a day|The standard of care arm will receive a placebo colchicine pill once a day
75393205|NCT05327764|Other|Work to rest cycles of 40:20 minutes|Walking in a hot environment for 2 hours with repeated 40 minutes of work and 20 minutes of rest
75393206|NCT05327764|Other|Work to rest cycles of 20:10 minutes|Walking in a hot environment for 2 hours with repeated 20 minutes of work and 10 minutes of rest
75393207|NCT05321420|Drug|Placebo|placebo
75393208|NCT05321420|Drug|Pirfenidone|pirfenidone 801 mg TID
75393209|NCT05321420|Drug|Deupirfenidone|Deupirfenidone
75393210|NCT05309577|Behavioral|Behavioral Self-Monitoring + Motivational Interviewing|Participants (n=20) will wear a iWatch to continuously measure their objective sleep-wake activity. The iWatch data sync to the new myRhythmWatch app, where participants will monitor their behavioral rhythm. Participants will also interact with a 'health coach' about their recorded behaviors weekly. This health coach will use motivational interviewing to enhance older adult caregivers' confidence and intrinsic motivation to engage in regular self-care.
75393211|NCT05299931|Drug|Ustekinumab|dose escalation from every 8 weeks to every 4 weeks only in arm 2
76035322|NCT03043157|Drug|rocuronium|intravenous rocuronium infusion
76035323|NCT05339113|Diagnostic Test|68Ga-FAPI-46 PET/CT|Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.
75393212|NCT05295628|Device|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
75393213|NCT05295628|Device|SENTINEL™ Cerebral Protection System|The SENTINEL CPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
75393214|NCT05287113|Drug|Retifanlimab|Retifanlimab 500mg will be administered intravenously every 4 weeks.
75393215|NCT05287113|Drug|INCAGN02385|INCAGN02385 350mg will be administered intravenously every 2 weeks.
75393216|NCT05287113|Drug|INCAGN02390|INCAGN02390 400 mg will be administered intravenously every 2 weeks.
75393217|NCT05287113|Drug|Placebo|Placebo will be administered intravenously.
75393218|NCT05280067|Device|ZetaFuse™ Bone Graft|The ZetaFuse™ Bone Graft will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.
75393219|NCT05277740|Device|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
75393220|NCT05263648|Other|Virtual Reality Session|"VR-based education sessions will be used to influence patients' perceived emotional and social distress while undergoing radiation therapy (RT).~Emotional and social distress levels will be evaluated using questionnaires at baseline (prior to the first VR experience), at completion of RT, and at 30-60 days post RT."
75393221|NCT05260892|Device|Narrow GM implants|Rehabilitation of superior lateral incisors or inferior central and lateral incisors with narrow implants supporting single unit or partial prostheses
75870179|NCT05276245|Behavioral|Structured Protocol of Nature Contact|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
75393222|NCT05258435|Device|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
75393223|NCT05246566|Other|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
75393224|NCT05244304|Drug|Tinlarebant|Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
75393225|NCT05244304|Drug|Placebo|Not active drug
75393226|NCT05235321|Device|Standard GAT|Standard Goldmann Applanation Tonometry (GAT): this is the standard method for IOP measurement in clinical practice
75393227|NCT05235321|Device|Fixed force GAT|An investigational device similar to standard GAT
75393228|NCT05235321|Device|Upright applanating prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device
75545103|NCT02270788|Drug|Sorafenib|"Days 8-28 of course 1: given orally once each day.~All subsequent courses: given orally on days 1-28 once per day~This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered."
75545104|NCT02270788|Drug|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
75545105|NCT02270827|Drug|Aminophylline|intravenous medication
75545106|NCT02270827|Drug|Hydrocortisone|Intravenous medication
75545107|NCT02270866|Device|TNM(trademark) - thermoneuromodulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
75870180|NCT05275777|Drug|ADG106|Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
75870181|NCT05275777|Drug|Doxorubicin|Administered as an intravenous infusion.
75545108|NCT00290121|Drug|Olanzapine|
75545109|NCT02270905|Device|dCELL® Meniscus|decellularised porcine xenograft
75870182|NCT05275777|Drug|Cyclophosphamide|Administered as an intravenous infusion.
75870183|NCT05275777|Drug|Paclitaxel|Administered as an intravenous infusion.
75870184|NCT02985398|Biological|ALD403 (Eptinezumab)|
75870185|NCT05275621|Device|Virtual Reality|"A Virtual Reality game is provided through a headset. Subjects play in a virtual environment. Positioning of the headset occurs before starting the procedure and is maintained throughout the procedure. The headset used will be Oculus Rift 2 by Facebook Tech. ltd.. The software is designed specifically for the purpose by Softcare Studios. The game played is called Drums."
75870186|NCT05275621|Procedure|PICC positioning|A PICC is inserted under ultrasound guidance through a modified Seldinger technique in a deep vein of the upper arm. The skin is infiltrated with 0.5-1ml 2% lidocaine before dilation of the skin. Tip guidance and positioning is achieved through intracavitary ECG.
75393229|NCT05235321|Device|Supine Applanating Prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device performed in the supine position
75393230|NCT05216809|Behavioral|Habitual Physical Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain >7,000 steps/day.
75393231|NCT05216809|Behavioral|Step-Reduction|Participants will be required to reduce their daily step-counts to <2,000 steps/day. Further, they will be required to refrain from structured physical activity.
75393232|NCT05216432|Drug|RLY-2608|RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
75393233|NCT05216432|Drug|Fulvestrant|500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
75393234|NCT05216432|Drug|Palbociclib 125mg|125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
75545110|NCT04709744|Drug|Vitamin D|Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
75545111|NCT04709744|Diagnostic Test|ELISA|Measure vitamin D level
75545112|NCT02271022|Other|Non-Interventional Study|Non-Interventional Study
75545113|NCT02271100|Device|ultrasound guidance|use of ultrasound for entry position estimation
75545114|NCT02271100|Device|palpation guidance|use of palpation for position estimation
75393235|NCT05216432|Drug|Ribociclib 400mg|400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
75393236|NCT05216432|Drug|Ribociclib 600mg|600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
75393237|NCT05215275|Behavioral|exercise|"the exercise consists of two different modalities: moderate-intensity continuous training (MICT): the main MICT program will be designed to last 30 minutes. The MICT will be designed to involve core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).~high-intensity interval training (HIIT): The HIIT motions will be a mix of spiderman mountain climbers, standing oblique crunches, squats, froggers, jumping jacks, foot fire, jump squats, and mountain climbers. A total of four sets will be performed with 1-minute rests between sets. Each set comprises eight motions, with each motion lasting 30 seconds and a rest interval of 10 seconds between motions. Participants in the HIIT group will perform the most repetitions possible within 30 seconds."
75708111|NCT05378776|Dietary Supplement|sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.
75545115|NCT00270972|Device|Bilayered Cellular Matrix (OrCel)|
75545116|NCT00256802|Device|MR-angiography, GTN|
75545117|NCT02271139|Drug|Alectinib|Alectinib 600 mg administered orally with food.
75545118|NCT02271178|Other|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
75545119|NCT02271178|Other|Conventional therapy|Usual therapy
75545120|NCT00256841|Drug|Chemotherapy|
75545121|NCT00256841|Procedure|Radiation Therapy|
75545122|NCT02271295|Drug|Enoxaparine|Enoxaparine 4000UI/day during 24 months
75708112|NCT05378776|Dietary Supplement|Standard rehydration solution|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
75870187|NCT04460144|Diagnostic Test|Mass spectrometry|Proteomic analysis
75870188|NCT03310723|Device|Face Mask preoxygenation|Standard face mask preoxygenation.
75393240|NCT05202860|Biological|HPV Vaccine|(Gardasil 9 human papilloma vaccine)
75393241|NCT05202860|Biological|PLACEBO vaccine|Isotonic saltwater sham vaccine
75393242|NCT05200559|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
75393243|NCT05200559|Drug|E7777|E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
75393244|NCT05194722|Behavioral|Wysa mobile app|"Wysa is a digital mental health intervention (i.e., mobile app) that uses an artificial intelligence based chatbot and text-based conversation with master's level human coach counselors to deliver cognitive behavioral therapy, mindfulness training, and sleep tools. In this study, a customized version of Wysa will be used which is specifically designed for users with coexisting chronic pain. The customized experience includes additional features based on behavioral activation. This version is not currently commercially available."
75545123|NCT02271373|Behavioral|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
75393245|NCT05185622|Drug|Vamorolone|Oral administration of vamorolone for 12 weeks.
75545124|NCT02271412|Drug|LY03005|LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
75545125|NCT02271412|Drug|Placebo|Placebo
75545126|NCT00256880|Drug|GW786034|
75545127|NCT00271050|Other|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
75708113|NCT05373095|Behavioral|PKC (adapted adherence counseling) and Conditional Cash Transfers|The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically <$1.
75393246|NCT05178732|Dietary Supplement|Bolus ingestion of protein|Different phases of the menstrual cycle
75393247|NCT05178732|Dietary Supplement|a blend of protein and polyphenol|a blend of protein and polyphenol
75393248|NCT05173987|Biological|pembrolizumab|Intravenous (IV) infusion
75393249|NCT05173987|Drug|carboplatin|IV infusion
75393250|NCT05173987|Drug|paclitaxel|IV infusion
75393251|NCT05173987|Drug|docetaxel|IV infusion
75545128|NCT02271568|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
75545129|NCT02271568|Other|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
75545130|NCT02271607|Device|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
75545131|NCT00256919|Drug|GW856553|
75545132|NCT02271646|Drug|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
75545133|NCT00271089|Procedure|PBSC Collection|
75545134|NCT00271089|Procedure|Bone Marrow Harvest|
75545135|NCT00271089|Device|CliniMacs Cell Selection System|
75545136|NCT02271685|Other|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
75708114|NCT05372016|Biological|Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9vHPV vaccine ,0.5mL, three doses, 0,2,6 months
75393252|NCT05173987|Drug|cisplatin|IV infusion
75393253|NCT05171179|Procedure|Breast Reconstruction (Mammaplasty)|Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander
75393254|NCT05171179|Device|Pecs blocks|Pectoral nerve (Pecs) blocks I and II function by blocking the pectoral, intercostal, intercostobrachial nerves, and/or long thoracic nerve. These are used primarily for breast surgeries and are gaining momentum as simple administers of local analgesics. Pecs blocks utilize ultrasound to guide injection of local analgesic. It is less invasive and more accurate than most current modes of analgesia administration.
75393255|NCT05171179|Drug|Exparel|Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel, bupivacaine is released from the multivesicular liposomes over a period of time.
75393256|NCT05171179|Drug|Bupivacaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arms 2 and 3.
75393257|NCT05171179|Drug|Lidocaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arm 1.
75393258|NCT05161754|Procedure|Hemostasis|Hot hemostasis include bipolar and monopolar diathermy. Cold hemostasis include surgical knotting of the tonsil pillar and compression.
75393259|NCT05160922|Drug|crizotinib|crizotinib oral treatment
75870189|NCT03310723|Device|OptiFlow preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
75393260|NCT05149443|Behavioral|theory-based mHealth-intervention (app)|Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.
75545137|NCT02271685|Other|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
75545138|NCT02271685|Other|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
75870190|NCT02760290|Procedure|Extraperitoneal cesarean section|
75870191|NCT02760290|Procedure|Intraperitoneal cesarean section|
75870192|NCT05672212|Device|ANI (Analgesia/Nociception Index) monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.
75870193|NCT05672212|Device|standard monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.
75393261|NCT05149443|Behavioral|theory-based mHealth-intervention (app)|"After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days."
75393262|NCT05139615|Drug|APD418|Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
75393263|NCT05139615|Drug|APD418|Participants will receive a single dose of APD418 as an IV infusion.
75393264|NCT05139615|Drug|Placebo|Participants will receive a single dose of APD418 matching placebo as an IV infusion.
75393265|NCT05115292|Biological|BJ-005|dosed with intravenous infusion
75393266|NCT05111223|Device|Real transcranial magnetic stimulation (TMS) before conditioning|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
75393267|NCT05111223|Device|Real transcranial magnetic stimulation (TMS) before devaluation test|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
75393268|NCT05111223|Device|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
75708115|NCT05372016|Biological|Active Comparator: GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
75393269|NCT05105399|Procedure|Serratus plane block (continuous or single-shot)|Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block
75545139|NCT02271685|Other|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
75545140|NCT02271763|Other|ultrasound|subjects' neck will be scanned using ultrasound
75545141|NCT00256958|Procedure|total knee replacement|
75545142|NCT02271802|Dietary Supplement|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
75545143|NCT02271802|Dietary Supplement|NaCl|
75545144|NCT02271841|Device|PVI|Pleth Variability Index
75545145|NCT02271958|Drug|Mifepristone|
75545146|NCT02271958|Drug|PLACEBO|
75545147|NCT00257036|Drug|levofloxacin|
75708116|NCT05366556|Behavioral|Virtual reality|"The patient, whose blood will be drawn, will be asked to wear virtual reality glasses after sitting in the blood collection chair. One minute before the start of the blood collection process, Nature Hiking will be watched from the virtual reality. Meanwhile, the researcher will complete the preparations for blood collection and will start the blood collection process. It is thought that the blood collection process takes 2-3 minutes on average. During this period, virtual reality will be applied. While blood is being drawn from the patient, the researcher will assess the patient's level of pain with the VAS during the procedure. After the blood draw is completed, the virtual reality glasses will be removed. Then, the patient will be taken to the waiting area and the state anxiety scale will be applied."
75870194|NCT05672212|Drug|Sufentanil|Sufentanil
75393270|NCT05100004|Device|Accelerated Theta Burst Stimulation|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
75545148|NCT02272036|Procedure|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
75545149|NCT02272036|Device|mobile phone|SMS received by mobile phone
75545150|NCT00271167|Drug|INO-1001|
75708117|NCT05360446|Drug|Inclisiran sodium 300 mg|Subcutaneously administered on Days 1, Month 3 (Day 90), and every 6 months thereafter.
75708118|NCT05360446|Drug|Placebo|Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
75870195|NCT05275309|Other|Exploration of optimal PEEP in supine and prone position|"General anesthesia is done in routine manner~A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~One hour after prone position, optimal PEEP is determined again."
75870196|NCT02388022|Device|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
75708119|NCT05359068|Drug|SPH3127 tablet|1 tablet
75708120|NCT05359068|Drug|SPH3127 tablet|2 tablets
75708121|NCT05359068|Drug|SPH3127 tablet|4 tablets
75870197|NCT02725892|Other|NIS observational stud|NIS observational study : Epidemiologic registry
75870198|NCT05275153|Other|Home based cognitive rehabilitation program|The home based cognitive rehabilitation program intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
75545151|NCT02272153|Other|Egg refined grain|
75545152|NCT02272153|Other|Egg Whole Grain|
75393271|NCT05100004|Device|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
75393272|NCT05074381|Other|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leadi
75393273|NCT05074381|Other|Sham Needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
75545153|NCT02272153|Other|Cereal Refined grain|
75545154|NCT00257075|Drug|Risperidone, oral tablets|
75708122|NCT05359068|Drug|Valsartan|1 valsartan capsule
75708123|NCT05359068|Drug|SPH3127 tablet|2 tablets
75708124|NCT05359068|Drug|Valsartan|1 valsartan capsule
75708125|NCT05358418|Other|AIS,START with films transferring|Excluding patients with incomplete clinical data of treatment
75708126|NCT05357027|Biological|TC-E202 cells|T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
75708127|NCT05357027|Drug|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
75708128|NCT05357027|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
75708129|NCT05357027|Drug|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
75393274|NCT05066672|Drug|NV-5138|NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling
75393275|NCT05066672|Drug|matched placebo|matched placebo oral capsules
76035324|NCT04843163|Behavioral|NAMI Basics|NAMI Basics is a peer service program for caregivers of children with mental health needs. It was created by the National Alliance on Mental Illness (NAMI) and was adapted from their empirically supported model for caregivers of adult children with mental illness (Family-to-Family). The child-focused intervention, NAMI Basics, is a six-class curriculum focused on increasing caregiver knowledge about mental illness, empowering parents to advocate for their children across service systems, and introducing skills that assist in family problem-solving and communication (Brister et al., 2012). The program is currently available widely throughout the U.S. through certified trainers who volunteer with local NAMI affiliates and is provided free of charge to caregivers in a non-stigmatizing community setting (e.g., local school, church, community center). It is open to all caregivers, regardless of mental health diagnosis or time within a treatment system.
75393276|NCT05064865|Dietary Supplement|Freeze-dried table grape powder|Consumption of 46g/day freeze-dried table grape powder
75708130|NCT05352074|Procedure|subtotal colectomy with cecal-rectal anastomosis|The intervention involves, after a complete mobilization of the colon, a resection 2-3 cm distal to the ileocecal junction and at the upper part of the rectal ampulla; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. In the laparoscopic approach we use 5 trocars (trocar 1 periumbilical, trocars 2-3-4-5 drawing a 15-cm side square around trocar 1), using a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
76035325|NCT03103477|Other|Urine stability|This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
76035326|NCT04840433|Device|MACE|Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
75393277|NCT05064865|Dietary Supplement|Placebo of the table grape powder|Consumption of 46g/day placebo version of the freeze-dried table grape powder
75393278|NCT05060549|Drug|Cariprazine|Participants will receive 6 weeks of cariprazine treatment
75708131|NCT05352074|Procedure|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis (end to end) is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
75708132|NCT05350878|Other|Implementation Intervention|Virtual and in-person implementation support
76035327|NCT05332795|Drug|Metformin|gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.
75393279|NCT05044351|Device|Fluobeam LX|See arm description
75393280|NCT05044351|Other|Conventional surgery without NIRAF assistance|Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
75393281|NCT05041621|Device|Sensor augmented MDI therapy plus mobile application|"Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions.~All participants will be asked to complete the:~(i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention.~(ii) mHealth usability questionnaire (MAUQ) at post-intervention."
75393282|NCT05041127|Biological|Cetuximab|Given IV
75393283|NCT05041127|Other|Questionnaire Administration|Ancillary studies
75393284|NCT05028101|Procedure|Delayed autologous breast reconstruction|SOC: Delayed autologous breast reconstruction
75393285|NCT05028101|Behavioral|Perioperative Functional Medicine (FM) Care|SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.
75393286|NCT05020912|Drug|ALA|At first visit, ALA applied to one BCC lesion
75393287|NCT05020912|Procedure|PDT|PDT with blue light (for 30 min (~20 mJ/cm2))
75393288|NCT05008172|Procedure|Splenic Artery Embolization|The decision for proximal or distal (selective) embolization is at the discretion of the Interventional Radiologist. For patients with angiographically evident injury, the choice of embolization site will be left to the discretion of the operator. For patients without angiographically evident injury, proximal splenic embolization will be performed with approved materials (coils or plugs for most patients) within the main splenic artery. The embolization endpoint will be hemostasis in the main splenic artery.
75708133|NCT05347199|Drug|Amisulpride Pill|Two single low doses amisulpride (100 mg); orally
75393289|NCT04987346|Other|Walking on an instrumented treadmill|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
75393290|NCT04987346|Other|Walking on an instrumented treadmill while dual-tasking|Participants aged between 6 and 17 years will be asked to walk at comfortable walking speed while playing either a cognitive (Stroop Color and Word Test) or motor (requiring arm swing) game.
75393291|NCT04963738|Drug|JNJ-73763989|JNJ-73763989 will be administered as a single SC injection.
75708134|NCT05347199|Drug|Placebo|two doses, orally
75393292|NCT04959396|Device|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
75393293|NCT04951050|Device|Rapamycin target eluting stent|Rapamycin target eluting stent
75393294|NCT04946552|Diagnostic Test|PET Scan|Participants will come to the PET Center to undergo the whole body [11C]MRB PET scan. An intravenous bolus dose of MRB (~20mCi) will be injected by an infusion pump. PET data will be acquired dynamically for 120 min using the Siemens mCT-X whole-body PET/CT scanner using continuous bed motion to image multiple PET bed acquisitions from the top of the head to the lower abdominal region.
75393295|NCT04946552|Dietary Supplement|Mixed Meal Test|High Carbohydrate Mixed Meal Test (MMT): participants will be studied after a 10-hour overnight fast. A nurse will insert an intravenous (IV) catheter and subjects will ingest a liquid meal (65% carbohydrate, 20% fat, and 15% protein, corresponding to 40% of daily energy expenditure, in ~16 ounces) to be prepared by the Hospital Research Unit Metabolic Kitchen. Blood samples will be collected at -10, 0, 15, 30, 60, 90, and 120 min) for measurement of glucose, insulin and C-peptide concentrations. Plasma samples will be drawn at baseline and throughout the MMT for measurement of additional hormones (such as thyroid hormones, and catecholamines) and free fatty acids (FFA) levels.
75545155|NCT02272192|Behavioral|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is a comprehensive developmental and behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures based in applied behavioral analysis to deliver this content. The teaching format focuses on trained therapists delivering the intervention 1:1 by engaging reciprocally with children in typical toddler activities involving play or daily routines, adding additional structure for children who need it to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches.
75708135|NCT05346588|Other|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
75708136|NCT05346588|Other|Anesthetic technique inhaled agent|must administer inhaled agent.
75708137|NCT05340374|Drug|Cabazitaxel|Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.
76035328|NCT05332795|Drug|Placebo|gouty patients, will receive placebo tablets once daily for about 3 months.
76035329|NCT03040349|Behavioral|Training|The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
76035330|NCT03040349|Behavioral|Provider and Patient Tools|Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
75393296|NCT04946552|Diagnostic Test|Muscle sympathetic nerve activity (MSNA)|Recording of multiunit postganglionic muscle sympathetic nerve activity (MSNA) will be made from the common peroneal nerve as it winds around the fibular head with the subject in the supine position with the subject's thigh comfortably supported. This procedure requires to first trace the course of the nerve using small electrical stimuli applied to the surface of the skin over the nerve or use of ultrasound to visually assist.
75708138|NCT05340374|Drug|177Lu-PSMA-617|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.
75708139|NCT05335356|Biological|Stelara|45 mg , 90 mg at Week 0, 4, 16, 28 and 40; Before dosing at Week 16, patients in the Stelara group were randomly assigned in a 1:1 ratio to receive either Bmab 1200 or Stelara
75708140|NCT05335356|Biological|Bmab1200|45 mg , 90 mg at Week 0, 4, 16, 28 and 40
75708141|NCT05329025|Drug|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
75870199|NCT02390674|Drug|Ciclosporin|Comparison between ciclosporin and placebo
75870200|NCT02390674|Drug|Saline|
75870201|NCT03657290|Drug|vadadustat|Vadadustat Tablets
75870202|NCT02390830|Other|Falls Prevention|
75870203|NCT02390830|Other|Reduction of limitations at body function and activity levels|
75870204|NCT03622346|Procedure|Semi-constrained total knee arthroplasty|Semi-constrained total knee arthroplasty
75393297|NCT04946552|Diagnostic Test|Oral Glucose Tolerance Test|Following a 10-hour overnight fast, a nurse will insert an intravenous (IV) catheter. Subsequently, subjects will ingest 7.5 oz of Glucola, which contains 75 g of dextrose in orange flavored water. Blood samples will be taken at -15, 0, 10, 20, 30, 60, 90 and 120 minutes (after glucola ingestion) for the measurement of plasma glucose, insulin, and C-peptide concentrations, and calculation of measurements of insulin sensitivity index (Matsuda Index). Approximately 40 mL of blood will be drawn at this visit.
75393298|NCT04946552|Other|Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)|will be assessed using bioelectrical impedance analysis Tanita® scale; which is a special multi frequency segmental body composition analyzer that delivers a very mild electrical current that allows measurement of fat mass, percent body fat, fat free mass, total body water, and percent body water. This test will be performed at screening visit.
75393299|NCT04946552|Diagnostic Test|CT Scan|A CT scan will be performed for attenuation correction and to help delineate the BAT and other regions of interest (ROIs). Images will be reconstructed with an ordered subset expectation maximization algorithm using point spread function correction and time-of-flight information. To delineate fat (WAT, BAT) and skeletal muscle regions of interests (ROIs), CT images are first resliced to match the resolution and location of PET images. As performed in previous studies 2, a supraclavicular ROI is first manually drawn on the CT images. Within that area, the fat ROI is segmented using the CT images and an intensity window from -200 to -50 HU. Subsequently the fat ROI is segmented into WAT and BAT ROIs by using the 11C-MRB PET images: Standardized Uptake Value (SUV) ≥ 1.25 for BAT, SUV < 1.25 for WAT.
76035331|NCT03040349|Behavioral|E-blast and Webinars|In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
75393300|NCT04946552|Other|Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)|For better accuracy, measurement of percent fat and percent body water will be obtained with whole body Dual X-Ray Absorptiometry (DXA) scan (Hologic®) on screening-OGTT visit. The scanner arm will move over the participant's body from feet to head. The machine uses a small amount of radiation (one tenth of the amount of radiation from a chest x-ray) to measure body fat, muscle and bone density.
75393301|NCT04944836|Drug|Clomiphene Citrate|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. In the control group, these will be placebo. These will be taken every other day for seven months beginning four weeks prior to surgery and extending for six months after surgery. After enrollment patients will be randomized. Patient will be assigned to the 2 groups using a permuted block randomization scheme with blocks of size 2, 4, and 6. Prior to initiation of the study opaque sealed envelopes will be prepared and thoroughly shuffled and then used sequentially during the study. These randomization assignments will be available to the pharmacy in a web-based format or by cards in sealed envelopes. A nonparticipant in the study (the pharmacy at our institution) will administer this process.
75393302|NCT04944836|Procedure|Rotator Cuff Repair|The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
75393303|NCT04923477|Other|Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome|Therapeutic exercise of resistance and mobility via a combination of HEP and in-person/virtual visits 5 days/ wk. Exercise program instruction in person, then 2-3 visits /wk x 8 wks (in-person or virtual) with a trained professional for the progression of exercises. Adherence to exercise will be measured daily via text and recorded in a mobile app. Patients will start with Phase 1 exercises of shoulder external & internal rotation, scapular stabilization, and active shoulder elevation; resistance levels of elastic bands will be assigned and progressed based on patient-reported shoulder pain and perceived difficulty. Patients will be advanced to Phase 2 when they complete Phase 1. The exercise protocol will be delivered with the methods previously published by Tate, 2010 and Mintken 2016.
75393304|NCT04918615|Procedure|PCI|Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.
75393305|NCT04908683|Biological|Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF|Participants will receive a single IM injection of an RSV vaccine.
75393306|NCT04908683|Biological|Placebo|Participants will receive a single IM injection of matching placebo.
75393307|NCT04890171|Procedure|Endoscopic submucosal dissection|Endoscopic submucosal dissection by a endoscopist using endoscopic devices
75870205|NCT02613728|Behavioral|Accelerated Recovery Plan|
75870206|NCT02613728|Behavioral|Early Discharge|
75870207|NCT02613728|Other|Telemedicine|
75870208|NCT02613728|Behavioral|Standard Enhanced Care|
76035332|NCT05224453|Other|Physical training and high protein diet|In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d)
75393308|NCT04890171|Procedure|Surgery|Gastrectomy with lymph node dissection by a surgeon
75393309|NCT04877756|Drug|OLX10010|Lyophilized cake reconstituted with WFI and injected intradermally
75393310|NCT04876092|Drug|JNJ-67856633|Participants will receive JNJ-67856633 orally.
75393311|NCT04876092|Drug|Ibrutinib|Participants will receive Ibrutinib orally.
75393312|NCT04866914|Behavioral|Acceptance and Commitment Therapy for Insomnia|ACT-I treatment group: Participants diagnosed with chronic insomnia will receive group treatment. The six sessions will be aimed at psychoeducation about sleep added to the therapeutic processes of acceptance, mindfulness, availability, values, defusion and commitment, used in ACT.
75393313|NCT04866914|Behavioral|Cognitive Behavioral Therapy for Insomnia|Active control group CBT-I: Participants diagnosed with chronic insomnia will receive treatment in a group. The six sessions will be aimed at cognitive-behavioral components, such as education and sleep hygiene, stimulus control, sleep restriction and demystification / restructuring of belief beliefs.
75393314|NCT04865419|Drug|AZD0466|AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
75393315|NCT04865419|Drug|Voriconazole|Voriconazole film-coated tablet will be administered orally.
75393316|NCT04861818|Behavioral|Moderate-intensity aerobic exercise|Eligible participants will come into the lab on day 1 and 3 at the same time of day (either morning at 7-10am or afternoon at 3-5pm). They will be then randomly assigned for a rest or an exercise session prior to the memory test. For the rest condition, they will be required to sit and relax while watching Planet Earth for 30 minutes on a cycle ergometer. During the exercise session, they will complete a moderate-intensity cardiovascular exercise for 20 minutes following a 5-min warm-up and followed by a 5-min cool-down on a cycle ergometer. They will start the memory test immediately after the rest/exercise session.
76035333|NCT05224453|Other|Physical training and low protein diet|In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (<1 g/kg aBW/d)
75870209|NCT02390596|Drug|Anakinra|The dose of Anakinra will be 2mg/kg (patients <10kg and/or <8 months: 4mg/kg). If the patient remains febrile (fever >38°C), he will receive a double dose of anakinra 4mg/kg (patients <10kg and/or <8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients <10kg and/or <8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
76035334|NCT05218837|Other|Vaginal birth|Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
75393317|NCT04837586|Other|Standard Care|Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
75393318|NCT04837586|Device|Simple Scale|Individuals will be encouraged to perform daily weighing at home on a simple scale.
75393319|NCT04837586|Device|EHR-Connected Scale|Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
75708142|NCT05326568|Other|Complementary treatment practice|Applying sesame oil to the patients assigned to the intervention group by applying 10 drops to the 10 cm circumference of the cannula for 10 minutes
76035335|NCT05211193|Device|eTNM delivered by URIS I nerve stimulation device|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
76035336|NCT03042923|Drug|lactulose:mannitol (L:M) oral challenge|
76035337|NCT05178355|Drug|KVD824|Active
76035338|NCT05178355|Drug|Placebo to KVD824|Placebo
76035339|NCT04429295|Biological|DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
76035340|NCT04429295|Biological|DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
76035341|NCT04429295|Biological|Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
76035342|NCT04429295|Biological|Poliomyelitis Vaccine bivalent types 1 and 3|Pharmaceutical form:Oral suspension Route of administration: Oral
75393320|NCT04834414|Biological|Cold Stored Platelets|Platelets stored at 1-6 degree Celsius
75708143|NCT05322096|Drug|RGH-706|"Capsules~Oral administration"
75393321|NCT04834414|Biological|Room Temperature Platelets|Platelets stored at 20-24 degrees Celsius
75393322|NCT04827966|Other|Clinpro® 5% sodium fluoride plus tri calcium phosphate varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride
75708144|NCT05322096|Drug|Placebo|"Capsules~Oral administration"
75708145|NCT05320796|Diagnostic Test|upper endoscopy|A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
75545156|NCT02272192|Behavioral|Early Intensive Behavioral Intervention (EIBI)|EIBI is a one-to-one instructional approach based in applied behavior analysis used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Trial by trial data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
75545157|NCT00290277|Biological|HPV-16/18 L1/AS04|
75545158|NCT02272270|Drug|Minocycline with chemoradiation (temozolomide and radiation therapy)|Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
75708146|NCT05310487|Biological|162|The investigational product 162 is a novel neutralizing antibody targeting HBsAg, for the treatment of patients with chronic hepatitis B
75708147|NCT05310487|Other|Placebo|an intervention that appearance is the same as 162, but contains no active ingredients
75708148|NCT05295758|Behavioral|PAL2|"Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education~Other Names:~Pragmatic personalized, adaptable approach to lifestyle and life circumstance"
75393323|NCT04827966|Other|Tooth Mousse® - Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP)s|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization.
75393324|NCT04827966|Other|MI Paste® -Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF)|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes.
75708149|NCT05294120|Device|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided|"Patients will undergo RCM/OCT with an imaging specialist in the Dermatology Service.~This is not expected to take longer than 30 minutes. Prior to imaging, a digital photograph will be taken of the biopsy proven BCC."
75708150|NCT05294120|Radiation|Radiation Therapy|After the completion of skin imaging, patients will undergo simulation and tumor radiotherapy. An equivalent total dose in 2 Gy fractions (EQD2) of 45-46 Gy will be delivered for treatment.
75870210|NCT02663674|Drug|Fluconazole|Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
76035343|NCT04429295|Biological|Human Rotavirus, live attenuated|Pharmaceutical form:Oral suspension Route of administration: Oral
75393325|NCT04827966|Other|Zap® 1.23% APF gel - Acidulated phosphate fluoride|1.23% APF (Acidulated phosphate fluoride) gel is routinely used professional based fluoride for patients with high caries risk.
75393326|NCT04827966|Other|Listerine fluoride mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts
75545159|NCT02272387|Dietary Supplement|Vitamin D3 (Cholecalciferol)|
75545160|NCT02272387|Other|Placebo|
75545161|NCT00257114|Drug|bortezomib|
75545162|NCT02272426|Behavioral|CARET|Combined Aerobic and Resistance Exercise Training
75545163|NCT02272426|Behavioral|CTI|Cognitive Training Intervention
75545164|NCT02272426|Behavioral|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
75545165|NCT02272426|Behavioral|Sham CTI|Sham Cognitive Training Intervention
76035344|NCT04429295|Biological|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
75393327|NCT04818359|Behavioral|MoviS Training|Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).
75393328|NCT04796974|Device|Cention|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques
75393329|NCT04796194|Combination Product|LTX-315 in combination with pembrolizumab|"Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22.~Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first."
75393330|NCT04790799|Other|Treatment at the skin department at Gentofte Hospital|Treatment in a hospital setting at Gentofte Hospital skin department
75393331|NCT04780776|Device|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
75393332|NCT04780776|Device|Sham comparator|5+16 weeks of visible light exposure
75393333|NCT04772300|Combination Product|Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter|PTA with an sirolimus drug-coated balloon catheter (SRL-DCB) in the infrapopliteal artery
75393334|NCT04772300|Device|Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)|PTA with an non-coated balloon catheter (POBA) in the infrapopliteal artery
75393335|NCT04766710|Other|Community-based ART delivery (CAD)|The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months.
75393336|NCT04766710|Other|ART multi-month dispensing (MMD)|The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months.
75393337|NCT04763031|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
75545166|NCT02272465|Other|No intervention|Observational study
75545167|NCT00257153|Device|Coronary thrombus aspiration catheter|
75545168|NCT00271206|Drug|Progesterone|compared to placebo
75870211|NCT02663674|Other|Placebo|Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
75870212|NCT02908880|Device|MANTA vascular closure device|The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
76035345|NCT05258851|Drug|Ceftazidime-avibactam|Experimental
76035346|NCT05258851|Drug|Colistin|Control
76035347|NCT04843085|Other|Proteomic analysis|: Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples
75393338|NCT04756570|Other|Control|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
75393339|NCT04756570|Other|Robotic Group 1|Individuals in this group will receive one session of robotic rehabilitation in addition to conventional therapy each week
75393340|NCT04756570|Other|Robotic Group 2|Individuals in this group will receive two sessions of robotic rehabilitation in addition to conventional therapy each week
75393341|NCT04752137|Drug|Indocyanine green|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
75393342|NCT04752137|Device|SPY-PHI|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
75393343|NCT04741256|Behavioral|Education booklet & standardized discharge training|Tracheostomy education booklet and tracheostomy teaching performed by nurses during hospitalization as dictated by the booklet.
75545169|NCT00271206|Drug|sugar pill|Compared to progesterone
75545170|NCT02272543|Dietary Supplement|Fish surimi peptide|
75545171|NCT02272582|Device|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
75545172|NCT02272582|Other|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
75393344|NCT04739865|Drug|Psilocybin|Open label
75393345|NCT04722341|Behavioral|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
75393346|NCT04722341|Behavioral|Control|More than equal to a 12-hour daily eating period
75545173|NCT02272621|Procedure|Minimally invasive aortic valve replacement|
75545174|NCT02272621|Procedure|Full sternotomy aortic valve replacement|
75393347|NCT04705467|Device|Gynecological brachytherapy|Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
75393348|NCT04680715|Radiation|Per-Operative Radiotherapy technique by Papillon +TM|20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
75545175|NCT00290316|Procedure|Endoscopy ultrasound|
75545176|NCT02272660|Drug|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
75545177|NCT02272660|Drug|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
75545178|NCT02272699|Drug|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
75545179|NCT02272699|Drug|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
76035348|NCT03103243|Behavioral|Mindfulness Based Group Sessions|In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
75545180|NCT02272699|Drug|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
75545181|NCT02272699|Radiation|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
75545182|NCT02272699|Procedure|Surgery|Esophagectomy
75545183|NCT02272738|Drug|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
75545184|NCT02272738|Drug|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
75545185|NCT00271245|Dietary Supplement|200 µg selenium as selenate|200 µg selenium as selenate
75545186|NCT00271245|Dietary Supplement|400 µg selenium as selenate|400 µg selenium as selenate
75545187|NCT00271245|Dietary Supplement|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
75545188|NCT00271245|Dietary Supplement|Placebo|Placebo
76035349|NCT03043001|Drug|Memantine|All the subjects will receive add-on memantine for 12 week
75708151|NCT05294107|Procedure|additional biopsies|"After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~6 biopsies are taken on average in clinical routine~4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing."
75708152|NCT05292404|Drug|alirocumab|In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months
75708153|NCT05292404|Other|conventional treatment|conventional treatment were given according to international uniformguidelines
75708154|NCT05292209|Drug|Riluzole 50 MG|Riluzole 50mg tablets
75708155|NCT05281796|Diagnostic Test|GCF obtaining|GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
76035350|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
76035351|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
76035352|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
75393349|NCT04656028|Genetic|Genetic Testing|DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database <0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
76035353|NCT04843007|Drug|Pemetrexed|Alvopem® was administered every 3 weeks with a dose of 500 mg/m2
75393350|NCT04656028|Behavioral|Motivational Counseling|"Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits.~The goals of motivational counseling:~Increasing motivation for a healthy lifestyle;~Increasing adherence to treatment;~Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling."
75393351|NCT04656028|Diagnostic Test|Lipid analysis|Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
75393352|NCT04656028|Other|Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)|All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
75393353|NCT04656028|Other|Visit 1|"Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
75545189|NCT02272855|Biological|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
75545190|NCT02272894|Procedure|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
75545191|NCT00257270|Drug|gabapentin|
76035354|NCT04840745|Drug|CKD-841 A-1 3.75mg|Single injection, subcutaneous injection
75708156|NCT05281796|Diagnostic Test|saliva obtaining|Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
76035355|NCT04840745|Drug|CKD-841 A-1 1.88mg|Single injection, subcutaneous injection
76035356|NCT04840745|Drug|CKD-841 D 2.92mg|Single injection, subcutaneous injection
76035357|NCT04840745|Drug|Leuplin Inj. 3.75 mg|Single injection, subcutaneous injection
76035358|NCT04842851|Device|cardiac resynchronization therapy|Cardiac resynchronization therapy in patients with systemic right ventricle
75545192|NCT02272933|Device|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
76035359|NCT05073757|Device|Personalized guides and plates|Patients will be included in the study and then followed clinically according to the routine care of orthognathic surgery with personalized guides and plates. The only specific act this study is the completion of an OQLQ quality of life questionnaire by patients preoperatively and between 8 to 12 months postoperatively.
75393354|NCT04656028|Other|Visit 2|"Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days"
75393355|NCT04656028|Other|Visit 3|"Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
75393356|NCT04656028|Other|Visit 4|"Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
75393357|NCT04638465|Procedure|Transoral robotic surgery|Transoral resection with neck dissection
75393358|NCT04638465|Drug|Cisplatin - Dose Level 1|6 Cycles of 40 mg/m2
75393359|NCT04638465|Drug|Cisplatin - Dose Level 2|7 Cycles of 40 mg/m2
75393360|NCT04638465|Radiation|Dose Level 1|60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week
75393361|NCT04638465|Radiation|Dose Level 2|70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
75393362|NCT04630522|Drug|Drug: JMT103- 120 mg SC Q4W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
75393363|NCT04630522|Drug|Drug: JMT103- 120 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
75393364|NCT04630522|Drug|Drug: JMT103- 180 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
75393365|NCT04630522|Dietary Supplement|Dietary Supplement: Calcium Dietary Supplement: Vitamin D|Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
75393366|NCT04623996|Drug|TP-0184|Oral dose
75393367|NCT04615013|Drug|Capecitabine|Not applicable to this study
75393368|NCT04615013|Drug|Carboplatin|Not applicable to this study
75393369|NCT04615013|Drug|Docetaxel|Not applicable to this study
75393370|NCT04615013|Drug|Fluorouracil|Not applicable to this study
75393371|NCT04615013|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or IN
75393372|NCT04615013|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75393373|NCT04615013|Drug|Leucovorin|Not applicable to this study
75393374|NCT04615013|Drug|Oxaliplatin|Not applicable to this study
75393375|NCT04615013|Drug|Paclitaxel|Not applicable to this study
75393376|NCT04597190|Drug|Selective serotonin reuptake inhibitor|Prescribers and patients choose among three selective serotonin reuptake inhibitors (SSRI), sertraline, paroxetine, or fluoxetine based on patient's treatment history (i.e., failed SSRI trials due to side-effects or lack of efficacy) and preference. If a patient experiences problematic side effects after taking their choice of SSRI, the provider may switch them to another of the SSRI options during the first 8 weeks of follow-up. Patients on any antidepressant (including SSRIs) at enrollment will be cross-tapered over four weeks to either fluoxetine, sertraline or paroxetine (i.e., the old drug will be tapered down while the new drug is tapering up).
75393377|NCT04597190|Drug|Serotonin-norepinephrine reuptake inhibitor|Prescribers will prescribe venlafaxine.
75545193|NCT02272933|Device|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
75545194|NCT00290394|Drug|rosiglitazone(drug), blood pressure lowering effect|
75545195|NCT02273011|Procedure|caesarean section|elective caesarean section under regional anesthesia
75545196|NCT02273089|Device|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
75545197|NCT00416247|Behavioral|Hypnosis|Hypnosis
75545198|NCT00257348|Drug|Capecitabine|
75545199|NCT00257348|Drug|Docetaxel|
75545200|NCT01580215|Device|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
75545201|NCT02273128|Genetic|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
75545202|NCT00290550|Drug|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
75708157|NCT05281237|Device|AveCure 16 Gauge Flexible Microwave Ablation Probe|Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
76035360|NCT04840355|Drug|Sintilimab Injection|The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
76035361|NCT04435405|Other|Observational|video footage analysis of group and individual behavioral processes.
76035362|NCT04842695|Device|electroacupuncture group|compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
76035363|NCT05073289|Behavioral|Sandplay activity|The sandplay in psychiatric care, with a creative and fun approach, makes it easier for patients to verbally express their personal life stories and feelings in a safe environment, individually or as a group.
76035364|NCT05073289|Other|Routine Care|Routine care is the care given to the control group by the nurse to the patients in the psychiatry clinic.
76035365|NCT04840043|Other|Osteopathic sympathic harmonization|Treatments that harmonize at the sympathetic nerves or plexus, e.g., sympathetic trunk stimulation by means of the rib-raise technique or stimulation of the prevertebral ganglia.
76035366|NCT04840043|Other|Sham intervention|Different location, size and time of the rib-raise technique or stimulation of the prevertebral ganglia.
76035367|NCT04534933|Device|Evone|Airway ventilation device
75393378|NCT04597190|Behavioral|Written Exposure Therapy|Written Exposure Therapy will be delivered during six 30 minute sessions. The first session includes psychoeducation about symptoms of PTSD, provides a treatment rationale for approaching the trauma memory, and discusses the use of writing as a means of doing so. In sessions 2-6, patients will write about the memory of their worst traumatic event for 20 minutes, with a focus on details of the event and thoughts and feelings that occurred during the event. Patients are directed to write about the same trauma memory during each session. The session ends with the therapist instructing the patient to allow themselves to experience any trauma-related memories, images, thoughts, and feelings in the interval between sessions. The therapist reads the narrative between sessions to make sure instructions were followed. Feedback about the narrative is provided to the patient at the beginning of sessions 3-6. This feedback is used to prompt the patient for writing in the current session.
75393379|NCT04582578|Device|CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive CS-CRT
75393380|NCT04579523|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
75393381|NCT04579523|Biological|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
75393382|NCT04579523|Drug|Cyclophosphamide|Given IV
75393383|NCT04579523|Drug|Fludarabine Phosphate|Given IV
75393384|NCT04579523|Radiation|Total-Body Irradiation|Undergo TBI
75393385|NCT04577170|Diagnostic Test|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
75393386|NCT04576130|Device|Implantable cardioverter defibrillator|Implantation of an ICD for secondary prevention
75393387|NCT04575961|Drug|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles
75393388|NCT04575363|Other|Blood sample|Blood sample
75393389|NCT04550728|Combination Product|Ankle robot training group|Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.
75545203|NCT00257387|Drug|Cyclosporine|
75545204|NCT02273245|Radiation|Thoracic aortogram CT|With and without contrast dye
75545205|NCT02273401|Drug|BI 11054 CL|
75545206|NCT02273401|Drug|Placebo|
75545207|NCT00257426|Drug|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
76035368|NCT04534933|Device|Primus|Airway ventilation device
76035369|NCT04842617|Drug|SHR6390|SHR6390 combined with endocrine therapy
76035370|NCT04842617|Drug|placebo|placebo combined with endocrine therapy
76035371|NCT04860557|Other|cognitive skill, dual task and physical activity assessment|Montreal Cognitive Assessment Test, Trail Making Test (TMT) A & B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
75545208|NCT01601353|Device|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
75545209|NCT01601392|Procedure|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
75708158|NCT05277896|Drug|Ketamine|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation
75708159|NCT05277896|Drug|Etomidate|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation
76035372|NCT05073211|Procedure|PDT|A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
75393390|NCT04550728|Combination Product|Ankle robot training and functional electrical stimulation(FES) group|Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
75708160|NCT05275894|Behavioral|Implant hygiene instructions and removal of the prosthesis|Verbal instructions on implant hygiene practices and removal of the implant supported prosthesis
75393391|NCT04549519|Other|No intervention|No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control
75393392|NCT04545840|Device|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
75708161|NCT05275894|Procedure|Non-surgical peri-implantitis treatment /microsurgery|Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA) after applying local anestesia
75708162|NCT05275894|Procedure|Implant surface decontamination 1(ultrasonic device)|Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).
75708163|NCT05275894|Procedure|Implant surface decontamination 2 (air polishing)|Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).
76035373|NCT04842539|Other|Fecal Microbiota Transplantation|In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.
75545210|NCT01601392|Procedure|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
75545211|NCT01601392|Procedure|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
75708164|NCT05275894|Procedure|Implant surface decontamination 3 (electrolytic cleaning)|Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.
75708165|NCT05275894|Drug|Antibiotic treatment (Metronidazole)|Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).
75708166|NCT05275894|Procedure|Modification and polishing of the prosthesis|If necessary, modification and polishing of the prosthesis to make it cleanable.
75393393|NCT04537364|Diagnostic Test|combined diagnosis of renal parenchymal damage|"This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity >1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time."
75393394|NCT04535271|Drug|Trabectedin|This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
75708167|NCT05273697|Procedure|Underwater Cold Snare Polypectomy|"The procedure of Underwater Cold Snare Polypectomy (UP) will be as follows:~Complete suction of air from the intestinal tract~Partial opening of the intestinal lumen by using sterile room temperature water via a water pump~Complete immersion of the lesion in water~Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
75393395|NCT04533997|Drug|Hypertonic saline solution plus intravenous furosemide|"Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide > 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%"
75393396|NCT04533997|Drug|Intravenous furosemide|"Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide > 160 mg"
75393397|NCT04533555|Genetic|Broad gene panel for young adult cancers|Genetic testing will occur using a broad gene panel for young adult cancers
76035374|NCT04842539|Other|Standard of care|Nutritional supplementation and other supportive measures as per standard guidelines
75393398|NCT04533555|Genetic|Standard|Those in the standard group who are considered high risk will have genetic testing done using the standard of care panel as selected by their care provider.
76035375|NCT05072899|Procedure|platelet rich plasm|local injection of shoulder joint by platelet rich plasm
76035376|NCT05072899|Procedure|Hyaluronic acid|local injection of shoulder joint by Hyaluronic acid
76035377|NCT04860479|Device|ultrasound|ultrasonography to inguinal region
75393399|NCT04511052|Dietary Supplement|Probiotic|Daily intake of 10 x 10^9 CFU of a proprietary strain for a total duration of 10 weeks
75393400|NCT04511052|Other|Placebo|1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
75393401|NCT04511052|Dietary Supplement|Carotenoid supplement|1 capsule daily containing ~20 mg of total carotenoids for a total duration of 10 weeks
75393402|NCT04506814|Device|Endocardial PVI|Catheter based PVI
75393403|NCT04506814|Device|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI
75708168|NCT05273697|Procedure|Conventional Cold Snare Polypectomy|"The procedure of Conventional Cold Snare Polypectomy (CCSP) will be as follows:~If the entry during the endoscopy has been made with water, the water will be aspirated, and the intestinal lumen will be re-stretched using air / CO2~Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
75870213|NCT03657212|Drug|Zolpidem|The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
76035378|NCT02647645|Device|Transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.
76035379|NCT02647645|Procedure|Cognitive training|Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
76035380|NCT02647645|Device|Sham transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
76035381|NCT04842305|Diagnostic Test|Blood- and saliva tests|Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
76035382|NCT04839653|Drug|Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h|The oral paste will be applied topically on the oropharyngeal mucosa q6h.
76035383|NCT04839653|Drug|Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h|The suspension will be administered through the nasogastric tube q6h.
76035384|NCT04839653|Drug|Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd|Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic
76035385|NCT05072587|Behavioral|Plant-based diet with no oxysterols|This group will be given 3 prepared plant-based meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
75393404|NCT04500275|Drug|Vancomycin Hydrochloride|Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure
75393405|NCT04500275|Other|Normal Saline|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure
75393406|NCT04495543|Behavioral|Brief Skills for Safer Living|Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
75393407|NCT04494425|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
75393408|NCT04494425|Drug|Capecitabine|Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
75393409|NCT04494425|Drug|Paclitaxel|Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
75708169|NCT05269992|Other|Real food products|As per arm/group descriptions.
75870214|NCT03310411|Drug|Lasmiditan|Administered orally
75870215|NCT03310411|Drug|Sumatriptan|Administered orally
75870216|NCT03310411|Drug|Placebo for Lasmiditan|Administered orally
76035386|NCT05072587|Behavioral|Standard ADA Diet (SADA)|This group will be given 3 prepared meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
76035387|NCT04842149|Dietary Supplement|Bif195 capsules|1 capsule daily for 8 weeks
76035388|NCT04842149|Dietary Supplement|Placebo capsules|1 capsule daily for 8 weeks
76035389|NCT04919941|Other|A Guide to Conservative Care|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
75393410|NCT04494425|Drug|Nab-Paclitaxel|Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
75393411|NCT04486742|Behavioral|Itch CBT|Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.
75708170|NCT05265065|Biological|Tozinameran - Standard Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose."
75708171|NCT05265065|Biological|Tozinameran - Fractional Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose."
75393412|NCT04473833|Procedure|Serial Transvaginal Ultrasonography|Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
75393413|NCT04472195|Other|Simulation Airway Coaching|Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
75393414|NCT04446832|Other|Vaccine immunogenicity|Evaluation of the vaccine immunogenicity by standard approved serological tests
75393415|NCT04442893|Behavioral|Rumination-Focused Cognitive Behaviour Therapy|Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.
75393416|NCT04442893|Other|Health Education programme|Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
75870217|NCT03310411|Drug|Placebo for Sumatriptan|Administered orally
75870218|NCT03301831|Behavioral|Resourcefulness Training|Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
75870219|NCT02909504|Drug|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
75870220|NCT02505230|Behavioral|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
75870221|NCT02390440|Drug|EXPAREL|
75393417|NCT04439331|Drug|Defactinib Hydrochloride|Given PO
75393418|NCT04439279|Drug|Trametinib Dimethyl Sulfoxide|Given PO
75870222|NCT03677830|Drug|Acetaminophen|Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
75870223|NCT03677830|Drug|Saline|Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
75870224|NCT02387866|Drug|AG-221|
75870225|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
75393419|NCT04428788|Drug|CC-94676|Specified dose on specified days
75393420|NCT04428788|Drug|CC1083611|Specified dose on specified days
75393421|NCT04428788|Drug|CC1083610|Specified dose on specified days
75393422|NCT04409847|Diagnostic Test|ABPM|24 hour ambulatory blood pressure monitoring
75393423|NCT04409847|Diagnostic Test|ECG|Electrocardiogram
75545212|NCT01601509|Drug|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
75557992|NCT00439452|Other|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
75708172|NCT05264480|Procedure|Bone augmentation with minimally invasive corticotomy (piezotomy)|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Trough the vertical releasing incisions a piezosurgical device is used to perform corticotomy. 1 week after surgery OTM is initiated."
75708173|NCT05264480|Procedure|Bone augmentation without corticotomy|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Corticotomy is not performed in this group. 1 week after surgery OTM is initiated."
75708174|NCT05261828|Behavioral|Education and rehabilitation associated with personalized follow-up|short multidisciplinary program including education and rehabilitation and a personalized follow-up for patients with subacute and chronic low back pain
75708175|NCT05261828|Behavioral|Reassuring messages and advices|Reassuring messages and advices in agreement with current recommendations
75393424|NCT04409847|Diagnostic Test|FMD|Flow mediated dilatation
75393425|NCT04409847|Diagnostic Test|PWV|Pulse wave velocity
75393426|NCT04409847|Diagnostic Test|Rarefaction|nailbed capillaroscopy
75393427|NCT04409652|Procedure|Head on bed|During emergence, head is kept on bed without pillow.
75708176|NCT05260333|Device|Butterfly iQ transperineal ultrasound exam|Transperineal ultrasound
75393428|NCT04409652|Procedure|Head on pillow|During emergence, head is kept on pillow.
75393429|NCT04400981|Procedure|Remote ischemic conditioning|Remote ischemic conditioning will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
75393430|NCT04400981|Other|standard medical therapy|"Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
75393431|NCT04369573|Combination Product|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
75393432|NCT04369573|Other|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
75393433|NCT04365868|Drug|belapectin|intravenous
75393434|NCT04365868|Drug|Placebo|intravenous
75393435|NCT04343859|Drug|IMMH-010|After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
75545213|NCT01601509|Drug|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
75545214|NCT00416325|Dietary Supplement|lycopene|
75545215|NCT00416325|Other|laboratory biomarker analysis|
75393436|NCT04340895|Other|Faecal Calprotectin Home Test|"A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.~This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator."
75545216|NCT00257465|Biological|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
75545217|NCT00257465|Biological|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
75545218|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|2.5 million cells
75393437|NCT04340895|Other|PRO-2 Scoring|Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
75393438|NCT04335799|Behavioral|Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training|12-month evidence based weight loss intervention with additional training on stress management strategies
75545219|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0.5 million cells
75545220|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0 cells
75393439|NCT04335799|Behavioral|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics|12-month evidence based weight loss intervention with an attention control of general women's health topics
75393440|NCT04335487|Behavioral|PSP PTSD Course|A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
75545221|NCT01601548|Behavioral|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
75870226|NCT02199691|Biological|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, IM
75870227|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
75393441|NCT04335487|Behavioral|PSP Wellbeing Course|A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
75708177|NCT05259813|Genetic|JWCAR029 (Relmacabtagene Autoleucel)|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
75393442|NCT04329676|Procedure|Deep Brain Stimulation|Patients with PD who are eligible to bilateral STN DBS surgery and chose to get directSTIM System implanted will be followed over a 6-month period to evaluate changes in their condition.
75393443|NCT04328116|Device|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use)
75393444|NCT04308941|Diagnostic Test|Intraocular pressure|The intraocular pressure will be measured using one of three devices
75393445|NCT04294966|Drug|Dextrose|Administering dextrose to healthy volunteers for our placebo group
76035390|NCT04839263|Procedure|"FAST TRACK protocol"|"Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~Hospitalization on surgery day~No prolonged fasting~Perioperative strategy:~Pain control based on limited systemic opioid therapy use~Anti-nausea prophylaxis~Anaesthesia via IV propofol / remifentanyl~Bladder catheter removal postoperative~Postoperative strategy:~Pain control using balanced analgesia~Gum chewing~Early oral refeeding and rapid mobilization~Venflon removal 6 hours post-op"
75393446|NCT04294966|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
75708178|NCT05255159|Diagnostic Test|18F-DOPA with furosemide|Diagnostic 18F-DOPA PET/CT scan
76035391|NCT04353895|Device|Guidance for pedicle screw insertion (Mazor Stealth)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
76035392|NCT04353895|Device|Guidance for pedicle screw insertion (O-arm Navigation)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
76035393|NCT04842383|Drug|Hemp Oil|Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
75393447|NCT04294966|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
75545222|NCT01601665|Device|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
75545223|NCT01601665|Device|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
75870228|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
75870229|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
75393448|NCT04294576|Drug|BJ-001|BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.
75393449|NCT04294576|Drug|Pembrolizumab|"BJ-001 dosed via SC injection in combination with Pembrolizumab~One cycle is 6 weeks."
75708179|NCT05253560|Diagnostic Test|The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.|Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
75870230|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
75393450|NCT04277546|Drug|Brazikumab Maintenance Dose|Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
75393451|NCT04277546|Drug|Brazikumab Induction Dose|Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
76035394|NCT05072353|Device|SEFFICARE|"The SEFFI is a 5-step technique:~Preparation: the lower/lateral abdomen is chosen as the donor site.~Anesthesia: the donor site is injected with a local anesthetic.~Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound."
75393452|NCT04274361|Drug|Ketamine|Ketamine infusion
75393453|NCT04274361|Drug|Placebo|Placebo infusion
75870231|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
75393454|NCT04245215|Drug|Ustekinumab|re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
75393455|NCT04218825|Drug|chlormethine gel|Gel to be applied to all skin areas affected by MF-CTCL
75393456|NCT04214990|Drug|Aspirin 100mg|Daily aspirin 100 mg for 5 years
75545224|NCT01601665|Device|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
75870232|NCT05671978|Procedure|back-up head elevated position|The patient was then placed in the back-up head elevated position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table
75870233|NCT05671978|Procedure|neutral position|The patient was then placed in the netural position
75870234|NCT05667454|Drug|Atropine Ophthalmic 0.05%|Atropine 0.05% sulphate ophthalmic solution
75870235|NCT05667454|Drug|Atropine Ophthalmic 0.5%|Atropine 0.5% sulphate ophthalmic solution
75870236|NCT02390128|Other|observational only|
75393457|NCT04214990|Drug|Placebo oral tablet|Daily placebo for 5 years
75393458|NCT04211740|Drug|OCH-NCNP1|OCH-NCNP1 3mg is supplied as granules and take orally once a week.
75393459|NCT04211740|Drug|Placebo|Placebo is supplied as granules and take orally once a week.
75393460|NCT04198727|Other|DPD activity assessment|Phenotyping DPD with enzyme activity measure and uracil dosage
75393461|NCT04198727|Drug|Capecitabine|Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
75393462|NCT04166864|Device|Transcranial magnetic Stimulation|Transcranial magnetic stimulation delivered at the Subject's SCC-determined frequency. Each Subject will receive 40 pulses every 26 seconds, over 75 trains.
75393463|NCT04162431|Diagnostic Test|spectroscopic measurement|measurement of the tissue with spectroscopy
75393464|NCT04162431|Diagnostic Test|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
75393465|NCT04162431|Diagnostic Test|histopathology and cytology|Histopathology and cytology will be performed on the samples
75393466|NCT04142632|Procedure|clinical and paraclinical examination|Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
75393467|NCT04128072|Drug|Mogamulizumab|• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
75393468|NCT04128072|Radiation|Total Skin Electron Beam Therapy (TSEB)|"After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~Mogamulizumab is stopped during TSEB administration."
75393469|NCT04128072|Drug|Mogamulizumab (subsequent cycles post TSEB)|"• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion."
75545225|NCT01601665|Device|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
75393470|NCT04123548|Biological|StrataGraft skin tissue|StrataGraft skin tissue was delivered as a single topical application to no more than 3 separate burn sites, totaling up to approximately 2000 cm^2 of treatment area using no more than 20 tissues.
75545226|NCT01601665|Device|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
75545227|NCT01601743|Behavioral|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
75545228|NCT01601743|Behavioral|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
76035395|NCT04884139|Drug|Dolutegravir/Lamivudine as a single pill|- Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.
75545229|NCT01601743|Behavioral|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
75870237|NCT03113578|Device|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
76035396|NCT04884139|Drug|Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.|"Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg~Route of adminstration: oral~Schedule of administration: once a day for 96 weeks."
76035397|NCT04860167|Drug|Propofol|Injection propofol was given to keep the BIS value 60-80 during the ERCP procedure
75545230|NCT01601899|Drug|Stavudine|30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg
75545231|NCT01601899|Drug|Stavudine|20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg
75870238|NCT03105856|Biological|CERVARIX|- HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
76035398|NCT04860167|Drug|Diclofenac Sodium and Lignocaine 10 % spray|Injection Diclofenac sodium was given in the preoperative area 30 minutes before the procedure and four squirts of 10% lignocaine were given 5 minutes prior to the start of the procedure
76035399|NCT04841993|Drug|Cannabis decoction|A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
76035400|NCT04841993|Drug|Cannabis oil|A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
76035401|NCT04841993|Drug|Vaporized cannabis|100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
76035402|NCT05072431|Other|SVVR training program|The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
76035403|NCT04839341|Drug|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
75545232|NCT01601899|Drug|Tenofovir|300 mg po QD
76035404|NCT05071885|Other|games based exercise|Range of motion and strengthening exercises
76035405|NCT04841915|Dietary Supplement|High-Protein Diet|Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
75545233|NCT01601938|Dietary Supplement|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
76035406|NCT04841915|Behavioral|Clinical dietician|Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
76035407|NCT04841915|Behavioral|Weight loss|4 weeks eucaloric diet ~13 MJ/day followed by, 20 weeks hypocaloric diet ~9 MJ/day until 5% weight loss is achieved.
75545234|NCT01601938|Dietary Supplement|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
75545235|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
75545236|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
76035408|NCT02514031|Drug|ARQ-761|"Dose Level 1:~ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15~Dose Level 2:~ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15~Dose Level 3:~ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15~Expansion Dose Level:~ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15"
75393471|NCT04113603|Diagnostic Test|Urinary malignancy|Single bolus three phase CTU
75393472|NCT04101396|Dietary Supplement|diabetic diet|Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
75393473|NCT04097548|Behavioral|CenteringPregnancy|Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
75393474|NCT04095364|Procedure|Biopsy|Undergo tumor biopsy
75393475|NCT04095364|Procedure|Biospecimen Collection|Undergo blood sample collection
75393476|NCT04095364|Drug|Carboplatin|Given IV
75393477|NCT04095364|Procedure|Imaging Technique|Undergo medical imaging
75393478|NCT04095364|Drug|Letrozole|Given PO
76035409|NCT02514031|Drug|Gemcitabine|"Therapy after lead in Phase:~You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
76035410|NCT02514031|Drug|nab-paclitaxel|"Therapy after lead in phase:~You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
76035411|NCT04841603|Device|Mindshift CBT|A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
76035412|NCT04841603|Device|Treatment as Usual|Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
75393479|NCT04095364|Drug|Paclitaxel|Given IV
75393480|NCT04068597|Drug|CCS1477|Oral capsule
75393481|NCT04068597|Drug|Pomalidomide|oral capsule
75393482|NCT04068597|Drug|Dexamethasone|oral tablet
75708180|NCT05253534|Device|GlaucoT Glaucoma Treatment Device|"In this study, flicker light therapy, the effectiveness of which was investigated in the treatment of glaucoma based on some methods used in different diseases, is described for the first time in glaucoma.~Studies investigating the neurodegenerative properties of glaucoma have found similarities in the pathophysiology of Alzheimer's disease and glaucoma.~40 Hz flicker of light Alzheimer 's the positive effects on the knitted cortex have also been shown in studies. 40 Hz flicker light is aimed to reduce glaucoma and retinal ganglion cell loss due to glaucoma, by reducing neurodegeneration by decreasing amyloid and metabolite accumulation by increasing both microglial phagocytic activation effect and retinal blood flow."
75393483|NCT04068597|Drug|Azacitidine|Powder suspension for Injection
75393484|NCT04068597|Drug|Venetoclax|Oral tablet
75393485|NCT04066374|Device|Peripheral Nerve Stimulation|Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
75393486|NCT04063826|Device|PET MRI|All participants will have a liver scan
75393487|NCT04061720|Behavioral|Enhanced Chronic Care|Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).
75393488|NCT04061720|Behavioral|Standard Care|Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.
75393489|NCT04040842|Diagnostic Test|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
75393490|NCT04022733|Drug|Moderate neuromuscular block|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
75393491|NCT04022733|Drug|Deep neuromuscular block|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
75393492|NCT04004442|Drug|Avelumab|Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)
76035413|NCT04823533|Dietary Supplement|Probiotic-placebo supplement|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
75393493|NCT04004442|Drug|AVB-S6-500|AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)
75393494|NCT03983954|Combination Product|Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)|"Obinutuzumab is given intravenous (I.V.) 1,000 mg concentrate for solution for infusion.~NAP is given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days."
75708181|NCT05241730|Other|Training intervention|The training intervention will be a 10 week training plan for endurance runners. The plan consists of five sessions per week (three basic endurance sessions and two interval sessions)
75870239|NCT03105856|Biological|GARDASIL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp & Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
75870240|NCT03299881|Device|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
75870241|NCT03299881|Behavioral|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
75393495|NCT03983954|Combination Product|Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)|NAP is given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.
75393496|NCT03976154|Other|Thoracic Epidural Catheter Fixation Techniques|"All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms."
75393497|NCT03969420|Drug|Alvocidib (flavopiridol) and cytarabine (Ara-C)|Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
75393498|NCT03969420|Drug|Alvocidib (flavopiridol)|Administered intravenously
75708182|NCT05241730|Other|High Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
75708183|NCT05241730|Other|LCHF|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
75708184|NCT05241730|Other|Low Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
75870242|NCT02389972|Drug|Dasatinib|
75870243|NCT03105934|Procedure|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
75870244|NCT03299101|Other|Prehabilitation|Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
75870245|NCT02663128|Drug|Lanabecestat|Administered orally
75870246|NCT02389582|Drug|Dabigatran|Use for 5 days
75870247|NCT02389582|Drug|Enoxaparin|Use for 5 days
75870248|NCT03298867|Biological|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
75870249|NCT03298867|Other|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
75393499|NCT03945305|Device|Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.
75393500|NCT03945305|Other|Previous antihypertensive treatment|Patients are only treated with previous antihypertensive treatment.
75393501|NCT03921242|Drug|Metformin|Newly Initiated and regular metformin dosage as prescribed by each patient's medical care provider
75393502|NCT03921242|Drug|Sulfonylurea|Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider
75393503|NCT03921242|Drug|DPP-4 inhibitor|Newly initiated and regular DPP-4 inhibitor dosage as prescribed by each patient's medical care provider
75393504|NCT03921242|Drug|SGLT2 inhibitor|Newly initiated and regular SGLT2 inhibitor dosage as prescribed by each patient's medical care provider
75393505|NCT03921242|Drug|GLP1 receptor agonist|Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
75393506|NCT03914443|Biological|Nivolumab|240 mg or 360 mg
75393507|NCT03914443|Drug|5-FU|750 or 800 mg^2
75393508|NCT03914443|Drug|CDDP|70 or 80 mg/m^2
75708185|NCT05239403|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
75393509|NCT03914443|Drug|DTX|70 mg/m^2
75393510|NCT03900598|Drug|JNJ-67856633|JNJ-67856633 capsule will be administered orally.
75708186|NCT05239403|Other|Questionnaire Administration|Complete questionnaires
75708187|NCT05236374|Other|Beef protein|Animal protein source
75708188|NCT05235633|Diagnostic Test|Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment|Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.
75393511|NCT03875573|Drug|Durvalumab|an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.
75393512|NCT03875573|Radiation|Stereotactic Body Radiotherapy|Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.
75393513|NCT03875573|Drug|Oleclumab|an anti-CD73 intravenous administration at 3000 mg every 2 weeks for the first 4 administrations then every 4 weeks for the last 3 administrations.
75393514|NCT03873844|Behavioral|Speed of Processing Training|"Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block."
75545237|NCT00257543|Procedure|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
75545238|NCT01602133|Procedure|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
75545239|NCT00416403|Drug|fluvastatin sodium|Given orally
75545240|NCT00416403|Procedure|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
75545241|NCT01602211|Other|Internet-Based Intervention|Receive full access to INSPIRE
75870250|NCT02906930|Drug|semaglutide|Oral administration once daily.
75870251|NCT02906930|Drug|placebo|Oral administration once daily.
75870252|NCT02389426|Device|TCD baseline|"Measurement of cerebral circulation parameters with transcranial doppler baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
75870253|NCT02389426|Device|TCD after bosentan administration|"Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
75545242|NCT01602211|Other|Internet-Based Intervention|Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site
76035414|NCT03042845|Device|Tiger cardiac catheter|Tiger cardiac catheter
75393515|NCT03873844|Behavioral|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
75393516|NCT03867617|Other|Regulatory T cells|Single infusion of expanded regulatory T cells.
75393517|NCT03867617|Drug|Tocilizumab|Treatment during first month post-transplant.
75393518|NCT03867617|Other|Bone marrow|Infusion of donor bone marrow cells.
75393519|NCT03867617|Procedure|Kidney transplant|Living donor kidney transplantation.
75393520|NCT03867617|Other|Immunosuppressive drug therapy|Immunosuppressive drug therapy.
75393521|NCT03863119|Drug|Vamorolone|2.0 mg/kg/day, 4.0 mg/kg/day, or 6.0 mg/kg/day at physician discretion
75545243|NCT01602211|Other|Medical Chart Review|Ancillary studies
75545244|NCT01602211|Other|Quality-of-Life Assessment|Ancillary studies
75870254|NCT02389426|Device|NIRS baseline|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
75393522|NCT03861767|Drug|Metformin ER|tablet
75393523|NCT03861767|Drug|Placebo|Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
75393524|NCT03842696|Drug|Vorinostat|"HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant"
75393525|NCT03842696|Procedure|Blood and Marrow Transplant (BMT)|Undergo allogeneic BMT according to local site institutional practice.
75393526|NCT03842696|Drug|Tacrolimus (or cyclosporine)|Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.
75393527|NCT03842696|Drug|Methotrexate|HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.
75393528|NCT03842696|Drug|Mycophenolate Mofetil (MMF)|Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.
75545245|NCT01602211|Other|Questionnaire Administration|Ancillary studies
75545246|NCT01602250|Drug|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
75545247|NCT01602250|Drug|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
75545248|NCT00257582|Drug|Cetirizine Dry Syrup|
75545249|NCT01602289|Biological|LY2875358|Administered IV
75545250|NCT01602289|Drug|Erlotinib|Administered orally
75545251|NCT01602289|Drug|Gefitinib|Administered orally
75545252|NCT00416442|Drug|RSV604|
75545253|NCT01602328|Biological|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
75545254|NCT01602328|Biological|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
75545255|NCT00257621|Drug|GW640385|
75545256|NCT00257621|Drug|Ritonavir|
75545257|NCT01602406|Drug|LJM716|LJM716
75545258|NCT01602406|Drug|Trastuzumab|Trastuzumab
76035415|NCT03042845|Device|Judkins 3.5L/4R cardiac catheters|Judkins 3.5L/4R cardiac catheters
76035416|NCT02473549|Device|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
76035417|NCT02473549|Device|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
76035418|NCT02473549|Device|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
75393529|NCT03842696|Drug|Cyclophosphamide|Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.
75393530|NCT03758625|Biological|a1DC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
76035419|NCT02473549|Device|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
75708189|NCT05234983|Behavioral|LifeFirst SWASTH brief advice intervention|This intervention will support tobacco cessation among patients of high-reach, low-resource community healthcare settings in Mumbai (TB clinics, dental practices, and NGO-run health centers). The intervention will also use technology to build the capacity of practitioners in these settings to use evidence-based practices in their work and allow them to network and exchange best practices with one another.
75708190|NCT05233085|Drug|AZD4041|Participants will receive oral solution of AZD4041 as stated in arm description.
76035420|NCT04841681|Behavioral|Video-based Psychotherapy|"Participants in the group watched three short videos. Therapeutic elements in the three consecutive short videos included relaxation therapy, managing thoughts and feelings, and mindfulness. Each video has a duration of just over 10 minutes.~In the first video, the participants were introduced to the purpose and benefits of relaxation techniques. These included rhythmic breathing techniques, progressive muscle relaxation, imagining a comforting and quiet place, and positive self-talk. In the second video about managing thoughts and feelings, the participants were introduced to the notion of acceptance of their condition. They were invited to recognize the emergence of negative feelings and thoughts related to acceptance. In the last video about mindfulness, patients were introduced to three basic mindfulness skills: observation, elaboration, and participation."
76035421|NCT03042533|Device|Conventional Compression|Method of Nail fitting
76035422|NCT03042533|Device|Standard Backslapping|Method of Nail fitting
76035423|NCT03042533|Device|Dynamic Locking with Backslapping|Method of Nail fitting
76035424|NCT04751461|Other|Product A|P0213420, a 1.8% nicotine ENDS product
75393531|NCT03758625|Biological|a1DC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
75708191|NCT05233085|Other|Placebo|Participants will receive oral solution of placebo as stated in arm description.
75708192|NCT05232825|Drug|Ocrelizumab IV|IV Injection
75708193|NCT05232825|Drug|Ocrelizumab SC|SC Injection
76035425|NCT04751461|Other|Product B|P0213520, a 1.8% nicotine ENDS product
76035426|NCT04751461|Other|Product C|P0211220, a 1.8% nicotine ENDS product
75393532|NCT03758625|Biological|a1DC + no antigen|Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
75393533|NCT03758625|Biological|pgDC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
75545259|NCT00290628|Drug|anti-thymocyte globulin|
75545260|NCT00290628|Drug|busulfan|
75708194|NCT05232825|Drug|Methylprednisolone IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
75708195|NCT05232825|Drug|Diphenhydramine IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
75708196|NCT05232825|Drug|Dexamethasone given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
75708197|NCT05232825|Drug|Desloratadine given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
75708198|NCT05230550|Drug|Somapacitan|Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
76035427|NCT04751461|Other|Product D|P0211820, a 1.8% nicotine ENDS product
76035428|NCT04751461|Other|Product E|P0213417, a 2.4% nicotine ENDS product
76035429|NCT03038711|Drug|BMS-986166|Specified dose on specified days
76035430|NCT03038711|Other|Placebo matching BMS-986166|Specified dose on specified days
75393534|NCT03758625|Biological|pgDC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
75393535|NCT03758625|Biological|pgDC + no antigen|Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
75393536|NCT03756298|Drug|Atezolizumab|Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
75393537|NCT03756298|Drug|Capecitabine|capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
75393538|NCT03723252|Drug|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd
75393539|NCT03723252|Drug|Placebo|Participants will receive placebo po qd
75393540|NCT03716349|Diagnostic Test|Pulp vitality testing|each tooth will be tested to determine if the pulp of the tooth responds to cold
75393541|NCT03716349|Other|Photos|Photos of teeth (Photos will be taken with a DSLR camera settings will be determined with optimal settings) and captured periodically throughout the study. Photographs will be made of the cavity preparation. Photographs will be made post-operatively
75393542|NCT03716349|Drug|local and/or topical anesthetic|Local and/or topical anesthetic will be applied as necessary to the teeth or gingiva
75393543|NCT03716349|Device|rubber dam|The area will be isolated with rubber dam isolation
75393544|NCT03716349|Other|tooth surface cleaned|The tooth surface will be cleaned with flour of pumice on a prophy cup only, cavity preparation will be performed as usual for caries removal.
75393545|NCT03716349|Procedure|enamel margins|Enamel margins will be beveled with a long flame diamond bur (8863.314.012 Komet) at 45 degrees to the external tooth surface to achieve the desired bevel length. Along with the use of the diamond bur, infinite invisible margins will be created by contouring and smoothing with a dark orange Sof-LexTM extra-thin contouring and polishing disc (3M).
75393546|NCT03716349|Procedure|Adhesive Systems|Adhesive systems will be applied according to manufacturer's instructions and selective etching of the enamel will be performed. The dental composite will be incrementally placed using a two- layer or one-layer technique based on the cavity size and light-cured (detailed adhesive instruction sheet will be chairside for reference)
75393547|NCT03716349|Procedure|cavity preparation|The technique to be used will be determined by the size of the final cavity preparation. For small preparations a one-layer technique will be used. No backing material is necessary for the Tokuyama system, Filtek Supreme Ultra will be determined by manufacturer's wheel. A two-layer technique will be used for a large cavity preparation. Large cavity preparation is defined as being 4mm in length or more and/or at least 2mm in depth.
75393548|NCT03716349|Other|Shade selection using Easy Shade 5|A1 (shade determined by Easy Shade 5), ECM-001/Backing material, A1E/A2D (shade will be selected by shade wheel) A4 (shade determined by Easy shade5), ECM-001/Backing material, A3E/A6D (shade will be selected by shade wheel
75393549|NCT03716349|Procedure|Light Curing|A Valo Grand curing unit (Ultradent) with an exitant irradiance with no less than 500 and no greater than 1500 mW/cm2 as measured with MARC Light Collector will be used in standard mode to deliver the required radiant exposure J/cm2 for adhesive and dental composite increments.
75393550|NCT03716349|Procedure|Contoured and polished|The restoration will be contoured and polished with - Long flame diamond bur (8863.314.012 Komet), Sof-Lex Medium (orange) Contouring and Polishing Discs (3M), Green Jiffy cup pre-polisher (Ultradent Products, Inc.), Blue and grey silicone points composite polisher gloss plus finisher (Kerr Hawe)
75393551|NCT03716349|Other|Consent|The consent form will be signed, copy will be provided to the patient
75393552|NCT03716349|Other|Health Questionnaire|The health questionnaire will be completed at initial visit and updated at each follow-up visit
75545261|NCT00290628|Drug|cyclophosphamide|
75545262|NCT00290628|Drug|cyclosporine|
75870255|NCT02389426|Device|NIRS after bosentan administration|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
75393553|NCT03716349|Radiation|xray|When necessary a radiograph (xray) will be obtained
75393554|NCT03716349|Other|Release of medical information signed|The release of medical information form will be signed
75393555|NCT03716349|Other|Oral Exam|An Oral Exam will be completed
75393556|NCT03716349|Other|Teeth Assessment|The teeth assessment by subject will be completed using the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS) at the follow-up visits 1 month after restoration, 1 year, 2 years and 3 years post restoration.
75393557|NCT03716349|Other|Clinical Assessment|A clinical assessment will be completed by the evaluators
75393558|NCT03716349|Device|Tokuyama Universal Bond|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system with Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan)
75393559|NCT03716349|Device|ScotchBond|Scotch Bond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M)
75393560|NCT03710343|Drug|Metformin|Single case ABA study design. Phase B (intervention period) with metformin administered orally (or by gastrostomy tube) for 16 weeks.
75393561|NCT03691935|Drug|Ropivacaine|Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
75393562|NCT03691935|Drug|Normal saline|Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
75393563|NCT03686345|Drug|Midostaurin|Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
75393564|NCT03677141|Drug|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab.
75545263|NCT00290628|Drug|filgrastim|
75545264|NCT00290628|Drug|melphalan|
75545265|NCT00290628|Drug|methylprednisolone|
75545266|NCT00290628|Drug|mycophenolate mofetil|
75545267|NCT00290628|Procedure|radiation therapy|
75545268|NCT00290628|Procedure|umbilical cord blood transplantation|
75545269|NCT01602523|Drug|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
75545270|NCT01602523|Drug|Placebo|Placebo inhaler once daily 28 days
75545271|NCT00415298|Drug|DACH polymer platinate AP5346|
75545272|NCT00415298|Drug|oxaliplatin|
75393565|NCT03677141|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV.
75393566|NCT03677141|Drug|Rituxumab|Participants will receive rituxumab via IV.
75393567|NCT03677141|Drug|Cyclophosphamide|Participants will receive cyclophosphamide via IV.
75393568|NCT03677141|Drug|Doxorubicin|Participants will receive doxorubicin via IV.
75393569|NCT03677141|Drug|Vincristine|Participants will receive vincristine via IV.
75393570|NCT03677141|Drug|Prednisone|Participants will receive oral prednisone.
75393571|NCT03677141|Drug|Tocilizumab|Participants will receive tocilizumab via IV.
75393572|NCT03636074|Procedure|Hypothermia during Extracorporeal Circulation|Normothermia during Extracorporeal Circulation
75393573|NCT03633955|Drug|FLT|F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
75545273|NCT00415298|Genetic|gene expression analysis|
75545274|NCT00415298|Other|immunohistochemistry staining method|
75545275|NCT00415298|Other|pharmacological study|
75545276|NCT00415298|Procedure|biopsy|
75870256|NCT05274841|Other|Support of relatives|Screening of the support needs of relatives
75870257|NCT02389660|Behavioral|Blended Cognitive Behavioural Therapy (CBT)|
75870258|NCT02389660|Behavioral|Treatment as usual|
75545277|NCT01602601|Drug|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
75545278|NCT01602601|Drug|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
75545279|NCT01602640|Drug|Morphine infusion|Conventional dose
75393574|NCT03617679|Drug|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
75393575|NCT03617679|Drug|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
75393576|NCT03616821|Drug|Brazikumab|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
75393577|NCT03616821|Drug|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
75545280|NCT01602640|Drug|Fentanyl and Midazolam infusion|Conventional dose
75393578|NCT03602092|Other|Observation|This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
75393579|NCT03593915|Combination Product|Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine|"PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine."
75393580|NCT03587038|Drug|OKN 007|400 mg OKN-007/mL in a phosphate buffer
75393581|NCT03587038|Drug|Temozolomide|75 mg/m2
75393582|NCT03587038|Radiation|Photon/Proton IMRT|standard of care treatment to be given 1 to 2 hours after OKN-007
75545281|NCT00290667|Biological|pegfilgrastim|
75545282|NCT00290667|Biological|rituximab|
75545283|NCT00290667|Drug|cyclophosphamide|
75545284|NCT00290667|Drug|doxorubicin hydrochloride|
75545285|NCT00290667|Drug|prednisone|
75545286|NCT00290667|Drug|vincristine sulfate|
75545287|NCT00290667|Other|pharmacological study|
75545288|NCT00290667|Radiation|radiation therapy|
75545289|NCT01602757|Drug|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
75545290|NCT02961101|Drug|Anti-PD-1 antibody|Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
75545291|NCT02961101|Drug|Decitabine|Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
75545292|NCT02961101|Drug|Chemotherapy|Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
75545293|NCT01602913|Drug|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
75545294|NCT01602913|Drug|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
75870259|NCT04580407|Biological|TAK-672|B-Domain Deleted Recombinant Porcine Factor VIII
75393583|NCT03572634|Drug|TP-0903|"Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression."
75393584|NCT03572634|Combination Product|TP-0903 and ibrutinib combination therapy|"Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period)."
75393585|NCT03563716|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
75393586|NCT03563716|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
75393587|NCT03563716|Drug|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
75393588|NCT03541850|Drug|Antiandrogen Therapy|Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
75393589|NCT03541850|Other|Quality-of-Life Assessment|Ancillary studies
75393590|NCT03541850|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75393591|NCT03535272|Drug|Bismuth subsalicylate|We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
75393592|NCT03535272|Drug|Placebo Oral Tablet|Placebo manufactured to mimic pepto bismol
75393593|NCT03517137|Drug|Brentuximab Vedotin|For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)
75393594|NCT03517137|Drug|Adriamycin|For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
75393595|NCT03517137|Drug|Vinblastine|For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)
75393596|NCT03517137|Drug|Dacarbazine|For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
75393597|NCT03517137|Drug|Etoposide|For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)
75393598|NCT03517137|Drug|Cyclophosphamide|For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)
75393599|NCT03517137|Radiation|Radiation Therapy|Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.
75393600|NCT03511534|Behavioral|Psychotherapy|Evidenced based psychotherapy by a trained psychologist
75393601|NCT03511534|Other|Pharmacotherapy|Pharmacotherapy by a psychiatrist
75393602|NCT03500081|Device|MRI Scan|The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
75393603|NCT03485677|Drug|Eliglustat GZ385660|"Pharmaceutical form: Capsule, Liquid~Route of administration: Oral"
75393604|NCT03485677|Drug|Imiglucerase GZ437843|"Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous"
75393605|NCT03462030|Drug|Baked non-fat cow's milk powder|Oral immunotherapy with increasing quantities of baked milk.
75393606|NCT03462030|Drug|Placebo: Tapioca Powder|Placebo control.
75393607|NCT03456336|Other|Active Treatment|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.
75393608|NCT03456336|Other|Expectant Management|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
75393609|NCT03452007|Device|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of [5-6-5]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
75393610|NCT03442309|Device|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
75393611|NCT03442309|Device|Fluoride Varnishes|Fluoride varnish (FV)
75393612|NCT03442309|Device|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
75393613|NCT03419052|Behavioral|Speed of processing training|Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) which tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.
75393614|NCT03419052|Behavioral|MIND foods|"The MIND diet (created by the Rush Aging & Memory group) specifically emphasizes foods high in polyphenols such as berries, nuts, cocoa, black beans, olive oil, and green leafy vegetables. Participants select these foods from the digital study application and receive them through home delivery."
75870260|NCT02389504|Other|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
75393615|NCT03419052|Behavioral|Cognitive training control|Control training is provided by the Internet-based BrainHQ program from Posit Science, Inc.These are inert games such as tic-tac-toe, connect 4, battleship, etc.
75393616|NCT03419052|Behavioral|Control foods|Foods contain low polyphenols. Participants select these foods from the digital study application and receive them through home delivery.
75393617|NCT03396809|Device|Punctal plug|Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
75393618|NCT03384836|Other|Laboratory Biomarker Analysis|Correlative studies
75393619|NCT03384836|Biological|Pembrolizumab|Given IV
75393620|NCT03384836|Drug|Propranolol Hydrochloride|Given PO
75393621|NCT03336333|Drug|Zanubrutinib|Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)
75393622|NCT03336333|Drug|Bendamustine|Administered intravenously (IV) at a dose of 90 mg/m^2/day on the first 2 days of each cycle for 6 cycles.
75393623|NCT03336333|Drug|Rituximab|Administered intravenously (IV) at a dose of 375 mg/m^2 on day 0 of cycle 1, and at a dose of 500 mg/m^2 on day 1 of cycles 2 to 6
75393624|NCT03336333|Drug|Venetoclax|400 mg tablets administered orally once daily.
75393625|NCT03329521|Other|Multicomponent intervention|Patients in 13 of the 26 CKD programs will receive a multicomponent intervention or usual care. The intervention has four main components: (1) support for local quality improvement teams and administrative needs; (2) tailored education and resources for staff, patients, and living kidney donor candidates; (3) support from kidney transplant recipients and living kidney donors; and (4) program-level performance reports and oversight by program leaders.
75557993|NCT00439452|Other|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
75557994|NCT03279302|Drug|Glepaglutide|Solution for injection
75557995|NCT03279263|Drug|MLR-1023|MLR-1023 Tablets
75870261|NCT02389504|Other|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
75393626|NCT03298737|Behavioral|Covert Spatial Attention|"During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar."
76035431|NCT03038633|Other|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
75545295|NCT01602913|Drug|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
75545296|NCT01602952|Drug|Radotinib|50mg, 100mg or 200mg Capsule BID
76035432|NCT04622917|Drug|MethylPREDNISolone 40 Mg/mL Injectable Suspension|intramuscular injection
75393627|NCT03283449|Drug|18F-AV-1451|
75393628|NCT03283449|Device|PET|PET scanner for brain imaging
75545297|NCT01602991|Procedure|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
75545298|NCT01602991|Procedure|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
75870262|NCT05256589|Diagnostic Test|Sona Saliva C-19 Rapid Self-test|Rapid Antigen diagnostic device performance comparative to RT-PCR
76035433|NCT04622917|Drug|NaCl 9 MG/ML Injectable Solution|Intramuscular injection
76035434|NCT03039803|Procedure|uterine closure during cesarean section|
76035435|NCT03038477|Drug|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
76035436|NCT04004533|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
75393629|NCT03275285|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75393630|NCT03275285|Drug|carfilzomib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75393631|NCT03275285|Drug|dexamethasone|"Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous"
75393632|NCT03250767|Device|Integra Titan Modular Shoulder System 2.5|Primary Shoulder Joint Replacement
75393633|NCT03240874|Behavioral|SweetMama Focus Groups|Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.
75393634|NCT03240874|Behavioral|SweetMama Individual Testing|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 2 weeks, engage in periodic check-ins with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage."
75393635|NCT03240874|Behavioral|SweetMama Feasibility Testing - Pilot Randomized Trial|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will determine acceptability, feasibility, and pilot procedures in anticipation of a fully powered randomized controlled trial. Women will use SweetMama from enrollment (early pregnancy) to up to 8 weeks postpartum, engage in periodic check-ins with the research assistant, and participate in surveys and a semi-structured interview upon completion of SweetMama usage."
75870263|NCT02387320|Other|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
75870264|NCT05255497|Device|Biodex Balance Exercise System|Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management.
76035437|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
76035438|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10^11 Sf2WC cells administered orally on Days 0, 28, and 56
75870265|NCT02389348|Drug|DSM265|Single oral doses of DSM265
75393636|NCT03240068|Drug|Angiotensin 1-7|This is a biologically active hormone of the renin-angiotensin system. It may play a beneficial role in regulation of blood pressure by dilating blood vessels and reducing inflammation.
75393637|NCT03240068|Drug|Saline|Normal saline will be used as the placebo comparator.
75870266|NCT02389348|Drug|OZ439|Single oral doses of OZ439
76035439|NCT03038243|Other|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
76035440|NCT03101449|Other|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
76035441|NCT03101449|Other|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
76035442|NCT03038321|Drug|sofenacin|solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
76035443|NCT03038321|Drug|Tavanic|levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
75545299|NCT00257699|Drug|Metronidazole placebo|
75545300|NCT00257699|Drug|ciprofloxacin placebo|
75870267|NCT05255341|Procedure|roll pedicle connective tissue graft with bovine bone|rotated pedicle connective tissue graft together with bovine bone applied for socket preservation after tooth extraction
76035444|NCT03038321|Drug|Xefo|lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
75393638|NCT03229057|Drug|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
75393639|NCT03229057|Drug|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
75870268|NCT03656978|Behavioral|dynamic|Use the according methods in dynamic arm descriptions.
75870269|NCT03656978|Behavioral|Regular-triangle|Use the according methods in regular-triangle arm descriptions.
75393640|NCT03229057|Drug|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
75393641|NCT03136445|Drug|Tranexamic acid (TXA).|IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.
75393642|NCT03136445|Drug|Placebo|IV (saline) or oral placebo tablets
75393643|NCT03121469|Device|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
75545301|NCT00257699|Drug|ciprofloxacin|500 mg bid po
75545302|NCT00257699|Drug|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
75545303|NCT01603030|Drug|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
75870270|NCT02383108|Drug|DTG +DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
75545304|NCT01603030|Drug|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
75545305|NCT01603069|Drug|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
75870271|NCT02383108|Drug|SOC|Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
76035445|NCT02531373|Biological|V114 Medium Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
75393644|NCT03089554|Drug|Therapeutic Intervention|Therapeutic Intervention
76035446|NCT02531373|Biological|V114 High Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
75393645|NCT03083665|Drug|Placebo|"Pharmaceutical form: Film-coated tablets~Route of administration: Oral use"
75393646|NCT03083665|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablets~Concentration: 25 mg tablets and 50 mg tablets~Route of administration: Oral use"
75393647|NCT03070184|Other|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
75545306|NCT01603069|Drug|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
75545307|NCT01603069|Drug|Placebo|Placebo to AZD3241 BID
75545308|NCT00257738|Biological|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
75545309|NCT00257738|Biological|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
75545310|NCT01603108|Drug|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
75557996|NCT03279263|Other|Placebo|Matching Placebo Tablets
75870272|NCT02383186|Procedure|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
75870273|NCT02383186|Procedure|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
75393648|NCT03070184|Dietary Supplement|Standardized meals|Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
76035447|NCT02531373|Biological|V114 Medium Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
75393649|NCT03070184|Other|Exercise challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
75393650|NCT03070184|Drug|Metoprolol Succinate ER|Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
75545311|NCT01603108|Drug|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
75545312|NCT00290823|Drug|Albendazole|400 mg tablet taken orally twice daily
75708199|NCT05229393|Other|Cervical plus Diaphragmatic Manual Therapy plus Breathing Reeducation Exercises|"Diaphragmatic Manual Therapy consists of techniques intended to indirectly stretch and mobilize the diaphragmatic muscle fibers. This will help to improve muscle contraction and decrease tension. The experimental maneuvers include the Doming Diaphragmatic Technique as described by Leon Chaitow, Lewit, and the Manual Diaphragmatic Release Technique as described by Leon Chaitow. Both maneuvers are performed in two sets of 10 repetitions, within a 1-minute interval.~Cervical Manual Therapy consists of vertebral mobilization techniques according to the Mulligan technique.~Breathing Reeducation Exercises consist of i) recognition of the abnormal breathing pattern, ii) relaxation techniques for all the primary and accessory respiratory muscles, iii) diaphragm breathing reeducation iv) pursed lips exercise v) reeducation of the normal breathing rate"
75708200|NCT05229393|Other|Cervical Manual Therapy plus sham Diaphragmatic Manual Therapy|"Ultrasound sham as Diaphragmatic Manual techniques. Disconnected ultrasound will be applied in the same position as for the experimental group for 15 min as a placebo treatment.~Cervical Manual Therapy: will consist of vertebral mobilization techniques according to Mulligan -"
76035448|NCT02531373|Biological|V114 High Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
76035449|NCT02531373|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
76035450|NCT03101683|Radiation|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
76035451|NCT03042377|Other|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
76035452|NCT03042377|Drug|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
76035453|NCT03042377|Drug|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid & antibiotic paste and the cavity was filled with temporary restorative material.
75545313|NCT00290823|Drug|Dexamethasone|6mg or 8mg taken daily
75393651|NCT03059030|Device|TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.|The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.
75545314|NCT00290823|Drug|Omeprazole|20 mg tablet taken orally daily
75545315|NCT01603186|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
75545316|NCT01603186|Drug|Quetiapine Fumarate|25 mg tablet once a day
75545317|NCT02484937|Other|Group 2 (PCP Treatment)|For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
75545318|NCT02484937|Other|Group 1 (PMS Treatment)|For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
75545319|NCT00257777|Procedure|Myocardial protection techniques|
75545320|NCT00271284|Drug|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
75545321|NCT00271284|Drug|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
75393652|NCT03045276|Behavioral|Behavioral Feedback and Economic Incentives: Arm 1|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 1, participants will not receive personalized feedback, nor will they receive the extra incentive of $10 for meeting their adherence goal."
75393653|NCT03045276|Behavioral|Behavioral Feedback and Economic Incentives: Arm 2|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 2, participants will receive personalized feedback, and an extra incentive of $10 for meeting their adherence goal."
75393654|NCT03033342|Drug|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
75393655|NCT03033342|Drug|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
75393656|NCT03033342|Drug|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
75393657|NCT03033342|Drug|Oral single doses of placebo|Single doses of placebo to match MRX-4
75557997|NCT03276741|Dietary Supplement|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
75557998|NCT03279146|Drug|Tenofovir exalidex (TXL)|Oral formulations
75870274|NCT03656822|Diagnostic Test|Routine CT|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.
75393658|NCT03033342|Drug|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
75545322|NCT02480257|Behavioral|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
75545323|NCT02487043|Behavioral|A telephone-based case-management intervention|Regular Telephone support delivered by Health coaches
75545324|NCT00257816|Drug|Topotecan|"(First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual."
75545325|NCT00257816|Drug|Cisplatin|40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
75545326|NCT01603303|Behavioral|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
75545327|NCT01603303|Other|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
75545328|NCT01603303|Other|Luvena|Use vaginally 2 or 3 times a week.
75708201|NCT05229393|Other|Conventional Physiotherapy Program|Conventional Physiotherapy Program consists of TENS for 15min, Microwave pulsed Diathermy for 10min, soft tissue techniques for 15min
75870275|NCT03656822|Diagnostic Test|Routine imaging CT with a 3D printed model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model
75870276|NCT03656822|Diagnostic Test|Routine imaging MRI with a 3D printed model|will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model
75708204|NCT05222555|Drug|Tafasitamab|tafasitamab will be administered intravenously at protocol defined timepoints
75393659|NCT03033342|Drug|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
75708205|NCT05222555|Drug|Lenalidomide|lenalidomide will be administered orally at protocol defined timepoints
75708206|NCT05221762|Diagnostic Test|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) at 3 Tesla
75393660|NCT02958670|Other|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
75393661|NCT02957968|Drug|Doxorubicin|60 mg/m2 once every 2 weeks for 4 cycles.
75393662|NCT02957968|Drug|Cyclophosphamide|cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
75393663|NCT02957968|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
75708207|NCT05218694|Diagnostic Test|CCTA guided focused coronary angiography examination.|Focused examination based on Images from CCTA, by choice of optimal catheter used and projection.
75708208|NCT05214911|Drug|Desloratadine , Prednisolone|FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA
75708209|NCT05214911|Drug|Desloratadine|Desloratadine 0.5 mg/mL (Leg® - Eurofarma Laboratórios SA)
75870277|NCT03656822|Diagnostic Test|Routine MRI|will measure post-operative lesion volume as visualized on the post-operative MRI
75870278|NCT03656822|Diagnostic Test|Routine imaging CT with a VR model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model
75393664|NCT02957968|Drug|Carboplatin|carboplatin IV 1.5 area under curve (AUC) once weekly for 12 weeks.
75393665|NCT02957968|Drug|Decitabine|Given IV
75393666|NCT02957968|Drug|Pembrolizumab|Given IV
75393667|NCT02889653|Drug|Any oral antithrombotics (antiplatelets or anticoagulants)|
75393668|NCT02819518|Biological|Pembrolizumab|IV infusion
75393669|NCT02819518|Drug|Nab-paclitaxel|IV infusion
75393670|NCT02819518|Drug|Paclitaxel|IV infusion
75870279|NCT03656822|Diagnostic Test|Routine imaging MRI with a VR model|will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
75393671|NCT02819518|Drug|Gemcitabine|IV infusion
75393672|NCT02819518|Drug|Carboplatin|IV infusion
75393673|NCT02819518|Drug|Normale Saline Solution|IV infusion
75545329|NCT01603303|Other|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
75545330|NCT01603303|Other|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
75870280|NCT02387242|Drug|Rifampicin|Single oral dose of rifampicin
75870281|NCT03656588|Drug|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
75870282|NCT03656588|Drug|Iodine scrub and ChloraPrep alone|Iodine scrub and ChloraPrep alone
75870283|NCT02387086|Drug|Thalidomide|
75870284|NCT02387086|Drug|placebo|
75545331|NCT01603303|Behavioral|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
75557999|NCT00439491|Behavioral|Hypocaloric diet|
75870285|NCT02387086|Drug|Gefitinib|
75870286|NCT02387086|Drug|Aspirin|
75393674|NCT02786277|Other|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
75393675|NCT02759133|Device|Metal wire|Localization technique for breast surgery using metal wire
75393676|NCT02759133|Device|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
75393677|NCT02718066|Drug|HBI-8000 in combination with nivolumab|"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."
75393678|NCT02661022|Drug|SL-401 7 µg/kg/day|SL-401 7 µg/kg/day in combination with pom/dex
75393679|NCT02661022|Drug|SL-401 9 µg/kg/day|SL-401 9 µg/kg/day in combination with pom/dex
75393680|NCT02616796|Behavioral|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
75393681|NCT02599363|Drug|Ribociclib (LEE011)|
75393682|NCT02599363|Drug|Paclitaxel|
75393683|NCT02578797|Drug|Apalutamide|Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
75393684|NCT02505750|Radiation|3D conformal EBRT|External Beam Radiation Therapy
75393685|NCT02505750|Device|Contact X-ray brachytherapy 50 kV|
75393686|NCT02505750|Drug|Capecitabine|
75393687|NCT02503709|Drug|CDK Inhibitor AT7519|Given IV
75393688|NCT02503709|Other|Laboratory Biomarker Analysis|Correlative studies
75393689|NCT02503709|Drug|Onalespib|Given IV
75393690|NCT02503709|Other|Pharmacological Study|Correlative studies
75393691|NCT02475681|Drug|Acalabrutinib|
75393692|NCT02475681|Drug|Obinutuzumab|
75393693|NCT02475681|Drug|Chlorambucil|
75393694|NCT02464046|Drug|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
75708210|NCT05209685|Other|Resistance exercise on the lower extremities|Resistance exercise mainly on the lower extremities will be executed by carrying weight according to each participant's tolerance while performing certain movements, such as side step-up, sit-to-stand, and tip-toe-standing.
75393695|NCT02464046|Drug|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
75393696|NCT02413736|Drug|Imatinib|Imatinib 400 mg/day
75393697|NCT02407119|Drug|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
75393698|NCT02407119|Drug|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
75393699|NCT02369406|Drug|Nevirapine|
75870287|NCT02383030|Drug|Fulvestrant|After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
75870288|NCT02382952|Device|Differential Dissector|
75393700|NCT02369406|Drug|Kaletra|
75393701|NCT02369406|Drug|Lamivudine|
75393702|NCT02369406|Drug|Zidovudine|
75393703|NCT02251665|Other|No intervention|a single-center prospective observational study
75393704|NCT02232126|Other|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
75393705|NCT02127073|Drug|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
75545332|NCT01603303|Behavioral|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
75558000|NCT00441935|Device|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
75708211|NCT05209685|Other|Resistance exercise on the lower extremities with blood flow restriction|Blood flow restriction on the thigh of the dominant leg will be used in combination with resistance exercise.
75870289|NCT02382952|Other|Standard Dissection Method|
75393706|NCT02112214|Drug|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
75393707|NCT02112214|Other|Placebo|Placebo for bismuth-based quadruple therapy
75393708|NCT02095808|Procedure|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
75393709|NCT02078544|Other|Integrated Molecular Analysis|
75393710|NCT02074267|Drug|Carbatin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
75558001|NCT03275571|Behavioral|cCBT intervention|During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
75558002|NCT00442052|Drug|aspirin|
75558003|NCT00442052|Drug|omeprazole|
75558004|NCT00477243|Behavioral|Questionnaire|8 questionnaires will take about 40 minutes to complete.
75558005|NCT00442091|Drug|dandelion juice|10 ml bid for 20-30 days
75393711|NCT02074267|Drug|Neurontin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
75545333|NCT00271323|Drug|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
75393712|NCT01905813|Drug|INCB040093|Escalating doses starting at 100 mg every day (QD)
75393713|NCT01905813|Drug|INCB040093|INCB040093 monotherapy - dose to be determined at completion of Phase I of the study
75393714|NCT01905813|Drug|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
75393715|NCT01901562|Device|Ductoscopic papillectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
75393716|NCT01678027|Drug|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
75545334|NCT00271323|Radiation|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
75870290|NCT02386930|Behavioral|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
75870291|NCT02389114|Other|Soy Protein|Soy protein is commonly consumed in Asian diet.
75393717|NCT01678027|Drug|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
75393718|NCT01658670|Behavioral|Enhanced Usual Care Group|The EUC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
75393719|NCT01658670|Behavioral|HEART Camp (HC) Intervention Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
75545335|NCT01603342|Drug|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
75545336|NCT01603342|Drug|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
75545337|NCT01603381|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
75545338|NCT00257855|Drug|Lamotrigine|
75558006|NCT00477282|Drug|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
75393720|NCT01121588|Drug|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
75558007|NCT00477282|Drug|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
75393721|NCT00930319|Other|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
75393722|NCT00819247|Drug|Degarelix|Given as a subcutaneous injection.
75393723|NCT00739986|Drug|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
75393724|NCT00739986|Drug|Semapimod|Semapimod 60 mg IV x 3 days
76035454|NCT03042377|Drug|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
75393725|NCT00739986|Drug|Placebo|placebo IV x 3 days
75545339|NCT00290862|Device|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
75545340|NCT01603498|Drug|Dexamethasone|Dexamethasone 8mg
76035455|NCT05071573|Other|Optimised electronic patient records|Viral load champions trained in the monitoring of patient on antiretroviral therapy to aid prompt identification of virological failure and institution of appropriate clinical management
76035456|NCT05071417|Drug|Semaglutide|Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
76035457|NCT03039881|Device|Non-Invasive Respiratory Volume Monitor|The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
75393726|NCT00716976|Drug|sodium thiosulfate|Given IV
75870292|NCT02389114|Other|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
75870293|NCT02386852|Drug|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
76035458|NCT04859777|Drug|MPT-0118|MPT-0118 is an inhibitor of MALT1 protease
76035459|NCT04859777|Drug|MPT-0118 + pembrolizumab|MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
76035460|NCT03039725|Other|Observational|Retrospective chart review on vaccine compliance
76035461|NCT05071261|Diagnostic Test|Hepatitis C Virus Screening|1-2 Blood Screenings for Hepatitis C Virus
76035462|NCT05562609|Drug|Tranexamic acid|Ampoules and packaging for all arms will be identical in appearance.
76035463|NCT05562609|Other|Placebo|Ampoules and packaging for all arms will be identical in appearance.
76035464|NCT04370873|Drug|MK-5475|MK-5475 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization
76035465|NCT04370873|Drug|Placebo|Placebo administered as dry powder inhalation according to randomization
75393727|NCT00716976|Procedure|examination|Patients undergo audiological assessments periodically
75393728|NCT00634634|Drug|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
75393729|NCT00634634|Drug|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
75393730|NCT00509353|Drug|irinotecan hydrochloride|
75393731|NCT00509353|Drug|vincristine sulfate|
75393732|NCT00509353|Radiation|iobenguane I 131|
75393733|NCT00271934|Biological|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
75545341|NCT01603498|Drug|Methylprednisolone|Methylprednisolone 40mg
76035466|NCT05388201|Other|N95|3M N95 Respirator
76035467|NCT05388201|Other|KN95|KN95 Mask (with and without clip)
76035468|NCT05388201|Other|KF94|KF94 Mask (with and without clip)
76035469|NCT05388201|Other|Surgical|Surgical Mask (with and without clip)
75393734|NCT00049595|Biological|bleomycin sulfate|
75393735|NCT00049595|Biological|filgrastim|
75393736|NCT00049595|Biological|pegfilgrastim|
75393737|NCT00049595|Drug|ABVD regimen|
75393738|NCT00049595|Drug|BEACOPP regimen|
75393739|NCT00049595|Drug|cyclophosphamide|
75393740|NCT00049595|Drug|dacarbazine|
75393741|NCT00049595|Drug|doxorubicin hydrochloride|
75393742|NCT00049595|Drug|etoposide|
75393743|NCT00049595|Drug|prednisone|
75393744|NCT00049595|Drug|procarbazine hydrochloride|
75393745|NCT00049595|Drug|vinblastine sulfate|
75870294|NCT02386852|Drug|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
76035470|NCT03632707|Radiation|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
76035471|NCT03632707|Procedure|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
75393746|NCT00049595|Drug|vincristine sulfate|
75870295|NCT02386852|Drug|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
75393748|NCT03578796|Diagnostic Test|ECAS-N|assessing ALS-specific cognitive impairment
75393749|NCT03578796|Diagnostic Test|MoCA|assessing cognitive impairment
75393750|NCT03578796|Diagnostic Test|CDR|assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
75393751|NCT03578796|Other|Questionnaire|Questions related to work situation and car driving
75393752|NCT03668106|Procedure|sperm processing method|different sperm processing method for selcting most proper sperm for ICSI
75393753|NCT03807336|Behavioral|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
75393754|NCT03807336|Behavioral|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
75393755|NCT03575052|Drug|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
75393756|NCT03575052|Drug|Placebo|Placebo, tablets, once daily by mouth (provided as two placebo tablets)
75393757|NCT03574896|Other|Computer model predictions of acute kidney injury|Comparison of the performances of AKIpredictor and physicians in predicting AKI stage 2 or 3 in the 7 days following ICU admission
75545342|NCT01603576|Device|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
75870296|NCT02388802|Procedure|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
76035472|NCT04429451|Biological|4SCAR-PSMA T cells|Infusion of 4SCAR-PSMA T cells at 10^6 cells/kg body weight via IV
75393758|NCT04762056|Other|Chelsea Critical Care Physical Assessment Tool|Chelsea Critical Care Physical Assessment Tool is a bedside assessment tool firstly reported in 2013 to measure physical morbidity in the critical care population, consisting of 10 items (respiratory function, cough, moving within the bed, supine to sitting on the edge of bed, dynamic sitting, standing balance, sit to stand, transferring from bed to chair, stepping, and grip strength) rated on a 6-point scale from complete dependency (level=0) to independency (level=5). Therefore, the CPAx sum score ranges from 0 (worst condition) to 50 (best functioning/independence)
75393759|NCT04761900|Diagnostic Test|the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases|
75393760|NCT03804528|Behavioral|Aerobic Exercise|Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session.
75393761|NCT03556020|Drug|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
75393762|NCT03570918|Biological|MGD014|HIV-1 x CD3 bispecific DART molecule
75393763|NCT05347524|Other|Baseline blood draw and blood-based biomarkers analyses|Baseline blood draw and blood-based biomarkers analyses
75393764|NCT01677546|Device|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
75393765|NCT01677546|Device|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
75393766|NCT04403724|Drug|Bupivacaine-fentanyl-Morphine.|2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
75393767|NCT04403646|Dietary Supplement|ARBOX|dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg
75393768|NCT04403646|Other|PLACEBO|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX
75393769|NCT04403568|Drug|Ursolic Acid|Ursolic Acid 150mg
75393770|NCT04403568|Drug|Curcumin|Curcumin 600mg
75393771|NCT03552822|Other|ERAS Protocol Implementation|Implementation of ERAS Protocol Implementation
75545343|NCT01603654|Drug|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
75558008|NCT00442130|Biological|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
75558009|NCT00442130|Procedure|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
75558010|NCT00477321|Drug|CYT 107|3 dose levels: 3, 10 and 20µg/kg/week.3administrations
75558011|NCT03279107|Other|Soluble corn fiber|soluble corn fiber
75558012|NCT03279107|Other|maltodextrin|maltodextrin
75393772|NCT03551028|Device|HPV self collection|The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
76035473|NCT03101527|Drug|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
75545344|NCT01603654|Drug|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
75545345|NCT00257972|Drug|aripiprazole|
75545346|NCT00271362|Behavioral|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
75545347|NCT00271362|Procedure|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
75545348|NCT01603693|Device|Bio-Oss (by Geistlich)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
75545349|NCT01603693|Device|BondBone (by Augma)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
75545350|NCT01603771|Other|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
75545351|NCT02960685|Procedure|Echocardiography|
75393774|NCT03547986|Diagnostic Test|Duplex Ultrasound (DUS)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
75545352|NCT01603810|Other|OCT|Optical coherence tomography of periocular basal cell carcinoma
75558013|NCT00439530|Drug|oseltamivir|
75558014|NCT00439530|Drug|probenecid|
75870297|NCT02388802|Procedure|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
76035474|NCT05367219|Device|Air sterilizer|The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
76035475|NCT04838873|Procedure|Open radical cystectomy|Standard open radical cystectomy and urinary diversion
75393775|NCT03547986|Diagnostic Test|IVUS with Intraarterial pressure measurement (IAP) if needed|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
75393776|NCT03546738|Procedure|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
75393777|NCT03546738|Procedure|Sham spinal cord stimulation|No spinal cord stimulation is provided
75393778|NCT03546738|Device|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead."
75393779|NCT03564756|Dietary Supplement|Vitamin C|1000mg Vitamin C per day
75393780|NCT03561246|Other|Incline treadmill walking|Those with a Pp 0.47 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
75545353|NCT00258050|Drug|Midazolam|Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
75545354|NCT00258050|Drug|Lapatinib|Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
75545355|NCT01603888|Other|no intervention|
75545356|NCT00271401|Other|Angioplasty|
75545357|NCT00271401|Other|Intracoronary Stent|
75545358|NCT00271401|Drug|Abxicimab|
75545359|NCT00271401|Drug|Heparin|
75870298|NCT02388802|Procedure|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
76035476|NCT04838873|Procedure|Laparoscopic-assisted radical cystectomy|Laparoscopic-assisted radical cystectomy and extracorporeal urinary diversion
75393781|NCT03561246|Other|Decline treadmill walking|Those with a Pp 0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
75393782|NCT03462966|Drug|Rifaximin|Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
75545360|NCT00271401|Drug|Placebo|
75545361|NCT01604005|Radiation|Prophylactic Irradiation of Tracts (PIT)|21 Gy in 3 fractions
75545362|NCT00258089|Drug|Levofloxacin|
75870299|NCT02388802|Drug|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
76035477|NCT03039959|Diagnostic Test|No intervention|No intervention
76035478|NCT04544839|Device|ADLC attachment system with PEEK inserts|"Each patient will receive 2 implants in the canine region using a guided-surgery protocol and a pre-prepared surgical stent. A healing abutment of an adequate size will be placed on the implant for transmucosal healing. The flaps will be subsequently sutured around the healing abutments. Patients' existing prostheses will be adjusted. Suture removal will be performed one week post implant placement.~Three months later, implant level impressions will be made using the open tray technique. Each patient will be then be randomized using eCRF (electronic Case Report Form) to either ADLC group or LOC group. A final cast of the patients will be obtained and the attachments will be installed using an in-direct technique by a calibrated prosthodontists."
75545363|NCT01604044|Drug|Meropur 150 a day|one subcutaneous injection a day
75545364|NCT01604044|Drug|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
75545365|NCT01604161|Drug|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
75545366|NCT00290901|Drug|Tramadol Hydrochloride 50mg|
75545367|NCT00290901|Drug|Celebrex 200mg|
75545368|NCT00258167|Behavioral|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
75545369|NCT01604200|Behavioral|focus group|key informant review
75545370|NCT01604239|Drug|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
75545371|NCT01604356|Procedure|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device [Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
75545372|NCT04708314|Drug|Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]|Vyondys 53
75545373|NCT00258245|Dietary Supplement|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide [ATO] days 1, 4, 8, 11
75870300|NCT02388802|Procedure|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
75870301|NCT02388802|Procedure|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
75870302|NCT02386696|Other|Ultrasound|Lung ultrasound examination on healthy volunteers
75393783|NCT03462654|Behavioral|iLiFE|In the individual LiFE (iLiFE), the program is taught in seven visits in the individuals' homes within eleven weeks. Participants are supervised in a face to face situation by one qualified trainer (physiotherapist or sports scientist). Each home visit takes between 1 and 1.5 hours. A total of five balance exercises, seven strength exercises for the lower extremities, and two exercises to increase physical activity are taught. In addition to the home visits, all participants receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
75393784|NCT03462654|Behavioral|gLiFE|The group-based LiFE (gLiFE) program consists of seven group sessions (n = 8-12 participants) which are held over the course of eleven weeks, with a maximum duration of 2 hours per session. Each session is led by two qualified trainers (physio therapists or sports scientists), i.e., one main and one co-trainer. In all group sessions, trainers will teach the participants how to perform and integrate the LiFE program, i.e., LiFE balance and strength activities into their daily routines. After the group sessions have ended, participants will receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
75393785|NCT01678872|Drug|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
75545374|NCT00258245|Drug|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
75545375|NCT00258245|Drug|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
75545376|NCT00258245|Drug|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
75545377|NCT00258245|Drug|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
75545378|NCT00258245|Drug|Aspirin|Aspirin - 325 mg by mouth (PO) every day
75545379|NCT01604434|Procedure|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
75545380|NCT01604434|Procedure|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
75393786|NCT03535818|Procedure|Radiofrequency ablation|RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
75393787|NCT03794700|Other|Hospice Decision Aids|Paper and video hospice decision aid
75393788|NCT04403412|Procedure|Left atrial appendage closure group|Left atrial appendage closure Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
75545381|NCT01604590|Radiation|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
75545382|NCT00271440|Procedure|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
75545383|NCT01604629|Drug|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
75545384|NCT01604629|Drug|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
75545385|NCT00258284|Drug|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
75545386|NCT00258284|Drug|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
75545387|NCT00290940|Drug|CS-917|
75545388|NCT00290940|Drug|metformin hydrochloride|
75545389|NCT00290940|Drug|pioglitazone|
75545390|NCT01604707|Other|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
75545391|NCT00258323|Drug|cisplatin|20mg/m2d/IV continuous infusion x days
75545392|NCT00258323|Drug|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
75545393|NCT00258323|Drug|Iressa|250mg po qd days 1-28 then x 2 years
75545394|NCT00258323|Procedure|conventional surgery|conventional surgery
75545395|NCT00258323|Radiation|radiation therapy|150 cGy bid
75558015|NCT00442208|Drug|PN 200|
75393789|NCT04403412|Procedure|Radiofrequency ablation group|Radiofrequency ablation Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
75393790|NCT04403412|Procedure|LAAC combined with radiofrequency ablation group|LAAC combined with radiofrequency ablation group Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
75393791|NCT03458676|Procedure|Advanced Magnetic Resonance Imaging Scan|"AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete"
76035479|NCT05071339|Drug|Ganirelix Acetate, Cetrolix Acetate|3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
76035480|NCT04838483|Device|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
76035481|NCT04521829|Other|Walking with different optic flow speeds with 2 different VR devices|Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.
75393792|NCT03458676|Procedure|Standard of Care Brain Biopsy and Tumor Removal|"During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed."
75393793|NCT03458598|Procedure|Rectus sheath block|Rectus sheath block under ultrasound
75545396|NCT01604746|Biological|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
75545397|NCT01604863|Drug|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
75545398|NCT01604863|Drug|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
75545399|NCT01604863|Drug|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
75545400|NCT00290979|Drug|insulin glulisine|
76035482|NCT05386485|Other|None intervation|Observational Study
76035483|NCT02606279|Drug|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
75393794|NCT03458598|Procedure|Bilateral rectus sheath catheter|A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.
75393795|NCT03458598|Drug|Patient controlled opioid analgesia (PCA)|Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
76035484|NCT02606279|Other|Placebo|
75545401|NCT00258401|Dietary Supplement|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
75545402|NCT00258401|Procedure|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
75545403|NCT00258401|Procedure|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
75545404|NCT01604902|Other|4 mm punch biopsies|4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
75545405|NCT01604980|Dietary Supplement|Protein intake.|protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
75393796|NCT03458598|Procedure|Subcutaneous injection saline placebo|Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
75393797|NCT01674816|Device|Repeated Measurements of Knee Alignment and Kinematics|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
75393798|NCT01674816|Device|Computer Guidance of Surgical Actions|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
75545406|NCT00271479|Biological|A, C, Y, W135 meningococcal polysaccharide vaccine|
75545407|NCT01605331|Drug|sustained-release recombinant human GH (SR-rhGH)|
75558016|NCT00442247|Device|Pelvicol|
75558017|NCT00439686|Drug|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
75393799|NCT01672242|Device|HFNC|Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
75393800|NCT01672242|Device|CPAP|Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
75393801|NCT03791736|Procedure|Injection of sandostatine|Intramuscular injection of sandostatin 30 mg 3 days before surgery
75393802|NCT01672008|Drug|NOX-100|
75558018|NCT00477360|Device|Humeral surface replacement hemiarthroplasty (CAP)|C.A.P hemiarthroplasty
75393803|NCT01676376|Device|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
75393804|NCT01676376|Other|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
75545408|NCT01605409|Procedure|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
76035485|NCT03037697|Other|TheraTogs Arm|TheraTogs Arm Received Soft Orthotic undergarments
75393805|NCT01679964|Drug|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
75393806|NCT02404818|Procedure|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
75393807|NCT02404818|Procedure|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
75870303|NCT05358964|Behavioral|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
75393808|NCT05346822|Procedure|integrated rehabilitation (the collaborative patient education)|Pre-operative education and rehabilitation. During hospitalization: group rehabilitation education program. Discharge: post-operative care navigation for total knee arthroplasty
75870304|NCT02382874|Biological|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
75870305|NCT02382718|Biological|FAST fish mCyp c 1|Subcutaneous immunotherapy
75870306|NCT02382718|Biological|Placebo|Subcutaneous immunotherapy
76035486|NCT03037697|Other|Traditional Treatment|"Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board"
76035487|NCT04859855|Procedure|Restrictive transfusional strategy|Transfusion of Red Blood Concentrates (RBCs) if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
76035488|NCT04859855|Procedure|Liberal transfusional strategy|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL
76035489|NCT04859621|Drug|Vitamin D3 4000 IU|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
75393809|NCT03524898|Drug|Nab-Paclitaxel|150 mg/m2 / 125 mg/m2
75393810|NCT03524898|Drug|gemcitabine|1000 mg/m2
75393811|NCT03524820|Drug|Cetuximab|Administration of drug
75393812|NCT03524508|Drug|Onivyde|The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
75393813|NCT03524508|Drug|5-FU/LV|The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
75393814|NCT03521856|Behavioral|shoulder exercise|Exercises performed 3 times a week for 12 weeks
75870307|NCT02382484|Device|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
76035490|NCT04859621|Drug|Vitamin D3 2000 IU|Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
76035491|NCT04859621|Drug|Placebo|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
75870308|NCT02382562|Behavioral|Brief Behavioral Activation Intervention|Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
75393815|NCT03521856|Behavioral|education|
75393816|NCT03457818|Drug|Denosumab 60 mg/ml [Prolia]|Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
75393817|NCT03457818|Other|Placebo|Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
75393818|NCT01676844|Drug|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
75870309|NCT02386306|Drug|GC021109|
75870310|NCT02386306|Other|Placebo|
76035492|NCT04859621|Other|standard antibiotic therapy|standard antibiotic therapy
75393819|NCT01676844|Drug|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
75393820|NCT04403334|Drug|Levofloxacin Ophthalmic|0.1 ml of unpreserved 0.5% levofloxacin
75393821|NCT04403334|Drug|Moxifloxacin Ophthalmic|0.1 ml of unpreserved 0.5% moxifloxacin
75393822|NCT03779646|Drug|Bisoprolol Fumarate|Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate <75bpm and systolic blood pressure <90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
75393823|NCT03500016|Other|High intensity interval training|See under arm description.
75393824|NCT03499080|Behavioral|Medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
75393825|NCT03499080|Behavioral|Treatment as usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
75393826|NCT03499080|Behavioral|Treatment as usual Åråsen|Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
75708212|NCT05208411|Behavioral|Project ImPACT: Improving Parents As Communication Teachers|"Project ImPACT (Improving Parents As Communication Teachers, Ingersoll & Dvortcsak, 2019) is a promising evidence-based parent-mediated intervention that is part of a class of naturalistic, developmental, behavioral interventions (NBDIs). NBDIs involve the use of behavioral principles of learning to teach skills chosen from a developmental sequence in naturalistic play-setting and using natural rewards. Skills selected as relevant for intervention are those that allow the child to participate more fully within reciprocal interactions with the adult. In recent years the program has been adapted for use with infants and toddlers at elevated likelihood of ASD. These adaptations have made this program appropriate for younger children and children who are experiencing social communication delays but do not have an ASD diagnosis."
75870311|NCT02382172|Behavioral|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
75870312|NCT02382172|Other|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
76035493|NCT04859387|Other|set of pragmatic shoulder technique|Group A received pragmatic intervention which includes Pectoralis major and minor stretch, AC joint mobilization, rotator cuff facilitation for subscapularis and infraspinatus, serratus anterior stretch, thoracic manipulation and posterior capsular stretch.
75393827|NCT05346744|Other|Chairside CAD/CAM ceramic materials for dental restoration|"6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)"
75393828|NCT00089778|Drug|117-126:Fibroblast growth factor 5 (FGF-5)|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
75393829|NCT00089778|Drug|Fibroblast growth factor 5 (FGF-5):172-176/217-220|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
75870313|NCT02983604|Drug|GS-5829|Tablet(s) administered orally once daily
75870314|NCT02983604|Drug|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
75870315|NCT02983604|Drug|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
76035494|NCT04859387|Other|traditional physical therapy|Group B received traditional interventions which includes modalities such as TENS and hot pack, soft tissue mobilization, joint mobilization, stretching and strengthening etc. other than pragmatic intervention
76035495|NCT03039491|Biological|Pneumococcal polysaccharide vaccine 23 valent|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
75545409|NCT01605409|Procedure|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
75545410|NCT00258479|Drug|ModafinilNicotine Replacement Therapy|A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
75393830|NCT00089778|Other|IL-2|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
75393831|NCT00089544|Drug|Dacarbazine|Given IV
76035496|NCT03039491|Biological|13 valent conjugated pneumococcal vaccine|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
76035497|NCT03037853|Other|Healthy volunteers|MRI scanner
76035498|NCT03037775|Other|Baseline|measurement of baseline hemodynamic parameters
76035499|NCT03037775|Device|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
75545411|NCT00258479|Drug|Modafinil|See Modafinil Intervention Description above.
75545412|NCT00271518|Drug|growth hormone (somatropin)|dosing regimen is weight based.
76035500|NCT03037775|Device|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
76035501|NCT03037775|Device|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
76035502|NCT03039257|Dietary Supplement|Vitamin A|Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
76035503|NCT04838093|Diagnostic Test|PCR|"Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials."
76035504|NCT04859309|Behavioral|ActiveHip+ mobile application|The mobile application with the educational and multidisciplinary tele-rehabilitation program.
75393832|NCT00089544|Drug|Doxorubicin Hydrochloride|Given IV
75393833|NCT00089544|Biological|Filgrastim|Given subcutaneously
75393834|NCT00089544|Drug|Ifosfamide|Given IV
75393835|NCT00089544|Other|Laboratory Biomarker Analysis|Correlative studies
75393836|NCT00089544|Radiation|Radiation Therapy|Undergo radiotherapy
75393837|NCT00089544|Drug|Thalidomide|Given orally
75393838|NCT00089544|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
75393839|NCT00089076|Biological|ipilimumab|Given IV
75393840|NCT00089076|Other|laboratory biomarker analysis|Correlative studies
75393841|NCT03774654|Genetic|CD19.CAR-aNKT cells|"Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose Level 1: 1 x 10^7/m2. Dose Level 2: 3 x 10^7/m2. Dose Level 3: 1 x 10^8/m2."
75393842|NCT00088374|Drug|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
75393843|NCT00088374|Drug|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
75393844|NCT00088374|Drug|[15-O] H2O|[15-0] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
75393845|NCT00088374|Drug|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
75870316|NCT02386618|Procedure|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN < 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN > 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN > 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
75393846|NCT03773250|Behavioral|Behavioral intervention|The intervention has an intensive phase and a maintenance phase.
75393847|NCT03493620|Procedure|Device arm|Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
75393848|NCT03493620|Procedure|Sham arm|Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
75870317|NCT03656432|Drug|CPP-ACP paste|The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
76035505|NCT04859309|Procedure|Standard care in a hip fracture|The participants of this group will receive the standard treatment for a hip fracture in the Andalusian healthcare system.
76035506|NCT04859543|Device|FoundationOneHeme|Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
75393849|NCT03772548|Diagnostic Test|MRI|We will examine acute (<4 weeks post SCI) to chronic (>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
75393850|NCT03772548|Diagnostic Test|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
75393851|NCT00087594|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
75393852|NCT00087594|Drug|ribavirin|1000/1200mg (< or >= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
76035507|NCT04789967|Behavioral|Guided Imagery|Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
75393853|NCT03770286|Device|5% Fluoride Varnish|Topical varnish
75393854|NCT03770286|Device|38% Silver diamine fluoride|Topical varnish
75393855|NCT03770286|Device|Floss|Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
75393856|NCT03492528|Biological|blood samples|blood samples
75393857|NCT03769350|Device|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
75545413|NCT01340014|Drug|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
75393858|NCT05347056|Diagnostic Test|Lumbar Spine Magnetic Resonance|Metal artifact reduction sequence (mars), axial t2 sequence
75393859|NCT05347056|Diagnostic Test|Isokinetic trunk flexion-extension trunk muscle strength and endurance test|To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s
75393860|NCT05347056|Diagnostic Test|Lomber Region Range of motion assessment|To evaluate for lomber region ROM with digital inclinometer
75545414|NCT01340014|Drug|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
75545415|NCT00258518|Procedure|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
76035508|NCT04789967|Behavioral|Progressive Muscle Relaxation|Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.
76035509|NCT04789967|Other|Educational Audiobook|Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
76035510|NCT04833569|Biological|ICG-PDT|An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
76035511|NCT04833569|Device|peri-implant mechanical debridement|The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
75545416|NCT00291057|Drug|MALG|30 minute application
75545417|NCT00258557|Drug|LPV/RTV|400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
76035512|NCT04837781|Procedure|Micro-osteoperforation|Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.
76035513|NCT03038009|Drug|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
75393861|NCT05347056|Diagnostic Test|Radiograph|spinal radiograph AP/Lateral
75393862|NCT05347056|Behavioral|SRS 22|SRS-22 Patient Questionnaire
75393863|NCT00087516|Drug|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
75393864|NCT00087516|Drug|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
75393865|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
75870318|NCT02386462|Drug|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
75870319|NCT02386462|Drug|Propofol|
76035514|NCT03466801|Drug|Prednisone|Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
75393866|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
75870320|NCT03656276|Behavioral|Tool to improve Participation In Clinical Trials (ToPIC)|The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
75545418|NCT00258557|Drug|TMC-114/RTV|two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
75545419|NCT00271557|Drug|nesiritide|
75545420|NCT01339897|Drug|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
75870321|NCT02382328|Drug|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
75393867|NCT00087516|Drug|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
75545421|NCT01339897|Drug|Placebo|Same administration procedures as active
75545422|NCT01339897|Drug|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
75545423|NCT01339897|Drug|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
75545424|NCT00271635|Drug|Placebo|Placebo 4 capsules b.i.d. during 1 year
75393868|NCT03768960|Drug|Daratumumab|Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
75393869|NCT00087126|Drug|topotecan hydrochloride|
75393870|NCT03767946|Diagnostic Test|Quantiferon Gold Plus Test|Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
75393871|NCT03490734|Dietary Supplement|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
75545425|NCT00271635|Drug|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
75545426|NCT01339429|Device|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
75393872|NCT03490734|Dietary Supplement|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
75393873|NCT03490734|Dietary Supplement|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
75393874|NCT03490734|Dietary Supplement|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
75393875|NCT03490734|Other|Water|Three mL administered per associated logo presentation only during MRI procedure.
75393876|NCT04763382|Other|experimental group: Training of caregivers|Pre-test, post-test, retention test, education, guide booklet delivery, android application installation and urinalysis
75393877|NCT04763382|Other|Control gruop|Pre-test, post-test and urinalysis
75545427|NCT00258596|Device|sirolimus-eluting stent|
75545428|NCT01339390|Behavioral|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
75870322|NCT02382328|Drug|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
76035515|NCT03466801|Drug|MP and CTX|Methylprednisolone(MP) was injected for 3 day(if weight >60kg ,500mg/d<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
76035516|NCT04833725|Device|wearable devices|All patients use wearable devices and IoT technology for information collection and data management. Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
76035517|NCT03101605|Other|e-learning teaching module|As described
76035518|NCT03101605|Other|Standard teaching method|As described
76035519|NCT05069779|Drug|Diazepam|Oral administration of 10 mg of diazepam
76035520|NCT04837469|Procedure|fissure sealant application|fissure sealants were placed after differnt adhesive strategies used
76035521|NCT03251911|Drug|Ivacaftor (VX-770)|of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
75393878|NCT03489564|Behavioral|Active|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
75545429|NCT01339390|Behavioral|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
75870323|NCT03656198|Biological|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
75393879|NCT03489564|Behavioral|Sedentary|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
75545430|NCT01339273|Procedure|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
75870324|NCT03656198|Drug|Sterile Water Injection|The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
75870325|NCT02382250|Behavioral|Survey|Survey will be given to all participants
75870326|NCT02388490|Drug|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
76035522|NCT04824755|Procedure|Yune Zhao|Yune Zhao did congenital cataract surgeries
76035523|NCT04837391|Device|Near Infrared Spectroscopy (NIRS)|Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.
76035524|NCT04837391|Diagnostic Test|Blood sample|Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.
76035525|NCT04837391|Diagnostic Test|Addenbrooke Cognitive Examination III (ACE-III)|ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.
75545431|NCT01339273|Procedure|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
76035526|NCT04837391|Diagnostic Test|Confusion Assessment Method|Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
76035527|NCT02643355|Drug|Olanzapine|
75393880|NCT04763304|Other|Gown personal protective equipment (PPE-G) suit|Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
75545432|NCT00271674|Device|Q-switched YAG laser|
75545433|NCT01334866|Procedure|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
75545434|NCT04709315|Drug|dexemedetomidine and rocuronium|In the DR group, patients received pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg was the intubating muscle relaxant
75545435|NCT04709315|Drug|0.9% saline and succinyl choline 1mg/ kg|0.9% saline over 10 minutes, and succinyl choline 1mg/ kg
75545436|NCT01334710|Drug|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
75545437|NCT00271713|Drug|ibandronate, calcium and vitamin D|1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
75545438|NCT00271713|Drug|placebo,calcium and vitamin D|2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
75545439|NCT00258713|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg BID
75545440|NCT01334554|Drug|Sildenafil|20 mg three times a day.
75545441|NCT01334554|Drug|Placebo|No active drug
75870327|NCT02386540|Behavioral|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
75870328|NCT02377414|Drug|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
75545442|NCT00291213|Drug|levetiracetam|
76035528|NCT02643355|Drug|Clonidine|
76035529|NCT03036527|Procedure|Activity-based locomotor training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).
76035530|NCT03036527|Procedure|Activity-based stand training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.
75545443|NCT00291213|Drug|placebo|
75870329|NCT02377414|Drug|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
75870330|NCT02377336|Drug|GS-6615|GS-6615 tablets administered orally
75870331|NCT02377336|Drug|Placebo|Placebo to match GS-6615 tablets administered orally
75870332|NCT02381938|Behavioral|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
75870333|NCT02381938|Other|Healthy Finances|6-month intervention to educate and improve financial health
75870334|NCT02662582|Drug|Reldesemtiv|Oral tablet
75870335|NCT02662582|Drug|Placebo|Oral tablet
75870336|NCT02382094|Drug|Bicalutamide|
76035531|NCT03036527|Procedure|Activity-based upper arm ergometry|The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.
76035532|NCT02604017|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
76035533|NCT03036605|Drug|Bupivacaine|%0.5 bupivacaine
76035534|NCT03036605|Drug|Dexamethasone|8 mg Dexamethasone
76035535|NCT04837079|Other|Clinical observational study|Clinical observational study
76035536|NCT03099967|Device|Transcatheter closure of an atrial septal defect or patent foramen ovale.|In a prospective study in adults troponin T (TnT) serum concentrations were determined before and the day after transcatheter closure of an atrial septal defect (ASD) or patent foramen ovale (PFO).
76035537|NCT03098875|Drug|Sevoflurane|General anesthesia using sevoflurane as a hypnotic agent
76035538|NCT03098875|Drug|Propofol|General anesthesia using propofol as a hypnotic agent
76035539|NCT03098875|Drug|Remifentanil|General anesthesia using remifentanil as an analgesic.
75545444|NCT01332799|Drug|allopurinol or placebo|Daily active drug (allopurinol administered orally) administered orally for 3 years.
75545445|NCT01332799|Other|Placebo|Sugar pill administered orally for 3 years.
75545446|NCT00258752|Behavioral|IPT-AST|IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
75545447|NCT00258752|Other|Enhanced IPT-AST|Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
75545448|NCT00258752|Other|School counseling|Usual care consists of standard treatments, including individual counseling with guidance counselor.
75545449|NCT00271752|Procedure|Earlier therapeutic changes regarding infection|For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
75545450|NCT00258791|Drug|Ibuprofen|
76035540|NCT04837157|Device|Exoskeleton rehabilitation|The participants will perform physical therapy with the ATLSA2030 device, for 90 minutes per session.
75393881|NCT04763304|Other|Coverall personal protective equipment (PPE-C) suit|Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
75708213|NCT05202080|Other|Opioid Counseling and Pain Coping Skills Video|The intervention will be in the form of a video of a PowerPoint presentation with instructions and exercises designed to coach patients about catastrophizing, coping skills, mindfulness and behavioral modification techniques, in addition to providing education regarding postoperative analgesia and opioid use.
75870337|NCT04439500|Behavioral|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
75870338|NCT04439500|Behavioral|Brain Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
76035541|NCT03099031|Drug|Tinzaparin|Subcutaneous injection of 175 IU/kg once daily for 6 months
76035542|NCT03037151|Drug|Grazaoprevir/Elbasavir|treatment naive
75708214|NCT05199324|Drug|Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the intervention arm will be switched early to oral antibiotics (within 72 hours from index blood culture collection)
75708215|NCT05199324|Drug|Standard of care intravenous antibiotics (e.g. ceftriaxone, cefazolin)|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the standard arm will continue to receive an active intravenous antibiotic therapy for at least another 24 hours post-randomisation before clinical re-assessment and decision making by the treating doctor
76035543|NCT03037151|Drug|Grazaoprevir/Elbasavir/RBV|treatment experienced
76035544|NCT03101059|Procedure|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
75708216|NCT05198310|Drug|KPL-404|Humanized monoclonal antibody
75870339|NCT02386150|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
75870340|NCT02908100|Drug|GDC-0853|Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
76035545|NCT03037229|Device|Smartphone ECG|
75393882|NCT00086346|Drug|Sirolimus (Rapamune)|
75393883|NCT00086346|Drug|Cyclosporine or Tacrolimus|
75393884|NCT00085566|Drug|everolimus|
75393885|NCT00085566|Drug|gefitinib|
75393886|NCT00085098|Biological|filgrastim|Given by infusion or injection
75393887|NCT00085098|Drug|carboplatin|Given IV over 1 hour
76035546|NCT03037229|Device|Standard 12-lead ECG|
76035547|NCT03100981|Behavioral|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
75393888|NCT00085098|Drug|cisplatin|Given IV over 6 hours
75393889|NCT00085098|Drug|cyclophosphamide|Given IV over 1 hour
75393890|NCT00085098|Drug|etoposide|Given IV over 2 hours
76035548|NCT03100981|Behavioral|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
76035549|NCT03036371|Behavioral|High Intensity Interval Exercise|6 week at-home aerobic exercise protocol
76035550|NCT03101215|Dietary Supplement|phosphorus|adding of phosphorus to high carbohydrate meal
76035551|NCT04824287|Other|pelvic floor muscle exercise|pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
75393891|NCT00085098|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week
75393892|NCT00084864|Dietary Supplement|calcitriol|Given orally
75393893|NCT00084864|Drug|dexamethasone|Given orally
75393894|NCT00084864|Other|clinical observation|No intervention before surgery
75393895|NCT03487302|Other|Brain MRI|Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans
75393896|NCT03487302|Other|Neuropsychological test battery|"Mini Mental State Examination (MMSE), Measso et al. (1993);~Frontal Assessment Battery (FAB), Appollonio et al. (2005);~Symbol Digit Test, Amodio et al. (2002);~Digit Cancellation Test, Della Sala et al. (1992);~Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~Digit Span, Orsini et al (1987);~Corsi block-tapping test, Orsini et al. (1987);~Babcock story recall test, Carlesimo et al. (2002);~Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~Semantic verbal fluency, Novelli (1986);~Imitating gestures, De Renzi et al. (1980);~Coloured Progressive Matrices (CPM47), Measso et al. (1993)."
75393897|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
75708217|NCT05198310|Drug|Placebo|Matching placebo
75393898|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
75393899|NCT01677702|Dietary Supplement|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
75393900|NCT01677780|Drug|RO5045337|Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m^2) to 1800 mg/m^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
75393901|NCT05346978|Dietary Supplement|Nasturtium (Tropaeolum majus)|Freeze dried nasturtium (Edible flower)
75393902|NCT05346978|Dietary Supplement|Placebo|collagen colored with green pigment used in the food industry
75393903|NCT03485196|Other|Microsatellite instability|The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
75393904|NCT01473108|Drug|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
75393905|NCT01473108|Drug|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
75393906|NCT01473108|Drug|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
75393907|NCT01473108|Drug|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
75545451|NCT00291369|Drug|Interleukin-2|
75545452|NCT00291369|Drug|Interferon alfa|
75545453|NCT00291369|Drug|medroxyprogesterone acetate|
75545454|NCT00291408|Procedure|Skin Prick Test|
75708218|NCT05198258|Other|Implementation strategy - experimental group|On-line theoretical education and three hours of practical training by the project leaders. Contact with the project team via e-mail, phone and on-line repetition of the education for remaining of the clinical examination, neck-specific program and the progression of exercises.
75545455|NCT00291408|Procedure|Impulse Oscillometry|
75545456|NCT00291408|Procedure|Exhaled Nitric Oxide|
76035552|NCT03101137|Drug|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
75393908|NCT00084318|Biological|cetuximab|400 mg/m^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m^2 intravenously over 60 minutes in weeks 2 through 7.
75870341|NCT02908100|Drug|Placebo|Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
75393909|NCT00084318|Drug|cisplatin|30 mg/m^2 intravenously infused over over 60 minutes in weeks 2 through 7.
75545457|NCT00291408|Procedure|Spirometry|
75870342|NCT02377180|Procedure|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
75545458|NCT00291408|Procedure|Reversibility|
75545459|NCT00291408|Procedure|Exhaled Breath Condensate|
75545460|NCT00291408|Procedure|Sputum Induction|
76035553|NCT03101137|Drug|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
75545461|NCT00258947|Biological|Smallpox vaccine, LISTER strain, from chick embryo cells|
75545462|NCT00271791|Drug|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
75545463|NCT00271791|Drug|Prednisone|PO, Placebo, 17 days
75545464|NCT00258986|Procedure|Living donornephrectomy|
75545465|NCT01332331|Drug|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
75870343|NCT02377180|Procedure|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
75393910|NCT00084318|Drug|docetaxel|15 mg/m^2 intravenously infused over 30 minutes in weeks 2 through 7.
75393911|NCT00084318|Radiation|radiation therapy|60 Gy (2 Gy once a day, 5 times a week)
75545466|NCT01332331|Drug|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
75545467|NCT00259025|Drug|lipid emulsion with a high content of n-3 fatty acids|
75545468|NCT00291564|Device|Cardiac Resynchronization Therapy Device|
75545469|NCT00259064|Drug|Gefitinib|
75393912|NCT00084084|Drug|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
75393913|NCT00083616|Biological|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
75393914|NCT04402710|Behavioral|Self-compassion|Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes
75393915|NCT04402710|Behavioral|Control Group|Six week behavioural change program aimed to increase physical activity plus information on general health topics.
75393916|NCT00083226|Drug|doxorubicin|Given IV
75393917|NCT00083226|Drug|bortezomib|Given IV
75545470|NCT00259064|Other|Placebo|
75545471|NCT01332292|Drug|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
75545472|NCT01332292|Drug|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
75545473|NCT00271869|Procedure|Extracorporeal photoimmunotherapy|
75545474|NCT00271908|Behavioral|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
75545475|NCT00291603|Device|FX-class of dialyser|
75545476|NCT00259103|Drug|Serelaxin|
75545477|NCT00259103|Drug|Placebo|
75545478|NCT00259142|Drug|Chloroquine, sulphadoxine-pyrimethamine|
75545479|NCT00259181|Procedure|saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation|
75393918|NCT05346510|Procedure|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
75393919|NCT00082758|Biological|hu14.18-Interleukin-2 fusion protein|Given IV
75393920|NCT01678014|Procedure|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
75545480|NCT00291720|Drug|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
75545481|NCT00291720|Drug|Placebo|matching placebo
75545482|NCT00259220|Drug|erythomycin|erythomycin
75545483|NCT00259220|Procedure|gastric lavage alone|gastric lavage alone
75545484|NCT00259220|Procedure|erythromycine and gastric lavage|erythromycine and gastric lavage
75545485|NCT00259259|Behavioral|SALATRIM|
75545486|NCT00291759|Drug|Tamoxifen|
75393921|NCT01678014|Procedure|Capsulotomy|
75393922|NCT04403178|Diagnostic Test|Radiographic examination with a Migration of > 40 %|Radiographic examination
75393923|NCT03424512|Behavioral|Group Metacognitive Therapy|Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
75393924|NCT03424200|Behavioral|Routine care|Participants will receive routine care
75545487|NCT00291759|Drug|Anastrozole|
75545488|NCT00272025|Drug|Escitalopram|10mg to 20mg tablet daily for 6 weeks
75545489|NCT00272025|Drug|placebo|
75545490|NCT00291798|Procedure|rate of remission|
75545491|NCT04709081|Drug|ACH-0145228|ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.
75545492|NCT04709081|Drug|Midazolam|Midazolam was dosed at 2 mg (1 milliliter [mL] of a 2 mg/mL syrup).
75545493|NCT04709081|Drug|Digoxin|Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.
75545494|NCT04709081|Drug|Itraconazole|Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
75545495|NCT00272064|Drug|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal < 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
75545496|NCT00272064|Drug|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) <= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
75545497|NCT00272064|Drug|Metformin|1000 mg b.i.d, since the qualification phase, oral
75545498|NCT00259337|Biological|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
75545499|NCT00259376|Drug|Dronedarone (SR33589)|oral administration
75545500|NCT00259376|Drug|placebo|oral administration
75545501|NCT00415337|Procedure|endobronchial ultrasound|EBUS
75545502|NCT01332019|Drug|peginterferon beta-1a|Administered as specified in the treatment arm
75545503|NCT00291837|Drug|CT-2106|
75545504|NCT02961140|Other|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
75545505|NCT02961140|Other|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
75393925|NCT03424200|Other|Coaching plus routine care|Participants will receive coaching plus routine care
75393926|NCT03438318|Drug|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
75393927|NCT03438318|Drug|Atezolizumab|Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
75545506|NCT00272103|Drug|Itopride (drug)|
75393928|NCT03438318|Radiation|Radiation Therapy|Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
75545507|NCT04718688|Other|CO-OP rehabilitation|"The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them."
75393929|NCT03087942|Drug|QAW039|450 mg
75393930|NCT03087942|Drug|QAW39A|450 mg
75393931|NCT03087942|Drug|QAW39A2107|450 mg
75393932|NCT03087942|Drug|QAW39A2107|450 mg
75393933|NCT01678092|Biological|omalizumab|
75393934|NCT04402320|Drug|Midazolam|reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
75393935|NCT04402320|Device|ventilator|reconnected to mechanical ventilation before extubation for one hour with sedation
75393936|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
75393937|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
75393938|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
75393939|NCT03436056|Drug|Pembrolizumab|Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
75545508|NCT00415376|Drug|levetiracetam|
75545509|NCT00415376|Procedure|quality-of-life assessment|
75545510|NCT00415454|Genetic|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
75545511|NCT00259415|Behavioral|Caregiver support via telephone|
75545512|NCT00272142|Drug|Zinc|
75545513|NCT00272142|Drug|Placebo|
75545514|NCT00259454|Behavioral|In-home intervention|occupational therapy techniques to reduce caregiver stress
75545515|NCT00291915|Drug|Adalimumab|
75545516|NCT00291915|Drug|Methotrexate|
75708219|NCT05198258|Other|Implementation - control group|Physiotherapists in the control group will receive the same theoretical and practical training as the experimental group but without repetition of the education or support from the research team.
75708220|NCT05179824|Other|Observation|No Intervention
75708221|NCT05174975|Behavioral|App-based Positive Psychological Intervention|The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
75870344|NCT02377180|Procedure|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
75870345|NCT02377024|Dietary Supplement|TF 600mg|
75708222|NCT05172271|Device|MagPro TMS Stimulator and coil|TMS measurements of cortical excitability pre and post study intervention
75708223|NCT05172271|Device|Thymatron System IV|The Thymatron System IV (Somatics LLC, Venice, FL, USA)is an FDA 510(k)-cleared ECT device. For TESt, we will be using it in a non FDA-approved manner--stimulating without intending to induce seizures.
75870346|NCT02377024|Dietary Supplement|TF 1200mg|
75870347|NCT02377024|Dietary Supplement|placebo|
75870348|NCT02377102|Procedure|Physical Therapy|12 weeks of supervised physical therapy.
75870349|NCT02386228|Genetic|collection of CSF and blood|collection of CSF and blood
75870350|NCT03656120|Drug|0.2mg group|Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
75870351|NCT03656120|Drug|0.5mg group|Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
75870352|NCT03656120|Drug|placebo control group|Participants only take placebos for 12 weeks during the research.
76035554|NCT03101137|Drug|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
76035555|NCT01881451|Drug|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
76035556|NCT01881451|Procedure|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
75393940|NCT03088176|Drug|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
75393941|NCT03088176|Drug|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
75393942|NCT03088176|Drug|Dabrafenib|150mg PO qday
75393943|NCT03088176|Drug|Trametinib|2mg PO qday
75393944|NCT00087984|Biological|MB-002|Dendritic Cell Immunotherapy
75393945|NCT01678404|Drug|131I-rituximab|
75393946|NCT03087864|Drug|Atezolizumab|Atezolizumab 1200 mg i.v. day 1-22-43-64-85
75393947|NCT03087864|Drug|Carboplatin|Chemotherapy
75870353|NCT04341298|Other|11-point pain scale|Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.
75870354|NCT04341298|Other|Headache diary|Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.
75393948|NCT03087864|Drug|Paclitaxel|Chemotherapy
75393949|NCT03087864|Radiation|Radiotherapy 23 x 1.8 Gy|Radiotherapy
75393950|NCT03087630|Behavioral|Reasoned-Based Intervention|Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
75393951|NCT03087630|Behavioral|Social-Based Intervention|Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
75393952|NCT03087630|Behavioral|Integrated Intervention|Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
75393953|NCT03087630|Behavioral|Attention Control|Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
75393954|NCT01678482|Device|light based device for treatment of acne|
75393955|NCT01678716|Behavioral|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
75393956|NCT01678716|Dietary Supplement|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
75393957|NCT01678716|Behavioral|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
75393958|NCT00081510|Drug|Lonafarnib|
75393959|NCT00081510|Drug|Placebo|
75393960|NCT00081510|Drug|anastrozole|
75393961|NCT00088452|Drug|Ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
75393962|NCT00088452|Drug|Lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
75393963|NCT00088452|Drug|Valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
75393964|NCT03417570|Procedure|Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)|-The second endoscopist will be blinded to the results of the initial exam.
75393965|NCT03417570|Device|Olympus Disposable Distal Attachment Cap|-The second endoscopist will be blinded to the results of the initial exam.
75393966|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
75870355|NCT04341298|Device|Avulux®|Avulux® device
75870356|NCT04341298|Device|Sham Avulux®|Sham Avulux®
75393967|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
75393968|NCT03087474|Other|Non-Interventional|Non-Interventional
75708224|NCT05172271|Device|Magnetic Resonance Imaging Scanner|Conventional MRI studies in this protocol are considered non-significant risk (NSR) devices. While operated in research mode, the MRI will be under the International Electrotechnical Commission (IEC) 60601-2-33 First Level Controlled Operating Mode, which allows for research pulse sequences to be used within the FDA/IEC safety limits for MRI devices.
75708225|NCT05172271|Other|ECT device without stimulation|Anesthesia alone
76035557|NCT04429139|Drug|photodynamic therapy|PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
75393969|NCT01679106|Other|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
76035558|NCT04428125|Diagnostic Test|Magnetic Resonance Scan of Thoracic outlet region|Both groups will undergo Magnetic Resonance Scan of cervicothoracobrachial region in order to study the anatomy of this region.
75393970|NCT01679106|Other|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
75708226|NCT05169866|Drug|Nifekalant|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.
75393971|NCT04403100|Drug|Hydroxychloroquine Sulfate Tablets|Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
75393972|NCT04403100|Drug|Lopinavir/ Ritonavir Oral Tablet|tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
75393973|NCT04403100|Drug|Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|"Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days"
75393974|NCT04403100|Drug|Placebo|Placebo tablets - 01 tablet twice daily from day 01 through day 10.
75708227|NCT05169866|Drug|Amiodarone|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.
75708228|NCT05169840|Other|Genetic Risk Score for Coronary Artery Disease|Blood samples will be genotyped for million of genetic risk variants for Coronary Artery Disease (CAD)
76035559|NCT04428125|Diagnostic Test|Duplex Ultrasound assessment of Upper limbs|Both groups will undergo Duplex Ultrasound assessment of Upper limbs, in order to study diameters and flow of the vascular system of the upper limbs.
76035560|NCT05069077|Other|Music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
75393975|NCT03087318|Behavioral|Physical activity|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~during 3 months."
75393976|NCT03086538|Drug|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
75708229|NCT05160480|Diagnostic Test|Total-body PET imaging|Total-body PET imaging at different timepoints
75708230|NCT05153239|Drug|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 & 8 q3wk
75708231|NCT05153239|Drug|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
75708232|NCT05153239|Drug|Irinotecan|Irinotecan 350 mg/m² intravenously Day 1 q3wk
75393977|NCT03086538|Drug|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
75393978|NCT04761276|Device|Surgical implantation of intra ocular lens|Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.
75393979|NCT03473730|Procedure|Biopsy|Undergo biopsy
75708233|NCT05153239|Drug|Topotecan|Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk
75708234|NCT05153239|Drug|Lurbinectedin|Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
75708235|NCT05148052|Device|Virtual reality exergames|Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
75708236|NCT05148052|Behavioral|Conventional occupational therapy|Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
75708237|NCT05144191|Device|Insignia uncemented Hip Stem|Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
75393980|NCT03473730|Biological|Daratumumab|Given IV
75393981|NCT03473730|Other|Laboratory Biomarker Analysis|Correlative studies
75708238|NCT05131919|Drug|Pembrolizumab|Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.
75393982|NCT03473730|Procedure|Metastasectomy|Undergo metastasectomy
75393983|NCT03473730|Procedure|Nephrectomy|Undergo nephrectomy
75393984|NCT01679262|Device|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
75393985|NCT02984748|Device|Cochlear implant|
75393986|NCT03081858|Drug|TSD-001|Administered via intravesical instillation.
75393987|NCT03082560|Diagnostic Test|Boston Grade of Activity in Lichen Planopilaris|A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
75393988|NCT01679340|Drug|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
75393989|NCT01679340|Drug|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
75393990|NCT01679340|Drug|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
75393991|NCT03087084|Device|Cardiac Pacing and Impedance Measurement system|Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
75393992|NCT03089814|Procedure|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
75393993|NCT03089970|Diagnostic Test|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
75708239|NCT05127434|Drug|Placebo|0.9% sodium chloride (normal saline) injection
75393994|NCT03087006|Other|Automatic Self Transcending Meditation (ASTM)|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
75393995|NCT03087006|Other|Treatment as Usual|Usual Care includes usual care of the participants including dry eye disease medications
75393996|NCT01679574|Drug|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
76035561|NCT05069077|Other|No music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
76035562|NCT04833257|Drug|GP combine with Tislelizumab neoadjuvant therapy+CCRT|chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
76035563|NCT03098953|Drug|Loteprednol Etabonate|one drop per eye for each eye
75393997|NCT01679574|Drug|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
75393998|NCT01679574|Drug|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
75393999|NCT01679652|Drug|Nebivolol|Tablet i blinded in capsula
75394000|NCT01679652|Drug|placebo|
75394001|NCT05346198|Drug|CART-BCMA|The CART-BCMA (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
75394002|NCT03086928|Other|lava ultimate|resin nano ceramic material
75394003|NCT03086928|Other|E.max cad|Lithium disilicate glass ceramic
75394004|NCT04761744|Drug|Nivolumab|Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
75394005|NCT01679886|Radiation|Rubidium PET|Rubidium PET
75394006|NCT04402476|Device|Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
75545517|NCT00259493|Procedure|Off-Pump Coronary Artery Bypass Graft Surgery|
76035564|NCT03099889|Behavioral|Physical Activity|Physical activity intervention based upon stage of change and social cognitive theory based interventions
75708240|NCT05127434|Drug|mRNA-1345|Sterile liquid for injection
75394007|NCT03089736|Behavioral|Education|Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
75394008|NCT03089736|Behavioral|Self Care|The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
75394009|NCT03089736|Other|Treatment as usual (TAU)|pharmacological treatment + advices
75394010|NCT03432000|Other|Performances of patients and controls on temporal task|To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)
75394011|NCT03089502|Other|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
75394012|NCT03089658|Drug|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
75394013|NCT03089190|Dietary Supplement|DC7-2|Effects on appetite
75394014|NCT03089190|Dietary Supplement|DC7-2 + potato protein isolate|Effects on appetite
75545518|NCT00272181|Drug|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
75545519|NCT00259532|Procedure|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
75545520|NCT00291954|Biological|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
75394015|NCT03089190|Dietary Supplement|Potato protein isolate|Effects on appetite
75394016|NCT03089190|Dietary Supplement|Placebo|Inactive whey protein, not expected to affect appetite.
75394017|NCT03089424|Device|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
75545521|NCT00291954|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
75545522|NCT00259571|Drug|retarded release phosphatidylcholine|2g daily, given orally QTD
75545523|NCT00259688|Device|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
75545524|NCT00272220|Behavioral|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
75545525|NCT00272259|Procedure|Participants will interact with up to two small robots and a visual display|
75545526|NCT00259766|Drug|Budesonide|
75545527|NCT00259766|Drug|Formoterol|
75545528|NCT00259766|Drug|Terbutaline|
75545529|NCT00292071|Drug|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
75545530|NCT04709159|Other|Call for Life Uganda|"Call for Life™ Uganda (C4LU) is a web-based mHealth tool that provides treatment support to patients in the form of daily or weekly pill adherence reminders, health messages, clinic appointment reminders and a remote symptom reporting service. The tool interacts with patients by text message (SMS) or using voice and tone input via keypad (Interactive Voice Response - IVR) on both analogue and smart phones.~The tool uses CONNECT FOR LIFE technology, which is on an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation. It was supported by Janssen, the Pharmaceutical Companies of Johnson and Johnson and was released under the terms of the MOTECH open source license agreement."
75545531|NCT00292110|Drug|Methadone|100 mg/day orally
75545532|NCT00292110|Behavioral|Contingency Management|Incentives given for cocaine abstinence
75545533|NCT00292110|Drug|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
75545534|NCT00292110|Behavioral|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
75870357|NCT02166242|Drug|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
75870358|NCT03656042|Drug|Filgrastim (75mcg/0.3ml)|"Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~Non-treatment"
75870359|NCT02381860|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
76035565|NCT04823507|Device|BIOFLEX DUO+|"Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment.~Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine.~Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test.~Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared."
76035566|NCT03099577|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
76035567|NCT03099577|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
75394018|NCT03089424|Device|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
75394019|NCT03089346|Diagnostic Test|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
75394020|NCT03089346|Diagnostic Test|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
75870360|NCT02381860|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
75870361|NCT03655964|Drug|Olmesartan|At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset
76035568|NCT03099577|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
75394021|NCT03081234|Drug|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
75394022|NCT03081234|Drug|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
75394023|NCT03081234|Drug|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
75394024|NCT03417492|Drug|Sildenafil Citrate|Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
75394025|NCT03080922|Biological|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
75394026|NCT04402164|Device|Herbst appliance|telescopic appliance for mandibular advancement
75708241|NCT05126888|Drug|SCI-110|SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
75394027|NCT03080532|Other|dietary habits|
75394028|NCT03080766|Drug|Decitabine|Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
75394029|NCT03080688|Device|Prizma Oxygen Saturation Measurement|"A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1)."
75394030|NCT03080298|Drug|BP101|
76035569|NCT03099577|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
75394031|NCT03080298|Drug|Placebo|
75394032|NCT04401618|Other|Retrospective evaluation of RMGI and GIC Class V Restorations|Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
75394033|NCT03080376|Other|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
75394034|NCT03080376|Other|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
75394035|NCT03080376|Other|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
75394036|NCT03080844|Behavioral|Delay time to first cigarette|Participants asked to delay time until they smoke first cigarette of the day.
75394037|NCT03080844|Behavioral|Therapy|Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
75394038|NCT03392064|Biological|AMG 119|Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
75394039|NCT03080064|Behavioral|Health Coach Intervention|Please see arm description.
75394040|NCT04761354|Procedure|Unilateral adrenalectomy|
75708242|NCT05126888|Other|Placebo|Pill that matches in taste, odour and appearance to SCI-110 active pills
75870362|NCT03655964|Drug|Nebivolol|At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset
76035570|NCT03099577|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
75870363|NCT03655964|Other|No antihypertensive treatment|Patients will be left without treatment
75870364|NCT02385994|Device|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
75870365|NCT02381236|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
75394041|NCT03089112|Drug|HGP1607|Take it once per period
75394042|NCT03089112|Drug|HGP1501|Take it once per period
75394043|NCT03089112|Drug|HGP1607+HGP1501|Take it once per period
75394044|NCT03083886|Other|Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care|Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.
75394045|NCT03083886|Other|Individualized Postural Therapy (IPT) + PCP led care|IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.
75394046|NCT03083886|Other|Usual PCP led care|Primary care provider will direct patients' care pathway.
75545535|NCT00259805|Drug|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
75545536|NCT00259844|Biological|TroVax|
75394047|NCT04279626|Procedure|LETS-M|A 1.5-centimeter skin incision was made over the umbilicus, and the abdominal wall was opened layer by layer with an open method. A wound retractor (Alexis, 2-4 centimeter; Applied Medical Resources Corp., Rancho Santa Margarita, CA) was placed, and the glove port was set up, with a 10-millimeter trocar in the thumb over patient's right side, and a 5-millimeter trocar in the little finger over the left side. The pneumoperitoneum was established. A 10-millimeter rigid laparoscope was inserted via the 10-millimeter trocar and controlled by the assistant. The ancillary 5-millimeter port was made over the left lower abdomen under laparoscope inspection. The surgeon performed the surgery via the two 5-millimeter trocars.
75394048|NCT03088956|Other|Assessments|Cognitive, Behavioral and Functional as described in the Outcome Measures
75394049|NCT03088722|Other|Training CHEWs to provide contraceptive implants|Training CHEWs to provide contraceptive implants
75394050|NCT03088644|Drug|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
75394051|NCT03088644|Drug|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
75394052|NCT03088254|Drug|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
75394053|NCT03088254|Drug|Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
75394054|NCT03088254|Drug|Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)|Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
75394055|NCT03088488|Diagnostic Test|fasting venous blood samples|
75394056|NCT05685420|Drug|Herombopag|Thrombopoietin receptor agonist
75394057|NCT04279080|Other|low anterior resection syndrome evaluation|evaluation of postoperative functional bowel outcome
75870366|NCT02982590|Drug|Apixaban 5 MG Oral Tablet [ELIQUIS]|Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
75545537|NCT00259883|Drug|paroxetine|1 or 2 tablets once a day
75870367|NCT02982590|Drug|Warfarin Sodium|as controlled arm since warfarin is the standard therapy for LV thrombus
75870368|NCT02381548|Drug|Adavosertib|Given PO
75870369|NCT02381548|Drug|Belinostat|Given IV
75870370|NCT02381548|Other|Laboratory Biomarker Analysis|Correlative studies
75870371|NCT02381548|Other|Pharmacological Study|Correlative studies
75870372|NCT02103140|Behavioral|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
76035571|NCT03099577|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
76035572|NCT03099577|Radiation|radiochemotherapy 7|concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
76035573|NCT04833179|Biological|fecal transplant|"Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. All donors will undergo a screening process that will include a detailed medical history, blood work and fecal tests. Only after passing the screening, the donor will be added to the groups of donors that will participant in this study.~The treatment will be givenin the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment."
75394058|NCT05689086|Other|Virtual Heart Failure Optimization Program|"Participants referred to the Virtual Heart Failure Optimization Program will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation.~Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well.~All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming."
76035574|NCT04833179|Other|placebo|placebo
76035575|NCT03036137|Device|Transcranial Direct Current Stimulation|Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
76035576|NCT03036137|Device|Sham Transcranial Direct Current Stimulation|Sham tDCS sessions will last 20 minutes
76035577|NCT05069233|Other|UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
76035578|NCT04833101|Biological|recombinant Ad5 vectored COVID-19 vaccine|This vaccine contains 5×10^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
76035579|NCT04833101|Biological|RBD-based protein subunit vaccine (ZF2001) against COVID-19|This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
75394059|NCT03086772|Behavioral|Tai Chi|Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
75394060|NCT03086772|Behavioral|Light Exercise|Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
75394061|NCT05689008|Biological|UC-MSCs treatment|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1*10^6 cells/kg suspended in 100 ml albumin solution.
75394062|NCT05688930|Other|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk soccer players.
75394063|NCT05688930|Other|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
75394064|NCT05684484|Drug|Roflumilast 500 Ug ORAL TABLET [Daliresp]|Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
75394065|NCT05684484|Drug|corticosteroids +immune suppressive +amino salicylic acid|conventional treatment
76035580|NCT04833101|Biological|trivalent split influenza vaccine|This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
76035581|NCT03100903|Drug|BI 655130|single dose
76035582|NCT04837313|Procedure|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
75394066|NCT03391908|Diagnostic Test|cardiac imaging tests|Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
75394067|NCT03086382|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
76035583|NCT05068765|Other|Communication skills psychoeducation|Intervention explanations are explained in the groups section.
75394068|NCT03086382|Drug|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
75394069|NCT04401696|Device|Bubble CPAP|"The bCPAP will be delivered using an oxygen flow meter as the oxygen source. This inspiratory limb containing oxygen from the flow meter will be connected to humidifier and tubing from humidifier will be connected to short binasal prongs, which would be applied to neonate with the help of adhesive bandage on both cheeks. It will be ensured that binasal prongs make appropriate seal. An orogastric tube will be placed for gastric decompression. A 1000 ml/500ml bottle filled with sterile water be used and marks will be made on it at 1cm distance, with '10' marked at base and '0' mark at the water interface.~The expiratory limb from the nasal prongs was connected to tubing that will be dipped in water up to the desired level to provide positive end expiratory pressure. Pressure is varied by varying the depth of the dipped end of tubing."
75394070|NCT04401696|Other|Nasal Oxygen|The oxygen will be delivered from a wall oxygen source, delivered between 1 to 6 L/min and the rate varied via a flow regulator.
75394071|NCT05680428|Other|early feeding|oral feeding within 12hours after stoma reversal
75394072|NCT05680428|Procedure|conventional feeding|oral feeding after 48hours of NBM after stoma reversal
75394073|NCT03086304|Device|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation is same to the traditional Chinese medicine acupuncture treatment,treat diseases by stimulate different acupuncture points.
75394074|NCT03086304|Device|no transcutaneous acupoint electrical stimulation|the choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation.
75394075|NCT03415308|Other|Focus Groups|Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
75394076|NCT03415308|Other|Cognitive Interviews|To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
75394077|NCT03415308|Other|Pilot Testing of Implicit Bias Training|Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
75708243|NCT05126849|Other|Allogenic transplantation|"Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~Stem cell source Bone Marrow~GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
75708244|NCT05123482|Drug|AZD8205|AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, and endometrial cancers
75708245|NCT05121597|Device|HugeMed Videolaryngoscope|Macintosh laryngoscope
75708246|NCT05120856|Behavioral|AAT-App|Participants will receive the active AAT-App on their smartphone, which includes ApBM training, and prompted to engage with the app during the 28-day intervention period.
75394078|NCT04279002|Other|Brief 15-question questionnaire|Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
75708247|NCT05120856|Behavioral|Minimal AAT-App|Participants will receive the minimal version of AAT-App, which does not include ApBM training, on their smartphone and prompted to engage with the app during the 28-day intervention period.
75708248|NCT05117294|Drug|Bocidelpar|Oral
75708249|NCT05115838|Drug|Islatravir|ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
75708250|NCT05115838|Drug|Placebo|Placebo implantable rod placed subdermally on the upper arm.
76035584|NCT05068765|Other|General psychoeducation|İntervention descriptions are explained in the intervention groups section.
76035585|NCT00794599|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
76035586|NCT00794599|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
76035587|NCT04836611|Procedure|1 blood sample|2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
76035588|NCT00783133|Drug|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
76035589|NCT00783133|Drug|fexofenadine|Allegra 180 mg daily x 7 days
76035590|NCT04823819|Device|Magnetic Stimulator DuoMag|Stimulation of the left dorsolateral prefrontal cortex
75394079|NCT03414996|Other|Exercise training|Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
75708251|NCT05106647|Behavioral|Reduce screen time|The intervention is information provided via email on how to set up an automated response to emails received during their weekend off, reduce screen time for duration of leisure time, and uninstall work applications from their mobile device.
75708252|NCT05105100|Procedure|Biopsy|Tumor tissue collection
75708253|NCT05105100|Procedure|Biospecimen Collection|Intravenously Blood draw
76035591|NCT04823819|Device|neuroConn DC-STIMULATOR|One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
75870373|NCT02103140|Behavioral|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
75870374|NCT02381314|Biological|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
75870375|NCT02345408|Drug|CCX872-B|Tablets (oral administration)
75870376|NCT02386072|Drug|mirabegron|oral
75545538|NCT04718376|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
75545539|NCT02961335|Procedure|Bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
75545540|NCT02961335|Procedure|Confocal microendoscopy|Confocal microendoscopy will be performed during this initial bronchoscopy
75870377|NCT02386072|Drug|antimuscarinic medication|oral
75870378|NCT03655730|Other|weekly psychotherapeutic individual sessions|weekly psychotherapeutic individual sessions following the IPT method during one year
76035592|NCT03098719|Behavioral|Active Mobility|see detailed discription
76035593|NCT04823429|Behavioral|High intensity-interval training (HIIT)|"Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.~Without any exercise training"
76035594|NCT04823429|Behavioral|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
75394080|NCT03086226|Drug|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
75708254|NCT05101265|Drug|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose."
75708255|NCT05101265|Drug|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose"
76035595|NCT03098407|Drug|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
76035596|NCT03098407|Drug|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
75394081|NCT03086226|Drug|Itraconazole|This will be the active comparator
75394082|NCT03085992|Drug|FOLFOXIRI plus Bevacizumab|"BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
75394083|NCT03085992|Other|Chemoradiotherapy plus Bevacizumab|"FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
75394084|NCT03362424|Biological|Mesenchymal stem cell|Mesenchymal stem cells applies at the end of rotator cuff repair in de active group
75394085|NCT03362424|Procedure|Rotator cuff repair|Rotator cuff repair
75394086|NCT03086070|Drug|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
75394087|NCT03086070|Drug|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
75394088|NCT05688306|Drug|Recombinant Human Interleukin-11 for Injection|received rhIL-11 injection for at least 5 consecutive days
75394089|NCT03086148|Drug|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
75545541|NCT02961335|Procedure|Biopsy sampling|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
76035597|NCT04836143|Drug|Intravitreal anti-vascular endothelial growth factor injection|Intravitreal injection of either ranibizumab or aflibercept
75394090|NCT03086148|Drug|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
75394091|NCT03359538|Drug|Rapamycin|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
75394092|NCT03359538|Drug|Placebo Oral Tablet|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
75545542|NCT00272415|Drug|INO-1001|Intravenous repeating dose
75545543|NCT00272415|Drug|temozolomide|Oral repeating dose
75394093|NCT04272138|Behavioral|Calm Meditation|"The intervention will run for 4-weeks. Participants will complete the 30 day, How to Meditate meditation series that provides daily 10-minute meditations. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions participants and will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice ecological momentary assessment question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview."
75545544|NCT00259922|Drug|Placebo|Placebo
76035598|NCT01595555|Behavioral|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
76035599|NCT05068453|Drug|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|OH2：less than 8mL/time，Q2W，i.t.；
76035600|NCT05068453|Drug|Recombinant humanized anti-PD-1 monoclonal antibody for injection|HX-008：200mg/time，Q3W，i.v.；
76035601|NCT05068453|Radiation|RT|3 times radiation，totally 24-30 Gy for each lession.
75394094|NCT04272138|Behavioral|Educational Podcast Control|The intervention will run for 4-weeks. Control group participants will listen to daily 10-minute health education podcasts. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions and participants will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.
75394095|NCT05345808|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide formulated with chondroitin sulfate and sodium hyaluronate
75545545|NCT00259922|Drug|Alvimopan|0.5 mg QD
75545546|NCT00259922|Drug|Alviompan|0.5 mg BID
75545547|NCT00272454|Drug|Cilostazol|
75545548|NCT00272454|Drug|Aspirin|
76035602|NCT00751075|Drug|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
76035603|NCT00751075|Drug|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
75545549|NCT00272493|Biological|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
75545550|NCT00272493|Biological|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
75545551|NCT00259961|Procedure|open fundoplication|
75545552|NCT00259961|Procedure|laparoscopic fundopliaction|
75545553|NCT00292266|Drug|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
75545554|NCT00292266|Drug|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
75545555|NCT00260000|Drug|5,6,7,8-tetrahydrobiopterin|
75545556|NCT00292305|Procedure|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
75545557|NCT00260039|Biological|Comparator: Gardasil|0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
75545558|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 1|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
75870379|NCT03655730|Other|Usual care|the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
75545559|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 2|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
76035604|NCT00751075|Drug|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
76035605|NCT00751075|Drug|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
76035606|NCT04823741|Genetic|PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
75708256|NCT05101174|Behavioral|Integrated Intervention Group (IIG)|"The IIG attends 150 min exercise per week, which consists of one 90-min trainer-supervised session and multiple online sessions for 6 months. Each session consists of (1) warm-up, (2) resistance exercise and flexibility exercise, (3) resistance exercise and coordinative exercise from the Eastern exercise perspective, (4) social interaction exercise, and (5) cool-down and meditation."
76035607|NCT00731185|Drug|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
76035608|NCT00731185|Drug|Placebo|
76035609|NCT04836299|Drug|Ivermectin|Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.
76035610|NCT04836299|Drug|Placebo|Participants will be randomly assigned to receive a single of placebo.
75545560|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 3|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
75545561|NCT00292344|Drug|Rifaximin and loperamide|
75545562|NCT00260117|Behavioral|Exercise|Referal to a website
75545563|NCT00272532|Drug|Thiocolchicoside|
75708257|NCT05101174|Behavioral|Control Group|The Control Group is informed to maintain their lifestyles and invited to attend one 60-min online educational course per week. The participants are required to provide their physical activity behavior once every month for 6 months (6 times).
75413859|NCT04511442|Other|Evaluation of food preferences during a standardized and validated buffet.|"The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~high / low in fat (HF / LF)~high / low in carbohydrates (HC / LC)~high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants."
75870380|NCT03656900|Device|rTMS BA9/BA46|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.
75870381|NCT03656900|Device|rTMS BA46/BA9|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.
75870382|NCT03656900|Radiation|brain MRI|T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
75870383|NCT03656900|Other|Medical evaluation|complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
75870384|NCT03656900|Other|Psychological assessment|Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
75413860|NCT04507815|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
75870385|NCT03655496|Device|Home-based tool|The tool consists of a tablet computer and a Bluetooth connected weight scale. The patient is encouraged to use the tool daily. The weight is titrates the dose of diuretics and a short tip about how to improve living with heart failure, this is presented on the screen. Every five days the patient assess their self-perceived symptoms on the tablet computer. If the weight increases by 2kg or more in 3 days or less, the high dose is recommended for two days, after which the effect on the weight is assessed. If the weight increased was reverted, the dose is returned to normal and if it is still elevated, an alert on the table computer. If the self-assessed symptoms deteriorate, the same type of alert will appear on screen, urging the patient to contact the health care provider.
75870386|NCT04439422|Behavioral|Short ADHD Intervention|Short, intensive psychological intervention based on CBT and DBT practices
75870387|NCT04439422|Other|Self-help material with limited therapist support|Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
75870388|NCT02381470|Drug|Faropenem|Faropenem 600mg
75870389|NCT02381470|Drug|Amoxicillin/clavulanic acid|Amoxicillin 500mg/ clavulanic acid 125mg
75870390|NCT02381470|Drug|Cefadroxil|Cefadroxil 1g
75870391|NCT02381470|Drug|Rifampicin|Rifampicin 10mg/kg
75870392|NCT02381158|Drug|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
75870393|NCT04241536|Procedure|Blood draw and urine collection|Patients will collect blood and urine for metabolome analysis
75413861|NCT04507815|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
75413862|NCT04501120|Drug|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
75413863|NCT04501120|Drug|Reduced-dose HHT|1mg IV QD on Days 1-14 (28-day cycle).
75413864|NCT04501120|Drug|standard-dose HHT|2mg/m^2 IV QD on Days 1-7 (28-day cycle).
75870394|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
75870395|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
75870396|NCT02385838|Behavioral|5-CNL|The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
75870397|NCT02385838|Behavioral|MTL|The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
75870398|NCT02385838|Behavioral|GDA|The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
75870399|NCT02385838|Behavioral|Tick|The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
75870400|NCT02381080|Drug|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
75870401|NCT02381080|Drug|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
75870402|NCT02381080|Drug|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
75870403|NCT04724824|Device|Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis that will be activated by the brain-computer interface based on hand movement intention.
75870404|NCT04724824|Device|Sham Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis which activation will be independent of the output of the brain-computer interface based on hand movement intention.
75870405|NCT02385760|Drug|CTX-4430|
75870406|NCT02385760|Drug|Placebo|
75870407|NCT04694248|Drug|Rivaroxaban|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
75870408|NCT04694248|Drug|Aspirin|For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
75870409|NCT02376478|Drug|TNF-alpha inhibitors|therapy for at least 6 months
75870410|NCT02376478|Drug|Alternative/no medication|therapy for at least 6 months or no therapy
75870411|NCT02376478|Other|Alternative/no medication|phototherapy for at least 6 months
75394096|NCT04401228|Other|predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?|"patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact < one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded"
76035611|NCT00651391|Drug|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
76035612|NCT00651391|Drug|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
76035613|NCT00651391|Drug|Placebo|oral placebo once daily in the evening for 12 weeks
76035614|NCT05067751|Device|hearing aid with directionality|Hearing directionality allows users the ability to focus on voices and other signals of interest, reducing background noises that are unimportant.
76035615|NCT04823351|Behavioral|Surgical Mask|The randomized wards will be wearing either FFP2 masks or surgical masks for 8 weeks. Then a cross-over will occur for another 8 weeks.
76035616|NCT04434859|Other|No intervention|No intervention
75394097|NCT02336958|Drug|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
75394098|NCT02336958|Drug|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
75708258|NCT05096767|Other|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed
75708259|NCT05091957|Other|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
75708260|NCT05091957|Other|Usual Care|Participants in both groups will receive a written summary of available resources
75708261|NCT05083754|Drug|Retifanlimab|Anti-PD-1 Therapy
76035617|NCT04823117|Other|music therapy|music includes nature sounds recommended by the Turkish Psychological Association
76035618|NCT00650689|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
76035619|NCT00650689|Drug|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
75708262|NCT05083754|Drug|Temozolomide|Anti-PD-1 Therapy
75708263|NCT05083754|Radiation|Radiation Therapy|Standard of Care
76035620|NCT05067517|Drug|Nintedanib|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
75708264|NCT05075759|Behavioral|Behavioral Intervention|Receive personalized clinician-led self-management telehealth sessions
76035621|NCT05067517|Drug|Placebo|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
76035622|NCT05067361|Procedure|Aerobic Exercise|Jogging was performed for 20 minutes. Jogging was performed by experimental group for 3 weeks and 4 sessions per week.
76035623|NCT05067361|Procedure|Ball Exercises|Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
76035624|NCT03100669|Procedure|Pectus surgery|Patients undergoing surgical repair of pectus excavatum or carinatum
76035625|NCT03100513|Drug|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
76035626|NCT03100513|Drug|Polyethylene Glycol|PEG as single dose of (3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
75394099|NCT02336958|Drug|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
75394100|NCT02336958|Drug|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
75394101|NCT03409926|Dietary Supplement|Acacia Gum|dietary supplement will be added to the participant's usual diet
75394102|NCT04760886|Other|Type of hospital (rural DGH vs Urban MTC)|In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.
76035627|NCT05059561|Radiation|X-ray radiograghy|Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
76035628|NCT02530905|Drug|SRP-4045|SRP-4045 solution for IV infusion.
75708265|NCT05075759|Behavioral|Behavioral Intervention|Receive personalized goal setting for daily steps and activity and dietary goals
76035629|NCT02530905|Drug|Placebo|SRP-4045 placebo-matching solution for IV infusion.
76035630|NCT00552097|Drug|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
75394103|NCT03085602|Behavioral|Cognitive behavioral therapy|Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
75708266|NCT05075759|Behavioral|Behavioral Intervention|Remote sessions with a health coach
76035631|NCT00552097|Drug|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
76035632|NCT05067049|Device|Connected application arm|"patients have to respond different questionnaires about their quality of life on the mobile app.~And follow-up visits with the physicians as usual"
76035633|NCT05067049|Device|Unconnected arm|Follow-up visits with the pysicians as usual
75394104|NCT03085602|Behavioral|Health education|Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
75413865|NCT04501120|Drug|Azacitidine|75 mg/m^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
75545564|NCT00417768|Drug|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
76035634|NCT00396175|Drug|MK0906, finasteride / Duration of Treatment : 48 Weeks|
76035635|NCT00396175|Drug|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
76035636|NCT02530671|Device|Toothbrushing with manual toothbrush|
76035637|NCT02530671|Device|Toothbrushing with power toothbrush|
76035638|NCT02603393|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
76035639|NCT02603393|Drug|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
76035640|NCT02603393|Drug|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
75413866|NCT04501120|Drug|APG-2575|APG-2575 orally once daily for 14 days, every 28 days as a cycle.
75413867|NCT04477317|Drug|4% Articaine Hydrochloride with 1:100,000 Adrenaline|new Egyptian articane anesthetic solution.
75545565|NCT00417768|Other|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
75545566|NCT00292383|Procedure|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
75708267|NCT05075759|Other|Survey Administration|Ancillary studies
75870412|NCT02376478|Drug|Purine/folic acid analogues|therapy for at least 6 months
75870413|NCT02385448|Drug|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
75870414|NCT02385448|Drug|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
76035641|NCT04832945|Drug|Ivermectin 6 Mg Oral Tablet|Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
76035642|NCT02642653|Drug|Lovastatin|Once per day dosing
76035643|NCT02642653|Other|Placebo|Once per day dosing
75394105|NCT04401306|Other|Home-based self-regulated simulation training (SRST)|Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
75394106|NCT04401306|Other|Centralized instructor-regulated simulation training (IRST)|Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
75394107|NCT03356496|Device|AirLife 4000 cc incentive spirometry device|Incentive spirometry device provides improved lung expansion and respiratory muscle strength
75394108|NCT03085446|Behavioral|PDM nutritional intervention|personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
75394109|NCT03085446|Behavioral|General information on nutrition and health|General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
75413868|NCT04477317|Drug|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin|Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.
76035644|NCT01659567|Drug|Pegylated Interferon Alfa-2a|Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
75870415|NCT02376634|Behavioral|Hypnosis|Patients will be taught self-hypnosis.
75870416|NCT02376400|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29 or 57.
75870417|NCT02376400|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29 or 57.
75545567|NCT00258635|Biological|RagweedMATAMPL|
75394110|NCT03085368|Drug|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
75394111|NCT03085290|Other|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
75394112|NCT03085290|Other|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
75394113|NCT05687760|Biological|bromelain|is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication
75545568|NCT00260234|Biological|Allogeneic Cultured Islet Cells (human); Encapsulated|
75545569|NCT00272571|Procedure|External counter pulsation therapy|
75708268|NCT05074849|Behavioral|A 90-minute self-care education + bi-weekly 30-minute one-on-one follow-up phone discussion|A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Follow-up Care: A biweekly 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, addressing feedback and questions regarding the intervention and prevention of foot-related complications).
75870418|NCT02376400|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
75545570|NCT00260273|Behavioral|Cognitive Behaviour Therapy|therapy
75870419|NCT03106012|Procedure|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
75545571|NCT00272610|Drug|0.4% Retinol Cream|
75545572|NCT00260312|Biological|Inactivated Polio Vaccine given at an accelerated schedule|
75545573|NCT00292422|Drug|BG9924|
75545574|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
75545575|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
75394114|NCT05687760|Drug|Calcium hydroxide|calcium hydroxide
75394115|NCT03409380|Dietary Supplement|Arginine Drink|10 g of arginine in a formulated drink
75545576|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
75545577|NCT00292500|Device|Automated distal anastomotic device|CABG
76035645|NCT01659567|Drug|Ribavirin|Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
76035646|NCT04832633|Diagnostic Test|Different contrast media injection methods|Different contrast media injection methods
75545578|NCT00272688|Drug|Levodopa (drug), intraduodenal administration|
75545579|NCT00260390|Drug|Testoviron|
75545580|NCT00292539|Device|Any pacemaker with right ventricular pacing option|
75545581|NCT00260468|Other|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
75545582|NCT00292578|Procedure|NAET Testing Modalities|
75545583|NCT00260546|Procedure|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
75545584|NCT00292656|Procedure|NAET|
75545585|NCT00260624|Drug|Escitalopram (Lexapro)|
75545586|NCT00292695|Other|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
75545587|NCT00260663|Procedure|Group hearing aid fittings|
75545588|NCT00260663|Procedure|Group hearing aid follow-up|
75545589|NCT00292734|Drug|Zolpidem|
75545590|NCT00260702|Drug|Omalizumab (Xolair)|
75545591|NCT00260741|Drug|Smoked Cannabis|
75708269|NCT05074238|Other|Zinc containing suncreen|"The study participant will be randomized via a randomization tool within the REDCap database as to which half of the wound (A or B) the patient will be asked to apply zinc containing sunscreen for the duration of the study."
76035647|NCT04835909|Behavioral|Modern board and card games group|Modern board and card games group
75394116|NCT03409380|Dietary Supplement|Plain Drink|formulated drink
75394117|NCT03085134|Other|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
75394118|NCT03085134|Other|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
76035648|NCT04835909|Behavioral|Paper and pencil tasks group|Paper and pencil tasks group
75394119|NCT03084978|Procedure|General Anesthesia|General anesthesia by standard endotracheal intubation.
75394120|NCT03084978|Procedure|Conscious Sedation|Conscious sedation
75394121|NCT03084744|Behavioral|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
75394122|NCT03084744|Behavioral|Active monitoring|Active tele-monitoring by clinical psychologists.
75394123|NCT03084588|Drug|methadone|Patients will be given methadone at induction of anesthesia
75394124|NCT03084588|Procedure|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
75394125|NCT03408366|Procedure|Laparotomy|Laparotomy via vertical midline incision and after the planned surgical procedure is complete.
75394126|NCT03408366|Other|ICG|ICG will be injected intravenously ICG is a fluorescent iodide dye.
75394127|NCT03408366|Other|Spectrum NIR imaging system|The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
75545592|NCT00260780|Behavioral|The MISTERS Intervention for Post Jail Release Men|
75394128|NCT03084276|Other|High-fat meal|High-fat meal
75394129|NCT03084276|Other|Low-fat meal|Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
75394130|NCT03084432|Diagnostic Test|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
75545593|NCT00260819|Drug|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
76035649|NCT05032729|Other|Trypophan, Theanine and 5'AMP|250 ml beverage consumed at 21:00 hours
75394131|NCT05345652|Procedure|deep anterior lamellar keratoplasty|DALK is a partial-thickness corneal transplant which involves only the donor stroma, leaving the recipient's own Descemet's membrane and endothelium
75394132|NCT05345574|Drug|dexmedetomidine infusion|dexmedetomidine as anaesthetic adjuvant
75394133|NCT05345574|Drug|remifentanil infusion|remifentanil as anaesthetic adjuvant
75394134|NCT03084198|Procedure|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
75394135|NCT03084198|Procedure|Standard care for ALF|A standard of care for subjects with acute liver failure.
75394136|NCT05598606|Drug|Denosumab Injection|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
75394137|NCT05598606|Drug|Zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
75394138|NCT03350880|Other|Flexibility training|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
75394139|NCT05597358|Radiation|High Intensity Laser Therapy (HILT)|Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
75394140|NCT05597358|Radiation|Sham High Intensity Laser Therapy|Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
75394141|NCT03084120|Other|Collection of bloods samples for the mother|-During pregnancy, childbirth and after delivery
75394142|NCT03084120|Other|Retrieval of umbilical cord blood.|-During childbirth
75394143|NCT03084120|Other|Retrieval of placenta.|-During childbirth
76035650|NCT05032729|Other|Placebo|250 ml beverage consumed at 21:00 hours, matched in appearance and taste to the active beverages
76035651|NCT04835753|Device|shock wave|true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)
76035652|NCT04835753|Other|traditional physical therapy program|lower limbs muscles stretch and strength in addition to balance and gait training
76035653|NCT05059171|Device|OneSahpe single file|The rotary motion of OneShape single file
76035654|NCT05059171|Device|WaveOne Gold single file|reciprocation motions of WaveOne Gold single file
76035655|NCT04822805|Drug|Anlotinib hydrochloride|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
76035656|NCT05059249|Procedure|Hot Pack|Superficial Heating
75394144|NCT03084120|Other|Collection of newborn's and mother's lock of hair.|-During childbirth
75708270|NCT05073692|Drug|SU|Exposure to the class of drugs known as Sulfonylureas (SU)
75708271|NCT05073692|Drug|DPP4|Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
75708272|NCT05073692|Drug|SGLT2i|Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
75394145|NCT03084120|Other|Dietetic Patient Outcomes Questionnaires for the mother.|-During pregnancy and after delivery
75394146|NCT03084120|Other|Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire).|-At 2 years of age
75394147|NCT03084042|Device|fMRI|
75394148|NCT04400916|Drug|Tranexamic acid|A single drop administered topically
75394149|NCT04400916|Other|Balanced Salt Solution|A single drop administered topically
75394150|NCT03406104|Genetic|GS010|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
75394151|NCT03406104|Other|Sham Intravitreal Injection|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
75413869|NCT04469959|Drug|L-Dopa|"Generic 25/100mg carbidopa/levodopa (Sinemet)tablets will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at150 mg /daily to maximum of 450 mg patch/daily three times a day for three weeks.~After one week of taper they will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days."
75545594|NCT00260819|Drug|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
76035657|NCT05059249|Procedure|Manual Traction|Manual Traction for 10 minutes
76035658|NCT05059249|Procedure|Mechanical Traction|Mechanical Traction for 10 minutes
76035659|NCT05059249|Procedure|Joint Mobilization|3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions
76035660|NCT05059249|Procedure|TENS|TENS for 10 minutes with hot pack
76035661|NCT04835285|Diagnostic Test|Npf.|3T MRI and 1,5 T MRI scanners. For myocardium, pancreas and pituitary gland iron overload
75394152|NCT04761042|Other|WAYA-Wilderness|"The wilderness intervention includes challenging tasks in order to help participants' overcome and master new physical and psychological challenges in an unknown environment, with the idea to support self-efficacy, self-esteem, and ability to recover from adversity. The program is designed to encourage participants to connect with nature as to experience gratitude for the richness of the natural world, a sense of calmness and trust upon spending time in nature, and to be more physically active in nature.~Elements previously described Participants will continue in a three-month program at home (on-line supported) after the initial 8-days in order to empower participants to incorporate elements of the onsite wilderness program into their daily life. An individualized a plan for activities will be developed together with the participant.~After three months, there will be a re-visit with follow up on outcome measures and reconnection."
76035662|NCT04095637|Device|Medial knee arthroplasty|Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
76035663|NCT04835207|Other|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured: 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"
75394153|NCT04761042|Other|WAYA-Holiday|"An attention control group (information in Detailed description)"
75545595|NCT00292773|Procedure|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
75545596|NCT00260858|Drug|Test Meal: Reference food (glucose or white bread)|
75545597|NCT00260858|Drug|Test Meal: Pirate's Booty|
75394154|NCT04400526|Behavioral|A video competition|Each Individual/group will be required to produce a maximum of 2-minute video on one of the following themes: (1) the hazardous effects of drug especially less psychotropic drugs such as Cannabis, (2) encouraging messages to drug abusers, and (3) existing anti-drug services.
75394155|NCT04400526|Behavioral|A training workshop|The workshop will last for 6 hours, and will be delivered by an experienced counsellor from C.H.O.I.C.E. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
75545598|NCT00260858|Drug|Test Meal: Ceaprove wafer|
75545599|NCT00260858|Drug|Test Meal: Stretch Island Strawberry Fruit Leather|
75545600|NCT00298311|Behavioral|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
75545601|NCT00292812|Drug|Nutritional supplementation (nucleotides)|
75545602|NCT00415571|Drug|Fispemifene (once daily for 8 weeks)|
75545603|NCT00298350|Drug|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
75708273|NCT05073692|Drug|GLP-1RA|Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
75708274|NCT05073692|Drug|SGLT2i or GLP-1RA|Exposure to either SGLT2i or GLP-1RA
76035664|NCT05058937|Diagnostic Test|Comprehensive genomic profiling|TSO500 (523 genes + MTB + MSI)
76035665|NCT04832555|Radiation|Non elective radiotherapy|Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.
76035666|NCT04832789|Device|Venovenous ECMO|Venovenous ECMO
76035667|NCT05066893|Other|telehealth visits|intensive visits with doctor
76035668|NCT04435093|Other|MFM-Play|Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
76035669|NCT03100435|Device|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
76035670|NCT03100435|Other|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
76035671|NCT03036995|Drug|Apremilast|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
75394156|NCT04400526|Behavioral|A mass promotional campaign|Children who complete the training workshop in phase 2 will be invited to join phase 3. They are encouraged to design their own promotional activities for community members in the targeted districts. The activities can be delivered by a group (a maximum of 5 ADAs per group) or by an individual. Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites. Likewise, if the ADAs encounter any drug abuser in their social circles, the ADAs will be asked to deliver a brief advice based on the AWARD model.
75708275|NCT05073692|Drug|Linagliptin (DPP4)|Exposure to agent Linagliptin (DPP4)
75708276|NCT05073692|Drug|Exenatide (GLP-1RA)|Exposure to agent Exenatide (GLP1-RA)
75708277|NCT05073692|Drug|Liraglutide (GLP-1RA)|Exposure to agent Liraglutide (GLP-1RA)
75394157|NCT05686746|Drug|Baricitinib 4 MG|4 mg oral daily
76035672|NCT03036995|Other|Placebo|Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
76035673|NCT03100279|Behavioral|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, & Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
75394158|NCT05686746|Drug|Baricitinib 2 MG|2 mg oral daily
75394159|NCT05686746|Drug|MMF|1000 mg oral daily
75394160|NCT03083574|Device|Photopheresis Theraflex ECP™|The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
75394161|NCT03832452|Drug|Lucerastat (Treatment A)|2000 and 4000 mg; hard capsules for oral administration
75394162|NCT03832452|Other|Placebo|hard capsules for oral administration
75394163|NCT03832452|Drug|Moxifloxacin|400 mg; film-coated tablets for oral administration
75394164|NCT03832452|Drug|Lucerastat (Treatment B)|1000 mg; hard capsules for oral administration
75394165|NCT03832452|Drug|Lucerastat (Treatment C)|4000 mg; hard capsules for oral administration
75394166|NCT03343860|Procedure|AT case 1.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
75394167|NCT03343860|Procedure|AT case 2.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
75413870|NCT04469959|Drug|Placebo|Step 1(3weeks) Carbidopa/levodopa-matched placebo tablet 3 times. Followed by 1 week of taper Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.
75413871|NCT04434196|Drug|CC-99282|CC-99282
75413872|NCT04434196|Drug|Obinutuzumab|Obinutuzumab
75708278|NCT05073692|Drug|Empagliflozin (SGLT2i)|Exposure to agent Empagliflozin (SGLT2i)
75708279|NCT05073692|Drug|Glimepiride (SU)|Exposure to agent Glimepiride (SU)
75708280|NCT05073692|Drug|Glipizide (SU)|Exposure to Glimepiride (SU)
75708281|NCT05073692|Drug|Glimepiride (SU) or Glipizide (SU)|Exposure to agent Glimepiride (SU) or Glipizide (SU)
75708282|NCT05073692|Drug|SU or DPP4 (excluding saxagliptin and alogliptin)|Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
75708283|NCT05073692|Drug|Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)|Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
75708284|NCT05071222|Genetic|ARTEGENE drug product|Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
75394168|NCT03343860|Procedure|AT case 1.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
75413873|NCT04426461|Behavioral|Behavioral Activation|Behavioral activation will be delivered as a 10-week, manualized, behavioral intervention focused on enhancing engagement in meaningful and reinforcing activities.
75708285|NCT05068271|Behavioral|Multi-Domain Exercise Program|The multi-domain exercise consisted of the main exercise (e.g., aerobic exercise, resistance exercise, flexibility training, and coordinative exercise), social interaction, and meditation. Participants are encouraged to engage in 150 min exercise per week consisting of one 90-min on-site session and multiple online sessions for 6 months.
75708286|NCT05068271|Behavioral|Control Group|"The usual physical activity group, as the control group, is informed to maintain their lifestyles. In addition, participants are invited to attend one 60-min online educational course per week. The logs of physical activity behavior will be obtained from the participants once per month during the intervention period."
75545604|NCT00298428|Procedure|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
75708287|NCT05067335|Drug|Romosozumab|Subjects will receive romosozumab in a specified sequence during the treatment Period.
75708288|NCT05067335|Drug|Placebo|Subjects will receive Placebo in a specified sequence during the treatment Period.
75708289|NCT05066789|Device|Type of stent|1:1 randomization to biodegradable polymer DES (Orsiro Mission) and polymer-free DCS (Biofreedom)
75708290|NCT05066789|Drug|Duration of DAPT|1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)
76035674|NCT03100279|Behavioral|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, & Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
75394169|NCT03343860|Procedure|AT case 1.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps"
75394170|NCT03343860|Procedure|AT case 1.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
75394171|NCT03343860|Procedure|AT case 2.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, ablation of the subsequent AT will be performed until sinus rhythm restoration. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
75545605|NCT02960451|Other|PRIME care|Specialist medication, cognitive behavior therapy, family-focused therapy
75545606|NCT02960451|Other|Usual care|Medication and psychotherapy as available form community providers
75545607|NCT00292890|Device|insulin needle|
75545608|NCT00292929|Drug|Intravenous artesunate|
75545609|NCT00298467|Drug|MDX-060|
75394172|NCT03343860|Procedure|AT case 2.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
75394173|NCT03343860|Procedure|AT case 2.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
75394174|NCT03343860|Procedure|SR Case 1|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
75545610|NCT00424853|Drug|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
75545611|NCT00424853|Drug|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
75545612|NCT00298506|Drug|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
75545613|NCT00292968|Behavioral|Computer based care|
75545614|NCT00292968|Behavioral|Telephone counseling|
75545615|NCT00292968|Behavioral|Group visits|
75545616|NCT00292968|Behavioral|Usual care|
75545617|NCT00424892|Drug|Desvenlafaxine Sustained Release|
75545618|NCT01331239|Drug|LCI699|Osilodrostat 1 mg and 5 mg capsules, was prepared by Novartis and supplied to the Investigator. The capsule formulation of osilodrostat was later changed to tablets and this change was implemented in the study with Protocol amendment 6. Osilodrostat was open labeled 1 mg, 5 mg, 10 mg and 20 mg tablets.
75545619|NCT00424931|Drug|JNJ-17216498|50mg one time
75394175|NCT03343860|Procedure|SR Case 2|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 10 consecutive AT)"
75394176|NCT03083496|Drug|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
75394177|NCT03083496|Drug|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
75394178|NCT03083418|Device|control group|No EDP treatment
75394179|NCT03083418|Device|EDP|Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
75394180|NCT05548920|Other|Ultrasound guided Superior Vena Cava Collapsibility Index|Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured
75394181|NCT05548920|Other|Inferior Vena Cava Collapsibility Index|Preoperative Inferior Vena Cava Collapsibility Index will be measured.
75394182|NCT03083340|Behavioral|Deprexis|Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
75394183|NCT05547984|Device|Dual Mobility Cup|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup
75394184|NCT05547984|Device|Standard Acetabular component|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
75708291|NCT05062226|Dietary Supplement|PKU/TYR GMP Protein Substitute|After a 1-day baseline period during which patients will consume their usual protein substitute, each patient will receive one the case study product for 4 weeks (28 days).
75708292|NCT05061706|Drug|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
75394185|NCT04279938|Drug|Tinostamustinein|Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles
75394186|NCT04279938|Drug|Pembrolizumab|Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)
75394187|NCT04279938|Drug|Rituximab|Rituximab 375 mg/m2 IV Q3W for 6 cycles
75394188|NCT03083262|Other|no intervention|None, there is no intervention
75394189|NCT05686434|Drug|Osimertinib|This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
75545620|NCT00424931|Drug|JNJ-17216498|10mg one time
75545621|NCT00424931|Drug|Modafinil|200 mg X 2
75545622|NCT00298545|Drug|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
75545623|NCT00298545|Drug|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
75545624|NCT01331161|Biological|ZOSTAVAX|shingles vaccine, one dose
75708293|NCT05061706|Drug|Placebo|Matching capsules administered orally, once daily.
75708294|NCT05060562|Other|COVID 19 positive|Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.
75708295|NCT05060562|Other|COVID 19 negative|Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.
76035675|NCT04835051|Behavioral|Breastfeeding promotion|The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child <6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
75394190|NCT03083106|Device|Elevoplasty|The Elevo™ Kit Snoring Intervention Device is designed to facilitate deployment of the Elevo™ suture implant into the submucosal tissue of the soft palate via a minimally invasive, outpatient procedure performed by an otolaryngologist in a medical office setting.
75394191|NCT03338244|Drug|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
75394192|NCT03338244|Drug|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
75394193|NCT03083028|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
75394194|NCT03083028|Procedure|Open reduction internal fixation of the ankl|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
75394195|NCT03082950|Diagnostic Test|polymerase chain reaction|PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
76035676|NCT04001101|Combination Product|RT and Anti-PD-1|limited metastatic site radiation
76035677|NCT04001101|Drug|Anti-PD-1|anti-PD-1 therapy alone
75394196|NCT03082794|Dietary Supplement|NCD|Negative Calorie Diet
75394197|NCT03082794|Dietary Supplement|LCD|Low Calorie Diet
75394198|NCT05685888|Other|Medication history|The study was retrospective and did not involve the application of interventions
75545625|NCT00424970|Drug|acetazolamide|
75545626|NCT00298584|Procedure|Percutaneous Suprapubic Aspiration|
75545627|NCT00298584|Procedure|Urethral Catheterization|
75545628|NCT01331005|Drug|nepafenac 0.1% drops|One drop three times per day for one year
75545629|NCT01331005|Other|Nepafenac Vehicle|Placebo
75545630|NCT00293046|Biological|ALK Grass tablet - use of compliance device|
75394199|NCT03400410|Behavioral|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
76035678|NCT04299893|Drug|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
75545631|NCT01330459|Drug|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
75708296|NCT05058664|Behavioral|A-F texting component|Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.
75394200|NCT04348188|Behavioral|Education program on healthy habits|6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
75545632|NCT01330459|Drug|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
75545633|NCT01330459|Drug|Ibuprofen|800 mg oral ibuprofen
75545634|NCT01330459|Drug|Lorazepam|2 mg oral lorazepam
75545635|NCT01330459|Drug|Lidocaine|20 ml 1% buffered lidocaine, injected
75545636|NCT00298623|Drug|XP13512 (GSK1838262)|
75545637|NCT00298623|Other|placebo|
75545638|NCT00293085|Drug|Docetaxel|
75545639|NCT00293085|Drug|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
75545640|NCT00261053|Drug|i.v. recombinant human C1 inhibitor|
75394201|NCT03082404|Other|Inspiratory muscle training|Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
75545641|NCT00298662|Drug|Interferon beta-1b and Tacrolimus|
75545642|NCT01330381|Drug|prucalopride|"prucalopride~subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~subjects with weight >50 kg: prucalopride 2 mg tablet once daily"
76035679|NCT04299893|Drug|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
75394202|NCT03334344|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
75394203|NCT04348344|Behavioral|pulmonary rehabilitation|"Patients receive health education of pulmonary rehabilitation, using the home-based rehabilitation exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training."
75545643|NCT01330381|Drug|Placebo|Matching oral solution or oral tablets given once daily
75545644|NCT01330381|Drug|PEG 4000|
75394204|NCT05505864|Behavioral|Health Action Process Approach (HAPA)|Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change
76035680|NCT04834895|Other|mhealth exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the M.ü Neck Exercises application according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
76035681|NCT04834895|Other|brochure exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
76035682|NCT05066425|Dietary Supplement|Soluble Corn Fiber|Participants will be asked to consume a packet of 22g Soluble Corn Fiber/day for 4 weeks
76035683|NCT05066425|Dietary Supplement|Maltodextrin|Participants will be asked to consume a packet of 22g Maltodextrin/day for 4 weeks
76035684|NCT04832243|Other|Survey questionnaire|Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
75394205|NCT03832218|Diagnostic Test|Psychiatric assessment|"Psychiatric assessment and neuropsychological tests~Test : Wechsler Intelligence Scale for Children (WISC-V)~Test :Behavior Rating Inventory of Executive Function (BRIEF) : BRIEF-Parents, BRIEF-Teacher~Global Assessment of Functioning Scale~Scale : Brief Psychiatric Rating Scale (BPRS)~Test : Children Depression Inventory (CDI)~Scale : Revised-Children's Manifest Anxiety Scale (R-CMAS)~Survey : Pediatric Quality of Life Inventory Version 4.0 (PedsQL™ 4.0)~Scale : Conners' scale (parents and teachers)"
75394206|NCT05454228|Behavioral|postoperative delirium|Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.
75545645|NCT00261092|Drug|Oxaliplatin|
75545646|NCT01330303|Drug|Reference formulation|SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
75545647|NCT01330303|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
75545648|NCT00293124|Drug|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
75545649|NCT01330108|Drug|ambrisentan|ambrisentan 2.5mg, 5mg, & 10mg. Daily dosage.
75545650|NCT00261131|Drug|Botulinum Toxin A|
75545651|NCT00298701|Biological|ALK Grass tablet|
75545652|NCT00261170|Drug|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
75545653|NCT00261170|Other|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
75545654|NCT00261209|Drug|Collagenase|Collagenase injection into adhesion restricting tendon gliding
75545655|NCT00261209|Drug|Collagenase injection|injection of collagenase into adhesion restricting tendon gliding
75394207|NCT03082092|Drug|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
75394208|NCT03082092|Drug|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
75394209|NCT04401852|Drug|MgSo4|a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.
75394210|NCT04401852|Drug|Isotonic saline|equal volume of isotonic 0.9% saline over 15-20 minutes
75394211|NCT04761510|Behavioral|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile-health adaptation of MBTR-R - a mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs. During participation in the Mindfulness-SOS for Refugees intervention program, participants will be encouraged to complete 2 sessions per week and practice each day for 4 weeks but can choose to extend this up to 8 weeks. Delivery of Mindfulness-SOS for Refugees entails administrative guidance as well as adherence-focused guidance.
75394212|NCT03081936|Dietary Supplement|Oral consumption of Nutricia Aptamil Stage 1 formula|Daily oral consumption of Nutricia Aptamil Stage 1 formula
75394213|NCT03081936|Dietary Supplement|Oral consumption of a2® Platinum Stage 1 formula|Daily oral consumption of a2® Platinum Stage 1 formula
75708297|NCT05058664|Behavioral|P-F texting component|Over the course of the 6 week intervention, parents will receive between 1-2 messages, depending on randomization (in addition to A-F component messages)
75708298|NCT05052580|Other|COVID-19 Testing|Participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known COVID-19 exposure on day 0. If the COVID-19 tests are negative, the participant will remain in the school environment. A positive COVID-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines.
76035685|NCT04831931|Other|Exercise Program Applied by Telerehabilitation|"Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups."
75545656|NCT04718298|Device|ProFlor laparoscopic technique|Inguinal hernia repair laparoscopic
75545657|NCT00261248|Biological|Immunization with inactivated bacteria|
75545658|NCT00261287|Drug|Ciclesonide|
75545659|NCT00261326|Drug|simvastatin|80 mg once daily
75545660|NCT00261326|Drug|placebo|calcium tablets once daily
75545661|NCT00293163|Device|Hylaform, Hylaform Plus (hylan B gel)|
76035686|NCT05066035|Drug|Neostigmine|"The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge."
75394214|NCT03081936|Dietary Supplement|Oral consumption of breast milk|Daily oral consumption of breast milk
75394215|NCT03318120|Behavioral|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
75394216|NCT03398538|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
75394217|NCT03398538|Other|Additional (outer) Dressing Application|Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
75545662|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
75545663|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
75545664|NCT00293280|Drug|lomustine|
75545665|NCT00261404|Drug|TNFerade™|
75545666|NCT00298779|Drug|omeprazole and bortezomib|
75545667|NCT00261482|Drug|norelgestromin + ethinyl estradiol|
75545668|NCT00261521|Drug|epoetin alfa|
75545669|NCT00298857|Drug|Valproic acid|
75545670|NCT00261560|Drug|acetaminophen|
75545671|NCT00261599|Drug|AQUAVAN® (fospropofol disodium) Injection|
75545672|NCT00261599|Drug|Midazolam HCI|
75545673|NCT00293319|Biological|filgrastim|
75545674|NCT00293319|Radiation|iobenguane I 131|
75545675|NCT00293358|Drug|carboplatin|
75545676|NCT00293358|Drug|cisplatin|
75394218|NCT03398538|Other|Mirragen Wound Matrix Dressing|Application of Mirragen to wound site along with standard of care treatment
75394219|NCT03398538|Other|Fibracol Wound Dressing|Application of Fibracol Alginate along with standard of care treatment
75394220|NCT03081780|Biological|FATE-NK100|"Preparative regimen:~Fludarabine 25 mg/m2 x 5 days start Day -6~Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
75394221|NCT04278612|Other|Quality improvement intervention to strengthen health service provision|Quality improvement intervention comprising of regular improvement meetings based at clinics.
75394222|NCT05430282|Other|Only vestibular rehabilitation|Vestibular adaptation exercises, static and dynamic balance exercises, proprioceptive and conditioning exercises.
75394223|NCT05430282|Other|Cervical exercises in addition to vestibular rehabilitation|Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
75394224|NCT03082482|Behavioral|Self-help materials|Self-help smoking cessation materials
75545677|NCT00293358|Drug|etoposide phosphate|
75708299|NCT05049525|Drug|Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.|Itraconazole capsules of 100 mg, antifungal agent. Terbinafine tablets 250 mg (as terbinafine hydrochloride), antifungal agent.
76035687|NCT05066035|Drug|Sugammadex|The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to >0.9 in the recovery room before discharge to the ward.
76035688|NCT04428593|Drug|Treamid 5 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
76035689|NCT04428593|Drug|Treamid 15 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
75394225|NCT03082482|Drug|nicotine patch|Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke <10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
75394226|NCT03082482|Behavioral|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
75394227|NCT03082482|Other|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
75394228|NCT03082170|Device|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
75394229|NCT03082170|Diagnostic Test|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
75394230|NCT03082170|Behavioral|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
75394231|NCT05096598|Drug|ZP8396|Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
75394232|NCT05096598|Drug|Placebo (ZP8396)|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
75545678|NCT00293358|Drug|ifosfamide|
75545679|NCT00293358|Procedure|adjuvant therapy|
75545680|NCT00293358|Procedure|conventional surgery|
75545681|NCT00293358|Procedure|neoadjuvant therapy|
75545682|NCT00293358|Radiation|radiation therapy|
75394233|NCT03308916|Diagnostic Test|transient elastography|Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
75394234|NCT03308916|Diagnostic Test|Enhanced liver fibrosis test|Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
76035690|NCT04428593|Drug|Treamid 50 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
76035691|NCT04428593|Drug|Placebo|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
76035692|NCT03852667|Behavioral|Pain Neuroscience Education|The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
76035693|NCT03852667|Other|Exercise therapy|The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
76035694|NCT03753373|Other|Acupuncture|Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
76035695|NCT03753373|Other|Home Exercise Program|Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
76035696|NCT04831853|Other|nasopharyngeal swabbing procedure (self swabbing first)|Patient realises the nasal swabbing himself first, then undergoes conventionnal swabbing
75545683|NCT00261677|Drug|epoetin alfa|
76035697|NCT04831853|Other|nasopharyngeal swabbing procedure (conventionnal swabbing first)|patient undergoes conventionnal swabbing first then realises the nasal swabbing himself
76035698|NCT05058625|Device|Dry Needling plus normal volleyball training|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
76035699|NCT05058625|Other|Control Group|Normal volleyball training
75394235|NCT03308916|Diagnostic Test|Indirect serum markers of liver fibrosis|Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
75545684|NCT00298935|Procedure|Osteopathic manipulative treatment (OMT)|
75545685|NCT00298974|Drug|hydrocodone / acetaminophen extended release|2 tablets twice daily
75545686|NCT00298974|Drug|Placebo|2 tablets twice daily
76035700|NCT04831463|Behavioral|Increasising Health Awareness Program for Immigrant Men|The IHAPIM program is a health promotion intervention. The aim of intervention improve health perception and responsibilitiy
76035701|NCT03099811|Behavioral|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
75394236|NCT03308916|Diagnostic Test|Direct serum markers of liver fibrosis|Serum markers that reflect liver extracellular matrix turnover and -accumulation
75394237|NCT03308916|Diagnostic Test|LiverTRAIL|Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
75394238|NCT03308916|Diagnostic Test|Cytokeratin 18|Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
76035702|NCT03099811|Behavioral|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
76035703|NCT03722095|Device|active tDCS|A current of 2 milliampère (mA) through electrodes of 5x5cm.
76035704|NCT03722095|Device|sham tDCS|Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
76035705|NCT03722095|Device|iTBS|54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
75394239|NCT03308916|Diagnostic Test|Omics markers|Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
75394240|NCT03081702|Drug|Hydroxychloroquine|Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
75394241|NCT03081702|Drug|Itraconazole|Itraconazole is approved and used for the treatment of certain systemic fungal infections.
75394242|NCT05345964|Drug|GST-HG151|Subjects will take GST-HG151 orally(once daily) on Day 1
75394243|NCT05345964|Drug|Placebo|Subjects will take Placebo orally(once daily) on Day 1
75545687|NCT00261794|Behavioral|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
76035706|NCT04822415|Drug|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
76035707|NCT04822415|Drug|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
75394244|NCT05345964|Drug|GST-HG151|Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
75394245|NCT05345964|Drug|Placebo|Subjects will take Placebo orally (once daily) from day 1 to day 7
75394246|NCT05345964|Drug|GST-HG151|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
75394247|NCT05345964|Drug|GST-HG151|Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
75545688|NCT00261794|Behavioral|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
75545689|NCT00293436|Drug|celecoxib|
75545690|NCT00293436|Drug|erlotinib hydrochloride|
75545691|NCT00293436|Procedure|adjuvant therapy|
75545692|NCT00261872|Drug|Methylphenidate|
75708300|NCT05049525|Drug|Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.|Matching placebo of itraconazole capsules of 100 mg, antifungal agent. Matching placebo of terbinafine tablets 250 mg, antifungal agent.
75394248|NCT04399824|Radiation|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
75394249|NCT04399824|Other|Quality-of-Life Assessment|Ancillary studies
75394250|NCT04399824|Other|Questionnaire Administration|Ancillary studies
75545693|NCT00293475|Drug|Carboplatin|Given IA
75545694|NCT00293475|Drug|Mannitol|Given IA
75545695|NCT00293475|Drug|Methotrexate|Given IA
75545696|NCT00293475|Other|Quality-of-Life Assessment|Ancillary studies
75545697|NCT00293475|Biological|Rituximab|Given IV
75545698|NCT00293475|Drug|Sodium Thiosulfate|Given IV
75708301|NCT05046418|Other|Hypoallergenic formula containing synbiotics|An extensively hydrolysed formula containing synbiotics or an amino acid formula containing synbiotics.
75545699|NCT00261911|Drug|sibutramine|
75545700|NCT00299013|Drug|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
75545701|NCT00299013|Drug|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
75545702|NCT00293514|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|
75545703|NCT00299052|Device|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
75545704|NCT00299052|Biological|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
75545705|NCT00293553|Procedure|Electronic Barostat|
75545706|NCT00299091|Drug|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
75545707|NCT00299169|Behavioral|N of 1 Trials|N of 1 Trials of statin therapy
75545708|NCT00299208|Drug|Artesunate|
75545709|NCT00299208|Drug|Azithromycin|
75545710|NCT00299208|Drug|Quinine|
75545711|NCT00262145|Drug|tea extracts|
75545712|NCT00418119|Drug|erythropoietin|
75545713|NCT00293592|Drug|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
75545714|NCT00293631|Drug|Lornoxicam 8 mg|
75545715|NCT00293631|Drug|Lornoxicam 16 mg|
75545716|NCT00293631|Drug|Ketorolac 30 mg|
75545717|NCT00293631|Drug|Placebo|
75545718|NCT00262184|Drug|Soy Isoflavone|
75545719|NCT00262262|Drug|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
75394251|NCT04399824|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75394252|NCT04279782|Other|Comprehensive treatment|Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.
75545720|NCT00418158|Behavioral|use of Airlife (therapy)|
75708302|NCT05046314|Biological|TK216+Vincristin|TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m^2 and 1.5mg/m^2 from the second cycle，every 28 days is a study cycle.
75870420|NCT03106012|Procedure|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
75870421|NCT02385370|Drug|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
75394253|NCT05397210|Device|Infinity-Lock Button System|Infinity-Lock Button System
75708303|NCT05043337|Behavioral|Maternal voice|"The recordings were made in a quiet and separate consultation room. For infants in the maternal voice group, mothers were recorded what they wanted to say to their baby and read an independently published children's book, Xiao Qi's yellow persimmon which describes how mothers with premature babies care for their infants. After reviewing the quality of the recordings, the maternal voice recordings were edited for 13 minutes using a sound organizer. Respiration, heart rate, oxygen saturation, and Neonatal Infant Pain Scale (NIPS) were measured and recorded 3 minutes before, during, 1 minute, 3 minutes, and 10 minutes after the puncture."
75708304|NCT05043337|Behavioral|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.
75708305|NCT05043337|Behavioral|Maternal voice combined with lullaby|"The recordings were made in a quiet and separate consultation room. For infants in the  Maternal voice combined with lullaby group,  mothers were recorded what they wanted to say to their baby and read an independently published children's book-Xiao Qi's yellow persimmon , and giving mother listening to the Brahms Lullaby at the same time, the maternal voice recordings were edited for 13 minutes using a sound organizer. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture."
76035708|NCT03661333|Behavioral|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
76035709|NCT05065177|Biological|Investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
76035710|NCT05065177|Biological|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
75708306|NCT05042895|Procedure|Group A|"Office diagnostic hysteroscopy for assessment of the following:~cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone [FSH], LH, thyroid-stimulating hormone [TSH], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
75870422|NCT02385370|Drug|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
75870423|NCT02385058|Drug|Mebendazole|Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
75870424|NCT02385058|Drug|Quinfamide|Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
75870425|NCT02385058|Drug|Placebo|Placebo tablet orally once starting on Day 21.
75870426|NCT02376088|Drug|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
75394254|NCT05393076|Drug|Linerixibat|Linerixibat dose and administration as per study intervention.
75394255|NCT05385510|Biological|R21/Matrix-M™|Adjuvanted malaria vaccine
75394256|NCT05381220|Other|early mobilization|Received early activities provided by the Institute 24 hours after stroke
75545721|NCT00262340|Other|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
75708307|NCT05042895|Procedure|Group B|"Office diagnostic hysteroscopy for assessment of the following:~cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone [FSH], LH, thyroid-stimulating hormone [TSH], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
75394257|NCT05378958|Other|Individual interview|"Individual semi-directed explication interview with phenomenological questioning centered on lived experience.~The individual interview aims to collect data by questioning the participants using interview communication techniques, essentially on the reformulation technique. The interview is structured using an interview guide containing the list of open questions with prompts to be answered during the discussion."
75394258|NCT04347876|Diagnostic Test|Tuberculin test|Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
75394259|NCT05059704|Other|Circuit Class Training|Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
75394260|NCT05059704|Other|Individual Task specific training|Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
75394261|NCT05006352|Drug|DNL343|Oral repeating dose
75394262|NCT05006352|Drug|Placebo|Oral repeating dose
75394263|NCT05418192|Other|Enriched Environment|Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.
75394264|NCT05418192|Other|Traditional Physcial Therapy|Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
75394265|NCT04399434|Other|test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity|test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
75394266|NCT04760574|Diagnostic Test|Testosterone|Serum total testosterone and free testosterone level
75394267|NCT03237390|Drug|Gemcitabine Hydrochloride|Given IV
75394268|NCT03237390|Other|Laboratory Biomarker Analysis|Correlative studies
75394269|NCT03237390|Other|Pharmacological Study|Correlative studies
75394270|NCT03237390|Drug|Ribociclib|Given PO
75394271|NCT05328804|Drug|rhTPO|subcutaneous injection
75394272|NCT05328804|Drug|Herombopag|Orally by mouth
75394273|NCT05348850|Device|Tensiomayography (TMG)|Quadriceps muscle contractile properties will be assessed using tensiomayography
75394274|NCT05340348|Other|Blood samples (36 mL) + fecal samples + hair sample|Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
75394275|NCT03293238|Procedure|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
75394276|NCT03293238|Procedure|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
75394277|NCT03293238|Procedure|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
75545722|NCT00293670|Drug|Goserelin (Zoladex)|
75545723|NCT00262379|Drug|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
75870427|NCT03310021|Biological|Andexanet alfa|fXa inhibitor antidote
75394278|NCT03293238|Procedure|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
75394279|NCT03292068|Combination Product|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
75545724|NCT00299247|Drug|sulfadoxine/pyrimethamine|
75394280|NCT03292068|Dietary Supplement|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
75394281|NCT03292068|Other|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
75394282|NCT04400136|Drug|Lansoprazole oral tablets 30 mg|Post operative prescription
75394283|NCT04941066|Behavioral|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the rumination-related brain functional connectivity.
75394284|NCT04941066|Behavioral|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
75394285|NCT04938336|Behavioral|Delphi Procedure and interviews|Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers
75394286|NCT04932252|Drug|A4368 or placebo tablet|orally administered
75394287|NCT04278300|Biological|blood sampling|dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
75394288|NCT04278300|Biological|faecal sampling (optional)|analysis of the microbiota by DNA sequencing
75394289|NCT02984436|Procedure|Blood Sample|Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
75394290|NCT02984436|Behavioral|HEART Score|The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0-10.
75394291|NCT05266014|Drug|tinlarebant|"Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months."
75394292|NCT03693144|Other|Full LIITA3H App|This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
75394293|NCT03693144|Other|Partial LIITA3H App|This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
75394294|NCT03693144|Other|LIITA3H Location only|This is a version of the LIITA3H mobile app that will only track participants' location.
75394295|NCT04902768|Other|This is an observational study, there is no intervention|This is an observational study, there is no intervention. Hence, this is not applicable.
75394296|NCT02984670|Behavioral|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
75394297|NCT02984670|Behavioral|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
75394298|NCT02984670|Behavioral|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
75394299|NCT04592406|Other|CVP screening|An appropriate dual screening process including both renal and cardiac parameters to minimize the risks of post-contrast renal adverse outcomes and of prophylactic hydration in eGFR<30mL/min/1.73m2 patients.
75870428|NCT03310021|Drug|Apixaban|factor Xa inhibitor
75870429|NCT03310021|Drug|Rivaroxaban|factor Xa inhibitor
75870430|NCT03310021|Drug|Edoxaban|factor Xa inhibitor
75870431|NCT03310021|Drug|Placebo|Placebo
75394300|NCT02984592|Behavioral|physical exercise|regular exercise programs in the previous 6 months.
75870432|NCT04630717|Other|Medical hypnosis session|"the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient"
75870433|NCT04630717|Other|control groupe|the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
75394301|NCT04746144|Procedure|Total knee arthroplasty|
75870434|NCT03333109|Biological|Erenumab|70 mg/mL pre-filled syringe administered subcutaneously
75870435|NCT03333109|Other|Placebo|Matching placebo in pre-filled syringe administered subcutaneously
75394302|NCT04857840|Drug|Firibastat (QGC001) Period 1|1000 mg (2 x 500 mg) tablets QD per Os
75394303|NCT04582968|Other|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Drug combined with radiation
75394304|NCT04563468|Procedure|Strength inspiratory muscle training|Two training sessions per day consisting of 30 breaths (against external load of ~50% Pi,max; 4-5 minutes per session), 7 days/week (once/month supervised at the research center), for 6 months will be performed using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) according to an established method. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain external load at ~50% of Pi,max values. Ratings of perceived inspiratory effort on a modified Borg scale (4-5 out of 10) will also be used to support decisions on increasing training load.
75870436|NCT02940223|Drug|Ethyl Icosapentate|Given by mouth 2 gm orally daily plus physical activity
75394305|NCT04563468|Procedure|Endurance inspiratory muscle training|Two daily sessions of 30 breaths using TFRL device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) and will train at an inspiratory load of no more than 10% of their initial Pi,max. This training load will not be changed during the entire study period. Participants in the control group will be offered the active treatment upon completion of the study.
75394306|NCT03261570|Drug|Pyridostigmine|60mg by mouth
75394307|NCT03261570|Drug|Digoxin|0.5 (500mcg) by mouth
75394308|NCT03261570|Drug|Placebo|Lactulose 50mg by mouth
75394309|NCT05296902|Device|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
75394310|NCT05292612|Behavioral|iCBT(C&W) for SAD|iCBT(C&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.
76035711|NCT04821947|Other|Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine|"for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine"
75394311|NCT03227562|Drug|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
75394312|NCT04277364|Dietary Supplement|phosphatidic acid supplementation|The total daily doses will be distributed in 3 individual doses: in the group that will ingest 750mg per day, the individual doses will be 250mg, while in the group that will ingest 375mg per day, the individual doses will be 125mg. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
75394313|NCT04277364|Other|Placebo (corn starch supplementation)|Three individual doses of corn starch will be consumed per day. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
75394314|NCT04277364|Other|Strength training|All participants will be submitted to a 8-week strength training program, with 3 training sessions per week, totaling 24 training sessions.
75394315|NCT05277168|Drug|SHR-A1904|Single Arm ：It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors
76035712|NCT03037073|Drug|Duloxetine|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
75708308|NCT05038527|Device|ABM/P-15 bone graft|RCT (single blinded) where the patients will be randomized into two groups. One group receiving the standard bone graft which is a mix of locally autologous harvested bone and a morselized femoral head (allogenic) and the other group will receive bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15).
75394316|NCT05276778|Diagnostic Test|Diabetic Retinopathy Screening|Screenings are performed in the diabetes consultation in general practice
75394317|NCT04557228|Dietary Supplement|Placebo|4 weeks of placebo supplements
75394318|NCT04557228|Dietary Supplement|Phosphatidylserine|4 weeks of 900mg phosphatidylserine supplements
75394319|NCT04278378|Dietary Supplement|Riboflavin|1.6 mg riboflavin / day for 24 weeks
75394320|NCT04278378|Dietary Supplement|Folic acid|0.4 mg folic acid / day for 24 weeks
75545725|NCT00262418|Drug|Administration of ivermectin or permethrin|
75708309|NCT05030441|Drug|Ivosidenib|. Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
75708310|NCT05028725|Device|EsophaCap Sponge|Non-invasive strategy to sample esophageal tissue
75708311|NCT05028725|Procedure|Chromoendoscopy|Lugol's iodine chromoendoscopy is a technique that is used to identify mucosal abnormalities of the esophagus
75394321|NCT04278378|Dietary Supplement|Placebo|
75708312|NCT05028725|Device|EsoCAN assay|Biomarker Test
75394322|NCT04399512|Procedure|Nonsurgical root canal treatment|Nonsurgical root canal treatment will be given
76035713|NCT03037073|Drug|Placebo oral capsule|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
76035714|NCT03099421|Procedure|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
75708313|NCT05026749|Drug|AZM Group|AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
75394323|NCT04399278|Diagnostic Test|Diagnostic Test: end-expiratory occlusion (EEO) test|"A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~T0: baseline.~T1: At the end of the first EEO (15 sec or 30 sec)~T2: 1 minute after completion of the first EEO. Return to baseline.~T3: At the end of the second EEO (15 sec or 30 sec)~T4: 1 minute after completion of the second EEO. Return to baseline.~T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.)."
75394324|NCT04797468|Drug|HLX23|administered IV.
75394325|NCT04785924|Drug|Imipenem+Relebactam|Antibiotic treatment for KPC producing CRE-containing gram-negative infections
75394326|NCT04765176|Device|Endovascular Repair|Endovascular repair of the infrarenal aorta using a AAA stent graft.
76035715|NCT04834739|Other|6 minute walk test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. 30 m long corridor is used for this test .
75394327|NCT04514562|Device|NeVa Stent Retrievers|mechanical neurothrombectomy
75394328|NCT04509180|Procedure|Catheter ablation|Endovascular approach
75708314|NCT05026749|Other|Control Group|Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
75394329|NCT04509180|Procedure|Convergent procedure|Surgical and endovascular approach
75394330|NCT04509024|Behavioral|Incidental training|Nonspeech perceptual building block categories are established, which may be used to scaffold language learning.
75394331|NCT04509024|Behavioral|Explicit training|Traditional explicit language training, which involves establishing sound to meaning.
75394332|NCT04348110|Dietary Supplement|Placebo tablets|consume 2 tablets per day for 8 weeks
75394333|NCT04348110|Dietary Supplement|Blueberry Chewable Tablets|consume 2 tablets per day for 8 weeks
75708315|NCT05021185|Other|Interactive Mobile Doctor (iMD)|Video educational tool
75708316|NCT05009992|Drug|ONC201|Given orally (PO)
75708317|NCT05009992|Radiation|Radiation Therapy|Undergo radiation therapy
75708318|NCT05009992|Drug|Paxalisib|Given PO
75708319|NCT05002374|Other|Vestibular rehabilitation with optokinetic stimulation|Vestibular rehabilitation incorporated with optokinetic stimulation in virtual reality environment for five consecutive days
75708320|NCT05002374|Other|Vestibular rehabilitation|Customized vestibular rehabilitation for five consecutive days
75870437|NCT02940223|Behavioral|Exercise Intervention|Complete resistance exercises and undergo walking program
75394334|NCT04506294|Behavioral|eScreen system|The eScreen system is composed of a child screening component and a parent information component. The child screening component is delivered via a game-like interface and includes assessment of current pain, PTSS, and functional recovery. Children are asked to play the game at least 3x/week. The parent information component consists of text / email messages sent to parents at least weekly that summarize child ratings and include a link to an online dashboard with additional personalized information for parents.
75394335|NCT05251818|Other|acupressure|A suitable environment will be prepared for postpartum women where privacy can be protected. Application points will be determined by choosing the most comfortable position of the mother. LI4 and TH were selected as the most preferred points among the points reported to be effective on intestinal functions by scanning the literature on the determined points. Acupressure will be applied to the LI4 and TH6 points for a total of 12 minutes in the first hour after the surgery. Light pressure will be applied with the thumb of the practitioner's hand. After applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is done without interruption
75394336|NCT05251818|Other|Control|No application will be made to puerperant women in this group. Only hourly follow-up will be done until the first bowel sound is heard. In addition, defecation and gas extraction will be questioned every 12 hours.
75394337|NCT04398810|Procedure|robotic single port cholecystectomy|"Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~Residual gas aspiration~Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~Warming of the washing solution in the abdominal cavity"
75394338|NCT02084628|Drug|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
75394339|NCT04760418|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)|A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use
76035716|NCT04834739|Other|1 minute Sit to Stand Test|The 1-minute STS test is performed with a chair of standard height of 46 cm without arm rests. The patient should be ensured to be seated upright on the chair positioned against a wall. The patient sat with the knees and hips flexed to 90°, feet placed flat on the floor hip-width apart, and the hands placed on the hips.The number of repetitions is measured.
76035717|NCT04834739|Other|Fatigue Severity Scale|The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders
75394340|NCT04277520|Procedure|Root canal therapy|Different types of instrumentation motions during root canal therapy
75708321|NCT05001555|Drug|Dexketoprofen/Vitamin B|1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
75708322|NCT05001555|Drug|Dexketoprofen|1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
76035718|NCT04834739|Other|Medical Research Council (MRC) dyspnea scale|"The MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness: grade 1, I only get breathless with strenuous exercise; grade 2, I get short of breath when hurrying on the level or up a slight hill; grade 3, I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level; grade 4, I stop for breath after walking 100 yards or after a few minutes on the level; grade 5,  I am too breathless to leave the house."
75394341|NCT04399902|Device|Thermal Blanket|Ready-Heat 6-Panel Blanket (Military style, manufactured by Techtrade LLC). The 6-panel military-style blanket (86cm x 152 cm, 1.13kg) warms to 40˚C in approximately 15-20 minutes and maintains this temperature for 10 hours.
75394342|NCT04277754|Other|Observational|To Observe and describe motor and visual development
75394343|NCT04451772|Drug|Elsubrutinib|Oral; Capsule
75394344|NCT04451772|Drug|Placebo for Elsubrutinib|Oral; Capsule
75394345|NCT04451772|Drug|Upadacitinib|Oral; Tablet
75708323|NCT04999345|Other|Rehabilitation|Progressive resistance exercise and graded aerobic exercise will be provided for those in the experimental group.
75708324|NCT04999345|Other|Health education|Health education and gross joint range of motion exercise for bilateral upper and lower extremities will be provided for those in the control group.
75708325|NCT04995172|Procedure|Computed Tomography|Undergo mobile CT-assisted bronchoscopy
75708326|NCT04995172|Other|Electronic Health Record Review|Patients' medical records are reviewed
75708327|NCT04995172|Procedure|Endobronchial Ultrasound Bronchoscopy|Undergo radial probe EBUS
75870438|NCT02940223|Behavioral|Exercise Intervention|Meet with exercise specialist and complete stretching exercises
76035719|NCT04834739|Other|SF-12|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
76035720|NCT04834739|Other|Beck Depression Inventory|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
75545726|NCT00299286|Drug|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
76035721|NCT04834739|Other|Beck Anxiety Inventory|Beck Anxiety Scale is a 21-item, internationally valid, self-report rating inventory that measures the anxiety level.
76035722|NCT04834739|Other|5 times sit to stand test|The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back (43-45 cm, 17-18 inches high). Then the instruction is given by asking the test taker to sit on the chair by resting their back. Also, the test taker is instructed to fold their arms across their chest. Then the test taker should be instructed to do sit-to-stand five times, as quickly as possible, at the count of go and without their back or leg resting on the chair between the interval of repetition.
76035723|NCT04834739|Other|6 point Likert Scale|"Job performance was assessed by asking How do you evaluate your job performance? on 6-point Likert scale.A 6 point likert scale forces choice and gives better data.The 6 point Likert scale offers options for ''Excellent, very good, good, fair, poor and very poor''. 6 point scale anges from 1(very poor) to 5 (excellent)."
76035724|NCT03100357|Other|Thyroidectomy|Thyroid surgery for benign nodular goiter
76035725|NCT05058235|Other|Active Release Technique|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
76035726|NCT05058235|Other|Bent leg raise|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
75394346|NCT04451772|Drug|Placebo for Upadacitinib|Oral; Tablet
75394347|NCT03831984|Drug|0,09% Bromfenac|topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
75394348|NCT03831984|Drug|0,1% sodium hyaluronate|topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
76035727|NCT03100201|Other|Intervention Armeo®Spring|The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
75394349|NCT02084706|Procedure|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
75708328|NCT04990596|Biological|additional blood sample|One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
75394350|NCT02084706|Drug|2% Lidocaine|
75394351|NCT02084706|Drug|Triamcinolone (20 g)|
75394352|NCT02084706|Procedure|J-tip lidocaine administration|
75394353|NCT02084706|Procedure|Triamcinolone (20 g) Injection over the A1 pulley.|
75708329|NCT04984356|Biological|WU-CART-007|A single IV infusion of WU-CART-007 Cells on Day 1
75708330|NCT04978584|Drug|Acalabrutinib|Given PO
75708331|NCT04978584|Drug|Cyclophosphamide|Given IV
75708332|NCT04978584|Drug|Doxorubicin Hydrochloride|Given IV
75708333|NCT04978584|Drug|Lenalidomide|Given PO
75708334|NCT04978584|Drug|Prednisone|Given PO
75708335|NCT04978584|Biological|Rituximab|Given IV
76035728|NCT03100201|Other|Control Group|The control group will receive conventional occupational- and physiotherapy over 3 weeks
76035729|NCT03099343|Behavioral|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
76035730|NCT05058079|Behavioral|Intraoperative Hand Held|Intraoperative hand holding
76035731|NCT03423589|Dietary Supplement|VSL#3|VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.
75394354|NCT04686084|Device|Dual-energy computed tomography scan|Diagnostic CT scan
75394355|NCT04433988|Drug|Pentoxifylline|Pentoxifylline 400 mg SR tablet
75394356|NCT04433988|Drug|Placebo|Placebo tablet
75394357|NCT04425408|Device|Consecutive trial of two different devices for the treatment of positional sleep apnoea, for 3 nights with each device (positional pillow and vibrating belt).|Patients will be randomly allocated to use either a positional pillow or a vibrating belt for three consecutive nights at home followed by three nights with the other device.
75394358|NCT04685538|Drug|Chloroprocaine 3%|"Administration: three IMP drops instillation as follow:~1st Drop instillation, then wait for 5 minutes~Eye Disinfection, then wait for 2 minutes~2nd Drop instillation, then wait for 1 minute~3rdDrop instillation, then wait for 1 minute~Start of Surgery."
75394359|NCT04685538|Drug|Tetracaine 0.5%|"Administration: three IMP drops instillation as follow:~1st Drop instillation, then wait for 5 minutes~Eye Disinfection, then wait for 2 minutes~2nd Drop instillation, then wait for 1 minute~3rdDrop instillation, then wait for 1 minute~Start of Surgery."
75708336|NCT04978584|Biological|Tafasitamab|Given IV
75708337|NCT04978584|Drug|Vincristine|Given IV
75708338|NCT04973163|Drug|BI 1823911|BI 1823911
75708339|NCT04973163|Drug|BI 1701963|BI 1701963
75708340|NCT04973163|Drug|Midazolam|Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
75708341|NCT04971785|Drug|Semaglutide (SEMA)|Administered as subcutaneous (SC) injection
75708342|NCT04971785|Drug|Cilofexor (CILO)/Firsocostat (FIR)|Tablets administered orally
75708343|NCT04971785|Drug|PTM SEMA|Administered as SC injection
75708344|NCT04971785|Drug|PTM CILO/FIR|Tablets administered orally
75708345|NCT04971694|Other|No interventions or procedures|This is a retrospective observational study and data will be collected from the subject's existing medical record. No interventions or procedures will be required for this study.
75708346|NCT04970576|Drug|Rivaroxaban|Dose of 20 mg once a day for three months followed by transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
75394360|NCT03255798|Device|G2 and G3|Two iStent inject devices and one iStent supra device
76035732|NCT05064475|Diagnostic Test|PET/CT|Patients with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients will underwent 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT. The final diagnosis of relapse will be derived from histopathological sampling As much as possible or radiological follow up for at least 6 months will be compared with PET/CT results.
75394361|NCT04746222|Biological|Oral capsule faecal microbiota transplantation|Single dose of 30 oral capsules containing healthy donor stool from a stool bank
75708347|NCT04970576|Drug|Warfarin|Dose as per the target INR of 2 to 3 with transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
75708348|NCT04964739|Behavioral|Cognitive Behavioral Therapy (CBT4CBT)|Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
75708349|NCT04961112|Device|Cranial Electrotherapy Stimulation|Participants will receive cranial electrotherapy stimulation stimulation on one of two separate visits (within-subjects).
75708350|NCT04961112|Device|Sham Cranial Electrotherapy Stimulation|Participants will receive sham stimulation on one of two separate visits (within-subjects).
76035733|NCT05057299|Other|retrospective data analysis|chart review, analysis and reporting outcomes
76035734|NCT05057455|Procedure|cytokine hemadsorption|the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
76035735|NCT05057533|Other|a questionnaire based on Rome IV Diagnostic criteria of IBS|"The Rome IV criteria for the diagnosis of IBS require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following~Related to defecation (may be increased or unchanged by defecation)~Associated with a change in stool frequency~Associated with a change in stool form or appearance The Rome IV criteria (May 2016) only require abdominal pain in defining this condition; discomfort is no longer a requirement owing to its nonspecificity, and the recurrent abdominal pain. [2] Supporting symptoms include the following:Altered stool frequency Altered stool form Altered stool passage (straining and/or urgency) Mucorrhea Abdominal bloating or subjective distention."
76035736|NCT05063773|Device|Mixed reality heads up display|Physician will use a mixed reality headset for image guidance of the procedure
76035737|NCT02897479|Drug|Savolitinib|Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
75708351|NCT04948554|Biological|MK-2225|Administered Subcutaneously (SC)
75708352|NCT04948554|Biological|Placebo|Administered SC
75708353|NCT04943744|Device|Entero-tracker|Esophageal STRING test (Entero-tracker)
75708354|NCT04941716|Drug|Acalabrutinib|Given PO
76035738|NCT05046925|Procedure|postoperatively transferral to PACU|patients undergoing major thoracic and abdominal surgery will be transferred to PACU for postoperative care.
76035739|NCT05046925|Procedure|postoperatively transferral to ICU|patients undergoing major thoracic and abdominal surgery will be transferred to ICU for postoperative care.
76035740|NCT04470973|Drug|Cefuroxime|Patients receive cefuroxime as part of standard care.
76035741|NCT04470973|Drug|Amikacin|Patients receive amikacin as part of standard care.
76035742|NCT05046457|Dietary Supplement|Beta-cryptoxanthin (BCX)|Subjects will be randomised into one of the three study treatment arms.
75394362|NCT04746222|Other|Placebo|Single dose of 30 oral placebo capsules
75394363|NCT04746768|Combination Product|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
75394365|NCT04344678|Drug|Sildenafil Citrate|Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily
75394366|NCT04344678|Drug|Placebo oral tablet|Esitalopram 20 mg tablet plus placebo tablet once daily
75708355|NCT04941716|Drug|Venetoclax|Given PO
75708356|NCT04940780|Other|Acupuncture|Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms
75708357|NCT04940780|Other|Touch Therapies|Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch
75870439|NCT02940223|Other|Laboratory Biomarker Analysis|Correlative studies
75870440|NCT02940223|Other|Placebo|Given PO
76035743|NCT05056675|Procedure|PENG block|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.
75394367|NCT03212118|Behavioral|Treatment as usual (TAU-0)|"The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees."
75394368|NCT03212118|Behavioral|Structured talks (TAU-2)|Two structured talks (not including elements from motivational interviewing)
75394369|NCT03212118|Behavioral|motivational interviewing (MI)|Two structured talks (must have a valid motivational interviewing content).
75394370|NCT04056312|Behavioral|Group Memory retraining exercises|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
75394371|NCT04056312|Behavioral|Placebo controlled group memory exercise training|Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
75394372|NCT03249558|Drug|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
75394373|NCT03249558|Drug|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
75394374|NCT03249558|Drug|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
75394375|NCT04054596|Behavioral|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
75394376|NCT03246828|Other|Omission of gliclazide|Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
75394377|NCT04746300|Procedure|Biopsy|A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing
75394378|NCT04746300|Procedure|Blood sample|Blood samples will be taken for additional translational research
75394379|NCT02476812|Behavioral|Positive Piggy Bank|Already noted.
75394380|NCT04316442|Biological|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
75394381|NCT02295306|Device|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
75394382|NCT02090712|Procedure|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
75394383|NCT03206190|Other|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
75394384|NCT03206190|Behavioral|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
75545727|NCT00299286|Drug|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
75545728|NCT00262457|Device|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
75545729|NCT00262496|Drug|Botox|
75545730|NCT00293787|Drug|Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
75545731|NCT00293787|Other|Timolol Vehicle|Placebo
75545732|NCT00293787|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
75870441|NCT02940223|Behavioral|Quality-of-Life Assessment|Ancillary studies
75394385|NCT03206190|Diagnostic Test|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
75394386|NCT03206190|Diagnostic Test|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
75394387|NCT03206190|Diagnostic Test|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
75394388|NCT03206190|Diagnostic Test|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
76035744|NCT05056675|Procedure|Placebo|ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
76035745|NCT05063071|Drug|Tenofovir Alafenamide 25 MG|After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
76035746|NCT05045911|Procedure|Endoscopic Barbed-clips Suturing|Endoscopic Barbed-clips Suturing
76035747|NCT05045989|Behavioral|Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)|SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.
76035748|NCT05045599|Behavioral|Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health|Community engagement to improve awareness, and use of family planning products and services
76035749|NCT05062681|Drug|Dexamethasone|Patients will receive dexamethasone 8 mg q12hours
76035750|NCT05062681|Drug|Methylprednisolone|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
76035751|NCT05045521|Other|plyometric warm up group|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 * 8 squat jumps, 2 * 8 scissor jumps, and 2 * 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos."
76035752|NCT05045521|Other|resistance warm up|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest"
76035753|NCT05045521|Other|control warm up group|"participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests."
76035754|NCT05056519|Biological|Live Attenuated Influenza Vaccine|Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
76035755|NCT05056519|Biological|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
76035756|NCT05045287|Radiation|hypofractionated radiotherapy|Undergo hypofractionated RT，obeserve reconstruction failure，cosmetic result and recurrence rate
76035757|NCT05045131|Procedure|Left atrial combined pulmonary vein isolation and posterior wall isolation|
75394389|NCT03206190|Diagnostic Test|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
75394390|NCT04277052|Device|Determination muscles sections by Ultrasonography|Determination muscles sections by Ultrasonography
76035758|NCT05045053|Drug|Xiidra 5% Ophthalmic Solution|lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
75394391|NCT03909282|Procedure|Lumpectomy|Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
75394392|NCT03909282|Radiation|Partial breast irradiation prior to surgery|Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
75394393|NCT03204396|Drug|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
75394394|NCT03204396|Drug|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl]) once weekly for 12 weeks
75394395|NCT04398498|Diagnostic Test|Diagnostic Test: TruGraf® Testing|5 mL collection PAXgene blood sample
75394396|NCT03631680|Procedure|Bilateral Oophorectomy Surgery|Women undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.
75394397|NCT03174132|Device|Restylane Perlane Lidocaine|Intradermal injection
75394398|NCT03174132|Device|Restylane Perlane|Intradermal injection
75394399|NCT04271904|Other|Placebo Diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
75394400|NCT01825278|Device|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
75394401|NCT01812252|Drug|Azacitidine|Given IV or SC
76035759|NCT05044741|Procedure|Emergency surgical enterostomy|Emergency surgical enterostomy
76035760|NCT03097627|Drug|ICG Intervention|The intervention to be administered is the drug indocyanine green.
75708358|NCT04933331|Drug|Curodont Repair Fluoride Plus|Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.
76035761|NCT03097627|Device|Near Infrared Camera|The intervention to detect the administered drug, indocyanine green.
76035762|NCT05055739|Device|Rigid plate X steel wires|Compare the sternal alignment between the fixation with rigid plate X steel wires.
76035763|NCT05055895|Drug|Anticholinergic burden|"The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1."
76035764|NCT05055583|Drug|Toripalimab in Combination With Platinum-based Chemotherapy|Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.
76035765|NCT05055583|Procedure|Surgical treatment stage|After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.
75394402|NCT01812252|Drug|Decitabine|Given IV or SC
75394403|NCT01812252|Other|Quality-of-Life Assessment|Ancillary studies
75394404|NCT05005806|Drug|Omega 3 fatty acid|omega 3 fatty acid soft gel
75394405|NCT05005806|Drug|Placebo|placebo soft gel
75394406|NCT04233528|Diagnostic Test|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
75394407|NCT01680510|Dietary Supplement|Alga Dunaliella Bardawil|
75394408|NCT01680510|Other|Placebo (starch)|
75394409|NCT04398186|Diagnostic Test|Anogenital distance measurement|Measurements of AGD and perineal muscle strength
75394410|NCT03818802|Dietary Supplement|Nicotinamide Riboside|It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.
75394411|NCT03818802|Dietary Supplement|Placebo|It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
75394412|NCT03817632|Device|Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1|Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1
75708359|NCT04933331|Device|Silver Diamine Fluoride|Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.
75708360|NCT04933331|Device|Glass Ionomer Sealant|A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.
75545733|NCT00293787|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
75394413|NCT03817632|Device|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0|Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
75394414|NCT04398108|Drug|Margetuximab Margetuximab-IV|Drug: Chosen Chemotherapy (Capecitabine) -Oral Capecitabine tablet Drug: Chosen Chemotherapy (Vinorelbine) Vinorelbine -IV Drug: Chosen Chemotherapy (Gemcitabine) Gemcitabine -IV
75394415|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
75394416|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
75394417|NCT01625286|Drug|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
75545734|NCT00299364|Drug|Black Cohosh (iCR) or tibolone|
75394418|NCT01625286|Drug|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
75413874|NCT04426461|Behavioral|Exposure-based therapy|Exposure-based therapy will be delivered as a 10-week, manualized, behavioral intervention focused on decreasing avoidance to allow for inhibitory learning and challenging negative expectations.
75413875|NCT04426461|Behavioral|Supportive therapy|Supportive therapy will be delivered as a 10-week, manualized intervention focused on encouraging patients to talk openly about their thoughts, emotions, and any past or current concerns.
75545735|NCT00415649|Biological|VRC-HIVDNA016-00-VP|
75545736|NCT00415649|Biological|VRC-HIVADV014-00-VP|
75545737|NCT00415649|Biological|Vaccine placebo|Placebo comparator
75545738|NCT00293826|Drug|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
75545739|NCT00293826|Drug|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
75413876|NCT04416191|Other|Limb immobilization|Participants will undergo a 2-week period of leg immobilization
75545740|NCT00293826|Drug|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
75545741|NCT00293826|Drug|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
75545742|NCT00415688|Behavioral|Low carbohydrate, ketogenic diet|
75545743|NCT00415688|Behavioral|Low glycemic index, reduced calorie diet|
75545744|NCT00299403|Procedure|Right prefrontal lowfrequency ( 1 hz) rTMS.|"Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2"
75545745|NCT00299403|Procedure|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
75545746|NCT00415727|Device|auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation|
75545747|NCT00299442|Behavioral|Self-help Triple P Behavioural Family Intervention|10-week self-help workbook and videos
75545748|NCT00262574|Drug|Nesiritide,|PCI
75545749|NCT00293865|Procedure|sentinel node|detection of the sentinel node in breast cancer
75545750|NCT00293865|Procedure|GAS|
75545751|NCT00262613|Drug|sodium pyruvate in 0.9% sodium chloride solution|
75545752|NCT00293904|Biological|CYT005-AllQbG10|
75545753|NCT00262652|Drug|sodium pyruvate|
75545754|NCT00262769|Drug|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
75545755|NCT00262769|Drug|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
75545756|NCT00299520|Drug|intravenous iclaprim or intravenous linezolid|
75870442|NCT02940223|Other|Questionnaire Administration|Ancillary studies
75394419|NCT04277130|Behavioral|Intervention with active video games|Participants in intervention group were paired up by their teachers. Each participant had a classmate playing with him/her, and the waiting time is minimal because Xbox 360 Kinect allowed double play mode. The intervention group was provided with an AVG, the Xbox 360 Kinect technology (Kinect Sports Seasons I & II, including bowling, soccer, boxing, track and field, table tennis, beach volleyball, golf, tennis). The AVG intervention consisted of two 30-min sessions per week, for a total of 12 weeks. Participants either played in PE classes and/or recess. They had no other specific routing of activities but straight played the AVG during the intervention. They could free to choose games they like in the Xbox 360. The AVGs of Xbox 360 chosen was of moderate to vigorous intensity (3-6 METs) and no matter what games they chose, their PA level would be between moderate and vigorous intensity.
75708361|NCT04933331|Device|Fluoride varnish|2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.
75708362|NCT04933331|Drug|Fluoride toothpaste|Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
75870443|NCT01312831|Other|Vitamin B12 (cyanocobalamin)|
75394420|NCT03801174|Behavioral|Partner-assisted intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
75394421|NCT03801174|Behavioral|Patient-only intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
76035766|NCT05055583|Drug|Adjuvant treatment stage|Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
75394422|NCT03796962|Drug|XEN1101|Oral dose
76035767|NCT05061589|Procedure|permanent colostomy|An operation that creates an opening for the colon through the abdomen
75394423|NCT05158062|Biological|pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
75545757|NCT00261755|Procedure|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
76035768|NCT03097705|Diagnostic Test|OCT (Optical coherence tomography)|RNFL AND IOP MEASUREMNTS
75394424|NCT05158062|Drug|olaparib|olaparib 300 mg twice daily (BID) during maintenance period
76035769|NCT05060809|Drug|oral vitamin k1 (phylloquinone)|The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
76035770|NCT03097549|Device|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
75394425|NCT05158062|Biological|bevacizumab|bevacizumab 15 mg/kg Q3W
75394426|NCT05158062|Drug|carboplatin|carboplatin AUC=5 or 6 Q3W during treatment period
75394427|NCT05158062|Drug|paclitaxel|paclitaxel 175 mg/m2 Q3W during treatment period
75394428|NCT05158062|Drug|docetaxel|docetaxel 60 ~ 70 mg/m2 Q3W during treatment period
75394429|NCT01076868|Drug|Primaquine|Primaquine x 14 days
75394430|NCT03193866|Drug|Rituximab|Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
75394431|NCT05151432|Device|Pulsed Ultrasound|Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W
75394432|NCT05151432|Device|Pulsed Electromagnetic field|The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.
75394433|NCT05151432|Other|Traditional exercise program|Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening
75394434|NCT05151432|Device|Sham Pulsed US & Electromagnetic field|The patients will receive Sham Pulsed US & Electromagnetic field.
75394435|NCT04199052|Behavioral|LinkPositively|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
75394436|NCT04195776|Drug|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
75394437|NCT04193826|Device|Left Atrial Appendage Closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the LAAC device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
75394438|NCT03708588|Drug|Ticagrelor|Chewed
75394439|NCT03708588|Drug|Ticagrelor|Integral
75394442|NCT03681054|Other|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
75394443|NCT03681054|Other|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
75394444|NCT03667404|Dietary Supplement|Resistant maltodextrin|Resistant maltodextrin powder
75394445|NCT03667404|Dietary Supplement|maltodextrin|maltodextrin powder
75394446|NCT04276662|Drug|DS-3201b|1 dose of 50 mg DS-3201b
75394447|NCT04130802|Drug|OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL|OCS-01 eye drops
75394448|NCT04130802|Drug|Placebo|Vehicle eye drops
75708363|NCT04930445|Drug|Oxbryta® (voxelotor) 500mg Tablets|Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
75708364|NCT04906746|Drug|Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.|There will be intra-patient dose escalation of ruxolitinib in every patient enrolled on study.
75708365|NCT04906616|Behavioral|Mlambe|A combined economic and relationship-strengthening intervention at the couple level to redirect funds spent on alcohol into financial investments (e.g., education, income-generating business) and to improve couple relationships and adherence to ART.
75708366|NCT04904822|Procedure|Vaginal bisection|Uterine bisection vaginally by scalpel 24
75708367|NCT04904822|Procedure|Abdominal bisection|Uterine bisection by endokinfe
75394449|NCT04276350|Procedure|Acupuncture|Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
75394450|NCT04276350|Procedure|Best Medical Therapy|Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
75394451|NCT03613740|Drug|Fucoxanthin|Intervention will be administered 30 minutes before breakfast.
75394452|NCT03613740|Drug|Placebo|Intervention will be administered 30 minutes before breakfast.
75394453|NCT04110522|Other|Direct to patient PsA Screening Questionnaire|Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST ≥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.
75413877|NCT04415931|Procedure|Local infiltration analgesia|"Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL"
75708368|NCT04903561|Device|ColliPee|The GP will hand over the self-sampling kit to the women, after obtaining informed consent, and the women then takes the self sample at home or in the doctor's office (predefined), according to the respective users manual.
75708369|NCT04900155|Drug|Atorvastatin 80mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
75708370|NCT04900155|Drug|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
75708371|NCT04899076|Device|Stool Processing Kit|The Stool Processing Kit is a centrifuge-free stool processing solution that allows preparation of stool samples for testing with the Xpert Ultra MTB/RIF assay
75394454|NCT03166098|Diagnostic Test|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
75545758|NCT00261755|Other|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
75545759|NCT00261755|Other|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
75870444|NCT01312987|Dietary Supplement|Lipid-based nutritional supplement|"After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months"
75545760|NCT00262808|Biological|sargramostim|
75545761|NCT00262808|Drug|fluorouracil|
75545762|NCT00262808|Drug|leucovorin calcium|
75545763|NCT00262808|Drug|oxaliplatin|
75545764|NCT00262808|Procedure|adjuvant therapy|
75545765|NCT00262808|Procedure|conventional surgery|
75545766|NCT00262808|Procedure|neoadjuvant therapy|
75545767|NCT00262886|Biological|anti-thymocyte globulin|
75545768|NCT00262886|Biological|graft-versus-tumor induction therapy|
75708372|NCT04897893|Other|Eicosapentaenoic acid monoglycerid (MAG-EPA)|MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
75870445|NCT04431193|Drug|Oxytocin|Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
75870446|NCT03295201|Other|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
75545769|NCT00262886|Biological|therapeutic allogeneic lymphocytes|
75545770|NCT00262886|Drug|cyclophosphamide|
75545771|NCT00262886|Drug|fludarabine phosphate|
75545772|NCT00262886|Drug|mycophenolate mofetil|
75545773|NCT00262886|Drug|tacrolimus|
75545774|NCT00262886|Procedure|allogeneic bone marrow transplantation|
75545775|NCT00262886|Procedure|peripheral blood stem cell transplantation|
75545776|NCT00263003|Drug|Irbesartan/hydrochlorothiazide|
75545777|NCT00263003|Drug|Irbesartan|
75545778|NCT00299559|Drug|smart textiles containing menthol, camphor, cineol|application to skin
75545779|NCT00263081|Drug|Lapaquistat acetate and current lipid-lowering treatment|"Cohort 1: Weight is less than 50 kg:~Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.~Cohort 2: Weight is more than 50 kg:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks."
75545780|NCT00263081|Drug|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
75545781|NCT00293982|Behavioral|Physician knowledge of parental expectations for the visit|
75545782|NCT00263120|Behavioral|Pain Questionnaire|
75545783|NCT00299598|Device|alkylated polyethylenimine nanoparticles antibacterial evaluation|
75545784|NCT00263159|Procedure|Pharmaceutical care for asthma patients|
75545785|NCT00263198|Drug|PTK787/ZK222584|
75545786|NCT00263198|Drug|Letrozole|
75545787|NCT00294099|Biological|Aluminum hydroxide|Aluminum hydroxide adjuvant.
75870447|NCT03295201|Other|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
75394455|NCT03087162|Drug|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
75545788|NCT00294099|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
76035771|NCT03097549|Device|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
76035772|NCT03097471|Device|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
76035773|NCT05055349|Other|corneal ring segments|ring hard segments inserted within corneal stroma using femtolaser
76035774|NCT03098095|Behavioral|Physical Activity|Moderate physical activity
75545789|NCT00263237|Drug|STA-5326|
75545790|NCT00299676|Drug|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
75545791|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
75870448|NCT03293485|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
75870449|NCT03309943|Drug|Propranolol|Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
76035775|NCT05061043|Other|Routine physical therapy treatment|Control group will receive the routine physical therapy treatment that will include EMS, Infrared and Intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes for 5 days a week
76035776|NCT05061043|Other|Routine physical therapy along with orofacial therapy|Experimental group will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes)
76035777|NCT05054959|Other|consolidation chemotherapy|6 cycles CAPOX after chemoradiotherapy
75394456|NCT03165942|Other|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
75394457|NCT03165942|Other|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
75394458|NCT03165942|Drug|Ethanol|
75394459|NCT03163992|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
75394460|NCT04397328|Drug|Hydroxychloroquine|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
75545792|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
75545793|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
75545794|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
75545795|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
75545796|NCT00263276|Drug|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
75545797|NCT00263276|Drug|metformin|Tablets, Oral, >/= 1500 mg, Once daily, 12 weeks.
75545798|NCT00299754|Drug|Misoprostol|
75545799|NCT00263315|Drug|nebulised liposomal amphotericin B|
75545800|NCT00417807|Drug|Imatinib mesilate|
75708373|NCT04896164|Drug|Curcumin Lozenges|Curcumin lozenges (each containing 100 mg of curcumin) will be given at a dose of 4 lozenges (total dose 400 mg curcumin) BD. Formulation is Solid Lipid Curcumin Particle (SLCP). Oral curcumin lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
76035778|NCT05054959|Other|induction chemotherapy|4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
75394461|NCT04397328|Drug|Placebo|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
75394462|NCT04100538|Behavioral|health coach|"The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes."
75394463|NCT03163602|Drug|Control group|Access flap and debridement
75394464|NCT03163602|Device|Test group|Regenerative treatment
75545801|NCT00263354|Drug|Oxaliplatin|
75545802|NCT00299832|Drug|Aliskiren|
75545803|NCT00263393|Drug|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
75545804|NCT00263393|Behavioral|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
76035779|NCT03097393|Diagnostic Test|measure Serum procalcitonin level|measuring procalcitonin level
76035780|NCT03097237|Other|Wholegrain rye|Cereal products based on wholegrain rye
75545805|NCT00263471|Drug|7-methylxanthine|
75545806|NCT00299871|Drug|LIXISENATIDE (AVE0010)|
75545807|NCT00263549|Biological|House dust mite Novo Helisen Depot|
75708374|NCT04896164|Other|Placebo Lozenges|Placebo lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
75708375|NCT04894825|Drug|M108|Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)
75708376|NCT04894825|Drug|M108|IV infusion Q3W. (21-day cycles)
75545808|NCT00299910|Drug|Montelukast|
75545809|NCT00263627|Biological|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
75545810|NCT00263627|Other|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
75545811|NCT00294177|Device|atomic force microscopy|
75545812|NCT00294177|Device|dual polarisation interferometry|
75545813|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 1|
75545814|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 2|
75545815|NCT00425594|Drug|NuLYTELY|
75545816|NCT00294216|Drug|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
75545817|NCT00294255|Drug|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
75545818|NCT00263705|Drug|Adjuvant capecitabine|Capecitabine 2000 mg/m² daily six cycles
75545819|NCT00263705|Drug|capecitabine in aduvant setting|capecitabine in aduvant setting in ederly with breast cancer
75545820|NCT00263744|Biological|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
75708377|NCT04893226|Behavioral|Time-Restricted Feeding (TRF)|Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.
75708378|NCT04890730|Other|Esophagogastroduodenoscopies|Each enrolled patient needs to undergo Esophagogastroduodenoscopies and elastography
75870450|NCT03309943|Drug|Placebo|Participants will take one dose of Placebo on two separate occasions.
76035781|NCT03097237|Other|Refined wheat|Cereal products based on refined wheat
76035782|NCT05060419|Drug|Meropenem- FL058|"Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h"
76035783|NCT05060419|Drug|Piperacillin -tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
76035784|NCT05060419|Drug|Saline|180min
76035785|NCT05060419|Drug|Saline|30min
75394465|NCT03084354|Other|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
75394466|NCT04398576|Behavioral|Training and support|GP's receive the tools to make early identification of harmful and hazardous alcohol use possible. They are given guidelines to apply a brief intervention. At the start of the study, the T&S-group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months.
75394467|NCT04398576|Behavioral|Community actions|There will be embedded community-based actions within a local strategy.
75394468|NCT03081468|Device|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
75394469|NCT03081468|Device|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
75394470|NCT03392376|Drug|Haloperidol Injection|ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
75394471|NCT03392376|Other|Saline (0,9%)|ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
75394472|NCT05243628|Biological|Afrezza (insulin human) Inhalation Powder|"Pharmaceutical form: powder~Route of administration: inhalation"
75394473|NCT05243628|Biological|insulin degludec|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75708379|NCT04885036|Behavioral|EFST intervention|EFST extended intervention is a stand-alone treatment that consist of a two days EFST group course followed by six weekly individual sessions of parental guidance by a licensed EFST therapist. The treatment is given indirectly to the child through work with the parent, thus it might remove or diminish the pressure on the children that suffer from mental health problems to solve their disorder themselves. In this condition a total of 19 hours of EFST treatment is provided.
76035786|NCT05055193|Drug|Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome|Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
75394474|NCT05243628|Device|Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)|Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
75870451|NCT01313065|Drug|VX15/2503|Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
76035787|NCT05060185|Device|the Flow Diverter|Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
75394475|NCT05249478|Procedure|bupivacaine and fentanyl|bupivacaine and fentanyl will be infused through the catheter
75394476|NCT04083222|Drug|Placebo|ISIS 757456-matching placebo solution administered as SC injection.
75394477|NCT04083222|Drug|ISIS 757456|ISIS 757456 administered as SC injection.
76035788|NCT05060107|Biological|Exosomes (sEVs)|Exosomes 3-5x10e11 particles/dose
75413878|NCT04415931|Procedure|Interscalene block|Standard interscalene brachial plexus regional block
75708380|NCT04885036|Behavioral|Treatment As Usual|In the TAU condition, the families will receive treatment as usual that does not include EFST treatment. Recent research indicates that this is therapy of high quality carried out by highly qualified staff (Tilden et al., 2020; Zahl-Olsen et al., 2020).The therapists are educated psychologists, psychiatrist and family therapists. The TAU intends to be the best treatment for the child/ family based on the type of symptoms presented and requests from the patient and his/her family. We will measure the intensity and type of therapy given in this condition by information from the therapists and investigate that it did not include the main elements of EFST treatment.
75708381|NCT04882514|Biological|p*17-K4S2|Administer p*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
75708382|NCT04882514|Biological|J8-K4S2|Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
75413879|NCT04410380|Behavioral|Electronic tablet provision with teaching|Spanish-speaking parents are provided with an electronic tablet and taught how to use it to access health information for their children.
75413880|NCT04395430|Behavioral|Usual Care|"Participants will receive standard care which consist of the following:~a lifestyle counseling visit~educational materials~goal-setting by a healthcare professional, and~information about general weight management resources.~weighing scale and measuring tape with instructions to use~fitness tracker"
76035789|NCT05060263|Drug|HOT-1030|HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
76035790|NCT05036551|Diagnostic Test|Kellgren Lawrence classification|The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
76035791|NCT03096925|Behavioral|Guided self-help|Web-based guided self-help intervention
75394478|NCT05249946|Other|FoodStep - a sustainable health-promoting model for food services and early childhood education and care|The investigators create a sustainable food system model that reduces the climate impact of the food system in early childhood education and care. In practice, the investigators i) promote plant-rich recipes, sustainable food purchases and consumption through municipality food services, ii) renew food education, and iii) reduce food waste in early education and care. To ensure the feasibility and long-term commitment, the investigators bring together municipal stakeholders and key actors within the food system and education sectors to co-create the content of a sustainable food system intervention. The randomized controlled intervention will be carried out at 26 daycare centers within four municipalities in Finland. The impact of the changes at a food system level on children's dietary intake and nutritional status, costs of the whole food system, the climate impact of the menus and children's diets as well as food waste in the daycare centers will be examined.
75394479|NCT04276506|Other|music group|to reduce anxiety, some selected music pieces will have patients listened by headset.
75394480|NCT04276506|Other|information group|A visual information booklet which is prepared by the researchers will be used
75394481|NCT03148080|Procedure|Cognitive Assessment|Complete CogState
75394482|NCT03148080|Other|Questionnaire Administration|Complete Self-Report Questionnaire
75545821|NCT00263744|Other|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
75545822|NCT00294294|Biological|Prevenar|
75545823|NCT00294294|Biological|Infanrix hexa|
75545824|NCT00263783|Drug|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. [As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.]
76035792|NCT03097159|Procedure|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
76035793|NCT03097003|Drug|Apremilast|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
76035794|NCT03098251|Procedure|3D typing|typing the patient with 3D typing system and give specific treatment
76035795|NCT03098251|Procedure|routine typing|typing the patient with routine typing system and give specific treatment
75394483|NCT05246124|Other|Zumba dance exercise|The intervention was Zumba dance done 3 times a week during the 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
75394484|NCT05244252|Drug|dexmeditomidine and bupivacaine|Transversus abdominis plane block will be given bilaterally
75394485|NCT05244252|Drug|Bupivacaine|bupivacaine
75394486|NCT05249790|Drug|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
75545825|NCT00300105|Drug|Tesaglitazar|
75708383|NCT04882514|Biological|Rabavert vaccine|Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.
75708384|NCT04881825|Drug|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
76035796|NCT05055037|Other|Neurofeedback|In neurofeedback (NF), the brainwave activity is measured by an electro-encephalography and fed back to the person as an auditory or visual signal, rewarding the person each time progress is made toward normalizing dysregulated neural activity. The learning mechanism is at its base considered to be operant conditioning, where the behavior of the participant-in this case, neurological activity-is gradually changed through repeated reinforcement. In neurofeedback, this simple learning mechanism is accelerated by continuous and instant feedback, with rewards occurring as often as every second. The NF intervention included 12 NF training sessions, one session per week, off approximately 12-20 min. The protocol was a replicate of the setup of recent NF studies investigating NF as a treatment for chronic PTSD. The feedback was based on a single channel recording, rewarding brainwave frequencies associated with a calm and relaxed state and inhibiting drowsiness and hyperarousal.
76035797|NCT05043727|Combination Product|Exer gaming|exer gaming treatment plan will include perfect ten balance, wii skiing, wiicycling. Each Patient will receive twenty four sessions. Each treatment session was of 50 minutes with two minutes rest between each exercise.
76035798|NCT05043727|Combination Product|conventional treatment plan|it will receive conventional treatment plan which includes balance training, gait training, stretching and strengthening exercises.Each patient will receive twenty four sessions of conventional physical therapy. Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.
75545826|NCT00263822|Drug|erlotinib hydrochloride|
75545827|NCT00294372|Drug|BILR 355 BS|
75545828|NCT00294372|Drug|Placebo|
75545829|NCT00263861|Procedure|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
75545830|NCT00294411|Procedure|elective cesarean section|
75545831|NCT00263900|Device|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
75545832|NCT00300222|Drug|NGX-4010|
75545833|NCT00263939|Behavioral|Homing in on Health|A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
76035799|NCT02605967|Drug|Spartalizumab|Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
75394487|NCT05249790|Drug|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
76035800|NCT02605967|Drug|Investigator choice of chemotherapy|Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
75394488|NCT03370224|Behavioral|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
75394489|NCT03370224|Behavioral|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
75394490|NCT03304314|Diagnostic Test|objective chromatic multifocal pupillometer|objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
75394491|NCT03286842|Drug|Olaparib|Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
75394492|NCT05243784|Behavioral|MOVI-HIIT intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities."
75394493|NCT05247060|Other|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
75394494|NCT05245188|Other|Chocolate milk shakes - Product 1|11.3 glucose
75394495|NCT05245188|Other|Chocolate milk shakes - Product 2|8.84 glucose
75394496|NCT05245188|Other|Chocolate milk shakes - Product 3|4.24 glucose
75394497|NCT05245188|Other|Chocolate milk shakes - Product 4|4.36 glucose
75394498|NCT05240274|Drug|Metformin|metformin 500mg OD for 3 months to start within 10 days post-renal transplant
75394499|NCT05240274|Drug|Placebo|placebo 500mg OD for 3 months to start within 10 days post-renal transplant
75394500|NCT05240196|Other|music|playing binaural or non-binaural music
75545834|NCT00300261|Behavioral|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
75545835|NCT00294450|Device|Fistula Pouching System|3 different sizes of fistula pounching system
76035801|NCT05043571|Biological|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
76035802|NCT04473079|Dietary Supplement|Lacidofil|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
75545836|NCT00263978|Drug|Defibrotide|
75394501|NCT05240586|Procedure|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
75394502|NCT05240586|Procedure|acupuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
75545837|NCT00300300|Procedure|Computer-assisted surgery|no description
75545838|NCT00264056|Device|hyperthermia|
75394503|NCT05240586|Procedure|physical therapy, medication(prn)|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
75394504|NCT05244018|Drug|Vitamin D3 tablets|Vitamin D3 tablets 50,000 IU units
75708385|NCT04871282|Drug|AL102|AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
76035803|NCT04473079|Dietary Supplement|Placebo|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
76035804|NCT05036161|Other|Nasal high flow|Newborns with respiratory distress treated with NHF.
75708386|NCT04871282|Other|Placebo|Placebo to match AL102
75708387|NCT04867616|Other|Placebo|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous infusion~Participants will receive Placebo during the Double-blind Treatment Period."
76035805|NCT05036161|Other|Continuous Positive Airway Pressure|Newborns with respiratory distress treated with CPAP.
75394505|NCT05244018|Drug|Vitamin D tablets|Vitamin D tablets 5000 units as daily requirements
76035806|NCT03036059|Drug|400 μg/kg Ivermectin + 400 mg Albendazole|400ug/Kg, tablet, given orally once or twice a year.
75394506|NCT03103932|Other|Biomarker guided discharge algorithm|participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
75708388|NCT04867616|Biological|Bepranemab|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period."
75708389|NCT04865302|Procedure|SSC|"Incubator phase I: After feeding the neonates will be brought in a prone position in the incubator and the NIRS sensor will be applied on the forehead for continuous cStO2 measurements throughout the study period. The neonate will rest in this position for 60 minutes.~SSC phase: The neonate will be brought on the mother's or father's chest (skin to skin) in a prone position and will stay in this position for 60 minutes.~Incubator phase II: The neonates will be brought back into the incubator for another 60 minutes in prone position. After 180 minutes the study period is over and the NIRS sensor will be removed."
76035807|NCT03096769|Other|Ergonomist|The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
76035808|NCT04834427|Drug|Conventional therapy + S (+)-Ketamine|"In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1~0.25 mg/kg; Bolus intravenous injection (dose 0.1~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02~0.1 mg/kg/h for 24~48 h.~Intramuscular injection：The dose is 2~4 mg/kg."
76035809|NCT04834427|Drug|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
76035810|NCT05035849|Drug|sitagliptin and acarbose|One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
76035811|NCT03095443|Other|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
76035812|NCT03095443|Other|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
76035813|NCT03095443|Other|Attention Control|Participant receives an audio-book.
75394507|NCT04396314|Behavioral|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources. It is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits
75394508|NCT04396314|Behavioral|Psychological treatment|Cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
75394509|NCT04276818|Procedure|PRP group|Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns
75394510|NCT04276818|Procedure|conventional treatment group|The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.
75394511|NCT04396392|Behavioral|VR-based training|"All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to."
75394512|NCT02395224|Other|cancer treatment and follow-up according to current regional and national guidelines|
75545839|NCT00264095|Procedure|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
75545840|NCT00293943|Procedure|Pulmonary vein ablation|
75545841|NCT00264134|Drug|Docetaxel|
75545842|NCT00264134|Drug|Irinotecan|
75545843|NCT00264134|Drug|Carboplatin|
75545844|NCT00300339|Drug|SL650472, Clopidogrel|
75545845|NCT00264173|Drug|Valproate sodium|
75545846|NCT00294528|Device|Nexgen LPS-flex and AGC|
75708390|NCT04862975|Drug|Dolutegravir|Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
76035814|NCT04821479|Biological|Mesenchymal stem cells (MSC)|Intrathecal injections of autologous bone marrow derived mesenchymal stem cells
76035815|NCT05043493|Procedure|Injection in the intraarticular space of glenohumeral joint|U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
75394513|NCT02391402|Behavioral|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
75545847|NCT00264212|Drug|irbesartan and irbesartan-hydrochlorothiazide|
75545848|NCT00300378|Drug|desvenlafaxine 50 mg|
75545849|NCT00300378|Drug|desvenlafaxine 100 mg|
75545850|NCT00264251|Behavioral|Weight loss through diet and exercise|
75545851|NCT00264251|Drug|Rosiglitazone insulin sensitizing agent|
75708391|NCT04862975|Drug|Efavirenz|Efavirenz will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
75545852|NCT00294567|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
75708392|NCT04862975|Drug|Emtricitabine|Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
75708393|NCT04862975|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
75870452|NCT01732627|Biological|Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
75545853|NCT00264329|Other|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
75394514|NCT02391402|Behavioral|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
75394515|NCT04397640|Diagnostic Test|Sonovue|Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
75394516|NCT02398500|Biological|LMG324|IVT injection
75394517|NCT02398500|Biological|Ranibizumab 0.5 mg|IVT injection
75394518|NCT02398500|Biological|Sham|Fake injection used for masking purposes
75394519|NCT03042858|Other|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
75708394|NCT04854863|Diagnostic Test|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
75394520|NCT03042858|Other|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
75394521|NCT03039660|Behavioral|RefreshMD|Online Sleep Improvement Course
75394522|NCT03039660|Behavioral|Bond Between Us|Online Educational Course
75708395|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
75394523|NCT03037476|Behavioral|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
75545854|NCT00300417|Drug|VRC-WNVDNA020-00-VP|
75545855|NCT04708925|Other|conservative versus plasmapharesis therapy|conservative versus plasmapharesis therapy
75394524|NCT03037476|Behavioral|Assessment Only|The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
75394525|NCT04276896|Biological|Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs|Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
75394526|NCT02984514|Radiation|Positron emission tomography with tracer 18F-deoxy glucose|Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
75545856|NCT00294606|Drug|Comparison of Effects of Phenylephrine and Norepinephrine|
75545857|NCT00300534|Device|Abbott Laboratories Determine test for syphilis|
75545858|NCT00300534|Device|Investigational syphilis immunochromatographic strip test|
75545859|NCT04708964|Drug|Flurbiprofen|Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
75545860|NCT04708964|Drug|saline solution|Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
75545861|NCT00294801|Drug|flex-a-new (food supplement)|
75545862|NCT00264368|Drug|intravenous (IV) ganciclovir|
75545863|NCT00264407|Drug|Hormone Replacement Therapy - HRT|
75394527|NCT04276428|Drug|LY3209590|Administered SC.
75394528|NCT04276428|Drug|Insulin Degludec|Administered SC.
75394529|NCT05248932|Drug|Norepinephrine bolus|5 microgram bolus therapy
75394530|NCT05248932|Device|cardiometry|cardiac output, stroke volume and fluid responsiveness monitoring
75394531|NCT05248932|Drug|Norepinephrine infusion|2.5 microgram/min infusion
75394532|NCT05246826|Other|Clinical Pilates Exercises|Pilates exercises; warm-up and cool-down exercises will be performed for 5 repetitions, while other exercises will be performed by the same physiotherapist as 10 repetitions depending on the patient's pain and fatigue. The exercises will be advanced at the end of the 3rd week.
75394533|NCT05246826|Other|Clinical Pilates Exercises and Conventional Treatment|In addition to pilates exercises, a conventional treatment program will be applied. As part of the conventional treatment program, 20 minutes of Hotpack to the cervical area, 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation (TENS) to the painful area (80 Hertz (Hz), 100 microseconds (μs), until tingling is felt, asymmetrical biphasic rectangular waveform), 8 minutes to the cervical area Ultrasound (US) (4 minutes + 4 minutes, 1.5 watts/cm2, 1 MHz, continuous) will be applied.
75545864|NCT00300573|Drug|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
75545865|NCT00300612|Biological|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
75545866|NCT00264446|Drug|ADH300004|
75545867|NCT00300651|Behavioral|Cognitive Behavioral Therapy|
75545868|NCT00264485|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
75545869|NCT00294840|Device|PET-CT|
75545870|NCT00300690|Device|6 mm Uni-graft® (B-Braun)|
75545871|NCT00300690|Device|6 mm Gore-Tex® (WL Gore)|
75545872|NCT00264524|Procedure|venipuncture to withdraw patient's blood|
75545873|NCT00294879|Procedure|pressure support ventilation at 0, 5, and 10% IRT|
75545874|NCT00264563|Behavioral|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
75545875|NCT00264563|Behavioral|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
75870453|NCT01732627|Biological|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous (SC)
75394534|NCT05247528|Drug|MANP|Novel designer peptide to represent a pGC-A/cGMP therapeutic
75394535|NCT05247528|Drug|Placebo|Placebo Comparator
75394536|NCT03140514|Drug|Rejection treatment according to clinical standard-of-care|Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
75394537|NCT03007758|Procedure|open ventral hernia repair|An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
75394538|NCT03007758|Procedure|robotic ventral hernia repair|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
75394539|NCT02395614|Drug|Chlorhexidine irrigation|- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
75394540|NCT02395614|Drug|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
75545876|NCT00294918|Drug|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
75545877|NCT00264680|Drug|lamotrigine|
75545878|NCT00264680|Drug|valproic acid|
75545879|NCT00300729|Drug|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
75708396|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
75708397|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program|Inoculate 1 dose of control vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
75708398|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program|Inoculate 1 dose of control vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
75708399|NCT04840927|Drug|E7386|Regimen A: 40 milligram (mg) IR Oral Tablet.
75708400|NCT04839406|Behavioral|Structured support of caregivers at the ICU|Structured support of caregivers at the ICU provided by a trained group of 10-15 ICU nurses
75708401|NCT04839081|Other|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
75394541|NCT04396938|Drug|Lamotrigine|Active Drug Capsule
75394542|NCT04396938|Drug|Placebos|Placebo Capsule
75708402|NCT04835987|Diagnostic Test|Holter ECG|Measurement of the modification of the sympathomimetic balance
75708403|NCT04835987|Behavioral|Questionary|Lifestyle questionary (time spent in front of television, physical activity)
75708404|NCT04835987|Diagnostic Test|Pupillometry|Monitoring of nociception and autonomic nervous system by pupillometry in intraoperative.
75870454|NCT03307837|Drug|CA-008|Local administration during surgery
75394543|NCT00639678|Drug|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
75394544|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
75394545|NCT00639678|Drug|placebo|40 mg/kg placebo, single dose (day 0), Group 4
75394546|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
75394547|NCT02914158|Drug|Goserelin|
75394548|NCT02914158|Drug|Tamoxifen|
75394549|NCT02914158|Drug|Aromatase Inhibitors|
75394550|NCT02914158|Drug|Leuprolide|
75394551|NCT02765802|Drug|Peginterferon Lambda-1A|
75394552|NCT05241132|Drug|Tislelizumab plus chemotherapy|"Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
75394553|NCT03132792|Genetic|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells
75394554|NCT05241054|Drug|Bupivacaine|With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
75394555|NCT05241054|Drug|Nitroglycerine|This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
75394556|NCT05241054|Drug|Propofol|General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
75394557|NCT05241054|Drug|Fentanyl|fentanyl 1 microgram.kg
75394558|NCT05241054|Drug|Atracurium Besylate|Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
75708405|NCT04835766|Diagnostic Test|Urodynamic study|Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).
75708406|NCT04829448|Dietary Supplement|Protein supplement|Protein supplement equivalent to Metagenics Ultrameal
75394559|NCT05241054|Procedure|Mechanical ventilation|Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg
75394560|NCT05241054|Drug|Sevoflurane|Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
75394561|NCT05241054|Drug|Lactated Ringers|Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
75394562|NCT05241054|Other|Head-up tilt|The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
75394563|NCT05241054|Drug|Paracetamol|paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
75394564|NCT04760106|Diagnostic Test|gastric ultrasound|"For the qualitative assessment, every participant was scanned once by both examiners. Each scan session lasted no longer than 5 minutes to mitigate the confounding effect of gastric emptying time.~For the quantitative assessment, the participants were put in a right lateral decubitus position and the antral cross-sectional area (CSA) is measured in the sagittal plane."
75394565|NCT05240820|Procedure|multi-layer wound closure|We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
75394566|NCT03182400|Behavioral|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
75394567|NCT03182400|Behavioral|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
75394568|NCT00638508|Drug|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
75394569|NCT00638508|Drug|Ketorolac and Ropivacaine|Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
75708407|NCT04825834|Other|Blood Sample Collection|Subjects enrolled in the DELFI-L101 will have blood specimens collected (~40 mL) at enrollment.
75708408|NCT04822064|Drug|Intranasal dexmedetomidine and ketamine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
75394570|NCT05240430|Drug|Mesenchymal Stem Cell Antigen-1, Human|Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies
75394571|NCT00637806|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
75394572|NCT00637806|Drug|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
75394573|NCT00637806|Drug|Placebo|Placebo oral suspension, 5 mL once daily
75394574|NCT04396782|Other|Physioterapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
75394575|NCT04396782|Other|standard physiotherapy rehabilitation|"static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.~This group will perform only five minutes of virtual reality play, but will not use their lower limbs. This way, the results of rehabilitation will not be affected and therapists and patients will be blinded."
76035816|NCT05043181|Biological|Low Density Lipoprotein Receptor mRNA Exosomes|"The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase."
75394576|NCT00637728|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
75394577|NCT00637728|Drug|Placebo|Placebo oral suspension, 5 mL once daily
75394578|NCT01922466|Procedure|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~1st week - SC 0.2cc/day, 2 days/week~2nd week - SC 0.4cc/day, 2 days/week~3nd week - SC 0.8cc/day, 2 days/week"
75394579|NCT01922466|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
75394580|NCT05248074|Other|High-fat meal (over 900 kcal)|High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.
75394581|NCT05248074|Drug|ABN401 (investigational product)|The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.
75394582|NCT00637572|Drug|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
75545880|NCT00300729|Drug|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
75545881|NCT00264719|Drug|Metoclopramide (Maxolon)|Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
75545882|NCT00264719|Drug|placebo|placebo 10 mg
75545883|NCT00264758|Device|Conventional hemodialysis|Three times per week in-center hemodialysis
75545884|NCT00264758|Device|Frequent hemodialysis|Six times per week in-center hemodialysis
75545885|NCT00264914|Drug|SR121463B|
75545886|NCT00300807|Drug|XTL 6865|
75394583|NCT00637572|Drug|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
75394584|NCT00637416|Drug|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
75394585|NCT00637416|Other|Placebo|placebo taken by mouth daily for 3 months
75394586|NCT03154320|Other|Same-Day Treatment|Treatment with ART or TB medication on day of HIV diagnosis
75394587|NCT03154320|Other|Standard treatment|Standard treatment
75394588|NCT00636792|Drug|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
75394589|NCT00636792|Drug|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
75394590|NCT00636792|Drug|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
75394591|NCT03558984|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
75545887|NCT00264953|Drug|Adriamycin|
75545888|NCT00264953|Drug|Bleomycin|
75545889|NCT00264953|Drug|Vinblastine|
75545890|NCT00264953|Drug|DTIC|
75545891|NCT00264953|Drug|Etoposide|
75545892|NCT00264953|Drug|Procarbazine|
75545893|NCT00264953|Drug|Prednisone|
75545894|NCT00264953|Drug|Vincristine|
75545895|NCT00264953|Radiation|radiation therapy|20 or 30Gy IF-RT
75545896|NCT00300846|Drug|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
75545897|NCT00300846|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
75545898|NCT00294996|Drug|Myocet|
75545899|NCT02960945|Drug|CTP-543, 16 mg (2 x 8 mg tablet)|
75545900|NCT02960945|Drug|Jakafi 15Mg Tablet|
75545901|NCT00265031|Drug|Cyclophosphamide|
75545902|NCT00265031|Drug|Adriamycin|
75545903|NCT00265031|Drug|Etoposide|
76035817|NCT03035981|Other|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
75394592|NCT03558984|Other|Standard of Care|"The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice."
75545904|NCT00265031|Drug|Procarbazine|
75545905|NCT00265031|Drug|Prednisone|
75545906|NCT00265031|Drug|Vincristine|
75545907|NCT00265031|Drug|Bleomycin|
75545908|NCT00265031|Procedure|radiation therapy|
75545909|NCT00300924|Drug|Rizatriptan co-administered with Acetaminophen|
75545910|NCT00265070|Drug|Gefitinib|250 mg tablet oral daily dose
75545911|NCT00295035|Drug|CELECOXIB|
75545912|NCT00295035|Drug|CURCUMIN|
75545913|NCT00418197|Device|Total Facet Arthroplasty System® (TFAS®)|
75708409|NCT04822064|Drug|Oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
75545914|NCT00295074|Procedure|neuropsychologic testing|
75708410|NCT04821843|Drug|Platinum based chemotherapy|q1-3W according to physician's preference
75708411|NCT04821843|Drug|Paclitaxel based chemotherapy|q1-3W according to physician's preference
75708412|NCT04821843|Radiation|Radiotherpay|40-50Gy/1.8-2.2Gy/20-25f
75708413|NCT04821843|Procedure|Surgery|Radical esophagectomy
76035818|NCT03035981|Other|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
76035819|NCT03035981|Other|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
76035820|NCT03035981|Other|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
76035821|NCT03035981|Other|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
75545915|NCT00265226|Biological|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
75545916|NCT00295113|Procedure|EFR|
75545917|NCT00265265|Drug|Atomoxetine|
75545918|NCT00418275|Genetic|Recombinant Human Plasminogen Activator (HTUPA)|
75545919|NCT00265304|Drug|Ketoprofen|
75545920|NCT00295152|Behavioral|community occupational therapy in dementia|
75545921|NCT00295191|Procedure|high-flux membrane|high-flux dialyser
75545922|NCT00295191|Procedure|low-flux membrane|low-flux dialyser
75708414|NCT04821843|Drug|Immunotherapy|Anti-PD-1/PD-L1 Antibody
75708415|NCT04821843|Drug|5-FU Analog based chemotherpay|W1-5 qW or d1-14, q3W according to physician's preference
75708416|NCT04821843|Drug|Nimotuzumab|200-400mg, d1,qW
75394593|NCT03108924|Drug|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
75394594|NCT04506918|Other|IVR survey|Participants will receive an IVR survey
75394595|NCT04506918|Other|SMS survey|Participants will receive a SMS survey
75394596|NCT04499508|Device|Optima Coil System|Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
75545923|NCT00295191|Procedure|conventional dialysate|conventional dialysate
75545924|NCT00295191|Procedure|ultrapure dialysate|ultrapure dialysate
75545925|NCT00265421|Procedure|Suture technique for perineal repair after delivery|
75545926|NCT00265460|Drug|Oliwer Twist smokeless tobacco (tobacco)|
75545927|NCT00300963|Drug|Talnetant|
75545928|NCT00265499|Procedure|Skeletonization of the internal thoracic artery|
75545929|NCT00295230|Procedure|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
75545930|NCT00301002|Drug|Alefacept|
75545931|NCT00265694|Drug|vinorelbine, gemcitabine and carboplatin|
75545932|NCT00301041|Other|laboratory biomarker analysis|
75545933|NCT00301041|Procedure|adjuvant therapy|
75545934|NCT00301041|Radiation|radiation therapy|
75545935|NCT00265733|Drug|capecitabine|
75545936|NCT00265733|Drug|paclitaxel poliglumex|
75545937|NCT00301158|Behavioral|exercise intervention|
75545938|NCT00301158|Other|counseling intervention|
75545939|NCT00301158|Other|educational intervention|
75545940|NCT00301158|Procedure|complementary or alternative medicine procedure|
75545941|NCT00295269|Drug|Mythylprednisolone|
75545942|NCT00265772|Drug|MODULEN IBD (R) (specific Enteral Nutrition)|
75545943|NCT00265772|Drug|prednisolon|
75545944|NCT00301197|Behavioral|Behavioral Skills Maintenance|
75545945|NCT00301197|Behavioral|Social Facilitation Maintenance|
75545946|NCT00265811|Drug|Folfox|
75545947|NCT00265811|Drug|Cetuximab|
75545948|NCT00295308|Drug|Clonidine|clonidine up to 0.3 mg/day oral
75545949|NCT00295308|Drug|Placebo|oral capsules daily
75545950|NCT00265928|Drug|bortezomib|
75545951|NCT00265928|Drug|rituximab|
75708417|NCT04821817|Drug|Normal saline|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
75870455|NCT03307837|Drug|Placebo|Local administration during surgery
75394597|NCT01922778|Procedure|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
75394598|NCT00636636|Drug|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
75708418|NCT04821817|Drug|Rocuronium|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
75394599|NCT00636636|Drug|Placebo|Once daily; 300 mg and 600 mg tablets
75708419|NCT04819191|Behavioral|SHARING Choices|SHARING Choices is a multicomponent communication intervention to proactively engage family members or friends and to support advance care planning in primary care
75394600|NCT05244954|Drug|Dihydroartemisinin-Piperaquine|Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.
75545952|NCT00265928|Procedure|antibody therapy|
75545953|NCT00265928|Procedure|biological therapy|
75545954|NCT00265928|Procedure|enzyme inhibitor therapy|
76035822|NCT03035981|Other|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
75545955|NCT00265928|Procedure|monoclonal antibody therapy|
75394601|NCT05244954|Drug|Chloroquine|Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.
76035823|NCT03035981|Other|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
76035824|NCT05035381|Drug|Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen|MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
75545956|NCT00295347|Drug|Spironolactone|
75394602|NCT00635778|Drug|dalotuzumab|Administered as an IV infusion over one to two hours
75394603|NCT04396470|Device|tVNS|Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.
76035825|NCT03035903|Device|Not holding, then holding the MedGem®|Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
75394604|NCT01929252|Drug|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
75394605|NCT01929252|Drug|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
75394606|NCT04275960|Drug|Selitrectinib (BAY2731954)|Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
75545957|NCT00295347|Drug|fludrocortisone|
75545958|NCT00295347|Drug|escitalopram|
75545959|NCT00265967|Drug|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
75545960|NCT00295386|Behavioral|Cognitive behavior therapy (CBT)|
75545961|NCT00295386|Drug|Zopiclone|
75545962|NCT00266006|Drug|eptacog alfa (activated)|
75545963|NCT00301236|Drug|Dexmethylphenidate HCl extended-release capsules|
75545964|NCT00295425|Drug|Cyclosporine A versus mycophenolate mofetil for psoriasis|
75545965|NCT00266123|Drug|Sirolimus|
75545966|NCT00301314|Procedure|Autologous stem cell transplant|
75545967|NCT00266162|Drug|Bosentan administration|
75545968|NCT00295464|Drug|Betamethasone sodium phos (drug)|
75545969|NCT00415766|Drug|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
75545970|NCT00415766|Drug|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
76035826|NCT03035903|Device|Holding, then not holding the MedGem®|Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
76035827|NCT05043025|Other|Identification of the cricothyroid membrane|The cricothyroid membrane is identified using a laryngeal handshake technique in different patient positions.
76035828|NCT04152187|Other|Inspiratory muscle training|The treatment group will receive inspiratory muscle training.
76035829|NCT04821323|Drug|Indomethacin|Indomethacin capsules will be administered orally.
75545971|NCT00415766|Drug|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
75545972|NCT00301353|Drug|Isoflavones-enriched foods|
75545973|NCT00301392|Other|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
75545974|NCT00301392|Drug|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
75394607|NCT04276038|Device|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
75545975|NCT00415844|Drug|ELC200 (carbidopa+levodopa+entacapone)|
75545976|NCT00301431|Drug|DVS-233|
75545977|NCT00415883|Drug|Valsartan|
75545978|NCT00301470|Device|MR urography|undergoing both renal scintigraphy and MR within a month
75545979|NCT00266240|Drug|GK Activator (2)|Escalating doses po bid
75545980|NCT00266240|Drug|Placebo|po bid
75545981|NCT00295542|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
75394608|NCT04275804|Device|Low Magnitude High Frequence Vibration Platform|with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement <0.1mm)
76035830|NCT04821323|Diagnostic Test|Lactulose-mannitol|Lactulose-mannitol solution will be administered orally.
76035831|NCT04821557|Dietary Supplement|Protease + Protein|Participant will consume a microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
75394609|NCT04275804|Other|Conventional Dressing|Alternate Day Dressing
75545982|NCT00295542|Procedure|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
75545983|NCT00295542|Drug|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
75545984|NCT00295542|Drug|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
75708420|NCT04816955|Behavioral|Dietary recommendations|Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
75394610|NCT00634920|Drug|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
75394611|NCT00634920|Drug|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
75545985|NCT00295542|Drug|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
75545986|NCT00295542|Drug|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
75545987|NCT00295542|Procedure|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
75545988|NCT00266318|Drug|Interferon Alfacon-1 and Ribavirin|
75545989|NCT00295581|Drug|PpPfs25/ISA51 & ScPvs25/ISA51|
75545990|NCT00266357|Drug|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
75545991|NCT00266357|Drug|Placebo / Duration of Treatment: 2 days for screening period|
75545992|NCT04719026|Other|Full-mouth periodontal examination using computerised Florida probe|It is an observational study to investigate the prevalence of periodontitis in cases and controls.
75545993|NCT00301509|Drug|peginterferon and ribavirin|
75545994|NCT00266396|Behavioral|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
75545995|NCT00266396|Behavioral|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
75545996|NCT00301548|Drug|perioperative chemotherapy|
75545997|NCT00266474|Other|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
75545998|NCT00295698|Drug|Diethylcarbamazine|
75545999|NCT00266552|Drug|risperidone|
75546000|NCT00301587|Drug|Norgestimate-ethinyl estradiol, with or without folic acid|
75546001|NCT00266591|Drug|topiramate|
75394612|NCT00634920|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
75394613|NCT00634920|Drug|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
75394614|NCT00634920|Drug|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
75394615|NCT01923012|Drug|Vitamin K2 (Menaquinone)|
75394616|NCT01923090|Drug|Finasteride|Finasteride 5mg once daily for 3 weeks
75394617|NCT01923090|Drug|Dutasteride|Dutasteride 0.5mg once daily for 3 weeks
75394618|NCT01929330|Drug|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
75394619|NCT01929330|Drug|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
75394620|NCT01929564|Other|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
75394621|NCT01929564|Other|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
75394622|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
75394623|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
75394624|NCT04396548|Drug|Midodrine Oral Product|Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.
75394625|NCT04396548|Drug|Inert tablet containing sugar (placebo)|: Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
75394626|NCT01923246|Behavioral|Single WEB intervention|Brief WEB intervention recieved once
75394627|NCT01923246|Behavioral|Repeated WEB intervention|WEB intervention recieved twice.
75394628|NCT01923246|Behavioral|Single IVR intervention|IVR intervention recieved once
75394629|NCT01923246|Behavioral|Repeated IVR intervention|IVR intervention recieved twice
75394630|NCT01923324|Behavioral|Physician telephone consultation|Pain physician support for family physician treating patient
75394631|NCT01923324|Behavioral|Usual family physician care|Usual family physician care without telephone consultation with pain physician
75394632|NCT04395456|Drug|AMY-101|C3 complement inhibitor
75394633|NCT04395456|Other|WFI 5% glucose|Placebo
75394634|NCT01929720|Behavioral|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
75394635|NCT01929798|Device|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
75394636|NCT01929954|Biological|Gintuit|One time placement of Gintuit over socket graft.
75394637|NCT01929954|Device|Bio-Gide|One time placement of Bio-Gide over socket graft.
75394638|NCT04395690|Procedure|Dental Implant Placement in the posterior mandible|Surgery done in the posterior mandible with missing teeth for placing dental implants.
75394639|NCT00633984|Behavioral|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
75546002|NCT00295737|Procedure|bronchoscopy, allergen/endotoxin instillation|
75546003|NCT04719299|Behavioral|Tell-Play-Do|Using smart phone application
76035832|NCT04821557|Dietary Supplement|Placebo + Protein|Participant will consume a placebo supplement (250 mg maltodextrin) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
75394640|NCT00633984|Drug|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
75394641|NCT00633984|Drug|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
75394642|NCT04395612|Drug|niraparib combined with brivanib|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
75394643|NCT04395612|Drug|niraparib combined with toripalimab|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.
75394644|NCT01923558|Drug|Donepezil|Donepezil Hydrochloride tablets,23 mg
75394645|NCT01920048|Procedure|Percutaneous Coronary Intervention|
75394646|NCT01920048|Drug|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
75394647|NCT01920048|Device|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
75394648|NCT01926990|Device|perfusion computed tomography|Undergo perfusion CT
75394649|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
75394650|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
75394651|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
75708421|NCT04815304|Diagnostic Test|peripheral lymphocytes subsets|The data were collected during the first and the second wave of epidemic in COVID-19 patients with acute respiratory distress syndrome. At the moment of hospitalization, at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans (lung ultrasound score, diaphragmatic thickness and motion), arterial blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation ), and pain assessed by using numeric rating scale. Macroscopic and microscopic hypopharynx and larynx damages were also evaluated by video-laryngoscopy and light miscoscopy.
76035833|NCT04434703|Procedure|Platelet rich fibrin (PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
76035834|NCT04434703|Procedure|Advanced platelet rich fibrin (A-PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
75394652|NCT01921218|Drug|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
75708422|NCT04811716|Drug|Pozelimab|Administered Sub-cutaneous (SC) per protocol
75394653|NCT01921218|Drug|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
75394654|NCT01921218|Drug|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
75394655|NCT01921218|Drug|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
75394656|NCT01920438|Procedure|Percutaneous Endoscopic Gastrostomy|PEG
75394657|NCT01920438|Procedure|Radiologically-guided insertion of Gastrostomy|RIG
75708423|NCT04811716|Drug|Cemdisiran|Administered SC per protocol
75708424|NCT04810611|Drug|MBG453|Anti-TIM3 monoclonal antibody
75708425|NCT04810611|Drug|NIS793|Anti-TGF-β monoclonal antibody
75394658|NCT00633750|Drug|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
75394659|NCT00633750|Genetic|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
75708426|NCT04810611|Drug|canakinumab|Anti-IL-1β monoclonal antibody
75708427|NCT04809324|Procedure|Gross examination of the resection specimen|measurement of the surgical margin by the operating surgeon using sterile scale, margins <7mm will be revised on table
75394660|NCT00633750|Genetic|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
75394661|NCT00633750|Other|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
75394662|NCT00633750|Other|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
75394663|NCT00633750|Other|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
75394664|NCT00633750|Other|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
75394665|NCT00633750|Other|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
75394666|NCT00633750|Procedure|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
75394667|NCT01922856|Biological|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
75708428|NCT04809324|Procedure|Frozen section|frozen section evaluation of the specimen by the pathologist
76035835|NCT04434703|Procedure|blood clot|following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
76035836|NCT03035825|Dietary Supplement|Oral moisturizing jelly|Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
76035837|NCT03035825|Other|Artificial saliva|A non-edible oral lubricating gel for dry mouth patients
76035838|NCT04834037|Behavioral|Behavioral|The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
75708429|NCT04809168|Other|Questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
75394668|NCT01922856|Other|No Intervention|Controls only receive challenge
75708430|NCT04797481|Procedure|Exercise|Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.
76035839|NCT05035069|Drug|Ciprofol|Ciprofol infusion, starting with 0.8 ~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 ~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
75394669|NCT00633360|Drug|Drospirenone and ethinyl estradiol|Once daily by mouth
75708431|NCT04797481|Procedure|Self-managed exercise|Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
75394670|NCT00633360|Drug|Placebo|Once daily by mouth
75394671|NCT00988260|Drug|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
75708432|NCT04796324|Drug|Ixabepilone Injection|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
76035840|NCT05035069|Drug|Propofol|Propofol infusion, starting with 4 ~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 ~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
76035841|NCT05035147|Drug|albumin-bound paclitaxel|Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle
76035842|NCT01668173|Drug|AUY922|AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
76035843|NCT05042713|Other|WaveOne Gold, One Curve, OneFlare|During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
76035844|NCT03036761|Procedure|Auriculotherapy|3 sessions of auriculotherapy at one month intervals.
75870456|NCT05065255|Device|SpeediCath® catheters|Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.
75394672|NCT00988260|Drug|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
75394673|NCT00988260|Drug|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
75870457|NCT04296799|Drug|SMP-100|SAD/MAD
75870458|NCT04296799|Drug|Placebo|Placebo
75870459|NCT03637933|Procedure|endoscopic tattooing|The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
75394674|NCT00633126|Drug|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
75394675|NCT00989664|Biological|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
75394676|NCT01923870|Drug|Androxal 25 mg|
75394677|NCT00632736|Drug|Ropinirole XL (formerly CR)|
75394678|NCT01923948|Drug|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
75870460|NCT03331315|Drug|Celecoxib|
75394679|NCT01923948|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
75394680|NCT00989196|Biological|Human-cl rhFVIII|50 IU/kg for PK dose
75394681|NCT00989196|Biological|Kogenate FS|50 IU/kg for PK dose
75394682|NCT04288362|Other|Intervention Group|Participants in this arm will undergo the new care model for management of diabetes mellitus polyclinics.
75394683|NCT04288362|Other|Control Group|Participants in this arm will continue to undergo the existing care model for management of diabetes mellitus in the polyclinics.
75394684|NCT03100110|Device|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
75394685|NCT00632502|Drug|Navarixin|Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
75394686|NCT00632502|Drug|Placebo|Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
75394687|NCT00632502|Drug|Rescue medication|Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
75394688|NCT00632424|Drug|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
75394689|NCT00631488|Drug|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
75394690|NCT00631488|Drug|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
75394691|NCT00631488|Drug|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
75394692|NCT00631488|Drug|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
75394693|NCT00631488|Drug|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
75870461|NCT03331315|Drug|Ketorolac|
75870462|NCT03329989|Biological|Collagenase Clostridium Histolyticum|During 3 treatment visits 12 injections will be given per treatment area
75870463|NCT03287869|Drug|Brexpiprazole|Brexpiprazole tablets
75870464|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
75870465|NCT02661490|Drug|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
75870466|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
75870467|NCT03287791|Drug|Generic Azelaic Acid Foam|Topical foam, generic formulation of the brand product.
75870468|NCT03287791|Drug|Finacea® (Azelaic Acid) Foam|Topical foam, brand product.
75870469|NCT03287791|Drug|Vehicle Foam|Topical foam, placebo. Has no active ingredient.
75394694|NCT00631488|Drug|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
75394695|NCT01924104|Drug|Low molecular weight heparin|2500 mIU/day, subcutaneously
75394696|NCT01924104|Drug|Low dose aspirin|75 mg/day, orally
75394697|NCT01924104|Drug|Heparin & aspirin|Aspirin (70 mg/day, orally) & heparin (40 mg/day, subcutaneously)
75394698|NCT01924104|Other|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
75394699|NCT00988884|Biological|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
75394700|NCT00988884|Biological|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
75394701|NCT00988884|Biological|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
75394702|NCT00988884|Biological|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
75870470|NCT03287791|Other|Cleanser|A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
75870471|NCT03287791|Other|Sunscreen|Sunscreen provided to participants, so they can apply it to their face when outdoors.
75394703|NCT00988884|Biological|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
75394704|NCT00631020|Behavioral|CBME|6 weeks of once a week one-on-one CBME
75394705|NCT00631020|Drug|Optional NRT|NicoDerm CQ nicotine transdermal patch
75394706|NCT00987402|Other|Plain soap and water (PSW)|Presence or absence of infection
75394707|NCT00987402|Other|Alcohol-based hand rub (ABHR)|Presence or absence of infection
75394708|NCT00630864|Drug|Fx-1006A|During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
75394709|NCT01924338|Device|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
75394710|NCT01924338|Device|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
75394711|NCT01924338|Procedure|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
75394712|NCT01924416|Behavioral|Enhanced Care (intervention group and comparison group)|Decision aid coupled with immediate QL-PRO results
75394713|NCT01924416|Behavioral|Usual care (routine chemotherapy cycles and imaging studies)|Usual care does not receive intervention
75394714|NCT00630786|Drug|Panitumumab|Administered by intravenous infusion
75394715|NCT00630786|Drug|Conatumumab|Administered by intravenous infusion
75394716|NCT00630396|Drug|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
75394717|NCT00636480|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
75394718|NCT00636480|Drug|ChloraPrep One Step|Administer topically
75546004|NCT04719299|Behavioral|Tell-Show-Do|Using traditional behavior management technique
75546005|NCT00301626|Behavioral|smoking reduction intervention (including NRT)|
75546006|NCT00301665|Biological|Botulinum toxin type A|
75870472|NCT03287791|Other|Towel|A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
75394719|NCT00636480|Drug|Sterile saline|0.9% NaCl solution
75394720|NCT01924572|Procedure|cord clamping at 2 minutes|
75870473|NCT03287791|Other|Moisturizing Lotion|Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
75870474|NCT02381002|Other|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
75394721|NCT01924572|Procedure|cord clamping at 5 minutes|
75546007|NCT00295776|Drug|Lamictal in the treatment of Post-Herpetic Neuralgia|
75546008|NCT00266669|Drug|Topical organogel with nitroglycerin|
75394722|NCT01924572|Procedure|cord milking|
75394723|NCT01924728|Device|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
75394724|NCT01924728|Device|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
75394725|NCT00985686|Other|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
75394726|NCT00635934|Device|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
75394727|NCT00630552|Other|Placebo|Inactive dummy of AMG 655.
75394728|NCT00630552|Drug|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
75546009|NCT00417924|Behavioral|Patient education|
75546010|NCT00266747|Drug|SR58611A|
75546011|NCT00418002|Drug|AQW051|
75546012|NCT00266786|Drug|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
75546013|NCT00266786|Drug|Intranasal Placebo|Intranasal Placebo
75546014|NCT00295815|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
75546015|NCT00295815|Drug|lomustine|100-130 mg/m2, oral once, every 6 weeks until PD
75546016|NCT00266981|Device|APOS - exercise component|
75546017|NCT00267137|Device|Pacing Algorithms|
75546018|NCT00295971|Biological|anti-thymocyte globulin|
75394729|NCT00630552|Drug|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
75394730|NCT01924962|Device|revascularisation|revascularisation of chronic occluded coronary artery
75394731|NCT03098394|Device|Cepheid Xpert CT/NG Rapid Turnaround Test|This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.
75394732|NCT03098394|Device|Polymerase chain reaction (PCR)|This is the standard of care for diagnosis of a suspected sexually transmitted infection.
75394733|NCT01920126|Drug|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
75394734|NCT01920126|Drug|Saline|
75394735|NCT00984594|Other|Primary injury site|Autograft will be placed in the primary defect site.
75394736|NCT00984594|Other|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
75394737|NCT01925118|Biological|Irradiated donor lymphocyte infusion|
76035845|NCT04821167|Procedure|laparoscopic orchiopexy for intra-canalicular testis|laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
76035846|NCT05054101|Other|Real-time assessment using the VieCovid2020 smartphone application|a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
76035847|NCT03036449|Behavioral|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation…..~Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists…"
76035848|NCT05034757|Other|HA only|HA injection only
76035849|NCT05034757|Other|ESWT once|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
75394738|NCT01925352|Drug|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
75394739|NCT01925430|Device|Screening device|Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
75394740|NCT01925430|Device|Comparative product|A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
75394741|NCT01920204|Drug|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
75394742|NCT00984204|Device|Therapy Cool Path Duo|All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
75394743|NCT04508010|Other|IVR|Participants will receive an IVR survey
75394744|NCT04508010|Other|CATI|Participants will receive a CATI survey
76035850|NCT05034757|Other|ESWT twice|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
75394745|NCT00983892|Behavioral|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
75394746|NCT02984202|Device|auditory midbrain implant (AMI)|
75394747|NCT04275258|Other|Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan|"PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed.~If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations.~If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation.~The collaborative pain care and opioid taper intervention ends at 20 weeks."
75546019|NCT00295971|Biological|therapeutic allogeneic lymphocytes|
75546020|NCT00295971|Drug|fludarabine phosphate|
75546021|NCT00295971|Drug|thiotepa|
75546022|NCT00295971|Procedure|allogeneic bone marrow transplantation|
75546023|NCT00295971|Procedure|allogeneic hematopoietic stem cell transplantation|
75394748|NCT01925664|Behavioral|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
75394749|NCT01925742|Other|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
75546024|NCT00295971|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75546025|NCT00295971|Radiation|total-body irradiation|
75394750|NCT01925742|Other|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
75546026|NCT00267176|Drug|lumiracoxib|
75546027|NCT00296010|Drug|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
75546028|NCT00296010|Drug|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
75870475|NCT03287635|Drug|Corticotropin 80Unit/Ml Repository Injection|H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
75394751|NCT01925742|Other|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
75394752|NCT01925742|Other|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
75546029|NCT00296010|Drug|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
75546030|NCT00296010|Procedure|adjuvant therapy|
75546031|NCT00296010|Radiation|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
75546032|NCT00267215|Drug|Lumiracoxib|
75546033|NCT00296049|Drug|daptomycin|
75546034|NCT00296049|Drug|vancomycin|
75546035|NCT00267254|Drug|torcetrapib/atorvastatin|
75546036|NCT00267254|Drug|simvastatin|
75546037|NCT00301782|Biological|bleomycin sulfate|
75546038|NCT00301782|Drug|carboplatin|
75546039|NCT00301782|Drug|cisplatin|
75546040|NCT00301782|Drug|etoposide phosphate|
75394753|NCT01925742|Other|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
76035851|NCT05034523|Radiation|MRI Voxel based morphometry|Voxel based morphometry through analysis of 3D T1 weighted sequence to assess total intracranial volume. All participants were scanned on the 1.5Tesla MR scanner (Achieva, Philips Medical Systems, Best, NL) with a 16-channel head coil at the diagnostic radiology department.
75546041|NCT00301782|Drug|vincristine sulfate|
75708433|NCT04787341|Drug|Regorafenib|"regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~RAS and BRAF wt ct-DNA at the time of screening."
75708434|NCT04787341|Drug|Panitumumab|"panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~RAS and BRAF wt ct-DNA at the time of screening."
75708435|NCT04786275|Drug|Fentanyl|Standard dose of 2 ug/kg after tetanic stimulation.
75708436|NCT04786275|Other|Tetanic stimulation|Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
75394754|NCT01925820|Drug|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
75394755|NCT01925898|Drug|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
75394756|NCT01925898|Drug|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
75394757|NCT00983580|Drug|Aspirin|Given PO
75708437|NCT04782284|Other|Comprehensive swallowing rehabilitation|The treatment time per session is 30 minutes. Total 12 sessions are provided for 6 weeks.
75708438|NCT04782284|Other|Swallowing education|The education is 30 minutes. Total 1 session is provided immediately after baseline evaluation.
75708439|NCT04748874|Procedure|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
75708440|NCT04745026|Drug|GWP42003-P|GWP42003-P oral solution (100 milligrams per milliliter [mg/mL] cannabidiol [CBD] in sesame oil with anhydrous ethanol, ethanol [10% v/v] sweetener [sucralose], and strawberry flavoring), administered twice a day (morning and evening)
75708441|NCT04745026|Drug|Placebo|Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
75394758|NCT00983580|Drug|Eflornithine|Given PO
75394759|NCT00983580|Other|Laboratory Biomarker Analysis|Correlative study
75708442|NCT04741009|Device|CI632 Slim Modiolar Electrode|Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode
76035852|NCT04427813|Behavioral|questionaire to husband and wife|a form of questions will be asked to every partner
76035853|NCT04834115|Drug|Ivermectin Tablets|Oral ivermectin at a one time dose
76035854|NCT04834115|Other|Placebo|Oral placebo at a one time dose
75394760|NCT00983580|Other|Placebo|Given PO
75394761|NCT00983580|Other|Telephone-Based Intervention|Ancillary studies
75394762|NCT01920672|Behavioral|Timed Planned Activity|
75394763|NCT01920672|Behavioral|Home Safety and Education Program|
75394764|NCT00982878|Drug|Maraviroc|150mg twice daily
75546042|NCT00267332|Drug|Modafinil|
76035855|NCT04820777|Other|perturbation training|external or internal postural perturbations. External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
76035856|NCT04820777|Other|Conventional' balance training|Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor. Rehash with your correct leg, exchanging to and fro between legs for a s
75394765|NCT00982488|Drug|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
75394766|NCT00982488|Drug|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
75394767|NCT00982410|Behavioral|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
75394768|NCT00982410|Behavioral|educational supportive group|A control condition providing social support and education about pain and/or drug use.
75394769|NCT00982020|Drug|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
75394770|NCT00982020|Behavioral|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
75558019|NCT03278990|Behavioral|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
76035857|NCT04821011|Device|electronic stethoscope|Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.
76035858|NCT04821011|Device|acoustic listening of mother's heartbeats|Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.
75870476|NCT02380924|Drug|DSP loaded RBC using EryDex System|Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
75870477|NCT02380924|Drug|Sham treated RBC using the EryDex System|Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
75546043|NCT00267410|Behavioral|Healthy Relationships|"Healthy Relationships, grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts."
75708443|NCT04738786|Procedure|1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers|"Surgical resection including 1.5 cm normal tissue around the gross tumors~Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side)."
75708444|NCT04738786|Procedure|1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers|Surgical resection including 1.0 cm normal tissue around the gross tumors
75708445|NCT04738734|Device|CellFX System Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
75708446|NCT04738734|Device|Cryosurgery Liquid Nitrogen Sprayer|Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.
75708447|NCT04738695|Diagnostic Test|Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)|Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
75870478|NCT04051918|Behavioral|Piano Training|Cognitive training via music learning
75870479|NCT03694405|Biological|MenACWY-CRM|Booster vaccination with MenACWY-CRM
75870480|NCT03694405|Biological|MenACWY-DT|Booster vaccination with MenACWY-DT
75394771|NCT00982020|Behavioral|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
75394772|NCT01926054|Drug|Acthar gel|
75394773|NCT01926132|Drug|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
75394774|NCT01926132|Drug|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
75394775|NCT02984358|Other|Animal protein based diet|
75394776|NCT02984358|Other|Low-nucleotide mycoprotein based diet|
75394777|NCT02984358|Other|High-nucleotide mycoprotein based diet|
75394778|NCT01920906|Procedure|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
75546044|NCT04718649|Drug|Celebrex with Joins or not|The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
75546045|NCT00301860|Biological|anti-thymocyte globulin|
75546046|NCT00301860|Biological|filgrastim|
75546047|NCT00301860|Biological|therapeutic allogeneic lymphocytes|
75394779|NCT01926210|Other|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
75394780|NCT01926210|Other|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
75394781|NCT01926288|Drug|Entecavir maleate tablets|
75394782|NCT01926288|Drug|blank Baraclude tablets|
75394783|NCT01926288|Drug|Blank maleate entecavir tablets|
75394784|NCT01926288|Drug|Baraclude tablets|
75394785|NCT01926366|Drug|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
75394786|NCT01926366|Drug|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
75394787|NCT00981084|Drug|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
75394788|NCT00980148|Drug|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
75394789|NCT00980148|Drug|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
75394790|NCT03064854|Drug|PDR001|Powder for solution for infusion
75394791|NCT03064854|Drug|Cisplatin|Intravenous infusion
75394792|NCT03064854|Drug|Gemcitabine|Intravenous infusion
75394793|NCT03064854|Drug|Pemetrexed|Intravenous infusion
75394794|NCT03064854|Drug|Carboplatin|Intravenous infusion
75394795|NCT03064854|Drug|Paclitaxel|Intravenous infusion
75394796|NCT03064854|Drug|Canakinumab|Subcutaneous injection
75546048|NCT00301860|Drug|cyclosporine|
75546049|NCT00301860|Drug|fludarabine phosphate|
75546050|NCT00301860|Drug|melphalan|
75546051|NCT00301860|Drug|methotrexate|
75546052|NCT00301860|Procedure|allogeneic hematopoietic stem cell transplantation|
75546053|NCT00301860|Procedure|peripheral blood stem cell transplantation|
75546054|NCT00267449|Device|SoftScan Optical Breast Imaging System|
75546055|NCT00301899|Biological|pertuzumab|
75546056|NCT00301899|Biological|trastuzumab|
75546057|NCT00267527|Drug|CJC 1295|
75546058|NCT00296127|Drug|Celecoxib|
75708448|NCT04733768|Diagnostic Test|18F-PSMA-1007|18f-PSMA-1007 PET/CT scan
75708449|NCT04728932|Drug|Levosimendan|A continuous infusion of Levosimendan over 24h
75394797|NCT01921530|Procedure|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
75394798|NCT01921530|Procedure|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
75546059|NCT00267566|Behavioral|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
75708450|NCT04728932|Drug|Placebo of Levosimendan|A continuous infusion of Placebo of Levosimendan over 24h
75394799|NCT01926678|Other|Swedish massage therapy|
75394800|NCT01926678|Other|Light touch therapy|
75394801|NCT01926756|Procedure|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
75394802|NCT01926756|Procedure|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
75546060|NCT00296166|Procedure|Catheter ablation|
75708451|NCT04718883|Biological|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 will be administered at dose level: 1 x 10^8 CAR+T cells
75708452|NCT04718129|Behavioral|Youth Mindful Awareness Program (YMAP)|The Mindfulness Intervention is an internet-based program that involves a coach. It is 9 weekly sessions and involves practicing the skills between sessions.
75870481|NCT03694405|Biological|MenACWY-TT|Booster vaccination with MenACWY-TT
75394803|NCT01926834|Drug|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
75394804|NCT01926834|Drug|placebo|normal saline, 500ml,i.v.,qd, for 7 days
76035859|NCT04821011|Device|Recording of the newborn's heart rate|"Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used."
76035860|NCT01505465|Drug|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
76035861|NCT01505465|Drug|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
76035862|NCT05618015|Procedure|Supervised progressive resistance training|Exercises were performed with cable resistance training machine
75546061|NCT00296166|Procedure|Thoracoscopic epicardial ablation|
75546062|NCT00267605|Behavioral|FHPADHD|Evidence-based psychological and behavioural distance intervention
76035863|NCT05618015|Procedure|Home-based progressive resistance training|In the first session, with the help of a physiotherapist, strengthening exercises were shown and taught to the patients. Two weeks after the beginning of the home-based PRT program, patients were called to check whether they were doing the exercises in the home program correctly. After the checking for exercise training, the patients were called by phone every two weeks for follow-up.
75870482|NCT03287089|Drug|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
75394805|NCT01921608|Device|PrePex™ device|PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
75394806|NCT01926912|Drug|No intervention|This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
75546063|NCT00267605|Behavioral|ADHD Standard Care|
75870483|NCT03287089|Drug|Placebo Oral Tablet|Matching placebo
75870484|NCT02380768|Device|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
75394807|NCT04395378|Device|Continuous Glucose monitoring DEXCOM G6|Continuous glucose monitoring during flight and normal living life
75546064|NCT00296205|Drug|Cyclophosphamide|
75546065|NCT00296283|Behavioral|integrative behavior couples therapy|
75546066|NCT00267722|Drug|Visilizumab|
75546067|NCT00301938|Drug|7-hydroxystaurosporine|Given IV
75546068|NCT00301938|Drug|perifosine|Given orally
75870485|NCT02380768|Device|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
76035864|NCT04833881|Other||
76035865|NCT04833803|Behavioral|eBLISS|a novel instrument -Eating Behaviour Lapse Inventory Survey Singapore (eBLISS)- will be developed
76035866|NCT04833647|Diagnostic Test|Cardio-Pulmonary-Exercise-Testing (CPET)|Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
76035867|NCT05617937|Other|Massage|The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
75546069|NCT00301938|Other|pharmacological study|Correlative studies
75546070|NCT00267839|Behavioral|physical exercise, wellness|
75546071|NCT00296361|Drug|Tacrolimus|immunosuppression
75546072|NCT00296439|Behavioral|Behavior|
75546073|NCT00415922|Drug|ELC200 (carbidopa+levodopa+entacapone)|
75546074|NCT00302016|Drug|AMN107|
75870486|NCT02384980|Device|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
75870487|NCT02385136|Drug|Temozolomide|
75870488|NCT02380534|Procedure|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
75394808|NCT03385512|Behavioral|OPEN High Touch|This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.
75394809|NCT03385512|Behavioral|OPEN High Tech|The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
75394810|NCT03385512|Behavioral|ASK Poster in Exam Rooms|This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
75394811|NCT01921764|Behavioral|Workplace physical exercise|
75394812|NCT01921764|Behavioral|Home physical exercise|
75394813|NCT00983814|Drug|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID, provided as oral capsules taken TID from Baseline to end of Week 8
75394814|NCT00983814|Drug|Placebo|Placebo matched oral capsules taken TID from Baseline to end of Week 8
75394815|NCT01921842|Behavioral|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
75394816|NCT03088332|Procedure|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
75394817|NCT01921920|Drug|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
76035868|NCT04820543|Drug|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
76035869|NCT04816487|Drug|Potassium Iodide or Glutathione|Patient will receive either Glutathione or Potassium iodide
75546075|NCT00415961|Device|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
75870489|NCT02375932|Behavioral|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
75870490|NCT02375932|Behavioral|Usual Care Control|Patients continue to receive usual care from their primary care provider
76035870|NCT04360577|Procedure|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
76035871|NCT04831229|Other|Children will perform activities on interactive tablet|AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.
75394818|NCT04275414|Drug|Bevacizumab Injection|Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
75394819|NCT04395924|Diagnostic Test|Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta|"During labor and delivery~Sample of amniotic fluid~2 samples of blood cord after the birth of the new born~2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)"
75394820|NCT04395144|Procedure|Awake Prone Positioning|Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h
75394821|NCT04395144|Procedure|Standard care|Patients will not receive any special instructions with regards to proning.
75546076|NCT00416039|Drug|Midazolam|0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
75546077|NCT00416039|Drug|Placebo|placebo at 0.2 mg/kg and morphine 0.5 mg/kg
75546078|NCT00296478|Drug|Endometrin|Endometrin 100mg BID x 10weeks
75546079|NCT00296478|Drug|Endometrin|Endometrin 100mg TID x 10weeks
75870491|NCT03113188|Drug|CBP501|CBP501, CDDP plus Nivolumab
75870492|NCT02376322|Radiation|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
76035872|NCT04831229|Other|Children will perform passive on interactive tablet|"The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions."
76035873|NCT04830371|Biological|EuTCV (Vi-CRM Typhoid conjugate vaccine)|Single dose, Intramuscular administration
76035874|NCT04830371|Biological|Typbar-TCV|Single dose, Intramuscular administration
76035875|NCT04820699|Other|post isometric relaxation and muligan bent leg raise|6 week intervention
76035876|NCT04820699|Other|muligan bent leg raise|muligan bent leg raise
76035877|NCT04830293|Procedure|Carotis Doppler Ultrasound|Neck was rotated about 30-45 ° to the opposite side of the image. The common carotid artery and internal jugular vein were viewed transversely on the B Mode USG image. Then, the probe was rotated approximately 90 ° and the carotid artery was visualized in the longitudinal plane. The probe and guide line were adjusted so that the Doppler angle was 60 °. The image was created with the guiding line parallel to the blood flow. After imaging of the carotid artery bifurcation, measurements were made 1 cm distal to this level.
76035878|NCT04816409|Other|conventional therapy|"Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing~- Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,"
76035879|NCT04816409|Other|Neurodevelopmental therapy|"Starting Posture~Start and evaluate the supreme effective posture to move from(usually straight)~Reassemble to mid plane (head/trunk)~Neutral position of body (47) Identify the Missing Components Detect starting posture and compare to normal.(47)~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.(48) 2. Developmental movement patterns training: Obstacle crawl, hold swing's ropes in kneeling and half kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of~li"
76035880|NCT04820465|Other|Non available due to cross-sectional study design|Non available since this study (survey) has a cross-sectional design
75394822|NCT04395768|Dietary Supplement|Vitamin C|In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)
75394823|NCT04395768|Drug|Hydroxychloroquine|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
75394824|NCT04395768|Drug|Azithromycin|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
75394825|NCT04395768|Dietary Supplement|Zinc Citrate|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
75394826|NCT04395768|Dietary Supplement|Vitamin D3|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
75394827|NCT04395768|Dietary Supplement|Vitamin B12|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
75394828|NCT04396158|Radiation|radioactive iodine|80-200 mCi of radioactive iodine will be given to thyroid cancer patients
75394829|NCT01927224|Drug|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
75394830|NCT01927224|Drug|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
75546080|NCT00296478|Drug|Crinone|Crinone QD x 10weeks
75546081|NCT00302172|Drug|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
75394831|NCT01927224|Drug|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
75394832|NCT03831750|Other|Stress Reduction Intervention|The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
75394833|NCT01921998|Procedure|Biomarker and health economics|Biomarkers CK18 and FLT3 Ligand will be collected
75394834|NCT01927458|Device|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
75394835|NCT04396080|Procedure|Partial restoration in posterior teeth|Teeth in need of onlays that will be treated with this type of treatment, choosing the most suitable material for each patient and following the manufacturer's instructions for their cementing and adhesion.
75394836|NCT01927536|Device|White LED Flashlight|white light setting
75394837|NCT01927536|Device|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
75394838|NCT01927614|Radiation|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~Prospectively gated calcium scoring.~Stress-myocardial CT perfusion.~Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
75394839|NCT01927692|Other|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
75394840|NCT01927692|Other|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
75394841|NCT01922154|Drug|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
75394842|NCT01922154|Procedure|Trabeculectomy with mitomycinC|All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
75546082|NCT00268151|Drug|Oxaliplatin|
75708453|NCT04716400|Behavioral|Stop sexual harassment|Teachers will be introduced to a digital course on the prevention of sexual- and gendered harassment. In the course they will provided with a manual containing eight lessons to be held for the pupils. Each lesson will last 45 minutes and consist of a short lecture and practical activities for the pupils.
75870493|NCT02375776|Other|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
75546083|NCT00268151|Drug|Capecitabine|
75546084|NCT00418080|Drug|bicalutamide|
75546085|NCT00296556|Drug|Rivenprost (drug)|
75546086|NCT00268229|Drug|cytarabine|300 mg/m2/day
75546087|NCT00268229|Drug|daunorubicin hydrochloride|45 mg/m2/day
75546088|NCT00268229|Drug|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
75870494|NCT02376244|Other|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
75546089|NCT00302250|Drug|ALT-711 (alagebrium chloride)|
75546090|NCT00268307|Drug|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
76035881|NCT04816331|Other|Medical records and clinical measurements|"Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling."
76035882|NCT04830059|Behavioral|Exercise|Two types of exercise intervention and control group
75394843|NCT04554576|Behavioral|Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish|"The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)"
75394844|NCT04554576|Behavioral|Remote feedback active group|After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)
75394845|NCT04554576|Behavioral|Remote feedback control group|After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.
75394846|NCT03060642|Device|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
75394847|NCT03060642|Device|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
75546091|NCT00302289|Drug|tyrosine, green tea, caffeine|
75708454|NCT04712643|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.
75708455|NCT04712643|Drug|Becavizumab|Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.
75708456|NCT04712643|Device|Transarterial chemoembolization (TACE)|TACE will be performed by clinical demand.
75708457|NCT04710641|Drug|MTL-CEBPA|Administered once every 3 weeks on Day 1 of each 3 week cycle.
75708458|NCT04710641|Drug|Sorafenib|Oral adminstration twice a day
75708459|NCT04707599|Other|Reminder plus (telephone call from therapist)|Reminder plus (telephone call from therapist)
75708460|NCT04707196|Drug|Abemaciclib|Administered orally
75708461|NCT04707196|Drug|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole or anastrozole administered orally (physician choice)
75708462|NCT04707196|Drug|Fulvestrant|Administered intramuscularly
76035883|NCT04830059|Behavioral|Air purification|Air purification in order to reduce the PM2.5 and PM10
76035884|NCT04820621|Drug|Runcaciguat (BAY1101042)|Given as 1 x 15 mg modified release [MR] tablet
76035885|NCT04816253|Drug|Normal saline|Normal saline irrigation and No other drug placed after extraction
76035886|NCT04816253|Drug|Hyaluronic acid|Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
75546092|NCT00268502|Other|study of socioeconomic and demographic variables|
75546093|NCT00268502|Procedure|fatigue assessment and management|
75546094|NCT00268502|Procedure|management of therapy complications|
75546095|NCT00268502|Procedure|psychosocial assessment and care|
75546096|NCT00268502|Procedure|quality-of-life assessment|
75546097|NCT00296595|Behavioral|Nutrition|
75546098|NCT00268541|Behavioral|Physical activity|
75546099|NCT00296634|Drug|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
75708465|NCT04693858|Behavioral|Child Anxiety Learning Modules (CALM)|CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
76035887|NCT04816253|Drug|Methylprednisolone|Methylprednsolone will be injected half an hour preoperatively
76035888|NCT04816253|Drug|Methylprednisolone and Hyaluronic acid|Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
75708466|NCT04693858|Behavioral|Child Anxiety Learning Modules--Relaxation (CALM-R)|CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
75870495|NCT02376244|Other|Standard care|Standard care cardiac rehabilitation according to current guidelines
76035889|NCT04820231|Other|intra-articular PRP injection|
76035890|NCT04816097|Drug|Dexamethasone phosphate|4 doses of dexamethasone 6mg IM 48h before elective CS.
76035891|NCT04815941|Other|Soft ball tissue release exercises|"Exercise program were given to patients with low back pain secondary to hip muscle tightness using soft balls, i.e. tennis balls plus core stability exercises.~3 days a week for four weeks."
76035892|NCT04363619|Diagnostic Test|OCT and OCTA|Fundoscopy, OCT and OCTA will be performed 4 times in patients
75394848|NCT01927848|Dietary Supplement|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
75394849|NCT01927848|Dietary Supplement|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
75546100|NCT00296634|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
75546101|NCT00268580|Behavioral|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
75546102|NCT00268619|Drug|Ramipril|
75546103|NCT00296673|Device|Rehabilitation device|
75546104|NCT00268658|Device|SmartStep(tm) biofeedback device|
75546105|NCT00296712|Drug|escitalopram + bupropion|same dosing as for monotherapy arms
75546106|NCT00268697|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
75546107|NCT00268697|Drug|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
75546108|NCT00268697|Drug|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
75546109|NCT00296751|Procedure|ECG recording|
75546110|NCT00296751|Procedure|Epidural catheter insertion|
75546111|NCT00296751|Drug|Intravenous meperidine injection|
75546112|NCT00296751|Drug|Epidural Bupivacaine and fentanyl injection|
75546113|NCT00268775|Behavioral|training and follow-up of pharmacists|
75546114|NCT00268775|Behavioral|patient-directed discontinuation letter|
75546115|NCT00302367|Drug|OROS methylphenidate hydrochloride|
75546116|NCT00302367|Drug|immediate release methylphenidate hydrochloride|
76035893|NCT04363073|Device|Annabella Breast Pump|Milk will be expressed using Annabella breast pump for 4 consecutive days (at least 24h apart)
75546117|NCT00296790|Drug|zolpidem tartrate|
75546118|NCT02961296|Other|No intervention|No intervention will be needed.
75546119|NCT00302406|Drug|methylphenidate hydrochloride|
75546120|NCT00302406|Drug|OROS methylphenidate hydrochloride (CONCERTA)|
75708467|NCT04691518|Other|Acute Intermittent Hypoxia|30 minute session of Acute Intermittent Hypoxia
75708468|NCT04691518|Other|Sham Acute Intermittent Hypoxia|30 minute session of Sham Acute Intermittent Hypoxia
76035894|NCT04363073|Device|Control Breast Pump|Milk will be expressed using Control breast pump for 4 consecutive days (at least 24h apart)
75708469|NCT04691206|Other|briefing objectives, intraoperative teaching, and debriefing feedback|A standardized step-wise operative curriculum amongst general surgeons will be implemented among all general surgery residents. Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID).
75558020|NCT03278990|Behavioral|Control writing exercise|In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
75558021|NCT03279744|Drug|Radion™-pdt|The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm^2 and properly cover the entire lesion.
75394850|NCT01927926|Dietary Supplement|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
75394851|NCT01927926|Dietary Supplement|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
75394852|NCT01922310|Behavioral|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
75394853|NCT04552470|Drug|Placebo|3 matching placebo tablets taken twice a day (BID)
75394854|NCT04552470|Drug|PF-06882961|Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
75394855|NCT04550130|Device|TLA Gut™|The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.
75394856|NCT04556916|Diagnostic Test|Blood sample|"Per patient 49 ml of peripheral blood sample :~21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation."
75394857|NCT03423342|Dietary Supplement|nicotinamide riboside|nicotinamide riboside capsule
75394858|NCT03423342|Drug|Placebo|matching placebo capsule
75394859|NCT01928160|Drug|pemetrexed disodium|Given IV
75394860|NCT01928160|Drug|carboplatin|Given IV
75708470|NCT04675164|Device|Laser Assisted Immotile Sperm Selection|LAISS will be performed using diode laser system at the lowest working power with a single laser shot at the lower one third of the sperm tail. If sperm tail curling occurred, the sperm is then viable and will be utilized for ICSI after immobilization in PVP.
75708471|NCT04675164|Procedure|Hypo-osmotic Swelling Test|HOST will be performed by transferring immotile sperms from incubation droplet into HOST droplet, with any sperm showing tail swelling will be identified as viable and will be utilized for ICSI after immediate transfer and immobilization.
75708472|NCT04667663|Drug|Daratumumab|Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.
75708473|NCT04667663|Drug|Cyclophosphamide|Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
75708474|NCT04667663|Drug|Pomalidomide|Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.
75708475|NCT04667663|Drug|Dexamethasone|Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
75394861|NCT01928160|Drug|cisplatin|Given IV
75394862|NCT01928160|Drug|erlotinib hydrochloride|Given PO
75394863|NCT01928160|Other|laboratory biomarker analysis|Correlative studies
75394864|NCT04274946|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.
75394865|NCT01928238|Device|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
75394866|NCT01928238|Device|Noninvasive pressure support ventilation (NPSV)|
75394867|NCT01928316|Drug|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
75558022|NCT03278951|Behavioral|Video Conferencing Group|
75558023|NCT03278951|Behavioral|In Person Group|
75558024|NCT03279705|Device|Water jet channel|The separate water jet channel was used for infusing water.
75558025|NCT03279705|Device|Accessory channel|The accessory channel was used for infusing and/or suctioning water
75558026|NCT03278834|Device|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
75558027|NCT03278834|Device|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
75394868|NCT01928316|Drug|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
76035895|NCT04820153|Device|Physical Activity Monitoring Device|Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.
75708476|NCT04659863|Drug|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
76035896|NCT04820153|Behavioral|Lifestyle Redesign Coaching|Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
76035897|NCT04819529|Behavioral|Early and Intensive Occupational Therapy|"Occupational therapists will implement the following activities:~Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 1 one session each 48 h and SAS 2 one session each 24 h.~Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS <2, 6> environmental orientation will be considered~Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~Education: daily visits by trained family members and health staff about the intervention process"
76035898|NCT04829825|Diagnostic Test|18F-GP1 PET/MR|Patients will receive 1-3 18F-GP1 PET/MR
76035899|NCT04815863|Diagnostic Test|Assessment of somatic symptom disorder with SSS-CN|SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms
76035900|NCT04815863|Diagnostic Test|Assessment of depressive symptoms disorder with PHQ-9|PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms
76035901|NCT04815863|Diagnostic Test|Assessment of anxiety disorder with GAD-7|GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
76035902|NCT04815629|Radiation|Radiotherapy|Radiotion therapy squamous cell carcinoma in cancer bladder
76035903|NCT03035591|Drug|ODM-207|
76035904|NCT04819685|Drug|KANG FU PEN|FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
76035905|NCT04819607|Other|model of care|Multidisciplinary model of care for BMFS patients.
75870496|NCT03286543|Device|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
75870497|NCT02380846|Other|White rice|Control - white rice
75394869|NCT04346472|Other|Repeated Measurements of the relative regional cerebral blood volume|Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
75394870|NCT04551846|Dietary Supplement|Oligomeric enteral feeding|Oligomeric enteral feeding will be administered to the PICU patients
75546121|NCT02961023|Other|Exercise therapy|"3-week residential phase and 12-week outpatient phase.~Residential phase~Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~1.5 to 2 hours of exercise will be performed daily, with rest intervals.~At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~Participants will be provided with a cycle ergometer, weights and a HR monitor~Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary"
75546122|NCT00302445|Drug|Efalizumab|
75870498|NCT02380846|Other|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
75394871|NCT04551846|Dietary Supplement|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
75546123|NCT00302445|Device|Narrow Band Phototherapy|
75394872|NCT04550520|Diagnostic Test|Glucagon|Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
75394873|NCT04550520|Diagnostic Test|Placebo|As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
75394874|NCT04759482|Diagnostic Test|polysomnography|Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
75394875|NCT01928628|Drug|Lercanidipine 10mg|
75394876|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg|
75394877|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg|
75394878|NCT01928628|Drug|Lercanidipin 10mg Placebo|
76035906|NCT02600351|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
76035907|NCT02600351|Drug|RBV|Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75394879|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg Placebo|
75394880|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg Placebo|
75394881|NCT01928706|Other|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
76035908|NCT02640235|Device|CELSTAT|
76035909|NCT02640235|Device|Surgicel Original|
76035910|NCT05053789|Device|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
76035911|NCT05053789|Device|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
76035912|NCT04829435|Drug|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
76035913|NCT04829435|Drug|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
76035914|NCT05042635|Drug|Ixekizumab+Jueyin Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
76035915|NCT05042635|Drug|Ixekizumab+Jueyin placebo Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
75394882|NCT01928706|Other|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
75394883|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
75394884|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
75394885|NCT03084900|Other|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
75394886|NCT01929096|Drug|Compound Edaravone Injection|
75394887|NCT01929096|Drug|Edaravone Injection|
75546124|NCT00268814|Drug|Diacetylmorphine|Diacetylmorphine (i.v.), daily
76035916|NCT04815395|Drug|Oxytocin|Administration of oxytocin (24IU) orally
76035917|NCT04815395|Drug|Oxytocin|Administration of oxytocin (24IU) intranasally
76035918|NCT04815395|Drug|Placebo|Administration of placebo orally
76035919|NCT04819139|Other|Active Excersises|Active thumb exercises
76035920|NCT04819139|Other|Reeducation ADL|Reeducation in the activities daily life
75394888|NCT05600790|Behavioral|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
75546125|NCT00268814|Behavioral|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
75546126|NCT00268814|Drug|Methadone|Methadone (p.o.), daily
76035921|NCT04819139|Other|Joint protection|Used of a thumb orthosis
76035922|NCT04819139|Other|Proprioception exercises|Specific proprioception exercises
76035923|NCT05034679|Biological|Vcinated|Patients who were vacinated.
75394889|NCT03059004|Behavioral|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
75708477|NCT04659863|Drug|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
75708478|NCT04657354|Procedure|Assessment|Early surgical assessment
75394890|NCT03059004|Behavioral|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
75394891|NCT03059004|Behavioral|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
75708479|NCT04655573|Procedure|Breast Cancer Tumor Resection|Patients with ABC will be receiving a biopsy, and a PDMO from the patient's biopsies will be generated from it. It is a model correlating clinical response with PDMO sensitivity to the most common forms of chemotherapy used in advanced breast cancer care.
76035924|NCT03096691|Device|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
76035925|NCT03096535|Procedure|Cooling|Individualized cooling protocol.
75394892|NCT03059004|Behavioral|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
75394893|NCT04554888|Drug|Doxepin Topical|Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
75394894|NCT04554888|Drug|Papain|Papain will be applied by 1 SPT prick thought the skin
75394895|NCT04554888|Drug|Histamine|Histamine will be applied by 1 SPT prick thought the skin
75394896|NCT04554888|Other|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
75558028|NCT00477399|Behavioral|The Evje Model|
75558029|NCT04700813|Diagnostic Test|search for rare pathogenic mutations|search for rare pathogenic mutations causing diabetes type 2
75558030|NCT00477477|Other|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
75558031|NCT00477477|Other|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
75558032|NCT00442325|Drug|Atorvastatin (Lipitor)|
75558033|NCT00439764|Behavioral|General health talk|Routine clinical practice and talk on general health
75558034|NCT00439764|Behavioral|Handout of The Back Book|Talk on health of the back and handout of The Back Book
75394897|NCT04553016|Biological|Vaccine|IM vaccination with ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4
75394898|NCT04553016|Biological|Placebo|IM administration of 0.9% sterile sodium chloride solution
75394899|NCT03374592|Radiation|Volumetric Intensity-Modulated Arc Therapy|Advanced radiotherapy technique
76035926|NCT03096535|Procedure|Thermoneutral|Thermoneutral control day.
75708480|NCT04652076|Drug|NP137|Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
75546127|NCT00268814|Behavioral|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
76035927|NCT05034445|Diagnostic Test|Next generation sequencing|Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
76035928|NCT05034211|Procedure|Programmed intermittent bolus epidural|one arm will receive programmed intermittent boluses of local anesthetic via the epidural catheter on fixed time intervals. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
76035929|NCT05034211|Procedure|Provider administered analgesia on patient request|one arm will receive bolus of local anesthetic via the catheter upon patient request. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
76035930|NCT02599961|Drug|UX007|UX007 is a liquid intended for oral (PO) administration.
76035931|NCT03096301|Device|Low-intensity laser|Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
75708481|NCT04652076|Drug|Pembrolizumab|Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
75708482|NCT04652076|Drug|Paclitaxel|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
75708483|NCT04652076|Drug|Carboplatin|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
75708484|NCT04640480|Drug|SNB-101|SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
75708485|NCT04637698|Biological|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
75394900|NCT03374592|Radiation|Conventional Radiotherapy|Conventional radiotherapy technique
75708486|NCT04632758|Drug|WX-0593 Tablets|tablets, 60 mg→180mg, QD
76035932|NCT03096301|Device|occlusal plates|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
75394901|NCT04553406|Drug|SPR720|Capsules for oral administration
75394902|NCT04553406|Drug|Placebo|Capsules for oral administration
75394903|NCT04553406|Drug|Open-label Standard of Care|"Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days."
75394904|NCT04395300|Other|Web Based Survey|On line survey distributed electronically
75546128|NCT00296829|Biological|Inactivated, split-virion influenza vaccine|
75708487|NCT04632758|Drug|crizotinib|Capsules, 250mg, BID
75708488|NCT04629209|Drug|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
75708489|NCT04627285|Drug|Lacosamide|"Pharmaceutical form: Oral-solution~Route of administration: Oral use~Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period."
75708490|NCT04618315|Device|Hearing Aids|Receiver-in-the-ear hearing aids.
75708491|NCT04600362|Drug|Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Subcutaneous
75708492|NCT04597658|Behavioral|Bodyweight supported treadmill training (BWSTT)|In the BWSTT group, walking training will be given by asking the patients to walk on the treadmill as fast as they can, without exceeding the medium intensity according to the Borg scale. Bodyweight support will be gradually reduced according to the patient's tolerance.
75870499|NCT02380846|Other|Rice with fish|Treatment 2 - steamed white rice with steamed fish
75870500|NCT02380846|Other|Rice with egg white|Treatment 3 - steamed white rice with egg white
75394905|NCT04124796|Other|Semi-structured interviews|Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
75394906|NCT04124718|Genetic|high caries experience|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
75394907|NCT04394052|Diagnostic Test|MR imaging|Medical imaging
75394908|NCT05601960|Other|anti-acne dermocosmetic|Topical application once daily for 2 months
75546129|NCT00268853|Drug|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
75546130|NCT00268853|Drug|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
75394909|NCT05605002|Drug|SSRIs|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
75394910|NCT05605002|Procedure|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
75394911|NCT05605002|Procedure|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20*1.5mm or φ0.20*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
75546131|NCT00302484|Drug|Zoledronate|
75546132|NCT00296868|Drug|ascorbic acid (vitamin C) versus placebo|
75546133|NCT00268931|Behavioral|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
75708493|NCT04597658|Behavioral|Conventional rehabilitation|The conventional rehabilitation program includes posture and breathing exercises, lower extremity stretching, active-assistive range of motion and strengthening, balance-coordination exercises, and walking with a physiotherapist on a smooth surface.
75870501|NCT02380846|Other|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
75546134|NCT00268931|Behavioral|Social Training|This group underwent special social interactions with their parents two times each day.
75708494|NCT04596384|Other|Best Practice|Participate in a surgeon-only perioperative care program
75870502|NCT02380222|Other|Interview|Single interview lasting approximately one hour
76035933|NCT03096301|Device|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
76035934|NCT04829513|Other|kinesio taping|In kinesiology taping with the inhibition method, an I-shaped tape of 15-20 cm in length will be applied on the sacroiliac joint on both sides without stretching the ends with 50% stretching in the middle. In addition, a 25-30 cm long I band will be applied over the right spina iliaca posterior superior, towards the left spina iliaca posterior superior. In the facia correction technique, 2 bands with no cut ends, a 10-15 cm web-shaped band divided into 4 or 5 parts with a width of 1-15 cm will be applied cross over the sacroiliac joint, without stretching the ends with 50% stretching in the middle.
76035935|NCT05033977|Other|Exercise (center-based)|Exercise therapy with a physical therapist in a clinic.
75546135|NCT00296907|Behavioral|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
75870503|NCT03306433|Device|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
75870504|NCT02380144|Other|Fresh orange fruit and pasteurized fruit juice|
76035936|NCT05033977|Other|Exercise (home-based)|Patients did exercises at home every day and 3 times per day.
76035937|NCT05034055|Drug|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
76035938|NCT05617703|Drug|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes
76035939|NCT03095365|Other|Dry needling|Insertion of solid filament needles in the muscle
75708495|NCT04596384|Procedure|Functional Assessment|Complete a functional assessment
76035940|NCT03095365|Other|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
75546136|NCT00268970|Drug|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
76035941|NCT03095365|Other|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
76035942|NCT03096613|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
75546137|NCT00296946|Drug|ipratropium bromide (drug)|
76035943|NCT05042245|Drug|Ornithine aspartate granule|Ornithine aspartate granules in the experimental arm.
76035944|NCT05042245|Drug|Silymarin capsule|Silymarin capsules in the active comparator arm.
76035945|NCT05042245|Drug|Silymarin capsule simulant|Silymarin capsule simulant in the experimental arm.
76035946|NCT05042245|Drug|Ornithine aspartate granule simulant|Ornithine aspartate granule simulant in the active comparator arm.
76035947|NCT04427657|Procedure|autologous microfragmented lipoaspirate tissue (Lipogems®).|patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
76035948|NCT04427657|Procedure|arthroscopic debridment|patient in supine position. Under sedation is perform an arthroscopic debridement
76035949|NCT03035669|Behavioral|Mindfulness group|8 week program
75394912|NCT05604846|Dietary Supplement|ProPrems|The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
75546138|NCT00269009|Behavioral|CHERL|
76035950|NCT03035669|Behavioral|Reading group|8 week program
76035951|NCT03095209|Drug|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
76035952|NCT03095209|Drug|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
75394913|NCT04124484|Drug|DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
75394914|NCT04124484|Drug|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
75394915|NCT04124484|Drug|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
75546139|NCT00296985|Device|Fresenius Cellsaver|
75546140|NCT00269048|Drug|SB-480848|SB-480848
75546141|NCT00269048|Drug|placebo|placebo
75546142|NCT00302523|Drug|Tacrolimus|FK506,0.1mg/kg/d
75546143|NCT02960412|Drug|furosemide|10mg lasix given intraoperatively
75546144|NCT02960412|Drug|Normal Saline|Normal saline given intraoperatively as placebo
75546145|NCT04717947|Procedure|Interval between NAT and surgery|Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.
75546146|NCT00269126|Drug|fluticasone propionate/salmeterol combination DISKUS|
75546147|NCT00269126|Drug|salmeterol xinafoate|
75546148|NCT00269165|Procedure|Balloon Aortic Valvuloplasty|
75546149|NCT00269165|Procedure|External Beam Radiation|
75546150|NCT00297024|Procedure|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
76035953|NCT03095209|Radiation|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
76035954|NCT05617547|Diagnostic Test|Pulse Oximeter (Massimo)|The Massimo LNCS (low noise cabled sensors) pulse oximeter will be used to estimate the oxygen saturation and compared to the gold standard, the arterial oxygen saturation in the blood as measured by co-oximetry. The pulse oximeters is FDA cleared for this purpose so patients will not be exposed to any interventions that are not standard of care.
76035955|NCT05034133|Drug|Durvalumab|Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles
76035956|NCT03096379|Diagnostic Test|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
75546151|NCT00269204|Drug|niacin (+) laropiprant|Duration of Treatment - 24 weeks
75546152|NCT00269204|Drug|ER-niacin|Duration of Treatment - 24 weeks
75546153|NCT00297141|Drug|Capecitabine|chemotherapy oral use
76035957|NCT03096457|Drug|Paromomycin Sulfate|topical application 2 times a day during 20 days
76035958|NCT03096457|Drug|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
75546154|NCT00297141|Drug|Oxaliplatin|chemotherapy intravenous use
75546155|NCT00269243|Drug|Quinapril|
76035959|NCT03096457|Other|Placebo|topical application 2 times a day during 20 days
76035960|NCT03096223|Drug|KHK4083|IV administration
76035961|NCT05617469|Other|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis
76035962|NCT03096145|Behavioral|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
75546156|NCT04718064|Drug|Fingolimod|fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
75546157|NCT04718064|Drug|placebo|placebo once daily, for three consecutive days,
75546158|NCT00297180|Drug|GW869682|
75546159|NCT00302601|Procedure|Scintigraphic interpretation|Not relevant
75546160|NCT00269282|Behavioral|Self-Management Training|Asthma education and self-monitoring strategies
75546161|NCT00269282|Behavioral|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
75546162|NCT00297219|Drug|Low dialysate calcium|1.25 mmol/L dialysate calcium
75546163|NCT00297219|Drug|high dialysate calcium|1.75 mmol/L dialysate calcium
75546164|NCT00269321|Procedure|Chiropractic Manual treatment + home exercise (procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
75558035|NCT00439764|Behavioral|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
75708496|NCT04596384|Other|Medical Device Usage and Evaluation|Wear an actigraph
75708497|NCT04596384|Procedure|Nutritional Assessment|Complete a nutritional assessment
76035963|NCT03096145|Behavioral|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
75708498|NCT04596384|Other|Quality-of-Life Assessment|Ancillary studies
75708499|NCT04596384|Other|Questionnaire Administration|Ancillary studies
75708500|NCT04596384|Other|TapCloud|Use TapCloud app
76035964|NCT03096145|Behavioral|Health incentive|Smokers receive a $25 gift card if they call the quitline
76035965|NCT04814303|Procedure|Intrathecal morphine|After applying standard monitoring of pulse oximetry, ECG, NIBP; while the patient in the sitting position following complete sterile aseptic condition after sterilization bovine bethidine spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral levels using a 25- gauge Whitacre needle. Intrathecal morphine 150 μg will be added to patients of both groups. Supplemental oxygen will be administered via a simple face mask.
75394916|NCT04124484|Drug|Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
75546165|NCT00269321|Procedure|Supervised rehabilitative exercise+home exercise|"The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
75870505|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
75546166|NCT00269321|Behavioral|Home exercise|Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
75546167|NCT00302640|Drug|Alinia (nitazoxanide)|
75546168|NCT00269360|Procedure|Chiropractic + Supervised Rehabilitative Exercise|"Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises."
76035966|NCT04814303|Procedure|Adductor Canal block|The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, short-bevel echogenic needle is advanced in plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in group 1 received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
75546169|NCT00269360|Procedure|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
75546170|NCT00269360|Behavioral|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
75546171|NCT00297297|Other|No intervention. Applying gene profiling on needle aspirates|
75546172|NCT00269438|Drug|5 ASA, enemas, suppositories, corticosteroids|
75546173|NCT00418353|Drug|Betamethasone(Celestone soluspan) and Dexamethasone|
75546174|NCT00269516|Drug|pardoprunox|fixed dose 6 mg
75546175|NCT00269516|Drug|Pardoprunox|fixed dose 12 mg
75546176|NCT00269516|Drug|Pardoprunox|12-42mg
75546177|NCT00269516|Drug|Placebo|Placebo
75546178|NCT00418392|Procedure|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
75394917|NCT04124016|Dietary Supplement|Inulin|Powder of inulin fractions dissolved into 250 ml of water
75394918|NCT04124016|Dietary Supplement|green tea extract|Powder of green tea extract dissolved into 200 ml of water
75394919|NCT04124016|Dietary Supplement|grape seed|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
75394920|NCT04124016|Dietary Supplement|grape seed extract|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
75546179|NCT00418392|Procedure|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
75546180|NCT00269555|Drug|Genistein Combined Polysaccharide (GCP)|
75546181|NCT00418431|Drug|Intravitreal injection of Bevacizumab|
75546182|NCT00269594|Drug|Lamictal (lamotrigine)|
75546183|NCT00418470|Procedure|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
75546184|NCT00418470|Procedure|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
75546185|NCT00269672|Biological|13-valent Pneumococcal Conjugate Vaccine|
75546186|NCT00302757|Drug|Radioimmunotherapy|
75546187|NCT00302757|Procedure|allogeneic hematopoietic cell transplantation|
75546188|NCT00416117|Procedure|Manual Physical Therapy and Exercise|
75546189|NCT00416117|Procedure|Minimal Intervention|
75546190|NCT00416156|Behavioral|Lifestyle modification|
75546191|NCT00302796|Drug|Bioclavid|500 + 125 mg times 3 or 6
75546192|NCT00302796|Drug|Placebo|
75546193|NCT00425633|Drug|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
75546194|NCT00302835|Drug|non-phenacetin containing analgesics|
75546195|NCT00302874|Behavioral|Implementation of a protocol for treatment of hyperglycemia|
75546196|NCT00269750|Drug|OROS® oxybutynin or Ditropan®|
75546197|NCT00269789|Drug|Ritalin|
75546198|NCT00269789|Drug|OROS Methylphenidate HCl|
75546199|NCT00269789|Drug|Placebo|
75546200|NCT00302913|Drug|Adjustment of clopidogrel dose|
75546201|NCT00269828|Drug|paclitaxel|
75870506|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
75546202|NCT00269828|Drug|paclitaxel poliglumex|
75546203|NCT00269867|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
75546204|NCT00269867|Drug|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
75394921|NCT04124094|Drug|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
75394922|NCT04124094|Drug|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
75394923|NCT04124094|Other|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
75394924|NCT05604612|Procedure|Corticision|Incisions in the cortical plate of maxillary bone
75394925|NCT03033576|Biological|Ipilimumab|Given IV
75394926|NCT03033576|Biological|Nivolumab|Given IV
75394927|NCT05604378|Procedure|Gastrectomy|All patients in our study underwent gastrectomy.
76035967|NCT04814303|Procedure|Peri-articular Infilteration|the surgeon will perform the PAI intra-operatively; 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone. Half of the solution will be administered into the posterior capsule and posterior soft tissues of the knee under direct vision after osteotomy but before insertion of the implants. The remaining half of the solution will be administered into the anterior soft tissues after placement of the implants and before skin closure. All local infiltration will be carried out while a thigh tourniquet (used to limit surgical bleeding) was inflated at a pressure of 300 to 350 mm Hg.
75394928|NCT04123782|Device|F-ESW Treatment|The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).
75394929|NCT04123782|Device|Placebo F-ESW Treatment|Very low concentration of F-ESW.
75546205|NCT00269867|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
75546206|NCT00303030|Procedure|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
75546207|NCT00303030|Procedure|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
75546208|NCT00269906|Drug|Abciximab|
75546209|NCT00269906|Drug|Placebo|
76035968|NCT05053477|Drug|mehylprednisolone injection|(40 mg)
76035969|NCT05053477|Device|pulsed radiofrequency (PRF)|. PRF lesion will be carried out for 120 seconds at a 2 Hz frequency and pulse width of 20 ms at 42°C
76035970|NCT05053477|Biological|platelet-rich plasma|2 ml of PRP
76035971|NCT04814459|Other|HOP-UP-PT Program|Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
76035972|NCT05033587|Drug|Anlotinib|Anlotinib a multi-target receptor tyrosine kinase inhibitor.
76035973|NCT05033587|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
76035974|NCT05033587|Radiation|Radiotherapy|The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
76035975|NCT05053009|Drug|Brufen Retard|800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
75394930|NCT03831438|Drug|AVID200|Intravenous infusion of AVID200 Q2 weeks for 3 doses
76035976|NCT03095131|Device|Heart Spectrum Blood Pressure Monitor|The Heart Spectrum Blood Pressure Monitor provides a convenient and effective filtering application compared with traditional methods that require a visit to a physician for a 12-lead ECG.
75394931|NCT04123392|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
75394932|NCT04123392|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
75394933|NCT04123392|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
75394934|NCT04393038|Drug|ABX464|ABX464 50mg QD for 28 days + Standard of Care
75394935|NCT04393038|Drug|Placebo|Placebo 50mg QD for 28 days + Standard of Care
75394936|NCT03030924|Device|Solace|Noninvasive physiologic monitor
75546210|NCT02960373|Other|White Bread (Control)|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
75546211|NCT02960373|Other|Dried Fruit - Glycemic Index|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
75546212|NCT02960373|Other|Catalytic Fructose Dose Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
75546213|NCT02960373|Other|High GI Displacement Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
75546214|NCT00269945|Drug|epoetin alfa|
75394937|NCT05601258|Other|Age, gender, hospitalization and mortality rates will be compared|Age, gender, hospitalization and mortality rates will be compared
75394938|NCT05607966|Device|ORIGIN® CR devices|It is planned to include consecutive eligible subjects which will be treated with the ORIGIN® CR devices.
75394939|NCT04760262|Drug|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance, BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
75546215|NCT00303147|Behavioral|Expressive Writing|
75394940|NCT04760262|Drug|Propofol|BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
75394941|NCT04127292|Behavioral|Emotional Self Awareness (ESA) Individual Feedback|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
75394942|NCT04123002|Other|Miswak chewing sticks|Chewing stick are routinely used by this population
75394943|NCT04123236|Other|Age 0-18|Patients under 18 years of age
75546216|NCT00269984|Drug|Epoetin alfa|
75546217|NCT00297336|Drug|Topiramate|80 patients with diagnosed with migraine
75546218|NCT00270023|Drug|epoetin alfa|
75546219|NCT00297375|Drug|tramadol HCl/acetaminophen|
75546220|NCT02960984|Other|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
75546221|NCT00297414|Other|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
76035977|NCT05617235|Device|Kinesiology taping|"On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. Investigators applied kinesiology taping as described below:~In order to stimulate the facilitation of the diaphragmatic function~Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~In addition, kinesiology taping can be performed on the trigger pain point of the patient .~After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively."
76035978|NCT03095911|Other|News items with spin|Interpretation of news items with spin
76035979|NCT03095911|Other|News items without spin|Interpretation of news items without spin
75394944|NCT04123236|Other|Age 18-26|Patients over18 years of age
75394945|NCT04123236|Other|Girls|Girls
75394946|NCT04123236|Other|Boys|Boys
75546222|NCT00270062|Drug|epoetin alfa|
75546223|NCT00297453|Behavioral|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
75546224|NCT00297453|Behavioral|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
75870507|NCT02384902|Other|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
75870508|NCT02940691|Drug|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
75870509|NCT02379910|Drug|AM1030-CREAM or placebo|
75870510|NCT04949269|Drug|Deucravacitinib|Specified dose on specified days
75870511|NCT04949269|Drug|Famotidine|Specified dose on specified days
75394947|NCT03047928|Drug|Nivolumab|Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
75394948|NCT03047928|Biological|PD-L1/IDO peptide vaccine|The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
75394949|NCT04122846|Behavioral|Emotional Awareness and Expression Therapy|"Very much based on Unlearn your pain by Howard Schubiner."
75394950|NCT05607810|Genetic|ADVM-022|Long term follow-up of subjects who previously received ADVM-022
75394951|NCT05607654|Device|active iTBS|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
75394952|NCT05607654|Device|sham rTMS|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
76035980|NCT03095989|Behavioral|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
75394953|NCT04127682|Other|Antibiotic KAP questionnaire|• Self-administered questionnaire will be used and containing following Physician information (age, sex, place of work, specialty, years of experience, place of work, and post graduate studies and trainings), Practice information (number of days for outpatient's practice/week, average number of patients /day and average percentage of children with ARIs/day), Antibiotic prescription practice (using of guidelines and causes of prescribing antibiotics in acute URIs), Knowledge about antibiotic resistance and attendance of any conference or educational activities concerned with antibiotic use during the last year, Attitude as regard antibiotic prescription.
75394954|NCT05607576|Other|Uncovered CGM during radiologic procedures|Dexcom G6 CGM will not be covered during radiologic procedures.
75394955|NCT04122144|Behavioral|ENHANCED -SPS intervention|a) Enhanced VL counseling: Explanation of VL & Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
75394956|NCT04122066|Drug|sofosbuvir \daclatsvir|study the effect of the new oral antihepatitis C drugs on the respiratory system
75394957|NCT03228264|Device|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
75394958|NCT03228264|Device|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
75394959|NCT05607264|Other|Kinsiotaping|Patients received the kinesiotaping over supraspinatus muscle and deltoid muscle, tape will be removed every three days and subjects will return back to the clinic to reapplication of tape again. Patients received the same therapeutic treatment 3 times/ week for four weeks. KT is air permeable and water resistant, allowing it to stay in place for three to five days.
75394960|NCT05607264|Other|Motion-controlled VR games|Virtual Rehab utilizes the unique characteristics of Microsoft Kinects motion technology to track and capture the movements of the patients so that patients become immersed in a 3D environment where they interact with the game. Subjects will include in a supervised virtual reality exergaming program for shoulder movements for 4 weeks, 3 days per week and 10 minutes for session.
75870512|NCT02380066|Drug|Anyu Peibo|Placebo
75870513|NCT04938271|Device|HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve|Using a bluetooth connected iPhone, subject activates the HEAL-122 electroceutical device that is docked onto an e-textile sports knee sleeve worn on the osteoarthritic knee
75870514|NCT02379754|Drug|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
75870515|NCT02375620|Biological|PEG-somatropin|
75708501|NCT04587531|Device|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
75394961|NCT05607264|Other|Conventional treatment|patients received conventional treatment for chronic shoulder impingement syndrome only.
75394962|NCT04122300|Drug|Euphrasia Officinalis Preparation|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
75870516|NCT04911673|Behavioral|music|Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation).
75394963|NCT04122300|Drug|Placebo|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
75870517|NCT04911673|Dietary Supplement|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per a day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them.
75870518|NCT02384824|Procedure|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
75870519|NCT01313377|Drug|gemcitabine hydrochloride|
75870520|NCT01313377|Drug|oxaliplatin|
75870521|NCT01313377|Other|clinical observation|
75870522|NCT01313377|Procedure|adjuvant therapy|
75870523|NCT01313377|Procedure|quality-of-life assessment|
75394964|NCT04121910|Drug|Savolitinib|On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
75394965|NCT04121910|Drug|Itraconazole|Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
75394966|NCT04274478|Device|Auditive cueing|Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
75394967|NCT03830736|Combination Product|Oat Beverage 1|Oat based beverage with added different concentration of extracted oat component.
75394968|NCT03830736|Combination Product|Oat Beverage 2|Oat based beverage with added different concentration of extracted oat component.
75394969|NCT03830736|Combination Product|Oat Beverage 3|Oat based beverage with added different concentration of extracted oat component.
75394970|NCT03830736|Combination Product|Oat Beverage 4|Oat based beverage with added different concentration of extracted oat component.
75394971|NCT03830736|Combination Product|Control product|Glucose based beverage without added test components is used as control product
75394972|NCT04393818|Behavioral|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep disorders), work environment, and social support.
75394973|NCT04393896|Behavioral|WeChat-based integrative family intervention (WIFI)|The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
75394974|NCT04129788|Drug|Bisacodyl 5 milligram|three doses taken, one per day on three consecutive days
75394975|NCT04129788|Drug|Placebo oral tablet|three doses taken, one per day on three consecutive days
75394976|NCT03831126|Drug|Betamethason Sodium Phosphate|First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh
75394977|NCT05607186|Radiation|neoadjuvant long course chemoradiotherapy|neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks
75394978|NCT04073784|Drug|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
75394979|NCT05606796|Drug|Latanoprost 0.005% Ophthalmic Solution|1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
75394980|NCT04121208|Drug|JNJ-40346527|Active study drug
75394981|NCT04121208|Other|Placebo|Non-active study drug
75394982|NCT04393740|Diagnostic Test|scheimpflug imaging using pentacam|corneal tomography imaging using pentacam device (based on Scheimpflug principle )
75394983|NCT03831204|Device|biopac|"Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus."
75394984|NCT03831204|Diagnostic Test|prognostic scores|Effect and GWTGHF were calculated for every patient
75870524|NCT02384746|Drug|Fulvestrant|500 mg intramuscular every 28 days
75546225|NCT00297453|Behavioral|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
75546226|NCT00270101|Drug|epoetin alfa|
75546227|NCT00297531|Device|PerioWave|
75546228|NCT00297531|Procedure|Scaling and Root Planing|
75546229|NCT00270140|Drug|epoetin alfa|
75546230|NCT00270179|Drug|epoetin alfa|
75870525|NCT02384746|Drug|MLN9708|Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
75546231|NCT00270218|Biological|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
75546232|NCT00270218|Biological|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
75546233|NCT00270218|Biological|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
75546234|NCT00270218|Biological|PBS|phosphate buffered saline
75546235|NCT00297570|Drug|Pegylated Interferon and Imatinib|
75546236|NCT00270335|Drug|Propofol|
75546237|NCT00297687|Biological|MnB rLP2086|
75546238|NCT00270374|Drug|nesiritide|
75546239|NCT00297726|Behavioral|Self-Management Program|
75870526|NCT02375464|Drug|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
75394985|NCT05606640|Diagnostic Test|Biopsychological pain assessment|At baseline (T0) patients underwent the somatosensory pain assessment, joint structure and function assessment and filled in all questionnaires. During one month after baseline (T1) patients wore an activity tracker and filled in the Illness Perceptions Questionnaire and the International Physical Activity questionnaire. During one year after the baseline assessment (T2) patients filled in every month The Brief Pain Inventory, Illness Perceptions Questionnaire and the EQ-5D-5L quality of life questionnaire.
75394986|NCT04129710|Drug|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
75394987|NCT04129710|Drug|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
75708502|NCT04586257|Procedure|Erector spinae plane block|While patients in the prone position, 1.4-5.1 MHz low-frequency probe (C5-1s convex transducer) will be first placed in a longitudinal orientation in the midline to identify the spinous process of at the appropriate lumbar level, then it will be scanned laterally about 2-3 cm until visualization of the paraspinal muscles and the transverse process at the same time. After standard sterilization, a 21-G short bevel nerve block needle will be advanced in a cephalad-to-caudal direction, in-plane under real- time ultrasound guidance, through skin, subcutaneous tissue, and erector spinae muscles until reaching the transverse process. After negative aspiration of blood or cerebral spinal fluid, a small volume of local anesthetic was injected to confirm the position of the needle tip between the erector spinae muscles and the transverse process. A total of 20 ml of 0.0.25% plain bupivacaine will be incrementally injected with intermittent negative aspiration on each side.
75394988|NCT04129710|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
75394989|NCT04129710|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
75870527|NCT02375386|Procedure|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
75394990|NCT04129710|Drug|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
75394991|NCT04129710|Drug|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
75394992|NCT03200808|Drug|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
75394993|NCT05603598|Drug|LEAP-2 Protein, Human|Intravenous infusion, mixed meal test, ad libitum meal test
75394994|NCT02983656|Biological|live attenuated varicella vaccine|
75394995|NCT04121130|Device|F-ESWT Group|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
75394996|NCT04121130|Device|sham F-ESWT|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
75394997|NCT04129476|Behavioral|Cooperative Education Program based on Precede-Proceed Model|The study population is pregnant women in Gonabad city between 30 and 35 weeks of gestation. In the experimental group, the training program was based on the PRECEDE-PROCEDURE model, including training on anatomy and prenatal physiology, prenatal and postnatal care, prenatal and postnatal mental health, as well as prenatal and postnatal events, and Mothers' feelings and attitudes, as well as postpartum problems and strategies will be discussed. The training period is 60 minutes in 4 consecutive sessions. Predisposing, reinforcing and enabling factors inventory, General health questionnaire (GHQ), Edinburgh depression inventory Will be filled Before the intervention, immediately after the intervention and 4 to 6 weeks after the intervention.
75546240|NCT00270452|Drug|WT1 and PR1 Peptide Vaccine|
75546241|NCT00270491|Drug|Paclitaxel|
75394998|NCT04128852|Device|MagnetOs Putty|MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
75394999|NCT04129008|Drug|Indobufen and aspirin mimetic|Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
75395000|NCT04129008|Drug|Aspirin and indobufen mimetic|Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
75395001|NCT04121052|Drug|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
75395002|NCT04120896|Behavioral|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
75395003|NCT04120896|Behavioral|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
75395004|NCT04128930|Device|PAP titration at home|Fixed CPAP or APAP titration at home
75395005|NCT05603130|Other|routinely collected clinical information|medical history, epidemiological characteristics, clinical examination, biological assessment (blood glucose, NFS, CRP, D-dimer,etc...)
75395006|NCT04128462|Drug|MNK-6105|L-Ornithine Phenylacetate for IV infusion
75395007|NCT04128462|Drug|Placebo|Matching placebo for IV infusion
75395008|NCT04128462|Drug|Standard of Care|Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
75395009|NCT04394520|Other|Modified Introduction|A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.
75395010|NCT04394520|Other|Active Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-in to the survey, if they do not respond, the survey will terminate.
75395011|NCT04394520|Other|Active Opt-out|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-out to the survey, if they do not respond, the survey will continue.
75395012|NCT04394520|Other|Passive Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to passively opt-in to the survey, if they do not hang-up, the survey will continue.
75395013|NCT04128618|Device|CyMedica e-vive NMES|Neuromuscular Electrical Stimulation (NMES) therapy
75546242|NCT00270491|Drug|Capecitabine|
75546243|NCT00270530|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
75546244|NCT00297765|Drug|Tacrolimus, Prograf®|
75546245|NCT00270569|Drug|PhyxolTM, Cisplatin|
75546246|NCT00297804|Device|TAXUS Express Paclitaxel-Eluting Coronary Stent System|Paclitaxel-Eluting Coronary Stent System
75395014|NCT03309306|Other|Natural Environment/Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
75708503|NCT04586257|Procedure|Throacolumbar interfacial plane block|USG-guided TLIP block will be performed using a high-frequency linear probe while the patient in prone position. The probe will be covered with sterile sheath positioned transversally in a midline position at approximately the level of the 3rd lumbar vertebra (L3). The corresponding spinous process and interspinal muscles will be identified, and the probe will be slid laterally to identify the multifidus (MF) muscle and longissimus (LG) muscle. Sliding the probe from midline to laterally helps in the correct identification of various muscles. After identifying the muscles, TLIP block will be performed aseptically on both sides of L3 vertebra. Under ultrasound guidance, an insulated echogenic needle will be inserted in-plane in a lateral to medial orientation in-plane USG guided through the belly of LG toward the MF. When needle reach deep to middle of MF/LG interface, 20 ml 0.25% bupivacaine will be injected after negative aspiration. The block will be administered bilaterally.
76035981|NCT04813913|Drug|Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV|Enrollement of major patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, naive in antineoplastic treatment and eligible to start a systemic carcinological treatment comprising bevacizumab in combination with chemotherapy based on fluoropyrimidine IV. The main objective is to show that there is an increase in the stiffness of the carotid artery at 4 months in patients with stage IV colorectal cancer exposed to bevacizumab.
76035982|NCT03095755|Other|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
76035983|NCT03095755|Other|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
76035984|NCT04828889|Device|Anal dilators|Anal sphincter training for relaxation
76035985|NCT04828889|Procedure|lateral internal sphincterotomy|lateral internal sphincterotomy is a firmly established method for treating anal fissures.
76035986|NCT05033509|Other|supervision the Kidney fonction on ECMO|patients who benefited from ECMO, and presented an acute kidney injury afterwards
76035987|NCT04828655|Behavioral|Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.|Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
76035988|NCT05033197|Behavioral|CBBS intervention|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
76035989|NCT05041933|Drug|outsourcing of chemotherapy to Hospital at Home|outsourcing of chemotherapy to Hospital at Home
76035990|NCT04828499|Procedure|Progressive Cracking Technique|Performing the cataract surgery with our phaco chop-progressive cracking technique.
76035991|NCT04828499|Procedure|Conventional Chop Technique|Performing the cataract surgery with Conventional Chop Technique.
76035992|NCT05042089|Other|No intervention will be applied.|The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.
75546247|NCT00297804|Device|Control stent|control stent
75546248|NCT00270608|Procedure|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
75546249|NCT00270608|Procedure|MRI of the spine and the right knee|a single time 45 minutes procedure
75395015|NCT03309306|Behavioral|Natural Environment/Reduce Food Waste|"Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~Feedback on the amount of food waste their household created during the first week,~A goal to reduce the next week's food waste by 20% or more, and~Tips on how to reduce household food waste adapted from current consumer campaigns"
75395016|NCT04120662|Procedure|Intramedullary screw fixation|A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.
76035993|NCT04819061|Other|tDCS Active|This group will undergo the motor training and active tDCS. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks. We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.
76035994|NCT04819061|Other|tDCS sham|"This group will undergo the motor training and tDCS sham. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks.~We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies."
76035995|NCT04814381|Drug|Ketamine + Magnesium sulfate (drug combination)|A single infusion will be performed over 2 hours with 90 days follow-up.
76035996|NCT05041777|Device|Optical Coherence Tomography|OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. [2] In such ways, microscopic details of lesions and tissues can be visualized. This information could be used to identify a lesion as BCC, and further specify the subtype. Therefore, the use of the OCT can reduce the number of biopsies and the accompanying morbidity.
76035997|NCT04819217|Dietary Supplement|Active bamboo charcoal|During this 6 months' trial, eligible 120 patients with eGFR 15 < eGFR < 45 ml/min/1.73m2 and UACR > 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.
76035998|NCT04819217|Dietary Supplement|Probiotics|Probiotics
76035999|NCT05041465|Other|Clay mask|Clay mask powders- French green, Rhassul and bentonite
75395017|NCT04120662|Device|Focused Shock Wave Treatment|3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
75395018|NCT04120506|Drug|VPRIV|Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
75546250|NCT00270608|Procedure|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
75546251|NCT00297843|Procedure|allergen challenge (grass pollen), nasal lavage|
76036000|NCT04818905|Dietary Supplement|Helichrysum italicum infusion|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
75395019|NCT04120350|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
75395020|NCT04120350|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
75395021|NCT04120350|Drug|Lenalidomide|"In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years."
75708504|NCT04573738|Procedure|Robotic assisted transanal total mesorectal excision|Robotic assisted transanal total mesorectal excision for rectal cancer patients
76036001|NCT04818905|Other|Hot water|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
76036002|NCT05052619|Drug|Preventive use of advanced antibiotics|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
76036003|NCT05052619|Other|Routine|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
76036004|NCT04813679|Diagnostic Test|Bed side Ultrasound Sonography|Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
76036005|NCT05052775|Other|Chlorhexidine Mouthwash|Patients were given chlorhexidine mouthwash 2 times per day for 15 days
76036006|NCT05052775|Other|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
76036007|NCT05052775|Other|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
75395022|NCT04394598|Drug|Dendrobium Huoshanense Granules|3g tid per day for 5weeks
75708505|NCT04573738|Procedure|Laparoscopic assisted transanal total mesorectal excision|Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
75708506|NCT04571281|Diagnostic Test|capillary lactate measurements|In this study capillary lactate will be measured every 10 minute during CPR.
76036008|NCT04427423|Other|physical therapy treatment|the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
76036009|NCT05052463|Other|electrolyte imbalance analysis|ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
75395023|NCT04394598|Radiation|Pelvic Radiation|50Gy/25Fx
75395024|NCT04394598|Drug|Capecitabine|625mg/m2 bid Monday-Friday per week
75395025|NCT04394598|Drug|Irinotecan|80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
75395026|NCT04394598|Other|Placebo|3g tid per day for 5weeks
75395027|NCT04120272|Procedure|Spine surgery|Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
75395028|NCT04394832|Behavioral|Brief cognitive intervention|See the information provided in the experimental arm description.
75395029|NCT04127916|Drug|Bendamustine|To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
75395030|NCT04127760|Radiation|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
75395031|NCT03302130|Behavioral|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
75395032|NCT03302130|Device|Arterial spin labeling MRI|Single PLD PCASL
75395033|NCT03302130|Device|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
75395034|NCT04127370|Procedure|Bariatric Surgery|The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
75395035|NCT02984046|Drug|Protein CC16|
75708507|NCT04570709|Other|Palliative And supportive Care inTervention (PACT)|Using the Adaptive Leadership Framework for Chronic Illness as a guide. The nurse, occupational and physical therapists will meet with the patient and caregiver after the baseline assessment to discuss their Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals. Additionally, the occupational and physical therapists will provide the patient a PACT intervention binder. Regular phone calls or visits from a registered nurse, occupational therapists, and physical therapists for patients and caregivers in the intervention.
75708508|NCT04568369|Device|rTMS|See treatment arm description.
75395038|NCT04127526|Other|Connection to Environment with Cognitive Therapy (CONNECT)|8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
75546252|NCT00270647|Dietary Supplement|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
75546253|NCT00270647|Dietary Supplement|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
75395039|NCT04274790|Procedure|Scheduled and planned surgery|Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.
75395040|NCT05602428|Drug|esketamine sub-anesthetic,|the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
75546254|NCT00270647|Dietary Supplement|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
75546255|NCT00270647|Dietary Supplement|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
75708509|NCT04567368|Diagnostic Test|Xpert MTB/XDR|Cepheid Xpert MTB/XDR assay for detection of resistance to INH, FQ and SLID
75395041|NCT05602428|Drug|esketamine sub-anesthetic|Esketamine subanesthetic dose combined with lumbar plexus block was used
75395042|NCT05602428|Drug|esketamine sub-anesthetic|general anesthesia was performed with esketamine subanesthetic dose.
75395043|NCT02983890|Drug|Dicloxacillin|"Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
75395044|NCT02983890|Drug|Placebos|"No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
75395045|NCT03022968|Drug|[18F]T807 PET|Imaging with [18F]T807 PET
75546256|NCT00297921|Drug|tandutinib|
75546257|NCT00297960|Drug|ziprasidone or olanzapine|
75546258|NCT00297960|Procedure|hyperinsulinaemic euglycaemic clamp|
75546259|NCT00297960|Procedure|microdialysis (skeletal muscle)|
75708510|NCT04564339|Drug|Ravulizumab|Dosages (loading and maintenance) will be based on the participant's body weight.
75708511|NCT04564339|Drug|Placebo|Dosages (loading and maintenance) will be based on the participant's body weight.
75708512|NCT04564339|Other|Background Therapy|Participants will receive background therapy consistent with the standard of care.
75708513|NCT04562480|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75708514|NCT04562480|Other|Quality-of-Life Assessment|Ancillary studies
75708515|NCT04562480|Other|Questionnaire Administration|Ancillary studies
75395046|NCT04129944|Drug|UBX0101|Investigational drug intra-articular injection
75395047|NCT04129944|Other|Placebo|Placebo intra-articular injection
75546260|NCT00270803|Drug|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
75546261|NCT00270881|Procedure|Cord blood transplantation|unrelated cord blood transplantation
75546262|NCT00270881|Radiation|TBI|Total body irradiation (TBI) 12Gy
75546263|NCT00270881|Drug|cyclophosphamide|cyclophosphamide 120mg/kg
75546264|NCT00270881|Drug|cytarabine|cytarabine 3g/m2x4
75546265|NCT00270920|Behavioral|Lactation counseling|
75546266|NCT00270959|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
76036010|NCT04813367|Procedure|Surgery of twisted fallopian tubes|Patients diagnosed with twisted fallopian tube go through surgery.
76036011|NCT03094741|Other|CancerLife|CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
75395048|NCT05602350|Behavioral|Self-administered survey|Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
75395049|NCT05602350|Behavioral|Enumerator-administered survey|Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
75395050|NCT04124172|Device|Real rTMS (Magstim)|See arm description
75395051|NCT04124172|Device|Sham rTMS|See arm description
75546267|NCT00270959|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
75546268|NCT00270959|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
75546269|NCT00270959|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
75546270|NCT00298194|Drug|Z-338|
75546271|NCT00271037|Procedure|Colpocleisis prolapse repair surgery|
75546272|NCT00271037|Procedure|sling or other to treat or prevent stress incontinence|
75546273|NCT00306306|Device|Reprieve Endovascular Temperature Therapy System|
75546274|NCT00271076|Procedure|IVUS|
75546275|NCT00271076|Device|CAS|
75546276|NCT00271076|Procedure|CEA|
75546277|NCT00306345|Behavioral|Outreach|
75546278|NCT00271115|Behavioral|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
75546279|NCT00306423|Procedure|Other: Exercise|exercise 3 times per week for 12 weeks
75546280|NCT00271193|Behavioral|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
75546281|NCT02960256|Device|ekocardiogram test|ekocardiogram test
75546282|NCT00271232|Device|Cardiac resynchronization therapy|
75546283|NCT00418548|Drug|Etanercept|
75546284|NCT00416234|Procedure|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
75708516|NCT04562480|Procedure|Resection|Undergo surgical resection
75870528|NCT02375386|Procedure|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
75870529|NCT02375386|Procedure|fMRI|Both groups will receive an fMRI.
75870530|NCT02375386|Behavioral|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
75870531|NCT02375386|Other|Questionnaires|Both groups will receive Questionnaires
75395052|NCT04393194|Drug|Vaginal Cream with Applicator [Dose Form]|Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.
75395053|NCT04126980|Behavioral|Rates of readmission and reoperation|All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.
75395054|NCT04127058|Drug|Iloperidone|Oral Tablet
75870532|NCT02375386|Behavioral|Physical Impairment|Both groups will receive testing on physical impairment.
75870533|NCT03113344|Drug|cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
75395055|NCT05600010|Other|Microplastics|Detection of microplastics as a yes/no value
75395056|NCT03012360|Drug|ceftriaxone|2 g iv every 24h
75395057|NCT03012360|Drug|ciprofloxacin|400 mg iv every 8h
75395058|NCT03012360|Drug|imipenem|1 g iv every 8h
75395059|NCT03012360|Drug|linezolid|600 mg iv every 12h
75546285|NCT00416234|Procedure|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
75546286|NCT00418587|Drug|Cholecalciferol|800 IU oral daily
76036012|NCT04818437|Other|BALANCE TRAINING|Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
76036013|NCT04818437|Other|CORE STABILITY EXERCISES|"Abdominal bracing while lying in supine position.~Abdominal bracing with heel slide while lying in supine position.~Abdominal bracing with Leg lifts while lying in supine position.~Abdominal bracing with bridging while lying in supine position.~Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying"
76036014|NCT03095677|Other|Program of training with exercises including apnea|16 training session on cycle ergometry with exercises including apneas.
76036015|NCT03095677|Other|Program of training with exercises without apnea|16 training session on cycle ergometry with exercises without apnea
76036016|NCT04813757|Other|exercise|each group will perform 2 shoulder strength exercise at the therapy session and 3 exercise at home session-2 strength exercise and one stretching exercise. they will perform the exercises 5 times per week
76036017|NCT04813757|Other|manual therapy|on each treatment session both group will receive 15 minutes of manual therapy which will include: massage,3-4 trigger point treatment posterior capsule stretch and mobilization with movement
75870534|NCT03112954|Drug|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
76036018|NCT03094897|Drug|18F-Al-NOTA-MATBBN PET/CT|18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
75546287|NCT00418587|Drug|Cholecalciferol|2000 IU oral daily
75546288|NCT00418587|Drug|Cholecalciferol|4000 IU oral daily
76036019|NCT03094897|Device|PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT.
76036020|NCT04813523|Drug|Pembrolizumab Injection [Keytruda]|Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
76036021|NCT05032261|Drug|Circulatory shock with norepinephrine in ICU|Circulatory shock with norepinephrine in ICU
76036022|NCT04812977|Drug|Group A|Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
76036023|NCT05040997|Diagnostic Test|Small airways assessment|Small airways assessment
75546289|NCT00416273|Drug|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
75546290|NCT00416273|Drug|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
75546291|NCT00306462|Drug|Magnesium sulfate|Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is < 6/hour.
75708517|NCT04559932|Other|Tracheostomy Training Course|A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
76036024|NCT05052073|Diagnostic Test|oral glucose load at rest|oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.
76036025|NCT05052073|Diagnostic Test|oral glucose load and exercise|oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber
75395060|NCT03012360|Drug|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
75395061|NCT04121598|Other|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
75395062|NCT04120974|Behavioral|Optimal insulin injection|subjects receive training in optimal injection technique.
75546292|NCT00306462|Drug|Oral Nifedipine or placebo|Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is < 6/hour.
75546293|NCT00416390|Dietary Supplement|lycopene|
75395063|NCT05609838|Other|Hot water foot bath|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
75395064|NCT04392882|Behavioral|Legume enriched diet group|"Replacing 1/3 refined rice intake with legumes three times per day~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~Regular 30-min walk after dinner each day"
75546294|NCT00416390|Other|laboratory biomarker analysis|
75546295|NCT00416390|Procedure|biopsy|
75546296|NCT00306501|Procedure|Swallowing Training|Swallowing Training with press of button
75546297|NCT00416429|Biological|aldesleukin|
75546298|NCT00416429|Biological|recombinant interferon alpha-2a|
75546299|NCT00416429|Drug|medroxyprogesterone|
75546300|NCT00306540|Drug|Quetiapine Fumarate|oral flexible dose
75546301|NCT00306540|Drug|quetiapine fumarate placebo|oral 0 mg
75546302|NCT00271271|Drug|oxaliplatine / gemcitabine / Vinorelbine|
75546303|NCT00271310|Drug|hypertonic saline|
75708518|NCT04558073|Behavioral|Body Project (BP)|"The BP intervention offers discussions and exercises to make participants realize the cost of pursuing social ideals valuing thinness. This produces cognitive dissonance, a cognitive discomfort due to a contradiction between speech and beliefs, which motivates to modify one's beliefs. The curriculum includes discussions on techniques of the advertising industry and the unique ideal of beauty promoted worldwide, as well as on the costs of pursuing the thin-ideal. Participants are also challenged to try behaviours they avoid because their appearance bother them. Societal activism actions are also discussed."
75708519|NCT04558073|Behavioral|Healthy Weight Program (HW)|The HW intervention allows participants to make personalized changes in their diet and physical activity each week gradually, to aim for a health-ideal rather than a thin-ideal. The intervention is based on small changes, based on behavioural change techniques. Advice is given on what types of changes introduce to promote health, and how to implement changes sustainably. Difficulties are discussed in the group with a problem-solving approach. The last session introduces a long-term view of lifestyle change.
75870535|NCT03112954|Drug|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
75395065|NCT04126668|Drug|CM082 with fed or fasting|The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
75395066|NCT04126434|Device|mask|facemask
75546304|NCT00306618|Drug|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
75546305|NCT00271349|Drug|Budesonide|
75546306|NCT00306657|Procedure|Optic nerve sheath fenestration|
75546307|NCT00271388|Device|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
75546308|NCT00306696|Drug|Rosiglitazone|
75546309|NCT00306696|Drug|spironolactone|
75395067|NCT04126512|Other|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
75395068|NCT02979678|Other|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
75395069|NCT04126122|Diagnostic Test|Ultrasonography to assess fetus and mother|to assess fetal growth and maternal outcome
75546310|NCT00306696|Drug|hydrochlorothiazide|
75546311|NCT00306696|Drug|frusemide|
75546312|NCT00271427|Drug|L-Selenomethionine|
75546313|NCT00271466|Drug|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
75546314|NCT00306735|Drug|Palonosetron|
75546315|NCT00271583|Drug|CDB-2914|
75546316|NCT00271583|Drug|levonorgestrel|
75546317|NCT00306774|Dietary Supplement|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
75546318|NCT00306774|Dietary Supplement|Placebo|Placebo capsule per day for 2 years
75546319|NCT00271700|Behavioral|Order Set, Education, Feedback|
76036026|NCT04813133|Other|Synchronized Lifestyle Modification Program|Synchronization of dietary intake with circadian rhythm of the body.
75546320|NCT00306813|Drug|Revlimid|
75546321|NCT00271778|Procedure|mastoidotympanoplasty and tympanoplasty|
75546322|NCT04718142|Device|vNEP|Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
75546323|NCT00306930|Device|Acetabular cup|Acetabular cup replacement
75546324|NCT00271973|Drug|Oxycodone|
75395070|NCT04758936|Drug|Clonidine|The doses administered (clonidine 1500mg diluted in NaCl0.9% solution of 50 ml) ranged from 0.01μg/kg/min to 0.03μg/kg/min.
75395071|NCT04758936|Drug|Dexmedetomidine|The doses administered (dexmedetomidine 200mg diluted in NaCl0.9% 50ml) ranged from 0.4μg/kg/h and can be titrated up to 1.4μg/kg/h.
75546325|NCT00306969|Drug|bexarotene|
75546326|NCT00306969|Device|photopheresis|
75546327|NCT00272012|Drug|Insulin glulisine|
75546328|NCT00307008|Biological|Pneumovax 23™|Single dose intramuscular injection
75546329|NCT00272051|Drug|SR57746A|
75546330|NCT00307203|Drug|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
75395072|NCT03830814|Procedure|Echocardiography|Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
75395073|NCT04126044|Drug|PF-06439535 (CN)|This is the test drug Pfizer biosimilar of bevacizumab-EU.
75395074|NCT04126044|Drug|bevacizumab - EU|This is the reference drug bevacizumab sourced from EU
75708520|NCT04554368|Procedure|intra-arterial contrast enhanced Flat Detector CT|After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
75708521|NCT04553497|Device|Interferential current|"Interferential current or sham were applied to the patients before the each exercise session. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."
75395075|NCT03822390|Device|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
75708522|NCT04553497|Other|Rehabilitation program|The orthopedic rehabilitation programme was applied to all patients three times a week for 4 weeks under the guidance of the same physiotherapist. The first phase (0-3 weeks) involved the elbow, wrist, and hand active range of motion (ROM) and pendulum (clockwise and counterclockwise) exercises in the 0-2 weeks of the non-displaced fracture. For displaced fractures, elbow, wrist, and hand active range of motion was started immediately, but pendulum exercises were initiated two weeks later. The patients were instructed to continue exercises 3-5 times per day for 30 minutes. After two weeks, active assistive ROM and isometric exercises were performed supine position. During the second phase (3-6 weeks), active forward elevation in supine was carried out and then progressed to sitting and standing position. At the end of the sixth week, a home exercise program was given by the physiotherapist, including resistance exercises using an elastic band (Thera-Band).
75395076|NCT03822858|Drug|Intrathecal MSC-NP injection|"Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
75395077|NCT03829878|Drug|CP101|Orally administered donor derived full spectrum microbiota
75395078|NCT03829878|Drug|Placebo|Placebo for CP101
75395079|NCT03829800|Dietary Supplement|Ensure® Abbott Nutrition|Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
75395080|NCT03829800|Dietary Supplement|Glucerna® Abbott Nutrition|Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
75395081|NCT03829800|Dietary Supplement|Diasip® Nutricia Advanced|Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
75395082|NCT03829800|Dietary Supplement|Glicolab®|Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
75395083|NCT04125810|Biological|Probiotic|Probiotic
75395084|NCT04125810|Other|Placebo|Placebo
75395085|NCT04758858|Other|Insulin treatment optimization with participant's usual diet|Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
75708523|NCT04552288|Drug|Benralizumab|All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
75708524|NCT04551963|Drug|Zanubrutinib|Capsules administered at a dose and frequency as specified in the treatment arm
75708525|NCT04551963|Drug|Fluconazole|Capsules administered at a dose and frequency as specified in the treatment arm
75708526|NCT04551963|Drug|Diltiazem|Capsules administered at a dose and frequency as specified in the treatment arm
75708527|NCT04551963|Drug|Voriconazole|Capsules administered at a dose and frequency as specified in the treatment arm
75558036|NCT03278756|Behavioral|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
75558037|NCT03278756|Behavioral|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
75558038|NCT00477516|Procedure|exposure to a high-calcium dialysate bath|Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
75558039|NCT00477555|Device|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
75558040|NCT03278639|Behavioral|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
75558041|NCT03278639|Behavioral|Kinesiology|Training will be directed to ameliorate gait and balance
75395086|NCT04758858|Device|Abbott's FreeStyle Libre|During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
75395087|NCT04758858|Other|Three-day food journal|Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
75395088|NCT04758858|Other|Medical visit|During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
75546331|NCT00307203|Behavioral|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
75546332|NCT00307203|Drug|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
75546333|NCT00272090|Drug|Insulin glargine|
75546334|NCT00307320|Behavioral|Relaxation Training|Relaxation techniques training
75870536|NCT03113266|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
76036027|NCT04813133|Other|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronization of dietary intake with circadian rhythm of the body along with Physiotherapy ( Aerobics, flexibility, resistance and balance exercises.)
76036028|NCT04813133|Other|Physiotherapy|Only Physiotherapy training which includes ( Aerobics, flexibility, resistance and balance exercises.)
75395089|NCT04758858|Other|Blood pressure measurements|Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
75395090|NCT04758858|Other|Anthropometric parameters measurements|Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
75395091|NCT04758858|Other|Indirect calorimetry test|Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
75395092|NCT04758858|Other|Well-being questionnaire|Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
75395093|NCT04758858|Other|Diet appreciation questionnaire|Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
75546335|NCT00272207|Drug|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
75546336|NCT00307515|Drug|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
75546337|NCT00307515|Device|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
75546338|NCT00272246|Procedure|deep brain stimulation of the internal globus pallidus|
75546339|NCT00272285|Drug|Ramosetron|IV, concomitant administration with dexamethasone
75546340|NCT00272285|Drug|Granisetron|IV, concomitant administration with dexamethasone
75546341|NCT00307554|Biological|Pneumococcal (vaccine)|
75546342|NCT00272324|Drug|Aspirin|
75546343|NCT00272324|Drug|Folate|
75546344|NCT00307593|Drug|Infliximab|Infliximab
75546345|NCT00307593|Drug|Rituximab|Rituximab
75546346|NCT00272402|Behavioral|Cognitive Behavioral Intervention|Intervention consists of simulated case based learning for physicians.
75870537|NCT02375230|Procedure|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
76036029|NCT05032027|Other|probiotics|recieving probiotics at the first day of chemoradiotherapy daily
75546347|NCT00272402|Behavioral|Office System Redesign Intervention|Intervention consists of clinical decision support within the electronic medical record.
76036030|NCT04813211|Procedure|mobile artificial cervical vertebrae replacement|"Position: The patient is in a supine position with the neck hyperextended, ensuring his/her neck and shoulders in a stable and neutral position before surgery and the cervical spine in a physiological curvature position.~Anesthesia: General anesthesia via oral tracheal intubation.~Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebral body between them will be removed. A curette is used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. Intraoperatively, the midlines of the segment and the vertebra to be replaced should be mapped out. When decompression, the midline for decompression should not be deviated from the planned midlines."
75546348|NCT00307632|Drug|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
75546349|NCT00272441|Drug|inhaled corticosteroids|
75546350|NCT00272480|Drug|Zidovudine/lamivudine|
75546351|NCT00272480|Drug|Placebos|
75546352|NCT00307671|Drug|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
75546353|NCT00307671|Drug|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
75546354|NCT00307671|Drug|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
75546355|NCT00272519|Behavioral|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
75546356|NCT00307710|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
75546357|NCT00272558|Drug|Carboplatin and Vinorelbine|
75546358|NCT00272597|Drug|Risperidone|See Detailed Description.
75546359|NCT00307749|Drug|Placebo|once daily for 24 weeks
75546360|NCT00307749|Drug|MCC-257|20mg, once daily for 24 weeks
75546361|NCT00307749|Drug|MCC-257|40mg, once daily for 24 weeks
75546362|NCT00307749|Drug|MCC-257|80mg, once daily for 24 weeks
75546363|NCT00307788|Procedure|acupuncture|acupuncture
75708528|NCT04551963|Drug|Clarithromycin|Capsules administered at a dose and frequency as specified in the treatment arm
75395094|NCT04758858|Device|Pedometer (PiezoRxD)|Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
75395095|NCT04758858|Other|Hepatic imaging (MRI)|Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
75395096|NCT04758858|Other|Glucagon efficiency test|The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
75395097|NCT04758858|Other|Body composition : Dual Energy X-ray absorptiometry (DEXA)|Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
75395098|NCT04758858|Other|Blood tests|Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
76036031|NCT04813211|Procedure|anterior cervical corpectomy and fusion|"Position: The patient is in a supine position with the neck hyperextended.~Anesthesia: General anesthesia via oral tracheal intubation.~Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebrae between them will be removed. A curette will be used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. The removed vertebral bone will be trimmed into cancellous bone particles and filled in a cervical titanium cage with an appropriate size. The titanium cage will be implanted into the vertebral space, and fixed with adjacent vertebrae using anterior cervical titanium plates and screws."
75395099|NCT04758858|Other|Stool sample collections (optional)|Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
75546364|NCT00272636|Procedure|Radiofrequency catheter ablation|
75546365|NCT00272636|Drug|Amiodarone and cardioversion|
75546366|NCT00281970|Drug|cisplatin|
75546367|NCT00281970|Drug|docetaxel|
75546368|NCT00281970|Procedure|adjuvant therapy|
75546369|NCT00272675|Drug|Chlorhexidine gluconate (drug) vs placebo|
75546370|NCT00307827|Drug|Visilizumab|Visilizumab administered intravenously once per day for two days
75546371|NCT00282009|Behavioral|Basic Internet|Basic Internet control intervention
75546372|NCT00282009|Behavioral|Enhanced Internet|enhanced Internet cessation intervention
75546373|NCT00282009|Behavioral|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
75708529|NCT04527107|Drug|THR-149 dose level 1|3 intravitreal injections of THR-149 dose level 1, 1 month apart
75546374|NCT00272753|Drug|budesonide/formoterol Turbuhaler|
75546375|NCT00272753|Drug|formoterol Turbuhaler|
75546376|NCT00272753|Drug|salbutamol|
75546377|NCT00307866|Procedure|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
75546378|NCT00272831|Drug|Cilostazol|Cilostazol 100 mg twice daily
75708530|NCT04527107|Drug|THR-149 dose level 2|3 intravitreal injections of THR-149 dose level 2, 1 month apart
75708531|NCT04527107|Drug|THR-149 dose level 3|3 intravitreal injections of THR-149 dose level 3, 1 month apart
75708532|NCT04527107|Drug|THR-149 0.13mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection
75708533|NCT04527107|Drug|THR-149 0.13mg + aflibercept 2mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by an intravitreal injection of aflibercept 2mg
75395100|NCT04758858|Other|Hypoglycemia journal|During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
76036032|NCT03098017|Other|Short pasta (dry)|50g available carbohydrate portion of penne (~71g uncooked) will be cooked according to package instructions and served with 500mL water
75395101|NCT04758858|Other|Ketone journal|During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
75708534|NCT04527107|Drug|aflibercept 2mg + THR-149 0.13mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by an intravitreal injection of THR-149 0.13mg (selected dose level)
75708535|NCT04527107|Drug|Aflibercept 2mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by a sham (pretend) injection
75708536|NCT04515342|Diagnostic Test|DXA|Each participant will undergo one DXA scan
75395102|NCT04758858|Other|Adherence to the diet (Keenoa)|During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
75395103|NCT04125888|Drug|Allergy immunotherapy (AIT)|Immunotherapy for different types of allergies
75708537|NCT04515342|Other|Muscle strength and function assessment|Each patient will have their muscle strength and function assessed with the measurements of handgrip strength, 10 m gait speed and a 30 s sit-to-stand test. They will also fill out a questionnaire assessing Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls (SARC-F questionnaire).
75708538|NCT04515342|Other|Blood samples|Each patient will undergo a physical examination and also deliver blood samples.
75708539|NCT04512287|Drug|Autologous Platelet Rich Plasma|2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.
76036033|NCT03098017|Other|Long pasta (dry)|50g available carbohydrate portion of spaghetti (~71g uncooked) will be cooked according to package instructions and served with 500mL water
76036034|NCT03098017|Other|Couscous|50g available carbohydrate portion of couscous (~70g uncooked) will be cooked according to package instructions and served with 500mL water
75395104|NCT04759092|Device|transcranial direct current stimulation (tDCS)|Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.
75395105|NCT02975310|Procedure|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
75395106|NCT02975310|Procedure|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
75708540|NCT04512287|Other|Saline Solution|2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.
75708541|NCT04505553|Procedure|Acupuncture Therapy|Undergo acupuncture
75708542|NCT04505553|Procedure|Acupressure Therapy|Undergo acupressure
75708543|NCT04505553|Procedure|Oral Cryotherapy|Undergo oral cryotherapy
75708544|NCT04505553|Other|Questionnaire Administration|Ancillary studies
75708545|NCT04505553|Other|Quality-of-Life Assessment|Ancillary studies
75395107|NCT02975310|Other|General Anesthesia|ESS will be performed under general anesthesia in the operating room
75395108|NCT02975310|Other|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
75395109|NCT05609136|Other|Bobath+Scapular Stabilization Exercises|Scapular stabilization exercises will be given to patients in addition to Bobath therapy. It will be applied with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
75395110|NCT04394208|Drug|Silymarin|Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
75395111|NCT04394208|Drug|Placebo|Placebo comparator
75395112|NCT05608980|Drug|0.01% hypochlorous acid|once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
75395113|NCT05608980|Drug|Placebo|once daily eyelid wipes for 2 weeks
75395114|NCT03829566|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
75546379|NCT00272831|Drug|Placebo|1 tablet twice daily
75546380|NCT00417105|Procedure|hemodialysis|group 1: twice weekly, four hours
75546381|NCT00417105|Procedure|hemodialysis|group 2: twice weekly, eight hours
75870538|NCT02375230|Procedure|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift."
75870539|NCT02384590|Behavioral|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
75870540|NCT02384278|Behavioral|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
75870541|NCT02379598|Dietary Supplement|Aminoacid based formula|Formula based on aminoacid
75870542|NCT02379598|Dietary Supplement|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
75870543|NCT02379676|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
75870544|NCT02379676|Drug|Clopidogrel|Clopidogrel 75mg once daily for 30 days
75708546|NCT04504422|Device|transcranial Direct Current Stimulation (tDCS)|tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).
75395115|NCT03829566|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
75395116|NCT03829566|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
75395117|NCT03829566|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
75395118|NCT03829566|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
75395119|NCT03829566|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
75395120|NCT03829566|Biological|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
75708547|NCT04503278|Biological|CLDN6 CAR-T/CLDN6 CAR-T(A)|administered as an i.v. infusion.
75395121|NCT03829566|Biological|Autologous Stem Cells|Infusion of patient's own stem cells
75395122|NCT03933306|Drug|Dexmedetomidine|Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.
75546382|NCT00417105|Procedure|hemodialysis|group 3: every other day, eight hours
75546383|NCT00417105|Procedure|hemodialysis|group 4: six days a week, eight hours
75546384|NCT00416468|Drug|Aliskiren|
75546385|NCT00416468|Drug|Valsartan|
75546386|NCT00307905|Drug|Traumeel S|homeopathic remedy
75546387|NCT00307905|Drug|Placebo remedy|identical size, shape and taste of treatment medication
75546388|NCT02960828|Procedure|Subthreshold Laser Photocoagulation|Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
75546389|NCT02960828|Drug|intravitreal Anti-VEGF injection|To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
75546390|NCT02960828|Device|Subthreshold Laser|
75708548|NCT04503278|Biological|CLDN6 unmodified RNA-LPX/CLDN6 modified RNA-LPX|administered as an i.v. injection at protocol-specified intervals.
75395123|NCT03933306|Drug|Placebo|Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
75395124|NCT03933306|Other|Goal-directed blood pressure management|Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
75546391|NCT00307944|Drug|Pantoprazole|
75546392|NCT00416507|Drug|fluorouracil|
75546393|NCT00416507|Drug|gemcitabine hydrochloride|
75870545|NCT02379364|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
76036035|NCT03098017|Other|Glucose|50g available carbohydrate portion of glucose monohydrate (~55g) will be dissolved in 500mL water
76036036|NCT05619341|Dietary Supplement|psyllium|psyllium 20g
76036037|NCT05619341|Dietary Supplement|inulin|long chain fructan
75395125|NCT03933306|Other|Routine blood pressure management|Blood pressure is maintained according to routine practice, i.e., systolic blood pressure > 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
75395126|NCT04125576|Diagnostic Test|magnetic resonance imaging(MRI)|magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network
75395127|NCT04125654|Device|mNGS for pathogen detection|This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
75395128|NCT04394442|Drug|Hydroxychloroquine|400mg BD first day then 200 mg BD for 5 days
75395129|NCT04125264|Device|Intense Therapeutic Ultrasound|Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
75395130|NCT02972424|Drug|Teriparatide Prefilled Syringe|TPTD 20 mcg
75395131|NCT02972424|Drug|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
75546394|NCT00416507|Drug|liposomal cisplatin|
75546395|NCT00416546|Drug|AEB071|
75546396|NCT00282126|Dietary Supplement|Potassium citrate|kcitrate
75546397|NCT00272870|Drug|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
75546398|NCT00272870|Genetic|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
75546399|NCT00272870|Device|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
76036038|NCT05040919|Other|collection of medical and socio-demographic data|collection of medical and socio-demographic data
75395132|NCT04393428|Other|[TIMP-2]*[IGFBP-7]|[TIMP-2]*[IGFBP-7] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
75708549|NCT04502381|Drug|Inhaled amp B deoxycholate+intravenous liposomal amp B|"Intravenous liposomal amphotericin B (beginning with 3mg/kg) along with inhaled amphotericin as below: Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited), will be dissolved in 10 mL distilled water. 2 mL of the reconstituted amphotericin B solution will be transferred into the drug chamber of a breath actuated nebulizer (Lupineb Ultra kit breath actuated nebulize which contains aeroclipse XL Reusable Breath Actuated Nebulizer and DeVilbiss 3655 compressor). 3 mL of distilled water is added to 2 mL of the reconstituted amphotericin B. The nebulization is continued till the chamber is emptied of the drug or the patient does not tolerate the therapy.~The first three doses of amphotericin B nebulization will be under the direct supervision of a physician. If tolerated, nebulization will be continued twice a day till tolerated or till response.The patient will complete a VAS score for cough after nebulization."
75708550|NCT04502381|Drug|Intravenous liposomal amphotericin B alone|Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
75708551|NCT04489719|Procedure|Biospecimen Collection|Undergo collection of blood samples
76036039|NCT05040607|Other|Data Collection|"The first stage of the study:~Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL).~The second stage of the study~Retrospective data of pulmonary function, respiratory muscle strength, functional capacity before and after supervised inspiratory muscle training with POWERbreathe K5 device and airway clearance techniques performed for 6 weeks in PCD with decreased respiratory muscle strength (Intervention Group).~Retrospective data of pulmonary function, respiratory muscle strength, and functional capacity before and after airway clearance techniques performed for 6 weeks as home-based therapy in PCD with decreased respiratory muscle strength (Control group)."
75395133|NCT05608590|Drug|Lipiodol UltraFluid|The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
75395134|NCT04393584|Drug|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
75395135|NCT04393584|Drug|5-FU|d1-2 5-FU 2450 mg/m² every two weeks
75395136|NCT04393584|Drug|Leucovorin|d1 Leucovorin 200 mg/m² every two weeks
75395137|NCT04393584|Drug|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
75395138|NCT04393584|Drug|Docetaxel|d1 Docetaxel 50mg/m2 every two weeks
75395139|NCT02316366|Device|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
75395140|NCT03828864|Device|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
75395141|NCT03828864|Device|Placebo Pulsed Shortwave Therapy|Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
75546400|NCT00308022|Device|High Frequency Percussive Ventilation|
75546401|NCT00272909|Drug|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
76036040|NCT05040607|Other|Data Collection|-Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL)
76036041|NCT05040529|Procedure|pure laparoscopic donor hepatectomy|pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital
76036042|NCT05040529|Procedure|conventional open donor hepatectomy|conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
76036043|NCT05040139|Procedure|Malone Procedure|Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.
75395142|NCT02315352|Drug|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
75395143|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
75395144|NCT02315352|Drug|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
75395145|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
75395146|NCT02315352|Drug|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
75546402|NCT00272909|Drug|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
76036044|NCT05040139|Procedure|Percutaneous endoscopic caecostomy|Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
76036045|NCT05031793|Other|TCM|TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.
76036046|NCT05031793|Other|Western medicine|Western medicine include nasal spray steroid, oral antihistamine
75546403|NCT00272909|Drug|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
75546404|NCT00282165|Drug|naratriptan|four weeks double blind experimental treatment using oral naratriptan
76036047|NCT05039905|Drug|99mTc-MSA-ICG|Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
76036048|NCT05039983|Other|EGCG|EGCG use various concentrations dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls.
76036049|NCT05031403|Other|Telerehabilitaton|Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.
75395147|NCT04125108|Other|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
75395148|NCT05608356|Biological|injectable platelet rich fibrin(i-prf)|I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.
75395149|NCT05608356|Drug|Sham Injection|Sham injection as a placebo injection
75395150|NCT03828474|Drug|Acetazolamide Pill|Acetazolamide pill
75395151|NCT04394364|Device|Bispectral index|The BIS monitor will be attached to patients' forehead before anesthetized and kept until the end of the surgery
75395152|NCT05608122|Other|Obervation|This study is an observational study without any intervention
75395153|NCT05608122|Other|Obervation|This study is an observational study without any intervention
76036050|NCT05031403|Other|Home Exercise|Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.
75395154|NCT04120818|Procedure|secondary IOL implantation|reopened the fibrotic, closed capsular bag and achieve IOL placement
75546405|NCT00282165|Drug|placebo|four weeks double blind placebo treatment
75546406|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d
75546407|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
75546408|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
75546409|NCT00308100|Drug|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
75546410|NCT00308100|Drug|5% Albumin|5% albumin, administered intra- and perioperatively
75395155|NCT04120818|Procedure|primary IOL implantation|lensectomy and anterior vitrectomy and primary IOL implantation
75395156|NCT03822156|Other|Observation of AFB smear/culture|Observation of the patients from group for their AFB smear/culture results
75395157|NCT03822234|Procedure|Modified ileal conduit|Modified ileal conduit (Extraperitonealization)
75546411|NCT00273026|Drug|salmeterol xinafoate/fluticasone propionate|
76036051|NCT05039827|Other|Mobilization with movement|Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.
75546412|NCT00282204|Behavioral|antenatal hypnosis + audio compact disc on hypnosis|
75546413|NCT00282204|Behavioral|Audio compact disc on hypnosis|
76036052|NCT05039827|Other|Soft Tissue Mobilization|Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
75395158|NCT03827928|Behavioral|Yoga/meditation|A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
75546414|NCT00308178|Drug|Abraxane|Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
75546415|NCT00282321|Behavioral|High Protein diet|
75546416|NCT00282321|Behavioral|High carbohydrate diet|
75546417|NCT00282360|Drug|Trimetazidine|
75395159|NCT04392414|Biological|COVID-19 convalescent hyperimmune plasma|Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
75546418|NCT00273065|Drug|Neosaxitoxin|
75546419|NCT00418626|Drug|Nilotinib|
75546420|NCT00418704|Drug|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
75546421|NCT00418704|Drug|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
75546422|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
75546423|NCT00313950|Biological|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
75546424|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
75546425|NCT00273104|Procedure|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
75708552|NCT04489719|Other|Questionnaire Administration|Ancillary studies
75708553|NCT04489719|Drug|Radium Ra 223 Dichloride|Given IV
75395160|NCT04392414|Biological|Non-convalescent fresh frozen plasma (Standard plasma)|Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
76036053|NCT05040061|Behavioral|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
76036054|NCT05040061|Behavioral|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI prompted participants to notice and write current thoughts and feelings, plan the day's major activities, remember and write about their daily events, and anticipate upcoming important events.
75395161|NCT03828084|Drug|Decitabine|Combination drugs containing decitabine and tetrahydrouridine
75395162|NCT03827772|Other|Fecal Microbiota Transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
75395163|NCT03827772|Other|Standard of care treatment|Nutritional supplementation, supportive management.
75546426|NCT00273104|Behavioral|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
76036055|NCT05051371|Device|Train of four monitoring|Train of four monitoring in postoperative care unit
75546427|NCT00273221|Procedure|Glaucoma Implant Surgery|
75546428|NCT00273221|Procedure|trabeculectomy|
76036056|NCT05051839|Procedure|Implant surgery and restoration|Implants with two different transmucosal neck configuration are placed.
76036057|NCT05031559|Behavioral|Episodic Future Thinking|Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.
75395164|NCT03822000|Other|Survival|Elderly patients with fall-induced femoral fracture who were survived.
75395165|NCT03822000|Other|Death|Elderly patients with fall-induced femoral fracture who were dead.
75395166|NCT02315430|Drug|Cabozantinib S-malate|Given PO
76036058|NCT05031559|Behavioral|Compassion Training|Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.
75395167|NCT02315430|Other|Laboratory Biomarker Analysis|Optional correlative studies
75546429|NCT00273221|Procedure|phacoemulsification|
76036059|NCT05031559|Behavioral|Sham|Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
76036060|NCT05039749|Device|Human Centric Lights|Bright light is emitted during the day from 06:00, then auto-dimmed light is used at night, beginning 19:00.
75546430|NCT04708691|Other|Aerobic exercise|aerobic exercise
75546431|NCT02960178|Behavioral|Perturbation-based training|Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
75546432|NCT02960178|Behavioral|Conventional walking training|Over-ground practice of stepping and balance tasks in standing. One hour in duration.
75546433|NCT00273260|Behavioral|individualised bone density feedback and education|
75546434|NCT00273299|Drug|valsartan plus hydrochlorothiazide|
75546435|NCT00314028|Behavioral|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
75395168|NCT04274244|Drug|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"Regenerative periodontal therapy + Cross-linked hyaluronic acid 1.8%:~The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~Application of Hyadent BG® 1,8% filling the bone defect from the bottom upwards in the test group.~Single internal modified mattress suture (5/0 Vicryl, Ethicon).~Sutures will be removed after two weeks."
75546436|NCT00314028|Other|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
75546437|NCT00418782|Drug|naproxen|
75546438|NCT00418782|Drug|CE-224535|
75546439|NCT00418782|Drug|placebo|
75546440|NCT00273338|Drug|calcitriol|
75546441|NCT00273338|Drug|docetaxel|
75546442|NCT00314067|Procedure|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
75546443|NCT00314067|Procedure|Physician training|
75546444|NCT00314067|Procedure|Practice team training|
75546445|NCT00273377|Other|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
75546446|NCT00273377|Other|Supplemental oxygen (80% vs. 30%)|
75546447|NCT00273377|Drug|Dexamethasone|4 mg
75546448|NCT00273377|Drug|Placebo|placebo
75546449|NCT00273416|Drug|PF-00592379|
76036061|NCT05039437|Dietary Supplement|MGF-4|Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
75546450|NCT00273416|Drug|Sildenafil 100mg|
75546451|NCT00314184|Drug|quetiapine fumarate|
75546452|NCT00273455|Drug|bimatoprost 0.03%|
75546453|NCT00273455|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
75546454|NCT00273455|Drug|placebo|
75546455|NCT00273494|Procedure|Surgery|
75546456|NCT00308256|Behavioral|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
75546457|NCT00273533|Drug|Ramipril|
75546458|NCT00273572|Other|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
75546459|NCT00273572|Other|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
75546460|NCT00308295|Drug|Fish oil capsules|
75546461|NCT00308295|Drug|matched placebo capsules|
75546462|NCT00273611|Behavioral|Pharmacist Education about Vitamin D|
75546463|NCT00314301|Device|loaded sit-to-stand training|
75546464|NCT00273689|Drug|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
75546465|NCT00273689|Drug|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
76036062|NCT05039437|Dietary Supplement|MGF-7|Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
76036063|NCT05030779|Biological|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
76036064|NCT05031091|Other|standardised exposure questionnaire|A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
75546466|NCT00273728|Drug|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
75546467|NCT00308334|Drug|Domperidone|10 mg po TID X 14 days
75546468|NCT00308334|Drug|Placebo- Sugar pill|placebo po TID x 14 days
75546469|NCT00273767|Drug|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
75546470|NCT00273767|Drug|placebo|60ml of NaCl IV slow
75546471|NCT00314379|Drug|Vitamin E 400IU/day|
75546472|NCT00273806|Behavioral|Intervention for 4 behavioral risks by medical assistants.|
75546473|NCT00273845|Behavioral|Motivational interviewing|One session
75546474|NCT00273845|Behavioral|Strengths-Based Case Management|5 sessions
75546475|NCT00273884|Drug|Amonafide L-Malate|
75546476|NCT00273884|Drug|Cytarabine|
76036065|NCT05051683|Procedure|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer|endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
76036066|NCT04814069|Drug|Tislelizumab|Tislelizumab 200mg q3w
76036067|NCT05031169|Procedure|interdental papilla surgical reconstructiion|Surgical treatment of receding interdentalpapillae
76036068|NCT05051137|Biological|Infliximab|Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.
76036069|NCT05051137|Drug|Sulfasalazine + Hydroxychloroquine|Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
75546477|NCT00308373|Drug|Metformin vs Thiazolidinedione (Pioglitazone)|
75546478|NCT00273962|Drug|ipratropium plus salbutamol UDV|
75546479|NCT00273962|Drug|salbutamol UDV|
75546480|NCT00314418|Procedure|Colonoscopy in the prone position|
75546481|NCT00274001|Drug|Nevirapine|
75546482|NCT00308412|Biological|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
75546483|NCT00308412|Biological|Placebo|Placebo for rHPIV3cp45 vaccine
75546484|NCT00274040|Drug|Tiotropium|
75546485|NCT00274040|Drug|Ipratropium|
75546486|NCT00314457|Drug|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
75546487|NCT00308451|Drug|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
75546488|NCT00274079|Drug|SPIRIVA|
75546489|NCT00274118|Drug|telmisartan|
75546490|NCT00274118|Drug|enalapril|
75546491|NCT00419055|Procedure|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
75546492|NCT00274157|Behavioral|Behavior|
75546493|NCT00274157|Behavioral|diet control, smoking cessation, exercize|
75546494|NCT00308490|Drug|iron sucrose|
75546495|NCT00416585|Drug|isotretinoin (Roaccutane)|
75546496|NCT00274196|Procedure|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
75708554|NCT04472910|Drug|Modified Folforinox (mFFX)|Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
75708555|NCT04468113|Device|Tumark® Vision clip|Suspicious intramammary lesion is marked with clip
75546497|NCT00274196|Procedure|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
75395169|NCT04274244|Drug|Enamel Matrix Proteins (Active comparator group)|"Regenerative periodontal therapy + Enamel matrix proteins:~The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~Application of Emdogain® filling the bone defect from the bottom upwards in the active comparator group.~Single internal modified mattress suture (5/0 Vicryl, Ethicon).~Sutures will be removed after two weeks."
75395170|NCT04274322|Other|Nutrition support|Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement
75546498|NCT00308529|Drug|irinotecan|
75546499|NCT00308529|Drug|carboplatin|
75546500|NCT00308529|Drug|bevacizumab|
75546501|NCT00308529|Procedure|Radiation Therapy|
75546502|NCT00274235|Drug|sulfadoxine-pyrimethamine / mefloquine|
75546503|NCT00308568|Behavioral|Mailed educational brochure|
75546504|NCT00274274|Drug|insulin detemir|
75546505|NCT00274274|Drug|insulin aspart|
75708556|NCT04466566|Other|Saline|Saline will serve as the control
75870546|NCT02379130|Behavioral|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
75870547|NCT02379130|Behavioral|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
76036070|NCT05039125|Radiation|ultrasonic cavitation|"From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~Part III: 3cm above the umbilicus to 2cm below the umbilicus~After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months"
75546506|NCT00308607|Drug|Bevacizumab (Avastin)|
75546507|NCT00308607|Drug|dacarbazine|
75546508|NCT00308607|Drug|interferon-alfa-2a (Roferon-A)|
75546509|NCT00274313|Drug|552-02|
75546510|NCT00314613|Drug|Antipsychotic/Risperidone Consta|
75546511|NCT00274352|Drug|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
75546512|NCT00416663|Procedure|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
75708557|NCT04466566|Biological|Exendin-9,39|Exendin-9,39 will block the GLP-1 receptor
75708558|NCT04466475|Biological|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
75708559|NCT04466475|Drug|Melphalan|Given via infusion
75708560|NCT04466475|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
75708561|NCT04454697|Device|tissue retractors|Patients receive a tissue retractor to spare healthy tissue during the course of radiation
75395171|NCT04273698|Behavioral|Parent-infant psychotherapy|Brief psychoanalytic parent-infant psychotherapy
75395172|NCT04274166|Drug|secukinumab 150 mg (2 injections per dose|secukinumab 150 mg (2 injections per dose
75395173|NCT04274088|Procedure|Cataract surgery|Phacoemulsification surgery
75395174|NCT02983968|Other|Description of the cirrhosis management|
75395175|NCT05606952|Device|Color Doppler|color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter
75395176|NCT02983734|Drug|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
75395177|NCT02983734|Drug|Placebos|Sugar pill
75546513|NCT00314652|Drug|Buprenorphine transdermal delivery system|
76036071|NCT05038969|Drug|Stomopral|1 capsule contains 40 mg Esomeprazole
75395178|NCT03821454|Drug|Capecitabine|Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
75395179|NCT03821454|Drug|Placebos|Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
76036072|NCT05038969|Drug|Nexium|1 capsule contains 40 mg Esomeprazole
75546514|NCT00274391|Drug|7% NaCl|
75546515|NCT00274391|Drug|Amiloride HCl|
75546516|NCT00308724|Behavioral|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
75546517|NCT00308724|Behavioral|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
75546518|NCT00274430|Drug|dexamethasone 8 mg bid|
75546519|NCT00274430|Drug|tadalafil 10mg bid|
75546520|NCT00314691|Genetic|Blood samples|
75546521|NCT00274547|Drug|Tiotropium|
75546522|NCT00308763|Drug|Nicotine Patch|"After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.~If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off."
75546523|NCT00308763|Drug|Sustained Release Bupropion|Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
75546524|NCT00314730|Device|handheld Personal Digital Assistant (PDA)|
76036073|NCT04434547|Biological|PRP|During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
75395180|NCT03827148|Other|Pharmaceutical Care|Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
75395181|NCT04392492|Device|MANTA vascular closure device|Femoral access site closure using the MANTA closure device
76036074|NCT04434391|Other|QF-PCR for GBS screening|QF-PCR for GBS screening in pregnant women,compared with GBS culture test.
76036075|NCT05030389|Behavioral|Adapted Physical Activity (APA)|The APA program lasts 12 weeks and consists in three one-hour at-home sessions a week (total of 36 sessions), including two aerobic dominant web-based sessions and one muscle strengthening self-guided session.
75546525|NCT00274586|Drug|Aggrenox® modified release capsules|
75546526|NCT00274586|Drug|Aggrenox® modified release capsules matching placebo|
75546527|NCT00308802|Procedure|Kidney transplantation|Participants in this study will have had a kidney transplant
75546528|NCT00274664|Device|6 hours occlusion by patching|
75546529|NCT00274664|Device|12 hours occlusion by patching|
75546530|NCT00274703|Drug|mepolizumab|
75395182|NCT04392570|Diagnostic Test|Fasting|blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
75395183|NCT03827304|Device|Virtual Reality Distraction from Burn Pain|Patients wore a VR headset while undergoing a burns dressing change
75546531|NCT00274820|Dietary Supplement|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
75546532|NCT00274820|Drug|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
75546533|NCT00274820|Drug|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
75546534|NCT00274820|Drug|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience < grade 1 thalidomide-attributed toxicity using CTC criteria.
75546535|NCT00308841|Drug|Lidocaine (drug)|
75395184|NCT03820674|Other|Energy Conservation plus Problem Solving Therapy|EC-PST is a client-centered intervention aiming to guide people with chronic fatigue to create their own solutions so that they can generalize those learned solutions and strategies to other fatigue-related problems even after completing the study participation. Some of the topics covered during the first two introductory sessions are facts regarding fatigue, budgeting and banking energy, and the introduction of EC+PST Intervention.
75395185|NCT03820674|Other|Health Education Intervention|The interventionist will be the PI, an occupational therapist (co-I), or OT graduate student who will be trained in the health education topics. During the Health Education sessions, participants will be educated on health-related topics relevant to CHF and EC strategies, although they will not learn how to apply the information to their daily life. Health Education Workbook containing information on the topics taught during the sessions will be provided during the Pretest visit and used throughout the Health Education sessions.
75395186|NCT03820518|Drug|Calcitriol|
75870548|NCT02379286|Other|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
75870549|NCT04439812|Other|Observation|The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
75870550|NCT04655326|Biological|Flore|personalized blend of GRAS approved probiotic strains, prebiotics, and botanicals
75870551|NCT02375308|Behavioral|HDT|20 sessions, individual psychotherapy
75870552|NCT02375308|Behavioral|ACDT|20 sessions, individual psychotherapy
75395187|NCT03820440|Diagnostic Test|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
75546536|NCT00274859|Drug|gemcitabine hydrochloride|
75546537|NCT00274859|Drug|oxaliplatin|
75546538|NCT00314847|Device|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
75546539|NCT00274898|Drug|celecoxib|
75546540|NCT00274898|Drug|docetaxel|
76036076|NCT05030389|Behavioral|Bright Light Exposure (BLE)|Bright light exposure (BLE) consists in using lamps for light therapy during 12 weeks, at the rate of five one-hour at-home sessions a week.
75546541|NCT00274898|Procedure|adjuvant therapy|
75546542|NCT00274898|Radiation|radiation therapy|
75546543|NCT00308880|Drug|Transamin|
75546544|NCT00277160|Drug|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
75546545|NCT00314886|Drug|Diet|
75546546|NCT00277199|Drug|Abatacept|
75870553|NCT02375074|Behavioral|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
76036077|NCT05030389|Behavioral|Galvanic Vestibular Stimulation (GVS)|The GVS program lasts 2 weeks and consists in five 20-minutes at-home sessions a week (total of 10 sessions), using a portable galvanic stimulator.
76036078|NCT05030389|Behavioral|Health Education program (HE)|The HE program lasts 14 weeks and consists in one one-hour at-home session a week (total of 14 sessions). This web-based intervention includes courses on general health (sleep habits, diet, physical activity, cardiovascular diseases, etc.).
76036079|NCT05038579|Procedure|Musiquence|The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
75395188|NCT03820440|Diagnostic Test|Lung recruitment manovre (LRM)|The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
76036080|NCT05038657|Drug|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
75395189|NCT01453764|Procedure|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
75395190|NCT03820206|Drug|Tranexamic Acid|1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
75395191|NCT03820206|Procedure|Cesarean section|Lower segement transverse cesarean section
75395192|NCT02955654|Behavioral|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
75395193|NCT02955654|Drug|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
75395194|NCT02955654|Behavioral|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
75395195|NCT01453842|Dietary Supplement|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
75546547|NCT02960100|Other|Informational Intervention|Receive standard HPV vaccine information (HPV VIS)
75546548|NCT02960100|Other|Media Intervention|Receive targeted HPV vaccine narrative-style video
75546549|NCT02960100|Other|Survey Administration|Ancillary studies
75546550|NCT00277277|Behavioral|Healthium|
75546551|NCT00308919|Drug|WST09|Treatment with WST09 Vascular Photodynamic therapy
75546552|NCT00277316|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
75546553|NCT00308958|Device|High frequency chest wall oscillator|
75546554|NCT00314925|Drug|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10^7 vp/kg), IV (in the vein) over 1 hour in a single administration
75395196|NCT01453842|Dietary Supplement|Olive oil|Carrot and olive oil and 1½ g of paracetamol
75395197|NCT01453842|Dietary Supplement|Carrot|Carrot and 1½ g of paracetamol
75395198|NCT03826836|Behavioral|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
75395199|NCT04392648|Drug|TAK-573|TAK-573 intravenous infusion.
75395200|NCT04392648|Drug|Pomalidomide|Pomalidomide capsules orally.
75395201|NCT04392648|Drug|Bortezomib|Bortezomib injection subcutaneously.
75395202|NCT04392648|Drug|Cyclophosphamide|Cyclophosphamide tablets orally.
75395203|NCT04392648|Drug|Dexamethasone|Dexamethasone tablets orally.
75395204|NCT03826602|Drug|Tucatinib|150mg administered orally twice daily
75395205|NCT03826602|Drug|Metformin|850mg administered orally
75395206|NCT03826602|Drug|Iohexol|1500 mg administered intravenously (IV)
75395207|NCT03820128|Other|Early diet intervention|Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.
75395208|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
75395209|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
75395210|NCT03821220|Behavioral|Motivational Interview support and Dietitian support|Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
75546555|NCT00277433|Other|Buccal Swab|collection of buccal swab
75546556|NCT00314964|Drug|PD-0299685|
75395211|NCT03821220|Behavioral|Activity tracker plus usual care|Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
75870554|NCT02375074|Behavioral|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
75395212|NCT03821220|Behavioral|Personalized physical activity prescription|Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.
75395213|NCT03820908|Drug|Bisantrene|The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
75395214|NCT02953548|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
75395215|NCT02953002|Device|Calibrated Automated Thrombogram (CAT)|The Calibrated Automated Thrombogram (CAT). Thrombogram describes the concentration of thrombin in clotting plasma and is therefore a general physiologic function test of the thrombotic hemostatic system. The CAT measures thrombotic as well as bleeding tendency.
75546557|NCT00277472|Drug|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
75546558|NCT00277472|Drug|HCTZ|25 mg taken once daily orally
75546559|NCT00277511|Drug|Levofloxacin|
75546560|NCT00315003|Drug|Telithromycin|
75546561|NCT00315003|Drug|Azithromycin|
75870555|NCT02375152|Procedure|Anterior Capsulotomy|
75870556|NCT03113032|Other|P-SEC Pre-Surgical Care|The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
75395216|NCT02952456|Other|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
75395217|NCT02952222|Drug|Dexmedetomidine|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
75395218|NCT02952222|Drug|Propofol (Group P)|Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
75546562|NCT00277550|Drug|Tegaserod and Placebo|
75546563|NCT00309036|Biological|Recombinant grass pollen|
75546564|NCT00277589|Drug|Levothyroxin-Na|1 tablet 30 minutes before breakfast
75546565|NCT00277589|Drug|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
75870557|NCT03113032|Other|Normal pre-surgical care|Routine pre-surgical care
75870558|NCT03105544|Other|simulation-based training|As described under group descriptions
75870559|NCT03105622|Behavioral|TV and music|Watching TV or listening to music while running on a treadmill
75870560|NCT02378974|Biological|Cordstem-ST|
75395219|NCT02952222|Drug|Propofol (Group DP)|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
75546566|NCT00277589|Drug|Iodide|1 tablet 30 minutes before breakfast
75870561|NCT02378974|Biological|Placebo|
75546567|NCT00277589|Drug|Placebo|1 tablet 30 minutes before breakfast
75546568|NCT00315042|Drug|Telithromycin (HMR3647)|
75546569|NCT00315042|Drug|Penicillin|
75546570|NCT00277667|Drug|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
75870562|NCT02378896|Behavioral|Personalized Computer Program|Training with a personalized computerized inhibitory training program
75870563|NCT02378896|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
75870564|NCT02378818|Behavioral|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
76036081|NCT03094585|Other|Written and oral information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
76036082|NCT03094585|Other|Written information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
76036083|NCT05038501|Other|To study comorbidities in patients undergoing Oncosurgeries|In the Preoperative Anaesthesia checkup we will study prevalence of comorbidities as Coronary artery Disease, Hypertension, Diabetes Mellitus , Hypothyroidism and prior Corona Virus Infection in patients undergoing Oncosurgeries
75395220|NCT03826446|Procedure|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
75546571|NCT00315081|Drug|Bromocriptin|
75546572|NCT00277706|Procedure|Periodontal surgery|
75546573|NCT00277706|Drug|FORTEO|parathyroid hormone; self-administration for 6 weeks
75546574|NCT00277706|Drug|Placebo|placebo; self administration for 6 weeks
75546575|NCT00277706|Dietary Supplement|Vitamin D and Calcium|PO, QD, for six weeks
75546576|NCT00309075|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
75546577|NCT00277745|Device|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
75546578|NCT00419133|Biological|Killed bivalent whole cell oral cholera vaccine|"Each 1.5 mL dose, given orally, contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
75546579|NCT00419133|Biological|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
75546580|NCT00277784|Procedure|Ultrasound examination|one ultrasound examination
75546581|NCT00309114|Procedure|bacterial interference|
75546582|NCT00277823|Drug|DVS-SR 50 mg|
75546583|NCT00277823|Drug|DVS-SR 100 mg|
75546584|NCT00277823|Drug|Placebo|
75546585|NCT00277862|Drug|Pegylated IFN- alpha 2b|
75546586|NCT00277862|Drug|Ribavirin|
75546587|NCT00309231|Procedure|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
75546588|NCT00315159|Procedure|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
75708562|NCT04451135|Diagnostic Test|Electroencephalographic (EEG)|EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
76036084|NCT03095833|Other|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
75558042|NCT00477711|Drug|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
75558043|NCT03278561|Procedure|Sputum induction|Sputum induction according to the ERS protocol
75558044|NCT03278561|Procedure|Blood sample|A blood sample of 100ml will be taken.
75558045|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
76036085|NCT03095833|Other|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
76036086|NCT03095833|Other|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
75558046|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
75558047|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
75558048|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
76036087|NCT03095833|Other|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
75395221|NCT03826056|Behavioral|Current standard discharge educational intervention|The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
75558049|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
75558050|NCT00439803|Biological|AVX601|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
75558051|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
75558052|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
75558053|NCT00442403|Drug|chloroquine|
75395222|NCT03826056|Behavioral|Personalized discharge educational intervention|The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
75395223|NCT03821688|Procedure|SAS-JB|single anastomosis sleeve jejunal bypass
76036088|NCT03095833|Other|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
75395224|NCT03821688|Procedure|OAGB|one anastomosis gastric bypass
75546589|NCT04719260|Behavioral|Nutrition Thinking®|In the first session, the nutritionist will carry out the anamnesis through the Empathy Map and assessment of the nutritional status to define the Nutrition Briefing. The steps described by Design Thinking as understanding, observation, and point of view comprise the first phase of this session. The ideation process will proceed from the definition of the Nutrition Challenge. Prototyping is the final stage of the first session, where an initial prototype of the diet will be co-created based on visual thinking tools and the description underlying the creation of diets. Within 24 hours the individual will receive a summary of the material developed by email. The period between sessions will comprise the testing phase and the follow-up sessions the iteration phase where the experience and previous steps are revisited in order to create new insights, anthropometric measurements will be seen as reflections of the experience and not as primary outcomes of the intervention.
75546590|NCT04719260|Behavioral|Standard Nutritional Approach|In the first session the nutritionist will carry out the food and nutritional anamnesis and assessment of the nutritional status. From this information, the nutritionist will generate the diagnostic hypothesis and determine the specific nutritional needs. The professional will be responsible for generating the dietary prescription defining the characteristics of the diet that will be delivered printed to the individual after a period of 15 days, in the second session of the protocol. The follow-up session will be based on adherence to the established conduct and monitoring of anthropometric variations.
75395225|NCT03821688|Procedure|LSG|laproscopic sleeve gastrectomy
75395226|NCT03826368|Dietary Supplement|Hemp-derived botanical dietary supplement|Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
75395227|NCT03825354|Behavioral|BIC|World Health Organization, WHO, Brief Intervention and Contact (BIC)
75395228|NCT04391478|Drug|Milrinone|milrinone lactate, 1mg/ml, for intra venous use only
75395229|NCT04391478|Drug|Sildenafil|50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube
75395230|NCT03828006|Dietary Supplement|Red Rice Yeast|Participants will take one tablet per day of a dietary supplement based on red rice yeas for a period of six months
75395231|NCT03828006|Other|Placebo Group|Participants of this group will take one tablet of placebo per day for a period of six months
75395232|NCT03823014|Device|Elator|Measurement for device, use of device
75395233|NCT04346706|Device|Extraction and Implant insertion (test)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated. Tooth extractions were carried out atraumatically using periotomes. Implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ, at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
75546591|NCT00315198|Device|Eye Patch|2 hours daily patching
75546592|NCT00315198|Procedure|Near activities|near visual activities while patching
75546593|NCT00315198|Procedure|Distance activities|distance visual activities while patching
75546594|NCT00315237|Drug|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
75546595|NCT00278018|Procedure|Immunotherapy treatment for solid tumors|
75546596|NCT00309270|Drug|Campath-1H|
75870565|NCT02374684|Drug|Methosulide|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)"
75546597|NCT00278057|Drug|dialysisis with and without glucose in the dialysis|
75870566|NCT02374684|Drug|Placebo|Placebo to match with experimental groups
75546598|NCT00315276|Drug|Modafinil|
75546599|NCT00278096|Behavioral|occupational therapy|
75546600|NCT00309309|Drug|Rosiglitazone|
75546601|NCT00278135|Dietary Supplement|DHA (nutritional supplement) or placebo|oral 900mg/day
75546602|NCT00315315|Procedure|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
75546603|NCT00315315|Procedure|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
75558054|NCT00442403|Drug|dehydroepiandrosterone sulphate|
75546604|NCT00315315|Procedure|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
75546605|NCT00278174|Biological|recombinant interferon alpha-1b|
75546606|NCT00309348|Other|Weekly measurement of graft flow|
76036089|NCT03095833|Other|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
75546607|NCT00416702|Drug|QAB149|
76036090|NCT03095833|Other|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
76036091|NCT03095833|Other|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
75546608|NCT00278213|Biological|alemtuzumab|
75546609|NCT00278213|Drug|cyclophosphamide|
75546610|NCT00278213|Drug|fludarabine phosphate|
75546611|NCT00278213|Drug|mitoxantrone hydrochloride|
75546612|NCT00315354|Other|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
75546613|NCT00315354|Other|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
75546614|NCT00315354|Other|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
75546615|NCT00278252|Drug|etoposide|
75546616|NCT00278252|Procedure|conventional surgery|
75546617|NCT00315432|Drug|Pegylated Interferon and Ribavirin|
75546618|NCT00278330|Drug|alvocidib|Given by infusion
75546619|NCT00278330|Drug|vorinostat|Given orally
75546620|NCT00315510|Drug|Rosuvastatin|
75558055|NCT00477789|Drug|allopurinol|
75558056|NCT00442442|Device|mosquito coils|mosquito coil / night mosquito coil & LLIN / night
75558057|NCT00442442|Device|LLIN|Sleep under LLIN every night
76036092|NCT03095833|Other|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
76036093|NCT03095833|Other|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
75546621|NCT00278369|Biological|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
75546622|NCT00278369|Biological|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
75546623|NCT00315549|Drug|Telithromycin|
75546624|NCT00315549|Drug|Penicillin|
76036094|NCT03095833|Other|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
75546625|NCT00278408|Biological|filgrastim|
75546626|NCT00278408|Biological|rituximab|
75546627|NCT00278408|Drug|cyclophosphamide|
75546628|NCT00278408|Drug|doxorubicin hydrochloride|
75546629|NCT00278408|Drug|prednisone|
75546630|NCT00278408|Drug|vincristine sulfate|
75546631|NCT00278408|Radiation|radiation therapy|
75546632|NCT00315666|Drug|memantine|
75546633|NCT00278447|Behavioral|Chronic Disease Management for substance abuse|Referral to primary medical care & longitudinal, multidisciplinary care for persons with substance dependence.
75546634|NCT00278447|Behavioral|Standard care|Referral to primary medical care for persons with substance dependence.
75546635|NCT00315744|Drug|Salmeterol/fluticasone|Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
75546636|NCT00315744|Drug|Fluticasone propionate|Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
75546637|NCT00315744|Drug|Salbutamol|Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
75546638|NCT00278486|Biological|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
75546639|NCT00278603|Biological|Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Injection
75546640|NCT00309543|Drug|Fluorouracil|
75546641|NCT00309543|Drug|Leucovorin|
75546642|NCT00278642|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
75558058|NCT00439842|Behavioral|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
75558059|NCT00442481|Drug|Escitalopram|
75558060|NCT00442481|Procedure|A baseline overnight polysomnography (oPSG)|
75870567|NCT02374528|Procedure|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
75870568|NCT02374528|Procedure|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
76036095|NCT05038423|Behavioral|5R Shared Leadership Program|"The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., & Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., & Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176"
76036096|NCT05038423|Behavioral|12-week structured walking program|Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
76036097|NCT05038189|Diagnostic Test|Gait parameters|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
75395234|NCT04346706|Device|Implant insertion (control)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated, the implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ. This was done at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
75395235|NCT03825900|Device|Sham OR active Transcranial direct current stimulation|Sham OR active transcranial direct current stimulation over the motor cortex
75395236|NCT03826134|Drug|[11C]PXT012253|Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
75395237|NCT03825978|Behavioral|Prenatal Genetic Counseling|In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
75395238|NCT03826212|Dietary Supplement|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
75395239|NCT03826212|Dietary Supplement|Placebo|Placebo 1,600 mg/day for 12 weeks.
75395240|NCT03078348|Other|Fecal Immunochemical Test (FIT) Kit|Free FIT Kits distributed at study entry.
75395241|NCT03078348|Behavioral|Culturally targeted Photo Novella Booklet|Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
75708563|NCT04451135|Diagnostic Test|Closed loop acoustic stimulation (CLAS)|Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
75708564|NCT04451135|Diagnostic Test|Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
76036098|NCT05038189|Diagnostic Test|Spine posture|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
75395242|NCT03078348|Behavioral|Screen for Life Brochure|Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
75395243|NCT03829956|Device|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
75395244|NCT04391868|Drug|Viagra Tablet|50 mg tablet on Day 1 of each period
75395245|NCT04391868|Drug|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
75395246|NCT04391868|Drug|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
75395247|NCT03827616|Radiation|Hypofractionated IMRT using helical Tomotherapy.|70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
75395248|NCT03827616|Radiation|Hypofractionated IMRT using helical Tomotherapy.|60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
75395249|NCT03823794|Other|No intervention|Observational analysis of usual care only
76036099|NCT05038189|Diagnostic Test|Trunk position sense|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
75395250|NCT03821532|Other|Constipation Action Plan|Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
75558061|NCT00439881|Drug|SB-681323|
76036100|NCT05051215|Other||
75708565|NCT04451135|Diagnostic Test|Ictal Electroencephalographic (EEG) Measurements|A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
75708566|NCT04451135|Diagnostic Test|Post-Ictal Electroencephalographic (EEG) Suppression Measurements|A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
75708567|NCT04451135|Diagnostic Test|Quantitative Measurements of Sleep Microstructure|Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
75395251|NCT03821766|Device|Ballistocardiography and seismocardiography|SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
75870569|NCT02378740|Drug|Saline|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
75870570|NCT02378740|Drug|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
75395252|NCT01454310|Device|Wound coverage by acellular skin substitute|Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
75708568|NCT04432597|Biological|PRGN-2009 (Phase I)|On the phase I portion of the protocol PRGN-2009 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. The dose level given as booster will be the same dose participants will be receiving for D1, D15 and D29.
75708569|NCT04432597|Biological|PRGN-2009 (Phase II)|On the phase II portion of the protocol PRGN-2009 will be administered on just Day (D)1 and D15.
75870571|NCT02383732|Behavioral|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention & Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
76036101|NCT04973059|Device|SmartDrive Summer|The SmartDrive is a power assist accessory for a manual wheelchair
76036102|NCT04973059|Device|SmartDrive Winter|The SmartDrive is a power assist accessory for a manual wheelchair
76036103|NCT05038111|Drug|Dexmedetomidine|perioperative dexmedetomidine infusion
75395253|NCT01454310|Device|Autologous skin|Matched burn wound is covered by autologous skin after tangential excision.
75395254|NCT03827382|Behavioral|Lifestyle Intervention|Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
75395255|NCT03829332|Biological|Pembrolizumab|IV infusion
75395256|NCT03829332|Drug|Lenvatinib|oral capsule
75395257|NCT03829332|Drug|Placebo for lenvatinib|oral capsule
75395258|NCT03825666|Other|ProvideXtra® Fresenius Kabi|Improving wellbeeing
75395259|NCT01454388|Other|breakfast|
75546643|NCT00278681|Drug|Zinc and ORS|"One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water."
75558062|NCT03279666|Other|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
75708570|NCT04432597|Biological|M7824|"Subjects enrolled to Arm 1B will receive M7824 (MSB0011359C) via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
75708571|NCT04432597|Diagnostic Test|MRI|MRI (with gadolinium) of the neck, chest, skull, and/or sinonasal, if indicated, will be used when computed tomography (CT) scan is not an option to follow the disease.
75708572|NCT04432597|Diagnostic Test|Bone scan|Bone scans and other imaging assessments may also be performed as clinically indicated.
75708573|NCT04432597|Diagnostic Test|CT scan|Imaging of the neck, chest, skull, and/or sinonasal, if indicated, will be performed every 8 weeks. In the event of a partial response (PR) or complete response (CR) tumor imaging assessments may be performed every 3 months (+/- 2 weeks) at the discretion of the investigator.
76036104|NCT05030077|Drug|Anlotinib|Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle
76036105|NCT05030077|Drug|Cisplatin|Cisplatin (70 mg/m2) IV day 1
76036106|NCT05030077|Drug|Carboplatin|If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1
76036107|NCT05030077|Drug|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
76036108|NCT05038033|Behavioral|Interpersonal Psychotherapy (IPT)|The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.
75546644|NCT02960139|Device|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
75546645|NCT00278759|Procedure|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
75546646|NCT00278837|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
75546647|NCT00315861|Drug|pemetrexed|
75708574|NCT04432597|Diagnostic Test|Brain CT|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
75708575|NCT04432597|Diagnostic Test|Brain MRI|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
76036109|NCT05038033|Behavioral|Cognitive Behavioral Theory (CBT)|The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
75708576|NCT04432597|Procedure|Biopsy (Phase I)|"Where feasible, optional biopsies may be done at baseline as well as at week 9 and will likely be computed tomography (CT) guided. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy for phase I participants.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 9 (phase I participants)."
75708577|NCT04432597|Procedure|Biopsy (Phase II)|"Where feasible, biopsies will be done at baseline as well as at week 4-5. Biopsies will be done by ear, nose and throat (ENT) under direct visualization. Where feasible at least 2 cores will be obtained. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 4-5 (phase II participants)."
75708578|NCT04416555|Device|Placebo comparator: VR googles and the non reality experience|parallel assignment (this arm will receive a static presentation in the same device)
75546648|NCT00315861|Drug|topotecan|
75395260|NCT01454466|Procedure|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
75546649|NCT00279032|Drug|GW406381|
75546650|NCT00309660|Drug|Rosiglitazone|
75395261|NCT01454544|Biological|AIT Tablet|1 tablet per day in 12 months
75546651|NCT00279071|Device|Acupuncture og acupressure when diagnosed with dystocia|Acupuncture points: sp6 li4 ki3 ki6 bl60 Acupressure points: bl67
75546652|NCT00315900|Drug|Depakote ER|depakote ER
75546653|NCT00315900|Drug|Seroquel|seroquel
75546654|NCT00279110|Behavioral|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
75546655|NCT00309699|Drug|Placebo|Daily for 3 weeks
75546656|NCT00309699|Drug|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
75546657|NCT00309699|Drug|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
75546658|NCT00279149|Procedure|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
75546659|NCT00315978|Device|Heart-to-Heart Decision Aid|
75546660|NCT00279188|Procedure|Guiding therapy by bronchial hyperrsponsiveness|
75546661|NCT00309816|Drug|sildenafil|
75546662|NCT00279266|Drug|Thiamine|
75546663|NCT00316095|Drug|telmisartan|
75546664|NCT00316095|Drug|simvastatin|
75546665|NCT00279344|Drug|Fentanyl (Matrifen)|
75546666|NCT00418860|Drug|Aspirin, Clopidogrel|Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
75546667|NCT00316134|Procedure|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
75546668|NCT00316212|Drug|INS50589 Intravenous Infusion|
75546669|NCT00309855|Drug|Placebo|im and orally
75546670|NCT00309855|Drug|Testosterone|injections
75546671|NCT00309855|Drug|Anastrazole|orally x 21 days
75708579|NCT04416555|Device|Active Comparator: VR googles and the real VR program to enter act with and experience|Parallel assignment (this arm will receive the full immersive virtual reality experience
75708580|NCT04408612|Diagnostic Test|Scales for assessment of symptoms|"Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale."
75546672|NCT00309855|Drug|Dutasteride|orally x 21 days
75546673|NCT00279383|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
75546674|NCT00316251|Device|Vibration Plate Therapy|
75546675|NCT00279422|Drug|visilizumab|
75546676|NCT00279422|Drug|visilizumab|
75546677|NCT00309894|Biological|sargramostim|
75546678|NCT00309894|Drug|ketoconazole|
75546679|NCT00309894|Drug|therapeutic hydrocortisone|
75546680|NCT00279461|Drug|Placebo in arm A and Vitamin D in arm B|Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
75546681|NCT00279461|Drug|vitamin D 3 for arm A ,and matching placebo for arm B|Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
75546682|NCT00316329|Drug|Artesunate + Amodiaquine|
75546683|NCT00279539|Genetic|Vascular Endothelial Growth Factor (VEGF1)|
75546684|NCT00279578|Drug|ReFacto (Recombinant factor VIII) and Tranexamic acid|
75546685|NCT00316368|Device|Ethicon TPW32 60 cm (pacing wires x 2)|
75546686|NCT00279617|Drug|levetiracetam|open label levetricetam
75546687|NCT00309972|Drug|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
75546688|NCT00309972|Drug|Experimental arm (CON):|concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
75546689|NCT00310011|Drug|cisplatin|
75546690|NCT00310011|Drug|gemcitabine hydrochloride|
75546691|NCT00310011|Drug|paclitaxel|
75546692|NCT00310011|Procedure|conventional surgery|
75546693|NCT00279656|Behavioral|Pharmaceutical care|
75546694|NCT00316407|Drug|lapatinib (GW572016)|1000 mg po qd
75546695|NCT00316407|Drug|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
76036110|NCT05029531|Combination Product|the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.|two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
76036111|NCT05037643|Procedure|TIPS|Transjugular Intrahepatic Portosystemic Shunt is performed to prevent / treat symptomatic portal hypertension
76036112|NCT05029453|Drug|Apatinib|In experimental group, the drug used with apatinib and chemotherapy.
76036113|NCT04434625|Drug|Polyethylene glycol|Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score<3 in IM group and those in the control group underwent colonoscopy directly
75395262|NCT03824730|Device|Stenting of the Common and/or External Iliac Arteries|"Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries."
75395263|NCT03824886|Other|Implementation of skin care algorithm|Implementation of structured and standardized skin care regimen
75395264|NCT02983188|Drug|Berberine|Berberine tablets, 0.3g every time, two times daily
75395265|NCT02983188|Drug|Placebos|Placebo tablets, 0.3g every time, two times daily
75546696|NCT00316407|Drug|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
75546697|NCT00279695|Procedure|high frequency ultrasound examination|high frequency ultrasound examination of the eye
75546698|NCT00310089|Biological|filgrastim|
75546699|NCT00310089|Biological|pegfilgrastim|
75546700|NCT00310089|Drug|cediranib maleate|
75546701|NCT00310089|Drug|cyclophosphamide|
75546702|NCT00310089|Drug|docetaxel|
75546703|NCT00310089|Drug|doxorubicin hydrochloride|
75546704|NCT00310089|Other|laboratory biomarker analysis|
75546705|NCT00310089|Procedure|conventional surgery|
75546706|NCT00310089|Procedure|neoadjuvant therapy|
75546707|NCT00279734|Drug|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
75546708|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
75546709|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
75546710|NCT00279734|Drug|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
75546711|NCT00310128|Drug|cisplatin|
75546712|NCT00310128|Drug|cytarabine|
75546713|NCT00310128|Drug|etoposide|
75546714|NCT00310128|Drug|methylprednisolone|
75546715|NCT00310128|Drug|rituximab|
75546716|NCT00310128|Drug|yttrium Y 90 ibritumomab tiuxetan|
75546717|NCT00310128|Procedure|antibody therapy|
75546718|NCT00310128|Procedure|biological therapy|
75546719|NCT00310128|Procedure|chemotherapy|
75546720|NCT00310128|Procedure|monoclonal antibody therapy|
76036114|NCT05029765|Dietary Supplement|Mediterranean diet|"Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates"
75546721|NCT00310128|Procedure|radiation therapy|
75546722|NCT00310128|Procedure|radioimmunotherapy|
75546723|NCT00310128|Procedure|radioisotope therapy|
75708581|NCT04400708|Procedure|adductor canal block|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of 0.5% ropivacaine 15ml is given.
76036115|NCT05029765|Dietary Supplement|Healthy diet (WHO recommendations)|Recommendations according to WHO
75708582|NCT04400708|Procedure|control group|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of normal saline15ml is given.
76036116|NCT05029765|Dietary Supplement|Placebo|Placebo
76036117|NCT05029765|Dietary Supplement|Biopolis-MIX42|Biopolis-MIX42: a capsule containing 10^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
76036118|NCT02640157|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
76036119|NCT02640157|Drug|Sofosbuvir|Tablet
76036120|NCT02640157|Drug|Daclatasvir|Tablet
76036121|NCT04471519|Biological|BBV152A - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
76036122|NCT04471519|Biological|BBV152B - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
76036123|NCT04471519|Biological|BBV152C - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
76036124|NCT04471519|Biological|Placebo - Phase I|0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14
75395266|NCT02983188|Drug|Antipsychotic Agents|Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
75395267|NCT01450176|Drug|Olopatadine hydrochloride 0.2%|1 drop in each eye once daily for 2 weeks
75395268|NCT01450176|Drug|Bepotastine besilate ophthalmic solution 1.5%|1 drop in each eye twice daily for 2 weeks
75395269|NCT01450254|Device|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
75546724|NCT00279773|Drug|TKI258|
75546725|NCT00418899|Behavioral|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
75546726|NCT00416741|Behavioral|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting [plasma flucose
75546727|NCT00416780|Other|counseling intervention|
75546728|NCT00416780|Other|educational intervention|
75546729|NCT00416780|Procedure|psychosocial assessment and care|
75546730|NCT00310167|Radiation|radiation therapy|
75546731|NCT00316563|Drug|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
75546732|NCT00316563|Other|Placebo|
75546733|NCT00416819|Biological|filgrastim|
75546734|NCT00416819|Biological|rituximab|
76036125|NCT04471519|Biological|BBV152A - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
76036126|NCT04471519|Biological|BBV152B - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
76036127|NCT05037565|Dietary Supplement|Partially hydrolyzed guar gum|Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
76036128|NCT05037721|Other|gargling with green tea|experimental group using 0.5% green tea gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
76036129|NCT05037721|Other|gargling with water|using water gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
76036130|NCT05037253|Drug|Vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
76036131|NCT05029297|Drug|Capsaicin|
75395270|NCT01450254|Other|Control|No intervention will be prescribed to the control group during participation in the study.
75708583|NCT04398992|Other|observation|Data were collected by a designed form. Statistic software was used to analyze clinical data.
76036132|NCT05028907|Drug|5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
75395271|NCT01454622|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
75546735|NCT00416819|Drug|cytarabine|
75546736|NCT00416819|Drug|etoposide phosphate|
75546737|NCT00416819|Drug|leucovorin calcium|
75546738|NCT00416819|Drug|methotrexate|
75708584|NCT04397874|Diagnostic Test|; Computerized cardiotocography (cCTG)|To estimate the correlation between the maternal perception of fetal movement and antepartum computerised cardiotocography parameters.
76036133|NCT05028907|Drug|sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
76036134|NCT03094117|Other|News items with spin|Interpretation of news items with spin
76036135|NCT03094117|Other|News items without spin|Interpretation of news items without spin
76036136|NCT05050201|Device|Sleepio|Digital CBT application for insomnia
76036137|NCT05026411|Diagnostic Test|T 0 Diffusion Tensor MR|Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment
75546739|NCT00416819|Drug|temozolomide|
75870572|NCT02383732|Behavioral|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
76036138|NCT05026411|Diagnostic Test|T 1 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.
75395272|NCT01454622|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
75546740|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
75546741|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
75546742|NCT00279890|Drug|Topical SR-01|
75546743|NCT00316641|Drug|Lipid-lowing Tea|
75708585|NCT04396483|Procedure|Pomeroy's tubal sterilization|Both Fallopian tubes will be grasped by allis forceps and a kokher forceps will be applied below the allis forceps then excision of tubal part above kokher and transfixation of both ends away from each other during cesarean section
75708586|NCT04396483|Procedure|Salpingectomy|Both fallopian tubes will be completely removed during cesarean section
76036139|NCT05026411|Diagnostic Test|T 2 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
75395273|NCT01450332|Device|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
75546744|NCT00310245|Procedure|STI (structured Treatment Interruption)|
75546745|NCT00279929|Procedure|DHEA Replacement|
76036140|NCT03094351|Procedure|esophagectomy|Robot assisted esophagectomy with extended two field lymphadenectomy.
75546746|NCT00279968|Device|ICD|
75546747|NCT00280007|Drug|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
75546748|NCT00316680|Biological|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
75546749|NCT00280046|Drug|biphasic insulin aspart|
75546750|NCT00310284|Behavioral|Computerized delivery of cognitive-behavioral treatment of insomnia|
75708587|NCT04390971|Biological|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
75708588|NCT04390308|Procedure|Ovarian puncture|Egg collection
75546751|NCT00310284|Behavioral|Self-help manual to improve insomnia symptoms|
75546752|NCT00280085|Procedure|MR imaging|
75546753|NCT00280085|Procedure|Glucose clamp|
75546754|NCT00280085|Drug|Arginine|
75546755|NCT00310323|Drug|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
75546756|NCT00310323|Drug|Caffeine|Administered as 4 ounces of Coca-Cola
75708589|NCT04390308|Other|Hormonal blood Test|AMH (ng/ml), FSH (IU/mL), E2(pg/mL), P4(ng/mL), LH (IU/mL)
75708590|NCT04390308|Diagnostic Test|Transvaginal ultrasound|Doppler of arteria ovarica. Resistance index
75708591|NCT04389203|Procedure|Unilateral tubal disconnection + Spontaneous follow up for pregnancy|Unilateral tubal disconnection + Spontaneous follow up for pregnancy
75708592|NCT04389203|Procedure|Unilateral tubal disconnection + ICSI|Unilateral tubal disconnection + ICSI
75546757|NCT00310479|Device|Magnetic Resonance Spectroscopy (3Tesla)|
75546758|NCT00280280|Drug|intramuscular Botox versus oral baclofen|Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
75546759|NCT00316758|Drug|GK Activator (2)|Escalating doses bid
75546760|NCT00316758|Drug|Metformin|As prescribed, in patients who were in study BM18249
76036141|NCT03094351|Procedure|esophagectomy|Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
75395274|NCT01450410|Drug|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
75395275|NCT01450410|Drug|Placebo|Placebo treatment will last for 12 weeks.
75395276|NCT02950818|Behavioral|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
75395277|NCT03824418|Procedure|Surveillance colonoscopy with chromoendoscopy|Surveillance colonoscopy with chromoendoscopy
75546761|NCT00280319|Behavioral|interpersonal psychotherapy for groups|psychotherapy
75546762|NCT00280319|Behavioral|creative play therapy|consisted of play activities
75546763|NCT00280358|Drug|Fluticasone Propionate|
75546764|NCT00280358|Drug|Formoterol Fumarate|
75558063|NCT00442637|Drug|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
75558064|NCT00442637|Other|observation|observation after induction treatment
75558065|NCT00477828|Device|Continuous positive airway pressure|
75558066|NCT00442676|Drug|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
75558067|NCT00442676|Drug|Placebo|Gelatin capsules of lactose
76036142|NCT03094273|Procedure|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
76036143|NCT05025319|Radiation|X-ray image|Bedside x-ray at intensive unit.
76036144|NCT05025553|Dietary Supplement|Gut mobilization|Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
75395278|NCT04391712|Device|MLS Laser|Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
75870573|NCT02383732|Behavioral|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
75395279|NCT04391712|Other|Regular Inpatient Medical Care|Regular inpatient medical care
76036145|NCT05028127|Drug|Bimekizumab|Subjects will be receiving bimekizumab at pre-specified time-points.
75395280|NCT04391634|Other|volume guarantee|volume guarantee assist-control mechanical ventilation
75395281|NCT04391634|Other|pressure-controlled|pressure-controlled assist-control mechanical ventilation
75395282|NCT01450488|Drug|masitinib|masitinib 3 mg/kg/day
75395283|NCT01450488|Drug|masitinib|masitinib 6 mg/kg/day
75870574|NCT01411267|Drug|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
76036146|NCT05024695|Device|MINIject™ Implant|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
76036147|NCT05049811|Behavioral|mini program|To design, construct, and test the mini program in patients managing cancer pain
76036148|NCT05049811|Behavioral|conventional pharmaceutical care|Regular education includes medication guidance from doctors, nurses and pharmacists.
76036149|NCT05028049|Drug|Sufentanil injection|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
76036150|NCT05028049|Drug|Remifentanil Hydrochloride|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
76036151|NCT05028049|Other|plain areas|Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
75395284|NCT01450566|Drug|Lidocaine|Use of lidocaine
75395285|NCT01450566|Drug|Saline|Saline
76036152|NCT05028049|Other|plateau areas|Patients should be long staying residents in plateau areas (altitude level>3000 meters above sea level)
76036153|NCT05024461|Diagnostic Test|Salivary test for COVID19|"Results of nasopharyngeal and salivary samples taken at the Cayenne hospital and the Caen university center,~Pre-analytical particularities and analytical particularities~Cycle threeshold~Demographic variables~Clinical variables~Clinical criteria~Questionnaire on the perception of the 2 sampling methods"
75395286|NCT03824262|Device|HICO-VARIOTHERM 550|Warming during perioperative period.
75395287|NCT03824262|Device|Mistral-Air Plus forced air warming device|Warming during perioperative period.
75395288|NCT03043014|Drug|Mifépristone versus Misoprostol|The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
75558068|NCT00477867|Procedure|quality-of-life assessment|
75558069|NCT00442715|Procedure|Exercise chalenge test|
75708593|NCT04379765|Behavioral|Exercise and physical therapy|Decompression operation
75558070|NCT00477906|Biological|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
75558071|NCT00442754|Biological|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
75558072|NCT00477945|Drug|clofarabine|"Cohort N Clofarabine (mg/m2/day)~3-6 30~3-6 40~3-6 50~3-6 60~6-10 70"
75395289|NCT01450644|Other|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
75395290|NCT02983344|Drug|Ropivacaine|Fascia iliaca compartment block using ropivacaine
75395291|NCT02983344|Drug|Fentanyl|Intravenous fentanyl
75395292|NCT02983344|Device|Ultrasound|Ultrasound-guided fascia iliaca compartment block
75395293|NCT01450878|Drug|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
75395294|NCT02914314|Drug|perampanel|oral suspension.
75395295|NCT01451034|Procedure|WHYX cancer group|WHYX cancer diagnosed by pathologic report
75395296|NCT03824340|Drug|Doxycycline before ICSI|Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
75395297|NCT03824028|Device|Clareon® IOL AutonoMe™ automated preloaded delivery system|Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
75395298|NCT03823872|Other|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
75870575|NCT01411267|Drug|Cytarabine|"All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~20 mg for patients age <1 yr~30 mg for patients age 1-1.99 years of age~50 mg for patients age 2-2.99 years of age~70 mg for patients >3 years of age"
75395299|NCT03823872|Other|Normal feeding|Normal feeding= consume food per normal schedule
75395300|NCT01455246|Drug|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
75395301|NCT01455246|Drug|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
75395302|NCT01455324|Device|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
75395303|NCT01451112|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
75395304|NCT02910648|Behavioral|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
75395305|NCT01455480|Drug|RPh201, botanical drug product|topical
75395306|NCT03823950|Drug|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
75395307|NCT02914782|Other|Observational Study|
75395308|NCT01451190|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
75395309|NCT01451268|Drug|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
75395310|NCT01451268|Drug|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
75395311|NCT01451346|Dietary Supplement|B. Infantis 35624|One sachet daily for 12 weeks
75870576|NCT01411267|Drug|Etoposide|150 mg/m2/day IV on days 1 through 5.
75395312|NCT03823638|Dietary Supplement|Oral D-Mannitol of Placebo|Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
75395313|NCT01455558|Drug|Pletaal|"Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart"
75395314|NCT02884908|Drug|Pregabalin plus BBCET|Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment
75395315|NCT02884908|Other|Placebo plus BBCET|Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment
76036154|NCT03093649|Other|adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|The intervention was administrated through APP
75546765|NCT00316797|Drug|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
75546766|NCT00310518|Drug|ARQ 501|
75708594|NCT04377555|Drug|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
75708595|NCT04375033|Drug|Sublingual buprenorphine with naloxone|The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit.
75870577|NCT01411267|Drug|Methotrexate|"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~6 mg for patients age < 1yr~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
75395316|NCT01451580|Drug|Lipo-Dox|
75395317|NCT01451658|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
75870578|NCT02378584|Other|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
76036155|NCT03093649|Other|do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|patients receive normal care and visit
76036156|NCT05024617|Other|conservative treatment|All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.
75395318|NCT01455792|Procedure|Biopsies using image fusion|MRI and soft image fusion guided biopsy
75395319|NCT01455792|Procedure|Gold standard biopsy|Gold standard TRUS biopsy
75546767|NCT00280436|Drug|GW679769|
75546768|NCT00280475|Device|Whole brain radiation therapy arm|Whole brain radiation therapy arm
75546769|NCT00280475|Device|Salvage stereotactic radiosurgery arm|Salvage stereotactic radiosurgery arm
75546770|NCT00316836|Procedure|mammography|
76036157|NCT05049109|Behavioral|Integrated Telehealth After Stroke Care|"• 3 week and 8 week follow up visits with pharmacy through telehealth~Patients will provide home blood pressure monitoring kits at discharge for the first three months. The telemonitor that can send blood pressure readings, wirelessly or through telephone, to a secure server where study staff can look at the readings. Any blood pressure readings that are not within normal range will trigger an alert to be sent to study staff who will then follow up with the patient. A trained staff member will show the patient how to use the blood pressure monitor. Patients will be asked to take blood pressure at least 3 days per week and transmit the readings to study staff.~Patients will also be asked to wear an activity monitor starting at 4 weeks."
76036158|NCT05049109|Behavioral|Usual post-stroke follow-up care|"1-2 weeks follow up visit with primary care.~4-6 week and 12 week follow up visit with stroke practitioner~At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life"
76036159|NCT05027659|Other|virtual reality glasses|Virtual reality (VR) glasses have a detachable screen frame compatible with smartphones. A VR headset has earphones and sensors that track the user's head movements, giving them the impression that they are moving around in a virtual environment. The investigators used a smartphone and VR glasses to perform the intervention. They connected the phone to the VR headset via a 360 degree VR video app. Experimental participants wore the VR glasses and watched a 360 degree VR video of nature scenes with ambiance music during colonoscopy. They put on the VR glasses right before the procedure and took them off right afterward.
76036160|NCT03093571|Device|Auricular stimulation|Auricular stimulation with indwelling fixed needles
76036161|NCT03093571|Behavioral|Relaxation|Progressive muscle relaxation
76036162|NCT05023915|Drug|dexamethasone|40 mg qd for 4 days
76036163|NCT05023915|Drug|diammonium glycyrrhizinate enteric-coated capsule|150mg tid for 3 months
76036164|NCT05024071|Device|Wushu athletes in the experimental group used a Swiss ball for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~Static action under steady state.~No load movement in steady state.~Static action under unstable state.~Movement to overcome its own resistance in an unstable state.~Free strength exercise in unstable state.~Core explosive power exercise under unstable conditions."
75546771|NCT00280514|Drug|cefpirome and moxifloxacin administration|
75870579|NCT03113110|Drug|Empagliflozin 10 mg|PTDM patients on previous antidiabetic treatment (<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
75395320|NCT01451892|Other|Dance Therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
75395321|NCT01451892|Other|patient education|overweight individuals participating in a patient education program
75546772|NCT00280553|Drug|bupivicaine|PCA and bupivicaine infusion for up to five days
75546773|NCT00280553|Other|Saline infusion|PCA and pump with saline infusion for up to five days
75546774|NCT00310557|Drug|Gadopentetate dimeglumine (Magnevist)|Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
75870580|NCT02661880|Behavioral|preferred music|listening to preferred music choices
75395322|NCT04392258|Diagnostic Test|TSH determination|Determination of serum concentration of thyrotropin (TSH)
75395323|NCT04392258|Diagnostic Test|FT4 determination|Determination of serum free thyroxine (FT4) concentration
75395324|NCT04392258|Diagnostic Test|FT3 determination|Determination of serum free triiodothyronine (FT3) concentration
75395325|NCT04392258|Diagnostic Test|SPINA-GT|Calculation of thyroid's secretory capacity (SPINA-GT)
75546775|NCT00280592|Drug|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
75395326|NCT04392258|Diagnostic Test|SPINA-GD|Calculation of total deiodinase activity (SPINA-GD)
75395327|NCT01455948|Device|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
75395328|NCT01455948|Procedure|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
75708596|NCT04375033|Drug|Injectable subcutaneous buprenorphine|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit.
76036165|NCT05024071|Device|Wushu athletes in the experimental group used a balance board for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~Static action under steady state.~No load movement in steady state.~Static action under unstable state.~Movement to overcome its own resistance in an unstable state.~Free strength exercise in unstable state.~Core explosive power exercise under unstable conditions."
75395329|NCT02851056|Biological|Survivin Vaccine|"Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered."
75395330|NCT02851056|Procedure|Autologous Hematopoietic Cell Transplantation|The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
75395331|NCT02851056|Biological|Prevnar 13|13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
75395332|NCT02851056|Drug|Granulocyte-colony Stimulating Factor|After the first survivin vaccination, participants will be mobilized with G-CSF.
75395333|NCT02937948|Other|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
75395334|NCT02937948|Radiation|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
75708597|NCT04372914|Dietary Supplement|BRB Lozenges|Each lozenge is made from 1 gram of freeze-dried black raspberry powder (equivalent to ~5 black raspberries) in the form of a dissolvable slow-release lozenge.
75395335|NCT02936466|Behavioral|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~At least one connection per week during 4 weeks~Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
75395336|NCT02935374|Drug|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
75395337|NCT02935374|Drug|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
75395338|NCT02935374|Drug|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
75395339|NCT01452204|Other|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
75708598|NCT04370704|Drug|INCAGN02385|INCAGN02385 administered intravenously
75708599|NCT04370704|Drug|INCAGN02390|INCAGN02390 administered intravenously
75708600|NCT04370704|Drug|INCMGA00012.|INCMGA00012 administered intravenously
75546776|NCT00280592|Drug|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
75546777|NCT00316875|Drug|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
75546778|NCT00316875|Drug|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
75546779|NCT00280631|Drug|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
75708601|NCT04356638|Drug|Midazolam|Oral Midazolam and intranasal placebo
75395340|NCT01452438|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
75395341|NCT01452594|Drug|Diphenylcyclopropenone|Topical administration
75395342|NCT01452594|Drug|Placebo|Placebo
75395343|NCT01452750|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
75395344|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
75395345|NCT01452750|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
75395346|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
75708602|NCT04356638|Drug|Dexmedetomidine|Intranasal Dexmedetomidine and oral placebo
75395347|NCT01452750|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
75395348|NCT01452750|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
75395349|NCT04273308|Device|whole-body vibration training|The experimental group participated in a 12-week whole-body vibration training that was conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time. The control group were provided home DVDs on resistance exercise and manuals for preventing frailty
75395350|NCT01452828|Drug|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
75395351|NCT01452828|Drug|TR-701 FA|Two separate infusions of 200 mg
75546780|NCT00316953|Drug|dasatinib|Given orally
75546781|NCT00316953|Other|pharmacological study|Correlative studies
75395352|NCT01452828|Drug|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
75395353|NCT01452906|Drug|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
75395354|NCT01452906|Drug|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
75395355|NCT01452906|Drug|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
75395356|NCT01453218|Drug|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
75708603|NCT04356638|Other|Placebo|Placebo orally and intranasally
75395357|NCT02837250|Behavioral|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
75395358|NCT02837250|Behavioral|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
75708604|NCT04347434|Drug|Atorvastatin 80mg|Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
75708605|NCT04343170|Drug|Placebo|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
75708606|NCT04343170|Drug|ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
75395359|NCT02795598|Procedure|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
75395360|NCT02795598|Procedure|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
75395361|NCT03849378|Dietary Supplement|Sargassum Horneri Extract group|This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
75395362|NCT03849378|Dietary Supplement|Placebo group|This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
75546782|NCT00316953|Other|laboratory biomarker analysis|Correlative studies
75395363|NCT02730780|Dietary Supplement|Low-Salt Diet|The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.
75395364|NCT02730780|Dietary Supplement|High-Salt Diet|The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
75395365|NCT03823092|Diagnostic Test|polarization sensitivity|test of polarization vision as described in Study Description
75546783|NCT00280670|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
75546784|NCT00419172|Drug|Deferasirox|
75546785|NCT00419172|Drug|Rifampicin|
75546786|NCT00280709|Device|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
75546787|NCT00280787|Drug|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
75546788|NCT00280787|Drug|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
75708607|NCT04342026|Other|Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors|Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
75395366|NCT03823248|Drug|MoLuoDan|oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
75546789|NCT00280787|Drug|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
75870581|NCT03306277|Biological|Onasemnogene Abeparvovec-xioi|Non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
75395367|NCT03823248|Drug|Sanchi powder|oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
75395368|NCT03823248|Drug|Folic Acid Tablet|oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
75395369|NCT03823248|Drug|MoLuoDan simulation|oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
75395370|NCT03823248|Drug|Sanchi powder simulation|oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
75395371|NCT03823248|Drug|Folic Acid Tablet simulation|oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
75395372|NCT03822936|Drug|Preoperative chemotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
75395373|NCT03822936|Radiation|Preoperative radiotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
75395374|NCT03822624|Dietary Supplement|Probiotic|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.
75395375|NCT03822624|Other|Placebo|Placebo comparator with maltodextrin as a carrier.
75395376|NCT03822546|Other|Conventional cigarette|Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
75395377|NCT03822546|Other|myblu 25 mg freebase|E-cigarette used for 10 inhalations every 30 seconds
75395378|NCT03822546|Other|myblu 16 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
75395379|NCT03822546|Other|myblu 25 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
75395380|NCT03822546|Other|myblu 40 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
75395381|NCT03822546|Other|blu PRO 48 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
75395382|NCT04391088|Other|vaccine coverage assessment|vaccine coverage assessment
75395383|NCT04273152|Diagnostic Test|advanced glycation endproducts reader|advanced glycation endproducts reader
75546790|NCT00280787|Drug|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
75546791|NCT00280787|Radiation|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
75546792|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
75546793|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
75546794|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
75546795|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
75870582|NCT02383888|Drug|BI 425809|
75870583|NCT02383888|Drug|BI 425809|
75870584|NCT02383888|Drug|Placebo|
75870585|NCT02383888|Drug|BI 425809|
75870586|NCT04664569|Other|observational study|observational study
75395384|NCT01453452|Behavioral|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be < 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
75546796|NCT00310596|Drug|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
75546797|NCT00310596|Drug|Placebo|0,9% saline at 0,6mL/kg at bolus rate
75546798|NCT00280865|Drug|Tesaglitazar|
75546799|NCT00280865|Drug|Pioglitazone|
75546800|NCT00280865|Behavioral|Dietary and Lifestyle Modification Counseling|
75870587|NCT02378194|Drug|Placebo|24 weeks, once daily oral administration
75546801|NCT00310635|Biological|Meningococcal C conjugate vaccine|
75870588|NCT02378194|Drug|HD-003 (800mg/day)|24 weeks, once daily oral administration
75870589|NCT02378194|Drug|HD-003 (1600mg/day)|24 weeks, once daily oral administration
75870590|NCT00579709|Biological|Thymus Tissue for Transplantation|"3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained <4000/cumm Csa weaned over 8 weeks. If T cell >4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, & mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx."
75870591|NCT02374294|Device|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of ~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
75870592|NCT02374216|Procedure|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
75546802|NCT00316992|Drug|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
75870593|NCT02383498|Other|GI-6301 Placebo|GI-6301 Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of GI-6301 placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
75546803|NCT00317031|Drug|Acamprosate or Naltrexone|mg&d 90 days
75870594|NCT02383498|Biological|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
75395385|NCT01453452|Behavioral|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
75395386|NCT01453452|Other|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
75395387|NCT01453452|Procedure|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
75395388|NCT02910024|Device|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
75546804|NCT00280982|Biological|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
75546805|NCT00310674|Biological|Meningococcal C Conjugate Vaccine|
75546806|NCT00281060|Procedure|primary stenting|
75546807|NCT00317070|Drug|dimethyl sulfoxide|intravesical installation 50 ml
75546808|NCT00317070|Drug|IC Cocktail|"Heparin 10,000 units~Gentamicin 80 mg~Hydrocortisone sodium succinate (Solucortef) 100 mg~Lidocaine hydrochloride 1% 10 ml~Sodium Bicarbonate 8.4% 5 ml"
75546809|NCT00317148|Drug|Placebos|Placebo capsule
75546810|NCT00317148|Drug|DHEA capsule|One capsule of DHEA
76036166|NCT05027581|Drug|Bone marrow mesenchymal stem cells|The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.
75395389|NCT02910024|Device|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
75395390|NCT01453686|Drug|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
75395391|NCT01453686|Drug|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
75870595|NCT02383498|Radiation|Radiotherapy|Standard of care
76036167|NCT05027581|Drug|hyaluronic acid|(60 mg/3 mL hyaluronic acid [HA])
75395392|NCT02983266|Device|InTENsity MicroCombo|An electrotherapy device.
75395393|NCT01459926|Drug|TD-1211|once daily
75395394|NCT01459926|Drug|TD-1211|Once daily
75395395|NCT01459926|Drug|TD-1211|Once daily
75395396|NCT01459926|Drug|Placebo|Once daily
75395397|NCT01456182|Drug|AFX-2|Dose level 1
75395398|NCT01456182|Drug|AFX-2|Dose level 2
75395399|NCT01456182|Drug|AFX-2|Dose level 3
75395400|NCT01456182|Drug|AFX-2|Dose level 4
75395401|NCT01456182|Drug|AFX-2|Dose level 5
75395402|NCT01455870|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
75395403|NCT01455870|Drug|sitagliptin|oral sitagliptin 100 mg/day
75395404|NCT01456260|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
75395405|NCT01456260|Drug|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
75395406|NCT01456260|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
75395407|NCT01456260|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
76036168|NCT01673347|Biological|Meniscal Allograft|Meniscal allograft
75395408|NCT01456260|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
75395409|NCT01456260|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
75395410|NCT01452516|Device|nanOss Bioactive Bone void filler|Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
75395411|NCT01452516|Device|Interbody FCage|Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
75395412|NCT01890408|Drug|wound infusion ropivacaine|"Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
75546811|NCT00281177|Behavioral|Asthma Disparity Reduction Strategy|
75546812|NCT00310713|Biological|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
75546813|NCT00310752|Device|DermaStream(tm) application and Streaming of Saline|
75546814|NCT00281255|Drug|Allopurinol|
75546815|NCT00281255|Drug|Dobutamine|
75395413|NCT01890564|Other|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
75395414|NCT01890564|Other|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
75395415|NCT01890564|Other|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
75395416|NCT01456338|Behavioral|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
75395417|NCT01456338|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
75546816|NCT00317187|Biological|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
75546817|NCT00317187|Biological|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
75546818|NCT00281294|Drug|Fontolizumab|
75558073|NCT00442793|Drug|Epoetin beta|As prescribed, 3 times weekly
75558074|NCT00442793|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv every 2 weeks
76036169|NCT05027191|Diagnostic Test|Neutrophil Gelatinase-Associated Lipocalin (NGAL)|The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
76036170|NCT05027191|Drug|Desflurane|Desflurane
76036171|NCT05027191|Drug|Sevoflurane|Sevoflurane
76036172|NCT03094507|Drug|Tivicay|50 mg once daily
75395418|NCT01890798|Drug|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
75395419|NCT01890876|Other|Walking uphill|ascending about 500 m
75395420|NCT01890876|Other|Walking downhill|descending about 500 m
75395421|NCT04844658|Dietary Supplement|NASAFYTOL®|Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
75395422|NCT04844658|Dietary Supplement|FULTIUM® -D3 800|Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
75395423|NCT04844658|Drug|Strandard of care treatment|Strandard of care treatment for Covid-19 infection
75395424|NCT04841538|Drug|ES101|The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
75395425|NCT02450292|Procedure|Bioabsorbable screw fixation|
75395426|NCT04849650|Drug|Amisulpride IV|A single 10mg IV dose of Amisulpride given over 1 minute
75395427|NCT04849650|Drug|Amisulpride Oral Tablet|A single 10mg dose given as an oral tablet
75395428|NCT05587140|Device|Acupuncture like TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes
75395429|NCT05587140|Device|Conventional TENS|Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes
75395430|NCT05587140|Device|Sham TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
75395431|NCT01456728|Dietary Supplement|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
75395432|NCT01456728|Dietary Supplement|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
75395433|NCT01891110|Procedure|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
75395434|NCT01891110|Procedure|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
75395435|NCT01891110|Procedure|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
75395436|NCT01891266|Procedure|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
75395437|NCT01891266|Procedure|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
75870596|NCT02383498|Device|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
75870597|NCT02378350|Device|Hemodialysis treatment (no specific device is defined)|
75395438|NCT01891500|Drug|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
75395439|NCT01891500|Drug|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
75395440|NCT01891500|Drug|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
75395441|NCT02862132|Drug|Vedolizumab|
75870598|NCT02378350|Drug|Peritoneal Dialysis treatment (no specific drug is defined)|
76036173|NCT03094507|Drug|Rezolsta|darunavir 800 mg/cobicistat 150 mg once daily
75558075|NCT00439920|Drug|High-dose anthracycline|
75558076|NCT00442832|Drug|TD-1792|TD-1792 2 mg/kg/day IV
75558077|NCT00442832|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
76036174|NCT02528253|Biological|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
75708609|NCT04338152|Behavioral|Family Focused Therapy for Clinical High Risk Youth (FFT-CHR)|Family-Focused Therapy (FFT) has been tested in randomized trials involving persons with bipolar disorder, depression, and clinical high-risk syndromes. FFT-CHR provides families with psychoeducation (sessions 1-6) about prodromal symptoms and the role of the family in helping maintain stability. Clients are supported in building coping skills and monitoring thoughts, perceptions, and mood. The family formulates a prevention action plan to prevent prodromal symptoms from escalating into full episodes. Communication training (sessions 7-13) teaches families to express positive and negative feelings, listen actively, make positive requests for change, and communicate clearly through role-playing and between-session practice. In problem solving (sessions 14-18) participants learn to break down problems into smaller ones, evaluate pros/cons, and choose solutions to implement.
75395442|NCT02859402|Drug|Busulfan|intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)
75870599|NCT02383654|Procedure|Autologous Adipose-Tissue Derived Stem Cells|"Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
75870600|NCT02378116|Procedure|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
75395443|NCT02859402|Drug|Fludarabine|intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
75395444|NCT02857374|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
75395445|NCT02857374|Drug|Fluorescein Sodium Injection|Given IV
75395446|NCT02857374|Other|Laboratory Biomarker Analysis|Correlative studies
75395447|NCT02857374|Procedure|Sentinel Lymph Node Biopsy|Undergo standard of care sentinel node biopsy
76036175|NCT02528253|Biological|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
75395448|NCT04273074|Radiation|sonographic assessment|preoperative sonographic assessment to airway
75395449|NCT04843722|Biological|hAd5-S-Fusion+N-ETSD vaccine|Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.
75395450|NCT04844268|Biological|Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT (HDT-301)) at a dose of 1 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
75395451|NCT04844268|Biological|Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 5 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
75395452|NCT04844268|Biological|Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 25 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
75395453|NCT04844268|Biological|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
75395454|NCT04842552|Drug|Hydralazine hydrochloride 25mg tablets|Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
75395455|NCT04842552|Drug|Placebo|Placebo
75395456|NCT01891656|Behavioral|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller & Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
75395457|NCT01891656|Behavioral|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere & Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman & Massey, 2008). As discussed by Hester & Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
75395458|NCT04390932|Other|Enhanced TA|The enhanced TA is characterized by the personalization of the conversation, the verbalization of a joint participation in the process, the full presence of the therapist in the development of the exercise protocol, and the inclusion of behaviors such as active listening, empathy, and encouragement. In addition, therapist's body language transmits confidence, security, and attention.
75395459|NCT04390932|Other|Limited TA|The limited TA does not consider the personalization of the conversation, uses a unidirectional verbalization and is imperative about the instructions provided to the participant, the therapist is intermittently absent during the therapeutic exercise sessions and uses a neutral or negative nonverbal language cues.
75546819|NCT00310869|Behavioral|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
75546820|NCT00281333|Behavioral|"Karate exercises and strengthening exercises"|
75395460|NCT04390932|Other|Therapeutic exercise protocol.|Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.
75546821|NCT00317265|Procedure|Coronary bypass surgery|
75870601|NCT02377960|Behavioral|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
76036176|NCT02528253|Biological|Tanezumab 5 mg SC|Tanezumab 5 mg SC
76036177|NCT02528253|Biological|Tanezumab 10 mg SC|Tanezumab 10 mg SC
75395461|NCT01456884|Behavioral|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
75395462|NCT01456884|Behavioral|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
75546822|NCT00310908|Drug|Tramadol Hcl|Active Comparator
76036178|NCT02528253|Biological|Tramadol PR oral|Tramadol PR oral
76036179|NCT03093103|Drug|Empagliflozin 10 mg|Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI
75395463|NCT04842630|Drug|SHR-1916|All participants receive SHR-1906 alone
75395464|NCT02813928|Genetic|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
75395465|NCT01891812|Drug|Nitrous oxide 50%|
75546823|NCT00281411|Procedure|Computed Tomography Angiography|Computed Tomography Angiography
75546824|NCT00281411|Procedure|Magnetic Resonance Angiography|Magnetic Resonance Angiography
75546825|NCT00317304|Behavioral|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
75558078|NCT00477984|Drug|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
76036180|NCT03093103|Drug|Placebo|Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
75546826|NCT00281450|Behavioral|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
75546827|NCT00281489|Device|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
75546828|NCT00281489|Behavioral|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
75546829|NCT00317343|Drug|Bivalirudin (thrombin specific anticoagulant)|Percutaneous Coronary Intervention
76036181|NCT03092947|Other|No intervention|
76036182|NCT03092869|Other|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
76036183|NCT03092869|Other|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
75546830|NCT00416858|Drug|cisplatin|
75546831|NCT00416858|Drug|fluorouracil|
75546832|NCT00416858|Procedure|adjuvant therapy|
75546833|NCT00416858|Procedure|conventional surgery|
75546834|NCT00416858|Procedure|neoadjuvant therapy|
76036184|NCT03094039|Procedure|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
76036185|NCT03094039|Procedure|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
76036186|NCT03093805|Dietary Supplement|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
76036187|NCT05026879|Biological|Inactivated COVID-19 vaccine (CoronaVac)|The adverse events due to an inactivated COVID-19 vaccine.
76036188|NCT03093883|Drug|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
75546835|NCT00416858|Radiation|radiation therapy|
75546836|NCT02960061|Drug|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
75395466|NCT01457274|Other|Sedation depth|"The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (<60) than those in the light sedation group (BIS 70-80)."
75395467|NCT01892046|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
75395468|NCT04389996|Other|No intervention|Patients will be sent a survey incl. EORTC QLQ-C30
75395469|NCT01892124|Behavioral|Motivational Interviewing/Cognitive Behavioral-based Therapy|
75546837|NCT02960061|Procedure|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
75546838|NCT02960061|Drug|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
75546839|NCT02960061|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
75546840|NCT00416897|Drug|chemotherapy|
75546841|NCT00416897|Drug|dexamethasone|
75870602|NCT02377960|Behavioral|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
75870603|NCT02377960|Behavioral|Usual care|Usual care
75395470|NCT01892202|Other|Cohort|
75395471|NCT01892358|Behavioral|SKIN Intervention|
75870604|NCT02377804|Other|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
75870605|NCT02377804|Other|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
76036189|NCT03093883|Drug|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
76036190|NCT05047861|Procedure|socket shield technique with autogenous dentin graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After the final preparation of the socket shield, Graft will be placed using autogenous dentin graft from the discarded palatal part of the tooth"
75395472|NCT01892358|Other|Treatment as Usual|
75395473|NCT04840836|Behavioral|Telehealth-supported LARC provision|"Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as adolescents)."
75395474|NCT04272684|Other|Driving Assessment|Participants will undergo a driving assessment approximately two months after returning home from hospital
75395475|NCT01457664|Drug|Placebo|Placebo to RO4995819 once daily for 14 days
75546842|NCT00416897|Procedure|plasmapheresis|
75546843|NCT00317382|Device|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
75546844|NCT00310986|Behavioral|Breathing Meditation|
75558079|NCT00442871|Drug|eltrombopag|eltrombopag 50 mg oral
75558080|NCT00439959|Drug|GSK625433/placebo|
75558081|NCT00442910|Drug|3% SPL7013 Gel (VivaGel)|3% vaginal gel
75558082|NCT00442910|Drug|Placebo Gel|Placebo for SPL7013 gel
75558083|NCT00442910|Drug|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
75558084|NCT00478101|Drug|oxycodone fentanyl|
76036191|NCT05047861|Procedure|socket shield technique with alloplast graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After final preparation of socket shield, Graft will be placed Alloplast graft"
75395476|NCT01457664|Drug|RO4995819|RO4995819 doses once daily for 14 days
75395477|NCT04390464|Drug|Ravulizumab|Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
75395478|NCT04390464|Drug|Baricitinib|Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.
76036192|NCT03094429|Drug|NaBen®|2000 mg/day or 1000 mg/day, twice daily
75870606|NCT02377804|Device|stainless steel needles (0.3mm x 50mm)|
76036193|NCT03094429|Other|Placebo|0 mg total, twice daily
75558085|NCT00442949|Procedure|Catheterization immediate PCI|Catheterization immediate PCI
75870607|NCT02373748|Device|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
75870608|NCT02373904|Device|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
76036194|NCT05023759|Dietary Supplement|Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules|Formula30A Full Spectrum Hemp-Derived Cannabidiol (CBD) 25mg Capsules taken once daily for 8 weeks.
76036195|NCT05023447|Behavioral|BRIDGE Intervention|Intensive clinical assessment; >16 sessions of Cognitive Analytic Therapy (CAT); Development of a shared formulation
75395479|NCT04390464|Other|Standard of care|Regular standard of care for COVID-19 patients
75558086|NCT00442949|Procedure|delayed PCI|delayed PCI
75558087|NCT00439998|Procedure|Ultrasound|ultrasound scan of the lumbar spine with 2-5 MHz curved array probe
75558088|NCT00443027|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
75870609|NCT02372032|Procedure|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
75870610|NCT02372032|Procedure|ozone therapy|percutaneous intradiscal ozone injection
76036196|NCT05023447|Behavioral|Service as Usual|Likely to range from social services, mental-health services, forensic services to no intervention
76036197|NCT05026255|Procedure|alveolar recruitment manoeuvre by pressure step|The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.
76036198|NCT03090607|Device|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
76036199|NCT03090607|Drug|Saline|Endoscopic injection of saline
75870611|NCT03130959|Biological|Nivolumab|Specified dose on specified days
75870612|NCT03130959|Biological|Ipilimumab|Specified dose on specified days
75870613|NCT02371954|Behavioral|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
75870614|NCT02371954|Other|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
76036200|NCT04964635|Device|TetraGrip II system|"This main aim of this whole research project is to evaluate the performance of the TetraGrip II system in improving the upper limb functions in people with C4-C7 tetraplegia i.e. people who have damaged their spinal cord in the neck resulting in loss of function in all four limbs. The Tetragrip system uses a technique called Functional Electrical Stimulation (FES) in which small electrical impulses are used to activate paralysed muscles and hence provide movement. The stimulation is controlled by sensors which measure the movement of the other shoulder and enable the person to regain the use of their hand via stimulating electrodes placed on the skin over the relevant muscles.~The feasibility of using this FES based system in restoring the upper arm functions will be evaluated by clinically trying the device on participants with C4-C7 tetraplegia."
76036201|NCT03092557|Other|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
75395480|NCT04390542|Behavioral|Psychoeducation|"6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning"
75870615|NCT02373670|Behavioral|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
75870616|NCT02373670|Behavioral|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
75870617|NCT01367769|Other|No intervention|There will be no intervention in this study.
75870618|NCT02373592|Behavioral|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
75870619|NCT02373592|Device|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
75870620|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
76036202|NCT03090529|Other|Exercise Group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
76036203|NCT03092167|Other|Physical exercises|Physical exercises
75395481|NCT04845750|Device|Rodeo Micro Mapping Catheter|The Rodeo Micro Mapping Catheter is used during cryoablation of atrial fibrillation patients for determination of pulmonary vein isolation
75558089|NCT00440076|Drug|Velcade|
75546845|NCT00416975|Other|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
75870621|NCT01370031|Drug|Clenil® Modulite® via Volumatic™ spacer|Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
75395482|NCT04844424|Drug|Milvexian|Milvexian will be administered orally or via nasogastric route as tablets or capsules.
75395483|NCT01892670|Other|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
75395484|NCT01892748|Drug|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
75395485|NCT01892748|Drug|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
76036204|NCT01672957|Drug|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
75395486|NCT01892826|Drug|hCG|5000IU
75395487|NCT01892904|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
75395488|NCT01892982|Behavioral|Problem Solving Education tailored to NICU|
75395489|NCT01893060|Drug|Povidone-Iodine|Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
75395490|NCT01893060|Drug|Chlorhexidine gluconate|Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
75395491|NCT01893060|Drug|Pluronic Cream|Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
75395492|NCT01893060|Other|control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
75395493|NCT01457742|Device|Ivivi SofPulse|15 minute Pulsed Radio Frequency (PRF) treatment twice per day
75870622|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
76036205|NCT01672957|Drug|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
76036206|NCT05018065|Behavioral|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)|sexual dysfunction assesment
76036207|NCT05022979|Other|Observational only|"The investigator collected the patient's data from the medical record and interviewed the patient to complete the nutritional questionnaire.~The required biological, blood and urine samples were collected during routine blood sampling upon entry and hospitalization."
76036208|NCT05023213|Behavioral|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
75395494|NCT01457742|Device|Ivivi SofPulse|15 minute simulated treatment using Sham Device twice per day
75395495|NCT02314650|Other|acupoint stimulation|stimulation was given at acupoints
75395496|NCT02314650|Other|non-acupoint stimulation|stimulation was given at non-acupoints
75395497|NCT02314650|Other|electrodes attached|electrode were attached to skin
75395498|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
75395499|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
75395500|NCT01457820|Drug|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
75395501|NCT01457898|Device|VPAP II®|VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
75395502|NCT04758156|Drug|CleanViewAL|1L PEG + ascorbic acid bowel preparation for colonoscopy
75395503|NCT04758156|Drug|SUPREP|Oral sulfate solution for colonoscopy bowel preparation
75395504|NCT05020782|Drug|Belimumab|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
75558090|NCT00443105|Drug|Tacrolimus 0.03% ointment (Protopic)|
75558091|NCT00443144|Drug|recombinant human growth hormone|
75558092|NCT00440154|Drug|AVE5530|
75870623|NCT01370031|Drug|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
76036209|NCT05047393|Other|Current blood vitamin D level and painDetect questionairre score will be detected|PainDETECT neuropathic pain questionnaire will be used to evaluate the presence of nociceptive, mixed and neuropathic pain in patients. Patients with a total questionnaire score of 12 or less are considered nociceptive pain without a neuropathic pain component. If the total score is in the range of 13-18, the result is uncertain, but it is accepted that the neuropathic component can be found in the mixed type, and in the scores of 19 and above, it is accepted that the neuropathic pain component is present. Patients with previously obtained and finalized vitamin D levels < 20 ng/mL, 20-30 ng/mL, and ˃30 ng/mL will be grouped as deficiency, insufficiency and normal, respectively.
76036210|NCT05047081|Behavioral|Scoring Your College Goals Workshop|A two-hour virtual college readiness workshop.
75395505|NCT05029986|Behavioral|Socialization phase|Control condition: does not involve speech-related exercises
75395506|NCT05029986|Behavioral|Speech breathing intervention|Experimental condition: involves speech-related exercises
75395507|NCT01893294|Drug|gemcitabine hydrochloride|Given IT
75395508|NCT01893294|Drug|fluorouracil|Given IV
75395509|NCT01893294|Radiation|radiation therapy|Undergo radiation therapy
75395510|NCT01893294|Other|laboratory biomarker analysis|Correlative studies
76036211|NCT05047081|Other|Placebo|Placebo Treatment-As-Usual Group which does not receive the workshop intervention
75558093|NCT00440154|Drug|placebo|
75395511|NCT01458054|Drug|Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)|GSK2336805 and Omeprazole
75870624|NCT02373514|Drug|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
75870625|NCT02373514|Drug|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
75870626|NCT01364493|Drug|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
75870627|NCT02371798|Drug|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
75395512|NCT01458054|Drug|Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)|GSK2336805 and Ritonavir
75558094|NCT00440154|Drug|ezetimibe|
75558095|NCT00478374|Drug|Sorafenib|Sorafenib 400mg bid
75558096|NCT00478374|Procedure|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
75558097|NCT00478452|Biological|DC-Ova|
75558098|NCT00478452|Biological|DC Ova with Cyclophosphamide|
75395513|NCT05028270|Procedure|Balloon technology;Microcatheter technology|Describe each group's intervention in sufficient detail, including how and when to give the intervention Suspend or modify the criteria for interventions that have been assigned to the subject (such as changing the dose of the drug due to hazards or subject requirements or improvement/deterioration of the condition, etc.) Strategies to improve the compliance of intervention programs, and other measures to monitor compliance (such as the return of drug tablets, laboratory inspections, etc.) Related care and interventions allowed or prohibited during the trial
75395514|NCT01458444|Device|Non invasive ventilation (VNI)|BIPAP® vision
75395515|NCT01458444|Device|Non invasive ventilation|OPTIFLOW system
75395516|NCT05029518|Drug|SMP-100|In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.
75395517|NCT02784756|Device|Quantiferon-CMV assay|
75395518|NCT01893450|Drug|Methimazole|
75395519|NCT01893450|Drug|Bromocriptine|
75395520|NCT01893450|Drug|Pentoxifylline|
75395521|NCT05027100|Drug|Anlotinib Tislelizumab Irinotecan|Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
75546846|NCT00416975|Other|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
76036212|NCT05022745|Other|Multimodal, multidisciplinary approach|The patient management is adapted pre-operatively, per-operatively and post-operatively
75395522|NCT02374944|Procedure|Hardware removal|Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
75395523|NCT02887794|Other|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
75395524|NCT05020938|Other|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
75395525|NCT05027568|Drug|Single ascending doses of IOA-289|Single dose, oral administration of liquid-filled capsules, with a starting dose of 30 mg
75395526|NCT05027568|Drug|Placebo single doses|Single dose, oral administration of liquid-filled capsules, matching placebo
75395527|NCT02775162|Device|Normothermic Machine Perfusion (NMP)|
75395528|NCT02775162|Other|Standard of Care (Ice)|
75395529|NCT01458600|Drug|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
75395530|NCT01458600|Drug|Methimazole|T Methimazole 5 mg 3x2 for 18 months
75395531|NCT01458600|Drug|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
75395532|NCT01458600|Drug|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
75395533|NCT01458600|Drug|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
75395534|NCT01893528|Drug|REGN2009|
75395535|NCT01893528|Other|placebo|
75395536|NCT02771028|Behavioral|Emotional Freedom Techniques|
75395537|NCT02764788|Other|Specific auriculotherapy|Specific auriculotherapy with needles
75395538|NCT02764788|Other|non-specific auriculotherapy|non-specific auriculotherapy with needles
75395539|NCT02764788|Other|seed auriculotherapy|non-specific auriculotherapy with seeds
75395540|NCT04272528|Other|uniform care|The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
75395541|NCT04272528|Other|conventional care|Nurses carry out the routine care procedures.
75395542|NCT02839278|Biological|Blood sample|
75395543|NCT02832570|Drug|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
75395544|NCT02832570|Drug|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
75395545|NCT02832492|Behavioral|pupil near response|
75395546|NCT02763150|Behavioral|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
75708610|NCT04338152|Behavioral|Enhanced Care (EC)|Enhanced care (EC) has been tested as a family educational treatment in CHR and bipolar youth. The first 3 sessions of EC involve the CHR person and family (parents, siblings) and cover the same content as the psychoeducational module of FFT in abridged form. The objective of these sessions is to develop a prevention action plan. Then, the CHR person is offered monthly individual sessions with the same clinician over the next 5 months, for a total of 8 sessions over 6 months. The individual sessions focus on applying the prevention action plan when symptoms emerge, and supportive, nondirective problem-solving regarding areas of conflict with family, with peers or in the educational or occupational arena. The clinician also serves as case manager.
75708611|NCT04337242|Behavioral|B-DIT|Blended Dynamic Interpersonal Therapy
75708612|NCT04337242|Behavioral|B-CBT|Blended Cognitive Behavioral Therapy
76036213|NCT05017987|Drug|ATB-101, ATB-1011, ATB-1012|"Test drug~- Code name: ATB-101~Control drug1~Code name: ATB-1011~Active ingredient: Olmesartan~Control drug2~Code name: ATB-1012~Active ingredient: Dapagliflozin"
75395547|NCT02763150|Other|Health Promotion|The health promotion group will receive education on healthy eating and activity
75395548|NCT02761746|Behavioral|MESA|MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
75395549|NCT02759484|Behavioral|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
75395550|NCT02759484|Behavioral|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
75395551|NCT02757300|Device|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
75395552|NCT02757300|Device|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
75708613|NCT04337242|Behavioral|DIT|Dynamic Interpersonal Therapy
75708614|NCT04337242|Behavioral|Cognitive Behavioral Therapy|CBT
75708615|NCT04336111|Procedure|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
76036214|NCT04465435|Other|Web-based self-report questionnaires|Web-based self-report questionnaires based on well established instruments.
76036215|NCT04465435|Other|Focus Group Interviews|Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
76036216|NCT03090217|Behavioral|Pelvic Physiotherapy|1) daily pelvic floor muscle training (PFMT).
75395553|NCT02509260|Device|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
75395554|NCT02509260|Other|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
75395555|NCT01458834|Behavioral|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
75395556|NCT01458834|Behavioral|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
75395557|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
76036217|NCT03090217|Behavioral|Standard care (SC)|1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
76036218|NCT05022277|Behavioral|Low tech health SMS messages|Weekly health-related SMS messages are provided to adolescents.
75708616|NCT04336046|Procedure|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
76036219|NCT05022277|Behavioral|Low tech health Phone + SMS messages|Weekly health-related phone calls plus SMS messages are provided to adolescents.
76036220|NCT05022043|Diagnostic Test|Serum Presepsin|Estimation of Serum Presepsin at time of admission
76036221|NCT05021887|Drug|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
76036222|NCT05021887|Drug|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
76036223|NCT05022199|Device|SPY fluorescent angiography|This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
76036224|NCT05021575|Other|Data collection on outpatient care|"Outpatient data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Outpatient data related to cardiovascular diseases (CVD) were collected as described:~data on visits were collected using ICD-10 codes I00-I99 and other CVD related codes (e.g., certain Z, Q codes, J81.0, R57.0)~data were collected from CVD prevention program~data on interventional cardiology were collected from day care facility regardless of the diagnosis.~Date of the visit, patient age, sex and municipality, service level (primary, secondary or tertiary), type of service and main diagnosis were recorded."
76036225|NCT05021575|Other|Data collection on hospitalisation|"Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code."
75395558|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
75870628|NCT02373358|Behavioral|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
75870629|NCT01367925|Device|Stryker Triathlon® CS Tibial Insert|
75870630|NCT01367925|Device|Stryker Triathlon® PS Tibial Insert|
76036226|NCT05021575|Other|Data collection on cardiovascular mortality|Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.
75395559|NCT01458912|Drug|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
75395560|NCT01458912|Drug|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
75870631|NCT01370187|Drug|Montelukast|Montelukast 4mg daily for 2 months
76036227|NCT05021575|Other|Data collection of patients presenting to the tertiary care centre with acute coronary syndrome|Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
76036228|NCT05021419|Other|Streamlined protocol|A streamlined drug protocol for optimizing heart failure medication
76036229|NCT05021419|Other|Standard Protocol|Current standard optimization protocol as per NICE and ESC
76036230|NCT05021731|Drug|Rifampicin plus Isoniazid|Administration of rifampicin plus isoniazid for latent tuberculosis
76036231|NCT05021731|Drug|Rifapentine plus Isoniazid|Administration of rifapentine plus isoniazid for latent tuberculosis
76036232|NCT05021731|Drug|Rifampicin alone|Administration of rifampicin alone for latent tuberculosis
76036233|NCT05009953|Drug|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
76036234|NCT05009953|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL
76036235|NCT05009953|Drug|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
76036236|NCT05009953|Drug|Leucovorin|Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
75395561|NCT02747862|Other|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP [i.e. identifiable APC mutation], and/or a compatible family history or personal adenoma burden of > 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
75395562|NCT02743728|Device|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
75395563|NCT02743728|Device|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
75395564|NCT02743728|Behavioral|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
76036237|NCT05009407|Biological|Immunohistochemistry and clinical analyses on patients and corneas|Immunohistochemistry and clinical analyses on patients and corneas
75395565|NCT02743338|Behavioral|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
75546847|NCT00416975|Procedure|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
75546848|NCT00311025|Procedure|intensive endurance, strength and balance exercises|
75546849|NCT00417014|Drug|chlorambucil|
76036238|NCT05009641|Dietary Supplement|L-carnitine|
75546850|NCT00417014|Drug|prednisolone|
75546851|NCT00417014|Drug|procarbazine hydrochloride|
75546852|NCT00417014|Drug|vinblastine sulfate|
76036239|NCT03079453|Drug|Dexamethasone|The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
76036240|NCT03090373|Device|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
76036241|NCT03090451|Behavioral|Aerobic Exercise|Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
76036242|NCT03090139|Drug|Anti-TNF Therapy|Anti-TNF therapy.
76036243|NCT05610813|Drug|VER-01|Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
76036244|NCT05610813|Drug|Opiod therapy|"The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made before randomization (at visit 1) to ensure that the outcome of the randomization does not influence the opioid selection.~Preferably oral administration~Preferably retarded release preparations~Titration and dosage according to SmPC (maximum titration phase 3 weeks)~The dosage and the chosen opioid (opioid rotation) can be adapted to the patient's specific needs in the course of the study."
76036245|NCT03090061|Diagnostic Test|Light induced fluorescence intraoral camera|assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
76036246|NCT03090061|Diagnostic Test|Visual-tactile assessment method according to FDI criteria|assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
76036247|NCT05009563|Radiation|FDG-PET/CT|whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
75546853|NCT00417014|Radiation|radiation therapy|
75395566|NCT02743338|Behavioral|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
75395567|NCT02743338|Behavioral|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
75395568|NCT02742324|Drug|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
75395569|NCT02742324|Drug|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
75395570|NCT05026632|Drug|NPI-002 Intravitreal Implant|Implant inserted during vitrectomy.
75395571|NCT01459146|Drug|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
75395572|NCT01459146|Drug|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
75395573|NCT01459146|Drug|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
75546854|NCT00317421|Drug|Sildenafil citrate|
75546855|NCT00417053|Biological|filgrastim|
75395574|NCT05020158|Other|Family Talk Intervention|A psychosocial family-based intervention that is designed to give support to an entire family when a child has life-threatening illness.
75395575|NCT05028894|Other|No intervention|No intervention
75395576|NCT05024136|Device|Limon essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of Limon essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
75546856|NCT00417053|Drug|busulfan|
75546857|NCT00417053|Drug|carboplatin|
75546858|NCT00417053|Drug|cyclophosphamide|
75546859|NCT00417053|Drug|doxorubicin hydrochloride|
75546860|NCT00417053|Drug|etoposide phosphate|
75546861|NCT00417053|Drug|melphalan|
75546862|NCT00417053|Drug|vincristine sulfate|
75546863|NCT00417053|Procedure|autologous bone marrow transplantation|
75546864|NCT00417053|Procedure|bone marrow ablation with stem cell support|
75546865|NCT00417053|Procedure|conventional surgery|
75546866|NCT00417053|Procedure|peripheral blood stem cell transplantation|
75546867|NCT00417053|Radiation|radiation therapy|
75546868|NCT00317460|Other|Physician Management|Standard physician care
75546869|NCT00317460|Behavioral|Counseling|Physician Management and Counseling
75546870|NCT00311064|Behavioral|physical activity|
75546871|NCT00281567|Drug|Tiotropium|
75546872|NCT00281567|Device|Respimat SMI|
75395577|NCT05024136|Device|Vetiver essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of vetiver essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
76036248|NCT05021341|Dietary Supplement|Berberine|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
76036249|NCT05021341|Dietary Supplement|Dihydroberberine 200|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
75395578|NCT05026398|Drug|Fenfluramine|Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
75546873|NCT00281567|Device|HandiHaler|
75546874|NCT00317499|Other|Placebo|Placebo
75546875|NCT00317499|Drug|Etanercept|Etanercept
75546876|NCT00281606|Drug|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
75546877|NCT00311103|Procedure|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
76036250|NCT05021341|Dietary Supplement|Dihydroberberine 100|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
75395579|NCT05026398|Other|Placebo|The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
75546878|NCT02960789|Other|Formalized clinical assessment of hydration status|Undertake and record a standard formalized clinical hydration assessment
75546879|NCT02960789|Other|Take a measurement of body weight on calibrated scales|Standard body weight measurements conducted on calibrated scales
75546880|NCT02960789|Device|"RF wristband hydration status measurement"|"Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device"
75395580|NCT01895244|Drug|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
75546881|NCT02960789|Other|Measure capillary refill time with manual stopwatch|A standard visual assessment of capillary refill time, aided by the use of a stopwatch
75546882|NCT02960789|Device|"CRT device hydration status measurement"|"Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time"
75546883|NCT00317538|Drug|infliximab, etanercept|
75546884|NCT00281645|Drug|Bicifadine|
75546885|NCT00281645|Drug|Standard of Care (pharmacological analgesic treatment)|
75546886|NCT00281723|Drug|Pro-Pe adhesive tablet|
75546887|NCT00317577|Drug|brimonidine, timolol|
75546888|NCT00417092|Procedure|Postoperative Pacing|
75546889|NCT00281762|Drug|NSAID|
75546890|NCT00317655|Drug|Glucosamine sulphate|
75546891|NCT00317655|Drug|Ginger|
75546892|NCT00317655|Drug|Ginger-Avocado-Soya|
75546893|NCT00317655|Drug|Ginger-ibuprofen|
75546894|NCT00281801|Procedure|psychosocial assessment and care|psychosocial assessment and care
75546895|NCT00281801|Procedure|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
75546896|NCT00311220|Drug|tuberculin for skin test|
75546897|NCT00281996|Drug|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
75546898|NCT00281996|Drug|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
75546899|NCT00311259|Drug|Melatonin (drug)|
75546900|NCT00311259|Drug|Laktose|
75870632|NCT04483960|Drug|Nafamostat Mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
75546901|NCT00282035|Radiation|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
75546902|NCT00282035|Radiation|Whole breast irradiation|Whole breast irradiation
75546903|NCT00282074|Procedure|laparoscopic bilateral hernia repair|
75870633|NCT04483960|Drug|Enoxaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h."
75395581|NCT02724930|Behavioral|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
75395582|NCT05586750|Drug|Atorvastatin 40 Mg Oral Tablet|40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
75395583|NCT05586750|Drug|Placebo|2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
75395584|NCT01893606|Drug|N-acetyl-D-glucosamine|
76036251|NCT05021341|Dietary Supplement|Placebo|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
75395585|NCT01893606|Drug|placebo|
75546904|NCT00317733|Drug|Ketoprofen in Transfersome|
75546905|NCT00311298|Dietary Supplement|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
76036252|NCT05020561|Behavioral|Group life-coaching|"Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document."
76036253|NCT05020561|Behavioral|Individual life-coaching|In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
75395586|NCT02085720|Device|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
76036254|NCT05017909|Behavioral|Face to face education|Face to face education techniques on the acquisition of the mothering Role
75395587|NCT02716974|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
76036255|NCT05017909|Behavioral|Web based education|web based education techniques on the acquisition of the mothering Role
76036256|NCT05017909|Behavioral|No education|Control group will not be educated
76036257|NCT05020639|Drug|TQB3820 tablets|TQB3820 is a novel cereblon-modulating agent.
76036258|NCT05009017|Drug|Bevacizumab|Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab
76036259|NCT05008939|Drug|Sevoflurane|Patients receive 1% sevoflurane and 30% oxygen for 1 hour.
76036260|NCT05008939|Drug|Placebo|Patients received 30% oxygen for 1 hour.
75395588|NCT02716974|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
75395589|NCT02716974|Drug|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
75395590|NCT02716974|Procedure|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
75395591|NCT02716974|Radiation|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
75395592|NCT01890096|Radiation|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
75395593|NCT01890096|Radiation|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
76036261|NCT05361525|Procedure|modified saldhana's technique|tummy tuck with anatomic definition using liposuction
76036262|NCT05361525|Procedure|Traditional abdominoplasty|uses the traditional technique of abdominoplasty with liposuction with v-shaped dissection till the coastal margin
75708617|NCT04336046|Procedure|sham bilateral ultrasounded guided erector spinae block|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
75708618|NCT04336046|Drug|normal saline|using 1 mg /kg normal saline
76036263|NCT05361369|Drug|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
76036264|NCT05020093|Procedure|Injection molding|preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design
75708619|NCT04336046|Drug|Bupivacaine|bupivacaine
75708620|NCT04335994|Device|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
76036265|NCT05020093|Procedure|Incremental packing|Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
76036266|NCT05360823|Other|Birth ball|Exercises for childbirth
76036267|NCT05360823|Other|Squatting|Exercises for childbirth
76036268|NCT05017285|Procedure|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum
76036269|NCT05017285|Procedure|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
76036270|NCT05610501|Procedure|Ultrasound guided tru-cut biopsy|Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
75708621|NCT04335994|Device|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
75708622|NCT04331418|Drug|Dexmedetomidine|1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
75708623|NCT04331418|Procedure|caudal block|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
75870634|NCT04483960|Drug|Dalteparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h."
76036271|NCT05008861|Procedure|Capsulized Fecal Microbiota Transplant|Capsules contained washed fecal microbiota.
76036272|NCT05008861|Drug|Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody|Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.
76036273|NCT05008861|Drug|Platinum based chemotherapy|Standard dose of Platinum based Chemotherapy every 3 weeks.
76036274|NCT05016739|Device|CADISS|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5~Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
76036275|NCT04434235|Other|axial load|With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
76036276|NCT05383053|Device|NeuroAI|"NeuroAI is an artificial brain diagnostic software that determines whether to perform amyloid PET tests for Alzheimer's by specialists through the detection of amyloid PET positive rates based on brain MR images (T1 weighted MRI, T2 FLAIR MRI) and clinical information (age, gender, and APOE) genotype.~When using this product, input gender, birth year, and apolipoproteinE (APOE) genotype and upload T1 MR image and T2 Flair image, input data and image analysis result data are integrated to infer the positive rate of amyloid PET by PET positive prediction model. The result report provides image analysis results and amyloid PET positive prediction results compared to normal groups."
75395594|NCT01459380|Biological|Bevacizumab|Given IV
75870635|NCT04483960|Drug|Tinzaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia)."
75870636|NCT04483960|Biological|Hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation. Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma
75870637|NCT01370343|Drug|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
75870638|NCT01370343|Drug|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
75870639|NCT01368003|Drug|STA9090|200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
75870640|NCT01368003|Drug|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
75870641|NCT01364571|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
75870642|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
76036277|NCT04433923|Device|Phototherapy with aluminum foil|
76036278|NCT04433923|Device|Phototherapy without aluminum foil|
76036279|NCT03091933|Biological|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
76036280|NCT05016973|Drug|RC48-ADC|2.0mg/kg, Intravenous drip on days 1 every 21 days
76036281|NCT05016973|Drug|Triplizumab|240mg, Intravenous drip on days 1 every 21 days
75395595|NCT01459380|Drug|Carboplatin|Given IV
75395596|NCT01459380|Other|Laboratory Biomarker Analysis|Correlative studies
75395597|NCT01459380|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75395598|NCT01459380|Drug|Veliparib|Given PO
75395599|NCT04346004|Drug|Normal saline|"Participants in Control group are administered IV 100cc normal saline & IM normal saline (1cc) 1 day before surgery."
75395600|NCT04346004|Drug|Iron isomaltoside|"Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) & IM Vitamin B12 (1mg) 1 day before surgery."
75395601|NCT02680314|Drug|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
75395602|NCT05586672|Device|EEG-HR|Passation EEG-HR
75395603|NCT05586672|Diagnostic Test|ADI-R|Passation of ADI-R scale
75870643|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
75870644|NCT01364571|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
75870645|NCT01364571|Procedure|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
75870646|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
75870647|NCT01364571|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
75708624|NCT04326153|Drug|Sintilimab Injection|"Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total."
75708625|NCT04317859|Behavioral|Behavioural Activation|Behavioural Activation (BA) is a therapy previously shown to be effective in depressive disorders. This form of therapy involves modification of activities in order to change perceptions of specific situations, thereby improving mood. The BA treatment program will consist of 18 two-hour visits over 14 weeks (twice weekly group visits for the first 8 weeks, followed by two individual visits over 6 weeks).
75395604|NCT05586672|Diagnostic Test|ADOS-2|Passation of ADOS-2 scale
75708626|NCT04307511|Drug|Ticagrelor|60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
75870648|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
75870649|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
75870650|NCT01364571|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
75708627|NCT04307511|Drug|Aspirin|Aspirin
75708628|NCT04304183|Procedure|total colectomy, ileorectal anastomosis|all patients underwent total colectomy and ileorectal anastomosis.The anastomosis was stapled in all patients.
75708629|NCT04301011|Biological|TBio-6517|Engineered Oncolytic Vaccinia Virus
75870651|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
75870652|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
75395605|NCT05586672|Diagnostic Test|IDE|Passation of IDE scale
75395606|NCT05586672|Diagnostic Test|MSEL|Passation of MSEL scale
75395607|NCT05586672|Diagnostic Test|Dunn|Passation of Dunn scale
75395608|NCT02707692|Biological|Fluarix|Intramuscular injection with Fluarix® .
75395609|NCT02707692|Biological|Pneumovax|Intramuscular injection with Pneumovax.
75395610|NCT02707692|Other|Placebo|Intramuscular injection with sterile saline (placebo).
75395611|NCT02706678|Drug|Tacrolimus sustained-release capsule|Oral
75395612|NCT02703948|Device|Restylane Silk with Lidocaine|
76036282|NCT03091855|Other|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
76036283|NCT03091855|Diagnostic Test|Magnetic Resonance Imaging|MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
75546906|NCT00311298|Dietary Supplement|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
75546907|NCT00282230|Drug|FK778|
75546908|NCT00311337|Drug|bortezomib|
76036284|NCT05359575|Behavioral|Audio kit|MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application
75395613|NCT02697006|Device|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
75395614|NCT02666742|Drug|DOAC|DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
75546909|NCT00282269|Procedure|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
75546910|NCT00317811|Dietary Supplement|ascorbic acid|
75395615|NCT02666742|Drug|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
75395616|NCT04390776|Drug|PF-06651600|PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.
75395617|NCT01893762|Biological|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
75546911|NCT00317811|Drug|bortezomib|
75546912|NCT00317811|Drug|melphalan|
75870653|NCT04469296|Dietary Supplement|iso-caloric ketogenic diet|Each patient will be offered a daily diet plan that includes the different groups of low glycemic index foods to bring to each meal and snack, with the notion of quantity. Carbohydrate-free foods can be consumed ad libitum. Dietary advice will be given to increase the consumption of lipid foods (vegetable oils, butter, cheeses, fatty fish, etc.) so that 65% of the total energy intake is provided by lipids. In addition, a list of unauthorized sugars and sweeteners substitutes will be proposed as well as a low glycemic index food composition table centered on carbohydrates for better control of food choice
76036285|NCT05359575|Behavioral|Instructional flashcard (version 1)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.
76036286|NCT05359575|Behavioral|In-person training|10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).
76036287|NCT05359575|Behavioral|Instructional flashcard (version 2)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
75395618|NCT01893762|Biological|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
75395619|NCT01893684|Behavioral|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
75546913|NCT00282386|Drug|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
76036288|NCT03091699|Drug|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
75546914|NCT00282386|Drug|Placebo/ Duration of Treatment: 156 weeks|
75546915|NCT00282425|Biological|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
75546916|NCT00317850|Drug|Gabapentin (Neurontin)|
75546917|NCT00282503|Drug|Methoxsalen+ECP, Methylprednisolone|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be > 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10"
75546918|NCT00282503|Procedure|Ecp|ECP or Extra Corporeal Phototherapy will be used with UVADex
75546919|NCT00311415|Biological|Meningococcal C conjugate vaccine|"Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"
76036289|NCT03091699|Behavioral|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
76036290|NCT05016115|Behavioral|survey|The Turkish reworded student version of the Jefferson scale of physician empathy was used. Empathy scores were compared related to study years and gender.
75546920|NCT00317889|Procedure|Bone preparation technique: compaction|
75546921|NCT00317889|Procedure|Bone preparation technique: broaching|
75546922|NCT00282542|Procedure|Hepatocyte Infusion|
75546923|NCT00311454|Drug|T.R.U.E.Test|
75546924|NCT00282581|Biological|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
75546925|NCT00317928|Drug|Metformin|
75546926|NCT00282620|Drug|Magnesium L-lactate|
75546927|NCT00282659|Drug|magnesium L-lactate|
75546928|NCT00311493|Biological|Tick-Borne Encephalitis vaccine|
75546929|NCT00282698|Drug|Insulin infusion with a goal|
75546930|NCT00317967|Drug|Atorvastatin|80 mg pills daily
75546931|NCT00317967|Drug|Placebo|80 mg pills daily
75546932|NCT00318006|Procedure|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
75546933|NCT00318006|Procedure|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
75546934|NCT00282776|Behavioral|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
75546935|NCT00282776|Behavioral|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
76036291|NCT03091543|Drug|Madopar® HBS 125|1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.
76036292|NCT03091543|Drug|Placebo|2 capsules of placebo
76036293|NCT03091543|Drug|BIA 6-512 25 mg dose|1 capsule of 25 mg plus 1 capsule of placebo
75546936|NCT00318045|Device|Eyeglass lenses|
75546937|NCT00311571|Drug|Ethidronate|
75546938|NCT00311571|Behavioral|Physical training|
75546939|NCT00282893|Procedure|transluminal ballooning|
75546940|NCT00282893|Other|currently existing therapies for the treatment of vasospasm|
75546941|NCT00318084|Drug|Esomeprazole|
75546942|NCT00318084|Procedure|Ambulatory 24-hour esophageal pH-monitoring|
75546943|NCT00282932|Drug|Detrol LA|
75546944|NCT00318123|Drug|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
75546945|NCT00318162|Drug|low dose naltrexone|
75546946|NCT00283088|Procedure|hypothermia|"Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups."
75546947|NCT00283088|Drug|tissue plasminogen activator|tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
75546948|NCT00311610|Drug|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
75546949|NCT00283127|Procedure|Home sampling (urine test) for uro-genital C.trachomatis.|
75546950|NCT00318201|Drug|Erythromycin|
75546951|NCT00318201|Drug|Diltiazem|
75546952|NCT00283166|Behavioral|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
75546953|NCT00311649|Biological|Inactivated Influenza A Vaccine A/H5N1|
75546954|NCT00318240|Device|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
76036294|NCT03091543|Drug|BIA 6-512 50 mg dose|2 capsules of 25 mg
76036295|NCT03091543|Drug|BIA 6-512 100 mg dose|1 capsule of 100 mg plus 1 capsule of placebo
76036296|NCT03091543|Drug|BIA 6-512 200 mg dose|2 capsules of 100 mg
76036297|NCT04253457|Drug|1ml of triamcinolone (40mg/1ml)|Single injection of 1ml of triamcinolone (40mg/1ml)
76036298|NCT05380947|Drug|BI 1810631 - trial formulation 1 (TF1)|BI 1810631 - trial formulation 1 (TF1)
76036299|NCT05380947|Drug|BI 1810631 - new formulation (NF)|BI 1810631 - new formulation (NF)
76036300|NCT05380947|Drug|Rabeprazole sodium|Rabeprazole sodium
75546955|NCT04708652|Other|No intervention|No intervention
75546956|NCT00311688|Drug|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
75546957|NCT02960750|Behavioral|"A workplace sit less and move more web-based program for Spanish office employees"|W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided
75546958|NCT02960750|Behavioral|Active Comparison group|The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
75546959|NCT00283322|Other|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
75546960|NCT00318279|Device|Surgical simulator to practice vascular anastomosis|
75546961|NCT00283361|Drug|ZP120|
75870654|NCT04469296|Dietary Supplement|protein restricted diet|A diet reducing by 20% the amount of protein compared to the usual intake of the patient will be proposed. This new ration will be carried out by calculating the proportion of total energy intake provided by the amount of protein reduced by 20% compared to the usual intake, and by modifying lipid and carbohydrate intakes to obtain an isocaloric ration.
75870655|NCT02371720|Behavioral|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
75870656|NCT04223583|Drug|Anlotinib Hydrochloride|The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
75395620|NCT01893684|Behavioral|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
75546962|NCT00283361|Procedure|I.v. catherization|
75546963|NCT00283361|Procedure|6-minutes walk performance|
75546964|NCT00283361|Behavioral|Dyspnea severity assessment|
75870657|NCT02373436|Other|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
75870658|NCT02373436|Other|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
75546965|NCT00283361|Procedure|Blood sampling for laboratory tests|
75546966|NCT00283361|Procedure|ECG|
75546967|NCT00283361|Procedure|Physical examination|
75546968|NCT00311727|Biological|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
75546969|NCT00283478|Drug|Iscar Quercus|
75546970|NCT00283478|Drug|Gemcitabine|
75546971|NCT00318318|Drug|Premarin|
75870659|NCT03634761|Behavioral|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
75395621|NCT01893684|Behavioral|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
76036301|NCT05008471|Dietary Supplement|Formula nutrition|The target energy of radiotherapy patients is recommended to be 25-30kcal/(kg·d), and the target energy of the intervention group should be increased by an additional 50% daily from the beginning of radiotherapy. Specifically, under the condition of ensuring the daily target energy 14kcal/(kg·d), formula nutrition should be added daily.
76036302|NCT05342727|Device|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
76036303|NCT05342727|Device|transcranial alternating current stimulation (tACS)|In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
76036304|NCT03088969|Other|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
76036305|NCT02525133|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
75546972|NCT00311805|Biological|Autologous Stem Cells (CD34+)|Intramuscular Injections
75546973|NCT00283010|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
75870660|NCT03634761|Behavioral|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
75870661|NCT02371564|Device|High flow humidified oxygen|
75870662|NCT02371564|Device|Standard flow humidified oxygen|
75870663|NCT02371486|Procedure|hysteroscopic repair of cesarean section defect|Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated
75870664|NCT02371486|Procedure|Diagnostic Hysteroscopy|Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.
75870665|NCT02371486|Procedure|Ultrasound Scan|"Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina."
76036306|NCT02525133|Other|Placebo|Plain collagen implant (vehicle)
76036307|NCT05356299|Other|Magnetictape bandage application|The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
75395622|NCT02684292|Biological|pembrolizumab|IV infusion
75395623|NCT02684292|Biological|brentuximab vedotin|IV infusion
75546974|NCT00283010|Other|Educational DVDs|
75546975|NCT00318396|Procedure|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
75546976|NCT00318396|Procedure|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
75546977|NCT00283517|Drug|antipsychotics|as prescribed
75546978|NCT00318435|Device|Stent or stent-graft deployment|
75546979|NCT00311883|Drug|hydroxychloroquine|
75870666|NCT02371486|Procedure|IVF Cycle|Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
76036308|NCT05016427|Biological|VT301|VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
75708630|NCT04301011|Biological|Pembrolizumab|Immune checkpoint inhibitor.
75708631|NCT04268134|Dietary Supplement|Omega-3 fatty acid supplement|4 capsules taken by mouth each day for 24 weeks (starting at the week 12 visit).
75870667|NCT04961697|Behavioral|Hospital diaries|Diaries will be used by family members, PICU staff or even the patient himself. They will take daily notes expressing feelings and thoughts and describing events that might help chronologically to better understand the course of disease and PICU stay. Photographs and other important PICU memories may also be used in the diary.
75870668|NCT02377648|Device|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS <70%) associated with concomitant signs or symptoms of myocardial ischemia.
75870669|NCT01368159|Device|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
75870670|NCT02371408|Drug|ravidasvir hydrochloride|200 mg
75870671|NCT02371408|Drug|sofosbuvir|400 mg
75870672|NCT02371408|Drug|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
76036309|NCT05602311|Drug|General anesthetic|Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
76036310|NCT05016349|Drug|All trans-retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
76036311|NCT05016349|Drug|13-Cis Retinoic Acid plus Tocopherol|13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
76036312|NCT05016349|Drug|Mifepristone|Mifepristone 200mg capsules daily for 28 days
76036313|NCT05016349|Drug|Cannabidiol|Liquid taken orally for daily for 28 days
76036314|NCT05016349|Drug|9 cis retinoic acid|9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
76036315|NCT05016349|Drug|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
76036316|NCT05016349|Drug|Standard therapy|Patients will receive the approved standard therapy tamoxifen
76036317|NCT05355675|Other|blood sample|collecting 15ml peripheral blood samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
75870673|NCT01364805|Drug|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
75395624|NCT04391010|Other|Surgical masks|Surgical masks will be applied in health care providers
76036318|NCT05355675|Other|stool sample|collecting 50mg fresh stool samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
76036319|NCT05016193|Device|Axem Home Prototype Device|The Axem Home prototype device is a rehabilitation system designed to be used independently by a stroke survivor to facilitate physical rehabilitation exercises in their home environment. The device uses a functional near-infrared spectroscopy (fNIRS) headband that measures the hemodynamic response to rehabilitation exercises and displays this brain activity information to the user.
76036320|NCT05016193|Behavioral|Rehabilitation Exercise Program|Individual exercise program prescribed by a therapist in the Early Supported Discharge Program.
76036321|NCT05380635|Drug|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
76036322|NCT03091309|Other|Interactive educational video|A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
75395625|NCT04391010|Other|Filtering respirators|Filtering respirators will be applied in health care providers
75395626|NCT02983032|Behavioral|BBTI|3 group sessions over 4 weeks
75708632|NCT04261192|Other|Constitution of tumor and blood samples|Constitution of tumor and blood samples
75708633|NCT04227483|Drug|Deflazacort|Deflazacort for 4 months
75708634|NCT04227483|Drug|Prednisolone|Prednisolone for 4 months
75395627|NCT01459692|Other|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
75395628|NCT04390074|Other|COVID-19 and Intensive Care|No intervention, observational.
75708635|NCT04219254|Drug|BI1206|"BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase"
75395629|NCT02649426|Device|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
75708636|NCT04200534|Other|Best Practice|Receive usual care counseling
75708637|NCT04200534|Drug|Nicotine Patch|Given nicotine patches
75708638|NCT04200534|Other|Quality-of-Life Assessment|Ancillary studies
76036323|NCT03091309|Behavioral|Initial in-person counseling with an IBD nurse|This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
75395630|NCT02649426|Device|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
75395631|NCT01459770|Other|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
75395632|NCT01459770|Other|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
75395633|NCT02377206|Other|ADAS-Cog evaluation|[18F]DPA-714 PET imaging
75395634|NCT01894074|Behavioral|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
75395635|NCT01894074|Behavioral|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
75395636|NCT01459848|Behavioral|block play|30 minutes of block play
75395637|NCT01459848|Behavioral|baby dvd|30 minutes of dvd viewing
75395638|NCT04390854|Biological|Blood clot scaffold|"Bleeding will be induced in the canal by passing a size 30 sterile K-file 3 mm beyond the apex with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. Bleeding will be stopped just below the cemento enamel junction.~Biodentine will be placed approximately 3-4 mm below the cementoenamel junction."
75546980|NCT00283556|Drug|Irinotecan (Camptosar, CPT-11)|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
75546981|NCT00283634|Drug|erlotinib and bortezomib|
75546982|NCT00318513|Drug|Bevacizumab|
75546983|NCT00283673|Behavioral|Exercise|
75708639|NCT04200534|Other|Questionnaire Administration|Ancillary studies
75708640|NCT04200534|Other|Tobacco Cessation Counseling|Receive counseling over the phone
75708641|NCT04195633|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
75708642|NCT04195633|Drug|Cyclophosphamide|Given IV
75708643|NCT04195633|Drug|Cyclosporine|Given IV or PO
75708644|NCT04195633|Biological|Filgrastim|Given IV
75708645|NCT04195633|Drug|Fludarabine|Given IV
75708646|NCT04195633|Drug|Mycophenolate Mofetil|Given IV or PO
75708647|NCT04195633|Drug|Mycophenolate Sodium|Given PO
75708648|NCT04195633|Radiation|Total-Body Irradiation|Undergo total-body irradiation
75708649|NCT04195633|Drug|Treosulfan|Given IV
75708650|NCT04190823|Drug|RC98|Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
75708651|NCT04189783|Drug|Liposomal Bupivacaine|Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
76036324|NCT03091309|Behavioral|Motivational interviewing|The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
75395639|NCT04390854|Biological|Blood clot scaffold combined with PRF|Platelet-rich fibrin will be prepared by drawing the patient blood into a 10mL test tube without the addition of an anticoagulant. To prevent the blood from coagulating after coming in contact with the glass tube, it will be centrifuged immediately using a table top centrifuge** at 400 g force for 12 minutes. Then platelet-rich fibrin membrane will be placed into the canal space to a level 3 mm below the cemento-enamel junction using hand plugger following the induction of apical bleeding by passing a number 30 sterile hand file 3 mm beyond the apex of the tooth. Biodentine cap will be placed over the platelet-rich fibrin scaffold.
75395640|NCT02630316|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
75395641|NCT02630316|Drug|Placebo|Placebo administered four times daily
75395642|NCT02875704|Other|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
75395643|NCT02359968|Drug|FOLFOX|radiochemotherapy before surgery
75395644|NCT02359968|Drug|CarboP-pacliT|radiochemotherapy before surgery
75395645|NCT02354820|Other|Evidence Based Constipation Reminders|
75395646|NCT02624544|Drug|esomeprazole|esomex 40 mg twice daily
75546984|NCT00318552|Drug|Meropenem|
76036325|NCT03091309|Behavioral|Telemedicine-based follow-up|The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
76036326|NCT03091309|Other|Monthly follow-up questionnaires|Web-based short questionnaires, administered monthly, will be used to assess medication adherence [self-reported using the 5 item Medication Adherence Report Scale (MARS-5)] and IBD related disease activated [self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity].
75546985|NCT00283751|Drug|insulin detemir|
75546986|NCT00283751|Drug|insulin glargine|
75546987|NCT00311922|Behavioral|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
75546988|NCT00311922|Behavioral|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
75546989|NCT00318630|Drug|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
75546990|NCT00318630|Drug|Placebo|Subjects will also receive placebo oral tablet.
75546991|NCT00283790|Drug|zolpidem tartrate|
75546992|NCT00318669|Drug|Paroxetine hydrochloride hydrate|
75395647|NCT02624544|Drug|desonide|topical corticosteroid desonid 0,1% b.i.d
75395648|NCT02620410|Device|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
75395649|NCT01893840|Device|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
75395650|NCT02613936|Device|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
75395651|NCT02613936|Behavioral|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
75546993|NCT00283829|Drug|docetaxel|chemotherapy
75708652|NCT04189783|Drug|Quadratus Lumborum Block|"Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery"
75708653|NCT04189783|Other|Questionnaire Administration|Ancillary studies
75708654|NCT04188600|Dietary Supplement|Libicare|"The main ingredients of Libicare® are:~Trigonella Foenum-graecum (Trigonella)~Tribulus Terrestris (Tribulus)~Turnera Diffusa (Damiana)"
75395652|NCT02603328|Drug|Atorvastatin|40-80 mg OD
75395653|NCT02603328|Other|Placebo|inactive
75395654|NCT02335788|Device|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
75395655|NCT02327286|Behavioral|Promote and support healthy behaviors|"Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
75546994|NCT00283829|Drug|IL2|immunotherapy
75546995|NCT00311961|Drug|Intravenous prednisolone|
75546996|NCT00311961|Drug|Oral prednisolone|
75546997|NCT00419211|Behavioral|Exercise|Tailored exercise program
75546998|NCT00283946|Drug|Zolpidem MR|Oral
75546999|NCT00283946|Drug|Zolpidem|Oral
75547000|NCT00312000|Drug|capecitabine-irinotecan|"st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1"
75547001|NCT00312000|Drug|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
75547002|NCT00283985|Drug|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
75547003|NCT00283985|Drug|Methotrexate|3 gr/m2 at J1
75547004|NCT00283985|Drug|Dexamethasone|40 mg/ per os at J1, J2 and J4.
75547005|NCT00283985|Drug|Erwinase|"In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
75547006|NCT00419250|Drug|lenalidomide|
75547007|NCT00419250|Drug|lenalidomide|
75547008|NCT00419250|Drug|lenalidomide|
75547009|NCT00419250|Drug|lenalidomide|
75547010|NCT00419250|Drug|lenalidomide|
75547011|NCT00284024|Drug|domperidone|
75547012|NCT00284102|Procedure|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
75547013|NCT00312078|Dietary Supplement|Yogurt Supplementation|
75547014|NCT04718831|Dietary Supplement|Spirulina|Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.
75547015|NCT00318747|Drug|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
75547016|NCT00284219|Device|Transcranial Magnetic Stimulation 10Hz|3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
75547017|NCT00284219|Device|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
75708655|NCT04188600|Dietary Supplement|active control|Selenium and vitamins B complex
75870674|NCT01364805|Drug|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
75395656|NCT01451970|Other|High Fat Diet|Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
75395657|NCT02598258|Other|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
75395658|NCT01450722|Procedure|bypass surgery, stent placement|bypass surgery, stent placement
75395659|NCT01450722|Procedure|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
75395660|NCT01456104|Biological|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
75395661|NCT01451736|Drug|paliperidone palmitate|long-acting injectable
75395662|NCT01451736|Drug|risperidone|oral
75395663|NCT02310594|Other|cytology specimen collection procedure|Undergo blood sample collection
75395664|NCT02310594|Other|laboratory biomarker analysis|Correlative studies
75395665|NCT02868918|Drug|biodentine|tricalcium silicate cement used to replace the carious dentin
75395666|NCT02868918|Drug|glass ionomer cement|high viscosity glass ionomer used as a base material
75395667|NCT02868918|Device|DigoraH optium|digital Xray for follow up
75395668|NCT02586870|Device|Intravascular Ultrasound|
75547018|NCT00312117|Drug|Sodium bicarbonate|
75547019|NCT00284258|Drug|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
75547020|NCT00284258|Drug|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
75547021|NCT00318786|Drug|biphasic insulin aspart|
75547022|NCT00284336|Drug|Caelyx|
75547023|NCT00284336|Drug|endoxan|
75395669|NCT02378766|Behavioral|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
75395670|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
75395671|NCT04757844|Device|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
75395672|NCT04758078|Other|Inhaled corticosteroids|Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
75547024|NCT00312156|Drug|insulin detemir|
75547025|NCT00312156|Drug|insulin NPH|
75870675|NCT04399018|Other|Diagnostic Test: Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection.~Blood sample will be stained according to the manufacturers' recommendations with a lyophilized cocktail (LyotubeTM ready-to-use, BD Bioscience).~At least 10,000 neutrophils will be acquired on a 3-laser, 8-color BD FACSCanto-II TM flow cytometer (BD Biosciences, San José, CA).~Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
75547026|NCT00312156|Drug|insulin aspart|
76036327|NCT03091309|Other|Comprehensive questionnaires|Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence [self-reported using the Medication Adherence Report Scale (MARS-5)], patient trust in physician [self-reported using the Trust in Physician Scale (TIPS)], IBD related disease activated [self-reported using the PRO-2 or 6-Point Mayo Score], IBD-specific health related quality of life [self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)], patient satisfaction [self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire]and IBD specific knowledge [self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire].
75547027|NCT00284414|Procedure|Ultrasonography or MRI|
75395673|NCT04758078|Other|Placebo|Nebulized 0.9% saline will be given four times per day
75547028|NCT00284453|Procedure|Peripheral blood sampling|blood samples will be collected within 72 hours of subjects receiving >2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
75547029|NCT00318825|Drug|Nitrous oxide|
75547030|NCT04718753|Behavioral|Mindful breathing intervention|Mindful breathing intervention audio, which is used in mindfulness-based interventions, will be sent to the participants once per day.
75870676|NCT01370889|Drug|resveratrol|Given PO
76036328|NCT05015959|Other|observation|quality
76036329|NCT03091387|Diagnostic Test|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
75395674|NCT01450956|Drug|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
75547031|NCT02959788|Other|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
75547032|NCT00284492|Procedure|Traditional chinese medicine type acupuncture|10 acupuncture sessions
75547033|NCT00284492|Behavioral|Self Care|Lifestyle advice on diet, physical activity
75547034|NCT00312234|Behavioral|Aerobic exercise|
75547035|NCT00312234|Behavioral|Qigong exercise|
75547036|NCT00284531|Drug|Daclizumab|
75547037|NCT00312273|Drug|Aminophylline (250mg IV +/- a second dose of 250mg IV)|
75547038|NCT00312312|Biological|Specific immunotherapy|
75395675|NCT01450956|Other|Control|Patients will receive only oxygen and air through oxygenator
75395676|NCT02300922|Drug|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
75395677|NCT02300922|Drug|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
75395678|NCT02300922|Drug|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
75395679|NCT02297724|Other|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
75395680|NCT01453530|Drug|Sugammadex|A single dose of sugammadex 2 mg/kg iv
75395681|NCT01453530|Drug|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
75395682|NCT01453530|Other|Placebo|Placebo
75708656|NCT04188327|Procedure|Stellate ganglion block|"While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~Acyclovir 800 mg orally every 5 times per day 7 days.~Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
75395683|NCT02983422|Drug|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
75708657|NCT04188327|Procedure|Sham Stellate ganglion block|"The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~Acyclovir 800 mg orally every 5 times per day for 7 days.~Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
75395684|NCT02983422|Drug|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
75395685|NCT02983422|Drug|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
75395686|NCT02295540|Radiation|hypofractionated radiation therapy|Undergo hypofractionated IMRT
75870677|NCT01370889|Other|laboratory biomarker analysis|Correlative studies
75395687|NCT02295540|Radiation|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
75395688|NCT02295540|Procedure|therapeutic conventional surgery|Undergo surgery
75395689|NCT02295540|Other|laboratory biomarker analysis|Correlative studies
75395690|NCT05585892|Other|Elaboration and individual mailed feedback|see above
75870678|NCT01364883|Biological|Vaccination Schedule One|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
76036330|NCT04254393|Behavioral|Early Adolescent Skills for Emotions (EASE) Program|EASE has been developed to manage and reduce symptoms of depression, anxiety and distress in adolescents. EASE is designed to be delivered by non-specialists in low resource settings such as a trained school-health counsellor. The intervention comprises of 7 young adolescent group sessions, each lasting 90 minutes and involves the empirically supported components of psycho education, problem solving, stress management (slow breathing), behavioural activation, and relapse prevention and 3 caregiver group sessions, each lasting 120 minutes and involve psycho education, active listening, quality time, praise, caregiver self-care and relapse prevention.
76036331|NCT04254393|Other|Treatment As Usual (TAU)|Evidence based health practices are not available in schools to manage the mental health problems of children. No structured programs are being implemented in school settings for at-risk children. During the study, participants in TAU showing severe psychiatric symptoms that require immediate specialist treatment and follow-up, will be referred to the Institute of psychiatry (IoP)-the tertiary mental health care facility of the region.
75395691|NCT05585814|Drug|Capecitabine|Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3weeks for 3 cycles
75708658|NCT04187352|Drug|CS1001+ Fluorouracil+Cisplatin|"CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
75395692|NCT05585814|Drug|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 3cycles
75395693|NCT05585814|Drug|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 3 cycles
75708659|NCT04187352|Drug|Placebo+ Fluorouracil+Cisplatin|"Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
75708660|NCT04186208|Drug|NOVOCART 3D|Autologous Chondrocyte Implantation
75708661|NCT04185701|Other|SiVIEW software|Eye examination by a technician with the SiVIEW software
75708662|NCT04185701|Other|Expert|Eye examination by an expert including optimal correction in distance and near vision
75708663|NCT04181606|Drug|Esmolol infusion|The Esmolol loading dose will be 0.5 mg/kg fat free mass/min administered over the first 3 minutes, followed by a maintenance dose of 0.25 mg/kg fat free mass/min for the remainder of the protocol (maximum of 60 minutes).
75708664|NCT04181606|Drug|Saline infusion|Saline will be rate/volume matched to the calculated esmolol dose.
75708665|NCT04181606|Other|Pre exercise baseline|Subject rests quietly while drug infusion begins (3 min loading dose followed by 10 min of maintenance dose) until heart rate and blood pressure stabilize.
76036332|NCT03079609|Procedure|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
76036333|NCT03079609|Procedure|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
75395694|NCT05585814|Drug|Pembrolizumab|Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles
75395695|NCT05585736|Drug|Cycloplegics|they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
75395696|NCT01989780|Drug|Paclitaxel|
75395697|NCT01989780|Drug|Bevacizumab|
75395698|NCT01989780|Drug|Letrozole|
75395699|NCT01989780|Drug|Anastrozole|
75708666|NCT04181606|Other|Isometric handgrip exercise|The subject will grip at 40% of their maximum and maintain that grip for 90 seconds. Once at rest and once during heavy intensity cycling.
75708667|NCT04181606|Other|Semi-recumbent cycling|Subjects will pedal for 2-4 minutes at a very light intensity (20W), followed immediately by 5 minutes at a moderate intensity (at a workload intended to elicit 85% of the oxygen consumption observed at the lactate threshold), and 5 minutes of cycling at a heavy intensity (at a workload estimated to elicit oxygen consumption half way between those observed at the lactate threshold and respiratory compensation point). Subjects will then continue cycling at the heavy intensity for 90 seconds while performing isometric handgrip exercise.
75395700|NCT01989780|Drug|Exemestane|
75395701|NCT01989780|Drug|Fulvestrant|
75395702|NCT01989780|Drug|Goserelin|
75395703|NCT01989780|Drug|leuprorelin|
75395704|NCT02265588|Behavioral|Cognitive behavioral therapy|A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
75395705|NCT02549898|Drug|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
75395706|NCT02549898|Drug|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
75395707|NCT02549898|Other|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
75395708|NCT02549898|Other|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
75395709|NCT02545608|Device|Restylane Vital|
75395710|NCT01894464|Behavioral|Teacher led intervention|
75395711|NCT01981044|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
75395712|NCT04756986|Drug|malic acid|1% malic acid spray
75395713|NCT02513784|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
75395714|NCT02510742|Device|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
75547039|NCT00284609|Behavioral|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
75547040|NCT00284609|Behavioral|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
75547041|NCT00318864|Behavioral|Cognitive behavioral therapy|
75547042|NCT00284648|Procedure|Surgical repair Achilles tendon rupture|
75547043|NCT00284648|Procedure|Non-surgical repair Achilles tendon rupture|
75547044|NCT00312351|Drug|Pegaptanib sodium|
75547045|NCT00284687|Drug|Artesunate|PO Artesunate
75708668|NCT04164940|Other|Brief alcohol intervention|Brief alcohol intervention already implemented in daily routine by the individual hospitals.
75708669|NCT04159103|Biological|mRNA-3927|mRNA-3927 dispersion for IV infusion
75708670|NCT04139733|Procedure|Prone positon|Prone position within 24 hours after VV-ECMO support. Prone position for at least conservative hours per day for a minimum of 5 days.
75395715|NCT02510742|Device|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
75395716|NCT02283996|Other|Physical Therapy|"The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.~Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:~http://www.brighamandwomens.org/Patients_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf"
75395717|NCT02283996|Drug|Depot Methylprednisolone|40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
75395718|NCT02253030|Device|Optical Coherence Tomography|
75395719|NCT02251704|Procedure|Blood sampling|Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
75395720|NCT02251704|Diagnostic Test|Assessment of body temperature|Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
75395721|NCT02369484|Drug|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
75395722|NCT04390152|Drug|Wharton's jelly derived Mesenchymal stem cells.|IV Wharton's jelly derived Mesenchymal stem cells, two doses
75547046|NCT00318942|Drug|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
75547047|NCT00318942|Drug|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
75547048|NCT00318942|Drug|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
75547049|NCT00318942|Drug|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
75547050|NCT00284765|Procedure|flector|
75547051|NCT00312390|Procedure|Flicker|
75547052|NCT00312390|Procedure|Retinal Vessel Diameter|
75547053|NCT00312390|Procedure|Retinal Blood Flow|
75547054|NCT00312429|Procedure|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
75547055|NCT00284921|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
75708671|NCT04139733|Procedure|Supine positon|Conventional supine position ventilation, no prone position.
75708672|NCT04137159|Other|Functional Electrical Stimulation rowing exercise|Full-body aerobic exercise
75708673|NCT04135300|Genetic|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
75395723|NCT04390152|Drug|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)|Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
75395724|NCT04390230|Procedure|Penile prostheses implantation|Penial implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France
75395725|NCT02238834|Drug|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
75870679|NCT01364883|Biological|Vaccination Schedule Two|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
75870680|NCT01364883|Biological|Vaccination Schedule Three|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
75870681|NCT01364883|Biological|Vaccination Schedule Four|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
75870682|NCT01364883|Biological|Vaccination Schedule Five|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
75870683|NCT01364883|Biological|Vaccination Schedule Six|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
75870684|NCT01364883|Biological|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
75870685|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
75870686|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
75870687|NCT01368237|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
76036334|NCT05538819|Drug|Glimepiride|Glimepiride 1-4 mg/day
76036335|NCT05015647|Dietary Supplement|LP group|LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
75395726|NCT02238834|Drug|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
75395727|NCT02238834|Drug|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
75395728|NCT02238834|Drug|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
75395729|NCT02498730|Behavioral|Interval Training|High Intensity Interval Training at 100% VO2Max
75395730|NCT02498730|Behavioral|Continuous Training|Continuous Stimulous at 60% VO2Max
75395731|NCT02498730|Behavioral|Control|Only Dependent Variables Measures
76036336|NCT05015647|Other|NP group|NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
75395732|NCT02496936|Other|SFA|High saturated fatty acid/SFA oil source
75395733|NCT02496936|Other|MUFA|High monounsaturated fatty acid/MUFA oil source
75395734|NCT02496936|Other|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
75395735|NCT02496936|Other|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
75395736|NCT02496936|Other|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
75395737|NCT02496780|Drug|novolog insulin|3x daily rapid-acting insulin
75395738|NCT02496780|Drug|levemir insulin|basal insulin once a day
75395739|NCT02496780|Drug|placebo|once or 3x daily
75395740|NCT01953588|Drug|fulvestrant|Fulvestrant 500 mg IM
75395741|NCT01953588|Drug|anastrozole|Anastrozole 1 mg oral tablet
75870688|NCT01368315|Drug|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
75870689|NCT01368315|Drug|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
75395742|NCT01953510|Biological|PCV10|PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein
75395743|NCT01953510|Biological|PCV13|PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
75547056|NCT00319059|Drug|systemic administration of 99mTc-HYNIC-Annexin A5|
75870690|NCT01368315|Drug|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
75870691|NCT01368315|Drug|No intervention|No intervention to one out of four test fields marked on the patient's back.
75870692|NCT02371096|Drug|MabThera (rituximab)|
75870693|NCT02371096|Drug|RGB-03|
76036337|NCT05354583|Drug|Appropriate treatment|Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
76036338|NCT03079219|Drug|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
75395744|NCT02475252|Procedure|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
75395745|NCT02177058|Other|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
75395746|NCT02177058|Other|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
75395747|NCT02174016|Dietary Supplement|Ketogenic diet|
75395748|NCT02456532|Drug|placebo|
75395749|NCT02456532|Drug|Zolpidem CR|
75395750|NCT02456532|Drug|Eszopiclone|
75395751|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
75395752|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
75870694|NCT04420455|Drug|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
75870695|NCT01368393|Procedure|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
75870696|NCT01368393|Procedure|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
75870697|NCT02372968|Other|Full body composition and of plasma and urine metabolites|"Full body composition in lean, fat and bone mass will be assessed from DXA scans.~Plasma and urine metabolites will be measured using metabolomics"
75547057|NCT00319059|Behavioral|10 minutes of ischemic handgripping|
75395756|NCT05578950|Drug|itraconazole|100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
75395757|NCT05578950|Drug|terbinafine|one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
75395758|NCT05586126|Drug|Sevoflurane|sevoflurane inhalation
75547058|NCT00284999|Drug|Soothe|
75547059|NCT00284999|Drug|Refresh Tears|
75708674|NCT04122469|Radiation|Stereotactic Body Radiotherapy|The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
75708675|NCT04120636|Drug|Episcleral Celecoxib|Sustained Release Transscleral Celecoxib
75708676|NCT04120311|Drug|Episcleral Dexamethasone|Sustained Release Episcleral Dexamethasone
76036339|NCT03079219|Drug|Experimental drug: Ondansetron|Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
75395759|NCT01893996|Drug|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
75395760|NCT01893996|Drug|Placebo|
75395761|NCT02442180|Drug|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
75395762|NCT02442180|Drug|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
75395763|NCT02442180|Drug|placebo|equivalent to G-CSF doses
75395764|NCT01924260|Drug|alisertib|Given PO
75395765|NCT01924260|Drug|gemcitabine|Given IV
75395766|NCT02439762|Behavioral|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
75395767|NCT02439762|Behavioral|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
75547060|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by lavage)|
75547061|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by bolus)|
75547062|NCT00312546|Drug|Enfuvirtide|90 mg subcutaneously twice daily
75547063|NCT00312546|Drug|Valproic acid|500 to 750 mg, taken orally twice daily
75547064|NCT00285077|Drug|SR57667B|
75708677|NCT04116528|Drug|Ketamine|0.5mg/kg
75708678|NCT04116528|Drug|Buprenorphine|Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
75708679|NCT04116528|Drug|Placebo oral tablet|Buprenorphine or Placebo orally dissolving tablet
75708680|NCT04107883|Biological|fresh frozen plasma|perform plasma transfusion in different phases during perioperation
76036340|NCT03079219|Drug|Experimental drug: Dexamethasone|Day 1: 12mg QD
76036341|NCT03079219|Drug|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
75395768|NCT02983110|Procedure|Anoscopy with Rectal Tissue Sampling|All subjects will provide 10 pieces of rectal tissue
75547065|NCT00319137|Drug|GW274150|
75547066|NCT00425009|Drug|Berberine|
75547067|NCT00425009|Drug|Metformin|
75547068|NCT00312585|Procedure|Acupuncture|
75547069|NCT00312585|Procedure|Sham comparator|
75547070|NCT00285116|Procedure|Clinical examination and radiological evaluation|
75547071|NCT00312624|Procedure|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
75547072|NCT04718402|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
75547073|NCT00319215|Drug|Ramelteon 8 mg|
75547074|NCT00319215|Drug|Zopiclone 7.5 mg|
75547075|NCT00285155|Drug|Bupropion|
75547076|NCT00285194|Drug|Allogeneic Islets of Langerhans|
75547077|NCT00285194|Drug|hOKT3γ1 (Ala-Ala)|
75547078|NCT00319293|Drug|Metformin|
75547079|NCT00285233|Biological|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
75547080|NCT00319332|Drug|Ibritumomab Tiuxetan|
75547081|NCT00319332|Drug|Iodine I 131 Tositumomab|
75708681|NCT04107883|Diagnostic Test|blood sample|get blood samples at several specific points in time during perioperation
75708682|NCT04103983|Device|Sensory retraining device|All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.
76036342|NCT03079219|Drug|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
76036343|NCT03079219|Drug|Standard: Ondansetron|Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
76036344|NCT03079219|Drug|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
76036345|NCT03078985|Procedure|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
75395769|NCT02983110|Procedure|Phlebotomy|• Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.
75395770|NCT02983110|Procedure|Female Genital Tract Sampling|Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
75395771|NCT02432742|Device|Restylane Perlane|Intradermal injection
75547082|NCT00285350|Drug|mycophenolate mofetil|
75708683|NCT04103476|Combination Product|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
75708684|NCT04103476|Other|Placebo|Placebo
75708685|NCT04102007|Drug|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
75870698|NCT03124407|Drug|Capsaicin Topical Solution|Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin
75395772|NCT02432742|Device|Restylane|Intradermal injection
75395773|NCT02430558|Biological|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
75395774|NCT05585970|Diagnostic Test|procalcitonin|The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens
75395775|NCT02086500|Drug|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
75395776|NCT02086500|Other|Saline control|Saline Control
75395777|NCT04757064|Other|standard rehabilitation protocol|they will receive knee flexion exercises and increase the extensor strength
75395778|NCT01894386|Drug|FF 400 mcg|100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
75395779|NCT01894386|Drug|UMEC 500 mcg|125 mcg powder for inhalation delivered by DPI
75395780|NCT01894386|Drug|UMEC 250 mcg|62.5 mcg powder for inhalation delivered by DPI
75870699|NCT03124407|Other|Drug product vehicle|This is the vehicle for the active treatment drug product, but without capsaicin
75395781|NCT01894386|Drug|VI 100 mcg|25 mcg powder for inhalation delivered by DPI
75547083|NCT00312741|Procedure|empirical versus microbiological guided treatment|
75547084|NCT00285389|Drug|Adriblastin|
75547085|NCT00285389|Drug|dexamethasone|
75547086|NCT00285389|Drug|Chlorambucil|
75547087|NCT00285389|Drug|rituximab|
75870700|NCT02371018|Dietary Supplement|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
75870701|NCT01370967|Other|Study formula feeding|Infants who are exclusively fed the new study formula at time of enrollment
75395782|NCT02104986|Drug|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
75395783|NCT02104986|Drug|Vepeside-ifosfamide-Cisplatin|
75708686|NCT04100213|Behavioral|Trier Social Stress Test|The TSST-G is a psychological paradigm which combines high levels of social-evaluative threat and uncontrollability in a group setting. The TSST-G will proceed in groups of three to five participants (from the same diagnostic group). The TSST-G consists of three phases: a briefing; the psychological test itself, followed by a debriefing phase. Each phase will last 40, 20 and 60 minutes, respectively. The briefing and debriefing of the TSST-G will be conducted by experienced psychotherapists. The TSST-G itself will be conducted by personal unknown to the participants.
75870702|NCT01370967|Other|Human milk feeding|Infants who are exclusively fed human milk at time of enrollment
75870703|NCT01370967|Other|Mixed feeding|Infants who are exclusively fed human milk and the new study formula at time of enrollment
75395784|NCT04757454|Diagnostic Test|5-item SARC-F questionnaire|Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
75395785|NCT01894932|Behavioral|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams & Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
75395786|NCT01894932|Behavioral|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
75395787|NCT04757532|Drug|Bupropion|300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.
75395788|NCT04757532|Drug|Anastrozole|1 mg of anastrozole (1 tablet) administered orally in a single dose.
75395789|NCT04757532|Drug|Testosterone cyclopentylpropionate|100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).
75395790|NCT04757532|Drug|Danazol|200 mg of danazol (1 capsule) administered orally in a single dose.
75395791|NCT04757532|Drug|Chlorthalidone|50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
75547088|NCT00285389|Drug|cyclophosphamide|
75547089|NCT00285389|Drug|alkeran|
75708687|NCT04089215|Biological|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 be administered at dose level: 1 x 10^8 CAR+T cells and 1.5 x 10^8 CAR+T cells
75870704|NCT02370940|Other|High phytate intake|
75870705|NCT02370940|Other|Low phytate intake|
75708688|NCT04072978|Device|Intraocular lens implantation|Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.
75708689|NCT04054401|Device|DRG Neurostimulation with Spinal Fusion|Surgeons will implant a neurostimulator during the same open back procedure as fusion devices (spinal fusion hardware and interbody cage) and begin neurostimulation in a short time following surgery (24 hours).
75708690|NCT04052555|Drug|Berzosertib|Given IV
75708691|NCT04052555|Procedure|Biospecimen Collection|Correlative studies
75395792|NCT01890954|Device|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
75395793|NCT02065830|Device|EKSO|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
75395794|NCT02064114|Procedure|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
75395795|NCT02064114|Procedure|control group|Followed for a period of 3,6 and 12 months after the procedure.
75395796|NCT04756830|Biological|Adsorbed COVID-19 (inactivated) Vaccine|Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
75547090|NCT00285389|Procedure|Total body irradiation (8Gy/4fr)|
75708692|NCT04052555|Other|Quality-of-Life Assessment|Ancillary studies
75708693|NCT04052555|Other|Questionnaire Administration|Ancillary studies
76036346|NCT03078985|Device|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
76036347|NCT03078829|Drug|Treatment with a GnRh agonists|All patients will be treated with GnRH agonists
75547091|NCT00285389|Drug|vincristine|0,4 mg/day day 1 to day 4
75708694|NCT04052555|Radiation|Radiation Therapy|Undergo RT
75708695|NCT04045301|Biological|Omalizumab 16mg/kg|Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
75708696|NCT04045301|Biological|Omalizumab 8mg/kg|Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
75395797|NCT02063022|Drug|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
75395798|NCT02063022|Drug|Intensified chemotherapy|"Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
75547092|NCT00312780|Drug|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
75547093|NCT00285428|Drug|hA20-humanized anti-CD20 antibody|once weekly iv dosing for 4 weeks
75547094|NCT00312819|Drug|chemotherapy +/- disulfiram|
75547095|NCT00319410|Procedure|vaginoscopic hysteroscopy|
75708697|NCT04045301|Biological|Placebo|Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
75708698|NCT04045301|Other|Multi-food oral immunotherapy (OIT)|Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
75708699|NCT04044404|Diagnostic Test|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
75708700|NCT04017650|Biological|Cetuximab|Given IV
75708701|NCT04017650|Drug|Encorafenib|Given PO
75708702|NCT04017650|Biological|Nivolumab|Given IV
75708703|NCT04005430|Drug|Episcleral Dexamethasone|Sequestered Transscleral, Controlled-Release Dexamethasone
75708704|NCT04002830|Drug|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
75708705|NCT03998735|Drug|Herbal Snuff (Smokeless Tobacco)|4 levels of [D4]nornicotine in herbal snuff
75708706|NCT03982888|Procedure|Deep Brain Stimulation|Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.
76036348|NCT05019469|Device|Rhythmic vibration cueing (lower leg)|A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.
75870706|NCT01368471|Device|MGuard|MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
76036349|NCT03091153|Other|Medication Review|In depth medication review with a focus on deprescribing
75547096|NCT00312936|Behavioral|Mindfulness-based Stress Reduction (MBSR)|8 week program
75547097|NCT00319488|Drug|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
75547098|NCT00319488|Drug|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
75547099|NCT00319488|Drug|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
75547100|NCT00285623|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
75547101|NCT00285662|Drug|Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo|Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
75547102|NCT00319566|Drug|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
75547103|NCT00285701|Drug|hexaminolevulinate|
75547104|NCT00319605|Drug|Levetiracetam|
75547105|NCT00285740|Behavioral|Cognitive Behavioral Therapy (CBT) in a Group Format|
75708707|NCT03982888|Device|DBS|"Use of the Medtronic DBS device. DBS device consists of 2 parts:~DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses"
75708708|NCT03978507|Behavioral|Intelligent cueing|1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected
76036350|NCT05015179|Procedure|mixed reality technology in laparoscopic partial nephrectomy|All patients undergo contrast-enhanced computed tomography before surgery. DICOM files are converted to a 3D model. This model is then sent to HoloLens 2 smart glasses using HLOIA software
75708709|NCT03978507|Behavioral|Feedback about the number of steps|Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
75708710|NCT03967379|Behavioral|Mobile App + enhanced standard care|An intervention to help address sexual dysfunction among HCT survivors
75708711|NCT03967379|Other|Enhanced Standard Care|Standard of care administered by the institution
75708712|NCT03958721|Drug|Capecitabine|1,000 mg/m2 twice daily taken by mouth every other week
75870707|NCT01368471|Device|Control BMS or DES|Control BMS or DES
75870708|NCT02365246|Device|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
76036351|NCT05019781|Other|Therapeutic tape|Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, & Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.
75395799|NCT02059668|Biological|Biomarker analyses head & neck cancer tissue, blood specimen|For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
76036352|NCT05019781|Other|Placebo tape|The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
76036353|NCT05019391|Device|transcranial doppler|it provides an accurate, noninvasive, and simple method for the diagnosis of VBI. Through the diagnosis results, it will be clear about the blood flow status of single vessel and vascular compliance, which is helpful for accurate reflection of the subtle changes of VBI
75395800|NCT01895010|Device|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
75395801|NCT01895010|Drug|tropisetron|only tropisetron 6mg before TACE
75395802|NCT02039388|Procedure|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
75547106|NCT00313053|Drug|Human mAb 216|Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
75708713|NCT03958721|Radiation|Radiotherapy|Once daily (Monday through Friday) for six weeks
75708714|NCT03938649|Radiation|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
75708715|NCT03938649|Drug|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
75708716|NCT03937700|Device|CPWalker Robotic Exoskeleton|The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
75870709|NCT01364961|Dietary Supplement|Resveratrol capsules|2 x 75 mg resveratrol each day, for 4 weeks
75870710|NCT02370862|Drug|Neostigmine and Glycopyrrolate|
75547107|NCT00313053|Drug|Vincristine|Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
75395803|NCT04389528|Other|Neuromodulation by tDCS|The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
75547108|NCT00285896|Drug|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
75395804|NCT05413356|Drug|Ruxolitinib|Oral ruxolitinib twice daily
75395805|NCT00613860|Device|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
75547109|NCT00285896|Drug|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
75547110|NCT00319683|Drug|ADH300004|
75547111|NCT00286052|Drug|Low Dose Naloxone|
75547112|NCT00319761|Drug|Calcitriol|
75547113|NCT00286130|Drug|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
75547114|NCT00286130|Drug|FOLFOX 6|"FOLFOX 6:~Oxaliplatin 100 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
75708717|NCT03930056|Device|C-Brace II|"Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing."
75870711|NCT01371045|Other|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
75395806|NCT00603330|Biological|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
75395807|NCT01896336|Drug|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD"
75395808|NCT04293666|Dietary Supplement|Kefir|28 days supplementation kefir drink (prepared by inoculating pasteurized 9.2% reconstituted skim milk with powder kefir starter culture and fermented at 37 °C for 16 h. The fermented milk was then pasteurized at 100 °C for 30 min and freeze dried. The powder kefir starter culture used for inoculation was composed of defined lactic acid bacteria strains which contains Lactobacillus fermentum DSM 32784 (LF26), L. helveticus DSM 32787 (LH43), L. paracasei DSM 32785 (LPC12), L. rhamnosus DSM 32786 (LRH10), and Streptococcus thermophilus DSM 32788 (ST30)), 200ml/day
75547115|NCT00286130|Drug|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m² day 1 concurrent with~Leucovorin 400 mg/m² followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
75547116|NCT00313092|Device|nCPAP treatment|treatment with positive air pressure during night
75547117|NCT00286208|Drug|Mifepristone, misoprostol|
75547118|NCT00319800|Drug|Gefitinib|
75547119|NCT00319800|Drug|Irinotecan|
75547120|NCT00286247|Genetic|INGN 201|
75547121|NCT00313131|Drug|tinidazole+fluconazole vs metronidazole+clotrimazole|
75547122|NCT00425048|Procedure|wearing gloves|
75547123|NCT00286286|Device|Intraperitoneal Aerosolization System, IntraMyst|
75547124|NCT00319878|Drug|Sirolimus|"Oral loading dose followed by a once daily dose:~Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
75547125|NCT00319878|Drug|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
75547126|NCT00286364|Drug|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
75547127|NCT00319917|Drug|tacrolimus|oral
75547128|NCT00319917|Drug|placebo|oral
75547129|NCT00286403|Drug|Fenoldopam Mesylate and/or MESNA|
75547130|NCT00313287|Drug|clevudine|
75547131|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
75547132|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
75547133|NCT00286481|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
75547134|NCT00425139|Behavioral|Re-Mission|
75547135|NCT00286520|Procedure|Transanal irrigation with Peristeen Anal Irrigation|
75547136|NCT00320034|Drug|R-albuterol, S-albuterol|
75547137|NCT00286559|Drug|SonoVue|
75547138|NCT00286559|Drug|Optison|
75395809|NCT04293666|Dietary Supplement|placebo|Maltodextrin, same calorie as kefir, 200ml/day
75395810|NCT00556218|Behavioral|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
75547139|NCT02959710|Drug|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
75395811|NCT00556218|Behavioral|No Meditation|No meditation; usual care.
75547140|NCT02959710|Drug|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
75547141|NCT02959710|Drug|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz [237 mL of Ensure® Original] at Hour 0 on Day 1)
75547142|NCT00286598|Behavioral|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
75547143|NCT00425178|Drug|FGF-1|
75547144|NCT00286676|Drug|Nutropin|
75395812|NCT00532740|Radiation|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
75708718|NCT03930056|Device|Traditional Care KAFO intervention|Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
75708719|NCT03906877|Procedure|Acid hyaluronic injection laryngoplasty|Hyaluronic acid is injected into the paralyzed vocal fold
75708720|NCT03906877|Behavioral|Voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises"
75708721|NCT03906877|Other|Sham of injection|Injection of physiological saline under the skin of the neck (sham of injection).
75708722|NCT03906877|Other|Sham of voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture."
75708723|NCT03905707|Drug|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
76036354|NCT05019157|Other|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic for familiarization with the training modalities, the wearable sensors and the data uploading. Afterwards, the participants will proceed with the telerehabilitation program at their homes. The participants will be lent the wearable sensors and will undergo an exercise - based program 3 times/week, comprising of 10' warm up exercises, 40' aerobic, resistance, balance exercises and 10' cool down.Training sessions will be monitored, in real time, by the study investigator. Participants should upload the recorded data to Polar Flow web platform after every training session and should visit the outpatient clinic every month to upload the accelerometry's recorded data to a secure personal computer) application. Educational and informational videoconferences will be held every week for upright training exercise sessions, physical activity counseling, diet/nutritional and smoking cessation counseling.
75395813|NCT00530010|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
75395814|NCT00508794|Behavioral|Yoga Group|3 sessions of yoga each week for 6 weeks.
75395815|NCT00508794|Behavioral|Stretching Control Group|3 sessions of stretching each week for 6 weeks
75395816|NCT00508794|Behavioral|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
75395817|NCT00508794|Other|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
75395818|NCT04253652|Other|Fasted breath samples|Will be completed pre and post iron therapy
75395819|NCT04253652|Other|IBS-SSS|Will be completed pre and post iron therapy
75395820|NCT04253652|Other|Daily diary|Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
75547145|NCT00286676|Procedure|Oral Glucose Tolerance Test|
75547146|NCT00286676|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
75547147|NCT00286676|Procedure|Computed Tomography (CT) Scan|
75547148|NCT00320073|Drug|erlotinib hydrochloride|75 mg to 150mg
75547149|NCT00320073|Drug|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
75547150|NCT00320073|Drug|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
75547151|NCT00286832|Procedure|PET scan|One extra PET scan after 1 cycle of treatment.
75547152|NCT00313326|Procedure|Adaptative Support Ventilation|Adaptive Support Ventilation (ASV) is a new protocol of weaning of the tracheal prosthesis after surgery which maintains a preset ventilation by an operator, and this whatever the activity of the patient
75547153|NCT00286871|Drug|Neoral|
75547154|NCT00286871|Drug|Tacrolimus|
75547155|NCT00417326|Drug|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
75547156|NCT00417326|Drug|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
75547157|NCT00320229|Drug|abciximab|
75547158|NCT00313365|Procedure|Surgical Lavage (Arthrotomy)|
75547159|NCT00313365|Procedure|Arthrocentesis (Serial needle aspiration)|
75547160|NCT00417365|Device|WaterWorks Douching Device|
75547161|NCT00320268|Drug|Quetiapine fumarate|
75547162|NCT00417404|Drug|Aquasol A|IM Aquasol A 10,000IU three times weekly
75547163|NCT00417404|Drug|aquasol A|10,000 IU three times weeks, by intramuscular injection
75395821|NCT04253652|Other|Exploratory research: stool samples|Completed pre and post iron therapy for a subset of patients enrolled in the study
75708724|NCT03904043|Radiation|Radiation therapy|-Monday-Friday treatment is strongly recommended
75395822|NCT02087748|Drug|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
75547164|NCT00417404|Other|sham injection|sham injection
75547165|NCT00313404|Biological|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
75547166|NCT00417443|Drug|Clonidine|
75547167|NCT00313482|Drug|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
75547168|NCT00313482|Drug|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
75547169|NCT00313482|Drug|Prednisone|5 mg orally BID on Day 1 continuously
75547170|NCT00417521|Behavioral|Family-Based Treatment|
75547171|NCT00286988|Drug|Topiramate|
75708725|NCT03904043|Drug|FOLFOX regimen|-CAPOX can be given as alternative
75708726|NCT03904043|Other|Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire|-Baseline, completion of chemotherapy (3-8 weeks after the end of chemotherapy), and 10 to 14 months after radiotherapy
75708727|NCT03904043|Procedure|Rectal biopsy samples|-Multiple biopsy samples of the rectal tumor will be taken from the patient tumor prior to treatment initiation for genomic extraction. For patients at affiliate sites who do not have enough tissue from the diagnostic biopsy, a repeat pre-treatment biopsy is optional.
75708728|NCT03904043|Procedure|Blood for ctDNA|-Prior to the start of treatment, Post radiation therapy labs (with standard of care (SOC) CBC/CMP prior to start of cycle 1 of chemotherapy), Day 1 of cycle 2 of chemotherapy (with SOC CBC/CMP), Completion of chemotherapy (3-8 weeks after the end of chemotherapy), 10-14 months after RT (if this visit aligns with a follow-up time point, one draw can be used to satisfy both time points), months 3, 6, 9, 12, 16, 20, 24 until salvage surgery or 2 years from completion of chemotherapy (whichever is first)
75708729|NCT03901001|Drug|sirolimus and oseltamivir|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
75547172|NCT00320307|Drug|abacavir|
75547173|NCT00287027|Drug|Risperdal Long Acting Injectable Antipsychotic Medication|
75547174|NCT00320346|Biological|Pandemic Influenza Vaccine|
75547175|NCT02960906|Drug|Nivolumab|"For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
75547176|NCT02960906|Drug|Ipilimumab|"For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol."
75708730|NCT03901001|Drug|Oseltamivir|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
75708731|NCT03900988|Drug|N-acetyl cysteine|N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
75395823|NCT02087748|Drug|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
75395824|NCT04755738|Combination Product|Almonertinib plus microwave ablation|Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.
75395825|NCT04755270|Device|VR Glasses|techniques of hypnofertility and VR glasses
75547177|NCT02960906|Drug|Pazopanib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
75547178|NCT02960906|Drug|Sunitinib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
75547179|NCT04717830|Drug|Gamezumab|solution for infusion
75547180|NCT00287066|Drug|Inhaled Human Insulin|
75547181|NCT00287066|Drug|Regular Human Insulin|
75547182|NCT00313521|Drug|thiotepa|
75547183|NCT00313521|Procedure|adjuvant therapy|
75547184|NCT00313521|Radiation|radiation therapy|
75547185|NCT00320463|Biological|DTPa-HBV-IPV/Hib vaccine|
75547186|NCT00419289|Behavioral|follow-up rehabilitation of participants with COPD|
75547187|NCT00287183|Drug|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
75547188|NCT00287183|Other|Placebo|Placebo
75547189|NCT00419406|Procedure|UVA1 phototherapy|
75547190|NCT00419406|Procedure|NB-UVB phototherapy|
75547191|NCT00287261|Drug|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
75547192|NCT00313599|Drug|lapatinib|
75547193|NCT00313599|Drug|paclitaxel|
75547194|NCT00287300|Drug|Sulfadoxine-Pyrimethamine|
75547195|NCT00287300|Drug|Azithromycin|
75547196|NCT00287300|Drug|Artesunate|
75547197|NCT00313755|Procedure|Narrow Band Imaging|
75547198|NCT00320502|Drug|BXT-51072|
75547199|NCT00287378|Drug|omalizumab|omalizumab as per weight and IgE
75547200|NCT00320580|Drug|norelgestromin/ethinyl estradiol|
75547201|NCT00287417|Device|echography|
75547202|NCT00287417|Other|blood sample|
75395826|NCT04755504|Diagnostic Test|EEG behind the ear|2 additional electrodes behind each ear will record EEG
75547203|NCT00320619|Drug|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
75547204|NCT00320619|Drug|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
75547205|NCT00287456|Device|Insulin Pump|
75547206|NCT00287456|Drug|Insulin|0
75708732|NCT03900988|Drug|5% Dextrose|5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
75708733|NCT03900377|Drug|SyB L-0501RI|The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
75708734|NCT03898960|Device|NIMBUS Device|NIMBUS Geometric Clot Extractor
76036355|NCT05019157|Other|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer. Total training attendance rate will be documented by the cardiac rehabilitation centre staff. Patients will be instructed to wear a tri - axial accelerometer during the entire 12 weeks study period. Participants should upload recorded data to the local server every month. Educational videoconferences will be held every week for physical activity counseling, diet/nutritional and smoking cessation counseling.
76036356|NCT05008237|Drug|docetaxel plus Cisplatin|D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks Treatment will be continued until disease progression or unacceptable toxic effects.
76036357|NCT05014711|Drug|Remifentanil|Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT < 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
75395827|NCT01490502|Drug|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
75395828|NCT02317692|Behavioral|Parent training|
75395829|NCT01435746|Behavioral|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
75547207|NCT00287456|Procedure|Oral Glucose Tolerance Test|0
75547208|NCT00287456|Procedure|Whole body Protein Turnover|0
75547209|NCT00313833|Drug|Buprenorphine transdermal delivery system|
75547210|NCT00287495|Drug|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
75547211|NCT00320658|Biological|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
75708735|NCT03895489|Device|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
75708736|NCT03895489|Device|Stryker|Stryker Triathlon Total Knee prosthesis
75395830|NCT01428024|Device|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
75547212|NCT00320658|Biological|CPG 7909|Adjuvant
75547213|NCT00287534|Drug|Anastrozole|oral
75547214|NCT00287534|Drug|Tamoxifen|oral
75547215|NCT00313872|Drug|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre & Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre & post hydration (if Mg <WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
75708737|NCT03895489|Device|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
75708738|NCT03874104|Dietary Supplement|Extensively Hydrolysed Formula containing Pre- & Probiotics|Extensively Hydrolysed Formula containing Pre- and Probiotics
75708739|NCT03863093|Device|Electro Medical Systems AIRFLOW®|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
75708740|NCT03863093|Device|Electro Medical Systems Piezo|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
75547216|NCT00313872|Drug|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
75547217|NCT00287573|Device|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
75547218|NCT00287573|Procedure|Brachytherapy (beta source)|Brachytherapy (beta source)
75870712|NCT02365324|Behavioral|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
75870713|NCT02365324|Behavioral|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
75870714|NCT04945083|Other|Experimental Nutritional Pudding|High Calorie, High Protein pudding
75870715|NCT02370628|Procedure|Percutaneous vertebroplasty|"The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.~In our trial, vertebroplasty shall be performed in two steps:~Step 1: facet block~Step 2: cement infusion~Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention."
75870716|NCT02370628|Procedure|Facet block|"A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty."
75870717|NCT02929407|Drug|FE 204205|"In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial."
75395831|NCT01428024|Device|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
75395832|NCT01895790|Device|Pancreatic Duct Stent Placement|
75547219|NCT00320697|Drug|bupropion + nicotine patch + nicotine gum or lozenges|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
75547220|NCT00320697|Drug|Placebo pill + placebo patch|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
75395833|NCT01412970|Other|volume loading|volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
75547221|NCT00287612|Procedure|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
75547222|NCT00287612|Procedure|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
75395834|NCT01935414|Device|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
75395835|NCT01935414|Device|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
75395836|NCT01896414|Dietary Supplement|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
75547223|NCT00287651|Procedure|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
75547224|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
75870718|NCT02929407|Drug|Placebo|In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
75395837|NCT01896414|Dietary Supplement|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
75395838|NCT01412190|Device|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
75395839|NCT01412190|Other|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
75395840|NCT01895868|Other|Simulation-based ultrasound training|
75395841|NCT02318550|Other|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:~Normal operating mode~SAR ≤ 2.0 W/kg per patient."
75395842|NCT02319174|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
75395843|NCT01393314|Device|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
75395844|NCT01341444|Device|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
75395845|NCT01341444|Other|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
75395846|NCT01331148|Drug|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
75708741|NCT03853616|Biological|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
75395847|NCT01331148|Other|Placebo|placebo with daily calcium/Vitamin D soft chews
75395848|NCT01311492|Behavioral|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
75395849|NCT01311492|Behavioral|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
75708742|NCT03843385|Drug|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
75708743|NCT03843385|Drug|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
75708744|NCT03843385|Drug|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
75708745|NCT03824327|Procedure|Blood Oxygen Level Dependent Imaging|Undergo BOLD fMRI
76036358|NCT05014711|Drug|Fentanyl|Before infusion, fentanyl is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT < 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
75395850|NCT04969302|Diagnostic Test|Follow-up|"The primary outcome of this study was SSI within 30 days of surgery, as defined by the Centers for Disease Control and Prevention. Secondary outcomes were identification of the causative organism, and investigation of clinical factors such as body mass index (BMI), operation time, days of hospitalization, etc. that may be associated with SSI.~All patients were followed up for SSI until discharge from hospital and at the outpatient visits. SSI surveillance data forms were used for the collection of primary and secondary outcome data.~SSI rates and distribution of identified micro-organisms for each group will measured"
75395851|NCT01862718|Procedure|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
75395852|NCT01862718|Procedure|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
75395853|NCT01286922|Other|Behavioral: exercise|"Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group."
75395854|NCT01855464|Procedure|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
75708746|NCT03824327|Drug|Papaverine Hydrochloride|Given IV
75708747|NCT03824327|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75708748|NCT03822728|Diagnostic Test|3D-DESS MRI (3 dimensional double echo steady state MRI)|3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
75708749|NCT03815825|Drug|IONIS-FB-LRx|IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks
75708750|NCT03815825|Drug|Placebo|Placebo matching solution, administered subcutaneously every 4 weeks
75708751|NCT03809013|Drug|RC48-ADC|2.0mg/kg IV every 2 weeks
75708752|NCT03802240|Drug|Sintilimab|200mg IV Q3W
75708753|NCT03802240|Drug|IBI305|15mg/kg IV Q3W
76036359|NCT03087721|Behavioral|HIIT-LV|"Supervised endurance treadmill training as walking/running uphill, 3 times/week during 12 weeks starting at 85-90% of previously determined maximum oxygen consumption (VO2 max). Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week."
75708754|NCT03802240|Drug|Pemetrexed|500mg/m2 IV Q3W
75708755|NCT03802240|Drug|Cisplatin|75mg/m2 IV Q3W
75395855|NCT01855464|Procedure|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
75395856|NCT00273624|Drug|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
75395857|NCT00273624|Drug|Placebo|placebo
75395858|NCT00224796|Device|V.A.C. ® System|
75395859|NCT01253070|Procedure|Biopsy|Undergo biopsy
75395860|NCT01253070|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspirate
75395861|NCT01253070|Drug|Cytarabine|Given IV
75395862|NCT01253070|Drug|Daunorubicin Hydrochloride|Given IV
75395863|NCT01253070|Other|Laboratory Biomarker Analysis|Correlative studies
75395864|NCT01253070|Other|Quality-of-Life Assessment|Ancillary studies
75395865|NCT01253070|Other|Questionnaire Administration|Ancillary studies
75395866|NCT01253070|Drug|Sorafenib Tosylate|Given PO
75395867|NCT01252914|Device|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
75547225|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
75547226|NCT00322296|Drug|Bexarotene 1% gel|
75547227|NCT00320736|Drug|galantamine|
75547228|NCT00287768|Drug|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
75547229|NCT00287768|Drug|S-1|S-1 po days 1-28 every 6 weeks
75708756|NCT03802240|Drug|Placebo1|Placebo1 IV Q3W
75395868|NCT01840956|Biological|HAVG|HAVG is implanted into patients' arm.
75547230|NCT00320775|Drug|VEGF Trap|"Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap."
75547231|NCT00287807|Behavioral|Self-monitoring of blood glucose (SMBG)|2 times a week (one in weekend and one during week) self measurement of blood glucose: fasting and three times post prandial
75547232|NCT00320814|Drug|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
75547233|NCT00287846|Drug|imatinib mesylate|
75547234|NCT00322413|Drug|Epoetin|
75547235|NCT00320853|Drug|Vitamin D|
75547236|NCT00287885|Drug|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m^2/day up to dose level 6 of 6.4 mg/m^2/day
75547237|NCT00287924|Drug|methotrexate|
75395869|NCT02087514|Procedure|Blood Transfusion|A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
75395870|NCT02087514|Other|Packed red blood cells|"Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~1 week~2 weeks~3 weeks~4 weeks~5 weeks~6 weeks"
75395871|NCT01212822|Biological|bevacizumab|Given IV
75395872|NCT01212822|Drug|oxaliplatin|Given IV
75395873|NCT01212822|Drug|leucovorin calcium|Given IV
75395874|NCT01212822|Drug|fluorouracil|Given IV
75395875|NCT01212822|Procedure|therapeutic conventional surgery|Undergo surgical resection
75395876|NCT01212822|Other|laboratory biomarker analysis|Correlative studies
75395877|NCT00163566|Drug|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
75395878|NCT04389606|Other|Study Formula (SF)|New infant formula for term infants fed ad lib
75395879|NCT04389606|Other|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
75395880|NCT04705662|Diagnostic Test|Lactulose breath test|Participants will complete a 3 hour breath test pre and post iron supplementation. This will include taking 4 exploratory samples for volatile organic compound (VOC) analysis.
75395881|NCT04705662|Other|Stool sample|Participants will provide a stool sample pre and post iron supplementation
75395882|NCT04705662|Other|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis
75547238|NCT00287924|Procedure|adjuvant therapy|
75547239|NCT00322530|Procedure|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
75547240|NCT00287963|Drug|topotecan hydrochloride|
75708757|NCT03802240|Drug|Placebo2|Placebo2 IV Q3W
75708758|NCT03799328|Other|multi-OIT|low dose OIT to multiple foods
75708759|NCT03796572|Drug|Ropivacaine|Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
75708760|NCT03796572|Other|Puncture Wound and Dressing|No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
75547241|NCT00287963|Drug|vinorelbine tartrate|
75547242|NCT00320892|Drug|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
75708761|NCT03787693|Behavioral|VR - Virtual Reality|Subjects in the experimental group will perform the split-belt task in a VR environment
76036360|NCT03087721|Behavioral|CAE|Supervised moderate intensity treadmill training, 3 times/week for 12 weeks starting at 70% of VO2 max. Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.
76036361|NCT05007457|Other|Telerehabilitation|"Patients belonging to the experimental group will receive the brochure and, weekly a telematic comparison will take place lasting about 30 minutes, with a physiotherapist to be asked questions. The physiotherapist will be able to evaluate and modify the training program based on the patient's response.~The tele-rehabilitation sessions will take place: once / week for the first month, once every 2 weeks for the second month and from the third month from the third month the patient can contact the professionals in case of doubts or questions regarding the exercises he is taking place at home."
76036362|NCT05018923|Drug|Rabeprazole|20mg bid
75395883|NCT04705662|Other|Irritable Bowel syndrome severity scoring system (IBS-SSS) questionnaire|Participants will complete the questionnaire pre and post iron supplementation
75395884|NCT04705662|Dietary Supplement|Ferrous Sulphate|Participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
76036363|NCT05018923|Drug|Bismuth potassium citrate|0.6g bid
75395885|NCT04687020|Drug|Viltolarsen|Received during weekly intravenous infusions
75547243|NCT00288002|Biological|trastuzumab|
75547244|NCT00288002|Drug|capecitabine|
75547245|NCT00288002|Drug|cyclophosphamide|
75547246|NCT00288002|Drug|docetaxel|
75547247|NCT00288002|Drug|epirubicin hydrochloride|
75547248|NCT00288002|Procedure|adjuvant therapy|
75547249|NCT00288002|Procedure|conventional surgery|
75547250|NCT00288002|Procedure|neoadjuvant therapy|
75870719|NCT02373280|Drug|10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)|In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
76036364|NCT05018923|Drug|Metronidazole|0.4g qid
76036365|NCT05018923|Drug|Doxycycline|0.1g bid
76036366|NCT05018923|Drug|Tetracycline|0.5g qid
76036367|NCT03090919|Biological|Platelet transfusion|
76036368|NCT03090919|Other|Saline|
75547251|NCT00322569|Device|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
75547252|NCT00322569|Device|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
75547253|NCT00322569|Device|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
75547254|NCT00288041|Drug|carboplatin|Given IV
75547255|NCT00288041|Drug|paclitaxel|Given IV
75547256|NCT00288041|Drug|bortezomib|Given IV
75547257|NCT00320970|Drug|Candesartan|
75547258|NCT00322608|Drug|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
75547259|NCT00288158|Drug|Allopurinol|
75547260|NCT00288158|Drug|Probenecid|
75547261|NCT00288158|Drug|Placebo|
75547262|NCT04717752|Drug|Ovidrel|recombinant human chorionic gonadotropin for injection
75547263|NCT04717752|Drug|Troprilin|triptorelin acetate injection
75547264|NCT00288197|Drug|voriconazole|
75547265|NCT00288236|Drug|Rimonabant (SR141716)|
75547266|NCT00288236|Drug|Placebo|
75547267|NCT00322686|Drug|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
76036369|NCT05019079|Other|electroacupuncture|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
75395886|NCT04784286|Other|Telemedicine 30-day post-op visit|Consented subjects randomized to the telemedicine visit arm will do their 30-day post-op visit via secure telemedicine video application through the Center of Connected Care. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
75395887|NCT04784286|Other|In-Person 30-day post-op visit|Consented subjects randomized to the in-person visit arm will physically come to a clinical visit with the bariatric surgery midlevel providers. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
75708762|NCT03786237|Drug|Rigosertib Oral Capsules / Rigosertib Intravenous|"Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter."
75708763|NCT03780322|Device|Armeo Spring Pediatric|"Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions."
75708764|NCT03780322|Other|Conventional physical and occupational therapy|"Conventional therapy will combine physical and occupational therapy, including the following activities:~Upper extremity weight bearing exercises.~Approximation techniques on wrist, elbow and shoulder.~Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~Scapulothoracic joint mobilization.~Stretching of shoulder abductors and external rotators.~Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions."
75395888|NCT05391984|Other|Activity oriented treatment|15 patients will be treated with activity oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
75395889|NCT05391984|Other|Structural oriented treatment|15 patients will be treated with structural oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
75708765|NCT03779217|Other|screening mammography|As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.
75708766|NCT03779217|Procedure|mastoplasty and breast fat excission|As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.
75708767|NCT03776552|Other|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up
75708768|NCT03776552|Other|Gradual weight loss (GWL) program|16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
75708769|NCT03760328|Device|Upper Airway Stimulation|hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
75708770|NCT03758118|Dietary Supplement|Citicoline|Citicoline administered in oral solution
75708771|NCT03740490|Combination Product|Smart-T + NRT|Smart-Treatment App and Nicotine Replacement Therapy
75870720|NCT02373280|Drug|7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)|the participants received PPI based triple therapy[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)]
75395890|NCT04783818|Radiation|Adjuvant Radiotherapy|PMRT
75395891|NCT04783116|Dietary Supplement|Plant stanols (3g/day)|Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
75395892|NCT04783116|Dietary Supplement|Placebo|Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
75395893|NCT04782960|Drug|Iocal anaesthetic bupivacaine|Local anaesthetic Subconjunctival bupivacaine
75395894|NCT04782960|Drug|Placebo|0.9 saline
75395895|NCT01075230|Procedure|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
75395896|NCT04480242|Drug|Inhaled Corticosteroids (ICs)|Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
75395897|NCT04480242|Drug|Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)|Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
75395898|NCT04480242|Drug|Other treatments|Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
75547268|NCT00322686|Drug|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
75708772|NCT03740490|Combination Product|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
75708773|NCT03734237|Biological|Egg based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
75708774|NCT03734237|Biological|Recombinant influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
75708775|NCT03734237|Biological|Cell-culture based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
75395899|NCT04480242|Drug|Inhaler device|Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.
75395900|NCT04480242|Behavioral|Regularly monitoring of the Inhalation technique through mobile app|App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
75395901|NCT01026012|Drug|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
75395902|NCT02088216|Drug|N-acetylcysteine|600mg po twice a day for 12 months
75395903|NCT02088216|Other|On-demand treatment|receive as-needed therapy
75395904|NCT04782648|Procedure|transit bipartition|transit bipartition as revisional bariatric surgery for weight regain after sleeve gastrectomy
75547269|NCT00321087|Drug|T2000|Dose escalation from 600 to 1000 mg
75547270|NCT00321087|Drug|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
75547271|NCT00321087|Drug|T2000|Placebo followed by dose escalation from 600 to 1000
75547272|NCT00288314|Procedure|Magnetic Resonance Imaging, Functional|Structural and functional MRI
75547273|NCT00321126|Drug|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
75547274|NCT00288353|Drug|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
75547275|NCT00288353|Drug|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
75547276|NCT00288392|Drug|Soluble beta-1,3/1,6-glucan|
75708776|NCT03733990|Biological|FP-1305 (bexmarilimab)|The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
75395905|NCT04782882|Behavioral|Progressive muscle relaxation+laughter therapy|"Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music."
75547277|NCT00322764|Drug|Uridine|
75547278|NCT00288431|Drug|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
75547279|NCT00288431|Drug|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
75547280|NCT00321165|Drug|taurolidine|
75547281|NCT04718363|Other|PNF stretching|A contract-relax PNF stretching technique will be applied to hamstring muscle.
75547282|NCT04718363|Other|Non-vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
75547283|NCT04718363|Other|Vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
75547284|NCT00322803|Drug|ELB139|
75708777|NCT03729765|Device|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
75870721|NCT02373280|Drug|7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]|moxifloxacin triple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)].
75395906|NCT01014936|Drug|MSC2156119J|
75395907|NCT01896180|Drug|ALZ-1101|ALZ-1101 Ophthalmic Solution
75708778|NCT03693872|Drug|Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
75870722|NCT02373280|Drug|7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)|bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
75395908|NCT01896180|Drug|Latanoprost|Latanoprost 0.005% Ophthalmic Solution
75395909|NCT00981162|Drug|sorafenib tosylate|Given PO
75395910|NCT00981162|Drug|everolimus|Given PO
75395911|NCT00981162|Other|laboratory biomarker analysis|Correlative study
75395912|NCT00981162|Other|pharmacogenomic studies|Correlative study
75547285|NCT00417560|Biological|inactivated influenza A/H5N1 vaccine|
75547286|NCT00321204|Procedure|TZD reducing the incidence of atrial arrhythmias|
75547287|NCT00417599|Behavioral|Lifestyle Intervention|lifestyle intervention .
75547288|NCT00417599|Other|control group|waiting list control group
75547289|NCT00322920|Drug|Topotecan|
75547290|NCT00322920|Drug|Cisplatin|
75547291|NCT00417638|Device|Endovascular cooling by the Celsius Control System|
75547292|NCT00417638|Other|Standard of care|
75547293|NCT00321009|Drug|Enoxaparin|
75547294|NCT00417677|Drug|Combination of Temsirolimus and Sunitinib|
75547295|NCT00417716|Drug|Intravitreal Bevacizumab|
75547296|NCT00321243|Behavioral|Visual clues|
75547297|NCT00321282|Procedure|Atrial Fibrillation|
75547298|NCT00288470|Device|Hylaform, Hylaform Plus (hylan B gel)|
75547299|NCT00321360|Drug|Propofol|
75547300|NCT00321360|Device|Patient maintained sedation|
75547301|NCT02960594|Biological|INO-1400|
75547302|NCT02960594|Biological|INO-9012|
75547303|NCT02960594|Biological|INO-1401|
75547304|NCT00288548|Drug|Metoprolol|
75547305|NCT00321477|Drug|GW679769 oral tablets|
75547306|NCT00288665|Device|Export catheter (Medtronic)|
75547307|NCT00321516|Drug|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
75547308|NCT06140303|Biological|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
75547309|NCT06140303|Other|Control|"Standard care is defined in this protocol to include the following:~Debridement~Collagen dressing~Local offloading~Foam~Multi-layer compression dressing~Off-loading device such as a controlled ankle motion (CAM) boot"
75547310|NCT06140277|Procedure|extraction with chitosan particles as a replacement for bone graft with collagen membrane|to replace the bone at the extraction site we will put either chitosan or allograft particles
75547311|NCT06140277|Procedure|extraction with placing of allograft particles with collagen membrane|to replace the bone at the extraction site we will put allograft particles
75395913|NCT00981162|Other|pharmacological study|Correlative study
75395914|NCT00960102|Device|cochlear implant|Multichannel Nucleus cochlear implant
75395915|NCT00960102|Device|hearing aid|Phonak hearing aid
75395916|NCT04755894|Drug|HDDO-1756|single dose
75395917|NCT04755894|Drug|HDDO-17561/HDDO-17562|single dose
75395918|NCT04782024|Dietary Supplement|7-Keto 50mg|
75395919|NCT04782024|Dietary Supplement|7-Keto 25mg|
75395920|NCT04782024|Dietary Supplement|Placebo|
75395921|NCT04389762|Dietary Supplement|daily ingestion of Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
75395922|NCT04346160|Diagnostic Test|Schirmer Test I|Collection of tear fluid
75547312|NCT06140277|Procedure|tooth extraction only|hopeless tooth will be extracted without any intervention
75547313|NCT06140264|Other|Acupuncture dry needle|The muscles that have been treated iliocostalis lumborum, quadratus lumborum, gluteus medius and piriformis muscles. The patients received 2 sessions per week for 2 weeks.
75547314|NCT06140251|Drug|Sodium-glucose cotransporter 2 inhibitor|Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.
75547315|NCT06140238|Drug|Parecoxib|Parecoxib administration 15 minutes before start surgical operation
75547316|NCT06140238|Drug|Normal saline|Normal saline administration 15 minutes before start surgical operation
75395923|NCT04755348|Other|Product A|A 4mg nicotine pouch product
75395924|NCT04755348|Other|Product B|A 4mg nicotine pouch product
75395925|NCT04755348|Other|Product C|A 2mg nicotine lozenge product
75395926|NCT04755348|Other|Product D|A 2mg nicotine lozenge product
75395927|NCT04755348|Other|Product E|A 2mg nicotine lozenge product
75547317|NCT06140225|Behavioral|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
75547318|NCT06140225|Behavioral|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
75395928|NCT04755348|Other|Product F|A 2mg nicotine lozenge product
75395929|NCT04755036|Other|Survey and case vignette|We sent a survey and case vignette cases to every responsible in each center
75395930|NCT04754958|Device|Immersion in virtual reality using Nordic Neurolab(™) Visual System|In addition to the standard MRI procedure, the VR intervention group will be looking at stereoscopic computer generated images through a pair of head-coil-mounted googles (Nordic Neurolab ™ Visual System). Two markers (color balls) will be fixed on their knees to capture their movement (camera tracking from the outside of the MRI room). The VR scenario will consist in showing a replication of the actual MRI examination room, as seen from the point of view of the participant lying on the MRI bed, but without the MRI tunnel. Participant can see themselves in the large room (a simplified gender-matched avatar), and an entertaining video can be displayed.
75395931|NCT00909012|Dietary Supplement|high oleic sunflower oil|placebo, which does not provide DHA
75395932|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
75870723|NCT01368549|Other|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
76036370|NCT03086863|Device|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
76036371|NCT03086863|Device|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
76036372|NCT05019001|Procedure|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
76036373|NCT05019001|Procedure|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
75395933|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
75870724|NCT02370550|Drug|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
75395934|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
75395935|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
75395936|NCT00875004|Biological|epoetin beta|
75395937|NCT00875004|Drug|systemic chemotherapy|
75395938|NCT00875004|Procedure|quality-of-life assessment|
75395939|NCT04781790|Other|Bone Marrow Failure|without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
75547319|NCT06140225|Behavioral|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
75547320|NCT06140225|Behavioral|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
75547321|NCT06140225|Behavioral|"JEFIT APPLICATION"|It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.
75547322|NCT06140225|Behavioral|"FITBIT-FLEX APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
75870725|NCT02370550|Drug|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
75547323|NCT06140225|Behavioral|"MEIZU BONG 2S APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
76036374|NCT05019313|Device|Evaluation of diaphragmatic contractility by ultrasound|Lung ultrasound is performed during mechanical ventilation weaning. The diaphragmatic thickening fraction is evaluated positioning a linear probe in midaxillary line. Inspiratory and expiratory measurements are bilateral and are M-mode images. Right diaphragmatic thickening fraction has been considered as true and reproducible measurement.
76036375|NCT03086473|Drug|Caffeine Citrate|The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
76036376|NCT03086473|Drug|Placebo (Normal Saline)|The intervention in this study is timing of the initial caffeine dose. In the Placebo arm, participants will receive Normal Saline (0.9%NaCl) 1ml/kg IV within 2 hours of life, and Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) at 12 hours of life.
75395940|NCT05320692|Drug|TACE+Camrelizumab+Apatinib mesylate|TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.
75395941|NCT05320692|Procedure|TACE|TACE Alone.
75395942|NCT01895166|Procedure|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
75395943|NCT01895166|Procedure|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
75870726|NCT02370550|Drug|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
75547324|NCT06140212|Behavioral|Montreal Cognitive Assessment (MoCA)|MoCA would be used to assess participants cognitive functioning.
75547325|NCT06140212|Behavioral|Chinese ICOPE screening tool (self-administration and interview versions)|The ICOPE screening tool would be used to assess participants health status, including cognitive decline, auditory and visual capabilities, mobility restrictions, nutritional status, and depressive symptoms.
75870727|NCT02370550|Drug|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
75395944|NCT04781556|Other|No intervention|All patients treated between 01/01/2017 and 12/31/2018 in the Fracture sector will be screened through the computerized medical file. For patients who meet all the eligibility criteria, the information note, study questionnaire and a stamped envelope will be sent to them by post. Without feedback from him within 30 days of this submission, the patient is considered not to have objected to the study. The patient's information as well as his non-objection will be recorded in his medical file.
75395945|NCT01763580|Drug|Tacrolimus|Oral
75395946|NCT01763580|Drug|Prednisolone|Oral
75395947|NCT04754724|Diagnostic Test|GIMate|Use of GIMate to detect lactose malabsorption
75395948|NCT04754724|Diagnostic Test|H2 Check|Use of H2 Check to detect lactose malabsorption
75395949|NCT04781010|Device|MRI|MRI pattern in children with Leukodystrophy
75547326|NCT06140212|Behavioral|Frailty status assessment (Edmonton frail scale and Frailty criteria by Dr. Fried)|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status.
75870728|NCT02365168|Other|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
76036377|NCT03086005|Drug|Metformin|
76036378|NCT03079141|Drug|Eplerenone|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
76036379|NCT03079141|Other|Photodynamic therapy|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
76036380|NCT03085615|Other|Jevity 1.5|Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
76036381|NCT03090763|Genetic|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
75395950|NCT00857922|Other|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
76036382|NCT03085849|Drug|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
76036383|NCT03085849|Drug|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
76036384|NCT03085849|Drug|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
75395951|NCT00826098|Biological|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
75395952|NCT01753830|Device|Durolane|4.5 mL
75395953|NCT01753830|Device|PBS|4.5 mL
75395954|NCT03990948|Other|Blood sampling|Blood sample collection
75708779|NCT03693872|Drug|Dopaminergic Agonist + Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
75708780|NCT03686696|Drug|Beta blocker|Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
75870729|NCT02365168|Other|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
75870730|NCT02365168|Other|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
75870731|NCT02365168|Other|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
75870732|NCT02365402|Drug|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
75395955|NCT01745250|Device|Emervel Lips|Lip treatment of both upper and lower lip
75395956|NCT01745250|Device|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
76036385|NCT03090685|Procedure|True auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
75547327|NCT06140199|Procedure|Pit-picking surgery|Patients are placed in left-side position. After shaving, cleaning and scrubbing of the skin with alcoholic chlorhexidine, double strong tape is placed on the right buttock in order to increase exposure. Local anaesthesia is administered before incision with 20 ml xylocaine or lidocaine 1-2%. In principle, all sinusoidal pits are cut out with a margin of at least 1 mm with a biopsy core punch (4 mm, 6 mm or 8 mm depending on pit size) or an oval excision of the pits is performed. Hair and debris is removed from the sinus tracts with a small surgical spoon or mosquito clamp. Rigorous de-epithelialisation of the underlying sinus is performed with the spoon through every pit, whilst removing even more debris and hairs. At the end of the procedure a debris washout is performed with saline solution, the wounds are left open for secondary healing and sterile dressings are applied.
76036386|NCT03090685|Procedure|Placebo Auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
75547328|NCT06140199|Procedure|Pit-picking surgery with Sinus Laser assisted Closure|The pit picking procedure is described above. Subsequently, a radial diode laser probe at 1470 nm wavelength is used for delivering homogeneous (360 degrees) energy to the surrounding epithelium. The laser energy is 13 Joule, given continuously. First, a 'preparatory laser treatment' is performed to extract any missed hairs or debris, after which the sinus tracts are cleansed with a surgical spoon again. During the following definitive procedure, the probe is withdrawn at an approximate speed of 1 cm per three seconds, causing the small sinus tracts to shrink and close. Large sinus tracts remain open because very large sinus tracts or cavities cannot be closed with the 3mm laser fibre. The injury to the endothelium will cause granulation and create oedema for collapsing of the tract. The remaining open wounds are left open for secondary healing and sterile dressings are applied.
76036387|NCT03079063|Biological|Eptacog alfa, biosimilar|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
76036388|NCT03079063|Biological|Novoseven|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period.
76036389|NCT03085303|Device|Full Body Blue Light Device|Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
75395957|NCT00760812|Behavioral|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
75547329|NCT06140160|Procedure|Doppler ultrasound|To carry out an additional measurement using Doppler ultrasound (non-invasive examination). Doppler ultrasound measurements of the diameter and length of the perforating artery using a high-frequency Doppler ultrasound probe following a Doppler ultrasound of the supra-aortic trunks.
75395958|NCT00760812|Behavioral|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
75547330|NCT06140134|Procedure|Liver Transplant|Whole liver allotransplantation will be performed for patients on the liver transplant waiting list
75547331|NCT06140095|Drug|Evolocumab|See arm description
75547332|NCT06140082|Genetic|GSTP1 A313G （AA）|Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.
75547333|NCT06140069|Other|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
75547334|NCT06140056|Other|Airway pressure release ventilation|Mechanical ventilation mode
75547335|NCT06140056|Other|Volumen controlled mechanical ventilation|Mechanical ventilation mode
75547336|NCT06140043|Other|Patient consultation|Providing information about the current clinical problem of orthognatic surgery patients and the proposed treatment for it.
75547337|NCT06140017|Behavioral|Msingi Bora responsive parenting and family wellbeing program|Msingi Bora's structured curriculum of 16 biweekly sessions and monthly boosters thereafter are organized around five key messages: love and respect within the family, responsive talk, responsive play, hygiene, and nutrition.
75547338|NCT06139978|Behavioral|ultrasound observation|The relationship between the anteroposterior diameter of the CM and the gestational age and gender
75395959|NCT01740492|Drug|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
75547339|NCT06139965|Other|Validity and Reliability|Assessment study
75547340|NCT06139952|Drug|Atorvastatin 80mg|Atorvastatin 80mg taken Once before coronary angiography
76036390|NCT04434079|Other|Regular critical care|Clinical demographic data, daily and cumulative FB (input minus output) with and without insensible fluid losses, and daily and total BW changes are recorded, as well as survival outcome.
75395960|NCT01740492|Drug|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
75395961|NCT01740492|Other|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
75395962|NCT04780386|Drug|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)
75395963|NCT04780386|Drug|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
75547341|NCT06139952|Drug|N-acetyl cysteine|200mg 3 times daily 2 days before coronary angiography
75547342|NCT06139952|Other|Normal Saline|adequate hydration using Normal Saline (1ml/kg/hr)
75547343|NCT06139939|Procedure|Double layer technique|Double layer technique for alveolar ridge augmentation (first layer autograft followed by xenograft second layer).
76036391|NCT05015101|Other|Cohort observation|Cohort observation
76036392|NCT01659255|Drug|Tirabrutinib|Capsules administered orally
76036393|NCT05014633|Other|EI skills training|EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
76036394|NCT05308485|Other|Events exposure questionnaire|Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
76036395|NCT05341089|Drug|LY3502970|Administered orally.
76036396|NCT05001529|Biological|anti IL5 receptor antibodies|Subjects with severe uncontrolled asthma will be assigned to treatment with Omalizumab (anti Ig E antibodies) or Mepolizumab (anti IL-5 antibodies) according to medical advice and standardized protocols for asthma treatment.
76036397|NCT05307159|Dietary Supplement|bean protein supplement|They will have a snack with bean protein for 21 days Participants will follow their usual diet, which will be quantified and evaluated.
75708781|NCT03686696|Drug|ACEI|Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
75708782|NCT03686696|Drug|ARB|Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
75708783|NCT03679650|Drug|decitabine|Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
75708784|NCT03679650|Biological|DC/AML fusion cells|An investigational agent that tries to help the immune system to recognize and fight against cancer cells
76036398|NCT05001061|Drug|Misoprostol Pill|sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
76036399|NCT05531955|Drug|Pirfenidone Oral Capsule|pirfenidone capsules were added to patients receiving basic treatment
76036400|NCT05531955|Other|Placebo Oral Capsule|placebo oral capsules were added to patients receiving basic treatment
76036401|NCT05006911|Drug|Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound|To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
75395964|NCT04780308|Procedure|Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires|The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.
75395965|NCT04780854|Drug|Metformin|Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration
75395966|NCT04780854|Drug|Placebo|Participants in the placebo group will be administered metformin free tablet as placebo twice daily
75395967|NCT04780152|Device|Transcranial Direct Current Stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).
75547344|NCT06139926|Drug|Dexmedetomidine administered intranasally|Intranasal administration of dexmedetomidine (plain) was given at the bedside of the ward as per the pre-tested recommended dose. The patient's vital signs were maintained. On the day of surgery, 30 min before induction of anesthesia, intranasal dexmedetomidine (original solution) was administered in the operating room at the pre-tested recommended dose.
75547345|NCT06139913|Other|aerobic exercise|moderate intensity aerobic exercise using treadmill
75558099|NCT03279549|Procedure|Routine dressing change|Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.
75708785|NCT03679078|Dietary Supplement|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
75708786|NCT03654898|Behavioral|VITAL Start: Video-based pre-ART counseling|Patients in the experimental group will receive VITAL start pre-ARV counseling (approximately 27 minutes video followed by 10 minute guided Q & A to reinforce key messages and provide an opening for individual counseling=approximately total 37 minutes). This will be delivered by study staff.
75708787|NCT03654898|Behavioral|Standard of Care|Patients randomized to the control arm will receive the usual standard of care (SOC) pre ARV initiation education with the National ARV Educational Flipchart
76036402|NCT05339295|Drug|Levofloxacin 500mg|A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.
75708788|NCT03654742|Procedure|tonsillectomy|removal of tonsil tissue as described in the study arms
75708789|NCT03651648|Device|SENSITACT System|the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
76036403|NCT05353491|Behavioral|Technology assisted Thinking Healthy Program (THP-TA)|A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app.
76036404|NCT05353491|Behavioral|Standard Thinking Healthy Program|This intervention paper-based manual delivered by lady health workers ie government employed community health workers with health training background.
76036405|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
76036406|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
76036407|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
76036408|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
76036409|NCT05307081|Drug|Artificial Tears|Artificial Tears are an FDA approved intervention
75395968|NCT04780152|Device|Placebo-simulation of transcranial direct current stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.
75708790|NCT03651648|Device|SENSITACT System|the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
75870733|NCT02370472|Other|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
76036410|NCT05306535|Procedure|Occlusal reduction|Occlusal reduction of the experimental single rooted tooth after root canal completion will be done to evaluation reduction in postoperative pain and sensitivity to percussion
76036411|NCT05350995|Other|No intervention|No intervention
75395969|NCT04780152|Drug|Fluoxetine Tablets|Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
75395970|NCT01737528|Procedure|Transcatheter Aortic Valve Replacement|Minimal invasive implantation of a biological prothesis in Aortic Position
75395971|NCT04779840|Other|anemia assessment|evaluation of anemia status
75395972|NCT01735656|Device|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
75395973|NCT00644280|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
75395974|NCT00641316|Procedure|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
75395975|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
75395976|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
75395977|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
75395978|NCT04779762|Other|Crohn's disease exclusion diet (CDED)|Dietary therapy for Crohn's disease
75395979|NCT04779762|Drug|Ustekinumab Injection [Stelara]|Drug for Crohn's disease
75395980|NCT04779996|Diagnostic Test|Laboratory Samples|"After full vaccination with a Covid 19 vaccine, the following laboratory samples will be taken one time only, two weeks after full dose vaccination: i. Serologic rapid test (IgG, IgM) ii. Serum quantitative immunoglobulin levels iii. CD4 level iv. CD8 level~Laboratory samples will be taken at Hospital Auxilio Mutuo Laboratorio Clínico. Likewise, the Immuno Reference Lab might be used as an alternative.~Since monoclonal antibody therapy can induce hypogammaglobulinemia, we will measure gammaglobulin levels to correlate with antibody response to vaccine. Similarly, we will evaluate the CD4 and CD8 counts."
75395981|NCT04778202|Diagnostic Test|blood sample collection|blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
75395982|NCT04777968|Drug|Silver diamine fluoride|a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
75395983|NCT04779606|Drug|Ocular gel|3 drops instilled in the right eye
75395984|NCT05295654|Other|Kinect validation|Participants will perform several movements while both the vicon and kinect are measuring.
75395985|NCT01722708|Drug|Clindamycin|Oral clindamycin 300 Milligrams*2/Day for a week
75395986|NCT01722708|Drug|Metronidazole|Oral metronidazole 500 Milligrams*2/Day for a week
75395987|NCT04779450|Other|Kinesiotherapy protocol|The kinesiotherapy protocol is an exercise-based treatment designed to gain upper limb range of motion and muscle strengthening.
75395988|NCT04779450|Other|Usual orientations|Usual orientations for post-breast cancer women, such as skin care, return to activities, upper limb functionality, self-care, lymphedema, and physical activity practice.
75395989|NCT04777890|Other|suboccipital inhibition|The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
75708791|NCT03644277|Other|Acute Intermitted Hypoxia|Subjects will be fitted with a latex-free full non-rebreather mask with a custom neoprene head strap, mask and oxygen delivery system are commonly used for altitude training. The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask.
76036412|NCT04462705|Procedure|Usual physiotherapeutic intervention and Abdominal Massage|Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
75395990|NCT04777890|Other|INYBI|The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
75547346|NCT06139887|Behavioral|BESST|The BESST intervention is a suicide prevention program designed to meet the unique needs of Veterans receiving care from community mental health treatment settings. BESST can be delivered by a trained mental health staff member, such as a mental health nurse, social worker, psychologist, or psychiatrist. The intervention consists of two synergistic components that work to support the patient after a mental health-related discharge in community settings: 1) Brief educational session, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study interventionist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed.
75708792|NCT03644277|Procedure|Massed Practise|"Address gross upper extremity movements, grip and pinch strength, and coordination.~Tasks utilized may include, but are not limited to: lifting a weighted can, squeezing, cutting paper, popping bubble wrap, translating different resistance clothespins, etc. The ultimate goal of the session is to achieve a total of 300 repetitions during training. Task difficulty may be progressed (making it more difficult), if the participant is able to achieve >100 repetitions in less than 15 minutes, on two different occasions. A task may be made easier if the participant is unable to achieve 50 repetitions of a task within 15minutes. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for a task to be deemed successful, increasing/decreasing the size of the object used. The number of total repetitions and any item progressions will be recorded."
75870734|NCT02364934|Drug|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
76036413|NCT02637895|Drug|Placebo|Placebo pill matching Vortioxetine.
75395991|NCT04777890|Other|INYBI + upper cervical manipulation|The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
75395992|NCT04778124|Procedure|Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)|All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.
75395993|NCT04778124|Procedure|Excision of thrombosed hemorrhoid / Hemorrhoidectomy /|One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
75395994|NCT04777812|Diagnostic Test|Rectal and buccal swabs|The oral and intestinal flora is collected from buccal and rectal swabs.
75395995|NCT02316678|Other|No intervention|There is no intervention
75870735|NCT02364934|Drug|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
76036414|NCT02637895|Drug|Vortioxetine|Immediate Release 10 mg. Vortioxetine Pill
76036415|NCT05013697|Drug|Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib|TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
75395996|NCT03726528|Diagnostic Test|Measurements of left ventricular pressure and volume|Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
75395997|NCT04777578|Other|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
75395998|NCT04754568|Other|Virtual reality instructional design|60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
75395999|NCT04754568|Other|Role-playing instructional design|60 minute traditional role-playing with standardized patient
75547347|NCT06139887|Other|Standard Mental Health Care|Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.
75547348|NCT06139848|Other|Traditional Physical Therapy|Conventional therapy include heating therapy for 10 mints, Bridging exercises (10 rep, 3 sets), Paraspinal muscle stretch.
75547349|NCT06139848|Other|Posterior-anterior spinal mobilization, prone press up Techniques|"Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions."
75870736|NCT02364856|Device|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording."
76036416|NCT05013697|Drug|Paclitaxel + Cisplatin + TQB2450 injection|TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
76036417|NCT05305911|Drug|Dapagliflozin|Dapagliflozin once daily for six months
75396000|NCT01896492|Drug|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
75396001|NCT04754490|Diagnostic Test|Speech Recognition|Speech Recognition
75547350|NCT06139835|Biological|Tartarase|Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
75547351|NCT06139822|Other|Experimental Group|Hamstring stretching is the main intervention which is being used along with convention protocol for plantar fasciitis.
75547352|NCT06139822|Other|Control Group|Control group included Cold pack for 7 to 10 mins. Followed by stretching of plantar fascia .
75870737|NCT02372656|Drug|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
75870738|NCT02372656|Drug|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
76036418|NCT05305911|Drug|Placebo|Placebo once daily for six months
75547353|NCT06139809|Procedure|Intubation|Intubation will take place according to our local standard protocol for nasal intubation using NIPPV delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the SpO2 and HR.
76036419|NCT05013775|Diagnostic Test|Computed tomography|Computed tomography to gauge response after preoperative chemotherapy cycles and excluded the development of interval metastases or irresectable disease
75396002|NCT01711632|Drug|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
75396003|NCT04756206|Drug|Dutasteride 0.5 mg|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
75396004|NCT04756206|Drug|Placebo|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
75396005|NCT04777500|Device|Auricular transcutaneous electrical nerve stimulation device|We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.
75396006|NCT04777188|Procedure|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
75396007|NCT04745598|Behavioral|Control group: Dental Model|- Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
75396008|NCT04745598|Behavioral|Computer-assisted teaching format group|- Patients receive a Powerpoint presentation containing:
75547354|NCT06139796|Drug|DRV/r FDC (120/20mg)|Initiation of DRV/r FDC (120/20mg) as part of antiretroviral therapy (ART) with an Optimized Background Therapy (OBT)
75708793|NCT03644277|Other|Rapael Glove|The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement and hand function during a 45 minute session. Additional time may be required for device set up and activity selection/modification. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. Tasks will be modified based on participants' perceived fatigue and challenge levels, as determined by a rating from 0-10. The participant goal will be to maintain the task difficulty between a 5-8/10 range. This would depict a moderate to difficult task rating, but an ability to complete the task. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for task success, and increasing the duration of contraction. The number of total repetitions and activity outcomes will be recorded.
75870739|NCT02372656|Drug|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
75870740|NCT03123939|Biological|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10^8 CTL019 transduced viable T cells (for patients > 50 kg)
75396009|NCT04745598|Behavioral|Plaque-disclosing group|- Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
75396010|NCT04745598|Behavioral|Intra-oral camera group|- An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
75396011|NCT04779060|Drug|intrathecal fentanyle|25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
75396012|NCT04779060|Drug|dexamethasone|8 mg dexamethasone give intrathecally for spinal anaesthesia
75396013|NCT04779060|Drug|saline|normal saline will be mixed with bupivacaine intrathecally
75396014|NCT04778826|Procedure|Lymphadenectomy|radical bloc dissection of all mediastinal lymph node stations
75396015|NCT04777110|Drug|Esketamine|The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
75547355|NCT06139783|Procedure|Exercise and dietary recommendations|Online physical exercise program and online nutritional assessment with personalized health and dietary recommendations
75547356|NCT06139770|Behavioral|Family based therapy- Metacognitive therapy|Family based therapy and Metacognitive therapy
75547357|NCT06139744|Drug|DAO supplement|One tablet of the supplementary study product is taken orally before morning, lunch and dinner every day, and each tablet contains 4.2mg of dehydrated pea seedling powder.
75547358|NCT06139744|Drug|Placebo|Placebo is orally supplemented with one tablet each day before morning, lunch and dinner, and placebo does not contain dehydrated pea seedling powder 4.2mg.
75547359|NCT06139705|Other|Walking outdoor|The individuals will walk in park along a pre-designated route 20 min.
75547360|NCT06139705|Other|Walking indoor|The individuals will walk in a gym on a treadmill 20 min.
76036420|NCT05013775|Diagnostic Test|Diagnostic laparoscopy with peritoneal lavage|Diagnostic laparoscopy lavage to exclude (small-volume) metastases and determine local resectability
75547361|NCT06139679|Procedure|ASD closure with fenestrated/non-fenestrated patch|A PTFE patch is used to surgically close the interatrial defect. If closure with fenestrated patch is deemed necessary, a small opening is created on the patch
75708794|NCT03643770|Combination Product|Upper extremity training/Armeo Spring|Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
75870741|NCT01368627|Device|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
75870742|NCT02358681|Drug|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
75396016|NCT04777110|Other|Saline|The main anesthesiologist standing on the right side of the patient injects saline (0.05ml/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30 s
75396017|NCT04776876|Biological|Retifanlimab|Given IV
75396018|NCT04776876|Drug|Telotristat Ethyl|Given PO
75396019|NCT04776642|Other|Biobank for Left atrial appendage tissue|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
75396020|NCT04776642|Other|Biobank for Blood|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
75396021|NCT04776642|Other|Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
75396022|NCT01982058|Other|communication intervention|
75396023|NCT01982058|Other|counseling intervention|
75396024|NCT01982058|Other|nutrition intervention|
75870743|NCT02358681|Drug|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
75870744|NCT02358681|Drug|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
75396025|NCT01982058|Other|questionnaire administration|
75396026|NCT04753944|Dietary Supplement|Active Comparator: Probiotic|The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.
75396027|NCT04753944|Dietary Supplement|Placebo group|Patients will be introduced for 5 weeks with placebo consisting of starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily. The treatment will be administered two times a day, during breakfast and supper.
75870745|NCT02358681|Drug|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
75396028|NCT01895400|Drug|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
75396029|NCT01895400|Drug|Placebo|Take placebo drug 1T bid po medication for 8 weeks
75396030|NCT04753866|Device|Facial scanner|The Bellus3D facial scanner will be used to scan the patient before and after implant rehabilitation in order to produce .obj files that allow 3D comparisons and to obtain discrepancy values regarding lip support.
75396031|NCT05605626|Other|the better retaining of skills|identify which teaching program has the better retaining of skills
75396032|NCT04753554|Device|ORI group|The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
75396033|NCT04753554|Other|Conventional group|In this patient group oxygenation will be managed as usual, using blood gas analysis.
75396034|NCT05272098|Other|Group A will receive myofascial release therapy + conventional physical therapy|myofascial release therapy (4 sessions per week). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the myofascial release therapy + hot pack (15min) + back care advice and postural modification. A total of 45 min session four times a week.
75396035|NCT05272098|Other|Group B will receive endurance training of the trunk extensor muscles + conventional physical therapy|It will be treated with endurance training of trunk extensor muscles. Erector spinae and latissimus dorsi will be included. The exercise protocol will be in four levels Bilateral shoulder left in prone position+ contralateral arm and leg lift in prone position+ both hands behind head and bilateral shoulder lift +bilateral shoulder lift with arm fully elevated + Hot pack (10 min) + back care advice and postural modification. A total of 45 min sessions four times a week.
75396036|NCT04753476|Biological|Injection of Secretome-MSCs|"Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours"
75396037|NCT04753476|Drug|Standard treatment of Covid-19|Patients will be given Standard treatment of Covid-19 which accordance with National protocol
75396038|NCT05605392|Other|Deinstitutionalization process|"Phase 1: Comprehensive geriatric assessment to evaluate who might be a candidate for deinstitutionalization.~Phase 2: Intervention:~Support plan: design a plan agreed upon with the participant to provide resources to the person's needs and which guarantees support during the transition and beyond.~Transition process: progressive withdrawal of support in the institution and implementation of support and adaptation in the community, with different types of accommodation depending on the needs and preferences of each participant. Coordination with primary care teams, social services, and other community resources.~Case follow-up and gradual withdrawal of the project team. If the process does not go as the person expects, or difficulties are encountered that cannot be resolved, the participant will have the option and choice, if desired, to return to the residence at any time during the process."
75396039|NCT05171946|Drug|S.opt.FL COVID-19 pDNA vaccine|Low-Dose: (1mg) level
75396040|NCT05171946|Drug|S.opt.FL COVID-19 pDNA vaccine|Mid-Dose: (2mg) level
75396041|NCT05171946|Drug|S.opt.FL COVID-19 pDNA vaccine|High-Dose: (4mg) level
75396042|NCT05605314|Other|Cyclosporine|eye drop
75396043|NCT04775940|Procedure|Perforated collagen membrane|Horizontal Bone Augmentation using Perforated Collagen Membrane
75870746|NCT03123861|Drug|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
75870747|NCT03123861|Drug|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
75870748|NCT01368705|Dietary Supplement|Standard protein delivery|Protein delivery of 1.5 g/kg/day.
75870749|NCT01368705|Dietary Supplement|Intervention 1 (2.2g/kg/day)|protein delivery of 2.2g/kg/day
75870750|NCT01368705|Dietary Supplement|Intervention 2 (3.0 g/kg/day)|protein delivery of 3.0 g/kg/day
76036421|NCT05007067|Device|DELTA Multihole TT|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
75396044|NCT04775940|Procedure|Occlusive collagen membrane|Occlusive collagen membrane
75396045|NCT02089464|Device|NBS-guided rTMS|
75396046|NCT02089464|Device|Sham rTMS|
76036422|NCT05349435|Drug|Fezagepras|Investigational drug
75558100|NCT03279549|Procedure|Limited debridement & Acellular dermal matrix dressing|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair."
75396047|NCT02089464|Procedure|Task oriented rehabilitation|
75396048|NCT04775862|Drug|investigator choice re-challenge with anti EGFR Rx|Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
75396049|NCT05605158|Drug|Pioglitazone 30mg|Pioglitazone 30 mg will be administered orally once daily for 24 weeks.
75708795|NCT03631173|Procedure|Surgical og radiological intervention, antibiotics|Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
76036423|NCT05349435|Drug|Sodium phenylbutyrate|Investigational drug
76036424|NCT05007223|Drug|Doxycycline|200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
76036425|NCT05305599|Drug|ZED1227|ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
76036426|NCT05305599|Drug|Placebo|Placebo
76036427|NCT03083587|Behavioral|Normal lifestyle|Normal lifestyle
76036428|NCT03083587|Behavioral|Exercise|Mild exercise 3 min every half hour
76036429|NCT03083587|Procedure|muscle and fat biopsy|Biopsy under local anesthesia
76036430|NCT03083587|Device|Continuous glucose monitoring|Glucose concentrations during the study period
76036431|NCT03083587|Device|Activity monitoring (ActivePal)|Objective measurements of standing and sitting time
76036432|NCT05000281|Drug|Ibuprofen|600 mg Ibuprofen 3 times a day for up to six weeks.
75396050|NCT05605158|Drug|Empagliflozin 10 MG|Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
75396051|NCT04754880|Diagnostic Test|Comparison of oxidative and antioxidative markers between groups|Oxidant and anti-oxidant markers
75396052|NCT05598762|Genetic|Tape strips|Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
75708796|NCT03598894|Other|Ambulatory blood pressure measurements|Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
76036433|NCT05348889|Drug|1A46 Injection|Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).
76036434|NCT03081949|Drug|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
75396053|NCT01053234|Dietary Supplement|Standardised meals|
75396054|NCT02090088|Drug|Not applicable- observational study|
75708797|NCT03584464|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 5.0 mm
75708798|NCT03573882|Drug|Voxelotor|300mg or 500mg Tablet, Oral, With or Without Food
75708799|NCT03567824|Drug|Magnesium L-lactate dihydrate|Magnesium L-lactate dihydrate 10 mEq extended release caplets
75708800|NCT03567824|Drug|Placebo Oral Tablet|Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
75708801|NCT03565159|Biological|Prevenar 13|Pneumococcal polysaccharide conjugate vaccine
76036435|NCT04999579|Device|T scan|Occlusal load analysis
76036436|NCT04999813|Combination Product|Comprehensive intensive intervention|"Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~Weight loss guidance."
75396055|NCT03433170|Procedure|Quadrupled semitendinosus graft|Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
75396056|NCT03433170|Procedure|ST-Gracilis graft|Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
75558101|NCT03279549|Procedure|Limited debridement & Epidermal cell spraying|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site."
75708802|NCT03565159|Other|Sodium Chloride 0.9%|Placebo
75708803|NCT03561220|Radiation|Standard of Care IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
75708804|NCT03561220|Radiation|Standard of Care Proton Therapy|As this trial is pragmatic, all treatment will be standard of care.
75708805|NCT03561220|Radiation|Proton Arm 1: Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions
75708806|NCT03561220|Radiation|Proton Arm 2: Hypofractionated Proton Therapy|60.0 Gy (RBE) in 20 fractions
75708807|NCT03550040|Procedure|Radical prostatectomy|Surgical removal of the prostate
75708808|NCT03541291|Device|SMART-SYNC LM03|Doppler ultrasound cardiac gating device for fetal MRI application
76036437|NCT05347797|Diagnostic Test|therascreen® KRAS RGQ PCR Kit|To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
76036438|NCT05347563|Procedure|Electrical impedance tomography|All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment…)
75708811|NCT03531320|Drug|D07001-softgel capsules|Active Ingredient:Gemcitabine hydrochloride
75396057|NCT04775238|Other|Silver nanoparticles|AgNPs (19±5 nm)
75396058|NCT04775238|Other|Copper nanoparticles|CuNPs (150-350 nm)
75396059|NCT05595798|Diagnostic Test|Airmod breathing sound monitoring|Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
75396060|NCT01896882|Other|Sodium restriction|
75396061|NCT05580042|Drug|AC-1101|For each patient, once daily (QD)
75396062|NCT04775160|Device|SmartSafe|"The SmartSafe Ecological Momentary Intervention is contained in the MEmind smartphone application and consists of a Safety plan, an Enhanced contact via app (app-EC) intervention, and a mental toolbox. The Safety plan is a set of personalized coping strategies that the patient can use in a suicidal crisis. Our safety plan was adapted to a digital environment, including the possibility to activate pre-recorded messages, lead to websites with health resources, or put the patient in contact with the emergency services. The Enhanced contact via app (app-EC) intervention is inspired by the SIAM project and consists in messages that will be sent via the MEmind app inquiring patients about their mental well-being and informing them of the means to request preferential or urgent care. The mental toolbox contains videos relaxation techniques videos and behavioral activation and mentalization exercises."
75396063|NCT03288480|Drug|PT-112|This is a single arm study
75708812|NCT03529201|Procedure|QLB|On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
75708813|NCT03529201|Device|PCA|Patient-controlled analgesia
75708814|NCT03529201|Procedure|GA|General anesthesia
75708815|NCT03529201|Drug|Oxycodone|administered by PCA
75708816|NCT03529201|Drug|Sevoflurane|Inhalational anesthetic during GA
75708817|NCT03529201|Drug|Fentanyl|painkiller during GA
75708818|NCT03529201|Drug|Rocuronium|muscle relaxant during GA
75708819|NCT03510208|Procedure|Near-Infrared Fluorescence Imaging|Undergo NIR imaging
75708820|NCT03510208|Biological|Panitumumab|Given IV
75708821|NCT03510208|Drug|Panitumumab-IRDye800|Given IV
75708822|NCT03510208|Device|POINPOINT-IR9000|"Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table)."
75396064|NCT01895478|Behavioral|PACCI-ED use|Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
75396065|NCT03095742|Diagnostic Test|Low MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
75396066|NCT03095742|Diagnostic Test|High MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
75396067|NCT03094026|Behavioral|Lumosity|Computer-based online cognitive training program using the Lumosity cognitive training program.
75396068|NCT03094026|Behavioral|Lumosity (waitlist control)|Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
75547362|NCT06139666|Drug|Exparel Injectable Solution|"Patients randomized to this arm will receive an interscalene block with Exparel solution, an extended-release formulation of bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine), approved for use at the study institution. This will be administered preoperatively on the day of surgery. The anesthesiologist administering the injection will be not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
75708823|NCT03500380|Drug|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
75708824|NCT03500380|Drug|Lapatinib|Lapatinib 1250 mg orally once daily during each 21-day cycle.
75708825|NCT03500380|Drug|Capecitabine|Capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle.
75708826|NCT03496623|Drug|Inhaled treprostinil solution|Treprostinil inhalation solution
76036439|NCT03076255|Procedure|Computed Tomography|Undergo CT simulation
75396069|NCT04774770|Behavioral|HED-Start|The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.
76036440|NCT03076255|Device|Medical Device|Given thermoplastic mask
75396070|NCT01614990|Drug|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
76036441|NCT03076255|Device|Medical Device|Given MID
76036442|NCT03076255|Procedure|Cone-Beam Computed Tomography|Undergo CBCT imaging
76036443|NCT03076177|Other|Taping application|Kinesio taping application will be applied for experimental group; non specific taping application for control
76036444|NCT03076411|Drug|Pepsin|
75396071|NCT01614990|Drug|Placebo|placebo (Powerade®) daily for 7 days.
75396072|NCT05433558|Other|Neuropsychological Rehabilitation|Neuropsychological Rehabilitation
75708827|NCT03496623|Drug|Placebo solution|Placebo solution
75708828|NCT03473561|Drug|Racecadotril plus ORS|"1.5 mg/kg of Racecadotril will be administered, 3 times daily, via the oral route (in addition to standard treatment i.e. oral rehydration solution).~In infants less than 9 kg: one 10 mg sachet 3 times daily. In infants from 9 kg to < 13 kg: two 10 mg sachets 3 times daily. In children from 13 kg to 27 kg: one 30 mg sachet 3 times daily. In children of more than 27 kg: two 30 mg sachets 3 times daily."
75708829|NCT03471260|Drug|Azacitidine|Given IV or SC
75708830|NCT03471260|Drug|Ivosidenib|Given PO
75708831|NCT03471260|Drug|Venetoclax|Given PO
75708832|NCT03466450|Drug|PF-04449913|"Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration."
76036445|NCT05006755|Combination Product|Mineral Trioxide Aggregate|Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair
76036446|NCT05006755|Combination Product|Biodentine|Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
75396073|NCT04774614|Procedure|anterior laminate veneers|VITA ENAMIC multiColor
76036447|NCT05347173|Drug|Dexmedetomidine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
76036448|NCT05347173|Drug|Nalbuphine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
75708833|NCT03466450|Drug|Temozolomide Oral Capsule|"During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
75708834|NCT03459820|Diagnostic Test|18F-DCFPyL PET/CT|18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
75708835|NCT03455517|Drug|Venetoclax|Venetoclax and rituximab association
75396074|NCT05074134|Drug|[14C]-TNP-2092|Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi [14C]-TNP-2092 administered over 60 minutes (± 10 minutes).
75708836|NCT03455517|Drug|Rituximab|Venetoclax and rituximab association
75396075|NCT03318978|Drug|[14C]-benzo[a]pyrene|Oral micro-dose range (25, 50, 100 and 250 ng)
75396076|NCT05421546|Dietary Supplement|Spermidine or Placebo|The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.
75708837|NCT03431168|Drug|Azithromycin/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
75708838|NCT03431168|Drug|Placebo/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
75708839|NCT03419481|Drug|pembrolizumab|200mg every 3 weeks infusion
75708840|NCT03412630|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
75708841|NCT03404908|Procedure|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
75396077|NCT05390970|Procedure|Platelet-rich plasma injection|Injection of autologous platelet-rich plasma into the anterior vaginal wall
75396078|NCT04773756|Drug|Sofosbuvir 400 MG/ Daclatasvir 60mg|Giving these two drugs for treatment of COVID patients
75708842|NCT03404908|Procedure|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
75708843|NCT03404908|Drug|Ropivacaine|In both groups (TAP&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
75708844|NCT03404908|Device|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
75708845|NCT03404908|Drug|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
75708846|NCT03404908|Drug|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
75708847|NCT03404908|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
76036449|NCT05006287|Drug|Non-vitamin K oral anticoagulants (NOACs)|"NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated."
75708848|NCT03404908|Drug|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
75396079|NCT03012984|Drug|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
75396080|NCT03012984|Drug|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
75396081|NCT01574118|Behavioral|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
75708849|NCT03399032|Drug|Caspofungin|"Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day~Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days."
75708850|NCT03386617|Drug|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
75708851|NCT03383354|Other|Sleep-related disturbances (exposure)|Sleep-related disturbances such as sleep-disordered breathing (e.g. sleep apnea), sleep fragmentation, abnormal sleep architecture, and periodic limb movements (PLMs)
75708852|NCT03366272|Drug|Nivolumab|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
75708853|NCT03366272|Drug|Rituximab|eight cycles of R-GemOx in 2-wk intervals
75708854|NCT03366272|Drug|Gemcitabine|eight cycles of (R)-GemOx in 2-wk intervals
75708855|NCT03366272|Device|Oxaliplatin|eight cycles of (R)-GemOx in 2-wk intervals
75396082|NCT01574118|Behavioral|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
75396083|NCT01574118|Behavioral|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
75396084|NCT01574118|Behavioral|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
75396085|NCT01574118|Behavioral|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
75396086|NCT01574118|Behavioral|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
75396087|NCT01574118|Behavioral|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
75396088|NCT01574118|Behavioral|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
75396089|NCT04773990|Device|Biodex Balance System|Subjects will receive several unique training modules using biodex
76036450|NCT05006287|Drug|Warfarin|"Warfarin Group (Comparator):~Patients randomized to the warfarin group will receive warfarin titrated to achieve a target International Normalized Ratio (INR) of 2.5 (range 2.0 to 3.0). Warfarin will be started as early as post-operative day 1 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until INR is 2.0 or above."
76036451|NCT05303415|Other|Neuromodulation with low-intensity focused ultrasound|Application of LIFU to induce temporary neuromodulation, effects tested with resting state and heat evoked (QST) fMRI signals
76036452|NCT05013151|Dietary Supplement|Dates|Consumption of 6 dates a days until 41 weeks of gestation
76036453|NCT05013151|Dietary Supplement|Castor oil|One time consumption of 60 CC Castor oil
76036454|NCT05303337|Other|Stool sampling|Stool samples will be collected from participants at baseline and W52
76036455|NCT05303337|Other|Blood plasma collection|Blood plasma collection to assess persistent inflammation, immune activation and HIV reservoir at baseline,W24,W52
76036456|NCT05006365|Device|Transcranial Pulse Stimulation|A total of 30 participants (both TPS group and the waitlist control group) will receive six 30 minute-TPS sessions (300 pulse in each session, total: 1800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up at 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on depressive symptoms.
75396090|NCT04773990|Other|specific physical therapy exercise program|Subjects will receive recommended PT program
75396091|NCT05051202|Other|Sugars from Fiber|Proprietary blend of Sugars from Fiber baked into 50 g flapjack
76036457|NCT05006209|Other|One visit root canal treatment|
75396092|NCT05051202|Other|Resistant Maltodextrin|Resistant Maltodextrin baked into 50 g flapjack
75396093|NCT05290974|Other|Self exploring of available online material on supraclavicular brachial plexus block|Potential new method of learning a specific regional anesthesia technique
75396094|NCT05290974|Other|Conventional in-person teaching on supraclavicular brachial plexus block|Conventional method of learning a specific regional anesthesia technique
75396095|NCT02866344|Procedure|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
75396096|NCT02866344|Procedure|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
75396097|NCT04773132|Other|Low Protein|Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
75396098|NCT01565382|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)
75396099|NCT04773444|Behavioral|Eccentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
75708856|NCT03363217|Drug|Trametinib|Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
76036458|NCT05006209|Other|Two visit root canal treatment|
75396100|NCT04773444|Behavioral|Concentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
75396101|NCT01895556|Other|Information|
75396102|NCT01895556|Other|Control|
75396103|NCT02744430|Drug|Mirabegron|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
75396104|NCT02744430|Other|Placebo|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
75396105|NCT05208138|Device|Senhance Surgical System from Asensus|Bariatric operation with the Senhance Surgical System
75396106|NCT05204706|Other|MyManis app|The women will receive a brochure outlining the app features and step guide on how to download the app which will be available in both Bahasa Melayu and English languages. A link to download the app via text message will also be sent to participants for convenience. Once the app has been downloaded, participants will be invited to set up an account. Once completed this will give them full access to the MyManis app. The key component of MyManis app content presented under six main tabs which are homepage, information, diet, exercise, wellbeing and GDM monitoring. The women will be invited to join group peer support through WhatsApp facilitated by a dietitian trained in motivational interviewing. The women will be notified via text message if an update of the app is required. If there's women who have not accessed the app for over a two-week period will be flagged and a notification will be sent via the app to motivate app engagement.
75396107|NCT04772976|Other|Observational study, not applicable|Observational study, not applicable
75396108|NCT00054756|Drug|TRH (Thyrotropin Releasing Hormone)|
75396109|NCT04772430|Radiation|snow globe|"Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure."
75396110|NCT04772508|Procedure|Scaling and root planing|15 sites with periodontal pockets ≥ 5mm received only SRP
75396111|NCT04772508|Biological|Amnion membrane|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
75708857|NCT03334708|Diagnostic Test|Blood Draw|"If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:~Patients and controls weighing 50kg or more~For draw amounts up to 50mL, there is no required hemoglobin threshold.~For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.~Patients and controls weighing < 50kg~For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time."
75396112|NCT04772508|Drug|Taurine|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
75396113|NCT01896960|Drug|Bupivacaine with 15 micrograms of fentanyl|Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
75396114|NCT02091102|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
75396115|NCT00055692|Biological|bevacizumab|Given orally
75396116|NCT05043012|Device|flexible AIR coil|mpMRI scan
75396117|NCT05043012|Device|endorectal coi|mpMRI scan
75396118|NCT04772352|Drug|febuxostat treatment|According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
75396119|NCT04772352|Behavioral|lifestyle intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
75396120|NCT00056472|Drug|Olanzapine|10-20mg/day
75396121|NCT00056472|Drug|Sertraline|150-200mg/day
75396122|NCT00056472|Other|placebo|tablet that ressembles sertraline but contains no medication
75396123|NCT00056550|Biological|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
75708858|NCT03334708|Diagnostic Test|Tumor Tissue Collection|Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
75708859|NCT03334708|Diagnostic Test|Cyst Fluid|Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
75708860|NCT03330418|Biological|Placebo|Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
75708861|NCT03330418|Biological|RC18 160 mg|In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
75708862|NCT03319797|Drug|NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
75708863|NCT03314805|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
75547363|NCT06139666|Drug|Bupivacaine Injectable Solution|"Patients randomized to this arm will receive a standard interscalene block consisting of 25 cc of bupivacaine alone. This will be administered preoperatively on the day of surgery.~The anesthesiologist administering the injection will not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
75708864|NCT03314805|Drug|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
75708865|NCT03314805|Procedure|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
75708866|NCT03313804|Drug|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
75396124|NCT04752930|Diagnostic Test|ctDNA monitoring|Patients who undergoing radical surgery for colorectal cancer for 6~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled, and diagnostic laparoscopy will be performed immediately after enrollment. Patients with positive peritoneal metastasis (PCI score <20) will be treated with CRS+HIPEC. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months in patients with negative peritoneal metastasis. Laparoscopy will be performed when imaging suggested peritoneal metastasis (oligometastases). Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
75396125|NCT04752930|Diagnostic Test|Imageology|Patients who undergoing radical surgery for colorectal cancer for 6~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled. and there will be no need to conduct endoscopic exploration immediately after enrollment. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months until imaging suggested peritoneal metastasis (oligometastases). Patients with positive peritoneal metastasis (PCI score <20) will be treated with CRS+HIPEC. Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
75396126|NCT04271826|Procedure|laparoscopic appendectomy|cases with normal CT underwent laparoscopic appendectomy
75708867|NCT03313804|Radiation|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
75708868|NCT03293810|Other|Observational study|Post-Authorization Safety Study
75708869|NCT03287193|Biological|Blood sample|for patient and its parents
75708870|NCT03287193|Genetic|high-throughput sequencing|exome or whole genome sequencing
75708871|NCT03283033|Behavioral|New salad bar|New salad bar placed in school
75708872|NCT03283033|Behavioral|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
75708873|NCT03269981|Radiation|Whole breast irradiation|Radiotherapy to the whole breast alone.
75708874|NCT03269981|Radiation|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
75708875|NCT03241537|Radiation|Intensity modulated radiotherapy|
75708876|NCT03239626|Radiation|POHIM-RT|postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
75708877|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
75708878|NCT03229200|Drug|Ibrutinib|Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
75708879|NCT03224507|Drug|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
75708880|NCT03224507|Drug|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
76036459|NCT05346003|Procedure|TCSP|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human BLS mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a BLS mock-up in a home environment, and after blended e-learning, they will be able to perform BLS iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice BLS in a real simulation model two weeks after the blended e-learning.
75708881|NCT03215030|Drug|Modakafusp alfa|Modakafusp alfa intravenous infusion.
75708882|NCT03215030|Drug|Dexamethasone|Dexamethasone.
75708883|NCT03193190|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
75708884|NCT03193190|Drug|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
76036460|NCT03081013|Behavioral|Social information|Social comparison information will be provided to the study participants weekly via SMS
75396127|NCT04771884|Drug|meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid|The use of antimicrobial agents depends on the clinical practice
75396128|NCT02538744|Drug|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
76036461|NCT03081013|Device|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
76036462|NCT05335629|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
76036463|NCT03078673|Other|training intervention, motor skill training|cross country specific motor skill strength training
75396129|NCT02538744|Drug|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 [placebo], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
75708885|NCT03193190|Drug|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
75708886|NCT03193190|Drug|Leucovorin|Leucovorin will be administered as per the schedule specified in the respective arm.
75708887|NCT03193190|Drug|Fluorouracil|Fluorouracil will be administered as per the schedule specified in the respective arm.
75708888|NCT03193190|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
75708889|NCT03193190|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
75708890|NCT03193190|Drug|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arm.
75708891|NCT03193190|Drug|BL-8040|BL-8040 will be administered as per the schedule specified in the respective arm.
75708892|NCT03193190|Drug|Selicrelumab|Selicrelumab will be administered as per the schedule specified in the respective arm.
75396130|NCT02538744|Drug|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
75396131|NCT02538744|Drug|Placebo|
75396132|NCT00060528|Drug|Recombinant Fowlpox-GM-CSF|
75396133|NCT00060528|Drug|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
75396134|NCT00060528|Drug|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
76036464|NCT03078673|Other|training intervention, maximal strength training|general maximal strength training
75396135|NCT00060528|Drug|Recombinant Human GM-CSF|
75396136|NCT02255838|Device|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
75396137|NCT02255838|Device|Bronchoscope disposable (aScope 4)|Bronchoscopy and alveolar lavage
75396138|NCT04696224|Drug|Tranexamic acid|The surgical technique consists in patient in supina position with previous reduction with lower limb traction (on a traction table or manual) associated or not with the use of percutaneous reduction clamps. Longitudinal lateral incision of 3-5 cm proximal to the greater trochanter, approximately 5 cm long, will be performed. After the skin and subcutaneous incision, the fascia lata will be incised in the same direction, with exposure of the gluteal muscles and the proximal femur. The awl will be introduced at the tip of the greater trochanter and then, at the same location, an intramedullary guidewire, towards the proximal shaft, crossing the fracture. A 3 cm incision to the thigh and inferior to the initial incision with template to introduce the screw in the center of the femoral head. Then, a 2cm incision will be made at the distal end of the nail, and a hole in the femur for the distal lock in dynamic nail hole with a 4.5mm drill where a cortical screw will be inserted.
75396139|NCT04696224|Other|Saline solution|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2
75396140|NCT04690452|Behavioral|Compassion Cultivation Training|The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
76036465|NCT03078673|Other|control group|regular training
75396141|NCT04689438|Diagnostic Test|gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
75396142|NCT04688580|Drug|XW10172|Various formulations
75396143|NCT04753008|Drug|Dopamine administration|Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
75396144|NCT04771494|Other|Power and execution speed as a function of instability experience|"Each subject performed 3 repetitions for the light load (40% RM; VMP > 1.0 m/s), with 1 minute rest; 2 repetitions for the medium load (60% RM; 0.65 m/s ≤ VMP ≤ 1.0 m/s) with 2 minutes rest and 1 repetition for the heavy load (80% RM; VMP < 0.65 m/s) with 4 minutes rest. A metronome was used for the start countdown and to time the eccentric and concentric portions of the exercise.~Subjects began the bench press with their elbows fully extended, maintaining a grip distance slightly greater than shoulder width. The bar was then lowered to their chest and then applying as much thrust as possible until full elbow extension on a 2-1-0 count. The timing sequence involved 2 seconds for the eccentric phase, a 1 second hold (to minimise the contribution of the rebound effect and allow for more reproducible and consistent measurements) and for the concentric up phase the highest possible execution speed, until the bar returned to the starting position."
75708893|NCT03193190|Drug|Bevacizumab|Bevacizumab will be administered as per the schedule specified in the respective arm.
76036466|NCT03075787|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
76036467|NCT03076099|Drug|Dexmedetomidine|1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
76036468|NCT03076099|Other|normal saline|equal volume of normal saline was administered intravenously constantly after tracheal extubation.
75396145|NCT04771104|Dietary Supplement|Amino Acid Challenge (AAC)|The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.
75558102|NCT03279549|Procedure|Limited debridement & Basic fibroblast growth factor|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds."
75708894|NCT03193190|Drug|RO6874281|RO6874281 will be administered as per the schedule specified in the respective arm
75870751|NCT04116645|Other|genital and rectal swab|6. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
75870752|NCT01368783|Drug|atazanavir|400 mg/day for 2 days
75870753|NCT01368783|Drug|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
76036469|NCT05301621|Other|Akcelerometry follow up|The patients and control group will be followed up with single accelerometer.
75870754|NCT01368783|Drug|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
75870755|NCT01368783|Drug|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
75870756|NCT01509339|Drug|Vancomycin|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
76036470|NCT03075709|Other|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
75396146|NCT00060606|Procedure|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
75396147|NCT00060606|Procedure|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
75396148|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
75396149|NCT00063570|Drug|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
75396150|NCT00063570|Drug|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
75396151|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
75396152|NCT04770714|Diagnostic Test|Breast MRI|Standard of Care Breast MRI
75708895|NCT03193190|Drug|AB928|AB928 will be administered as per the schedule specified in the respective arm.
75708896|NCT03193190|Drug|Tiragolumab|Tiragolumab will be administered as per the schedule specified in the respective arm.
75708897|NCT03193190|Drug|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the respective arm.
75870757|NCT01371279|Device|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
75870758|NCT03123471|Drug|Apremilast|Apremilast 30 mg tablets BID from weeks 0 to 32.
75870759|NCT03123471|Other|Placebo|Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
76036471|NCT03075631|Other|Questionnaire|Questionnaires
76036472|NCT03075865|Device|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
76036473|NCT05554965|Drug|Propofol|Remifentanil maintenance analgesic dose was 1.2-9 μg/kg/h. If the CPOT score ≥3 at the time of maintenance administration, dose adjustment can be considered. Propofol was used for sedation at a loading dose of 0.5mg/kg and a maintenance dose of 1.5mg/kg/h.
76036474|NCT05554965|Drug|Remimazolam besylate|Remifentanil was administered at a maintenance dose of 1.2-9 μg/kg/h for analgesia. If CPOT score ≥3 during maintenance administration, dose adjustment could be considered. For sedation, remazolam besylate was given a load of 0.1-0.2mg/kg and a maintenance dose of 0.1-0.3mg/kg/h.
76036475|NCT03078517|Device|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
76036476|NCT03078517|Device|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
76036477|NCT05300217|Other|Strategies for promoting mental health|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health"
76036478|NCT05300217|Other|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
75396153|NCT04770714|Diagnostic Test|Contrast Enhanced Mammography|Standard of Care Contrast Enhanced Mammography
75396154|NCT01897038|Drug|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
75396155|NCT01897038|Drug|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
76036479|NCT05335161|Device|Home-based leg heat therapy|The Aquilo system consists of a garment that contains an inner water-circulating pad that is compressed by air bladders. The volume of air inflating the air bladders is pressure-controlled so the garment automatically adjusts to the shape and size of all legs. The touch screen console contains pre-programmed settings for ease of use. After baseline characteristics are established, patients will be provided with the Aquilo device and will be instructed on how to operate the equipment and how to rapidly remove the system if the alarm sounds or if they have any unusual feeling. Patients in both groups will also receive a logbook to record their sessions. Patients will undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. Water at 42ºC will be perfused through the water-circulating garment for 90 min, with the goal of increasing skin temperature in the calf to ~37ºC.
75396156|NCT04770792|Other|2% chlorhexidine gluconate with mineral trioxide aggregate.|2% chlorhexidine gluconate with mineral trioxide aggregate.
76036480|NCT05268471|Device|Positional device (PD)|OSA treatment with PD for 6 months
76036481|NCT05268471|Device|Continuos Positive Airway Pressure (CPAP)|OSA treatment with CPAP for 6 months
75396157|NCT04770792|Other|Mineral trioxide aggregate.|Mineral trioxide aggregate.
75396158|NCT00064038|Drug|dexamethasone|Given orally
75396159|NCT00064038|Drug|lenalidomide|Given orally
75396160|NCT00064038|Other|placebo|Given orally
75396161|NCT04770558|Other|Interactive Exergame|The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
75396162|NCT01960530|Drug|Hydrocortisone granules|Multi-particulate granules
75396163|NCT01960530|Drug|Hydrocortisone Tablet|Standard hydrocortisone tablets
76036482|NCT05299749|Other|stg-rt-fMRI-Neurofeeback|the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
76036483|NCT05299749|Other|sham-rt-fMRI-Neurofeedback|the patients will receive real-time feedback from the brain activity of the somato-motor cortex
76036484|NCT05299047|Other|Group US-guided|An ultrasound system with a 5-2 MHz curved transducer will be used. The division of the abdominal aorta into the common iliac arteries was located using oblique sonography. Then, the transducer will image the body of the fifth lumbar vertebra, at which level bilateral common iliac vessels will be seen leaving a space in the midline. a 20 cm long, 22 gauge Chiba needle will be introduced into the hypogastrium, with out-of-plane technique to access the fifth lumbar vertebral body at its anterior-most point, so that injected drug spreads equally bilaterally along the anterior curvature of the fifth lumbar vertebral body.Suction was applied to the needle to confirm that it was not within a vessel and 10 ml of 50% ethanol will be injected for neurolysis.
76036485|NCT05299047|Other|Group fluoroscopy-guided|The patient will be placed in the supine position. The L5-S1 inter-discal space was identified under fluoroscopy.After providing local cutaneous and subcutaneous anesthesia with 2% Lignocaine solution nearly 3-4 cm below the umbilicus, a 20 cm long, 22 gauges Chiba needle is advanced to the anterior portion of the 5th vertebral body under ongoing fluoroscopic guidance. Once bony resistance is reached, gently inject 2-5 ml contrast which typical reveals a characteristic triangular blob of contrast with no vascular opacification.Before injection the needle is aspirated to confirm there is no blood. A preliminary test dose of about 3 cc of 0.5% bupivacaine is then injected. If there is no change in heart rate or neurological status, rest of the 20 cc phenol 10% is injected slowly with intermittent aspiration.
76036486|NCT05267769|Drug|AP707|Preparation of Cannabis flowers (Cannabis flos)
75396164|NCT01960530|Drug|i.v. Hydrocortisone Injection|Standard hydrocortisone solution for intravenous injection
75396165|NCT01960530|Other|Dexamethasone|Challenge agent
75396166|NCT01897350|Other|Cardiac magnetic resonance imaging|
75396167|NCT01737060|Device|Reverse total shoulder arthroplasty|
75396168|NCT04389372|Behavioral|Mindfulness|Mindfulness by smartphone combined to video calls for clinical evaluation in patients with chronic migraine and medication overuse after withdrawal program
75396169|NCT04770168|Behavioral|Cognitive Behavioral Therapy Curriculum|"The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient."
75547364|NCT06139653|Device|Moment 1: IMT. Moment 2 CardioBreath.|"Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
75870760|NCT02661178|Drug|emodepside (BAY 44-4400)|
75870761|NCT02661178|Drug|placebo|
76036487|NCT05267223|Other|Semi-structured interviews|Semi-structured interviews with individuals with paraplegia
75396170|NCT04769934|Device|Penguin RFA|to evaluate the peri-implant bone level changes (marginal bone level) around the implant platform.
75396171|NCT01897428|Drug|Test-Bepotastine salicylate 9.64 mg|
75396172|NCT01897428|Drug|Reference-bepotastine besilate 10 mg|
75396173|NCT05606562|Procedure|Dental care|Participants will be offered free dental care
75396174|NCT00067236|Drug|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
75396175|NCT00067236|Drug|Placebo tablet|placebo tablet, twice a day for 90 days
75396176|NCT04753398|Device|Blood Pressure Monitor, medication dispenser, telemonitoring technology|The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.
75396177|NCT00007644|Procedure|Radical prostatectomy|Surgical removal of the prostate
75396178|NCT00068718|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
75396179|NCT00024102|Drug|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 & 8 and 5-FU 600 mg/sq m IV push d 1 & 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
75396180|NCT00024102|Drug|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
75558103|NCT00478530|Procedure|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
75396181|NCT05606250|Other|Ultrasound-Guided Percutaneous Neuromodulation|Ultrasound guided percutaneous neuromodulation in femoral nerve. Patients were placed in supine lying with the anterior aspect of the hip uncovered. The intervention consisted of the application of a biphasic square wave electric current, with a frequency of 2 Hz, a phase duration of 250μs, and a maximum tolerable intensity to cause an exacerbated muscle contraction for 15minutes in total
75396182|NCT05606016|Behavioral|Facilitated Self-Sampling Intervention (FSSI)|CHWs will consent and enroll participants to the FSSI from the randomized PBGs. FSSI will consist of Community Health Worker (CHW) delivered education intervention about COVID-19 testing at a home visit. In addition, the participant will receive a batch of 4 rapid antigen tests which can be shared with people in the household or other close contacts if needed. The CHWs will provide low-literacy instructions for administering the tests, including print and video. The CHWs will also provide guidance if they tested positive (e.g. quarantine, notify contacts, wearing a mask). The CHWs will also be available by phone to the participants for any follow-up questions. CHW will follow-up via text and phone with the participants during the two months post intervention. In addition to the intervention, the participants will be asked to complete the pre and post test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
75547365|NCT06139653|Device|Moment 1: CardioBreath and moment 2: IMT.|"CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act.~Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks."
75547366|NCT06139640|Other|Damask Rose Essential Oil|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
75547367|NCT06139627|Other|Best Practice|Receive usual care
75547368|NCT06139627|Procedure|Biospecimen Collection|Undergo blood and stool sample collection
76036488|NCT04422483|Other|Realist evaluation|In-depth exploration of individual service models will be carried out to determine the interrelationship of context, intervention, mechanisms and outcomes as they occur in their natural setting. Data will be gathered within case studies using mixed methods at two levels: (i) service model and (ii) individual child/ family. Methods will include semi structured realist Interviews, focus groups, and document reviews to assemble a comprehensive description of the service and model. Interviewees will include commissioners, service managers, clinicians, referrers, parents and young people. Interviews will be recorded and transcribed, proceeding to qualitative analysis based on components of the programme theory. Regular team meetings will discuss coding, address inconsistencies, and refine collective understanding of coding framework. Coded data will be collated using NVivo software.
75708898|NCT03169985|Drug|Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
75547369|NCT06139627|Other|Communication Intervention|Receive GA assessment summary and assessment-based recommendations
75547370|NCT06139627|Other|Comprehensive Geriatric Assessment|Complete GA
76036489|NCT05297097|Dietary Supplement|Trulacta breastmilk supplement|one supplement daily
75708899|NCT03169985|Drug|Rosuvastatin 20 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
75708900|NCT03153527|Drug|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
76036490|NCT05266053|Device|PICO 7 dressing|The PICO 7 dressing consists of a negative pressure wound therapy pump (NPWT) connected to an absorbent gentle adhesive dressing that is applied to a wound. When the pump is activated, it acts by pulling excess fluid from the wound. The dressing absorbs this fluid and helps to prevent bacteria from entering the wound. It has been shown to prevent wound infections and promote healing.
76036491|NCT05266053|Other|Standard wound dressing|Standard abdominal dressing at the time of cesarean
76036492|NCT05501379|Other|No intervention - observational study only|No intervention - observational study only
76036493|NCT05331573|Device|apomorphine pump|observationnal
76036494|NCT05262075|Other|Online Mindfulness Resiliency Program|An approximate 20 minute online mindfulness resiliency program offered 3/wk x 4 weeks.
76036495|NCT05261451|Other|Workshop|Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
76036496|NCT05260359|Drug|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation|SU E 101413 85
76036497|NCT05260359|Drug|6% Bemotrizinol (BEMT) dispersion in petrolatum|SU-E-101413-82
76036498|NCT05260359|Other|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT|SU E 101413 91
76036499|NCT05260359|Other|Petrolatum vehicle|SU-E-101413-83
75547371|NCT06139627|Other|Electronic Health Record Review|Ancillary studies
75547372|NCT06139627|Other|Survey Administration|Ancillary studies
75558104|NCT00443183|Behavioral|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
75558105|NCT00443183|Behavioral|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
75558106|NCT03275142|Device|Icare tonometer|Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
75558107|NCT03271983|Drug|Metronidazole gel 1|RLD gel
76036500|NCT05260359|Other|0.9% Saline|low irritancy control
75870762|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder [one 20 U, two 20 U and one 40 U cartridges)
76036501|NCT05260359|Other|Sodium Lauryl Sulfate 0.1% (SLS)|positive control
76036502|NCT05260359|Other|Undosed patch|negative control
75547374|NCT06139562|Behavioral|Time-Restricted Feeding|Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
75558108|NCT03271983|Drug|Metronidazole gel 2|generic gel
75558109|NCT03271983|Drug|Metronidazole cream|generic cream
75708901|NCT03153527|Other|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
75870763|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder [one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)])
75870764|NCT02370316|Behavioral|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
75870765|NCT02370316|Behavioral|Clinical Structured Treatment|structured case management and symptom-targeted medication
75870766|NCT02372500|Dietary Supplement|Chewing gum|Sugar free chewing gum
75708902|NCT03151278|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
75708903|NCT03151278|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
75870767|NCT03840447|Behavioral|Chronic Disease Self-Management programme|"The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens."
75870768|NCT02372812|Drug|dexamethasone|12 mg of dexamethasone
75396183|NCT05606016|Behavioral|Testing Navigation Intervention (TNI).|CHWs will consent and enroll participants to the TNI from the randomized PBGs. The TNI will consist of CHW-led intervention at a home visit where they will provide low health literacy materials about how and when to conduct a COVID 19 test (including antigen and PCR) using a decision tree model and provide navigation to nearby PCR testing sites, locations to purchase antigen tests and support in accessing federal government antigen tests if not already obtained by the participant. In addition to the intervention, the participants will be asked to complete the pre and post-test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
75396184|NCT05606016|Behavioral|Control|Participants in the Control arm will receive CDC-designed COVID-19 testing brochures, and pre and post surveys only.
75396185|NCT00074802|Drug|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
75558110|NCT04700982|Other|Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and > 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
75558111|NCT00443222|Drug|Infliximab|
75396186|NCT00074802|Behavioral|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
75396187|NCT05605938|Drug|Tenoten for children|Oral administration
75396188|NCT05605938|Drug|Placebo|Oral administration
75396189|NCT00156390|Device|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
75396190|NCT00156390|Other|LV lead placement as per standard of care (without echo guidance)|
75396191|NCT00029172|Other|case management|
75558112|NCT00440349|Drug|Tamoxifen|
75558113|NCT00440349|Drug|Prednisone|
75558114|NCT03270930|Procedure|Emergency laparotomy|All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
75558115|NCT00443339|Drug|Darbepoetin|
75558116|NCT03272763|Device|F&P Toffee mask|Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
75547375|NCT06139562|Behavioral|Extended-Time Feeding|Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
75708904|NCT03148054|Device|Computer Tomography and Endoscopy|"Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system."
75708905|NCT03119012|Drug|Clopidogrel|75mg/day
76036505|NCT05330091|Dietary Supplement|Once Daily Women's Probiotic|Active product
76036506|NCT05330091|Other|Placebo|Placebo product
75547376|NCT06139549|Other|Gross motor development group session|Group session for gross motor development
75708906|NCT03119012|Drug|Ticagrelor|120mg/day
75708907|NCT03119012|Drug|Aspirin|100mg/day
75708908|NCT03117036|Drug|Chemotherapy|Systemic chemotherapy with curative intent
75708909|NCT03117010|Drug|Steroids|High dose dexamethasone 20 mg PO or IV
75708910|NCT03117010|Drug|Etoposide|Etoposide 150mg/BSA
75708911|NCT03116763|Behavioral|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype calls conducted over 5-12 weeks.
75708912|NCT03116763|Other|Active Comparator: Control Group|The control group will receive standard care but without the iPeer2Peer program.
75870769|NCT02372812|Drug|Placebo|
75870770|NCT02365012|Drug|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
75870771|NCT01369017|Drug|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
75396192|NCT04592562|Device|the Terumo Hydropearl® microspheres device|"Genicular artery embolization (GAE) is a new, minimally invasive investigational not yet approved therapy. In previous studies, this procedure has provided pain relief in patients with mild to moderate OA in the short to midterm. We will be utilizing the Terumo Hydropearl® microspheres particle beads during the GAE procedures. The procedure will take place utilizing fluoroscopic and ultrasound guidance. Following catheterization of the femoral artery, angiography of the affected limb will be performed to define the genicular arterial anatomy. Genicular arteries demonstrating abnormal vascularity and corresponding to the site of the patient's pain will be catheterized and embolized using microspheres. Prior to and after embolization, parametric imaging will be performed utilizing proprietary software to quantify changes in blood flow to the target area~The intended use of the Terumo Hydropearl® microspheres device is to embolize the geniculate artery branch."
75396193|NCT00030264|Drug|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
75396194|NCT00030264|Drug|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
75708913|NCT03085147|Drug|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
75870772|NCT01369017|Drug|Placebo|Injection of NS
75396195|NCT01897116|Drug|Hydroxychloroquine (HCQ)|
75396196|NCT01897116|Drug|Vemurafenib (VEM)|
75870773|NCT01371357|Drug|TEST 1|2.4 g/day of guanidinoacetic acid
75870774|NCT01371357|Drug|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
75870775|NCT01371357|Drug|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
76036507|NCT05295849|Behavioral|Building Habits Together Online Weight Loss 6-Week Usability Trial|The intervention includes: the Facebook-delivered Diabetes Prevention Program (DPP) Lifestyle Intervention, MyFitnessPal and the Habit app. The DPP will be delivered within a counselor-led private Facebook group. It uses behavioral strategies to help participants 1) achieve a program assigned calorie goal based on amount needed to lose 1-2 pounds per week, 2) develop a healthy diet, and 3) engage in 150-300 minutes per week of moderate intensity exercise. Participants will be instructed to use MyFitnessPal for the first two weeks, the Habit app slip tracker and exercise planner for two weeks, and the Habit app problem solver for two weeks.
75870776|NCT01371357|Drug|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
76023152|NCT05236205|Procedure|Partial removal of carious tissue with the administration of Papacarie™, application of Bixa Orellana extract (20%) and LED (aPDT)|"Initial radiographs;~Relative isolation;~Microbiological sample with otoscope curette to standardize volume of carious tissue;~Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes and the blue light-emitting diode (LED) irradiation with 440-480 nm. Removal of carious tissue around lateral walls of the cavity with noncutting curette;~Irradiation of dental tissue for 1 minute on a single point;~Second microbiological sample of remaining dentin with curette;~Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
75708914|NCT03074305|Device|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~DEB strategy~DES strategy"
75708915|NCT03046862|Drug|Durvalumab|Durvalumab 1.12 g iv on D1 every 3 weeks
75708916|NCT03046862|Drug|Tremelimumab|Tremelimumab 75mg iv on D1 every 3 weeks
76023153|NCT05093387|Drug|Carboplatin|Given IV
76023154|NCT05093387|Biological|Pembrolizumab|Given IV
75396197|NCT00036738|Drug|Cyclosporine|Given IV or PO
75396198|NCT00036738|Drug|Dasatinib|Given PO
75396199|NCT00036738|Drug|Fludarabine Phosphate|Given IV
75396200|NCT00036738|Drug|Imatinib Mesylate|Given PO
75396201|NCT00036738|Drug|Mycophenolate Mofetil|Given PO
75396202|NCT00036738|Drug|Nilotinib|Given PO
75396203|NCT00036738|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
75396204|NCT00036738|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
75708917|NCT03046862|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 iv on D1& D8 every 3 weeks
75708918|NCT03046862|Drug|Cisplatin|Cisplatin 25 mg/m2 iv on D1& D8 every 3 weeks
76023155|NCT05093387|Genetic|Transferrin Receptor-Targeted Liposomal p53 cDNA|Given IV
75396205|NCT00036738|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
75396206|NCT00036738|Radiation|Total-Body Irradiation|Undergo TBI
75396207|NCT00038610|Drug|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
75396208|NCT00038610|Drug|Cyclophosphamide|300 mg/m^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m^2) for courses 1, 3, 5, 7.
75396209|NCT00038610|Drug|Doxorubicin|50 mg/m^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
75396210|NCT00038610|Drug|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
75396211|NCT00038610|Drug|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
75396212|NCT00038610|Drug|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
75396213|NCT00038610|Drug|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
75708919|NCT03042078|Device|Zero-fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
75708920|NCT03042078|Device|Conventional fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
75708921|NCT03037385|Drug|pralsetinib (BLU-667)|pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
75708922|NCT03031626|Biological|Medical Air vs Oxygen|Medical Air/Oxygen will be given
76023156|NCT02399293|Behavioral|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
75396214|NCT00038610|Drug|Mesna|600 mg/m^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
75396215|NCT00038610|Drug|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
75396216|NCT00156936|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
75396217|NCT00156936|Drug|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
75396218|NCT00076050|Dietary Supplement|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
75396219|NCT00076050|Dietary Supplement|Placebo|Placebo soy isoflavones
75396220|NCT00046566|Dietary Supplement|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
75396221|NCT00046566|Dietary Supplement|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
75396222|NCT00046566|Behavioral|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
75396223|NCT00077922|Drug|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
75396224|NCT01897974|Other|Survey|Families complete survey to measure medication compliance.
75396225|NCT00161382|Behavioral|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
75547377|NCT06139510|Other|Quantitative sensory testing|Quantitative sensory testing is a standard type of pain testing that measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
75547378|NCT06139484|Device|Transcranial Magnetic Stimulation|The stimulations were performed by Magstim RAPID.
76036508|NCT05328063|Other|Control group|"All subjects will carry out a gluteus maximus strengthening work out. The exercises should be performed at a frequency of 3 times/week and with a dosage of 3 sets of 8 repetitions.~1-4 Weeks: 1. Bilateral gluteal bridge: Supine decubitus with knees and hips bent and feet supported. To raise the pelvis until the knees are flexed to 90° and then returns to the starting position. 2.Clam shell: Lateral decubitus with knees and hips bent to 45º, working leg placed on top of the other. Separate this knee while feet remain in contact using a medium density Theraband on the distal thighs. Bilateral work. 3. Side-Step: Bipedestation with Knees and hips bent. The exercise then consists of two steps taken in one direction followed by two steps in the opposite direction to return to the starting position. The elastic band shall be placed above the knees.~4-8 Weeks: 1.Unilateral gluteal bridge. 2 Clam shell: hips bents to 60º. 3. Side-Step: placing the elastic band over the ankles"
76036509|NCT05328063|Other|Intervention group|"All subjects will receive a specific program of manual therapy on the hip joint. 10 sessions of manual therapy will be applied during 8 weeks, 1 session per week, except the first week when two sessions will be applied.~The protocol consists of passive manual joint therapy at low speed on the hip, applying each mobilization in 3 series of 10 repetitions. It also includes muscle stretching, performing 3 series and holding the stretch for 25 seconds.~Manual therapy includes: 1. Anteroposterior (AP) and posteroanterior (PA) displacement of the hip. 2. Lateromedial and mediolateral displacement of the hip. 3. Distraction of the long axis/traction of the hip. 4. Lower slip in internal rotation (IR) and external rotation (ER) of the hip. 5. Iliopsoas stretch. 6. Piriformis stretch.To perform the protocol, the patient shall be placed in the supine decubitus position.~In addition to the same gluteus maximus strengthening programme used for the control group."
75547379|NCT06139471|Behavioral|Virtual Reality-Enhanced Gagne's Instructional Model|Virtual Reality-Enhanced Gagne's Instructional Model
75547380|NCT06139419|Radiation|Hypofractionated radiotherapy|Participants were treated with hypofractionated radiotherapy followed by hypo-boost
75547381|NCT06139419|Drug|induction chemo-immunotherapy|All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.
75547382|NCT06139419|Drug|concurrent chemotherapy|Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).
75396226|NCT00161382|Behavioral|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
75396227|NCT00079326|Biological|trastuzumab|Given IV
75396228|NCT00079326|Drug|ixabepilone|Given IV
75547383|NCT06139419|Drug|Immunotheapy consolidation|Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.
75547384|NCT06139419|Drug|Thymosin Alpha1|"Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages:~Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle.~Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly.~Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months."
75547385|NCT06139393|Drug|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.
75547386|NCT06139393|Drug|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
75547387|NCT06139367|Drug|TQB3454 tablets|TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.
75547388|NCT06139276|Procedure|Small Needle-Knife|"The small needle-knife therapy originated from the ancient Chinese acupuncture instrument known as the Pi needle from the Nine Needles, which resembled a sword, had two sharp edges, and was originally used for abscess drainage. It is currently widely applied in treating conditions such as myofascial adhesions, chronic pain, or nerve compression.~The small needle-knife features a flat and rounded tip design, with its handle made of solid steel. This construction provides excellent toughness and flexibility, minimizing tissue damage, and facilitating microadhesiolysis, an intervention aimed at releasing adhesions."
75396229|NCT00079326|Other|laboratory biomarker analysis|Correlative studies
75396230|NCT02187354|Drug|Blinatumomab|A single cycle of blinatumomab (CIVI) treatment is 6wks, 4wks of treatment followed by a 2wk treatment-free interval. Up to 5 cycles will be administered per subject. In the first cycle, for patients with an M3 bone marrow, the initial dose will be 5μg/m2/day for the first 7days, escalated to 15μg/m2/day on D8-D29. For all subsequent cycles 15μg/m2/day will be the dose for all 4wks of continuous treatment. In case of M2 bone marrow or M1 bone marrow with an MRD relapse at screening, the initial dose will start at 15μg/m2/day for the first 7days of treatment & no dose step at D8. For all subsequent cycles the dose will remain 15μg/m2/day. A dose of 9μg/day for the initial dose (if applicable) & 28μg/day for the escalated dose after dose step should not be exceeded.
75396231|NCT02187354|Other|Extension of LTFU as per ProtocolAmendment7 7Jun18|LTFU (Long Term Follow-Up) will extend past 18 months for patients already ended the study/still on study or to be enrolled at European sites if they did not receive a transplantation after blinatumomab treatment. For subjects to be included in the additional LTFU, data will be captured until subjects are 18yrs old (every 6 months by phone contact). The following will be captured: relapse (medullary or extra-medullary relapse and its specific location), second tumor (which type), alive/died and cause of death, hospitalization and reason for hospitalization.
75396232|NCT01898052|Drug|single anaesthetic drug|inject periarticular tissue of the knee after implantation
75547389|NCT06139276|Other|Standard treatment|Standard treatment
75547390|NCT06139237|Other|High-protein supplement|High protein supplement 200 mL
75547391|NCT06139237|Other|Balanced supplement|Balanced supplement 200 mL
75547392|NCT06139211|Biological|JS015|JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
75547393|NCT06139211|Biological|Toripalimab|Toripalimab will be administered intravenously (IV) on day 1 every 21 day cycle.
76023157|NCT02399293|Behavioral|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
76023158|NCT03952793|Other|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
76023159|NCT02698423|Device|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
75396233|NCT01898052|Drug|multimodal drug injection|inject periarticular tissue of the knee
75396234|NCT00051168|Drug|Travatan|Travoprost (0.004%) 1 drop each eye once daily
76023160|NCT02698423|Other|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
75396235|NCT00083382|Drug|Pamidronate|Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
75396236|NCT00083382|Drug|Thalidomide|"All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.~Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)"
75396237|NCT00083382|Drug|Zometa|Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
75547394|NCT06139211|Biological|Paclitaxel|Paclitaxel will be administered intravenously (IV) on day 1 every 21 day cycle.
75547395|NCT06139211|Drug|Irinotecan|Irinotecan will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
75547396|NCT06139211|Drug|Capecitabine|Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.
75547397|NCT06139211|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.
76023161|NCT02967965|Other|Imagery|MRI at year 3
75396238|NCT04506840|Other|Physical activity|Patients will participate in a program of physical exercise. Resistance training, endurance training, balance and flexibility will be trained with the objective to reduce the side effects of chemotherapy and, in order to improve their quality of life
75547398|NCT06139211|Biological|Bevacizumab|Bevacizumab will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
75547399|NCT06139211|Drug|Fluorouracil|Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
75547400|NCT06139211|Drug|Leucovorin|Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
75547401|NCT06139211|Drug|Gemcitabine|Gemcitabine will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
75547402|NCT06139211|Drug|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
75708923|NCT03031210|Drug|Amoxicillin|(90 mg/kg/day) twice daily
76023162|NCT02850263|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
76023163|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
75547403|NCT06139198|Behavioral|Self-MAnagement intervention for Reducing The epilepsy burden among Ugandans|SMART-U sessions are operationalized in written curricula, including an intervention manual, participant manual, slides, and handouts typically delivered over a period of 10-12 weeks.
75558117|NCT04700228|Drug|Bupivacaine Hydrochloride|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
75708924|NCT03025984|Behavioral|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
76036510|NCT05257707|Diagnostic Test|Molecular biology|"Samples will be taken as part of routine care consultations. These include~Smears taken with cytobrushes adapted to the anatomical site (cervix, vulva, vagina, penis, anus, upper aerodigestive tract...).~Blood samples taken to isolate plasma, cells or serum.~CSF and effusion samples taken with a suitable puncture needle (lumbar puncture, ascites puncture, pleural puncture, etc.).~Urine samples collected in sterile ECBU jars.~Biopsies taken according to the recommendations of good clinical practice using specific forceps adapted to the anatomical site.~Surgical parts.~Eyebrows.~Saliva samples or gargle samples."
76036511|NCT05294835|Drug|Ketamine|ketamine infusion
76036512|NCT04422405|Procedure|One Anastomosis Gastric Bypass (OAGB)|"The procedure is performed laparoscopically. The GIA stapler divides the stomach at the junction of the body and antrum. An Ewald tube, roughly the diameter of the esophagus, is passed by the anesthetist and held against the lesser curvature. The division of the stomach against the tube is completed, with 5- 6 lines of staples. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 200 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to perform the anastomosis between the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel."
76036513|NCT02522481|Drug|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
75396239|NCT00167388|Other|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
75396240|NCT00167544|Drug|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
75396241|NCT00167544|Drug|Placebo|Saline
75396242|NCT00167934|Drug|Valproate|Depakote ER 500 mg to 3000 mg taken every night
75396243|NCT00167934|Drug|Placebo|Placebo given at same frequency as Valproate
75396244|NCT00168324|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
75396245|NCT00168324|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
75396246|NCT00168324|Other|Sham Injection|Sham injection on Day 0.
75396247|NCT00084552|Radiation|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
75708925|NCT03025932|Procedure|repair of giant hiatal hernia with mesh and anterior fundoplication|
75396248|NCT02091882|Drug|Placebo|Oral placebo-embedded IEM tablet.
75396249|NCT02091882|Combination Product|Combination product of Aripiprazole + IEM + Sensor + MIND1 Application|Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone
75558118|NCT04700228|Drug|Dexmedetomidine|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
75708926|NCT03018262|Device|TMS - sub-study 1|TMS pulses will be applied to the motor hotspot of the surround muscle to identify the TMS-evoked potentials corresponding to motor surround inhibition (SI)
75870777|NCT01369173|Other|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
75870778|NCT01369251|Behavioral|Hygiene|
75870779|NCT01369251|Procedure|Usual alcohol care|
76036514|NCT02522403|Procedure|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
76036515|NCT02522403|Device|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
76036516|NCT04243785|Drug|BTX-A51|Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, and 2.0 mg.
76036517|NCT05326581|Device|mri|The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
76036518|NCT02522325|Drug|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
76036519|NCT02522325|Drug|Cocaine|Intranasal cocaine will be administered during experimental sessions.
75396250|NCT00085254|Drug|cilengitide|Given IV
75396251|NCT00085254|Drug|temozolomide|Given orally
75396252|NCT00085254|Radiation|radiation therapy|Undergo radiotherapy
75870780|NCT02660944|Drug|RSLV-132|RNase-Fc fusion protein
75870781|NCT02660944|Drug|Placebo|Saline placebo
75870782|NCT01365351|Other|Growth hormone|Drug given by prescription
75870783|NCT02370082|Device|Localization of breast lesion|localization of breast lesion for removal
75870784|NCT03625245|Other|Control Yogurt|125 g/day
75870785|NCT03625245|Other|Yogurt Variety 1|125 g/day
76036520|NCT02522325|Drug|Placebo|Placebo capsules will contain only cornstarch.
75396253|NCT00085254|Other|laboratory biomarker analysis|Correlative studies
75396254|NCT00085254|Other|pharmacological study|Correlative studies
75396255|NCT01897272|Behavioral|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
75396256|NCT00253890|Drug|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
75396257|NCT00253890|Drug|Placebo|1-3 at bedtime
75396258|NCT00254592|Drug|Doxorubicin|60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
75396259|NCT00254592|Drug|Cyclophosphamide|600 mg/m2 IV once a day every 14 days x 2-4 cycles
75396260|NCT00254592|Drug|Carboplatin|AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose
75396261|NCT00254592|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose
75396262|NCT00254592|Drug|GM-CSF|250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
75396263|NCT00254592|Drug|Trastuzumab|4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
75870786|NCT03625245|Other|Yogurt Variety 2|125 g/day
76036521|NCT04243395|Other|Pork|1 oz lean pork
76036522|NCT04243395|Other|Egg|1 large whole egg
76036523|NCT04243395|Other|Black beans|0.5 cups cooked black beans
76036524|NCT04243395|Other|Almonds|0.5 oz almonds
76036525|NCT01672879|Biological|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
76036526|NCT01672879|Biological|SIM|Intravenous infusion over 30 minutes every 2 weeks
76036527|NCT02601209|Drug|Pazopanib|Given PO
76036528|NCT02601209|Drug|Pazopanib Hydrochloride|Given PO
76036529|NCT02601209|Drug|Sapanisertib|Given PO
76036530|NCT05012839|Other|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
76036531|NCT01659021|Drug|Idelalisib|150 mg tablets administered orally twice daily
76036532|NCT01659021|Drug|Ofatumumab|Administered intravenously
75396264|NCT00254592|Drug|Bevacizumab|10mg/kg q 2 wks
75396265|NCT00255684|Biological|graft-versus-tumor induction therapy|
75396266|NCT00255684|Drug|cyclophosphamide|
75708927|NCT03018262|Device|TMS - sub-study 2|TMS will be used to stimulate the motor cortex and an inhibitory region of the inferior parietal lobe
75708928|NCT03018262|Device|TMS - sub-study 3|TMS pulses will be delivered to the primary motor cortex at rest, at the onset of the motor task, or during the motor task
75708929|NCT03017586|Device|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
75708930|NCT03001869|Drug|68Ga-HBED-CC-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT Scan
75396267|NCT00255684|Drug|cyclosporine|
75708931|NCT02988921|Device|MRI and CT|
75708932|NCT02988921|Radiation|Ratiotherapy|
75708933|NCT02988921|Drug|Paclitaxel, platinum-based drug|
75708934|NCT02986672|Dietary Supplement|Calanus oil|Omega-3 oil in form of calanus oil
75708935|NCT02986672|Other|Medical Paraffin|2ml per day
76023164|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
76023165|NCT04481815|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
75396268|NCT00255684|Drug|fludarabine phosphate|
75396269|NCT00255684|Drug|mycophenolate mofetil|
75396270|NCT00255684|Procedure|umbilical cord blood transplantation|
75396271|NCT00255684|Radiation|radiation therapy|
75396272|NCT00256776|Drug|Velcade (Bortezomib)|
75396273|NCT00256776|Drug|Thalidomide|
75396274|NCT00256776|Drug|Dexamethasone|
75396275|NCT00257322|Drug|GM-CSF|250ug/m^2 SQ QD with a cap of 500mcg SQ QD
75396276|NCT00258180|Biological|filgrastim|Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
75396277|NCT00258180|Drug|cyclophosphamide|Administered IV over 1 hour on days 1-4
75396278|NCT00258882|Biological|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
75396279|NCT01899222|Device|Handheld fundus photography|diagnostic imaging with two types of retina camera
75396280|NCT00176202|Drug|Divalproex Sodium|Divalproex sodium is a mood stabilizer
75396281|NCT00176202|Drug|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
75396282|NCT00176592|Drug|Betaseron|Betaseron 250 micrograms injected SQ every other day
75396283|NCT00176592|Drug|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
75396284|NCT00176826|Procedure|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
75396285|NCT00176826|Drug|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
75708936|NCT02983565|Device|Intelligent oxygen therapy system (iO2Ts)|
75708937|NCT02981615|Drug|Levofloxacin|one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
75708938|NCT02981615|Drug|Placebo Oral Tablet|one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
75708939|NCT02963363|Other|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
75708940|NCT02944799|Drug|Placebo|Discontinuation of alendronate treatment
75708941|NCT02944799|Drug|Alendronate|
75708942|NCT02944799|Drug|Calcium|Daily dietary supplement of 800mg calcium
75708943|NCT02944799|Drug|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
75708944|NCT02940951|Other|QPSS|Home care providers use the QPSS that includes standardized instruments for assessing patient and family caregiver quality of life in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
75708945|NCT02940951|Other|Usual care|Home healthcare services provided by nurses and, where applicable, multi-professional teams.
75708946|NCT02931279|Device|PASS OCT® Spinal System|Posterior osteosynthesis of the cervical and upper thoracic spine
75396286|NCT00176904|Procedure|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
75396287|NCT00176904|Drug|Busulfan, Cyclophosphamide, Antithymocyte Globulin|"Subjects will receive BUSULFAN intravenously (IV)- patients < or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients > 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
75396288|NCT00179478|Drug|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
75396289|NCT02134782|Behavioral|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
75396290|NCT02134782|Other|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
75396291|NCT00182754|Drug|octreotide acetate|Given subcutaneously
75396292|NCT00182754|Other|placebo|Given subcutaneously
75708947|NCT02923947|Drug|Osimertinib; AZD9291|80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
75708948|NCT02914535|Drug|Filgotinib|Tablet(s) administered orally once daily
75708949|NCT02914535|Drug|Placebo|Tablet(s) administered orally once daily
75870787|NCT04894071|Drug|QA102|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
75870788|NCT04894071|Drug|Placebo|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
76036533|NCT05012449|Procedure|Arthrography-assisted joystick technology.|Arthrography-assisted joystick technology.
76036534|NCT05012215|Procedure|Paravertebral|Ultrasound-guided paravertebral block
76036535|NCT05012215|Procedure|Caudal block|Caudal block
76036536|NCT05012137|Procedure|Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB) with 0.5% ropivacaine|all the patients received Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
75558119|NCT00440427|Drug|Desvenlafaxine Sustained Release (DVS SR)|
75558120|NCT00443378|Behavioral|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
75558121|NCT00478686|Procedure|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
75558122|NCT03278522|Drug|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
75558123|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
75708950|NCT02903680|Drug|Dexamethasone group|The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
75708951|NCT02903680|Drug|Placebo group|Normal Saline 0,9% same volume
75396293|NCT00183456|Behavioral|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
75547404|NCT06139172|Behavioral|Functional Behavioral Training (FBT)|Function-based treatment (FBT) is a term for behavioral intervention approaches that use objective and systematic data collection to identify the cause of challenging behavior and teach a more prosocial replacement behavior. FBTslDD incorporates standard elements of FBT protocols with adaptations made specifically to support application to the syndromic IDD population. FBTslDD will include the following steps: (1) Syndromic IDD screening; (2) Stimulus preference assessment; (3) Indirect and descriptive assessments; (4) Screening for automatic function; (5) Functional analysis (FA); and (6) FBT intervention phase. If steps 1 - 5 determine a participant's challenging behavior serves a social function, Functional Communication Training (FCT) will be administered. If steps 1 - 5 determine a participant's challenging behavior serves an automatic function Competing Stimulus Treatment (CST) will be administered.
75396294|NCT00183456|Behavioral|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
75547405|NCT06139172|Other|Positive Parenting Strategies-Treatment as Usual|Using the Planned Adaptation approach, to identify proactive adaptations seeking to improve the fit of FBTsIDD with the unique needs of the syndromic IDD population. Triangulating mixed methods data from systematic video observations, questionnaires, and qualitative interviews, then the Framework for Reporting Adaptations and Modifications-Expanded24 (FRAME) will be used to develop a rich understanding of these and any additional adaptations made to the intervention when delivered by non-specialist providers within medical hubs serving syndromic IDD populations.
75547406|NCT06139159|Other|Outreach/navigator|"Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct informal screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues to clinics for triage.~Document outreach, screening, and referral activities in LHW database"
75708952|NCT02864004|Drug|Apomorphine|Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
76036537|NCT05012137|Drug|different volume of 0.5% ropivacaine|According to the subject's response to the injection dose, the next subject will be injected with a different volume of the drug according to the preset rules
75396295|NCT00184548|Drug|eptacog alfa (activated)|"Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours."
76036538|NCT05291559|Dietary Supplement|Enterade|Enterade is a glucose-free, amino acid-based medical food containing specific amino acids (aspartic acid, valine, serine, threonine and tyrosine) in addition to electrolytes and a non-sugar sweetener.
76036539|NCT05291559|Dietary Supplement|Placebo|The placebo is an identical product to Enterade except without added amino acids.
75558124|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
75558125|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
75558126|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
75558127|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
75708953|NCT02864004|Other|Best Medical Treatment|Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
75870789|NCT02372422|Other|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
75870790|NCT02372422|Other|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
75870791|NCT03550287|Dietary Supplement|Experimental product|10 g/day
76036540|NCT03075319|Procedure|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
75558128|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
75558129|NCT04700306|Behavioral|Sophrology|Patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology.
75870792|NCT03550287|Dietary Supplement|Placebo product|10 g/day
76036541|NCT03075319|Procedure|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
76036542|NCT04999033|Other|no intervention|This is a cross-sectional study, and no intervention will be included
76036543|NCT04818203|Biological|Clusters of Autologous Dermal Fibroblasts|Dose: 1 x 10^7 cells/1 mL/vial
76036544|NCT04818203|Other|Placebo|The injection solution without clusters of autologous dermal fibroblasts
76036545|NCT05252793|Behavioral|Education based on the health belief model|After the intervention, it is expected that the scores of the patients on the healthy lifestyle behaviors scale will increase.
76036546|NCT04827797|Device|balls|Birth balls to exercise
75870793|NCT02372266|Other|Early Maternal-Newborn Infant Discharge|Discharge from the hospital between 12-24 hours of life
75870794|NCT02372266|Other|Routine discharge|Discharge of the mother and newborn 2 to 3 days after delivery
75396296|NCT00184548|Drug|placebo|placebo
75396297|NCT00085410|Drug|bortezomib|Given IV
75396298|NCT00186498|Drug|memantine|Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT
75396299|NCT00186498|Drug|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
75396300|NCT00265200|Drug|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
75708954|NCT02842424|Drug|Ramipril|Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
75708955|NCT02834364|Drug|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
75708956|NCT02834364|Drug|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
75708957|NCT02823041|Behavioral|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
75708958|NCT02823041|Behavioral|Aerobic Exercise|Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
76036547|NCT04999189|Other|Mobile app forDiabetes (Tessera Multimedia, 2020)|Patients will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
76036548|NCT05290779|Procedure|selective lumbar nerve root injection|selective lumbar nerve root steroid injection for treatment of radicular pain.
75396301|NCT00087672|Drug|CC-5013|10 mg orally (2 capsules) daily
75870795|NCT03293667|Other|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
75870796|NCT01372449|Drug|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but <60 kg, and 6 mg for subjects weighing ≥ 20 kg but < 40kg.
76036549|NCT05252481|Device|Active tDCS|Eight sessions of transcranial current direct stimulation
76036550|NCT05252481|Device|Sham tDCS|Eight sessions of transcranial current direct stimulation (sham)
75558130|NCT00440583|Drug|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
75396302|NCT00265512|Behavioral|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
75396303|NCT00265512|Behavioral|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
75396304|NCT00265980|Drug|Subcutaneous Placebo|Twice daily injections of saline in the same volume as will be used for leptin injections.
75558131|NCT04700384|Behavioral|Virtual Operative Assistant Training|Individuals receive the same basic information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistant assessment of their performance and audiovisual feedback.
75558132|NCT04700384|Behavioral|Remote-Based Expert Instructor Training|Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
75558133|NCT00440622|Drug|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
75708959|NCT02823041|Behavioral|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
75708960|NCT02823041|Behavioral|Individual Placement and Support|An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
76036551|NCT04998955|Behavioral|Maximal strength training|Exercise intervention utilizing 4 x 4 repetitions heavy resistance training
75708961|NCT02810743|Drug|ddAC-CP-Olaparib|ddAC-CP-Olaparib
75708962|NCT02810743|Drug|ddAC-mini CTC|ddAC - mini CTC
75708963|NCT02759835|Drug|osimertinib|Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.
75547407|NCT06139159|Other|Auxiliary to care|"Arrange consultation for those at-risk, suspected, or affected individuals at clinics for triage.~Introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit.~Reviews care plan with patient and help reduce patient and system barriers impeding psychological wellbeing~Support patients in achieving management goals; help patients address barriers through education, referral, and navigation to ancillary community services (SAVAME, legal, housing, economic, etc);~Engage, activate, and empower patients to participate in the care process~Frequent contact with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~Assist with group sessions: affinity groups~Identify community-based resources.~Document outreach, screening, referral, and auxiliary care activities in LHW database"
75547408|NCT06139159|Other|Stepped care and task shifting|"Support counselling initiated by the psychologist~Reinforce patient education about depression, anxiety, trauma, and other syndemic conditions.~Work with patients' families and peers to reduce stigma, address syndemic factors and social conditions.~Contact frequency with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~Co-lead group sessions: affinity groups~Provide Mental Health First Aid to members of the community.~Document outreach, screening, referral, auxiliary and stepped care activities in LHW database"
75708964|NCT02759835|Other|Local Ablative Therapy (LAT)|local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
75708965|NCT02720302|Behavioral|SOFT|SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
75708966|NCT02720302|Behavioral|TeleSOFT|The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
75708967|NCT02720094|Drug|Cabotegravir Oral Tablet|30 mg tablet
75708968|NCT02720094|Drug|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
75708969|NCT02720094|Drug|Placebo for TDF/FTC tablets|
75708970|NCT02720094|Drug|Placebo for cabotegravir oral tablet|
75708971|NCT02720094|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
75396305|NCT00265980|Drug|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
75708972|NCT02720094|Drug|Placebo for CAB LA|Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
76036552|NCT04827641|Other|Severity Grading assessment in children with perioperative unexpected events|Systematic documentation of all unexpected events was carried out by designated team members during daily routine team conferences. Briefly, on-call team members and all other staff reported on any unexpected event that had occurred within the previous 24 hours, after weekends during the past 72 hours. Events included those that had occurred in inpatients, outpatients and in the pediatric emergency department. Data concerning each event included patient demographics, diagnoses, treatments/operations and types of events.
75708973|NCT02716012|Drug|MTL-CEBPA|Intravenous administration
76036553|NCT05324631|Drug|SHR0302|SHR0302, oral, once daily
75396306|NCT00187200|Device|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
75396307|NCT00187200|Device|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
75396308|NCT00088218|Drug|Clofarabine|1-hour IV infusion 30 mg/m^2 daily times 5 days (Days 1-5)
75396309|NCT00088218|Drug|Ara-C|20 mg/m^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
75396310|NCT00189228|Drug|Xolair|Patients are administered Xolair
75396311|NCT00091260|Drug|dexamethasone|dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
75396312|NCT00091260|Drug|lenalidomide|15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
75396313|NCT00193128|Drug|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
75396314|NCT00193128|Drug|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
75396315|NCT00193128|Drug|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
75708974|NCT02716012|Drug|Sorafenib 200mg|Sorafenib tablets
75708975|NCT02715518|Device|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~FFR-guided strategy arm~Angiography-guided strategy arm"
75870797|NCT01372449|Drug|Placebo|
75870798|NCT02369926|Procedure|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
75396316|NCT00193128|Radiation|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
75396317|NCT00193596|Drug|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
75870799|NCT02369926|Procedure|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
75870800|NCT04688541|Device|Optitip Catheter (LinC Medical)|The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
76036554|NCT05324631|Drug|SHR0302 placebo|SHR0302 placebo, oral, once daily
75396318|NCT00193596|Drug|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
75396319|NCT00193596|Drug|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
76036555|NCT05011747|Procedure|single-site rigid probe viscotrabeculotomy (VT)|single-site VT by the rigid probe trabeculotome is performed through a superonasal triangular scleral flap.
76036556|NCT05011747|Procedure|two-site rigid probe viscotrabeculotomy (VT)|Two-site VT by the rigid probe trabeculotome is performed through a superonasal and an inferotemporal triangular scleral flap.
75396320|NCT00193596|Drug|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
75396321|NCT00193596|Drug|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
75396322|NCT01899378|Dietary Supplement|Lactobacillus reuteri DSM 17938|10^8 CFU
75396323|NCT01899378|Dietary Supplement|Bifidobacterium longum infantis|10^9 CFU
75396324|NCT01899534|Other|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
75396325|NCT00091962|Behavioral|Psychoeducation; Treatment recommendations|Counseling program
75396326|NCT00091962|Drug|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
75396327|NCT00091962|Other|Usual Care|Physicians' Usual care
75396328|NCT00194532|Drug|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
75396329|NCT00194532|Drug|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
75396330|NCT00194610|Drug|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
75396331|NCT00194610|Other|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
75396332|NCT00093756|Radiation|3-dimensional conformal radiation therapy|
75558134|NCT00440622|Drug|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
75870801|NCT04688541|Device|Foley catheter|Foley catheter
76036557|NCT04422327|Dietary Supplement|Probiotic capsule|"Each probiotic capsule contains 5 x 10^8 CFU B. longum 35624® and 5 x 10^8 CFU B. longum 1714™ with corn starch and magnesium stearate.~The probiotic capsule will be supplied by PrecisionBiotics Ltd."
75708976|NCT02695498|Other|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class [9 total classes.] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
75396333|NCT00093756|Drug|bortezomib|Given IV
75870802|NCT02364622|Device|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
75870803|NCT02364622|Device|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
75870804|NCT02364622|Device|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
75396334|NCT00093756|Drug|paclitaxel|Given IV
75396335|NCT00093756|Drug|carboplatin|Given IV
75558135|NCT00440622|Drug|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
75558136|NCT00443417|Drug|SK-PC-B70M|dosage, frequency
75558137|NCT00440661|Drug|Diacerhein|
76023166|NCT04481815|Drug|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
76023167|NCT04481815|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
76023168|NCT05107037|Drug|TQ-B3234 capsule|TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor
75870805|NCT04666389|Drug|Atorvastatin|To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
75870806|NCT02364544|Behavioral|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
76036558|NCT03075475|Behavioral|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
75547409|NCT06139146|Other|Muscle energy technique (MET)|"MET treatment protocol of pectoral major:~The patient's position was supine lying. Starting with the position which took the affected fibres to just short of their restriction barrier, the patient introduced a light contraction involving adduction of the arm against resistance from the therapist for 7-10 seconds. As the patient exhaled the therapist stretched across the new barrier.~MET treatment protocol of upper trapezius:~The patient moved the stabilized shoulder in a shrug motion toward the ear, and the ear toward the shoulder, with a light resistance (20% of possible strength). The contraction was sustained for 7-1 0 seconds MET treatment protocol of levator scapula The patient was in a supine position, with the hand supinated and the arm of the side to be tested extended alongside the trunk.~Strengthening of deep neck flexors: Patient was instructed to his nod head to flatten the neck's curve. 10 reps for 10 sec."
75708977|NCT02695498|Other|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
75870807|NCT02364544|Behavioral|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
75870808|NCT02364544|Behavioral|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
75396336|NCT04389138|Other|Physiotherapy Intervention|Physiotherapy intervention will include an assessment to identify individual areas that physiotherapy should target. Intervention will be based on the core areas recommended by the European Physiotherapy Guideline for Parkinson's Disease: physical capacity (muscle power, tone, joint range of movement, exercise tolerance and pain), transfers, manual dexterity, balance and gait. Posture is incorporated as part of these 5 core areas. The intervention will be delivered over 4 visits.
75870809|NCT02364544|Behavioral|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
75396337|NCT04145154|Other|Application of platelet rich plasma in chronic wounds of diabetic origin|Application of plasma rich in autologous growht factors after advanced healing
75396338|NCT04118556|Biological|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
75870810|NCT02364544|Other|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
75870811|NCT01369407|Other|No Intervention|Not an interventional study
75396339|NCT04118556|Drug|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
75396340|NCT00267696|Drug|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
75396341|NCT00267696|Drug|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
75870812|NCT02372110|Drug|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
75870813|NCT02372110|Drug|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
75870814|NCT02372188|Other|water|Control
76036559|NCT06163469|Device|Bladder instillation with Irrisept|9 months of bladder instillations (3 months of saline and 6 months of chlorohexidine gluconate)
75396342|NCT00267696|Drug|Carboplatin|
75396343|NCT00267774|Device|Fractional flow reserve|
75396344|NCT00267774|Procedure|Angio-guided PCI|
75396345|NCT00195624|Biological|Alemtuzumab (Campath )|Campath administered at a dose of 10/mg/day for 10 days
75396346|NCT00195624|Drug|Cyclosporine|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
75396347|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
75396348|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
75396349|NCT00195702|Drug|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
75396350|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
75396351|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
75396352|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
75396353|NCT00196716|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
75396354|NCT00197184|Biological|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
75870815|NCT02372188|Dietary Supplement|caffeine|
76036560|NCT06163456|Other|Acute submaximal exercise|30 min of treadmill running at 70% of the participants maximal oxygen consumption
76036561|NCT06163430|Drug|TERN-701|TERN-701 orally QD
75870816|NCT02372188|Dietary Supplement|caffein + homoeriodictyol sodium salt|
75870817|NCT02372188|Dietary Supplement|homoeriodictyol sodium salt|
76036562|NCT06163417|Procedure|laparoscopic|laparoscopic
76036563|NCT06163378|Device|Rubato Life App|An algorithmically enhanced personalized music-based intervention
76036564|NCT06163339|Other|Cultural Formulation Interview|Usual Care is enhanced with the Cultural Formulation Interview (CFI) aimed at strengthening assessment and treatment adherence
75870818|NCT02369692|Device|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
75870819|NCT04652505|Other|Questionnaire Administration|Complete questionnaires
75870820|NCT01371435|Drug|Paroxetine|
76036565|NCT06163326|Drug|Ritlecitinib|Ritlecitinib 50 mg capsule once daily
76036566|NCT06163326|Drug|Ritlecitinib 100 mg|Ritlecitinib 100 mg capsule once daily
75396355|NCT00197184|Biological|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
76036567|NCT06163326|Drug|Placebo|Matching capsule once daily
75396356|NCT00198042|Procedure|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
75547410|NCT06139146|Other|Core stability exercises:|"Warm up: The cat and camel stretches~Exercises:~It included Crook lying, abdominal bracing, and 10 second - 20 repetitions (reps).~Crook lying, abdominal Bracing with leg lifts holding the position for 3 second for 10 reps.~Crook lying, abdominal Bracing with bridging with 10 reps with a 10 second hold.~It included a Quadruped position with abdominal bracing for 10 s - 10 reps~Quadruped position arm lifts with abdominal bracing 10 reps on each side.~Quadruped position leg lifts with abdominal bracing 10 reps on each side.~Quadruped position alternate arm and leg lifts with abdominal bracing holding position for 3 s - 10 reps on each side.~The curl-up in hook lying, Fold arms across the torso. Lift shoulder blades off the ground. 1 to 2 seconds holds - 10 reps.~Side plank on knees; holding position for 10 s - 5 reps ."
75547411|NCT06139120|Diagnostic Test|Assessment of hypersensitivity|Assessment of pain hypersensitivity in body segments was performed using pressure pain measurement
76036568|NCT06163313|Other|Observation of patients suffering from kidney stones who undergo endoscopic surgery|Clinical data will therefore be acquired through a collection of medical history, physical examination, blood chemistry and instrumental test reports;
76036570|NCT06163248|Other|Chrono nutrition|An integral nutritional strategy involving timing, order and distribution of macronutrients
76036571|NCT06163248|Other|Standard|Conventional nutritional strategy involving isocaloric distribution with no specific timing
76036572|NCT06163235|Other|Obemar platform|Online platform for education and follow-up
76036573|NCT06163196|Other|acupressure|Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
76036574|NCT06163183|Device|Edi catheter|
76036575|NCT06163170|Drug|Nivolumab +/- ipilimumab|Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma
76036576|NCT06163170|Drug|Nivolumab|Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma
76036577|NCT06163157|Other|Connective tissue massage(CTM)|CTM will be applied by a trained physiotherapist for 3 days/week for 4 weeks. Application time will be approximately 15-20 minutes.
76036578|NCT06163144|Other|lab investigation|"Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.~*Automated cell counters~Advia 2120 8 difference~PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected."
76036579|NCT06163092|Other||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
75396357|NCT00201240|Biological|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ >5 x 10*6/kg and CD3+ < 1 x 10*5/kg
75396358|NCT00098670|Biological|alemtuzumab|Given SC
75396359|NCT00098670|Biological|rituximab|Given IV
75396360|NCT00098670|Drug|fludarabine phosphate|Given IV
75547412|NCT06139081|Other|Oxygen delivery mode|After the implantation of the mirror, nasal catheter was used to give oxygen through the mouth
75396361|NCT04098588|Behavioral|BEAST|See Arm Description
75396362|NCT04098588|Behavioral|Descriptive Feedback|See Arm Description
75396363|NCT00100230|Drug|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
75396364|NCT00201864|Drug|Exemestane|25 mg orally per day
75396365|NCT00201864|Drug|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
75396366|NCT00202722|Drug|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
75708978|NCT02688777|Behavioral|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
75547413|NCT06139068|Other|Narrative Group Counseling|Two of the principles that explain how narrative therapy works are: to always maintain a stance of curiosity on the part of the practitioner and to ask questions to which the practitioner does not actually know the answers and to which the answer is known to the participants. To guide therapeutic conversations that include these questions, Michael White and David Epston have designed a series of conversation maps in the application of narrative therapy. Taking these maps into consideration, the sessions were planned with the guidance of relevant literature and structured with expert opinions. Group counseling will be applied to the intervention group once a week in 8 sessions. The application will be carried out face to face, in a calm, quiet and bright classroom where the circle seating plan will be made. 90 min. The duration of a group session is 10 minutes once. It will be completed with a break.
75547414|NCT06139068|Other|stress coping interviews|In addition to the students' routine practices, four sessions of stress coping interviews will be held for the control group, with an interval of two weeks, after the information meeting.
75547415|NCT06139055|Drug|GSBR-1290 (Capsule/Tablet)|Participants will receive GSBR-1290 oral capsules or tablets.
75547416|NCT06139055|Drug|GSBR-1290|Participants will receive GSBR-1290 oral tablets.
75547417|NCT06139055|Drug|Placebo|Participants will receive matching-placebo oral tablets.
75396367|NCT00100698|Drug|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
75396368|NCT00100698|Drug|placebo|placebo subcutaneously once a day, 18 months
75396369|NCT00103116|Biological|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
75396370|NCT00205374|Drug|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
75396371|NCT00205374|Drug|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
75396372|NCT00103194|Drug|lapatinib ditosylate|Given PO
75396373|NCT00103194|Other|laboratory biomarker analysis|Correlative studies
75396374|NCT00277446|Drug|Soy isoflavones|
75708979|NCT02648334|Device|IN.PACT drug coated balloon|
75396375|NCT00278538|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
75396376|NCT00208026|Drug|Pimecrolimus 1% Cream|Open label single arm
75708980|NCT02648334|Device|Lutonix drug coated balloon|
75708981|NCT02646618|Behavioral|Get Social|Online-delivered weight loss intervention
75708982|NCT02646618|Behavioral|Traditional|Group-delivered weight loss intervention
75396377|NCT00208494|Device|Total Hip Replacement|Total hip replacement
75396378|NCT00208494|Device|Total hip replacement|Total hip replacement
75396379|NCT00106392|Drug|Tacrolimus|oral
75396380|NCT00106392|Drug|Placebo|oral
75547418|NCT06139055|Drug|Placebo (Capsule/Tablet)|Participants will receive matching-placebo oral capsules or tablets.
75708983|NCT02646618|Device|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
75708984|NCT02628067|Biological|pembrolizumab|intravenous infusion
75708985|NCT02628067|Biological|pembrolizumab|intravenous infusion
75870821|NCT03634449|Device|i-gel|i-gel is a supraglottic airway devices with a gastric suction channel.
75396381|NCT00211692|Drug|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
75396382|NCT00211692|Drug|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
75547419|NCT06139042|Diagnostic Test|Blood drawing|The participants had their blood drawn.
75396383|NCT01899690|Drug|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
75708986|NCT02617186|Procedure|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
75708987|NCT02617186|Procedure|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
75708988|NCT02609425|Device|Stratafix PGA Suture|Subject leak Stricture rates post procedure
75708989|NCT02607722|Drug|Nintedanib|
75708990|NCT02567253|Procedure|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
76036580|NCT06163079|Behavioral|No intervention|No intervention. This is a retrospective study. Data will be collected from routine consultations Will be collectad the following datas : Number and evolution of requests, age, background, infertility timing, parenthood context, Appointment time, ART timing, Type of ART, ART outcome, Outcome time
75396384|NCT04378140|Other|zirconia wing bridge|The zirconia wing bridge consists of an artificial tooth made out of zirconia and porcelain on the front side with two zirconia wings that are bonded (glued) onto the back of the two adjacent teeth in the patient's mouth.
75396385|NCT01897584|Other|inverse IE|in only one group changes of I:E ratio would be applied
75396386|NCT01899846|Drug|Hydroxyprogesterone caproate 250 mg/ml|
75708991|NCT02567253|Drug|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
75396387|NCT00214890|Drug|Tenofovir|300 mg once daily
75396388|NCT00214890|Drug|Abacavir|600 mg once daily
75396389|NCT00216060|Drug|Risedronate|Daily oral risedronate combined with androgen deprivation
75396390|NCT00216060|Drug|Placebo|Daily oral placebo combined with androgen deprivation
75708992|NCT02567253|Drug|IPEC with Cisplatin (100mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
75708993|NCT02567253|Drug|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
75708994|NCT02567253|Drug|HIPEC with Cisplatin (100mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
75708995|NCT02564068|Drug|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
76036581|NCT06163066|Other|Newborn Basic Care Training|These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.
75396391|NCT00106938|Device|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
75396392|NCT00106938|Procedure|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
75396393|NCT02100072|Device|Nd:YAG 1440 nm laser|
75396394|NCT00110136|Drug|St. John's Wort|St. John's Wort 300mg tablet three times per day
75396395|NCT00282282|Drug|tacrolimus|Given orally just prior to and following stem cell transplant
75708996|NCT02563600|Behavioral|Pre-letter telephone call.|A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.
75396396|NCT00282282|Drug|sirolimus|Given orally just prior to and following stem cell transplant
75396397|NCT00282282|Drug|fludarabine|Given once daily over 30 minutes for 4 days
75708997|NCT02563600|Behavioral|Post-letter telephone call|A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
76036582|NCT06163053|Drug|Immunotherapy|Immune checkpoint inhibitors in approved indications
75396398|NCT00282282|Drug|busulfex|Given intravenously over 3 hours for 4 days
75396399|NCT00282672|Device|Ablation System plus anti-secretory medication|Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
75396400|NCT00282672|Device|Sham procedure plus anti-secretory medication|The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
75396401|NCT00282828|Drug|Sertraline|
75396402|NCT00282828|Drug|Venlafaxine|
75708998|NCT02549157|Procedure|Pelvic Floor Muscle Training|
75870822|NCT03634449|Device|endotracheal tube|Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
75870823|NCT01319643|Drug|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
75396403|NCT00282828|Drug|Placebo|
75396404|NCT00282828|Drug|Clonazepam|
75708999|NCT02546895|Other|chart review|"The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.~Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time."
75396405|NCT00112242|Biological|Melan-A ELA + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
75709000|NCT02521493|Drug|Asparaginase|Given IM or IV
75709001|NCT02521493|Drug|Asparaginase Erwinia chrysanthemi|Given IM or IV
75396406|NCT00112242|Biological|Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
75396407|NCT00112242|Biological|Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
75396408|NCT00112242|Biological|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
75396409|NCT00112242|Biological|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
75396410|NCT00284154|Drug|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
75396411|NCT01899924|Behavioral|Event Related Potentials recording|
75709002|NCT02521493|Drug|Cytarabine|Given IT and IV
75709003|NCT02521493|Drug|Daunorubicin Hydrochloride|Given IV
75709004|NCT02521493|Drug|Etoposide|Given IV
75709005|NCT02521493|Other|Laboratory Biomarker Analysis|Correlative studies
75709006|NCT02521493|Drug|Mitoxantrone Hydrochloride|Given IV
75547420|NCT06139016|Device|Virtual reality|Virtual reality gear and content will be used to affect and control the audiovisual perception of patients during a single treatment with ketamine/esketamine
75709007|NCT02521493|Drug|Thioguanine|Given PO
75709008|NCT02517749|Device|Chest Drain Insertion and Talc Pleurodesis|
75709009|NCT02517749|Device|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
75709010|NCT02514395|Other|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2[32] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
75870824|NCT02975336|Drug|Placebo|Participants received placebo matched to M2951 orally for 52 weeks.
75870825|NCT02975336|Drug|M2951|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
75870826|NCT02975336|Drug|M2951|Participants received 75 mg of M2951 orally QD for 52 weeks.
75709011|NCT02419495|Drug|Capecitabine|Given PO
75709012|NCT02419495|Drug|Carboplatin|Given IV
75709013|NCT02419495|Drug|Cyclophosphamide|Given IV
75709014|NCT02419495|Drug|Doxorubicin|Given IV
75709015|NCT02419495|Drug|Eribulin|Given IV
75709016|NCT02419495|Drug|Fluorouracil|Given IV
75709017|NCT02419495|Biological|Ipilimumab|Given IV
75870827|NCT02975336|Drug|M2951|Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
75870828|NCT02975336|Drug|M2951|Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
75870829|NCT01371513|Other|continuous screening|practice patterns for screening prostate cancer
75870830|NCT02364154|Other|Control group-Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
75870831|NCT02364154|Other|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
75870832|NCT02369614|Other|Active Comparator: 1 Hz rTMS|1 Hz rTMS
75870833|NCT02369614|Other|Active Comparator: 10 Hz rTMS|10 Hz rTMS
75396412|NCT00223236|Drug|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
75396413|NCT00223236|Drug|Placebo|Placebo matching active medication in all other aspects.
75396414|NCT00223704|Drug|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
75396415|NCT00223704|Drug|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
75396416|NCT00223704|Drug|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
75396417|NCT00224952|Other|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
75396418|NCT00225420|Drug|docetaxel|Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
75396419|NCT00225420|Drug|leuprolide acetate|Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
75396420|NCT00225420|Radiation|radiation therapy|The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
75396421|NCT00225498|Drug|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
75396422|NCT00225732|Other|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
75547421|NCT06139003|Device|3d Printed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
75547422|NCT06139003|Device|Conventionally constructed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
75547423|NCT06138977|Device|Powered prosthesis|A powered prosthesis will be used to restore normative leg biomechanics to above-knee amputee participants during different activities of daily life.
75547424|NCT06138964|Drug|siSPARC + siLR4A microneedle patches|siSPARC + siLR4A microneedle patch
75870834|NCT02369614|Other|Sham Comparator:|Sham rTMS
75396423|NCT00225732|Drug|Intravenous ibuprofen|"800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)"
75547425|NCT06138964|Drug|siSPARC microneedle patch|siSPARC microneedle patch
75709018|NCT02419495|Drug|Irinotecan Hydrochloride|Given IV
75396424|NCT02096718|Drug|Afatinib healthy|
75396425|NCT02096718|Drug|Afatinib severe renally impaired|
75709019|NCT02419495|Drug|Leucovorin Calcium|Given IV
75709020|NCT02419495|Biological|Nivolumab|Given IV
75709021|NCT02419495|Drug|Olaparib|Given PO
75709022|NCT02419495|Drug|Oxaliplatin|Given IV
75709023|NCT02419495|Drug|Paclitaxel|Given IV
75709024|NCT02419495|Biological|Pembrolizumab|Given IV
75709025|NCT02419495|Drug|Pemetrexed|Given IV
75709026|NCT02419495|Drug|Selinexor|Given PO
75709027|NCT02419495|Drug|Topotecan|Given IV
75396426|NCT02096718|Drug|Afatinib moderate renally impaired|
75396427|NCT00113022|Drug|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
75396428|NCT00113022|Drug|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
75396429|NCT02097732|Drug|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
75709028|NCT02400216|Drug|dual cholate|test for defining disease severity
75547426|NCT06138938|Other|Intraoperative abdominal irrigation|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
75709029|NCT02386917|Procedure|Gastric bypass|Weight loss surgery
76036583|NCT06163040|Drug|Elotuzumab in combination with pomalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
75396430|NCT02097732|Procedure|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
75547427|NCT06138925|Other|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)
75547428|NCT06138925|Other|Analysis of running|analysis of running on flat ground at different speeds (comfortable and fast)
75547429|NCT06138925|Other|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).
75709030|NCT02386917|Behavioral|Very low calorie diet|Non-surgical weight loss procedure
75709031|NCT02385617|Drug|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
75709032|NCT02385617|Drug|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
75709033|NCT02381249|Drug|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
75709034|NCT02381249|Drug|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
75709035|NCT02362464|Biological|Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine|dose of 20 x 10^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.
75709036|NCT02347930|Other|kidney ultrasound|kidney ultrasound
75709037|NCT02339922|Drug|Ixazomib Citrate|Given PO
75709038|NCT02339922|Other|Laboratory Biomarker Analysis|Correlative studies
75709039|NCT02339922|Biological|Rituximab|Given IV
75709040|NCT02332356|Drug|azathioprine or adalimumab and infliximab|
75709041|NCT02299596|Other|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
75709042|NCT02285114|Drug|F/TAF|F/TAF tablets administered orally once daily
75709043|NCT02285114|Drug|3rd ARV agent|A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).
75709044|NCT02285114|Drug|Boosted PIs|Boosted PIs of the participant's pre-existing regimen may include one of the following: ATV, LPV, or DRV.
75709045|NCT02252250|Procedure|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
75709046|NCT02252250|Procedure|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
75709047|NCT02250131|Procedure|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery > 280 mL/min/m2
75547430|NCT06138912|Radiation|plain radiography (x-ray)|Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
75547431|NCT06138886|Device|Pulsed electromagnetic therapy group|The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.
75547432|NCT06138873|Procedure|Ablation-index guided ventricular tachycardia ablation|As described in arms descriptions
75709048|NCT02193620|Drug|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
75709049|NCT02193620|Drug|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
75709050|NCT02193620|Drug|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
75396431|NCT04752306|Other|Interviews|Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.
75396432|NCT02028468|Procedure|hemiarthroplasty|
75396433|NCT00113334|Drug|ABT-510|100 mg subcutaneously twice daily
75396434|NCT00286182|Drug|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
75396435|NCT00286182|Drug|Placebo|Placebo
75396436|NCT00286728|Behavioral|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
75396437|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
75396438|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
75396439|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
75396440|NCT00226590|Drug|Gemcitabine|Induction Chemotherapy.
75396441|NCT00226590|Drug|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
75396442|NCT00226590|Drug|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
75396443|NCT00226590|Procedure|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
75396444|NCT00114114|Drug|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10* gms topically each day
75396445|NCT00114114|Drug|Goserelin acetate|3.6 gms sc every 4 weeks
75396446|NCT00227760|Drug|Cediranib Maleate|Given PO
75547433|NCT06138873|Procedure|Ventricular tachycardia ablation with no AI-guidance|As described in arms descriptions
75547434|NCT06138847|Diagnostic Test|electroencephalogram|Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages
75547435|NCT06138834|Drug|Low-dose Y-6 sublingual tablets|Take one Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
75709051|NCT02187848|Drug|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
75709052|NCT02183168|Drug|Meloxicam suppository|
75709053|NCT02183168|Drug|Meloxicam tablet|
75709054|NCT02183168|Drug|Indomethacin|
75709055|NCT02183129|Drug|Diclofenac|
75709056|NCT02183129|Drug|Meloxicam|
75709057|NCT02176967|Procedure|Biopsy|Undergo biopsy
75709058|NCT02176967|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
75709059|NCT02176967|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75709060|NCT02176967|Drug|Carboplatin|Given IV
75709061|NCT02176967|Other|Clinical Observation|Undergo clinical observation
75709062|NCT02176967|Procedure|Computed Tomography|Undergo CT
75709063|NCT02176967|Drug|Cyclophosphamide|Given IV
75709064|NCT02176967|Drug|Doxorubicin Hydrochloride|Given IV
75709065|NCT02176967|Drug|Etoposide|Given IV
75709066|NCT02176967|Procedure|Magnetic Resonance Imaging|Undergo MRI
75709067|NCT02176967|Procedure|Ultrasound|Undergo ultrasound
75709068|NCT02137850|Drug|turoctocog alfa pegol|For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
75709069|NCT02133196|Drug|Aldesleukin|Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.
75709070|NCT02133196|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
75709071|NCT02133196|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
75709072|NCT02133196|Biological|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
75709073|NCT02077621|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
75709074|NCT02077621|Drug|Placebo|500 mL normal saline
75709075|NCT02065011|Drug|Blood draw for the laboratory assessment|
75709076|NCT01994499|Device|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
75396447|NCT00227760|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
75396448|NCT00227760|Other|Laboratory Biomarker Analysis|Correlative studies
75396449|NCT00227760|Other|Pharmacological Study|Correlative studies
75396450|NCT00227994|Drug|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
75396451|NCT00227994|Drug|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
75396452|NCT04250454|Behavioral|CONTRACT|"The intervention will consist of four elements:~Personal meeting - detailed information to the parents before the age of 15 weeks CA (1-3 days)~Home Activity Plan (HAP)~Home-based Feedback training~Electrical muscle stimulation~Combination of these elements has been chosen in order to ensure that optimal muscle growth is achieved through multi-modal stimulation of the motor and cognitive development of the child."
75396453|NCT00114504|Drug|simvastatin|simvastatin 5-10 mg/day
75396454|NCT04247802|Other|Backwards Walking (BW) programme|A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
75547436|NCT06138834|Drug|High-dose Y-6 sublingual tablets|Take two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
75547437|NCT06138834|Drug|Low-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol) for 28 days continuously.
75709077|NCT01994499|Drug|Medical drainage|Medical pleural drainage
75709078|NCT01843530|Drug|Berinert|
75709079|NCT01843530|Drug|Clemastin|
75396455|NCT04247802|Other|Usual Care|A 12 week physiotherapy exercise programme EXCLUDING backwards walking
75396456|NCT00118248|Drug|tanespimycin|Given IV
75396457|NCT04245384|Other|Internet-based dietetic treatment with video calls|The dietitian meets the patient through video calls, no physical meetings
75396458|NCT04245384|Other|Traditional dietetic treatment|The dietitian meets the patient through physical meetings
75396459|NCT00230022|Behavioral|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
75396460|NCT01898676|Drug|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
75396461|NCT01898676|Drug|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
75396462|NCT04243902|Device|Fill and Flush Valve|"The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O"
75396463|NCT00230802|Drug|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
75396464|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
75547438|NCT06138834|Drug|High-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol) for 28 days continuously.
75547439|NCT06138834|Drug|Placebo|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
75547440|NCT06138821|Device|ESG|Endoscopic sleeve gastroplasty - reduce the size of the stomach using an endoscopic plicating device
75547441|NCT06138821|Drug|GLP1-RA|Prescription for semaglutide for weight loss for 12 months.
75709080|NCT01843530|Drug|Cortisone acetate|
75709081|NCT01843530|Drug|NaCl|
75709082|NCT01720563|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
75709083|NCT01720563|Drug|Placebo|500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
75709084|NCT01720563|Procedure|Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks|
75709085|NCT01720550|Drug|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
75709086|NCT01720550|Drug|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
75709087|NCT01696565|Drug|PG2|Injectable
75547442|NCT06138769|Drug|Lenvatinib|Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight < 60 kg) once orally every day
75709088|NCT01656902|Drug|NOVOCART® 3D plus|Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)
75396465|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
75396466|NCT00288366|Drug|ziprasidone vs. aripiprazole|ziprasidone vs. aripiprazole dosed according to package insert
75396467|NCT00288366|Drug|aripiprazole vs. ziprasidone|aripiprazole vs. ziprasidone dosed according to package insert
75396468|NCT00288600|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin
76036584|NCT06163040|Drug|Elotuzumab in combination with lenalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
75396469|NCT00288600|Drug|Normal saline solution|Normal saline solution 10 ml/Kg
75396470|NCT00290472|Drug|temsirolimus|
75396471|NCT04752852|Drug|Dexamethasone|8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
75396472|NCT04752852|Drug|Placebo|2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
75396473|NCT00291876|Biological|Havrix™|2 doses at 12 months interval
75396474|NCT01899144|Drug|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
75396475|NCT01899144|Drug|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
75547443|NCT06138756|Device|Nerivio|Neriio is a remote electrical neuromodulation (REN) device for the treatment of migraine
75547444|NCT06138743|Drug|ARO-DM1 for Injection|single or multiple doses of ARO-DM1 by intravenous (IV) infusion
75547445|NCT06138743|Drug|Placebo|calculated volume to match active treatment by IV infusion
76036585|NCT06163027|Device|Shotblocker|Shotblocher will be administered during spinal needle injection
76036586|NCT06163027|Other|Shotblocker(Plasebo)|The back side of the shotblocher will be applied during spinal needle injection
76036587|NCT06163014|Behavioral|My Symptoms eHealth programme|"My Symptoms supports patients' self-efficacy and behavioural changes. The programme is activated by the patient after prescription by the GP. The patient is free to choose relevant tasks corresponding to wishes, needs/requirements and own perspectives.~Summary of content:~Symptom explanations and facts about frequent symptoms including brief animated explanations~Physical energy (sleep, diet and activity)~Working with resources and strain in everyday life~Values and choices (meaning and existential issues)~Thoughts~Feelings (emotion regulation)~Self-care (attention incl. mindfulness and audio exercises)~Preparation for a follow-up visit with the GP and relapse prevention. The above modules connect to four general tools: symptom registration, 'don't break the chain', goal setting staircase and notebook.~After 6 weeks: Voluntary GP follow-up consultation. After 8 weeks: End-of-treatment."
76036588|NCT06163001|Behavioral|Supervised aerobic and resistance exercises|4 weeks of preoperative supervised aerobic and resistance exercises
75709089|NCT01656902|Procedure|Microfracture|single-step treatment: defect location (knee, femur) is debrided, then bone plate is drilled mechanically to allow cells from the bone marrow to move to the defect location and to develop a scar tissue
75709090|NCT01626079|Device|MitraClip System|Percutaneous mitral valve repair using MitraClip System
75396476|NCT01899144|Drug|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
75396477|NCT00234078|Drug|0.5% OPC-12759|
75396478|NCT00234078|Drug|1% OPC-12759|
75709091|NCT01560182|Genetic|OTL-200 Gene Therapy|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
75870835|NCT03124563|Behavioral|Control Group|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
76036589|NCT06163001|Dietary Supplement|Dietary supplementation|4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation
76036590|NCT06162988|Drug|68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.|68Ga-NOTA-H006：PET imaging； 18F-FDG：PET imaging
76036591|NCT06162962|Other|Retrospective analysis|Retrospective analysis
75396479|NCT00234078|Drug|2% OPC-12759|
75396480|NCT00234078|Drug|placebo|
75396481|NCT00118404|Behavioral|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
75396482|NCT00118404|Drug|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
75396483|NCT00118404|Other|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
75396484|NCT00118404|Behavioral|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
75396485|NCT00121836|Drug|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
75709092|NCT01502280|Drug|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
75709093|NCT01502280|Drug|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
75709094|NCT01485809|Drug|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
75709095|NCT01420237|Device|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
75870836|NCT03124563|Behavioral|Implementation Intention Condition|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
75396486|NCT00121836|Drug|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
75396487|NCT01898910|Procedure|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
75396488|NCT01898910|Procedure|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
75396489|NCT01898910|Drug|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
75396490|NCT00237666|Drug|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
75396491|NCT00296322|Drug|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
75396492|NCT00297102|Drug|Roflumilast|500 mcg, once daily, oral administration in the morning
75396493|NCT00297102|Drug|Placebo|once daily
75396494|NCT00123162|Drug|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
75396495|NCT00123162|Drug|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
75396496|NCT01897818|Device|communication system P300 Speller|
75396497|NCT04751838|Other|no intervention|no intervention
75396498|NCT00123630|Drug|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
75396499|NCT00123630|Drug|Placebo|Placebo given IV once every 2-4 weeks based on weight
75396500|NCT00124176|Drug|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
75396501|NCT00124176|Drug|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
75396502|NCT00240162|Drug|PTK787/ZK 222584|
75396503|NCT00299988|Drug|Intravenous Immunoglobulin|
75396504|NCT00299988|Other|Placebo|
75709096|NCT01413100|Biological|Anti-Thymocyte Globulin|Given IV
75709097|NCT01413100|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
75709098|NCT01413100|Drug|Cyclophosphamide|Given IV
75709099|NCT01413100|Biological|Filgrastim|Given SC
75709100|NCT01413100|Other|Laboratory Biomarker Analysis|Correlative studies
75396505|NCT04226352|Drug|Dextromethorphan|Dextromethorphan will be administered and its tolerability evaluated.
75396506|NCT00300456|Drug|ABT-335|135 mg, daily, 12 weeks
75396507|NCT00300456|Drug|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
75396508|NCT00300456|Drug|Placebo|Daily, 12 weeks, see Arm Description for placebo information
75709101|NCT01413100|Drug|Mycophenolate Mofetil|Given PO
75709102|NCT01413100|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
75709103|NCT01413100|Drug|Plerixafor|Given SC
75709104|NCT01413100|Other|Quality-of-Life Assessment|Ancillary studies
75709105|NCT01413100|Other|Questionnaire Administration|Ancillary studies
75709106|NCT01349959|Drug|Azacitidine|Given SC
75709107|NCT01349959|Drug|Entinostat|Given PO
75709108|NCT01349959|Other|Laboratory Biomarker Analysis|Correlative studies
75709109|NCT01349959|Other|Pharmacological Study|Correlative studies
75709110|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
75709111|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
76036592|NCT06162936|Diagnostic Test|Phagoburst|The main objective is to perform oxidative burst activity in pediatric patients with a definitive diagnosis of IBD and compare them with healthy controls.
76036593|NCT06162936|Diagnostic Test|Lymphocytes subsets|To determine lymphocytes subsets in patients with suspicion of IEI
75396509|NCT00125034|Biological|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
75396510|NCT00125034|Drug|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day IV over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
76036594|NCT06162936|Diagnostic Test|Genetic testing|Perform targeted genetic testing in those with reduced to absent oxidative activity in search of PIDs and susceptibility variants
75396511|NCT02100930|Biological|Anti-GD2 3F8 Monoclonal Antibody|
76036595|NCT06162923|Behavioral|On-site video group|Each participant will receive standard oral hygiene reinforcement verbally, followed by watching a pre-recorded oral hygiene instruction video on a tablet
76036596|NCT06162923|Behavioral|Remote video group|After receiving normal oral hygiene reinforcement verbally, each participant will be sent a video link Whatapps instant message, which they are required to watch at home
76036597|NCT06162910|Diagnostic Test|Daniels Water Swallow Test|Clinical water swallow dysphagia screening
76036598|NCT06162910|Diagnostic Test|Flexible Endoscopic Evaluation of Swallowing|Endoscopic evaluation of swallowing function
76036599|NCT06162897|Behavioral|Dyadic Case Management|Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals.
75396512|NCT02100930|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
75396513|NCT02100930|Drug|oral isotretinoin|
75547446|NCT06138717|Other|yoga based exercises|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.In group 2, in addition to aerobic exercises, spinal stretching, relaxation, respiration and meditation will be performed. A yoga-based exercise programme consisting of exercises will be applied for 40 minutes and 12 session
75870837|NCT02364232|Behavioral|bilateral training with and without mirror feedback|
76036600|NCT06162858|Other|IMU (Inertial Measurement Devices)|Functional placing and reaching of objects of different weights on different heights
76036601|NCT06162845|Behavioral|A smartphone based application free to download from the google play and iphone store to provide auditory and visual cues and counting for number of perscribed pelvic floor muscle contractions|Use of a smartphone-based home exercise application for pelvic floor muscle exercises with visual and auditory feedback for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
76036602|NCT06162845|Behavioral|Paper-based home exercise program for pelvic floor muscle exercise|Written instructions on a piece of paper for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
76036603|NCT06162832|Combination Product|Allograft and rHPDGF-BB|At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)
76036604|NCT06162832|Combination Product|Allograft and Saline solution|This will be used as the control group
76036605|NCT06162793|Behavioral|RehaPlus+|24-week eHealth intervention
76036606|NCT06162780|Diagnostic Test|ultrasonic cardiography|Trans-thoracic echocardiography is performed in the resting position. Trans-esophageal echocardiography is performed under surface anaesthesia with bupivacaine or intravenous anaesthesia. We comprehensively assess the severity of mitral regurgitation according to ASE guideline.
75396514|NCT00241176|Drug|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS & CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
75396515|NCT00125658|Other|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
75396516|NCT00125658|Other|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
75396517|NCT02102100|Drug|nicotine|In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
75396518|NCT02102100|Drug|menthol|In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
75396519|NCT02094534|Biological|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
75396520|NCT02094534|Other|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
75396521|NCT00242502|Drug|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
75396522|NCT00242502|Drug|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
75396523|NCT04389060|Dietary Supplement|Grape seed extract|Two capsule grape seed extract (total 600 mg)
75709112|NCT01331681|Procedure|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
75870838|NCT02359396|Drug|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
75870839|NCT01369719|Drug|osveral|receive 20 mg/kg daily orally
75870840|NCT01369719|Drug|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
75396524|NCT01899066|Drug|Lucentis, chemotherapy|"Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2."
75396525|NCT01899066|Drug|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
75396526|NCT01890720|Device|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
75396527|NCT01890720|Other|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
75396528|NCT00244140|Drug|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
75396529|NCT00244140|Drug|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
75709113|NCT01325233|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
75709114|NCT01325233|Drug|Placebo|500 ml normal saline, tiw, 2 weeks
75709115|NCT01286272|Drug|Bendamustine Hydrochloride|Given IV
75709116|NCT01286272|Drug|Bortezomib|Given IV or SC
75709117|NCT01286272|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET
75709118|NCT01286272|Other|Laboratory Biomarker Analysis|Correlative studies
75709119|NCT01286272|Biological|Ofatumumab|Given IV
75709120|NCT01286272|Procedure|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
75870841|NCT04479046|Other|PMMA crowns|New type of pediatric crowns
75870842|NCT01369797|Other|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
75870843|NCT02369380|Device|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
75870844|NCT02038816|Drug|Deferasirox + Azacitidine|"Deferasirox:~20 mg/kg/d for < 14ml/kg/mo pRBCs (~ <4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"
75870845|NCT02038816|Drug|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
76036607|NCT06162780|Procedure|Transcatheter mitral valve Edge-to-Edge Repair|There are two commercial systems including Mitraclip and Dragonfly for clinical use. The patient who receives general anaesthesia undergoes operation guided by X-ray and trans-esophageal echocardiography, according to the recommended surgical procedure. MR success is defined as DMR ≤ grade 2+ after TEER. After crossing the atrial septum during the operation, full dose heparin was given for anticoagulation. Post-intervention antithrombotic therapy was used as indicated. Anticoagulation was chosen if the patient has an indication for anticoagulation, otherwise aspirin was prescribed.
76036608|NCT06162767|Procedure|Esophagectomy by Ivor-Lewis Procedure|Esophagectomy was conducted by Ivor-Lewis Procedure.
76036609|NCT06162767|Procedure|Esophagectomy by Optimized Sweet Procedure|Esophagectomy was conducted by Optimized Sweet Procedure.
75396530|NCT00126750|Behavioral|VA MI Plus Interactive|The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
75547447|NCT06138704|Procedure|Retrograde Intrarenal Surgery|All RIRS procedures were performed under general anesthesia with direct videoscopic and fluoroscopic guidance. The decision to use a flexible or semirigid ureteroscope depended on the location of the Stones. If this was not enough to pass the ureteroscope, we placed a JJ catheter for passive dilatation. Stones were fragmented using a holmium-YAG laser and grasped by a stone basket when applicable. Contrast injection was performed at the end of the procedures to confirm the absence of extravasation and stone-free status. Ultrasonography (USG) was performed three months, six months, and one year after the procedures to evaluate stone recurrence and hydronephrosis.
75547448|NCT06138678|Device|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head."
75547449|NCT06138652|Behavioral|App|Participants completed games on an app and sessions with a mentor focused on alleviating anxiety over 8 weeks.
75547450|NCT06138639|Genetic|SGT-003|Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)
75547451|NCT06138613|Drug|Tradipitant|Oral Capsule
75396531|NCT00127062|Other|Oxford street|2 h walk around Oxford street
75709124|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
75870846|NCT04809831|Other|Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse|Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.
75870847|NCT04809831|Other|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)|Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.
75870848|NCT02359162|Drug|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
75870849|NCT02359162|Drug|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
76036610|NCT06162754|Other|A questionnaire and TREALD scales were applied to parents.|The survey, which included questions about sociodemographic characteristics and space maintainer awareness, was administered to parents face to face. Then, parents' oral health literacy levels were measured with TREALD-30 and TREALD-30A scales.
76036611|NCT06162741|Behavioral|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
75396532|NCT00127062|Other|Hyde park|2 h walk around Hyde park
76036612|NCT06162741|Behavioral|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act. The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion."
75396533|NCT00127218|Drug|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
75547452|NCT06138587|Biological|Cytokine Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
75547453|NCT06138587|Biological|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.
75547454|NCT06138574|Drug|Dexmedetomidine|After the induction of general anesthesia, one group (Group: 1) will be administered dexmedotomidin infizyon and group (Group :2)remifentanil
75547455|NCT06138574|Drug|Remifentanil|Remifentanil
76036613|NCT06162728|Drug|Briquilimab|Subcutaneous Administration
76036614|NCT06162728|Other|Placebo|Placebo Comparator
75547456|NCT06138561|Behavioral|Geriatric-8 Survey|A screening tool to evaluate frailty and at-risk participants by covering multiple domains that contribute to frailty, including mobility, functional status, pharmacologic burden, and underlying psychologic burden. A total score ranges from 0 to 17 with participants scoring > 14 points are more likely to be fit, or having a better health status, while those scoring 0 - 14 would benefit from further comprehensive geriatric assessment.
75709125|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
75870850|NCT02359162|Drug|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
75870851|NCT02359162|Drug|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
75870852|NCT02359162|Drug|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
75870853|NCT02359162|Drug|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
75870854|NCT02359162|Drug|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
76036615|NCT06162715|Drug|Tirzepatide|Tirzepatide will be initiated 3 months after patients undergo Roux-en-Y Gastric Bypass. Patients will be started on the lowest dose of 2.5 mg and the dose increased every 4 weeks until the maximum 15 mg dose or the maximum tolerated dose is achieved. Patients will then complete a final 4 weeks of the study drug.
76036616|NCT06162702|Procedure|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
76036617|NCT06162676|Behavioral|HPV game|A brief health game for parent-child dyads to promote child's HPV vaccination
75870855|NCT02359162|Drug|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
75870856|NCT02359162|Radiation|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
75396534|NCT00127218|Drug|niacin|long-acting niacin daily for 18 months
75396535|NCT00127218|Drug|Placebo|matching placebo pill daily for 18 months
75396536|NCT00127530|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
75396537|NCT00127530|Drug|Placebo|sugar pill, twice a day (b.i.d.)
75396538|NCT04346238|Other|Reuse of existing data from patients' medical records|Reuse of existing data from patients' medical records
75396539|NCT00250926|Drug|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
75396540|NCT00250926|Drug|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
75396541|NCT00250926|Drug|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
75396542|NCT00251238|Drug|Ginkgo biloba extract EGb 761|daily Ginkgo biloba extract EGb 761
75396543|NCT00251862|Behavioral|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
75870857|NCT03634605|Procedure|Chemical pleurodesis|
75870858|NCT03634605|Drug|Tetracycline Topical Ointment|
75870859|NCT03634605|Drug|Normal saline|
75870860|NCT03634605|Drug|Lidocaine 2% Injectable Solution|
75870861|NCT05653804|Procedure|tele-visit|The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
75396544|NCT00251862|Behavioral|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
75396545|NCT00251862|Behavioral|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
75396546|NCT00303966|Drug|sorafenib tosylate|Given orally
75396547|NCT00304512|Drug|migalastat HCl|
75396548|NCT00304746|Drug|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
75396549|NCT00304746|Drug|Placebo|Placebo
75396550|NCT05267730|Behavioral|Conectar Jugando Game Program|Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
75396551|NCT05267418|Device|Automated nasal O2 titration with FreeO2|The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
75396552|NCT00134004|Drug|cyclophosphamide|
75709126|NCT01215136|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
75709127|NCT01142401|Drug|Bortezomib|Given IV
75870862|NCT02363764|Procedure|Nasal swab|"Will be obtained by the physiotherapist in:~Expectorating CF patients~Non-expectorating CF patients~Bronchoscopy CF patients"
75870863|NCT02363764|Procedure|Cough swab|"Will be obtained by the physiotherapist in:~Expectorating CF patients~Non-expectorating CF patients~Bronchoscopy CF patients"
75870864|NCT02363764|Procedure|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:~- Expectorating CF patients"
75870865|NCT02363764|Procedure|Induced sputum|"Will be obtained by the physiotherapist in:~Non-expectorating CF patients~Bronchoscopy CF patients"
76036618|NCT06162663|Drug|Suvorexant Tablets|Suvorexant initially with 10-20 mg for 28 days
75547457|NCT06138561|Behavioral|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)|Patient reported, sixteen question survey focused on evaluation of quality of life in patients with bladder cancer.
75709128|NCT01142401|Drug|Fulvestrant|Given IM
76036619|NCT06162663|Other|Placebo Control|Matched Placebo Control for 28 days
76036620|NCT06162650|Radiation|Short-course radiotherapy|Short-course radiotherapy, 5×5 Gy.
75709129|NCT01142401|Other|Laboratory Biomarker Analysis|Correlative studies
75396553|NCT00134004|Drug|fludarabine phosphate|
75396554|NCT00134004|Drug|mycophenolate mofetil|
75396555|NCT00134004|Drug|tacrolimus|
75396556|NCT00134004|Procedure|allogeneic bone marrow transplantation|
75396557|NCT00134004|Radiation|radiation therapy|
75396558|NCT00135798|Drug|LADR Treatment|"PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was <0.5 ug/kg, PEGIFN was permanently discontinued."
75547458|NCT06138561|Behavioral|Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)|Patient-reported questionnaire that evaluates cancer-specific toxicity, developed based upon Common Terminology Criteria for Adverse Events.
75547459|NCT06138535|Device|digital stabilizing splint|3D Printed stabilizing splint that has been digitally designed on a modern software
75547460|NCT06138509|Other|Dosage of serotonin and metabolites|The dosages of serotonin and its metabolites will be performed by the INSERM U1016 unit at Cochin Institute.
75709130|NCT01142388|Biological|Cixutumumab|Given IV
75709131|NCT01142388|Other|Laboratory Biomarker Analysis|Correlative studies
75709132|NCT01142388|Drug|Paclitaxel|Given IV
75709133|NCT01142388|Other|Pharmacological Study|Correlative studies
75709134|NCT01134614|Biological|Ipilimumab|Given IV
75709135|NCT01134614|Biological|Sargramostim|Given SC
75709136|NCT01111617|Procedure|Real-time fMRI feedback|Patients receive real-time fMRI biofeedback to modulate pain
75709137|NCT00870636|Drug|Bevacizumab (Avastin)|Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.
75709138|NCT00860600|Drug|PG2|500mg/vial, iv infusion, 3 ~ 5 times/week, 2.5 ~ 3.5 hr/time
76036621|NCT06162650|Drug|mFOLFOX6|Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
76036622|NCT06162624|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in behavior change. Delivered over 8 weeks of self-guided study and homework assignments.
75396559|NCT00136812|Behavioral|stage-tailored intervention|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
75396560|NCT00137280|Behavioral|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
75396561|NCT01790334|Other|Ultrasonography|
75396562|NCT00138294|Biological|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
75396563|NCT02103114|Drug|Anti-thrombin III|"Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level*%) X body weight)/1.4~expressed as a % normal level based on functional ATIII assay"
75396564|NCT02103114|Other|Placebo|Normal saline placebo
75396565|NCT00140244|Drug|r-metHuLeptin|
75396566|NCT00140244|Drug|Placebo|
75396567|NCT02103270|Drug|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
75547461|NCT06138509|Other|Blood parameters|The characterization of blood parameters : complete blood count (CBC), reticulocytes, C-reactive protein (CRP), iron studies (ferritin, serum iron, transferrin and transferrin saturation), hemoglobin electrophoresis, erythropoietin, will be added using standard methods at the Necker hematology laboratory if not carried out as part of the routine care.
75547462|NCT06138496|Drug|Cadonilimab Combined With Lenvatinib|"3.7.1 Lenvatinib Treatment Lenvatinib (8mg [body weight < 60 kg] or 12 mg [body weight ≥ 60 kg]) orally once daily, with or without food.~3.7.2 Intravenous Infusion of Cardonilli (Injection) Infuse Cardonilli at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles."
75396568|NCT02103270|Drug|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
75547463|NCT06138470|Dietary Supplement|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
75396569|NCT02103270|Drug|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
75396570|NCT01790412|Behavioral|Exercise group|Combined two land aerobic sessions and one aquatic activities session
75547464|NCT06138470|Dietary Supplement|Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
75709139|NCT00633828|Behavioral|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
75396571|NCT01790022|Drug|Methylprednisolone|
75396572|NCT00140556|Radiation|Chemoradiotherapy|External beam radiation daily (M-F)
75396573|NCT00140556|Drug|Cisplatin|Cisplatin week 1 and 5 of radiation
75547465|NCT06138470|Dietary Supplement|Saffron and Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
75396574|NCT00140556|Drug|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
75396575|NCT00140556|Drug|Erlotinib|Erlotinib daily during radiation
75396576|NCT05215392|Behavioral|Family Connections program|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
75396577|NCT00142116|Drug|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
75547466|NCT06138470|Dietary Supplement|Placebo (maltodextrin)|Food supplements are taken during 6 weeks by healthy volunteers
75396578|NCT00142116|Drug|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
75547467|NCT06138444|Dietary Supplement|Functional beverages from the submerged fermentation of Cordyceps militaris|The Cordyceps militaris submerged fermentation in fruit juice.
75547468|NCT06138444|Other|Fruit juice|Fruit juice is used as a placebo.
75547469|NCT06138431|Behavioral|CBT|Virtual CBT groups
75547470|NCT06138418|Procedure|Neurotomy|Surgical treatment of spastic foot
75547471|NCT06138405|Behavioral|Immediate intervention Group|The immediate intervention group will be video recorded in office and participate in the training workshop and assessment methods two months after.
75396579|NCT05201430|Drug|FOLFOXIRI|irinotecan* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
75396580|NCT05201430|Drug|CapeOX|oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
75547472|NCT06138405|Behavioral|Delayed intervention (control) Group|The delayed training group will also be video recorded in office but will wait an additional two months and then participate in the training and assessment methods as with the original training group.
75709140|NCT00584532|Drug|Placebo|10 Placebo Capsules taken orally every day.
75396581|NCT05188560|Other|Action observation therapy|Subject is asked to observe videos with motor contents
75396582|NCT05188560|Other|motor imagery|mental simulation of a motor task
75396583|NCT00142506|Drug|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
75547473|NCT06138392|Device|Dental implant (ELEMENT RC INICELL, Thommen Medical)|Dental implant
75547474|NCT06138379|Other|Experimental: 1st Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
75547475|NCT06138379|Other|Experimental: 2nd Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
75547476|NCT06138340|Drug|Dexmedetomidine|Participants will be sedated and maintained by dexmedetomidine during the surgery.
75547477|NCT06138340|Drug|Propofol|Participants will be sedated and maintained by propofol during the surgery.
75547478|NCT06138327|Drug|BMN 255|Oral Capsule
75547479|NCT06138327|Drug|Placebo|Oral Capsule
75547480|NCT06138314|Other|Physical Exercise Program|The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
75547481|NCT06138314|Other|Neural Mobilization|Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
75709141|NCT00584532|Drug|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
75709142|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
75709143|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
76036623|NCT06162624|Behavioral|Cognitive Behavioral Therapy (CBT)|"As control condition, CBT book Feeling Good Self-Help Book will be used"
75547482|NCT06138301|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT is a psychotherapeutic intervention that focuses on challenging and changing cognitive distortions (such as thoughts, beliefs, and attitudes) and their associated behaviours to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, patients with SI will undergo 8 sessions of CBT (45 min, once a week), remotely. Techniques and strategies of the intervention will be based on a short telepsychotherapy protocol previously published by our group (Biagianti et. al., 2021). Instead, the content of each session will be adapted to the psychopathology associated with social isolation and the age of the subject. The psychotherapeutic sessions of the patients will be audio-recorded in order to conduct retrospective analyzes of the patient's speech.
75709144|NCT00523107|Drug|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
75709145|NCT00523107|Drug|Placebo|500 ml normal saline t.i.w. per week
75709146|NCT00482807|Drug|bicalutamide|
75709147|NCT00482807|Drug|docetaxel|
75709148|NCT00482807|Drug|goserelin|
75709149|NCT00482807|Radiation|intensity-modulated radiation therapy|
75709150|NCT00474604|Procedure|diffusion-weighted magnetic resonance imaging|A scan will be performed.
75709151|NCT00474604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
75709152|NCT00474604|Procedure|magnetic resonance spectroscopic imaging|A scan will be performed.
75709153|NCT00202371|Procedure|Red Blood Cell transfusion|
76036624|NCT06162598|Other|Ventriloquist Puppet|one day preparation intervention applied by researcher for children under the inhaler treatment. Preparation will be 30 minutes long
76036625|NCT06162572|Drug|S095018|Via IV infusion on Day 1 of each 21-day cycle
76036626|NCT06162572|Drug|S095024|Via IV infusion on Day 1 of each 21-day cycle
76036627|NCT06162572|Drug|S095029|Via IV infusion on Day 1 of each 21-day cycle
76036628|NCT06162572|Drug|S095018 Recommended Dose Expansion (RDE)|Via IV infusion on Day 1 of each 21-day cycle
75870866|NCT02363764|Procedure|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:~- Bronchoscopy CF patients"
76036629|NCT06162572|Drug|S095024 RDE|Via IV infusion on Day 1 of each 21-day cycle
76036630|NCT06162572|Drug|S095029 RDE|Via IV infusion on Day 1 of each 21-day cycle
75870867|NCT02363764|Other|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients >6 years of age
76036631|NCT06162572|Drug|Cemiplimab|350 mg via IV infusion on Day 1 of each 21-day cycle
76036632|NCT06162546|Other|Registry|Registry Participation, providing data and clinical specimen
76036633|NCT06162533|Biological|Vaccination against SARS-CoV-2|Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2
76036634|NCT06162520|Other|Contrast-enhanced computed tomography (CECT) and 3D morphological analysis|Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.
76036635|NCT06162507|Biological|CM310|CM310 injection
76036636|NCT06162468|Procedure|Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel|EUS-PCA using gemcitabine and paclitaxel
76036637|NCT06162455|Drug|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
76036638|NCT06162455|Drug|200- ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
75396584|NCT00142506|Drug|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
76036639|NCT06162442|Drug|Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)|"The procedures during the study consist of ophthalmological activities and attention to the participating subject with a diagnosis of DED and who starts using a specified ocular lubricant, free of preservatives. The ophthalmologist will notify the subject of the wash out, which will consist of suspending the usual treatment medication for 7 days, to then start with the lubricant Glicolub Ultra®, with a dosage of 1 drop every 6 hours in both eyes. Self-assessment questionnaires will be delivered for their respective completion. An assessment will be made by the comprehensive ophthalmologist in all clinical tests for dry eye with a mild to moderate diagnosis, under compliance with the TOSF DEWS II criteria and study inclusion criteria."
75396585|NCT05266794|Drug|Alpha lipoic acid|20 patients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
75396586|NCT05266794|Drug|Selenium|23 patients who received Selenium 200µg once daily with their routine therapy just a
75396587|NCT00142818|Drug|Naltrexone|150 mg daily for males; 100 mg daily for females
75396588|NCT00142818|Drug|Modafinil|400 mg daily
75396589|NCT00142818|Drug|Placebo|400 mg and/or 100-150 mg placebo pills
75396590|NCT05266716|Behavioral|Affect Methamphetamine Treatment Program|"Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change."
75396591|NCT00147030|Procedure|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
75396592|NCT05266560|Drug|ciprofol|A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-[(1R)-1-cyclopropylethyl]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
75396593|NCT05266560|Drug|Propofol|Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
75547483|NCT06138301|Behavioral|Cognitive Remediation (CR)|The cognitive training will consist of 10 hours (30 minutes/session) of computer-based exercises focusing on working memory, attention, executive functions and social cognition, which will be performed online using BrainHQ software. This software allows for the customization of the training based on the specific characteristics of each subject. For example, it allows automatic adjustment of the difficulty of the exercises, trial by trial and session by session, in order to guarantee an adequate level of attention and motivation for the entire duration of the training and therefore favor optimal learning rates.
75547484|NCT06138262|Other|Health promotion of education pre-conception nutritional preparation|Providing education on pregnancy nutritional preparation during the preconception period 3 months before the wedding
75547485|NCT06138249|Dietary Supplement|Vitamin D|Vitamin D
76036640|NCT06162403|Other|Peripheral Nerve Stimulation|The leads are inserted through a needle. If needed, the study team may give participants anesthetic (for example, as a cream/gel on your skin and/or as an injection) to numb the area where the leads will be injected.
75396594|NCT00147966|Drug|rituximab|treatment with rituximab
75396595|NCT04528212|Drug|Glimepiride Tablets|Glimepiride (4 mg) per Day
75547486|NCT06138236|Drug|Collagen hydrolyzed peptides|infiltration near the heal spur of 2ml of Arthrys
75396596|NCT04528212|Drug|glimepiride plus fenofibrate|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
75396597|NCT04528212|Drug|glimepiride plus curcumin|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
75396598|NCT05265936|Procedure|Passing a guidewire through a double j stent|The previously placed double J stent is removed up to the urethral meatus with a cystoscope and forceps and kept fixed at the meatal level without further pulling. Then, after reaching the kidney by passing a guidewire through it, the double j stent is removed. Followed by the routine lithotripsy procedure.
75396599|NCT05265936|Procedure|Double J stent removal and guidewire insertion|The double j stent is completely removed with the cystoscope and forceps, and the guidwire is inserted into the ureter by visualizing it with the cystoscope. Followed by the routine lithotripsy procedure.
75396600|NCT05265858|Procedure|Total Hip Arthroplasty|Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
75396601|NCT00148668|Drug|Herceptin|One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
75396602|NCT00148668|Drug|Navelbine|Weekly injections given starting week 3 and ending week 14
75396603|NCT00148668|Drug|Taxotere|Given every three weeks starting week 3 and ending on week 14
75396604|NCT00148668|Drug|Carboplatin|Given every three weeks starting week 3 and ending on week 14
75396605|NCT05265780|Procedure|kinesiotape|an elastic adhesive tape
75396606|NCT05265780|Procedure|sham taping|a sham taping without the tension
75396607|NCT00149838|Procedure|Prefrontal rTMS|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
75396608|NCT00149838|Drug|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
75396609|NCT00149838|Procedure|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
75396610|NCT01790646|Other|intubation|intubation using Glidescope videolaryngoscope
75396611|NCT04410822|Other|Clinical tests|Semi-qualitative interviews and questionnaire FITAS
75396612|NCT00324870|Drug|vorinostat|Given orally
75396613|NCT00324870|Drug|bevacizumab|Given IV
75396614|NCT00151320|Drug|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
75396615|NCT00326196|Device|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
75396616|NCT00326196|Procedure|Coronary artery bypass graft (CABG)|coronary bypass
76036641|NCT06162390|Drug|Remifentanil|"Following a sequential allocation scheme, the predetermined Ce of remifentanil for each patient will be determined by the Dixon up-and-down method. The Ce of remifentanil for the first patient will be 4.0 ng/ml, and then the remifentanil Ce will be increased or decreased in 0.5 ng/ml increments for subsequent patients depending on the success or failure of intubation.~The Ce of remifentanil to provide acceptable intubation at low dose neuromuscular blockade, the primary outcome, will be determined by obtaining seven crossovers of patients with acceptable intubation/unacceptable intubation and then calculating the mean of the midpoint doses for each independent pair of patients. According to previous studies that estimated EC50 by Dixon's up-and-down method, 6-8 failure/success crossover pairs are required, so this study aims to collect independent data of 7 pairs of intubation acceptable/unacceptable patients."
76036642|NCT06162351|Drug|PLX038|"Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection) after at least a first cycle at 1300mg/m2.~Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death."
76036643|NCT06162338|Biological|LY-M001 Injection|With 5.0 × 10^12 vg/kg as the initial effective dose (first dose group), 1 to 2 subjects are expected to be included. The first dose group was enrolled by sentinel method, and the first subject in this group was observed for at least 28 days after receiving LY-M001 (dose-limited toxicity [DLT] observation period) to enroll the next subject. After the first participant completes the safety evaluation of dosing for at least 28 days, the investigator (PI) and the partner discuss the safety and efficacy data and decide to maintain the first dose or increase/reduce it to another dose group
76036644|NCT06162299|Biological|YS-HBV-002|YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant
76036645|NCT06162286|Drug|Omadacycline|Omadacycline IV/PO
76036646|NCT06162286|Drug|Moxifloxacin|Moxifloxacin IV/PO
76036647|NCT06162273|Device|IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
75396617|NCT04332198|Other|biological test|dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
75396618|NCT00328770|Drug|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
75396619|NCT05105568|Behavioral|Process-based therapy|Process-based therapy (PBT) is a meta-theoretical model of evidence-based therapies that organizes adaptive and maladaptive processes of change using complex and dynamic networks based on an evolution science framework. Depending on the participant's presentation, PBT would be shaped by different evidence-based techniques. Examples of evidence-based procedures include: behavioral activation, exposures, mindfulness, self-compassion, values exploration, and contingency management.
75396620|NCT04281654|Other|Active Social Conversation|Active Social Conversation
75396621|NCT04952376|Behavioral|SMS delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
75396622|NCT04952376|Behavioral|Personalized text message delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
75709168|NCT00871312|Device|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
75709169|NCT00871312|Device|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
75709170|NCT00740012|Other|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
75396623|NCT04952376|Behavioral|Interactive or 2-way SMS delivery of information|This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
75396624|NCT04177680|Drug|Omega 3 pentaenoic acid|Encapsulated omega-3 pentaenoic acid
75396625|NCT04177680|Drug|icosapent ethyl|Encapsulated omega-3 acid ethyl esters
75396626|NCT01790724|Behavioral|Walking exercise|
75396627|NCT00330876|Drug|Pitavastatin|
75396628|NCT01792206|Drug|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
75396629|NCT01792206|Drug|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
75396630|NCT00333606|Behavioral|Acupuncture|Body acupuncture of 1 specific point per trial session
76036648|NCT06162260|Procedure|ICU readmission|Children who underwent liver transplantation at Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 1, 2018 to December 31, 2021 and were transferred out of ICU for the first time during the same hospitalization cycle.
75396631|NCT04947852|Device|Investigation Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
75396632|NCT04947852|Device|Comparator Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
75396633|NCT00334074|Drug|Clofarabine and Cytarabine|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
75396634|NCT00335478|Drug|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm^3.
75396635|NCT01790802|Device|2RT nanosecond laser|active laser therapy
75396636|NCT01790880|Behavioral|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
75396637|NCT01790880|Behavioral|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
76036649|NCT06162208|Other|Standard exercise program based on telerehabilitation|Exercises included in a standard exercise program based on telerehabilitation; Week 0-3 Patellar mobilization Isometric quadriceps femoris exercise Terminal extension exercise Active assisted knee flexion Straight leg lift Active hip abduction Active assisted knee flexion in sitting SAFTE Cold pack application Week 3-6 Straight leg raises with weights Hip abduction in weighted side lying Knee flexion in the prone position Knee extension in weight-bearing sitting Sliding forward in the chair to increase the knee flexion angle Standing weighted hip abduction Standing knee flexion with weight Squat Walking Climbing stairs Action observation therapy will be practiced by watching videos of all exercises with a focus on close-up action.
75396638|NCT02103816|Device|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
75396639|NCT04870164|Drug|Ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.
75396640|NCT04870164|Drug|Placebo|One administration at day 1 by infusion.
75396641|NCT01791036|Procedure|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
75396642|NCT01791036|Procedure|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
75396643|NCT04345926|Drug|Propofol|Stepped propofol concentration after 20 min of LOS
75396644|NCT04345926|Device|Electroencephalogram recording|Acquisition of EEG activity
75709171|NCT00740012|Other|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
75709172|NCT00740012|Other|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
75709173|NCT00740012|Other|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
75396645|NCT03974646|Behavioral|Nurse-led self-management Program|Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
75709174|NCT00740012|Other|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
75709175|NCT00740012|Other|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
75709176|NCT04064268|Dietary Supplement|Whey|45 g whey + 20 g maltodextrin
75709177|NCT04064268|Dietary Supplement|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
75709178|NCT00740090|Drug|AMA1-C1/Alhydrogel plus CPG 7909|
75709179|NCT00738660|Drug|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
75870868|NCT03655418|Other|Resilience Curriculum (RESCUR)|"The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience."
75870869|NCT02363842|Device|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
75396646|NCT00337350|Drug|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
75396647|NCT00337350|Drug|placebo|matched placebo for rosiglitazone 4mg/day
75709180|NCT00740168|Drug|bevacizumab treatment|single infusion 10 mg/kg
75709181|NCT05225974|Drug|Liraglutide injection|At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection
76036650|NCT06162195|Device|The H1 Implant|Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.
75709182|NCT05225974|Drug|Liraglutide injection(Victoza®)|At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
75709183|NCT00740246|Drug|VIT-45|
75709184|NCT00729638|Drug|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
75709185|NCT00729638|Drug|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
75709186|NCT00734682|Drug|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m^2 (wild type) or 60 mg/m^2 IV q3 weeks.
75709187|NCT00876538|Drug|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
75709188|NCT00876538|Drug|Placebo Control|Placebo Control 2 capsules once day with the noon meal
75709189|NCT00732108|Drug|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
75709190|NCT00732108|Drug|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
75396648|NCT00338598|Drug|Glycine|Glycine, 0.8 gr per kg given in two daily doses
75396649|NCT00338598|Drug|placebo|
75396650|NCT00338988|Drug|Capecitabine|1500 mg/m^2 PO twice daily x 14 days.
75396651|NCT00338988|Drug|Oxaliplatin|130 mg/m^2 IV over 2 hours on day 1 of cycle.
76036651|NCT06162195|Device|Cementless total hip replacement|Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
75396652|NCT00343044|Drug|Topotecan|Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
75396653|NCT00343044|Drug|Bevacizumab|bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
75396654|NCT04724304|Diagnostic Test|Real-Time Myocardial Echocardiography (RTMPE)|Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.
75396655|NCT04724304|Diagnostic Test|Magnetic resonance image (MRI)|Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
75396656|NCT00344370|Drug|Pitavastatin|Pitavastatin 4 mg QD
75396657|NCT00344370|Drug|Atorvastatin|Atorvastatin 40 mg
75870870|NCT02363842|Other|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
75870871|NCT02369302|Drug|DWC20141|Tablet
76036652|NCT06162182|Diagnostic Test|electrical impedance device,|The electrical resistance of the residual dentine underneath each measurement point was determined between an electrode and the crown pulp (Prepometer, Hager & Werken, Duisburg, Germany). Assigning the electrical resistance of the dentin. high values are considered to represent more residual dentine than low values.
76036653|NCT06162182|Diagnostic Test|Reference test: Digital Radiographic examination|A digital periapical radiograph using paralleling technique was taken
76036654|NCT06162169|Drug|JAB-21822|JAB-21822 was administered orally
76036655|NCT06162169|Drug|Itraconazole|Itraconazole was administered orally
76036656|NCT06162169|Drug|Omeprazole|Omeprazole was administered orally
76036657|NCT06162169|Drug|Midazolam , Rosuvastatin calcium and digoxin|Midazolam , Rosuvastatin calcium and digoxin was administered orally
76036658|NCT06162169|Drug|Rifampicin|Rifampicin was administered orally
76036659|NCT06162156|Other|Back massage|For the intervention group, massage will be given to the participant's back area by the researcher for 20 minutes, 12 hours after the cesarean birth. Preliminary data forms will be filled out by the participant before the massage. One hour after the massage, 'Visual Analog Scala' and 'Physiological Parameter Form' data will be filled in again. The final data forms will be filled out by the participant 24 hours after the cesarean birth, that is, 12 hours after the back massage.
76036660|NCT06162130|Diagnostic Test|Eccentric quadriceps exercises|The activation of the vastus medialis, vastus lateralis, and rectus femoris muscles will be measured using surface electromyography (sEMG) during four distinct quadriceps eccentric exercises: Reverse Nordic, Pistol squat, Suspension-based Bulgarian split squat, and Bulgarian split squat. Participants will be instructed to perform three successful repetitions for each exercise. A 30-second break will be provided between each repetition, and there will be a minimum of 10 minutes of rest between each of the four exercises. Due to the belief that fatigue could impact exercise performance, the modified Borg scale will be used to ensure that fatigue does not occur before each exercise. Exercise recording will commence when scores reported using the modified Borg scale are 1 or lower.
76036661|NCT06162065|Drug|Oxybutynin Pill|pharmacological antimuscarinic treatment
76036662|NCT06162065|Dietary Supplement|Boldo supplement|treatment supplemented with boldo
76036663|NCT06162052|Other|Tele-Rehabilitation|Technology will be used to enhance rehabilitation.
76036664|NCT06161961|Device|WRL TTP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
75396658|NCT00344682|Drug|memantine|memantine 5mg - 20mg PO daily
75396659|NCT00344682|Drug|Placebo|5mg - 20mg PO daily over 8 weeks
75870872|NCT02369302|Drug|DWC20142|Tablet
76036665|NCT06161948|Other|Time-restricted enteral nutrition therapy group|Control the daily enteral nutrition time to 8-12 hours, enteral nutrition start time: 06:00 ~ 08:00, end time: 16:00 ~ 18:00. Enteral nutrition lasts until the patient discontinues enteral nutrition, the patient dies, the patient is transferred from the ICU, or enteral nutrition is used until 28 days, whichever event occurs first.
75396660|NCT00345384|Drug|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
75870873|NCT02369302|Drug|DWC20141, DWC20142|Tablet
75870874|NCT03079869|Drug|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
75396661|NCT00345384|Other|Placebo (Normal Saline)|
75547487|NCT06138223|Other|Exercise intervention|During 12 weeks, patients will visit twice a week a trained oncology physiotherapist for one hour per session. This training includes supervised aerobic and resistance exercises to increase aerobic condition and muscle resistance, based on their own fitness level as assessed at baseline. Additionally, physiotherapists will educate participants on how to increase their daily activity. To this end, all participants will receive an activity tracker to monitor their daily activities.
76036666|NCT06161948|Other|Continuous enteral nutrition control group|The control group was continuous enteral nutrition (24 hours), which lasted until the patient stopped taking enteral nutrition, the patient died, the patient was transferred from the ICU, or enteral nutrition was used until 28 days, whichever event occurred first.
76036667|NCT06161909|Drug|sintilimab|200mg fixed dose Q3W,1 year
75709191|NCT00735800|Behavioral|Family Intervention:Telephone Tracking Support- Caregiver|Family-based problem solving treatment
76036668|NCT06161896|Diagnostic Test|Stool samples|Analysis of microbiome, mutations, alterations in body composition and lifestyle
75396662|NCT01791114|Other|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
75547488|NCT06138223|Other|Nutrition intervention|Once every two weeks patients in the intervention group will receive a nutritional assessment and intervention by a trained dietician for optimization of their nutritional intake to improve their nutritional status, following the ESPEN guideline on nutrition in cancer patients and the national guidelines of the National Nutritionists Oncology Working Group (NNOWG; in Dutch: Landelijke Werkgroep Diëtisten Oncologie, LWDO).
75547489|NCT06138210|Drug|exosomes derived from human induced pluripotent stem cell for injection|Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, protein concentration 1mg/mL).
75547490|NCT06138210|Drug|a placebo of exosomes derived from human induced pluripotent stem cell for injection|Exosomes placebo, 3.0ml
75547491|NCT06138171|Other|Psychological self-reported measures assesment (questionnaire)|The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).
75547492|NCT06138158|Procedure|Exercise and Education Group|Physical exercise and pain education
75547493|NCT06137690|Device|other antifungal agents,breathing machine|If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
75547494|NCT06137105|Drug|eltrombopag and romiplastim|"Group I: eltrombopag and romiplastim~Group II : recived corticosteroid."
75547495|NCT06136754|Drug|Varnishes, Fluoride|Fluoride varnish containing 5.0% NaF
75547496|NCT06136572|Diagnostic Test|Rathus Assertiveness scale|Questionnaire completion
76036669|NCT06161883|Other|Soffritto|The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
76036670|NCT06161870|Drug|individualized vancomycin dosing based on the population pharmacokinetics (PK) model|The experimental group will be guided at the bedside with individualized vancomycin dosing by a drug dosimetry software tool that incorporates a PK model developed by Roberts JA et al. for data from sepsis patients. The model developed by Roberts JA et al. has been validated in multiple centers to have a good ability to predict the concentration-time data of patients. Once the basic information of participants such as gender, age, body weight, and creatinine clearance rate (CCR) is entered, the software tool can calculate the dosing regimen that is estimated to achieve the pharmacodynamic (PD) target. The area under the curve (AUC24) of 400-600mg·h/L is identified as the PD target of vancomycin.
75870875|NCT03653936|Device|HITT device|Rebion has developed a noninvasive, handheld device that uses retinal polarization scanning (RPS) to rapidly assess eye fixation and retinal integrity in adults and children. RPS can automatically detect the fixation of the human eye with proprietary technology that uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. RPS requires no calibration or imaging, and eye movement recordings are not required. The HITT device is a repurposed Pediatric Vision Scanner (PVS), Rebion's first commercial product which has passed all applicable safety and performance standards.
75870876|NCT02363920|Device|HOF|the addition of high oxygen flow to patients breathing spontaneously
76036671|NCT06161870|Drug|empirical vancomycin dosing|The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
75547497|NCT06136247|Diagnostic Test|Neurocognitive battery|The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).
75547498|NCT06136247|Diagnostic Test|fNIRS|Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm [35,36].
75870877|NCT02363920|Device|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
75870878|NCT03654794|Biological|Cell pharmacokinetics of tacrolimus|"Three levels of tacrolimus will be tested. Each aliquot will be supplemented with an amount of tacrolimus to achieve one of these three levels of concentration.~At 0, 5, 15, 30, 60, 120, 240mn, the samples will be separated into 2 aliquots : one dedicated to the determination of tacrolimus in mononuclear cells, the other dedicated to the determination of calcineurin activity. in mononuclear cells."
75547499|NCT06135948|Drug|Extra dose of L-thyroxine, 25 mcg during Ramadan|Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
75870879|NCT03654170|Drug|BI 425809 mixed with [C-14] BI425809|Oral Solution
75870880|NCT03000153|Other|Completing the Goals Form|The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
75870881|NCT02369146|Drug|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
76036672|NCT06161857|Other|No intervention|There is no intervention this is an observational study to develop a diagnostic test
75396663|NCT01791114|Other|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
75396664|NCT01791114|Other|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
76036673|NCT06161831|Behavioral|Text Message/automated phone reminder|Receipt of text message or automated phone reminders notifying when the next HPV vaccine dose is due (either first or second)
76036674|NCT06161818|Drug|FLOT-CROSS or CROSS-FLOT|Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT
76036675|NCT06161792|Drug|0.8 mg RCN3028|Oral
75396665|NCT01791114|Other|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
75396666|NCT01791114|Other|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
75396667|NCT01791114|Other|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
75396668|NCT01791114|Other|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
75396669|NCT04271592|Drug|ABI-H3733 Liquid Oral Dosage Form|ABI-H3733 liquid oral dosage form
75396670|NCT04271592|Drug|ABI-H3733 Solid Oral Dosage Form|ABI-H3733 solid oral dosage form
75547500|NCT06135831|Other|Functional olive paste|Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.
76036676|NCT06161792|Drug|Placebo|Oral
76036677|NCT06161779|Other|Surgical reconstruction|submental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer
76036678|NCT06161766|Drug|terlipressin or noradrenalin plus albumin|Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed CKD who had received vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.
75396671|NCT04271592|Drug|Placebo to ABI-H3733 Liquid Oral Dosage Form|Placebo to ABI-H3733 liquid oral dosage form
75396672|NCT04271592|Drug|Placebo to ABI-H3733 Solid Oral Dosage Form|Placebo to ABI-H3733 solid oral dosage form
75396673|NCT04271514|Drug|RPT193|Antagonist of the CCR4 chemokine receptor
75396674|NCT04271514|Drug|Placebo|Matching placebo
75396675|NCT01791192|Drug|FTY720|Fingolimod
75396676|NCT01791192|Drug|Oral Corticosteroid|Oral Corticosteroid
75396677|NCT01793766|Device|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
75396678|NCT01793766|Device|Sham modulation|
75396679|NCT04019418|Dietary Supplement|Maltodextrin (carbohydrate)|A drink containing 300ml of water and 75g of maltodextrin
75396680|NCT04019418|Other|Exercise|30 minutes on a cycle ergometer working at 75% VO2 max
75547501|NCT06135831|Other|Calciovitmag (CDCaMg)|Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day
75547502|NCT06135831|Other|Phosporovitmag (PDCaMg)|Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily
75870882|NCT02363452|Drug|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
75870883|NCT02939313|Device|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
75870884|NCT02939313|Device|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
75870885|NCT02939313|Device|sham|sham stimulation
76036679|NCT06161740|Procedure|muscle strengthening|The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.
76036680|NCT06161727|Other|HPV exposure|According to group descriptions
75870886|NCT02363608|Other|standard post surgery care|
75709192|NCT00735800|Behavioral|Telephone Support|Supportive telephone counseling about caregiving
75870887|NCT02363608|Behavioral|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
75870888|NCT02363608|Behavioral|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
75870889|NCT03634137|Drug|Afamelanotide Group 1|One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
75870890|NCT03634137|Drug|Afamelanotide Group 2|One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
75547503|NCT06135831|Other|Control|Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily
75709193|NCT00876616|Drug|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
75709194|NCT00876616|Drug|Cyclophosphamide|CTX 0.75g/m2 BSA
75709195|NCT04064502|Diagnostic Test|CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:|Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
75870891|NCT02358772|Other|thrombolysis in a pre-hospital setting (STEMO concept)|
75870892|NCT02358694|Dietary Supplement|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
75396681|NCT04019418|Other|Rest|30 minutes laying on a bed
75396682|NCT04019418|Other|Water|A drink containing 300ml of water
75396683|NCT00347022|Drug|Xenetix|300 mg of iodine/ml
75396684|NCT00347022|Drug|Visipaque|270 mg of iodine/ml
75396685|NCT04714866|Behavioral|Cognitive behavioral therapy for ADHD|CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
75396686|NCT00350142|Radiation|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
75396687|NCT00350142|Drug|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
75396688|NCT00350142|Other|4D pancreatic protocol CT scan|Patients will undergo this imaging procedure prior to treatment for planning purposes.
75396689|NCT00350142|Radiation|FDG PET scan|Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
75396690|NCT00350220|Other|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb >13.0 g/dl
75396691|NCT00350220|Other|Low Hb transfusion group|RBCs will not be transfused unless the Hb < 9.0 g/dl
75396692|NCT01791348|Other|d2 test of attention|
75396693|NCT03962400|Procedure|Reinforcement Learning|New computer based procedure for determining dose using a decision support tool
75547504|NCT06135428|Other|Education Group|"Training content was prepared in three stages according to the resilience model in midwives. The training will be in the form of 45-minute presentations and sharings, and individual studies will be carried out in the form of homework according to people's methods of coping with stress. These homework assignments may occasionally include more or less individual meetings depending on the person's coping situation. However, at least 3 meetings will be held. Training and interviews will be conducted by researchers. For this, at least one of the researchers will receive training including personal awareness and motivational interviews."
75547505|NCT06135311|Device|Pulse Width 260us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 260us, intensity setting to patient's tolerance, duration 30 days
75547506|NCT06135311|Device|Pulse Width 50us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 50us, intensity setting to patient's tolerance, duration 30 days
75709196|NCT00729716|Biological|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
75396694|NCT03962400|Procedure|Heath Care Provider|Warfarin dose will be determined by a qualified health care provider
75396695|NCT04588272|Device|DualGuard|DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.
75396696|NCT03860610|Diagnostic Test|Muscle strength test|Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
75396697|NCT03860610|Diagnostic Test|Dynamic stability test during level and uphill walking|Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
75396698|NCT03860610|Diagnostic Test|Postural stability test|The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
75396699|NCT03860610|Diagnostic Test|EuroQol Group Health questionnaire (EQ-5D-5L)|Overall health will be assessed using the EQ-5D-5L health questionnaire
75396700|NCT03860610|Diagnostic Test|HOOS/ KOOS|Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
75396701|NCT03860610|Diagnostic Test|Muscle activity test|Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
75396702|NCT03860610|Diagnostic Test|Passive range of motion|Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
75396703|NCT01791426|Device|Artelac Rebalance|Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
75396704|NCT01791426|Device|Vismed|Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
75396705|NCT03821844|Behavioral|Music and Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
75870893|NCT02358694|Other|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
75396706|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
75396707|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
75870894|NCT04473807|Drug|Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation|The hypothesis to be tested is that the intravenous loading regimen followed by oral sotalol administration 4 hours after the conclusion of the IV infusion (every 12 hours thereafter) will result in sotalol peak concentrations at the end of IV loading dose (IV to oral loading) which are comparable to the steady state and maximum QTc seen on Day 3 after the last in-hospital oral dose.
75396708|NCT00351000|Drug|Ziprasidone|
75396709|NCT00351936|Drug|Aripiprazole|
75396710|NCT00351936|Drug|placebo|
75870895|NCT02323659|Drug|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
75396711|NCT00352794|Drug|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
75396712|NCT00352794|Drug|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
75396713|NCT04421118|Other|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient based on three-dimensional modeling and fluid dynamics simulation
75870896|NCT02323659|Drug|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
75396714|NCT00353418|Drug|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
75396715|NCT00353418|Drug|Ribavirin|800 mg orally daily for 48 weeks
75547507|NCT06135220|Diagnostic Test|New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.|The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
75547508|NCT06134609|Behavioral|Sexual intercourse|Sexual intercourse without barrier contraceptive at the evening/night after the embryo transfer
75547509|NCT06133621|Other|dosage dRVVT|Blood test dRVVT assay on two tubes of blood in the haemostasis laboratory of the Center de Biologie et de Pathologie Est
75870897|NCT01372527|Other|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
75870898|NCT02358460|Device|Ventilation delivered by SLE5000 ventilator|"In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
75870899|NCT02368834|Behavioral|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
75870900|NCT03634059|Drug|Apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
75870901|NCT02358382|Drug|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
75396716|NCT00353418|Drug|Ribavirin|1000 mg or 1200 mg (based on patient weight of < 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
75396717|NCT00353652|Drug|Study#1: chlorthalidone (CTD), titrated dose|Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP < 130/80 mmHg
75396718|NCT00353652|Drug|Study #1: spironolactone (SP), titrated dose|Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP < 130/80 mmHg.
75396719|NCT00353652|Drug|Study# 2 chlorthalidone (CTD), fixed dose|Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
75396720|NCT00353652|Drug|Study# 2 spironolactone (SP), fixed dose|Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
75396721|NCT00353652|Drug|Study# 2 irbsesartan (IR), fixed dose|Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
75396722|NCT01792362|Other|Weight loss diet|Control the patients diet to make them loosing weight
75396723|NCT03740880|Other|Dual trigger|dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
75396724|NCT02982798|Drug|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
75396725|NCT02982798|Drug|JLP-1310|administration of JLP-1310
75396726|NCT03709914|Drug|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
75396727|NCT03709914|Drug|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
75870902|NCT03633981|Other|clinical examinations|"Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery:~right and left pupillometry (3 times)~BIS values~right and left NIRS values~right and left transcranial Doppler~neurological clinical examination"
75870903|NCT03633981|Other|neurological assessment when a neurological event occurs|"next neurological event:~seizures~pupillary asymmetry~myoclonias~brain stem reflex abnormalities~osteotendinous reflex abnormalities"
75870904|NCT03633981|Other|mortality assessment|to 28 days
75870905|NCT02358304|Drug|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
75870906|NCT02358304|Drug|Placebo|
75870907|NCT02363218|Radiation|CyberKnife|Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
75870908|NCT01319955|Biological|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
75870909|NCT02363530|Device|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
75870910|NCT02363530|Device|BSS|Balanced Salt Solution including normal saline and glucose
76036681|NCT06161714|Drug|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|4% articaine with 1:100,000 epinephrine buccal infiltration
75870911|NCT02363140|Other|Will undergo a single MRI assessment with intravenous dye|
75870912|NCT02363140|Other|pre and post surgery MRI scan|
75547510|NCT06133582|Behavioral|Internet Based Psychodynamic Psychotherapy|"This is a 10-week intervention, delivered on a website called 'Iterapi' which was developed in Sweden. The programme involves creative and interactive web-based content- worksheets, audio, video, expressive writing exercises. Additionally, each participant is assigned a Therapeutic Support Worker (TSW). The TSW logs into the platform and views the questionnaires and other data provided by the participants that they are supporting. Each week, the TSW sends each of their participants a reflective message in response to the data they have provided when interacting with the programme over the last week. The participant can reply to this message.~The principal objective of the iPDT intervention is to reduce depressive symptoms through the promotion of emotional awareness and emotional experience. The intervention is an affect-focused therapy and draws on Malan's Triangle of Conflict (Malan, 1995)."
75870913|NCT02362906|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
76036682|NCT06161714|Drug|Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml|2% Lidocaine with 1:100,000 epinephrine buccal infiltration
76036683|NCT06161701|Other|no intervention|no intervention
76036684|NCT06161688|Drug|Ensitrelvir|Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
75547511|NCT06133439|Behavioral|Colorectal Screen rates with implementation of evidence-based intervention|Mailed FIT kits, Cologuard, and diagnostic colonoscopies.
75547512|NCT06133400|Other|Questionnaire|Questionnaire about socio-demographical status, health status and lifestyle habits
75870914|NCT02362906|Drug|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
76036685|NCT06161688|Other|Placebo|Matching placebo for Ensitrelvir
76036686|NCT06161662|Other|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will be given
75547513|NCT06133400|Other|Physical measurements|Measurement of height, weight, waist circumference, blood pressure and skin pigmentation
75547514|NCT06133400|Other|Biological samples|Collect venous blood, saliva and stool samples
75547515|NCT06133244|Diagnostic Test|Imaging, blood samples, fuctional tests and physical examination|Imaging, blood samples, fuctional tests and physical examination
75547516|NCT06133166|Drug|EG017 ointment|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
76036687|NCT06161662|Other|Control|Electrodes will be attached on the surface of acupoints but no stimulation will be given
76036688|NCT06161623|Behavioral|Laughter Yoga Application|The intervention group took eight sessions of laughter yoga, that is, two sessions per week for 4 weeks. The participants in the intervention group were asked to fill in the data collection tools before the laughter yoga sessions, and after the 4th and 8th yoga sessions.
75547517|NCT06133166|Drug|EG017 ointment placebo|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
76036689|NCT06161610|Device|LITT|The patients in the intervention group will receive LITT, other treatments, including systematic therapy and radiology therapy, would be not restricted except the craniotomy of resection before tumor progression or emergency. The patient is supposed to receive LITT post-randomization within 7 days.
76036690|NCT06161610|Other|Control|The patients in the control group will receive the best medical management under guidelines except LITT before tumor progression. Craniotomy will not be restricted,
75396728|NCT03921840|Behavioral|ELDERFITNESS|"In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps & minutes of moderate activity) using the smartwatch. The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer.~Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans. Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects."
75396729|NCT03921840|Other|Control|General education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
75870915|NCT02362906|Drug|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
75870916|NCT02362906|Drug|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
75396730|NCT01794078|Drug|Aminophylline 400 mg|Xanthine derivative
75396731|NCT01794078|Drug|Ambrisentan 5 mg|Endothelin receptor antagonist
75396732|NCT01794078|Other|Placebo|
75396733|NCT03436680|Other|Best Practice|Receive standard of care
75396734|NCT03436680|Behavioral|Neurofeedback|Complete neurofeedback training sessions
75396735|NCT03436680|Other|Quality-of-Life Assessment|Ancillary studies
75396736|NCT03436680|Other|Questionnaire Administration|Ancillary studies
75396737|NCT01791504|Device|TissuGlu Surgical Adhesive|Standard Wound Closure Techniques Plus TissuGlu and no drains.
75870917|NCT02362906|Drug|second generation cephalosporin|
75870918|NCT02362906|Drug|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
75870919|NCT02362906|Drug|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
75870920|NCT02368912|Drug|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
75870921|NCT02368912|Drug|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
75870922|NCT02368912|Drug|ASP1707 single dose fasted|Oral, healthy young male
75870923|NCT02368912|Drug|ASP1707 single dose fed|Oral, healthy young male
75870924|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
75870925|NCT02368912|Drug|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
75870926|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
75870927|NCT02368912|Drug|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
75870928|NCT02368912|Drug|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
75870929|NCT02368912|Drug|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
75870930|NCT03160144|Procedure|open lung approach|
75396738|NCT00354978|Drug|5-Fluorouracil|"400 mg/m^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m^2 injection."
75396739|NCT00354978|Drug|Bevacizumab|"5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle."
75396740|NCT00354978|Drug|Leucovorin|400 mg/m^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
75396741|NCT00354978|Drug|Irinotecan|180 mg/m^2 by vein over 90 minutes on Day 1 of 14 day cycle.
75396742|NCT01794156|Behavioral|Cognitive behavior therapy|
75396743|NCT01794156|Behavioral|Mindfulness-based stress reduction|
75396744|NCT01794156|Behavioral|Inference-based therapy|
75870931|NCT04059796|Device|Omega Gemini III Rev 2 Device|Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
75870932|NCT04059796|Device|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
75396745|NCT04194060|Combination Product|Enhanced Recovery after Surgery group|"Tracheal intubation and with General anesthesia~Short acting anesthetic agents,avoid opioid agents~Omental patch repair with placement of sub hepatic drain~Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Post operative nausea and vomiting prophylaxis.~Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward~Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~Avoid opiod analgesics."
75870933|NCT02362984|Drug|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
75396746|NCT04194060|Combination Product|Conventional|"Tracheal intubation~Short acting anesthetic agents, avoid opiod anesthesia agents.~Omental patch repair along with sub hepatic drain placement.~Post operative nausea and vomiting prophylaxis.~Ambulation-as per patients' own request.~Initiation of oral feed- after passage of 1st flatus.~Nasogastric tube removal-output <300ml/day with resolution of ileus.~Removal of urinary catheter- when patient sits on bed side/ambulate.~Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~Patient will receive opiod analgesics."
75396747|NCT00355914|Procedure|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
75396748|NCT01792596|Other|Pasta with protein|Pasta with Protein
75396749|NCT01792596|Other|Pasta with Fiber|Pasta with Fiber
75396750|NCT01792596|Other|Pasta|Pasta
75396751|NCT00356304|Behavioral|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
75396752|NCT00356304|Behavioral|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
75396753|NCT03138096|Biological|Pb(PfCS@UIS4)-infected mosquitoes|Pb(PfCS@UIS4)-infected mosquitoes
75547518|NCT06133062|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
75870934|NCT02362984|Drug|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
75396754|NCT03138096|Other|Challenge infection P. falciparum|Challenge infection with bites of five infected Pf mosquitoes
75396755|NCT02855892|Other|Placebo|
75396756|NCT02855892|Drug|GV1001|
75396757|NCT02816580|Other|Blood collection|
75396758|NCT02713854|Procedure|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
75396759|NCT04182516|Drug|NMS-03305293|All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
75396760|NCT00357162|Drug|belinostat|Given IV
75396761|NCT04011072|Radiation|Far infrared radiation|The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
75396762|NCT00358332|Biological|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
75396763|NCT00358332|Biological|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
75870935|NCT02362750|Other|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
75870936|NCT02362750|Other|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
75870937|NCT02362750|Other|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
75396764|NCT01792908|Device|Kinesio tape|The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
75396765|NCT02442414|Drug|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
75396766|NCT01773486|Drug|Hesperidin|Citrus polyphenol, hesperidin
75396767|NCT01773486|Drug|Placebo|Placebo matching hesperidin
75396768|NCT03984240|Drug|Midazolam|Participant will be sedated by midazolam.
75396769|NCT03984240|Drug|Dexmedetomidine|Participant will be sedated by dexmedetomidine.
75558138|NCT03278444|Other|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
75396770|NCT00359736|Drug|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
75396771|NCT00360126|Drug|lamotrigine|
75396772|NCT00360360|Drug|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
75396773|NCT00360360|Drug|carboplatin|Carboplatin AUC 6.0 IV Day 1
75396774|NCT00360360|Drug|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
75396775|NCT00360360|Drug|erlotinib|Erlotinib 150 mg by mouth daily
75396776|NCT01552590|Drug|Tolvaptan|
75396777|NCT01552590|Drug|Placebo|
75396778|NCT01496664|Procedure|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
75396779|NCT01105884|Procedure|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
75396780|NCT01105884|Procedure|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
75870938|NCT02362750|Other|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
75396781|NCT01105884|Procedure|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
75396782|NCT01105884|Procedure|Hydrogel|All the subjects in this group will be treated with Hydrogel
75396783|NCT01105884|Procedure|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
75396784|NCT00549978|Drug|Cilostazol|cilostazol, then cilostazol/probucol
75396785|NCT00549978|Drug|Probucol|Probucol probucol/ cilostazol
75396786|NCT03983226|Procedure|Surgery|Tumor debulking surgery (surgery in recurrent ovarian disease)
75396787|NCT03983226|Drug|carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...|Salvage chemotherapy
75396788|NCT03983226|Drug|Niraparib|Niraparib maintenance therapy
75396789|NCT04346082|Behavioral|online mindfulness group|Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
75396790|NCT00360672|Drug|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
75396791|NCT00360828|Drug|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride [CPT-11; CAMPTOSAR] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
75396792|NCT00360828|Drug|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
75396793|NCT00361140|Drug|Busulfan|"Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs."
75396794|NCT00361140|Drug|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
76036691|NCT06161597|Behavioral|Family Check-Up Online|Families will be provided with access to the FCO program, available in English or Spanish. Parents complete a tutorial and five different modules focused on distinct parenting skills. Each module starts with a survey and feedback to help identify relative strengths and challenges with the targeted parenting skills. Parents are then guided through various online activities including videos that model right and wrong ways to handle comm on situations and explanations of parental self-management and problem-solving strategies. Parents are complete activities to practice the parenting skills taught. Parents will have access to the online program for 8 and they are encouraged to practice the program strategies during this time period. At the end of the 8 weeks, parent re-complete the brief questions that they filled out at the beginning of each module and then receive feedback indicating which of the parent's domain scores have improved since they completed each module.
76036692|NCT06161584|Drug|Pegcetacoplan|Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
75558139|NCT03278444|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
75558140|NCT03278444|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
75558141|NCT00440739|Drug|etoricoxib|etoricoxib 120 mg
75558142|NCT00440739|Drug|flavoxate|flavoxate 200 mg 3 times
75558143|NCT00440739|Drug|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
75558144|NCT00440739|Drug|placebo|placebo once and placebo 3 times
75558145|NCT00443495|Drug|Chitin microparticles by nasal route|
75558146|NCT00478725|Drug|GW786034, oral|oral, 800 mg
75558147|NCT00478725|Drug|GW786034, IV|IV, 5 mg
75558148|NCT00478725|Drug|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
75396795|NCT01794468|Other|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
76036693|NCT06161493|Drug|ZEN003694|A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.
75396796|NCT00361374|Dietary Supplement|eicosapentaenoic acid|1 gram/day
75547519|NCT06133062|Drug|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
75547520|NCT06133062|Radiation|Proton radiotherapy|"72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~66 CGE in 10 fractions for tumors >1 cm from the hepatic hilum, bowel, and heart."
75547521|NCT06130423|Drug|Music intervention|Music therapy carried out with Music Care
75547522|NCT06130423|Drug|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
75547523|NCT06129916|Drug|long-acting depot buprenorphine (LADB)|The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.
75547524|NCT06129682|Other|Self rehabilitation at home|6 week program of exercise at home of gradual intensity and duration
75547525|NCT06128538|Device|Auricular acupuncture|we will implement 12 weeks of BFA. These sessions will be done every other week (total of 6 sessions over 12 weeks). During these sessions, Dr. Quinlan (Co-I) and another BFA-trained provider (Dr. Wilbur or Dr. Butler; also research team members) will perform the group BFA protocol with all 20 participants. During this 12-week acupuncture phase, participants will receive the same SMS messages twice a week to collect pain intensity scores. The group BFA protocol involves taking vitals for all patients (similar to a regular medical visit) and placing all 10 acupuncture needles (5 in each ear) while the patient remains seated in a chair. Once the acupuncture needles are placed, the patient will be asked to move around and remain in the room for 30 minutes (for any questions or medical concerns.
75558149|NCT00443573|Drug|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
75558150|NCT00478764|Drug|intraocular triamcinolone and gatifloxicin|
76036694|NCT06161493|Drug|Niraparib|An anti-cancer medication (PARP inhibitor) used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer .
76036695|NCT06161480|Device|Weighted Blanket|Weighted Blanket is an occupational therapy modality which has been associated with significant increases in grounding, orientation to reality, soothing, and quality of life.
76036696|NCT06161467|Device|Ultrasound devices|Safe , no radiation
75396797|NCT00361374|Dietary Supplement|docosahexaenoic acid|1 gram/day
75396798|NCT00361374|Drug|Placebo|980 milligram/day
75396799|NCT00362466|Drug|Dasatinib|Tablets, Oral, Once daily, 5-7 years
75396800|NCT00362466|Drug|Imatinib|Tablets, Oral, Once daily, 5-7 years
75396801|NCT00305682|Biological|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
75396802|NCT00305682|Drug|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
75396803|NCT00305682|Drug|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
75547526|NCT06128538|Behavioral|Visual Analog Scale for Pain|During the first 12 weeks of the trial, the research manager will collect weekly pain scores using the visual analog scale (pain scale 1-10). During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect pain scores using the visual analog scale at each acupuncture session immediately before and 30 minutes after the acupuncture protocol by the research team, and then twice a week thereafter.
75547527|NCT06128538|Behavioral|Roland-Morris Disability Questionnaire|During the first 12 weeks of the trial, the research manager will collect weekly Roland -Morris Disability questionnaire data. During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect disability scores using the Roland-Morris Disability Questionnaire at each acupuncture session (6 sessions in total).
75547528|NCT06127836|Procedure|ICG guided sentinel lymph node biopsy|The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only. Once the surgeon has identified the SLN in this way, he or she will be unblinded to the results of the lymphoscintigraphy and will use the results of preoperative imaging and an intraoperative gamma counter to confirm the SLNs.
75547529|NCT06127667|Behavioral|aerobic exercise|use of single bout of aerobic exercise
75547530|NCT06127108|Diagnostic Test|Panbio™|The Panbio™ COVID-19/Flu A&B Panel is a visual lateral flow in vitro immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B in anterior nasal swab samples from individuals with symptoms and suspected of COVID-19 or Flu infection by their healthcare provider.
75547531|NCT06124313|Dietary Supplement|Vaginal Probiotic|"This product contains:~Probiotic Blend - 5 Strains Lactobacillus acidophilus Lactobacillus rhamnosus Lactobacillus gasseri Lactobacillus acidophilus (NCFM) Lactobacillus casei"
75396804|NCT00305682|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
75547532|NCT06119867|Procedure|Japanese pathological investigation|Japanese pathological investigation
75547533|NCT06119867|Procedure|European pathological investigation|The European pathology evaluation method involves the analysis of fresh and intact specimens. Pathologists carefully inspect the entire specimen's appearance and assess the surgical resection plane and capture complete photographs for documentation purposes before further sectioning the specimen. During specimen processing, the CRM is initially marked with ink or other markers. After fixation, macroscopic data are recorded, and the entire length of the intestine is cut into cross-sections at intervals of 3-4 millimeters. These sections are then undergoing subsequent systematic pathological examination. However, the surgeon will be involved in the Japanese pathological investigation method. Intraoperative markings will be made 10 cm bilaterally from the primary tumor area. The resected colon will be incised at 1 cm intervals, after which the pericolic lymph nodes will be harvested. Each single retrieved lymph node will be packed up independently and will be examined by the pathologist.
75547534|NCT06119451|Behavioral|Traditional Music Therapy|Intervention using traditional music therapy as an alternative therapy for burnout syndrome
75547535|NCT06114680|Device|CochSyn test prototype|The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.
75547536|NCT06114680|Device|Universal Smart Box (USB)|Commercially available EEG system intended for use in the diagnosis of hearing related disorders, hearing threshold detection, and other conditions that may affect the responses to auditory, tactile, or visual stimuli. The USB Box hardware and accompanying software programs can be used with patients of all ages. It is intended for use by trained personnel in a hospital, nursery, clinic, audiologist's office, or other appropriate setting.
75547537|NCT06114433|Other|3D printed educational model|Slide-based presention plus 3D printed educational model
75547538|NCT06114433|Other|Traditional model education|Slide-based presention plus traditional model
76036697|NCT06160492|Drug|5-aminolevulinic acid|Patients were randomly assigned to 5-aminolevulinic acid (20 mg/kg bodyweight）Those randomly allocated to 5-aminolevulinic acid were scheduled to receive freshly prepared solutions of 5-aminolevulinic acid orally 3 h (range 2-4) before induction of anaesthesia. Solutions were prepared by dissolving the contents of a vial (1·5 g) in 50 mL of drinking water.
75396805|NCT00305682|Procedure|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
75396806|NCT00305682|Radiation|total body irradiation|Administered Day -1, 200 cGy
75396807|NCT00305682|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
75547539|NCT06114186|Device|FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data|using remote monitoring and real-time glucose data sharing with a Follower.
75396808|NCT00305760|Drug|Cetuximab|Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
75396809|NCT00305760|Biological|Pancreatic tumor vaccine|Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
75396810|NCT00305760|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
75396811|NCT00309738|Drug|pitavastatin|
75396812|NCT00309738|Drug|simvastatin|
75396813|NCT00310050|Drug|pemetrexed disodium|500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
75396814|NCT00310050|Device|Radiotherapy|During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
75396815|NCT00363168|Drug|Ranibizumab|0.3 mg/0.05 ml dose
75396816|NCT00363168|Drug|Ranibizumab|0.5 mg/0.05 ml dose
75396817|NCT03723798|Drug|SA001 Low dose|3 tablets b.i.d for 12 weeks
75396818|NCT03723798|Drug|SA001 Mid dose|3 tablets b.i.d for 12 weeks
75396819|NCT03723798|Drug|SA001 High dose|3 tablets b.i.d for 12 weeks
75396820|NCT03723798|Drug|Placebo|3 tablets b.i.d for 12 weeks
75396821|NCT01794546|Behavioral|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
75547540|NCT06114186|Other|standard of care|self reported HbA1C or GMI
75547541|NCT06113679|Device|RDX-19|RD-X19 device with a 5 minute, 32 J/cm2 dose, 2X/day, 7 days. Each treatment at least 6 hours apart.
75547542|NCT06112704|Drug|HS-20093|Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
75547543|NCT06103617|Drug|Penicillamine|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
75547544|NCT06099977|Procedure|Binaural sound|Binaural sound: Binaural sound will be applied.
75396822|NCT00365274|Drug|Cyclophosphamide|Given IV 750 mg/m^2 day 1
75396823|NCT00365274|Drug|Doxorubicin hydrochloride|Given 50 mg/m^2 IV day 1
75396824|NCT00365274|Drug|vincristine sulfate|Given 1.4 mg/m^2 IV
75396825|NCT00365274|Drug|prednisone|100 mg orally daily days 1 - 5
75396826|NCT00365274|Drug|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
75396827|NCT00310362|Behavioral|Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures|Interactive voice response system (IVR) calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
75396828|NCT00311376|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
75396829|NCT00311376|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at > 12 weeks interval
75396830|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
76036698|NCT06159361|Behavioral|Balance targeted exercises|6-week exercise program, 3 sessions per week (2 sessions in person, 1 session of home exercises. Participants will receive a booklet with information about the home exercises and will receive a text message reminder), each session will last 60 minutes.
75547545|NCT06099977|Procedure|Placebo|Only headphone without sound will be applied.
75547546|NCT06096025|Drug|pneumoniae bacteremia therapy|To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.
76036699|NCT06155786|Device|transcranial direct current stimulation (tDCS) active stimulator|In tDCS the electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
75547547|NCT06094426|Biological|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
75547548|NCT06092970|Drug|RBT-1|Intravenous administration
75547549|NCT06092970|Drug|Placebo|Intravenous administration
75547550|NCT06091059|Diagnostic Test|Ultrasound MRI fusion|Fused MRI images with direct ultrasound guidance
75547551|NCT06088784|Drug|ATH-399A|Orally administered drug in capsule form.
75547552|NCT06088784|Drug|Placebo|Orally administered drug in capsule form.
75547553|NCT06085859|Device|Routine nasal catheter group|The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter as described in the guide
75547554|NCT06085859|Device|Mask group|The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
75396831|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at > 12 weeks interval
75396832|NCT03238170|Device|MRI scan|MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
75396833|NCT02104830|Biological|Empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
75396834|NCT02104830|Biological|Filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
75396835|NCT02104830|Biological|Placebo №1|Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
75396836|NCT02104830|Biological|Placebo №2|Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
75396837|NCT02104830|Biological|Empegfilrastim 7.5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
75396838|NCT00311766|Drug|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
75396839|NCT00311766|Drug|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
75396840|NCT00313560|Drug|erlotinib hydrochloride|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
75396841|NCT01791738|Procedure|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
75547555|NCT06083480|Drug|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
75547556|NCT06083480|Drug|Placebo|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
75870939|NCT02362750|Other|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
75396842|NCT00314106|Biological|Melanoma Reactive TIL|
75396843|NCT00314106|Drug|Cyclophosphamide|60 mg/kg/ day x 2 days intravenous
75396844|NCT00314106|Biological|IL-2|720,000 IU/kg/dose every 8 hours for up to 15 doses
75396845|NCT00314106|Drug|Fludarabine|25 mg/m^2/day intravenous x 5 days
75396846|NCT00314106|Radiation|1200 total body irradiation (TBI)|1200 cGY total body radiation
75558151|NCT00440778|Drug|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
75558152|NCT03278405|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
75558153|NCT00440817|Other|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
75396847|NCT00315120|Procedure|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
76036700|NCT06155786|Device|transcranial random noise stimulation (tRNS)|Here, an alternating electrical current is applied at a mix of frequencies it is called transcranial random noise stimulation (tRNS), which can be delivered in low (between 0.1-100 Hz) or high (between 101-640 Hz) frequency stimulation
75396848|NCT00315120|Procedure|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
75396849|NCT00315120|Procedure|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
75396850|NCT00315120|Procedure|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
75396851|NCT00315588|Drug|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
75396852|NCT01793064|Behavioral|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
75396853|NCT01793064|Behavioral|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
75396854|NCT00367380|Other|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
75396855|NCT00367380|Other|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
75396856|NCT00367380|Other|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
75396857|NCT00368316|Biological|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
75396858|NCT00368940|Behavioral|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
75709197|NCT00729716|Procedure|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
76036701|NCT06155786|Device|transcranial direct current stimulation (tDCS) sham stimulator|Here a sham electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
75547557|NCT06083259|Device|Gelatin sponge stabilization with suture and cyanoacrylate|The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
75558154|NCT00443612|Drug|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
76036702|NCT06155773|Procedure|Highly viscous glass ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
76036703|NCT06155773|Procedure|Low shrinkage Flowable Composite (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
75547558|NCT06083259|Procedure|Gelatin sponge stabilization with cyanoacrylate|Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) (test group)
75547559|NCT06080594|Behavioral|High-intensity exercise training|Eight sessions of high-intensity knee extensor exercise are conducted on separate days over a 2-week period.
75547560|NCT06064578|Behavioral|Project SOLVE|Project SOLVE is a ~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
75547561|NCT06060626|Drug|Sedation using only Propofol.|Patients in whom only propofol will be administered during sedation.
76036704|NCT06155773|Procedure|Resin Modified Glass Ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
76036705|NCT06155773|Procedure|Bioactive Ionic Resin (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
76036706|NCT06155721|Device|Virtual Reality Cognitive Stimulation Program|Intervention Type: Device Intervention Name: Virtual Reality Cognitive Stimulation Program Description: This program utilizes virtual reality to conduct cognitive stimulation exercises aimed at improving memory, executive functions, and attention in individuals with Mild Cognitive Impairment (MCI). It includes interactive tasks such as virtual shopping, payment simulations, and recipe sequencing, along with 360-degree video sessions for attention and episodic memory training.
76036707|NCT06155591|Other|Community Nurse Case Manager (CNCM)|"Their action protocol has been designed and sequenced according to the circumstances in which the Complex and Pluripathological Chronic Patient finds themself:~Pre-hospital discharge. The hospital Nurse Case Manager (HNCM) will contact the CNCM to inform of the imminent hospital discharge.~Hospital discharge: A comprehensive nursing assessment of the CPCP based on Marjory Gordon's functional patterns will be carried out.~Planned visits: An infographic will be provided to identify signs and symptoms of decompensation/exacerbation and a direct dial telephone number.~Proactive telephone follow-up: The CNCM will make comfort calls every week for the first month, every 15 days until the 3-months visit and every month until the 6- and 12-months visits.~Exacerbations/decompensations: An appointment will be arranged with their Primary Care physician.~Hospital readmission: The CNCM will be kept informed of the process through the HNCM and CPCP's digital clinical history."
76036708|NCT06154720|Drug|Antibiotics|After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
75547562|NCT06060626|Drug|Sedation using combination of Propofol and Fentanyl.|Patients in whom combination of propofol and fentanyl will be administered during sedation.
75547563|NCT06060613|Biological|OBX-115|"A tumor sample is obtained from each participant for autologous OBX-115 manufacture.~After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by a short course of acetazolamide."
75547564|NCT06059014|Drug|177Lu-PSMA-1 (radiopharmaceutical)|7.4 GBq (or 5.9 GBq in case of lower actvity) of 177Lu-PSMA-1, every 6 weeks for 4 administirations
75547565|NCT06058767|Diagnostic Test|Otoacoustic Emissions Testing|An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.
75547566|NCT06058767|Diagnostic Test|Pure Tone Audiometry|The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
75547567|NCT06055309|Drug|Cannabis (up to three doses)|a dose of cannabis will be baked into brownies
75547568|NCT06053853|Biological|Diphtheria Antitoxin|"Dosage form: Solution for injection~Dosage:~Perform sensitivity tests, and desensitization if necessary.~Give the entire treatment dose of antitoxin IV (or IM) in a single administration (except for series of injections needed for desensitization).~The recommended DAT treatment dosage ranges (pediatric and adult) are:~Pharyngeal or laryngeal disease of 2 days duration 20,000 - 40,000 unit~Nasopharyngeal disease 40,000 - 60,000 unit~Extensive disease of 3 or more days duration, or any patient with diffuse swelling of neck 80,000 - 100,000 unit~Skin lesions only (rare case where treatment is indicated) 20,000 - 40,000 unit"
75547569|NCT06052072|Device|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
75870940|NCT02362750|Other|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
76036709|NCT06154434|Drug|Chlorpromazine HCl 100mg Tablets|single-dose administered after a 10-hour overnight fast.
75547570|NCT06051305|Behavioral|Sensory Training|Participants will use gamified sensory training technology once daily for 8 weeks. This will involve participants completing a 15 minute sensory training session using the provided technology. The tool used in this study has two components. The first is a game that can be downloaded onto any smartphone device. The second component is two tactile devices that can be attached to the body.
75547571|NCT06047509|Procedure|Focal Laser Ablation|Removal of cancerous tissue through the direct application of laser energy
75396859|NCT00368940|Behavioral|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
75396860|NCT00369564|Drug|glutamic acid|Given orally 3 times daily
75396861|NCT00369564|Other|placebo|Given orally 3 times daily
75396862|NCT00315822|Other|80% oxygen|Supplemental oxygen will be administered during surgery
75396863|NCT00315822|Other|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
75547572|NCT06044649|Behavioral|Cognitive Behavioral Therapy|CBT endorses a pain management model and teaches people skills to cope with chronic pain.
75709198|NCT00863200|Behavioral|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
75870941|NCT02362750|Other|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
76036710|NCT06154213|Behavioral|Building Habits Together|"Private, hidden Facebook group Building Habits Together includes 24 weeks on content based on the Diabetes Prevention Program and the Habit app."
75396864|NCT01794624|Behavioral|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
75396865|NCT01794624|Behavioral|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
75396866|NCT00316524|Biological|MVA-BN® (IMVAMUNE)|1x 10E8_TCID50
75396867|NCT00316524|Biological|Placebo|Tris-Buffer
75547573|NCT06044649|Behavioral|Acceptance and Commitment Therapy|ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.
75547574|NCT06044649|Behavioral|Emotional Awareness and Expression Therapy|EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
75547575|NCT06044649|Other|Treatment as Usual|Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.
75547576|NCT06040567|Other|Validity and reliability of outcome measures in polyneuropathy|Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.
75547577|NCT06040567|Other|Healthy controls|Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.
75547578|NCT06038136|Behavioral|Decreased Neuro Checks overnight|If a patient is randomized to the intervention group, the team will discontinue neuro-checks between 8pm and 4am. They will otherwise receive the same care, including overnight vital signs. If the patient has a neurologic or hemodynamic change, the primary team may elect to restart the overnight neuro-checks.
75547579|NCT06037525|Device|PowerGlide™ Pro Midline Catheter|Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease
75709199|NCT00863200|Behavioral|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
76036711|NCT06154213|Behavioral|Getting Healthy Together|"Private, hidden Facebook group Getting Healthy Together includes 24 weeks on content based on the Diabetes Prevention Program and the MyFitnessPal app."
76036712|NCT06154057|Procedure|Dental Implants installed in an grafted area (sinus lifting)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
76036713|NCT06154057|Procedure|Dental Implants installed in an grafted area (ridge augmentation)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
76036714|NCT06154057|Procedure|Dental Implants installed in an grafted area (extraction sites)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
75396868|NCT02994498|Drug|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
75396869|NCT00317226|Drug|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
75396870|NCT05288010|Combination Product|Cannabis|The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
75396871|NCT01793298|Drug|ASM-024|Ascending doses of ASM-024
75396872|NCT02973126|Procedure|FFRct and SPECT|enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
75396873|NCT05287854|Device|Virtual reality headset|Once the patient is on the operating table, the nurse proposes the different possible VR scenarios and installs the RV headset and an audio headset.
75396874|NCT05287776|Device|Narrow band UVB|Narrow band UVB emitting UVB at wavelength 311nm
75547580|NCT06033664|Behavioral|Fresh Funds|Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.
75547581|NCT06033261|Biological|mRNA-1608|Sterile liquid for injection
75547582|NCT06033261|Biological|BEXSERO|A vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B.
75547583|NCT06026228|Dietary Supplement|Limosilactobacillus reuteri|"The BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10^8 CFU*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour.~*Colony forming Unit"
75547584|NCT06026228|Other|Placebo|The placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.
75547585|NCT06020144|Drug|TLL-018|Oral tablets administered 2pieces BID for 52 weeks.
75547586|NCT06020144|Drug|Tofacitinib|Oral tablets administered 1pieces BID for 52 weeks.
75547587|NCT06006858|Biological|Moderna COVID-19 Vaccine|Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
75547588|NCT06006416|Drug|Fenugreek Fibre|Daily dose of 2 x 10g per day with/in food
75547589|NCT06002490|Drug|P1101|"The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms."
75558155|NCT00443612|Drug|Irbesartan|Administration of irbesartan 150 mg/day
76036715|NCT06153836|Procedure|Neurotization Procedure|Undergo placement of nerve graft
76036716|NCT06153836|Other|Questionnaire Administration|Ancillary studies
76036717|NCT06153836|Procedure|Subcutaneous Mastectomy|Undergo standard of care NSM
76036718|NCT06153719|Other|12-weeks combined exercise intervention|This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations
75396875|NCT05287698|Other|Cold vapor|Before surgery, socio-demographic data of the patients, ASA and Mallampati scores, sore throat level, and dysphagia level will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
75547590|NCT06002490|Drug|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
75547591|NCT06002490|Procedure|Phlebotomy|Phlebotomy is performed aiming at a hematocrit < 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
75547592|NCT06000540|Device|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
75547593|NCT06000410|Biological|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
75547594|NCT06000410|Drug|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
75547595|NCT05995275|Biological|mRNA-1769|Sterile liquid for injection
75547596|NCT05995275|Other|Placebo|0.9% sodium chloride injection (normal saline)
75709200|NCT00734760|Behavioral|education|face-to-face education and counseling intervention
75709201|NCT00740324|Drug|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
75396876|NCT01794858|Other|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
75396877|NCT00318708|Drug|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
76036719|NCT06153303|Behavioral|Acceptance and commitment therapy|The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
76036720|NCT06153004|Behavioral|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
76036721|NCT06153004|Drug|Antidepressant medication (ADM)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
76036722|NCT06150612|Behavioral|Unwinding Anxiety|In the Unwinding Anxiety arm, participants will receive 6 weeks of an educational app and weekly facilitated mindfulness groups.
76036723|NCT06150534|Other|No Intervention|This is a non-interventional study.
76036724|NCT06150456|Procedure|extraction|extraction: in all groups, extraction will be performed
75396878|NCT00318708|Drug|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
75396879|NCT00318708|Drug|placebo clarithromycin|placebo clarithromycin twice daily
75396880|NCT00319644|Device|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
75396881|NCT02422446|Drug|Icosapent ethyl|icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
75709202|NCT00740324|Drug|NPO-11|NPO-11 after administration of NPO-11
76036725|NCT06150456|Radiation|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
76036726|NCT06150456|Biological|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
76036727|NCT06147518|Drug|Metformin|Metformin: 1.5g/d CTPA,1g/d CTPB
76036728|NCT06147518|Drug|Sitagliptin|Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c>7%
76036729|NCT06147518|Drug|Dapagliflozin|Assess HbA1c/HBSG at 8 weeks, increase Dapagliflozin to 10 mg if HbA1c>7%
75709203|NCT00740324|Drug|NPO-11|1 mg glucagons after administration of NPO-11
75396882|NCT05287386|Drug|Pemigatinib|The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
75396883|NCT02405676|Drug|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
75396884|NCT02405676|Drug|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
76036730|NCT06145698|Device|Cross-frequency transcranial alternating current stimulation via the Neuroelectrics Starstim 32 transcranial electric stimulation device|Stimulation will be delivered via the Neuroelectrics Starstim 32 transcranial electric stimulation device, an investigational electrical non-invasive brain stimulation device that is being used for clinical and translational research.
75396885|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 60mg/m2, D3~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1;
75396886|NCT02405676|Drug|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
75396887|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 100mg/m2, D3~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
75396888|NCT02405676|Drug|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
75396889|NCT02056704|Device|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
75396890|NCT05287152|Device|titanium tacks or pins|using tacks or pins made of titanium 2.5 mm diameter and 4mm length for free gingival graft fixation.
76036731|NCT06145048|Drug|VGT-309|Intravenous drug to be given over 15-20 minutes by syringe pump.
76036732|NCT06144593|Other|Dietary macronutrient composition|Intermittent carbohydrate restriction
76036733|NCT06143683|Procedure|Early Mobilization|On post-operative day (POD) 1, active range of motion exercises of the elbow joint will be initiated under the observation and guidance of the physical therapy team. On POD 3, the patient will be transitioned to active as well as active-assisted range of motion exercises. The physical therapy team will provide an exercise sheet handout to patients (Appendix 5) and encourage patients to do the exercise for 10 repetitions, 2 times a day, holding each stretch for 30 seconds. On POD3, patients with non-meshed sheet hand grafts will undergo active range of motion exercises of the hands under the observation and guidance of the physical therapy team. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions.
76036734|NCT06143683|Procedure|Late Mobilization|Following surgery, the patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint. From POD 1 to 4, the patient's affected extremity will be kept elevated and immobilized with a flexion blocking splint. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions. The physical therapy team will guide the patient on POD5 through range of motion exercises, starting with active, then active assisted, then passive as tolerated.
75396891|NCT05286840|Diagnostic Test|64Cu-SAR-bisPSMA|Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)
75396892|NCT05286606|Behavioral|Exercise and Social Groups|"Participants in the exercise program, which will include a 2-3 time a week 30-45-minute group exercise programme over a 3-month period, 2 x three months. The intervention consists of a 30-45-minute exercise programme. The exercise programme is created by the Good Boost AI based on pre-registration questions or premade sessions, these are either generic sessions with options of strength, aerobic flexibility and balance/coordination exercise with intensity adjusted according to the user's feedback.~In this program the intervention content is standardised through the Good Boost exercise program. The standard program involves all users to be registered to a single group and to log on to the group, through, zoom, and the facilitator welcomes them. The group then performs the exercise programme they would like to do guided through the app, and afterwards they all meet on a group chat and get peer support."
75396893|NCT04271670|Other|Ginger powder footbaths|20-minute footbath with 12 liters of 40°C warm water and an additive of 80g dried ginger powder (reaching up to mid-calf level)
75870942|NCT02368678|Procedure|Scaling and Root Planning (SRP)|"Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
75709204|NCT00871468|Procedure|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
75396894|NCT04271670|Other|Mustard powder footbaths|20-minute footbath with 12 liters of 40° C warm water and an additive of 80g dried mustard powder (reaching up to mid-calf level)
75396895|NCT04271670|Other|Warm water only footbaths|20-minute footbath with 12 liters of 40° C warm water without any additive (reaching up to mid-calf level)
75396896|NCT04750746|Other|Control group|Conventional Therapy Passive ROM and/or AROM exercises Muscle strengthening; Therapeutics stretching of the shoulder, the elbow, the wrist, and the fingers. Activities of daily living training, including eating, grooming, dressing, toileting, and transfer
75396897|NCT04750746|Other|Experimental Group|Interventional therapy Xbox Kinect (Xbox 360, Microsoft,) For training, programs such as Boxing and Bowling in the Kinect sports pack and Rally Ball, 20,000 Leaks, and Space Pop in the Kinect adventure pack, all of which required the use of the upper extremities, will be selected
76036735|NCT06143059|Drug|Ethanol|Sterile, 95% ethanol will be administered through IV infusion
75396898|NCT04750668|Other|Multisensory Balance Training|Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
75396899|NCT04750590|Procedure|en bloc resection, morcellation|Laser en bloc resection with subsequent tumor morcellation will be performed. This tissue will be sent for histology in order to estimate the histological subtype and differentiation grade. Next stage laser resection of the tumor basis will be performed with subsequent histology to determine the depth of invasion and the status of surgical margin.
75709205|NCT00871468|Procedure|anterior-inferior plate|ORIF clavicle with anterior inferior plate
75396900|NCT04750590|Procedure|piecemeal resection, tissue removal by loop|Tumor piecemeal resection will be performed with electric loop. Then fragments of the tumor will be removed by the loop or Janet's syringe. Fragments from the base of the tumor will be sent separately in order to assess which stage the tumor is at and its surgical margin status.
75396901|NCT04750200|Procedure|Embolization of the Middle Meningeal Artery|EMMA is performed inside of the blood vessels where tiny catheters are used to deliver polymer embolic agents to block small blood vessels supplying the brain coverings. A particulate polymer embolic agent (also called polyvinyl acrylate, PVA) or a liquid embolic agents (polymers of ethynyl vinyl alcohol, EVOH) can be used.
76036736|NCT06143059|Drug|Saline|Saline is administered as the placebo
76036737|NCT06141239|Procedure|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
76036738|NCT06141239|Drug|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration
76036739|NCT06141239|Other|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
76036740|NCT06140108|Drug|Empagliflozin 10 MG|Each participant will receive empagliflozin 10mg daily for 3 months.
75396902|NCT00321594|Drug|belinostat|Given IV
75396903|NCT04751214|Procedure|APPENDICECTOMY|
75709206|NCT00738738|Drug|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
75709207|NCT00735956|Behavioral|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
75709208|NCT04040998|Behavioral|Compensatory Cognitive Training|Teach the participants compensatory cognitive skills and strategies
76036741|NCT06140108|Drug|MetFORMIN 500 Mg Oral Tablet|Each participant will receive metformin 1000mg daily for 3 months.
76036743|NCT06134440|Dietary Supplement|Impact Oral®|All patients will follow low-fiber diet according to ERAS protocol during the study period. Patients assigned to the experimental arm will assume also Impact Oral®, an oral nutritional supplement with immune-nutrients (hyper-proteic formula), manufactured and commercialized by Nestlé Health Science S.p.a. It is a liquid drink packaged in a brick of 237 ml. Patients will assume Impact Oral® for 5 days before surgery and 5 day after surgery.
76036744|NCT06134258|Other|mixed meal test|mixed meal test after fasting
76036745|NCT06132139|Device|VisAR|The study device is a Microsoft HoloLens which uses Novarad's proprietary software and is collectively known as VisAR.
76036746|NCT06128889|Behavioral|Supporting Transition and Resilience to Clinical Nursing Education (STRONG) Program|The STRONG program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher. Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics. Overall, the program will be delivered over in one week lasting six hours.
76036747|NCT06114199|Behavioral|Produce Prescription Program (PPRx) Standard|Participants will receive biweekly deliveries of 20 lbs (~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.
75396904|NCT04751136|Drug|cerebrolysin|Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
76036748|NCT06114199|Behavioral|Smartphone App|Participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.
76036749|NCT06112392|Diagnostic Test|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
76036750|NCT06112392|Diagnostic Test|Treatment （Oral standard anti-Parkinson's drugs）|Treatment （Oral standard anti-Parkinson's drugs）
76036751|NCT06112015|Other|Bulgarian split squat exercise variations|The participants performed 4 different sessions of Bulgarian split squat exercises-Bulgarian split squat with trunk flexion (BSS flexion), Bulgarian Split squat with trunk neutral (BSS neutral), suspension based Bulgarian split squat with trunk flexion (SBSS flexion), suspension based Bulgarian split squat with trunk neutral (SBSS neutral)-with EMG recordings being taken from the dominant extremity throughout each session. For each exercise, participants were instructed to perform three successful repetitions. Between each repetition, there was a 30-second break, and there was at least 10 minutes in between each of the 4 exercises. The movement was standardized by a metronome. The modified Borg scale was used to ensure that fatigue did not occur before each exercise since it was believed that fatigue could affect exercise performance. When scores reported using the modified Borg scale were 1 or lower, exercise recording was started.
76036752|NCT06108154|Behavioral|Educational breastfeeding traning session|Educational breastfeeding training session base on dialogical, visual attractive and training session on Proper LATCH techniques and breastfeeding positions to prevent from nipplesoreness.
76036753|NCT06106009|Drug|PF-07976016|Oral solution, oral suspension or solid oral formulation(s)
75396905|NCT04750980|Other|food allergy|food allergy
75396906|NCT04750980|Other|respiratory allergy|respiratory allergy
76036754|NCT06106009|Drug|Placebo|Oral solution, oral suspension or solid oral formulation(s)
76036755|NCT06106009|Drug|Midazolam|Midazolam oral solution
76036756|NCT06101823|Biological|OpSCF|Monoclonal Antibody
76036757|NCT06101823|Biological|Placebo|Formulation buffer without active agent
75396907|NCT04750980|Other|healthy controls|healthy controls
75709209|NCT05575440|Procedure|Computed Tomography|Undergo a PET/CT scan
75709210|NCT05575440|Radiation|Fluorine F 18 Tetrafluoroborate|Given IV
75709211|NCT05575440|Procedure|Positron Emission Tomography|Undergo a PET/CT scan
76036758|NCT06101823|Biological|OpSCF (Open Label Extension)|Subjects may continue on an Open Label Extension after completing the 16-week randomized portion of the study
76036759|NCT06098729|Behavioral|Digital Exercise|A mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently
76036760|NCT06097312|Other|Data collection|The schedule of office visits and all treatment regimens will be determined by the treating health care provider. No interventions are administered as part of this protocol (observational study).
75396908|NCT00390234|Drug|ziv-aflibercept|Given IV
76036761|NCT06096935|Other|bood sample|Exome measurements
75396909|NCT00391716|Drug|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
75396910|NCT00391716|Behavioral|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
75709212|NCT05575440|Other|Survey Administration|Ancillary studies
76036762|NCT06095401|Other|Inelastic adjustable compression garment (INCOM)|Immediately following surgery, participants randomized to INCOM will wear an inelastic adjustable compression garment set to a minimum of 30mm Hg of compression utilizing a standardized garment tensioning tool. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
76036763|NCT06095401|Other|Elastic compression garment (CONTROL)|Immediately following surgery, participants randomized to CONTROL will wear a thigh-length elastic compression garment (thromboembolism-deterrent [TED] hose) for the first 3 weeks after TKA. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
75396911|NCT00391716|Drug|placebo|lactose capsule compounded to mimic gabapentin capsules
76036764|NCT06087237|Drug|Pentoxifylline|400 mg pentoxifylline oral tablets three times per day starting from the day before surgery till two weeks after the surgery.
75396912|NCT00391716|Drug|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
75396913|NCT00392496|Drug|sunitinib malate|Given orally
75547597|NCT05992376|Behavioral|Food system and demand generation|The Vegetables for All program will create FitFood Zones (FFZs) in low-income estates in urban and peri-urban areas with a minimum of 1,000 households and 10 mama mbogas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will support mama mbogas to source vegetables from Good Agricultural Practices (GAP)-compliant suppliers, support the uptake of digital solutions for mama mbogas to access vegetables, create business-to-business mentorship opportunities, and support county governments to improve market infrastructure. To encourage BoP parents of children 3-11 years to buy and consume more vegetables, the program will include a demand generation component. This will be implemented through a communication campaign, including above-the-line (ATL) activities (mass media such as radio and television), below-the-line (BTL) activities (market activations and others), and FFZ branding.
76036765|NCT06087237|Drug|Placebo|placebo tablets three times per day starting from the day before surgery till two weeks after the surgery.
76036766|NCT06084247|Device|Curved KARL STORZ fetoscope|The KARLZ STORZ curved scope is used to see the inside of a pregnant person's uterus during minimally invasive surgery, similar to conventional scopes. The curved scope is rounded and thought to help visualize the anterior placenta because of its position on the uterus.
75547598|NCT05976165|Other|Breath Testing|Subjects drink a small carbohydrate solution, and then provide a breath sample every 15 minutes for one hour, and then every 30 minutes for the next two hours
76036767|NCT06084247|Device|Conventional Scopes|The conventional scopes are regularly used during laser photocoagulation of placental anastomoses.
76036768|NCT06074315|Device|Nail Genesis DLSO Product|Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).
75396914|NCT01958190|Drug|Tacrolimus and Sirolimus|"Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician"
75396915|NCT01958190|Drug|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
75396916|NCT01571778|Behavioral|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
75547599|NCT05975788|Drug|Staphylococcus and Neisseria Tablets|Staphylococcus and Neisseria tablets is used as an adjuvant treatment drug for respiratory disease in acute attack period, such as chronic tracheitis, bronchitis and various types of colds. It has been proved to effectively shorten the course of disease. In this study, Staphylococcus and Neisseria tablets will be administered with 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months according to clinicians.
76036769|NCT06074315|Device|Nail Genesis DLSO Product (vehicle only)|The Nail Genesis DLSO product poly-urethane vehicle
75396917|NCT04388982|Biological|low dosage MSCs-Exos administrated for nasal drip|Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
75396918|NCT04388982|Biological|mild dosage MSCs-Exos administrated for nasal drip|Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
75396919|NCT04388982|Biological|high dosage MSCs-Exos administrated for nasal drip|Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
76036770|NCT06072664|Behavioral|Caloric Compensation Index (COMPX)|Researcher gives child opportunity to consume high- and low-calorie preloads and then free access to a palatable snack
76036771|NCT06072651|Behavioral|Relative Reinforcing Value of Food|Researcher gives child opportunity to press a button to earn three types of rewards: a high-reward food, a low-reward food, and a non-food reward.
76036772|NCT06072638|Behavioral|Eating in Absence of Hunger|Researcher gives child free access to palatable foods following a satiating meal.
76036773|NCT06070090|Procedure|Acupuncture|The traditional East Asian methods of treating disease by inserting needles along specific pathways or meridians.
76036774|NCT06067958|Drug|Dexmedetomidine|Intranasal administration of dexmedetomidine will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
76036775|NCT06067958|Drug|Saline|Intranasal administration of saline 0.9% will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
76036776|NCT06062511|Dietary Supplement|ESIT12 D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12
76036777|NCT06062511|Dietary Supplement|ESIT12 4D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12
75396920|NCT05286216|Behavioral|effectiveness of education|"The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools."
75396921|NCT00638898|Drug|busulfan|Given IV
75396922|NCT00638898|Drug|melphalan|Given IV
75396923|NCT00638898|Drug|topotecan hydrochloride|Given IV
75396924|NCT00638898|Other|laboratory biomarker analysis|Correlative studies
75396925|NCT00638898|Biological|filgrastim|Given IV or subcutaneously
75396926|NCT00638898|Procedure|autologous hematopoietic stem cell transplantation|Undergo transplantation
75396927|NCT00638898|Other|pharmacological study|Correlative studies
75547600|NCT05975476|Behavioral|Physical Activity|Participants will be asked to continuously move at a moderate pace along a park trail for 30 minutes, with limited rest periods. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
76036778|NCT06062511|Dietary Supplement|Placebo|Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix
76036779|NCT06055231|Behavioral|Vape device|Consume THC via vape defice
76036780|NCT06055231|Behavioral|Joint|Consume THC via joint
76036781|NCT06055231|Drug|Marijuana via vape device|Given via vape device
76036782|NCT06055231|Drug|Marijuana via joint|Given via joint
75396928|NCT00638898|Procedure|autologous bone marrow transplantation|Undergo transplantation
75396929|NCT01793454|Other|Fraction of inspired oxygen 40%|
75396930|NCT01793454|Other|Fraction of inspired oxygen 80%|
75396931|NCT00393978|Drug|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
75709213|NCT00863278|Procedure|pulsed dye laser treatment|On one side of the face according to Arm placement.
75396932|NCT00393978|Drug|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
75396933|NCT00396006|Biological|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
75396934|NCT00397020|Drug|divalproex ER|Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
75396935|NCT00397020|Drug|quetiapine|Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
75396936|NCT00371436|Procedure|Progressive Audiologic Tinnitus Management|The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
76036783|NCT06048237|Diagnostic Test|Diagnostic Ultrasound Imaging of the diaphragm|"In this reliability study, ultrasound imaging will be utilized by trained physiotherapists to assess diaphragm thickness and excursion. Participants will be positioned in a semi-recumbent position, while the scanning area will be marked with a surgical skin marker according to specific anatomical landmarks recommended, to ensure reproducibility of the procedure. Ultrasound probe will be placed at the zone of apposition to visualize the diaphragm through the liver window.~Diaphragm thickness will be assessed during both full inhalation and exhalation, capturing images in B-mode to measure distance between the diaphragmatic pleura and peritoneal fascia. Diaphragm excursion will be assessed during tidal volume diaphragmatic breathing, using M-mode to track the craniocaudal displacement of the diaphragm during respiratory cycle. Data obtained will contribute to the evaluation of the reliability of diaphragm thickness and excursion measurements for potential future clinical applications."
75396937|NCT00371436|Procedure|Usual Care|Typical audiologic care that would be received in a VA Audiology Clinic.
75396938|NCT00397878|Drug|saracatinib|Given orally
75396939|NCT00397878|Other|laboratory biomarker analysis|Correlative studies
75396940|NCT00400686|Biological|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
75396941|NCT05215938|Diagnostic Test|MRI examination|"The magnetic resonance imaging session will be performed in a clinical 3T MRI scanner (GE healthcare). A commercial human intent non-diagnostic RF coil (PulseTeq) will be used for 23Na MRI.~The scanner, coils and sequences are regularly used in research projects and validated for the same safety requirements as routinely used in the clinic. Nevertheless, the complete MRI session will be performed in research mode to use the advanced options (limits the usage to non-diagnostic purposes).~Participants will be placed in a supine position with coils covering the area of interest (AOF).~MRI examination will be performed by trained personnel."
75396942|NCT00373386|Drug|growth hormone|Growth Hormone treatment
75396943|NCT05154552|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.
75547601|NCT05975476|Behavioral|Sensory Engagement|Participants will be asked to stay within a specific area of the park, relax and enjoy the scenery and engage their senses (see, touch, smell, and listen to nature). In addition, the participant will be told they can engage in meditation, mindfulness, and daydreaming. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
75547602|NCT05971888|Behavioral|Food system and demand generation|GAIN's program to increase dairy consumption among BoP children and workers will include components to increase demand, improve access, and support the enabling environment. In Amhara, the demand generation component will share messages through radio, community influencers, and community conversations led by health extension workers targeting rural BoP households with children 6 months up to 7 years. GAIN will train milk houses and cooperatives on dairy safety and quality assurance and better business practices and will assist with cold chain and milk dispensing technology to improve milk availability and access. In industries and large-scale farms, GAIN will use a demand generation strategy to inform workers about the importance of dairy products and other nutritious foods and to encourage them to purchase them at their workplaces. GAIN will work with local businesses to launch and maintain dairy dispensers and arrange provision of other nutritious foods at work sites.
75547603|NCT05969795|Diagnostic Test|Transvaginal ultrasound|Intermittent transvaginal ultrasound throughout the cycle to monitor follicular growth
75709214|NCT00863278|Drug|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
75709215|NCT00740558|Procedure|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
75709216|NCT00740558|Procedure|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
75709217|NCT03784924|Diagnostic Test|MRI prostate|MRI and laboratory biomarkers
76036784|NCT06048094|Drug|18F fluciclovine|Participants will receive 5-mCi dose (± 20%) of 18F-fluciclovine intravenously as a bolus injection immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
76036785|NCT06034236|Other|Resistance training|"Task oriented resistance training will be performed, there will be 10 workstations:~Sitting at a table and reaching in different directions for objects located beyond arm's length.~Sit to stand from various chair heights~Stepping forward, backward and sideways onto blocks of various heights.~Heel lifts in standing~Standing with narrow base of support, feet in parallel and tandem stance and reaching for objects, including down to the floor.~Reciprocal leg flexion and extension.~Sit ups~Standing up from chair, walking a short distance and returning to the chair.~Walking races between participants~Walking over various surfaces and obstacles"
75396944|NCT05154552|Other|Routine physical therapy|"Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
75396945|NCT01796574|Dietary Supplement|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
75547604|NCT05969795|Diagnostic Test|Serial serum LH, E2, P4|Serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4 )levels throughout the cycle to determine ovulation. LH-surge is identified when a rise of 180% above the previous level occurred and ovulation is confirmed with a decrease in E2 concentration, and a rise of progesterone level to ≥ 1.0 ng/ml (Irani et al., 2017).
75547605|NCT05969795|Drug|Progesterone 100 Mg Vaginal Insert|On day of ET procedure, to administer 200 mg of vaginal progesterone and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy
75547606|NCT05969795|Diagnostic Test|Serum P4 day of ET - Control Group|Serum P4 will be drawn before starting LPS in form of vaginal progesterone on the day of ET procedure
75547607|NCT05969795|Diagnostic Test|Serum P4 day of ET - Study Group|Serum P4 will be drawn when study group participants are admitted to the clinic for the ET procedure.
75547608|NCT05969795|Procedure|Embryo transfer|The procedure in which embryo is placed in the uterus.
75547609|NCT05969795|Diagnostic Test|Serum hCG 10 days after ET|Pregnancy will be confirmed / excluded by measurement of serum hCG 10 days after ET procedure and a level of > 15 IU will be regarded as positive result. The definitions of biochemical, ectopic, clinical and ongoing pregnancy follow the ICMART criteria (Zegers-Hochschild, 2006)
75547610|NCT05969795|Diagnostic Test|Serum P4 10 days after ET|Serum P4 will be drawn on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure
75396946|NCT01795404|Behavioral|Inquiry Based Stress Reduction (IBSR)|
75709218|NCT00729794|Drug|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
75396947|NCT04271124|Other|exercise training|The patients are allocated to PR+ET group or PR Each group receive an exercise training
75396948|NCT00373698|Behavioral|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
75396949|NCT00374088|Drug|N-acetylcysteine|"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."
75396950|NCT00374088|Drug|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
75396951|NCT00401622|Behavioral|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
75396952|NCT00401622|Behavioral|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
75396953|NCT04270890|Device|Abdominal compression belt system|"The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position."
75396954|NCT00374244|Drug|Pimozide|half of the subjects are randomized to the active drug group
76036786|NCT06034236|Other|Otago Exercises|"It has total 17 exercises, out of which 12 exercises are performed to improve balance and 5 are performed to improve strength.~1. First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~2. Second component is muscle strengthening exercises, it includes: i. Front knee strengthening exercise ii. Back knee strengthening exercise iii. Side hip strengthening exercise iv. Calf raises (with support and without support) v. Toe raise (with support and without support). 3. Third component is balance exercises, it includes: i. Knee bends ii. Backward walking iii. Heel toe standing iv. Heel toe walking v. One leg stand vi. Heel walking vii. Sideways walk viii. Toe walking ix. Heel toe walking backwards x. Walk and turn around (figure of 8) xi. Sit to stand xii. Stair walks"
76036787|NCT06034223|Other|Proprioceptive training using head mounted laser|Exercises include head relocation practice, i.e., relocating the head back to the natural head posture and to pre-determined positions in range with eyes open using feedback from a laser attached to their head. And then tracing the figure of eight with the help of laser.
76036788|NCT06034223|Other|Conventional Physical therpay|Conventional physical therapy for mechanical neck pain which includes cervical range of motion (flexion, extension, lateral rotation, and rotation), neck isometric exercises, stretching's (scalene, trapezius, SCM) and TENS with heating pad.
76036789|NCT06033872|Combination Product|Focused education, medication adjustment and telemonitoring|"Focused diabetes education session for Ramadan fasting~Participants will be taught to record~Meal plans~Physical activities~Blood glucose monitoring, and~Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software."
75396955|NCT00374244|Drug|placebo|half of the subjects are randomized to placebo group
75709219|NCT00729794|Drug|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
75709220|NCT00871546|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
75396956|NCT04270812|Behavioral|Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)|"TranS-C adopts a modular approach to reversing the psychosocial, behavioral, and cognitive processes maintaining sleep problems via 4 cross-cutting modules (introduced in the first session and included in every session thereafter), 4 core modules and 7 optional modules. TranS-C typically involves 6-8 individual, weekly 50-minute sessions."
75396957|NCT00377832|Drug|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
75396958|NCT00401778|Drug|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
75396959|NCT00402714|Procedure|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
75396960|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
75396961|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
75396962|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
75396963|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
75396964|NCT00405288|Drug|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
75709221|NCT00871546|Drug|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
75396965|NCT00458406|Device|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months"
75396966|NCT00458406|Device|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months."
75396967|NCT00381810|Drug|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
75396968|NCT00381810|Drug|Methylprednisolone|
75396969|NCT00381810|Drug|Acetaminophen|
75396970|NCT00381810|Drug|Diphenhydramine|
75396971|NCT00458952|Drug|Ultratrace Iobenguane (MIBG) I 131|Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
75396972|NCT00459732|Dietary Supplement|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
75709222|NCT00871546|Biological|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
76036790|NCT06033157|Behavioral|Physiotherapist supervised training|"A 12 week physiotherapist supervised training program. The patient will receive supervision by a physiotherapist 6 times during the intervention period.~The patient is strongly encouraged to do the assigned training protocol at home 3 times a week. The supervised physiotherapy consists of introduction, review and progression of the assigned exercises. In addition, the patient will receive education and guidance in daily use of the arm and appropriate load on the shoulder."
75870943|NCT02368678|Procedure|Full Mouth Scaling (FMS)|"Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
75396973|NCT00459732|Dietary Supplement|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
75396974|NCT00459810|Drug|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
75396975|NCT00459810|Drug|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
75396976|NCT00405522|Drug|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
75396977|NCT00405522|Drug|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
75396978|NCT00381966|Device|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
75396979|NCT00461292|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection > Week 12; injections into detrusor
75396980|NCT00461292|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
75396981|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection > 12 weeks; injections into detrusor
75396982|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
75396983|NCT00382590|Drug|5-Azacytidine|75 mg/m^2 daily for 7 days (days 1-7) via subcutaneous injection.
75396984|NCT00382590|Drug|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
75709223|NCT00732186|Biological|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
75870944|NCT02358226|Behavioral|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
75870945|NCT02358226|Behavioral|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
76036791|NCT06022159|Procedure|Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior to surgery.|"Early post-radiotherapy toxicity will then be assessed 1 month after the end of radiotherapy.~Post-operative follow-up: post-operative complications will be followed at 3 and 6 weeks post-surgery.~A visit at 6 months post-surgery will also be carried out to evaluate post-operative complications and late adverse effects of radiotherapy.~Long-term follow-up would also be performed every 6 months from the 6-month post-surgery visit up to 3 years post-surgery (M12, M18, M24, M30 and M36)."
75396985|NCT00382590|Drug|Valproic Acid (VPA)|50 mg/m^2 orally daily days 1-7.
75396986|NCT00382824|Dietary Supplement|Coenzyme Q10|active drug
75396987|NCT00382824|Other|Placebo|Placebo
75396988|NCT00462072|Drug|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
75396989|NCT00462228|Drug|Memantine|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
75709224|NCT04064996|Other|Routine rehabilitation program patient education|"Patient education~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS), hand-held dynamometer, range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test, circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
75709225|NCT04064996|Other|Routine rehabilitation program + foot exercise training|"In addition to the patient education , foot exercise training will be performed. Patients will be applied exercise training consisted of aerobic, strengthening, sensory training and stretching exercises for 3 days/week, 8 weeks.~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) ,hand-held dynamometer,range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test,circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
75396990|NCT00462228|Drug|Placebo|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
75396991|NCT00408564|Biological|cetuximab|
75396992|NCT00408564|Drug|capecitabine|
75396993|NCT00408564|Drug|oxaliplatin|
75396994|NCT00408564|Procedure|conventional surgery|
75396995|NCT00408564|Radiation|radiation therapy|
75396996|NCT00408564|Drug|Gemcitabine|
75396997|NCT02110758|Other|Pilot of Patient-Centered Oncology Care|Patient-Centered Oncology Care addresses six domains: track & coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track & coordinate care, and measure and improve performance.
75396998|NCT02111772|Biological|Rhinovirus|
75396999|NCT00383448|Drug|Clofarabine|days -7 through -3: 40 mg/m^2 intravenously over 2 hours
75397000|NCT00383448|Procedure|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
75397001|NCT00383448|Drug|Melphalan|day -2: 140 mg/m^2 intravenously over 30 minutes
75397002|NCT00383448|Biological|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
75397003|NCT00383448|Drug|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
75397004|NCT00383448|Drug|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR<25 mL/minute corrected)
75547611|NCT05966220|Device|Hip surgery with FH Ortho devices|"This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons."
75547612|NCT05965817|Drug|SGM-101 op top of ICG|SGM-101 op top of ICG
75547613|NCT05961189|Drug|Azithromycin|Standard of care, 5 days of drug per manufacturer's instructions.
76036792|NCT06022159|Procedure|Patient will undergo surgery before receive the adjuvant hypofractionated radiation therapy (40 Gy in 15 fractions).|"Post-operative follow-up: postoperative complications will be followed at 3 and 6 weeks post-surgery (before the start of irradiation). Early post-radiotherapy toxicity will then be assessed 1 month after the end of radiotherapy.~A 6-month post-surgery check-up will also be carried out to assess post-operative complications and acute side effects of radiotherapy.~Long-term follow-up would also be performed every 6 months from the 6-month post-surgery visit up to 3 years post-surgery (M12, M18, M24, M30 and M36)."
75397005|NCT00383448|Device|Cyclosporine A|"Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).~CsA taper begins at day +100."
75397006|NCT00383448|Drug|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
75547614|NCT05957081|Drug|PMC-309 monotherapy|PMC-309 will be administered intravenously.
75547615|NCT05957081|Drug|PMC-309 Dose Escalation in Combination with Pembrolizumab|Both PMC-309 and pembrolizumab will be administered intravenously. At the time of the combination therapy (Week 1/Day 1 of each cycle), participants will be dosed with pembrolizumab first, administered over 0.5 hours (± 10 minutes). Following an interval of 1 hour (± 15 minutes), participants will be dosed with PMC-309 administered over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.
75547616|NCT05957081|Drug|PMC-309 Dose Expansion|"Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts:~Cohort A: PMC-309 monotherapy therapy~- PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab"
76036793|NCT06016829|Diagnostic Test|Nutrition Risk Screening 2002 (NRS-2002)|Nutritional status assessment tool
75397007|NCT00383760|Drug|eribulin mesylate|Given IV
75870946|NCT02368600|Behavioral|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
76036794|NCT06016829|Diagnostic Test|Global Leadership Initiative on Malnutrition (GLIM)|Nutritional status assessment tool
76036795|NCT06016829|Other|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
76036796|NCT06016829|Diagnostic Test|Dietary inflammatory index (DII)|The Dietary Inflammatory Index (DII) is a scoring algorithm that indicates the inflammatory potential of the diet.
75397008|NCT00384774|Drug|Lasmiditan|Administered as intravenous infusion
76036797|NCT06016829|Diagnostic Test|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Quality of life assessment tool
76036798|NCT06016829|Diagnostic Test|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer 29 (EORTC-QLQ-CR29)|Quality of life assessment tool
76036799|NCT06016829|Diagnostic Test|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
76036800|NCT06016829|Diagnostic Test|Neutrophil-Lymphocyte Ratio (NLR)|The neutrophil-to-lymphocyte ratio (NLR) is calculated as the simple ratio between neutrophil and lymphocyte counts.
75397009|NCT00384774|Drug|Placebo|Administered as intravenous infusion
75397010|NCT00410280|Biological|IMA-638 is a biologic|
75397011|NCT00410826|Drug|erlotinib hydrochloride|Given orally
75709226|NCT00729872|Biological|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
75870947|NCT03085914|Drug|Epacadostat|Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.
75870948|NCT03085914|Drug|Pembrolizumab|Pembrolizumab
76036801|NCT06014307|Behavioral|Diet order: PBMA, Animal|Participants will follow the PBMA, and Animal diets (in this order) for 4-6 weeks each.
76036802|NCT06014307|Behavioral|Diet order: Animal, PBMA|Participants will follow the Animal, and PBMA diets (in this order) for 4-6 weeks each.
76036803|NCT06004752|Drug|Ciclosporin|Cyclosporine was taken orally at 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml
76036804|NCT06004752|Drug|Avatrombopag|Avatrombopag was administrated at 40 mg/d and increased by 20 mg/d during the biweekly follow-up if platelet was not 20 × 109/L higher than baseline. AVA dose was gradually reduced if PLT ≥ 150 × 109/L. The maximum dose was 60 mg/d, while the minimum was 20 mg/week.
76036805|NCT06003764|Other|Pulsed electromagnetic field|low-frequency PEMFT (15 Hz, 50% intensity output for 5 s/min for 20 minutes)
75397012|NCT00410826|Drug|cisplatin|Given IV
75397013|NCT00410826|Radiation|3-dimensional conformal radiation therapy|35 fractions
75397014|NCT00410826|Radiation|intensity-modulated radiation therapy|35 fractions
75397015|NCT00410826|Procedure|quality-of-life assessment|Ancillary studies
75397016|NCT00464646|Drug|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
75397017|NCT00464646|Drug|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
75397018|NCT00464646|Drug|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
75870949|NCT03085914|Drug|Oxaliplatin|Oxaliplatin
75870950|NCT03085914|Drug|Leucovorin|Leucovorin
75870951|NCT03085914|Drug|5-Fluorouracil|5-Fluorouracil
75870952|NCT03085914|Drug|Gemcitabine|Gemcitabine
75870953|NCT03085914|Drug|nab-Paclitaxel|nab-Paclitaxel
75870954|NCT03085914|Drug|Carboplatin|Carboplatin
75397019|NCT00464646|Drug|Trastuzumab|"Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses"
76036806|NCT06003764|Other|traditional skin care|traditional skin care( the patients will receive the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing will be used. Additionally, the patient will be advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing
75397020|NCT00464646|Drug|Bevacizumab|"Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses"
75397021|NCT00385008|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
75547617|NCT05953753|Behavioral|Food system and demand generation|The project is focused on improving egg consumption through enhanced availability, accessibility, and improved demand. To achieve this goal, the project intervention mix will work through three pathways: access, enabling environment, and demand. The access pathway aims to sustain availability and consumption of eggs by school children (age 6-9 years) from BoP households through interventions targeted at the Poultry Association of Nigeria (PAN) and state lead egg aggregators for the HGSFP. The enabling environment pathway focuses on the broader institutional, governance, and political factors to support accessibility, availability, improved consumption, and increased consumer demand for eggs. The demand pathway will be addressed by mass media and interpersonal communication to increase the willingness and motivation of parents/caregivers in BoP households to support and sustain egg consumption by pre-school children in Kaduna State.
75397022|NCT00385008|Drug|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
75397023|NCT00466206|Device|Magnetic Mini-Mover Procedure (3MP)|"A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.~A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.~In another outpatient procedure, the Magnimplant is explanted 18 months after implantation."
75397024|NCT00466206|Device|Magnatract (external magnet in a removable external brace)|"An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed."
75397025|NCT00466206|Procedure|3MP (Magnetic Mini-Mover Procedure)|"Subject has EKG performed to measure baseline cardiac activity.~Magnimplant is implanted.~After one week, Magnatract is fitted.~Chest x-ray and 2nd EKG performed 30 days post-implantation.~Patient and parents complete QoL questionnaire 30d post-implantation.~Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.~At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.~At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.~Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.~CT scan and third EKG performed after explanation.~Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation."
75397026|NCT00410904|Drug|cediranib maleate|
75397027|NCT00410904|Drug|pemetrexed disodium|
75397028|NCT00385788|Drug|Gemcitabine|800 mg/m^2 IV over 30 minutes on Day -7 (1 day)
75397029|NCT00385788|Drug|Fludarabine|33 mg/m^2 IV over 30 minutes Day -5 to Day -2 (4 days)
75547618|NCT05953064|Other|DHA-NAT|Endogenous metabolite of omega-3 fatty acid docosahexaenoic acid
75547619|NCT05953064|Other|Placebo|Vehicle control (H2O) for the intervention used in the experimental arm (DHA-NAT).
75547620|NCT05935436|Device|Cardiac Shock Wave Therapy|When operating CSWT, it is necessary to determine the target myocardium for treatment, adjust the height of the water bladder, set the energy that the patient can tolerate, and then start the treatment. During the treatment, the vital signs of the subjects should be detected.
75709227|NCT00729872|Other|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
75397030|NCT00385788|Drug|Melphalan|70 mg/m^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
75397031|NCT00385788|Drug|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
75397032|NCT00385788|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
75397033|NCT00385788|Drug|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
75397034|NCT00385788|Drug|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
75547621|NCT05935384|Diagnostic Test|Guardant360|Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
75547622|NCT05931302|Diagnostic Test|68Ga-FAPI-46 PET scan|"68Ga-FAPI-46 is a radiotracer for the detection of Fibroblast Activation Protein (FAP) in cancer patients.~68Ga-FAPI-46 will be administered intravenously at a dose of 2MBq/kg. Patients will be scanned 60 minutes after administration of 68Ga-FAPI-46."
75547623|NCT05923866|Drug|ONO-2808|Oral administration of ONO-2808 at low, middle or high doses once a daily for 24 weeks
75547624|NCT05923866|Drug|Placebo|Oral administration of placebo once a daily for 24 weeks
75397035|NCT00385788|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
76036807|NCT06002581|Device|rTMS real stimulation stage1|In the first stage, the early treatment group use low-frequency rTMS real stimulation,
75397036|NCT00411684|Drug|CDB-2914|
75397037|NCT00386256|Device|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
75397038|NCT00386256|Other|Telephone counseling|
75397039|NCT00412074|Drug|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
75397040|NCT00412074|Drug|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
75397041|NCT00412074|Drug|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
75397042|NCT00412464|Drug|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
75397043|NCT00466752|Drug|sorafenib tosylate|Given PO
75397044|NCT00466752|Genetic|microarray analysis|Correlative studies
75547625|NCT05921760|Drug|Ivosidenib|ivosidenib taken once daily
75397045|NCT00466752|Other|immunohistochemistry staining method|Correlative studies
75397046|NCT00466752|Genetic|gene expression analysis|Correlative studies
75397047|NCT00466752|Procedure|needle biopsy|Correlative studies
75397048|NCT00466752|Procedure|therapeutic conventional surgery|Undergo prostatectomy
75397049|NCT00466752|Other|laboratory biomarker analysis|Correlative studies
75397050|NCT00466752|Genetic|western blotting|Correlative studies
75397051|NCT00466752|Genetic|RNA analysis|Correlative studies
75397052|NCT02115750|Drug|Etanercept|Head-to-head comparison
75397053|NCT02115750|Drug|CHS-0214|
75397054|NCT02115828|Drug|Vismodegib|
75397055|NCT02115984|Drug|Panagen|
75397056|NCT02115984|Drug|Placebo|
75397057|NCT02115984|Procedure|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
75397058|NCT00413166|Drug|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
75397059|NCT00413166|Drug|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
75397060|NCT00413166|Drug|Idarubicin|"12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
75397061|NCT00413166|Drug|Gemtuzumab Ozogamicin|Induction: 9 mg/m2 on day 1 of induction
75397062|NCT00386880|Other|Sounds|
75547626|NCT05921760|Drug|Recommended Combination Dose (RCD) of ivosidenib|The RCD of ivosidenib taken once daily
76036808|NCT06002581|Device|rTMS shame stimulation stage1|In the first stage, the control group (delayed treatment group) all use sham stimulation.
75397063|NCT00413400|Drug|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
75397064|NCT00413400|Drug|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
75397065|NCT00413478|Drug|5-Azacytidine|Starting dose level: 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
75397066|NCT00413634|Drug|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
75397067|NCT00413634|Drug|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
75397068|NCT00467298|Behavioral|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
75397069|NCT00467298|Behavioral|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
75547627|NCT05921760|Drug|Nivolumab|Nivolumab taken by intravenous infusion
75547628|NCT05921760|Drug|Ipilimumab|Ipilimumab taken by intravenous infusion
75547629|NCT05918055|Drug|KPT-8602|5-10 mg PO daily for 10-14 days based on dose level
75709228|NCT04039828|Drug|Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)|Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for > 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
75709229|NCT00876772|Drug|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
76036809|NCT06002581|Device|rTMS real stimulation stage 2|In the second stage, both the early treatment group and the control group (delayed treatment group) will be treated with true stimulation low-frequency rTMS.
75397070|NCT00467298|Behavioral|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
76036810|NCT05998239|Other|Bootle Boot Camp Home Exercise App - with Virtual Coach Botley|Bootle Boot Camp exercise sessions offered with movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the no feedback condition for a period of 4 weeks (4 sessions/week). Movement feedback will be guided by skeletal data captured by the 3D motion tracking camera and based on predefined movement acceptability criteria for each exercise. Feedback will take the form of visual markers, text/audio cues and rewards.
75397071|NCT00467844|Drug|GTx-024|1 mg GTx 024
75397072|NCT00467844|Drug|GTx-024|3 mg GTx-024
75397073|NCT00467844|Drug|Placebo|Matching Placebo
75397074|NCT00387036|Drug|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
75397075|NCT00387036|Drug|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
75397076|NCT04388592|Other|Nurse Practitioner (NP) Led Care Arm|The NP will conduct baseline consultation visits with the participants and their caregivers (if applicable). They will then initiate treatment for the participant's symptoms as appropriate (ie: depression treatment for depressive symptoms, fatigue management strategies), connect to resources in the community as needed (ie: rehabilitation programs, home care support, psychologist support) to optimize functioning. There will be scheduled follow visits and/or phone calls with the NP at 3 and 6 months.
75397077|NCT00470106|Behavioral|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
75397078|NCT00470106|Behavioral|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
75397079|NCT00470106|Behavioral|hybrid intervention|A combination of the two groups listed above.
75397080|NCT00470106|Behavioral|skills training|Skills training in how to identify symptoms of illness and medication side effects.
75397081|NCT00387660|Drug|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
75397082|NCT00387660|Drug|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
75547630|NCT05918055|Drug|Inqovi|Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.
75709230|NCT00729950|Biological|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
75709231|NCT00616018|Drug|acetaminophen|4 g/day for 10 consecutive days
75397083|NCT00472056|Drug|Carmustine|300 mg/m^2 IV for 1 Day
75397084|NCT00472056|Drug|Etoposide|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
75397085|NCT00472056|Drug|Cytarabine|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
76036811|NCT05998239|Other|Bootle Boot Camp Home Exercise App - without Virtual Coach Botley|Bootle Boot Camp exercise sessions offered without movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the movement tracking feedback condition for a period of 4 weeks (4 sessions/week).
75397086|NCT00472056|Drug|Melphalan|140 mg/m^2 IV x 1 Day
75397087|NCT00472056|Drug|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion.
75397088|NCT00415506|Drug|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
75397089|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
75397090|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
75397091|NCT01795092|Other|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
75397092|NCT00475878|Drug|escitalopram|10mg escitalopram/day for 3 months
75397093|NCT00475878|Drug|placebo|placebo capsule/day for 3 months
75397094|NCT01795170|Dietary Supplement|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) [23,24], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
75397095|NCT01795170|Drug|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
75709232|NCT04064970|Behavioral|patient acceptable symptom state (PASS)|The Severity Index for Urinary Incontinence, which documents incontinence frequency and severity, pelvic floor distress, patient global impression of severity and improvement, physical function, depression, sleep disturbance, anxiety, global health and ability to participate in social roles and activities.
75709233|NCT00740948|Drug|Rituximab (mabthera) Injection|2 * 1g of Rituximab at the 1st day and at the 14th day.
76036812|NCT05996341|Device|blood flow restriction|12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg
76036813|NCT05987124|Drug|Defibrotide|HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
76036814|NCT05986682|Drug|Blenrep|Belantamab Mafodotin - blmf (BLENREP) given for the treatment of relapsed and/or refractory multiple myeloma.
76036815|NCT05971602|Drug|Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)|D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
76036816|NCT05971602|Drug|Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)|P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
76036817|NCT05971602|Drug|Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)|Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care [SOC]). All the doses administered will be weight-based.
76036818|NCT05971602|Drug|Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)|X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration
75397096|NCT01796886|Other|pupillometry data|
75397097|NCT00477204|Drug|Simvastatin|simvastatin 20 mg daily
75397098|NCT00477204|Drug|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
75397099|NCT00528450|Drug|arsenic trioxide|
75397100|NCT00528450|Drug|idarubicin|
75870955|NCT03085914|Drug|Paclitaxel|Paclitaxel
75397101|NCT00528450|Drug|tretinoin|
75397102|NCT00478218|Drug|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
75397103|NCT00478218|Drug|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 & 22
75397104|NCT00478218|Drug|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
75397105|NCT00479154|Drug|Botulinum Toxin A|Maximum dose of 90 units/leg was injected.
75397106|NCT04270656|Procedure|Insulin pump therapy|5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)
75397107|NCT04270656|Procedure|Multi-injection treatment ( MDI ).|Corresponds to an outpatient visit if the patient is randomized into the multi-injection group
75397108|NCT00422448|Genetic|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
75397109|NCT00424554|Drug|temozolomide|"Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."
75709234|NCT00740948|Drug|Placebo: NaCl 0.9% or Glucose 5%|2* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
75709235|NCT00871702|Genetic|CD34-TK75 transduced donor lymphocytes|
76036819|NCT05971485|Drug|Melatonin 10 mg|Melatonin 10 mg will be used. 5 mg·kg-1 dissolved in 2 ml of distilled water via enteral route in one single dose 30 minutes before the venous cannula insertion
76036820|NCT05956002|Drug|Estraimod Immediate Release (IR)|an immediate release tablet
76036821|NCT05956002|Drug|Etrasimod Mini Tab in water|very small tablet mixed in water
76036822|NCT05956002|Drug|Etrasimod Mini Tab in chocolate pudding|very small tablet mixed in chocolate pudding
76036823|NCT05956002|Drug|Etrasimod Mini Tab in yogurt|Very small tablet mixed in yogurt
76036824|NCT05956002|Drug|Etrasimod Mini Tab in applesauce|Very small tablet mixed in applesauce
76036825|NCT05955183|Drug|AZD5055|AZD5055 will be given orally to randomized participants as per the arm they are assigned.
76036826|NCT05955183|Drug|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
76036827|NCT05946603|Drug|Administration of IS-002|Intravenous administration of IS-002 approximately 24 hours prior to surgery
76036828|NCT05946603|Device|Firefly fluorescent imaging|Near-infrared fluorescence imaging using Firefly technology will allow fluorescence imaging of IS-002
75397110|NCT02117310|Drug|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
75397111|NCT00425802|Biological|anti-thymocyte globulin|
75397112|NCT00425802|Biological|filgrastim|
75709236|NCT00871702|Radiation|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
75709237|NCT00732342|Behavioral|Contingency Management|Prizes given for targeted behavior of abstinence
75709238|NCT00876850|Drug|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
76036829|NCT05946603|Procedure|robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection|Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
76036830|NCT05939401|Other|Biopsies|Biopsies and blood samples will be taken at time of diagnosis or recurrence
76036831|NCT05935514|Behavioral|WW Intervention|The core of the WW food program is the Points® system which assigns each food and beverage a Points® value. Participants will be assigned a personalized daily and weekly Points® Budget, based on reported goals, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure. Participants will also be provided with the FreeStyle Libre 2 Flash Glucose Monitoring System, which is intended to monitor interstitial fluid glucose levels to aid users in the management of diabetes. The System consists of the following primary components: 1) A disposable sensor that incorporates a subcutaneously implanted electrochemical glucose sensor and associated on-body electronics, and 2) A disposable, sensor application device, which is used to adhere the sensor to the skin of the user and to insert the sensor tail just below the surface of the skin.
75709239|NCT00876850|Drug|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
75870956|NCT03085914|Drug|Pemetrexed|Pemetrexed
75870957|NCT03085914|Drug|Cyclophosphamide|Cyclophosphamide
76036832|NCT05935514|Behavioral|Usual Care|The Usual Care arm will continue to receive routine medical care by their provider, in addition to a 50-minute virtual, on-line session with a Registered Dietician, with additional materials at the time of their 6- and 12-month follow-up assessments.
75709240|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
76036833|NCT05928039|Biological|TNFa Antagonist - Infliximab|• Infliximab 5 mg/kg intravenously [IV] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks
75397113|NCT00425802|Biological|graft-versus-tumor induction therapy|
75709241|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
75870958|NCT03085914|Drug|Carboplatin|Carboplatin
75870959|NCT03085914|Drug|Cisplatin|Cisplatin
76036834|NCT05928039|Biological|TNFa Antagonist - Adalimumab|• Adalimumab subcutaneously [SC] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks
76036835|NCT05928039|Biological|Anti-IL12/23 or anti-IL23 - Ustekinumab|• Ustekinumab ~6 mg/kg IV x1, then 90 mg SC every 8 weeks
76036836|NCT05928039|Biological|Anti-IL12/23 or anti-IL23 - Risankizumab|• Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks
75397114|NCT00425802|Biological|rituximab|
75397115|NCT00425802|Drug|cyclophosphamide|
75397116|NCT00425802|Drug|cyclosporine|
75397117|NCT00425802|Drug|fludarabine phosphate|
75397118|NCT00425802|Drug|mycophenolate mofetil|
75397119|NCT00425802|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75397120|NCT00425802|Radiation|total-body irradiation|
75397121|NCT00530634|Drug|cisplatin|
75397122|NCT00530634|Drug|gemcitabine hydrochloride|
76036837|NCT05928039|Biological|Anti-integrin - Vedolizumab IV|• Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks
76036838|NCT05928039|Biological|Anti-integrin - Vedolizumab IV and SC|• Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks
76036839|NCT05918328|Drug|Albumin paclitaxel+trastuzumab+pyrrolitinib|Albumin paclitaxel 260mg/m 2+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+pyrrolitinib (400mg, QD), one cycle every 21 days.
76036840|NCT05918328|Drug|Docetaxel+Carboplatin+trastuzumab+Parstuzumab|Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days
76036841|NCT05909566|Other|Clinical Decision Support (CDS)|Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.
76036842|NCT05909566|Device|HHFNC Weaning|Wean patient off oxygen and flow as oxygenation and work of breathing improves.
76036843|NCT05908357|Other|Exergaming|Use of the exergame XboX 360 series with kinect sensor
76036844|NCT05908357|Other|Booklet|Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
76036845|NCT05904210|Drug|SEVENFACT®|Coagulation Factor VIIa (Recombinant)
76036846|NCT05903781|Diagnostic Test|Prostate MRI|MRI of the prostate
75397123|NCT00530634|Genetic|gene expression analysis|
75397124|NCT00530634|Genetic|reverse transcriptase-polymerase chain reaction|
75397125|NCT00530634|Other|immunohistochemistry staining method|
75397126|NCT00530634|Procedure|adjuvant therapy|
75397127|NCT00530634|Procedure|conventional surgery|
75397128|NCT00530634|Radiation|radiation therapy|
75397129|NCT02113410|Behavioral|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
75397130|NCT02113410|Behavioral|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
75397131|NCT00531882|Drug|Pioglitazone|30 mg once a day
75397132|NCT00531882|Drug|Simvastatin|40 mg once a day
75397133|NCT00531882|Drug|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
75397134|NCT00428298|Drug|Valacyclovir|Subjects take two 500 mg capsules twice daily for 16 weeks.
75397135|NCT00428298|Drug|Placebo|Subjects take two 500 mg capsules twice daily for 16 weeks.
75397136|NCT00486018|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
75397137|NCT00486018|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
75397138|NCT00486018|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
75397139|NCT00486642|Drug|Bicalutamide|Given PO
75397140|NCT00486642|Other|Laboratory Biomarker Analysis|Correlative studies
75397141|NCT00486642|Drug|Pazopanib Hydrochloride|Given PO
75558156|NCT00478803|Procedure|Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty|"Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta."
76036847|NCT05903040|Drug|Lasmiditan|Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks
76036848|NCT05903027|Drug|Rimegepant 75 MG Disintegrating Oral Tablet|Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
75397142|NCT00486642|Other|Pharmacological Study|Correlative studies
75397143|NCT04388514|Procedure|Medical Ozone procedure|The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
75709242|NCT00734916|Dietary Supplement|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
76036849|NCT05901831|Drug|Finerenone|Dose A, Dose B, oral
76036850|NCT05901831|Other|Placebo|Oral
76036851|NCT05896670|Drug|licaminlimab|ophthalmic suspension 60 mg/mL Subjects will receive licaminlimab eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
76036852|NCT05896670|Other|vehicle of OCS-02|inert ophthalmic suspension vehicle of OCS-02 Subjects will receive vehicle eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
76036853|NCT05896514|Device|ultrasound-guided carotid artery flow time measurement|Ultrasound-guided corrected carotid artery flow time will be measured before anestesia induction.
76036854|NCT05893160|Drug|JAN101 SR|The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
76036855|NCT05893160|Other|Placebo|Inert placebo formulation
76036856|NCT05889689|Behavioral|Relationship Smarts Plus & Mind Matters|18.5 hours long intervention that combines the Relationship Smarts Plus teen pregnancy prevention curriculum with lessons from the Mind Matters trauma-coping skills curriculum
76036857|NCT05889689|Behavioral|Relationship Smarts Plus alone|14-hour-long curriculum that addresses pregnancy prevention within the context of teaching relationship skills for young teens.
76036858|NCT05889689|Behavioral|Preparing Adolescents for Young Adulthood (PAYA).|A financial literacy curriculum
76036859|NCT05883631|Device|Ablacath™ Mapping Catheter, Ablacath™ Mapping Catheter Accessory Cables, Ablamap® System inclusive of Amplifier, Monitor/Workstation with installed Ablamap® Software|EGF-Mapping and EGF-Guided Ablation of AF Sources
76036860|NCT05878249|Procedure|wound lavage with normal saline|After removing caries and achieving hemostasis after removing caries and achieving hemostasis, wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
75397144|NCT00428922|Drug|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
75397145|NCT00428922|Drug|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
75397146|NCT00428922|Drug|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
75397147|NCT00533442|Drug|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
75397148|NCT00533442|Drug|Mycophenolate Mofetil|MMF 1 gm BID beginning 1st day postoperative day
75397149|NCT00533442|Drug|Tacrolimus|Part of standard maintenance.
75397150|NCT00533442|Drug|Steroids|Part of standard maintenance
75397151|NCT00533910|Drug|Rifaximin|550mg BID rifaximin for 8 weeks
75397152|NCT00533910|Drug|placebo|same as the experimental arm
75397153|NCT01954524|Drug|IV bolus injection of Sildenafil|"Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil."
75397154|NCT00535002|Drug|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
75397155|NCT00535002|Drug|Placebo|
75397156|NCT02117934|Biological|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
75397157|NCT02117934|Biological|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
75397158|NCT00429702|Drug|Decadron®|Given IV
75397159|NCT00429702|Drug|Benadryl®|Given IV
75397160|NCT00429702|Drug|Ativan®|Given IV
75397161|NCT00429702|Drug|ondansetron hydrochloride|Given IV
75397162|NCT00535392|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.~Dosage for subjects not on levetiracetam at study entry was based on weight: if <50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily)."
75709243|NCT00872092|Other|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
75397163|NCT00535782|Drug|Tocilizumab|Administered by intravenous infusion, 8 mg/kg every 4 weeks.
75397164|NCT00535782|Drug|Placebo|Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
75397165|NCT00535782|Drug|Methotrexate|Administered orally or parenterally, 7.5-25 mg weekly.
75397166|NCT00431184|Drug|Pentazocine|see arms description
75397167|NCT00431184|Drug|Lorazepam|see arms description
75397168|NCT00535938|Other|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
75397169|NCT00537576|Biological|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10^8 CFU), administered vaginally once a day for 5 consecutive days
75397170|NCT00537576|Biological|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
75397171|NCT00537576|Biological|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
75397172|NCT00537576|Other|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
75397173|NCT00537576|Other|Medium dose Placebo|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
75397174|NCT00537576|Other|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
75397175|NCT01795794|Drug|omeprazole|
76036861|NCT05878249|Procedure|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds,Subsequently the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets
76036862|NCT05878249|Procedure|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12% Ethylenediaminetetraacetic acid for 5minutes ,Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
75397176|NCT01795950|Drug|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
75397177|NCT01796028|Drug|METFORMIN|
75397178|NCT01796028|Drug|Placebo|
75397179|NCT01796028|Drug|TAXOTERE®|
75397180|NCT00491244|Drug|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
75397181|NCT00491244|Drug|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
75397182|NCT00492336|Drug|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
75397183|NCT00492336|Drug|Placebo|Placebo 1 tablet each day
75397184|NCT00538434|Biological|Reslizumab|
75397185|NCT00538434|Other|Saline|
75397186|NCT00538512|Biological|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
75397187|NCT00538512|Biological|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
75397188|NCT00538512|Other|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
75397189|NCT00538824|Drug|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
75558157|NCT00478803|Device|Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots|Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
75870960|NCT03085914|Drug|5-Fluorouracil|5-FU
75558158|NCT00443690|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
75558159|NCT00443690|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
75558160|NCT00440856|Behavioral|Presentation of excised intervertebral disc fragments|
75397190|NCT00538824|Drug|thalidomide|"Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
75558161|NCT00443807|Device|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
75397191|NCT00538824|Drug|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of < 40cc/min*"
76036863|NCT05878249|Procedure|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|fter removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes.Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
76036864|NCT05869851|Other|Pavlik Harness|The Pavlik harness is an abduction brace used for treatment of hip dysplasia in infants. It keeps the hips in proper alignment to allow for appropriate growth and development of the joint.
75397192|NCT00539526|Drug|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
75397193|NCT00539526|Drug|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
75397194|NCT00539526|Drug|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
75547631|NCT05916651|Behavioral|Learning to Offset Stress (LOS) (in Dutch: Leren Omgaan met Stress) training|The investigational treatment is the LOS training, which is an adaptation of two previously validated mindfulness-based programs: Mindfulness-Based Cognitive Therapy (MBCT) developed by Segal, Williams, and Teasdale (2002) and the Mindful2Work (M2W) program developed by de Bruin, Formsma, and Bögels (2018). The M2W program combines mindful physical activity, yoga, and mindfulness meditation to target stress symptoms and burn-out in adults. The LOS training was adapted from these programs to meet the needs of youth with internalizing problems. The training consists of 8 weekly 2-hour sessions that each comprise three elements: mindful physical activity (15-20 minutes), yoga (15-20 minutes), and mindfulness meditation exercises (80-90 minutes). In addition to attending group sessions, participants are invited to practice at home on a daily basis. Home practice consists of daily mindfulness practices comprising mindfulness exercises, yoga and mindful physical activity.
75709244|NCT00738816|Other|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
76036865|NCT05862870|Behavioral|painTRAINER|patient self-administered pain management web application
75397195|NCT00496860|Biological|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
75558162|NCT00443807|Device|EEGo vs BIS|comparison of two processed EEG monitors.
75558163|NCT00440895|Drug|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
76036866|NCT05862493|Diagnostic Test|FOCUS echocardiography|Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs
76036867|NCT05842343|Other|Stool sample|Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness
76036868|NCT05842343|Other|Food intake evaluation|Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates
75397196|NCT01796106|Device|Resin infiltration|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth, the study lesions will be treated using the resin infiltrant Icon (DMG, Germany) according to manufactures´ instructions. Essentially, the treatment consists of the following parts: 1) isolating the tooth with a rubber dam and cleaning its surface; 2) removing/ conditioning the surface layer of the lesion (using Icon-Etch) to open the lesion body; 3) drying of the exposed porous enamel; 4) infiltrating the existing pore volume with the resin infiltrant (Icon Infiltrant); 5) light curing of the resin infiltrant; 6) repeating the infiltration step including light curing; followed by 7) finalizing using interproximal finishing/polishing strips.
75397197|NCT01796106|Device|Fluoride varnish & Oral hygiene instruction|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth oral hygiene instruction and topical fluoridation therapy will be provided. For topical fluoridation Duraphat Fluoride Varnish (Colgate, USA) will be used according to manufactures´ instructions.
76036869|NCT05822492|Procedure|Group QLB3|"Patients who applied the QLB3 block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
75397198|NCT03371004|Drug|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
75397199|NCT00541242|Drug|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
75397200|NCT00541242|Drug|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
75709245|NCT00877084|Other|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
75709246|NCT00877084|Other|Usual care|usual care according to clinical pathway for COPD, No training
75870961|NCT03085914|Drug|Investigator's choice of platinum agent|Investigator's choice of platinum agent: carboplatin or cisplatin
75397201|NCT00438204|Biological|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
75397202|NCT00438204|Drug|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
75397203|NCT00438204|Drug|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
75397204|NCT00438750|Other|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
75397205|NCT00438750|Other|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
75397206|NCT00439296|Drug|ABT-751|"Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest."
75397207|NCT00439296|Drug|Dexamethasone|"In Treatment Course 1 only:~10 mg/m2/day divided BID.~Take dexamethasone by mouth days 1-14."
75709247|NCT00735150|Behavioral|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
75397208|NCT00439296|Drug|PEG-asparaginase|"In Treatment Course 1:~2500 IU's/m2/day.~Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~2500 IU's/m2/day.~Intramuscular injection (IM) on day 15."
75870962|NCT02357680|Other|Diary|"The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU."
75709248|NCT05157412|Drug|Doxycycline 100 mg Oral Tablet|Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis
75870963|NCT01736956|Procedure|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
75397209|NCT00439296|Drug|Doxorubicin|"In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1."
75397210|NCT00439296|Drug|Cytarabine|"Given Intrathecally on day 1 of course 1 at the dose defined by age below.~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients >3 years of age~Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12."
75397211|NCT00439296|Drug|Methotrexate|"In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose"
75397212|NCT00439296|Drug|Cyclophosphamide|Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
75397213|NCT00439296|Drug|6-thioguanine|Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
75397214|NCT00542490|Radiation|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
75709249|NCT05157412|Drug|Prednisolone 20 mg|Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
75870964|NCT01081288|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
75397215|NCT03117660|Drug|Vitamin A|vitamin A daily X3-4 weeks
75397216|NCT00439374|Drug|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
75397217|NCT00439374|Other|Placebo Oil|Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
75397218|NCT00439608|Drug|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
75397219|NCT01797042|Behavioral|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
75709250|NCT00732420|Drug|topotecan|Topoisomerase I inhibition.
75709251|NCT00732420|Drug|pazopanib|Tyrosine kinase inhibitor
75709252|NCT00877162|Behavioral|Controlled crying and routines|Behavioural (teaching and support)
75709253|NCT00877240|Behavioral|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
76036870|NCT05822492|Procedure|Group ESPB|"Patients who applied ESP block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
76036871|NCT05822492|Other|Group Control|"Patients who did not use block before PCNL surgery were included in this group.~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
75397220|NCT00500448|Device|Electrical Stimulation|Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
75397221|NCT04750122|Drug|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning|The choice of chemotherapy is based on the PTC drug sensitivity results.
75397222|NCT04749576|Dietary Supplement|saffron supplement for IBD|anti inflammatory effect
75397223|NCT00441558|Drug|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
75397224|NCT01797276|Drug|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
75397225|NCT00443352|Drug|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
75397226|NCT00445302|Drug|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
75397227|NCT00502944|Behavioral|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
75397228|NCT00502944|Behavioral|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
75397229|NCT00504504|Drug|Rituximab|375 mg/m^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
75397230|NCT00504504|Drug|Adriamycin|25 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
75547632|NCT05916651|Behavioral|Care as usual|"Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen."
75547633|NCT05915975|Behavioral|Behavioral Care Coordinated with Medical Care Intervention|Participants will be meeting with a behavioral health provider during their clinic visit. Subsequent visits can be held either via telehealth or in-person. Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months. Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.
75709254|NCT04719156|Drug|Indocyanine green solution administered at 2.0mg/kg.|Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
75709255|NCT04719156|Device|Stryker SPY-PHI Imaging Device|The SPY-PHI system is used with the ICG dye to provide fluorescence images.
75709256|NCT00863590|Drug|odanacatib|[Intervention Name: odanacatib (Panel A)] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
75709257|NCT00863590|Drug|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
75709258|NCT00863590|Drug|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
75397231|NCT00504504|Drug|Bleomycin|10 U/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
75397232|NCT00504504|Drug|Vinblastine|6 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
75397233|NCT00504504|Drug|Dacarbazine (DTIC)|375 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
75397234|NCT00504660|Drug|Capecitabine|Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.
75397235|NCT00504660|Drug|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
75397236|NCT00504660|Drug|Temozolomide|Arms 1,3 = 150 mg/m^2 PO Daily On Day 4-8.
75397237|NCT00504660|Drug|Lomustine|Arms 2,3 = 100 mg/m^2 PO on Day 4.
75397238|NCT00504660|Drug|6-Thioguanine|Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.
75709259|NCT00863590|Drug|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
75709260|NCT00735228|Device|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
75709261|NCT03843892|Drug|OFEV|twice daily
75709262|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
75709263|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
75709264|NCT00863668|Drug|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
75397239|NCT00505362|Procedure|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
75397240|NCT00505518|Drug|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
75397241|NCT00505518|Behavioral|Collaborative psychiatric and primary medical care|Regular care visits from health workers
75397242|NCT00544674|Drug|PR104|administered at a dose of 1100 mg/m^2 by intravenous infusion over 1 hour and repeated every three weeks
75397243|NCT00544674|Other|F-18-fluoromisonidazole|administered intravenously prior to PET scan
75397244|NCT00544908|Drug|dasatinib|
75397245|NCT00544908|Other|immunoenzyme technique|
75709265|NCT00863668|Drug|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
75709266|NCT00863668|Procedure|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
75397246|NCT00544908|Other|immunohistochemistry staining method|
75709267|NCT00863668|Procedure|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
75709268|NCT00739206|Drug|SAR97276A|Dose based on body weight
75709269|NCT00735540|Other|Observational|Data summary only
75397247|NCT00544908|Other|laboratory biomarker analysis|
75397248|NCT00544908|Procedure|quality-of-life assessment|
75397249|NCT00447330|Drug|capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)|"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."
75397250|NCT04388280|Diagnostic Test|Echocardiography|Functional assessment of coronary artery disease
75397251|NCT04388280|Diagnostic Test|CT angiography|Anatomical assessment of coronary artery disease
75397252|NCT02115048|Drug|Letrozole|
75709270|NCT00739284|Device|nephrostomy tube and ureteral stent|
75397253|NCT02115048|Drug|Afatinib|
75397254|NCT00546156|Drug|Doxorubicin|Standard chemotherapy regimen
75397255|NCT00546156|Drug|Cyclophosphamide|Standard chemotherapy regimen
75397256|NCT00546156|Drug|Paclitaxel|Standard chemotherapy regimen
75547634|NCT05915975|Behavioral|Behavioral Care Not Coordinated with Medical Care Intervention|Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance. The participants will be responsible for calling the clinics to set up their appointments. Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
75397257|NCT00546156|Drug|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
76036872|NCT05820659|Behavioral|peer rejection task and impossible puzzle task|"Peer rejection task: Adolescents will be informed that two peers will take turns to choose who they will chat with for different topics. Participants will not be chosen by virtual White peers 75% of the time. In reality, White peers are computerized avatars and whether or not adolescents are chosen by those peers is programmed with PsychoPy software.~Impossible puzzle task: Adolescents will be asked to fit all puzzle pieces into a wooden frame with a wrong piece provided."
75870965|NCT02467608|Drug|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
75397258|NCT00449046|Drug|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
75397259|NCT00508716|Behavioral|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
75397260|NCT00509496|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days.
75397261|NCT00509496|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenous
75397262|NCT00509496|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
75397263|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes."
75397264|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes."
75397265|NCT00547638|Device|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
75397266|NCT00547638|Device|cyanoacrylate|Topical Skin Adhesive
75397267|NCT00510744|Drug|pancreatic enzyme supplement|4 caps with meals, 2 with snacks
75397268|NCT00548418|Drug|Topotecan|
75397269|NCT00548418|Drug|Cisplatin|
75397270|NCT00548418|Drug|Bevacizumab|
75397271|NCT00511914|Biological|cTIV|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
75397272|NCT00511992|Drug|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"
75397273|NCT00511992|Drug|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
75397274|NCT00511992|Drug|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
75397275|NCT00451698|Drug|acyanotic erythropoietin|Single dose IV push
75397276|NCT00451698|Drug|acyanotic placebo|Single dose IV push
75397277|NCT01796262|Dietary Supplement|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
75397278|NCT01796262|Dietary Supplement|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
75397279|NCT01796340|Behavioral|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
75397280|NCT01796340|Behavioral|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
75397281|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
75397282|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
75397283|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
75397284|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
75547635|NCT05913401|Behavioral|Aerobic Exercise|20 minutes of supervised aerobic exercise on a treadmill prior to each TMS session
75870966|NCT02467608|Drug|HRZE|the same as experimental group,without the excipient of HUEXC030 only
75870967|NCT02368288|Drug|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
75397285|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
76036873|NCT05820256|Dietary Supplement|Milk Protein Isolate (MPI)|Study participants will consume two smoothies per day containing a milk protein isolate (MPI) for 31 days.
75397286|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
75397287|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
75397288|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
75397289|NCT01797354|Behavioral|Cognitive-behavioral therapy and hypnosis group|
75397290|NCT01797354|Behavioral|Support group|
75397291|NCT00549042|Drug|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
75397292|NCT00549042|Drug|Placebo|Placebo
75397293|NCT00452868|Drug|Donepezil|Donepezil 5 milligrams a day for 6 weeks
75397294|NCT00453336|Drug|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
75397295|NCT00453336|Procedure|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
75397296|NCT00549822|Drug|Letrozole|Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
75397297|NCT00550290|Drug|Cefazolin PostOperatively|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
75870968|NCT01380054|Behavioral|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
75547636|NCT05913401|Behavioral|Video Watching|20 minutes of watching documentaries or educational videos prior to each TMS session
75547637|NCT05907057|Drug|Ivosidenib 500mg Oral Tablet|Provided as tablets, taken orally as two 250mg tablets once daily.
75397298|NCT00550290|Drug|Cefazolin Preoperatively|Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
75397299|NCT03255408|Drug|Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
75397300|NCT03255408|Drug|Drug Lowering CBF and Intermittent Hypoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
75870969|NCT01063114|Radiation|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
75870970|NCT02450136|Drug|pazopanib|
75397301|NCT03255408|Drug|Placebo and Normoxia Sleep|The study participants will take Placebo and sleep under Normoxia Exposure
75547638|NCT05907057|Drug|Azacitidine|Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
75709271|NCT00872248|Procedure|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
75870971|NCT05421312|Drug|sampling blood|During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
76036874|NCT05820256|Dietary Supplement|Soy Protein Isolate (SPI)|Study participants will consume two smoothies per day containing a soy protein isolate (SPI) for 31 days.
76036875|NCT05820139|Procedure|Control Group|Patients will be randomized to a 200mL (control group)
75397302|NCT03255408|Drug|Placebo and Intermittent Hypoxia Sleep|The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
75397303|NCT01797198|Drug|ASP3652|Oral
75397304|NCT01797198|Drug|Gemfibrozil|Oral
75397305|NCT01797198|Drug|Repaglinide|Oral
75397306|NCT00550368|Biological|Biological intervention: Enteropathogenic E. coli|5x10^8 or 1x10^9 organisms of EPEC were administered to all participants.
75397307|NCT00551070|Other|Laboratory Biomarker Analysis|Correlative studies
75397308|NCT00551070|Other|Pharmacological Study|Correlative studies
75397309|NCT00551070|Drug|Selumetinib|Given PO
75397310|NCT00551070|Drug|Selumetinib Sulfate|Given PO
75397311|NCT00552786|Drug|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
75397312|NCT00552786|Drug|glucose|1 gm glucose capsule
75397313|NCT01797744|Other|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
75397314|NCT00517530|Drug|Obinutuzumab|Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
75397315|NCT00518154|Drug|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
75397316|NCT00553098|Biological|Alemtuzumab|Given IV
75397317|NCT00553098|Procedure|Allogeneic Bone Marrow Transplantation|Undergo HCT
75547639|NCT05903391|Device|3D-Printed Finger Splints|The intervention is wearing a novel finger splint produced by a 3D-printer
75709272|NCT00872248|Procedure|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
75870972|NCT05421312|Drug|Sampling synovial fluid|During the reimplantation 1 synovial fluid sample will be taken prior to incision.
75870973|NCT05421312|Drug|Sampling bone tissue|During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
75870974|NCT02368054|Drug|Bupivacaine|Infiltration anesthesia
76036876|NCT05820139|Procedure|Test Group|Patients will be randomized to a cut-off of 150mL (test group)
76036877|NCT05800743|Device|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
76036878|NCT05800743|Device|GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)|Endovascular aortic repair of the ascending aorta/aortic arch
76036879|NCT05800743|Procedure|Surgery|Open surgical repair of the ascending aorta and/or the aortic arch
75397318|NCT00553098|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
75397319|NCT00553098|Drug|Cyclosporine|Given PO or IV
75397320|NCT00553098|Drug|Fludarabine Phosphate|Given IV
75397321|NCT00553098|Other|Laboratory Biomarker Analysis|Correlative study
75547640|NCT05903391|Device|Conventional Finger Splints|This intervention is wearing a finger splint produced by a conventional method using thermoplastic material typically used in a clinical setting
76036880|NCT05800405|Procedure|Biospecimen Collection|Undergo blood sample collection
75397322|NCT00553098|Drug|Mycophenolate Mofetil|Given PO or IV
75397323|NCT00553098|Radiation|Total-Body Irradiation|Undergo low dose TBI
75397324|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
75397325|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
75397326|NCT00554970|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
75397327|NCT00554970|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
75397328|NCT00554970|Drug|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
75547641|NCT05900908|Device|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
75547642|NCT05900908|Radiation|Stereotactic Radiation Therapy|External Beam Radiation Therapy
75547643|NCT05895565|Drug|PMG1015|Strength: 100 mg/2 mL/vial. Dosage and Administration: Intravenous infusion of PMG1015 at 15 mg/kg, 30 mg/kg and 40 mg/kg for 30 min (±5 min), once every 4 weeks, for 3 doses.
75547644|NCT05895565|Drug|PMG1015 placebo|The placebo injection of PMG1015 contains the same excipients as PMG1015 Injection, only without the active substance. Strength: 2 mL/vial. Dosage and Administration: A single dose of placebo. Intravenous infusion for 30 min (±5 min), once every 4 weeks, for 3 doses.
75547645|NCT05886712|Other|Naloxone|Naloxone
75397329|NCT00554970|Drug|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
75397330|NCT00520884|Drug|Ghrelin Infusion - Healthy|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
75397331|NCT00520884|Drug|Ghrelin Infusion - Frail|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
75397332|NCT00520884|Other|Placebo Infusion -Healthy|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
75397333|NCT00520884|Other|Placebo Infusion - Frail|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
75547646|NCT05886712|Other|Usual intervention|usual administered drug for overdose
75547647|NCT05884866|Drug|Dapagliflozin 10mg Tab|see arms
75547648|NCT05884866|Drug|Balcinrenone 50mg Capsule|see arms
75547649|NCT05884866|Drug|Balcinrenone 100mg Capsule|see arms
75547650|NCT05884866|Drug|Dapagliflozin matching Placebo|see arms
75547651|NCT05884866|Drug|Balcinrenone 50mg matching Placebo|see arms
75547652|NCT05884866|Drug|Balcinrenone 100mg matching Placebo|see arms
75709273|NCT00732576|Dietary Supplement|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
75709274|NCT00732576|Dietary Supplement|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
75709275|NCT00732576|Dietary Supplement|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
76036881|NCT05800405|Biological|Chimeric Antigen Receptor T-Cell Therapy|Receive CAR-T per standard of care
75397334|NCT00521352|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
75397335|NCT00521352|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
75709276|NCT00863902|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
75397336|NCT00523302|Device|Active TMS|Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.
75709277|NCT00863902|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
75870975|NCT02368054|Drug|Adrenaline|Infiltration anesthesia
76036882|NCT05800405|Procedure|Computed Tomography|Undergo PET/CT
75397337|NCT00523302|Device|Sham TMS|Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
75397338|NCT00524472|Other|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
75397339|NCT00524472|Other|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
75547653|NCT05880940|Device|Boost - Moveable Wheelchair Armrest|"The movable wheelchair arm rest device is a novel wheelchair armrest that quickly clicks into a manual wheelchair frame just like a conventional armrest. However, unlike a conventional armrest, the movable wheelchair arm rest device allows users to activate arm muscles in a way that is appropriate for the early stages of stroke recovery and consistent with the Feys et al. rocking chair approach: with biomechanical support of the shoulder, without high cognitive demand, and focusing on the out-of-synergy movement pattern that requires elbow extension. For the study, the investigators ask participants to exercise using Boost for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit."
75547654|NCT05880940|Behavioral|Electronic Arm and Hand Exercise Program|These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at ARU. These exercises will be monitored and supervised by therapists who have been trained in the study protocol. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study. For this study, the investigators ask participants to exercise following this customized arm and hand exercise program for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.
76036883|NCT05800405|Radiation|External Beam Radiation Therapy|Undergo radiation therapy
75397340|NCT00524940|Biological|Inactivated, Split-Virion Influenza Virus|0.5 mL, Intramuscular
76036884|NCT05800405|Procedure|Leukapheresis|Receive leukapheresis
76036885|NCT05800405|Procedure|Magnetic Resonance Imaging|Undergo MRI
75397341|NCT00525174|Device|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
75397342|NCT00525174|Device|Patching|2 hours daily patching of the sound eye
76036886|NCT05800405|Procedure|Positron Emission Tomography|Undergo PET/CT
75397343|NCT00525174|Procedure|Near activities|one hour near visual activities
75397344|NCT04384848|Other|EMPATHY Pilot|The goal of this pilot is to develop and pilot a tailored monitoring intervention targeting symptomatic, Patient-reported adverse events (AEs) in chronic myeloid leukemia (CML) Patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy. The tailored monitoring intervention will draw primarily from the PRO-CTCAE Item Library, with additional items drawn from the FACIT and EORTC Item libraries as necessary. After identifying the full set of AEs to be monitored, we will load the Patient assessment and report program into tablets for electronic administration in the busy clinic setting. We will then pilot a six-month intervention aimed to monitor and manage emerging AEs, coupled with assessment of intervention feasibility, Patient acceptability and satisfaction, provider acceptability and clinical management utility, adherence to TKI therapy, and HRQoL. We expect that adherence to therapy, clinical response, and HRQoL will be enhanced by such an intervention.
76036887|NCT05776251|Device|taVNS|"Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold."
76036888|NCT05774977|Other|Aviation Noise Only (AN)|The aviation noise (AN) night will expose subjects to a pre-programmed recording of aviation noise during sleep from 2300-0700.
75397345|NCT04166916|Other|Acoustic stimulation|Acoustic stimulation to modulate slow waves.
75397346|NCT04166916|Other|SHAM acoustic stimulation|This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
76036889|NCT05774977|Other|Pink noise, 50 dBA only (BN50)|The BN50 night will consist of exposure to continuous pink noise throughout the sleep period at a level of 50 A-weighted decibels (dBA).
76036890|NCT05774977|Other|Aviation noise plus earplugs (AN+EP)|The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.
75397347|NCT00555048|Biological|alemtuzumab|
75397348|NCT00555048|Drug|busulfan|
76036891|NCT05774977|Other|Aviation noise plus white noise 40 dBA (AN+BN40)|The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
75397349|NCT00555048|Drug|cyclophosphamide|
76036892|NCT05774977|Other|Aviation noise plus white noise 50 dBA (AN+BN50)|The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
75397350|NCT00555048|Drug|methotrexate|
75397351|NCT00555048|Drug|tacrolimus|
76036893|NCT05774977|Other|Control Night (CTRL)|Control night (CTRL) without noise exposure and without earplugs.
76036894|NCT05773261|Device|MobilLINK TrabecuLINK cup|THA with MobilLINK TrabecuLINK cup and LCU stem
75397352|NCT00555048|Procedure|allogeneic hematopoietic stem cell transplantation|
75397353|NCT00555048|Procedure|peripheral blood stem cell transplantation|
75397354|NCT00525798|Drug|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
75397355|NCT00525798|Drug|SMC021 Placebo|SMC021 - Placebo, once daily
75397356|NCT00555360|Behavioral|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
75397357|NCT00555360|Behavioral|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
75397358|NCT00525876|Drug|Cyclophosphamide|"Matched Donors:~750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
75397359|NCT00525876|Drug|Fludarabine|"30 mg/m^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
75397360|NCT00525876|Drug|Rituximab|"Matched Donors:~375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m^2 given intravenously, then 1000 mg/m^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m^2 then 1000 mg/m^2 weekly x 3 if immunomanipulation is undertaken for persistent disease."
75397361|NCT00525876|Drug|Alemtuzumab|"Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
75397362|NCT00525876|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells.
75397363|NCT00555750|Drug|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
75397364|NCT00555750|Drug|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
75397365|NCT00526188|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
75397366|NCT00556140|Drug|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
75397367|NCT00527124|Drug|cediranib maleate|Given orally
76036895|NCT05773261|Device|Pinnacle Gription cup|THA with Pinnacle Gription cup and Coral stem
76036896|NCT05755620|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.
76036897|NCT05755620|Other|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
76036898|NCT05755620|Biological|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 [PEG lipid]).
76036899|NCT05750459|Drug|Artesunate|Artesunate is a succinic ester of artemether.
76036900|NCT05743166|Procedure|Bariatric surgery|JDF11 JDF41 JDF97
76036901|NCT05742646|Behavioral|MATADORS|Youth will have access to the MATADORS app to include basic information and expanded educational features. They will be asked to log into the app daily for one month and they will be asked to report within the app how they are feeling each day and their medications taken.
75547655|NCT05875441|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
76036902|NCT05742646|Behavioral|MATADORS Control|Youth will have access to the MATADORS app basic information. They will be asked to log into the app daily for one month and they will be asked to report within the app their medications taken.
76036903|NCT05724030|Device|integrated pulmonary index|integarted pumobary index monitoring
76036904|NCT05724030|Device|saturation|saturation monitorization
76036905|NCT05722938|Drug|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
76036906|NCT05722938|Drug|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
76036907|NCT05702281|Device|ReLARC|ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.
76036908|NCT05698121|Device|CapriXpress|The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
76036909|NCT05695417|Drug|OTX-TKI|Injection of OTX-TKI
76036910|NCT05695417|Drug|Sham|Sham Injection of OTX-TKI
76036911|NCT05694676|Other|Assessment of the quality of Genaral Movements (GMs)|The variation, complexity and fluency of movements over a video recording is done and the quality of GMs is classified as normal-optimal, normal-suboptimal, mildly abnormal, and definitely abnormal movements.
76036912|NCT05694676|Other|State-Trait Anxiety Inventory-Trait, (STAI-T)|The scale consists of 20 items in total and provides a four-point Likert type measurement (1- anxiety symptom is not present, 4- the symptom lasts all the time). Scores range from 20 (low anxiety) to 80 (high anxiety).
76036913|NCT05694676|Other|Beck Depression Inventory, (BDI)|BDI contains 21 items and rates the depressive symptoms for the last week. Each item has four options and is scored between 0 and 3. The total score ranges from 0 to 63. Higher scores indicate more severe depression
75547656|NCT05875441|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
76036914|NCT05688748|Other|Dengue self-monitoring system|The system has a symptom monitoring algorithm whereby patient would be asked to report their symptoms thrice daily (9am, 2pm and 8pm). The algorithm is developed by the researchers which consist of primary care doctors, emergency physician and infectious disease specialists. If the patient reports warning symptoms (persistent vomiting, persistent diarrhoea, abdominal pain, bleeding, difficulty breathing, feel like fainting, difficulty carrying out usual activities, drowsiness, reduced urine output and reduced urine output), the system will advise patients to seek earlier medical care instead of waiting for the scheduled appointment the next day/other days.
75547657|NCT05875441|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
76036915|NCT05681039|Drug|Tiragolumab|Given by IV (vein)
76036916|NCT05681039|Drug|Atezolizumab|Given by IV (vein)
75547658|NCT05875441|Drug|Placebo|16 placebo capsules will be administered as a single dose.
76036917|NCT05681039|Behavioral|Standard of Care|after care from surgery
76036918|NCT05681039|Behavioral|Questionnaires|Quality of life
76036919|NCT05681039|Radiation|Cisplatin|Given by IV (vein)
76036920|NCT05681039|Radiation|Carboplatin|Given by IV (vein)
75547659|NCT05873868|Other|Six minutes walk test|Six minutes walk test just before first intake of treatment and after 1 and 2 years
75547660|NCT05873868|Other|Kansas City questionnaire|Kansas City questionnaire just before first intake of treatment and after 1 and 2 years
75870976|NCT01569282|Procedure|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
75397368|NCT00527124|Drug|docetaxel|Given IV
75397369|NCT00527124|Drug|prednisone|Given orally
75397370|NCT00527124|Other|laboratory biomarker analysis|Correlative studies
75397371|NCT00527592|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
75397372|NCT00527592|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
75397373|NCT02121912|Device|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
75397374|NCT02121912|Device|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
75397375|NCT00556452|Drug|Clofarabine/Busulfan x 4|"Clofarabine IV (dose levels)~1st dose level: 20 mg/m2/day x 5 days~2nd dose level: 30 mg/m2/day x 5 days~3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days"
75397376|NCT00556452|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
75397377|NCT00556452|Radiation|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
75397378|NCT03158376|Drug|Gabapentin|
75397379|NCT03158376|Drug|Placebo|
75397380|NCT01797510|Behavioral|Web Based Health Coaching|
75397381|NCT02126748|Other|inhalation 4ml hypertonic saline 3% 3x/day|
75397382|NCT02126748|Device|Intrapulmonary Percussive Ventilation|
75397383|NCT02126748|Procedure|Assisted Autogenic Drainage|
75397384|NCT05622630|Procedure|Four-cell bath|Four-cell bath:Treatment with direct current
75397385|NCT05622630|Procedure|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
75397386|NCT01797900|Drug|Cisplatin|induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
75397387|NCT01797900|Drug|Paclitaxel|induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
75397388|NCT01797900|Radiation|IMRT|69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume
75397389|NCT03746808|Behavioral|EMA + App/Treatment Messages|"This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use."
75397390|NCT04747704|Behavioral|Three Principles Counseling|A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
75397391|NCT05622552|Device|active group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
75547661|NCT05873868|Other|COMPASS31 self questionnaire|Compass31 self questionnaire assessing dysautonomia just before first intake of treatment and after 1 and 2 years
75547662|NCT05869682|Procedure|Bright White Light Therapy|Wear AYOpro BWL therapy
75547663|NCT05869682|Drug|Combination Drug Therapy|Receive SOC ADT combination therapy
75547664|NCT05869682|Other|Electronic Health Record Review|Ancillary studies
75547665|NCT05869682|Other|Quality-of-Life Assessment|Ancillary studies
75547666|NCT05869682|Other|Questionnaire Administration|Ancillary studies
75547667|NCT05866237|Device|Patient Engagement tool|The study intervention (PET) aims to increase uptake of vaccines that are already recommended through national guidance.The PET will help educate and inform individuals about the benefits of COVID-19 vaccination through culturally adapted educational support, including content, design, mode and timing of delivery of messages (text, video or voice messages).
75870977|NCT01569282|Procedure|Stent strategy|Biliary and/or enteral stents on demand
75547668|NCT05863312|Procedure|Pars plana vitrectomy|Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.
75709278|NCT00732732|Dietary Supplement|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
75397392|NCT05622552|Device|sham group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
75547669|NCT05863312|Procedure|Pars plana vitrectomy with scleral buckle|In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.
75547670|NCT05863312|Other|Sulfur hexafluoride gas tamponade|At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.
75547671|NCT05863312|Other|Perfluoropropane gas|At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.
75547672|NCT05857774|Other|Sonographic measurements|Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction
75547673|NCT05857774|Other|Physiological measurements|Airway occlusion pressure, maximal inspiratory pressure, muscle research council score
75709279|NCT00732732|Other|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
75709280|NCT00732810|Drug|SCH 727965|SCH 727965 50 mg/m^2 IV on Day 1 of each 21 day cycle until disease progression.
75709281|NCT00732810|Drug|Capecitabine|Capecitabine 1250 mg/m^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
75709282|NCT00732810|Drug|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
75397393|NCT03572790|Drug|Prucalopride|1mg prucalopride capsule, once daily for seven days
75547674|NCT05857774|Other|Biological measurements|Skeletal troponin-I
75547675|NCT05857566|Drug|RDX-002|A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
75709283|NCT00732888|Drug|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
75709284|NCT00732888|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
75709285|NCT00732966|Drug|losartan|with losartan 50 mg once daily for one month
75709286|NCT00732966|Drug|valsartan|valsartan 160 mg once daily
75709287|NCT00739440|Biological|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
75709288|NCT00735774|Drug|11C-ORM-13070|Single dose of i.v. solution
75709289|NCT03901560|Other|Music Therapy|
75709290|NCT00735852|Drug|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
75397394|NCT03572790|Other|Placebo|Lactose placebo capsule, once daily for seven days
75709291|NCT00739518|Procedure|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
75397395|NCT05622474|Drug|Induction chemotherapy plus Concurrent chemotherapy|"Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2，D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles）~Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation."
75397396|NCT05622474|Drug|Concurrent chemotherapy|Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.
75397397|NCT05622474|Radiation|IMRT|Radical radiation: Intensity-modulated radiotherapy
75397398|NCT03428802|Other|Laboratory Biomarker Analysis|Correlative studies
75397399|NCT03428802|Biological|Pembrolizumab|Given IV
75709292|NCT00424021|Drug|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
75397400|NCT03379194|Behavioral|Antibiotic stewardship program|Routine feedback on antibiotic prescriptions in addition to evidence based guidelines for the management of acute respiratory and urinary tract infection and patient leaflets for using antibiotics wisely
75709293|NCT00733044|Behavioral|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
75397401|NCT02319486|Drug|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
75397402|NCT02319486|Drug|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
75397403|NCT03271554|Drug|Alectinib|According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
75397404|NCT03093636|Device|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
75397405|NCT03093636|Other|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
75397406|NCT05622162|Drug|Radiopharmaceutical 18F-JK-PSMA-7|"The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study."
75397407|NCT05622162|Drug|Radiopharmaceutical 18F-Fluorocholine|"The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study."
75558164|NCT04697706|Dietary Supplement|Moonstone|"Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
75709294|NCT00733044|Other|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
75397408|NCT00546390|Device|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
75397409|NCT00860652|Radiation|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
75397410|NCT00860652|Radiation|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
75397411|NCT04039074|Behavioral|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
75547676|NCT05857358|Procedure|lipoaspiration|"Adipose tissue harvest will be conducted by a surgeon under under local and intra-veinous sedation anesthesia. Once the patient is asleep and just before the laying of the operating drapes, the skin will be thoroughly disinfected, in order to avoid bacteriological contamination. Each entry point will be disinfected with betadine before and regularly during the procedure and will receive local anesthesia.~The lipoaspiration sites will be infiltrated using a closed system, thanks to a Khoury canula. Adipose tissue will be harvested after waiting at least 5 minutes, in order to limit hematoma and excessive blood harvesting. A 3mm incision will be made then the tissue collection will be performed using a canula, manually, by gentle aspirations into a syringe then directly transferred into a connected sterile bag.~The incision will be closed with 1 stitch of 6-0 absorbable and a paraffin gauze dressing. Then, patient will be awaken and transported to the recovery room."
75397412|NCT04039074|Behavioral|Iyengar Yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
75397413|NCT04039074|Behavioral|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
75397414|NCT05622084|Device|Inperia Advance|Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device
75397415|NCT00556842|Device|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
75397416|NCT00556842|Device|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
75397417|NCT00558012|Drug|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
75397418|NCT00558012|Dietary Supplement|Vitamin D 800 IU/daily|Daily divided dose
75397419|NCT00558012|Dietary Supplement|Calcium 1200 mg/daily|supplement plus diet
75397420|NCT00558246|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
75397421|NCT00558246|Device|Suture|Topical Suturing
75397422|NCT00558792|Drug|Isovue 370, 70 mL|70 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
75397423|NCT00558792|Drug|Isovue 370, 80 mL|80 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
75397424|NCT00558792|Drug|Isovue 370, 90 mL|90 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
75397425|NCT03884634|Device|Dabir Micropressure Overlay|"The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off."
75397426|NCT00561600|Device|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
75397427|NCT00561600|Device|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
75397428|NCT00561834|Drug|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
75397429|NCT04388202|Drug|Sertraline|FDA approved antidepressant
75709295|NCT00735930|Drug|Alvocidib Hydrochloride|Given IV
75709296|NCT00735930|Drug|Lenalidomide|Given PO
75709297|NCT00735930|Other|Pharmacological Study|Correlative studies
75397430|NCT04388202|Drug|Escitalopram|FDA approved antidepressant
75397431|NCT02128074|Drug|KRX-0502|1g tablets of KRX-0502
75397432|NCT02128230|Device|myPRS|Genome expression profiling used to identify high-risk and low-risk multiple myeloma
75397433|NCT02128230|Drug|Induction 1 - MEL-10+CFZ-TD-PACE|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days 1, 5, & 6; MEL 10mg/m2 on day 3; T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 400 mg/m2/d, and E 40 mg/m2/d on days 5-8; G-CSF 10 mcg/kg/day from day 11 through end of Peripheral Blood Stem Cell (PBSC) collection.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 1st transplant."
75397434|NCT02128230|Drug|First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 & -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 & -2; PBSC transplant on day 0.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until inter-therapy."
75397435|NCT02128230|Drug|Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 27 mg/m2 on days 1-2; MEL 5 mg/m2/d, T 200 mg/d, D 20 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 75 mg/m2/d, and E 60 mg/m2/d on days 1-4.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 2nd transplant."
75397436|NCT02128230|Drug|Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 & -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 & -2; PBSC transplant on day 0.~Optional Bridging with T 50mg/d and D 20 mg on day 1-4 every 21 days until consolidation."
75397437|NCT02128230|Drug|Consolidation - CFZ-TD-PACE|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), adriamycin (A), cyclophosphamide (C) and etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter.~Regimen: CFZ 27 mg/m2 on days 1-2; T 200 mg/d, D 40 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 300 mg/m2/d, and E 30 mg/m2/d on days 1-4."
75547677|NCT05857358|Drug|Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)|"Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~2 for the sublingual glands (0.5mL for each gland)~2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose."
75547678|NCT05853731|Device|Green light emitting diode|Green light therapy via light emitting diode (LED) in the 520 nanometers (nm) range at 4 lux intensity for up to 5 hours per day, as tolerated.
75547679|NCT05853731|Device|White light emitting diode|Filtered white light via light emitting diode (LED) displayed for up to 5 hours per day, as tolerated
75547680|NCT05849038|Drug|Baricitinib|Patients will receive baricitinib at a dose of 2 mg oral daily.
75547681|NCT05849038|Other|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.
75709298|NCT00735930|Other|Laboratory Biomarker Analysis|Correlative studies
76036921|NCT05679570|Drug|Satralizumab (Genetical Recombination)|"Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period[1]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period[2]:~Subjects completed continuation dosing period[1], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period."
75397438|NCT02128230|Drug|Maintenance - CFZ-R(T)-D|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) and lenalidomide (R) are capsules and dexamethasone (D) is a pill; all will be taken by mouth.~Regimen: For Cycles 1-12 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, & 22; lenalidomide (R) 15 mg/d on days 1-21. For Cycles 13-24 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, & 22. T may be substituted for R at 100 mg/day at the treating physician's discretion."
75397439|NCT03416244|Drug|Nivolumab|Nivolumab 240 mg IV fixed dose every two weeks
75397440|NCT03416244|Drug|Ipilimumab|Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
75397441|NCT05560776|Procedure|Endobronchial ultrasound|Two or three passes per lymph node
75397442|NCT05560620|Behavioral|Sleep Deprivation|Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.
75397443|NCT05560620|Other|Caffeine|On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.
75397444|NCT05560620|Other|No Caffeine|De-caffeinated coffee
75397445|NCT04388124|Drug|Bosentan|vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
76036922|NCT05677581|Other|iodine nutrition status|iodine nutrition status
75397446|NCT04388124|Drug|Placebo|Placebo
75397447|NCT05560152|Drug|Yiqihuayu Decotion|Per os, twice a day, for 7 days.
75397448|NCT02130258|Device|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
75397449|NCT02130258|Procedure|Epidural Steroid Injection (ESI)|Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
75397450|NCT03172416|Drug|Oxaliplatin|This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
75547682|NCT05848375|Procedure|Arthroscopic rotator cuff repair|The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.
75547683|NCT05848375|Drug|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
75547684|NCT05848375|Drug|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
75547685|NCT05847673|Behavioral|Online Smoking Cessation Intervention|Receive EQQUAL A intervention
75547686|NCT05847673|Behavioral|Online Smoking Cessation Intervention|Receive EQQUAL B intervention
75397451|NCT03172416|Drug|Oxaliplatin & Nivolumab|PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
75397452|NCT03033420|Device|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
75397453|NCT01798212|Procedure|endoscopic full thickness plication|
75397454|NCT05560074|Device|Buzzy|In the Buzzy® group, 30 seconds before the blood collection procedure and during the procedure, the Buzzy® device ist placed 3-5 cm above the area from where the blood would be taken by the PhD qualified nurse researcher
75547687|NCT05847673|Other|Questionnaire Administration|Ancillary studies
75397455|NCT05560074|Other|DistrACTION® Cards|In the DistrACTION® Cards group, picture cards containing various hidden pictures and patterns are used during blood collection by the PhD qualified nurse researcher
75547688|NCT05847673|Other|Health Promotion and Education|Receive motivational messages and smoking cessation information via SMS text messages
75547689|NCT05843747|Other|Sampling|During thier bariatric surgery, samples of adipose tissue will be done
75709299|NCT03902262|Procedure|appendicectomy|
75709300|NCT00736008|Other|Observational|Data summary only
75709301|NCT00736086|Device|Vessel Closure (StarClose™)|
75547690|NCT05834036|Drug|Amoxicillin Oral Capsule|Amoxicillin 875mg every 12 hours for 7 days.
75547691|NCT05828355|Other|Knee Care@Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
75870978|NCT02357602|Drug|GS-7340|Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
75397456|NCT05559996|Device|Injectable form of multifractional intercalated cross-linked hyaluronic acid (Armonia®, Regenyal, Italy)|2 mL of Armonia was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
75397457|NCT05559840|Device|S-Condom Uterine Tamponade|The condom catheter will be inflated with air
75870979|NCT01379196|Drug|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
75397458|NCT05559840|Device|Traditional condom catheter|The condom catheter will be inflated with saline following national protocol
75397459|NCT02812212|Device|ultrasonography|bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
75397460|NCT02812212|Device|diuretic renography|diuretic renography to measure the cortical transit time.
75397461|NCT02601378|Drug|LXS196|LXS196 as a single agent
75397462|NCT02601378|Drug|LXS196 and HDM201|LXS196 in combination with HDM201
75547692|NCT05826912|Drug|Atorvastatin Calcium|Capsule, 80 mg/day, with no loading dose, for 28 days
75547693|NCT05826912|Drug|Minocycline Hydrochloride|Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
75547694|NCT05826912|Drug|Candesartan Cilexetil|Capsule, 8 mg once on Day 1, then 16 mg daily for 27 days
75547695|NCT05826912|Drug|Placebo|Capsule, 2x/day for 28 days
75870980|NCT03112720|Device|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
75870981|NCT03112720|Drug|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
75397463|NCT02434848|Drug|Engerix B|"Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years."
75397464|NCT02434848|Drug|Fendrix|"Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years."
75397465|NCT05559450|Drug|Blinatumomab|Blinatumomab will be bridged to conventional BUCY conditioning regimen.
75397466|NCT05559450|Other|Conventional therapy|Control group will be given conventional BUCY conditioning regimen.
75547696|NCT05813275|Drug|AD109|Oral administration at bedtime
75547697|NCT05813275|Drug|Placebo|Oral administration at bedtime
75870982|NCT01382316|Behavioral|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
75870983|NCT01382316|Behavioral|Usual care|Group format, six weekly education sessions about alcohol and drugs
75870984|NCT01382238|Drug|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
75397467|NCT01669200|Other|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
75397468|NCT01669200|Other|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
75397469|NCT05559294|Behavioral|Professional Development of Early Childhood Education and Care Staff for Science|A nine-month program consisting of three e-learning modules and three group workshops
75397470|NCT05559294|Behavioral|Education and care as Usual (ECAU)|Active control
75397471|NCT05559138|Other|no intervention|no intervention
75397472|NCT00564954|Drug|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
75397473|NCT00564954|Drug|Placebo|orally once a day for 7 days
75397474|NCT00565110|Behavioral|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
75397475|NCT00565266|Drug|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
75397476|NCT00565266|Drug|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
75870985|NCT01382238|Drug|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
75397477|NCT00565266|Drug|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
75397478|NCT05609526|Other|Compression Therapy|6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.
75397479|NCT05609526|Other|Inspiratory muscle training|Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
75397480|NCT05609526|Other|Calf muscle exercise training|A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.
75397481|NCT02124018|Procedure|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
75397482|NCT02124018|Device|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
75397483|NCT04346316|Drug|SHR0302|Oral tablets taken once daily (QD)
75397484|NCT05567328|Device|Research FibroScan|"Once the inclusion and exclusion criteria are validated, the investigator can propose the study to the patient. After taking the time needed to consider the study, the patient will decide if he/she wants to participate in the study and to sign off the informed consent form.~The following examinations will be performed for each patient using the probe as per recommendations displayed on the screen. The same probe must be used for examinations.~Patients #1 to #70:~Exam 1: Exploratory exam with the Research FibroScan and the M+ or XL+ probe. Exam 2: Reference exam with the CE-marked FibroScan and the M+ or XL+ probe.~Patients #71 to #100:~Exams 1 and 2: Two consecutive exploratory exams with the Research FibroScan and the M+ or XL+ probe.~Exams 3 and 4: two consecutive reference exams with the CE-marked FibroScan and the M+ or XL+ probe."
75397485|NCT00567840|Drug|PA-824|200 mg, 600 mg, 100 mg, 1200 mg qd
75397486|NCT00568386|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
75397487|NCT00568386|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
75397488|NCT01798290|Behavioral|narrative medicine: reading workshop|
75397489|NCT01798290|Behavioral|critical reading|
75397490|NCT03830970|Dietary Supplement|Canned beans of multiple varieties|Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
75397491|NCT03830970|Dietary Supplement|White Rice|Minute Rice Long Grain White Rice
75397492|NCT01797978|Drug|Intravenous methylene blue administration|Initial history taking and physical examination --> enrollment --> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
75397493|NCT01797978|Drug|Placebo|
75397494|NCT05363202|Drug|Fluticasone propionate Inhalation Aerosol 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning & evening approximately. 12 h apart, Mode of Administration: Oral inhalation
75547698|NCT05812534|Drug|Cadonilimab|Subjects who met the study population conditions were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2. Every 3 weeks is a cycle, with a total of 4-6 cycles (the number of chemotherapy cycles is determined by the researchers). Cadonilimab 10mg/kg, bevacizumab 7.5 mg/kg and pemetrexed 500mg/m2 were then maintained until disease progression, intolerable toxicity or other causes specified in the regimen occurred. When the subject first has imaging disease progression, if the researcher judges that it is clinically beneficial and tolerant to the test drug, he will be allowed to continue treatment.
75397495|NCT05363202|Drug|FLOVENT HFA 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning & evening approximately. 12 h apart, Mode of Administration: Oral inhalation
75397496|NCT05363202|Drug|Matching Placebo inhaler|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning & evening approximately. 12 h apart, Mode of Administration: Oral inhalation
75397497|NCT05439174|Other|Intradialytic Parenteral Nutrition|"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."
75397498|NCT05394012|Biological|RQ3013|Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days
75397499|NCT05394012|Biological|Comirnaty|Two doses of 30 μg/0.3 mL at an interval of 28 days
75547699|NCT05799274|Drug|RAD301 ([68Ga]-Trivehexin)|Whole body PET scan
75547700|NCT05799144|Biological|DNA Vaccine|Given pBI-11 IM
75547701|NCT05799144|Biological|Human Papillomavirus Tumor Antigen Vaccine|Given into a muscle
75547702|NCT05799144|Biological|Pembrolizumab|Given into vein
75397500|NCT02129478|Drug|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
75397501|NCT02129556|Drug|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
75397502|NCT05362500|Drug|Glycolic Acid 70%|Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing
75397503|NCT05362500|Drug|Tranexamic acid injection|Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
75397504|NCT05161806|Drug|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
75397505|NCT05161806|Device|Prefilled Syringe (PFS)|Prefilled Syringe (PFS)
75397506|NCT05362188|Drug|Nicotinamide Topical|"Patients with discoid lupus erythematosus (face & scalp) will be given topical nicotinamide in two concentrations (2&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream & gel)."
75397507|NCT01798368|Device|PBASE system 2.0|
75397508|NCT05353374|Drug|Sodium Fusidate 2 % Topical Ointment|Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.
75397509|NCT05353374|Drug|Petrolatum ointment|Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
75397510|NCT05292300|Dietary Supplement|Cornelian Cherry (Cornus mas L.)|"Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement."
75397511|NCT05292300|Behavioral|Diet|"Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician."
75397512|NCT05214222|Drug|Anlotinib/Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~Anlotinib: once a day, 1 capsule each time (10mg for body weight <60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~Paclitaxel: According to 135-175mg/m2, intravenous infusion> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
75397513|NCT05214222|Drug|Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~Paclitaxel: According to 135-175mg/m2, intravenous infusion> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
75397514|NCT05195268|Procedure|Intracardiac Catheter Ablation|Both arms will receive intracardiac catheter ablation procedures as described.
75397515|NCT05108064|Diagnostic Test|Artificial intelligence model|Results of artificial intelligence model will be compared with the gold standard
75397516|NCT05198232|Behavioral|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
75547703|NCT05799144|Procedure|Computed Tomography (CT)|Undergo a CT
75547704|NCT05799144|Procedure|Magnetic Resonance Imaging (MRI)|Undergo an MRI
75547705|NCT05799144|Procedure|Magnetic Resonance Imaging|Undergo blood sample collection
75547706|NCT05799144|Procedure|Biopsy|Undergo tumor biopsy
75547707|NCT05796375|Procedure|Cystoscopy|Cystoscopy entails direct inspection of the bladder via a cystoscope that is inserted into a patient's urethra.
75397517|NCT05198232|Behavioral|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
75547708|NCT05796375|Diagnostic Test|Bladder EpiCheck urine test|The Bladder EpiCheck is a laboratory-developed test for early-stage non-muscle invasive bladder cancer. The Bladder EpiCheck test is a DNA methylation test that is run on DNA extracted from cell pellet from centrifuged urine according to Standardized Operating Procedures. The test has internal controls and a dedicated software to ensure required quality assurance processes and prompt reporting of results.
75547709|NCT05796375|Diagnostic Test|Xpert Bladder Cancer Monitor urine test|A 4.5 ml sample of voided urine is added to Xpert® Urine Transport Reagent, mixed, and then 4ml of treated urine are transferred to the Sample Chamber of the cartridge. In the cartridge, cells in the urine sample are captured on a filter and lysed by sonication. The released nucleic acid is eluted, mixed with dry RT-PCR reagents, and the solution is transferred to the reaction tube for RT-PCR and detection.
75870986|NCT03112564|Other|Avoidance of rocuronium/cisatracurium|Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.
75547710|NCT05792774|Drug|Bupivacain|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
76036923|NCT05675007|Dietary Supplement|Colon-delivered multivitamin supplement|Colon-delivered multivitamin supplement containing the following dose of the indicated vitamin: vitamin B2 (10 mg), vitamin B3 (4.0 mg), vitamin B6 (1.4 mg), vitamin B9 (400 μg), vitamin C (200 mg) and vitamin D3 (15ug). Vitamin capsules are filled with microcrystalline cellulose and magnesium stearate up to 200 mg. Control of release in the colon is achieved by the Eudragit S 100 coating layer technology that surrounds the vitamins contained in the core capsules.
76036924|NCT05675007|Dietary Supplement|Placebo capsule|Placebo capsule containing microcrystalline cellulose and magnesium stearate up to 200 mg. Placebo capsules are coated with the Eudragit S 100 coating layer.
76036925|NCT05655507|Drug|Zuranolone|Administered as capsules
76036926|NCT05654467|Biological|Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)|The nOPV3 vaccine containing approximately 10^5.5, 10^6.0, or 10^6.5 CCID50 per dose.
76036927|NCT05654467|Biological|Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 control and challenge vaccine (mOPV3) containing ≥ 10^5.8 CCID50 per dose.
75547711|NCT05792774|Other|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
75547712|NCT05792137|Other|High saturated fat challenge meal|High saturated fat challenge meal made with palm oil
75870987|NCT03112564|Drug|Sevoflurane 8% + Intravenous fentanyl|Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
76036928|NCT05622591|Drug|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
75397518|NCT05175690|Diagnostic Test|Diagnostic Software as Medical Device|"AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses.~The AudibleHealth Dx is a cloud-based AI/ML (locked ML) diagnostic software as medical device (Dx SaMD) with a mobile app based graphical user interface (GUI) designed to operate with COTS Android Operating System (OS) and Apple OS based mobile devices. The AudibleHealth Dx system uses a forced cough vocalization (FCV) signal data signature (SDS) to diagnose COVID-19 illness in ambulatory adults. Results are sent to ordering physicians, State Health Departments, and participants using Health Level 7 (HL7) compliant communication protocols."
75397519|NCT05048550|Device|Near vision spectacles|Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
75397520|NCT04932018|Behavioral|Virtual Community of Support|The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
75397521|NCT04932018|Behavioral|Mentorship Incubator|The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
75397522|NCT02829528|Behavioral|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
75397523|NCT04747236|Drug|Azacytidine|Azacytidine, 300 mg po daily on Days 1-14
75397524|NCT04747236|Drug|Romidepsin|Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
75397525|NCT04747236|Drug|Belinostat|Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
75547713|NCT05792137|Other|High mono unsaturated fat challenge meal|High mono unsaturated fat challenge meal made with olive oil
75709302|NCT00617734|Biological|IMC-A12 (cixutumumab)|IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
75709303|NCT00617734|Biological|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
75397526|NCT04747236|Drug|Pralatrexate|Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
75397527|NCT04747236|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
75397528|NCT04742946|Other|Digital Physiotherapy Practice (Telerehabilitation)|Online Physiotherapy services
75397529|NCT01797666|Drug|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
75397530|NCT05017194|Drug|Emodepside|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.
75397531|NCT04993248|Other|Dialog Circle|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
75547714|NCT05789446|Behavioral|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
75397532|NCT04853394|Behavioral|MASLIHAT|peer educator intervention
75397533|NCT04853394|Behavioral|TANSIHAT|health education intervention
75397534|NCT04850820|Dietary Supplement|Novel essential amino acid supplementation|This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
75547715|NCT05787366|Other|usual care and follow-up by a nurse|follow-up by a nurse and referral to a specialist(s) according to symptoms
75709304|NCT00733122|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
75709305|NCT00733200|Procedure|Minor or Major Liver Resection|
75709306|NCT00877318|Device|SCAD information system|Cardiac rehabilitation at home by telemedicine
76036929|NCT05622110|Procedure|Adhesive glue closure|Incision closure with adhesive glue
75709307|NCT00577460|Drug|Pramipexole|Pramipexole ER 0.375 -4.5 mg
75709308|NCT00577460|Drug|Placebo|Placebo tablets identical to Pramipexole ER tablets
76036930|NCT05622110|Procedure|Subcuticular closure|Incision closure with 3-0 vicryl subcuticular sutures
76036931|NCT05622097|Other|0.9% Saline warmed to 37 degrees Celsius|0.9% Saline warmed to 37 degrees Celsius
76036932|NCT05622097|Other|0.9% Saline warmed to 24 degrees Celsius|0.9% Saline warmed to 24 degrees Celsius
75397535|NCT04850820|Dietary Supplement|Branched-chain amino acid supplementation (BCAA)|This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
75397536|NCT04850820|Dietary Supplement|Isocaloric carbohydrate supplementation|This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
75397537|NCT04778748|Diagnostic Test|Under-mattress sleep monitor|Under-mattress sleep monitor for patients with a confirmed diagnosis of Obstructive Sleep Apnea.
75397538|NCT04520100|Behavioral|Clinical Hypnosis performed by the PI|The patient will receive clinical hypnosis by the PI prior to examination and listen to recorded session during their MRI.
75397539|NCT04520100|Behavioral|Care by technician trained in empathic communication|The patient will be taken care of by an MRI technician who has been previously trained in empathic communication.
75397540|NCT04501380|Drug|AEMCOLO (Rifamycin SV MMX)|Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
75397541|NCT04465734|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
75397542|NCT04465734|Drug|HLX04|HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
75397543|NCT04465734|Drug|Sorafenib|Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
75397544|NCT04448808|Drug|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
75397545|NCT04448808|Drug|Placebo|Placebo of BX-1, oral solution
75397546|NCT04388358|Drug|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day|All patients were treated with mixed formula of Chinese medicine for one month
75397547|NCT04417296|Diagnostic Test|antepartum computerised cardiotocography analysis|A common obstetric methodical to evaluate the fetal well-being is the antepartum fetal heart rate (FHR) monitoring through cardiotocography (CTG)
75397548|NCT04954872|Behavioral|Standard Problem Management Plus training (training as usual)|10-day training on Problem Management Plus.
75397549|NCT04954872|Behavioral|Equip-based Problem Management Plus training|Training and supervision for Problem Management Plus in which the trainers and supervisors use the EQUIP platform for competency assessment and feedback.
75397550|NCT02132520|Device|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
75397551|NCT02132520|Behavioral|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
75547716|NCT05787366|Other|Personalized Multifactorial Intervention (IMP)|"The content of the intervention is defined according to the result of the initial assessment in relation to the person's needs and the nature of his or her persistent symptoms. The patient, depending on his or her needs, may choose to participate in the following workshops :~Knowledge of the disease and specific management, (led by the nurse)~Covid-19 and anxiety/depression, (psychologist)~Fatigue and adapted physical activities (video capsules)~Covid-long and social link (professional and voluntary activities...) (social worker and/or nurse)~The Recovery Café aims to provide a space for patients to listen to each other and share their experiences around themes related to the different dimensions of recovery: medical and psychological, economic, professional, social and existential."
75547717|NCT05781542|Biological|sD-NP-GT8 DNA|0.4 mg or 1.6 mg
75709309|NCT00877396|Biological|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
76036933|NCT05610072|Drug|n-acetylcysteine|Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.
76036934|NCT05610072|Drug|Hydromorphone|Subjects will receive up to 144 mg oral hydromorphone daily.
76036935|NCT05610072|Drug|Placebo n-acetylcystine|Subjects will be randomized to receive placebo n-acetylcysteine daily.
75397552|NCT04020198|Other|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
75397553|NCT03885336|Other|No Interventions|There are no interventions in this study. Participants are observed.
75397554|NCT03869814|Other|Blood Draw|Blood Draw
75397555|NCT03856632|Drug|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
75547718|NCT05781542|Biological|IL-12 DNA|0.1 mg or 0.4 mg
75547719|NCT05781542|Biological|Trimer 4571|100 mcg
75709310|NCT00877396|Biological|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
75709311|NCT00877474|Drug|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
75870988|NCT01379976|Drug|Acetylcarnitine|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
75397556|NCT03856632|Other|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
75397557|NCT03856632|Drug|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
75397558|NCT03856632|Procedure|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
75397559|NCT03821142|Device|Transvaginal mesh for anterior pelvic organ prolapse repair|synthetic mesh for anterior pelvic organ prolapse with or without apical vaginal wall involvement via the vaginal route in a highly selected patient population
75397560|NCT04256460|Behavioral|Healthy diet, regular exercises and peer support|After assessing the exercise and nutritional status of the participants, health staff in community health centers implemented personalized healthy diet and regular exercises intervention, including coaching on healthy exercises and developing personalized dietary prescriptions for participants. Besides, peer support is implemented as a self management strategy in community health service centers or community self management groups to enhance the behavioral change support for these participants.
75397561|NCT03725046|Other|Optimized information transmission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
75547720|NCT05781542|Biological|3M-052-AF|5 mcg
75547721|NCT05781542|Drug|Alum|500 mcg
75547722|NCT05781217|Drug|triptorelin, goserelin, leuprorelin|ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
75547723|NCT05775471|Procedure|Biopsy|Undergo tissue biopsy
75547724|NCT05775471|Procedure|Biospecimen Collection|Undergo blood and urine collection
75547725|NCT05775471|Drug|Enfortumab Vedotin|Given IV
75547726|NCT05775471|Procedure|MR Urography|Undergo MRU
75547727|NCT05775471|Procedure|Nephroureterectomy|Undergo nephroureterectomy
75709312|NCT00872326|Procedure|Autologous Bone Marrow Mononuclear Cells|Infusion > 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
76036936|NCT05610072|Drug|Placebo hydromorphone|Prior to some experimental sessions, subjects will receive placebo hydromorphone
76036937|NCT05609123|Diagnostic Test|Endothelial glycocalyx damage assessment|Degradation products of endothelial glycocalyx will be assessed in the blood and urine.
76036938|NCT05608408|Device|Low Frequency Stimulation (LFS) of site with the Medtronic Percept PC system|Stimulation of site with the Medtronic Percept PC system using low frequency stimulation at 0.5 Hz.
76036939|NCT05608408|Device|Standard of Care (SOC) High Frequency Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system|Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system using standard of care high frequency stimulation parameters.
76036940|NCT05608291|Drug|Fianlimab|Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
76036941|NCT05608291|Drug|Cemiplimab|Cemiplimab will be administered by IV infusion Q 3 weeks
76036942|NCT05608291|Drug|Pembrolizumab|Pembrolizumab will be administered by IV infusion Q 3 weeks
75547728|NCT05775471|Biological|Pembrolizumab|Given IV
75547729|NCT05773378|Device|Pessary Intervention|Participants will receive a 3-size fitting kit and will fit the appropriate size based on manufacturer instruction. Once the size is verified, the participants will be asked to use the pessary while running over a 12-week period.
75547730|NCT05773378|Device|Tampon Intervention|Participants will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 12-week period.
75547731|NCT05770752|Procedure|Elevated pressure ventilation|Elevated pressure ventilation is defined as a raise in PIP and PEEP by 10 cmH2O from each patients original pressure setting, although never higher than a PIP of 30 cmH2O.
75870989|NCT01379976|Drug|Placebo|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
75870990|NCT01379898|Drug|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
75870991|NCT01379898|Drug|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
75397562|NCT01798602|Drug|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
75397563|NCT01798602|Drug|Placebo|Identical placebo for rosuvastatin
75397564|NCT03722082|Behavioral|Enhancing Cognitive Reserve|The intervention is aimed at improving cognitive reserve in offsprings of patients diagnosed with schizophrenia or bipolar disorder. The program is composed of 12 sessions of 60 minutes and will be adapted according the three different age groups (6-12) (13-18) (18-25). Each group will include between 6-to-8 offsprings and conducted by 4 experienced neuropsychologists in both children and adults. The sessions are the following:
75397565|NCT03722082|Behavioral|Support intervention|The support group will schedule meetings with the participants in order to talk about their daily life with the possibility to talk about the difficulties they encounter.
75397566|NCT00604890|Drug|API 31510 3% Topical Cream|Topical treatment 3% active cream applied to the lesion
75397567|NCT00604890|Drug|API 31510 1.5% Topical Cream|Topical treatment 1.5% active cream applied to the lesion
75397568|NCT00604890|Other|Placebo|Topical treatment placebo applied to the lesion
75397569|NCT03694704|Device|FineHearing strategy|Cochlear implant with FineHearing strategy
75397570|NCT02783430|Drug|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
75397571|NCT02783430|Drug|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
75397572|NCT02783430|Drug|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
75547732|NCT05768269|Other|No Intervention|As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
75547733|NCT05767736|Drug|Diroximel Fumarate|Administered as specified in the treatment arm.
75547734|NCT05767736|Drug|Dimethyl Fumarate|Administered as specified in the treatment arm.
75397573|NCT03656328|Dietary Supplement|Lactobacillus Reuteri 4659|supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
75547735|NCT05767736|Drug|Disease-Modifying Therapies (DMTs)|Administered as specified in the treatment arm.
75397574|NCT03656328|Dietary Supplement|Placebo|supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
75397575|NCT03642366|Other|Dornier Aries2 LiST Device + 5mg Tadalafil (1)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
75547736|NCT05766345|Biological|BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331|Nothing to add
75547737|NCT05766345|Biological|Placebo|Nothing to add
75547738|NCT05764928|Drug|BLEX 404|BLEX 404 Oral Liquid, PO, BID
75547739|NCT05763121|Drug|Dexpramipexole Dihydrochloride|oral administration of dexpramipexole tablet
75547740|NCT05763121|Drug|Placebo|oral administration of placebo tablet
75870992|NCT02368366|Behavioral|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
76036943|NCT05608291|Drug|Placebo|Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
76036944|NCT05608044|Drug|Botensilimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
75547741|NCT05762471|Drug|GSBR-1290|Patients will receive GSBR-1290 or matching Placebo
75547742|NCT05762471|Drug|Placebo|Patients will receive GSBR-1290 or matching Placebo
75547743|NCT05759936|Dietary Supplement|500mg seaweed|4 week supplementation of 1 capsule per day of seaweed
75547744|NCT05759936|Other|Placebo|4 week placebo supplement of 1 capsule per day
75397576|NCT03642366|Other|Dornier Aries2 LiST Device + 5mg Tadalafil (2)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
75397577|NCT03642366|Other|Sham LiST Device + 5mg Tadalafil|Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
75397578|NCT05246436|Procedure|warming saline media|use warm saline as a distention media in office hysteroscopy
75397579|NCT05246436|Procedure|room temperature saline media|use room temperature saline as a distention media in office hysteroscopy
75397580|NCT05246358|Device|ChoniSense Polso|"A range of stable respiratory rates was elicited from each volunteer test subject. The rates were 5, 10, 15, 20, 25, 30, 35, 40 and 45 breaths per minute; with some natural variation from these exact numbers.~Each subject was instrumented with an open system mask that allows for measurement of the end tidal carbon dioxide (EtCO2) respiratory rate and tidal volume. The EtCO2 monitor was used as the Accuracy Reference Device (Reference) in this study."
75397581|NCT00604968|Drug|Caelyx (pegylated liposomal doxorubicin; SCH 200746)|Caelyx will be administered intravenously at a dose of 40 mg/m^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses >=90 mg).
75397582|NCT00605202|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
75397583|NCT00605202|Dietary Supplement|Licorice|Licorice candy 32 grams a day for 14 days.
75397584|NCT00605358|Behavioral|Open Door intervention|"Open Door intervention subjects will:~receive an evaluation~receive a referral to a local mental health provider~identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
75397585|NCT05245578|Drug|KX01 ointment 1%|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
75397586|NCT05245578|Drug|Placebo ointment|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
75397587|NCT00605826|Device|NASHA/Dx (Solesta) Gel|Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
75397588|NCT00605826|Device|Sham Injection|Sham injection at the start of the blinded phase.
75397589|NCT05216562|Drug|Exosome-MSC Intravenous injection|Intravenous injection of Exosome-MSC
76036945|NCT05608044|Drug|Balstilimab|An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody.
75397590|NCT05216562|Drug|Placebo Intravenous Injection|Intravenous injection of Placebo
75397591|NCT05216562|Drug|COVID-19 Standard Treatment|Specific drugs considered standard treatment for COVID-10 by each location may vary
75397592|NCT03381300|Procedure|Ovarian tissue cryopreservation|Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue
75709313|NCT00736112|Other|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
75397593|NCT02132598|Drug|cabozantinib|
75397594|NCT00605904|Drug|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
75397595|NCT00605904|Drug|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
75397596|NCT00605904|Drug|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
75709314|NCT00736112|Procedure|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
75397597|NCT00605904|Drug|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
75397598|NCT01798914|Drug|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
75397599|NCT00607620|Behavioral|Brief Intervention|Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
75397600|NCT05175768|Other|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
75397601|NCT05175768|Other|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
75397602|NCT05175768|Other|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
75397603|NCT05128500|Procedure|Total Shoulder Arthroplasty with Permedica's MIRAI|Total Shoulder Arthroplasty with Permedica's MIRAI Modular Shoulder Prosthesis System
76036946|NCT05608044|Drug|Standard of Care|Regorafenib or trifluridine and tipiracil.
76036947|NCT05604300|Dietary Supplement|Vitamin E incorporated oat supplement|A twice daily supplementation of Vitamin E incorporated oat for 12 weeks
76036948|NCT05604300|Dietary Supplement|Oat supplement|A twice daily supplementation of oat for 12 weeks
75397604|NCT05097846|Drug|Group1 Vonoprazan Fumarate + amoxicillin + doxycycline|Vonoprazan Fumarate + amoxicillin + doxycycline
75397605|NCT05097846|Drug|Group2 Vonoprazan Fumarate + furazolidone + doxycycline|Vonoprazan Fumarate + furazolidone + doxycycline
75397606|NCT05097846|Drug|Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
75397607|NCT05097846|Drug|Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
75397608|NCT04388046|Device|Herbst fixed functional appliance|Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
75397609|NCT00608634|Drug|perillyl alcohol|Applied as topical cream
75397610|NCT00608634|Other|placebo|Applied as topical cream
75397611|NCT03088566|Procedure|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
75397612|NCT03088566|Procedure|Conventional foot screening|The foot screening is performed with clinical conventional methods.
75397613|NCT02897700|Drug|Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
75397614|NCT02897700|Drug|cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
75709315|NCT00736112|Procedure|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
75709316|NCT00863980|Drug|Micardis (Telmisartan)|40-80 mg/day oral administration
75709317|NCT00863980|Drug|Blopress (Candesartan)|8-12 mg/day oral administration
76036949|NCT05603884|Drug|Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen|"venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC > 20×109/L"
76036950|NCT05599386|Diagnostic Test|Preoperative test|Patients are subject to quantitative sensory testing, questionnaires, and biomarker analysis prior to surgery.
76036951|NCT05597150|Dietary Supplement|Magnesium Citrate|Each participant should receive a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.
76036952|NCT05596214|Combination Product|Curcumin-Berberine (coptis)|dietary supplement
76036953|NCT05596214|Combination Product|Placebo|Placebo
75870993|NCT02368366|Behavioral|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
75397615|NCT02897700|Drug|Placebo|Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
75397616|NCT02889666|Drug|Cisplatin|Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
75397617|NCT02889666|Drug|Carboplatin|Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
75397618|NCT02889666|Drug|Docetaxel|Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
75397619|NCT02889666|Drug|Gemcitabine/Carboplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
75397620|NCT02889666|Drug|Gemcitabine/Cisplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
75870994|NCT02368366|Behavioral|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
75397621|NCT02889666|Drug|Docetaxel/Oxaliplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
75870995|NCT02367898|Other|Lumosity Cognitive Training|adaptive online cognitive training
75870996|NCT02367898|Other|Crossword Puzzles|timed online crossword puzzles
75870997|NCT04479280|Device|Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA|studying coagulation disorders in COVID19 critically ill patients
75397622|NCT02889666|Drug|Docetaxel/Carboplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
75397623|NCT02889666|Drug|Placebo|Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
75397626|NCT04955340|Drug|[14C]-resminostat|1 single dose of 400 mg [14C]-resminostat
75397627|NCT04815330|Other|increment sweep gas flow|If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
75397628|NCT04815330|Other|non-invasive ventilation|In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
75397629|NCT02740374|Device|ROTEM|ROTEM coagulation assessment and guided transfusion management.
75547745|NCT05757687|Device|Omega device|"The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra."
75397630|NCT02740374|Other|Standard of Care|Standard Coagulation Tests assessment and guided transfusion management
75397631|NCT00609804|Drug|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
75397632|NCT00609804|Drug|Erlotinib|Erlotinib 150 mg once daily by mouth
75547746|NCT05745467|Drug|Povidone Iodine 5% Soln,Top,Kit|5% povidone iodine will be swabbed in patients nares of the experimental group.
75397633|NCT00610116|Device|Electronic Repositioning|Change of pacing vectors for CRT pacing
75397634|NCT00610428|Drug|Staccato Placebo|Inhaled Staccato Placebo
75397635|NCT00610428|Drug|Staccato Prochlorperazine 5 mg|Inhaled Prochlorperazine 5 mg
75397636|NCT00610428|Drug|Staccato Prochlorperazine 10 mg|Inhaled Prochlorperazine10 mg
75709318|NCT00415519|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
75547747|NCT05741788|Device|Various Stimulation Patterns|Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
75397640|NCT00610740|Drug|topical gemcitabine hydrochloride|Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.
75547748|NCT05738499|Other|Character strengths-based structured treatment and education programme (CSSTEP)|This CSSTEP intervention included both psychological and educational contents, and the intervention type was psycho-educational intervention. The implementation process lasted for three weeks. CSSTEP mainly includes two main components. The first part is character strengths-based intervention. The second part is educational intervention, which is structured treatment and education programme for stroke patients. The two components were combined and optimized on the basis of theoritical and empirical evidences, and then this kind of complex intervention suitable for Chinese clinical stroke patients was obtained.
75547749|NCT05738499|Other|Structured treatment and education programme (STEP)|The STEP programme is aimed at the treatment needs of stroke patients, considering the education level and cultural background of patients, screening important health education content, and planning and grading of patients' education. The intervention consisted of three educational sessions, focusing on patients' daily life, post-stroke rehabilitation and secondary prevention.
75870998|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
75547750|NCT05718843|Drug|BI 425809|BI 425809
75397641|NCT00610740|Procedure|therapeutic conventional surgery|hysterectomy
75397642|NCT02444676|Other|Stratification and outcomes|No necessary
75397643|NCT04470180|Behavioral|Virtual Teach to Goal|Participants will complete inhaler education on a tablet device.
75397644|NCT04470180|Behavioral|Brief Instruction|Participants will be read out loud instruction on how to use their inhaler.
75397645|NCT00611442|Drug|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
75397646|NCT00611442|Drug|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
75397647|NCT02136420|Drug|Promethazine|Subject receives promethazine
75397648|NCT02136420|Behavioral|Hyper gravity training|Subject receives hypergravity training before testing
75397649|NCT02136420|Drug|Placebo|Placebo
75397650|NCT02136420|Behavioral|No hypergravity training|Subjects do not receive normal Earth gravity
75397651|NCT02136498|Drug|Varenicline|Standard 12 week course of varenicline, provided in both arms
75397652|NCT02136498|Behavioral|Cognitive-behavioral self-help|Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
75547751|NCT05716048|Behavioral|KF-mSMT Plus Aerobic Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
75547752|NCT05716048|Behavioral|KF-mSMT Plus Stretching Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
75870999|NCT03160066|Dietary Supplement|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
75871000|NCT03160066|Dietary Supplement|Placebo|Placebo
75397653|NCT02136498|Behavioral|MyMAP (My Mobile Advice Program)|Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
75397654|NCT00612222|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
75397655|NCT00612222|Biological|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
75547753|NCT05712707|Drug|BXCL501 (180 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
75547754|NCT05712707|Drug|BXCL501 (240 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
75547755|NCT05712707|Other|Placebo|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
75397656|NCT00612222|Biological|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
75397657|NCT00612222|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
75397658|NCT00612222|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
75547756|NCT05712707|Other|Lofexidine (Positive Control)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
75547757|NCT05708547|Biological|Blood samples|at the beginning of the extracorporeal circulation, at the end of the extracorporeal circulation and at D1
75547758|NCT05708547|Procedure|myocardial tissue samples|use of usually harvested right auricular tissue
75709319|NCT00415519|Drug|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
75397659|NCT01931436|Drug|Qing'E pill|Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
75397660|NCT01842360|Biological|Placebo|The subjects will receive daily dose of placebo during 12 months
75397661|NCT01842360|Biological|MV130|The subjects will receive daily dose of MV130 during 12 months
75397662|NCT00612768|Biological|TRUE Test allergens Fragrance Mix and Thimerosol|"Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
75397663|NCT01711242|Drug|Capecitabine|
75397664|NCT01711242|Drug|Oxaliplatin|
75397665|NCT01711242|Radiation|Radiotherapy|
75397666|NCT04405908|Biological|SCB-2019|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
75397667|NCT04405908|Biological|SCB-2019 with AS03 adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
75397668|NCT04405908|Biological|SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
75397669|NCT04405908|Biological|SCB-2019 with Alum adjuvant|SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
75397670|NCT04333368|Biological|Umbilical cord Wharton's jelly-derived human|Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.
75397671|NCT04333368|Other|NaCl 0.9%|NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5
75397672|NCT04331496|Other|Hypertonic solution|Hypertonic serum 4 ml 3%, administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
75547759|NCT05708547|Other|Data collection|pre-operative data: demographic data, severity scores, co-morbidities, treatments administered, collection of the presence and stage of arteriosclerotic disease, SYNTAX score Collection of data on the procedure Data from the clinical evaluation and daily biological examinations until D7 data from the follow-up consultation between D30 and D60: late complications, total length of stay in intensive care and hospital
75547760|NCT05707078|Procedure|Neck dissection|Based on PET/CT scan patients will undergo neck dissection.
75547761|NCT05692154|Drug|Fexofenadine|Fexofenadine oral tablet
75547762|NCT05692154|Drug|Placebo|Fexofenadine matching placebo oral tablet
75547763|NCT05670418|Device|Quantitative Electroencephalography|Each qEEG examination of one person lasted about 20 minutes and included two stages: the first-recording of brain waves with eyes closed (5 min), the other with eyes open (5 min)
75547764|NCT05660655|Drug|Baricitinib 4 MG Oral Tablet|baricitinib 4 mg once daily
75547765|NCT05660655|Drug|Baricitinib 2 MG|baricitinib 4mg once daily in group A
75709320|NCT00736268|Behavioral|Telephone-based Enhanced Coping Skills Training (CST)|Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
75547766|NCT05657301|Drug|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
75547767|NCT05649956|Drug|Letrozole|Letrozole 2.5 mg PO daily
75547768|NCT05645900|Biological|Quadrivalent influenza virus subunit vaccine|This vaccine（0.5ml） is produced by Ab&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
75547769|NCT05645900|Biological|Quadrivalent influenza virus subunit vaccine|This vaccine（0.25ml） is produced by Ab&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
75547770|NCT05645900|Biological|Quadrivalent split influenza virus vaccine|This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection
75547771|NCT05638217|Combination Product|Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%|"1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence."
75547772|NCT05634863|Device|Implantable Doppler probe manufactured by COOK Medical Company.|The continuous audible Doppler signals produced by the monitoring device represent the blood flowing in the renal artery. This is an indicator of graft perfusion. Cessation of audible Doppler signals is the key that may suggest hampered blood flow due to vascular complications. In the intervention group, the monitoring device will be used as an added mechanism to monitor graft perfusion.
76036954|NCT05594199|Behavioral|Virtual Smoking Cessation Program|"This program consists of an e-learning smoking cessation education module and a tailored email messaging program.~The e-learning module addresses the potential health benefits to quitting smoking regarding surgery or recovering from a fracture. In addition, it provides information on getting support through the process of quitting smoking based on the individual's level of smoking dependence.~Email frequency and content will vary based on the participant's score and level of motivation. Information will include the risks associated with smoking before surgery or how quitting smoking can improve recovery from a fracture injury. Additional information includes the benefits of quitting smoking and developing coping strategies during a quit attempt. Motivational emails and references to free resources for additional smoking cessation support will also be provided."
75547773|NCT05630053|Device|Cementless Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
75547774|NCT05630053|Device|Cemented Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
76036955|NCT05589233|Biological|Vaccionation eighter started or full course|Vaccination against SARS-CoV-2 at any number of doses
76036956|NCT05575076|Drug|Simufilam|simufilam 100 mg oral tablet, twice daily
76036957|NCT05568797|Biological|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine administered intramuscularly.
76036958|NCT05568797|Biological|FLU vaccine|One dose of FLU vaccine administered intramuscularly.
76036959|NCT05565105|Radiation|Total Body Irradiation (TBI)|Hyper-fractioned TBI is administered by a linear accelerator at a dose rate of < 15 cGy/minute.
76036960|NCT05565105|Drug|Thiotepa|Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).
76036961|NCT05565105|Drug|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m^2 x 5 if cyclophosphamide is contraindicated
75871001|NCT02367742|Behavioral|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
76036962|NCT05565105|Drug|Busulfan|Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
76036963|NCT05565105|Drug|Melphalan|Melphalan: 70 mg/m^2/day x 2
76036964|NCT05565105|Drug|Fludarabine|Fludarabine: 25 mg/m^2/day x 5
75397673|NCT04331496|Other|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
75397674|NCT04304274|Procedure|Paravertebral block-ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
75397675|NCT04304274|Procedure|Paravertebral block-saline|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
75547775|NCT05627661|Device|Biosensor|Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
75871002|NCT02367742|Behavioral|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
76036965|NCT05539807|Behavioral|Mindful Eating Conscious Living|"MECL is a 8 week mindfulness-based group intervention. Each session is of 2.5-3 hours duration. During the sessions, theories about eating-related difficulties in general are presented, participants are guided in mindfulness practices and participants who want to share their experiences in the group can do so. Topics include: (1) What is mindfulness, why and how can we use mindfulness in relation to eating (2) slowing down, taking breaks and noticing different types of hunger (e.g. physical hunger and the hunger for comfort - heart hunger) (3) working with satiety and satisfaction (4) becoming aware of patterns associated with one's eating behaviors, (5) awareness of feelings and bodily sensations (6) Food and mood (7) craving, and finally (8) working with heart hunger and emotional eating. Six to 10 participants participated in each group."
76036966|NCT05536154|Drug|Etoposide|Day 1~Day 2: 75mg/m^2
75397676|NCT04304274|Drug|patient controlled analgesia with morphine|Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
75547776|NCT05625945|Behavioral|Physical activity monitoring|Physical activity patterns will be measured using the activPAL3 micro monitor
75547777|NCT05624658|Combination Product|Combined Lipid-lowering Therapy|the effect of high-dose combined lipid-lowering therapy (statins+ezetimibe vs statins+PCSK9 inhibitors) on the vulnerability characteristics of atherosclerotic plaques assessed using multimodal imaging (coronary artery computed tomography and optical coherence tomography), as well as biomarkers in patients with acute coronary syndrome for 52 weeks.
75547778|NCT05619731|Other|Geriatric oncology tele-consultation and pharmaceutical tele-expertise|tele consultation
75547779|NCT05609448|Procedure|MRI-guided radioembolization|Catheter placement will be performed using fluoroscopy, after which patients are transferred to the MRI scanner, where holmium microspheres are administered based on MRI dosimetry. Thereby, patients get a personalized dose administration.
75871003|NCT04334356|Behavioral|Mobile Web App|App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
75871004|NCT02362516|Drug|BI 425809|
75397677|NCT04290780|Other|nosocomial infection/hospital acquired infection|"When there is suspicion of a community-acquired case (admission of an infected patient) or nosocomial case (infection of a patient already hospitalized), a case report form including demographic data, medical history, and clinical and biological data on the infectious episode will be completed for each case, either patient, caregivers or health care professionals, presenting clinical signs or symptoms compatible with SARS-CoV-2 infection. The suspected cases will undergo nasopharyngeal swab collection and detection of SARS-CoV-2 in nasopharyngeal swabs will be done by real-time RT-PCR assay.~Hygiene measures applied by the service will be collected using a questionnaire as well as recommendations of the learned societies within the country regarding the risk of infection by coronavirus. In addition, data characterizing the service and hospital will also be collected (specialty, number of beds, number of nurses, doctors, etc.)."
75547780|NCT05606770|Behavioral|Structured Exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity. Classes will gradually progress in intensity throughout the program. Classes will include a full body warm up followed by a circuit of eight strengthening exercises. This will be repeated for increasing sets and adding resistance through the use of resistance bands . Exercises will involve simple full body exercises and movements for each major muscle group. This will ensure that exercises that can be completed regardless of possible unilateral weakness or physical impairment. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
75397678|NCT04253496|Other|Tumor samples and MRI|We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
75547781|NCT05606770|Behavioral|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
75547782|NCT05606406|Other|Nocturnal Oxygen|Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
75547783|NCT05597098|Drug|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
75871005|NCT02367664|Biological|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
75397679|NCT01285362|Drug|Fish Oil Supplementation|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
75397680|NCT01285362|Drug|Placebo Supplementation|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
75397681|NCT00612924|Device|Anaconda Stent Graft System|Endovascular device
75397682|NCT00612924|Device|Anaconda ONE-LOK Stent Graft System|Endovascular device
76036967|NCT05536154|Drug|Cytarabine|Day 1~Day 2: 200mg/m^2, q12h
76036968|NCT05536154|Drug|PEG-rhG-CSF|Day 6: 6mg
75397683|NCT02132832|Drug|Buspirone|Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
75397684|NCT02132832|Drug|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
75397685|NCT00614406|Drug|Celebrex|One 400mg tablet daily.
75397686|NCT00614406|Drug|Placebo|One tablet daily.
75397687|NCT02132910|Other|RESTORE Intervention|
75397688|NCT02133066|Procedure|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
75397689|NCT02133066|Device|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
76036969|NCT05534971|Procedure|Central venous catheter insertion|The clinical team will use the technique to establish central venous access
76036970|NCT05530135|Other|Exercise program|Exercise program
75397690|NCT02133066|Procedure|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
75709321|NCT00736268|Other|Usual Medical Care and COPD education and symptom monitoring (UMC)|COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
75397691|NCT00614484|Radiation|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
75397692|NCT00614484|Drug|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
75397693|NCT00614484|Drug|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
75397694|NCT04159974|Drug|Durvalumab 50 MG/ML|IV Infusion
75397695|NCT04159974|Drug|Tremelimumab|IV Infusion, Combination with Durvalumab
75397696|NCT04142502|Drug|Propofol|Propofol as a sedation drug
75397697|NCT04142502|Drug|Dexmedetomidin|Dexmedetomidine as a sedation drug
75397698|NCT00615420|Dietary Supplement|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
75397699|NCT00615420|Dietary Supplement|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
75709322|NCT01323907|Drug|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
75709323|NCT01323985|Drug|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
75397700|NCT00568854|Biological|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
75709324|NCT01323985|Drug|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
76036971|NCT05530135|Other|Cognitive behavioural therapy|Cognitive behavioural therapy
76036972|NCT05530135|Other|Standard clinical care|Standard clinical care
76036973|NCT05523674|Other|Warm-up exercise|The warm-up exercise will be performed on a treadmill.
76036974|NCT05523674|Other|Warm-up exercise with Blood Flow Restriction|The warm-up exercise will be performed on a treadmill and pressure cuffs will be used for the blood flow restriction technique.
76036975|NCT05519254|Dietary Supplement|Lactoferrin|Caregivers of children will be instructed to provide 41.5g of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
75397701|NCT00569010|Drug|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days
75397702|NCT00569010|Drug|Ara-C|"Group 1 and 2 at Low-Dose = 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m^2 Daily CIV for 4 days (age<65 years) or 3 days (age>=65 years)"
75397703|NCT00616122|Drug|cyclophosphamide|
75397704|NCT00616122|Drug|methotrexate|
75397705|NCT00616122|Drug|sunitinib malate|
75397706|NCT00616122|Other|laboratory biomarker analysis|
75397707|NCT00616200|Other|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
75397708|NCT00617058|Drug|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
75397709|NCT00617058|Behavioral|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
76036976|NCT05519254|Dietary Supplement|Lysosyme|Caregivers of children will be instructed to provide 41.5g of lysosyme daily mixed with 125 mL of porridge or other complimentary food.
76036977|NCT05519254|Combination Product|Lactoferrin + Lysosyme|Caregivers of children will be instructed to provide 40 grams of Lysosure with 1.5 grams of bovine lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
76036978|NCT05519254|Other|Placebo|Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder produced by Ventria Bioscience Inc daily mixed with 125 mL of porridge or other complimentary food.
75397710|NCT00618540|Biological|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
75397711|NCT00618540|Drug|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age <12 months)
75397712|NCT00618540|Drug|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age <12 months)
75397713|NCT00618540|Procedure|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
75397714|NCT00570960|Drug|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
75397715|NCT00570960|Biological|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
75397716|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
75397717|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
75397718|NCT00571428|Drug|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
75397719|NCT00571974|Device|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
75397720|NCT00571974|Drug|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
75709325|NCT02568176|Drug|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
75709326|NCT02568176|Drug|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
75709327|NCT02568176|Drug|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
75709328|NCT01033591|Behavioral|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
75709329|NCT01033591|Behavioral|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
76036979|NCT05515562|Drug|Omadacycline Injection|All participants will receive Intravenous (IV) omadacycline
76036980|NCT05500001|Behavioral|Supporting Patients by Family Education in Psychotic Illness Group|Psychoeducation for families supporting young adults with psychosis.
76036981|NCT05499676|Device|SilverCloud Health Mobile Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
75871006|NCT02367664|Biological|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
75397721|NCT00571974|Procedure|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
75397722|NCT00621348|Drug|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
75397723|NCT00621348|Drug|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
75397724|NCT00621348|Drug|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
75397725|NCT00574236|Drug|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
75397726|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
75397727|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
75397728|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
75397729|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
75397730|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
75397731|NCT00574704|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 6 visits
75397732|NCT00574704|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 6 visits
75397733|NCT00574704|Drug|CYT003-AllQbG10 in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
75397734|NCT00574704|Drug|CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
75397735|NCT04309630|Procedure|intercostal block|pain control by intercostal block
75397736|NCT04309630|Procedure|erector spina plane block|pain control by erector spina plane block
75397737|NCT01168219|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
75397738|NCT01168219|Biological|Anti-Thymocyte Globulin|Given IV
75397739|NCT01168219|Drug|Azacitidine|Given SC or IV
75397740|NCT01168219|Drug|Busulfan|Given IV
75397741|NCT01168219|Drug|Fludarabine Phosphate|Given IV
75397742|NCT01168219|Other|Laboratory Biomarker Analysis|Correlative studies
76036982|NCT05499676|Device|Social Networking Intervention: Facebook|Facebook is a social networking site that will offer participants the opportunity to interact with study team posts, post themselves, and connect with others in the study experiencing similar struggles in a private group
75397743|NCT01168219|Drug|Methotrexate|Given IV
75397744|NCT01168219|Other|Pharmacological Study|Correlative studies
75397745|NCT01168219|Drug|Tacrolimus|Given PO or IV
75871007|NCT02367664|Biological|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
75871008|NCT05421000|Procedure|WALANT|Wide awake local anesthesia without tourniquet for distal radius fracture surgery
75871009|NCT05421000|Procedure|Locoregional anesthesia and tourniquet|Locoregional anesthesia and tourniquet for distal radius fracture surgery
76036983|NCT05487599|Genetic|LY3884961|• LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
76036984|NCT05477979|Other|Exposure: psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
75397746|NCT01115803|Drug|LY2584702|Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
75397747|NCT01115803|Drug|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
75397748|NCT01115803|Drug|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
75397749|NCT01115569|Drug|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
75397750|NCT01107886|Drug|Saxagliptin|5 mg or 2.5 mg once daily
75397751|NCT01107886|Drug|Placebo|
75397752|NCT01107457|Biological|Ixekizumab|Administered subcutaneously
75397753|NCT01107457|Drug|Placebo|Administered subcutaneously
75397754|NCT05767008|Other|Sunscreen -R43|Long wear metal oxide particles
75397755|NCT05766969|Drug|CBD/PEA|A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
75397756|NCT05766969|Drug|Placebo|An inactive compound.
75397757|NCT05766865|Procedure|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
75397758|NCT05766865|Procedure|Conservative treatment|Standard treatment for intracerebral hemorrhage
75397759|NCT05766826|Other|Coupons for safe water program: Treatment|Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.
75397760|NCT05766826|Other|Coupons for safe water program: Control|Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
75397761|NCT05766696|Procedure|Atraumatic Restorative Treatment (ART)|"Conventional glass-ionomer restorations are placed using the Atraumatic Restorative Treatment (ART) technique. Essentially, cavities are prepared using hand instrument excavators. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a class room.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
75547784|NCT05595746|Procedure|dental implant placement|In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.
75547785|NCT05595018|Other|End user|Participants will provide their opinions in two rounds to reach consensus
75547786|NCT05595018|Other|Demand side- management|Participants will provide their opinions in two rounds to reach consensus
76036985|NCT05444335|Device|Wearable cardiac monitor -Zio patch|Women older than 70 years old will be asked to wear a cutaneous cardiac monitor for 2 weeks.
75547787|NCT05595018|Other|Supply side|Participants will provide their opinions in two rounds to reach consensus
75547788|NCT05595018|Other|Funder|Participants will provide their opinions in two rounds to reach consensus
75547789|NCT05595018|Other|Academia|Participants will provide their opinions in two rounds to reach consensus
76036986|NCT05443737|Behavioral|Multi-component oncofertility care intervention|The multi-component oncofertility care intervention includes: (1) an adaptive and smart default electronic health record-based oncofertility needs screen and referral pathway, (2) telehealth oncofertility counseling as indicated, and (3) telehealth oncofertility financial navigation as indicated.
75547790|NCT05592353|Other|Brace|Brace following hip arthroscopy
75547791|NCT05585151|Drug|Evolocumab 140 MG/ML|Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times
75547792|NCT05585151|Drug|Intensive statin treatment|Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
75547793|NCT05585125|Drug|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs Off [B]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta-blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.~Other names:~atenolol betaxolol bisoprolol metoprolol nebivolol nadolol propranolol acebutolol penbutolol pindolol carvedilol labetalol sotalol metoprolol succinate metoprolol tartrate"
75871010|NCT04275934|Behavioral|Health Management; Blood Pressure|Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
76036987|NCT05442216|Drug|Tagraxofusp (Cycles 1-2)|12 mcg/kg intravenously Days 1-5
76036988|NCT05442216|Drug|Azacitidine|75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
76036989|NCT05442216|Drug|Tagraxofusp (Cycles 3-12)|12 mcg/kg intravenously Days 1-3
76036990|NCT05430334|Combination Product|e-liquid 1|30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated
76036991|NCT05430334|Combination Product|e-liquid 2|30/70 PG/VG ratio with nicotine concentration 10mg/ml protonated
75397762|NCT05766696|Procedure|Conventional Cavity Preparation|"Conventional glass-ionomer restorations are placed after conventional cavity preparation. Essentially, cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a mobile clinic.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
75397763|NCT05766644|Other|Education|An 8-week program providing educational materials via a mobile app for chronic kidney disease management. Materials consist of videos, card news, and live online seminars with a Q&A session. Topics are on general disease information, nutrition, and exercise.
75397764|NCT05766618|Procedure|Injectable platelet rich fibrin (i-PRF): in acceleration of orthodontic tooth movement|"Preparatory phase~Space closure will be done on a 17x25 stainless steel wire~Both molars will be indirectly anchored to the miniscrew~Extend closing coil spring of suitable length from the canine hock to the first molar hock for retraction.~Apply a force of 150gm for each side. The force is measured by a force gauge and activated each visit to keep it constant all over the retraction phase. PRF Injection protocol~The First injection will be 3 weeks before extraction~By the end of the fourth week the patients will be referred for pre-intervention records. Upper arch CBCT will be obtained to take preintervention measurements of the alveolar bone.~At the time of canine retraction patient will receive another injection immediately and an alginate impression will be taken~follow up every month and injection will be repeated month after month with an observational period of 5 months."
75397765|NCT05766605|Drug|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
75397766|NCT05766605|Drug|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
75397767|NCT05766605|Drug|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
75397768|NCT05766605|Drug|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
75397769|NCT05766605|Drug|Oxaliplatin, Leucovorin, fluorouracil|"Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions"
76036992|NCT05430334|Combination Product|e-liquid 3|30/70 PG/VG ratio with nicotine concentration 4mg/ml free base
76036993|NCT05430334|Combination Product|e-liquid 4|30/70 PG/VG ratio with nicotine concentration 10mg/ml freebase
76036994|NCT05430334|Combination Product|e-liquid 5|30/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
75397770|NCT05766605|Drug|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
75397771|NCT05766527|Biological|KM602|Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.
76036995|NCT05426213|Device|Robot-assisted Bronchoscopy (Monarch Platform)|Robotic assisted bronchoscopy biopsy procedures will be performed using the Monarch platform.
75397772|NCT05766436|Drug|Dexmedetomidine|receive placebo ODF and 3 µ/kg nebulized dexmedetomidine (Precedex™ rxlist) prepared in 0.9% normal saline to a final volume of 3ml. Nebulization was performed using a wall nebulizer and wall oxygen source on 4 l/min.
75709330|NCT03899870|Procedure|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
75709331|NCT03899870|Drug|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil [5-FU] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
76036996|NCT05419050|Drug|denosumab|monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis
75397773|NCT05766436|Drug|Melatonin|will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining
75397774|NCT05766436|Drug|Placebo|placebo ODF and 0.9% normal saline nebulizer
75397775|NCT05766397|Drug|Methoxyflurane|Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetic gases
75397776|NCT05766384|Drug|Hyperpolarized Xe129|Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
76036997|NCT05418907|Radiation|68Ga-NODAGA-exendin-4 PET/CT|PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4
75397777|NCT05766319|Device|Withings ScanWatch|"Withings ScanWatch, from which the following features will be used:~Measurement of peripheral oxygen saturation (%)~Automatic recording of heart rate (beats/min)~Automatic recording of activity (step count) (numbers/day)"
75397778|NCT05766319|Device|Withings BPM Connect|"Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)"
75397779|NCT05766319|Device|Withings Body|"Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)"
75397780|NCT05766293|Device|extracorporeal shockwave device|Fibroblast cell lines (n=10) were subjected to Shockwaves from extracorporeal shockwave device
76036998|NCT05395026|Other|electrical stimulation of vagus nerve|VNS electrical stimulation parameters (pulse duration, pulse amplitude, and pulse frequency) will be systematically changed to determine the effect on vagus nerve activation, laryngeal muscle contraction, and heart rate.
76036999|NCT05387434|Behavioral|Diabetes Prevention Program-Remote (DPP-R)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Zoom.
75397781|NCT05766293|Other|Fibroblast cell lines not subjected to shockwaves from extracorporeal shockwave device|Fibroblast cell lines (n=10) without shockwave exposure
75397782|NCT05766228|Other|Web-Based Intercultural Midwifery Training|The training program is a program where students can log in via the internet using the password given to them by a smartphone or computer. The web base is compatible with mobile phones and is suitable for use at any time of the day. The trainings were prepared and explained by the researchers on the web page in the form of a video presentation with the theory-based didactic classroom technique using a Power Point presentation. The training program covered six weeks and consisted of two sessions of 30 minutes each week. In the first five weeks, general information on the development of intercultural midwifery and the main components of cultural competence models are explained. In the last week, training was completed with case presentations in the form of two sessions.
76037000|NCT05387434|Behavioral|Diabetes Prevention Program-Facebook (DPP-FB)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Facebook.
75397783|NCT05766176|Diagnostic Test|COVID-19 Antibody|This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.
75397784|NCT05766137|Procedure|Alveolar ridge preservation|Socket preservation
75397785|NCT05766098|Genetic|Genotyping|Characterization of genetic profile of tumor tissues
75397786|NCT05766085|Diagnostic Test|Dexamethasone suppression test|Determination of cortisol levels at 9.00 am after taking 1 mg of dexamethasone the previous evening at 11.00 pm (1mg DST)
75397787|NCT05766072|Other|EMOTION Kids coping with anxiety and depression (Kendall et. al, 2013) (Mestrende barn in Norwegian) Martinsen et al, 2014|The intervention is transdiagnostic and based on cognitive behavioral therapy where the children and their parents meet i groups led of school health nurses. They are learning coping skills to meet challenging and avoided situations, learning about emotion regulation, physical symptoms conitive restructuring and exposure/behavioral activation. Te manual is publshed in a US/English version and in a Norwegian version.
75397788|NCT05766059|Device|Transcranial Magnetic Stimulation|The standard PAS protocol will be compared with the mirrorPAS protocol.
75397789|NCT05766033|Other|Enamel conditioning with a novel etchant paste|The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
75397790|NCT05765994|Diagnostic Test|Modified hydrogen breath test|A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
75397791|NCT05765981|Drug|VGN-R09b|VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
75397792|NCT05765916|Behavioral|Online mindfulness and acceptance intervention|"Session 1 aims to encourage participants to share their experiences; and introduce the purpose, content, delivery mode, duration, and frequency of the intervention.~Session 2 aims to explain how negative illness perceptions lead to fear of cancer recurrence; and introduce the signs, screening, treatment and prognosis of breast cancer, ways to reduce the risk of recurrence, and symptom management.~Session 3 aims to guide the participants to practice body scan and seated meditation.~Session 4 aims to guide the participants to practice detached mindfulness, promoting reflection on the negative effect of indulging in unhelpful thoughts.~In session 5, participants will receive several forms covering work, health, parenting style, intimate relationships, self-development and so on. Participant will be asked to choose one or two forms and set action plans.~In session 6, the facilitator will invite participants to recall positive experiences and practice the Self-care exercise."
75397793|NCT05765877|Drug|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
75397794|NCT05765825|Drug|serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
75397795|NCT05765825|Drug|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
76037001|NCT05363280|Drug|AL8326 low dose group|Taken AL3826 at low dose orally
76037002|NCT05363280|Drug|AL8326 middle dose group|Taken AL3826 at middle dose orally
75397796|NCT05765825|Drug|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
75397797|NCT05765825|Drug|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
75397798|NCT05765825|Radiation|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.Following the induction phase, participants will continue maintenance therapy with serplulimab thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 30 Gy in 10 fractions in the fifth and sixth cycle
75397799|NCT05765799|Other|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).
75397800|NCT05765773|Biological|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
75397801|NCT05765747|Drug|Yunnan Baiyao|Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
75397802|NCT05765747|Drug|Celecoxib 200mg|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
75397803|NCT05765721|Behavioral|FRAIL-SM Program|Patients in experimental group will receive a 8 week family-based frailty self-management program; patients in control group maintain their usual life activities.
75397804|NCT05765708|Other|Motor Imagery|Motor imagery is the mental execution of a movement without any overt movement or without any peripheral (muscle) activation. It has been shown that motor imagery leads to the activation of the same brain areas as an actual movement. Therefore, it is used to acquire new motor skills. Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
75397805|NCT05765708|Diagnostic Test|Action Observation|Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
75397806|NCT05765695|Procedure|Radiofrequency ablation performed with a 19 gauge STARmed needle.|The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
75547794|NCT05585125|Drug|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs Off [B]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta-blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.~Other names:~atenolol betaxolol bisoprolol metoprolol nebivolol nadolol propranolol acebutolol penbutolol pindolol carvedilol labetalol sotalol metoprolol succinate metoprolol tartrate"
75547795|NCT05574192|Behavioral|Social Engagement Intervention|"The intervention includes social visiting with women affected by violence. Social visiting is carried out by trained peer-workers. Peers are women who share life histories with the target study population. Peer-workers will establish a visiting schedule (day/time) and provide a detailed list of activities in two categories:~arts-based activities.~physical activities.~The peer will meet with the participant at the scheduled place and times to accompany the participant and engage in the activities with the participant.~Participation in scheduled social activities that target the interest and ability of women affected by violence is considered to improve social connectedness by increasing the quality and quantity of a woman's social interactions with a supportive, trained person who shares life experiences. Shared, consistent and reliable social activities also are hypothesized to reduce loneliness by contributing to a sense of belonging and sense of being cared for."
76037003|NCT05363280|Drug|AL8326 high dose group|Taken AL3826 at high dose orally
76037004|NCT05361395|Drug|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
76037005|NCT05361395|Drug|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion.
76037006|NCT05361395|Drug|Etoposide|Etoposide will be administered as an intravenous (IV) infusion.
75397807|NCT05765656|Behavioral|GP - pharmacist collaboration and pharmacist motivational interviewing|"Patients in the GP-CP clusters randomized to the intervention arm will be offered a joint GP-CP deprescribing intervention by their GP.~After the encounter, the patients will go to the pharmacy to get their medication dispensed. They will be given education materials. The pharmacist will plan with the patients 3 Motivational Interviews which will address the risks of using BZDR, and the benefits and modalities of stopping them. The pharmacists will receive a 2-day training course in MI. They will be given guidelines on BZDR deprescribing. If required, the pharmacists will be supported in their first MI.~Following each interview, the pharmacist will inform the GP by means of a formalized report of the points discussed. The pharmacist will inform the GP of the patient's choice or not to get involved in a deprescribing process and of the protocol followed. The objective of this exchange is to formalize the joint GP-CP intervention and to secure the deprescribing of BZDR."
75397808|NCT05765643|Other|Nurse parental support in symptom management using a mobile health App|Parents in this group will receive a mobile App that includes health assessment, monitoring, health education and nurse support using phone calls over a 3-month period
75397809|NCT05765630|Biological|BLOOD SAMPLES|BLOOD SAMPLES
75397810|NCT05765617|Drug|Calcitriol|The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
75397811|NCT05765617|Other|Placebo|Placebo give 2x1 per day for five day
75397812|NCT05765591|Other|Balneotherapy and aquatic exercises|Information has already been included in arm/group descriptions
75397813|NCT05765565|Device|Octaray multi-electrode catheter|Newly designed multi-electrode catheter for creating 3D electroanatomical CARTO maps.
75397814|NCT05765565|Device|Pentaray multi-electrode catheter|Current standard multi-electrode catheter for creating 3D electroanatomical CARTO maps.
75397815|NCT05765552|Other|Dual-Task Training|Motor-cognitive dual-task exercises will be applied for 2 days a week for 8 weeks.Sessions will last for 30 minutes.
75397816|NCT05765552|Other|Control Group|Upper and lower extremity range of motion exercises will be applied for 8-10 repetitions for 1 set 2 times a week for 8 weeks.
76037007|NCT05361395|Drug|Atezolizumab|Atezolizumab will be administered as an intravenous (IV) infusion.
76037008|NCT05361395|Drug|Durvalumab|Durvalumab will be administered as an intravenous (IV) infusion.
76037009|NCT05353257|Drug|HLX10|"Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
76037010|NCT05353257|Drug|carboplatin/cisplatin-etoposide|"Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice."
75397817|NCT05765539|Device|echOpen O1 Handheld Ultrasound device|"The performance of the Handheld ultrasound device (echOpen O1 device) will be assessed during these visits for all evaluation criteria.~One examination with the US machine by the midwife focused on 4 targets ;~One examination with a classic US machine by the same midwife (comparator) including the search for the four targets ;~One examination with the US machine by a second operator ; Review of the images obtained by the US machine by the referring radiologist at a separate point of time.~The mode of delivery and the vital status of the mother and newborn will also be collected.~Operator A will start by using either the echOpen O1 device or the US machine (random order, via sealed envelopes) and will then perform the other type of examination.~Another operator (Operator B) will come to perform an examination with the Handheld ultrasound device (blind to the result of the first operator).~The switch between operators A and B will also be random."
76037011|NCT05353257|Radiation|Thoracic radiotherapy|Standard Thoracic Radiotherapy
76037012|NCT05353257|Drug|Placebo|Placebo Q3W
76037013|NCT05353257|Radiation|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
76037014|NCT05345132|Drug|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
75397818|NCT05765474|Behavioral|Practice Variable|This group receives the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
75397819|NCT05765474|Behavioral|No Practice Variable|This group does not receive the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
75397820|NCT05765422|Other|salivar and gum sampling|Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum
75397821|NCT05765409|Other|TIMCA|"TIMCA is an individual therapy that will include the parents at certain points in the therapy .~It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.~Out of 10 sessions, there will be three with the parents and the adolescent together."
76037015|NCT05345132|Drug|Magnesium sulfate|Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
76037016|NCT05343806|Drug|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
75397822|NCT05765409|Other|Treatment as Usual|"TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.~Each therapist will be asked to specify the approach used as well as the therapeutic axes."
75397823|NCT05765357|Drug|Trastuzumab for injection|Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
75397824|NCT05765357|Drug|Herceptin|Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
75871011|NCT02367274|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
76037017|NCT05343806|Drug|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
75871012|NCT01379820|Device|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
75871013|NCT02357212|Procedure|coronary angiography|invasive procedure performed to determine coronary anatomy
75871014|NCT02357212|Procedure|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
75871015|NCT01382160|Biological|adalimumab|40 mg every two weeks, by subcutaneous way
75397825|NCT05765331|Device|Chatbot|The AI chatbot is a kind of artificial intelligence technology that can help increase knowledge and understanding of men's health issues. That interacts with subjects through literal text and provides educational resources, advice, and assistance related to lifestyle changes. The chatbot is a valuable aid to increase men's health by providing information about enlarged prostate with urination problems and erectile dysfunction.
75397826|NCT05765292|Dietary Supplement|Probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa
75397827|NCT05765292|Dietary Supplement|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
75397828|NCT05765279|Drug|HH-120 nasal spray 1|HH-120 nasal spray 5 times daily for 3 consecutive days
75397829|NCT05765279|Drug|HH-120 nasal spray 2|HH-120 nasal spray 8 times daily for 3 consecutive days
75547796|NCT05566821|Behavioral|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
75547797|NCT05563584|Behavioral|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support
75547798|NCT05561855|Behavioral|lifestyle intervention|"During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of Weight Loss and Glucose Control.They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data."
75547799|NCT05557708|Drug|212-Lead Pentixather|Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
75547800|NCT05557708|Diagnostic Test|203-Lead Pentixather SPECT/CT|Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.
75547801|NCT05556629|Other|No Intervention|This is a non-interventional study.
75547802|NCT05546164|Other|Assessment of hand grip strength|Assessment of hand grip strength
75547803|NCT05546164|Other|Assessment of pinch strength|Assessment of pinch strength
75547804|NCT05546164|Other|Assessment of upper limb dexterity|Assessment of upper limb dexterity
75871016|NCT00735748|Drug|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
75871017|NCT00735748|Drug|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
75397830|NCT05765279|Drug|Placebo Comparator 1|Placebo nasal spray 5 times daily for 3 consecutive days
75397831|NCT05765279|Drug|Placebo Comparator 2|Placebo nasal spray 8 times daily for 3 consecutive days
75397832|NCT05765240|Drug|Hyaluronic Acid Topical Gels|Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.
75397833|NCT05765240|Procedure|Diode Laser Biostimulation|Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
75547805|NCT05545202|Other|Pentaisomaltose|Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
75547806|NCT05541497|Drug|Varenicline Tartrate|Days 1-3: 0.5mg study pill once per day, Days 4-7: 0.5mg study pill twice per day, Weeks 2-8: 1mg study pill twice per day
75547807|NCT05541497|Drug|Placebo|Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
75871018|NCT03630900|Other|Sequential O2 Culture|We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
75871019|NCT02367196|Drug|CC-90002|
75871020|NCT02367196|Drug|Rituximab|
75871021|NCT05418504|Drug|Dental anesthesia|Dental anesthesia, used to do any dental procedure
75871022|NCT02362126|Device|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
75397834|NCT05765188|Other|loop electrosurgical excision procedure|A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.
75397835|NCT05765162|Behavioral|Patient reported ourcomes|Full screening for the perioperative periode
75397836|NCT05765149|Other|No intervention|This is an observational study, no intervention will be implemented.
75397837|NCT05765110|Other|Dopaminergic OFF drug state|Experiment will be performed without dopaminergic medication
75397838|NCT05765110|Other|DBS OFF state|Turning off the stimulation during experiment
75397839|NCT05765110|Other|Dopaminergic ON drug state|Experiment will be performed with dopaminergic medication
75709332|NCT03899870|Drug|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
75709333|NCT00741182|Drug|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
75397840|NCT05765110|Other|DBS ON state|Experiment will be performed with stimulation (ON condition)
75397841|NCT05765097|Device|Artificial pancreas treatment|five to seven days treatment by artificial pancreas system
75397842|NCT05764980|Behavioral|visual function evaluation|visual function evaluation
75397843|NCT05764902|Behavioral|Patient-tailored intervention|The intervention group will receive various tailored interventions designed to address multiple patient preferences, including sleeping, eating, and resting habits, hobbies, visitation preferences, religious and spiritual needs, preferences for independence and privacy, and any other specific requests or requirements.
75397844|NCT05764850|Genetic|Genome sequencing|"100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis."
75397845|NCT05764837|Other|Foam Rolling|Foam rolling was performed for 4 minutes with the goal of affecting the entire myofascial posterior chain.
75397846|NCT05764811|Drug|Canagliflozin 100mg|100 mg daily for a month
75397847|NCT05764798|Drug|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
75397848|NCT05764798|Drug|Control group: Placebo combined with zolpidem|Placebo and zolpidem orally for 8 consecutive weeks
75709334|NCT00872404|Drug|CP-751,871|20mg/kg/3 weeks
75709335|NCT00423943|Drug|modafinil|200 milligrams daily dose
75709336|NCT00423943|Drug|Placebos|capsule containing placebo
75397849|NCT05764746|Drug|Artemether-lumefantrine and Amodiaquine Drug Combination|AL and AQ will be given together for three days then followed by placebo for three days
75397850|NCT05764746|Drug|Artemether-lumefantrine then Artesunate amodiaquine|AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days
75397851|NCT05764746|Drug|Artemether-lumefantrine|This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
75397852|NCT05764707|Drug|Acetaminophen|Patients will received 1000mg of intravenous acetaminophen within 30 minutes of skin closure.
75709337|NCT00736346|Behavioral|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
75709338|NCT00736346|Behavioral|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
75709339|NCT00736346|Drug|paroxetine|40 mg die, for 6 months
75709340|NCT00864058|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Actavis formulated products under fasting conditions
75397853|NCT05764707|Drug|Placebo|Patients will received 1000mg of normal saline within 30 minutes of skin closure.
75397854|NCT05764668|Drug|Zihua Wenfei Zhisou Granule|14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
75397855|NCT05764668|Drug|Placebo|14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
75397856|NCT05763602|Drug|povidone-iodine topical ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
75397857|NCT05762367|Diagnostic Test|3T MRI with Gadobutrol injection|MRI will be performed in all participants before and after Gadobutrol injection
75397858|NCT05762315|Behavioral|Audio Storytelling|The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
75397859|NCT05762172|Other|early 18F-FDOPA uptake|"During the usual patient care protocol for the 18F-FDOPA TEP examination, a 10 min acquisition starts after a 15 minutes waiting period following the injection of the radiotracer. This allows the reconstruction of a single late image volume. In the framework of this project, the patient is placed in the machine at the time of injection so as to acquire early 18F-FDOPA uptake and then reconstruct intermediate image volumes in addition to the usual final volume.~The total duration of the patient's examination is therefore not changed."
75397860|NCT05761184|Diagnostic Test|Serum collection for proteomic analysis|Serum collection for proteomic analysis
75397861|NCT05761145|Diagnostic Test|Blood sample collection|Blood sample collection
75709341|NCT00864058|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
75709342|NCT00864136|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
75709343|NCT00864136|Drug|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
75709344|NCT00864136|Drug|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
75397862|NCT05759676|Device|Cre8™/Cre8™ EVO drug-eluting stent|Patient with CAD who undergoing PCI with Cre8™/Cre8™ EVO drug-eluting stent
75397863|NCT05759637|Diagnostic Test|1mg DST|measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
75397864|NCT05759117|Procedure|thoracentesis|A type of pleural procedure that will yield pleural fluid for subsequent analysis
75397865|NCT05757622|Drug|Propofol|Procedural sedation provided with propofol and remifentanil using target controlled infusions
75397866|NCT05757622|Drug|Remifentanil|Procedural sedation provided with propofol and remifentanil using target controlled infusions
75397867|NCT05746650|Procedure|Electrical stimulation|Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
75397868|NCT05746650|Drug|Growth hormone (somatropin)|Daily injection of growth hormone
75397869|NCT05746650|Other|Control (No electrical stimulation, nor growth hormone)|No electrical stimulation, nor growth hormone
75397870|NCT05745649|Other|Resistance exercises|Resistance exercises
75397871|NCT05745649|Other|Ankle weights|Ankle weights
75397872|NCT05731726|Drug|Serplilumab|"Serplilumab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w"
75397873|NCT05731726|Drug|Capecitabine|Given PO
75709345|NCT05742308|Behavioral|Laughter yoga|Laughter yoga program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. The sessions included a combination of different laughter exercises. The last step, which included yoga nidra took 5 minutes.
75709346|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
75709347|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
75397874|NCT05731726|Drug|Oxaliplatin|Given IV
75871023|NCT05406414|Behavioral|Transdiagnostic sleep and circadian treatment|"The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks. The sessions are delivered individually and have the following content:~Assessment and introduction to the sleep diary~Review of sleep diary - agreements on behavior changes and goals.~Information on normal sleep, sleep problems and circadian rhythm~Cognitive techniques~Introduction to relaxation training~Follow-up on goals and plan for prevention relapse of sleep problems"
75871024|NCT05406414|Behavioral|Active waitlist control group|The control group receives sleep hygiene education consisting of a single session in which 10 points of sleep advice are presented. They receive a booklet on how to promote good sleep practice and must work on their own for the next 6 weeks to implement this while waiting for the intervention.
75397875|NCT05731726|Drug|Celecoxib|celebrex
75397876|NCT05715931|Drug|Toripalimab|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
75709348|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
75871025|NCT01377792|Drug|Hypertonic saline|comparison of different dosages of drug
75397877|NCT05715931|Drug|Trastuzumab|Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
75397878|NCT05715931|Drug|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle."
75397879|NCT05714774|Device|HIFU treatment of prostate cancer|HIFU treatment using Focal One (EDAP TMS) combined with the acquisition of additional ultrasound images before, between, and after HIFU shots will be performed.
75547808|NCT05541458|Other|Food as medicine|"Encourage participants to make dietary changes by increasing consumption of nutritious foods, particularly fruits and vegetables.~Reduce food insecurity by making it easier for participants to access nutritious foods to ensure they are eating a balanced diet.~Increase nutrition literacy.~Improve health-related outcomes of participants by decreasing chronic health conditions by decreasing health metrics using food as medicine."
75547809|NCT05536219|Diagnostic Test|Serum anti-IFN-I antibodies|Anti-IFN-I autoantibodies presence will be assessed through serological methods (ThermoFisher Kit)
75547810|NCT05527847|Behavioral|Peers LEAD|Two group session focusing on beliefs about medicines and diabetes, discrimination/mistrust, and communication with providers, and 2 peer-based phone calls from Ambassadors to occur weekly for weeks 3-8, then bi-weekly for weeks 9-12.
75547811|NCT05527847|Behavioral|HLWD|Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
75547812|NCT05525520|Drug|EP547|Once daily
75547813|NCT05525520|Drug|Placebo|Once daily
75709349|NCT00864214|Drug|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
75709350|NCT05742230|Drug|Henagliflozin 10 mg|Participants will receive 10 mg single oral tablets orally once daily.
75709351|NCT05742230|Drug|blank control|standard treatment
75709352|NCT00872482|Drug|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
75709353|NCT00428389|Drug|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
75709354|NCT00428389|Drug|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
75709355|NCT00736424|Device|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
75709356|NCT00616642|Drug|rosiglitazone maleate|Given orally
75709357|NCT02568488|Drug|Metformin|850 mg orally twice daily for 6 months
75709358|NCT01324063|Biological|sargramostim|
75871026|NCT02356978|Device|Arm1 homemade phototherapy treatment|"session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights."
75871027|NCT02356978|Device|DRAP|
75871028|NCT03408886|Drug|Vancomycin|Oral vancomycin is administered to reduce pathogenic bacteria.
75709359|NCT01324063|Drug|amsacrine|
75709360|NCT01324063|Drug|cytarabine|
75709361|NCT01324063|Drug|daunorubicin hydrochloride|
75709362|NCT01324063|Procedure|quality-of-life assessment|
75709363|NCT00923624|Other|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
75709364|NCT00923624|Behavioral|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
75871029|NCT03408886|Drug|MoviPrep|MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
75397880|NCT05708183|Dietary Supplement|Multiple micronutrient supplementation (MMS)|Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
75397881|NCT05708183|Dietary Supplement|Iron folate supplementation (IFA)|IFA delivered as part of routine antenatal care, according to current policy
75709365|NCT03994549|Drug|Dual GLP-1/GLP-2 Receptor agonists|Eight ascending doses of ZP7570
75397882|NCT05699317|Other|Thermal stimuli|"Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).~Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.~Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied."
75397883|NCT05698992|Other|evidence-based individualized rehabilitation|The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
75547814|NCT05510687|Device|Glasses to correct presbyopia|Participants will receive eyeglasses to correct presbyopia, as per the power determined in the eye examination.
75709366|NCT00736658|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
75547815|NCT05501275|Behavioral|psychotherapy|Psychotherapy and psychoeducation in patients after stroke.
75709367|NCT00736658|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
75871030|NCT03408886|Biological|Full Spectrum Microbiota|Gut bacteria from healthy human donors are administered orally in a pill form
75547816|NCT05500105|Other|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
75547817|NCT05489523|Drug|Tafamidis 61 MG|Tafamidis 61 mg by mouth daily for 12 months
75547818|NCT05483283|Other|Empowerment and Navigation|Empowerment and Navigation
75547819|NCT05483283|Other|SOC|SOC
75547820|NCT05459688|Drug|CIN-107|2 mg of CIN-107, once a day for 52 weeks
75547821|NCT05458323|Device|Free near and Distance Vision glasses|Intervention Description: All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction.
75547822|NCT05453656|Behavioral|exercise|physical activity promotion and engagement following kidney transplantation
75547823|NCT05452590|Procedure|Ultrasound-guided wire-in-needle technique for central venous catheter placement|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
75871031|NCT02357056|Other|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
75547824|NCT05452005|Drug|[18F]-αvβ6-BP|Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
75547825|NCT05445050|Diagnostic Test|Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)|"Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer~Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neoadjuvant chemotherapy~Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity"
75547826|NCT05440708|Drug|TTI-101|Oral tablet
75547827|NCT05440708|Drug|Pembrolizumab|Intravenous (IV) infusion
75547828|NCT05440708|Drug|Atezolizumab|Intravenous (IV) infusion
75397884|NCT05698914|Behavioral|Telehealth mindfulness-based intervention (MBI)|The telehealth MBI is adapted from Mindfulness-based cognitive therapy for chronic pain and consists of eight, weekly 75-minute individual sessions (90 minutes allotted for the first session) with a mindfulness interventionist delivering the intervention over telehealth (online with audio and video camera) in addition to the patient receiving their usual postsurgical care. Participants will begin the intervention after completing the 2-week postoperative assessment and within 4 weeks after surgery. Participants will be asked to practice skills between sessions approximately 20-40 minutes per day.
75397885|NCT05698914|Behavioral|Telehealth Education|Participants will receive a written educational booklet at the time of randomization (within 2-4 weeks after surgery) and 8, weekly telehealth sessions lasting 30 minutes in addition to usual postsurgical care. The educational materials are reviewed individually with the participant during weekly telehealth sessions (online with audio and video camera) by a physical therapist.
75547829|NCT05440708|Drug|Bevacizumab|Intravenous (IV) infusion
75547830|NCT05439590|Behavioral|High dose CSO|Participants in the high-dose CSO arm of the study will consume two smoothies containing a total of 60 g of CSO per day for 4 weeks.
75397886|NCT05695378|Drug|KM-819|Subjects will receive KM-819 400 mg orally daily.
75547831|NCT05439590|Behavioral|Low dose CSO|Participants in the low-dose CSO arm of the study will consume two smoothies containing a total of 30 g of CSO per day for 4 weeks.
75547832|NCT05439590|Behavioral|Low dose OO|Participants in the low-dose OO arm of the study will consume two smoothies containing a total of 30 g of OO per day for 4 weeks.
75547833|NCT05439590|Behavioral|High dose OO|Participants in the high-dose OO arm of the study will consume two smoothies containing a total of 60 g of OO per day for 4 weeks.
75547834|NCT05435885|Other|Pulmonary Tele-Rehabilitation|12 supervised training sessions via a specific mobile messenger during four weeks. (3 sessions/week)
75547835|NCT05435885|Other|Control (Education)|Usual care with only one educational session.
75547836|NCT05435547|Drug|Dexamethasone|Will take Dexamethasone pre-operatively
75547837|NCT05435547|Drug|Placebo|Will take Placebo pre-operatively
75547838|NCT05432986|Device|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
75547839|NCT05424276|Drug|IkT-148009|Oral administration gelatin capsule
75547840|NCT05424276|Drug|Placebo|Oral administration gelatin capsule
75871032|NCT02357056|Other|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
75871033|NCT02357056|Other|Virtual Reality|daVinci Surgical Skills simulation
75547841|NCT05415969|Other|CKD-aP|Identification of CKD-aP prevalence and severity among patients on dialysis.
75547842|NCT05415319|Behavioral|Laboratory tasks in middle childhood/pre-adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
76037018|NCT05343312|Drug|AL (Coartem)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
75397887|NCT05695378|Drug|Placebo|Subjects will receive Placebo orally daily.
75397888|NCT05686200|Behavioral|Forearm isometric exercise intervention program|Experimental group using the intelligent gripper for forearm isometric exercise in the 3rd to 8th participants after operation, and using the smart mobile phone to install the forearm isometric exercise training game program software to provides an interactive and real- time exercise grip strength feedback mechanism, which are uses the interest of the participant to complete the forearm isometric exercise every day, and can implement the isometric exercise training for fistulization. Study nurses will track exercise adherence with telephone interviews 2, 4 and 8 participants after participant exercise intervention.
75547843|NCT05414747|Device|ABV-1701|ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)
75547844|NCT05414747|Device|SF6 Gas|SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)
75547845|NCT05413239|Behavioral|Psychoeducation to reduce diabetes distress and improve glycemic outcomes|The intervention includes two types of sessions - those targeting an improvement in glycemic outcomes and those targeting a reduction in diabetes distress. Evidence indicates that psychoeducation and support are needed to improve self-care behaviors and optimize use of advanced diabetes technologies, which, in turn, can help improve diabetes control while also reducing diabetes distress. Participants will receive 4 one-on-one glycemic sessions and 8 one-on-one distress sessions, each lasting ~30 minutes. Sessions will be conducted in-person or remotely. The virtual sessions are intended to provide the extra psychoeducation and support needed for this high risk group without increasing the burden associated with frequent face-to-face sessions.
75547846|NCT05394259|Drug|Piflufolastat F18|Given by vein (IV)
75547847|NCT05388838|Biological|Blood sample|Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
75547848|NCT05388084|Behavioral|Male peer engagement|Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.
75547849|NCT05388084|Behavioral|SOC and delayed intervention|Females receive standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
75547850|NCT05380973|Other|Short fiber resin composite|resin composite reinforced with short glass fibers
75547851|NCT05380973|Other|Polyethylene ribbon fiber|resin composite reinforced with polyethylene ribbon fiber
75547852|NCT05380739|Behavioral|Working Memory Training|A 10-session working memory (WM) training program
75547853|NCT05379127|Other|Patient-empowered follow up|"The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used."
75547854|NCT05379127|Other|Standard follow-up|Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
75709368|NCT05225896|Genetic|Description of clinical characteristic and genetic tumors|"This is a non-interventional study involving clinical data and biological samples (DNA). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
75709369|NCT00872560|Device|NovoFine® needle 6 mm|
75397889|NCT05648838|Device|Pivot Balloon Catheter|mornitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
75397890|NCT05645744|Biological|Prior MB-102 CAR-T cell investigational product.|No investigational product will be administered.
75397891|NCT05645744|Biological|Prior MB-106 CAR-T cell investigational product.|No investigational product will be administered.
75397892|NCT05640089|Other|fMRI-based neurofeedback|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
75397893|NCT05635669|Device|Sacral acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached transversely to the needle handles at bilateral Huiyang(BL35) and Zhongliao(BL33) .
75397894|NCT05635669|Device|Abdominal acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached to the needle handles respectively at Zhongji(RN3) and one side of Dahe(KI12), as well as Guanyuan(RN4) and another side of Dahe(KI12).
75397895|NCT05635669|Device|Alternating acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. The application of electroacupuncture is the same as Sacral group and Abdominal group.
75397896|NCT05633680|Diagnostic Test|Peripheral blood sampling for circulating tumor cells|Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.
75397897|NCT05594823|Other|Ambulatory heart failure management with Flexible Diuretic Regimen with furosemide|Subjects will be given a regimen that determines a variable daily dose of diuretic (furosemide) based on daily self-measured weights as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
75397898|NCT05594823|Other|Ambulatory heart failure management with fixed dose furosemide|Subjects will be prescribed a fixed daily dose of diuretic (furosemide) as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
75547855|NCT05376137|Device|continuous positive airway pressure (CPAP)|CPAP comfort settings will be modified in the active group to be personalized to each participant
75547856|NCT05367843|Drug|PRIME-2-CoV_Beta|Intramuscular (IM) injection
75709370|NCT00872560|Device|NovoFine® needle 8 mm|
75709371|NCT04645394|Dietary Supplement|Aronia melanocarpa|Administered once (acute study)
75709372|NCT04645394|Dietary Supplement|Fermented Aronia Melanocarpa high dose|Administered once (acute study)
75397899|NCT05590741|Behavioral|Emotion Regulation Therapy via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
75397900|NCT05589272|Other|Active tDCS|cognitive training + active-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
75397901|NCT05589272|Other|Sham tDCS|cognitive training + sham-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
75397902|NCT05587491|Device|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation
75397903|NCT05586022|Procedure|endovascular revascularization|percutaneous balloon dilatation, stent implantation, plaque resection, laser plasty, cutting balloon, drug balloon, cryoballoplasty, thrombolytic therapy with drugs or thrombectomy
75397904|NCT05582915|Diagnostic Test|Blood sampling|4 ml of blood will be collected into EDTA tube for proteomic analysis at visit 0 and visit 1
75397905|NCT05581797|Other|Psilocybin-assisted psychotherapy|8 sessions of interpersonal therapy and 2 doses of psilocybin
75397906|NCT05577741|Behavioral|Multisensory virtual reality pod (SENSIKS©)|Six sessions of 20 minutes of mindfulness.
75397907|NCT05577741|Behavioral|Cognitive bike (Vélo-cognitif®)|Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
76037019|NCT05343312|Drug|AS-AQ (Carsucam)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, and 28 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
75709373|NCT04645394|Dietary Supplement|Fermented Aronia Melanocarpa low dose|Administered once (acute study)
75397908|NCT05577741|Other|Standard treatment|Standard of care treatment
75397909|NCT05573503|Other|Bring it up - Assessment and support of patients' sexuality in cancer nursing|"Participants will attend a five week online university course, Bring it up - Assessment and support of patients' sexuality in cancer nursing. The course addresses theories and models about sexuality in relation to cancer illness, conversation techniques, models for addressing sensitive topics, methods for assessing the impact of cancer on sexuality, methods for preventing and treating sexual problems in relation to cancer, relevant nursing interventions for person-centred counselling about sexuality, and ethical aspects.~The teaching consists of literature, online lectures, seminars, clinical practice, and written exams. A university certificate will be issued to participants who pass all exams."
75397910|NCT05572580|Other|questionnaire|the patients are asked to fill in a questionnaire
75709374|NCT04645394|Dietary Supplement|Placebo|Administered once (acute study)
75547857|NCT05367141|Other|"CDSS (MedicBK)"|"Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care."
75709375|NCT01589029|Drug|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
75709376|NCT00877786|Behavioral|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
75709377|NCT02568332|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
75709378|NCT02568332|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
75709379|NCT01033669|Device|CRC-749|There is no drug being used. This is a device.
75709380|NCT01033669|Device|Diskus|There is no drug being used. This is a device.
75709381|NCT01033669|Device|Twisthaler|There is no drug being used. This is a device.
75709382|NCT01033669|Device|Miat Monohaler|There is no drug being used. This is a device.
76037020|NCT05343312|Drug|DHP|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
75397911|NCT05565196|Behavioral|Birth companions|The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
75397912|NCT05556226|Drug|ABBV-154 Dose Formulation A|Subcutaneous Injection
75397913|NCT05556226|Drug|ABBV-154 Dose Formulation B|Subcutaneous Injection
75397914|NCT05542758|Other|Total Body HIIT Program|One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
75397915|NCT05534815|Behavioral|Employment-based abstinence reinforcement|Participants will earn stipends for working with the employment specialist and wage supplements for working in a community job, but the stipends and wage supplements will depend on providing drug-free urine samples.
75397916|NCT05520073|Dietary Supplement|Lactobacillus plantarum|Lactobacillus product 1 pack daily
75397917|NCT05520073|Dietary Supplement|Vitamin C|Vitamin C tablet 1 pack daily
75397918|NCT05512260|Device|Individual decision aid (iDA)|A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
75397919|NCT05510544|Drug|Plerixafor,G-CSF|"G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8.~Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours."
75397920|NCT05510492|Other|EDUCATION|THE EXPERIMENT GROUP WAS GIVEN THEORETICAL AND APPLIED EDUCATION,
75397921|NCT05510492|Other|APPLIED EDUCATION|"the injection was applied on the model by the researcher with the demonstration method according to the Procedure Steps of Intramuscular Injection with the Z Technique from the Ventrogluteal Region. This process was first ensured by the nurses, and then"
75397922|NCT05509699|Drug|Surufatinib|The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.
75397923|NCT05509699|Drug|Anti-PD-1/L1|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
75397924|NCT05506618|Diagnostic Test|Nasal Swab|Collection of one more nasal swabs
75397925|NCT05506618|Diagnostic Test|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
75397926|NCT05505903|Diagnostic Test|Temerature measurement|Temerature measurement on admission to WBN or NICU
75397927|NCT05500365|Procedure|Catheter ablation therapy|Pace mapping procedure performed during catheter ablation therapy
75397928|NCT05495126|Diagnostic Test|Standard Limbic Access pathway|Relevant information for clinical referral (e.g. demographics) and basic clinical information (e.g. PHQ-9 & Gad-7 scores) are collected during the self-referral process which is then attached to the referral notes in order to facilitate the clinical assessment conducted by the clinician.
75709383|NCT00872638|Procedure|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
76037021|NCT05343312|Drug|PA|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
75397929|NCT05495126|Diagnostic Test|Limbic Access with AI pathway|"The same information as in the Limbic Access pathway is collected. However, additional information (i.e. disorder specific questionnaires) are collected for the most likely problem descriptors based on the ML-model predictions.~All information is attached to the referral in order to facilitate the clinical assessment conducted by the clinician."
75397930|NCT05488119|Behavioral|Intervention to increase diabetes technology uptake|The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment. I will recruit 20 families or providers to participate in the delivery of the pilot intervention designed in Phase 1 of the study via a stakeholder advisory board.
75547858|NCT05358717|Drug|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
75547859|NCT05358717|Drug|Placebo|Placebo matching to PTC518 will be administered per schedule specified in the arm.
75547860|NCT05343572|Drug|Plerixafor|A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing >83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
75547861|NCT05342675|Procedure|Rapid Rollover|Repositioning of the participant post biopsy
75547862|NCT05329337|Diagnostic Test|Blood test|Sixteen mL of blood will be collected on EDTA for the purpose of this study
75547863|NCT05327829|Combination Product|External non-invasive stimulation|The participants are randomized into the block design of sham or tACS/tnVNS during the first three appointments or the last three appointments. Eye tracking will be used to test the predominant focus of decisions during the gaze phase on costs or difficulty levels during the COGED. The study is investigating the use of neuromodulation after TBI for improved cognitive function.
75547864|NCT05327829|Behavioral|COGED|The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).
75547865|NCT05325879|Other|VAGUS-NDT|Neurodynamic test for vagus nerve
75547866|NCT05315726|Other|Dynamometer|Measurement of elbow/wrist spasticity
75709384|NCT00872638|Procedure|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
75709385|NCT00877864|Behavioral|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
75709386|NCT00877864|Behavioral|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
75709387|NCT00877864|Behavioral|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
75397931|NCT05460715|Device|Quadra P anteverted|"Assess clinical performance by Harris Hip score collected during preoperative and postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~Assess radiological performance by standard radiographic examination performed before surgery, after surgery before discharge and during postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~Assessing the patient's perception of the prosthetic joint by means of FJS questionnaire collected during the preoperative visit and postoperative visits at 3 months and at 1, 2, 5, 7 and 10 years after surgery.~Assessment of functional recovery by gait analysis study~Collect the rate of complications throughout the course of the study"
75397932|NCT05444803|Other|femoral nerve block|Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.
75397933|NCT05444803|Other|peri-capsular nerve group block|Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
75397934|NCT05764915|Drug|RGT-264 phosphate tablets|RGT-264 phosphate tablets will be administered orally once daily (QD).
75397935|NCT05443399|Behavioral|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
75397936|NCT05443399|Behavioral|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
75397937|NCT05443399|Behavioral|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 2D
75397938|NCT05426200|Behavioral|Health Coaching|Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
75397939|NCT05410366|Other|Safe harbor clinical practice guideline|A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
75397940|NCT05407376|Other|Produce prescription (weekly produce delivery)|Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
76037022|NCT05342883|Device|Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)|At the initiation of the surgical phase maximal safe resection will be undertaken, and after 25 + 4 from surgery participants will start the concomitant phase and receive daily temozolomide (TMZ, 75mg/m2) and 20 fractions external beam radiation (EBRT). The EBRT treatment will be to the operative bed and any residual disease identified at the time of the imaging obtained for EBRT planning. The EBRT planning will utilize the GT implant dosimetry with the intent that the dose received from the GT will be accounted for during the EBRT treatment planning process. Twenty-eight days ±7 after the completion of concomitant TMZ and EBRT, participants will enter the adjuvant phase and will be treated with TMZ (150-200mg/m2) for 5 days at the start of every 28- day cycle, for 6 cycles.
76037023|NCT05328960|Other|Diagnosed during or not during the pandemic|We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
76037024|NCT05327868|Other|Low Fat Diet (LFD)|Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
75397941|NCT05396170|Procedure|phlebotomy|500ml of blood phlebotomized per standard of care to reduce symptoms from polycythemia
75397942|NCT05378386|Device|Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).
75397943|NCT05338125|Procedure|Micro-electrode measurement|Electrophysiological measurement with single-unit micro-electrode
75709388|NCT00877864|Behavioral|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
75397944|NCT05335772|Behavioral|Action Observation and following Action Execution|VR-AOT patients will observe, rehearse and execute specific upper limb motor task belonging to activities of daily living.
75397945|NCT05335772|Behavioral|Landscape Observation and following Action Execution|VR-LO participants will observe virtually explorable landscapes lasting for a matched duration. Then, they will be asked to actively perform the same set of hand actions requested to VR-AOT experimental groups.
75397946|NCT05327647|Drug|Bicalutamide|Induction intravesical BCG with bicalutamide 150 mg for 90 days
75397947|NCT05327647|Biological|Control Arm|Induction BCG
75547867|NCT05315726|Other|Muscle vibrations|1 session of 10 minutes
75547868|NCT05315726|Other|Muscle vibrations|3 times/week for 6 weeks
75709389|NCT00877864|Behavioral|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
75709390|NCT00877864|Behavioral|Control|No exercise program provided by the study
75709391|NCT00736736|Other|Additional Hip Muscle Strengthening to Leg Press Exercise|
75709392|NCT00736736|Other|Leg Press Exercise|
75709393|NCT00864448|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
75709394|NCT00864448|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
75709395|NCT00406315|Drug|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
75709396|NCT05740904|Other|New defocus spectacle lenses|The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.
76037025|NCT05327868|Other|High Fat Diet (HFD)|Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
75709397|NCT05740904|Other|Convenional aspheric single-vision spectacle lenses|The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
75397948|NCT05321342|Behavioral|BCCU|BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, & Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator [developed at UCF; Dieker, Hynes, Hughes, & Smith, 2008], and self-monitoring) and utilizing motivational interviewing (Miller & Rollnick, 2012) to empower teacher practice change.
75397949|NCT05315570|Other|BD4QoL platform|The BD4QoL platform consists of a set of services to allow patient monitoring and empowerment, through two main tools: Point of Care application to manage all patients data and follow-up by clinical investigators, and a mobile application (App) installed on participating subject's smartphone. Also, a web-form tool is delivered to allow the QoL questionnaire completion.
75397950|NCT05315310|Device|Soft Exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
75397951|NCT05294718|Procedure|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
75397952|NCT05294718|Procedure|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
75547869|NCT05315726|Other|Placebo muscle vibration|3 times/week for 6 weeks
75547870|NCT05314283|Device|DV3395 C1|Participants will be exposed to and swallow DV3395 C1 once. The participants will stay at the clinic research center for up to 6 days .
75547871|NCT05313620|Drug|Tofacitinib|Tofacitinib 5 MG/day per clinical practice
76037026|NCT05326308|Drug|Zanubrutinib|according to the Summary of Product Characteristics (SmPC).
75709398|NCT00872716|Drug|Quetiapine XR|100 mg single-dose Quetiapine XR
75709399|NCT00872716|Other|Placebo|Placebo
75709400|NCT05740826|Device|Algometer|The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
75709401|NCT00864526|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
75709402|NCT00864526|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
75709403|NCT02568410|Procedure|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
76037027|NCT05326308|Drug|Obinutuzumab|according to the Summary of Product Characteristics (SmPC).
76037028|NCT05324254|Device|Weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
76037029|NCT05319808|Other|Manual therapy|Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
76037030|NCT05319808|Device|Telehealth exercises|A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.
75397953|NCT05288595|Device|CliniMACS Plus Instrument|Miltenyi Biotec's CliniMACS Plus Instrument is to be used to TCRαβ CD19 deplete products utilized in this protocol. The CliniMACS Plus is an automated cell separation platform which is functionally closed, maintaining a sterile system for cell depletion and enrichment utilizing a magnetic separation column. Reagents and supplies are to be used for research only but are manufactured and tested under a quality system certified to ISO 13485. Should CD34 selection be required to augment stem cell dose, Miltenyi Biotec's CliniMACS® Plus CD34 Reagent System is FDA approved as a Humanitarian Use Device (HUD). The approved indication was the treatment of patients with acute myeloid leukemia (AML) undergoing myeloablative transplant from matched related allogeneic donors. The CliniMACS® Plus reagent system was approved to obtain an enriched CD34+ cell population for hematopoietic reconstitution without the need for GVHD prophylaxis.
75397954|NCT05269953|Device|Active stimulation|Participants assigned to the active stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 120% the intensity needed to produce a visible contraction within the thenar muscle.
75397955|NCT05269953|Device|Sham stimulation|Participants assigned to the sham stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 50% the intensity needed to produce a visible contraction within the thenar muscle.
75397956|NCT05256641|Drug|Acalabrutinib|Given PO
75397957|NCT05249543|Behavioral|Unified protocol|Transdiagnostic cognitive-behavioral therapy
75709404|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
76037031|NCT05319808|Other|Non-computer based exercises|Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
76037032|NCT05318300|Dietary Supplement|tested formula with fiber|formula containing fibers
76037033|NCT05318300|Dietary Supplement|Control|formula without fiber
76037034|NCT05315700|Drug|ORIC-114|ORIC-114 oral daily
75397958|NCT05249543|Behavioral|Diagnosis-specific cognitive-behavioral therapy|Diagnosis-specific cognitive-behavioral therapy
75397959|NCT05228652|Other|Questionnaire|Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.
75397960|NCT05226130|Device|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
76037035|NCT05315700|Drug|Chemotherapy drug|21 days for up to 4 cycles
76037036|NCT05313256|Drug|Lidocaine epinephrine buffered with sodium bicarbonate|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.
75397961|NCT05226130|Device|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
75397962|NCT05219916|Procedure|Blood collection.|"One additional 80 mL blood collection will be collected from HIV patients during a scheduled blood collection as part of their regular follow-up.~Samples will be transported within 3-5 hours by a carrier approved for the transportation of infectious biological samples from the Croix Rousse hospital to the P3 laboratory of the Ecole Normale Supérieure, Lyon for analysis."
75397963|NCT05219318|Drug|Combination PD-1/PD-L1 ICI + VEGFR-TKI|The study will enroll patients achieving an objective response after 12 months of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
75397964|NCT05219318|Other|Treatment pause|Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression
75397965|NCT05214534|Other|blood supar measurement|The supar values will be measured afterwards on the tube bottoms of the patients included in the study from their usual collection
75397966|NCT05187533|Other|Osteopathic protocol of Sphenopalatine Ganglion Stimulation|Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
75397967|NCT05177588|Drug|Metformin Hydrochloride|Metformin 2000 mg/day
75397968|NCT05174078|Other|Medically-tailored meals|Medically tailored meals delivered to patients' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
75397969|NCT05174078|Other|Produce box and recipes|Weekly produce box and access to recipes via internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
75397970|NCT05171660|Drug|Sintilimab Injection|Sintilimab Injection: 200 mg, i.v., D1, Q3W, 8 courses
75397971|NCT05171660|Drug|Control Test|XELOX + Bevacizumab
75397972|NCT05156034|Drug|SRK-001|Participants will receive IV doses of SRK-001.
75397973|NCT05156034|Drug|Placebo|Participants will receive IV doses of placebo.
75397974|NCT05133258|Other|Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension|Micro-aspirate of middle ear fluid will be taken from participants with a Juhn Tym-Tap specimen trap following standard-of-care delivery of ciprofloxacin 0.3% and dexamethasone 0.1% suspension. Samples will be analyzed to measure antibiotic concentration in the middle ear fluid.
75397975|NCT05059873|Drug|Prednisone|Oral prednisone 40mg/day for five consecutive days
75397976|NCT05059873|Drug|Placebo|Oral placebo of 40mg/day for five consecutive days
75397977|NCT05055024|Drug|Mazindol|Drug: NLS-2
75397978|NCT05051644|Behavioral|Steps 2 Change (S2C)|Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
75397979|NCT05051644|Behavioral|Control|The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
75397980|NCT05045664|Radiation|Standard|12 x 2 Gy involved site radiotherapy plus Rituximab
75397981|NCT05045664|Radiation|Experimental|2 x2 Gy involved site radiotherapy plus Obinutuzumab
75397982|NCT05045664|Drug|Standard|Rituximab with 12 x 2 Gy involved site radiotherapy
75397983|NCT05045664|Drug|Experimental|Obinutuzumab with 2 x2 Gy involved site radiotherapy
75397984|NCT05037552|Procedure|Bipolar coagulation|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by bipolar coagulation. Then, the remnant tissue will be examined using irrigation and coagulated with minimal bipolar power (20-W current) on any sites that are bleeding."
75547872|NCT05313620|Drug|Infliximab Adalimumab y Golimumab|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
75547873|NCT05306574|Drug|Telitacicept|subcutaneous injection weekly for 52 weeks
75547874|NCT05306574|Drug|Placebo|subcutaneous injection weekly for 52 weeks
75709405|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
76037037|NCT05313256|Drug|Lidocaine epinephrine|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
76037038|NCT05305859|Drug|venetoclax combining chidamide and azacitidine (VCA)|information already included in arm/group descriptions
76037039|NCT05302271|Biological|AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN|AAVrh.10hFXN will be administered intravenously.
76037040|NCT05302271|Drug|Prednisone|All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.
75397985|NCT05037552|Procedure|Coagulation by FLOSEAL haemostatic agent|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by either hemostatic sealants (FloSeal). Using a laparoscopic applicator, FloSeal will be applied to the surface of bleeding sites under direct vision and the ovarian cortex was gently pressed for 2 min with small gauze."
75558165|NCT04697706|Other|Water|"Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
75558166|NCT00440934|Device|Amplitude-modulated electromagnetic fields|
76037041|NCT05281731|Device|Sonobiopsy|Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy
76037042|NCT05281731|Procedure|Research blood|No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)
76037043|NCT05281731|Genetic|Cancer Personalized Profiling|Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.
76037044|NCT05281731|Device|Definity®|Being used off-label in this trial
76037045|NCT05280314|Drug|IO102-IO103|IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
76037046|NCT05280314|Drug|Pembrolizumab|Pembrolizumab administered intravenously
75547875|NCT05302518|Behavioral|Cognitive behavioral therapy with exposure in virtual reality|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells. The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in VR:~We will use 360° 3D videos for exposure using an HTC Vive Pro headset. Six different videos will be used for exposure: 1) Taking a seat on a bench in a public park, 2) Being introduced as a new employee, 3) Performing a presentation at a meeting, 4) Entering and shopping in a grocery store, 5) Visiting a café and 6) Using public transportation. The therapist can choose the length of the exposure as well as the difficulty of the exposure. While the participant is in the VR-scenario HR and EDA are measured. These data are collected to continuously estimate the anxiety levels."
75547876|NCT05302518|Behavioral|Cognitive behavioral therapy with exposure in vivo|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells.The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in vivo:~Exposure is taking place at Centre for Telepsychiatry and the surrounding areas. The therapist is planning the exposure with the participant and is accompanying the participant during the exposure."
75547877|NCT05293288|Device|EEG-guided general anesthesia|pEEG monitoring will start with the beginning of induction of general anesthesia and will end with the end of surgery (surgical suture). In the EEG-guided group, depth of anesthesia will be adjusted to target PSI values between 25 and 50 and spectral edge frequency between 10 and 15. In case of contradictory values, the raw EEG waveforms, ARTF, EMG, as well as the overall clinical situation will be evaluated for decision making.
75547878|NCT05285917|Drug|Hydroxyurea|Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.
75547879|NCT05278975|Drug|RSO-021|A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
75709406|NCT04064138|Procedure|Peritoneal block|At the beginning of surgery, immediately after insertion of the first port 2 mg/kg lidocaine and 25mg/kg magnesium sulfate and 1/200 000 epinephrine in a total volume 50 ml (completed with saline .9%) will be given intra-peritoneal 10 min before the surgeon proceeds . At the end of the surgery another similar lidocaine-magnesium-epinephrine injection will be instillated before removal of the last port and the drain will be kept closed for 30 min.
75547880|NCT05278494|Drug|Dextromethorphan Hydrobromide|PO
75547881|NCT05278494|Drug|Placebo|PO
75547882|NCT05275244|Device|KD Intra-Articular® gel|Depending on the joint, 3 injections will be administrated to the patient: KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%) in the case of shoulder and hip, or KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%) in the case of the ankle and base of the thumb. The administration of the infiltrations will be with an interval of one week.
76037047|NCT05279300|Drug|CS5001|CS5001 will be administered every 3 weeks (21 days) by intravenous (IV) infusion, and 3 weeks (21 days) is considered as one treatment cycle.
75547883|NCT05273385|Device|Nanodropper|Device to apply liquid medication to eyes
75547884|NCT05271357|Procedure|Bilateral TMS|Stimulation begins with continuous TBS to the right dorsolateral prefrontal cortex (DLPFC) (120 seconds of uninterrupted bursts; 600 pulses per session) followed by intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds per hemisphere.
75547885|NCT05271357|Procedure|Unilateral TMS|Stimulation involves only intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds.
75558167|NCT00440973|Drug|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
75558168|NCT00440973|Drug|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T & B lymphocyte proliferation
75558169|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
75558170|NCT00443924|Drug|Placebo|One drop of placebo in each eye every 12 hours for three days
75558171|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
76037048|NCT05277571|Biological|UCB1381|UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
76037049|NCT05277571|Drug|Placebo|Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
75547886|NCT05261425|Device|Monocryl buried interrupted|Participants randomized to this group will receive the Monocryl (suture) buried interrupted (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
75709407|NCT04064138|Procedure|Ultrasound guided erector spinae plane block|Before general anesthesia, ESPB will be performed under ultrasound guidance. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. The patient's skin will be anesthetized with 3 mL of 2% lidocaine. A 21 gauge 10cm needle will be inserted using an in plane superior to inferior. The tip of the needle will be placed into the facial plane on the deep aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process on ultrasonographical imaging. The calculated dose of lidocaine (2mg/kg) with 150 mg MgSo4 and 1/200 000 epinephrine will be injected on each side.
75709408|NCT04064138|Other|General anesthesia|General anesthesia
75547887|NCT05261425|Device|Gut (FDA Approved) not buried interrupted|Participants randomized to this group will receive the Gut (FDA Approved) (suture) not buried interrupted (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
75709409|NCT01323751|Drug|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
76037050|NCT05275959|Other|A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China|"Myopia and obesity in children and adolescents have become serious public health problems that endanger public health, especially in China. Unhealthy lifestyle behaviors are environmental drivers of both myopia and obesity. This protocol describes a study to evaluate the effectiveness of 22510SS, that is 2 h of daytime outdoor activities ('2'); Limit screen time to no more than 2 h per day ('2'); Consume at least 5 servings of fruits and vegetables daily ('5'); Attain 1 h of physical activity daily ('1'); Consume 0 sugar-sweetened beverages ('0'); Reasonable sleep duration ('S'); Regular supervision ('S'). A school-based, multifaceted intervention strategy for myopia and obesity prevention, and to assess and explore the implementation of 22510SS with regards to acceptability, feasibility, adoption, usage and maintenance."
76037051|NCT05269381|Drug|Cyclophosphamide|Given IV
76037052|NCT05269381|Biological|Neoantigen Peptide Vaccine|Receive personalized neoantigen vaccine SC
76037053|NCT05269381|Biological|Pembrolizumab|Given IV
75397989|NCT05012631|Drug|Losartan|Losartan dosing for participants <16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
75709410|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose, 1 day
75547888|NCT05252585|Drug|Everolimus|"Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be:~Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment)~Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)"
75547889|NCT05240001|Device|Thulium Fibre Laser|Participants will undergo treatment using the TFL
76037054|NCT05269381|Biological|Sargramostim|Given SC
76037055|NCT05247827|Other|Targeted phantom limb motor execution (exercise)|The targeted phantom motor execution is a specific training program for people with TTA that has been designed to improve the muscles' strength, coordination, and flexibility at the amputated and contralateral intact sides. Such training consists of repeated short-term, short rest interval, and moderate-intensity exercises (Schoenfeld 2010, Krutki, Mrowczynski et al. 2017). Targeted phantom motor execution can improve the body image considering its induced muscular impacts. People with TTA will be trained to follow specific movements of their foot-ankle complexes simultaneously, in order to increase PLA, as well as induce muscular morphologic and brain neuroplastic changes (Moseley and Brugger 2009).
76037056|NCT05227209|Drug|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
75709411|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
75547890|NCT05240001|Device|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
75709412|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
75709413|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
75709414|NCT05741996|Behavioral|Taping|Taping types and brace acute effects for knee osteoartritis
75709415|NCT00872794|Device|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
75709416|NCT00878176|Procedure|First stage tined lead procedure|bilateral first stage tined lead placement
75709417|NCT00711594|Drug|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
75709418|NCT00711594|Drug|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
75709419|NCT00711594|Drug|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
75709420|NCT00711594|Drug|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
75709421|NCT02543866|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
75709422|NCT00872872|Drug|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
76037057|NCT05225415|Drug|CT1812|Orally administered CT1812
76037058|NCT05223582|Drug|Abiraterone acetate|Patients would be treated with 1000mg abiraterone qd.
75397992|NCT04990479|Biological|GAd-PEV|Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).
75397993|NCT04990479|Biological|MVA-PEV|Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).
75397994|NCT04985227|Other|Home weight monitoring|Parents will be provided with weighing scales to weigh their infant at home and plug in the weight in the patient portal for review by their primary care provider.
75547891|NCT05222529|Drug|Glycopyrronium bromide 25ug|25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
75547892|NCT05222529|Drug|Placebo|Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
75547893|NCT05222529|Drug|Glycopyrronium bromide 12.5ug|12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler
75547894|NCT05216835|Drug|AZD7789|Patients will receive AZD7789 (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.
75547895|NCT05203172|Drug|Binimetinib only treatment|Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Parent Studies C4211001 and C4211003 with water irrespective of food, continuously, starting on Day 1.
75547896|NCT05203172|Drug|Encorafenib only Treatment|Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.
75547897|NCT05203172|Drug|Encorafenib & Binimetinib Treatment|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
75397995|NCT04966091|Other|Completion of questionnaires|The quality of life questionnaire will be completed before starting the treatment and then during the embryo transfer and will be followed up at each embryo transfer over a maximum period of 18 months. We will also evaluate by means of a specific questionnaire the importance of work/life interactions management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains).
75547898|NCT05203172|Drug|Treatment of Encorafenib & Binimetinib & Ribociclib|Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binimetinib tablets BID. The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area.
75547899|NCT05203172|Drug|Treatment of Encorafenib & Binimetinib & Cetuximab|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
75709423|NCT00864760|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
75547900|NCT05202327|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
75547901|NCT05202327|Drug|Placebo|The placebo contained corn starch.
75547902|NCT05194397|Dietary Supplement|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
75547903|NCT05194397|Dietary Supplement|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
75709424|NCT00864760|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
75397996|NCT04954196|Drug|Amlodipine 5mg|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~The frozen embryo transfer will be performed 6 days after progesterone initiation.~The HRT will be maintained until the pregnancy test is performed: If the test is positive,HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative,HRT will be stopped gradually~Amlodipine administration: On the day of the first monitoring Dm (corresponding to D13 D16 of the cycle), a single per os dose of amlodipine 5 mg is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.The treatment will be maintained until the pregnancy test is performed then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
75397997|NCT04954196|Drug|Placebo|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~The frozen embryo transfer will be performed 6 days after progesterone initiation.~The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
75397998|NCT04944290|Drug|Brinzolamide/brimonidine ophthalmic suspension|Test product
75397999|NCT04944290|Drug|Simbrinza 0.2%/1% Ophthalmic Suspension|Reference product
75547904|NCT05194397|Other|Exercise Intervention|The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
75547905|NCT05169710|Drug|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)
75547906|NCT05169710|Drug|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
75709425|NCT00710762|Drug|BIBF1120|
75709426|NCT00710762|Drug|Placebo|
75709427|NCT05137912|Biological|Immunotherapy|"Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.~Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy."
75547907|NCT05169710|Drug|Placebo|Placebo tablet (supplied in two tablets)
75709428|NCT00736814|Drug|carboplatin|Given intravenously
75709429|NCT00736814|Drug|docetaxel|Given intravenously
75709430|NCT00736814|Drug|gemcitabine hydrochloride|Given intravenously
75709431|NCT00736814|Drug|vinorelbine tartrate|Given intravenously
75709432|NCT04063904|Drug|Mifepristone|One 200 mg pill (oral)
75709433|NCT04063904|Drug|Misoprostol|Two 400 mcg pills (sublingual)
75709434|NCT00573430|Drug|Candesartan Cilexetil|8 mg oral once daily dose
75709435|NCT00573430|Drug|Candesartan Cilexetil|16 mg oral once daily dose
75398000|NCT04937166|Biological|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
75398001|NCT04937166|Drug|Azacitidine|Azacitidine is an analog of the pyrimidine nucleoside cytidine.
75398002|NCT04937166|Drug|Venetoclax|Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
75709436|NCT00573430|Drug|Candesartan Cilexetil 32mg|32 mg oral once daily dose
75709437|NCT00711516|Drug|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
76037059|NCT05223582|Drug|Fluzoparib|Patients would be treated with 150mg fluzoparib bid.
76037060|NCT05223582|Drug|Prednisone|Patients would be treated with 5mg prednisone bid.
75547908|NCT05151757|Other|A standard image training set|The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
75547909|NCT05130190|Device|RF Treatment|ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
75547910|NCT05117242|Biological|Acasunlimab|Acasunlimab will be administered intravenously (IV)
76037061|NCT05223582|Drug|Androgen deprivation therapy|Patients would get medical castration.
76037062|NCT05223582|Procedure|Radical Prostatectomy|Patients would get radical prostatectomy after the neoadjuvant treatment.
75398003|NCT04922840|Behavioral|High-intensity exercise (HIIT)|12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.
76037063|NCT05222373|Behavioral|CBT-based lifestyle intervention|The standard care plus a theoretically-based, diet, activity, and mental health lifestyle intervention integrated within a culturally sensitive curriculum (materials in Spanish and English). Trained CHWs will promote CBT-based lifestyle-change aims and assist in goal setting with participants to reach the primary goal of appropriate glycemic control (fasting blood glucose and HbA1c) and weight reduction, in addition to decrease in depressive symptoms and stress and an increase in quality of life. Participants' body weight, body composition, metabolic measures, and mental health outcomes will be obtained at enrollment and at the end of the intervention.
75398004|NCT04921488|Device|screening colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
75398005|NCT04920032|Drug|TAS-102|Given PO
75398006|NCT04920032|Drug|Irinotecan|Given IV
75398007|NCT04920032|Combination Product|Standard Treatment|6 cycles for a 2-week regimen (infusional 5FU based) and up to 4 cycles for a 3-week regimen (oral capecitabine based) after randomization
75398008|NCT04920032|Diagnostic Test|Signatera MRD ctDNA Assay|To be performed within 6-8 weeks of Cycle 1 Day 1. A Mid-treatment ctDNA is to be completed within 6 - 8 weeks of starting treatment. ctDNA is to also be completed within four weeks after completion of study treatment (+/- two weeks)
76037064|NCT05219175|Drug|MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (~80 mg MDMA) to 140 mg MDMA HCL (~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (~100 mg MDMA) to 180 mg MDMA HCL (~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (~280 mg MDMA) to 500 mg MDMA HCL (~435 mg MDMA)"
76037065|NCT05206448|Drug|Letrozole|Letrozole tablet
76037066|NCT05206448|Drug|Clomiphene Citrate|Clomiphene Citrate tablet
76037067|NCT05193604|Drug|TQB2858 injection|TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
76037068|NCT05193604|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
75398009|NCT04908176|Drug|Avapritinib|avapritinib tablets
75398010|NCT04908176|Drug|midazolam|midazolam syrup
75398011|NCT04906525|Behavioral|Resistance training|Participants will undergo 6 weeks of supervised resistance training
75398012|NCT04906525|Other|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
75398013|NCT04882540|Drug|brivaracetam|"Pharmaceutical form: Film-coated tablets~Concentration: 100 mg tablets~Route of administration: Oral use"
75547911|NCT05117242|Biological|Pembrolizumab|Pembrolizumab will be administered IV
75547912|NCT05117229|Device|MetaWear Sensor|Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
75547913|NCT05114096|Drug|Celestone + placebo|"After the first intramuscular injection of Celestone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
75547914|NCT05114096|Drug|Celestone + Celestone|"After the first intramuscular injection of Celestone, participants randomized to the Active Comparator group will receive 1 intramuscular injection of Celestone."
75547915|NCT05111509|Drug|[203Pb]VMT-α-NET|3 to 5 miliCuries of [203]Pb administered intravenously 60 minutes before the start of the scans.
75398014|NCT04881721|Procedure|Urethropexy|Suture based (Mesh-free) surgery to stabilize the urethra for the treatment of stress urinary incontinence
75398015|NCT04871100|Behavioral|Unified Protocol- Alcohol|Transdiagnostic cognitive behavior therapy for emotional disorders modified to include CBT for alcohol use.
75398016|NCT04871100|Behavioral|Problem Solving therapy|Skills based approach for managing negative moods and stress.
75398017|NCT04859829|Other|Current Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dysmotility that are receiving Intravenous Immunoglobulin (IVIG) treatment.
75398018|NCT04859829|Other|No Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dismotility that are not receiving Intravenous Immunoglobulin (IVIG) treatment.
75398019|NCT04851158|Device|Effectiveness of ShotBlocker on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: ShotBlocker will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
76037069|NCT05193604|Drug|Gemcitabine hydrochloride for injection|Chemotherapy medicine for metastatic pancreatic cancer
75398020|NCT04851158|Device|Effectiveness of local vibrator device on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: Local vibrator device will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
75398021|NCT04808076|Procedure|Shunt surgery|Shunt operation
75398022|NCT04801680|Device|Mpact 3D metal cup|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. They'll receive the Mpact 3D metal cup device
75398023|NCT04801654|Diagnostic Test|blood sample|preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
75398024|NCT04788043|Drug|Magrolimab|200 mg max, starting 1 mg/kg IV Infusion
75398025|NCT04788043|Drug|Pembrolizumab|200 mg IV infusion
75398026|NCT04788043|Procedure|PET/CT|Scan
75398027|NCT04784260|Other|Microbiome analysis|Evaluate the bacterial composition in sperm from the different groups
75398028|NCT04778267|Drug|Bupivacaine Hydrochloride|We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
75398029|NCT04778267|Drug|Dexamethasone phosphate|used as additive to bupivacaine
75398030|NCT04744454|Drug|Isauvuconazole group|Patients who are treated with Isavuconazole according to its protocol label.
75398031|NCT04735471|Genetic|ADI-001|Anti-CD20 CAR-T
75709438|NCT00711516|Drug|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
75709439|NCT05741762|Other|Retrospective chart review|The retrospective chart review will be done for patient admitted into ICU between 01/06/2017 to 01/06/2022
75709440|NCT00864838|Drug|Acetazolamide|250 mg 1 hour before intravitreal injection
75709441|NCT00864838|Drug|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
75709442|NCT00864838|Procedure|Anterior chamber paracentesis|Immediately after bevacizumab injection
75709443|NCT05740748|Drug|Tezepelumab|tezepelumab 210 mg sc q4wks for 20 weeks
75398032|NCT04735471|Drug|Fludarabine|Chemotherapy for Lymphodepletion
75398033|NCT04735471|Drug|Cyclophosphamide|Chemotherapy for Lymphodepletion
75398034|NCT04718181|Drug|risdiplam|Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
75398035|NCT04718181|Drug|omeprazole|Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
75398036|NCT04696497|Diagnostic Test|Ultrasound|"Ultrasound measurements of muscle thickness, using a linear probe (high frequency) on four muscle groups:~Shoulder Side muscular compartment~Anterior Arm muscular compartment~Anterior thigh muscular compartment~Antero-lateral leg muscular compartment"
75398037|NCT04696497|Diagnostic Test|Dynamometric muscular assessment|"The principle of electronic dynamometry is to measure an isometric force. To carry out these measurements, the examiner will stand on the side who has to be tested by exerting a pressure diametrically opposite to the patient's movement, thus preventing him/her from carrying out the movement. The patient will perform 3 tests for each movement, the best value will be collected by the examiner.~The reference position is :~Patient elbowed to the body bent at 90°, with trunk inclination at 30° in the resuscitation bed, lower limbs flat."
75398038|NCT04696497|Diagnostic Test|Manual muscular Assessment (MRC-SS)|Following the same positions as for the dynamometer, the examiner will evaluate the 12 motor functions according to the following 60-point rating. With the maximum quote of 5 point representing normal strength and 0 point the total absence of any muscular contraction
75398039|NCT04682366|Drug|Tamsulosin|Oral drug: 10 days of 0.4 mg of oral Tamsulosin
75709444|NCT05740748|Drug|Placebo|placebo sc q4wks for 20 weeks
75398040|NCT04682366|Drug|Placebo|Oral drug: 10 days of identical-appearing placebo
75398041|NCT04661384|Biological|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given ICV
75398042|NCT04656301|Drug|Psilocybin|A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
75547916|NCT05111509|Device|SPECT/CT|Scans are administered over 3 days: 1 hour post injection, 4 to 8 hours post-injection, 24 to 30 hours post-injection, and 42 to 52 hours post-injection.
75709445|NCT00873028|Other|In Hospital Cardiopulmonary Rehabilitation|The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
75709446|NCT04039516|Drug|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
75398043|NCT04651153|Drug|UCB7853|Subjects will receive UCB7853 at pre-specified time-points.
75398044|NCT04651153|Other|Placebo|Subjects will receive Placebo at pre-specified time-points.
75398045|NCT04644692|Other|Lung ultrasound|A lung ultrasound before and at the end of the stress test.
75398046|NCT04598711|Behavioral|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
75398047|NCT04598711|Behavioral|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
75398048|NCT04598711|Behavioral|Muscle Power training|All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.
75398049|NCT04598711|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.
75398050|NCT04598711|Behavioral|Treadmill Training|All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.
75398051|NCT04597047|Diagnostic Test|Capillary Collection & Testing|Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test
75398052|NCT04597047|Diagnostic Test|Venous Draw & Testing|One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test
75398053|NCT04587518|Behavioral|Personality-Based Cognitive Behavioral Therapy|The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons [long and short-term consequences] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.
75398054|NCT04573504|Drug|Augmentin/Flagyl or Augmentin/Clindamycin|Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
75398055|NCT04573504|Drug|Placebo|Placebo
75398056|NCT04560972|Drug|Atezolizumab|Given IV
75709447|NCT00873106|Device|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
75709448|NCT05741684|Behavioral|Internet-delivered Cognitive Behavioral Therapy|iCBT was administered in an unguided fashion without human therapeutic support. Participants were instructed to progress through the eight core modules over an 8-week period. The modules comprised psychoeducational content centered around CBT, aimed at promoting the development of skills such as self-monitoring of emotions, cognitive distancing, cognitive reframing/restructuring, problem-solving, and mindfulness. In the event of technical difficulties during the intervention, participants were able to seek assistance.
75871034|NCT02367508|Behavioral|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
76037070|NCT05193604|Drug|Paclitaxel for injection (albumin bound)|Chemotherapy medicine for metastatic pancreatic cancer
75398057|NCT04560972|Drug|Carboplatin|Given IV
75398058|NCT04560972|Drug|Etoposide|Given IV
75398059|NCT04560972|Drug|Protein Phosphatase 2A Inhibitor LB-100|Given IV
75398060|NCT04545385|Drug|TEV-48574|subcutaneous infusion
75398061|NCT04545385|Drug|Placebo|Matching Placebo
75398062|NCT04542421|Diagnostic Test|Lung ultrasound use in patients hospitalized with COVID|Hospitalists will be taught to use lung ultrasound in the management of their patients with COVID
75398063|NCT04532814|Other|Exercise|Cycling 60% VO2 max
75398064|NCT04521335|Drug|Disulfiram|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
75398065|NCT04521335|Drug|Copper Gluconate|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
75398066|NCT04515615|Drug|Camrelizumab|Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
75398067|NCT04515615|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.
75398068|NCT04515615|Drug|Tegafur gimeracil oteracil potassium capsule|Tegafur gimeracil oteracil potassium capsule: 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
76037071|NCT05188261|Drug|IW-3300|A single dose of IW-3300 administered rectally (as a low-volume [20 mL] enema) following a fast of at least 6 hours.
75398069|NCT04508582|Diagnostic Test|Cardiovascular magnetic resonance|Imaging of the heart with CMR, without use of contrast agents.
75398070|NCT04508582|Diagnostic Test|Echocardiography|Imaging of the heart with ultrasound.
75398071|NCT04508582|Diagnostic Test|Blood test|Time- matched blood samples will be taken from patients to assess immune cell phenotype and function, paying particular attention to neutrophil and T-cell phenotype. Plasma samples will be collected for the analyses of cardiac specific factors (BNP, troponin) as well as measurement of steroid hormones (progesterone and oestradiol), and soluble inflammatory and anti-inflammatory mediators
75398072|NCT04502563|Other|Remote monitoring and predictive analytics|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
75398073|NCT04502563|Other|Sham comparator|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
75398074|NCT04462458|Device|Medacta Anatomic Ribbon Surgery (M-ARS ACL)|M-ARS ACL allows to reconstruct the anterior cruciate ligament using the Anatomic Ribbon Technique
75398075|NCT04454645|Behavioral|mABC|Intervention targets parenting sensitivity and nurturance.
75398076|NCT04454645|Behavioral|mDEF|Intervention targets parenting enhancing infant cognitive development
75398077|NCT04438161|Behavioral|PERCCS: Personalized Education Regarding Clinical and Community Supports|A brief follow-up to the screening provided to 50% of the consented families (randomly assigned) that links their specific familial risks to community interventions.
75398078|NCT04431661|Procedure|Optical Coherence Tomography|OCT (DragonFly, Abbott Vascular) will be performed after angiography. OCT images will be acquired using the 6F guide catheter compatible DragonFly System (Abbott Vascular, Santa Clara, USA). The catheter will be introduced into the first coronary artery via a standard 0.014-inch angioplasty wire, after prior injection of an intracoronary bolus of nitro-glycerine (according to the hemodynamic conditions of the patient). To remove all blood adequately from the imaging site, nonocclusive flushing will be performed using continuously inject via an automated power injector, and the OCT catheter will be pulled back at a speed of 18 mm/second to guarantee sufficient time to acquire images of a 54 mm long segment (frame density: 10 frames/mm).
75547917|NCT05109728|Drug|[177Lu]Lu-DOTA-TATE|"Group 1: [177Lu]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: [177Lu]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed."
75547918|NCT05109728|Drug|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
75547919|NCT05109728|Other|Temozolomide|"Concomitant Phase: Temozolomide 75mg/m2/d p.o until last day of EBRT.~Maintenance Phase: Temozolomide p.o 150 mg/m2/d during cycle 1 then 200 mg/m2/d for the following cycles if tolerated well in Cycle 1. 6 cycles total (1 cycle = every 28 days)"
76037072|NCT05188261|Drug|Placebo|A single dose of placebo administered rectally (as a low-volume [20 mL] enema) following a fast of at least 6 hours.
76037073|NCT05186090|Behavioral|24-week resistance exercise program|This group will perform a 24-week resistance exercise program. Participants will engage in 180 minutes/week of resistance exercise (3 supervised sessions peer week, 60 min/session). The training will consist of a combination of upper and lower body exercises using elastic bands and participants' body weight as the primary resistance. Exercise load and intensity will be based on the number of repetitions (i.e.,10-12 repetitions), resistance of the elastic bands, in ascending order with seven intensities, and also on the exercises' difficulty (i.e., three levels). The prescribed targeted intensity will reach 70-80% of the participants' maximum rating perceived exertion (i.e., 7-8 RPE).The progression (horizontal) will be standardized according to the execution time and RPE, and individualized according to execution speed and band resistance. Heart rate will be monitored in all sessions. Further, intrinsic motivation before and after session and sleep quality will be registered.
76037074|NCT05181553|Other|Canada's Food Guide principles (CFG diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
76037075|NCT05181553|Other|Standard North American diet (NAD diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the eating habits of Canadians.
76037076|NCT05159999|Other|Dry weight target adjustment|Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.
76037077|NCT05159999|Drug|Anti-hypertensive medications|Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.
75547920|NCT05109728|Other|Radiotherapy|2 Gy/day, 5 days per week followed by 2 days of rest, for 6 consecutive weeks
75547921|NCT05100979|Other|The Art of Medicine Series|The Art of Medicine Series is a smartphone-based educational tool focused on teaching communication strategies to clinicians and patients.
75398079|NCT04431661|Procedure|Coronary Angiography|The coronary angiography will be performed according to the strategies described in the consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups.Transradial or transfemoral 6F/7F approaches are recommended. The choice of diagnostic catheters, guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation is let to the investigator's discretion.
75398080|NCT04431661|Procedure|Per cutaneous coronary intervention|Based on coronary angiography and OCT analyses by the investigators, PCI will be performed, preferentially for the identified culprit lesion(s) only. The guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation are left to physician discretion. The use of semi- or non-compliant balloons number and diameter of drug eluting stent(s) will also be left to the physician discretion, but post dilation will be strongly recommended in case of PCI. OCT can eventually be performed after stent implantation to guide, post dilation strategy.
75398081|NCT04419675|Other|Observational Cohort, usual care = physical therapy|usual care = physical therapy
75398082|NCT04406584|Procedure|Injection into olfactory cleft|Already stated above.
75398083|NCT04399772|Behavioral|Cognitive Functional Therapy+ pathway|"The CFT+ intervention comprises 4 main components: (1) making sense of pain: context-based patient education focusing on the multidimensional nature of pain and disability, while reducing the threat of structural damage and correcting unhelpful beliefs; (2) exposure with control: graded exposure to painful, feared, or avoided activities with body relaxation; (3) lifestyle changes: encouraged to perform physical activity based on preference and taught strategies to manage stress and poor sleep, (4) focus on coping strategies in life and how these strategies influence the current situation.~After CFT+, patients can be offered the comparator pathway should that be clinically indicated from these criteria: the patient does not feel ready to stop treatment AND Analgesic treatment is inappropriate OR Social situation is problematic OR Significantly psychological distress that requires further treatment by psychologist. This decision is based on a multidisciplinary team conference."
75398084|NCT04399772|Behavioral|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Individualized combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects), (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs."
75398085|NCT04293341|Behavioral|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
75547922|NCT05092295|Device|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
75709449|NCT05741684|Behavioral|Attention Bias Modification|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 96 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
76037078|NCT05153876|Other|Questionnaires|Headache attack descriptions, Headache related disability descriptions, Questionnaires, MIDAS, MSQv2.1, SF36
76037079|NCT05146245|Other|Therapeutic Drug Monitoring|Physician receives dosing advice based on risperidone plasma level.
76037080|NCT05146245|Other|Risperidone plasma level|Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.
76037081|NCT05145387|Behavioral|Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)|Students randomized to TEAMSS will receive reading materials on transitioning to middle school and a a school tour with the middle school clinician (in 5th grade) and the TEAMSS group sessions (in 6th grade) delivered over 10 weeks. During the 10 weeks of TEAMSS, parents of students will attend two group meetings and clinicians will consult with at least one teacher (usually the advisory/homeroom teacher).
76037082|NCT05143853|Procedure|non-absorbable tape fixation around AC joint|fixation around AC joint with tape in different configurations
75398086|NCT04293341|Behavioral|Cognitive Processing Therapy for PTSD|CPT is a well established evidence-based psychotherapy for PTSD. CPT focuses on teaching patients to evaluate and change the upsetting thoughts that they have had since their trauma.
75398087|NCT04293341|Behavioral|Cognitive Behavioral Therapy for MDD|CBT for MDD is a well established evidence-based psychotherapy for depression. CBT for MDD focuses teaching patients how to change their behaviors and challenge their negative thoughts to improve their mood.
75398088|NCT04293341|Behavioral|Cognitive Behavioral Therapy for Panic Disorder|CBT for Panic Disorder is a well established evidence-based psychotherapy. CBT for Panic Disorder focuses teaching patients how to change their behaviors through exposure practices and challenge their anxious thoughts to reduce their experience of panic attacks and avoidance.
75398089|NCT04288921|Diagnostic Test|Swab|Swab samples for diagnostic test
76037083|NCT05143853|Procedure|no fixation around AC joint|there will be no additional fixation around AC joint in this group
76037084|NCT05143853|Procedure|coracoclavicular (CC) fixation|mandatory coracoclavicular fixation with to suspensory systems, comprised of non-absorbable tapes and metal buttons
76037085|NCT05129605|Diagnostic Test|Prostate cancer screening|Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
76037086|NCT05110924|Other|Standard of care|Patients in the treatment arm will receive standard care.
76037087|NCT05110924|Other|Monitoring|Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices based on multispectral dermoscopy, reflectance confocal microscopy to determine the exact histology and high definition optical coherence tomography for imaging and volume calculation of the BCC.
76037088|NCT05096754|Device|OCS Liver|Transplant with an OCS preserved liver.
76037089|NCT05094037|Device|Removable cam walker boot|Standard of care device given to diabetic foot ulcer patients.
75398090|NCT04263194|Device|rTMS|25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).
75398091|NCT04263194|Device|Sham rTMS|Placebo intervention will consist in the same procedure but using a sham rTMS coil.
75398092|NCT04247126|Drug|SY-5609|An oral CDK7 Inhibitor
75398093|NCT04247126|Drug|Fulvestrant|Estrogen receptor antagonist
75398094|NCT04247126|Drug|Gemcitabine|Nucleoside metabolic inhibitor
75398095|NCT04247126|Drug|Nab-paclitaxel|Taxane-type chemotherapy
75398096|NCT04241250|Device|EAW+SCES (exoskelton and spinal cord epidural stimulation)|Three months of exoskeleton training followed by 6 months of epidural stimulation.
75398097|NCT04241250|Device|EAW+TS (exoskelton and transspinal stimulation)|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
75547923|NCT05092295|Diagnostic Test|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
75398098|NCT04182425|Other|Infant formula|Healthy full-term infants fed on an infant formula marketed on the French market
75398099|NCT04168489|Device|active rTMS|(rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.
75398100|NCT04168489|Device|sham rTMS|The sham rTMS is inactive and similar to placebo effect.
75398101|NCT04163432|Drug|Durvalumab|Durvalumab is administered at a dose of 1500mg for patients who weigh >30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized
75398102|NCT04163432|Drug|Pemetrexed|Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is < 45 mL/min, pemetrexed is dosed at 400 mg/m2.
75398103|NCT04163432|Drug|Carboplatin|Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.
76037090|NCT05094037|Other|Counseling|Additional education, counseling and encouragement of use of the orthosis beyond the current standard of care.
76037091|NCT05090345|Other|Biorepository Trial|participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
75398104|NCT04152954|Device|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
75398105|NCT04151706|Drug|CD8+ Memory T Cell Infusion|Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
75398106|NCT04151706|Drug|Thiotepa|5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
75398107|NCT04151706|Drug|Fludarabine|25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
75398108|NCT04151706|Radiation|Hyperfractionated TBI|Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
75398109|NCT04151706|Drug|Busulfan|6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg
75398110|NCT04151706|Drug|Cyclophosphamide|60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
75709450|NCT00615550|Drug|progesterone|8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
75398111|NCT04147468|Other|Virtual Reality|For the VR intervention, we focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the participant. The research team will travel to the family to conduct the intervention to ensure the treatment adherence. The participants will be asked to move their arms to 'pop' as many virtual objects as possible.
75398112|NCT04147468|Other|Functional Strength Training|For the functional strength training, participants will receive repetitive progressive resistance exercise during goal-directed functional activity with the participants focus on the activity being performed. The research team will also go to the family to conduct the FST intervention.
75398113|NCT04125186|Diagnostic Test|Baseline EpiNP survey|The survey takes approximately 20 to 30 minutes to complete, and consists of the following: Short Form Health Survey version 2.0 (SF-12v2.0); Lower Urinary Tract Symptoms (LUTS) Tool; Patient Perception of Bladder Condition (PPBC); Self-report Medical History and Current Medication Form; Nocturia Impact Diary (NID); Disease-Specific Healthcare-Seeking Behavior and Treatment; Epworth Sleepiness Questionnaire (ESS); Patient Reported Outcome Measurement Information System Fatigue-Short Form version 1.0 (PROMIS F-SFv1.0); Patient Health Questionnaire (PHQ-8); Work Productivity and Activity Index (WPAI-SHP); Sexual health questions; lifestyle and sociodemographic questions; additionally, only men will complete the International Prostate Symptom Score (IPSS).
75398114|NCT04125186|Diagnostic Test|Bladder diary|It consists of four components: measurement of waist and neck circumference, daily voiding diary (to assess voiding patterns, including frequency, volume, associated urgency, and incontinence episodes over a 24-hour period), NID (to assess nocturia impact), and assessment of morning sleepiness for 3 consecutive days and nights (including the morning of the fourth day).
75547924|NCT05085951|Device|20 mm CRE balloon|Endoscopic balloon that is used to dilate pylorus
75547925|NCT05085951|Diagnostic Test|OGD|OGD (No dilatation)
75709451|NCT00615550|Drug|placebo|vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
75709452|NCT04039594|Device|VA ECMO|VA ECMO for cardiopulmonary support
75709453|NCT00873184|Behavioral|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
76037092|NCT05072808|Other|View PACCI-ED and referral recommendations|Results of parent completed PACCI-ED and referral recommendations
76037093|NCT05059652|Device|Ischemic Preconditioning|The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.
75398115|NCT04125186|Diagnostic Test|Testing of EpiNP baseline survey, bladder diary and a qualitative interview|This part briefly reviews the usability of the EpiNP survey and bladder diary. The feedback obtained after qualitative interview will be used to refine and finalize the instructions sent to the participants in the main part.
75547926|NCT05069766|Other|BioXmark™|During a scheduled outpatient gastroscopy, the tumor margins will be endoscopically marked by BioXmark™. BioXmark™ will be implanted at the most proximal margin of the tumor and 5 cm proximally of the tumor border.
75547927|NCT05068700|Device|Integrated Pulmonary Index|Medtronic Capnostream 35p monitoring parameter
75547928|NCT05068700|Device|Standard capnography monitoring|Medtronic Capnostream 35p monitoring parameter
75547929|NCT05047965|Procedure|Dixon MRI|Undergo Dixon MRI
75871035|NCT02362204|Behavioral|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
76037094|NCT05058469|Device|Tracheotomy|Tracheotomy in patients +/- antiplatelet therapy
75871036|NCT03078582|Drug|Zilucoplan (RA101495)|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
76037095|NCT05047185|Drug|Deucrictibant low dose|Deucrictibant softgel capsules for oral use (PHVS416)
76037096|NCT05047185|Drug|Deucrictibant high dose|Deucrictibant softgel capsules for oral use (PHVS416)
75398116|NCT04125186|Other|No other intervention|No other intervention
75398117|NCT04119453|Drug|Rivoceranib|Film-coated tablets
75398118|NCT04114734|Behavioral|Park Rx|Participants will be advised to visit a specific park at a specific frequency and duration
75398119|NCT04097353|Behavioral|Harvesting Hope for Kids (HH4K)|Weekly meetings at university-based farm
75398120|NCT04097353|Behavioral|Surviving Strong for Kids (SS4K)|Enhanced usual care
75398121|NCT04093986|Other|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
75398122|NCT04093986|Other|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
75398123|NCT04065438|Device|LIPOSORBER® LA-15|"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
75398124|NCT04006119|Biological|Ad-RTS-hIL-12|"intratumoral injection of Ad-RTS-hIL-12~2.0 x 10^11 viral particles (vp) per injection"
75398125|NCT04006119|Drug|Veledimex|20mg/day 15 oral daily doses of veledimex
75398126|NCT04006119|Drug|Cemiplimab-Rwlc|Infusion every 3 weeks (350mg)
76037097|NCT05047185|Drug|Placebo|Matching placebo capsules for oral use
75547930|NCT05047965|Procedure|Magnetic Resonance Imaging|Undergo standard MRI
75547931|NCT05043792|Drug|TT-00920|TT-00920 Tablets
75547932|NCT05043792|Drug|TT-00920 Placebo|TT-00920 Placebo Tablets
75547933|NCT05036291|Drug|NB004 tablets|"Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets & Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets & Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA ."
75871037|NCT02361892|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
75871038|NCT04013334|Drug|MTG201|MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
75871039|NCT04013334|Drug|Nivolumab Injection [Opdivo]|Nivolumab 480 mg by IV infusion every 4 weeks
76037098|NCT05040217|Genetic|AAV2-BDNF Gene Therapy|AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
76037099|NCT05040217|Biological|AAV2-BDNF Gene Therapy|Gene therapy is a biological therapy delivering the BDNF gene to the brain
76037100|NCT05034042|Drug|Fezolinetant|oral
75398127|NCT04004793|Behavioral|Intensive lifestyle intervention|Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500~750 kcal/day) for 3 months, with <35% as fat, >15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).
75398128|NCT04004793|Drug|Dapagliflozin 10 MG Oral Tablet|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
75547934|NCT05034601|Procedure|ESPB group|A 21-gauge 100-mm needle will be inserted into the fascial layer beneath the iliocostalis, longissimus, and spinalis muscles. A bolus of 0.25% ropivacaine 0.5 ml/kg will be injected into the fascial layer. Contralateral ESPB will be performed similarly.
75547935|NCT05034601|Procedure|TPVB group|A 21-gauge 100-mm insulated needle will be inserted into the paravertebral space via an in-plane parasagittal approach. After perforating the costotransverse ligament, 0.25% ropivacaine 0.5 ml/kg will be injected. Anterior movement of the pleura indicated the appropriate spread of the local anesthetics in the paravertebral space. The process will be repeated on the contralateral side.
75398129|NCT04004793|Drug|Placebo Oral Tablet|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
75558172|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
75398130|NCT04002011|Drug|Warfarin|It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of [2.0-3.0]. Other anticoagulants will be not administrated.
75398131|NCT04002011|Drug|Dabigatran|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
75398132|NCT04002011|Drug|Rivaroxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
75398133|NCT04002011|Drug|Apixaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
75871040|NCT03285412|Drug|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
75558173|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
75398134|NCT04002011|Drug|Edoxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
75398135|NCT03968991|Diagnostic Test|VISIODOL® (Diagnostic tool)|Tool for assessing pain in the blind subject (with congenital or acquired deficiency)
75558174|NCT00441051|Drug|Diclofenac sodium 1mg/g|
75558175|NCT00443963|Drug|Esomeprazole Magnesium|PPI compared to H2RA
75871041|NCT03285412|Other|Endocrine therapy|Hormone therapy
75398136|NCT03968107|Other|Reference ultrasound examination|Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
75558176|NCT00441207|Drug|Ascorbic Acid|Delivered via IV Infusion.
75871042|NCT03077724|Drug|Fish oil|Fish oil supplementation
75871043|NCT03077724|Drug|Placebos|Olive Oil capsules
75871044|NCT02361814|Procedure|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
76037101|NCT05034042|Drug|Placebo|oral
76037102|NCT05025865|Drug|Sodium Hyaluronate|Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
76037103|NCT05025865|Drug|Placebo|A placebo will be given in capsule form to study participants.
75398137|NCT03934437|Behavioral|mLTCR|mHealth-enhanced Linkage to Care and Retention
75398138|NCT03934437|Behavioral|LTCR|Linkage and Retention Services (Standard-of-Care)
75398139|NCT03903692|Device|Marine polysaccharide dressing|The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
75398140|NCT03903692|Device|Carboxymethylcellulose dressing|The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
75398141|NCT03886610|Other|Healthy controls|individuals without spinal cord injury
75398142|NCT03886610|Other|Subacute SCI patients|individuals with spinal cord injury ≥ 2 weeks
75398143|NCT03886610|Other|Chronic SCI patients|individuals with spinal cord injury ≥ 24 months
75398144|NCT03878849|Drug|2X-121|Every patient will receive daily oral administrations of 3 x 200 mg 2X-121 hard gelatin capsules in a 28-day cycle.
75398145|NCT03878849|Device|2X-121 DRP®|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
75398146|NCT03877796|Device|Drug Response Predictor® (DRP)|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
75398147|NCT03789591|Drug|Hydroxyurea|The alternative arm will use PK data to choose a starting hydroxyurea dose to achieve an AUC of 115 mg*h/L to approximate maximum tolerated dose. On the standard arm, participants will start at the traditional, weight-based dose of 20 mg/kg/day. Following selection of the starting dose, all participants will follow the same dose escalation and laboratory monitoring procedures.
76037104|NCT05012618|Drug|LUNA18|LUNA18 Capsule
76037105|NCT05012618|Drug|Cetuximab|Cetuximab as a IV infusion
75398148|NCT03783026|Drug|Apremilast|Tablets for oral administration
75398149|NCT03775460|Drug|Methotrexate|Participants in the intervention group will receive methotrexate along side prednisolone
75398150|NCT03775460|Drug|Placebo|Participants in the control arm will receive placebo along side prednisolone
75398151|NCT03775460|Drug|Prednisolone|Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
75398152|NCT03735797|Diagnostic Test|Bone marrow aspirate or peripheral blood sample collection|Collection of specimen samples only
75398153|NCT03651830|Device|Prosthetic Foot Emulator|Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
75398154|NCT03651830|Device|Commercially available prosthetic feet|"Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet."
75398155|NCT03635112|Drug|Placebo|Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
75398156|NCT03635112|Drug|TD-1473|TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
75398157|NCT03591731|Drug|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
75398158|NCT03591731|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
75398159|NCT03588728|Other|Transcranial Direct Current Stimulation|Transcranial direct current stimulation targeting the right inferior frontal gyrus
75398160|NCT03588728|Behavioral|Cognitive Remediation (CR)|Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
75398161|NCT03547947|Device|Medacta Shoulder System|Total Shoulder Arthroplasty
75398162|NCT03535584|Behavioral|Exercise Program|Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
75398163|NCT03534726|Device|7 T CMR|7 tesla MRI device
75558177|NCT04701255|Procedure|phacoemulsification with intraocular lens implantation|treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
76037106|NCT04996680|Device|Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction
76037107|NCT04996680|Other|Standardised low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises
76037108|NCT04996680|Device|Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
75558178|NCT04701255|Device|ocular aberrometer assesment|evaluate total ocular wavefront, corneal wavefront & internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
75558179|NCT00444041|Drug|Bevacizumab|neoadjuvant therapy prior to elective surgery
75558180|NCT00441246|Drug|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
75871045|NCT01379742|Device|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
75398164|NCT03513081|Behavioral|Educative session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
75398165|NCT03500354|Dietary Supplement|Nutrient drink|High calorie drink with therapeutic supplements
75398166|NCT03455582|Other|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
75398167|NCT03455582|Other|Ecological evaluation|Virtual reality task and Actual reality
75398168|NCT03455582|Other|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
75398169|NCT03455582|Other|Psychological evaluation|questionnaires for depression, anxiety and fatigue
75398170|NCT03455582|Device|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
75398171|NCT03448926|Other|Treatment Recommendation Surveys|Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
76037109|NCT04993482|Other|No intervention|This project contains a longitudinal observational study design. The investigator will collect data out of a group with type 2 diabetes mellitus patients and out of group with control adults on three time points (baseline, follow-up after one year, and follow-up after two years). Therefore, the investigator will only collect observational data and the participants will not be exposed to a certain intervention.
75398172|NCT03439033|Drug|PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
75398173|NCT03439033|Drug|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have two visits (the second visit being optional) within two years. During each visit, they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
75398174|NCT03439033|Drug|PET/CT with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/CT with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
75398175|NCT03412812|Radiation|Dose Escalated Five Fraction Stereotactic Radiosurgery|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
75709454|NCT05127538|Diagnostic Test|Gait analysis|Gait analysis Zebris Rehawalk (Zebris Medical GmbH, Germany) computerized gait evaluation system is used to assess the kinetic and kinematic analysis of the gait. The system consists of a treadmill and a computer. For gait assessment, patients walk at their preferred comfortable walking speed.
76037110|NCT04990687|Device|gammaCore™|"Implantable VNS (iVNS), the electrical stimulation of the nervous system to modulate or modify function, has been FDA approved in the United States since the late 1990s. Implantable VNS therapy has been approved for use in epilepsy and depression.~When treating major depression with implanted VNS, the widely held belief is that chronic stimulation is required for therapeutic effect. In trials of implantable VNS in major depression, more patients respond at 12 months than at 3 months. Once depressed patients respond to VNS, the effects have been demonstrated to continue for up to five years with continued stimulation. This finding suggests that VNS gradually changes brain function through neuroplasticity."
76037111|NCT04983186|Device|Wearable sensor and smartphone application|Empatica E4 wearable sensor and custom-made headache smartphone application
76037112|NCT04978675|Drug|Fluorine F 18 rhPSMA-7.3|Given IV
76037113|NCT04978675|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
75398176|NCT03405558|Other|No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine
75398177|NCT03405311|Device|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device
75871046|NCT01379742|Device|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
75871047|NCT02361658|Other|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
76037114|NCT04978675|Procedure|Positron Emission Tomography|Undergo PET/MRI
76037115|NCT04976855|Drug|INDV-2000|Capsule for oral administration
76037116|NCT04976855|Drug|Placebo|Capsule for oral administration
75398178|NCT03405311|Other|Palpation|The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
75398179|NCT03400982|Diagnostic Test|Bone densitometry measurement|Bone densitometry and measurement of body composition
75398180|NCT03380962|Drug|Clazakizumab|All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
75398181|NCT03380377|Drug|Clazakizumab|Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
75398182|NCT03330886|Drug|Atezolizumab|Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
75398183|NCT03282799|Drug|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
75398184|NCT03264261|Device|robotic training|robotic training, 3 times/week for 6 weeks
75709455|NCT05127538|Diagnostic Test|Balance Assessment|Static and dynamic balance Static and dynamic balance and stability limit values are evaluated with the E-LINK FP3 Force Plate (Biometrics Ltd, United Kingdom) system. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals are asked to place their feet on the marked places on the platform and hold an object on the computer screen at a fixed point for 30 seconds without support from their hands. For dynamic balance, individuals need to follow a moving object on the computer screen for 30 seconds by putting their body weight forward, backward, and sideways with their feet.
75709456|NCT00736164|Dietary Supplement|selenomethionine|Given orally
76037117|NCT04976855|Drug|SUBOXONE® sublingual film|Administered either under the tongue (sublingual) or between the gum and cheek (buccal)
75398185|NCT03264261|Device|treadmill training|treadmill training only, 3 times/week for 6 weeks
75398186|NCT03263546|Behavioral|Internet-delivered cognitive behavioral therapy (ICBT)|"Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks."
75398187|NCT03263546|Behavioral|Cognitive behavioral therapy (CBT)|"Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks."
75398188|NCT03192020|Procedure|Percutaneous needle fasciotomy (PNF)|The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.
75398189|NCT03192020|Drug|Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
75398190|NCT03192020|Procedure|Limited fasciectomy (LF)|LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
75398191|NCT02991248|Device|robotic training|robotic training by applying pelvis force perturbation
75398192|NCT02991248|Device|spinal cord electrical stimulation|Applying direct current electrical stimulation on spinal cord
75398193|NCT02991248|Device|treadmill|conventional treadmill training only
75398194|NCT02987543|Drug|olaparib|300 mg (2x 150 mg tablets) twice daily
75398195|NCT02987543|Drug|enzalutamide|160 mg (4 x 40 mg capsules) once daily
75398196|NCT02987543|Drug|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
75398197|NCT02987543|Drug|abiraterone acetate|1,000 mg (2 x 500 mg tablets) once daily
75398198|NCT02987543|Drug|enzalutamide|160 mg (4 x 40 mg tablets) once daily
75398199|NCT02983045|Drug|Dose Escalation Doublet: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels.
75398200|NCT02983045|Drug|Dose Expansion Doublet: Combination of NKTR-214 + nivolumab|Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
75398201|NCT02983045|Drug|Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.
75398202|NCT02983045|Drug|Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
75398203|NCT02944136|Behavioral|enhanced usual care|usual care from health providers
75709457|NCT00736164|Other|placebo|Given orally
75709458|NCT00739830|Drug|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
76037118|NCT04919226|Drug|177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
75709459|NCT00739830|Drug|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
75709460|NCT00739830|Drug|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
75709461|NCT05111782|Other|Symptom Modulation Approach, Movement Control Approach, Functional Optimization Approach|Based on the patients' symptoms and level of disability, either symptom modulation or movement control or functional optimization exercises will be used. The exercises will be provided on alternate days for a duration of 30 minutes in each session preceded by electrotherapeutic modalities for pain relief and muscle relaxation. These modalities will be given for 15 min in each session. The total no. of sessions will be based on the patient's progress for a maximum of 4 weeks.
75709462|NCT00577382|Drug|Sunitinib|
75398204|NCT02944136|Behavioral|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
75398205|NCT02923440|Biological|blood sample|
75398206|NCT02894398|Drug|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
75398207|NCT02894398|Drug|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
75398208|NCT02894398|Drug|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
75398209|NCT02894398|Drug|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
75398210|NCT02894398|Drug|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
75398211|NCT02871752|Behavioral|Health promotion|mindfulness-based stress reduction
75398212|NCT02869399|Dietary Supplement|dietary intervention in addition to standard recommendations|"The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~eat mostly food of plant origin~eat lean meat, limit intake of red meat and avoid processed meat~increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries"
75398213|NCT02855034|Other|Blood samples|Blood samples for dosage: copeptin and protein S100B
75398214|NCT02708810|Device|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
75398215|NCT02708810|Radiation|80 Gy Radiation|
75709463|NCT00733434|Drug|Prostaglandin E1|PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
75709464|NCT00733434|Other|Saline|500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
75709465|NCT04039282|Device|myfood24|online website for dietary analysis
75871048|NCT02361658|Other|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
75398216|NCT02678689|Biological|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
75398217|NCT02678689|Device|Intraventricular access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
75398218|NCT02678052|Drug|Vedolizumab|Vedolizumab exposure
75398219|NCT02678052|Biological|Other Biological Agent|Other Biological Agent exposure
75398221|NCT02564263|Biological|pembrolizumab|200 mg administered as IV infusion on Day 1 of every 21-day cycle
75398222|NCT02564263|Drug|paclitaxel|80-100 mg/m^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle
75398223|NCT02564263|Drug|docetaxel|75 mg/m^2 administered as IV infusion on Day 1 of every 21-day cycle
75398224|NCT02564263|Drug|irinotecan|180 mg/m^2 administered as IV infusion on Day 1 of every 14-day cycle
75398225|NCT02540018|Device|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|"Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied."
75547936|NCT05019261|Other|Multi-component Family Support Intervention|The multi-component intervention is designed to enhance the quality of clinician-family communication and help families manage the emotional and cognitive complexities of surrogate decision-making. It involves: 1) proactive clinician-family meetings; 2) use by surrogates of an interactive web-based tool throughout the ICU stay which is narrated by family members of ICU patients and includes stories and experiences from other families, self-care strategies, brief videos explaining what to expect during family meetings, a question prompt list, an interactive values clarification exercise, and an explanation of different treatment pathways for critically ill patients. 3. Prior to the proactive family meetings, the ICU team is provided with a summary of the family's main questions/concerns, their prognostic expectations, a summary of the patient's values and preferences, and surrogates' current ratings of the extent to which their psychosocial needs are being addressed in the ICU.
75547937|NCT05017623|Drug|YH003|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
75547938|NCT05000814|Device|DLT|VDLT versus the use of DLT with fiberoptic bronchoscope
75709467|NCT00736320|Drug|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
75709468|NCT00736320|Radiation|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
75709469|NCT00878566|Other|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
76037119|NCT04919226|Drug|CAPTEM (Capecitabine and Temozolomide)|Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
75709470|NCT00878566|Other|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
76037120|NCT04919226|Other|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
75398226|NCT02540018|Device|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
75398227|NCT02522247|Procedure|UPP|surgery with cold steel in general anesthesia
75709471|NCT04065282|Drug|Sintilimab|3 cycles before radical surgery
75709472|NCT04065282|Drug|Oxaliplatin|85mg/m2 Q3W, 3 cycles perioperation
76037121|NCT04919226|Drug|Everolimus|Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
76037122|NCT04919226|Drug|FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)|Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
75398228|NCT02513056|Other|MRI|MRI
75398229|NCT02423265|Drug|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
75398230|NCT02423265|Drug|Placebo|Matching placebo: up-titration after 1 week
75398231|NCT02416050|Procedure|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
75398232|NCT02379819|Device|Nucleus Hybrid L24 Implant|
75398233|NCT02368886|Drug|Clobetasol Propionate|Given topically
75398234|NCT02368886|Other|Pharmacological Study|Correlative studies
75398235|NCT02368886|Other|Quality-of-Life Assessment|Ancillary studies
75398236|NCT02368886|Drug|Regorafenib|Given PO
75398237|NCT02332369|Device|Capsular Tension Ring|
75398238|NCT02301286|Drug|Acetylsalicylic acid|
75398239|NCT02301286|Drug|Placebo Acetylsalicylic acid|
75398240|NCT02262221|Other|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
76037123|NCT04904692|Procedure|Blood draw|8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.
75398241|NCT02227238|Drug|DTG|DTG is supplied as 50 mg tablets
75398242|NCT02227238|Drug|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
75398243|NCT02227238|Drug|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
75398244|NCT02225925|Radiation|Brachytherapy|
75398245|NCT02216305|Procedure|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
75398246|NCT02216305|Procedure|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
75871049|NCT02361658|Other|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
75547939|NCT05000294|Drug|Atezolizumab|Subjects on both the phase Ib and phase II portions of this study will receive 1680 mg intravenously of atezolizumab on Day 1 of each 28 day cycle.
75547940|NCT05000294|Drug|Tivozanib|Subjects in both the phase Ib and phase II portions of the study will take tivozanib orally once daily on Days 1-21 of each 28 day cycle. Subjects on the phase Ib will be assigned to receive either 1.34 mg/day (Dose level 0) or 0.89 mg/day (Dose level -1). Subjects in the phase II portion of the study will receive 0.89 mg/day.
75871050|NCT02356744|Other|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
75398247|NCT02126969|Radiation|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
75547941|NCT04981860|Drug|Betadine|One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye
75547942|NCT04981860|Drug|Avenova|One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye
75547943|NCT04979910|Drug|Ixekizumab|a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
75398248|NCT02126969|Drug|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
75547944|NCT04979910|Drug|Placebo|matching placebo
75547945|NCT04976465|Drug|Anticoagulation|"Drug:~Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ~Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~Other Names: Asp~Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH"
75709473|NCT04065282|Drug|Capecitabine|1000mg/m2 bid po D1~14 Q3W, 3 cycles perioperation
75871051|NCT02356510|Procedure|Primary PCI|
75398249|NCT02121743|Device|strattice|use of a strattice
76037124|NCT04904692|Procedure|Bronchoalveolar lavage|Only in case of diagnostic or therapeutic indication.
75398250|NCT02121743|Procedure|No strattice|no use of a strattice
75398251|NCT02099188|Drug|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
75398252|NCT02099188|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
75398253|NCT02099188|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
75398254|NCT02099188|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
75398255|NCT02099188|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
75871052|NCT02366884|Drug|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
75871053|NCT02366884|Drug|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
75871054|NCT02366884|Drug|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
75871055|NCT02356276|Procedure|D2 lymphadenectomy|
75871056|NCT02356276|Procedure|Hyperthermic Intraperitoneal Chemotherapy|The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.
75871057|NCT02356276|Drug|Systemic chemotherapy (XELOX or SOX regimens)|"XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40 mg/m^2 bid, po, day 1-14 (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles."
75871058|NCT02361502|Drug|mirabegron|
76037125|NCT04904692|Procedure|SARS CoV-2 swabs|Nasopharyngeal, oropharyngeal and nasal swabs
75398256|NCT02099188|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
75709474|NCT00873262|Drug|Skin test panel and desensitization kit|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:~Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
75871059|NCT02361502|Drug|placebo|
75709475|NCT00873262|Drug|Skin test panel and solvent|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
75871060|NCT02356354|Procedure|Skin biopsy|2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
75709476|NCT00736970|Drug|ridaforolimus|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.
75709477|NCT00736970|Drug|trastuzumab|single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
75871061|NCT02366962|Biological|ASP7374|subcutaneous
75871062|NCT02356120|Other|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
75871063|NCT02367118|Drug|Prednisone|
75871064|NCT02367118|Drug|Placebo|
75871065|NCT02361268|Behavioral|Intradialysis-yoga|The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
75871066|NCT02361268|Behavioral|Educational program|The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
75871067|NCT02355808|Behavioral|Tailored Leaflet|
75398257|NCT02099188|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
75398258|NCT02099188|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost with ENI:~HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
75547946|NCT04976465|Drug|Without Anticoagulation|"Drug:~Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ"
75709478|NCT00879736|Behavioral|THT PACE Training|Patient training
75709479|NCT00879736|Behavioral|THT PACE Training|Patient training
75709480|NCT00879736|Other|placebo|
75871068|NCT02355808|Behavioral|GP visit|
75871069|NCT02355730|Procedure|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
75871070|NCT00979212|Drug|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
75871071|NCT00979212|Drug|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
75871072|NCT00979212|Drug|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
75871073|NCT00979212|Procedure|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
75871074|NCT02356042|Other|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
75871075|NCT02355964|Behavioral|Exercise|Aerobe exercise 3 times a week in 8 weeks
75871076|NCT02355964|Behavioral|Diet|Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
75871077|NCT02355652|Device|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
76037126|NCT04865978|Drug|Apixaban|Patients randomized to apixaban will be started on a dose of 5 mg BID.
75398259|NCT02099188|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
75398260|NCT02099188|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
75398261|NCT02099175|Drug|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
75547947|NCT04975776|Behavioral|Sleep restriction therapy|The intervention includes psychoeducation and sleep restriction therapy, sleep restriction instructions, problem-solving, and support for participants in adjusting sleep restriction instructions to their individual needs and life circumstances. At the final session, participants create an individual plan for maintaining new sleep habits and coping with insomnia relapse. During the intervention, participants are free to seek and receive standard care for insomnia.
75709481|NCT00873340|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
75709482|NCT00740064|Drug|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
76037127|NCT04865978|Drug|Warfarin|Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.
76037128|NCT04865978|Device|LVAD implant|Subjects will undergo HeartMate 3 LVAD implant prior to randomization
75398262|NCT02099175|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
75547948|NCT04975776|Behavioral|Sleep hygiene|The control condition will include written, general information about sleep and lifestyle and environmental factors that could improve or disturb sleep. The participants will be free to seek and receive standard care for insomnia.
75547949|NCT04969380|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
75558181|NCT03278288|Device|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
75558182|NCT00478842|Device|Deep brain stimulation|Deep brain stimulation
75558183|NCT00478959|Drug|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
75558184|NCT00444158|Drug|MOA-728|
75558185|NCT00441324|Procedure|recombinant human LH|
75709483|NCT00736398|Procedure|Spinal fusion|Spinal fusion
75709484|NCT00614926|Drug|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
75709485|NCT00614926|Drug|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
76037129|NCT04861558|Drug|5Fluorouracil|Injection of 250-850 mg/m2.
76037130|NCT04861558|Drug|Irinotecan|Injection of 360 mg/m2
76037131|NCT04861558|Drug|Oxaliplatin|Injection of 460 mg/m2
76037132|NCT04858061|Behavioral|Virtual Reality Cue Exposure Therapy|Exposure to alcohol-related cues within virtual environments
76037133|NCT04858061|Behavioral|Treatment-as-usual|Pharmacotherapy and psychotherapy
76037134|NCT04851964|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
76037135|NCT04851964|Other|Placebo|Placebo subcutaneous injection
76037136|NCT04851587|Behavioral|In-Person (or Remote) Intervention|Participants will be asked to engage in self-administered activities during the intervention including pleasant activity scheduling, values clarification, mindfulness practice, goal setting, standard pain coping skills, and weight management including nutrition education and physical activity monitoring.
75398263|NCT02099175|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
75398264|NCT02099175|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
75398265|NCT02099175|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
75398266|NCT02099175|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
75398267|NCT02099175|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
75547950|NCT04964297|Device|Obtaining bowel gas samples|"The Perf-AlertTM prototype consists of a 15 x 13 x 7 unit containing gas sensors and valves, a small box containing a one-way, ultra-low pressure pump, user controls (buttons), and software algorithms, which control the operation of the device. It is used in conjunction with a single-use, disposable kit of sterile tubing and filters used for sample collection. The sensing unit will be connected via a sterile tube/filter set to any trocar port in use during the procedure. At specific time points during surgery, a one-way valve will be opened, and the unit's pump turned on and withdrawing a small amount of gas from the abdominal cavity. The system is configured that sample collection, transport, analysis, and feedback occur in a single step such that sample collection and sensor feedback occur in real-time. A standard laptop running an analytical software program is connected to the unit to record and log sensor readings."
75547951|NCT04945538|Other|Scatter radiation exposure measurement|Scatter radiation exposure of the operator and sterile assistant is recorded with digital live dosimeters at 3 locations of the operator (frontal head at eye level, left lateral head, below the left shoulder) and at 2 locations of the sterile assistant (left neck and below the left shoulder)
75547954|NCT04937153|Biological|Acasunlimab|Acasunlimab will be administered intravenously (IV) once every 21 days.
75547955|NCT04937153|Biological|Pembrolizumab|Pembrolizumab will be administered IV once every 21 days.
75547956|NCT04931147|Drug|RXC007|"RXC007 will be administered in the form of oral capsules at selected doses starting at 2 mg to 4 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one single dose on one occasion and for Part B, dosing frequency is single doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~All participants in Part C (24) will receive active RXC007 in the form of oral capsules as single doses."
76037137|NCT04851366|Behavioral|PROCARE+ (with add-on modules)|The modules will mainly consist in therapy sessions to provide the adolescents with tools to confront risk situations such as communication skills, coping skills to manage stress, etc. The group will include education about discussing thoughts, feelings, and behaviour as parts of emotion, and emphasis on providing support around the specific risks factors detected.
75398268|NCT02099175|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"Particle boost with ENI:~HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
75398269|NCT02099175|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
75398270|NCT02099175|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost:~HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively."
75398271|NCT01840150|Procedure|breath test|Undergo NA-NOSE breath test
75398272|NCT01840150|Other|laboratory biomarker analysis|Correlative studies
75558186|NCT00444197|Behavioral|Mentoring and violence prevention curriculum with parental monitoring|
75558187|NCT00444236|Drug|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
75558188|NCT00444236|Drug|Placebo|matching placebo for active drug
75558189|NCT00478998|Drug|Tamsulosin|
76037138|NCT04851366|Behavioral|PROCARE (UP-A for selective purposes)|This core intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
75547957|NCT04931147|Drug|RXC007 Matching Placebo|"The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~There is no placebo intervention for Part C of the study."
75709486|NCT00873418|Behavioral|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
75709487|NCT00873496|Drug|Hydroxychloroquine|
75398273|NCT01754610|Behavioral|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
75398274|NCT01716026|Drug|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
75398275|NCT01715285|Drug|Abiraterone acetate|Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
75398276|NCT01715285|Drug|Prednisone|Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
75398277|NCT01715285|Other|Androgen deprivation therapy (ADT)|All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
75709488|NCT04040140|Other|APA Treatment|Light touch using vaccaria seeds on corresponding ear points related to patient's pain.
76037139|NCT04851366|Behavioral|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
75398278|NCT01715285|Drug|Abiraterone acetate Placebo|Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
75547958|NCT04928534|Diagnostic Test|Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination|"Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~Cognitive function tests, including RPQ, MMSE and MoCA.~Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination"
75709489|NCT00879892|Drug|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
75709490|NCT00879892|Other|Hypothermia|24 hour, target core temperature 33
75709491|NCT00873574|Biological|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
75398279|NCT01715285|Drug|Prednisone Placebo|Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
75398280|NCT01705184|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
75398281|NCT01705184|Drug|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
75398282|NCT01705184|Drug|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
75398283|NCT01285817|Drug|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
75398284|NCT01285479|Drug|Fingolimod|fingolimod 0.5 mg/day, including generic versions of fingolimod
75398285|NCT01250496|Drug|Aminophylline|75 mg of intravenous aminophylline
75398286|NCT01250496|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
75398287|NCT01134757|Biological|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
75558190|NCT02957279|Drug|Antibiotics|In the sepsis group, antibiotics were used when needed.
75709492|NCT00878956|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
76037140|NCT04848896|Device|CORI Robotics|Total knee arthroplasty (TKA) treated with CORI Robotics System.
76037141|NCT04848896|Procedure|Conventional Procedure|Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
76037142|NCT04840862|Drug|Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]|Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
76037143|NCT04840862|Drug|Rifabutin 300mg|After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
76037144|NCT04840615|Biological|LMB-100|administered into lesion on days 1 and 4 during cycle 1
75398288|NCT01105975|Drug|LY2484595|Administered daily by mouth for 12 weeks
76037145|NCT04840615|Drug|ipilimumab|administered intravenously once per cycle up to three 21 day cycles. Administration will occur during cycles 2,3,4.
76037146|NCT04838626|Drug|[18F]CTT1057|PET/CT imaging with [18F]CTT1057
76037147|NCT04837638|Behavioral|Diet|No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
76037148|NCT04803214|Device|ReActiv8|Market-approved ReActiv8 device implanted
76037149|NCT04800484|Device|Tall Soft|Tall heel wedge made of soft foam
76037150|NCT04800484|Device|Tall Firm|Tall heel wedge made of firm foam
75398289|NCT01105975|Drug|Atorvastatin|Administered daily by mouth for 12 weeks
75398290|NCT01105975|Drug|Simvastatin|Administered daily by mouth for 12 weeks
75398291|NCT01105975|Drug|Rosuvastatin|Administered daily by mouth for 12 weeks
75398292|NCT01105975|Drug|Placebo for LY2484595|Administered daily by mouth for 12 weeks
75398293|NCT01105975|Drug|Placebo for Statins|Administered daily by mouth for 12 weeks
75398294|NCT00831623|Radiation|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
75398295|NCT00831623|Radiation|Proton|As above
75398296|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin)|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)"
75398297|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~Bevacizumab 15 mg/kg D1 (D1=D22, until progression)"
75398298|NCT00639639|Biological|tetanus toxoid|Given by injection
75398299|NCT00639639|Biological|therapeutic autologous dendritic cells|Given intradermally
75398300|NCT00639639|Biological|therapeutic autologous lymphocytes|Given IV
75398301|NCT00591695|Procedure|Stent bridge to surgery + elective surgery|positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
75398302|NCT00591695|Procedure|Emergency Surgery|Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
75558191|NCT00479076|Drug|aflibercept (AVE0005)|intravenous infusion
75558192|NCT00479076|Drug|S-1|oral administration
75558193|NCT00441519|Drug|aspirin|
75558194|NCT00441519|Drug|omeprazole|
75558195|NCT03278171|Behavioral|Impact Event Scale Revisited|Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
75558196|NCT00441597|Drug|atorvastatin|atorvastatine 80mg, during 3 days
75558197|NCT03278132|Biological|EV71 vaccine|Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
75709493|NCT00878956|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
75558198|NCT04701372|Behavioral|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.
75398303|NCT00280202|Procedure|Biopsy of the major carinal area|Biopsy performed intraoperatively
75398304|NCT00280202|Procedure|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
75709494|NCT00740142|Drug|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
75709495|NCT00740142|Drug|placebo and lactulose|placebo 3 times a day for 7 days
75709496|NCT00873652|Biological|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
75709497|NCT02568774|Other|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
75398305|NCT00280202|Procedure|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
75398306|NCT00280202|Procedure|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
75398307|NCT00280202|Procedure|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
75709498|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
75398308|NCT00280202|Procedure|Analysis of lymph nodes|Tissues banked for future analysis
75398309|NCT00079417|Drug|Carboplatin|Given IV
75398310|NCT00079417|Procedure|Cryosurgery|
75709499|NCT04039048|Device|cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
75709500|NCT04039048|Device|Sham cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
75709501|NCT04039048|Other|Balance training|Balance training will be performed through the Biodex Balance System for 20 minutes.
75398311|NCT00079417|Procedure|Infrared Laser Therapy|
75398312|NCT00079417|Radiation|Iodine I-125|Undergo radioactive therapy
75398313|NCT00079417|Radiation|Radiation Therapy|Undergo radioactive therapy
75398314|NCT00079417|Radiation|Ruthenium Ru-106|Undergo radioactive therapy
75398315|NCT00079417|Drug|Vincristine Sulfate|Given IV
75558199|NCT00479193|Drug|bacitracin/xeroform|single layer, change every 3 days
75558200|NCT00479193|Drug|Polymem|single layer of Polymen, change every 3 days
75558201|NCT03278054|Other|Root Canal Treatment with hand instruments|Root canal treatment was performed with K files.
75709502|NCT00423319|Drug|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
75709503|NCT00423319|Drug|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
75709504|NCT00423319|Drug|Enoxaparin-matching placebo|Administered as injection
75709505|NCT00423319|Drug|Apixaban-matching placebo|Administered as oral tablets
75709506|NCT05224492|Drug|Sulforaphane|40 mg of Sulforaphane powder once daily.
75709507|NCT05224492|Other|Placebo|Placebo
75709508|NCT00733668|Drug|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
75709509|NCT00879112|Drug|MB07811|Oral
75709510|NCT00879112|Drug|Placebo|Oral
75871078|NCT02355652|Device|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
76037151|NCT04800484|Device|Short Soft|Short heel wedge made of soft foam
76037152|NCT04800484|Device|Short Firm|Short heel wedge made of firm foam
75398316|NCT04387968|Diagnostic Test|Covid-19 presto test|Use an auto-test in 15 minutes get the results about covid-19 anticorps
75398317|NCT04387890|Diagnostic Test|Serologic SARS-CoV-2 screening|Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up
75398318|NCT04387578|Device|fixed orthodontic appliance and arch wires|leveling and aligning stages in orthodontics
75398319|NCT04387266|Radiation|modified reduce-volume target IMRT|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
75398320|NCT04386876|Drug|Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
75709511|NCT00736710|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
75871079|NCT03630744|Other|Fluid therapy|"Analyze the type of fluid administered:~crystalloids:~Saline serum 0.9% ....... ml~Ringer Lactate ........ ml~Isofundin ® ........ ml~Plasmalyte® ... ... ml~Glucose Serum 5% ....... ml~Glucose serum 10% ........ ml~Glucosaline serum ........ ml~colloids:~Hydroxyethyl starch 130 / 0.4 ... ... ml~Hydroxyethyl alimdon 130 / 0.42 ... .... ml~Gelatins ... ....... ml~Albumin 5% .......... ml~Albumin 20% .......... ml.~Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~Analyze the form of administration:~Standard~Standard with dosimeters~on pump"
75871080|NCT03160534|Other|preoperative exercise|Each intervention session contains a stretching part and aerobic training
75871081|NCT01379586|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
75871082|NCT01379586|Drug|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
75871083|NCT02038738|Drug|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
76037153|NCT04792892|Other|Questionnaires|Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months
76037154|NCT04792008|Biological|YQ23|Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated
76037155|NCT04792008|Biological|Matching placebo|Single dose of 0.9% normal saline via intravenous route as matching placebo
76037156|NCT04786379|Procedure|Arthroscopic Irrigation and Debridement|Patients with confirmed septic arthritis treated with multiple small incisions to perform irrigation and debridement with partial synovectomy.
75398321|NCT04386876|Drug|Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet|Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH & Co.-Germany)
75398322|NCT04387032|Other|HVLA Manipulations|The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.
75398323|NCT04387032|Other|Sham Manipulation|The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
75398324|NCT04386486|Other|Bathe anamnesis method|BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.
75558202|NCT03278054|Other|Root canal treatment with Protaper instruments|Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
75558203|NCT03278054|Other|Root canal treatment with hybrid instrumentation|Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
75558204|NCT00441636|Device|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
75558205|NCT03278015|Drug|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
75558206|NCT03278015|Drug|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
75558207|NCT03278015|Drug|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
75558208|NCT00441675|Procedure|Symptom Score|Symptom Score
75558209|NCT00441675|Procedure|Symptom Score and PD20|Symptom Score and PD20
75398325|NCT04386486|Other|standart anamnesis|standart anamnesis is applied to second group and preoperative examinations are completed.
75398326|NCT04386642|Drug|Tranexamic acid|Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.
75547959|NCT04928209|Other|Speech-Language Teletherapy|Access to speech-language teletherapy will be provided as a supplement to Usual Care for subjects randomized to this group. Access is provided by way of 1) direct referral by the clinical team to a teletherapist; 2) availability of a teletherapy slot. All teletherapy providers will be licensed speech-language pathologists (SLPs) and/or credentialed teachers of the deaf (TODs) with specialized training to work with children who are D/HH using an LSL approach. Fluent English and Spanish speaking providers will be matched to the child's home, native language. Teletherapy itself is within routine clinical care and is not considered a research activity. Children who randomize to the Low TT study arm will receive access to an 18-month course of weekly teletherapy, in accordance with the centers' standard of care. The exact details of the therapy course and frequency will be determined based on individual family needs.
75709512|NCT00736710|Procedure|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
76037157|NCT04786379|Procedure|Open Arthrotomy with irrigation and debridement|Patients with confirmed septic arthritis treated with a single large incision, open arthrotomy to perform irrigation and debridement with partial synovectomy.
76037158|NCT04778410|Drug|Magrolimab|Administered intravenously
76037159|NCT04778410|Drug|Azacitidine|Administered either subcutaneously or IV, 75 mg/milligram per square (m^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
75709513|NCT04039126|Drug|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION|Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
75709514|NCT04039126|Drug|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE|20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.
75871084|NCT02361424|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
75871085|NCT02361424|Drug|placebo|
76037160|NCT04778410|Drug|Venetoclax|Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
76037161|NCT04778410|Drug|Mitoxantrone|Administered intravenously, 8 mg/m^2 on Days 1-5 during Cycle 1 to Cycle 3
76037162|NCT04778410|Drug|Etoposide|Administered intravenously, 100 mg/m^2 on Days 1-5 during Cycle 1 to Cycle 3
75398327|NCT04386642|Drug|Placebo|normal saline solution in a clear 50-ml syringe
75398328|NCT04386408|Combination Product|Combination of plant extracts (BSL_EP027)|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
75398329|NCT04386408|Combination Product|Placebo|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
76037163|NCT04778410|Drug|Cytarabine|Administered intravenously, 1000 mg/m^2 on Days 1-5 during Cycle 1 to Cycle 3
76037164|NCT04778410|Drug|CC-486|Administered orally, 300 mg on Days 1-14 during each cycle
76037165|NCT04776083|Drug|first line systemic therapy|first line systemic therapy according to the genetic mutation 0f the patient
76037166|NCT04776083|Radiation|3D radiotherapy or IMRT|Hypo-fractionated radiotherapy to the primary lesion
75398330|NCT04386564|Diagnostic Test|mRNA in urine test|Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
75547960|NCT04910776|Drug|avalglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
75547961|NCT04906902|Drug|Acalabrutinib|Tablet taken by mouth twice daily
75709515|NCT00880126|Behavioral|Community Development Teams|CDTs bring together counties who are implementing a new practice
75547962|NCT04893265|Behavioral|Text Messaging Only|Active Comparator
75709516|NCT00880204|Behavioral|ESS-EMCH training|"The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET)."
76037167|NCT04772521|Behavioral|General health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
75398331|NCT04385628|Behavioral|the patient' relatives satisfaction questionnaire|The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
75398332|NCT04385784|Other|Balance exercise program.|Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
75398333|NCT04385784|Other|Home-based exercise program.|Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
75398334|NCT04385550|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
75398335|NCT04385550|Drug|AK105 injection|AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
75398336|NCT04385550|Drug|Paclitaxel injection|Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.
75709517|NCT00873808|Drug|clodronate disodium|
75398337|NCT04385550|Drug|Docetaxel injection|Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.
75709518|NCT00873808|Drug|demeclocycline hydrochloride|
75398338|NCT04385316|Diagnostic Test|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor."
75547963|NCT04893265|Behavioral|INFORMED|Experimental
75547964|NCT04889664|Drug|Ketamine|Repeated intravenous Ketamine infusions.
75547965|NCT04889664|Behavioral|Written Exposure Therapy|WET is a brief, 5-session evidence-based written trauma-focused therapy
75547966|NCT04871295|Behavioral|Noom Healthy Weight|Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
75547967|NCT04867668|Behavioral|Anti-vaping and anti-smoking digital advertising|Delivery of social media based advertising to prevent vaping and smoking among young adults ages 18-24.
75547968|NCT04850274|Behavioral|Remote Therapy Intervention (RTI)|A single ED session followed by 5 remote therapy sessions
75547969|NCT04850274|Behavioral|Artificial Intelligence Remote Therapy Intervention|Optimized by reinforcement learning to step up or down the intensity of treatment between three levels based on patient response to daily assessments.
75547970|NCT04836195|Drug|PCLX-001|To ensure maximal safety in this first-in-human trial, the starting dose level was chosen to be 20 mg daily on a 28-day cycle.
75547971|NCT04827992|Drug|Medical Marijuana|Patients in this group can choose what type, how much, and when to use medical marijuana to use.
75709519|NCT00873808|Drug|ibandronate sodium|
75709520|NCT00873808|Drug|tetracycline hydrochloride|
75709521|NCT00873808|Drug|zoledronic acid|
75709522|NCT00873808|Other|laboratory biomarker analysis|
75709523|NCT00873808|Procedure|adjuvant therapy|
75709524|NCT00873808|Procedure|computed tomography|
75398339|NCT04385316|Diagnostic Test|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor."
75398340|NCT04385316|Diagnostic Test|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor."
75547972|NCT04827992|Behavioral|Prescription Opioid Taper Support (POTS)|Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.
75398341|NCT04384926|Procedure|Elective Cancer Surgery|Planned, curative cancer surgery
75398342|NCT04384614|Diagnostic Test|Test PCR|Viral load (COVID+) testing by PCR
75398343|NCT04384614|Genetic|TDR|IDR and blood sampling for testing DNA Cheque
75398344|NCT04384614|Other|Clinical Examination|COVID 19 symptoms and Physical Examination
75558210|NCT00444314|Drug|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
75558211|NCT00444314|Drug|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
75558212|NCT00479271|Behavioral|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
75558213|NCT00479271|Behavioral|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
75709525|NCT00873808|Procedure|dual x-ray absorptiometry|
75709526|NCT04064190|Drug|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
75709527|NCT00873886|Drug|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
75709528|NCT00873886|Procedure|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
75709529|NCT00736788|Drug|AZD1704|single dose oral suspension, 4 different dose levels
75558214|NCT00444353|Device|DL6049 (injectable poly-L-lactic acid)|
75709530|NCT00736788|Drug|Placebo|single dose oral suspension
75709531|NCT00740454|Other|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
75709532|NCT00880282|Biological|cixutumumab|Given IV
75558215|NCT00444392|Behavioral|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
75558216|NCT00444431|Procedure|Pyeloplasty|
75558217|NCT00441714|Procedure|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
75709533|NCT00880282|Drug|temsirolimus|Given IV
75709534|NCT00880282|Other|pharmacological study|Correlative studies
75558218|NCT03277898|Behavioral|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
75871086|NCT05347368|Other|Control group (conventional therapy)|Physical therapy will be performed using physical agent modality that include hot pack (15 min), and therapeutic exercises (5 repetition per set, 2 sets each session) therapeutic exercises include spinal extension exercise, prone hip extension exercise, posterior pelvic tilt, cat-camel exercise
75398345|NCT04384536|Procedure|Neural therapy application|Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
75398346|NCT04384380|Drug|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
75398347|NCT04384458|Drug|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.
75871087|NCT05347368|Other|Primal Reflex release Technique|The SI/Lumbar release Iliopsoas release Piriformis release Hamstring release Gastrocnemius release
75871088|NCT02366416|Behavioral|Exercise training|Physical activity
75871089|NCT01377558|Other|Aerobic endurance training intervention|"The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week"
75871090|NCT01377558|Other|Strength endurance training intervention|"The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week"
75871091|NCT01377558|Other|Combined aerobic endurance and strength endurance training|"week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week"
75398348|NCT04384458|Drug|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
75871092|NCT05331612|Behavioral|Blended intervention condition|Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
75871093|NCT02361190|Drug|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
75871094|NCT02361190|Drug|Placebo|Administration of 1ml aqueous saline spray
75871095|NCT02361112|Drug|pyrotinib combined with capecitabine|
75871096|NCT03080454|Device|sham Doublestim|PathMaker MyoRegulator device
75398349|NCT04383990|Other|Timing of taking insulin|To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)
75398350|NCT04384224|Other|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
75398351|NCT04383834|Device|NobelActive® TiUltra™ implants and On1™ Base/Xeal™ along with On1 components|"The NobelActive® TiUltra™ implant is an ultra-hydrophilic multi-zone anodized implant surface. NobelActive® TiUltra™ features a gradual change in topography, from a minimally rough non-porous nanostructured implant collar to a moderately rough porous apex: more than roughness. NobelActive® TiUltra™ collar features surface chemistry and topography that promote early osseointegration and are designed to support bone stability. In addition, the Protective Layer preserves the pristine surface chemistry and hydrophilicity.~The second new product is the Base/Xeal™ new surface, which is covered by a titanium oxide layer, created by electrochemical anodization of a titanium machined component, resulting in a yellow hue nano-structured surface."
75398352|NCT04383678|Device|Extracorporeal membrane oxygenation|Veno-venous or veno-arterial extracorporeal oxygenation
75871097|NCT03080454|Device|anodal Doublestim|PathMaker MyoRegulator device
75871098|NCT05327712|Behavioral|Control group|No outreach during the intervention period beyond an initial eligibility notice.
75398353|NCT04383600|Procedure|Micro-osteoperforation|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
75398354|NCT04383366|Device|Pentacam® (Oculus, Inc., Wetzlar, Germany)|Scheimpflug imaging
75398355|NCT04383366|Device|Casia II (Tomey Germany, Nürnberg)|Anterior segment optical coherence tomography
75398356|NCT04383366|Device|Spectralis Anterion (Heidelberg Engineering, Heidelberg, Germany)|Anterior segment optical coherence tomography
75398357|NCT04383054|Behavioral|'More minutes' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
75398358|NCT04383054|Behavioral|'one minute' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
75398359|NCT04382742|Behavioral|Dynamic Resistance Exercises|Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
75398360|NCT04382040|Drug|ArtemiC|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
75709535|NCT00880282|Other|laboratory biomarker analysis|Correlative studies
75709536|NCT00740532|Genetic|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
75709537|NCT00879268|Device|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
75871099|NCT05327712|Behavioral|Email only|Email reminders in addition to an initial eligibility notice.
75871100|NCT05327712|Behavioral|Phone only|Phone call offering enrollment assistance in addition to an initial eligibility notice.
75398361|NCT04382040|Drug|Placebo|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
75398362|NCT04381884|Drug|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
75398363|NCT04381962|Drug|Azithromycin Capsule|Azithromycin 500 mg OD PO 14 days
75871101|NCT05327712|Behavioral|Phone and email|Phone call and email reminders in addition to an initial eligibility notice.
75871102|NCT02943304|Other|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV|
75398364|NCT04382430|Procedure|Ultrasound guided venous access|Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.
75398365|NCT04382430|Procedure|Conventional technique|Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
75558219|NCT03277898|Behavioral|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
75558220|NCT02274051|Dietary Supplement|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
75558221|NCT03277859|Behavioral|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
75558222|NCT00444470|Drug|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
75558223|NCT00444470|Drug|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
75398366|NCT04381572|Behavioral|High fidelity simulation training|At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
75398367|NCT04381026|Dietary Supplement|Botanical dry extracts combination|Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)
75398368|NCT04381026|Dietary Supplement|Placebo|Filler agent
75398369|NCT04381104|Drug|Paracetamol|The intervention arm will receive 2 capsules of paracetamols of 500mg.
75398370|NCT04380870|Dietary Supplement|Chinese Herbal Medicine|Chinese Herbal Medicine (CHM) has been used in the prevention and treatment of epidemic diseases dating back to the Han, Ming and Qing Dynasties and extending al the way through modern times. CHM formulas may contain plant elements of root, seed, back, stem or leaf in addition to minerals and other natural substances. All herbs dispensed in this trial will be from Spring Wind Herb Company.
75398371|NCT04380558|Other|Pulmonary rehabilitation|"Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
75398372|NCT04380402|Drug|Atorvastatin|Atorvastatin 40 mg tablet
75398373|NCT04380246|Other|Qualitative Interview|There is no intervention as part of this study. Clinicians will participate in a qualitative interview.
75398374|NCT04380012|Drug|Pyrotinib|Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer
75871103|NCT02360956|Drug|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
75871104|NCT02360956|Drug|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
75398375|NCT04380012|Drug|Pyrotinib in combination with trastuzumab|Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer
75558224|NCT00479310|Drug|Summers 5% L.A.|
75558225|NCT00444509|Drug|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
76037168|NCT04772521|Behavioral|Personalized chat-based interactions|Individual chat-based interactions last 3 months and consist of 2 parts. First part is regular message. The schedule will be adjusted according to the participants' quitting and mental health status. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using the acceptance and commitment therapy (ACT) model for smoking cessation and reliving mental health problems. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
75398376|NCT04380168|Procedure|Modified pec11 trunk block|Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
75398377|NCT04379934|Dietary Supplement|3-hydroxybuturate|3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model
75398378|NCT04379856|Drug|NM-002|NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
75709538|NCT05741268|Behavioral|Dialectical behavior therapy|14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
75709539|NCT00879346|Drug|AZD8931|160mg oral single dose (4 x 40mg tablets)
75709540|NCT00874042|Drug|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
75709541|NCT00736866|Drug|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
75709542|NCT00736866|Drug|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
75709543|NCT00879424|Dietary Supplement|cholecalciferol (vitamin D)|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
75709544|NCT00879424|Dietary Supplement|Placebo|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
75871105|NCT05461716|Device|periodic use of Continuous Glucose Monitoring (CGM)|Identification of hypoglycaemia events, based on use of Continuous Glucose Monitoring (CGM) for at least 14days, in subgroups of T2DM patients with high risk of hypoglycaemia
76037169|NCT04772521|Behavioral|Text message|Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
76037170|NCT04772521|Behavioral|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
75398379|NCT04379388|Behavioral|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
75398380|NCT04379310|Drug|ACE Inhibitors and Calcium Channel Blockers|effect of drugs on patients with covid-19 pneumonia
75398381|NCT04378998|Other|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
75871106|NCT02367976|Drug|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
76037171|NCT04772521|Drug|Mailed nicotine replacement therapy (NRT)|Full course of NRT treatment (8 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
75398382|NCT04378686|Other|dialysis|treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis
75398383|NCT04378608|Drug|OBV/PTV/r) ± ribavirin (RBV)|
75398384|NCT04378218|Behavioral|High Intensity Interval Training (HIIT)|A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
75398385|NCT04377906|Behavioral|Modification Lifesyle|high protein-fiber and exercise
75398386|NCT04377828|Device|Pigment laser|one to two session of pigment laser (532 nm)
75398387|NCT04377750|Drug|Tocilizumab|The placebo treatment arm will include 100 ml of normal saline administered along 60 min
75398388|NCT04377516|Other|pelvic floor muscle training|pelvic floor muscle training
75398389|NCT04377516|Other|pelvic floor muscle combined global muscle exercise training|pelvic floor muscle combined global muscle exercise training
75398390|NCT04377516|Other|education of pelvic girdle|education of pelvic girdle
75398391|NCT04377282|Other|Food-1|Cooked buckwheat
75398392|NCT04377282|Other|Food-2|Cooked couscous
75709545|NCT00710684|Drug|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
75709546|NCT00710684|Drug|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
76037172|NCT04768257|Behavioral|Physical activity|We will assess physical activity patterns of patients at baseline (at discharge from hospital or at patients' home), at 12 weeks and 6 months, through an objective measurement (triaxial accelerometer).
75709547|NCT00710684|Drug|Placebo|Placebo added to existing donepezil
75709548|NCT00710684|Drug|donepezil 5-10mg|existing donepezil treatment
75709549|NCT00874198|Procedure|Ventriculo-peritoneal Shunt|Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system [pressure settings: 30 - 200 mmH20]
75709550|NCT00740688|Procedure|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
75709551|NCT00740688|Procedure|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
75398393|NCT04377282|Other|Food-3|Water
75398394|NCT04376970|Drug|FLUCON®|"The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen."
75871107|NCT05461638|Procedure|Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with MyKnee Custom guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Unrestricted KA places the implant in a custom position for each patient, completely matching individual anatomy and restoring natural alignment to that of the prearthritic knee.
75398395|NCT04376970|Drug|Cyclosporine A eye drops 0.5%|The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
75398396|NCT04377048|Drug|Nivolumab|"as described in NGS Arm"
75398397|NCT04377048|Drug|Gemcitabine|"as described in NGS Arm"
75398398|NCT04377048|Drug|Tegafur-Gimeracil-Oteracil|"as described in NGS Arm"
75398399|NCT04376892|Other|Quality of life measurement|Quality of life measurement by St. George Respiratory questionnaire
75398400|NCT04376814|Drug|Favipiravir|Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days
75398401|NCT04376814|Drug|Hydroxychloroquine|200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
75398402|NCT04376814|Drug|Lopinavir / Ritonavir|Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
75398403|NCT04376034|Biological|Convalescent Plasma 1 Unit|"Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma."
75398404|NCT04376034|Biological|Convalescent Plasma 2 Units|"Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma."
75398405|NCT04376034|Other|Standard of Care|Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
75398406|NCT04376190|Radiation|low level laser therapy|In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
75398407|NCT04375566|Other|Patient Decision Aid|More than 20 IT specialists, 15 doctors and 15 patients
75398408|NCT04375488|Other|Resistance Exercise Training|60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week
75398409|NCT04375488|Other|Inspiratory Muscle Training|with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
75398410|NCT04375098|Biological|COVID-19 convalescent plasma|COVID-19 convalescent plasma
75398411|NCT04375176|Diagnostic Test|Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2|Phenotypic and functional analysis of monocytes and NK cells
75398412|NCT04375254|Other|NbB psychopharmacology training|a two part course in psychopharmacology based on Neuroscience based Nomenclature
75398413|NCT04375020|Drug|GABA|GABA nutritional supplement 750mg per day for 6 months
75398414|NCT04374942|Drug|Hydroxychloroquine|Oral Hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent COVID-19 in health care workers in the emergency department.
75398415|NCT04374942|Drug|Placebo oral tablet|Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
75709552|NCT00710606|Drug|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
75398416|NCT04374786|Device|Calm Meditation App|"Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
75398417|NCT04374864|Drug|Trelagliptin|Anti diabetic
75398418|NCT04374396|Procedure|Real ultrasound-guided single shot erector spinae plane block (ESP B)|"ESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~After negative aspiration, 0.3 mL/kg- of bupivacaine 0.25% will be injected confirming correct position by visualizing the solution lifting the ESM off the transverse process .Spread of LA between the L1 and L4 transverse processes will be thereafter visually tracked with the transducer. In the control group, no local anesthetics will be injected."
75558226|NCT00444509|Drug|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
75709553|NCT00710606|Drug|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
75398419|NCT04374396|Radiation|Sham ultrasound-guided single shot erector spinae plane block (ESP B)|"EESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~No local anesthetics will be injected"
75398420|NCT04374318|Drug|Dexmedetomidine|INTRATHECAL AND INTRAVENOUS
75398421|NCT04374552|Drug|Hydroxychloroquine sulfate &Azithromycin|Drug - Hydroxychloroquine sulfate &Azithromycin
75398422|NCT04374552|Drug|Placebo|Drug - placebo
75398423|NCT04374162|Procedure|PEEP|different PEEP set on the anesthetic machine
75398424|NCT04373850|Behavioral|Home Visit|Physical exam, medication dose titration
75398425|NCT04374006|Drug|Dienogest|1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
75398426|NCT04374006|Drug|Propolis|The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
75398427|NCT04374006|Other|placebo|we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
75398428|NCT04373772|Other|abdominal massage|the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
75398429|NCT04373538|Behavioral|Trans-C for sleep and circadian function + Memory Support|The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
75871108|NCT05461638|Procedure|Mechanical Alignment and Restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Restricted KA places the implant in a custom position for each patient, closely matching with anatomy and natural alignment of the individual's knee.
75398430|NCT04373304|Other|low FODMAP diet|A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
75398431|NCT04373070|Combination Product|CAir|The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 [2017], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
75398432|NCT04372836|Procedure|Vasopressin injection|The intervention consists of five steps: rupture the ovarian endometrial cyst and remove the ''chocolate fluid;'' inject diluted vasopressin solution into the interface between endometrioma and ovarian parenchyma; stop injecting until the solution overflow; separate the endometrioma away from the ovarian parenchyma; and coagulate bleeding spots and suture the ovary.
75398433|NCT04372290|Other|Product A|Usual brand (UB) filtered, combustible cigarette
75398434|NCT04372290|Other|Product B|Nicorette® White Ice Mint 2 mg nicotine gum
75398435|NCT04372290|Other|Product C|CSD1904-01, a nicotine pouch, 2 mg nicotine
75398436|NCT04372290|Other|Product D|CSD1904-02, a nicotine pouch, 4 mg nicotine
75398437|NCT04372290|Other|Product E|CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
75558227|NCT02957175|Other|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
75558228|NCT00444548|Drug|[S,S]-Reboxetine|
75558229|NCT00444665|Drug|Travatan-Z|
75558230|NCT00479349|Drug|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
75558231|NCT00444704|Drug|PRA-027|
75871109|NCT02360800|Procedure|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
75871110|NCT02360800|Procedure|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
75398438|NCT04372212|Device|Hernia sac inversion and Snaring|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
75398439|NCT04372134|Device|repetitive transcranial magnetic stimulation therapy|A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
76037173|NCT04764357|Device|Paxman Scalp Cooling System|Scalp cooling will begin at least 30-45 minutes prior to administration of each chemotherapy (45 minutes for those with thick or coarse hair types). Scalp temperature will be maintained at +3°C (37°F) throughout drug administration and for at least 120-180 minutes after discontinuing the infusion. Scalp cooling will occur with each dose of chemotherapy.
75398440|NCT04371978|Drug|Linagliptin 5 MG|Linagliptin 5 mg PO once daily
75871111|NCT02360878|Device|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
75871112|NCT03501966|Drug|Acetazolamide|Medical therapy including diet
76037174|NCT04764357|Other|Alopecia Assessments|Photographs of the hair will be taken before initiation of chemotherapy (baseline) and at a visit 4 weeks (3-6 week window) after the last dose of chemotherapy for those being treated for a non-cancerous condition. Patient with solid tumors will have photographic documentation at baseline, 2-5 weeks after every 2 cycles of chemotherapy, and at end of study (approximately 4 weeks following the last chemotherapy treatment with a range of 3-6 weeks).
76037175|NCT04764357|Other|Patient Reported Outcomes Questionnaires|"Selected questions from NCI PRO-CTCAE™, Chemotherapy-Induced Alopecia Distress Scale (CADS), and PediQUEST Memorial Symptom Assessment Scale, at the following time points: baseline, end of chemotherapy administration, and 4 week follow up.~Tolerability Questionnaire each time the cooling cap is used and at the end of study"
75398441|NCT04371822|Drug|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
75398442|NCT04371822|Drug|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin and Sunlight exposure
75398443|NCT04371822|Drug|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
75398444|NCT04371822|Drug|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
75398445|NCT04371822|Other|placebo|No Intervention
75398446|NCT04370886|Behavioral|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
75398447|NCT04370964|Other|Lausanne Trilogy Play|"Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together."
75709554|NCT00713544|Drug|AZD5672|20 mg oral, once daily
75709555|NCT00713544|Drug|Etanercept|50 mg, subcutaneous injection, weekly
75709556|NCT00713544|Drug|Placebo|placebo, oral, once daily
75709557|NCT00713544|Drug|AZD5672|50 mg oral, once daily
75709558|NCT00713544|Drug|AZD5672|100 mg oral, once daily
75709559|NCT00713544|Drug|AZD5672|150 mg oral, once daily
75709560|NCT00737126|Drug|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
75871113|NCT03501966|Procedure|Optic Nerve Sheath Fenestration|Medical therapy including diet + optic nerve sheath fenestration
75871114|NCT03501966|Procedure|Ventriculoperitoneal CSF Shunting|Medical therapy including diet + ventriculoperitoneal CSF Shunting
75871115|NCT02361034|Drug|GRC 27864|
75871116|NCT02361034|Drug|Placebo|
75871117|NCT02355184|Drug|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
75871118|NCT05326854|Other|supportive care|After Medical Termination Navigation Assisted Care Program admission to the service will be held in the form of three interviews in the clinic before and after termination. The planned training will be given in three sessions and a different training module will be applied in each meeting. After the patient is discharged, three sessions will be held remotely via telephone.
75871119|NCT02355262|Other|Informational Intervention|Receive CATCH-UP intervention
75871120|NCT02355496|Other|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
75398448|NCT04370964|Other|Lausanne Family Play|Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
75398449|NCT04370808|Other|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
75398450|NCT04370262|Drug|SOC + Intravenous Famotidine|Standard of Care treatment plus IV famotidine
75398451|NCT04370262|Drug|SOC + Placebo|Standard of Care treatment plus IV placebo
75709561|NCT00737126|Drug|Placebo|Administration of an oral placebo pill
75709562|NCT04063436|Device|New nasal pillows mask with PAP therapy|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
75871121|NCT03477630|Biological|Platelet Rich Plasma|intra-articular infiltration of 8 ml of autologous PRP every 15 days.
75398452|NCT04370340|Device|BabySlide|Application of BabySlide during vacuum-assisted births for perineal protection
75398453|NCT04369872|Procedure|Microwave ablation|Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
75398454|NCT04369716|Other|Whole oranges|Navel oranges (227 g total)
75398455|NCT04369716|Other|Whole Apples|Red Delicious apple with skin (230 g)
75398456|NCT04369716|Other|Orange juice + orange pomace|Orange Juice (149 g) + orange pomace (100g) [40% pomace by weight]
75398457|NCT04369716|Other|Apple juice + apple pomace|Apple Juice (129 g) + apple pomace (106 g) [45% pomace by weight]
75398458|NCT04369716|Other|Orange juice|Orange Juice (250 g)
75398459|NCT04369716|Other|Apple juice|Apple Juice (235 g)
75398460|NCT04369404|Behavioral|Pelvic organ prolapse decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of pelvic organ prolapse
75709563|NCT00740766|Behavioral|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
75871122|NCT03477630|Drug|Hyaluronic Acid|intra-articular infiltration of a single dose of HA
75398461|NCT04369404|Behavioral|Stress urinary incontinence decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of stress urinary incontinence.
75871123|NCT01379040|Other|Cystic Fibrosis patients|
75871124|NCT02981342|Drug|Abemaciclib|Administered orally
75871125|NCT02981342|Drug|LY3023414|Administered orally
75871126|NCT02981342|Drug|Gemcitabine|Administered IV
75871127|NCT02981342|Drug|Capecitabine|Administered orally
75871128|NCT02794246|Biological|CART-19 cells|
75871129|NCT02355106|Device|PolarStart System|Atrial flutter Ablation
75398462|NCT04369404|Behavioral|Overactive bladder decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of overactive bladder.
75398463|NCT04369248|Other|hepassocin|hepassocin levels in polycystic ovary syndrome
75398464|NCT04369092|Other|DYMUS|DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.
75398465|NCT04369170|Device|prosthesis connected directly to the implants|dental prostheses connected directly to the dental implants
75398466|NCT04369170|Device|Intermediate abutment|dental prostheses connected with an intermediate abutment to the implant
75398467|NCT04368624|Other|Skin Tape|Skin sample collection: samples of human stratum corneum will be obtained with squame adhesive tape disks typically at the time of their clinic appointment. The tape will be placed on the inside of the forearm and the procedure will be repeated up to five times per patient to have sufficient corneocytes for analysis. This type of sampling is non-invasive.
75398468|NCT04368624|Diagnostic Test|Blood Draw|Blood specimens: blood will be obtained for serum amino acids/phenylalanine levels. This sample is obtained for disease monitoring as part of routine standard of care. Results from up to three clinic visits will be correlated with the tape sample obtained on the same day.
75398469|NCT04368546|Drug|Sunitinib|
75398470|NCT04368312|Other|No intervention|No intervention, just of questionnaire including validated tests
75398471|NCT04368000|Behavioral|Intermittent prone positioning instructions|Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.
75398472|NCT04368000|Behavioral|Usual care positioning with no instructions|Participants will not be given instructions to lie in the prone position for any duration.
75398473|NCT04367532|Other|Foam rolling|Foam rolling performed on cuff muscles in 3 sets of 30 seconds per each muscle part in duration with a 15-second rest between sets. The first sets on the central part of the cuff muscles, the second on the medial and third on the lateral side of the cuff.
75398474|NCT04367532|Other|Tissue flossing|A standard cuff muscle bandaging technique on cuff muscle. After the application, each participant is asked to perform a 2 min ankle-exercise program.
75398475|NCT04367376|Other|mobilization|central postroanterion mobilization on the most painful vertebral level at the lumbar spine
75547973|NCT04804020|Procedure|NC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
75547974|NCT04804020|Procedure|mNC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
75398476|NCT04367376|Other|manual therapy|manual therapy
75398477|NCT04367376|Other|instrumental manual therapy|instrumental manual therapy
75398478|NCT04367454|Other|Use of Personal Protective Equipment|As described in the arm descriptions
75398479|NCT04366986|Other|Tested for SARS-CoV-2 (regardless of the result)|This is an observational study with no intervention
75398480|NCT04366986|Other|Clinical diagnosis of COVID-19 by a health care professional|This is an observational study with no intervention
75871130|NCT02360722|Other|Oral Nutritional Supplement|Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
75398481|NCT04366674|Procedure|cleft palate repair|restoration of tensor veli palatini for the purpose of the muscle function recovery.
75398482|NCT04366596|Device|Angioplasty with paclitaxel eluting balloon|The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon
75398483|NCT04366596|Device|Angioplasty with plain old balloon|Angioplasty with plain old balloon
75398484|NCT04366284|Other|No Facilitation Support|Clinicians will have full use of the NOCTEM platform. They will not have scheduled and/or structured contacts with the facilitation teams, however can reach out to the NOCTEM team or their local point of contact and coordinator with questions or technical issues that may arise.
75398485|NCT04366284|Other|External Facilitation Support|Clinicians will have full use of the NOCTEM platform and the NOCTEM team will provide external facilitation via bi-weekly consult or supervision teleconference, or via telephone. The NOCTEM team will also be available by email and text messaging on an as needed basis.
75709564|NCT00415363|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
75709565|NCT00415363|Drug|placebo|oral, daily
75871131|NCT02360722|Other|Nutritional Education|Two nutritional education courses at baseline and 3 months after intervention
75398486|NCT04366284|Other|External and Internal Facilitation Support|Clinicians will have full use of the NOCTEM platform and external facilitation support. In addition to external facilitation by the NOCTEM team a local point of contact and coordinator will serve as a more proximal facilitator.
75398487|NCT04366128|Drug|CAPA indution immunotherapy|"Camelirumab 200mg Intravenous injection on day 1.~Apatinib 250mg taken orally once daily.~Pegaspargase 2000U/m2 Intramuscular injection on day 1."
75398488|NCT04365972|Behavioral|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this open trial. ABM will be comprised of 5 sessions with a variation of the dot-probe task in which the target probe always replaces the neutral stimuli to induce diversion of attention away from threat. This condition was found effective in reducing anxiety symptoms.
75398489|NCT04365894|Other|Transformative learning theory|According to the transformative learning theory, learning methods in education should include four activities as investigate, collaborative, higher-order thinking and interactive learning activities
75398490|NCT04365816|Other|Interview|A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
75398491|NCT04365738|Other|Rehabilitation|Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
75398492|NCT04365582|Drug|Azithromycin|500 mg day 1 ; 250 mg/day for 4 days
75398493|NCT04365582|Drug|Hydroxychloroquine|200 mg x 3/day for 10 days
75398494|NCT04365582|Drug|Lopinavir 200Mg/Ritonavir 50Mg Tab|400/100 mg (2 tablets) x 2/day for 15 days
75398495|NCT04365270|Drug|Glass Ionomer|Glass ionomer filling material would be modified accordingly or used as is
75398496|NCT04365270|Drug|Chitosan Low Molecular Weight (20-200 Mpa.S)|deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
75709566|NCT04063046|Drug|General anesthesia|General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 ~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
75547975|NCT04804020|Procedure|AC|The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
75547976|NCT04781166|Behavioral|Calm program|7 online modules designed to teach cognitive behavioral skills
75547977|NCT04758650|Drug|68GaNOTA-Anti-MMR-VHH2|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~For patients in cohorts 1 and 2 : an optional injection of the IMP during or after therapy can be administered if a patient is treated with non-surgical modalities. Patients in cohorts 6 and 7 who receive standard-of-care treatment can receive an optional injection of the IMP."
75398497|NCT04365270|Drug|Chlorhexidine Diacetate|Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
75398498|NCT04365270|Drug|Titanium Dioxide|Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), >99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
75398499|NCT04365504|Diagnostic Test|Dual energy X ray absorbtiometry|The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.
75398500|NCT04365192|Device|I-gel|"The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary."
75547978|NCT04754672|Behavioral|Continuous aerobic and resistance exercise intervention|Continuous aerobic and resistance exercises intervention
75709567|NCT04063046|Drug|Peripheral nerve block|ultrasound-guided popliteal sciatic nerve block is performed
75709568|NCT00740844|Device|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
75709569|NCT05529056|Drug|Atropine Sulfate 01|Atropine sulfate 01 ophthalmic solution
75398501|NCT04365192|Device|Self-pressurized air-Q|The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
75871132|NCT02360644|Dietary Supplement|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
75398502|NCT04365426|Device|Mechanical stimulus|Electrical dynamometer to measure mechanical pressure
75398503|NCT04365426|Procedure|Thermal (cold) stimulus|Water cold bath
75547979|NCT04754672|Behavioral|Continuous aerobic and aerobic interval exercise intervention|Continuous aerobic and aerobic interval exercise intervention
75547980|NCT04747613|Drug|Iptacopan|Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
75547981|NCT04740671|Drug|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.
75547982|NCT04740671|Drug|ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
75547983|NCT04734262|Drug|Sitravatinib|Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
75547984|NCT04734262|Drug|Tislelizumab|Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody
75547985|NCT04734262|Drug|Nab-paclitaxel|Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
75547986|NCT04733443|Device|Biolimus|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group
75547987|NCT04733443|Device|SeQuent® Please Neo|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group
75547988|NCT04704661|Drug|Ceralasertib|Given PO
75547989|NCT04704661|Biological|Trastuzumab Deruxtecan|Given IV
75871133|NCT02354716|Device|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions & function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- & post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, & what characteristics determine & predict refractory & recurrent strictures.
75547990|NCT04702308|Other|Clinical Decision Rule Alerts|The
75871134|NCT02366026|Biological|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
75871135|NCT02354794|Dietary Supplement|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
76037176|NCT04763174|Behavioral|mHealth Coping Skills Training for Symptom Management (mCOPE)|mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
75547991|NCT04701398|Other|Multimodal prehabilitation|Exercise + nutritional supplementation + psychological advice
76037177|NCT04755322|Drug|Hydroxychloroquine|Hydroxychloroquine 400 mg at start of pregnancy
75398504|NCT04365426|Other|Oral contraceptive (OC)|Oral contraceptive (OC)
75398505|NCT04365426|Other|No oral contraceptive (No OC)|No oral contraceptive (No OC)
75398506|NCT04367220|Diagnostic Test|Diagnostic testing performed as per routine care|
75547992|NCT04701112|Device|Temporary His bundle pacing|"Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration."
75547993|NCT04698291|Procedure|Blood Donation|The blood donation will take place at the Gene & Health clinical assessment centre facilities. A trained member from Gene & Health program will be responsible for taking the blood samples.
75547994|NCT04684212|Device|LAmbre PlusTM Left Atrial Appendage Closure System|The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
75709570|NCT05529056|Drug|Atropine Sulfate 02|Atropine sulfate 02 ophthalmic solution
75709571|NCT05529056|Drug|Atropine Sulfate 03|Atropine sulfate 03 ophthalmic solution
75709572|NCT05529056|Drug|Placebo|Placebo ophthalmic solution
75709573|NCT00740922|Drug|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
75709574|NCT00741000|Procedure|Cervical Stairstep|Cervical low force mobilization procedure.
75871136|NCT02354794|Dietary Supplement|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
75871137|NCT03159910|Behavioral|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
75871138|NCT03159910|Behavioral|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
76037178|NCT04755322|Drug|Folic acid|5 mg
76037179|NCT04755322|Drug|Low-dose aspirin|75 mg
75398507|NCT04364724|Other|CT-based finite element analysis|"CTFEA is a computerized analysis of CT-scans which simulates stress testing of finite element models of various bones (in this study - femurs and vertebrae).~No intervention is planned - the study is observational. CT scans are performed for follow-up as an accepted standard of care. Secondary use of CT scans for CTFEA is in addition to the standard of care.~In a case when CTFEA analysis detects a high risk of pathologic fracture, the treating hematologist will be informed and will refer the patient for evaluation at the National Unit of Orthopedic Oncology."
75709575|NCT05740436|Other|Geriatric rehabilitation program based on CGA|Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.
75398508|NCT04365036|Drug|Toripalimab|toripalimab 240mg, d1, intravenous drip
75398509|NCT04365036|Drug|Pegaspargase|pegaspargase, 2000U/m2, d1, intravenous drip
75398510|NCT04365036|Drug|Gemcitabine|gemcitabine, 1000mg/m2, d1,d8, intravenous drip
75547995|NCT04684212|Drug|Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)|Continuation of market approved OAC drug.
75547996|NCT04679012|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.
75547997|NCT04679012|Drug|Rituximab|Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
75709576|NCT00741078|Drug|statin, amlodipine|
75871139|NCT03159442|Drug|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
75871140|NCT03159442|Drug|Placebo|Powder for inhalation administered via single dose DPI
75871141|NCT02360332|Behavioral|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
75398511|NCT04365036|Drug|Oxaliplatin|oxaliplatin, 130mg/m2, d1, intravenous drip,
75398512|NCT04365036|Radiation|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25~26 days
75398513|NCT04364490|Device|Copernicus noVF|Advanced gait training sessions by the computerized BWS system, named Copernicus®, without visual feedback.
75709577|NCT02568800|Drug|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
75709578|NCT02568800|Drug|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
75709579|NCT00415051|Biological|RVF MP-12|Administer 1 ml SQ
75709580|NCT00741234|Drug|SB939|SB939 taken orally in a 4-week cycle.
75709581|NCT00741234|Drug|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
75398514|NCT04364490|Device|Copernicis VF-Plus|Advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance.
75398515|NCT04364490|Other|Control group|Usual care
75398516|NCT04364022|Drug|Lopinavir/ritonavir|2x 200mg/50mg, twice daily for 5 days (bid, PO)
75398517|NCT04363710|Other|Low Calorie Diet|800-1000 Kcal/day
75398518|NCT04363866|Drug|Hydroxychloroquine|Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
75547998|NCT04679012|Drug|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
75547999|NCT04679012|Drug|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
75398519|NCT04363866|Drug|Placebo|A placebo is a pill that looks like the study drug but has no real medicine in it.
75398520|NCT04363788|Procedure|double gloves|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
75398521|NCT04363554|Other|Fluid intake|The participants will intake fluid
75398522|NCT04363554|Other|Thirsting|The participants will thirst
75398523|NCT04363476|Other|SHRED Osteoarthritis program|Combined exercise and education intervention
75398524|NCT04363086|Behavioral|iFightDepression online self-help tool|Computerized cognitive behavior therapy
75398525|NCT04363086|Behavioral|Treatment as Usual|TAU
75398526|NCT04363086|Behavioral|phone call|phone call
75398527|NCT04363398|Other|Comprehensive Follow-up|Trained research staff members will provide weekly support to coaches on the NMT warm-up.
75398528|NCT04363398|Other|Standard Follow-up|Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
75398529|NCT04362384|Drug|Vitamin E ovules|Endoanal vitamin E ovules will be prescribed
75398530|NCT04362384|Drug|Prednisolone ointment|Endoanal Prednisolone ointment will be prescribed
75398531|NCT04361916|Other|home care monitoring|home care active monitoring of patients with suspected of confirmed COVID-19
75548000|NCT04679012|Drug|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
75871142|NCT03160300|Device|Music with Binaural Beats|Relaxing music with embedded binaural beats at a frequency of 5 Hz
75871143|NCT03160300|Device|Music|Relaxing music without a binaural beat component
75398532|NCT04361760|Device|single-puls TMS|Medical Device (MD): MagPro X100
75548001|NCT04679012|Drug|Hydroxydaunomycin|Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
75548002|NCT04671901|Drug|Romiplostim|Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 10 mcg/kg, and subsequent doses w ill vary based on chemotherapy regimen for a target of platelet count > 75,000- 200,000/mcL. Participants will continue romiplostim until completion of MAP or D9803, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.
75548003|NCT04662281|Drug|Placebo|LX9211 matching-placebo, tablets will be administered orally.
75548004|NCT04662281|Drug|LX9211|LX9211, 200 mg, tablets will be administered orally.
75398533|NCT04361760|Device|sham stimulation|Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.
75398534|NCT04361526|Device|Cytokine Adsorption|Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.
75398535|NCT04361604|Biological|Biological collection (patients co infected HIV Sras-CoV-2)|Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
75548005|NCT04659993|Behavioral|Telemental Health Sessions, Support Groups and Questionnaires|Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
76037180|NCT04738409|Other|Lifestyle intervention|The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA&T), in terms of improvement in androgens level and immune-metabolic risk parameters
75548006|NCT04633278|Drug|CMP-001|Subjects will receive CMP-001 10mg weekly for 2 doses after which CMP-001 will be administered every 3 weeks. The first dose of CMP-001 may be administered subcutaneously (SC) or Intratumorally (IT) at the discretion of Investigator. All subsequent doses will be injected intratumorally every 3 weeks (Q3W).
75548007|NCT04633278|Drug|Pembrolizumab|Pembrolizumab 200 mg IV is administered Q3W.
75548008|NCT04629716|Other|Medical Cannabis|Medical marijuana is defined by Florida state statue 381.986 as all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a medical marijuana treatment center for medical use by a qualified patient.
75548009|NCT04612790|Biological|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
75709582|NCT00741312|Behavioral|Regular aerobic physical exercise|"Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.~The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises."
75709583|NCT00741312|Behavioral|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
75871144|NCT02360566|Behavioral|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
75871145|NCT03428100|Drug|Baricitinib|Administered orally.
75871146|NCT03428100|Drug|Placebo|Administered orally.
75871147|NCT03428100|Drug|Topical corticosteroid|Administered as standard-of-care.
75871148|NCT02365948|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringes~Concentration: 200 mg/mL~Route of Administration: Subcutaneous injection"
75871149|NCT02365948|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Prefilled syringes~Concentration: 0.9 % Saline~Route of Administration: Subcutaneous injection"
76037181|NCT04738409|Other|Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls|The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.
75871150|NCT02360410|Behavioral|Check Yourself App with Feedback|
76037182|NCT04721795|Drug|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
76037183|NCT04721795|Drug|Standard anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
75709584|NCT02568228|Dietary Supplement|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
75709585|NCT02568228|Other|Lean and fatty fish|The fish group will be open labeled.
75871151|NCT02360176|Procedure|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
75871152|NCT02360176|Procedure|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
75871153|NCT02354950|Drug|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
75398536|NCT04361604|Other|Auto-questionnaires (patients co infected HIV Sras-CoV-2)|4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
75398537|NCT04361604|Other|Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)|Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
75398538|NCT04361448|Other|samling of oropharynx and nasopharynx|Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
75398539|NCT04361292|Procedure|INTRAUTERINE INSEMINATION|Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.
75398540|NCT04361214|Drug|Leflunomide|Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.
75398541|NCT04361370|Drug|Olaparib-Pembrolizumab-Bevacizumab|"Olaparib 300mg (twice daily [BID])~Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions~Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)"
75398542|NCT04361136|Drug|Delgocitinib cream|Cream for topical application
75709586|NCT02568228|Dietary Supplement|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
75709587|NCT02568306|Drug|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose [SD] or multiple dose [MD] with daily dosing.
75398543|NCT04361136|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
75398544|NCT04360902|Other|Anemia Controller|"Model Predictive Controller software (called Anemia Controller) that utilizes our physiology-based erythropoiesis model to provide ESA dosing recommendations in order to guide a patient's Hgb level towards a predefined target value."
76037184|NCT04717336|Other|SODIUM CHLORIDE|It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
76037185|NCT04717336|Other|placebo|placebo capsules, salt treatment
76037186|NCT04707066|Behavioral|Treatment As Usual (TAU)|Treatment As Usual
76037187|NCT04707066|Behavioral|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1|Collaborative Assessment and Management of Suicidality
75548010|NCT04612790|Biological|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
75548011|NCT04602377|Drug|Pembrolizumab 25 MG/ML [Keytruda]|"Pembrolizumab (200mg flat dose) will be administred in combinaison with PAVEP chemotherapy for the first 6 cycles (21-day cycle)~Then, Pembrolizumab (200mg flat dose) will be administred in monotherapy until one year for patients with complete response and up to two years for patients with Stable disease or Progression response after the end of first-sequence therapy (PAVEP chemotherapy +/- High dose chemotherapy) or until disease progression."
75709588|NCT02568306|Drug|placebo|Administered subcutaneously (s.c., under the skin) single dose [SD]) or multiple dose [MD] with daily dosing.
75709589|NCT00713258|Drug|Parathyroid hormone (PTH) (1-84)|100 µg PTH(1-84) daily
75709590|NCT00713258|Drug|Alendronate|70 mg alendronate weekly
75709591|NCT00710034|Other|Oral tobacco|Snus
76037188|NCT04707066|Behavioral|Dialectical Behavior Therapy (DBT) - Phase 2|Dialectical Behavior Therapy
76037189|NCT04707066|Behavioral|Maintenance/Monitoring - Phase 2|Maintenance/Monitoring
76037190|NCT04707066|Behavioral|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
76037191|NCT04705415|Drug|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
76037192|NCT04705415|Drug|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
75398545|NCT04360668|Other|Muscle Energy Technique (MET)|The Contract-Relax Agonist-Contract (CRAC) technique will be used, which belongs to the broad MET group. The participant will be in the supine position. The therapist will set the cervical segment in the lateral flexion until a slight soft tissue tension is felt. The technique will consist of two stages. In the first phase (contraction phase), the upper trapezius will be activated against the therapist's resistance (shoulder girdle elevation) - 10 seconds. Then the person undergoing the procedure breathes in and out deeply. Then 10 seconds of antagonist group contraction (shoulder girdle depression) will be performed. Next, the therapist will passively move the participant's shoulder girdle towards the depression. Then the second phase will follow (stretching phase), during which the participant will passively lie in the back position for 30 seconds. Both phases will make up the therapeutic cycle. Each participant will have 5 cycles on each side of the upper trapezius.
75398546|NCT04360668|Other|Trigger Point Therapy (TPT)|The technique of Positional Release (PR) will be used, which is one of the broadly understood Trigger Point Therapy. It will consist in compressing the trigger point with a simultaneous shortening of muscle attachments (slight lateral flexion towards the relaxed muscle). The muscle on both sides will be treated. The pressure exerted by the therapist's pincer grip will be acceptable to the patient. The duration of the technique will be 2 minutes for each muscle. While performing this technique, the participant will passively lie on his back.
75398547|NCT04360668|Other|Muscle Energy Technique (MET) combined with Trigger Point Therapy (TPT)|For this type of intervention, TPT will first be performed on both sides of the upper trapezius muscle, followed by MET, which will also be performed bilaterally. The detailed method of performing the applied therapeutic techniques for the combined procedure will be identical as in the case of isolated (single) methods.
75398548|NCT04360512|Procedure|Posteriorization of the talus|Three sets of a 30-s grade IV mobilization
75398549|NCT04359966|Drug|Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,|First line therapy
75398550|NCT04359966|Drug|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|First line therapy second arm
75398551|NCT04359966|Drug|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|Second line therapy for Helicobacter pylori infection
75398552|NCT04359966|Drug|Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg|Second line therapy for Helicobacter pylori infection second arm
75548012|NCT04587869|Behavioral|CBT Coping Intervention|A cognitive behavior therapy group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
75548013|NCT04581902|Device|rTMS therapy|rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.
75398553|NCT04360122|Drug|Levamisole|Levamisole (150 mg/day for two days per week for 2 months
75398554|NCT04360122|Drug|Isoprinosine|Isoprinosine (1 g 3 times per day daily) for two months
75398555|NCT04360122|Drug|Levamisole and Isoprinosine|Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
75398556|NCT04360356|Combination Product|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
75398557|NCT04360356|Other|Standard Care|Oxygen via Ventilators
75548014|NCT04579380|Drug|tucatinib|300 mg orally twice daily
76037193|NCT04693494|Other|Training program|Training program consisting in 4 sessions with information about milestones to achieve and advices for motor development. Triptychs and short videos containing the main points containing the main points.
76037194|NCT04662164|Drug|hepalatide|3 different dosage will be given sequentially to T2D patients
76037195|NCT04654468|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.
76037196|NCT04647162|Procedure|hematoma evacuation by craniotomy|The intervention method of hematoma evacuation is under craniotomy.
76037197|NCT04647162|Procedure|hematoma evacuation by stereotactic puncture|The intervention method of hematoma evacuation is under stereotactic puncture.
75398558|NCT04359576|Diagnostic Test|Primary and secondary hemostasis|Focus on platelet aggregation, primary and secondary hemostasis parameters
75548015|NCT04579380|Drug|trastuzumab|Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
75548016|NCT04579380|Drug|fulvestrant|Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
75548017|NCT04574024|Drug|NBT-NM108 (60 g/day)|Patients will receive NBT-NM108 at 60 g/day.
75548018|NCT04574024|Other|NBT-NM108 (0 g/day)|Patients will receive NBT-NM108 at 0 g/day.
75548019|NCT04573205|Drug|FSME-IMMUN Vaccine|0.5 ml intramuscular injection scheduled in the two different arms
75709592|NCT00710034|Drug|Nicotine Gum|4 mg Nicotine gum
75398559|NCT04359810|Biological|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2
75398560|NCT04359810|Biological|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)
75398561|NCT04359264|Other|Cash transfer|Cash transfer of $1000
75398562|NCT04359342|Dietary Supplement|HIIT + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
75398563|NCT04359342|Dietary Supplement|HIIT + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
75398564|NCT04359342|Dietary Supplement|HIIT and resistance training + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
75398565|NCT04359342|Dietary Supplement|HIIT and resistance training + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
75548020|NCT04573140|Biological|Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)|The Phase I, Stratum 1 dose-escalation study will be performed in up to 28 adult participants using a Bayesian optimal interval (BOIN) design with an initial embedded accelerated titration design (ATD) to efficiently identify the maximally tolerated dose (MTD). For the initial ATD, patients will be enrolled and treated in cohorts of size 1 starting at dose level -4 to dose level -1, and will expand to a cohort size of 3 after the first DLT is observed or at dose level 0. There are 8 dose levels to potentially be assessed including the possibility of 4 dose levels for the ATD and 4 for the BOIN.
75548021|NCT04572295|Drug|E7090|E7090 oral tablet.
75548022|NCT04572295|Drug|Fulvestrant|Fulvestrant intramuscular injection.
75548023|NCT04572295|Drug|Exemestane|Exemestane oral tablet.
75548024|NCT04571970|Genetic|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
75548025|NCT04569747|Combination Product|Pertuzumab+TRASTUZUMAB|Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose
75398566|NCT04358952|Diagnostic Test|Global Longitudinal Strain|Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction
75548026|NCT04569747|Drug|ADJUVANT ENDOCRINE THERAPY|Oral, daily per cycle
75709593|NCT02567942|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation
75398567|NCT04358796|Device|Hyperbaric oxygent treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 2 ATA. They will breath 100% oxygen while solving cognitive tests designed to assess their cognitive capacities
75398568|NCT04358796|Device|Control hyperbaric oxygen treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 1.2 ATA for a short while and the decreased back to 1 ATA. They will breath air while solving cognitive tests designed to assess their cognitive capacities
75398569|NCT04358718|Procedure|general anesthesia|Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.
75398570|NCT04358718|Procedure|general anesthesia combined with epidural analgesia|Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
75548027|NCT04569123|Device|real stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver vibration for the treatment group.
75548028|NCT04569123|Device|No stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver no vibration for the control group during therapy.
75548029|NCT04568616|Drug|Letrozole 2.5mg|Aromatase Inhibitor
75548030|NCT04568434|Drug|Olezarsen|Olezarsen will be administered by SC injection.
75398571|NCT04358562|Drug|Gefitinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
75398572|NCT04358562|Drug|Anlotinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
75398573|NCT04358094|Other|Conversational hypnosis script|Conversational hypnosis during peripherical veinous catheter set up
75398574|NCT04358094|Other|Standard script|Standard script during peripherical veinous catheter set up
75548031|NCT04568434|Drug|Placebo|Olezarsen-matching placebo will be administered by SC injection.
75548032|NCT04567238|Behavioral|Mobile contingency management|Mobile contingency management is a mobile-phone based behavioral therapy that provides positive reinforcement (i.e., money) for abstinence that is highly effective at reducing substance use.
75548033|NCT04554160|Device|Loop recorder implantation|A loop recorder is implanted in the start of the study after informed consent is signed and enables continuous cardiac monitoring.
75548034|NCT04554160|Device|A smartwatch|A subgroup of the patients will be given an apple watch after informed consent to enables continuous monitoring via this non-invasive modality.
75398575|NCT04358484|Behavioral|Incredible Years - ASD and Language Delay®|"The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language."
75709594|NCT02567942|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
75709595|NCT00414973|Drug|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
76037198|NCT04647162|Procedure|hematoma evacuation by neuroendoscopy|The intervention method of hematoma evacuation is under neuroendoscopy.
75398576|NCT04358172|Other|'Oral and Denture Guide' mobile application|'Oral and Denture Guide' mobile application provides evidence-based information about cleaning aids and material for dentures, denture care and oral hygiene instructions.
75548035|NCT04544189|Drug|Alpelisib|300mg (oral) once daily, in a 28-day cycle
75548036|NCT04544189|Drug|Fulvestrant|Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
75548037|NCT04544189|Drug|Placebo|300 mg by mouth once daily, in a 28-day cycle
75548038|NCT04543409|Biological|Benralizumab|Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
75709596|NCT00414973|Drug|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
75871154|NCT02980874|Drug|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
75871155|NCT02980874|Drug|suprachoroidal sham|suprachoroidal sham procedure
75398577|NCT04357860|Drug|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 200 mg
75398578|NCT04357860|Drug|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 400 mg
75398579|NCT04357860|Drug|Best available treatment|Best available treatment up to 14 days
75398580|NCT04358016|Drug|Terlipressin|Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
75398581|NCT04358016|Drug|Somatostatin|Somatostatin
75398582|NCT04357548|Device|FEEDBACK|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
75398583|NCT04358250|Procedure|Direct Superior Approach|GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.
75398584|NCT04358250|Procedure|posterolateral approach|GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
75398585|NCT04357626|Other|Inpatient Rehabilitation|Observational electronic records review study during inpatient rehabilitation
75398586|NCT04357704|Other|S0N0|(no ITD)
75398587|NCT04357704|Other|S0N500|(ITD +500µs on noise)
75398588|NCT04357704|Other|S-500N500|(ITD -500µs on signal and +500 µs on noise)
75398589|NCT04357704|Other|S0N1000|(ITD + 1000 µs on noise)
75548039|NCT04543409|Biological|Matching placebo|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
75548040|NCT04538144|Other|Simulated heat wave|Individuals will be exposed to thermoneutral climate conditions and two simulated heat wave conditions.
75548041|NCT04518813|Device|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
75709597|NCT00423085|Drug|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm^2 (4.5 mg), 5 cm^2 (9 mg), 7.5 cm^2 (13.5 mg), and 10 cm^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
75709598|NCT00423085|Drug|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm^2, 5 cm^2, 7.5 cm^2 and 10 cm^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
75398590|NCT04357704|Other|S0Nuncorr|(no ITD cue, with uncorrelated stimulation frame)
75398591|NCT04357938|Device|CT-imaging|Chest CT to rule out pneumonia in PCR negative, nonspecific symptomatic patients to prevent the spread of SARS-CoV-2 within the hospital.
75398592|NCT04357470|Other|Hand Therapy|The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
75398593|NCT04357392|Drug|Prednisone|Prednisone 10mg, TID * 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
75398594|NCT04357002|Drug|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
75398595|NCT04357002|Drug|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
75548042|NCT04497727|Other|Gene Expression|Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
75548043|NCT04495088|Drug|mFOLFOX (neoadjuvant)|neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
75709599|NCT00414661|Drug|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
75709600|NCT01608451|Drug|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
75709601|NCT01608451|Drug|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
75398596|NCT04357002|Drug|vaginal placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
75398597|NCT04357080|Procedure|Urethroplasty|Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft
75398598|NCT04356846|Drug|LP-108 tablet|Taken orally within 30 minutes after a meal at the designated dose, once daily.
75398599|NCT04356378|Other|Data record|Data record
75398600|NCT04356222|Drug|Durvalumab|Intravenous infusion once every two weeks ,once 10mg/kg.
75398601|NCT04356222|Drug|methotrexate|Intrathecal chemotherapy specified dose on specified days
75398602|NCT04356144|Diagnostic Test|Thrombin Generation Assay (TGA)|"TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the Thrombin Generation Curve (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP)."
75398603|NCT04356144|Diagnostic Test|Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)|Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.
75398604|NCT04356300|Biological|Exosome of MSC|Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
75398605|NCT04356456|Dietary Supplement|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
75398606|NCT04355988|Procedure|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
75398607|NCT04356066|Diagnostic Test|serum cxcl10 by ELISA|serum sample
75398608|NCT04355754|Device|Ventil - a gas flow divider|Checking ventilation parameters set and obtained and clinical parameters while ventilating the patient and an artificial lung simultaneously, using inspiratory flow divider.
75398609|NCT04355910|Behavioral|Calorie restriction|"Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat."
75398610|NCT04355676|Drug|Selinexor|20 mg selinexor oral tablet.
75398611|NCT04355598|Drug|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
75398612|NCT04355598|Drug|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
75398613|NCT04355598|Drug|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
75398614|NCT04355286|Drug|Bemotrizinol|Market-image topical sunscreen formulation containing BEMT (6%)
75709602|NCT00405067|Drug|BMS-201038 (AEGR-733)|
75709603|NCT00405067|Drug|Ezetimibe|
75398615|NCT04355520|Drug|TQ-B3525|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
75398616|NCT04355520|Drug|Fulvestrant injection|Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
75398617|NCT04355442|Procedure|Facial fractures reduction or osteosynthesis|Facial fractures reduction or osteosynthesis
75398618|NCT04355208|Other|(3M™ Filtek™ Universal )|universal nanofillers resin composite (3M™ Filtek™ Universal )
75398619|NCT04355052|Drug|hydroxychloroquine in combination with camostat mesylate|Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)
75398620|NCT04355052|Drug|Hydroxychloroquine in combination of Azithromycin|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
75398621|NCT04354974|Behavioral|Evaluation|Evaluation of a cognitive remediation program for mood disorders
75398622|NCT04354662|Drug|Toripalimab|240mg d1
75398623|NCT04354662|Drug|Docetaxel|50mg/m2, d1;
75398624|NCT04354662|Drug|Fluorouracil|2600 mg/m², d1
75398625|NCT04354662|Drug|Leucovorin|200 mg/m², d1
76037199|NCT04647162|Other|life support|The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。
75398626|NCT04354662|Drug|Oxaliplatin|85 mg/m², d1
75398627|NCT04354350|Drug|Ramipril|Ramipril dispensing claim is used as the reference
75548044|NCT04495088|Drug|XELOX (neoadjuvant)|neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
75548045|NCT04495088|Drug|mFOLFOX (adjuvant)|adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
75398628|NCT04354350|Drug|Telmisartan|Telmisartan dispensing claim is used as the exposure
75398629|NCT04354740|Procedure|with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)|"II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:"
75548046|NCT04495088|Drug|XELOX (adjuvant)|adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
75548047|NCT04495088|Drug|Capecitabine (adjuvant)|adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
75709604|NCT00708708|Drug|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
76037200|NCT04644016|Drug|Clofarabine|Clofarabine 30 mg/m2
76037201|NCT04644016|Drug|Fludarabine|Fludarabine 10 mg/m2
75398630|NCT04354194|Procedure|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in sitting and supported with a pillow under the head, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the cervical region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
75398631|NCT04354194|Procedure|Osteopathic Manupilative Treatment|Osteopathic Manupilative Treatment consist of stretching the fascia to the cervical region, soft tissue mobilization to the surrounding muscles, cervical manual traction, passive joint mobilization to the 7 cervical spine, passive joint mobilization to the 1st costa, passive joint mobilization to the clavicle and passive joint mobilization to the sternum mobilization in supine and prome positions.
75398632|NCT04354116|Device|Rapid maxillary expansion|Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
75398633|NCT04354116|Device|Maxillary Protraction|Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
75398634|NCT04353882|Other|Assess the difference in MOR-1 expression between healthy and tumor tissue|Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
75398635|NCT04353570|Other|clinical interview|This interview can be carried out face to face or remotely. In the latter case, it is part of telemedicine, which is recognised by the health authorities in France.
75398636|NCT04353336|Drug|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine
75548048|NCT04495088|Drug|"infusional 5-FU/FA AIO regimen (adjuvant)"|adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
75548049|NCT04495088|Drug|"infusional 5-FU/FA de Gramont (adjuvant)"|adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
75548050|NCT04486989|Behavioral|Cardiovascular Conditioning Protocol|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
76037202|NCT04644016|Drug|Busulfan|Busulfan per PK
76037203|NCT04644016|Drug|Cyclosporine-A|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
76037204|NCT04644016|Drug|Mycophenolate Mofetil|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
76037205|NCT04644016|Biological|Cord Blood Graft|The CB graft will be infused on day 0 per standard practice
76037206|NCT04626921|Drug|CNM-Au8|30 mg of CNM-Au8
75398637|NCT04353726|Other|Weight management|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
75548051|NCT04486989|Other|Voice Production Exercises|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
75548052|NCT04474184|Procedure|Biospecimen Collection|Receive vaginal kit for biospecimen collection
75709605|NCT00404755|Drug|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
75709606|NCT00404755|Drug|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
76037207|NCT04622176|Diagnostic Test|MMUS|MMUS will be used to perform diagnostics, we will compare with MRI and histology
76037208|NCT04615910|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
75398638|NCT04353180|Drug|Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|"After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
75398639|NCT04353180|Drug|Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|"Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
75548053|NCT04474184|Behavioral|Focus Group|Attend focus group
75548054|NCT04474184|Other|Survey Administration|Ancillary studies
75709607|NCT00404755|Drug|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
75709608|NCT03742453|Diagnostic Test|contrast-enhanced ultrasound|CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
75709609|NCT03742453|Diagnostic Test|EOB-MRI|EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
75709610|NCT03904381|Drug|5-fluorouracil|5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.
75709611|NCT03904381|Procedure|Transconjunctival needling|Transconjunctival needling was administered according to predetermined criteria.
75709612|NCT03904381|Procedure|Transconjunctival revision|Transconjunctival revision was administered according to predetermined criteria.
75709613|NCT02568150|Biological|Single group, open-label|
75709614|NCT01535911|Other|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
75709615|NCT00737256|Drug|Aripiprazole|15-30 mg
75709616|NCT00737256|Drug|Perphenazine|8-16 mg
75709617|NCT00614614|Biological|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
75709618|NCT00614614|Biological|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
75709619|NCT00614614|Biological|Infanrix®|One dose as intramuscular injection
75709620|NCT00614614|Biological|ActHIB®|Three doses in the priming phase as intramuscular injection
75709621|NCT00614614|Biological|Pediarix®|Three doses in the priming phase as intramuscular injection
75871156|NCT02980874|Drug|IVT aflibercept|2 mg intravitreal injection of aflibercept
76037209|NCT04603924|Drug|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
75398640|NCT04353180|Drug|Isotretinoin (13 cis retinoic acid ) capsules|13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
75398641|NCT04353180|Drug|Aerosolized 13 cis retinoic acid|Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
76037210|NCT04603924|Drug|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
76037211|NCT04596657|Dietary Supplement|Vitamin D supplementation|Daily vitamin D3 supplementation (5000 IU)
76037212|NCT04585958|Procedure|Biopsy|Undergo biopsy
75398642|NCT04353180|Drug|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
75709622|NCT00713310|Drug|Asacol 400 mg|"High dose:~17-<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
75709623|NCT00713310|Drug|Asacol 400 mg|"Low dose:~17-<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
75709624|NCT00737334|Device|EEGo, BIS, FORE-SIGHT cerebral oximeter|"The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed."
75709625|NCT05740488|Drug|Apalutamide|240mg, po, qd
75709626|NCT05740488|Drug|89Sr|100~150MBq(based on weight), iv, q90d
75709627|NCT05740488|Drug|Luteinizing Hormone-Releasing Hormone Analog|sc, 3.6mg, q30d or 10.8mg, q90d
76037213|NCT04585958|Procedure|Biospecimen Collection|Undergo collection of blood samples
75709628|NCT05740410|Device|ClotTriever Catheter|Treatment of iliofemoral deep vein thrombosis with the ClotTriever catheter
76037214|NCT04585958|Procedure|Computed Tomography|Undergo CT
76037215|NCT04585958|Procedure|Echocardiography|Undergo echocardiography
76037216|NCT04585958|Drug|Olaparib|Given PO
75709629|NCT00874354|Drug|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
75709630|NCT05742126|Drug|HSK36273|Multiple continuous IV infusion ascending doses for 5 days
75709631|NCT05742126|Drug|Placebo|Matching placebo
75709632|NCT05742126|Drug|Heparin sodium injection|Matching positive control
76037217|NCT04585958|Biological|Trastuzumab Deruxtecan|Given IV
76037218|NCT04569058|Device|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
76037219|NCT04562766|Drug|Rilzabrutinib|400mg Caplet
76037220|NCT04562766|Drug|Placebo|400mg Caplet
76037221|NCT04553757|Other|Survey Administration|Complete survey
76037222|NCT04528082|Drug|Apremilast|Participants will receive apremilast orally.
76037223|NCT04528082|Drug|Placebo|Participants will receive the matching placebo orally.
76037224|NCT04527731|Device|Accelerometry|Participants are asked to wear an accelerometer during the day for a period of seven days.
76037225|NCT04519827|Other|New Rice-based hydrolysate|A rice-based hydrolysed infant formula with new ingredient
76037226|NCT04519827|Other|Amino Acid-based infant formula|An amino acid-based infant formula
75398643|NCT04352868|Device|Intelliwave multifocal, toric, soft contact lens|This is a quarterly disposable, multifocal, toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
75398644|NCT04352868|Device|Intelliwave toric, soft contact lens|This is a quarterly disposable toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
75398645|NCT04352946|Drug|Hydroxychloroquine Pre-Exposure Prophylaxis|HCQ PreP 400mg daily
75398646|NCT04352946|Drug|Placebo oral tablet|Placebo tablets 400mg daily
76037227|NCT04518085|Behavioral|Medical hypnosis|Single session 20 minutes hypnosis session originally developed and tested by Montgomery et al. (2007) in a similar setting. Delivered by an experienced clinical psychologist.
76037228|NCT04518085|Behavioral|Internet-based Acceptance and Commitment Therapy (iACT)|Access to an online platform developed to this study containing video clips and audio files with ACT consistent material
76037229|NCT04518085|Behavioral|Mindfulness session|Single session mindfulness session delivered by audio file
76037230|NCT04518085|Behavioral|Treatment as Usual (TAU)|Treatment as usual as part of post-surical care
76037231|NCT04513067|Biological|YQ23|YQ23 as a single agent will be given in Stage 1.
76037232|NCT04513067|Combination Product|Pembrolizumab|Pembrolizumab will be given in combination with YQ23 in Stage 2
76037233|NCT04513054|Genetic|Blood collection for genetic analysis|Blood collection for genetic analysis
75398647|NCT04352712|Other|blood sampling|blood sampling
75398648|NCT04352634|Other|Exposure to the SARS-CoV-2 and its consequences|This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
75548055|NCT04448366|Behavioral|Cognitive behavioral therapy|Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
75548056|NCT04438317|Procedure|Pleural drainage procedure with Seldinger procedure|Pleural drainage using Seldinger technique.
75548057|NCT04438317|Procedure|Pleural drainage procedure with surgical-like technique|Pleural drainage using Surgical-like technique.
75548058|NCT04434937|Drug|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
75548059|NCT04421560|Drug|Ibrutinib|Capsule, taken by mouth daily
75709633|NCT00737412|Other|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
75709634|NCT00737412|Other|Placebo|Matching capsules devoid of microorganisms
76037234|NCT04505410|Drug|Tofacitinib|10mg tofacitinib tablets taken twice daily for eight weeks
76037235|NCT04505410|Other|Fast Mimicking Diet|FMD is a five day meal plan that includes foods such as soups, snacks, bards, teas and supplements (omega-3 fatty acids) for a total of 66 items per box. The diet is plant-based, gluten free and dairy free without any artificial preservatives, chemicals or biologically active ingredients.
75709635|NCT00882856|Drug|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
76037236|NCT04505410|Drug|Ustekinumab induction|Participant will be initiated with ustekinumab induction therapy as second line biologic therapy
76037237|NCT04505410|Drug|Infliximab induction|Participant will be initiated with infliximab induction therapy as second line biologic therapy
76037238|NCT04488289|Other|Lifestyle|Cardiovascular risk and lifestyle
76037239|NCT04479696|Other|Educational Intervention|Receive standard of care verbal and written education materials
76037240|NCT04479696|Other|Questionnaire Administration|Ancillary studies
76037241|NCT04479696|Other|Survey Administration|Complete optional survey
76037242|NCT04479696|Other|Video|Watch NIRS video
75398649|NCT04352322|Dietary Supplement|A+HA(tm)|oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
75398650|NCT04352322|Dietary Supplement|Placebo|oral solution with no active ingredients
75398651|NCT04352478|Diagnostic Test|Histopathological result|Incidental gallbladder cancer and other pathology
75398652|NCT04351932|Biological|bone marrow mesenchymal stem cells|intrarticular bone marrow mesenchymal stem cells injection
75398653|NCT04351932|Biological|Adipose Mesenchymal stem cells|intrarticular adipose mesenchymal stem cells injection
75398654|NCT04351932|Biological|bone marrow & adipose mesenchymal stem cells injection|intrarticular bone marrow and adipose stem cells injection.
75398655|NCT04352088|Procedure|Nasal provocation test|Allergen extract under controlled conditions will be applied into nasal mucous.
75398656|NCT04351542|Dietary Supplement|Ayurveda|Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.
75398657|NCT04351542|Other|Usual Care|Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.
75398658|NCT04351464|Other|physical therapy and reflexology|
75548060|NCT04421560|Drug|Pembrolizumab|Given as an intravenous injection through a vein (IV) every 3 weeks
75548061|NCT04421560|Drug|Rituximab|Given as infusion into a vein (intravenous, IV)
75548062|NCT04405167|Drug|Tasquinimod|Tasquinimod will be supplied as oral capsules.
75548063|NCT04405167|Drug|IRd chemotherapy|IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
75709636|NCT00882856|Drug|Placebo|placebo
75548064|NCT04395365|Drug|Co-Trimoxazole 960Mg Dispersible Tablet|Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis
75548065|NCT04395365|Drug|Placebo oral tablet|Placebo
76037243|NCT04478266|Drug|Amcenestrant-matching placebo|Pharmaceutical form: Tablets Route of Administration: Oral
75398659|NCT04351308|Drug|MAPI chemotherapy|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²)"
76037244|NCT04478266|Drug|SAR439859|Pharmaceutical form: Tablets Route of Administration: Oral
76037245|NCT04478266|Drug|Palbociclib|Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
75548066|NCT04391114|Procedure|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay [4]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low [5]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay [6].
76037246|NCT04478266|Drug|Letrozole|Pharmaceutical form: Capsules Route of Administration: Orally
76037247|NCT04478266|Drug|Goserelin|Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
75398660|NCT04351308|Drug|Apatinib Mesylate|anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily
75398661|NCT04351308|Drug|Camrelizumab|anti-PD-1 antibody 200mg ivgtt. Q2W
75398662|NCT04351152|Biological|Lenzilumab|Administered as an intravenous (IV) infusion
75398663|NCT04351152|Drug|Standard of Care|Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
75398664|NCT04351074|Procedure|LIFT|ligation of the intersphincteric fistula track
75398665|NCT04351074|Procedure|fistulectomy|excision of the fistulous track with its internal and external orifices
75398666|NCT04350918|Device|Muscle Enery Techniques|Group of patients that underwent muscle energy technique as a mean of treatment for the complaint
75398667|NCT04350918|Device|Static Stretching|Set of patients that had static stretching technique for the treatment for the complaint
76037248|NCT04478266|Drug|Letrozole-matching placebo|Pharmaceutical form: Capsules Route of Administration: Orally
76037249|NCT04466488|Behavioral|Choice Architecture|"Providers will receive general training on TPT benefits, indications, and contra-indications.~Providers will be provided with updated ART and TPT prescribing approach, including an ink stamp or pre-printed sticker for quick entry of the ART prescription along with TPT and cotrimoxazole.~The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
75398668|NCT04350996|Other|Wearable alcohol sensor|BACtrack Skyn, is a novel transdermal blood alcohol sensor developed by BACtrack, a company established for police-grade breathalyzers, and winner of the Wearable Alcohol Biosensor Challenge sponsored National Institute on Alcohol Abuse and Alcoholism.
76037250|NCT04460586|Drug|Omadacycline Injection [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
76037251|NCT04460586|Drug|Omadacycline Oral Tablet [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
75398669|NCT04350528|Drug|Chlorpromazine or Pentobarbital|Sedation
75398670|NCT04350684|Drug|Umifenovir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
75398671|NCT04350684|Drug|Interferon-β 1a|This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
75398672|NCT04350684|Drug|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
75398673|NCT04350684|Drug|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
75398674|NCT04350684|Drug|Standards of Care|This Drug will be used in all arms as mandated by our governmental guidelines.
75398675|NCT04350450|Drug|Hydroxychloroquine|400 mg tablet
75398676|NCT04350216|Drug|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|"The treatment of sarilumab 200mg will be administered every two weeks subcutaneously.~Each patient will be followed for 6 months from the start of treatment. The last administration of Sarilumab will be 2 weeks before the end of the study."
75398677|NCT04349592|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
75398678|NCT04349592|Drug|Azithromycin|Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
75398679|NCT04349592|Other|Placebo Tablet|Oral, one tablet three times a day for 7 days
75398680|NCT04349592|Other|Placebo capsules|Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
75548067|NCT04391114|Procedure|Top-Down HoLEP|The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
75398681|NCT04349748|Behavioral|Health education, and regular HIV and STDs testing prompting service|Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
75398682|NCT04349748|Behavioral|Health status inquiry through app (partner notification)|The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
75548068|NCT04389853|Procedure|Flexible ureteroscopy|Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
75398683|NCT04349202|Diagnostic Test|EUROIMMUN assay|Serology testing to detect SARS-CoV-2 antibodies
75398684|NCT04348812|Behavioral|ABMT|mobile attention bias modification training for anxiety, using the app Personal Zen
75398685|NCT04348812|Other|Transcranial direct current stimulation|Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
75548069|NCT04389853|Procedure|Mini-percutaneous nephrolithotomy|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
75398686|NCT04348890|Drug|Vamorolone 4% suspension for oral dosing|vamorolone 6 mg/kg/day orally once daily for 8 weeks.
75548070|NCT04386941|Procedure|Xpeeda Fibre Laser Vaporesection of the Prostate|"Both interventions are currently used standard of care treatments for the Holmium laser enucleation of the prostate (HoLEP) for patients with bothersome lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).~Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue."
75709637|NCT02568462|Device|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
75398687|NCT04347642|Procedure|Umbilical port placement|The port will be inserted in the midline at the level of the umbilicus.
75398688|NCT04347642|Procedure|Paraumbilical port placement|The port will be inserted 3-4cm laterally to the midline at the level of the umbilicus.
75398689|NCT04347252|Drug|Glucagon|Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
75398690|NCT04346940|Other|Telerehabilitation|15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.
75398691|NCT04346940|Other|Exercise brochure|The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
76037252|NCT04457778|Drug|M6223|Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.
76037253|NCT04457778|Drug|Bintrafusp alfa|Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.
76037254|NCT04457778|Drug|M6223|Participants will receive an IV infusion of M6223 at escalated doses Q2W on Day 1 of each Cycle (Each cycle is of 21 days) according to the recommendation of the SMC until the MTD has been reached or confirmed disease progression.
76037255|NCT04456504|Biological|Recombinant hepatitis B vaccine with CpG adjuvant|Each participant will receive two doses of hepB-CpG separated by one month and blood draw to measure antibody to the hepatitis B surface antigen prior to dose 2 and one month after dose 2.
76037256|NCT04450693|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
75548071|NCT04386941|Procedure|Greenlight XPS Vaporization of the Prostate|The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser.11 It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibers required in these situations.
75548072|NCT04381338|Other|Pulmonary and Motor Rehabilitation|Pulmonary and Motor Rehabilitation in ICU
76037257|NCT04450693|Other|Standard care|"Standard care is defined in this protocol to consist of the following:~Debridement;~Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~Appropriate use of systemic antibiotics."
76037258|NCT04435288|Drug|week 24|"At the week 24 timepoint, there are 3 possible scenario's:~In patients that do not reach a state of clinical remission at week 24, blinded study medication will be interrupted and all patients will start open-label SC golimumab for an additional 36 weeks (up to max. week 60).~In patients that achieve sustained clinical remission at week 24, defined as absence of clinical arthritis, enthesitis and dactylitis at both week 12 and week 24, all study medication will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B.~In patients that reach a state of clinical remission at week 24, but that did not yet reach this status at week 12, blinded study medication will be continued without any change in the treatment schedule for another 12 weeks."
75548073|NCT04375800|Drug|Doravirine|DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.
75548074|NCT04375800|Drug|2 NRTIs|Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
75709638|NCT00882934|Other|Induction to efficient treatment|Informative letters.
75709639|NCT00882934|Other|Doubt to the efficacy of treatment|Informative letters.
75548075|NCT04340947|Other|Very low nicotine cigarettes|Participants will be randomized to smoke menthol and non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory
75548076|NCT04338763|Drug|RP72|RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
75548077|NCT04338763|Drug|Gemcitabine|Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.
75709640|NCT00882934|Other|Induction to ineffective treatment|Informative letters
76037259|NCT04435288|Drug|week 36|"At week 36, patients that have continued the blinded study medication, will be re-assessed regarding sustained clinical remission (at week 24 and 36): if yes, all study medication will again be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. If no, these patients will start open-label SC golimumab for an additional 24 weeks (up to max. week 60).~If patients were in the open-label golimumab treatment arm, effectiveness of the treatment will be assessed by using the PASSI-question. Inadequate responders will be discontinued from the study and will be treated with standard-of-care medication at the discretion of their treating rheumatologist, whereas patients with an acceptable improvement in signs and symptoms will continue with the same (open-label) medication schedule."
76037260|NCT04435288|Drug|Week 48|"At week 48, all patients still remaining in SPARTACUS Phase A will have been treated with open-label golimumab (for a minimum of 12 weeks, but potentially up to 48 weeks). In patients reaching at this timepoint sustained clinical remission (at week 36 and 48), golimumab will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. For the other patients there are 3 possible scenarios:~If clinical remission for the first time at week 48, continuation without any change in the treatment schedule for another 12 weeks.~If an inadequate response (based on the PASSI-question), discontinuation from the study and standard-of-care medication~If an acceptable improvement (but no clinical remission), continuation open-label golimumab for an additional 12 weeks, with open-label methotrexate (unless contra-indicated) to fulfil Belgian reimbursement criteria for TNFi."
76037261|NCT04435288|Drug|Week 60|At week 60 (final study visit of SPARTACUS Phase A), patients reaching sustained clinical remission (at week 48 and 60), will roll-over into SPARTACUS Phase B. All other patients will be discontinued and will be treated with standard-of-care medication (including TNFi, if in accordance with Belgian reimbursement criteria).
75398692|NCT04347096|Behavioral|mHealth Intervention|"The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention."
75398693|NCT04347096|Behavioral|Control Intervention|The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
75398694|NCT04346862|Drug|Acetyl-L-carnitine hydrochloride 500mg|The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
75398695|NCT04346862|Drug|Placebo|The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
75548078|NCT04328532|Device|MRI|MRI examination (45 min max) with potential oxygen delivery for 10 min
75548079|NCT04318886|Behavioral|ENABLE Cornerstone|The ENABLE (Educate, Nurture, Advise, Before Life Ends) Cornerstone intervention is led by a specially-trained lay coach who is overseen by an interdisciplinary outpatient palliative care team, who employs health coaching techniques and caregiver distress assessment to behaviorally activate and reinforce psychoeducation on managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning over 6 brief in-person/telephonic sessions plus monthly follow-up from diagnosis through early bereavement.
75709641|NCT00874588|Biological|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
75709642|NCT04064658|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
75709643|NCT04064658|Procedure|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
75709644|NCT04064658|Procedure|Encephaloduroarteriosynangiosis|Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
75398696|NCT04347174|Drug|Suspension of heat killed (autoclaved) Mycobacterium w|Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
75548080|NCT04306120|Other|Traditional Rehabilitation Therapy|The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.
75398697|NCT04347174|Drug|Placebo|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
75398698|NCT04346784|Behavioral|maintaining positive working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
75398699|NCT04346784|Behavioral|repressing negative working memory training|Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.
75398700|NCT04346784|Behavioral|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
75398701|NCT04346784|Behavioral|Positive placebo ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
75398702|NCT04346550|Other|Suction drain|Post operatively, in both arms including drain group and no drain group, parameters of pain was assessed by visual analog scale (VAS) from 0 (no pain) to 10 (worst pain), assessed at 1st postoperative day by the duty doctor or the nurse. VAS > 3 was considered as post surgical pain. The total number of hospital stay was noted from the day of operation till the day of discharge and discharge criteria was taken as a patient having pain as per VAS<3, no fever and tolerating oral intake
75398703|NCT04345848|Drug|Enoxaparin|Two different doses of anticoagulation
75398704|NCT04345770|Procedure|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
75398705|NCT04345770|Drug|SOX neoadjuvant or postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
75548081|NCT04301401|Other|Vaginal swabs|On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
75548082|NCT04301401|Other|Stool samples|Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
75548083|NCT04301401|Other|Urine samples|Urine samples will also be taken before surgery and 6 weeks after surgery.
75709645|NCT00883012|Biological|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms**, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms**, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms** Two doses, one month apart"
75709646|NCT00883012|Biological|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
76037262|NCT04426968|Drug|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
75398706|NCT04345770|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
75398707|NCT04345692|Drug|Hydroxychloroquine|oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
75398708|NCT04345380|Other|Implantation of an Alcon Acrysof SN60WF intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
75398709|NCT04345380|Other|Implantation of an AMO Tecnis ZCB00 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
75398710|NCT04345380|Other|Implantation of an Envista MX60 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
75398711|NCT04345458|Drug|prefilled liquid etanercept(Yisaipu)|
75398712|NCT04345458|Drug|lyophilized etanercept powder(Yisaipu)|
75398713|NCT04345614|Drug|Auxora|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
75398714|NCT04345614|Drug|Placebo|Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
75398715|NCT04344912|Other|Data collection|Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
75548084|NCT04279067|Device|BCI-FES dorsiflexion therapy|"BCI technology enables direct brain control of external devices such as assistive devices and prostheses by translating brain waves into control signals. When BCI systems are integrated with functional electrical stimulation (FES) systems, they can be used to deliver a novel physical therapy to improve movement after stroke. The automated software will analyze the data to generate and calibrate a BCI decoder. In the online phase, the subjects will perform 20-25 BCI-FES runs. In each run, subjects will follow 10 alternating epochs of 10-s long idling/dorsiflexion textual cues, and respond by either idling or attempting dorsiflexion to elicit BCI-FES mediated contractions of the TA muscle."
75548085|NCT04279067|Behavioral|Physiotherapy one hour|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
75548086|NCT04279067|Behavioral|Physiotherapy two hours|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
75548087|NCT04271046|Behavioral|STAR-C-VTF|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study and to acquaint the caregiver with the STAR-VTF components of good dementia care; distribute printed educational material (and links to same material online);~Six 30-minute follow-up phone calls with the caregiver following each of the 6 learning modules to review STAR-VTF concepts, and further brainstorm strategies to modify identified activators and consequences with the objective of reducing behavioral symptoms;~secure message support, as needed, with the coach to help with personalizing the STAR-VTF curriculum for up to 6 months."
76037263|NCT04426968|Drug|Hepalatide 4.2mg|4.2mg/day subcutaneously (s.c.) for 24 week
75709647|NCT00737490|Other|"Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm~Using one of the FDA approved St. Jude devices, depending on MD preference."
75709648|NCT00737490|Other|"Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"simultaneous BiV pacing.~Using one of the FDA approved St. Jude devices, depending on MD preference."
76037264|NCT04426968|Drug|Hepalatide 6.3mg|6.3mg/day subcutaneously (s.c.) for 24 week
76037265|NCT04426968|Drug|placebo 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
76037266|NCT04426968|Drug|placebo 4.2mg|4.2 mg/day subcutaneously (s.c.) for 24 week
76037267|NCT04426968|Drug|placebo 6.3mg|6.3 mg/day subcutaneously (s.c.) for 24 week
75398716|NCT04344990|Procedure|Epidural analgesia - Group E|Postoperative analgesia with continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
75398717|NCT04344990|Procedure|Femoral blockade - Group F|Postoperative analgesia with continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min) .
75398718|NCT04344990|Procedure|Intraarticular infusion - Group I|Postoperative analgesia with continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
76037268|NCT04426968|Drug|Pegylated Interferon|180 ug/week subcutaneously (s.c.) for 28 week
76037269|NCT04406974|Procedure|Surgery or treatment for local recurrence|Surgery or treatment for local recurrence
75398719|NCT04344834|Diagnostic Test|A questionnaire or scales|A questionnaire or scale to assess the participants mental health.
75398720|NCT04344756|Drug|Tinzaparin or unfractionated heparin|Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
75398721|NCT04344288|Drug|Prednisone|The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
75398722|NCT04344288|Other|Control group|The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
75398723|NCT04344522|Procedure|Descemet membrane endothelial keratoplasty DMEK|DMEK : it involves separating the Descemet membrane from a corneal donor graft , doing a descematorhexis in the recepient cornea , loading and injection of the graft into the anterior chamber , unfolding and fixing the graft to the recepient cornea by intracameral air bubble.
75398724|NCT04344522|Procedure|IOL exchange|IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.
75398725|NCT04344522|Procedure|iridoplasty|iridoplasty : repairing any iris defect by using 10/0 prolene.
75398726|NCT04344522|Procedure|Inferior peripheral iridectomy|Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .
75398727|NCT04344210|Behavioral|Tele-interventions related to diabetes management and mental well-being|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
76037270|NCT04406974|Procedure|Surgery for advanced colorectal cancer|Surgery for advanced colorectal cancer
76037271|NCT04379505|Device|Ring gantry kV-CBCT combined with linear accelerator (Halcyon)|-Varian Medical Systems is the manufacturer
75558232|NCT03279354|Behavioral|Family Move app intervention|All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
75709649|NCT00737646|Behavioral|Usual care|No intervention will be conducted in this arm of the study.
75709650|NCT00737646|Behavioral|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
76037272|NCT04379505|Radiation|Quad shot radiation|Treatment of each cycle should ideally take place on two consecutive days. Allowing for holidays, weekends, and other scheduling issues or unexpected delays, treatment may be completed within five calendar days.
76037273|NCT04356352|Drug|Lidocaine|1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
75398728|NCT04343742|Drug|chlorine dioxide 3000 ppm|"Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots)."
75398729|NCT04343508|Other|Fortified rice|100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
75398730|NCT04343196|Radiation|Diagnostic Angiography (DSA or DVA based on randomization result)|After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
75398731|NCT04343118|Procedure|Hardware Removal|elective removal of plate osteosynthesis at the clavicle
76037274|NCT04356352|Drug|Esmolol|0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
76037275|NCT04356352|Other|Placebo|saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
75398732|NCT04342728|Dietary Supplement|Ascorbic Acid|Readily available marketed open label ascorbic acid
75398733|NCT04342728|Dietary Supplement|Zinc Gluconate|Readily available marketed open label zinc gluconate
75398734|NCT04342728|Dietary Supplement|Ascorbic Acid and Zinc Gluconate|Readily available marketed open label ascorbic acid and zinc gluconate
75398735|NCT04342728|Other|Standard of Care|Readily available prescribed medications/ supplements- None study supplements
75398736|NCT04342650|Drug|Chloroquine Diphosphate|150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
75548088|NCT04271046|Behavioral|Control|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study. Controls will receive usual care from their primary care provider and/or psychiatrist. We will give participants an information package from the Alzheimer's Association including a list of resources. To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia. Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association. This attention control is proposed to assess the additional impact of STAR-VTF above treatment as usual. Investigators do not intend to track non-study training receipt in the control arm."
75548089|NCT04270045|Device|Non-invasive forced airway oscillometry|This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.
75548090|NCT04268771|Biological|Experimental: Arm A: DRL_RI|Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion
75871157|NCT02354872|Drug|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
75871158|NCT02354872|Behavioral|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
76037276|NCT04350463|Drug|CC-90011|CC-90011
76037277|NCT04350463|Drug|Nivolumab|Nivolumab
76037278|NCT04286295|Drug|Cytisine|Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.
75398737|NCT04342650|Drug|Placebo oral tablet|150mg placebo tablets
75398738|NCT04342416|Behavioral|Visiospatial Interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
75398739|NCT04342104|Other|Monitoring for aggravation|"Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~lymphopenia~thrombocytopenia~CRP~ferritin~LDH~troponin I~NT-ProBNP~Liver enzymes~D-dimers~radiologic aggravation  1 day and 1 week after starting NIV or CPAP"
75871159|NCT02354872|Behavioral|5Rs Motivation Counseling|"The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions."
75398740|NCT04342104|Other|Evaluate HACOR score effectivity in this patients|Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
75398741|NCT04341714|Other|Satisfaction evaluation|Assessement of satisfaction of the telephone consultation
75398742|NCT04341402|Drug|Antifungal Nail Gel Study|Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
75398743|NCT04341636|Radiation|Bitewing X ray|"Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol ."
75398744|NCT04341480|Drug|Chemotherapy|Routine chemotherapy for individual tumor type.
75398745|NCT04341168|Other|this study is non- interventional|this study is non- interventional
75398746|NCT04341324|Other|It is an observational study.|
75398747|NCT04340544|Drug|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
75398748|NCT04340544|Drug|Placebo|Placebo capsules
75398749|NCT04340622|Device|supra-luminous LED|810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.
75548091|NCT04268771|Biological|Arm B: Rituxan®/Mabthera®|Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion
75398750|NCT04340622|Device|Sham|Light-emitting diode covered with aluminium foil
75398751|NCT04340934|Device|REZUM system|Rezūm is a system uses water steam energy to remove the particular part of the prostate that enlarges and causes symptoms due to BPH. Rezum involves a radiofrequency (RF) generator system and an endoscopic device that is introduced into the body via the urethra.
75398752|NCT04340778|Drug|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
75548092|NCT04260243|Other|Experimental-Myofascial + Respiratory rehabilitation|6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
75548093|NCT04260243|Other|Sham Myofascial + Respiratory rehabilitation|6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
75548094|NCT04253145|Drug|PM 01183|Lyophilisate for solution for infusion
76037279|NCT04286295|Drug|Nicoderm C-Q Transdermal Product|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
76037280|NCT04286295|Drug|Nicorette Lozenge Product|Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
75398753|NCT04340778|Drug|Lidocaine-prilocaine Cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
75398754|NCT04340778|Drug|placebo|inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
75398755|NCT04340466|Other|No intervention|No intervention
75548095|NCT04253145|Drug|Atezolizumab|Concentrate for solution for infusion
75548096|NCT04251741|Diagnostic Test|Adalimumab trough concentration|In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration
75548097|NCT04251741|Other|Usual care|In the usual care group, switch to subsequent biological is based on secondary randomisation
75548098|NCT04246606|Diagnostic Test|IHC4 score|"The IHC4 score is a prognostic tool that incorporates immunohistochemical parameters of ER (H-score), PR (% of positive cells), HER2 (positive or negative status), and Ki67 (% of positive cells).~IHC4 score, combined with nodal status and tumor grade, age, and the type of endocrine therapy (tamoxifen or aromatase inhibitors) provides a clinical score IHC4+C.~IHC4+C provides a prognostic risk of distant recurrence at 10 years for patients who underwent endocrine therapy for 5 years. IHC4+C defined three distinct risk categories:~<10%: low risk~[10-20%]: intermediate risk~>20%: high risk"
75548099|NCT04244188|Other|Collection of datas|Collection of datas: pre- and postoperative scanner and endoprosthesis characteristics
75548100|NCT04239339|Drug|Escitalopram 20 mg|20mg daily for approximately 3 weeks.
75548101|NCT04239339|Drug|Placebo|Placebo daily for approximately 3 weeks.
75548102|NCT04238715|Drug|E7090|E7090 tablets orally.
75548103|NCT04225832|Behavioral|CBT Coping Intervention|A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
75871160|NCT02354872|Behavioral|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
75871161|NCT02354872|Other|No Treatment|No Treatment
76037281|NCT04286269|Other|Music Based Intervention|Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.
76037282|NCT04286269|Other|Sham Treatment|Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
76037283|NCT04286087|Procedure|neck incisions closed at bedside at the time of drain removal under local anesthesia|Participants allocated to the investigational group will have neck incisions closed at bedside at the time of drain removal under local anesthesia
75398756|NCT04340388|Drug|Dolutegravir 50 MG|15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
75398757|NCT04340388|Drug|Antiretroviral/Anti HIV|15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
75398758|NCT04340310|Diagnostic Test|Home respiratory polygraphy|Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission
75398759|NCT04340232|Drug|Baricitinib|Subjects will receive a 2 mg oral dose of baricitinib.
75398760|NCT04339842|Other|Assessment of Dietary Changes in Adults in the Quarantine|The online survey will help to collect demographic data from the volunteers. Personal information and contact details, such as email, will not be asked. The survey will include questions about any increase or decrease in the consumption of main meals, snacks and fluid intake. If the participants of the study have observed changes in their dietary pattern since the beginning of the quarantine, details of these changes, such as an increase in the amount of main meal consumption, will be questioned.
75398761|NCT04339686|Diagnostic Test|Thoracic CT Scan|Retrospective analysis of the thoracic CT scan results compared to final discharge summary
75398762|NCT04338672|Other|COVID-19 Pandemic|Exposure: the novel coronavirus disease (Covid-19) outbreak
75548104|NCT04222920|Other|Dose reduction to 2mg/L|Adalimumab dose reduction aiming drug concentration of 2mg/L
75548105|NCT04222920|Other|Dose reduction to 5mg/L|Adalimumab dose reduction aiming drug concentration of 5mg/L
75548106|NCT04222920|Drug|Adalimumab|Adalimumab
75548107|NCT04208230|Device|XtremeCT|HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
75548108|NCT04201353|Behavioral|Conditional Cash Transfer|The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (~$10) for up to 6 months conditional on visit attendance.
75398763|NCT04338906|Drug|Camostat Mesilate|400 mg tid, d1-d7
75398764|NCT04338906|Drug|Placebo|Instead of Camostat Mesilate, tid, d1-d7
75398765|NCT04338906|Drug|Hydroxychloroquine|400 mg bid on day 1, 200 mg bid d2-d7
75398766|NCT04338282|Drug|toripalimab|240mg/d, every 3 weeks, for up to one year or until disease progression, whichever comes first
75398767|NCT04338438|Drug|Apatinib Mesylate tablets combined with S-1 capsules|Apatinib Mesylate tablets combined with S-1 capsules, p.o.
75398768|NCT04338126|Drug|Tranexamic acid|previously described
75398769|NCT04338126|Drug|Placebo oral tablet|previously described
75398770|NCT04337736|Other|Physical exercise|
75398771|NCT04337658|Drug|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
76037284|NCT04286087|Procedure|standard treatment|Participants in the control group will have standard treatment performed as per current practice,their incision will be left to close by secondary intention
75548109|NCT04198506|Other|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring -TDM) and additionally depending on TTV viral load.
75548110|NCT04198506|Other|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
75548111|NCT04198272|Behavioral|CyberRwanda|The CyberRwanda intervention consists of three primary components: 1. Guide to Teen Success: The CyberRwanda curriculum empowers youth to learn about FPRH and employment skills and to set goals for their futures through age-appropriate, interactive, digital and printed stories and activities. 2. Ask Mutoni / Ask Ntwali: The Q&A platform answers questions and provides referrals to local youth-friendly services through 'Mutoni' and 'Ntwali,' virtual peer educators who provide evidence-based, teen-friendly information and signposting to clinics. 3. Youth can directly purchase health products, including menstrual hygiene and contraceptive products (emergency contraception, condoms, and oral contraceptive pills) online and via SMS. The online and SMS clinic finder tool links youth clients to clinics for longer-acting methods. All participating pharmacies will be trained using the custom digital training game that supports them to give unbiased, nonjudgmental information and services.
75548112|NCT04196972|Other|Communication Intervention|Receive ECHO telementoring intervention
75548113|NCT04196972|Other|Questionnaire Administration|Ancillary studies
75548114|NCT04196972|Other|Waiting List|Placed on wait-list
75548115|NCT04194827|Diagnostic Test|Adalimumab serum trough concentration|Dose reduction based on adalimumab serum trough concentration
75548116|NCT04194827|Diagnostic Test|Disease activity|Dose reduction based on adalimumab diseas activity
75548117|NCT04194827|Drug|Adalimumab|Adalimumab
75871162|NCT02354638|Behavioral|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
76037285|NCT04285671|Biological|Necitumumab|Given IV
76037286|NCT04285671|Drug|Osimertinib|Given PO
76037287|NCT04285671|Other|Quality-of-Life Assessment|Ancillary studies
75398772|NCT04337658|Drug|Trastuzumab|Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
75398773|NCT04337658|Drug|Fulvestrant|500mg intramuscular injections at day 1, 15, 28 and 4 weeks thereafter
75398774|NCT04337658|Drug|Capecitabine|1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
75398775|NCT04337502|Diagnostic Test|Machine learning model|Machine learning, such as logistic regression, random forest, and deep learning
75398776|NCT04337424|Diagnostic Test|Sampling salivary|Collection of 1 to 2 ml of saliva
76037288|NCT04285671|Other|Questionnaire Administration|Ancillary studies
76037289|NCT04285671|Biological|Trastuzumab|Given IV
75398777|NCT04337190|Biological|blood sampling|blood sampling at the day of admission, day 3 and day 7
75398778|NCT04337268|Drug|Glucagon-Like Peptide 1|Intravenous infusion (1.5 pmol/kg/min) for 60 min.
75398779|NCT04337268|Drug|saline 0.9%|Intravenous infusion for 60 min.
75398780|NCT04337112|Drug|viltolarsen|Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).
75398781|NCT04336566|Dietary Supplement|Melatonin|Melatonin 5mg
75398782|NCT04336566|Dietary Supplement|Placebo|Comparable Good Neighbor Pharmacy placebo tablet
75398783|NCT04336254|Biological|allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
75398784|NCT04336254|Other|Intravenous saline injection (Placebo)|Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
75398785|NCT04336488|Drug|Matrix Metalloproteinase Inhibitors (Orochem)|topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
75398786|NCT04336488|Drug|Kenacort A,|topical application of both drugs 3 times daily for 3 weeks as an active control
75548118|NCT04177914|Procedure|Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)|Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.
75548119|NCT04177914|Device|Ventriculoperitoneal Shunt|The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
75709651|NCT00737646|Behavioral|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
75398787|NCT04336176|Device|PulseFlow DF boot|Offloading boot
75398788|NCT04336176|Device|Usual standard of care|Usual standard of care (offloading device)
75398789|NCT04336176|Device|Sham|Sham shoe (closest to barefoot or baseline pressures)
75398790|NCT04335864|Procedure|Laparoscopic salpingectomy|39 patients with hydrosalpinx will have laparoscopic salpingectomy
75398791|NCT04335864|Procedure|Hystroscopic proximal tubal occlusion|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
75398792|NCT04335786|Drug|Valsartan (Diovan)|"At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d."
75398793|NCT04335786|Drug|Placebo oral tablet|At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
75709652|NCT00880672|Drug|dutasteride|5mg, oral, daily, 2-4 weeks
75709653|NCT04064034|Other|Lateral Flow Assay (LFA)|Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
75709654|NCT00874666|Other|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
75709655|NCT00874666|Dietary Supplement|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
75709656|NCT03900546|Device|MostCare|CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason
75709657|NCT00737724|Drug|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
75709658|NCT00737724|Drug|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
75398794|NCT04335630|Diagnostic Test|Electrocardiogram, telemetry, echocardiogram, laboratory values|Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
75398795|NCT04335474|Procedure|Surgical drainage strategy|A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.
75548120|NCT04177849|Procedure|ACDF|A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
75548121|NCT04177849|Procedure|PF|A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
75548122|NCT04176523|Drug|Carglumic Acid|Maintenance therapy with carglumic acid
75548123|NCT04173442|Drug|dupilumab|Dupilumab cohort
75548124|NCT04158258|Drug|Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
76037290|NCT04275726|Device|Myval THV Series|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
76037291|NCT04275726|Device|Contemporary Valves (Sapien THV Series and Evolut THV Series)|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
75398796|NCT04335474|Procedure|Percutaneous drainage strategy|The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.
75548125|NCT04158258|Drug|Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
75548126|NCT04158258|Drug|Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
75548127|NCT04158258|Drug|Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
75548128|NCT04158258|Drug|Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
75548129|NCT04158258|Drug|Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
75548130|NCT04152603|Behavioral|BRIEF Educational Module|The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).
75548131|NCT04149288|Dietary Supplement|High-polyphenol olive oil|High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
75709659|NCT00880828|Other|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
75398797|NCT04335318|Device|AI-assisted colonoscopy|Colonoscopies performed with assistance of an AI tool that highlights the areas that are susceptible to be a polyp.
75398798|NCT04334694|Device|Atrial flow regulator (Occlutech® AFR device)|Atrial septostomy followed by implantation of AFR.
75398799|NCT04334928|Drug|Emtricitabine/tenofovir disoproxil|Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.
75398800|NCT04334928|Drug|Hydroxychloroquine|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.
75709660|NCT00880828|Other|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
75709661|NCT00880828|Drug|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
75398801|NCT04334928|Drug|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil
75398802|NCT04334928|Drug|Placebo: Hydroxychloroquine|Placebo: Tablets similar in appearance to Hydroxychloroquine
75398803|NCT04334850|Procedure|Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.
75398804|NCT04334850|Other|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
75871163|NCT02354638|Drug|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
75398805|NCT04334616|Device|Video Laryngocope|VDL used for VDL arm
75398806|NCT04334616|Device|Macintosh Conventional Laryngocope|Used for Conventional laryngocope arm
75398807|NCT04334226|Other|Interview|Interviews will explore the patient's and caregiver's experiences and perceptions of ostomy surgery prior to the Bootcamp and after the Bootcamp from a physical, psychological, social, and spiritual perspective
75398808|NCT04334382|Drug|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight < 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.
75398809|NCT04334382|Drug|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
75398810|NCT04333758|Device|Jintronix Virtual Reality Telerehabilitation System|"System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training."
75398811|NCT04333992|Drug|propofol and remifentanil|intravenous propofol and remifentanil using target-controlled infusion (TCI) devices
75398812|NCT04333992|Drug|sevoflurane and remifentanil|inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
75398813|NCT04333836|Device|Removable Clear Aligners|"Plaster dental models will be poured from the rubber base impression.~Digital dental models will be created through scanning of plaster dental models.~Planning of the aligners will be done on 3 shape clear aligner studio®.~Aligners will be fabricated on 3d printed models using vacuum formers.~Anchorage reinforcement for posterior segments by using buccal miniscrews.~Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~Patient will receive the following aligner after 2 weeks.~Follow up visits every 2 weeks until complete canine retraction."
75398814|NCT04332978|Drug|Fluticasone Propionate|
75398815|NCT04332900|Device|Elastic hip strap|The SERF Strap consist of a thin, elastic material that is secured to the proximal aspect of the leg, wraps in a spiral fashion around the thigh, and is anchored around the pelvis. The line of action of the SERF Strap pulls the hip into abdcution and external rotation.
75398816|NCT04332900|Device|Insole|Foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each that is made from a block of ethyl vinyl acetate with a thermo-moldable polymer (shore hardness of 45 A) and is manufactured through an automated computer numeric control machine (CNC routers).
75398817|NCT04333212|Device|DR. Chip HPV genotyping IVD kit|HPV typing by gene chip
75398818|NCT04332666|Drug|Angiotensin 1-7|endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
75548132|NCT04149288|Dietary Supplement|Low-polyphenol olive oil|Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
75548133|NCT04144972|Device|Medtronic Summit RC+S|The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.
75548134|NCT04126135|Drug|Cytisine|Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
75871164|NCT02354404|Biological|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
75871165|NCT02354404|Biological|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
75398819|NCT04332666|Drug|Placebos|infusion of NaCl 0.9% without diluted peptide in it
75398820|NCT04332822|Drug|R-pola-mini-CHP|"Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6"
75398821|NCT04332822|Drug|R-mini-CHOP|"Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
75398822|NCT04332510|Other|Intact formula|600 ml of infant formula with intact protein
75398823|NCT04332510|Other|Partially hydrolyzed formula|600 ml of infant formula with partially hydrolyzed protein
75398824|NCT04332510|Other|High protein formula|600 ml of infant formula with high protein level
75398825|NCT04332510|Other|Human breast milk|600 ml of breast milk, safe for human consumption
75398826|NCT04332276|Drug|A-dopamine|"During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days."
75398827|NCT04332276|Drug|optimized oral treatment|The patient will received his usual dopaminergic treatment.
75398828|NCT04332354|Other|routine care. No intervention|no intervention
76037292|NCT04267744|Other|Myia Health® remote patient monitoring unblinded treatment arm|"After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)"
76037293|NCT04241068|Drug|Aducanumab|Administered as specified in the treatment arm.
75398829|NCT04332042|Drug|Tofacitinib|Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
75398830|NCT04332120|Procedure|tubal sterilization|
75398831|NCT04341870|Drug|Sarilumab|Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
75398832|NCT04341870|Drug|Azithromycin|Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
75398833|NCT04341870|Drug|Hydroxychloroquine|Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
75398834|NCT04331808|Drug|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
75398835|NCT04331184|Procedure|RFA using combined bipolar and monopolar energy deliver|RFA technique combining bipolar mode and switching monopolar mode using dual / Twin Cooled-wet electrodes is performed on residual tumors after transarterial chemo-embolization.
75398836|NCT04330872|Drug|Enteric Coated Aspirin Tablet|Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).
75398837|NCT04330872|Drug|Plain Aspirin|Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
75398838|NCT04331028|Device|Shockwave therapy|A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
75398839|NCT04330794|Other|NMFACT|caries index
75398840|NCT04330794|Other|DMF index|caries index chart to collect data about decayed missed filled teeth
75398841|NCT04331106|Diagnostic Test|Online Questionnaire|Online Questionnaire via SoSci Survey
76037294|NCT04233216|Drug|ISL|ISL 0.75 mg capsule taken by mouth.
76037295|NCT04233216|Drug|DOR|DOR 100 mg tablet taken by mouth.
76037296|NCT04233216|Drug|DOR/ISL|100 mg DOR/0.75 mg ISL FDC taken by mouth.
75398842|NCT04330404|Behavioral|Cognitive strategy training|The Cognitive strategy training, including awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments
76037297|NCT04233216|Drug|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
76037298|NCT04233216|Drug|Placebo to DOR|Placebo tablet matched to DOR taken by mouth.
75548135|NCT04126135|Drug|Nicotine Replacement Therapy (NRT)|Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
75548136|NCT04116541|Drug|HDM201|HDM201 120mg, Every 3 weeks, Per os
75871166|NCT02354404|Biological|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
75398843|NCT04330404|Behavioral|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
75398844|NCT04330326|Drug|Metabolic Cofactor Supplementation|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
75398845|NCT04330326|Drug|Sorbitol|As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
75398846|NCT04329936|Behavioral|Retention center Geispolsheim population|All recently held individuals in the retention center can be included in the study after signing the information and consent protocol.
75398847|NCT04329858|Procedure|silver modified glass ionomer|occlusal cavity filled with silver modified
75398848|NCT04329858|Procedure|zinc modified|occlusal cavity filled with zinc modified
75398849|NCT04329858|Procedure|conventional glass ionomer|occlusal cavity filled with conventional glass ionomer
75398850|NCT04329468|Device|DS-MCE|"The subjects swallowed the MCE to investigate the esophagus repeatedly by pulling up or down the string. After completion of the esophageal examination, MCE reached the stomach and was lifted away from the posterior wall, rotated if necessary and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination, the capsule would enter the duodenum due to peristalsis when the pylorus opened. Then DS-MCE tried to inspect the duodenum repeatedly under the string and magnetic field control, including view of major papilla in the descending part of duodenum and retrograde view of pylorus in duodenal bulb with a 360-degree automatic scanning mode. After completion of the duodenum examination, the capsule started to view the small bowel."
75398851|NCT01628250|Procedure|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
75398852|NCT01628250|Procedure|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
75398853|NCT01620996|Behavioral|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
75548137|NCT04116541|Drug|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
75548138|NCT04116541|Drug|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
75548139|NCT04116541|Drug|Alectinib|Alectinib, 600mg twice daily, Per os
75548140|NCT04116541|Drug|Regorafenib|Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
75548141|NCT04116541|Drug|Trametinib|Trametinib 2 mg/day, continuous, Per os
75548142|NCT04116541|Drug|Dabrafenib|Dabrafenib 150 mg twice daily, Per os
75548143|NCT04116541|Drug|Avapritinib|300 mg/day,continuous, Per os
75548144|NCT04111835|Diagnostic Test|Offering an alternative cervical cancer screening method - hrHPV molecular testing.|"Women randomized to this screening strategy group will take a hrHPV molecular test.~hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -> colposcopy~Normal reflex LBC -> repeat LBC in 6 months~Positive - colposcopy~Negative - rescreen in 3 years~HPV-negative - rescreen in 5 years"
75871167|NCT01066052|Drug|r-hGH|Subcutaneous administration.
75548145|NCT04086823|Drug|RZL-012|Subcutaneous injection to the submental fat area
75548146|NCT04086823|Drug|Placebo|Placebo
75548147|NCT04085744|Drug|Lidocaine 10% Spray|lidocaine will be apply on the cuff
75548148|NCT04085744|Drug|Mometasone nasal spray|mometasone spray will be applied on the cuff
75548149|NCT04060693|Device|P0.5|Investigational Medical Device collecting spectral raman data from tissue.
75709662|NCT05741970|Procedure|Scaling and root planing|Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.
75871168|NCT02360254|Drug|Insulin degludec|Once daily injection of insulin degludec
76037299|NCT04218409|Drug|OxyCODONE 5 mg Oral Tablet|Oral oxycodone 5 mg orally
76037300|NCT04218409|Drug|Oxytocin nasal spray|Intranasal oxytocin administration (48 IU)
76037301|NCT04218409|Other|Placebo Oxycodone|Oxycodone 0 mg orally
76037302|NCT04218409|Other|Placebo oxytocin|Intranasal placebo administration
76037303|NCT04218409|Drug|OxyCODONE 2.5 mg Oral Tablet|Oral oxycodone 2.5 mg orally
75709663|NCT00883402|Procedure|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
76037304|NCT04217408|Device|Deep brain stimulation|Active continuous deep brain stimulation of the ventral capsule/ventral striatum
75709664|NCT00422461|Drug|placebo|placebo, oral, tablets, once daily, for 28 days
76037305|NCT04198857|Behavioral|Develop a mobile app that supports self- management and treatment for Nepalese GDM patients|We will use a user-centered design approach to develop a mobile app for GDM (GDM-DH) that matches the needs and technological sophistication of the target users. The goal of the app would be to assist patients in self management of GDM by improving their adherence to the recommended diet and physical activity regimens. The app will be used to collect information such as the carbohydrate consumption, the daily activity status and blood glucose and blood pressure measurements taken at home by the patients. The app will be set up in the phone of the participants and their data will be collected. The participants will be able to assess the usability and feasibility of the app. The app will also help clinicians by generating easily digestible visual displays of patient data and behaviors, which can aid in their clinical decision-making and counseling.
75398854|NCT01620996|Behavioral|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
75398855|NCT01620996|Behavioral|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours."
75398856|NCT00704106|Drug|Entecavir|0.5 or 1 mg dose qd
75398857|NCT05620992|Device|Echocardiography|Echocardiography 3 and 6 months post operative
75398858|NCT05620680|Biological|CD7 CAR-T cells|patient was subjected to 0.5-2×10^6 cells/kg of CD7 CAR- T
75398859|NCT05620602|Other|Remedial treatment within 3 months|"The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
75398860|NCT05620602|Other|Remedial treatment within 3 to 6 months|"The interval between the time of this treatment and the last day of the last therapy is 3-6 months.~Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
75709665|NCT00422461|Drug|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
75709666|NCT00422461|Drug|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
75709667|NCT00422461|Drug|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
75709668|NCT04346134|Procedure|mini-PNL|Percutaneous nephrolithotomy using miniature nephroscope. The procedure will be performed under general or spinal anesthesia under fluoroscopy guidance.
76037306|NCT04173507|Drug|Avelumab|Given IV
76037307|NCT04173507|Drug|Talazoparib|Given PO
76037308|NCT04173507|Drug|Talazoparib Tosylate|Given PO
76037309|NCT04165798|Diagnostic Test|Tumor Imaging|Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
75398861|NCT05620602|Other|Remedial treatment within 6 to 12 months|"The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
75398862|NCT05620602|Other|Remedial treatment after 12 months|"The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
75871169|NCT02360020|Device|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
75871170|NCT03112642|Procedure|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered.
75398863|NCT05620446|Procedure|endoscopy|the technique was done by two doctor the patients were sedated then colonoscopy was done for the patients while the patients were put in lithotomy position , we identified the site of sigmoid colon fixation by radiological colongraphy then tip of artery forceps was moved at outer skin at anterior abdominal wall at left lower quadrant to meet tip of colonscopy at multiple point where fixation was done . fixation was done by exploratory puncture of skin by scalpel about (2-3 mm puncture) at site of these points then widening the puncture by artery forceps at level of subcutaneous tissue. A 2- shot anchor device was used to fix the sigmoid colon against anterior abdominal wall. The 2-shot anchor device was passed through the puncture to be entered inside the sigmoid colon and the thread with a metal T-bar was detachd and pulled towards the anterior abdominal wall. This was repeated at multiple point of fixation .
75398864|NCT05620056|Drug|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs|medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
75398865|NCT05619978|Other|3L Therapy|Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
75398866|NCT05619978|Other|T315I|Patients with chronic myeloid leukemia with T315I mutation
75398867|NCT05619666|Procedure|Acute rehabilitation program|Patients included in the study started the rehabilitation program when they were hemodynamic stable, when it was determined that it was safe for patients. Until discharge from the hospital, a re-evaluation of neuromuscular and respiratory function was performed.
75548150|NCT04053582|Behavioral|AMT|The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 3 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).
75871171|NCT03112642|Device|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
76037310|NCT04165798|Procedure|Tumor Tissue Collection|Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
75398868|NCT05614752|Drug|Fexuprazan|Fexuclue Tablet 40mg
75548151|NCT04053582|Behavioral|Sham|The session will be done on an individual basis. Sham group will receive artificial neurofeedback while focusing on the physical sensations of the breath. The session will last one hour, including 3 sham neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with artificial neurofeedback (70s).
76037311|NCT04165798|Procedure|Blood Sample Collection|"Participants will have blood samples drawn for analysis of:~genetics~ribonucleic acid (RNA)~serum biomarker~plasma biomarker~circulating tumor DNA (ctDNA)"
76037312|NCT04157348|Biological|Benralizumab|30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)
76037313|NCT04157348|Biological|Mepolizumab|3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)
75398869|NCT05578638|Combination Product|Aloe Vera rosemary tropical application|10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
75398870|NCT05578638|Combination Product|aloevera tropical application|10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
75398871|NCT05578638|Combination Product|rosemary tropicalapplication|10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
75398872|NCT05345106|Procedure|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
75548152|NCT04030143|Drug|Aripiprazole|Administered as an intramuscular (IM) depot injection.
75709669|NCT04346134|Procedure|SWL|Extracorporal shockwave lithotripsy using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
76037314|NCT04157348|Biological|Placebo to Mepolizumab|Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)
76037315|NCT04157348|Biological|Placebo to Benralizumab|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
76037316|NCT04124393|Procedure|Colon Polypectomy|Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.
76037317|NCT04121260|Drug|Daratumumab|Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
76037318|NCT04118660|Other|Tissue Banking|Blood, tissue, and fluid collection
76037319|NCT04084249|Diagnostic Test|ctDNA-analysis|Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
76037320|NCT04084249|Other|Intensified Follow-up Schedule|PET/CT-scans every 3. month
76037321|NCT04082689|Behavioral|Assisted Infant Toilet Training|"The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty."
76037322|NCT04077411|Other|Observational|This is an observational study with no interventions.
76037323|NCT04075864|Behavioral|Behavioral Counseling and Exercise|exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
76037324|NCT04074330|Drug|TAK-981|TAK-981 intravenous infusion.
76037325|NCT04074330|Drug|Rituximab|Rituximab intravenous infusion.
75398873|NCT05285826|Biological|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection
75398874|NCT05285826|Other|Placebo|Sterile saline solution administered as a 0.5 mL IM injection
75398875|NCT05281536|Other|Ppostural change from 45° to 10° in supine position|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
75398876|NCT05278884|Behavioral|Advanced Cardiac Life Support Training|Advanced Cardiovascular Life Support (ACLS) is a resuscitation course to teach recognition and treatment of cardiopulmonary arrest in patients.
75709670|NCT00712920|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
75709671|NCT00712920|Drug|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
75709672|NCT00712920|Drug|Placebo|Placebo
76037326|NCT04047303|Drug|CC-90010|CC-90010
76037327|NCT04035226|Other|No intervention|No intervention will be administered as a part of this study.
76037328|NCT04011852|Device|Electrical Impedance tomography|Monitoring with Electrical impedance tomography during spontaneous breathing trials on T-piece in children
75398877|NCT05278884|Behavioral|Vital Anesthesia Simulation Training|The Vital Anesthesia Simulation Training (VAST) Course focuses on core clinical practices and non-technical skills needed to respond to the most common urgent and emergent clinical challenges found in hospitals in resource-limited settings like Rwanda.
75548153|NCT04030143|Drug|Aripiprazole|Administered as an IM depot injection.
75709673|NCT01037647|Other|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
75709674|NCT00874744|Drug|Bevacizumab|1.25mg bevacizumab (0.05ml)
75709675|NCT00874744|Drug|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
75709676|NCT03993769|Other|A19010-F|A snus product
75709677|NCT03993769|Other|B19010-F|A snus product
75709678|NCT04038658|Behavioral|Move-It|
76037329|NCT04007874|Drug|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
76037330|NCT04007874|Drug|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
76037331|NCT04001946|Device|Button Huggie|low profile, external securement device for G-buttons
76037332|NCT03978624|Drug|Pembrolizumab|200 mg IV on day 1 and day 22
75398878|NCT05136690|Drug|Nicotine patch|Nicotine 21 mg transdermal nicotine patch.
75398879|NCT05136690|Drug|MK-4334|MK-4334 250 mg capsule taken by mouth.
75398880|NCT05136690|Drug|Placebo patch|Placebo patch.
75398881|NCT05136690|Drug|Placebo capsule|Placebo capsule taken by mouth.
75548154|NCT04025814|Device|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
75548155|NCT04025814|Behavioral|Behavioral Parent Training (CLS Parent Group)|Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
75709679|NCT05736744|Drug|MgSO4|The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
75709680|NCT05736744|Drug|Rocuronium Bromide|Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval
75709681|NCT05736744|Drug|Cis-Atracurium|Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
75709682|NCT04270084|Behavioral|Alive-Family|All participants receive lifestyle modification through use of m-health app
75709683|NCT00920868|Drug|dasatinib|dasatinib at 50 mg PO BID)
75709684|NCT00920868|Drug|bevacizumab|7.5 mg/kg IV day 1
75709685|NCT00920868|Drug|Oxaliplatin|130 mg/m2 IV day 1
75709686|NCT00920868|Drug|Capecitabine|850 mg/m2 PO BID on days 1-14
75709687|NCT00880984|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
75709688|NCT00874900|Other|Educational game|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department."
75709689|NCT00874900|Other|Educational game + motivational interview|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques."
75709690|NCT00874900|Other|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
75709691|NCT00881062|Drug|Proellex|A single oral dose administered after at least a 10 hour fast
75709692|NCT05741814|Drug|Propofol|Gynecologist guided individualised propofol only sedation
75871172|NCT01377324|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with ~200MBq 18F-FES
75871173|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1mg, tid
76037333|NCT03978624|Drug|Entinostat|5 mg given orally on day 1, day 8 and day 15
76037334|NCT03971474|Drug|Docetaxel|Given IV
76037335|NCT03971474|Drug|Gemcitabine|Given IV
76037336|NCT03971474|Drug|Gemcitabine Hydrochloride|Given IV
76037337|NCT03971474|Biological|Pembrolizumab|Given IV
76037338|NCT03971474|Drug|Pemetrexed|Given IV
76037339|NCT03971474|Drug|Pemetrexed Disodium|Given IV
76037340|NCT03971474|Biological|Ramucirumab|Given IV
76037341|NCT03954314|Drug|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
76037342|NCT03931460|Drug|Medical Abortion|Medical Abortion
76037343|NCT03930992|Drug|Colaren in HIV positive|1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
76037344|NCT03930992|Drug|standard treatment in HIV positive|2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
76037345|NCT03930992|Drug|Colaren in HIV negative|3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
76037346|NCT03930992|Drug|standard treatment in HIV negative|4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
75398882|NCT05135754|Device|Heylo|Test of the supporting product (test product) for a 12 weeks period. No measurement will be conducted. All endpoints are captured via surveys send to the subjects every 14 days.
75398883|NCT05064462|Other|Collection of EDTA blood sample (5 to 7 ml)|"For all the patients included in the study, the samples to measure the viral load will be taken during the transplantation, then at each of the consultations planned as part of the usual care during the first year post-transplant (at minimum once and maximum twice a month).~These samples will be taken at the same time as those taken as part of standard care."
75398884|NCT05035680|Biological|Unadjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection
75398885|NCT05035680|Biological|SWE adjuvant mixed with unadjuvanted seasonal influenza vaccine shortly before dosing (SWE + QIV)|Single 0.8 mL IM injection
75398886|NCT05035680|Biological|MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
75398887|NCT04902066|Other|Cognitive Behavioural Virtual Reality Therapy.|Cognitive Behavioural Therapy augmented with Virtual Reality.
75398888|NCT04902066|Other|Traditional Cognitive Behavioural Therapy|Traditional Cognitive Behavioural Therapy for psychosis.
76037347|NCT03927027|Drug|Isosulfan Blue|Given SC
76037348|NCT03927027|Procedure|Axillary Lymph Node Dissection|Undergo ALND
76037349|NCT03927027|Procedure|Mapping|Undergo ARM
76037350|NCT03927027|Other|Quality-of-Life Assessment|Ancillary studies
76037351|NCT03927027|Other|Questionnaire Administration|Ancillary studies
75398889|NCT04578678|Other|Steering|Fine tuning of the STN-DBS settings
75398890|NCT04505358|Drug|PU-AD|active vs placebo
75398891|NCT04505358|Drug|Placebo|active vs placebo
75398892|NCT04133142|Procedure|peripheral nerve block, inter fascial nerve block|regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block
75398893|NCT03956082|Device|Ultravision™ Visual Field Clearing System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
75398894|NCT03956082|Device|Ultravision Ionwand™|The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
75398895|NCT03538314|Drug|UV1|UV1 (300 microgram)
75398896|NCT03538314|Drug|GM-CSF|GM-CSF (37,5 or 75 microgram)
75398897|NCT03233802|Behavioral|Individualized Assess & Treatment (IATP)|See previous description
75398898|NCT03233802|Behavioral|Packaged Cognitive-Behavioral (PCBT)|See previous description
75398899|NCT03233802|Behavioral|Case Management (CaseM)|See previous description
75398900|NCT03063450|Drug|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
75398901|NCT03063450|Other|Placebo|Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
75398902|NCT02882646|Device|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
75398903|NCT02788344|Other|Daily practice care for patients with suspected of STEMI|N/A: Practice care evaluation in real-life setting
75398904|NCT01436292|Drug|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; < 10 gr/L: 150 g of 5% HAS."
75398905|NCT01326000|Drug|FOLFIRI|standard iv chemotherapy
75398906|NCT01326000|Drug|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
75398907|NCT01326000|Drug|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
75398908|NCT00807456|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
76037352|NCT03926130|Drug|Mirikizumab|Administered IV
76037353|NCT03926130|Drug|Mirikizumab|Administered SC
76037354|NCT03926130|Drug|Ustekinumab|Administered IV
76037355|NCT03926130|Drug|Ustekinumab|Administered SC
76037356|NCT03926130|Drug|Placebo|Administered IV
76037357|NCT03926130|Drug|Placebo|Administered SC
76037358|NCT03919526|Biological|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
76037359|NCT03919526|Drug|Fludarabine|30mg/m2/d
76037360|NCT03919526|Drug|Cyclophosphamide|300mg/m2/d
76037361|NCT03905798|Drug|Lorazepam|"The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses."
75398909|NCT03035214|Drug|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
75398910|NCT03035370|Biological|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
75398911|NCT03035370|Biological|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
75398912|NCT03035370|Biological|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
75398913|NCT03035370|Biological|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
76037362|NCT03901079|Other|single-arm study|single-arm study
75398914|NCT03035058|Drug|Vedolizumab|Vedolizumab intravenous infusion
75398915|NCT03035058|Drug|Placebo|Placebo
75398916|NCT03034824|Procedure|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
75398917|NCT03034824|Procedure|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
75398918|NCT03034824|Procedure|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
75398919|NCT03034746|Other|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
75398920|NCT03034746|Other|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
75398921|NCT03034980|Other|Training intensity (workload) during ergospirometry|The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
75398922|NCT03034590|Other|questionnaire|
75398923|NCT03034434|Device|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
75398924|NCT03034668|Dietary Supplement|CS16-003 Full dose|350 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts
75398925|NCT03034668|Dietary Supplement|CS16-003 Half dose|175 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts + maltodextrin 175 mg
75398926|NCT03034668|Dietary Supplement|Placebo|Maltodextrin: 350 mg
75398927|NCT03034278|Other|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
75398928|NCT03033966|Device|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
75398929|NCT03033810|Device|Fractional flow reserve and instantaneous wave-free ratio|"To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~The development of software for the automatic detection of the lowest point of microvascular resistance."
75398930|NCT03033654|Other|Sunscreen, Actinica|Two Consecutive Sunscreen Applications
75398931|NCT03033732|Drug|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
75548156|NCT04005547|Behavioral|Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder|Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication *Bring your Trusted Adult* Session 6 - Let's Talk About Growing Up
75871174|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
76037363|NCT03881696|Drug|Omalizumab|Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
76037364|NCT03881696|Drug|Placebo for Omalizumab|Placebo contains the same ingredients as the omalizumab formulation, excluding omalizumab. Placebo will be supplied in pre-filled syringes (PFS). PFS of placebo will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
75548157|NCT04003428|Device|High Intensity Focused Ultrasound|HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
75709693|NCT04721626|Drug|Chlorhexidine Gluconate|"Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)"
75398932|NCT03033732|Drug|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
75398933|NCT03033498|Drug|ABBV-951|ABBV-951 administered by subcutaneous infusion.
75398934|NCT03033888|Behavioral|Health-Literacy Focused Education Session|
75398935|NCT03033264|Drug|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
75398936|NCT03033264|Device|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
75398937|NCT03033030|Diagnostic Test|Ultrasound|Ultrasound examination
75398938|NCT03032874|Procedure|Colonoscopy|They all had screening colonoscopy
75398939|NCT03032952|Other|"Feel Stress Free mobile application"|This online and mobile application uses relaxation techniques, thought challenging, mini-games and mood tracking to help reduce feelings of stress, anxiety and depression.
75398940|NCT03032796|Behavioral|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
75398941|NCT03032796|Behavioral|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
75871175|NCT01569516|Drug|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
75398942|NCT03032796|Behavioral|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
75398943|NCT03032796|Behavioral|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
75398944|NCT03032562|Diagnostic Test|Multimodal measurement of respiratory muscle function and strength|Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound
75398945|NCT03032718|Behavioral|Whole-body vibration training|Whole-body vibration exercise
75398946|NCT03032094|Procedure|connective tissue graft|palatal connective tissue graft to attain root coverage
75398947|NCT03031860|Other|Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score
75398948|NCT03031704|Procedure|Endoscopic mucosectomy|Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
75398949|NCT03031548|Device|Point-of-care ultrasound exam|No intervention
75398950|NCT03031548|Radiation|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
75398951|NCT03031314|Device|barbed suture|
75398952|NCT03031314|Device|standard suture|
75398953|NCT03031158|Behavioral|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
75398954|NCT03031158|Behavioral|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
75398955|NCT03031470|Drug|Reparixin|Reparixin 168 hrs continuous infusion
75398956|NCT03031470|Other|Standard care procedures|Standard procedures for administration of Immunosuppressive and support post transplant therapies
75398957|NCT03031080|Device|Thermoplastic Hand Splint|Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
76037365|NCT03881696|Drug|Multi-Allergen Oral Immunotherapy|"Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours).~A prescription for each participant for the appropriate dose of each of the allergens will be prepared. The pharmacist will compound the appropriate allergens and dispense the Multi-allergen OIT dose in a blinded (masked) fashion. The Clinical Research Unit (CRU) staff will administer food flour to the participant orally in an age-appropriate food vehicle (e.g., applesauce, pudding, etc.). Dosage will be administered according to the study protocol."
76037366|NCT03881696|Drug|Placebo for Multi-Allergen Oral Immunotherapy|Oat flour will be used for placebo for Multi-allergen OIT. Route: by mouth/oral. Dosage will be administered according to the study protocol.
76037367|NCT03881696|Other|Double-Blind Placebo-Controlled Food Challenge Based Treatment|"Each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods. A treatment plan will include instructions for one of the following:~Long-term follow-up with dietary consumption of a food; or~Long-term follow-up with avoidance of a food; or~Rescue OIT for a food. The treatment plan for each food may change depending on a participant's response to prescribed treatment over time."
76037368|NCT03845296|Drug|Rucaparib|Given PO
76037369|NCT03841448|Drug|Placebo|Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
76037370|NCT03841448|Drug|Cemdisiran|Cemdisiran was administered by SC injection.
75398958|NCT03031002|Behavioral|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
75398959|NCT03030768|Drug|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
75398960|NCT03030768|Behavioral|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
75398961|NCT03030846|Other|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
76037371|NCT03819296|Other|Best Practice|Receive standard of care
76037372|NCT03819296|Other|Biospecimen Collection|Undergo collection of stool, blood, and tissue samples
75398962|NCT03030846|Other|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
75398963|NCT03030690|Other|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
75398964|NCT03030690|Other|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
75548158|NCT03994874|Drug|PolyCore (Polydextrin, L-Carnitine, D-xylitol)|A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
75548159|NCT03993873|Drug|elzovantinib (TPX-0022)|Oral elzovantinib (TPX-0022) capsules
75709694|NCT04721626|Drug|Povidone-iodine|"Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine."
75871176|NCT01569516|Drug|Placebo|0mg, tid
76037373|NCT03819296|Procedure|Endoscopic Procedure|Undergo endoscopy
76037374|NCT03819296|Procedure|Fecal Microbiota Transplantation|Undergo FMT
75398965|NCT03030690|Other|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
75398966|NCT03030456|Device|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
75398967|NCT03031392|Diagnostic Test|Sensitivity test|Routine clinical and radiographic examination
75398968|NCT03031236|Behavioral|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
75398969|NCT03030144|Other|Evidence based nursing recommendations|The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
75398970|NCT03030300|Drug|Novolin 30R;Pioglitazone;Metformin|"Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
75548160|NCT03973489|Behavioral|Magnetic resonance imaging (MRI)|On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
75548161|NCT03973489|Drug|Methamphetamine Hydrochloride Tablets|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
75548162|NCT03973489|Drug|Placebo oral tablet|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
76037375|NCT03819296|Biological|Infliximab|Given intravenously (IV)
76037376|NCT03819296|Other|Laboratory Biomarker Analysis|Ancillary studies
75398971|NCT03029442|Drug|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
75548163|NCT03966612|Other|Questionnaires|"Questionnaires about:~Socio-professional situation~Lifestyle~Health~NME 1~specific breast cancer survey~Imaging"
75548164|NCT03961919|Drug|Fludarabine|Fludarabine i.v. 30 mg/m²/d day -6 to -2
75548165|NCT03961919|Drug|ARA-C|Cytarabine i.v. 2 g/m²/d day -6 to -2
75548166|NCT03961919|Drug|Treosulfan|Treosulfan i.v. 10 g/m²/d day -6 to -4
76037377|NCT03819296|Drug|Prednisone|Given orally
75398972|NCT03029442|Other|Placebo (normal saline)|Identical Denosumab volume of normal saline
75398973|NCT03029286|Behavioral|Usual Care Arm|Health information provided by the American Cancer Society Website
75548167|NCT03961919|Procedure|Peripheral Blood Stem Cell Transplant|"Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3"
75709695|NCT04721626|Drug|Tetracycline Ointment|Postoperative: ~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
75871177|NCT02359942|Drug|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
75871178|NCT02359708|Procedure|Surgical hand disinfection.|Bacterial recolonization
76037378|NCT03819296|Biological|Vedolizumab|Given IV
76037379|NCT03814850|Device|Standard Manual Aneroid Sphygmomanometer|Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
76037380|NCT03809520|Radiation|pedCAT|Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.
76037381|NCT03805581|Drug|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
76037382|NCT03790943|Diagnostic Test|cardiac assessment|Personal history, physical examination including anthropometry with hip/waist-ratio, electrocardiogram, echocardiography, 1-minute-sit-to-stand test, questionnaires on health-related quality of life (SF-36), diet, physical activity, and fatigue
76037383|NCT03769766|Drug|Curcumin|Take medication one 500 mg pill of BCM-95 taken twice daily
76037384|NCT03769766|Drug|Placebo|Take medication one 500mg pill twice daily
75398974|NCT03029286|Behavioral|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
75398975|NCT03027492|Other|Gluten free diet|The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
75398976|NCT03025620|Dietary Supplement|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
76037385|NCT03755167|Drug|IPL344|IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
75398977|NCT03025620|Dietary Supplement|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
75398978|NCT03024372|Device|AV Fistula creation with sutures|End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
75398979|NCT03024372|Device|AV Fistula creation with clips|End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
75398980|NCT03023514|Dietary Supplement|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
75398981|NCT03023514|Drug|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
75398982|NCT03022812|Other|Neck-specific exercise|Neck-specific exercise
75398983|NCT03022266|Behavioral|Financial Incentive and Mobile Phone App|Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
75398984|NCT03021252|Device|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
75398985|NCT03021252|Device|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
75398986|NCT03020784|Drug|Placebo|Placebo
75398987|NCT03020784|Drug|PF-06818883|Treatment
75398988|NCT03019926|Biological|Hydroxychloroquine dosage|Blood sample from a 6 ml tube, performed in the common practice.
75398989|NCT03019848|Dietary Supplement|Curcumin|
75398990|NCT03019848|Other|Placebo|
75398991|NCT03019770|Behavioral|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
75398992|NCT03019614|Drug|Hydrocortisone|Generic hydrocortisone
75398993|NCT03019614|Drug|Chronocort|Modified formulation of hydrocortisone
75398994|NCT03019380|Device|removing cerumen from external ear (Wondertip)|The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
75398995|NCT03019302|Device|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
75548168|NCT03955068|Other|Strict Classic Ketogenic Diet|Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
75548169|NCT03950635|Dietary Supplement|Dietary Intervention|Consume whole-foods, fiber-rich diet
75398996|NCT03019224|Procedure|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
75398997|NCT03019224|Procedure|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.~The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
75398998|NCT03019224|Procedure|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
75398999|NCT03019224|Procedure|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
75548170|NCT03950635|Dietary Supplement|Dietary Intervention|Consume high fat, low carbohydrate (ketogenic) diet
75548171|NCT03950635|Other|Questionnaire Administration|Ancillary studies
75548172|NCT03947385|Drug|IDE196|IDE196 dosed orally, twice daily for each 28-day cycle
75548173|NCT03947385|Drug|Binimetinib|Binimetinib dosed orally, twice daily for each 28-day cycle
75548174|NCT03947385|Drug|Crizotinib|Crizotinib dosed orally, twice daily for each 28-day cycle
75548175|NCT03942328|Biological|Atezolizumab|Given IV
76037386|NCT03746873|Behavioral|COPD Web|"The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52)."
75548176|NCT03942328|Biological|Bevacizumab|Given IV
75399000|NCT03019224|Procedure|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
75399001|NCT03019224|Drug|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
75548177|NCT03942328|Radiation|External Beam Radiation Therapy|Undergo high-dose EBRT
75548178|NCT03942328|Procedure|Pheresis|Undergo apheresis
75548179|NCT03942328|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
75548180|NCT03942328|Biological|Therapeutic Autologous Dendritic Cells|Given IT
75709696|NCT04064892|Behavioral|Exercise Intervention|The intervention will use peer mentors, motivational interviewing, and technology (Fitbit, Fitbit Coach App, & Fitbit message board) to support behavior change. All participants will receive phone or video calls from their peer mentors every other week, and interact with their peer mentor and other participants through a private Fitbit message board at least weekly. Peer mentors will use Fitbit data to identify participants who need additional support to increase their activity.
75399002|NCT03019224|Procedure|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
75399003|NCT03019146|Other|HIIT|
75399004|NCT03019146|Other|HOLD|
75399005|NCT03019146|Other|HUG|
75709697|NCT00881140|Drug|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
75709698|NCT05741736|Behavioral|five-days small group-based lifestyle modification program|healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
75871179|NCT05461248|Procedure|stoma drainage reinfusion|1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
75871180|NCT05461248|Procedure|Standard of Care - No Return of Stoma Drain|No Return of Stoma Drain
75871181|NCT02359630|Device|EasyTube|Insertion for ventilation
75399006|NCT03018990|Other|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
75399007|NCT03018600|Behavioral|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
75399008|NCT03018522|Other|Postoperative cognitive dysfunction|Neuropsychological tests of all patients will conduct on the one day prior to surgery, the 7th day after surgery, and the 3rd month after surgery
75399009|NCT03018756|Drug|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
75399010|NCT03018756|Drug|Placebo|0.9% saline solution will be inhaled via nebulizer
75399011|NCT03018444|Drug|Atorvastatin|Atorvastatin tablet
75399012|NCT03018444|Other|Placebo|Placebo tablet
75399013|NCT03018210|Procedure|Surgical repair of the rotator cuff|
75399014|NCT03018132|Other|mental health screening, education and referral program|"I. Psychosocial assessments:~Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.~Exercise, smoking & substance use, sleep and nutrition.~II. If women are above cutoff values the SCID will be conducted.~III. Education and referral information via Maternal Mental Health NOW:~All receive a brochure entitled, Speak Up When You Are Down~If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID~Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.~IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral."
75399015|NCT03018054|Drug|E6007|once daily administration
75871182|NCT02359630|Device|Endotracheal tube|Insertion for ventilation
75871183|NCT02354560|Drug|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
75871184|NCT01378884|Drug|Domperidone|Patient to receive treatment with Domperidone
75399016|NCT03018054|Drug|Placebo|once daily administration
75871185|NCT05457504|Behavioral|Remote blood pressure monitoring|Participants assigned to this arm will participate in the experimental intervention
75399017|NCT03017664|Other|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
75399018|NCT03017664|Other|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
75399019|NCT03017196|Other|My Life, My Healthcare Discussion Aid|The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
75399020|NCT03017430|Drug|Pregabalin|Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
75399021|NCT03017430|Drug|Clonidine|Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
75399022|NCT03017430|Drug|Doxylamin|
75399023|NCT03017430|Drug|Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)|
75399024|NCT03017352|Drug|Exenatide|
75399025|NCT03017352|Drug|Placebos|
75399026|NCT03016884|Biological|Zostavax vaccine|After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
75399027|NCT03016962|Device|cap-assisted colonoscopy|cap-assisted colonoscopy
75399028|NCT03016962|Device|Standard colonoscopy|Standard colonoscopy
75399029|NCT03017274|Other|Abdominal ultrasound examination|All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
75399030|NCT03016572|Behavioral|Standard of Care|Follow-Up Calls, Questionnaires
75399031|NCT03016572|Behavioral|Crisis Intervention|Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
75399032|NCT03016572|Behavioral|Wraparound Services|Tapestry will be assigning case management services for participants randomized into the third arm of the study.
75399033|NCT03016728|Behavioral|Physical Activity|Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
75399034|NCT03016806|Radiation|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
75399035|NCT03016806|Radiation|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
75399036|NCT03016806|Drug|Cyclophosphamide|50 mg/kg or 60 mg/kg
75871186|NCT05457504|Behavioral|Usual Care|Participants assigned to this arm will participate in a placebo intervention
75399037|NCT03016806|Drug|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
75399038|NCT03016806|Procedure|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
75399039|NCT03016806|Drug|Busulfan|0.8 mg/kg x 16 doses
75399040|NCT03016806|Drug|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
75399041|NCT03016806|Drug|Melphalan|140 mg/m2
75399042|NCT03016650|Drug|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
75399043|NCT03016650|Drug|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
75399044|NCT03016494|Drug|Co-administration of DWC20155 and DWC20156|
75399045|NCT03016494|Drug|DWJ1386 Tab.|
75399046|NCT03016260|Biological|Infliximab|Anti-TNF alpha originator
75399047|NCT03016260|Biological|Adalimumab|Anti-TNF alpha originator
75399048|NCT03016260|Biological|Etanercept|Anti-TNF alpha originator
75399049|NCT03016260|Biological|Golimumab|Anti-TNF alpha originator
75399050|NCT03016260|Biological|Certolizumab Pegol|Anti-TNF alpha originator
76037387|NCT03737318|Behavioral|Biofeedback-ultrasound|In ultrasound biofeedback, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
76037388|NCT03737318|Behavioral|Biofeedback--visual-acoustic|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
75399051|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
75399052|NCT03016260|Biological|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
75399053|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
75399054|NCT03016182|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
75399055|NCT03016182|Procedure|Control|Control group witnout remote ischemic preconditioning
75399056|NCT03016026|Procedure|ERAS|Undergo an ERAS program
75399057|NCT03015870|Behavioral|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
75399058|NCT03015870|Behavioral|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
75399059|NCT03015714|Other|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
75399060|NCT03015714|Other|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
75399061|NCT03015948|Drug|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
75399062|NCT03015948|Drug|Placebo|a single dose of placebo (n=2) for each dose cohort .
75548181|NCT03934931|Other|Streamlined weekly DOT visits|Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects
75871187|NCT02354326|Radiation|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
75709699|NCT00883636|Other|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
75709700|NCT00883636|Other|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
75399063|NCT03015480|Behavioral|Remote counseling|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
75399064|NCT03015636|Behavioral|Adjusted CBT-i for ADHD|This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
75399065|NCT03015636|Other|Treatment as Usual|Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
75399066|NCT03015246|Drug|Extended release morphine|Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.
75399067|NCT03015246|Drug|Buprenorphine/Naloxone low dose|Buprenorphine/Naloxone dose of 1.4/0.36 mg/day
75399068|NCT03015246|Drug|Buprenorphine/Naloxone moderate dose|Buprenorphine/Naloxone dose of 4.2/1.08 mg/day
75399069|NCT03015246|Drug|Buprenorphine/Naloxone high dose|Buprenorphine/Naloxone dose of 12.8/3.16 mg/day
75399070|NCT03015246|Drug|Active stressor|Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
75399071|NCT03015246|Drug|Placebo stressor|Lactose
75709701|NCT00883636|Other|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
75709702|NCT00883714|Other|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
75709703|NCT00883714|Other|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
75399072|NCT03014856|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
75399073|NCT03015168|Radiation|capecitabine and concurrent intensity modulated radiotherapy|patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
75548182|NCT03934931|Other|Weekly DOT visit reminders|Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits
75548183|NCT03934931|Other|Cost reimbursement DOT|Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)
75548184|NCT03934931|Other|99DOTS|99DOTS-based digital adherence technology to monitor and promote adherence
75548185|NCT03934931|Other|Weekly SAT dosing reminders/check-ins|Weekly SMS or IVR phone call dosing reminder/check-in for side effects
75709704|NCT05733078|Drug|Vitamin C|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
75871188|NCT02354326|Radiation|computed tomography|Undergo CT without VNC
75871189|NCT02039050|Drug|Tiotropium|
75871190|NCT02039050|Drug|Aclidinium|
75871191|NCT05764200|Dietary Supplement|Two day supplementation of a complex fiber mixture|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
75399074|NCT03015012|Genetic|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
75709705|NCT05733078|Drug|Oral Rehydration Salt Formulations|The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
76037389|NCT03737318|Behavioral|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
76037390|NCT03735238|Other|SMILE Computerized Decision-Aid|SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
75399075|NCT03015012|Other|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
75399076|NCT03014544|Device|Computer- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.
75399077|NCT03014544|Device|Examiner- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.
75399078|NCT03014778|Drug|The Chlorhexidine gluconate 0.05%|Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
75399079|NCT03014778|Drug|10% Povidone iodine|Washing vagina pre- operatively with 10% Povidone iodine
75871192|NCT05764200|Dietary Supplement|Placebo supplementation|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
76037391|NCT03728088|Other|Rating scales concerning non-technical attributes|
75709706|NCT00883792|Procedure|Colonoscopy|Once-only colonoscopy screening
75399080|NCT03014466|Behavioral|Use of Video Projector|Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia
75709707|NCT00874978|Drug|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
76037392|NCT03725956|Procedure|Endoscopic sinus surgery|"Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice"
76037393|NCT03715933|Drug|INBRX-109|Tetravalent DR5 Agonist Antibody
76037394|NCT03715933|Drug|Carboplatin|Chemotherapy
76037395|NCT03715933|Drug|Cisplatin|Chemotherapy
75399081|NCT03014466|Behavioral|Use of Video Tablet|7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
75399082|NCT03014310|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
75399083|NCT03014310|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
75399084|NCT03014310|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
75399085|NCT03014154|Other|Training|
76037396|NCT03715933|Drug|Pemetrexed|Chemotherapy
76037397|NCT03715933|Drug|5-fluorouracil|Chemotherapy
76037398|NCT03715933|Drug|Irinotecan|Chemotherapy
76037399|NCT03715933|Drug|Temozolomide|Chemotherapy
75709708|NCT04063254|Radiation|Stereotactic Radiotherapy|"High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc)."
75399086|NCT03014232|Procedure|SLED-f with HCO dialyzer|Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
75399087|NCT03014232|Procedure|SLED-f with HF dialyzer|Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
75709709|NCT00737880|Other|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
75709710|NCT05728632|Drug|Nebivolol|Nebivolol, capsule, 5 mg once daily, for 12 months
75709711|NCT05728632|Drug|Placebo|Placebo, capsule, once daily, for 12 months
75709712|NCT04180540|Device|Percutaneous Closure|The PerClose Proglide system will be used to deliver a suture to close the venous puncture following completion of ablation for treatment of atrial fibrillation.
75871193|NCT02354248|Procedure|Triple stimulation technique|Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
75399088|NCT03014388|Other|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
75399089|NCT03014388|Other|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
75399090|NCT03014076|Drug|GP2 peptide + GM-CSF vaccine plus trastuzumab|HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
75399091|NCT03014076|Drug|Trastuzumab|HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
75399092|NCT03013842|Device|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
75399093|NCT03013686|Procedure|Interval appendectomy|Laparoscopic appendectomy
75709713|NCT04180540|Other|Manual Compression|"Manual compression is the standard method of attaining hemostasis following ablation for treatment of atrial fibrillation. Manual compression may be performed with or without figure of eight suture for hemostasis at the discretion of the treating physician)."
75709714|NCT05741580|Procedure|Evolution of symptoms|percentage of patients with improvement in their symptoms
75709715|NCT05577936|Device|XPERIENCE Advanced Surgical Irrigation|A clear, colorless, aqueous solution that is indicated for use in the cleansing and removal of debris, including microorganisms, from wounds. Soak for 3 minutes for a total volume of 1L
75709716|NCT05577936|Other|Standard of Care Irrigation|17.5 mL povidone-iodine with 500 mL normal saline: solution (0.35%) for 3 minutes for a total volume of 1L (including a normal saline rinse)
75709717|NCT00612586|Drug|Enzastaurin|1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease
75871194|NCT02354170|Drug|Mifepristone|
75871195|NCT02354170|Drug|Placebo|
76037400|NCT03713580|Drug|Venetoclax|"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."
75399094|NCT03013686|Procedure|Follow-up with MRI|Abdominal MRI
75709718|NCT00612586|Drug|Placebo|oral, daily (up to 1 yr or until progressive disease)
75709719|NCT00612586|Drug|Leucovorin (LV)|400 milligram per meter squared (mg/m^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
75709720|NCT00612586|Drug|5-fluorouracil (5-FU)|400 mg/m^2 bolus then 2400 mg/m^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
75709721|NCT00612586|Drug|Bevacizumab (Bev)|5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
76037401|NCT03712657|Combination Product|ERAS|"preoperative pain control;~avoiding application of ureter;~avoiding application of gastric tube;~avoiding application of irrigation;~avoiding application of drainage;~early exercising postoperatively;~early oral feeding postoperatively;~early discharging."
75399095|NCT03013764|Behavioral|normal protein diet|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
75399096|NCT03013764|Behavioral|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
75399097|NCT03013530|Procedure|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
75399098|NCT03013296|Other|GIP-A|GIP-A
75399099|NCT03013296|Other|Placebo|Placebo
75399100|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Exendin[9-39]
75399101|NCT03013296|Other|GIP-A + Exendin[9-39]|GIP-A + Exendin[9-39]
75399102|NCT03013452|Device|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
75399103|NCT03013452|Behavioral|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
75399104|NCT03013608|Procedure|Simple relocation of the nail plate in nailbed injuries in paediatric population|Repositioning the nail bed without sutures
75399105|NCT03013140|Drug|Fluid therapy|"Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV<5%"
75399106|NCT03013140|Procedure|Spinal anaesthesia|Inject marcaine and fentanyl to CSF for anaesthesia
75399107|NCT03012906|Other|the prevalence of ischemic events|
75399108|NCT03012516|Behavioral|PAP-treatment by physiotherapist|
75399109|NCT03012516|Behavioral|Ordinary PAP-treatment at the health care center|
75399110|NCT03012750|Drug|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
75399111|NCT03012204|Device|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
75399112|NCT03012204|Device|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
75399113|NCT03012204|Device|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
75399114|NCT03012204|Device|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
75399115|NCT03012438|Device|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
75399116|NCT03012048|Device|Silver-impregnated ceramic tablet|"A silver-impregnated ceramic disk used for drinking water treatment that was developed by engineers at the University of Virginia. When the ceramic disk is placed in a household water storage container, silver diffuses through the porous ceramic into the water at a release rate that is effective for continual disinfection of waterborne pathogens while remaining below the silver drinking water standard. The disk is effective for daily treatment of 10 to 15 liters for at least six months.~This intervention was removed from the study in July 2017 (approximately at 1 year of follow-up)."
75399117|NCT03012048|Device|Silver-impregnated ceramic water filter|"Silver-impregnated ceramic water filter are well-developed, tested, and widely-used devices. In addition to mechanically removing pathogens, the filter is treated with silver to reduce live pathogens that pass through the filter and to provide residual disinfectant to reduce risk of recontamination after treatment.~This intervention was replaced with ceramic filters without silver in Dec 2017 (approximately at 1.5 years of follow-up)."
75399118|NCT03012048|Device|Safe-storage water container|The safe-storage water containers used in this study are plastic buckets with a spigot, purchased locally.
75399119|NCT03012126|Behavioral|Healthy Weight Clinic|
75399120|NCT03012126|Behavioral|Healthy Weight and Your Child|
75399121|NCT03011970|Drug|Oxytocin|
75399122|NCT03011970|Drug|Placebo|
75399123|NCT03011736|Other|Laboratory Biomarker Analysis|Correlative studies
75399124|NCT03011736|Procedure|Parathyroidectomy|Undergo parathyroidectomy
75399125|NCT03011658|Procedure|venepuncture|for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
75399126|NCT03011502|Other|Biological samples collection of blood and feces|
75399127|NCT03011424|Device|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
75399128|NCT03011580|Dietary Supplement|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
75399129|NCT03011580|Dietary Supplement|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
75399130|NCT03011190|Behavioral|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
75709722|NCT05741424|Diagnostic Test|Innovative diagnostic technologies|Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
75399131|NCT03010878|Other|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures"
76037402|NCT03703856|Drug|Memantine|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
76037403|NCT03703856|Drug|Placebo|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
76037404|NCT03699540|Drug|Marijuana|Experimental, non-therapeutic administration of active marijuana dose(s)
75399132|NCT03010878|Other|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
76037405|NCT03699540|Drug|Alcohol|Experimental, non-therapeutic administration of active alcohol dose(s)
76037406|NCT03699540|Drug|placebo alcohol|Experimental, non-therapeutic administration of inactive alcohol dose(s)
76037407|NCT03699540|Drug|Inactive marijuana|Experimental, non-therapeutic administration of inactive marijuana dose(s)
75399133|NCT03011112|Procedure|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
75399134|NCT03010722|Drug|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
75709723|NCT05741424|Diagnostic Test|Reference diagnostic technique|Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
75709724|NCT00883870|Drug|mesenchymal stem cells|Intramuscular injection
75709725|NCT00883870|Drug|Plasmalyte A|Intramuscular injection
75399135|NCT03010644|Other|n/a - observational study|n/a - observational study
75709726|NCT04038892|Other|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
76037408|NCT03691714|Drug|Durvalumab|Two hour infusion
76037409|NCT03691714|Drug|Cetuximab|Two hour infusion for loading dose followed by weekly one hour infusion
76037410|NCT03673657|Dietary Supplement|Early Nutrition Intervention from the start of CCRT|Nutrition counseling and oral nutritional supplements from the start of radiotherapy; weekly counseling sessions; daily energy intake of approximately 30 kcal/kg.
75709727|NCT04038892|Other|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
76037411|NCT03673657|Radiation|Thoracic radiotherapy|Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy
76037412|NCT03673657|Drug|Weekly DP chemotherapy concurrent with thoracic radiotherapy|Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
75399136|NCT03010098|Device|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
75399137|NCT03010098|Device|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
75871196|NCT05348382|Procedure|Intradermal acupuncture|In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.
75871197|NCT05348382|Procedure|Sham intradermal acupuncture|In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
75399138|NCT03010332|Biological|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
75399139|NCT03010020|Behavioral|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
75399140|NCT03010020|Behavioral|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
75709728|NCT04038892|Other|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
75399141|NCT03009864|Drug|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
75399142|NCT03009864|Drug|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
75399143|NCT03009708|Other|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
75399144|NCT03009630|Procedure|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
75399145|NCT03009630|Device|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
75399146|NCT03009786|Other|Measurement of salivary flow|A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
75399147|NCT03009474|Drug|CJ-30060|Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
75399148|NCT03009474|Drug|Exforge tab 5/160mg, Crestor tab 10mg|Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
75399149|NCT03009552|Procedure|speckle tracking echocardiography|Speckle tracking echocardiography is used for measuring parameters of cardiac mechanics: left ventricle strain and strain rate; left ventricle twist, untwist and torsion; left atrium strain and strain rate; right ventricle longitudinal strain and strain rate. Echocardiography will be performed within 24 hours of admission, 72 hours after admission and 1 month after discharge.
75709729|NCT00614380|Drug|telmisartan/amlodipine 40/5 mg fixed combination|
75548186|NCT03934931|Other|Cost reimbursement SAT|Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
75548187|NCT03929718|Drug|Spironolactone|receive spironolactone treatment after CTI ablation
75399150|NCT03009318|Other|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
75399151|NCT03009084|Behavioral|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
75399152|NCT03008694|Device|PET/CT|pet/ct is used as radiotherapy simulation
75399153|NCT03008928|Behavioral|Alcooquizz|
75548188|NCT03929718|Drug|No Spironolactone|no spironolactone treatment
75548189|NCT03927144|Drug|AMG334|Subcutaneous Injection
75548190|NCT03927144|Drug|Oral Prophylactic|SOC Oral Tablet/Capsule
75548191|NCT03919708|Device|Retinal Birefringence Imager|Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
75709730|NCT00614380|Drug|telmisartan/amlodipine 80/5 mg fixed combination|
75709731|NCT05525130|Dietary Supplement|Food supplement|FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
76037413|NCT03656718|Biological|nivolumab|(Subcutaneous) Specified dose on specified days
76037414|NCT03656718|Drug|rHuPH20|Specified dose on specified days Permeation enhancer
76037415|NCT03656718|Biological|nivolumab|(IV) Specified Dose on Specified Days
75399154|NCT03009006|Drug|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
75399155|NCT03009006|Drug|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
75548192|NCT03918642|Behavioral|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
75548193|NCT03918642|Behavioral|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
75548194|NCT03917381|Biological|Acasunlimab|Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles)
75548195|NCT03917381|Biological|Acasunlimab in combination with docetaxel (in a single expansion cohort)|Acasunlimab and docetaxel will be administered intravenously once every 21 days
75548196|NCT03917381|Biological|Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)|Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively
75709732|NCT05525130|Dietary Supplement|Placebo|Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
75709733|NCT05507190|Other|Self-management of post COVID-19 respiratory outcomes|Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.
75709734|NCT02567994|Drug|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
75709735|NCT00738192|Drug|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
75399156|NCT03008850|Drug|MgSo4|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
75399157|NCT03008850|Drug|Placebo|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
76037416|NCT03652805|Drug|IPL344|"The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose."
75399158|NCT03008538|Other|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
75399159|NCT03008538|Other|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
75399160|NCT03008304|Drug|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
75399161|NCT03008226|Device|Implementation of 9 mm intrabronchial valves|
75399162|NCT03008148|Radiation|CCRT|CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
75399163|NCT03008148|Drug|Temozolomide|Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
75399164|NCT03008148|Drug|Siroquine|"Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
75399165|NCT03007992|Drug|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
75399166|NCT03007836|Biological|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
75399167|NCT03007446|Drug|Apatinib|Apatinib :A starting dose of apatinib was administered 500 mg daily
75709736|NCT00738192|Drug|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
75399168|NCT03007446|Drug|Oxaliplatin|Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
75399169|NCT03007446|Drug|S-1|S-1:40mg，bid，d1-14，po，in a 21 day cycle.
75399170|NCT03007368|Other|Rice|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
75399171|NCT03007368|Other|Potato|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .
75399172|NCT03007368|Other|Pasta|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
75548197|NCT03917381|Biological|Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)|Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days
75709737|NCT00738192|Drug|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
76037417|NCT03645928|Biological|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by IL-2 administration. Lifileucel will be administered to patients once (on Day 0) during the study.
75399173|NCT03007368|Other|Sorghum thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
75399174|NCT03007368|Other|Millet thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
75399175|NCT03007368|Other|Millet couscous|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
75399176|NCT03007368|Other|Millet thin porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
75399177|NCT03007368|Other|Millet thin monikuru porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
75709738|NCT00875134|Other|Verbal prompt|Patient hears a voice recording
75709739|NCT00875134|Other|Skin Stimulus|Patient receives either a skin stimulus
75548198|NCT03904251|Drug|Gemtuzumab Ozogamicin|Given IV
75548199|NCT03904251|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
75709740|NCT05697978|Device|Monofocal intraocular lens Clareon (Alcon LLC)|monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
76037418|NCT03645928|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.
76037419|NCT03645928|Drug|Pembrolizumab|"Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years."
75871198|NCT03112876|Other|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
75399178|NCT03007602|Other|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
75399179|NCT03007680|Other|Core muscle activation|
75709741|NCT04681534|Device|AlphaDBS System|AlphaDBS can be programmed with two different types of stimulation: conventional DBS and adaptive DBS, that automatically adjusts the energy delivered to patient using a biosignal, local field potential (LFP), in a close loop configuration.
75709742|NCT00883948|Behavioral|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
75399180|NCT03007524|Drug|High dose Rosuvastatin|20mg/d qN, at least 6 months
75399181|NCT03007524|Drug|Low dose Rosuvastatin|10mg/d qN, at least 6 months
75399182|NCT03007290|Other|Therapeutic drug monitoring|Therapeutic drug monitoring for colistin
75399183|NCT03007134|Other|Retrospective Chart Review|No intervention.
75399184|NCT03007212|Procedure|transarterial chemoembolization versus the standard treatment with sorafinib|TACE procedures were performed by the interventional radiologist through femoral artery approach in all patients. Super-selective cannulation of the main feeders was performed using a microcatheter whenever possible. The c-TACE protocol consisted of intra-arterial infusion of cisplatin 50-100 mg mixed with lipiodol ,Just prior to injection, emulsion is prepared by intensive mixing of equal volumes of cytotoxic drug solution and iodized oil using the pumping method with two syringes and a three way stop cock. Injection is guided by fluoroscopy and results in dense accumulation of the emulsion within the tumor vascular bed. Injection of poor iodized oil up to a maximum volume of 10-20 cc is an option and is followed by embolization of feeding arteries by Gelfoam cubes .Endpoints of conventional TACE are complete filling of the tumor vascular bed with iodized oil and stop-flow in subsegmental and segmental feeding arteries..
75399185|NCT03006900|Other|Pilates|Pilates
75399186|NCT03006900|Other|Massage|Massage
75399187|NCT03006978|Device|TearCare|
75399188|NCT03006978|Device|Warm Compress|
75399189|NCT03007056|Other|High flow nasal cannula|High flow nasal cannula added to the therapeutic arsenal in neonatal care
75709743|NCT00883948|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
75399190|NCT03006822|Other|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
75399191|NCT03006822|Other|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
75709744|NCT05695326|Behavioral|3D printing technology learning program|The study is aimed to evaluate a 3D printing technology learning program for rehabilitation professionals
75709745|NCT00738348|Drug|sivelstat|sivelstat sodiumhydrate
75399192|NCT03006822|Other|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
75399193|NCT03006744|Behavioral|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
75399194|NCT03006744|Behavioral|Reading enjoyment training|Training on how to make reading enjoyable for children.
75548200|NCT03901339|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
75709746|NCT00738348|Drug|glucose|glucose
75548201|NCT03901339|Drug|Eribulin|Administered intravenously per NCCN guidelines
75548202|NCT03901339|Drug|Capecitabine|Administered orally per NCCN guidelines
75548203|NCT03901339|Drug|Gemcitabine|Administered intravenously per NCCN guidelines
75548204|NCT03901339|Drug|Vinorelbine|Administered intravenously per NCCN guidelines
75871199|NCT03077646|Behavioral|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
75871200|NCT03077646|Behavioral|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
75548205|NCT03900923|Drug|98% pure CBD|A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
75709747|NCT00884026|Device|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
75709748|NCT00884026|Device|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
75709749|NCT05678946|Other|Integrated face-to-face rehabilitation and telerehabilitation|Kela´s integrated face-to-face rehabilitation and telerehabilitation services for family caregivers include two 5-day periods of face-to-face rehabilitation and a 12-week telerehabilitation period between them. It is for those over the age of 18 who work as family caregivers on a daily basis and need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. The service, provided free of charge, is carried out in a Finnish rehabilitation centre and online over a period of 8 months, and it is implemented by a multidisciplinary team of rehabilitation experts. During the 12-week telerehabilitation period, the service providers utilise The Own Path, an acceptance and commitment therapy -based guided web intervention found beneficial for older Finnish family caregivers (Lappalainen et al. 2021). Telerehabilitation is independent of time and place.
75871201|NCT03077646|Behavioral|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
76037420|NCT03645928|Biological|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145-S1) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.
76037421|NCT03645928|Drug|Ipilimumab|"Monoclonal antibody~Ipilimumab will be administered as a single dose prior to tumor resection."
75399195|NCT03006588|Procedure|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
76037422|NCT03645928|Drug|Nivolumab|"Monoclonal antibody~Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks for up to 2 years."
75399196|NCT03006510|Other|Hypoglycemia prediction alert|"In real time, for a patient with a glucose <90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is >35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia."
75399197|NCT03005886|Procedure|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
75548206|NCT03896750|Drug|PA-824|PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
75548207|NCT03895879|Drug|Tocilizumab|Tocilizumab sc (162 mg) once every 2 weeks
75548208|NCT03895879|Drug|Tocilizumab|Tocilizumab sc (162 mg) once every week
76037423|NCT03577431|Biological|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10^6 total cells. If a minimum arTreg-CSB dose of 1 to < 2.5 x 10^6 cells, the product will be infused. If the dose obtained after product manufacture is < 1 x 10^6 cells, the product will not be infused. When the dose obtained after product manufacture is > 125 x 10^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10^6 cells, and ≥ 2.5 to 125 x 10^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
76037424|NCT03577431|Procedure|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion."
76037425|NCT03577431|Drug|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
76037426|NCT03577431|Drug|mesna|Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
76037427|NCT03577431|Drug|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
75399198|NCT03005886|Procedure|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
75399199|NCT03005886|Procedure|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
76023169|NCT02407093|Behavioral|High-Intensity Functional Training|Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
75399200|NCT03006120|Procedure|Retroperitoneal hematoma due to cardiac catheterization|
75399201|NCT03006042|Drug|Bupivacaine|
75399202|NCT03005496|Drug|Zinc|included in intervention arm
75399203|NCT03005496|Drug|Nifedipine|included in intervention and control arm
75399204|NCT03005496|Drug|Beta Carotene|included in intervention arm
75399205|NCT03005496|Drug|Vitamin D3|included in intervention arm
75399206|NCT03005496|Drug|Dexamethasone|included in intervention and control arm
75399207|NCT03005808|Drug|Ropivacaine|Surgery for appendicitis
75399208|NCT03005730|Other|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
75399209|NCT03005730|Other|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
75399210|NCT03005652|Behavioral|Mindfulness weekly courses for 8 weeks|The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
75399211|NCT03005652|Behavioral|Health education weekly courses for 8 weeks|The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
75548209|NCT03885713|Biological|Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid)
75548210|NCT03874858|Drug|Nilotinib|Nilotinib oral 300 mg QD hard capsules
75548211|NCT03874858|Drug|Nilotinib|Nilotinib oral 300 mg BID hard capsules
75548212|NCT03874858|Drug|Asciminib|Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
75871202|NCT02359240|Procedure|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
75399212|NCT03005574|Behavioral|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
75399213|NCT03005574|Behavioral|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
75399214|NCT03005262|Drug|MLN8237|
75399215|NCT03005340|Drug|Treatment B|Bazedoxifene 20 mg
75871203|NCT02359240|Procedure|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
76037428|NCT03528642|Other|Questionnaire Administration|Ancillary studies
75871204|NCT02352610|Procedure|LRTI|
75871205|NCT02352610|Device|Biotenodesis Screw|
75399216|NCT03005340|Drug|Treatment C|Cholecalciferol granule 10 mg
75399217|NCT03005340|Drug|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
75399218|NCT03005184|Drug|Valsartan 80 mg bid|oral medication during run-in and washout period
75399219|NCT03005184|Drug|Enalapril 10 mg bid|oral medication
75399220|NCT03005184|Drug|Sacubitril-Valsartan 200 mg bid|oral medication
75399221|NCT03005184|Drug|Icatibant|intravenous medication
75399222|NCT03005184|Drug|Placebo|intravenous medication
75399223|NCT03004794|Other|medical records review|
76037429|NCT03528642|Radiation|Radiation Therapy|Undergo RT
76037430|NCT03528642|Drug|Telaglenastat Hydrochloride|Given PO
76037431|NCT03528642|Drug|Temozolomide|Given PO
76037432|NCT03486067|Drug|CC-93269|Specified dose on specified days
76037433|NCT03481881|Drug|Standard of care drug|This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
75871206|NCT02927964|Drug|Ibrutinib|Given PO
75871207|NCT02927964|Radiation|Radiation Therapy|Undergo radiation therapy
75871208|NCT02927964|Drug|TLR9 Agonist SD-101|Given IT
75871209|NCT03147586|Drug|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
75871210|NCT03147586|Drug|placebo|placebo
75871211|NCT01377246|Drug|Octreotide-LAR|40 mg every 28 days (in two intragluteal 20 mg injections) for three years
75871212|NCT01377246|Other|Saline solution.|At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
75399224|NCT03004560|Procedure|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
75399225|NCT03004560|Procedure|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
75399226|NCT03004716|Other|Aerobic training|"5 consecutive patients with chronicle obstructive pulmonary disease are offered to participate in the protocol when they have reached 45 min of aerobic training during their pulmonary rehabilitation program.~During 5 sessions of 45 min, they are monitored with an oximeter device (Nonin 3150) which records heart rate (HR) and oxygen transcutaneous saturation (SpO2). The device also communicates with a telemedicine medical gateway which sends these data to a remote telemedicine center. Data are then provided on a secured online platform and compared with data recorded on the device (Nonin 3150)."
75399227|NCT03004092|Procedure|blood sample|Twice weekly blood sample, and at every outpatient visit
75548228|NCT03869892|Drug|Trifluridine/tipiracil hydrochloride (S95005)|Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
75548229|NCT03869892|Drug|Capecitabine|Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
75709750|NCT05678946|Other|Social Holidays|MTLH's Social Holidays for family caregivers are 5-day holidays in a Finnish hotel, spa, sports institute, or rehabilitation centre. The theme, content, and level of available assistance in Social Holidays vary, and the rehabilitation concept is lighter than that of Kela's rehabilitation services. Social Holidays include full-board accommodation and holiday activities, e.g. lectures, group discussions, instructed exercise, and a pampering treatment. MTLH organises Social Holidays for family caregivers as well as family caregivers and care recipients. The participants cover their travel expenses and pay a fixed sum of €125. Other than that, Social Holidays are provided free of charge. Social Holidays are intended for family caregivers who need recreational activities, rest, and peer support.
75399228|NCT03004170|Behavioral|Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training|
75709751|NCT05678946|Other|Face-to-face rehabilitation|Kela's rehabilitation services for family caregivers and the care recipients include three 5-day periods of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation centre over a 10-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation services for family caregivers and the care recipients are provided free of charge. The service is intended for persons over the age of 18 who work as family caregivers on a daily basis with or without family caregiver support and who need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation.
75709752|NCT00875290|Device|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
75709753|NCT00884104|Drug|Solifenacin|Oral
75709754|NCT04140214|Drug|Hypertonic saline|Nebulized hypertonic saline solution (6%)
75871213|NCT02353936|Drug|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH & Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily"
75548230|NCT03869892|Biological|Bevacizumab experimental|Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
75709755|NCT04140214|Drug|Carbocysteine 750 MG|Carbocisteine tablet
75709756|NCT00612508|Drug|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
75709757|NCT00612508|Drug|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
75709758|NCT00881218|Drug|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
75548231|NCT03869892|Biological|Bevacizumab control|Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
75709759|NCT00613834|Drug|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
75709760|NCT00613834|Drug|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
75709761|NCT00875368|Drug|maraviroc|maraviroc dose dependent on co-medication
75709762|NCT00875368|Drug|Placebo|Placebo drug
75709763|NCT00884182|Biological|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
75709764|NCT00875446|Drug|PLACEBO|Placebo
75709765|NCT00875446|Drug|GSK1223249|I.V Infusion
75871214|NCT02353858|Other|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
75871215|NCT02353858|Radiation|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
75399229|NCT03004170|Behavioral|Telephone-Administered Coping Effectiveness Training|
75399230|NCT03004014|Other|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
75399231|NCT03003858|Device|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
75399232|NCT03003702|Device|Nonin|
75399233|NCT03003936|Behavioral|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
75399234|NCT03003624|Device|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
75399235|NCT03003624|Device|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
75399236|NCT03003624|Device|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
75399237|NCT03003234|Procedure|Duodenogastroscopy|Catheter goes through the mouth in the duodenum to take duodenal biopsies.
75548232|NCT03859973|Drug|BI 425809|Tablet
75548233|NCT03859973|Drug|Placebo|Tablet
75548234|NCT03831932|Procedure|Biospecimen Collection|Undergo blood sample collection
75548235|NCT03831932|Procedure|Computed Tomography|Undergo CT scan
75548236|NCT03831932|Procedure|Magnetic Resonance Elastography|Undergo MRI
75548237|NCT03831932|Drug|Osimertinib|Given PO
75548238|NCT03831932|Procedure|Positron Emission Tomography|Undergo PET scan
75399238|NCT03003234|Device|Duodenal aspiration catheter|Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
75399239|NCT03003234|Dietary Supplement|Nutri drink|Liquid meal of 200 ml.
75399240|NCT03003156|Procedure|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
75399241|NCT03003156|Procedure|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
75548239|NCT03831932|Drug|Telaglenastat Hydrochloride|Given PO
75548240|NCT03831932|Procedure|X-Ray Imaging|Undergo x-ray imaging
75548241|NCT03814876|Behavioral|Group session psycho-education|Active comparator - control group
75548242|NCT03814876|Behavioral|FITS|Manualized family intervention
75548243|NCT03784677|Drug|TRPV6 Calcium Channel Inhibitor SOR-C13|Given IV
75548244|NCT03761394|Device|Testing Devices|Pulsewatch system testing application on smartphone with smartwatch.
75871216|NCT02353858|Drug|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
76023170|NCT02407093|Behavioral|Army Physical Readiness Training|Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
75548245|NCT03761394|Device|Cardea Solo by Cardiac Insight|Gold-standard cardiac monitor for comparison of testing devices.
75548246|NCT03761394|Device|Kardia Mobile by AliveCor|Mobile ECG device for comparison of testing devices during the extended use period.
75548247|NCT03724318|Procedure|closure of the left atrium appendage|closure of the left atrium appendage in addition to the planned Heart operation
75548248|NCT03721952|Behavioral|Facilitator-Based Intervention|Facilitators interact in person or by telephone with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email 5 days per week. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
75548249|NCT03718065|Drug|Lofexidine|Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.
75548250|NCT03718065|Drug|Placebo|Placebo comparator.
75399242|NCT03002844|Drug|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
75399243|NCT03002844|Drug|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
75399244|NCT03002844|Drug|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
75399245|NCT03002922|Drug|BAY987517|Sunscreen formula Y65-158
75399246|NCT03003078|Device|OncoSil™|The implantation of OncoSil™
75399247|NCT03002688|Other|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
75399248|NCT03002766|Procedure|Breast conservative surgery|
75548251|NCT03714711|Procedure|total hip arthroplasty|Total hip replacement
75548252|NCT03714711|Procedure|total knee arthroplasty|Total knee replacement
75548253|NCT03701230|Other|low temperature rota-flush solution|Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
76023171|NCT05106959|Behavioral|Motivational Interviewing Informed Shame Resilience Training|Shame resilience involves four elements. Understating shame, normalizing shame thoughts, reaching out, and speaking shame. Motivational interviewing will be used to elicit and guide participants through these four elements.
75399249|NCT03002532|Radiation|whole brain radiotherapy|
75399250|NCT03002220|Drug|radium-223|Radium-223 at a dose of 55 kBq
75399251|NCT03002298|Behavioral|DMD gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
75399252|NCT03002298|Behavioral|DMD button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
75399253|NCT03002298|Behavioral|Control group gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
75399254|NCT03002298|Behavioral|Control group button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
75399255|NCT03002376|Drug|REGN2810|REGN2810 treatment
75399256|NCT03002064|Drug|Docetaxel|60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
75399257|NCT03002064|Drug|Fluorouracil|5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
75399258|NCT03002064|Drug|Cisplatin|Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
75399259|NCT03001908|Other|glenohumeral mobilization-oscillation|posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds
75399260|NCT03001908|Other|glenohumeral mobilization-sustained|posterior glide mobilization, sustained 4 x 30 seconds
75399261|NCT03002142|Device|Hearing aids|Phonak Audéo B-R (Target V 5.0)
75399262|NCT03002142|Device|Placebo|Phonak Audéo B-R (Target V 5.0) without amplification
75399263|NCT03001752|Device|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
75399264|NCT03001752|Device|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
75399265|NCT03001752|Device|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
75399266|NCT03001596|Procedure|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
75399267|NCT03001596|Procedure|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
75399268|NCT03001596|Procedure|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
75399269|NCT03001440|Other|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
75399270|NCT03001284|Other|NO intervention|
75399271|NCT03001050|Device|PINPOINT System|To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
75399272|NCT03000972|Procedure|Cement augmentation|
75709766|NCT03920098|Other|Nutrition and mental health during pregnancy|Altered metabolic milieu is defined as a fasting glucose level >100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels > 92 mg/dL and/or plasma glucose levels > 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose >100 mg/dL and/or > 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.
75399273|NCT03000972|Procedure|PFN-A Nail|
75399274|NCT03001206|Device|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
75399275|NCT03001128|Drug|Antiretroviral treatment pause|Antiretroviral treatment pause
75399276|NCT03000894|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
75399277|NCT03000660|Drug|Venetoclax|Venetoclax at one of four escalating doses
75548254|NCT03700567|Other|low temperature contrast|UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
75399278|NCT03000660|Drug|Dexamethasone|Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
75399279|NCT03000582|Dietary Supplement|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
76037434|NCT03474731|Behavioral|Diabetes Self Management Program|"Diabetes Self Management Program (DSMP) in a group setting: The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).~Groups randomized to one of two arms (DSMP only and CCN) will receive the DSMP. The DSMP has demonstrated significant improvements in communication with physicians, healthy eating, and hypoglycemia at six and twelve months. The DSMP and other self-management programs have been shown to increase self-efficacy, knowledge, and skill building; ensure accountability/monitoring; improve patient-provider interaction; leverage local assets; address sustainability, and be cost effective."
76037435|NCT03474731|Behavioral|Tailored Patient Navigation (PN) only|Tailored Patient Navigation (PN) only: The goal of this arm of the project is to try to get participants to attend their recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs. We will have to add an additional eligibility criterion for this group-they have to be out of compliance with medical appointments. Most participants will need PN services, owing to missed, rescheduled, or infrequent appointments. This means not attending their office visits, as recommended, which typically is every 3 months. We will interact with them to verify attendance and, at times, to access patient medical records if needed.
76037436|NCT03474731|Behavioral|DSMP AND Tailored Patient Navigation|DSMP AND Tailored Patient Navigation : Both group education classes and patient navigation
76037437|NCT03409185|Device|Alcon 1 piece SA60AT lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer
76037438|NCT03409185|Device|AMO 1-piece AABOO lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
75399280|NCT03000582|Dietary Supplement|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
76037439|NCT03407144|Biological|pembrolizumab|2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
75399281|NCT03000582|Dietary Supplement|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
76037440|NCT03407144|Drug|doxorubicin|"25 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
76037441|NCT03407144|Drug|vinblastine|"6 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
75399282|NCT03000582|Dietary Supplement|Placebo|Placebo (6.5 g dextrose)
75548255|NCT03699020|Behavioral|Acceptance and Commitment Therapy (ACT)|Empirically based behavioral intervention that encourages acceptance of circumstances with commitment and behavioral change strategies to improve psychological flexibility.
75399283|NCT03000816|Radiation|SBRT|Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
75399284|NCT03000504|Device|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
75399285|NCT03000270|Device|Impella unloading prior to PPCI|Impella unloading prior to PPCI
75399286|NCT03000114|Procedure|Percutaneous Needle Aponeurotomy|
75399287|NCT03000114|Drug|XIAFLEX|
76037442|NCT03407144|Drug|dacarbazine|"375 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
76037443|NCT03407144|Drug|cyclophosphamide|500 mg/m^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
75399288|NCT03000036|Drug|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
75399289|NCT03000036|Device|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
75399290|NCT03000036|Drug|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
75399291|NCT02999802|Behavioral|Exercise|Progressive resistance exercise training
75548256|NCT03699020|Other|Chronic Pain Education|Education materials about living with chronic pain developed by Weill Cornell Universitys Translational Research Institute for Pain in Later Life
75548257|NCT03689335|Procedure|Operative|Open reduction and internal fixation, using a plate and screws (the exact surgical approach and fixation technique utilised will be at the discretion of the treating surgeon)
75709767|NCT03912298|Other|Opioid Taper Pain perception|Pain Responses: The primary dependent variable, pain, will be measured using two highly reliable and valid pain induction techniques, the CPT and QST, employing procedures consistent with those described in the literature. Order of pain testing will vary, and three aspects of the pain response will be captured at each study session: evoked pain; temporal summation; and conditioned pain modulation, which map on to the hypothesized peripheral, spinal and supra-spinal mechanisms of OIH. Protocols for each assay have been uploaded.
76037444|NCT03407144|Drug|vincristine|"1.5 mg/m^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
76037445|NCT03407144|Drug|prednisone/prednisolone|"60 mg/m^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
76037446|NCT03407144|Drug|bleomycin|10 units/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
76037447|NCT03407144|Drug|etoposide|125 mg/m^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
76037448|NCT03407144|Radiation|Radiotherapy (RT)|RT administered daily, dose dependent on randomization group and disease response.
76037449|NCT03396276|Drug|Suboxone|8mg of buprenorphine/2mg of naloxone
76037450|NCT03396276|Behavioral|Brief counseling in the ED|"Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers."
75548258|NCT03689335|Device|Humeral brace|Immobilisation in a U-slab or hanging cast, followed by application of a lightweight prefabricated humeral brace
76037451|NCT03396276|Behavioral|Referral to outpatient treatment|A referral will be made to one of the affiliated MAT clinics.
75709768|NCT02543710|Procedure|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with <50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with <50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 <50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
76037452|NCT03396276|Behavioral|Follow-up coaching|A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
76037453|NCT03382782|Behavioral|BWLI|"BWLI includes group weight management classes, physical activity classes, individual sessions with a facilitator to address goals and barriers to weight loss, and weigh-ins.~A punch card system will be implemented to incentivize participation for BHL classes. Each participant from the BWLI condition will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in."
75548259|NCT03684811|Drug|FT-2102|FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
75548260|NCT03684811|Drug|Azacitidine|Azacitidine will be administered per the site's standard of care.
75548261|NCT03684811|Biological|Nivolumab|Nivolumab will be administered per the site's standard of care.
75548262|NCT03684811|Drug|Gemcitabine and Cisplatin|Gemcitabine and cisplatin will be administered per the site's standard of care.
75548263|NCT03672773|Drug|Talazoparib|Given PO
75548264|NCT03672773|Drug|Temozolomide|Given PO
75548265|NCT03665337|Behavioral|mTranS-C|MOBILE HEALTH
75548266|NCT03665337|Behavioral|Control|MOBILE HEALTH
75548267|NCT03661723|Drug|Pembrolizumab|Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
75548268|NCT03661723|Drug|Bevacizumab|"Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels."
75548269|NCT03661723|Radiation|Re-irradiation|Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
75548270|NCT03635801|Device|MyoVista 12 lead Electrocardiogram (ECG)|MyoVista 12 Lead Electrocardiogram (ECG)
75548271|NCT03634124|Biological|Blood test|Additional blood test of 4,5 ml of venous blood
75548272|NCT03634124|Other|Doppler ultrasound|Vascular ultrasonic vascular exploration of the lower limbs
75548273|NCT03629340|Drug|Metformin|500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
75548274|NCT03629340|Drug|Placebo oral capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
75548275|NCT03598595|Drug|Docetaxel|Given IV
75548276|NCT03598595|Drug|Gemcitabine|Given IV
75548277|NCT03598595|Drug|Hydroxychloroquine|Given PO
75548278|NCT03569956|Other|556 Razor|In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
75399292|NCT02999412|Procedure|Comprehensive medication review|"A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature [4]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
75548279|NCT03568994|Drug|Atovaquone|"Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations."
75548280|NCT03568994|Drug|Cytarabine|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
75548281|NCT03568994|Drug|Daunorubicin|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
75548282|NCT03568994|Drug|Etoposide|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
75548283|NCT03568994|Drug|Gemtuzumab Ozogamicin|As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
75548284|NCT03566043|Genetic|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
75548285|NCT03509012|Drug|Durvalumab|IV (intravenous)
75548286|NCT03509012|Drug|Tremelimumab|IV
75548287|NCT03509012|Drug|Cisplatin (dose level 4)|IV
75548288|NCT03509012|Drug|Cisplatin (dose level 3)|IV
75548289|NCT03509012|Drug|Carboplatin (dose level 1)|IV
75548290|NCT03509012|Drug|Carboplatin (dose level 2)|IV
75548291|NCT03509012|Drug|Etoposide (dose level 1)|IV
75548292|NCT03509012|Drug|Etoposide (dose level 2)|IV
75548293|NCT03509012|Drug|Paclitaxel|IV
75548294|NCT03509012|Drug|Pemetrexed|IV
75548295|NCT03509012|Radiation|External beam radiation (dose level 1)|radiation therapy
75548296|NCT03509012|Radiation|External beam radiation (dose level 2)|radiation therapy
75548297|NCT03509012|Radiation|External beam radiation (hyperfractionated)|radiation therapy
75548298|NCT03509012|Drug|Cisplatin (dose level 1)|IV
75548299|NCT03509012|Drug|Cisplatin (dose level 2)|IV
75548300|NCT03509012|Radiation|External beam radiation (standard)|radiation therapy
75548301|NCT03502018|Drug|Bupivacaine liposome|A long-acting liposomal bupivacaine
75548302|NCT03502018|Drug|Saline|Saline injection used as control
75548303|NCT03499236|Device|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.
75548304|NCT03499236|Other|Control|Right heart catheterization, invasive echocardiography.
75548305|NCT03484299|Procedure|Irreversible Electroporation (IRE)|Non-thermal ablation of tumor
75548306|NCT03484299|Drug|Gemcitabine|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
75548307|NCT03484299|Drug|FOLFIRINOX|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
75548308|NCT03471624|Drug|Tenofovir Alafenamide|Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
75399293|NCT02999412|Procedure|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:~In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
75399294|NCT02999412|Procedure|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
75399295|NCT02998944|Other||not any intervention for this study
75548309|NCT03445689|Other|Assessment of oxygenation instability|Recordings of SpO2 and heart rate will be analyzed by dedicated software to obtain frequency, duration and severity of episodes of hypoxemia and hyperoxemia.
75548310|NCT03445689|Other|Determination of mechanisms of hypoxemia episodes|Recordings of SpO2, heart rate, esophageal pressure, tidal volume, minute volume, respiratory rate and transcutaneous PCO2 will be analyzed to determine the prevalence, severity and duration of hypoxemia episodes produced by the different mechanisms.
75548311|NCT03445689|Other|Assessment of respiratory instability|Recordings of tidal volume, minute volume and respiratory rate will be analyzed to determine frequency of apnea, periodic breathing, distribution of inter-breath intervals.
75548312|NCT03445689|Other|apneic threshold of CO2|In mechanically ventilated infants the apneic threshold of CO2 will be measured by transcutaneous PCO2 following a step wise increase in ventilator rate until spontaneous breathing ceases transiently. In spontaneously breathing infants the apnea threshold of CO2 will be measured during episodes central apnea.
75548313|NCT03445689|Other|Assessment of peripheral chemoreceptor function|The Dejours test will be used to assess peripheral chemoreceptor function by measuring the immediate ventilatory response to high-inspired oxygen.
75548314|NCT03445689|Other|Assessment of central chemo-receptor function|Central chemo-receptor function will be assessed by measuring the ventilatory response to inspired CO2.
76037454|NCT03382782|Behavioral|BWLI & Peer Navigator|Participants receive the BWLI condition and partner with a peer navigator. Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on BWLI homework, attending health care appointments, and facilitating diet and exercise activities). A punch card system will be implemented to incentivize participation for BHL classes. Each participant from BWLI & Peer Navigator will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in.
75399296|NCT02998008|Behavioral|high intensity interval training|
75399297|NCT02996292|Device|Traditional brackets|Treating of crowding using traditional brackets
75399298|NCT02996292|Device|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
75399299|NCT02996292|Device|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
76037455|NCT03382782|Behavioral|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
76037456|NCT03377062|Diagnostic Test|EEG monitoring|Five-minute of EEG monitoring accompanied with auditory stimulation.
76037457|NCT03362970|Device|BioFire Gastrointestinal Panel FilmArray®|The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in ~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.
75399300|NCT02995824|Other|Raltegravir-based antiretroviral therapy|To analyze retrospectively the efficacy and safety of raltegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTI) [lamivudine (3TC) or emtricitabine.(FTC) plus abacavir (ABC) or tenofovir (TDF)] [Group 1] versus other ART regimens including boosted PI or NNRTIs [Group 2] in 271 HIV/HCV-coinfected patients who underwent liver transplantation between 2002 and 2012 and were followed until December 2016.
75399301|NCT02995356|Other|Collecting cervical liquid and sera samples|
75399302|NCT02989974|Behavioral|KY LEADS Survivorship Care|"Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment"
75399303|NCT02989740|Procedure|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
75399304|NCT02989896|Device|perfusion index|
75399305|NCT02989350|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
75399306|NCT02989350|Dietary Supplement|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
75399307|NCT02989428|Procedure|Early parathyroidectomy group (EPTX-group)|Participants will undergo parathyroidectomy as soon as possible
75399308|NCT02989116|Behavioral|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
75399309|NCT02989116|Behavioral|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
75399310|NCT02989116|Behavioral|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
75399311|NCT02989116|Behavioral|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
75399312|NCT02989116|Genetic|Saliva collection|Collection of a saliva sample for genotyping
75399313|NCT02989116|Procedure|Brain Magnetic Resonance Imaging|Structural and functional MRI
75399314|NCT02989116|Behavioral|Cognitive testing|Battery of cognitive and academic tasks on executive functions
75709769|NCT02543710|Drug|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
75709770|NCT00884260|Drug|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
75548315|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 1: 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
75548316|NCT03441048|Drug|Cladribine|Cladribine 5mg/m^2/day IV over two hours on days 2-6.
75399315|NCT02989272|Drug|Sulfate, Magnesium|magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
75399316|NCT02989272|Other|saline group|saline group (30 patients) who will receive pretreatment by saline solution
75399317|NCT02989038|Other|Very Low Nicotine Content Cigarettes|cigarettes with 0.03 nicotine yield with 0.4 mg/g nicotine content and 9.0 mg tar yield
75399318|NCT02989038|Other|Intermediate Nicotine Content Cigarettes|cigarettes with 0.12 nicotine yield with 2.4 mg/g nicotine content and 9.0 mg tar yield
75399319|NCT02989038|Other|Normal Nicotine Content Cigarettes|cigarettes with 0.8 nicotine yield with 15.8 mg/g nicotine content and 10.5 mg tar yield
75399320|NCT02988804|Device|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
75548317|NCT03441048|Drug|Cytarabine|Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.
75548318|NCT03441048|Drug|Mitoxantrone|Mitoxantrone 10mg/m^2/day IV on days 2-4.
75548319|NCT03441048|Drug|G-CSF|G-CSF at a dose of 300 µg on days 1-6.
75548320|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 2: 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
75548321|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 3: 0.75 μCi/kg with 4.7μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
75548322|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 4: 1.00 μCi/kg with 6.4 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
75548323|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 5: 1.25 μCi/kg with 8.0 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
76037458|NCT03362970|Other|Standard of Care|Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
76037459|NCT03360916|Drug|Lipitor 20Mg Tablet|One tablet by mouth every day for 12 weeks.
75399321|NCT02988804|Device|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
75399322|NCT02988726|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
75709771|NCT04038814|Procedure|Routine prevention of VAP|Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) < 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
75399323|NCT02988648|Radiation|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
75399324|NCT02988570|Behavioral|computer-evaluation of the language|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
75399325|NCT02988492|Device|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
75399326|NCT02988024|Drug|LY03005|LY03005
75548324|NCT03441048|Biological|Lintuzumab-Ac-225 (Recommended Phase 2 Dose)|The maximum-tolerated dose for lintuzumab-Ac225 is defined as the highest level at which no more than one patient experiences a dose-limiting toxicity. The RP2D is defined as the dose level below the dose where two or more dose-limiting toxicities were observed. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
75548325|NCT03429907|Behavioral|Mind-Body Exercises|Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
75871217|NCT02578758|Behavioral|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
76037460|NCT03360916|Drug|Lipitor 80Mg Tablet|One tablet by mouth every day for 12 weeks.
76037461|NCT03360916|Drug|Placebo|One matching placebo tablet by mouth every day for 12 weeks.
75548326|NCT03429907|Behavioral|Questionnaires|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
75548327|NCT03414983|Biological|Nivolumab|Specified dose on specified days
75548328|NCT03414983|Drug|Oxaliplatin|Specified dose on specified days
75548329|NCT03414983|Drug|Leucovorin|Specified dose on specified days
75548330|NCT03414983|Drug|Fluorouracil|Specified dose on specified days
76037462|NCT03360916|Behavioral|Exercise Program|Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
75548331|NCT03414983|Drug|Bevacizumab|Specified dose on specified days
75548332|NCT03411499|Procedure|Early surgery|Surgery within 72 hours from endocarditis diagnosis
76037463|NCT03351998|Drug|Lipitor 20Mg Tablet|20 mg/day pills.
76037464|NCT03351998|Drug|Lipitor 80Mg Tablet|80 mg/day pills.
76037465|NCT03351998|Drug|Placebo Oral Tablet|Matching placebo pill.
75399327|NCT02988024|Drug|Pristiq|
75399328|NCT02988102|Other|Following S100B and NSE in head trauma|Following S100B and NSE in head trauma in correlation with Head CT and post concussion syndrome and Lisat11
75399329|NCT02988258|Genetic|CMV-TCR transduced donor-derived T cells|Dose escalation
75399330|NCT02988180|Other|basic services|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
75548333|NCT03411499|Procedure|Conventional therapy|Delayed surgical intervention or medical treatment according to the current guidelines
75548334|NCT03398161|Other|Quality-of-Life Assessment|Ancillary studies
75399331|NCT02988180|Other|the play-based developmental stimulation|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
75399332|NCT02987790|Other|C-reactive protein|PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are <35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak> 100mg / L), with a limit of seven days, if there is clinical improvement.
75709772|NCT04038814|Procedure|Modified prevention of VAP|"3 modifications of the routine bundle in the prevention of VAP:~Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~Automatic continuous subglottic secretion drainage"
75709773|NCT00881296|Drug|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
75399333|NCT02987712|Other|Thromboelastography based protocol|patients will be treated according to a new thromboelastography based protocol
75399334|NCT02987556|Device|Continuous Glucose Monitoring|Collection of glucose data
75548335|NCT03398161|Other|Questionnaire Administration|Ancillary studies
75548336|NCT03398161|Radiation|Radiation Therapy|Undergo ultra low dose radiation therapy
75709774|NCT00881296|Drug|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
75709775|NCT02543788|Procedure|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
76037466|NCT03331380|Device|MRI scan - obj 1|For objective 1 (protocol optimization), healthy volunteers undergo imaging using an investigational low SAR CMR scanner for up to two hours, some without and some with administration of intravenous gadolinium based contrast agents (GBCAs).
76037467|NCT03331380|Device|MRI scans - obj 2|For objective 2 (comparative scanning of normals), healthy volunteers undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
76037468|NCT03331380|Device|MRI scans - obj 3|For objective 3 (comparative scanning of patients), subjects with known stable cardiovascular disease undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
75399335|NCT02987556|Device|External Insulin Pump|insulin delivery
75399336|NCT02987556|Other|telemdecine|Remote follow up by care health providers team
75548337|NCT03396575|Biological|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
75548338|NCT03396575|Biological|TTRNA-xALT|During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
75548339|NCT03396575|Drug|Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
75548340|NCT03396575|Drug|Dose-Intensified TMZ|After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
75548341|NCT03396575|Drug|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
75709776|NCT02543632|Device|Parachute Implant System|The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
75709777|NCT00884338|Other|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
75709778|NCT00884338|Other|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
75709779|NCT00881374|Drug|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
75399337|NCT02987556|Device|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
75399338|NCT02987400|Drug|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
75548342|NCT03396575|Biological|Autologous Hematopoietic Stem Cells (HSC)|During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
75709780|NCT00613366|Drug|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
76037469|NCT03331380|Device|MRI scans - obj 4|For objective 4 (comparative scanning of patients), subjects with known or suspected disease, including neurological, musculoskeletal disease, abdominal or lung disease, will undergo two MR examinations on two different MRI scanners (investigational low SAR CMR and conventional MR).
75399339|NCT02987400|Drug|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
75399340|NCT02987244|Drug|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
75399341|NCT02987244|Drug|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
75548343|NCT03395847|Biological|Pembrolizumab|Given IV
75709781|NCT00613366|Dietary Supplement|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
75709782|NCT00875602|Device|EverOn (EarlySense) contactless monitoring device|Hospitalized patients on the study unit are monitored by a contactless device
75709783|NCT00875680|Device|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
75399342|NCT02987244|Drug|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
75399343|NCT02987244|Drug|Vindesine|vindesine (4mg)was administered intravenously on d1;
75399344|NCT02987244|Drug|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
75399345|NCT02987244|Drug|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
75548344|NCT03340675|Drug|Ifetroban|Weight based, once daily oral ifetroban
75548345|NCT03340675|Drug|Placebo|Matching oral placebo
75548346|NCT03340506|Drug|dabrafenib|dabrafenib is available in capsules (50mg and 75mg) taken twice a day
75548347|NCT03340506|Drug|trametinib|trametinib is available in tablets (0.5mg, 2mg dose)
75709784|NCT00612352|Drug|Ethanol High Dose, Ethanol Low Dose, and Placebo|Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
75709785|NCT00884416|Drug|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
75548348|NCT03335670|Drug|[68Ga]Pentixafor|68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
75709786|NCT04675996|Drug|INT-1B3|60-min i.v. infusions twice per week in 21-day cycles
75548349|NCT03304613|Behavioral|Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management|Already noted.
75548350|NCT03304613|Behavioral|Promoting Resilience through Innovative Self-Management|Already noted.
75548351|NCT03301805|Drug|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~28 days a cycle."
75709787|NCT00875758|Procedure|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
75709788|NCT00875758|Procedure|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
75399346|NCT02987166|Radiation|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
75399347|NCT02987166|Drug|Pembrolizumab|200 mg
75399348|NCT02987088|Drug|Sodium Nitrite|
75548352|NCT03298659|Diagnostic Test|iFR|Treatment guided by instantaneous wave-free ratio
75548353|NCT03298659|Diagnostic Test|CMR|Treatment guided by stress perfusion CMR
75548354|NCT03296774|Behavioral|Healthy Beyond Pregnancy|Web-based intervention grounded in behavioral economics and designed to improve adherence with postpartum care.
75548355|NCT03296774|Behavioral|Usual Care|
75709789|NCT04018300|Dietary Supplement|Ferrous sulfate|65 mg Fe as ferrous sulfate
75548356|NCT03288974|Drug|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
75548357|NCT03275610|Genetic|Blood sample|5 mL of blood withdrawn from patients with history of pulmonary embolism post total hip arthroplasty or total joint arthroplasty
75548358|NCT03272477|Drug|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
75548359|NCT03272477|Drug|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
75399349|NCT02987322|Dietary Supplement|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
75399350|NCT02986932|Device|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
75399351|NCT02987010|Drug|IDH305|Isocitrate Dehydrogenase 1 inhibitor
75399352|NCT02986776|Behavioral|Inpatient Care|21 days of inpatient substance misuse treatment
75399353|NCT02986776|Behavioral|Outpatient Care|21 days of outpatient substance misuse treatment
75399354|NCT02986542|Procedure|Femoral artery catheterization|The intervention will be performed by a single experienced individual.
75399355|NCT02986152|Behavioral|Cancer Distress Coach Mobile App|"Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care."
75399356|NCT02986464|Device|Virtual Reality Prototype|VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
75399357|NCT02986464|Other|Standard Pharmacological Treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and the pain clinic nurse.
75709790|NCT04018300|Dietary Supplement|Aspiron|65 mg Fe as iron-enriched koji culture, called AspironTM
75399358|NCT02986308|Other|No intervention|
75399359|NCT02982642|Drug|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
75548360|NCT03272477|Drug|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
75548361|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
75548362|NCT03272477|Drug|Epirubicin|12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
75709791|NCT04018300|Other|Placebo|Contains maltodextrin.
75709792|NCT00875914|Procedure|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
75709793|NCT02543164|Other|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
75709794|NCT02543164|Other|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
75709795|NCT00884494|Drug|Ghrelin infusion to assess effects on insulin sensitivity|
75709796|NCT00875992|Device|ETN with ASLS|Angle stable locking of ETN using ASLS
75709797|NCT00875992|Device|ETN locked with conventional locking bolts|Conventional surgical procedure
75709798|NCT00881686|Drug|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
75548363|NCT03272477|Drug|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
75709799|NCT00885508|Drug|Lenalidomide|"Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
75709800|NCT02543086|Drug|KAE609|Study drug
75399360|NCT02982642|Drug|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
75399361|NCT02982486|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
75548364|NCT03272477|Drug|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
75548365|NCT03272477|Drug|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
75709801|NCT02543086|Drug|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
75709802|NCT00885586|Device|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
75548366|NCT03272477|Drug|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
75709803|NCT00885586|Drug|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
75709804|NCT00885586|Procedure|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
76037473|NCT03276676|Drug|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor > 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
75709805|NCT02543242|Device|InToneTM (InControl Medical, LLC) - Medical Device|
75709806|NCT02543008|Procedure|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
75709807|NCT02543008|Procedure|Physical activity|Information already included in arm/group descriptions.
75709808|NCT02543008|Procedure|Placebo|Information already included in arm/group descriptions.
76037474|NCT03255200|Device|ReActiv8 Implantable Stimulation System|Implantable electrical stimulation system.
76037475|NCT03211741|Drug|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
75548367|NCT03272477|Drug|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
75709809|NCT02542930|Radiation|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
75709810|NCT02542930|Drug|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
75709811|NCT00704730|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
76037476|NCT03203525|Biological|Bevacizumab|Given IV
76037477|NCT03203525|Drug|Fluorouracil|Given via pump
75548368|NCT03272477|Drug|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
75548369|NCT03272477|Drug|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
75548370|NCT03272477|Drug|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
75709812|NCT00704730|Drug|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
75709813|NCT00881764|Procedure|Inguinal hernia surgery|Non-experimental procedure
75709814|NCT00881764|Procedure|General anesthesia|Non-experimental procedure/treatment
75709815|NCT04038034|Dietary Supplement|CoQ10- MINIACTIVES|COQUN oral formulation 100 mg BID
76037478|NCT03203525|Drug|Leucovorin|Given via pump
75709816|NCT04038034|Dietary Supplement|Placebo|Placebo
75709817|NCT04037878|Procedure|Transversus Abdominis Plane Block(TAP Block)|Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
75709818|NCT04037878|Procedure|Intra-peritoneal infiltration|Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine
76037479|NCT03203525|Drug|Oxaliplatin|Given via pump
76037480|NCT03203525|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
76037481|NCT03203525|Drug|Temsirolimus|Given IV
76037482|NCT03203525|Procedure|Tumor Treating Fields Therapy|Use NovoTTF-100L(P) system
76037483|NCT03195140|Device|Predictive Low Glucose Suspend|Application of Predictive Low Glucose Suspend
75399362|NCT02982486|Drug|Nivolumab|Ninolumab 240 mg IV every 2 weeks
75399363|NCT02982408|Dietary Supplement|High carbohydrate overfeeding|"All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to ~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period."
75399364|NCT02982408|Behavioral|Exercise|"Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel."
75399365|NCT02982408|Behavioral|Normal physical activity|"The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior."
75399366|NCT02982252|Behavioral|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
75399367|NCT02982330|Behavioral|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing <10% carbohydrate, ~75% fat, and 15% protein. Matched for calories to the active comparator arm.
75399368|NCT02982330|Behavioral|Guidelines Breakfast|A low fat breakfast containing ~55% carbohydrate, <30% fat, and 15% protein. Matched for calories to the experimental arm.
75399369|NCT02981784|Drug|Ponatinib (Iclusig®)|Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.
75399370|NCT02981784|Procedure|allogeneic stem cell transplantation|
75399371|NCT02981862|Other|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
75399372|NCT02981706|Procedure|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
75399373|NCT02981706|Procedure|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
75548371|NCT03272477|Drug|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
75548372|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
75548373|NCT03272477|Drug|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
75548374|NCT03272477|Drug|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
76037484|NCT03188042|Device|rtACS Stimulation|Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
75548375|NCT03272477|Drug|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
75871218|NCT02578758|Behavioral|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
75871219|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
75871220|NCT02353702|Procedure|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
75399374|NCT02981394|Procedure|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
75399375|NCT02981316|Biological|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
75399376|NCT02981238|Dietary Supplement|Phytostandard® Eschscholtzia / Valerian|
75548376|NCT03272477|Diagnostic Test|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
75548377|NCT03272477|Procedure|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
75548378|NCT03270631|Other|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
75548379|NCT03270631|Other|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
75709819|NCT04037878|Drug|PCIA Tramadol|All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
75709820|NCT00881842|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
75709821|NCT00651261|Drug|cytarabine|Given IV
75709822|NCT00651261|Drug|daunorubicin|Given IV
75709823|NCT00651261|Drug|midostaurin|Given orally
75709824|NCT00651261|Other|placebo|Given orally
75709825|NCT00651261|Drug|dexamethasone acetate|ocular medication administration
75709826|NCT00885820|Drug|Tacrolimus|Oral
75709827|NCT00885820|Drug|MMF|Oral
75709828|NCT00885820|Drug|Corticosteroids (Prednisone)|Oral
75399377|NCT02981160|Other|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
75709829|NCT02542618|Behavioral|Inquiry Based Stress Reduction (IBSR)|
75399378|NCT02980926|Drug|Mepivacaine|This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
75709830|NCT02542618|Behavioral|Cognitive Behavioral Therapy (CBT)|
75709831|NCT02542774|Other|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
75399379|NCT02980926|Drug|Bupivacaine|This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
75399380|NCT02980614|Device|4D flow imaging|To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
75399381|NCT02980458|Drug|Deferiprone 500Mg Tablet|
75709832|NCT02567838|Drug|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
75709833|NCT02567838|Drug|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
75709834|NCT00885898|Procedure|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
75399382|NCT02980458|Drug|Deferiprone 500 MG Oral Tablet [Ferriprox]|
75548380|NCT03270631|Other|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
75548381|NCT03270631|Other|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
75548382|NCT03265314|Behavioral|LeadHer|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
75709835|NCT00885898|Procedure|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
75709836|NCT05462574|Other|No Intervention|No Intervention
75709837|NCT00651183|Drug|Pramipexole immediate release|
75709838|NCT00810381|Drug|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
75709839|NCT00810381|Drug|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
75709840|NCT00810381|Drug|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
75709841|NCT00810381|Drug|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
75709842|NCT02553057|Device|mechanical ventilation|
75709843|NCT00800319|Drug|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
75709844|NCT00800319|Drug|Placebo|Volume matched placebo; oral solution; single dose
75709845|NCT00813501|Biological|immunosuppressive therapy|
75709846|NCT00813501|Other|immunological diagnostic method|
75709847|NCT00813501|Procedure|allogeneic hematopoietic stem cell transplantation|
75709848|NCT00699972|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
76037485|NCT03188042|Device|Sham Intervention|A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
76037486|NCT03184454|Device|Medtronic Percept Deep Brain Stimulation|"Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety)."
76037487|NCT03182192|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT scan
76037488|NCT03173924|Drug|18F-NaF|Baseline IV followed by PET/CT IMAGING
76037489|NCT03173924|Drug|18F-DCFPyL|Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.
76037490|NCT03173924|Drug|18F-FDG|Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.
76037491|NCT03137771|Radiation|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
76037492|NCT03137771|Drug|Docetaxel|Given IV
76037493|NCT03137771|Drug|Gemcitabine|Given IV
76037494|NCT03137771|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
76037495|NCT03137771|Drug|Pemetrexed Disodium|Given IV
76037496|NCT03137771|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
76037497|NCT03137771|Drug|Erlotinib Hydrochloride|Given PO
76037498|NCT03137771|Drug|Pembrolizumab|Given IV
75709849|NCT00699972|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
75709850|NCT00699972|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
75709851|NCT00800475|Drug|Gemfibrozil Tablets|
75709852|NCT00810849|Drug|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
75709853|NCT00810849|Biological|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
75709854|NCT00922311|Drug|Aliskiren|Titrate from 150 mg daily to 300 mg daily
76037499|NCT03134755|Drug|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
76037500|NCT03096262|Behavioral|Output-Focus Condition|Users are asked to tag more, and force feedback is exerted the more points the user has
76037501|NCT03096262|Behavioral|Input-Focus Condition|Users are asked to tag more and force feedback is exerted based on the number of images the user has analyzed.
76037502|NCT03083184|Drug|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
76037503|NCT03083184|Drug|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
76037504|NCT03023631|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
75548383|NCT03265314|Behavioral|Sassy Science|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
76037505|NCT02999009|Device|Trident II Tritanium Acetabular Shell|A hemispherical acetabular shell indicated for cementless application.
75399383|NCT02980380|Other|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication."
75399384|NCT02980302|Procedure|Cutaneous biopsy|Under local anesthesia
75399385|NCT02980146|Other|Non interventional study|
75548384|NCT03261674|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I)
75548385|NCT03261674|Behavioral|ABT-I|Arousal-Based Therapy for Insomnia (ABT-I)
75548386|NCT03255070|Drug|ARX788|An antibody drug conjugate
75548387|NCT03253848|Other|Best Practice|Discussion between doctors and APL expert
75548388|NCT03253848|Other|Laboratory Biomarker Analysis|Correlative studies
75548389|NCT03253848|Procedure|Supportive Care|Receive simplified guidelines and support
75548390|NCT03229356|Other|Best Practices Advisory (BPA)|"BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement."
75548391|NCT03229356|Other|BPA + Enhanced Education|BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
75548392|NCT03176953|Drug|topiramate|active medication
75709855|NCT00810927|Procedure|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
75399386|NCT02979912|Biological|Platelet Lysate|Eye drops of Platelet Lysate
75399387|NCT02979990|Other|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
75399388|NCT02979990|Other|Control Video|The control group will have access to a video about the IVF process
75399389|NCT02979756|Procedure|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
75399390|NCT02979288|Drug|Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Probiotic vaginal tablets vith active probiotic strains
75399391|NCT02979288|Other|NO Intervention|NO Intervention
75399392|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
75399393|NCT02979210|Other|Phosphate Buffered Saline|200 microliters of phosphate buffered saline
75399394|NCT02978976|Drug|Betamethasone|will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
75548393|NCT03176953|Behavioral|prolonged exposure|psychotherapy
75548394|NCT03176953|Drug|placebo|non-active medication
75709856|NCT00810927|Procedure|Laser Doppler flowmetry|Measurement of choroidal blood flow
75709857|NCT00810927|Procedure|Measurement of intraocular pressure|
76037506|NCT02983292|Device|PyroTITAN™ HRA|Humeral Resurfacing
76037507|NCT02965716|Biological|Pembrolizumab|Given IV
76037508|NCT02965716|Biological|Talimogene Laherparepvec|Given IL
75709858|NCT00813657|Behavioral|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, ~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (~8 minutes), followed by toning and very light resistance exercises (~20 minutes) and a light intensity cool-down (~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
76037509|NCT02946528|Device|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
76037510|NCT02946528|Device|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
76037511|NCT02916108|Other|Reading EEG|EEG recording for 5 minutes (not an intervention)
76037512|NCT02877693|Radiation|Thoracic MRI Scan|The ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
76037513|NCT02876328|Biological|Ad26.ZEBOV|0.5 mL at a dose of 5x10^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
76037514|NCT02876328|Biological|MVA-BN-Filo|0.5 mL at a dose of 1x10^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
76037515|NCT02876328|Biological|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
76037516|NCT02876328|Biological|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
76037517|NCT02876328|Biological|rVSV boost|1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
76037518|NCT02875223|Drug|CC-90011|Specified dose on specified days
75399395|NCT02978976|Drug|saline|saline placebo injection in the same regimen.
76037519|NCT02875223|Drug|Rifampicin|Specified dose on specified days
75709859|NCT00811005|Radiation|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
75871221|NCT02353702|Drug|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
76037520|NCT02875223|Drug|Itraconazole|Specified dose on specified days
76037521|NCT02870920|Drug|Tremelimumab|
76037522|NCT02870920|Drug|Durvalumab|
76037523|NCT02870920|Other|Best Supportive Care|
76037524|NCT02869217|Drug|Cyclophosphamide|
76037525|NCT02869217|Biological|TBI-1301|
76037526|NCT02869217|Drug|Fludarabine|
76037527|NCT02863523|Behavioral|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
76037528|NCT02804061|Behavioral|NELIP|
76037529|NCT02697630|Drug|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
76037530|NCT02697630|Drug|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
76037531|NCT02691338|Other|EEG|EEG analysis
75399396|NCT02979132|Drug|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
75399397|NCT02979132|Drug|Ferinject(R)|Single-dose Ferinject(R) administration
75548395|NCT03128775|Behavioral|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
76037532|NCT02691338|Other|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
75548396|NCT03128775|Behavioral|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
75709860|NCT00811005|Radiation|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
75709861|NCT00813735|Drug|Eszopiclone|Eszopiclone 2mg daily at bedtime
76037533|NCT02676180|Other|Group|
76037534|NCT02639806|Drug|Sevoflurane|
75548397|NCT03128775|Behavioral|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
75548398|NCT03110978|Biological|Nivolumab|Given IV
75709862|NCT00813735|Drug|Placebo|Placebo daily at bedtime
75709863|NCT00813735|Drug|Escitalopram|Escitalopram 10mg or 20mg
75709864|NCT05066217|Drug|Clemizole HCl|Double-Blind Randomized
75709865|NCT05066217|Drug|Placebo to match EPX-100|Double-Blind Randomized
75709866|NCT00811083|Drug|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
75399398|NCT02979132|Dietary Supplement|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
75709867|NCT00642759|Drug|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
75709868|NCT00642759|Drug|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
75709869|NCT00642759|Drug|Bevacizumab|IV infusion
76037535|NCT02639806|Drug|Lidocaine|
76037536|NCT02633553|Radiation|adjuvant radiotherapy|50Gy/25Fx
75399399|NCT02978664|Procedure|Air insufflation|Air insufflation during colonoscopy including insertion phase
75399400|NCT02978664|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
75399401|NCT02978664|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
75399402|NCT02978820|Other|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
75548399|NCT03110978|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
75548400|NCT03091075|Drug|Oxandrolone|Treatment group will receive Oxandrolone daily for 12 weeks postoperatively
75548401|NCT03091075|Drug|Placebo|Placebo group will receive placebo for 12 weeks postoperative
75709870|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
75871222|NCT02353702|Device|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
75548402|NCT03080974|Drug|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
76037537|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.
76037538|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.
76037539|NCT02542059|Radiation|68Ga-exendin PET/CT|68Ga-exendin PET/CT
76037540|NCT02477696|Drug|Acalabrutinib|Participants will receive oral acalabrutinib as stated in arm description.
75548403|NCT03080974|Procedure|Irreversible Electroporation|Non-thermal ablation of tumor
75871223|NCT02353702|Drug|Infusion of placebo during 48 hours|
75871224|NCT02353702|Drug|NaCl|
76037541|NCT02477696|Drug|Ibrutinib|Participants will receive oral ibrutinib as stated in arm description.
76037542|NCT02468232|Drug|LCZ696|The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
75548404|NCT03071913|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
75548405|NCT03071913|Other|Laboratory Biomarker Analysis|Correlative studies
75548406|NCT03059563|Drug|Varenicline|Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
75548407|NCT03059563|Other|Placebo|A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
75548408|NCT03040973|Drug|Capmatinib|Tablet for oral use; 150 mg, 200 mg; twice a day
75548409|NCT03040973|Drug|Nazartinib|Capsule for oral use; 25 mg, 50 mg; once a day
75548410|NCT03040973|Drug|Gefitinib|tablets for oral use; 250mg; once a day
76037543|NCT02468232|Drug|Enalapril|The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
76037544|NCT02468232|Drug|Placebo to LCZ696|LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
76037545|NCT02468232|Drug|Placebo to Enalapril|Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
76037546|NCT02262780|Drug|Low dose of telmisartan|
76037547|NCT02262780|Drug|High dose of telmisartan|
76037548|NCT02262780|Drug|HCTZ|
75548411|NCT03040973|Drug|Osimertinib|Tablets for oral use; 40 mg, 80 mg; once a day.
75548412|NCT03031730|Drug|Carfilzomib|Given IV
75548413|NCT03031730|Drug|Dexamethasone|Given PO
75709871|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
75709872|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
75709873|NCT00817557|Drug|Loteprednol|Anti-inflammatory
75871225|NCT02532660|Drug|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
75871226|NCT02532660|Drug|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
75871227|NCT02532660|Drug|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
75871228|NCT02532660|Drug|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
76037549|NCT02221778|Radiation|SBRT|"SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below:~Prescription dose(Gy) / (MLD) (Gy)~50 / 13~45 / 15~40 / 15~35 / 15.5~30 / 16~27.5 / 17~If the dose constraints cannot be met, prescription will be according to the level immediately bellow.~Treatment will be delivered in 5 fractions in consecutive working days"
76037550|NCT02210117|Biological|Bevacizumab|Given IV
76037551|NCT02210117|Procedure|Biopsy|Undergo biopsy
76037552|NCT02210117|Biological|Ipilimumab|Given IV
76037553|NCT02210117|Other|Laboratory Biomarker Analysis|Correlative studies
76037554|NCT02210117|Procedure|Metastasectomy|Undergo metastasectomy
76037555|NCT02210117|Biological|Nivolumab|Given IV
76037556|NCT02210117|Procedure|Therapeutic Conventional Surgery|Undergo nephrectomy
76037557|NCT02199600|Device|GMK Sphere Knee Replacement|
76037558|NCT02185443|Radiation|SBRT|"60Gy in 3 fractions (20Gy/fraction) over 14 days~60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above"
75548414|NCT03031730|Drug|Dexamethasone Sodium Phosphate|Given IV
75548415|NCT03031730|Drug|Lenalidomide|Given PO
75548416|NCT03031730|Drug|Navtemadlin|Given PO
75709874|NCT00817557|Other|Rewetter|
75709875|NCT00811161|Device|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
75709876|NCT00611026|Drug|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
75871229|NCT01377168|Drug|oral naltrexone|
76037559|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
75548417|NCT03004287|Drug|Carfilzomib|Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
75709877|NCT00611026|Drug|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
75548418|NCT03004287|Drug|Thalidomide|Given by mouth at bedtime: days 1-4 of Induction
75548419|NCT03004287|Drug|Dexamethasone|Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
75548420|NCT03004287|Drug|Daratumumab|Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
75548421|NCT03004287|Drug|Cisplatin|Given by vein: days 1-4 (continuous infusion) of Induction
75709878|NCT00611026|Drug|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
75709879|NCT00813969|Biological|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
75709880|NCT02552589|Other|Amine fluoride|toothpaste
75709881|NCT02552589|Other|Placebo|toothpaste
75709882|NCT00811239|Drug|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
75709883|NCT00811239|Other|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
75709884|NCT00814047|Drug|Yohimbine hydrochloride|
75709885|NCT00646113|Device|OsseoSpeed™ TX 3.0S|OsseoSpeed™ TX 3.0 mm diameter
75871230|NCT01377168|Drug|Placebo pill|
75548422|NCT03004287|Drug|Adriamycin|Given by vein: days 1-4 (continuous infusion) of Induction
75548423|NCT03004287|Drug|Cyclophosphamide|Given by vein: days 1-4 (continuous infusion) of Induction
75548424|NCT03004287|Drug|Etoposide|Given by vein: days 1-4 (continuous infusion) of Induction
75548425|NCT03004287|Drug|Melphalan|Given by vein: days -4 - -1 of Transplant(s)
75548426|NCT03004287|Procedure|ASCT|day 0 of Transplant(s)
75548427|NCT03004287|Drug|Lenalidomide|Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
75548428|NCT03004287|Drug|Bortezomib|Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
75548429|NCT02986659|Drug|Metformin|
75548430|NCT02986659|Drug|Placebo|
75548431|NCT02933489|Diagnostic Test|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
75548432|NCT02933489|Diagnostic Test|Digital Tomosynthesis Mammography|Undergo DBT
75548433|NCT02933489|Other|Quality-of-Life Assessment|Ancillary studies
75548434|NCT02933489|Other|Questionnaire Administration|Ancillary studies
75709886|NCT00814125|Drug|Anastrozole (Arimidex)|1mg, orally, once daily
75709887|NCT00814125|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
75709888|NCT00814125|Drug|Nolvadex placebo|
75709889|NCT00814125|Drug|Arimidex placebo|
75871231|NCT02892149|Drug|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
75548435|NCT02837978|Drug|Tacrolimus|Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
76037560|NCT02161380|Drug|injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
76037561|NCT02161380|Drug|injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)|injection of Total Volume of each intravitreal injection is 100 µL
76037562|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)|injection of Total Volume of each intravitreal injection is 100 µL
76037563|NCT01994239|Drug|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
76037564|NCT01994239|Radiation|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
76037565|NCT01985230|Device|ReActiv8 Implantable Stimulation System implanted and activated.|
76037566|NCT01895933|Device|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
76037567|NCT01804816|Procedure|Acupuncture|Standardized acupuncture administration for 10 sessions.
75399403|NCT02978820|Other|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
75399404|NCT02978742|Behavioral|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
75709890|NCT04016883|Other|Problem Solving Therapy offered through a web platform|Problem Solving Therapy offered through a web platform. There will be four sessions, during the first four weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; different ways to reach goals are discussed and evaluated; action plans are created, and its effectiveness is evaluated to achieve the objectives. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model.
75709891|NCT04016883|Other|Conventional web platform|The conventional web platform, which will contain the general content on stress coping techniques.
75709892|NCT00817713|Drug|Praziquantel, Ivermectin, Albendazole|"Standard HIV care plus triple anthelminthic treatment~Praziquantel 2400mg single dose~Ivermectin 12 mg, single dose~Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months."
75709893|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
75871232|NCT02892149|Drug|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
75399405|NCT02978742|Behavioral|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
75548436|NCT02837978|Drug|MTX|MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
75548437|NCT02833402|Device|InterStim Therapy|Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
75548438|NCT02802423|Drug|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
75548439|NCT02777346|Device|Absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
75548440|NCT02777346|Device|Non absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
75548441|NCT02743806|Drug|Vedolizumab|Vedolizumab IV infusion
75548442|NCT02694666|Other|Controlled whole-body vibration training|The intervention is an 8-week program
75709894|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
75709895|NCT00422383|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
75709896|NCT00814281|Other|placebo|Placebo
75709897|NCT00814281|Drug|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
75709898|NCT00817791|Device|Hyperbaric oxygen pretreatment (GR2200)|2 hours/day,5 days before surgery
75871233|NCT02353624|Behavioral|Cycling|Cycling distance of 2880 km in 14 days
75871234|NCT02352532|Other|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
75399406|NCT02978586|Device|[Ga-68]PSMA PET/MR|All participants will undergo at least 1 baseline [Ga-68]PSMA PET/MR. If participants test positive for [Ga-68]PSMA tumor uptake, they will under up to 2 additional scans
75399407|NCT02978274|Drug|MMF|MMF withdrawal by engraftment post haplo-SCT
75399408|NCT02978274|Drug|MMF|MMF withdrawal by 2 month post haplo-SCT
75709899|NCT00811551|Device|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
75399409|NCT02978430|Device|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
75399410|NCT02978430|Other|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
75871235|NCT02352532|Other|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
75399411|NCT02978352|Other|learning|
75709900|NCT02542540|Other|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
76037568|NCT01804816|Other|No Intervention|No intervention during this period. This was a control period. Each subject acted as their own control.
75709901|NCT00811629|Other|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
76037569|NCT01803555|Drug|Budesonide/Formoterol SPIROMAX®|BF Spiromax will be administered per dose and schedule specified in the arm.
76037570|NCT01803555|Drug|SYMBICORT® TURBOHALER®|Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
76037571|NCT01803555|Drug|SYMBICORT placebo|SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
75709902|NCT02542228|Other|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
75871236|NCT02348476|Other|No Intervention|No study drug is administered in this study.
75871237|NCT05046912|Behavioral|Yoga|8 weeks of online weekly yoga or chair yoga class
75871238|NCT05046912|Behavioral|Mindfulness|8 weeks of online weekly mindfulness class
75871239|NCT02348398|Drug|Pazopanib|600 mg by mouth daily in a 28 day cycle.
75871240|NCT02348398|Drug|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
75399412|NCT02977962|Behavioral|Cognitive-Behavior Therapy|This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
75871241|NCT02348398|Behavioral|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
75871242|NCT02352688|Procedure|Enhanced Colorectal Geriatric Care|
75399413|NCT02977962|Other|Treatment as Usual|Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
75871243|NCT03147352|Device|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
75871244|NCT02352454|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
76037572|NCT01803555|Drug|SPIROMAX Placebo|SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
76037573|NCT01499628|Behavioral|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
75871245|NCT01378806|Behavioral|Nutrition and exercise education and coping skills training|A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
76037574|NCT01499628|Behavioral|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
76037575|NCT01499628|Behavioral|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
75548443|NCT02693652|Biological|CVI-HBV-002|"Investigational product: CVI-HBV-002~Dose: 20ug or 40ug~Frequency: 3 or 6 times~Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~Administration route: Intramuscular injection"
75709903|NCT00814359|Drug|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
75871246|NCT03147274|Behavioral|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
75871247|NCT05278338|Drug|JMT103|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
75871248|NCT05278338|Drug|Denosumab|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
75871249|NCT05278338|Drug|Placebo|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
75871250|NCT03721757|Biological|Nivolumab, Surgery, Radiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
75871251|NCT03721757|Biological|Nivolumab, Surgery, Chemoradiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy
75399414|NCT02978040|Drug|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
75871252|NCT02352376|Other|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
75548444|NCT02692170|Biological|CVI-HBV-001|Investigational Product
75871253|NCT02352376|Other|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
75871254|NCT03727607|Drug|Desflurane|Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
75399415|NCT02978040|Drug|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old) .
75399416|NCT02978040|Drug|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
75399417|NCT02977416|Other|anti-TNFα|
75871255|NCT05157516|Procedure|erector spinea block|the patients will receive a single injection erector spinea block after induction of general anesthesia
75871256|NCT05157516|Procedure|Caudal epidural block|the patients will receive caudal epidural block after induction of general anesthesia
75399418|NCT02977728|Other|Olfactory Evaluation|The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
75548445|NCT02692170|Biological|Conventional Hepatitis B vaccine (20 μg)|Investigational Product
75709904|NCT00814359|Drug|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
75871257|NCT02348242|Device|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
75399419|NCT02987634|Other|PeriActive|mouthwash
75548446|NCT02674100|Other|Registry|
75548447|NCT02668653|Drug|Chemotherapy|
75548448|NCT02668653|Drug|Quizartinib|
75548449|NCT02668653|Drug|Placebo|
75709905|NCT00817869|Other|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
76037576|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization"
75709906|NCT00612040|Drug|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
75871258|NCT02348242|Device|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
75871259|NCT02348242|Device|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
76037577|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization."
76037578|NCT01297764|Drug|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~15 15 300 40~20 15 300 40~20 25 300 40~20/27* 25 300 40~20/27* 25 400 40"
76037579|NCT01245179|Drug|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~15 mg MWF 3 weeks on, 1 week off (if needed)~15 mg MWF every week (starting dose)~20 mg MWF 3 weeks on, 1 week off~20 mg MWF every week"
76037580|NCT01112306|Drug|ACT-293987|Tablets, twice daily
76037581|NCT00967863|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
76037582|NCT00967863|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy
76037583|NCT00633633|Other|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
76037584|NCT00633633|Behavioral|Exercise Training|Exercise training 3 times a week.
75399420|NCT02977650|Procedure|Endoscopic ultrasonography-guided fine needle aspiration|
75709907|NCT00612040|Drug|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
75709908|NCT00612040|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
75709909|NCT00612040|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
76037585|NCT00633633|Behavioral|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
76037586|NCT00607828|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
76037587|NCT00574886|Biological|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
75399421|NCT02977338|Other|Retrospective review|
75399422|NCT02977104|Other|Maestro ECG|Telemetry is obtained through the Maestro handheld ECG device.
75709910|NCT00422227|Drug|Etanercept , Methotrexate|"Etanercept: 25 mg twice weekly over 16 weeks, SC~Methotrexate: > 7.5 mg/week and no more than 25 mg/week, PO"
75709911|NCT00422227|Drug|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
75709912|NCT02551497|Drug|CNV1014802|
75709913|NCT00811785|Drug|Copper Histidine|Daily subcutaneous injections for three years
76037588|NCT00542438|Behavioral|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
76037589|NCT00542438|Behavioral|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
75399423|NCT02977182|Other|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
75399424|NCT02977260|Other|Thin/Low Energy|Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
75399425|NCT02977260|Other|Thin/High Energy|Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
75548450|NCT02661997|Behavioral|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
75709914|NCT00814515|Drug|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
75709915|NCT00814515|Drug|NOVA22007|Vehicle
75709916|NCT00814593|Biological|lymphokine-activated killer cells|Instilled into the tumor bed cavity
76037590|NCT00242814|Drug|Micardis|
75399426|NCT02977260|Other|Thick/Low Energy|Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
75399427|NCT02977260|Other|Thick/High Energy|Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
75399428|NCT02976870|Radiation|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
76037591|NCT00242814|Drug|Amlodipine|
75709917|NCT00814593|Drug|polifeprosan 20 with carmustine implant|Intracranial placement
75709918|NCT02542306|Drug|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
76037592|NCT00242814|Procedure|Abdominal biopsy|
76037593|NCT00168857|Drug|telmisartan|
76037594|NCT00168857|Drug|losartan|
75399429|NCT02977026|Behavioral|CYD|
75399430|NCT02977026|Behavioral|AHC|
75399431|NCT02976558|Behavioral|Clown theatrical Performance|
75399432|NCT02976558|Procedure|Acupuncture|Acupuncture according to Traditional Chinese Medicine
75399433|NCT02976558|Behavioral|Music Therapy TaKeTiNa|
75399434|NCT02976324|Device|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
75399435|NCT02976402|Radiation|SBRT|"Postoperative RT consisting in:~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
75399436|NCT02976168|Other|12° head down tilt|supine head down tilt
75399437|NCT02976246|Dietary Supplement|Vitamin K2 (MK7)|One tablet of vitamin K2 (MK7) 360 micrograms given once daily.
75399438|NCT02976246|Other|Placebo|One tablet of placebo given once daily.
76037595|NCT04827329|Other|Questionnaire|Patients will complete a questionnaire regarding their anesthesia history, course and possible complications, and Questions about their treatment for their sleep disorder.
75399439|NCT02976480|Procedure|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
75399440|NCT02976480|Procedure|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
75399441|NCT02975856|Dietary Supplement|Table Red Wine|
75399442|NCT02975856|Dietary Supplement|Young Port Red Wine|
75399443|NCT02976012|Drug|Aflibercept|. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
75399444|NCT02976012|Procedure|Endolaserless Vitrectomy|Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
75399445|NCT02975778|Device|Pain Monitor™|Pain measured by Pain Monitor™
75709919|NCT00817947|Device|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
75709920|NCT00421993|Drug|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
75709921|NCT00421993|Drug|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
75709922|NCT00421993|Drug|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
75709923|NCT00421993|Drug|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
75709924|NCT00884884|Drug|Double Placebo|1 capsule daily
75709925|NCT00884884|Drug|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
75709926|NCT00884884|Drug|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
75709927|NCT00884884|Drug|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
75399446|NCT02975388|Drug|RO7079901|Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
75399447|NCT02975466|Device|Insertion of AirQ Blocker and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
75399448|NCT02975466|Device|Insertion of AuraGain and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
75709928|NCT00884884|Drug|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
75709929|NCT00884884|Drug|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
75399449|NCT02975466|Device|Insertion of I-Gel and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
75399450|NCT02975622|Procedure|Central venous catheterization|Ultrasound guided central venous catheterization
75399451|NCT02975544|Behavioral|CRECES programme|The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
75399452|NCT02975076|Drug|Sanchitongshu|The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
75709930|NCT00884884|Drug|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
75709931|NCT00884884|Drug|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
75709932|NCT00884884|Drug|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
75709933|NCT00884884|Drug|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
75709934|NCT00884962|Device|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
76037596|NCT05251467|Other|Focus group|Focus group to confirm PROM conceptual framework
76037597|NCT05251467|Other|Patient interview (n = approximately 10)|Patient interviews to refine possible questions for the PROM
75709935|NCT00814749|Procedure|midureteral sling|midureteral sling
75709936|NCT00814749|Other|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
75709937|NCT01037725|Drug|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
75709938|NCT01037725|Drug|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
76037598|NCT05251467|Other|Questionnaire (n = 180)|Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population
75709939|NCT02551029|Other|Capsaicin|
76037599|NCT05251467|Device|Testing of the pilot PROM in a smartphone app (n = 100)|Daily testing of the pilot PROM in a smartphone app for 2 weeks
76037600|NCT04925167|Drug|Argatroban|Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
75709940|NCT02551029|Other|Placebo|
75709941|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
76037601|NCT04925167|Drug|unfractionated heparin|unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
76037602|NCT04812587|Behavioral|exercise intervention program|The experimental group will receive a 12-week combined exercise intervention program with extra emphasis on balance, muscle strength, and walking ability which involved two 2-hour sessions once per week.
76037603|NCT04998565|Other|Routine care|Reverse pressure applied to the areola
76037604|NCT04998565|Procedure|Electrical Acupuncture|Acupuncture on Hegu, Sanyinjiao, Zusanli and Taichong with electrical stimulation
76037605|NCT04998565|Procedure|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation over bil breasts
76037606|NCT04427267|Other|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
75399453|NCT02975076|Drug|placebo of Sanchitongshu|The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
75399454|NCT02975076|Drug|Aspirin|
75399455|NCT02975076|Drug|Clopidogrel|
75709942|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
76037607|NCT04817657|Biological|Ad26.COV2.S|Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1*10^11 virus particles per milliliter (vp/ml) as intramuscular injection.
76037608|NCT04812431|Biological|Neural precursor cells derived from human embryonic stem cell line|When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.
76037609|NCT05011669|Drug|Lurasidone|Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
76037610|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
76037611|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
76037612|NCT02524665|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
76037613|NCT02524665|Other|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
76037614|NCT02524665|Other|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
75399456|NCT02975076|Drug|placebo of clopidogrel|
75399457|NCT02975232|Behavioral|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
75399458|NCT02975232|Behavioral|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
75709943|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
75709944|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
76037615|NCT02524665|Other|Skin Perfecting Lotion|Available over the counter.
76037616|NCT04812353|Other|Follow-up of Io-Fix type fixation|Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
76037617|NCT03079843|Other|exposure to particulate matter with N 95 facemask|2 hours' / day exposure to particulate matter face mask worn during exposure.
75548451|NCT02661997|Behavioral|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
75548452|NCT02652052|Other|Standard of Care - Observation Only|Control Arm - Observation only
75548453|NCT02652052|Drug|Group 2: Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
75548454|NCT02652052|Drug|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
75709945|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
75709946|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
75709947|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
75709948|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
75709949|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
75709950|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
75709951|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
75399459|NCT02975154|Device|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
75399460|NCT02974920|Drug|Rivaroxaban 10 MG|Rivaroxaban 10 mg once daily for 180 days
75709952|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
75709953|NCT00413959|Drug|VELCADE®|1.6 mg/m^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
75709954|NCT00413959|Drug|Rituximab|375 mg/m^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
76037618|NCT03079843|Other|exposure to particulate matter with no face mask|2 hours'/ day exposure to particulate matter with no face mask
75709955|NCT00413959|Drug|Cyclophosphamide|400 mg/m^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
75709956|NCT00413959|Drug|Decadron|40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
75709957|NCT00814905|Drug|saline|A saline infusion after delivery (one dose)
76037619|NCT04433689|Device|Non-Contact measurement of corneal properties|Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
75399461|NCT02974920|Drug|Aspirin|Aspirin 100 mg once daily for 180 days
75399462|NCT02974764|Other|No intervention/exposures|
75399463|NCT02974530|Other|Neurological evaluation|
75399464|NCT02974530|Other|Laryngological evaluation|
75399465|NCT02974530|Other|MRI evaluation|
75399466|NCT02974530|Other|Breathing investigation|
75399467|NCT02974530|Other|MRI and articulatory investigation|
75399468|NCT02974530|Other|Postural investigation|
75399469|NCT02974530|Other|Voice and soundscape investigation|
75399470|NCT02974374|Drug|PF-06835919|Single or repeated, escalating dose
75399471|NCT02974374|Other|Placebo|Single or repeated, escalating dose
75709958|NCT00814905|Drug|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
75399472|NCT02974062|Other|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
76037620|NCT04817423|Other|No intervention|No intervention
75709959|NCT00814905|Drug|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
75709960|NCT00814905|Drug|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
75709961|NCT00645567|Device|Unassisted Manual Transfer|No device assistance
75709962|NCT00645567|Device|Standard Transfer Board|Flat surface board
75399473|NCT02973906|Other|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
75399474|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
75399475|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
75399476|NCT02973672|Drug|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
75399477|NCT02973360|Drug|Docosahexaenoic Acid|Oral Capsule
75399478|NCT02973360|Drug|Placebo|Oral Capsule
75399479|NCT02973282|Other|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
75399480|NCT02973204|Drug|Sorafenib|
75399481|NCT02973204|Procedure|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
75399482|NCT02973204|Drug|Everolimus|
75399483|NCT02973204|Drug|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
75709963|NCT00645567|Device|Glide n' Go|Flip down power lift chair
75709964|NCT00645567|Device|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
75709965|NCT00645567|Device|Ryno lift|Lift for the wheelchair
75709966|NCT00611884|Drug|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
75709967|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
75709968|NCT00611884|Drug|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
75709969|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
75709970|NCT00611884|Drug|metformin|Tablets, 1500-2000 mg/day
75709971|NCT03867825|Device|Non-invasive hemodynamic monitoring|Impedance cardiography
75709972|NCT00420745|Biological|Rotarix™|Two-dose oral vaccination.
76037621|NCT03079765|Behavioral|Behavioral skills training|Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.
76037622|NCT03079765|Behavioral|Protocol Only|Participants will be given a written protocol describing how to conduct the target assessment procedure.
75709973|NCT00420745|Biological|Placebo|Two-dose oral administration
76037623|NCT04998175|Procedure|ventriculo-peritoneal shunt|A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
75399484|NCT02972970|Device|Aveera|Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
75399485|NCT02972736|Radiation|Radiation dose expressed as DAP|
75399486|NCT02972814|Device|Laboratory based troponin test|acquisition of blood troponin level by Roche Cobas E 603
75399487|NCT02972814|Device|Point of care based troponin test 1|acquisition of blood troponin level by Radiometer EQT 90 Flex
75399488|NCT02972814|Device|Point of care based troponin test 2|acquisition of blood troponin level by Philips Minicare I-20
75399489|NCT02959476|Drug|Ropivacaine|Anesthetic
75399490|NCT02959476|Drug|Placebos|Inactive comparator
75399491|NCT02959398|Device|Standard mammography|Standard mammography
75709974|NCT00611806|Dietary Supplement|Folic Acid|Folic acid 2mg po daily
75709975|NCT00611806|Dietary Supplement|B12|B12 400 micrograms po daily
75399492|NCT02959398|Device|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
75399493|NCT02959008|Device|measure TOI and BP|Both groups measure TOI and BP.
75399494|NCT02958930|Device|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
75399495|NCT02958852|Drug|Letrozole|
75399496|NCT02958852|Drug|Letrozole and atorvastatin|
75399497|NCT02958852|Drug|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
75399498|NCT02958774|Radiation|Hypofractionated Radiation Therapy|Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
75709976|NCT00611806|Other|Placebo|1 capsule po daily
75709977|NCT00413413|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
76037624|NCT04427969|Behavioral|prone position|to lay in prone position at least 12 hour in a day at ICU
75709978|NCT00413413|Drug|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
75548455|NCT02649972|Drug|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
75709979|NCT00413413|Drug|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
75399499|NCT02676804|Other|High-intensity, aerobic exercise.|"Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of ~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of ~10 - 12 and participants will be asked to complete this on their own."
75399500|NCT02641782|Drug|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
75399501|NCT02641782|Drug|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
75548456|NCT02615119|Drug|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
75548457|NCT02615119|Drug|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
75548458|NCT02558010|Drug|Methadone|Perioperative IV methadone to be given
75548459|NCT02558010|Other|Normal Saline|control arm
75548460|NCT02558010|Drug|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
75709980|NCT00886132|Drug|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
75709981|NCT01040455|Drug|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
75709982|NCT01040455|Drug|placebo|placebo once daily for eight weeks
75399502|NCT02641782|Drug|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
75399503|NCT02641782|Drug|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
75399504|NCT02641782|Drug|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
75709983|NCT01040611|Behavioral|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
75709984|NCT01040767|Other|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
75709985|NCT01040923|Device|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
75709986|NCT01041001|Biological|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
75709987|NCT01041001|Procedure|Microfracture treatment|
75548461|NCT02550548|Drug|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
75548462|NCT02550548|Drug|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
75709988|NCT01041157|Other|Resistance training|Neck muscle trainings effect on botulinum toxin efficiency
75709989|NCT01041235|Drug|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
75399505|NCT02641314|Drug|metronomic therapy|"Propranolol 0.5 mg/kgxd p.o. day 1,~mg/kgxd p.o. day 2,~mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
75399506|NCT01711710|Device|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
75709990|NCT01041313|Drug|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
75399507|NCT04769622|Procedure|Non-surgical periodontal treatment|all included patients will be subjected to non-surgical periodontal therapy
75399508|NCT04769622|Other|Questionnaires|"All patients will be asked to complete a set of questionnaires regarding:~adherence to Mediterranean Diet;~sleep quality;~physical activity;~perceived stress."
75399509|NCT04769778|Drug|Valsartan 80Mg Oral Tablet|treatment with 80mg /day of valsartan
75399510|NCT04769076|Combination Product|Paclitaxel（Albumin-bound）|Three courses of albumin-bound paclitaxel combined with cisplatin and PD-1 monoclonal antibody neoadjuvant treatment followed by cisplatin combined with IMRT (intensity modulated conformal radiotherapy) concurrent radiotherapy and chemotherapy
75399511|NCT04769232|Device|EG-760Z endoscope by Fujifilm|"Within a single endoscopic procedure under propofol sedation, images of the esophageal wall will be acquired and biopsies will be taken. All patients will be examined using the EG-760Z endoscope by Fujifilm.~In all patients as part of the clinical routine 4 biopsies of the proximal and 4 biopsies of the distal esophagus will be taken."
75548463|NCT02550548|Drug|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
75548464|NCT02545673|Behavioral|Enhanced linkage to care|
75399512|NCT04768998|Other|Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Observatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care.
75399513|NCT04768842|Drug|LY3209590|Administered SC.
75548465|NCT02545673|Behavioral|Standard-of-care plus|
75548466|NCT02534233|Device|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
75548467|NCT02530502|Other|Laboratory Biomarker Analysis|Correlative studies
75548468|NCT02530502|Biological|Pembrolizumab|Given IV
75548469|NCT02530502|Radiation|Radiation Therapy|Undergo focal RT
75548470|NCT02530502|Drug|Temozolomide|Given PO
75548471|NCT02494700|Radiation|External Beam Radiation Therapy|Undergo orbital EBRT
75548472|NCT02494700|Drug|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
75548473|NCT02484404|Drug|Olaparib|Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID) Ph II - MEDI4736 + Olaparib at RP2D
75548474|NCT02484404|Drug|Cediranib|Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily) Ph II - MEDI4736 + Cediranib at RP2D
75548475|NCT02484404|Drug|Durvalumab|Ph I - Durvalumab will be administered once every 2 weeks for 12 months.
75548476|NCT02460783|Other|Boost (R) 5-2 diet|Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
75548477|NCT02460783|Other|Healthy Living Diet|Counseling and educational material on diet portion, consistency
75548478|NCT02437318|Drug|Fulvestrant|
75548479|NCT02437318|Drug|Alpelisib|
75548480|NCT02437318|Drug|Alpelisib placebo|
75548481|NCT02305238|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
75548482|NCT02234934|Biological|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10^6 cells per kg of body weight transduced ex vivo with 1 x 10^8 IG/mL of lentiviral vector to achieve > 0.3 integrated copies per cell."
75709991|NCT01041313|Drug|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
75399514|NCT04768764|Procedure|Ultrasound Guided Middle Adductor Canal Block|"Middle adductor canal block will be applied post-operatively with guidance of USG.~Drug:Bupivacaine 0.25% Injectable Solution"
75399515|NCT04768764|Procedure|Ultrasound Guided Femoral Nerve Block.|Femoral nerve block will be applied post-operatively with guidance of USG. Drug:Bupivacaine 0.25% Injectable Solution
75709992|NCT01041391|Procedure|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
75399516|NCT04768764|Drug|Bupivacain|10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution. Bupivacaine 0.25% Injectable Solution
75399517|NCT04768764|Procedure|Spinal Anesthesia|Patients will be placed in the lateral decubitus position.Subarachnoid space will be entered through the most suitable intervertebral space.Bupivacaine 0.5% Heavy will be given in the appropriate dose.
75399518|NCT04768530|Procedure|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
75399519|NCT04768530|Drug|Nitazoxanide hydrogel|Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
75399520|NCT04768140|Procedure|Bobath treatment approach|scapulothoracic mobilization exercise, reaching in different directions in the supine position and upper extremity weight transfer exercise.
75399521|NCT04768140|Procedure|Conventional physiotherapy|range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
75399522|NCT04749654|Other|The Salivary pH measured|The saliva samples were obtained at 10-12 a.m. from all children. The saliva was collected into plastic cylinders and the salivary pH was measured with a pH meter (Compact pH meter B-212 twin pH, HORIBA, Osaka, Japan).
75399523|NCT04749654|Other|The saliva flow rate was measured|The saliva flow rate was estimated by during the first 30 s of paraffin chewing. The saliva was collected into plastic cylinders for a period of 5 minutes. Afterward, the saliva were weighed with a in a precision balance (Mettler PC 400, Zurich, Switzerland) and the flow rate was computed in gms/ml.
75399524|NCT04749654|Other|Streptococcus mutans and Lactobacillus counts in saliva were measured|The saliva samples were obtained according to described above. Numbers of colony-forming units (CFU) of S. mutans were counted on TSY20B agar and Lactobacilli were counted on Rogosa agar.
75399525|NCT04749498|Other|White Bread|Test breakfast with white bread was served after 12-hours of fasting and participants were asked to consume the meal in full, within 15 minutes.
75399526|NCT04749498|Other|Whole Wheat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
75548483|NCT02176148|Drug|fluocinonide 0.05% cream|
75548484|NCT02175004|Drug|Inotersen|Inotersen SC
75548485|NCT02143050|Drug|Dabrafenib|
75548486|NCT02143050|Drug|Trametinib|
75548487|NCT02143050|Drug|Metformin|
75548488|NCT02107976|Dietary Supplement|Vitamin C|500mg twice a day after discharge, for a minimum of 8 weeks
75399527|NCT04749498|Other|Barley Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
75548489|NCT02075840|Drug|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
75548490|NCT02075840|Drug|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
75399528|NCT04749498|Other|Oat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
75399529|NCT04749342|Other|Physiotherapy Treatment|Physical Therapy sessions for treatment of advanced Lymphedema Cases
75548491|NCT01961557|Device|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
75548492|NCT01957956|Other|Laboratory Biomarker Analysis|Correlative studies
75709993|NCT03760939|Other|Clinical and economical evaluation|Evaluation of the clinical and the economical impact of a colorectal surgery
75709994|NCT00610714|Drug|AZD0530|oral once daily dose
75399530|NCT04749420|Other|Survey study|Cervical Radiculopathy Impact Scale (CRIS) will be applied
75399531|NCT04748562|Drug|Progesterone|Taking prontogest vaginally
75399532|NCT04745286|Drug|S-ketamine|Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Agent preparation method of S-ketamine group (Group S): Draw the dosage of S-ketamine 0.25mg ·kg -1 and dilute it with normal saline to 5ml in opaque 5-ml syringes.
75399533|NCT04745286|Drug|normal saline group|"Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Normal saline group (Group N): 5ml of normal saline, labeled as study agents."
75548493|NCT01957956|Biological|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
75548494|NCT01957956|Drug|Temozolomide|Given PO
75548495|NCT01863550|Drug|Bortezomib|Given SC or IV
75548496|NCT01863550|Drug|Carfilzomib|Given IV
75548497|NCT01863550|Drug|Dexamethasone|Given PO
75548498|NCT01863550|Other|Laboratory Biomarker Analysis|Optional correlative studies
75548499|NCT01863550|Drug|Lenalidomide|Given PO
75548500|NCT01863550|Other|Quality-of-Life Assessment|Ancillary studies
75548501|NCT01686334|Biological|DC vaccine|Autologous WT1 mRNA-electroporated DCs
75548502|NCT01620203|Other|No intervention/treatment is given|
75548503|NCT01572506|Drug|Biotin RBC survival|
75548504|NCT01465490|Behavioral|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
75709995|NCT00610714|Drug|Carboplatin|intravenous injection
75709996|NCT00610714|Drug|Paclitaxel|intravenous infusion
76037625|NCT04998253|Drug|Effects in oxygenation and hypoxic pulmonary vasoconstriction|"Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution."
76037626|NCT05289999|Device|Virtual reality headset for first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
76037627|NCT05289999|Device|Virtual reality headset for second injection|Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
76037628|NCT04827017|Other|follow up|follow up population
75548505|NCT01334983|Behavioral|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
75548506|NCT00866957|Procedure|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
75548507|NCT00105378|Behavioral|Dutch EASYcare Study Geriatric Intermediate Care Programme|
75548508|NCT00091637|Drug|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
75548509|NCT00091637|Drug|Placebo infusion|bolus infusion over a 10 minute period once
75709997|NCT00403585|Drug|adefovir dipivoxil 10mg|
75709998|NCT04038112|Other|psychological therapy Method of Levels (MOL)|Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
75709999|NCT00886210|Procedure|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
75548510|NCT00288743|Drug|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
75548511|NCT00321633|Drug|carboplatin|
75548512|NCT00321633|Drug|docetaxel|
75710000|NCT00886210|Procedure|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
75548513|NCT02960633|Device|Corail with collar.|
75548514|NCT02960633|Device|Corail without collar.|
75548515|NCT00288782|Drug|Mirtazapine|
75548516|NCT01059825|Drug|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
75548517|NCT01059825|Drug|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
75548518|NCT01059825|Drug|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
75548519|NCT01059825|Drug|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
75548520|NCT01059825|Drug|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
75548521|NCT01059825|Drug|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
75548522|NCT01059825|Drug|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
75548523|NCT00288899|Other|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
75548524|NCT00288899|Other|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
75548525|NCT00321750|Drug|1% pimecrolimus cream|
75548526|NCT00321867|Procedure|Graft augmented posterior repair|Posterior repair with graft
75710001|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
75399534|NCT04745364|Behavioral|A 4-week Bharatanatyam course from the organization Mindful Kala|The 4-week Mindful Kala program focuses on three components of Bharatanatyam: nritta (i.e. technical movements), natya (i.e. storytelling), and nritya (i.e. a combination of movements and narration; nritta + natya).
75399535|NCT04745442|Drug|Antithrombin + best available treatment|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
75399536|NCT04745442|Drug|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
75548527|NCT00321867|Procedure|Control|Native tissue repair
75548528|NCT00288977|Procedure|Islet Infusion|
75548529|NCT00321945|Procedure|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
75548530|NCT00323076|Drug|18F-FAZA PET Imaging|"Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient."
75548531|NCT00323154|Drug|Nalbuphine|
75548532|NCT00289055|Device|stent|Cordis SMART™ Nitinol Stent
75548533|NCT00289055|Device|angioplasty|balloon angioplasty
75548534|NCT00323232|Device|2 Versus 4 Hole DHS|See Detailed Description.
75548535|NCT00289172|Biological|Live attenuated human rotavirus vaccine|
75548536|NCT00323349|Procedure|Oral Glucose Tolerance Testing|
75548537|NCT00323349|Behavioral|Education tailored to learning style preferences|
75548538|NCT00289250|Drug|Sulfadoxine-pyrimethamine|
75548539|NCT00289250|Drug|Sulfadoxine-pyrimethamine plus artesunate|
75548540|NCT00289367|Drug|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
75548541|NCT00289367|Drug|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
75548542|NCT00323505|Drug|Pegylated Interferon|
75548543|NCT00323505|Drug|Interferon-alpha2a|
75548544|NCT00289406|Drug|S-amlodipine gentisate|
75548545|NCT00289406|Drug|Amlodipine besylate|
75548546|NCT00323544|Drug|zidovudine and lamivudine (Combivir®)|
75548547|NCT00323544|Drug|emtricitabine and tenofovir DF|
75548548|NCT00289445|Drug|Mitomycin C|
75399537|NCT04744740|Device|in-home sleep recording|in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
75399538|NCT04745052|Other|Clinical observation index|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
75399539|NCT04744896|Device|cryolipolysis(3 max cool shaping)|cryolioplysis applied over abdomen area
75548549|NCT00289445|Drug|5-FU|
75548550|NCT00289445|Drug|Folinic acid|
75710002|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
76037629|NCT03078439|Other|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
76037630|NCT05324475|Dietary Supplement|BCAA|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
76037631|NCT05324475|Dietary Supplement|Micronutriments|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
75399540|NCT04744896|Device|Treadmill (jkexer focus 8020A)|aerobic training ( high intensity interval training)
75399541|NCT04744506|Device|Tissue Marker Clip|Tissue Marker Clip Placed in Metastatic Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
75399542|NCT04744038|Device|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
75399543|NCT04743882|Other||
75399544|NCT04743648|Behavioral|Innovative Thinking Development Program (ITDP)|With the implementation of the program, nursing students are expected to develop innovative thinking skills.
75399545|NCT04743414|Drug|CTP-543|Itraconazole in solution dosage form
75548551|NCT00323583|Drug|paclitaxel|
75548552|NCT00323583|Drug|oxaliplatin|
75548553|NCT00323583|Drug|leucovorin|
75710003|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
75548554|NCT00323583|Drug|5-fluorouracil|
75548555|NCT00323583|Drug|glutathione|
75548556|NCT00323583|Drug|calcium and magnesium|
75548557|NCT00323583|Procedure|Chemotherapy|
75548558|NCT00323583|Procedure|Chemoprotection|
75548559|NCT00323583|Procedure|Complementary and alternative therapy|
75548560|NCT00289484|Drug|Omega-3 Polyunsaturated Fatty Acids|
75548561|NCT00323661|Device|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
75548562|NCT00323661|Device|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
75548563|NCT00289562|Drug|forodesine hydrochloride (BCX-1777)|
75548564|NCT00289601|Drug|eptifibatide|
75548565|NCT00323778|Drug|Hyalgan|
75548566|NCT00289679|Device|Hip prosthesis revision|
75548567|NCT00323817|Drug|Z-338|
75548568|NCT00289796|Biological|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
75399546|NCT04743336|Other|Measuring pocket depth|Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
75399547|NCT04743180|Device|LUMINOR© Paclitaxel eluting balloon|Patients will be treated with the Luminor paclitaxel eluting balloon
75399548|NCT04743258|Procedure|MAXILLARY PREMOLAR EXTRACTION|Patients will undergo bilateral maxillary 1st premolar extraction before bonding followed by leveling & alignment.
75399549|NCT04743258|Procedure|DISTALIZATION|Maxillary arch will be distalized with the help Zygomatic miniplates will be placed bilaterally.
75399550|NCT04742790|Diagnostic Test|Scalp electroencephalography (EEG)|Resting EEG will be recorded before initiation of the combination treatment (visit 1) and 7-10 days after treatment (visit 2). Drug-induced sedation-related changes in the EEG frequency spectrum. Five minutes of resting EEG eyes-open will be recorded in a quiet room while participants are asked to focus on an image displayed on a wall. Then, they will be asked to close their eyes for an additional 2 minutes. The alpha power ratio eyes open/eyes closed will be computed (alpha attenuation coefficient; Kaida et al., 2006). Changes in this coefficient will be used as a measure of drug-induced sedation.
75399551|NCT04742790|Diagnostic Test|Laser-evoked potentials (LEPs)|Laser-evoked potentials (LEPs) will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short pulses (50-100 ms) of radiant heat generated by a C02 laser stimulator will be applied to the skin of the left or right hand dorm to briefly and selectively activate heat-sensitive pain receptors. A concomitant EEG recordings will be used to measure the amplitude and latency of the elicited laser-evoked potentials. Changes in LEP amplitude (expressed as percentage of change) will be used as a measure of drug-induced effects on the state of the thermonociceptive system.
75399552|NCT04742790|Diagnostic Test|Cognitive auditory-evoked potentials (P300)|Cognitive auditory-evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short-lasting auditory tones will be delivered using a three-stimulus oddball paradigm combining standard tones (90% of stimuli), slightly different target tones that the subject must attend and detect (10% of stimuli), and strongly different distractor non-target tones (10% of stimuli). The stimuli will be delivered binaurally using headphones. Participants will be instructed to press a button when they detect a target tone, and to ignore the standard and distractor non-target tones. The EEG recordings will be used to measure the amplitude and latency of the cognitive P3a and P3b potentials (Komerchero & Polich 1999). Changes in P3a/P3b amplitude will be used as a measure of drug-induced effects on cognition (expressed as percentage of change).
75399553|NCT04742790|Diagnostic Test|Cervical somatosensory-evoked potentials|Cervical spinal-cord evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. The responses will be elicited by transcutaneous electrical stimulation of the median nerve. The N13 component of this response is mediated by large myelinated non-nociceptive fibers and reflects a segmental postsynaptic response of dorsal horn interneurons at the level of lumbar spinal cord (Cruccu et al., 2008). Changes in magnitude of the N13 will be used as a measure of drug-induced effects on spinal cord function (expressed as percentage of change).
75548569|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
75548570|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
75548571|NCT00323895|Device|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
75548572|NCT00289835|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
75548573|NCT00303225|Drug|Vaccine: SIGA-246|
75548574|NCT00323934|Drug|MGCD0103|Oral dosage 2 times weekly.
75548575|NCT00290030|Drug|Alfuzosin|
75548576|NCT00303264|Drug|dexloxiglumide|
75548577|NCT00303264|Drug|Nexium (esomeprazole)|
75548578|NCT00290069|Drug|Tacrolimus|
75548579|NCT00290069|Drug|Rapamycin|
75548580|NCT04718259|Drug|intrathecal bupivacaine|The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
75548581|NCT04718259|Drug|midazolam|midazolam
75548582|NCT00290108|Drug|Propofol|
75548583|NCT00323973|Drug|Bisoprolol|10 mg qd
75548584|NCT00290225|Behavioral|Breath Water Sound Course and Traumatic Incident Reduction|
75399554|NCT04742790|Diagnostic Test|Pupillometry|Pupillometry measurements will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Pupillometry has been proposed as a method to assess opioid pharmacodynamics. The extent of pupil dilatation can provide an index of nociceptive input via autonomic innervation of the iris muscles, while the extent of the attenuation of this pupillary response during exposure to opioid analgesics could provide an index of pharmacological effects reflecting the extent of opioid receptor occupancy in the CNS. Pupillometry (static pupil diameter, variability of pupil diameter [variation coefficient of pupillary dilation, VCPD, Charier et al. 2017]), light-evoked speed of pupil constriction [maximum pupil constriction velocity, PCV, Connely et al., 2014]) will be measured using a handheld pupillometry device routinely used for clinical evaluations.
76037632|NCT05324475|Dietary Supplement|standard treatment + placebo|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
75548585|NCT00324012|Drug|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
75548586|NCT00290264|Drug|Budesonide/formoterol|
75548587|NCT00303342|Behavioral|mind body treatment|regulation of attention, respiration and posture
75548588|NCT00303342|Behavioral|desensitization|mentation on insomnia behaviors and cognitive activity
75548589|NCT00290303|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
75548590|NCT00324051|Drug|olanzapine therapy|
75548591|NCT00303381|Drug|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
75399555|NCT04742790|Diagnostic Test|Saccadic Peak Velocity|The saccadic peak velocity (SPV; m/s) will be measured before before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Saccadic peak velocity is one of the most sensitive parameters for sedation. Recording of eye movements will be performed in a quiet room with dimmed lightning. Average values of saccadic peak velocity (expressed as degrees/second) of all correct saccades will be measured.
75399556|NCT04742790|Diagnostic Test|Adaptive tracking test|The test will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Adaptive tracking is a pursuit-tracking task sensitive to impairment of eye-hand coordination by drugs. It has been proven useful for measuring CNS effects of alcohol, various other psychoactive drugs, and sleep deprivation.
76037633|NCT03078283|Other|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
75399557|NCT04742790|Diagnostic Test|Body Sway Test|Body sway will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, using a body sway meter and with eyes closed. The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. The method has been used to demonstrate effects of sleep deprivation, ethanol and psychoactive drugs. All body movements over a 2-min period are integrated and expressed as millimeters of sway.
76037634|NCT03075007|Radiation|Florbetaben F18|10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
75548592|NCT00303381|Drug|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
75548593|NCT00303381|Drug|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
75548594|NCT00290420|Drug|Chloroquine profilaxis|"Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
75548595|NCT00324090|Behavioral|High and low glycemic index|
75548596|NCT00303420|Drug|"Alteplase push protocol"|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
75548597|NCT00303420|Drug|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
75548598|NCT00324129|Drug|MGCD0103|MGCD0103 given orally three times per week.
75548599|NCT00290576|Dietary Supplement|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
76037635|NCT03075007|Procedure|Transcranial Doppler|All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
75548600|NCT00303537|Drug|metformin|
75548601|NCT00290849|Drug|Bivalirudin|
75548602|NCT00290927|Drug|insulin glulisine|
75548603|NCT00303576|Drug|dapivirine (TMC120) vaginal gel|
75548604|NCT00290966|Drug|XRP6976|
75548605|NCT00324285|Drug|Amylase resistant starch added ORS|
75548606|NCT00291005|Drug|ARD6562, Docetaxel|
75548607|NCT00303615|Drug|Fluoxymesterone 10 mg|
75548608|NCT00303615|Drug|Anastrozole 1 mg|
75548609|NCT00291044|Other|testing for HSV 1 and 2 IgG type specific antibosy|
75548610|NCT00324324|Drug|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
75548611|NCT00324324|Drug|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
75548612|NCT00303654|Procedure|biopsy|
75548613|NCT00303654|Procedure|therapeutic conventional surgery|
75548614|NCT00291122|Drug|celecoxib 400 mg BID|
75548615|NCT00324363|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
75548616|NCT00324363|Drug|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
75710004|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
75710005|NCT04037644|Procedure|Fluid loading with Albumin|Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
75710006|NCT04037644|Procedure|Fluid loading with Ringer Lactate|Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
75710007|NCT00403273|Drug|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
75710008|NCT00403273|Drug|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
75710009|NCT00885274|Drug|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
75399558|NCT04742790|Diagnostic Test|N-back working memory test|"Working memory performance will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. In this test, a series of letters are shown to the participant on a computer screen. The test includes three conditions with increased working memory load. The 0-back condition simply requires to indicate whether the presented letter is the letter X or another letter. In the 1-back condition, participants are requested to indicate whether the displayed letter is identical to the preceding letter. In the 2-back condition, participants are required indicate whether the letter is repeated with one other letter in between (e.g., B … C … B)."
75548617|NCT00303732|Drug|RAD001 (everolimus)|
75548618|NCT00303732|Drug|PTK787 (vatalanib)|
75548619|NCT00291239|Behavioral|partial sleep deprivation|
75710010|NCT00885274|Drug|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
75710011|NCT00885430|Drug|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
75710012|NCT00886366|Drug|AZD6714|Oral single doses a-h suspension
75710013|NCT00886366|Drug|Placebo|Oral single doses suspension
75710014|NCT00886366|Drug|AZD6714|Oral single doses a-d suspension
75710015|NCT00886366|Drug|AZD6714|Oral single doses d and g suspension
75710016|NCT00886444|Drug|Ferucarbotran (Resovist)|single time intravenous bolus injection of a contrast agent
75548620|NCT00291356|Drug|GSK189075 oral tablets|
75548621|NCT00291356|Drug|GW869682 oral tablets|
75548622|NCT00291395|Drug|PGI2|
75548623|NCT00303771|Drug|fluorouracil|
75548624|NCT00303771|Drug|irinotecan hydrochloride|
75548625|NCT00303771|Drug|leucovorin calcium|
75548626|NCT00291473|Drug|CHP-HER2, CHP-NY-ESO-1|
75399559|NCT04742790|Other|Patient-reported outcomes|Before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, but also daily between the two visits, 14 days, 1 month, 3 months and 6 months after treatment initiation, patient-reported outcomes will be collected to assess clinical effects and side-effects of the combination treatmen These include the short form of the Brief Pain Inventory (BPI), the PROMIS PQ-NEURO score for neuropathic pain, the Stanford Sleepiness Scale (SSS), and the PROMIS Neuro-QOL self-assessment of cognitive functioning.
75548627|NCT00324441|Device|Iratherm® 1000|
76037636|NCT03078205|Other|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
76037637|NCT03078205|Other|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
76037638|NCT02638129|Drug|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
76037639|NCT02638129|Drug|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
75399560|NCT04742478|Procedure|Rotational Atherectomy|Rotational atherectomy (RA) has been the most used atherectomy modality since its first inception in1988. RA uses high speed rotation (140,000 - 180,000 rpm) to ablate inelastic plaque, resulting in debris averaging 5µm in size24. The main focus of RA in the era of DES stent has been on plaque modification rather that plaque debulking with more papers showing improved PCI success rates.
75399561|NCT04742244|Dietary Supplement|Lvemon verbena extract|Each capsule contained 200 mg of lemon verbena extract 2 capsules/day, 14 days
76037640|NCT03079687|Drug|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
75399562|NCT04742244|Dietary Supplement|maltodextrin|Each capsule contained 0 mg of lemon verbena extract 2 capsules/day, 14 days
75710017|NCT00888550|Procedure|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
75710018|NCT00888550|Procedure|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
75710019|NCT00888706|Behavioral|Control Condition|The group participated in the usual nursing home activities and routines.
76037641|NCT04997551|Drug|Colchcine|"In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~Day 1: 1 single dose of 1 mg orally, in a single dose.~Days 2 to 6: 0.5 mg every 12 hours v.o.~Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day"
76037642|NCT04997707|Drug|Propofol Abbott|in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group
76037643|NCT04997707|Drug|Sevoflurane Inhalation Solution|in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.
76037644|NCT04997707|Diagnostic Test|transcranial motor evoked potential(Tcm|using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.
75710020|NCT00888706|Behavioral|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
75399563|NCT04741854|Device|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
75399564|NCT04741152|Procedure|Pancreatic resection|Different pancreatic resections
75399565|NCT04740840|Drug|Levamlodipine|According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
75548628|NCT00291512|Behavioral|Theory-based counseling program|
75548629|NCT00303810|Drug|carboplatin|
75548630|NCT00303810|Drug|cisplatin|
75548631|NCT00303810|Drug|cyclophosphamide|
75548632|NCT00303810|Drug|etoposide phosphate|
75548633|NCT00303810|Drug|high-dose chemotherapy|
75548634|NCT00303810|Drug|lomustine|
75399566|NCT04740840|Drug|Amlodipine|According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
75710021|NCT00888706|Behavioral|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
75399567|NCT04740762|Behavioral|Intervention group|The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
75710022|NCT00888706|Behavioral|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
75710023|NCT00402727|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
75710024|NCT00402727|Drug|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
75710025|NCT04037722|Dietary Supplement|Whey|45 g whey + 20 g maltodextrin
75710026|NCT04037722|Dietary Supplement|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
75710027|NCT02541916|Other|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy & LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
75710028|NCT00923494|Drug|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
75710029|NCT00923494|Drug|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
76037645|NCT04997863|Device|Sericin hydrogel sheet impregnated with EBN extract|Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
76037646|NCT04997863|Device|Placebo hydrogel sheet|Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
75399568|NCT04740528|Diagnostic Test|fto gene testing|Blood samples were collected after a 12-h fasting by Prodia Laboratory for DNA isolation and biochemical analysis
75399569|NCT04740450|Device|Kinesio taping|skin colored Kinesio-Tex Gold tape, 50 mm _ 5 m (Kinesio Holding Corp, Albuquerque, NM) tapped in technique described by Gozluklu et al in 2020
75399570|NCT04740450|Device|Wound Tape|skin colored wound tape tapped in technique described by Gozluklu et al in 2020
75399571|NCT04740216|Behavioral|exercise therapy plus jaw device|The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.
75399572|NCT04740216|Behavioral|exercise therapy|the control group performed 20-minute stretching exercises each time.
75548635|NCT00303810|Drug|methotrexate|
75548636|NCT00303810|Drug|thiotepa|
75548637|NCT00303810|Drug|vincristine sulfate|
75548638|NCT00303810|Radiation|radiation therapy|
75548639|NCT00291590|Behavioral|DHEP|
75548640|NCT00324480|Drug|alvocidib|Given IV
75548641|NCT00324480|Drug|vorinostat|Given orally
75710030|NCT00923494|Drug|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
75548642|NCT00324480|Other|pharmacological study|Correlative studies
75548643|NCT00291629|Drug|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
75548644|NCT00291629|Procedure|collection of mobilized peripheral blood stem cells|
75548645|NCT00291629|Procedure|Intracoronary infusion of mobilized cells|
75548646|NCT00303888|Drug|docetaxel|Given IV
75548647|NCT00303888|Drug|idronoxil|Given orally
75548648|NCT00303888|Other|placebo|Given orally
75548649|NCT00291707|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
75548650|NCT00291707|Drug|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if >6000 cGy to be delivered)
75548651|NCT00291707|Procedure|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
75548652|NCT00324519|Device|Foley bulb|
75548653|NCT00324519|Drug|misoprostol|
75548654|NCT00291746|Drug|Esomeprazole|
75710031|NCT00886522|Procedure|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
76037647|NCT05010889|Procedure|Peroral endoscopic myotomy (POEM)|POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
75399573|NCT04740138|Behavioral|Dialectical Behavioral Therapy Skills + Parent Training|"The DBT/Parent training group intervention is a novel integration of three evidence-based treatments (i.e. DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC)). The DBT Skills portion of each session follows the DBT Skills Training Manual Second Edition and DBT Skills Training Handouts and Worksheets Second Edition. DBT Skills portions cover the four modules of traditional DBT Skills: mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness.~PMT portions of the intervention cover: praise, positive interactions and parental attention, reward systems, effective commands, use of consequences, and problem solving. EC portions of the intervention cover: psychoeducation on children's emotional development, teaching children to identify and label emotions, validation of children's emotions, handling children's negative emotions, fostering children's positive emotions and parental modeling of emotion regulation and expression."
75399574|NCT04740684|Other|Standardized diet|Standardized diet is prepared in a commercial kitchen and packaged in single serve portions to provide to participants to consume for 7 days
75399575|NCT04739904|Other|Normoxia|48 hours experimental protocol conducted at sea level
75399576|NCT04739904|Other|Normobaric hypoxia|24 hours experimental protocol conducted in a normobaric hypoxic facility
75548655|NCT00291746|Procedure|Bravo technique|
75548656|NCT00303927|Drug|capecitabine|
75548657|NCT00419484|Drug|pioglitazone|
75548658|NCT00291785|Drug|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 & 29 of each 42-day cycle
75548659|NCT00291785|Drug|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
75548660|NCT00291785|Drug|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
75548661|NCT00304005|Drug|laromustine|
76037648|NCT05010499|Drug|Levobupivacaine|femoral nerve block receives 20 ml of levobupivacaine 0.25%
75548662|NCT00291824|Behavioral|Cardiovascular risk factors and willingness to change|
75548663|NCT00324558|Drug|Bemiparin|subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
75548664|NCT00291863|Drug|Simvastatin|
75710032|NCT00402649|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
75710033|NCT00888784|Procedure|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
76037649|NCT05010499|Drug|Levobupivacaine|Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
76037650|NCT05010187|Behavioral|Behavioral: Motivational Interview (MI)|Single-session, brief motivational interview.
75548665|NCT00304200|Drug|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
76037651|NCT05010187|Behavioral|Behavioral: Health Coaching (HC)|Single-session health coaching.
75399577|NCT04739904|Other|Hypobaric hypoxia|72 hours experimental protocol conducted at terrestrial altitude
76037652|NCT03075241|Drug|Zolpidem|Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights
75710034|NCT00888784|Drug|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
75710035|NCT00886678|Drug|pemetrexed|500 mg/m2, IV, q 21 days x 2 cycles
75399578|NCT04739748|Diagnostic Test|complete blood picture|Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
75548666|NCT00291902|Drug|SB-681323|
76037653|NCT03075241|Drug|Zoplicone|Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights
76037654|NCT03075241|Drug|Placebo|Inactive or inert pill which will be used as a comparator
76037655|NCT03074929|Behavioral|Novel risk communication|The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
76037656|NCT04997083|Device|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
76037657|NCT04997083|Device|Petit face mask|The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
75399579|NCT04739202|Drug|Atezolizumab + Ipatasertib|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
75399580|NCT04739202|Drug|Atezolizumab + Bevacizumab|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
75548667|NCT00291941|Biological|Henogen HBV vaccine|20µg, Month 0, 2 and 6
75548668|NCT00291941|Biological|FENDRIX|20 µg,Months 0, 1, 2 and 6
75548669|NCT00291980|Biological|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
76037658|NCT04994119|Drug|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
76037659|NCT04994119|Drug|Warfarin|Oral Warfarin (Coumadin) 5 mg film coated tablets
76037660|NCT03074851|Dietary Supplement|low sodium salt|To give free low sodium salt intervention for 2 months
75548670|NCT00291980|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
75548671|NCT00324597|Drug|gemcitabine hydrochloride|
75548672|NCT00324597|Drug|motesanib diphosphate|
75548673|NCT00324597|Other|pharmacological study|
75548674|NCT00292019|Procedure|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
75548675|NCT00324714|Drug|risedronate sodium|
75548676|NCT00324714|Other|diagnostic laboratory biomarker analysis|
75548677|NCT00292058|Device|Videoconference equipment (telepsychiatry)|
75548678|NCT00304317|Drug|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
75548679|NCT00304317|Other|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
75548680|NCT00292097|Procedure|Early tracheostomy|early conversion - less than or equal to 72 hours
75548681|NCT00292097|Procedure|Late tracheostomy|Late conversion (10-14 days)
75710036|NCT00886678|Drug|carboplatin|AUC=5,IV,q 21 days x 2 cycles
75710037|NCT00886678|Radiation|thoracic radiation|66 Gy over 33 fractions
75710038|NCT00886756|Drug|AZD8529|Oral
75710039|NCT00886756|Drug|Placebo|Oral
75548682|NCT00324792|Drug|intensive insulin therapy|
75710040|NCT00402337|Drug|linaclotide acetate|oral, once daily.
75710041|NCT00402337|Drug|Matching placebo|oral, once daily
75710042|NCT00888862|Drug|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
75710043|NCT00886912|Other|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
76037661|NCT03074851|Other|informational intervention|to give reporter informational intervention.
76037662|NCT01658943|Drug|Akt Inhibitor MK2206|Given PO
76037663|NCT01658943|Drug|Fluorouracil|Given IV
75399581|NCT04739514|Other|Exercises for dysphagia rehabilitation|Diet modifications, postural exercises, compensatory exercises, swallowing exercises
75399582|NCT04739046|Drug|Theragene arm|Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
75399583|NCT04738656|Dietary Supplement|Diet plan|Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
75399584|NCT04738266|Diagnostic Test|Amyloid Cardiomyopathy|Echocardiographic red flags of Amyloid Cardiomyopathy to guide the suspicion of disease and to proceed with second level diagnostic work up including cardiac scintigraphy with bone tracers and search of monoclonal component in serum and urine
75399585|NCT04738500|Procedure|PENG Block combinated with PCA|After spinal anesthesia PENG block will be performed
75399586|NCT04738500|Procedure|PCA|PCA will be applied after surgery
75399587|NCT04738032|Other|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
75548683|NCT00292175|Procedure|Narrow Band Imaging|
75548684|NCT00292175|Procedure|colonoscopy|
75548685|NCT00292214|Drug|Paracetamol (acetaminophen)|
75548686|NCT00324831|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
75399588|NCT04738188|Procedure|DEB-TACE|Drug-eluting beads transcatheter arterial chemoembolization
75399589|NCT04738188|Procedure|cTACE|Transcatheter arterial chemoembolization
75548687|NCT00324831|Drug|cyclophosphamide|
75548688|NCT00324831|Drug|doxorubicin hydrochloride|
75710044|NCT00886912|Other|normoxia|training under normoxic conditions
75399590|NCT04738188|Device|Drug-eluting Beads|Drug-eluting beads
75710045|NCT04037332|Other|Blood sample (combined with malaria RDT) followed by gentoyping analysis|Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
75710046|NCT00886990|Drug|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
75710047|NCT00886990|Drug|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
75710048|NCT00650091|Drug|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
75399591|NCT04738188|Drug|Epirubicin|Chemotherapy drug for intra-arterial infusion
75399592|NCT04737798|Other|oil pulling with coconut oil|using oil pulling therapy with coconut oil
75399593|NCT04737798|Other|oil pulling with sesame oil|using oil pulling therapy with sesame oil
75399594|NCT04737486|Drug|AV-001|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
75548689|NCT00324831|Drug|prednisone|
75548690|NCT00324831|Drug|rituximab|
75548691|NCT00324831|Drug|sargramostim|
75548692|NCT00324831|Drug|vincristine|
75710049|NCT00650091|Drug|Placebo|Participants will receive placebo each day.
75710050|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
76037664|NCT01658943|Drug|Oxaliplatin|Given IV
76037665|NCT01658943|Drug|Selumetinib|Given PO
76037666|NCT02600819|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
76037667|NCT02600819|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily
75399595|NCT04737486|Other|Placebo|D-PBS
75399596|NCT04737564|Behavioral|Attachment and Biobehavioral Catch-up (ABC10)|"The ABC parenting targets include: nurturing children when they are distressed (Sessions 1 and 2), following the child's lead in play (Sessions 3 and 4), and avoiding harsh or frightening behavior (Sessions 5 and 6). Sessions 7 and 8 help parents consider how their own experiences of being parented affect their sensitivity, and Sessions 9 and 10 consolidate gains with additional practice. Session content focusing on parenting targets is guided by a manual. Additionally, parent coaches make frequent in-the-moment comments (at least once per minute) about parent-child interactions as they occur in session, and use video feedback."
75548693|NCT00324831|Procedure|Intervention/procedure|
75548694|NCT00324831|Procedure|antibody therapy|
75548695|NCT00324831|Procedure|biological therapy|
75548696|NCT00324831|Procedure|chemotherapy|
75548697|NCT00324831|Procedure|colony-stimulating factor therapy|
75548698|NCT00324831|Procedure|cytokine therapy|
75548699|NCT00324831|Procedure|monoclonal antibody therapy|
75548700|NCT00324831|Procedure|non-specific immune-modulator therapy|
75548701|NCT00324831|Procedure|therapeutic procedure|
75548702|NCT00324831|Procedure|tumor cell derivative vaccine|
75548703|NCT00324831|Procedure|vaccine therapy|
75548704|NCT00292253|Device|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
75548705|NCT00292253|Device|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
75548706|NCT00292331|Procedure|cyanoacrylate injection to treat gastric variceal hemorrhage|
75548707|NCT00304434|Drug|Oseltamivir|
75548708|NCT00304434|Drug|Probenecid|
75548709|NCT00292409|Drug|Aripiprazole|
75548710|NCT00324909|Drug|Hyperbaric Oxygen Therapy|
75548711|NCT00304473|Drug|Quetiapine fumarate|
75548712|NCT00292448|Drug|Ba 679 BR Respimat|
75710051|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
75710052|NCT00889096|Drug|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
75710053|NCT00889096|Drug|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
76037668|NCT03077971|Behavioral|ACT Self-Help|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
75710054|NCT00818103|Drug|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
75710055|NCT00818103|Drug|β-interferon|β-interferon 50ug i.m. qod for 2 years
76037669|NCT03077971|Behavioral|ACT Self-Help with Telephone Support|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
76037670|NCT04433533|Drug|Rosuvastatin 20|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
75548713|NCT00292448|Drug|Tiotropium (Spiriva) inhalation capsule 18 ug|
75548714|NCT00324948|Drug|Topical alprostadil (PGE-1)|
75548715|NCT00304551|Drug|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
75548716|NCT00304551|Drug|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
75548717|NCT00304551|Drug|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
75548718|NCT00325026|Drug|Misoprostol|
75710056|NCT00818103|Drug|EPO|EPO 10000U i.h. bid for 5 days
75710057|NCT00642369|Drug|quetiapine fumarate|600-750mg/day
75710058|NCT00642369|Drug|haloperidol|6-40mg/day
75710059|NCT02551575|Drug|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
75710060|NCT02551575|Drug|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
75399597|NCT04737564|Behavioral|Attachment and Biobehavioral Catch-up, Brief (ABC3)|The 3-session Attachment and Biobehavioral Catch-up intervention (ABC 3) is a brief version of the standard protocol. Parents who receive ABC 3 will receive the first 3 sessions of the ABC intervention, which focus on enhancing parental sensitivity (i.e., nurturance to distress, following the child's lead) by providing in-the-moment feedback on parent-child interactions, video feedback, and discussion of manualized content. ABC 3 was adapted from the standard protocol based on modeling of session-by-session data that demonstrated that, on average, most of the change in parental sensitivity happens in the first several sessions of the intervention.
75548719|NCT00325026|Device|Foley bulb|
75548720|NCT00304590|Drug|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
75548721|NCT00292487|Drug|Iopamidol 370 mgI/mL|
75548722|NCT00325104|Procedure|Parathyroid hormone testing|
75548723|NCT00325104|Procedure|Serum calcium testing|
75548724|NCT00292526|Drug|Enalapril|enalapril orally administered
75548725|NCT00418509|Drug|Mometasone furoate|
75548726|NCT00418509|Drug|Formoterol fumarate|
75548727|NCT00292721|Drug|Celecoxib|celecoxib: loading and maintenance for 6 months
75548728|NCT00292760|Drug|Alemtuzumab|
75548729|NCT00292760|Drug|Methyprednisolone|
75548730|NCT00325182|Drug|Levetiracetam|
75548731|NCT00325182|Other|Historical controls|
76037671|NCT04433533|Drug|Rosuvamibe 10/10|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
75548732|NCT00292799|Drug|Orlistat Vs Metformin|
75548733|NCT00304629|Drug|galantamine|
75548734|NCT00292838|Drug|fluticasone 25, 50, 100, 200 mcg|
75548735|NCT00304668|Drug|dapivirine (TMC120) vaginal gel|
75710061|NCT02551575|Drug|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
76037672|NCT04996459|Drug|Tislelizumab|Tislelizumab 200mg iv q3w
75548736|NCT04718324|Other|e-PROMS|Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention
76037673|NCT04811963|Device|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
76037674|NCT04993105|Other|Exercise + Graston.|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surae and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restrictionIce was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
76037675|NCT04993105|Other|exercise only|gastrocnemius and plantarstretching
75399598|NCT04737564|Behavioral|Safe Environment for Every Kid (SEEK)|Safe Environment for Every Kid (SEEK) is an evidence-based screening and referral system to facilitate parents' access to services for risk factors for maltreatment, including: mental health, substance abuse, intimate partner violence, harsh parenting, major parental stress, and food insecurity. Parents first complete the SEEK Parent Questionnaire with the help of an outreach worker. Following the SEEK protocol, handouts will be provided that address the identified problems and parents will be referred to partnering organizations in the community. Any additional work is completed by phone. The developer of the intervention, Howard Dubowitz, is a consultant on this application and will provide support around effective implementation.
75399599|NCT04737408|Drug|Rosuvastatin 40mg|Rosuvastatin 40 mg
75399600|NCT04737174|Drug|ES-481|28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
75399601|NCT04736784|Other|Food-based - beetroot juice|Beetroot juice containing approximately 340 mg nitrate daily
75399602|NCT04736784|Other|Food-based - leafy green vegetable juice|Leafy green vegetable juice containing approximately 340 mg nitrate daily
75399603|NCT04736238|Procedure|Arthroscopy surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. Establish an anteromedial channel at the inner side of the tibial anterior tibial tendon at the level of the tibiotalar joint, and establish an anterolateral channel at the lateral angle of the talus. Exploring and clearing the ankle joint and dealing with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then observe the lateral sulcus through the anterior medial channel, clean the synovium in the lateral sulcus, and explore the anterior talofibular ligament. A double-line anchor was inserted into the fibula side stop of the anterior talofibular ligament through the anterolateral channel. The anterior talofibular ligament was sutured using an outside-in technique in the anterior inferior safety zone of the distal end of the fibula. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
75548737|NCT04718324|Other|p-PROMS|Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
75548738|NCT00292877|Drug|SB-240563 (Mepolizumab)|
75548739|NCT00292916|Behavioral|whole body vibration|
75548740|NCT00292916|Behavioral|resistance exercise|
75548741|NCT00292916|Behavioral|"wellness"|
75548742|NCT00325221|Device|HM on|Home Monitoring activated after implantation
75548743|NCT00325221|Device|HM Off|Home Monitoring activated 9 months after implantation
75548744|NCT00292955|Drug|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
75548745|NCT00325260|Biological|Influvac; subunit influenza vaccine|
75548746|NCT00292994|Behavioral|Exercise|
76037676|NCT03074773|Drug|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
76037677|NCT03074773|Device|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
76037678|NCT03074773|Procedure|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
76037679|NCT03074773|Drug|Bupivacaine|it is an amino amide local anesthetic drug
76037680|NCT03074773|Other|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
76037681|NCT03077581|Drug|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
75399604|NCT04736238|Procedure|BrostrÖm surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. The first ankle arthroscopy is performed to deal with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then, open surgery was performed, and an arc incision was made at the anterior edge of the lateral malleolus to the tip of the fibula. After separating the subcutaneous tissue, the anterolateral joint capsule and talofibular ligament are exposed. A double-line anchor was placed at the fibular side stop of the anterior talofibular ligament. Tighten and suture the anterior talofibular ligament, anterolateral joint capsule, and extensor support belt with an anchor band. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
75399605|NCT04736160|Other|collect data|The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators
75399606|NCT04735848|Dietary Supplement|Iron-supplement application|The participants will take the corresponding amount of iron-supplement supervised at 8am.
75399607|NCT04735380|Device|TCM-5 Flex monitor connected to a Sensor 84 (Radiometer Medical Aps, Brønshøj, Denmark)|Patients undergo 2-3 hrs of observation while wearing the device.
75399608|NCT04735302|Other|Radiographic Feature|Radiographic rewiev
75399609|NCT04734912|Other|gastroscopy in transnasal techique|All patients with indication for gastroscopy in transnasal technique are included.
75548747|NCT00292994|Behavioral|Weight Loss|
75548748|NCT00293072|Drug|Rituximab|
75548749|NCT00293111|Drug|SDX-101 (R-Etodolac)|
75548750|NCT00304785|Drug|latanoprost 0.005%|
75548751|NCT00304785|Drug|Fotil|
75548752|NCT00304785|Drug|placebo|
75548753|NCT00293150|Drug|Eplerenone|
75548754|NCT00325299|Drug|Magnesium|
75548755|NCT02960334|Device|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
75548756|NCT00293228|Drug|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
75548757|NCT00293228|Drug|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
75548758|NCT00325338|Biological|Ragweed MATAMPL|
75548759|NCT00293345|Drug|gemcitabine hydrochloride|
75548760|NCT00293345|Drug|triapine|
75548761|NCT00293501|Drug|tinzaparin sodium|
75548762|NCT00325377|Procedure|MME Procedure|
75399610|NCT04735146|Other|Adapted physical activity|"Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity."
75548763|NCT00293618|Device|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
75548764|NCT00293618|Other|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
75548765|NCT00293618|Other|Feedback|Feedback about the physician's personal performance on prevention of PONV
75399611|NCT04734522|Device|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
75399612|NCT04734756|Device|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
75548766|NCT00325455|Drug|MK0859|
75399613|NCT04734834|Dietary Supplement|"Prodovite® VMP35"|"Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo"
76037682|NCT03077581|Drug|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
75399614|NCT04734600|Device|Electronic Treadmill device|"group A:PN-7001M Panasonic Treadmill 130 kg, frequency 50 HZ, input voltage AC220 V, input power 100W+_ 10 will usefor aerobic training program ,start by 1pbm grading to 2pbm speed and increase according to patient abilities during sessions ,0% treadmill inclination angle for two month as a total treatment period for study group patients.~Patients in this group will participate in aerobic training as march walking on treadmill for 45 mints duration for session 3 times per week, start with 5 mints warm up beginning and 5 mints cooling down at end session, in addition to their medical program and burger exercises"
75548767|NCT00293657|Drug|Lornoxicam 8 mg|
76037683|NCT03077581|Drug|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
76037684|NCT04993573|Other|Questionnaire|Questions about the impact of COVID-19 in their works
75548768|NCT00293657|Drug|Lornoxicam 16 mg|
75548769|NCT00293657|Drug|Placebo|
75548770|NCT00325494|Drug|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m^2 up to 400 mg/m^2.
75548771|NCT00293696|Drug|bicalutamide (Casodex), goserelin (Zoladex)|
76037685|NCT04993573|Other|Individual interview|Discussion between the searcher and the participant about representations of COVID-19 and experiences about confinement.
75548772|NCT00304863|Drug|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
75548773|NCT00293735|Drug|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours"
75548774|NCT00293735|Drug|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
75548775|NCT00293852|Procedure|Outpatient clinic follow-up|
76037686|NCT03073447|Other|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
75548776|NCT00304980|Drug|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
75548777|NCT00293891|Drug|Tacrolimus Cream|
75548778|NCT00325533|Behavioral|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
75548779|NCT00325533|Other|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
75548780|NCT00293930|Drug|Tacrolimus|
75548781|NCT00305019|Drug|clevudine|
75548782|NCT00293969|Drug|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
75548783|NCT00325611|Behavioral|Multidisciplinary palliative care team met with patient|
75548784|NCT00294008|Drug|Risperdal Consta|flexible dosage for 24 months
75548785|NCT00305097|Dietary Supplement|Decaffeinated coffee|5 cups per day for 8 weeks
75548786|NCT00305097|Dietary Supplement|Caffeinated coffee|5 cups per day for 8 weeks
75548787|NCT00305097|Dietary Supplement|No coffee|
76037687|NCT03074461|Procedure|Side-to-End Anastomosis|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
75399615|NCT04734600|Other|myofascial release technique|"group B:The myofascial release technique group will receive a 45 mints session time, for3 times per week for two months in addition to their medical program and burger exercises. Before the MF will starte, patient will rested in a relaxed prone position for 15 to 30 mints and also after end session time, MF protocol will applied as follow sequence over all period of total treatment sessions (8) week.:~thoracolumbar cross hand facial release technique for at least 5 mints for every barrier depth area, started by one hand will place on high thoracic area with pressure applied cephalic, the other hand was placed directly on the lower lumbo -sacrum area pushing caudal and arms are crossed to maximize as leverage as the barrier sense of softening will occurre and release sense on fascia under hand (release done at transverse alternative with longitudinal direction)alternation same methods to affected leg"
75399616|NCT05314842|Drug|Formocresol|dressing agents in pulpotomized primary molas using formocresol in cariously exposed vital primary molars
75399617|NCT05314842|Drug|Premixed bioceramic MTA|dressing agents in pulpotomized primary molas using premixed bioceramic MTA in cariously exposed vital primary molars
75399618|NCT05314530|Behavioral|ReTA-model|Validating the rehabilitation model ReTA
76037688|NCT03074461|Procedure|Transverse Coloplasty|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
75710062|NCT02541448|Device|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar & Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
75710063|NCT02552043|Other|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
75399619|NCT05314140|Diagnostic Test|Coronary artery calcium score evaluation|The evaluation of the coronary artery calcium score will be performed with chest CT scan
76037689|NCT04996537|Other|Micro-video digiral learning|On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
75399620|NCT05313984|Device|Sacral neuromodulation|"Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator."
75399621|NCT05313906|Drug|RC48+AK105+cisplatin|RC48 plus AK105 and cisplatin
75399622|NCT05313828|Drug|Acyclovir|acyclovir 4 times /day
75399623|NCT05313828|Drug|Tobramycin|tobramycin 4 times /day
76037690|NCT04996303|Drug|Routine steroid administration group|Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
76037691|NCT04996303|Device|Steroid pulse therapy group|Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg ~ 1g) pulse 3 days -> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
76037692|NCT03077503|Drug|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
75399624|NCT05313828|Drug|Fluorometholone|Fluorometholone 4 times/ day
75399625|NCT05313828|Drug|Sodium Hyaluronate|Sodium Hyaluronate 4 times/day
75399626|NCT05313750|Drug|anti-infective therapy sitafloxacin|anti-infective therapy
75399627|NCT05313750|Drug|anti-infective therapy levofloxacin|anti-infective therapy
75399628|NCT05313126|Other|sterile insect technique (TIS)|Sterile male Aedes albopictus mosquitos are released in the area/neighborhood
75399629|NCT05290350|Other|OSA|EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
75548788|NCT00294086|Drug|valsartan 160 mg|
75548789|NCT00294086|Drug|valsartan 160 mg BID|
75548790|NCT00325689|Drug|Quetiapine or Risperidone + Aripiprazole|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
76037693|NCT03077503|Drug|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
76037694|NCT03077503|Drug|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
75399630|NCT05248464|Other|The Patient Dignity Inventory instrument (PDI)|The PDI is an instrument made up of 25 items integrated into 5 factors that include: symptoms, existential anguish, dependency, peace of mind, and social support, prior to its application, adaptation, and validation will performer
75399631|NCT05248464|Other|WHOQOL-BREF (quality of life) instrument|The WHOQOL-BREF is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment, it consists of 24 items.
75399632|NCT05213910|Dietary Supplement|Lactichoc|dosage form: mix of 8 strains containing 1.2x10^11 CFU frequency, and duration: 2 capsules/day during 10 days
75399633|NCT05213910|Other|Stool sampling|3 stool samples are taken during the study (D0, D10 and D30)
75548791|NCT00325689|Drug|Quetiapine or Risperidone + placebo|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
75548792|NCT00294125|Drug|Flavocoxid|Daily flavocoxid for 12 weeks
75548793|NCT00294125|Drug|Placebo|Daily placebo for 12 weeks
75548794|NCT00294164|Drug|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
75548795|NCT00294164|Drug|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
75548796|NCT00325728|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
75548797|NCT00325728|Drug|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
75548798|NCT00417794|Drug|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
75548799|NCT00417794|Drug|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
75548800|NCT00417833|Drug|Intravitreal Bevacizumab|
75548801|NCT00305214|Procedure|T Wave Alternans Test|
76037695|NCT03077503|Device|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
76037696|NCT04993417|Other|Motor imagery technique along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.
75399634|NCT05201196|Other|Conventional physical therapy|Targeted muscle stretching and Strengthening (flexors, Extensors, abductors, internal and external rotators, of Shoulder, Elbow, forearm (supination & pronation) and hand 10 repetitions×1 set, 4 days/ week. Transcutaneous Electrical nerve Stimulation for 10-20 min, 4 days/ week. Total of 16 sessions were given each consisting of 45 mins.
75548802|NCT00417872|Drug|Nitazoxanide|
75399635|NCT05201196|Other|Task Oriented Training|"Experimental group was given Task oriented protocol including activities such as Table-top polishing, Arm cradling, Reach forward and pick-up or touch an object, Reached sideway to pick-up an object and transferring it to a table in front, Pouring~½ cup of water from a measuring pot into wide mouth glass held in opposite hand, Picking up pen from thumb and first two fingers, lifting a basket and placing it on the table 10 repetitions×1 set for each activity, 4-5days/week. Total of 16 sessions were given each consisting of 45 mins"
75548803|NCT00417872|Drug|Metronidazole|
75710064|NCT02541994|Device|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
76037697|NCT04993417|Other|Mime Therapy along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
75399636|NCT05158530|Other|Aerobic training|Aerobic training ( with cycle ergometer, 5-minute warm-up 15 - 30 minute cycle +5 minute cooldown) 40%-60% intensity calculated through Karvonen formula 3 days/ week
75399637|NCT05158530|Other|Pulmonary Exercises|"4 weeks protocol~Deep breathing Exercises* 10 Reps 3 sets~Postural drainage (10 minutes * 2 sets /day)~Incentive spirometry* 10 Reps 3 sets~Bed activities (Active ankle and hand pumping exercise * 10 Reps 3 sets)"
75548804|NCT00294203|Drug|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
75548805|NCT00294203|Other|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
75548806|NCT00305292|Drug|Modafinil-Alcohol Interactions|
75548807|NCT00294242|Procedure|membrane sweeping|
75548808|NCT00305331|Drug|Domperidone (drug)|
75548809|NCT00294281|Device|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
75548810|NCT00325767|Drug|nebulized albuterol (2.5 mg/3ml/dose)|
75548811|NCT00325767|Drug|nebulized levalbuterol (1.25 mg/3ml/dose)|
75399638|NCT05138952|Behavioral|Mindfulness Meditation|"30-day mediation program comprising:~Weekly group mediation tuition and support sessions delivered online. Sessions will last 45-60 minutes and focus on mindfulness meditation theory and techniques, and trouble shooting barriers to practice and engagement.~10-minutes of daily mindfulness meditation practice with the Headspace Inc app."
75399639|NCT04662684|Drug|Rivaroxaban 10 MG|No intervention
75399640|NCT04661202|Other|combined resistance and aerobic exercise training|"A supervised moderate-intensity exercise training session, which will include aerobic exercise with a stationary exercise bike, resistance exercise using dumbbell, theraband band, or gym ball for each major muscle groups and core muscles (including pelvic floor muscle (PFM) training with biofeedback), and stretching exercise, twice a week for 8 weeks. All exercises will be individualized based on participant's heart rate reserve and Rate of Perceived Exertion (RPE). An oximeter and a sphygmomanometer will be used to monitor the heart rate, oxygen saturation and blood pressure of the participants to ensure safety.~A home exercise program will include a walking exercise for 30 minutes per day and a PFM training with the aim of completing 1~3 sets of 8~12 submaximal contraction of PFM by holding 6~10 seconds with 12~20 seconds of rest between each contraction, and it will end with 3 maximal PFM contractions by holding 1~3 seconds 3~6 seconds of rest between each contraction."
75399641|NCT04634682|Dietary Supplement|MYODM|Formulated composition containing Theobroma cacao supplemented with caffeine
75399642|NCT04531410|Dietary Supplement|linoleic acid supplementation|Oils given daily at morning meal with extra enzymes
75399643|NCT04531410|Dietary Supplement|oleic acid supplementation|Oils given at morning meal with extra enzymes
75399644|NCT04497246|Other|Questionnaire|Data collection by means of various questionnaires
75399645|NCT04442256|Drug|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
75399646|NCT04175106|Other|a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value|"150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
75399647|NCT04175106|Other|a standard commercially available blueberry variety (i.e., cultivar)|"150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
75548812|NCT00325767|Drug|nebulized placebo (3ml/dose)|
75548813|NCT00294359|Drug|Mitomycin C; Capecitabine; Bevacizumab|
75548814|NCT00294437|Drug|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
75548815|NCT00305370|Drug|Aripiprazole|
75548816|NCT00325806|Drug|Ramipril|
75548817|NCT00294476|Drug|IVIG|
75399648|NCT04175106|Other|"a minimally processed blueberry-rich protein bar"|"A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
75710065|NCT02541994|Device|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
75710066|NCT00889408|Biological|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
76037698|NCT03074383|Behavioral|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
76037699|NCT03074383|Behavioral|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
75399649|NCT04175106|Other|a control beverage of matched-nutritive content|"The matched nutritive content of the blueberry-rich protein bar will be dissolved in whey protein~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
75399650|NCT04081428|Radiation|Stereotactic Body Radiotherapy|Daily collection of breath and blood before and after each of the 5 radiotherapy treatment sessions. Before and after daily cone beam CT image collection
75399651|NCT04044144|Dietary Supplement|Probiotic Dietary Supplement|Dietary supplement containing a combination of 8 probiotic strains
75399652|NCT04713930|Drug|JNJ-61393215|JNJ-61393215 will be administered orally.
75399653|NCT04713930|Drug|Placebo|Placebo will be administered orally.
75548818|NCT00294476|Procedure|Biological Therapy|
75548819|NCT00305409|Drug|Synbiotic (Synergy I / B.longum)|
75548820|NCT00294593|Drug|folinic acid|
75548821|NCT00325845|Procedure|Synvisc viscosupplementation|
75548822|NCT00294710|Drug|Aliskiren|
75548823|NCT00294749|Drug|Ciprofloxacine|
75548824|NCT00325923|Behavioral|Decision aid|
75548825|NCT00294788|Biological|Fluvax|
75548826|NCT00294788|Drug|PCC® (Lactobacillus fermentum VRI 003)|
75548827|NCT00325962|Drug|6R-BH4 (sapropterin dihydrochloride)|
75548828|NCT00294866|Drug|Paricalcitol|Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
75548829|NCT00305487|Drug|Ciclesonide nasal spray|
75548830|NCT00294905|Behavioral|Implementation of a combined smoking cessation strategy|
75548831|NCT00305526|Device|Contak Renewal (CRT-D)|
75548832|NCT00294944|Drug|Idazoxan|
75399654|NCT04713696|Other|Functional training|Functional training refers to exercises that targets the muscles of the lumbopelvic-hip complex in order for them to more appropriately support and control the spine.
75548833|NCT00326040|Device|Glaucoma Surgery|
75548834|NCT02960477|Other|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain.
75548835|NCT02960477|Other|Biomedical Education|A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
76037700|NCT05518695|Drug|BAT2022|Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
76037701|NCT05285475|Other|Exercise and Water Intake|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
75710067|NCT00887614|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
76037702|NCT05285319|Radiation|Prostate Only Radiation|Prostate Only Radiation for Intermediate and High Risk Prostate cancer
75399655|NCT04713696|Other|Routine training|Routine training refers to general exercises that perform before and after practice, including jogging, stretching and strengthening exercises for upper and lower extremities
76037703|NCT05285319|Radiation|Prostate and Pelvic Lymph Node Radiation|Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
76037704|NCT04136067|Drug|NNC0268-0965|One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
76037705|NCT04136067|Drug|insulin glargine|One daily dose of 3.0 nmol/kg administered s.c. for 6 days
76037706|NCT03073291|Behavioral|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
76037707|NCT05244291|Other|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week or 6 times in 2 weeks.
75548836|NCT00326079|Device|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
75548837|NCT00326157|Drug|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
75548838|NCT00295100|Drug|Tamoxifen|
75548839|NCT00326235|Drug|Buspirone|
75548840|NCT00295178|Drug|Daptomycin|
75548841|NCT00295178|Drug|Vancomycin|
75548842|NCT00305799|Procedure|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
75548843|NCT00295217|Device|ExAblate 2000|
75548844|NCT00305838|Drug|tamoxifen citrate|
75548845|NCT00305838|Other|diagnostic laboratory biomarker analysis|
75548846|NCT00295256|Behavioral|nurse case manager|
75548847|NCT00295295|Device|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
75548848|NCT00295295|Other|Standing|Standing 10 min/day
75548849|NCT00326274|Drug|Helioblock® SX Cream|
75548850|NCT00305916|Procedure|Multislice spiral computed tomography coronary angiography|
75548851|NCT00305916|Procedure|conventional coronary angiography|
75548852|NCT00295334|Drug|alcohol|
75548853|NCT00295373|Drug|Rosuvastatin|
75548854|NCT00295373|Behavioral|Exercise Training|
75548855|NCT00305955|Device|Spectacles|optimal spectacle correction
75710068|NCT00889564|Device|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
75548856|NCT00295412|Drug|quetiapine (drug)|
75548857|NCT00295529|Behavioral|Multifaceted educational intervention|Educational materials available at end of study
75548858|NCT00326352|Drug|Sedation with propofol and remifentanil|
75548859|NCT00419601|Drug|Remifentanyl|Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
75548860|NCT00419601|Drug|Fentanyl|start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
75710069|NCT01154335|Drug|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
75710070|NCT01154335|Drug|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
75710071|NCT00889642|Device|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
75710072|NCT00889642|Device|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
75710073|NCT02541526|Drug|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
75710074|NCT02541526|Drug|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
75710075|NCT01037959|Drug|Norfloxacin|400 mg/day (per os) for 6 months
75710076|NCT01037959|Drug|Placebo|1 pill/day (per os) for 6 months
75710077|NCT00887692|Behavioral|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
75710078|NCT01038037|Drug|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
75710079|NCT01038037|Drug|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
75710080|NCT01038037|Drug|panitumumab|i.v. day 1: 9 mg/kg q3w
75710081|NCT01038115|Procedure|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
75710082|NCT00645099|Drug|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
75710083|NCT00645099|Drug|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
75710084|NCT04401982|Drug|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
75710085|NCT01038271|Other|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
75548861|NCT00306033|Drug|Intravenous ImmuneGlobulin|
75548862|NCT00306072|Drug|nutritional herbal extract from Salacia oblonga|
75548863|NCT00295607|Drug|Tacrolimus|immunosuppression
75548864|NCT00295607|Drug|steroids, monoclonal anti-IL2R antibody|immunosuppression
75548865|NCT00326391|Drug|methylphenidate hydrochloride extended-release tablets|
75710086|NCT01038271|Other|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
75710087|NCT01038349|Other|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
75548866|NCT00306111|Drug|pegfilgrastim|Single dose (6mg) one day after chemotherapy
75548867|NCT00295685|Drug|Antacids|
75548868|NCT00306150|Drug|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
75548869|NCT00306150|Drug|Placebo|Placebo is used according to the description of Arm 1
75548870|NCT00295724|Drug|Bicifadine|
75548871|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
75548872|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
75548873|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
75710088|NCT00889954|Biological|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
75399656|NCT04713384|Device|Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games|20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
75399657|NCT04712682|Other|Assessment of neck posture.|pain, pain threshold, CVA angle, muscle strenght test, joint position sense test
75399658|NCT04712916|Behavioral|Health education|Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
75399659|NCT04708002|Other|early integrated palliative approach model|From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
75399660|NCT04708080|Procedure|thoracic epidural analgesia|A thoracic epidural catheter is routinely placed in patients undergoing open heart surgery in our hospital, at least 1 hour before heparin administration during the operation. After standard monitoring (ECG, SpO2, NIBP) is applied to the patients in the operating room, sedoanalgesia is provided with 1-3mg of midazolam and 50-100mcg of fentanyl. Then, by providing sterilization conditions, an epidural catheter is inserted through the T5-T6 interval with Tuohy needle. After confirming the location of the epidural catheter, 25mg / 10ml bupivacaine is administered as a bolus and then 3ml / hour bupivacaine infusion is started from the solution prepared as 3mg / ml and continues until the 48th postoperative hour. On the postoperative 2nd day, the catheter is removed 10-12 hours after LMWH administration and 2-4 hours after UFH, as recommended by the guidelines, paying attention to the anticoagulant administration times applied to the patients.
75399661|NCT04707924|Device|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
75548874|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
75548875|NCT00295763|Drug|Thyrogen (thyrotropin alfa for injection)|"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."
76037708|NCT03073135|Behavioral|Psychodrama Group Therapy (PGT)|"The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem."
75548876|NCT00326430|Behavioral|Cognitive Therapy, Interpersonal Therapy|
75710089|NCT04601623|Other|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
75710090|NCT00887770|Drug|AZD5672|12 x 50mg tablet, oral, single dose
75399662|NCT04707456|Other|Training operator|"After recruitment, the participants were divided into two groups to perform first-trimester ultrasound scan by two different levels of proficiency.~First group : operator has experience more than 3 years in NT scan and second trimester ultrasound scan Second group : operator has experience less than 3 years in NT scan and second trimester ultrasound scan"
75399663|NCT04707612|Other|No intervention.|No intervention.
75548877|NCT00417911|Drug|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
75548878|NCT00326469|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
75548879|NCT00417950|Drug|Acarbose|
75548880|NCT00306267|Drug|epoetin alfa|
76037709|NCT03073135|Behavioral|Supportive Group Therapy (SGT)|SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
76037710|NCT03072979|Radiation|Stereotactic body radiotherapy|Stereotactic body radiotherapy
75548881|NCT04718597|Procedure|Robotic assisted inguinal hernia repair|Robotic assisted inguinal hernia repair with DaVinci Xi system instead of open repair
75548882|NCT04718597|Procedure|Open inguinal hernia repair|Classical approach (open repair)
75548883|NCT00326508|Drug|Daclizumab|
75548884|NCT00295802|Device|Integrated Imaging High Intensity Focused Ultrasound|
75548885|NCT00295802|Device|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
75548886|NCT00326586|Drug|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
75548887|NCT00295841|Drug|clofarabine|
75548888|NCT00295841|Drug|cytarabine|
75548889|NCT00326664|Drug|Cediranib Maleate|Given orally
75399664|NCT04707378|Device|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
75548890|NCT00295919|Drug|fenretinide lipid matrix|
75548891|NCT00295919|Drug|ketoconazole|
75548892|NCT00295919|Other|laboratory biomarker analysis|
75548893|NCT00295919|Other|pharmacological study|
75548894|NCT04930809|Drug|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
75548895|NCT00295958|Biological|LMB-2 immunotoxin|
75548896|NCT00295958|Biological|MART-1 antigen|
75548897|NCT00295958|Biological|gp100 antigen|
75710091|NCT00887770|Drug|Moxifloxacin|1 x 400mg capsule, oral, single dose
75710092|NCT00887770|Drug|placebo|12 x matched to AZD5672 50 mg tablet
75399665|NCT04706988|Other|Treatment of asthma according to GINA guideline|Pharmacological treatment depending on level of control of asthma
75399666|NCT04706832|Device|Thoracic Splanchnic Magnetic Neuromodulation Therapy|ThorS-MagNT is performed by low-frequency, low-intensity repetitive magnetic stimulation bilaterally around T7-8 intervertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
75548898|NCT00295958|Biological|incomplete Freund's adjuvant|
75548899|NCT00295997|Biological|anti-thymocyte globulin|
75548900|NCT00295997|Biological|filgrastim|
75710093|NCT00887770|Drug|AZD5672|3 x 50mg tablet, oral. single dose
75710094|NCT00887770|Drug|placebo|9 x matched to AZD5672 50mg tablet
75710095|NCT00887770|Drug|placebo|1 x matched to Moxifloxacin capsule
75710096|NCT01038505|Drug|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
75399667|NCT04706286|Drug|CKD-501, D759, D150|CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
75548901|NCT00295997|Biological|graft-versus-tumor induction therapy|
75548902|NCT00295997|Biological|therapeutic allogeneic lymphocytes|
75548903|NCT00295997|Drug|busulfan|
75710097|NCT00890032|Biological|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10^6, 5x10^6, and 2x10^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
75710098|NCT01038583|Drug|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
75710099|NCT01038583|Drug|Placebo|100 mg enteric-coated placebo
75710100|NCT02551107|Device|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
75710101|NCT02541682|Other|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
75710102|NCT00818181|Drug|Biological: AL0206st|
75710103|NCT00887848|Other|Lokomat training|15 sessions of Lokomat training within 5 weeks (3 trainings/week)
75399668|NCT04706286|Drug|CKD-393 0.5/100/1000 mg|CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
75399669|NCT04706052|Other|Superficial Parotidectomy|Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity
75399670|NCT05139966|Drug|Mouthwash Product|The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
75548904|NCT00295997|Drug|cyclophosphamide|
75548905|NCT00295997|Drug|fludarabine phosphate|
75548906|NCT00295997|Drug|methotrexate|
75710104|NCT01038661|Drug|Docetaxel|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV"
75710105|NCT01038661|Drug|Cisplatin|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV"
75710106|NCT01038661|Other|Best supportive care (BSC)|Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator
75710107|NCT02355613|Radiation|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
75548907|NCT00295997|Drug|mycophenolate mofetil|
75548908|NCT00295997|Drug|tacrolimus|
75548909|NCT00295997|Procedure|allogeneic bone marrow transplantation|
75548910|NCT00295997|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75548911|NCT00295997|Procedure|peripheral blood stem cell transplantation|
75548912|NCT00296114|Procedure|Serum and DNA Samples|To collect serum and DNA samples from subjects
75548913|NCT00296153|Drug|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
75548914|NCT00326703|Procedure|Hypobaric hypoxia|
75548915|NCT00418067|Device|Endeavor|Zotarolimus-eluting stent
75548916|NCT00418067|Device|Cypher|Sirolimus-eluting stent
75548917|NCT00418067|Device|Taxus Liberte|Paclitaxel-eluting stent
75548918|NCT04869969|Procedure|percutaneous nephrolithotomy (supine position)|percutaneous nephrolithotomy to be done in the supine position
75548919|NCT04869969|Procedure|percutaneous nephrolithotomy ( prone position)|percutaneous nephrolithotomy in the prone position
75548920|NCT00296270|Behavioral|Memory for truth|
75548921|NCT00296309|Drug|Tacrolimus|Immunosuppression
75548922|NCT00296348|Drug|tacrolimus|immunosuppression
75548923|NCT00296348|Drug|mycophenolate mofetil|oral
75548924|NCT00296348|Drug|daclizumab|oral
75548925|NCT00296348|Drug|steroids|oral
75710108|NCT02355613|Radiation|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
75399671|NCT05138718|Diagnostic Test|18F-FDG PET/CT|Perform a 18F-FDG PET/CT to patients with history of myocardial infarction
75710109|NCT01038817|Drug|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
75399672|NCT05138640|Other|Not applicable. The study is designed as an observational cohort study|Not applicable. The study is desigend as an observational cohort study
75399673|NCT05138562|Drug|Placebo Comparator: Placebo|4 x placebo capsules, QD
75399674|NCT05138562|Drug|Active Comparator: TU2670 320mg|320mg (80mg x 4), QD
75399675|NCT05138562|Drug|Active Comparator: TU2670 240mg|240mg (80mg x 3 + placebo x 1), QD
75399676|NCT05138562|Drug|Active Comparator: TU2670 120mg|120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
75399677|NCT00575016|Biological|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U > Week 12; injection into the detrusor
75710110|NCT01324219|Behavioral|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
75710111|NCT01324219|Behavioral|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
75710112|NCT00420511|Drug|Sitagliptin|sitagliptin 100 mg once a day
75710113|NCT00420511|Drug|Placebo|placebo once a day
75710114|NCT00420511|Drug|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
75710115|NCT01038895|Drug|Ramipril|tablet; 10 mg; od; 3 months
75710116|NCT01038895|Drug|Experimental|tablet; 300 mg; od; 3 months
75710117|NCT00420199|Drug|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
75399678|NCT00575016|Biological|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
75399679|NCT00575016|Biological|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
75399680|NCT00575016|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
75399681|NCT00577512|Drug|DTPACE|"Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~Thalidomide 200 mg by mouth (PO) Days 1-7~Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~Adriamycin 15 mg/m2 Days 1-4~Cyclophosphamide 600 mg/m2 Days 1-4~Etoposide 60 mg/m2 Days 1-4"
75399682|NCT00577590|Drug|Metformin|Metformin is taken alone
75399683|NCT00577590|Drug|Rosiglitazone|Rosiglitizone is taken with Metformin
75399684|NCT00577590|Drug|Lovaza|Lovaza is taken with Metformin
75399685|NCT00578214|Drug|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
75399686|NCT00578214|Other|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
75399687|NCT00578214|Drug|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
75399688|NCT00578214|Drug|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (>45 to 77 kg, 10 mg; >77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
75399689|NCT00580398|Behavioral|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
75399690|NCT00580398|Drug|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
75399691|NCT00581256|Radiation|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
75710118|NCT00420199|Drug|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
76037711|NCT05284383|Behavioral|Closed-label nocebo conditioning|"Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials)."
75710119|NCT01039051|Behavioral|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
75710120|NCT00649389|Drug|Olmesartan medoxomil|40mg olmesartan medoxomil
75710121|NCT00649389|Drug|Amlodipine|Amlodipine 10mg
75710122|NCT00649389|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg
76037712|NCT05284383|Behavioral|Closed-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
75399692|NCT00581256|Radiation|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
75399693|NCT00582660|Drug|Celecoxib|400 mg twice a day for 7 days prior to surgery
75399694|NCT00582660|Drug|Placebo|one tablet of placebo will be given for 7 days prior to surgery
75399695|NCT00582894|Drug|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
75399696|NCT00583050|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
75710123|NCT00402103|Drug|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
75710124|NCT00402103|Drug|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
75710125|NCT00402103|Drug|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
75399697|NCT00583908|Device|senofilcon A|toric contact lens
75399698|NCT00583908|Device|balafilcon A toric|toric contact lens
75399699|NCT00583908|Device|lotrafilcon B toric|toric contact lens
75399700|NCT00583908|Device|omafilcon A|toric contact lens
75399701|NCT00584220|Device|senofilcon A toric|contact lens
75399702|NCT00584220|Device|alphafilcon A toric|contact lens
75399703|NCT00584922|Procedure|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
75548926|NCT04835376|Device|Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis|Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
75548927|NCT00296387|Drug|Rosuvastatin|
75548928|NCT00296387|Drug|Atorvastatin|
75548929|NCT00326742|Behavioral|Trier Social Stress Test|
75548930|NCT00296426|Procedure|New technology - PAML|
75548931|NCT00326820|Drug|ibandronate sodium|
75548932|NCT00326820|Drug|zoledronic acid|
75548933|NCT00326820|Drug|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
76037713|NCT05284383|Behavioral|Open-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
75710126|NCT00815217|Procedure|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
75710127|NCT00815217|Other|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
75710128|NCT00812175|Drug|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
75710129|NCT00815373|Drug|Dorzolamide+Timolol Maleate0.5%|Cosopt* b. i. d.
75710130|NCT00815373|Drug|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom* QHS
76037714|NCT05284383|Behavioral|Closed-label extinction|"Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials)."
76037715|NCT04995991|Behavioral|RRT rhythm only|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.
75548934|NCT00296465|Drug|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
75548935|NCT00296465|Drug|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
75548936|NCT00296465|Drug|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
75548937|NCT00296465|Drug|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
75548938|NCT00326859|Drug|remifentanil|
75548939|NCT00326976|Drug|FX06|400 mg as intravenous injection in two divided boluses
75710131|NCT00641667|Drug|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
75710132|NCT00704184|Drug|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
75710133|NCT00704184|Drug|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
75548940|NCT00326976|Procedure|Percutaneous coronary intervention|
75548941|NCT00296582|Behavioral|Gastric Motor Function Measurement|
75710134|NCT00704184|Drug|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
75710135|NCT00704184|Drug|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
76037716|NCT04995991|Behavioral|RRT rhythm + visual cue|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
75548942|NCT00296621|Drug|L-Glutamine|L-Glutamine
75548943|NCT00296621|Drug|placebo|placebo
75548944|NCT04717011|Diagnostic Test|PCR test|PCR test in two different semen samples from each patient: first with positive diagnosis for COVID-19 and the second after negative diagnosis for COVID-19.
75548945|NCT04762407|Drug|HGP1910|Take it once per period.
75548946|NCT04762407|Drug|HGP1909|Take it once per period.
75548947|NCT04762407|Drug|HCP1903|Take it once per period.
75548948|NCT00296699|Drug|Duloxetine|"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.~* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."
75548949|NCT00296738|Device|SPECT/CT|GE INFINIA HAWKEYE
75710136|NCT00641043|Drug|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
75710137|NCT00641043|Drug|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
75710138|NCT04062318|Device|Online active TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold."
75710139|NCT02551965|Other|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
75548950|NCT04581486|Other|Optimal-Massive Intervention|Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).
75548951|NCT04581486|Other|Control (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
75548952|NCT00296777|Drug|Escitalopram|8 weeks: up to 40 mg/day
75399704|NCT00585780|Drug|Prazosin Tablet|Target medication dosing was three times/day (t.i.d. dosing) with 5 mg in the morning, 5 mg in the afternoon and 6 mg at night reached at the end of the 2-week period, and maintained at this or their highest tolerated dose until week 11, followed by a 5-day taper in week 12, as in previous research.The titration schedule was as follows: 1 mg dose at bedtime for 2 nights, followed by a 1mg dose morning and night (8 AM/8 PM) on day 3, then 2 mg dose t.i.d., on days 4-6, 3 mg dose (2 pills each) morning and afternoon, and 4 mg dose (2 pills) at night for days 7-9, increased to 4 mg dosing t.i.d. on days 10-13, and from day 14 through week 11, 5 mg (1 pill) each in the morning and afternoon, and 6 mg for the night (2 pills) dose. This was followed by a 5-day taper in week 12. Patients were initiated on study medication upon presenting with a negative breathalyzer without any minimum pre-treatment alcohol abstinence period prior to medication initiation.
75399705|NCT00585780|Drug|Placebo Tablet|Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
75399706|NCT00586170|Device|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
75399707|NCT00586170|Device|Placebo Device|10 hours of treatment per day for up to 24 weeks
75710140|NCT02567058|Device|Ultrasound exam|"Ultrasound exam with :~2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~1 succession of 3 measures for group III"
75710141|NCT02567058|Behavioral|IPAQ questionnaire|IPAQ questionnaire
75710142|NCT00815451|Dietary Supplement|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
75399708|NCT00586170|Procedure|Surgery|Open Reduction and Internal Fixation of the nonunion site
75399709|NCT00586482|Drug|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
75399710|NCT00586482|Drug|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
75399711|NCT00586482|Behavioral|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
75399712|NCT03708354|Drug|placebo softgel|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
75399713|NCT03708354|Drug|DeltaGold® Tocotrienol 70%|Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
75399714|NCT03297684|Drug|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
75399715|NCT01685424|Drug|Etoricoxib|As per routine clinical practice in the United Kingdom
75399716|NCT01327638|Drug|etoricoxib|Patients with SpA/AS who took etoricoxib
75399717|NCT01327638|Drug|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
75399718|NCT01327638|Drug|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
75399719|NCT00393354|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
75399720|NCT00393354|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
75399721|NCT00166530|Drug|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
75399722|NCT00166530|Drug|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
75399723|NCT00166530|Drug|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
75399724|NCT00588900|Drug|cediranib maleate|
75710143|NCT00815451|Dietary Supplement|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
75710144|NCT00812409|Dietary Supplement|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
75399725|NCT00588900|Drug|irinotecan hydrochloride|
75548953|NCT00296777|Drug|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
75399726|NCT00589056|Drug|cisplatin|
76037717|NCT03077113|Diagnostic Test|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
75399727|NCT00589056|Drug|etoposide|
75710145|NCT00812409|Other|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
75399728|NCT00589056|Drug|nelfinavir mesylate|
75548954|NCT00296777|Drug|Imipramine|"8 weeks: up to 300mg/day~*if patient does not have contraindication."
75548955|NCT00327054|Drug|Nigella sativa seed|
75710146|NCT02567604|Behavioral|Focus Groups|at least three focus groups lasting approximately one hour
75710147|NCT00815529|Device|Acupuncture, Pak-sham needle|25*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
75399729|NCT00589056|Genetic|protein expression analysis|
75399730|NCT00589056|Other|immunohistochemistry staining method|
75399731|NCT00589056|Other|laboratory biomarker analysis|
75399732|NCT00589056|Procedure|biopsy|
75399733|NCT00589056|Radiation|radiation therapy|
75548956|NCT00296855|Drug|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
75548957|NCT00296894|Drug|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
75548958|NCT00296894|Drug|Placebo|Placebo
75548959|NCT00296933|Drug|Escitalopram|
75548960|NCT00296933|Drug|Bupropion XL|
75399734|NCT00590226|Drug|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
75399735|NCT00590226|Drug|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
75548961|NCT00296972|Drug|peg interferon plus ribavirin|
75548962|NCT00297011|Drug|valacyclovir+clobetasol gel|
75710148|NCT02551419|Dietary Supplement|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
75710149|NCT02551419|Dietary Supplement|placebo|6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
75710150|NCT04063644|Device|Vis Glyc Neo|1 drop in each eye, three times a day.
75710151|NCT04063644|Device|Physiological saline solution|1 drop in each eye, three times a day.
75710152|NCT04045275|Behavioral|Calm|"Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice."
75710153|NCT05325138|Other|Interview|Parents of girls aged 9-14yearsold will undergo an interview to determine their knowledge, attitudes and beliefs concerning HPV vaccination
75710154|NCT00812643|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
75710155|NCT02567916|Drug|Fresofol|
75710156|NCT02567916|Drug|Propofol|
76037718|NCT03077113|Diagnostic Test|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
75399736|NCT00590460|Biological|CAMPATH-1H|Given intravenous on days -8, -7, and -6
75399737|NCT00590460|Biological|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg"
75399738|NCT00590460|Drug|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2"
75399739|NCT00590460|Procedure|Stem cell infusion|Stem cells are infused on day 0
75399740|NCT00590772|Drug|montelukast|10 mg po each day (compared to placebo for 2 weeks)
75399741|NCT00590772|Drug|placebo|placebo for 2 weeks
75548963|NCT00327093|Drug|cetuximab|indication : second intention treatment
75548964|NCT00327093|Drug|bevacizumab|Indication: first intention treatment
75548965|NCT00297050|Drug|Peramivir|
75548966|NCT04708587|Drug|dual anti-platelet therapy at least 6 months|Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
75548967|NCT04708587|Drug|dual anti-platelet therapy 3months or less|Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
75548968|NCT00297128|Drug|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
75548969|NCT00297128|Drug|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
75548970|NCT00327132|Drug|Omeprazole, Amoxicillin, Clarithromycin|
76037719|NCT03072901|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
75399742|NCT00591942|Device|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
75399743|NCT00592176|Drug|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
75399744|NCT00592488|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
75399745|NCT00593346|Radiation|brachytherapy|brachytherapy (radioactive implants)
75399746|NCT00595530|Drug|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~Patients begin the ketamine infusion at 0.05 mg/kg/hr.~4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~patient's pain has not improved to an acceptable level~side effects remain acceptable~4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation."
76037720|NCT03073057|Drug|Budesonide/formoterol|2 inhalations as a single dose
75399747|NCT00596622|Drug|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
75399748|NCT00597246|Drug|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
75548971|NCT00297206|Drug|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
75548972|NCT04478019|Drug|10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse|2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse
75548973|NCT00297245|Drug|cognitive function|
75548974|NCT00327210|Behavioral|Blood Glucose Awareness Training|
76037721|NCT03073057|Other|Charcoal|
75399749|NCT00597246|Other|PET Scan|GE Advance PET scanner for sequential body imaging
76037722|NCT03073057|Drug|Symbicort Turbuhaler|2 inhalations as a single dose
76037723|NCT03073369|Drug|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
75399750|NCT00597402|Drug|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
76037724|NCT03073369|Drug|Placebo|Oral Placebo - one capsule once daily for 6 weeks
76037725|NCT04995757|Device|Stent Retriever|Stent Retriever for acute ischemic stroke
75399751|NCT00597402|Drug|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
75548975|NCT00297284|Drug|Modafinil|
75548976|NCT04392531|Drug|Cyclosporine|In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
75548977|NCT04392531|Drug|Standard treatment|Standard of care according to hospital protocol
75548978|NCT00297323|Drug|Topiramate|75 patients over the age of 2 years old with epilepsy.
75548979|NCT00327249|Drug|imexon|
75548980|NCT00327288|Drug|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
75548981|NCT00327288|Drug|docetaxel|IV once every 21 days for duration of study
75548982|NCT04344600|Drug|Peginterferon lambda alfa-1a subcutaneous injection|Peginterferon lambda-1a 180 micrograms by subcutaneous injection
75548983|NCT04344600|Other|Saline|Saline subcutaneous injection
75548984|NCT04333134|Drug|SHR3162|Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
75548985|NCT00327327|Drug|imexon|30-60 minutes IV, days 1,8,15 every 28 days
75548986|NCT00327327|Drug|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
75548987|NCT00327366|Procedure|Light therapy|
75548988|NCT04303104|Other|GeneXpert Edge|Screening intervention: novel diagnostic for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at point-of-contact in a mobile van
75399752|NCT00597402|Radiation|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
75399753|NCT00597402|Drug|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
75399754|NCT00597558|Drug|Egg white protein|Egg white protein powder
75399755|NCT00598806|Drug|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
75399756|NCT00598806|Drug|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
75399757|NCT00598806|Procedure|TURBT|TransUrethral Resection of the Bladder Tumor
75399758|NCT00601146|Procedure|chest computed tomography scan|Once a year for three years
75399759|NCT00601926|Biological|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
75399760|NCT00603018|Drug|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
75399761|NCT00603408|Drug|Cisplatin|
75399762|NCT00603408|Radiation|Radiation Therapy|
75548989|NCT04303104|Other|GeneXpert Ultra|Screening intervention: novel diagnostic test for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
75710157|NCT00815607|Drug|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
75399763|NCT00603408|Procedure|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
75399764|NCT00603564|Procedure|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
75548990|NCT00297362|Drug|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
75548991|NCT00297440|Behavioral|Cognitive-behavioral treatment|
75548992|NCT00297440|Behavioral|Exercise|
75548993|NCT00327483|Behavioral|Internet based education software|
75399765|NCT00603720|Drug|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
75548994|NCT05459220|Drug|SHR0410 Injection|SHR0410 Injection（Low Dose）
75399766|NCT00603720|Drug|L-Arginine|aids in nitric oxide production
75548995|NCT05459220|Drug|SHR0410 Injection|SHR0410 Injection（High Dose）
75399767|NCT00603720|Drug|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
75399768|NCT00622518|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
75399769|NCT00625404|Drug|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
75399770|NCT00625404|Other|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
75399771|NCT00626340|Drug|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
75548996|NCT05459220|Drug|Placebo|Placebo for SHR0410 Injection.
75548997|NCT00297518|Device|PerioWave|
75548998|NCT00297518|Procedure|Scaling and Root Planing|
75710158|NCT00815607|Biological|INXN-3001|Intratumoral injection
75710159|NCT04045509|Device|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
75710160|NCT04045509|Device|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
75710161|NCT04045509|Device|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
75399772|NCT00626340|Drug|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
75399773|NCT00626340|Drug|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
75548999|NCT04231773|Drug|Nitric Oxide|40 parts per million dosage
75549000|NCT04231773|Drug|Placebo|Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
75549001|NCT00297635|Device|GlucoDYNAMIX™ intervention system|
75549002|NCT00297635|Device|GlucoMON™ telemetry device|
75549003|NCT04224012|Other|Exercise and respiratory therapy|Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home
75549004|NCT00297674|Drug|Intravenous Clarithromycin|
75549005|NCT00297713|Drug|ALTU-238|
75710162|NCT02567526|Behavioral|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
75710163|NCT00402025|Biological|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
75399774|NCT00626340|Drug|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
75399775|NCT00626574|Drug|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
75710164|NCT00812721|Other|Preservative Free Saline|One drop will be instilled into each eye once
75710165|NCT00812721|Other|Optive|One drop will be instilled into each eye once
75710166|NCT00812721|Other|Refresh Moderate/Severe|One drop will be instilled into each eye once
75710167|NCT00812721|Other|Systane|One drop will be instilled into each eye once
75399776|NCT00626574|Drug|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
75399777|NCT00626808|Drug|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
75710168|NCT00812721|Other|Systane Ultra|One drop will be instilled into each eye once
75710169|NCT00812799|Drug|Oralgen|19.000 BU daily
75710170|NCT00812799|Other|placebo control|placebo control
75710171|NCT00815763|Drug|ginsenoside-Rd|infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
75710172|NCT00815763|Drug|placebo|infusion placebo once a day and continued for 14 day
75710173|NCT00609622|Drug|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
75710174|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
75710175|NCT00609622|Drug|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
75710176|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
75399778|NCT00626886|Drug|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
75399779|NCT00626886|Drug|placebo collagen sponge|collagen
75399780|NCT00627978|Drug|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
75399781|NCT00628134|Drug|calfactant|single inhaled dose by nebulizer
75399782|NCT00628134|Drug|isotonic saline|single inhaled dose by nebulizer
75399783|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
75399784|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
75399785|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for patients in this group
75399786|NCT00632970|Drug|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
75399787|NCT00632970|Drug|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
75399788|NCT00632970|Drug|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
75710177|NCT04045119|Other|Topical Moisturizer|The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
75710178|NCT00818415|Drug|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
75710179|NCT00818415|Drug|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
75399789|NCT00635232|Drug|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
75399790|NCT00635232|Drug|placebo|placebo capsules once daily for 12 weeks
75399791|NCT00635232|Drug|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
75399792|NCT00635232|Drug|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
75399793|NCT00635232|Drug|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
75399794|NCT00637494|Drug|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
75399795|NCT00637494|Drug|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
75549006|NCT04207593|Drug|Oxygen|Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2>90% or pO2 >60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
75549007|NCT00297752|Drug|ceriumnitrate silversulfadiazine (flammacerium)|treatment of patients with facial burns with CE-SSD
75399796|NCT00638274|Procedure|Air|3 mls used for identifying epidural space
75399797|NCT00638274|Procedure|Saline|3 mls of saline used to identify epidural space
75399798|NCT00638820|Procedure|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
75549008|NCT00297752|Drug|silversulfadiazine (flammazine)|treatment of patients with facial burns with SSD
75399799|NCT00638820|Drug|Campath, Busulfan, Clofarabine|"12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~11 Campath-1H 0.3 mg/kg intravenously over 2 hours~10 Campath-1H 0.3 mg/kg intravenously over 2 hours~9 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~8 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~7 Rest~6 Clofarabine 40 mg/m2 intravenously over 2 hours~5 Clofarabine 40 mg/m2 intravenously over 2 hours~4 Clofarabine 40 mg/m2 intravenously over 2 hours~3 Clofarabine 40 mg/m2 intravenously over 2 hours~2 Clofarabine 40 mg/m2 intravenously over 2 hours"
75399800|NCT00638820|Procedure|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
75549009|NCT00297791|Procedure|surgery|randomized to open or laparoscopic technique
75549010|NCT05459142|Drug|Medical Abortion|Medical Abortion
75549011|NCT00297869|Procedure|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
75710180|NCT04045197|Behavioral|Relaxation Focused Nursing Care|"Relaxation Focused Nursing Care is composed of HypnoBirthing and Transactional Model. Hypnobirthing Philosophy is based on the laws of mind and aims to create positive thoughts and emotions. The Transactional Model defines stress as a special relationship between the person and the environment. Therefore, Relaxation Focused Nursing Care; positive language, positive environment and reducing stressors."
75710181|NCT00815841|Drug|METHYLPHENIDATE|15-20mg during one of the two sessions
76037726|NCT03072823|Dietary Supplement|n-3 Polyunsaturated fatty acid|2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
76037727|NCT03072823|Dietary Supplement|placebo|olive oil ethyl esters
76037728|NCT04995679|Procedure|Implant of metaphyseal sleeves in Total knee arthroplasty|Implant of metaphyseal sleeves in Primary and revision TKA
75399801|NCT00641862|Dietary Supplement|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
75399802|NCT00641862|Other|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
75399803|NCT00643578|Drug|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
75399804|NCT00643578|Drug|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
75399805|NCT00643578|Device|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
75399806|NCT00644592|Drug|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
75399807|NCT00644592|Drug|Fenofibrate|160 mg/day orally for 4 weeks
75399808|NCT00645450|Drug|Propranolol|Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
75399809|NCT00645450|Drug|Placebo|Weekly doses of placebo (inactive pill) following recollection of traumatic memory
75549012|NCT05459103|Other|Bidirectional remote interaction intervention|Intervention group participants engaged in a 12-week bidirectional remote interaction. All interactions were conducted through the same group on Line. A one-hour interactive online group intervention was held every Monday to Friday from 14:30 to 15:30, for a total of 60 hours. The online interactive interventions were conducted in a structured course format, with a facilitator conducting live classes and alternating between static and dynamic classes.
76037729|NCT04995289|Other|Prone position on ECMO patient|blood gas analysis before and after PP
76037730|NCT03076957|Drug|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
76037731|NCT03077035|Other|glass ionomer sealants|
75549013|NCT05459103|Other|Unidirectional remote interaction intervention|Control group participants engaged in a 12-week unidirectional remote interaction. All interactions were conducted through the same group on Line. Research assistants posted a YouTube video on the Line group at 14:30 every day, Monday through Friday, covering art, music, senior sports, long-term care resources, travel, and food preparation.
75549014|NCT00297947|Drug|quetiapine|Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
75549015|NCT00297947|Drug|quetiapine|Participant will receive 600 mg/day of quetiapine for 8 weeks.
75871260|NCT04187092|Other|KneeBright Group|"The KneeBRIGHT group will use KneeBright device which consists of an EMG biofeedback interface software that guides users through exercise routines. The wireless EMG sensors includes two small electrodes that will be made to stick to the quadriceps muscles both sides. KneeBRIGHT software features a virtual world wherein patients complete challenges controlling the in-game avatar with the EMG units during exercises specific to knee osteoarthritis rehabilitation.~The KneeBRIGHT software will incorporates a variety of exercises for strengthening the quadriceps and will employ algorithms based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique, in which the quantity of repetitions performed in these sets is then used to determine the appropriate increase (or possibly decrease) in target resistance for the next sets/sessions."
75549016|NCT05459025|Behavioral|Aromatherapy yoga|The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.
75549017|NCT05459025|Behavioral|Yoga|The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
75399810|NCT00645762|Device|RS-Series Rhinosinusitis Treatment System|Single arm
75399811|NCT00645762|Device|FinESS Balloon|
75399812|NCT00647400|Biological|adalimumab|Adalimumab 40 mg every other week, subcutaneous
75399813|NCT00647400|Biological|adalimumab|Adalimumab 80 mg every other week, subcutaneous
75399814|NCT00652080|Drug|API 31510|Topical Cream; 3% active; AM & PM application
75399815|NCT00652314|Device|Thrombi-Gel|Applicaton of Hemostatic product during surgery
75399816|NCT00654030|Drug|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
75399817|NCT00654654|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm biopsies~Two injection treatments of facial wrinkles and creases~Conduct of study assessments"
75399818|NCT00656448|Drug|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
76037732|NCT03077035|Other|resin-based sealant|
75399819|NCT00659802|Drug|HMPL-004 low dose|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day).
75399820|NCT00659802|Drug|Placebo|Matching dose of Placebo
75399821|NCT00659802|Drug|HMPL-004 high dose|HMPL-004, 600 mg (3 x 200 mg) t.i.d. (total of 1800 mg/day).
75549018|NCT04718714|Drug|Midazolam|loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.
75549019|NCT04718714|Drug|Propofol|loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.
75549020|NCT04718714|Drug|Dexmedetomidine|loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
75549021|NCT04009239|Behavioral|Time Restricted Feeding|Consuming energy during a short interval during the day
75549022|NCT00297986|Device|Helmet|Evaluation of different interfaces for NPPV
75710182|NCT04044963|Behavioral|Exercise and Prehabilitation|"All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey."
75710183|NCT02567760|Dietary Supplement|MP1|Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
75710184|NCT02567760|Other|Placebo|Subjects receive Placebo drink after meal for 8 weeks.
75399822|NCT00660504|Drug|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
75549023|NCT05458635|Procedure|Right heart catheter|Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.
75549024|NCT00298025|Drug|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is >=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
75549025|NCT00298025|Drug|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is >=14 mm until r-hCG day.
75549026|NCT00298025|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
75710185|NCT00813033|Other|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
75399823|NCT00660504|Drug|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
75399824|NCT00661674|Drug|Palonosetron|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
75399825|NCT00661674|Drug|Hydroxyzine|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
75399826|NCT00661674|Other|Placebo|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
75399827|NCT00662298|Drug|prednisolone|40mg of prednisolone once a day for 14 days
75399828|NCT00666666|Drug|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
75710186|NCT03897192|Drug|Bevacizumab|Anti-vascular endothelial growth factor (VEGF)
76037733|NCT04992325|Diagnostic Test|Anterior segment-optical coherence tomography|Each subject underwent anterior segment -optical coherence tomography to evaluate the total corneal, epthelium and stromal thicknesses.
76037734|NCT03074071|Behavioral|Hope Enhancement Workshop|Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
75399829|NCT00666666|Drug|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
75399830|NCT00666666|Other|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
75549027|NCT00298025|Drug|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
75710187|NCT00813189|Device|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
75710188|NCT02551263|Drug|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
75710189|NCT02567214|Drug|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
75710190|NCT02567214|Drug|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
75710191|NCT04044885|Behavioral|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
75710192|NCT00888004|Drug|AFQ056|
75399831|NCT00666978|Behavioral|smoking cessation intervention|
75710193|NCT00888004|Drug|Placebo|
75399832|NCT00666978|Drug|bupropion hydrochloride|
75399833|NCT00666978|Genetic|gene expression analysis|
75399834|NCT00666978|Genetic|polymerase chain reaction|
75399835|NCT00666978|Other|counseling intervention|
75399836|NCT00666978|Other|educational intervention|
75710194|NCT00813267|Biological|mesenchymal stem cell infusion|
75399837|NCT00666978|Procedure|psychosocial assessment and care|
75399838|NCT00668382|Biological|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
75399839|NCT00669552|Procedure|Percutaneous coronary intervention|PCI previously electively scheduled.
75399840|NCT00670956|Drug|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
75399841|NCT00670956|Drug|Placebo|PLACEBO: IM x 2 doses 24 hours apart
75399842|NCT00671502|Drug|Carisoprodol SR|700 mg twice daily
75399843|NCT00671502|Drug|Carisoprodol SR|500 mg twice daily
75399844|NCT00671502|Drug|Placebo|Placebo tablet
75399845|NCT00671970|Drug|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs & 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
75549028|NCT00298025|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of >=18 mm and two additional follicles of >=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
75549029|NCT03923439|Device|Multi-b diffusion sequence MRI|Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
75710195|NCT00813267|Biological|bone marrow mononuclear cell infusion|
75710196|NCT00890110|Biological|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
75549030|NCT03917745|Behavioral|eHealth mindfulness intervention|The web-based intervention consists of eight sessions including psycho-education about the mechanisms of stress, coping and relaxation, especially related to pregnancy, practicing mindfulness skills (i.e. mindful breathing, mindful moving, observing and letting-go of thoughts and emotions with a non-judgmental attitude), sharing experiences, and doing home assignments. The sessions have been developed specifically for pregnant women and acknowledge pregnancy-related distress. An online coach will review questions and home assignments of the participants. Women will start the training at 16 weeks gestation.
75549031|NCT00298142|Procedure|Usual Care provided by a medical doctor (GP or Neurologist)|
75399846|NCT00672204|Biological|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
75549032|NCT00298142|Procedure|Usual care plus Physio-/ Manual Therapy|
75549033|NCT00298181|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
75549034|NCT05458518|Procedure|Cesarean wound dressing removal|The cesarean wound dressing is to be removed and the surgical wound exposed
75549035|NCT00298220|Behavioral|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
75549036|NCT00298220|Behavioral|Dissemination guideline and patient information letters|
75549037|NCT00298220|Behavioral|Tailored educational training|for GP(T)s
75399847|NCT00672204|Drug|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
75399848|NCT00672204|Drug|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
75549038|NCT00298220|Behavioral|Tailored outreach based facilitator support|in the practices of the GPTs
75549039|NCT00298220|Behavioral|Facilitation of co-operation with local addiction services|
75549040|NCT00298220|Behavioral|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
75549041|NCT00298220|Behavioral|Reminder-card for GP's desk|
75549042|NCT00298220|Behavioral|Personal feedback to patients|Patients receive advise based on their premeasurement answers
75549043|NCT05458089|Diagnostic Test|18F-FDG|18F-FDG intravenous injection
75549044|NCT00298259|Procedure|operative fixation of fractured ribs|ORIFof fractured ribs in flail chest patients
75549045|NCT03826641|Drug|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
75549046|NCT03826641|Drug|HCP1801|Dapagliflozin/Metformin 10/1000mg
75399849|NCT00672204|Drug|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
75399850|NCT00672438|Drug|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
75399851|NCT00672438|Other|Saline placebo infusion|Intravenous infusion of normal saline
75549047|NCT00298298|Biological|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
75549048|NCT03754140|Drug|Polidocanol Injection|Sclerotic agent
75549049|NCT00298337|Drug|Mixture of probiotic bacteria and prebiotic oligosaccharide|
75549050|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
75549051|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
75549052|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
75549053|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
75549054|NCT03528486|Behavioral|Music Training I|Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
75549055|NCT00298415|Drug|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
75399852|NCT00672594|Drug|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
75549056|NCT00298415|Drug|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
75871261|NCT04187092|Other|Standard Rehabilitation group|Participants in this group will undergo standard clinic based knee rehabilitation. Both groups will perform exact same exercises, however, no KneeBRIGHT device will be used in this group.
76037735|NCT01652911|Device|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
76037736|NCT03073993|Procedure|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
76037737|NCT04433611|Drug|2% lidocaine|"intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy~The VAS consisted of a 10 cm line ranging from 0 to 10 (anchored by 0=no pain and 10=very severe pain). Patients were asked to mark the number that represented their perceived level of pain. Based on the VAS scores, the pain level ratings were classified as: mild (rated 1-3), moderate (4-6) or severe (7-10)."
76037738|NCT04433611|Drug|0.9 % normal saline|intrauterine infusion of 0.9 % normal saline
76037739|NCT04992559|Drug|Consolidation Toripalimab|Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
76037740|NCT04992481|Procedure|PMTC|In patients from the study groups I, II, III, IV a professional mechanical tooth cleaning (PMTC) including air-polishing was proceeded on every visit using a glycine-based prophylaxis powder (Air-Flow Soft, EMS, Switzerland).
76037741|NCT04992481|Procedure|fluoride varnish|In patients from groups I, II, III, IV a fluoride varnish of 5% NaF (Profluorid Varnish, Voco, Germany) was applied with a microbrush. Every patient was instructed to stop from drinking and eating for the next two hours (as recommended by the manufacturer).
75399853|NCT00673764|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
76037742|NCT04992481|Procedure|gaseous ozone therapy|Patients from groups II and IV were additionally subjected to in-office ozone therapy using OzonyTron-OZ (Mymed, Germany). Ozone was applied on a silicone double-jaw tray of a proper size (allowing even ozone distribution in the oral cavity) following professional mechanical tooth cleaning. A Full Mouth Desinfection program lasting 5 minutes was used.
76037743|NCT04992481|Procedure|domestic octenidin mouth rinse|Patients from groups III and IV received a domestic mouthrinse (Octenidol MD, Schülke, Germany) and were recommended to use 15 ml of the liquid for 30 seconds after evening toothbrushing.
76037744|NCT04992091|Other|constructive debriefing|Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
75399854|NCT00673764|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
75399855|NCT00674466|Drug|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
75399856|NCT00674466|Drug|Placebo|twice-a-week
75399857|NCT00674622|Drug|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
75399858|NCT00674622|Procedure|Placebo|Saline/lidocaine
75399859|NCT00675558|Procedure|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.~MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.~All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) & fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
75399860|NCT00675558|Procedure|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
75399861|NCT00675792|Drug|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
75399862|NCT00675792|Drug|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
75399863|NCT00675792|Drug|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
75399864|NCT00676182|Other|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
75399865|NCT00676572|Other|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
75399866|NCT00676806|Biological|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.
75399867|NCT00676806|Biological|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
75549057|NCT00298454|Drug|Furosemide|
75549058|NCT04708392|Device|Spinal Cord Stimulator|A spinal cord stimulator is a surgically implanted device that delivers an electrical signal to a patient's spinal cord to reduce the perception of pain
75871262|NCT05084976|Behavioral|COVID 19 vaccine counseling|After surveys are completed, pulmonary provider (nurse practitioner or physician) will provide counseling via phone or in person about the COVID 19 vaccine. Safety, efficacy and side effects will be reviewed.
76037745|NCT02597933|Drug|Nintedanib|
76037746|NCT02597933|Drug|Placebo|
76037747|NCT03072667|Drug|Omegaven|Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
75549059|NCT03517956|Drug|Rogaratinib (BAY1163877)|"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
75549060|NCT03517956|Drug|Copanlisib (BAY80-6946)|"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
75549061|NCT00298493|Procedure|Sedation management strategy|
76037748|NCT04995367|Device|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke patients.|The participants will carry out 4 tasks with a BCI system integrated to the T-FLEX device. The task consists of 1 session that includes 4 conditional experiments: Active ankle movement, passive ankle movement, Motor Imagery Detection with Visual cue, and Motor Imagery Detection with Tactile Stimulation and visual cue.
76037749|NCT05004415|Drug|AT-527 (R07496998)|Study participants will receive a single radiolabeled dose of 550 mg AT-527.
76037750|NCT04912843|Drug|NR082 injection|Intravitreal injection（IVT）
76037751|NCT04912843|Device|Sham Injection|Sham Intravitreal Injection
76037752|NCT04995133|Drug|Colistin|intravenous administration
76037753|NCT04827173|Procedure|transcutaneous medium-frequency alternating current|Patients receive nerve block of right forearm through transcutaneous medium-frequency alternating current
76037754|NCT04994821|Device|transcranial direct current stimulator (tDCS)|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
76037755|NCT04994821|Behavioral|Cognitive Reappraisal|Emotion regulation therapy
76037756|NCT04361669|Other|Medication safety review|Implementation of a medication safety review using a clinical decision support system
76037757|NCT04361591|Other|Observational only|Observational Study
76037758|NCT04991623|Device|Kinesiology taping|We used kinesiology taping in abdominal muscles
76037759|NCT04991623|Other|Conventional physiotherapy|We used conventional physiotherapy to comparate
75549062|NCT00298532|Procedure|Advanced Life Support|
75549063|NCT03505476|Device|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
76037760|NCT04360889|Drug|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
75399868|NCT00677898|Behavioral|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
75549064|NCT03505476|Other|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
75710197|NCT02566824|Behavioral|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
75710198|NCT02566824|Behavioral|Supportive Group Therapy|This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
75871263|NCT02352142|Other|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
75399869|NCT00677898|Behavioral|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
76037761|NCT04360889|Drug|Tocopherol|patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
76037762|NCT04360889|Other|Elastic compression|patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
76037763|NCT03072589|Drug|Regadenoson infusion|Dose escalation of Regadenoson when given as an infusion
76037764|NCT04994743|Drug|CORT113176|CORT113176 lipid capsule formulation for oral administration
75399870|NCT00678444|Other|Educational video|Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
75399871|NCT00678834|Dietary Supplement|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
76037765|NCT04994743|Drug|Placebo matching CORT113176|Placebo matching CORT113176 lipid capsule formulation for oral administration
76037766|NCT04812041|Other|CAM-ICU 7 score|A 7-point rating scale (0-7) was derived from the CAM-ICU and RASS assessments 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.
76037767|NCT04812041|Other|4C Mortality Score|4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters
75549065|NCT03505476|Other|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
75549066|NCT00298571|Drug|.5% bupivacaine with epinephrine|
75399872|NCT00678834|Dietary Supplement|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
75399873|NCT00678834|Dietary Supplement|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
75399874|NCT00679380|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
75549067|NCT00419679|Procedure|x-ray diffraction of human hair|
75399875|NCT00679380|Drug|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
75399876|NCT00679380|Drug|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
75399877|NCT00679380|Drug|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
75399878|NCT00679380|Drug|Placebo|Placebo
75399879|NCT00680706|Drug|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
75399880|NCT00680706|Drug|Placebo|D5W (50 ml)
75399881|NCT00682734|Drug|metoclopramide|metoclopramide 20 mg
75399882|NCT00682734|Drug|metoclopramide|metoclopramide 40 mg
75399883|NCT00682734|Drug|metoclopramide|metoclopramide 10 mg
75399884|NCT00682734|Drug|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
75399885|NCT00683046|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
75399886|NCT00683046|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
75399887|NCT00683046|Drug|Stem cells|Stem cell infusion on day 0.
75399888|NCT00683046|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
75399889|NCT00683826|Dietary Supplement|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
75399890|NCT00683826|Other|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
75399891|NCT00683826|Dietary Supplement|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
75399892|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
75399893|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
75399894|NCT00685932|Device|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
75399895|NCT00687102|Drug|tamoxifen|oral tamoxifen plus placebo daily for 5 years
75399896|NCT00687102|Drug|raloxifene|oral raloxifene plus placebo daily for 5 years
75399897|NCT00688662|Procedure|ERCP with sphincterotomy|cutting the biliary sphincter muscle (sphincterotomy)
75399898|NCT00688662|Procedure|ERCP without sphincterotomy|ERCP with sphincter manometry, but no sphincterotomy
75399899|NCT00690924|Drug|calcitriol|Oral
75399900|NCT00690924|Other|laboratory biomarker analysis|Correlative Study
75399901|NCT00690924|Other|pharmacological study|Correlative Study
75549068|NCT00298649|Behavioral|Lay Health Advisor|
75549069|NCT00298688|Drug|Gefitinib|
75549070|NCT00298727|Behavioral|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
75549071|NCT00298727|Behavioral|ePBL|Online Problem-Based Course
75549072|NCT05457894|Biological|Flu-M, Inactivated split influenza vaccine|solution for intramuscular injection, 0.5 ml
75549073|NCT05457894|Biological|Ultrix®, Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
75549074|NCT03448653|Other|Colonoscopy with NBI|Colonoscopy with NBI
75549075|NCT03439839|Drug|iptacopan|iptacopan bid orally administered
75549076|NCT03439839|Combination Product|Standard of Care|Standard of Care (SoC) is defined as an antibody with anti C5 activity. At the time of study start, eculizumab was the only available SoC; eculizumab will be hereafter referred to as SoC.
75549077|NCT05457777|Behavioral|Motivational interview in digital game addiction|Motivational interviewing, which is a technique developed by William Miller that aims to change behavior by revealing the contradiction of problematic behavior with the value judgments of the person and creating motivation by the counselor, will be applied to the individuals with digital game addiction.
75710199|NCT02566824|Other|Treatment as Usual - community resources|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
75710200|NCT02566824|Drug|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
75399902|NCT00691002|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
75399903|NCT00691002|Drug|LEO 80190 Vehicle|
75399904|NCT00691002|Drug|Hydrocortisone|
75399905|NCT00691002|Drug|Calcipotriol|
75399906|NCT00693498|Biological|Standard leukoreduced irradiated blood cell transfusion|standard vs washed blood cell transfusions
75549078|NCT00298883|Drug|Myfortic|Myfortic 360mg PO BID for six weeks
75710201|NCT00813345|Other|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
75399907|NCT00693498|Biological|Washed leukoreduced irradiated blood cell transfusions|washed leukoreduced irradiated blood cell transfusions
75399908|NCT00693654|Drug|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
75399909|NCT00693654|Drug|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
75549079|NCT00298922|Drug|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
75549080|NCT00298922|Drug|Placebo|tablet orally thrice weekly for 24 weeks
75549081|NCT05457738|Other|E-REVA® app|Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.
75549082|NCT05457738|Other|No E-REVA® app|No use smartphone
75399910|NCT00695292|Drug|irinotecan|irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
75399911|NCT00695292|Drug|Carboplatin|carboplatin AUC=4 on Day 1
75399912|NCT00695292|Drug|sunitinib|sunitinib 25 mg orally (PO) daily after initial chemotherapy
75399913|NCT00696618|Drug|Fleet Enema|hyper-osmolar preparation
75399914|NCT00696618|Drug|tap water enema|hypo-osmolar preparation
75399915|NCT00696618|Drug|Normosol-R enema|iso-osmolar preparation
75399916|NCT00700440|Drug|C225 (cetuximab)|one week before and then weekly during radiotherapy
75399917|NCT00701376|Other|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
75399918|NCT00702780|Drug|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
75399919|NCT00702780|Drug|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
75549083|NCT00298961|Device|Videoconference equipment FALCON/IP|
75549084|NCT00299039|Drug|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
75549085|NCT00299039|Drug|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
75549086|NCT05457621|Other|Effaclar serum|Effaclar serum has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. It acts in particular on imperfections and persistent marks due to acne.
75399920|NCT00704028|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
76037768|NCT03076879|Behavioral|Promoting participation in cervical cancer screening|"Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.~Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.~Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.~Brochure; The brochure for cervical cancer and screening will be given after group training."
76037769|NCT04811885|Other|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
75710202|NCT00813345|Other|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
75710203|NCT00890188|Drug|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
75710204|NCT05388942|Procedure|Virtual reality hypnosis|VRH offers predefined hypnosis sessions with no need of trained physician or nurse or caregiver mobilization. Consisting of a headset including headphones and a virtual reality screen, VRH allow patients to select a visual and sound environment (e.g.: tropical beach, space, underwater…) into which the hypnotic speech is delivered. That way, the patient's attention is distracted and muscular relaxation is obtained, a major relaxation factor. HRV is simple, quick, and presumably safe.
75710205|NCT05388942|Drug|Nitrous oxide|inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
76037770|NCT03072355|Other|Elastic Band|Localized muscle resistance test for shoulder
76037771|NCT03072355|Other|Isokinetic dynamometer|Localized muscle resistance test for shoulder
75399921|NCT00704028|Drug|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
75399922|NCT00704262|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
75399923|NCT00706446|Drug|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
75710206|NCT04037566|Genetic|XYF19 CAR-T cell|Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
75710207|NCT04037566|Drug|Cyclophosphamide|A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
75710208|NCT04037566|Drug|Fludarabine|A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
75399924|NCT00706446|Drug|Salmeterol|salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
75399925|NCT00706446|Drug|Formoterol|formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
75549087|NCT00299117|Behavioral|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
75710209|NCT00699660|Behavioral|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
75710210|NCT00699660|Behavioral|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
75710211|NCT00888082|Drug|Goserelin acetate|3.6 mg depot injectable preparation
76037772|NCT04426877|Behavioral|Experimental group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
76037773|NCT04426877|Behavioral|Control group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
76037774|NCT03076801|Behavioral|Choral Singing|In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
76037775|NCT04426799|Other|lemon essential oil|A randomized, pre-test-post-test design was carried out to examine the effectiveness of lemon essential oil in reducing test anxiety in first-year students of the Faculty of Medical Sciences of a private university in Istanbul
75399926|NCT00706446|Drug|Fluticasone propionate|Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
75399927|NCT00706446|Drug|budesonide|Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
75399928|NCT00706836|Drug|Pregabalin 50mg|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
75710212|NCT00627705|Drug|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
75710213|NCT00627705|Other|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
76037776|NCT04994353|Dietary Supplement|No supplementation|1st Week: No supplementation
76037777|NCT04994353|Dietary Supplement|High Performance (HP) Inulin|2nd Week: Subjects consumed 20% v/v HP Inulin. Ingredients: 20 gram HP-Inulin diluted with 100 ml distilled water.
76037778|NCT04994353|Dietary Supplement|Isomalto-oligosaccharide (IMO)|3rd Week: Subjects consumed 20% v/v Isomalto-oligosaccharide (IMO). Ingredients: 20 gram IMO diluted with 100 ml distilled water.
75399929|NCT00706836|Drug|Pregabalin 200 MG|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
75399930|NCT00706836|Drug|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
76037779|NCT04994353|Dietary Supplement|Combination HP-Inulin and IMO|"4th Week: Subjects consumed20% v/v combination of HP-Inulin and Isomalto-oligosaccharide (IMO).~Ingredients: 20 gram IMO-HP Inulin Mix diluted with 100 ml distilled water."
75399931|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
75399932|NCT00708942|Drug|Placebo|Placebo suppository, for 3-7 hours application
75399933|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
75399934|NCT00708942|Drug|Placebo|Placebo ointment for 5 hours application
75399935|NCT00709878|Procedure|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
75399936|NCT00710814|Drug|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
75399937|NCT00710814|Other|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
75399938|NCT00711828|Drug|Bortezomib|Given IV
75399939|NCT00711828|Biological|Rituximab|Given IV
75399940|NCT00711828|Drug|Cyclophosphamide|Given PO
75399941|NCT00711828|Drug|Dexamethasone|Given PO
75399942|NCT00711828|Other|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
75399943|NCT00711828|Other|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
76037780|NCT04994353|Dietary Supplement|Dextrose solution|5th Week:Subjects consumed20% v/v Dextrose solution. Ingredients: 20 gram Dextrose powder diluted with 100 ml distilled water.
76037781|NCT04994353|Dietary Supplement|Glucose solution|6th Week:Subjects consumed 20% v/v Glucose solution. Ingredients: 20 gram glucose diluted with 100 ml distilled water.
75399944|NCT00712296|Drug|ASHMI 4|4 capsules orally twice a day
75399945|NCT00712296|Drug|ASHMI 12|12 capsules orally twice a day
75399946|NCT00712296|Drug|Placebo|Placebo 6 capsules twice a day
75399947|NCT00712530|Biological|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
75399948|NCT00712530|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
75399949|NCT00715104|Biological|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
75549088|NCT00299234|Drug|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
75549089|NCT00299273|Behavioral|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
75399950|NCT00715104|Biological|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
75399951|NCT00715650|Behavioral|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
75399952|NCT00715650|Behavioral|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
75399953|NCT00715728|Device|Intraoperative warming with Bair Hugger forced air system|Intraoperative warming with Bair Hugger forced air system
75399954|NCT00715728|Device|Intraoperative warming with Hotdog resistive heating system|Intraoperative warming with Hotdog resistive heating system
75399955|NCT00715884|Device|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
75399956|NCT00715884|Device|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
75399957|NCT00715962|Behavioral|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
75549090|NCT05457543|Diagnostic Test|Adult|Investigational use of a novel liver function diagnostic test that involves a paper-based test device and a smartphone application.
75549091|NCT00299351|Drug|Depsipeptide|
75549092|NCT00299390|Drug|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
75549093|NCT00299429|Procedure|Stenting and minimally invasive bypass surgery|
76037782|NCT04826783|Device|Lasers|The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
75399958|NCT00715962|Other|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
75399959|NCT00715962|Other|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
75399960|NCT00716586|Drug|2% dorzolamide|Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)
75399961|NCT00716742|Drug|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
75549094|NCT00299429|Procedure|PCI with DES|PCI with DES
75549095|NCT00299468|Behavioral|Patient Activation Measure Intervention Package|
76037783|NCT03072745|Diagnostic Test|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
75549096|NCT00299585|Procedure|"using PD VitalOs Cement with dental implants"|supporting dental implants with Vitalos bone cement
75549097|NCT02808585|Drug|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
75399962|NCT00716820|Drug|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
75399963|NCT00717054|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
75399964|NCT00717054|Drug|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
75399965|NCT00717288|Drug|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
75399966|NCT00717288|Drug|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
75399967|NCT00717288|Drug|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
75399968|NCT00717912|Other|Experimental sweetener syrup|3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber
75710214|NCT04062162|Behavioral|Walking football training|Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.
75710215|NCT04037488|Diagnostic Test|Inbody 320|Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
75399969|NCT00717912|Other|Classical sweetener syrup|1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber
75399970|NCT00717912|Other|Classical sugar syrup|3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
75549098|NCT02808585|Drug|Placebo Injection|Four weekly subcutaneous injections of placebo.
75549099|NCT02751762|Other|Observation Only|No Intervention
75549100|NCT00299780|Drug|Stem cell mobilization|
75399971|NCT00718302|Device|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
75399972|NCT00718302|Device|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
75399973|NCT00719160|Drug|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
75549101|NCT05457348|Procedure|Planned incisions during phacoemulsification|Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
76037784|NCT04807829|Drug|Nabilone|Nabilone is a synthetic endocannabinoid and CB1 agonist.
76037785|NCT04807829|Drug|Placebo|Inactive placebo comparator
75399974|NCT00719160|Drug|Placebo|Placebo 20 mg twice a day for 9 days
75399975|NCT00720330|Drug|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
75549102|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
75549103|NCT00299819|Biological|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
75549104|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
75549105|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
75549106|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
75549107|NCT04716660|Other|Sensory block level check|Patients will have their sensory block level checked multiple times following administration of their epidural bolus for labor analgesia.
75549108|NCT00299858|Drug|Theophylline|"Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time."
75549109|NCT00299897|Drug|SP01A|
75549110|NCT05455944|Drug|Pregabalin 150mg|Two capsules of pregabalin is administered orally to patients
75549111|NCT05455944|Drug|Placebo|Two identical placebo capsules is administered orally to patients
75549112|NCT00299936|Drug|Ribavirin, PEG-Intron|
76037786|NCT04994275|Other|no intervention, but presence of ID or not|This is an observational study regarding patients admitted to undergo a major elective surgery supposed to last more than an hour. Investigators will analyzed the incidence of postoperative infections up to 90 days after surgery according to the preoperative iron status: iron deficiency (defined as a ferritin of less than 100 µg/L or <300 µg/L And TSAT<20%) or no iron deficiency
76037787|NCT05619029|Radiation|X-ray|Chest radiographs
76037788|NCT03076645|Behavioral|Facilitator support and education|Group engaged with facilitator support and education
76037789|NCT03072511|Behavioral|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
75549113|NCT00300014|Procedure|Intravitreal triamcinolone injection|
75549114|NCT00300014|Procedure|Air-fluid exchange|
75549115|NCT00300092|Drug|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
75549116|NCT00300131|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
75549117|NCT01785459|Drug|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
75549118|NCT01785459|Drug|Standard Care|10 mg Intravenous injection of Prochlorperazine
75549119|NCT04716894|Drug|BI 474121|BI 474121 oral solution
75549120|NCT04716894|Drug|Itraconazole|Itraconazole oral solution
75549121|NCT00300287|Drug|Vildagliptin|
75549122|NCT00300326|Procedure|Computer assist|same implant using a computer-assisted surgical technique.
75549123|NCT05451732|Procedure|Nanofat grafting|Naofat grafting in the urethral stricture. The autologous adipose tissue is transferred by injection and in this way, the access to the urethral stricture is carried out with a minimal incision of the male urethra while in the female urethra is transferred exclusively with injections, without incision of urethral tissue.
75549124|NCT00300404|Drug|daraprim|
75549125|NCT00300404|Drug|pyrimethamine|
76037790|NCT03072511|Drug|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
76037791|NCT05616611|Radiation|High-Intensity laser|intervention that lasted 3 sessions/week for 12 weeks).
75399976|NCT00720330|Drug|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
75399977|NCT00720330|Other|placebo|placebo
75399978|NCT00721188|Drug|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
76037792|NCT05616611|Other|Traditional physiotherapy exercises|intervention that lasted 3 sessions/week for 12 weeks).
75399979|NCT00721500|Device|etafilcon A|contact lens
75399980|NCT00721500|Device|narafilcon A|contact lens
75399981|NCT00722124|Drug|S-Adenosyl-L-Methionine|800 mg dose per day for 8 weeks
75399982|NCT00722124|Drug|S-Adenosyl-L-Methionine|1600 mg per day for 8 weeks
75549126|NCT00300404|Drug|folinic acid|
75549127|NCT01539447|Drug|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
76037793|NCT05616611|Radiation|Shock Wave therapy|intervention that lasted 3 sessions/week for 12 weeks).
75399983|NCT00722124|Other|placebo|4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
75399984|NCT00722436|Drug|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
75399985|NCT00722436|Drug|saline|Placebo
75399986|NCT00724308|Other|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
75399987|NCT00724308|Other|Telephone Care Coordination with state Quitline|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
75549128|NCT01539447|Drug|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
75549129|NCT00300443|Drug|bimatoprost|
75549130|NCT00300521|Genetic|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
75549131|NCT00300560|Drug|Colistin|
75710216|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
75710217|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
76037794|NCT04991545|Device|Application of Infrared (Active IRD/ IRRIS) device|"The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~Group A: control group~Group B: Intervention group using Infrared"
75399988|NCT00724464|Biological|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
75399989|NCT00724464|Drug|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
75399990|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
75399991|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
75710218|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
75710219|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose|Injection in the muscle
75399992|NCT00727740|Drug|Indomethacin|Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
75399993|NCT00727740|Drug|Placebo suspension|A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
75399994|NCT00728910|Drug|Atorvastatin|10 mg QD for 4 weeks
75399995|NCT00728910|Drug|ABT335|135 mg QD added to atorvastatin for 8 weeks
75399996|NCT00728910|Drug|ER Niacin|2000 mg QD added to atorvastatin and ABT335 for 10 weeks
75399997|NCT00729846|Drug|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
75399998|NCT00729846|Device|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence [600mW/cm2].
75399999|NCT00729846|Device|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2].
75400000|NCT00729924|Drug|Raltegravir|400mg orally every 12 hours for 7 days
75400001|NCT00731094|Behavioral|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
75400002|NCT00731640|Device|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
75400003|NCT00731874|Drug|Tacrolimus|Dosed to achieve target trough concentrations.
75400004|NCT00732030|Device|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
75400005|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
75400006|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
75400007|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
75400008|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
75400009|NCT00733278|Device|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
75400010|NCT00733356|Drug|Vyvanse|Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
75400011|NCT00733512|Device|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
75400012|NCT00735306|Drug|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
75400013|NCT00735306|Drug|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
75400014|NCT00735306|Radiation|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
75400015|NCT00735462|Drug|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
75400016|NCT00735462|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
75400017|NCT00735462|Drug|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
75400018|NCT00735618|Other|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
75400019|NCT00736242|Biological|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
75400020|NCT00736242|Drug|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
75400021|NCT00736632|Drug|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
75400022|NCT00736632|Drug|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
75400023|NCT00737178|Device|CuT380A|Comparison of different timing of IUD insertion
75400024|NCT00738426|Device|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
75400025|NCT00738426|Device|Sham device|non-therapeutic light energy output
75400026|NCT00739752|Behavioral|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
75400027|NCT00739752|Behavioral|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
75871264|NCT02352142|Behavioral|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
75871265|NCT02896127|Drug|Secukinumab|"Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment."
75400028|NCT00739752|Behavioral|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
75400029|NCT00739752|Behavioral|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
75400030|NCT00739752|Behavioral|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
75400031|NCT00739752|Behavioral|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
75400032|NCT00740376|Device|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
75400033|NCT00740376|Device|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
75400034|NCT00741156|Drug|Enalaprilat|Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute
75400035|NCT00741390|Device|BD/33G|BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
75400036|NCT00741390|Device|OTM / 33G|OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
75400037|NCT00741390|Device|OTU/28G|OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
75400038|NCT00741390|Device|ACC/28G|Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
75400039|NCT00741390|Device|OTM/28G|OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
76037795|NCT04811807|Device|Subthalamic Nucleaus Deep brain stimulation|In deep brain stimulation (DBS) therapy, a specific anatomical target in the brain is stimulated via surgically fixed electrodes. These electrodes release electrical currents of a specific voltage, wavelength, and frequency. They are connected via subcutaneous wires to a device called an implantable pulse generator (IPG) which is surgically fixed on chest wall, beneath the clavicle. After electrodes and IPG are successfully installed, a clinician will be able to adjust and modulate the stimulation via a remote device connected to the IPG to obtain a maximum potential benefit. Deep brain stimulation has been used in clinics to treat various neurologic diseases including neurodegenerative disorders, mainly movement disorders.
75400040|NCT00741468|Drug|Proellex|2, 25 mg Proellex capsules administered daily
75400041|NCT00741468|Drug|CYP1A2 probe|Caffeine (200 mg)
75400042|NCT00741468|Drug|CYP2C9 probe|Tolbutamide (250 mg)
75400043|NCT00741468|Drug|CYP2C19 probe|Omeprazole (20 mg)
75400044|NCT00741468|Drug|CYP2D6 probe|Dextromethorphan (30 mg)
75400045|NCT00741468|Drug|CYP3A4 probe|Midazolam (2mg)
75400046|NCT00741858|Procedure|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
75871266|NCT02896127|Drug|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
75400047|NCT00741858|Procedure|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
75400048|NCT00742170|Device|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
75400049|NCT00742872|Drug|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
75400050|NCT00742872|Drug|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
75400051|NCT00743574|Dietary Supplement|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
75400052|NCT00743574|Drug|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
75871267|NCT02351986|Procedure|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
75871268|NCT02351986|Other|ice pack|
76037796|NCT03073681|Device|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
75549132|NCT00300638|Procedure|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
75549133|NCT00300638|Behavioral|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
75871269|NCT03153592|Procedure|Transpulmonary pressure driven ventilation strategy|Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
76037797|NCT04807751|Drug|Delgocitinib cream|Cream for topical application
76037798|NCT04807751|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
75400053|NCT00743574|Dietary Supplement|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
75400054|NCT00743574|Dietary Supplement|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
75400055|NCT00743730|Other|Pain and standard side effect management for PNCA with basal method.|"Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
75400056|NCT00743730|Other|Pain and standard side effect management with PNCA without basal|"Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
75400057|NCT00743730|Other|Pain and standard side effect management with IV on an as needed basis method.|"Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol."
75400058|NCT00745290|Drug|Bupivacaine HCl|200 mg bupivacaine HCl
75549134|NCT00327522|Biological|pneumococcal vaccine|
75549135|NCT04718051|Drug|Shen Pu Yang Gan Wan|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.
75549136|NCT04718051|Drug|Placebo|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
75400059|NCT00745290|Drug|SKY0402|600 mg SKY0402 (study drug).
75400060|NCT00748410|Drug|SB-656933|7 days repeat dose
75400061|NCT00748956|Drug|Low dose NPY|50nmol, administered intranasally
75549137|NCT00327561|Procedure|Intensive periodontal therapy|
75549138|NCT00327561|Procedure|Community based periodontal therapy|
75549139|NCT00300716|Drug|Memantine|
75549140|NCT04717167|Other|Dry Needling|
75549141|NCT04717167|Other|Sham Needling|
75400062|NCT00748956|Drug|High dose NPY|100nmol administered intranasally
75400063|NCT00748956|Drug|Placebo|placebo comparator (0nmol)) administered intranasally
75400064|NCT00749268|Device|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
75400065|NCT00749268|Device|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
75400066|NCT00750282|Drug|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
75400067|NCT00750360|Biological|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
75400068|NCT00751530|Drug|raltegravir|New combination ART incorporating raltegravir with other ARVs.
75400069|NCT00753636|Drug|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
75400070|NCT00753948|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
75400071|NCT00754494|Drug|erlotinib hydrochloride|Given PO
75400072|NCT00754494|Other|placebo|Given PO
75400073|NCT00754494|Other|laboratory biomarker analysis|Correlative studies
75400074|NCT00755040|Drug|cyclosporine ophthalmic emulsion|Given as eye drops
75400075|NCT00755040|Other|placebo|Given as eye drops
75549142|NCT00300794|Drug|Ketamine|
75400076|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
75400077|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
75400078|NCT00756600|Drug|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
75400079|NCT00756600|Drug|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
75400080|NCT00756678|Drug|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days'
75400081|NCT00756678|Drug|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
75400082|NCT00758550|Device|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
75400083|NCT00758550|Device|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
75400084|NCT00758784|Drug|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
75400085|NCT00758862|Drug|2% TD1414 Cream|Application 3 times daily for 7 days
75400086|NCT00759330|Drug|Placebo Tape (Arm 1)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
75400087|NCT00759330|Drug|Flurbiprofen Tape (Arm 2)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
75400088|NCT00759330|Drug|Placebo Tape (Arm 3)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
75400089|NCT00759330|Drug|Flurbiprofen Tape (Arm 4)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
75400090|NCT00759408|Drug|BQ-123|6-120 µg/min
75400091|NCT00759642|Drug|lapatinib|lapatinib 1500 mg PO daily
75400092|NCT00759798|Drug|Fludarabine|25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
75400093|NCT00759798|Drug|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
75400094|NCT00759798|Drug|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
75400095|NCT00760578|Drug|Placebo|Once daily, oral
75400096|NCT00760578|Drug|Pioglitazone|Once daily, oral
75400097|NCT00760578|Drug|MSDC-0160 90 mg|Once daily, oral
75400098|NCT00760578|Drug|MSDC-0160 220 mg|Once daily, oral
76037799|NCT03072277|Dietary Supplement|Docosa Hexaenoic Acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
75400099|NCT00761202|Drug|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
75400100|NCT00761202|Drug|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
75400101|NCT00761592|Biological|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
75400102|NCT00761592|Biological|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
75710220|NCT00890422|Biological|FSME vaccination (FSME-Immun)|intra muscular 0.5 ml
75710221|NCT00816075|Drug|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
75400103|NCT00762216|Device|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
75400104|NCT00762450|Drug|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
75400105|NCT00762450|Drug|fluoride|Rinse 3 times daily with assigned toothpaste slurry
75400106|NCT00762450|Drug|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
75400107|NCT00762528|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
75400108|NCT00762528|Drug|Sodium monofluorophosphate toothpaste|Twice daily usage
75400109|NCT00765570|Radiation|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
75710222|NCT02541370|Biological|anti-CD133-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
75871270|NCT03153592|Procedure|Conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
75871271|NCT03724097|Other|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
75400110|NCT00765570|Radiation|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
75400111|NCT00765570|Radiation|Standard radiation|15 Standard radiation treatments
75400112|NCT00765570|Radiation|Standard radiation|standard radiation treatment
75871272|NCT03724097|Other|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
75400113|NCT00765648|Drug|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
75549143|NCT05373303|Biological|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
75549144|NCT05373303|Biological|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
75549145|NCT00300833|Drug|Tirofiban|pci
75549146|NCT00327600|Drug|imexon|
75549147|NCT00327600|Drug|DTIC|
75549148|NCT00300872|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
75549149|NCT00300872|Device|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
75549150|NCT00300911|Drug|Rosiglitazone(drug), cardiac adverse effects|
75549151|NCT00327678|Drug|Rituximab|
75549152|NCT00327678|Drug|Imatinib Mesylate|
75400114|NCT00765648|Drug|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
75400115|NCT00766116|Drug|5-Azacitidine|Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.
75400116|NCT00766116|Drug|Gemtuzumab ozogamicin|Mylotarg given 2 times over 2 weeks
75400117|NCT00767364|Biological|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
75400118|NCT00769314|Drug|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
75400119|NCT00769314|Drug|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
75549153|NCT00300950|Biological|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
75549154|NCT00300950|Drug|Gemcitabine|Chemotherapy
75549155|NCT05372601|Dietary Supplement|Relax+|Prebiotics, daily administered
75549156|NCT05372601|Dietary Supplement|Maltodextrin|Placebo, daily administered
75549157|NCT00300989|Device|Inion OTPS Biodegradable Fixation System|
75549158|NCT00327756|Drug|Coenzyme Q10|
75549159|NCT00301106|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
75549160|NCT00301145|Behavioral|smoking cessation intervention|
75549161|NCT00301145|Drug|varenicline|
75549162|NCT00301145|Other|counseling intervention|
75710223|NCT05045820|Procedure|acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis. Acupuncture treatment will last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of treatment which contains 10 treatment sessions."
75871273|NCT03724097|Drug|target drug with the score above 0,1|target drug with the score above 0,1
75871274|NCT03724097|Drug|target drug with the score equal or below 0,1|target drug with the score equal or below 0,1
75871275|NCT03724097|Drug|non-target drug|non-target drug
75871276|NCT03724097|Drug|palliative care|palliative care
75549163|NCT00301145|Other|internet-based intervention|
75549164|NCT05366946|Other|Prevalence study|Prevalence study of chronic pain in COPD vs healthy controls
75871277|NCT03157414|Drug|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
75400120|NCT00769392|Drug|Proparacaine Ophthalmic|Drops of Proparacaine on the eye, administered as described in the package insert
75400121|NCT00769392|Drug|Tetracaine Ophthalmic|Drops of Tetracaine on the eye, administered as described in the package insert
75549165|NCT00301223|Drug|Pregabalin|
75710224|NCT05045820|Other|Sham|"Non-Tradition Acupuncture or a Placebo Comparator will be used as sham acupuncture which uses mock laser acupuncture approach. Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin. The laser will not be turned on during the treatment. Sham treatment will also last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of sham treatment which contains 10 treatment sessions."
75710225|NCT00610168|Biological|Boostrix TM|Single booster dose of vaccine
75871278|NCT03157414|Other|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
75871279|NCT03157024|Device|Ring Sham (RS)|
75871280|NCT03157024|Device|Real Needle (RN)|
75871281|NCT03157024|Device|Kim Sham (KS)|
75871282|NCT03546647|Device|Dailies Aqua Comfort Plus Toric|Daily disposable soft toric contact lens
75400122|NCT00769392|Drug|Lidocaine 4%|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
75549166|NCT00301301|Drug|Gemcitabine|
75549167|NCT00301301|Drug|Cisplatinum|
75549168|NCT00301301|Drug|Rituximab|
75400123|NCT00769392|Drug|Lidocaine 2% Injectable Solution|A subconjunctival injection of Lidocaine 2%
75400124|NCT00770874|Drug|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
75400125|NCT00770874|Drug|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
75400126|NCT00771264|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
75400127|NCT00772590|Drug|Raltegravir|Tablets, 400mg, twice daily
75400128|NCT00772590|Drug|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
75400129|NCT00772590|Other|raltegravir placebo|One tablet, twice daily
75549169|NCT05320302|Drug|[11C]-Lu AF88370|PET ligand in a single intravenous bolus injection
75549170|NCT00301340|Drug|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
75549171|NCT04717206|Other|Plyomtric training to male badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
75549172|NCT04717206|Other|Plyomtric training to female badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
75871283|NCT03546647|Device|Dailies Aqua Comfort Plus Sphere|Daily disposable soft spherical contact lens
75871284|NCT03156478|Behavioral|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
75871285|NCT03156478|Behavioral|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
75871286|NCT03727529|Other|Treadmill + VR|Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
75549173|NCT00301496|Device|Coban 2 Layer Compression System|
75549174|NCT00301535|Drug|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
75549175|NCT00301574|Drug|galantamine|
75549176|NCT00327834|Drug|atomoxetine|
75710226|NCT00921102|Drug|Bupivacaine|12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
75400130|NCT00772590|Other|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
75400131|NCT00772590|Drug|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
75400132|NCT00773370|Behavioral|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
75710227|NCT00921102|Drug|Morphine|200 µg of a 200 µg/ml solution, intrathecally
75871287|NCT03727529|Other|Treadmill|Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
75871288|NCT01310543|Behavioral|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
76037800|NCT03072277|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
76037801|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16 virus
75400133|NCT00773370|Behavioral|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
75400134|NCT00773604|Device|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
75871289|NCT02348164|Other|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
76037802|NCT03072121|Drug|Shexiang Baoxin pill|Conventional western medicine & shexiang baoxin pill
76037803|NCT03072121|Drug|SBP placebo|Conventional western medicine & placebo (for shexiang baoxin pill)
75400135|NCT00775944|Behavioral|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
75549177|NCT00301613|Drug|Mycophenolate mofetil|MMF,1.0g/d
75549178|NCT00327873|Other|Oxygen|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
75400136|NCT00775944|Behavioral|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
75400137|NCT00775944|Drug|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
75400138|NCT00780234|Procedure|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
75400139|NCT00780234|Procedure|quantitative high resolution CT scan|High resolution CT scan of the chest
75549179|NCT00327873|Other|Medical Air|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
75549180|NCT00301652|Drug|mycophenolate mofetil|MMF,1.0g/d
75549181|NCT00327912|Procedure|Laparoscopic Biliopancreatic diversion with Duodenal switch|
75710228|NCT00921102|Drug|Isotonic saline solution|"0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine"
76037804|NCT03072121|Drug|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
76037805|NCT03072121|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
76037806|NCT03072121|Drug|Atorvastatin Calcium|10 mg tablet, two tablets each night.
76037807|NCT03072121|Drug|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
76037808|NCT03072121|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
75549182|NCT00327912|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
75549183|NCT00301691|Behavioral|behavioral dietary intervention|
75549184|NCT00301691|Other|educational intervention|
75549185|NCT00301691|Other|preventative dietary intervention|
76037809|NCT03072121|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
75400140|NCT00780234|Drug|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
75400141|NCT00781950|Dietary Supplement|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
75400142|NCT00781950|Dietary Supplement|Placebo|Wheat and Mixed Dietary Oils
75400143|NCT00784524|Biological|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
75400144|NCT00784524|Biological|aldesleukin|Subcutaneous aldesleukin (10 x 10^6 International Units) will be given on day 7 and day 8 after each LMI injection.
75400145|NCT00785772|Drug|Gabapentin|100-200mg once a day
75710229|NCT00921102|Drug|Atropine|"100 µg of a 1 mg/ml preservative-free solution~intrathecally in group Intrathecal Atropine~intravenously in group IV Atropine"
75710230|NCT00890500|Drug|Fludarabine|30mg/m2/day IV x 6 days
75710231|NCT00890500|Drug|Melphalan|100 mg/m2/day IV x 1 day
76037810|NCT05618873|Device|Flutter device|The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
75871290|NCT02348164|Other|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
75871291|NCT03147196|Drug|Bicalutamide|Given PO
75871292|NCT03147196|Other|Laboratory Biomarker Analysis|Correlative studies
75871293|NCT03147196|Other|Questionnaire Administration|Ancillary studies
75871294|NCT03147196|Drug|Raloxifene Hydrochloride|Given PO
75871295|NCT03153436|Biological|Myoinositol|
75871296|NCT03077412|Drug|Filgotinib|Tablet(s) administered orally once daily
75871297|NCT03077412|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
75871298|NCT03544229|Drug|TAK-906 Maleate|TAK-906 maleate capsules.
75871299|NCT03544229|Drug|Placebo|TAK-906 maleate placebo-matching capsules.
75871300|NCT03147118|Diagnostic Test|Arthrogram|Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 radiograph views of the thumb.
75871301|NCT02353312|Drug|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
75871302|NCT02351908|Drug|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
75871303|NCT02351908|Drug|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
75871304|NCT02351908|Drug|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
75400146|NCT00785772|Drug|Gabapentin|200-500mg once a day
75400147|NCT00785772|Drug|Gabapentin|400-1000mg (200-500 mg twice a day)
75400148|NCT00787332|Drug|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
75400149|NCT00787722|Procedure|Hematopoietic Stem Cell Transplantation|Infusion of participant's own stem cells
75400150|NCT00787722|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
75400151|NCT00787722|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
75400152|NCT00787722|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
75400153|NCT00787722|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
75400154|NCT00787722|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
75710232|NCT00890500|Drug|Antithymocyte Globulin|1mg/kg/day x 4 days
75710233|NCT00890500|Drug|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
75710234|NCT00890500|Drug|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
75710235|NCT00890578|Procedure|adhesive to suture|surgical closure
75710236|NCT00890734|Drug|CYT003-QbG10|subcutaneous injection
75710237|NCT00890734|Drug|Placebo|subcutaneous injection
75710238|NCT04061772|Drug|Bortezomib|Bortezomib injection
76037811|NCT05618873|Device|positive expiratory pressure mask|"The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times."
76037812|NCT04993963|Other|Cycle Ergometery Training (Prehabilitation)|Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion <13 on Borg scale 20-30 min/session/day (intermittent of exercise 2-3 mint, followed by 1-2 min of active recovery) Cool down (5 minutes) AROM +Body stretch
75400155|NCT00787722|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
75400156|NCT00788892|Drug|CPX-351|
75400157|NCT00788892|Drug|Cytarabine|
75400158|NCT00788892|Drug|Daunorubicin|
76037813|NCT04993963|Other|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
75549186|NCT05252871|Device|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
76037814|NCT05618795|Other|minimal gap arthoplasty v/s aggressive gap arthoplasty|Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
76037815|NCT04994041|Other|Pelvic floor muscle plus adductor strengthening|20 sessions of pelvic floor muscle strengthening plus adductor is strengthening
76037816|NCT04994041|Other|Pelvic floor muscle exercises|20 sessions of pelvic floor muscle strengthening
75400159|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
75549187|NCT00301730|Biological|aldesleukin|
75549188|NCT00301730|Biological|therapeutic tumor infiltrating lymphocytes|
75549189|NCT00301730|Biological|trastuzumab|
76037817|NCT02597855|Drug|Aflibercept|Total 4 times of intravitreal aflibercept injection was performed
76037818|NCT02597855|Drug|Indocyanine green angiography (intraveonus indocyanine green dye)|At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
76037819|NCT04987567|Dietary Supplement|ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)|Pearls of DHA (BrudyNen)
76037820|NCT04987567|Dietary Supplement|PLACEBO (OLIVE OIL)|Pearls manufactured to mimic DHA (BrudyNen).
75400160|NCT00789672|Device|patching|2 hours daily patching
75549190|NCT00301730|Drug|paclitaxel|
75549191|NCT00301730|Procedure|conventional surgery|
75549192|NCT00301769|Drug|SJG-136|Given IV
75549193|NCT00301847|Drug|sorafenib tosylate|
75549194|NCT00327990|Drug|Ibandronate|
75549195|NCT00327990|Drug|Alendronate|
76037821|NCT04811495|Other|Physiotherapy treatment|A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
76037822|NCT05004103|Other|Cosmetic products application|Female healthy volunteers applied cosmetic products (cleanser and moisturizer) in the morning and afternoon for 1 month. Seven days wash out period will be conducted prior study starts. The evaluation will be conducted before, two weeks after treatment starts, and at the end of the study.
76037823|NCT04807049|Other|Observational|Observational
76037824|NCT05003869|Procedure|Scar tissue is removed|The patients were divided into two groups according to whether the scar tissue was removed during TCRA operation: study group: resection of uterine scar tissue during TCRA operation;In the control group, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips using needle-like electrodes, and the scar tissue was not excised.
76037825|NCT04806815|Other|A survey of 60 questions was created through the internet-based 'Google Forms surveys' site.|"The following tests will be used together with the survey;~Menstrual Symptom Questionnaire~Fatigue Severity Scale~Short Form Of Coronavirus Anxiety Scale"
76037826|NCT03072199|Drug|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
75549196|NCT00301886|Drug|ibandronate|
75549197|NCT00301886|Drug|zoledronate|
75710239|NCT04061772|Drug|Etoposide|Etoposide injection
75710240|NCT04061772|Drug|Cyclophosphamide|Cyclophosphamide injection
76037827|NCT04811105|Procedure|steam ablation|32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
75549198|NCT00301886|Procedure|quality-of-life assessment|
75549199|NCT00301925|Biological|pegfilgrastim|
75549200|NCT00301925|Drug|capecitabine|
75549201|NCT00301925|Drug|cyclophosphamide|
75549202|NCT00301925|Drug|epirubicin hydrochloride|
75549203|NCT00301925|Drug|fluorouracil|
75549204|NCT00301925|Drug|methotrexate|
75549205|NCT00301925|Procedure|adjuvant therapy|
75549206|NCT00302120|Procedure|Contrast-enhanced MR mammography|
75710241|NCT04061772|Drug|Pharmorubicin|Pharmorubicin injection
75710242|NCT04061772|Drug|Prednisone|Prednisone tablet
75400161|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
75400162|NCT00789750|Drug|Colesevelam|Colesevelam 625 mg tablets
75400163|NCT00789750|Drug|Placebo|Placebo tablets appearing to be colesevelam
75400164|NCT00789750|Drug|Pioglitazone|30 mg or 45 mg pioglitazone therapy
75400165|NCT00790062|Drug|Oxytocin|See arms
75400166|NCT00793572|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
75400167|NCT00793572|Drug|Bortezomib|Given SC
75549207|NCT00328029|Drug|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
75549208|NCT00328029|Procedure|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
76037828|NCT04990999|Procedure|Vestibular Root Extraction|a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
76037829|NCT04990999|Procedure|Atraumatic extractions using periotomes followed by conventional forceps|a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
75549209|NCT00328029|Procedure|pharmacokinetics, done during the treatment|"12 blood collections :~after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.~3 hours after 2nd taken of Busulfan~3 hours after 3rd taken of Busulfan~3 hours after 4th taken of Busulfan~3 hours after 5th taken of Busulfan~3 hours after 6th taken of Busulfan."
75400168|NCT00793572|Drug|Cyclosporine|Given IV
75400169|NCT00793572|Drug|Cyclosporine|Given PO
75400170|NCT00793572|Drug|Fludarabine Phosphate|Given IV
75400171|NCT00793572|Other|Laboratory Biomarker Analysis|Correlative studies
75400172|NCT00793572|Drug|Melphalan|Given IV
75549210|NCT00302198|Behavioral|ALS Registry|
75400173|NCT00793572|Drug|Mycophenolate Mofetil|Given PO
75400174|NCT00793572|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
75400175|NCT00793572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
75400176|NCT00793572|Procedure|Syngeneic Bone Marrow Transplantation|Undergo transplantation
75400177|NCT00793572|Radiation|Total-Body Irradiation|Undergo radiotherapy
75400178|NCT00793650|Drug|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
75400179|NCT00793650|Drug|Melphalan|"All patients received melphalan (100 mg/m^2/day × 2; days~-3 and -2), for a total dose of 200 mg/m^2."
75400180|NCT00793650|Procedure|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
75400181|NCT00794508|Biological|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
75400182|NCT00795210|Drug|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
75400183|NCT00795210|Drug|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
75400184|NCT00795288|Drug|Simvastatin, 80 mg/day for 21 days|Active treatment group
75400185|NCT00795288|Drug|placebo|Control group
75400186|NCT00795366|Drug|arginine vasopressin|Titrated to cerebral perfusion pressure greater than 60 mm Hg
75400187|NCT00795366|Drug|Standard catecholamine|Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
75400188|NCT00796302|Drug|Methylphenidate HCl|"For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily."
75400189|NCT00796302|Drug|Risperidone|"For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day."
75400190|NCT00796302|Behavioral|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
75400191|NCT00796302|Drug|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
75400192|NCT00796926|Drug|Systane Ultra eyedrops|Four times a day
75400193|NCT00796926|Drug|Refresh eye drops|Four times a day
75710243|NCT04061928|Drug|PD-1|2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
75400194|NCT00798018|Drug|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
75400195|NCT00798018|Drug|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
75549211|NCT00302237|Device|RX ACCULINK, RX ACCUNET Embolic Protection System|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
75549212|NCT05234775|Drug|lerodalcibep|300 mg of each drug given SC as single dose
75549213|NCT05231889|Device|Silverway guidewire|The Silverway guidewire is a newly developed guidewire to overcome the problems the Radifocus guidewire has
75549214|NCT05231889|Device|Radifocus guidewire|The Radifocus guidewire is a hydrophilic coated guidewire that is used when a standard J-tip guidewire does not cross a vascular anomaly
75549215|NCT00302276|Drug|Metobes-compound|
75710244|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
75549216|NCT00302315|Device|transcutaneous electrical nerve stimulation|
75549217|NCT00302354|Drug|OROS methylphenidate HCl|
75710245|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
75710246|NCT00644787|Drug|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
75400196|NCT00798018|Drug|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
75400197|NCT00798018|Drug|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
75400198|NCT00798486|Device|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
75549218|NCT00302354|Drug|SODAS methylphenidate HCl|
75549219|NCT00302393|Drug|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
75549220|NCT00302393|Drug|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
75549221|NCT00328107|Biological|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
75549222|NCT00302432|Behavioral|Behavior therapy, cigarette holders, Flowers Menthol|
75549223|NCT00328146|Other|Observation of sternal reentry|Observation of sternal reentry
75710247|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
75710248|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
75710249|NCT00699582|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
75710250|NCT00699582|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
75710251|NCT00699582|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
75400199|NCT00798720|Drug|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
75400200|NCT00798720|Drug|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
75400201|NCT00799578|Drug|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
75400202|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
75400203|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
75400204|NCT00799812|Drug|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
75400205|NCT00799812|Other|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
75400206|NCT00799812|Other|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
75400207|NCT00801138|Drug|saline|2 ml 0.9% saline (placebo)
75400208|NCT00801138|Drug|Dexamethasone|dexamethasone 8 mg (2 ml)
75400209|NCT00801138|Drug|ropivacaine|30 ml 0.5% ropivacaine
75400210|NCT00801138|Drug|Bupivacaine|30 ml 0.5% bupivacaine
75400211|NCT00801684|Drug|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
75400212|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
75400213|NCT00801684|Drug|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
75400214|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
75400215|NCT00801684|Drug|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
75400216|NCT00803010|Drug|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
75400217|NCT00803010|Drug|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
75400218|NCT00803010|Drug|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
75400219|NCT00803400|Drug|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
75549224|NCT00302471|Drug|Comparator: MK0429|"Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease."
75549225|NCT00302471|Drug|Comparator: MK0429|Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
75549226|NCT00302471|Drug|Comparator: MK0429|Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
75710252|NCT00821301|Drug|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
75710253|NCT04062084|Device|Multifunctional Cataract-assisted Retractor|Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
75710254|NCT03860727|Diagnostic Test|Welch Allyn IExaminer|Fundus Examination
75400220|NCT00803400|Drug|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association)."
75710255|NCT00640341|Device|PureVision Contact Lens|contact lens for daily wear
75710256|NCT00640341|Device|Acuvue Oasys Contact Lens|contact lens for daily wear
75710257|NCT00640341|Device|O2Optix Contact lens|contact lens for daily wear
75710258|NCT00816153|Other|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
75710259|NCT00699348|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
75549227|NCT00302471|Drug|Comparator: MK0429|Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
75710260|NCT05327634|Other|self-questionnaire|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
75400221|NCT00804648|Drug|Timolol Maleate in Sorbate|0.5%
75400222|NCT00804648|Drug|Timolol hemihydrate|0.5%
75549228|NCT00302510|Procedure|immunoadsorption|immunoadsorption
75400223|NCT00804648|Drug|Timolol maleate gel forming solution|0.5%
75549229|NCT00419913|Dietary Supplement|Dehydroepiandrosterone|DHEA 25 mg tid
75549230|NCT00302549|Drug|FK506|FK506,0.1mg/kg/d
75710261|NCT04062786|Other|Pmsf-PVC gradient measurement|implementation of standard standard hemodynamic monitorin
76037830|NCT04811183|Behavioral|Pharmaceutical consultation|"Selection of patients for a pharmaceutical consultation with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week after consultation. Elements on knowledge and adherence of treatment will be collected."
75549231|NCT04716855|Other|Quality of life and daily living activities assessment tests|
75549232|NCT00419991|Drug|Tigecycline|All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
75710262|NCT00643851|Drug|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
75710263|NCT00643851|Drug|Metformin XR|Tablets, Oral, Once daily, 24 weeks
75710264|NCT00816231|Behavioral|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
75710265|NCT00816231|Other|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
75710266|NCT00816231|Other|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
75400224|NCT00805038|Behavioral|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
75400225|NCT00805038|Behavioral|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
75400226|NCT00806598|Drug|Thymoglobulin|"3.5 or 2.5 mg/kg/day IV for 5 days~Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~MDS patients <55 years receive 3.5 mg/kg/day for 5 days~MDS patients >55 years receive 2.5 mg/kg/day for 5 days"
75400227|NCT00806598|Drug|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
75549233|NCT04718090|Procedure|PENG Block|Pericapsular nerve group block in shoulder surgery.
75549234|NCT04716816|Procedure|Stripping massage|Stripping massage for rhomboid myofascial trigger points
75549235|NCT00302627|Drug|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
75549236|NCT00302627|Drug|vitamin D|baseline, 6,12 months
75549237|NCT00302627|Drug|Calcium Carbonate|baseline, 6,12 months
75710267|NCT04062864|Device|Pupil size|Measures the diameter of pupil before and after painful stimuli
75710268|NCT00821457|Drug|Juvista|250ng
75710269|NCT00821457|Drug|Placebo|Powder for solution for injection
75710270|NCT00821457|Drug|Juvista|500ng
75710271|NCT03667690|Drug|Rezafungin for Injection|Intravenous antifungal therapy
75710272|NCT03667690|Drug|Caspofungin|Intravenous antifungal therapy
75710273|NCT03667690|Drug|Fluconazole|Oral antifungal therapy
75710274|NCT03667690|Drug|intravenous placebo|Normal saline
75710275|NCT03667690|Drug|oral placebo|Microcrystalline cellulose
75400228|NCT00806598|Drug|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
75400229|NCT00806598|Drug|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
75400230|NCT00806676|Drug|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
75400231|NCT00807768|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
75400232|NCT00807768|Drug|Carboplatin|Given IV
75400233|NCT00807768|Radiation|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
75400234|NCT00807768|Radiation|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
75400235|NCT00807768|Other|Laboratory Biomarker Analysis|Correlative studies
75400236|NCT00807768|Drug|Paclitaxel|Given IV
75400237|NCT00807768|Other|Quality-of-Life Assessment|Ancillary studies
75400238|NCT00807768|Other|Questionnaire Administration|Ancillary studies
75400239|NCT00808470|Drug|beta-carotene, vitamins C and E, magnesium|"6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene."
75400240|NCT00808470|Other|Placebo|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
75400241|NCT00810498|Device|Trilogy|Exposure for one hour on the Trilogy ventilator
75400242|NCT00810498|Device|Standard of Care|Exposure to participants current ventilator
75549238|NCT05129943|Device|active distraction|The subject receives the injection of local anesthesia while playing a game on a mobile phone mounted on the VR device using a PS4 controller.
75549239|NCT05129943|Device|passive distraction|The subject receives the injection of local anesthesia while watching a cartoon on a mobile phone mounted on the VR device.
75549240|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
75549241|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
75710276|NCT00821535|Drug|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
75710277|NCT04062006|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
75549242|NCT05070741|Behavioral|Heat Therapy|Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged ~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted ~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
75549243|NCT00328302|Drug|Candesartan|
75549244|NCT00328302|Drug|Placebo|
75549245|NCT00418340|Drug|probiotic (bacterial/dietary supplement)|
75710278|NCT04872582|Drug|PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab|combined
75710279|NCT04061538|Dietary Supplement|zinc sulfate|zinc 20mg tablets
75710280|NCT04061538|Dietary Supplement|Placebo|Sugar pill manufactured to mimic zinc 20mg tablet
75710281|NCT00888316|Procedure|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
75710282|NCT00888316|Procedure|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
75710283|NCT04351620|Drug|Hydroxychloroquine|Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
75400243|NCT00810576|Drug|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
75400244|NCT00810576|Drug|Bortezomib|Dose of 1.3 mg/m^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
75400245|NCT00810888|Drug|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
75400246|NCT00810888|Drug|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
75400247|NCT00811434|Drug|Lactulose|1.5cc/kg/day po for three months
75400248|NCT00811434|Drug|placebo|1.5 ml sugar water/kg day for three months
75400249|NCT00812604|Drug|Ping On Ointment|Ping On Ointment
75549246|NCT00418418|Procedure|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
75710284|NCT00888394|Procedure|chiropody|basic procedure of chiropody in podiatry
75710285|NCT00888394|Procedure|basic orthesis|individual basic orthesis of foot
75710286|NCT00888394|Procedure|advantage orthesis|advantage orthesis of foot with special material and design
75710287|NCT00888394|Procedure|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
75400250|NCT00812604|Drug|Vaseline|Placebo
75400251|NCT00812838|Drug|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
75710288|NCT02541760|Drug|Monteleukast|4 ml monteleukast daily for one month
75400252|NCT00812838|Other|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
75400253|NCT00812838|Drug|100 units Botulinum Toxin A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
75400254|NCT00812916|Procedure|RF ablation, using specialized CFAE software|RF ablation
75549247|NCT00418418|Procedure|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
75549248|NCT00418418|Biological|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
75549249|NCT00418418|Biological|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
75549250|NCT00328380|Drug|Rifaximin|
75710289|NCT02541760|Drug|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
75710290|NCT00888472|Procedure|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
75710291|NCT00627393|Drug|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
75400255|NCT00814788|Drug|Bicalutamide|50 mg oral tablet daily
75400256|NCT00814788|Drug|Everolimus|10 mg oral capsule daily
75710292|NCT00627393|Biological|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10^10 per collection (or proportionately less for participants less than 30 kg in weight).
75710293|NCT00627393|Drug|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
75710294|NCT00627393|Device|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
75871305|NCT01371240|Drug|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
75400257|NCT00815490|Device|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
75400258|NCT00816348|Drug|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
75400259|NCT00817596|Device|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
75400260|NCT00820872|Biological|trastuzumab|
75400261|NCT00820872|Drug|carboplatin|
75549251|NCT00418496|Drug|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
75400262|NCT00820872|Drug|docetaxel|
75400263|NCT00820872|Drug|lapatinib ditosylate|
76037831|NCT04901533|Procedure|O-A-A|patient is supine, and the therapist stands on the side to be manipulated. The cranial hand of the therapist globally grasps the patient's skull and turns the patient's neck on that same side. The caudal hand is placed on the patient's face. The technique is performed by an impulse in pure rotation on the side that the cervical region is rotated, with a helical movement.
75400264|NCT00821184|Drug|Vesicare (solifenacin)|5mg po qd
75400265|NCT00821184|Behavioral|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
75400266|NCT05237154|Other|Intervention with intermittent fasting.|Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).
75400267|NCT05237154|Other|Intervention with high-intensity interval training.|Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
75400268|NCT05236686|Procedure|Hepato-celiac lymphadenectomy|Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
75549252|NCT00418496|Drug|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
75549253|NCT05024721|Drug|HIP2101|Test drug
75549254|NCT05024721|Drug|RLD2101|Reference drug
75549255|NCT05024721|Drug|HPP2101|Placebo drug
75710295|NCT04534959|Other|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 >96% or PaO2 >100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air [no supplemental oxygen] for non-mechanically ventilated patients).
75710296|NCT00816309|Device|Acapella Physiotherapy|twice daily- around 20 minutes
75400269|NCT05235594|Device|Wearable sensor|The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.
75400270|NCT05215860|Behavioral|Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|WHO toolkit for Tobacco cessation (5A's and 5R's model)
75400271|NCT05215860|Other|visual exposure to personal intraoral photographs of oral lesions at baseline and review|Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
75400272|NCT05206812|Drug|durvalumab|"durvalumab 1500 mg QD*~Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)"
75400273|NCT05131152|Drug|Cyclosporine|0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
75549256|NCT05024721|Drug|HPP2102|Placebo drug
75549257|NCT00302705|Drug|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
75549258|NCT00302705|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
75549259|NCT00302705|Procedure|Missing one dose|Patients skip the dose the second day of monitoring
75549260|NCT00328419|Device|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
75549261|NCT00328419|Device|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
75549262|NCT00302783|Behavioral|Multi-Source Feedback: including self-assessment & coaching|
75710297|NCT00821691|Drug|Amantadin|Amantadin caps
75710298|NCT00821691|Drug|Placebo|Placebo caps
75710299|NCT00821847|Other|DEXA scan|DEXA scan
75710300|NCT00816387|Procedure|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
75400274|NCT05131152|Device|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
75400275|NCT05110872|Behavioral|Cigarette flavor restricted and e-cigarette flavor restricted|"Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
75400276|NCT05110872|Behavioral|Cigarette flavor restricted and e-cigarette flavor unrestricted|"Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
75400277|NCT05110872|Behavioral|Cigarette flavor unrestricted and e-cigarette flavor restricted|"Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
75400278|NCT05110872|Behavioral|Cigarette flavor unrestricted and e-cigarette flavor unrestricted|"Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
75710301|NCT00816387|Procedure|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
75710302|NCT05260866|Other|national population-based study|No intervention
75400279|NCT04982718|Diagnostic Test|OraQuick® HCV Self-Test|"Self-testing will be performed using the OraQuick® HCV Self-Test manufactured by OraSure Technologies Inc., USA. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the OraQuick® HCV Rapid Antibody Test is prequalified by WHO and CE marked for professional use (sensitivity 98.1%, specificity 99.6%).~As it is not approved for self-test use in Malaysia, the OraQuick® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
75400280|NCT04982718|Diagnostic Test|First Response® HCV Self-Test|"Self-testing will be performed using the First Response® HCV Card Test (Self Test) manufactured by Premier Medical Corporation, India. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the First Response® HCV Card Test is CE-marked and currently under WHO review for professional use (sensitivity 100%, specificity 100%).~As it is not approved for self-test use in Malaysia, the First Response® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
75400281|NCT04956276|Drug|ALXN1830|Administered as an SC infusion.
75400282|NCT04956276|Drug|Placebo|Administered as an SC infusion.
75710303|NCT00821925|Procedure|bone densitometry|All patients do a bone densitometry after the inclusion.
75710304|NCT00816465|Dietary Supplement|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
75710305|NCT00816465|Other|Placebo|PO Placebo pill
75710306|NCT00822003|Drug|Oral GLP-1|GLP-1 tablet (2mg)
75710307|NCT00822003|Drug|Placebo|Control tablet
75710308|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
75710309|NCT00822081|Drug|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
75549263|NCT05015712|Behavioral|moderate intensity continuous training|Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
75549264|NCT00302822|Drug|enfuvirtide|from week 0 to 24
75549265|NCT00302822|Drug|emtricitabine/tenofovir|1 pill/day
75549266|NCT00302822|Drug|lopinavir or efavirenz|investigator choice
75710310|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
75710311|NCT00822081|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
75710312|NCT00822159|Device|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
75710313|NCT00696774|Drug|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
75710314|NCT00608842|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
75710315|NCT00608842|Drug|Placebo|Matching vehicle placebo administered via intralipomal injection.
75710316|NCT00626925|Drug|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
75710317|NCT00626925|Drug|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
75710318|NCT02566746|Device|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
75710319|NCT02566746|Drug|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde At 12 months : implantation of the Chait Trapdoor caecostomie catheter
75710320|NCT00891280|Drug|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
75710321|NCT00816543|Drug|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
75400283|NCT04905342|Drug|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
75400284|NCT04905342|Drug|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
75400285|NCT04900116|Drug|Bupivacaine HCl 0.5 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
75400286|NCT04900116|Drug|Bupivacaine HCl 0.25 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
75400287|NCT04900116|Drug|Bupivacaine HCl 0.125 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
75400288|NCT04900116|Drug|NaCl 0.9%|In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
75400289|NCT04690530|Procedure|mechanical ventilation|mechanical vantilation will be performed
75400290|NCT04690530|Drug|Sedation|sedation wil be performed
75400291|NCT04640298|Device|Cingal|CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe.
75400292|NCT04603248|Drug|Nivolumab|Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
75400293|NCT04340700|Drug|THC or Placebo|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
75400294|NCT04213248|Drug|Umbilical Mesenchymal Stem Cells derived Exosomes|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.
75400295|NCT03936270|Drug|Palbociclib 125mg|The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
75400296|NCT03936270|Drug|Letrozole 2.5mg|Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
75400297|NCT03878394|Other|aerobic exercise and balance exercises|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
75400298|NCT03878394|Other|aerobic exercise and balance exercises with cognitive exercises|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
75400299|NCT03763656|Drug|Hydroxyurea|Oral Hydroxyurea
75400300|NCT03419676|Device|Hemopatch|Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
75400301|NCT03166722|Other|Control group|SpO2 and HR monitoring and routine treatment during immediate transition
75400302|NCT03166722|Device|Study group|Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
75400303|NCT02682888|Behavioral|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
75400304|NCT02682888|Drug|Oxytocin|intranasal administration of oxytocin
75400305|NCT02682888|Drug|Placebo|intranasal administration of placebo
75400306|NCT02641236|Drug|Vancomycin-polymyxin B|
75400307|NCT02402088|Behavioral|Stress Imagery|"The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work."
75400308|NCT02402088|Behavioral|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
75549267|NCT00328458|Drug|EPO906 (epothilone B)|
75549268|NCT00302861|Biological|MyVax|
75400309|NCT02402088|Behavioral|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
75400310|NCT00284700|Drug|Iron|
75400311|NCT00142272|Drug|Ciprofloxacin|
75400312|NCT00821886|Drug|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
75400313|NCT00821886|Drug|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
75400314|NCT00821886|Drug|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
75400315|NCT00821964|Drug|imiquimod|Given topically
75710322|NCT00816543|Drug|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
75710323|NCT00816543|Drug|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
75710324|NCT00819117|Device|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
75710325|NCT00892684|Dietary Supplement|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
75710326|NCT00892684|Dietary Supplement|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
75400316|NCT00821964|Drug|Abraxane|Given IV
75400317|NCT00821964|Other|laboratory biomarker analysis|Correlative studies
75710327|NCT00816621|Behavioral|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
75400318|NCT00821964|Genetic|RNA analysis|Correlative studies
75400319|NCT00821964|Other|immunoenzyme technique|Correlative studies
75400320|NCT00822354|Drug|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
75400321|NCT00822510|Behavioral|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
75400322|NCT00822510|Behavioral|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
75400323|NCT00822588|Device|Sangvia® System|Sangvia® Intra- and Post-op System
75400324|NCT00824070|Drug|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
75400325|NCT00824070|Drug|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
75400326|NCT00824070|Drug|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
75400327|NCT00824460|Drug|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
75710328|NCT00816621|Behavioral|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
75710329|NCT00698646|Drug|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
75710330|NCT00698646|Drug|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
75710331|NCT00698646|Drug|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
76037832|NCT04901533|Procedure|cranial listening|The patient is in the supine position, and the therapist sitting at the head of the patient. The therapist places his hands on the head of the patient, the thumbs touch each other, without touching the vault cranial. A perception of the cranial rhythm is carried out passively.
75400328|NCT00824460|Drug|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
75400329|NCT00824460|Drug|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
75400330|NCT00824460|Drug|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
75400331|NCT00824460|Drug|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
75400332|NCT00824460|Drug|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
75400333|NCT00824538|Drug|sunitinib malate|
75549269|NCT04716582|Behavioral|Sitting interrupted by light physical activity|Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.
75710332|NCT00891358|Behavioral|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
75710333|NCT02541292|Other|No intervention, observational|
75710334|NCT02565888|Drug|Daclatasvir|
75710335|NCT02565888|Drug|Atazanavir|
76037833|NCT04825925|Device|DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)|Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, the Platinum was infused. BAI (Bronchial Arterial Infusion ) chemotherapy was followed by DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with Vinorelbine were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
76037834|NCT05003479|Biological|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
76037835|NCT05003479|Biological|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
76037836|NCT04806659|Drug|SH1573 Capsules|Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
76037837|NCT03070093|Drug|gilteritinib|oral
76037838|NCT04806581|Drug|Allogeneic Hepatocyte|Allogeneic hepatocyte with cell numbers L,M,H respectively.
75400334|NCT00824538|Other|flow cytometry|
75400335|NCT00824538|Other|immunohistochemistry staining method|
75549270|NCT04716582|Behavioral|Sitting with cognitive task|Participants will perform online cognitive task during prolonged sitting.
75549271|NCT04716582|Behavioral|uninterrupted sitting|Participants will watch documentary during prolonged sitting.
75549272|NCT00302900|Behavioral|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
75549273|NCT00302900|Behavioral|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
75710336|NCT02565888|Drug|Ritonavir|
75710337|NCT02565888|Drug|Cobicistat|
75710338|NCT04061616|Behavioral|PASIPD-Fr|Fill-out the PASIPD-Fr self questionaire twice (2 completions at a 2-week interval)
75710339|NCT00609466|Drug|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
75710340|NCT00609466|Drug|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
75710341|NCT00609466|Drug|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
75400336|NCT00824538|Other|laboratory biomarker analysis|
75400337|NCT00825318|Procedure|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
75400338|NCT00825786|Drug|Ropivacaine|ropivacaine (15 ml).
75400339|NCT00825786|Drug|Mepivacaine|One syringe will contain mepivacaine (15 ml)
75549274|NCT00302900|Behavioral|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
75549275|NCT04716621|Other|Early intervention|"The Pain Management Support System for Primary Care (PMSS-PC) generated best practice alerts and gave clinicians access to a pain assessment template, measures of psychological distress and substance use, guidelines for drug and non-drug therapies, and facilitated referrals. At implementation, clinicians at the practices were offered in-person and virtual education through six webinars on best practices for pain."
75400340|NCT00826800|Drug|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
75549276|NCT04716621|Other|Delayed intervention|Delayed wait-list control group. The second arm involved three additional sites receiving the PMSS-PC intervention 6 months after the first arm. Initial outcomes from the PMSS-PC Experimental Intervention arm were compared to those of this Wait-list Control arm.
75549277|NCT00302978|Behavioral|Behavior therapy|
75549278|NCT00303017|Dietary Supplement|flavocoxid|flavonoid mixture
75549279|NCT00303017|Drug|Naproxen|non-steroidal anti-inflammatory drug
75549280|NCT00303056|Drug|HOE140 Icatibant|
76037839|NCT04806737|Drug|Teriflunomide Oral Tablet|The study will be conducted with two treatment groups in the form of a 2:1 parallel group comparison and will serve to compare oral treatment with 14 mg/d teriflunomide vs. placebo in subjects with well-controlled coeliac disease undergoing gluten challenge. The screening period will be up to 8 weeks, followed by a 7-day run-in treatment period with a loading dose of teriflunomide followed by a 6 day therapeutic maintenance dose, an initial 4-week treatment-free follow-up period and a 6 month closing follow-up.
76037840|NCT03070249|Behavioral|Professional Quality of Life (ProQoL) scale|COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
75400341|NCT00830076|Drug|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
75400342|NCT00830076|Drug|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
75400343|NCT00830076|Drug|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
75400344|NCT00830076|Drug|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
75400345|NCT00830232|Device|closed-cell stent (Xact stent)|"Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.~Carotid stenting was used on standard fashion using filters as embolic protection device."
75549281|NCT00328497|Drug|Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
75710342|NCT00822315|Drug|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
75710343|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
75710344|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
76037841|NCT04825691|Diagnostic Test|Immunohistochemistry of prostate biopsy|Sections of formalin fixed paraffin embedded tissue blocks will be stained with ERG oncoprotein. Antibody dilution, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions
76037842|NCT04991233|Procedure|Endoscopic surgery|The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
75400346|NCT00830232|Device|Open-cell stent (Acculink carotid)|"Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.~Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device."
75549282|NCT00303134|Drug|Islet Cell Transplantation|Islet Cell Transplantation for patients with type 1 diabetes mellitus
75549283|NCT00303173|Behavioral|Guided Imagery|
75549284|NCT00328536|Drug|Omacor|
75710345|NCT00608530|Behavioral|Cognitive Behavioral Therapy-Psychologist-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
75710346|NCT00608530|Behavioral|Supportive Psychotherapy-Psychologist-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
76037843|NCT04991233|Procedure|Suboccipital craniotomy surgery|The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
76037844|NCT04810637|Drug|GX-I7|Recombinant human interleukin-7 hybrid Fc
75400347|NCT00830310|Behavioral|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
75400348|NCT00830310|Behavioral|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
75400349|NCT00830310|Behavioral|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
75400350|NCT00830310|Behavioral|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
75400351|NCT00830388|Drug|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
75400352|NCT00831480|Drug|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
75400353|NCT00832338|Drug|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
75400354|NCT00832338|Drug|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
75400355|NCT00834210|Drug|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
75400356|NCT00834210|Drug|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
75400357|NCT00834288|Drug|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
75400358|NCT00834288|Drug|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
75871306|NCT02353390|Other|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
75400359|NCT00834678|Drug|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
75400360|NCT00834678|Drug|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
75400361|NCT00834678|Drug|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
75400362|NCT00835224|Drug|L-NAME|A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
75400363|NCT00835224|Drug|Midodrine|To treat low blood pressure.
75400364|NCT00835224|Drug|Placebo|A pill with an inactive substance that looks like the study drug.
75871307|NCT02352064|Procedure|PET (18-FDG)|Every patient will have a PET
75400365|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
75400366|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
75400367|NCT00837252|Drug|Finasteride|Participants received 5mg of oral finasteride daily for three months.
75400368|NCT00839982|Drug|clofarabine|Given PO
75400369|NCT00839982|Drug|cytarabine|Given SC
75400370|NCT00842946|Behavioral|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
75710347|NCT00608530|Behavioral|Cognitive Behavioral Therapy Nurse-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
75710348|NCT00608530|Behavioral|Supportive Psychotherapy-Nurse-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
75871308|NCT03078816|Device|Activa PC Primary Cell Neurostimulator - (Model 37601)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
76037845|NCT04353167|Other|observational evaluation|Patients will be evaluated only observationally without intervention
75400371|NCT00842946|Behavioral|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
75400372|NCT00843180|Other|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
75400373|NCT00845130|Biological|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
75400374|NCT00848016|Drug|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
75400375|NCT00848172|Drug|Octanoic Acid|4mg/kg
75400376|NCT00848172|Drug|Placebo|identical capsules
75400377|NCT00849810|Drug|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
75400378|NCT00849810|Drug|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
75400379|NCT00856050|Drug|letrozole|Taken orally once a day continuously
75400380|NCT00857532|Drug|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
75400381|NCT00858390|Dietary Supplement|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
75549285|NCT00303212|Other|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
75710349|NCT00642993|Drug|SCH 497079|100 mg capsule administered orally
75710350|NCT00642993|Drug|Placebo|Placebo capsules matching SCH 497079 administered orally
75710351|NCT02541136|Behavioral|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, < 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
75400382|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
75400383|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
75400384|NCT00858858|Drug|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
75400385|NCT00859950|Device|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
75400386|NCT00862446|Drug|Omegaven|1 gram/kg/day daily until on feeds
75400387|NCT00864084|Other|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
75400388|NCT00864708|Device|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
75400389|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
75400390|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
75400391|NCT00868140|Drug|pioglitazone|pioglitazone 45 mg
75400392|NCT00868140|Drug|Placebo|placebo daily
75400393|NCT00868218|Biological|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
75400394|NCT00868374|Drug|Quetiapine XR|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
75400395|NCT00868374|Drug|Placebo|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
75400396|NCT00868452|Drug|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
75400397|NCT00868452|Drug|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
75400398|NCT00869622|Drug|Risedronate|35 mgs/week + calcium and vit d
75400399|NCT00869622|Drug|Placebo + Calcium and Vitamin D|sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
75400400|NCT00871260|Drug|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
75400401|NCT00874614|Radiation|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
75400402|NCT00875550|Drug|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
75400403|NCT00875550|Drug|Midazolam|Rescue medication for sedation according to UMSS scores
75400404|NCT00875550|Drug|Fentanyl|Rescue medication for pain based on UMSS scores
75400405|NCT00875550|Drug|Morphine|Rescue medication for pain based on UMSS scores.
75400406|NCT00878436|Drug|Panobinostat|
75400407|NCT00878436|Drug|Bicalutamide|
75400408|NCT00878826|Drug|Enoxaparin|"Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation."
75400409|NCT00879060|Drug|Spironolactone|spironolactone 50mg daily
75400410|NCT00879060|Drug|Placebo|inactive placebo pill daily
75400411|NCT00880230|Device|Scuba Iliac Stent System|The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
75400412|NCT00880464|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
75400413|NCT00882102|Drug|Decitabine|Decitabine 20 mg/m^2 IV over 1-1/2 hours daily for 5 days.
75400414|NCT00882102|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m^2 IV on day 5.
75400415|NCT00884052|Drug|Low dose levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
75400416|NCT00884052|Drug|High dose levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
75400417|NCT00884754|Device|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
75400418|NCT00884910|Device|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
75400419|NCT00885768|Procedure|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
75400420|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
75871309|NCT03078816|Device|Activa RC Rechargeable Neurostimulator - (Model 37612)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
75871310|NCT03078816|Device|Activa SC Single Cell Neurostimulator (Models 37602/37603)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
75400421|NCT00886236|Drug|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
75400422|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
75400423|NCT00886626|Drug|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
75400424|NCT00886704|Dietary Supplement|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|"Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil."
75400425|NCT00886704|Dietary Supplement|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
75871311|NCT03078816|Device|DBS Lead - (Model 3387|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
75400426|NCT00887562|Drug|Idebenone|900 mg/day for 1 month
75400427|NCT00887562|Drug|Idebenone|2250 mg/day for 1 month
75400428|NCT00887562|Other|Placebo|Placebo - No idebenone
75400429|NCT00887640|Drug|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
75400430|NCT00887640|Drug|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
75400431|NCT00889200|Drug|eszopiclone|6 weeks standard oral therapy
75400432|NCT00889512|Drug|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
76037846|NCT04987411|Diagnostic Test|Measurement of methane concentrations in exhaled breath|To measure methane concentrations, a near-infrared laser technique-based photoacoustic apparatus will be attached to the exhalation outlet of the ventilator upon arrival of severely injured patients. Exhaled methane levels will be monitored continuously during the first 72 in-hospital hours and will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission).
76037847|NCT04987411|Diagnostic Test|Videomicroscopy of the sublingual microcirculation|Orthogonal polarization spectral imaging technique (Cytoscan A/R, Cytometrics) will be used to visualize the microcirculation of the sublingual mucosa of the patients. The OPS technique utilizes reflected, polarized light at the wavelength of the isobestic point of oxyhemoglobin and deoxyhemoglobin (548 nm). The diminution of sublingual microcirculation can refer to circulatory redistribution due to hemorrhage. Sublingual microcirculation of the patients will be visualized and evaluated at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
75400433|NCT00889512|Drug|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
75400434|NCT00889824|Device|balance prosthesis|vibrotactile stimulation
75400435|NCT00890682|Drug|SKY0402|Local infiltration of 8cc SKY0402
75400436|NCT00890682|Drug|Placebo|Local infiltration of 8cc Placebo
75400437|NCT00890916|Device|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
75549286|NCT00328575|Radiation|Intensity-Modulated Radiotherapy (IMRT)|"The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.~For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing."
75549287|NCT00303290|Drug|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
75400438|NCT00892710|Drug|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
75400439|NCT00892710|Drug|Bevacizumab|15 mg/kg IV every 21 days
75549288|NCT00303290|Drug|Ara-C (cytosine arabinoside)|10 mg under the skin daily
75400440|NCT00892710|Drug|Carboplatin|AUC=5 IV every 21 days
75400441|NCT00894504|Drug|Panitumumab|6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
75400442|NCT00894504|Drug|Carboplatin|AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
75400443|NCT00894504|Drug|Gemcitabine|1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
75549289|NCT00328692|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
75549290|NCT00328692|Drug|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
75710352|NCT00696696|Drug|Gemcitabine|1000 mg/m^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
75710353|NCT00696696|Drug|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
75710354|NCT00696696|Drug|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
75400444|NCT00894738|Procedure|Testing (MRS, US, DEXA, blood tests)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
75400445|NCT00895752|Drug|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
75400446|NCT00895830|Drug|APD405|IV
75400447|NCT00895830|Drug|Placebo|IV
75400448|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
75400449|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
75710355|NCT00822393|Drug|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
75710356|NCT00822393|Drug|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
75710357|NCT00892840|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
75710358|NCT00892840|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
75710359|NCT00819195|Drug|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
75549291|NCT04718246|Other|Dental Implants Placed In hyperlipidemia patients|"A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~Penetration of cortical bone will be achieved with no. 6 round burs.~The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks"
75549292|NCT00419718|Drug|inhaled human insulin|
75549293|NCT00303407|Drug|nadroparin|
76037848|NCT04987411|Diagnostic Test|Blood gas and laboratory analysis|Arterial blood gas analysis and laboratory testing of venous blood are routine examinations in clinical practice. Base deficit and lactate are considered as global markers of blood loss and shock, and can be obtained rapidly with blood gas analysis. Hemoglobin and hematocrit values can correspond to the severity of blood loss, and are measured routinely both from arterial and venous blood. Sampling of arterial and venous blood for blood gas and laboratory analyses will be performed at pre-determined time points (directly upon arrival, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
75549294|NCT00328731|Procedure|Procedure|
75400450|NCT00896298|Drug|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
75400451|NCT00896298|Drug|Placebo|Sugar pill
75400452|NCT00898560|Drug|eslicarbazepine acetate and Microginon®|"eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period"
75400453|NCT00898560|Drug|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
75400454|NCT00899574|Drug|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
75400455|NCT00900666|Drug|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
75549295|NCT00303524|Drug|Goserelin acetate|Injection 3.6 mg monthly
75549296|NCT00303524|Drug|Goserelin acetate|injection 10.8 mg every 3 months
75549297|NCT00419796|Drug|Lumiracoxib|
75549298|NCT00303563|Drug|P38 Inhibitor (4)|50mg po qd
75549299|NCT00303563|Drug|P38 Inhibitor (4)|150mg po qd
75549300|NCT00303563|Drug|P38 Inhibitor (4)|300mg po qd
75400456|NCT00900666|Drug|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
76037849|NCT04987411|Diagnostic Test|Hemodynamic monitoring|Hemodynamic monitoring is an essential part of emergency trauma care. Non-invasive monitoring of blood pressure, heart rate and respiratory rate of patients will be started immediately upon arrival. After patients are stabilized, invasive arterial blood pressure (IABP) monitoring can be started. IABP is considered as the gold standard of blood pressure measurement in critical care as it reflects the fluctuations of blood pressure in real time. Blood pressure and heart rate values will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
75400457|NCT00900822|Device|Straumann Bone Ceramic|Granules applied once during surgery
76037850|NCT04991155|Drug|BIA 5-1058|BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
75400458|NCT00900822|Device|BioOss|Granules that are applied once during surgery
75400459|NCT00902226|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
75400460|NCT00903162|Drug|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
75871312|NCT03078816|Device|DBS Extension - (Models 37085/6)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
76037851|NCT04825457|Procedure|Anchoring-tip vs. Conventional|"Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection."
76037852|NCT03070015|Behavioral|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI > 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables & no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch & 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (~50% kcal from carbohydrate,~25% from protein,~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
76037853|NCT03070015|Behavioral|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts & sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day & men ate 1500 kcal/day. Subjects with BMI >40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
75400461|NCT00903162|Drug|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
75400462|NCT00903162|Drug|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
75400463|NCT00904488|Drug|Addition of oral Metolazone|Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
75400464|NCT00904488|Drug|Furosemide dose escalation|Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
75400465|NCT00905580|Drug|Pregabalin|Pregabalin 150 mg orally
75400466|NCT00905580|Drug|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
75400467|NCT00908388|Device|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
75549301|NCT00303563|Drug|Placebo|po qd
75549302|NCT00419835|Drug|enalapril|
75400468|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
75400469|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
75400470|NCT00909324|Drug|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
76037854|NCT03071653|Procedure|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
75710360|NCT00891514|Behavioral|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
76037855|NCT03071653|Other|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
75400471|NCT00909324|Drug|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
75400472|NCT00911586|Drug|Testosterone undecanoate|
75400473|NCT00911742|Drug|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
75400474|NCT00911742|Drug|Zytram|1 Zytram 200 mg tablet as a single dose
75400475|NCT00911898|Drug|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
75400476|NCT00912990|Drug|Cisatracurium|One intravenous dose: 0.2mg/kg/dose
75400477|NCT00912990|Drug|Normal saline|One Intravenous dose
75710361|NCT00891514|Behavioral|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
75710362|NCT02567682|Drug|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
75710363|NCT00892918|Drug|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
75871313|NCT03078816|Device|Patient Programmer - (Model 37642)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
76037856|NCT02604407|Drug|SHP465 12.5mg capsules (one capsule daily)|one capsule daily
76037857|NCT02604407|Other|Placebo|Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
76037858|NCT02604407|Drug|SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)|One capsule daily
76037859|NCT04462315|Drug|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
76037860|NCT04462315|Device|Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)|Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation
75400478|NCT00913068|Procedure|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
76037861|NCT04825535|Behavioral|Standard psychiatry and cognitive behavioral online intervention|The cognitive behavioral online intervention has been assessed in a prior trial. Ritvo, P, Knyahnytska, Y, Pirboglou, M, Wang, W, Tomlinson, G, Zhao, H, Linklater, R, Kirk, M., Katz, J., Harber, L., Daskalakis, ZJ An online mindfulness-based cognitive behavioural therapy intervention for youth diagnosed with major depressive disorders: J Med Internet Res 2021, Mar 17; 23 (3), e24380
75549303|NCT00419835|Drug|losartan|
76037862|NCT04825535|Behavioral|Standard psychiatry and cognitive behavioural in-person intervention|The effectiveness of standard care office-based group CBT-MM at CAMH is indicated in a past study (n = 119) where depression symptoms reduced (after 16 weeks treatment) by 27% [3,18 ]. The office-based groups follow a carefully conceived structure that centers on the workbook Mind Over Mood (MOM) (Guilford Press) [41]. Key CBT concepts and procedures are conveyed via work sheets that structure personal and group exploration.
76037863|NCT04461067|Diagnostic Test|ultrasonography|Ultrasonography of the stomach is performed to measure the diameter of the antrum
75549304|NCT00328809|Drug|spironolactone|spironolactone administered to ESRD patients at low dose
75549305|NCT00303641|Device|Medtronic Resting Heart Bypass System|
76037864|NCT04806425|Drug|Intralipid|intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia
76037865|NCT04806425|Drug|Placebo|normal saline is given in same volume to normal saline group over the same duration
76037866|NCT04460677|Behavioral|Emotional Support Plan|The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.
76037867|NCT04460677|Behavioral|Daily Monitoring|The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.
76037868|NCT03071731|Drug|Bronchodilators|Administration of a nebulized combination of bronchodilators before the administration of a functional test.
75400479|NCT00913068|Procedure|standard post op pain control|opiates
75400480|NCT00914862|Drug|Ramelteon|Ramelteon tablets, orally for one day only.
75400481|NCT00915798|Behavioral|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
75400482|NCT00915798|Behavioral|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
76037869|NCT03071731|Drug|Placebos|Administration of a nebulized placebo before the administration of a functional test
75400483|NCT00915954|Diagnostic Test|Oral Glucose Tolerance Test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
75400484|NCT00915954|Diagnostic Test|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
75400485|NCT00915954|Diagnostic Test|Placebo|Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
75400486|NCT00916032|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
75400487|NCT00919932|Behavioral|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
75549306|NCT00420030|Drug|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
75549307|NCT00303758|Drug|cisplatin|
75549308|NCT00303758|Drug|fluorouracil|
75549309|NCT00303758|Drug|gemcitabine hydrochloride|
75549310|NCT00303758|Drug|leucovorin calcium|
75549311|NCT00332280|Drug|AMT2003|
75549312|NCT00303797|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
75549313|NCT00303797|Drug|sorafenib tosylate|
75549314|NCT00420069|Device|MRTX device|device for ventilation
75549315|NCT00303836|Drug|cyclophosphamide|Given IV
75549316|NCT00303836|Drug|fludarabine phosphate|Given IV
75549317|NCT00303836|Biological|therapeutic autologous lymphocytes|Given IV
75549318|NCT00303836|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
75549319|NCT00303836|Biological|gp100 antigen|Given SC
75549320|NCT00303836|Biological|MART-1 antigen|Given SC
75549321|NCT00303836|Biological|incomplete Freund's adjuvant|Given SC
75549322|NCT00303836|Biological|filgrastim|Given SC
75549323|NCT00303836|Biological|aldesleukin|Given IV
75710364|NCT04739280|Device|CardioFlux Magnetocardiography|Magnetocardiography
75710365|NCT02551185|Drug|ACY-241|
75710366|NCT00892996|Drug|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
75400488|NCT00919932|Device|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
75400489|NCT00922194|Drug|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
75710367|NCT00892996|Drug|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
75710368|NCT02567448|Other|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
75549324|NCT00303875|Behavioral|behavioral dietary and exercise intervention|
75549325|NCT00420186|Drug|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
75549326|NCT00420225|Device|Low-weight prolypropylene mesh|
75549327|NCT00303992|Biological|trastuzumab|
75549328|NCT00303992|Drug|irinotecan hydrochloride|
75549329|NCT00304226|Drug|valsartan|
75710369|NCT02551341|Procedure|higher PEEP ventilation|
75871314|NCT03078816|Device|Test Stimulator - (Model 3625)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
75871315|NCT03078816|Device|N'Vision Clinician Programmer - (Model 8840)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
75871316|NCT03078816|Device|N'Vision Software Application Card - (Model 8870)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
75871317|NCT02039128|Dietary Supplement|Krill oil or Fish oil|
75871318|NCT02039128|Dietary Supplement|Placebo|
75549330|NCT00304226|Drug|amlodipine|
75549331|NCT00420264|Device|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
75549332|NCT00304304|Behavioral|Asthma education|Research assistant worked with CCC staff on asthma prevention
75549333|NCT00332319|Drug|GW679769|
75549334|NCT00304382|Biological|Prevnar|0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
75549335|NCT00304382|Biological|Pneumovax|0.5 ml IM one time
75549336|NCT00328848|Behavioral|Behavioral|Group Treatment(patient education, self management support, caregiver support)
75549337|NCT00328848|Behavioral|behavioral|patient education, self management support, caregiver support
75549338|NCT00304421|Drug|rabeprazole|
75549339|NCT00304421|Drug|pantoprazole|
75549340|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
75549341|NCT00332397|Device|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
75549342|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
75549343|NCT00304460|Biological|aldesleukin|
75549344|NCT00304499|Drug|Oxybutynin|
75549345|NCT00328887|Genetic|CD40 Gene Transfer|gene transfer, intratumoral administration
75549346|NCT00304538|Drug|very low dose (VLD) glucagon|
75549347|NCT00420498|Drug|Atomoxetine (Strattera™)|
75549348|NCT00304577|Procedure|Bilateral recession|
75549349|NCT00304577|Procedure|Unilateral recession and resection|
75549350|NCT00328965|Drug|Lacidipine|Lacidipine 2, 4, 6mg
75549351|NCT00304616|Drug|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
75549352|NCT00332436|Drug|brimonidine/timolol fixed combination|
75400490|NCT00923598|Drug|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
75400491|NCT00923910|Drug|WT1 Peptide-Pulsed Dendritic Cells|
75400492|NCT00923910|Drug|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
75400493|NCT00923910|Drug|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
75400494|NCT00923910|Drug|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
75400495|NCT00923910|Drug|WT1 Peptides|dendritic cell vaccine
75549353|NCT00304655|Drug|Aripiprazole|
75549354|NCT00329004|Drug|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
75549355|NCT00304733|Device|cast vs. shoe|
75549356|NCT00332514|Behavioral|telephone call by a pharmacist|
75549357|NCT00332553|Drug|Raloxifene|
75400496|NCT00923910|Drug|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
75710370|NCT00891592|Biological|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~1xE5 cells/kg~2xE6 cells/kg~3xE7 cells/kg~4xE8 cells/kg"
75871319|NCT03723941|Drug|Cisplatin plus Etoposide|"Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl."
75871320|NCT03723941|Other|Observation or Mitotane|Observation or mitotane alone according to the investigator's preference
75400497|NCT00923910|Drug|Diphenhydramine|Pre-medication
75400498|NCT00923910|Drug|Acetaminophen|Pre-medication
75400499|NCT00924066|Drug|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m^2 for a total of 30mg/m^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
75400500|NCT00924612|Drug|Oral testosterone undecanoate (containing 300 mg T)|
75400501|NCT00925782|Drug|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
75400502|NCT00925782|Drug|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
75549358|NCT00332553|Drug|medroxyprogesterone acetate|
75549359|NCT00332553|Drug|estrogen|
75549360|NCT00332553|Drug|17 beta estradiol|
75549361|NCT00329121|Drug|PEP005|
75549362|NCT00332631|Drug|N-acetylcysteine|
75549363|NCT00332631|Drug|Placebo|
75549364|NCT00304772|Drug|Fluconazole|400mg/day
75549365|NCT00304772|Drug|Micafungin|150mg/day
75549366|NCT00332670|Procedure|10.000lux blue 1 hour every day during three weeks|10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
75549367|NCT00332670|Procedure|50lux dim red 1 hour every day during three weeks|50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
75549368|NCT00304811|Drug|Vancomycin|
75549369|NCT00304811|Drug|Vancomycin plus Gentamicin|
75549370|NCT00304811|Drug|Vancomycin plus Rifampin|
75549371|NCT00304811|Drug|Vancomycin plus Gentamicin plus Rifampin|
75549372|NCT00332787|Drug|Fluoxetine|
75549373|NCT00304850|Behavioral|polyamine-free diet|Polyamine-free diet in the 7 days befor surgery
75549374|NCT00304850|Drug|Ketamine or placebo|Peroperative and post operative (48h) ketamine injection
75400503|NCT00925938|Drug|misoprostol|One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
75400504|NCT00925938|Drug|placebo|placebo
75400505|NCT00926952|Drug|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
75400506|NCT00926952|Device|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
75400507|NCT00927264|Behavioral|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits & 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
75400508|NCT00927264|Behavioral|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
75400509|NCT00927576|Behavioral|Digit span testing|Testing of short-term verbal memory with digit span
76037870|NCT04809779|Drug|Sintilimab|The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
75400510|NCT00927576|Behavioral|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
76037871|NCT04809935|Drug|98% dehydrated alcohol|"coeliac plexus is identified and punctured~Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol."
75400511|NCT00927576|Behavioral|Finger tapping|Testing motor speed with a finger tapping test.
75400512|NCT00927576|Behavioral|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
75400513|NCT00927576|Behavioral|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
75400514|NCT00927576|Behavioral|Verbal fluency|Evaluating how many words are produced in 90s.
76037872|NCT04809935|Device|19G EUSRA needle, Taewoong Medical, Korea|"10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan"
75400515|NCT00927576|Behavioral|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
75400516|NCT00927576|Behavioral|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
75400517|NCT00927576|Behavioral|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
75400518|NCT00927576|Behavioral|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
75400519|NCT00927888|Drug|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
75400520|NCT00927888|Drug|Placebo|placebo is identical in appearance in comparison to active drug.
75400521|NCT00928200|Drug|Erwinase|"The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion."
75400522|NCT00928200|Drug|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
75400523|NCT00928200|Drug|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14.
75400524|NCT00928200|Drug|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
76037873|NCT04255927|Drug|Coated Vicryl plus|Vicryl plus (Coated Polyglactin 910 with Triclosan)
76037874|NCT04255927|Drug|Coated vicryl|Vicryl (Coated Polyglactin 910 without Triclosan)
75400525|NCT00928200|Drug|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
75400526|NCT00928200|Drug|Methotrexate|Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
76037875|NCT04809857|Other|Exercise|
76037876|NCT03069781|Drug|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
76037877|NCT03069781|Drug|Polycose|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
76037878|NCT04986553|Device|Arthrex Clavicle Plates|Arthrex Clavicle Plate for treatment of clavicle fractures
75400527|NCT00928200|Drug|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
75400528|NCT00928200|Drug|Dexrazoxane|Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
76037879|NCT04427111|Device|Non-titratable-customized mandibular advancement device|The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.
76037880|NCT03069625|Behavioral|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
75400529|NCT00929838|Behavioral|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
75400530|NCT00929838|Behavioral|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
75400531|NCT00929838|Behavioral|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
75400532|NCT00929838|Behavioral|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
75400533|NCT00931164|Drug|Sodium Oxybate|dosage is by weight
75400534|NCT00931242|Drug|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
75549375|NCT00329199|Behavioral|Attachment-Based Family Therapy|
76037881|NCT03069625|Behavioral|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
75549376|NCT00329277|Procedure|perimetry|
75400535|NCT00932022|Drug|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
75549377|NCT00329316|Drug|Crinone Gel 8%|
75549378|NCT00305045|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
75549379|NCT00332826|Drug|Technosphere Insulin|
75549380|NCT00305201|Drug|pravastatin|
75549381|NCT00332865|Behavioral|Swallowing Exercises|Daily exercises
75549382|NCT00305240|Procedure|T Wave Alternans Test|
75400536|NCT00932022|Other|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
75400537|NCT00934596|Procedure|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV & Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
75400538|NCT00934596|Drug|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
75400539|NCT00935064|Drug|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
75400540|NCT00935064|Other|Placebo|Placebo orally one tablet once a day for 6 weeks.
75400541|NCT00935766|Drug|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
75549383|NCT00329355|Drug|sumatriptan succinate/naproxen sodium|
75549384|NCT00305279|Other|Dietary|Dietary
75549385|NCT00305279|Other|Dietary|Dietary
75549386|NCT00305279|Other|Dietary|Dietary
75549387|NCT00332904|Drug|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
75549388|NCT00332904|Drug|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
75549389|NCT00329394|Drug|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
75549390|NCT00305396|Drug|Sirolimus|
75549391|NCT00332943|Procedure|MR colonography with fecal tagging|
75549392|NCT00305435|Drug|Romiplostim (AMG-531)|Romiplostim (AMG-531)
75549393|NCT00329472|Drug|gemcitabine, cisplatin|
75549394|NCT02960399|Biological|Zostavax®|Zostavax® immunization
75549395|NCT00332982|Behavioral|Focused knowledge translation strategies|
75549396|NCT00305474|Drug|Risperidone|Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
75549397|NCT00329511|Drug|methyldopa vs. clonidine|Comparison of compliance
75549398|NCT00329511|Drug|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
75549399|NCT00305513|Procedure|The phasic alerting treatment|
76037882|NCT04809389|Biological|DelNS1-nCoV-RBD LAIV|Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2
76037883|NCT04809389|Biological|Matching placebo|0.9% NaCl solution
76037884|NCT03069391|Behavioral|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
76037885|NCT03069391|Device|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
76037886|NCT03069391|Device|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
76037887|NCT04805723|Procedure|VATS|"Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung."
75710371|NCT00891592|Other|Observation Arm|Single infusion of Cord Blood Cells
75549400|NCT00333021|Drug|Fondaparinux sodium|
75710372|NCT00822471|Behavioral|Diabetes Self-Management Education|"DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor."
75710373|NCT00893230|Dietary Supplement|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
75710374|NCT00893230|Dietary Supplement|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
75710375|NCT00891670|Drug|cilostazol|100mg twice daily for at least 1 month
75710376|NCT00891670|Drug|clopidogrel|"75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)"
75710377|NCT00891670|Drug|aspirin|aspirin 100mg
75710378|NCT00699192|Drug|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
75710379|NCT00699192|Drug|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
75710380|NCT00699192|Drug|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
75400542|NCT00935766|Drug|Placebo|
75549401|NCT00333021|Drug|GSK576428|
75549402|NCT00305552|Drug|THALIDOMIDE|THALIDOMIDE
75549403|NCT00329589|Drug|Velcade (bortezomib)|
75710381|NCT00699192|Drug|Placebo|1 capsule placebo to match valsartan orally once daily
75710382|NCT00891748|Genetic|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
75710383|NCT00921180|Drug|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
75710384|NCT00921180|Drug|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
75710385|NCT00891826|Dietary Supplement|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
75710386|NCT00891826|Dietary Supplement|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
76037888|NCT04805723|Procedure|Thoracotomy|Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
75400543|NCT00937794|Behavioral|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
75400544|NCT00937794|Other|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
75871321|NCT03153046|Dietary Supplement|prebiotics|Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
75871322|NCT03153046|Dietary Supplement|Maltodextrin|Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
76037889|NCT03071575|Biological|Measles-rubella (MR) vaccine at 6 and 9 months|Arm A will receive MR vaccine dose at 6 and 9 months of age
76037890|NCT03071575|Biological|Measles-rubella (MR) vaccine at 9 months|Arm A will receive MR vaccine dose at 9 months of age
76037891|NCT04798391|Drug|Dexamethasone|Steroids and analgesics
76037892|NCT03071497|Diagnostic Test|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
75400545|NCT00939120|Drug|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
75400546|NCT00939120|Drug|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
75400547|NCT00939120|Drug|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
75400548|NCT00939198|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
75400549|NCT00939900|Drug|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
75400550|NCT00940290|Other|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
75400551|NCT00940446|Device|Insorb staples|absorbable staples required for wound closure
75400552|NCT00940446|Device|metal staples (Ethicon metal stapler)|wound closure with metal staples
75400553|NCT00943098|Drug|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
75400554|NCT00943098|Drug|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
75400555|NCT00943488|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
75549404|NCT00305591|Drug|l-ornithine l-aspartate|
75549405|NCT00333060|Drug|OT-551 ophthalmic solution|
75710387|NCT04060992|Drug|Elagolix 200 MG Oral Tablet [Orilissa]|oral tablet given twice daily
75710388|NCT04061304|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
75710389|NCT04061304|Device|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
75400556|NCT00943800|Drug|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
75400557|NCT00943800|Procedure|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
75400558|NCT00943800|Procedure|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
75400559|NCT00943800|Drug|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
75400560|NCT00943800|Drug|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
75400561|NCT00943878|Biological|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
75400562|NCT00943878|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
75400563|NCT00943878|Drug|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
75400564|NCT00945282|Drug|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
75400565|NCT00945282|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
75400566|NCT00945282|Drug|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
75400567|NCT00945282|Drug|Placebo|Placebo is a capsule with no drug in it.
75400568|NCT00945282|Drug|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
75400569|NCT00945594|Device|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
75549406|NCT00305630|Drug|Periocular injection of triamcinolone acetonide 40mg|
75549407|NCT00329628|Drug|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
75549408|NCT00329628|Drug|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
75400570|NCT00945750|Drug|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
75400571|NCT00945750|Drug|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
75400572|NCT00947310|Device|Standard ICD programming|Standard ICD programming
75400573|NCT00947310|Device|High rate cutoff|Programming of a high rate cutoff
75400574|NCT00947310|Device|Long delay|Programming of a prolonged delay
75400575|NCT00948090|Drug|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
75400576|NCT00948792|Procedure|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
75400577|NCT00948792|Procedure|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
75400578|NCT00950352|Drug|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
75400579|NCT00950352|Drug|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
75400580|NCT00953862|Drug|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
75400581|NCT00955032|Device|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
75549409|NCT00305669|Biological|sargramostim|
75710390|NCT00921336|Drug|KW-2450|Dose escalation may proceed once >= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
76037893|NCT05616455|Drug|Propionibacterium Acnes|Application of the gel every 12 hours for 40 days
76037894|NCT05616455|Drug|glyceryl trinitrate|Application of the gel every 12 hours for 40 days
75549410|NCT00305669|Other|immunohistochemistry staining method|
75549411|NCT00305669|Other|immunological diagnostic method|
75549412|NCT00305669|Other|laboratory biomarker analysis|
75549413|NCT00305669|Procedure|conventional surgery|
75549414|NCT00305669|Procedure|neoadjuvant therapy|
75549415|NCT00333099|Dietary Supplement|Impact (R) Enteral Nutrition|mucositis frequency, treatment tolerance
75549416|NCT00333099|Other|impact|"1500 calories every day :~-5 days before the begining of the chemoradiotherapy and until the last day of the treatment"
75549417|NCT00305708|Biological|anti-thymocyte globulin|
75549418|NCT00305708|Drug|busulfan|
75549419|NCT00305708|Drug|fludarabine phosphate|
75549420|NCT00305708|Procedure|allogeneic bone marrow transplantation|
75549421|NCT00305708|Procedure|peripheral blood stem cell transplantation|
75400582|NCT00955032|Device|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
75400583|NCT00955266|Drug|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
75400584|NCT00955266|Drug|Placebo|Normal saline, 50cc delivered over 5 minutes
75400585|NCT00957684|Drug|eslicarbazepine acetate|once-daily oral tablet
75400586|NCT00957684|Drug|placebo|once daily placebo comparator
75400587|NCT00958308|Other|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
75400588|NCT00958308|Other|Placebo|Placebo is devoid of microorganisms.
75549422|NCT00305708|Procedure|umbilical cord blood transplantation|
76037895|NCT04986319|Diagnostic Test|Serum vitamin D assay|"Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency."
76037896|NCT02593097|Drug|Metformin|Metformin 500mg twice daily
75400589|NCT00959166|Other|PET scan|PET brain scan
75400590|NCT00961662|Drug|D-Tagatose|powder to be dissolved in water prior to dosage.
76037897|NCT02593097|Drug|Matching Placebo|Matching Placebo twice daily
76037898|NCT05003011|Device|Cardiospire|Non-invasive hemodynamic monitoring
76037899|NCT05002855|Other|Enhanced Recovery After Surgery (ERAS)|Multidisciplinary approach to perioperative care.
76037900|NCT04805801|Drug|Emicizumab subcutaneous injection|Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.
76037901|NCT04990765|Behavioral|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 3 weekly treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations (6 different scenes from a restaurant) in virtual reality. From scene 1 to scene 6, alchol-related cues increase in intensity in order to perform gradual exposure therapy as a part of CBT. Furthermore, VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
76037902|NCT04990765|Behavioral|CBT|The active comparator receives 3 conventional cognitive behavioral therapy sessions with 1 week intervals.
76037903|NCT04797923|Drug|1. Treatment: IP chemotherapy + Systemic chemotherapy|1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
75400591|NCT00962598|Drug|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
75400592|NCT00962598|Dietary Supplement|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
75549423|NCT00305708|Radiation|radiation therapy|
75549424|NCT04716543|Diagnostic Test|ILI and COVID-19 detection|"All participants presenting with ILI symptoms will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.~All family members more than 6 months living with SARS-CoV-2 positive individuals will have will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire."
75400593|NCT00962754|Procedure|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
75400594|NCT00964548|Drug|Dantrolene|1.25 mg/kg IV once over 60 min
75400595|NCT00964548|Drug|Dantrolene|2.5 mg/kg IV once over 60 min
75400596|NCT00905268|Drug|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
75400597|NCT00905268|Drug|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
75400598|NCT00965250|Drug|IMC-12|20 mg/kg intravenously once every three weeks
75400599|NCT00966186|Procedure|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
75400600|NCT00967044|Drug|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
75400601|NCT00967044|Drug|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
75400602|NCT00968838|Procedure|White Blood Cell Transfusion|"4 Transfusions, each taking approximately 1 hour:~Patients <50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients >50 years of age are randomized to receive either radiated or non radiated transfusions."
75400603|NCT00970320|Other|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
75400604|NCT00973752|Drug|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
75871323|NCT03155698|Combination Product|microneedling and Platelet rich plasma|"Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days."
75871324|NCT03155698|Radiation|NB-UVB phototherapy|All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
75400605|NCT00973752|Drug|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
75400606|NCT00973752|Drug|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
75549425|NCT00305747|Drug|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
75871325|NCT03723863|Behavioral|Occupational Therapy|Receive in-person occupational therapist-led work consultation
75400607|NCT00973752|Drug|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
75400608|NCT00973752|Drug|Cytarabine|Intrathecally during Induction and CNS therapy
75400609|NCT00973752|Drug|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
75400610|NCT00973752|Drug|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
75400611|NCT00973752|Drug|Clofarabine|Intravenously during Consolidation 1 Therapy
75400612|NCT00973752|Drug|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
75400613|NCT00974142|Drug|Cyclosporine|Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
75400614|NCT00974142|Drug|Placebo|Fifteen patients will receive will receive placebo.
75400615|NCT00974376|Drug|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
75400616|NCT00974376|Drug|Placebo|1200mg/day of placebo for 12 weeks
75549426|NCT00333255|Drug|Nepafenac Ophthalmic Suspension, 0.1%|
75400617|NCT00974376|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
75549427|NCT00305786|Drug|gemcitabine hydrochloride|
75549428|NCT00305786|Drug|oxaliplatin|
75400618|NCT00976248|Drug|RAD001|Taken orally once a day
75400619|NCT00976404|Biological|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
75400620|NCT00976404|Drug|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
75400621|NCT00976404|Drug|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
75400622|NCT00977184|Procedure|50 HZ Repetitive TMS|
75400623|NCT00977184|Procedure|Sham rTMS|
75400624|NCT00977808|Device|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
75400625|NCT00977808|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
75400626|NCT00981474|Drug|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised
75400627|NCT00981474|Device|Control group|Institutional standard of care.
75400628|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
75871326|NCT03155308|Device|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
75871327|NCT03721679|Biological|Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months|Same as above
75400629|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
75400630|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
75400631|NCT00981630|Biological|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
75400632|NCT00983346|Drug|Bortezomib|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
75400633|NCT00985140|Radiation|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
75400634|NCT00986856|Drug|Fucidin® cream|
75549429|NCT00329667|Device|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
75549430|NCT00305825|Biological|bevacizumab|
75549431|NCT00305825|Drug|letrozole|
75871328|NCT04674228|Other|Electronic Health Record Review|Review of medical records
75871329|NCT03639948|Drug|Carboplatin|Intravenous solution
75871330|NCT03639948|Drug|Docetaxel|Intravenous solution
75871331|NCT03639948|Drug|Pembrolizumab|Intravenous solution
75871332|NCT03639948|Drug|Pegfilgrastim|Injectable product
75549432|NCT00333294|Drug|Gefitinib|
75549433|NCT00333294|Procedure|Radiation therapy|
75549434|NCT00333294|Drug|Cisplatin|
75549435|NCT00333294|Drug|Vinorelbine|
75549436|NCT00305903|Drug|Rivastigmine, memantine|
75400635|NCT00987480|Drug|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
75710391|NCT04036786|Behavioral|study group|We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.
75710392|NCT04036786|Behavioral|standard care|standard pregnancy follow up
75710393|NCT05195112|Drug|MT921|Active ingredient
76037904|NCT04797923|Procedure|2. Response evaluation after 4 cycles of IP + systemic chemotherapy|"2. Response evaluation after 4 cycles of IP + systemic chemotherapy~Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~IP chemotherapy should not exceed total of 8 cycles."
76037905|NCT04798157|Radiation|transcranial doppler|Transcranial Doppler ultrasonography will be done using the ultrasound machine by placing a transducer over the relatively thinner temporal and occipital bones in order to visualize and evaluate the velocities at the circle of Willis.
76037906|NCT04990453|Other|RPD frameworks fabricated from PEEK material|extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
75400636|NCT00987480|Device|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
75400637|NCT00987558|Drug|Eslicarbazepine acetate|
75400638|NCT00987558|Drug|Simvastatin|
75400639|NCT00987948|Drug|maraviroc (Selzentry)|dosage varies with other medications being taken; will follow package insert guidelines
76037907|NCT03071419|Behavioral|Nutrition and Parenting Intervention|The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
75400640|NCT00989586|Biological|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
75400641|NCT00989586|Biological|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
75400642|NCT00989586|Procedure|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
75400643|NCT00989586|Procedure|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
75400644|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
75710394|NCT05195112|Drug|Placebo|Normal Saline
75710395|NCT05190978|Device|Acellular Dermal Matrix|Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
76037908|NCT04805567|Device|endocuff|The Endocuff is a device that can be mounted on the tip of an endoscope and may assist to inspect a greater surface of the colonic mucosa by pulling backwards, flattening, and stretching the colonic folds as the endoscope is gradually withdrawn.
75400645|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
75400646|NCT00989586|Procedure|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
75400647|NCT00989586|Biological|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
75400648|NCT00990288|Drug|Hemostatic Matrix|FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
75400649|NCT00991458|Drug|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
75400650|NCT00991458|Drug|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
75400651|NCT00991458|Drug|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
75400652|NCT00993798|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
75400653|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
75400654|NCT00993798|Drug|Bupivacaine HCl Treatment 1c|20.0 ml
75400655|NCT00993798|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
75400656|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
75400657|NCT00993798|Drug|Bupivacaine HCl Treatment 2c|20.0 ml
75400658|NCT00995904|Drug|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
75400659|NCT00995904|Drug|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
75400660|NCT00995904|Drug|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
75400661|NCT00996372|Drug|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
75710396|NCT05190978|Procedure|Reconstruction without ADM|Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
76037909|NCT04985617|Other|Warmed Fluids|The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
75400662|NCT00996372|Drug|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
75549437|NCT00329706|Procedure|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
75549438|NCT00329823|Drug|Etanercept sc 50mg per week for 12 weeks|
75710397|NCT00893386|Procedure|LV Lead Extraction|Removal of a LV lead using any tools & techniques.
75710398|NCT04062474|Procedure|Epidural Intervention with TNF-α inhibitor|Epidural administration with TNF-α inhibitor
75710399|NCT02541214|Device|Trial Nasal Mask|
75710400|NCT00892138|Behavioral|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
75710401|NCT02567370|Drug|AMG 581|Active drug
75710402|NCT02567370|Drug|Placebo|Placebo
76037910|NCT03071029|Behavioral|Monthly PAFP rates displayed at clinics.|Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
75549439|NCT00306020|Drug|topical morphine|
75549440|NCT00329862|Procedure|Laparoscopic Truncal Vagotomy|
75710403|NCT00893542|Drug|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
75710404|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay.
75549441|NCT00306137|Drug|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~Stratum 1: complete primary pneumonectomy~Stratum II: decortication or completion pneumonectomy~Stratum III: esophagectomy by transhiatal approach~Stratum IV: esophagectomy by transthoracic approach"
75549442|NCT00306137|Drug|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
75400663|NCT00997620|Drug|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
75400664|NCT00997620|Drug|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
75400665|NCT00997932|Drug|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
75400666|NCT00998010|Drug|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
75400667|NCT00999102|Drug|Metoprolol|Metoprolol 50 mg, Metoprolol 100 mg,
75400668|NCT00999102|Drug|Nebivolol|Nebivolol 5 mg, Nebivolol 10 mg.
75549443|NCT00329940|Drug|Letrozole|
75549444|NCT00306176|Drug|Rosiglitazone|
75400669|NCT01000662|Radiation|Daily Radiation Therapy|15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
75400670|NCT01000662|Radiation|Weekly Radiation Therapy|15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
75400671|NCT01000818|Drug|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
75549445|NCT00333333|Procedure|Cord blood|Cord blood will be obtained at the time of delivery.
75549446|NCT00329979|Behavioral|vascular access site|Randomized vascular access site
75549447|NCT00333372|Drug|Z-338|
75549448|NCT00330018|Drug|Valganciclovir|Valganciclovir
75549449|NCT00330018|Drug|Acyclovir|Acyclovir
75549450|NCT00333450|Biological|Pneumococcal vaccine|
75549451|NCT00306254|Drug|PD 0348292|
75549452|NCT00306254|Drug|Enoxaparin|
75549453|NCT00333489|Drug|valsartan|
75400672|NCT01000818|Drug|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
75400673|NCT01000818|Drug|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
75400674|NCT01001052|Drug|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
75400675|NCT01001442|Drug|BT062|intravenous administration
75400676|NCT01002456|Other|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
75400677|NCT01002456|Other|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
75400678|NCT01003080|Device|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
75400679|NCT01003080|Other|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
75549454|NCT00333528|Drug|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
75549455|NCT00333528|Drug|Placebo: Normal saline|Intramuscular administration
75549456|NCT03275753|Other|Visual Function Tests|All subjects will undergo a battery of visual function tests
75549457|NCT00330096|Drug|Hesperidin|
76037911|NCT03071107|Behavioral|Multi-disciplinary intervention|Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
75400680|NCT01003938|Drug|Topotecan|
75400681|NCT01003938|Drug|Erlotinib|
75400682|NCT01004718|Radiation|Fludeoxyglucose F18|Undergo FDG PET/CT scans
75400683|NCT01004718|Procedure|Computed Tomography|Undergo FDG PET/CT scans
75400684|NCT01004718|Procedure|Positron emission tomography|Undergo FDG PET/CT scans
75400685|NCT01005576|Drug|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
75400686|NCT01005810|Drug|N-Acetylcysteine|1200 mg twice daily for 8 weeks
75400687|NCT01005810|Drug|placebo|2 capsules twice daily for 8 weeks
75400688|NCT01005810|Behavioral|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
75400689|NCT01005888|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
75549458|NCT00330096|Other|Placebo|
75400690|NCT01005888|Drug|Placebo (saline)|
75710405|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
75710406|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 100 mg
75710407|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 50 mg
75400691|NCT01007136|Device|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
75400692|NCT01007136|Device|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
75400693|NCT01007526|Other|CCRT followed by VIDL chemotherapy|CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
75549459|NCT03275714|Device|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
75549460|NCT00330135|Drug|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
75549461|NCT00330135|Drug|placebo injection|placebo injection - 1 injection
75549462|NCT03275558|Drug|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
75710408|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
75710409|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg
75710410|NCT00401245|Drug|Placebo|Tapering placebo
75710411|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
75710412|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
75400694|NCT01007994|Drug|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril < 40 kg starting dose 2.5 mg titrate to 5 mg > 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine < 40 kg 2.5 mg > 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol <40 kg starting dose 10 mg titrate to 20 mg >40 kg starting dose 20 mg titrate to 40 mg"
75400695|NCT01008462|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
75400696|NCT01008462|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
75400697|NCT01008462|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
75400698|NCT01008462|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
75400699|NCT01008462|Drug|Carmustine|Given IV
75400700|NCT01008462|Drug|Cyclophosphamide|Given IV
75549463|NCT03275558|Drug|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
75710413|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
75400701|NCT01008462|Drug|Cytarabine|Given IV
75710414|NCT04036474|Other|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
75710415|NCT04036240|Other|Finger feeding|After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
75400702|NCT01008462|Drug|Etoposide|Given IV
75400703|NCT01008462|Drug|Fludarabine Phosphate|Given IV
76037912|NCT04990063|Drug|Chemotherapy|Standard chemotherapy drug
76037913|NCT04990063|Biological|Adoptive TKC transfer therapy|TKC: co-cultured autologous NK cells and γδT cells
75400704|NCT01008462|Other|Laboratory Biomarker Analysis|Correlative study
75400705|NCT01008462|Drug|Melphalan|Given IV
75400706|NCT01008462|Drug|Mycophenolate Mofetil|Given PO
75400707|NCT01008462|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
75400708|NCT01008462|Drug|Tacrolimus|Given IV or PO
75400709|NCT01008462|Radiation|Total-Body Irradiation|Undergo TBI
75400710|NCT01010568|Drug|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
75400711|NCT01011816|Biological|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
75400712|NCT01011816|Drug|Saline|One injection of up to 4 mL of saline using the Biostat Delivery Device
75400713|NCT01011894|Drug|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
75400714|NCT01012362|Drug|Pazopanib|Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
75400715|NCT01012362|Drug|Ixabepilone|Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
75400716|NCT01012674|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
75400717|NCT01012674|Other|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
75400718|NCT01013844|Behavioral|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter > or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
75400719|NCT00986544|Procedure|no drain|drain positioned on the skin
75400720|NCT00986544|Procedure|drain positioned|drain positioned in the subhepatic space
75549464|NCT03275558|Drug|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
75549465|NCT00330213|Behavioral|red wine and cognac consumption|
75549466|NCT03275519|Other|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
75400721|NCT00986544|Procedure|drain not positioned|Drain positioned in the abdominal wall
75400722|NCT01014390|Device|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
75400723|NCT01015170|Drug|bupropion HCl|150mg BID for up to 8 weeks + counseling
75400724|NCT01015326|Other|Questionnaire|Administered questionnaire
75549467|NCT03275519|Other|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
75710416|NCT00696384|Drug|Azilsartan medoxomil|"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and <130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit."
75710417|NCT00696384|Drug|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
75710418|NCT00696384|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
75710419|NCT04036162|Behavioral|Cognitive tasks|MagnetoEncephaloGraphy (MEG) records
75710420|NCT01041625|Drug|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
75710421|NCT02566356|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
75871333|NCT03146728|Other|exercise|energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
75871334|NCT02347852|Drug|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
75400725|NCT01015326|Other|Questionnaire|Administered questionnaire
75710422|NCT02566356|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
75871335|NCT02347696|Behavioral|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
75871336|NCT02347696|Behavioral|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
75400726|NCT01016106|Genetic|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
75400727|NCT01016652|Device|etafilcon A multifocal contact lens|low-add multifocal contact lens
75400728|NCT01016652|Device|etafilcon A Contact Lens|standard sphere contact lens
75400729|NCT01017042|Drug|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
75400730|NCT01018056|Drug|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
75549468|NCT00333567|Drug|Lumiracoxib|
75549469|NCT02956694|Behavioral|Professional e-learning program on shared decision making|Clinicians will have access to a, e-learning program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. They will receive five DBs by email, at a rate of 1 per week for 5 weeks.
75549470|NCT00330252|Drug|Rituximab|Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
75400731|NCT01018056|Drug|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
75400732|NCT01018056|Drug|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
75400733|NCT01018134|Drug|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
75400734|NCT01018134|Drug|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
75400735|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
75400736|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
75400737|NCT01018134|Drug|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
75400738|NCT01018134|Drug|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
75400739|NCT01019928|Drug|AZD1386|95 mg, oral solution, single dose
75400740|NCT01019928|Drug|Placebo to AZD1386|Placebo, oral solution, single dose
75400741|NCT01020006|Drug|PCI-27483|"Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.~All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are >3.50,a reduced dosage will be calculated."
75400742|NCT01020006|Drug|Gemcitabine|
75400743|NCT05395962|Drug|Carboplatin|treatment with bleomycin and carboplatin in association with electroporation
75400744|NCT05395962|Drug|Bleomycin|treatment with bleomycin in association with electroporation
75400745|NCT05395728|Other|Deflate the tracheostomy cuff early|The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation
75710423|NCT00893620|Device|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
75400746|NCT05395728|Other|Deflate the tracheostomy cuff after complete weaning mechanical ventilation|The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
75400747|NCT05395572|Device|Kinesio® Tape|In order to increase the activity of underactive muscles, the tape is applied from origin to insertion with a 15-25% tension. The Kinesio® Tape mechanical muscle correction will be performed with one Y-strip of Kinesio® Tape over the bilateral cervical multifidus and semispinalis cervicis muscles, while also including portions of other cervical extensor muscles (the semispinalis capitis, splenius cervicis, levator scapulae, upper trapezius, longus coli, and splenius capitis).
75710424|NCT01039129|Procedure|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
75710425|NCT01039129|Procedure|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
75710426|NCT01039129|Procedure|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
75400748|NCT05394480|Diagnostic Test|Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.|Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
75400749|NCT05394090|Diagnostic Test|saliva stimulation|In 50 patients with ischemic stroke, saliva was the option of a neurologopedic massage of choice
75710427|NCT00892450|Drug|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
75710428|NCT01566565|Drug|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
75871337|NCT02347696|Behavioral|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~weeks 1-4: 14.2 kcal*kg-1*week-1;~weeks 5-8: 18.9 kcal*kg-1*week-1;~weeks 9-12: 23.6 kcal*kg-1*week-1."
75400750|NCT05391048|Drug|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
76037914|NCT04985461|Device|dental occlusion ties maxillo-mandibular fixation|"This research study is being done to determine if dental occlusion ties can adequately align and stabilize jaw fractures. The chief goal of jaw fracture repair is to ensure that the teeth align normally. Traditionally, alignment has been accomplished by using steel wires and bars (having the jaw wired). Dental occlusion ties are newer devices similar to cable ties or zip ties that are wrapped around and/or between some of the teeth and secured. This procedure is intended to hold the teeth in similar alignment as wires, yet with less application time and less damage to the gums."
75400751|NCT05391048|Drug|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
75400752|NCT05387538|Procedure|One-layer Duct-to-mucosa Pancreaticojejunostomy|To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used
75400753|NCT05387538|Procedure|Two-layer Duct-to-mucosa Pancreaticojejunostomy|The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
75549471|NCT00330252|Drug|Alemtuzumab|Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
76037915|NCT04985149|Other|Electromyographic measurement:|"Nerve conduction studies; assesses nerve function and includes motor, sensory, and mixed nerve tests.~Micromed (Italy 2020) EMG device will be used in the electrophysiological examination. Sensory and motor conduction studies will be performed in the lower and upper extremities by paying attention to the extremity temperatures of the cases.~Nerve conduction studies will be performed by another physician who is unaware of the diagnosis of the patients. Bilateral lower extremity sural sensory responses of the patients will be taken.~In the antidromic method in sural nerve conduction examination, the bipolar superficial electrode is placed behind the lateral malleolus; stimulation will be made with bipolar surface electrodes 12-15 cm proximal to the recording site. Initial latency should be < 3.8 ms, amplitude > 10 Mv, and conduction velocity > 36 m/sec in sensory response of the sural nerve."
75549472|NCT00333645|Drug|Caspofungin|
75549473|NCT04698473|Other|NCPAP|NCPAP infants will be randomized into two different non invasive ventilation groups
75549474|NCT04698473|Other|NIPPV|NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
75871338|NCT02347696|Behavioral|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~weeks 1-4: 14.2 kcal*kg-1*week-1;~weeks 5-8: 18.9 kcal*kg-1*week-1;~weeks 9-12: 23.6 kcal*kg-1*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~Progression: increase of 1-2.5 kg*week-1~Training of all muscle groups in the same session"
75871339|NCT02347696|Behavioral|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
75549475|NCT00330291|Drug|Xyrem|
75549476|NCT04698707|Other|Vascularized lymph node flap transfer|Patients who have received VLNT as their primary treatment but with minimal improvement
75549477|NCT04698707|Other|Patients without prior lymphedema surgery|Patients without prior lymphedema surgery
75400754|NCT05017584|Drug|Hyperbaric bupivacaine|"The dose for the first subject (A#X) will be 12 mg 0.75% hyperbaric bupivacaine. Two possible outcomes will be recorded: satisfactory or unsatisfactory anesthesia which is determined by occurrence of intraoperative pain and the need for intraoperative analgesia supplementation. Satisfactory analgesia will be defined as a sensory block to the T8 dermatome and the patient shall require no further supplementation for discomfort during her procedure. Unsatisfactory analgesia will be defined as a block not achieving a T8 dermatomal level or when a patient requests additional medication for discomfort at any time during her procedure.~The dose for the next (A#X+1) will be adjusted based on the outcome from previous subjects respectively using up-down sequential allocation method with a biased-coin design. This process will continue in similar fashion with dose adjustments for next subjects to be based on outcome from subjects immediately prior."
75400755|NCT05010096|Drug|Copanlisib|Given IV
75400756|NCT05010096|Drug|Elimusertib|Given PO
75400757|NCT04403880|Other|Sample collection|"Optional nasal specimen(s)~Blood collection"
75710429|NCT01039363|Drug|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|"Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~Gemtuzumab will be omitted in a consolidation schedule.~Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT."
75710430|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
75710431|NCT01039441|Procedure|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
75400758|NCT04147416|Drug|HSK3486 0.1-0.2 /0.3 mg / kg group|Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
75400759|NCT04147416|Drug|Propofol 0.5-1.0/1.5 mg/kg group|Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
76037916|NCT04985149|Other|Ultrasonographic measurement:|Sural nerve ultrasonography (US) will be performed by another clinician (Merve Akdeniz leblebicier) who is experienced in musculoskeletal ultrasonography and unaware of clinical evaluation, using a 6-18 Mhz linear probe. (Mindray -UMT 200, United States) Both sural nerve joints of the patients will be evaluated. The patient will lie on the stretcher in the prone position, the ankle will be out of the bed. The 14 cm above the malleolus will be marked as the main line, the nerve will be detected in the lateral of the tendon of the gastrocnemius muscle and the proximal of the saphenous vein. Nerve diameter measurement will be measured 3 times in mm2 and the average will be taken. Then, possible inflammatory pathologies will be ruled out by providing clinical confirmation using the Doppler mode (11).
76037917|NCT05001997|Dietary Supplement|Lactose free probiotic yogurt|Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.
75710432|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
75400760|NCT04129866|Behavioral|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
75710433|NCT01039441|Other|normal saline|
75710434|NCT01034917|Drug|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
75710435|NCT01034917|Drug|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
75710436|NCT01039597|Drug|ORE1001|Oral capsules containing 300 mg of the active, study drug
75710437|NCT01039597|Drug|Placebo|placebo capsules
76037918|NCT01657461|Drug|Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
75710438|NCT01041937|Procedure|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
75710439|NCT01041937|Procedure|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
76037919|NCT01657461|Device|Solitaire revascularization device|Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
75549478|NCT00451100|Drug|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
75710440|NCT00816699|Other|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
75710441|NCT00822549|Drug|intravenous morphine titration|intravenous morphine titration
75710442|NCT00822627|Drug|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
75710443|NCT00822627|Behavioral|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
75710444|NCT00819351|Drug|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
76037920|NCT05001919|Procedure|GTR|intrabony defects treated by surgery and bone graft +collagen membrane
75710445|NCT00819351|Drug|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
75871340|NCT02347696|Behavioral|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
75871341|NCT04879914|Dietary Supplement|Butyrate|3 cps/die 300 mg/cps
76037921|NCT05001919|Procedure|concentrated growth factor|intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
75549479|NCT00451100|Drug|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
75549480|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 100 and 150
75549481|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
75549482|NCT00420537|Drug|Mycophenolate mofetil|mycophenolate with low doses
75549483|NCT00420537|Drug|Everolimus|
75549484|NCT00451139|Drug|artemether/lumefantrine|
75549485|NCT00451139|Drug|quinine|
75871342|NCT04879914|Dietary Supplement|Placebo|3 cps/die 300 mg/cps
75871343|NCT02353234|Other|Bread|In each arm subjects consume bread
76037922|NCT05001763|Drug|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
76037923|NCT05001763|Drug|Placebo|Glucose, 2mg, tablet.
75400761|NCT04129866|Behavioral|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
75400762|NCT03984318|Procedure|Blood sample|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
75400763|NCT03899532|Device|Remote Ischemic Conditioning|Standard manual blood pressure cuff
75400764|NCT03899532|Other|No-Remote Ischemic Conditioning|No-Remote Ischemic Conditioning
75400765|NCT03786042|Behavioral|E-cigarette ad exposure|Participants view a series of e-cigarette TV commercials
75400766|NCT03786042|Other|non e-cigarette TV commercials|Participants view a series of non e-cigarette TV commercials
75400767|NCT03767010|Other|Control (no PLM)|Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
75400768|NCT03767010|Other|PLM|PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
75400769|NCT03660072|Other|Non-Interventional|Non-Interventional
75400770|NCT03554850|Device|Trevo® Retriever|Stent retriever procedure
76037924|NCT04989985|Drug|Oxaliplatin+S-1|"Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40~60mg Bid，d1~14, q3w"
76037925|NCT04989985|Drug|Sinitilimab+oxaliplatin+S-1|"Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40~60mg Bid，d1~14, q3w"
75400771|NCT03178890|Device|OHMG|Device will be implanted in all enrolled patients.
75400772|NCT03125148|Device|Enteral stenting|Enteral stent for malignant duodenal obstruction
75400773|NCT03029364|Behavioral|Study Protocol|"Participants will complete three study protocols 7 - 28 days apart which includes:~3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention."
75400774|NCT02406222|Drug|Pomalidomide|Chemotherapy
75400775|NCT02406222|Drug|Dexamethasone|Chemotherapy
75549486|NCT00451139|Drug|atovaquone/proguanil|
75400776|NCT02406222|Drug|Cyclophosphamide|Chemotherapy
75871344|NCT01569360|Device|Corset|the patients are assigned the use of a custome made corset during daytime
75871345|NCT03510455|Drug|BGJ398|BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
75549487|NCT00333684|Device|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
75400777|NCT02247726|Drug|Saline Placebo (0.5mL injection)|
75400778|NCT02247726|Drug|RSV F vaccine (0.5mL injection)|
75400779|NCT00475488|Procedure|Coronary artery bypass grafting|Surgery performed due to coronary artery disease.
75400780|NCT00458796|Drug|zoledronic acid|
75400781|NCT00458796|Procedure|quality-of-life assessment|
75400782|NCT01021956|Drug|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
75400783|NCT01022190|Drug|Etoricoxib (Arcoxia)|Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
75400784|NCT01024296|Device|Port Close|Device for applying loop suture to close surgical site
75400785|NCT01024686|Biological|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
75400786|NCT01024686|Biological|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
75400787|NCT01024686|Biological|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
75549488|NCT00451256|Drug|AVI-5126|
75549489|NCT00330330|Drug|ISIS 113715|
75549490|NCT00330408|Behavioral|GP training|
75549491|NCT00451295|Drug|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
75400788|NCT01025076|Device|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
75400789|NCT01026402|Drug|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
75400790|NCT01027806|Drug|Montelukast|1 pill per day for 4 months
75400791|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push."
75400792|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg."
75400793|NCT01029912|Device|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
75400794|NCT01032330|Device|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
75400795|NCT01032954|Drug|Botulinum toxin|"Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~Crow's feet wrinkles - 70 units~Glabella - 50 units~Forehead - 40 units~Mid face:~Lower eyelid - 5 units~Nasal wrinkles - 20 units~Malar wrinkles - 10 units~Lower face:~Peri-oral wrinkles - 15 units~Asymmetric smile or gummy smile - 5 units~Cellulitic chin - 20 units~Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs."
75400796|NCT01033422|Drug|CF101|CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
75400797|NCT01033422|Drug|Placebo for|Matching placebo tablets orally every 12 hours for 16 weeks
75549492|NCT00451295|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
75549493|NCT00330486|Drug|Acamprosate|
75549494|NCT00451373|Device|CVVH and SLED|
75549495|NCT00451373|Drug|Vancomycin|
75549496|NCT00451373|Drug|Daptomycin|
75871346|NCT02353156|Other|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
75871347|NCT02353156|Other|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
75549497|NCT00451373|Device|FX60, AV600 (dialyzer)|
75871348|NCT03630432|Behavioral|Pulmonary rehabilitation|"The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes."
75549498|NCT00333723|Drug|Rosiglitazone|
75871349|NCT03630432|Other|Usual Care|Usual Care
75549499|NCT00451412|Drug|Certoparin|3000 U anti XA of certoparin in 0.3 ml solution, once daily
75871350|NCT02353000|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
75871351|NCT02353000|Radiation|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
76037926|NCT05242653|Procedure|pressure by a cotton swab|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.
75871352|NCT02351596|Other|Physiotherapy Core Stability Group Programme|"The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this."
75871353|NCT02351596|Other|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
75400798|NCT05593848|Procedure|Intratissue Percutaneous Electrolysis|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided Intratissue Percutaneous Electrolysis in the myofascial trigger points of the infraspinatus muscle
75400799|NCT05593848|Procedure|Dry Needling|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided dry needling in the myofascial trigger points of the infraspinatus muscle
75400800|NCT05593380|Device|Non-invasive intracranial pressure monitoring|Treatment based on readings from Bioelectrical impedance analysis monitor（intracranial pressure and perturbation index (PI)）.
75400801|NCT05593380|Other|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
75400802|NCT05593380|Other|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
75400803|NCT05593224|Device|Intracranial Stent (Tonbridge)|The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
75400804|NCT05593068|Procedure|MRI|Pancreatic MRI
75400805|NCT05592834|Behavioral|positive deviance hearth strategy|"The PD-program is run for 3-months with 2 weeks (12 days) of nutrition education and rehabilitation sessions (NERS) conducted in each month. Each day session includes an half hour education session and a one and half hour peer led cooking session. Caretakers learn how to rehabilitate their malnourished children under the supervision and the support of caregivers who have well-nourished children (positive deviants). Children are nutritionally assessed by trained nutrition assistants or clinician on the 1st day of the NERS sessions and after three months.~During the rehabilitation sessions, caregivers learn how to prepare nutrient-rich meals for their children from locally available food identified during the positive deviance-inquiry, and actively practice good feeding and hygiene practices. Caregivers together prepare food menus based on the PD-inquiry good foods or what they can conveniently access but of equal nutritional value."
75400806|NCT05592834|Behavioral|Parent facilitator trainings|Primary caregivers of children with CP residing in the study setting are trained as parent facilitators by expert physical rehabilitation therapist . Trained parent facilitators then hold fellow caregiver workshops each lasting approximately two hours long and includes between 6-10 caregivers. To ensure quality and consistency of the workshops, the Parent Facilitators follow a detailed manual adapted from the Carer-2-Carer Programme translated into Lusoga, the local language. No expert therapists is involved in the parent facilitator training workshops. Parent facilitator training workshops involve 7 sessions that expose caregivers to understanding CP and how to improve body functioning: session1: what is CP? session2: CP as a way of life, Session 3: Getting my child's body ready to move, Session 4: Eating and drinking a healthy diet, Session 5: communication, Session 6: Play, and Session 7: Central visual impairment.
75549500|NCT00451412|Drug|Unfractionated Heparin|solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
76037927|NCT05242653|Procedure|stromal hydration with the balanced salt solution（BSS）|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
75400807|NCT05592834|Other|Control|This group will receive neither the PD nor the PFT interventions but care as usual
75400808|NCT05525988|Procedure|Hemi-Hamate Transfer for Proximal Pole Scaphoid Reconstruction|"Surgical Technique:~The participants will be positioned in the supine decubitus on the surgical table with the operated upper limb put on a C-arm (Mobile fluoroscopy device) compatible surgical arm-board. After anesthesia, a pneumatic tourniquet will be placed with a cuff pressure raised to 250 mmHg, then the limb is draped in the regular sterile fashion. Through a dorsal approach to the wrist joint, the proximal pole of scaphoid bone will be assessed before resectioning for confirmation that it cannot be preserved. The hamate bone will be exposed through capsulotomy and the measurements of the resected scaphoid will be transferred. The harvested H-H autograft will be placed and fixed to the distal scaphoid segment. Wound closure is then performed in layers in the usual fashion, and the wound will be covered by a sterile gauze, then a short-arm thumb spica splint will be put on."
75400809|NCT05517564|Drug|GM-60106|The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
75400810|NCT05517564|Other|Placebo|Placebo-to-match GM-60106 capsules
75400811|NCT05489328|Other|Candidate-1|Biological
75400812|NCT05489328|Other|Candidate-2|Biological
75400813|NCT05489328|Other|Candidate-3|Biological
75400814|NCT05489328|Other|Candidate-4|Biological
75400815|NCT05489328|Other|Candidate-5|Biological
75549501|NCT04717245|Drug|Promestriene Vaginal|Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
75549502|NCT04717245|Other|Fractional CO2 LASER|"LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.~Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1"
75549503|NCT04717245|Other|Microablative Fractional radiofrequency|"Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.~The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.~All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third."
75549504|NCT00451490|Drug|Agomelatine|
76037928|NCT05239845|Dietary Supplement|Prebiotic|The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
76037929|NCT05239845|Other|Control|Maltodextrin
76037930|NCT05001841|Procedure|Lung Transplantation|Double lung transplant
76037931|NCT05239221|Drug|AZP-3601|Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
76037932|NCT05239221|Drug|Placebo|Saline solution visually matching active medication
75400816|NCT05489328|Other|Candidate-6|Biological
75549505|NCT00451490|Drug|Fluoxentine|
76037933|NCT05001607|Device|Bronchial Blocker|Trial of four methods of pulmonary blockade; one novel method and three published methods.
75400817|NCT05489328|Other|Candidate Control|Biological
75549506|NCT00330525|Drug|sibutramine|
76037934|NCT05321355|Device|Implantation of vagus nerve stimulation according to clinical indication|no interventions, only observation
75400818|NCT05489328|Biological|13vPnC|13-valent pneumococcal conjugate vaccine
75400819|NCT05489328|Biological|PCV15|15-valent pneumococcal conjugate vaccine
76037935|NCT04989673|Other|Biological sampling and collection (serum)|Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups
75400820|NCT05479344|Behavioral|A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
75400821|NCT05412498|Behavioral|BR-30|Battle rope training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
75400822|NCT05412498|Behavioral|BR-45|Battle rope training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
75549507|NCT03275441|Diagnostic Test|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
75549508|NCT00333918|Drug|bromfenac ophthalmic solution|
75549509|NCT00333918|Drug|placebo comparator|
75549510|NCT04716738|Diagnostic Test|Blood analyses and coprological|We will take a blood and stool sample
75549511|NCT00451568|Drug|Metformin|500 mg 2 tablets 2 times a day
76037936|NCT04989673|Other|Biological sampling and collection (placenta)|Detection of dengue virus in the placenta of GE patients (additional tube of placenta)
76037937|NCT04989673|Other|Questionnaire|Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).
75400823|NCT05402826|Dietary Supplement|Oral zinc + vitamin E|In the zinc + vitamin E supplementation group, patients will receive a cumulative dose of 120 mg of oral zinc supplementation plus a cumulative dose of 1200 IU of oral vitamin E before surgery. After surgery, from the second day to the end of the hospital stay, patients receive 30 mg of zinc supplement plus 200 units of vitamin E per day.
75400824|NCT05402826|Dietary Supplement|Placebo|Patients in the placebo group will receive placebo pills before and after surgery.
75400825|NCT05376930|Drug|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
75400826|NCT05246202|Behavioral|Alcohol-Anxiety Personalized Feedback Intervention 2.0|AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.
75400827|NCT05246202|Behavioral|Control Personalized Feedback Intervention|C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
75400828|NCT05244798|Drug|Sintilimab|Sintilimab: D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W)
76037938|NCT04989673|Other|Data collection|Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).
76037939|NCT02592551|Drug|MEDI4736|MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
76037940|NCT02592551|Drug|Tremelimumab|Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume [w/v]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.
75549512|NCT00451568|Drug|Desorelle|1 tablet/day in 21 days
75400829|NCT05244798|Radiation|radiotherapy|Radiotherapy: According to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week.
76037941|NCT02592551|Other|no other name|Neither MEDI4736 nor Tremelimumab will be used.
76037942|NCT04989127|Diagnostic Test|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
75400830|NCT05244798|Drug|Chemotherapy|Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
75400831|NCT05193708|Device|Windowed Bonding|A 3D printed tray/guide with open window for the orthodontic brackets
75400832|NCT05193708|Device|Digital Indirect bonding tray|Vacuum formed on a 3d printer cast with brackets
75400833|NCT05179668|Drug|Dapagliflozin 10 MG|administered orally once daily
75400834|NCT05179668|Drug|Placebo|administered orally once daily
75400835|NCT05088564|Procedure|Hand-sewn|Doudenojejunal anastomosis by hand-sewn method
75400836|NCT05088564|Procedure|Hemi-double stapling|"Doudenojejunal anastomosis by hemi-double-stapling method EEA25 - Covidien EEA Circular Stapler DST Series 25.0mm x 4.8mm is used for anastomosis"
75400837|NCT05048628|Other|Comparıson|"Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated."
75400838|NCT04910724|Other|Energy Deficit|A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
75400839|NCT04799418|Device|Open Label Extension Study|This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
75400840|NCT04627038|Drug|LY3556050|LY3556050 Given orally
76037943|NCT04989127|Procedure|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
75400841|NCT04627038|Drug|Placebo|Placebo Given orally
75400842|NCT04460430|Drug|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
75400843|NCT04316910|Drug|General anesthetic|General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
75400844|NCT04241796|Device|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
75400845|NCT04104594|Diagnostic Test|Sniffin Stick Test|"The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic."
75400846|NCT04104594|Other|numerical evaluation scale for olfaction|numerical rating scale from 0 (no smell) to 10 (perfect smell)
75400847|NCT04104594|Other|numerical evaluation scale for nasal obstruction|numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
75400848|NCT04104594|Other|nasal outcome test|"list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days"
75400849|NCT04104594|Biological|dosage of 17 cytokines|dosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α
75549513|NCT04716465|Other|Dysautonomia|Indicators of dysautonomia
75549514|NCT00330603|Procedure|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
75549515|NCT00451646|Drug|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
75710446|NCT00636675|Behavioral|Falls QI|"Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~In-House Falls Coordinator training on content and falls processes.~Case-based modules about fall prevention and tailored for various team members.~Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~Toolbox: Handbook of useful measures and worksheets."
75871354|NCT03630510|Other|Ventilator hyperinflation|The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
75871355|NCT03509675|Drug|Ibuprofen suspension 5mg/100ml|Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
76037944|NCT04989127|Biological|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
76037945|NCT04989127|Drug|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
76037946|NCT04989127|Drug|Analgesic|Analgesics are prescribed for the patients.
75871356|NCT03509675|Drug|Placebos|Placebo
76037947|NCT04989127|Drug|Antibiotic|Patients with penicillin allergy
76037948|NCT05320653|Dietary Supplement|Medical nutrition|Nutrition therapy of the critically ill patients
75871357|NCT01376934|Procedure|procedure hysteroscopy|office hysteroscopy with gas or saline solution
76037949|NCT04984213|Device|Karma Posterior Fixation Device|Posterior Fixation
76037950|NCT03070873|Device|Perigee and Apogee Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
76037951|NCT03070873|Device|Gynecare Prolift Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
76037952|NCT03070873|Procedure|Traditional Surgery|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
76037953|NCT05320185|Device|RuiXin-CoronaryAI software|RuiXin-CoronaryAI, based on Computed Tomography Angiography (CTA) and was independently designed by RaysightMed Inc., which has been already authorized by National Medical Products Administration (NMPA).
76037954|NCT05238753|Device|Non-invasive electromagnetic stimulation|Non-invasive bilateral electromagnetic stimulation of the phrenic nerve
75549516|NCT00451724|Drug|Intranasal ketamine|
75549517|NCT00451763|Drug|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
76037955|NCT04984135|Procedure|Percutaneous coronary intervention|All patients were treated with a loading dose of clopidogrel 300 or 600 mg before the procedure followed by maintenance clopidogrel 75 mg daily for 6 months. 100 U/ kg of unfractionated heparin was injected intravenously to maintain an activated clotting time ≥ 250 s during the procedure. For DCB treatment, the patient underwent predilation with an optimal-sized balloon (non-compliant balloon or cutting balloon) based on angiography (balloon-to-vessel ratio of 1.0), with the standard balloon shorter than the intended DCB size. The DCB was sized at 1:1 balloon-to-vessel ratio, delivered rapidly (median of 15 s) and inflated at nominal pressure for 60 s.
75400850|NCT03952416|Behavioral|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
75710447|NCT00636675|Behavioral|Connect|"Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~In-class learning sessions introduce interaction strategies.~Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role."
75400851|NCT03446664|Device|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
75400852|NCT03149562|Drug|plasma transfusions|These critical ill neonates with plasma transfusions
75871358|NCT02351752|Drug|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR>60)
76037956|NCT04797377|Biological|Autologous ovarian PRP injection|The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
75871359|NCT02353078|Drug|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
75400853|NCT03149562|Drug|non-plasma transfusions|These critical ill neonates without plasma transfusions
75400854|NCT01842672|Drug|Clofarabine|Dose Escalation of Clofarabine
75400855|NCT01842672|Drug|Mitoxantrone|
75400856|NCT01531374|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
75400857|NCT01240902|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
75400858|NCT01240902|Device|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
75400859|NCT01034592|Drug|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
75400860|NCT01037790|Drug|PD-0332991|Given orally, 125 mg QD on a 21-day
75549518|NCT04716348|Procedure|muscle energy technique|muscle energy technique for suboccipital muscles
75549519|NCT00330720|Device|Emergency Response System (Device)|
75400861|NCT01038336|Behavioral|Multimedia Hearing Loss Prevention Program|Interactive, multimedia, computer-based HLPP that provides hands-on education and training about hearing loss, tinnitus, hearing protection, and general hearing health care for Veterans.
75400862|NCT01038336|Behavioral|Hearing Conservation Brochure|Hearing Conservation brochure provides knowledge-based information similar to that of the multimedia HLPP, but in written form.
75400863|NCT01040052|Biological|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
75400864|NCT01040208|Drug|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
75400865|NCT01040208|Drug|flibanserin 100 mg qhs|100mg qhs
75400866|NCT01040208|Drug|placebo 2 tablets qhs|50 mg placebo
76037957|NCT04989205|Behavioral|Cannabis cessation Program|Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising ~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
75400867|NCT01043094|Drug|Pitavastatin 4mg|Pitavastatin 4mg single dose
75400868|NCT01043562|Diagnostic Test|Defibrillator threshold testing|Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.
76037958|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
75549520|NCT00451841|Device|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
75710448|NCT00699998|Drug|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
75400869|NCT01043562|Other|Observation of post-shock intrinsic cardiac rhythm|Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole >4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a >10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
75710449|NCT00699998|Drug|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
75400870|NCT01043640|Drug|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
75400871|NCT01043640|Drug|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
75549521|NCT00330798|Drug|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
76037959|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
76037960|NCT04982809|Drug|Betamethasone, Dexamethasone, Prednisolone|Corticosteroids
75549522|NCT00330798|Other|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
75549523|NCT00451880|Drug|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
75549524|NCT00451880|Drug|famotidine|single dose, supplied as 20-mg or 40-mg tablets
75549525|NCT00451997|Drug|Gleevec|600 mg (capsules) by mouth once daily
75549526|NCT00451997|Drug|Ara-C|10 mg as an injection under the skin daily for 21 days of every 28 day cycle
75549527|NCT00330993|Drug|mifepristone, misoprostol|
75710450|NCT00699998|Drug|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
76037961|NCT04797533|Device|The Body Information Management Systems (BIMS)|"The Body Information Management Systems (BIMS) are advanced biological sensors which monitor human behaviour, activity and basic vital signs. There is a combination of four separate ultra-sensitive weighing scales attached to each of the individual legs of a hospital bed measuring:~Micro-changes in weight distribution~Activity/sleep pattern~In addition to the bed-based system, there will be a wrist worn wearable (Samsung fit gear) that will monitor participants when they are both in and out of bed. These are about the size of a small watch, light weight, water resistant, and will be worn 24/7 by participants. These measure:~Movement and sleep~Heart rate"
76037962|NCT04808765|Procedure|Immediate Breast reconstruction|immediate mastectomy with breast reconstruction with implants or expanders
76037963|NCT05518071|Drug|CRGD-ZW800-1|Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide
75400872|NCT01043640|Drug|Busulfan|Administered every 6 hours: If < or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If > 12 kg then 0.8 mg/kg/dose IV
75400873|NCT01043640|Procedure|Allogeneic stem cell transplantation|Administered > 24 hours after last dose of busulfan.
75549528|NCT00331032|Drug|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
75549529|NCT00331032|Drug|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
75549530|NCT00452075|Drug|erlotinib|150mg daily
75549531|NCT00331071|Drug|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
75549532|NCT00331071|Drug|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
75549533|NCT00452153|Procedure|Characterization Legionnella|"Characterisation Legionnella by polymerase chain reaction (PCR)~Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region"
75549534|NCT00331110|Device|Laterally-Wedged Insole with Ankle Strapping|
75549535|NCT00331110|Device|Laterally-Weged Insole|
75549536|NCT02956889|Drug|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
75549537|NCT02956889|Radiation|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
75549538|NCT00333996|Drug|Dexamethasone|
75549539|NCT00452192|Drug|Telmisartan|telmisartan 80 mg daily over 2 weeks
75549540|NCT00334035|Drug|Quetiapine|
75710451|NCT00696072|Drug|Dasatinib|Tablets, Oral, 100 mg once daily, up to 2 years
75710452|NCT00696072|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
75400874|NCT01043640|Drug|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~If body weight is ≤ 40 kg dosing will be 3 times daily~If body weight is > 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
75400875|NCT01043640|Drug|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC>500 x 10^6 neutrophils/L x 3 days and chimerism >90%), whichever is later.
75400876|NCT01044030|Drug|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
75400877|NCT01044030|Drug|Placebo|7.5 mL by mouth three times daily
75400878|NCT01044966|Drug|ITV DepoCyt + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
75400879|NCT01045122|Drug|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
75400880|NCT01045122|Drug|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
75549541|NCT03275363|Diagnostic Test|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black & white), verbal fluency, digit forward and backward span."
75400881|NCT01049802|Device|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
75400882|NCT01050582|Drug|Risperidone|As per local prescribing practices
75710453|NCT00816855|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
75400883|NCT01050582|Drug|Other atypical antipsychotic drugs|As per local prescribing practices
75549542|NCT03275363|Diagnostic Test|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
75400884|NCT01050660|Other|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
75710454|NCT00822705|Drug|Placebo tablet|Control arm
75710455|NCT00822783|Drug|Omalizumab|
75549543|NCT03275363|Biological|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
75549544|NCT03275363|Diagnostic Test|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
75549545|NCT03275363|Diagnostic Test|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
75710456|NCT00822783|Drug|Placebo|
75710457|NCT00816933|Procedure|appendectomy|appendectomy according to the number of trocar
75400885|NCT01050660|Other|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
75710458|NCT00634647|Drug|Satraplatin|80 mg/m^2 days 1-5 of every 35 day cycle
75400886|NCT01051440|Drug|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
75400887|NCT01051440|Drug|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
75400888|NCT01051518|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
75400889|NCT01051596|Drug|Temozolomide|150mg/m2 Days 1-5 of each 28 day cycle
75400890|NCT01051596|Drug|ABT-888|40mg orally BID Days 1-7 of each 28 day cycle
75400891|NCT01053000|Drug|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
75400892|NCT05822453|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle
75400893|NCT05822453|Drug|S1|S1 (60 mg/day if body surface area < 1.25 m2, 80 mg/day if body surface area = 1.25~1.50 m2) will be administered by PO on Day 1 ~ 14 of each 21-day cycle
75549546|NCT00334152|Drug|casopitant|
75710459|NCT00634647|Drug|prednisone|5 mg twice daily every 35 days
75710460|NCT00576732|Drug|Placebo|Oral solution qd or bid for 6 weeks
75710461|NCT00576732|Drug|Risperidone high dose|Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
75400894|NCT05822453|Drug|Tislelizumab|Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
75400895|NCT05822401|Behavioral|Blood flow restriction (BFR)|Blood flow restricted training integrated into the daily work tasks for 8 weeks.
75400896|NCT05822401|Behavioral|Usual care (control)|Will continue their work as usual
75400897|NCT01028820|Drug|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
75400898|NCT05822349|Behavioral|picograms-enriched label|The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
75549547|NCT03275324|Device|Capnostream20p|Observational study of patients connected to the Capnostream20p monitor.
75549548|NCT00334191|Drug|Sodium Bicarbonate|
75710462|NCT00576732|Drug|Risperidone low dose|Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
75871360|NCT02353078|Procedure|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
75549549|NCT00334191|Drug|Placebo|
75710463|NCT02550639|Other|BIOMARKER- elispot test|ELISPOT TEST
75710464|NCT00822861|Drug|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
75710465|NCT00822861|Drug|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
75710466|NCT00822861|Drug|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
75710467|NCT00822861|Drug|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
75400899|NCT05822336|Other|Duration of Intramuscular Injections|This study was a single-group crossover clinical trial, where each participant acted as their own control. Two intramuscular injections into the right and left Dorsal Gluteal Region (DRG) were recorded for each participant. One was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. A day after, the same nurse gave the other injection in the opposite DGR, taking 40 seconds to administer. The five-second injections were considered the control group, while the 40 seconds injections were the intervention group. The order of interventions was randomized. The pain level was determined and recorded immediately after each injection.
75400900|NCT05822323|Other|BTX-A|Vials of 100 U Allergan Botox® (Allergan, Inc., Irvine, California) were diluted with 2 ml of physiological saline and made ready for use. The midline was determined at the mentum region. 5 U of BTX-A was injected into the mental muscle approximately 1 cm away from the chin tip and the midline
75549550|NCT04698512|Device|AVFistuloplasty with Sirolimus coated balloon|After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
75400901|NCT05822323|Procedure|free gingival graft|The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.
75549551|NCT04698668|Device|fusion imaging|To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
75549552|NCT00334269|Behavioral|Health messaging at weekly home visits by health counsellor|
75871361|NCT02353078|Device|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
76037964|NCT05518071|Device|Intraoperative near-infrared fluorescence imaging|Intraoperative imaging will be performed with at least one of the following CE-marked near-infrared (NIR) fluorescence imaging systems: Quest Spectrum imaging platform (v2/3.0) for open-procedures, the Olympus or Karl-Storz system for the diagnostic laparoscopy or the Intuitive Surgical Da Vinci Xi (Firefly-mode) for minimally invasive robot-assisted procedures. With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure.
75549553|NCT00334269|Behavioral|Weekly home delivery of bottled spring water|
76037965|NCT03068533|Other|8% L-Arginine/calcium carbonate containing toothpaste|use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
76037966|NCT03068533|Other|use of strontium acetate toothpaste|use of strontium acetate toothpaste to relieve hypersensitivity
76037967|NCT04804865|Other|prognostic assessment|determination of a prognostic score with 3 clinical and 5 biological parameters.
75549554|NCT00334269|Behavioral|Weekly afterschool physical activity program for 5-18y.o.|
76037968|NCT05281341|Drug|Growth Hormone|In GH groups (Group 4A & 3A), patients will receive additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection), daily beginning on the initial day of gonadotropin stimulation until triggering the oocyte maturation by hCG. Control groups (Group 4B & 3B) will receive only standard COS without GH supplementation
76037969|NCT03068377|Dietary Supplement|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
75549555|NCT00334269|Behavioral|Cooking classes and grocery store tours with dietician|
75549556|NCT00334269|Behavioral|Pedometers to track/increase weekly physical activity|
75549557|NCT04698551|Genetic|Non invasive prenatal diagnosis|Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
75549558|NCT00334308|Procedure|Barley protein bread or control (casein) bread|
75549559|NCT00334347|Drug|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
75549560|NCT00334347|Drug|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
75549561|NCT00334386|Drug|Torasemide Prolonged Release (loop diuretic)|
75549562|NCT00334386|Drug|Torasemide Immediate Release (loop diuretic)|
75549563|NCT00452231|Drug|D-cycloserine|
75549564|NCT00452231|Behavioral|Cognitive-Behavioral Therapy|
75549565|NCT00334425|Drug|MENOPUR; GONAL-F|
75549566|NCT03275207|Drug|saline|an equal volume of saline
76037970|NCT03068377|Dietary Supplement|Placebo|soft gel capsules without test material
75549567|NCT03275207|Drug|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
75549568|NCT00334464|Drug|Standard of care or genotyping dosing of warfarin dosing|
75400902|NCT05822310|Procedure|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.
75400903|NCT05822310|Procedure|intraairticular steroid injection|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The femoral neck was detected under ultrasonography and the joint capsule was entered with a 22G 9 cm spinal needle. Then, 5 cc bupivacaine and 5 mg betamethasone were given and the procedure was terminated.
75400904|NCT05822310|Procedure|pericapsular nerve group (PENG) block|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The high-frequency linear ultrasonography probe was placed on the anterior superior iliacspina (ASIS). Later, the anterior inferior iliac spine (AIIS) was detected by descending caudally. Afterwards, the probe was brought to the oblique position and AIIS, iliopubikeminence, psoas muscle and tendon were seen. Using a 22G 90-mm Quinckespinal needle, the tendon of the iliopsoas muscle was entered in the lateral-medial direction in the in-plane plane and bone contact was achieved. After negative aspiration, 15 ml of 0.5% bupivacaine were administered by seeing the appropriate drug distribution.
75400905|NCT05822284|Diagnostic Test|NGS and ctDNA-MRD detection|NGS and ctDNA-MRD detection
75400906|NCT05822271|Procedure|Orthognathic Surgery|Type of surgery performed to correct skeletal malocclusions
75400907|NCT05822232|Device|FreeStyle Libre 2 CGM|FreeStyle Libre 2 CGM is FDA-approved and will be used according to FDA-approved labeling
75400908|NCT05822232|Device|FreeStyle Libre Pro blinded CGM|FreeStyle Libre Pro blinded CGM is FDA-approved and will be used according to FDA-approved labeling
75400909|NCT05822232|Device|FreeStyle Precision Neo blood glucose meter|FreeStyle Precision Neo blood glucose meter is FDA-approved and will be used according to FDA-approved labeling
75400910|NCT05822206|Behavioral|CBT-TSC|Cognitive Behavioral Therapy for Trauma and Self-Care
75400911|NCT05822206|Behavioral|Life Steps and Sexual Decision-Making|
75710468|NCT05180370|Other|Questionnaies|Data entry staff who will be assigned to the centers for 2 weeks will apply a questionnaire consisting of different questions to the patients referred to them by clinicians with the diagnosis of HF (presented in the appendix to this protocol). In addition, Pittsburg Sleep Quality Index will be applied to all cases.
75710469|NCT00817011|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
76037971|NCT04809155|Behavioral|Girl2Girl|The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
75400912|NCT05822193|Other|Multiple exposures|Exposures variables (observational study): age, gender, education, comorbidities, vaccination status, severity of the acute episode of COVID-19, treatments used for acute COVID-19.
75400913|NCT05822180|Drug|NANOS1 , argent colloïdal ,|orally, during 5 day
75400914|NCT05822167|Other|High Protein Meal at Cold Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Cold meal will be served at 25 degree C and below."
75400915|NCT05822167|Other|High Protein Meal at Warm Temperarute|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
75400916|NCT05822167|Other|High Protein Meal at Hot Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at hot temperature i.e., 60 degree C and above."
75400917|NCT05822167|Other|High Carbohydrate Meal at Cold Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Cold meal will be served at 25 degree C and below."
75400918|NCT05822167|Other|High Carbohydrate Meal at Warm Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
75710470|NCT00817011|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
75710471|NCT04061460|Procedure|mechanical plaque control|supra and sub gingival debridment ( plaque control)
75710472|NCT00823017|Other|Patient-preferred music|Music of patients' preference
75710473|NCT00823017|Other|Relaxation Music|Relaxation music compiled from results of first three stages of study
75710474|NCT00823017|Other|Standard Care Environment|Control, no interventions
75710475|NCT00823173|Biological|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
75710476|NCT00819429|Dietary Supplement|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
76037972|NCT04988659|Other|Exposures|Exposures
75400919|NCT05822167|Other|High Carbohydrate Meal at Hot Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at hot temperature i.e., 60 degree C and above."
75400920|NCT05822167|Other|High Fat Meal at Cold Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Cold meal will be served at 25 degree C and below.
75710477|NCT00819429|Behavioral|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
75710478|NCT00819429|Other|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
75400921|NCT05822167|Other|High Fat Meal at Warm Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
76037973|NCT05280249|Other|both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air.
76037974|NCT05635981|Other|Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions|A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
76037975|NCT04797689|Behavioral|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
75400922|NCT05822167|Other|High Fat Meal at Hot Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at hot temperature i.e., 60 degree C and above.
75400923|NCT05822037|Biological|CT0594CP|Cell injection
75400924|NCT05822024|Behavioral|Promoting Pupils' Physical Literacy Intervention|The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
75400925|NCT05821946|Other|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|Before discharge, individuals will be given a user name and password to enter the website by the researcher. The first access to the website will be made via the researcher's computer, and the website will be introduced. Individuals will be shown how to access the compatible website on Android and IOS phones and tablets by the researcher. Web-based multi-source training for individuals to prevent urinary tract infections will begin. The researcher will check the use of educational materials by individuals from the administrator's menu. To increase the effectiveness of the training, reminder, motivating, and supportive messages will be sent to the patients twice a week.
75549569|NCT03275012|Drug|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and >15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
75549570|NCT03275012|Drug|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
75549571|NCT00334503|Drug|Miglitol|
75549572|NCT04698395|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy for children with cerebral palsy
75549573|NCT04698395|Behavioral|Regular care|customary or usual care given to any infant/toddler with cerebral palsy
75549574|NCT00334581|Drug|Irbesartan|Administration throughout the study period
75710479|NCT00697788|Drug|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
76037976|NCT04797689|Behavioral|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
75549575|NCT00334581|Drug|Irbesartan|Administration throughout the study period
75549576|NCT00452270|Drug|Xylometazoline|
75549577|NCT00334620|Procedure|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
75400926|NCT05821920|Device|MUST MINI system|cervical posterior fixation system
75400927|NCT05821894|Other|Observational study|
75400928|NCT05821881|Other|Discontinuation of levothyroxine treatment|Step-wise reduction of levothyroxine treatment guided by thyroid function and symptoms
75400929|NCT05821803|Other|Using Insoles|FootBalance %100 Control Orthopedic insoles used for 4 weeks.
75400930|NCT05821803|Other|Foot Core Exercises|4 weeks including
75400931|NCT05821790|Other|Surgical waste and Data collect|Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection. Data necessary for the study will be collected from the patient's medical records, MRI examinations, and data specific to the characteristics of the surgical waste.
75400932|NCT05821751|Dietary Supplement|inulin|"Inulin will be given to enrolled patients according to manufacturer label indications.~ICIs (i.e. nivolumab and pembrolizumab) alone or in combination with chemotherapy, if clinically indicated, and their administration scheduling will be planned as per international and local guidelines."
75400933|NCT05821751|Drug|Pembrolizumab|Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
75710480|NCT02568878|Drug|Creatine monohydrate|
75710481|NCT00817167|Device|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
75710482|NCT00817167|Device|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
75710483|NCT00400153|Drug|Atrovent Respimat (20 mcg)|
75710484|NCT00400153|Drug|COMBIVENT MDI (36/206 mcg)|
75710485|NCT00400153|Drug|Combivent Respimat (20 mcg/100 mcg)|
75400934|NCT05821751|Drug|Nivolumab|Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
75400935|NCT05821712|Drug|0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash|mouthwash
75400936|NCT05821712|Drug|0.057% sodium fluoride Mouthwash|mouthwash
75400937|NCT05821673|Procedure|Argon plasma pre-treated abutment insertion|abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
75400938|NCT05821673|Procedure|abutment insertion|the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
75400939|NCT05821647|Other|HPI guided treatment advice|Administer hemodynamic altering intervention aimed at either a preload, contractility, or afterload problem to prevent impending hypotension. Treatment options include: administering either fluids, inotropes, vasopressors, positional changes, or a combination.
75400940|NCT05821621|Other|no intervention|observational study : there is no intervention
75400941|NCT05821452|Drug|Camrelizumab|200mgQ3w
75400942|NCT05821452|Drug|Paclitaxel|175mg/m2，D1，Q3w
75400943|NCT05821452|Drug|Cisplatin|75mg/m2，D1，Q3w
75400944|NCT05821452|Radiation|Radiotherapy|41.4Gy, 1.8Gy each time, 5 times a week
75400945|NCT05821400|Other|observational study|observational study
75400946|NCT05821361|Drug|HAIC+Cadonilimab+Bevacizumab|Cadonilimab: 10mg/kg, iv,q3w Bevacizumab: 7.5mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
75400947|NCT05821348|Diagnostic Test|salivary markers|a description of the salivary biochemical profile of GER infants vs. GERD, so that we can develop non-invasive diagnostic strategies and detect personalized therapeutic treatments.
75400948|NCT05821270|Other|Ashtanga Vinyasa Yoga Supta|Ashtanga (asta - eight, anga - parts); Vinyasa (freely sequenced practice); Yoga (practice for evolution); Supta (closed eyes)
75400949|NCT05821257|Other|Evaluation of the arm swing during gait|Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.
75400950|NCT05821257|Other|Functional Tests|To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
75400951|NCT05821192|Drug|Rituximab|375mg/m2 by IV infusion once every 3 weeks
75400952|NCT05821192|Drug|Gemcitabine|1 g/m2 on Days 1 by IV infusion once every 3 weeks
75549578|NCT00334659|Drug|apricitabine|
75400953|NCT05821192|Drug|Dexamethasone|40 mg on Days 1 to 4 of each 3-week cycle by IV infusion
75400954|NCT05821192|Drug|Cisplatin|75 mg/m2 on Days 1 by IV infusion once every 3 weeks
75400955|NCT05821192|Drug|PD-1 monoclonal antibody|200mg on Days 2 by IV infusion once every 3 weeks
76037977|NCT04988581|Other|Intensively integrated care of microvascular risk factors in the intervention group|The intensively integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment for diabetes and comorbidities in a primary care setting, will be delivered by trained primary care physicians, health managers and diabetes specialists. Diabetic microvascular risk factors (glycated hemoglobin [HbA1C], urinary albumin-to-creatinine ratio [ACR], blood pressure [BP], estimated glomerular filtration rate [eGFR], uric acid [UA] and low-density lipoprotein cholesterol [LDL]) will be tested every 3 month for the intervention group and clinical treatment decisions based on the test results will be implemented accordingly when necessary. The intensively integrated care intervention will last for 36 months. HbA1C, ACR, BP, eGFR, UA, LDL, other variables and co-morbidities will be measured at baseline and follow-up visits every 3 month.
76037978|NCT05516511|Diagnostic Test|Angiotensin Converting Enzyme test|blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
75400956|NCT05821166|Device|moderate Whole Body Hyperthermia (mWBH)|Patients receiving 3-4 times mWBH
75400957|NCT05821153|Drug|Aldesleukin|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
75549579|NCT00452465|Behavioral|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
75400958|NCT05821140|Procedure|dental treatment for global oral rehabilitation|dental treatment can include conservative, orthodontic, prosthetic or surgical procedures
75400959|NCT05821140|Other|oral health check up|regular preventive follow-up visit (every 6 months)
75400960|NCT05821114|Other|Head elevation_H|High flow_Head-elevation
75400961|NCT05821114|Other|Supine_H|High flow_Supine
75400962|NCT05821114|Other|Head elevation_L|Low flow_head elevation
75710486|NCT00400153|Drug|Placebo via corresponding inhaler for blinding purposes|
75710487|NCT04062890|Drug|Vigabatrin Pill|Oral Vigabatrin Pill
75710488|NCT04062890|Drug|Placebo oral tablet|Oral Placebo Pill
75710489|NCT02566512|Other|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
76037979|NCT04796987|Diagnostic Test|Convolutional Neural Network|Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
76037980|NCT05237895|Diagnostic Test|Serum Endocan Levels|Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes
76037981|NCT05453539|Drug|DSPE-DOTA-Gd Liposomal Injection|Single dose, intravenous infusion
76037982|NCT04796753|Other|Basketball Injury Defense|To establish a specific evaluation protocol for youth basketball players.
75400963|NCT05821114|Other|Supine_L|Low flow_supine
75400964|NCT05821062|Other|standard Aspirin (ASA) + clopidogrel (CLP) therapy|ASA100mg + CLP 75mg daily
75400965|NCT05821062|Other|standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy|ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily
75400966|NCT05821062|Other|standard ASA therapy|ASA 100 mg daily
75400967|NCT05821036|Behavioral|Activitiy Management|"Activity Management training will be applied for 5 weeks, 2 sessions per week, and the 1st and 10th sessions will be pre and post-training evaluation, a total of 10 individual, internet-based sessions.~Week 1:Awareness training and ergonomics training including spine anatomy, correct posture use, ergonomic strategies were planned to increase awareness about FMS. Week 2:Focusing on the challenging activities stated by the individuals, it is aimed to change the behavior by arranging the activity resting cycle in daily life. In addition, the management, adaptation and modification of the activities will be provided within the scope of time management training. Week 3: Joint and energy conservation principles training will be given and it is aimed to create body mechanics and proper posture suitable for activities.Week 4: Relaxation training will be provided as a method of coping with pain.Week 5: Re-evaluation/review of the targets set to reduce pain during activities will be provided."
75400968|NCT05821010|Combination Product|LFMT-capsules|Lyophilized fecal microbiota transplantation capsules
75400969|NCT05820984|Other|SPIRIT checklist plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)"
75549580|NCT00452504|Drug|SRA-444|
75549581|NCT00452582|Drug|Sildenafil (Viagra)|Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
75549582|NCT00452582|Other|Usual care|Physical therapy, occupational therapy, speech therapy
75549583|NCT00452621|Procedure|blood draw|
75549584|NCT00334698|Drug|Cetirizine|
75549585|NCT00334698|Drug|Pseudoephedrine|
75549586|NCT00334698|Drug|Cetirizine with Pseudoephedrine|
75549587|NCT00334776|Biological|MART-1 antigen|
75549588|NCT00334776|Biological|gp100:209-217(210M) peptide vaccine|
76037983|NCT05237271|Other|Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)|Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
75400970|NCT05820984|Other|Usual practice|Peer review as it is usual practice at the journal
76037984|NCT05237271|Other|Educational Materials on the CVD-T2D and Bundled Metabolic Panel|Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
75710490|NCT02566512|Other|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
76037985|NCT03068299|Other|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
76037986|NCT03068299|Other|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
76037987|NCT05280015|Dietary Supplement|microbiotherapy (GynMDD)|multi-target microbiotherapy add-on venlafaxine
76037988|NCT05280015|Other|placebo|placebo add-on venlafaxine
76037989|NCT03070795|Procedure|early feeding|start oral sips four hours after cesarean section
76037990|NCT03070795|Procedure|delayed feeding|start oral feeding on post operation day 1 (>12hours) after surgery
76037991|NCT04805099|Drug|Checkpoint inhibitor|Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease
76037992|NCT04808687|Drug|Nab paclitaxel and S-1|Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area < 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 < 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
76037993|NCT05635825|Other|Observational Survey|Collection of a 4-day food record
76037994|NCT04804397|Dietary Supplement|Sucrose|Sucrose sweetened soft drinks
75400971|NCT05820958|Other|Shantali massage|"The tactile contact of a mother with the newborn was intensified by means of Shantali massage applied at least 2 times a day, 10 min. Additional, spontaneous sessions were allowed as well. This started on the 3rd day after delivery and lasted until the end of the 12th week after delivery. A total of 169 mandatory sessions should have been provided plus spontaneous sessions, if any.~The order of application:~face and chest; 4 types of movements 10reps each;~upper extremity; 4 types of movements, 10 reps each (left and right separately);~abdomen; 2 types of movements, 10 reps each;~lower extremity; 3 types of movements, 10 reps each (left and right separately);~back; 2 types of movements, 10 reps each;~final integration; 3 types of movements, 10 reps each."
75400972|NCT05820945|Other|Pharmacist-led medication review|Clinical review by a primary care pharmacist of the primary care clinical history and the pharmacological treatment plan. After the review process, a meeting will be held between the pharmacist and the responsible physician in order to present proposals for pharmacotherapeutic optimization.
75549589|NCT00334776|Biological|therapeutic autologous dendritic cells|
75400973|NCT05820919|Behavioral|LOCK Sleep Program|The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).
75400974|NCT05820919|Other|No intervention (control period/baseline data collection)|Each NH serves as its own control. During the control period, baseline data will be collected.
75400975|NCT05820880|Drug|Fixed [Per/Ind/Aml]|Fixed Dose combination of Perindopril/Indapamide/Amlodipine
75400976|NCT05820880|Drug|Free [Per/Ind + Aml]|Free dose combination of Perindopril/Indapamide and Amlodipine
75549590|NCT00334776|Biological|tyrosinase peptide|
75549591|NCT00452660|Drug|Exjade|
75710491|NCT00823251|Device|IlluminOss device|The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
75710492|NCT00817245|Drug|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
75710493|NCT02566278|Other|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
76037995|NCT05279703|Drug|Epinephrine 0.03|epinephrine infusion rate of 0.03 mcg/kg/min
76037996|NCT05279703|Drug|Epinephrin 0.02|epinephrine infusion rate of 0.02 mcg/kg/min
76037997|NCT05279703|Drug|Epinephrin 0.01|epinephrine infusion rate of 0.01 mcg/kg/min
76037998|NCT05635747|Device|Relizorb Enzyme Cartridge|Tube feeds run across device to digest fats.
76037999|NCT04796519|Procedure|Total knee arthroplasty|Surgical procedure
76038000|NCT03070639|Behavioral|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
76038001|NCT03070639|Behavioral|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
75400977|NCT05820867|Procedure|Single-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
75400978|NCT05820867|Procedure|Two-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
75400979|NCT05820789|Other|Family support|Before the extubation procedure, the patient's relatives will be informed, and the patient will be allowed to enter the intensive care unit, and the patient will be able to express that he is with the patient by holding his hand and talking.
75549592|NCT00452738|Behavioral|Therapy dog|
75549593|NCT00452738|Behavioral|Costumed character|
75549594|NCT00452738|Behavioral|Parents-only|
75549595|NCT00334854|Drug|doxorubicin hydrochloride|
75549596|NCT00334854|Drug|ifosfamide|
75549597|NCT00334854|Procedure|adjuvant therapy|
75549598|NCT00334854|Procedure|conventional surgery|
75549599|NCT00334854|Procedure|neoadjuvant therapy|
75549600|NCT00334854|Radiation|radiation therapy|
75549601|NCT03274973|Drug|Zomacton|Injection
75549602|NCT00334932|Drug|bortezomib|
75549603|NCT00334932|Drug|melphalan|
75549604|NCT00334932|Drug|pegylated liposomal doxorubicin hydrochloride|
75549605|NCT00452777|Drug|BVT.115959|
75400980|NCT05820776|Other|pulmonary rehabilitation|The intervention is PR delivered via a telemedicine. The intervention is PR delivered via a telemedicine. The program is delivered by the multidisciplinary via a remote application for two sessions per week for ten weeks. Remotely supervised exercise includes: 1) deep breathing reinforcing pursed lip and diaphragmatic breathing; 2) warm up breathing and stretching exercise; 3) a cardiorespiratory aerobic exercise battery; 4) resistance training, and; stretching cool down. There is also an educational component. The secondary (maintenance) program includes ongoing remotely supervised exercise and education once a week for six months (24 sessions). All patients successfully completing the initial PR are offered the maintenance program.
75400981|NCT05820750|Device|photodynamic therapy|root canal treatment of primary molars using photodynamic therapy
75400982|NCT05820750|Procedure|pulpectomy with metapex|root canal treatment using standard technique
75400983|NCT05820620|Procedure|TAP block|The transversus abdominis plane (TAP) block was introduced as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle.
75400984|NCT05820620|Procedure|QLB block|"Quadratus lumborum block is a block of the posterior abdominal wall, interfascial plane block, which is performed exclusively under ultrasound guidance. It was described as a variant of the TAP block."
75400985|NCT05820620|Other|Control Group|Control Group + Patient Control Analgesia (PCA)
75549606|NCT00452777|Drug|Placebo|
75549607|NCT00334971|Procedure|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
75549608|NCT00452816|Behavioral|Workplace Solutions Consulting approach|"Consulting process includes:~baseline measure of best practices~gap analysis and recommendations reporting~delivery of solution set toolkits for each practice chosen for implementation"
75549609|NCT00452816|Behavioral|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
75549610|NCT00335010|Drug|Nitroglycerin|
75549611|NCT00452855|Procedure|Sevoflurane-remifentanil anaesthesia|
75549612|NCT00335088|Drug|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
75549613|NCT00452894|Drug|varenicline tartrate|
76038002|NCT05279001|Drug|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
75400986|NCT05818774|Procedure|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning|"Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
75549614|NCT00335166|Drug|Pardaprunox|12-42 mg
75549615|NCT00335166|Drug|pramipexole|1.5-4.5 mg
75549616|NCT00335166|Drug|Placebo Comparator|Placebo
75549617|NCT00452972|Drug|Spinal Anesthesia|
75549618|NCT00335205|Drug|ropinirole|
75549619|NCT00453011|Device|posterior chamber intraocular lens|
75549620|NCT00453011|Device|anterior chamber intraocular lens|
75549621|NCT03274934|Behavioral|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
75549622|NCT03274934|Behavioral|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
75549623|NCT03274934|Behavioral|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
75549624|NCT00335361|Device|Intra Vas Device (IVD)|
75549625|NCT00453050|Drug|imiquimod|
75549626|NCT00453050|Drug|indocyanine green solution|
75549627|NCT00453050|Other|flow cytometry|
75549628|NCT00453050|Other|immunologic technique|
75549629|NCT00453050|Other|laboratory biomarker analysis|
75549630|NCT00335400|Drug|Anesthetic Dilating Gel|
75549631|NCT00453089|Drug|VG101|
75549632|NCT00420576|Drug|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
75549633|NCT00420615|Drug|Patupilone and Omeprazole|
75549634|NCT00420615|Drug|Patupilone + Midalzolam|
75549635|NCT00453167|Drug|Paclitaxel|Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
75549636|NCT00453167|Drug|Gemcitabine|Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
75549637|NCT00420654|Drug|Growth Hormone|1.25 mg, 6 months
75549638|NCT00420654|Drug|Placebo|Equivalent to 1.25 mg, 6 months
75549639|NCT00420654|Other|Healthy controls|Healthy controls
75549640|NCT00420693|Drug|sevoflurane|
75400987|NCT05818774|Procedure|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae|"Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets."
75400988|NCT05818189|Device|Personalized tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.
75400989|NCT05818189|Device|Fixed tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.
75400990|NCT05817162|Drug|Ropivacaine injection|Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the without affecting the motor ones. Ropivacaine comes as solution for injection.
75400991|NCT05817162|Procedure|temporomandibular joint arthrocentesis|Temporomandibular arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ.
75400992|NCT05817162|Drug|PRP injection|Platelet-Rich Plasma (PRP) is an orthobiological adjuvant treatment. PRP has properties to restore intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis and balances joint angiogenesis. It is often used as a viscosupplement in TMJ arthrocentesis
75400993|NCT05817162|Drug|Ringer's Lactate solution|Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.
75400994|NCT05816421|Behavioral|KEEP|The KEEP model focuses on optimizing the role of foster/kin parents as the agents of positive change for children and youth. Parent KEEP groups for children (ages 4-12) and KEEP-Safe groups for teens (ages 13-19) are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-10 foster/kin parents attends each week. Each KEEP group follows a manualized curriculum that emphasizes tailoring the content to the unique needs of the parents and youth in the group. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting.
75400995|NCT05816421|Behavioral|Non-Affinity KEEP|Non-Affinity KEEP
75400996|NCT05815628|Diagnostic Test|DISQVER|NGS based infection diagnosis
75400997|NCT05814809|Drug|JP-1366 20mg tablet|T : JP-1366 20mg tablet
76038003|NCT04804475|Other|Exercise Trainig|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
76038004|NCT04808375|Other||
75400998|NCT05814809|Drug|JP-1366 20mg capsule|R : JP-1366 20mg capsule
75400999|NCT05812690|Other|This is a non intervention - observation only study|This is non intervention study
75401000|NCT05810402|Biological|Liquid Biopsy|"30mL blood sample:~1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis~1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL),~2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell)."
75401001|NCT05809180|Drug|Rituximab|Rituximab 375mg/m2 ivgtt d1;
75401002|NCT05809180|Drug|Orelabrutinib|Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
75549641|NCT00420810|Drug|MK0928 / Duration of Treatment : 8 Weeks|
76038005|NCT04808063|Procedure|Prophylactic mesh implantation|Use of an algorithm for prophylactic mesh implantation in high risk patients after emergency midline laparotomy.
76038006|NCT03070561|Biological|sublingual film with peanut extract|
76038007|NCT05514951|Diagnostic Test|Blood sampling|Blood sampling
76038008|NCT04796441|Biological|CAR-γδT|Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
75401003|NCT05809180|Drug|Pomalidomide|Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
76038009|NCT04988737|Other|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
75401004|NCT05809180|Drug|Pro-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
75401005|NCT05809180|Drug|R-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
75401006|NCT05807854|Procedure|Arthroscopy|The surgeon reattaches the torn tendon to the bone with anchors and sutures.
75401007|NCT05807854|Device|Reverse Shoulder Arthroplasty|It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
75401008|NCT05802238|Drug|Tranexamic acid (TXA)|1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
75401009|NCT05802238|Other|Saline|control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.
76038010|NCT05278845|Drug|SLC-391|SLC-391 is an AXL inhibitor
75401010|NCT05802173|Drug|TDM-105795, 0.0025%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
76038011|NCT05392933|Diagnostic Test|Ultrasound guided piriformis muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
76038012|NCT04796675|Drug|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
75549642|NCT00453323|Drug|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
76038013|NCT04954677|Other|AI-box|Automatic quality-control system（AI-box）could real-time measure endoscopic inspection completeness, evaluate gastric cleanliness.
75549643|NCT00453323|Drug|Capecitabine|capecitabine 900mg/m2 bid po on day 1~14, 1 weeks rest, until disease progression
75710494|NCT05457686|Other|kinesio tape|According to this, the proximal part of the band is located close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate tapes are applied so that the strips cross each other
76038014|NCT05233839|Other|Telerehabilitation|Application based video home exercise for the degenerative meniscus injury
76038015|NCT05233839|Other|Paper Based Rehabilitation|Paper instruction based home exercise for the degenerative meniscus injury
75401011|NCT05802173|Drug|TDM-105795, 0.02%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
75401012|NCT05802173|Drug|TDM-105795 topical vehicle solution|The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
75401013|NCT05799807|Procedure|Conservative treatment|Patients with negativ weight-bearing CT will be treated conservative
75401014|NCT05799807|Procedure|Minimally invasive stabilization|Patients with positive weight-bearing CT will be operated by minimally invasive stabilization (eg, isolated homerun screw)
75401015|NCT05796570|Drug|Decitabine|Nucleoside metabolic inhibitor, via IV infusion.
75401016|NCT05796570|Drug|Filgrastim|Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
76038016|NCT05233761|Drug|Defined CBD|300 mg CBD and 8 mg Terpenes administered as two small capsules.
76038017|NCT05233761|Drug|Placebo|Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
75401017|NCT05781438|Behavioral|In-home standing and walking intervention|"Parents/legal guardians will be educated on and provided an activity booklet on intensive standing and walking play activities for their infant in a 9 by 9 foot body-weight support system (BWS). Activities include: squatting play at a couch or table, cruising along and between furniture, walking with a push toy or with one or two hands held, walking without support, and kicking and throwing a soft ball.~For 16 weeks, parents/legal guardians will be encouraged to implement the parent-led, intensive standing and walking intervention using BWS for at least 5 days/week for 30-60 min/day, with weekly telehealth calls and monthly home visits to coach parents in identifying key activities and progressing the program."
75549644|NCT00335439|Drug|ketorolac tromethamine 0.5% (Acular®)|
75549645|NCT00453401|Drug|NB-001|
75549646|NCT00453440|Procedure|Cheek swab & blood test|Cheek swab & blood test
75710495|NCT05457686|Other|Sham taping|In the same procedure and time as kinesiotaping, inelastic tape will be used instead of kinesiotape.
76038018|NCT04803929|Biological|anti-ILT3 CAR-T|Autologous T cells genetically modified with anti-ILT3 CAR
76038019|NCT04796207|Dietary Supplement|Fish Oil (DPA+EPA 2:1 ratio) Capsules|The Treatment Arm intervention consists of providing participants with 3 grams of DHA and EPA (2:1 weight ratio) in capsular form. In order to meet the required 3 grams of DHA and EPA, participants were given 6 capsules to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season.
75401018|NCT05768295|Device|Axiom BL X3|collecting data on the use of Axiom BL X3 and patient satisfaction
75710496|NCT05457686|Other|Exercise|Routine exercise and physiotherapy program applied after knee arthroplasty surgery will be applied
76038020|NCT04796207|Dietary Supplement|High Oleic Safflower Oil Capsules|"The Placebo Arm intervention consists of providing participants with 3 grams of high-oleic safflower oil in a 1:1 allocation ratio in capsular form. In order to maintain the study masking, participants in the Placebo Arm were given 6 capsules (the same as the Treatment Arm) to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season."
75401019|NCT05755945|Other|eHealth Application|"Custom phone application that integrates data from smart watch. Subjects will complete daily To-Do-Lists where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache."
75710497|NCT05132634|Other|Hand Massage|Like a massage, the superficial kneading technique which is included in the Swedish massage technique will be applied in a way to create a slight pressure on the patient, and it will be terminated again with the effleurage technique. The procedure was concluded in a way that each massage technique was applied and the massage was for a total of 15-20 minutes.
75710498|NCT03859791|Other|THA|Study participants have received a total hip arthroplasty due to arthritis. We do not make further intervention.
75401020|NCT05751837|Biological|Lipopolysaccharide|One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
75401021|NCT05749848|Drug|[¹⁴C]-LY3372689|Administered orally.
75401022|NCT05728970|Diagnostic Test|LumiraDx SARS-CoV-2 Ag Ultra|The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.
75401023|NCT05728970|Diagnostic Test|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 & Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
75401024|NCT05714098|Behavioral|Gerofit Exercise Program|The tele-Gerofit exercise intervention has training focused on meeting the physical activity guidelines and incorporating cardiovascular, strength, and balance training. Sessions will also include a mindfulness component, warm up, cool-down, and safety checks. Exercises are personalized to each person's functional status. Intensity of exercises will be determined by participants providing a rating of perceived exertion (RPE) on a scale of 0 (easy) to 10 (very hard) throughout the session. Initial exercise sessions will start at low-intensity and will gradually increase the duration and intensity to allow each person to reach recommended exercise levels at their own pace. Exercises are done virtually via Zoom. Each cohort will have 5-8 participants. The exercise program will be optimized after each cohort with modifications based on participant and exercise expert feedback.
75710499|NCT00823329|Device|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
75710500|NCT02550483|Other|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
76038021|NCT05317923|Other|Flow Controlled Ventilation|Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
75871362|NCT03509207|Drug|Vorinostat Oral Capsule|Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
76038022|NCT04786925|Other|Control diet|Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
76038023|NCT04786925|Other|Nutriprecision diet|Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
75401025|NCT05699031|Device|APP|Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.
75401026|NCT05699031|Other|PHYSICAL THERAPY|Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
75401027|NCT05689853|Drug|AK119|AK119 is an anti-CD73 monoclonal antibody.
75401028|NCT05689853|Drug|AK112|AK112 is a bispecific monoclonal antibody against VEGF and PD-1.
75401029|NCT05686083|Dietary Supplement|C6 ketone di-ester|C6 ketone di-ester
75401030|NCT05686083|Dietary Supplement|Novel ketone di-ester|Novel ketone di-ester
75401031|NCT05668286|Drug|A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%)|patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance. A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) were injected to all patients.
75401032|NCT06024083|Behavioral|Dialectical Behavior Therapy skills video intervention|A series of 14 animated videos (9 acceptance-oriented and 5 change-oriented skills videos) available in both English and Mandarin Chinese.
75401033|NCT06024057|Drug|LX101|LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye
75401034|NCT06024031|Drug|N-acetyl-L-cysteine|N-acetyl-L-cysteine (Yiweishi) capsules (Guangdong Renrenkang Pharmaceutical Industry) will be given orally 400mg three times a day from day 1 to day 28 after chemotherapy. In case of drug allergy such as nausea, vomiting, rash and bronchospasm, and disease relapse, to discontinue the drug immediately.
75401035|NCT06024018|Device|high intensity electromagnetic technology device, diet restriction, and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months
75401036|NCT06024018|Behavioral|diet restriction and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
75401037|NCT06024005|Drug|Oral Solifenacin 5mg|Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
75401038|NCT06024005|Device|Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)|Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
75401039|NCT06023979|Other|Full weight bearing|Full weight bearing monitored with a bio-feedback insole
75871363|NCT03727295|Drug|Idebenone/placebo|The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
75871364|NCT03145792|Behavioral|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
75401040|NCT06023979|Other|Partial weight bearing|Partial weight bearing monitored with a bio-feedback insole
75401041|NCT06023940|Dietary Supplement|High fiber|A pea fiber supplement is added to a diet of regular foods. Participants receive 25g fiber daily.
75401042|NCT06023914|Other|STRENGTH EVALUATION WITH ELECTROSTIMULATOR|Evaluation of isometric strength using an electrostimulator.
75401043|NCT06023914|Other|STRENGTH EVALUATION WITHOUT ELECTROSTIMULATOR|Evaluation of isometric strength not using an electrostimulator.
75401044|NCT06023901|Diagnostic Test|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
75401045|NCT06023888|Other|Mapping strategy|The ablation strategy was based on the mapping results of periodicity.
75401046|NCT06023888|Other|Mapping strategy|PVI+ non-PV trigger
75401047|NCT06023875|Drug|Cadonilimab|Cadonilimab 10mg/kg. The drug was administered every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
75401048|NCT06023875|Drug|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
75401049|NCT06023875|Drug|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
75401050|NCT06023849|Device|IUD insertion|Trans Caesarean Intra Uterine Contraceptive Device Insertion and Conventional Postpartum 6 Weeks Insertion
75401051|NCT06023810|Behavioral|Watson's human care theory-based motivational interviewing method|The Motivational Interviewing Program based on Watson's Theory of Human Caring will be conducted over an 8-week period, with sessions taking place once a week. The initial session will have a duration of 60 minutes, while the subsequent weekly sessions will last for 30 minutes
75401052|NCT06023797|Drug|Neoadjuvant immunochemotherapy|Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
75401053|NCT06023784|Procedure|left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
75871365|NCT03145792|Behavioral|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
75401054|NCT06023784|Procedure|right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
75401055|NCT06023771|Procedure|Invasive intervention for acute pancreatitis|Invasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
75401056|NCT06023758|Drug|KN026|KN026：30 mg/kg Q3W
75710501|NCT02550483|Other|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
75401057|NCT06023758|Drug|KN046|KN046：5 mg/kg Q3W
75401058|NCT06023758|Drug|XELOX|Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
75871366|NCT03727217|Diagnostic Test|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative
75401059|NCT06023745|Genetic|genotyping|Genotyping. Measurement of SOD serum level. Measurement of IL-35 serum level.
75871367|NCT04438798|Other|F Group|In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
75871368|NCT04438798|Other|H Group|In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
75871369|NCT01378650|Drug|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
76038024|NCT05230875|Behavioral|self-administered questionnaire|"All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program."
75710502|NCT02550483|Other|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
76038025|NCT05276037|Other|Liver transplantation|Both groups will receive the same advantages on the LT waiting list (SE points)
76038026|NCT04803617|Other|Assessment of pulmonary function and pectoralis muscle strength|In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
76038027|NCT05229939|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
76038028|NCT05275413|Behavioral|family-based mHealth Intervention|The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.
76038029|NCT05275413|Behavioral|mother-only mHealth Intervention|The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.
76038030|NCT05275413|Other|Health education|The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
75549647|NCT04698083|Diagnostic Test|Electrocardiography ,Tomographic imaging|Based on electrocardiographic follow-up analyses,the two main groups were compared in terms of rotation condition (i.e., Cwr, normal transition, or CCwr), electrocardiographic intervals, and laboratory findings In our study,CO-RADS5 was considered an advanced tomographic finding(e.g., multifocal ground glass opacities with consolidation, vascular thickening,crazy paving pattern,mixed pattern),while CO-RADS1,2,3, and 4 were considered non-advanced tomographic findings.
75549648|NCT00335595|Drug|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
75549649|NCT00335595|Drug|XELOXA-A|"XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks"
75871370|NCT01378650|Drug|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
75871371|NCT03721601|Device|Heart rate monitor chest strap|Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
75549650|NCT00453518|Device|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
75549651|NCT00453557|Drug|rhGH|
75401060|NCT06023693|Behavioral|i-Sleep & BioClock|Module 1 Psychoeducation about normal sleep and insomnia, Psychoeducation on the biological clock: the circadian rhythm, chronotypes, zeitgebers, importance of light behaviour Basic sleep hygiene: information about behaviours that are known to promote or impede sleep e.g. performing physical exercise or the use of caffeine Module 2 Sleep restriction and stimulus control: patients are taught to use the bedroom only to sleep and to restrict the time in bed to the average amount of night-time sleep Module 3 Worrying and relaxation: audio files with progressive muscle relaxation exercises are offered and techniques to stop worrying (e.g. thought blocking, evaluation and worry time) Module 4 Erroneous cognitions about sleep: the basics of cognitive behavioural therapy are explained and the most common erroneous ideas about insomnia are discussed Module 5 Summary and plan for the future
75401061|NCT06023693|Behavioral|Online Psychoeducation|Online psychoeducation about sleep and the biological clock, basic sleep hygiene
75401062|NCT06023381|Other|Sliding sign|"All women had Transabdominal Ultra-sonography using SAMSUNG WS80 elite ultrasound machine during the preoperative examination, using the real-time Transabdominal pelvic features (the relative motion between the maternal abdominal and uterine wall).~The patient was asked to breathe deeply, accentuating her respiratory movements and the sonographer recorded a video clip in a mid-sagittal plane lateral to umbilicus focus on the infra-umbilical space, to determine whether the structure glided freely in relation to adjacent structures. To be considered as sliding, the structures had to glide easily, one against the other (positive sliding sign); no motion of the structure in question signaled a negative sliding sign."
75401063|NCT05814042|Drug|Next Generation ORS (oral rehydration solution) (including placebo|Nutrition used to stop diarrhea
75401064|NCT05814042|Drug|Current standard control ORS (oral rehydration solution)|current standard control ORS in diarrheic patients with cholera
75401065|NCT05557877|Procedure|Biospecimen Collection|Undergo collection of blood
75401066|NCT05557877|Drug|Low-Dose Aspirin|Given PO
75401067|NCT05557877|Other|Questionnaire Administration|Ancillary studies
75401068|NCT05557877|Procedure|Ultrasound-Guided Biopsy|Undergo ultrasound-guided breast biopsy
75401069|NCT05549661|Procedure|Biospecimen Collection|Undergo collection of blood samples
75401070|NCT05549661|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
75401071|NCT05549661|Drug|Onvansertib|Given PO
75401072|NCT05549661|Procedure|Ultrasound Imaging|Undergo ultrasound imaging
75401073|NCT05365061|Other|periosteal electrical dry needling with no maintenance treatments|periosteal electrical dry needling
75549652|NCT00335673|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
75549653|NCT00335712|Drug|ONO-5129|
75549654|NCT00453635|Drug|Docetaxel|Docetaxel at the dose of 75mg/m^2 IV on day 1 every 3 weeks for 6 consecutive cycles
75549655|NCT00453635|Drug|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
75549656|NCT00453635|Drug|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
75549657|NCT00453635|Drug|Vinorelbine|Vinorelbine at the dose of 60mg/m^2 per os,weekly
75549658|NCT00335751|Procedure|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
75549659|NCT04698278|Device|PanOptix Trifocal Intraocular Lens|This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
75549660|NCT00335790|Procedure|Hyperbaric Therapy|
75549661|NCT00335868|Drug|danusertib|
75549662|NCT00335868|Other|laboratory biomarker analysis|
75549663|NCT00335868|Other|pharmacological study|
75549664|NCT04698200|Other|Cold exposure|Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.
75401074|NCT05365061|Other|periosteal electrical dry needling with maintenance treatments every other month|periosteal electrical dry needling with maintenance treatments every other month
76038031|NCT04795349|Procedure|Vacuum-assisted breast biopsy|In those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen.
76038032|NCT04786535|Procedure|Expanded Hemodialysis|"Single-use Theranova 400 Dialyzer~Blood flow (Qb) minimum of 300 mL/min~Dialysis flow (Qd) 500 mL/min~Minimum therapy time of 4 hours~Ultrafiltration necessary to achieve dry weight"
75549665|NCT00335907|Procedure|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
75401075|NCT05365061|Other|periosteal electrical dry needling with monthly maintenance treatments|periosteal electrical dry needling with monthly maintenance treatments
75401076|NCT05297396|Other|Slow Tapering of Chronic Opioid Therapy|Clinically prescribed daily opioids reduced by no more than 10 morphine milligram equivalent per day (MMED) each month for 12 months
75401077|NCT05092516|Device|Active tDCS|2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.
75401078|NCT05092516|Device|Sham tDCS|Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.
75549666|NCT00335946|Device|HANS non-needle acupuncture|
75710503|NCT04646382|Dietary Supplement|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
75549667|NCT00335946|Procedure|Stimulation of two acupuncture points bi-lateral|
75710504|NCT04646382|Dietary Supplement|Control|Microcrystalline cellulose
75710505|NCT00817323|Procedure|Dietary amino-acid depletion|See detailed description
75401079|NCT05023291|Diagnostic Test|Positron Emissie Tomografie - Computer Tomografie|In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
75401080|NCT04831125|Other|Data collection|Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.
75549668|NCT00335985|Drug|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
75710506|NCT05739188|Biological|Anti-GPRC5D CAR-T cells infusion|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10^6 /kg±20%; Dose level two:6.0×10^6 /kg±20%; Dose level three:1.0×10^7 /kg±20%."
75401081|NCT04609735|Other|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
75710507|NCT02566434|Dietary Supplement|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
75710508|NCT00737750|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
75710509|NCT00737750|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
75710510|NCT00737750|Behavioral|Control|Voluntary quadriceps muscle contractions.
75710511|NCT04608318|Biological|Ibrutinib|Cycles 1 - X: 420 mg daily, d1-28 p.o.
75710512|NCT04608318|Biological|Venetoclax|"Arm VG~Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.~Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.~Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.~Arm VI~Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.~Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o."
75401082|NCT04609735|Other|Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound vs. Manual Therapy, Exercise and Ultrasound
75710513|NCT04608318|Biological|Obinutuzumab|Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.
75871372|NCT03721601|Device|Wrist band photoplethysmography|Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
75401083|NCT04609709|Other|Thrust Manipulation, Electric Dry Needling and Exercise|Thrust Manipulation, Electric Dry Needling
75401084|NCT04609709|Other|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS
75401085|NCT04035408|Other|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
75401086|NCT03968614|Other|Electric dry needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
75401087|NCT03968614|Other|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
75549669|NCT00335985|Drug|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
75401088|NCT03695471|Biological|Pembrolizumab|Given IV
76038033|NCT04786535|Procedure|High-flux Conventional Hemodialysis|"Single-use high-flux hemodialyzer~Blood flow (Qb) minimum of 300 mL/min~Dialysis flow (Qd) 500 mL/min~Minimum therapy time of 4 hours~Ultrafiltration necessary to achieve dry weight"
75401089|NCT03167710|Other|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
75401090|NCT03167710|Other|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
75401091|NCT03085043|Procedure|Bone Scan|Undergo bone scan
75401092|NCT03085043|Procedure|Computed Tomography|Undergo CT of the abdomen and pelvis
75401093|NCT03085043|Procedure|Magnetic Resonance Imaging|Undergo pelvic MRI
75401094|NCT03085043|Procedure|Magnetic Resonance Whole Body Diffusion-Weighted Imaging|Undergo magnetic resonance whole body diffusion-weighted imaging
75401095|NCT02464696|Drug|Methylprednisolone|IPS cohort only
75401096|NCT02464696|Procedure|Oxygen Therapy|Receive high flow oxygen therapy
75401097|NCT02464696|Device|Positive Air Pressure Device|Undergo NIPPV
75401098|NCT02389309|Drug|Cyclophosphamide|Given PO
75401099|NCT02389309|Drug|Dasatinib|Given PO
75401100|NCT02389309|Other|Laboratory Biomarker Analysis|Correlative studies
75401101|NCT02389309|Drug|Temsirolimus|Given IV
75401102|NCT02231775|Drug|Dabrafenib|Given PO
75401103|NCT02231775|Other|Laboratory Biomarker Analysis|Correlative studies
75401104|NCT02231775|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75549670|NCT00336102|Other|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
75710514|NCT05733806|Other|chemotherapy, surgery|this is an observational prospective study, therefore no intervention is planned. Patients perform medical and surgical treatment as per standard of case.
75710515|NCT04063358|Drug|Lucentis|Lucentis 0.5 MG Per 0.05 ML Injection
75710516|NCT00921258|Procedure|prostate biopsy|"patient of control group will have :~1 prostate biopsy 3 months after diagnostic biopsy~1 prostate biopsy each year during 2 years~1 prostate biopsy each 2 years during 8 years"
75710517|NCT00631917|Drug|Aliskiren|Aliskiren 300 mg once a day
75710518|NCT00631917|Drug|Ramipril|Ramipril 10 mg once a day
75710519|NCT00631917|Other|Placebo to Ramipril|Placebo capsules to match ramipril.
76038034|NCT04786535|Procedure|Hemodiafiltration|"Single-use high-flux hemodialyzer~Post-dilution mode~Minimum convective volume of 23 L~Blood flow (Qb) minimum of 300 mL/min~Dialysis flow (Qd) 700 mL/min~Minimum therapy time of 4 hours~Ultrafiltration necessary to achieve dry weight"
76038035|NCT05272917|Other|Sensorial tests|Patients will be included in the study between 3 to 6 months after the end of treatment and go to the Paul Bocuse Research Institute to perform several sensorial tests. The same sensorial tests will be completed by healthy volunteers to compare.
76038036|NCT05272917|Behavioral|food preferences questionnaires|Patients will be included in the study between 3 to 6 months after the end of treatment and go at Institut Paul Bocuse to complete food preferences questionnaires. The same questionnaires will be completed by healthy volunteers to compare.
75401105|NCT02231775|Drug|Trametinib|Given PO
75401106|NCT02135874|Drug|Clofarabine|Given IV
75401107|NCT02135874|Drug|Cytarabine|Given IV
75401108|NCT02135874|Drug|Dexamethasone|Given IV
75401109|NCT02135874|Drug|Idarubicin|Given IV
75401110|NCT02135874|Biological|Rituximab|Given IV
75401111|NCT02135874|Drug|Sorafenib|Given PO
75401112|NCT02135874|Drug|Sorafenib Tosylate|Given PO
75401113|NCT02135874|Drug|Vincristine|Given IV
75401114|NCT02135874|Drug|Vincristine Sulfate|Given IV
75401115|NCT02114138|Procedure|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
75401116|NCT02114138|Diagnostic Test|urine collection|urine collection will be performed on both the control group and hospitalized participants
75401117|NCT01738139|Drug|Imatinib Mesylate|Given PO
75401118|NCT01738139|Biological|Ipilimumab|Given IV
75401119|NCT01719718|Procedure|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
75401120|NCT01719718|Procedure|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
75401121|NCT00791635|Other|Quality-of-Life Assessment|Ancillary studies
75401122|NCT00791635|Other|Questionnaire Administration|Complete questionnaires
75401123|NCT00501826|Drug|Cyclophosphamide|Given IV
75401124|NCT00501826|Drug|Cytarabine|Given IV
75401125|NCT00501826|Drug|Dexamethasone|Given IV or PO
75401126|NCT00501826|Drug|Doxorubicin Hydrochloride|Given IV
75401127|NCT00501826|Drug|Mercaptopurine|Given PO
75401128|NCT00501826|Drug|Methotrexate|Given IV and PO
75401129|NCT00501826|Drug|Nelarabine|Given IV
75401130|NCT00501826|Drug|Pegaspargase|Given IV
75401131|NCT00501826|Drug|Prednisone|Given PO
75401132|NCT00501826|Drug|Venetoclax|Given PO
75401133|NCT00501826|Drug|Vincristine Sulfate|Given IV
76038037|NCT04803695|Diagnostic Test|Microbial biofilm diagnose|Usage of new microbiological methods for biofilm detection
76038038|NCT05316987|Radiation|Narrow band ultraviolet B|48 sessions of narrow band ultraviolet
76038039|NCT04925895|Other|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization will be given in the following sequence, In supine position with 90˚ flexion of knee and hip joint deep longitudinal strokes will be applied from distal to proximal direction along with the tightened area of hamstring while passively stretching the hamstring. Total 5 longitudinal strokes will be applied followed by shaking for 20 seconds. Then progressed to the next dynamic technique in the above-mentioned sequence but the patient will be asked to do leg extension actively to achieve reciprocal inhibition of the hamstring muscle. In The next step, the subject will apply a force to the therapist's hand to engage the hamstring eccentrically as the muscle will be lengthened to its end range. In that position, the therapist will apply 5 deep longitudinal strokes from the distal towards the proximal direction on tight hamstring muscles.
76038040|NCT04925895|Other|Proprioceptive neuromuscular facilitation stretching|The position of the patient will be supine lying with 90⁰ flexion of hip. Therapist will passively extend the knee joint where patient will feel a mild stretch. Then therapist will ask the patient to do knee flexion in counter resistance applied by the therapist by using about 50% of his maximum strength and isometric contraction of hamstring muscles will be achieved. Patient will maintain that isometric contraction for 8 seconds then relax on therapist command. Just after relaxation therapist will further stretch the hamstring muscle to the point of mild to moderate painless stretch and patient will hold it for 30 seconds. Three repetitions will be applied in each session.
76038041|NCT04925895|Other|Cryotherapy|application of cold pack on knee joint for 10 minutes
76038042|NCT04925895|Other|Isometric knee strengthening excercises|"i. Isometric hip adductors exercises in crook lying: Two sets of 10 repetitions with a 10-seconds hold will be carried out.~ii. Isometric quadriceps strengthening exercises in supine lying: A towel roll underneath the knee joint will be used to perform this exercise. Two sets of 10 repetitions with a 10-seconds hold will be performed."
75401134|NCT00492817|Procedure|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
75710520|NCT00631917|Other|Placebo to Aliskiren|Placebo tablets to match aliskiren.
76038043|NCT04795115|Other|Auditory rhythmical cueing|Auditory rhythmical cueing intervention targeting balance and gait for 30 minutes x5 per week for 3 weeks.
76038044|NCT05616377|Other|Surgery or Radiotherapy|Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group
76038045|NCT05616377|Other|before or after target therapy|Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.
76038046|NCT04785755|Drug|Oral standard diuretics therapy|Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
76038047|NCT04785755|Drug|Hypertonic saline solution|Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
75401135|NCT00323674|Device|Polysoft Mesh|Polysoft Mesh is used.
75401136|NCT00323674|Device|Light Weight Mesh|Light Weight Mesh is used.
75401137|NCT05646628|Behavioral|Qualitative Interviews|Semi-structured Qualitative Interviews
75401138|NCT05645471|Behavioral|Together After Cancer|This is an online couples intervention for Latina breast cancer survivors and their intimate partners.
75401139|NCT05643859|Dietary Supplement|Dietary Fiber|Given PO
75401140|NCT05643859|Procedure|Proctoscopy or anoscopy with Biopsy|Undergo proctoscopy or anoscopy
75401141|NCT05643859|Other|Questionnaire Administration|Ancillary studies
75401142|NCT05636059|Other|Therapeutic exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
75401143|NCT05636059|Other|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
75401144|NCT05636059|Other|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
75401145|NCT05622500|Procedure|Deep venous stenting|Endovascular reconstruction encompasses balloon venoplasty and venous stenting. A dedicated venous stent will be used, the brand of which the individual interventionist will decide.
75549671|NCT00336102|Procedure|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
75710521|NCT00823407|Drug|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
75710522|NCT00823407|Drug|Placebo|Subjects will receive a single oral dose of placebo
75401146|NCT05622500|Combination Product|Best medical therapy|Compression stockings encompass a range of therapies used to provide an externally applied graduated-pressure up the length of the limb aiming to improve venous function and decrease lower limb swelling. Compression stockings can be classified by size and grade, i.e. the pressure the stockings applies to the limb. For the purpose of this trial Class II and Class III graduated compression stockings should be used, with the aim of providing Class III if tolerated. Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.
75401147|NCT05620472|Drug|Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1|One single intravenous injection of [99mTc]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
75401148|NCT05618951|Other|Lower Trapezius Strengthening Exercises|"Lower Trapezius strengthening exercise includes:~Latissimus pull down~Prone V- raise~Modified Prone Cobra"
75401149|NCT05588583|Device|Mepilex Up|"Mepilex Up is a highly conformable dressing that absorbs both low and high viscous exudates, maintains a moist wound environment and minimises the risk of maceration. The dressing has a Safetac® wound contact layer that is a unique adhesive technology. It minimises pain to patients and trauma to wounds and the surrounding skin at dressing removal.~Mepilex Up consists of:~a soft silicone wound contact layer (Safetac)~a flexible absorbent pad of compressed polyurethane foam~an outer polyurethane film which is breathable but waterproof~Dressing material content:~Silicone, polyurethane"
75401150|NCT05581823|Drug|Tavapadon|Oral tablets
75401151|NCT05581823|Drug|Carbamazepine|Extended-release oral tablets
75401152|NCT05553951|Behavioral|Controlgroup|The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
75401153|NCT05553951|Behavioral|Intervention|Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
75401154|NCT05540704|Behavioral|iACT|Treatment is based on Acceptance and Commitment Therapy (ACT), a contemporary cognitive behavioral therapy (CBT) that improves human functioning and adaptability by increasing psychological flexibility. Individual therapy sessions are paired with mobile phone delivered interventions.
75401155|NCT05540704|Other|Usual Care|Usual care for problems in Type 1 diabetes management
75401156|NCT05526976|Other|PERISCOPE-care|Patients with planned elective surgery will be asked to complete the PERISCOP3E-Care questionnaire (modified-Althaus & Kalkman, DN4, HADS, Stait-trait, NRS, MPI, EQ-5D-5L) preoperative. One month and three months post op the patients will be contacted to check if they developed persistend postoperative pain and they will also complete questionnaires (DN4, HADS, Stait-trait, NRS, MPI and EQ-5D-5L).
76038048|NCT04785755|Drug|Etilefrine|Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
76038049|NCT04244253|Drug|OPC-64005 20 mg , Once-daily|Active, High Dose
76038050|NCT04244253|Drug|OPC-64005 10 mg , Once-daily|Active, Low Dose
76038051|NCT04244253|Drug|Placebo, Once-daily|Placebo
75401157|NCT05498116|Drug|Montelukast|10mg daily
75401158|NCT05498116|Other|Placebo|1 capsule daily
75401159|NCT05489978|Behavioral|"Cervical Cancer Stigma Reduction Intervention"|"Change in knowledge:~Cervical cancer burden in Nepal, signs and symptoms, preventive measures available, lifestyle modifications, HPV vaccination, early diagnosis, screening, and treatment.~Change in Stigma~Para-social contact~Video of a person facing cervical cancer what symptoms she got, how she dealt with it, and how she overcame it.~Experiences of a cervical cancer survivor so that women personalize the information by relating it to their own life experiences by changing their attitude and behavior.~Participatory learning techniques~Personal stories: Voluntary self-reflection of any stigma they perceive on cervical cancer or their community perceives cervical cancer.~Group Discussion: Discuss the drivers of stigma, facilitators of sigma, types of stigma prevalent in your community, and consequences of stigma.~Myths vs facts: Negative attitudes, myths, and misconceptions about cervical cancer will be contraindicated by factual information."
76038052|NCT04785833|Drug|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
76038053|NCT04240899|Other|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
75710523|NCT04514523|Other|QBSAfe Toolkit|The QBSAfe toolkit focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety.
75710524|NCT00419341|Biological|Human Normal Immunoglobulin for Subcutaneous Administration|
75710525|NCT00694122|Drug|Lantus (glargine)|Described in Arm Description
75871373|NCT02351830|Other|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
76038054|NCT04785911|Drug|Antiemetic Combinations|Evaluation of response to treatment of hyperemisis gravidarum (antiemetics and other methods ) by PUQE score
75710526|NCT00817401|Device|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
75710527|NCT03934086|Drug|rimegepant|rimegepant 75 mg
75710528|NCT02550951|Procedure|lymphangiography|
75710529|NCT05417048|Diagnostic Test|Blood Sample|Up to 5mL of blood via venipuncture
75710530|NCT03922620|Drug|Liposomal bupivacaine|Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area
75710531|NCT03922620|Drug|Peripheral Nerve Block|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
76038055|NCT04795193|Procedure|Minimal invasive coronary surgery|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
76038056|NCT04795193|Procedure|Off-pump coronary artery bypass surgery|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
76038057|NCT05615441|Device|Analgesia Nociception Index monitor|Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
76038058|NCT05615441|Device|Standard monitoring|Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring
76038059|NCT04243941|Drug|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
76038060|NCT04794959|Diagnostic Test|Dual-energy CT|CMI patients planned for endovascular stent placement will be contacted and informed about this study prior to their procedure. If they wish to take part in the study, then a date for a pre-operative DECT scan will be arranged. Before scanning the patient will be given a standardized calorie dense drink (Nutridrink). This will take place one week prior to their surgical procedure. Following the surgical procedure, the patient will undergo another DECT scan before discharge.
75710532|NCT00419263|Drug|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
75710533|NCT00419263|Drug|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
75710534|NCT00419263|Drug|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
75710535|NCT01034995|Drug|SSR125543|"Pharmaceutical form: capsule~Route of administration: oral"
75871374|NCT02351830|Procedure|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
75710536|NCT01034995|Drug|escitalopram|"Pharmaceutical form: encapsulated tablets~Route of administration: oral"
75710537|NCT01034995|Drug|placebo|"Pharmaceutical form: capsule~Route of administration: oral"
75710538|NCT00921414|Drug|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
75710539|NCT00921414|Other|Watch and wait|No treatment patient follow-up every 2 months during 3 years
75871375|NCT04530162|Procedure|Ultrasound guided nerve block|nerve block using bupivacaine and dexamethasone.
76038061|NCT05218941|Procedure|Implant surgery assisted by passive robotics|Implant surgery without flap assisted by passive robotics (X-Guide®)
75401160|NCT05483686|Behavioral|Shine|This tailored, multifaceted mobile intervention aims to improve HIV-related outcomes and increase gender affirmation among African American transgender women. Potential users will opt-in by texting from their own mobile phone and, once registered, will be enrolled into a program that will be theory-based, targeted, tailored, and personalized. Users will receive three main types of texts: informational, motivational, and skill-building. Finally, the program will include three web-based video components: scripted vignettes, unscripted peer narratives, and educational instruction. By developing an intervention using a technology that is part of the everyday lives of most African Americans, the aim is to reduce HIV disparities. The proposed intervention can be used by clinics and community-based organizations that serve transgender women.
75401161|NCT05483686|Behavioral|Control|A playlist of CDC-developed videos designed to provide information on HIV for transgender women
75401162|NCT05450484|Drug|Fluorescence endoscopy using durvalumab-680LT|"Tracer administration: The PD-L1-targeted fluorescent tracer durvalumab-680LT will be administered intravenously 2-4 days prior to the endoscopy at the UMCG. Afterwards, patients will be monitored for half an hour by measurements of vital parameters for potential side-effects, such as infusion-related reactions.~Endoscopy procedure: Patients will undergo two endoscopies, before and after neoadjuvant therapy. First, routine high-definition white-light (HD-WL) inspection is used. Quantification of fluorescence using multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed both in vivo and ex vivo. Subsequently, fluorescence molecular endoscopy (FME) and endoscopic ultrasound (EUS) will be performed. EUS enables single fiber reflectance/single fiber fluorescence (SFR/SFF) spectroscopy measurements via fine needle aspiration (FNA) to gain insight in the drug distribution throughout the tumor. Additionally, biopsies will be obtained."
75401163|NCT05430373|Biological|GT101|Autologous tumor infiltrating lymphocyte injection
76038062|NCT05218941|Procedure|Conventional implant surgery|Flap implant surgery
75401164|NCT05412446|Drug|ADAPT6-SPECT|Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes
75401165|NCT05408377|Other|MA group|We will select Ashi points (the most obvious local pain over the breast), Tanzhong(CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong(SI11), Geshu (BL17), Ganshu(BL18), Hegu(LI4), Sanyinjiao (SP6) and Taichong (LR3)in this trial.After insertion, all needles will be manually manipulated (equal manipulations of twirling, lifting, and thrusting)to achieve De qi sensation.
75710540|NCT04060914|Drug|Ticagrelor 90mg|Ticagrelor 90 mg plus aspirin for 12 months
76038063|NCT04785599|Behavioral|Exercices|An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
76038064|NCT04785599|Behavioral|Informative talk|An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
75710541|NCT04060914|Drug|Ticagrelor 90mg/60mg|1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
75710542|NCT04060914|Drug|Clopidogrel 75mg|Clopidogrel 75mg plus aspirin for 12 months
76038065|NCT04785599|Device|Compression garment|"Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity."
76038066|NCT05314101|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
76038067|NCT05314101|Drug|bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
76038068|NCT05314101|Drug|TAS-102|Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
76038069|NCT02595749|Drug|Oxytocin|
76038070|NCT02595749|Drug|Placebo|
76038071|NCT05218707|Other|GUEDEL Airway|GUEDEL Airway of size '000,00,0,' and '1' will be used.
75710543|NCT03894696|Drug|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
75710544|NCT00399763|Drug|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
76038072|NCT01657305|Drug|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
76038073|NCT01657305|Device|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
76038074|NCT04785209|Other|Mean platelet volume, lymphocyte number, STEMI clinical risk scores|Lab parameters
75401166|NCT05408377|Other|SA group|The SA group will use a special needle in which the tip is blunt and the pedestal is opaque. There is an adhesive pad below the base to ensure that the whole pedestal can adhere to the points. Participants will receive superficial touch at bilateral sham GV8(Jinsuo), sham GV7(Zhongshu), sham GV6(Jizhong), sham GV5(Xuanshu), sham GV4(Mingmen), sham BL37(Yinmen), and sham BL57(Chengshan), the needles will touch the skin and not be inserted into the skin, then lift and twist each point evenly for 3 times, make the subject feel the similar sensation of deqi.
75401167|NCT05404412|Procedure|Epidural Steroid Injection|This intervention is applied mostly for cervical or lumbar radiculopathy. The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then a combined local anesthetic and glucocorticoids are delivered to the epidural space.
75401168|NCT05398484|Drug|Psilocybin 25 mgs|One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
75401169|NCT05398484|Drug|Niacin 100mg|One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
75710545|NCT00399763|Drug|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
75710546|NCT05324904|Drug|Vitamin D|"- Vitamin D~The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts > 10 mm need multiple injections at different sites)~Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions"
75710547|NCT05324904|Drug|acyclovir|"-Acyclovir~Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions"
75710548|NCT02085265|Drug|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
75710549|NCT02085265|Drug|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
75710550|NCT00699842|Drug|Lenalidomide|"Dose Level Lenalidomide Schedule~15mg/day for d1-21 out of 28 days~20mg/day for d1-21 out of 28 days~25mg/day for d1-21 out of 28 days"
75710551|NCT01589107|Behavioral|video decision aid|video decision aid
75401170|NCT05398484|Behavioral|Psychotherapy|The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
75710552|NCT02567630|Behavioral|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
75710553|NCT03897608|Behavioral|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
75710554|NCT02565498|Radiation|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
75710555|NCT02565498|Radiation|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
75710556|NCT00399529|Biological|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
75710557|NCT00399529|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
75401171|NCT05389982|Other|mHealth (GetWell)|GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.
75401172|NCT05389982|Other|Standard Care|Office based pathway
75401173|NCT05388786|Behavioral|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in ILND for penile cancer, vulvar cancer, and melanoma.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the ILND complications and adverse events definition and classification with a series of 5-point Likert scale assessments and options for free-text responses relating to the surgeon's perception.~The experts will fill out the online questionnaire. For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
75401174|NCT05387733|Drug|10 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of >2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of >3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of >5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514."
76038075|NCT04803461|Diagnostic Test|serum and urinary catecholamines|estimation of level of serum and urinary catecholamines before and after excimer light treatment for patient with non segmental vitiligo.
75401175|NCT05387733|Drug|15 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of >2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of >3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of >5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514."
75401176|NCT05386615|Device|Body System - Functional|MR-Guided Focused Ultrasound
75401177|NCT05374655|Other|Preoperative blood glucose control|Patients included in this group, under the guidance of endocrinologists, develop hypoglycemic strategies for patients, follow up and guide patients to take medication, review HbA1c levels after 6 weeks, perform surgical treatment if they meet preoperative HbA1c<7.5%, continue hypoglycemic therapy if still above standards, and administer drugs according to the corresponding type of heart disease during this period.
75401178|NCT05372757|Procedure|Partial Heart Transplantation|The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.
75401179|NCT05366699|Procedure|axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
75401180|NCT05366699|Procedure|Axillary lymphadenetomy alone|oncologic axillary lymphadenectomy
75401181|NCT05336084|Behavioral|Ultradian sleep/wake protocol|120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
75401182|NCT05334979|Other|Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic|"Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks."
75401183|NCT05327296|Drug|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
75401184|NCT05327296|Drug|Propofol|Intravenous infusion of propofol
75710558|NCT00399529|Drug|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
75710559|NCT00921050|Drug|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
75710560|NCT00921050|Drug|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
76038076|NCT04794881|Other|24 hours|Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
76038077|NCT04794881|Other|48 hours|Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
75710561|NCT01035307|Genetic|gene expression analysis|
75710562|NCT01035307|Genetic|microarray analysis|
75710563|NCT01035307|Genetic|proteomic profiling|
75710564|NCT01035307|Other|laboratory biomarker analysis|
76038078|NCT04426721|Drug|Ozone|10 cc of oxygen-ozone
76038079|NCT04426721|Drug|Hyaluronic Acid|Sinovial forte 32 mg\2ml
76038080|NCT05221359|Device|ExOlin®|"Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.~Device explanted with a safety follow-up."
76038081|NCT05221359|Drug|Insulin aspart|Use of NovoRapid insulin during all periods of the clinical investigations
75401185|NCT05317026|Procedure|Vertebroplasty|"SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~Decubitus position for 2 hours following procedure, then hospital discharge on the same day."
75401186|NCT05317026|Procedure|Stereotactic Body Radiation Therapy only|SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
75401187|NCT05292755|Drug|Carboxymethylcellulose (CMC) Artificial Tears|A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.
75401188|NCT05292755|Drug|Preservative-free, CMC-free Artificial Tears (control)|A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
75401189|NCT05289752|Procedure|dental implants in the mandible|placement of two interforaminal dental implants in the canine region in the mandible
75401190|NCT05289752|Device|locator attachment and overdenture|placement of locator attachment and insertion of mandibular overdenture
75401191|NCT05283395|Drug|Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%|Enrolled subjects will be instructed to self-instill 1 drop of Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% in each eye daily in the evening
75401192|NCT05277532|Behavioral|High intensity interval training (HIIT)|HIIT performed either in the morning or in the afternoon
75401193|NCT05270863|Drug|BRIMOCHOL™ PF|A single drop in each eye at a visit.
75401194|NCT05270863|Drug|Carbachol PF|A single drop in each eye at a visit.
75401195|NCT05270863|Drug|Brimonidine tartrate|A single drop in each eye at a visit.
75401196|NCT05269511|Drug|Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.|Oral administration, twice per day.
75401197|NCT05264857|Behavioral|Thyroid Nodule Management Education|Participants will receive information about thyroid nodules and their management
75401198|NCT05251298|Other|"Coordination through the online platform JamesAKTIV"|"Coordination of the treatment through the online platform JamesAKTIV that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment"
75401199|NCT05237219|Procedure|Passive heating|Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
75401200|NCT05237219|Procedure|Thermoneutral|Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
76038082|NCT04803071|Dietary Supplement|Experimental group of n-pufas improving cognitive formula|Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks
75401201|NCT05237141|Drug|Etonogestrel implant|Implant insertion in second menstrual cycle prior to ovulation
75401202|NCT05232409|Biological|Zeaxanthin|The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.
75401203|NCT05232409|Combination Product|Zeaxanthin Plus Pembrolizumab|"The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab."
75401204|NCT05226078|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral treatment of insomnia
75401205|NCT05218369|Drug|IL6 Antagonist|Patients will receive IL-6 antagonist therapy at the consultant's discretion.
76038083|NCT04803071|Dietary Supplement|General fish oil formula product adjuvant treatment control group|The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks
76038084|NCT04803071|Dietary Supplement|Placebo assisted treatment group|Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
76038085|NCT04794413|Drug|Pimavanserin|Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
76038086|NCT04802993|Other|Resection rates|All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
75401206|NCT05213741|Device|Autonomous navigation of a magnetic colonoscope|The proposed magnetic-assisted colonoscope system consists of an megnetic field nevigator, magnetic-assisted colonoscope, and image receiving decoder. All participants will receive the magnetic-assisted colonoscopic examination by using this proposed magnetic-assisted colonoscope system
75401207|NCT05163795|Procedure|Lateral locking plate|Plating of the distal femur fracture with lateral locking plate.
76038087|NCT02634307|Drug|ALKS 8700|Administered as specified in the treatment arm.
75401208|NCT05137301|Device|X-ray bone age instrument|Bone age films were taken by X-ray bone age instrument
75401209|NCT05137015|Other|Injury prevention program|"The execution of the program takes 10-15 minutes. The program will be performed in the training sessions, after the usual warm-up.~The program is based on scientific evidence that has previously shown good efficacy on injury prevention in football. The exercise categories address 7 aspects:~Balance~Core stability~Hamstring eccentrics~Glute activation~Plyometrics~Running~Games The games are included with the aim to increase the attractiveness of the program.~Each category contains 2 exercises and the coach is free to decide which one to choose in every training session. All exercises are organized in five or six levels with increasing difficulty (physically and cognitively)."
75401210|NCT05130398|Biological|rVSVΔG-ZEBOV-GP, V920|The experimental vaccine is the rVSVΔG-ZEBOV-GP, an Ebola vaccine.
76038088|NCT01365273|Device|Mepitel One|Dressing
76038089|NCT04793945|Combination Product|topical steroid and 308nm-Excimer light therapy|applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata
76038090|NCT05312775|Procedure|Double-layer uterine closure|In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
75401211|NCT05130398|Dietary Supplement|Fibre and equilibrate breakfast and lunch|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days.
75401212|NCT05130398|Diagnostic Test|Active detection and treatment of pathogens|Monthly diagnostic and treatment of childhood infections Active detection and treatment of pathogens.
75401213|NCT05130398|Combination Product|Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days and diagnostic and treatment of childhood infections Active detection and treatment of pathogens every month for 12 months
75401214|NCT05130398|Biological|Chikenpox or Varicella vaccine (VARILRIX)|The active comparator vaccine, a Varicella vaccine (VARILRIX®)
75401215|NCT05130398|Other|Placebo|About 30 children do not receive diet, nor active pathogen detection
75401216|NCT05124691|Combination Product|Albendazole and Ivermectin fixed dose coformulation|400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin
75401217|NCT05124691|Drug|Albendazole|Albendazole 400mg single dose
75401218|NCT05107336|Drug|AZD2693|Participants will receive subcutaneous injection of AZD2693, once per month.
75401219|NCT05107336|Drug|Placebo|Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection [0.9% saline solution]), once per month.
75401220|NCT05097274|Other|MRI pelvis or CT imaging under clinical management for Pr Ca|Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
75401221|NCT05097274|Other|Whole body bone scan imaging|bone scan of the whole body (under clinical diagnosis).
75401222|NCT05097274|Other|PET-CT imaging|Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
75710565|NCT02565966|Other|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
75871376|NCT03721523|Diagnostic Test|3 Dimensional tomographic Ultrasound|3-D tUS at five timepoints following acute ipsilateral stroke or Transient Ischaemic attack (TIA) to document carotid plaque volume and presence or absence of adverse plaque features.
76038091|NCT05312775|Procedure|Single-layer uterine closure|The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
75401223|NCT05036785|Other|Timing of suture removal|Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery
75401224|NCT05014087|Drug|Intravenous digoxin|"Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial.~Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing.~Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed."
75401225|NCT05012878|Behavioral|Cardiac rehabilitation - high intensity interval training (HIIT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 4x4-min high intensity aerobic intervals at a rating of perceived exertion 15-17 (hard to very hard), interspersed by a 3-min active recovery at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (4-min) and cool-down (3-min) at a light intensity.
75401226|NCT05012878|Behavioral|Cardiac rehabilitation - moderate intensity continuous training (MICT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 34-min of continuous aerobic exercise at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (3-min) and cool-down (3-min) at a light intensity.
75401227|NCT05012878|Behavioral|Cardiac rehabilitation - control|Participants will receive exercise advice in line with usual hospital discharge procedures. This involves exercise physiologists providing verbal and written information on achieving the national physical activity guidelines (150min/week of moderate intensity exercise) 60 and range of movement exercises for surgical patients with sternotomy. However, no structured or supervised exercise training program or other contact with participants will be provided after hospital discharge, to reflect the usual care process for patients that decline cardiac rehabilitation.
75401228|NCT05012878|Behavioral|Cardiac rehabilitation - observational|During cardiac rehabilitation (12-weeks), program frequency and exercise training protocol will align with clinical care decisions and/or patient choice rather than random assignment.
75401229|NCT05007093|Drug|Anlotinib hydrochloride|If intolerance occurs, the dose can be downregulated
75401230|NCT05005793|Drug|Sodium bicarbonate|Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day
75401231|NCT05005793|Drug|Placebo|Placebo at 0.5 mEq/kg-lean body weight/day
75401232|NCT04982640|Behavioral|Iyengar yoga|60 minute group-classes of Iyengar yoga delivered twice weekly for 12 weeks
75871377|NCT03721523|Diagnostic Test|Platelet Aggregometry|Blood test to test for platelet resistance to aspirin or clopidogrel and to measure effect of acute inflammatory response post event.
75401233|NCT04982640|Behavioral|Standard Exercise|60 minutes, twice weekly for 12 weeks, group-based walking program
75401234|NCT04982640|Behavioral|Nutrition Counseling|One, 30-minute session with registered dietitian
75401235|NCT04970134|Other|Immunohistochemistry (IHC)|VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices
75401236|NCT04970134|Other|Fluorescence In-Situ Hybridization (FISH)|FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)
75401237|NCT04970134|Other|Oncomine Focus Assay Platform with 52 genes|Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices
75401238|NCT04966351|Behavioral|Time-restricted feeding|Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.
75401239|NCT04966351|Behavioral|Circadian Misalignment|Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.
75710566|NCT01035385|Drug|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
75710567|NCT00712712|Drug|Acetaminophen|Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).
75710568|NCT00712712|Drug|Morphine Sulfate|Patient-controlled analgesia (PCA), allowing morphine consumption to be titrated to the patient's needs and thus allowing morphine doses to be adapted to an increase in pain in the patient's post-operative period or a rapid analgesic effect of radiofrequency.
75710569|NCT00712712|Other|Questionnaire administration|"Pain notebook will allow the patient to describe the pain specific to the metastasis concerned, containing information on :~The intensity of the minimum, average and maximum pain of the last 24 months. hours as well as the intensity of the pain of the moment according to a scale 11-point digital,~the background morphine analgesic treatment during the last 24 hours,~the morphine analgesic treatment taken during painful attacks,~the possible undesirable effects of morphine treatment.~the morphinic, non-morphinic and co-antalgic treatment is noted, as well as that the total dose of oral morphine or oral morphine equivalent"
75401240|NCT04955678|Drug|Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes|ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
75401241|NCT04955678|Drug|Placebo|Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
75401242|NCT05175547|Drug|Clevidipine|Blood pressure management with Clevidipine
75401243|NCT04948866|Behavioral|ADRD-PC Program|Included in arm/group descriptions
75401244|NCT04924166|Drug|Placebo|Inactive dose of capsules that appear identical to active dose
75401245|NCT04924166|Drug|Hydrocortisone|Hydrocortisone 180 mg in capsule form
75401246|NCT04921787|Other|Low Intensity|Training and education only, a low-intensity strategy inclusive of an HBOT manual, one-time live training on how to use the HBOT manual, and 7 video conference presentations.
75401247|NCT04921787|Other|High Intensity|Practice facilitation, a high-intensity strategy inclusive of low-intensity training, plus practice facilitation that is based in part on a program planning model. This study is a hybrid implementation effectiveness design, testing an implementation strategy while observing and gathering information on the clinical intervention's impact on relevant outcomes.
75871378|NCT04796922|Drug|parsaclisib|parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
75401248|NCT04919681|Other|Stretch exercises|The intervention comprises of six weeks daily bi-lateral static stretching of the knee flexors. Stretches are performed seated on the ground. The participant sits upright on the floor with one leg straight. The sole of the other foot should be placed on the inside of the outstretched leg. The participant leans slightly forward, trying to touch their toes while maintaining full knee extension. Stretching is performed to the point of discomfort, and each stretch is held for 30-seconds for three repetitions.
75710570|NCT00712712|Procedure|Quality-of-life assessment|Patients' quality of life will be assessed using the quality of life questionnaire EORTC QLQ-C30 at inclusion in the study and at 8 weeks after radiofrequency. ablation.
75710571|NCT00712712|Procedure|Radiofrequency ablation|"Recent technique of thermal destruction of tumors.~This technique consists of inserting an electrode needle into the tumour under X-ray or ultrasound guidance or intraoperatively under laparoscopy for example. This needle carries a current or a light wave depending on the characteristics of the generator to which it is connected (radiofrequency, laser).~Radio frequencies are radiation non-ionising electromagnets. In this context of tissue ablathermia wavelengths ranging from 400kHz to 500kHz."
75710572|NCT00411151|Drug|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
75710573|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
75401249|NCT04908371|Procedure|Selective Trunk Block|"It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL)."
75401250|NCT04908371|Procedure|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)|"It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA."
75401251|NCT04893551|Biological|Tilvestamab|Tilvestamab will be administered as IV infusion.
75401252|NCT04893512|Drug|Orally Suspension of CoV2-OGEN1|CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
75710574|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
75401253|NCT04863313|Dietary Supplement|Probiotic|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
75401254|NCT04863313|Dietary Supplement|Placebo|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
75401255|NCT04838379|Drug|Dexmedetomidine|Ninety patients were randomized to receive ultrasound-guided RSB&tap block After the induction of anesthesia and patient stabilization, the abdomen was sterilized and draped. Then, under complete aseptic conditions, ultrasound-guided Bilateral Rectus Sheath Block & tap block was performed
75401256|NCT04830878|Drug|Methotrexate|Systemic and intraoperative intravitreal injection of methotrexate
75710575|NCT00893698|Procedure|bilateral allotransplantation|bilateral allotransplantation of upper limbs
75401257|NCT04815889|Behavioral|PRIMUS parent training Group|"The parents offered a PRIMUS Group-based parent support program for 5 half days. This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The teachers will be offered a teacher group for half a day together with the parents.~For those families who need more intervention the PLUSS toddler team (from the specialist Healthcare) is established.~The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~Support in the child's everyday environment home / preschool~Targeted Parent Groups: toilet, sleep, food, everyday structure, handle behavioural problems~Web courses"
75401258|NCT04812366|Drug|Apalutamide 60mg Tab|4 tablets by mouth once a day for 24 weeks
75401259|NCT04812366|Drug|Abiraterone Acetate 250mg|4 tablets by mouth on an empty stomach once a day for 16 weeks
75401260|NCT04812366|Drug|Prednisone 5mg Tab|1 tablet by mouth once daily while taking abiraterone acetate
75401261|NCT04812366|Drug|Docetaxel|Infusion every 3 weeks for 6 cycles (each cycle has 3 weeks)
75401262|NCT04812366|Drug|Niraparib 100mg Oral Capsule|3 capsules by mouth once daily for 16 weeks
75710576|NCT04035850|Drug|Vortioxetine Tablets|Strength 5-20 mg
75710577|NCT00699608|Drug|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
75401263|NCT04812366|Drug|Atezolizumab|1200mg infusion every 3 weeks for 6 cycles
75401264|NCT04800107|Biological|Curcumin-phosphatidylcholine|500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl
75401265|NCT04800107|Biological|Placebo capsule|Placebo capsule
75401266|NCT04796051|Device|Neck orthosis - with posterior cervical weight|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull.
75401267|NCT04796051|Other|Deep cervical flexors exercise|The participant will lay down in crook lying position, participant's head relaxed on the flat surface. Each participant will passively tuck in his/her chin without activation of superficial cervical muscles. Participants of this group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
75710578|NCT00893776|Other|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
75710579|NCT00895570|Drug|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
75710580|NCT00895570|Drug|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
75710581|NCT00895648|Drug|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
75710582|NCT00895648|Drug|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
75401268|NCT04786782|Diagnostic Test|PPG-detecting software|Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.
75401269|NCT04786782|Diagnostic Test|LSM and PLT count|Patients whose LSM >15kPa, or PLT count < 150*10^9 should be screened with upper GI endoscopy
75401270|NCT04786574|Drug|Tolvaptan (OPC-41061)|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 2 years.
75401271|NCT04783857|Drug|Progesterone 200 MG Oral Capsule|Progesterone, 200mg, once daily, oral tablet/capsule
75401272|NCT04783857|Other|Placebo Oral Tablet|Placebo oral tablet, once per day
75401273|NCT04769986|Behavioral|Mobile Mindfulness-Relapse Prevention (mMBRP)|Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).
75401274|NCT04769986|Behavioral|Exercise/healthy eating mobile app|Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
75401275|NCT04761159|Drug|Ketamine|Different mixture of ketamin-propofol will apply for anesthesia induction.
75710583|NCT05361512|Device|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
75710584|NCT05361512|Device|epidural waveform analysis|A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
75710585|NCT00893854|Drug|Diclophenac|
75710586|NCT00893854|Drug|Triamcinolone|
75710587|NCT00895726|Drug|APD209|Oral tablets twice per day for 56 days
75710588|NCT00895804|Drug|MDMA|capsule, 1.6 mg/kg body weight, single dose
75710589|NCT00895804|Drug|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
75710590|NCT00895882|Drug|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
75710591|NCT00895882|Drug|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
75710592|NCT00895882|Drug|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
76038092|NCT04794257|Device|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
75710593|NCT00895882|Drug|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
75710594|NCT00895882|Drug|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
75710595|NCT03823404|Drug|COR388 capsule|BID (twice daily)
75710596|NCT03823404|Drug|Placebo capsule|BID
75871379|NCT04796922|Drug|rituximab|rituximab will be administered intravenously on select days as per protocol.
75710597|NCT00706706|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
75710598|NCT00894010|Drug|carbamazepine 400mg|
75710599|NCT00894010|Drug|levetiracetam 1000mg|
75710600|NCT00895960|Drug|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
75710601|NCT00895960|Radiation|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
75871380|NCT04796922|Drug|obinutuzumab|obinutuzumab will be administered intravenously on select days as per protocol.
75871381|NCT03721445|Device|continuous positive airway pressure|Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
75871382|NCT04305678|Drug|Mepolizumab|Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
75871383|NCT03723785|Drug|Insulin icodec|Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
75710602|NCT00895960|Drug|TMZ (Temozolomide)|75 mg/m^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles.
75710603|NCT00894088|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
75871384|NCT05255614|Device|Virtual reality Simulator|LapSim is a device designed by Surgical Science Device & software at Swedan
75401276|NCT04723641|Other|functional training exercises|progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
75710604|NCT00737828|Other|Perioperative care pathway guided by CPX results|"AT > 11ml/min/kg no myocardial ischaemia or Ve/VO2 <35 - Level 1 Ward Care~AT > 11ml/min/kg with myocardial ischaemia or Ve/VO2 >35 - Level 2/3 (ITU) Critical Care Unit~AT <11mls/min/kg - Level 2/3 Critical Care Unit~AT <8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure"
75710605|NCT03818178|Dietary Supplement|Intralipid|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
75710606|NCT03818178|Dietary Supplement|Palm Oil Emulsion|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
75710607|NCT03818178|Other|Saline|All participants will serve as their own controls with a saline infusion study day.
75710608|NCT00896194|Behavioral|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
75871385|NCT05255614|Device|Pelvic trainer:|Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
75871386|NCT05255458|Biological|AK102|Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
76038093|NCT04794179|Device|Naida Link CROS|Individuals 65+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
76038094|NCT05311449|Other|Acupressure|The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
76038095|NCT05311449|Other|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
76038096|NCT05214729|Diagnostic Test|Fast ultrafiltration challenge|"The fast ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The fast ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 1000 ml/h, applied for 15 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
75401277|NCT04716296|Drug|Ketamine|Ketamine will be given for the second stage of the DBS surgery.
75401278|NCT04716296|Drug|Saline|Saline will be given for the second stage of the DBS surgery.
75401279|NCT04704141|Drug|Hormone replacement therapy|A hormone replacement regimen using any medication of a number of standard treatment options
75401280|NCT04682041|Dietary Supplement|Bovine Plasma-Derived Immunoglobulin Concentrate|EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.
75401281|NCT04682041|Other|Standard of care|Standard of care PSMAR protocol for COVID-19 patients.
75401282|NCT04652661|Drug|Dexmedetomidine|30 children will be sedated with 2 μg/kg intranasal DEX.
75401283|NCT04652661|Drug|Midazolam|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
75401284|NCT04650451|Biological|chimeric antigen receptor (CAR) T cell therapy|HER2-targeted dual-switch CAR-T cells
75401285|NCT04637165|Other|This is a non-interventional study|This is a non-interventional study
75401286|NCT04623931|Other|Quality-of-Life Assessment|Ancillary studies
75401287|NCT04623931|Other|Questionnaire Administration|Ancillary studies
75401288|NCT04623931|Radiation|Radiation Therapy|Undergo radiation therapy
75401289|NCT04623931|Drug|Temozolomide|Given PO
75401290|NCT04611542|Behavioral|Fathering In Recovery|Fathering In Recovery (FIR) will be designed to address the unique needs of fathers in treatment for opioid misuse. FIR integrates evidence-based parenting interventions that have well-documented positive outcomes on children, parents, and families, with innovative web-based mobile technology to maximize accessibility, fidelity, and consistency of intervention and support.
75401291|NCT04607330|Other|High protein liquid|After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
75401292|NCT04600323|Drug|Sodium Bicarbonate Tablets|Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
75401293|NCT04600323|Drug|Placebo|Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
75401294|NCT04590781|Biological|XmAb18087|Monoclonal bispecific antibody
75401295|NCT04590781|Drug|XmAb18087 ± Pembrolizumab|XmAb18087 ± Pembrolizumab
75401296|NCT04573751|Drug|Standard therapy|Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
76038097|NCT05214729|Diagnostic Test|Slow ultrafiltration challenge|"The slow ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The slow ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 500 ml/h, applied for 30 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
75401297|NCT04573751|Drug|Epinephrine|Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
75401298|NCT04573751|Drug|Verapamil|Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
75401299|NCT04573751|Drug|Epinephrine + verapamil|Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
75401300|NCT04545437|Other|Admission to ICU|Exposure is admission to an Intensive Care Unit
75401301|NCT04539704|Device|magnet and sham|In same subject some areas will have magnet and others will have sham
75710609|NCT00896194|Behavioral|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
75710610|NCT00921128|Drug|Muscimol|
75401302|NCT04536701|Behavioral|Mood Monitoring and Behavioral Recommendation System|The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions will be provided to family caregivers via text messages on project Smart phones at the right moments aimed to help improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers.
75401303|NCT04526834|Drug|CD30.CAR-T|"Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)"
75401304|NCT04522622|Drug|Teriparatide|20 micrograms
75401305|NCT04522622|Diagnostic Test|DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT|All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 18 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 18 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.
75401306|NCT04522622|Procedure|Bone biopsy|All participants are invited to undergo a bone biopsy after 18 months, but it is not a must to have the procedure done to participate in the study.
75401307|NCT04522622|Diagnostic Test|Cardiac tests|All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.
75710611|NCT04035460|Device|Helmet|The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.
75710612|NCT04035460|Device|High Flow Nasal Oxygen|Large-bore nasal prongs through which oxygen is delivered at high flow rates
75710613|NCT05508776|Drug|LEO 152020|"Film-coated tablet~Route of administration: Orally~50 mg tablets"
76038098|NCT04784741|Other|Conventional static hamstring muscle stretching|Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.
75710614|NCT05508776|Drug|Moxifloxacin|"Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet"
75710615|NCT05508776|Drug|Placebo|"Film-coated tablet~Route of administration: Orally~No active ingredient"
75710616|NCT02565342|Procedure|Interscalene brachial plexus block|
75401308|NCT04522622|Other|Blood and urine samples and physical examination|All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.
75401309|NCT04511962|Other|Tele-Pulmonary rehabilitation|The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.
76038099|NCT04784741|Device|Low amplitude whole body vibration therapy|"Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.~Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle."
75401310|NCT04474483|Drug|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
75401311|NCT04474483|Other|Placebo (Methylcellulose) capsule|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
75401312|NCT04432207|Biological|IMU-201 (administered as PD1-Vaxx) - Regimen 1|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
75401313|NCT04432207|Biological|IMU-201 (administered as PD1-Vaxx) - Regimen 2|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
75401314|NCT04432207|Biological|IMU-201 (administered as PD1-Vaxx) - Regimen 3|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
75401315|NCT04432207|Drug|Atezolizumab|Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
75401316|NCT04432207|Drug|Standard of care chemotherapy|Chemotherapy to be administered according to the prescribing information.
75401317|NCT04425447|Drug|Tumescent local anesthesia|"Surgical disinfection of the area will be performed, skin inﬁltration with 2 mL of 1% lidocaine will be done, and wetting fluid will be used (1000 ml normal saline, 20 ml lidocaine 2%, and 1 mg epinephrine).~Infiltration will be initiated with a 25-gauge needle. The 25-gauge needles cause little discomfort and provide enough local anesthesia to allow painless, more complete infiltration using a 20-gauge spinal needle. After the glandular nipple tissue is made somewhat tumescent, a larger (20-gauge) spinal needle can be more easily passed through the otherwise dense and resistant tissue."
75401318|NCT04425447|Drug|Thoracic paravertebral block|The paravertebral block (PVB) will be performed in the sitting position. Surgical disinfection of the thoracic paravertebral area will be done. A linear high-frequency transducer will be used. The scanning process (longitudinal out-of-plane technique) will be started at 5 to 10 cm lateral to the spinous process to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until transverse processes are identiﬁed as more squared structure and deeper to the ribs. Once the transverse processes will be identiﬁed, skin inﬁltration with 2 mL of 1% lidocaine will be done. A 100-mm, 22 G needle will be inserted out of the plane to contact the transverse process and then walk off the transverse process 1 to 1.5 cm deeper searching for loss of resistance to inject 20 mL (5mL lidocaine 2% and 15 mL bupivacaine 0.25%) at each level of T4.
75871387|NCT05255458|Drug|Placebo|Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
75871388|NCT04441320|Device|Coated metal ureteral stent(CMUS)|Coated metal ureteral stent aims to treat the patients with refractory ureteral stricture, such as radiation induced ureteral stricture. In this study, CMUS is indwelled to observe the efficacy and safety in the treatment of radiation induced ureteral stricture compared with Double-J stent.
76038100|NCT04784741|Device|Biodex Balance System|Pre and post balance assessment by Biodex balance system
76038101|NCT04784741|Procedure|Range of motion of hamstring muscle|Straight Leg Raising to check pre and post Range of Motion by using Goniometer
75871389|NCT04441320|Device|Double-J stent(DJS)|Double-J stent is commonly used for treatment of kinds of ureteral stricture. In this study, DJS is indwelled as a controlled group.
75871390|NCT04478656|Biological|BBV121|BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
76038102|NCT05635279|Other||
75401319|NCT04425447|Drug|Thoracic interfascial plane block|"Total LA injected was 80 mL (10 mL lidocaine 2% and 70 mL bupivacaine 0.25%) The linear probe will be placed below the outer third of the clavicle to detect anatomical landmarks, such as the serratus anterior muscle (SAM), external intercostal muscle (EIM), pectoralis muscles, thoracoacromial artery, and second rib. A test bolus of 1-2 ml of LA will be injected; upon confirmation of diffusion of the test dose between the external intercostal muscles and the SAM, a total of 20 ml of LA will be injected. The needle will be then carefully moved in the direction of the third and fourth ribs while confirming the expansion of the fascial plane.~In the performance of the pecto-intercostal fascial plane block (PIFB), a probe will be placed parallel to the long axis of the sternum at a distance greater than 2 cm from the attachment of the second rib and sternum to identify the pectoralis muscles, EIM, and second rib. A"
75710617|NCT00896350|Drug|Standard Care Chemoradiation|"External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician."
76038103|NCT04802915|Procedure|Intraoperative ERM and ILM staining with their assessment and removal|ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
76038104|NCT05616143|Device|Isthmus Logic|Patient implanted with Isthmus Logic stent for the treatment of peripheral iliac artery disease
76038105|NCT04988191|Drug|Toripalimab|"Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.~Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles."
76038106|NCT04988191|Drug|Bevacizumab|Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.
75401320|NCT04345718|Drug|Extended Release Buprenorphine|XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
75401321|NCT04345718|Drug|Treatment as Usual|Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
75401322|NCT04338581|Biological|AMG 714|anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)
75401323|NCT04338581|Biological|Placebo|Placebo for AMG 714
75401324|NCT04338581|Procedure|nbUVB phototherapy|Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.
75401325|NCT04323787|Other|observational|No Intervention
75401326|NCT04323449|Device|Compare two control methods for a wheelchair-mounted robotic manipulator|Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
76038107|NCT04988191|Drug|Irinotecan|Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.
76038108|NCT05310201|Behavioral|Be Well Care Well|Be Well Care Well addresses teacher well-being through activities implemented in the classroom aimed at reducing teacher stress and improving physical activity. A subset of teachers involved in the program will complete classroom observations and cortisol testing to examine additional measures of stress.
75401327|NCT04298541|Drug|Ga-68- DOTATATE|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
76038109|NCT02595437|Drug|Triferic|
76038110|NCT04784975|Other|No intervention|No intervention
76038111|NCT03069001|Drug|Sofosbuvir-Simeprevir|-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
76038112|NCT03069001|Drug|Sofosbuvir-Ribavirin|-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
76038113|NCT04784195|Behavioral|Observation|Verification of morfology and functionality of neck muscles
75710618|NCT02565264|Other|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
75401328|NCT04298541|Drug|Ga-68-DOTATOC|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
75401329|NCT04272736|Dietary Supplement|Low calorie protein substitute|The evaluated dietary supplement is a lower calorie amino acid based liquid protein substitute designed for patients with PKU.
75401330|NCT04261673|Procedure|Decompressive Craniectomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. The bone flap should not be replaced at the end of the operation. DC has an advantage in controlling brain swelling, but patient is necessary to have another operation of cranioplasty to reconstruct the skull in the future.
75401331|NCT04261673|Procedure|Craniotomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. However, the bone flap must be replaced and fixed with fixation system (plates and screws). The patient will not need an additional operation to rebuild the skull in the future. But undisciplinable brain swelling and increased intracranial pressure may happen in some patients, and additional decompressive craniectomy is recommended in these cases.
75401332|NCT04248868|Device|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
75401333|NCT04248868|Drug|r-tPA|Pulse spray and infusion
75401334|NCT04246138|Procedure|alignment types|types of alignment mechanical versus kinematic of TKA to be studied
75401335|NCT04217993|Drug|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
75401336|NCT04211831|Drug|URO-902|intradetrusor injection
75401337|NCT04211831|Drug|Placebo|intradetrusor injection
75401338|NCT04205656|Biological|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
75401339|NCT04205656|Biological|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
75401340|NCT04205656|Other|Control group (Placebo)|Participants will undergo ACLR surgery with no injection into their knee.
75401341|NCT04169074|Drug|Abemaciclib|Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
75401342|NCT04148105|Drug|Cilostazol 100 MG|The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
75401343|NCT04148105|Other|Placebo|The standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
75401344|NCT04139122|Drug|SJP-0132|SJP-0132 is administered as an eye drop
76038114|NCT03070717|Procedure|Observation & Diagnosis|SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
76038115|NCT04239651|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
76038116|NCT04239651|Other|Internet-Delivered Cognitive Behavior Therapy (iCBT)|Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
76038117|NCT04784273|Procedure|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
75401345|NCT04139122|Drug|Placebo|Placebo is administered as an eye drop
75401346|NCT04121676|Drug|AGEN2373|An Anti-CD137 Monoclonal Antibody
75401347|NCT04121676|Drug|Botensilimab|Anti-CTLA-4 Monoclonal Antibody
75401348|NCT04067518|Biological|SHP674|SHP674: powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m^2: 2500 IU/m^2 every 14 days if BSA <0.6 m^2: 82.5 IU/kg every 14 days
75401349|NCT04033419|Drug|Memantine|"memantine dose~Week 1: 5 mg dose once daily~Week 2: 5 mg dose twice daily~Week 3: 5 mg each morning/10 mg each evening~Week 4 through the end of Chemotherapy: 10 mg dose twice daily~Total duration: 12 - 26 weeks (depending on chemotherapy regimen)"
75401350|NCT04026607|Dietary Supplement|Protein Supplementation|Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
75401351|NCT04019197|Drug|Semaglutide Injectable Product|semaglutide subcutaneous injection
75401352|NCT04019197|Drug|Placebo|placebo injection
75401353|NCT04014283|Dietary Supplement|Selenium supplementation or placebo treatment|Patients from this group will receive selenium supplement to achieve optimal selenium level
75401354|NCT04014283|Other|Diet modification|Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.
76038118|NCT04784273|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
75401355|NCT04014283|Other|Selenium supplementation or placebo treatment and diet modification|In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
75401356|NCT03958006|Device|Cochlear implant|Tumor resection with cochlear implant
75871391|NCT03149926|Other|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
75871392|NCT03543137|Drug|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
75401357|NCT03912233|Drug|VX-121|Tablets for oral administration.
75401358|NCT03912233|Drug|TEZ|TEZ tablet for oral administration.
75871393|NCT03543137|Drug|Nicorette Mini Lozenge|A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
75871394|NCT04478188|Other|Measuring Pressure Volume Loop Pre and Post Device Placement|To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
75871395|NCT03723629|Other|No intercention|No intercention
75401359|NCT03912233|Drug|VX-561|Tablets for oral administration.
75401360|NCT03912233|Drug|TEZ/IVA|Fixed-dose combination tablets for oral administration.
75401361|NCT03912233|Drug|IVA|Tablets for oral administration.
75401362|NCT03912233|Drug|Placebo|Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
75401363|NCT03888105|Drug|Odronextamab|Administered by intravenous (IV) infusion
75401364|NCT03879668|Device|eIPOS|Electronic version of IPOS
75401365|NCT03842865|Biological|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
76038119|NCT04793789|Other|monofocal toric lens|not applicable as patients are already implanted with the monofocal toric lens
75401366|NCT03834870|Behavioral|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
75549672|NCT00336102|Procedure|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
75549673|NCT00453791|Drug|GW805858|GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
75401367|NCT03781817|Drug|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
75401368|NCT03781817|Drug|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
75401369|NCT03729648|Behavioral|Expressive Arts Therapy|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
75401370|NCT03689868|Behavioral|Virtual Reality|Virtual Reality headset with calming scenery
75401371|NCT03636451|Drug|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
75401372|NCT03636451|Drug|20cc 1% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
75401373|NCT03576989|Dietary Supplement|EPA+DHA|EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil
75401374|NCT03576989|Other|placebo|placebo contains mineral oil
75401375|NCT03546062|Other|patients treated by HTx|From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
75401376|NCT03539952|Drug|Penicillamine (D1-W12)|Penicillamine during baseline period (D1-W12)
75401377|NCT03539952|Drug|TETA 4HCL (W12-60)|TETA 4HCL during post randomisation and 1st extension period (W12-W60)
75401378|NCT03539952|Drug|Penicillamine (W12-W60)|Penicillamine during rondomisation and 1st extension period period (W12-W60)
75401379|NCT03539952|Drug|TETA 4HCL (60-<W108)|TETA 4HCL during 2nd extension period (W60-<W108)
75401380|NCT03479697|Device|HIRREM|Technology
75401381|NCT03479697|Other|Continued Current Care|Continue their current clinical care.
75710619|NCT00896428|Drug|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
75710620|NCT00896428|Drug|Placebo.|1 tablet morning and evening for 12 months
75401384|NCT03355365|Biological|Intrathecal MSC-NP injection|MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.
76038120|NCT05163171|Other|questionnaire|questionnaire for conjugal violence prevalence
76038121|NCT05353621|Behavioral|VAS reported Stress|VAS reported Stress measurement during simulation
76038122|NCT04426643|Biological|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space
75401385|NCT03355365|Other|Intrathecal saline injection|Placebo
75401386|NCT03332550|Procedure|Laparoscopic lavage|Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
75549674|NCT00453791|Drug|Placebo|Placebo MDI will be given to the subjects.
75549675|NCT00336141|Drug|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
75549676|NCT00453830|Procedure|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
75549677|NCT00336180|Behavioral|HealthWise South Africa curriculum|18 classroom lessons
75401387|NCT03332550|Procedure|Colon resection|Operation with colon resection for perforated diverticulitis Hinchey 4
75401388|NCT03278691|Drug|Saline|1 ml saline IV Q6H
75401389|NCT03278691|Drug|Ketorolac|15 mg (15 mg/ml) IV Q6H
76038123|NCT04426643|Other|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
75401390|NCT03253991|Device|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
75710621|NCT02962050|Procedure|Videofluoroscopic Swallowing Study (VFSS)|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
75401391|NCT03044158|Device|GeneXpert I|Onsite molecular testing with GeneXpert I as a replacement for microscopy
75401392|NCT03044158|Behavioral|Process re-design|Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
75401393|NCT03044158|Other|Performance Feedback|Feedback of TB diagnostic evaluation quality indicators to health center staff
75401394|NCT02948569|Drug|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
75401395|NCT02929108|Behavioral|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
75401396|NCT02929108|Behavioral|ACCESS|"Intervention will have two components.~Participants will be enrolled in a Secret Facebook group for social support and education~Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
75401397|NCT02880631|Device|BAROSTIM NEO™ System|
75401398|NCT02880618|Device|Barostim Neo™ System|
76038124|NCT03070405|Drug|Tenofovir disoproxil fumarate 300mg|Single oral dose on the first day of each period
76038125|NCT03070405|Drug|Para-aminosalicylic acid Ca granule 5.28 g|Twice daily oral administration from the first day of each period to the seventh dose
75401399|NCT02876042|Device|BAROSTIM NEO™ System|Implantation of the BAROSTIM NEO™ System
75401400|NCT02726763|Device|Transcranial Direct Current Stimulation (tDCS)|
75401401|NCT02726763|Behavioral|Questionnaires|
75401402|NCT02705846|Other|Observation of treatment outcomes via Questionnaire|
75401403|NCT02661295|Drug|Ferric Citrate|Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and < 50% and ferritin ≥ 200 and < 500 ng/ml after a 2 week wash out period.
75710622|NCT02962050|Device|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
76038126|NCT04238949|Other|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with new onset type 1 diabetes for 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
76038127|NCT03068065|Drug|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
76038128|NCT03068065|Drug|Metformin|the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
76038129|NCT03068065|Drug|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
76038130|NCT05109117|Drug|ChapStick Active Performance Unscented|Sunscreen lip balm.
75401404|NCT02657265|Device|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
75401405|NCT02657265|Device|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
75401406|NCT02653716|Behavioral|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
75401407|NCT02653716|Behavioral|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
75401408|NCT02621489|Drug|Bydureon|2 mg Once Weekly
75401409|NCT02621489|Drug|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
75401410|NCT02621489|Drug|Metformin|Metformin 1g BID
75401411|NCT02596880|Drug|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
75401412|NCT02596880|Drug|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
75401413|NCT02596880|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
75549678|NCT02273648|Device|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
75549679|NCT00336219|Drug|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
75549680|NCT04698239|Device|LASER MILESMAN 445 NM|Laser application
75549681|NCT00453869|Other|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
75549682|NCT00336297|Procedure|Woman Abuse Screening Tool|
75549683|NCT00336297|Procedure|Partner Violence Screen|
75549684|NCT00336297|Procedure|Computerized screening|
75710623|NCT02962050|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
76038131|NCT04988347|Combination Product|Spirulina platensis|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
76038132|NCT04988347|Other|Placebo comparator|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
75401414|NCT02553525|Procedure|Therapeutic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
75401415|NCT02553525|Procedure|Symptogenic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
75401416|NCT02522520|Behavioral|Pedometer intervention|12 weeks physical activity intervention (supervised/non-supervised)
75401417|NCT02522520|Behavioral|Pedometer + hospital based intervention|12 weeks physical activity intervention (supervised/non-supervised)
75401418|NCT02522520|Device|Omron Walking Style pro. 20|
75401419|NCT02474368|Radiation|Intensity Modulated Radiation Therapy (IMRT)|
75401420|NCT02474368|Drug|Cisplatin|
75401421|NCT02474368|Radiation|Stereotactic Body Radiotherapy (SBRT)|
75401422|NCT02412748|Behavioral|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
76038133|NCT05473169|Device|Videofluoroscopy|Swallowing assessment
76038134|NCT04452097|Biological|Human umbilical cord mesenchymal stem cells + best supportive care|hUC-MSC product will be administered intravenously in addition to the standard of care treatment.
76038135|NCT04452097|Other|Placebo control + best supportive care|Placebo control will be administered intravenously in addition to the standard of care treatment.
75401423|NCT02412748|Behavioral|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
75401424|NCT02305095|Drug|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
75401425|NCT02272946|Drug|Canakinumab|150mg Canakinumab received subcutaneously
75401426|NCT02272946|Drug|Placebo|150mg Placebo received subcutaneously
75401427|NCT02115698|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
75401428|NCT02115698|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
75401429|NCT02115698|Dietary Supplement|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
75401430|NCT02115698|Dietary Supplement|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
75401431|NCT02115698|Dietary Supplement|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
75401432|NCT02040714|Procedure|Osteotomy + Long Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
75401433|NCT02040714|Procedure|Osteotomy + Short Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
75401434|NCT02040714|Procedure|Nonoperative Observation|Group will not undergo any surgical or invasive procedures during course of treatment.
75549685|NCT00336297|Procedure|Face to face screening|
76038136|NCT05213091|Other|Otago Exercise Programme|The first four weeks will be Otago Exercise Programme training and practice. For the next weeks, there will be institution visits and telephone interviews. Individuals will be given an Otago Exercise Programme training booklet, exercise chart and exercise diary to better manage this process. The research will be conducted in small groups (average 6-8).
76038137|NCT04802369|Diagnostic Test|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.
76038138|NCT04988269|Diagnostic Test|Blood sampling|Assessment of circulating levels of plasma ACTH, plasma aldosterone and serum interleukin -6 levels at day 1
76038139|NCT04988269|Diagnostic Test|Saliva sampling|Assessment of diurnal variation of cortisol and DHEA levels in the saliva at 4 different time points during the day (0.800, 12.00, 18.00, 22.00) at day 2.
76038140|NCT05109039|Dietary Supplement|Creatine|Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
75401435|NCT02040714|Procedure|Multiple Epiphyseal Drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
75401436|NCT01995344|Drug|Cyclophosphamide|
75401437|NCT01995344|Drug|Fludarabine|
75401438|NCT01995344|Genetic|Tumour Infiltrating Lymphocytes|
75401439|NCT01995344|Drug|Interleukin-2|
75401440|NCT01923662|Device|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
75401441|NCT01845688|Drug|Losartan Tablets & QingReMoShen Granule|
75401442|NCT01845688|Drug|Losartan Tablets & Placebo Granule|
75401443|NCT01844726|Drug|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
75401444|NCT01844726|Drug|Placebo|Single injection of placebo (saline)
75401445|NCT01679132|Device|BAROSTIM NEO System and Medical Management|"Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators."
75401446|NCT01591291|Drug|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
75710624|NCT02962050|Drug|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
75710625|NCT02962050|Device|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
76038141|NCT05109039|Dietary Supplement|Placebo|Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
75549686|NCT00336297|Procedure|Written screening on forms|
75401447|NCT01591291|Drug|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
75401448|NCT01471834|Device|BAROSTIM NEO System|
75401449|NCT01471834|Drug|Medical Management|
75401450|NCT01093300|Device|Paclitaxel-eluting balloon catheter|
75401451|NCT01093300|Device|Everolimus-eluting stent|
75401452|NCT00852124|Biological|VSL#3|VSL#3 2 times daily
75401453|NCT00852124|Biological|VSL#3 or placebo|1 packet 2 x daily of placebo
76038142|NCT05211921|Device|Multi-Gyn ActiGel Plus|vaginal gel
76038143|NCT04987801|Other|Drug Toxicity|Patients who took over dose of Drugs
75401454|NCT01053078|Drug|Naltrexone|1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
75401455|NCT01053078|Other|Placebo|1 month treatment; placebo tablet once daily for 28 days
75401456|NCT01053156|Drug|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
75401457|NCT01053156|Drug|Placebo|Placebo will be given daily for 3 months.
75401458|NCT01053312|Drug|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of [18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels (MBq).
75401459|NCT01054404|Drug|Furosemide|Furosemide 0.3 mg/kg
75401460|NCT01054404|Drug|Placebo|Placebo (up to 5mL)
75401461|NCT01055184|Biological|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
75401462|NCT01056198|Drug|Santyl|2 mm Santyl applied once daily.
75401463|NCT01056198|Procedure|Control|Daily gauze and optional sharp debridement
75401464|NCT01058070|Device|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
75401465|NCT01060020|Drug|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
75401466|NCT01060098|Drug|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
75401467|NCT01061034|Drug|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
75401468|NCT01064076|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
75401469|NCT01065480|Behavioral|Live teleconference supervision|Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
75401470|NCT01065480|Behavioral|Taped Review Supervision|Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
75401471|NCT01065558|Drug|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
75549687|NCT00453908|Drug|Alfuzosin|
76038144|NCT05161611|Drug|Zinc sulfate|10 mg of oral zinc sulfate will be given to neonates per day
75401472|NCT01065714|Drug|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
75710626|NCT02962050|Other|Eating Assessment Tool 10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
75710627|NCT02962050|Other|The Center for Neurologic Study Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
75710628|NCT00410605|Biological|bevacizumab|Given IV
75871396|NCT02347462|Device|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
76038145|NCT05161611|Other|Placebo|10 mg of normal saline will be given to neonates per day
76038146|NCT05161611|Other|Phototherapy|Neonates will be put under phototherapy
75710629|NCT00410605|Drug|lenalidomide|Given orally
76038147|NCT05634655|Other|no interventions between two groups|no interventions between two groups
75710630|NCT00410605|Drug|dexamethasone|Given orally
75710631|NCT00742638|Drug|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
75710632|NCT00742638|Drug|Sodium valproate|Sodium valproate tablet 200 mg
76038148|NCT04802525|Other|Moderate-intensity aerobic exercise training|The first group has received Moderate-intensity aerobic exercise training without dietary control, the second group has received a low-fat diet program without exercise intervention, and the third group has received Moderate-intensity aerobic exercise training plus a low-fat diet program for 10 consecutive weeks
76038149|NCT03660475|Drug|Naltrexone|naltrexone formulated as ophthalmic solution
76038150|NCT03660475|Drug|Placebos|Placebo ophthalmic solution
76038151|NCT04802213|Other|Rehabilitation exercise|Rehabilitation exercise use the methods that suggested by previous studies including finger wall climbing, pendulum exercise, and arms lifting.
76038152|NCT04802213|Device|joint mobilization device treatment|The joint mobilization treatment used the mobilization device that developed in this research.It is a device developed by using the design of the vibration force generated by the vibration mechanism and the technologies to simulate the mobilization of the shoulder joint.When the subject uses the device, first sit on a seat that can be adjusted according to the user's body shape and buckle the shoulder fixation device. Then use the specially designed shoulder movement setting mechanism of the device to set the user's shoulder movement and movement angle.The next step is to set the direction and magnitude of the vibration force applied by the device to the shoulder joint in accordance with the joint mobilization technique (posterior, anterior, and inferior) that the therapist or user intends to perform to achieve the effect of simulating joint mobilization and increasing joint mobility.
75401473|NCT01065714|Drug|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
75549688|NCT00336336|Drug|n-3 PUFA|1 g die per os
75710633|NCT00418717|Drug|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
75710634|NCT01042249|Other|Pelvic Floor Muscle training|12 week training program including home exercises
75710635|NCT00572572|Drug|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
75710636|NCT00572572|Drug|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
75710637|NCT00896662|Other|immunologic technique|immunologic technique
75710638|NCT00896662|Other|laboratory biomarker analysis|laboratory biomarker analysis
75871397|NCT02347462|Other|Standard care|Standard care according to the hospital severe asthma protocol
75549689|NCT00336336|Drug|Rosuvastatin|10 mg die per os
75549690|NCT00336336|Drug|Placebo|1 gram c. per os
75549691|NCT00336336|Drug|Placebo|10 mg c. per os
75710639|NCT00896662|Other|pharmacological study|pharmacological study
75710640|NCT00896740|Genetic|microarray analysis|
75710641|NCT00896740|Procedure|biopsy|
75710642|NCT00896818|Genetic|DNA analysis|
75710643|NCT00896818|Genetic|genetic linkage analysis|
75710644|NCT00896818|Genetic|loss of heterozygosity analysis|
75710645|NCT00896818|Genetic|polymorphism analysis|
75871398|NCT02895347|Behavioral|Surgical Simulation Practice Modules|The surgical simulation practice modules simulate surgical settings for suturing.
75871399|NCT05763966|Other|No intervention|Observational study where participants are followed over time
75871400|NCT02347306|Other|Telephone interview|
75401474|NCT01066026|Procedure|hyaluronic acid with metallic cannula or standard needle.|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
75401475|NCT01066026|Drug|Hyaluronic acid injected with the new tool.|hyaluronic acid with metallic cannula.
75401476|NCT01072032|Device|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
75710646|NCT00896818|Other|laboratory biomarker analysis|
75710647|NCT00896818|Other|medical chart review|
76038153|NCT04802213|Device|laser acupuncture device treatment|The laser acupuncture treatment use the laser acupuncture device that developed in this research. A gallium-aluminium-arsenide (GaAlAs, infrared laser) continuous wave diode laser device with a wavelength of 850nm (invisible), a power output of 100 mW, and a spot area of 0.07cm2 was used for laser acupuncture.When performing laser acupuncture treatment, the laser emitted by the device is irradiated on the selected acupuncture points .The acupuncture points (GB 21, LI 4, LI 11, LI 14, LI15, LI 16, SI 9, SI 10, SI 11, TE 14, and TE 15) were determined according to the literature regarding acupuncture application in shoulder pain based on traditional chinese acupuncture.
76038154|NCT05211609|Diagnostic Test|Plasmatic 3-O-Methyldopa dosage|Plasmatic 3-O-Methyldopa dosage
75549692|NCT00336375|Drug|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
75549693|NCT00336414|Drug|cyclophosphamide-prednisone-azathioprine|
75549694|NCT00336453|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
75549695|NCT00336453|Biological|Influenza Vaccination|0.25mL dose for intramuscular injection
75549696|NCT00336531|Drug|itraconazole|2.5 mg/kg twice daily for the first two days --> once daily
75549697|NCT00453947|Device|CPAP and Non Invasive Ventilation|
75549698|NCT00454064|Behavioral|cognitive-behavioral treatment|
75549699|NCT00322062|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
75549700|NCT00322062|Drug|Sodium Phosphate Solution|1 x 45ml solution, BID
75549701|NCT00454103|Drug|123I-Iodometomidate|
75549702|NCT00336648|Drug|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
75549703|NCT00336648|Drug|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
75710648|NCT00896818|Other|questionnaire administration|
76038155|NCT05615987|Drug|Onabotulinumtoxina for Injection|200iu/2ml in both groups
75549704|NCT00336648|Procedure|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
75549705|NCT03274817|Drug|Escitalopram Pill|Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
75549706|NCT03274817|Drug|Venlafaxine Pill|Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
75710649|NCT00896896|Other|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
75710650|NCT00896896|Other|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
75710651|NCT00896974|Other|Laboratory Biomarker Analysis|Correlative studies
75710652|NCT00896974|Other|Pharmacological Study|Correlative studies
75710653|NCT00896974|Drug|Retinoid 9cUAB30|Given orally
75710654|NCT00418561|Biological|rhASA - Dose Level 1|Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks
75710655|NCT00418561|Biological|rhASA - Dose Level 2|Intravenous infusion 100 U/kg every other week for 26 weeks
75710656|NCT00418561|Biological|rhASA - Dose Level 3|Intravenous infusion 200 U/kg every other week for 26 weeks
75710657|NCT00897052|Genetic|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
75710658|NCT00897052|Other|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
75401477|NCT01072188|Device|Arginine/Calcium Carbonate|One time treatment
75401478|NCT01072188|Device|Nupro - Fluoride Free|Brush twice daily
75401479|NCT01072656|Device|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
75401480|NCT01076244|Procedure|Minimally Invasive Lumbar Decompression|This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
75401481|NCT01083654|Behavioral|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
75401482|NCT01083654|Behavioral|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
75710659|NCT00897130|Drug|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
75710660|NCT00894400|Procedure|catheter ablation|catheter ablation using radiofrequency energy
75710661|NCT00398047|Drug|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
75549707|NCT03274817|Drug|Placebo Oral Tablet|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
75549708|NCT00322140|Drug|CDDO|
75549709|NCT00230087|Procedure|blood donation|phlebotomy until iron depleted
75710662|NCT04016584|Behavioral|Diabetes Pueblo|These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
75401483|NCT01083732|Drug|dabigatran etexilate|Experimental dose chosen based on age and weight
75401484|NCT01084278|Drug|Colchicine|Colchicine tablets
75710663|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
75401485|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
75401486|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
75401487|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
75401488|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
75401489|NCT01085760|Drug|Vancomycin|Comparison of different drug doses
75401490|NCT01086228|Device|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
75549710|NCT00230204|Procedure|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
75549711|NCT00230321|Drug|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
75710664|NCT00631371|Drug|Temsirolimus|Temsirolimus 25 mg IV weekly
75549712|NCT02959632|Behavioral|Animal Assisted Therapy|Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
75710665|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
75710666|NCT00631371|Drug|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
75710667|NCT00897208|Other|high performance liquid chromatography|
75710668|NCT00897208|Other|laboratory biomarker analysis|
75549713|NCT00230399|Drug|Celecoxib|
75549714|NCT00230399|Drug|Capecitabine|
75549715|NCT00230399|Drug|Irinotecan|
75710669|NCT00897208|Other|mass spectrometry|
75549716|NCT00336765|Drug|XL647|Tablets supplied in 50-mg strength administered orally daily
75710670|NCT00897208|Other|medical chart review|
75710671|NCT00897208|Procedure|evaluation of cancer risk factors|
75710672|NCT00409747|Drug|Minocycline|
75710673|NCT04016740|Drug|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
75710674|NCT04016740|Drug|Ketamine|Intraoperative infusion
75710675|NCT04016740|Drug|Remifentanil|Intraoperative infusion
75710676|NCT04016740|Drug|Dexmedetomidine|Intraoperative infusion
75710677|NCT04016740|Drug|Rocuronium|Intraoperative intermittent bolus
75710678|NCT04016740|Drug|Propofol|Intraoperative infusion
75710679|NCT04016740|Drug|Sevoflurane|Intraoperative inhaled as needed
75549717|NCT00230438|Procedure|External Beam Radiotherapy|
75710680|NCT04016740|Drug|Dexmedetomidine|Post-operative infusion
75401491|NCT01086852|Biological|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
75401492|NCT01088646|Device|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.~Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.~The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
75710681|NCT04016740|Drug|Propofol|Post-operative infusion
75710682|NCT04016740|Device|EEG monitoring|Perioperative monitoring
75549718|NCT00336843|Drug|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
75549719|NCT00230477|Drug|Hepsera|
75549720|NCT00230477|Drug|Hepsera and lamivudine|
75549721|NCT00230516|Drug|Nexium|
75549722|NCT00230516|Drug|Prevacid|
75549723|NCT00336882|Drug|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
75549724|NCT00336882|Drug|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
75710683|NCT01035541|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
75710684|NCT02540512|Procedure|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
76038156|NCT05478135|Device|NAVIFY Oncology Hub|NAVIFY Oncology Hub is a platform that aggregates and organizes disparate data into an intuitive, longitudinal view of the patient's cancer care journey. The platform is designed to optimize and support oncology workflows and decision-making by providing quick access to the most relevant data in one place, so that providers can make decisions more efficiently and collaborate more seamlessly.
76038157|NCT03069157|Procedure|lung recruitment maneuver|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
75710685|NCT02540512|Device|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
75710686|NCT02540512|Procedure|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
75710687|NCT02540512|Drug|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
75710688|NCT02540512|Drug|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
75401493|NCT01090752|Drug|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
75401494|NCT01090752|Drug|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
75710689|NCT01039909|Drug|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
75401495|NCT01093014|Behavioral|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
75401496|NCT01093014|Behavioral|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
75401497|NCT01093014|Behavioral|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
75401498|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
75549725|NCT00306332|Procedure|T-cell and B-cell depletion|
75549726|NCT00336921|Drug|Alfuzosin|Once daily
75549727|NCT00336921|Drug|Placebo|Once daily
75549728|NCT00306371|Device|1450nm diode laser|
75549729|NCT00336960|Drug|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
75710690|NCT01039909|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
76038158|NCT05107557|Biological|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
75710691|NCT00825903|Behavioral|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
75710692|NCT03742375|Diagnostic Test|HPV genotyping|Quantitative HPV genotyping on anal swab
76038159|NCT02594735|Drug|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight < 50 KG).
76038160|NCT03645499|Drug|Topical TA-102 A|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
76038161|NCT03645499|Drug|Topical TA-102 B|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
75871401|NCT02343484|Drug|Gelified ethanol combined to pulsed radiofrequency|Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
76038162|NCT03645499|Drug|Topical TA-102 C|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
76038163|NCT03645499|Drug|Topical TA-102 D|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
75549730|NCT00336960|Drug|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
75549731|NCT00336960|Procedure|conventional surgery|4-10 weeks after completion of chemoradiotherapy
75549732|NCT00336960|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
75549733|NCT00336960|Procedure|tumor biopsy|at baseline and then at the time of surgical resection
75549734|NCT00336960|Other|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
75549735|NCT00306410|Drug|colecalciferol|
75549736|NCT00340080|Drug|Abacavir|
75549737|NCT00418535|Drug|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
75401499|NCT01093794|Drug|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
75401500|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
75401501|NCT01093794|Drug|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
75401502|NCT01094106|Drug|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
75401503|NCT01094106|Drug|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
75549738|NCT00337038|Drug|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
75549739|NCT02960243|Device|Deep Brain Stimulation|"DBS System Medtronic~DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~These settings will be used to evaluate effects of voice tremor as well"
75549740|NCT00418613|Drug|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
75710693|NCT00894478|Procedure|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
75401504|NCT01094574|Drug|Alfentanil|An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.
75401505|NCT01094574|Drug|Propranolol|An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.
75401506|NCT01094574|Drug|Placebo|An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
75401507|NCT01095510|Biological|CINRYZE|
75401508|NCT01096290|Drug|lubiprostone|24mcg BID, capsule, oral 30days
75401509|NCT01096290|Drug|Matched placebo|Twice daily for 30days, oral
75401510|NCT01096680|Drug|SPD489 20 mg|Single oral dose of 20 mg
75871402|NCT02343484|Drug|Gelified ethanol|Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
75549741|NCT00418613|Drug|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
76038164|NCT03645499|Drug|Topical TA-102 E|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
76038165|NCT04793243|Dietary Supplement|Vitamin D3|Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
76038166|NCT05158569|Other|Slow breathing exercise group|The patient will be first asked to close one nostril with a thumb and slowly breathe in completely through the other for 6 seconds. This nostril will be then closed and the patient will exhale through the other nostril over a period of 6 seconds. These steps complete one breathing cycle. An attempt will be made to keep the breathing rate is about 5-6 breaths per minute. Such alternate nostril breathing cycles will be repeated continuously for a period of about 15 minutes (3 sets of 5 minutes) in one sitting.
75401511|NCT01096680|Drug|SPD489 50 mg|Single oral dose of 50 mg
75401512|NCT01096680|Drug|SPD489 70 mg|Single oral dose of 70 mg
75401513|NCT01096680|Drug|Armodafinil|Single oral dose of 250 mg
75401514|NCT01096680|Drug|Placebo|Single oral dose
75401515|NCT01096992|Drug|Bendamustine|"Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)"
75401516|NCT01096992|Drug|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
75401517|NCT01096992|Drug|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
75401518|NCT01097304|Drug|Ursodiol|Given PO
75549742|NCT04715841|Other|gait assessment|gait assessment were done using 3DMA system
75549743|NCT02960711|Drug|Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]|
75401519|NCT01097304|Other|Laboratory Biomarker Analysis|Correlative studies
75401520|NCT01097460|Drug|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
75401521|NCT01098006|Other|Blood withdrawal|A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
75401522|NCT01098318|Dietary Supplement|Herbal extract|340-1,360 mg daily
75401523|NCT01098318|Drug|Sertraline|50-200 mg daily
75401524|NCT01098318|Other|Lactose monohydrate|1-4 capsules daily
75401525|NCT01100112|Drug|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
75401526|NCT01100268|Drug|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
75710694|NCT00894478|Procedure|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
75401527|NCT01101750|Biological|Quadrivalent HPV for types 6, 11, 16 and 18|"Per standard of care, Gardasil 0.5ml IM injection on day one, month 2, and month 6.~Serum samples on day one, month 3 and month 7."
75401528|NCT01102218|Drug|Erythropoietin|Standard of Care
75401529|NCT01102218|Drug|Erythropoietin|Standard of Care
75401530|NCT01102218|Drug|Pentoxifylline|400 mg qd po for 6 months
75401531|NCT01102764|Behavioral|Telemedicine|Prolonged Exposure (PE) therapy provided at patients house via telemedicine
75401532|NCT01102764|Behavioral|In Person|PE therapy delivered in person at the VAMC
75401533|NCT01103934|Drug|Vitamin D3|4000 IU once daily
75401534|NCT01103934|Drug|Placebo|Placebo taken once daily
75401535|NCT01103934|Drug|Fluticasone Propionate|200 mcg daily, intranasal
75401536|NCT01104090|Device|C-MAC direct laryngoscopy|Patients will be intubated using C-MAC with direct laryngoscopy.
75710695|NCT00897442|Other|Laboratory Biomarker Analysis|Correlative studies
75871403|NCT03630276|Diagnostic Test|Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP|Lab
75871404|NCT03539549|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
75401537|NCT01104090|Device|C-MAC Indirect laryngoscopy|Patients will be intubated using C-MAC with indirect laryngoscopy.
75401538|NCT01104402|Device|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
75401539|NCT01105650|Drug|Fludarabine|Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).
75401540|NCT01105650|Drug|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
75401541|NCT01105650|Drug|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
75401542|NCT01105650|Biological|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10^7 cells/kg will be given.
75401543|NCT01105650|Drug|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m^2 3 times per week for 6 doses).
75549744|NCT02960711|Drug|Ludipress, mg stereate, micronized hydrated silica, talcum|Tablet
75401544|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
75710696|NCT04017676|Other|Supervision assissted by measures|In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
75710697|NCT04035772|Other|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
75710698|NCT00897520|Biological|recombinant interferon alfa|
75401545|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
75401546|NCT01105650|Drug|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m^2 3 times per week for 6 doses).
75401547|NCT01106040|Drug|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
75401548|NCT01110252|Drug|Stem cells stimulation|Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
75401549|NCT01110252|Procedure|stem cells collection|pullout of 200ml of bone marrow through the puncture of the iliac crest
75401550|NCT01110252|Genetic|stem cells infusion|slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
75401551|NCT01110876|Drug|Vorinostat|"Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I."
75401552|NCT01110876|Drug|Erlotinib|"Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I."
75401553|NCT01110876|Drug|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
75710699|NCT00897520|Genetic|proteomic profiling|
75710700|NCT00897520|Other|immunoenzyme technique|
75710701|NCT00897520|Other|laboratory biomarker analysis|
75710702|NCT00894634|Drug|Brompheniramine maleate|
75401554|NCT01112358|Drug|r-FSH|r-FSH will be administered as specified in the arm description.
75710703|NCT02540278|Behavioral|Positive Prevention PLUS|PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
75710704|NCT00630747|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
75710705|NCT00894712|Other|Sulforaphane-containing broccoli sprout extracts (active agent)|Topical application, prepared with acetone, 280 nml daily, 3 times a week.
75710706|NCT00894712|Device|Vehicle (inactive control)|Subjects will have measurements of skin erythema using a device called a chromometer
75401555|NCT01112358|Drug|r-hLH|r-hLH will be administered as specified in the arm description.
75401556|NCT01112358|Drug|Analogous GnRH antagonist|Analogous GnRH antagonist will be administered as specified in the arm description.
75710707|NCT00897754|Genetic|gene expression analysis|
75710708|NCT00897754|Genetic|protein expression analysis|
75710709|NCT00897754|Genetic|reverse transcriptase-polymerase chain reaction|
75401557|NCT01112358|Drug|r-hCG|r-hCG will be administered as specified in the arm description.
75401558|NCT01112358|Drug|Progesterone|Progesterone will be administered as specified in the arm description.
75710710|NCT00897754|Other|immunoenzyme technique|
75710711|NCT00897754|Other|immunohistochemistry staining method|
75710712|NCT00897754|Other|immunologic technique|
75710713|NCT02540902|Device|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
75401559|NCT01112670|Drug|Sitagliptin|sitagliptin 100 mg x 1 dose
75401560|NCT01112670|Drug|atorvastatin|atorvastatin 40 mg x 5 doses
75710714|NCT05278078|Other|psychological support|psychological support will be given to the patients in the experimental group.
75710715|NCT05278078|Other|nutritional education|nutritional education will be given to the patients in the experimental group.
75710716|NCT05278078|Other|psychological support and nutritional education|psychological support and nutritional education will be given to the patients in the experimental group.
75710717|NCT05278078|Other|no intervation|No intervention will be applied to the control group
75710718|NCT00823485|Procedure|fibrinolysis in situ|intraventricular injection of actilyse
75401561|NCT01114620|Biological|Arepanrix™|Intramuscular administration, one dose
75401562|NCT01115556|Drug|Ranibizumab|2.0 mg
75401563|NCT01115556|Drug|Ranibizumab|0.5 mg
75401564|NCT01116024|Device|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
75401565|NCT01116102|Drug|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
75401566|NCT01118988|Behavioral|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
75401567|NCT01119222|Drug|Gabapentin|Capsule, single 1200mg dose
75401568|NCT01119222|Drug|Diphenhydramine|Tablet, single 50mg dose
75401569|NCT01119222|Drug|Morphine|IV, single 10mg dose
75401570|NCT01119222|Drug|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
75401571|NCT01119456|Biological|IMC-RON8|"5 milligrams per kilogram (mg/kg) intravenously (IV)~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 1"
75710719|NCT00823485|Procedure|drainage|drainage
75401572|NCT01119456|Biological|IMC-RON8|"10 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 2"
75401573|NCT01119456|Biological|IMC-RON8|"15 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 3"
75401574|NCT01119456|Biological|IMC-RON8|"15 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 4"
75401575|NCT01119456|Biological|IMC-RON8|"20 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 5"
75401576|NCT01119456|Biological|IMC-RON8|"25 or 30 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 6"
75710720|NCT00897832|Other|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
75710721|NCT02550405|Behavioral|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
75871405|NCT04173000|Other|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
76038167|NCT05158569|Other|Diaphragmatic breathing exercise group|"Patients would be instructed to Sit or lie down in a comfortable place and put their hands on their belly.~Relax the muscles in their neck and shoulders. Breathe in slowly through the nose, keeping their mouth closed. Feel the lungs fill with air and inflate like a balloon while their belly moves outward. Such breathing cycles will be repeated continuously for a period of about 15 (3 sets of 5 minutes) minutes in one sitting."
75401577|NCT01119456|Biological|IMC-RON8|"30, 35, or 40 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 7"
75401578|NCT01119456|Biological|IMC-RON8|"20 or 25 mg/kg IV~Once every week for each 4-week treatment cycle, for a total of four doses per cycle.~Cohort 8"
75401579|NCT01120236|Drug|Bicalutamide|Given PO
75401580|NCT01120236|Biological|Cixutumumab|Given IV
75401581|NCT01120236|Drug|Goserelin Acetate|Given SC
75401582|NCT01120236|Other|Laboratory Biomarker Analysis|Correlative studies
76038168|NCT05472467|Drug|Camrelizumab|200mg IV Q3W. Every three weeks is a cycle
76038169|NCT05472467|Radiation|stereotactic body radiation therapy|stereotactic body radiation therapy for Oligometastases 35Gy/5f(7.0Gy/f,5f per week)
75401583|NCT01120236|Drug|Leuprolide Acetate|Given IM
75401584|NCT01120236|Other|Pharmacological Study|Correlative studies
75401585|NCT01120704|Drug|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes >10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
75549745|NCT00306449|Behavioral|Small group seminar-based educational intervention|
75549746|NCT00306566|Biological|CYT004-MelQbG10|
75549747|NCT00337116|Drug|iso sorbide dinitrate iv bolus or s/l|
75549748|NCT00306605|Behavioral|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
75549749|NCT00340314|Procedure|Circumferential Pulmonary Vein Ablation|
75549750|NCT00340314|Drug|Antiarrhythmic Drug Therapy|
75549751|NCT00306644|Drug|Rosiglitazone|study drug
75549752|NCT00337233|Procedure|yoga therapy|10 week yoga class
75549753|NCT00306683|Drug|DIAZOXIDE|
76023172|NCT02404831|Other|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
76038170|NCT05472467|Drug|Chemotherapy|"Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles."
76038171|NCT04760639|Diagnostic Test|Breath test|Participants provide a breath sample
76038172|NCT05634421|Other|E-learning|The E-learning is under development at the department of Dermatology from MUMC+.
76038173|NCT04793165|Device|Non-hybrid closed-loop system with ARG algorithm|To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
75549754|NCT00306722|Drug|AQUAVAN® (fospropofol disodium) Injection|
75549755|NCT00337389|Drug|5- Fluorouracil (5-FU)|
75549756|NCT00337389|Drug|bevacizumab (Avastin)|
75549757|NCT00337389|Drug|Leucovorin|
75549758|NCT00337389|Drug|CoFactor (ANX-510)|
75549759|NCT00306761|Device|Dynamic Wheelchair Seating System|
75549760|NCT00306800|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
75549761|NCT00340431|Drug|MSP1(42)-FVO & MSP1(42)-3D7|
75401586|NCT01120704|Drug|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes >10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
75401587|NCT01120704|Behavioral|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 & 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
75401588|NCT01120704|Behavioral|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
75401589|NCT01120704|Behavioral|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
75710722|NCT00897988|Genetic|gene expression analysis|
75710723|NCT00897988|Genetic|mutation analysis|
75710724|NCT00897988|Genetic|polyacrylamide gel electrophoresis|
75710725|NCT00897988|Genetic|polymerase chain reaction|
75710726|NCT00897988|Genetic|protein expression analysis|
75710727|NCT00897988|Genetic|reverse transcriptase-polymerase chain reaction|
75710728|NCT00897988|Other|flow cytometry|
75710729|NCT00897988|Other|immunoenzyme technique|
75710730|NCT00897988|Other|immunologic technique|
75710731|NCT00897988|Other|laboratory biomarker analysis|
75710732|NCT00897988|Other|pharmacological study|
75710733|NCT00823641|Drug|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
75710734|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
75710735|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
75710736|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
75710737|NCT00898066|Genetic|cytogenetic analysis|marrow and peripheral blood
75710738|NCT00898066|Genetic|fluorescence in situ hybridization|marrow and peripheral blood
75710739|NCT00823875|Drug|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
75401590|NCT01120704|Behavioral|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 & 23."
75401591|NCT01121250|Behavioral|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
75401592|NCT01121250|Behavioral|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
75401593|NCT01122030|Drug|Naldemedine|Tablets or solution for oral administration
75401594|NCT01122030|Drug|Placebo|Tablets or solution for oral administration
75401595|NCT01122108|Drug|Cholestyramine|Cholestyramine 12 grams, one time dose
75401596|NCT01122108|Drug|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
75401597|NCT01123512|Device|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
75401598|NCT01124370|Device|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
75401599|NCT05307042|Diagnostic Test|Deamino Arginine Vasopressin (dDAVP)|After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
75401600|NCT05306730|Device|ECHOcardiography, Point-of-Care UZ|Emergent echocardiography is reproducible method providing clinically significant information during primary survey of acute cardiovascular diseases. Possible benefit is the risk stratification of acute non-stemi coronary syndromes and differentiation from other serious conditions, such as pulmonary embolism or aortic dissection. The aim of interest is to consider riscs and benefits of the ultrasound of heart done by non-cardiologist after standardized course.
75401601|NCT05306184|Procedure|Electroconvulsive therapy (ECT)|ECT
75401602|NCT05291442|Other|To integrate Family System Care and Theme Care Action Module|"First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
75401603|NCT05289960|Other|lung ultrasound|Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea
75401604|NCT05288478|Combination Product|Dentoxol mouthrinse dosages|Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
75401605|NCT05115942|Drug|Hydronidone capsules|After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 52 weeks.
75401606|NCT05115942|Drug|The placebo capsules|After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 52 weeks.
75401607|NCT04974138|Drug|Amlodipine besylate tablets|The amlodipine used in this study is a listed product. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
75401608|NCT04974138|Drug|Amlodipine besylate and folic acid tablets|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
75401609|NCT04973982|Drug|Envarsus|3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
75401610|NCT04973982|Drug|Adoport|3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
75401611|NCT04973514|Procedure|Cardiac surgery in grown-up congenital heart disease patients|Analysis of patient blood management, influence on 30 day and 6 month outcome
75549762|NCT00306839|Procedure|standardized Lichtenstein technique|
75401612|NCT04733664|Device|VFI using the FAST PV Technology|The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
75401613|NCT04503720|Device|CLoWI|Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
75401614|NCT04503720|Device|PCA|Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
75401615|NCT04487964|Dietary Supplement|Licorice extract|"LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour"
75401616|NCT04461600|Drug|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
75401617|NCT04342182|Biological|Convalescent plasma|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
75401618|NCT04237974|Device|computed tomography pulmonary angiography|The radiological severity of pulmonary embolism will be assessed by using the computed tomography pulmonary arterial obstruction index (CT-PAOI)
75401619|NCT04142892|Drug|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
75401620|NCT04125498|Other|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
75401621|NCT04125498|Other|Placebo treatment|Similar to OMT without pressure
75401622|NCT04125498|Other|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
75401623|NCT04017702|Device|Expiron respirator|Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
75401624|NCT03829098|Other|Intervantions for anastomotic leakage after esophagectomy|nil by mouth regime; antibiotic treatment according to local protocols; NG tube placement (with/without suction); NG tube repositioning (with/without suction); tube placement though anastomotic defect; endoVAC/endoSponge placement; stent placement (stent type if applicable); endoscopic clipping; nasoduodenal/nasojejunal feeding tube placement; radiologic drainage (thoracic cavity, mediastinum); bedside surgical chest tube placement; reoperation; reoperation approach; reoperation procedure (drainage only, suturing of the leak; resection of the leak and re-anastomosis; repair of anastomosis with muscle flap; disconnection and cervical esophagostomy; surgical jejunal feeding tube).
75401625|NCT03795168|Device|Transcranial vibrating system|The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.
75401626|NCT03795168|Device|Transcranial vibrating system sham|A transcranial vibrating system (TCVS) sham set at an irrelevant vibrating frequency will be worn by participants performing vestibular physical therapy (PT) exercises in arm 2. The TCVS sham vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS sham will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises.
75401627|NCT03792360|Drug|SVF (Stromal Vascular Fraction)|The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
75401628|NCT03749928|Device|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
75549763|NCT00340470|Behavioral|Driver Education|
75549764|NCT00306878|Drug|Abatacept|
75549765|NCT04715724|Other|Positioning and Attachment video-based simulation (telesimulation)|Participants will teach a standardized patient actor (SP) to position and attach the baby doll at the breast of the Lactation Simulation Model in a video-based simulation (telesimulation)
75549766|NCT00306956|Behavioral|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
75549767|NCT02960165|Behavioral|Virtual interface group|First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).
75549768|NCT02960165|Behavioral|Real interface group|First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
75549769|NCT00337506|Drug|Dexamethasone|
75710740|NCT00823875|Drug|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
76038174|NCT04793399|Drug|Bosutinib 400 MG Monotherapy|One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
75549770|NCT00337506|Drug|velcade|
75710741|NCT00823875|Drug|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
75549771|NCT00307073|Device|Implantable Pulse Generator|
75710742|NCT00823875|Drug|control group|routine treatment
75710743|NCT00898144|Other|Papanicolaou test|
75710744|NCT00898144|Other|laboratory biomarker analysis|
75710745|NCT01042327|Device|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
75549772|NCT04717856|Other|screening: HCV RNA test and risk factors questionaire|Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
75710746|NCT01042327|Device|Fresenius FX100 dialyzer|
75710747|NCT04035928|Device|3D digital scanning for maxillofacial prosthetics|The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
75710748|NCT00823953|Drug|Momordica charantia|escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
75710749|NCT00823953|Other|starch powder|The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
75710750|NCT04036084|Diagnostic Test|Cerebral Magnetic resonance imaging (MRI)|Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
75710751|NCT00397189|Drug|Circadin|Prolonged release melatonin 2 mg
75710752|NCT00397189|Drug|placebo circadin|placebo circadin tablets
75710753|NCT00824109|Device|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
75710754|NCT00898300|Other|biologic sample preservation procedure|
75710755|NCT00898300|Procedure|biopsy|
75710756|NCT01035619|Drug|moxidectin|Single Dose Moxidectin 4 mg
75710757|NCT00819819|Dietary Supplement|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
75710758|NCT00819819|Dietary Supplement|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
75710759|NCT04044651|Drug|Lenvatinib|lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
75710760|NCT04044651|Drug|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
75710761|NCT00606034|Drug|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
75710762|NCT00898378|Genetic|gene expression analysis|gene expression analysis
75710763|NCT00898378|Genetic|polymerase chain reaction|polymerase chain reaction
75710764|NCT00898378|Genetic|polymorphism analysis|polymorphism analysis
75710765|NCT00898378|Genetic|protein expression analysis|protein expression analysis
75710766|NCT00898378|Genetic|proteomic profiling|proteomic profiling
75710767|NCT00898378|Other|gas chromatography|gas chromatography
75710768|NCT00898378|Other|laboratory biomarker analysis|laboratory biomarker analysis
75710769|NCT00898378|Other|liquid chromatography|liquid chromatography
75710770|NCT00898378|Other|mass spectrometry|mass spectrometry
76038175|NCT04793399|Drug|Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection|12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
76038176|NCT05634265|Behavioral|Vijana-SMART|The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
75401629|NCT03749928|Device|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
75401630|NCT03697356|Drug|Lenalidomide, Bortezomib, Rituximab, Dexamethasone|"step 1; R-VRD induction : rituximab, bortezomib, lenalidomide, and dexamethasone induction~Rituximab 375 mg/m2 intravenous on day 1~Bortezomib 1.3mg/m2 subcutaneous on day 1, 8, 15~Lenalidomide 15mg p.o on day 1-21~Dexamethasone 20 mg/m2 intravenous or p.o on day 1-4~Step 2 ; Maintenance Beginning 8 weeks after completion of induction therapy, patients receive lenalidomide 10mg once day 1-21 for 4 weeks. Treatment repeats every 1 months for 24 months."
75401631|NCT03616782|Drug|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
75401632|NCT03336372|Drug|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
75401633|NCT03099798|Other|Questionnaires|"All patients will complete a number of questionnaires at different time points.~SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~1 week, 1 month, 3, 6 and 12 months after treatment"
75401634|NCT03099798|Diagnostic Test|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
75401635|NCT02410512|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Atezolizumab will be administered intravenously.
75401636|NCT02410512|Drug|MOXR0916, a humanized agonist anti-OX40 monoclonal antibody|MOXR0916 will be administered intravenously.
75401637|NCT02364492|Drug|MAG-TN3 + AS15|
75710771|NCT00898378|Other|questionnaire administration|questionnaire administration
75710772|NCT00819975|Dietary Supplement|Casein|
75710773|NCT00819975|Dietary Supplement|Whey Isolate|
75710774|NCT00819975|Dietary Supplement|Whey Hydrolysate|
75710775|NCT00819975|Dietary Supplement|Alphalact-Albumin|
75401638|NCT00849888|Biological|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects >4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg & serum free (SF) in other. After first 2 subjects >10% naïve T cells, 3rd receives only SF thymus. After 3rd subject >10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant & thymus biopsy. Followed by immune evaluations.
75401639|NCT00849888|Other|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg & serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, >10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject >10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy & skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
75401640|NCT00255138|Drug|Atomoxetine|
75401641|NCT01125774|Drug|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
76038177|NCT05157711|Drug|Anusol|Daily at night and in the morning and after each bowel movement for two weeks
75401642|NCT01125774|Drug|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
76038178|NCT05157711|Drug|Relief [Name]|Daily at night and in the morning and after each bowel movement for two weeks
75401643|NCT01128192|Drug|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
75401644|NCT01128270|Drug|Dichloroacetate environmental dose|On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
75401645|NCT01128270|Drug|Chloral Hydrate environmental dose|Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
75401646|NCT01128270|Drug|Dichloroacetate therapeutic dose|Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
75401647|NCT01128270|Drug|Chloral Hydrate therapeutic dose|Subject is given 25 mg/kg of Chloral Hydrate for five nights.
75401648|NCT01128426|Other|No Intervention|No Intervention
75401649|NCT01128972|Drug|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
75710776|NCT00825981|Other|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
75710777|NCT04044417|Procedure|currettage|open flap debridement
75710778|NCT04044417|Drug|curcumin simvastatin paste|Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
75401650|NCT01128972|Drug|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
75401651|NCT01128972|Drug|Sterile water|Sterile water rinse
75401652|NCT01129206|Drug|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
75401653|NCT01129206|Drug|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
75401654|NCT01129206|Radiation|fludeoxyglucose F 18|Correlative studies
75401655|NCT01129206|Procedure|positron emission tomography|Correlative studies
75401656|NCT01129440|Device|Fluoride Varnish|Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
75401657|NCT01129440|Device|Glass Ionomer Sealant|"Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.~After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar."
75401658|NCT01130844|Drug|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
75401659|NCT01130844|Drug|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
75710779|NCT04044417|Drug|EDTA root conditioning|EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
75710780|NCT00397033|Drug|Paliperidone ER|6mg/day paliperidone er for 6 weeks
75401660|NCT01130844|Drug|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
75710781|NCT00397033|Drug|Paliperidone ER|12mg/day paliperidone er for 6 weeks
75710782|NCT00397033|Drug|Placebo|Placebo for 6 weeks
75710783|NCT00820053|Drug|epirubicin and lipiodol|using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
75710784|NCT00572728|Procedure|CT|Undergo 18F-FLT PET/CT
75710785|NCT00572728|Drug|18F-FLT|Undergo 18F-FLT PET/CT
75401661|NCT01134198|Drug|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
75401662|NCT01134198|Drug|placebo|placebo
75401663|NCT01134276|Procedure|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
75401664|NCT01134900|Other|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
75401665|NCT01135368|Drug|Lansoprazole|Lansoprazole capsules
75401666|NCT01136226|Drug|Eligard (TM)|Eligard (TM) 22.5 mg administered at baseline and Month 3
75401667|NCT01137006|Biological|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
75401668|NCT01137006|Biological|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
75401669|NCT01137006|Biological|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
75401670|NCT01137006|Biological|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
75401671|NCT01137006|Biological|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
75401672|NCT01137006|Biological|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
75401673|NCT01137006|Biological|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
75401674|NCT01137396|Drug|Modafinil|Modafinil 400mg PO QDaily following up-titration for ~8weeks
75401675|NCT01137396|Behavioral|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
75401676|NCT01138098|Biological|Engerix™-B|Intramuscular, single dose
75401677|NCT01139190|Drug|PL3100|Oral administration
75401678|NCT01139190|Drug|Naproxen|Oral administration
75710786|NCT00572728|Procedure|PET|Undergo 18F-FLT PET/CT
75710787|NCT00820131|Procedure|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
75710788|NCT00820131|Procedure|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
75710789|NCT03857295|Other|No interventions|No intervention
75710790|NCT00699374|Drug|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
75710791|NCT00699374|Drug|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
75401679|NCT01139814|Device|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
75401680|NCT01140360|Drug|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
76038179|NCT05157711|Drug|Placebo|Daily at night and in the morning and after each bowel movement for two weeks
75401681|NCT01141374|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
75401682|NCT01141374|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
75401683|NCT01141608|Other|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
75710792|NCT00898534|Device|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
75401684|NCT01141608|Other|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
75401685|NCT01142310|Drug|Lamotrigine|Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
75401686|NCT01142310|Drug|Placebo|
75401687|NCT01143636|Device|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
75401688|NCT01143792|Behavioral|Community Reinforcement Approach (CRA) + HIV prevention|12 sessions of the CRA and 2 sessions of HIV prevention.
75401689|NCT01143792|Behavioral|Case Management + HIV Prevention|12 sessions of case management and 2 sessions of HIV prevention.
75401690|NCT01143792|Behavioral|Motivational Enhancement Therapy (MET) + HIV prevention|2 sessions of MET and 2 sessions of HIV prevention.
75401691|NCT01143870|Other|"Diabetes Report Card"|"Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade."
75710793|NCT00824187|Drug|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
75401692|NCT01144026|Biological|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
75401693|NCT01144026|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
75401694|NCT01144338|Drug|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
75401695|NCT01144338|Drug|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
75401696|NCT01146600|Drug|Clarithromycin followed by placebo|Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
75401697|NCT01146600|Drug|Placebo then Clarithromycin|Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
75401698|NCT01146834|Drug|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
75401699|NCT01146834|Drug|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
75401700|NCT01146834|Drug|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
76038180|NCT04793321|Device|Baby carrier|"It is made in china.~It is made of Cotton-Polyester.~It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~It is suitable for newborn to 12-months baby~It is available online at babyshopstores https://www.babyshopstores.com/"
75401701|NCT01146834|Drug|Plerixafor|plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
75401702|NCT01147302|Biological|Placebo|
75401703|NCT01147302|Biological|C1 Esterase Inhibitor (Human)|
75401704|NCT01147380|Biological|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
76038181|NCT04793321|Device|Biodex Balance System|"The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance."
75401705|NCT01149876|Other|Nu Skin Product|Thin layer of Nu Skin product applied to face.
75401706|NCT01149876|Other|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
76038182|NCT04793321|Other|Infant mannequin|The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
76038183|NCT04793321|Device|Biodex gait trainer 2 TM|"Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~Heart Rate Monitoring~Handrail~Open Platform"
75401707|NCT01149876|Drug|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
75549773|NCT04715607|Diagnostic Test|Sequence of testing.|The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.
75549774|NCT00307229|Biological|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
76038184|NCT05105997|Drug|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
76038185|NCT05105997|Drug|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
76038186|NCT04801433|Other|Boleda Supramolecular Active Zinc Conditioner|Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
75710794|NCT00824187|Drug|Placebo|Inert tablet
75710795|NCT00826137|Dietary Supplement|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
76038187|NCT04801433|Drug|Capotetriol scalp solution|Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
76038188|NCT04801433|Other|Supramolecular Hydrogel|Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
76038189|NCT05105607|Drug|D-4517.2|Subcutaneous (SC) injection
75401708|NCT01149876|Other|CeraVe moisturizer|Thin layer of CeraVe applied to face.
75401709|NCT01150500|Device|MDT-4107 Zotarolimus-Eluting Coronary Stent|
75401710|NCT01151046|Drug|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
75710796|NCT00826137|Dietary Supplement|Placebo|Placebo is base powder of product with no oligosaccharides.
75710797|NCT00606892|Drug|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
75710798|NCT00606892|Drug|Placebo|Sugar Pill
76038190|NCT04793087|Diagnostic Test|Magnetic Resonance Imaging|Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis
75401711|NCT01151046|Drug|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
75401712|NCT01151046|Drug|Exemestane|Exemestane (25 mg) administered orally once per day
75401713|NCT01151436|Device|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
75401714|NCT01152294|Behavioral|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
75549775|NCT00337584|Procedure|Pre-surgical screening|
75549776|NCT00307307|Drug|Niacin/simvastatin compared to simvastatin alone at 2 doses|
75549777|NCT00337623|Drug|Prednisolone|
76038191|NCT05206383|Behavioral|Positive message - placebo|"Subjects who will be told that the applied plastering method significantly increases muscle strength (positive message - placebo)."
76038192|NCT05206383|Behavioral|Negative message - nocebo|"Subjects who will be told that the applied plastering method has no effect on muscle strength (negative message - nocebo)."
76038193|NCT05206383|Behavioral|Neutral message|"Subjects who will be told that the applied plastering method is currently under investigation and the investigators do not know its effects (neutral message)."
76038194|NCT04450459|Diagnostic Test|ergospirometer test|ergospirometric test will be done before cardiac catheterisation and invasive measurement of FFR
76038195|NCT04421781|Other|Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT|Patients were treated using dedicated post-EBRT parameters (5-s pulse, 5-s waiting period, 90% of the acoustic power). Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
76038196|NCT04801511|Drug|Vitamin C|High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
76038197|NCT04159675|Biological|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
76038198|NCT05471765|Device|Withdrawal of Continuous Positive Airway Pressure device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of < 5 while on treatment. At random, a group of participants will cease to use the Continuous Positive Airway Pressure. And they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
75401715|NCT01153620|Drug|Lavasept 0.04%|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes"
75401716|NCT01153620|Other|Ringer's Solution|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes"
75401717|NCT01154322|Device|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
75401718|NCT01154634|Drug|AZD2516, 5 mg|Capsule, oral
75549778|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 8 weeks
75549779|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.
76038199|NCT05471765|Device|Alternation usage of Continuous Positive Airway Pressure Device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of < 5 while on treatment. Randomly, these patients will alternatively use The Continuous Positive Airway Pressure device every other day (e.g. They will use the device 4 days and not use it for 3 days of the week) and they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
75401719|NCT01154634|Drug|AZD2516, 16 mg|Capsule, oral
75549780|NCT00307424|Device|AutoCPAP|
75549781|NCT00307424|Device|FixCPAP|
75549782|NCT00307463|Procedure|strict volume control policy|strict volume control by UF and dietary salt restriction
75549783|NCT00307463|Procedure|antihypertensive drugs administration|continue antihypertensive medications
75549784|NCT00421005|Drug|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
75401720|NCT01154634|Drug|AZD2516, 40 mg|Capsule, oral
75401721|NCT01154634|Drug|Placebo|Capsule, oral
75401722|NCT01155180|Drug|Leptin|Hormone - daily self injections for 6 months
75401723|NCT01155180|Drug|Placebo|Placebo
75401724|NCT01155336|Drug|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
75401725|NCT01155336|Drug|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
75401726|NCT01161420|Device|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
75401727|NCT01163214|Drug|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
75401728|NCT01163214|Drug|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
75401729|NCT01163604|Drug|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
75401730|NCT01163604|Drug|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
75401731|NCT01163760|Device|etafilcon A|daily disposable contact lens
75401732|NCT01163760|Device|ocufilcon D|daily disposable contact lens
76038200|NCT05156229|Biological|CDK-003|CDK-003 administered subcutaneously
75401733|NCT01167504|Other|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
75401734|NCT01168674|Drug|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
75401735|NCT01168674|Drug|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
75401736|NCT01168908|Drug|Sildenafil|20mg tablet three times daily
75401737|NCT01168986|Other|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
75401738|NCT01168986|Other|Exercise|Participants perform an exercise to strengthen the deep neck flexors
75401739|NCT01169064|Device|Silver-containing surgical dressing|Dressing placed over surgical incision and remain for 3-5 days
75401740|NCT01169064|Device|Cloth adhesive dressing|Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
75401741|NCT01170390|Drug|All participants (Aviane)|20 mcg EE/0.1 mg LNG cyclically
75401742|NCT01170390|Drug|Portia|30 mcg EE/0.15 mg LNG cyclically
75401743|NCT01170390|Drug|Aviane|20 mcg EE/0.1 mg LNG continuously dosed
75401744|NCT01170546|Other|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
76038201|NCT03069235|Behavioral|Family member / peer support|supplemental individualized counselling
75401745|NCT01170546|Other|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
75401746|NCT01170546|Other|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
75401747|NCT01134510|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
75401748|NCT01134510|Drug|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
76038202|NCT03069235|Behavioral|Enhanced intervention with counselor support|"hands on EBF demonstrations"
76038203|NCT03069235|Behavioral|standard of care|one on one and in-group counselling
76038204|NCT04793009|Device|funnel-shaped, intraperitoneal mesh placement|Implantation of a prophylactic, 3D funnel-shaped, intraperitoneal, non-absorbable and synthetic mesh (Dyna Mesh IPST 2x15x15 cm™ and 3x16x16 cm™, FEG Textiltechnik, Aachen, Germany,)
76038205|NCT05615909|Radiation|Online MR-guided radiotherapy|Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).
75401749|NCT01171794|Drug|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
76038206|NCT05615909|Radiation|CT-guided radiotherapy|CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
75401750|NCT01171794|Drug|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
75549785|NCT00337740|Procedure|endoscopic variceal banding|
75549786|NCT00337740|Drug|propranolol|
75549787|NCT00307502|Drug|Nevirapine|tablets 200 mg, 400 mg/day
76038207|NCT04453891|Device|Monitoring physiological data with the Hexoskin smart shirt|Participants will be monitored using a validated biometric garment (Hexoskin smart shirt). Cardiorespiratory and activity data will be collected over a 28-day monitoring period. Participants will be invited to wear the shirt during the day and at night.
75401751|NCT01172184|Procedure|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
75401752|NCT01175148|Drug|Atorvastatin calcium (Lipitor)|40 mg PO daily
75549788|NCT00307502|Drug|Efavirenz|tablets 600 mg, 600 mg/day
75710799|NCT00606892|Drug|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
75710800|NCT00826215|Device|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
75710801|NCT00826215|Device|Sham laser acupuncture|Sham laser acupuncture
75710802|NCT00826293|Procedure|Stabilization belt|Patients receive true stabilization.
75710803|NCT00826293|Procedure|Stabilization belt|Patients receive sham stabilization.
75710804|NCT04035538|Drug|CKD-320, D012|R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
76038208|NCT05471687|Device|dual-energy dual-layer spectral scanner|Realization of dual-energy dual-layer spectral scanner with stress protocol
76038209|NCT05471687|Drug|Stress protocol with adenosin during dual-energy dual-layer spectral scanner|Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner
76038210|NCT04230369|Behavioral|Exposure-based Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
76038211|NCT04230369|Other|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
76038212|NCT03068845|Device|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
75401753|NCT01175226|Drug|BTA798|BTA798 twice daily
75401754|NCT01175226|Drug|Placebo|Placebo twice daily
75401755|NCT01175850|Device|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
75401756|NCT01175850|Device|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
75401757|NCT01177098|Drug|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
75549789|NCT00307502|Drug|Indinavir/ritonavir|"Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
75549790|NCT00307502|Drug|Nelfinavir|tablets 250 mg, 2500 mg/day
75549791|NCT00307502|Drug|Saquinavir/ritonavir|"Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day"
75710805|NCT01042483|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
75710806|NCT00894946|Procedure|Lipiodol + IVF|IVF preceded by lipiodol
75710807|NCT00894946|Procedure|IVF|IVF alone
75710808|NCT00737906|Procedure|Surgical turbinate reduction procedure|Surgical turbinate reduction using the COBLATION device
75549792|NCT00307502|Drug|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
75549793|NCT00307502|Drug|Atazanavir|capsules 200 mg, 400 mg/day
75710809|NCT00898690|Genetic|cytogenetic analysis|
75710810|NCT00898690|Genetic|gene expression analysis|
75710811|NCT00898690|Genetic|microarray analysis|
75710812|NCT00898690|Genetic|mutation analysis|
76038213|NCT03068845|Device|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
75401758|NCT01177098|Drug|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
75401759|NCT01177956|Biological|Cetuximab|"The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.~Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab."
75710813|NCT00898690|Genetic|reverse transcriptase-polymerase chain reaction|
75401760|NCT01177956|Drug|Cisplatin|Subjects will receive 75 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
75401761|NCT01177956|Drug|5-Fluorouracil|Subjects will receive 750 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
75401762|NCT01178268|Device|XIENCE V EECSS|Patients who will receive this stent.
75401763|NCT01178268|Device|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
75401764|NCT01179984|Device|Bard® LifeStent® Vascular Stent System|Stent Implantation
75401765|NCT01181076|Dietary Supplement|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
75549794|NCT00307502|Drug|Atazanavir/ritonavir|"Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
75549795|NCT00307502|Drug|Fos-amprenavir/ritonavir|"Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
75549796|NCT00307502|Drug|Tipranavir/ ritonavir|"Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day"
75549797|NCT00307502|Drug|Darunavir/ritonavir|"Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
75549798|NCT00307541|Biological|Pneumococcal (vaccine)|
75549799|NCT00307580|Drug|Cathflo Activase (Alteplase)|
75549800|NCT00307619|Drug|topiramate|
75549801|NCT00340938|Procedure|Blood testing|
75549802|NCT00307658|Drug|Intravenous immunoglobulins (human immunoglobulins G)|
75549803|NCT00337974|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
75549804|NCT00337974|Other|Educational DVDs|
75549805|NCT00307697|Procedure|receipt of copy of psychiatic assessment letter|
75549806|NCT00337545|Drug|RAD001|
75549807|NCT00307775|Drug|oestradiol|
75549808|NCT04715919|Diagnostic Test|Chest Computed Tomography|Evaluation of Lung Structure
75549809|NCT04715919|Diagnostic Test|Pulmonary Function Tests|Respiratory Capacity
75710814|NCT00898690|Other|immunohistochemistry staining method|
75549810|NCT04715919|Other|Six Minutes Walk Test|Exercise Capacity
75549811|NCT04715919|Other|Quality of Life|Physical disability assessment tool
75549812|NCT00307814|Drug|Epoetin Alfa|
75549813|NCT00341055|Drug|Epoetin alfa|
75549814|NCT00307853|Drug|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
75710815|NCT05312996|Other|Heart Rate Variability|Caretaker Heart Rate Variability ECG wrist monitor and chest patch.
75710816|NCT05312996|Other|Galvanic Skin Response (Biopac)|Galvanic Skin Response- measuring autonomic response-via perspiration
75710817|NCT01035775|Procedure|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
75710818|NCT01035775|Procedure|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
75549815|NCT00307853|Other|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
75549816|NCT00307853|Other|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
75549817|NCT00338052|Drug|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
75549818|NCT00307892|Drug|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
75549819|NCT00307892|Drug|Placebo|placebo remedy
75549820|NCT00338091|Drug|Benazepril|
75549821|NCT00338091|Drug|Losartan|
75549822|NCT00307970|Drug|HFA FP MDI|
76038214|NCT05370729|Drug|N-acetyl cysteine|Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
75401766|NCT01182480|Behavioral|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
75401767|NCT01183650|Drug|Tadalafil|5 mg, administered orally, daily for 10 days
75401768|NCT01183728|Other|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
75401769|NCT01184898|Drug|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
75401770|NCT01184898|Drug|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
75401771|NCT01184898|Drug|Etoposide|100 mg/m2/day IV
75401772|NCT01184898|Drug|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
75401773|NCT01188876|Drug|carboplatin|Given intravenously on Day 1 of each 28-day cycle
75549823|NCT00307970|Device|conventional chamber/mask; anti-static chamber/mask|
75549824|NCT00308009|Procedure|Vaginal Repair for prolapse, TVT procedure|"TVT at the time of Vaginal Repair~TVT 3 months after Vaginal Repair"
75549825|NCT00308009|Procedure|TVT and Prolapse surgery|"TVT at the time of Prolapse surgery~TVT 3 months after Prolapse Surgery"
75549826|NCT00308048|Drug|Pegylated Interferon alfa 2b and ribavirin|
75549827|NCT00338130|Drug|AZD6244|Oral liquid or Capsule
75549828|NCT00338130|Drug|Temozolomide|oral
75549829|NCT00308126|Drug|Hydroxyethyl Starch 130/0.4 (Voluven)|
75549830|NCT00308165|Procedure|Convection-Enhanced Delivery|microinfusion pumps to deliver chemotherapy directly into brain tumors
75549831|NCT00308165|Drug|Topotecan|chemotherapeutic drug for the treatment of brain tumors
75549832|NCT00338208|Behavioral|Training in the Use of Low Vision Devices|
75549833|NCT00418652|Device|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
75549834|NCT00418652|Device|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
75549835|NCT00418652|Device|TMS over the vertex|10Hz TMS for over vertex.
75549836|NCT00418769|Drug|Nilotinib|
75549837|NCT00308204|Drug|Raptiva|injection
75549838|NCT00425334|Drug|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
75549839|NCT00425334|Drug|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
75549840|NCT00308243|Drug|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
75549841|NCT00338247|Drug|lapatinib + capecitabine|Experimental
75549842|NCT00308321|Drug|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
75549843|NCT00308321|Drug|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
75401774|NCT01188876|Drug|pralatrexate|Given intravenously on Day 1 and Day 15 of each 28-day cycle.
75401775|NCT01188876|Drug|Folic Acid|Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
75401776|NCT01188876|Drug|Vitamin B12 Injection|Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
75401777|NCT01189110|Device|Auriculotherapy using TENS unit Stim Flex 400A|Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
75401778|NCT01192542|Device|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
75401779|NCT01192542|Device|enfilcon A lens|Marketed silicone hydrogel contact lens
75710819|NCT00737984|Procedure|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
76038215|NCT05471531|Biological|Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
75401780|NCT01193010|Procedure|Computer-Assisted Surgical Planning|Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
75401781|NCT01193010|Procedure|distal radius osteotomy|In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
75401782|NCT01193868|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
75401783|NCT01193868|Other|laboratory biomarker analysis|Correlative studies
75710820|NCT04035616|Dietary Supplement|microbial cell preparation [MCP]|active microbial cell preparation
76038216|NCT05471531|Biological|Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.
75401784|NCT01193868|Other|pharmacological study|Correlative studies
75401785|NCT01195116|Drug|Dexmedetomidine|1 mcg/kg/hour
75401786|NCT01195116|Drug|Normal Saline|1mcg/kg/hr
75401787|NCT01196442|Other|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
75401788|NCT01196442|Other|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
75401789|NCT01197612|Drug|pulmicort|applied to nasal packing after surgery
75401790|NCT01198158|Biological|Bevacizumab|Given IV
75401791|NCT01198158|Drug|Everolimus|Given PO
75401792|NCT01198158|Other|Laboratory Biomarker Analysis|Correlative studies
75401793|NCT01198158|Other|Pharmacological Study|Correlative studies
75401794|NCT01199952|Behavioral|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
75401795|NCT01200030|Behavioral|electrical stimulation with exercises|electrical stimulation with exercises
75401796|NCT01200030|Behavioral|placebo stimulation with exercises|placebo stimulation with exercises
75401797|NCT01200498|Drug|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
75401798|NCT01203774|Drug|Glargine insulin|20-180 units per day
75401799|NCT01205568|Device|Transcatheter Cutting Balloon therapy|
75401800|NCT01205568|Procedure|High Pressure Balloon Angioplasty|
75401801|NCT01205646|Drug|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
75549844|NCT00308360|Drug|Risperidone, divalproex|
75549845|NCT00308399|Drug|Itopride|
75710821|NCT04035616|Other|placebo|inactive ingredient
75710822|NCT01035853|Drug|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
75401802|NCT01205646|Device|PET Scan|2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
75401803|NCT01206660|Drug|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
75401804|NCT01206660|Drug|placebo|Placebo administered to affected area twice a day for 28 days
75401805|NCT01206738|Behavioral|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
75401806|NCT01206738|Behavioral|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
75401807|NCT01206738|Behavioral|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
75401808|NCT01207752|Drug|Systane Balance|Artificial tear emulsion drop
75401809|NCT01207752|Drug|Optive Lubricant Eye Drops|Artificial tear eye drop
75401810|NCT01207908|Drug|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
75401811|NCT01208220|Device|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
75710823|NCT05289362|Device|Basket group|Under ERCP, the basket is preferentially used to remove the pancreatic duct stones, and then the balloon is used to evaluate the effect and remove the residual stones.
75401812|NCT01208220|Biological|Collagenase Ointment|Apply TIW
75710824|NCT05289362|Device|Balloon group|Under ERCP, the balloon is preferentially used to remove the pancreatic duct stones, and then the basket is used to evaluate the effect and remove the residual stones.
76038217|NCT04426331|Behavioral|Voucher Without Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free."
76038218|NCT04426331|Behavioral|Voucher With Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free."
75710825|NCT01042639|Behavioral|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
75710826|NCT04035304|Other|Mindfulness Coach|"Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises."
75710827|NCT05274542|Other|high intensity with blood flow restriction|Participants in high intensity with blood flow restriction group (n=12) will be given high-intensity resistance exercise training that restricts blood flow. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. A blood pressure cuff will be used to restrict blood flow. By applying the cuff to the proximal of the muscle, the blood flow will be restricted with a pressure of 150 mmHg and the muscle will be exercised in this way. After the exercise, the cuff will be removed and evaluations will be made after 2 minutes of rest.
75401813|NCT01208922|Drug|Rifamycin SV-MMX®|2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
75401814|NCT01208922|Drug|Ciprofloxacin|1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
75401815|NCT01209702|Biological|tocilizumab|Administered intravenously (iv) every 4 weeks
75401816|NCT01209702|Drug|Placebo|Placebo to tocilizumab administered intravenously every 4 weeks
75401817|NCT01210170|Drug|placebo|placebo inhalation before albuterol.
75401818|NCT01210170|Drug|mometasone 400 mcg|mometasone inhalation before albuterol.
75401819|NCT01210170|Drug|mometasone 200 mcg|200ug mometasone before albuterol.
75401820|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
75401821|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
75401822|NCT01210560|Drug|Tolvaptan MR|60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
75401823|NCT01210560|Drug|Tolvaptan IR|90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
75401824|NCT01210560|Drug|Tolvaptan MR|120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
75401825|NCT01210716|Device|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
75401826|NCT01211106|Behavioral|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
75401827|NCT01211106|Behavioral|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
75401828|NCT01211340|Behavioral|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
75401829|NCT01211730|Drug|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
75401830|NCT01212900|Drug|Statins, HMG CoA|Statin therapy
75401831|NCT01215240|Device|Peritoneal dialysis|Prophylactic peritoneal dialysis
75401832|NCT01215318|Device|modified vaginal tampon|modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
75401833|NCT01215786|Drug|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
75401834|NCT01215786|Drug|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
75401835|NCT01215786|Drug|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
75401836|NCT01216410|Drug|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
75401837|NCT01216410|Drug|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
75401838|NCT01216410|Drug|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
75401839|NCT01218048|Drug|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
75401840|NCT01218048|Procedure|Surgery|Surgery for tumor
75401841|NCT01218048|Radiation|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
75401842|NCT01218048|Drug|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
75401843|NCT01218672|Device|Photoselective Vaporization of the Prostate|"GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.~GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator."
75401844|NCT01218672|Device|Transurethral Resection of the Prostate|Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.
75401845|NCT01218984|Drug|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
75401846|NCT01218984|Drug|Medisorb naltrexone 150 mg|Single administration via IM injection.
75401847|NCT01218984|Drug|Medisorb naltrexone 300 mg|Single administration via IM injection.
75401848|NCT01218984|Drug|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
75401849|NCT01218984|Drug|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
75401850|NCT01220466|Device|STAR S4IR LASIK with iDesign Aberrometer|CustomVue LASIK targeted for emmetropia
75710828|NCT05274542|Other|high intensity without blood flow restriction group|Participants in high intensity without blood flow restriction group (n=12) will be given high-intensity resistance exercise training. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. After the exercise, after 2 minutes of rest, evaluations will be made.
75710829|NCT01036243|Dietary Supplement|test formula 1|hydrolyzed formula with probiotics
75401851|NCT01222260|Drug|Bendamustine|"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
75710830|NCT01036243|Dietary Supplement|test formula 2|acidified hydrolyzed formula
75710831|NCT01036243|Dietary Supplement|test formula 3|hydrolyzed formula without probiotics
75710832|NCT01036243|Dietary Supplement|reference formula|standard infant formula
75871406|NCT04173000|Other|Mehealth for ADHD software without medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
75871407|NCT04478032|Device|deep transcranial magnetic stimulation with H7 coil|low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
75710833|NCT00895024|Behavioral|Phone Interview/Questionnaire|35-minute questionnaire over the phone.
75871408|NCT04158024|Other|Erector Spinae Plane Block|The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
75871409|NCT02039206|Device|Deep TMS|1Hz Stimulation
75401852|NCT01222260|Drug|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
75401853|NCT01222494|Behavioral|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
75871410|NCT03506477|Drug|Enstilar® foam|for 4 weeks
75401854|NCT01222494|Behavioral|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
75401855|NCT01222572|Radiation|Stereotactic boost|
75710834|NCT01042717|Drug|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
75710835|NCT00898768|Procedure|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
75710836|NCT03506932|Dietary Supplement|Untreated|Bread made with 20% yellow pea flour that was untreated.
75710837|NCT03506932|Dietary Supplement|Heat treated with 0% moisture|Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
75710838|NCT03506932|Dietary Supplement|Heat treated with 10% moisture|Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
75710839|NCT03506932|Dietary Supplement|Wheat|Bread made with 100% wheat
75871411|NCT03506477|Drug|Vehicle foam|for 4 weeks
75871412|NCT03149692|Other|Penile allograft transplantation|Proof of concept of surgical procedure
75871413|NCT02351206|Radiation|x-ray, MRI|
75710840|NCT00738140|Behavioral|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
75710841|NCT00625443|Drug|Blinded (placebo)|"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
75710842|NCT00625443|Drug|Open Label (Avatrombopag tablets)|"Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
75871414|NCT03629964|Device|Wiersma Head Stabilizer|Experimental device attached to treatment table.
75710843|NCT00625443|Drug|Blinded (Avatrombopoag tablets)|"Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
75401856|NCT01222572|Radiation|Conventional RT|
75401857|NCT01222572|Drug|Etoposide|
75401858|NCT01222572|Drug|Cisplatin|
75401859|NCT01222884|Drug|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
75401860|NCT01222884|Drug|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
75710844|NCT00898846|Drug|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
75401861|NCT01223352|Drug|bosentan|32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
75401862|NCT01224210|Drug|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
75401863|NCT01224444|Other|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
75401864|NCT01224678|Dietary Supplement|vitamin D|Given orally
75401865|NCT01224678|Other|placebo|Given orally
75401866|NCT01225068|Drug|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
75401867|NCT01225068|Drug|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
75401868|NCT01225926|Device|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
75401869|NCT01225926|Device|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
75401870|NCT01226706|Drug|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
75401871|NCT01226706|Drug|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
75401872|NCT01231230|Drug|fluticasone|220- mcg once
75401873|NCT01231230|Drug|placebo inhalation|placebo inhalation once
75401874|NCT01231230|Drug|Salmeterol|50 mcg salmeterol once
75401875|NCT01231230|Drug|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
75710845|NCT00920894|Dietary Supplement|plant stanol ester|the effect of plant stanol esters on plasma lipids
75871415|NCT03629964|Device|AlignRT system|The AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
75401876|NCT01232946|Drug|liraglutide|1.8mg subcutaneous qd for 3 months
75401877|NCT01232946|Drug|insulin detemir|5units subcutaneous bid titrated to fasting glucose of <130mg/dL for 3 months
75401878|NCT01232946|Drug|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose <130mg/dL for 3 months.
75401879|NCT01233726|Dietary Supplement|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
75401880|NCT01233726|Dietary Supplement|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
75401881|NCT01233726|Dietary Supplement|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
75401882|NCT01235910|Drug|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
75401883|NCT01236300|Device|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
75401884|NCT01236378|Drug|Sirolimus|Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
75401885|NCT01236768|Drug|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
75401886|NCT01236768|Drug|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
75401887|NCT01237080|Device|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
75401888|NCT01237080|Device|Fastrach|The Fastrach is an intubation laryngeal mask.
75401889|NCT01238640|Drug|Code STD|"2 mg Single-dose of experimental nicotine product coded STD"
75401890|NCT01238640|Drug|Code STE|"2 mg Single-dose of experimental nicotine product coded STE"
75401891|NCT01238640|Drug|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
75401892|NCT01240122|Device|Biotrue MPS|Multi-purpose contact lens care solution
75401893|NCT01240122|Device|Investigational MPS|Multi-purpose contact lens care solution
75401894|NCT01241916|Device|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
75401895|NCT01241916|Device|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
75401896|NCT01243320|Drug|10ppm Oral Silver Particle|Silver nanoparticles at 10ppm
75401897|NCT01243320|Drug|32ppm Oral Silver Particle|Silver nanoparticles at 32ppm
75401898|NCT01245270|Dietary Supplement|Bilberry capsule first, then control cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
75401899|NCT01245270|Dietary Supplement|Control capsule first then bilberry cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
75401900|NCT01245972|Procedure|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
75710846|NCT00824343|Drug|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
75710847|NCT00895102|Drug|ABT-333 Tablet|See Arm Description for more information.
75710848|NCT00895102|Drug|Placebo|See Arm Description for more information.
75710849|NCT00895102|Drug|ABT-333 Capsule|See arm description for more information
75401901|NCT01246050|Other|HF training|These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
75401902|NCT01246050|Other|No HF training|These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
75401903|NCT01247064|Drug|Nebulized 3% saline|4 mL of nebulized 3% saline once
75401904|NCT01247064|Drug|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
75401905|NCT01247220|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
75401906|NCT01247220|Procedure|Peripheral Laser|Angiography-directed peripheral laser
75401907|NCT01247298|Combination Product|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
75401908|NCT01249872|Drug|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
75401909|NCT01249872|Drug|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
75401910|NCT01249872|Drug|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
75401911|NCT01249872|Drug|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
75401912|NCT01249872|Drug|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
75401913|NCT01249872|Drug|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
75401914|NCT01250184|Other|Physical therapy|Twelve sessions (3 per week)
75401915|NCT01250184|Drug|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
75401916|NCT01250184|Other|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
75401917|NCT01250730|Drug|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
75401918|NCT01250730|Drug|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
75401919|NCT01250730|Drug|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
75401920|NCT01251042|Device|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
75401921|NCT01251588|Biological|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
75401922|NCT01251588|Procedure|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
75401923|NCT01251978|Drug|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
75401924|NCT01251978|Drug|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
75710850|NCT00820287|Procedure|Biopsy of testicular tumor|testicular biopsies performed through open surgery
75549846|NCT04715802|Procedure|Immediate breast reconstruction with implant|Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
75401925|NCT01253148|Device|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
75401926|NCT01253460|Drug|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
75401927|NCT01253460|Drug|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
75549847|NCT04715802|Procedure|delayed breast reconstruction with implant|The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
75401928|NCT01253460|Drug|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
75401929|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
75401930|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
75401931|NCT01254552|Drug|iobitridol|Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
75401932|NCT01254552|Drug|gadoterate meglumine|Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
75401933|NCT01256034|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
75401934|NCT01244724|Drug|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
75401935|NCT01256424|Drug|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
75401936|NCT01256424|Drug|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
75401937|NCT01256424|Drug|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
75401938|NCT01256424|Drug|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
75401939|NCT01257750|Drug|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
75401940|NCT01258374|Drug|Raltegravir|Raltegravir, 400 mg bid
75401941|NCT01258374|Drug|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
75401942|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
75401943|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
75401944|NCT01262118|Drug|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
75401945|NCT01263132|Drug|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
75549848|NCT04715802|Procedure|delayed breast reconstruction with autologous fat transplantation|Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
75401946|NCT01263132|Drug|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
75401947|NCT01264614|Behavioral|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
75401948|NCT01267422|Drug|rAAV2-ND4|injection
75401949|NCT01267656|Device|Lubricating and Rewetting Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
75549849|NCT00341250|Drug|AMA1-C1/Alhydrogel Malaria Vaccine|
75549850|NCT00308438|Drug|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
75401950|NCT01267656|Device|AMO Blink Contacts Lubricant Eye Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
75401951|NCT01269372|Device|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
75401952|NCT01269372|Device|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
75401953|NCT01270542|Drug|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
75401954|NCT01270542|Other|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
75401955|NCT01271244|Drug|Escitalopram|10-20mg daily for 12 weeks
75401956|NCT01271868|Biological|IB1001|
75401957|NCT01271946|Device|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
75401958|NCT01272882|Device|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
75549851|NCT00338325|Behavioral|Reading program|Reading of children's story/picture books preoperatively
75549852|NCT00308477|Drug|dexamethasone|
75549853|NCT00308594|Drug|Dexamethasone|
75549854|NCT00341328|Biological|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
75549855|NCT00338364|Behavioral|PAT|Coping and Distraction Intervention
75549856|NCT00308789|Procedure|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
75549857|NCT00308789|Procedure|CPAP|Continuous positive airway pressure
75549858|NCT00308867|Procedure|Photodynamic Therapy|
75549859|NCT00308867|Procedure|Cryosurgery|
75549860|NCT00341445|Behavioral|Effect of Cockroach Allergen|
75549861|NCT00308906|Drug|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
75401959|NCT01272960|Device|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
75401960|NCT01272960|Device|Interval Insertion|Insertion of Mirena 4-8 weeks post partum after vaginal delivery
75401961|NCT01273896|Drug|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
75401962|NCT01274520|Device|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
75401963|NCT01275300|Drug|Aspirin|
75401964|NCT01275300|Drug|Placebo|
75401965|NCT01275300|Drug|Niacin|
75401966|NCT01276314|Drug|anti- TNF-a|25mg BIW, SC
75401967|NCT01276314|Drug|Prednisolone|1-1.5 mg / kg / day
75401968|NCT01276860|Device|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
75401969|NCT01280058|Drug|Carboplatin|Given IV
75401970|NCT01280058|Other|Laboratory Biomarker Analysis|Correlative studies
75401971|NCT01280058|Drug|Paclitaxel|Given IV
75401972|NCT01280058|Biological|Wild-type Reovirus|Given IV
75401973|NCT01280604|Drug|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
75401974|NCT01282242|Drug|IV rt-PA|open-label
75401975|NCT01283022|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
75401976|NCT01285050|Drug|Antiretroviral therapy (ART)|Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
75401977|NCT01285050|Drug|raltegravir|raltegravir is an HIV medication given 400 mg twice daily by mouth
75401978|NCT01285050|Drug|Emtricitabine and tenofovir disoproxil fumarate|Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
75401979|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
75401980|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
75401981|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
75401982|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
75401983|NCT01286454|Drug|fesoterodine|single dose of tablet
75401984|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
75401985|NCT01287078|Drug|Cyclosporine Inhalation Solution|sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
75401986|NCT01290978|Drug|ChloraPrep|The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
75401987|NCT01290978|Drug|DuraPrep|The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
75549862|NCT00338403|Procedure|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
75549863|NCT00308945|Drug|travoprost 0.004% (drug)|local drop application
75549864|NCT00308945|Drug|latanoprost 0.005% (drug)|local drop application
75401988|NCT01291056|Other|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
75401989|NCT01291056|Drug|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
75401990|NCT01292304|Drug|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
75401991|NCT01292538|Device|Erchonia GLS|532 nm green diode low level laser light device
75401992|NCT01292538|Device|Placebo laser|Sham light output with no therapeutic benefit
75401993|NCT01293396|Drug|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
75401994|NCT01293396|Drug|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
75401995|NCT01293396|Drug|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
75401996|NCT01294098|Drug|Marcaine|0.75 cc/kg of 1/4% Marcaine
75401997|NCT01295112|Drug|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
75401998|NCT01295112|Drug|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
75401999|NCT01296360|Biological|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
75402000|NCT01296360|Biological|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
75402001|NCT01298544|Procedure|Blood draw|One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
75402002|NCT01299090|Device|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
75549865|NCT00338442|Drug|VariZIG™|Biological / Vaccine
75402003|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
75710851|NCT04035148|Diagnostic Test|Cardiopulmonary exercise test|we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.Transthoracic Echocardiography(TTE) : The first step non-invasive method to diagnose PHT.
75710852|NCT00826371|Drug|ranibizumab 0.5 mg|
75871416|NCT03726983|Other|Experimental group|Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
76038219|NCT05104671|Other|scapular stabilization exercises.|"General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~towel slide~Scapular Clock:~Scapular Proprioceptive Neuromuscular facilitation:~Inferior Glide.~Scapular Orientation Exercise (SOE):~Protraction and retraction in front of a mirror:"
75402004|NCT01301742|Drug|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
75402005|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
75402007|NCT01303224|Drug|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
75549866|NCT00338481|Drug|Morphine p.o.|"Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c."
75549867|NCT00338481|Drug|Morphine s.c.|"False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg"
75549868|NCT00309062|Biological|Recombinant birch pollen|
75549869|NCT00309101|Drug|tacrolimus|Oral
75710853|NCT00824499|Other|Complex regional intervention|"Components of the complex intervention:~Introduction of a program coordinator~Introduction of a self-management education program~Bottom up development of a interdisciplinary care protocol~Support program for the intiation of insulin therapy in primary care~Regional audit"
75871417|NCT02343328|Biological|Fecal Microbiota Transplant|
76038220|NCT05104671|Other|Thoracic manipulation.|• Thoracic Thrust Manipulation: The participants were in high sitting and in prone lying position. The therapist was standing next to the patient in a diagonal stance and also behind the patient during high sitting. Thoracic thrust manipulation demonstrated to manipulate specific thoracic segment mainly mid thoracic.
75402008|NCT01303224|Drug|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
75402009|NCT01303224|Drug|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
75402010|NCT01303224|Drug|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
75549870|NCT00309218|Drug|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
75402011|NCT01304082|Drug|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
75402012|NCT01304082|Drug|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
75402013|NCT01304082|Drug|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
75402014|NCT01304238|Drug|lepirudin|lepirudin
75402015|NCT01304238|Drug|danaparoid|danaparoid
75402016|NCT01304238|Drug|argatroban|argatroban
75402017|NCT01304238|Drug|fondaparinux|fondaparinux
75549871|NCT00309296|Behavioral|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
75549872|NCT00338637|Device|APOS shoe kit|
75549873|NCT00309335|Drug|Phentolamine Mesylate (NV-101)|
75710854|NCT02540824|Drug|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
75549874|NCT00341640|Procedure|Blood testing|
75402018|NCT01305252|Drug|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
75402019|NCT01305252|Drug|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
75402020|NCT01307748|Other|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
75549875|NCT00309374|Drug|LPS 2ng/kg intravenous bolus|
75549876|NCT00309374|Drug|Simvastatin 80mg; administered daily p.o. over 5 days|
75549877|NCT00309374|Drug|Rosuvastatin 40mg; administered daily p.o. over 5 days|
75549878|NCT00309413|Drug|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
75710855|NCT02540122|Device|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
75710856|NCT02540122|Device|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
75710857|NCT02540122|Device|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
75710858|NCT02540122|Device|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
75710859|NCT02540590|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
75710860|NCT02540590|Device|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
75710861|NCT00826527|Drug|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
75710862|NCT00898924|Genetic|molecular diagnostic method|
75710863|NCT00898924|Genetic|mutation analysis|
75871418|NCT02343328|Biological|Placebo|
75402021|NCT01308060|Drug|Botulinum Toxin Type A|During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
75402022|NCT01308060|Other|Placebo|
75402023|NCT01308294|Biological|2 vaccine injections in 1 limb|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
75402024|NCT01308294|Biological|2 vaccine injections in distinct limbs|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
75402025|NCT01308294|Biological|"2 vaccine injections in distinct limbs"|
75402026|NCT01308840|Drug|Panitumumab|Day 1 and 15 = 6 mg/kg IV
75402027|NCT01308840|Drug|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
75402028|NCT01308840|Drug|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
75549879|NCT00309413|Drug|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
75402029|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
75402030|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
75402031|NCT01310400|Biological|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
75402032|NCT01311102|Drug|Lidocaine|1.33 cc 2% liquid lidocaine
75402033|NCT01311102|Drug|Normal Saline|1.33cc normal saline
75402034|NCT01312038|Drug|Simethicone|single 125 mg chewable tablet
75402035|NCT01312038|Drug|Placebo|chewable calcium tablet
75402036|NCT01312272|Drug|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
75402037|NCT01312272|Drug|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
75402038|NCT01312818|Drug|Bortezomib|1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
75402039|NCT01312818|Drug|Vorinostat|180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
75402040|NCT01312818|Drug|Dexamethasone|6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.
75402041|NCT01312818|Drug|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
75402042|NCT01312818|Drug|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16."
75402043|NCT01313520|Drug|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
75402044|NCT01313520|Drug|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
75402045|NCT01313910|Dietary Supplement|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
75402046|NCT01315002|Drug|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
75402047|NCT01315002|Drug|Placebo patch|Placebo patch
75402048|NCT01315158|Drug|Propofol Alone|"Recommended Propofol doses before considering crossover:~Induction: 2-2.5 mg/kg~Maintenance: 0.1-0.2 mg/kg/min"
75402049|NCT01315158|Drug|Propofol+Benzo/Opioids|"Recommended Versed:~a. Prior to intubation~patient is < 50 kg = 1 mg Versed~patient is 50-75 kg = 1.5 mg Versed~patient is > 75 kg = 2 mg Versed~Recommended Fentanyl~Prior to intubation = 0.5 ug/kg~Total procedural dose = 1 ug/kg"
75402050|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
75402051|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
75402052|NCT01317030|Other|Non-Contact Lens Wear|No intervention
75402053|NCT01318278|Drug|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
75402054|NCT01318278|Drug|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
75710864|NCT02550717|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
75710865|NCT02550717|Drug|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
75710866|NCT00820365|Drug|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
75710867|NCT00895258|Behavioral|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
75710868|NCT00895258|Behavioral|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
75710869|NCT02550249|Drug|Nivolumab|Intravenous administration of nivolumab
75402055|NCT01318356|Behavioral|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
75402056|NCT01318356|Drug|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
75710870|NCT00824811|Drug|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
75710871|NCT00824811|Drug|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
75710872|NCT00824811|Drug|Fluorometholone Eye Drops (FML Forte®)|"Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®."
76038221|NCT05104671|Other|Myofascial release.|The subject will be treated with IASTM.applied to the pectoral muscles and medial brachium with the subject in supine and the glenohumeral joint(GH). placed in 120 º abduction to place adequate tension on the selected tissues in the style of pectoral tightness test .The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers with the instrument held at a 45 º angle to the skin.The same IASTM protocol of 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers was applied to the posterior cuff musculature of the GH joint with the subject in prone and arms in 90 º abduction and internal rotation draped over the side of the plinth . While in the same position, the technique was applied to the periscapular musculature including the, trapezoids, rhomboids, teres minor, teres major, and latissimus dorsi.
76038222|NCT04792619|Other|Bobath Approach|The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients
76038223|NCT04792619|Other|Isometric scapular exercises|Isometric scapular exercises were performed to the patients included to the study group in a sitting position and at 900 of the shoulder flexion and 900 of the shoulder abduction. The patients were exercised by a physiotherapist using isometric contraction in protraction and retraction by a physiotherapist. Isometric contractions lasted 5 seconds and each exercise was repeated 2x15 times. One minute rest period was given between sets
75402057|NCT01318356|Drug|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
75402058|NCT01322022|Behavioral|ParentTraining|5 sessions of individual parent training
75402059|NCT01322022|Other|Parent Education|Parent Education to control for time and attention
75402060|NCT01324128|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
75402061|NCT01324128|Drug|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
75402062|NCT01324128|Drug|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
75710873|NCT00625365|Drug|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
75710874|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
75710875|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
75710876|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
75710877|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
75710878|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
75402063|NCT01324518|Drug|ORM-12741|60mg twice a day
75710879|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
75710880|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
75710881|NCT00824967|Other|Training and valuation of the treating personnel|Training and valuation of the treating personnel
75402064|NCT01324518|Drug|ORM-12741|200mg twice a day
75402065|NCT01324518|Drug|Placebo for ORM-12741|Placebo twice a day
75402066|NCT01326780|Drug|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
75402067|NCT01326780|Drug|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
75710882|NCT00820521|Drug|active|
75710883|NCT00820521|Drug|placebo|
75402068|NCT01326780|Drug|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
75402069|NCT01326780|Other|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
75402070|NCT01328184|Drug|levonorgestrel|multiple doses
75402071|NCT01328184|Drug|levonorgestrel|multiple doses
75402072|NCT01328184|Drug|Ethinylestradiol|multiple doses
75402073|NCT01328184|Drug|Microgynon + BI 10773|multiple doses BI 10773
75402074|NCT01328184|Drug|Ethinylestradiol|multiple doses
75549880|NCT04715880|Procedure|Paravertebral block/Intercostal Block (PVB/ICB) group|A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
75549881|NCT04715880|Procedure|Paravertebral Block (PVB) group|A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
75549882|NCT00309491|Drug|Tamoxifen alone|2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
75710884|NCT00606580|Drug|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
75710885|NCT00606580|Drug|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
76038224|NCT04801199|Drug|CPL-2009-0031 140 mg|Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
76038225|NCT04801199|Drug|Sitagliptin 100mg|Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
76038226|NCT05104359|Other|Observational|HIV-positive versus HIV-negative patients, individuals with at least 2 measurements of antibody levels, and boosted individuals are the subgroups of interest.
76038227|NCT05102877|Device|Neuromuscular electrical stimulation|Motor stimulation was administered at an intensity sufficient to produce muscle contractions. Sensory stimulation was defined as the threshold when the patient feels a tingling sensation on their skin.
75710886|NCT00606580|Drug|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
75710887|NCT00826683|Biological|Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures|
75710888|NCT00899002|Genetic|comparative genomic hybridization|
76038228|NCT05154357|Other|Elastic Sac|Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
76038229|NCT05154357|Other|Control|Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
76038230|NCT05153421|Device|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
75402075|NCT01328964|Drug|Fluticasone propionate|fluticasone propionate 44 mcg
75402076|NCT01328964|Drug|Budesonide|budesonide
75402077|NCT01328964|Drug|Montelukast|montelukast
75402078|NCT01329198|Device|NeuroPace RNS® System Deep Brain Stimulator|Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
75402079|NCT01330134|Drug|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
75402080|NCT01330134|Drug|lidocaine|1% lidocaine subcutaneous injection alone
75402081|NCT01330290|Drug|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
75402082|NCT01331304|Drug|Lithium|600-900mg per day over 6 months
75402083|NCT01331304|Drug|Quetiapine|100-800mg a day over 6 months
75402084|NCT01331694|Drug|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
75402085|NCT01331694|Drug|tiotropium|patients initiating treatment with tiotropium
75402086|NCT01331694|Drug|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
75402087|NCT01333098|Drug|Mifepristone|300mg per day, by mouth, for 21-28 days
75402088|NCT01333488|Device|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
75402089|NCT01333488|Drug|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
75710889|NCT00899002|Genetic|molecular genetic technique|
75402090|NCT01335204|Drug|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
75402091|NCT01335750|Other|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
75402092|NCT01335750|Other|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
75402093|NCT01335750|Other|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
75402094|NCT01335750|Other|Multipurpose Solution #4|Saline Solution
75402095|NCT01336296|Drug|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
75402096|NCT01337076|Device|cochlear implant|Cochlear implant surgery
75402097|NCT01337700|Drug|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
75402098|NCT01337700|Drug|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
75402099|NCT01339260|Drug|Netupitant and Palonosetron|
75710890|NCT00899002|Genetic|mutation analysis|
75710891|NCT00899002|Genetic|polymerase chain reaction|Not noted
75710892|NCT00899002|Genetic|proteomic profiling|
75710893|NCT00899002|Other|immunohistochemistry staining method|not noted
75402100|NCT01339260|Drug|Palonosetron|
75402101|NCT01339260|Drug|Dexamethasone|
75402102|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
75402103|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
75402104|NCT01341912|Biological|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
75402105|NCT01342458|Other|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
75402106|NCT01342770|Other|Laboratory Biomarker Analysis|Correlative studies
75402107|NCT01342770|Drug|Pioglitazone Hydrochloride|Given PO
75402108|NCT01342770|Other|Quality-of-Life Assessment|Ancillary studies
75402109|NCT01343004|Drug|Placebo|Placebo 0 mcg subcutaneous daily
75402110|NCT01343004|Drug|BA058 80 mcg|BA058 80 mcg subcutaneous daily
75402111|NCT01343004|Drug|teriparatide|teriparatide 20 mcg subcutaneous daily
75402112|NCT01343160|Device|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
75402113|NCT01347060|Drug|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
75402114|NCT01347060|Drug|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
75402115|NCT01351740|Drug|atazanavir|switch to unboosted atazanavir 400 mg daily
75402116|NCT01351740|Drug|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
75402117|NCT01352286|Genetic|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
75402118|NCT01352442|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
75402119|NCT01352598|Radiation|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
75402120|NCT01257438|Device|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
75402121|NCT01257438|Device|Percutaneous Transluminal Angioplasty only|Treatment of in-stent restenosis
75402122|NCT01353144|Drug|aspirin|aspirin, 100 mg, qd x 8 weeks
75402123|NCT01355484|Drug|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
75402124|NCT01355484|Drug|placebo|subject will receive placebo for the duration of the trial
75710894|NCT00899002|Other|laboratory biomarker analysis|not noted
75710895|NCT00899002|Other|mass spectrometry|not noted
75710896|NCT00899002|Other|medical chart review|not noted
75710897|NCT02550327|Drug|Nab-paclitaxel|125 mg/m2
75710898|NCT02550327|Drug|Gemcitabine|1000 mg/m2
75710899|NCT02550327|Drug|Cisplatin|25 mg/m2
75710900|NCT02550327|Drug|Anakinra|100 mg
75710901|NCT00881998|Procedure|Minimally Invasive Total Hip Arthroplasty|
75402125|NCT01355796|Drug|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
75402126|NCT01355796|Drug|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
75402127|NCT01356498|Biological|pegloticase|8 mg intravenous infusion
75402128|NCT01357356|Drug|SER120 (750 ng/day)|
75402129|NCT01357356|Drug|SER120 (1000 ng/day)|SER120 (1000 ng/day)
76038231|NCT05203575|Behavioral|Fast-forwarding in Cycle 1|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 1 (first 14 weeks)."
76038232|NCT05203575|Behavioral|Goal-Setting plus Weekly Nudge in Cycle 1|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks)."
75402130|NCT01357356|Drug|SER120 (1500 ng/day)|
75402131|NCT01357356|Drug|Placebo|
75402132|NCT01357512|Device|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
75549883|NCT00309491|Drug|Tamoxifen + Aminoglutethimide|"2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~1st therapy week:125mg/-/125mg Aminoglutethimide daily~2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily"
75549884|NCT02960048|Device|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
75549885|NCT02960048|Device|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
75402133|NCT01362192|Device|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~Spot Size: 5 mm~Fluence: 13-15 J/cm2~Pulse Duration: 40 ms~Epidermal contact-cooling: 5° Celsius"
75402134|NCT01362894|Device|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
75402135|NCT01362894|Device|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
75402136|NCT01363050|Drug|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
75402137|NCT01363128|Drug|Cyclophosphamide|Given IV
75402138|NCT01363128|Drug|Cytarabine|Given IV
75402139|NCT01363128|Drug|Dexamethasone|Given IV or PO
75549886|NCT00309530|Drug|5-fluorouracil, levamisol, interferon|
75549887|NCT00309569|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2
75402140|NCT01363128|Drug|Doxorubicin Hydrochloride|Given IV
75402141|NCT01363128|Other|Laboratory Biomarker Analysis|Correlative studies
75402142|NCT01363128|Drug|Methotrexate|Given IV
75402143|NCT01363128|Biological|Ofatumumab|Given IV
75402144|NCT01363128|Drug|Vincristine Sulfate|Given IV
76038233|NCT05203575|Behavioral|Fast-forwarding in Cycle 2|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 2 (second 14 weeks)."
75402145|NCT01365624|Drug|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
75402146|NCT01367262|Drug|LY2886721|Administered orally
75402147|NCT01369758|Device|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
75402148|NCT01371786|Drug|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
75549888|NCT00309569|Drug|Methotrexate|Methotrexate 40mg/m2
75549889|NCT00309569|Drug|Fluorouracil|Fluorouracil 600mg/m2
75549890|NCT00309569|Drug|Epirubicin|Epirubucin 60mg/m2 (only node-positive patients)
76038234|NCT05203575|Behavioral|Goal-Setting plus Weekly Nudge in Cycle 2|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks)."
76038235|NCT05445791|Drug|Metformin Hydrochloride|Metformin 500 mg twice daily until disease progression.
76038236|NCT05445791|Other|Placebo|Placebo 500 mg twice daily until disease progression
76038237|NCT05152875|Other|biological|fungal colonization by weekly cultures
76038238|NCT04801277|Procedure|Electroacupuncture on acupoints vs sham points|Randomized double blinded clinical trial
76038239|NCT05150457|Drug|BNA035|Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody
76038240|NCT04792229|Other|Whole Body Viberation|WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
76038241|NCT05102175|Other|Focus Group|Eligible participants will be invited to a semi-structured focus group discussion. Each group will include 8 -12 participants.
76038242|NCT04800653|Procedure|Stellate ganglion block|Find the position of the stellate ganglion under ultrasound guidance, and inject 0.375% ropivacaine near the stellate ganglion to block the sympathetic nerves in the upper chest and head and neck
75402149|NCT01371786|Drug|mometasone Aqueous (AQ) nasal spray|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
75402150|NCT01373580|Device|The Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
75402151|NCT01374438|Drug|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
75402152|NCT01374438|Drug|Placebo|Placebo capsules given once daily for 90 days
75402153|NCT01377636|Drug|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
75549891|NCT00309569|Other|Surgery|Surgery
75549892|NCT00338715|Device|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
75549893|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
75549894|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1)|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
75549895|NCT00309686|Drug|Paliperidone ER|
75710902|NCT00881998|Procedure|Conventional Total Hip Arthroplasty|
76038243|NCT05203263|Device|(810A-v1) device prototype|Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).
75710903|NCT00825045|Drug|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
76038244|NCT05203263|Device|(810B-v1) device prototype|Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).
75402154|NCT01378416|Drug|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m^2 of decitabine.
75549896|NCT00309725|Drug|galantamine|
75710904|NCT00895336|Biological|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
75402155|NCT01379664|Drug|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
75402156|NCT01379664|Drug|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
75402157|NCT01380366|Drug|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
75402158|NCT01380366|Procedure|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
75549897|NCT00309764|Behavioral|Telemedicine|
75549898|NCT00338754|Drug|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
75549899|NCT00309803|Device|FiberNet Embolic Protection Device|
75710905|NCT00899080|Genetic|gene expression analysis|
76038245|NCT05203263|Device|(810C-v1) device prototype|Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
75402159|NCT01380366|Procedure|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
75402160|NCT01380366|Other|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
75402161|NCT01380366|Other|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
75402162|NCT01380366|Other|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
75402163|NCT01383720|Device|Lotus Valve System|The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
75402164|NCT01386528|Drug|nonacog beta pegol|The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
75402165|NCT01387464|Drug|ISV-303|0.075% bromfenac in DuraSite dosed QD
75402166|NCT01387464|Drug|Bromday™|0.09% bromfenac dosed QD
75710906|NCT00899080|Genetic|reverse transcriptase-polymerase chain reaction|
75710907|NCT00899080|Other|immunoenzyme technique|
75402167|NCT01388946|Drug|Ropivacaine 0.75|
75402168|NCT01388946|Drug|Normal saline|
75402169|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
75402170|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
75402171|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
75402172|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
75549900|NCT00338793|Drug|prednisolone|
75710908|NCT00899080|Other|laboratory biomarker analysis|
75402173|NCT01391286|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
75402174|NCT01391286|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
75710909|NCT00899080|Other|platelet aggregation test|
75710910|NCT02550015|Behavioral|High intensity interval training|Uphill treadmill walking
75710911|NCT02550015|Behavioral|General information|Standard care
76038246|NCT04792307|Other|Neuromuscular electrical stimulation , no high protein ice cream supplementation|"A trained operator applies Neuromuscular electrical stimulation treatment to one leg, for approximately 30 minutes per session, three sessions per week with or without high protein ice cream. Treatment can stimulate the nerve controlling the vastus lateralis muscle in the thigh or the nerve controlling the tibialis anterior muscle in the lower leg, or both. In our study, we will aim to stimulate both nerves and muscle groups, on the basis that the maximal effect with result from the maximal amount of muscle stimulated.Treatment is adjusted to generate a specific force and maintained for up to 5 minutes, followed by a rest period and then repeated three times over the typical 30-minute session. The stimulation can vary according to the frequency (pulses per second, typically 10-50Hz).~Additional protein supplementation: high protein ice cream :a single doses of a high protein supplement after each bout of neuromuscular electrical stimulation,"
75402175|NCT01391364|Device|SofLens in investigational solution|SofLens in investigational solution, worn on a daily disposable basis for 7 days.
75402176|NCT01391364|Device|SofLens in currently marketed solution|SofLens packaged in currently marketed solution, worn on a daily disposable basis for 7 days.
75549901|NCT00418847|Drug|miglustat|Target dose of 320 mg/m^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA > 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
75549902|NCT00309881|Biological|rituximab|
75549903|NCT00309881|Drug|cyclophosphamide|
75549904|NCT00309881|Drug|doxorubicin hydrochloride|
75549905|NCT00309881|Drug|prednisone|
75402177|NCT01393392|Behavioral|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
75549906|NCT00309881|Drug|vincristine sulfate|
75549907|NCT00309920|Biological|darbepoetin alfa|
75549908|NCT00309920|Drug|cyclophosphamide|
75402178|NCT01393392|Behavioral|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
75402179|NCT01393704|Drug|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
75402180|NCT01395966|Drug|DF289|Ear drops
75402181|NCT01395966|Drug|DF277|Ear drops
75402182|NCT01395966|Drug|DF289 plus DF277|Ear drops
75402183|NCT01396044|Other|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
75549909|NCT00309920|Drug|docetaxel|
75549910|NCT00309920|Drug|doxorubicin hydrochloride|
75549911|NCT00309920|Drug|epirubicin hydrochloride|
75549912|NCT00309920|Drug|fluorouracil|
75549913|NCT00309998|Biological|bevacizumab|
75549914|NCT00309998|Drug|vinorelbine tartrate|
75549915|NCT00338832|Behavioral|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
75710912|NCT00826761|Dietary Supplement|probiotic|One capsule per meal test (high dose or low dose)
75710913|NCT00826761|Dietary Supplement|placebo|1 capsuel every morning
75710914|NCT03855969|Procedure|Removal of a central venous access device|We are interested in those patients for which a central venous access device was removed.
75710915|NCT00820677|Behavioral|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
75710916|NCT00629265|Device|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
75549916|NCT00338832|Behavioral|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
75402184|NCT01396044|Other|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
75402185|NCT01399008|Drug|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
75549917|NCT00338871|Procedure|home exercise|
75549918|NCT00310115|Behavioral|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
75402186|NCT01399008|Drug|Allopurinol|Allopurinol 300 mg as active comparator
75402187|NCT01399008|Drug|Colchicine|0.6 mg colchicine daily as flare prophylaxis
75402188|NCT01399008|Drug|Placebo|Placebo
75549919|NCT00310115|Behavioral|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
75549920|NCT00310115|Behavioral|Counseling Intervention|2 in-person counseling sessions
75710917|NCT00606502|Drug|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
75710918|NCT00606502|Drug|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
75402189|NCT01399866|Drug|D-cycloserine|2 single weekly doses, 50 mg capsule
75549921|NCT00310154|Drug|docetaxel|
75549922|NCT00310154|Drug|gefitinib|
75402190|NCT01399866|Drug|Placebo|
75549923|NCT00310154|Other|laboratory biomarker analysis|
75549924|NCT00310154|Radiation|radiation therapy|
75549925|NCT00338910|Drug|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
75549926|NCT00310232|Drug|Epoetin Alfa|
75549927|NCT00418730|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
75549928|NCT00310271|Biological|pPJV7630 with pPJV2012 administered by PMED|
75871419|NCT04428606|Dietary Supplement|Metabolic Rheostat|Metabolic Rheostat™ Ingredients: Ginseng extract, Ginseng root extract, berberine chloride, Livaux (gold kiwi powder), MegaSporeBiotic, and MenaquinGold (vitamin K2-7) powder
75871420|NCT04428606|Dietary Supplement|Butyrate Ultra|An anerobic probiotic supplement that contains butyrate-producing Butyricicoccus pullicaecorum 25-3T, vitamin K2, and fenugreek to maintain healthy glucose balance.
75871421|NCT04428606|Dietary Supplement|Placebo|Placebo
75549929|NCT00310349|Biological|23 valent pneumococcal polysaccharide vaccine|
75549930|NCT00342108|Behavioral|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
75549931|NCT00310505|Drug|Amphotericin B deoxycholate given as daily administration|
75549932|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
75549933|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
75549934|NCT00339066|Drug|Sertraline|
75549935|NCT00310583|Drug|Pregabalin|
75549936|NCT00310622|Device|HyperQ Signal recording|
75710919|NCT00606502|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
75871422|NCT02343016|Device|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
75871423|NCT02343094|Drug|PBA 7,5g/d|Treatment for 14 days with PBA
75871424|NCT02343094|Drug|PBA 15g/d|Treatment for 14 days with PBA
75871425|NCT03073980|Drug|IV Acetaminophen|IV Acetaminophen for pain control during procedure
75871426|NCT03073980|Drug|PO Acetaminophen|PO Acetaminophen for pain control during procedure
75871427|NCT03073980|Other|Placebo IV Acetaminophen|Placebo IV Acetaminophen
75871428|NCT03073980|Other|Placebo PO Acetaminophen|Placebo PO Acetaminophen
75871429|NCT02347384|Device|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head & SL-TWIN Stem
75871430|NCT02347384|Device|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head & SL-PLUS Stem
75871431|NCT03146416|Drug|Evinacumab|SC or IV administration of Evinacumab
75402191|NCT01401582|Other|Implementation of Dementia Care Manager|"Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers."
75402192|NCT01402050|Drug|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
75402193|NCT01402050|Device|FOLEY BALLOON|INDUCTION OF LABOR
75402194|NCT01402128|Dietary Supplement|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
75402195|NCT01402128|Dietary Supplement|Placebo|Placebo for 12 weeks
75402196|NCT01403376|Drug|teriflunomide|"Film-coated tablet~Oral administration"
75549937|NCT00310661|Drug|Sarizotan|The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
75549938|NCT00310661|Other|Placebo|Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
75549939|NCT00421044|Drug|Patupilone/EPO906|
76038247|NCT05101473|Other|Exercise Therapy|The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
75549940|NCT00310700|Biological|Meningococcal C conjugate vaccine|
75549941|NCT04715256|Behavioral|Cognitive assessment of obsessive-compulsive and impulsive behaviours|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
75549942|NCT04715256|Genetic|Genomic analysis|A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
75549943|NCT04715256|Diagnostic Test|Glucoregulation assessment|Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
76038248|NCT05101161|Behavioral|Neurofeedback|Modulating brain oscillations based on visual neurofeedback
76038249|NCT04800419|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a third generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. ACT increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting cancer survivors in aligning behavior with their personal values. The objectives of the therapy are for client to learn to focus on behaviors and actions that are in line with their individual values - the things they care about most. ACT facilitates development and maintenance of health behavioral improvements by targeting internal barriers, such as emotional discomfort and self-defeating thoughts, and by fostering connection and commitment to personal values associated with self-management of positive health behaviors. ACT is useful in cancer patients, because it can help them to deal with the negative emotions caused by cancer instead of avoiding these.
75402197|NCT01403376|Drug|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
75402198|NCT01403376|Biological|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
75402199|NCT01404078|Drug|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
75402200|NCT01404078|Drug|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
75402201|NCT01404936|Drug|Interferon-2A|4 (x106 IU/m^2) subcutaneously on days 1-4.
75402202|NCT01404936|Drug|Adriamycin|25 mg/m^2 by vein on day 4.
75402203|NCT01404936|Drug|Bleomycin|10 mg/m^2 by vein on day 4.
75402204|NCT01404936|Drug|Velban|6 mg/m^2 by vein on day 4.
75402205|NCT01404936|Drug|Dacarbazine|375 mg/m^2 by vein on day 4.
75402206|NCT01405794|Drug|32ppm Silver Particle|Oral silver dose of 32ppm
75402207|NCT01405794|Drug|Placebo|Sterile Water No Silver
75402208|NCT01408992|Procedure|Audiometry|Standard hearing test performed by audiologists
75402209|NCT01408992|Other|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
75402210|NCT01410084|Dietary Supplement|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
75402211|NCT01410084|Dietary Supplement|Vitamin E|400 IU vitamin E once monthly for 5 months
75402212|NCT01410552|Device|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
75549944|NCT00425217|Drug|Rituximab|
75549945|NCT00310778|Drug|high sodium diet|high sodium diet
75549946|NCT00310778|Drug|low sodium diet|low sodium diet
75402213|NCT01411488|Device|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
75402214|NCT01413750|Drug|Paclitaxel|Given IV
75402215|NCT01413750|Drug|Carboplatin|Given IV
75402216|NCT01413750|Drug|Vorinostat|Given PO
75402217|NCT01413750|Other|Placebo|Given PO
75402218|NCT01413750|Other|Laboratory Biomarker Analysis|Correlative studies
75402219|NCT01415232|Device|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
75549947|NCT00310778|Drug|ramipril 10 mg|ramipril 10 mg
75549948|NCT00310778|Drug|valsartan 160 mg|valsartan 160 mg
75549949|NCT00310778|Drug|candesartan 8 mg|candesartan 8 mg
75549950|NCT00310778|Drug|atenolol 50 mg|atenolol 50 mg
75549951|NCT00421083|Drug|tadalafil|
75549952|NCT00310895|Drug|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
75549953|NCT00425256|Drug|Bremelanotide|
75549954|NCT00310934|Drug|methadone|
75549955|NCT00310934|Drug|buprenorphine / methadone sequence|
75549956|NCT00310934|Behavioral|Relapse prevention|
75549957|NCT00310934|Behavioral|Contingency management|
75549958|NCT00421122|Drug|budesonide/formoterol (Symbicort)|inhalation therapy
75549959|NCT00421122|Drug|budesonide (Pulmicort)|inhalation
75549960|NCT00421122|Drug|terbutaline sulfate (Bricasol)|inhalation therapy
75549961|NCT00310973|Behavioral|Social Network Intervention|
75549962|NCT00425295|Behavioral|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
75549963|NCT00311012|Drug|Aliskiren|
75402220|NCT01415934|Other|discontinue statins|patients will be randomized to either continue taking statins or discontinue.
75402221|NCT01417026|Drug|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
75549964|NCT00421161|Drug|olive oil and omega 3 in a combined cream|
75549965|NCT00311051|Drug|ramatroban|
75549966|NCT00311051|Drug|montelukast|
75549967|NCT00311129|Drug|Fludarabine Phosphate (Fludara)|Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
75710920|NCT00606502|Dietary Supplement|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
75710921|NCT02549625|Biological|Autologous Bone Marrow-derived Mononuclear Cells|
75402222|NCT01420146|Drug|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
75402223|NCT01420848|Other|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
75402224|NCT01420848|Other|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
75402225|NCT01421472|Drug|MM-121|MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
75549968|NCT00311129|Drug|Rituximab|Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
75549969|NCT00311285|Device|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
75549970|NCT04715412|Other|patient counseling and adherence support|"Technical interventions include; identification of possible reasons for non-adherence, adherence support by developing simplified schedules for taking medications that were customized to individualized patient's lifestyle. Reminders for dose as well as tools/strategies the RTR may use to follow the dosing schedules if needed as pillbox were provided as needed~Clinical pharmacists' guided patient training was individualized, repetitive, covered 6 months, and included more aspects and provided practical hints and strategies for medication management.~Initial clinical pharmacist face-to-face session will be up to 60-minute then 30-minute follow-up sessions will be conducted monthly for 6 months during the scheduled post-transplant clinic visits as coordinated with the transplant physician to allow for single office visits for transplant related issues and comorbidities."
75549971|NCT00311441|Biological|Tick-Borne Encephalitis vaccine|
75549972|NCT00342381|Drug|3,4-diaminopyridine|Single dose 3,4 diaminopyridine
75549973|NCT00342381|Drug|Placebo|Single dose placebo treatment
75402226|NCT01421472|Drug|Paclitaxel|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
75402227|NCT01428336|Procedure|1 ug ACTH stimulation test|1 ug cortrosyn dose
75549974|NCT00311480|Biological|Influenza vaccine surface antigen adjuvanted with MF59|
75549975|NCT00311519|Drug|Hylenex|
75549976|NCT00311558|Biological|recombinant interferon alfa-2b|SSG x 5 week
75549977|NCT00311558|Drug|sodium stibogluconate|SSG & IFN
75549978|NCT00311558|Drug|SSG & interferon|1 arm study with SSG & interferon
75549979|NCT00418925|Drug|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
75549980|NCT00311597|Procedure|Radiosurgery|single fractionated radiation therapy
75871432|NCT03146416|Drug|Placebo|Matching placebo
75402228|NCT01428336|Procedure|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
75402229|NCT01428336|Procedure|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
75402230|NCT01428336|Procedure|Insulin tolerance test|subjects will undergo an insulin tolerance test
75402231|NCT01429272|Drug|Minocycline|100 mg po bid for 6 weeks
75549981|NCT00339417|Drug|Albendazole|
75549982|NCT00339417|Drug|Ivermectin|
75549983|NCT00311636|Drug|cyclophosphamide|
75549984|NCT00311636|Drug|docetaxel|
75549985|NCT00311636|Drug|doxorubicin hydrochloride|
75549986|NCT00311636|Drug|epirubicin hydrochloride|
75549987|NCT00311636|Drug|fluorouracil|
75549988|NCT00311636|Drug|methotrexate|
75549989|NCT00311636|Drug|paclitaxel|
75549990|NCT00311636|Drug|triptorelin|
75549991|NCT00311636|Procedure|adjuvant therapy|
75549992|NCT00311675|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
75402232|NCT01429272|Drug|Aspirin|81 mg po bid for 6 weeks
75549993|NCT00311714|Drug|CS-8958 formulated as dry powder|
75549994|NCT00311714|Other|Placebo|
75549995|NCT00339456|Drug|HAART|
75402233|NCT01429272|Drug|placebo|placebo for minocycline and/or aspirin
75402234|NCT01429350|Drug|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
75402235|NCT01429350|Device|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
75402236|NCT01431300|Drug|gadofosveset|Intravenous administration of the specified dosage of gadolinium contrast agent
75402237|NCT01431846|Behavioral|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
75402238|NCT01432236|Drug|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
75402239|NCT01432236|Drug|placebo|placebo capsules twice a day for 14 weeks
75402240|NCT01434030|Behavioral|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
75402241|NCT01434186|Drug|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
75402242|NCT01434186|Drug|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
75402243|NCT01434186|Drug|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
75402244|NCT01434186|Drug|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
75402245|NCT01434342|Drug|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, & 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
75402246|NCT01435512|Behavioral|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
75402247|NCT01435824|Drug|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
75549996|NCT00311753|Drug|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
75549997|NCT00311753|Drug|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
75549998|NCT00311792|Behavioral|LapSimGyn training until expert proficiency level is reached|Two consecutive simulations reaching predefined expert level
75549999|NCT00311792|Behavioral|Traditional clinical education|
75550000|NCT00311831|Behavioral|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
75402248|NCT01435824|Drug|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
75402249|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
75550001|NCT00311831|Behavioral|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
75550002|NCT00311870|Drug|nisoldipine|
75550003|NCT00311870|Drug|lisinopril|
75550004|NCT00311948|Behavioral|Telephone counseling + interactive website = more abstinence|
75550005|NCT00311948|Behavioral|Behavioral: interactive website|
75550006|NCT00311987|Drug|3,5-Diiodothyropropionic acid (DITPA) therapy|
75710922|NCT00825123|Drug|Ivabradine|Ivabradine 10 mg once
75710923|NCT00825123|Drug|Metoprolol|Metoprolol 50 mg once
75550007|NCT00342849|Drug|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
75402250|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
75550008|NCT00342849|Drug|Placebo|
75550009|NCT00312026|Drug|efalizumab|
75550010|NCT00312065|Device|Application of reflective heat shield to thermistor probe|
75710924|NCT00825123|Drug|Placebo|Lactose powder
76038250|NCT04800419|Behavioral|Mindfulness-based Stress Reduction (MBSR)|The term 'mindfulness' refers to mindful awareness as a way of being - a knowing and experiencing of feelings, thoughts, and perceptions as they arise and pass away each moment. It is a way of relating to all experiences in an open, receptive way, without judging experiences as good or bad (grasping at them or pushing them away). Mindfulness employed two styles of meditations: concentrative meditation involves intentionally focusing attention on a chosen object (e.g. the sensations of breathing) in a sustained way, while receptive meditation involves monitoring the content of experience (e.g. sensations, emotions, thoughts, sounds, etc.) in a non-reactive and non-judgmental way, from moment to moment, with the goal being to recognize the nature of emotional and cognitive patterns. Mindfulness-based stress reduction (MBSR) is an 8-week, standardized group intervention consisting of mindfulness meditation and gentle yoga that is designed to have applications for stress, pain, and illness
76038251|NCT05100537|Behavioral|Mindfulness Based Stress Reduction|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.
76038252|NCT05100537|Other|continuing a routine life|No intervention will be made in the control group.
76038253|NCT04800575|Device|semi-permeable film|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
76038254|NCT04800575|Device|sterile gauze and tape|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
76038255|NCT05203029|Other|Online exercise|Patients in each group will be added to the specific group on Whatsapp, and the schedule and information about the exercise will be explained there. Furthermore, patients will be joined to particular pages on Instagram, and exercises will be performed through Live on that pages. All the patients will exercise for 12 weeks, two or three times every week.
76038256|NCT04349111|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
76038257|NCT02634151|Drug|Gemcabene|Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.
76038258|NCT02634151|Drug|Placebo|Three placebo tablets administered orally once daily for 12 weeks.
75402251|NCT01437852|Biological|StrataGraft Skin Tissue|
75550011|NCT00312104|Drug|insulin detemir|
75710925|NCT02540746|Behavioral|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
75710926|NCT02540746|Behavioral|Motivational Enhancement|Three week Motivational Enhancement group
75710927|NCT02540746|Behavioral|Family Skills Training|12-week group-based family skills training using Family Connections model
75710928|NCT00826839|Drug|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
75710929|NCT00826839|Drug|E2 patch/antagonist|"Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses."
75710930|NCT04017988|Dietary Supplement|Ethanol Extracts of Porphyra Tenera(PTE10)|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
75710931|NCT04017988|Dietary Supplement|Placebo|Placebo for 8 week
75710932|NCT00899158|Other|immunologic technique|
75402252|NCT01438008|Drug|24% sucrose po solution|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure."
75402253|NCT01438008|Drug|Placebo po|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure"
75402254|NCT01438710|Drug|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
75402255|NCT01438710|Drug|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
75402256|NCT01442844|Device|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
75402257|NCT01443546|Drug|HCG|hCG Trigger
75402258|NCT01443546|Drug|Lupron Trigger|leuprolide acetate 2 mg SQ
75402259|NCT01443546|Drug|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
75402260|NCT01444716|Biological|Ofatumumab|Given IV
75402261|NCT01445028|Drug|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
75402262|NCT01447914|Drug|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
75710933|NCT00899158|Other|laboratory biomarker analysis|
75710934|NCT00899158|Procedure|biopsy|
75710935|NCT00825201|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
75402263|NCT01447914|Other|Diagnostic laboratory biomarker analysis|Correlative studies
75402264|NCT01447914|Other|Questionnaire administration|Ancillary studies
75402265|NCT01447914|Procedure|Quality-of-life assessment|Ancillary studies
75710936|NCT00825201|Other|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
75710937|NCT00825201|Other|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
75710938|NCT00825201|Other|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
75710939|NCT00825201|Other|laboratory biomarker analysis|Correlative studies
75402266|NCT01449240|Other|No treatment|
75402267|NCT01449864|Radiation|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
75402268|NCT01452126|Drug|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
75550012|NCT00312104|Drug|insulin glargine|
75550013|NCT00312104|Drug|insulin aspart|
75402269|NCT01456494|Other|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
75550014|NCT00339690|Other|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
76038259|NCT04799951|Other|a survey questionnaire to find knowledge, attitude and practices in treatment of breast cancer.|an electronic webbased survey to assess knowledge, attitudes and practices amongst surgeons with regards to breast conservation surgery and mastectomy
75402270|NCT01456494|Other|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
75402271|NCT01457196|Diagnostic Test|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
75402272|NCT01457430|Drug|Icatibant|30 mg subcutaneous dose of Icatibant
75710940|NCT00901030|Procedure|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
75710941|NCT00825279|Device|Bare Metal Stent|Stainless steel stent
76038260|NCT05202639|Other|Questionnaire|"A questionnaire will be sent by e-mail to the mother and to the father separately. A return of the completed questionnaire is expected within 6 weeks via a secure internal platform pertained to the HCL (Hospices Civils de Lyon).~The aim of this questionnaire is to identify the factors associated with the continuation or not of pregnancy after diagnosis of severe fetal pathology and after legal authorization of medical termination of pregnancy given by the Multidisciplinary Center of Prenatal Diagnosis."
76038261|NCT05147337|Drug|E2511|E2511 tablets.
76038262|NCT05147337|Drug|Placebo|E2511 matched placebo tablets.
76038263|NCT04791605|Other|Gait analysis|Kinematic and kinetic analysis
75550015|NCT00312143|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
75550016|NCT00343005|Biological|AMA1-C1|
75550017|NCT00343005|Drug|AMA1-C1/alhydrogel Malaria Vaccine|
75550018|NCT00312182|Drug|Nelfinavir|
75550019|NCT00312260|Drug|Gabapentin|Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
75550020|NCT00312260|Drug|Amitriptyline|Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
75710942|NCT00825279|Device|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
75710943|NCT00820833|Other|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
76038264|NCT04791683|Other|sexaul counseling|Sexual counseling includes interviews about sexual problems in couples who are in the process of infertility treatment and suggestions for solving these problems.
76038265|NCT04799873|Drug|AAT( Alpha 1 Antitrypsin)|AAT administration based on clinical indication
76038266|NCT05145699|Device|VR-based post-stroke hemineglect evaluation system|Evaluation system applied with virtual environment using Pico Neo 2 eye
75710944|NCT00820833|Other|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
75710945|NCT00820911|Drug|cyclosporine (reduced exposure) / everolimus|twice daily
75402273|NCT01458288|Drug|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
75402274|NCT01458990|Drug|Omeprazole|20mg PO BID for 20 days
75402275|NCT01460940|Drug|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
75402276|NCT01460940|Drug|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
75550021|NCT00343122|Procedure|echocardiography for intrapulmonary vasodilatation|
75550022|NCT00312299|Device|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
75550023|NCT00312299|Device|Round edge PMMA IOL|Round edge PMMA IOL
75550024|NCT00312299|Device|Acrysof IOL|Acrysof IOL
75550025|NCT00312299|Device|square Edge PMMA IOL|Square edge PMMA intra ocular lens
75550026|NCT00312299|Device|Square Edge PMMA IOL|Square Edge PMMA IOL lens
75402277|NCT01462812|Drug|Sumatriptan|Sumatriptan 20mg
75402278|NCT01462812|Drug|Placebo|Matching placebo
75402279|NCT01463202|Drug|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
75402280|NCT01463202|Drug|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
75402281|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
75402282|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
75402283|NCT01467882|Drug|Triptorelin|Powder and solution for solution for injection
75402284|NCT01468350|Drug|dalfampridine-ER 10mg|
75550027|NCT00312416|Drug|Clonidin|
75402285|NCT01468350|Other|Placebo|
75402286|NCT01468584|Drug|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
75402287|NCT01468584|Drug|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
75402288|NCT01468584|Drug|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
75402289|NCT01468974|Device|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
75402290|NCT01471626|Device|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
75402291|NCT01472718|Device|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
75402292|NCT01472718|Device|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
75402293|NCT01472874|Drug|Once a day Trientine|Trientine at a dosage of ~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
75402294|NCT01474122|Drug|Macitentan 3 mg|Macitentan 3-mg tablet once daily
75550028|NCT00312416|Drug|Brimonidine|
75550029|NCT00339768|Drug|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
75402295|NCT01474122|Drug|Macitentan 10 mg|Macitentan 10-mg tablet once daily
75402296|NCT01474122|Drug|Placebo|Placebo tablet matching macitentan tablet, once daily
75550030|NCT00312455|Drug|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
75550031|NCT00312455|Drug|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
75550032|NCT00312455|Drug|Placebo|5 capsules/day
75550033|NCT00343161|Drug|esomeprazole|
75550034|NCT00343161|Drug|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
75402297|NCT01474590|Drug|Epiduo/Tactuo|topical to the face, once daily in the evening
75402298|NCT01474590|Other|vehicle gel|topical to the face, once daily in the evening
75550035|NCT00312533|Drug|Hylan F- 20|
75402299|NCT01474590|Drug|doxycycline 200mg|oral, 2 capsules once daily in the morning with aglass of water and with food
75402300|NCT01474590|Drug|Isotretinoin|oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
75402301|NCT01477320|Drug|Pantoprazole 40 mg IV daily and tube feed.|"Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily."
75402302|NCT01477320|Other|Placebo and tube feed|"Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo."
75550036|NCT00312611|Device|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
75550037|NCT00312650|Drug|liposomal doxorubicin and gemcitabine|
75550038|NCT00343200|Drug|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
75710946|NCT00820911|Drug|AEB071 300 mg b.i.d. / everolimus|twice daily
75402303|NCT01477710|Procedure|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
75402304|NCT01477710|Procedure|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
75402305|NCT01477710|Procedure|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
75402306|NCT01478256|Drug|Erythromycin|Topical erythromycin ointment twice a day
75402307|NCT01478256|Drug|Besifloxocin|Topical Besifloxocin twice a day
75402308|NCT01479270|Drug|TAP Block|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
75402309|NCT01479348|Drug|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|18FdCyd radiotracer
75402310|NCT01479348|Drug|Tetrahydrouridine intravenous (IV)|Total dose of THU = 350 mg/m^2, IV
75402311|NCT01479348|Drug|Tetrahydrouridine (oral)|Total dose of THU is 3000 mg, oral
75402312|NCT01479348|Diagnostic Test|Positron emission tomography (PET)/Computed tomography (CT)|One prior CT and 3 sequential whole body PET
75402313|NCT01479426|Dietary Supplement|EFLA400|EFLA400(960mg/day)for 12 weeks
75402314|NCT01479426|Dietary Supplement|Placebo|Placebo(960mg/day) for 12 weeks
75402315|NCT01483560|Drug|Metformin|3 years treatment duration
75710947|NCT00820911|Drug|AEB071 200 mg b.i.d. / everolimus|twice daily
75710948|NCT00605722|Drug|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
75710949|NCT00605722|Drug|erlotinib (Tarceva)|150 mg orally (po) daily.
75710950|NCT00826995|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
75710951|NCT00820989|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
75871433|NCT03146572|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
75402316|NCT01483560|Drug|Placebo|3 years duration
75402317|NCT01484340|Drug|Nicotine|"The nicotine patch be given in three phases:~2 weeks of patches at enrollment~6 weeks of patches at two-week follow-up visit~2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg."
75550039|NCT00343200|Drug|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
75871434|NCT03146572|Other|Handout|Handout providing written descriptions of strategies to encourage positive parenting behaviors
75871435|NCT03149458|Other|dance|dance program
75871436|NCT03149458|Other|control|upper limb rehabilitation
75871437|NCT03930186|Drug|Apremilast|Tablets for oral administration
75402318|NCT01484340|Behavioral|Intensive Counseling|"The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~Baseline~2-week follow-up (Quit Day)~1-month follow-up~2-month follow-up~3-month follow-up~6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again."
75710952|NCT00882076|Drug|Clofarabine|For Treatment Clofarabine will be administered on Days 2-6 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Clofarabine will be administered on Days 1-4 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
75710953|NCT00882076|Drug|Mitoxantrone|For Treatment Mitoxantrone will be administered on Days 1-3 at the dose of 8mg/m2 in Cohort 1, 2, 3 and on Days 1-5 for Cohort 4 and on Days 1-3 8mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Mitoxantrone will be administered on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 1, 2 and 3 and on Days 1-4 (4 doses) at the dose of 8mg/m2 in Cohort 4, and on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
75710954|NCT00882076|Drug|Etoposide|For Treatment Etoposide will be administered on Days 1-5 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Treatment Cohort 1). For Retreatment Etoposide will be administered on Days 1-4 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Retreatment Cohort 1).
75710955|NCT00825435|Procedure|Coronary CT Angiogram|Coronary CT Angiogram
75710956|NCT00901108|Procedure|Trabectome-IOL|"Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.~Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery."
75710957|NCT00901108|Procedure|Trab-IOL|"Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.~Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C."
75710958|NCT00827151|Drug|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
75710959|NCT00882154|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
75710960|NCT00882154|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
75710961|NCT00825591|Dietary Supplement|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
75871438|NCT03930186|Drug|Topical Therapy|Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
76038267|NCT04799561|Behavioral|Multimodal Teleprehabilitation|"Exercise Prescription: patients will be instructed on how to perform aerobic exercise (5 times/week: minimum 30-minute/day) and resistance training (3 times/week: 2-3 sets of 6-8 exercises repeated 8-12 times) at home. Exercise counseling will be weekly, using the video-conferencing application (Zoom).~Nutrition: nutritional status and dietary intake will initially be assessed by the nutritionist using zoom. All patients will receive daily whey protein supplements. Special precautions will be considered if patients have specific medical conditions.~Psychosocial intervention: Patients will have access to 1.5 hours of mental relaxation and coping mechanisms session within the first week of enrolment, using Zoom.~Smoking Cessation: Patients with smoking habits will meet with a respiratory specialist using Zoom, who will establish recommendations and contact the physician for the recommended smoking cessation protocol.~More counseling sessions will be provided as needed."
75402319|NCT01484652|Drug|COV795|2 tablets taken every 12 hours
75710962|NCT00825591|Dietary Supplement|Placebo Comparator|Oral administration before bed. 6 week duration.
75710963|NCT00899704|Genetic|microarray analysis|
75710964|NCT00899704|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
75710965|NCT00899704|Other|diagnostic laboratory biomarker analysis|
75871439|NCT02351362|Behavioral|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
75871440|NCT02351440|Drug|duloxetine|patients will be randomized to receive either duloxetine or placebo
75871441|NCT02351440|Drug|placebo|placebo
75402320|NCT01484652|Drug|Placebo|2 tablets taken every 12 hours
75402321|NCT01485588|Drug|hI-con1™ 60µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
75710966|NCT00825669|Drug|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
75871442|NCT03504917|Drug|Balovaptan|Participants will receive 10 mg of oral administration balovaptan once a day (QD).
75871443|NCT03504917|Drug|Placebo|Participants will receive matching placebo.
75871444|NCT02343172|Drug|HDM201|
75871445|NCT02343172|Drug|LEE011|
75402322|NCT01485588|Drug|hI-con1™ 150µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
75402323|NCT01485588|Drug|hI-con1™ 300µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
75402324|NCT01488318|Drug|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
75710967|NCT00825669|Procedure|Laser ablation|Laser ablation is given to the PVTT.
75402325|NCT01488318|Drug|Dasatinib|Dasatinib 150 mg po
75402326|NCT01488708|Drug|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
75402327|NCT01488708|Drug|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
75402328|NCT01490892|Drug|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
75402329|NCT01491984|Device|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
75402330|NCT01491984|Device|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
75402331|NCT01495572|Drug|Fludarabine|25 mg/m^2 IV (in the vein) for 5 days (day -5 to -1)
75402332|NCT01495572|Drug|Cyclophosphamide|60 mg/kg IV (in the vein) for days -7 and -6
75402333|NCT01495572|Drug|Aldesleukin|Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
75402334|NCT01495572|Drug|MART-1 Reactive CD8+ PBL|Intravenous (IV) over 30 minutes on day 0
75402335|NCT01496352|Drug|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
75402336|NCT01496352|Drug|Placebo|DFA-02 placebo
75402337|NCT01497756|Device|CAPP use|Any abdominal pelvic pressure
75402338|NCT01499862|Device|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
75402339|NCT01504854|Drug|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
75402340|NCT01504854|Drug|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
75710968|NCT00821067|Dietary Supplement|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
75710969|NCT00821067|Dietary Supplement|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
75710970|NCT00821145|Procedure|conventional surgery|AAA patients operated using a conventional incision
76038268|NCT05199519|Drug|IBI345|IBI345 CAR-T cell injection by intravenous infusion
76038269|NCT04799639|Drug|Sindilimab +paclitaxel+ cisplantin|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
75402341|NCT01505166|Biological|Vigil™ Vaccine|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
75402342|NCT01505166|Drug|Placebo|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
75402343|NCT01508052|Device|sequential compression device|applying sequential compression device during the surgery
75402344|NCT01508052|Device|elastic stockings|applying elastic stockings during the surgery
75402345|NCT01508832|Drug|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
76038270|NCT05614973|Procedure|Conventional method|The conventional method utilizes a 18G biopsy gun to acquire three or more tissue cores with the corresponding number of liver capsule punctures. Plugging of the biopsy needle track is not performed.
75402346|NCT01508832|Drug|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
75402347|NCT01509612|Drug|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
75402348|NCT01509612|Drug|Homeopathic Placebo globules|Homeopathic placebo globules every 2 to 3 months
75402349|NCT01510704|Drug|APD421|IV
75402350|NCT01510704|Drug|Placebo|IV
75710971|NCT00821145|Procedure|laparoscopic AAA resection|laparoscopic AAA resection
75710972|NCT00821145|Procedure|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
75710973|NCT00900016|Genetic|protein expression analysis|
75710974|NCT00900016|Genetic|western blotting|
75710975|NCT00900016|Other|immunohistochemistry staining method|
75402351|NCT01511016|Drug|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
75402352|NCT01511016|Drug|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
75710976|NCT00900016|Other|immunologic technique|
75710977|NCT00900016|Other|laboratory biomarker analysis|
75402353|NCT01511640|Drug|Pregabalin|pregabalin 2x daily for duration of study
75402354|NCT01511640|Drug|Placebo|placebo 2x daily for duration of study
75402355|NCT01513122|Drug|Lopinavir / ritonavir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
75402356|NCT01513122|Drug|2-3N(t)RTI|
75402357|NCT01513122|Drug|raltegravir|raltegravir 400mg 1 tablet twice daily.
75550040|NCT00312767|Drug|Fabrazyme (agalsidase beta)|
75550041|NCT00312806|Drug|Pantoprazole|Pantoprazole 40 mg o.d.
75710978|NCT00900094|Genetic|fluorescence in situ hybridization|
75710979|NCT00900094|Genetic|polymerase chain reaction|
75710980|NCT00900094|Genetic|protein expression analysis|
75710981|NCT00900094|Other|immunohistochemistry staining method|
75710982|NCT00900094|Other|laboratory biomarker analysis|
75710983|NCT00900094|Other|mass spectrometry|
75710984|NCT00882232|Device|Cross-linked hyaluronan gel|"Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy."
75710985|NCT04038424|Other|Art therapy|Art therapy including coloring, painting and listening to music
75710986|NCT00900172|Biological|bevacizumab|
75710987|NCT00900172|Drug|carboplatin|
75550042|NCT00347685|Drug|tramadol ER|
75710988|NCT00900172|Drug|paclitaxel|
75402358|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
75402359|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
75402360|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing <30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
75402361|NCT01514292|Device|Continuous Glucose Monitoring of glucose levels (Dexcom)|Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
75402362|NCT01515072|Other|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
75402363|NCT01515540|Drug|lidocaine|5% lidoderm patch
75402364|NCT01515540|Drug|placebo|placebo
75402365|NCT01515696|Drug|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
75402366|NCT01515696|Drug|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
75710989|NCT00900172|Genetic|gene expression analysis|
76038271|NCT05614973|Procedure|Coaxial method with needle-track plugging|The coaxial method utilizes a 17G coaxial needle with 18G biopsy gun to acquire three or more tissue cores with a single liver capsule puncture. Biopsy needle track is plugged using a slurry of gelatin particles (EGgel S Plus 2000-4000 μm).
76038272|NCT04799093|Diagnostic Test|EyeBOX|Eye-Tracking based diagnostic
75710990|NCT00900172|Genetic|polymerase chain reaction|
75710991|NCT00900172|Genetic|polymorphism analysis|
75402367|NCT01516632|Behavioral|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
76038273|NCT04790981|Other|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
76038274|NCT04790981|Other|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern including.
75402368|NCT01518270|Other|No treatment|No treatment will be provided
75402369|NCT01519284|Drug|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
75402370|NCT01519284|Drug|Entacapone|Entacapone 200 mg
75402371|NCT01519284|Drug|Placebo|placebo (four times a day)
75402372|NCT01519284|Drug|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
75402373|NCT01519284|Drug|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
75402374|NCT01519284|Drug|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
75710992|NCT00900172|Other|laboratory biomarker analysis|
75402375|NCT01520454|Drug|Saline|IV saline at 0.83 mL/kg/hr for six hours
75402376|NCT01520454|Drug|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
75402377|NCT01520454|Dietary Supplement|Water|Water by mouth
75402378|NCT01520454|Dietary Supplement|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
75402379|NCT01520454|Drug|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
75402380|NCT01520532|Other|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
75402381|NCT01520688|Drug|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
75402382|NCT01520688|Drug|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
75871446|NCT03899688|Procedure|Maxillary sinus augmentation|Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
75402383|NCT01520688|Drug|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
76038275|NCT05142501|Other|Blood samples|Four consecutive blood sampling throughout the overall follow-up period of 12 months.
76038276|NCT03068689|Procedure|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is > 185mm HG the cuffs are inflated to 15 mmHG above that level.
76038277|NCT03068689|Other|Placebo|Placebo
76038278|NCT04798937|Other|Motivational interviewing|a health education program based on motivational interviewing provided by a nurse
75402384|NCT01520688|Drug|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
75402385|NCT01520688|Drug|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
76038279|NCT05629897|Other|Sessions of cognitive stimulation|40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
75402386|NCT01520688|Drug|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
75402387|NCT01521546|Drug|eplerenone|25mg tablet, once daily by mouth for 12 months
75402388|NCT01521546|Drug|placebo|one tablet by mouth daily for 12 months
75402389|NCT01521780|Procedure|MRI|Participants undergo volumetric & diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
75402390|NCT01521780|Procedure|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
75402391|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
75402392|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
75402393|NCT01523496|Drug|Vitamin D control dose|18,000 IU per month
75402394|NCT01523496|Drug|Vitamin D supplementation-|60,000 IU per month(medium dose) or 120,000 IU/month(high dose)
75871447|NCT02351128|Drug|Lanreotide|
75550043|NCT00312962|Behavioral|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
76038280|NCT05154539|Diagnostic Test|Remote digital assessment|Remote digital assessment of test group participants
76038281|NCT05154539|Diagnostic Test|Conventional physical assessment|Conventional physical assessment of control group participants
75871448|NCT01378182|Genetic|allogeneic mesenchymal stem cell transplantation|1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)
75871449|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
75402395|NCT01523808|Drug|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
75402396|NCT01523964|Other|Testing with EIM|
75402397|NCT01526538|Drug|d-cycloserine|50 mg d-cycloserine
75402398|NCT01526538|Drug|sugar pill|placebo
75402399|NCT01527162|Device|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
75402400|NCT01527162|Other|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
75402401|NCT01528332|Device|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
75871450|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
75871451|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
76038282|NCT04798703|Drug|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase) followed by maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months in patients who achieved a complete response (CR) after the 12 weekly instillations.
75871452|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
75550044|NCT00312962|Behavioral|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
75871453|NCT02342938|Procedure|MEG or fMRI And INtracranial EEG|
75402402|NCT01528332|Device|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
75871454|NCT02342938|Procedure|fMRI|
75871455|NCT01569672|Behavioral|Patient Navigator matched with subject|Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
75871456|NCT01569672|Behavioral|Subjects are mailed informational/educational materials|Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
76038283|NCT04798313|Drug|MW031|Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.
76038284|NCT04798313|Drug|Prolia®|Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
75402403|NCT01528878|Radiation|Stereotactic Radiosurgery using the CyberKnife System.|"Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy."
75402404|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
75402405|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
75402406|NCT01529502|Drug|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
75402407|NCT01532700|Drug|Ofatumumab with GSK2110183|"GSK2110183 125mg OD continuously~Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
75402408|NCT01533948|Drug|axitinib|Given PO
75402409|NCT01533948|Other|laboratory biomarker analysis|Correlative studies
75710993|NCT00605566|Drug|Sorafenib|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
75710994|NCT00605566|Drug|Cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
75710995|NCT00900250|Other|Cytology Specimen Collection Procedure|Correlative studies
75871457|NCT02342860|Other|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~Software: operations and maintenance (O&M) training for teachers, hygiene training, and basic hygiene package."
75871458|NCT03146260|Procedure|Conventional TESE|usual procedure for sperm extraction
75402410|NCT01534416|Drug|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
75402411|NCT01534416|Drug|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
75402412|NCT01535664|Other|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~On drug Day-7 (visit 1) through Day 1 (visit 2)~Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~On drug Day 15±2 days (visit 5)"
75402413|NCT01535976|Drug|Placebo|"Placebo Comparator: Placebo~.9 normal saline infusion"
75402414|NCT01535976|Drug|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
75550045|NCT00343239|Drug|Docetaxel|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
75871459|NCT03146260|Procedure|Microdissection TESE|Procedure of extraction is performed under the operating microscope
75402415|NCT01536366|Drug|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
75550046|NCT00343239|Drug|Cisplatin|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
75550047|NCT00343239|Drug|Fluorouracil|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days"
75550048|NCT00313001|Drug|biphasic insulin aspart|
75550049|NCT00313001|Drug|exenatide|
75402416|NCT01536366|Drug|Repaglinide|0.5 mg repaglinide (single-dose)
75402417|NCT06115291|Other|Smell Test|Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
75402418|NCT06115265|Behavioral|Ketogenic diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
75402419|NCT06115265|Behavioral|Low Fat diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
75402420|NCT06115252|Behavioral|Motivational Interviewing (MI)|Motivational interviewing with peer dyads starts with an open-ended exploration of the dyad's hazardous drinking behavior via personal stories about alcohol use. It includes a values clarification task and age-matched norms along with personalized feedback regarding the dyad's alcohol use. The goal of the session is to engage the dyad in a thoughtful conversation about drinking and the implications it may have on their lives, with an eye to bolstering and supporting inherent drive for behavior change.
75402421|NCT06115239|Other|Questionnaires|The patients will fulfill the EORTC-LC29 and HADS questionnaires in 5 different moments.
75402422|NCT06115213|Behavioral|Patient counselling|Patient counseling, lifestyle modifications, medication evaluation, and adherence
75402423|NCT06115187|Diagnostic Test|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
76038285|NCT01655823|Drug|Placebo|Sham treatment acting as control arm
76038286|NCT01655823|Drug|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
76038287|NCT01360645|Drug|OPC-34712 + ADT|Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
76038288|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
76038289|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
75710996|NCT00900328|Other|laboratory biomarker analysis|Correlative Studies
75710997|NCT00882388|Drug|aspirin|aspirin 100 mg qd for 7 days
75402424|NCT06115187|Diagnostic Test|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
75550050|NCT00343278|Drug|Valaciclovir Hydrochloride|
75550051|NCT00313040|Behavioral|Brief Consultation with Health Counselor, workbook|
75550052|NCT00313040|Behavioral|Usual Care wait list|
75550053|NCT00343317|Drug|Intrapartum Cefoxitin (2g) vs. placebo|
75550054|NCT00313079|Drug|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
75550055|NCT00313079|Drug|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
75550056|NCT00343356|Drug|Trement|
76038290|NCT05132855|Biological|BNT162b2|BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
76038291|NCT05132855|Biological|mRNA-1273|mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
76038292|NCT05132855|Biological|MVC-COV1901|MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
75710998|NCT00882388|Drug|celecoxib|celecoxib 200 mg bid * 7 days
75550057|NCT00347724|Drug|Tramadol HCl ER|
75550058|NCT00313157|Drug|Metoprolol|
75550059|NCT00313157|Drug|Diltiazem|
75550060|NCT00313157|Drug|Verapamil|
75550061|NCT00313157|Drug|Carvedilol|
75710999|NCT00882388|Drug|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
75711000|NCT00882388|Drug|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
75711001|NCT00882388|Drug|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
75711002|NCT00901420|Procedure|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
75711003|NCT00901420|Behavioral|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
75711004|NCT00900406|Genetic|gene expression analysis|blood collection
76038293|NCT05141799|Device|high intensity laser therapy|Laser treatment is noninvasive and painless and can be easily administered in therapy units for a wide range of conditions. High-intensity laser therapy (HILT) has gained importance for the treatment of different kinds of sports injuries such as tendon injuries, contusions, and muscle spasms.
75402425|NCT06115174|Drug|Pentoxifylline|"Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy [15].~The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) [16]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes [17]."
75402426|NCT06115174|Radiation|FOLFOX|(leucovorin, fluorouracil, oxaliplatin)
75402427|NCT06115174|Radiation|XELOX|(oxaliplatin + capecitabine)
75402428|NCT06115174|Drug|Monoclonal antibodies (target therapy)|target therapy (Bevacizumab).
75402429|NCT06115161|Device|Instrumented Orthosis|Gait analysis will be performed with the instrumented orthosis as well as the reference system.
75402430|NCT06115148|Other|Feeding|Nutrition beverages will be provided to meet the nutrient needs described in the Feeding Arm.
75550062|NCT00343395|Drug|AVANDAMET|2/500 mg
75550063|NCT00347763|Procedure|10% permethrin in water applied as low volume spray|
75550064|NCT00313235|Biological|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
75871460|NCT03536663|Device|Optiflux and Dialyzer with Endexo|Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.
75871461|NCT03770052|Drug|duvie|take the intervention drug once daily according to the randomized groups
75871462|NCT02351050|Device|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
76038294|NCT05105711|Behavioral|QI coaching intervention|The intervention consists of two main components: a webinar communication workshop and use of the Checkup Coach mobile app. The Checkup Coach intervention begins with a brief (<1 hour), communication training workshop that reviews evidence on HPV vaccination, models guideline-consistent recommendations, trains providers to address parent concerns, and facilitates discussion of shared goals for improving. Next, providers are invited to download and use the Checkup coach mobile app at their discretion for the 12-week study period. Providers complete in-app self-assessments and receive tailored feedback about their HPV vaccine recommendation quality, progress toward improving recommendation practices, a dashboard of aggregate HPV vaccination coverage for patients in their clinic, and tips for addressing parents' concerns about HPV vaccination every time they use the app.
76038295|NCT04345289|Biological|Convalescent anti-SARS-CoV-2 plasma|Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)
76038296|NCT04345289|Other|Infusion placebo|Saline 0.9% (600 ml) as an iv single dose infusion
76038297|NCT05195463|Other|Exercise intervention|Women with diastasis recti abdominis will do core stabilization exercises for the transversus abdominis muscle with 10 repetitions 3 days a week for 8 weeks. The exercises include diaphragmatic breathing exercises, core stabilization exercises for the transversus abdominis muscle, and pelvic floor contractions
75871463|NCT02351050|Other|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
75871464|NCT02350894|Behavioral|Graded and behavevial theraphy|Graded and behavevial theraphy
75871465|NCT03565211|Drug|Progesterone vaginal ring|A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
75871466|NCT02346994|Dietary Supplement|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
75402431|NCT06115148|Other|Fasting|Water will be consumed as described during the Fasting Arm.
75402432|NCT06115122|Other|Pre-eclampsia screening program|Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.
75402433|NCT06115083|Other|Pelvic floor re-education using bio-feedback and home training|Pelvic floor re-education using bio-feedback and home training
75402434|NCT06115070|Drug|Alteplase|intravenous alteplase(0.9 mg/kg;maximum dose, 90mg; 10% administered as a 1-minute bolus,the remaining infused over 1 hour)
75550065|NCT00347802|Drug|Bimatoprost 0.03%, Travoprost 0.004%|
75550066|NCT00313274|Drug|Clevudine|
75550067|NCT00343434|Behavioral|behavioral dietary intervention|
75550068|NCT00343434|Behavioral|exercise intervention|
76038298|NCT05195463|Other|Exercise intervention by wearing abdominal corset|In this group, in addition to the first group, core stabilization exercises will be performed by wearing an abdominal corset. Participants will be asked to wear their corsets while performing their exercises.
75402435|NCT06115057|Dietary Supplement|Fiber|"Subjects in this study are to consume the study product twice daily during regular meals.~The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption."
76038299|NCT05195463|Other|Corset intervention|Participants included in this group will be required to wear only this corset all day (except for the bathroom) for 8 weeks.
75711005|NCT00900406|Genetic|microarray analysis|Blood collection
75711006|NCT00900406|Genetic|polymorphism analysis|Blood collection
75711007|NCT00900406|Genetic|proteomic profiling|Blood collection
75711008|NCT00900406|Other|flow cytometry|Blood collection
75871467|NCT02346994|Dietary Supplement|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
76038300|NCT04343105|Procedure|pecto-intercostal plane block|under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles
76038301|NCT04342793|Drug|Placebo oral tablet|Placebo
76038302|NCT04342793|Drug|ALS-L1023 1,200mg|ALS-L1023
76038303|NCT04342793|Drug|ALS-L1023 1,800mg|ALS-L1023
76038304|NCT05095389|Device|ADRCs|Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer
76038305|NCT05095389|Other|standard care|standard care
76038306|NCT05095389|Other|Placebo|placebo
76038307|NCT04790747|Drug|CAR-T cells|Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion
75402436|NCT06115044|Procedure|Intermittent diurnal nutrition|Calculated daily nutritional requirement given as three equal bolus feeds in daytime with prolonged overnight fast
75402437|NCT06115044|Procedure|Continuous|Calculated daily nutritional requirement given over 24 hours
76038308|NCT03068221|Other|anaerobic exercise|assessing anaerobic exercise status
76038309|NCT05181085|Drug|NST 6179|orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
75402440|NCT06115018|Procedure|Palatal surgery|Palate surgery has evolved from the ablative partial palate resections, which favored the removal of the soft tissue that obstructed the upper airway (UA), to more recent innovative reconstructive procedures that not only address the level of palatal obstruction, but the type of palatal or lateral pharyngeal wall collapse.
75550069|NCT00343434|Dietary Supplement|soy isoflavones|
75550070|NCT00343434|Dietary Supplement|soy protein isolate|
75550071|NCT00343434|Other|counseling intervention|
75550072|NCT00343434|Other|educational intervention|
75550073|NCT00343434|Procedure|psychosocial assessment and care|
75550074|NCT00343434|Procedure|quality-of-life assessment|
75550075|NCT00419042|Drug|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
75550076|NCT00419042|Drug|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein-called intravenous infusion (IV). This will take about 30 minutes
75550077|NCT00347841|Drug|Bimatoprost 0.03%, Latanoprost|
75550078|NCT00425126|Drug|Epoetin Alfa|
75550079|NCT00343551|Drug|Aliskiren|
75550080|NCT04715334|Device|Mollii suit|The Mollii suit is a new technology of electrical stimulation in the form of whole-body garment with multiple electrodes individually programmed to stimulate the selected muscles. Based on preliminary studies, it is suggested that the Mollii suit improves spasticity. Recent studies also proposed that it improves mobility, gait, function and quality of life. However, these studies are based on qualitative and subjective measures.
75550081|NCT00347997|Device|217z Laser|LASIK correction of myopia and myopic astigmatism
75550082|NCT00343590|Device|Whole Body Vibration machine|
75550083|NCT00343629|Drug|sulindac|
75711009|NCT00900406|Other|immunologic technique|Blood collection
75711010|NCT00900406|Other|laboratory biomarker analysis|Blood collection
75711011|NCT00900406|Procedure|biopsy|Blood collection
75711012|NCT00396877|Drug|Clopidogrel (SR25990)|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
75711013|NCT00396877|Drug|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
75871468|NCT02346760|Drug|UB-621|100 mg/ml, subcutaneous injection
76038310|NCT05181085|Drug|Placebo|inactive analogue
76038311|NCT05195385|Procedure|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
76038312|NCT05056103|Device|TrachFlush|The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
75402441|NCT06115018|Behavioral|Oropharyngeal rehabilitation|Oropharyngeal rehabilitation (OPR) focus on the upper airway muscle including tongue muscle, palatal muscles and paryngeal muscles. The OPR for the treatment groups included three 30-minute sessions of OPR per day, and the exercise would be performed 3-5 days per week for 3 months. The performance of the home exercise will also be recorded by the force-sensing resistor. In addition to home exercise sessions, there will also be twice-weekly clinical visits to adjust the contents of OPR program and monitor training progress.
75402442|NCT06115018|Combination Product|Palatal surgery combined oropharyngeal rehabilitation|Participants will receive palatal surgery and post-surgery oropharyngeal rehabilitation (OPR). The palatal surgery and OPR describe as above.
75402443|NCT06115005|Biological|Plasma rich in growth factors ( PRGF )|"Plasma rich in growth factors (PRGF) is characterized by a moderate concentration of platelets, in the absence of leukocytes.~This absence of leukocytes is based on the fact that they synthesize matrix metalloproteinases, free radicals, and proinflammatory cytokines, which do not contribute and even impair the altered tissue regeneration"
75402444|NCT06114992|Device|Servo-n HFOV modes|Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care
75402445|NCT06114979|Drug|Silodosin|Each patient will receive 8 mg of silodosin tablet once daily.
75402446|NCT06114979|Drug|Placebo|Each patient will receive placebo tablet.
75871469|NCT02342626|Behavioral|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
76038313|NCT04336163|Device|Optical Coherence Tomography|Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
75402447|NCT06114966|Other|CADCAM|Milling of Final prosthesis over dental implants using CADCAM milling machine
75402448|NCT06114953|Drug|Mizoribine|Mizoribine+glucocorticoid+tacrolimus after kidney transplantation
75402449|NCT06114953|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation
75402450|NCT06114940|Drug|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
75402451|NCT06114940|Drug|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
75402452|NCT06114940|Drug|Lenvatinib|18 mg by mouth once each day for 12 weeks prior to nephrectomy
75402453|NCT06114940|Drug|Sunitinib|Subjects will receive a 21-day cycle of oral 50mg once a day for 14 days and then rest for 7days, requiring 4 cycles for a total of 12 weeks
75402454|NCT06114901|Other|SleepFix|SleepFix mobile application uses Sleep Retraining Therapy (SRT) which aims to reduce excess time spent in bed and reset sleep by matching time in bed (minimum of five and a half hours) to total sleep time (TST). There are four stages to the dBTi application and participants will progress based on completion of each stage. At the commencement of SleepFix application, participants enter sleep and bedtime data into the smartphone application for baseline referencing. These data are used to determine the sleep therapy based on a pre-determined algorithm that calculates optimum sleep efficiency.
75871470|NCT03723395|Drug|tucatinib|300mg dose, orally administered
76038314|NCT05139381|Drug|Mepolizumab|Treatment with Mepoluzimab
76038315|NCT05614505|Dietary Supplement|Ready to use therapeutic foods|locally produced therapeutic foods
75402455|NCT06114901|Other|Sleep health Education modules|Three Sleep Health education modules that contain information about sleep hygiene and introduces strategies on how to reduce insomnia severity and increase sleep quality.
75402456|NCT06114823|Procedure|carpal tunnel release mini-incision|Patients were subjected to a longitudinal mini-incision started just above the proximal flexor wrist crease and then extended for 1.5 - 2 cm in a proximal direction
75402457|NCT06114823|Procedure|carpal tunnel release conventional incision|Patients were subjected a longitudinal incision which was created between the thenar and hypothenar eminences along the longitudinal axis of the ring finger. Then, it was extended to the proximal flexor wrist crease.
75402458|NCT06114797|Other|Chamomile|"Chamomile was topically applied to the oral mucosa as oral rinse.~Based on this protocol, patients had oral rinses 3 times per day.~Patients were instructed to perform chamomile rinses in the oral mucosa.~Patients were instructed not to swallow the chamomile oral rinse."
75402459|NCT06114797|Other|Saline mouthwash|Saline mouthwash was used by elderly patients in the control arm.
75402460|NCT06114771|Other|strepsilis|Throat lozenge (strepsilis) was given to patients 30 minutes before the operation (the dissolution rate of the lozenge was proven to be 6-9 minutes).
75871471|NCT03723395|Drug|itraconazole|200mg dose
75871472|NCT03723395|Drug|rifampin|600mg dose
75402461|NCT06114771|Other|Placebo|Sugar dragee in the same size and shape was given to 30 patients 30 minutes before the operation. In order not to cause any complications, sugar patients were sucked and told not to chew.
75402462|NCT06114758|Drug|Cytotec 200Mcg Tablet|the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered
75402463|NCT06114758|Drug|Transamine|1 gram intravenous slow infusion intraoperatively as we start the laparatomy
75402464|NCT06114732|Behavioral|Walking exercise behaviour change intervention + TENS|"MOSAIC: Participants in this group receive two 60-minute individual video telehealth consultations (on weeks one & two) and two 20-minute follow-up telephone calls (weeks six & 12) delivered at a convenient time over the internet. All sessions are delivered by a trained senior/band 6 physiotherapist. All participants randomized to this arm are provided with a pedometer and a patient manual which include information on intermittent claudication (IC), risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.~HF-TENS - TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin. Participants will be asked to use TENS during their everyday walking-based tasks, and any planned walking activity they undertake."
75402465|NCT06114706|Behavioral|Physicians assess patients|Physicians are asked to assess patients following the current Swedish guideline
75402466|NCT06114706|Behavioral|Nurses assess patients|Nurses are asked to assess patients following the current Swedish guideline
75402467|NCT06114706|Behavioral|Pharmacists assess patients|Pharmacists are asked to assess patients following the current Swedish guideline
75402468|NCT06114641|Drug|Enoxaparin sodium injection|Originator Enoxaparin with a trade name is Lovenox.
75402469|NCT06114576|Other|Orange juice enriched with vitamin D3 and encapsulated probiotics|25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.
75711014|NCT02540044|Behavioral|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
75402470|NCT06114576|Other|Conventional orange juice|25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.
75402471|NCT06114550|Other|High intensity resistance training|The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.
75402472|NCT06114550|Other|Low intensity resistance training|For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.
75402473|NCT06114537|Drug|Acetazolamide|"The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks."
75402474|NCT06114524|Other|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied for 15 min before the procedure.
75402475|NCT06114485|Behavioral|VIPA Treatment Program|Participants will receive and Alexa device with a behavioral activation program, along with a detailed guidebook about how to utilize the Alexa device and the VIPA program
75402476|NCT06114485|Behavioral|Alexa with Guidebook|Participants will receive an Alexa device with a detailed guidebook on how to use the device.
75402477|NCT06114459|Drug|Sodium Chloride|Post surgery disinfection
75402478|NCT06114420|Procedure|salvage surgery|Some patients who cannot undergo surgery
75871473|NCT03723395|Drug|gemfibrozil|600mg tablets
75711015|NCT02540044|Behavioral|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
75402479|NCT06114381|Other|Home Based Physical Exercise|"Home Exercise protocol consists of one hour divided to 3 minutes warm up,9 minutes' full body (lower limbs, abdomen, back and upper limbs) exercise composed of (aerobic and strengthening) and 3 minutes cool down 4 times per day and 15 minutes for each session 6 days with one day recovery and, with every day follow up with each patient to ensure they did the whole sets and instructed them the ways to each exercise, The total duration was 36 sessions (6 weeks) for each patient. Daily communication with all subjects through sending mobile messages 3 times every day. The message was to remind the participants and confirmation of their response."
75402480|NCT06114381|Dietary Supplement|Vitamin D3 Supplements|Vitamin D3 supplement (400mg) once daily.
75402481|NCT06114381|Other|Diet Management|Patients receive weekly diet program contains dietary sources of Vitamin D such as yolk eggs, tuna and milk.
75402482|NCT06114381|Behavioral|Sun Exposure|Patients regular exposure to sun once a day 30 minutes of sun exposure, between 10 a.m. and 4 p.m. daily. Exposure to the face, arms, hands, and legs without sunscreen
75402483|NCT06114355|Procedure|EUS Portal pressure measurement|Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM)
75402484|NCT06114316|Behavioral|individualized nursing interventions based on the Roy Adaptation Model /experimental|"The personal behaviors that could be related to recurrence (physiological, self-concept, role function, and mutual commitment) and the stimuli that caused recurrence (focal and affecting) were assessed, objectives were determined, and nursing interventions were carried out in line with these objectives. The interventions planned for diagnosing ineffective coping were selected according to the patients' needs among the support coping interventions under the title of the behavioral area in the Nursing Intervention Classification (NIC). A total of 10 individual interviews were made twice a week for about 45 to 60 minutes. The interviews were evaluated by determining the area specific Nursing outcome classification (NOC) (self respect, social support, mood management, role performance)."
75402485|NCT06114303|Other|Stool sampling|1 stool sample is taken during the study with a stool sample kit
75711016|NCT00900484|Other|biologic sample preservation procedure|
75711017|NCT00900484|Other|immunohistochemistry staining method|
75711018|NCT00900484|Other|laboratory biomarker analysis|
75402486|NCT06114264|Behavioral|Multimodal + Resistance Programs|"Exercise: will focus on working the all body by performing functional tasks. Behaviour change: An 'idle alert' of the wrist-worn activity prompter will be set to vibrate after 45 min without movement. Participants will be encouraged to take a 1-2 min activity break.~Education: The basic contents will explain to the patient the main mechanism of chronic pain (pain as a protective system, consequences, etc).~The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group and a Mindfulness practice.~Resistance functional exercises will replicate functional movements, such as standing from a bed, carrying bags, picking up groceries from the ground, etc."
75402487|NCT06114264|Other|Control group|No experimental intervention. The group will receive the same multimodal intervention as the experimental group when the experimental period is over.
75402488|NCT06114251|Diagnostic Test|Diagnosis of postoperative recurrence of liver cancer|HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.
75402489|NCT06114238|Drug|Itepekimab AI|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous AI
75550084|NCT00343629|Other|pharmacological study|
75711019|NCT03633253|Other|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
75711020|NCT01040065|Procedure|distal clavicle resection|Presence of tenderness at 2 years after surgery
75402490|NCT06114238|Drug|Itepekimab PFS|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous PFS
75711021|NCT00124891|Drug|Double-blind investigational anti-arrhythmic|
75711022|NCT00124891|Drug|GAP-486|
75711023|NCT00882466|Drug|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
75711024|NCT00901498|Drug|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
75711025|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
75711026|NCT00901498|Drug|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
75711027|NCT00901498|Drug|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
75711028|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
76038316|NCT04790591|Procedure|Same-day surgery|To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.
75711029|NCT00628251|Drug|AZD2281|400mg Oral twice daily
75711030|NCT00628251|Drug|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
75711031|NCT00628251|Drug|AZD2281|200mg oral twice daily
75550085|NCT00343668|Drug|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
75711032|NCT01036399|Drug|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
75711033|NCT01040221|Drug|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
75711034|NCT00901654|Biological|ACE527 vaccine|"First cohort: Two doses, each of 3x10^9 cfu of each strain (9x10^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10^10 cfu of each strain (9x10^10 cfu total per dose) administered on Days 0 and Day 21"
75871474|NCT03723395|Drug|repaglinide|1mg dose
76038317|NCT02633527|Drug|Placebo|Placebo was administered once daily
76038318|NCT02633527|Drug|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
76038319|NCT02633527|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
75550086|NCT00348036|Behavioral|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
75550087|NCT00348036|Other|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
75402491|NCT06114225|Combination Product|metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy|participants first receive concurrent SBRT and penpulimab (PD-1 blockade) and two cycles of GP regimen (gemcitabine d1,d8 and Penpulimab d8 per a 21-day cycle), followed by complete pulmonary metastasectomy. After surgery, participant receive another 4 cycles of GP regimens followed by Penpulimab monotherapy maintenance. The rationale is that pre-operative SBRT could boost the immune microenvironment, leading to a long-term effect of immunotherapy post-metastasectomy and eventually resulting in better long-term survivorship compared to the histological control for pulmonary resectable recurrence of osteosarcoma .
75402492|NCT06114212|Device|dTMS stimulation via the H4 coil|Deep repetitive transcranial magnetic stimulation (dTMS) uses transient electromagnetic fields to stimulate the brain and is approved by Health Canada and the FDA for the treatment of depression, anxious depression, obsessive-compulsive disorder, and tobacco use disorder. Compared to the traditional TMS, dTMS is able to target brain depths ranging from 2 to 6 cm. With the use of various H-coils, dTMS has been used to target specific neural networks with the aim of producing desired clinical effects in psychiatric populations. The intervention in this study is the H4 dTMS coil which stimulates the lateral prefrontal cortex and the insula in the brain.
75711035|NCT00901654|Biological|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
75402493|NCT06114173|Drug|Cardunilizumab|Cardunolizumab 6mg/kg was administered every 2 weeks, with the first evaluation at 8 weeks of treatment and subsequent evaluations every 12 weeks.
75550088|NCT00343707|Drug|vestipitant|
75550089|NCT00343707|Drug|paroxetine|
75550090|NCT00313391|Drug|Risperdal Consta|
75402494|NCT06114134|Dietary Supplement|Fenobet|receiving fenugreek extract (3 capsules of 500 mg, 1 capsule half an hour before meals)
75402495|NCT06114134|Dietary Supplement|Placebo|Placebo
75550091|NCT00348075|Device|Neurovision|
75550092|NCT00348114|Procedure|Transplantation of cultivated limbal epithelium|
75711036|NCT00821223|Procedure|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
75711037|NCT00821223|Procedure|manual small incision surgery|
75711038|NCT00821223|Procedure|phacoemulsification|cataract surgery
75711039|NCT00900640|Procedure|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
76038320|NCT02633527|Drug|300mg SPN-812|300mg SPN-812 was administered once daily and compared to placebo
75402496|NCT06114121|Procedure|erector spinae plane block (ESP)|nerve block for abdominal pain. administered once immediately prior to spinal anesthetic standard of care.
75402497|NCT06114121|Drug|Duramorph|100 micrograms (mcg) of morphine administered in the spinal medications one time.
75550093|NCT00343902|Drug|Crataegus Special Extract WS 1442|
75550094|NCT00348153|Drug|Adalimumab|
75550095|NCT00313508|Biological|Autologous Dendritic Cells (DC)|Given intranodally
75550096|NCT00313508|Drug|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
75550097|NCT00313508|Biological|Autologous Lymphocyte Infusion (ALI)|Infusion
75550098|NCT00343941|Drug|Tucaresol tablets 25 mg|
75550099|NCT00313547|Drug|Quinapril 40 mg|
75550100|NCT00313547|Drug|Quinapril 10 mg and amlodipine 5 mg|
75550101|NCT00348192|Drug|SB-742457|
75550102|NCT00348192|Drug|donepezil|
75550103|NCT00313625|Drug|busulfan|
75550104|NCT00313625|Drug|melphalan|
75550105|NCT00313625|Drug|methotrexate|
75711040|NCT00625131|Drug|Nicotine|Delivered through transdermal nicotine patch
75711041|NCT00625131|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
75711042|NCT00625131|Drug|Bupropion Sustained Release (SR)|Antidepressant
75711043|NCT00625131|Drug|Placebo patch|Pre-treatment placebo transdermal patch
75711044|NCT01036633|Device|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
76038321|NCT02633527|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
75550106|NCT00313625|Drug|tacrolimus|
75550107|NCT00313625|Procedure|allogeneic hematopoietic stem cell transplantation|
75550108|NCT00313625|Procedure|peripheral blood stem cell transplantation|
75550109|NCT00343980|Drug|rosiglitazone|Tablets, 4 mg once or twice a day.
75550110|NCT00343980|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
75550111|NCT00343980|Drug|glimepiride|Tablets, 4 mg/day.
75550112|NCT00313859|Drug|simvastatin|
75550113|NCT00348231|Drug|dual-action insulin analog|
75550114|NCT00313898|Drug|sildenafil (viagra)|
75550115|NCT00313937|Drug|Insulin glargine|
75550116|NCT00348270|Device|Tecnis Z9000 intraocular lens|
75550117|NCT00348270|Device|MA60 intraocular lens|
75550118|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
75550119|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
75550120|NCT00344097|Procedure|Soy protein|
75402498|NCT06114121|Drug|Ropivacaine|Ropivacaine 0.5% between 20-40 milliliters will be administered once in the ESP block (in the spine) depending on patient weight to keep under the maximum dose.
75402499|NCT06114121|Drug|Bupivacaine Injection|Bupivacaine 0.75% 1.4-1.7 milliliters (10-12 milligrams) spinal medication. administered one time.
75402500|NCT06114082|Procedure|IDA-TACE|Stable chemoemulsion will be produced by dissolving 10 mg of idarubicin powder (Zavedos; Pfizer, New York, NY, USA) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
75711045|NCT00900718|Device|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
75711046|NCT00900718|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
75402501|NCT06114082|Procedure|DOX-TACE|Stable chemoemulsion will be produced by dissolving 50 mg of doxorubicin powder (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Republic of Korea) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
75402502|NCT06114069|Procedure|implant supported maxillary fixed prosthesis|Maxillary fixed prosthesis according to all on four or all on six concept
75402503|NCT06114030|Procedure|Deep margin elevation with composite resin and Lithium disilicate glass-ceramic crowns|Restoration of the deep margin by composite restorations such as: Filtek Supreme XTE, Tetric EvoCeram, Estelite Sigma Qquick followed by Lithium disilicate glass-ceramic CAD/CAM crowns (IPS e.max CAD).
75550121|NCT00314054|Drug|HCV-796|HCV-796 1000mg single dose
75550122|NCT00348387|Biological|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
75550123|NCT00348387|Biological|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
75550124|NCT00314171|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
75550125|NCT00314171|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
75550126|NCT00348426|Drug|Botulinum AntiToxin|
75550127|NCT00348426|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
75550128|NCT00348426|Procedure|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
75550129|NCT00314210|Drug|Quetiapine SR|
75550130|NCT00344214|Behavioral|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
75550131|NCT00344214|Behavioral|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
75550132|NCT00314288|Drug|Sarizotan HCl|
75550133|NCT00348465|Procedure|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
75871475|NCT03723395|Drug|tolbutamide|500mg dose
75871476|NCT03723395|Drug|midazolam|2mg dose
75871477|NCT03723395|Drug|digoxin|0.5 mg dose
75550134|NCT00344253|Drug|Interferon beta|
75550135|NCT00344253|Drug|Methotrexate|
75871478|NCT01377948|Behavioral|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
75550136|NCT00314405|Drug|Methylene blue (1%)|
75402504|NCT06114017|Behavioral|Social Media Abstention|People will stop or reduce their social media use for one week.
75402505|NCT06114004|Drug|Selinexor 20 MG|After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor
75402506|NCT06114004|Drug|Gemcitabine|Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
75402507|NCT06113978|Procedure|Thoracoscopic sympathectomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathectomy.
75402508|NCT06113978|Procedure|Thoracoscopic sympathotomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, who underwent thoracoscopic bilateral simultaneous sympathotomy.
75550137|NCT00314405|Drug|Rhenium sulfure|
75550138|NCT00314405|Procedure|Surgical procedure|
75550139|NCT00314405|Procedure|Anatomo-pathologic procedure|
76038322|NCT04790669|Procedure|Daily adjustable progressive resistance exercises (DAPRE)|Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale & sphygmomanometer.
76038323|NCT04790669|Procedure|Close kinetic chain exercises (CKC).|Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline & post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale & sphygmomanometer.
75550140|NCT04715295|Drug|Doxycycline Tablets|Doxycycline 200 mg daily for 7 days
76038324|NCT05092971|Behavioral|Multi-arm bandit tasks|Part 1 to be completed in the clinic. Subject participation is for one part and is pseudo-randomly.
76038325|NCT05092971|Device|Multi-arm bandit tasks|Part 2 to be completed in the scanner. Subject participation is for one part and is pseudo-randomly.
75402509|NCT06113978|Procedure|Thoracoscopic sympathetic chain clipping|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, treated by thoracoscopic bilateral simultaneous sympathetic chain clipping.
75402510|NCT06113965|Other|Peripheral Nerve Stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
75402511|NCT06113939|Device|airway clearance|mechanical suctioning of airway secretions
75402512|NCT06113926|Other|Bystander Acknowledgment|"The experimenter said That is so messed up that they excluded you in the task. And honestly, I would say it was racist… acknowledgment of the participants experience, …this shouldn't have happened, and I'm really sorry it did… an apology, and …I'm going to talk to the primary investigators of the study to figure out how we can make sure that this won't happen to other people a plan of action."
75402513|NCT06113900|Drug|Dapagliflozin 10mg Tab orally once daily|Sodium glucose co-transporter 2 inhibitors
75402514|NCT06113874|Other|Hurriseal desensitizer|"Patients will receive Hurriseal desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
75550141|NCT04715295|Drug|Rivaroxaban 15Mg Tab|Rivaroxaban 15 mg tablets daily from day 1 to day 10
75550142|NCT04715295|Combination Product|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5
75550143|NCT00314483|Drug|Mesenchymal Stem Cell Infusion|
75550144|NCT00348504|Drug|levosimendan|
75550145|NCT00348504|Drug|dobutamine|
75550146|NCT00348543|Procedure|laser treatment|
75550147|NCT00314561|Drug|Pioglitazone, Rosiglitazone|
75550148|NCT00344409|Drug|darbepoetin alfa|
75550149|NCT00314600|Device|above and below elbow cast|
75402515|NCT06113874|Other|Gluma desensitizer|"Patients will receive Gluma desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
75402516|NCT06113861|Diagnostic Test|Quantiferon Gold|Test for TB infection
75402517|NCT06113861|Diagnostic Test|HIV serology|Test for HIV infection
75402518|NCT06113861|Diagnostic Test|Respiratory secretion culture (sputum or gastric aspirate_|TB culture by MODS
75402519|NCT06113861|Diagnostic Test|Chest radiograph|Chest imaging test by traditional X ray
75402520|NCT06113861|Diagnostic Test|Lung ultrasound|Chest imaging test by ultrasound
75402521|NCT06113861|Diagnostic Test|cell free DNA test|Blood test for TB infection
75402522|NCT06113848|Drug|Intra-Arterial TNK and Albumin|The study population was divided into four groups, one of which had intra-arterial TNK and albumin.
75402523|NCT06113848|Drug|Intra-Arterial TNK|The study population was divided into four groups, one of which had intra-arterial TNK .
75402524|NCT06113848|Drug|Intra-Arterial Albumin|The study population was divided into four groups, one of which had intra-arterial albumin.
75402525|NCT06113848|Other|sham|The study population was divided into four groups, one of which had no intra-arterial TNK and albumin.
75402526|NCT06113835|Procedure|CTO PCI|percutaneous coronary intervention
75402527|NCT06113809|Drug|Palbociclib|"Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab"
75402528|NCT06113809|Drug|Pembrolizumab|"Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)"
75402529|NCT06113796|Other|Surgery|Robotic rectal resection, either sphincter preserving or extirpation
75402530|NCT06113783|Device|HYALUBRIX 60|1.5% solution of non-modified HA (60mg/4ml) obtained from bacterial fermentation with high molecular weight.
76038326|NCT05092893|Other|Online parental questionnaires|"The SRS-2 is a parental 65-item questionnaire to detect difficulties in social responsiveness in children with autism spectrum disorder. Four different forms are available: preschoolers (2.5-4.5 years), school-aged children (4-18 years), adults (≥ 19 years) and adults self-report. In this study, only the form for school-aged children will be used.~The DCDQ'07 is a parental 15-item questionnaire to detect the risk of DCD in children between 5 and 15 years of age. Parents are asked to compare their child's motor performance to his/her peers using a 5-point Likert scale. The total sum score is compared to age-specific cut-off scores to determine the risk of DCD. Belgian norms are available since 2007."
76038327|NCT01667549|Other|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
76038328|NCT05092581|Drug|casirivimab+imdevimab|Single dose weight-based equivalent administered intravenously (IV)
75402531|NCT06113757|Device|Signal Therapy provided by Dr.Biolyse device|Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. Electrical signal will be applied to the lung and upper leg area for 90 minutes in the morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on the 4th and 5th days, to the lung and upper leg area. During your first hospitalization, blood will be drawn from you daily for 5 days and evaluated in terms of various biochemical parameters and detailed molecular analyzes.
75402532|NCT06113757|Other|Liquid Support Treatment|The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
75402533|NCT06113718|Procedure|Abdominal Exercise (digital rectal stimulation, abdominal massage)|"The recommended bowel exercise program consisted of three steps:~Patients will perform a 2-3 minute massage starting from the cecum approximately 20-30 minutes after breakfast, moving along the colon.~Patients will assume a suitable position and perform circular massage on the anal walls with their finger for approximately 30 seconds (digital rectal stimulation).~Patients will try to defecate while sitting on the toilet."
75402534|NCT06113705|Diagnostic Test|18F-GE-180 PET|PET examination of glioblastoma using 18F-GE-180 PET radio-metabolic marker
75402535|NCT06113705|Diagnostic Test|Advanced MRI|MRI examination using advanced sequences to characterize tumor microstructure and function
75402536|NCT06113705|Other|Collection of hematopoietic stem cells|Hematopoietic stem cells will be collected by the aspiration of bone marrow during the surgical intervention for tumor resection
75402537|NCT06113705|Other|Blood withdrawal|blood withdrawal for evaluation of plasma biomarkers of inflammation, circulating microvesicles, and RNA
75402538|NCT06113705|Other|Collection of Cancer Stem Cells|Glioblastoma stem cells (GSCs) will be isolated from the tumor
75402539|NCT06113692|Biological|mRNA-1273|intramuscular injection
75550150|NCT00348582|Drug|Ketorolac, Nepafenac|
75871479|NCT02350738|Other|Period I MCET (8 wks)|MCET_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock_MCET group: mock-therapy (3 sessions/wk)
76038329|NCT04790357|Other|Current guidelines|doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory
76038330|NCT04790357|Other|cc-MRI|of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
75402540|NCT06113653|Other|Prospective study|Prospective study of outcomes and predictors of mortality among preterm infants with neonatal sepsis
75550151|NCT00314639|Drug|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
76038331|NCT04756193|Diagnostic Test|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry
75402541|NCT06113627|Other|Resistance Therapeutic Exercise|"Strength exercises will be aimed at large muscle groups, such as the shoulder, chest, back and also muscle groups of the lower extremities. In the initial 2 weeks, intervention will start with low intensities of around 55-65% of 1RM, which allows to perform around 15-20 repetitions. The first week there will be performed 2 series, while in the second week it will be 3 series.~Moderate intensity in the 2nd week, corresponding to 65-75% of 1RM and allowing for around 8-12 repetitions. 3 series will be maintained throughout this period of time.In addition to the progressive change in intensity, throughout the intervention the load will be increased by 5-10% when the patient performs the exercise too easily or when they can perform more repetitions than estimated. Rest between sets will be 2-3 minutes."
75402542|NCT06113614|Procedure|Physiotherapy|All participants will be treated with the standardized physiotherapy protocol suggested by Ratajczak et al. 2019 and the AO TRAUMA group (https://www.aofoundation.org/trauma). To receive physiotherapy treatment, participants will need to attend a 30-minute session, twice a week, for 12 weeks.
75550152|NCT00348621|Procedure|Visual impairment intervention program|enhanced access to eye care services
75550153|NCT00314678|Drug|Topotecan|
75550154|NCT00314678|Drug|Cisplatin|
75550155|NCT00314678|Drug|Paclitaxel|
76038332|NCT05614427|Diagnostic Test|Innova Lateral Flow Test|Lateral flow test performed on anterior nasal or buccal swabs
75402543|NCT06113614|Device|Photobiomodulation|The PBM will be applied with LED devices in the form of a shoulder brace. The applications will occur every day starting 24 hours after the surgical procedure. The shoulder brace from the brand Cosmedical (Mauá, SP, Brazil) contains 70 red LEDs and 70 infrared LEDs. The area corresponding to the fixation plate will not be irradiated (no LEDs will be placed). PBM will be applied every day for 10 minutes using a device containing 318 light-emitting diodes (LEDs), including 159 LEDs at 660 nm (28.5 mW; 12 J/cm2 to 17 J) and 159 LEDs at 850 nm (23 mW; 10 J/cm2 to 14 J).
75402544|NCT06113614|Device|Simulation of photobiomodulation|The simulation of PBM will use the same LED devices in the form of a shoulder brace but without active light. It will be applied following the same regimen of the Photobiomodulation group.
75402545|NCT06113601|Other|There is no intervention.|There is no intervention in the study.
75402546|NCT06113562|Procedure|PFO closure|The participants will receive a onetime closure of a small hole in heart. The procedure usually takes up to an hour. The procedure is done with local anesthesia and conscious sedation. A catheter is inserted into a vein in upper thigh and threaded to heart to deploy the closure device. Either Gore septal occluder or Amplatzer PFO occluder
75402547|NCT06113536|Diagnostic Test|Ultrasonographic evaluation|Ultrasonographic evaluation for assessment of possible meniscal extrusion
75402548|NCT06113523|Biological|monogenic obesity|The DNA samples will be sequenced for the 71 obesity genes especially for the study.
75550156|NCT00314717|Behavioral|Control diet|
75550157|NCT00314717|Behavioral|Low GI diet|
75550158|NCT00344526|Drug|Melphalan|
75550159|NCT00344526|Drug|Dexamethasone|
75550160|NCT00344526|Procedure|Autologous stem cell transplantation|
75550161|NCT00344565|Drug|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
75550162|NCT00344565|Behavioral|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
75550163|NCT00314834|Drug|Intradialytic parenteral nutrition|
75550164|NCT00348699|Drug|AFP464|Given IV
75550165|NCT00348699|Other|pharmacological study|Correlative studies
75550166|NCT00348699|Other|laboratory biomarker analysis|Correlative studies
75550167|NCT00314873|Drug|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
75871480|NCT02350738|Other|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
76038333|NCT04089371|Device|ReUnion Total Shoulder Arthroplasty (TSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
76038334|NCT04089371|Device|ReUnion Reverse Shoulder Arthroplasty (RSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
76038335|NCT04010981|Other|study group|The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
76038336|NCT04010981|Other|control group|The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
76038337|NCT05191017|Drug|NUV-422|NUV-422 is an investigational drug for oral dosing.
76038338|NCT05191017|Drug|Enzalutamide|Enzalutamide
76038339|NCT05190159|Device|Monster Screw System|Subjects who have undergone a foot and/or ankle procedure involving the index device
76038340|NCT03973385|Device|Cryotherapy|patients recieving cryotherapy for skin anesthesia for artérial blood gas
75402549|NCT06113419|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed using the standard American 4-port technique, insufflation will be achieved using CO2 to 15mmHg of pressure. Calot's triangle will be dissected until the critical view of safety is reached, being careful to dissect above the R4U line. After reaching the critical view of safety, two proximal and one distal clip will be placed on both the cystic conduct and artery separately, cutting the clips and then dissecting the gallbladder in a cystfundic direction. When the critical view of safety is not reached, the surgeon may perform a fundus-first cholecystectomy, subtotal cholecystectomy, conversion to open procedure, intraoperative cholangiography or cholecystostomy to their own discretion. It will also be the surgeon's criteria to employ or not a drain system in the surgical site. The decision for theses interventions will be taken intraoperatively and will be according to findings during the procedure.
75402550|NCT06113406|Behavioral|Classroom Training|Active Comparator
75402551|NCT06113406|Behavioral|Virtual Reality Training|Experimental
75402552|NCT06113393|Procedure|GRV thresholds|Hold enteral feeding when GRV reaches 200 mL(current standard)
75402553|NCT06113380|Device|NTUH-ii, am upper limb rehabilitation robot arm|Rehabilitation programs are planned based on the subject's capabilities, and the differences between assisted rehabilitation with a robot and traditional rehabilitation are compared.
75402554|NCT06113380|Other|Traditional upper limb physical therapy|Traditional upper limb physical therapy is performed by the therapist.
75402555|NCT06113367|Other|Evaluation of anti-PD-(L)1 immunotherapy efficacy|Non Applicable, research on data
75402556|NCT06113289|Drug|ASTX727|Given by PO
75402557|NCT06113289|Drug|ASTX029-01|Given by PO
75402558|NCT06113276|Radiation|Low dose computed tomography to evaluate biomechanical parameters in the lung|In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
75402559|NCT06113250|Device|shortwave diathermy|Shortwave diathermy (SWD) is a modality that produces heat by converting electromagnetic energy into thermal energy. pulsed shortwave diathermy (PSWD), uses high-frequency electromagnetic waves to heat tissues up to 5 cm deep. Heat is produced by the resistance of tissue to the passage of energy. Although it heats to the same depth as 1-MHz ultrasound, PSWD heats a much larger area than ultrasound does, making it ideal to heat larger joints, such as the elbow, shoulder, hip, knee, and ankle
75402560|NCT06113250|Device|ultrasound waves|Ultrasound is sound with a frequency above 20,000 Hertz (Hz) and is undetectable by the human ear. However, clinical ultrasound uses much high frequencies of between 1 and 20 megahertz (MHz) and sometimes up to 75 MHz in specialized areas such as dermatology and ophthalmology. Clinically, ultrasound is used for a number of applications ranging from visualizing structures to allow safe insertion of lines and catheters to diagnostic imaging including the assessment of the movement of cardiac Production of ultrasound waves is the first part of the clinical ultrasound process. Ultrasound is generated by piezoelectric crystals. These crystalline materials contain randomly oriented electric dipoles, and when a force is applied that deforms the crystal, the dipoles are rearranged and a net charge induced across the crystal
75402561|NCT06113250|Other|traditional physical therapy program|splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises
75402562|NCT06113224|Procedure|Blood collection T0|2 blood samples will be taken in addition to the pre-operative check-up.
75711047|NCT02549547|Behavioral|Group Medical Visits|"Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:~Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes~Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes~Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity."
75711048|NCT00923338|Device|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
75871481|NCT02350738|Other|Period II MCET (8 wks)|MCET_Mock group: mock therapy (MCET) (3 sessions/wk) Mock_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
75871482|NCT04459728|Behavioral|Wellness Element 1: Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
76038341|NCT05137431|Other|HFNO and NIV|"Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~Respiratory parameters (respiratory rate)~SpO2~Ventilator settings~Patient's tolerance (VAS; between 0-100)~Arterial blood gas (HFNO and NIV at 1 hour)~Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~Loss of consciousness~Agitation~Persistent hypotension~Need for fluid resuscitation~Need for vasopressor~Respiration rate ≥40/min~SpO2 <92~pH<7.30"
75871483|NCT04459728|Behavioral|Wellness Element 2: Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
76038342|NCT05135871|Drug|Mavacamten|Single fasted oral dose of Mavacamten 15/25 mg on Day 1
76038343|NCT04338659|Biological|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
76038344|NCT05190003|Other|Experimental Study|On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises.
75402563|NCT06113224|Procedure|Blood collection 6 months|1 blood sample will be taken 6 months after surgery.
75402564|NCT06113198|Biological|rMenB+OMV NZ|3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.
75402565|NCT06113172|Other|Hip flexion|during the delay phase, the patients are asked to bend their knee in order to achieve the maximum degree of hip flexion
75402566|NCT06113133|Diagnostic Test|measurement of oxygen uptake|oxygen uptake is obtained during a maximal exercise test
75402567|NCT06113055|Drug|L-serine|Active comparator
75402568|NCT06113055|Drug|Placebo|Placebo comparator
75402569|NCT06113003|Dietary Supplement|Prebiotic|Wheat dextrin fiber
75402570|NCT06113003|Dietary Supplement|Probiotic|Probiotic packet
75402571|NCT06112977|Procedure|Prepectoral implant-based immediate breast reconstruction|Prepectoral implant based breast reconstruction is an immediate breast reconstruction whereby a fixed volume implant or expander is placed on top of the chest wall muscle (Pectoralis Major) to reconstruct the breast after mastectomy.
75711049|NCT00825747|Device|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
75711050|NCT01040299|Device|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
75402572|NCT06112951|Procedure|Extracorporeal Photopheresis|Patients randomized into the interventional group will receive ECP. ECP will be started within one week after randomization. Initially a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
75402573|NCT06112938|Drug|Antibiotic|We aim to examine differences in clinical outcomes and failure rates between standard and alternative treatment strategies such as minocycline (or moxifloxacin, ciprofloxacin, ceftazidime) alone or in combination with TMP-SMX, alternative TMP-SMX dosing regimens, or variations in durations of therapy for the treatment of S. maltophilia infections within Methodist Health System (MHS).
75402574|NCT06112925|Other|Medication Therapy Management|The medication therapy management intervention was delivered via the five (5) core components which include medication therapy review, personal medication record, medication-related action plan, intervention, and documentation and follow-up. The interventions was also given via educating patients about diabetes, hypertension, complications of diabetes and hypertension, impact of having diabetes and hypertension, antidiabetes and antihypertensive medications, goals of therapy for diabetes and hypertension, health promoting behaviours (healthy diet, regular exercise, salt reduction, & smoking cessation), drug adherence, and self-monitoring of the diseases.
75402575|NCT06112912|Other|REAL Essentials Advance|"REA is a relationship education curriculum developed by the Center for Relationship Education for high school-age youth. REA teaches youth critical relationship skills and practical approaches for navigating the social dynamics of friendship and love. The curriculum draws on several theories of behavior change, including social cognitive theory, theory of planned behavior, social inoculation theory, social norms theory, and behavior change theory.~REA includes 87 lessons organized into 10 units. The units cover topics such as healthy relationships, effective communication, commitment, planning for the future, job readiness, and sexual health."
75550168|NCT00348738|Drug|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of >14g/dl, <15g/dl is reached or until the end of the radiation therapy.
75550169|NCT00314912|Drug|Tramiprosate (3APS)|
75550170|NCT00344604|Behavioral|Role of psychosocial and quality of life parameters prior to and following LASIK.|
76038345|NCT03744611|Dietary Supplement|CE|550mg capsule (Eucommia ulmoides Oliver extract)
75550171|NCT00314990|Drug|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
75550172|NCT00344643|Device|Silicone Hydrogel Soft Contact Lenses|
75550173|NCT00315029|Behavioral|evidence based decision aid|evidence based decision aid
75711051|NCT01040299|Device|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
75711052|NCT01040299|Other|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
75711053|NCT00901732|Device|Caphosol|Oral Mouth Rinse
75711054|NCT00837291|Drug|CF101|CF101 tablets 1 mg BID
75711055|NCT00837291|Drug|Placebo|Placebo tablets BID
75871484|NCT04459728|Behavioral|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
76038346|NCT03744611|Dietary Supplement|Placebo|550mg capsule (Placebo)
75402576|NCT06112899|Behavioral|Nordic Hamstring Exercise|The NHE, also referred to as the nordic curl, is designed to improve eccentric strength of the hamstring muscles. Individuals start in a kneeling position, with the torso from the knees upward held rigid and straight. The training partner ensures that the individual's feet are in contact with the ground throughout the exercise by applying pressure to the player's heels/lower legs. The individual then lowers his upper body to the ground, as slowly as possible to maximize loading in the eccentric phase. Hands and arms are used to break his forward fall and to push him back up after the chest has touched the ground, to minimize loading in the concentric phase.The exercise protocol is planned as 5 sets of 8 repetitions and 2 minutes of rest between each set.
75402577|NCT06112886|Other|There was no intervention in this study|There was no intervention in this study
75402578|NCT06112873|Other|Quality of Life Questionnaire|Patient (or Parent)-Reported Outcomes via specific questionnaires
75550174|NCT00315029|Behavioral|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
75711056|NCT00882622|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
75711057|NCT00882622|Procedure|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
75711058|NCT02547909|Procedure|probe-based Confocal Laser Endomicroscopy|"Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue."
75711059|NCT02547909|Device|Cellvizio|
75711060|NCT02547909|Drug|fluorescein 10%|
75711061|NCT00882700|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
75711062|NCT00882700|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
76038347|NCT04755179|Procedure|Laparoscopic appendectomy|"Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~Conventional laparoscopy (three-trocar technique)~In case of purulent fluid: Suction and no peritoneal lavage procedure~Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~Closure of wounds as appropriate"
75871485|NCT04459728|Behavioral|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on social connectedness; adherence documented online daily
75402579|NCT06112834|Biological|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
75402580|NCT06112821|Other|Data collection in medical records|Data collection in medical records
75402581|NCT06112821|Other|Blood sampling|Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.
75402582|NCT06112717|Other|Supportive-Educative Nursing Care|Adolescents in the intervention group were received Supportive-Educative Nursing Care based on Orem's Self Care Deficit Nursing Theory
75402583|NCT06112158|Behavioral|Education Intervention|"The BSE training program for the early diagnosis of breast cancer will be offered to students in two ways: face-to-face and via web support.~Content of training Session 1: Topics such as the structure of the breast, the definition of breast cancer, its prevalence, risk factors and symptoms Session 2: Teaching the importance of early diagnosis in breast cancer, the importance and benefits of BSE, the technique of performing BSE, the obstacles to the application of BSE.~Session 3: Teaching the risk factors that cause breast cancer. Session 4: Discussion of case reports of patients diagnosed with breast cancer. Supporting education with web support"
75550175|NCT00348777|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
75402584|NCT06111846|Drug|human Bone Marrow Mesenchymal Stem Cell (hBMMSC)|Group 1: 1.0×10^6 cells/kg (participant's body weight) single dose (n=3) Group 2: 2.0×10^6 cells/kg (participant's body weight) single dose (n=3) Group 3: 2.0×10^6 cells/kg (participant's body weight) administered twice (n=4)
75402585|NCT06111144|Behavioral|Polarized training intensity distribution (TID) and mental training using mindfulness|Polarized TID model group with mindfulness program (POL+)
75402586|NCT06111144|Behavioral|Pyramidal training intensity distribution (TID) and mental training using mindfulness|Pyramidal TID model group with mindfulness program (PYR+)
75402587|NCT06111144|Behavioral|Polarized training intensity distribution (TID) without mindfulness|Polarized TID model group without mindfulness program (POL-)
75402588|NCT06111144|Behavioral|Pyramidal training intensity distribution (TID) without mindfulness|Pyramidal TID model group without mindfulness program (PYR-).
75402589|NCT06111092|Other|Design Thinking|Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.
75402590|NCT06111092|Other|Focus Groups|Participants attend the FG that includes the introduction. discussion, and reflection.
75402591|NCT06110897|Behavioral|High Dose Resistance Exercise Training|Progressive resistance exercise training
75402592|NCT06110897|Behavioral|Low Dose Resistance Exercise Training Group|Progressive resistance exercise training
75402593|NCT06110689|Other|VU-AMS device|Patients will wear the VU-AMS monitor prior to MRI.
75402594|NCT06110559|Device|Active transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~Patients received 1.5 mA stimulation for 30 minutes."
76038348|NCT04755179|Procedure|Open appendectomy|"Open appendectomy will be performed according to the following standardized key points:~Gridiron incision at the right lower quadrant. (McBurney's point)~After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~The appendiceal stump will be closed by ligation, not a purse string suture.~Closure of wounds as appropriate"
76038349|NCT04755179|Procedure|Non-operative treatment|"Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~Combination A:~Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children <40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children > 40 kg~Gentamicin 7mg/kg once daily~Combination B:~Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical."
76038350|NCT04755179|Procedure|Direct appendectomy|laparoscopic or open appendectomy as described
76038351|NCT05133999|Biological|Plasma determination of iron, transferrin and ferritin|Iron, transferrin and ferritin levels in plasma
75402595|NCT06110559|Device|Sham transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~Patients received effective stimulation of 1.5 mA for 30 seconds, after which the current was switched off. The entire session lasted 30 minutes, with 29 minutes and 30 seconds without stimulation."
76038352|NCT05133999|Other|Fundus Examination by wide field digital imaging camera (PanocamTM camera)|ROP screening using wide field digital retinal imaging according to current recommendations.
76038353|NCT05133219|Other|Occupational Therapy|Occupational therapy is the only profession that helps people across the lifespan to do the things they want and need to do through the therapeutic use of daily activities (occupations). Occupational therapy practitioners enable people of all ages to live life to its fullest by helping them promote health, and prevent-or live better with-injury, illness, or disability.
76038354|NCT05131503|Other|Survey Research|Non-applicable. There is no intervention. This study is descriptive research.
75402596|NCT06110247|Device|NIRS|After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.
75402597|NCT06110247|Other|Taking a blood sample|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.
75402598|NCT06110169|Device|Anodal Transcranial Direct Current Stimulation (Anodal tDCS)|Battery driven tDCS will be applied at 2 mA intensity to the dorsolateral prefrontal cortex and primary motor cortex for 20 minutes.
75402599|NCT06110169|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of sham anodal tDCS
75402600|NCT06110130|Drug|Empagliflozin 10 MG|Take Empagliflozin 10 mg orally daily for 4 months
75402601|NCT06110130|Drug|Placebo|Take Placebo 10 mg orally daily for 4 months
75402602|NCT06110117|Device|Sterimar Stop & Protect Irritation & Dryness|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for seven days.
75402603|NCT06109532|Other|hyponatremia|hyponatremia at admission in dengue infected patients
75402604|NCT06108895|Other|ilio-inguinal/ilio-hypogastric nerve block (IINB)|Ultrasound-guided IINBs will be performed by scanning the anterior abdominal wall superior and medial to the anterior superior iliac spine in a line between the anterior superior iliac spine and umbilicus using a linear probe (4-12hertz). Ilioinguinal and iliohypogastric nerves will be identified in the plane between internal oblique muscle and transversus abdominis muscle. After negative aspiration of blood, 20 ml plain bupivacaine 0.25% plus 4mg dexamesathone will be injected. The same technique will be performed in the other side.
75402605|NCT06108895|Other|intrathecal morphine|200 mcg morphine intrathecally with bupivacaine
75402606|NCT06108817|Other|Information material|The intervention consists of the distribution of a poster for the waiting room and flyers to be given to patients aiming to inform both patients and GPs with respect to the correct indications for treatment of dyspepsia. After signing up, practices assigned to the intervention group received a package containing 60 flyers and one waiting room poster to use during consultations. The flyer and poster provide a short description of the correct indications for treatment of dyspepsia. Additionally, both the flyers and posters contained a QR-code linking to a decision aid explaining the correct indications and causes of dyspepsia.
75402607|NCT06108817|Other|No Intervention|These practices do not receive information material
75402608|NCT06106230|Combination Product|Bee venom phonophoresis|Bee venom gel preparation with low freq ultrasound Bee venom solution (100 mg/mL) that was prepared and preserved at the correct temperature was purchased from the Egyptian Organization for Biological Products & Vaccines (Vacsera). The solution was a mix of a crude form of BV dissolved in sterile normal saline with a concentration ratio of 1:1 vol/vol. Then, the BV gel was prepared at the laboratories of the Faculty of Pharmacy, Modern University, Cairo, Egypt, by dissolving the previous mixture in 10% propylene glycol, followed by the addition of 0.01% butylparaben. To make bee venom gel, the resulting mixture was mixed with the matrix. The BV gel had a homogeneous and translucent appearance and a pH of 7.53. There was no discoloration, phase separation, or off-putting odor. Stratification was not observed after 30 min of centrifugation at 2,500 rpm at 25◦C, used with low frequency ultrasound Device: low intensity ultrasound
75402609|NCT06106178|Other|Simulator for Basic Ultrasound Skills|Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
75402610|NCT06106178|Other|Serious Video Game|"The serious video game Underwater uses a 3D-printed ultrasound probe for maneuvering. During gameplay, coins must be collected in an underwater world using the aforementioned simulated ultrasound probe. The main focus of this game is to improve hand-eye coordination while using an ultrasound probe."
75402611|NCT06106035|Behavioral|low-fat vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
75402612|NCT06102083|Drug|TDI01 suspension|"Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily."
75402613|NCT06101303|Other|Psychophysical assessment|"Thermal stimuli: The Thermal Sensory Analyzer will be used to deliver heat and cold stimuli. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water bath or an electronic electronic temperature-controlled water bath. Participants will be free to pull out of the water bath at any time.~Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer. These devices have a round probe that allows quantifying the amount of pressure that is being applied by real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.~Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (<1 mm²) and texture."
75550176|NCT00348777|Drug|3 days access to watering place at 6 months|access to watering place for movement in swimming pool, sauna and hammam.
75550177|NCT00315107|Drug|Alesse|
75550178|NCT04715490|Other|The Multimedia Symptom Management Program Intervention|"The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support. The first part of the program will be conducted in the cardiology outpatient department. Participants will be instructed to read a HF handbook.~The second part of the program, structured telephone support, allowed the nurses to maintain contact with the participants in order to follow their progress. The participants will be scheduled to receive eight telephone coaching calls over a 3-month period."
75711063|NCT00408499|Drug|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
75711064|NCT00408499|Drug|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
75711065|NCT00837369|Drug|Regadenoson|400ug IV bolus injection, single dosage
76038355|NCT05090553|Procedure|Lumbar Spinal Fusion Surgery|During surgery will be collected five disc fragments and five fragments of muscle-ligament tissue adjacent to the collected disc.
76038356|NCT05090553|Biological|Bacterial culture|Samples will be seeded on blood agar and anaerobic blood agar plates. After sowing in solid media, the swab will be inoculated in thioglycolate medium, where it will remain for 14 days
76038357|NCT05090553|Genetic|Phenotypic and genotypic characterization|"The phenotypic identification of the species will be carried out through mass spectrometry, with the MALDI-TOF equipment.~PCR analyzes performed in two phases, the first to confirm the presence of bacteria (target and non-target) using primers capable of amplifying eubacteria ribosomal deoxyribonucleic acid (rDNA) 16s and the second directed to confirm C. acnes through specific rDNA 16s primers."
76038358|NCT05090553|Genetic|Multiomics analysis|Whole Genome Sequencing, proteomics and metabolomics analysis
76038359|NCT04789811|Other|Stretching exercise|Stretching exercise: Stretching exercises were planned for 30 seconds, ten repetitions for each stretching, 10 minutes in total, four days a week, for two weeks.
76038360|NCT04789811|Other|Dry needling|Dry needling: A total of 3 sessions of dry needling, once a week, were applied to the gastrocnemius muscle.
76038361|NCT05089461|Drug|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
75402614|NCT06101303|Behavioral|Psychophysical assessments of experimental pain|"Pain ratings- Pain intensity and pain unpleasantness ratings will be assessed~Pain thresholds to heat, cold and/or pressure will be tested and participants will be instructed to press a button the first moment they feel pain.~Temporal summation- participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli.~Conditioned pain modulation (CPM) efficiency - CPM testing includes the application of a test stimulus without conditioning (heat or pressure stimuli) and a subsequent application of the same test stimulus together with a conditioning stimulus (cold stimulus).~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). During the OA paradigm, real time pain intensity ratings will be obtained~Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold water bath. Tolerance will be defined by the time of hand/foot withdrawal."
75402615|NCT06101303|Diagnostic Test|Blood, urine and saliva samples|Blood (approximately 2 tablespoons), urine and saliva samples will be collected and sent to ZRT Laboratory, LabCorp, or internal Washington University lab for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone). Additional samples will be stored in a biobank for future processing.
75402616|NCT06101303|Procedure|Biopsy and surgery-related data.|During the surgery, biopsies will be collected from the endometriosis lesions as well as from a healthy peritoneum. If there are no endometriosis lesions, biopsies will be taken of two common locations where endometriosis lesion grows (the infra-ovarian fossa). The lesions will be characterized based on their appearance and invasiveness of the lesions (i.e., powder-burn lesions, nonclassical red or white lesions, and superficially or deeply infiltrating (>5mm) lesions). In addition, surgery-related data such as the incision size, type of anesthesia, pain ratings after the surgery, analgesic medication after the surgery, and side effects will be documented. Blood, saliva, urine, and samples will be collected for hormonal analyses or stored in a Biobank for future analyses.
75402617|NCT06099353|Behavioral|Heart Age|Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.
75402618|NCT06099353|Behavioral|Heart Age-HOPE-CVD App|Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.
75402619|NCT06099353|Behavioral|Communication of Genetic Risk Score|General practitioners will draw 3ml of blood from each patient participant for analysis of the patient's genetic risk score of having cardiovascular disease. This genetic risk score will be communicated to the patient, and the communication will include informing patients what cardiovascular disease genetic risk is, what their genetic risk category compared to the population in Singapore is, and what their score means for the future.
75402620|NCT06099223|Device|Acupuncture needles|"The acupuncture intervention includes a combination of auricular and body acupuncture. The auricular points used are Shen men, Zero point, Tranquilizer point, and Master cerebral.~The body points used are the wrist PC6."
75402621|NCT06098742|Drug|Antareit|A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake
75402622|NCT06090266|Drug|OR502|IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.
75402623|NCT06090266|Drug|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
75402624|NCT06087419|Drug|chidamide|30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)
75402625|NCT06087419|Drug|Venetoclax Oral Tablet|400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)
75402626|NCT06087419|Drug|Inotuzumab Ozogamicin|0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
75550179|NCT04715490|Other|Control group|The control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
75550180|NCT02960126|Drug|Aspirin|
75550181|NCT02960126|Drug|Clopidogrel|
75550182|NCT00348855|Other|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
75550183|NCT00348855|Behavioral|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
75711066|NCT00900874|Drug|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
75711067|NCT00900874|Drug|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
75711068|NCT00901810|Device|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
75711069|NCT00901810|Device|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
76038362|NCT04789343|Other|Root canal treatment|The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.
76038363|NCT05730439|Procedure|Biospecimen Collection|Undergo collection of blood
76038364|NCT05730439|Drug|Nicotine Oral Pouch|Receive ZYN brand NP
76038365|NCT05730439|Drug|Nicotine Oral Pouch|Receive Rogue brand NP
76038366|NCT05730439|Other|Questionnaire Administration|Ancillary studies
75550184|NCT00348855|Behavioral|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
75711070|NCT00830661|Procedure|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
75711071|NCT00830661|Procedure|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
75402627|NCT06085508|Behavioral|Digital patient education to reduce kinesiophobia after MI and/or AF|Group-meetings 7 times via Zoom® video with a tutor (nurse, physiotherapist) and learn about PA, kinesiophobia, AF and/or MI. Scenarios start the problem-based learning process involving recorded lectures, behavioral activation, and exposure to PA. Week1: Programme intro. Formulation of individual goals. Home assignment (HA): Lecture PA after MI/AF. Week 2. Discuss HA. Scenario 1: Why PA after MI/AF? (PBL) Formulate questions*. HA: Answer the questions. Week 3. Follow-up HA. Scenario 2. What is MI/AF.* Week 4. Discuss HA. Scenario 3. Living with MI/AF and kinesiophobia - How to make a change?* HA: Map weekly activities, rate as frightening/non-frightening. List PA and choose one to implement. Use SMART GOALS. Lecture: Kinesiophobia. Week 5. Discuss HA. Scenario 4. How can I reduce my fear for PA.* SMART, the activity. Week 6. Discuss HA. Week 7. Own individual work. HA: Evaluate, revise, and perform activities. Week 8. Follow-up of the activity plan. Summarize the program.
75711072|NCT02539810|Device|Renal artery Angioplasty plus stenting.|renal artery stenting
75402628|NCT06083246|Other|Hybenix gel|Clinical application of Hybenix gel after professional dental hygiene of peri-implant mucositis sites.
75402629|NCT06083246|Other|Chlosite gel|Clinical application of Chlosite gel after professional dental hygiene of peri-implant mucositis sites.
75402630|NCT06082921|Behavioral|Beef Diet Intervention|Participants will eat prepared meals including beef for 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
75402631|NCT06082921|Behavioral|Impossible Beef Diet Intervention|Participants will eat prepared meals including impossible beef for one portion 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
75402632|NCT06078150|Behavioral|Active video games intervention（1-6weeks）|"Experimental:~Experimental group for weeks 1-3: enter the subject's basic information. The Fitness Ring Adventure requires subjects to be proficient in wearing two Joy-Con devices. Therefore, during the three interventions in the first week, subjects were able to fully understand how the AVG was worn, the game mechanics, and the game modes. Familiarise yourself with the warm-up and stretching patterns in the preparation phase of the game in order to be better prepared for subsequent interventions.~Experimental group for weeks 4-6: to supervise and assist subjects during this intervention phase and to organize a speed passing competition at the end of week 6 to reward the subjects. Variables related to the subjects' activity, mental health, and physical composition were tested and recorded while testing proficiency in the game."
75402633|NCT06078150|Behavioral|Active video games intervention（7-12weeks）|"Experimental:~Experimental group in weeks 7-9: continue to warm up before each game and then play the game. Passing tasks were set for each subject from week 7 onwards, and they had to pass 2 tasks during each weekly intervention.~Experimental group in weeks 10-12: weekly intervention ensured that subjects were able to complete the pass 2 task, and if they completed the pass within the allotted time they were able to review the previously passed task. A boss fight was held in week 12, with a prize awarded to the person who took the shortest time."
75550185|NCT00348855|Behavioral|Stop Smoking|Minimal intervention
75550186|NCT00348855|Behavioral|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
75550187|NCT00348855|Other|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
75550188|NCT00315185|Drug|Cetuximab|
75550189|NCT00344721|Dietary Supplement|Omega-3 fatty acid supplement|Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.
75550190|NCT00344721|Dietary Supplement|Placebo|Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
75550191|NCT00315224|Behavioral|heart-rate controlled 12 week exercise program|
75550192|NCT00344760|Drug|Enfuvirtide|subcutaneously twice a day
75871486|NCT04459728|Behavioral|Wellness Element 5 - Nutrition|Daily wellness element focusing on nutrition; adherence documented online daily
75871487|NCT04459728|Behavioral|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
76038367|NCT05730439|Drug|Smokeless Tobacco|Receive usual SLT
76038368|NCT03683147|Other|Laboratory Biomarker Analysis|Correlative studies
76038369|NCT03683147|Behavioral|Meditation-Based Stress Reduction Program|Participate in 6-week online program
76038370|NCT03683147|Other|Quality-of-Life Assessment|Ancillary studies
76038371|NCT03683147|Other|Questionnaire Administration|Ancillary studies
75402634|NCT06075290|Behavioral|internet plus model|Intelligent transcutaneous bilirubin meter and Internet plus model for neonatal jaundice monitoring at home and remote follow-up
75402635|NCT06075290|Behavioral|control|follow-up by conventional methods; hospital or community follow-up depending on arrangement
75402636|NCT06074263|Drug|Dexamethasone 8mg|Dexamethasone 8mg will be taken orally just prior to surgery.
75402637|NCT06074263|Other|Placebo|Placebo capsule which looks identical to dexamethasone capsule
75402638|NCT06064695|Device|Whole-body Electrical Muscle Stimulation Exercise|This is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs using an iPad App. The stimulation suit (fitted shorts/shirt, vest, leg straps, arm straps) will be donned with the assistance of trained research personnel. Muscle groups stimulated include biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings. The stimulation level of each individual muscle group can be tailored to participant responses and tolerance (i.e. stimulation of the quadriceps and biceps can occur at different settings). While the participant is following along with the video, a qualified health care professional will be monitoring and adjusting the stimulation levels based on participant responses; rate of perceived exertion will also be monitored to ensure safe moderate intensity levels are maintained.
75550193|NCT00344760|Drug|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
75550194|NCT00348894|Drug|[S,S]-Reboxetine|[S,S]-reboxetine
76038372|NCT05730361|Biological|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
76038373|NCT05730361|Biological|ScTIL injection and B lymphocytes adjuvant|B lymphocyte are also isolated from PBMCs. If the percentage of subject's B lymphocyte in total lymphocytes is > 5%, the autologous B lymphocyte adjuvant will be prepared. If this percentage is ≤ 5%, PBMCs will be collected from haploidentical donor of the subject via apheresis, and B lymphocyte will be isolated for preparation of allogeneic B lymphocyte adjuvant.
75402639|NCT06063876|Procedure|Induction of experimental peri-implant mucositis|Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.
75402640|NCT06063876|Procedure|Resolution of experimental peri-implant mucositis|Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.
75402641|NCT06059794|Other|PUQE score|The Pregnancy-Unique Quantification of Emesis (PUQE) is a scoring system to quantify the severity of nausea and vomiting of pregnancy (NVP). Based on quantification of the 3 physical symptoms of NVP (nausea, vomiting and retching)
75402642|NCT06059794|Other|GAD-7|"The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include not at all, several days, more than half the days and nearly every day"
75402643|NCT06054516|Diagnostic Test|13C-enriched pyruvate|Before starting the hyperpolarization injection procedure, the patient will be scanned using the standard MR imaging defined in the clinical protocol and 13C prescriptions and a pre-scan will be completed. The clinical investigator will mount the administration syringe in the MR compatible power-injector with pre-adjusted injection volume calculated according to body weight (0.43 ml /kg bw). This setting is checked by the scanning operator and clinical investigator. The injection valve is set for agent delivery, and agent injected at a rate of 5 ml/s. The timings are monitored using a stopwatch on the SPINLAB. Following injection of hyperpolarized [1-13C]-Pyruvate , 20 ml of sterile saline in a separate syringe, already attached to the patient line, will be used to flush the IV line at the same injection rate (5 ml/s).
75402644|NCT06048107|Drug|Teniposide|Teniposide is semisynthetic analogues of podophyllotoxin, and they are used in the treatment of leukemia, lymphoma, and certain sorts of solid tumors.In addition, tiniposide has central permeability and is commonly used in the treatment of central nervous system tumors.
75402645|NCT06047119|Procedure|Blood pressure|Blood pressure targets during general anesthesia and 2 hours after
75550195|NCT00348894|Drug|Any|Any standard of care treatment for DPN
75402646|NCT06047119|Procedure|Positive end expiratory pressure|Positive end expiratory pressure during general anesthesia
75550196|NCT00315536|Drug|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
75550197|NCT00348972|Drug|Lantus® (insulin glargine)|
75550198|NCT00315575|Procedure|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
75550199|NCT00315692|Device|Biomarker Assay (CA125 and HE4)|
75550200|NCT00315770|Procedure|weight loss diets for young adults|
75550201|NCT00344838|Device|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
75550202|NCT00349050|Device|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
75402647|NCT06047119|Procedure|Tidal volume|Tidal volume during general anesthesia
76038374|NCT04789187|Procedure|High-Intensity-Interval-Training|Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.
75711073|NCT02539810|Drug|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is < 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
75402648|NCT06047119|Procedure|Fraction of inspired oxygen|Fraction of inspired oxygen during general anesthesia and 2 hours after
75402649|NCT06046001|Device|AirWaze|AirWaze - easy and advanced tools for CBCT guided lung interventions
75402650|NCT06043817|Drug|STX-721 (Escalated)|STX-721 dose will be escalated per Safety Evaluation Team (SET) decision and BLRM-design.
75402651|NCT06043817|Drug|STX-721 (2 doses)|Participants will receive 2 doses of STX-721.
75402652|NCT06043817|Drug|STX-721 (RP2D)|Participants will receive the RP2D of STX-721.
75550203|NCT00349050|Procedure|transcranial magnetic stimulation|"There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS."
75550204|NCT00349089|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
75550205|NCT00349089|Drug|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
75550206|NCT00349089|Drug|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
75550207|NCT00349128|Drug|fenofibrate and metformin combination (drug)|
75550208|NCT00349167|Drug|PR-104|
75550209|NCT00349167|Other|laboratory biomarker analysis|
75871488|NCT04459728|Behavioral|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
76038375|NCT04789187|Procedure|General Physical Activity Recommendations|Patients will be given general physical activity recommendations during chemotherapy.
75550210|NCT00349167|Other|pharmacological study|
75550211|NCT00315848|Drug|Buprenorphine transdermal delivery system|
75550212|NCT00349206|Drug|sorafenib tosylate|Given orally
75550213|NCT00349206|Drug|temsirolimus|Given IV
75402653|NCT06041841|Drug|LB54640|LB54640 QD Oral
75550214|NCT00315887|Drug|Buprenorphine transdermal delivery system|
75550215|NCT00421395|Biological|90Y-hLL2|weekly dosing for either 2 or 3 weeks
75550216|NCT00315926|Drug|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
75550217|NCT00315926|Drug|Placebo|a mixture of ethanol and physiological saline
75550218|NCT00421434|Drug|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
75550219|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
75550220|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
75550221|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
75550222|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
75550223|NCT00315965|Drug|Nitric oxide, Carbon monoxide, Helium|
75550224|NCT00349245|Drug|Remifentanil|
75402654|NCT06041581|Behavioral|Sleep Healthy Using The Internet (SHUTi)|Sleep Healthy Using The Internet (SHUTi) is an empirically supported internet intervention. It uses a fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. Each session has the same structure: objectives, sleep diary and homework review, new intervention material, homework assignment, and summary. SHUTi is enhanced through interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program. We provide basic tablet skills training and tablets with data plans when needed.
75402655|NCT06041581|Behavioral|Telephonic CBT-I|Telephonic CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Telephonic CBT-I will be delivered from a central location - the Insomnia Clinical Specialist's office. Telephonic CBT-I has been shown to be acceptable, feasible, and effective, with effect sizes similar to face-to-face CBT-I.
75402656|NCT06041581|Behavioral|Face-to-Face CBT-I|Face-to-face CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Face-to-face CBT-I will be delivered at the Insomnia Clinical Specialist's office. CBT-I is the clear first-line treatment for insomnia.
75402657|NCT06041581|Other|Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care|A designated trial research assistant will have two calls with each AC patient - one 45-minute call on insomnia education and one 45-minute call on sleep hygiene practices. The same research assistant will also call AC patients monthly to assess insomnia symptoms and will notify clinical staff to encourage additional care when indicated. AC patients will receive usual primary care for insomnia. The targeted clinics utilize a team care approach for behavioral health issues, as PCPs are supported by behavioral health clinicians and psychiatrists available for brief counseling and medication management. However, there is no routine screening for insomnia, and behavioral treatment for insomnia is typically limited to sleep hygiene practices.
75402658|NCT06038617|Biological|mRNA COVID-19 Vaccine|ACIP Recommended Vaccine
75402659|NCT06038617|Biological|Routine Childhood Vaccinations|ACIP Recommended Vaccines
75402660|NCT06035263|Other|FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME|the prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.
75402661|NCT06035263|Other|Health education programme:|"instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group."
75402662|NCT06035198|Other|Stroke|No intervention
75402663|NCT06033859|Diagnostic Test|Clinical measurements|With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
75402664|NCT06033859|Diagnostic Test|Radiographic measurement|A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
75402665|NCT06033859|Procedure|Dental prophylaxis or maintenance|Dental prophylaxis or maintenance will be performed every 3 months.
75402666|NCT06031662|Device|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting MT
75402667|NCT06031662|Device|Sham Intermittent Theta-Burst Stimulation|Magventure Active/Placebo B70 coil specifically designed for randomized clinical trials with TMS. This system uses electrodes placed on the scalp to provide stimulation mimicking the active treatment condition
75402668|NCT06025721|Behavioral|Cardiovascular Risk Homeless Support|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular health behaviors. The coach will encourage a focus on smoking>medication>sleep>physical activity>healthy eating to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed in participants' preferred format (handout, video, audio, etc.).
75402669|NCT06004336|Drug|Pembrolizumab|Given by vein (IV)
75402670|NCT06004336|Radiation|Radiation therapy|Given by vein (IV)
75550225|NCT00349245|Drug|Dexmedetomidine|
75550226|NCT00316043|Behavioral|Written information for parents|
75871489|NCT02350972|Biological|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
75871490|NCT02342470|Drug|Placebo|Drug : Placebo
75871491|NCT02342470|Drug|PMK-S005 1|Drug : PMK-S005 1 (50mg)
75402671|NCT05997732|Drug|Phenylephrine Hydrochloride|Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
75402672|NCT05997732|Drug|Isoproterenol Hydrochloride|Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.
75402673|NCT05997732|Drug|Norepinephrine Bitartrate|Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
75402674|NCT05997732|Drug|Propranolol Hydrochloride|Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.
75402675|NCT05997732|Drug|Phentolamine Mesylate|Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.
75402676|NCT05997732|Drug|Phenylephrine Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.
75402677|NCT05997732|Drug|Isoproterenol Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.
75402678|NCT05997732|Drug|Propranolol Hydrochloride|Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.
75402679|NCT05979454|Diagnostic Test|Krebs von den Lungen-6 (KL6)|KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).
75402680|NCT05970614|Other|Eye masks and ear plugs|Eye masks and ear plugs will be applied to patients for 3 days between 22:00 and 06:00.
75402681|NCT05961514|Diagnostic Test|Target biopsies|MRI/Fusion target biopsies combine magnetic resonance imaging (MRI) with ultrasound-guided biopsy techniques to obtain tissue samples from areas of the prostate gland that appear abnormal on MRI.
75402682|NCT05961514|Diagnostic Test|systemic biopsies|transrectal ultrasound (TRUS) guided prostate systemic biopsies
75402683|NCT05958628|Other|Conventional physiotherapy|"The treatment program was designed in line with the patients' compliance, functional capacities and rehabilitation goals as neurodevelopmental therapy based on the ability to adapt to change, reorganization and healing in the brain by focusing on neuroplasticity from neurodevelopmental treatment approaches; Proprioceptive neuromuscular facilitation techniques to increase selective and voluntary movement; functional exercises to increase motor control skills, stretching exercises for spasticity and neuromuscular electrical stimulation.~The control group received conventional physiotherapy exercises for 45 minutes and neuromuscular electrical stimulation for 15 minutes."
76038376|NCT05550493|Behavioral|Cognitive Behavioral Therapy|The cognitive behavioral therapy program consisted of eight interactive sessions, each requiring approximately 15 minutes to complete. Each ICBT session includes interactive multimedia modules (videos, pictures, and texts), the contents of which were based on the community reinforcement approach. The ICBT sessions covered the following topics: (1) introduction to digital therapeutics and CBT, (2) recognizing the triggers of craving, (3) coping with craving, (4) refusing skills/assertiveness, (5) problem-solving skills, (6) changing thoughts about drugs, (7) seemingly irrelevant decisions, and (8) HIV risks and prevention.
76038377|NCT05550493|Behavioral|Counseling|Counseling provided by social workers and psychotherapists on topics including work, family, stress management, and drug craving suppression.
76038378|NCT05550493|Behavioral|Approach Bias Modification|In an ApBM session, users were instructed to swipe upward (downward) when they saw portrait (landscape) format images. A shrinking (growing) animation comes after swiping upward (downward) to simulate the visual effect of moving away (moving towards). The images were related to methamphetamine usage (methamphetamine crystals, powders, and paraphernalia) or healthy lifestyles (wealth, sports, gourmet, family activities, etc.). Each ApBM session was composed of presenting each one of the healthy lifestyle (methamphetamine) cues 12 times in landscape (portrait) and once in portrait (landscape).
76038379|NCT05550493|Behavioral|Cognitive Training|The DTx application incorporated a game-based cognitive function training module for improving working memory. In this game, a matrix of squares is displayed at the center of the screen. Between 3 and 5 target symbols are randomly placed in the matrix and displayed for 2 seconds. Next, the symbols disappear, and the matrix randomly rotates. The participants were asked to click the correct locations of the target symbols within the prescribed time limit. The game becomes more difficult as the size of the matrix, the number of target symbols, and the complexity of the matrix rotation change at each level. Each cognitive function training session lasted between 3 and 5 minutes.
75550227|NCT00316043|Behavioral|Distance learning package for General Practitioners|
75550228|NCT00316043|Behavioral|Distance learning package for practice assistants|
75871492|NCT02342470|Drug|PMK-S005 2|Drug : PMK-S005 2 (100mg)
75871493|NCT02342470|Drug|PMK-S005 3|Drug : PMK-S005 3 (150mg)
76038380|NCT03671291|Behavioral|self-administrated questionnaire|Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
76038381|NCT05730283|Drug|ORC-13661|High-dose intervention (30mg daily)
76038382|NCT05730283|Drug|ORC-13661|Low-dose intervention (12mg daily)
76038383|NCT05730283|Drug|Placebo|Placebo intervention
76038384|NCT05087667|Device|Implantation of Ortholoop cerclage|implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention
76038385|NCT05087667|Device|Implantation of Cerclage used in current practice|implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
76038386|NCT05613959|Device|Veress +|The Veress+ safety mechanism was used
76038387|NCT05613959|Device|Conventional Veress|The Conventional Veress Needle was used
76038388|NCT05730049|Device|Transcutaneous auricular vagus nerve stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
75402684|NCT05958628|Other|Robotic Hand Exoskeleton System|In the treatment applications with the robotic hand exoskeleton system, which is designed to accelerate the healing process of patients in need of hand rehabilitation, to gain motor skills, to provide strength training and to increase participation in treatment, the patient will be asked to allow the system to move the hand at adjusted angles for 10 minutes and to accompany this movement. In the applications, while the patient is sitting comfortably and safely, the patient will be asked to place the stroke-affected hand into the system. The hand of patients who may have difficulty due to the functional status of the upper extremity and the severity of spasticity will be placed with the help of the physiotherapist. The physiotherapist will be with the patient throughout the application.
75711074|NCT04044183|Behavioral|Active Brains 1|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
76038389|NCT04226937|Other|Not Applicable as this is a translational, sample collection study.|"Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor.~Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable.~Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate."
76038390|NCT04517279|Behavioral|Invest in My Recovery Bank|The intervention has not be fully developed. It will be created in partnership with individuals serving in peer provider roles.
75711075|NCT04044183|Behavioral|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
75711076|NCT00900952|Other|Clinical record review|
75711077|NCT00901888|Drug|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
75711078|NCT00901888|Drug|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
75871494|NCT04436952|Device|H7 coil|The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.
75402685|NCT05943314|Biological|CLL1/+CD33 CAR-T|CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.
75402686|NCT05942326|Behavioral|Sleep GOALS|Web-based interventions
76038391|NCT04517279|Behavioral|Usual Care Peer Services|Usual peer services involves supporting the process of change for individuals with mental health disorder to improve their health and wellness, live a self-directed life, and strive to reach their full potential.
75711079|NCT04416711|Behavioral|Personalized Feedback|The personalized feedback consists of four components: normative feedback, risk/protective feedback, decisional balance/goal setting, and protective strategy review. Personalized feedback targets include readiness to change, perceptions of risk, and misperceptions of peer attitudes/behaviors.
75711080|NCT04416711|Behavioral|Cognitive Skills Training|We will address three cognitive targets: focus on affective cues, focus on non-affective cues, and over-perception of sexual interest. The first module targets enhanced focus on women's affective cues and reduced over-perception of sexual interest. We will introduce the role of men's sexual-perception skills in satisfying social and sexual interactions with women, as well as problematic sexual behavior including RSB and SAB. Next, we will instruct participants that affective information is the best-available nonverbal information about how a woman is feeling about a specific man. This instruction will focus on distinguishing four primary dating relevant cues: sexual-interest, friendliness, sadness, and rejection. More detailed focus on each cue will emphasize the increased difficulty of reading these cues with a new partner and under the influence of alcohol and sexual arousal, as well as the importance of checking verbally on assumptions about a woman's current sexual interest.
75711081|NCT04416711|Other|Services As Usual|These participants will receive services as usual
75711082|NCT00908362|Drug|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
75402687|NCT05942326|Behavioral|Education|Brochures from the American Academy of Sleep Medicine (e.g., sleep hygiene, sleep in women) and SNAP education connection (e.g., family-friendly activities, meal planning)
75871495|NCT04436952|Device|Cool D-B80|The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation
75871496|NCT04436952|Behavioral|Exposure Response Prevention (ERP)|The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours
75871497|NCT03531905|Drug|Bempedoic acid + Ezetimibe FDC Oral Tablet|Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
75402688|NCT05941858|Other|Best Practice|Receive standard cessation treatments
75402689|NCT05941858|Procedure|Carbon Monoxide Measurement|Undergo CO test
75871498|NCT03531905|Drug|Ezetimibe 10 mg Oral Tablet|Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
75871499|NCT03531905|Drug|Placebo Oral Tablet|Placebo tablet, matched for the FDC product for blinding purposes
75871500|NCT03531905|Drug|Placebo oral capsule|Placebo over-encapsulated for blinding purposes
76038392|NCT04789031|Dietary Supplement|Oral nutritional supplementation (ONS)|Patients received a renal specific ONS (Novasource Renal, Nestle) providing 475 kcal and 21.7g of protein per serving on a daily basis for 6 months. This was a ready-to- drink formula available in a tetrabrik pack. Patients consumed the product 30 minutes after commencing their dialysis session or at home after completion of dialysis.
76038393|NCT05126745|Device|color flow Doppler ultrasonography|Doppler ultrasonography
75402690|NCT05941858|Other|Internet-Based Intervention|Receive access to WaQi program
75402691|NCT05941858|Drug|Nicotine Replacement|Receive referral for NRT
75402692|NCT05941858|Other|Survey Administration|Ancillary studies
75402693|NCT05941858|Other|Tai Chi|Practice Tai Chi
75550229|NCT06165796|Device|routine cataract surgery and intraocular lens implantation|routine cataract surgery and intraocular lens implantation
75402694|NCT05935917|Drug|Brincidofovir|100 mg tablet of Form H and 100 mg tablet of Form II
75402695|NCT05918302|Drug|177Lu-edotreotide|6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
75402696|NCT05918302|Drug|Everolimus|10 mg orally once daily (QD)
75402697|NCT05917301|Radiation|hypofractionation|This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.
75402698|NCT05910567|Diagnostic Test|Focused Assessment with Sonography for Trauma (FAST) Examination|A bedside Focused Assessment with Sonography for Trauma (FAST) Examination will be conducted on those participants who are randomized to the FAST arm.
75550230|NCT06165770|Procedure|laparoscopy|Conservative or surgery treatment for cornual pregnancies
75550231|NCT06165731|Behavioral|Diaphragmatic Breathing Exercises|Mindful deep breathing cycle comprised of a 3-second inhale causing abdominal wall movement followed by a 5-second exhale, which will be completed for a total of 10 minutes of daily exercise
75402699|NCT05910567|Other|No Intervention: Standard of Care - Without the FAST Examination|Participants randomized to usual care will be evaluated per the standard operating procedures of the institution/site for the condition under study without the FAST exam.
75402700|NCT05895825|Drug|EOC237|EOC237 for orally
75402701|NCT05891548|Drug|CLS-AX|CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.
75402702|NCT05891548|Drug|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
75402703|NCT05891249|Biological|Luspatercept|Specified dose on specified days
75402704|NCT05881161|Behavioral|Adherence self-efficacy-enhancing exercise|This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.
75550232|NCT06165731|Behavioral|Bladder Hygiene Education|Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
75550234|NCT06165692|Biological|PRF|Post-operative PRF placement in the post-extraction socket after third molar surgery
75871501|NCT02350426|Other|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
76038394|NCT04789421|Device|Clinical, dermoscopy and Reflective confocal microscopy evaluations|Adjunctive reflective confocal microscopy to dermoscopy and clinical dermatological evaluation.
75402705|NCT05881161|Behavioral|Med-Stress Student|Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
75402706|NCT05881148|Other|Carbon sprinting spiked-shoes|Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
75402707|NCT05881148|Other|Standard carbon-free sprinting spiked-shoes|cf
76038395|NCT04789421|Device|Clinical, dermoscopy evaluations|Dermoscopy and clinical dermatological evaluation only
75402708|NCT05871996|Other|Palliative Care and Oncology Survey on Terminology (POST)|Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
75402709|NCT05870670|Drug|NNC0519-0130|Administered subcutaneously.
76038396|NCT05126199|Other|Time restricted eating|"Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
75402710|NCT05870670|Drug|Placebo|Administered subcutaneously.
75402711|NCT05869838|Device|Colonoscopy|Screening or surveillance colonoscopy
75711083|NCT00908362|Drug|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
75871502|NCT02350426|Other|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
75550235|NCT06165679|Drug|Prilocaine|The patients will receive a single injection of spinal anesthesia using prilocaine plus fentanyl
75550236|NCT06165679|Drug|Bupivacaine|The patients will receive a single injection of spinal anesthesia using Bupivacaine plus fentanyl
75550237|NCT06165666|Other|Approach by functional objectives|The therapeutic approach that will be administered to the EG will be based on the training of specific tasks aimed at functional objectives. Each session will begin with activities to activate the muscles of the trunk, pelvis and lower limbs, to modify atypical movement patterns and prepare the muscles for a more effective contraction. Subsequently, activity training will be carried out in a functional and meaningful context, aimed at specific and significant functional objectives for the participant and previously agreed upon with them.
75711084|NCT00908362|Drug|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
75711085|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
75711086|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
75711087|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
75871503|NCT02350426|Other|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
75871504|NCT02346682|Drug|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
76038397|NCT05126199|Other|Normal ad libitum diet|"Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
75402712|NCT05869383|Drug|Ophiochepalus striatus extract|Ophiochepalus striatus extract 2x5 grams
76038398|NCT04789265|Other|instrumented- assisted soft tissue mobilization (IASTM)|IASTM is a new, non-invasive, conservative therapeutic approach. Instead of the therapist's hands and fingers in treatment, these devices are used to provide contact mobilization power. AYDM intervention, such as friction, rubbing massage treatments, requires the therapist to apply a significant amount of pressure. The main purpose of IASTM is to eliminate scar tissue and to restore the normal function of the tissue following soft tissue regeneration.
76038399|NCT05493787|Behavioral|Reminder|Patient portal, SMS, email, and/or another modality
76038400|NCT05613569|Drug|KLS-2031|KLS-2031 administered by transforaminal epidural injection
75402713|NCT05869383|Drug|Placebo|Placebo 2x5 grams
75402714|NCT05862792|Drug|Liposomal bupivacaine|We will inject liposomal bupivacaine into the surgical bed.
75402715|NCT05855317|Other|Blood sample|Additional blood samples will be taken on a catheter, used for standard care.
75402716|NCT05849454|Device|Messy Memories Intervention|"Messy Memories is a mobile application that allows users to self-administer exposure therapy techniques outside of the traditional psychotherapy context. Participants are asked to audio record a difficult (messy) memory, including what they did, felt, thought, smelled, saw, etc. They are then asked questions about what it was like to re-experience the memory, such as what emotions were elicited (e.g., sadness, anger, fear). Next, participants are asked to process what the memory means to them. They are then instructed to listen to their recording as often as they like, until the memory becomes easier to re-experience. They respond to processing questions each time they listen to their prior difficult memory."
75402717|NCT05849337|Behavioral|Brief imagery-competing task|Two digital self-guided sessions of a brief digital imagery-competing task. A memory cue followed by playing a computer game with mental rotation instructions.
75402718|NCT05849337|Behavioral|Brief psychoeducation and signposting task|Two digital self-guided sessions and access to psychoeducation and signposting regarding resources for psychological trauma in Iceland.
75711088|NCT02549469|Drug|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
75711089|NCT00908440|Behavioral|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
75711090|NCT00905866|Other|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
75711091|NCT00837525|Procedure|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
75871505|NCT04385706|Behavioral|Applied Coaching Model|The Applied Coaching Model incorporates key learning opportunities and coaching strategies with evidence-based practices, approaches and theories and will serve as a tool for all healthcare providers wanting to implement coaching techniques within their practice.
75402719|NCT05849337|Other|Treatment as usual (TAU)|Routine care that participants would otherwise receive if having intrusive memories of traumatic events
75402720|NCT05845788|Procedure|Peripheral nerve block|Ultrasound guided peripheral nerve block
75711092|NCT02539576|Drug|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
75711093|NCT00837603|Behavioral|Training|Controlled home ergometer training
75711094|NCT00905944|Other|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
75711095|NCT00923793|Device|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
75711096|NCT00923793|Device|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
75711097|NCT02548533|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
75402724|NCT05835999|Drug|Everolimus 0.5 MG once per day|Everolimus is considered an mTOR kinase inhibitor
75402725|NCT05835999|Drug|Everolimus 5 MG once per week|Everolimus is considered an mTOR kinase inhibitor
75402726|NCT05835999|Drug|Placebo once per day|No therapeutic effect
75402727|NCT05835999|Drug|Placebo once per week|No therapeutic effect
75402728|NCT05832268|Other|Obstetric Anal Sphincter Injury|We will investigate if a new vaginal delivery in those with a previous obstetric anal sphincter injury affects the function of anal musculature negatively
75402729|NCT05831293|Behavioral|Mindfulness Based Stress Reduction Program|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
75402730|NCT05829603|Drug|Dimethyltryptamin (DMT) & Harmine|Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
75402731|NCT05804708|Drug|GH001|GH001 is administered via inhalation
75402732|NCT05800275|Drug|Tucatinib Oral Tablet|300 mg, twice daily
75402733|NCT05800275|Drug|Capecitabine tablets|1000 mg/m², twice daily on days 1-14 of each 21-day cycle
75402734|NCT05800275|Drug|Trastuzumab Injection|Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
75402735|NCT05798975|Other|Aerobic Exercise. 1 session of acute exercise|40 minutes on cycle ergometer, 60% of heart rate reserve
75402736|NCT05798975|Other|Resistance Exercise. 1 session of acute exercise|2 exercises for lower limbs and 2 for upper limbs with 4 sets of 12 repetitions at 60% 1-RM. 40 minutes
75402737|NCT05798975|Other|no exercise|Rest
75711098|NCT02548533|Drug|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
75402738|NCT05788783|Behavioral|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
75711099|NCT02548533|Drug|EMLA cream|Topical application 2 hours prior to the treatment.
75711100|NCT02549391|Drug|KHK7580|Oral administration
75711101|NCT02549391|Drug|KRN1493|Oral administration
75871506|NCT03131934|Biological|Autologous EBV-CTL transduced with vector SFG-CNA12|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
75402739|NCT05788783|Other|Canine Education & Bonding|Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
75550238|NCT06165666|Other|Treatment protocol|The therapeutic approach of the participants assigned to the CG will be aimed at maintaining joint ranges and transfer work, passive mobilization of the paretic lower and upper limb, maintenance of sitting posture with/without assistance, transfer from sitting to standing, from standing to sitting. and coordination work. Subsequently, initiation of walking with a support product and/or help, if possible.
75550239|NCT06165588|Other|Tour de France|Participating in the Tour de France as cyclist
75550240|NCT06165523|Other|Water|340 mL plain tap water consumed immediately following glycogen depleting exercise
75550241|NCT06165523|Other|Flavored Kefir|320 mL kefir consumed immediately following glycogen depleting exercise
75550242|NCT06165523|Other|Flavored Milk|240 mL flavored milk consumed immediately following glycogen depleting exercise
75550243|NCT06165510|Device|Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.|2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.
75550244|NCT06165510|Procedure|Standard Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
75711102|NCT00902122|Drug|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
75711103|NCT00902122|Procedure|surgery|removal of thyroid tumor
75711104|NCT00902122|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
76038401|NCT04830163|Combination Product|Brain state-dependent paired corticomotoneuronal stimulation (PCMS)|Paired corticomotoneuronal stimulation (PCMS) involves delivering precisely timed pairs of transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) so that the neuronal activity evoked by such stimulation arrives synchronously at corticospinal-motoneuronal synapses. This synchronous arrival is postulated to cause long-term potentiation via spike timing-dependent plasticity, which then improves corticospinal transmission and hand function. In this study, paired corticomotoneuronal stimulation (PCMS) will be applied during specific brain states that reflect increased recruitment of motoneurons via the corticospinal tract. This increased recruitment is expected to enhance the beneficial effects of PCMS on human hand function after stroke.
76038402|NCT04788719|Other|Gait analysis|Gait analysis
75711105|NCT00902122|Radiation|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
75711106|NCT02538172|Other|T-Track® CMV assay|
75711107|NCT00837837|Drug|Chlorpheniramine|
75402740|NCT05787496|Drug|NC525|Monoclonal antibody specific for LAIR-1
75402741|NCT05784402|Drug|Semaglutide J|Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.
75402742|NCT05784402|Drug|Semaglutide C|Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.
75402743|NCT05782517|Device|Supraglottic Airway Device|Placement of an I-gel Supraglottic Airway Device.
75402744|NCT05782517|Device|Endotracheal Tube|Placement of an Endotracheal Tube.
75402745|NCT05781958|Drug|Cadonilimab+Gem/Cis|Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine（1000 mg/m^2 orally according to Body Surface Area (BSA)，BID，Q3W，on Days 1-14）as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.
75550245|NCT06165497|Behavioral|Meditation practices|Participants will listen to recordings of short meditation practices drawn from the Healthy Minds Program.
75550246|NCT06165497|Other|Internet-as-usual|Participants will be instructed to use the internet as they typically do.
76038403|NCT05125263|Other|kinesiotaping group|"Kinesio-taping with conventional therapy 24, 48 and 72 hours standardized therapeutic KT application along with conventional therapy (hot pack, strengthening and stretching exercises). The patient laid supine.To maintain proprioceptive stimulation in the quadriceps (from origin towards insertion) and to alleviate the tension of hamstring muscle, a 'Y'-shaped kinesiotaping will be applied. Afterward, 2 pieces of 'I'-shaped tapes were stretched by 75% through the mechanical correction technique and will be applied around the patellar circumference in the way that it would allow the patella to move naturally in the femoral cavity while the knee was in 45 flexion~CONVENTIONAL THERAPY:~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps* 3 sets, 1 min interval)"
76038404|NCT05125263|Other|mulligan taping group|"Mulligan taping will be applied while patient in standing position and the hip, knee will be internally rotated and flexed to 20 degree. Rigid tape will be applied from neck of fibula which will be passing anteriorly over the tibia to secure internal rotation of tibia at the knee, and passing below the medial joint line and behind the knee, 2 superimposed layers of 38-mm rigid tape will be applied in a spiral fashion. Tape will be applied for 24, 48 and 72 hours. And it must come off immediately if any pain and skin irritation is experienced. Along with conventional therapy.~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps* 3 sets, 1 min interval)"
76038405|NCT04805515|Behavioral|Nicotine Corrective Messages|Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
76038406|NCT05124873|Device|Moisture Management Liner|A prototype liner designed to reduce heat that builds up on the limb.
75550247|NCT06165445|Device|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.
76038407|NCT05729971|Procedure|nasogastric tube|The intervention consists in removing or not the nasogastric tube at the end of the surgery.
75550248|NCT06165445|Device|multichannel transcranial direct current stimulation (tDCS)|In multichannel tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through more than two and smaller round electrodes over the target regions.
76038408|NCT05170919|Drug|Mirtazapine|Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.
76038409|NCT05170919|Drug|Olanzapine|the participant will be prescribed a dosage of 2.5mg per day if > 65 yrs. and 5 mg/per day if <65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
76038410|NCT05729893|Other|root canal sealers|different sealer used in obturating root canals (resin and bio ceramic)
76038411|NCT05602285|Device|Dislodgement device|Breakaway device that prevents IV dislodgement
76038412|NCT05729737|Diagnostic Test|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in pancreatic tumors, it is safe and widely used in liver and pancreatic disease.
75550249|NCT06165432|Drug|Topical Benzocaine|Benzocaine topical anesthetic gel will be used a pre-injection anesthetic on one half of the palate before giving greater palatine nerve block
75550250|NCT06165432|Other|Topical ice|For the other half of the palate topical ice would be used before greater palatine nerve block
75550251|NCT06165406|Procedure|Distal radial access|Distal radial access for coronary procedures
75550252|NCT06165393|Dietary Supplement|Slow-release CHO-AA|Slow-release CHO-AA, alginate encapsulated
75402746|NCT05770011|Device|intraoral scanner of nonsplinted scan bodies|scanning of non splinted scan bodies
75402747|NCT05770011|Device|impression material|conventional recording
75402748|NCT05770011|Device|intraoral scanner of splinted scan bodies|scanning of splinted scan bodies
75402749|NCT05769478|Drug|Amifampridine|a single dose of amifampridine (20mg) will be orally administered
75402750|NCT05757206|Diagnostic Test|Syn-One Test|Participating subjects will have three small skin punch biopsies.
75402751|NCT05755152|Other|polyphenol-lecithin precipitate (PLP)|Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).
75402752|NCT05755152|Other|control formulation|Chewing gum made with material produced from conventional technology (e.g cranberry extract).
75402753|NCT05753930|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
75402754|NCT05744739|Procedure|Biospecimen Collection|Undergo blood sample collection
75402755|NCT05744739|Drug|Tomivosertib|Given PO
75402756|NCT05737602|Behavioral|3RP-VHL|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.
75402757|NCT05729282|Drug|Diazoxide oral suspension, 1 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).
75402758|NCT05729282|Drug|Diazoxide oral suspension, 2 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
75711108|NCT00908674|Drug|Cyproterone acetate (Androcur)|"The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).~Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.~Administration period: 12 months."
75711109|NCT00906022|Device|Astron Pulsar Stent|Stenting with Astron Pulsar
75711110|NCT00906022|Device|PTA alone|Balloon angioplasty alone
75711111|NCT00902356|Drug|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
75711112|NCT00902356|Drug|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
75402759|NCT05729282|Drug|Placebo|Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
75402760|NCT05729282|Device|FreeStyle Libre Pro|All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.
75402761|NCT05729282|Drug|Deuterated water (2H2O/D2O)|All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.
75402762|NCT05724316|Dietary Supplement|Vitamin D supplement|N/A (says not to repeat information here)
75402763|NCT05724264|Diagnostic Test|Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays|"LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.~All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery."
75402764|NCT05724134|Drug|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
75402765|NCT05724134|Drug|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
75402766|NCT05724134|Drug|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
75402767|NCT05724134|Drug|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
75402768|NCT05724134|Other|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
75550253|NCT06165393|Dietary Supplement|Slow-release CHO|Slow-release CHO, alginate encapsulated
75402769|NCT05724134|Drug|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
75402770|NCT05724134|Dietary Supplement|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp."
75402771|NCT05724134|Dietary Supplement|CORE Bar|Energy bar used as a standardized snack on the day before the pancreatic clamp.
75402772|NCT05724134|Device|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
75550254|NCT06165393|Dietary Supplement|CHO|Carbohydrate-only, control
75550255|NCT06165315|Behavioral|Parenting program|Villages in the intervention group will receive the parenting program. The parenting program consists of 20 total sessions, whereby groups will meet twice a month for 10 months.
75711113|NCT00621777|Drug|Varenicline|"At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks."
75871507|NCT03131934|Biological|Autologous EBV-CTL transduced with control vector SFG-CNA8|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
75402773|NCT05724134|Device|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
75402774|NCT05723588|Device|active repetitive transcranial magnetic stimulation|Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.
75402775|NCT05723588|Device|sham repetitive transcranial magnetic stimulation|Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.
75402776|NCT05723588|Behavioral|cognitive behavioral therapy for smoking cessation|All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
75402777|NCT05723588|Drug|nicotine replacement therapy|"All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a rescue method such as nicotine lozenge or nicotine gum."
75402778|NCT05722873|Behavioral|Fasting arm|Study participants will fast one day per week for 12 weeks
75402779|NCT05722873|Behavioral|Weight maintenance|Study participants will be counseled to maintain body weight
75402780|NCT05722873|Behavioral|Counseling|Study participants will be counseled on optimal diet and activity recommendations for maintaining/achieving a normal BMI
75550256|NCT06165302|Behavioral|Exercise Intervention|12 weeks of prescribed exercise intervention.
75402783|NCT05712018|Drug|Hydroxyethyl starch coload - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75550257|NCT06165289|Other|PRP Injection|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with different concerntrations
75550258|NCT06165276|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
75550259|NCT06165276|Biological|Meningococcal Group C-CRM197 Conjugate Vaccine|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
75402784|NCT05712018|Drug|Hydroxyethyl starch coload - 5 ml/kg|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75402785|NCT05712018|Drug|Hydroxyethyl starch coload - 10 ml/kg|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75402786|NCT05705492|Procedure|Biospecimen Collection|Undergo blood specimen collection
75402787|NCT05705492|Procedure|Computed Tomography|Undergo a CT scan
75402788|NCT05705492|Drug|Olanzapine|Given PO
75402789|NCT05705492|Drug|Placebo Administration|Given PO
75402790|NCT05705492|Other|Questionnaire Administration|Ancillary studies
75711114|NCT00621777|Drug|Placebo|"At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks."
75402791|NCT05704543|Drug|Buprenorphine Extended-Release Injection|Administered as a subcutaneous injection.
75402792|NCT05673902|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
75402793|NCT05669911|Device|Teal Health Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of cervicovaginal cells using the Teal Health Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A Pap smear will be performed by a clinician before or after self-collection.
75402794|NCT05661448|Behavioral|Cognitive remediation|The goal of this program is to improve performance on cognitive domains known to hinder functioning. It aims to promote positive attitudes towards learning and facilitate the development of independent learning skills to foster competence and confidence. Another aim is to increase patients' awareness of their cognitive strengths and weaknesses and their own problem solving strategies.
75550260|NCT06165237|Drug|BR6001-1|One tablet administered alone, Once a day
75711115|NCT02538718|Drug|MgSO4|
75711116|NCT02538718|Drug|YTP(Ritodrine)|
75711117|NCT00827229|Device|Labor Monitor|
75711118|NCT02539420|Device|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
75711119|NCT04018599|Drug|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using an auto-injector.
75711120|NCT04018599|Drug|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
75711121|NCT00902512|Drug|Treatment A|Viagra® 100 mg tablet, administered with water single dose
76038413|NCT05179629|Drug|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 30 ml (15 ml for each side) of %0,25 bupivacaine.
75550261|NCT06165237|Drug|BR6001-2|One tablet administered alone, Once a day
75711122|NCT00902512|Drug|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
75711123|NCT00902512|Drug|Treatment B|Sildenafil 100 mg CT administered with water single dose
75711124|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
75550262|NCT06165211|Other|Nature sound listening|The intervention group listened to nature sounds for 30 minutes during hemodialysis. Nature sounds consisting of bird, wind and tree sounds will be played.
75402795|NCT05661448|Behavioral|MetaCognitive Training|The metacognitive training (MCT) program is based on the theoretical foundations of cognitive models of schizophrenia but employs a slightly different focus in its therapeutic approach targeting the specific cognitive biases underlying delusions. The modules aim to raise awareness of these biases and prompts participants to critically reflect on and update their problem-solving repertoire.
75402796|NCT05636852|Drug|Altropane (123I) Injection|Each subject will receive a single IV administration of 5 mCi (185 MBq) Altropane.
75711125|NCT00902512|Drug|Treatment C|Sildenafil 100 mg CT administered without water single dose
75550263|NCT06165211|Other|Routine care|Patients will watch the program they want on the bedside TV during hemodialysis.
75711126|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
75711127|NCT00830973|Other|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
75711128|NCT00830973|Other|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
75711129|NCT04034914|Other|Questionnaire administration|Ancillary studies
75711130|NCT00827307|Drug|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
75550264|NCT06165198|Device|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed-loop tACS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
75550265|NCT06165185|Other|Water|Please see the associated arm description
75550266|NCT06165185|Other|Coffee|Please see the associated arm description
75550267|NCT06165185|Other|Control|Please see the associated arm description
75711131|NCT00827307|Drug|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
75711132|NCT04034602|Other|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
75711133|NCT04034602|Other|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
75711134|NCT00837915|Drug|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
75711135|NCT00908986|Drug|Rituximab|375mg/m2 q week x 4; repeated in 6 months
75711136|NCT02539264|Other|Smoking|Influence of smoking on parameters derived from overnight PSG
75711137|NCT02539264|Other|Obesity|Influence of obesity on parameters derived from overnight PSG
75711138|NCT02539264|Other|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
75711139|NCT00827463|Biological|dosage of the NFS and iron|a blood test will be made.
75711140|NCT00909142|Drug|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
75711141|NCT00906256|Drug|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
75711142|NCT00906256|Drug|Placebo|Placebo
75402797|NCT05631743|Behavioral|VR-CBT|The therapy is focused on emotion regulation through guided learning in virtual reality. The manual is a modified conventional cognitive behavioral therapy to include these aspects and the suggestions of an advisory committee of Inuit and non-Inuit health service providers (e.g., cultural adaptation).
75402798|NCT05631743|Behavioral|Self-management|The previously developed commercial VR program involves guided relaxation and meditation techniques.
75402799|NCT05627375|Drug|Full-dose anticoagulant therapy (AC)|Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE
75402800|NCT05627375|Drug|Antiplatelet therapy (AP)|Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
75550268|NCT06165172|Device|MyoRegulator®|Study participants will receive treatment using the MyoRegulator® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.
75711143|NCT00838071|Drug|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
75711144|NCT02539186|Biological|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
75402801|NCT05623683|Other|Intermittent Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will walk on the treadmill for 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
75402802|NCT05623683|Other|Continuous Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will rest for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
75402803|NCT05614947|Dietary Supplement|Powdered tart cherry|500 mg freeze-dried tart cherry per capsule
75550269|NCT06165159|Other|children and adolescents with type 1 diabetes and their parents|"Children over the age of 8 with type 1 diabetes diagnosed more than 6 months ago in France, followed in one of the hospitals that are members of the Aide aux Jeunes Diabétiques (AJD) association.~Parents or people involved in the day-to-day life of children with type 1 diabetes diagnosed at least 6 months ago, whose child is being followed in France in one of the hospitals affiliated to the AJD association."
75550270|NCT06165146|Drug|Repaglinide|Administered orally.
75711145|NCT02539186|Device|splint|
75711146|NCT04044573|Procedure|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
75711147|NCT02538640|Other|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
75711148|NCT02538640|Other|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
75711149|NCT00902824|Biological|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10^7 pfu TBC-M4 (IM)
75711150|NCT00902824|Biological|TBC-M4|Receive 5x10^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
75711151|NCT00902824|Other|Placebo|"Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM."
75550271|NCT06165146|Drug|Pirtobrutinib|Administered orally.
75550272|NCT06165133|Other|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP)|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP) through an accredited training programme prior to commencing participation in the study
75550273|NCT06165133|Other|Mesh inguinal hernia repair performed by fully trained surgeons|Mesh inguinal hernia repair performed by fully trained surgeons, recognised by the Ghana College of Surgeons and Physicians and other recognised Surgical Colleges around the globe.
75711152|NCT02547519|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
75711153|NCT02547519|Drug|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
75711154|NCT02547285|Other|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
75711155|NCT00909454|Dietary Supplement|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
75711156|NCT00909454|Dietary Supplement|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
75402804|NCT05614947|Dietary Supplement|Placebo|500 mg colored cornstarch per capsule
75871508|NCT03131934|Procedure|Leucapheresis|Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
75550274|NCT06165120|Procedure|Bracka's repair using preputial graft|"Staged repair:~Correction of ventral chordee: by degloving of the penile skin, transection of the urethral plate &/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~Preputial graft placement: a graft will be designed on the inner layer of the preputial hood, according to the length of the urethra defect. Fixation of the free graft will be performed along the whole defective urethral plate. A compression dressing will be used for the transplanted graft. At the end of the surgery, a urinary catheter will be placed through the ectopic meatus.~Tubularisation of the graft: this stage will be performed 6 months later. The new graft will be tubularised over a catheter. Then a protective layer may be made over the tubularization using a dartos or tunica vaginalis flap. After suturing of the penile skin and dressing of the penis, a urethral catheter would be retained for urinary diversion."
75711157|NCT04312737|Device|Self-Collecting Devices|FLOQSwab (Copan) Colli-Pee (Novosanis)
75711158|NCT04312737|Diagnostic Test|In Vitro Diagnostic Assays|Papilloplex (GeneFirst) HPV Oncopredict DNA (Hiantis) HPV Oncopredict RNA (GeneFirst)
75711159|NCT04035070|Combination Product|co-amoxiclav-clindamycin solution|antibiotic-containing solution will be prepared by mixing equal quantities of 1.2gm Co-amoxiclav solution and 600mg Clindamycin solution at a ratio of 1:1 by volume to be used as a root canal irrigating solution
76038414|NCT05613491|Drug|Intranasal insulin|Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
76038415|NCT05613491|Drug|Intranasal saline|Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
76038416|NCT05082207|Other|Remote Ischemic Preconditioning|Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.
76038417|NCT05082207|Other|sham group|a deflated cuff placed on the upper arm for 30 min
76038418|NCT05157425|Dietary Supplement|Food Supplement|Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
75402805|NCT05606133|Diagnostic Test|NavDx(R)|NavDx® is a blood test that utilizes digital droplet PCR in order to quantify fragments of tumor-specific DNA shed by HPV-associated cancer cells in the blood. The technology has the ability to distinguish tumor-tissue modified virus particles present in the plasma cell-free DNA from non-cancer associated sources of HPV DNA.
75402806|NCT05599958|Diagnostic Test|sweat chloride test|assessing chloride (Cl-) concentration in sweat of the patient
75711160|NCT04035070|Combination Product|MTAD|mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution
75711161|NCT04035070|Combination Product|2.5% sodium hypochlorite|It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
75711162|NCT00838149|Dietary Supplement|Glutamine|"Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
75871509|NCT03531827|Drug|enzalutamide|enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer
76038419|NCT05157425|Dietary Supplement|Placebo|One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
76038420|NCT05179317|Drug|QL1706|"Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion"
75402807|NCT05599958|Genetic|genetic testing|detection of CFTR mutation
75711163|NCT00838149|Dietary Supplement|Whey protein|"Whey protein group:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
75711164|NCT02548377|Procedure|Remote ischemic preconditioning|
75711165|NCT02548377|Procedure|Sham|
75711166|NCT02538874|Drug|BMS-986171|
76038421|NCT03276065|Device|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
76038422|NCT03276065|Other|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
76038423|NCT05177757|Other|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
76038424|NCT04410679|Biological|injectable PRF|blood sample and centrifuged to obtain i-PRF
76038425|NCT04788407|Drug|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID for 7 days
75711167|NCT02538874|Other|Placebo|
75402808|NCT05557578|Drug|Tislelizumab combined with GEMOX (GOT) regimen|Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks
75402809|NCT05549479|Behavioral|Peer Matching|Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.
75402810|NCT05549479|Behavioral|Qualified Exercise Professional Support Sessions|Dyads will participate in weekly virtual sessions with a QEP for 10 weeks. Each session will last up to 1 hour. The QEP (i.e., registered kinesiologist) will provide a tailored exercise program, focusing on aerobic activity for both individuals in the dyad based on personal circumstances, cancer-related characteristics, side effects, current fitness level (consistent with home-based exercise strategies), and personal preferences.
75402811|NCT05531487|Other|Questionnaire Survey|All students received a 'QR code' link to the survey.
75402812|NCT05523778|Procedure|placement of pancreatic duct stents before enucleation surgery|Advance placement of pancreatic stents endoscopically
75402813|NCT05523778|Procedure|Direct enucleation surgery|Patients will receive direct enucleation surgery
75402814|NCT05500586|Drug|Glucagon response study|Please see information in group descriptions
75711168|NCT00408421|Drug|Duloxetine|
75711169|NCT00408421|Drug|placebo|
75711170|NCT00604786|Drug|omalizumab|Dosing is based on IgE level and weight given every 2 or 4 weeks
76038426|NCT04788407|Drug|Placebo|Subjects will receive placebo TID for 7 days
75711171|NCT00604786|Drug|placebo|Dosing is based on IgE level and weight given every 2 or 4 weeks
75711172|NCT00902980|Other|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
75711173|NCT04034758|Procedure|Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)|heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
75711174|NCT04034758|Procedure|placebo capsule|Oral administration of 30 placebo capsule containing edible pigmented starch
75711175|NCT00903136|Other|questionnaire administration|
75711176|NCT00903136|Procedure|comparison of screening methods|
75711177|NCT00903136|Procedure|diagnostic endoscopic procedure|
75711178|NCT00903136|Procedure|esophagogastroduodenoscopy|
75711179|NCT00903136|Procedure|tethered capsule endoscopy|
75711180|NCT01042873|Drug|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
75711181|NCT00906490|Device|Intravenous Blood Glucose monitoring system|Insertion of blood glucose monitoring sensor into peripheral vascular IV line.
76038427|NCT03066427|Drug|Sunitinib|Sunitinib 50 mg/d
76038428|NCT04788485|Drug|Diosmectite|use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
76038429|NCT05118087|Procedure|Webril Padded Plaster Splint|Patients in the coaptation splint group will have a webril padded plaster splint that is placed around the humerus. The forearm and wrist are then suspended in a cuff and collar.
75711182|NCT01042951|Biological|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
75402817|NCT05483127|Device|Verofilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
75402818|NCT05483127|Device|Stenfilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
75402819|NCT05482516|Drug|Atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,
75402820|NCT05482516|Drug|Bevacizumab|Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.
75402821|NCT05482269|Other|no intervention|no intervention
75402822|NCT05479552|Diagnostic Test|Syn-One Test|CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.
75402823|NCT05476276|Drug|ISA specific|ISA specific interventions will be listed in their protocols.
75402824|NCT05475873|Drug|normal saline|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
75402825|NCT05475873|Drug|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
76038430|NCT05118087|Procedure|Pre-Fabricated Fracture Brace|Patients in the sarmiento group will be given a fitted pre-fabricated fracture brace with a cuff and collar for the forearm. The patients will be educated on brace maintained, tightening, and care during at the time of the ER encounter.
76038431|NCT03067909|Other|CIED surgery|
76038432|NCT05177133|Drug|Capecitabine|PO Capecitabine
76038433|NCT05177133|Drug|Oxaliplatin|IV Oxaliplatin
76038434|NCT05177133|Drug|Retifanlimab|IV retifanlimab
75402826|NCT05475873|Drug|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
75402827|NCT05470595|Drug|Atezolizumab|Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
75402828|NCT05464186|Behavioral|Whole milk|Weekly home delivery of whole milk, daily text messages, monthly virtual visits
75402829|NCT05464186|Behavioral|Nonfat milk|Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
75711183|NCT01042951|Other|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
75711184|NCT01037023|Drug|Topotecan|patients administrated Topotecan according to the prescribing information
75711185|NCT00604708|Biological|IC51|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
75711186|NCT00604708|Biological|JE-VAX|JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
76038435|NCT03065803|Procedure|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
76038436|NCT03065803|Procedure|Guided bone regeneration technique for post-extraction dental socket preservation|After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
76038437|NCT02994563|Device|Thrombectomy Device|The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
76038438|NCT03066505|Device|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
76038439|NCT03066505|Device|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
76038440|NCT02866643|Drug|Etonogestrel-Immediate|The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
76038441|NCT02866643|Drug|Etonogestrel-Delayed|The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
76038442|NCT05729581|Behavioral|The educational programme on sustainable and healthy diet and breastfeeding|In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)
75402830|NCT05462977|Behavioral|Group exercise program|Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
75402831|NCT05458271|Device|VCMX|A flap will be raised and VCMX will be placed in order to increase the soft tissue volume
75711187|NCT00909688|Drug|BLI-489|
75711188|NCT00909688|Drug|placebo|
76038443|NCT05176821|Drug|esomeprazole plus amoxicillin|amoxicillin 750mg QID + esomeprazole 20mg QID for 14 days
76038444|NCT05176821|Drug|amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole|amoxicillin 1000mg BID + furazolidone 100mg BID + bismuth potassium citrate 600mg BID + esomeprazole 20mg BID for 14 days
75402832|NCT05458271|Procedure|CTG|A flap will be raised and a CTG will be harvested from the palate and placed in order to increase the soft tissue volume
75402833|NCT05441670|Behavioral|Art and Physical Therapy|45 minutes of Art Therapy followed by 30 minutes of Physical Therapy, Monday through Friday for 2 weeks
75402834|NCT05441670|Behavioral|Physical Therapy|30 minutes of Physical Therapy, Monday through Friday for 2 weeks
75402835|NCT05432193|Drug|[Ga-68]-PNT6555|[Ga-68]-PNT6555 IV administered as imaging agent for PET/CT
75402836|NCT05432193|Drug|[Lu-177]-PNT6555|Patients with FAP-avid disease as determined by the [Ga-68]-PNT6555 screening PET/CT will receive [Lu-177]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
75711189|NCT00903214|Drug|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
75711190|NCT00903214|Genetic|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
75402837|NCT05425667|Other|virtual reality walking training|The sensory integration training of this project will combine virtual reality technology and balance interference treadmill, and manipulate vision, vestibular sense and proprioceptive systems as the main training goals. It is expected to train twice a week for 1 hour, for a total of 6 weeks of training , in order to improve the balance and walking ability of patients with lumbar stenosis and neurological claudication, and to promote the ability of subjects to transfer the effect to daily life after training.
75402838|NCT05412875|Other|Best Practice|Given usual care
75402839|NCT05412875|Drug|Nicotine Replacement|Given JUUL
75402840|NCT05412875|Other|Quality-of-Life Assessment|Ancillary studies
75402841|NCT05412875|Other|Questionnaire Administration|Ancillary studies
75402842|NCT05385796|Other|Loop taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. Care is taken to avoid erasing skin markings for respective algometer and ultrasound assessment by these wipes. The therapist applies 1-inch-width Elastikon tape around the heel, encircling and bunching the fat pad to centralize it and enhance its fullness and resilience to compression. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied to ensure strong support during weight-bearing activities. Participants will be instructed to wear the loop taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
75711191|NCT00903214|Procedure|axillary lymph node biopsy|
75711192|NCT00903214|Procedure|digital image analysis|
75711193|NCT00903214|Procedure|needle biopsy|
75711194|NCT00903214|Procedure|sentinel lymph node biopsy|
75711195|NCT00903214|Procedure|therapeutic conventional surgery|
75871510|NCT03531827|Drug|CRLX101|CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
75402843|NCT05385796|Other|Control taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. The therapist applies 1-inch-width Elastikon tape around the heel, lightly encircling the heel fat pad without any force/pressure or attempt to bunch or centralize the fat pad. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied. Participants will be instructed to wear the control taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
75402844|NCT05375513|Other|PMI@Home|"Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control."
75402845|NCT05375513|Other|Brain Health Pro|"Online Modules:~Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~Physical Activity~Cognitively Stimulating Activities~Diet~Sleep~Social and Psychological Health~Vascular health~Vision and Hearing~Lifestyle Risk Impact Surveys~Goal Setting"
75402846|NCT05342493|Drug|Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution|The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
75402847|NCT05320198|Drug|DISC-0974|DISC-0974 is administered subcutaneously.
75402848|NCT05318469|Drug|Ivermectin|Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).
75402849|NCT05318469|Drug|Balstilmab|Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
75550275|NCT06165120|Procedure|STPIF (Staged Transverse Preputial Island Flap) repair using preputial flap|"Staged repair:~Correction of ventral chordee; by degloving of the penile skin, transection of the urethral plate &/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~Preputial flap placement: according to the distance between the ectopic meatus and the glans tip, a transverse rectangular flap will be dissected from the inner layer of the dorsal prepuce. The flap will be placed along the defective urethral plate. Eventually, a silicon indwelling catheter will be placed through the ectopic meatus.~Tubularisation of the flap: this stage procedure would be performed 6 months after the first procedure. Tubularisation of the the preputial flap will be done over a catheter. Byar's flaps may be created and transposed to cover the neourethra. Eventually, the penis will be dressed, and a urethral catheter will be retained for urinary diversion."
75550276|NCT06165107|Other|No intervention|No intervention
76023173|NCT02404831|Other|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
75402850|NCT05318131|Other|Sleep and Lifestyle Advice Website|Participants will be asked to view a website at least once a week for 3 months (remotely). The website includes information about exercise, nutrition and sleep. Participants will also have a check-in call with a health coach at 6 weeks, and will be sent email newsletters at approximately 1 and 2 months with additional information about sleep, nutrition, and exercise.
75550277|NCT06165042|Other|glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply glass hybrid restorative system (Equia Forte, GC Europe, Leuven, Belgium)
75550278|NCT06165042|Other|Fluoride varnish + Glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
75402851|NCT05318131|Other|Surveys and Sleep Monitors|At baseline and at 3 months, participants will be asked to complete online surveys and to wear an ActiGraph sleep monitor for one week. ActiGraph sleep monitors are wristbands that measure continuous sleep/wake activity information. The recorded ActiGraph data is deidentified and no individual personally identifiable information is collected. A unique serial number identifies each wrist monitor. At the end of the study, participants will also have a telephone exit interview with the study team to provide feedback on their progress during the study and about the website.
75402852|NCT05288283|Drug|GWP42003-P|oral solution
75402853|NCT05288283|Drug|Placebo|oral solution
75402854|NCT05259280|Other|Wellinks|Digital health and virtual care program for COPD management.
75550279|NCT06165016|Device|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
75550280|NCT06165016|Device|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
75711196|NCT04034836|Drug|Scalp blocks with ropivacaine plus parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
75711197|NCT04034836|Drug|Scalp blocks with ropivacaine and intravenous parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
76023174|NCT05106803|Drug|ciprofloxacin|Antibiotics used in vitro n the study
75402855|NCT05242029|Drug|Placebo|Participants will receive placebo in a clinical setting.
75402856|NCT05242029|Drug|Psilocybin|Participants will receive 40mg psilocybin in a clinical setting.
76023175|NCT02404753|Drug|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
76023176|NCT02404753|Procedure|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
76023177|NCT02404753|Procedure|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
76023178|NCT02404753|Drug|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
76038445|NCT05555641|Drug|Nafamostat Mesylate|ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
76038446|NCT05555641|Drug|Unfractionated Heparin|ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
76038447|NCT05116527|Drug|Marijuana, Hash, THC, or Grass|Marijuana flower with a high THC content
76038448|NCT05116527|Drug|Placebo|Placebo THC - marijuana flower with no THC content
76038449|NCT03067831|Biological|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
75402857|NCT05227014|Procedure|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
75402858|NCT05226780|Drug|NBI-921352|Administered orally
75402859|NCT05220410|Drug|Psilocybin|Open-Label
75402860|NCT05218850|Drug|Butyrate|Butyrate enemas will be administered once a day for 12 weeks
75402861|NCT05209802|Other|Group A: High intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
75402862|NCT05209802|Other|Group B: moderate intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
75402863|NCT05189262|Other|Blood and urine collection|No intervention - Biological specimen collection
75402864|NCT05186363|Drug|Chemopreventive Agent - SPAQ|Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.
75402865|NCT05186363|Drug|Control Test - no drugs given|This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
75402866|NCT05140876|Behavioral|START mHealth Intervention|The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
75402867|NCT05136703|Behavioral|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months.
75402868|NCT05136703|Behavioral|Antiretroviral Therapy (ART) Adherence Counseling|"This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach."
75402869|NCT05131451|Diagnostic Test|Point of Care Autonomous AI diabetic retinopathy exam|Participants will get a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
75402870|NCT05122897|Device|Rings made of PA (test)|Rings made of PA (test) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Test rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
75402871|NCT05122897|Device|Rings made of TAN (control)|Rings made of TAN (control) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Control rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
75402872|NCT05121948|Drug|HC-7366|HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration. Each capsule contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Capsules are supplied in 3 strengths: 10, 25, and 100 mg HC-7366 free acid equivalent.
75402873|NCT05115968|Procedure|Tonsillectomy|Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI <1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
76038450|NCT05175729|Diagnostic Test|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
76038451|NCT01672801|Drug|Placebo|oral administration
76038452|NCT01672801|Drug|Nimodipine|oral administration
76038453|NCT04939259|Device|New Music Program|A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
76038454|NCT04939259|Device|Standard Listening Program|A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
76038455|NCT05080257|Device|Lung Ultrasonography|"The ultrasonography will be done using the curved probe of the SONOACE R3 SAMSUNG ultrasonography machine, SN: S0GYM3HCC00016M, manufacture date: 12-2012.~Assessment of lung condition using the Lung Ultrasonography Score (total score calculated from the 12 standard examined areas, from 0 to 3 in each area, with a minimum of 0 up to 36)"
76038456|NCT05729269|Diagnostic Test|Sarcopenia_CT|measurement of skeletal muscle through abdominal computed tomography
76038457|NCT04787861|Other|motorized movement therapy|The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
75402874|NCT05112809|Device|Cochlear Stimulation System (CSS)|Cochlear stimulation with surround sound and noise cancellation
75402875|NCT05110456|Behavioral|Telephone support|"Participants will receive 10 telephone counseling calls by trained coaches: 9 during pregnancy (one call/week) and 1 at 6 weeks postpartum. We have included individual telephone calls by a trained coaches aimed to :~encourage the use of online material;~identify strategies for overcoming obstacles;~help apply content to real-life settings; and~underscore the participants' success in using effective coping strategies"
75402876|NCT05108922|Drug|Donanemab|Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
75402877|NCT05108922|Drug|Aducanumab|Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
75550281|NCT06165003|Other|Use of broselow tape|"In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses."
75550282|NCT06164990|Other|PEKK framework|PEKK (Pekkton) framework in mandibular implant-supported complete fixed dental prostheses with All-on-four treatment concept
75550283|NCT06164977|Procedure|Percutaneous coronary intervention.|Revascularization of chronic total coronary occlusion.
75711198|NCT04034836|Drug|Scalp blocks with ropivacaine and intravenous saline|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
75711199|NCT02806336|Behavioral|Multi Modal Balance Training|Group balance class, obstacle course, strengthening exercises
75711200|NCT02806336|Behavioral|Weight Loss|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
75711201|NCT00407797|Drug|Pregabalin|150 to 600 mg/day during 21 weeks
76038458|NCT05612087|Device|Confocal laser endomicroscopy|Confocal laser endomicroscopy at jejunum, duodenum and stomach
76038459|NCT05729113|Behavioral|Distraction technique|Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
75402878|NCT05101317|Drug|HMI-115|HMI-115 is human monoclonal antibody
75402879|NCT05101317|Drug|Placebo|Placebo
76038460|NCT05613335|Procedure|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
76038461|NCT05613335|Procedure|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
75402880|NCT05094804|Drug|OR2805|IgG1 monoclonal antibody that binds specifically to the CD163 protein.
75402881|NCT05094804|Drug|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
75402882|NCT05094804|Drug|Docetaxel|An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
75402883|NCT05094089|Device|Hernia repair with mesh|Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery
75550284|NCT06164964|Diagnostic Test|study of higher cognitive functions|"General objective: increase knowledge about neural correlates:~of the cognitive processing of stimuli of a social nature; of decision-making processes in the context of individual choice; of the influence of the social context on individual decision-making processes."
75550285|NCT06164938|Diagnostic Test|Diagnostic accuracy|The aim is to obtain a regional measure of brain glucose metabolism in each normal subject because this is a functional measure of brain activity.
75550286|NCT06164912|Other|Transcranial Magnetic Simulation with Pseudofeedback|Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.
75550287|NCT06164912|Other|Transcranial Magnetic Simulation with Neurofeedback|Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
75550288|NCT06164886|Other|Waiting list|patient on the waiting list for scheduled surgical admissions
75550289|NCT06164873|Drug|IBI362|Once-weekly injections of gradually increased doses of IBI362
75550290|NCT06164873|Drug|Placebo|Once-weekly injections of volume-matched placebo
75402884|NCT05077748|Other||
75402885|NCT05076032|Drug|OXO-001|OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
75402886|NCT05076032|Drug|Placebo|Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
75402887|NCT05047237|Behavioral|Pharmacist-Led Optimization Intervention|Educational information mailed to participants and up to three pharmacist visits.
75402888|NCT05045872|Drug|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
75402889|NCT05030415|Drug|Ixekizumab Auto-Injector|160 mg week 0 followed by 80 mg every two weeks
75402890|NCT05027464|Behavioral|Moving to COVID-19 Vaccine Acceptance Intervention|The intervention utilizes a multi-pronged approach to increase Veteran vaccine acceptance. First, the research team will train Health Behavior Coordinators (HBCs) at VAI sites. HBCs will then train PACT teams at their site and Whole Health Coaches, Peer Specialists and other VA Staff in VAI strategies to use with unvaccinated Veterans. Whole Health Coaches, Peer Specialists and other VA Staff will conduct outreach calls, using strategies, with unvaccinated Veterans.
75402891|NCT05021562|Drug|Niraparib|Niraparib capsules
75402892|NCT05020951|Other|Medidata RAVE|Data collection done exclusively through Medidata Rave. Medidata Rave is a clinical data management system being used for data collection for this trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.
75402893|NCT04995029|Drug|Transmucosal Buprenorphine|Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)
75402894|NCT04995029|Drug|Extended-release Buprenorphine|Administered by subcutaneous injection
75402895|NCT04982926|Drug|TAS2940|Study participants with solid tumors and EGFR or HER2 aberrations will receive TAS2940 tablets daily at increasing doses until MTD is reached.
75402896|NCT04982926|Drug|TAS2940|Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.
75402897|NCT04982874|Drug|Furosemide 40 mg|Administered with 240 mL of water
75402898|NCT04982874|Drug|Lasix® 40 mg Tablet|Administered with 240 mL of water
76038462|NCT05508997|Device|respiratory parameters on mechanical ventilator (PEEP)|"The 3rd & 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~Secondary outcome.~Ventilation by PaCO2 value from ABGs.~Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups."
75550291|NCT06164860|Other|Meditteranean Diet|The MD provided 20% proteins, 40% fat and 40% carbohydrates. Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period
75711202|NCT00903292|Drug|erlotinib (Tarceva)|chemotherapy with erlotinib
75711203|NCT00903292|Drug|pemetrexed (Alimta)|Chemotherapy with pemetrexed
75711204|NCT02539030|Procedure|Microfracture|simple microfracture
75711205|NCT02539030|Device|CartiFill|add collagen when doing microfracture
75711206|NCT00906646|Dietary Supplement|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
75711207|NCT00906646|Dietary Supplement|Placebo|Placebo tablets
75711208|NCT00903604|Drug|AP214|Three 10-minutes infusions of sequential ascending dosages of AP214
75711209|NCT00903604|Drug|Placebo|Three 10-minutes infusions of isotonic saline solution
75711210|NCT00924274|Dietary Supplement|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
75711211|NCT00924274|Dietary Supplement|sunflower oil|sunflower oil
76038463|NCT05612009|Combination Product|Toothpastes|"Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride)."
76038464|NCT01655901|Behavioral|Active video gaming|
75711212|NCT00903838|Drug|pardoprunox|1.5 to 12 mg/day
75711213|NCT00903838|Drug|pramipexole|0.75-4.5 mg/day
76023179|NCT03780803|Other|home cardiac rehabilitation and respiratory rehabilitation|
76038465|NCT01655901|Behavioral|Passive video gaming|
76038466|NCT01655901|Behavioral|Resting|
75402899|NCT04972786|Device|Repetitive Transcranial Magnetic Stimulation|TMS pulses will be delivered through an air-cooled coil in either a figure-eight or double-cone shape, with the latter being particularly useful for targeting deeper structures such as dACC. The first phase of the TMS protocol will involve a standardized motor-thresholding procedure, wherein peripheral responses evoked by single TMS pulses are recorded via an electromyographic recording device. In this phase, the TMS coil's stimulation intensity is titrated to a level that is comfortable yet effective at reliably exciting neuronal populations orthogonal to the coil (50% motor-evoked potentials ≥50 microvolts; typical duration≈20-40 mins). Then repetitive TMS (rTMS) will be administered to a pre-determined cortical target based on the individual's pre-TMS fMRI scan using a Localite Neuronavigation system (duration≈10-20 mins). The rTMS protocol will involve the delivery of a train of TMS pulses over a cortical target prior to performance of behavioral tasks during a post-rTMS fMRI scan.
75402900|NCT04966585|Drug|Posaconazole Delayed Release Oral Tablet|Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
75402901|NCT04966585|Drug|Matching Placebo Tablet|Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
75402902|NCT04961177|Other|EITC & ACEs Training|We will deliver up to 56 trainings to 65 frontline health workers and 25 staff of our partner organizations. The training will include: 1.) Information about what ACEs are, and the risk and protective factors associated with ACEs and 2.) Information regarding EITC benefits, eligibility, application procedure and logistics, referrals for free tax preparation assistance, and use of EITC tools., and 3.) frontline health workers will receive additional training in protocols for reporting to support Objective #2.
75402903|NCT04961177|Other|EITC Outreach & Screening|"Our partners will screen and refer a minimum of 5200 clients (65 CHWs x 10 clients per quarter x 2 years) for EITC. Our evaluation team will track the number of individuals screened, the number found to be eligible/not eligible, the number referred out and to which free tax prep service, and if available, the number who use the free tax prep service, the number who file a tax claim for EITC, the number who receive EITC benefits, and the amount of the benefit.~We will conduct community-level EIT outreach by integrating EITC outreach and education into planned community events in the neighborhoods and service areas of our partners. The events will provide information about the EITC to the public. We will have a minimum of 48 events to reach a minimum of 480 potential filers (48 events x 10 participants each)."
75550292|NCT06164860|Other|Ketogenic Diet|The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates. The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med. Lunch and dinner were natural protein-rich dishes. Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.
75550293|NCT06164834|Drug|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
75550294|NCT06164834|Drug|Tegoprazan 25 mg|Tegoprazan 25 mg tablet
75550295|NCT06164834|Drug|Esomeprazole 20mg|Esomeprazole 20 mg tablet
75550296|NCT06164808|Device|HeartWatch|The HeartWatch is indicated for the extended diagnostic evaluation of patients with symptomatic and transient symptoms such as light-headedness, syncope, and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. It is an armband consisting of the main body of the device with an additional sensor located on the band. It is worn around the upper left arm to obtain heart electrical signals. The device is paired with the HelpWear application on a smartphone where the signals are stored and then will be uploaded to a secure network for analysis.
75550297|NCT06164756|Other|Cognitive Behavior Therapy (CBT)|Participants will receive 10 weeks of CBT
75550298|NCT06164756|Other|Treatment As Usual (TAU)|Participants will receive standard of care treatment
75550299|NCT06164730|Drug|VERVE-102|Intravenous (IV) infusion
75711214|NCT00924430|Drug|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
75711215|NCT00924430|Drug|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
75711216|NCT03743506|Diagnostic Test|With feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
76023180|NCT02404675|Drug|icotinib|
75402904|NCT04961177|Other|Assistance with EITC|"We will conduct a statistical analysis of the impact of EITC funds on ACEs risk and protective factors in the lives of EITC benefit recipients. Project CHW team members will invite 200 clients who qualify to receive EITC benefits to participate in the study using an approved recruitment script. With those who agree to participate, the CHW team member will obtain consent and administer a baseline survey. A post-survey will be administered at 4 months.~In addition, we will gather qualitative data to help us understand impacts of this project. The post-survey will contain an open/qualitative response question asking participants to describe how the EITC benefit impacted them, how they felt when they received it, how important it was, and what they did with the funds. In Y2, the Research Team will conduct interviews with a subset of 20 clients who participated in the pre/post survey."
75402905|NCT04941599|Drug|2-Hydroxybenzylamine|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
75402906|NCT04941599|Other|Placebo|Placebo 250 mg three tabs TID (po) for 6 weeks.
75402907|NCT04935177|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
75550300|NCT06164717|Behavioral|Auditory feedback perturbation during speech|The intervention consists of manipulating real-time auditory feedback during speech production. In our lab, such feedback perturbations can be implemented with either a stand-alone digital vocal processor (a device commonly used by singers and the music industry) or with software-based signal processing routines (see Equipment section for details). Note that the study does not investigate the efficacy of these hardware or software methods to induce behavioral change in subjects' speech. Rather, the study addresses basic experimental questions regarding the general role of auditory feedback in the central nervous system's control of articulatory speech movements.
75550301|NCT06164717|Behavioral|Visual feedback perturbation during reaching|The intervention consists of manipulating real-time visual feedback during upper limb reaching movements. In our lab, such feedback perturbations can be implemented with a virtual reality display system.
75550302|NCT06164717|Other|DBS stimulation ON/OFF|"Patients who have been previously implanted with a DBS stimulator for their clinical care will be tested in two speech motor learning tasks with the stimulation ON and with the stimulation OFF.~Note that (1) patients routinely turn the stimulation OFF and back ON (examples are, for some patients, to sleep, to save battery, etc), and (2) we are not in any way evaluating the stimulator itself or its clinical effectiveness but only whether or not two forms of speech motor learning (adaptation to auditory feedback perturbation and speech sequence learning) are affected differently by having the stimulation ON or OFF.~implant ON/OFF prior to participation in the speech auditory-motor learning tasks and speech sequence learning tasks. This intervention can be implemented by the subject themselves as all patients have a hand- held controlled that they use to switch stimulation ON/OFF."
75402908|NCT04935177|Procedure|PLEX|PLEX is performed according to the respective site's standard procedure for desensitization.
75550303|NCT06164691|Device|Blue light|Participants undergoing this intervention will be exposed to blue (442nm) light.
75550304|NCT06164691|Device|Amber light|Participants undergoing this intervention will be exposed to amber (617nm) light.
75550305|NCT06164691|Other|Ambient White Light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments
76038467|NCT05504551|Procedure|ultrasound guided superficial cervical plexus block|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
75402909|NCT04935177|Drug|IVIg|IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
75402910|NCT04935177|Drug|Anti-CD20 antibodies|Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.
75402911|NCT04935177|Drug|Eculizumab|Eculizumab according to the respective site's standard procedure for desensitization.
76038468|NCT05173779|Procedure|Left atrial isolation by catheter ablation|Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
76038469|NCT05475353|Behavioral|Asyncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar.
76038470|NCT05475353|Procedure|Syncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar. Then, participants will complete the 6 weeks of exercise training at an online video conference program two times a week under the physiotherapist's supervise.
76038471|NCT05113797|Diagnostic Test|Lower Quarter Y-Balance Test|Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.
75550306|NCT06164665|Drug|Pioglitazone 15mg|Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days
75550307|NCT06164665|Other|Placebo|100% microcrystalline cellulos
76038472|NCT05113797|Behavioral|OPTIMAL motor learning theory|OPTIMAL theoretical framework instructions and coaching will be utilized to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task.
76038473|NCT05172687|Behavioral|Overprescribing letter to attributed physician|Letter telling patient's attributed physician they were under review for high prescribing
75402912|NCT04935177|Other|Remain on wait list|Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate
75402913|NCT04923880|Other|Implementation of Primary Palliative Care Intervention in CF Centers|"Individuals with CF ages 12 years and above will complete an annual palliative care needs assessment with the CF care team using the IPOS (Integrated Palliative Care Outcome Scale).~Individuals with CF under 12 years of age will complete an annual palliative care needs assessment with the CF care team using IPOS as a conversation guide.~Caregivers of Individuals with CF of all ages will be offered the BASC (Brief Assessment Scale for Caregivers).~In addition to annual needs assessment, palliative care needs assessment will take place when triggered by changes in disease status, such as hospitalization, new diagnosis of CF related Diabetes or referral to transplant."
75402914|NCT04919369|Biological|Atezolizumab|Given IV
75402915|NCT04919369|Drug|Tretinoin|Given PO
75402916|NCT04910308|Radiation|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
75402917|NCT04908956|Drug|Osimertinib|"Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home."
75402918|NCT04908956|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered using risk-adapted SBRT with a maximum of 5 SBRT fractions.
75402919|NCT04900298|Device|SafeHaven Automated Hand Hygiene Device|Anesthesia providers in the intervention arm will be given a personal hand hygiene device, containing 64% ethyl alcohol, which provides actionable real-time performance feedback. The personalized device will be affixed to the provider's waist and will remain there for use throughout the perioperative period. Performance feedback is given to the anesthesia provider in real time with the number of personal hand hygiene events and an hourly hand hygiene rate, which is displayed on the device. Devices will be handed out to participating providers in the preoperative bay and retrieved in the post-anesthesia care unit upon case completion.
75550308|NCT06164652|Device|walking with Ceriter Stride One|Subjects walk on the GAITRite with the CSO insole in their shoes.
75550309|NCT06164639|Behavioral|aspiration|Based on whether the patient meets the diagnosis of aspiration pneumonia.
76038474|NCT05172687|Behavioral|Placebo letter to attributed physician|Letter to patient's attributed physician about unrelated Medicare regulation
76038475|NCT04787081|Other|Sleep Care Positioning Training Program GRP1|Video-based tutorial covering six nighttime postural care topic areas which contained narration and closed captioning. This 2-hour online training program was delivered in a University classroom via D2L Brightspace.
75402920|NCT04899024|Behavioral|PARTI|PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.
75402921|NCT04899024|Behavioral|Attention-Control|Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.
75402922|NCT04899024|Behavioral|Contingency Management for PrEP Adherence|Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.
75402923|NCT04884594|Drug|AAV8-hCocH|2e12 vg/kg single infusion intravenous
75402924|NCT04884594|Drug|AAV8-hCocH|6e12vg/kg single infusion intravenous
75402925|NCT04884594|Drug|AAV8-hCocH|2e13 vg/kg single infusion intravenous
75402926|NCT04883411|Device|CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
75402927|NCT04882904|Device|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
75402928|NCT04880837|Other|Educational Intervention|Attend educational session
75402929|NCT04880837|Other|Informational Intervention|Receive handouts
75402930|NCT04880837|Other|Survey Administration|Complete surveys
75402931|NCT04874636|Drug|LY3556050|Administered orally
75402932|NCT04874636|Drug|Placebo|Administered orally
75550310|NCT06164639|Diagnostic Test|bronchial alveolar fluid|Performing bronchoscopy.
75550311|NCT06164600|Dietary Supplement|Bovine colostrum|A powdered form of the first 6 hours bovine colostrum [65 mg lactoferrin, lactoperoxidase: 2.8 unit and immunoglobulins in the form of 350 mg IgG, 35.3 mg of Ig A and 25.3 mg Ig M]
75550312|NCT06164600|Drug|Placebo|Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
75550313|NCT06164574|Other|Survival analysis|Immunotheray responses and long-term survival were evaluated in classical and other EGFR-mutant lung adenocarcinomas
75550314|NCT06164535|Drug|Control group|35 T2DM patients will be given placebo (only adjust their drugs to control blood glucose level)
75550315|NCT06164535|Drug|DPP-4 inhibitor group|35 T2DM patients will be given DPP-4 I once or twice daily
75550316|NCT06164535|Drug|DPP-4 inhibitor + metformin group|35 T2DM patients will be given DPP-4 I + metformin once or twice daily
75550317|NCT06164509|Drug|Alphintern® , tablet, Amoun, Egypt|Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
75402933|NCT04863872|Other|Proactive Care Management|Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
75402934|NCT04863872|Behavioral|my hypo compass education program|Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
75402935|NCT04851184|Device|Gaze stabilization Exercises using Virtual Reality Device|Participants will utilize a wireless virtual reality headset to perform their gaze stabilization exercises to better control the background and visual field as well as collect data related to speed, excursion, and duration of head movements.
76038476|NCT04787081|Other|Sleep Care Positioning Training Program GRP2|Web-link based tutorial covering six nighttime postural care topic areas which contained mostly written content. This self-paced online training program was delivered in a University classroom via D2L Brightspace.
75402936|NCT04851184|Behavioral|Gaze stabilization non-instrumented|Participants will perform gaze stabilization exercises in a non-instrumented manner. Subjects are instructed to focus on a letter on a piece of paper held at arm's length. They are instructed to move their head back and forth as quickly as they can while keeping the letter in focus. The total duration of the exercise (from 10 - 240 seconds) and background complexity (simple to complex moving) are increased gradually according to patient symptoms.
75550318|NCT06164483|Diagnostic Test|Auditory test|"The patients will perform:~Pure Tone Auditory test + Tympanometry and Stapedial Reflex~Speech Perception test~In case of tinnitus: tinnitus questionnaire and acuphenometry~DPOAEs~ABR"
76038477|NCT05729035|Radiation|POCUS|Point of Care Ultrasound is complementary to a medical examination performed by primary care physicians
75402937|NCT04850105|Other|Data Collection|"Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice."
75402938|NCT04848675|Other|Inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
75402939|NCT04848675|Other|Brisk walking|Participants will perform brisk walking.
75402940|NCT04840849|Biological|nirsevimab|Drug: injection, a single fixed IM dose on day 1 only.
75871511|NCT05764512|Other|Endorphin massage|"With the anterior surface of the fingertips of the hand, a V will be drawn slowly, starting from the sacral region and towards the ribs. The same process will be continued from the sacral region until the 7th cervical vertebra.~From the 7th cervical vertebra, the front surface of the fingertips will be descended first to the shoulders and then to the dorsal region of the upper and forearms in turn.~Starting from the dorsal region of the forearm, the first stage of the massage will end by descending to the upper arm, shoulders, 7th cervical vertebra, spine and sacral region with the back of the thumbs. These massage steps will be repeated until 20 minutes are completed.~Endorphin massage will be applied every 2 hours."
76038478|NCT05172375|Behavioral|Shared Care Model|The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties.
75402941|NCT04840849|Other|Placebo|Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.
75402942|NCT04838639|Drug|NO-13065|"Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065."
75402943|NCT04838639|Drug|Placebo|Two subjects per cohort will take a matched placebo.
75402944|NCT04812379|Drug|Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)|The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
75402945|NCT04809311|Other|Lifestyle|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
75402946|NCT04809311|Drug|Oral antidiabetetic drugs|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
75402947|NCT04809311|Drug|Basal insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
75402948|NCT04809311|Drug|Glucagon-like peptide-1 (GLP-1)|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
75550319|NCT06164483|Other|CSF sampling|Cerebrospinal Fluid will be collected by lumbar puncture and analyzed
76038479|NCT04911803|Behavioral|Anxiety Application|The Intellect mobile app (containing the anxiety application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
75550322|NCT06164418|Procedure|Dental restoration|Each patient will receive a cervical restoration using the corresponding group adhesive and restorative material
75550323|NCT06164405|Device|arterial dp/dtmax|to assess the variations of the arterial dp/dt max after drugs or fluids administration
75550324|NCT06164392|Drug|Indocyanine green|Intravenous administration of indocyanine green followed by fluorescence angiography imaging of the neuroma
75550325|NCT06164379|Drug|Finerenone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
75550326|NCT06164379|Drug|Spironolactone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
75550327|NCT06164366|Device|0 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 0 degrees
75550328|NCT06164366|Device|45 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 45 degrees
75711217|NCT03743506|Diagnostic Test|Without feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
75711218|NCT00924586|Drug|ONO-1101|Placebo for one minute IV
75711219|NCT00924586|Drug|ONO-1101|0.125 mg/kg for one minute IV
75711220|NCT00568126|Drug|Maca Root|3g/day of Maca Root for 12 weeks.
75871512|NCT04105816|Device|892.1550 Ultrasonic pulsed doppler imaging system|Use of the ultrasound to measure quadriceps volume
75402949|NCT04809311|Drug|Premixed insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
75402950|NCT04796272|Other|Adapted and individualized physical training program|Physical training program adapted and individualized according to each patient in this group
75402951|NCT04796272|Other|traditional training program|Same training program for all patients in this group
75402952|NCT04787497|Dietary Supplement|High Phenolic Extra Virgin Olive Oil|Participants will be assigned in two groups: the Experimental Group (N= 20) will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment, whereas the Control Group (N = 20) will be receiving their medical treatment as usual. The Experimental Group will be receiving the complementary treatment on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of treatment.
75402953|NCT04766892|Drug|mavacamten|mavacamten capsules
75402954|NCT04745637|Drug|Ruxolitinib|Patients receive Ruxolitinib
75402955|NCT04707157|Drug|LY3556050|given orally
75402956|NCT04707157|Drug|Placebo|given orally
75402957|NCT04700449|Drug|Double-Blind 0.2mg CBP-307|0.2 mg capsule oral administration
75402958|NCT04700449|Drug|Double-Blind Placebo|Placebo capsule oral administration
75402959|NCT04700449|Drug|Open-label CBP-307|0.2 mg capsule oral administration
75402960|NCT04700449|Drug|Double-Blind 0.1mg CBP-307|0.1 mg capsule oral administration
75402961|NCT04696471|Device|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
75402962|NCT04696471|Device|Sham Continuous Theta Burst Stimulation (Sham cTBS)|Sham cTBS goes through the motions of applying cTBS to the brain but administers very low current so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
75402963|NCT04695691|Device|Cutera Laser System|Subjects will receive laser treatments
75402964|NCT04683718|Device|Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management|The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.
75402965|NCT04681833|Drug|Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo|Low Repeat Dose
75402966|NCT04681833|Drug|Recombinant Respiratory Syncytial Virus Vaccine (BARS13)|High Repeat Dose/High Repeat Multiple Dose
75402967|NCT04681833|Drug|Placebo|Liquid diluent/Lyophilised Powder
75402968|NCT04667377|Drug|BI 456906|BI 456906
75402969|NCT04667377|Drug|Placebo|Placebo
75402970|NCT04655651|Other|No intervention|There is no intervention for both groups.
75402971|NCT04647526|Drug|[Lu-177]-PNT2002|Participants randomized to Arm A will receive 6.8 GBq (±10%) of [Lu-177]-PNT2002 every 8 weeks for 4 cycles
75402972|NCT04647526|Drug|Abiraterone|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
75402973|NCT04647526|Drug|Enzalutamide|Enzalutamide (160 mg orally qd)
75402974|NCT04634513|Biological|strain CVD 1208S-122|Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli
75402975|NCT04634513|Other|Placebo|Sodium bicarbonate buffer
75402976|NCT04629729|Drug|FT819|Experimental Interventional Therapy
75402977|NCT04629729|Drug|Cyclophosphamide|Lympho-conditioning agent
75402978|NCT04629729|Drug|Fludarabine|Lympho-conditioning agent
75402979|NCT04629729|Drug|IL-2|Biologic response modifier
75402980|NCT04629729|Drug|Bendamustine|Lympho-conditioning agent
75402981|NCT04617717|Procedure|Invasive cardiac electrophysiological study and ablation therapy|Invasive cardiac electrophysiological study with cathecholamine provocation and pacing procedures, as well as standard 3D mapping and PVC ablation
75402982|NCT04617717|Diagnostic Test|Cardiopulmonary exercise testing|Standard ergometer bicycle test
75402983|NCT04617717|Diagnostic Test|Cardiac MRI|Cardiac MRI with cine-imaging and late-gadolinium enhancement
75402984|NCT04617717|Diagnostic Test|Holter monitoring|24h 5 lead or 12 lead ECG recording
75402985|NCT04617717|Diagnostic Test|Transthoracic echocardiography|2D echocardiography
75402986|NCT04617717|Diagnostic Test|Coronary angiography|Conventional invasive coronary angiography or CT angiography as indicated
75402987|NCT04609202|Behavioral|Nurse led person centred care|Person centred care include patiens narratives, partnership and documentation of a health plan.
75402988|NCT04609202|Other|Usual care|Usual care provided by doctors
75711221|NCT00568126|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
75711222|NCT00903994|Drug|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
75711223|NCT00924742|Drug|Tapimycin (piperacillin 4 g + tazobactam 0.5g)|One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
75711224|NCT02539498|Device|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
75711225|NCT00904228|Other|placement of plastic cap during delivery room stabilization|placement of plastic cap during delivery room stabilization
75402989|NCT04602728|Behavioral|Back2Life|The Back2Life intervention uses an adaptive treatment approach with module-based treatment sessions selected on the basis of baseline assessment (rather than a fixed treatment approach) to allow flexibility in tailoring treatment components to meet individual family needs. All youth participants will receive the standard 6-session pain coping skills training program, consisting of learning ways to cope with and manage chronic sickle cell pain. The standard program includes topics that were identified by young people with chronic sickle cell pain and their parents as important skills for all youth with chronic pain and sickle cell disease. In addition to the standard 6-session program, youth participants may receive an additional 1 to 4 sessions that may help with specific problems and/or co-morbidities related to pain. At least one parent or guardian is required to attend the sessions with their child.
75402990|NCT04599101|Device|Nose Frida nasal suction device|Caregivers will be given a Nose Frida device to remove the child's nasal secretions.
75402991|NCT04599101|Device|Bulb syringe nasal suction device|Caregivers will be given a bulb syringe device to remove the child's nasal secretions.
75550329|NCT06164353|Biological|Partially demineralized dentin graft covered with a collagen membrane|The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
75711226|NCT00904228|Other|placement of routine cap during delivery room stabilization|
75711227|NCT00924976|Behavioral|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
75711228|NCT03824860|Behavioral|Yoga|"Participants will attend at least one group class per week (in-person or Zoom) and practice one self-guided yoga video class at home on their own per week, over eight weeks~Participants may choose to attend Flow Yoga and/or Chair Flow Yoga classes. These classes will be videotaped and made available to participants electronically.~Classes consist of:~guided breathing exercises,~upper and lower extremity stretching~structured postures and movements to improve balance and strength"
75711229|NCT00407563|Drug|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
75711230|NCT00407563|Drug|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
75711231|NCT00906724|Procedure|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
75711232|NCT01037101|Behavioral|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
75711233|NCT01037101|Behavioral|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
75711234|NCT01037101|Drug|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
75871513|NCT04105816|Diagnostic Test|Thigh circumference measurement|Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
75871514|NCT02346448|Procedure|endoscopic sphincterotomy|sphincterotomy during ERCP
75871515|NCT02346448|Procedure|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
75871516|NCT02346448|Procedure|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
75402992|NCT04597099|Drug|Micronized progesterone|oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
75402993|NCT04597099|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
75402994|NCT04597099|Drug|Flutamide|Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
75402995|NCT04597099|Drug|Estradiol patch|Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
75402996|NCT04584866|Procedure|Endonasal endoscopic pituitary surgery in semi-sitting position|Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.
75402997|NCT04584866|Procedure|Endonasal endoscopic pituitary surgery in supine position|Patients will be operated in the standard supine neutral position
75402998|NCT04583839|Behavioral|Patient Navigation Program|SWEET is a GDM-focused intervention that will apply barrier-reduction patient navigation strategies to improve health after a pregnancy with GDM. Women in SWEET will receive GDM-specific, tapered, individualized navigation services, including logistical support, psychosocial support, and patient education, through 1-year postpartum.
75402999|NCT04582383|Drug|Spironolactone|Dispensation of spironolactone according to the arm description.
75403000|NCT04582383|Drug|Doxycycline Hyclate|Dispensation of doxycycline hyclate according to the arm description.
75403001|NCT04576832|Behavioral|Mindfulness-Based Attention Training (MBAT) web-course|Pre-recorded weekly sessions for 4 weeks. Each session will consist of approximately 2 hours of video content per week and weekly mindfulness exercises. This video will include MBAT program lectures, pre-recorded testimony from military leaders, and teaching materials. The course will also include 15-min daily mindfulness practice drills.
75403002|NCT04573920|Drug|Atrasentan|Film-coated tablet
75403003|NCT04569799|Drug|Lumason|2.4 mL per lesion
75403004|NCT04546672|Drug|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow
75550330|NCT06164327|Drug|BEBT-908 for Injection|BEBT-908 for Injection,dosage of administration:15mg/m^2 or 22.5mg/m^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
75550331|NCT06164327|Drug|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.
75550332|NCT06164327|Drug|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
75550333|NCT06164327|Drug|Oxaliplatin Injection|Oxaliplatin Injection，dosage of administration:100mg/m^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
75550334|NCT06164327|Drug|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.
75550335|NCT06164327|Drug|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m^2,24 hours of continuous intravenous drip，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
75403005|NCT04546672|Drug|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered
75403006|NCT04738292|Drug|Onapristone|Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.
75711235|NCT01037101|Drug|Placebo|50 mg placebo administered 30 minutes before the session
75403007|NCT04738292|Drug|Fulvestrant|Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling.
75403008|NCT04537923|Drug|Tirzepatide|Administered SC
75403009|NCT04537923|Drug|Insulin Lispro (U100)|Administered SC
75403010|NCT04513080|Behavioral|Video-chat psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
75550336|NCT06164327|Drug|Carboplatin Injection|Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
75711236|NCT00904306|Dietary Supplement|Sugar Pill|placebo oral tablet taken once per day
75711237|NCT00904306|Dietary Supplement|chromium picolinate|1000 ug/day chromium picolinate for 6 months
75711238|NCT00904306|Dietary Supplement|chromium picolinate|600 ug/day chromium picolinate
75711239|NCT01788553|Other|remission prevalence of generalized anxiety disorder|
75403011|NCT04513080|Behavioral|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
75403012|NCT04513080|Behavioral|Message-based psychotherapy with monthly video chat (Premium Plan)|The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care will be based on CBT, PST or IPT.
75403013|NCT04513080|Behavioral|Message-based psychotherapy with weekly video chat (Ultimate Plan)|The Ultimate Plan allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT.
75403014|NCT04508543|Other|Non-verbal communication score|1. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
75403015|NCT04502732|Other|NSSM and GEBT|The time to half gastric emptying (T1/2) will be assessed via Gastric Emptying Breath Tests (GEBT) and Nuclear Scintigraphy of a Solid Meal (NSSM) at baseline, 2 months, and 6 months. This data will be collected from seven adult subjects, with obesity, who have recently received Endoscopic Bariatric and Metabolic Therapy.
75403016|NCT04496817|Other|Docosahexaenoic Acid and Lutein Enriched Eggs|Consumption of 2 docosahexaenoic acid and lutein enriched eggs daily (at least 5 days our week) for 6 weeks
75403017|NCT04496817|Other|Regular Eggs|Consumption of 2 non enriched eggs daily (at least 5 days our week) for 6 weeks
75403018|NCT04489017|Dietary Supplement|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day
75403019|NCT04489017|Dietary Supplement|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day
75403020|NCT04488666|Device|npSIMS|incisional NPWT
75403021|NCT04484623|Drug|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
75403022|NCT04484623|Drug|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
75403023|NCT04484623|Drug|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
75403024|NCT04484623|Drug|Bortezomib|Proteasome Inhibitor will be administered.
75711240|NCT00906802|Procedure|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
75403025|NCT04437485|Behavioral|Good Days Ahead (GDA)|GDA (Empower Interactive) is an empirically supported, HIPAA compliant, computerized CBT for depression appropriate for primary care patients and people with little computer experience. GDA uses an interactive, multimedia format to deliver 9 45-minute sessions, the structure and content of which mirror face-to-face CBT. General topics include identifying and modifying automatic thoughts, using behavioral activation and other behavioral methods, identifying and modifying schemas, using effective coping strategies, and employing other core CBT methods. GDA is empirically supported - it is acceptable to patients, achieves superior depression outcomes to waitlist comparators, and yields equivalent (noninferior) depression outcomes to standard face-to-face CBT. To minimize time/transportation barriers, GDA sessions occur at the PI's lab or a location with internet access selected by the patient (patient's, family member's, or friend's home).
75403026|NCT04437485|Behavioral|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is an established, manualized, empirically supported CBT developed for primary care. During the 6-10 30-minute sessions, patients are taught skills for solving problems contributing to depression. We will deliver PST-PC by phone, which has been found to be feasible and efficacious.
75403027|NCT04437485|Drug|Antidepressant Medications|We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
75711241|NCT00567892|Device|rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
75711242|NCT00623103|Drug|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
75711243|NCT00623103|Drug|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm^2/day delivering 9.5 mg over a 24 hour period.
75711244|NCT01043341|Behavioral|educative folder|folder about HPV infection and vaccines
75711245|NCT01043419|Drug|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
75403028|NCT04437485|Other|Active Control|(1) The graduate research assistant (RA) will have a 50-minute call with AC patients to review depression materials. The RA will provide a list of Eskenazi Health mental health services and will encourage patients to follow-up with their PCP. We will then send an electronic health record message to the PCP encouraging them to address their patient's depression, note that there are no care restrictions, and provide the same list of services. (2) The RA will call AC patients every 4 weeks to assess depressive symptoms and will notify clinical staff to encourage additional care when indicated. (3) AC patients will receive current primary care for depression. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
75403029|NCT04428333|Drug|Feladilimab|Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
75403030|NCT04428333|Drug|Pembrolizumab|Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
75403031|NCT04428333|Drug|Placebo|Sterile normal saline
75403032|NCT04428333|Drug|Platinum based chemotherapy|Cisplatin/carboplatin
75403033|NCT04428333|Drug|Fluorouracil (5FU)|5-fluorouracil
76038480|NCT04911803|Behavioral|Procrastination Application|The Intellect mobile app (containing the procrastination application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
76038481|NCT04838405|Drug|CT-388|Synthetic Peptide
76038482|NCT04838405|Drug|Placebo|Placebo
75403034|NCT04360265|Other|No Investigational Product|No investigational product will be administered in this follow-up trial.
75403035|NCT04360265|Drug|Adjuvant Immunosuppression (IS) Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IS therapy.
75403036|NCT04359472|Device|Application of Autologous Amniotic Fluid|Collection and reapplication of amniotic fluid at wound layers during a cesarean section.
75403037|NCT04338399|Drug|Buparlisib & Paclitaxel|Investigation drug plus paclitaxel
75403038|NCT04333537|Procedure|Computed Tomography (CT)|Undergo SPECT/CT scan
75403039|NCT04333537|Drug|Imaging Agent|Receive imaging agent via injection
76038483|NCT05111301|Device|Control-IQ technology 1.5|"All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor.~Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level."
75403040|NCT04333537|Procedure|Neck Dissection|Undergo standard elective neck dissection
75711246|NCT01037335|Drug|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
75403041|NCT04333537|Procedure|Planar Imaging|Undergo planar imaging
75403042|NCT04333537|Procedure|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
75403043|NCT04333537|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT scan
75403044|NCT04306510|Procedure|Blood samples for immunoglobulins|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.
75403045|NCT04306510|Procedure|Blood samples for inflammatory markers|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for inflammatory markers at a clinic visit every 4 months for up to 2 years.
75711247|NCT00925210|Procedure|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
75871517|NCT03057678|Other|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
75403046|NCT04306510|Procedure|Blood samples for anti-drug antibodies|Patients taking TEGSEDI as prescribed by their physician per the product label, patients will have additional blood samples for anti-drug antibodies at various time-points as indicated in the event of hypersensitivity reactions.
75403047|NCT04286425|Other|seminal plasma|Seminal plasma free of sperm, from donor men with normal sperm parameters, and tested for HIV1, HIV2, Hepatitis B, Hepatitis C, Syphilis, Chlamydia and Gonorrhea on blood and urine
75403048|NCT04286425|Other|saline solution|saline solution
75403049|NCT04254198|Behavioral|TERTULIAS structured dialogue peer support groups|"TERTULIAS will involve structured dialogue groups using the model developed and tested by the investigators through their preliminary research. Each group will have 10 women and will meet weekly for two hours over a 12-month period. Group meetings will be conducted in Spanish, led by a team of two FMI facilitators. Facilitation will use the structured dialogue approach. In the last two months of each cohort, participants will be invited to write their own stories or recipes, or produce poetry or art representing their experience to share with the group. These contributions will be gathered and reproduced in booklet form and each participant will receive a copy."
75403050|NCT04254198|Behavioral|Modified Attention Placebo Control (MAPC)|MAPC participants will receive a phone call every other month from the project coordinator to document that their contact information is up to date, to remind them that they are in the study and to tell them that the study is continuing. Survey data and hair samples will be gathered from them at baseline and 12 months
75711248|NCT04604821|Behavioral|Enhanced Milieu Teaching|A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.
75403051|NCT04241029|Dietary Supplement|IDOFORM®Travel|Four capsules IDOFORM®Travel orally every 24 hour (12*10^9 cfu/day) for eight weeks.
75711249|NCT04604821|Behavioral|Parent Education|Parents receive information on child developmental milestones.
76038484|NCT05475275|Procedure|pancreaticojejunostomy|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was <0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
75403052|NCT04232306|Drug|Liposomal bupivacaine|Bupivacaine liposome injectable suspension
76038485|NCT05078463|Device|Microneedle|Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.
75403053|NCT04232306|Drug|Bupivacaine HCl|Bupivacaine HCl surgical-site incision infiltration
75403054|NCT04210024|Other|Diabetes Empowerment Education Program|Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
75403055|NCT04171830|Other|modified Hospital One-year Mortality Risk (mHOMR)|"Every inpatient will automatically be given the intervention (an mHOMR/HOMR Now! score) upon admission to hospital and considered for secondary interventions based on their score. Baseline threshold will be set as >0.21 (59% sensitivity and 90% specificity for 12-month mortality with mHOMR).~At minimum each individual identified by the tool will receive two assessments to screen for severe symptoms and desire to engage in advance care planning (ACP):~Edmonton Symptom Assessment System Revised: scores >6 will be flagged as severe. Clinical teams will address the symptoms as appropriate for the patient.~4-item Advanced Care Planning Engagement Survey: Scores of 3-4 indicate readiness to discuss ACP. Clinical teams may choose to discuss ACP and goals of care themselves, activate a local ACP intervention, or distribute ACP documentation.~Both of these assessments will be done by a member of the treating team within 72 hours of the patient's hospital admission."
75403056|NCT04168320|Radiation|SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)|Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
75403057|NCT04160468|Drug|Exebacase|Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
75403058|NCT04160468|Drug|Placebo|Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
75403059|NCT04099121|Device|Ultrasound Imaging|3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.
75711250|NCT02538952|Device|Xpert device|"Interventions in the Experimental phase of this stepped-wedge trial include: (a) ensuring WHO-recommended TB screening adopted, (b) situating trained TB case finding nurses in the clinics, (c) training clinic personnel in the TB diagnostic algorithms, and (d) activation of the Xpert diagnostic device."
75711251|NCT02538952|Other|Intensified TB Case Finding (ICF)|Interventions in the active comparator phase of this stepped wedge trial only include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only the standard of care microscopy algorithm (smear microscopy and chest x-ray) are available during this phase.
75711252|NCT04015492|Biological|Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
75711253|NCT04015492|Biological|Rurioctocog alfa pegol (Adynovi)|Single dose, 50 IU/kg Adynovi
75871518|NCT01377870|Biological|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
75403060|NCT04087109|Other|Electronic decision support for deprescribing (MedSafer tool)|During the intervention phase, MedSafer will provide users with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. Patients or proxy will also receive educational medications brochures (EMPOWER) from the research assistant or staff at the nursing home, as applicable to the medications they are taking (PPI, sedative-hypnotic, antipsychotic, antihistamine, sulfonylurea, NSAID, opioid/narcotic).
75403061|NCT04082442|Drug|Evolocumab|420 mg evolocumab.
75403062|NCT04082442|Drug|Placebos|Matching placebo.
75403063|NCT04065399|Drug|SNDX-5613|SNDX-5613 orally
75403064|NCT04065399|Drug|cobicistat|Phase 1 Arm C participants will receive 150 mg cobicistat daily.
75403065|NCT04054752|Biological|Recombinant human IL-7-hyFc (NT-I7)|NT-I7 administered at escalating doses of 720, and 960g/kg to determine OBD of NT-I7
75403066|NCT04054752|Biological|Vaccine sequence 1|Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
75403067|NCT04054752|Biological|Vaccine sequence 2|Day 1 Immunization Pre-NT-I7: Hep A#1, Hep B#1 Day 64, Immunization Post-NT-I7:Td and Polio Day 106: no Vaccine 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
75403068|NCT04039191|Behavioral|SMS education|Patients will receive additional educational SMS messages post-operatively
75403069|NCT04039191|Behavioral|SMS survey|Patients will receive survey questions about post-operative pain and opioid use but no education
75403070|NCT04003285|Drug|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
75871519|NCT01377870|Biological|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
76023181|NCT05025761|Other|Personal protection package|The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
75403071|NCT04003285|Drug|Allopregnanolone|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
75403072|NCT04003285|Drug|Allopregnanolone|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
75403073|NCT03989492|Other|systemic and local stressors|Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.
75403074|NCT03987841|Behavioral|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. The intervention will comprise components of MBSR and DSME and will be delivered in a group setting with 8 weekly sessions. A trained masters-level interventionist will deliver the integrated intervention.
75403075|NCT03983720|Other|Evaluation of degree chronic fatigue.|Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
75403076|NCT03983720|Other|Questionnaires|"Fatigue Severity Scale (FSS)~Modified Fatigue Impact Scale (MFIS)~Godin Leisure-Time Exercise Questionnaire (GLTEQ)~Scale of life quality of multiple sclerosis (SEP-59)~Center for Epidemiologic Studies Depression (CES-D)~Pittsburgh Sleep Quality Index (PSQ-I)"
76023182|NCT03106441|Device|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
75403077|NCT03983720|Biological|Blood sample|Blood sample will be realized to evaluate anemia and inflammations.
75403078|NCT03983720|Other|Cardiopulmonary evaluation|Cardiopulmonary evaluation will be realized with a cycle ergometer.
75403079|NCT03983720|Device|Capacity of muscular oxygen extraction|Measure the capacity of muscular oxygen extraction with a cycle ergometer.
75711254|NCT04015570|Biological|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
76038486|NCT05078463|Drug|1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)|1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
75403080|NCT03983720|Device|Sleep assessment|Sleep assessment will be measured by actigraphy during 15 days.
75403081|NCT03983720|Device|Metabolic fatigue|Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
76038487|NCT05078463|Drug|1 Finger Tip Unit (FTU) EMLA (15-minute application time)|1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand
75403082|NCT03983720|Other|Neuromuscular evaluation|"Neuromuscular evaluation will be measured by the composite of the results of:~Fatigue test~Measure of voluntary isometric force~Surface electromyography~Peripheral nerve stimulation~Transcranial Magnetic Stimulation (TMS)~Perceived fatigue~Cognitive fatigue~Thermoregulation"
75403083|NCT03970590|Behavioral|CTC Intervention|"An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
75403084|NCT03970590|Behavioral|Control|6-month HTN management assessment text messages without narrative component
75403085|NCT03967288|Drug|Chloroprocaine Injection [Clorotekal]|1% chloroprocaine Hydrochloride Injection (50 mg/5 mL) for intrathecal use
75403086|NCT03967288|Drug|Bupivacaine Hydrochloride 0.75% Injection Solution|0.75% bupivacaine Hydrochloride injection in 8.25% dextrose for intrathecal use
75403087|NCT03961945|Device|Sponge Capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
75403088|NCT03957434|Other|Physiotherapy|Education, pelvic floor muscle exercises with biofeedback and home exercises.
75403089|NCT03933800|Device|High flow nasal cannula|High flow nasal cannula therapy
75711255|NCT04015570|Other|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
75711256|NCT00904462|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
76038488|NCT05078463|Drug|0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)|0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
76038489|NCT05078463|Device|Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
76038490|NCT05077137|Biological|Tetanus Diptheria Vaccine|tetanus and diphtheria toxoids
76038491|NCT05077137|Biological|Polio Boost Immunization|trivalent inactivated polio vaccine
76038492|NCT04786769|Drug|Ferric carboxymaltose|Intravenous ferric carboxymaltose according to baseline weight and hemoglobin
75403090|NCT03933800|Device|Continuous positive airway pressure|Continuous positive airway pressure therapy
75403091|NCT03924856|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
75403092|NCT03924856|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, IV infusion on Days 1 and 8 of each 21-day cycle
75403093|NCT03924856|Drug|Cisplatin|Cisplatin 70 mg/m^2, IV infusion on Day 1 of each 21-day cycle
75403094|NCT03924856|Procedure|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
75403095|NCT03924856|Drug|Placebo|Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
75403096|NCT03919162|Drug|PQ912|PQ912 150 mg tablets
75403097|NCT03919162|Other|Placebo|Placebo tablets to mimic PQ912 150 mg tablets
75403098|NCT03884101|Drug|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
75403099|NCT03884101|Biological|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
75403100|NCT03884101|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV infusion given on Day 1 of each cycle.
75403101|NCT03884101|Drug|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
75403102|NCT03850054|Procedure|AADI glaucoma shunt|"Implantation of the nonvalved AADI glaucoma shunt instead of the Bearveldt tube shunt, in eyes with intractable glaucoma.~It is not a RCT study, but a prospective evaluation of the AADI device, and the study has been approved as a quality control study at the Department of Ophthalmology, at Odense University Hospital"
75403103|NCT03847480|Radiation|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
75403104|NCT03844399|Device|Ablation|The medical device will passively record image data during the standard care ablation
75403105|NCT03844399|Device|Biopsy|The medical device will passively record image data during the standard care biopsy
75403106|NCT03843034|Genetic|Measure endometrial markers|Endometrial biopsies will be taken from participants in both groups
75403107|NCT03834766|Drug|AMPH ER Tab 5, 10, 15 and 20 mg|Amphetamine
75403108|NCT03834766|Drug|AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg|Placebo
75403109|NCT03780309|Behavioral|Exercise Self-Monitoring|Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
75403110|NCT03780309|Behavioral|Blood Pressure Self-Monitoring|Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
75403111|NCT03761056|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
75711257|NCT00904462|Drug|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
75711258|NCT00396565|Drug|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
75711259|NCT00396565|Drug|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
76038493|NCT05611541|Behavioral|Diet therapy, Progressive Muscle Relaxation training, Progressive Muscle Relaxation group|The group that received Progressive Muscle Relaxation training and applied progressive muscle relaxation for 8 weeks.
75711260|NCT00396565|Drug|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
75711261|NCT00925366|Other|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
75711262|NCT00906880|Drug|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
75711263|NCT00925444|Device|FOREseal|a pair of alginate sleeves for linear cutting staplers used in lung surgery
75711264|NCT00925444|Device|Stapling|Stapling alon or associated with sealants
75403112|NCT03761056|Drug|Fludarabine|Administered according to package insert
76023183|NCT03106441|Device|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
75403113|NCT03761056|Drug|Cyclophosphamide|Administered according to package insert
75403114|NCT03747120|Drug|Paclitaxel|All subjects will receive Paclitaxel weekly for 12 weeks
75403115|NCT03747120|Drug|Trastuzumab|All subjects will receive Trastuzumab every 3 weeks
75403116|NCT03747120|Drug|Pertuzumab|Arm A and Arm B subjects will receive Pertuzumab every 3 weeks
75403117|NCT03747120|Drug|Pembrolizumab|Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks
75403118|NCT03729557|Procedure|Nephrectomy|Unilateral nephrectomy
75403119|NCT03602105|Behavioral|Exercise|Exercises in group and/or individually
75403120|NCT03592888|Drug|mDC3/8-KRAS Vaccine|Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
75403121|NCT03586089|Drug|Phenobarbital Sodium|Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)
75403122|NCT03586089|Drug|Inactive placebo|Single dose of inactive placebo prepared in 250 ml D5W).
75403123|NCT03585764|Drug|MOv19-BBz CAR T cells|intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
76038494|NCT05611541|Behavioral|The group who received diet therapy and practiced their daily activities.|The group who received diet therapy and practiced their daily activities.
76038495|NCT05170113|Dietary Supplement|Alpinia galanga formulation|Alpinia galanga formulation capsule- 1 capsule daily
75403124|NCT03585764|Device|Alpha Folate Receptor expression test|Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
75403125|NCT03546686|Drug|Pembrolizumab|Pembro will be administered 1-20 days before the cryoablation date per SOC and q3 weeks after surgery for 9 cycles per SOC.
75403126|NCT03546686|Procedure|Core Biopsy/Cryoablation|US-guided core biopsy and cryoablation 7-10 days prior to surgery.
76038496|NCT05170113|Dietary Supplement|Theacrine formulation|Theacrine formulation capsule- 1 capsule daily
76038497|NCT05170113|Dietary Supplement|Caffeine formulation|Caffeine formulation capsule- I capsule daily
75403127|NCT03546686|Procedure|Breast Surgery|Standard-of-care definitive surgery.
75403128|NCT03546686|Drug|Ipilimumab|ipilimumab 1mg/Kg IV is administered 1-5 days prior to cryoablation.
75403129|NCT03546686|Drug|Nivolumab|nivolumab 240mg IV flat dose is administered 1-5 days prior to cryoablation and 240mg IV every 2 weeks ± 3 days starting 3 (+/-1) weeks after surgery.
75403130|NCT03508921|Drug|Periprocedural Antibiotics|"One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection."
75403131|NCT03508921|Drug|Extended Antibiotics|"Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only."
75403132|NCT03508921|Procedure|Injection of OnabotulinumtoxinA (BTX-A)|Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
75403133|NCT03494127|Device|Use of GEL BALL FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
75403134|NCT03494127|Device|Use of SQUISHINS FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
75403135|NCT03493295|Drug|Levonogestrel IntraUterine System (LNG-IUS)|At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
75403136|NCT03426826|Biological|FMT versus placebo|"Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT"
75403137|NCT03401047|Drug|Estradiol|Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
75403138|NCT03349450|Biological|DPX-Survivac|DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
75403139|NCT03349450|Biological|Pembrolizumab|Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
75403140|NCT03349450|Drug|Cyclophosphamide 50mg|Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
75403141|NCT03315026|Drug|Siltuximab|Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.
75403142|NCT03315026|Behavioral|The M.D. Anderson Symptom Inventory (MDASI)|assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
75711265|NCT00904852|Drug|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
75711266|NCT00394771|Drug|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
76038498|NCT05170113|Dietary Supplement|Placebo|Placebo capsule- 1 capsule daily
75711267|NCT00394771|Drug|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
75403143|NCT03307616|Biological|Ipilimumab|Given IV
75403144|NCT03307616|Biological|Nivolumab|Given IV
75403145|NCT03307616|Radiation|Radiation Therapy|Undergo radiation therapy
75403146|NCT03289195|Procedure|MRI Biopsy|Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
75403147|NCT03287453|Other|Educational Intervention|View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts
75403148|NCT03287453|Other|Survey Administration|Ancillary studies
75403149|NCT03280147|Drug|7-day course of antibiotics|"Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
76038499|NCT05475119|Device|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
76038500|NCT05475119|Device|High Flow Nasal Cannula (HFNC)|High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
75403150|NCT03280147|Drug|14-day course of antibiotics|"Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
75403151|NCT03276572|Drug|225Ac-J591|225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
75403152|NCT03261622|Device|Sacral nerve stimulation at different stimulation amplitudes|Exploring the effect of different stimulation amplitude in a randomized study
75403153|NCT03240406|Other|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
75403154|NCT03240406|Other|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
75403155|NCT03240289|Behavioral|Texting group|Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
75550337|NCT06164288|Drug|Human Amniotic Epithelial Stem Cell Injection|"The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~Dose Level 1: 1×106 cells/kg;~Dose Level 2: 2×106 cells/kg;~Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients."
75403156|NCT03220893|Procedure|Digital Tomosynthesis Mammography|Undergo DBT
75403157|NCT03220893|Radiation|Scintimammography|Undergo MBI
75403158|NCT03202069|Other|Even protein|Intake of even protein 5 day rotating menu
75550338|NCT06164275|Procedure|Biopsy|Undergo tumor biopsy
75550339|NCT06164275|Procedure|Biospecimen Collection|Undergo blood sample collection
75550340|NCT06164275|Procedure|Computed Tomography|Undergo CT scan
75403159|NCT03202069|Other|Skewed protein|Intake of skewed protein 5 day rotating menu
75403160|NCT03200236|Behavioral|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
75550341|NCT06164275|Drug|Dacarbazine|Given IV
75550342|NCT06164275|Drug|Doxorubicin|Given IV
75550343|NCT06164275|Procedure|Echocardiography|Undergo echocardiography
75550344|NCT06164275|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
75550345|NCT06164275|Biological|Pembrolizumab|Given IV
75550346|NCT06164275|Procedure|Positron Emission Tomography|Undergo PET scan
75550347|NCT06164275|Drug|Vinblastine|Given IV
75550348|NCT06164262|Other|Individuals with CSVD|This does not entail the application of interventions.
75403161|NCT03200236|Behavioral|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
75403162|NCT03181152|Diagnostic Test|Impulse Oscillometry|"1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result."
75403163|NCT03125642|Drug|Etoposide|"BEAM: 100 mg/m^2 IV over 2 hours BID on Days -5, -4, -3, -2 | CBV: 150 mg/m^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
75403164|NCT03125642|Drug|BCNU|BEAM & CBV: 300 mg/m^2 IV over over 2 hours on Day -6
75550349|NCT06164249|Other|strength training|Strength training, three times a week, during nine weeks.
75550350|NCT06164223|Device|VR Baby Pump|VRBaby-Pump application is a video application specially prepared with virtual reality glasses and a milking pump placed inside a toy doll. In the video content, the mother is breastfeeding her baby on an armchair in the baby room prepared for a newborn baby.
75550351|NCT06164158|Other|Procedural Videos|A randomized controlled trial was conducted at Pakistan Institute of Medical Sciences (PIMS) Islamabad between September 1, 2023 to November 30, 2023 under ethical approval from the Institutional ethical review board.
75550352|NCT06164158|Other|No procedural videos|No procedural videos
75403165|NCT03125642|Drug|AraC|BEAM: 100 mg/m^2 IV over 1 hour BID on Days -5, -4, -3, -2
75403166|NCT03125642|Drug|Melphalan|BEAM: 140 mg/m^2 IV over 20 minutes on Day -1
75403167|NCT03125642|Procedure|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
75403168|NCT03125642|Biological|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3
75403169|NCT03125642|Drug|Cyclophosphamide|"CBV: 1.5 gm/M^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 | CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
75403170|NCT03125642|Radiation|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
75403171|NCT03105843|Drug|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
75403172|NCT03105843|Diagnostic Test|Eucapneic Voluntary Hyperventilation (EVH)|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
75403173|NCT03105843|Drug|Mannitol Inhalation Kit|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
75403174|NCT03068910|Drug|Micronized progesterone|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
75403175|NCT03068910|Drug|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
75403176|NCT03068910|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
75403177|NCT03028246|Device|ExAblate 4000 System|Focused ultrasound
75403178|NCT03005418|Biological|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
75403179|NCT02984761|Radiation|Stereotactic Radiotherapy|Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.
75403180|NCT02984761|Procedure|Anatomic Pulmonary Resection|An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
75403181|NCT02978638|Device|Finetech Vocare Bladder System|Participants will be implanted with the existing FDA-approved Finetech Vocare Bladder System stimulator and electrodes.
75403182|NCT02925195|Dietary Supplement|Vitamin D3|cholecalciferol (vitamin D3) 2000 IU capsules daily
75403183|NCT02925195|Drug|Placebo|
75711268|NCT00394771|Drug|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
75711269|NCT00396409|Drug|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
75403184|NCT02921581|Radiation|FDG-PET guided dose painting|
75403185|NCT02864277|Procedure|No Intervention Conventional Strategy|"The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
75403186|NCT02864277|Procedure|ERAS|"The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
75403187|NCT02840877|Behavioral|DOT Adherence Monitoring|Study participants will meet with a study-employed DOT worker daily during weekdays throughout the course of their TB treatment
75403188|NCT02835287|Other|Protocol-based integrated care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
75403189|NCT02831985|Procedure|general practice follow-up|Post-surgery follow-up by general practitioner
75403190|NCT02831985|Procedure|ear-nose-throat (ENT) specialist follow-up|Post-surgery follow-up by ear-nose-throat (ENT) specialist
75711270|NCT00396409|Drug|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
75403191|NCT02795533|Behavioral|Clinical follow-up|"All included patients will have a clinical follow-up consisting of:~A medical examination~Quality of life questionnaires~Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice."
75403192|NCT02793375|Drug|Montelukast|Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
75403193|NCT02793375|Drug|Placebo|Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
75403194|NCT02716246|Biological|ABO-102|Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
75403195|NCT02716246|Drug|Adjuvant Immunosuppression (IS) Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IS therapy. Not all participants may receive IS therapy.
75403196|NCT02694185|Other|Caplan IVR|This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
75403197|NCT02684903|Behavioral|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
75403198|NCT02633111|Other|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
75403199|NCT02633111|Other|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
75403200|NCT02633111|Device|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
75403201|NCT02621424|Device|RTMS|stimulation of the brain with magnetic pulses
75403202|NCT02621424|Device|sham|sham noise to block the sound of stimulation
75403203|NCT02616185|Biological|PF-06755992|PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
75403204|NCT02616185|Biological|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
75403205|NCT02616185|Device|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
75403206|NCT02616185|Biological|Tremelimumab|PF-06753388 will be administered every 28 days.
75403207|NCT02616185|Biological|PF-06801591|PF-06801591 will be administered every 28 days.
75403208|NCT02616185|Biological|PF-06753512|Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
75403209|NCT02611128|Other|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
75403210|NCT02560129|Other|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
75403211|NCT02520362|Drug|denosumab|subcutaneous injection
75403212|NCT02520362|Drug|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate [Fosamax®], risedronate [Actonel®], ibandronate [Boniva®/Bonviva®] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate [Reclast®/Aclasta®].
75403213|NCT02486718|Drug|Atezolizumab|Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
75403214|NCT02486718|Drug|Cisplatin|Participants will receive cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of up to four 21-day cycles.
75403215|NCT02486718|Drug|Vinorelbine|Participants will receive vinorelbine 30 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
75403216|NCT02486718|Drug|Docetaxel|Participants will receive docetaxel 75 mg/m^2 IV on Day 1 of each of the four 21-day cycles.
75403217|NCT02486718|Drug|Gemcitabine|Participants will receive gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
75403218|NCT02486718|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
75403219|NCT02453737|Radiation|Brachytherapy APBI|
75403220|NCT02453737|Radiation|3D-CRT (photon) APBI|
75403221|NCT02453737|Radiation|Proton APBI|
75403222|NCT02346747|Biological|Vigil|The bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine, Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
75403223|NCT02346747|Other|Placebo|"To maintain placebo effect and eliminate bias due to volumetric differences, the number of Vigil doses manufactured from harvested tissue (except if below 4) will be used to guide manufacture of the same number of doses of placebo for each subject. Placebo will consist of freeze media [10% DMSO (dimethyl sulfoxide; Cryoserv USP; Mylan Institutional USP), 1% Human Serum Albumin (ABO Pharmaceuticals) in Plasma-Lyte A, pH 7.4 (Baxter)]. Depending upon randomization assignment, placebo or Vigil will be delivered in identical vials and drawn up in 'covered' syringes for intradermal injection."
75403224|NCT02324387|Procedure|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
75403225|NCT02324387|Drug|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
75403226|NCT02291523|Biological|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
75403227|NCT02278744|Radiation|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 17 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
75403228|NCT02278744|Device|MRI and/or CT|
75403229|NCT02267252|Other|Antibody-sperm binding|
75403230|NCT02266329|Drug|prazosin hydrochloride|Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
75403231|NCT02266329|Drug|placebo|Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
75403232|NCT02155933|Other|Blood sampling|Blood sampling for later hormone measurements
75403233|NCT01967888|Drug|Reparixin|Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
75711271|NCT00396409|Drug|Placebo|Placebo given during the 2006 core study
75403234|NCT01967888|Drug|Placebo|Physiologic solution administered at 0.25 mL/kg/hour
75403235|NCT01961219|Procedure|Manipulation Under Anesthesia|Closed manipulation under anesthesia.
75403236|NCT01961219|Procedure|Arthroscopic capsular release|Arthroscopic capsular release
75403237|NCT01910818|Device|Fractional CO2 laser treatment|Patient will be treated with fractional laser treatment over the areas with fibrosis.
75403238|NCT01910818|Other|No treatment|Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
75403239|NCT01873131|Drug|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
75403240|NCT01873131|Device|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
75403241|NCT01508949|Drug|liraglutide|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
75403242|NCT01508949|Drug|placebo|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
75403243|NCT01507285|Drug|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
75403244|NCT01507285|Drug|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
75403245|NCT01486862|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
75403246|NCT01428089|Drug|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
75403247|NCT01428089|Drug|Placebo|Placebo
75403248|NCT01425541|Drug|estrace|0.5-1 mg once a day PO for 7 days
75403249|NCT01425541|Drug|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
75403250|NCT01388244|Other|Screening|Screening by risk factor assessment (FRAX) followed by DXA
75403251|NCT01388244|Other|Control|Observation by use of register data
75403252|NCT01167114|Drug|STA-9090|Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
75403253|NCT01156155|Radiation|Digital xray of jaw and teeth|one time xray of jaw and teeth
75403254|NCT01156155|Procedure|Blood draw|Three to four tablespoons of blood drawn.
76038501|NCT05110521|Behavioral|PROMPTS|PROMPTS is a two-way Short Message Service (SMS) digital health platform that connects mothers with information, advice and referrals to care during the prenatal and postnatal period. The platform also collects information from women on care experience that is reported back to maternity facilities.
75403255|NCT01156155|Other|questionnaires|completed questionnaires regarding patient's health and functional ability.
75403256|NCT01156155|Procedure|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
75403257|NCT01156155|Other|Bilateral digital xray of hands|One time digital xray of hands
75403258|NCT00930228|Drug|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
75403259|NCT00930228|Drug|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
75403260|NCT00918151|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study
76038502|NCT05110521|Behavioral|MENTORS|MENTORS is a program in which in facility nurse-mentors are trained and supported to offer training to nurses, midwives and other maternity facility staff on aspects of basic and emergency obstetric and newborn care.
75403261|NCT00874159|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
75403262|NCT00849316|Drug|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
75403263|NCT00773851|Procedure|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
75403264|NCT00773851|Procedure|mesh fixation by staples|mesh fixation by staples
76038503|NCT01295723|Radiation|Hypofractionated Whole Breast Radiation Therapy|"Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~Single reference dose per fraction: 2.7 Gy (ICRU)~Number of fractions: 15~Number of fractions per week: 5~Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy"
76038504|NCT01295723|Radiation|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
75403265|NCT00773773|Other|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
75403266|NCT00745433|Drug|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
75403267|NCT00745433|Drug|metformin|Start dose and frequency at the discretion of the physician following clinical practice
75403268|NCT00712478|Drug|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75403269|NCT00705172|Drug|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
75403270|NCT00701155|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
75403271|NCT00687453|Drug|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
75403272|NCT00687453|Drug|NPH twice-daily|Addition of morning NPH to bedtime NPH
75403273|NCT00687063|Drug|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
75403274|NCT00653068|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
75403275|NCT00653068|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC rescue
75403276|NCT00653068|Drug|Carboplatin|Given IV
75403277|NCT00653068|Drug|Cisplatin|Given IV
75403278|NCT00653068|Drug|Cyclophosphamide|Given IV
75403279|NCT00653068|Drug|Etoposide|Given IV
75403280|NCT00653068|Biological|Filgrastim|Given IV or SC
75403281|NCT00653068|Other|Laboratory Biomarker Analysis|Correlative studies
75403282|NCT00653068|Drug|Leucovorin Calcium|Given IV or PO
75403283|NCT00653068|Drug|Methotrexate|Given IV
75403284|NCT00653068|Drug|Thiotepa|Given IV
75403285|NCT00653068|Drug|Vincristine Sulfate|Given IV
75403286|NCT00521690|Drug|insulin detemir|
75403287|NCT00504673|Drug|insulin detemir|
75403288|NCT00504673|Drug|insulin NPH|
75403289|NCT00504673|Drug|insulin aspart|
75403290|NCT00476437|Drug|biphasic insulin aspart|
75403291|NCT00476437|Drug|biphasic human insulin|
75403292|NCT00414648|Drug|Sirolimus|A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.
75403293|NCT00414648|Drug|Placebo|A placebo dose of 2 tablets per day for 1 year.
75403294|NCT00337155|Drug|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
75403295|NCT00313742|Drug|insulin detemir|
75403296|NCT00313742|Drug|insulin glargine|
75403297|NCT00313742|Drug|insulin NPH|
75403298|NCT00267683|Drug|insulin aspart|
75403299|NCT00267683|Drug|glibenclamide|
75711272|NCT01323829|Other|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
75403300|NCT00101751|Drug|biphasic insulin aspart|
75403301|NCT00101751|Behavioral|dietary regimen|
75403302|NCT00077285|Biological|filgrastim|
75403303|NCT00077285|Drug|carboplatin|
75403304|NCT00077285|Drug|cyclophosphamide|
75403305|NCT00077285|Drug|dexrazoxane hydrochloride|
75403306|NCT00077285|Drug|doxorubicin hydrochloride|
75711273|NCT02924376|Drug|Pemigatinib|Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
75711274|NCT00921492|Device|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
76038505|NCT05611463|Drug|Camrelizumab Plus Docetaxel and Cisplatin|Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
75403307|NCT00077285|Drug|etoposide|
75403308|NCT00077285|Drug|ifosfamide|
75403309|NCT00077285|Drug|irinotecan hydrochloride|
75403310|NCT00077285|Drug|vincristine sulfate|
75403311|NCT00077285|Procedure|conventional surgery|
75403312|NCT00077285|Radiation|radiation therapy|
75403313|NCT01537302|Device|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
75403314|NCT01537926|Drug|N-acetylcysteine|NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
75403315|NCT01537926|Drug|Placebo|sugar pill manufactured to minic NAC 600mg capsule
75403316|NCT01538862|Drug|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
75403317|NCT01540266|Procedure|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
75403318|NCT01540266|Procedure|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
75403319|NCT01541358|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
75403320|NCT01541358|Procedure|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
75403321|NCT01542372|Drug|Medication augmentation|
75403322|NCT01542372|Behavioral|CBT|
75403323|NCT01542684|Drug|Azacytidine|Starting dose: 40 mg/m^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
75403324|NCT01542684|Drug|GM-CSF|250 mcg/m^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
75403325|NCT01543074|Dietary Supplement|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
75403326|NCT01543074|Dietary Supplement|Garlic oil|1 pill = 30 mg garlic oil/day
75403327|NCT01543074|Drug|BSE|2 pills = 200 micromoles of Sulforaphane/day
75403328|NCT01543074|Dietary Supplement|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
75403329|NCT01544088|Behavioral|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
75403330|NCT01544088|Behavioral|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
75403331|NCT01544166|Drug|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants <2 years of age.
75403332|NCT01545336|Drug|Anastrozole|1 mg tablet to be taken 1 time daily
75403333|NCT01545336|Drug|Placebo|1 mg tablet to be taken 1 time daily
75403334|NCT01546194|Other|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
75711275|NCT00921492|Other|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
75711276|NCT02564328|Genetic|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
75711277|NCT03687762|Behavioral|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
75403335|NCT01548690|Drug|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups [~18 with minimal renal dysfunction (Cohort 1) & ~18 w/ comprised renal function (Cohort 2)] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (~6 Cohort 1 & ~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
75403336|NCT01551030|Drug|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
75403337|NCT01551186|Dietary Supplement|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
75403338|NCT01551264|Device|Foot Abduction Brace (FAB)|After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
75403339|NCT01551888|Drug|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
75403340|NCT01551888|Drug|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
75403341|NCT01553058|Drug|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
75711278|NCT03687762|Behavioral|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
75403342|NCT01553058|Drug|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
75403343|NCT01553058|Other|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
75403344|NCT01553292|Device|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
75403345|NCT01553292|Device|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
75403346|NCT01556100|Drug|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
75550353|NCT06164132|Other|Evaluation of Phenotypes of PCOS, Anthropometric parameters, Body composition parameters, and Ovarian Doppler parameters|Evaluation through PCOS Phenotypes, measurements of Body weight, height, waist and hip circumferences, Dual-energy X-ray absorptiometry, and Sonographic examination.
75550354|NCT06164106|Behavioral|Virtual Crisis Response Planning|Individuals complete a chat-based experimental collaborative suicide intervention virtually.
75550355|NCT06164106|Behavioral|In-Person Crisis Response Planning|Individuals complete a collaborative suicide intervention in-person.
75550356|NCT06164106|Behavioral|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
75403347|NCT01556724|Drug|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
75403348|NCT01557894|Other|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
75403349|NCT01558128|Drug|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
75711279|NCT03687762|Behavioral|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
75711280|NCT04060836|Drug|Xyntha|Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.
75711281|NCT04060836|Drug|Recombinant Coagulation Factor VIII Injection|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
75711282|NCT00693420|Drug|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
75711283|NCT00693420|Drug|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
76038506|NCT05110365|Other|Proprioceptive Neuromuscular Facilitation|"The patient will be provided with mild to moderate resistance PNF pattern which is a type of Endurance training which decreases BP through a reduction in systemic vascular resistance(15).In a regimen as follow with the frequency of 3 days a week, a repetition of 3 sets for one hour and a total duration of 3 months(16). The PNF patterns will be diagonal 1 (D1) and diagonal 2 (D2) patterns. Both patterns are subdivided into: A) Moving into Flexion: the toes start flexed and ends extended. Ankle and foot start plantar flexed; everted and ends dorsiflexed inverted. Tibia starts externally rotated and ends internally rotated. Knee starts extended, and ends flexed. The hip starts extended, abducted, internally rotated and ends flexed, adducted, externally rotated.B) Moving into Extension: The start and end are reversed to D1 Moving into Flexion"
76038507|NCT05110131|Device|Device for performing biopsy via electromagnetic navigation bronchoscopy|Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
76038508|NCT05611385|Other|Difference in development of Acute Lung Injury in Amphetamine positive and negative patients|No Intervention
75403350|NCT01558128|Procedure|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
75403351|NCT01559064|Device|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
75711284|NCT00742794|Other|Observation|Observation of sting frequency
76038509|NCT05475041|Procedure|Major liver resection|Major liver resection (3 or more contiguous segments)
75711285|NCT04034524|Drug|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
76038510|NCT05475041|Procedure|Technically major liver resection|Minor liver resection (<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
76038511|NCT01656759|Drug|Evicel Fibrin Spray|10cc syringe dose, once at the end of TKA
76038512|NCT04234737|Behavioral|Hypnotherapy|Hypnotherapy
76038513|NCT05053815|Other|Pharmacogenomic Testing|Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.
76038514|NCT04998747|Drug|AMG 701|AMG 701 will be administered as SC or intravenous injection.
75403352|NCT01559922|Drug|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
75711286|NCT04034524|Drug|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
75711287|NCT00925834|Behavioral|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
75711288|NCT04034680|Other|TIME|The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
75403353|NCT01559922|Device|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
75403354|NCT01560624|Drug|Treprostinil Diolamine|Active
75403355|NCT01560624|Drug|Placebo|Placebo
75403356|NCT01561716|Device|Wii Fit|This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
75403357|NCT01562886|Drug|Rilpivirine|Rilpivirine 26mg
76038515|NCT04998747|Drug|AMG 701|AMG 701 will be administered as SC injection.
75403358|NCT01563198|Behavioral|Comfort Talk®|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
75403359|NCT01564914|Drug|TRC105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
75403360|NCT01564914|Drug|Bevacizumab|IV
75711289|NCT04034680|Other|Education-only intervention|Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
76038516|NCT02631577|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ]|Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
76038517|NCT02631577|Drug|Lenalidomide|Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
76038518|NCT02631577|Drug|Obinutuzumab|Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
76038519|NCT01667081|Drug|Grazoprevir|Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
76038520|NCT04998045|Behavioral|Screening and brief intervention for substance use|Screening will be done using the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST). The brief intervention will be delivered based on ASSIST risk scores: low risk - verbal positive reinforcement and brief advice on harmful consequences of substance use (ii) moderate risk - brief motivational interviewing (BMI) (iii) high risk - BMI and referral to child psychiatry out-patient clinic. The BMI will be delivered in a single session (approximately 15 minutes) using Feedback Listen Options model (15): (i) providing feedback on screening results (ii) exploring pros and cons of substance use, enquiring about importance of change (iii) exploring options for change.
76038521|NCT05052411|Other|App usage assessments and analytics|All participants will be given a brief overview of the purpose of the study followed by a survey on participant characteristics and barriers to accessing HIV testing and PrEP uptake and P/SUD support services. The participant will be observed downloading the JomPrEP app and instructed with a brief tutorial on the onboarding process. The participant will be told to keep the app for 1 month and encouraged to use all app components. At 30 days, the participant will complete a post-survey, to which the Systems Usability Scale will be added. App analytics will also be collected (e.g., the number of logins). Participants will be asked to provide feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention.
76038522|NCT04545619|Device|QDOT MICRO System|QDOT Micro Catheter with nGEN Generator
76038523|NCT05474885|Biological|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
75403361|NCT01565538|Drug|Erlotinib|150 mg Given orally
75403362|NCT01565538|Drug|Pemetrexed|500mg/m2 Given IV
75403363|NCT01565616|Drug|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV"
75403364|NCT01566084|Drug|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
75403365|NCT01566084|Other|placebo|Placebo tablets are administered to maintain the low sodium condition.
75403366|NCT01566162|Drug|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
75403367|NCT01566630|Drug|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
75403368|NCT01566630|Drug|RLX030|RLX030 1 mg/mL vials
75403369|NCT01567020|Other|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
75403370|NCT01569126|Drug|LY110140|Administered orally as capsules
75711290|NCT00925912|Procedure|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
75711291|NCT00925912|Procedure|Perianal block|0.25% bupivacaine injected at perianal region
75711292|NCT04060602|Behavioral|Personalized Feedback|A report comparing the participant's cannabis use to peer usage, and summarizing problems experienced and risk associated with future use.
75403371|NCT01569126|Drug|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
75403372|NCT01569828|Drug|LCZ696A|
76038524|NCT05728879|Combination Product|APR-TD011 (RLF-TD011)|APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.
75403373|NCT01569828|Drug|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
75403374|NCT01573260|Other|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
75403375|NCT01573260|Other|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
75403376|NCT01573572|Drug|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
75403377|NCT01575522|Other|Laboratory Biomarker Analysis|Correlative studies
75403378|NCT01575522|Drug|Tivantinib|Given PO
75403379|NCT01575756|Biological|Octafibrin|Octafibrin was supplied as a powder for reconstitution with water for injection.
75403380|NCT01575756|Biological|Haemocomplettan® P or RiaSTAPTM|Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
75403381|NCT01575912|Other|experimental pain tests|
76038525|NCT04421469|Drug|Triprilimab(JS001)|"JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~JS001 maintenance treatment."
76038526|NCT03067753|Drug|Monosialoganglioside Ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
76038527|NCT03067753|Drug|Methylprednisolone (Steroid Hormone)|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
76038528|NCT03067753|Drug|Prednisolone|
75403382|NCT01577238|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
75403383|NCT01577238|Drug|Placebo|Vaginal gel, daily for 7 days
75403384|NCT01577706|Drug|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
75403385|NCT01577706|Drug|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
75403386|NCT01577706|Other|Placebo|Placebo, gel-capsule, single-dose, 1-day
75403387|NCT01580592|Drug|Omalizumab|150mg, s.c., every 4 weeks
75403388|NCT01580592|Drug|Omalizumab|300mg, s.c., every 4 weeks
75403389|NCT01580592|Drug|Placebo|Placebo, s.c., every 4 weeks
75403390|NCT01580904|Behavioral|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
75403391|NCT01583868|Device|B&L RD2135-01 lens C|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
75403392|NCT01583868|Device|B&L RD2135-01 lens D|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
75403393|NCT01583868|Device|PureVision2|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
75403394|NCT01583868|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
75403395|NCT01588158|Drug|Acetaminophen|325 mg
75403396|NCT01588158|Drug|Vicodin|Vicodin 5/325 mg
75403397|NCT01588236|Drug|high dose KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
75403398|NCT01588236|Drug|lower dose KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
75403399|NCT01588236|Drug|Placebo|3 capsules of placebo tid (morning, midday, and evening)
75403400|NCT01588470|Drug|pioglitazone|45 mg per day for 6 months
75403401|NCT01589484|Device|SWL - Compact Delta Dornier Med Tech|All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
75403402|NCT01590264|Device|Bimodal rTMS|"High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
75403403|NCT01591044|Drug|Placebo|1 puff bid or 2 puffs bid
75403404|NCT01591044|Drug|R940343 1mg|R343 1mg, 1 puff bid
76038529|NCT05073861|Behavioral|STEM learning|"Classes will be randomly assigned to the experimental group and to the control group. As treatment, the experimental group will be assigned to an intervention that uses a STEM blended learning app with gamified videos for content knowledge along with hands-on experiments. The videos are fictitious educational narratives related to the content knowledge and students were asked to step into the shoes of the cartoon scientist (a chipmunk) to solve various problems during the stories. The science experiments will be completed with step-by-step video guidance on the app. The control group will be assigned to read the same content on an e-book and receive an arts-and-craft kit for each lesson that is unrelated to the content knowledge."
76038530|NCT05613179|Procedure|Group1 (lever positioning manipulation)|The specific lever positioning manipulation is as follows: the patient lies prone at the mouth-open position with muscles relaxed, waist exposed, knees and hips bent, and ankle joints crossed. The practitioner uses the right elbow olecranon to point at the lumbar vertebrae, then hold the patient's two ankle joints in both hands to cause the lumbar vertebra to make hyperextension and flexion movements through the arms and pull the patient backward and upwards hard. When pulling upwards to the trigger point, the practitioner pulls wit lever quickly with a technique and then senses a clatter or looseness at the positioning point. When the practitioner pulls with lever manipulation, the patient is asked to exhale and then inhale at the end of the manipulation.
76038531|NCT05613179|Procedure|Group2 (placebo group)|The specific sham lever positioning manipulation is as follows: the patient lies prone with his mouth open, muscles relaxed, waist exposed, knees bent at the hip and ankles crossed. The practitioner points to the lumbar spine with the right elbow olecranon, and then holds the patient's two ankles in both hands, so that the lumbar spine through the arm for overextension and flexion, and forcefully pulls the patient back and up. When pulling up to the trigger point, maintain this movement for a short period of time, depending on the patient's endurance, about 1-5 minutes. After finishing, ask the patient to rest in prone position.
75403405|NCT01591044|Drug|R940343 2mg|R343 2mg, 2 puffs bid
75403406|NCT01591746|Drug|Botulinum Toxin Type A|
75403407|NCT01591746|Drug|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
75403408|NCT01597128|Device|Flex HD|Flex HD mesh for hernia repair
75403409|NCT01597128|Device|Strattice|Strattice mesh for hernia repair
75403410|NCT05566860|Procedure|Positional Therapy|After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.
75403411|NCT05566860|Procedure|Intraoral Negative Pressure Therapy|If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.
75403412|NCT05566860|Procedure|Oral Appliances|If the patient is effective with oral appliances use, it was used be for three months.
75403413|NCT05566860|Procedure|Surgery|If the interventions mentioned above are ineffective, or the patient does not want to try the above treatments, surgery is required. The surgical patients were divided into three groups according to their body weight. One group was overweight patients (BMI>32) who were treated with upper airway surgery and/or bariatric surgery, and/or postoperative diet education; the other group was overweight people with a BMI between 27 and 32, upper airway surgery and/or bariatric surgery, and/or postoperative diet education will be done; if the weight is normal with the BMI is less than 27, or those patients who are overweight but are not willing receive above mentioned weight loss treatment, upper airway surgery will be done.
75711293|NCT04060602|Behavioral|Education|Canada's Lower-Risk Cannabis Use Guidelines prepared by the Centre for Addiction and Mental Health which outlines methods to help reduce health risks associated with cannabis use.
75711294|NCT00904930|Device|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
75711295|NCT00904930|Device|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
75711296|NCT03545256|Procedure|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search|"The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloids labeled with technetium99, around the primary tumor. A planar CT image acquisition is performed to identify the sentinel lymph nodes (Gs(s)) which are then marked on the skin with an indelible marker.~Surgery on D0:~The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG.~The main tumor is operated by mouth."
75711297|NCT00695136|Drug|Donepezil hydrochloride|
76038532|NCT04997499|Behavioral|watch an instructional video|watch instructional video and then perform self injection of subcutaneous depot-medroxyprogesterone based on the video teaching
75403414|NCT05566860|Procedure|Tongue Muscle Strength Training|If the tongue strength of the aforementioned patient is insufficient, it is recommended that the patient need to do tongue muscle strength training at the same time for three months. If the ambient temperature and humidity have an impact, we will recommend patients to control the ambient temperature and humidity and use the ECG patch to track the changes before and after three months.
75711298|NCT00695136|Behavioral|Increase REM sleep percentage|
76038533|NCT04331639|Dietary Supplement|vitamin D3|Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.
76038534|NCT05073393|Behavioral|Sugar stress|Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
76038535|NCT04212351|Genetic|Frameshift Array blood sample test|Patient blood test samples will be collected and evaluated for frameshift peptide mutations.
75403415|NCT05566470|Diagnostic Test|Assessment of Central Neuromuscular Dysfunction, Shoulder Physical Functionality and Psychological Factors|Each of the 2 groups will be evaluated in terms of functional level and psychological factors; American Shoulder and Elbow Surgeons evaluation form (ASES), Connor-Davidson Psychological Resilience Scale (CDPRS) and the Depression, Anxiety, Stress-21 Scale (DASS-21) will be used to evaluate these factors. Furthermore, the corticospinal excitability of the deltoid muscle will be assessed with Transcranial Magnetic Stimulation (TMS). Both deltoid muscles of the patient will be evaluated by saving motor evoked potentials signals that respond to TMS, and motor excitability will be compared between the affected arm and the unaffected arm. In addition, the control group will also be assessed in terms of functional level and psychological factors with TMS, ASES, DASS-21 and CPDRS.
75403416|NCT05566314|Dietary Supplement|Amunizer|12 oz. herbal, probiotic and antioxidant herbal beverage
75403417|NCT05566314|Other|Placebo|12 oz. flavored beverage
75403418|NCT05566236|Behavioral|board game|A board game was designed based on situated learning theory and the results of relevant studies. This board game contains a summary, answer booklet, and multiple card game tasks including situations of interpersonal interaction. The participants must discuss, share personal experiences, and find the answer together.
75403419|NCT05565924|Other|Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
75403420|NCT05565924|Other|Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
75403421|NCT05565924|Other|Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
75403422|NCT05565924|Other|Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
75403423|NCT05565924|Other|Group- E; Control group|"Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study."
75403424|NCT05565690|Device|MRS|It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain
75403425|NCT05565300|Other|Cycling exercise|30 minutes of cycling (90 rpm).
75403426|NCT05565300|Other|Cognitive tasks|30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
76038536|NCT05050149|Drug|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
76038537|NCT05471245|Device|Magic Touch SCB by Concept Medical Inc.|PCI with drug-coated balloon
76038538|NCT05557799|Radiation|Photobiomodulation|The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
76038539|NCT05557799|Radiation|Placebo Photobiomodulation|The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
76038540|NCT05613101|Procedure|Erector Spinae Plane Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed parasagittally 2-3 cm lateral to the spinous process at the L3 or L4 level and the transverse process was visualized. The peripheral block needle (85 mm B Braun Stimuplex A) was advanced in plane up to the transverse process and 10 ml 0.5% bupivacaine hydrochloride 10 ml 0.9% isotonic NaCl mixture was applied on the erector spina muscle.
76038541|NCT05613101|Procedure|Adductor Canal Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed in the middle between the medial condyle and the SIAS, and the superficial femoral artery (FSA) was visualized under the sartorius muscle. By following the FSA distally, the point where the sartorius muscle crosses the adductor magnus muscle, which is the beginning of the adductor canal, was found and the saphenous nerve was visualized hyperechoic in the anterolateral aspect of the FSA. 20 cc 0.5% bupivacaine hydrochloride was applied
76038542|NCT05613023|Radiation|SBRT|Stereotactic Body Radiotherapy
76038543|NCT03067597|Drug|Dinoprostone|The DVI contains 10 mg dinoprostone
75403427|NCT05564988|Other|Preconditionning|"Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days."
75711299|NCT00905008|Procedure|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis <30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
75711300|NCT00905008|Device|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
76038544|NCT02518971|Drug|Tamsulosin|0.4 mg daily
76038545|NCT02518971|Drug|Placebo|one capsule daily
76038546|NCT03067519|Other|Fast track surgery|early feeding and mobilization after surgery
76038547|NCT03067519|Other|Conventional management|Management per the primary surgeon
76038548|NCT04733963|Drug|Fruquintinib Plus Capecitabine|Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
75550357|NCT06164093|Other|RNA sequencing is performed on the remaining LPCs|RNA sequencing is performed on the remaining LPCs previously transplanted back into the patients. And the results are analysed combined with the data from the previous clinical trial. (Please note that patients will not receive cell transplantation again as they have already received the treatment in the previous trial [NCT03655808])
75550358|NCT06164093|Other|Immunofluorescence staining is performed in the surgically resected lung tissue sections|The aim of this intervention is to detect Krt5 protein expression by staining the surgically resected lung tissue sections. This is done to confirm the presence of a small number of LPCs in the lung tissue of patients with bronchiectasis and to investigate their distribution.
75550359|NCT06164080|Other|participants receiving Corticosteroid|Pregnant women using antenatal corticosteroids for any reason before 34 weeks
75550360|NCT06164067|Other|abortus within 24 hours or 24-48 hours|second trimester medical termination
76038549|NCT04733963|Drug|Bevacizumab Plus Capecitabine|Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
75711301|NCT02565420|Other|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
75711302|NCT02565420|Other|Lactated Ringer's solution|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
75711303|NCT00905086|Other|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
76038550|NCT03066115|Drug|L-NMMA|See arm description.
76038551|NCT03066115|Drug|Ketorolac|See arm description.
76038552|NCT03066115|Drug|Ascorbic Acid|See arm description.
76038553|NCT03066115|Procedure|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
76038554|NCT03066115|Procedure|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
76038555|NCT04212039|Drug|Saline Solution|0.5 ml/kg saline
76038556|NCT04212039|Drug|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
75403428|NCT05564832|Drug|Pilocarpine 1.25% Eye drop|One millimeter of pilocarpine eye drop (Bakhtarbiochemistry Company, Iran) contains pilocarpine hydrochloride 1.25% (12.5 mg) as an active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. The medication preservative is 0.0075% benzalkonium chloride. Inactive ingredients in the ophthalmic are boric acid, sodium citrate dihydrate, sodium chloride, purified water. Another pilocarpine eye drop was Vuity® (1.25% pilocarpine; Allergan company) contains the active intergradients of pilocarpine hydrochloride 1.25% (12.5 mg/mL), equivalent to 1.06% (10.6 mg/mL) pilocarpine free-base and the preservative agents was 0.0075% benzalkonium chloride.
75403429|NCT05564676|Dietary Supplement|flaxseed oil and pomegranate dry extract|The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.
75403430|NCT05564676|Dietary Supplement|sunflower oil and microcrystalline cellulose|The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.
75403431|NCT05564442|Drug|20% benzocaine gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
75403432|NCT05564442|Device|Transcutaneous electric nerve stimuli|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
75403433|NCT05564442|Drug|Emla gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
75403434|NCT05564442|Other|Ice application|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
75403435|NCT05532774|Device|AI defocusing frame glasses|AI defocusing frame glasses have the function of eye behavior management, which can delay the progression of myopia through scientific management of eye behavior including outdoor light exposure (≥2 hours/day), duration of continuous close eye use (30 seconds rest every 30 minutes) and close eye distance (one punch, one foot and one inch), etc.
75403436|NCT05493540|Drug|Ibuprofen oral suspension|"The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~Moderate/Severe PDA on Echocardiography~Prolonged ventilation or Increased ventilatory setting~Prolonged use of inotropes or vasopressors or escalating dose~Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
75403437|NCT05493540|Drug|Placebo|"Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~Prolonged Ventilation or Escalating Ventilatory Setting~Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~After 5 days of recruitment~Moderate/Severe PDA on Echocardiography~Prolonged ventilation or Increased ventilatory setting~Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
76038557|NCT03066037|Procedure|regional-anaesthesiological infiltration|Patients with therapy refractory chronic pain are treated with local infiltration techniques using e.g. local anaesthetics, opioids or drug combinations. Targeted structures are e.g. Ganglion stellatum, Ganglion pterygopallatinum, Trigeminal nerve branches (V1-V3). Patients receive a context- sensitive number of blocks in a series of infiltrations depenting on their pain course.
76038558|NCT04433377|Procedure|Suprascapular nerve block|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector
76038559|NCT04433377|Procedure|Subacromial injection|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
76038560|NCT05048589|Drug|Standard-Dose Quadrivalent Influenza Vaccine|For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.
76038561|NCT05048589|Drug|High-Dose Quadrivalent Influenza Vaccine|For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
76038562|NCT05728567|Other|whether the participants had T2DM|whether the participants had T2DM
76038563|NCT03067285|Drug|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
76038564|NCT03067285|Drug|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
76038565|NCT01365039|Device|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
75403438|NCT05427240|Other|Pre-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
75403439|NCT05427240|Other|Standard of Care|Standard of Care with a Genetic Counselor by Remote Services
75403440|NCT05427240|Other|Post-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
75403441|NCT05214924|Biological|Injectable platelet-rich fibrin|Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
75403442|NCT05214924|Biological|Platelet-rich plasma|Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
75403443|NCT05672940|Behavioral|Aerobic plus resistance training|Aerobic plus resistance training
75403444|NCT05672940|Behavioral|Stretching plus breathing training|Stretching plus breathing training
75403445|NCT05672706|Procedure|CFR and IMR group|Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement
75403446|NCT05672472|Drug|Sivelestat sodium|Continuous infusion of sivelestat sodium for 5 days
75403447|NCT05672394|Procedure|Continuous Serratus anterior plane block|in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
75403448|NCT05672394|Procedure|Thoracic Epidural|A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
75403449|NCT05672394|Drug|Bupivacaine|bupivacaine
75403450|NCT05672394|Drug|lidocaine with epinephrine|3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
75403451|NCT05672160|Diagnostic Test|CT evaluated sarcopenia|At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.
75550361|NCT06164054|Device|Virtual Reality Rehabilitation System|Participants of the experimental group will undergo treatment with Virtual Reality, both IVR and HB. The intervention will consist of 12 sessions lasting about 1 hour each and carried out with a frequency of three days per week within four weeks. Before starting the rehabilitation, arm illusion with the Handbox is inducted to explore the ability of the patients to perceive the virtual arm as their own. During this task, patients sit on a chair with the injured arm inside the Handbox and are invited to perform slow movements with the hand, such as moving the fingers one at a time and moving the wrist up and down. Moreover, they are invited to keep their attention to the virtual arm project on the screen that follows their natural movements. The arm illusion lasts 3 minutes, and the embodiment questionnaire is administered. Then, the treatment starts with IVR and HB sessions, which are counterbalanced to avoid the learning effect
75711304|NCT00905086|Procedure|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
76038566|NCT01365039|Device|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
75403452|NCT05672004|Other|PUMP-fit strategy (implementation toolbox)|"Healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting (during the control period).~Healthcare professionals will be informed about the platform and toolbox. Healthcare professionals receive a personal log-in for the online platform. Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible on the platform Within the separate environment of the online platform, healthcare professionals can access their implementation toolbox. The toolbox is tailored to their personal context based on the results of the 'Readinesstool'."
75711305|NCT00905086|Procedure|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
75711306|NCT00905086|Procedure|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
76038567|NCT03067207|Behavioral|MARS-A|The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
75403453|NCT05672004|Other|Implementation as usual|"First, healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting.~At the end of the training healthcare professionals are informed about the mandatory conditions to implement ProMuscle (champion, material, approval of management).~Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible. Results contain a graph of possible barriers for implementation in their practice.~Hereafter they will be instructed to start with implementation as usual."
75403454|NCT05607342|Drug|Osanetant|To evaluate the effect of Osanetant on the testosterone levels.
75403455|NCT05597904|Genetic|Genetic predisposition|Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
75403456|NCT05572242|Procedure|Premolar extraction and socked preservation with L-PRF|"Partially edentulous patients in need of a single-tooth extraction in the premolar region[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.~L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.~After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
75403457|NCT05572242|Procedure|Premolar extraction and socked preservation with Xenogenic bone and collagen membrane.|"Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.~In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.~The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .~After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
75403458|NCT05464992|Other|Additional CEST sequences during PET/MRI exam|CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
75403459|NCT05392296|Other|Power ball|experimental group getting the power ball training with conventional treatment.
75403460|NCT05392296|Other|isometric hand grip strengthening exercises|conventional treatment (isometric hand grip training exercises)
75403461|NCT05274828|Device|H7-Coil Deep TMS for CUD|The Study group will receive dTMS treatment three times a day for ten days.
75403462|NCT05194956|Procedure|Intraoral scan|An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.
75403463|NCT05194956|Procedure|Alginate impressions|Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.
75711307|NCT00921570|Drug|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
75711308|NCT00921570|Drug|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
75711309|NCT00926068|Drug|HO/03/03 10µg|
76038568|NCT03065881|Device|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV [1] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
75711310|NCT00926068|Drug|Placebo|
75403464|NCT04997616|Dietary Supplement|Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)|Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
75403465|NCT04594200|Behavioral|Audit and Feedback (A&F)|"In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing"
76038569|NCT05047575|Other|REASSURE|REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
76038570|NCT03065959|Drug|reldesemtiv|oral
76038571|NCT03065959|Drug|Placebo|oral
76038572|NCT05463939|Drug|Teclistamab|Teclistamab will be administered subcutaneously (SC).
76038573|NCT04993365|Biological|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
76038574|NCT04993365|Biological|Control Group|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
76038575|NCT03067363|Drug|MOR107|MOR107 solution for injection
76038576|NCT03067363|Drug|Placebo|Solution for injection manufactured to match MOR107 solution for injection
76038577|NCT03067363|Other|Low sodium diet|Diet designed to restrict sodium intake to 40 mmol/day
76038578|NCT05428813|Behavioral|art therapy techniques|Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
75550362|NCT06164054|Behavioral|Traditional therapy|Participants randomly assigned to the control group will receive rehabilitation treatment as per usual clinical practice. Specifically, patients will be directed to rehabilitation facilities according to standard clinical rehabilitation pathways. They will be assigned to a physiotherapist who will administer the rehabilitation treatment for the upper limb impairment. Patients in the control group will receive the same amount of rehabilitation for the recovery of upper limb impairment as the treatment group, which means 3 physiotherapy sessions lasting 1 hour 3 times a week for 4 weeks.
76038579|NCT05046561|Drug|STRI Formula|STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
76038580|NCT05046561|Drug|Placebo|Placebo oral capsule
75711311|NCT00905242|Drug|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
76038581|NCT05419219|Device|the multi-domain Tai Chi Digital therapy Software Application|regular Tai Chi exercise, 40 Hz gamma sound stimulation and 18 BPM breath control exercise
75711312|NCT02710890|Drug|Lacosamide|"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
76038582|NCT04447651|Other|Recommendation for treatment with immunotherapy|Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
76038583|NCT05370703|Behavioral|My A:care|Mobile application with Motivational messages
76038584|NCT05370703|Behavioral|Smart Coach|Mobile application with Motivational messages
76038585|NCT01364727|Drug|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
76038586|NCT02633215|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
76038587|NCT04990869|Dietary Supplement|Nicotinamide Riboside|The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
76038588|NCT04990869|Dietary Supplement|Placebo|Placebo
76038589|NCT05728177|Combination Product|Inhalation Aromatherapy|"Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care."
76038590|NCT01364649|Drug|Vortioxetine|Vortioxetine tablets
76038591|NCT01364649|Drug|Escitalopram|Escitalopram tablets
75711313|NCT00742950|Procedure|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
75711314|NCT00742950|Procedure|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
75711315|NCT00742950|Procedure|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
76038592|NCT01364649|Drug|Placebo|Vortioxetine Placebo-matching capsules
76038593|NCT03065569|Drug|Bupivacaine|16 mL of 0.125% bupivacaine
76038594|NCT05723419|Procedure|axillary block using 5 ml local anesthetics|ultrasoud guided axillary block
76038595|NCT03065491|Dietary Supplement|Combined nutraceutical|Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
76038596|NCT03065491|Other|Placebo|Oral administration: 1 tablet per day
76038597|NCT02588261|Drug|naquotinib mesilate|Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
75403478|NCT04493658|Diagnostic Test|Questionnaires|Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects
75550363|NCT06164041|Behavioral|The use of mobile applications promoted from the physical education classroom to improve adolescent health.|"Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken."
75550364|NCT06164015|Diagnostic Test|3D Ultrasound scan with power Doppler angiography|The study group and the control group will be offered a 3D ultrasound scan as a part of this trial.
76038598|NCT02588261|Drug|Erlotinib|Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
76038599|NCT02588261|Drug|Gefitinib|Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
76038600|NCT03065257|Procedure|Endoscopic Resection|Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
75711316|NCT05322642|Behavioral|UPA|UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
76038601|NCT05040633|Device|BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))|Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
76038602|NCT05040633|Other|Standard Exercise Therapy|Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
76038603|NCT05711407|Genetic|Gene Polymorphisms of MMP-8|Saliva Samples
76038604|NCT05286229|Drug|ABBV-383|Intravenous (IV) Infusion
76038605|NCT04426487|Drug|Progesterone|Intramusculer progesterone
76038606|NCT03797937|Other|Magnetic resonance imaging (MRI)|MRI scanner
76038607|NCT04989465|Biological|Investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection
75403479|NCT04493658|Diagnostic Test|Tear fluid sampling|Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.
75403480|NCT04493658|Diagnostic Test|Impression Cytology|Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
75550365|NCT06164002|Other|change in restoration material and margin design.|comparing two different materials and two different designs. use artificial intelligence in the prediction of follow up results
75711317|NCT05322642|Behavioral|Active control condition (Progressive Relaxation Training)|Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
75403481|NCT04421352|Drug|CS1001|"low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned."
75403482|NCT03861468|Other|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
75403483|NCT03729258|Drug|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
75403484|NCT03729258|Drug|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
75403485|NCT03593772|Behavioral|Mission Reconnect|This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
75403486|NCT03355170|Combination Product|Lansoprazole/Domperidone|Experimental
75403487|NCT03355170|Drug|Lansoprazole|Active comparator
75403488|NCT02819778|Procedure|usual care|
75403489|NCT02819778|Procedure|S100B|
75403490|NCT02538666|Biological|Nivolumab|
75403491|NCT02538666|Biological|Ipilimumab|
75403492|NCT02538666|Other|Placebo|
75403493|NCT02438358|Drug|LUM015|
75403494|NCT02438358|Device|LUM 2.6 Imaging Device|
75711318|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
75711319|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
75711320|NCT00605176|Drug|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
75711321|NCT04060290|Other|Observational study|Observational study of this study, no interventions involved
75403495|NCT02407236|Drug|Placebo IV|Placebo will be administered as intravenous infusion.
75403496|NCT02407236|Drug|Placebo SC|Placebo will be administered Subcutaneously.
75403497|NCT02407236|Drug|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
75403498|NCT02407236|Drug|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
75403499|NCT01893138|Other|Placebo|Placebo control is the vehicle solution used for the study product.
75403500|NCT01893138|Biological|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10^6 cells.
75403501|NCT00221598|Procedure|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
75403502|NCT05120076|Drug|Dexamethasone 4 Mg/mL Injectable Solution|s. arm/group description
75403503|NCT05120076|Drug|NaCl 0.9%|s. arm/group description
75403504|NCT05079204|Other|Intra oral scan|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.
75403505|NCT05079204|Other|No intervention|No intervention
75550366|NCT06163989|Drug|TheaLoz Duo Eyedrop|TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
75550367|NCT06163989|Drug|Saline Eyedrop|Saline 0.9% eyedrop is used as a control eyedrop and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
75403506|NCT05030844|Behavioral|IMB model based Diabetes Education and Motivational Interviewing|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
75403507|NCT04946916|Diagnostic Test|blood sample taken|Comparaison of Neurofilament light chain serum concentration between the arms
75403508|NCT04868760|Drug|Ipilimumab|Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
75403509|NCT04868760|Drug|IBI310|Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
75403510|NCT04865952|Procedure|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
76038608|NCT04989465|Biological|Control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd. 25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of light disodium phenol phosphate, sodium hydrogen phosphate and sodium chloride per injection
75403511|NCT04865952|Other|HA application|HA will be applied at the end of the surgical procedure, at the level of the vertical released incisions (VRIs) and over VRIs
75403512|NCT04803708|Biological|TP-102|One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10^9 plaque forming units per milliliter (PFU/mL).
75403513|NCT04651452|Behavioral|Value Affirmation|Participants will complete writing tasks regarding their personal values.
75403514|NCT04651452|Behavioral|Reflective Journaling|Participants will complete writing tasks regarding their least important values and discuss why they may be important to others. They will also describe aspects of daily life.
75403515|NCT04508166|Drug|Dexmedetomidine|Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
75403516|NCT04508166|Drug|Gamma-Hydroxybutyrate|Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory
76038609|NCT05557565|Drug|QL1706|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
76038610|NCT03066895|Device|BabyGentleStick|Experimental device.
75550368|NCT06163963|Diagnostic Test|Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer|This is a single arm interventional prospective study. Sentinel lymph node detection rate of the tracer injected in cervix (ICG- indocyanine green) before operation and the second tracer injected in uterine fundal subserosa (sterile charcoal black) at the start of operation are investigated. It is anticipated that additional tracer used in the uterine serosa may overcome the insufficiency (or increase the detection rate) of the standard single tracer injected in cervix for detection rate of sentinel lymph nodes, especially in paraaortic sentinel lymph nodes.
75550369|NCT06163950|Other|Fatigability assessment|An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
76038611|NCT03066895|Device|Standard Lancing Device|HMC standard of care.
76038612|NCT05040243|Other|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
75403517|NCT04508166|Drug|Placebo|Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
75403518|NCT04508166|Behavioral|Experimental Model Trauma Film|Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
75403519|NCT04444440|Drug|Ciprofloxacin|Fluoroquinolone antibiotic.
75403520|NCT04444440|Other|Placebo Pill|Placebo Pill
75403521|NCT04420026|Radiation|Interact Active Tracker|Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
75550370|NCT06163937|Other|Glucose as reference food|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75550371|NCT06163937|Other|Orange juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from orange juice, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
76038613|NCT05040243|Other|placebo acupoint application|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
75550372|NCT06163937|Other|Mixed fruit juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from mixed fruit juice (consisted of apple, orange, grape, and pomegranate), tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75550373|NCT06163911|Device|ECG|Routine care 12-lead electrocardiogram
75550374|NCT06163911|Device|Echocardiography|Routine care echocardiography
75550375|NCT06163898|Drug|Alnuctamab|Specified dose on specified days
75403522|NCT04309500|Behavioral|Personalized DAT Risk Disclosure Protocol|Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
75403523|NCT04279236|Other|Abbreviated Profile Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.
75403524|NCT04279236|Other|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.
75403525|NCT04279236|Other|Additional follow-up visit|There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
75403526|NCT04265196|Other|cognitive behavioral group therapy|A unique protocol that includes cognitive-behavioral psychological therapy with emphasis on coping with pain
76038614|NCT05697133|Other|SEMSTOP|This program has been developed based on Story Theory and will be implemented individually online. The session content, units and topics in the program are arranged according to the conceptual content and flow of the theory. The program has been created in a certain flow, based on the concepts of purposeful dialogue, connecting with itself and facilitating the theory.
75403527|NCT04265196|Other|Mindfulness-based group therapy|Unique protocol that includes mindfulness-based psychological therapy with emphasis on coping with pain
75403528|NCT04175964|Behavioral|ketogenic diet|The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
76038615|NCT05697133|Other|control|control grup
75403529|NCT04175964|Combination Product|caloric diet with Metformin|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.
75711322|NCT00926146|Behavioral|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
76038616|NCT04988217|Drug|Interferon-Alpha2B|Nebulized interferon alpha 2B
76038617|NCT04988217|Drug|Placebo|Nebulized placebo
76038618|NCT01359449|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
75403530|NCT04175964|Behavioral|caloric diet|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
75403531|NCT03678402|Device|PUP™ sock|The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
75403532|NCT03626532|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc."
75403533|NCT03626532|Behavioral|Lifestyle Education (LifeEd)|This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
76038619|NCT01359449|Biological|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
76038620|NCT01672723|Drug|Naltrexone|
76038621|NCT04443673|Dietary Supplement|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
76038622|NCT05037903|Behavioral|Cognitive-behavioral therapy|Cognitive and behavioral interventions aimed at increasing behavioral activation, and reducing procrastination and inattentive symptoms.
76038623|NCT05065593|Other|resistance and aerobic exercise|Resistive exercises allow loading the muscle under suitable conditions with various weights or resistances. In order to increase the level of physical fitness with the increase of muscle strength and bone mass in individuals, resistance exercises were preferred. Aerobic exercises, on the other hand, are a special type of exercise that develops both the musculoskeletal system and the cardiovascular system, which includes large muscle groups and should be performed for at least 20 minutes when the heart rate accelerates at certain rates. Aerobic exercise was preferred in order to increase cardiovascular endurance, accelerate fat burning and reduce fatigue.
76038624|NCT05065593|Other|physical activity recommendation|Patients will be informed about the importance of lifestyle change in disease management, walking training will be given to increase their physical activity level, and participants will be asked to follow a 45-minute walking program every day within their own means.
76038625|NCT05033145|Drug|AZVUDINE|AZVUDINE 5 tablets QD + standard treatment, for up to 14 days
76038626|NCT05033145|Drug|AZVUDINE placebo|5 tablets QD + standard treatment, for up to 14 days
76038627|NCT05031975|Drug|Irinotecan|Irinotecan 100 mg/smq intravenous infusion every 14 days
75403534|NCT03624270|Drug|Oral arsenic Trioxide, ATRA and ascorbic acid|Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
75403535|NCT03588468|Other|Electrophysiological biomarkers|Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
75403536|NCT03588468|Other|MRI biomarkers|T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
75711323|NCT00926146|Behavioral|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
75711324|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
75711325|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
76038628|NCT05031975|Drug|Temozolomide|Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
76038629|NCT05029947|Procedure|Microsurgical Clipping of Unruptured Intracranial Aneurysm|Microsurgical Clipping of Unruptured Intracranial Aneurysm
76038630|NCT02632747|Drug|Empagliflozin|Empagliflozin will be taken once daily
75403537|NCT03455088|Behavioral|Dialectical Behavioral Group Therapy|DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.
75403538|NCT03455088|Drug|Drug: fluoxetine|Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
75403539|NCT02481336|Other|Questionnaires|EORTC CIPN20 and EQ-5D-3L
75403540|NCT02481336|Procedure|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
75403541|NCT02481336|Genetic|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
75403542|NCT01597440|Drug|N-carbamylglutamate|"Active NCG & Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
75403543|NCT01597440|Other|Standard of Care|Standard of Care
75403544|NCT01598064|Dietary Supplement|GK#10|GK#10, 1 pack tid
75403545|NCT01598064|Drug|Placebo|Placebo 1 pack tid po
76038631|NCT02632747|Drug|Placebo (matching empagliflozin)|Placebo will be taken once daily
76038632|NCT02632747|Drug|ramipril|Ramipril will be taken once or twice daily
75711326|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
75711327|NCT00905320|Procedure|Metallic Fasteners and Sutures|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
76038633|NCT04217811|Other|No intervention|No intervention
76038634|NCT04217343|Diagnostic Test|Allosure/Allomap/Cytokines testing|All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
76038635|NCT04216797|Drug|Diazepam Tablets|Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.
76038636|NCT05029401|Drug|DMX-1002|Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)
76038637|NCT05029401|Drug|Placebo|Matching placebo to the IMP (DMX-1002)
76038638|NCT05029011|Device|BRAEBON VTS|The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours.
76038639|NCT05028855|Diagnostic Test|Cerebral autoregulation assessment|Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
76038640|NCT05025813|Drug|Pembrolizumab|Delivery of neo-adjuvant Pembrolizumab
75403546|NCT01600170|Drug|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
75403547|NCT01600170|Drug|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
75403548|NCT01600482|Device|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
75403549|NCT01600638|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
75403550|NCT01600950|Drug|LY2963016|Single 0.3 U/kg dose administered subcutaneously
75403551|NCT01600950|Drug|Lantus|Single 0.3 U/kg dose administered subcutaneously
75403552|NCT01603056|Biological|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
75403553|NCT01603056|Biological|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
75403554|NCT01604772|Drug|Akt Inhibitor MK2206|Given PO
75403555|NCT01604772|Other|Laboratory Biomarker Analysis|Correlative studies
75403556|NCT01605942|Drug|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
75550376|NCT06163898|Drug|Mezigdomide|Specified dose on specified days
75403557|NCT01605942|Drug|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
76038641|NCT04033237|Other|Very low nicotine content cigarettes|Cigarettes containing 0.4 mg nicotine/g tobacco
75403558|NCT01607112|Biological|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
75403559|NCT01607658|Drug|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
75403560|NCT01607658|Drug|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
75403561|NCT01607658|Drug|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
75711328|NCT00905320|Procedure|Metallic Fasteners Alone|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
75711329|NCT00926224|Device|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
75711330|NCT02538796|Other|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
76038642|NCT05064501|Diagnostic Test|spirometry|Lung function test: pre and post bronchodilator spirometry
76038643|NCT05064501|Other|Asthma control test|Asthma control test
76038644|NCT05064345|Drug|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
76038645|NCT05064345|Drug|Placebo|Palcebo
75403562|NCT01607658|Drug|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
75403563|NCT01608672|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
75403564|NCT01610154|Drug|Sitagliptin|Sitagliptin 100 mg QD for 12 weeks
75403565|NCT01611948|Drug|Aprepitant|125mg/day for 8 weeks
75403566|NCT01611948|Drug|Placebo|125mg/d placebo pill for 8 weeks
75403567|NCT01611948|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
75403568|NCT01612494|Drug|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
75403569|NCT01612494|Other|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
75403570|NCT01612884|Drug|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
75403571|NCT01612884|Drug|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
75403572|NCT01614210|Drug|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
75403573|NCT01614210|Procedure|Breast cancer surgery|Breast cancer surgery
75403574|NCT01616082|Behavioral|Low Calorie Diet (LCD)|A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.
75550377|NCT06163898|Drug|Dexamethasone|Specified dose on specified days
75550378|NCT06163885|Other|Stoma care education with flipped classroom|Flipped classroom model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
75403575|NCT01616082|Drug|Phentermine|"Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
75550379|NCT06163885|Other|Stoma care education with peer-supported education model|Peer-supported education model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
75550380|NCT06163872|Behavioral|survey study|survey study
75550381|NCT06163833|Drug|Mesenchymal stromal cell low dosage-80*10^6 cells|"MSCs have to be administered at the dosage of 80*10^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
75550382|NCT06163833|Drug|Mesenchymal stromal cell low dosage-160*10^6 cells|"MSCs have to be administered at the dosage of 160*10^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
75550383|NCT06163833|Other|Placebo-storage solution|Placebo has to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. It has to be diluted 1:2 in a saline solution for a total of 36mL.
75550384|NCT06163807|Drug|Antiasthmatic|real-life
75871520|NCT03146026|Behavioral|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
76038646|NCT05623735|Other|Instrument Assisted Soft Tissue Mobilization Group While Lying Prone|"Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
75403576|NCT01616160|Drug|mometasone furoate|2 sprays/nostril BID
75403577|NCT01618422|Other|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
75550385|NCT06163781|Device|Blood culture prediction tool|Machine learning based predicition tool
75550386|NCT06163768|Procedure|Insulin resistance|Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
75550387|NCT06163755|Drug|Methylprednisolone 40 MG Injection|Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
75550388|NCT06163729|Drug|Camrelizumab+Apatinib+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy|Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Apatinib, 250mg, Po, d1 d2, q3w Durg ：Oxaliplatin, 130mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks
75550389|NCT06163716|Behavioral|Multidomain intervention (MD-Int) group|The MD-Int program included: 1) individual follow-up visits every three months for cardiovascular risk factor monitoring and nutritional counselling with primary health care providers; 2) two nutritional workshops led by a nutritionist; 3) 20 hours of cognitive stimulation delivered through group sessions and 4) 40 hours of individual cognitive training exercises. Participants in the MD-Int group received recommendations to practice 2 to 6 hours of physical exercise per week and get involved in sports activities. Social stimulation was promoted through group activities.
75871521|NCT02342392|Drug|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
75403578|NCT01618422|Other|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
75403579|NCT01619982|Drug|Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is > 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is > 8 hours in duration.
75403580|NCT01619982|Drug|Cefazolin 30 mg/kg body weight|"Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery."
75403581|NCT01620216|Other|Antitumor Drug Screening Assay|Undergo pre clinical kinase inhibitor activity screening
75403582|NCT01620216|Drug|Dasatinib|Given PO
75403583|NCT01620216|Drug|Idelalisib|Given PO
75403584|NCT01620216|Other|Laboratory Biomarker Analysis|Correlative studies
75403585|NCT01620216|Drug|Pacritinib|Given PO
75403586|NCT01620216|Other|Pharmacological Study|Correlative studies
75403587|NCT01620216|Drug|Ponatinib|Given PO
75403588|NCT01620216|Drug|Ponatinib Hydrochloride|Given PO
75403589|NCT01620216|Drug|Ruxolitinib|Given PO
75403590|NCT01620216|Drug|Sorafenib|Given PO
75403591|NCT01620216|Drug|Sorafenib Tosylate|Given PO
75403592|NCT01620216|Drug|Sunitinib|Given PO
75403593|NCT01620216|Drug|Sunitinib Malate|Given PO
75403594|NCT01621230|Drug|Epidural Bupivacaine plus fentanyl|The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.
75403595|NCT01621230|Drug|Epidural fentanyl|The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
75403596|NCT01621776|Drug|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
75403597|NCT01621776|Drug|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
75403598|NCT01621776|Drug|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
75403599|NCT01622010|Behavioral|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
75403600|NCT01622010|Other|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
75403601|NCT01622010|Device|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
75403602|NCT01624350|Device|Permacol collagen paste|Collagen paste intended to reinforce soft tissue where filling is required such as to repair fistulas, including anal and rectal fistulas.
75403603|NCT01624740|Device|Low Rate Stimulation|Stimulation was given at a rate of 2 Hz.
75403604|NCT01624740|Device|High Rate Stimulation|Stimulation was given at a rate of 1200 Hz.
75871522|NCT02342236|Device|cemented or cementless type of hip prothesis|
75403605|NCT01627002|Biological|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
75403606|NCT01627002|Other|Placebo|Subcutaneous
75871523|NCT02342158|Procedure|biopsy or surgical sampling|
75871524|NCT02342158|Other|blood sampling|
75403607|NCT01628016|Behavioral|a word dot-probe task for training procedure|In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
75403608|NCT01628718|Behavioral|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
75403609|NCT01628718|Behavioral|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
75711331|NCT02538796|Other|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
75711332|NCT02538796|Other|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
75403610|NCT01630200|Drug|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
75403611|NCT01630200|Drug|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
75403612|NCT01631682|Drug|Propranolol|40mg single pill
75403613|NCT01631682|Behavioral|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
75403614|NCT01631682|Drug|Mifepristone|1800mg, 9 tablets
75403615|NCT01631682|Drug|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
75403616|NCT01633398|Genetic|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
75403617|NCT01634256|Dietary Supplement|Placebo|Placebo(3.0g/day)
75403618|NCT01634256|Dietary Supplement|Fermented turmeric|Fermented turmeric(3.0g/day)
75403619|NCT01635504|Biological|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
75403620|NCT01636206|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: ~1 year
75403621|NCT01636206|Drug|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: ~1 year
75403622|NCT01636284|Biological|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
75403623|NCT01638468|Device|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
75403624|NCT01639872|Drug|Clozapine|Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
75403625|NCT01639872|Drug|Risperidone|Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
75403626|NCT01640340|Drug|aprepitant|Given by mouth
75403627|NCT01640340|Drug|palonosetron hydrochloride|Given IV(intervenous infusion)
75403628|NCT01640340|Drug|ondansetron|Given PO
75403629|NCT01640340|Drug|dexamethasone|Given PO
75403630|NCT01641042|Biological|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
75403631|NCT01641120|Drug|Avonex|Intramuscular injection administered using 25 gauge or 30 gauge needle
75403632|NCT01642056|Drug|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
75711333|NCT02538796|Other|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
75711334|NCT00905398|Drug|Nilotinib|400mg, Oral, Bid, Daily for three years
75711335|NCT00905710|Procedure|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
75711336|NCT00926302|Drug|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
75711337|NCT00926302|Drug|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
75711338|NCT00907036|Biological|alemtuzumab|
75403633|NCT01642056|Drug|Placebo|
75403634|NCT01643382|Drug|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
75403635|NCT01643382|Drug|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
75403636|NCT01643616|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
75403637|NCT01643616|Drug|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
75403638|NCT01643616|Drug|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
75403639|NCT01643616|Drug|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
75403640|NCT01643616|Device|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
75711339|NCT00907036|Biological|donor lymphocytes|
75711340|NCT00907036|Drug|cyclosporine|
75403641|NCT01643616|Device|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
75403642|NCT01644240|Drug|TD-8954|Intravenous infusion
75403643|NCT01644240|Drug|Placebo - saline|Intravenous infusion
75403644|NCT01644396|Biological|Adalimumab|
75403645|NCT01645098|Drug|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
75403646|NCT01645098|Drug|Dexmedetomidine|0.5 mcg/kg/hr IV
75403647|NCT01646346|Radiation|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
75550390|NCT06163677|Biological|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
75550391|NCT06163664|Behavioral|Use of chatGPT for 1 week|Use of chatGPT for 1 week
75711341|NCT00907036|Drug|fludarabine phosphate|
75711342|NCT00907036|Drug|melphalan|
75711343|NCT00907036|Procedure|allogeneic hematopoietic stem cell transplantation|
75711344|NCT02538406|Other|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
75711345|NCT00905788|Procedure|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
75711346|NCT00927238|Device|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
75711347|NCT00927238|Other|Lumbar fusion surgery|Lumbar fusion surgery
75711348|NCT00926614|Drug|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
75711349|NCT00926614|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
75711350|NCT00694356|Biological|Dalotuzumab|IV infusion
75711351|NCT00926692|Other|Blood draw|Subject will have blood draw.
75711352|NCT00907114|Drug|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
75403648|NCT01647438|Behavioral|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
75711353|NCT00907114|Drug|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
75711354|NCT00692406|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
75403649|NCT01647438|Other|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
75403650|NCT01648452|Biological|NT-501 CNTF-releasing implant|20 ng/day released into the eye
75403651|NCT01648530|Other|No Treatment|No Treatment
75403652|NCT01648920|Device|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
75403653|NCT01650324|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
75403654|NCT01650324|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
75403655|NCT01650402|Other|Anti-hypertensive therapy to SBP 130 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
75403656|NCT01650402|Other|Anti-hypertensive therapy to SBP 145 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
75403657|NCT01651104|Biological|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
75403658|NCT01651806|Drug|Tranexamic Acid standard dose|Uniform 1 gram dosing
75403659|NCT01651806|Drug|Females Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
75403660|NCT01651806|Drug|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
75403661|NCT01651806|Drug|Males Weighted Dose TA|Weighted dose--20mg/kg of the drug will be given
75403662|NCT01652040|Device|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
75403663|NCT01652040|Drug|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
75403664|NCT01652976|Drug|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
75403665|NCT01652976|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
75403666|NCT01653288|Behavioral|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
75403667|NCT01654068|Radiation|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
75403668|NCT01598922|Behavioral|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
75403669|NCT01656252|Drug|Phase I- Cytarabine & Eltrombopag|"Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.~One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
75403670|NCT01656252|Drug|Phase II- Sequence A|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
75403671|NCT01656252|Drug|Phase II- Sequence B|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
75403672|NCT01660230|Biological|3K3A-APC, diluted in 0.9% sodium chloride in water|
75403673|NCT01660230|Drug|0.9% NaCl in water|
75403674|NCT01660698|Dietary Supplement|Maltodextrin|maltodextrin powder
75403675|NCT01660698|Dietary Supplement|Probiotic|probiotic blended in maltodextrin powder
75403676|NCT01661088|Drug|FOLFIRINOX|"Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1."
75403677|NCT01661088|Radiation|Intensity-modulated radiotherapy (IMRT)|50.0Gy in 2.0Gy per fraction
75403678|NCT01661088|Procedure|Surgical Exploration|Patients without metastatic disease will be offered surgical exploration.
75403679|NCT01661712|Device|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
75403680|NCT01661712|Device|Sham stimulation|Sham stimulation for one night (no electrical stimulation)
75711355|NCT00927316|Biological|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml."
75711356|NCT03889938|Diagnostic Test|Serum and urinary assessment|Assess bioactive lipid mediators in blood and biopyrins in urine
75403681|NCT01661946|Drug|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
75403682|NCT01661946|Drug|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
75403683|NCT01662882|Drug|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
75403684|NCT01662960|Behavioral|Mirror therapy|A home-based therapy involving mirrored visual feedback
75403685|NCT01662960|Behavioral|Divider therapy|A home-based therapy involving removed visual feedback.
75403686|NCT01663272|Drug|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
75403687|NCT01663272|Drug|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
75403688|NCT01667250|Device|GammaCore Active Device|
75403689|NCT01667250|Device|GammaCore Sham Device|
75403690|NCT01667406|Drug|Kisspeptin 1.6nmol/kg|single kisspeptin dose 1.6 nmol/kg subcutaneously
75403691|NCT01667406|Drug|Kisspeptin 3.2nmol/kg|single kisspeptin dose 3.2 nmol/kg subcutaneously
75403692|NCT01667406|Drug|Kisspeptin 6.4nmol/kg|single kisspeptin dose 6.4 nmol/kg subcutaneously
75403693|NCT01667406|Drug|Kisspeptin 9.6nmol/kg|single kisspeptin dose 9.6 nmol/kg subcutaneously
75403694|NCT01667406|Drug|Kisspeptin 12.8nmol/kg|single kisspeptin dose 12.8 nmol/kg subcutaneously
75403695|NCT01667406|Drug|Kisspeptin 9.6 nmol/kg double|kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
75403696|NCT01667406|Drug|Kisspeptin 9.6 nmol/kg + saline|kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
75403697|NCT01667796|Dietary Supplement|Vitamin D3|
75403698|NCT01668030|Drug|Enzymatic agent|Enzymatic agent
75403699|NCT01668030|Drug|Bacitracin|
75403700|NCT01669434|Drug|ACEI continuation|These chronic medications will be taken without interruption preoperatively.
75711357|NCT03415464|Other|Exercise|neuromuscular training
75711358|NCT03384108|Other|5-13C-Glutamine|Intravenous infusion of 5-13C-Glutamine
75403701|NCT01669434|Drug|ACEI omission|Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
75403702|NCT01670760|Device|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
75403703|NCT01673022|Drug|IC Green|IC Green
75403704|NCT01673256|Device|SJM Confirm ICM|
75403705|NCT01673568|Device|ETO garments|patients wearing abdominal binder for 7 days postoperatively
75403706|NCT01673802|Drug|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
75403707|NCT01675830|Device|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
75403708|NCT01676298|Device|Spartan FRX CYP2C19 Test System|
75403709|NCT01676532|Other|Students attending SBHC|School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
75403710|NCT01677312|Procedure|Pancreatic Biopsy|A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
75403711|NCT01677312|Procedure|Histological Samples|The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
75403712|NCT01678794|Drug|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
75403713|NCT01678794|Drug|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
75403714|NCT01679028|Drug|T89 Group A|150mg single dose on day 1
75403715|NCT01679028|Drug|Placebo Group A|150mg single dose
75550392|NCT06163638|Behavioral|GRANDPACT Project|To investigate whether grandparents and grandchildren are more co-physically active, have a better cognitive function, psychosocial well-being, quality of the family relationship and expectations regarding aging and motor competence due to the intervention, 2 arms were created to test the effets.
75711359|NCT03384108|Other|Bone marrow aspiration|Bone marrow aspiration of bone marrow aspirate
75711360|NCT02564094|Drug|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
75711361|NCT00745914|Drug|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
75711362|NCT00745914|Drug|Placebo comparator|Placebo comparator
75711363|NCT00746070|Other|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
75403716|NCT01679028|Drug|Placebo Group B|300mg single dose
75403717|NCT01679028|Drug|T89 Group B|300mg single dose
75403718|NCT01679028|Drug|Placebo Group C|225mg bid
75403719|NCT01679028|Drug|T89 Group C|225mg bid
75403720|NCT01680666|Procedure|central line placement|central line placement
75403721|NCT01680666|Device|Ultrasound|Ultrasound guided central venous access
75403722|NCT01680900|Drug|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
75403723|NCT01680900|Drug|placebo capsules|placebo capsules matched to drug capsules.
75403724|NCT01682538|Drug|Nitisinone, capsule|
75403725|NCT01682538|Drug|Nitisinone, suspension|
75403726|NCT01684020|Biological|ARTISS human fibrin sealant|
75403727|NCT01684410|Biological|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
75403728|NCT01684410|Biological|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
75403729|NCT01684410|Biological|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
75403730|NCT01684566|Device|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
75403731|NCT01684566|Other|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
75403732|NCT01686750|Behavioral|Integrated care centers|
75550393|NCT06163625|Device|Repetitive Transcranial Magnetic Stimulation|For those with depression where medication and psychotherapy have limited benefit, repetitive transcranial magnetic stimulation (rTMS) is an effective treatment. rTMS is a treatment that involves stimulating certain areas of the brain with magnetic field pulses. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region. This can be helpful in treating some kinds of psychiatric and neurological disorder, including MDD.
75711364|NCT00746148|Other|Reflexology|10 weekly sessions of 45 minutes each
75711365|NCT00746226|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10^9 CFU of a combination of L. acidophilus and B. lactis
75403733|NCT01688310|Procedure|Gomco Clamp with Tissue Adhesive|"According to WHO (2011), the Gomco clamp has …an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC."
75403734|NCT01688310|Procedure|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
75403735|NCT01688856|Device|Electrical Stimulator|"The 12-week treatment period consists of two components:~Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes."
75403736|NCT01689324|Biological|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
75403737|NCT01692756|Drug|Kenalog or placebo|
75403738|NCT01692756|Drug|Kenalog then Placebo|
75403739|NCT01692756|Drug|Kenalog|
75403740|NCT01692756|Drug|Placebo|
75403741|NCT01695330|Drug|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
75403742|NCT01698528|Device|Tablet Computer|
75403743|NCT01698684|Drug|Placebo|One dose 15 minutes before attempting intercourse
75711366|NCT00746226|Biological|Placebo|"Microcrystalline cellulose~As capsule which could be opened"
75550394|NCT06163625|Behavioral|Research Interview, Questionnaires|"Research Interview: A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 30 minutes.~Research Questionnaires: A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. Questionnaires will be completed via pen and paper at each visit. These questionnaires will take approximately 90 minutes to complete."
75871525|NCT02342080|Other|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
75871526|NCT02342080|Device|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
75403744|NCT01698684|Drug|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
75403745|NCT01698684|Drug|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
75403746|NCT01699542|Device|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
75403747|NCT01699542|Device|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
75403748|NCT01699698|Other|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
75403749|NCT01701024|Drug|ACYC|ACYC active, topically applied to the face for 12 weeks
75403750|NCT01701024|Drug|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
75403751|NCT01701102|Procedure|Mepivacaine (24 mg) plus fentanyl|Mepivacaine (24 mg) and fentanyl (10 µg)
75403752|NCT01701102|Procedure|Mepivacaine (27 mg) plus fentanyl|Mepivacaine (27 mg) and fentanyl (10 µg)
75403753|NCT01701102|Procedure|Mepivacaine (30 mg) plus fentanyl|Mepivacaine (30 mg) and fentanyl (10 µg)
75403754|NCT01701102|Procedure|Mepivacaine|Mepivacaine 37.5 mg
75403755|NCT01701414|Drug|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
75550395|NCT06163625|Behavioral|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes, and there will be a recovery period for 40 minutes. The participant will be given instructions about these tasks outside of the scanner. This brain scan will happen at St. Michael's Hospital.
75871527|NCT05764434|Diagnostic Test|Magnetic Resonance Imaging|Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)
75550396|NCT06163625|Biological|Saliva Samples|The participant will be asked to provide six 1mL saliva samples during the MRI scan and recovery period so that the investigators can measure molecular markers associated with depression. In order to provide the sample, the investigators will collect their saliva using a cotton swab and test tube. Each sample should take no more than 5 minutes.
75550397|NCT06163612|Behavioral|Clinical Interview|A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 1 hour.
75871528|NCT05462964|Behavioral|Pacifiers Group (İntervention Group 1)|Camera recording was started 2 minutes before OGT placement and only a pacifier was given to the newborn. After the pacifier in the OGT intervention group was placed in the mouth of the given baby in the form of leaking from the mouth, it was inserted by advancing the baby's swallowing reflex from the esophagus to the stomach. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.
75403756|NCT01701414|Drug|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
75403757|NCT01703598|Device|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
75403758|NCT01703598|Procedure|DBS surgery|Placement of DBS electrodes
75403759|NCT01706952|Drug|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
75403760|NCT01706952|Drug|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
75403761|NCT01707108|Device|Dental Implant (MIS Technologies)|MIS Technologies Ltd. C1 Dental implants
75403762|NCT01707420|Drug|Gabapentin|The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
75403763|NCT01707420|Drug|liquid placebo|Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
75403764|NCT01707654|Device|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
75403765|NCT01708122|Drug|Fentanyl|100 mcg in 1 mL intranasal spray
75403766|NCT01708122|Drug|saline|Sodium Chloride 0.9% intranasal spray
75403767|NCT01708278|Drug|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
75403768|NCT01708278|Other|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
75403769|NCT01708590|Drug|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
75403770|NCT01708590|Drug|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
75403771|NCT01708590|Drug|placebo|Placebo administered subcutaneous (SC)
75403772|NCT05711004|Behavioral|Education via SMS|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
75403773|NCT05710458|Device|25 gauge 20,000 cpm Hypervit Dual Blade|Vitrectomy blade with increased cutting rate to 20,000 cut/min
75403774|NCT05710458|Device|25 gauge 10,000 cpm Ultravit Vitrectomy Cutter|Existing Vitrectomy blade with cutting rate 10,000 cut/min
75403775|NCT05710302|Other|Investigation of the diagnostic accuracy of EHMRG risk score in patients with acute heart failure|Prospective validation of the EHMRG score in patients with acute heart failure in the emergency department
75403776|NCT05710146|Drug|Tranexamic acid|1 injection of 15mg/kg of TXA in 100mL of normal saline
75403777|NCT05710146|Drug|Placebo|1 injection of 100mL of normal saline
75550398|NCT06163612|Behavioral|Clinical Questionnaires|A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. If the participant opts to complete these questionnaires at home, they will be emailed them within 24 hours of this visit. These questionnaires will take approximately 1-2 hours.
75550399|NCT06163612|Other|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes.
75550400|NCT06163612|Behavioral|Behavioural Games|The participant will be asked to complete two behavioural games inside the scanner. One of these games includes a monetary payout. They will be given instructions about these tasks outside of the scanner.
76038647|NCT05623735|Other|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
75403778|NCT05710068|Device|RF Microneedle|Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
75403779|NCT05710068|Drug|Combination cream|5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
75403780|NCT05709522|Behavioral|Neurocognitive tools|Neurocognitve and psychological tools
75403781|NCT05706636|Drug|oral mini pulse|5mg / week oral dexamethasone
75403782|NCT05706636|Drug|Topical cream|topical fluticasone cream for body lesions and topical tacrolimus for face lesions
75403783|NCT05706636|Device|targeted phototherapy|twice weekly targeted excimer light sessions
75403784|NCT05703438|Other|Nutritionally balanced low-calorie diet|Dietary interventions were given with a calorie deficit of 500-600 kcal from the participants' usual daily intake.
75403785|NCT05683548|Drug|REP 2139-Mg|REP 2139-Mg is the magnesium chelate complex of REP 2139
75403786|NCT05683548|Drug|Tenofovir Disoproxil Fumarate|
75403787|NCT05683548|Drug|Pegylated interferon alpha2a|
75403788|NCT05661942|Drug|Calcium pre-treatment|The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.
75550401|NCT06163586|Other|Neonatal Touch and Massage Therapy|Structured touch and massage therapy performed by certified providers.
75711367|NCT00396331|Drug|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2*10^6 CD34+ cells/kg were collected.
75403789|NCT05661942|Other|No Intervention|Placebo/ no calcium pre-treatment.
76038648|NCT04421547|Drug|Letrozole 2.5mg|This study will investigate the role of Letrozole in patients affected by heavily pretreated platinum resistant ovarian cancer, compared to standard treatment.
76038649|NCT04421547|Drug|Standard single agent chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
76038650|NCT03910075|Behavioral|I-ACQUIRE - High Dosage|Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
75403790|NCT05648214|Drug|ALN-PNP|Solution for subcutaneous (SC) injection
75403791|NCT05648214|Drug|Placebo (PB)|matching placebo, solution for SC injection
75403792|NCT05647824|Device|Capillary Testing|Testing Contour Fit BGMS with capillary blood
76038651|NCT03910075|Behavioral|I-ACQUIRE - Moderate Dosage|Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
75403793|NCT05647824|Device|Alternative Site Testing (AST)|Testing Contour Fit BGMS using blood from alternative site
75403794|NCT05647824|Device|Venous Testing|Testing Contour Fit BGMS with venous blood
75403795|NCT05641740|Device|Single-session of Radiofrequency|"The experimental group continue with their usual conservative and pharmacological treatment and will receive a single-session of monopolar dielectric capacitive radiofrequency in their hands. An Biotronic Advance Develops® (ABD-S25v) with a carrier wave frequency of 800-900 KHz of 850 KHz will be used. Patients will be placed in a seated position, with the forearms supinated and resting on a wooden table. An almond oil conductor will be applied to the hands. The application will be carried out with a circular head of 5 cm2 and for a total of 10 minutes on each of the palms of the hands.~They will be evaluated at baseline and post-session."
75403796|NCT05641740|Device|Control Placebo single-session of Radiofrequency|"The control placebo group continue with their usual conservative and pharmacological treatment and will receive a placebo single-session of radiofrequency. This group will follow the same protocol and treatment time, but they will receive a placebo treatment (the device remains in paused mode), so that radiofrequency will not be applied.~They will be evaluated at baseline and post-session."
75403797|NCT05639010|Device|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
76038652|NCT03910075|Behavioral|Usual & Customary Treatment (U&CT)|Children in this group will receive the same U&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
76038653|NCT05061771|Drug|nomacopan (rVA576)|Nomacopan an inhibitor of complement C5 and LTB4
76038654|NCT05061771|Other|Placebo|Placebo
76038655|NCT05061069|Diagnostic Test|cervical vestibular evoked myogenic potentials (cVEMP)|cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
75403798|NCT05639010|Device|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
75403799|NCT05636436|Biological|Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
75403800|NCT05636436|Biological|High Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
75403801|NCT05636436|Biological|Low dose adjuvant|0.5 mL per dose, containing low dose MA105 adjuvant.
75403802|NCT05636436|Biological|High dose adjuvant|0.5 mL per dose, containing high dose MA105 adjuvant.
75550402|NCT06163573|Biological|N-TEC|Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.
75550403|NCT06163573|Biological|Platelet rich plasma|"Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks.~Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks."
75403803|NCT05636436|Biological|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
75403804|NCT05636436|Biological|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
75403806|NCT05463354|Biological|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
75403807|NCT05463354|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
75403808|NCT05449470|Device|CDSS|A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction
75403809|NCT05449470|Device|Patient Portal|A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
75403810|NCT05293548|Biological|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm
75403811|NCT05293548|Biological|Inactivated COVID-19 vaccine (Vero cells)|Biological/Vaccine: Inactivated COVID-19 vaccine (Vero cells) Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
75550404|NCT06163560|Device|"Smartphone app Happy Baby HK"|"Happy Baby HK will provide developmental stage, developmental aspects, parenting videos and cartoon images created for new mothers."
75550405|NCT06163560|Device|Family Health Service parenting booklet|The parenting booklet is publicly available and provides brief caretaking tips for mothers with children under 3 years of age.
75550406|NCT06163547|Radiation|MMA embolization|Middle meningeal artery embolization
75403812|NCT05157360|Drug|HAT|hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
75403813|NCT05157360|Drug|Placebo|normal saline solution
75403814|NCT05136066|Other|massage with peppermint oil|Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
76038656|NCT03885583|Procedure|thoracic epidural block|thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound
75403815|NCT04988412|Dietary Supplement|Investigational product 1|Test group 1 will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
75403816|NCT04988412|Dietary Supplement|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 12 weeks.
75403817|NCT04988412|Dietary Supplement|Investigational product 2|Test group 2 will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
75550407|NCT06163508|Drug|Q-Cells®|Long term observational study of patients who received 1 of 3 different amounts of Q-Cells®.
75550408|NCT06163391|Drug|SOT201|intravenous infusion
75403818|NCT04988412|Dietary Supplement|Investigational product 3|Test group 3 will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
75403819|NCT04943874|Device|Technology Based Intervention Group 1|In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
76038657|NCT03885583|Procedure|paravertebral block|paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
75403820|NCT04943874|Device|Technology Based Intervention Group 2|Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
75403821|NCT04676802|Drug|NSAID capsules|1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
75403822|NCT04676802|Drug|Opioid capsule|1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
75403823|NCT04627896|Device|Katty focal therapy|Microwave ablation with TATO3 generator (Katty system) under guidance of ultrasound/mpMRI fusion image device Trinity
75403824|NCT04174482|Procedure|morphological and functional evaluation of adult flat foot|Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
75403825|NCT03979560|Other|Intervention|Nutritional support in seven sessions spread over three months, combined with an adapted physical activity intervention (APA), also at a frequency of seven sessions spread over three months, or fourteen home sessions.
75403826|NCT03828708|Other|Iron in infant formula|Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
75403827|NCT03671304|Device|Fitbit Versa|"Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days."
75403828|NCT03447990|Drug|MYK-491|Single Ascending Dose and Multiple Ascending Dose of MYK-491
75403829|NCT03447990|Drug|Placebo|Single Ascending Dose and Multiple Ascending Dose of placebo
75403830|NCT03032640|Other|Oral Glucose Tolerance Test (OGTT)|Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
75403831|NCT03032640|Other|Assessment of dietary compliance|Assessment of consumption of non-caloric artificial sweeteners
75403832|NCT03032640|Other|Stool sampling|Subjects will provide a stool sample.
75403833|NCT03032640|Other|Sodium Saccharin|Subjects in group 1 and group 3 will be provided with sodium saccharin.
75403834|NCT03032640|Other|Placebo|Subjects in group 2 will be provided with placebo.
75403835|NCT03032640|Other|Lactisole|Subjects in group 3 and group 4 will be provided with lactisole.
75403836|NCT01376778|Drug|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
75403837|NCT01376778|Other|Placebo|The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
76038658|NCT03066817|Drug|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
76038659|NCT03066817|Drug|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
76038660|NCT05060913|Drug|EMLA Cream|Effect of 5% Emla cream on pricking pain measured on VAS scale.
76038661|NCT05060913|Drug|Benzocaine Gel|Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
76038662|NCT05060367|Dietary Supplement|Liposomal multivitamin/mineral|Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.
75403838|NCT01309074|Drug|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
75403839|NCT01309074|Drug|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
75403840|NCT01074294|Drug|OPDC-34712|OPDC-34712 tablets, daily, Orally.
75403841|NCT01074294|Drug|Placebo|Matching-placebo tablets, daily, Orally.
75403842|NCT01074294|Drug|Stimulant Therapy|Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
75403843|NCT01074138|Drug|KX2-391|KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
75403844|NCT00951132|Drug|rosuvastatin|10mg tablets, once daily in three months
75403845|NCT00951132|Drug|Placebo|tablet, once daily, three months
75403846|NCT01710306|Behavioral|Nurse Care Manager (NCM)|Nurse care manager interventions with telephone implemented shared decision making protocol compared to outreach as usual OEF/OIF/OND outreach.
75403847|NCT01713660|Device|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
75403848|NCT01715064|Behavioral|Exercise|1 hour of moderate-intensity exercise
75403849|NCT01716468|Other|Ketogenic Diet|modified ketogenic diet
75403850|NCT01717014|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
75403851|NCT01717872|Device|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
75403852|NCT01718028|Other|Propylene glycol 0.6% ocular emulsion|
75550409|NCT06163209|Diagnostic Test|Nasal Ultrasonography|"Ultrasonography of the external nose will be performed with the use of a high-resolution transducer (Clarius L20HD3 8-20 MHz) and a 3mm-thick disposable gel pad, according to the following protocol:~Sagittal plane, along the most prominent part of nasal dorsum.~Transverse plane, level of nasion.~Transverse plane, level of intercanthal line.~Transverse plane, level of rhinion.~Along inferior border of the right nasal bone.~Along inferior border of the left nasal bone.~Along medial part of the right orbital rim below frontomaxillary suture.~Along medial part of the right orbital rim below frontomaxillary suture.~Along the line connecting right frontomaxillary suture and the tip of the nose.~Along the line connecting left frontomaxillary suture and the tip of the nose.~At each location the transducer position will be adjusted until it is held perpendicular to the bone surface and a single image will be saved for further assessment."
75550410|NCT06163209|Diagnostic Test|Computed Tomography Scan of the Face|"A standard computed tomography scan of the face will be performed and the following areas will be assessed by an experienced radiologist:~Bony part of the nasal septum~Left nasal bone - part proximal to the intercanthal line~Right nasal bone - part proximal to the intercanthal line~Left nasal bone - part distal to the intercanthal line~Right nasal bone - part distal to the intercanthal line~Frontal process of the left maxilla~Frontal process of the right maxilla"
75403853|NCT01718028|Other|Sodium chloride 0.9% saline solution|
75550411|NCT06158867|Device|FMD WK|micro-needle patches containing active anti-wrinkle ingredients
75403854|NCT01719900|Dietary Supplement|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
75403855|NCT01719900|Dietary Supplement|Control|Control biscuit with no yellow pea hull fibre.
76038663|NCT05060367|Dietary Supplement|Standard multivitamin/mineral|Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
75403856|NCT01721226|Device|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
75403857|NCT01721226|Other|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
75403858|NCT01721460|Drug|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
76038664|NCT05059821|Biological|Peptide cancer vaccine|Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
76038665|NCT05165251|Drug|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET QD
75403859|NCT01722318|Drug|Plecanatide|
75403860|NCT01722318|Drug|Placebo|
75403861|NCT01722552|Behavioral|adherence feedback|
75403862|NCT01722552|Behavioral|standard of care|
75403863|NCT01723722|Drug|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
75403864|NCT01723722|Drug|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
75403865|NCT01728636|Drug|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
75403866|NCT01729338|Drug|Velcade|Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles [10,12,14, etc.]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
75403867|NCT01729338|Drug|Cyclophosphamide|Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
75403868|NCT01729338|Drug|Revlimid|"Lenalidomide (odd cycles [9,11,13, etc.]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.~Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately."
75550412|NCT06158412|Drug|All-trans Retinoic Acid in combination with the KPD Regimen|"Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~The last ATRA dose will be given in the evening on the day of carfilzomib administration.~Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~Pomalidomide 4mg orally daily, d1-21;~Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; >75 years: 20 mg/day."
76038666|NCT05165251|Drug|Amlodipine 5mg|amlodipine 5mg QD
75403869|NCT01729494|Drug|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
75550413|NCT06158399|Drug|Azacitidine in combination with R-CHOP|"Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5"
76038667|NCT05165251|Other|Lifestyle intervention|Lifestyle intervention
76038668|NCT04209075|Dietary Supplement|Biomebliss|BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.
75403870|NCT01729494|Drug|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
75403871|NCT01729494|Drug|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
75403872|NCT01729494|Drug|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
75403873|NCT01729494|Drug|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
75403874|NCT01729494|Drug|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
75403875|NCT05317338|Behavioral|Group-based exercise training during hospitalization|Multicomponent exercises for 5-7 days with acutely hospitalized older.
75403876|NCT05317260|Drug|Antiviral Agents|The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
75403877|NCT05316948|Other|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients attending psychiatry study care during the month of the assessment.
75403878|NCT05316870|Behavioral|Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions|Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
76038669|NCT04209075|Drug|Metformin|Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.
76038670|NCT04209075|Dietary Supplement|Placebo|Placebo Comparator
76038671|NCT05151601|Dietary Supplement|Experimental|2 x sachets per day
76038672|NCT05151601|Other|Placebo|2 x sachets per day
76038673|NCT04433221|Biological|Multiple sarcoma-specific CAR-T cells and sarcoma vaccines|1 infusion, CART 1x10^6~1x10^7 cells/kg via IV and vaccines 1-5x10^6 irradiated cells via subcutaneous injection
76038674|NCT05125939|Other|Comparison of ADR|The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
76038675|NCT03065101|Device|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
76038676|NCT03065101|Other|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
76038677|NCT03065101|Device|Sliding Hip Screw|Sliding Hip Screw
75403879|NCT05316870|Behavioral|Conventional general practitioner management model|The current general practitioner anticoagulation management model was continued in the control group.
75403880|NCT05316792|Other|walking|30 min walking on the treadmill and tartan floor
75403881|NCT05316636|Device|Vibrational forces|
75403882|NCT05316636|Procedure|Orthodontic treatment with clear aligners|
75403883|NCT05316480|Drug|Nimotuzumab|nimotuzumab 200mg/week
75403884|NCT05316402|Other|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
75403885|NCT05316402|Other|dosimetry|dosimetry
75403886|NCT05316246|Drug|Brentuximab Vedotin in Combination with Tislelizumab|Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
76038678|NCT02520531|Device|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
76038679|NCT02520531|Device|Scorpio NRG PS|Implantation of total knee prosthesis
75403887|NCT05316090|Procedure|Core stability exercises program|Strengthening to the trunk muscles
75403888|NCT05316090|Procedure|Traditional physical therapy program|Neurodevelopmental training excercises
75403889|NCT05315856|Biological|either BNT162b2 or ChAdOx1 vaccine|Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
75403890|NCT05315778|Biological|autologous anti-BCMA chimeric antigen receptor T cells|Lymphoadenodepletion chemotherapy with FC (fludarabine 30mg/ m2 for 3 consecutive days and cyclophosphamide 300mg/m2 for 3 consecutive days) will be given at day -5, -4 and -3 before CAR T-cells infusion. A total of 1.0-2.0×10e7/Kg autologous anti-BCMA CAR T-cells will be infused by dose-escalation after the lymphoadenodepletion chemotherapy. Dose of CAR T-cells are allowed to be adjusted according to the severity of cytokine release syndrome.
75403891|NCT05315466|Procedure|Non-surgical treatment|Analgesics, anti-inflammatories, muscle relaxants, physical therapy, Global Postural Rehabilitation, magnetic therapy, laser therapy, transcutaneous electrical nervous stimulation (TENS), massage, cognitive-behavioral therapy and all those procedures that can bring benefit to back and leg pain.
75403892|NCT05315466|Procedure|Surgical treatment for spinal stenosis|Decompression of nerve structures by laminotomy or laminectomy and posterior lumbar fusion if stabilization of the column is required.
75403893|NCT05315388|Other|Immersion therapy in nature - Vitamin N|"Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements."
75403894|NCT05315154|Procedure|No axillary surgery|In the study arm will be omitted surgery in axilla
76038680|NCT05023473|Procedure|Pericapsular nerve group block|patients will receive pericapsular nerve group block
76038681|NCT05023473|Drug|Morphine Sulfate|morphine will be given to both groups as patient-controlled analgesia PCA
76038682|NCT03066661|Drug|Entrectinib|Open-label expanded access, capsules
75403895|NCT05315154|Procedure|SLNB|in the control arm will be realized SLNB
75403896|NCT05309850|Behavioral|Lifestyle tool|Regular use of the digital Lifestyle tool
75403897|NCT05257356|Behavioral|psychophysical tasks|"Substudy 1: All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simulta-neously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible altera-tions in the patients. Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.~Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits."
75403898|NCT05237232|Other|Magnetic Resonance Angiography (MRA) additional acquisition time|Additional acquisition time, time of flight, during brain MRA of the care allowing to obtain the same quality of vascular anatomical visualization as the brain MRA with gadolinium contrast medium injection performed for the care of the patients treated with jugulocarotid ECMO.
76038683|NCT04943497|Other|ribociclib|There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.
76038684|NCT04943497|Other|aplelicib|There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.
75403899|NCT05237232|Other|Modeling cerebral vascularization|"The modeling of cerebral vascularization from CRIMSON software (CaRdiovascular Integrated Modeling & Simulation) requires several inputs:~The MRA images~The cardiac function curve~The cerebral blood flow~Measurement of systolic, diastolic and mean arterial blood pressure"
75403900|NCT05202366|Drug|CGB-400 Topical Gel|CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
75403901|NCT05009706|Other|Self-care in Older frail Persons with Heart failure Intervention (SOPHI)|Patients who are randomized to the Self Care group will receive oral and written information, advice and support on following activities: excercise (from physiotherapist), nutrition (dietician) and symptom management (nurse), based on patient´s individual needs and abilities. The Self Care group will perform the activities daily at home. Once a week, patients come to the hospital to exercise with the support of a physiotherapist. Once a week or every other week patients will meet (at hospital or by phone) the dietician and nurse to solve possible problems and to follow-up food/nutrition intake and symptoms/symptom management.
75403902|NCT04894188|Radiation|radiation therapy|Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
75403903|NCT04894188|Drug|Goserelin 3.6 MG|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
75403904|NCT04894188|Procedure|radical prostatectomy|Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
75403905|NCT04866420|Behavioral|The MenFAS Study|A cross over repeated exposure randomized design observational study
75403906|NCT04775628|Procedure|Inferior glide humerus in GH joint|Supine inferior glide GH joint
75403907|NCT04769544|Device|total knee arthroplasty with medial pivot tibial insert or symmetrical insert|standard surgical implantation of total knee arthroplasty
75403908|NCT04767750|Other|Blood sample collection|"5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~Total RNA extraction from PBMCs by Trizol reagent and spin column.~Reverse transcription to cDNA.~The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR"
75403909|NCT04724772|Drug|Tranexamic acid injection|Injection of tranexamic acid preoperatively
75403910|NCT04717518|Other|Measurement of Pain|Patients will fill out a brief survey concerning the current visit to the ED.
76038685|NCT04943497|Other|mono endocrine therapy|There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
75403911|NCT04696614|Behavioral|exercise|intervention groups provided different sequential modality of exercise
75403912|NCT04648878|Other|Hybrid combination of physical therapy and powered exoskeleton|18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks
76038686|NCT04943497|Other|chemotherapy|There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.
75403913|NCT04648878|Other|Powered Exoskeleton Only|18 visits of powered exoskelton only, three times a week for approximately 6 weeks
75403914|NCT04648878|Other|Physical Therapy only|18 visits of physical therapy only, three times a week for approximately 6 weeks
75403915|NCT04398264|Other|COVID-19 positive via testing|Pregnant women admitted to Obstetric Units undergo RT-PCR testing for the detection of SARS-Cov2 (COVID-19 infection)
75403916|NCT04379076|Drug|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
75403917|NCT04379076|Drug|Placebos|Intramuscular (IM) placebo (normal saline) at the same frequency
75403918|NCT04320498|Biological|prp injection|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
75403919|NCT04320498|Drug|Anrecta|self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
75403920|NCT04320498|Behavioral|sitz bath|participants were told to take a hot water sitz bath once a day
75403921|NCT04320498|Dietary Supplement|nutrition regulation|The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
75550414|NCT06158386|Drug|Chidamide combined with Linperlisib|Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
75550415|NCT06158165|Device|Mostcare (Vytech, Vygon, Padua, Italy)|Parameters were observed through the utilization of the MostCare (Vytech, Vygon, Padua, Italy) device employing the Pressure Recording Analytic Method (PRAM).
75550416|NCT06156514|Drug|Gemcitabine|Weekly application of gemcitanibe at 300 mg/m2 intravenously in a 30-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
75550417|NCT06156514|Drug|Cisplatin|Weekly application of Cisplatin at 40 mg/m2 intravenously in a 60-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
75550418|NCT06156475|Procedure|Proprioception exercises|Patients trained for proprioception exercises.
75550419|NCT06156475|Procedure|Proprioception exercises with Electromyographic Biofeedback|Patients trained for Proprioception exercises with Electromyographic Biofeedback
76038687|NCT05105503|Device|Eko CORE Digital Stethoscope|The digital stethoscope will be used to take 9 recordings around each subject's maturing AVF once per week until study participation is over
76038688|NCT05020977|Other|Blood pressure, physical activity, health|Observational study of work environment, leisure time, blood pressure, physical activity and health
76038689|NCT03775629|Drug|Polmacoxib and Tramadol combination|Tramadol hydrochloride , Polmacoxib
76038690|NCT03775629|Drug|Polmacoxib|Polmacoxib
76038691|NCT03775629|Drug|Tramadol hydrochloride|Tramadol hydrochloride (HCl)
75403922|NCT04270500|Behavioral|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
76038692|NCT04978311|Behavioral|Mirror therapy (MT) priming with task-specific training|In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
75403923|NCT04187742|Behavioral|Social Comparison Email vs. Standard Email|Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
75403924|NCT04187742|Behavioral|Maintenance Certification Email vs. Standard Email|Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
75871529|NCT05462964|Behavioral|Pacifier group sweetened with 25% dextrose (İntervention Group 2)|Camera recording was started 2 minutes before OGT insertion and the newborn was given a pacifier sweetened with 25% dextrose. After the dextrose-sweetened pacifier in the OGT intervention group was placed in the mouth of the baby in the form of a leak from the mouth, it was inserted by advancing the baby's esophagus and then to the stomach with the swallowing reflex of the baby. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the registration was stopped.
75871530|NCT02342002|Drug|Mifepristone|Mifepristone for treatment of missed abortion
75871531|NCT02342002|Drug|Misoprostol|Misoprostol for treatment of missed abortion
75403925|NCT04187742|Behavioral|Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)|Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
75403926|NCT04086732|Procedure|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be milliampere. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
75403927|NCT03878472|Drug|SHR1210|The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
75550420|NCT06156475|Procedure|Wand Exercise|Patients were educated with wand exercises.
75871532|NCT04478110|Behavioral|interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.|The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.
75871533|NCT04478110|Behavioral|Education Session on General Health|Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
76038693|NCT04978311|Behavioral|Mirror therapy priming with impairment-oriented training|In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
76038694|NCT04978311|Behavioral|Control therapy|The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
75403928|NCT03878472|Drug|Apatinib|The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
75403929|NCT03878472|Drug|S1|The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
75403930|NCT03878472|Drug|Oxaliplatin|The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
75403931|NCT03772626|Device|Heated Humidified High-flow Nasal Cannula|Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
75403932|NCT03721926|Other|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
75403933|NCT03721926|Other|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
75403934|NCT03681912|Behavioral|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 45-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
75403935|NCT03681912|Behavioral|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
75403936|NCT03681912|Behavioral|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
76038695|NCT04976205|Radiation|Total Marrow (Lymph-node) Irradiation|To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
75403937|NCT03667170|Biological|KN035|subcutaneous injection
75403938|NCT03485820|Behavioral|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
75403939|NCT03485820|Behavioral|Stroke education|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
75403940|NCT03404076|Diagnostic Test|Dual Energy CT|Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
75403941|NCT03245580|Diagnostic Test|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
75550421|NCT06156423|Other|Motor control exercise|Motor control exercises include stabilization exercises for the scapula with external focus by activating the correct alignment and kinetic chain by providing verbal feedback and visual feedback.
75550422|NCT06156423|Other|Standard exercise|The standard rehabilitation group received a rehabilitation program via video call 3 days a week for 12 weeks.
75871534|NCT02341768|Device|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
76038696|NCT01671319|Drug|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
75403942|NCT03162510|Drug|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
76038697|NCT05055609|Drug|TRE-515|TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
76038698|NCT05019105|Drug|Placebo|Oral matching placebo
76038699|NCT05019105|Drug|ALKS 1140|Active oral dose of ALKS 1140
76038700|NCT04933747|Drug|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants
76038701|NCT04933747|Drug|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
76038702|NCT05018325|Procedure|Colonoscopy with 6 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
75403943|NCT03162510|Drug|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
75403944|NCT03162510|Drug|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
75403945|NCT03162510|Drug|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
75403946|NCT03049644|Procedure|Mechanical Diagnosis and Therapy|Identification of directional preference.
75403947|NCT03049644|Procedure|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
75403948|NCT02996760|Drug|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
75403949|NCT02987946|Device|IPD Device delivered by Converis|After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.
75403950|NCT02987946|Drug|Fraxiparine|All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
75403951|NCT02733900|Procedure|femoral head removal|
75403952|NCT02718300|Drug|Parsaclisib|Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
75403953|NCT02718300|Drug|Parsaclisib|Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
75403954|NCT02718300|Drug|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
75403955|NCT02718300|Drug|Parsaclisib|20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
75403956|NCT02718300|Drug|Parsaclisib|"2 dose strategies will be compared:~5 mg parsaclisib beginning on Day 1 until end of treatment.~20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
75550423|NCT06156280|Drug|TQH2929 injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
76038703|NCT05018325|Procedure|Colonoscopy 9 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
75550424|NCT06156280|Drug|Placebo injection|Placebo comparator
75871535|NCT02341846|Other|Qualitative interviews|
76038704|NCT05018325|Procedure|Colonoscopy 12 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
76038705|NCT03064711|Diagnostic Test|Electronyugraphy|Surface electromyography (sEMG) recorded diaphragmatic muscle activity during rest and while performing maximal voluntary ventilation
76038706|NCT03064945|Device|Livia|Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
76038707|NCT05016141|Behavioral|digital fall prevention program|The participants will receive a digital fall prevention program consisting of fall risk reduction education (modified Matter of Balance), Otago Exercise Program, Personalized S.M.A.R.T Goals, and will use the app to keep track of their health and health events, including falls.
75711368|NCT00927550|Drug|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
75871536|NCT05230966|Device|Remote Ischemic Conditioning (RIC)|RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
75871537|NCT02350582|Device|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
76038708|NCT03763305|Drug|Propofol continuous infusion|Propofol intravenous continuous infusion for anesthetic induction and maintenance
76038709|NCT03763305|Drug|Remifentanil|Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
76038710|NCT03763305|Drug|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
76038711|NCT03763305|Drug|Desflurane|1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
76038712|NCT03763305|Drug|Propofol bolus injection|Propofol intravenous injection for anesthetic induction
76038713|NCT03763305|Drug|Fentanyl|Fentanyl intravenous injection for anesthetic induction
76038714|NCT05054361|Diagnostic Test|MAIT cells analysis|For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.
75711369|NCT00927550|Drug|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
75871538|NCT02350504|Behavioral|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
75871539|NCT03149536|Diagnostic Test|Pharmacogenetic test|To develop a pharmacogenetic prediction test
75711370|NCT00926926|Drug|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
75711371|NCT00926926|Drug|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
75711372|NCT00396253|Drug|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
76038715|NCT05054361|Diagnostic Test|MAIT cytokines production analysis|Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
76038716|NCT05054361|Diagnostic Test|Lactulose/Mannitol Test|After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
75403957|NCT02542644|Device|Ultrahigh resolution Spectral Domain OCT|"The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed."
75403958|NCT02394132|Drug|Imiquimod|
75403959|NCT02394132|Radiation|Radiotherapy|
75871540|NCT02341690|Other|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
76038717|NCT05054361|Procedure|UGI Endoscopy|Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
76038718|NCT05054361|Diagnostic Test|Coxsackie virus B infection status|Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
76038719|NCT05054361|Diagnostic Test|Coxsackie virus B infection status|Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
76038720|NCT03066973|Behavioral|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
76038721|NCT05015283|Procedure|The laparoscopic One-anastomosis gastric bypass will consist of:|gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter < 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
75403960|NCT02102880|Genetic|the polymerase chain reaction (PCR)|
75403961|NCT01894542|Dietary Supplement|Cod protein from presscake|6g protein per day for 8wk
75403962|NCT01894542|Dietary Supplement|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
75403963|NCT01894542|Dietary Supplement|Control|
75403964|NCT00700596|Drug|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
75403965|NCT00700596|Drug|Placebo|Control or Placebo SA (30 % ethanolic solution)
75711373|NCT00927628|Procedure|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
75711374|NCT00927706|Device|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
75711375|NCT00927004|Drug|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
75711376|NCT00927004|Drug|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
75871541|NCT02341690|Other|control|Standard care at the promotion centre in the municipality
75403966|NCT01733472|Drug|GA-arm, remifentanil|"Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm"
75403967|NCT01733472|Drug|RA-arm|Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
75403968|NCT01736358|Drug|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
75403969|NCT01736358|Drug|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
75403970|NCT01737684|Drug|Vibegron|50 mg tablet, oral
75403971|NCT01740258|Radiation|Radiation Therapy|
75403972|NCT01740258|Drug|Temozolomide|
75403973|NCT01740258|Drug|Bevacizumab|
75871542|NCT03657264|Drug|P03277 0.1 mmol/kg|Single intravenous bolus injection at 2 mL/sec
75871543|NCT03657264|Drug|Moxifloxacin 400mg|One tablet per os
75403974|NCT01740414|Drug|MN-166 (50 mg) First|In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
75403975|NCT01740414|Drug|Placebo First|This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
75403976|NCT01740726|Behavioral|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
75403977|NCT01740726|Drug|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
75403978|NCT01741350|Behavioral|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
75403979|NCT01741350|Behavioral|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
75403980|NCT01741272|Procedure|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
75403981|NCT01741272|Procedure|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
75403982|NCT01742208|Drug|Sotagliflozin|Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
75403983|NCT01742208|Drug|Placebo|Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
75403984|NCT01742208|Drug|Sotagliflozin|Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
75403985|NCT01742364|Device|Bioject ID Pen|Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
75403986|NCT01742364|Device|Needle and syringe|Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
76038722|NCT05015283|Procedure|The laparoscopic Roux-en-Y gastric bypass will consist of:|the laparoscopic Roux-en-Y gastric bypass gastric sac size < 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter < 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
75403987|NCT01745952|Device|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
75403988|NCT01745952|Device|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
75403989|NCT01745952|Device|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
75403990|NCT01746264|Dietary Supplement|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
76038723|NCT03066583|Biological|trephination with placebo|trephination under US guidance and placebo injection
76038724|NCT03066583|Biological|trephination with platelet rich plasma|trephination under US guidance and platelet rich plasma injection
75403991|NCT01746420|Drug|rhPDGF-BB Injection|Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
75403992|NCT01746420|Drug|Placebo|sodium acetate buffer (0 mg rhPDGF-BB)
75403993|NCT01748916|Other|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
75403994|NCT01748916|Other|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
75403995|NCT01748916|Other|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
75403996|NCT01749930|Drug|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
75403997|NCT01749930|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening.
75403998|NCT01749930|Drug|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
75403999|NCT01750086|Drug|Teriparatide 40-mcg subcutaneous injection|
75404000|NCT01750086|Drug|Denosumab Injection|One-time Denosumab injection
75404001|NCT01750086|Drug|Alendronate Oral Tablet|weekly alendronate for 8 weeks
75404002|NCT01750398|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
76038725|NCT04972305|Other|Exercise and ergonomics|12 week exercise and fit bike
76038726|NCT04972305|Other|Ergonomics|Fit bike
75404003|NCT01750398|Drug|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
75404004|NCT01750398|Drug|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
75404005|NCT01751022|Device|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
75404006|NCT01752426|Other|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
75404007|NCT01752426|Drug|PCI-32765|420 mg orally once daily.
75404008|NCT01753362|Drug|liraglutide|
75404009|NCT01753362|Drug|placebo|
75404010|NCT01757964|Biological|Bacteriotherapy|
75404011|NCT01758588|Drug|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
75404012|NCT01759602|Drug|C1-esterase inhibitor (Cinryze)|
75404013|NCT01760304|Drug|Budesonide / Formoterol|"Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
75404014|NCT01760304|Drug|Placebo|"Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
75404015|NCT01761084|Behavioral|Exercise and behaviour change strategies|"cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~perform muscle strengthening and balance training exercises ≥ 3 days a week~the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day."
75404016|NCT01762722|Device|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
75404017|NCT01763346|Drug|Metformin|metformin 1000 mg bid
75404018|NCT01763346|Device|gastric banding|LAP-BAND
75404019|NCT01763970|Radiation|SBRT|
75871544|NCT03657264|Drug|NaCl 0.9%|Single intravenous bolus injection at 2 mL/sec
75404020|NCT01765530|Device|ETT cleaning maneuver|"EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
75404021|NCT01766466|Drug|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
75404022|NCT01766466|Drug|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
75404023|NCT01767636|Drug|Pazopanib Hydrochloride|Given PO
75871545|NCT03657264|Drug|P03277 0.3 mmol/kg|Single intravenous bolus injection at 2 mL/sec
75871546|NCT02345824|Drug|Ribociclib|CDK4/6 INHIBITOR
75871547|NCT02345902|Drug|Haloperidol|haloperidol 1.25 mg P.O q.d
75871548|NCT02345902|Other|Placebo|placebo 1.25 mg P.O q.d
76038727|NCT03064477|Behavioral|Unified Protocol|Intervention group that carries out the Unified Protocol in a group format
76038728|NCT03064477|Behavioral|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
75404024|NCT01769274|Drug|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
75404025|NCT01769274|Drug|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
76038729|NCT04906213|Drug|Empagliflozin10Mg Tab|Empagliflozin10 Mg daily or placebo daily for 18 months
76038730|NCT04906213|Drug|Placebo|10Mg Placebo Tab
76038731|NCT01670539|Device|HomMed Telemonitor|"A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses."
76038732|NCT04431895|Drug|Tofacitinib 5 MG|tofacitinib 5 mg tablet administered twice a day for 6 months
76038733|NCT02516163|Device|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
75404026|NCT01769586|Drug|Diphenhydramine|
75404027|NCT01769586|Drug|Midazolam|
75404028|NCT01770366|Device|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
75404029|NCT01770366|Device|Usual Care|
75404030|NCT01773954|Drug|Intravitreal Aflibercept Injection|Increased or decreased time between visits
75404031|NCT01778634|Drug|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
75404032|NCT01778634|Drug|Placebo|D5W
76038734|NCT03064633|Drug|dexamethasone 8 mg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
76038735|NCT03064633|Drug|dexmedetomidine 80 µg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
76038736|NCT03064633|Drug|Bupivacaine 0.25% Injectable Solution|38 ml of the solution will be prepared to be used in transversus abdominis plane block
76038737|NCT02589665|Drug|Mirikizumab|
76038738|NCT02589665|Drug|Placebo|
76038739|NCT01905397|Device|Conventional wound therapy|Sterile bandages and wound coverings
75404033|NCT01779024|Drug|Ghrelin|
75404034|NCT01779024|Drug|Placebo|
75404035|NCT01779024|Procedure|fMRI|
75404036|NCT01779024|Drug|Alcohol|
75404037|NCT01780350|Device|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
75404038|NCT01781208|Device|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
75404039|NCT01783080|Behavioral|Behavioral Activation for return to work|See Arm Description
75404040|NCT01783236|Drug|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
75404041|NCT01783236|Drug|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
75404042|NCT01783470|Drug|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
75404043|NCT01783860|Drug|Azithromycin|
75404044|NCT01783860|Drug|Doxycycline|
75404045|NCT04420182|Other|Virtual Care at Home|Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
75404046|NCT01784796|Behavioral|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
75404047|NCT01784796|Behavioral|Health Education Program|8 week Health Education Program
75404048|NCT01785186|Drug|SQ109|SQ109 300 mg
76038740|NCT01905397|Device|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
76038741|NCT05010603|Genetic|Blood Draw|Collection of blood samples for genetic testing
75550425|NCT06155695|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS will be administered using the Starstim system. We will use the freely available Simulation of Non-Invasive Brain Stimulation (SimNIBS) software to optimally target the rVLPFC and left TPJ in each subject. Finite element models will be generated using T1 and T2 scans. We will generate multiple models to maximize on-target stimulation and minimize off-target stimulation, as determined by ratio of the summed current density within and beyond target regions of interest (ROIs). tDCS current in the active stimulation condition will be maintained at 2.0 milliamps (mA) for the first 45 minutes of each one-hour training session. Sham stimulation the same current, only the current will be ramped down to 0 mA after 30 seconds. Our previous research has shown this method to produce indistinguishable skin sensation. During tDCS, patients will be monitored for possible negative side effects.
75404049|NCT01785186|Drug|Rifampicin|Rifampicin 10 to 35 mg/kg
75711377|NCT00604162|Device|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
75711378|NCT00604162|Procedure|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
76038742|NCT05010603|Other|Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test|Memory Test
75711379|NCT02538328|Device|Harmonic scapel|different surgical devices used in the obesity surgery
75711380|NCT02538328|Device|Ligasure|Bipolar vessel sealing system used in obesity surgery
76038743|NCT04613843|Other|Water Stirring|Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.
75711381|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
75404050|NCT01785186|Drug|Moxifloxacin|Moxifloxacin 400mg
75404051|NCT01785186|Drug|isoniazid|isoniazid 75 mg
75404052|NCT01785186|Drug|pyrazinamide|pyrazinamide 400 mg
75404053|NCT01785186|Drug|ethambutol|ethambutol 275 mg
75404054|NCT01785186|Dietary Supplement|pyridoxine|pyridoxine 25 mg
75404055|NCT01785810|Drug|Maraviroc 300 mg|Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
75404056|NCT01786902|Drug|DA-3002|
76038744|NCT04613843|Other|No Water Stirring|Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
76038745|NCT04457453|Other|Macintosh in sniffing position|Macintosh direct intubation in sniffing position
76038746|NCT04457453|Other|Macintosh in Trendelenburg position and Sellick position|Macintosh direct laryngoscopic intubation in Trendelenburg position and Sellick position
75404057|NCT01787604|Procedure|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
75404058|NCT01787604|Procedure|Aortic Valve Reimplantation Procedure|David I
75404059|NCT01787916|Drug|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
75404060|NCT01787916|Drug|Placebos|placebo will be compared to liraglutide for 24 weeks in a cross-over design
75404061|NCT01788150|Device|Coronary Stenting|
75404062|NCT01790178|Procedure|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
75404063|NCT01790490|Drug|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
75404064|NCT01790490|Drug|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
75404065|NCT01790490|Drug|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
75404066|NCT01791972|Drug|Albuterol Spiromax|Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).
75404067|NCT01791972|Drug|Placebo Spiromax|Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
75404068|NCT01792986|Behavioral|water-only 24-hour fasting once per week for 6 weeks|
75711382|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
75404069|NCT01794702|Drug|Decitabine|Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
75404070|NCT01794702|Drug|Idarubicin|Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
75404071|NCT01794702|Drug|Cytarabine|Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
75404072|NCT01794702|Drug|Clofarabine|"Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion)."
75404073|NCT01795716|Drug|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
75404074|NCT01795716|Drug|Glivec|Single and multiple oral Glivec 400mg qd
75404075|NCT01800318|Device|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
75711383|NCT00907192|Behavioral|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
75711384|NCT00907192|Behavioral|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
75871549|NCT02345902|Other|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
75404076|NCT01800318|Behavioral|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
75871550|NCT05462808|Drug|High viscosity glass ionomer cement|High viscosity glass ionomer cement
75404077|NCT01800318|Device|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
75404078|NCT01800318|Behavioral|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
75404079|NCT01800786|Device|CPAP|
75404080|NCT01803204|Other|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
75404081|NCT01805154|Device|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
75404082|NCT01809834|Device|Etafilcon A|
75404083|NCT01809834|Device|Stenfilcon A|
75404084|NCT01769352|Drug|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
75404085|NCT01810692|Device|Group1:Spiriva® Respimat®|COPD patients using Respimat®
75404086|NCT01810692|Device|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
75711385|NCT05277610|Diagnostic Test|iron studies|Pulmonary function testing was performed using standardized spirometry for asthmatic patients with iron deficiency anemia and those without iron deficiency anemia
75711386|NCT04014946|Device|ICD implantation|implantation of the Lumax 540 single/dual chamber ICD or successor
75711387|NCT00931450|Drug|exemestane|Given orally
75711388|NCT00931450|Drug|sunitinib malate|Given orally
75711389|NCT00931450|Other|placebo|Given orally
75711390|NCT00928330|Drug|GDC-0941|Oral repeating dose
75711391|NCT00928330|Drug|Trastuzumab|Intravenous repeating dose
75711392|NCT00928330|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
75404087|NCT01811004|Device|miraDry|miraDry
75404088|NCT01811004|Device|Nd:YAG Laser|Nd:YAG 1440 nm Laser
75404089|NCT01811004|Device|Botox®|Botox®
75404090|NCT01811316|Other|Probiotics|
75404091|NCT01811940|Drug|Adderall-ER|MAS-ER 60mg/day
75404092|NCT01811940|Drug|Topiramate|Topiramate 100 mg bid.
75404093|NCT01811940|Other|Placebo|Placebo
75404094|NCT01813110|Drug|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
75404095|NCT01813110|Drug|Placebo|olive oil
75404096|NCT01813734|Drug|Ponatinib|28 day cycle
75550426|NCT06155695|Behavioral|Auditory Cognitive Control Training (ACCT)|ACCT incorporates a subset of components from Cognitive Enhancement Therapy found to have early benefits on the cognitive deficits of interest to the proposed studies and can be conducted more time-efficiently to achieve our specific goals. ACCT involves approximately 3 hours of computerized neurocognitive training using cognitive control and processing speed training software developed by Ben-Yishay and colleagues. Deficits in cognitive control are addressed with computer training exercises containing simple stimuli with little inherent emotional or motivational salience. ACCT requires individuals to be vigilant, inhibit irrelevant stimuli, and shift attention between auditory and visual modalities. Computer training exercises facilitate reaction time in a temporal mode using auditory cues (The Attention Reaction Conditioner), spatial focusing with visual cues (the Zero Accuracy Conditioner), and temporal vigilance with auditory and visual cues (Time Estimates).
75871551|NCT05462808|Device|Stainless steel crown|Stainless steel crown
76038747|NCT04457453|Other|AceScope in Trendelenburg position and Sellick position|AceScope videolaryngoscopic intubation in Trendelenburg position and Sellick position
76038748|NCT04426409|Drug|tarivid ointment|Vaseline ointment is applied to both noses.
75871552|NCT03149614|Other|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
76038749|NCT04966923|Other|No intervention in this study|Analyses of pathogenic variant TP53 and variants in genetic test
75404097|NCT01816230|Drug|NiCord®|
75404098|NCT01816776|Device|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
75550429|NCT06153888|Procedure|Ultrafiltration rate|Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).
75404099|NCT01816776|Device|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
75404100|NCT01817712|Behavioral|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
75404101|NCT01817712|Behavioral|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
75404102|NCT01818414|Drug|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D&E
75404103|NCT01818414|Drug|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D&E
75404104|NCT06020651|Diagnostic Test|Arterial Doppler for Flow Mediated Reserve measurement|Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs
75404105|NCT06020638|Device|Experimental group|THE EFFECTS OF NASOPHARYNGEAL SUCTION POSITIVE PRESSURE
75711393|NCT00928798|Drug|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
76038750|NCT04421157|Other|Schroth Exercises|The Schroth approach consists of 3D scoliosis-specific exercises based on kinesthetic and sensorimotor principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. The treatment program consists of scoliotic posture correction and a breathing pattern with the help of proprioceptive and exteroceptive stimulations and mirror control. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. Schroth group received Schroth exercises in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
75404106|NCT06020638|Device|control group|THE EFFECTS OF NASOPHARYNGEAL SUCTION NEGATIVE PRESSURE
75404107|NCT06020625|Genetic|Diagnostic Test|"In order to proceed with molecular characterization, the tumor sample already taken for histological diagnosis will undergo DNA and RNA extraction, which will be analyzed for qualitative and quantitative evaluation. Based on the quantitative data, the method to be used for profiling will be decided.~Multigenic genomic profiling will be performed for each patient on already taken tumor tissue using different panels depending on the quality and quantity of nucleic acids, in particular the following will be used: comprehensive Genome Profiling (CGP, ≥500 genes), if at least 40 ng of material is available; Profiling with identification of actionable mutations by targeted sequencing with panels of size >50 genes, if <40 ng material available."
75404108|NCT06020612|Other|Assessment by dermatopathologists|Histological assessment of the cSCCs by eight dermatopathologists.
75404109|NCT06020586|Other|hair lotion|ECOHAIR
75404110|NCT06020560|Drug|Dalteparin Prefilled Syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
75404111|NCT06020560|Drug|Tinzaparin profiled syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
75404112|NCT06020495|Drug|DDAVP|Posology: 4µg in 2ml IV solution Route of administration: Intravenous Duration of treatment: 48h maximum (additional doses every 6h)
75404113|NCT06020495|Drug|Standard hyponatremia treatment|"Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
75711394|NCT00928798|Drug|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
75550430|NCT06153394|Drug|Redesca (enoxaparin sodium for injection)|Redesca is low molecular weight heparin and a biosimilar biologic drug (biosimilar) to Lovenox. Indications have been granted on the basis of similarity between Redesca and the reference biologic drug Lovenox. As such, Redesca (enoxaparin sodium) is indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield.
75404114|NCT06020482|Other|Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity|The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.
75404115|NCT06020456|Drug|Desmopressin|For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels
75404116|NCT06020378|Drug|Hydroxychloroquine|Hydroxychloroquine was administered during pregnancy
75711395|NCT00931840|Drug|EZN-2208, Cetuximab and Irinotecan|"Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C)."
75404117|NCT06020365|Other|sequential fecal microbiota transplant combined with small intestinal fluid transplant|for eligible patients, the investigator use rifaximin, three times daily, 0.4 g each time, lasting 6 days followed by fecal microbiota transplant combined with small intestinal fluid transplant for 6 days. These procedures were repeated every 28 days.
75404118|NCT06020352|Drug|KN046 plus Axitinib|KN046 combined with axitinib as a neoadjuvant treatment regimen
76038751|NCT04421157|Other|Core stabilization Exercises|Each exercise session consisted of a warm-up exercise, core stabilization exercise, and a cool-down exercise. The core stabilization exercise was designed with consideration of local, global muscle stability training, global muscle mobility training,and strengthening training of these core structures was carried out progressively advancing more difficult. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. The Stabilization group received Core stabilization in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
75404119|NCT06020313|Dietary Supplement|Resveratrol Experimental|The amount of 500mg per day will be offered for seven days distributed in doses of 100mg per schedule (7am, 10am, 1pm, 4pm and 7pm).
75404120|NCT06020300|Drug|Oral Colchicine 0.6 mg|Anti-Inflammatory Effects
75404121|NCT06020300|Drug|Oral Pyridoxine 10 mg|Colchicine look alike placebo
75404122|NCT06020287|Procedure|the robot-assisted laparoscopic radical prostatectomy|We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.
75404123|NCT06020235|Drug|5% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
75404124|NCT06020235|Drug|10% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
75404125|NCT06020235|Drug|Placebo|Placebo gel is either applied once per day or twice per day to the infected ulcer.
75404126|NCT06020222|Device|cryotherapy|Both hands and feet received cryotherapy gloves and boots, and the frequency was once every three weeks. Each cycle was 90 minutes, and the cycle was performed 4 times.
75404127|NCT06020222|Other|education|Provide preventive CIPN education leaflets
75404128|NCT06020196|Procedure|surgical rectus sheath block|Local anaesthetic will be administered into the rectus sheath space by the surgeon, towards the end of the operation, at the time of closure of the anterior abdominal wall (before the closure of peritoneum)
75404129|NCT06020196|Procedure|subdermal local anaesthetic infiltration|After closure of the subcutaneous fat, the edges of the skin become more stable; subdermal Infiltration with moving needle technique was done to optimize distribution of the local anesthetic solution
75404130|NCT06020131|Procedure|Thoracic Mobility Rehabilitation|Thoracic mobility exercises: Thoracic extension on foam roller, Sidelying thoracic rotation, Quadruped thoracic rotation, Squat with extension and rotation ( 10 reps x 3 set - 2 times x wk - 8 wk)
75404131|NCT06020131|Procedure|Lumbopelvic Stability Rehabilitation|Lumbopelvic Stabilization Exercises : Bridge with alternate leg, Single leg bridge, Four point kneeling with arm and leg extension, Side plank on front arm with knee flexed (right, left), Sitting on a Swiss Ball and hip flexion (10 reps x 3 set - 2times/wk - 8 wk)
75404132|NCT06020131|Procedure|Ankle Strengthening Home Exercises|Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)
75404133|NCT06020092|Procedure|Bone augmentation with I-BCP|The extraction socket will be filled after tooth extraction with I-BCP, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
75404134|NCT06020092|Procedure|Bone augmentation with BX|The extraction socket will be filled after tooth extraction with BX, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
75404135|NCT06020079|Other|laughter yoga|"According to the literature and the training received on laughter yoga, the time required for the treatment of depression is 50 minutes. The first 10 minutes includes relaxation, stretching and warm-up exercises. The next 30 minutes includes laughing exercises, and finally, the last 10 minutes includes relaxation exercises.~Steps of laughter yoga sessions:~Clapping hands and warm-up exercises: Participants clap their hands, fingers and palms. Then, sounds like ho-ho and ha-ha are added to the clapping exercises along with the rhythm.~Deep breathing exercises: Breathing exercises should be repeated 3-4 times while standing~Childlike games: Arms are raised, imitating the funny and clumsy behavior of a child.~Laughter exercises: The researcher names the exercise, explains how to do it, and the group performs the exercise together.~Dance and Relaxation"
75404136|NCT06020066|Drug|EGFR-TK Inhibitor|Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
75550431|NCT06153394|Drug|Fragmin (dalteparin)|Fragmin is a low molecular weight heparin indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield. Our institution uses this drug for standard of care thromboprophylaxis (30 days) in this patient population.
75711396|NCT00932074|Drug|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
75404137|NCT06020066|Radiation|Stereotactic radiotherapy|Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
75404138|NCT06020053|Procedure|saline irrigation at various temperatures (4°C, 25°C)|cold serum application
75404139|NCT06020040|Device|Heterograft|Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).
75404140|NCT06020014|Drug|AZD4604|AZD4604
75404141|NCT06020014|Other|Placebo|Placebo
75404142|NCT06019936|Drug|MT2004 Capsule|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
75404143|NCT06019936|Drug|MT2004 Capsule Placebo|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
75404144|NCT06019858|Other|Vitamin Energy Shot|"Vitamin Energy® shot is a naturally-caffeinated functional energy shot that contains:~Vitamin B3 Vitamin B6 Vitamin B12 Natural Caffeine (green tea extract) L-Carnitine Tartrate Potassium Sorbate Taurine Sucralose"
75404145|NCT06019715|Behavioral|Postpartum Remote Physical Activity Intervention|Includes 8 remote health coaching session to promote physical activity, use of a Fitbit device, and use of a home based blood pressure monitor.
75404146|NCT06019689|Behavioral|CAMI|Culturally Adapted manual-assisted problem solving training based Mobile Intervention (CAMI) for Suicidal Ideation. CMAP is a manual-assisted intervention which has been adapted from a self-help guide called Life After Self-Harm based on the principles of Cognitive behavioral therapy (CBT). This intervention is an evaluation of suicidal ideation, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships and relapse prevention strategies.
75404147|NCT06019663|Behavioral|The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP|"YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change."
75404148|NCT06019650|Behavioral|ECMAP|The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
75711397|NCT04034368|Drug|Tenofovir Alafenamide (TAF)|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
75404149|NCT06019585|Device|Splint inmmobilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with a plaster splint of París for 3 weeks
75404150|NCT06019585|Device|Bandage immovilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with compressive bandage for 3 weeks
75404151|NCT06019572|Procedure|Spine decompression and fixation surgery|Surgery is performed by either an anterior or posterior approach. Anterior approach is performed with either discectomy or corpectomy accompanied fusion, while the posterior approach consist in a bilateral laminectomy accompanied by fusion.
75404152|NCT06019533|Combination Product|LVDS|Levonorgestrel Vaginal Delivery System
75404153|NCT06019520|Drug|N-Acetylcysteine|Patients in the NAC arm will receive1200 mg of NAC (water-soluble granule Preparation) administered orally once daily at night for 7 consecutive days (1 days before chemotherapy, on the day of chemotherapy, and 5 days after chemotherapy) in each cycle of chemotherapy.
75404154|NCT06019520|Drug|Chemotherapy|Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
75404155|NCT06019507|Biological|TCD601|Investigational Product
75404156|NCT06019507|Biological|Cyclophosphamide|Conditioning Regimen
75711398|NCT00907270|Dietary Supplement|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
75871553|NCT03149614|Other|Vertebral Resonant Oscillation|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
75871554|NCT02350270|Other|gait and cognitive testing|
75871555|NCT04477954|Combination Product|Hyperbaric Oxygen|Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
75871556|NCT02345980|Drug|Sildenafil|
75871557|NCT02345980|Drug|Placebo|
75871558|NCT02346058|Drug|Esarin Gel|
75404157|NCT06019507|Drug|TAC|Immunosuppression Therapy
75404158|NCT06019507|Drug|MMF|Immunosuppression Therapy
75404159|NCT06019507|Drug|Corticosteroids|Immunosuppression Therapy
75550432|NCT06153225|Dietary Supplement|Protein products|In total 4 protein products will be tested containing a single or mixture of plant and dairy protein sources in a randomized order
75711399|NCT00907348|Drug|LR-CHOP21|"FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days"
75711400|NCT00375505|Drug|Zoledronic acid|
75711401|NCT00375505|Drug|Placebo|Placebo
76038752|NCT04432753|Behavioral|Lung Cancer Screening Decision Aid with Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.
76038753|NCT04432753|Behavioral|Lung Cancer Screening Decision Aid without Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
76038754|NCT05473793|Dietary Supplement|Dried chicory root particles|The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (~3mm).
76038755|NCT05473793|Other|Placebo|The control arm receives a placebo consisting of rice puff particles.
76038756|NCT01362595|Drug|leucine|"Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day"
75404160|NCT06019429|Behavioral|HiRO|"HiRO consists of weekly lessons. The lessons are aimed to promote social-emotional development. More specifically, lessons are designed to develop and enhance 1) trust, 2) collaboration, 3) respect, 4) self control, 5) resilience, 6) discipline, 7) joy. The annual program consists of four phases:~Phase 1 & 3: Fundamental phase (6 weeks) Engaging with the values through movement. In these phases, group formation and establishing behavioral expectations are central. In the Fundamental phase, one value is addressed school-wide each week. The entire school starts with trust and ends with discipline.~Phase 2 & 4: Theme weeks (12 lessons) A customized series of Experiential lessons for each class. Experiential learning is the guiding principle of the program, with a strong foundation based on the values upheld in judo. The learning cycle forms the basis for each experiential lesson within HiRO, and focusses on concrete experience, reflective observation, conceptualization, and practice."
76038757|NCT04421391|Dietary Supplement|QuadraMune(TM)|QuadraMune(TM) is a commercially available nutritional supplement
75550433|NCT06152835|Other|Data and breast milk samples collection|Breast milk samples and, clinical, anamnestic and lifestyle data collection
75550434|NCT06152809|Biological|Cytokine-Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
75550435|NCT06152809|Biological|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous (under the skin) injection per protocol.
75550436|NCT06152809|Drug|Venetoclax|Selective inhibitor of BCL-2 protein, 10, 50, or 100 mg tablets, via orally per standard-of-care.
75550437|NCT06151119|Diagnostic Test|68Ga FAPI PET/CT|68Ga FAPI PET/CT
75550438|NCT06151106|Drug|Chidamide combined with Duvillisib|Specified dose on specified days
75550439|NCT06151080|Drug|Lenalidomide combined with G-CHOP (LO CHOP)|Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)
75871559|NCT03895320|Behavioral|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
75711402|NCT00928876|Drug|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
75711403|NCT00928876|Drug|Placebo|placebo s/c daily for four weeks
75711404|NCT00907504|Drug|CP-751,871|CP-751,871 20mg/kg every 3 weeks
75711405|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
75711406|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
75711407|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
75711408|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
75711409|NCT00932230|Other|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
75711410|NCT00929032|Radiation|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
75404161|NCT06019429|Behavioral|HiRO +judo|In the condition HiRO with judo, students receive the same treatment as offered in the HiRO condition. In addition, they receive physical judo classes that are designed to translate the above-mentioned values to the behavioral level.
75404162|NCT06019429|Behavioral|School as usual|Any amount of classes offered to promote social-emotional development
75404163|NCT06019416|Behavioral|culturally tailored mindfulness-positive psychological intervention|"This 3-week culturally tailored mindfulness-positive psychological intervention instructs techniques to enhance positive emotions and meditation exercise lasting approximately 30 minutes. The culturally tailored mindfulness-positive psychological intervention consists of four modules: 1) noticing positive events, 2) amplifying positive events, 3) gratitude, and 4) mindfulness and meditation. This 3-dimensional software includes gamification features, including a virtual living room, Japanese garden, art gallery, and meditation garden.~A private office and/or space was utilized to implement the culturally tailored mindfulness-positive psychological intervention for older Korean Americans/immigrants, provided by the recruitment sites such as non-profit organization and church. The private room at the sites had a desktop (or laptop) computer, a virtual reality device (Oculus Quest 2), a chair, and a desk."
75404164|NCT06019390|Device|Presage care|A screening questionnaire completed by the family caregiver focused on functional and clinical autonomy of the patient (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with relative or their surroundings.
75404165|NCT06019377|Behavioral|Stronger Youth Networks and Coping (SYNC)|SYNC is a 10-module online curriculum adapted from evidence-based cognitive change methods, including Coping Effectiveness Training (CET), co-facilitated by service providers in Independent Living Programs (ILPs; federally-funded transition skill-building services accessed by most foster youth in the US) and near-peers (have lived experience in foster care). SYNC aims to increase youth capacity to appraise stress and regulate emotional responses, to flexibly select adaptive coping strategies, and to specifically promote informal and formal help-seeking as an effective coping strategy.
75404166|NCT06019351|Device|OrthoAnalyzer™ software|OrthoAnalyzer™ software module from 3Shape Software
75404167|NCT06019312|Dietary Supplement|Sanprobi IBS®|Patients will be treated with probiotics in combination with inulin, which is able to stimulate the growing of probiotic bacteria in gastrointestinal tract.
75404168|NCT06019299|Behavioral|Mindfulness Practice|Participants were instructed to practice mindfulness daily using their instructed approaches for a period of 4 weeks.
75711411|NCT00932308|Dietary Supplement|Western-style diet (WD)|Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
75711412|NCT00932308|Dietary Supplement|Prudent Diet (PD)|Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
75711413|NCT00932386|Drug|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
76038758|NCT05556941|Behavioral|Metacognitive Group Intervention|The investigators developed an initial Meta cognitive group intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored it to individuals with schizophrenia.
76038759|NCT05556941|Behavioral|Occupational therapy standard care|Occupational therapy standard care
76038760|NCT03064399|Procedure|without lateral ligament repairment|microfracture without repairment of the lateral ligament
76038761|NCT03064399|Procedure|lateral ligament repairment|microfracture combined with repairment of the lateral ligament
76038762|NCT04948983|Other|Decision aid (DA) for breast cancer screening|The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?
76038763|NCT04948983|Other|Standarised information for breast cancer screening|Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)
75404169|NCT06019286|Diagnostic Test|SCINEXA score|- 18 signs of extrinsic aging of SCINEXA score: sunburn, freckles, actinic lentigo, hyperpigmentation and/or melasma, change in phototype, yellowness, pseudoscars, coarse wrinkles, solar elastosis, cutis rhomboidalis, elastosis, comedones and cysts of Favre-Racouchot, xerosis, teleangectasias, permanent erythema, actinic keratosis, basal cell carcinoma, squamous cell carcinoma and malignant melanoma (extrinsic SCINEXA score). Each item will be scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). For some items (uneven pigmentation, cutis rhomboidalis nuchae, elastosis, comedones and cysts of Favre Racouchot, and malignant skin tumors, a binary scale was used: (yes) or (no). Maximun possible score is 54
75404170|NCT06019247|Other|Individual placement support (IPS)|IPS is the most studied psychiatric rehabilitation intervention in the world. It is based on eight principles: inclusion of all clients who have declared a desire to work, no pre-vocational training, benefits counseling, rapid job search, treatment team-level integration of vocational and clinical services, consideration of client preferences in all decisions, assistance in job development, provision of follow-up supports after finding employment, and a focus on competitive employment. We propose to adapt and pilot the IPS to improve employment and health among people with severe mental disorders in Mexico.
75711414|NCT00932386|Drug|normal saline|0.9% normal saline infusing
75711415|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose under fasted conditions
75404171|NCT06019169|Other|Yoga arm|Participation in YOGA classes. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.
75404172|NCT06019169|Other|storytelling activities|Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
75404173|NCT06019156|Behavioral|Exercise video distribution of Metaverse|Participants received a 10-minute exercise video each week with a load of about 4 to 8 metabolic equivalents of task (METs) in the metaverse space, for eight videos delivered to encourage exercise.
75404174|NCT06019156|Behavioral|Exercise video distribution of YouTube|Participants view exercise videos with the same content as the metaverse group.
75404175|NCT06019143|Behavioral|Goal Attainment Scaling (GAS) with a goal inventory|Goal Attainment Scaling (GAS) with a goal inventory (list of common goals) as a behavioral interventional tool
75404176|NCT06019143|Behavioral|Goal Attainment Scaling (GAS) without inventory|Goal Attainment Scaling (GAS) without a goal inventory (list of common goals) as a behavioral interventional tool
75404177|NCT06019130|Drug|Nivolumab|Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases
75404178|NCT06019130|Drug|Cisplatin|Cisplatin during induction chemotherapy and during radiochemotherapy in all groups
75404179|NCT06019130|Drug|5-Fluorouracil|5-Fluoruracil during induction chemotherapy in all groups except of adults > 25 years with metastatic disease at diagnosis
75404180|NCT06019130|Drug|Gemcitabine|Gemcitabine during induction chemotherapy in patients > 25 years with metastatic disease at diagnosis
75404181|NCT06019130|Radiation|Radiotherapy|After induction therapy in all patients
75404182|NCT06019130|Drug|Interferon beta-1a|In patients < 26 years after end of radiochemotherapy for 6 months
75404183|NCT06019130|Procedure|MRI|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy
75404184|NCT06019130|Procedure|PET|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI
75404185|NCT06019130|Behavioral|Patient-Reported Outcomes|For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment
75404186|NCT06019117|Dietary Supplement|Probiotic K10|clinical trial using 90 days of probiotic K10
75404187|NCT06019117|Drug|Placebo|clinical trial using 90 days of placebo controlled
75404188|NCT06019104|Other|Task-oriented training|"Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition."
76038764|NCT04426097|Procedure|Cervical Vagal Blockade|Cervical Vagal Blockade with 0.5 % ropivacaine 2.5 ml and 2% xylocaine 2.5 ml
75404189|NCT06019104|Other|Control group|Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
75404190|NCT06019065|Drug|AJA001|AJA001
75404191|NCT06019065|Other|Placebo|Placebo
75404192|NCT06019039|Drug|Normal Saline Flush|Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
76038765|NCT04426097|Procedure|Without Blockade|Without Blockade
76038766|NCT05556551|Other|Full Ceramic restoration|Two different dental restoration inserted in patient mouth ( split mouth)
76038767|NCT05556551|Other|Hybrid resin Ceramic restoration|Hybrid resin Ceramic restoration
76038768|NCT04411173|Dietary Supplement|Whey Protein|Each condition (both rice and whey protein) match in color, flavor, and serving size.
75550440|NCT06150859|Drug|Ayahausca-Assisted psychotherapy|"Drug: Two ayahuasca administrations (0.75 mg/kg DMT), after 3rd and 6th therapeutic session. Ayahuasca is a psychoactive mixture of plants which contains DMT as an active principle.~Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions."
75711416|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
76038769|NCT05556317|Behavioral|Resistive exercise|advices and resistive exercise
76038770|NCT04411407|Device|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
76038771|NCT05556083|Drug|Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
75404193|NCT06019039|Device|Doppler|"All color flow Doppler images will be performed with a Phillips CX50 ultrasound machine using a 5.0 MHz a low frequency curvilinear US probe. A two-dimensional transverse interspinous view was used to visualize the posterior complex (ligamentum flavum, epidural space and dura). After loss of resistance to normal saline, the color flow Doppler function will be turned on to examine flow through the epidural needle tip.~The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space ."
75404194|NCT06019013|Drug|QLF3108|QLF3108 will be administered independent of body weight.
75404195|NCT06018948|Drug|Dexmedetomidine 0.6|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.6 μg/kg/hr for one hour.
75404196|NCT06018948|Drug|Dexmedetomidine 0.3|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.3 μg/kg/hr for one hour.
75404197|NCT06018948|Drug|Saline|Patients received over 10 minutes comparable volume of normal saline (0.9%) 15 min after endotracheal intubation followed by infusion.
75404198|NCT06018922|Behavioral|Psychological treatment|The treatment is module-based, and the clinician are supposed to choose a small number of modules to work with depending on the patients need. The individual CBT modules are: 1) Behavioral activation, 2) Accepting thought, 3) Emotion regulation, 4) Impulse control, 5) Procrastination, 6) Relationships, 7) Problem-solving skills, 8) Structuring everyday-life, 9) Diet-Exercise-Sleep, and 10) Social anxiety. The family therapy modules are: 1) Psychoeducation about gaming, 2) Encourage other activities, 3) Positive time together, 4) Expectations and the patients abilities, 5) Making agreements in the family, 6) Emotional validation, and 7) Conflict management.
75404199|NCT06018909|Behavioral|Cognitive-Behavioral Interventions Package|CBIP was developed by researchers in line with the relevant literature according to the developmental characteristics of children. Opinions were obtained from experts in the field of pediatrics or psychiatric nursing regarding CBIP. CBIP consisted of cognitive and behavioral practices to prevent/reduce procedural pain and anxiety.
75404200|NCT06018896|Drug|Ascorbate|For patients with baseline serum Vitamin C concentration < 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
75404201|NCT06018805|Other|BMI≥30; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration ( in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
75404202|NCT06018805|Other|BMI:18,5-24,9; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
75550441|NCT06150859|Behavioral|Constructivist Psychotherapy|Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions
75711417|NCT00932542|Drug|Eutectic mixture|The eutectic mixture of lidocaine + prilocaine + bupivacaine.
75711418|NCT00932542|Drug|placebo|placebo
75711419|NCT00932542|Drug|lidocaine 2,5%; prilocaine 2,5%|lidocaine 2,5%; prilocaine 2,5%
76038772|NCT05556083|Drug|Placebo oral tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
75404203|NCT06018779|Other|Cryoultrasound therapy plus high-intensity laser therapy|Group A received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and cryo-sound therapy.
75404204|NCT06018779|Other|diathermy plus high-intensity laser therapy|Group B received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and diathermy.
75404205|NCT06018714|Drug|Fruquintinib|"Drug:~Maintenance treatment regimen:~Fruquintinib 5 mg, qd, po, with three weeks of continuous treatment followed by one week of drug discontinuation. Each treatment cycle lasts four weeks. The treatment will be continued for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~Adverse drug reactions that occur during the trial will be graded according to the NCI CTCAE version 5.0 and dose adjustments will be made according to the corresponding rules."
75404206|NCT06018675|Other|kinesiotherapy|Group 1: Kinesiotherapy Group 2: Dry needling Group 3: lidocain injection
75404207|NCT06018103|Behavioral|MBCT-vision|8-week mindfulness group learning course, using Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision). Participants meet once weekly only, with daily home practice between sessions.
75404208|NCT06015867|Dietary Supplement|Dietary Intervention with Wholemeal Bread with Yeast|Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).
75404209|NCT06015867|Dietary Supplement|Dietary Intervention with Wholemeal Sourdough Bread|Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.
75404210|NCT06015425|Device|MINDD STIM+|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
75404211|NCT06014944|Drug|Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody|neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.
75404212|NCT06014359|Drug|Saline|Patients will be Nebulized with 3 mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
75404213|NCT06014359|Drug|Dexmedetomidine|Patients will be Nebulized with Dexmedetomidine (1 mcg/kg) in 3mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
76038773|NCT05556005|Drug|Trimetazidine Dihydrochloride|Trimetazidine Dihydrochloride 35 mg modified release tablet used twice daily
76038774|NCT05556005|Drug|Placebo|Starch tablets used twice daily
75404214|NCT06014229|Device|cryoablation|Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
75404215|NCT06014229|Device|radiofrequency ablation|Single session with a radio frequency ablation device; an specific applicator will be used for the treatments; high impedance rates for RFA with moving-shot technique; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
75404216|NCT06011746|Drug|Ketamine + Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with 1ml ketamine (50mg)
75404217|NCT06011746|Drug|Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with (50mg) or normal saline
75550442|NCT06150859|Other|No treatment|No treatment during the control period
76038775|NCT04373603|Drug|Tranexamic acid|TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
76038776|NCT04373603|Other|Saline|sodium chloride and water for use as control
75550443|NCT06150755|Procedure|implant supported overdenture by ball|overdenture supported by two implant with ball attachment
75550444|NCT06150755|Procedure|implant supported overdenture by bar|overdenture supported by two implant splinted by intraoral welding titanuim bar
75404218|NCT06011473|Device|CGM (FreeStyle Libre 3)|"FreeStyle Libre 3 system consists of a sensor that measures interstitial glycemia every minute and a dedicated application on mobile phone. Measurements are transmitted via Bluetooth to a mobile phone, that collects the data in the mobile application. Moreover, the study subject's application is connected to the doctor's application which allows remote real-time glycemia monitoring on another device.~Other Name: continuous glucose monitoring, CGM, FreeStyle Libre 3"
75404219|NCT06010563|Device|Transcatheter pulmonary valve implantation (TPVI)|A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.
75404220|NCT06010563|Device|VenusP-ValveTM System|"VenusP-ValveTM System consists of two components:~Transcatheter Pulmonary Valve (TPV)~Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper."
76038777|NCT04373603|Drug|Hyaluronic acid|Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
76038778|NCT02519595|Drug|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
75404221|NCT06010173|Drug|Gadopiclenol|Dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.05 mmol/kg BW
75550445|NCT06150638|Behavioral|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
76038779|NCT02519595|Drug|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
76038780|NCT02519595|Drug|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
76038781|NCT05610917|Combination Product|CBRM (community-based rehabilitation management)|The case group patients will undergo drug treatment (Selective Serotonin Reuptake Inhibitors), health education, cognitive-motor dual task training, cognitive-training.
75404222|NCT06010173|Drug|Comparator|Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW
75711420|NCT00907582|Procedure|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
76038782|NCT05610917|Combination Product|TAR(treatment as routine)|Patients in control group will be treated rountinely which includes drug treatment (SSRIs) and traditional health education.
76038783|NCT04278755|Drug|Drospirenone-Ethinyl Estradiol Oral Tablet|3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
76038784|NCT04277975|Other|Liberal post-discharge opioid prescribing|Opioid prescribed all patients opioids 'in case they are needed' prior to surgery
76038785|NCT04277975|Other|Restricted post-discharge opioid prescribing|Opioid only if needed after discharge
76038786|NCT04093349|Genetic|SPK-3006|adeno-associated viral (AAV) vector
76038787|NCT04062695|Drug|Tofacitinib 5 MG Oral Tablet [Xeljanz]|verum tablets
76038788|NCT04062695|Drug|Placebo oral tablet|tablets containing placebo
76038789|NCT05555927|Device|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
75550446|NCT06150638|Behavioral|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.3 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
76038790|NCT04330235|Other|Healthy Default Kids' Beverage Policy|The healthy default kids' beverage policy requires that all restaurants serve only healthy beverages (water, milk, or 100% juice) instead of sugary beverages as the default beverage with children's meals. The policy has been enacted in New York City and Philadelphia and will go into effect in April 2020.
76038791|NCT04330079|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg once daily for 6 months.
75404223|NCT06007872|Device|Intracardiac Echocardiography (ICE)|ICE will be used to guide trans-septal puncture and to guide device implant.
75404224|NCT06005077|Other|Perineal Massage Group|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
75404225|NCT06005077|Other|Perineal Warm Compress Application Group|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
75404226|NCT06005077|Other|Perineal Massage and Perineal Warm Compress Application Group|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
75404227|NCT06004986|Drug|Dupilumab|Administering Dupilumab 300 mg at different dosing intervals.
75404228|NCT06004167|Radiation|Adaptive Bridging Radiation Therapy (ABRT)|Radiation Therapy
75404229|NCT06004141|Behavioral|Laguna Health|Laguna Health is a novel behavioral coaching intervention (Laguna Health) that provides supportive care to patients with cancer who are discharged from the hospital and their caregivers. The intervention includes four components: 1) behavioral coaching with a Laguna Health recovery coach; 2) digital psycho-educational content tailored to the needs of patients with cancer; 3) summary of post-discharge care tasks; and 4) behavioral strategies to promote self-efficacy.
75404230|NCT06000943|Other|Low vs Intermediate vs High surgical risk stratified according with SAPT/DAPT/OAC and OAC+SAPT|"All patients undergoing TAVR will be stratified according with surgical risk level and all combination of antithrombotic therapy at discharge~Low risk (SAPT vs DAPT and OAC vs OAC+SAPT) Intermediate risk (SAPT vs DAPT and OAC vs OAC+SAPT) High risk (SAPT vs DAPT and OAC vs OAC+SAPT)"
75404231|NCT06000475|Behavioral|Cognitive Processing Therapy|CPT as described in the treatment manual
75404232|NCT06000475|Behavioral|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
75404233|NCT05997134|Drug|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days .
75404234|NCT05997134|Drug|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days
75404235|NCT05997134|Drug|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
75404236|NCT05984290|Device|orthokeratology lens|Each subject will wear the study lenses in both eyes overnight for approximately 3 months.
76038792|NCT04330079|Other|Lifestyle modification|lifestyle modification (diet and exercise) for 6 months
75404237|NCT05982990|Drug|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
75404238|NCT05982990|Drug|ADVAIR DISKUS® 250/50|2 inhalations in one study period
75404239|NCT05981105|Device|ambIT pump with catheter|0.2% ropivacaine will be infused through a catheter pump at a rate of 10 ml/hr, 600 ml reservoir.
75404240|NCT05981105|Device|ambIT pump with sham catheter|sham catheter with no infusion
75404241|NCT05980650|Other|Reiki implication|Reiki will be implicate by researcher by putting hands on patient
75404242|NCT05979740|Drug|Disitamab Vedotin and Toripalimab|Each patient received RC48 injection [2.0 mg/kg, Q2W, iv] and Toripalimab injection [3mg/kg, Q2W, iv] for 1~2 cycles, and Radiotherapy radiotherapy at the second or third cycle. The total dose of bladder irradiation field was greater than 50Gy (about 30 times), and the safety monitoring of the subjects was conducted within 28 days after receiving the study drug treatment for the first time.
75404243|NCT05976854|Other|Pain neuroscience education|The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 Pain neuroscience education lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler & Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.
75404244|NCT05972655|Radiation|Modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
75404245|NCT05972655|Drug|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
75404246|NCT05972655|Drug|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
75404247|NCT05972655|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
75404248|NCT05971719|Diagnostic Test|Air Leaks: Aerosol glycerine System|A range of different leak will be done with different needle sizes on the lung. Perform localization on staple lines used surgically during pulmonary surgeries, as they are known to not consistently give an airtight closure. The lung will be put in the ex-vivo model and ask for a surgeon to localize the leaks with our system. The needle incisions will be repeat on another lung and ask the same surgeon to localize the leaks with the submersion test. To perform the submersion test the surgeon will have to submerge the lung in saline solution and to check the presence of air bubbles. The lung is inflated to pressures of 20 to 40 cm H209. The precision of both systems will be compared by the minimal incision the minimal incision the surgeon was able to localize.
75404249|NCT05962502|Drug|Cetuximab and irinotecan|chemotherapy plus targeted therapy
75404250|NCT05959343|Behavioral|Enhanced Recovery After Surgery program for Oblique Lumbar Interbody Fusion|In the ERAS CP group, the components of the ERAS are protocolized and implemented as a clinical pathway
75711421|NCT05277454|Drug|HMPL-653|"Dose-escalation Stage:~Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment.~Dose-expansion Stage:~The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment."
75550447|NCT06150248|Other|Education Intervention|"This intervention is based on the Social Cognitive Theory (SCT) and The Health Belief Model (HBM) to improve knowledge and promote lifestyle adherence in terms of healthy diet behaviour and physical activity among the undergraduate students. This program will include educational booklets and educational classes include six weeks of in-person education sessions and six weeks of social media messaging. The course will include six weekly teaching units (lectures and group discussions, 45-60 minutes each):~Topic 1: To understand the causes and prevention strategies for overweight and obesity.~Topic 2: To understand food based approaches to reduce or prevent overweight and obesity.~Topic 3: To understand the importance of regular physical activity. Topic 4: To demonstrate how snacking can be a healthy habit. Topic 5: To learn how to read and interpret food labels. Topic 6: To understand how to prepare healthy meals."
75711422|NCT00907660|Behavioral|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
75711423|NCT00907660|Dietary Supplement|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
75711424|NCT00375427|Drug|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
75711425|NCT00929266|Biological|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
75404251|NCT05957757|Drug|RC48|"RC48 was scheduled to be administered at a dose of 2.0mg/kg every 2 weeks, with the first dose on day 1 of the first cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
75711426|NCT04014634|Drug|Methylprednisolone|Single GON injection with methylprednisolone
75711427|NCT04014634|Other|Placebo|Single GON-injection with NaCl
75711428|NCT01043575|Drug|Rifapentine|During the first 8 weeks of therapy for TB participants > 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants < 45 kg participants will receive 450 mg orally given 5 days per week
75711429|NCT01043575|Drug|Rifampin|During the first 8 weeks of therapy participants will receive rifampin at standard doses (e.g. 600 mg) 5 days per week
75404252|NCT05957757|Drug|Tislelizumab|"Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
75550448|NCT06150248|Other|No intervention|They will have their regular curriculums and normal physical activity routine.
75550449|NCT06149793|Drug|Empagliflozin|Sodium glucose co-transporter 2 inhibitor
75404253|NCT05954169|Drug|SHR4640|SHR4640 single-dose
75550450|NCT06149793|Other|Placebo Control|Placebo Control
75711430|NCT00932776|Device|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
75711431|NCT00932776|Device|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
75711432|NCT00393913|Device|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
75404254|NCT05935020|Other|Usual care - Municipal exercise-based rehabilitation|"The patients in this group follow prescribed (by the orthopedic surgeon) usual care municipal exercise-based rehabilitation. The content of the rehabilitation is planned in collaboration between the patient and the physical therapist, based on the offered municipal treatment options (which varies between municipalities) and patient preferences (i.e., home-based exercise, outpatient exercise, group-based exercise, or a combination thereof). The contents of the municipal services offered will be described in detail in the trial report.~A prescribed therapeutic rehabilitation exercise plan could for instance be a 6-week combined home-exercise (1-2 times/week) and group-exercise (1 time/week) intervention, followed by encouragement to continue self-administered home exercise after the 6 weeks."
75404255|NCT05935020|Other|Return to Everyday life|"The patients in this group return to their desired pre-surgical activities, at their own speed, when they feel that they are ready for it. They are not prescribed any exercise-based rehabilitation (usual care) by their orthopedic surgeon.~This effectively means they will not receive a therapeutic progressive exercise plan; designed and prescribed to restore previous function or reducing pain or disability caused by injury, disease, or surgery - typically referred to as exercise therapy or therapeutic exercise."
75404256|NCT05935020|Behavioral|Symptom guide and encouragement to follow DHA/WHO recommendations for physical activity|"Participants in both groups receive a recovery-guide pamphlet at discharge, containing the following information: 1) Recommendations to follow DHA/WHO guidelines for physical activity, 2) Figures and tables describing common post-operative symptoms (symptom guide), and when to react (when the symptoms may require attention from a health-professional), 3) What to expect from the post-surgical period in relation to activities of daily living, 4) Common short- and long-term complications to total knee arthroplasty and 5) Trial-participant and ethics-committee information documents. Parts 2-4 are usual clinical practice, with slight variations in descriptions between sites.~After surgery, participants in both groups are encouraged to resume their desired pre-surgical activities when they feel they are able (within the limits given from the orthopedic wards)."
75404257|NCT05934227|Drug|Amoxicillin 500 milligrams capsules plus metronidazole 400 milligrams|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of amoxicillin (500 milligrams) + metronidazole (400 milligrams) three times a day for 7 days after SRP
75404258|NCT05934227|Other|placebo|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of placebo containing corn starch capsules three times a day for 7 days after SRP
75404259|NCT05933148|Device|Siemens 7T MRI|The active neurofeedback session will be done within the 7T MRI.
75550451|NCT06149741|Procedure|Defunctioning left-sided loop colostomy|Descending or left transverse double-barrelled loop colostomy in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision, and anastomosis.
75550452|NCT06147284|Behavioral|Preventive interventions|Parallel randomized controlled trial
75550453|NCT06146465|Other|speciality|Not
75550454|NCT06144502|Behavioral|5Ways@School|"The 5Ways@School intervention is a teaching material consisting of five elements; Take notice, Be active, Keep Learning, Connect, and Give. The intervention will be given in an ordinary classroom setting by the class' main teacher in two school hours of 45 minutes each week for six consecutive weeks, i.e., a total of 12 school hours. The teaching sessions will consist of presentations of the five elements, videos, reflection exercises, focused group discussions, creative group work, and giving the pupils small challenges to practice what they have learned between the weekly sessions."
75550455|NCT06142409|Dietary Supplement|Enzyme containing lozenge|Lozenge containing multiple enzyme combination
76038793|NCT05555693|Other|Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
75404260|NCT05933148|Device|Sham Neurofeedback|The sham Neurofeedback resembles the active condition but participants will not see their own brain activity and will instead view a past participant's active feedback from their same population group.
75404261|NCT05928650|Other|Evaluation of menstrual function|Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
75404262|NCT05925517|Other|Graded Motor Imagery (GMI)|"GMI includes three stages. Each session will be 30 minutes, and the GMI program will span over 8 weeks. The first 3 weeks will focus on lateralization, followed by 3 weeks of motor imagery, and the final 2 weeks will involve mirror therapy.~Lateralization: Patients will be asked to differentiate whether the extremities shown in the Recognise™ Knee application belong to the right or left side of their body.~Motor Imagery: Patients will be instructed to imagine slowly and smoothly moving their affected extremities to the posture depicted in the photos in the Recognise™ Knee application and then returning to the starting position.~Mirror Therapy: Using a mirror measuring 90x60 cm² placed between the lower extremities, patients will be instructed to progressively move only their unaffected extremity, then their affected extremity, and finally both extremities."
75404263|NCT05925517|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|Application will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes. The current will be applied to the most painful area of the affected knee. The four self-adhesive electrodes will be positioned in a square pattern, approximately 5 cm apart, centered over the pain point. Conventional TENS will be applied for 30 minutes at a frequency of 100 Hz, pulse width of 100 μs, and intensity below 10% of the motor threshold.
75404264|NCT05925517|Other|Conventional Physiotherapy Program|The routine 60-minute program for OA patients in conventional physiotherapy includes warming up, core stability, pelvic and hip stability, gluteus medius strengthening, knee control and stability (knee flexion and extension control, lunge exercises), knee strengthening exercises (wall-assisted leg press with a ball, step-ups with elastic bands), and functional exercises.
75404265|NCT05925517|Other|Home Exercise Protocol|The home exercises will include a warm-up consisting of a 10-minute walk at a normal pace on a flat surface while gently stretching the hamstring and calf muscles. The exercises will also involve straight leg raises, terminal knee extension, isometric contractions of the quadriceps femoris and adductor muscles using a pillow for support, toe raises, single-leg standing, toe taps, and quadriceps strengthening exercises included in the session.
75404266|NCT05918783|Combination Product|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.
75404267|NCT05917899|Behavioral|Virtual Family-Centered Rounds|The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and [if in attendance] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
75404268|NCT05912790|Device|eyeTube|Implantation of a drainage device in the eye, in combination with the eyeWatch implant
76038794|NCT00660673|Drug|Levodopa-Carbidopa Intestinal Gel (LCIG)|LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
76038795|NCT00660673|Device|CADD-Legacy® 1400 ambulatory infusion pump|Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
76038796|NCT00660673|Device|Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)|All participants previously had a PEG-J placed in one of the prior LCIG studies.
76038797|NCT05612867|Dietary Supplement|Vitamin C|Due to clinical research supporting high dose vitamin C, the institution's surgical intensivists started utilizing a high IV vitamin C dose in higher total body surface area burns while continuing to use the standard PO vitamin C dose of 500 mg to 1,000 mg daily on patients with lower total body surface area burns. Looking at the initial 72 hours, patients with smaller burns were given 2,500 mg PO vitamin C and larger total body surface area burns were given 15,000 mg IV vitamin C.
75404269|NCT05911880|Behavioral|Plant-based diet for 14 days in patients with rheumatoid arthritis.|Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.
75404270|NCT05911269|Other|TiMBRe|"1 & 2 Music Listening~Live music played by the music therapist (e.g., guitar, voice) and AYA selected music will be used to facilitate attention to the present moment and provide cues for breathing/relaxation.~3 & 4 Music Facilitated Breathing~The therapist will lead participants in music facilitated breathing exercises using rhythmic features of the music to cue structured breathing for relaxation and self-awareness~5 & 6 Music Facilitated Progressive Muscle Relaxation for Stress Reduction~Using music as a structured auditory cue for tensing and releasing of muscles.~7 & 8 Body Percussion~The therapist will lead participants in a hands-on body percussion activity to bring attention to the sound of rhythm, sensation in their hands and body."
75404271|NCT05911269|Other|Control|Standard of care study staff calls and cancer survivorship resources
75404272|NCT05898932|Other|Medical Management|Participants will be managing condition with medication
75404273|NCT05898932|Other|Surgical Management|Participants will be managing condition with a surgery
76038798|NCT05473559|Procedure|Adductor canal block with Ipack block or selective tibial nerve block|Ultrasound guided
76038799|NCT05555459|Procedure|Operation|Bone fixation operation in foot or ankle area using bioabsorbable headless screw/s
75404274|NCT05898217|Other|Dairy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
75871560|NCT03895320|Behavioral|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
76038800|NCT03816137|Biological|ConM SOSIP|Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
76038801|NCT03816137|Biological|EDC ConM SOSIP|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC-ConM SOSIP. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
76038802|NCT03816137|Biological|ConS UFO|Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle
76038803|NCT03816137|Biological|EDC ConS UFO|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
76038804|NCT03816137|Biological|Mosaic SOSIPs|"Mosaic gp140 Env trimers designed to overcome the immunodominance of hypervariable regions of Env~The immunogen will be used at the dosage of 100 ug (3x33ug) and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle."
76038805|NCT05470907|Device|Hemoperfusion|Commercial membranes for extracorporeal blood purification (hemoperfusion)
76038806|NCT03644381|Other|Oral Immunotherapy|Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
76038807|NCT05612711|Drug|Dronabinol|All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
75404275|NCT05898217|Other|Soy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
75404276|NCT05898217|Other|Almond Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
75404277|NCT05898217|Other|Oat Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
75404278|NCT05886920|Drug|D3S-002|Oral
75404279|NCT05886296|Behavioral|Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process.|To evaluate the effect of the implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution of functionality, quality of life, empowerment and self-efficacy in the three months of the surgical intervention.
75404280|NCT05884138|Other|exercise and nutritional support|resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
75404281|NCT05880706|Drug|BL-B01D1|Administration by intravenous infusion
75404282|NCT05880706|Drug|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.
75404283|NCT05877924|Drug|NBL-020 for Injection|NBL-020 for Injection, Q3W, i.v.
75404284|NCT05877820|Biological|Tislelizumab|Intravenous infusion
75404285|NCT05877820|Drug|Lenvatinib|Oral tablet
75404286|NCT05875207|Behavioral|Mindfulness based practice|Physical therapists who are randomized to this arm will receive mindfulness training. This training will teach physical therapists to use the following with their patients: 1) use mindfulness to strengthen self-regulation of habitual and compulsive opioid use, and to mitigate pain by reinterpreting these experiences as innocuous sensory information, 2) use reappraisal to reframe stressors and maladaptive thoughts to decrease negative emotions and engender meaning in life, 3) use savoring of pleasant events and pleasurable sensations to enhance positive emotions and reward and, 4) to integrate mindfulness, reappraisal and savoring with evidence-based physical therapy.
75404287|NCT05875207|Behavioral|Control/Standard Physical Therapy|Physical therapists randomized to this arm will receive no additional training and will provide standard care to patients with chronic musculoskeletal pain and long-term opioid treatment. Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about their pain and opioid use before and after treatment. We plan on enrolling 2 patients for each physical therapist.
75404288|NCT05875077|Drug|Dexmedetomidine|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
75404289|NCT05875077|Drug|Propofol|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
75404290|NCT05868902|Device|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
75404291|NCT05866107|Device|self-monitoring of weight using smart body fat scale with high-precision weighing chip (Huawei Scale 2pro), a mobile phone app (Huawei Health), dietary management, and exercise management.|Participants will use a mobile phone app (Huawei Health) to collect data on sleep log, daily activities and calorie consumption. The smart body fat scale with high-precision weighing chip (Huawei Scale 2pro) will be used to collect heart rate, weight, BMI, body type, basal metabolic rate, fat rate, fat free body weight, skeletal muscle mass, bone salt content, visceral fat grade, body water (%), body protein rate and body composition, and all data will be uploaded to the app. Participants could also record their daily dietary intake (for calculation of calorie intake) in the health app; psychiatrists evaluate the patient's condition and conduct laboratory tests; nutrition instructors conduct dietary education and formulate individualized energy-limited balanced diet prescriptions; exercise instructors conduct behavioral ways and sports education, and individualized exercise prescriptions.
75404292|NCT05864612|Behavioral|Screening Questionnaires|Standard care screening questionnaires on anxiety and depression
75404293|NCT05852184|Other|Hb Scope APP|"The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., <=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use."
75404294|NCT05852158|Drug|Cefazolin 2 GM Injection|Single pre-op dose of 2g IV cefazolin
75404295|NCT05852158|Drug|Cefazolin Injection|Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
75404296|NCT05844228|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
75871561|NCT03895320|Behavioral|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
76038808|NCT04807309|Drug|Danazol Pill|Danazol 200 mg orally twice a day
75404297|NCT05833529|Behavioral|Virtual Reality Cue Exposure (VRCE) Therapy for Cocaine Craving - 2 weeks|"40 10 mins VRCEs for cocaine craving (desensitization to only cocaine craving cues; no others interventions). 4 VRCE and 2 different VRCE situations by meeting. Same VRCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard VRCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous VRCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention in any case of distress still over convenient levels. VRCE use Meta Quest 2, are visuo-auditively immersive (360°; 1st person), interactive (using virtual objects), semi-stationnary (360°-rotating stool and teleportation system). Participant skin color and cocaine using mode individualized."
75404298|NCT05833529|Other|Memory Focused Cognitive Therapy (MFCT) - 1 week|"In accordance with the Memory Focused Cognitive Therapy for Cocaine Use Disorder Therapist Guide (Marsden and Goetz, 2018), MFCT meetings will consist in 5 sequential components: Cognitive case conceptualisation of cocaine use disorder maintaining processes to inform a treatment plan; Education about cocaine's cognitive and physical effects; Cocaine related cue-induction to elicit images and affective responses; Memory reconsolidation procedures; Standard CBT techniques (e.g. behavioural experiments of cocaine-related expectancies and skills for adaptive emotion regulation)."
75404299|NCT05833529|Behavioral|Pictures-based Cue Exposure (PCE) Therapy for Cocaine Craving - 3 weeks|"60 x 10 mins PCE (desensitization to only cocaine craving cues; no others interventions). A standard audio of VRE songs is played in PCE. 4 PCE and 2 different PCE situations by meeting. Same PCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard PCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous PCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention if any distress over convenient levels. PCE use a laptop standard PowerPoint slide show (2D pictures from VRCE; non-spatialized audio from laptop speakers), are non-interactive (seated on a stool). Participant skin color and cocaine using mode individualized."
75404300|NCT05824377|Other|Continuous Feeds|Continuous feeds will be delivered via an indwelling nasogastric/orogastric tube with a continuous infusion pump.
75404301|NCT05824377|Other|Intermittent Bolus Feeds|Intermittent bolus feedings will be given by gravity every 3 hours over 15- 30 minutes.
75404302|NCT05817422|Biological|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
75404303|NCT05817422|Other|Placebo|0.9% NaCl solution for injection.
75404304|NCT05783362|Behavioral|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion. Conditioned pain modulation will be calculated as the average pain ratings of the second testing stimulus series minus the average pain ratings of the first testing stimulus series.
75871562|NCT03895320|Behavioral|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
76038809|NCT04807309|Drug|Placebo|Placebo twice a day
75404305|NCT05776979|Drug|Isatuximab|Given by vein over about 75 minutes
75404306|NCT05776979|Drug|lenalidomide|Given by PO
75404307|NCT05738213|Device|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
75404308|NCT05738213|Device|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
75404309|NCT05738213|Behavioral|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
75404310|NCT05738213|Behavioral|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
75404311|NCT05738213|Behavioral|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
75404312|NCT05738213|Behavioral|PedMIDAS (Pediatric Migraine Disability Assessment)|Adolescents with migraine will complete questions regarding their headache frequency. Migraine disability will be assessed using PedMIDAS (Pediatric Migraine Disability Assessment). This self-reported questionnaire assesses the number of days that headaches affect participant's daily activities. This is a widely used, reliable and validated tool to assess migraine disability.
75404313|NCT05738213|Diagnostic Test|Hormonal assessment|Blood samples (approximetly 2 tablespoons) will be collected for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone).
75404314|NCT05738213|Other|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-Wave 3 survey, which allows for differentiation between pre-, early-, late-, and post-pubertal status. Early puberty is defined as a score of 3 and no menarche, mid-puberty is defined as 4 and no menarche, late pubertal is defined as a score of 7 points or less and with menarche, and post pubertal is defined as a score of 8 and menarche. For boys, pubertal maturation status will be determined by the Physical Development Scale using the body hair growth voice change and facial hair questions. Early puberty is defined as a score of 4-5, mid-puberty is defined as a score of 6-8, late pubertal is defined as a score of 9-11 points, and post pubertal is defined as a score of 12.
75404315|NCT05727397|Drug|RC28-E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
75404316|NCT05727397|Drug|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
75404317|NCT05720104|Device|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
75404318|NCT05720104|Other|Standard oral hygiene instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
75404319|NCT05717842|Radiation|Nuclear Medicine Scan|Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
75404320|NCT05711628|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
75404321|NCT05711628|Drug|Bendamustine|Given IV
75404322|NCT05711628|Drug|Brentuximab Vedotin|Given IV
76038810|NCT04744649|Drug|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40~60mg Bid，d1~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40~60mg Bid,d1~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
75404323|NCT05711628|Drug|Carboplatin|Given IV
75404324|NCT05711628|Procedure|Computed Tomography|Undergo PET/CT and CT
75404325|NCT05711628|Drug|Etoposide|Given IV
75404326|NCT05711628|Drug|Gemcitabine|Given IV
75404327|NCT05711628|Drug|Ifosfamide|Given IV
75404328|NCT05711628|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75871563|NCT03895320|Behavioral|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
75404329|NCT05711628|Biological|Pembrolizumab|Given IV
75404330|NCT05711628|Procedure|Positron Emission Tomography|Undergo PET/CT
75404331|NCT05711628|Radiation|Radiation Therapy|Undergo RT
75404332|NCT05711628|Other|Transplant Conditioning|Receive standard preparative chemotherapy regimen
75404333|NCT05711628|Drug|Vinorelbine|Given IV
75404334|NCT05704634|Drug|Cemiplimab|Given by Injection under the skin every 2 weeks
75404335|NCT05704634|Drug|Kevzara (Sarilumab)|Given by IV (vein) over about 30 minutes every 3 weeks.
75404336|NCT05677490|Drug|Fluorouracil|Given IV
75404337|NCT05677490|Drug|Leucovorin Calcium|Given IV
75404338|NCT05677490|Drug|Oxaliplatin|Given IV
75404339|NCT05677490|Drug|Irinotecan|Given IV
75404340|NCT05677490|Biological|Nivolumab|Given IV
75404341|NCT05677490|Procedure|Magnetic Resonance Imaging|Undergo MRI
75404342|NCT05677490|Procedure|Computed Tomography|Undergo a CT Scan
75404343|NCT05677490|Procedure|Biospecimen Collection|Undergo blood sample collection
75404344|NCT05677490|Other|Questionnaire Administration|Ancillary studies
75404345|NCT05676489|Drug|[F-18]MeFAMP PET|Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-[F-18]fluoro-2-methyl-2-(methylamino)propanoic acid ([F-18]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
75404346|NCT05673278|Diagnostic Test|Bowel Ultrasound Scan|"Ultrasound scans will attempt to measure predefined criteria implemented in other research work using bowel ultrasound.~I - Bowel wall thickness II - Colour Doppler signal III - Loss of wall layer stratification IV - Loss of haustration V - Fatty wrapping VI - Motility in terminal ileum (TI) VII - Lymphadenopathy VIII - Abscess IX - Stricture~+ Image quality"
75404347|NCT05656664|Dietary Supplement|Folic Acid|Folic acid supplementation to assess for increased arsenic metabolite excretion
76038811|NCT04744649|Drug|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40~60mg Bid,d1~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
76038812|NCT04801225|Device|Non-invasive electromagnetic stimulation for acute stroke treatment|Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
76038813|NCT05612633|Drug|zelavespib|Oral zelavespib 100 mg will be administered once daily
76038814|NCT04793893|Device|ReLex Smile|With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
76038815|NCT04002661|Drug|Flibanserin|Flibanserin tablet
76038816|NCT04002661|Drug|Placebo|Oral Tablet
75404348|NCT05656664|Other|Placebo|Placebo group to assess arsenic metabolite excretion
75404349|NCT05654012|Device|MRI|Grey Matter Volume (T1) Resting state BOLD
75404350|NCT05654012|Device|Thermal Stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
75404351|NCT05654012|Device|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
75404352|NCT05654012|Behavioral|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 10 or 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
75404353|NCT05654012|Behavioral|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.
75404354|NCT05654012|Behavioral|Conditioned pain modulation (CPM) efficiency|The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.
75404355|NCT05654012|Diagnostic Test|Hormonal assessment|Blood samples will be collected for analyses of sex hormone levels
75404356|NCT05654012|Behavioral|Migraine-related measures|Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.
75404357|NCT05654012|Behavioral|Neural assessments|MRI and fMRI scans
75404358|NCT05654012|Diagnostic Test|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-
75404359|NCT05653089|Procedure|Choice and adjustment of the wheelchair according to the patient's needs|"After a personalized analysis of the patient and his needs, the occupational therapists define the equipment necessary for the good positioning of the patient:~Choice and adjustments of the wheelchair~Choice and adjustments of the wheelchair/patient interface"
75404360|NCT05644223|Drug|edaravone dexborneol|intravenous edaravone dexborneol 37.5mg twice daily
75404361|NCT05636371|Other|Written Communication|Written patient care updates provided to families of ICU patients each day
75404362|NCT05633147|Drug|Linaprazan glurate|"Investigational Medicinal Product: Linaprazan glurate (tablets).~Part I:~Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10.~Part II:~Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days."
75404363|NCT05633147|Drug|Drug drug interaction (DDI) - Clarithromycin (Part I)|Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
75404364|NCT05633147|Drug|Drug drug interaction (DDI) - Midazolam (Part 2)|Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).
75404365|NCT05629728|Behavioral|Tai Chi exercise|Sun-style Tai Chi (21 forms)
75404366|NCT05622318|Drug|Cyclophosphamide|25 mg/kg by IV on Days +3 and +4.
75404367|NCT05622318|Drug|Tacrolimus|Target level 5-10 ng/mL (If the subject experiences nausea and vomiting that prevents the oral intake of tacrolimus anytime during treatment, tacrolimus is to be given by IV at the appropriate dose that was used to obtain the therapeutic level [IV:PO ratio = 1:4]). Administered Days +5 through +90. Taper after Day +90 and discontinue on Day +180.
75404368|NCT05622318|Drug|Mycophenolate Mofetil|15 mg/kg tablet thrice daily Days +5 through +35 every eight hours.
75404369|NCT05622318|Drug|Ruxolitinib|5 mg tablet twice daily after engraftment through Day +365. Taper after Day +365.
75404370|NCT05620719|Behavioral|Cognitive Behavioral Therapy for Posttraumatic Headache|CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.
75404371|NCT05620719|Other|Treatment as Usual|Participants will continue to engage in medical care as usual for 8 weeks.
75404372|NCT05620719|Other|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
75404373|NCT05612048|Other|Survey|This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.
75404374|NCT05612048|Other|Intra-oral camera|Intraoral pictures of molars and incisors in 13 key regions
75404375|NCT05612048|Other|Optional Salvia sample|Cohort 1 only. Participant is responsible for collecting and bringing the salvia sample to clinic.
75404376|NCT05611840|Procedure|Robotic surgery|one-stage robotic common bile duct exploration and cholecystectomy
75404377|NCT05611840|Procedure|Endo-laparoscopic surgery|Two-stage therapeutic ERCP plus interval laparoscopic cholecystectomy
75404378|NCT05608083|Behavioral|HEARTS classes|HEARTS teaches autistic adults about friendship and healthy dating relationships. HEARTS is 6-sessions long and meets weekly over zoom. Each session is 90 minutes long.
75404379|NCT05608083|Behavioral|Online discussion group|A 90-minute discussion group will meet online weekly for 6 weeks to discuss friendships and healthy dating relationships for autistic adults.
75404380|NCT05597488|Device|EUS guided portal pressure gradient measurement|EUS-guided PPGM is performed under monitored anaesthesia. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein (Figure 3). A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle (Figure 4). Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The needle is then removed from the portal vein and liver, if necessary. The process is repeated for the hepatic vein (Figure 5). The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
76038817|NCT05458583|Procedure|Baseline periodontal measurements (T0)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the bonding session.
76038818|NCT05458583|Procedure|Periodontal measurements (T1)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 6 months after bonding.
75871564|NCT03895320|Behavioral|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
76038819|NCT05458583|Procedure|Periodontal measurements (T2)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 12 months after bonding.
75404381|NCT05593900|Behavioral|Nurse-to-Family Video Chat|A Nurse-To-Family Video Chat will be offered to parents/guardians to virtually connect with their post-transfer nurse; this intervention is changing the behavior of how providers deliver healthcare and how parents/guardians engage in their child's care.
75404382|NCT05584475|Behavioral|Mindful Awareness Practices (MAPs)|MAPs is an 8-session, group-based approach for individuals with ADHD to improve attentional difficulties and related impairments by enhancing attending to and accepting experiences in the present moment. Sessions typically last between 60 and 90 minutes, though may last up to 120 minutes.
76038820|NCT05458583|Procedure|Retainer failure rates|A retainer with at least one composite pad detachment was considered to be a failure during 1-year follow-up.
76038821|NCT03998605|Behavioral|Abuse Prevention Program|The abuse prevention program will be comprised of nine shared learning modules for the individual with Intellectual Disabilities (ID) and a care provider. Each shared module will contain an action step in the Individual Response Plan and will include video, guided practice and workbook activities to equip persons with ID with a range of judgment, decision-making skills and the efficacy needed for identifying, rejecting, and reporting abuse.
76038822|NCT03998605|Behavioral|Control Condition|The control group will receive worksheets from the ESCAPE-NOW curriculum.
75404383|NCT05572697|Behavioral|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|6 week sleep intervention delivered via a smartphone app while taking part in inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
75404384|NCT05572697|Behavioral|Usual care|Inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
75404389|NCT05568394|Other|Manual therapy combinded with therapeutic exercise|"The treatment includes cervical mobilization and specific therapeutic exercises: craniocervical and cervical flexors and extensors, axioscapular muscles, and postural correction (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
75404390|NCT05568394|Other|Routine physical therapy|"The treatment includes routine physical therapy (e.g., modalities, range of motion and/or gentle stretching exercise) (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
75404391|NCT05566574|Drug|RP-3500|RP-3500 on Days 1-5.
75404392|NCT05566574|Radiation|External Beam Radiotherapy (EBRT)|Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
75404393|NCT05563779|Other|Volume Control mode|Volume Control mode for mechanical ventilation
75404394|NCT05563779|Other|Pressure Control mode|Pressure Control mode for mechanical ventilation
75404395|NCT05563779|Other|Adaptive Pressure Control mode|Adaptive Pressure Control mode for mechanical ventilation
75404396|NCT05535829|Other|Laboratory analysis of samples|Laboratory analysis of samples
75404397|NCT05534854|Genetic|Gene test|Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
75404398|NCT05534477|Device|Verily Clinical Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
75404399|NCT05534477|Device|Verily Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
75404400|NCT05534477|Device|Vivalink ECG Patch|The Vivalink ECG Patch is a continuously recording ECG monitor and will be used as a reference device for measuring participants' pulse rate, pulse rate variability, and pulse rate coverage. The Vivalink ECG Patch is a medical device manufactured by VivaLNK Inc. and has been cleared by the FDA.
75404401|NCT05534477|Device|Modus StepWatch 4|Modus StepWatch 4 is an ankle-worn wearable medical device, and will be used as a reference device for measuring participants' ambulatory time and daily step count. The Modus StepWatch 4 is FDA listed.
75404402|NCT05528848|Drug|Carfentanil, C-11|Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.
75404403|NCT05528848|Drug|Naloxone|Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.
75404404|NCT05525065|Drug|GlucoCorticoid|Glucocorticoid as calculated in prednisone oral equivalents.
75404405|NCT05519527|Drug|Part 1 (STI-6129)|Given by vein (IV)
75404406|NCT05519527|Drug|Part 2 (STI-6129)|Given by vein (IV)
75404407|NCT05508542|Behavioral|Progressive relaxation exercises|Personal information form, Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be applied to the pregnant women at the first interview. Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. Afterwards, the Relaxation Exercises CD will be played and the exercises will be performed with the patient along with the CD. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.
75404408|NCT05504044|Other|Glucose control|50 g glucose dissolved in 250 mL water
75404409|NCT05504044|Other|Bread control|91.4 g white bread
75404410|NCT05504044|Other|Almond paste|88.7 g white bread and 15 g almond paste
76038823|NCT04983277|Other|no intervention|no intervention
75404411|NCT05504044|Other|Almond paste and inulin|88.7 g white bread, 15 g almond paste and 4 g inulin
75711433|NCT04437238|Other|KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
76038824|NCT03201575|Device|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
75404412|NCT05504044|Other|Low dose almond paste and inulin|89.6 g white bread, 10 g almond paste and 3.8 g inulin
75404413|NCT05492552|Behavioral|Active-at-home-HF|Increase daily step count by 2,000 and weekly telephone calls.
75404414|NCT05488301|Other|chest physiotherapy|"chest physiotherapy session including:~nasal ventilation~decrease of respiratory rate without increasement of Tidal volume~abdomino-diaphragmatic ventilation"
75404415|NCT05486078|Device|MD Tissue Collagen Medical Device|"The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode.~MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas."
75404416|NCT05481320|Behavioral|REACH VN Phone Intervention|4-6 intervention sessions delivered via phone over the course of 1-3 months.
75404417|NCT05481320|Behavioral|Enhanced Control|A single phone session providing education about dementia.
75404418|NCT05476328|Device|OPAL Sound Processing Strategy.|OPAL Sound Processing Strategy. OPAL sound processing strategy designed to improve perception of fundamental frequency (F0) as cue to lexical tone in tonal languages and to pitch in music. This research strategy will be implemented in the Nucleus 6 CP900 sound processors. The programming will be performed by the investigational software Cochlear Device Interface Tool (CDI Tool). Investigational firmware will be written on a commercially available N6 sound processor sound processor.
75404419|NCT05476328|Device|OPAL-EM|OPAL-EM (Enhanced Modulation) is a version of OPAL that improves temporal accuracy in the coding of F0 amplitude-modulation in the stimulus envelope. It is specifically designed to address the need for use of low stimulation rates (i.e., lower than the recommended OPAL rate of around 1200 pps/ch) but it is also expected to provided improvements for all stimulation rates by virtue of the improved temporal accuracy it provides.
75404420|NCT05476328|Device|SPACE|SPACE (Spread Precompensation Advanced Combination Encoder) is a sound coding strategy that is intended to improve spectral resolution, and hence hypothesised to improve cochlear implant (CI) speech understanding in noise. It is an alternative to the ACE sound coding strategy. It has been implemented on the Nucleus 7 CP1000 sound processor for CIC4-based implants.
75404421|NCT05476328|Device|FAST|FAST (Fundamental Asynchronous Stimulus Timing) is a low- and variable-rate coding strategy that has been shown to be power efficient and significantly increase sensitivity to ITD cues in bilateral subjects. It also explicitly codes low F0s as the rate of stimulation and may have tone and music benefits. It has been implemented on the Nucleus 5 CP800 sound processor for CIC4-based implants.
75404422|NCT05476328|Device|OPAL-SPACE|OPAL-SPACE (combined OPAL and SPACE strategy) aims to preserve as many of the significant features encoded by both OPAL and SPACE strategies individually. Since SPACE codes spectral envelope information, while OPAL codes temporal periodicity information, it is reasonable to suggest that both coding techniques can be combined to improve perception additively.
75404423|NCT05476328|Device|FAST-OPAL|FAST-OPAL (combined FAST and OPAL strategy) strategy was developed to improve FAST strategy performance in noisy environments. The processing techniques employed by FAST-OPAL retain the sparse, yet temporally precise coding of temporal envelope information, while improving coding of that information in noise and coding of relative across-channel intensity in noise.
75404424|NCT05476328|Device|Cochlear Device Interface Tool|For all strategies, programming will be performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool). Investigational software will be used to stream stimulation sequences to a commercially available N6 sound processor using the Cochlear NIC4.1 interface.
75404425|NCT05465642|Other|Collect stool and blood samples from patients|Collect stool and blood samples from patients
76038825|NCT03201575|Device|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
76038826|NCT04426955|Drug|Camrelizumab|IV infusion
76038827|NCT04426955|Drug|Paclitaxel|IV infusion
76038828|NCT04426955|Drug|Cisplatin|IV infusion
76038829|NCT04426955|Drug|Placebo|IV infusion
76038830|NCT04426955|Radiation|Radiation|Concurrent Radiation
75404426|NCT05459272|Dietary Supplement|Aquilea Sueno Forte|"The test product consists of a dietary supplement in the form of tablets with three layers containing: melatonin (1.95 mg/tablet) and herbal products (extracts from Griffonia, Passiflora, California poppy, Valerian, Melissa).~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
75404427|NCT05459272|Other|Placebo|"The placebo will consist of tablets with three layers and with the same appearance as the dietary supplement under study, but containing no active ingredients.~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
75404428|NCT05451576|Dietary Supplement|Zelnite®|2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).
75404429|NCT05451576|Dietary Supplement|Placebo|Placebo will be given for 7 weeks (5 days/week).
75404430|NCT05445323|Genetic|Low dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
75404431|NCT05445323|Genetic|Mid Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
75404432|NCT05445323|Genetic|High Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
75404433|NCT05436756|Other|Biological sampling and collection|"Biological sampling and collection:~whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)~urine: 1 bottle of 30ml~Freezing of serum after centrifugation~Storage~Collection of clinico-biological data on a dedicated eCRF"
75404434|NCT05420948|Drug|Pembrolizumab|A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.
75404435|NCT05420948|Drug|Carboplatin|A chemotherapy drug used to treat cancer.
75404436|NCT05420948|Drug|Paclitaxel|A chemotherapy drug used to treat cancer.
75404437|NCT05419999|Device|Soterix 1x1 tDCS mini CT|During stimulation, a current flows between the electrodes passing through the brain to complete the circuit. tDCS is hypothesized to modulate intrinsic neuronal activity by enhancing neuronal resting potential, or altering the likelihood that a neuron will (or will not) depolarize.
76038831|NCT02630563|Drug|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
75404438|NCT05419999|Other|Sham Soterix 1x1 tDCS Mini CT|Sham setting is used on the Soterix transcranial electrical stimulator
75404439|NCT05419999|Behavioral|Written Exposure Therapy (WET)|An exposure-based, behavioral psychotherapy for PTSD.
75404440|NCT05418348|Drug|GTX-104|new formulation of nimodipine injection for IV infusion
75404441|NCT05418348|Drug|Nimodipine Capsules|Nimodipine capsules (reference formulation)
76038832|NCT02630563|Drug|Cyclosporine|Cyclosporine will be administered as per center practice.
76038833|NCT02630563|Drug|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
76038834|NCT05700695|Drug|Branch Chain Amino Acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
76038835|NCT05700695|Drug|Lactulose|Oral lactulose will be given to patients in both arms
76038836|NCT04982341|Procedure|prone position|patients are returned from prone to supine position while receiving oxygenation through HFNC
75404442|NCT05416320|Drug|Calcipotriol|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
75404443|NCT05416320|Drug|Subject's already prescribed drug|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
75404444|NCT05403216|Other|no intervention|
75711434|NCT04437238|Other|Control - Usual care|Participants allocated to the control condition will receive care as usual.
76038837|NCT04432987|Drug|Pulmozyme|"PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days"
76038838|NCT05412329|Biological|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
76038839|NCT05555381|Behavioral|young-D program|"needs detection by means of survey and interviews (mixed-methods)~6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
76038840|NCT05397743|Other|Quality of Life|Questionnaire Perceived stress scale (PSS) + Questionnaire Short form 36 (SF-36) + Questionnaire Visual functioning questionnaire 25 (VFQ-25)
76038841|NCT05555225|Other|Methylome|Epigenetic study : analysis of DNA methylation
75404445|NCT05399121|Behavioral|Piano Learning then Free Improvisation|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~The patient will then be asked to perform exercise 2. Exercise 2: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically. The therapist will use various MT accompaniment techniques.~Both exercises will be performed for the same amount of time (5 minutes each)."
75404446|NCT05399121|Behavioral|Free Improvisation then Piano Learning|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically interacts with them. The therapist will use various MT accompaniment techniques.~The patient will then be asked to perform exercise 2. Exercise 2 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~Both exercises will be performed for the same amount of time (5 minutes each)."
75550457|NCT06132789|Biological|Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried|This vaccine（1.0ml） is produced by Ab&b Biotechnology Co., Ltd.JS. Subjects will receive the Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried vaccinated by intramuscular injection.
75404447|NCT05393557|Other|Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury|Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR < 60, or SBP <100 mmHg) + 2 cycles of intermittent balloon inflation
75550458|NCT06125925|Procedure|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
75550459|NCT06125925|Drug|Medical Therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
75550460|NCT06124677|Drug|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
75550461|NCT06120647|Dietary Supplement|Essential amino acids (EAA)|intake of 240 mg EAA per kg lean body mass after a resistance exercise session
75550462|NCT06118892|Device|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
75550463|NCT06110091|Behavioral|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy is a behavioral program that includes education, lifestyle habits management, cognitive, relaxation, and behavioral conditioning for nocturia and insomnia
75711435|NCT01045837|Drug|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
75711436|NCT01045837|Behavioral|Gluten free diet|Only gluten free diet will be given in this group
75404448|NCT05387720|Procedure|Manual diaphragmatic facilitation (PNF) technique|"Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs."
75404449|NCT05387720|Procedure|Trigger sensitivity adjustment on mechanical ventilation|The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP
75404450|NCT05387720|Procedure|concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique|Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
75404451|NCT05381285|Other|No intervention|Non-interventional study
75404452|NCT05378672|Drug|Dasiglucagon|Dasiglucagon, 0.6 mg/0.6 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the abdominal region.
75404453|NCT05378087|Radiation|Concurrent chemoradiation|Standard concurrent chemoradiation: A point/HCR-CTV D90 ≥80Gy (+20%) by using IMRT or TOMO technics. Patients with image-positive common iliac lymph nodes or para-aortic lymph nodes receive extended-field EBRT. Brachytherapy should begin after 15-20F external radiotherapy. A radiation dose for the image-positive nodes can range from 55Gy to 60Gy. Five cycles of concurrent platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period one week) and CCRT should be completed within 56 days. CCRT one week later, if the cervix biopsy shows residual tumour and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes in the pelvic and abdominal cavity, three cycles of adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy will be performed (A point/HR-CTV D90 ≤ 96Gy).
75404454|NCT05378087|Procedure|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (height of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation should be performed postoperatively within 28 days.) The chemoradiation is consistent with the image staging group, except for extended-field EBRT determined by pathological positive para-aortic lymph nodes.
75550464|NCT06110091|Behavioral|Health Education Program|Health Education Program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment.
75550465|NCT06105684|Drug|Capecitabine Pill|Will be given once per day by mouth
75550466|NCT06099678|Behavioral|Elastic Band Training|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises.
75550467|NCT06099678|Behavioral|Elastic Band Training with Maximal Mental Effort|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises, where participants will perform maximal mental effort by imagining maximal muscle contraction during each exercise.
75550468|NCT06096246|Procedure|Pulmonary vein isolation|The catheter ablation (with a CE [Conformité Européenne] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
75404455|NCT05377606|Procedure|Pars plana vitrectomy with silicone oil|Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
75550469|NCT06096246|Procedure|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
75550470|NCT06096246|Device|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
75550471|NCT06096246|Procedure|Femoral sheath insertion|Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
75550472|NCT06082310|Other|Exercise|Two HIIT modalities
75404456|NCT05377606|Procedure|Pars plana vitrectomy with SF6|Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
75550473|NCT06081309|Device|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
75871565|NCT03895320|Behavioral|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
75871566|NCT02345746|Drug|Oxaliplatin|infusion over 12 hours via HAI
75871567|NCT02345746|Drug|Folinic Acid|as a 2-hour infusion via HAI on day 2
75871568|NCT02345746|Drug|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
75871569|NCT03629808|Procedure|4-6cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.
75871570|NCT03629808|Procedure|2-4cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.
75404457|NCT05374681|Other|Medical treatment|Medical treatment alone
75404458|NCT05374681|Other|Surgical treatment|Surgical treatment alone
75404459|NCT05374681|Other|embolization of the MMA|The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
75550474|NCT06080399|Other|Continuous subcutaneous apomorphine infusion (CSAI)|the CSAI proposed in the usual healthcare pathway of each PD patients included
75550475|NCT06075823|Device|TEER|transcatheter edge-to-edge mitral valve repair for significant mitral regurgitation
75550476|NCT06075823|Other|Optimal Medical Therapy|optimal heart failure management of ATTR-CM
75550477|NCT06073938|Drug|NHWD-870|The base dosage administered is 2.0 mg/dose/day, and the frequency and dose of administration may be adjusted based on safety data.
75550478|NCT06059443|Behavioral|mLab App Plus|Participants will use the mLab Plus app to test for Syphilis and HIV using the DPP HIV/Syphilis Test
75550479|NCT06058949|Behavioral|Health Protection and Promotion|An adaptive integrated Total Worker Health® program. Virtual 8-week program that's been contextualized to the physical and mental health needs of sign language interpreters. It will examine biomechanics, sleep hygiene, vicarious trauma and burnout, demand-control schema, physical activity, emotional management strategies, proper nutrition and examination of worksite.
75404460|NCT05374577|Other|pulmonary vascular dysfunction|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
75404461|NCT05374577|Other|pulmonary vascular function|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
75404462|NCT05374018|Diagnostic Test|urinary kit for pneumococcus antigen assay|urine test for detection of pneumococcus antigen
75404463|NCT05373823|Other|MSS enhancement|Focuses on MSS enhancement using stakeholder collaboration
75404464|NCT05373823|Other|Educational webpage on SSE|Longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
75404465|NCT05373823|Other|Assess implementation outcomes|A mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.
75404466|NCT05372367|Drug|BI 907828|BI 907828
75550480|NCT06058949|Behavioral|General Health Program|Virtual 8-week program that addresses participant sleep hygiene, physical activity and proper nutrition.
75404467|NCT05372367|Drug|Rifampicin|Rifampicin
75404468|NCT05372367|Drug|Itraconazole|Itraconazole
75404469|NCT05359562|Behavioral|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
75404470|NCT05351242|Other|Thermotherapy/sauna bath|Thermotherapy/sauna bath
75404471|NCT05350371|Drug|Pirfenidone Oral Tablet|Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.
75404472|NCT05350371|Drug|Placebo|The placebo tablets will be an exact replica of the pirfenidone tablet.
75404473|NCT05348200|Drug|Monad 1|Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
75550481|NCT06050616|Other|MRI scans|"Neuroimaging data will be collected with magnetic resonance imaging (MRI).~Structural neuroimaging will include T1 and T2-weighted scans, and diffusion tensor imaging (DTI).~Functional neuroimaging will include scans under the stop-signal task, monetary incentive delay task, and emotional faces task, and resting state."
75711437|NCT00932854|Procedure|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
75404474|NCT05348200|Drug|Monad 2|Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
75404475|NCT05348200|Drug|Monad 3|Single therapy cream containing Halobetasol Propionate (high strength).
75404476|NCT05348200|Drug|Combination - CITI-002 (low dose)|Combination cream containing Lidocaine and HBP (low)
75404477|NCT05348200|Drug|Combination - CITI-002 (high dose)|Combination cream containing Lidocaine and HBP (high)
75404478|NCT05338216|Behavioral|Traditional EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name 9 pictures back-to-back four times/day."
75404479|NCT05338216|Behavioral|Micro-Interaction EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name one picture at a time, 36 times/day."
75404480|NCT05325502|Dietary Supplement|caffeine|two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon
75404481|NCT05325502|Dietary Supplement|mannitol|two doses per day: 200 mg in the morning & 100 mg in the afternoon
75404482|NCT05321108|Other|Group A (GA)(Aerobic exercise group)|Aerobic Exercise has been demonstrated to be a safe strategy to improve several health outcomes in Systemic lupus erythematosus (SLE)SLE, including depressive symptoms or, even more importantly, fatigue and quality of life.
75404483|NCT05321108|Other|Group B (GB) (Whole-body vibration (WBV) group)|(WBV) has been growing over the years. WBVE occurs when the subject is in contact with the vibrating platform in operation and is exposed to the generated mechanical vibrations. WBV has a positive action on muscle strength, bone formation, balance, flexibility, functional capacity and fatigue.
75404484|NCT05307744|Dietary Supplement|PS128|Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.
75404485|NCT05307744|Other|Placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
75404486|NCT05298748|Other|Womb sound recordings|"Womb sounds will be chosen from commercially available (Amazon) womb recordings using a recording that most closely resembles the womb including maternal heart rate, fetal heartbeat, respiratory sounds, bowel popping sounds and frequency spectra as described by Parga, Daland 2018 et al."
75404487|NCT05290961|Other||The study is an observational trial, which don't have any intervention.
75404488|NCT05285384|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
75404489|NCT05265195|Other|Mixed Methods study|Mixed Methods study
75550482|NCT06050616|Other|Psychological measures|"Cognitive performance assessed by Wechsler Adult Intelligence Scale 4th Edition.~Personalities assessed by NEO Five-Factor Inventory (NEO-FFI), Substance Use Risk Profile Scale (SURPS), and Temperament and Character Inventory (TCI).~Other psychological assessments include Interpersonal Reactivity Index, Perceived Stress Scale, Kirby Monetary Choice Questionnaire, Passive Avoidance Learning Paradigm, and Stimulus-response compatibility."
75404490|NCT05264623|Device|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser use for refractive surgery
75404491|NCT05261191|Biological|MGD020|MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
75404492|NCT05261191|Biological|MGD014|MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
75404493|NCT05250778|Behavioral|Nudge|Room intervention
75404494|NCT05249127|Drug|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
75404495|NCT05235737|Drug|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
75404496|NCT05235737|Drug|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
75404497|NCT05223608|Other|ImmuCCo Cohort|Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
75404498|NCT05222763|Behavioral|Web-assisted patient education intervention designed according to the self-regulation model|Implementation of patient education with the website created about care and compliance needs in mastectomy patients obtained as a result of qualitative research.
75404499|NCT05222763|Behavioral|The website where the mastectomy patients handbook|The site where the patient booklet is available as pdf
75404500|NCT05218356|Drug|Covidir injections|administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
75550483|NCT06050616|Other|Life experiences|Self-report questionnaires on experiences of bullying and trauma.
75404501|NCT05218356|Diagnostic Test|Quantitative PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
75404502|NCT05218356|Diagnostic Test|IgM and IgG dosage|lood collection for dosage of Anti SARS-CoV-2 antibodies.
75404503|NCT05218356|Diagnostic Test|Screening Blood tests|omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.
75711438|NCT00933088|Other|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.~Mothers will be asked to complete data form."
75711439|NCT00567268|Drug|Gabapentin|"GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration."
75404504|NCT05218356|Diagnostic Test|Electrocardiogram|valuation by the principal investigator or assistant physician with a complete physical examination
75404505|NCT05218356|Other|NEWS-2 score|assessment of the participant by the NEWS-2 score.
75711440|NCT00907894|Drug|LDT600 (Telbivudine)|LDT600 (Telbivudine)
75711441|NCT03976648|Drug|GLPG1690|film-coated tablets of GLPG1690 to be administered orally
75404506|NCT05218356|Other|WHO score|assessment of the participant by the score of the World Health Organization.
75404507|NCT05218356|Other|Physical examination|evaluation by the principal investigator or assistant physician
75404508|NCT05218356|Other|COVID-19-Related Symptoms assessment|will be completed by the study staff member based on patient status and answers.
75404509|NCT05204719|Procedure|Prophylactic Delivery Room Continuous Positive Airway Pressure|Prophylactic Delivery Room Continuous Positive Airway Pressure (DR-CPAP) of 5-6 cm H20 will be provided for 20 minutes through the face mask or the appropriate size of nasal prong after the initial steps as per the participating institution's neonatal resuscitation protocol.
75404511|NCT05176015|Device|Frenzel Lens|pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.
75404512|NCT05176015|Diagnostic Test|Diagnostic Algorithm|"A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test.~Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers.~Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score"
75871571|NCT02341612|Other|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
75404513|NCT05175430|Drug|Paroxetine|Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
76038842|NCT05555147|Drug|nerve block with 0.5% ropivacaine|After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
75404514|NCT05175430|Drug|Lysergic Acid Diethylamide|LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
76038843|NCT05555147|Other|without any nerve block|Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
76038844|NCT02587247|Drug|TF2 antibody/68Ga-IMP-288|TF2 antibody coupled with 68Ga-IMP-288
75404515|NCT05175430|Drug|Placebo|Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
75404516|NCT05169398|Device|EUS-guided hepaticogastrostomy|EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent (Niti-S, Taewoong Medical, Gyeonggi-do, Korea)
75404517|NCT05168995|Drug|BDP/FF NEXThaler® 100/6 micrograms|"BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)"
75404518|NCT05152615|Dietary Supplement|Short Chain Fatty Acids (SCFA) Dietary Supplement|Butryate 1000 mg three times daily will be used in this study.
76038845|NCT02555111|Drug|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
75404519|NCT05148117|Diagnostic Test|Suspected Sepsis Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
75404520|NCT05148117|Diagnostic Test|Control Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
75550484|NCT06050616|Biological|Blood and urine samples|Blood and urine samples will be collected but will not undergo analysis in this study. Instead, these samples will be stored in a biobank for potential analysis in future research.
76038846|NCT02521415|Drug|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
76038847|NCT02521415|Drug|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
76038848|NCT02521415|Drug|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
75550485|NCT06050616|Other|Mental health symptoms|"Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview."
75404521|NCT05140343|Diagnostic Test|KARDIA Mobile ECG Monitoring (KMCM)|The KMCM will be introduced to the patient of the KMCM arm in the outpatient clinic. The activation and configuration will be done together with the physician in the outpatient clinic (installation of the ECG app, enabling heart rate rhythm notification). Patients are requested to acquired ECGs twice weekly plus additional ECGs if symptomatic. In case of symptoms the patient is asked to generate an ECG and communicate the event timely to the investigator and to the treating physician by sending a report through the ECG app. An e-mail account created for the study will be checked at least once a day. The arrhythmia diagnosis will be performed by the clinician based on the ECG information, independently of the arrhythmia classification automatically performed by the device. In case of stronger symptoms of any kind at any time the patient is asked to request medical help regardless of the KMCM notifications. Change of management will be collected.
75404522|NCT05139277|Diagnostic Test|CONVIVO system|Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.
75404523|NCT05139277|Other|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
75404524|NCT05138432|Behavioral|Fruit and Vegetable Prescription Voucher|Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
75404525|NCT05133791|Drug|Annexin A5|Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
75404526|NCT05127915|Device|Adient absorbable filter + best practice VTE prophylaxis|Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
75550486|NCT06050278|Other|Tapestry technology|The study involves the immediate freezing and preservation in liquid nitrogen of a tumor histological sample from surgical resection, obtained from the operating room, within one hour of removal. Surgery is part of the normal clinical practice of patients with lung cancer.
75550487|NCT06050252|Procedure|Biopsy|Undergo tissue biopsy
75550488|NCT06050252|Procedure|Biospecimen Collection|Undergo blood sample collection
75550489|NCT06050252|Drug|Cisplatin|Given IV
75550490|NCT06050252|Procedure|Computed Tomography|Undergo CT scan
75550491|NCT06050252|Biological|Durvalumab|Given IV
75550492|NCT06050252|Drug|Gemcitabine|Given IV
75550493|NCT06050252|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
76038849|NCT02461511|Other|Therapeutic Education|participation in a therapeutic education program on diabetes
76038850|NCT02078141|Drug|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
76038851|NCT02588339|Drug|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
76038852|NCT02588339|Drug|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
76038853|NCT02588339|Drug|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
76038854|NCT05554913|Drug|QL0911|This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
76038855|NCT05554913|Drug|Placebo|Placebo comparator
76038856|NCT05554757|Device|conventional rubber dam system|rubber dam is a protective sheet with a hole that a dental professional positions over a tooth during an endodontic procedureEndodontists . This allows to isolate the treatment area with a dental clamp around the tooth. The dental sheet is placed around the in the Dental Rubber Dams and then a u-shaped device is hooked around. This isolates the single tooth where dental treatment will be conducted.
75550494|NCT06050252|Procedure|Resection|Undergo surgical resection
75404527|NCT05127915|Device|best practice VTE prophylaxis|Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
75404528|NCT05125822|Other|Meal replacement and lifestyle modification|Meal replacement and lifestyle modification
75404529|NCT05115513|Drug|Medium THC|Marijuana flower with medium THC
75404530|NCT05115513|Drug|Placebo THC|Marijuana flower with no THC
75404531|NCT05113199|Behavioral|Virtual Dignity Therapy|Virtual Dignity Therapy will be facilitated by a registered nurse or medical doctor trained in Dignity Therapy.
75404532|NCT05105542|Drug|11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor|The radiotracer, [11C]EMO, will be administered at the beginning of each PET scan.
75404533|NCT05101707|Device|transcutaneous auricular vagus nerve stimulation|Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
75404534|NCT05101707|Other|Constraint induced movement therapy|Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
75404535|NCT05099991|Device|Single Foley Balloon|Foley Balloon will be placed through the cervix and inflated with 30mL of saline or water on the day prior to the procedure
75404536|NCT05099991|Device|Dilapan-S|Dilapan S will be placed through the cervix on the day prior to the procedure
75404537|NCT05090839|Behavioral|Weekly Emotional Disclosure (WED)|Online writing session with each session lasting approximately 30 minutes. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.
75404538|NCT05089760|Other|No intervention|This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.
75404539|NCT05080075|Biological|Platelet Rich Plasma Injection|Research participants own blood will be used to prepare the platelet rich plasma injectate, which will be injected into the affected knee using ultrasound guidance.
75550495|NCT06047366|Drug|Sodium bicarbonate|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
75711442|NCT04014556|Device|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
75711443|NCT04014556|Drug|Aflibercept|Aflibercept
75404540|NCT05071170|Behavioral|Ad libitum energy intake|Investigate post meal satiety and subsequent post meal energy intake according to degree of food processing and eating behaviour
75404541|NCT05067244|Drug|MDMA|MDMA assisted psychotherapy
75404542|NCT05063487|Other|Return of recent classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a recent classification (i.e., having acquired an HIV infection within the last year) will be returned to study participants during a scheduled 1-month visit following initial HIV diagnosis.
75404543|NCT05063487|Other|Return of long-term classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a long-term classification (i.e., having acquired an HIV infection more than one year ago) will be returned to study participants during the scheduled 1-month visit following initial HIV diagnosis.
75404544|NCT05062057|Device|Adhesive ambulatory ECG recording patches|All women in both groups will undergo sequential placement of two 14-day adhesive ambulatory ECG recording patches for a total of 28 days of ECG recording
75404545|NCT05060887|Biological|OVX836-003|One single administration intramuscularly at Day 1.
75404546|NCT05060887|Biological|Saline solution|One single administration intramuscularly at Day 1.
75711444|NCT00929812|Drug|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
75404548|NCT05041036|Drug|Nirogacestat (Gamma Secretase Inhibitor)|Patients will receive nirogacestat tablets to be taken orally.
75404549|NCT05032703|Device|Arm ergometer|"The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises."
75550496|NCT06047366|Drug|Lidocaine w/ epi|Septodont's standard formulation of 2% lidocaine with epinephrine
75550497|NCT06047366|Drug|Articaine w/ epi|Septodont's standard formulation of 4% articaine with epinephrine
75550498|NCT06047366|Drug|Mepivacaine plain|Septodont's standard formulation of 3% mepivacaine
75550499|NCT06043531|Other|Experimental: EVOO|Subjects will consume 50g of cold pressed EVOO per day for 28 days.
75711445|NCT00929812|Drug|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
75711446|NCT00933322|Dietary Supplement|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
75404550|NCT05031468|Biological|Licensed or EUA SARS-CoV-2 vaccine|Several SARS-CoV-2 vaccines utilizing different platforms (e.g., mRNA, viral vector, etc.), are available under EUA (and soon to be licensed) and are being administered to individuals who are pregnant or postpartum who belong to high-risk priority groups for vaccination. Participants will receive the SARS-CoV-2 vaccine of their choice or the type that is available to them. The researchers anticipate including up to 3 vaccines, whether given as part of the primary series or additional doses, as part of this non-interventional study.
75404551|NCT05031117|Procedure|Conventional Epidural Technique|Standard Lumbar Epidural Technique at L4-5 interspace using Tuhoy needle (18G) then epidural catheter (20G) inserted, then 15ml 0.5% Bupivacane and 50ug fentanyl given.
75404552|NCT05031117|Procedure|25G Dural Puncture Epidural Technique|25G pencil point spinal needle will be inserted at L4-5 interspace through the tuhoy needle
75404553|NCT05028166|Drug|Mirdametinib (MEK Inhibitor)|Patients will receive oral mirdametinib.
75404554|NCT05027945|Drug|Post-Transplant Cyclophosphamide (PTCY)|Post-Transplant Cyclophosphamide: 50 mg/kg IV daily over 2 hours on days +3 and +4, dosed according to ideal body weight
75404555|NCT05027945|Drug|Cyclophosphamide (CY)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, prior to transplant 14.5 mg/kg IV daily on days -6 and -5
75404556|NCT05027945|Drug|Fludarabine|40 mg/m2 IV over 30 mins daily For 8/8 Matched Related or Unrelated Donor Fludarabine dose will be on days -6, -5, -4, and -3 For 7/8 Matched Related or Unrelated or Haploidentical Donor Fludarabine dose will be on days -6, -5, -4, -3, and -2
75404557|NCT05027945|Radiation|Total Body Irradiation (TBI)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, 200cGy on day -1
75404558|NCT05027945|Drug|Busulfan|AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 8/8 Matched Related or Unrelated Donor Busulfan dose will be on days -6, -5, and -4 For 7/8 Matched Related or Unrelated or Haploidentical Donor Busulfan dose will be on days -4 and -3
75404559|NCT05027945|Drug|Sirolimus|Sirolimus: on day +5 5mg PO loading dose q4h for 3 doses, then 5 mg PO q24h starting on day +6
75404560|NCT05027945|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil (MMF): 15 mg/kg IV over 2 hours BID starting on day +5 until approximately day +35 (+/-2 days)
75404561|NCT05027945|Drug|Busulfan test dose|0.8 mg/kg IV over 2 hours
75404562|NCT05027945|Procedure|Allogeneic HSCT|stem cell transplant on day 0
75404563|NCT05012124|Other|Collaborative care|Receive u-CoCM
75404564|NCT05012124|Other|Interview or Focus Group|Participate in an interview or focus group
75404565|NCT05012124|Other|Media/technology Intervention with collaborative care|Use t-CoCM digital platform with collaborative care
75550500|NCT06041672|Behavioral|Warm Water Hand Baths|"Patients in the experimental group receive warm water hand baths as an intervention on the evening before surgery.~The intervention is carried out in the patient's room, room temperature was adjusted to 26°C and the timing is determined based on the patient's preference.~The study utilizes a foldable water bucket with temperature maintenance capability.Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes in a comfortable lying position."
75550501|NCT06041646|Drug|Sublingual film containing Igalmi|Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
75711447|NCT00933322|Dietary Supplement|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
75711448|NCT00933322|Dietary Supplement|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
75711449|NCT00933400|Procedure|CT Coronary Angiography|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
76038857|NCT05554757|Device|OPTRADAM|OptraDam Plus is a three-dimensional rubber dam that is flexible and has an anatomical shape, automatically stretched in an oral direction, an automatic hold of the device in the oral cavity is ensured.
76038858|NCT05612321|Device|Vacuum application|vacuum-assisted delivery
75404566|NCT05012124|Other|Survey Administration|Complete surveys
75404567|NCT05006157|Device|ViaOne device|ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
75711450|NCT00933400|Procedure|Traditional, Standard of Care|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
75711451|NCT00907972|Dietary Supplement|Vitamin D3|Vitamin D3
75404570|NCT04999059|Other|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
75404571|NCT04987541|Device|intermittent theta burst stimulation|stimulatory protocol
75550502|NCT06039709|Combination Product|5-ALA and Low-Intensity Focused Ultrasound (SDT)|5-ALA (20mg/kg orally) given ~6 hours prior to LIFU. Focused ultrasound will target a maximum of 50% of the tumor.
75711452|NCT00907972|Other|Placebo|Placebo
75711453|NCT03799744|Genetic|VCN-01|Dose level 1: 3.3x10^12 viral particles/patient and Dose level 2: 1x10^13 viral particles/patient
75711454|NCT03799744|Biological|Durvalumab|Dose: 1500 mg Q4W
75711455|NCT00933478|Device|Clay|Small dime sized piece of clay.
75711456|NCT00933556|Dietary Supplement|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
75711457|NCT00933556|Dietary Supplement|sugar pill (placebo)|placebo identical to the active product will be given
76038859|NCT05317247|Diagnostic Test|Cough sounds|The investigators will discover a cough audio signature and then validate it.
76038860|NCT05242601|Other||no intervention
76038861|NCT05554523|Device|Photoacoustic imaging|Photoacoustic imaging
75404572|NCT04986943|Device|Using ABTHERA Advance without a Wittmann Patch|In this group, patients will be receiving only the ABTHERA Advance product, without the use of the Wittmann Patch
75404573|NCT04978805|Behavioral|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
75404574|NCT04978298|Other|Placebo|Placebo
75404575|NCT04978298|Drug|Rasigiline|Rasigiline
75404576|NCT04978298|Drug|Phenelzine|Phenelzine
75404577|NCT04978298|Drug|Ozanimod|Ozanimod
75404578|NCT04975919|Drug|Decitabine and Cedazuridine|Given PO
75404579|NCT04975919|Drug|Venetoclax|Given PO
75404580|NCT04951583|Combination Product|FMT + ICI|"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."
75404581|NCT04941222|Other|"With robotic seal PARO"|The PARO robot will be made available to the patient by the caregiver in charge of the patient for 5mn before a toilet and during the duration of the care (about 10mn), at the frequency of twice a week for 16 weeks
75404582|NCT04939727|Other|OUD-CDS + Suicide Risk Model associated CDS|Access to OUD-CDS + Suicide Risk CDS
75404583|NCT04935619|Behavioral|Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
75404584|NCT04935619|Behavioral|Non-Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
75404585|NCT04930341|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
75404586|NCT04921527|Drug|chiauranib|50mg orally once daily
75404587|NCT04921527|Drug|Placebo|50mg orally once daily
75404588|NCT04921527|Drug|Paclitaxel|at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
75404589|NCT04913220|Drug|THOR-707|Solution for infusion: intravenous infusion
75404590|NCT04913220|Drug|Cemiplimab|Solution for infusion: intravenous infusion
75404591|NCT04902378|Device|Tandem t:slim X2 insulin pump with Control IQ technology|The intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology during pregnancy.
75404592|NCT04898504|Drug|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution.
75404593|NCT04898504|Procedure|Liver Transplantation|Patients randomized to this arm will be given 2nd line chemotherapy (regimen given at the discression of the treating oncologist) followed by liver-Tx
75404594|NCT04896021|Diagnostic Test|Cardiovascular disease risk assessment|Intervention in which the addition of guideline-recommended absolute cardiovascular disease risk assessment is embedded into point-of-care blood collection services for cholesterol measurement and results (including risk score) are reported to referring doctors.
75404595|NCT04896021|Diagnostic Test|Usual care assessment|Usual care in which blood cholesterol results are reported to referring doctors
75404596|NCT04876079|Other|Test to induce a decline in plasma glucose|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.
75404597|NCT04876079|Device|Dexcom G6|Participants will have to wear a Dexcom G6 during study interventions
75404598|NCT04876079|Other|Dex4|When the glycemic threshold is reach, participants will be given 16g of Dex4
75404599|NCT04876079|Drug|Insulin|A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
75404600|NCT04865523|Other|Manual Lymphatic Drainage|Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
75404601|NCT04852211|Procedure|Open or laparoscopic surgery|"Patients, with their consent, will be recruited to participate by investigators after considering the inclusion and exclusion criteria. Treatment allocation to the eligible patients will follow a randomization schedule. A total of 212 subjects will be randomized 1:1 to one of the two treatment arms:~Laparoscopic group: LMH~Open group: OMH"
75404602|NCT04845035|Drug|Dasatinib|By mouth
75404603|NCT04845035|Drug|Ponatinib|By mouth
75404604|NCT04845035|Drug|Berlin-Frankfurt-Münster Chemotherapy|with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone
75404605|NCT04845035|Drug|Methotrexate and Cytarabine|Intrathecal
75404606|NCT04832113|Other|Adapted Physical Activity and Dietetic|session in addtion conventional management dietetic, hydratation and physical activity
75404607|NCT04832113|Other|conventional management|Dietary and hydratation advices according to the recommendations
75404608|NCT04811573|Drug|EU-sourced Otezla®|Test product
75404609|NCT04811573|Drug|US-sourced Otezla®|Reference product 1
75404610|NCT04811573|Drug|Japan-sourced Otezla®|Reference product 2
75404611|NCT04801316|Behavioral|Steady Feet exercise programme|"Steady Feet (SF) is a 6-month community-based structured exercise programme aimed at improving physical strength and balance among older adults (aged 60 years and above) who are at high risk of falls.~This exercise programme was developed by Changi General Hospital's physiotherapists and exercise physiologist from evidence found in the literature."
75404612|NCT04801316|Behavioral|Steady Feet Video|About an hour-long video showcasing the exercise steps of the Steady Feet exercise programme
75404613|NCT04795362|Biological|blood sample|"5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml)."
75404614|NCT04789694|Other|Physiological intervention|"Rehabilitation specialist consultation (3x)~Individualized home-based exercise plan~Functional capacity measuring"
76038862|NCT04426565|Behavioral|motivational enhancement interview|Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
76038863|NCT04426565|Behavioral|the individual psychotherapy|It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
76038864|NCT04426565|Behavioral|the group psychotherapy|Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.
75404615|NCT04789694|Behavioral|Psychological intervention|"Clinical psychologist consultation (3x)~Anxiety and depression scoring~Psychological support"
75404616|NCT04789694|Dietary Supplement|Nutritional intervention|"Nutritional specialist consultation (3x)~Malnutrition scoring~Dietary supplementation"
75404617|NCT04783207|Dietary Supplement|Mitopure|Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily
75711458|NCT00929890|Behavioral|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
75711459|NCT00929890|Behavioral|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
75404618|NCT04783207|Dietary Supplement|Placebo|Softgel containing only excipients. 4 soft-gels to be taken daily
75404619|NCT04774913|Procedure|Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)|CTO PCI completed as a two step procedure with an initial planned CTO modification and a completion procedure after 8-12 weeks
75404620|NCT04774094|Drug|Zavicefta, Ceftazidime-Avibactam|Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.
75404621|NCT04770545|Drug|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
75711460|NCT04015258|Dietary Supplement|Blueberries|fresh spanish blueberries
75711461|NCT04015258|Dietary Supplement|Blueberry powder|freeze-dried blueberry powder
75711462|NCT04015258|Dietary Supplement|Blueberry components capsules|encapsulated blueberry components (microcrystalline cellulose powder in actual)
75711463|NCT00933634|Procedure|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
75711464|NCT00933634|Drug|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
75711465|NCT00933712|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
75871572|NCT02341612|Other|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
75404622|NCT04768270|Other|no intervention|It is an observation trial.
75404623|NCT04753437|Drug|Clarithromycin|Clarithromycin tablets.
75404624|NCT04753437|Drug|Amoxicillin|Amoxicillin capsules.
75404625|NCT04753437|Drug|Bismuth potassium citrate|Bismuth potassium citrate tablets.
75404626|NCT04753437|Drug|Esomeprazole|Esomeprazole tablets.
75404627|NCT04753437|Drug|Vonoprazan|Vonoprazan tablets.
75404628|NCT04743310|Drug|tozuleristide|tozuleristide 24 or 36 mg administered intravenously 1-24 hours prior to surgery
75404629|NCT04743310|Device|Canvas imaging system|imaging device attached to surgical microscope
75404630|NCT04743310|Procedure|Surgical resection of tumor|Standard of care surgical resection of tumor
75404631|NCT04740164|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with LMA Gastro
75404632|NCT04740164|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with standard nasal cannula
75404633|NCT04736355|Drug|DAOIB|oral, for 24 weeks
75404634|NCT04736355|Drug|Placebo|oral, for 24 weeks
75404635|NCT04725058|Other|Medical Group Visit|A group of 20 or more participants will receive obesity management through endocrinologist and registered dietitian in a group seetting.
75550503|NCT06036134|Behavioral|Baseline surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, gender, income, education level, relationship to the child), parental COVID-19 vaccine hesitancy, intentions to vaccinate child against COVID-19, and parents' attitudes, perceived norms, and perceived behavioral control about vaccinating their child against COVID-19,
75550504|NCT06036134|Behavioral|Digital Storytelling Intervention|In Aim 1, the investigators are creating intervention materials for Study Aim 2. These intervention materials include ten digital stories (each 2-3 minutes long) with a diverse sample of Hispanic parents and legal guardians who transformed from being COVID-19 vaccine-hesitant to vaccine-accepting. Each story uses individuals' own brief first-person visual narratives/stories that use digital images, audio recordings, music, and text to document personal experiences.
75550505|NCT06036134|Behavioral|Information Control Intervention|The control group participants will receive a CDC COVID-19 vaccine information sheet appropriate for their child's age.
75550506|NCT06035809|Behavioral|SMART|A movement and body-based intervention in which participants are encouraged to explore the use of sensory equipment, which may help reduce symptoms related to psychological trauma/PTSD. Sensory equipment includes exercise balls, mini-trampoline, weighted blankets, and a hammock swing.
75550507|NCT06029842|Other|Collaborative approach of clinical pharmacist with physicians in a medical center|For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.
75404636|NCT04725058|Other|Dietitian Individual Visit|Participant receives obesity management individually from a registered dietitian.
75550508|NCT06028282|Radiation|SPECT|SPECT of thyroid traced with I-131
75550509|NCT06026891|Drug|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
75404637|NCT04722237|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an evidence-based psychological therapy that has been used to improve physical and mental health among adults with health conditions, including cancer (Graham, Gouick, Krahe, & Gillanders, 2016). It fosters engagement with, rather than avoidance of, painful experiences, to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing problems.
75404638|NCT04653220|Other|Control 1|25g glucose dissolve in 250ml of water
75404639|NCT04653220|Other|Control 2|25g glucose dissolve in 250ml of water
75404640|NCT04653220|Other|Standard Crokao|Standard Crokao containing 25g of available carbohydrate
75404641|NCT04653220|Other|Low sugar variant 1|Low sugar variant 1 containing 25g of available carbohydrate
75404642|NCT04653220|Other|Low sugar variant 2|Low sugar variant 2 containing 25g of available carbohydrate
75404643|NCT04653220|Other|Low sugar variant 3|Low sugar variant 3 containing 25g of available carbohydrate
75404644|NCT04653220|Other|Low sugar variant 4|Low sugar variant 4 containing 25g of available carbohydrate
75404645|NCT04653220|Other|Low sugar variant 5|Low sugar variant 5 containing 25g of available carbohydrate
75404646|NCT04647630|Diagnostic Test|urine test|test for pneumococcal antigen in urine
75404647|NCT04619017|Biological|Segmental allergen challenge|All subjects will undergo bronchoscopy with administration of standardized allergen extract to one segment of the lung.
75404648|NCT04613557|Biological|CYAD-211|Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
75404649|NCT04613557|Drug|Endoxan|Preconditioning chemotherapy
76038865|NCT04426565|Behavioral|the family therapy|"According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence."
76038866|NCT04328831|Biological|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
76038867|NCT05558657|Other|Caregiver-led, acupressure combined with nursing intervention|"The intervention group will focus on the Hegu, Zusanli, Tianshu and Zhongwan acupoints. The caregivers can perform acupressure two hours after meals and once a day. And they can first perform acupressure on Zhongwan acupoints, and then Tianshu points on right and left abdomen. And then press Quchi point on the right and left arm. They can use the plan of the hand to massage clockwise on the position which is two inches from the navel for 8 minutes.~Besides, the intervention group will also receive nursing interventions on the basis of receiving acupressure intervention including (1) dietary guidance: help patients to formulate a reasonable diet plan, (2) cultivate regular defecation in patients, ( 3 ) Moderate exercise to increase gastrointestinal motility."
75404650|NCT04613557|Drug|Fludara|Preconditioning chemotherapy
75404651|NCT04605094|Biological|Benralizumab|Benralizumab by subcutaneous injection until Week 16, and then benralizumab by subcutaneous injection during the extension period.
75404652|NCT04605094|Biological|Placebo / Benralizumab|Placebo by subcutaneous injection until Week 16, then benralizumab by subcutaneous injection until Week 52.
75404653|NCT04605081|Drug|Naltrexone and Bupropion (NB) medication|NB medication will be taken daily in pill form.
75404654|NCT04605081|Other|Placebo|Placebo will be inactive and taken daily in pill form.
75404655|NCT04603014|Combination Product|Interdialytic peritoneal ultrafiltration with 10% dextrose solution|Interdialytic peritoneal ultrafiltration with incremental doses of a 10% dextrose solution, after hemodialysis twice weekly for three consecutive weeks
75404656|NCT04599504|Drug|Lisdexamfetamine Dimesylate (Medication)|Medication will be taken daily in pill form.
75404657|NCT04599504|Other|Placebo|Placebo will be inactive and taken daily in pill form.
75404658|NCT04599478|Drug|Naltrexone and Bupropion medication|NB medication will be taken daily in pill form.
75404659|NCT04599478|Behavioral|Behavioral Weight Loss|Behavioral Weight Loss (BWL) counseling includes weekly sessions.
75404660|NCT04599478|Other|Placebo|Placebo will be inactive and taken daily in pill form.
75404661|NCT04599439|Diagnostic Test|Cardiac magnetic resonance imaging|All patients will undergo a cardiac magnetic resonance test to calculate their border zone channel (BZC) mass. This will not be used to decide further interventions, but all the patients will be treated according to standards of care.
75550510|NCT06024174|Drug|BMS-986466|Specified dose on specified days
75404662|NCT04578639|Drug|Rituximab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
75550511|NCT06024174|Drug|Adagrasib|Specified dose on specified days
75550512|NCT06024174|Drug|Cetuximab|Specified dose on specified days
75550513|NCT06014723|Procedure|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
75711466|NCT00933790|Drug|ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)|Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
75711467|NCT02538250|Dietary Supplement|Nutricomp Drink Plus|Oral nutritional supplementation
75404663|NCT04578639|Drug|Ocrelizumab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
75404664|NCT04573296|Device|Vitadio|A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.
75404665|NCT04573296|Behavioral|Conventional high-intensity lifestyle intervention program|A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.
76038868|NCT05558657|Other|Caregiver-led, sham acupressure combined with nursing intervention|Control group will receive sham acupressure once a day for 10 days. Sham acupressure is the only difference compare with the intervention group. We will train the caregivers to perform acupressure on Tibia next to Zusanli, the lateral epicondyle of the humerus next to Quchi, the radius next to the tributary groove and last the second metacarpal next to Hegu. Also, they can do massage to the abdomen for 8 minutes. And they use same force as the intervention group.
76038869|NCT05700851|Dietary Supplement|Immuno-nutrition supplement|Oral Impact® is a powdered oral nutritional supplement that contains a unique combination of ingredients with immuno-modulating properties, namely omega-3 fatty acids, arginine and nucleotides, as well as soluble fibre.
75404666|NCT04555577|Drug|Peposertib|Given PO
75404667|NCT04555577|Radiation|Radiation Therapy|Undergo radiation therapy
75550514|NCT06014125|Other|psychoeducative program|"The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.~The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment.~The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.~A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.~The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent."
75550515|NCT06004830|Drug|Spironolactone|All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
76038870|NCT05612165|Device|Transcranial Direct Current Stimulation(tDCS)|The tDCS intervention was conducted for 20 minutes(1000μA) each time, 5 times a week for 2 weeks, a total of 10 times.
75404668|NCT04555577|Procedure|Resection|Undergo surgical resection
75404669|NCT04555577|Drug|Temozolomide|Given PO
75404670|NCT04555265|Device|Radiofrequency ablation or microwave ablation|Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
75550516|NCT06004180|Drug|Lu AF28996|Hard capsule, orally, per schedule specified in the arm description.
75550519|NCT05996107|Drug|Ribociclib|400 mg daily with a possibly dose reduction to 200 mg daily if required
76038871|NCT05612165|Device|Sham Transcranial Direct Current Stimulation(sham tDCS)|The sham tDCS intervention was conducted for 20 minutes(0μA) each time, 5 times a week for 2 weeks, a total of 10 times.
75711468|NCT00930124|Procedure|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
75404671|NCT04534296|Other|early mobilization|Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.
75404672|NCT04534296|Other|routine care|In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
75404673|NCT04530006|Diagnostic Test|Amantadine Hydrochloride|"Patients who are eligible for the study will be administered a regular 200 mg dose of FDA approved drug amantadine. This will be done at the following timepoints:~Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
75404674|NCT04526639|Behavioral|Virtual Reality-based Interactive Cognitive Training Program|Three virtual reality-based games designed to train inhibitory control, working memory, and cognitive flexibility among children with TBI
75404675|NCT04526639|Behavioral|Placebo Virtual Reality Game|A virtual playground for control group to interact without training executive functions
75404676|NCT04526210|Drug|ALXN1840|ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.
75404677|NCT04526210|Drug|Bupropion Hydrochloride|Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).
75404678|NCT04519970|Behavioral|Case Management|Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
75404679|NCT04504968|Other|Multimodal intervention|"Optimal control: HbA1c between 7.6-8.5% (60-69 mmol/mol) and Blood Pressure<150/90 mmHg~The physical exercise program that will be used will be the Vivifrail program (Erasmus + UE). Vivifrail includes: Strength for arms and legs, balance and gait, flexibility and resistance. The duration will be 16 weeks. (3 weeks to explain the program in the Trial site and the rest of weeks, it will be carried out at home).~Nutritional and educational program to increase diabetes knowledge, develop practical self-care skills for diabetes and increase the likelihood of improving glycemic control safely. The intervention aims to minimize the risk of hypoglycemia, ensure optimal nutritional status and help to maintain functional status. Seven separate sessions of 45 minutes each one twice a week for a period of 3-4 weeks in small groups. They will be moderated by a physician or diabetes educator and focused on behavioral changes and key points."
75404680|NCT04504968|Other|Usual care group|The level of usual health care that a patient with diabetes receives from their local national health system
75404681|NCT04478201|Other|back sleep positioning|sleeping on the back.
75404682|NCT04478201|Other|side sleep positioning|sleeping on the side
75404683|NCT04477005|Device|ERCP and insertion ofBio-degradable bile duct stent|ERCP is an accepted mode of treatment and patients rarely need surgery for bile leaks and bile duct stents. Endoscopic management involves sphincterotomy (cutting open the Sphincter of Oddi) and insertion of a plastic or metal stent. Instead of placing a plastic stent bio-degradable stent will be placed. They will be followed up on Day 1, 7,30, 60,90 and 180 days. they will have abdominal x-ray on day 90 and day180.
75404684|NCT04473222|Behavioral|Sleep Well!|Sleep Well! is a brief, behavioral sleep intervention. The intervention was originally comprised of healthy sleep advice and tested in the context of a sleep health education campaign for impoverished children. Based on preliminary research regarding the need for sleep intervention in primary care, Investigators have expanded the intervention to more comprehensively address poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers who are living in disadvantaged contexts. Intervention components are based on effective pediatric behavioral sleep treatments.
75404685|NCT04473222|Behavioral|Sleep education|Sleep education for caregivers of toddlers and preschoolers is provided via a Parent Family Education handout available to families and clinicians in the CHOP primary care network. The handout contains evidence-based advice about healthy sleep in early childhood.
75404686|NCT04451213|Diagnostic Test|MRI head|MRI head
75404687|NCT04443608|Drug|Patiromer Powder for Oral Suspension [Veltassa]|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
75404688|NCT04443608|Drug|Placebo|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
75711469|NCT00930124|Procedure|Distraction osteogenesis|
75711470|NCT00566254|Drug|Zonisamide|8mg/kg per day for approximately 24 weeks.
75711471|NCT00566254|Drug|Placebo|
75711472|NCT00930202|Drug|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
75711473|NCT00933868|Drug|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
75404689|NCT04440540|Behavioral|Dietitian led life style modification intervention|lifestyle changes supervised by dietitians
75404690|NCT04440540|Behavioral|Conventional care (control)|receive routine care
75404691|NCT04435691|Drug|Azacitidine|Given SC or IV
75550520|NCT05996107|Radiation|Postoperative Radiation Therapy|50 Gy in 25 fractions or 42.56 Gy in 16 fraction +/- 10 Gy boost including comprehensive nodal
75404692|NCT04435691|Biological|Magrolimab|Given IV
75404693|NCT04435691|Drug|Venetoclax|Given PO
75404694|NCT04435444|Other|Masterful supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form* (MSAS-SF)"
75404695|NCT04435444|Other|Attention control supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form* (MSAS-SF)"
75404696|NCT04422652|Drug|Bupropion|Bupropion is an anti-depressant medication.
75404697|NCT04422652|Behavioral|Behavioral activation therapy|Brief behavioral activation treatments administered via video tele-conferencing.
75711474|NCT00933868|Drug|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
75711475|NCT00908206|Drug|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
75711476|NCT00393523|Biological|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
75550521|NCT05984810|Procedure|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
76038872|NCT05554055|Biological|Anti Xa activity measurement.|Arterial blood samples of 3cc will be taken during the procedure at each ACT. Blood samples will be sent to the lab for anti Xa activity measurement.
75404698|NCT04422652|Drug|Placebo|Double-blind placebo.
75711477|NCT00393523|Biological|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
76038873|NCT05558345|Behavioral|Contingency Management|A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.
75404699|NCT04422652|Other|Clinical Management|Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.
75404700|NCT04411810|Device|Nevisense 3.0|Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in the US. Nevisense 3.0 will be used as a one-time exposure of <8 seconds per lesion. Disposable electrodes that contact the participant are 5mm x 5mm in size. Nevisense 3.0 measures electrical impedance of skin lesions and provides an output called the electrical impedence spectroscopy (EIS) score. Electrical impedance is a measure of a material's overall resistance to the flow of alternating electric currents of various frequencies. The principle is that electrical impedance is different in normal versus abnormal tissue.
75550522|NCT05980806|Drug|Selinexor 60 mg|Participants will receive selinexor 60 mg oral tablets QW.
75550523|NCT05980806|Drug|Selinexor 40 mg|Participants will receive selinexor 40 mg oral tablets QW.
75550524|NCT05980806|Drug|Ruxolitinib|Participants will receive ruxolitinib 5 mg or 10 mg twice daily.
75550525|NCT05980806|Drug|Pacritinib|Participants will receive pacritinib 200 mg twice daily.
75550526|NCT05980806|Drug|Momelotinib|Participants will receive momelotinib 200 mg once daily.
75550527|NCT05979051|Drug|SHR-1703|SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
75550528|NCT05979051|Drug|SHR-1703 Placebo|SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.
75550529|NCT05972772|Drug|Doxycyclin|100-mg film-coated tablets; Pfizer
75711478|NCT03993067|Procedure|Hemopatch|Hemopatch is a collagen based sealant is a hemostat agent. We want to investigate his role in the prevention of post operative biliary fistula
75711479|NCT03993067|Procedure|Fribrin glue and Tabotamp|Fibrin glue and Tabotampis the standard treatment
75711480|NCT00393367|Drug|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
76038874|NCT05543291|Behavioral|renal function|levels of eGFR
75550530|NCT05972772|Drug|Azithromycin|250-mg capsules; Pfizer
76038875|NCT05549843|Other|Manual therapy|Each session will last approximately 50-60 minutes, with 1 physiotherapy session per week over a period of 3 weeks. Each session is made up of 10 steps, of which 9 correspond to manual interventions commonly used in the field of manual therapy.
75711481|NCT00393367|Drug|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
75871573|NCT02341612|Other|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
75404701|NCT04411810|Device|Dermlite Cam|Dermlite Cam is a digital camera that captures images of the skin under cross-polarized and non-polarized light and is 510(k) exempt. The DermLite Cam device appears as a single piece camera with a charging cable and USB computer cable. As part of the camera unit, an extensor arm exists to allow for the capture of standardized clinical images. The DermLite Cam will be used to acquire 3 images of <5 seconds per lesion (one clinical, one polarized dermoscopic, and one non-polarized dermoscopic).
75404702|NCT04411810|Procedure|Skin biopsy|A skin biopsy is a small procedure that removes a sample of skin from the surface of the body. The method utilized will be either a shave or punch technique. The maximum size of a punch biopsy will be 6mm and these wounds are generally closed with no more than 2-3 sutures. A skin biopsy takes <15 minutes including preparation time, administration of intradermal anesthesia using lidocaine 1% with epinephrine 1:100,000, removal of the skin sample, achievement of hemostasis, dressing the wound, and providing instructions for home care. Samples will be placed formalin for routine processing.
75404703|NCT04402541|Drug|CB-5339|25mg and 75mg capsules
75404704|NCT04384692|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
75404705|NCT04384692|Drug|Busulfan|Given IV
75404706|NCT04384692|Drug|Cyclophosphamide|Given IV
75404707|NCT04384692|Drug|Fludarabine|Given IV
75404708|NCT04384692|Drug|Melphalan|Given IV
75404709|NCT04384692|Drug|Methotrexate|Given IV
75404710|NCT04384692|Drug|Mycophenolate Mofetil|Given IV or PO
75404711|NCT04384692|Drug|Ruxolitinib|Given PO
75404712|NCT04384692|Drug|Tacrolimus|Given IV and PO
75404713|NCT04384692|Radiation|Total-Body Irradiation|Undergo TBI
75404714|NCT04377451|Drug|Metformin|"The trial will be conducted in two phases, with a dose escalation of metformin. Metformin dosing will begin at 500mg (children) and 850mg (adults) once daily for 5 days in cohort 1.~Cohort 2 will be received weight-based doses; 5 days of 1000mg (500mg twice daily) for those weighing <60kg and 5 days of 1500mg (1000mg mane, 500mg nocte) for those weighing ≥60kg"
75404715|NCT04367311|Drug|Atezolizumab|Atezolizumab 1200 mg
75404716|NCT04367311|Drug|Docetaxel|Docetaxel 60-75 mg/m^2
75404717|NCT04367311|Drug|Cisplatin|60-75 mg/m^2
75404718|NCT04367311|Drug|Pemetrexed|Pemetrexed 500mg/m^2
75404719|NCT04363307|Device|AF Ablation|Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT
75404720|NCT04363307|Device|MRI|Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation
75404721|NCT04351776|Other|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora application
75404722|NCT04351776|Other|VR-Distraction|Participants will be instructed to use one of three applications
76038876|NCT05553899|Radiation|PET-MRI|magnetic resonance imaging with positron emission tomography scanning using the tracer 18F-FDG
75404723|NCT04351776|Other|360 Video|Participants will be instructed which video to view
75404724|NCT04335942|Other|"Alert AFNOR 3.6."|This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),
75404725|NCT04335942|Other|"Alertes  AFNOR 3.6  et alertes  Guidelines ."|By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes over a period of 1 minute 51 for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block.
75404726|NCT04329325|Biological|Blinatumomab|Please see detailed summary.
75404727|NCT04329325|Drug|dasatinib|Please see detailed summary.
75404728|NCT04329325|Drug|dexamethasone|Please see detailed summary.
75404729|NCT04329325|Drug|methotrexate|Please see detailed summary.
75404730|NCT04317781|Biological|Tagraxofusp-erzs|Given IV
75404731|NCT04283175|Other|Posturological examination on KPlates and AMTI platforms|By an unique evaluator
75404732|NCT04283175|Other|Berg Balance Scale (BBS)|Falls and fera of falling, motor and sensory impairments
75404733|NCT04281485|Genetic|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 1 for Cohort 1.
75404734|NCT04281485|Other|Placebo|Placebo will be administered as a single IV infusion at Year 1 for Cohort 2.
75404735|NCT04281485|Other|Placebo|Placebo will be administered as a single IV infusion at Year 2 for Cohort 1.
75404736|NCT04281485|Genetic|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 2 for Cohort 2
75404737|NCT04273347|Other|standard of care for patient with brain trauma and spinal cord injury|neurological examination, examination of articulation, infectious status, respiratory status, inflammatory status,kinesitherapy
75404738|NCT04272463|Other|No intervention|Patients currently in treatment with benralizumab as per approved indication and clinical practice
75404739|NCT04239157|Biological|Canakinumab|Given SC
75404740|NCT04229797|Procedure|Mandibular distalization using extra-radicular miniscrews|Distalization of the Mandibular first molars using mandibular buccal shelf mini-screws in the presence of unerupted third molars
75404741|NCT04216719|Behavioral|OCM-RISE|OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
75404742|NCT04216667|Procedure|Catheter ablation|Catheter ablation
75404743|NCT04209946|Procedure|Less Invasive Surfactant Administration LISA|Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.
75404744|NCT04209946|Procedure|Continuous Positive Airway Pressure CPAP|Infant will remain on CPAP Therapy during spontaneous respirations
75404745|NCT04190056|Biological|Pembrolizumab|Given IV
75404746|NCT04190056|Drug|Tamoxifen|Given PO
75404747|NCT04190056|Drug|Vorinostat|Given PO
75404748|NCT04189757|Drug|Acalabrutinib|Given PO
75404749|NCT04179539|Diagnostic Test|V/Q PET/CT|Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired
75404750|NCT04179539|Diagnostic Test|CTPA|CTPA will be done according to the usual protocol in the radiology department of the investigator center
75404751|NCT04162171|Radiation|Stereotactic Body Radiotherapy (SBRT) ablation of VT|"Additional imaging for SBRT planning and implementation:~Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems."
75404752|NCT04156880|Other|mammography|standard mammography including craniocaudal (CC) and mediolateral oblique (MLO) views
75404753|NCT04149964|Drug|Acetaminophen 325 mg Oral Tablet|Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
75711482|NCT00393367|Drug|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
75711483|NCT00393367|Drug|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
75711484|NCT00395863|Drug|Multihance|0.5 M at a single injection
75711485|NCT00395863|Drug|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
75711486|NCT01045915|Biological|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
75871574|NCT02341612|Other|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
75404754|NCT04149964|Drug|Acetaminophen 650 mg Oral Tablet|Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
75404755|NCT04149964|Drug|OxyCODONE 5 mg Oral Tablet|Oxycodone 5 mg every 4 hours as needed for breakthrough pain
75404756|NCT04149964|Drug|Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet|Acetaminophen 325 mg/ Hydrocodone 7.5 mg oral tablet every 4 hours as needed for breakthrough pain
75404757|NCT04146649|Procedure|Arthrocentesis|Patients will receive a joint arthrocentesis to remove fluid from the joint.
75404760|NCT04115657|Other|Starch 1|Consumption of milk tea with sucrose and boba pearls made from tapioca starch
75404761|NCT04115657|Other|Starch 2|Consumption of milk tea with sucrose and boba pearls made from high amylose
75404762|NCT04115657|Other|Starch 3|Consumption of milk tea with sucrose and boba pearls made from kithul flour
75404763|NCT04115657|Other|Starch 4|Consumption of milk tea with sucrose and boba pearls made from sago flour
75404764|NCT04115657|Other|Sugar 1|Consumption of milk tea with pure palatinose and boba pearls made from tapioca starch
75404765|NCT04115657|Other|Sugar 2|Consumption of milk tea with blend of sucrose and palatinose and boba pearls made from tapioca starch
75404766|NCT04114981|Radiation|Single Fraction Stereotactic Radiosurgery|Undergo SSRS
75404767|NCT04114981|Radiation|Fractionated Stereotactic Radiosurgery|Undergo FSRS
75404768|NCT04114981|Procedure|Quality-of-Life Assessment|Ancillary studies
75871575|NCT02341612|Other|passive recovery|The control group was exposed to treatment after the EIMD protocol.
75404769|NCT04114981|Other|Questionnaire Administration|Ancillary studies
75404770|NCT04088669|Other|Home-based Pulmonary Rehabilitation|Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.
75404771|NCT04088669|Other|Education and Recommendations|The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
75404772|NCT04076579|Drug|Olaparib|Olaparib taken by mouth twice daily
75404773|NCT04076579|Drug|Trabectedin|Trabectedin administered intravenously (IV) every 21 days
75404774|NCT04071366|Drug|Itacitinib|Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
75404775|NCT04071366|Drug|Immune effector cell therapy|Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
75404776|NCT04071366|Drug|Placebo|Participants will receive placebo twice daily.
76038877|NCT05553821|Other|Cold sand bag|A sand bag weighing 3.5-4 kg is applied to the CAG area of patients.
75404777|NCT04071366|Biological|Yescarta|Eligible participants are receiving Yescarta (An infusion of chimeric antigen receptor (CAR)-transduced autologous T cells) for relapsed or refractory larbe B-cell lymphoma or follicular lymphoma intravenously.
75404778|NCT04049110|Drug|Forxiga 10mg|Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
75404779|NCT04049110|Drug|Placebo|Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
75404780|NCT04016415|Behavioral|Mindfulness Based Stress Reduction|Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.
75404781|NCT04016415|Behavioral|Stress Management Education|Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
75404782|NCT04000659|Device|Episealer Knee System|The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
75404783|NCT04000659|Procedure|Microfracture|Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.
75404784|NCT03995758|Device|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
76038878|NCT05553821|Other|A sand bag|A sand bag
75404785|NCT03974932|Drug|HTX-011|Dual-acting local anesthetic. Dose 1.
75404786|NCT03974932|Drug|Ibuprofen|NSAID.
75404787|NCT03974932|Drug|Acetaminophen|Analgesic.
75404788|NCT03974932|Drug|Celecoxib|NSAID.
75404789|NCT03974932|Drug|+/- Bupivacaine HCl|Local anesthetic.
75404790|NCT03974932|Device|Luer Lock Applicator|Applicator for instillation.
75404791|NCT03974932|Drug|HTX-011|Dual-acting local anesthetic. Dose 2.
76038879|NCT05543135|Diagnostic Test|basic audiological evaluation|pure tone audiometry&immitancemetry
76038880|NCT05543057|Radiation|3DCRT|Three-dimensional conformal radiotherapy (3DCRT)
75404792|NCT03967522|Drug|Cabozantinib|All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
75871576|NCT02341378|Biological|TissueGene-C(Low dose)|TissueGene-C at 6.0x10^6 cells
76038881|NCT05549375|Device|MyHand System Hand Rehabilitation|15 1-hour patient specific sessions using the MyHand System to help improve Hand function in the affected hand of stroke survivors
75404795|NCT03930316|Device|NOX T3|portable sleep study device
75404796|NCT03900403|Other|Walnut Intake|40g of daily walnut intake for 12 weeks
76038882|NCT05700617|Drug|1:1 Randomization to receive milrinone or dobutamine|Randomized to receive either inotropic agent: milrinone or dobutamine
75404797|NCT03875625|Procedure|Bariatric surgery|Use of the normal bariatric surgery procedures commonly conducted in our hospital, such as: Laparoscopic Roux-en-Y gastric bypass (RYGB) and Laparoscopic sleeve gastrectomy (LSG)
75404798|NCT03875625|Behavioral|Dietitian led life style modification intervention|Intensive 6 months life style changes supervised by diatitians.
75404799|NCT03875625|Behavioral|Conventional care (control)|receive routine care
75404800|NCT03842969|Drug|RO7234292 (RG6042)|Intrathecal injection
75404801|NCT03835312|Procedure|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
75404802|NCT03823690|Device|EUS-guided gastrojejunstomy|As listed in the arms description
75404803|NCT03823690|Device|The pyloro-duodenal stent|As listed in the arms description
75550531|NCT05972122|Drug|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
75711487|NCT01043731|Procedure|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
75711488|NCT00395629|Drug|Deferasirox (ICL670)|
75711489|NCT00392665|Drug|Bevacizumab|Given intravenously on day one of each 3 week cycle
75404804|NCT03819387|Drug|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
75404805|NCT03777813|Drug|Durvalumab|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions
75404806|NCT03777813|Combination Product|IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)
75404807|NCT03754933|Biological|Ad/PNP|Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase
75404808|NCT03754933|Drug|Fludarabine Phosphate|Fludarabine phosphate is an anticancer agent currently used to treatment patients with chronic lymphocytic leukemia.
75711490|NCT00392665|Drug|erlotinib|Given orally once a day
75550532|NCT05965570|Drug|Brensocatib|Oral tablets.
75550533|NCT05965570|Drug|Clarithromycin|Oral tablets.
75711491|NCT00392665|Drug|Sulindac|Given orally twice a day
75711492|NCT01046071|Procedure|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
75404809|NCT03725878|Procedure|Standard tertiary interventions of birth defects|Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations). But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al. Regular antenatal cares are required, such as deformity screening by ultrasound. Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
75404810|NCT03725878|Procedure|Additional preconception health care|Various studies have revealed that folate is essential in early embryo development, whereas folate level evaluation in periconception women is not included in routine health cares. Therefore, we evaluate subject's folate level by serum and red blood cell folate examination. By combination of folate supplement obtained by questionnaire,folate level evaluated by examinations and folate metabolism ability evaluated by genotyping key enzymes in folate metabolism, an individualized folic acid supplementary guide is given to subjects. Red blood cell folate concentration >400 ng/ml before pregnancy is recommended.
75404811|NCT03725878|Procedure|Additional health care procedures during and after pregnancy|Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions. A 6-months follow up will be conducted to follow children's birth outcomes. It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
75404812|NCT03722654|Behavioral|MTFS-I Installation|MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
75404813|NCT03721120|Diagnostic Test|InvisionFirst® molecular panel|"During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:~regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.~regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS-,LKB1-, NTRK and/or RET mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.~for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis."
75404814|NCT03694262|Drug|Rucaparib|Rucaparib 600mg orally twice daily by continuous dosing
75711493|NCT01046071|Procedure|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
76038883|NCT05700617|Drug|1:1 Randomization to receive dobutamine or milrinone|Randomized to receive either inotropic agent: milrinone or dobutamine
75404815|NCT03694262|Drug|Bevacizumab|15mg/kg IV on day 1 of every cycle
76038884|NCT05542979|Drug|HH-003 injection|HH-003 injection is administrated via I.V. infusion
76038885|NCT05542979|Drug|Placebo|Placebo is administrated via I.V. infusion
76038886|NCT05542745|Device|palatal and buccal retraction|comparison
76038887|NCT05553587|Drug|Amara drops|"The investigational drug is approved with a reduced dossier without indication according to Art. 25 para. 1 KPAV (SR 812.212.24). This study follows the indication text licensed by Swissmedic: … Weleda Amara-Drops can be used for digestive complaints such as heartburn, flatulence and bloating after meals, to stimulate the bile flow and for loss of appetite and nausea. The effect of Weleda Amara drops is based on a balanced mixture of medicinal plants with tonic (invigorating) and aromatic bitter substances, which are suitable for stimulating digestion. Further, no side effects have been reported in past studies so far. All these reasons lead us to the conclusion that this study is only associated with minimal risks and should be classified in risk category A."
75404816|NCT03694262|Drug|Atezolizumab|1,200mg IV on day 1 of every cycle
75404817|NCT03685539|Procedure|Dual-Energy Computed Tomography|Undergo DECT
75711494|NCT01043809|Behavioral|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
76038888|NCT04322747|Diagnostic Test|Distortion product otoacoustic emissions (DPOAE)|Audiometry for extended high frequencies, DPOAE, and, ECochG measurements will be collected before and after skull-based surgeries.
76038889|NCT02629159|Drug|Placebo for Adalimumab|Administered by subcutaneous injection once every other week
76038890|NCT02629159|Drug|Adalimumab|Administered by subcutaneous injection once every other week
76038891|NCT02629159|Drug|Placebo for Upadacitinib|Tablets taken orally once a day
75404818|NCT03653702|Drug|Lumason|Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
75404819|NCT03646812|Other|Glucose Reference 1|Glucose contains 50g of available carbohydrates
75871577|NCT02341378|Biological|TissueGene-C(High dose)|TissueGene-C at 1.8x10^7 cells
75871578|NCT03794778|Drug|pegylated liposomal doxorubicin|PLD 30 mg/m2, i.v.,d1; once every 21days
76038892|NCT02629159|Drug|Upadacitinib|Tablets taken orally once a day
75871579|NCT03794778|Drug|paclitaxel|paclitaxel 175 mg/m2, i.v.,d1; once every 21days
75404820|NCT03646812|Other|Glucose Reference 2|Glucose contains 50g of available carbohydrates
75404821|NCT03646812|Other|Glucose Reference 3|Glucose contains 50g of available carbohydrates
75550534|NCT05959421|Biological|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
75711495|NCT01043809|Behavioral|expanded school-based handwashing promotion|Procter & Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
75711496|NCT01043887|Drug|ridaforolimus|single oral dose administration 10 mg ridaforolimus
75711497|NCT01324297|Other|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
75711498|NCT01043965|Drug|Metformin|Metformin 850mg
75711499|NCT01044043|Procedure|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
75711500|NCT01044121|Other|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
75711501|NCT00622869|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
75871580|NCT03794778|Drug|Carboplatin|carboplatin AUC 5, i.v.,d1; once every 21days,
75871581|NCT03530345|Drug|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
75871582|NCT03530345|Drug|Placebo|Glass vials with matching placebo.
75404822|NCT03646812|Other|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
75404823|NCT03646812|Other|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
75404824|NCT03646812|Other|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
75550535|NCT05959421|Biological|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
75871583|NCT02350114|Procedure|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
75871584|NCT03790332|Drug|Ibrutinib|Ibrutinib capsule, tablet, or suspension administered orally once daily
75871585|NCT02350192|Behavioral|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
75871586|NCT02341300|Device|Cast Iron Pot|Cast iron pot
75871587|NCT02341300|Device|Alumnium Pot|Aluminum Skillet
75871588|NCT02341222|Device|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
75404825|NCT03646812|Other|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
75404826|NCT03646812|Other|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
75404827|NCT03646812|Other|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
75404828|NCT03639935|Drug|Rucaparib|Rucaparib 600 mg PO BID days 1-28
75404829|NCT03639935|Drug|Nivolumab|Nivolumab 240 mg IV days 1 and 15
75404830|NCT03624231|Drug|Durvalumab|Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
75404831|NCT03624231|Drug|Tremelimumab|Tremelimumab (75 mg) for up to 4 doses/cycles
75404832|NCT03624231|Radiation|Radiotherapy|Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
75404833|NCT03603405|Drug|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
75404834|NCT03596086|Drug|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
75404835|NCT03568669|Other|NIH Toolbox Cognition Battery|An app-based cognitive assessment of executive function, attention, memory, and language that takes approximately 45 minutes to complete on an iPad
75404836|NCT03564509|Drug|FE 999302 (1 μg) and follitropin delta|Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
75404837|NCT03564509|Drug|FE 999302 (2 μg) and follitropin delta|Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
75404838|NCT03564509|Drug|FE 999302 (4 μg) and follitropin delta|Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
76038893|NCT05548829|Biological|Disease severity|Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
75404839|NCT03564509|Drug|FE 999302 (8 μg) and follitropin delta|Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
75404840|NCT03564509|Drug|FE 999302 (12 μg) and follitropin delta|Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
75404841|NCT03564509|Other|Placebo and follitropin delta|Daily dose of placebo; individualized follitropin delta dose.
75404842|NCT03556384|Drug|Temozolomide|"Temozolomide 85 mg/m2 will be administered orally for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters"
75404843|NCT03507894|Behavioral|Multimodal Exercise Rehabilitation Program|Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
75404844|NCT03483662|Behavioral|Multicomponent Intervention|The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
75404845|NCT03483662|Behavioral|Enhanced Usual Care|The investigators will provide an up-to-date clinical guideline for hypertension management to providers. A webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial will be conducted. Otherwise, the investigators will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients
75404846|NCT03483597|Other|TSQM-II|Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
75550536|NCT05950191|Other|long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)|Next-generation bed net combining insecticides with different modes of action
75711502|NCT00622869|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
75711503|NCT00622869|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
75711504|NCT00622869|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
76038894|NCT05553431|Device|Left bundle branch pacing|Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
76038895|NCT05553197|Behavioral|Cognitive Behavioural Therapy (CBT)|20 sessions of face-to-face, individual CBT
75404847|NCT03426579|Device|NeuroSENSE ®in children|Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.
75404848|NCT03400137|Diagnostic Test|Increasing of intraocular pressure (IC)|intraocular pressure will be increased using an ophthalmodynanometer
75404849|NCT03366012|Device|Cytosponge|The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
75404850|NCT03327532|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
75404851|NCT03327532|Procedure|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
75404852|NCT03327532|Biological|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
76038896|NCT05553197|Other|Ecological Momentary Assessment (EMA)|Two four-week blocks of twice daily ecological momentary assessment (EMA) of symptoms and inter-session processes
75404853|NCT03327532|Other|Telephone interview|Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
75404854|NCT03327532|Biological|Urinary sample retrieved for biological assessment and biobanking|Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
75404855|NCT03327532|Procedure|jugular and renal ultrasound (optional)|optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
75404856|NCT03259503|Drug|Busulfan|Given IV
75404857|NCT03259503|Drug|Gemcitabine|Given IV
75404858|NCT03259503|Drug|Melphalan|Given IV
75404859|NCT03259503|Drug|Olaparib|Given PO
75404860|NCT03259503|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
75404861|NCT03259503|Other|Pharmacokinetic Study|Correlative studies
75404862|NCT03259503|Biological|Rituximab|Given IV
75404863|NCT03259503|Drug|Vorinostat|Given PO
75404864|NCT03242915|Drug|Pembrolizumab|200mg IV every 3 weeks
75404865|NCT03242915|Drug|Carboplatin|AUC 5 IV every 3 weeks
75404866|NCT03242915|Drug|Pemetrexed|500 mg/m^2 IV every 3 weeks
75404867|NCT03240016|Drug|Pembrolizumab|200mg IV D1
75404868|NCT03240016|Drug|Abraxane|100mg/m^2 D1 and D8
75404869|NCT03229499|Drug|Anastrozole|"Anastrozole is an aromatase inhibitor indicated for:~adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
75404870|NCT03229499|Drug|Placebo Oral Tablet|matching placebo tablet
75404871|NCT03223025|Drug|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
75404872|NCT03223025|Drug|Nordilet®|0.03 mg/kg daily subcutaneous injections
75404873|NCT03190889|Other|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
75404874|NCT03190889|Other|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
75404875|NCT03150693|Drug|Allopurinol|Given PO
75404876|NCT03150693|Drug|Cytarabine|Given IT, IV, SC
75404877|NCT03150693|Drug|Daunorubicin Hydrochloride|Given IV
75404878|NCT03150693|Drug|Vincristine Sulfate|Given IV
75404879|NCT03150693|Drug|Dexamethasone|Given PO or IV
75404880|NCT03150693|Drug|Pegylated L-Asparaginase|Given IV
75404881|NCT03150693|Drug|Methotrexate|Given IT, IV, PO
75404882|NCT03150693|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
75404883|NCT03150693|Drug|Cyclophosphamide|Given IV
75404884|NCT03150693|Drug|Mercaptopurine|Given PO
75404885|NCT03150693|Biological|Rituximab|Given IV
75404886|NCT03150693|Drug|Doxorubicin|Given IV
75404887|NCT03150693|Drug|Thioguanine|Given PO
75404888|NCT03150693|Biological|Inotuzumab Ozogamicin|Given IV
75404889|NCT03150693|Other|Laboratory Biomarker Analysis|Correlative studies
75404890|NCT03135730|Genetic|ROHHAD|Suspected and Confirmed ROHHAD cases
75404891|NCT03118037|Device|Sonata System|Transcervical access for radiofrequency ablation of uterine fibroids
75404892|NCT03007030|Drug|Brentuximab Vedotin|Given IV
75404893|NCT03007030|Other|Laboratory Biomarker Analysis|Correlative studies
75404894|NCT02976389|Other|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
75404895|NCT02976389|Other|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
75404896|NCT02976389|Other|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
75404897|NCT02972580|Genetic|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
75404898|NCT02947633|Drug|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
75404899|NCT02947633|Drug|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
75404900|NCT02938520|Drug|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
75404901|NCT02938520|Drug|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose."
75404902|NCT02938520|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
75404903|NCT02938520|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
76038897|NCT05542511|Diagnostic Test|NanoString nCounter assay|The NanoString nCounter assay by NanoString Technologies will be used to measure blood transcriptional signatures in presumptive TBs. Non-TB participants with elevated transcriptional signature readouts will be investigated for respiratory infections other than Mycobacterium tuberculosis using a next-generation sequencing (NGS)-based respiratory pathogen panel.
75404904|NCT02938520|Drug|ABC/DTG/3TC STR - Tablet|"It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate."
75404905|NCT02938520|Drug|DTG Tablet|"It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate."
75404906|NCT02889627|Drug|Fecal microbiota suspension|The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
75404907|NCT02830360|Drug|Antiarrythmic Drug Therapy|Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
75550537|NCT05950191|Other|long lasting insecticidal nets with PBO-pyrethroid (PermaNet)|Next-generation bed net combining an insecticide with a synergist
76038898|NCT05552885|Other|Evaluation|The Standardized Mini Mental Test, The American National Institutes of Health Stroke Scale, the Figure of 8 Walk Test, the double-task octagonal gait test, the timed up-and-go test, the 10-meter walk test, and the modified four-square step test will be applied to the stroke patients.
76038899|NCT04982263|Diagnostic Test|Blood coagulation profile|Venous blood sample for measurement of blood coagulation profile
75404908|NCT02830360|Procedure|Catheter ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
75550538|NCT05950191|Behavioral|Social Behavior Change Communication|The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
76038900|NCT05548673|Behavioral|Psychoeducation|The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
75550539|NCT05949918|Behavioral|Stage-matched interventions|"The study intervention will be designed based on each Stage of Change of the Transtheoretical Model of Change in that participants in each Stage of Change will receive the intervention that matches the Stage of Change they would be in.~A 12-week interval would be considered between administering the intervention and posttest 1 and the same interval would be used between posttest 1 and posttest 2."
76038901|NCT04727359|Other|FIT64b model project|FIT64b model project: The SHI funds AOK Baden-Württemberg and SVLFG (as an agricultural health insurance fund) have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT64b hospital, UKT). This contract encourages the model hospital an alternative treatment of their patients (with the above mentioned SHI fund), for example fewer inpatient and more outpatient treatment.
76038902|NCT05548595|Dietary Supplement|Investigational|2 tablets are taken with water around the same time every day, ideally after a meal
76038903|NCT05548595|Other|Placebo|2 tablets are taken with water around the same time every day, ideally after a meal
76038904|NCT02628769|Drug|Solithromycin|
76038905|NCT02628769|Drug|Placebo|
76038906|NCT05552807|Drug|SCT-I10A|Administered intravenously
76038907|NCT05552807|Drug|SCT200|Administered intravenously
76038908|NCT05552807|Drug|paclitaxel|Administered intravenously
76038909|NCT05552807|Drug|docetaxel|Administered intravenously
75404909|NCT02768766|Drug|Selumetinib, 100mg|"100mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
75404910|NCT02768766|Drug|Selumetinib, 125mg|"125mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
75404911|NCT02768766|Drug|Selumetinib, 150mg|"150mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
75404912|NCT02768766|Drug|Selumetinib, 175mg|"175mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
75404913|NCT02768766|Drug|Selumetinib, 200mg|"200mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
75550540|NCT05949892|Behavioral|Expanded Health Belief Model-Based Intervention|A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance
75550541|NCT05949086|Behavioral|Work Chat|Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
75550542|NCT05943756|Behavioral|Signature Strengths|The treatment group will complete 6 web-based sessions of Signature Strengths(1 sessions per week for 6 weeks), designed to teach lessons focused on the Aware-Explore-Apply interventional framework. Sessions are approximately 60 minutes long.
75550543|NCT05943756|Behavioral|TBI Education Course|The control group will complete 6 web-based sessions of a TBI Education Course(1 sessions per week for 6 weeks), designed to teach lessons based on the TBI Model Systems Knowledge Translation Center's fact sheets. Sessions are approximately 60 minutes long.
75550544|NCT05937373|Device|Continuous Glucose monitor|Perioperative glucose management beginning preoperative through postoperative monitoring
75711505|NCT00622869|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
75711506|NCT00622869|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
76038910|NCT04432909|Diagnostic Test|The level of CNV|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
75550545|NCT05937373|Other|Standard of Care|no study intervention. participant follows current medical providers recommendations for glucose management
75550546|NCT05936229|Biological|Interferon Beta-1A|Given IV
75550547|NCT05936229|Procedure|X-Ray Imaging|Undergo x-ray
75550548|NCT05936229|Procedure|Echocardiography|Undergo ECHO
75550549|NCT05936229|Procedure|Multigated Acquisition Scan|Undergo MUGA
75550550|NCT05936229|Procedure|Computed Tomography|Undergo CT
75550551|NCT05936229|Procedure|Positron Emission Tomography|Undergo PET/CT
75550552|NCT05936229|Procedure|Lumbar Puncture|Undergo LP
75550553|NCT05936229|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
75550554|NCT05936229|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75550555|NCT05936229|Procedure|Biospecimen Collection|Undergo blood and CSF sample collection
75550556|NCT05936229|Procedure|Biopsy|Undergo tissue biopsy
75550557|NCT05935748|Drug|NKT2152|Oral HIF2a inhibitor
75550558|NCT05935748|Drug|palbociclib|a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
75550559|NCT05935748|Other|sasanlimab|an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration
75550560|NCT05930613|Drug|Certolizumab (CIMZIA® ; TNF-α antagonist)|400mg of certolizumab injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
75550561|NCT05930613|Drug|Placebo (NaCl 0.9 % solution)|NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
75550562|NCT05925348|Diagnostic Test|Patients with cardiopulmonary bypass|"Due to the observational design of the study, no study-specific interventions are performed.~Blood samples are measured to analyze blood-levels of endotoxin"
75550563|NCT05917574|Other|n/a (non-interventional)|Non-interventional (Realist Evaluation study)
75550564|NCT05912426|Behavioral|Reduced-sodium potassium-enriched salt|Supply and use of a reduced-sodium, potassium-enriched iodised salt (66% potassium chloride, 34% sodium chloride).
75550565|NCT05910008|Procedure|O-Arm Stereotactic imaging|Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)
75550566|NCT05910008|Procedure|Standard Stereotactic imaging|Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)
75550567|NCT05909878|Device|Virtual Reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
75404914|NCT02768766|Drug|Selumetinib, 225mg|"225mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
75404915|NCT02764541|Drug|Letrozole|
75404916|NCT02764541|Drug|Tamoxifen|
75404917|NCT02764541|Drug|Palbociclib|
75404918|NCT02764541|Drug|Endocrine Therapy|
75404919|NCT02750826|Other|Health Education Program|
75404920|NCT02750826|Other|Weight Loss Intervention|
75404921|NCT02745184|Biological|Lung stem cells|Patients will receive 0.5-5x10^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
75404922|NCT02649790|Drug|KPT-8602|Participants will receive KPT-8602 oral tablets.
75404923|NCT02649790|Drug|ASTX727|ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.
75404924|NCT02649790|Drug|Dexamethasone|Participants will receive dexamethasone oral tablets.
75404925|NCT02595060|Drug|inhaled molgramostim (rhGM-CSF)|
75404926|NCT02595060|Drug|inhaled placebo|formulated as the active substance without molgramostim
75404927|NCT02587065|Drug|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
75404928|NCT02572856|Device|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
75404929|NCT02544503|Device|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
75404930|NCT02544503|Device|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
75404931|NCT02544503|Device|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.
75404932|NCT02544503|Device|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at study visits.
75404933|NCT02492867|Radiation|Response-driven Adaptive Radiation Therapy|
75404934|NCT02492867|Drug|Carboplatin|AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV
75404935|NCT02492867|Drug|Paclitaxel|40 mg/m^2 IV concurrent with RT; 200 mg/m^2 during consolidation. Given IV
75404936|NCT02492867|Device|FDG-PET|
75404937|NCT02492867|Device|V/Q SPECT|
75404938|NCT02492867|Drug|Durvalumab|10 mg/kg during consolidation. Given IV
75404939|NCT02375204|Drug|paclitaxel|IV
75404940|NCT02375204|Drug|ifosfamide|IV
75404941|NCT02375204|Drug|cisplatin|IV
75404942|NCT02375204|Drug|pegylated G-CSF|IV
75404943|NCT02375204|Drug|G-CSF|IV
75404944|NCT02375204|Drug|carboplatin|IV
75404945|NCT02375204|Drug|etoposide phosphate|IV
75404946|NCT02375204|Procedure|stem cell reinfusion|surgical procedure
75404947|NCT02365792|Procedure|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
75404948|NCT02343042|Drug|Selinexor|Oral tablets
75871589|NCT02341222|Device|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
75404949|NCT02343042|Drug|Dexamethasone|Oral tablets
75404950|NCT02343042|Drug|Lenalidomide|Oral capsule
75404951|NCT02343042|Drug|Pomalidomide|Oral tablets
75404952|NCT02343042|Drug|Bortezomib|Subcutaneous Injection (single use vial)
75550568|NCT05909878|Other|Standard Protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. Specifically at the hospital (HSJ), standard care also includes access to a television mounted near the MRI playing videos.The research nurse will be able to complete any information should they find it incomplete or substandard.
75404953|NCT02343042|Drug|Daratumumab|Intravenous Infusion
75404954|NCT02343042|Drug|Carfilzomib|Intravenous infusion
75404955|NCT02343042|Drug|Ixazomib|Oral capsule
75404956|NCT02343042|Drug|Elotuzumab|Intravenous infusion
75404957|NCT02343042|Drug|Clarithromycin|Tablets
75404958|NCT02343042|Drug|Belantamab Mafodotin|Intravenous infusion
75404959|NCT02339168|Drug|Enzalutamide|Given PO
75404960|NCT02339168|Drug|Metformin Hydrochloride|Given PO
75404961|NCT02295891|Device|MiraDry ®|Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
75404962|NCT02276495|Other|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
75404963|NCT02276495|Drug|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
75404964|NCT02276495|Drug|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
75404965|NCT02269319|Drug|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
75404966|NCT02269319|Drug|Linezolid|Oral linezolid 600mg given twice a day for 10 days
75404967|NCT02120404|Drug|Esmolol administration|"Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours."
75550569|NCT05908149|Device|Insole Splint|Insole splint used in 'Pes equinus' in patients with hemiplegia
75550570|NCT05905133|Drug|CBP-201|subcutaneous injection
75871590|NCT03723317|Procedure|Liver transplantation|First deceased-donor liver transplantation
75550571|NCT05903807|Drug|68Ga-FAPi-46|Ovarian cancer patients undergo 68Ga-FAPI-46 at primary staging and at restaging
75871591|NCT05462418|Procedure|electrosurgery|incisions completed using use the unipolar diathermy from Whiteline till we reach the parietal peritoneum (cutting the Whiteline then coagulation till reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
75550572|NCT05901415|Procedure|Combined anterior lumbar plexus and lateral sacral plexus block in a semi-supine position|We proposed a modified approach of combined anterior LPB and lateral SPB with the patients posed in a semi-supine position aiming to reduce the pain and discomfort induced by position changing effectively.
76038911|NCT05552729|Drug|Vitamin D|The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
75711507|NCT02548065|Other|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
75711508|NCT02548065|Other|Placebo|Bath with Thermal tap water
75711509|NCT00395083|Behavioral|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
75711510|NCT00366457|Drug|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
75711511|NCT00366457|Drug|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
75711512|NCT00366457|Drug|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
75871592|NCT05462418|Procedure|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
75871593|NCT03721211|Drug|[11C]Martinostat|a type of dye used for radiographic imaging of the HDAC protein
75871594|NCT03721211|Device|MR-PET scanner|PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
76038912|NCT05548049|Device|Bone harvesting from ramus area with piezosurgery for autogenous bone augmentation|In this invervention, the piezo-surgical device settings were set to irrigation: '4', function: 'cortical', light: 'auto'. After the full-thickness flap was lifted with the periosteal elevator, superior and vertical osteotomies were performed with the OT-12 piezo-surgical tip. Lower horizontal osteotomies were performed using OT8-L or OT-8-R piezo tips according to the studied quadrant, combining the vertical osteotomy.
76038913|NCT05548049|Device|Bone harvesting from ramus area with conventional burs for autogenous bone augmentation|In control group, After the full-thickness flap is lifted with the periosteal elevator, using a thin #9 fissure burand the surgical handpiece S-11 Straight tip , the physiodispenser settings are according to the manufacturer's recommendations. The osteotomy was performed after it was adjusted to 40,000 rpm as appropriate. Bone incisions were completed with a round bur to combine the lower horizontal osteotomies and 2 vertical osteotomies. The osteotomies were completed with the help of a thin flat drill, and the block graft was carefully separated from the donor site.
76038914|NCT05547971|Radiation|intensity-modulated radiation therapy|The patients got intensity-modulated radiation therapy during observation
76038915|NCT03062527|Other|Dietary Intervention: Low vs. moderate glycemic index|
76038916|NCT05547893|Other|simulation|participating a simulated clinical ethical situation with simulation patients
75550573|NCT05901415|Procedure|Combined anterior lumbar plexus and lateral sacral plexus block in a classical position.|Patients posed in a classical position and received combined anterior LPB and lateral SPB.
75711513|NCT00624819|Biological|GSK1024805A|No vaccination in this trial
75711514|NCT00624819|Biological|Prevenar|No vaccination in this trial
75711515|NCT00624819|Biological|Infanrix hexa|No vaccination in this trial
75711516|NCT00624819|Biological|Havrix|No vaccination in this trial
75711517|NCT00624819|Biological|Varilrix|No vaccination in this trial
75711518|NCT01049347|Drug|amitriptyline|150 mg oral, daily, single evening dose, 35 days
75711519|NCT01049347|Drug|paroxetine|40 mg oral, single dose, morning, 35 days
75711520|NCT01046149|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
75711521|NCT01046149|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
75711522|NCT01049425|Drug|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
75711523|NCT01049425|Drug|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
75711524|NCT01049425|Drug|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
75404968|NCT02103491|Dietary Supplement|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
75404969|NCT02103491|Dietary Supplement|Placebo administration|
75404970|NCT02055456|Drug|Nandrolone Decanoate|
75550574|NCT05900648|Drug|Regorafenib|Given by PO
75550575|NCT05900648|Drug|XmAb20717|Given by (IV) vein
75550576|NCT05899387|Procedure|Swap collection|"Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site."
75550577|NCT05899387|Procedure|Seroma punction|Puncturing of a seroma in case of occurence and clinical need
75711525|NCT01049425|Drug|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
76038917|NCT04981561|Drug|GATE-251|Single dose of GATE-251
76038918|NCT04981561|Drug|Placebo|Placebo
76038919|NCT02626819|Behavioral|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
76038920|NCT02626819|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
75711526|NCT01049425|Drug|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
76038921|NCT05552651|Drug|Envafolimab|300mg,sc,d1,Q3W;
76038922|NCT05552651|Drug|Albumin-Bound Paclitaxel|130mg/m2,iv,D1,D8,Q3W
76038923|NCT05552651|Drug|Carboplatin|AUC=5, iv,D1,Q3W
76038924|NCT05542199|Other|Multicomponent nutrition supplement (MCNS)|Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
75711527|NCT03832387|Device|Non-invasive mechanical ventilation|
76038925|NCT05542199|Behavioral|Behavioral weight loss program|Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
75404971|NCT02031250|Drug|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
75404972|NCT02031250|Drug|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
75404973|NCT02031250|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
75404974|NCT02031250|Radiation|Boost Radiation to Hypoperfused Volumes|
75404975|NCT01995669|Other|Laboratory Biomarker Analysis|Correlative studies
75404976|NCT01995669|Drug|Lenalidomide|Given PO
75711528|NCT03832387|Device|Continuous positive airway pressure|
75711529|NCT03832387|Device|Venturi mask|
76038926|NCT04981327|Drug|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|Apixaban 5 MG BID versus Apixaban 2.5 MG BID
76038927|NCT05699837|Device|Audio or visual alpha (10Hz) stimulation|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
75404977|NCT01995669|Biological|Obinutuzumab|Given IV
75404978|NCT01880567|Drug|Ibrutinib|Given PO
75404979|NCT01880567|Other|Laboratory Biomarker Analysis|Correlative studies
75404980|NCT01880567|Biological|Rituximab|Given IV
75404981|NCT01750567|Drug|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
75404982|NCT01740557|Biological|Aldesleukin|Given IV
75550578|NCT05899387|Procedure|Blood sampling|Blood sampling at defined time points according to protocol
75550579|NCT05890105|Drug|PF-07853578|PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
75711530|NCT03832387|Device|Reservoir mask|
75711531|NCT00838227|Drug|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
75711532|NCT00827619|Device|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
75711533|NCT04043559|Other|MRI scanner|MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.
76038928|NCT05547815|Biological|5 doses program|Inoculate 5 doses of rabies vaccine, and collect blood at fixed time points to detect neutralizing antibody
75404983|NCT01740557|Biological|CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
75404984|NCT01740557|Drug|Cyclophosphamide|Given IV
75404985|NCT01740557|Drug|Fludarabine Phosphate|Given IV
75404986|NCT01740557|Other|Laboratory Biomarker Analysis|Correlative studies
75404987|NCT01740557|Biological|NGFR-transduced Autologous T Lymphocytes|Given IV
75404988|NCT01740557|Other|Quality-of-Life Assessment|Ancillary studies
75404989|NCT01705977|Biological|Placebo plus standard therapy|Placebo plus standard therapy
75404990|NCT01705977|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
75404991|NCT01705977|Other|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
75550580|NCT05890105|Drug|Placebo|Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
75550581|NCT05879679|Behavioral|Food craving induction|Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
75404992|NCT01686711|Drug|AD-4833 15 mg|
75404993|NCT01686711|Drug|AD-4833 30 mg|
75404994|NCT01686711|Drug|Placebo|
75404995|NCT01664234|Other|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
75404996|NCT01664234|Other|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
75404997|NCT01568177|Behavioral|Mental Stress Testing|Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
75404998|NCT01568177|Other|Peripheral Arterial Tonometry (PAT) Testing|PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
75404999|NCT01568177|Other|Heart Rate Variability (HRV)|Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
75405000|NCT01568177|Other|RESPeRATE Breathing Trial|RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
75550582|NCT05879146|Drug|Nirogacestat|Given by PO
75405001|NCT01568177|Procedure|SPECT cardiac scan with 123I-mIBG and Myoview|Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
75405002|NCT01503632|Behavioral|Behavioral Intervention|Receive intervention program
75405003|NCT01503632|Behavioral|Compliance Monitoring|Correlative studies
75405004|NCT01503632|Other|Laboratory Biomarker Analysis|Correlative studies
75405005|NCT01503632|Drug|Mercaptopurine|Given orally
75405006|NCT01503632|Other|Questionnaire Administration|Ancillary studies
75405007|NCT01503632|Procedure|Standard Follow-Up Care|Receive usual standard of care
75405008|NCT01474889|Device|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
75550583|NCT05878236|Diagnostic Test|CyTOF Analysis|CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis
75550584|NCT05878106|Dietary Supplement|Creatine supplementation|"5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention.~The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily."
75550585|NCT05878106|Other|Resistance training|They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.
75550586|NCT05877014|Other|questionnaires|EQ-5D-5L and SF-12
75550587|NCT05877014|Other|scanner|CT scan at M9 and then at M12 if the humerus is not consolidated at M6
75550588|NCT05873816|Device|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
75550589|NCT05873816|Device|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
75711534|NCT04043559|Other|Contrast transoesophageal echocardiography|Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
75711535|NCT00366301|Drug|Insulin glargine injection|Once daily for 14 weeks
75711536|NCT00366301|Drug|metformin|Up to 4 pils per day (2g per day) maximum
76038929|NCT05541965|Other|Reflexology and kegel exercises|"Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence"
76038930|NCT05547737|Drug|Camrelizumab|Cross - line treatment of Camrelizumab in non-small cell lung cancer
76038931|NCT05547659|Drug|Pregabalin 150mg|Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group
76038932|NCT05547659|Drug|Acetaminophen 1 G Oral Tablet|Acetaminophen 1 G Oral Tablet preoperative in multi-modal group
76038933|NCT05547659|Drug|Celecoxib 400Mg Oral Capsule|Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
76038934|NCT05552417|Other|Pectointercostal facial plan block|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
75550590|NCT05861778|Drug|89Zr-Girentuximab|A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.
75550591|NCT05850988|Other|%80 Oxygen concentration|Patients will be administered %80 Oxygen for 3 minutes during preoxygenation.
75550592|NCT05850988|Other|%100 Oxygen concentration|Patients will be administered %100 Oxygen for 3 minutes during preoxygenation.
75711537|NCT00366301|Drug|Placebo pill|Up to 4 pills per day
75711538|NCT00831285|Dietary Supplement|food product|food product given at one of six visits
75711539|NCT00838305|Drug|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
75711540|NCT00838305|Drug|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
75711541|NCT00365989|Device|ExAblate Enhanced Sonication|
75711542|NCT00827697|Other|Gen-Probe APTIMA Combo2 (AC2)|Laboratory Test
75711543|NCT00838461|Drug|HSD-016|
75711544|NCT00838461|Drug|placebo|
75711545|NCT01324375|Device|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
75711546|NCT00831363|Procedure|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
75711547|NCT00831363|Procedure|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
75711548|NCT03495505|Device|WiSE-CRT|Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
75711549|NCT03488953|Procedure|Living donor liver transplantation with two-staged hepatectomy.|Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor.
75711550|NCT00622713|Drug|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm^2.
76038935|NCT04426175|Device|2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting|2D and 3D cutting methods were randomly used in same subjects
76038936|NCT05552105|Other|Blood test|Before and after 6-months of anti TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and LPS-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response, cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS)
75711551|NCT01046227|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
75711552|NCT04044339|Drug|TD-5202|Study Drug to be administered orally
75711553|NCT04044339|Drug|Placebo|Placebo to be administered orally
75871595|NCT03426072|Other|modified IHI breakthrough series|"There are five main elements to the intervention:~Establishment of the team and set up~Establishing baseline performance and knowledge~Ongoing developmental support~Learning sessions (3)~Action periods (3)~The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support"
76038937|NCT05541575|Other|VR films|A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
76038938|NCT05541419|Drug|Budesonide Nasal|The patient performed a lavage once daily with 2mg dilute budesonide. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
76038939|NCT05541419|Drug|Placebos|Composed of 1% glycerin diluted in water. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
75405009|NCT01407081|Behavioral|Telerehabilitation Cognitive Strategy Training|The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
75405010|NCT01231906|Drug|Cyclophosphamide|Given IV
75405011|NCT01231906|Drug|Dexrazoxane|
75405012|NCT01231906|Drug|Doxorubicin Hydrochloride|Given IV
75711554|NCT00392197|Drug|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
75711555|NCT00391807|Drug|Norethindrone acetate/ethinyl estradiol|one tablet per day
75711556|NCT00624585|Drug|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~Dose Level and Dose of dasatinib:~Starting dose (1-8 weeks)= 100 mg orally (po) daily~+1 (<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~Dose Level and Dose of dasatinib:~Starting dose = 100 mg po daily~-1 = 70 mg po daily~-2 = 50 mg po daily~OR~Dose Level and Dose of dasatinib:~Starting dose = 150 mg po daily~-1 = 120 mg po daily~-2 = 90 mg po daily~-3 = 50 mg po daily"
75405013|NCT01231906|Drug|Etoposide|Given IV
75405014|NCT01231906|Drug|Ifosfamide|Given IV
75405015|NCT01231906|Other|Laboratory Biomarker Analysis|Correlative studies
75405016|NCT01231906|Drug|Topotecan Hydrochloride|Given IV
75550593|NCT05849779|Drug|Inhaled sedation with sevoflurane|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
75711557|NCT01046305|Behavioral|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
75871596|NCT02341066|Device|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
75871597|NCT03726827|Other|Fibroscan screening|A single Fibroscan screening for fat content and liver stiffness
75871598|NCT05764356|Genetic|Detection of genotype and RNA profile in platelet and white blood cell|Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing
76038940|NCT05551637|Dietary Supplement|Kazu Gain Gold|"Kazu Gain Gold is an Oral Nutritional Supplementation made by AIWAIDO Food Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~User Manual: Mix 6 spoons of Kazu Gain Gold (equal to 49,2 grams) with 180 ml of warm water (The energy density reaches 1kal/ml). Consume 2 glasses per day or follow the directions from the medical staff. The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
75871599|NCT05764356|Other|Indicators test related to coagulation function|Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.
75405017|NCT01231906|Drug|Vincristine Sulfate|Given IV
75405018|NCT01154257|Procedure|Cleaning of teeth with a toothbrush|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
75405019|NCT01154257|Procedure|Cleaning of teeth with a foam swab|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
75871600|NCT05764356|Other|Indicators test related to platelet function|Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.
75405020|NCT01143961|Device|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
75405021|NCT00899223|Other|biologic sample preservation procedure|
75405024|NCT00788164|Biological|TA-HPV|Given intramuscularly
75405025|NCT00788164|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
75405026|NCT00788164|Drug|imiquimod|Given topically
75405027|NCT00724048|Drug|ACR16|ACR16 will be administered per dose and schedule specified in the arm description.
75405028|NCT00724048|Other|Placebo|Placebo matching to ACR16 will be administered per schedule specified in the arm description.
75405029|NCT00579605|Behavioral|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
75405030|NCT00572416|Behavioral|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
75405031|NCT00572416|Behavioral|Healthy Eating Control|Equal time and attention and information about healthy eating
75405032|NCT00468234|Drug|nicotine polacrilex|
75405033|NCT00468234|Drug|nicotine transdermal system|
75405034|NCT00468234|Drug|nicotine inhaler|
75405035|NCT00354393|Drug|Cisplatin|
75405036|NCT00354393|Drug|Methotrexate|
76038941|NCT05547113|Diagnostic Test|posturography|In our stabilometric laboratory we use for the posturography two Kistler stabilometric platforms (type 5619A, Switzerland) along with MARS software (version 5.0, Switzerland). We use the SYNAPSIS Subjective Vertical device (version 1.3.2, France) to examine the perception of the subjective visual vertical. The patients should also full fill 5 questionnaires to subjective evaluation of non-vestibular symptoms within ADL and QoL, namely for difficulties related to dizziness, tinnitus, orofacial function disorders and the occurrence of anxiety and depression. For this purpose we use Dizziness Handicap Inventory, Tinnitus Handicap Inventory, Facial Disability Index, Beck's Anxiety Inventory and Beck's Depression Inventory.
75405037|NCT00354393|Drug|Vinorelbine ditartrate|
75550594|NCT05849779|Drug|Intravenous sedation (current practice)|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
75550595|NCT05848440|Drug|AZD9550|Participants will be administered AZD9550 subcutaneously.
76038942|NCT05547035|Behavioral|Patient follow-up of depression|"All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists:~assess the depression severity by using MADRS scale~assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures~the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression."
76038943|NCT02630251|Drug|GSK2820151|GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
76038944|NCT04321109|Other|Allograft|Corticocancellous mineralized allograft
76038945|NCT04321109|Other|Collagen cone|Collagen matrix
76038946|NCT05551559|Procedure|bariatric surgery|bariatric surgery
75405038|NCT00354393|Procedure|Adjuvant therapy|
75405039|NCT00354393|Procedure|Conventional surgery|
75405040|NCT00354393|Procedure|Neoadjuvant Therapy|
75405041|NCT00354393|Radiation|3-dimensional conformal radiation therapy|
75405042|NCT00354393|Radiation|Intensity-modulated radiation therapy|
75405043|NCT00304070|Drug|Cisplatin|Given IV
75405044|NCT00304070|Procedure|Conventional Surgery|Patients undergo surgery
75405045|NCT00304070|Drug|Doxorubicin Hydrochloride|Given IV
75405046|NCT00304070|Drug|Etoposide|Given IV
75405047|NCT00304070|Biological|Filgrastim|Given subcutaneously
75405048|NCT00304070|Drug|Mitotane|Given orally
75405049|NCT00304070|Biological|Pegfilgrastim|Given subcutaneously
75405050|NCT00160680|Drug|Levocetirizine|"Pharmaceutical form: Tablet~Concentration: 5 mg~Route of administration: Oral use"
75405051|NCT01818804|Dietary Supplement|n-3PUFA|
75405052|NCT01818804|Dietary Supplement|olive oil|
75550596|NCT05848440|Drug|AZD9550|Participants will be administered AZD9550 intravenously.
75405053|NCT01820754|Drug|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
75405054|NCT01820754|Drug|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
75405055|NCT01821378|Drug|Lurasidone|Lurasidone 20 mg once daily
75405056|NCT01821378|Drug|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
75405057|NCT01821378|Drug|Placebo|Once Daily
75405058|NCT01821534|Other|No Intervention|No treatment (intervention) was administered.
75405059|NCT01822548|Drug|Vildagliptin|100 mg daily
75550597|NCT05848440|Drug|Placebo|Participants will be administered matching volumes of placebo subcutaneously or intravenously.
75405060|NCT01822548|Drug|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
75405061|NCT01822548|Drug|Metformin|concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
75405062|NCT01825122|Drug|Nadolol|
75405063|NCT01825122|Drug|Placebo|
75405064|NCT01825512|Drug|Deferiprone|Deferiprone 80 mg/mL oral solution
75405065|NCT01825512|Drug|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
75405066|NCT01827462|Biological|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
75405067|NCT01827462|Biological|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
75405068|NCT01827462|Biological|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
75405069|NCT01827930|Drug|Imatinib Mesylate 600 MG Oral Tablet|Imatinib Mesylate for CP CML
75405070|NCT01827930|Drug|Imatinib Mesylate 400 MG Oral Tablet|Imatinib Mesylate for CP CML
75550598|NCT05847634|Device|Masimo O3 NIRS cerebral oximetry and SedLine processed EEG|Non-invasive neuromonitoring device for observational study
75550599|NCT05847569|Biological|Belantamab Mafodotin|Given IV
75405071|NCT01827930|Drug|Imatinib Mesylate|Imatinib Mesylate for CP CML
75405072|NCT01828164|Device|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
75550600|NCT05847569|Procedure|Biospecimen Collection|Undergo collection of blood samples
75550601|NCT05847569|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspirate
75550602|NCT05847569|Procedure|Bone Marrow Biopsy|Undergo biopsy
75550603|NCT05847569|Procedure|Computed Tomography|Undergo CT scan
75550604|NCT05847569|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
75550605|NCT05847569|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75711558|NCT01046305|Behavioral|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
75711559|NCT01046305|Behavioral|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
75405073|NCT01828164|Device|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
75405074|NCT01828476|Drug|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
75405075|NCT01828476|Drug|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
75405076|NCT01828476|Drug|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
75405077|NCT01828554|Drug|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
75405078|NCT01832610|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
75405079|NCT01833078|Drug|ghrelin|ghrelin administration subcutaneously for 7 days
75405080|NCT01833936|Device|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
75405081|NCT01833936|Device|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
75550606|NCT05844566|Device|Decision Support System (DSS)|"This DSS will provide estimates of potential benefits in terms of ASCVD risk reduction (composite endpoint: combined non-fatal myocardial infarction, non-fatal ischaemic stroke and cardiovascular death) as a function of treatment duration and magnitude of LDL-C lowering.~The DSS does not recommend treatments but shows the expected ASCVD risk, absolute and relative ASCDV risk reductions and number needed to treat for the various treatments selected by the clinical user on the potential value of initiation of an add-on therapy for reducing the risk of recurrent Cardiovascular (CV) events. Implementing the patient-specific recommendation remains at the clinicians' discretion."
75550607|NCT05829044|Device|Pupillometry|Pupillometer measurement of pupil size in response to different light stimuli
75550608|NCT05829044|Device|Light box exposure|Using a light box to produce different wavelengths and intensities of light. Exposure to red light on Night 1 and blue/green light on Night 2 to determine circadian timing and suppression of hormone (melatonin)
76038947|NCT05541263|Behavioral|Mindfulness Based Stress Reduction|The intervention used is an MBSR training which is based on the Mindfulness-Based Stress Reduction programme as developed by Kabat-Zinn (1982). The training consists of 8 weekly sessions lasting 2,5 hours. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training includes formal exercises during which participants will practice the body scan, sitting meditation, walking meditation and mindful movement. Informal exercises are also included, such as performing a daily activity with full attention to the present experience. The training is led by qualified teachers meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (www.vmbn.nl)
75405082|NCT01834326|Biological|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
75405083|NCT01834326|Biological|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
75405084|NCT01834404|Drug|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
75405085|NCT01834404|Drug|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
75405086|NCT01834716|Behavioral|Aerobic vs. Non-Aerobic exercise|
75405087|NCT01835262|Drug|Morphine|Morphine: 0.1 mg /kg given as IVP
75405088|NCT01835262|Drug|Ketamine|Ketamine:0.3 mg/given as IVP
75405089|NCT01835496|Drug|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
75405090|NCT01766076|Other|atorvastatin, Lipitor®|PBMC collected for immune activation assays using flowcytometry
75405091|NCT01766076|Drug|Placebo|PBMC collected for immune activation assays using flowcytometry
75550609|NCT05826002|Behavioral|Digital self-guided psychological intervention for insomnia|A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.
75550610|NCT05817942|Drug|Filgotinib|Jyseleca
75711560|NCT01046383|Dietary Supplement|IMN1207|20 grams of IMN1207 per day for 40 weeks.
75711561|NCT01046383|Dietary Supplement|Casein|20 grams of Casein per day for 40 weeks
75405092|NCT01767792|Drug|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
75871601|NCT02345668|Behavioral|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
75871602|NCT02345668|Drug|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
75405093|NCT01794312|Device|T4020|
75405094|NCT01794312|Device|Vehicle|
75405095|NCT01797822|Drug|Dexamethasone|
75405096|NCT01797822|Drug|Artificial tear|
75550611|NCT05809414|Device|Transcranial Magnetic Stimulation|"TMS is a technique for electrical stimulation of brain tissue by generating a magnetic field, which modulates neural activity at the stimulation site and in interconnected neural networks.~The treatment will be applied to the left dorsolateral prefrontal region. Each patient will receive 3 sessions per week of approximately 10 minutes for 6 weeks.~In the case of TMS sham, a placebo coil will be used, which is indistinguishable from the therapeutic one. In addition, the sessions will be carried out with the same frequency, so the patient will be unaware of the treatment they are receiving."
75405097|NCT01809054|Drug|Arixtra|
75871603|NCT02345668|Behavioral|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
75871604|NCT03500159|Drug|AQX-1125 200 mg|Synthetic SHIP1 activator
75405098|NCT01809054|Device|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
75405099|NCT01809054|Drug|Aspirin|
75871605|NCT03500159|Drug|Placebo|Appearance and weight matched tablets without the active product ingredient
75871606|NCT02345278|Drug|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
75405100|NCT01827306|Drug|Biofreeze|
75405101|NCT01833546|Drug|Evofosfamide|Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
75405102|NCT01833546|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
75405103|NCT01837524|Behavioral|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
75405104|NCT01837524|Behavioral|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
75405105|NCT01838226|Behavioral|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
75405106|NCT01838304|Device|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
75405107|NCT01838304|Device|Monitoring|Manual recording of drug doses determined by CRNA
75405108|NCT01839318|Device|Nelfilcon A contact lenses|
75405109|NCT01839318|Device|Omafilcon A contact lenses|
75405110|NCT01839318|Device|Etafilcon A contact lenses|
75405111|NCT01839708|Behavioral|Lifestyle Counseling|The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
75405112|NCT01840722|Other|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
75405113|NCT01842594|Drug|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
75405114|NCT01842906|Device|Theravent|nasal EPAP device
75405115|NCT01842906|Device|Control|Sham device without EPAP
76038948|NCT04980937|Procedure|Microsurgical reconstruction of peroneal nerve with or w/o nerve grafts.|
75405116|NCT01843920|Drug|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
75405117|NCT01843920|Drug|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
75405118|NCT01844388|Drug|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
75405119|NCT01844388|Drug|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
75550612|NCT05809414|Drug|Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule|"It will be used at a dose of 100 mg, 1 capsule a day for 1 week, followed by 2 daily doses of 100 mg until completing 6 weeks in total. After completing the treatment phase, the dose will be de-escalated (1 capsule a day for 5 days and discontinued).~In the case of placebo amantadine capsules, they will have the same organoleptic characteristics as amantadine. The start, maintenance and de-escalation pattern will be identical."
75550613|NCT05805371|Biological|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
75550614|NCT05805371|Procedure|Biopsy|Undergo tumor biopsy
76038949|NCT03063229|Device|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
75550615|NCT05805371|Procedure|Biospecimen Collection|Undergo blood, stool, and urine sample collection
75550616|NCT05805371|Procedure|Bone Scan|Undergo bone scan
75550617|NCT05805371|Procedure|Computed Tomography|Undergo CT scan
75550618|NCT05805371|Radiation|External Beam Radiation Therapy|Undergo radiation
75550619|NCT05805371|Procedure|Leukapheresis|Undergo leukapheresis
76038950|NCT03063229|Other|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
76038951|NCT03063229|Procedure|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
76038952|NCT03063229|Device|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
75405120|NCT01845636|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
75405121|NCT01845636|Drug|Atropine|A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
75405122|NCT01845792|Drug|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
75405123|NCT01845792|Drug|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
75405124|NCT01846728|Drug|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
75405125|NCT01847196|Device|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
75405126|NCT01847430|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
75405127|NCT01848054|Drug|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
75405128|NCT01848054|Drug|Buprenorphine|Buprenorphine sublingual tablets
75405129|NCT01848366|Device|Biowave Treatment|Twelve weekly treatments
75405130|NCT01849068|Drug|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
75405131|NCT01849068|Drug|Placebo|Placebo for 12 weeks
75405132|NCT01849692|Drug|ESBA1008 solution|Intravitreal injection or infusion
75550620|NCT05805371|Procedure|Lymphodepletion Therapy|Undergo lymphodepletion
75550621|NCT05801029|Drug|Osimertinib|Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.
76038953|NCT03063229|Procedure|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
75405133|NCT01849692|Drug|Ranibizumab|Intravitreal injection
75405134|NCT01849770|Drug|Mexiletine|
75550622|NCT05801029|Drug|Amivantamab|Amivantamab will be administered as an IV infusion at 1050 mg (< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (from Day 1 every week for 4 weeks and then every 2 weeks) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg [body weight < 80 kg] or 1050 mg [body weight ≥ 80 kg] on day 2.
75550623|NCT05795517|Drug|HSK31679 low dose|HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
75550624|NCT05795517|Drug|HSK31679 medium dose|HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
75550625|NCT05795517|Drug|HSK31679 high dose|HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
75405135|NCT01849770|Drug|Placebo|
75405136|NCT01850394|Drug|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
75405137|NCT01850394|Drug|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
75405138|NCT01850550|Behavioral|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
75405139|NCT01851876|Device|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
75405140|NCT01852032|Radiation|Tomosynthesis Breast Scanning|The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography
75550626|NCT05795517|Drug|Placebo|placebo ，QD，oral，Day1 to week 12
75550627|NCT05795517|Drug|Ezetimibe 10mg|Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12
75550628|NCT05789784|Other|mymobility Physical Therapy|Physical therapy protocol administered at home through the mymobility application.
75550629|NCT05789784|Other|Standard Office-based Physical Therapy|Physical Therapy protocol administered through exercise handouts and formal office-based therapy directed by physical therapist.
75550630|NCT05783323|Drug|Larotrectinib monotherapy|Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
75550631|NCT05783323|Radiation|131I therapy|Patients will receive 131I therapy after 6 months of larotrectinib.
76038954|NCT03063229|Other|Food Diary|Participants will keep a 7 day weighed food diary.
76038955|NCT03063229|Device|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
76038956|NCT03063229|Other|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
75405141|NCT01852032|Radiation|Breast CT Scanning|"CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan."
75405142|NCT01852344|Drug|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
75405143|NCT01852344|Drug|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
75405144|NCT01852344|Behavioral|Easy Behavioral Task|Subjects do an easy version of the Letter E Task.
75405145|NCT01852344|Behavioral|Hard Behavioral Task|Subjects do a hard version of the Letter E Task.
75405146|NCT01854138|Device|Prevena Incision Management System|Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
75405147|NCT01856712|Drug|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
75405148|NCT01857258|Dietary Supplement|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
75405149|NCT01857882|Other|Decision Support Workshop|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~Social worker (30 mins): values clarification exercise~Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience"
75405150|NCT01858428|Device|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
75405151|NCT01858428|Device|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
75405152|NCT01861002|Drug|Azacytidine|Dose assigned at study entry (75 mg/m2/day). Given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
75405153|NCT01861002|Drug|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
75405154|NCT01861002|Drug|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
75550632|NCT05776134|Biological|Brexucabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
75550633|NCT05774756|Drug|Setmelanotide|Solution for daily subcutaneous injection
75550634|NCT05774756|Drug|Placebo|Placebo matched to setmelanotide for daily subcutaneous injection
75550635|NCT05761613|Device|CeraShield Endotracheal Tube|An endotracheal tube coated with with an antimicrobial hydrophilic coating containing ceragenins (CSAs)
75550636|NCT05761613|Device|Endotracheal tube with subglottic secretion drainage|An endotracheal tube with subglottic secretion drainage
75550637|NCT05758376|Behavioral|Recovery Bridge|Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
75550638|NCT05755165|Behavioral|Depression|~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery
75550639|NCT05755165|Behavioral|Depression, adjusted|~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery - and including explicit reference to the role of anti-Black racism as a contributing factor
75711562|NCT04044261|Procedure|Emotion induction using video|Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
76038957|NCT03063229|Procedure|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
76038958|NCT03063229|Procedure|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
76038959|NCT03063229|Drug|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
76038960|NCT03063229|Drug|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
76038961|NCT05541185|Biological|Nigella sativa oil|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
76038962|NCT05541185|Biological|Naproxen and lidocaine gel|1 ml of Naproxen and lidocaine gel was applied to both knee areas of the Naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
75550640|NCT05755165|Behavioral|Control|~90-second selfie video of an adolescent discussing everyday activities and interests, with no reference to depression or racism.
75550641|NCT05739942|Drug|[177Lu]Lu-NeoB|Radiopharmaceutical solution for infusion
75550642|NCT05739942|Drug|[68Ga]Ga-NeoB|Either provided as Kit for the radiopharmaceutical preparation of [68Ga]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
75550643|NCT05739942|Other|Temozolomide|Capsules/ lyophilized powder in single-dose vial for reconstitution.
75711563|NCT00838773|Behavioral|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
75405155|NCT01861002|Drug|Intrathecal (IT) Cytarabine|"Intrathecally to AML patients on day 1 of course 1 and 2.~Omit on day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~For patients with CNS disease, IT cytarabine can be given weekly until the CSF is clear. Two additional doses of IT cytarabine should be given weekly after the initial CSF clearing. It is permitted to change to intrathecal triple therapy (ITT) if persistent blasts are present in the CSF based on the treating physician's clinical judgment. Cytarabine dose defined by age:~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients >3 years of age~ITT Dosing:~Age (yrs) - Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~- 1.99 MTX: 8 mg, HC: 15 mg, ARAC: 30 mg~- 2.99 MTX: 10 mg, HC: 25 mg, ARAC: 50 mg~3 - MTX: 12 mg, HC: 35 mg, ARAC: 70 mg"
75550644|NCT05734196|Drug|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
75550645|NCT05727267|Biological|HEPLISAV B; TherVacB|Administration of the described combinations via the intramuscular route
75871607|NCT02345278|Other|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
75550646|NCT05727267|Biological|TherVacB|Administration of the described combinations via the intramuscular route
75550647|NCT05725408|Behavioral|Dialectical behavior therapy-informed group eating intervention protocol (telehealth)|A 10-week, skills-based group eating intervention. Online/telehealth meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
75550648|NCT05725408|Behavioral|Dialectical behavior therapy-informed group eating intervention protocol (in-person)|A 10-week, skills-based group eating intervention. In-person meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments, online) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
75550649|NCT05724602|Drug|Xevinapant|3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
75550650|NCT05724602|Drug|Placebo|3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
75871608|NCT03785340|Drug|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
75871609|NCT03785340|Drug|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
75871610|NCT02345590|Drug|Eplerenone|25mg of eplerenone
75871611|NCT03499067|Device|Test lens|Contact lens
75871612|NCT03499067|Device|Control lens|Contact lens
75550651|NCT05723510|Drug|Tegoprazan 50mg|Oral administration of one tablet of tegoprazan 50 mg once daily
75405156|NCT01861002|Drug|Intrathecal Methotrexate (IT MTX)|"Intrathecally to patients with ALL on day 1 of course 1 and 2.~Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~- 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~- 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~- 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg"
75405157|NCT01861704|Device|Lyric|Extended wear hearing instrument
75405158|NCT01861704|Device|Lyric2|Extended wear hearing instrument
75405159|NCT01863030|Device|Phasix mesh implant|
75405160|NCT01863498|Other|Epidural|Patients will have an epidural for pain control
75405161|NCT01863498|Other|PCA|Patients will have PCA for pain control
75550652|NCT05723510|Drug|Edoxaban 60mg|Oral administration of one tablet of edoxaban 60 mg once daily
75550653|NCT05723510|Drug|Apixaban 5mg|Oral administration of one tablet of apixaban 5 mg twice daily
75550654|NCT05723510|Drug|Rivaroxaban 20mg|Oral administration of one tablet of rivaroxaban 20 mg once daily
75550655|NCT05717400|Drug|Bevacizumab|Given by vein (IV)
75550656|NCT05717400|Drug|Atezolizumab|Given by vein (IV)
75550657|NCT05717400|Drug|Sofosbuvir|Given by PO
75550658|NCT05717400|Drug|Velpatasvir|Given by PO
75550659|NCT05717400|Drug|Voxilaprevir|Given by PO
75871613|NCT02345200|Procedure|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
75405162|NCT01864434|Device|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
75405163|NCT01864434|Device|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
75405164|NCT01866306|Biological|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
75405165|NCT01866306|Drug|LABA|Asthmatic participants were treated with LABA as part of their standard of care
75405166|NCT01867164|Drug|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
75405167|NCT01867164|Drug|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
75405168|NCT01867632|Device|Acellular Dermal Matrix|
75550660|NCT05717400|Drug|Ribavirin|Given by PO
75550661|NCT05710224|Biological|V181|0.5 mL SC dose of V181
75550662|NCT05710224|Biological|Butantan-DV|0.5 mL SC dose of Butantan-DV
75550663|NCT05709782|Procedure|Spine Radiosurgery|scan
75550664|NCT05709782|Device|Magnetic Resonance imaging|scan
75550665|NCT05709782|Radiation|MR-LINAC|scan
75550666|NCT05709210|Other|Recording of smartphone usage data|Recording of smartphone usage data
75871614|NCT02345200|Procedure|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
75871615|NCT05462184|Behavioral|Cognitive-Behavioral Therapy (CBT)|
75550667|NCT05704920|Other|IA|The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
75550668|NCT05704920|Other|Not IA|The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
75550669|NCT05704647|Drug|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV (vein)
75550670|NCT05704647|Drug|Nivolumab|Given by IV (vein)
75550671|NCT05704647|Drug|Relatlimab|Given by IV (vein)
75550672|NCT05696977|Drug|Cyclosporine Capsule|Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
75871616|NCT05462184|Behavioral|Acceptance and Commitment Therapy (ACT)|
75871617|NCT03146182|Behavioral|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
75871618|NCT03146182|Behavioral|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
75550673|NCT05695040|Behavioral|"dietary workshop proteins"|"The workshop will have 2 objectives:~Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety."
75550674|NCT05689892|Other|Decision Coach Sessions|"Participants in the intervention group and their families will be referred to the DC to meet independently and discuss recommended treatment pathways.~Multiple sessions may be necessary until a final decision is reached. All SDM consults will be done virtually using a secure videoconferencing platform. The Ottawa Family Decision Guide will be used to facilitate the discussion. A DA will be provided to the study participants in the form of information cards containing information about different treatment options in pediatric IBD. This includes administration schedule, side effects, risk of cancer, among others. The DA has been developed and provided by the Cincinnati Children's Hospital Medical Center and adapted to the Canadian setting with electronic version by this research group with approval from the authors."
76038963|NCT05541185|Biological|Massage|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
76038964|NCT02518113|Drug|LY3039478|Administered orally
75550675|NCT05689684|Dietary Supplement|AG+XOS+AXOS|4-month parallel randomized controlled study
75550676|NCT05689684|Dietary Supplement|Placebo Maltodextrin|4-month parallel randomized controlled study
75550677|NCT05686408|Drug|TNX-601 ER|Patients will take 1 pill orally once daily for 6 weeks.
75711564|NCT00838773|Behavioral|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
75871619|NCT03723083|Drug|CC-2001|CC-2001 will be administered orally
75550678|NCT05686408|Drug|Placebo|Patients will take 1 pill orally once daily for 6 weeks.
75550679|NCT05678218|Procedure|Endoscopic Ultrasound registration|Registration of all findings during Endoscopic Ultrasound
75550680|NCT05676294|Drug|Olanzapine|5 mg of oral olanzapine one hour prior to ambulatory surgery
75550681|NCT05676294|Drug|Placebo|oral matched placebo one hour prior to ambulatory surgery
75550682|NCT05665088|Drug|BXCL501|Sublingual Film
75871620|NCT03348540|Behavioral|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
75871621|NCT03348540|Behavioral|Comparison Task|Neutral- neutral stimuli prior to response task
75405169|NCT01868334|Behavioral|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
75405170|NCT01868334|Behavioral|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
75405171|NCT01868334|Behavioral|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
75405172|NCT01868334|Behavioral|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
75405173|NCT01870596|Drug|Cytarabine|Given IV
75405174|NCT01870596|Drug|CHK1 Inhibitor SCH 900776|Given IV
75405175|NCT01870596|Other|Laboratory Biomarker Analysis|Correlative studies
75405176|NCT01874262|Device|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
75550683|NCT05665088|Drug|Matching Placebo|Sublingual Placebo Film
75550684|NCT05665049|Behavioral|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Using results from a qualitative study, we identified the following culturally grounded social transfer options that is responsive to the identified needs of new mothers. Based on the monthly Lao PDR minimum wage and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately $75 would fairly subsidize women's breastfeeding efforts. Therefore all social transfer options equate to approximately 75 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
75550685|NCT05662241|Drug|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
75871622|NCT03562481|Drug|1% Buffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
76038965|NCT02518113|Drug|Dexamethasone|Administered orally
76038966|NCT02518113|Drug|Placebo|Administered orally
76038967|NCT05541107|Drug|MAT2203|oral lipid nanocrystal amphotericin B
75550686|NCT05662241|Other|Placebo|Placebo
75871623|NCT03562481|Drug|2% Unbuffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
75871624|NCT02349880|Behavioral|shared decision making training|
75871625|NCT04029298|Behavioral|Lifestyle Interventions|Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
75550687|NCT05661669|Drug|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
75550688|NCT05661669|Drug|Saline|The placebo will be a 0.9% saline solution administered over 40 minutes.
75871626|NCT03760224|Other|WhatsApp group|WhatsApp group will allow real-time group discussion for 8 weeks
75871627|NCT03760224|Other|SMS group|SMS group for 8 weeks
75550689|NCT05657275|Diagnostic Test|CRP dosage|multimodal algorithm
75550690|NCT05657275|Diagnostic Test|multiplex PCR|multimodal algorithm
75550691|NCT05657275|Diagnostic Test|chest scan without injection|multimodal algorithm
75871628|NCT03726593|Drug|Artesunate and Pyronaridine|Standard weight based dosing
75871629|NCT03726593|Drug|Atovaquone Proguanil and Artesunate Pyronaridine|Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
75871630|NCT03726593|Drug|Atovaquone Proguanil and Artesunate Mefloquine|Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
76038968|NCT05541107|Drug|Amphotericin B|Intravenous Amphotericin B
76038969|NCT03062839|Drug|Melatonin 5 mg|Melatonin 5 mg taken 30 minutes before bed time
76038970|NCT05540951|Drug|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
76038971|NCT05540951|Drug|Bevacizumab Plus Chemotherapy|Bevacizumab Plus Doublet or Triplet Chemotherapy
76038972|NCT03062293|Device|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
76038973|NCT05540639|Behavioral|Modified Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
76038974|NCT04981093|Drug|Dexamethasone Injection|"Intravenous injection after induction of anesthesia~Injection 0.15mg/kg dexamethasone (2ml)"
75405177|NCT01874262|Device|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
75405178|NCT01875510|Dietary Supplement|Fish-oil emulsions|"Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
75871631|NCT03971266|Device|Activity Monitor|Wear a Fitbit
76038975|NCT04981093|Drug|Normal saline|2ml of normal saline was injected intravenously after induction of anesthesia
75405179|NCT01875510|Dietary Supplement|soybean-oil emulsion|soybean-oil emulsion
75405180|NCT01875978|Dietary Supplement|Phytosterols & placebo|Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
75405181|NCT01876212|Biological|DC vaccine|
75871632|NCT03971266|Other|Media Intervention|Complete smartphone based PRO diary
75405182|NCT01876212|Drug|Dasatinib|
75405183|NCT01876992|Drug|Metformin|
75405184|NCT01877148|Device|tDCS|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
75871633|NCT03145948|Drug|ABBV-553|It is administered orally.
75871634|NCT03145948|Drug|Placebo|It is administered orally.
75871635|NCT03197064|Drug|Fosaprepitant 150 mg|Antiemetic used to prevent nausea and vomiting after general anesthesia.
75871636|NCT02345044|Drug|CS-3150|
75871637|NCT02345044|Drug|placebo|
75871638|NCT02345044|Drug|eplerenone|
75871639|NCT03529409|Behavioral|Project Khanya|This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
75871640|NCT02350036|Other|ultrasound monitoring|Uterine artery Doppler assessment
75871641|NCT03722771|Behavioral|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to surgery
75871642|NCT03722771|Other|Anxiety Questionnaires 1|Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
75871643|NCT03722771|Other|Anxiety Questionnaires 2|State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
75871644|NCT03722771|Diagnostic Test|Vital Signs 1|Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
75405185|NCT01877148|Behavioral|Physiotherapy|Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
75405186|NCT01877538|Other|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand [11C]donepezil
75550692|NCT05655494|Behavioral|Stand-alone Research Portal|The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
75405187|NCT01878006|Drug|Morphine|
75405188|NCT01878006|Drug|Placebo|
75405189|NCT01879176|Device|CytoSorb|
75405190|NCT01879332|Drug|Placebo|Matching placebo tablets for oral administration
75405191|NCT01879332|Drug|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
75405192|NCT01879332|Drug|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
75405193|NCT05329272|Other|Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display [HMD] in delivering the VR intervention), audio, and motor equipment.
75550693|NCT05655494|Behavioral|Portal with Virtual Community Health Educator (vCHE)|The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
75550694|NCT05650970|Other|routine therapy|Routine treatment program including massage, ice and activity training applied to hand thumb osteoarthritis patients
75550695|NCT05650970|Other|radial nerve mobilization exercise|Radial nerve mobilization exercise in addition to the routine treatment program applied to patients with hand thumb osteoarthritis
75871645|NCT03722771|Diagnostic Test|Vital Signs 2|Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
75871646|NCT03722771|Diagnostic Test|Vital Signs 3|Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
75405194|NCT05328882|Other|Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation|The implanted loop recorder will be interrogated to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then the late recurrence rate will be compared (3-12 months post-procedure) between groups with and without early recurrences.
75405195|NCT05327478|Procedure|NRP|Normothermic Regional Perfusion
75405196|NCT05327478|Procedure|DHOPE|Dual Hypothermic Oxygenated Perfusion
75550696|NCT05649072|Behavioral|Genetic Testing and Counseling|Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
75550697|NCT05649072|Behavioral|Screening Form|Participant will be answering demographic details
75871647|NCT03722771|Diagnostic Test|Vital Signs 4|Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
75871648|NCT02349802|Drug|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
75405197|NCT05327478|Procedure|COR-NMP|Controlled Oxygenated Rewarming Normothermic Machine Perfusion
75550698|NCT05641896|Drug|[18F]FAPI-74 PET/CT|[18F]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
75550699|NCT05641844|Device|RD2 Ver.02|Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.
75550700|NCT05641844|Other|Saline|Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.
75405198|NCT05327088|Drug|Dexmedetomidine|Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.
75405199|NCT05327088|Drug|Nalbuphine|Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
75405200|NCT05310474|Device|Knee Glider|The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA.
75405201|NCT05290194|Radiation|SBRT radiotherapy + Conventionally fractionated radiotherapy|Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.
75405202|NCT05290194|Drug|PD-1 inhibitor|Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
75405203|NCT05290194|Drug|Capecitabine|Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
75405204|NCT05279196|Other|Quadriceps microbiopsy and blood collection|"Microbiopsy of the quadriceps muscle using a needle, Tru-cut biopsy, associated with a blood sampling at the start and after 6 months of a muscle strengthening training program"
75405205|NCT05029674|Device|Whoop|Wear WHOOP Strap, complete surveys
75405206|NCT04774068|Drug|Parsaclisib|Given PO
75550701|NCT05636722|Behavioral|Unguided web-based intervention|An online unguided intervention based on Cognitive Behavioural Therapy and elements of Dialectical Behaviour Therapy, Problem Solving Therapy, and Mindfulness Based Cognitive Therapy. The intervention consists of 6 modules with each a theoretical part, a weekly assignment and (optional and mandatory) exercises. Participants are advised to complete one module weekly. The original intervention was adapted to students (language, addition of podcasts, examples that were more suited to their lives).
75550702|NCT05629845|Procedure|endoscopic ultrasound-guided therapy|EUS-guided glue injection will be used for secondary prevention of EV or GV rebleeding.
75550703|NCT05629845|Procedure|conventional endoscopic therapy|conventional endoscopic therapy (VBL for EV or glue injection for GV) for secondary prevention of EV or GV rebleeding.
75550704|NCT05626582|Procedure|pain delivery - learning only|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin just during the Day 1 learning period.
75405207|NCT04774068|Drug|Romidepsin|Given IV
76038976|NCT05699681|Diagnostic Test|Transthoracic and transesophageal echocardiography|"After induction of anaesthesia and stabilization of hemodynamics, transthoracic echocardiography will be done on a GE Vivid e9 workstation (GE Vingmed, Horton, Norway) with MS5 transthoracic probe with synchronized ECG.~From TTE the following views and measurements will be acquired :~Apical four chamber (A4C) view~Apical two chamber view (A2C) view~Right ventricle (RV) focused A4C view~Right ventricular systolic pressure (RVSP)~Pulmonary arterial acceleration time (PAAT),~Tricuspid annular plane systolic excursion (TAPSE),~Tricuspid annular plane systolic velocity (s'),~Right ventricular fractional area change (RV FAC)~RV free wall strain,~RV myocardial performance index (MPI),~RV isovolumic relaxation time (IVRT),~RV isovolumic acceleration time (IVA)~Invasive PA pressure measurement will be done after surgical exposure with a fine needle and a zeroed transducer by the Surgeon."
75405208|NCT04621344|Diagnostic Test|Guided bronchoscopy and/or endosonography|Endoscopic procedures aimed at sampling of intrathoracic lymph nodes or pulmonary lesions
75405209|NCT04304742|Procedure|hip standard radiography/ CT scan/ MRI|hip standard radiography/ CT scan/ MRI
75405210|NCT04260672|Behavioral|Child Centred Health Dialog (CCHD)|"The universal part of CCHD means a structured dialogue between the nurse and the child in presence of its parents using eight illustrations based on the most important practices associated with overweight in preschool children: fruit and vegetables consumption, intake of sweetened beverages and portion size, physical activity, sedentary behaviour tooth brushing and sleep routines. The health dialog is completed by demonstrating the BMI-growth chart to show BMI development to give parents an accurate weight perception, identify overweight and support parental readiness towards a healthy lifestyle.~When the child is identified with an overweight or obesity, the entire family is invited to participate in the targeted part of CCHD: the Family Guidance, a family consultation based on the evidence based Standardized Obesity Family Therapy (Nowicka, 2011)."
75405211|NCT04233138|Other|SUPPORT online platform for people with type 1 diabetes|"All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).~The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform."
75550705|NCT05626582|Procedure|pain delivery - learning and retention|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin during the Day 1 learning period and again during the Day 2 retention period.
75550706|NCT05625776|Procedure|pain delivery with capsaicin and heat|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful
75550707|NCT05625776|Procedure|distractor delivery with sensory TENS|Distractor stimulus delivered (sensory TENS electrical stimulation) that is short-term and attention-demanding but not painful
75550708|NCT05624944|Drug|TS-142 5 mg|Single-dose of 5 mg of TS-142
75550709|NCT05621616|Drug|mirabegron|"Participants will receive mirabegron prolonged-release microgranula-based oral suspension once daily. The initial dose of mirabegron will be based on the participant's weight.~The initial low dose will be up-titrated to a higher dose at weeks 2, 4 or 8 unless the participant is determined to be effectively treated with the low dose, based on urodynamics and the participants'e-diary."
76038977|NCT05004831|Drug|fruquintinib plus TAS-102|fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W
75405212|NCT04132206|Other|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
75405213|NCT04103034|Drug|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
75550710|NCT05616741|Device|Cerebri biofeedback|Daily use of a mobile application connected with two wireless sensors for measurement of muscle tension, heart rate variability, and peripheral finger temperature, to be used for home-based biofeedback treatment.
75550711|NCT05616741|Other|Cerebri headache diary|Daily registration of headache and medication with the Cerebri mobile application. This intervention is identical for both study arms.
75550712|NCT05610891|Drug|CLR 131|CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
75405214|NCT04103034|Drug|Desmopressin|Sterile solution for injection
75405215|NCT04103034|Drug|Placebo|Sterile saline for injection
75405216|NCT03916614|Behavioral|Screening Tool for Relief of Trauma (START)|The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,[30] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
75405217|NCT03916614|Behavioral|standard of care|Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
75405218|NCT03820596|Drug|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
75405219|NCT03820596|Drug|Chidamide|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
75405220|NCT03776760|Device|Fingerstick GeneXpert HCV RNA quantitative assay|All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
75405221|NCT03776760|Drug|sofosbuvir/velpatesvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
75550713|NCT05609994|Drug|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
75405222|NCT03776760|Drug|glecaprevir/pibrentasvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
75405223|NCT03423888|Device|high-flow nasal cannula oxygen therapy (HNFC)|"Set up of high-flow nasal oxygen for patient with dyspnea for a respiratory disease without possibility of curative care. Patients who require a treatment by oxygen are included.~After 7 days of treatment, acceptability is evaluated by the duration of use of HNFC."
75405224|NCT03394248|Device|Vector Mouthguard|The mouthguard will be used by athletes to measure the magnitude and number of impacts throughout one season.
75405225|NCT03393390|Diagnostic Test|Clinical Assessment Visit|Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
75405226|NCT03393390|Other|fMRI scan|Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
75405227|NCT03252834|Diagnostic Test|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
75405228|NCT03191526|Drug|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
75405229|NCT03191526|Drug|Placebo (saline)|Intravenous injection every 12 weeks.
75405230|NCT03158298|Other|Specimen collection|Maternal blood sample of 10 ml collected by venepuncture upon delivery
75871649|NCT02349802|Drug|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
76038978|NCT05546489|Behavioral|Lymfit intervention|Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
75405231|NCT03021096|Other|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
75405232|NCT02885220|Other|Conventional Program|No scheduled intermediate weight loss goals provided to patient
75550714|NCT05605691|Device|Renuvion APR System|"The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.~Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System."
75550715|NCT05591924|Procedure|Phelebotomy|Collection of 10mL of heparin anticoagulated blood, 10mL of EDTA anticoagulated blood, and 3mL of blood in a PAX gene tube
75871650|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Propofol infusion|The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
75871651|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Dexmedetomidine|The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
75871652|NCT03498287|Device|Study Device|Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
76038979|NCT04642729|Procedure|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery|Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
75871653|NCT03498287|Device|Sham Device|Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). *Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
76038980|NCT04981015|Diagnostic Test|Three-day bladder diary|A three-day bladder diary for recording voiding-flow pattern of a women
76038981|NCT05551247|Drug|Envafolimab|300mg,sc,d3,Q3W;
76038982|NCT05551247|Drug|recombinant human endostatin (endostatin)|210mg,civ,d1-3,Q3W
76038983|NCT05540561|Other|blood collection|Biological analyses in the framework of care with conservation of blood samples
76038984|NCT05540483|Drug|Disitamab Vedotin combined with Zimberelizumab|Treatment regimen: Disitamab Vedotin , 2.5mg/kg, intravenously D1, once every 14 days (Q2W), combined with Zimberelizumab, 240mg, intravenously D1, once every 14 days (Q2W).
76038985|NCT05002257|Other|music therapy|Patients included in the intervention arm with music therapy will choose among 3 possible music: music from elsewhere, classical music, today's music. These 3 music thearpy will have an identical duration of 20 minutes.
76038986|NCT05002257|Other|No music therapy|Usual care
76038987|NCT05546255|Drug|Eribulin Mesylate|The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
76038988|NCT05546255|Drug|Lobaplatin|The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
76038989|NCT05001477|Device|TULSA Procedure|Transurethral ultrasound ablation procedure
76038990|NCT05546177|Other|instrumented assisted soft tissue mobilization|The subject will be treated with instrumented assisted soft tissue mobilization, applied to the upper and lower fibers of Pectoral, Trapezius (upper, middle and lower), Rhomboids major , Rhomboids minor, Teres minor, Teres major, and Latissimus dorsi muscles. The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers of each one of the selected muscle
75405233|NCT02885220|Other|Goal-directed Program|Scheduled program with intermediate weight loss targets reinforced to patients during follow up.
75871654|NCT02349724|Biological|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
76038991|NCT05546177|Other|traditional therapy|the patients will receive Transcutaneous electrical nerve stimulation (TENS) to manage the pain,Ultrasound , Exercise including (Range of motion exercises, stretching exercises, and strengthening exercises (Scapular stabilization exercises and rotator cuff strengthening exercises)
75405234|NCT02232282|Device|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
76038992|NCT05551091|Dietary Supplement|glycomacropeptide (GMP)|For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
76038993|NCT02629861|Drug|Fremanezumab|"Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site."
75405235|NCT02232282|Device|Control Sham/Minimal Acupuncture|"Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints."
75405236|NCT01643460|Procedure|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size & amount of fluid aspirated from the cyst.
75550716|NCT05591924|Procedure|Broncheoalveolar Lavage|Bronchioalveolar lavage fluid (BALF) samples will be obtained from participants who are mechanically ventilated, and a bronchoscopy is indicated as part of routine clinical care. The BALF will be collected by a qualified ICU physician using standard clinical practice. Briefly, patients will receive appropriate sedation and analgesia, a flexible video-bronchoscope will be inserted into the patient's airway, and bronchial segments will be identified. The bronchoscope will be wedged in the most appropriate lung segment and 40-100mL of sterile normal saline (NS) as clinically indicated, will be injected into the bronchoscope port with using a 50mL syringe. Next, the instilled NS (i.e.: lavage fluid) will be collected in a sterile container using gentle suction. The BALF will then be partitioned and sent to clinical laboratories, and the remaining BALF (10-20mL) will be used in the ESTABLISH research study.
75550717|NCT05591924|Procedure|Tracheal Aspirate|Tracheal Aspirate (TA) will be obtained from participants who have an endotracheal tube or a tracheostomy in situ at the time of ICU admission through out the ICU admission on the study days, as long as distal airway access is available.
75550718|NCT05591924|Procedure|Rectal Swab|A Rectal will be obtained at the time of ICU admission and on all study days during the ICU admission
75550719|NCT05591196|Device|Non-invasive Electrical Spinal Cord Stimulation|Electrical stimulation of the spinal cord using surface electrodes
75550720|NCT05591196|Other|Activity Based Rehabilitation|Exercise therapy targeting paralyzed hand and arm
75405237|NCT00954876|Drug|capecitabine and cetuximab|"Cetuximab 500 mg/m2 IV infusion over 1-2 hours Once every 2 weeks~Capecitabine 1500 mg/m2 PO BID Days 1-7 followed by 7 days of no treatment and repeated every 2 weeks"
75405238|NCT01879800|Behavioral|Acceptance and Commitment Therapy plus Illness Management|
75405239|NCT05748132|Procedure|combined conventional and pulsed RF|"the classic Hartle technique is used to reach the Gasserian ganglion~Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given"
75405240|NCT05747898|Procedure|cannula- based subcision|Insertion of a needle into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
75550721|NCT05590260|Drug|IV iron infusion|single-dose IV iron infusion
75550722|NCT05590260|Drug|Oral iron tablets|60 mg of elemental iron
75550723|NCT05589480|Other|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
75871655|NCT02939820|Drug|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
75405241|NCT05747898|Procedure|common- needle based subcision|Insertion of a cannula into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
75405242|NCT05747820|Other|Observational study|This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit
75405243|NCT05747664|Drug|DWP16001|0.3mg
75405244|NCT05747508|Combination Product|INOpulse®|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
75405245|NCT05747508|Combination Product|Placebo|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
75405246|NCT05747508|Combination Product|Long Term Follow Up|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
75405247|NCT05747040|Diagnostic Test|monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline t1: pre-treatment t2: post-treatment t3: follow-up"
75550724|NCT05567315|Drug|local anaesthetic injection|Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
75871656|NCT03721055|Radiation|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
75550725|NCT05567315|Device|hypnosis with Virtual reality mask|A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
75871657|NCT05254522|Other|not aplicable since it is a Registry|not aplicable since it is a registry
75405248|NCT05746728|Drug|Surufatinib|"Safety run-in phase: 200-250mg, QD, Q3W~Dose expansion phase: according to the dose determined in the safety run-in phase"
75405249|NCT05746728|Drug|Tislelizumab|200mg, d1, iv, Q3W
75405250|NCT05743686|Device|Application|The participants will have access to an app allowing them to report their adverse effects to oral chemotherapy. Basic advices will be given and the hospital pharmacists will be warned.
75405251|NCT05714670|Drug|Curcumin Oral Capsule|Curcumin 1000 mg Oral Capsule beside the standard of care
75405252|NCT05670132|Other|Neurocardiac rehabilitation program|Patients receiving a neurocardiac rehabilitation program for 12 weeks.
75405253|NCT05670132|Other|Standard of care|No intervention during the neurocardiac rehabilitation program
75405254|NCT05606718|Drug|Dapagliflozin|dapagliflozin 10mg once daily for 3 months after randomization
75405255|NCT05606718|Other|guideline-directed medical therapy (GDMT)|guideline-directed medical therapy (GDMT)
75550726|NCT05566561|Drug|Postoperative analgesia management|Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
75550727|NCT05563220|Drug|Elacestrant|Elacestrant 86mg, 172mg, 258mg or 345mg QD in cycles of 28 days
75405256|NCT05592522|Other|External oblique intercostal block|EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .
75550728|NCT05563220|Drug|Alpelisib|Alpelisib 250 mg or 300 mg QD in cycles of 28 days
75711565|NCT00838773|Behavioral|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
75405257|NCT05592522|Other|Oblique subcostal TAP block|OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.
75405258|NCT05592522|Other|Posterior Rectus sheath block|Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
75405259|NCT05584566|Device|OSSIX Breeze|barrier membrane
75405260|NCT05584566|Device|Jason membrane|barrier membrane
75550729|NCT05563220|Drug|Everolimus|Everolimus 5.0mg, 7.5mg, or 10mg QD in cycles of 28 days
75550730|NCT05563220|Drug|Ribociclib|ribociclib 400mg or 600mg once daily for 21 days followed by 7 days off in cycles of 28 days
75550731|NCT05563220|Drug|Palbociclib|palbociclib 100 mg or 125mg once a day for 21 days followed by 7 days off in cycles of 28 days
75550732|NCT05557279|Drug|500 mg NDS-446|All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
75550733|NCT05541484|Drug|SGLT2 inhibitor|See above.
75711566|NCT00838851|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
75405261|NCT05548374|Device|Acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. Hwato-brand disposable acupuncture needles (size 0.30×40mm) will be inserted into the acupoints through the adhesive pads. Afterwards, the acupuncture will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance.
75405262|NCT05548374|Device|Sham acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. The needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
75405263|NCT05472948|Drug|Surufatinib|Surufatinib will be given 200/250 mg po. qd.
75405264|NCT05472948|Drug|Sintilimab|Sintilimab administered IV at a dose of 200mg every 3 weeks.
75405265|NCT05472948|Drug|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
75405266|NCT05460624|Other|Egg-containing breakfast|Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
75405267|NCT05460624|Other|Typical American-style breakfast excluding eggs|Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
75405268|NCT05448534|Diagnostic Test|Eletroencephalography|We used Sinek and Young Scale to classify electroencephalographic patterns and cognitive outcome with MOCA score.
75405269|NCT05294796|Combination Product|Short course of antibiotherapy|Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
75550734|NCT05541484|Device|Biosense Breath Ketone Analyzer|The hand-held device tests ketones in exhaled breath
75550735|NCT05540340|Other|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
75550736|NCT05538351|Device|Body Composition Monitor (BCM)|The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
75550737|NCT05535244|Drug|Cevostamab|Cevostamab will be administered by IV infusion in 21-day cycles.
75550738|NCT05535244|Drug|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
75550739|NCT05527886|Other|AAROM|AAROM with knee to wall exercise, 3x30 reps
75550740|NCT05527886|Other|Slow Load|Single leg heel raise, 3x10 reps
75550741|NCT05527886|Other|Plyometric|Double leg 5 inch wall hops, 3x10 sec
75405270|NCT05294796|Combination Product|Long course of antibiotherapy|Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
75405271|NCT05215470|Drug|Nivolumab|Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
75405272|NCT05215470|Drug|Ipilimumab|Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
75711567|NCT00831597|Drug|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
75711568|NCT00831597|Drug|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
75405275|NCT05166720|Behavioral|NIDCAP care|NIDCAP care was performed according to the best evidence of NIDCAP
75405276|NCT05151588|Drug|Docetaxel|Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
75405277|NCT05151588|Drug|Cis Platinum|Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
75550742|NCT05521464|Other|cast|Application of a short arm cast from just below the elbow to the finger's knuckles. The cast was from a Plaster of Paris bandage over a cotton pad. The participants who received this treatment modality were considered group 1 (control group)
75711569|NCT00622635|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
75711570|NCT00622635|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
75405278|NCT05151588|Drug|5-FU|5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
75405279|NCT05151588|Drug|Tazemetostat|Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
75405280|NCT05151588|Procedure|Surgery|Radical surgery
75405281|NCT05151588|Other|Chemoradiation|Chemoradiation as either radical treatment or post-operative treatment after surgery
76038994|NCT02629861|Drug|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
75550743|NCT05521464|Other|Robert Jones Bandage|Modified RJ bandage (firmly applied two layers of bulky cotton layers alternating with two layers of elastic bandage in the following order: bandage - cotton - bandage - cotton - bandage). It was applied from below the elbow to the finger's knuckles. The participants who received this treatment modality were considered group 2 (trial group).
75405282|NCT05117892|Other|Training, certification and marketing scheme|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
75405283|NCT05034354|Device|Remote physiological monitoring|Participants will be provided with a Bluetooth capable weight scale (A&D Medical UC-352BLE or Beurer BY90), oxygen saturation monitor (Contec Medical Systems CMS50D-BT) and automatic blood pressure monitor (A&D Medical UA- 651BLE) to use daily for at least 10 days of a 14-day trial period. Data will be sent via the Sphygmo App to the pediatric cardiology for monitoring. Parents and healthcare providers will be asked to participate in a qualitative interview and the end of the 14-day period to provide feedback on the devices and Sphygmo™ platform.
75405284|NCT04929834|Other|Hydrating emollient + body lotion for immunotherapy-related side effects|Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
75405285|NCT05260788|Procedure|Cystoscopy|Standard of care cystoscopy procedure
75711571|NCT00622635|Drug|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
76038995|NCT05540249|Dietary Supplement|carbohydrates|Patients will orally consume 355mL CHO after 20:00 the evening before surgery.
76038996|NCT05461287|Drug|QLS31904|QLS31904 ONLY
75711572|NCT00391027|Drug|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
75711573|NCT00391027|Drug|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
76038997|NCT05546021|Procedure|NOL monitor|"NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuous monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics and avoiding overdose or underuse of these drugs.~The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation). The nociception level is a composite score derived from a set of physiologic variables (i.e., peripheral effectors of the autonomous nervous system): heart rate, heart rate variability, the amplitude of the photoplethysmogram, skin conductance, skin conductance variability, and the time derivatives of these variables."
75871658|NCT02349958|Device|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
75871659|NCT02349958|Device|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
75405286|NCT04921332|Device|Bright Light Therapy (BLT) Lamp|With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
75405287|NCT04894734|Device|EES on|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
75711574|NCT00622401|Biological|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
75711575|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 30ng/kg
75711576|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 100ng/kg
75711577|NCT00827853|Procedure|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
75711578|NCT00827853|Procedure|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
75871660|NCT02349958|Device|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
75405288|NCT04894734|Device|EES off|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
75711579|NCT04018365|Drug|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
75711580|NCT02549235|Other|Ultrasound|Routine 2D/3D ultrasound assessment
75871661|NCT02349958|Device|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
76038998|NCT04958733|Procedure|Autologous bone grafting|Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
76038999|NCT04958733|Procedure|Absence of autologous bone grafting|Donor sites will be left unfilled
75405289|NCT04576182|Behavioral|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
75405290|NCT04576182|Behavioral|Emotions-Focused treatment|Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
75405291|NCT04470804|Drug|Sirolimus|Sirolimus treats in experimental group
75871662|NCT04872426|Other|Exercise, insulin infusion|Acute one-legged exercise, Insulin infusion 3 hours after one-legged exercise
75711581|NCT00831831|Behavioral|Safety planning|See detailed description
76039000|NCT05540015|Procedure|Third molar extraction by cutting and rotary tools|Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.
75405292|NCT04470804|Drug|Cyclosporine A|Cyclosporine A uses for active comparator group.
75405293|NCT04418466|Combination Product|Risperidone|Risperidone Implant
75711582|NCT00839007|Drug|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
75711583|NCT00621621|Device|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
75711584|NCT00828087|Drug|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
75711585|NCT00828087|Device|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
75711586|NCT00828165|Drug|ARRY-300, MEK inhibitor; oral|single dose, escalating
75711587|NCT00828165|Drug|Placebo|matching placebo
75711588|NCT00839085|Drug|GSE|grape seed extract (100 mg/6h), PO
75405294|NCT04389918|Other|Tality|Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.
75405295|NCT04360044|Drug|THC ~5%|4 puffs of vaporized flower containing THC ~5%
76039001|NCT05540015|Procedure|Third molar extraction by erbium laser with wavelength 2.94 nm|Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
75550744|NCT05517850|Behavioral|Therapist-guided cognitive behavioral therapy administered online|This intervention consists of 10 modules of education and interventions and lasts 12 weeks. An introduction provides information about CBT and AD. Step by step, the participants are introduced to the proposed active treatment components: mindfulness training, and exposure with response prevention. Through this whole process, the participant is guided by a therapist. The therapist may be contacted through a secure internet platform at any time and responds within 48 hours. Participants reads the education material, construct exercises to perform, describes their progress in homework assignments, and receives feedback from their therapist.
75711589|NCT00839085|Drug|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
75711590|NCT02549313|Procedure|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
75405296|NCT04360044|Drug|CBD ~12%|4 puffs of vaporized flower containing CBD ~12%
76039002|NCT05545709|Procedure|remote robot-assisted spine surgery|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
76039003|NCT05545631|Other|no intervention|no intervention in this study
75405297|NCT04360044|Drug|THC ~5% and CBD ~12%|4 puffs of vaporized flower containing THC ~5% and CBD ~12%
75405298|NCT04360044|Drug|Sham Cannabis|4 puffs of vaporized flower from which the THC and CBD have been extracted
75405299|NCT04337814|Drug|EMLA Cream|Topical anaesthetic cream
75405300|NCT04337814|Drug|Ibuprofen|Oral analgesic syrup (non-steroidal anti inflammatory drug)
75405301|NCT04337814|Drug|Placebo syrup|Placebo syrup similar to Ibuprofen
75405302|NCT04337814|Drug|Placebo cream|Placebo cream similar to EMLA
75405303|NCT04336332|Combination Product|Hydroxychloroquine Sulfate + Azithromycin|Given PO
75871663|NCT02039284|Device|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
75871664|NCT02039284|Device|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
75405304|NCT04336332|Drug|Hydroxychloroquine Sulfate|Given PO
76039004|NCT02482935|Drug|Abemaciclib|Administered orally
75405305|NCT03953508|Other|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
75405306|NCT03931356|Other|Pulmonary function tests|analysis of lung volume and diffusion capacity
75405307|NCT03882840|Biological|NK cell therapy|Infusion of itNK cells
75405308|NCT03870672|Device|Contralaterally Controlled Functional Electrical Stimulation|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.
75405309|NCT03870672|Device|New rTMS approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
75405310|NCT03870672|Device|Conventional rTMS approach|Facilitation of M1 will be achieved using 5Hz rTMS. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
75405311|NCT03870672|Device|Sham rTMS approach|In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
75405312|NCT03671148|Biological|Placebo|Placebo for risankizumab administered by subcutaneous (SC) injection
75405313|NCT03671148|Biological|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
75405314|NCT03465852|Behavioral|ChiCAS|Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
75405315|NCT03295344|Other|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
75405316|NCT03295344|Other|Tissue Doppler|Determine the threshold value for diaphragm mobility
75405317|NCT03198546|Biological|GPC3 and/or TGFβ targeting CAR-T cells|Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
75405318|NCT03064542|Drug|carbimazole (CMZ) or thiamazole (TMZ)|CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
75550745|NCT05517850|Behavioral|Self-guided digital intervention based on cognitive behavioral therapy|Participants will access a digital platform, read information, and perform exercises in their everyday life. The main treatment components are mindfulness and exposure with response prevention, with a specific focus on itch. Participants will be able to practice mindfulness with the help of instructions and examples. Participants will receive detailed instructions and guidance, and get to choose exposure exercises from a long list of examples. Participants will also be free to create their own relevant exposure situations within the intervention. Digital self-care consists of 8 modules. The only active interventions, mindfulness and exposure are introduced week 1 and 2, respectively. From week 3-7, no new interventions are introduced and participants are advised to continue practicing the interventions, but there is a new theme of education each week, to act as inspiration for exercises. The last 4 weeks, the participant is merely advised to continue practice.
75405319|NCT01430442|Drug|Rimegepant|Rimegepant capsules
75405320|NCT01430442|Drug|Placebo|Rimegepant placebo-matching capsules
75405321|NCT01430442|Drug|Sumatriptan|Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
75405322|NCT01420926|Drug|Bortezomib|Given SC
75405323|NCT01420926|Drug|Decitabine|Given IV
75405324|NCT01420926|Other|Laboratory Biomarker Analysis|Correlative studies
75405325|NCT01420926|Other|Pharmacological Study|Correlative studies
75405326|NCT01420926|Other|Quality-of-Life Assessment|Ancillary studies
75405327|NCT01420926|Other|Questionnaire Administration|Ancillary studies
75405328|NCT00941538|Diagnostic Test|Experimental: Screening with EBV VCA/EBNA1-IgA testing|Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.
75550746|NCT05511961|Behavioral|Healthier Wealthier Families|Budget and debt counselling will involve at least one meeting with a counsellor. Examples of assistance the counsellors can offer include: suggestions on ways to improve a participant's financial situation; checking eligibility and helping to apply for social welfare support; helping to organise finances and develop a budget; and assistance with debt management, threatening letters or harassment by debt collectors, or imminent house eviction. The municipal budget and debt counselling services involved in the trial will receive guidance on how to work preventatively with families, which will align with the content of the 'Your child, your money'. The book covers topics such as planning finances, consumer rights, private insurance, family law, parental leave, pensions, saving, and budgeting.
75550747|NCT05511428|Drug|Daratumumab and Hyaluronidase-fihj|Given SC
75405329|NCT00626964|Procedure|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
75405330|NCT00626964|Behavioral|Conservative Treatment:|Intensive Lifestyle Intervention Program
75405331|NCT01881828|Drug|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
75405332|NCT01881828|Other|oral placebo|
75405333|NCT01882062|Drug|Triheptanoin 1g/kg/day|
75550748|NCT05511428|Other|Questionnaire Administration|Ancillary studies
75405334|NCT01882764|Drug|HMPL-004|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given HMPL-004 orally three times per day with total daily dose of 1800 mg for 52 weeks.
75405335|NCT01882764|Drug|Placebo|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given Placebo orally three times per day with total daily dose of 1800 mg for 52 weeks.
75405336|NCT01883856|Device|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
75871665|NCT02039284|Device|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
75871666|NCT02039284|Device|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
75405337|NCT01883856|Device|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
75405338|NCT01887132|Drug|Donepezil|
75405339|NCT01887132|Drug|Placebo|
75405340|NCT01887990|Drug|Ketamine|single dose IV 0.2 mg/kg ketamine
75405341|NCT01887990|Drug|placebo|saline infusion
75405342|NCT01890642|Device|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
75405343|NCT01890642|Other|Pain Ease Spray|Cold Spray used to anesthetize the skin
75405344|NCT01890642|Drug|1% buffered lidocaine|Lidocaine placed using Jet Injection
75405345|NCT01890642|Other|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
75550749|NCT05511428|Other|Quality-of-Life Assessment|Ancillary studies
75550750|NCT05511428|Other|Interview|Ancillary studies
75550751|NCT05509036|Other|No interventions|No interventions
75405346|NCT01890642|Other|Sucrose|Oral Sucrose used for children < 1 year
75550752|NCT05506631|Procedure|Outpatient Foley balloon placement|Cervical ripening with balloon placement in the outpatient setting
75550753|NCT05506631|Procedure|Inpatient Foley Balloon placement|Cervical ripening with balloon placement in the inpatient setting
75550754|NCT05483608|Other|Vertical climbing ergometer exercise|Exercise using the CLMBR, a vertical climbing exercise ergometer.
75550755|NCT05483608|Other|Recumbent cycling|Exercise using a recumbent cycle ergometer
75405347|NCT01891734|Other|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
75550756|NCT05483491|Drug|KK-LC-1 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
75550757|NCT05483491|Drug|Aldesleukin 720,000 IU/kg IV every eight hours|Aldesleukin 720,000 IU/kg IV every eight hours after KK-LC-1 TCR-T cell infusion for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
75405348|NCT01891734|Other|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
75550758|NCT05482425|Other|Autologous facial fat graft injection|Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
75550759|NCT05479123|Drug|Propranolol three times a day|"Patients with larger (>2cm) or multiple (>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit."
75871667|NCT04806594|Device|Papix acne scar|PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration
75871668|NCT02344888|Drug|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
75871669|NCT02344888|Drug|Clomiphene citrate and folic acid|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
76039005|NCT05551013|Drug|APG-157|"APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~Progression post TMZ (will receive APG-157 only)~Ongoing Optune (will receive concurrent Optune + APG-157)~Progression post Optune (will receive APG-157 only)"
75405349|NCT01891968|Drug|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
75405350|NCT01893372|Drug|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
75405351|NCT01893372|Drug|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
75405352|NCT01895088|Device|AcuFocus Corneal Inlay ACI 7000 PDT|Inlay implanted in cornea for improvement of near vision
75405353|NCT01895634|Device|Rev-01|Treatment arm patients have used Rev-01 at least once
75871670|NCT02349334|Device|Percutaneous Tibial Nerve Stimulation|
75871671|NCT03497429|Drug|Niraparib|Niraparib capsule
76039006|NCT02513823|Dietary Supplement|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
76039007|NCT04980859|Drug|Zebutinib&BR or Zebutinib&FCR|Introduction period: Zebutinib 160 mg bid oral treatment for 3 months;Joint stage :6 sessions of Zebutinib FCR( under 60 years of age,Fludarabine 25 mg/m² Q3W, Cyclophosphamide 250 mg/m² Q3W,Rituximab 375 mg/m² Q3W) or BR (over 60 years of age, )(28 days and 1 cycle);Maintenance treatment: after the end of the combined phase, continue the treatment of zebutinib.
75405354|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
75405355|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
75405356|NCT01898754|Other|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
75405357|NCT01899300|Device|Metal Stent (WallFlex™ Esophageal RX)|
75405358|NCT01900392|Behavioral|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
75405359|NCT01900704|Drug|SER120 750 ng|SER120 750 ng
75405360|NCT01900704|Drug|SER120 1500 ng|SER120 1500 ng
75405361|NCT01900704|Drug|Placebo|Placebo
75405362|NCT01901250|Dietary Supplement|Xylitol gummy bears|The children receive xylitol gummy bears 3 times/day within the supervised school environment.
75871672|NCT02762604|Behavioral|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
75871673|NCT02762604|Behavioral|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
75871674|NCT03146104|Drug|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
76039008|NCT04432519|Procedure|Immediate dental implant placement|Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
75871675|NCT03146104|Drug|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
75871676|NCT04752150|Other|Analgesia management; group ESPB and RIB|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
75871677|NCT05254444|Behavioral|Social marketing|Multi-tiered nutrition social marketing intervention focused on sustainable fish nutrition, dietary diversity and food safety.
75871678|NCT05254444|Behavioral|social marketing + gear modification|Multi-tiered nutrition social marketing intervention plus fishing gear modification (basket trap) and training.
75871679|NCT04682340|Diagnostic Test|Serum BPA|Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
75871680|NCT05254366|Drug|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
75871681|NCT05254132|Procedure|Liquid biopsy|Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
76039009|NCT05545475|Drug|Low molecular weight heparin|Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
76039010|NCT05539703|Other|Invitation to get a 2nd booster dose of COVID-19 vaccine|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
75550760|NCT05479123|Drug|Propranolol twice a day|"Patients with larger (>2cm) or multiple (>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit."
75711591|NCT00828243|Drug|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids ([1-13C1] acetate) and of surfactant protein-B ([5,5,5-2H3] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
75711592|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
75711593|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
75711594|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
75711595|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
76039011|NCT02513745|Device|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
76039012|NCT02513745|Device|Refractive Cataract Suite (Verion + ORA)|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
76039013|NCT05545397|Drug|Propofol|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
76039014|NCT05545397|Device|EEG montior|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
75550761|NCT05479123|Drug|Timolol|Patients with a small (<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
75550762|NCT05476549|Dietary Supplement|Lemon verbena|Lemon verbena supplement administered at an estimated daily dose of 15mg/kg
75550763|NCT05476549|Dietary Supplement|Placebo|Placebo supplement containing carrier material only
75550764|NCT05475171|Drug|MGD019|Given by vein (IV)
75550765|NCT05474404|Diagnostic Test|Cervical smear test|collection of cervical cells using spatula
75711596|NCT00839163|Drug|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
75711597|NCT02549001|Drug|P-3058 10%|
75711598|NCT02549001|Drug|vehicle of P-3058 10%|
75711599|NCT02549001|Drug|amorolfine 5%|
76039015|NCT04952727|Biological|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
75405363|NCT01901250|Dietary Supplement|Sugar free fiber gummy bears|The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.
75405364|NCT01901250|Behavioral|Oral health education|Oral health education, toothbrush, and fluoride toothpaste
75405365|NCT01901250|Device|Fluoride varnish|The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
75405366|NCT01901250|Device|Dental sealant|The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
75711600|NCT00621543|Device|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
75405367|NCT01904448|Device|Auditory Brainstem Implantation in Children|
75405368|NCT01904526|Drug|Guanfacine|3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
75405369|NCT01906866|Drug|Circadin 2/5/10 mg|Active arm
75405370|NCT01906866|Drug|Placebo|
75405371|NCT01907334|Drug|Advair Diskus100/50 µg|Advair Diskus 100/50 µg
75405372|NCT01907334|Drug|Flovent Diskus 100 µg|Flovent Diskus 100 µg
75405373|NCT01907334|Drug|Methacholine Chloride|Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
75405374|NCT01907334|Drug|Albuterol|Albuterol will be administered at the end of each methacholine challenge.
75405375|NCT01907490|Drug|Ha44 Gel|Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
75405376|NCT01908972|Drug|Prednisolone|2mg/kg/day for 16weeks
75405377|NCT01908972|Drug|Propranolol|2mg/kg/day for 16weeks
75405378|NCT01910064|Drug|GK530G|
75405379|NCT01910688|Device|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
75405380|NCT01911390|Dietary Supplement|Bean powder|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
75405381|NCT01911390|Dietary Supplement|Rice bran|USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
75711601|NCT02548221|Device|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
75711602|NCT00832143|Behavioral|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
75711603|NCT00623805|Drug|Bevacizumab|Bevacizumab was supplied as a solution in single-use vials.
76039016|NCT04952727|Biological|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
75405382|NCT01911390|Dietary Supplement|Control arm|No bean or rice bran additive in smoothie or muffin.
75405383|NCT01911390|Dietary Supplement|Bean powder and rice bran|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
75405384|NCT01912716|Drug|high dose indomethacin|patients randomized to this intervention receive 200mg indomethacin
75405385|NCT01912716|Drug|standard dose indomethacin|patients randomized to this intervention receive 100mg indomethacin
75405386|NCT01914510|Drug|ENMD-2076|
75405387|NCT01918800|Behavioral|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
75405388|NCT01918800|Behavioral|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
75405389|NCT01920282|Drug|Nebivolol|
75405390|NCT01920282|Other|Lifestyle Modification|
75405391|NCT01920282|Other|Nebivolol plus Lifestyle Modification|
75405392|NCT01921296|Drug|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
75405393|NCT01921452|Device|Quantitative POC TSH Kit|A drop (approximately 30 microliter [mcL]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
75405394|NCT01921452|Device|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
75550766|NCT05471557|Procedure|pain delivery|Experimental pain paradigm delivered that is short-term and painful but not harmful.
75550767|NCT05471557|Procedure|distractor delivery|Distractor stimulus delivered that is short-term and attention-demanding but not painful.
75550768|NCT05461820|Drug|Methimazole|Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
75550769|NCT05459324|Device|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
75711604|NCT00623805|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
75871682|NCT03497039|Drug|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
76039017|NCT05539625|Dietary Supplement|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis) MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
75405395|NCT01921452|Device|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
75405396|NCT01929642|Drug|Sirolimus|
75405397|NCT01929642|Drug|Everolimus|
75405398|NCT01932060|Drug|Oxytocin Infusion|Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
75405399|NCT01932606|Drug|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
75550770|NCT05454969|Behavioral|One-4-ALL Initiative|We can successfully implement a patient app that will be used by families to 1) increase throughput for all patients, including minoritized, low-income, and low health literacy patients, and 2) reduce administrative burdens on providers.
75550771|NCT05454969|Behavioral|Control|Patients will receive standard of care.
75550772|NCT05450198|Biological|MK-6194|MK-6194 administered subcutaneously (SC)
75550773|NCT05450198|Biological|Placebo|Placebo comparator to MK-6194 administered SC
75550774|NCT05449756|Other|Self-administered questionnaires|Three-monthly self-administered digital questionnaires (accessed on smartphone, tablet or computer)
75405400|NCT01932606|Drug|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
75550775|NCT05445947|Behavioral|The EASEL (Enhancing And Supporting Early Development to Better Children's Lives) Approach|"The EASEL Approach consists of a set of educator-led practices that can be incorporated into the daily classroom environment for children three to six years of age. The overall purpose of this approach is to enhance early childhood educators' teaching practices that would promote children's SEB+EF development.~Nine EASEL practices were selected for inclusion in the EASEL Approach. These are a) core fundamental practices that are evidence-based, b) practices that expert stakeholders identified as ones for which local early childhood educators may need additional training, c) practices that are not already covered in pre-service training to avoid replication for educators, d) a combination of practices that educators may already be implementing and can enhance, and new practices, and e) a balance of antecedent and consequential practices (i.e., practices that can be implemented before and after a target behavior)."
75711605|NCT00623805|Drug|Oxaliplatin|Oxaliplatin was supplied as a lyophilized powder in vials.
75405401|NCT01933230|Device|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
75405402|NCT01933464|Drug|Cromolyn Sodium|
75405403|NCT01933464|Drug|Normal Saline|
75711606|NCT02548923|Drug|Dexmedetomidine|comparison to propofol
75405404|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
75405405|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
75405406|NCT01935180|Device|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
75405407|NCT01936662|Device|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
75405408|NCT01936662|Device|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
75405409|NCT01936896|Drug|Alpha 1-Antitrypsin|
75405410|NCT01937520|Device|acupuncture|One half of subjects will receive a standardized acupuncture regiment
75405411|NCT01937520|Device|no acupuncture|placebo
75711607|NCT04043871|Diagnostic Test|Systolic blood pressure|Systolic blood pressure measured by Foot-to-Apex Systolic Interval, conventional oscillometric measurement, and the auscultatory method
75711608|NCT00832221|Drug|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
75871683|NCT03497039|Other|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
76039018|NCT05539625|Other|Placebo|Placebo
76039019|NCT05539547|Device|Neuromuscular Electrical Nerve Stimulation|"Application of NMES on quadriceps muscle groups bilaterally~Frequency: >50Hz Pulse duration: 350 - 400µs Intensity: Maximal tolerance (visible quadriceps muscle contraction and/or maximally tolerated by the patient, eliciting a slight discomfort) Time: 30 minutes per session, 7 sessions per week Duty Cycle: 2s on / 18s off Duration: Until discharge to a maximum of 30 days"
75405412|NCT01937598|Drug|Placebo|Patients administered a single dose of placebo during a mixed meal challenge.
75405413|NCT01937598|Other|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
75405414|NCT01937598|Drug|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
76039020|NCT05539547|Other|Usual Physiotherapy treatment (Chest Physiotherapy and mobility)|Daily chest physiotherapy and mobility
76039021|NCT05545241|Behavioral|Neurofeedback + BART/EEG|"10 sessions of emotional neurofeedback (max of 2 sessions per week and max of 10 weeks).~Before (Baseline, Day 0) and at the study completion (after 10 neurofeedback sessions, Week 5), a EEG record is realized during the BART, assessing risk-taking behavior."
75405415|NCT01937598|Drug|Sitagliptin|Patients administered a single dose of Sitagliptin during a mixed meal challenge.
75405416|NCT01938066|Device|Procellera|bioelectric wound dressing
75405417|NCT01938066|Device|negative pressure therapy|
75405418|NCT01938378|Biological|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
75405419|NCT01939938|Device|Nasal and Oronasal PAP Mask|Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
75405420|NCT01942668|Drug|Estradiol|
75405421|NCT01942668|Drug|Progesterone|
75711609|NCT00832221|Drug|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
75711610|NCT00832221|Drug|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
75711611|NCT00828399|Dietary Supplement|Glutamine|Oral glutamine 30g/day
75711612|NCT00828399|Dietary Supplement|Whole protein|Oral whole protein 30 g/day
75405422|NCT01942668|Drug|Placebo|
75550776|NCT05445778|Drug|Mirvetuximab soravtansine plus Bevacizumab|Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks
75711613|NCT04044027|Behavioral|S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring|S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
75711614|NCT00839397|Drug|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI"
75405423|NCT01944930|Device|Laparoscopic narrow band imaging|
75405424|NCT01944930|Device|Standard white-light laparoscopy|
75550777|NCT05445778|Drug|Bevacizumab|Participants will receive Bevacizumab 15mg/kg every 3 weeks
75711615|NCT04043715|Device|Transcutaneous spinal stimulation|Physical therapy to improve standing and walking
75711616|NCT04043715|Device|Epidural spinal stimulation|Physical therapy to improve standing and walking
75711617|NCT00828477|Drug|Xibrom|Xibrom: two times a day for seven days in the first eye.
75711618|NCT00828477|Drug|Nevanac|Nevanac: three times a day for seven days in the second eye.
75711619|NCT00828555|Other|Vaccination Program|Design & implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, & pertussis
75711620|NCT00621309|Drug|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
75405425|NCT01948518|Drug|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
75405426|NCT01948986|Drug|Ertugliflozin|Single oral administration of 3 X 5 mg tablets.
75550778|NCT05429255|Behavioral|Aerobic Exercise|Bicycle training
75871684|NCT02340910|Procedure|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
76039022|NCT05545241|Behavioral|BART/EEG only|only the twice EEG record are realized during the BART, assessing risk-taking behavior (every corresponding to the pre and post-neurofeedback evaluations in arm I)
76039023|NCT05539235|Drug|different degrees of adjustment of the injection interval|"Treatment was an intravitreal injection of 0.5 mg conbercept using modified T&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks."
76039024|NCT04940403|Device|Burt|18 one-hour sessions of unimanual upper-limb tasks during robot-assisted training with the Burt.
75550779|NCT05429255|Behavioral|Exergame Training|Nintendo Wii
75550780|NCT05425992|Other|Interview|Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
75550781|NCT05425862|Drug|Pidnarulex|Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.
75550782|NCT05425862|Drug|Talazoparib|Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
75550783|NCT05415774|Device|1 : S-C1-C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
75550784|NCT05415774|Device|2 : S-C2-C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
75550785|NCT05415774|Device|3 : C1 - S - C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
75550786|NCT05415774|Device|4 : C1 -C2 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
75550787|NCT05415774|Device|5 : C2 - S - C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
75550788|NCT05415774|Device|6 : C2 - C1 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
75550789|NCT05413681|Diagnostic Test|a supra-maximal exercise test on a cycloergometer.|10 blood samples will be taken: before, during and during recovery from exercise: before the exercise test on the cycloergometer, 2 samples during exercise on the cycloergometer (middle of the threshold and peak of the exercise), 2 samples during recovery from exercise on the cycloergometer (at 2 and 10 minutes), and 1 sample at 24 hours.
75711621|NCT00621309|Dietary Supplement|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
75871685|NCT02340910|Procedure|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks ."
76039025|NCT04940403|Device|Burt + BurtVision|18 one-hour sessions of combination of unimanual and bimanual upper-limb tasks during robot-assisted training with the BurtVision.
75405427|NCT01949844|Drug|regadenoson|Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
75405428|NCT01949844|Drug|Optimark®|For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
75405429|NCT01949844|Device|Myocardial perfusion MRI|
75405430|NCT01950780|Drug|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
75405431|NCT01951326|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
75405432|NCT01951326|Drug|Placebo|5 placebo capsules administered orally BID
75405433|NCT01951950|Drug|Nicardipine|
75405434|NCT01951950|Drug|Esmolol|
75405435|NCT01952418|Device|Monitor size|"Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor."
75405436|NCT01953432|Drug|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
75405437|NCT01953432|Drug|Placebo|Matched placebo daily dosing
75405438|NCT01955382|Drug|Actidose Aqua|Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
75550790|NCT05413681|Diagnostic Test|handgrip muscle activity test.|2 bloods samples : at rest, after the 3 maximum contractions of the forearm, at 5 minute's recovery from the 30-second contraction of the grip test,
75550791|NCT05413668|Drug|RVP-001|Intravenous administration of RVP-001
75550792|NCT05413668|Drug|Placebo|Intravenous administration of saline placebo
75550793|NCT05413551|Drug|Low-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 5 mg/kg oral tablet (maximum 300 mg)
75550794|NCT05413551|Drug|Standard dose of isoniazid|15 mg/kg oral tablet (up to 900 mg)
75405439|NCT01955382|Drug|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
75405440|NCT01955382|Drug|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
75405441|NCT01957410|Drug|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
75405442|NCT01957410|Drug|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
75405443|NCT01958112|Drug|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
75405444|NCT01958112|Drug|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
75405445|NCT01958346|Other|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
75405446|NCT01958346|Other|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
75405447|NCT01958346|Device|Fiberoptic Intubation|
75405448|NCT05739864|Biological|FMT|This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT
75405449|NCT05739864|Other|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
75405450|NCT05739786|Drug|liq nitrogen|In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
75405451|NCT05739786|Drug|intralesional vitamin D3|Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
75405452|NCT05739708|Other|Questionnaires|The time to complete the different questionnaires is estimated to be 60 minutes.
75405453|NCT05739630|Drug|mitoxantrone liposome|Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
75405454|NCT05739630|Drug|ATG|Control group:the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
75405455|NCT05739318|Device|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is collapsed as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
75405456|NCT05739318|Device|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is inflated as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
75405457|NCT05739084|Radiation|pre-operative radiation|As per standard of care and institutional guidelines
76039026|NCT05545163|Device|I-gel with standard insertion technique|"Standard I-gel insertion technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down the manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate. Then I-gel slided downwards and backwards along hard palate with a continuous but gentle push until a definitive resistance is felt)~Modified jaw thrust technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate with gently advancing into oropharynx. Then after, I-gel left in oral cavity and both hands used to thrust jaw by lifting angle of mandible with little fingers and other fingers to stabilise jaw. And, at this point, both hand's thumbs used to apply balance force from I-gel stem head towards final placement position by looking at integral bite block mark at incisor teeth level)"
75405458|NCT05739084|Procedure|Standard surgery after rpreoprative radiation|As per standard of care and institutional guidelines
75405459|NCT05738928|Diagnostic Test|blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .
75405460|NCT05738772|Diagnostic Test|serum sample for ELIZA|Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
75405461|NCT05738616|Combination Product|Lenvatinib combined with TACE and Camrelizumab|After all subjects sign informed consent and pass screening, they are randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib alone), and randomization is stratified according to the number of tumors (single versus multiple) and portal vein tumor thrombus (Vp1 ~ 3 vs. Vp4). Eight sites in China will be included in this study with follow-up of 2 years.
75405462|NCT05738538|Drug|ziftomenib|
75550795|NCT05413551|Drug|High-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 25 mg/kg oral tablet (maximum 1500 mg)
75550796|NCT05413278|Behavioral|Behavioral|Patient education, information and empowerment
75550797|NCT05409664|Behavioral|Physical activity adoption|webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.
75550798|NCT05409664|Behavioral|Self monitoring|Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
75405463|NCT05738460|Drug|antibiotics|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
75405464|NCT05738382|Drug|BG2109|oral administration once daily
75405465|NCT05738382|Drug|Cetrorelix|0.25 mg, Subcutaneous injection once daily.
75405466|NCT05738226|Device|EpiCare@Home, wearable multimodal seizure monitoring system|"Two wearable devices (Byteflies Sensor Dots) will be used. One Sensor Dot will be placed in the neck with a skin adhesive and will be connected to EEG electrodes placed behind each ear. The second Sensor Dot will be placed on the chest with an adhesive ECG electrode (i.e., a cardiac patch)."
75405467|NCT05737680|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg daily
75405468|NCT05737680|Drug|Colchicine|Colchicine continued
75405469|NCT05737290|Device|Clear aligners|Patients with mild anterior crowding will be treated with non-extraction treatment using clear aligners.
76039027|NCT04433143|Drug|Minocycline hydrochloride capsules were taken orally|Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
76039028|NCT02477553|Behavioral|DA - Quantitative|
76039029|NCT02477553|Behavioral|DA - Verbal|
76039030|NCT01665911|Drug|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
76039031|NCT01665911|Drug|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
76039032|NCT01665911|Drug|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
76039033|NCT01665911|Drug|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
76039034|NCT01665911|Other|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
76039035|NCT03063073|Drug|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection [Precedex]
76039036|NCT03063073|Drug|Bupivacaine|
76039037|NCT02452359|Device|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
75405470|NCT05737290|Device|Fixed appliances|Patients with mild anterior crowding will be treated with non-extraction treatment using fixed appliances.
75405471|NCT05736510|Other|Binaural sound|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
75405472|NCT05736510|Other|Control|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
75405473|NCT05735964|Drug|Indocyanine green|Intravenous and endoluminal dosing
75405474|NCT05735574|Other|IPG infections|Infected IPGs
75405475|NCT05735418|Dietary Supplement|GI Biome #7|It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10^8 CFU/day.
75405476|NCT05735418|Dietary Supplement|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
75405477|NCT05735028|Drug|Centipeda minima+PD-1/PD-L1 inhibitor|Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
75405478|NCT05735028|Drug|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor
75405479|NCT05734950|Other|Translational study|Non-interventional, translational study
75405480|NCT05734872|Device|Virtual Reality Technology|Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
76039038|NCT04620733|Drug|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
76039039|NCT04620733|Drug|Placebo|One capsule daily for double-blind period, for a duration of up to 12 months
75405481|NCT05734872|Other|Routine mental health course training|Conduct mental health education for patients by making a speech.
75405482|NCT05734482|Biological|Secukinumab|for subcutaneous injection only
75405483|NCT05725200|Drug|Alectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
76039040|NCT04620733|Drug|Seladelpar 5 mg|If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
76039041|NCT05538923|Other|No intervention was given to the patients|This study was an observational epidemiological study.
76039042|NCT05544851|Other|Education|"Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups."
75405484|NCT05725200|Drug|Cetuximab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
76039043|NCT05550155|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment|a 4-month maintenance procedure of active rTMS
76039044|NCT05550155|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|a 4-month maintenance procedure of sham rTMS
76039045|NCT04429009|Device|ZEPHYRx Respiratory Therapy (RT) System|A breath controlled video game system for respiratory therapy
76039046|NCT04429009|Device|Standard Incentive Spirometer|A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
76039047|NCT02476617|Drug|ombitasvir/paritaprevir/ritonavir|ombitasvir/ABT-450/ritonavir tablets
76039048|NCT02476617|Drug|dasabuvir|dasabuvir tablets
76039049|NCT02476617|Drug|ribavirin|ribavirin tablets
76039050|NCT05550077|Diagnostic Test|Optical Coherence Tomography|Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
76039051|NCT05550077|Procedure|Percutaneous transluminal angioplasty and stenting|Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
75405485|NCT05725200|Drug|Crizotinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
76039052|NCT04428307|Other|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
75405486|NCT05725200|Drug|Dasatinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
76039053|NCT04428307|Other|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
76039054|NCT05538845|Device|Screw fixation|Screw fixation to patients
76039055|NCT05538845|Device|Suture button|Suture button for patients
76039056|NCT05699213|Diagnostic Test|Lung MRI|MRI of the lung
75871686|NCT04871087|Device|Green Light|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~It is not an implant It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
75871687|NCT02349490|Device|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
76039057|NCT05699213|Diagnostic Test|Blood Draw|Blood Draw
75405487|NCT05725200|Drug|Everolimus|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
75405488|NCT05725200|Drug|Encorafenib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405489|NCT05725200|Drug|Gemcitabine|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
75405490|NCT05725200|Drug|Idelalisib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405491|NCT05725200|Drug|Larotrectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405492|NCT05725200|Drug|Methotrexate|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405493|NCT05725200|Drug|Palbociclib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405494|NCT05725200|Drug|Panobinostat|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405495|NCT05725200|Drug|Pembrolizumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405496|NCT05725200|Drug|Petrozumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
76039058|NCT05535725|Drug|application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection|on the application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection at La Paix State University Hospital Haiti over 2 years.Both groups benefited from the same preoperative asepsis protocol. One hour before the incision, 1g of intravenous ceftriaxone is administered to the patients, this dose is maintained during the 48 hours postoperative every 12 hours. At discharged the two groups of patients received oral cloxacilin 500mg three times a day for one week. Patients are dressed every 2 days until the surgical wound has healed. Patients are seen in the outpatient clinic at 2, 4, and 6 weeks, then at one year. We selected 215 patients and retained 204.
76039059|NCT03062137|Diagnostic Test|blood gas sampling|
75405497|NCT05725200|Drug|Trastuzumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405498|NCT05725200|Drug|Talazoparib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405499|NCT05725200|Drug|Venetoclax|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
75405500|NCT05724966|Device|mHealth app|We wish to examine the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before.
75405501|NCT05722080|Other|Eyesi simulator|Eyesi simulator learning curve for new ophthalmology residents
75405502|NCT05722080|Other|Sleep deprivation|See how experienced residents perform after sleep deprivation using the Eyesi simulator
75405503|NCT05714592|Other|Blood sample|The referring haematologist will suggest that the patient participate in the study during the consultation. In these patients, the investigators will perform OGM on the cytogenetic sample
75550799|NCT05408169|Behavioral|Suggested deadline for return of screening test|"A screening invitation letter modified to state, highlighted in yellow: Please return your kit within [X] weeks (by [DD.MM.YYYY]) or as soon as possible."
75405504|NCT05606484|Other|Exercise with non-immersive virtual reality|Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
75405505|NCT05606484|Other|Exercise with a static pedal|Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
75405506|NCT05599698|Other|Chemotherapy|Standard chemotherapy protocols for adjuvant & neoadjuvant treatment for different types of solid malignancies
75405507|NCT05574894|Drug|Growth hormone|Growth hormone is supplemented during the ovarian stimulation till the day of trigger
75405508|NCT05574894|Drug|GnRH antagonist|GnRH antagonist protocol for ovarian stimulation
75550800|NCT05408169|Behavioral|Planning sheet|A planning tool presented on a separate single sheet of paper inserted into the screening invitation envelope. The colour illustrated tool prompts participants to identify concerns they have with using the bowel screening kit and to link them to a tip to help them overcome this concern.
75550801|NCT05407818|Drug|JNJ-63733657|JNJ-63733657 will be administered as an IV infusion.
75550802|NCT05403476|Drug|FE 999049|FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
75405509|NCT05562570|Behavioral|Physical activity intervention coupled with standard post-cancer directed treatment care|AYACS will participate in a 16-week physical activity program. AYACS will be instructed to start with a session duration of <15-min, three days per week at low intensity (e.g., activities expending >1.5 to 3 METs or intensity <5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize AYACS' success. AYACS will receive a Fitbit at the beginning of the intervention.
75405510|NCT05562570|Other|Standard post-cancer directed treatment care control|AYACS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Exercise Guidelines for Cancer Survivors will be offered to AYACS following completion of 16-week follow-up. Moreover, AYACS will receive a Fitbit following completion of 16-week follow-up
75405511|NCT05554614|Behavioral|BTW app with reward-based feedback|Teen drivers will be notified of their weekly driving performance via a driving safety score with information on the types of high-risk driving behaviors committed as well as progress on maintaining and/or improving weekly safe driving behaviors. Educational materials on different driving situations and scenarios associated with the high-risk driving behaviors (e.g. 90-second videos) will be provided for the driver to review at any point and time. Information on these driving behaviors and the education material will be provided via push notifications from the BTW app. Weekly leader boards will show the driver's driving safety score in comparison to other drivers of the same age. Consistently high driver safety scores in certain driving skill areas (e.g., cornering) and a total overall score above 70% of other users on that skill or total score will unlock gamification-based rewards (e.g., driving safety badges, driving safety score leader board, group challenges with winners).
75405512|NCT05554614|Behavioral|BTW app with situational supervised driving practice|Teen drivers will be provided bi-weekly push-notifications from the BTW app notifying them of situational supervised driving practice activities that are to be completed during the assigned week. There are 12 situational supervised driving activities and six skill-building driving activities (Table 1). Skill-building sessions are assigned for off weeks during the first half of the six months (weeks 2-12), allowing for skills to be further developed when the situations are encountered for a second time (weeks 15-23). Parents will be prompted to directly log situational supervised and skill-building driving activities in the app after the session within the BTW app to obtain the module completion date and duration time.
75405513|NCT05554614|Behavioral|Sham BTW app|Teens will be provided links to passive education materials and information on car maintenance every week. They will not be given feedback on their driving performances.
75405514|NCT05530278|Drug|Galicaftor|Oral
75405515|NCT05530278|Drug|ABBV-576|Oral
75405516|NCT05530278|Drug|Navocaftor|Oral
75405517|NCT05530278|Drug|Midazolam|Oral
75405518|NCT05438628|Diagnostic Test|Point of care ultrasound|Measurement of thickness of rectus abdominis, biceps brachii muscles
75550803|NCT05403476|Drug|Placebo|Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
75550804|NCT05401071|Other|Short Regimen with Rifapentine 10mg/kg|rifapentine 10mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, >71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
76039060|NCT05698355|Other|Telerehabilitation Treatment|Telerehabilitation includes self-massages for pelvic floor muscle, sex education, breathing, myofascial releasing with wand, and pelvic floor relaxing exercises.
75550805|NCT05401071|Combination Product|Standardized Regimen|"During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, >71kg 750mg daily; isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, >71kg 375mg daily; pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, >71kg 1600mg daily; ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, >71kg 1375mg daily; All treatment is taken orally.~During the continuation phase, rifampicin ≤50kg 450mg daily, >50kg 600mg daily; isoniazid 300mg daily; All treatment is taken orally."
75550806|NCT05401071|Other|Short Regimen with Rifapentine 15mg/kg|rifapentine 15mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, >71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
75711622|NCT00621309|Dietary Supplement|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
75711623|NCT00839553|Procedure|Intrapleural Minocycline application|
75711624|NCT00832611|Device|Arteriovenous Fistula (ROX AC1)|The percutaneous creation of an arteriovenous fistula.
75711625|NCT04018521|Behavioral|PPN|Delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY).
75550807|NCT05401071|Other|Short Regimen with Rifapentine 20mg/kg|rifapentine 20mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, >71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
75550808|NCT05398302|Procedure|Image Guided Biopsy|Undergo image-guided biopsy
75405519|NCT05436288|Drug|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)|KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
75405520|NCT05434962|Device|Cardiac resynchronization therapy|"Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be <3V@0,5ms and phrenic nerve stimulation (PNS) margin should be >1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be <2,5V@0,5ms"
75405521|NCT05378568|Other|the selection scheme of peripheral venous access devices|"Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations."
75405522|NCT05378568|Other|the existing nursing routine|To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
75550809|NCT05394337|Drug|Atezolizumab|Given by vein (IV)
75550810|NCT05394337|Drug|Tiragolumab|Given by vein (IV)
75550811|NCT05394324|Device|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with subject devices of this study.
76039061|NCT04980235|Diagnostic Test|transperineal 3D ultrasound|All ultrasound volumes were acquired 7days after delivery and another examination 6weeks post-delivery by one experienced sonographers using a GEVoluson p8 (GE Healthcare) equipped with a 4-8-MHz curved array 3Dultrasound transducer
75550812|NCT05388955|Other|None, transplantation recipients|None, observational
75550813|NCT05375162|Behavioral|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
75550814|NCT05375162|Behavioral|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
75711626|NCT04018521|Behavioral|CSC Usual Care|standard of care provided to youth following first episode of psychosis
75711627|NCT02549079|Other|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
75711628|NCT00832689|Drug|Irinotecan and Gemcitabine|
76039062|NCT05535647|Drug|Regorafenib and HAIC|Regorafenib: oral 80mg/day, D1-21, Q28d; HAIC with FOLFOX: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
76039063|NCT05535647|Drug|FOLFOX|Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
75405523|NCT05312658|Procedure|External aortic compression|External aortic compression by assistant in cesarean section.
75405524|NCT05256966|Other|Sauna (steam)|Steam Sauna
75405525|NCT05245734|Drug|Human Anti-D (rh) immunoglobulin|prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
75405526|NCT05242692|Drug|S-ketamine|Loading dose: 0.25mg/kg in 10 minutes Maintenance dose: 0.1mg/kg/h
75405527|NCT05242692|Drug|Dexmedetomidine|Loading dose: 0.2 ug/kg in 10 minutes Maintenance dose: 0.2 ug/kg/h
75405528|NCT05242692|Drug|Normal saline|Refer to either S-ketamine or Dexmedetomidine
75405529|NCT05236062|Behavioral|Exercise|aerobic and resistance exercise
75405530|NCT05236062|Behavioral|Attention control|stretching
75405531|NCT05175534|Procedure|monitoring|peroperative transesophageal echocardiography for monitoring in liver transplant surgery
75405532|NCT05131620|Procedure|Virtual Reality|It is planned that VR glasses are put on 5-10 minutes before the procedure and continued throughout the procedure, and the total monitoring time will continue for 30 minutes.
75405533|NCT05131620|Procedure|Acupressure|Acupressure will be applied 10 minutes before catheter extraction after CAG.
76039064|NCT03064321|Behavioral|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
75405534|NCT05110404|Other|The high-volume HIIT|patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
75405535|NCT05110404|Other|The low-volume HIIT|Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
75405536|NCT05087940|Drug|Add-on therapy|Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
76039065|NCT03064321|Other|Information Control|Information on websites that are general health promoting
75405537|NCT05077566|Other|Exercise at 60% vo2|15 minutes of exercise at 60% VO2 max.
75405538|NCT05077566|Other|Exercise at 90% vo2|15 minutes of exercise at 90% VO2 max.
75405539|NCT05069220|Drug|18F-MFBG|Patients with neuroendocrine malignancies receive 2-4 MBq/kg of 18F-MFBG intravenously followed by PET/CT after 60min of injection.
75405540|NCT04993326|Behavioral|emPOWERed To Change Program|Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
75405541|NCT04930770|Drug|MRNA-1273|Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified.
75405542|NCT04922658|Drug|Surufatinib|Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
75405543|NCT04922658|Drug|Surufatinib Plus Vinorelbine|Surufatinib, 250mg, qd, po; Plus Vinorelbine, 40 mg , each week d1, d3, d5; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
75405544|NCT04915404|Drug|Berubicin Hydrochloride|Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
75405545|NCT04879602|Behavioral|suction with bronchoscopy|suction with bronchoscopy
75405546|NCT04794660|Diagnostic Test|HPV DNA Test|Screening for HPV using a HPV DNA test
75405547|NCT04794660|Diagnostic Test|VIA triage test|"VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer"
75550815|NCT05375162|Behavioral|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the Opt2Move app.
76039066|NCT05535569|Drug|Nivolumab, Paclitaxel|Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
76039067|NCT04980079|Procedure|Primary ureterscopy URS|Ureteral dilatation will be done when the stone size exceeds 10 mm to facilitate the extraction of the fragments. Ureteroscopic lithotripsy will be done using a 6.5:7.5 Fr semi-rigid ureteroscope and holmium laser. The ureteric stent will last for one week after lithotripsy
76039068|NCT04980079|Procedure|deferred ureteroscopy URS|insertion of a double -J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done .
76039069|NCT05538455|Device|PC4L solutions|Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
76039070|NCT04980313|Device|Xenogenic collagen matrix|Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
76039071|NCT04980313|Device|Autogenous connective tissue graft|Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
75405548|NCT04794660|Procedure|Treatment by ablative treatment|Cryotherapy or Thermal Ablation are performed on the cervix.
75405549|NCT04794660|Procedure|Colposcopy|Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
75405550|NCT04660968|Behavioral|Dyadic health behaviour change intervention|The dyadic behaviour change intervention adopts a dyadic coping perspective wherein appraisal of shared responsibility, agreement on tasks, and collaboration are fostered throughout the intervention. The intervention will target four behaviour goals: reducing overall caloric intake, substituting empty calorie foods with healthier alternatives, reducing sedentary behaviour, and increasing physical activity. The specific behavioural change strategies will include motivational interviewing, self-monitoring, goal setting, stimulus control, problem solving, and relapse prevention. Each session will also include a short education component on healthy eating to improve participants' adherence to the updated Canada's Food Guide. Participants will have access to web-based exercise training sessions. Intervention sessions will be delivered online.
75550816|NCT05375162|Behavioral|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the Opt2Move app.
76039072|NCT05544539|Drug|Ozone-Based Agent|In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap
76039073|NCT05544539|Drug|Placebo|In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
75405551|NCT04660968|Behavioral|Dyadic nutrition counselling intervention|The couples-based education nutrition intervention will provide extensive information on healthy eating. However, it will not include any behavioural change principles. Topics will be based on Dietitians of Canada's Practice-based Evidence in Nutrition (PEN) discussions in the database that focus on healthy eating for older adults. The topics covered will include increasing fruits and vegetables, hidden (empty) calories, how to read food labels, portion control, reducing salt and saturated fat, plant-based proteins, and eating for healthy bones. Participants in this group will also be told to increase their levels of physical activity to 150 minutes of moderate to vigorous physical activity per week, as per the Canadian Guidelines. Participants will have access to web-based exercise training sessions. However, physical activity will not be discussed explicitly during the intervention. Intervention sessions will be delivered online.
75405552|NCT04594902|Behavioral|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
75405553|NCT04594902|Other|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
75405554|NCT04438902|Drug|osimertinib mesylate tablets and anlotinib hydrochloride capsules|osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle
75405555|NCT04329390|Drug|Anticoagulant drugs|Prescription of, or already on oral anticoagulant treatment.
75405556|NCT04326036|Procedure|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
75405557|NCT04326036|Device|Centricyte 1000|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
75405558|NCT04326036|Procedure|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
75405559|NCT04326036|Drug|Liberase Enzyme (Roche)|Sterile Collagenase Blend to separate cSVF from the AD-SVF
75405560|NCT04326036|Drug|Sterile Normal Saline for Intravenous Use|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
75405561|NCT04303572|Drug|Eloctate ITI|This is a factor VIII-Fc infusion protein.
75550817|NCT05375162|Behavioral|Buddy|Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the Opt2Move app modules the participant has access to for their assigned condition. The Opt2Move app will include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcasts (one every 3 weeks) during the first 12 weeks of the intervention. Each podcast will provide social support training and peer discussion of challenges and successes in providing YACS with MVPA support.
75550818|NCT05372887|Drug|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
75550819|NCT05372887|Drug|Placebo|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
75550820|NCT05371964|Drug|Imetelstat|Imetelstat sodium will be administered as intravenous (IV) every 28 days.
75550821|NCT05371964|Drug|Ruxolitinib|Ruxolitinib will be administered, orally (PO), twice daily (BID) as the standard of care per local prescribing guidelines.
75550822|NCT05365581|Drug|ASP2138|intravenous
75550823|NCT05358158|Procedure|Intraoperative air leak test|A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
75550824|NCT05358158|Procedure|Intraoperative chest drain removal|Chest drain is removed intraoperatively.
75550825|NCT05358158|Procedure|Standard chest drain placement|Chest drain is left in pleura.
75550826|NCT05351879|Biological|GAD-alum (Diamyd) 40 μg/mL|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) adsorbed to Alhydrogel at a concentration of 40 μg/mL and is given as a sterile solution for intralymphatic injection
75550827|NCT05348603|Other|Traditional Letter|Patients receive a traditional letter.
75550828|NCT05348603|Other|Direct to Patient Message|Patients receive a direct to patient message via the portal.
75550829|NCT05348603|Other|Chatbot|Patients are contacted by a chatbot via the portal.
75550830|NCT05348603|Other|Banner|Patients are exposed to a banner ad via the portal.
75405562|NCT04303572|Drug|Emicizumab|This is a bispecific monoclonal antibody FVIII mimic.
75405563|NCT04177602|Combination Product|Trifluridine/tipiracil chemoradiation|Trifluridine/tipiracil based chemoradiation
75405564|NCT04177602|Combination Product|Capecitabine based chemoradiation|Capecitabine based chemoradiation
75405565|NCT04135482|Other|colonic tissue biopsy|colonic tissue biospy of patients with severe crohn's disease using colonoscopy
75405566|NCT04098822|Device|Virtue male sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.
75405567|NCT03849066|Other|Parent-Reported Symptom Assessment|As the basis for PRSA, the investigator will use the PediQuest Memorial Symptom Assessment Scale (PQ-MSAS), which is an adapted pediatric-specific version of the validated adult MSAS that assesses 28 physical and psychological symptoms over the past week. The study instrument is designed to be completed by a full-proxy parent, and 2 versions tailored for specific age groups are available (0-3, 3-18 years-old). Spanish versions are available for both instruments. The PQ-MSAS contains 28 symptom items, each with 4-point scores for domains of frequency, severity, and extent of bother. Based on these components, a global symptom score and individual symptom scores can be calculated (0-100 scale, with 100 being the worst).
75405568|NCT03834168|Other|standardized Study Diet|Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
75550831|NCT05340790|Drug|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
75550832|NCT05340790|Drug|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
75550833|NCT05332925|Drug|Standard of care immune checkpoint inhbitors|This is NOT an interventional study.
75550834|NCT05323630|Device|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
75550835|NCT05323474|Other|Usual rehabilitation|"Usual rehabilitation according to the practice of the Haute Autorité de Santé (HAS)"
75550836|NCT05323474|Other|Rehabilitation optimized|Rehabilitation optimized according to the study protocol
75711629|NCT00567190|Drug|Pertuzumab|Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
76039074|NCT04979689|Other|Intensive physical therapy|Intensive physical therapy treatment protocol was given for 3 months 3 times a week including 1.5- 2-hour session. Pre and post treatment assessments were taken. It included stretching for 20 min, Proprioception on ball for 20 minutes, quadruped for 10 min, vibration therapy for 20 min, tapping twice a month for 5 days, sensory therapy with beans for 20 min, supine lying with hand below head for 10-15 min, texturing for 15 min and activity of making tower with cups and hitting in outward direction for 15-20 min.
75405569|NCT03816618|Drug|Medihoney Gel in A Tube|TREATMENT1
75711630|NCT00567190|Drug|Placebo|Placebo (matching pertuzumab) was administered intravenously.
75405570|NCT03816618|Drug|Hydrogel|PURLOIN GEL
75405571|NCT03816618|Drug|Fucidin Ointment|FUCIDIN ANTIBIOTIC OINTMENT 10%
75405572|NCT03770598|Behavioral|Standard of Care Distressed in study Arm Distressed|Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.
75405573|NCT03770598|Behavioral|Psycho-Education|Mindfulness based stress reduction class, yoga and education material
75405574|NCT03770598|Behavioral|Team Based Care|Psychiatrist, Oncologist, clinical social worker, study coordinator
75405575|NCT03770598|Behavioral|Standard of Care Non-Distressed|No psycho-education about wellness promotion or health. These patients will be monitored only.
75405576|NCT03692208|Behavioral|My Diabetes Goal Survey and Optional Care Management|The intervention is already described in the intervention arm description.
75405577|NCT03662646|Other|no intervention performed- observational only|no intervention performed- observational only
75405580|NCT03616236|Drug|Buprenorphine/Naloxone|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
75405581|NCT03616236|Other|Treatment as usual|Participants will receive a referral to buprenorphine treatment in the community
75405582|NCT03602820|Biological|AAV2-hRPE65v2|
75405583|NCT03590574|Biological|AUTO4|AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine), patients will be treated with doses from 25 to 900 x 10^6 RQR8/aTRBC1 CAR T cells in Phase I. Following dose determination patients will be treated with the selected doses of RQR8/aTRBC1 CAR T cells (AUTO4) in Phase II.
75405584|NCT03551730|Combination Product|PRT064445/Enoxaparin|
75405585|NCT03551730|Combination Product|Placebo/Enoxaparin|
75405586|NCT03551730|Drug|Placebo|
75405587|NCT03491592|Behavioral|Enhanced Physical Activity Intervention|Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.
75405588|NCT03491592|Behavioral|Original Physical Activity Intervention|Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
75405589|NCT03366480|Drug|ABTL0812 in combination with paclitaxel and carboplatin|ABTL0812 in combination with paclitaxel and carboplatin.
75405590|NCT03267108|Combination Product|INOpulse®|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
75405591|NCT03267108|Combination Product|Placebo|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
75550837|NCT05321563|Behavioral|iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)|iDECIDE is a 4 session curriculum that addresses topics such as the neurobiology of substance use, adolescent brain development, industry tactics, motivations for using substances, risk and protective factors, triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. Facilitators are selected by schools and community agencies to receive free trainings conducted by the iDECIDE team, which includes personnel from the Massachusetts Department of Public Health, Massachusetts General Hospital (MGH) Center for Addiction Medicine, and the Institute for Health and Recovery.
75550838|NCT05317936|Drug|Pirtobrutinib|Given by PO
75550839|NCT05317936|Drug|Venetoclax|GIven by PO
75550840|NCT05315544|Device|CSI pVAD system|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
75550841|NCT05291546|Drug|REGN9035|Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
75871688|NCT03720899|Drug|NicoBloc|For Session 1, participants will use one drop of NicoBloc (which will block 33% of tar and nicotine) on their conventional cigarette and then will smoke this cigarette in session. Following smoking, they will discuss the effects of the NicoBloc on their withdrawal, cravings, and overall enjoyment of their cigarette. To bolster their in vivo NicoBloc experience, participants will be provided with NicoBloc to use between sessions to acclimate to the NicoBloc and to make practice quit attempts (PQAs). Sessions 2 and 3 are similar to Session 1 except they will use more NicoBloc product during the session and will be instructed to use the product between sessions.
76039075|NCT04979689|Other|Non intensive physical therapy|Non intensive therapy included 45 min session 3 times a week for 3 months. Pre and post treatment assessments were taken. The protocol included stretching for 20 min, cross friction massage for 15 min, Ball catch and throw for 15 min. progression was made from light to heavy weight ball.
75405592|NCT03267108|Combination Product|Open Label Extension|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
75550842|NCT05291546|Drug|REGN5381|Part B: Selected doses administered by IV infusion on day 1.
76039076|NCT05538377|Other|Focal Vibration|This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
76039077|NCT05538377|Other|Control Group|This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
76039078|NCT03822871|Drug|CTT1403|Escalating doses of 0.75 GBq - 13.5 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
75550843|NCT05291546|Other|Placebo|Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
75550844|NCT05285813|Drug|Vibecotamab|Given by vein (IV)
75550845|NCT05285813|Drug|Dexamethasone|Given by vein (IV) over about 60 minutes before the dose
75550846|NCT05285813|Drug|Acetaminophen|Given by mouth (PO) about 30-60 minutes before the dose
75550847|NCT05285813|Drug|Diphenhydramine|Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose
75550848|NCT05283226|Drug|NRC-2694-A|300 mg orally once daily
75550849|NCT05283226|Drug|Paclitaxel|175 mg/m² IV infusion over approximately 3 hours
75405593|NCT03239808|Procedure|Incremental haemodialysis|It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
75405594|NCT03239808|Procedure|Conventional haemodialysis|It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
75550850|NCT05281809|Drug|Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)|This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
75550851|NCT05280613|Behavioral|Family Check-Up|See arm/group description
75550852|NCT05280613|Behavioral|Treatment as Usual|See arm/group description
75550853|NCT05271552|Drug|BXCL501|Sublingual Film
75550854|NCT05271552|Drug|Matching Placebo|Sublingual Placebo Film
75405595|NCT02923362|Procedure|Laparoscopic Fundoplication|The gastric fundus of the stomach is wrapped or plicated around the lower end of the esophagus and and stitched in place reinforcing the closing function of the lower esophageal sphincter. The hiatus is also narrowed down with sutures or mesh to prevent or treat a concurrent hiatal hernia.
75405596|NCT02923362|Device|LINX Antireflux|The LINX is a flexible band of interlocked titanium beads with a magnetic core. The LINX is placed around the lower esophageal sphincter to help restore the function of the LES by preventing reflux into the esophagus.
75405597|NCT02890758|Biological|Natural Killer (NK) Cells|Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10^7 cells/kg), dose Level-1 (1x10^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10^7) and Dose level 3 (5X10^7) is dependent on DLT
75405598|NCT02890758|Biological|ALT803|given at 6mcg/kg weekly for four weeks
75405599|NCT02867124|Drug|XR-NTX|Vivitrol
75405600|NCT02867124|Other|place of residence|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
75405601|NCT02867124|Other|opioid treatment program|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
75405602|NCT02683200|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
75405603|NCT02683200|Radiation|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
75405604|NCT02534844|Drug|Parts A/B: Adrabetadex|900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
75405605|NCT02534844|Other|Parts A/B: Sham Control|No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
75405606|NCT02534376|Drug|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
75550855|NCT05268224|Diagnostic Test|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
75550856|NCT05267951|Device|Open-loop Stimulation|Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
75550857|NCT05267951|Device|Close-loop Stimulation|Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.
75405607|NCT02391324|Procedure|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
75405608|NCT02391324|Procedure|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
75405609|NCT02391324|Procedure|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
75405610|NCT02216838|Drug|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
75405611|NCT02216838|Other|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
75405612|NCT02065596|Drug|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
75405613|NCT02065596|Procedure|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
75405614|NCT01976286|Other|Salicylic Acid Peels|
75405615|NCT01976286|Other|Glycolic Acid Peels|
75405616|NCT01818492|Biological|NI-0501|
75405617|NCT01688076|Procedure|Botulinum Toxin A|Forehead will be injected with Botox.
75405618|NCT01372566|Device|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
75405619|NCT01372566|Other|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
75405620|NCT01239030|Drug|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
75405621|NCT01239030|Drug|Placebo|Placebo capsules
75405622|NCT01129050|Dietary Supplement|Fish Oil|Fish oil capsule
75550858|NCT05267951|Other|Functional Task Practice|Exercise therapy consists of repeated functional hand and arm movements
75550859|NCT05264506|Drug|NOMAC-E2 COC|"Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28).~Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed."
75550860|NCT05249088|Other|Protocolised reduction of non-resuscitation fluids|"Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~Parenteral nutrition is administered according to local protocol~Intravenous medications are concentrated according to a predefined protocol~Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)"
75550861|NCT05249088|Other|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~Medications are concentrated according to local protocol"
75711631|NCT00567190|Drug|Trastuzumab|Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
75871689|NCT03720899|Drug|Nicotine Lozenge|Participants who receive nicotine lozenge (mini lozenge) will be given either a 2 or 4 mg lozenge to use in session, depending on how soon they smoke after waking. If a participant smokes within 30 minutes of waking, they start with the 4 mg lozenge; more than 30 minutes, they start with the 2 mg lozenge. They will be given lozenges between sessions to make PQAs.
75871690|NCT02340754|Behavioral|Mindfulness-based Stress Reduction|
75871691|NCT02340754|Behavioral|MS Education Control|
75871692|NCT03145870|Other|Echoing of the lower limbs and measuring the systolic pressure index|Echoing of the lower limbs and measuring the systolic pressure index
75871693|NCT03145636|Device|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
75405623|NCT01129050|Dietary Supplement|Flaxseed Oil|Flaxseed oil capsule
75405624|NCT01129050|Dietary Supplement|Placebo|Soybean oil capsule
75405625|NCT01086540|Biological|Rituximab|"Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions."
75405626|NCT01086540|Other|Placebo|"Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions."
75711632|NCT00567190|Drug|Docetaxel|Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m^2 (up to 100 mg/m^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
75711633|NCT00922389|Procedure|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
75405627|NCT01086540|Diagnostic Test|CMRI|Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
75405628|NCT01086540|Drug|prednisone|Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
75405629|NCT01086540|Drug|methylprednisolone|Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
75405630|NCT01086540|Drug|diphenhydramine|"Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
75405631|NCT01086540|Drug|acetaminophen|"Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
75711634|NCT00922389|Drug|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
75711635|NCT00922389|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
75711636|NCT00839631|Drug|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
76039079|NCT03822871|Drug|CTT1057|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
76039080|NCT03822871|Drug|68Ga-PSMA-11|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
76039081|NCT05544383|Behavioral|Interdisciplinary Pain Education Program|It is an operative group model, with the objective of promoting education in pain, where the patient occupies an active and central space in the learning process, with work focused on the dysfunctional beliefs of chronic pain, performing programmed tasks to promote autonomy in activities daily life and behavior change. The group works with one meeting per week, during the routine opening hours of the clinic, with each day a theme of a professional area being addressed, totaling 5 meetings, lasting approximately two hours.
75405632|NCT01959048|Drug|fecal microbiota transplantation|
75405633|NCT01962558|Device|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
75405634|NCT01962558|Device|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
75405635|NCT01962714|Behavioral|Loving-Kindness Meditation|12-week loving-kindness meditation course
75405636|NCT01962714|Behavioral|Cognitive Processing Therapy|12-week CPT course
75405637|NCT01962870|Drug|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
75711637|NCT00691938|Drug|LBH589|
75711638|NCT00691938|Drug|Decitabine|
75871694|NCT03145636|Other|vBloc Achieve Weight Management Program|Remotely accessible web-based program to add additional support to subjects with vBloc therapy
75871695|NCT03145636|Other|Control Weight Management (CWM) program|In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
75871696|NCT03145480|Drug|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
75871697|NCT03145480|Drug|Ibrutinib|560mg po daily
75871698|NCT03145480|Other|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
75405638|NCT01962870|Drug|Placebo|
75405639|NCT01965288|Device|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
75405640|NCT01965288|Device|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
75405641|NCT01965366|Behavioral|Virtual reality exposure therapy|Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
75405642|NCT01965366|Drug|0.5 mg DEX|A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
75405643|NCT01965756|Drug|Metformin|
75871699|NCT03726515|Biological|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
75405644|NCT01965756|Drug|Placebos|
75405645|NCT01966380|Device|Leia|
75405646|NCT01966458|Device|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
75405647|NCT01966458|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
75405648|NCT01966770|Device|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
75405649|NCT01966770|Device|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
75405650|NCT01966770|Device|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
75405651|NCT01966770|Device|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
75405652|NCT01966770|Device|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
75405653|NCT01966770|Device|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
75405654|NCT01966926|Behavioral|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
75405655|NCT01967784|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
75405656|NCT01967862|Procedure|computed tomography|Undergo CT
75711639|NCT00365365|Drug|Doxorubicin and cyclophosphamide (AC) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~doxorubicin 60 mg/m^2 IV push or infusion followed by cyclophosphamide 600 mg/m^2 IV push or infusion~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
75871700|NCT03726515|Biological|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
75405657|NCT01967862|Procedure|bone scan|Undergo bone scan
75405658|NCT01967862|Procedure|3-Tesla magnetic resonance imaging|Undergo axial MRI
75405659|NCT01967862|Procedure|diffusion-weighted magnetic resonance imaging|Undergo WB MRI
75711640|NCT00365365|Drug|Docetaxel (T) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~docetaxel 100 mg/m^2 IV~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m^2 if toxicity occurred that met the criteria for doxorubicin dose reduction"
75711641|NCT00365365|Drug|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~doxorubicin 50 mg/m^2 IV push or infusion followed by cyclophosphamide 500 mg/m^2 IV push or infusion followed by docetaxel 75 mg/m^2~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
75711642|NCT00365365|Drug|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~docetaxel in 75 mg/m^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
75871701|NCT02349568|Procedure|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
75871702|NCT02349568|Procedure|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
75871703|NCT05665283|Drug|Ensartinib Hydrochloride|oral ALK inhibitor
75871704|NCT03071094|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4
75871705|NCT03071094|Drug|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
75871706|NCT02340364|Behavioral|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
75405660|NCT01967862|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT
75405661|NCT01967862|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT
75405662|NCT01967862|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT
75405663|NCT01967862|Other|laboratory biomarker analysis|Correlative studies
75405664|NCT01974102|Behavioral|Lifestyle counseling|Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
75405665|NCT01974102|Behavioral|Parenting Mindfully for Health (PMH)|Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
75405666|NCT01975974|Device|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
75405667|NCT01976988|Drug|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
75405668|NCT01978314|Device|75 mg / 6 mL VFI™|Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
75405669|NCT01980654|Drug|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
75550862|NCT05245097|Device|Tango Belt|The Tango Belt is a patient-contacting electronic device made out of medical grade plastics and biocompatible fabrics worn around the waist. The Tango Belt contains a fall-in-progress detection algorithm which can detect a serious hip-impacting fall-in-progress using built-in sensors and deploy an automotive-grade cold-gas airbag to protect the hips from ground impact forces. When connected to Wi-Fi, the Tango Belt can send automated fall and impact alerts to caregivers and Healthcare Providers (HCPs) while recording motion and event data, which can then be analyzed for usage-based metrics viewable via a companion mobile app and/or desktop app. Alerts are sent in the form of short message service (SMS) texts and emails to alert recipients designated in the mobile or desktop Companion App. The Tango Belt can also detect non-serious hip-impacting or non-hip impacting falls in which the wearer may have incurred a minor injury (i.e., not a major hip injury) and/or may be unable to get up.
75405670|NCT01980654|Drug|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
76039082|NCT05544383|Other|Conventional Physiotherapy treatment|The therapeutic approach consists of rehabilitation methods and techniques, with the aim of restoring, developing and conserving the patient's physical capacity and functionality, including manual therapy and kinesiotherapy, in addition to the use of resources such as electrotherapy, thermotherapy and auriculotherapy. The treatment is performed at the Physiotherapy outpatient clinic, twice a week, with an average duration of 45 minutes, for a period that lasts an average of 10 sessions in clinical cases of chronic musculoskeletal pain.
76039083|NCT04425551|Procedure|laser light|laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
76039084|NCT05538299|Behavioral|questionnaire, KAP|Diagnostic studies including questionaire, CXR, spirometry, clinical assesment, occupational safety training
76039085|NCT03064165|Drug|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
76039086|NCT03064165|Procedure|Sham block|Injection as for obturator nerve block, but with placebo
76039087|NCT03064165|Procedure|Obturator nerve block|Postoperative obturator nerve block
76039088|NCT03064165|Drug|Sodium Chloride 9mg/mL|Placebo
76039089|NCT05544149|Radiation|Thoracic radiotherapy|Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors
76039090|NCT05535491|Other|Educational and Research Hospital|breathing exercise
75405671|NCT01981590|Device|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
75405672|NCT01983228|Behavioral|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
75405673|NCT01984398|Drug|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
76039091|NCT05535413|Drug|UTD1 combined with capecitabine|"UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle."
76039092|NCT03813199|Drug|ABX464 50mg|ABX464 is a new anti-inflammatory drug
76039093|NCT03813199|Drug|Matching Placebo|placebo matching with ABX464
76039094|NCT03813199|Drug|ABX464 100mg|ABX464 is a new anti-inflammatory drug
76039095|NCT03813199|Drug|Methotrexate|MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
76039096|NCT05537909|Other|Biological sample collection|All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
75405674|NCT01984398|Drug|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
75405675|NCT01984398|Drug|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
75405676|NCT01984398|Drug|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
76039097|NCT03064009|Other|Infection|This is an observational trial
76039098|NCT05699135|Drug|Avelumab first-line maintenance|Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
75405677|NCT01985958|Device|Radiation therapy|
75405678|NCT01987752|Drug|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
75405679|NCT01988376|Device|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
75405680|NCT01988376|Device|Conventional Pap smear|Conventional Pap smear
75405681|NCT01988922|Drug|ketamine|0.4 mg/kg oral racemic ketamine
75405682|NCT01991808|Radiation|Radiotherapy|
75405683|NCT01992354|Device|PET MR Device|GE PET/MRI system
75405684|NCT01994538|Other|Longer therapy duration|14 days of antimicrobial treatment
76039099|NCT03791593|Drug|Evolocumab|Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
76039100|NCT04732715|Behavioral|CaRE Course|Participants will complete the CaRE Course over a 6-8 week time period. The curriculum of the CaRE course will include topics addressing caregiving for a PLWD during a pandemic, navigating the healthcare system for a PLWD, guiding and managing daily life, and self care.
75550865|NCT05235009|Diagnostic Test|Combined free GAGome MCED test|The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score. The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
75550866|NCT05228964|Device|Focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min.
75550867|NCT05224362|Device|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability.|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. Bertec force plate analysis will be performed to assess the acute effects on balance and stability. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/ dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
75550868|NCT05222750|Other|Pre-COVID-19|Pre-COVID-19
75550869|NCT05222750|Other|COVID-19|COVID-19
75550870|NCT05222750|Other|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out
75550871|NCT05215769|Behavioral|Health Education|Participate in a video intervention
75550872|NCT05215769|Other|Questionnaire Administration|Complete questionnaires
75550873|NCT05215678|Other|Acceptance of invitation to trial participation|Individuals who are eligible for and accept participation in the INKA trial (NCT05172843)
75550874|NCT05215678|Other|Declining invitation to trial participation|Individuals who are eligible for participation in the INKA trial (NCT05172843) but decline the invitation to participate
75550875|NCT05211895|Drug|Durvalumab|Durvalumab IV (Intravenous infusion)
75405685|NCT01994538|Other|Shorter therapy duration|7 days of antimicrobial treatment
75405686|NCT01996644|Drug|Placebo vs Setraline|Placebo
75405687|NCT01996644|Drug|Setraline|250mg DCS
75405688|NCT01998360|Procedure|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
75405689|NCT01998360|Procedure|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
75405690|NCT01998438|Drug|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
75405691|NCT01999530|Drug|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
75405692|NCT01999920|Drug|Vilazodone|10mg to 40mg per day for 12 weeks
75550876|NCT05211895|Drug|Domvanalimab|Domvanalimab IV (Intravenous infusion)
75550877|NCT05211895|Other|Placebo|Placebo IV (Intravenous infusion)
75550878|NCT05211336|Drug|Obinutuzumab|Obinutuzumab 1000 mg IV (intravenous) days 1 and 2 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
75550879|NCT05211336|Drug|Prednisone|Prednisone 100 mg PO (by mouth) daily days 1-7 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
75550880|NCT05211336|Drug|Lenalidomide|Lenalidomide 10 or 15 mg PO (by mouth) on days 1-14 for 1 cycle (21 days); followed by Lenalidomide 10 or 15 mg PO daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
75550881|NCT05211336|Drug|Venetoclax|Venetoclax 800 mg PO (by mouth) on days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
75550882|NCT05211336|Drug|Ibrutinib|Ibrutinib 560 mg PO (by mouth) daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
75550883|NCT05209789|Behavioral|HUGS|Group therapy with the participation of two therapist positively encouraging mother-baby interactions in a non-judgmental manner
75550884|NCT05209789|Behavioral|Playtime|Very little intervention from the therapists
75871707|NCT02340364|Behavioral|Self-care Education|208 patients randomized to self-care education alone.
75405693|NCT01999920|Drug|Placebo|One to two pills per day for 12 weeks
75550885|NCT05209594|Behavioral|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.
75550886|NCT05209594|Behavioral|Standard GSA Programming|Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
75405694|NCT02000154|Drug|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
75550887|NCT05201183|Combination Product|Fludarabine + Total Marrow Irradiation|"Patients will receive total marrow irradiation TMI on Day -11 to Day -7 in two fractions per day. The TMI dose will be escalated in successive cohorts compromised of 3-6 patients as follows:~Cohort 1 1.4 (Gy/fraction) Cohort 2: 1.6 (Gy/fraction) Cohort 3 1.8 (Gy/fraction) Cohort 4 2.0 (Gy/fraction) Cohort 5 2.2 (Gy/fraction)~Patients will receive Fludarabine (30 mg/m2/day) on Day -6 to Day -2 followed by allo-HSCT on Day 0."
75550888|NCT05183841|Drug|Bronchodilator (Ipratropium and Fenoterol)|8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
75550889|NCT05183841|Other|Placebo|8 puffs of placebo via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
75550890|NCT05174221|Drug|Mezagitamab|TAK-079 subcutaneous injection.
75405695|NCT02001714|Behavioral|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
75405696|NCT02002494|Other|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
75550891|NCT05168033|Other|Motor imagery training|Mentally imagine to perform rehabilitation exercises or sport-specific tasks without generating actual motor output.
75550892|NCT05168033|Other|Classic rehabilitation|Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
75550893|NCT05166577|Drug|Nanatinostat|Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week
75550894|NCT05166577|Drug|Nanatinostat|Nanatinostat at the confirmed RP2D
75550895|NCT05166577|Drug|Valganciclovir|Valganciclovir starting at 900 mg orally daily
75550896|NCT05166577|Drug|Pembrolizumab|Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
75550897|NCT05163873|Procedure|Extra-peritoneal|Surgery procedure: a non-mesh prophylactic surgical technique to prevent PH
75711643|NCT00365365|Drug|Bevacizumab and trastuzumab maintenance therapy|"bevacizumab 15 mg/kg was infused IV followed by~trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
76039101|NCT03064243|Drug|apatinib|apatinib 500mg po. qd.
76039102|NCT05537831|Device|Ultrasound|The ultrasound will be used to assist with the delivery of a hematoma block in patients with distal forearm fractures.
76039103|NCT05543993|Drug|Bivalent COVID-19 Booster|Bivalent COVID-19 Booster by Pfizer or Moderna
76039104|NCT03765619|Drug|Aspirin|250 patients will be randomized to receive postoperative Aspirin.
76039105|NCT05698043|Drug|CKD-386(5)|Test
76039106|NCT05698043|Drug|D013, D326, D337|Reference
75405697|NCT02002650|Drug|Pre-ERCP rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP in all patients.
75405698|NCT02002650|Drug|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
76039107|NCT04979845|Other|Telerehabilitation|Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises
76039108|NCT04979845|Other|Video exercise|Patients will receive video instructions for home based exercises
75405699|NCT02003352|Procedure|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
75550898|NCT05162404|Behavioral|Video Education Program|"The following topics are addressed in each module of the videos:~Understanding cancer and cancer treatment - including an understanding of stage, site of origin, metastases, treatment options, toxicities and anticipated outcomes.~Care coordination basics (CC: Communication) - including navigating care related to appointments, how to handle issues after-hours, and the expected roles of other healthcare providers (e.g., PCPs).~How to be a self-advocate (CC: Navigation and Operational) - including how to ask questions, being empowered to talk to your doctor, when a second opinion is needed, when to explore clinical trials, and how to best incorporate a caregiver into your treatment."
75550899|NCT05159934|Drug|0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine|Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
75405700|NCT02004132|Drug|Axiron|Solution administered topically using pump and applicator
75550900|NCT05159934|Drug|Saline|Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline
75550901|NCT05159518|Drug|PRT2527|PRT2527 will be administered by intravenous infusion
75550902|NCT05150444|Other|Cognitive and physical exercise training|"12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (~30 minutes). The brain games on mentioned platform automatically adapt to individual cognitive abilities."
75711644|NCT00365365|Drug|Bevacizumab maintenance therapy|"- bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
76039109|NCT05699057|Behavioral|Suicide GROUP|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains. Finally, we will To document the prevalence of tendency to suicide among medical students in the Egyptian Universities and analyse associated risk factors and any correlated determents.
75405701|NCT03697278|Device|Smith medical CADDsolis|This group will be monitoring from a network.
76039110|NCT03062215|Behavioral|Space from Depression|Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
76039111|NCT05543603|Drug|Lacer Clorhexidina Colutorio|15 ml 0,12% Chlorhexidine, one minute rinse
76039112|NCT05543603|Drug|Lacer Clorhexidine 0.20% Colutorio|15 ml 0,2% Chlorhexidine, one minute rinse
75405702|NCT02004288|Dietary Supplement|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
75405703|NCT02004366|Drug|Linagliptin|Linagliptin once daily + correction doses of rapid acting insulin if needed
75405704|NCT02004366|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
75405705|NCT02004366|Drug|Linagliptin|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
75550903|NCT05139316|Genetic|DTX401|nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)
76039113|NCT05543603|Drug|Gingilacer Encías Delicadas Colutorio|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse
76039114|NCT05543603|Drug|Distilled water|15 ml distilled water, one minute rinse
75550904|NCT05139316|Other|Placebo|Normal Saline infusion
75405706|NCT02004366|Drug|Linagliptin + 50% Glargine dose on discharge|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
75405707|NCT02004366|Drug|Linagliptin + 80% Glargine|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
75550905|NCT05139316|Drug|Oral corticosteroids|Participants who receive DTX401 solution will receive oral corticosteroids
75550906|NCT05139316|Drug|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
75550907|NCT05132075|Drug|JDQ443|JDQ443 tablets, orally administered
75550908|NCT05132075|Drug|docetaxel|docetaxel concentrated solution for infusion, intravenously administered
75550909|NCT05127226|Drug|ION582|ION582 will be administered by IT injection.
75711645|NCT02564874|Other|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
75550910|NCT05121376|Genetic|Dose 1 of BMN 331|BMN 331 AAV Gene Therapy
75550911|NCT05121376|Genetic|Dose 2 of BMN 331|BMN 331 AAV Gene Therapy
75550912|NCT05121376|Genetic|Dose 3 of BMN 331|BMN 331 AAV Gene Therapy
75871708|NCT05761392|Other|Precise management|The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
75405708|NCT02004990|Procedure|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
75405709|NCT02005536|Biological|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
75405710|NCT02006160|Drug|dalfampridine|10 mg bid
75405711|NCT02006160|Drug|placebo|10 mg bid
75405712|NCT02010216|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
75405713|NCT02010996|Procedure|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
75550913|NCT05121376|Genetic|Dose 4 of BMN 331|BMN 331 AAV Gene Therapy
75550914|NCT05121376|Genetic|Dose 5 of BMN 331|BMN 331 AAV Gene Therapy
75550915|NCT05121376|Genetic|Dose 6 of BMN 331|BMN 331 AAV Gene Therapy
75550916|NCT05121376|Genetic|Dose 7 of BMN 331|BMN 331 AAV Gene Therapy
75550917|NCT05120427|Dietary Supplement|Lipid based nutrient Supplements (LNS):|LNS are 20 g/~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.
75550918|NCT05120427|Device|Growth Charts|Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.
75550919|NCT05108233|Other|Survey Administration|Complete survey
75405714|NCT02010996|Procedure|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
75405715|NCT02011464|Drug|Exparel|Exparel is infiltrated into posterior compartment for pain control
75405716|NCT02011464|Other|Saline|Saline is infiltrated into posterior compartment for control
75405717|NCT02058420|Drug|Low tocotrienols group|300 mg tocotrienols daily
75405718|NCT02058420|Drug|High tocotrienols group|600 mg tocotrienols daily
75405719|NCT02015442|Dietary Supplement|Sucrose|
75405720|NCT02016612|Device|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
75405721|NCT02020278|Drug|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period."
75550920|NCT05081128|Device|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
75550921|NCT05081076|Device|Glazing|The zirconia surface will be submitted to a vitrification procedure (glazing) in a specific ceramic oven using the Ceramill Stain & Glaze Kit, following the manufacturer's instructions.
75550922|NCT05081076|Device|Polishing|The zirconia surface will be submitted to a polishing procedure using a polishing rubbers kit in the sequence indicated by the manufacturer (EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
75405722|NCT02020590|Drug|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
76039115|NCT04979923|Drug|Lidocaine|Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
75405723|NCT02023944|Other|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
75405724|NCT02024646|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
75550923|NCT05081050|Other|Only Follow-up|No intervention is planned.
75711646|NCT01046461|Drug|Ramosetron, Aprepitant, Dexamethasone|"Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning"
75550924|NCT05078957|Other|Stool sampling|Stool samples will be collected from participants at baseline and annually during 5 years
75711647|NCT00623727|Biological|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
75711648|NCT00623727|Biological|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
75711649|NCT00933946|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
76039116|NCT05543525|Other|Echocardiography|Transthoracic echocardiography
75405725|NCT02024646|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
75711650|NCT01046539|Drug|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
76039117|NCT05543525|Other|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing
75405726|NCT02024646|Drug|Placebo|Placebo administered via subcutaneous injection until week 24.
75405727|NCT02024724|Drug|Bupivacaine|4 mL of 0.25% bupivacaine
75405728|NCT02024724|Drug|Triamcinolone|40 mg of Triamcinolone
75405729|NCT02024724|Drug|Dexamethasone|4 mg of Dexamethasone
75405730|NCT02025426|Drug|Phenylephrine|
75405731|NCT02025426|Drug|Ephedrine|
75711651|NCT01046539|Drug|Placebo|0 mg
75871709|NCT04478968|Other|presence of AVF|Functioning AVF may have cardiotoxic potential
75550925|NCT05078957|Other|Frailty phenotype|According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
75550926|NCT05078957|Other|Blood plasma collection|Blood plasma collection to measure persistent inflammation and immune activation
75550927|NCT05075382|Procedure|Elbow surgery for fracture|This group will undergo a surgery in order to fix a broken elbow.
75711652|NCT04015024|Drug|SKLB1028 150mg bid|150mg oral administration twice a day
75711653|NCT04015024|Drug|SKLB1028 200mg bid|200mg oral administration twice a day
75711654|NCT04015024|Drug|SKLB1028 300mg qd|300mg oral administration once a day
75711655|NCT01044199|Biological|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
75711656|NCT01044199|Biological|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
75711657|NCT00908284|Behavioral|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
75871710|NCT02525406|Other|All surgeries performed from Jan 01, 2010 to Aug 31, 2020|
76039118|NCT04519411|Diagnostic Test|Transpulmonary pressure measurements|Transpulmonary pressure measurements
76039119|NCT03714997|Procedure|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
76039120|NCT03706885|Drug|Sustiva Pill|One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
76039121|NCT01665599|Drug|Testosterone gel (FE 999303)|
76039122|NCT04979221|Drug|Cyproheptadine|Cyproheptadine 8mg three times a day during 10 days
76039123|NCT04503109|Device|Nalu Neurostimulation System|The Nalu Neurostimulation System is a Spinal Cord Stimulation system
75550928|NCT05071053|Drug|Ramucirumab (CYRAMZA®)|"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
75550929|NCT05071053|Drug|Tusamitamab ravtansine (SAR408701)|"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
75550930|NCT05063981|Drug|Mepolizumab|Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control
75550931|NCT05057182|Biological|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
75405732|NCT02026206|Device|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
75550932|NCT05057169|Biological|BNT162b2|BNT162b2 is a nucleoside-modified mRNA encoding the trimerized SARS-CoV-2 spike glycoprotein. The vaccine is formulated in lipid nanoparticles that increase the efficiency of delivery of the mRNA into cells after intramuscular injection. BNT162b2 encodes the SARS- CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation and more closely recreate the intact virus with which the elicited virus- neutralizing antibodies interact. mRNA vaccines use the pathogen's genetic code as the vaccine; hence they exploit the host cells to translate the code and generate the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response of the vaccinated individual. The mRNA is then degraded within days.
75550933|NCT05057169|Biological|CoronaVac|CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-propiolactone- inactivated vaccine based on the CZ02 strain. This strain of SARS-CoV-2 was isolated from the bronchoalveolar lavage of a hospitalized patient and is closely related to the 2019-nCoV- BetaCoV Wuhan/WIV04/2019 strain. Each 0.5 ml dose is composed of 3 μg of inactivated SARS-CoV-2 virus. The excipients are aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection.
75550934|NCT05050942|Drug|CAM2029|CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
75550935|NCT05050942|Drug|Octreotide LAR|Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
75550936|NCT05050942|Drug|Lanreotide ATG|Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
75711658|NCT00908284|Behavioral|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
75405733|NCT02026206|Device|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
75405734|NCT02028780|Drug|Placebo to dose|placebo
75550937|NCT05050617|Diagnostic Test|Point-of-care echocardiography|Subjects will undergo point-of-care echocardiography at the time of presentation/enrollment to assess for evidence of right sided heart dilation/strain.
75550938|NCT05035030|Drug|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
75550939|NCT05030909|Behavioral|transdiagnostic group treatment|The individual and group sessions will integrate core principles from Motivational interviewing (provide information, address barriers), Cognitive Behavioural Therapy (psychoeducation regarding emotions, enhancing emotional awareness, cognitive restructuring, behavioural experiments, relaxation) , Acceptance Commitment Therapy (mindfulness, grounding, emotional and body awareness, enhancing cognitive flexibility), and aspects of Islamic psychology.
75405735|NCT02028780|Drug|Idarucizumab|short infusion
75550940|NCT05004675|Biological|lerodalcibep|300 mg
75550941|NCT05004675|Drug|Inclisiran|284 mg
75550942|NCT05002218|Behavioral|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day.
75550943|NCT05002218|Behavioral|Balance Training|Balance training 5x a week for 30 minutes as instructed by a therapist. Standard of care.
75550944|NCT04998578|Device|Comparison of aesthetic techniques|Comparison of aesthetic techniques for rejuvenation and glazing of the genital region
75711659|NCT00828789|Drug|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
75711660|NCT00839709|Procedure|blood sampling|peripheral blood draw
75711661|NCT00930358|Drug|MEOPA|anaesthetic gaz inhalation
75711662|NCT00930358|Drug|general anaesthesia|Anaesthetic intravenous route
75711663|NCT00832845|Behavioral|CBSST plus treatment as usual|Patients will receive CBSST in addition to their regular treatment for 36 weeks.
75405736|NCT02028780|Drug|Placebo to Idarucizumab|Placebo to Idarucizumab
75405737|NCT02028780|Drug|dabigatran|2 capsules dabigatran
75405738|NCT02028780|Drug|Idarucizumab|short infusion
75405739|NCT02029872|Drug|Chlorhexidine gluconate soap|4% chlorhexidine gluconate (soap)
75405740|NCT02029872|Drug|Chlorhexidine gluconate oral rinse|chlorhexidine gluconate oral rinse 0.12%
75405741|NCT02029872|Drug|Mupirocin calcium 2 % ointment|nasal mupirocin calcium 2% ointment
75405742|NCT02030574|Drug|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
75550945|NCT04996758|Drug|Toripalimab and Anlotinib|Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.
75871711|NCT04595292|Other|older adults, assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
75405743|NCT02030886|Device|Sensimed Triggersfish® (TF)|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
75405744|NCT02032212|Other|EVP unflavoured|
75405745|NCT02032212|Other|EVP flavoured|
75405746|NCT02032212|Other|Nicotine inhalator|15 mg nicotine Nicorette
75405747|NCT02032212|Other|Conventional cigarette|
75405748|NCT02032680|Behavioral|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
75550946|NCT04986657|Device|ChromoSeq|Novel, streamlined whole genome sequencing approach
75711664|NCT00832845|Behavioral|Treatment as usual (TAU)|Patients will receive their regular treatment for 36 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians.
75711665|NCT00930436|Drug|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
75711666|NCT00372775|Drug|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
75711667|NCT00832923|Behavioral|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
75711668|NCT00936676|Drug|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
75711669|NCT00839787|Drug|Morphine Sulfate|Morphine Sulfate group: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
75711670|NCT01044355|Device|CPAP|6 weeks treatment with fixed CPAP
75711671|NCT01044355|Device|APAP|6 weeks of treatment with auto-titrating positive airway pressure
75871712|NCT03145402|Biological|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
75871713|NCT03145402|Biological|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
75405749|NCT02032680|Behavioral|In-persons Multi-Family Group Psycho-Education treatment|This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.
75405750|NCT02032680|Other|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
75405751|NCT02032758|Drug|Propranolol|Single oral dose of 10 mg propranolol
75405752|NCT02032758|Device|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
75405753|NCT02032758|Procedure|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
75405754|NCT02032758|Device|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
75405755|NCT02033694|Device|NIRS-IVUS Imaging (TVC Imaging System)|Diagnostic Imaging Catheter
75405756|NCT02036424|Drug|Ozurdex|intravitreal steroid
75405757|NCT02036424|Drug|Bevacizumab|antiVEGF
75405758|NCT02037204|Other|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
75711672|NCT01049659|Behavioral|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
75711673|NCT00936754|Dietary Supplement|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
75405759|NCT02037438|Other|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
75405760|NCT02037438|Other|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
75405761|NCT02038218|Drug|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
75550947|NCT04977414|Behavioral|Making Data Count Training intervention|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
75550948|NCT04974567|Other|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
75711674|NCT00936754|Dietary Supplement|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
75711675|NCT00934258|Drug|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
75711676|NCT00934258|Genetic|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
75871714|NCT04438876|Other|Functional Power Training|The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
75871715|NCT04438876|Other|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
75711677|NCT00372697|Drug|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
75711678|NCT04014478|Device|Endovascular Denervation|A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
76039124|NCT05697887|Dietary Supplement|Ketogenic diet|The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
76039125|NCT01671085|Drug|LY3015014|Administered SQ
76039126|NCT01671085|Drug|Placebo|Administered SQ
76039127|NCT05537363|Other|Health education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.
75711679|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
75871716|NCT04477798|Diagnostic Test|PCT-DIA/MS|PCT-DIA/MS will be validated to classify FNA biopsy specimens
75871717|NCT03148990|Biological|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
76039128|NCT05537363|Other|Multicomponent training|Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
76039129|NCT05537363|Other|Agility training|The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
75405762|NCT02042274|Dietary Supplement|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
75405763|NCT02044380|Drug|Afatinib|40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
75711680|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
75405764|NCT02045238|Drug|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
75405765|NCT02045238|Radiation|Chest X-Ray|
75405766|NCT02045238|Other|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
75550949|NCT04972318|Procedure|Positive end-expiratory pressure titration with driving pressure control|Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
75550950|NCT04972318|Procedure|ARDSNet ventilatory strategy|Positive end-expiratory pressure will be set according to fixed inspired oxygen fraction values.
75711681|NCT00934414|Drug|Technosphere Insulin Inhalation Powder|30U
75871718|NCT03148990|Biological|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
75871719|NCT02340598|Other|cold vest|The lowering of body temperature increases basal metabolic rate
75871720|NCT03559517|Biological|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
76039130|NCT03063931|Drug|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
75405767|NCT02047032|Procedure|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
76039131|NCT03063931|Drug|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
75405768|NCT02047032|Drug|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
75405769|NCT02047032|Procedure|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
75871721|NCT03559517|Other|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
75871722|NCT02340442|Other|Obstetrical care parameters|
76039132|NCT03621631|Behavioral|Optimized Tai Chi intervention|Optimized Tai Chi intervention
76039133|NCT03621631|Behavioral|Traditional Tai Chi intervention|Traditional Tai Chi intervention
75711682|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
75711683|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 800 mg/m^2 dose level, administered every 2 or 3 months.
75711684|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 625 mg/m^2 administered every 2 or 3 months.
75711685|NCT00930514|Drug|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m^2) administered every 2 or 3 months.
75711686|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 375 mg/m^2 administered every 2 or 3 months.
75871723|NCT02340442|Other|DVA measurements|
75871724|NCT02340442|Other|Fundus photographs|
75871725|NCT04477642|Drug|Abatacept|10mg/kg intravenously administered on Day 1
75405770|NCT02047344|Drug|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
75871726|NCT03149146|Other|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
75871727|NCT03149146|Other|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
76039134|NCT03063775|Device|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
75405771|NCT02047500|Drug|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
75405772|NCT02047500|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
75405773|NCT02047500|Drug|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
75405774|NCT02048670|Device|Balance Belt|Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
75405775|NCT02051790|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
75405776|NCT02054754|Drug|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
75405777|NCT02054754|Drug|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
75405778|NCT02054754|Drug|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
75405779|NCT02054754|Drug|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
75405780|NCT02054754|Drug|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
75405781|NCT02054754|Drug|Placebo|
75405782|NCT02057640|Drug|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
75405783|NCT02057640|Drug|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
76039135|NCT03063775|Other|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
76039136|NCT03063775|Other|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
75405784|NCT02057640|Drug|MLN9708|4mg on day 1, 8, 15, 28
75405785|NCT02057952|Behavioral|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
75405786|NCT02059512|Procedure|Group 1|Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.
75405787|NCT02059512|Procedure|Group 0|Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.
75405788|NCT02059512|Procedure|Group 2|Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.
75405789|NCT02059902|Drug|Lidocaine|Lidocaine infusion runs for a total of 24 hours
75405790|NCT02059902|Other|Placebo|Normal saline runs for a total of 24 hours
75405791|NCT02060058|Drug|Stop trial intervention for boceprevir, PEG-IFN and RBV|"Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped."
75405792|NCT02060526|Drug|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase [rhHNS]
75405793|NCT02060838|Procedure|Acute normovolemic hemodilution (ANH)|Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
75405794|NCT02061384|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
75405795|NCT02061384|Drug|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
75405796|NCT02061696|Device|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
75405797|NCT02061696|Procedure|Standard Manual Compression|Closure procedure by Manual Compression
76039137|NCT03063775|Device|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
75405798|NCT02061774|Drug|Acetaminophen|1 gram of intravenous Acetaminophen
75405799|NCT02061774|Drug|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
75405800|NCT02062008|Device|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
75405801|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
75405802|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
75405803|NCT02062710|Drug|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
75405804|NCT02062710|Drug|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
76039138|NCT03063541|Drug|Acetylsalicylic acid|100 mg daily as one tablet
75405805|NCT02062710|Drug|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
75405806|NCT02062710|Drug|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
75405807|NCT02063178|Behavioral|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
75405808|NCT02063178|Behavioral|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
75550951|NCT04969874|Other|Remote follow-up|"The feeling of swallowing will be assessed at the end of the stay at the rehabilitation center, which corresponds to the first visit, and then every month for 5 months during remote interviews and on discharge with the Deglutition Handicap Index (DHI), a self-assessment questionnaire for the swallowing handicap.~The quality of life will be assessed at the firs visit and 6 months after using the EORTC QLQ 30 quality of life scale and the H&N annex, a self-assessment questionnaire on the quality of life for people with cancer of the head and neck.~The satisfaction of users and the interest of city health professionals in the use of the MAX Educ tool as part of a monthly monitoring will be collected via the TUQ questionnaire, through the MAX platform at Month 6."
75711687|NCT00936988|Drug|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
75711688|NCT00934492|Drug|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
75711689|NCT00934492|Drug|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
75711690|NCT00934570|Drug|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
76039139|NCT03063541|Other|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
76039140|NCT04978753|Drug|Anlotinib|"Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA<1.6 m2), once a day orally, taking two weeks and stopping for one week;~Almonertinib: 110mg, orally once a day;"
75405809|NCT02063178|Behavioral|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
75405810|NCT02063178|Behavioral|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
75405811|NCT02063178|Behavioral|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
75405812|NCT02063178|Behavioral|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
75405813|NCT02063178|Behavioral|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
75405814|NCT02063178|Behavioral|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
75405815|NCT02063178|Behavioral|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
75405816|NCT02063178|Behavioral|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
75871728|NCT02344732|Drug|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
75871729|NCT02344732|Drug|Homatropine 2% eye drops thrice daily|
75871730|NCT02344732|Drug|Oxygen gas|
76039141|NCT03545737|Other|Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT
75405817|NCT02063178|Behavioral|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
75711691|NCT00934570|Drug|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
76039142|NCT03545737|Other|Formula|The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube
75405818|NCT02064270|Device|Single-Use Negative Pressure Wound Therapy|Application of PICO Single-Use Negative Pressure Wound Therapy
75405819|NCT02064270|Device|Standard postsurgical dressings|Use of Standard postsurgical dressings
75405820|NCT02064582|Drug|Enzalutamide|160mg by mouth each day
75550952|NCT04965246|Behavioral|Physical Activity|The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
75405821|NCT02064582|Drug|Leuprolide acetate|22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
75550953|NCT04965246|Other|Usual Care|Participants in the usual care group will receive no intervention
75550954|NCT04959331|Drug|Fosfomycin Trometamol Salt|Fosfomycin 3 g 2 sachets, taken orally, once daily for two days
75550955|NCT04959331|Drug|Nitrofurantoin|Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days
75711692|NCT00934570|Behavioral|Placebo Standard exercise|Standard exercise
75711693|NCT00934570|Behavioral|Intensive exercise|Placebo Intensive exercise
75871731|NCT03720743|Other|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
75871732|NCT02344654|Drug|Indocyanine green|
76039143|NCT03063853|Other|Removal of surgical clips at day 4 post operative vs day 8 post operative|Removal of surgical clips at day 4 post operative vs day 8 post operative
76039144|NCT03063853|Procedure|Elective cesarean delivery|non emergent elective cesarean delivery
76039145|NCT03062761|Other|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
75405822|NCT02064582|Radiation|radiation|External beam radiation will be delivered as per standard radiation therapy protocol
75405823|NCT02067000|Behavioral|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
75405824|NCT02067468|Device|HPV test|QIAGEN - The Digene HPV test®
75405825|NCT02067468|Procedure|COLPOSCOPY|Colposcopy routine health services
75405826|NCT02067468|Device|cytology|Cytology routine health services
75405827|NCT02067858|Radiation|Stereotactic Radiosurgery|
75405828|NCT02069184|Drug|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
75405829|NCT02069184|Other|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
75550956|NCT04959331|Drug|Pivmecillinam|Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days
75550957|NCT04959331|Drug|Fosfomycin Trometamol Salt|Fosfomycin 3 g one sachet, taken orally, for one day
75711694|NCT03702634|Behavioral|Spiritual Care Assessment and Intervention (SCAI) framework|The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
75711695|NCT00930670|Drug|Rosuvastatin-omeprazole|Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
75711696|NCT00930670|Drug|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
76039146|NCT03062761|Other|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
76039147|NCT03063151|Diagnostic Test|Surface Electromyography (EMG)|
75405830|NCT02070276|Procedure|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
76039148|NCT04978597|Drug|Opicapone 50 mg|Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
76039149|NCT04978597|Drug|Placebo|Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
75405831|NCT02070276|Procedure|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
75405832|NCT02134314|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
75405833|NCT02134314|Drug|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
75550958|NCT04948775|Other|Cervical stabilization exercises|A progressive home-based cervical stabilization exercise program which is aimed to train deep stabilizer muscles of the cervical spine and improve coordination between superficial and deep cervical muscles will be performed by the patients for 6 weeks. Exercises are going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.
75550959|NCT04916951|Drug|Amoxicillin|oral one-time dose of amoxicillin
75550960|NCT04916951|Drug|Cephalexin|oral one-time dose of cephalexin
75550961|NCT04912076|Drug|BM41|Subcutaneous injection of increasing doses of BM41
75550962|NCT04912076|Other|Placebo|Subcutaneous injections of placebo containing aluminium hydroxide.
75871733|NCT02344654|Device|Near-infrared illumination|To see the fluorescence from indocyanine green
75871734|NCT02344654|Drug|Urografin|
76039150|NCT03490513|Drug|anastrozole (1 mg/day)|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
75405834|NCT02135016|Drug|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
75405835|NCT02135016|Drug|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
75405836|NCT02135016|Drug|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
75405837|NCT02135094|Device|Active ultrasound therapy device|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
75405838|NCT02135094|Device|Placebo ultrasound therapy device|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
75405839|NCT02137512|Device|Closed-Loop Control System|"This investigational device system included the following components:~DiAs - a smart-phone medical platform;~Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class"
75405840|NCT02137512|Device|Sensor-Augmented Pump (SAP)|"This commercial device system included the following components:~Dexcom G4 Platinum CGM system;~Roche Accu-Chek insulin pump"
75405841|NCT02139228|Biological|Hib-CRM197|No vaccine administered in V37_07E2 study
75550963|NCT04912076|Drug|ALK Alutard SQ Betula verrucosa|Subcutaneous injections with increasing doses of Alutard according to cluster up-dosing scheme.
75550964|NCT04898413|Behavioral|Group-based acceptance and commitment therapy (ACT)|Group-based ACT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and experiential avoidance in caregiving, (b)mindfulness and acceptance of aversive emotions, sensations, and thoughts, (c) behavior management for care recipients' BPSD, and (d) clarifying and choosing one's value, and taking actions toward the chosen values. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based ACT intervention.
75550965|NCT04898413|Behavioral|Group-based cognitive behavioral therapy (CBT)|Group-based CBT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and distress in caregiving, (b) cognitive restructuring and relaxation, (c) behavior management for care recipients' BPSD, and (d) increasing pleasant activities. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based CBT intervention.
75871735|NCT02344654|Radiation|X-ray|
75871736|NCT03720665|Combination Product|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order [transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order [transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)]
76039151|NCT03490513|Drug|Placebo|Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
76039152|NCT03467191|Drug|Alcohol|target BAC .08%
76039153|NCT03467191|Other|Placebo|placebo beverage
75405842|NCT02139228|Biological|Hib-TT|No vaccine administered in V37_07E2 study
75405843|NCT02139540|Drug|Nitrous Oxide|"Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart."
75405844|NCT02139540|Drug|Placebo|50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup
75405845|NCT02146482|Other|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
75405846|NCT02148588|Drug|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)~Assessment of spontaneous and evoked pain responses~Completion of NPSI questionnaire~Mapping of the affected limb"
75405847|NCT02149290|Device|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
75405848|NCT02149524|Drug|Herceptin (trastuzuamb)|Intravenous administration
75405849|NCT02149524|Drug|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
75405850|NCT02150460|Procedure|One-site peribulbar injection|injection into the inferior medial orbital compartment
75405851|NCT02150460|Procedure|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
75405852|NCT02154048|Drug|Ropivacaine|
75405853|NCT02154048|Drug|Dexamethasone|
75405854|NCT02154048|Other|Placebo|
75550966|NCT04897269|Procedure|Progesterone supplementation|This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer
76039154|NCT04328779|Other|The multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks for 30 minutes per session, 3 times a week for 4 weeks.
75405855|NCT02154906|Device|DFDBA|
75405856|NCT02154906|Device|autologous platelet rich fibrin|
75871737|NCT05253742|Other|No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner|The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
76039155|NCT04328779|Device|The multi-task treadmill walking training|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill for 30 minutes per session, 3 times a week for 4 weeks.
75405857|NCT02156154|Drug|Intravenous Acetaminophen|
75550967|NCT04891419|Device|JUVÉDERM® VOLUMA® with Lidocaine|JUVÉDERM® VOLUMA® with Lidocaine injectable gel
75711697|NCT00930670|Drug|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
75405858|NCT02157168|Behavioral|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey."
75405859|NCT02158494|Device|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
75405860|NCT02158494|Device|Sham Device|The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
75405861|NCT02158572|Drug|AG200-15|Transdermal contraceptive delivery system
75405862|NCT02159118|Device|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
75405863|NCT02159118|Device|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
75405864|NCT02159898|Device|EndoMAXX Endoluminal Valve Technology (EVT)|
75405865|NCT02159898|Device|EndoMAXX|
75405866|NCT02159976|Drug|Pantoprazole|Pantoprazole 40mg bid
75405867|NCT02159976|Drug|Amoxicillin|Amoxicillin 1000mg bid
75405868|NCT02159976|Drug|Clarithromycin|Clarithromycin 500mg bid
75405869|NCT02159976|Drug|Metronidazole|Metronidazole 500mg tid
75405870|NCT02159976|Drug|Tetracycline|Tetracycline 1000mg bid
75711698|NCT00930670|Drug|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
76039156|NCT04328779|Other|Traditional rehabilitation|Traditional rehabilitation will train strength, balance, and gait for 30 minutes per session, 3 times a week for 4 weeks.
76039157|NCT03457675|Device|Activa PC+S DBS implant for OCD|"DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna"
76039158|NCT03457675|Other|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
75405871|NCT02159976|Drug|Bismuth|Bismuth 600mg bid
75405872|NCT02160288|Drug|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
75405873|NCT02160288|Drug|Normal Saline|Dispensed in a 5 cc syringe
75550968|NCT04881565|Other|Reactive balance training|During each one-hour session, participants will experience 40-50 perturbations (i.e. approximately one perturbation per training minute) during standing and/or walking activities. The perturbations will be applied in any direction (e.g. forwards, sideways, backwards, etc.) To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness at waist level. The perturbation will be sufficient in magnitude to elicit a stepping response from the participant. Throughout the session, participants will complete challenging balance tasks, customized to their ability level. Balance tasks will be organized into five categories: stable, quasi-mobile, mobile, unpredictable and participant-selected.
75550969|NCT04865289|Drug|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
75550970|NCT04865289|Biological|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
75550971|NCT04865289|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV infusion given on Day 1 of each cycle.
75871738|NCT05253664|Behavioral|Woman-Centered Care Group|Each woman in the experimental group was given woman-centered care as from 2 hours postpartum and this process continued until 24 hours postpartum. Physiological parameters (systolic-diastolic blood pressure, pulse, body temperature) of women assigned either to the experimental group or the control group were measured at 2 hrs postpartum. The State, Trait Anxiety, and Postpartum Comfort Scales were pretested. A dynamic interaction was ensured between the researcher and the women in the experimental group who received woman-centered care. In the processes of determining and meeting the care needs of women in the early postpartum period, both the women and the researcher took equal responsibilities and the common goal of achieving safe results was shared. Clinical guidelines were used while providing woman-centered care.
75550972|NCT04865289|Drug|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
75550973|NCT04852302|Behavioral|CALM Therapy|The CALM intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
75405874|NCT02160990|Drug|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
75550974|NCT04848506|Drug|CK-3773274 (5 - 20 mg)|CK-3773274 tablets administered orally
75550975|NCT04832724|Genetic|RGX-314|RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
75405875|NCT02160990|Drug|Placebo|placebo subcutaneously twice daily for 30 days
75405876|NCT02161536|Device|Motus Cleansing System|
75405877|NCT02163486|Device|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
75405878|NCT02163486|Device|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
75405879|NCT02164422|Drug|Guanfacine 3mg/day|3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
75405880|NCT02164422|Drug|Guanfacine 1.5mg/day|1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
75405881|NCT02164422|Drug|Placebo|
75405882|NCT02165124|Device|Artificial Embolization Device|Embosphere Microspheres
76039159|NCT04977973|Behavioral|Self-guided programme on body image|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
75405883|NCT02165904|Biological|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
75405884|NCT02167074|Device|25G FNA needle|
75550976|NCT04832399|Drug|Natalizumab|As described in the treatment arm.
75550977|NCT04832087|Drug|Teduglutide|Standard of care Teduglutide dosing
75550978|NCT04828018|Other|Coffee Morning|Coffee mornings (a maximum of n=2) will be held to raise awareness of the project and to promote participant recruitment. These will be held remotely via video conference if Covid-19 restrictions prevent in-person attendance by the researcher.
75550979|NCT04828018|Other|Recruitment Leaflets|Recruitment leaflets will be hand-delivered to all In-Pensioner residents at Royal Hospital Chelsea. Leaflets will be delivered internally by Royal Hospital Chelsea internal mail-room
75871739|NCT03722537|Procedure|Osteochondral Allograft|The arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface.
75405885|NCT02167074|Device|20G ProCore FNB needle|
75405886|NCT02170662|Drug|Bimatoprost|Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
75405887|NCT02170662|Drug|Placebo|
75405888|NCT02173392|Drug|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
75405889|NCT02178540|Drug|Placebo|one dose (4 capsules) of placebo
75405890|NCT02178540|Device|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
75405891|NCT02178696|Other|Placebo, identified as placebo to participants|White tablets
75405892|NCT02178696|Drug|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
75405893|NCT02178696|Other|"Placebo, identifed to participants as Active medication"|Blue Capsule
75405894|NCT02179788|Behavioral|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
75871740|NCT03722537|Procedure|Ligament Reconstruction Tendon Interposition|During the LRTI, the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
75871741|NCT04029844|Device|Colibri TAVI System|Implantation of Colibri heart valve
75871742|NCT03726281|Drug|Nivolumab|Nivolumab 240 mg, IV
75711699|NCT00930670|Drug|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
75405895|NCT02179788|Drug|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)"
75405896|NCT02179788|Drug|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~Days 1-7, take 1 capsule with evening meal~Days 8-14, take 3 capsules with evening meal~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
75405897|NCT02180100|Drug|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
75405898|NCT02180100|Drug|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
75405899|NCT02180646|Other|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
75405900|NCT02180646|Other|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
75405901|NCT02181426|Drug|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
75405902|NCT02184624|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
75405903|NCT02184624|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
75405904|NCT02184624|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
75405905|NCT02184624|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
75405906|NCT02184624|Device|HANDIHALER|Placebo inhaler containing lactose monohydrate in a capsule.
75405907|NCT02184624|Device|BREEZEHALER|Placebo inhaler containing lactose monohydrate in a capsule.
75405908|NCT02185404|Device|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
75405909|NCT02186808|Device|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
75550980|NCT04828018|Other|Consent Form completion|All participants will be asked to complete Consent Forms before engaging in the study. The researcher will be available to answer any questions via phone calls if required.
75405910|NCT02189382|Device|Potassium Oxalate|
75405911|NCT02189382|Other|Water|
75550981|NCT04828018|Other|Participant Information Sheet|All participants will receive Information Sheets which they will read in their own rooms (or elsewhere for Key Staff). The researcher will be available to answer any questions via phone calls if required.
75405912|NCT02189850|Drug|BLI800 - Dose 1|BLI800 oral solution
75405913|NCT02189850|Drug|BLI800 - Dose 2|BLI800 oral solution
75550982|NCT04828018|Other|New In-Pensioner Resident Information Pack|New In-Pensioner resident information packs will be distributed by a member of RHC staff as part of their 'arrivals' process and six months after residency at RHC. The researcher will be available to answer any questions via phone calls if required.
75550983|NCT04828018|Other|Key Staff Interviews|Key Staff interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
75550984|NCT04828018|Other|In-Pensioner Resident Interviews|In-Pensioner resident interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
75711700|NCT00930670|Drug|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
75711701|NCT00930670|Drug|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
75711702|NCT00930670|Drug|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
75405914|NCT02190552|Device|EmboTrap® Revascularization Device|
75405915|NCT02192814|Drug|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion"
75405916|NCT02195232|Drug|Isoquercetin|
75405917|NCT02195622|Device|Lumenis VersaCut Morcellator|
75405918|NCT02195622|Device|Wolf Piranha Morcellator|
75405919|NCT02196168|Drug|Cisplatin|Given IV
75405920|NCT02196168|Other|Laboratory Biomarker Analysis|Correlative studies
75405921|NCT02196168|Other|Pharmacological Study|Correlative studies
75405922|NCT02196168|Other|Placebo|Given PO
75711703|NCT00930748|Device|MR imaging with endorectal coil|MR imaging with endorectal coil
75711704|NCT00930748|Device|MRI with endo-rectal coil|MRI with endo-rectal coil
75405923|NCT02196168|Drug|WEE1 Inhibitor AZD1775|Given PO
75405924|NCT02200458|Device|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
75405925|NCT02200536|Other|Infant oral health promotion package|Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
75405926|NCT02200536|Other|Infant oral health pamphlet|Infant oral health pamphlet
75405927|NCT02201394|Drug|Ticagrelor loading dose|Single loading dose of Ticagrelor 180 mg
75711705|NCT00934804|Device|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
75711706|NCT00934882|Drug|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
75711707|NCT00937144|Drug|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
75711708|NCT00937144|Drug|placebo|
75405928|NCT02201394|Drug|Aspirin loading dose|Single loading dose of Aspirin 325 mg
75405929|NCT02201394|Drug|Ticagrelor maintenance dose|Ticagrelor 90 mg twice daily x 7 days
75405930|NCT02201394|Drug|Aspirin maintenance dose|Aspirin 81 mg once daily x 7 days
75405931|NCT02202252|Procedure|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
75405932|NCT02202252|Procedure|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
75405933|NCT02202252|Procedure|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
75405934|NCT02203578|Drug|romidepsin|Given IV
75405935|NCT02203578|Other|laboratory biomarker analysis|Correlative studies
75405936|NCT02204124|Device|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
75405937|NCT02204124|Device|Standard of care scissors, ligatures, clips, and sutures|
75405938|NCT02204748|Device|DePuy Attune posterior stabilizing fixed bearing knee system|
75405939|NCT02206776|Drug|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
75405940|NCT02206776|Drug|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
75405941|NCT02207322|Other|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
75405942|NCT02207478|Procedure|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
75405943|NCT02207478|Procedure|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
75405944|NCT02209272|Drug|bacteriostatic saline|
75405945|NCT02209272|Drug|buffered lidocaine|
75405946|NCT02210052|Device|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
75405947|NCT02210286|Dietary Supplement|Magtein|
75405948|NCT02211456|Procedure|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
75405949|NCT02211534|Device|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
75405950|NCT02211534|Device|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
75405951|NCT02213250|Drug|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
75405952|NCT02214420|Drug|Simeprevir|
75405953|NCT02214420|Drug|Sofosbuvir|
75405954|NCT02214420|Drug|Ribavirin|
75405955|NCT02215200|Drug|Anti-Thymocyte Globulin (ATG)|Thymoglobulin
75405956|NCT02215200|Drug|Granulocyte colony stimulating factor (GCSF)|Granulocyte colony stimulating factor (GCSF)
75405957|NCT02215200|Drug|Placebo (for ATG)|Normal saline administered by IV infusion to mimic ATG
75405958|NCT02215200|Drug|Placebo (for GCSF)|Placebo prepared to mimic 6mg subcutaneous injection of GCSF
75405959|NCT02217618|Drug|LY2409021|
75405960|NCT02218242|Device|Intraoperative ultrasound|Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
75405961|NCT02218320|Drug|Raltegravir|
75405962|NCT02218320|Drug|Dolutegravir|
75405963|NCT02218320|Procedure|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
75405964|NCT02219256|Drug|TAK-079|TAK-079 solution
75405965|NCT02219256|Drug|Placebo to TAK-079|Placebo to TAK-079 solution
75405966|NCT02222610|Drug|0.5 mg ranibizumab|
75405967|NCT02222610|Procedure|Targeted Retinal Photocoagulation (TRP)|TRP to areas of retinal ischemia
75405968|NCT02223702|Drug|Amoxicillin|500 mg, 3 times per day for 7 days
75405969|NCT02223702|Drug|Metronidazole|500 mg, 3 times per day, for 7 days
75405970|NCT02223702|Drug|Moxifloxacin|400 mg, once in a day for 7 days.
75405971|NCT02224404|Device|Fast Gelling Dressing (Exufiber)|
75405972|NCT02224482|Behavioral|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
75405973|NCT02225106|Drug|Methylphenidate|Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
75405974|NCT02227836|Device|Allergy Patch Testing|
75405975|NCT02229318|Dietary Supplement|FruitiVits|Daily administration of FruitiVits dietary supplement
75405976|NCT02229474|Behavioral|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
75405977|NCT02230566|Drug|UX003|UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
75405978|NCT02230566|Other|Placebo|Placebo consisting of the UX003 formulation buffer (without rhGUS)
75405979|NCT02233296|Drug|Lasmiditan|2 discrete doses separated by 6 days.
75405980|NCT02233530|Behavioral|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
75405981|NCT02233842|Behavioral|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
75550985|NCT04828018|Other|ICECAP-A Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
75405982|NCT02233998|Other|Mouth Rinse 1|
75405983|NCT02233998|Other|Mouth Rinse 2|
75405984|NCT02233998|Other|Mouth Rinse 3|
75405985|NCT02235870|Device|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
75405986|NCT02235870|Device|Sham Device|Sham Intragastric Balloon
75405987|NCT02235870|Behavioral|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
75405988|NCT02236338|Procedure|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
75405989|NCT02236338|Device|ClosureFAST radiofrequency catheter|
75405990|NCT02236338|Device|EVLT 980nm diode laser system|
75405991|NCT02237898|Behavioral|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application & Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
75405992|NCT02237898|Behavioral|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.
75405993|NCT02237898|Device|Sensordrone™ carbon-monoxide sensor|A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
75405994|NCT02237898|Device|MoMba Live Long Smartphone application|The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.
75405995|NCT02239380|Drug|Lorazepam|"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to < 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
75405996|NCT02239770|Drug|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
75405997|NCT02239770|Drug|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
75405998|NCT02241486|Drug|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
75405999|NCT02241720|Drug|regorafenib|
75406000|NCT02244840|Device|Electronic bidet|commercial electronic bidet
75406001|NCT02244840|Device|Sitz bath|Conventional sitz bath
75406002|NCT02244918|Drug|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
75406003|NCT02244918|Behavioral|Smoking Cessation Counseling|
75406004|NCT02246010|Dietary Supplement|Lactose- free milk|Lactose- free milk
75406005|NCT02247336|Behavioral|Family health history platform (MeTree)|Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
75406006|NCT02249052|Drug|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
75406007|NCT02249052|Drug|placebo|Placebo
75406008|NCT02250612|Drug|1 drop of 0.375% SYL040012 (bamosiran)|
75406009|NCT02250612|Drug|1 drop of 0.750% SYL040012 (bamosiran)|
75406010|NCT02250612|Drug|1 drop of 1.125% SYL040012 (bamosiran)|
75406011|NCT02250612|Drug|1 drop of 1.5% SYL040012 (bamosiran)|
75406012|NCT02250612|Drug|1 drop of 0.5 % timolol maleate|
75406013|NCT02251236|Drug|Stribild|To be administered orally, once daily with food.
75406014|NCT02251236|Drug|Genvoya|To be administered orally, once daily with food.
75406015|NCT02251938|Drug|DE-109 440 μg|Medium Dose
75406016|NCT02252562|Device|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
75406017|NCT02252718|Other|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
75406018|NCT02255604|Drug|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
75406019|NCT02255604|Drug|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
76039160|NCT04977973|Behavioral|Self-guided programme on cooperation|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
75550986|NCT04828018|Other|WHOQOL-BREF Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
75711709|NCT04014400|Other|Suprathel or Xeroform donor site application|The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
75711710|NCT00937222|Dietary Supplement|Peanuts and peanut butter|Peanuts and peanut butter
75711711|NCT00937300|Biological|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
76039161|NCT04285879|Device|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device following the Owens Recovery Science Protocol
76039162|NCT04977661|Drug|Vitamin E|Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.
76039163|NCT04977661|Drug|Ursodeoxycholic acid|is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)
76039164|NCT04977661|Drug|Pentoxifylline|"it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription"
76039165|NCT04977895|Diagnostic Test|Minimal residual disease (MRD) monitoring|Minimal residual disease (MRD) assay using IgH-V(D)J NGS and FCM
75711712|NCT00931060|Dietary Supplement|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
75711713|NCT00937456|Procedure|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
76039166|NCT04977427|Drug|Dextenza 0.4Mg Ophthalmic Insert|Dexamethasone inserted into lower punctum at the end of cataract surgery in order to control inflammation in the eye for the following 30 days after surgery.
75406020|NCT02255604|Drug|0.1 ml Isoton saline|4 injection into a lymphnode
75406021|NCT02256072|Other|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
75406022|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
75406023|NCT02258256|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
75406024|NCT02258412|Drug|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
75550987|NCT04820283|Behavioral|Care manager intervention (nurse)|In this intervention, a primary care nurse provides the participant with self-management support to manage stress-related problems. The participant meets with the nurse face-to-face for typically 2 to 6 sessions.
75550988|NCT04820283|Behavioral|CBT|In this intervention, the participant receives therapist supported self-help CBT. The participant randomized to this arm can choose to receive the treatment via an online treatment platform or via bibliotherapy, i.e., a self-help book.The treatment is comprised of 12 modules or chapters, which entail information about stress management techniques including behavioral activation and exposure. The participant that chooses online CBT is guided by a therapist who provides feedback on homework assignments through written asynchronous text messages; the patient who chooses bibliotherapy is guided by a therapist in typically 2 to 5 face-to-face sessions at a primary care clinic.
76039167|NCT04977427|Drug|Prednisolone Acetate 1% Oph Susp|Standard Prednisolone taper following cataract surgery, QID for one week, followed by TID for one week, BID for one week, and QDaily for one week, then stop.
76039168|NCT04275895|Behavioral|Evaluation of different attention or/and postural activities|"The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~They will give the name of an animal appearing at one of the windows displayed (visual search task)~They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~Growth trajectory will be retrieved from health booklet"
76039169|NCT04977505|Device|pushlock|The surgery procedure was performed with pushlock for fixation
76039170|NCT04977505|Device|gryphon|The surgery procedure was performed with Gryphon for fixation
75406025|NCT02258412|Drug|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
75406026|NCT02260440|Drug|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
75406027|NCT02260440|Drug|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
75406028|NCT02262078|Drug|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
75406029|NCT02262078|Other|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
75550989|NCT04818060|Other|Clinical Assessments|A neurological evaluation will be administered to all participants at baseline, 1 year and 2 year follow-up visits. Motor exams and premorbid IQ assessments will be video-recorded for rater reliability assessments conducted randomly throughout the research project.
75550990|NCT04818060|Diagnostic Test|MRI Scan|At baseline and 2 year follow-up all participants will undergo a 60-minute 3T MRI scanning session which will consist of measures of the volume of brain tissue and cerebral spinal fluid, as well as connections in the brain measuring water pathways and pictures of the brain active and at rest.
76039171|NCT03295123|Other|phone interview with the mother|it's a telephone survey about children's health
76039172|NCT03267043|Behavioral|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
76039173|NCT03267043|Behavioral|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
76039174|NCT04235257|Biological|HPV vaccine|Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
76039175|NCT04977193|Biological|LY011|CAR-T
76039176|NCT04977115|Procedure|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
75406030|NCT02267226|Drug|Octafibrin|
75406031|NCT02267382|Drug|VT-1161|
75406032|NCT02267382|Drug|Placebo|
75406033|NCT02267538|Drug|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of [0.1*kg] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
75406034|NCT02267538|Drug|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes, followed by continuous infusion at a rate of [0.1*kg] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h and continued until the end of mechanical ventilation after surgery."
76039177|NCT04977115|Procedure|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
76039178|NCT04224415|Drug|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
76039179|NCT04437199|Drug|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)"
76039180|NCT04437199|Drug|Placebo|Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
75711714|NCT04014010|Other|Blood pressure|"Systolic Blood Pressure (SBP)~Maximum change from preoperative SBP, in a) absolute change (mmHg), and b) relative change (%)(emergency and elective cases analyzed separately)~Cumulative duration (minutes) >=20% below preoperative SBP~Longest single episode (minutes) below a) 80, b) 90, and c)100 mmHg~Cumulative duration (minutes) below a) 80, b) 90, and c)100 mmHg~Mean Arterial Pressure (MAP)~Maximum change from preoperative MAP, in a) absolute change (mmHg), and b) relative change (%) (emergency and elective cases analyzed separately)~Cumulative duration (minutes) >=20% below preoperative MAP~Longest single episode (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg~Cumulative duration (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg"
75406035|NCT02267772|Drug|IV Acetaminophen|IV Acetaminophen
75406036|NCT02267772|Drug|IV Morphine|IV Morphine
75406037|NCT02267850|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
75406038|NCT02267850|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
75406039|NCT02267850|Device|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
75406040|NCT02268942|Device|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
75406041|NCT02268942|Procedure|Thoracotomy|Thoracotomy implant technique
75711715|NCT04014010|Other|Heart rate|"Maximum change (beats per minute, BPM) from preoperative heart rate (positive and negative)~Relative change (%) from preoperative heart rate (positive and negative)~Maximum pulse variation (maximum heart rate minus minimum heart rate)~Longest single episode (minutes) a) below 60, and b) above 100BPM~Cumulative duration (minutes) a) below 60, and b) above 100BPM"
75406042|NCT02269488|Drug|MEDI3250|MEDI3250
75406043|NCT02271906|Drug|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
75406044|NCT02272686|Drug|Ibrutinib|560 mg by mouth daily.
75711716|NCT04014010|Other|Use of hemodynamic medications (i.e. special medications for blood pressure)|"Vasopressor/inotrope use (yes vs. no): phenylephrine, norepinephrine, epinephrine, vasopressin, dobutamine, or milrinone~Infusion of any vasopressor/inotropes above (yes vs. no) (identified by unit of weight over time)~Phenylephrine/ephedrine bolus (yes vs. no) (identified by unit of weight only)~Vasodilator use (yes vs. no): labetalol, esmolol, nitroglycerin, nitroprusside~Infusion of any vasodilator above (yes vs. no) (identified by unit of weight over time)"
75711717|NCT04014010|Other|Oxygen saturation by pulse oximetry (SpO2)|"Longest single episode (minutes) below a) 88, and b) 90%~Cumulative duration (minutes) below a) 88, and b) 90%"
75406045|NCT02273310|Behavioral|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
75406046|NCT02274870|Drug|Liposome Bupivacaine|Administered via local tissue infiltration around the knee joint
75406047|NCT02274870|Drug|Bupivacaine HCl|Administered via CFNB
75406048|NCT02277054|Device|Collagen-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
75406049|NCT02278146|Device|ParaPatch|A device for the treatment of urinary incontinence
75406050|NCT02279082|Drug|DFN-02|Active Experimental Drug
75406051|NCT02279160|Drug|APD811|
75406052|NCT02279160|Drug|Placebo|Placebo
75406053|NCT02281344|Drug|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
75406054|NCT02281422|Drug|BIA 2-093|
75406055|NCT02282514|Biological|Autologous Hematopoietic Stem Cells|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
75406056|NCT02282514|Drug|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
75406057|NCT02282514|Drug|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
75406058|NCT02282514|Drug|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
75406059|NCT02282514|Drug|Methylprednisolone|Steroid
75406060|NCT02282514|Drug|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
75711718|NCT04014010|Other|End-tidal Carbon dioxide (EtCO2)|"Longest single episode (minutes) a) below 30, and b) above 45mmHg~Cumulative duration (minutes) a) below 30, and b) above 45mmHg"
75711719|NCT02226276|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
75711720|NCT02226276|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
75871743|NCT03148834|Procedure|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
75871744|NCT03148912|Diagnostic Test|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
75406061|NCT02282514|Drug|Rituxan|A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders
75406062|NCT02282904|Drug|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
75550991|NCT04818060|Diagnostic Test|Lumber Puncture (LP)|Participants will be asked to complete a LP at both onsite study visits (baseline and 2 year follow-up). Blood collection following the procedure will consist of about 80mL and will be stored at a repository for biomarker analysis.
75550992|NCT04806893|Drug|lerodalcibep|300 mg subcutaneous injection every month (Q4W)
75550993|NCT04806893|Other|Placebo|matching subcutaneous injection every month (Q4W)
75711721|NCT02226276|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
75871745|NCT03726203|Device|laparoscopic gynecologic surgery with the MiniLap System.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care, but using the MiniLap System instead of the conventional single-use trocars used usually.
75406063|NCT02282904|Biological|Donor peripheral blood stem cells.|Infuse donor graft.
75406064|NCT02282904|Drug|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
75406065|NCT02282904|Radiation|Total body 200cGy|Day -1
75550994|NCT04799912|Procedure|Elective labor induction|Elective labor induction at 39 weeks of gestation
75711722|NCT02226276|Biological|trastuzumab|Given IV
75871746|NCT03726203|Device|laparoscopic gynecologic surgery with the conventional single-use trocars.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care using the conventional single-use trocars used usually.
75871747|NCT05233306|Device|MRI scanner (7 Tesla)|MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
75871748|NCT03720353|Drug|SAS2094AH and SAS2094BH|SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
75871749|NCT03720353|Drug|SAS2094AL and SAS2094BL|SAS2094AL and SAS2094BL for 10 days
75871750|NCT03720353|Drug|Placebo|Placebo for 10 days. Capsules will mimic active treatments.
75406066|NCT02282904|Drug|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
75406067|NCT02282904|Drug|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
75406068|NCT02282904|Drug|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
75406069|NCT02283528|Device|Stryker Hybrid|Place Hybrid arch bars
75406070|NCT02283528|Device|Erich|Control group is Erich arch bars
75406071|NCT02283840|Drug|BIA 2-093|
75406072|NCT02284386|Drug|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
75406073|NCT02284386|Drug|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
75406074|NCT02284464|Drug|Prednisone withdrawal|Withdrawal of steroids
75406075|NCT02284464|Drug|Prednisone continuation|Continuation of steroids
75406076|NCT02284854|Drug|BIA 2-093|
75406077|NCT02284854|Drug|Carbamazepine|
75406078|NCT02285634|Drug|Oxymetazoline 0.05%|sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
75406079|NCT02285634|Drug|Phenylephrine 0.25%|sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
75711723|NCT02226276|Radiation|copper Cu 64-DOTA-trastuzumab|Given IV
75711724|NCT02226276|Procedure|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
75711725|NCT02226276|Biological|ado-trastuzumab emtansine|Given IV
75711726|NCT02226276|Other|laboratory biomarker analysis|Correlative studies
75711727|NCT03743272|Device|LiverMultiScan|Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
75550995|NCT04798274|Device|Continuous Theta Burst Stimulation|Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
75550996|NCT04797247|Drug|lerodalcibep|PCSK9 inhibitor
75406080|NCT02285634|Drug|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
75550997|NCT04797104|Drug|lerodalcibep|300 mg Q4W
75550998|NCT04783402|Other|e-OTCAT program|"The e-OTCAT program consists of a combination of cognitive training in terms of attention, memory and processing speed; and adaptive training based on metacognition and cognitive-behavioral strategies (psycho-education, relaxation techniques training, stress management, energy conservation techniques, time management, etc.).~This program also includes homework exercises consisting of a handbook of paper-and-pencil exercises, a cognitive training mobile app, and the practice of strategies seen in adaptive training sessions."
75406081|NCT02285634|Drug|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
75550999|NCT04783402|Other|Educational handbook and standard care|At the beginning of chemotherapy, the participants will receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care.
75551000|NCT04783155|Device|POWERBreathe Plus®|Commercially available pressure-threshold device
75551001|NCT04783155|Other|Cardiopulmonary rehabilitation post lung transplant|Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
75551002|NCT04782752|Radiation|Radiation: Varying Doses of RT|3+3 radiation dose escalation model to see the maximum tolerated dose
75551003|NCT04780568|Drug|Osimertinib|Given PO
75551004|NCT04780568|Drug|Tegavivint|Given IV
75551005|NCT04773873|Device|PFM Crowns on gold coping cast-on|Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
75551006|NCT04773873|Device|hybrid abutment lithium disilicate crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
76039181|NCT03239899|Drug|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
75406082|NCT02287350|Drug|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
75406083|NCT02288364|Drug|1% Lidocaine|
75406084|NCT02288364|Drug|1% Lidocaine plus sodium bicarbonate|
75406085|NCT02289222|Drug|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
75406086|NCT02289222|Drug|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
75406087|NCT02289222|Drug|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
75871751|NCT02344264|Drug|Ropivacaine|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
75871752|NCT02344264|Drug|Saline|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
75871753|NCT03148678|Behavioral|Mindfulness|Subjects are provided with smartphone-based mindfulness intervention.
75871754|NCT03148678|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
75871755|NCT03148678|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
75871756|NCT03148678|Behavioral|Mind Wandering|Subjects are provided with smartphone-based mind wandering intervention.
76039182|NCT03217045|Other|nutrition protocol introduction|Growth comparison of 2 cohorts of infants evaluated in a before-after design
75406088|NCT02291016|Drug|Formoterol|Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
75406089|NCT02291016|Other|Placebo|Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
75406090|NCT02291718|Drug|Isovue|iodine contrast
75406091|NCT02292186|Drug|Revusiran (ALN-TTRSC)|
76039183|NCT03061981|Drug|Placebo|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
76039184|NCT03061981|Drug|Metformin|Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
75406092|NCT02293044|Device|Crest® Sensi-Stop™ Strips|
75406093|NCT02293512|Behavioral|Coping Effectiveness Training|A CET psychoeducational intervention is provided to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
75406094|NCT02293512|Behavioral|Cognitive-behavioral therapy|CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
75406095|NCT02293512|Behavioral|Acceptance and Commitment Therapy|An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
75406096|NCT02296164|Drug|Valchlor|Valchlor gel 0.016%
75406097|NCT02297100|Drug|Onabotulinumtoxin A|100 units of botox spread out among 10 separate injections
75406098|NCT02297100|Procedure|injections upper aspect of trigone of urinary bladder|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
75406099|NCT02297100|Procedure|injections on posterior bladder wall excluding the trigone|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
75406100|NCT02299050|Drug|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
75406101|NCT02302092|Drug|Flomoxef|Flomoxef intravenous infusion
75406102|NCT02302092|Drug|Cefepime|Cefepime intravenous infusion
75406103|NCT02303184|Drug|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
75871757|NCT03112252|Other|no specifications. Depending on the patients|patients with allergic rhinitis
76039185|NCT03061981|Drug|DA-1241|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
76039186|NCT02510001|Drug|PF-02341066|PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
75551007|NCT04773873|Device|hybrid abutment ceramic polymer infiltrated crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
75551008|NCT04771156|Drug|Ketorolac|Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
76039187|NCT02510001|Drug|PD-0325901|PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
76039188|NCT02510001|Drug|Binimetinib|Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
75406104|NCT02303184|Drug|Sham|suprachoroidal sham procedure
76039189|NCT02452047|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
75871758|NCT02344030|Device|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
76039190|NCT02452047|Drug|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (~180 to 360 mg CMS), depending on renal function, once every 12 hours
75406105|NCT02303184|Drug|IVT aflibercept|2 mg intravitreal injection of aflibercept
76039191|NCT02452047|Drug|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
76039192|NCT02452047|Drug|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
76039193|NCT02475369|Drug|pancrelipase|
76039194|NCT02474589|Drug|tecovirimat|Study is based on Animal Regulatory Rule
75406106|NCT02304432|Drug|D-cycloserine|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
76039195|NCT02474589|Other|Placebo|Does not apply
76039196|NCT02586233|Drug|DS-1040b|DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
76039197|NCT02586233|Drug|Placebo|0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
76039198|NCT03936101|Diagnostic Test|Prenatal Genomic Sequencing|Whole genome sequencing (which initially will be masked and reported as exome only)
76039199|NCT05592431|Device|High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).
76039200|NCT05592431|Device|High Frequency Oscillatory Ventilation (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
76039201|NCT05537207|Device|low level laser therapy|low level laser therapy (LLLT) on the acupuncture points. inadition to non-steroidal anti-inflammatory drugs.The parameters of the laser device are wave length of 904 nm, maximum average power of 5 milli Watts, a maximum repetition rate of 5 kHz, energy of up to 30 J/cm², and energy density of 2 J/cm2
75406107|NCT02304432|Drug|DCS or placebo|Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
76039202|NCT05537207|Other|non-steroidal drugs|All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as described by their gynecologist.
75406108|NCT02304432|Drug|D-cycloserine|Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
75406109|NCT02306928|Other|Blood draw|
75406110|NCT02307318|Device|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
75406111|NCT02307552|Device|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
75406112|NCT02312154|Device|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
75406113|NCT02312310|Dietary Supplement|Cocoa Flavanol|12 weeks administration of cocoa flavanol
75406114|NCT02314104|Drug|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
75406115|NCT02314260|Other|bishop score calculation|Assessment of bishop score by vaginal examination
75551009|NCT04771156|Drug|Placebo|0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
75871759|NCT02344030|Device|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
76039203|NCT05537129|Procedure|Total Gastrectomy|The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
76039204|NCT02474355|Procedure|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
75406116|NCT02314260|Other|Trans-vaginal ultrasound|trans-vaginal ultrasound assessment of cervical length.
75406117|NCT02314260|Other|Modified bishop score calculation|using the cervical length and the original bishop score to calculate modified bishop score
75406118|NCT02314260|Procedure|labour induction|Induction of labor was carried out as per our hospital's standard protocol.
75406119|NCT02320812|Biological|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
75406120|NCT02321748|Drug|Montelukast|
75551010|NCT04767854|Behavioral|OA school|Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
76039205|NCT02474355|Procedure|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
76039206|NCT02474355|Procedure|Baseline ECG|ECG to ensure absence of any cardiac abnormality
76039207|NCT02474355|Procedure|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
75406121|NCT02321748|Drug|ASP2151|
75406122|NCT02322528|Drug|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
75406123|NCT02323854|Device|Ablation|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
75406124|NCT02323854|Procedure|Surgical Resection|The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
75406125|NCT02327052|Other|No intervention was performed.|No intervention was performed.
75406126|NCT02330094|Drug|Gabapentin|"Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
75406127|NCT02330094|Drug|Placebo|"Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
75406128|NCT02330172|Other|Injection of neostigmine or sugammadex|"At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected."
75406129|NCT02331108|Drug|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
75406130|NCT02340156|Genetic|SGT-53|SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
75406131|NCT02340156|Drug|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
75406132|NCT02343276|Drug|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
75406133|NCT02343276|Other|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
75406134|NCT02347410|Device|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
75406135|NCT02347488|Device|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
75406136|NCT02347488|Procedure|Tape|Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
75406137|NCT02348658|Drug|TAK-536TCH|TAK-536TCH tablets
75406138|NCT02349438|Device|senofilcon A|A soft spherical contact lens
75551011|NCT04767854|Other|Virtual Training mobile health application|Individually tailored home exercise programs delivered through a mobile health application
75551012|NCT04767854|Other|Usual care|Individually tailored exercise programs conducted in weekly supervised individual or group sessions
75551013|NCT04754906|Other|Sequence 1|perform arm movements towards a target
75551014|NCT04754906|Other|Sequence 2|judge the verticality of an object
76039208|NCT02474355|Drug|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
75551015|NCT04754906|Other|Sequence 3|In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
75551016|NCT04739943|Device|Mobile Monitoring Device|App for self monitoring device for respiratory symptoms
75551017|NCT04738162|Drug|5-Aminolevulinic Acid Hydrochloride, Oral|Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible
75551018|NCT04717934|Device|GAL1906|hyaluronic acid dermal filler gel
75551019|NCT04666636|Drug|Placebo|Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
75711728|NCT00935116|Drug|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
75711729|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
75551020|NCT04666636|Drug|Mirabegron|Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
75551021|NCT04659603|Drug|tusamitamab ravtansine|"Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion"
75711730|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
75711731|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
75711732|NCT04014088|Device|hCPAP vs fCPAP|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
75711733|NCT00935194|Drug|oseltamivir|75mg,bid,for 5 days
75711734|NCT00935194|Other|blank|no antiviral therapy
75711735|NCT00935194|Drug|chinese medicinal herbs|200ml,p.o,qid,for 5 days
75551022|NCT04659603|Drug|Gemcitabine|"Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion;~Route of administration: IV infusion"
75551023|NCT04644770|Drug|JNJ-69086420|Participants will receive IV injection of JNJ-69086420.
75871760|NCT03145246|Procedure|regeneration treated teeth loss|number of regeneration treated teeth loss
75406139|NCT02349438|Device|lotrafilcon B|
76039209|NCT02474199|Biological|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
76039210|NCT02474199|Drug|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
75406140|NCT02350998|Drug|OTO-201|
76039211|NCT02474199|Drug|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
76039212|NCT02474199|Drug|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
75406141|NCT02351700|Drug|IV Caldolor|IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
75406142|NCT02351700|Drug|IV Placebo|IV Placebo intraoperatively and postoperatively
75711736|NCT00935194|Drug|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
76039213|NCT02474199|Procedure|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
76039214|NCT02450487|Drug|Piroxicam|After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
76039215|NCT02473965|Drug|IGIV-C|"Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks"
75871761|NCT03145246|Procedure|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
75871762|NCT02343874|Other|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
75406143|NCT02353806|Drug|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
75406144|NCT02354352|Drug|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
75406145|NCT02354352|Drug|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
75406146|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1|packet containing 10^9 cells of Bifidobacteria adolescentis BD1
75406147|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10^9 cells of Bifidobacteria animalis subsp. lactis BB-12
75406148|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
75551024|NCT04636775|Diagnostic Test|Microbiome|Nasal and buccal swabs, and stool sample, as well as the extracted DNAs
75551025|NCT04629339|Drug|INCB086550|INCB086550 will be administered orally twice a day.
75406149|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
75406150|NCT02355210|Dietary Supplement|galactooligosaccharide|5 g galactooligosaccharide
75551026|NCT04618913|Drug|Apixaban|Anticoagulant
75711737|NCT00937534|Drug|Fimasartan|Fimasartan 240mg/day
75871763|NCT02340208|Drug|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
75871764|NCT02340052|Drug|Pain treatment|Registration af actual analgesic treatment and outcomes
75406151|NCT02355210|Dietary Supplement|Placebo|lactose powder, 5 grams
75871765|NCT02340130|Biological|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
75871766|NCT02340130|Biological|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
75871767|NCT03112330|Device|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
75406152|NCT02356692|Device|enfilcon A|Test lens
75551027|NCT04618913|Drug|Rivaroxaban|Anticoagulant
75551028|NCT04618913|Drug|Edoxaban|Edoxaban
75871768|NCT03112330|Device|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
75551029|NCT04618913|Drug|Dabigatran|Dabigatran
75551030|NCT04618913|Drug|VKA|Vitamin K antagonist
75406153|NCT02356692|Device|senofilcon A|Control lens
75406154|NCT02357394|Device|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
75406155|NCT02357706|Device|APAP A (ResMed AirSense AutoSet)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
75406156|NCT02357706|Device|APAP B (Apex iCH Auto)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
75406157|NCT02359110|Drug|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
75406158|NCT02359110|Other|Placebo|Patient will receive placebo tab less than 1 hour before surgery
75406159|NCT02360124|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
75406160|NCT02360124|Other|Water as placebo|topical application of water as a placebo in the control arm
75406161|NCT02360124|Other|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
75406162|NCT02364570|Other|Glucose (100g)|Ingestion of glucose (100g)
75551031|NCT04618913|Drug|LMWH|Low Molecular Weight Heparin
75551032|NCT04618770|Device|Triathlon PSR Tibial Insert|The Triathlon PSR Tibial Insert is intended to be used as a component in primary TKA and is designed to reduce rotational constraint at deep flexion.
75551033|NCT04612738|Behavioral|Hello (serious game)|Commercially available, 'Hello' 32 is a serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The creators developed the questions following interviews with palliative care clinicians, hospice nurses, and funeral directors, and then revised them through a series focus groups with >100 patients/caregivers from diverse backgrounds.
75551034|NCT04612738|Behavioral|The Conversation Project (CP) Starter Kit|"The CP Starter Kit is one of the most widely promoted and disseminated ACP tools nationwide, is available for free online, and does not require a healthcare professional for use. Like 'Hello', it is intended to help individuals have end-of-life conversations with loved ones. The 11-page workbook has open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so. It also prompts participants to rank priorities on a 5-point scale (e.g., What are your concerns about treatment? 1= I'm worried I won't get enough care, 5= I'm worried I'll get overly aggressive care). The CP website provides resources for running a community event using the 'CP Starter Kit', including a 23-page manual, Coaching the Conversation- A Guide to Facilitating Conversation Groups, with details on hosting a community-based program."
75871769|NCT03112486|Procedure|blood draw|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
75871770|NCT02339662|Drug|Gabapentin|muscles pain treatment
75406163|NCT02364570|Other|Glucose (75g)|Ingestion of glucose (75g)
75406164|NCT02364570|Other|Whole Eggs|Ingestion of 1.5 whole eggs
75406165|NCT02364570|Other|Egg Whites|Ingestion of 7 egg whites
75406166|NCT02364570|Other|Egg Yolks|Ingestion of 2 egg yolks
75406167|NCT02367066|Drug|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
75406168|NCT02367066|Other|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
75406169|NCT02369172|Drug|Bupropion|
75406170|NCT02369172|Drug|ASP2151|
75406171|NCT02369796|Drug|TAK-448|TAK-448 solution for subcutaneous injection
75406172|NCT02370810|Behavioral|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
75406173|NCT02371668|Biological|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
75406174|NCT02371668|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
75406175|NCT02372682|Device|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
75406176|NCT02373852|Device|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
75551035|NCT04612738|Other|Table Topics (general conversation game)|Table topics is a popular, commercially available conversation starter game that consists of question cards to prompt conversations (e.g., 'What do you love about your hometown?').
75551036|NCT04608552|Behavioral|OMT Exercises|Oral and oropharyngeal exercises
75551037|NCT04608552|Behavioral|Nasal Breathing Exercises|Nasal breathing exercises each week
75551038|NCT04608552|Other|Use of Nasal Lavage|Use of nasal lavage with application of 10ml of saline in each nostril two times per day
75551039|NCT04600791|Device|BATwire Implant Kit|The BATwire Implant Kit is a delivery system for the placement of the Barostim Carotid Sinus Lead.
75551040|NCT04599296|Device|Hip brace|Hip brace
75871771|NCT02339662|Drug|Amitriptyline|muscles pain treatment
75871772|NCT02343796|Other|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
75871773|NCT02343796|Device|everStick|GC, Belgium
75871774|NCT02343718|Drug|Vinblastine|
75871775|NCT02343718|Drug|Temsirolimus|
75871776|NCT02343562|Dietary Supplement|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
75871777|NCT02343562|Dietary Supplement|Placebo|Multivitamin off-the-counter.
75871778|NCT03148522|Drug|Escitalopram|receive escitalopram
75871779|NCT03148522|Drug|Duloxetine|receive duloxetine
75871780|NCT03148522|Drug|Mirtazapine|receive mirtazapine
75871781|NCT02339896|Biological|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
76039216|NCT02473965|Drug|Placebo|
75551041|NCT04588792|Drug|Nebulized Furosemide|Furosemide administered by nebulization through the ventilator circuit
75551042|NCT04588792|Drug|Nebulized Saline|Saline administered by nebulization through the ventilator circuit
75551043|NCT04576377|Biological|FluBlok|Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) containing 180μg antigen, 45μg for each influenza strain included.
75551044|NCT04576377|Other|Placebo|0.5mL saline placebo.
75551045|NCT04568603|Drug|Islatravir|ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
75551046|NCT04561544|Behavioral|Knowing Who You Are (Becoming): Cultural Identity Intervention|8-week cultural identity development program led by Alaska Native Elders
75551047|NCT04554940|Biological|vosoritide|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
75551048|NCT04554147|Behavioral|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
75551049|NCT04553549|Device|Transradial approach|"Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
75551050|NCT04552873|Drug|Urea|"the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered."
76039217|NCT04939311|Drug|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
75551051|NCT04552873|Other|PLACEBO|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
75551052|NCT04544709|Drug|Low back intradiscal injection of platelet rich plasma (PRP)|SOC Intradiscal Lumbar PRP Procedure : A small amount of blood is drawn from you, then it is spun in a centrifuge to obtain only the platelets and few other cells. After being spun the small amount of platelets will be injected into the specific disc that is believed to be causing pain in an attempt to help reduce inflammation and pain at the site. The injection will be done under fluoroscopic guidance (x-ray) that allows very careful and precise placement of the needle.
75551053|NCT04535921|Other|FCR7 questionnaire|A 7 item questionnaire about fear of cancer recurrence
75711738|NCT00690378|Drug|NXL104/ceftazidime|125mg/500mg TID
75711739|NCT00690378|Drug|Imipenem/Cilastatin|4 x daily
75871782|NCT03148444|Drug|cefalexin 500 mg qid or roxithromycin 150 mg bid|antibiotics treatment for five days following implantation of cardiac device
75871783|NCT03148132|Drug|Bevacizumab Injection|0.5mg/0.02 mL
75711740|NCT00937612|Radiation|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
75711741|NCT00574275|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
75711742|NCT00574275|Drug|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
75871784|NCT03148132|Drug|Ranibizumab Ophthalmic|0.25mg/0.025 mL
76039218|NCT04939311|Drug|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
75551054|NCT04532515|Device|Seal-G Surgical Sealant|"Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
75551055|NCT04532515|Device|Seal-G MIST System|"Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
75551056|NCT04528732|Behavioral|Group Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
75551057|NCT04528732|Behavioral|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
75551058|NCT04523207|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
75711743|NCT00574275|Drug|Gemcitabine|1000 mg/m^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
75406177|NCT02374164|Drug|Febuxostat XR|Febuxostat XR capsules
75406178|NCT02374398|Drug|Tranexamic Acid|see arm/group descriptions
75551059|NCT04523207|Drug|ADT|Participants will receive ADT intramuscular or subcutaneously during the main study.
75551060|NCT04523207|Drug|Relugolix|Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
75551061|NCT04505540|Other|Bridge Clinic|Specialized addiction bridge clinic
75551062|NCT04497870|Drug|Peppermint oil|Administration of peppermint oil at one of two daily doses.
75711744|NCT00931216|Procedure|Integrated ANC, PMTCT, HIV services|Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
75711745|NCT00743418|Device|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
75711746|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
75871785|NCT02339350|Drug|high dose methotrexate|HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
75871786|NCT02339350|Drug|Intrathecal triple chemotherapy|Intrathecal triple chemotherapy for SEG group instead of radiotherapy
75406179|NCT02374398|Device|Aquamantys System|see arm/group descriptions
75406180|NCT02374398|Other|Control|Standard Electro-cautery and Saline
75406181|NCT02377752|Biological|Olaratumab|Administered IV
75406182|NCT02377752|Drug|Doxorubicin|Administered IV
75406183|NCT02377986|Behavioral|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
75406184|NCT02377986|Behavioral|In-Home Decluttering|In-home decluttering practice
75406185|NCT02377674|Device|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
75406186|NCT02378844|Device|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
75406187|NCT02378844|Device|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
75711747|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|5.0 grams of PGX
75711748|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|0 grams of PGX
75711749|NCT00839865|Drug|herb ointment|a kind of ointment made from herb
75711750|NCT02564640|Device|videolaryngoscope|patients intubated by using the videolaryngoscope
75711751|NCT02564640|Device|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
75711752|NCT00839943|Other|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
75711753|NCT00746382|Drug|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
75711754|NCT00746382|Drug|Placebo cream|Placebo cream
75871787|NCT02339428|Drug|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
75871788|NCT02339428|Drug|Placebo|Inactive pill manufactured to mimic diclofenac tablet
75871789|NCT02337322|Drug|Dolutegravir|
75871790|NCT02337322|Drug|Darunavir/r|
75406188|NCT02379858|Drug|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
75406189|NCT02379858|Drug|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
75406190|NCT02381418|Biological|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
75406191|NCT02382744|Device|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
75406192|NCT02382744|Device|Ultrasound guidance + nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
75406193|NCT02384070|Procedure|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
75406194|NCT02384070|Drug|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
75406195|NCT02384070|Drug|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
75406196|NCT02384070|Drug|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
75406197|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Perrigo)|
75406198|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Reference)|
76039219|NCT02472795|Drug|Matching placebo|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
76039220|NCT02472795|Drug|Cenerimod|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
75406199|NCT02385240|Drug|Placebo gel|
75406200|NCT02385318|Drug|Ingenol Mebutate (Perrigo)|
75406201|NCT02385318|Drug|Ingenol Mebutate (Reference)|
75406202|NCT02385318|Drug|Placebo gel|
75406203|NCT02387268|Device|CleanC system|Cleansing liquid and fecal matter during a standard colonoscopy procedure
75406204|NCT02387502|Device|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
75406205|NCT02387502|Device|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
75406206|NCT02387502|Device|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
75406207|NCT02387814|Drug|Abemaciclib|Administered Orally
76039221|NCT02507349|Behavioral|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
76039222|NCT02507349|Behavioral|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
75406208|NCT02391714|Procedure|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
75406209|NCT02391714|Drug|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
76039223|NCT02506881|Drug|Darbepoetin alfa|
75871791|NCT02337166|Device|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
75406210|NCT02391714|Drug|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
75406211|NCT02391714|Other|Oxygen|100% oxygen via nasal mask.
75406212|NCT02391714|Other|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
75406213|NCT02392494|Drug|MK-1075|MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
75871792|NCT02337166|Procedure|Periodontal flap surgery|
76039224|NCT02506257|Drug|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
75406214|NCT02392806|Device|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus Bubbler at time of extubation
75406215|NCT02392806|Device|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to B&B Bubbler at time of extubation
75406216|NCT02394912|Device|vena cava filter implantation (LUMIFI with Crux VCF System)|
75406217|NCT02395692|Other|Treatment|Correlative studies
75551063|NCT04482582|Radiation|Cryoneurolysis|Patients will be offered a minimally invasive solution known as cryoneurolysis. By directly applying a cold cryoneurolysis probe to the nerves the axon is destroyed, resulting in Wallerian degeneration of the distal nerve without distorting epineurial or perineurial tissue. Application of cryoneurolysis will help reduce the amount of narcotics the patient would need to take and instead provide them longer term pain control with minimal risk.
75551064|NCT04482582|Other|Standard of Care|Patients will be provided regular standard of care at the Stanford Hospital with long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.
75406218|NCT02395692|Drug|Methoxyamine|Given PO
76039225|NCT02506257|Drug|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
75551065|NCT04467437|Other|Gait Training|Training that targets rehabilitation of walking function
75551066|NCT04467437|Device|Transcutaneous Spinal Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin combined with gait training
75551067|NCT04458272|Drug|DS-1001b|250 mg, twice daily, continuous oral administration
75551068|NCT04455815|Drug|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
75551069|NCT04454437|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
76039226|NCT02506257|Drug|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
75551070|NCT04420975|Procedure|Definitive Surgical Resection|Undergo definitive surgical resection
76039227|NCT02506257|Drug|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
75551071|NCT04420975|Biological|Nanoplexed Poly I:C BO-112|Given intratumorally
75406219|NCT02395692|Drug|Temozolomide|Given PO
75551072|NCT04420975|Biological|Nivolumab|Given IV
75871793|NCT03148288|Dietary Supplement|Vitamin D|VItamin D
75871794|NCT03148288|Dietary Supplement|placebo|placebo
75871795|NCT02339272|Other|non interventional|
75406220|NCT02396160|Dietary Supplement|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
75406221|NCT02396160|Other|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
75406222|NCT02397564|Device|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
75406223|NCT02397954|Drug|Zimura|Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.
75406224|NCT02401464|Drug|TAK-536 Tablet|TAK-536 10 mg tablet
76039228|NCT02506101|Device|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
76039229|NCT02505945|Drug|Omeprazole|
76039230|NCT02505945|Device|LINX Reflux Management System|
76039231|NCT02505867|Device|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
76039232|NCT02472639|Device|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
76039233|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not use device
75406225|NCT02401464|Drug|TAK-536 Dry Syrup Formulation|TAK-536 dry syrup formulation
75406226|NCT02401464|Drug|TAK-536 Ganule Formulation|TAK-536 granule formulation
75406227|NCT02401542|Drug|Vofatamab|
75406228|NCT02401542|Drug|Docetaxel|
75406229|NCT02401542|Drug|Placebo|
75406230|NCT02408796|Drug|OTO-201|
75406231|NCT02411916|Biological|misoprostol|rectal insertion
75406232|NCT02413008|Drug|estriol|0.005% estriol vaginal gel
75406233|NCT02413008|Drug|Placebo|placebo vaginal gel
75551073|NCT04420975|Radiation|Radiation Therapy|Undergo radiation therapy
75551074|NCT04415268|Behavioral|Exercise|Surpervised exercise program: Includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions.
75551075|NCT04415268|Behavioral|Unsupervised exercise|Unsupervised exercise program: The same exercise program learned during the supervised phase will be practiced at home.
75711755|NCT00833001|Device|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
75871796|NCT02348944|Other|serum and urine sample|Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
75406234|NCT02413320|Drug|Paclitaxel|
75406235|NCT02413320|Drug|Carboplatin|
75406236|NCT02413320|Drug|Doxorubicin|
75551076|NCT04415268|Drug|CFTR Modulators|"Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES"
75871797|NCT02039362|Drug|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
75871798|NCT04948138|Dietary Supplement|Glutamine oral supplementation|Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
75551077|NCT04404192|Drug|PH94B|Intranasal administration of 100 microliters to each nostril 4 times a day
75551078|NCT04404192|Drug|Placebo|Intranasal administration of 100 microliters to each nostril 4 times a day.
75551079|NCT04402073|Drug|Sonidegib|Sonidegib is a selective smoothened inhibitor that inhibits the sonic hedgehog-signaling pathway. It is used in patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
75406237|NCT02413320|Drug|Cyclophosphamide|
75406238|NCT02413320|Drug|Docetaxel|
75406239|NCT05719038|Diagnostic Test|observational study|observational study
75406240|NCT05718804|Other|Whether renal injury occurred and differences in intestinal flora|Whether renal injury occurred and differences in intestinal flora
75406241|NCT05718726|Other|Questionnaire, interview or observation study|Questionnaire administered by telephone
75406242|NCT05718492|Procedure|digital subtraction angiography.|Each patient received an artery catheter procedure guided by digital subtraction angiography.
75551080|NCT04402073|Drug|Cisplatin|Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.
75551081|NCT04402073|Drug|Lomustine|Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.
75551082|NCT04402073|Drug|Vincristine|Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.
75551083|NCT04402073|Radiation|radiotherapy|Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
75871799|NCT02348866|Other|method of laundering and donning scrubs|
75871800|NCT02339194|Procedure|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
75871801|NCT02339116|Drug|fluoruracil|
75871802|NCT02339116|Drug|Oxaliplatin|
75406243|NCT05718492|Drug|FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )|Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
75406244|NCT05718414|Device|Ultrasound via artifical intelligence|"The peripheral nerve and plan block regions (adductor canal, axillary brachial plexus, PECS, popliteal, rectus sheath, ESP, femoral, and superficial cervical plexus regions) and related anatomical landmarks are practised by 3 anesthesiology residents who were in the training program of regional anesthesia and qualified to perform ultrasound guided techniques . Then, scans of 8 block types for all 40 volunteers; when the scan success gauge on the AI software was 100% at the time the images were saved. Using this procedure, 960 ultrasound images were acquired in both raw and AI-processed forms for expert assessment ."
75871803|NCT02339116|Drug|Irinotecan|
75871804|NCT02339116|Drug|Bevacizumab|
75871805|NCT02349100|Device|Nellix Endoprosthesis|Implantation of Nellix
76039234|NCT02472405|Device|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
75406245|NCT05718336|Other|Integrated care|multi-discipline care program
75711756|NCT04060368|Procedure|Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
75711757|NCT04060368|Procedure|Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
76039235|NCT02472405|Device|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
76039236|NCT03194971|Other|Tumor samples from patients treated with TTFields at initial diagnosis.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
76039237|NCT03194971|Device|Tumor samples from patients treated with TTFields at tumor recurrence.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
75406246|NCT05717868|Other|Kinesiology taping|5 cm wide and 0.5 mm thick waterproof, porous and adhesive tape will be applied to the posterior neck of the participants while sitting comfortably in a neutral position. The first tape (Y-strip) is placed over the posterior cervical extensor muscles with approximately 25% tension. The top strip will be placed perpendicular to the Y strip on the mid-cervical region. The participant's cervical spine is flexed to obtain tension in the posterior structures.
75406247|NCT05717868|Other|Self-mobilization|The towel will be placed on the posterior arch of the fifth cervical vertebra and pulled horizontally across the face. The participant will be instructed to apply pressure to the towel and turn their head to the restricted side, then maintain the finishing interval for three seconds. The participant will be asked to apply extreme pressure in the bending position with towel support. The procedure should be painless and repeated 10 times.
75406248|NCT05717790|Drug|Nimotuzumab|"Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT ."
75551084|NCT04400500|Diagnostic Test|Approaches to differential diagnosis and risk stratification|Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
75551085|NCT04384770|Radiation|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT
75551086|NCT04384770|Radiation|MRI-guided Stereotactic Body Radiation Therapy|Undergo MRI-guided SBRT
75711758|NCT00828867|Drug|100 mg GSK investigational drug|
75711759|NCT00828867|Drug|200 mg GSK investigational drug|
75711760|NCT00828867|Drug|400 mg GSK investigational drug|
75711761|NCT00828867|Drug|800 mg GSK investigational drug|
75551087|NCT04384770|Other|Questionnaire Administration|Ancillary studies
76039238|NCT04213885|Combination Product|PXL 330 Platinum device/Riboflavin|30mW, 5 sec, 5 sec off, 10 minutes of illumination
76039239|NCT02448771|Drug|Palbociclib|
75551088|NCT04347330|Drug|Intensive BP Control|Participants in the Intensive group have a goal of home SBP <120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
75711762|NCT00828867|Drug|2000 mg GSK investigational drug|
75711763|NCT00828867|Drug|1500 mg GSK investigational drug|
75711764|NCT00828867|Drug|800mg fed GSK investigational drug|
75711765|NCT00828867|Drug|3000mg GSK investigational drug|
75711766|NCT00828867|Drug|4000mg GSK investigational drug|
75711767|NCT00746460|Behavioral|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
75711768|NCT00567112|Drug|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
75406249|NCT05717790|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
75406250|NCT05717790|Drug|Cisplatin|"Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles."
75406251|NCT05717790|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
75406252|NCT05717712|Biological|Ad-TD-nsIL12|This is a novel adenovirus 5-based Ad-TD, which had three gene deletions (E1ACR2, E1B19K and E3gp19K) but retains the E3B gene. This new mutant oncolytic adenovirus exhibited strong anti-tumor efficacy in vivo. On the basis of Ad-TD, Ad-TD-nsIL12 is armed with human non-secretory interleukin-12 (nsIL12, deletion of the signal peptide).
75871806|NCT02348710|Behavioral|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
76039240|NCT02448771|Drug|Bazedoxifene|
75406253|NCT05717634|Diagnostic Test|Hysteroscopy|Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
75551089|NCT04347330|Drug|Standard BP Control|Participants in the Standard group has a goal of home SBP <135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
75551090|NCT04322136|Procedure|Pleurodesis via Video-assisted thoracoscopic surgery|Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon. This is expected to take about 1 hour. Between one and three ports are used to insert a camera and instruments into the chest cavity. Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion. The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis. A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.
75551091|NCT04322136|Device|Indwelling pleural catheter (with talc pleurodesis if suitable)|Once the indwelling pleural catheter is inserted, the pleural fluid will be evacuated as completely as possible. If the lung fully re-expands, 4-5g of sterile graded talc will be instilled via the IPC. The participant will then be discharged on a daily drainage regimen for 14 days. At review in clinic on day 14, the participant will be assessed for spontaneous pleurodesis (<50ml drainage on 3 consecutive drainage attempts). If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal. Otherwise the participant will switch to a symptom-guided drainage regimen. If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc. The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate.
75551092|NCT04312126|Device|MRI system|MRI system - GE Discovery MR750 3T
75551093|NCT04312126|Device|MEG system|MEG system The CTF MEG 275 Magnetoencephalography (MEG) scanner system
75551094|NCT04290897|Drug|Anhydrous Enol-oxaloacetate|Given PO
75551095|NCT04290897|Other|Questionnaire Administration|Ancillary studies
75551096|NCT04276779|Other|Alcohol administration|Participants in the alcoholic beverage group will be provided a dose of 95% alcohol (0.99g/kg for males and 0.90 g/kg for females body weight) distributed in two equally spaced beverages (mixed with orange juice 1:5 ratio). This dose will produce a breath alcohol content ranging between .08-.10.
76039241|NCT02504541|Combination Product|Testosterone enanthate auto-injector|Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
76039242|NCT04924257|Drug|Esketamine nasal spray|Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS <10).
76039243|NCT04924257|Procedure|Electroconvulsive therapy|Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS <10).
76039244|NCT04924179|Drug|Tislelizumab plus Fruquintinib and SBRT|Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
75406254|NCT05717556|Procedure|Internal Jugular Vein Catheterization|Inserting a cannula into the internal jugular vein
75406255|NCT05707728|Device|intraoperative ultrasound|intraoperative cranial ultrasound
75406256|NCT05602272|Procedure|General anesthesia for per-oral endoscopic myotomy|Intra-abdominal pressure measurement
76039245|NCT04975945|Drug|Ceftriaxone Sodium|Intravenous vs local action
75406257|NCT05562648|Other|Manual therapy techniques|"Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors."
75711769|NCT00567112|Drug|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
75551097|NCT04276779|Other|Placebo administration|Individuals in the placebo condition will receive orange juice with 4 ml of alcohol layered on top of the juice. Ethanol will be sprayed on the rims of the glasses.
75711770|NCT00567112|Drug|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
75551098|NCT04276779|Behavioral|Positive mood induction|Participants will be randomized to either positive mood induction procedure. Both conditions involve listening to music that reliably induces positive mood, while simultaneously reading self-referent statements that also induce either positive mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
75551099|NCT04276779|Behavioral|Negative mood induction|Participants will be randomized to either negative mood induction procedure. Both conditions involve listening to music that reliably induces sad mood, while simultaneously reading self-referent statements that also induce either sad mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
75551100|NCT04236167|Device|Fractional CO2 laser treatment -|UltraPulse CO2 Laser (Lumenis, Israel). Patients will receive laser treatments at 4 to 8-week intervals for a total of 3 sessions. A combination of the SCAAR FX and Deep FX treatment modes, with or without Active FX treatment mode, will be used according to individual patient and scar characteristics. For SCAAR FX, the settings include energy (70-150mJ), density (1-5%), and frequency (150-250Hz).For Deep FX, the settings include energy (12.5-22.5mJ), density (5-15%) and frequency (300-600Hz). For Active FX, the settings include energy (80-125mJ), density (2-3%) and frequency (100-150Hz)
75711771|NCT00567112|Drug|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
75711772|NCT01742832|Drug|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
75711773|NCT01742832|Drug|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
75711774|NCT00833079|Drug|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
75711775|NCT00833079|Drug|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
75711776|NCT00833079|Drug|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
75711777|NCT00935506|Drug|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
76039246|NCT03053479|Procedure|Laparoscopic sacrocolpopexy|see arm/group descriptions
75711778|NCT00935506|Drug|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
75711779|NCT00833157|Drug|glucosamine sulphate|Subjects are administered glucosamine-sulphate tablets of 500 mg * 3 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks.
75711780|NCT00833157|Drug|ibuprofen|Subjects are administered 600 mg * 2 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks
75711781|NCT00833157|Drug|placebo|Subjects are administered placebo tablets, while they are performing a strength-training program (*3 weekly) with both legs for 12 weeks
75711782|NCT00931294|Behavioral|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
76039247|NCT03053479|Procedure|Transvaginal mesh procedure|see arm/group descriptions
76039248|NCT03053479|Procedure|Amreich-Richter procedure|see arm/group descriptions
76039249|NCT03034603|Dietary Supplement|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
76039250|NCT03034603|Dietary Supplement|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
76039251|NCT03061747|Device|Assesment of outcome of implantable device patients|Evaluation during follow-up of the occurrence of atrial arrhythmias, hospitalizations, and of death.
75711783|NCT00931294|Behavioral|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
75711784|NCT00833235|Other|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
75711785|NCT00935662|Drug|AZD8329|Oral solution, single ascending doses
75711786|NCT00935662|Drug|Placebo|Oral solution, placebo
75871807|NCT02348710|Behavioral|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
75871808|NCT03964402|Drug|intervention treatment|intervention treatment (any)
75871809|NCT02338804|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
75406258|NCT05562648|Other|Electrophysical agents|"TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord."
75406259|NCT05543694|Drug|Bupivacaine Hydrochloride|Subjects will receive a dose of bupivacaine as described in the arm section of this trial
75711787|NCT00931372|Drug|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
75711788|NCT00931372|Drug|Placebo|Subcutaneous injection
75711789|NCT00829257|Drug|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
75711790|NCT00829257|Drug|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
75871810|NCT02338804|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
75871811|NCT02338726|Other|Gynecological examination|Comparison of questionnaires and gynecological examination
75711791|NCT00829257|Drug|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
75871812|NCT04824274|Drug|fentanyl|Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
75871813|NCT04824274|Drug|morphine|Morphine 75 mcg will be injected intrathecally during spinal anesthesia.
75871814|NCT04824274|Procedure|Transversus abdominis plane block|Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.
75871815|NCT04824274|Procedure|Sham block|Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
75711792|NCT01618656|Drug|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
75711793|NCT01618656|Drug|Placebo|Sugar pill
75711794|NCT03978832|Drug|PERSERIS|PERSERIS is an extended-release SC injectable suspension administered once-monthly
75711795|NCT03978832|Drug|Risperidone|Oral risperidone
75711796|NCT00840255|Behavioral|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
75711797|NCT00840255|Other|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
75871816|NCT03112018|Behavioral|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
75871817|NCT03112018|Behavioral|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
75871818|NCT03112018|Behavioral|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
75406260|NCT05542602|Behavioral|Social intervention|The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff as part of the children's existing after-school program. The sessions follow a schedule and include social skills groups, social recreational games, and a reinforcement system to teach, practice, and reinforce targeted social knowledge and social skills. The sessions are manualized and include a specific instructional sequence and treatment (lesson) plan for the paraprofessional staff to implement. The children also earn points for use of the targeted skills (frequency of use) and each can earn a home or site-based reinforcer for reaching her/his targeted number of points each session. Each group is facilitated by two paraprofessionals, and includes 12-15 children including two with hfASD (the remaining will be typically-developing peers).
75406261|NCT05537142|Drug|BV100|Rifabutin for Infusion
75406262|NCT05519748|Behavioral|Online psychoeducational program|The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.
75406263|NCT05495568|Biological|CT-P17|CT-P17 40mg will be subcutaneous administered
75551101|NCT04234971|Drug|Intervention group (DBM/BMP)|All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
75551102|NCT04234971|Drug|Control group(autologous ICBG)|The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
75551103|NCT04220411|Drug|AR100DP1|topical ointment
75551104|NCT04209543|Drug|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily
75551105|NCT04209543|Drug|Placebo oral tablet|Placebo oral tablet will be administered orally once daily
75551106|NCT04209543|Drug|Progesterone oral tablet|Progesterone oral tablet will be administered orally once daily
75711798|NCT00840333|Drug|MP-376 (Levofloxacin solution for Inhalation)|DOSE BASED ON PATIENTS WEIGHT
75711799|NCT00840489|Drug|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
75711800|NCT00840489|Drug|Colchicine|Colchicine 0.5 mg bd for 24 weeks
75711801|NCT00743496|Biological|Anti-GD2 antibody|Anti-GD2 antibody
75711802|NCT00937846|Drug|GSK1034702|Single oral 5 mg dose in liquid formulation
75711803|NCT00833391|Drug|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
75711804|NCT04044105|Other|Pamphlet education|Patients receive an educational intervention explaining proper opioid disposal
75871819|NCT03112018|Behavioral|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
76039252|NCT03063307|Procedure|Atraumatic Restorative Treatment|
76039253|NCT03063307|Other|Silver Diamine Fluoride|
75711805|NCT04044105|Other|Pamphlet education + texts|Patients receive an educational intervention and text message explaining proper opioid disposal
75871820|NCT03112018|Behavioral|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
76039254|NCT03061825|Device|Zenith Alpha™ Abdominal Endovascular Graft|Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.
75406264|NCT05495568|Biological|EU-approved Humira|subcutaneous administration
75406265|NCT05493774|Other|Multi-person virtual reality simulation scenario training|Using multi-person virtual reality simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
75406266|NCT05493774|Other|Multi-person high-fidelity simulation scenario training|Using multi-person high-fidelity simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
75551107|NCT04194489|Other|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
75406267|NCT05488548|Drug|EP31670|EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
75406268|NCT05481762|Device|Aided read with contextflow DETECT Lung CT|Radiologists read chest CT scabs with and without the aid of contextflow DETECT Lung CT as a second reader
75551108|NCT04194450|Dietary Supplement|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.
75406269|NCT05476536|Behavioral|self-management skills and healthy technology APP|self-management skills and healthy technology APP
75406270|NCT05429424|Other|Verum acupuncture group|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
75406271|NCT05429424|Other|Sham control group I|The needle does not penetrate the skin and retract in the handle while the acupuncturist needling into the skin. The participants easily believe their intervention owing to the sensation of needling into the skin that the device mimics. The needles were fixed with a plastic ring and micropore on the body of the participants without manipulation.
75406272|NCT05429424|Other|Sham control group II|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
75551109|NCT04194450|Dietary Supplement|Placebo|Acute ingestion of taste-matched placebo prior to assessment of outcomes.
75871821|NCT03112096|Drug|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
75406273|NCT05367102|Behavioral|Supporting Healthy Relationships program|"The investigator will provide the following 4 activities: 1) marriage and relationship education [using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)"
75871822|NCT03111862|Diagnostic Test|NSTEMI Rule-Out according to hs-TnT|Rule-Out according to the rapid rule-out protocol of the current ESC Guidelines
75406274|NCT05365308|Behavioral|Clinical supports|Quality improvement tools for iron deficiency anemia that include computer-assisted identification, an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education
75406275|NCT05358834|Dietary Supplement|Melatonin|Oral melatonin administered as a single pill.
75406276|NCT05358834|Dietary Supplement|Placebo|Oral placebo administered as a single pill.
75871823|NCT02509494|Biological|Ad26.ZEBOV|Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles.
75406277|NCT05336682|Procedure|Lesion Sterilization and Tissue Repair with radicular instrumentation|Coronal and accessible radicular pulp tissue are extirpated using rotary files. After proper drying, the paste is placed in the cavity and the canals.
75406278|NCT05336682|Procedure|Lesion Sterilization and Tissue Repair without radicular instrumentation|Only the coronal pulp is removed, the pulpal floor is covered with triple antibiotic paste with propylene glycol mix.
75551110|NCT04190303|Other|Pragmatic, multi-component package|This system-level intervention will be tailored to the needs and capacity of each hospital site, co-developed with policymakers and hospital staff
75551111|NCT04188834|Device|Customized version of DAVID device|A customized version of the DAVID device will be used to expose patients to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.
75551112|NCT04188834|Device|Blackrock CereStim|The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
75551113|NCT04178018|Device|Photoacoustic imaging|-Emerging technique in which a short-pulsed laser beam penetrates diffusively into a tissue sample
75551114|NCT04178018|Device|Ultrasound|-The ultrasound is being used in conjunction with the photoacoustic imaging
75711806|NCT00829335|Procedure|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
75551115|NCT04158739|Drug|Cytarabine|Given IT
75551116|NCT04158739|Biological|Flotetuzumab|Given IV
75551117|NCT04147325|Drug|Antiretroviral Therapy|ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
75871824|NCT02509494|Biological|MVA-BN-Filo|MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit (Inf. U.).
75871825|NCT02509494|Biological|MenACWY|MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
75871826|NCT02509494|Biological|Placebo|0.9% saline for injection.
75871827|NCT02348554|Behavioral|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
75871828|NCT02348554|Behavioral|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
75871829|NCT02348788|Drug|Artemether-lumefantrine + Primaquine|
75871830|NCT02348788|Drug|Chloroquine + Primaquine|
75406279|NCT05336682|Procedure|Conventional pulpectomy|Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of ZOE.
75406280|NCT05333016|Behavioral|Multimodal exercise|Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises
75406281|NCT05295108|Other|Caring Connections|peer-based letter writing social connectedness intervention to improve social health outcomes
75406282|NCT05295108|Other|Attention control|informational materials provided to educate on life domains that are important to social health
75406283|NCT05273346|Behavioral|Traditional Chinese medicinal ointment|The Group1 will be treated using the Comprehensive Conservative TCM Treatment Group protocol.The special TCM ointment will be applied to the waist, and then Tuina, in order to play the comprehensive therapeutic role of Tuina and medicine, promoting blood circulation and removing stasis, warming and dispersing cold, strengthening tendons and strengthening bones, regulating qi and blood. The method of ointment is generally used with rubbing method, rubbing method, flat pushing method and kneading method. Treatment time: 7 minutes.
75406284|NCT05273346|Behavioral|Acupotomy|It is in the special acupoints or Ashixue for cutting, stripping and other different stimulation, in order to reduce the tension of soft tissue outside the spinal canal, reduce the trend of dynamic and static spinal canal stenosis, to achieve the purpose of relieving pain and removing disease, opening points and collaterals. Acupotomy can separate the adhesive tissue, which can improve the blood circulation of the local tissue and promote the absorption of inflammation. Most acupotomy points are tenderness points or induration points, such as yaojiaji and Shenshu. Treatment time: 3 minutes.
75406285|NCT05273346|Behavioral|Cupping therapy with bamboo cup|Put the bamboo cup with the thickness of the thumb into the cup and boil it, then find the meridian and select the acupoint, Pierce the skin with a needle at the appropriate acupoint, and remove the heated bamboo cup from the cup while it is hot. When the temperature of the steam in the bamboo cup is reduced, steam will condense into water quickly, which produces strong negative pressure. Through the medicinal force, heat and the suction of the bamboo cup, the blood stasis in the affected area is smoothly discharged, so that qi and blood can be unblocked and pain can be eliminated. Treatment time: 20 minutes.
75406286|NCT05273346|Other|Oral Chinese medicine granules|Oral Chinese medicine granules use to nourish liver and kidney, improve qi and blood. Patients voluntarily take it when they think it is necessary.
75551118|NCT04142697|Behavioral|Heading direction adaptation|Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
75551119|NCT04136275|Biological|CAR-37 T cells|CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells
75711807|NCT00829491|Behavioral|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
75711808|NCT02547051|Other|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
75711809|NCT00840567|Procedure|Skin biopsy|
75711810|NCT00840567|Procedure|Blood draw & sample|
75711811|NCT00829569|Dietary Supplement|Intralipid +/- Omegaven|"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."
75871831|NCT03147976|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
75551120|NCT04123093|Device|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
75871832|NCT05763108|Diagnostic Test|genetic test|COL1A1 or COL5A1 genetic test
75871833|NCT05763108|Other|Beighton joint laxity test|Based on Beighton scale.
76039255|NCT02970565|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
75406287|NCT05273346|Behavioral|Epidural Steroid Injections (ESIs)|The Group2 will be treated using the Modern Medicine Conservative Treatment Program Group protocol.All Epidural Steroid Injections(ESIs) will be performed by a physician in an outpatient surgical setting(a sterile operating room),the patient will be in prone position,while monitored the vital signs. After aseptic treatment, 1mg non-granular betamethasone plus 5mL 0.9% sodium chloride solution will be injected. Patients will repeat ESIs up to four times within three months after randomization, depending on the response to the previous ESIs, when the degree of pain increases or the degree of relief is less than 50%.
75551121|NCT04123093|Device|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
75551122|NCT04119440|Biological|MVA-MERS-S_DF1 - Low Dose|Administrations of the low dose via the intramuscular route
75551123|NCT04119440|Biological|MVA-MERS-S_DF1 - High Dose|Administrations of the high dose via the intramuscular route
75551124|NCT04119440|Other|Placebo|Administrations of placebo via the intramuscular route
75551125|NCT04091347|Behavioral|DAPPER|The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
75406288|NCT05273346|Behavioral|Interferential current therapy|The 30-50cm padded electrode will be properly fixed on the left and right sides of the lumbar spinal stenosis, and the two groups of current will be crossed at the lesion. Constant frequency output 90Hz, frequency conversion output 90-100Hz, the current intensity is generally suitable for patient tolerance, each treatment for 10min, a total of 20 minutes. Twice a week for 3 months.
75406289|NCT05273346|Behavioral|Thermal therapy|After the interferential current therapy, the patient will receive Bohm light for 5 minutes at the site of lumbar spinal stenosis and massage for 5 minutes at low back. Twice a week for 3 months.
75551126|NCT04082767|Drug|Precedex|Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team
75551127|NCT04082767|Drug|Midazolam|Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team
75551128|NCT04077320|Behavioral|Memory Self-Efficacy Training|The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.
75711812|NCT02548767|Other|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
76039256|NCT02970565|Behavioral|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
75711813|NCT02548767|Other|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
75406290|NCT05273346|Other|Oral painkillers|NSAID drugs, if necessary.
75406291|NCT05248776|Drug|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
75406292|NCT05248776|Drug|Placebo|Matching placebo tablet.
75551129|NCT04077320|Behavioral|General Education|The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
75551130|NCT04071990|Behavioral|FB-CBGT|CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
75551131|NCT04071990|Behavioral|CBGT|CBGT for OCD patients, without involvement of family members
75551132|NCT04068831|Drug|Talazoparib|1 mg talazoparib daily
75551133|NCT04068831|Drug|Avelumab|800 mg avelumab every 2 weeks
75551134|NCT04051242|Device|XenMatrix™ AB Surgical Graft|Graft implantation, radiographic, functional, and electrophysotherapy outcomes will be measured at various time points up to 24-28 weeks post-operatively. A CT scan or MRI will be collected at screening and pre-operative visits to evaluate tissue volume, then again at post-operative Visit 1 and Visit 6. Physical therapy training will be performed as a research procedure following Graft implantation for a maximum of 30 weeks. Additionally, Physical Therapy evaluations will be conducted at screening, pre-op visit 1, post-op, and at post-op Visits 3, and 4. A small core needle biopsy 1-5 grams will be collected at three time points to conduct histomorphological assessment of the tissue prior to Graft implantation (Operative visit, Visit 2 and at Visit 4).
75551135|NCT04012138|Drug|Salbutamol|10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
75406293|NCT05228730|Biological|Tozinameran - Standard dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A standard dose will be administered on day 0 of the study.
75551136|NCT04012138|Drug|Insulin Aspart|"Patients in the experimental group will receive either:~10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
75551137|NCT04011410|Drug|Hydroxychloroquine Sulfate 200Mg Tab|Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
75551138|NCT03992469|Drug|EBFAHF-2|EBFAHF-2 is a 0.55g capsule that is easy to swallow. The quality, safety and consistency of EBFAHF-2 are established per FDA guidance under a botanical drug title. Low dose (maximum of 2 capsules bid) and full dose (maximum of 5 capsules bid). Weight based dosing will ensure an equivalent amount is given to each individual.
75551139|NCT03992469|Drug|Placebo|Placebo capsules made of cornstarch
75711814|NCT02548767|Other|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
75711815|NCT02548767|Other|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
75711816|NCT00840645|Drug|YM178|Oral
75711817|NCT00566722|Biological|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
75711818|NCT00691704|Drug|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
75406294|NCT05228730|Biological|Tozinameran - fractional dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
75406295|NCT05228730|Biological|Elasomeran - standard dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."
75406296|NCT05228730|Biological|Elasomeran - fractional dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."
75406297|NCT05226234|Device|MRI|Late gadolinium enhancement cardiac magnetic resonance (LGE-MRI)
75406298|NCT05211960|Behavioral|Mindfulness-based meditation|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness.
75551140|NCT03989999|Procedure|Transcranial Doppler (TCD)|"In the Emergency Department (ED):~After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 8 hours of the brain injury.~If TCD is normal (FVd>25 cm/sec and PI <1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.~If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).~No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group."
75551141|NCT03989947|Drug|Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.|Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
75711819|NCT00691704|Drug|Sequential Maintenance Therapy|"Subjects who achieve >partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved > stable disease (SD) from maintenance (per discussion with physician):~325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
75711820|NCT00833625|Procedure|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
75871834|NCT04811482|Behavioral|TCIT-CALM (Teacher-Child Interaction Training-CALM)|This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
75406299|NCT05194254|Other|MRI-ET|coupled fMRI and Eye Tracking tools
75406300|NCT05146986|Device|Non surgical and Surgical|"For non-surgical group, patients will receive non-surgical treatment (analgesia and symptomatic management treatment).~For surgical group, patients will receive surgical treatment using RibFix Blu Thoracic Fixation System."
75406301|NCT05131776|Device|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
75551142|NCT03988569|Other|audiovisual decision aid|Will view AVDA and then have opportunity for questions with physician before signing consent forms
75551143|NCT03977571|Procedure|Cytoreductive nephrectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach.
75551144|NCT03977571|Other|Tissue sampling|Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
75711821|NCT00833625|Other|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
75711822|NCT00829647|Drug|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
75711823|NCT02564406|Device|LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR|
75871835|NCT02337010|Device|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
75406302|NCT05131074|Behavioral|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
75871836|NCT02337010|Device|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
75711824|NCT00935896|Procedure|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
75871837|NCT02337010|Drug|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
75406303|NCT05131074|Behavioral|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
75551145|NCT03972891|Other|intervention break of 12 weeks|"The intervention of this study is a break of the intervention for 12 weeks under the following conditions:~no therapeutic intervention during the break~no language-specific specific exercises~language-specific strategies in everyday life can be applied, e.g. modeling techniques"
75551146|NCT03969082|Behavioral|Bibliotherapy|Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
75406304|NCT05118906|Drug|BP1.4979 active drug|2 tablets 15 mg of BP1.4979 per day
75406305|NCT05118906|Drug|Placebo|2 tablets of placebo per day
75406306|NCT05112198|Device|Use of Noona web- based symptom tracking tool|Noona patient reported outcome (PRO) platform tool that summarizes symptoms and distress
75406307|NCT05105802|Behavioral|Mindfulness-Based Intervention|Using AmDtx MBI-based app, targeted MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal (Appendix 5). Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
75551147|NCT03964051|Drug|Omalizumab Injection|Omalizumab 300 mg for subcutaneous injection
75871838|NCT02337010|Drug|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
75871839|NCT02338570|Drug|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
75871840|NCT02348320|Biological|Personalized polyepitope DNA vaccine|
75406308|NCT05105802|Behavioral|Cognitive Sham + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. The sham journey will consist of playing an open-source cognitive math game delivered through the same app as MBI, but without the mindfulness content.
75551148|NCT03951467|Other|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge.~First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations.~Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire."
75551149|NCT03945032|Other|TICOP|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
75551150|NCT03912194|Behavioral|cognitive-behavioral withdrawal regulation strategies|Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
75551151|NCT03912194|Behavioral|relaxation strategies|Participants will generate and refine relaxation techniques with the aid of a therapist
75551152|NCT03912194|Behavioral|early withdrawal exposure|Exposure to the first 4 hours of abstinence across 4 separate sessions
75551153|NCT03910452|Drug|Busulfan|3 days of IV Busulfan. An alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of conditioning regimen for myelosuppressive properties as per package insert and standard of care.
75551154|NCT03910452|Drug|Alemtuzumab|5 days of IV Alemtuzumab. A humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complement-mediated lysis and antibody-dependent cellular toxicity. For this study, being used as part of the conditioning regimen per package insert and standard of practice.
75551155|NCT03910452|Drug|Cyclophosphamide|2 days of IV Cyclophosphamide. This is an antineoplastic, and for this study is bine used for its immunosuppressive mechanism of action per package insert and standard of care
75711825|NCT00935896|Procedure|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
75711826|NCT00935896|Other|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
75711827|NCT00829725|Device|screws-internal fixation|3-4-screws-internal fixation
75711828|NCT00829725|Device|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
75711829|NCT00939328|Biological|rituximab|
76039257|NCT04434313|Device|Delivery of iStride™ device gait treatment using telemedicine|The gait device used in this study mimics the actions of the split-belt treadmill but can be used during overground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking. This research aims to adapt the delivery mechanism of treatment with the iStride™ device to include telemedicine. The telemedicine platform of reference in this study, the Moterum Digital Platform, is an integrated therapeutic platform which offers an activity library, real-time video conferencing, and outcomes tracking. Our primary study objective is to determine if telemedicine is a safe and feasible delivery method for treatment with the iStride ™ gait device.
76039258|NCT04874935|Drug|Lansoprazole|administration of lansoprazole 60 mg twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
75406309|NCT05105256|Drug|Prednisolone|Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
75551156|NCT03910452|Drug|Sirolimus|Post Peripheral blood stem cell infusion. It is used for its immunosuppressive mechanism of action.
75711830|NCT00939328|Drug|bendamustine hydrochloride|
75551157|NCT03910452|Radiation|Total Body Irradiation|2 fractionated doses on -2 day. It is used for its immunosuppressive mechanism of action. It is SOP for conditioning for transplant.
75551158|NCT03910452|Biological|Allogeneic peripheral blood stem cell|IV infused donor peripheral blood stem cell. Stem cells are cells that give rise to the blood cells - red blood cells that carry oxygen, white blood cells that help the body to fight infections, and platelets that help make the blood clot. Collected and infused per the standard of operating procedures established by the Department of Transfusion Medicine.
75551159|NCT03905330|Drug|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
75551160|NCT03905330|Other|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
75551161|NCT03871816|Other|Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis|Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.
75551162|NCT03865706|Drug|Inulin Oral Suspension|Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
75551163|NCT03865706|Drug|Placebo Oral Suspension|250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
75551164|NCT03865706|Drug|Broad-spectrum antibiotics|Standard of care treatment for infections
75406310|NCT05105256|Drug|Platelet-rich plasma|Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
75551165|NCT03839758|Procedure|TSA standard|Glenoid preparation will be done with 2D CT-Scan
75551166|NCT03839758|Procedure|RTSA standard|Glenoid preparation will be done with 2D CT-Scan
75551167|NCT03839758|Procedure|TSA Blueprint|Glenoid preparation will be done with Blueprint software
75551168|NCT03839758|Procedure|RTSA Blueprint|Glenoid preparation will be done with 2D CT-Scan
75551169|NCT03835520|Drug|Immunotherapeutic Agent|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
75551170|NCT03835520|Drug|Molecular Target|Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
75551171|NCT03824769|Behavioral|Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
75551172|NCT03824769|Behavioral|Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
75551173|NCT03824158|Behavioral|Facilitated advance care planning (in-person or telephonic)|The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic, or telephonically. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.
75871841|NCT02337088|Procedure|Delayed cord clamping at 30 seconds|For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
75406311|NCT05083260|Drug|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
75406312|NCT05083260|Drug|placebo|Hard gelatin capsule containing only common excipients for oral formulations
75871842|NCT02337088|Procedure|Delayed cord clamping at 60 seconds|For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
75871843|NCT05114902|Diagnostic Test|Nasopharyngeal swab|A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage
75551174|NCT03824158|Behavioral|Web-based advance care planning|Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.
75551175|NCT03821233|Drug|ZW49|"Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC~Expansion: MTD or RD identified in the dose-escalation part of the study"
75551176|NCT03793478|Drug|Quizartinib|"Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28"
75711831|NCT00746538|Device|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
75711832|NCT00829881|Drug|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
75406313|NCT05081622|Behavioral|Interaction Competencies with Children - for Teachers (ICC-T)|"Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~A one-day ICC-T refresher workshop aiming to refresh and re-emphasize the key aspects of the intervention is implemented about 6 to 12 months after the initial intervention."
75406314|NCT05068128|Other|Flow MRI|"4 flow acquisitions based on the 2D cine phase contrast sequence (present on all MRI systems) will be performed.~This sequence requires a cardiac synchronization by a plethysmograph put on the patient's finger.~32 cardiac phases are reconstructed per acquisition. The processing of the flow MRIs and the analysis of the flow curves of the LCS and blood during the cardiac cycle will be performed using the Amiens software.~Parameters measured via flow MRI are:~- Cerebral vascular flow, intracranial LCS dynamic volume, extracranial LCS dynamic volume"
75406315|NCT05068128|Other|PERFUSION TEST|"The test will be performed will include:~Inserting a needle into the lumbar space, Ommaya reservoir or valve pre-chamber, as appropriate~Connect the needle to the pressure transducer via saline filled manometer lines connected via a 3-way valve. The other end of the 3-way connection will be connected to a saline~Recording of the opening pressure for 10 minutes~The infusion test is terminated either when the pressure stabilizes again on a new plateau, or when the average pressure exceeds 40 mmHg, or in case of adverse effects or symptoms such as headache, nausea/vomiting or visual disturbances.~At the end of the test, a depletion of 30 to 50 mL of CSF will be performed.~The pressure recording during the test is then used to calculate the parameters of the mechanical properties of the CSF circulation and reported to the neurosurgeon ordering the test."
75406316|NCT05062668|Procedure|cataract operation and istent|a cataract operation and the placement of one or two iStent inject or inject W at the same time
75406317|NCT05062668|Procedure|cataract operation only|Patients have a classic postoperative treatment after cataract.
75406318|NCT05046288|Other|Virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
75406319|NCT05016258|Device|KONTACT MB|Dental implant surgery
75551177|NCT03793478|Drug|Fludarabine|30 mg/m^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
75551178|NCT03793478|Drug|Cytarabine|"2000 mg/m^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18"
75551179|NCT03793478|Drug|Intrathecal (IT) triple chemotherapy prophylaxis|IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
75551180|NCT03793478|Drug|Etoposide|"Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5"
75711833|NCT00829881|Drug|Placebo Capsule|A single placebo capsule
75711834|NCT02563314|Device|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
75871844|NCT02338414|Drug|Romiplostim|Subcutaneous Romiplostim (weekly injection) -> if titrated with maintaining PLT count between 50-200 x 10^9/L -> Subcutaneous Romiplostim (biweekly injection)
76039259|NCT04874935|Drug|Placebo|administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
75711835|NCT02563314|Device|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
76039260|NCT04975477|Procedure|Esophagogasrtoduodendoscopy and liver stiffness|Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.
76039261|NCT04975477|Procedure|hepatic venous pressure gradient|A method was used to evaluate portal pressure.
75711836|NCT00936052|Other|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
75711837|NCT00936130|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
75406320|NCT05717946|Dietary Supplement|Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.|We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
76039262|NCT03061591|Dietary Supplement|Wholistic Turmeric capsules|Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
76039263|NCT03061591|Other|Placebo|Placebo capsules
76039264|NCT02961361|Drug|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
76039265|NCT02961361|Drug|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
76039266|NCT04974229|Other|In line with the Dutch guideline for non-specific low back pain, Standard usual care for non-specific low back pain was applied.|In line with the Dutch guideline for non-specific low back pain, Standard usual care or non-specific low back pain was applied.
76039267|NCT04974931|Device|PREVENA Incision Management System|Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
76039268|NCT04975165|Procedure|Total knee arthroplasty|Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
75406321|NCT05717946|Other|control group|We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
75406322|NCT04992546|Drug|PRN473 (SAR444727)|White to off-white gel suspension
75406323|NCT04992546|Drug|Placebo|White to off-white gel suspension
76039269|NCT04974073|Drug|PHY606|Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
76039270|NCT04975087|Other|Patients group|Patients will complete the mentioned questionnaires.
75406324|NCT04950894|Device|Hypoglossal Nerve Stimulation|Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)
75406325|NCT04921410|Device|Biofeedback Knee Sleeve|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. A 'bad' knee motion will provide a haptic output to the wearer (biofeedback) so that they can take note of what the previous motion was that caused the device to signal a warning.
75406326|NCT04921410|Device|Sham Biofeedback|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. This intervention will provide sham biofeedback during training sessions.
75406327|NCT04916886|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml|Containing 0.5E10vp
75406328|NCT04916886|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml|Containing 0.3E10vp
75406329|NCT04907682|Drug|Ribavirin iv|100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10
76039271|NCT04973995|Behavioral|several physical examinations|By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
76039272|NCT04974853|Combination Product|Cardio-complement|Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
76039273|NCT04973839|Behavioral|Video optimizing expectations before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
75551181|NCT03771105|Drug|phosphate|The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
75551182|NCT03757299|Diagnostic Test|HPV Test|Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
75551183|NCT03745287|Biological|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan.
75551184|NCT03736213|Behavioral|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I
75406330|NCT04907682|Drug|Favipiravir|Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
75406331|NCT04880304|Other|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
75551185|NCT03736213|Behavioral|Ultrasound biofeedback|In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
75551186|NCT03725332|Behavioral|Telemedicine|Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance abuse counselors, perinatal nurse educators, and/or Peer Health Specialists. Consultations will occur every two weeks until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
75551187|NCT03725332|Behavioral|Group Care|Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator and community-based peer support specialist. Small group care meetings will occur every two weeks until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1)Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
75551188|NCT03706365|Drug|Abemaciclib|Administered orally.
75551189|NCT03706365|Drug|Abiraterone Acetate|Administered orally.
75551190|NCT03706365|Drug|Prednisone|Administered orally.
75551191|NCT03706365|Drug|Placebo|Administered orally.
75711838|NCT00936130|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
75551192|NCT03693521|Device|Handgrip strength measurement|Measurement of handgrip strength with Jamar hand-held dynamometer as a complement to standard care of patients with diabetes type 2 by diabetes-nurses.
75551193|NCT03693521|Other|Standard care|Standard care of patients with diabetes type 2 by diabetes-nurses.
75551194|NCT03684564|Drug|Rivaroxaban|Oral tablet 15 mg twice daily for 24 months
75551195|NCT03684564|Drug|Warfarin|Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months
75551196|NCT03672825|Drug|REcycled CartiLage Auto/Allo IMplantation|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
75551197|NCT03652740|Drug|Effects of commonly used medications on mood and medication preference|"Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States."
75551198|NCT03643939|Device|High Flow Nasal Catheter|"HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2."
75551199|NCT03643939|Device|Noninvasive ventilation|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
75551200|NCT03609853|Drug|Placebo|Placebo vapor (distilled water)
75551201|NCT03609853|Drug|Vaporized THC, limonene, or THC and limonene|Acute drug exposure
75551202|NCT03608579|Drug|Autologous Adipose Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
75551203|NCT03587272|Drug|Alemtuzumab, low dose total body irradiation, Sirolimus|"The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on Days -5 to -3) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
75551204|NCT03580629|Behavioral|Liver Live Donor Champion Program|Even with adequate education of live donation, many liver transplant candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide instrumental support. A Live Donor Champion (LDC) is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed the Liver Live Donor Champion program to provide education and advocacy training to waitlist candidates and their LDCs. The support provided by the LDC bridges a critical link between education and action. Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
75406332|NCT04880304|Other|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
75406333|NCT04840992|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|Aerogen Solo
75406334|NCT04840992|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
75551205|NCT03579446|Drug|Hydrocodone|Given by PO
75551206|NCT03579446|Drug|Hydromorphone|Given by PO
75551207|NCT03579446|Drug|Levorphanol|Given PO
75551208|NCT03579446|Drug|Morphine|Given by PO
75551209|NCT03579446|Drug|Oxycodone|Given by PO
75551210|NCT03579446|Drug|Oxymorphone|Given by PO
75551211|NCT03579446|Other|Questionnaire Administration|Ancillary studies
75551212|NCT03574571|Drug|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
75551213|NCT03574571|Drug|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
75551214|NCT03574571|Drug|Radium-223|Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
76039274|NCT04973839|Behavioral|Video optimizing expectations before PMR (guided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
75871845|NCT02336776|Other|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
75871846|NCT02336854|Drug|Tacrobell tab. 2mg|
76039275|NCT04973839|Behavioral|Neutral video before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
75406335|NCT04840992|Biological|Placebo for Inhalation|Aerogen Solo
75871847|NCT02336854|Drug|Prograf cap. 2mg|
75871848|NCT02338024|Behavioral|Modified Antiretroviral Treatment Access Study intervention|
75406336|NCT04840992|Biological|Placebo|Intramuscular administration
75406337|NCT04832802|Behavioral|ACCESS|ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.
75406338|NCT04832802|Behavioral|IPS|IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
75406339|NCT04793022|Drug|TIVA with Propofol|Total intravenous anesthesia with propofol
75406340|NCT04793022|Drug|Inhaled Anesthesia|General anesthesia given with inhaled anesthetics
75551215|NCT03538301|Drug|ND-L02-s0201 (Low Dose)|Intravenous administration every 2 weeks
75551216|NCT03538301|Drug|ND-L02-s0201 (High Dose)|Intravenous administration every 2 weeks
75551217|NCT03538301|Other|Other: Placebo|Saline
75551218|NCT03537508|Biological|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
75711839|NCT00936130|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
75711840|NCT00936130|Behavioral|Low Calorie Diet|Low Calorie Diet Program
75711841|NCT00829959|Behavioral|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
75711842|NCT04016727|Biological|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
75711843|NCT04014244|Drug|Corticosteroid vs. Dextrose|US guided injection of corticosteroid in one hand and 5% glucose in the other will be performed in accordance with randomization. In a syringe both substances will be diluted using 0.9% NaCl to a total injection volume of 6 ml. In-plane ulnar approach will be used to visualize the median nerve at the level of the pisiform bone. A standard 23 gauge needle will be inserted in the carpal tunnel with the needle tip positioned between retinaculum and median nerve.
75711844|NCT04014244|Procedure|Corticosteroid or Dextrose vs. Surgery|Injection will be performed unilaterally, after randomization of sides, by the same examiner as in the first part of the study. In all patients included in the second part of the study surgical release will be performed by the same plastic surgeon. The procedure will be performed under local anesthesia, following the same standard protocol. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
75711845|NCT00743808|Other|quality improvement|3-phase quality improvement intervention
75406341|NCT04682496|Procedure|Intratendon vascularization|Ultrasonic exploration by power-Doppler of the intratratendon vascularization, making longitudinal cuts of the patellar tendon and with previously pre-established Doppler optimization parameters for all patients. The optimization parameters of the power-Doppler signal will be set at a Doppler frequency of 6.7 MHz, pulse repetition frequency (PRF) of 0.7 kHz. The lowest wall filter and a standardized gain just below the level that produces random noise will be applied. This examination will be repeated several times with different probe pressures, which will be quantitatively adjusted through the force sensor and maintained with the articulated arm. A 4-second static video will be recorded of the longitudinal section that presents a higher Doppler signal in each of the scans at different probe pressures.
75406342|NCT04633356|Device|EUS-portal pressure gradient measurement (PPGM)|EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
75406343|NCT04621500|Drug|cholecalciferol|Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
75711846|NCT00834015|Other|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
75406344|NCT04592484|Biological|CDK-002|CDK-002 administered intratumorally
75711847|NCT02548611|Drug|Prasugrel|see arm description
75406345|NCT04567524|Drug|LYN-005|LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
75551219|NCT03537508|Biological|MenACYW-135 conjugate vaccine|Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
75551220|NCT03537508|Biological|DTaP-IPV//Hib vaccine|DTaP-IPV//Hib vaccine at 2, 4, and 6 months of age, Intramuscular
75551221|NCT03537508|Biological|Pneumococcal 13-valent conjugate vaccine|Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
75711848|NCT02548611|Drug|Clopidogrel|see arm description
75711849|NCT00937924|Drug|Saline|Saline solution injections
75711850|NCT00937924|Drug|Diphenhydramine|Diphenhydramine injections
75711851|NCT00937924|Drug|Promethazine|Promethazine
75711852|NCT00743886|Biological|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
75711853|NCT00743886|Drug|saline|injection of 6 cc of saline into injured area
75711854|NCT00938002|Diagnostic Test|Acceler8 Pheno|
75711855|NCT00830193|Drug|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
75551222|NCT03537508|Biological|Pentavalent rotavirus vaccine|Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
75551223|NCT03537508|Biological|Hepatitis B vaccine|Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
75551224|NCT03537508|Biological|Measles, mumps, rubella (MMR) vaccine|MMR vaccine at 12 months of age, Subcutaneous
75551225|NCT03537508|Biological|Varicella vaccine|Varicella vaccine at 12 months of age
75551226|NCT03537508|Biological|Hepatitis A vaccine|Hepatitis A vaccine at 15 to 18 months of age
75551227|NCT03509558|Device|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
75551228|NCT03509558|Other|Physical Therapy|physical therapy to improve walking and standing functions
75551229|NCT03496675|Behavioral|Group Music Therapy|The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.
75551230|NCT03496675|Behavioral|Recreational Choir Singing|RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.
75406346|NCT04549038|Other|12-16 hour nutrition|Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.
75406347|NCT04506060|Other|serum withdrawal|Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.
75551231|NCT03496675|Other|Standard care|May include pharmacological and non-pharmacological interventions as locally available
75551232|NCT03492840|Drug|RZL-012|The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
75551233|NCT03485157|Biological|Micronized dHACM|Injection of 40 mg micronized dehydrated human amnion chorion membrane (dHACM) suspended in 1 mL 0.9% Sodium Chloride, USP
75406348|NCT04481412|Drug|Topical cetirizine|Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
75406349|NCT04481412|Drug|Placebo|96% ethanol that will be applied once daily.
75406350|NCT04481412|Drug|Topical minoxidil|Topical Minoxidil 5% that will be applied once daily.
75406351|NCT04475718|Behavioral|Fourth Trimester Mobile Tool|A mobile web-based tool for underserved women in the fourth trimester. The mobile platform teaches self-efficacy, care management, and coping skills to help reduce major health risks and provide tools and resources to maintain mental health.
75406352|NCT04473066|Procedure|Adenotonsillectomoy +/- turbinate reduction|Tonsillectomies were performed by bipolar electrocautery while adenoidectomies were done by monopolar suction diathermy. Turbinate reduction (by either submucosal bipolar diathermy or radiofrequency) would be offered if the subject had on-going history of allergic rhinitis and examination revealed at least grade II turbinate hypertrophy. (Grade I = no turbinate hypertrophy; Grade II = turbinate hypertrophy without touching the septum; Grade III = turbinate hypertrophy touching the septum).
75406353|NCT04465188|Procedure|Encircling scleral buckle surgical procedure|Encircling scleral buckle surgical procedure under general anesthesia
75406354|NCT04441554|Diagnostic Test|7 Tesla MRI|7 Tesla MRI of cervical spine
75406355|NCT04423458|Device|3D imaging|"The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes."
75551234|NCT03485157|Drug|Saline|Injection of 1 mL 0.9% Sodium Chloride, USP
75551235|NCT03424018|Drug|BMN 111|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
75551236|NCT03405155|Biological|Nivolumab|Given IV
75551237|NCT03383692|Drug|DS-8201a|DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
75551238|NCT03383692|Drug|Ritonavir|Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration
75551239|NCT03383692|Drug|Itraconazole|Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration
75551240|NCT03342196|Drug|Melphalan|"Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
75551241|NCT03342196|Drug|Thiotepa|"Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
75551242|NCT03342196|Drug|Fludarabine|"Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness."
75711856|NCT00830193|Drug|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
76039276|NCT04973839|Behavioral|Neutral video before PMR (guided)+ Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided).The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
76039277|NCT04839601|Device|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
75406356|NCT04412616|Biological|ZZ06|"The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg."
75406357|NCT04371276|Other|No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
76039278|NCT02426281|Drug|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
76039279|NCT02426281|Drug|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
76039280|NCT02448537|Drug|PM01183|
76039281|NCT02448537|Drug|Doxorubicin|
76039282|NCT02448537|Drug|Gemcitabine|
75406358|NCT04317300|Drug|Varenicline|Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
75406359|NCT04317300|Other|brief behavioral therapy|brief behavioral therapy
75406360|NCT04300218|Behavioral|internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)|"The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study."
76039283|NCT03062371|Behavioral|Playgroup|A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
76039284|NCT03062683|Other|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
76039285|NCT03060265|Drug|Paracetamol|Administrating Paracetamol IV pre-cesarean section
76039286|NCT03060265|Drug|PLACEBO|Administrating SALINE IV pre-cesarean section
76039287|NCT04836247|Behavioral|Disclosing Recovery: A Decision Aid and Toolkit|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
76039288|NCT04836247|Behavioral|Mindfulness|Participants will be able to choose from several guided meditations to promote mindfulness
76039289|NCT02504151|Drug|Cannabidiol|
76039290|NCT02504151|Drug|Placebo|
76039291|NCT03060109|Other|Blood draw within 12 hours of injury|
76039292|NCT02448381|Drug|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
76039293|NCT02448381|Drug|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
75551243|NCT03330132|Biological|Standard inactivated influenza vaccine (NH formulation)|0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
75551244|NCT03330132|Biological|MF 59 adjuvanted inactivated influenza vaccine (NH formulation)|0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
75711857|NCT00746772|Drug|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
75871849|NCT02338180|Other|proximal preventive sealants|On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
76039294|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
76039295|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FSPG PET/CT
76039296|NCT02448225|Radiation|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
75406361|NCT04300218|Other|Care as usual (CAU)|Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
75406362|NCT04251390|Device|trexo Home|12 week intervention, with weekly contact/assessments of the affects of using the trexo Home.
75406363|NCT04205370|Device|Deactivated Pregnancy Coach|Naturalistic monitoring of their typical sleep patterns and behaviors
75406364|NCT04205370|Device|Active Pregnancy Coach|The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
75406365|NCT04176510|Behavioral|Health Coach Intervention|A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
75406366|NCT04143204|Other|Oral nutritional intake|The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
75406367|NCT03977922|Other|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
75406368|NCT03971136|Diagnostic Test|pulmonary ultrasound|The subjects will have an ultrasound on admission and on day 1, 2 and 3
75406369|NCT03946332|Behavioral|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
76039297|NCT02448225|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
76039298|NCT02448225|Other|Laboratory Biomarker Analysis|Correlative studies
76039299|NCT02448225|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
76039300|NCT02448225|Procedure|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
76039301|NCT02503215|Device|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
75406370|NCT03946332|Behavioral|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
75406371|NCT03920982|Diagnostic Test|Determination of the blood concentration of indoxyl sulfate (IS)|IS concentration will be determined in blood of patients with septic shock and acute kidney injury. IS blood concentration will be done every day during 7 first days after patient will be admitted in intensive care unit. Relation between IS peak serum concentration and mortality at day 28 will be determined.
75406372|NCT03904914|Other|TOCI|TOCI staging evaluated
75551245|NCT03330132|Biological|High-dose inactivated influenza vaccine (NH formulation)|0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
75551246|NCT03330132|Biological|Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)|0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
75551247|NCT03309007|Drug|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
76039302|NCT02447991|Drug|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
75711858|NCT00746772|Drug|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
75871850|NCT02338180|Other|proximal therapeutic sealant|On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
75871851|NCT02039440|Other|Blood draw|One-time blood draw
75871852|NCT02332330|Device|VEST|
75871853|NCT02338102|Other|Saline mixture|premeasured salt packets mixed with distilled water
75406373|NCT03886740|Procedure|Reducing symptoms of Eustachian tube dysfunction|One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
75406374|NCT03876288|Device|GI Neuromodulation|The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
75406375|NCT03876288|Drug|Immunotherapy|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
75406376|NCT03876288|Procedure|Pyloric Therapies|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
75406377|NCT03818256|Drug|Miricorilant|Miricorilant 600mg
75406378|NCT03818256|Drug|Miricorilant|Placebo tablets for once daily oral dosing
75406379|NCT03812172|Drug|99mTc-PYP or 99m Tc-HDP|10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
75871854|NCT02332174|Drug|rufinamide|comparison of different doses, sex and medication conditions
76039303|NCT02447991|Drug|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
76039304|NCT02586155|Drug|Apabetalone|100 mg capsule
75406380|NCT03623958|Device|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
75406381|NCT03623958|Procedure|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
75551248|NCT03309007|Drug|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
75551249|NCT03261544|Procedure|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
75871855|NCT02338258|Device|Anti-rotational plate|
75871856|NCT02338258|Device|Exchanged Intramedullary nailing|
75871857|NCT02332252|Device|Scalpel|Skin incision performed with a scalpel during cesarean section.
75871858|NCT02332252|Device|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
75711859|NCT00938080|Biological|AG013|Mouth rinse once a day for 14 days
75711860|NCT00938080|Biological|AG013|Mouth rinse three times a day for 14 days
75711861|NCT00938080|Biological|AG013|Mouth rinse six times a day for 14 days
75871859|NCT02332252|Procedure|Skin incision|
75871860|NCT03493451|Drug|Tislelizumab|Administered intravenously
75871861|NCT02332096|Device|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
75871862|NCT03726125|Drug|LY3374849 - SC|Administered SC
75871863|NCT03726125|Drug|Insulin Degludec - SC|Administered SC
75871864|NCT03726125|Drug|LY3374849 - IV|Administered IV
76039305|NCT02586155|Drug|Placebo|Capsule manufactured to mimic RVX000222 100 mg capsule
76039306|NCT02586155|Drug|Atorvastatin|High-Intensity Statin
76039307|NCT02586155|Drug|Rosuvastatin|High-Intensity Statin
76039308|NCT05697731|Diagnostic Test|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
76039309|NCT02446743|Biological|rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)|One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
76039310|NCT02586077|Drug|Exparel|
76039311|NCT05536661|Other|Preservative free hyaluronic acid artificial tear|Ocular lubricant
76039312|NCT03241121|Behavioral|Time restricted feeding|To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake
75551261|NCT03206671|Drug|Rituximab window|Rituximab window (375 mg/m²)
75711862|NCT00938080|Other|Placebo|Mouth rinse once a day for 14 days
75711863|NCT00938080|Other|Placebo|Mouth rinse three times a day for 14 days
75711864|NCT00938080|Other|Placebo|Mouth rinse six times a day for 14 days
75711865|NCT00834327|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered QD for about 4 weeks
75551262|NCT03206671|Drug|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
75551263|NCT03206671|Drug|Cyclophosphamide|see detailed protocol description
75551264|NCT03206671|Drug|Cytarabine|see detailed protocol description
75711866|NCT02563938|Drug|AK001|Given parenterally.
75711867|NCT02563938|Drug|Placebo|
75711868|NCT00938158|Biological|albiglutide|single dose of subcutaneously injected albiglutide
75711869|NCT00840957|Biological|infliximab|chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
75711870|NCT00743964|Drug|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
75551265|NCT03206671|Drug|Dexamethasone|see detailed protocol description
75551266|NCT03206671|Drug|Doxorubicin hydrochloride|see detailed protocol description
75551267|NCT03206671|Drug|Vindesine Sulfate|see detailed protocol description
75711871|NCT00743964|Drug|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
75711872|NCT00939406|Device|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
75711873|NCT00830271|Device|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
75711874|NCT00830271|Device|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
75711875|NCT02563236|Other|Parabolic flight|
75711876|NCT00830349|Drug|Risperidone|1 mg Tablet
76039313|NCT03241121|Behavioral|Regular dietary advices|Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines
76039314|NCT03241121|Device|Eating patterns|Data collection on eating patterns via the smartphone app
76039315|NCT05591807|Other|Electroacupuncture|insert the acupuncture needle to SJ3(left side) and connect the electroacupuncture device for 15min, 2mA and 2Hz
76039316|NCT05536583|Procedure|Laparoscopic sleeve Gastrectomy|Laparoscopic sleeve Gastrectomy
76039317|NCT05536505|Genetic|Adjuvant treatment for MRD positivity|The MRD positive group would receive icotinib as adjuvant treatment. When the peripheral blood MRD turned negative, the subjects entered the drug withdrawal observation period. When the MRD turned positive again, the subjects resumed icotinib treatment. If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.
76039318|NCT05536271|Drug|Bisoprolol Fumarate|antihypertensive medicine prescribed for acute coronary syndrome patients
76039319|NCT05536193|Drug|Topical Metformin Emulgel and salicylic acid|"Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid"
75551268|NCT03206671|Drug|Etoposide|see detailed protocol description
75551269|NCT03206671|Drug|Ifosfamide|see detailed protocol description
75551270|NCT03206671|Drug|Methotrexate|see detailed protocol description
75551271|NCT03206671|Drug|Prednisolone|see detailed protocol description
75551272|NCT03206671|Drug|Vincristine|see detailed protocol description
76039320|NCT05536193|Diagnostic Test|Insulin- Like growth factor (ILGF-1)|3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
75406382|NCT03601026|Behavioral|Genetic counselling|Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
75551273|NCT03184792|Device|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
76039321|NCT05535881|Behavioral|Strengths to Grow Program|In an online, self-directed format, the Strengths to Grow program will present the principles of strength-based parenting using videos, pictures, reflection questions, and written text. The intervention will communicate that a) every child has a unique set of strengths and that b) noticing and developing these strengths can enhance child and family well-being. It will also provide concrete steps that parents can follow to talk with their child about strengths, and it will provide ideas for family activities that would allow family members to express strengths. Participants will be invited to respond to reflection questions at various points throughout the program.
75551274|NCT03184792|Other|Physical therapy|Physical therapy to improve arm and hand functions
75551275|NCT03178617|Other|Educational Intervention|Attend standard of care LIP
76039322|NCT04425707|Drug|Ivermectin|use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
76039323|NCT05697185|Drug|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
75551276|NCT03178617|Other|Educational Intervention|Attend HIP
76039324|NCT02583425|Drug|DFN-11 Injection|
76039325|NCT05535803|Biological|Olfactory mucosa-derived mesenchymal stem cells|Autologous olfactory mucosa-derived mesenchymal stem cells
76039326|NCT05535803|Other|Patients treated according to current clinical protocols|Patients treated according to current clinical protocols
75551277|NCT03178617|Other|Quality-of-Life Assessment|Ancillary studies
75551278|NCT03178617|Other|Questionnaire Administration|Ancillary studies
75551279|NCT03161431|Drug|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
75711877|NCT00830349|Drug|Risperidone|1 mg Tablets
75711878|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
75711879|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
75871865|NCT03726125|Drug|Insulin Degludec - IV|Administered IV
75406383|NCT03370302|Drug|TAK-228|TAK-228 Capsules.
75406384|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
76039327|NCT05511233|Dietary Supplement|feeding with breastmilk within 48 hours after surgery|Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
76039328|NCT02581163|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
75551280|NCT03161431|Biological|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
75551281|NCT03129126|Drug|LP-10|Intravesical tacrolimus
75551282|NCT03098563|Drug|Blinded study medication|Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
75551283|NCT03066960|Procedure|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
75551284|NCT03066960|Procedure|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
75711880|NCT00830427|Drug|PF-00610355|100 mcg, QD, dry powder inhaler
76039329|NCT02581163|Drug|Dasabuvir|Tablet
76039330|NCT02581163|Drug|Ribavirin|Tablet
75551285|NCT03048019|Drug|Tirofiban|Patients will receive Tirofiban during the PCI procedure
75711881|NCT00830427|Drug|PF - 00610355|600 mcg, QD, dry powder inhaler
75711882|NCT00830427|Other|Placebo|QD, dry powder inhaler
75711883|NCT00830427|Drug|PF - 00610355|300 mcg, QD, dry powder inhaler
76039331|NCT05591495|Procedure|laparoscopy in upper abdominal surgical emergencies in adults|evaluation the role of laparoscopy in upper GIT emergencies in adults
76039332|NCT05535179|Drug|honeysuckle and semen oroxyli solution|The patients in the treatment group were instructed to gargle the solution containing honeysuckle and semen oroxyli (25 mL) four times a day for 2 weeks.
76039333|NCT05462405|Procedure|Experimental group|In the setting phase subjects will be in recumbent position. A microneurography needle (0.2mm diameter isolated Tungsten micro-electrode) will be placed under the skin. An identical (not isolated) reference needle tip will be inserted within 2 cm of the first electrode. These are connected to a recording system (ADInstruments PowerLab). Once sympathetic activity can be measured using the needles, a sympathetic specific test will be used to calibrate the measurement and recording system. In the testing phase sequential pacing and CNT delivery will be programmed for a few minutes, the whole procedure expected to last less than 2 hours.
76039334|NCT05679089|Device|early detection test|Blood collection and early detection testing
76039335|NCT05591261|Behavioral|ePREP|6-session online psychoeducational program with supporting coach calls
76039336|NCT05589545|Device|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
76039337|NCT01938547|Drug|clevidipine|
75406385|NCT03327324|Behavioral|Sleep Using Mentored Behavioral and Environmental Restructuring|SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
76039338|NCT05685485|Procedure|Standard Implantation|Traditional Ahmed plantation without vicryl ligature
75406386|NCT03252522|Combination Product|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
75551286|NCT03048019|Drug|Cangrelor|Patients will receive Cangrelor during the PCI procedure
75551287|NCT03036007|Other|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
75551288|NCT03036007|Other|Exercises with Internet support|Neck-specific exercise with Internet support
75711884|NCT02563158|Procedure|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
75711885|NCT00841113|Drug|Abarelix|100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter
76039339|NCT05685485|Procedure|Tied off Tube|Ahmed implantation with vicryl ligature
75551289|NCT03035604|Other|Comprehensive Geriatric Assessment|Undergo nutritional geriatric assessment
75406387|NCT03252522|Dietary Supplement|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
75406388|NCT03191370|Other|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
75551290|NCT03030079|Device|Experimental Electrical Stimulation Regimen|The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
75551291|NCT03019133|Device|Sound reduction|Subjects will wear noise reduction headphones between the hours of 8:00 pm and 8:00 am.
75711886|NCT00841113|Drug|Goserelin plus Bicalutamide|Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
75711887|NCT00741546|Procedure|Cardiac Surgery|Cardiac Surgery
75711888|NCT00830505|Drug|fluticasone/salmeterol|2 puffs twice a day for 2 weeks
75711889|NCT00830505|Drug|fluticasone|2 puffs twice a day for 2 weeks
75711890|NCT00566020|Drug|BW430C (lamotrigine)|lamotrigine 50mg/day-400mg/day
75551292|NCT03019133|Device|Sound masking|Subjects will wear wear headphones playing relaxing music between the hours of 8:00 pm and 8:00 am.
75551293|NCT03006705|Drug|Nivolumab|Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
75551294|NCT03006705|Drug|Tegafur-gimeracil-oteracil potassium|Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
75551295|NCT03006705|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
75406389|NCT03191370|Drug|Local Anesthetics,Topical|Anesthetic spray
75406390|NCT03179436|Biological|Quavonlimab|Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
75406391|NCT03179436|Biological|Pembrolizumab|Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
75406392|NCT03179436|Drug|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
75406393|NCT03149874|Drug|Hepatitis B recombinant DNA vaccine|Hepatitis B recombinant DNA vaccine
75406394|NCT03149874|Drug|Combined hepatitis A and B vaccine|Combined hepatitis A and B vaccine given to the patients
75406395|NCT03142074|Other|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
75406396|NCT03142074|Radiation|ECG-gated CT|Image analysis of ECG-gated CT.
75406397|NCT02834052|Drug|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
75406398|NCT02834052|Drug|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"
75551296|NCT03006705|Drug|Capecitabine|Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
75711891|NCT02563782|Biological|Sub-retinal transplantation of MA09-hRPE cells|transplantation
75711892|NCT02563782|Drug|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
75406399|NCT02756364|Drug|Fulvestrant|Fulvestrant IM injection.
75406400|NCT02756364|Drug|Sapanisertib|Sapanisertib capsule.
75551297|NCT03006705|Drug|Placebo|Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
75551298|NCT02998645|Drug|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.
75711893|NCT02563782|Drug|Placebo tacrolimus and mycophenolate mofetil|placebo
75711894|NCT02563782|Procedure|Sham Surgery|Sham surgery
75711895|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
75711896|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
75711897|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
75711898|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
75406401|NCT02752542|Behavioral|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
75551299|NCT02998645|Drug|Cyclosporine|"Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows:~6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months~9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months~12-24 months: dose was maintained"
75551300|NCT02953899|Behavioral|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
75711899|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
75551301|NCT02953899|Behavioral|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
75551302|NCT02917720|Other|TKI discontinuation|2nd or 3rd TKI stop after pre-treatment with nilotinib.
75551303|NCT02917720|Drug|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
75711900|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
76039340|NCT05695625|Other|Spinal anesthesia + bilateral erector spine plane block|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides.~Postoperative period: If patients' VAS value >4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values >4, 1000mg paracetamol intravenously was administered."
76039341|NCT05695625|Other|Spinal anesthesia|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position.~Postoperative period: If patients' VAS value >4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values >4, 1000mg paracetamol intravenously was administered."
76039342|NCT05695547|Other|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
75406402|NCT02752542|Drug|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
75551304|NCT02805855|Drug|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
75551305|NCT02752035|Drug|gilteritinib|Tablet, oral
75551306|NCT02752035|Drug|azacitidine|Subcutaneous injection or intravenous infusion
75551307|NCT02724228|Drug|BMN 111|BMN 111 will be administered subcutaneously daily.
75551308|NCT02719327|Drug|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
75551309|NCT02719327|Other|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
75711901|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
75711902|NCT00741624|Other|Bandage|one application for one week
75711903|NCT00830583|Procedure|blood test|There is only a blood test at the beginning.
75406403|NCT02679378|Device|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
75406404|NCT02649738|Procedure|Corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
75711904|NCT00746928|Other|Chronic Intermittent Hypoxia|Chronic Intermittent Hypoxia mimicking the CIH undergone by patients suffering from Sleep Apnea Syndrome, is applied to Healthy subject during 8 hours a day (nights) for a 14 days period. The cycle of intermittent Hypoxia is 30 drop in SaO2 per hours with a 10% decrease in SaO2.
75711905|NCT00843453|Other|blood collection|blood collection
75711906|NCT00843453|Drug|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
75711907|NCT00921726|Drug|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
75711908|NCT00921726|Drug|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
75711909|NCT00938236|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
75711910|NCT02546739|Biological|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
75406405|NCT02519322|Biological|Ipilimumab|Given IV
75406406|NCT02519322|Other|Laboratory Biomarker Analysis|Correlative studies
75406407|NCT02519322|Biological|Nivolumab|Given IV
75406408|NCT02519322|Biological|Relatlimab|Given IV
75406409|NCT02519322|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75406410|NCT02460042|Procedure|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
75871866|NCT02337868|Biological|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
75406411|NCT02460042|Device|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
75711911|NCT00744198|Procedure|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
75871867|NCT02337868|Other|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
75871868|NCT02336620|Drug|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
75871869|NCT02336620|Drug|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
75871870|NCT03725969|Dietary Supplement|Camel milk|Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
75871871|NCT03725969|Dietary Supplement|Cow milk|Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
75406412|NCT02210988|Other|acupuncture|Intervention with acupuncture
75871872|NCT02336308|Drug|Ketamine|
75871873|NCT02336308|Drug|Placebo, Normal Saline|
75871874|NCT02332018|Radiation|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
75871875|NCT02336386|Drug|CDD|Chemotherapy
75406413|NCT02163408|Other|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
75406414|NCT02000934|Drug|TAK-659|TAK-659 tablet
75406415|NCT01906476|Behavioral|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
75406416|NCT01906476|Behavioral|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
75406417|NCT01793922|Procedure|PD|pneumodilation
75406418|NCT01793922|Procedure|POEM|peroral endoscopic myotomy
75406419|NCT00766584|Other|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
75406420|NCT05723094|Radiation|Ga-Al-As diode laser (Ilase, USA)|The laser parameter used in previous study： Laser type：Ga-Al-As Wavelength：940 nm Emission type：Continuous Irradiation dosage/per tooth：75J/cm2 Application technique：Direct contact with the mucosa Exposure time per point：6 second Laser classification：3B Laser application time：Once in a month (4-week intervals) for the maxilla and mandibular incisors and canines Output：100Mw Diameter of the optical fiber：0.04 cm2
75406421|NCT05723094|Other|placebo|Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
75406422|NCT05723016|Other|preimplantation genetic test for aneuploidies (PGT-a)|preimplantation genetic test for embryo aneuploidies after IVF
75406423|NCT05722626|Procedure|PRP|2 ml of platelet rich plasma intraarticular injection twice in one week interval
75406424|NCT05722626|Other|Normal Saline|NaCl 0.9%
75406425|NCT05722548|Drug|Indomethacin suppository|100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
75406426|NCT05722548|Other|Standard Medical Treatment|Standard Medical Treatment
75711912|NCT00744198|Procedure|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
75871876|NCT02336386|Drug|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
75871877|NCT02337712|Radiation|q.d. RT|65 Gy in 26 fractions
75871878|NCT02337712|Radiation|b.i.d.RT|45 Gy in 30 fractions
75871879|NCT02337712|Drug|etoposide and cisplatin|etoposide and cisplatin concurrent with radiotherapy
75871880|NCT03093844|Device|Miltenyi CliniMACS® CD34 Reagent System|Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
75871881|NCT02337556|Other|Peptamen Bariatric|Commercially available enteral diet
75871882|NCT02337556|Other|Replete|Commercially available enteral diet
75871883|NCT04564534|Other|MoCA cognitive assessment|cognitive assessment using the validated MoCA test administered via an application on an iPad
76039343|NCT05697107|Drug|Ripretinib Oral Tablet|Oral kinase inhibitor
75871884|NCT04490902|Procedure|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with single donor cornea
76039344|NCT05586737|Drug|Rituximab|1 gram rituximab twice with two weeks interval
76039345|NCT05678933|Drug|Azacitidine|Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
75406427|NCT05722470|Behavioral|eating disorders|Assessment of eating disorders among adolescents
75406428|NCT05722392|Procedure|Two-step Radical Prostatectomy|The first step is enucleation of the hyperplastic adenoma, and the second step is anterograde RP to residual gland
75406429|NCT05722002|Drug|NSAID|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)"
75406430|NCT05722002|Drug|Opioid|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses"
75406431|NCT05722002|Drug|Acetaminophen|Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
75406432|NCT05721924|Procedure|Pericapsular nerve group (PENG) block|In PENG group, the patient will be given PENG block 30mls of 0.2% ropivacaine
75406433|NCT05721924|Procedure|Supra-inguinal fascia iliaca compartment (S-FICB) block|Patients in group B (S-FICB group) will be supra-inguinal fascia iliaca compartment block 30mls of 0.2% ropivacaine
75551310|NCT02711709|Other|Frailty Measurements|"A frailty index will be determined as a combination of factors.~An older adult is considered physically vulnerable when they experience:~muscle weakness~fatigue~low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.~This will be collected at baseline, 3, 6 and 12 months."
75551311|NCT02711709|Other|Modified Minnesota Leisure Time Activities|A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
75551312|NCT02711709|Other|Computed tomography morphometrics|A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
75551313|NCT02711709|Other|Mobility Monitors|Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
75551314|NCT02710734|Drug|Methotrexate|Administered Day 1 of each 14 day cycle for 3 cycles
75551315|NCT02710734|Drug|Vinblastine|Administered Day 1 of each 14 day cycle for 3 cycles
75551316|NCT02710734|Drug|Doxorubicin|Administered Day 1 of each 14 day cycle for 3 cycles
75551317|NCT02710734|Drug|Cisplatin|Administered Day 1 of each 14 day cycle for 3 cycles
75551318|NCT02710734|Radiation|Intensity modulated radiation therapy (IMRT)|2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday
75551319|NCT02710734|Procedure|Transurethral Resection of Bladder tumor|Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
75551320|NCT02710734|Drug|5-FU|Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment
75551321|NCT02710734|Drug|Mitomycin C|Intravenous on day 1 with radiation treatment
75551322|NCT02669225|Other|[18F]florbetaben|PET radiotracer to image Amyloid beta (AB) load in human brain.
75551323|NCT02580994|Drug|Pembrolizumab|IV infusion at the dose of 200 mg on day 1 every 3 weeks
75551324|NCT02580994|Drug|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
75871885|NCT04490902|Procedure|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
76039346|NCT05678933|Drug|Chidamide|Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
75551325|NCT02546661|Drug|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
75551326|NCT02546661|Drug|MEDI4736|MEDI4736
75406434|NCT05721534|Other|Medication review|"Annual consultation focusing on pharmacological treatment. This specific consultation constituted the intervention. It included a structured review of the patient's health state, in addition to a structured medication review with a focus on appropriate medication and deprescribing."
75406435|NCT05721456|Biological|12-Valent Pneumococcal Conjugate Vaccine|PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
75551327|NCT02546661|Drug|Olaparib|MEDI4736 (durvalumab) + Olaparib
75551328|NCT02546661|Drug|AZD1775|MEDI4736 (durvalumab) + AZD1775
75551329|NCT02546661|Drug|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
75551330|NCT02546661|Drug|AZD9150|MEDI4736 (durvalumab) + AZD9150
75551331|NCT02546661|Drug|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
75551332|NCT02543567|Biological|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5*10^10 viral particles on Day 1
75551333|NCT02543567|Biological|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2*10^10 viral particles on Day 1
75551334|NCT02543567|Biological|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8*10^10 viral particles on Day 1
75551335|NCT02543567|Biological|MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57
75406436|NCT05721300|Drug|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combined with interferon treatments"|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
75551336|NCT02543567|Biological|MVA-BN-Filo 5*10^7 Inf. U.|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5*10^7 Inf. U. once on Day 57
75551337|NCT02543567|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
75551338|NCT02530489|Drug|Atezolizumab|Given IV
75551339|NCT02530489|Drug|Nab-paclitaxel|Given IV
75871886|NCT02337400|Behavioral|"Cognitive behavioral smoking reduction program Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
75871887|NCT02337400|Behavioral|15 minute counseling interview|
75406437|NCT05721300|Drug|"NAs （EntecavirorTenofovirorTenofovir alafenamide） treatments"|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） treatment at least 48 weeks"
75406438|NCT05721066|Diagnostic Test|ClotPro assessment|Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)
75406439|NCT05721066|Diagnostic Test|Laboratory analysis|Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)
75406440|NCT05721066|Other|Interview|Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
75871888|NCT02899858|Other|Movement Assessment|Documentation of ASIA A (T2-8) status at Belmont Gait Lab
75551340|NCT02519985|Device|ArcScan Insight 100 very high-frequency digital ultrasound|"The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.~The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath."
75551341|NCT02431780|Device|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
75551342|NCT02363205|Behavioral|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
75551343|NCT02253238|Behavioral|Quality of Life Survey|Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
75551344|NCT02253238|Behavioral|Health Management Surveys|Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
75551345|NCT02253238|Other|Monitoring Devices|Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
75551346|NCT02253238|Behavioral|Symptoms Surveys|"Behavioral: Symptoms survey 1; completed at weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.~Behaviorial: Symptoms survey 2; completed at baseline, weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT."
75871889|NCT02899858|Other|MRI Scan|Total MRI of spine to evaluate condition of spinal cord
75551347|NCT02253238|Behavioral|Device Usability Survey|Device usability survey; completed at weeks 1, 3, 5, and 7 days after RT.
75871890|NCT02899858|Procedure|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
75871891|NCT02899858|Other|Follow up clinical exam|All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.
76039347|NCT05678933|Drug|Cyclophosphamide|Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
75406441|NCT05720910|Other|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway
76039348|NCT05678933|Drug|Epirubicin|Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
76039349|NCT05678933|Drug|Vincristine|Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
75406442|NCT05720598|Procedure|Sentinel Node Assessment|The SN assessment will be conducted similarly to the method proposed by Märkl et al. All LNs will be stored in a -80 °C freezer, immediately after retrieval. Within 1 to 3 days, each LN will be individually measured and weighed. Small LNs (<5 mm in short diameter) will be bisected, and half of the node will be processed for histological evaluation while the remaining half will be used for OSNA analysis. For intermediate-sized LNs (5-10 mm), a middle slice of about 2 mm thickness will be cut out for the histology, and the remaining parts of the node will be processed by OSNA. In large LNs (>10 mm), at least two slices will be cut out for histology, and the remaining parts of the node will be analyzed by OSNA.
75406443|NCT05720598|Procedure|Staging laparoscopy|Pneumoperitoneum (10-12mmHg) will be obtained with Veress needle or 10mm trocar after minilaparotomy. Peritoneal cavity will be thoroughly assessed after insertion of two additional trocars. In cases of macroscopic dissemination, peritoneal cancer index (PCI) will be determined. After switching the optical camera into near-infrared / indocyanine green fluorescence mode, the primary tumor will be visualized, followed by assessment and possible dissection of sentinel lymph node with a high-energy device. The lymph node will be retrieved with a sterile bag, and the area of dissection will be marked with a clip. Trocars will be removed under visual assistance, and the pneumoperitoneum will be released through trocars in order to prevent port-site metastases.
75406444|NCT05720598|Procedure|Gastroscopy with indocyanine green (ICG) injection|Patients will undergo gastroscopy one day prior to staging laparoscopy. The ICG powder contains 0.125 mg/ml. Two milliliters of ICG (0.125mg/ml) solution is injected in the submucosa with into four peritumoral sites, 0.5 ml for each site.
76039350|NCT05678933|Drug|Prednisone|Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
76039351|NCT05678855|Behavioral|A randomızed Controlled Study with pre-test and post-test|The intervention in this study is to apply multimedia-based instruction in distance education to the experimental group. control group students received distance education through traditional teaching. Experimental group students received distance education through interactive teaching prepared with multimedia tools. Experimental group, interactions were made using applications such as Icebreaker, Puzzle, QR code, Mentimeter, and Padlet. In addition, animation, infographics, animated slides (Multimedia tools) were used for the experimental group.In the control group, plain narration was given. Tests were administered to both groups before and after the intervention.
75406445|NCT05720442|Drug|Tangweian Recipe|The Tangweian recipe is a combination of several Chinese herbs
75406446|NCT05720442|Drug|Mosapride Citrate|The mosapride citrate tablets will be administrated.
75551348|NCT02239341|Other|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
75551349|NCT02239341|Other|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
75711913|NCT00744198|Procedure|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
75871892|NCT02899858|Other|Post Op MRI Scan|An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.
76039352|NCT05357495|Behavioral|Affective Posner fMRI frustration induction task|During the frustration induction paradigm, children play a game with monetary reward. The game is rigged, thus inducing frustration. The control task does not have any reward component. All participants complete both the control task scanning session and the frustration induction scanning session.
75406447|NCT05720286|Device|Arthroscopic rotator cuff repair|Arthroscopic transosseous reinsertion of the rotator cuff is the most widely used arthroscopic technique. The tendons are repositioned on the greater and lesser tuberosities of the humerus with specific anchors. These anchors, placed in the humeral bone, are attached to sutures which are in turn tied to the tendon.
75406448|NCT05720208|Device|SCiP|Noninvasive Spinal Cord Neuromodulator
75406449|NCT05720052|Drug|MS-553|MS-553 oral tablet BID x 28-days
75406450|NCT05719974|Other|rehabilitation protocol|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.
75551350|NCT02227719|Device|CTI|CTI is the titanium mesh
75551351|NCT02227719|Device|Collagen membrane|
75711914|NCT00834951|Radiation|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
75711915|NCT04013776|Dietary Supplement|Phosphate supplemented diet|Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
75711916|NCT00741702|Other|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP >=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP>=13/80 mm Hg, increase verapamil to 240 mg/d
75711917|NCT00841347|Behavioral|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
75711918|NCT00841347|Behavioral|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
75711919|NCT00936286|Device|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
75711920|NCT00741780|Drug|Placebo|
75711921|NCT00741780|Drug|plerixafor|
75711922|NCT00741780|Drug|granulocyte colony-stimulating factor (G-CSF)|
75711923|NCT00936442|Drug|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
76039353|NCT05678777|Device|Galvanic Skin Response|The probe will be attached to the patient's finger and the Galvanic Skin Response will be measured
76039354|NCT05678621|Drug|trimethoprim-sulfamethoxazole (co-trimoxazole)|Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
75711924|NCT00936442|Other|Educational materials|Reception of educational material on regular basis.
75711925|NCT00744354|Drug|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
75711926|NCT00744354|Drug|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
75711927|NCT00744354|Drug|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
75711928|NCT04043325|Diagnostic Test|Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay|Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.
75711929|NCT00936520|Drug|SAR 1118 0.1%|Daily eye drops (twice daily, ~50 microliter [uL] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
75711930|NCT00936520|Drug|SAR 1118 1.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
75711931|NCT00936520|Drug|SAR 1118 5.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
76039355|NCT05678621|Drug|amoxycillin/clavulanic acid and ciprofloxacin|clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
75406451|NCT05719896|Drug|DT01 tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
75406452|NCT05719896|Drug|Placebo tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
76039356|NCT05678621|Drug|Immunoglobulins|Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
76039357|NCT05338073|Diagnostic Test|Known 3Dx Test|Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
75406453|NCT05719896|Drug|DT01-Placebo tablets|Each subject was given orally 2 DT01 tablets and 1 Placebo tablet, three times per day for 8 weeks
75406454|NCT05719818|Drug|biphosphonates|Initiation of bisphosphonate therapy
75406455|NCT05719818|Procedure|Dental care|Surgical dental care
75406456|NCT05719740|Diagnostic Test|osteocrin|laboratory routine test
75406457|NCT05719662|Other|Weight bearing exercises|Weight bearing exercises
75406458|NCT05719662|Other|Jaffrey's core stability exercises|Jaffrey's core stability exercises
76039358|NCT05334953|Device|ESWT|"Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
76039359|NCT05334953|Device|Phonophoresis|"Group 2 ( n=17) will be given five times a week total 10 sessions of diclofenac phonophoresis + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
76039360|NCT05334953|Device|Ultrasound|"Group 3 (n=17) will be given five times a week total 10 sessions of ultrasound therapy+ home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
75551352|NCT02223377|Drug|Morphine|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
75406459|NCT05719584|Other|hypopressive exercises|patients will receive pelvic floor muscle training with hypopressive exercises at outpatient department. Treatment will continue for 12 weeks 3 days per week. They will receive information about the localization and function of the PFM and transversus abdominis (TrA) muscles. Next, lying in a supine position with flexed knees and hips, they will localize their own pelvic floor with the help of touching their perineum. Then they will be instructed how to contract the PFM correctly, then they will directed to contract PFMs and in the end participants will be taught how to voluntarily contract the PFM simultaneously with diaphragmatic Aspiration(8-10 repetitions daily
75551353|NCT02223377|Drug|Hydromorphone|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
76039361|NCT05334953|Other|Control group|Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises
75711932|NCT02564562|Drug|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + [14C] PF-06463922
75711933|NCT05311566|Combination Product|Camrelizumab plus Concurrent chemoradiotherapy|Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.
75711934|NCT00564070|Behavioral|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
75711935|NCT00564070|Behavioral|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
76039362|NCT05240729|Procedure|Infraclavicular brachial plexus block|Using ultrasound in 3different techniques of infraclavicular brachial plexus block
76039363|NCT05530577|Drug|Semaglutide|Semaglutide (subcutaneous)
75406460|NCT05719584|Other|pelvic floor muscle training|patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
75406461|NCT05719506|Other|normal saline without drug|nebulizer session with normal saline only preoperative
75406462|NCT05719506|Drug|Dexmedetomidine|nebulizer session with dexmedetomidine preoperative
75406463|NCT05719506|Drug|Ketamine|nebulizer session with ketamine preoperative
75406464|NCT05717322|Behavioral|TENS|apply TENS after orthognathic surgery
75406465|NCT05717322|Behavioral|sham TENS|apply non active TENS after orthognathic surgery
75406466|NCT05717010|Device|Near infrared spectroscopy|The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
75406467|NCT05716932|Procedure|Dual focal laser and intravitreal Ranibizumab injection|Direct and perilesional focal laser followed by a single intravitreal 0.5 mg ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) injection
75406468|NCT05716776|Diagnostic Test|Optical coherence tomography (OCT)|Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography
75406469|NCT05716698|Dietary Supplement|Pleurotus citrinopileatus after bio-optics (10 ug group)|The participants took D2 10ug per day for a total of 4 weeks.
75711936|NCT00835029|Drug|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
76039364|NCT05530577|Drug|Sham/placebo|Sham subcutaneous injection
75711937|NCT00835029|Drug|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
75711938|NCT02562768|Drug|LY3154207|Administered orally
75711939|NCT02562768|Drug|Placebo|Administered orally
75871893|NCT02899858|Other|Follow up gait assessment|Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
76039365|NCT04718909|Drug|Regorafenib + sintilimab|"Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w."
75406470|NCT05716698|Dietary Supplement|Pleurotus citrinopileatus after bio-optics (100 ug group)|The participants took D2 100ug per day for a total of 4 weeks.
75406471|NCT05716620|Diagnostic Test|MRI|USG and MRI will be performed on the same day. US will be performed prior to MRI. There will be two rounds of screening 6 months apart using paired US and non-enhanced AMRI.
75406472|NCT05716464|Behavioral|Lifestyle medicine intervention|The lifestyle medicine intervention includes six weekly sessions (i.e., participants will receive the intervention once per week) that are related to the following topics: (a) lifestyle psychoeducation, (b) physical activity, (c) dietary recommendation, (d) stress management, (e) sleep management and (f) motivation and goal-setting techniques. Each topic will be delivered during each face-to-face session and the duration of each session will be around 120 minutes.
75551354|NCT02146508|Procedure|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
75551355|NCT02146508|Device|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
75551356|NCT02139020|Other|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
75551357|NCT02136160|Behavioral|attitude change, behavioral change|
75551358|NCT02136160|Behavioral|prevention program|
75711940|NCT00843609|Device|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
75711941|NCT00744510|Other|Reflexology|10 weekly sessions of 45 minutes each
75711942|NCT00835107|Drug|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
75871894|NCT03492281|Drug|vibegron|single daily oral dose of vibegron 75 mg for 12 weeks
75871895|NCT03492281|Drug|Vibegron placebo|placebo to match vibegron (experimental drug)
75551359|NCT02094261|Drug|AZD9291|Once daily tablet 80 mg
75551360|NCT02077192|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
75871896|NCT03492281|Drug|Tolterodine Tartrate ER|single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
75871897|NCT03492281|Drug|Tolterodine placebo|placebo to match tolterodine (active comparator)
75871898|NCT02331784|Behavioral|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
75871899|NCT02331784|Behavioral|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
75551361|NCT02074553|Drug|Ro542-4802/F03 (Reference)|Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.
75551362|NCT02074553|Drug|Ro542-4802/F07 (Test)|Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.
75551363|NCT02074553|Drug|Ro542-4802/F08 (Test)|Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
75551364|NCT02074553|Drug|Ro542-4802/F14 (Test)|Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
75711943|NCT00835107|Drug|placebo|placebo comparator, oral capsules, BID, for one month
75871900|NCT02327494|Drug|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
75711944|NCT02562846|Other|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
76039366|NCT04718909|Drug|Regorafenib|160 mg p.o. qd for 3 weeks of every 4 week cycle.
76039367|NCT05216549|Other|Water-based exercise|8 weeks x 2 times per week for 45 min
75871901|NCT02336152|Device|Anaesthesia, Teles Pro, Body suit|
76039368|NCT05216549|Other|Land-based exercise|8 weeks x 2 times per week for 45 min
76039369|NCT05183399|Device|GORE® VIABAHN® Endoprosthesis|
76039370|NCT05379881|Behavioral|Common Elements Toolbox (COMET)|COMET is an unguided single-session intervention (SSI) combining elements of cognitive-behavioral therapy (CBT) and positive psychology.
76039371|NCT04315337|Behavioral|Virtual Kitchen Training|VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
75406473|NCT05716464|Behavioral|Cognitive-behavioral therapy for depression (CBT-D)|The group-based CBT-D therapy includes six weekly sessions (i.e., participants will attend one 120-minute, face-to-face group therapy per week, and will be asked to practice taught-skills every day, for 42 days) that are related to the following topics: (a) psychoeducation, (b) cognitive restructuring, (c) behavioral activation, (d) self-care and relapse prevention.
75406474|NCT05716308|Behavioral|A continuous nursing intervention group was established.|Intervention group: Continuous nursing intervention was performed on the basis of the control group: ①A continuous nursing intervention group was established. The group members included chief physician, attending physician, head nurse, specialist nurse and nutritionist. ②The establishment of patient records, patients admitted to hospital by the primary nurse to record the basic situation of patients, including name, age, history of diabetes, DR staging, vision and blood glucose before treatment and other information. ③Personalized nursing intervention was given during hospitalization. Systematic health education was carried out for patients on admission. Targeted psychological counseling was given to some patients. ④After discharge to give continuous care, organize patients to join the WeChat group, group to share knowledge of DR-related diseases, to understand the patient 's medication, diet, vision, the patient 's questions and problems to guide and improve.
75406475|NCT05716230|Other|bowel function score questionnaire survey|Bowel function score(BFS, total 20 points) was approved by Rintala in 1995, and patients with a score ≥ 17 were considered to have normal bowel habits. 7 items were in BFS, including the ability to hold back defecation, feeling/reporting the urge to defecate, frequency of defecation, soiling, accidents, constipation. In December 2022, BFS questionnaire surveys were conducted on children with ARM who underwent surgical repair between January 2017 and December 2019 at Children's Hospital of Nanjing Medical University.
75406476|NCT05716152|Diagnostic Test|Morning blood sample and skin punch biopsy of 4 mm diameter.|"Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody"
75406477|NCT05716074|Other|Supervised exercise|The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.
75406478|NCT05716074|Other|Home exercise|The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.
75406479|NCT05715840|Drug|SG001 injection|360 mg，Q3W，IV infusion
75406480|NCT05715840|Drug|Paclitaxel|175 mg/m^2，Q3W，IV infusion
75711945|NCT00843765|Other|acupuncture, massage and basic TCM treatment|"During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.~After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes."
75871902|NCT02331862|Drug|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
76039372|NCT05160155|Procedure|Serratus Anterior Plane Block|Serratus anterior plane block will be performed unilaterally, under US guidance.
76039373|NCT05160155|Procedure|Intercostal Block|Intercostal Block will be performed unilaterally, under US guidance.
76039374|NCT02627677|Drug|Ponatinib 30 mg QD|Ponatinib 30 mg, taken orally once daily.
76039375|NCT02627677|Drug|Ponatinib 15 mg QD|Ponatinib 15 mg, taken orally once daily.
76039376|NCT02627677|Drug|Nilotinib 400 mg BID|Nilotinib 400 mg, taken orally twice daily.
76039377|NCT05660603|Other|control|patients will receive standard general anesthesia
76039378|NCT05660603|Procedure|LSP|patients will receive standard general anesthesia followed by ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.
76039379|NCT05660603|Procedure|CP|patients will receive standard general anesthesia followed by ultrasound-guided circum-psoas blocks with 40 ml of bupivacaine 0.25%.
76039380|NCT05660603|Device|Ultrasound|ultrasound
76039381|NCT03059875|Behavioral|Medical consultation for a Standardized Geriatric Evaluation|
76039382|NCT05677685|Device|VISUPRIME|twice daily
76039383|NCT05677685|Device|Placebo|twice daily
76039384|NCT04964479|Drug|TQB2450 injection|1200mg injection once every 3 week
75406481|NCT05715840|Drug|Cisplatin|50 mg/m^2，Q3W，IV infusion
75406482|NCT05715840|Drug|Carboplatin|AUC=5，Q3W，IV infusion
75406483|NCT05715840|Drug|Bevacizumab injection|15 mg/kg，Q3W，IV infusion
75406484|NCT05715840|Drug|SG001 placebo|Q3W，IV infusion
75406485|NCT05715762|Behavioral|prone postion|ventilation at prone positioning
75406486|NCT05715762|Drug|NO inhalation|NO inhalation at 20 ppm
75406487|NCT05715294|Other|Music Application|A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music Research and Promotion Society (TUMATA) was used. In the music application, the selecting instrumental music (ussak maqam which is Turkish Music Maqam) was used. The prepared Music CD will be played on the phones of patients with android processor phones. Patients will be told that they should listen to the music lying down and in a comfortable position, and that they should not use headphones while listening to music. Before going to bed, the patients will be listened to music composed in Ussak maqam for 50 minutes every day for 7 days.
75406488|NCT05713734|Diagnostic Test|Thrombin generation|Measurement of thrombin generation by ST Genesia
75406489|NCT05713734|Diagnostic Test|Fibrinolysis|Measurement of fibrinolysis by Lysis Timer
75406490|NCT05713734|Diagnostic Test|Fibrin clot structure|Measurement of fibrin polymerisation and permeability
75406491|NCT05713734|Diagnostic Test|Coated platelets|Measurement of coated platelets by flow cytometry
75406492|NCT05713656|Other|Physiotherapy care|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
75406493|NCT05713344|Other|Clinical history|Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
75406494|NCT05713344|Other|Clinical examination|Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
75406495|NCT05713344|Other|Evaluation of quality of life|Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
75406496|NCT05713344|Other|Evaluation of mental state|Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
75871903|NCT02327182|Drug|MT-4666|
75406497|NCT05713344|Diagnostic Test|Pancreatic quantitative sensory testing|Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
75406498|NCT05698758|Drug|Dextrometropine and 0.9% sodium chloride solution|Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
75406499|NCT05696184|Diagnostic Test|Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy|"Combined manometric/impedance/pH recording: we will use combined solid-state high-resolution manometry and impedance catheter with 36 circumferential pressure sensors, spaced 1 cm apart, 18 impedance sensor couplets spaced 2 cm apart, 3 pH sensors spaced 7 and 10 cm respectively. The catheter will be introduced trans-nasally.~Concurrent video-pharyngo-laryngoscopy: to monitor concurrently the pharynx and larynx for entry of simulated refluxate we will use a laryngo-pharyngo-scope passed through the other nostril and positioned within the pharynx such that the UES inlet, vocal cords and pyriform sinuses are visualized. The laryngo-pharyngo-scope images will be synchronized with manometric/impedance/pH recordings by importing and superimposing the endoscopic images onto high resolution manometric recordings. A specially designed timer will be superimposed on the video images for durational analyses of endoscopic images."
75551365|NCT02034617|Behavioral|LiMoNid|One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
75551366|NCT01751360|Drug|SYR-472|
75551367|NCT01697527|Biological|aldesleukin|Given SC
75551368|NCT01697527|Drug|fludarabine phosphate|Given IV
75551369|NCT01697527|Drug|cyclophosphamide|Given IV
76039385|NCT04964479|Drug|Anlotinib Hydrochloride Capsules|12mg capsule once daily
76039386|NCT04964479|Drug|Pembrolizumab injection|200mg injection once every 3 week
76039387|NCT04964479|Drug|Placebo|Placebo capsule once daily
76039388|NCT04964401|Procedure|Thoracic paravertebral block vs Erector spinae plane block|Thoracic paravertebral block and erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
75551370|NCT01697527|Other|laboratory biomarker analysis|Correlative studies
75551371|NCT01697527|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
75711946|NCT00843765|Other|rehabilitation and WM basic treatment|"there two steps:~during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education~After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet"
75406500|NCT05696184|Diagnostic Test|Slow and rapid intra-esophageal infusion|A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.
75406501|NCT05661864|Behavioral|Multi-Tiered Systems of Support for Teacher Training|In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
75406502|NCT05642520|Procedure|Oval section abutment of 2.9 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
75551372|NCT01697527|Biological|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
75551373|NCT01697527|Radiation|fludeoxyglucose F 18|Undergo PET scan using [18F] FDG tracer
75551374|NCT01697527|Procedure|positron emission tomography|Undergo fludeoxyglucose F18 PET
75551375|NCT01664598|Drug|Tocilizumab|8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
75551376|NCT01653678|Dietary Supplement|Vitamin D-3 (cholecalciferol), 2000 IU|
75711947|NCT00843921|Drug|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
75711948|NCT00690612|Drug|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
75711949|NCT02546505|Other|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
75711950|NCT02546505|Other|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
75711951|NCT00841503|Other|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
75711952|NCT00742014|Drug|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
75711953|NCT00742092|Drug|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
75711954|NCT00742092|Drug|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
76039389|NCT04964245|Device|accelometer|the respiration parameters are measured using an accelometer.
76039390|NCT04964245|Device|thermographic camera|the respiration parameters are measured using an thermographic camera.
76039391|NCT04964245|Device|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
75406503|NCT05642520|Procedure|Circular section abutment of 3.3 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
75406504|NCT05598918|Procedure|early active mobilization|In the active rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for active mobilization group.Then, the patients were asked to passively flex the injured side with their healthy hand and hold it in the flexion position for 3-5 seconds.
75551377|NCT01653678|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
75711955|NCT00841581|Drug|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
76039392|NCT04964245|Device|Mattress Sensor|the respiration parameters are measured using an Mattress pressure
76039393|NCT03059797|Drug|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
76039394|NCT03059797|Drug|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
75551378|NCT01653678|Dietary Supplement|Vitamin D placebo|
75551379|NCT01653678|Drug|Fish oil placebo|
75551380|NCT01632007|Drug|SYR-472|
75551381|NCT01632007|Drug|Alogliptin 25 mg|
75551382|NCT01632007|Drug|Placebo|
75551383|NCT01524926|Drug|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
75551384|NCT01402271|Drug|carboplatin|
75551385|NCT01402271|Drug|paclitaxel|
75551386|NCT01402271|Drug|pazopanib hydrochloride|
75551387|NCT01402271|Other|laboratory biomarker analysis|
75551388|NCT01402271|Other|pharmacological study|
75551389|NCT01387295|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
75551390|NCT01288378|Drug|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
75551391|NCT01280682|Drug|rituximab|anti-CD20 monoclonal antibody 125mg/m^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
75711956|NCT00742248|Drug|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
75711957|NCT00742248|Drug|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
76039395|NCT02501811|Biological|Mesenchymal Stem Cells (MSC)|15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
76039396|NCT02501811|Biological|c-kit+ cells|15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
76039397|NCT02501811|Biological|Placebo (Plasmalyte A)|15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
75406505|NCT05598918|Procedure|early passive mobilization|In the passive rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for passive mobilization group.
75551392|NCT01209936|Device|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
75551393|NCT01129505|Behavioral|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|"Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.~Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.~Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies."
75551394|NCT01072825|Other|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
75711958|NCT00742248|Drug|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
75711959|NCT04249167|Drug|Atezolizumab|Given IV
75711960|NCT04249167|Procedure|Cryosurgery|Undergo cryoablation of the primary tumor
75711961|NCT04249167|Drug|Nab-paclitaxel|Given IV
75711962|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
75711963|NCT00621153|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
75711964|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
75711965|NCT02546427|Radiation|Helical TomoTherapy (HT)|
76039398|NCT04432129|Behavioral|IBBIS II|"The IBBIS-II service consists of:~Mental health assessment.~Planned integrated service. The participant has the same employment specialists and care manager throughout the intervention. A joint plan is made with shared decisions between the participant, the employment specialist and the care manager. There is a focus on disclosure (openness about illness) and involvement of relatives and significant others.~Vocational rehabilitation. Focus on return to work with ongoing assessment of job goals, competencies and need of support. Participants receive help in contacting existing employers (employed) and potential employers (unemployed). Unemployed participants are offered an individualized job search effort. The focus is on competitive jobs within the community.~Treatment consists of stepped care with structured treatment guidelines.~When the participant has obtained work the team continues to offer support."
76039399|NCT04432129|Behavioral|Service as Usual|Service as usual consists of standard mental health care and vocational rehabilitation
76039400|NCT04964011|Other|Board game intervention|In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
76039401|NCT02585999|Device|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
76039402|NCT04963621|Behavioral|Child-Adolescent Emotion and Stress Intervention Program|Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
76039403|NCT05696951|Other|Transamine 200mg iv|In the intervention group, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes at the end of the surgery. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) SF. The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
76039404|NCT01444495|Radiation|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
76039405|NCT01444495|Procedure|Surgery|Total mesorectal excision of rectal cancer
75711966|NCT02546427|Radiation|CyberKnife SBRT|
75711967|NCT02546427|Radiation|Permanent Prostate Implant (PPI)|
75711968|NCT02546427|Radiation|HDR brachytherapy|
75406506|NCT05582226|Procedure|ACL reconstruction|"Orthopedic surgical operation in which a ruptured anterior cruciate ligament is repaired and reattached to the muscle connection points with a graft, a fashioned ligament that is meant to serve as a replacement for the ruptured muscle tissue."
76039406|NCT01439269|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
75711969|NCT00747084|Procedure|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
75711970|NCT00835419|Drug|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
75711971|NCT00747162|Device|Measure of muscle oxygenation|The investigators will use an INVOS oxymeter for muscle oxygenation measure.
75711972|NCT00747162|Device|Skin pigmentation determination|The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
75711973|NCT00574119|Drug|spironolactone|spironolactone 50 mg daily for 6 months
75711974|NCT00841737|Other|Psychoeducational group|The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
76039407|NCT02582255|Biological|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
75711975|NCT00841737|Other|Control Group|In the control group the depression is treated as usual with the conventional treatment.
75711976|NCT00705614|Biological|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
75711977|NCT00844155|Drug|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
76039408|NCT04973761|Other|Zirconium crowns|Prefabricated pirmary anteroir teeth zirconium crowns
76039409|NCT04973761|Other|Strip composite crowns|Strip composite crowns
76039410|NCT04973371|Diagnostic Test|Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test|Those who screen positive for TB using the standard 4-question screener will be offered a GeneXpert® [Cepheid, Sunnyvale, CA] MTB/RIF test in their home with referral for clinic-based TB treatment initiation for those who receive a positive MTB/RIF test result.
76039411|NCT03061435|Procedure|Screening anal Pap smear - No high-resolution anoscopy|75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy
75711978|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
75711979|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
75711980|NCT00620763|Other|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
75711981|NCT00620763|Other|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
75406507|NCT05582226|Procedure|Mesenchymal stem cell implantation|Stem cells are to be extracted from tissue at the stump of the ACL attachment point and inserted on the graft in the hopes of improving healing response
75406508|NCT05578560|Procedure|Prehabituation|chemical labyrinthectomy with intratympanically installed gentamicin
75406509|NCT05578560|Procedure|3D optokinetic stimulation in virtual reality space|3D optokinetic stimulation via virtual reality goggles with the software designed by Pro-Zeta comp.
75406510|NCT05578560|Procedure|Vestibular training|vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.
75406511|NCT05557812|Drug|non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies|non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
75551395|NCT01072825|Biological|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
75551396|NCT01072825|Other|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
76039412|NCT03061435|Procedure|Screening anal Pap smear - High-resolution anoscopy|25% of patients with negative cytology on their anal Pap smear will receive high-resolution anoscopy. All patients with positive (abnormal) cytology on their anal Pap smear will receive high-resolution anoscopy.
75406512|NCT05557812|Drug|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
75551397|NCT01072825|Other|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
75406513|NCT05549466|Drug|Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W."
75406514|NCT05549466|Drug|Apatinib, Camrelizumab|Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
75551398|NCT01072825|Other|Bone evaluation|PQCT scanner, BMD assessment
75871904|NCT02327026|Procedure|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
75406515|NCT05549466|Drug|Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W."
75406516|NCT05549466|Drug|Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.
75551399|NCT01050218|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
75551400|NCT00679029|Drug|doxorubicin hydrochloride|Given IV
76039413|NCT04432363|Device|Transcranial direct current stimulation|Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).
75406517|NCT05544318|Other|Diatary advices|Advice regarding energy, protein and nutrient intake during cancer treatment
75551401|NCT00679029|Drug|cyclophosphamide|Given IV
75551402|NCT00679029|Biological|bevacizumab|Given IV
75551403|NCT00679029|Drug|paclitaxel|Given IV
75551404|NCT00679029|Drug|gemcitabine hydrochloride|Given IV
75551405|NCT00679029|Other|laboratory biomarker analysis|Correlative studies
75551406|NCT00679029|Biological|pegfilgrastim|Given subcutaneously
75551407|NCT00548730|Procedure|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
75551408|NCT00519116|Drug|Rapamune® (Sirolimus)|
75551409|NCT00519116|Drug|Tacrolimus|
75551410|NCT00519116|Drug|Perioperative Corticosteroids|The corticosteroids use was left up to the investigators decision.
75551411|NCT00518375|Drug|Rapamune® (Sirolimus)|
75551412|NCT00518375|Drug|Neoral® (Cyclosporine)|
75551413|NCT00518375|Drug|Corticosteroids|Left up to local practice but steroids are typically used perioperatively
75551414|NCT00338689|Dietary Supplement|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
75406518|NCT05540652|Behavioral|Mindfulness-Based Queer Resilience (MBQR)|"Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community."
75406519|NCT05520450|Behavioral|Telematic support group|The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
75406520|NCT05519436|Other|Assessment|"Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System."
75406521|NCT05517252|Other|Tele - Yoga|Telehealth interventions with Yoga are called Tele-yoga. Tele-Yoga aims to provide Yoga support to patients at low cost with the same quality and safety as face-to-face
75551415|NCT00195429|Drug|Tacrolimus|
75551416|NCT00195429|Drug|Sirolimus|
75551417|NCT00195429|Drug|prednisone|
75551418|NCT00177268|Other|Blood draw, skin biopsy or urine collection|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
75551419|NCT00349284|Drug|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
75551420|NCT00316160|Drug|Bupropion Hydrochloride Extended-release|
75551421|NCT00316160|Drug|Extended-release Venlafaxine|
75551422|NCT00349323|Behavioral|Community directed treatment|
75551423|NCT02959931|Other|High Potassium Meal|Breakfast meal that provides ~2400 mg of dietary potassium. Meals are isocaloric.
75551424|NCT02959931|Other|Low Potassium Meal|Breakfast meal that provides ~540 mg of potassium. Meals are isocaloric.
75551425|NCT00349362|Drug|Testosterone|Sustanon- 200mg intramuscular testosterone
75551426|NCT00349362|Drug|0.9% saline|Saline intramuscular injection every two weeks
75711982|NCT00844233|Device|Irinotecan Bead|Irinotecan eluting bead
75551427|NCT00316238|Drug|olanzapine-RAIM|
75551428|NCT00316238|Drug|placebo|
75551429|NCT00349401|Drug|ketorolac|
75551430|NCT00349401|Drug|morphine|
75551431|NCT00316316|Behavioral|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
75711983|NCT00841893|Dietary Supplement|Mustard (dijon)|The specific spice added to a brunch meal
75711984|NCT00841893|Dietary Supplement|Placebo|Placebo added to a brunch meal
75711985|NCT05245682|Drug|Tolinapant|Given PO
75711986|NCT05245682|Radiation|Radiation Therapy|Undergo radiation therapy
75711987|NCT00844311|Drug|rFSH|150 iu/day of rFSH
75711988|NCT00844311|Drug|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
75711989|NCT00844311|Drug|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
75711990|NCT00844311|Drug|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
75711991|NCT02547597|Drug|Carvedilol|
75711992|NCT02547597|Drug|Atenolol|
75551432|NCT00316316|Behavioral|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
75551433|NCT00349440|Drug|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
75551434|NCT00316394|Device|Preventive Care Checklist Form|
75711993|NCT00844389|Device|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
75551435|NCT00349479|Behavioral|Barrier assessment / interactive educational intervention|"Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education."
75551436|NCT00316433|Drug|Irinotecan (CPT-11)|
75711994|NCT00844389|Device|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
75711995|NCT02567474|Behavioral|5 A model|self management program based on 5A model
75711996|NCT00835887|Dietary Supplement|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
75711997|NCT00738218|Other|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
76039414|NCT02500719|Device|Computational Model - Real-time Support Vector Machine|A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
76039415|NCT04963855|Drug|GT300|SIngle oral dose
76039416|NCT04963855|Drug|Microcrystalline cellulose|placebo
75406522|NCT05517252|Other|Thoracic Expansion Exercise|Thoracic expansion exercises are deep breathing exercises that focus on inspiration and help to loosen secretions on the lungs. Inspiration is active and usually combined with a three-second, end-inspiratory hold before a passive, relaxed and unforced expiration.
75711998|NCT00842049|Device|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
75406523|NCT05508360|Device|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
75711999|NCT00842049|Other|No lumbar drain|No lumbar drain
75712000|NCT05220878|Biological|GNR-069|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
76039417|NCT03061357|Behavioral|Activity tracker|Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
76039418|NCT05695235|Device|CGM|Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.
76039419|NCT05695235|Device|Oura ring|Wearable sleep tracking device
75406524|NCT05505162|Drug|Zibotentan|Participants will receive two capsules of Zibotentan orally QD from day 6-19.
75406525|NCT05505162|Drug|EE/LNG|Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
75551437|NCT00316433|Drug|Oxaliplatin (Eloxatin)|
75551438|NCT00349518|Drug|Dasatinib|
75551439|NCT00316472|Drug|Niacinamide|
75551440|NCT00316511|Drug|Aroplatin|
75551441|NCT00349557|Drug|bevacizumab, bicalutamide and goserelin|
75551442|NCT00349557|Procedure|intensity modulated radiation therapy (IMRT)|
75712001|NCT05220878|Biological|Nplate|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
75712002|NCT00844467|Biological|serotypes and resistance|screening patients with invasive pneumococci
75712003|NCT00842127|Drug|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
75712004|NCT04062500|Other|Mortality and Rehospitalization rate|Mortality and Re-hospitalization of acute decompensated heart failure
75712005|NCT00835965|Drug|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
75712006|NCT00835965|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
75712007|NCT00835965|Drug|Placebo Dexamethasone|
75712008|NCT02567786|Procedure|Surgery with CPB|
75406526|NCT05505084|Procedure|Tooth extraction and ridge preservation using different barrier mermbranes|The hopeless and unrestorable teeth are planned for extraction and implant placement.
75551443|NCT00316550|Drug|AV608|
75551444|NCT00349596|Drug|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
75551445|NCT00316628|Biological|influenza vaccine|
75551446|NCT00349635|Drug|Metformin and Metformin + Fenofibrate|
75871905|NCT02327026|Procedure|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
75551447|NCT00316745|Drug|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
75551448|NCT00316745|Drug|TS-1|S-1 Day1~14, everyday P.O.(Day 15~28 rest)
75551449|NCT00316745|Drug|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
75551450|NCT00316745|Drug|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
75551451|NCT00316745|Drug|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1~3 (48 hours) of each 28 day cycle.
75551452|NCT00349674|Drug|Azathioprine: 2 mg/kg/day|
75551453|NCT00349674|Drug|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
75551454|NCT00316784|Drug|IDEA-033 (and rescue medication)|
75551455|NCT00344916|Drug|Ng-monomethyl-L-arginine (drug)|
75551456|NCT00316823|Genetic|gene expression analysis|
75551457|NCT00316823|Genetic|polymerase chain reaction|
75551458|NCT00316823|Genetic|reverse transcriptase-polymerase chain reaction|
75551459|NCT00316823|Other|diagnostic laboratory biomarker analysis|
75551460|NCT00316823|Other|immunohistochemistry staining method|
75551461|NCT00316823|Procedure|needle biopsy|
75551462|NCT00344955|Drug|HMG-CoA reductase inhibition (atorvastatin)|
75871906|NCT02327104|Behavioral|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
75406527|NCT05504304|Procedure|open reduction and internal fixation plus primary subtalar arthrodesis|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
75406528|NCT05504304|Procedure|conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
75406529|NCT05473572|Behavioral|Fluency shaping exercises|Training for prolonged speech, easy onset, light contact and abdominal breathing moving from the level of single words till using short sentences describing pictures
75406530|NCT05436678|Drug|PrimeC 748 mg|PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
75406531|NCT05436678|Drug|Ciprofloxacin 750 MG|Ciprofloxacin
75406532|NCT05436678|Drug|Celecoxib 200mg|Celecoxib
75406533|NCT05426772|Other|exercise and kinesiotaping|"Exercise: Aerobic exercise will be performed on the treadmill for 20 minutes with a maximum heart rate of 55%-65% and a perceived exertion of less than 3. The Moxy muscle oxygen monitor will take measurements over the quadriceps femoris muscle at this time.~Kinesiotaping: After 3 days, the same participants will be called for kinesiotaping application. The application will be applied to the quadriceps femoris muscle with the facilitation technique by a physiotherapist who has a kinesio taping training certificate."
75406534|NCT05425134|Diagnostic Test|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting Occult Nodal Metastasis of Clinical N0 Non-small Cell Lung Cancer
75871907|NCT02327104|Other|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
75871908|NCT03070782|Drug|ISIS 681257|ISIS 681257 solution for SC injection.
75406535|NCT05405010|Other|Stair climbing and descending for 1 minute|Stair climbing and descending for 1 minute
75406536|NCT05405010|Other|Stair climbing and descending for 3 minutes|Stair climbing and descending for 3 minutes
75406537|NCT05405010|Other|Seated control|Seated control
75871909|NCT03070782|Drug|Placebo|Sterile normal saline (0.9% NaCl)
75871910|NCT02335840|Other|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
75406538|NCT05403060|Behavioral|ALIADA: Alimentación, Adolescencia y Ambiente|The objective of the educational nutritional intervention is to promote in adolescents an increase in their consumption of vegetables and fruits and a decrease in their consumption of ultra-processed foods, through the application of the TSC constructs, with the use of education by pairs as the main strategy (peer leaders). It lasts two months, includes three exclusive sessions for peer leaders and five sessions for all participants, where the leaders, together with the researchers, will lead the activities of the sessions, as well as a general event for all high school students. Intervention activities include: electronic presentations, videos, food preparation and label reading workshops, individual and team reflection activities, goal setting and monitoring, board games, contests, among others. In addition, each participant is given a workbook, which contains key messages and activities for each educational session.
75406539|NCT05352282|Procedure|Serratus Anterior Plane Block|SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.
75406540|NCT05352282|Procedure|Lumbar Intrathecal Fentanyl Injection|Patients will receive 25 microgram intracthecal fentanyl immediately preoperative.
75406541|NCT05343624|Device|continuous glucose monitoring|Use of continuous glucose monitoring in inpatient and ICU settings
75406542|NCT05333328|Drug|Ovarian function suppression with endocrine treatments|"Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~Either goserelin acetate or leuprorelin Acetate is allowed.~These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~Chemotherapy is omitted in these patients."
75406543|NCT05322330|Drug|Selinexor|40-60mg QW,w-3～d-3,PO
75551463|NCT00316901|Procedure|computed tomography|
75551464|NCT00316901|Procedure|positron emission tomography|
75551465|NCT00316901|Radiation|fludeoxyglucose F 18|
75551466|NCT00316940|Drug|bortezomib|
75551467|NCT00316940|Radiation|samarium Sm 153 lexidronam pentasodium|
75551468|NCT00344994|Drug|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
75551469|NCT00349791|Drug|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
75551470|NCT00349791|Drug|Placebo patch|placebo patch replaced twice a week for two years
75871911|NCT02335840|Other|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
75871912|NCT02335840|Other|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
75871913|NCT02335840|Other|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
75406544|NCT05322330|Drug|Flu|25-30 mg/m2，d-5 ～d-3，qd，ivgtt
75406545|NCT05322330|Drug|CTX|250-500 mg/m2，d-5 ～d-3，qd，ivgtt
75551471|NCT00316979|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
75551472|NCT00317018|Behavioral|Evidence-Based Quality Improvement|The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
75551473|NCT00345072|Device|Web-based decision aid system|
75551474|NCT00317057|Procedure|Patient education and disease management|
75551475|NCT00317096|Procedure|FCM|Active comparator: Chemotherapy
75551476|NCT00317096|Procedure|R-FCM|experimental: Chemotherapy with additional rituximab
75406546|NCT05322330|Drug|CAR-T|2-5×10^6 CAR-T/kg，ivgtt。
75406547|NCT05319990|Drug|Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)|PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
75406548|NCT05319990|Drug|Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)|Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
75406549|NCT05720754|Drug|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
75406550|NCT05720754|Device|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
75406551|NCT05312892|Drug|Amlodipine|Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
75406552|NCT05312892|Drug|Moxonidine|Moxonidine
75712009|NCT02567786|Other|Fresh Frozen Plasma|
75871914|NCT03756688|Device|RestoreX PTT - 6 months|Penile traction therapy in straight position for all 6 months.
75871915|NCT03756688|Device|RestoreX PTT - 3 months|Penile traction therapy in straight position for first phase (3 months)
75871916|NCT03525119|Biological|TDV|TDV SC injection
75406553|NCT05312892|Drug|Placebo|Placebo
75406554|NCT05311020|Dietary Supplement|Placebo drink|consume 1 bottle per day
75406555|NCT05311020|Dietary Supplement|Pitaya Ovule Extract Drink|consume 1 bottle per day
75406556|NCT05301504|Biological|ChAdOx1 biEBOV|ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
75551477|NCT00317096|Drug|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
75712010|NCT02567786|Other|Plasmalyte|
75712011|NCT00844623|Genetic|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
75712012|NCT05667740|Biological|Gamma-PN3|Inactivated whole-cell pneumococcal vaccine
75871917|NCT03525119|Biological|HAV Vaccine|HAV Vaccine IM injection.
76039420|NCT05695235|Behavioral|Cognitive tasks and questionnaires|Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.
76039421|NCT04973215|Other|no intervention|this is not an intervention study
75871918|NCT03525119|Biological|TDV Placebo|Placebo-matching (normal saline (0.9% NaCl) SC injection.
76039422|NCT05695001|Device|Efferon CT|Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross-linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.
76039423|NCT04963309|Other|endotracheal tube extubation in the operating room|endotracheal tube extubation in the operating room
76039424|NCT05019209|Drug|House Dust Mite Allergen|D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
76039425|NCT05019209|Other|Allergen-free air|No allergen added to room ventilation of allergen challenge chamber
76039426|NCT04963387|Other|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
76039427|NCT04963387|Other|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
76039428|NCT05694299|Device|Nasal bridle|Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)
76039429|NCT05694299|Other|Nasal patch|Regular adhesive tape for medical use.
76039430|NCT05674253|Drug|Dexmedetomidine + Hydrocortisone|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
76039431|NCT04954417|Diagnostic Test|Radiological scanning|The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.
75871919|NCT03525119|Biological|HAV Vaccine Placebo|Placebo-matching (normal saline (0.9% NaCl) IM injection.
76039432|NCT04954417|Other|Deep learning|We will use a conditional generation adversarial network-based image mapping technique to train the mapping model between MSCT images and Micro-CT images, find the correspondence between the image information contained in each of MSCT and Micro-CT, and finally obtain high-resolution micro-CT-like images.
75406557|NCT05286684|Procedure|Consultation|History of the disease, anatomopathological and molecular biological data concerning the initial tumor; Collection of treatments received and/or in progress by the patient for her meningeal tumor (chemotherapy, targeted therapy, radiotherapy, surgery, corticosteroids, antiepileptics); Evaluation of the general condition and neurological status.
75406558|NCT05286684|Procedure|Cerebral and medullary MRI, lumbar puncture, CSF sampling|diagnosis of leptomeningeal involvement
75406559|NCT05286684|Biological|biological test|5 ml of additional CSF after diagnostic lumbar puncture for proteomic analysis, 50-100 µl of breast aspiration fluid (NAF) for patients with an existing breast tumor, for proteomic analysis 10 ml of blood for proteomic analysis
75406560|NCT05251038|Drug|Sotorasib|Intervention instruction outlined in protocol
75406561|NCT05251038|Drug|Liposomal Irinotecan (nal-IRI)|Intervention instruction outlined in protocol
76039433|NCT04954417|Procedure|Bio-mechanical testing|we will cut a standardized cubic sample from the vertebral cancellous bone , obtain the bio-mechanical performance index of this cancellous bone sample by mechanical experiments, and analyze the correlation between bone structure of Micro-CT-like images and bio-mechanical index.
75406562|NCT05251038|Drug|5 Fluorouracil (5FU)|Per standard of care
75406563|NCT05251038|Drug|Leucovorin (LV)|Per standard of care
75406564|NCT05251038|Drug|Gemcitabine (GEM)|Per standard of care
75406565|NCT05251038|Drug|Nab paclitaxel|Per standard of care
75406566|NCT05244096|Other|No intervention|Observational study
75406567|NCT05220306|Device|Monitoring of vital signs|The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
75406568|NCT05219292|Other|Active music therapy|"Active music therapy is not a musical learning process. The restrictive character of classical respiratory rehabilitation will be alleviated by the playful aspect and the pleasure generated by the sessions, which will facilitate the commitment of the patients in their post-transplant respiratory rehabilitation.~The recorder was chosen among other wind instruments for several reasons:~Its use is simple,~It acts as an oscillating exhalation resistance device that generates a positive expiratory pressure (auto-PEP) produced by this wind instrument allows to obtain conditions similar to the treatment performed by a flutter (classical respiratory rehabilitation), a pressure on the expiratory flow with the obtaining of an oscillating effect during the trills, an increase of the respiratory capacities,~The characteristics of the sound it produces (duration, intensity, timbre and frequency) will generate auditory feedback allowing patients to become aware of their breathing patterns."
75406569|NCT05219292|Other|Questionnaires|"We chose the HAD (Hospital Anxiety and Depression Scale) to assess anxiety and depression. This test is a reference test, often used in studies of transplant patients. The results obtained in previous studies allowed us to create our hypotheses.~To measure pain we chose the visual analogue scale (VAS). This reference test is often used in pain studies. It has the advantage of being simple to perform and easy to understand.~Quality of life will be assessed using the SF-12 (Short Form 12 Health Survey Questionary). We consider it to be simple and easy for patients to understand."
75406570|NCT05203692|Drug|DS-7011a|Intravenous or subcutaneous administration, single dose
75406571|NCT05203692|Drug|Placebo|Intravenous or subcutaneous administration, single dose
75406572|NCT05195502|Diagnostic Test|Biopsy|Participants included in the study, will have additional biopsies performed during their colonoscopy
75406573|NCT05184894|Behavioral|AKI in Care Transitions (ACT) program|Multicomponent transitional support bundle that includes consultation from nurse educators before discharge to deliver kidney health education and coordination of appointments post-discharge.
75551478|NCT00317096|Other|observation only|no Intervention after completion of FCM or R-FCM
75712013|NCT05667740|Biological|Prevenar-13|Licensed polysaccharide conjugate pneumococcal vaccine
75871920|NCT04423614|Other|Inspiratory Muscle Training|Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
75551479|NCT00349947|Behavioral|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
75406574|NCT05181072|Behavioral|Enhanced in-person peer-motivation smoking cessation|Tobacco cessation classes will be offered in-person for a total of five sessions delivered weekly for five weeks and will utilize the CEASE Today Tobacco This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
75551480|NCT00317135|Biological|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
75406575|NCT05181072|Behavioral|Virtual peer-motivation smoking cessation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual
75406576|NCT05173428|Behavioral|Smoking Cessation Program Based on Transtheoretic Model|Conducting motivational interviews based on the transtheoretic model according to the stages of change that individuals are in.
75406577|NCT05166018|Diagnostic Test|SuMO Patient|"The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves."
75551481|NCT00317135|Biological|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
76039434|NCT02500641|Drug|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration > 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
75551482|NCT00345111|Procedure|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
75551483|NCT00317174|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
75551484|NCT00349986|Drug|Insuline glargine|
75406578|NCT05151822|Other|Training session with the virtual reality mask|Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).
75551485|NCT00317213|Drug|LIBERTAL- a phospholipid mixture|
75551486|NCT00345150|Drug|Ng-monomethyl-L-arginine (drug)|
75551487|NCT00317252|Drug|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
75712014|NCT05667740|Biological|Pneumovax-23|Licensed polysaccharide pneumococcal vaccine
75871921|NCT04423614|Other|Relaxation Breathing|Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
75871922|NCT05230654|Drug|Fosaprepitant|Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.
76039435|NCT02500641|Drug|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
76039436|NCT02500641|Drug|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
76039437|NCT02500641|Drug|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
75406579|NCT05151822|Other|Monitoring of the device|In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.
75712015|NCT05667740|Drug|Placebo|Saline
75871923|NCT05230654|Drug|Placebo(normal saline)|Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO.
76039438|NCT02500641|Drug|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
76039439|NCT05662553|Procedure|ENB guided MWA combined with VATS|"ENB guide MWA combine ENB, microwave ablation and 3D reconstruction technology, and guide the probe in the airway to the target lesion for ablation therapy, which is safe and effective. For patients with synchronous bilateral multiple primary pulmonary nodules, ENB guide MWA combined with VATS treatment can not only avoid the risk of bilateral surgery, but also complete the one-stop treatment, which is a new treatment mode."
75406580|NCT05151822|Other|Acceptability of the device|After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))
75406581|NCT05151822|Other|Patient state of anxiety|Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
75406582|NCT05151666|Other|Sunny Health & Fitness Magnetic Mini Exercise Pedal Cycle - SF-B020026 Gray|The intervention will be that the patient cycles in a sitting position within the first 2 hours of hemodialysis treatment for 15-60 minutes/as tolerated, either intermittent/continuous duration. - Graded duration will increase every 2 weeks. This will be supervised by a dialysis nurse as per the schedule of study assessments.
75406583|NCT05132478|Other|Emotionally Supportive Video|The video is approximately 6 1/2 minutes in length and portrays an emotionally supportive conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy with the addition of emotionally supportive statements and gestures.
75406584|NCT05132478|Other|Standard Video|The video is approximately 5 minutes in length and portrays a standard conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy.
75712016|NCT00842205|Drug|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
75712017|NCT00842205|Drug|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
75871924|NCT05761314|Diagnostic Test|Molecular characterization of solid tumor in RASopathies|NGS analysis on tumor sample
75871925|NCT02039518|Drug|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
76039440|NCT05662553|Procedure|sequential surgery|Bilateral surgery is a traditional treatment, but it will lead to increased intraoperative risk and postoperative complication rate, and more likely to lead to postoperative complications such as decreased quality of life and cardiopulmonary dysfunction.
76039441|NCT04973293|Drug|sintilimab|Sintilimab 200 mg, 4 cycles of treatment before surgery
75712018|NCT00738296|Drug|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
75871926|NCT02039518|Other|observation group|observation group
75871927|NCT02228304|Drug|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
75871928|NCT02228304|Drug|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
75871929|NCT03722381|Drug|Amlodipine Besylate|Pharmacokinetics
76039442|NCT04973293|Drug|bevacizumab|bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
76039443|NCT05657249|Diagnostic Test|Non-contrast focused MRI|non-contrast liver MRI focusing on HCC surveillance in a short scan time.
75551488|NCT04714788|Device|RECAP_MyLife mobile app|"The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention."
75551489|NCT04714788|Other|Usual data collection methods|Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
75551490|NCT00317291|Procedure|Acupuncture/Moxibustion|Acupuncture/Moxibustion: 16 scheduled sessions
75551491|NCT00317291|Other|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
75406585|NCT05117970|Other|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
75551492|NCT00345189|Drug|CNF2024|"CNF2024 capsules administered orally following 2 schedules:~starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment."
75551493|NCT00317330|Drug|Isoniazid|
75551494|NCT00317330|Drug|Pyrazinamide|
75551495|NCT00317330|Drug|Rifampin|
75551496|NCT00350064|Behavioral|Exercise Training|16 weeks of aerobic exercise training at two different intensities
75551497|NCT00317408|Biological|anti-thymocyte globulin|
75406586|NCT05103540|Behavioral|Comprehensive SEM-Based Program|The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
75551498|NCT00317408|Drug|busulfan|
75551499|NCT00317408|Drug|carboplatin|
75551500|NCT00317408|Drug|carmustine|
75551501|NCT00317408|Drug|cyclosporine|
75551502|NCT00317408|Drug|cytarabine|
75551503|NCT00317408|Drug|dexamethasone|
75551504|NCT00317408|Drug|etoposide phosphate|
75551505|NCT00317408|Drug|idarubicin|
75551506|NCT00317408|Drug|ifosfamide|
75551507|NCT00317408|Drug|leucovorin calcium|
75551508|NCT00317408|Drug|lomustine|
75551509|NCT00317408|Drug|melphalan|
75551510|NCT00317408|Drug|methotrexate|
75551511|NCT00317408|Drug|mitoxantrone hydrochloride|
75551512|NCT00317408|Drug|prednisolone|
75551513|NCT00317408|Drug|thiotepa|
75551514|NCT00317408|Drug|vinblastine sulfate|
75551515|NCT00317408|Drug|vindesine|
75551516|NCT00317408|Procedure|allogeneic hematopoietic stem cell transplantation|
75551517|NCT00317408|Procedure|autologous hematopoietic stem cell transplantation|
75551518|NCT00317408|Procedure|peripheral blood stem cell transplantation|
75551519|NCT00317408|Radiation|total-body irradiation|
75551520|NCT00345267|Device|Integrated Care Pathway|
75551521|NCT00317447|Drug|Oral Prednisone|
75551522|NCT00350103|Drug|SPM 929|
75551523|NCT00317525|Device|Spectacle Lenses|
75551524|NCT02959554|Drug|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
75551525|NCT02959554|Drug|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
75551526|NCT02959554|Drug|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
75551527|NCT00345306|Drug|Comparison between two different progesterone administration|
75551528|NCT00317681|Drug|Tacrolimus ointment|
75551529|NCT00350181|Drug|Sirolimus|Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
75551530|NCT00350181|Drug|MMF|Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
75551531|NCT00350181|Drug|BCNU|15 mg/kg, IV
75551532|NCT00350181|Drug|VP-16|60 mg/kg, IV
75871930|NCT04352608|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
75406587|NCT05101044|Behavioral|Acceptance-based Behavioral Therapy (ABBT) Intervention|This acceptance-based behavioral therapy (ABBT) intervention intends to enhance retention in HIV care for people who use substances by targeting stigma. ABBT promotes an accepting stance towards life's challenges and encourages participants to thoughtfully disclose the serostatus and/or substance abuse problems as a behavioral step towards challenging stigmatization fears. The central hypothesis is that increased tolerance of stigmatization, facilitated through increased acceptance of HIV status and substance use behaviors, will increase PWH's longitudinal commitment to care.
75406588|NCT05071872|Device|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
75406589|NCT05035602|Other|Physical activity assessment|Physical activity patterns will be obtained from google location history, using an Android phone
75406590|NCT05034978|Other|no intervention|evaluating the performance of a novel point-of-care test
75551533|NCT00350181|Drug|CY|For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
75551534|NCT00350181|Drug|FTBI|1320 cGy delivered in 11 120 cGy fractions over 4 day
75551535|NCT00350181|Drug|BU|BU 1 mg/kg every 6hr x 4 doses, IV
75551536|NCT00317759|Biological|therapeutic autologous lymphocytes|
75551537|NCT00317759|Drug|fludarabine phosphate|
75551538|NCT00317798|Biological|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
75551539|NCT00317798|Drug|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
75551540|NCT00345462|Biological|Trivalent virosomal influenza vaccine|
75871931|NCT04352608|Biological|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
75871932|NCT04352608|Biological|Two doses of placebo at the emergency vaccination schedule|Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.
76039444|NCT04972669|Device|Electrical Acupuncture Stimulation|Participants received acupuncture at bilateral Baliao. After skin disinfection, sterile adhesive pads were placed on bilateral Baliao, and acupuncture needles were inserted through the adhesive pads. Following needle insertion, small, equal manipulations of twirling, lifting, and thrusting were performed on all needles to reach de qi. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
76039445|NCT04972669|Device|sham Acupuncture|Participants received sham acupuncture at locations one inch besides bilateral Baliao without needle insertion. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
76039446|NCT05061173|Other|Aerobic exercise training Group|Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 30 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 30 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 30 minutes
75551541|NCT00345501|Drug|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
75551542|NCT00345501|Drug|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
75551543|NCT00317837|Procedure|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
75551544|NCT00317837|Procedure|bipolar hemiarthroplasty|bipolar hemiarthroplasty
75551545|NCT00345657|Drug|Niacin Extended Release/Lovastatin|
75551546|NCT00317876|Drug|cyclophosphamide|
75551547|NCT00317876|Drug|cyclosporine|
75551548|NCT00317876|Drug|methotrexate|
75551549|NCT00317876|Procedure|allogeneic bone marrow transplantation|
75871933|NCT04352608|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.
75406591|NCT05027646|Drug|Sancuso - Part 1|Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
75406592|NCT05027646|Drug|Sancuso - Part 2|Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
75406593|NCT05006976|Other|NSAC health only|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only."
75551550|NCT00317876|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75551551|NCT00317915|Drug|Irbesartan treatment|
75551552|NCT00317954|Drug|Spironolactone|
75551553|NCT00317993|Drug|ezetimibe|
75551554|NCT00317993|Drug|simvastatin|
75551555|NCT00317993|Drug|ezetimibe plus simvastatin|
75551556|NCT00350415|Drug|Mesalamine|"Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks"
75551557|NCT00318032|Drug|multi-factorial intervention|
75551558|NCT00318071|Device|Merci Retriever|"For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography."
76039447|NCT05061173|Other|Resistance Exercise Training Group|"Resistive Exercises includes (a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction.~At Week 1-2, 10 repetitions 1 set, 3 days/week, for 30 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 30 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 30 minutes"
75406594|NCT05006976|Other|NSAC health + MBW|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors."
75406595|NCT04988646|Drug|Acyclovir 200 MG|Administered with 240 mL of water
75406596|NCT04988646|Drug|Acyclovir 400 MG|Administered with 240 mL of water
75406597|NCT04988646|Drug|Zovirax 200 MG Tablet|Administered with 240 mL of water
75406598|NCT04988646|Drug|Zovirax 400 MG Tablet|Administered with 240 mL of water
75406600|NCT05404854|Other|Physical Activity|wearing an accelerometer for 7 days before and after the rehabilitation program
75406601|NCT05404854|Other|sedentarity|wearing an accelerometer for 7 days before and after the rehabilitation program
75551559|NCT00345696|Drug|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
75551560|NCT00345696|Drug|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
75551561|NCT00345696|Drug|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
75712019|NCT00738296|Drug|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
75871934|NCT04352608|Biological|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ
75871935|NCT04352608|Biological|Two doses of placebo at the routine vaccination schedule|Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.
75712020|NCT00738296|Drug|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
76039448|NCT05061173|Other|Combined Exercise Training Group|"Combined Exercise training includes [Aerobic: Treadmill walking + Resistive Training: a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction] Time will be reduced to 15 minutes for both trainings in respective weeks. Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 15 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 15 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 15 minutes~Resistive Exercises At Week 1-2, 10 repetitions 1 set, 3 days/week, for 15 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 15 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 15 minutes"
75712021|NCT00836043|Drug|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
76039449|NCT04962451|Drug|ticagrelor + ASA|On day 1, ticagrelor loading dose (2 tablets, ticagrelor 90mg) was given, followed by ticagrelor 90mg, twice daily Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
76039450|NCT04962451|Drug|Placebo+ASA|Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
76039451|NCT05059925|Other|Structured gym activities|"Planned and structured activities such as Strength training~Dumbbell Exercises (1kg with 2 sets of 10 repetitions)~Sit-ups (2 sets of 10 repetitions)~Stair climbing, (2 sets of 10 stairs up and down)~Squat (2 sets of 10 repetitions) Flexibility training • Tai chi (Peng. Lu, chi, an Tsai, lieh, chou, Kao (Hold each posture for 20 seconds)) • Pilates (Breathing., Shoulder bridge, Leg lifts (Hold each pose for 20 seconds)) • Stretching techniques (Neck stretch, Shoulder stretch, Side stretch Hold each stretch for 20 seconds))."
75406602|NCT05404854|Other|Measurement of explicit motivation|Explicit motivation will be assessed using self-report questionnaires. Explicit attitudes using a 7-point bipolar response scale, participants will be asked to indicate for each of the 4 pairs of positive and negative adjectives used how much they associate them with regular PA and sedentary behaviors, respectively. Perceived behavioral control using a 7-point bipolar response scale, patients will be asked to indicate how well they felt they were able to engage in regular PA, and limit their sedentary behaviors, respectively, based on two items. Intentions using a 7-point bipolar response scale, patients will be asked to indicate how much they intend to adopt regular physical activity, and limit their sedentary behaviors, respectively, according to two items. Fears and beliefs related to physical activity and work will be measured by the FABQ in its French version
75406603|NCT05404854|Other|Measurement of implicit attitudes|Implicit attitudes will be assessed by administering an Implicit Association Test on physical and sedentary activities. Sitting in front of a computer, participants will see a series of words appear in the middle of the screen referring to 4 conceptual categories - located at the top of the screen. Two represent the targeted behaviours (here, physical activity versus sedentary lifestyle) while the remaining two represent attributes (here, positive versus negative adjectives). The adjectives used will be the same as those used to measure explicit attitudes. The instructions given to the participant are to classify the words as quickly as possible, according to the semantic category to which they belong
75406604|NCT04912674|Device|Symphony OCT System|Surgical intervention will be patient specified by treating surgeon.
75406605|NCT04888104|Procedure|Index or revision spine surgery for complex adult spinal deformity|Adult patients receiving minimum 5 level posterior spinal fusion with pedicle screw fixation supplemented at the proximal aspect of the construct with the VersaTie System.
75406606|NCT04876638|Drug|Minocyclin|10mg/kg minocycline up to 700mg for 4 days following aneurysmal subarachnoid hemorrhage
75406607|NCT04854798|Device|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
75406608|NCT04844190|Diagnostic Test|EndoFLIP|During pre-G-POEM upper endoscopy, an EndoLIP catheter will be inserted through the patient's mouth into the stomach and across the pylorus. Once results of EndoFLIP are obtained, the catheter will be removed (5 minutes).
75551562|NCT00318110|Procedure|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
75551563|NCT04708236|Drug|ORTD-1 low dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
75712022|NCT02567396|Other|Laboratory Biomarker Analysis|Correlative studies
75712023|NCT02567396|Other|Pharmacological Study|Correlative studies
75712024|NCT02567396|Drug|Talazoparib|Given PO
75712025|NCT02547831|Other|Observational approach|Patients will be placed under wait and see approach without any specific treatment
75712026|NCT00738452|Other|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
75712027|NCT00738452|Other|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
75712028|NCT00738452|Procedure|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
75551564|NCT04708236|Drug|ORTD-1 mid dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
75551565|NCT04708236|Drug|ORTD-1 high dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
75406609|NCT04844190|Diagnostic Test|Antroduodenal Manometry|Following removal the EndoFLIP catheter, a manometry catheter will then be placed through the nose and advanced across the pylorus. Once catheter positioning is confirmed on endoscopy, the endoscope will be withdrawn. The manometry catheter will be taped to the nose and sedation stopped. The patient will be brought to the recovery area where they will wake-up with the catheter in place. In a private recovery room, the patient will have the catheter in place (no positioning or movement restrictions). When pyloric spasms are documented (0.5-4 hours), they will be given a standard small meal (water, toast/bread). Once motility is assessed with eating, the manometry catheter will be removed.
75551566|NCT04708236|Other|Vehicle control|Vehicle Control will be administered intravenously once daily for 5 consecutive days.
75551567|NCT00318188|Procedure|standardized reeducation and readaptation program|
75551568|NCT00350454|Device|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
75551569|NCT00350454|Device|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
75551570|NCT00350454|Device|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
76039452|NCT05059925|Other|Traditional aerobic activities|"Activities performed such as~Treadmill Time: 10 minutes Intensity: 60 to 80% of target heart rate~Cycle ergometer Time: 10 minutes Intensity: 60 to 80% of target heart rate~Elliptical exercises Time: 10 minutes Intensity: 60 to 80% of target heart rate"
76039453|NCT04962295|Other|No intervention|No intervention
76039454|NCT05010083|Behavioral|diet and lifestyle program|See description of main arm.
75551571|NCT00318227|Procedure|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
75551572|NCT00318266|Device|Nuclear Matrix Protein 22 Urine sample kit|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
75551573|NCT00345735|Drug|Fentanyl|
75551574|NCT00345774|Drug|PRX-08066|
75551575|NCT00318344|Drug|Atuna Racemosa|
75551576|NCT02959749|Drug|Osimertinib|80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
75551577|NCT02959749|Drug|docetaxel, bevacizumab|Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
75551578|NCT00318383|Biological|NicVAX conjugate vaccine|200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
75551579|NCT00318383|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
75551580|NCT00350571|Behavioral|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
75551581|NCT00350571|Behavioral|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
75551582|NCT00350571|Behavioral|standard care follow up|routine counselor phone calls and letters
75551583|NCT00318422|Drug|liraglutide|
75551584|NCT00318422|Drug|rosiglitazone|
75551585|NCT00318422|Drug|glimepiride|
75406610|NCT04827810|Drug|Gamitrinib|This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
75551586|NCT00345813|Dietary Supplement|soy isoflavones|Given orally
75551587|NCT00345813|Dietary Supplement|soy protein isolate|Given orally
75551588|NCT00345813|Other|placebo|Given orally
75551589|NCT00350610|Other|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
75712029|NCT00738452|Procedure|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
75712030|NCT00738452|Radiation|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
75712031|NCT00738452|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
75712032|NCT00836121|Procedure|right thoracotomy|complete surgical resection
75406611|NCT04789746|Behavioral|adapted Chicago Run running program|The intervention being piloted is a 6-8 week running program modified from a running curriculum designed for school-aged children. The children will use a RaceRunner device to facilitate their participation, but this device is not explicitly evaluated in this study. Depending on transportation, they may be given access to the device in their home or school between sessions after it has been fit for them. If given access, guardians will be instructed on care and usage.
75551590|NCT00350610|Behavioral|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
75551591|NCT00318500|Drug|ERB-041|
75551592|NCT00345852|Procedure|Fetoscopic Selective Laser Photocoagulation|
75551593|NCT00318539|Drug|Quetiapine|
75551594|NCT00345891|Behavioral|Coping-focused counseling telephone calls|
75712033|NCT05667428|Drug|leuprorelin|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of leprorelin in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
75712034|NCT05667428|Drug|normal saline|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
75551595|NCT00350649|Behavioral|Standard CBT|Manualized delivery of CBT by trained clinicians
75551596|NCT00350649|Behavioral|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
75551597|NCT00350649|Behavioral|CM/abstinence|Contingency Management
75551598|NCT00350649|Behavioral|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
75551599|NCT00318617|Drug|GW510516X|
75551600|NCT00350688|Radiation|Helical tomotherapy IMRT|Helical tomotherapy IMRT
75551601|NCT00419198|Procedure|Postconditioning|Postconditioning during angioplasty
75551602|NCT00419198|Procedure|standard angioplasty|standard angioplasty without postconditioning
75551603|NCT00346008|Genetic|mutation analysis|
75551604|NCT00346008|Other|high performance liquid chromatography|
75551605|NCT00346008|Other|laboratory biomarker analysis|
75551606|NCT00346008|Other|questionnaire administration|
75551607|NCT00419237|Drug|GW685698X|GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
75551608|NCT00350766|Procedure|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
75712035|NCT00844779|Procedure|Bariatric surgery|Gastric bypass.
75712036|NCT00844779|Procedure|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
75712037|NCT05664542|Other|ESPB (regional Block)|ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine
75406613|NCT04764318|Behavioral|Remote patient monitoring for hypertension|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician.
75551609|NCT00318695|Dietary Supplement|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
76039455|NCT04953793|Behavioral|TAY SUCCESS|TAY SUCCESS stands for transition age youth supported, comprehensive cognitive enhancement and social skills. The cognitive-behavioral intervention teaches a number of strategies for executive functioning, social cognitive functioning and social communication.
75551610|NCT00318695|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
75551611|NCT00346047|Drug|Placebo|Corresponding placebo is applied for 12weeks
75551612|NCT00346047|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
75551613|NCT00421200|Drug|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
75712038|NCT05664542|Drug|ropivacaine and dexmedetomidine|0.2 % ropivacaine and dexmedetomidine
75712039|NCT00562978|Biological|filgrastim|
76039456|NCT04953793|Other|Usual Care|Usual care involved the typical vocational supportive education program delivered in the educational setting
76039457|NCT04953871|Drug|TNF Inhibitor|TNF inhibitors are widely used in patients with spondyloarthritis
75406614|NCT04764318|Behavioral|Remote patient monitoring with care management|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician and providing care management services to support the enrollment and active use of this service.
75406615|NCT04754334|Drug|ORMD-0801|Oral Insulin
75551614|NCT00421200|Drug|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
75551615|NCT00350805|Procedure|EEG|One 20 minutes session
75551616|NCT00318773|Drug|sertraline|50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
75551617|NCT00318851|Device|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
75551618|NCT00350883|Behavioral|Cognitive Therapy|Goal-oriented talk therapy
75551619|NCT00350883|Other|Treatment as Usual|Keep getting usual care
75551620|NCT00318890|Drug|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
75551621|NCT00318890|Drug|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
75551622|NCT00318890|Procedure|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
75551623|NCT00318890|Drug|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
75551624|NCT00346086|Drug|AIC (Amb a 1 Immunostimulatory Conjugate)|
76039458|NCT03059719|Biological|Exenatide injection(Byetta)|
76039459|NCT03059719|Biological|PB-119 injection|
75406616|NCT04754334|Other|Placebo|Fish Oil
75406617|NCT04749732|Behavioral|WalkingPad plus Psychological Intervention - PsyWPad Group|The 24-week walking program will be monitored by the WalkingPAD application that will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Transtheoretical Model of Change and the Theory of Planned Behavior.
75551625|NCT00318968|Drug|Esomeprazole|
75551626|NCT00350922|Behavioral|Psychoeducation|
75551627|NCT00319007|Drug|Sulindac (drug)|
75551628|NCT00319007|Drug|VSL#3 (probiotic)|
75551629|NCT00319007|Drug|Inulin (probiotic)|
75551630|NCT00350961|Drug|Gemcitabine|
75551631|NCT00350961|Drug|Oxaliplatin|
75551632|NCT00350961|Drug|Capecitabine|
75551633|NCT00319085|Procedure|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
75551634|NCT00346242|Drug|Zoledronic Acid|
75551635|NCT00421473|Drug|Atovaquone / Proguanil|
75551636|NCT00319163|Drug|levonorgestrel/ethinyl estradiol|
75551637|NCT00346281|Device|32P BioSilicon|
75551638|NCT00319202|Drug|Candesartan|32 mg/d for 6 months
75551639|NCT00319202|Drug|Placebo|Placebo administration for 6 months
75551640|NCT00319241|Behavioral|Parenting Intervention|
75712040|NCT00562978|Drug|cyclophosphamide|
75712041|NCT00562978|Drug|etoposide|
75712042|NCT00562978|Procedure|AHSCT|
75712043|NCT00562978|Radiation|yttrium Y 90 ibritumomab tiuxetan|
76039460|NCT04980599|Dietary Supplement|probiotic drink with Lactobacillus paracasei K56|Probiotic drink (K56 10^11CFU) 350ml/d for 60days
75712044|NCT00921206|Biological|VAX102|1 ug i.m. compared to 2 ug s.c.
75406618|NCT04749732|Behavioral|WalkingPad plus Virtual Assistant - CyberWPad Group|The 24-week walking program will be monitored by the WalkingPAD application, which will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support will be provided by a virtual assistant through daily and on-the-spot interactions and through support and motivational messages.
75406619|NCT04749732|Behavioral|WalkingPad group - Paper WPad Group|The 24-week walking program will be supported by a printed prescription of an individualized HbET previously defined on the WalkingPAD platform. However, this group of patients will not have the support of an application to monitor and record adherence to the program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Trans-Theoretical Model of Change and the Theory of Planned Behavior.
75406620|NCT04748796|Other|echocardiography|Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
75712045|NCT00842439|Behavioral|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
75871936|NCT04352608|Biological|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
75406621|NCT04748796|Drug|Landiolol|Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
75406622|NCT04744194|Other|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
75406623|NCT04744194|Other|Assisted nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
75406624|NCT04725084|Other|Use of High Flow Nasal Cannula alone|Use of high flow nasal cannula oxygen therapy alone
75406625|NCT04725084|Other|Use of Non-invasive Ventilation|Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy
75406626|NCT04725084|Other|Use of Continuous Positive Airway Pressure|Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
75551641|NCT00421512|Drug|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
75712046|NCT00842439|Dietary Supplement|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
75712047|NCT00940264|Procedure|transvaginal hybrid cholecystectomy|transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
75712048|NCT04013230|Behavioral|Usual care|Visit doctor and nurse at the clinic.
75712049|NCT04013230|Behavioral|Web-COP|Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
75712050|NCT00842595|Drug|rituximab|6 courses every 28 days
75712051|NCT00842595|Drug|vinorelbine|6 courses every 28 days
75712052|NCT00842595|Drug|ifosfamide|6 courses every 28 days
75871937|NCT04352608|Biological|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
75871938|NCT04352608|Biological|Three doses of placebo at the emergency vaccination schedule|Three doses of placebo at the schedule of day 0,14,42
75871939|NCT04352608|Biological|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
76039461|NCT04980599|Dietary Supplement|maltodextrin|maltodextrin ,for 60days
76039462|NCT04980599|Dietary Supplement|Probiotic powder E3|Probiotic powder 3.0g/d (K56 10^10cfu) 60days;
76039463|NCT04980599|Dietary Supplement|Probiotic powder E5|probiotic powder 8g/day for 60days
76039464|NCT04980599|Dietary Supplement|probiotic capsule E7|probiotic k56 capsule, 2capsules/d (10^7cfu) for 60days
76039465|NCT04980599|Dietary Supplement|probiotic capsule E9|probiotic k56 capsule, 2capsules/d (10^9cfu) for 60days
75871940|NCT04352608|Biological|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
76039466|NCT04980599|Dietary Supplement|probiotic capsule E10|probiotic k56 capsule, 2capsules/d (10^10cfu) for 60days
75406627|NCT04707846|Device|Bright Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
75551642|NCT00319280|Procedure|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
75551643|NCT00351078|Drug|PTC124|4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
75551644|NCT00319319|Drug|Mecamylamine hydrochloride (Inversine)|
76039467|NCT04980599|Dietary Supplement|probiotic capsule E11|probiotic k56 capsule, 4capsules/d (10^11cfu) for 60days
76039468|NCT04972435|Diagnostic Test|Contrast sensitivity|All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
75551645|NCT00346359|Biological|anti-thymocyte globulin|
75551646|NCT00346359|Drug|busulfan|
76039469|NCT03060031|Drug|Oxytocin|Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
76039470|NCT03060031|Drug|Placebo|Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
76039471|NCT05619575|Device|CP1170 sound processor|The CP 1170 sound processor will be used to determine the hearing performance with the new implementation of ForwardFocus in SCAN 2 (SCAN 2 FF), as assessed by speech perception in noise.
75551647|NCT00346359|Drug|fludarabine phosphate|
75712053|NCT00842595|Drug|Mitoxantrone|6 courses every 28 days
75551648|NCT00346359|Drug|methotrexate|
75551649|NCT00346359|Drug|tacrolimus|
75551650|NCT00346359|Procedure|allogeneic hematopoietic stem cell transplantation|
75551651|NCT00346359|Procedure|peripheral blood stem cell transplantation|
75551652|NCT00319358|Dietary Supplement|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
75551653|NCT00319358|Dietary Supplement|Placebo|placebo
75551654|NCT00319397|Behavioral|Exercise-Training Program|
75551655|NCT00346437|Genetic|Ad5FGF-4 vs. Placebo|Intracoronary infusion
75551656|NCT00319475|Procedure|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
75551657|NCT00351117|Drug|St. John's Wort|SJW in capsule form 300 mg PO TID
75551658|NCT00351117|Drug|Lactose|lactose in gelatin capsule that same as St. John's wort
75551659|NCT00319514|Drug|Docetaxel|
75551660|NCT00346515|Device|FiberNet Emboli Protection System|
75551661|NCT00319670|Drug|MiraLax|
75551662|NCT00351195|Drug|Etoposide|
75551663|NCT00351195|Drug|Oxaliplatin|
75551664|NCT00351195|Drug|Capecitabine|
75712054|NCT00842595|Drug|Prednisone|6 courses every 28 days
75712055|NCT04013698|Other|PEEP level 5 cmH2O|PEEP level set for 45 minutes
75712056|NCT04013698|Other|PEEP level 15 cmH2O|PEEP level set for 45 minutes
75712057|NCT00845091|Behavioral|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
75712058|NCT00845091|Behavioral|Heart Healthy Education|Educational topics related to heart health (e.g., nutrition, smoking, sleep)
75712059|NCT00938626|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
75871941|NCT04352608|Biological|Three doses of placebo at the routine vaccination schedule|Three doses of placebo at the schedule of day 0,28,56
76039472|NCT05619575|Device|CP1150 Sound processor|Active comparator off the ear sound processor.
76039473|NCT02499783|Biological|adalimumab|subcutaneous injections of adalimumab
76039474|NCT02499783|Other|placebo|subcutaneous injections of placebo
76039475|NCT04972045|Drug|CuminUP60®|4 capsules, 400 mg / capsule
76039476|NCT04972045|Drug|Curcumin capsules|4 capsules, 400 mg / capsule
76039477|NCT04953481|Other|survey|The general information, home care status and functional status of ALS patients and family caregivers were collected.
76039478|NCT03059017|Drug|Salbutamol Sulphate|salbutamol sulphate packaged as aerosol
76039479|NCT03059017|Drug|Niosomes|Niosomes
76039480|NCT04971421|Diagnostic Test|ctDNA - circulating tumor DNA|lcWGS and WGS of circulating tumor DNA
76039481|NCT04971421|Diagnostic Test|TEP - Tumor Educated Platelets|sequencing miRNA from TEPs
75551665|NCT00319709|Drug|SR58611A|
75551666|NCT00346593|Device|Silicone hydrogel contact lens|
75551667|NCT00351234|Drug|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
76039482|NCT05691335|Procedure|Standard CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 30 minutes.
75406628|NCT04707846|Device|Dim Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
75406629|NCT04704258|Procedure|TAVI (Transcatheter Aortic Valve Implant)|Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures
75406630|NCT04704258|Device|FLOWer Embolic Protection System|FLOWer Embolic Protection System
75406631|NCT04673994|Behavioral|Single, acute bout of high intensity interval exercise|Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
75406632|NCT04628442|Procedure|Sinonasal Debridement Procedure|This is a medical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
75406633|NCT04628442|Procedure|Nasal Polyp Removal|This is a surgical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
75551668|NCT00319787|Drug|Iressa|
75551669|NCT00319826|Other|No intervention|This is an observational study with no intervention
75551670|NCT00319865|Drug|Velcade|
75551671|NCT00319865|Drug|Thalidomide|
75551672|NCT00319865|Drug|Adriamycin|
75712060|NCT00938626|Procedure|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
75406634|NCT04628442|Procedure|Biopsy|A biopsy is optional and will remove a sample of inferior turbinate tissue from the nasal passage. It will be performed during a nasal polyp removal surgery already scheduled for patient care.
75406635|NCT04625244|Other|Video assisted home therapy|Subjects will follow along with prerecorded therapy videos.
75712061|NCT00938626|Procedure|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
76039483|NCT05691335|Procedure|Accelerated CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
75406636|NCT04624698|Device|iStent Inject Implantation|Subjects will be implanted with the iStent Injection Micro-Bypass device
75406637|NCT04609722|Other|Solution-Focused Support Program|All participants will be given a program of 4 sessions for 4 weeks. Each session is planned to last approximately 50 minutes.
75551673|NCT00319865|Drug|Dexamethasone|
75551674|NCT00319943|Procedure|Computer-based training for Mild Cognitive Impairment (MCI)|
75551675|NCT00320021|Drug|Pyridorin (pyridoxamine dihydrochloride)|
75551676|NCT02959593|Device|VISIOR video goggles|View commercially available content through the VISIOR video goggles continuously for thirty minutes.
75551677|NCT00320060|Drug|Pyridorin (pyridoxamine dihydrochloride)|
75551678|NCT00320099|Drug|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
75551679|NCT00320099|Drug|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
75551680|NCT00320099|Drug|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
75551681|NCT00320099|Drug|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
75551682|NCT00346671|Other|Rest|30 min supine rest
75551683|NCT00346671|Other|Sham|30 min session with Sham practitioner
75551684|NCT00346671|Other|Reiki|30 min session with Reiki practitioner
75551685|NCT00320138|Procedure|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
75551686|NCT00351312|Device|special socks|
75551687|NCT00320294|Drug|irinotecan|
75551688|NCT00320294|Drug|cisplatin|
75712062|NCT05193344|Device|A digital care solution for patients with Heart Failure|A digital solution that provides remote symptom monitoring and support of lifestyle-changes by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
75712063|NCT05193344|Other|Standard of Care for patients with Heart Failure|The best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF.
75712064|NCT00842673|Drug|ST101|30 mg; administered once/day
75712065|NCT00842673|Drug|ST101|90 mg; administered once/day
75406638|NCT04599816|Drug|levosimendan at a dose of 3 mcg/kg|levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction
75406639|NCT04599816|Drug|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
75406640|NCT04599816|Drug|levosimendan at a dose of 12 mcg/kg|levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
75406641|NCT04572204|Other|Surgical|Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
75406642|NCT04566276|Biological|ChulaCov19 vaccine|SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
75406643|NCT04566276|Other|Placebo|Saline
75406644|NCT04563390|Behavioral|Projection-based augmented reality exposure therapy (P-ARET).|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
75406645|NCT04563390|Behavioral|In vivo exposure therapy|"The intervention will be based on traditional in vivo exposure therapy to real cockroaches. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
75406646|NCT04535310|Device|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
75406647|NCT04531878|Drug|4-Phenylbutyrate|4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
75406648|NCT04509414|Drug|Dexmedetomidine|For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.
75406649|NCT04509414|Drug|Midazolam|For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
75406650|NCT04430400|Diagnostic Test|integrated diagnostic algorithm|"Diagnostic management was as follows. An acute aortic syndrome will be considered to be ruled out without advanced aortic imaging, in clinically stable patients at low clinical pre-test probability (defined by ADD score ≤1) and a D-dimer level <500 ng/mL FEU. The other patients will be subjected to advanced aortic imaging for conclusive diagnosis.~Attending physicians will be allowed to derogate from protocol indications based on the clinical scenario and clinal gestalt, irrespective of patient's participation to the present study."
75406651|NCT04417764|Procedure|Transcatheter arterial chemoembolization|The patients are plan to operated by Transcatheter arterial chemoembolization(TACE).
75406652|NCT04417764|Biological|PD-1 knockout engineered T cells|The PD-1 knockout engineered T cells are prepared from autologous origin using CRISPR Cas9 technology. The patients are plan to receive 3 or more cycles of PD-1 knockout engineered T cells infusion by percutaneous fine needle liver puncture with a 4-weeks interval. A total of 1 to 3× 10^9 PD-1 edited T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent.
75406653|NCT04320342|Drug|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
75551689|NCT00351390|Other|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
75551690|NCT00351390|Other|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP <1000 pg/mL
75712066|NCT00842673|Drug|ST101|180 mg; administered once/day
75712067|NCT00842673|Drug|Placebo|placebo to match ST101 tablets
75406654|NCT04320342|Drug|Glycopyrronium Bromide|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
75551691|NCT00320333|Procedure|pulmonary rehabilitation programme|
75551692|NCT00346749|Drug|Salmeterol|
75551693|NCT00346749|Drug|Fluticasone Propionate/Salmeterol Combination Product|
75551694|NCT00320450|Drug|SB-681323|
75406655|NCT04320342|Drug|Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
75551695|NCT00346788|Procedure|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
75551696|NCT00419276|Procedure|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
75551697|NCT00351429|Device|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
75551698|NCT00351507|Drug|Vildagliptin|
75551699|NCT00320567|Drug|norgestimate/ethinyl estradiol|
75551700|NCT00346827|Drug|Apomorphine Nasal Powder|
75551701|NCT00346866|Drug|anecortave acetate|
75712068|NCT04013308|Procedure|Iontophoresis with 2% potassium iodide|10 iontophoresis treatments with 2% potassium iodide on the area of thyroid gland; electrodes with tin foil (Amperage:2mA, duration: 30min)
75871942|NCT03722303|Other|Fat Injection|Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.
75406656|NCT04307550|Drug|Isopropyl alcohol|10 inhalations of an isopropyl alcohol pad
75406657|NCT04307550|Other|Placebo|10 inhalations of a sterile saline pad
75551702|NCT00320723|Drug|bupropion, transdermal nicotine patch|
75551703|NCT00351546|Drug|Vildagliptin|
75551704|NCT00320762|Device|OculusGen Biodegradable Collagen Matrix Implant|
75551705|NCT00346944|Procedure|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
75551706|NCT00351585|Drug|Vildagliptin|
75712069|NCT00836199|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
75712070|NCT00836199|Biological|Placebo vaccine|Placebo vaccine given 6 times over 6 months
75406658|NCT04299594|Other|Questionnaire|For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.
75406659|NCT04297488|Dietary Supplement|Bifidobacteria and Lactobacilli triple viable capsules|Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wan he Pharmaceutical Co., Ltd., China) are bilayer mini pellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.
75551707|NCT00320879|Drug|irbesartan|
75551708|NCT00346983|Drug|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
75551709|NCT00346983|Drug|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
75712071|NCT05280262|Diagnostic Test|CogState Test|Computerized cognitive testing which provides a score/measurement of distinct cognitive functions
75871943|NCT03722303|Drug|Steroid Injection|Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
76039484|NCT05691335|Procedure|Transepithelial CXL|Epithelium-on CXL performed by instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
75551710|NCT00347061|Drug|afuzosin|
75551711|NCT00320957|Device|OculusGen Biodegradable Collagen Matrix Implant|
75551712|NCT00347100|Drug|Insulin Glargine|Throughout study period
75551713|NCT00347100|Drug|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
75551714|NCT00347100|Drug|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
75551715|NCT00347100|Drug|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
75551716|NCT00347100|Drug|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
75551717|NCT00347100|Drug|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
75551718|NCT00347139|Drug|GW642444 (25, 100 & 400 mcg/day)|25, 100 and 400mcg/dose
75551719|NCT00347139|Drug|Salmeterol 50mcg|Salmeterol 50mcg
75551720|NCT00321035|Device|OculusGen Biodegradable Collagen Matrix Implant|
75551721|NCT00347178|Procedure|Laser Peripheral Iridotomy|
75871944|NCT05203146|Device|PIMPmyHospital (mHealth tool)|Each participant will first be asked to retrieve a factious patient's laboratory results on the app when randomly made available, and then reach a colleague (role played by a study investigator) when asked to do so by a text message on the app.
75712072|NCT04062188|Other|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire developed based on the combination of Barthel Index questionnaire and simplified modified Rankin Scale questionnaire with internal rules.
75406660|NCT04294446|Device|Biodesign Hernia Graft|The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
75406661|NCT04240314|Biological|scAAV9.U7.ACCA|A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
75406662|NCT04208412|Drug|KVD900|KVD900 tablet 600 mg
75406663|NCT04208412|Other|Placebo|KVD900-matched Placebo Tablet
75406664|NCT04200300|Diagnostic Test|Online questionnaire|Online questionnaire via SoSciSurvey
75551722|NCT00321074|Drug|TACROLIMUS|Immunosuppression
75551723|NCT00321113|Drug|tacrolimus|immunosuppression
75712073|NCT04013386|Drug|Aprepitant and Dexamethasone|Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
75712074|NCT04013386|Drug|Mirtazapine and Dexamethasone|Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
75712075|NCT04013386|Drug|Dexamethasone|Dexamethasone 8 mg IVI
75712076|NCT02567084|Device|"CERAMENT™ |BONE VOID FILLER"|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
75712077|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
75712078|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
75712079|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
75712080|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
75871945|NCT05203146|Other|Conventional method|Each participant will first be asked to retrieve a factious patient's laboratory results from the emergency department's computerized patient data system when randomly made available, and then contact a colleague (role played by a study investigator) when asked to do so (request made by a second study investigator).
75551724|NCT00321113|Drug|mycophenolate mofetil|oral
75551725|NCT00321113|Drug|steroids|oral
75551726|NCT00347256|Drug|cisplatin|
75551727|NCT00347256|Procedure|targeted radiation therapy|
75551728|NCT00347256|Procedure|tumor resection|
75871946|NCT02326792|Other|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
75406665|NCT04194996|Procedure|Surgical intervention|Surgical interventions will be patient specified by treating surgeon.
76039485|NCT04772885|Drug|KT-474/Placebo|KT-474 or matching placebo oral tablet(s)
76039486|NCT04772885|Drug|KT-474|KT-474 oral tablet(s)
76039487|NCT04755413|Other|Medical/Behavioral therapy|"Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.~Overweight/Obese: Advise calorie reduction, dietician consultation.~Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.~High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.~b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.~d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of <55mg/dl in diabetes~Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.~Diabetes management: HbA1c goal 6.5%"
76039488|NCT04755413|Other|Standard of Care|Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.
76039489|NCT04755413|Other|Registry|Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.
75406666|NCT04156854|Diagnostic Test|Quantitated Blood Volume Analysis|Measurement of total blood volume, composed of red blood cell mass (RBCM) and plasma volume (PV) by administering low dose iodinated I-131 labeled albumin intravenously then taking blood samples at timed increments.
75406667|NCT04095858|Drug|Efprezimod alfa|IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
75406668|NCT04095858|Drug|Placebo|IV infusion, 100 ml at Day -1, Day 14, and Day 28.
75406669|NCT04095858|Drug|Methotrexate|IV, 15 mg/m^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
75712081|NCT00845169|Procedure|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
75406670|NCT04095858|Drug|Tacrolimus|Begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted
75406671|NCT04092348|Other|complete blood count|"total RNA is isolated from fresh blood samples~RNA is converted into complementary DNA c.DNA~cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene."
75406672|NCT04073862|Other|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
75406673|NCT04057716|Behavioral|Sleep restriction|Participants will be asked to restrict their time in bed to 8 hours each night for one week.
75712082|NCT00842907|Drug|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
75712083|NCT00842907|Drug|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
75712084|NCT05181488|Radiation|intraoperative radiotherapy, IORT|A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
75712085|NCT05180396|Other|Questionnaires|Application of a study based questionnaire described in the protocol
75712086|NCT04013074|Procedure|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt
75712087|NCT04013074|Other|Standard Medical Treatment|Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
75712088|NCT00620373|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
75406674|NCT04057716|Behavioral|Sleep extension|Participants will be asked to extend their time in bed to 11 hours each night for one week.
75406675|NCT04008108|Other|Activity sensor|Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
75551729|NCT00321152|Other|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
75551730|NCT00347295|Drug|Brotizolam|
75551731|NCT00347295|Drug|Estazolam|
75406676|NCT03958266|Device|MyIBD Care|Novel mobile phone application
75406677|NCT03937986|Drug|Suvorexant|The pharmacodynamic effects of suvorexant maintenance will be determined.
75871947|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
75406678|NCT03937986|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
75406679|NCT03937986|Drug|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
75406680|NCT03911856|Other|Echocardiography|We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
75406681|NCT03911856|Other|Pulmonary Gas Exchange|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
75406682|NCT03851796|Behavioral|TEENS+Parents as Coaches|Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.
75406683|NCT03851796|Behavioral|TEENS+Parent Weight Loss|Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
75551732|NCT00321191|Drug|No nitrous oxide|
75551733|NCT00321191|Drug|Administration of N2O|
75551734|NCT00351624|Behavioral|DHA|
75551735|NCT00351624|Behavioral|placebo|
75551736|NCT00321230|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|
75406684|NCT03836196|Radiation|LDR Brachytherapy and External Beam Radiation Therapy|Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
75406685|NCT03835884|Drug|AR-13503 Implant 10.6 Dose|AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
75406686|NCT03835884|Drug|AR-13503 Implant 21.2 Dose|AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
75406687|NCT03835884|Drug|AR-13503 42.4 Dose|AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
75406688|NCT03835884|Drug|AR-13503 63.6 Dose|AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
75406689|NCT03813030|Procedure|Intravenous infusion of lidocaine|Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.
75551737|NCT00351663|Drug|Enoxaparine|"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~Subcutaneous Enoxaparine 40mg x1/day"
75551738|NCT00321347|Drug|Lidocaine|
75551739|NCT00351702|Drug|Isoniazid with Ethambutol|Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
75551740|NCT00351780|Device|FFR measurement, side branch angioplasty|
75551741|NCT00321425|Procedure|brachial plexus block|
75551742|NCT00321425|Procedure|ultrasound guidance|
75551743|NCT00321425|Procedure|electrical nerve stimulation|
75551744|NCT00351858|Drug|ertumaxomab|
75551745|NCT00351897|Device|pulsed dye (585nm) laser therapy|
75551746|NCT00321542|Other|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
75551747|NCT00351975|Drug|Belinostat|Given IV
75551748|NCT00351975|Drug|Azacitidine|Given SC
75871948|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
75871949|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
75551749|NCT00351975|Other|Laboratory Biomarker Analysis|Correlative studies
75551750|NCT00321581|Drug|Cediranib, AZD2171, RECENTIN|
75551751|NCT00321659|Behavioral|Aerobic|3x/week of walking and cycling
75551752|NCT00321659|Behavioral|Strength training|3x/week of resistance training activities
75551753|NCT00321659|Behavioral|Combination|3x/week of aerobic and strength training activities
76039490|NCT04961983|Behavioral|Comprehensive Travel Health Education Model|"The comprehensive travel health education model consists of:~Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~The potential roles of tour guides in tourists' health,~The importance of travel health information for tourists,~Assessment of tourist's health risks,~Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~Weekly travel health Information sharing through WhatsApp group for 2 months."
75406690|NCT03813030|Drug|"Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)"|Topical application in dermal-sampling visit
75406691|NCT03813030|Drug|"Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)"|Intravenous infusion in clearance visit
75551754|NCT00321659|Behavioral|FSHC|Biweekly group education group meetings
76039491|NCT04961749|Other|Whole body vibration training|Whole-body vibration training applies a vibration stimulus to an individual as they are standing on a side-alternating platform. The vibration creates small muscle contractions in the lower extremity musculature which has been shown to improve function and ambulatory function.
76039492|NCT04953013|Drug|sodium bicarbonate|Drug exposure
75551755|NCT00352092|Drug|calcineurin inhibitor|
75551756|NCT00352092|Drug|sirolimus|
76039493|NCT04953169|Other|Biobank Video|The video describes the process of biobanking with visuals
76039494|NCT04953169|Other|Non-Video|The non-video group will receive a written informed consent
76039495|NCT04425655|Drug|Fludarabine|30mg/m2 days 1 through 5
76039496|NCT04425655|Drug|Vyxeos|100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
76039497|NCT04970719|Drug|Baricitinib|4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
76039498|NCT04970719|Drug|Dexamethasone|and 6 mg* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course
76039499|NCT04970719|Drug|Remdesivir|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
76039500|NCT02468193|Drug|Osilodrostat|Osirodrostat 1mg, 5mg & 10mg in the form of film-coated tablets was used for oral administration.
75406692|NCT03813030|Device|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
75551757|NCT00352092|Drug|mycophenolate mofetil|
75712089|NCT00620373|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
75406693|NCT03813030|Device|Dermal Microdialysis|"Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
75551758|NCT00322010|Procedure|early PT OT|"Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~Sessions began with active assisted and active range of motion exercises in the supine position.~If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~The session progresses to transfer training, and finally pre-gait exercises and ambulation.~Progression of activities is dependent on patient tolerance and stability.~Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
75551759|NCT00352131|Drug|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
75551760|NCT00322127|Drug|AMD3100|a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
75551761|NCT00352170|Dietary Supplement|calcium supplementation|calcium carbonate 1500 mg/day
75551762|NCT00352170|Dietary Supplement|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
75551763|NCT00352170|Dietary Supplement|Placebo|calcium and vitamin D3 placebo
75551764|NCT00322166|Other|Sunlight|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
75712090|NCT00620373|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
75712091|NCT02567318|Device|MRI-scan|Magnetic resonance imaging scan of the brain
75712092|NCT03360292|Other|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
75551765|NCT00322166|Other|Sunlight and calcium|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
75406694|NCT03813030|Procedure|Blood sampling in dermal sampling visit|1 sample is taken pre-dose and 12 samples are taken post-dose.
75406695|NCT03813030|Procedure|Blood sampling in clearance visit|1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
75406696|NCT03778944|Procedure|Mannitol infusion|Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
75551766|NCT00322166|Other|control|Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
75551767|NCT02959580|Drug|Hydrocortisone Butyrate|topical use
75551768|NCT02959580|Procedure|extended excision|Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
75551769|NCT00352248|Procedure|Tongue Acupuncture (Procedure)|
75551770|NCT00322205|Drug|zyban|
75551771|NCT00352287|Drug|Recombinant human growth hormone; pioglitazone|
75551772|NCT00322244|Procedure|Massage Therapy|
75551773|NCT00352326|Device|reprogramming assisted communication device interface|The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
75551774|NCT00322283|Drug|Oglemilast|Oglemilast, 15mg once per day, oral administration
75551775|NCT00322283|Drug|Placebo|Dose-marched placebo, once per day, oral administration
75551776|NCT00352404|Device|Endomicroscope|
76039501|NCT04970797|Drug|Xinglouchengqi decoction|the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
76039502|NCT04431817|Device|KinetiGait|This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.
75406697|NCT03778944|Procedure|Dopamine infusion|Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
75406698|NCT03778944|Procedure|Adequate hydration|Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
75406699|NCT03738150|Biological|Sotatercept|Sotatercept injection
75551777|NCT00322322|Drug|L-Carnitine|L-Carnitine
75551778|NCT00352443|Drug|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
75551779|NCT00352443|Drug|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
75551780|NCT00322361|Biological|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
75406700|NCT03738150|Other|SOC|SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
75406701|NCT03718728|Behavioral|Mind&Life|Acceptance and mindfulness-based group intervention program.
75406702|NCT03718728|Behavioral|Standard|Personalized diet and physical exercise recommendations.
75551781|NCT00322361|Biological|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
75551782|NCT00352482|Drug|Sildenafil (50 mg)|
75551783|NCT00322400|Drug|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
75551784|NCT00322400|Drug|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
75712093|NCT00940654|Other|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
76039503|NCT02466555|Behavioral|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
76039504|NCT04960969|Other|Time-restricted feeding for 4 weeks|Participants in this group will follow a time-restricted diet for 28 days. Consumption of only non-energy drinks will be allowed for 16 hours. During the 8-hour eating period, there will be no restriction on the content of the diets.
76039505|NCT04972201|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
76039506|NCT02466399|Drug|POLAT-001|Subconjunctival injection
76039507|NCT02466399|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
76039508|NCT03059251|Biological|Obinutuzumab|Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
76039509|NCT04936191|Device|DynamX Bioadaptor|Patients received percutaneous coronary intervention in a similar way to a traditional DES. Patients first receive radial artery or femoral artery cannulation with anticoagulation during the intervention. All coronary angiograms are carefully measured by at least 2 orthographic views and performed under the same standard conditions. After adequate predilatation of the target lesion, the coronary stenting will be performed. All patients will receive a loading dose of acetylsalicylic acid and a P2Y12 inhibitor pre-procedure followed by dual antiplatelet therapy for at least 6 months.
76039510|NCT04970251|Drug|Aflibercept Ophthalmic|Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.
76039511|NCT03058861|Behavioral|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
76039512|NCT04970017|Radiation|Cardiac MRI, Echocardiography|Magnetic resonance imaging, Echocardiography
75406703|NCT03654690|Diagnostic Test|HIV self-test|Home delivery of HIV self-test kits (OraSure OraQuick Rapid HIV test)
75406704|NCT03654690|Behavioral|Counseling|Post-Test HIV Risk ReductionCounseling
75406705|NCT03653052|Drug|Durvalumab|Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
75551785|NCT00322400|Drug|AMG 706|"Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.~Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days."
75551786|NCT00352521|Drug|bevacizumab|
75551787|NCT00352521|Drug|irinotecan|
76039513|NCT02465931|Other|Paper and Pencil Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
75406706|NCT03640728|Drug|Tenofovir Alafenamide|Tenofovir alafenamide 25 mg/day orally
75406707|NCT03640728|Drug|Entecavir|Entecavir 0.5 mg/day orally
75406708|NCT03640728|Drug|Tenofovir disoproxil fumarate|Tenofovir Disoproxil Fumarate 300 mg/day orally
75406709|NCT03607500|Behavioral|caloric intake reduction|The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
75406710|NCT03567174|Other|Integrated care van (ICV)|Structural service delivery intervention
75406711|NCT03562572|Procedure|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention
75551788|NCT00352521|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
75551789|NCT00322478|Behavioral|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
75712094|NCT00845247|Other|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
75406712|NCT03562572|Other|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
75406713|NCT03544632|Drug|Acellular Adipose Tissue (AAT)|"Participants (n=15) will be administered between 5cc and 20cc of AAT, depending on their assigned treatment group, via sterile subcutaneous injection into the target defect. The injection is intended to be permanent. After the 3-month study follow-up visit, participants will have the option to undergo additional AAT injection (up to 20cc per treatment) in order to fully correct the defect. Total injected AAT volume per patient will not exceed 40cc. Additional injection is dependent upon study- and patient-specific adverse / unanticipated events to date.~Each vial contains a 2 milliliter (mL) dose of the injectable AAT. This volume is similar to other commonly used injectable filler materials intended for soft tissue correction."
75406714|NCT03522870|Device|Flash glucose monitoring system|Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26
75406715|NCT03522870|Device|SMBG|Performing SMBG at least three times/day on Week 2-14 and Week 14-26
75551790|NCT00322478|Behavioral|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
76039514|NCT02465931|Other|Digital Informed Consent Tool|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
76039515|NCT04961125|Genetic|germline variants|Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
76039516|NCT04970329|Drug|Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,|Drugs will be given to two group and third group will kept on placebo.
76039517|NCT02465463|Procedure|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
76039518|NCT02465463|Device|flexible sigmoidoscopy|
76039519|NCT04970095|Device|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
76039520|NCT04970095|Device|Petit Face Mask|"The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion.~consist of forehead cap chin cap cross bar"
75406716|NCT04194138|Procedure|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
75551791|NCT00322478|Behavioral|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
75551792|NCT00352599|Drug|Lovastatin|
75551793|NCT00352599|Drug|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
75551794|NCT00352599|Drug|placebo pill|
75551795|NCT00352638|Other|counseling intervention|
75551796|NCT00352638|Other|educational intervention|
75551797|NCT00352638|Other|study of socioeconomic and demographic variables|
75551798|NCT00322595|Drug|Quetiapine fumarate|
75551799|NCT00322595|Drug|Paroxetine|
76039521|NCT04960657|Drug|glibenclamide|Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
76039522|NCT04960657|Drug|PACAP38|PACAP38 infusion
76039523|NCT02464059|Drug|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
75551800|NCT00352677|Drug|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
75406717|NCT03455868|Procedure|Bariatric surgery|Sleeve gastrectomy
75551801|NCT00352716|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
75551802|NCT00331149|Drug|Ropinirole prolonged release|
75551803|NCT00331149|Drug|ropinirole immediate release|
75551804|NCT00331188|Drug|Sanvar® (vapreotide)|
75551805|NCT00352833|Drug|catumaxomab|
75551806|NCT00322673|Drug|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
75551807|NCT00331305|Behavioral|Supervised Exercise|
75551808|NCT00331305|Behavioral|Home-Based Exercise|
75551809|NCT00331305|Drug|Sertraline (Zoloft)|
75551810|NCT00331305|Drug|Placebo Pill|
75551811|NCT00322751|Drug|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
75551812|NCT00352950|Drug|AMG 954/Panitumumab|
75551813|NCT00322907|Drug|Cotrifazid vs mefloquine or quinine+SP|
75551814|NCT00352989|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
75406718|NCT03445650|Drug|ADX-102 1% Topical Dermal Cream (reproxalap)|ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
75406719|NCT03445650|Drug|Vehicle of ADX-102 Topical Dermal Cream|Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
75551815|NCT00322946|Biological|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
75406720|NCT03436368|Procedure|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
75406721|NCT03436368|Procedure|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
75406722|NCT03393780|Drug|Follitropin Delta|The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.
75406723|NCT03202758|Drug|Durvalumab, Tremelimumab and ,FOLFOX|"Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"
75406724|NCT03186534|Behavioral|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
75406725|NCT03186534|Behavioral|Positive Affect Enhancement|coping skills for enhancing positive emotions, mindfulness
75406726|NCT03183102|Dietary Supplement|Flaxseed|2 months of dietary flaxseed supplementation
75406727|NCT03132948|Behavioral|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
75406728|NCT03122262|Drug|Dolutegravir|DTG 50mg Oral Tablet once daily
75406729|NCT03122262|Drug|Tenofovir Alafenamide|TAF/FTC 25/200mg Oral Tablet once daily
75551816|NCT00322946|Biological|Placebo|Placebo for rDEN4delta30-4995
75551817|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
75551818|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution Vehicle|Inactive ingredients used as a placebo comparator
76039524|NCT04969159|Other|no intervention|standard treatment in the clinical routine
75551819|NCT00322985|Drug|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
75551820|NCT00353028|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
75551821|NCT00353028|Drug|Placebo|Placebo
75551822|NCT00323024|Drug|NX1011|
75551823|NCT00331539|Device|Cochlear Implant|
75551824|NCT00323102|Drug|Multihance|
75551825|NCT00331578|Device|Excel drug-eluting coronary artery stent|
75406730|NCT03122262|Drug|Truvada|
75406731|NCT03122262|Drug|Atripla|
75406732|NCT03055416|Other|Mobile Men App Prototype|Testing of app functionality
75551826|NCT00353067|Drug|veliflapon (DG-031)|
75551827|NCT00323219|Drug|Cefazolin and Moxifloxacin|See Detailed Description.
75551828|NCT00353106|Behavioral|Interview|30-minute interviews of participating patients and their caregiver(s).
76039525|NCT04960501|Procedure|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
76039526|NCT04960423|Procedure|Long Segment Fixation and Fusion|Long Segment Fixation and Fusion
76039527|NCT02463357|Dietary Supplement|Quercetin|
75712095|NCT05081882|Drug|Kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
75871950|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
75871951|NCT03558503|Drug|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
76039528|NCT02463357|Drug|Nifedipine extended release|
76039529|NCT02463357|Drug|Methazolamide|
76039530|NCT02463357|Drug|Metformin|
76039531|NCT02463357|Drug|Placebo|
76039532|NCT02463357|Drug|Nitrite|
76039533|NCT04960345|Device|Brainlab Knee 3|Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
76039534|NCT02579759|Drug|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
76039535|NCT02579759|Drug|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
76039536|NCT02579759|Drug|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
75712096|NCT05081882|Drug|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 28 days.
75712097|NCT00845325|Behavioral|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
75712098|NCT00845325|Behavioral|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
75871952|NCT04351984|Device|MitraClip|Transcatheter Mitral Valvuloplasty with MitraClip
76039537|NCT04960189|Procedure|Acupuncture|Acupuncture will be performed bilateral on fibular aspect of the leg, in the depression anterior and distal to the head of the fibula by using 0,25x50mm needles.
76039538|NCT04935255|Other|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).
76039539|NCT04960267|Device|Use of pre-peritoneal drainage after rTAPP|Use of pre-peritoneal drainage after rTAPP
76039540|NCT04960033|Behavioral|FRAX|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
76039541|NCT04952935|Procedure|True Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at true acupuncture points.
76039542|NCT04952935|Procedure|Sham Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at non-acupuncture points.
75406733|NCT03051282|Drug|Enalapril|Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
75406734|NCT03042546|Drug|Calcium Sulfate|Calcium Sulfate with abx will be used in the defect
75551829|NCT00353106|Behavioral|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
75551830|NCT00331656|Device|Non-invasive positive pressure mask ventilators|
75551831|NCT00331656|Device|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
75551832|NCT00323375|Drug|AQ-13|A treatment dose of AQ-13 (1750 mg base) was administered orally to subjects randomized to AQ-13 over 3 days (as two capsules on days 1 and 2, plus one capsule on day 3).
75551833|NCT00323375|Drug|Chloroquine (CQ) Treatment|A treatment dose of CQ (1500 mg CQ base) was administered orally to subjects randomized to CQ over 3 days (as two capsules on days 1 and 2, and one capsule on day 3).
75551834|NCT00331695|Drug|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
75712099|NCT00940732|Other|Destigmatisation and Mental Health Literacy|"Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information."
75712100|NCT00940732|Other|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
75712101|NCT00940732|Other|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
75712102|NCT02567006|Behavioral|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
75712103|NCT02567006|Other|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
75712104|NCT00843063|Drug|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
75712105|NCT04013464|Drug|Escitalopram|Escitalopram 10-20mg/d
75871953|NCT05761236|Other|Exercise|Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
75712106|NCT04043247|Device|TEAS|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
75871954|NCT02331706|Drug|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
75871955|NCT02326870|Device|AutoLap|
75871956|NCT03489863|Drug|Prasugrel|Maintenance dose will be maintained for 10±3 days.
75406735|NCT03042546|Drug|PMMA|PMMA with abx will be used in the defect
75406736|NCT03042546|Other|No treatment|The defect will not be treated
75406737|NCT02948244|Dietary Supplement|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
75406738|NCT02948244|Dietary Supplement|Placebo|Placebo
75406739|NCT02734134|Procedure|One-stage exchange joint replacement surgery|
75406740|NCT02734134|Procedure|Two-stage exchange joint replacement surgery|
75551835|NCT00323531|Procedure|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
75551836|NCT00323531|Procedure|VATS decortication|thoracoscopic decortication
75551837|NCT00323570|Drug|activated recombinant human factor VII|
75551838|NCT00353145|Drug|Gemcitabine (Gemox)|1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 repeated every 14 days (one cycle).
75551839|NCT00353145|Drug|Oxaliplatin|100 mg/m^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
75712107|NCT04043247|Device|TEAS without electrical stimulation|Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
75406741|NCT02561754|Dietary Supplement|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
75406742|NCT02561754|Dietary Supplement|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
75406743|NCT02561754|Behavioral|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
75406744|NCT02561754|Behavioral|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
75406745|NCT02561754|Other|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
75712108|NCT04012918|Drug|Capecitabine plus aromatase inhibitor|Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
75406746|NCT02545998|Other|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
75712109|NCT04012918|Drug|A.I.|aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
75406747|NCT02524938|Dietary Supplement|Chlorogenic Acid (CGA) enriched coffee|"Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)"
75406748|NCT02524938|Dietary Supplement|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
75406749|NCT02524626|Procedure|Sham stimulation|Sham stimulation
75551840|NCT00353145|Behavioral|Questionnaire|Quality of Life Surveys
75551841|NCT00323648|Drug|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
75712110|NCT04062578|Behavioral|Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature|The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
75551842|NCT00353184|Drug|Montelukast 5-mg orally added to standard therapy|
75871957|NCT03489863|Drug|Ticagrelor|Maintenance dose will be maintained for 10±3 days.
75406750|NCT02524626|Procedure|Vagus stimulation|Vagus stimulation
75406751|NCT02420652|Drug|Aspirin|Given PO
75406752|NCT02420652|Other|Laboratory Biomarker Analysis|Correlative studies
75406753|NCT02420652|Drug|Metformin Hydrochloride|Given PO
75406754|NCT02420652|Other|Placebo|Given metformin hydrochloride placebo PO
75406755|NCT02420652|Other|Placebo|Given aspirin placebo PO
75406756|NCT02257242|Drug|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
75406757|NCT02257242|Drug|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
75406758|NCT02257242|Drug|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
75406759|NCT02034630|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
75406760|NCT02025036|Drug|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
75406761|NCT02025036|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
75406762|NCT02025036|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
75551843|NCT00323687|Drug|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
75551844|NCT02959515|Procedure|Capnothorax|Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
75551845|NCT02959515|Procedure|Capnothorax and CPAP|"Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.~Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager."
75551846|NCT00353223|Behavioral|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
75712111|NCT05131490|Behavioral|A mobile application intervention developed for gynecological cancer patients receiving chemotherapy|"The mobile application will consist of modules. It is planned to include four education modules and consultancy modules in the application.~Module 1: It will consist of sub-categories with information to be prepared in line with the current literature on gynecological cancer types and treatments applied. There will be information and short videos that will strengthen coping with physical symptoms, especially from chemotherapy.~Module 2: In this area, there will be meditation and relaxation/breathing exercises, information on relaxing complementary therapies, anxiety reduction and stress management techniques videos and audio recordings.~Module 3: Current developments on gynecological cancers will be included.~Module 4: Encouraging recovery stories and videos of cancer survivors will be included.~Module 5: Counseling module. This is the area where patients who cannot find answers in the frequently asked questions section can ask questions to the research team."
75712112|NCT00939718|Dietary Supplement|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
75712113|NCT00843141|Behavioral|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
75712114|NCT00843141|Behavioral|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
75871958|NCT03144934|Drug|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
75871959|NCT03144934|Drug|Placebo|This is the placebo of GX-I7 described above.
76039543|NCT05600465|Behavioral|Behavioral Activation + Occupational Therapy|In the BA-OT Approach, the PI will use an evidence-based 4-step process (Goal-Plan-Do-Check) to assist the older adults to develop strategies to plan and execute daily health self-management activities. BA-OT teaches older adults with MCC and functional limitations to 1) set achievable and meaningful activity goals, 2) engage in action planning that includes brainstorming strategies to overcome barriers, 3) evaluate the results after performing the activity, and 4) to modify the plan or choose a new goal, then generalize strategies to new problems. By assisting participants to develop daily routines and integrate safe health self-management activities into these routines, occupational therapists are providing strategies that support adaptation in the face of stressful situations.. Goal examples may include adapting and scheduling exercise plans, or exploring assistive devices and strategies for safe and healthy meal preparation.
76039544|NCT05600465|Behavioral|Enhanced Usual Care|Fitbit, 1 hour training, handout on managing chronic conditions
75406763|NCT02002572|Other|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
75406764|NCT01943916|Device|Imagio OA/US (US and OA/US)|opto-acoustic plus gray scale ultrasound
75406765|NCT01943916|Device|Imagio gray scale ultrasound|gray scale ultrasound alone
75406766|NCT01921686|Other|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
75406767|NCT01825356|Procedure|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
75406768|NCT01825356|Procedure|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
75406769|NCT01768338|Drug|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
75406770|NCT01564368|Procedure|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
75406771|NCT01345344|Behavioral|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
75551847|NCT00353223|Behavioral|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
75712115|NCT04062968|Other|Video education|"Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos ."
76039545|NCT04969393|Device|High intensity laser therapy|"Fifteen treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 5 weeks in succession via EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. Patients in group (A) received HILT along with the conventional physical therapy program. The session involved 3 subphases: (1) The Initial phase Analgesic phase, (2) In the intermediate phase Trigger point phaseand (3)The final phase Bio-stimulation phase was applied for 6 minutes with a slow scanning in several parallel longitudinal lines."
76039546|NCT04969393|Other|Conventional Physical Therapy|Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
75406772|NCT01345344|Behavioral|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
75406773|NCT00596154|Other|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
75406774|NCT00281658|Drug|Lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
75406775|NCT00281658|Drug|Paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
75406776|NCT00281658|Drug|Placebo|Paclitaxel Matching Placebo
75406777|NCT02417376|Device|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
75406778|NCT02417376|Device|Gracey curettes|set of 7 instruments number #1-14
75406779|NCT02417532|Device|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
75406780|NCT02417844|Drug|tamsulosin (Astellas)|
75406781|NCT02417844|Drug|Tamsulosin HCL|
75406782|NCT02418234|Other|mutation detection|
75406783|NCT02418234|Other|ARMS and ddPCR|
75712116|NCT00938938|Other|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
75406784|NCT02418234|Genetic|ctDNA analysis|
75406785|NCT02418312|Drug|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
75406786|NCT02418312|Drug|Placebo|placebo plus thienopyridine
75406787|NCT02418546|Behavioral|In-Person Nutritional Counseling by a Registered Dietitian|
75406788|NCT02418546|Behavioral|Nutritional counseling using an e-Health Application|
75406789|NCT02421354|Other|Laboratory Biomarker Analysis|Correlative studies
75406790|NCT02421354|Biological|Nivolumab|Given IV
75406791|NCT02421354|Other|Quality-of-Life Assessment|Ancillary studies
75406792|NCT02422290|Drug|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
75551848|NCT00323804|Biological|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
75551849|NCT00323804|Drug|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
75551850|NCT00323804|Drug|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
75551851|NCT00353340|Drug|n acetylcysteine|
75551852|NCT00353340|Drug|sodium bicarbonate|
75551853|NCT00353340|Drug|sodium chloride|
75551854|NCT00323843|Drug|Isoproterenol|
75712117|NCT00843219|Procedure|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
75551855|NCT00331812|Procedure|Mitochondrial functions and oxidative stress|
75551856|NCT00331851|Drug|liraglutide|
75551857|NCT00331851|Drug|insulin glargine|
75551858|NCT00331851|Drug|metformin|
76039547|NCT04960111|Device|RSA|application of tantalium microsphere around knee prosthesis and RSA X-ray post operative to detect early mobilization in follow up.
75551859|NCT00331851|Drug|glimepiride|
75551860|NCT00323999|Procedure|Hysteroscopic resection of fibroids, polyps and endometrium.|
75551861|NCT00331890|Drug|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
75551862|NCT00331890|Drug|Placebo|As active drug
75551863|NCT01059773|Drug|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients > 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
75551864|NCT01059773|Drug|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
75406793|NCT02425956|Device|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
75406794|NCT02427672|Device|Transcranial direct current stimulation|
75406795|NCT02427672|Device|Sham transcranial direct current stimulation|
75406796|NCT02427750|Biological|Aggripal®|TIV
75406797|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
75712118|NCT02568098|Drug|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
75712119|NCT02568098|Drug|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
75712120|NCT02568098|Drug|DHA-PQP|Regimen 6: DHA-PQP
75712121|NCT02732626|Procedure|radiofrequency ablation|
75712122|NCT00836667|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
75712123|NCT00836667|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
75406798|NCT02430090|Drug|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
75406799|NCT02430090|Drug|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
75406800|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
75406801|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
75406802|NCT02431572|Other|PBR PET|
75406803|NCT02431572|Biological|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
75406804|NCT02431572|Radiation|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
75406805|NCT02431650|Drug|OZ439|
75551865|NCT00353379|Drug|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
75551866|NCT00353379|Drug|Placebo|Participants will take placebo for 6 weeks.
75551867|NCT00324077|Drug|Dasatinib in combination with imatinib|
75551868|NCT00331929|Device|Minato A 500 AS spirometer|Spirometry at rest
75551869|NCT00324194|Drug|MGCD0103|MGCD0103 oral dose given 2 times per week.
75551870|NCT00324311|Drug|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
75551871|NCT00353613|Behavioral|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
75551872|NCT00324389|Drug|Interferon alpha|
75551873|NCT00332007|Drug|Tonabersat|two tablets once daily
75551874|NCT00332007|Drug|Placebo|two tablets once daily
75551875|NCT00353691|Drug|glimepiride|
75551876|NCT00353691|Drug|metformin|
75551877|NCT00324428|Procedure|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
75551878|NCT00332046|Drug|GW679769|
75551879|NCT00324467|Drug|Cyclophosphamide|"Dose: 750 mg/m^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
75551880|NCT00324467|Drug|Doxorubicin|"Dose: 50 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
75551881|NCT00324467|Drug|Vincristine|"Dose: 1.4 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
75551882|NCT00324467|Drug|Prednisone|"Dose: 45 mg/m^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
75406806|NCT02431650|Drug|Primaquine|
75406807|NCT02435706|Procedure|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
75406808|NCT02435706|Procedure|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
75406809|NCT02435706|Device|Implant and temporary crown|Both groups receive this intervention
75406810|NCT02437344|Drug|CI-581aa|92 minute infusion of CI-581aa
75406811|NCT02437344|Drug|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
75406812|NCT02440308|Drug|68Ga-DOTA-Bombesin|"68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl.~68Ga-DOTA-Bombesin is administered intravenously (IV)"
75551883|NCT00324467|Drug|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
75551884|NCT00324467|Drug|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
75551885|NCT00324467|Drug|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
75551886|NCT00324467|Drug|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
75551887|NCT00324467|Drug|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
75551888|NCT00324467|Drug|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
76039548|NCT04968691|Other|Telerehabilitation based exercise treatment|The telerehabilitation group will be shown how to do the exercises online by the researcher before each session, 3 sessions a week for 6 weeks, with mobile telecommunication applications, and it will be ensured that the patients do the exercises correctly and are followed up. In addition, at the beginning of each week, videos with the exercise content of that week will also be sent.
75406813|NCT02440308|Procedure|Magnetic Resonance Imaging (MRI) scan|
75406814|NCT02440308|Procedure|Positron Emission Tomography (PET) scan|
75406815|NCT02444988|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
75406816|NCT02444988|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
75406817|NCT02446314|Dietary Supplement|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
75406818|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
75406819|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
75406820|NCT02446314|Dietary Supplement|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
75406821|NCT02448654|Drug|Tolcapone|Tolcapone will be compared to sugar pill
75551889|NCT00324467|Drug|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
75551890|NCT00324467|Drug|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)"
75551891|NCT00324467|Drug|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
75406822|NCT02448654|Drug|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
75406823|NCT02449356|Device|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
75406824|NCT02451150|Drug|Azilsartan|Azilsartan tablets
75406825|NCT02452866|Drug|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
75406826|NCT02452944|Device|nerve stimulator (stimuplex HNS12)|whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
75406827|NCT02452944|Device|ultrasound|we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
75551892|NCT00324467|Drug|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
75551893|NCT00324467|Drug|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
75551894|NCT00324467|Drug|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
75551895|NCT00324467|Drug|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
75551896|NCT00324467|Drug|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
75551897|NCT00324467|Other|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
75551898|NCT00332085|Drug|Chromium Picolinate|
75406828|NCT02460666|Behavioral|Tai-Chi-Chih (TCC)|
75406829|NCT02460666|Behavioral|Health Education and Wellness Classes (HEW)|
75551899|NCT00324506|Drug|Mycophenolate Mofetil (CellCept)|
75551900|NCT00332124|Drug|Choline|900 mg every day until birth of infant
75551901|NCT00332124|Dietary Supplement|Placebo|Corn oil every day in place of choline
75551902|NCT00419432|Other|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
75712124|NCT03898232|Radiation|Computed Tomography (CT) Scan of the Lumbar Spine|Patients in the cohort who have not received a 12 month post-op CT scan will be asked to enroll in the study and undergo a CT of the lumbar spine.
75551903|NCT00419432|Other|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
75551904|NCT04714554|Drug|Relugolix/E2/NETA FDC|Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
75551905|NCT04714554|Drug|Relugolix|Relugolix 120-mg tablets; oral administration.
75551906|NCT04714554|Drug|Erythromycin|Erythromycin 500-mg tablets; oral administration.
75551907|NCT00419471|Drug|Escitalopram|Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
75551908|NCT00419471|Drug|Placebo|Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
75551909|NCT00419510|Behavioral|Culturally Tailored Genetic Counseling|
75551910|NCT00353769|Procedure|Hair Apposition Technique|
76039549|NCT04968691|Other|Home based exercise treatment|n the study, exercise cards were given to the control group and the exercise treatment they were asked to do at home 3 sessions a week for 6 weeks
76039550|NCT04959955|Diagnostic Test||
75406830|NCT02461992|Drug|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
75406831|NCT02462070|Drug|IDP-118 Lotion|Lotion
75406832|NCT02462070|Drug|IDP-118 Vehicle Lotion|Lotion
75406833|NCT02462148|Drug|Dexamethasone|Used in nerve block mixture
75406834|NCT02462148|Drug|Bupivacaine|Used in nerve block mixture
75406835|NCT02462148|Drug|Epinephrine|Used in nerve block mixture
75406836|NCT02462148|Procedure|Saphenous Peripheral Nerve Block|Peripheral nerve block.
75406837|NCT02462382|Procedure|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
75551911|NCT00324545|Behavioral|Medium-intensity Minimally-directive Counseling|
75551912|NCT00426348|Drug|Valsartan|Valsartan (80-160mg/day)
75551913|NCT00426348|Drug|Probucol|Probucol (750mg/day)
75551914|NCT00426348|Drug|Placebo|Placebo
75551915|NCT00324584|Device|Telemonitoring of glucose values using GlucoNet device|
75551916|NCT00353808|Drug|[S,S]-Reboxetine|
75551917|NCT00324623|Biological|Melan-A VLP vaccine, IMP321 adjuvant|
75551918|NCT00324623|Biological|adoptive immunotherapy|
75551919|NCT00324623|Biological|therapeutic autologous lymphocytes|
75551920|NCT00324623|Drug|cyclophosphamide|
75551921|NCT00324623|Drug|fludarabine phosphate|
75551922|NCT00353847|Device|Acupuncture|
75406838|NCT02462382|Drug|Ropivacaine|The study group will receive a pump with study drug attached to a catheter placed into the shoulder area by the anesthesiologist.
75712125|NCT00940030|Other|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
75551923|NCT00324662|Device|Implantable cardioverter-defibrillator|
75712126|NCT00940030|Other|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
75712127|NCT00845559|Drug|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
75712128|NCT00939016|Other|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
75551924|NCT00426426|Behavioral|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
75551925|NCT00426426|Behavioral|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
75712129|NCT02567240|Other|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
75712130|NCT00940810|Procedure|Plasma Disc Decompression/Nucleoplasty|"Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.~Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
76039551|NCT04951843|Dietary Supplement|Black soybean koji product|Black soybean koji product
75406839|NCT02462382|Drug|Saline|The control group will receive a pump with saine attached to a catheter placed into the shoulder area by the anesthesiologist.
75551926|NCT00426426|Behavioral|Waiting list|
75551927|NCT00324779|Biological|rituximab|
76039552|NCT04968769|Other|ischemic compression|manual therapy
76039553|NCT04968769|Other|kinesio taping|elastic therapeutic taping
76039554|NCT04968769|Other|exercise|posture exercises
75551928|NCT00353886|Procedure|TONI-3|
76039555|NCT04952155|Drug|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.
76039556|NCT04884971|Drug|Intestinal microbiota transplant (IMT)|Two size 00 capsules from a single lot will be taken daily. Approximately 2.0 x 10^11 bacteria from a healthy donor are contained in each capsule.
75551929|NCT00353886|Procedure|WRAT-3|
75551930|NCT00353886|Procedure|Connor's Rating Scales PRS & TRS|
75551931|NCT00353886|Procedure|Peabody Picture Vocabulary Test|
75551932|NCT00353886|Procedure|Children's Memory Scale|
75551933|NCT00353886|Procedure|WISC-3|
75551934|NCT00353886|Procedure|Behavioral Assessment System for Children PRS & TRS|
75551935|NCT00324818|Drug|metronidazole and azithromycin|
75551936|NCT00324974|Drug|Lansoprazole microgranules suspension|"Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks."
75551937|NCT00324974|Drug|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
75551938|NCT00325013|Drug|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
75551939|NCT00353964|Drug|rEV131|
75551940|NCT00353964|Drug|Prenisolone sodium phosphate 1.0%|
75551941|NCT00353964|Drug|rEV131 vehicle|
75551942|NCT00354003|Behavioral|A series of questionnaires|Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
75551943|NCT00325169|Drug|Tiotropium + SERETIDE 50/500|
75551944|NCT00426504|Procedure|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
75551945|NCT00325208|Device|partial-vacuum milk bottle|
75551946|NCT00325208|Device|anti-vacuum milk bottle|
75551947|NCT00426543|Drug|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
75406840|NCT02464176|Drug|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
75406841|NCT02464176|Drug|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
75406842|NCT02464176|Drug|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
75406843|NCT02464176|Procedure|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
75406844|NCT02464176|Drug|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
75551948|NCT00426543|Drug|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
75551949|NCT00325247|Drug|ZINC|
75551950|NCT00325286|Drug|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
75551951|NCT00354042|Drug|GW597901X|
75406845|NCT02466126|Behavioral|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
75406846|NCT02467842|Biological|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
75406847|NCT02467842|Biological|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
75406848|NCT02467842|Biological|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
75551952|NCT00325325|Drug|everolimus and tacrolimus|
75551953|NCT00325481|Drug|FluMist|
75551954|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
75551955|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
75551956|NCT00354081|Drug|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
75551957|NCT00354081|Drug|placebo|placebo, in a capsule, taken orally once a day
75551958|NCT00325559|Procedure|Normoinsulinemic eu- or hyperglycemic clamp|
75551959|NCT04705311|Other|Pain neuroscience education|Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.
75551960|NCT04705311|Behavioral|Rotator cuff repair rehabilitation|Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
75551961|NCT00325637|Drug|cilnidipine|Cilnidipine 10~20mg, qd, po for 4 weeks.
75551962|NCT04714593|Biological|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
75551963|NCT00426582|Drug|Patupilone|
75406849|NCT02468154|Device|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
75551964|NCT04717583|Procedure|Intense pulsed light (IPL) treatment|"After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
75551965|NCT00354198|Drug|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
75712131|NCT00940810|Procedure|Conservative Care (physiotherapy)|"Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.~Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
75406850|NCT02468154|Other|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
75406851|NCT02468700|Drug|Dexamethasone|
75406852|NCT02468700|Other|Placebo Vehicle|
75406853|NCT02469714|Behavioral|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
75406854|NCT02469870|Behavioral|Autism Parent Trainer (APT)|Experimental condition
75406855|NCT02469870|Behavioral|Teaching Routines (Control)|Content comparison group.
75406856|NCT02470494|Device|Sound amplification provided via the EarLens CHD|Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
75712132|NCT00843297|Device|Coolgard|invasive Cooling via femoral ICY-catheter
75712133|NCT00843297|Device|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
75712134|NCT00843297|Other|Conventional treatment|Intensive care-treatment without cooling
75712135|NCT05107778|Drug|ASC42 10mg|ASC42 10mg orally once daily;
75406857|NCT02472522|Drug|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
75406858|NCT02472522|Other|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
75406859|NCT02476032|Device|Prof applied oxalate|Crest Sensi-Stop strips (Procter & Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
75712136|NCT05107778|Drug|ASC42 15mg|ASC42 15mg orally once daily.
75406860|NCT02476032|Device|Self applied oxalate|Subjects will apply the strips (Procter & Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
75406861|NCT02476032|Device|Prof applied placebo|Crest Sensi-Stop strips (Procter & Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
75406862|NCT02476890|Drug|Gefapixant 100 mg|Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
75551966|NCT00354198|Drug|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
75551967|NCT00325676|Drug|Pantoprazole|
75712137|NCT05107778|Drug|ih PEG-IFN α-2a|ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
75712138|NCT05107778|Drug|Entecavir|Entecavir 0.5 mg orally once daily.
75712139|NCT05107778|Drug|Placebo|Placebo orally once daily.
75551968|NCT00325715|Drug|AGN 201904|
75712140|NCT00372619|Drug|clofarabine|Given IV for 5 days
75712141|NCT00372619|Drug|cytarabine|Given IV
75712142|NCT00372619|Drug|methotrexate|Given intrathecally or IT age based dosage
75712143|NCT00372619|Other|laboratory biomarker analysis|
75712144|NCT02546115|Device|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
75406863|NCT02476890|Drug|Placebo|Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
75406864|NCT02480166|Drug|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
75406865|NCT02480166|Drug|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
75406866|NCT02481258|Drug|Ataciguat (HMR1766)|
75551969|NCT00325715|Drug|esomeprazole|
75406867|NCT02481258|Other|Placebo Comparator: Matching Placebo|
75406868|NCT02483676|Device|Treadmill plus anklebot|This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.
75551970|NCT00354237|Other|Conventional antidiabetic treatment|No intensive treatment
75712145|NCT02546115|Other|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
75712146|NCT04477616|Drug|Day 7 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
75712147|NCT04477616|Drug|Day 3 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
75406869|NCT02483676|Behavioral|Treadmill only|This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period
75406870|NCT02484222|Drug|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
75406871|NCT02486016|Drug|Duragesic reference fentanyl TDS|25 µg/hour
75712148|NCT00851175|Drug|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
75712149|NCT00851175|Drug|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
75712150|NCT04043013|Device|Mini-Taurus® (Rocky Mountain©) Brackets|
75712151|NCT04043013|Device|Smart Clip® SL3 High Torque (3M Unitek©)|
75712152|NCT04043013|Device|Tip-Edge Plus® (TP Orthodontics©)|
75406872|NCT02486016|Drug|Apotex generic fentanyl TDS|25 µg/hour
75406873|NCT02486016|Drug|Mylan generic fentanyl TDS|25 µg/hour
75406874|NCT02486328|Drug|Midazolam|Dosage adjustment
75406875|NCT02486328|Drug|Meperidine|Dosage adjustment
75406876|NCT02486328|Drug|Remifentanil|Dosage adjustment
75406877|NCT02486328|Drug|Propofol|Dosage adjustment
75406878|NCT02491788|Drug|Suvorexant|
75406879|NCT02491788|Drug|Placebo|
75406880|NCT02491944|Drug|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
75406881|NCT02491944|Drug|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of [14C] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
75406882|NCT02492802|Drug|posaconazole|collection plasma samples for measuring posaconazole drug concentration
75406883|NCT02493036|Drug|SYN-010|
75406884|NCT02494518|Behavioral|Forced Exercise & Upper Extremity Repetitive Task Practice|
75551971|NCT00354237|Other|Intensive insulin treatment|Intensive insulin treatment
75406885|NCT02494518|Behavioral|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
75551972|NCT00325793|Drug|Nicardipine|
75551973|NCT00426621|Drug|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
75406886|NCT02494518|Behavioral|Stroke Education & Upper Extremity Repetitive Task Practice|
75406887|NCT02495454|Drug|Ga101|
75406888|NCT02500368|Device|silicone hydrogel lens (test)|contact lens
75551974|NCT00426621|Drug|Placebo|4 grams per knee, 4 times per day, for 12 weeks
75551975|NCT00325832|Device|BpTRU|
75712153|NCT04043013|Device|Victory® (3M Unitek©)|
75712154|NCT00845637|Drug|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
75712155|NCT00845637|Drug|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
75712156|NCT03992833|Other|lung cancer screening|"In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume < 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume > 300 mm3 (positive)."
76039557|NCT04959721|Combination Product|Injection with triamcinolone acetonide, bupivacaine, and normal saline|"Triamcinolone acetonide is a synthetic corticosteroid medication used intra-articularly to treat various joint conditions. Bupivacaine is a medication used to decrease feeling in a specific area. In nerve blocks, it is injected around a nerve that supplies the area, or into the spinal canal's epidural space. Saline is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.~The procedure will be performed with the patient in a prone position under a C-arm fluoroscopy scanner, with the thorax rests on 2 pillows, flexing the neck maximally, and the head turns 60-90° away from the side of injection. The C-arm tube will be angled cephalad, until it was at a tangent to the cervical facet joint space. A 26-gauge, 90 mm spinal needle will be inserted parallel to the C-arm beam. To confirm intra-articular placement of the needle tip, an arthrogram of the cervical facet joint will be performed by injecting 0.3 mL of contrast."
76039558|NCT04717739|Device|TTFields|Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
75406889|NCT02500368|Device|enfilcon A lens (control)|contact lens
75406890|NCT02500602|Drug|doxazosin|active medication
75406891|NCT02500602|Drug|placebo|placebo pill
75406892|NCT02500836|Drug|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
75406893|NCT02500836|Drug|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
75551976|NCT00325832|Device|Conventional mercury sphygmomanometry|
75551977|NCT04717778|Dietary Supplement|Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk|They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
75551978|NCT04714242|Drug|Ranibizumab Injection|Three monthly intravitreal injections of Ranibizumab
75551979|NCT00353535|Procedure|Total Lymphoid irradiation|
75551980|NCT00325871|Procedure|concurrent chemoradiation|
75551981|NCT00354276|Drug|cytarabine|
75551982|NCT00354276|Drug|laromustine|
75551983|NCT00325910|Drug|Metformin|
75551984|NCT00354315|Behavioral|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
75551985|NCT00325949|Drug|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
75712157|NCT02566226|Drug|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
75712158|NCT02566226|Drug|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
75712159|NCT00837057|Procedure|crrt|early CRRT (35 ml/kg/h)& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
75712160|NCT01046617|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
75712161|NCT00837135|Other|Screening|"A. SCREENING~Consent~Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)~Physical Exam, History, Blood Tests~Skin Test (for allergy to saccaromyces cerevisiae) yeast.~Collection of Blood for research~B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)~C. ENROLLMENT INTO ACTIVE PART OF STUDY~Consent~Chemotherapy~GI-4000 Vaccine #1 + Prevnar + Activated T Cells~GI-4000 Vaccine #2~Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
76039559|NCT04968613|Drug|Madopar monotherapy|In addition to basic treatment, the patient also received Madopar treatment
75406894|NCT02500836|Drug|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
76039560|NCT04968613|Drug|senfrol monotherapy|In addition to the basic treatment, the patient also received the rofosson treatment
75712162|NCT00837135|Biological|GI-4000 Vaccine|"Chemotherapy and Radiation~GI-4000 Vaccine #3~GI-4000 Vaccine #4"
75406895|NCT02503410|Behavioral|Usual care|Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
75551986|NCT00325949|Drug|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
75551987|NCT00325949|Drug|placebo|2 tablets BID
75551988|NCT04714476|Device|Made-to-measure compression garment|"Subjects will wear one of two made-to-measure compression garments:~(1) JOBST® Confidence leggins (BT) and (2) JOBST® Confidence Bermuda (ET)"
75712163|NCT00837135|Biological|GI-4000 Vaccine + Activated T Cells|"Apheresis #2~Chemoradiation~Activated T Cells + GI-4000 Vaccine #3~GI-4000 Vaccine #4"
75712164|NCT00837135|Biological|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.~B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
75712165|NCT00562588|Drug|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
75712166|NCT00562588|Drug|ASA 100 mg qd|
75712167|NCT00851331|Genetic|genome analyzes (genetic defects and pathophysiological mechanisms )|
75712168|NCT00845715|Other|Early motion|Early referral to physical therapy for range of motion (2 days post)
75712169|NCT00845715|Other|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
76039561|NCT04968613|Drug|placebo monotherapy|In addition to basic treatment, the patient also received selegiline treatment
76039562|NCT04968535|Device|StimaWELL|mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed
76039563|NCT03058549|Behavioral|Family Expectations|Relationship education and referral services for expectant couples.
75406896|NCT02503410|Behavioral|Interactive gaming|Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
75406897|NCT02507388|Drug|Brolucizumab 3 mg/50 μL|Administered as an intravitreal injection
75406898|NCT02507388|Drug|Brolucizumab 6 mg/50 μL|Administered as an intravitreal injection
75551989|NCT00326027|Drug|Pantoprazole|Efficacy of Pantoprazole
75551990|NCT01059318|Drug|Everolimus|Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
75551991|NCT00326066|Device|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
76039564|NCT04676555|Drug|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
76039565|NCT04676555|Drug|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
75406899|NCT02508480|Behavioral|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
75712170|NCT02546349|Drug|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
75712171|NCT00845793|Behavioral|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
76039566|NCT02445963|Biological|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
76039567|NCT04314167|Drug|Lowering cholesterol concentrations by PCSK-9 inhibitor|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
76039568|NCT04968301|Device|ultrasound Doppler|A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
75406900|NCT02508480|Behavioral|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
75406901|NCT02508636|Drug|Enzalutamide|Given orally
75406902|NCT02508636|Drug|Leuprolide|Given via intramuscular injection
75406903|NCT02508636|Radiation|Intensity-Modulated Radiation Therapy|A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
75406904|NCT02512224|Device|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
75406905|NCT02512224|Device|Enteral nutrition|Participants are retrospectively selected with propensity score matching
75406906|NCT02513940|Drug|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
75406907|NCT02513940|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
75406908|NCT02513940|Drug|Placebo|Subjects will receive placebo transdermal gel and placebo (lactose) capsules
75406909|NCT02513940|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
75406910|NCT02515656|Drug|POLYGYNAX®|
75406911|NCT02515656|Drug|GYNODAKTARIN®|
75406912|NCT02515656|Drug|Placebo|
75406913|NCT02515890|Drug|Dexmedetomidine|Selected subjects received this drug during a portion of the study
75406914|NCT02515890|Drug|Midazolam|Selected subjects received this drug during a portion of the study
75406915|NCT02515890|Device|Peripheral nerve stimulation|Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
75406916|NCT02515890|Drug|Ketamine|Selected subjects received this drug during a portion of the study
75406917|NCT02516046|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
75406918|NCT02516046|Procedure|PET Scan|positron emission tomography (PET) scan
75551992|NCT00326066|Procedure|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
75551993|NCT04714515|Drug|Montelukast|An FDA approved medicine to treat asthmatic patients
75551994|NCT04714515|Drug|Hydroxychloroquine|An FDA approved antiarthritis drug
75551995|NCT04714515|Drug|Ivermectin|An FDA approved anti-parasitic medicine
75551996|NCT00326105|Drug|Quetiapine fumarate|
75551997|NCT00354354|Drug|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
75406919|NCT02517996|Drug|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
75406920|NCT02517996|Drug|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
75406921|NCT02518230|Device|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
75406922|NCT02518230|Device|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
75406923|NCT02519244|Device|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
75406924|NCT02520414|Device|Symphion® Bipolar Hysteroscopic Tissue Resection System|
75551998|NCT00326144|Drug|Quetiapine fumarate|
75406925|NCT02521974|Biological|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
75551999|NCT01058655|Drug|Everolimus|
75552000|NCT01058655|Drug|Tivozanib|
75712172|NCT00851487|Drug|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
76039569|NCT05575427|Drug|Minocycline|The patients will receive minocycline oral between 7-28 days
76039570|NCT05575427|Drug|Levofloxacin or Cotrimoxazole|The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
76039571|NCT05575427|Drug|Placebo|Capsule without active compound
75552001|NCT00326222|Behavioral|Lifestyle counseling|Self-management group education
75552002|NCT00326261|Procedure|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
75552003|NCT00326261|Procedure|Ultrasound|
75552004|NCT00326300|Drug|methylphenidate hydrochloride extended-release tablets|
75712173|NCT00851487|Drug|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
76039572|NCT03059095|Behavioral|Yoga & Meditation|Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
76039573|NCT04959253|Combination Product|Psilocybin assisted therapy|A package of psychological therapy and a single dosing session of psilocybin.
75871960|NCT05763030|Behavioral|Adapted Sleep Well, Bee Well|The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
76039574|NCT04959253|Combination Product|Placebo assisted therapy|A package of psychological therapy and a single dosing session of placebo.
76039575|NCT02499159|Drug|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
76039576|NCT02499159|Drug|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
75406926|NCT02522442|Device|CPAP|Continuous positive airway pressure
76039577|NCT01664039|Drug|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
76039578|NCT01664039|Drug|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
75406927|NCT02522442|Device|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
75406928|NCT02523690|Drug|Lorcaserin|10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
75406929|NCT02523690|Drug|Placebo|Oral or enteral, single dose. Oral or enteral, single dose two days later
75406930|NCT02523924|Drug|18F-DCFPyL|18F-DCFPyL PET/CT
75406931|NCT02525718|Drug|Saline|If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)
75406932|NCT02525718|Drug|0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone|"If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively."
75406933|NCT02526654|Diagnostic Test|Heidelberg Edge Perimeter|HEP measures peripheral vision
75406934|NCT02526654|Diagnostic Test|Octopus Visual Field|OVF measures peripheral vision
75406935|NCT02526654|Diagnostic Test|Optical Coherence Tomography|OCT measures retinal nerve fiber layer thickness
75406936|NCT02527512|Drug|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
75406937|NCT02527512|Other|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
75406938|NCT02528370|Device|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
75406939|NCT02529072|Drug|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
75406940|NCT02529072|Biological|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
75406941|NCT02530476|Drug|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
75406942|NCT02530476|Drug|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
75406943|NCT02530554|Drug|CHG|Single application
75406944|NCT02531022|Behavioral|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
75406945|NCT02531022|Behavioral|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
75552005|NCT00426777|Drug|risedronate|risedronate 35mg tablet, weekly for 12 months
75406946|NCT02532036|Biological|Aerosol inhaled MVA85A|
75406947|NCT02532036|Biological|Intramuscular MVA85A|
75406948|NCT02532036|Biological|Intramuscular Saline placebo|
75406949|NCT02532036|Biological|Aerosol inhaled Saline placebo|
75552006|NCT00426777|Drug|risedronate|35mg weekly
75552007|NCT00426777|Drug|Control|risedronate-matched placebo weekly
75552008|NCT00326339|Drug|R788|R788 50 mg, 100 mg, or 150 mg PO bid
75552009|NCT00326339|Drug|Placebo|Placebo PO bid
75552010|NCT01058421|Procedure|intensive physical therapy|four week course of daily intensive physical therapy
75552011|NCT01058421|Procedure|control group|four weeks of routine physical therapy
75552012|NCT00419549|Drug|Glyceryl - trinitrate|Transdermal Patch once only
75712174|NCT00622167|Device|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
75712175|NCT00622167|Device|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
75712176|NCT02547675|Drug|Rociletinib|Rociletinib will be administered to patients orally
76039579|NCT04968145|Other|Home To Stay Mobile Health Application|"Home to stay is an integrated discharge monitoring system with a mobile application. Features of the application include a Daily Health Check to report on post-operative recovery, picture taking capability to photograph incisions/wounds and educational information on post-operative care at home.~Patients will complete a Daily Health Check on post-discharge Day #1-14, #21 and #30. The Daily Health Check consists of a series of questions specific to colorectal surgery as well as the Quality of Recovery (QoR-15) questionnaire. After completion, the participant will receive a list of recommendations tailored to their responses including relevant education modules, to contact the surgical team or in urgent cases to go to the nearest emergency room. The participants' responses will be monitored daily via a secure web site. Any participants' responses in the extreme ranges are automatically red flagged and notify the health care team that a follow up telephone call is required."
76039580|NCT02445573|Other|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
75406950|NCT02536248|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
75406951|NCT02536248|Drug|Placebo|Placebo for 6 weeks
75406952|NCT02537730|Device|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
75406953|NCT02537730|Device|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
75406954|NCT02537730|Device|comfilcon A|contact lens
75552013|NCT00419549|Drug|Valdecoxib|Single parenteral administration
75552014|NCT00354471|Procedure|Uterine Artery Embolization|
75552015|NCT00326378|Drug|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
75552016|NCT00326378|Drug|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
75552017|NCT00326573|Behavioral|Motivational Interviewing|
75552018|NCT04717232|Other|Blended learning approach to mentoring education for dental health care professionals|The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.
75552019|NCT04717232|Other|The interprofessional online mentoring education|The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.
75552020|NCT00326768|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
75552021|NCT00326768|Drug|Telmisartan 40 mg|
75552022|NCT00326768|Drug|Telmisartan 80 mg/HCTZ 12.5 mg|
75552023|NCT00326807|Drug|Naltrexone|
75712177|NCT04042857|Device|Next Science Treatment Gel|Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.
75406955|NCT02538042|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking <10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked <10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
75406956|NCT02538042|Drug|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
75406957|NCT02538042|Behavioral|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
75406958|NCT02538042|Behavioral|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
75406959|NCT02538354|Dietary Supplement|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
75406960|NCT02539992|Device|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
75406961|NCT02539992|Device|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
75406962|NCT02539992|Device|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
75406963|NCT02540226|Drug|Intravenous tranexamic acid|
75406964|NCT02540226|Drug|Topical tranexamic acid|
75406965|NCT02540226|Drug|Intravenous saline|
75406966|NCT02540226|Drug|Topical saline|
75406967|NCT02540772|Behavioral|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
75712178|NCT04235907|Other|Telerehabilitation|Internet-guided rehabilitation with weekly phone calls from a physical therapist.
75712179|NCT04235907|Other|Standard rehabilitation|Prescription for physical therapy and a printed list of exercises to complete.
75712180|NCT00562354|Biological|13vPnC|13vPnC for both stratum
75712181|NCT00372385|Drug|Ribavirin|tablet
75712182|NCT00372385|Drug|Pegylated Interferon Alfa 2a|Solution for injection
75712183|NCT00372385|Drug|Placebo|tablet
75712184|NCT00372385|Drug|Telaprevir|tablet
75712185|NCT03830281|Drug|Ultra-Rapid Lispro|Administered SC
75552024|NCT01058304|Other|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
75552025|NCT01058304|Other|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
75552026|NCT00327002|Drug|LY518674|
75552027|NCT01058265|Other|Integrative|Integrative Medicine medical evaluation.
75552028|NCT01058265|Other|Standard|Standard general medical evaluation.
75552029|NCT00354510|Drug|GW842470X cream|
75552030|NCT04717037|Biological|Olive Oil Massage|olive oil massage application.
75552031|NCT00354549|Drug|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
75552032|NCT00354549|Drug|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
75552033|NCT01057251|Drug|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
75406968|NCT02541864|Drug|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
75406969|NCT02541864|Drug|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
75406970|NCT02541942|Other|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
75406971|NCT02542410|Drug|Cabergoline|
75406972|NCT02542410|Drug|Norethindrone acetate|
75552034|NCT01057251|Drug|Placebo|5 mg or 20 mg once daily, oral administration
75552035|NCT04708353|Drug|placebo capsule (vitamin c)|the patient will receive one placebo capsule (vitamin c) once one hour before the operation
75552036|NCT04708353|Drug|Group pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
75552037|NCT04708353|Drug|Group pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
75552038|NCT04708574|Behavioral|Lifestyle intervention|
75406973|NCT02544984|Drug|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
75406974|NCT02544984|Drug|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
75552039|NCT04708574|Other|Placebo - Control|
75552040|NCT00425646|Biological|bevacizumab|
75552041|NCT00425646|Drug|imatinib mesylate|
75552042|NCT00327080|Procedure|MRI|
75552043|NCT00327080|Drug|L-NMMA|
75552044|NCT00327080|Drug|Acetylcholine|
75406975|NCT02546388|Drug|Indium-111 Pentreotide|
75406976|NCT02546388|Drug|Gallium-68 DOTATATE|
75406977|NCT02547012|Drug|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
75552045|NCT00426816|Drug|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
75552046|NCT00426816|Drug|Placebo|Placebo to match SB-649868
75552047|NCT00327119|Drug|ABX-EGF (panitumumab)|
75552048|NCT00426894|Procedure|samples from nostrils, mouth, axillas, perianal area and postoperative wound|
75552049|NCT00327158|Procedure|Transesophageal transducer|One time use of reamer during surgery
75552050|NCT00327158|Procedure|echocardiography|takes photos of right atrium during the reaming processes
75552051|NCT00426933|Drug|Daptomycin|
75552052|NCT00426933|Drug|Vancomycin|
75552053|NCT00327197|Drug|Prednisolone|Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
75552054|NCT00327197|Procedure|Bronchoscopy|All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
75406978|NCT02547012|Drug|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
75552055|NCT00425724|Drug|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
75552056|NCT00426972|Drug|estradiol (Zesteem)|
75406979|NCT02547714|Drug|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
75712186|NCT03830281|Drug|Insulin Lispro|Administered SC
75406980|NCT02548728|Drug|Intranasal Oxytocin Spray|10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
75406981|NCT02548728|Drug|Placebo|10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
75406982|NCT02549040|Drug|Treatment A: Doravirine 100 mg film coated tablet|Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
75406983|NCT02549040|Drug|Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)|Single doravirine NF Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1
75406984|NCT02549040|Drug|Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)|Single doravirine NF Type 2 dose (150 mg tablet [30% drug loaded granule])administered orally at the start of Period 3
75406985|NCT02549040|Drug|Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)|Single doravirine NF Type 3 dose (150 mg tablet [50% drug loaded granule])administered orally at the start of Period 4
75406986|NCT02549040|Drug|Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)|Single doravirine NF Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5
75406987|NCT02549508|Device|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on
75406988|NCT02549508|Device|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off
75406989|NCT02550132|Procedure|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
75406990|NCT02550132|Device|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
75406991|NCT02550210|Device|Breast Cancer Locator (BCL)|This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
75406992|NCT02551224|Other|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
75552057|NCT00327275|Behavioral|strength training|
75552058|NCT00327314|Procedure|Transplantation|
75552059|NCT00327314|Procedure|Hematopoietic cell transplantation|
75552060|NCT00425763|Drug|AQAS|AQAS dosed by body weight, on days 0, 1, 2
75552061|NCT00327353|Drug|formoterol (TURBOHALER)|
75552062|NCT00327353|Drug|Salmeterol (DISKUS)|
75712187|NCT00563368|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
75712188|NCT00563368|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
75712189|NCT00563368|Drug|topiramate|topiramate 46 mg, po once daily
75712190|NCT00563368|Drug|topiramate|topiramate 92 mg, po once daily
75712191|NCT00563368|Drug|phentermine|phentermine 7.5 mg, po once daily
75712192|NCT00563368|Drug|phentermine|phentermine 15 mg, po once daily
75712193|NCT00563368|Drug|VI-0521|placebo, po once daily
75712194|NCT02535013|Device|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
75406993|NCT02551770|Procedure|Scaling and root planing|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw.
75406994|NCT02551770|Procedure|Scaling and root planing without Emdogain|Using minimally invasive surgical procedure (scaling and root planing) without Emdogain application to treat one contra-lateral quadrant in subject's jaw.
75406995|NCT02551770|Device|Emdogain application|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw
75406996|NCT02553798|Drug|Glycopyrronium Topical Wipes|Glycopyrronium Topical Wipes
75406997|NCT02557698|Other|Balneum oil bath|
75406998|NCT02560038|Drug|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
75406999|NCT02560038|Drug|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
75552063|NCT00425841|Drug|gemcitabine hydrochloride|
75552064|NCT00425841|Drug|oxaliplatin|
75552065|NCT00425841|Procedure|adjuvant therapy|
75552066|NCT00425841|Procedure|neoadjuvant therapy|
75552067|NCT00425841|Radiation|hypofractionated radiation therapy|
75552068|NCT00425841|Radiation|stereotactic radiosurgery|
75552069|NCT00327431|Genetic|Cheek swab samples for DNA|
75552070|NCT00427050|Drug|PEP005|
75871961|NCT05665205|Other|Aerobic plus strength group|A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist
75552071|NCT05459168|Other|Calm Meditation Smartphone App Feedback|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
75871962|NCT05665205|Other|Aerobic group|This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
75871963|NCT04344444|Drug|Hydroxychloroquine|tablets provided as described in Arm B
75871964|NCT04344444|Drug|Azithromycin|tablets provided as described in Arm C
75407000|NCT02560038|Drug|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
75407001|NCT02560584|Drug|Hexaminolevulinate hydrochloride|Instillation in bladder
75407002|NCT02560584|Device|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
75407003|NCT02561130|Drug|insulin glargine|Dose is titrated to achieve fasting normoglycemia
75407004|NCT02561130|Drug|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
75552072|NCT05459168|Other|Cancer-Specific Meditation App Prototype Design|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
75552073|NCT05459168|Device|Cancer-Specific Meditation App Prototype|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
75552074|NCT05458895|Other|ECIG lab session 1|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
75407005|NCT02561130|Drug|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
75407006|NCT02561130|Behavioral|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
75407007|NCT02562066|Drug|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
75407008|NCT02562066|Drug|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
75552075|NCT05458895|Other|ECIG lab session 2|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
75552076|NCT05458895|Other|ECIG lab session 3|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
75552077|NCT05458895|Other|ECIG lab session 4|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
75871965|NCT03489551|Drug|Haldol|
75871966|NCT03144544|Procedure|Pediatric surgical procedures|Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
75871967|NCT05762952|Drug|Dapagliflozin 10mg Tab|Once daily oral dapagliflozin 10mg
75871968|NCT05762952|Drug|Placebo|Placebo capsules formulated by pharmacy to be indistinguishable from active drug
75871969|NCT03722225|Other|Carbohydrate loading and high intermittent carbohydrate intake during physical exercise|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during PE and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
75871970|NCT05202834|Device|UltraClear|Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on human skin
75712195|NCT00390013|Drug|Gabapentin|"300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~day 1 you will take 1 capsule for the day~day 2 you will take 1 capsule 2 times for that day~days 3-6 you will take 1 capsule 3 times for those days~days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~days 13-14 you will take 2 capsules 3 times each day~continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~at completion of study treatment you will titrate off study drug over a weeks time."
75407009|NCT02562924|Device|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
75407010|NCT02562924|Drug|Budesonide|Topical steroid
75712196|NCT00390013|Drug|Placebo oral capsule|"Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~day 1 you will take 1 capsule for the day~day 2 you will take 1 capsule 2 times for that day~days 3-6 you will take 1 capsule 3 times for those days~days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~days 13-14 you will take 2 capsules 3 times each day~continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~at completion of study treatment you will titrate off study drug over a weeks time."
75407011|NCT02562924|Drug|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
76039581|NCT02445573|Other|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
75407012|NCT02562924|Drug|Prednisone|Post-operatively, 40 mg daily for 7 days
75407013|NCT02562924|Procedure|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
75407014|NCT02562924|Drug|nasal saline spray|saline nasal mist every hour while awake
75712197|NCT00561652|Behavioral|Education & Exercise|Education & Exercise
76039582|NCT05645705|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
75407015|NCT02563860|Drug|Lovastatin|dose escallating
75407016|NCT02564016|Drug|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
75407017|NCT02564016|Other|Capped Epidural|epidural will be capped with no saline infusion.
75407018|NCT02566044|Other|Placebo|Placebo
75407019|NCT02566044|Drug|QBW276|0.3 mg and 1.5 mg strengths
75407020|NCT02566590|Device|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
75407021|NCT02566590|Dietary Supplement|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
75712198|NCT00561652|Procedure|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education & Exercise)
75712199|NCT00697346|Drug|Alisertib|Alisertib (MLN8237) PIC or ECT
75712200|NCT00562120|Drug|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
76039583|NCT05645705|Other|LISTERINE Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
75407022|NCT02566590|Dietary Supplement|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
75407023|NCT02568852|Procedure|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
75407024|NCT02568852|Procedure|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
75407025|NCT02569086|Other|Blood draw|
75407026|NCT02569632|Biological|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
75407027|NCT02570022|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
75407028|NCT02570022|Procedure|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
75407029|NCT02570022|Drug|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
75407030|NCT02572752|Drug|Nintedanib|1 soft gelatine capsule, single dose, oral
75407031|NCT02572752|Drug|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
75407032|NCT02572752|Drug|Nintedanib|
75407033|NCT02574858|Drug|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
75407034|NCT02577042|Drug|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
75407035|NCT02577042|Drug|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
75407036|NCT02577042|Drug|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
76039584|NCT05645705|Other|Listerine Advanced Gum Alcohol|Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.
76039585|NCT05645705|Other|Listerine Advanced Gum Zero|Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.
76039586|NCT05645705|Other|LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
75552078|NCT05458895|Other|ECIG lab session 5|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
75407037|NCT02577510|Drug|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament [7]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic [7]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
75407038|NCT02577510|Drug|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle [6]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
75407039|NCT02577822|Device|Taperloc standard length stem|
75407040|NCT02577822|Device|Taperloc short length stem|
75407041|NCT02577900|Device|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
75407042|NCT02577900|Device|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
75407043|NCT02577900|Device|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
75407044|NCT02580318|Device|breathalyzer|
75407045|NCT02582970|Drug|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
75407046|NCT02582970|Drug|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
75407047|NCT02582970|Drug|Irinotecan|Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
75407048|NCT02582970|Drug|Oxaliplatin|Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
75407049|NCT02583360|Diagnostic Test|Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy|Addition of research HRM along with diagnostic VFSS with parental choice of therapy
75407050|NCT02584140|Behavioral|Text Messaging|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
75407051|NCT02584140|Behavioral|Adherence Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of <1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of <1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
75407052|NCT02584140|Drug|Daily Oral PrEP|All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
75407053|NCT02584608|Drug|ACTIMMUNE|
75407054|NCT02584686|Drug|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
75407055|NCT02584686|Drug|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
75407056|NCT02584998|Other|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
76039587|NCT04968067|Device|App group|In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
75407057|NCT02584998|Other|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
75407058|NCT02585700|Biological|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.
75407059|NCT02585700|Other|Placebo|0.5 mL of phosphate buffered saline
75407060|NCT05249166|Other|ALINFA|Comparing the usual recommendations with the healthy diet designed and developed
75407061|NCT05249166|Other|Control|control group
75407062|NCT05248698|Behavioral|lifestyle change|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
75407063|NCT05248698|Other|exercise|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
75407064|NCT05248542|Other|Virtual Reality Usage on Oral Care Knowledge|Virtual Reality Usage on Oral Care Knowledge about independent older adults
75407065|NCT05248152|Combination Product|Paracetamol and Ibuprofen|Patients will receive paracetamol 1g and ibuprofen 400 mg before surgical incision.
75407066|NCT05248152|Drug|Pregabalin 150mg|Patients will receive pregabalin 150 mg in the hour before surgery
75407067|NCT05248152|Drug|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
75407068|NCT05247996|Procedure|Transcatheter arterial chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
75407069|NCT05247996|Drug|Multi-target Drug Therapy|Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight < 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
75407070|NCT05247996|Drug|Immunocheckpoint Inhibitor Therapy|Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
75407071|NCT05247996|Procedure|Systemic Intravenous Chemotherapy|GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
75407072|NCT05247762|Device|Acupuncture|The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
75407073|NCT05247684|Drug|AK112|IV infusion
75407074|NCT05247684|Drug|Carboplatin|IV infusion
75407075|NCT05247684|Drug|Cisplatin|IV infusion
75407076|NCT05247684|Drug|Paclitaxel|IV infusion
75407077|NCT04990986|Other|Complex intervention|Will be co-developed during the study.
75552079|NCT05458895|Other|ECIG lab session 6|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
75552080|NCT05458895|Other|ECIG lab session 7|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
75407078|NCT04845828|Procedure|Sentinel lymph node mapping|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy 2. Inject 1.25 mg/ml of ICG and a total of 6ml into the cornual area (0.5-1 cm deep) of the uterus. And then inject 1 ml of mucous membrane (1-3 mm deep) and 1 ml of substrate (1-2 cm deep) into the cervix, and a total of 4 ml in each direction of 3 and 9 o'clock.~3. Sentinel lymph node is excised"
75407079|NCT04845828|Procedure|Routine lymph node dissection|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy~Lymph node detection is performed."
75407080|NCT04808466|Drug|Paclitaxel|Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
75407081|NCT04808466|Drug|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
75407082|NCT04670640|Device|Vibration|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. There will be no explicit tasks or direction given in this intervention. Participants will experience smooth slowly varying breath-like vibration on their sternum. They will receive their assigned intervention for approximately 18 minutes.
75407083|NCT04670640|Behavioral|Breath Focus|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. The participant will be asked to focus on their breathing during this intervention. They will receive their assigned intervention for approximately 18 minutes.
75407084|NCT04670640|Behavioral|No Distractions|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. Participants will engage in a period of no-screen time; during this time there will be no outside visual or auditory distractions. There will be no explicit tasks or direction given in this intervention. They will receive their assigned intervention for approximately 18 minutes.
75407085|NCT04597554|Dietary Supplement|Cranberry|Cranberry beverage and gummies supplement
75407086|NCT04597554|Dietary Supplement|Placebo|Placebo beverages and gummies supplement
75407087|NCT04488900|Drug|CKD-508 Capsule|Investigational drug
75712201|NCT00562120|Drug|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
75712202|NCT00562120|Drug|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
75712203|NCT00562120|Drug|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
75407088|NCT04488900|Drug|Placebo Capsule|Placebo
75407089|NCT04488900|Drug|CKD-508 Tablet|Investigational drug
75407090|NCT04488900|Drug|Placebo Tablet|Placebo
75552081|NCT05458895|Other|ECIG lab session 8|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
75552082|NCT00427089|Drug|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
75712204|NCT00941044|Device|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
75712205|NCT00939172|Drug|TTP607|3.3 mg/m^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
75712206|NCT01563016|Dietary Supplement|glucose drink|participants will receive a drink rich in glucose
75712207|NCT00561730|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
75712208|NCT00697112|Drug|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
75712209|NCT00621855|Drug|placebo|matched placebo
75712210|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
75712211|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
75712212|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
75552083|NCT00427089|Drug|Sodium Phosphate solution (NaP)|45 ml solution; BID
75407091|NCT04003740|Device|Home-based transcranial direct current stimulation|The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
75407092|NCT03939234|Combination Product|PD-L1, PD-L2 peptides with Montanide ISA51|PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
75552084|NCT05458661|Device|Clinical Prototype BioBase (SN 07 and SN 08)|Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps >6mm diameter and corneal pachymetry maps >6mm.
75552085|NCT00427128|Drug|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
75552086|NCT00427128|Drug|placebo|Week 13-36.
75552087|NCT05458466|Other|Pilates training|Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
75552088|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
75552089|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
75552090|NCT00427167|Drug|AMA1-C1/Alhydrogel + CPG 7909|
76039588|NCT04968067|Device|Nursing telephone advice (NTA) group|All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
75407093|NCT03907176|Drug|HTX-011|300 mg
75407094|NCT03907176|Device|Luer lock applicator|Applicator for instillation
75407095|NCT03907176|Drug|Ibuprofen|600 mg
75407096|NCT03907176|Drug|Acetaminophen|1 g
75407097|NCT03675672|Drug|Misoprostol Oral Tablet|Misoprostol 200mcg
75407098|NCT03675672|Drug|Placebo Oral Tablet|Placebo Tablet
75407099|NCT02692950|Other|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
75552091|NCT00427206|Drug|acetaminophen (4g/day)|
75552092|NCT00427206|Drug|placebo|
75552093|NCT00425997|Drug|Valsartan/HCTZ|
75552094|NCT00425997|Drug|amlodipine|
75552095|NCT00425997|Drug|HCTZ|
75552096|NCT05458388|Procedure|Kimura-Takemoto classification|All patients were given two risk scores, the order of which was randomly determined.
76039589|NCT05644613|Other|aerobic exercise on land|aerobic exercise on land in form of walking on the treadmill
75407100|NCT02692950|Behavioral|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
75552097|NCT05458388|Procedure|EGGIM|All patients were given two risk scores, the order of which was randomly determined.
75552098|NCT00427245|Drug|cyclophosphamide|
75552099|NCT00427245|Drug|goserelin acetate|
75552100|NCT00427245|Procedure|adjuvant therapy|
75407101|NCT02108496|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
75552101|NCT00427245|Procedure|fertility assessment and management|
75552102|NCT00427245|Procedure|neoadjuvant therapy|
75552103|NCT05458349|Device|acellular dermis|
75552104|NCT00426036|Drug|Licarbazepine|
75552105|NCT05458154|Other|questionnaires|Participants were recruited from the Baheya Centre for Early Detection and Treatment of Breast Cancer institution. Patients were eligible if they had a previously post-mastectomy pain syndrome (PMPS), and were presented with pain within the surgical area lasting more than 3 months. They were evaluated by questionnaires and methods of pain assessment then received their physiotherapy program specific for pain relief for six sessions, and so re-evaluation. All women gave informed written consent in Arabic and English forms.
75552106|NCT00427323|Procedure|light exposure|
75552107|NCT05458115|Procedure|Liver resection|Patient underwent hepatic R0 resection within a week
75552108|NCT00426075|Device|Elastic stockings|
75712213|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
75712214|NCT04012762|Device|Whole body vibration training|Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
76039590|NCT05644613|Other|aerobic exercise in water|aerobic exercises in water in form of walking on the treadmill
75407102|NCT02108496|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
75407103|NCT02108496|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
75552109|NCT05458076|Drug|QLS1128 A-Dose 1~5 and Ritonavir|"Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo"
75552110|NCT05458076|Drug|QLS1128 C-Dose 1~3 and Ritonavir|"Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days"
75552111|NCT05458076|Drug|QLS1128 D-Dose 1 and Ritonavir|"Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5"
75552112|NCT00427362|Drug|Adalimumab|
75552113|NCT05458037|Procedure|Speed of tenaculum application|Fast or slow closure of the tenaculum for application to the uterine cervix
75552114|NCT00426114|Drug|Administration of an IV glucose-injection|
75552115|NCT00426192|Drug|i.v. mannitol|
75552116|NCT00426192|Procedure|hemofiltration|
75552117|NCT05457920|Behavioral|continuous treatment|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFN α-2b 180μg once a week, or every 8 weeks of injection, 4 weeks off, periodically, the total treatment course does not exceed 96 weeks.
75552118|NCT05457920|Behavioral|pulse therapy|pulse therapy
75552119|NCT00427401|Drug|PF-00915275|
75552120|NCT00425919|Drug|PPM-204|
75552121|NCT01056822|Drug|1|Continue with same dose of MMF as patient was taking before randomisation
75552122|NCT01056822|Drug|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
75552123|NCT05457764|Device|Virtual reality headset|"The VR headset was a Pico G2, Pico Interactive, San Fransisco, USA, offering a choice from 60 erotic videos each of 10-30 minutes duration. The men were allowed to watch any and as many of these video clips as they wished. The No VR arm, donors used the computer monitor available in the donation rooms."
76039591|NCT02445339|Drug|XR-NTX+CM (Extended-Release Naltrexone plus Care Management)|The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
76039592|NCT04951375|Procedure|arthroscopic repair|arthroscopic repair
76039593|NCT04951531|Procedure|BPTB double-bundle allograft|The patient underwent surgery of arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
75407104|NCT02108496|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
75552124|NCT05457530|Drug|DOR/3TC/TDF|100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
75552125|NCT05457530|Combination Product|DOR + FTC/TAF|100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)
75552126|NCT05457530|Drug|BIC/FTC/TAF|Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
75552127|NCT04705194|Procedure|Hepatectomy|Resection of one or more liver segments as treatment for primary or metastatic liver cancer
75552128|NCT04705194|Procedure|PVE or ALPPS|Embolization of the portal vein feeding the diseased liver segments or surgical liver partition and portal vein ligation of the diseased liver segments in order to induce growth of the future liver remnant ahead of the resection.
75712215|NCT04258280|Behavioral|Education and counseling|Education includes a workbook, counseling includes peer support.
75712216|NCT04258280|Behavioral|Education|Education includes a workbook.
75712217|NCT00940966|Dietary Supplement|standard ADA diet|standard ADA diet
75407105|NCT02056236|Drug|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
75407106|NCT02056236|Other|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
75407107|NCT01962246|Drug|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
75407108|NCT01962246|Other|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
75407109|NCT02588586|Drug|3BNC117|3BNC117 infusions
75407110|NCT02588586|Other|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
75407111|NCT02588976|Device|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
75407112|NCT02592486|Biological|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
75407113|NCT02592486|Biological|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
75407114|NCT02593032|Device|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
75407115|NCT05371938|Procedure|Volar locking plate|Volar locking plate is the intervention
75407116|NCT05371938|Procedure|external fixation|surgery with external fixation
75407117|NCT05371704|Dietary Supplement|Multivitamin Supplementation|Participants will supplement daily with an over-the-counter oral multivitamin pill
75407118|NCT05371704|Other|Dietary Replication|Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
75407119|NCT05371236|Other|Questionnaire|Phase I will use a descriptive qualitative approach to understand pediatric cancer patients' opinions related with spiritual issues and experience. The results of the qualitative study will be used to compare with the items of the original scale, and emerging themes will be used to generate new items. Phase Ⅱ will translates the original scale and validates the psychological properties of scale adapted for pediatric cancer patients.
75407120|NCT05371158|Behavioral|Online intervention|The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
75552129|NCT05457452|Device|Knee Brace|Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
75552130|NCT04705857|Combination Product|"Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene"|gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
75712218|NCT00940966|Dietary Supplement|energy restricted very-low carbohydrate diet|energy restricted very-low carbohydrate diet
75712219|NCT00940966|Dietary Supplement|low glycemic diet|restricted ketogenic diet
75871971|NCT02331550|Procedure|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
75871972|NCT02331550|Procedure|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
75871973|NCT02335684|Other|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
76039594|NCT04951531|Procedure|BPTB single-bundle allograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
75552131|NCT04705506|Drug|Gemigliptin|We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
75712220|NCT00851565|Procedure|Measurement of serum infliximab and anti-infliximab antibodies|"In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:~Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.~Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.~High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.~High s-infliximab in the presence of anti-infliximab Ab: Same as number 3."
75552132|NCT05457374|Procedure|PVE|Portal vein embolization (PVE) mainly embolizes the portal vein of the resected liver lobe, causing the non-tumor lobe to proliferate, and after tumor lobectomy, the volume of the non-tumor lobe proliferates so that patients with hepatocellular carcinoma that could not be directly surgically resected are given the opportunity to be surgically resected
75712221|NCT00851565|Procedure|Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status|In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
75712222|NCT00561574|Drug|Esmirtazapine|One tablet daily
75712223|NCT03898076|Device|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
75712224|NCT03898076|Other|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
76039595|NCT04951531|Procedure|BPTB single-bundle autograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
76039596|NCT04934787|Device|ENMS-BSF assisted gait training|"ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane."
75552133|NCT05457374|Procedure|LVD|Combining PVE and Hepatic Vein Embolization (HVE) in the same procedure
76039597|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
75552134|NCT04704960|Other|Diagnostic Test: liquid biopsy|detection of tumor DNA alteration in cf-DNA
75552135|NCT05457335|Procedure|undergoing PGT|Preimplantation genetic testing for aneuploidy
75552136|NCT00432393|Drug|levodopa-carbidopa|
76039598|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
75552137|NCT05455385|Other|standard 12-week rehabilitation program|The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
75552138|NCT05455385|Other|extra session hydrotherapy|The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
75552139|NCT05455385|Other|extra session ground exercises|The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
75712225|NCT03898076|Other|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
75712226|NCT00619827|Drug|300 IR grass pollen allergen extract tablet|300 IR grass pollen allergen extract tablet once daily during four months
75712227|NCT00619827|Drug|Placebo tablet|Placebo tablet once daily during four months
75712228|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
75712229|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
75552140|NCT04705077|Drug|SR419|2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
75407121|NCT05370846|Other|Clinical pharmacy antimicrobial stewardship intervention|"A new AMS group will be introduced in Tauernklinikum in Zell am See, based on the S3-AWMF-guideline Strategien zur Sicherung rationale Antibiotika-Anwendung im Krankenhaus on antibiotic use in hospitals. As part of this, a new formulary will be developed and gradually introduced where we determined which AMS guidelines need to be incorporated. Antimicrobial use will be audited after set-up of the local formulary against the data from before implementation (using defined daily dose, DDD, as suggested by the WHO). Data on antimicrobial use will be obtained from a recently purchased and installed AMS programme called HyBase® by epiNET AG. AMS group will be provided with implementation material and toolkits, baseline data for antimicrobial use within hospital will be obtained."
75407122|NCT05365854|Procedure|Alveolar Recruitment Maneuver (ARM)|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
75407123|NCT05365620|Device|Mechanical In-Line Inexsufflation|In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.
75407124|NCT05365620|Procedure|catheter suction|catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
75407125|NCT05346276|Diagnostic Test|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
76039599|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
75407126|NCT04970004|Other|No intervention|No study intervention will be administered as part of this study.
75407127|NCT04946214|Behavioral|Smart Water Bottle|Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
75407128|NCT04945122|Drug|Pitavastatin|Pitavastatin 4mg Qn
75407129|NCT04945122|Drug|Atorvastatin|Atorvastatin 20mg Qn
75407130|NCT04803630|Other|Quality-of-Life Assessment|Ancillary studies
75407131|NCT04803630|Other|Questionnaire Administration|Ancillary studies
75407132|NCT04803630|Procedure|Thermotherapy|Undergo thermal therapy
75552141|NCT05453045|Drug|Albendazole|tablet administration after a meal contaning approximate 15 g of fat
76039600|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
75407133|NCT04445064|Biological|IO102|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
76039601|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
76039602|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
76039603|NCT03674931|Behavioral|musical practice|Intensive weekly musical keyboard training over 12 months
75552142|NCT04705272|Other|Questionnaire|Pregnant women will be included in the study at the time of their first or second trimester ultrasound in the Hautepierre and CMCO ultrasound department. The period of inclusion should extend from 1 October 2020 to 31 October 2021 with a duration of participation of each subject of 9 months.
75552143|NCT05451251|Device|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine demyelinating lesion
76039604|NCT03674931|Behavioral|music education|Recreative weekly musical courses without practice over 12 months
76039605|NCT04959409|Drug|Topical analgesia (EMLA or AMETOP)|Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
76039606|NCT03058939|Drug|Paclitaxel|Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
76039607|NCT03058939|Drug|Perjeta|Only administered to patients with HER2-positive disease.
76039608|NCT03058939|Drug|Herceptin SC|Only administered to patients with HER2-positive disease.
76039609|NCT03058939|Drug|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
76039610|NCT03058939|Drug|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
76039611|NCT03058939|Drug|LHRH agonist|Administered to all premenopausal patients.
76039612|NCT03058939|Drug|FEC|Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
76039613|NCT03058939|Drug|Carboplatin|Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
76039614|NCT03061045|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
75407134|NCT04445064|Biological|IO103|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
76039615|NCT04951297|Other|None, just observation|None ,just observation test
75552144|NCT00432432|Drug|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
75552145|NCT02957487|Device|Denture supported by 3 dental implants|Metal-reinforced denture without palatal coverage incorporating nylon rings retained by friction to Locator abutments fitted on top of dental implants
75407135|NCT04227366|Biological|BCD-089|BCD-089 162 mg SC
75407136|NCT04227366|Biological|Placebo|Placebo
75712230|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
75407137|NCT04227366|Drug|Methotrexat|15 to 25 mg/week
75407138|NCT04113252|Other|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
75407139|NCT04113252|Other|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
75407140|NCT04113252|Behavioral|Coaching|Subjects will receive coaching prior to starting pain medication.
75552146|NCT05421494|Behavioral|written exposure therapy-revised version|WET-R is a manualized exposure-based therapy program consisting of 5-7 sequential individual sessions. The interval between every 2 consecutive sessions is 0-3 days. There will be 5-7 one to one online sessions in total (only one index trauma will be discussed), and 1-3 weeks to complete. Sessions are scheduled to last for 1 hour in the first session and 50 minutes in other sessions.
75712231|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
75712232|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
76039616|NCT03058471|Drug|Methotrexate|methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
76039617|NCT03058471|Drug|NSAID|this arm will be given NSAID to the tolerable full dose with pantoprazole
76039618|NCT03058471|Drug|Steroids|inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
76039619|NCT03060967|Behavioral|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
75712233|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
75712234|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
75712235|NCT00848055|Drug|AbGn168 subcutaneous injection|single dose subcutaneous injection
75712236|NCT00687804|Drug|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
75712237|NCT00687804|Procedure|Laser|Laser photocoagulation treatment
75712238|NCT00687804|Procedure|Sham laser|Sham to laser procedure.
75712239|NCT00687804|Drug|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
75712240|NCT00848133|Procedure|mini-midvastus surgical approach for total knee arthroplasty|
75407141|NCT04087122|Device|Esophageal warming device (Attune Medical, Chicago, IL|Prospective, single center pilot stud
75407142|NCT03963492|Other|Walking|Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
75407143|NCT03945162|Combination Product|Ruvidar® (TLD-1433) Bladder infusion and PDT|Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
75552147|NCT05421494|Behavioral|minimal contact control|Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.
75552148|NCT02957526|Behavioral|Prompts to report symptoms via study app|Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
75712241|NCT00848133|Procedure|mini-subvastus surgical approach for total knee arthroplasty|
75712242|NCT02568020|Drug|keto-amino acids|Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
75712243|NCT00848445|Device|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
75712244|NCT00848445|Device|Atrial pacing preference turned on or off|programing changes in the device
75712245|NCT02545881|Other|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
75712246|NCT02563704|Drug|Artesunate|
75712247|NCT02563704|Drug|Quinine|
75712248|NCT00848523|Drug|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
75407144|NCT03917316|Other|Language and neuropsychological tests|Tests related to language, narrative and specific and general cognitive function
75407145|NCT03560466|Drug|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
75407146|NCT03560466|Drug|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
75407147|NCT03560466|Drug|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
75407148|NCT03376698|Drug|Colchicine 0.5 mg|oral administration of Colchicine 0.5 mg once daily for 12 weeks
75712249|NCT00742404|Drug|bortezomib|
75712250|NCT00742404|Drug|dexamethasone|
76039620|NCT02579603|Drug|Nintedanib|Nintedanib 150mg bid
76039621|NCT02579603|Drug|Pirfenidone|
75407149|NCT03376698|Drug|Colchicine 0.25 mg|oral administration of Colchicine 0.25 mg once daily for 12 weeks
75712251|NCT00742404|Drug|pegylated liposomal doxorubicin hydrochloride|
75712252|NCT00742404|Genetic|protein analysis|
75712253|NCT00742404|Other|immunologic technique|
75712254|NCT05279950|Device|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
75712255|NCT05279950|Device|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
76039622|NCT04958629|Other|familial hypercholesterolemia|Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
76039623|NCT04958863|Other|Surgical mask|Use of a surgical mask during test
76039624|NCT04958863|Other|Polyester reusable mask|Use of a polyester reusable mask during test
75407150|NCT03376698|Drug|Placebo|oral administration of Placebo once daily for 12 weeks
75407151|NCT03295734|Behavioral|Aerobic exercise|Twice weekly centered based aerobic exercise + 3/week home-based walking
75407152|NCT03295734|Drug|Perindopril|4 mg qd titrated to 8 mg qd perindopril
75407153|NCT03295734|Drug|Losartan|50 mg qd titrated to 100 qd losartan
75407154|NCT03295734|Drug|HCTZ|12.5 mg qd titrated to 25 qd HCTZ
75407155|NCT03084666|Device|Zimmer ATS tourniquet system|The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
75407156|NCT02928978|Drug|Ruxolitinib|tablet (taken by mouth)
75712256|NCT00848601|Drug|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
75712257|NCT00742482|Drug|HL 10|Freeze dried HL 10
75712258|NCT00939250|Behavioral|Diabetes and depression intervention|Disease self management for diabetes and depression
75712259|NCT00939250|Behavioral|Diabetes intervention|Disease self management for diabetes
76039625|NCT04416841|Behavioral|Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
76039626|NCT04416841|Behavioral|Fitness Walking|Participants would take fitness walking training 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes fitness walking and 10 minutes cool-down exercises in the fitness walking training, the exercise intensity was 50% to 70% of the maximum heart rate. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
75407157|NCT02928978|Drug|Placebo (for Ruxolitinib)|tablet (taken by mouth)
76039627|NCT04416841|Behavioral|Standard Diabetic Care Education|Participants would take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
76039628|NCT05696639|Procedure|Aneurysm embolization|All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.
75407158|NCT00394758|Procedure|CO2 laser surgery|
75407159|NCT00394758|Procedure|ultrasonic surgical aspiration|
75407160|NCT02594826|Behavioral|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
75407161|NCT02594826|Behavioral|General health education control|General health and cancer education
75407162|NCT02595684|Drug|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
75407163|NCT02595684|Drug|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
75407164|NCT02599194|Drug|18F-FSPG|Administered intravenously (IV)
75407165|NCT02599194|Drug|18F-FDG|Administered intravenously (IV)
75407166|NCT02604810|Biological|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
75712260|NCT00744666|Drug|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
75712261|NCT04013620|Drug|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
75407167|NCT02604810|Biological|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
75407168|NCT02606604|Device|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
75407169|NCT02606838|Device|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
75407170|NCT02607618|Drug|Iclaprim|Experimental treatment
75407171|NCT02607618|Drug|Vancomycin|Active comparator
75407172|NCT02609100|Procedure|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
75407173|NCT02609100|Procedure|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
75407174|NCT02609100|Device|1.0 X 2.5 cm 'pill' containing a camera|
75871974|NCT02335684|Other|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
75407175|NCT02610972|Device|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
75407176|NCT02612688|Behavioral|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
75407177|NCT05732064|Drug|Dexmedetomidine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
75407178|NCT05732064|Drug|Esketamine|Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
75407179|NCT05732064|Drug|Normal saline|Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
75407180|NCT05731830|Other|Data extraction|"The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the ArpaLazio website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2 expressed in micrograms per cubic meter (µg/m3). Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed daily. Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS."
75407181|NCT05731830|Other|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.
75407182|NCT05731752|Drug|HX009|The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
75407183|NCT05731674|Other|Random selection of excercises|Participants in the intervention group will train using a random selection of excercises and complete the profiency-based traning program.
75407184|NCT05731206|Other|Hydrolyzed protein infant formula|Hydrolyzed protein infant formula
75407185|NCT05731206|Other|commercially available hypoallergenic infant formula|commercially available hypoallergenic infant formula
75712262|NCT02562222|Procedure|anodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
75871975|NCT05198388|Diagnostic Test|βeta endorphins, interleukin 6 and interleukin 38|"- Collection of peripheral blood samples in gel tube.~- Creparation of samples in centrifuge to obtain serum.~- Measurement of interleukin 6 and interleukin 38 and βeta endorphins using ELISA method."
76039629|NCT04967911|Other|Rhythmic stabilization exercises|"PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps).."
75552149|NCT02957526|Behavioral|Clinical Alerts|: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
75552150|NCT02957448|Drug|BMS 986141|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
75552151|NCT02957448|Drug|Rifampin|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
76039630|NCT04967911|Other|conventional treatment|Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
75407186|NCT05731050|Drug|NM8074|"NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed."
75407187|NCT05730738|Drug|Dalfampridine ER, 10 Mg Oral Tablet, Extended Release|The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels
75407188|NCT05730738|Drug|Placebo|placebo similar to Dalfampridine capsule
75407189|NCT05730660|Dietary Supplement|Quercetin group|2 capsules a day of Quercetin Fitosoma® of 250 mg each
75407190|NCT05730660|Dietary Supplement|Placebo group|2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
75407191|NCT05725434|Biological|CT-P47 AI (tocilizumab)|CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2
75407192|NCT05725434|Biological|CT-P47 PFS (tocilizumab)|CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
75407193|NCT05665842|Other|Music Application|The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
75552152|NCT00432471|Procedure|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
76039631|NCT04951141|Biological|anti-GPC3 CAR-T cells|A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.
76039632|NCT03060889|Drug|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
75552153|NCT04704765|Other|abdominal breathing training|The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
75552154|NCT00427596|Drug|Solabegron|
75552155|NCT00432510|Drug|C1 esterase inhibitor [human] (C1INH-nf)|
75552156|NCT05354258|Drug|Albendazole|Anthelminthic drugs for the treatment of soil-transmitted helminths
75552157|NCT05354258|Drug|Praziquantel|Anthelminthic drugs for the treatment of schistosomiasis
75407194|NCT05665842|Other|Sleep Hygiene Training|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal & Nunes, 2014; Dinis & Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
75407195|NCT05629416|Behavioral|Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples|"Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~Support simplified and improved strategies for booking an interpreter to increase uptake.~Implement retention strategies to ensure interpreters receive workplace support.~Provide training in health terminology for interpreters.~Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation."
75407196|NCT05627388|Other|Dreem 3 System At-Home Monitoring|Patients will be asked to wear the Dreem 3 System and actigraphy devices at home. Research support staff will teach patients how set up the device beforehand. Patients will wear Dreem and actigraph for 5 nights, while keeping the actigraph on during the day, to monitor sleep/wake cycle. Then, for an additional continuous 48hr measurement, patients will wear the Dreem and actigraph. The patient will be given 2 devices, as one device can record up to 24h of data continuously. Patients are not required to stay home during the 48hr testing period. However, patients will be instructed to refrain from participating in activities which may shift or require removal of Dreem. Patients who wish to remain home for the 48hr testing period should have adequate sustenance (i.e., groceries). Any caffeine and sleep medication intake will be logged by the patient in a sleep diary. If needed, patients will be given an off work order from work/school for the 48hr assessment.
75552158|NCT05354258|Drug|Amodiaquine|SMC partner drug
75552159|NCT05354258|Drug|Sulfadoxine pyrimethamine|SMC partner drug
75407197|NCT05555082|Other|Massage|10 times of 30 minutes Swedish classical Massage will be given monthly during one year. The massage will be give by a cerified masseur
75552160|NCT05338580|Drug|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
75552161|NCT00427674|Drug|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
75552162|NCT05306366|Drug|[11C]-Lu AF90103|PET ligand administrated as a single intravenous bolus injection
75552163|NCT01588899|Device|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
75552164|NCT02273466|Drug|Desipramine tablet|
75552165|NCT02273466|Drug|Crobenetine infusion|
75552166|NCT02273466|Drug|Placebo infusion|
75552167|NCT05245643|Device|Abbott Infinity Deep Brain Stimulation System|DBS is robot-assisted, with 3D intraoperative imaging control, under general anesthesia. Target is defined thanks to preoperative dedicated MRI with 2 independent experts' assessment.
75552168|NCT00427713|Drug|capecitabine|
75552169|NCT00427713|Drug|oxaliplatin|
75552170|NCT00427713|Procedure|adjuvant therapy|
76039633|NCT04950829|Device|Conventional brackets|These brackets are used in a conventional way, where the orthodontist used to apply elastic parts to engage the arch to the slot of the brackets.
75552171|NCT00427713|Procedure|standard follow-up care|
75552172|NCT02273505|Drug|Asasantin (ER)|
75407198|NCT05541120|Device|Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
75407199|NCT05515458|Drug|Chiglitazar|Oral single dose 48 mg
75407200|NCT05466552|Procedure|PCI procedure|During the PCI procedure, use of ECMO/Impella 5.0 is allowed hemodynamic instability (bail- out).
75407201|NCT05460702|Diagnostic Test|Soluble immune checkpoints|Blood collection from breast cancer patients with stage I-II
75407202|NCT05446272|Device|NIV-NAVA|Infants in the intervention arm will be managed with non-invasive neurally adjusted ventilatory assist (NIV-NAVA) using FDA-approved servos with associated FDA-approved Edi catheter.
75407203|NCT05446272|Device|NS-NIPPV|Infants in the active comparator arm will be treated with non-synchronized non-invasive positive pressure ventilation (NIPPV) through FDA-approved ventilators currently in use at each site.
75407204|NCT05419674|Drug|Vonoprazan|Potassium-competitive acid blocker
75407205|NCT05419674|Drug|Rabeprazole|Proton pump inhibitor
75407206|NCT05419674|Drug|Amoxicillin|Antibiotic for H. pylori eradication
75407207|NCT05419674|Drug|Clarithromycin|Antibiotic for H. pylori eradication
75407208|NCT05419674|Drug|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
75407209|NCT05409300|Biological|BBIBP-CorV|Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
75407210|NCT05386524|Drug|sintilimab|sintilimab 200mg, ivgtt，d1
75407211|NCT05386524|Drug|bevacizumab biosimilar|bevacizumab biosimilar 15mg/kg，ivgtt d1
75407212|NCT05386524|Drug|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 30mg/m2 d1，q3w
75407213|NCT05357664|Device|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
75407214|NCT05357664|Device|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
75407215|NCT05338554|Device|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered pcTBS protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (parallel to the hemispheric midline).
75712263|NCT02562222|Procedure|cathodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
76039634|NCT04950829|Device|Self-ligating brackets|These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.
75407216|NCT05338554|Device|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered 10HZ protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (45° away from the hemispheric midline).
75407217|NCT05318040|Drug|CMS121|CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
75407218|NCT05318040|Drug|Placebo|Placebo will be provided as visually matching placebo capsules.
75407219|NCT05214456|Other|Dry needling|The method of performing the dry needling technique will be based on the method presented by Dommerholt and Fernandez-de-las-Penas. The length of the needle (Tony, china) for each patient will be selected based on the size of the patient: 1) Multifidus: the patient will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. The needles will be inserted into the lumbar multifidus muscles, 1.5 to 2 cm lateral to the spinous process of all lumbar vertebrates, perpendicular to the lamina (after piercing the skin, needles are directed inferomedially). 2) Quadratus lumborum: The patient will be placed in the side lying position with the side to be treated facing up. After identifying the lateral border of the quadratus lumborum muscle, the needle will be aimed straight downward in the direction of the transverse process, followed by slight anterior, posterior, and caudal needling to explore the entire muscle.
76039635|NCT04950829|Procedure|Self-Ligating Brackets with flapless corticotomy|"These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.~Flapless corticotomy will be performed in order to stimulate acceleration in tooth movement during the orthodontic treatment in this group only."
75407220|NCT05214456|Other|Mobilization|To perform Maitland's mobilization for lumbar spine, the anterior-posterior mobilization technique will be used and it is performed by pushing the heel (pisiform grip) or thumbs (thumb grip) to the vertebrae and can immediately reduce pain and restore motor function. First, the complete physical orthopedic evaluation of manual therapies will be performed using the Maitland evaluation method. Then, based on the findings of the patient evaluation, the severity, rhythm, duration and the degree of the mobilization and the place of force (spine or lamina) will be determined. To apply mobilization, the person will sleep in a prone position and the physiotherapist will use the heel of the hand or the thumbs to apply force to the first to fifth vertebrae of the lumbar spine. In segments that do not have a problem based on evaluation, first grade of the anterior-posterior Maitland's mobilization will be applied to the spinous process of the segment.
75552173|NCT02273505|Drug|Persantin|
75552174|NCT02273505|Drug|Acetyl salicylic acid (ASA)|
75552175|NCT05210621|Drug|Ocrelizumab|ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
76039636|NCT05564195|Diagnostic Test|Postoperative cognitive function|"Digital cognitive tests - Mindmore-P, will be used to assess neurocognitive capacity and includes tests of verbal episodic memory, executive functions, visuospatial function and attention. The cognitive tests are self-administered on a touch screen tablet (10.1 20-30 min Windows). The Mindmore-P is a web-application running on a full-screen Chrome browser. The test is administered by using a capacitive touchscreen with features that record detailed information such as timing, pauses, and lifting of finger from the touchscreen. Speech recognition is used in the screening of verbal memory and language."
75552176|NCT00427752|Procedure|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
76039637|NCT04967755|Drug|Jing-Si-Herbal-Tea|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
76039638|NCT04950907|Diagnostic Test|vats|Use uniportal tubeless VATS to obtain the biopsy
76039639|NCT04950907|Diagnostic Test|CT-guided fine needle biopsy|Use CT-guided fine needle to obtain the biopsy
76039640|NCT04950595|Other|Plant-based mince|Spaghetti bolognaise meal made with plant-based mince
76039641|NCT04950595|Other|Beef mince|Spaghetti bolognaise meal made with beef mince
76039642|NCT04421365|Device|neurofeedback brain-computer interface (BCI)|The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
75552177|NCT00427830|Biological|MVA85A|
75552178|NCT05174156|Drug|Combination therapy|SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin
75552179|NCT00432549|Drug|Almotriptan|
75552180|NCT00432549|Drug|Topiramate|
75552181|NCT00427947|Drug|ropivacaine/placebo|Continuous sciatic nerve bloc
75552182|NCT00432588|Drug|misoprostol|
75552183|NCT00432588|Drug|dinoprostone|
75552184|NCT00427986|Drug|Galactose, intravenous|
75552185|NCT00428025|Drug|diclofenac|100 mg diclofenac rectal suppository
75552186|NCT00428025|Drug|placebo|similar shape and size suppository
75552187|NCT00428064|Drug|Sirolimus|
75552188|NCT00428064|Drug|cyclosporine|
75407221|NCT05044182|Procedure|Decompression and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
75407222|NCT05044182|Procedure|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
76039643|NCT04411589|Device|magnifying endoscopy with optical enhancement system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
75552189|NCT05011253|Other|Electronic Trigger Microhematuria Alert|To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
76039644|NCT04411589|Device|white light endoscopy system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
75871976|NCT03557801|Behavioral|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
76039645|NCT04958395|Diagnostic Test|FFR and d-FFR|Measure FFR and d-FFR
75552190|NCT00432627|Drug|Deferasirox|one dose of 20 mg/kg/day
75552191|NCT00419705|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
76039646|NCT03060733|Other|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
75407223|NCT05016024|Device|Colilen IBS|Patients will take Colilen IBS in First or Second Period
75407224|NCT05016024|Other|Placebo|Patients will take PlaceboS in First or Second Period
75552192|NCT00432705|Procedure|Checking stability of ankle|Flexing and walking
75407225|NCT04986540|Drug|SHR-1906；Placebo|"Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose"
75407226|NCT04965714|Biological|Nivolumab|Given IV
75407227|NCT04965714|Biological|Pegargiminase|Given IM
75871977|NCT03557801|Behavioral|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
75871978|NCT03557801|Other|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
76039647|NCT04311827|Other|Serratus Anterior Plane Block|Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
76039648|NCT04958317|Other|Early exercise|Participants will exercise for 30 minutes prior to an evening meal.
75407228|NCT04965714|Procedure|Resection|Undergo surgical resection
75552193|NCT00419783|Drug|bilastine|20 mg tablets.
75552194|NCT00419783|Drug|Bilastine|100 mg (5 tablets of 20 mg)
75552195|NCT00419783|Drug|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
75552196|NCT00419783|Drug|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
75407229|NCT04939350|Other|questionnaire|patients will complete a vaccination questionnaire
75407230|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
75552197|NCT00419783|Drug|Placebo|Placebo tablets
75552198|NCT04704492|Drug|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
75552199|NCT00419822|Procedure|Acupuncture|6 Acupuncture visits
75552200|NCT00419822|Procedure|Sham Acupuncture|6 Acupuncture visits with sham procedure
75871979|NCT05762874|Drug|Ruxolitinib|JAK inhibitor
76039649|NCT04958317|Other|Late exercise|Participants will exercise for 30 minutes after an evening meal.
75407231|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
75407232|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
75552201|NCT00419822|Other|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
75407233|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
75552202|NCT04703517|Diagnostic Test|Point of care ultrasound|Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
75407234|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
75407235|NCT04780698|Diagnostic Test|SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection|COVID-19 infection and antibody testing
75407236|NCT04669236|Behavioral|Intervention to promote healthy sleep behavior|An action group (6 - 8 pupils) was conducted at each school. Brainstorm sessions about effective strategies to change sleeping behavior in this population were held. Strategies, perceived as effective by the target population, will be summarized in an overview. Also feedback of adolescent, who are not part of the action group, will be asked. After feedback, the intervention will be developed by the intervention schools. Thereby, three different intervention strategies will be implemented and tested (one intervention at each school) to meet the individuals needs of each school. The action groups will develop the intervention materials during sessions this year. Afterwards, they will implement the intervention themselves in collaboration with teachers of the school and the researchers.
75552203|NCT04959305|Drug|HCP1803-3|Take it once daily for 8 weeks orally.
75871980|NCT04210180|Drug|Varenicline|0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
76039650|NCT04950751|Biological|candidate vaccine, SCB-2020S|a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
76039651|NCT04950361|Other|talocalcaneal coalition|patients with talocalcaneal coalition
76039652|NCT04967131|Other|PNF exercises|PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
75552204|NCT04959305|Drug|RLD2003|Take it once daily for 8 weeks orally.
75552205|NCT04959305|Drug|RLD2004|Take it once daily for 8 weeks orally.
75552206|NCT04959305|Drug|RLD2005|Take it once daily for 8 weeks orally.
75552207|NCT04959305|Drug|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
75552208|NCT04959305|Drug|HPP2005|Placebo drug. Take it once daily for 8 weeks orally.
75552209|NCT04704687|Other|Transcranial Direct Current Stimulation|Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
75552210|NCT00428103|Procedure|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
75871981|NCT04210180|Other|e-cigarette|Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.
75871982|NCT03523871|Drug|Mavyret|Patients will be on 8 weeks of Mavyret
75871983|NCT04017390|Drug|Theraworx Foam|Apply Theraworx Foam alone
76039653|NCT05546957|Drug|Aspirin|Administered orally once per day (QD)
75552211|NCT04906109|Drug|Vemlidy Tab|1T
75552212|NCT04906109|Drug|DA-2803 Tab|1T
75552213|NCT04871438|Device|Flash glucose monitoring|Group A will use FreeStyle Libre for two weeks of FGM-based titration of medications at two time-points: 1) At recruitment and 2) At 6 weeks. Outside of these time points, they will use SMBG (standard care) for monitoring of blood glucose.
75871984|NCT04017390|Drug|Placebo Foam|Apply placebo foam alone
75871985|NCT04017390|Other|Theraworx Foam and night splint|Apply Theraworx Foam and night time splint
75871986|NCT04017390|Other|Placebo Foam and night time splint|Apply placebo foam and night time splint
75871987|NCT03523715|Dietary Supplement|Prunes|12 oz of prunes daily
75871988|NCT03523715|Drug|Docusate Sodium|Oral docusate sodium twice daily
75871989|NCT03980730|Drug|Azeliragon|Azeliragon 5 mg capsule administered orally, once daily
75871990|NCT03980730|Drug|Placebo|Matching placebo capsule administered orally, once daily
75871991|NCT03523091|Drug|OnabotulinumtoxinA 100Unit Injection|Initial treatment with the option of repeat injections every 3 months
75871992|NCT02512510|Drug|TD-4208|
75871993|NCT02512510|Drug|Placebo|
75871994|NCT00753090|Device|Vanguard™ Deep Dish Rotating Platform Knee|Vanguard™ Deep Dish Rotating Platform Knee
75871995|NCT00753090|Device|Vanguard™ Cruciate Retaining Knee|Vanguard™ Cruciate Retaining Knee
76039654|NCT05546957|Drug|rivaroxaban low dose|Administered orally twice per day (BID)
76039655|NCT05546957|Drug|rivaroxaban high dose|Administered orally QD
76039656|NCT04950205|Drug|Sevoflurane inhalant product|propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
75407237|NCT04355130|Dietary Supplement|Iron, vitamin B12 and acid folic supplementation|Vitamin and iron supplementation is administered one-two weeks before donation, and consist of iron supplementation (i.v. infusion of 20 mg/Kg ferric carboxymaltose in saline 100 ml), s.c. injection of 1 mg of vitamin B12 and acid folic 5 mg/die per os until day +15 post BM donation. BM collection is carried out by the transplant team and a maximal dose of 20-22 ml/Kg of the donor body weight is collected under general anesthesia (induction with fentanyl 1-3 mcg/Kg, Propofol 2-3 mg/Kg, rocuronium 0,6 mg/Kg and mantenaince with sevoflurane 0,8 MAC). Noninvasive cardiac output, blood pressure and hemoglobin monitoring are carried out during the entire procedure and in in the recovery room using the ClearSight™ system (Edwards Clinical) and the Radical Pulse co oxymeter (Masimo). After discharge from the hospital, donors will be revaluated on day + 7 after BM collection, and blood tests will be repeated in outpatient setting.
75407238|NCT04293198|Device|KODEX-EPD System|The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure
75407239|NCT04293198|Device|Fluoroscopy with contrast dye|Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
75407240|NCT04199832|Dietary Supplement|Dietary guidance|Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.
75407241|NCT04116996|Device|DEEP BRAIN STIMULATION|NEUROMODULATION
75407242|NCT04107168|Drug|Nivolumab|A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
75407243|NCT04107168|Drug|Pembrolizumab|A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
75407244|NCT04107168|Drug|Ipilimumab|A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
75407245|NCT04107168|Drug|Durvalumab|A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
75407246|NCT04107168|Drug|Tremelimumab|A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
75407247|NCT04107168|Drug|Atezolizumab|A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
75407248|NCT04107168|Drug|Bevacizumab|A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
75407249|NCT03958344|Drug|Prednisolone|Oral Tablet
75552214|NCT04823897|Drug|CCI-001|"Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase."
75552215|NCT00428181|Behavioral|Brief alcohol intervention|Brief alcohol intervention
75552216|NCT00428181|Behavioral|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
75552217|NCT04703478|Other|Breathing exercise|Participants will carry out a breathing exercise program through the RespiraConNosotros mobile application. They will be asked to carry out the proposed exercises with a frequency of 3 times a week for 3 months.
75552218|NCT00432822|Drug|tetrahydrobiopterin (BH4)|
75552219|NCT00432861|Drug|PANCRECARB® (pancrelipase)|Capsules
75552220|NCT00432861|Drug|Placebo|Capsules
75552221|NCT00432900|Radiation|[(11)C]PBR28|PET Ligand
75552222|NCT04627805|Behavioral|MyPath tool|MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research & Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
75552223|NCT00428337|Biological|EP-1233|DNA-HIV-recombinant vaccine
75552224|NCT00428337|Biological|MVA-mBN32|HIV-recombinant viral vaccine
75407250|NCT03958344|Drug|Triamcinolone + Betamethason|A compound long acting and short acting injectable steroid
75407251|NCT03901950|Drug|XNW7201 tablets|A wnt pathway inhibitor
75407252|NCT03780816|Other|Observation of provider-patient interactions and interviews|Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
75552225|NCT04703400|Other|anonymous survey|anonymous survey with 25 mandatory questions
75552226|NCT00428376|Device|Building Blocks|
75552227|NCT04575233|Procedure|laparoscopic-assisted Transversus Abdominis Plane (TAP) block|"The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side."
75871996|NCT03438383|Device|Bi-PAP|The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
75871997|NCT03438383|Device|Sham Bi-PAP|"Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
75871998|NCT04477408|Other|plantar sensory exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
75871999|NCT05762016|Procedure|Bedside Mini-Incision and Self-Express (MISE)|To perform bedside mini incision and encourage patients to self express the pus following the intervention
76039657|NCT05544461|Behavioral|eNutri personalised nutrition advice|eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
76039658|NCT04415047|Device|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
75407253|NCT03734952|Radiation|Neoadjuvant Radiotherapy Program:|Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
75407254|NCT03734952|Drug|Neoadjuvant chemotherapy Program|Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
75407255|NCT03734952|Procedure|Esophagectomy program:|Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy
75407256|NCT03734952|Radiation|Postoperative radiotherapy program|A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
75407257|NCT03712410|Behavioral|PISCES|The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
75407258|NCT03139344|Other|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.
75872000|NCT03105310|Drug|Pegylated interferon alfa|Pegylated interferon alfa
75872001|NCT03105310|Drug|Ezetimibe|Ezetimibe
75872002|NCT05179434|Procedure|Retrograde renal graft reperfusion|Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion
75407259|NCT03139344|Other|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
75407260|NCT02960646|Drug|Cyclophosphamide|Given IV
75407261|NCT02960646|Biological|Filgrastim|Given SC
75407262|NCT02960646|Drug|Fludarabine Phosphate|Given IV
75407263|NCT02960646|Other|Laboratory Biomarker Analysis|Correlative studies
75872003|NCT05179434|Procedure|Conventional antegrade renal graft reperfusion (without retrograde reperfusion)|Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
75872004|NCT02326714|Other|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
75407264|NCT02960646|Drug|Melphalan|Given IV
75407265|NCT02960646|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
75407266|NCT02960646|Biological|Rituximab|Given IV
75407267|NCT02960646|Drug|Tacrolimus|Given IV or PO
75407268|NCT02960646|Radiation|Total-Body Irradiation|Undergo TBI
75407269|NCT02909556|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
75552228|NCT04575233|Procedure|ultrasound-assisted Transversus Abdominis Plane (TAP) block|Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
75712264|NCT02562222|Procedure|anodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
75872005|NCT02326714|Other|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
76039659|NCT05540093|Other|high power pain threshold ultrasound|After explaining the procedure, and the trigger points will be marked by a physical therapist that . Then, the hand placed next to the prone position with the head in the neutral position, and the hands placed next to the body. The frequency was set to 1 MHz, and the intensity increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe will be held there for 4 s; then, the intensity was reduced by 50%, and the probe was moved over and around the trigger point. This process is done several times for three minutes.
76039660|NCT05540093|Other|traditional therapy|the patients will receive traditional therapy in the form of postural correction exercise, active range of motion and stretching exercise for cervical muscles
76039661|NCT03924479|Device|PowerBreathe (Breathing muscle training)|The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
75407270|NCT02894658|Device|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
75407271|NCT02894658|Procedure|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
75407272|NCT02758626|Drug|ataluren|Powder formulation
75407273|NCT02758626|Drug|Placebo|Powder formulation
75407274|NCT02587572|Biological|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
75407275|NCT02357784|Device|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
75407276|NCT02022384|Other|Blood sample and life quality questionnaires|Blood will be drawn at distinct time points during and after radio(chemo)therapy
75552229|NCT04575233|Drug|Ropivacaine|a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
75552230|NCT04565951|Behavioral|PsychArmor S.A.V.E.|The intervention is called PsychArmor S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
75552231|NCT04565951|Behavioral|sham intervention|"A sham training consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
75872006|NCT03144466|Combination Product|Pembrolizumab|antiPD1 monoclonal antibody
76039662|NCT05696405|Procedure|VATS resection of MEPA|VATS resection of mediastinal parathyroid adenoma
75552232|NCT00428415|Drug|Tesofensine|
75552233|NCT00428454|Device|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
75552234|NCT00432978|Drug|Bosentan administration|
75712265|NCT02562222|Procedure|cathodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
75407277|NCT01448616|Drug|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
75872007|NCT03144310|Other|lung ultrasound|lung ultrasound and blood gas
75552235|NCT00433056|Other|STI|CD4 guided treatment interruption
75407278|NCT01448616|Drug|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints."
75407279|NCT01448616|Drug|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
75552236|NCT00433056|Drug|stable HAART|continuous therapy
75552237|NCT04460612|Device|Active IR sock|Subjects will be wearing the infrared socks for 60 minutes
76039663|NCT03838601|Drug|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
76039664|NCT05592041|Drug|Banaba Leaf Extract|a herbal extract in the form of Bigel
76039665|NCT02625259|Drug|TAK-117|TAK-117 capsules
75552238|NCT04460612|Other|Placebo socks|Placebo Socks will be placed on participants feet first for 60 minute
75552239|NCT00428532|Drug|Licorice root extract or Pomegranate juice|
75552240|NCT04401332|Other|mobile health app|asthma symptom monitoring via a clinically integrated mobile health (mHealth) app installed on patients' smartphones
75552241|NCT01051791|Drug|Everolimus 10mg daily|RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
75552242|NCT04346537|Device|INGEVITY+™ Pace/Sense Lead|The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.
75552243|NCT01056510|Drug|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
75407280|NCT01448616|Drug|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
75407281|NCT01320696|Biological|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
75407282|NCT00853632|Device|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
75407283|NCT00074412|Drug|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
75407284|NCT00074412|Drug|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
75407285|NCT02618772|Drug|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
75407286|NCT02618772|Drug|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
75552244|NCT01056510|Drug|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
75552245|NCT01056510|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
75552246|NCT01051323|Drug|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
75552247|NCT04321811|Other|Observation of patients with known, suspected, or at risk for COVID-19 infection|Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
75552248|NCT01056276|Drug|Bendamustine|Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
75552249|NCT01056276|Drug|Bortezomib|"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
75407287|NCT02619396|Procedure|Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 4 on LA posterior wall
75407288|NCT02619396|Procedure|Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 4 on LA posterior wall
76039666|NCT02625259|Drug|Lansoprazole|Lansoprazole capsules
75407289|NCT02619396|Procedure|Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 5 on LA posterior wall
75552250|NCT01056276|Drug|Dexamethasone|20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
75407290|NCT02619396|Procedure|Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 5 on LA posterior wall
75407291|NCT02620878|Device|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
75407292|NCT02620878|Other|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
75552251|NCT01055886|Drug|nicotine patch|Nicotine patch, 7-21 mg.
76039667|NCT02625259|Drug|TAK-117|TAK-117 tablets
76039668|NCT04958083|Diagnostic Test|multiphase ECG-gated contrast-enhanced CT|Compared with current standard CT imaging, the dynamic CT protocol provides incremental functional information, which is potentially helpful to the individuals under study (such as early awareness for future complications and potential prediction of outcomes). Due to the nature of the acquisition, a wider R-R acquisition window will result in a higher radiation burden than a standard protocol. However, the study protocol will replace the standard routine CT image protocol as it contains both the routine anatomic information and incremental functional information. The time required for the image acquisition and associated radiation will be slightly higher; the additional information from multiple reconstructed phases will justify a slightly higher radiation burden in a usually elderly population. The estimated radiation dose for the standard imaging protocol is approximately 8 mSv. The estimated radiation dose for the modified dynamic CT image acquisition is approximately 18 mSv.
75407293|NCT02621892|Drug|Tenapanor|
75407294|NCT02621892|Drug|Placebo|
75407295|NCT02624700|Drug|Experimental Arm A: Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
75552252|NCT01055886|Drug|placebo patch|placebo patch used from weeks 4-6
75552253|NCT00433095|Drug|Navelbine|
75552254|NCT00433095|Drug|Herceptin|
76039669|NCT02577107|Drug|ranibizumab|
76039670|NCT02577107|Drug|Conbercept|
76039671|NCT04958473|Drug|Sintilimab|PD-1 inhibitor，Sintilimab 200mg IV, every 3 weeks.
76039672|NCT04958473|Drug|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
75407296|NCT02624700|Drug|Experimental Arm A: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.
75407297|NCT02624700|Drug|Experimental Arm B: Pemetrexed|Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
75407298|NCT02624700|Drug|Experimental Arm B: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
75552255|NCT00433095|Drug|Navelbine (oraly)|
75552256|NCT01055613|Device|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
75552257|NCT01055613|Device|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
75552258|NCT00433134|Behavioral|Adherence|
75552259|NCT04301804|Drug|SHR6390|a selective small-molecule CDK4/6 inhibitor
75552260|NCT01055457|Device|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
75552261|NCT01055457|Device|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
75552262|NCT04148144|Other|No intervention included|No intervention included
75552263|NCT00428571|Procedure|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
75552264|NCT00428571|Procedure|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
75552265|NCT00428571|Procedure|Intensive Medical Management|lifestyle, diet, medication optimization
75552266|NCT04100291|Other|Faecal microbiota transplantation|FMT by daily enema with donor faeces
75552267|NCT04100291|Other|Placebo|Placebo by daily enema with placebo mixture
75552268|NCT04703283|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
75407299|NCT02625402|Behavioral|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
75407300|NCT02625402|Behavioral|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
75552269|NCT04046120|Other|Heel-free bandage|The bandage is made by leaving the heel uncovered.
75407301|NCT02627118|Device|FRESENIUS 160NR|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER
75407302|NCT02627118|Device|NIPRO ELISIO-15H|2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
75407303|NCT02631954|Drug|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
75407304|NCT02631954|Drug|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
75407305|NCT02632812|Drug|Rebamipide effervescent granules|Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
75407306|NCT02632812|Drug|Placebo effervescent granules|Placebo effervescent granules (oral), twice daily for 7 days
75407307|NCT02632812|Drug|Naproxen tablet|Naproxen tablet 550mg (tablet), twice daily for 7 days
75407308|NCT02633358|Device|Therapeutic hypothermia group|Therapeutic hypothermia
75407309|NCT02634684|Drug|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
75407310|NCT02634684|Drug|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
75552270|NCT04716647|Other|Ayurveda|Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.
75872008|NCT05173350|Other|RETAIN KY|The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.
75872009|NCT05173350|Other|Active Comparator|Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
75407311|NCT02635542|Drug|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
75407312|NCT02635542|Drug|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
75407313|NCT02636712|Device|ImageReady™ MR Conditional Pacing System|
75407314|NCT02637804|Device|stenfilcon A|contact lens
75407315|NCT02637804|Device|narafilcon A|contact lens
75407316|NCT02637804|Device|delefilcon A|contact lens
75407317|NCT02638974|Other|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
75407318|NCT02639286|Drug|ISIS 304801|300 mg of ISIS 304801 administered as SC
75407319|NCT02639286|Drug|Placebo|Placebo administered via SC
75407320|NCT02642952|Other|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
75407321|NCT05588544|Procedure|Er,Cr:YSGG laser|Use of laser at the degranulation step of the treatment
75407322|NCT05588076|Other|no intervention|no intervention
75407323|NCT05587218|Behavioral|Self-production|After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
75407324|NCT05585658|Biological|Erythropoietin alpha|To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
75407325|NCT05522634|Drug|TJAOA101|Once enrolled, participants will be administrated TJAOA101
75407326|NCT05510856|Other|Duloxetine|Duloxetine 30mg / day for 12 cycles (up to 6 months)
75407327|NCT05510856|Other|Gabapentin|Gabapentin 300 mg / day for 12 cycles (up to 6 months)
75552271|NCT04703049|Other|Blood Viscosity Testing|we calculated WBV using the formula [(0.12 × hematocrit) + (0.17 × (total protein - 2.07)]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.
75552272|NCT00428649|Dietary Supplement|20 µg selenium|20 µg selenium as selenomethionine
75552273|NCT00428649|Dietary Supplement|40 µg selenium|40 µg selenium as selenomethionine
75552274|NCT00428649|Dietary Supplement|60 µg selenium|60 µg selenium as selenomethionine
75552275|NCT00428649|Dietary Supplement|80 µg selenium|80 µg selenium as selenomethionine
75872010|NCT03105466|Procedure|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
75872011|NCT03105466|Device|Acellular Porcine Cornea|
76039673|NCT04957927|Drug|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
75552276|NCT00428649|Dietary Supplement|100 µg selenium|100 µg selenium as selenomethionine
75407328|NCT05510856|Other|Lacosamide|Lacosamide 50 mg / day for 12 cycles (up to 6 months)
75552277|NCT00428649|Dietary Supplement|120 µg selenium|120 µg selenium as selenomethionine
75552278|NCT00428649|Dietary Supplement|placebo|placebo
75552279|NCT03790709|Drug|High dose ANAVEX2-73|Oral capsule
75872012|NCT03105466|Drug|Tacrolimus eye drops|
75872013|NCT03105466|Drug|Tobradex eyedrops|
75872014|NCT02335528|Behavioral|SimCoach|
75407329|NCT05462028|Device|Vibration training|The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.
75552280|NCT03790709|Drug|Mid dose ANAVEX2-73|Oral capsule
75552281|NCT03790709|Drug|Placebo oral capsule|Oral capsule
75552282|NCT00419900|Procedure|diagnosis of breast cancer by x-ray diffraction of hair|
75552283|NCT00433173|Procedure|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
75872015|NCT03478787|Drug|risankizumab|Subcutaneous (SC) injection
75872016|NCT03478787|Drug|secukinumab|Subcutaneous (SC) injection
75872017|NCT03105154|Other|Prevena Dressing|Prevena dressing is applied on one groin
75872018|NCT03105154|Other|Conventional Dressing|Conventional dressing is applied on the contralateral groin
75552284|NCT00433173|Drug|testosterone|transdermal 7.5 g/per day for 3 months
75552285|NCT00433173|Drug|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
75552286|NCT00433173|Drug|goserelin acetate implant|single depot injection 10.8 mg 3 months
75552287|NCT00433173|Procedure|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
75552288|NCT00433173|Procedure|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
75552289|NCT00433173|Procedure|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
75872019|NCT03105076|Other|Decision aids|Shared decision making with decision aids
76039674|NCT01161953|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
75552290|NCT00433173|Procedure|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
75552291|NCT00433173|Procedure|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
75552292|NCT00433173|Procedure|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
75552293|NCT01055028|Drug|Bevacizumab|15 mg/kg, IV every 21 days x 6 cycles.
75407330|NCT05462028|Behavioral|ergometer exercise|ergometer exercise training
75552294|NCT01055028|Drug|Paclitaxel|"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"
75407331|NCT05393466|Drug|BPI-361175|BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
75407332|NCT05281770|Drug|Erenumab|treatment with erenumab as chosen by treating physician
75552295|NCT00433212|Device|nCPAP|Deliver non-invasive respiratory support via ventilator with nCPAP device
75552296|NCT00433212|Device|NIPPV|Deliver non-invasive respiratory support via ventilator with NIPPV device
75552297|NCT03611816|Biological|Blood taken|Collection of clinical data
75552298|NCT03611816|Genetic|Blood taken|Collection of DNA
75552299|NCT03611816|Genetic|Blood taken|Collection of plasma
75552300|NCT00428727|Drug|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
75552301|NCT00428727|Drug|placebo patch|daily application during 90 days
75552302|NCT03440957|Other|Osteopathic treatment|The patients meeting the inclusions criteria will be informed of the study and an osteopathic treatment holistic ,involving all the body will be applied, three time with 2 days between the treatments .Each meeting with the practitioner will last around 40 minutes. The pain and symptoms assessment will be done before and after the treatment .
75552303|NCT00433368|Drug|L-Ornithine L-Aspartate|
75552304|NCT00428766|Drug|MORAb-003|
76039675|NCT04957849|Procedure|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery
75407333|NCT05281770|Drug|Fremanezumab|treatment with fremanezumab as chosen by treating physician
75407334|NCT05281770|Drug|Galcanezumab|treatment with galcanezumab as chosen by treating physician
75407335|NCT05225610|Other|Valsalva Manoeuvre|Blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds
75552305|NCT04716569|Drug|intranasal ivermectin spray|usage of ivermectin as intranasal spray for treating early covid patiens
75552306|NCT00428805|Behavioral|classroom curriculum|"classroom curriculum for 3 & 4 year old children includes activities to increase intake of fruits, vegetables, & whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum."
75552307|NCT00428805|Behavioral|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
75552308|NCT00428805|Behavioral|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
75407336|NCT05225610|Drug|Dexmedetomidine Injection [Precedex]|The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released
75407337|NCT05225610|Drug|normal Saline|5 ml saline will be administered.
75407338|NCT05185830|Other|Interactive robots|Children will mobilize with the interactive robot when control group will mobilize with nurse.
75407343|NCT05079906|Device|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
75407344|NCT05079906|Device|High Definition Intravascular Ultrasound (HD-IVUS)|High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
75407345|NCT04922190|Behavioral|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
75407346|NCT04444050|Drug|BMS-986331|Specified dose on specified days
75407347|NCT04444050|Other|Placebo, Matching BMS-986331|Specified dose on specified days
75407348|NCT04225416|Other|Questionnaire/Structured Interview|No intervention
75407349|NCT03693846|Drug|Nivolumab|IV infusion per institutional guidelines and the Package Insert
75407350|NCT03693846|Drug|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
75407351|NCT03529890|Drug|Nivolumab|"Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1"
75407352|NCT03529890|Radiation|Radiation therapy of the pelvis|Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
75407353|NCT03529890|Procedure|Radical cystectomy with standardized pelvic lymphadenectomy|Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
75407354|NCT02751060|Other|No intervention|
75407355|NCT02703480|Biological|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
75407356|NCT02703480|Biological|Ti-mesh|Titanium mesh
75407357|NCT01690728|Behavioral|Physical Activity|The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
75407358|NCT00938106|Radiation|optimised magnetic resonance image-guided intra-uterine brachytherapy|Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
76039676|NCT04957849|Procedure|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach
75407359|NCT00793806|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
75407360|NCT00580944|Procedure|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
75407361|NCT00540540|Device|Diffuse Optical Spectroscopy|Breast properties scanning
75407362|NCT00540306|Device|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
75407363|NCT02644278|Drug|VX-984 120 mg + PLD 40 mg/m^2|Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
76039677|NCT04688801|Drug|Chemotherapy Drugs, Cancer|Chemotherapy± Radiotherapy after surgery
76039678|NCT04688801|Drug|Immunotherapy|Chemotherapy + Immuonotherapy ± Radiotherapy after surgery
75407364|NCT02644278|Drug|VX-984 240 mg + PLD 40 mg/m^2|Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
75407365|NCT02644278|Drug|VX-984 480 mg + PLD 40 mg/m^2|Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
75407366|NCT02644278|Drug|VX-984 720 mg + PLD 40 mg/m^2|Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
75552309|NCT00428805|Behavioral|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
75872020|NCT02331628|Device|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:~Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\52 from baseline until and including week 14\52, one dose every two weeks ± 3 days), administered by the principal investigator.~Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~The energy flux density (EFD) will be 'high level'~All participants will be supplied with headphones to reduce the noise level emitted by the machine."
76039679|NCT04957771|Other|Supervise and guide regular exercise|Aerobic exercise, evaluated by cardiopulmonary exercise test, 3-5 times a week
76039680|NCT00912041|Device|Placement of the BrainGate2 sensor(s) into the motor-related cortex|Up to four 4x4 mm BrainGate2 sensor(s) are placed into the motor-related cortex (including speech-related areas of cortex), connected to one or two percutaneous pedestals. Neural recordings are made at least weekly for a year or more.
76039681|NCT04966975|Other|neoadjuvant chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
76039682|NCT04957459|Other|No intervention|No intervention
75872021|NCT02887482|Biological|GLS-5700|GLS 5700 at 2 mg DNA/dose
75872022|NCT02887482|Biological|Placebo|
76039683|NCT04950049|Drug|Dexamethasone|receive 2ml dexamethasone (5mg/ml)
76039684|NCT04950049|Other|Diluted dexamethasone 5ml|receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
76039685|NCT04950049|Other|Diluted dexamethasone 10ml|receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose
76039686|NCT04950049|Other|Diluted dexamethasone 20ml|receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose
76039687|NCT04966897|Dietary Supplement|GlycosBio Nutritional Supplement + PERT placebo|"The lipid (fat) in the GlycosBio Nutritional Supplement (GBNS) was provided in the form of a re-structured lipid monoacylglyceride (MAG) produced by the study sponsor. MAGs are readily absorbed by enterocytes without the need of digestion by pancreatic lipases. The MAG oil is produced enzymatically from almond oil. The product also contains essential amino acids, carbohydrates as simple sugars and fat-soluble vitamins and minerals. The GBNS to be administered in a volume sufficient to supply 0.5 g of MAG per kg of body weight"
76039688|NCT04966897|Dietary Supplement|Standard Nutritional Supplement + PERT|A 5.9% fat triacylglycerol-based commercially available nutritional supplement (Boost Plus®, Nestlé Health Science, Bridgewater, NJ) in a volume sufficient to supply 0.5 g of TAG per kg of body weight over the same time period and PERT capsules (24,000 iu/capsule) at a dose of 2,500 iu of lipase activity per gram of fat ingested.
75407367|NCT02645760|Other|Core stabilization exercise|7-weeks of core stabilization exercise
76039689|NCT03737045|Other|Decision Aid|Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
75407368|NCT02645760|Other|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
75407369|NCT02648022|Behavioral|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
75407370|NCT02648178|Device|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
75407371|NCT02648646|Other|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
75407372|NCT02648880|Behavioral|Exercise program|"Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation."
75407373|NCT02648880|Other|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
75407374|NCT02649192|Biological|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
75407375|NCT02649192|Dietary Supplement|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
75712266|NCT02562222|Procedure|anodal tDCS on M1 and cathodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
76039690|NCT05587673|Drug|Methylprednisolone|High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
75552310|NCT00428805|Behavioral|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
75407376|NCT02649192|Other|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
76039691|NCT02444793|Drug|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
75407377|NCT02650440|Procedure|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
75552311|NCT00428805|Behavioral|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
75872023|NCT03488927|Behavioral|Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)|The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
76039692|NCT02444793|Drug|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
76039693|NCT04957381|Behavioral|Group exercises|Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.
75552312|NCT00428805|Behavioral|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
75552313|NCT03190577|Genetic|blood sample|two 5 ML EDTA tubes of blood will be collected once by patient
75872024|NCT02335372|Procedure|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
75872025|NCT02335372|Drug|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
76039694|NCT04957069|Procedure|fixation|double row fixation with 3-4 wire anchors
76039695|NCT04957069|Procedure|primary repair|end-to-end repair
76039696|NCT04966429|Drug|Maraviroc|Tablets
76039697|NCT04956913|Device|Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
76039698|NCT04956913|Device|Macintosh|Patients of this group were intubated using the Macintosh Laryngoscope
76039699|NCT04949659|Procedure|Laparoscopic appendectomy|Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum
76039700|NCT04949581|Other|bioelectric therapy|the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.
75552314|NCT03114059|Diagnostic Test|Glaucoma diagnostics|Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
75552315|NCT04703127|Drug|Tadalafil and Combined Dapoxietine|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
75552316|NCT04703127|Drug|Dapoxietine and Combined Lidocaine 5% Spray|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
75872026|NCT02335372|Drug|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
76039701|NCT04949581|Other|cardiac rehabilitation program|the patient will receive cardiac rehabilitation program
76039702|NCT04949971|Behavioral|High volume group|Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
75407378|NCT02650440|Procedure|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
75407379|NCT02652390|Drug|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
75407380|NCT02652390|Drug|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
75407381|NCT02652390|Other|Saline|2 mL saline + 1 mL lidocaine
75407382|NCT02652780|Biological|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
75407383|NCT02652780|Device|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
75407384|NCT02653560|Drug|Potassium chloride powder|
75407385|NCT02653560|Drug|Potassium magnesium Citrate (KMgCit)|
75407386|NCT02653560|Drug|Potassium citrate powder|
75407387|NCT02653560|Drug|Placebo|
75407388|NCT02653872|Drug|AZD7986|Oral solution, single dose, dilution from concentrate
75407389|NCT02653872|Drug|Verapamil|Extended release tablet for oral use
75407390|NCT02653872|Drug|Itraconazole|Oral solution
75407391|NCT02653872|Drug|Diltiazem|Extended release capsule
75407392|NCT02654652|Dietary Supplement|Symbiotic|Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment
75407393|NCT02654652|Dietary Supplement|Maltodextrin|Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment
75407394|NCT02654808|Device|AirSeal trocar|"The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes."
75407395|NCT02654808|Device|Standard trocar|"A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas."
75407396|NCT02655354|Behavioral|Motivational Interviewing|
75407397|NCT02655354|Behavioral|Cognitive Behavioral Therapy Elements|
75407398|NCT02655354|Behavioral|Care Management|
75407399|NCT02655354|Drug|Fluoxetine|Anti-depressant
75407400|NCT02655354|Drug|Fluvoxamine|Anti-depressant
75407401|NCT02655354|Drug|Paroxetine|Anti-depressant
75407402|NCT02655354|Drug|Sertraline|Anti-depressant
75407403|NCT02655354|Drug|Citalopram|Anti-depressant
75407404|NCT02655354|Drug|Venlafaxine|Anti-depressant
75407405|NCT02655354|Drug|Duloxetine|Anti-depressant
75407406|NCT02655354|Drug|Mirtazapine|Anti-depressant
75712267|NCT02562222|Procedure|cathodal tDCS on M1 and anodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
75552317|NCT00428883|Drug|N-acetylcysteine (NAC)|
75407407|NCT02655354|Drug|Diphenhydramine|Sleep medication
75407408|NCT02655354|Drug|Trazodone|Sleep medication
75407409|NCT02655354|Drug|Prazosin|Sleep medication
75552318|NCT03082391|Device|Heavy weight Mesh|Patients will undergo ventral hernia repair with heavy weight mesh.
75552319|NCT03082391|Device|Medium weight Mesh|Patients will undergo ventral hernia repair with medium weight mesh.
75552320|NCT04702971|Drug|Flunarizine|The flunarizine will be given per clinical routine
75552321|NCT04702971|Other|healthy control|no intervention for healthy control
75712268|NCT02562222|Procedure|sham tDCS|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
75712269|NCT04012684|Device|Transcranial magnetic stimulation|For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
75872027|NCT02335372|Procedure|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
75872028|NCT01569750|Drug|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
75872029|NCT01569750|Drug|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
75872030|NCT01569750|Drug|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
75407410|NCT02655510|Drug|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
75872031|NCT01569750|Drug|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
76039703|NCT04966195|Radiation|stereotactic body raiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
76039704|NCT04965883|Procedure|Excision and Grafting|reconstruction of deep burn by grafting
75407411|NCT02656836|Other|Home tonometry, diagnostic study|Evaluating intraocular pressure
75407412|NCT02657538|Other|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
75407413|NCT02657538|Other|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
75552322|NCT02841644|Procedure|Operatively treated traumatic arthrotomy|operatively treated traumatic arthrotomy.
75552323|NCT02841644|Other|Non-operatively treated traumatic arthrotomy|non-operatively treated traumatic arthrotomy.
75552324|NCT00433407|Biological|trastuzumab|
75552325|NCT00433485|Drug|sirolimus|
75552326|NCT00433485|Genetic|comparative genomic hybridization|
75552327|NCT00433485|Genetic|gene expression analysis|
75552328|NCT00433485|Genetic|microarray analysis|
75552329|NCT00433485|Genetic|protein expression analysis|
75552330|NCT00433485|Genetic|proteomic profiling|
75552331|NCT00433485|Other|laboratory biomarker analysis|
75552332|NCT00433485|Other|mass spectrometry|
75552333|NCT00433485|Procedure|biopsy|
75552334|NCT02676791|Drug|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
75552335|NCT00429000|Device|thermospot|
75552336|NCT01600079|Biological|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
75552337|NCT00429039|Drug|L-leucyl-L-leucine methyl ester (LLME)|
75552338|NCT01370486|Drug|melatonin|melatonin cp 2 mg 1x/d for 1 month
75552339|NCT01370486|Drug|placebo|placebo cp 1x/d for 1 month
75552340|NCT00429078|Genetic|2nd Generation Designer T Cells|
75552341|NCT00433524|Procedure|computed tomography|
75872032|NCT01569750|Drug|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
76039705|NCT04965883|Procedure|dressing then delayed grafting|multiple dressing and delayed grafting
75552342|NCT00429117|Behavioral|Survey|Internet survey lasting 30 to 40 minutes.
75552343|NCT00491309|Behavioral|exercise training|exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
76039706|NCT04949347|Biological|glaucoma drainage device implantation|Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
75407414|NCT02657538|Device|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
75552344|NCT00429156|Device|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
75552345|NCT00429156|Device|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
75552346|NCT00327548|Behavioral|guided imagery|
75552347|NCT00433602|Other|clinical observation|
75712270|NCT04012684|Device|Sham|For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
75712271|NCT05051228|Device|CardioFlux|Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
75407415|NCT02657538|Other|Visual examination and bitewing (BW) radiography|established diagnostic methods
75407416|NCT02657928|Other|Laboratory Biomarker Analysis|Correlative studies
75407417|NCT02657928|Drug|Letrozole|Given PO
75407418|NCT02657928|Drug|Ribociclib|Given PO
75407419|NCT02658240|Drug|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
75407420|NCT02658240|Drug|Epinephrine|0.5 mg epinephrine
75407421|NCT02660112|Drug|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
75407422|NCT02661126|Drug|MK-3682B|FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
75407423|NCT02661828|Other|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
75552348|NCT00433602|Procedure|management of therapy complications|
75552349|NCT00433602|Procedure|ultrasound imaging|
75552350|NCT00327587|Drug|Valsartan + amlodipine|
75552351|NCT00327587|Drug|Valsartan + HCTZ|
75552352|NCT00327587|Drug|Amlodipine + HCTZ|
75552353|NCT00327587|Drug|Valsartan + amlodipine + HCTZ|
75552354|NCT00429195|Behavioral|Dietary Fatty Acid Modification|
75552355|NCT00327665|Biological|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
75552356|NCT00327665|Biological|Pneumo 23™|Single-dose intramuscular injection.
75552357|NCT00327665|Biological|Placebo|1 intramuscular injection.
75552358|NCT00327665|Biological|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
75552359|NCT00433641|Drug|sibutramine|placebo
75552360|NCT00433641|Drug|sibutramine|oral 15 mg sibutramine once per day
75552361|NCT00433641|Drug|sibutramine|oral sibutramine 10 mg once per day
75712272|NCT00944788|Other|qi-gong|Physical activity similar to tai-chi
75712273|NCT00749112|Drug|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
75712274|NCT00848679|Drug|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
75552362|NCT00327704|Drug|albumin|albumin 20% 100 ml/8 hours for 3 days
75552363|NCT00327704|Drug|saline|saline 100 ml/8hours for 3 days
75552364|NCT01050816|Procedure|Chondron(autologous chondrocyte) Implantation|"Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation."
75552365|NCT00327821|Behavioral|calorie controlled diet|
75552366|NCT00429234|Drug|Dasatinib|Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
75872033|NCT02335138|Behavioral|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
76039707|NCT04956367|Procedure|Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma|Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
76039708|NCT04956367|Device|CO2 laser with PRP|CO2 laser with PRP
75552367|NCT00429234|Drug|Gemcitabine|Starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
75552368|NCT00327938|Device|Measuring of skin conductance|
75552369|NCT00327938|Procedure|Tetanic stimuli|
75552370|NCT00433680|Behavioral|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
75552371|NCT00433719|Drug|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
75552372|NCT00328055|Behavioral|AD-Easy (Advance Directive-Easy)|
75552373|NCT00328055|Behavioral|AD-Standard (Advance Directive-Standard)|
75552374|NCT04704297|Drug|Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.|We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
75552375|NCT04704297|Drug|Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.|Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
75552376|NCT04704297|Drug|Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.|60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
75552377|NCT04704414|Device|Exophthalmos measurement|Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
75552378|NCT00328211|Dietary Supplement|Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)|15 mg/kg/day for 18 days
75552379|NCT00328211|Dietary Supplement|Sphingomyelin|1000mg/day for 19 days
75712275|NCT00848679|Drug|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
75712276|NCT02567864|Other|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
75712277|NCT02567864|Other|control|participants maintain their daily activities.
75712278|NCT04012606|Drug|TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo|TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
75552380|NCT00328211|Other|C13 Stable isotope of Cholesterol|Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
75712279|NCT00744744|Other|informational intervention|Patient educational information
75712280|NCT00744744|Other|questionnaire administration|Survey
75712281|NCT00744744|Procedure|management of therapy complications|Survey
75712282|NCT00744744|Procedure|psychosocial assessment and care|Survey
75712283|NCT00744744|Procedure|quality-of-life assessment|Survey
75712284|NCT02545959|Drug|Rituximab IT|CSF injection of intrathecal rituximab (20mg)
75552381|NCT04704180|Behavioral|Facilitation Tuchking Position|The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
75552382|NCT00433758|Device|GlucoTrack|GT
75552383|NCT00419978|Procedure|Colectomy|
75552384|NCT01054560|Device|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
75552385|NCT01054560|Device|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
75552386|NCT00328250|Behavioral|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
75552387|NCT00328289|Device|transcutaneous muscle stimulation, treadmill|
75552388|NCT00433797|Dietary Supplement|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
75872034|NCT02335138|Behavioral|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
76039709|NCT04956367|Device|CO2 laser with placebo|CO2 laser with placebo
76039710|NCT04956601|Radiation|vaginal brachytherapy/pelvic external beam radiotherapy|high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy
75552389|NCT00328367|Drug|aripiprazole|aripiprazole augmentation of clozapine
75712285|NCT02545959|Drug|methylprednisolone IV|blood infusion of methylprednisolone IV (120mg)
76039711|NCT04966039|Other|No intervention.|There was no intervention.
76039712|NCT04956055|Other|Reflexology|The patient will be kept in a lying position. First, the patient will be given four minutes of hand reflexology on each hand with warming and stimulation techniques.Reflexology will be applied to the left hand with the thumb of the right hand, the thumb of the left hand and the special points in the right hand. It will be applied to the fingers, palm, back of the hand, and finally the wrists, respectively, starting with the fingertips and using special reflexology techniques (a total of six minutes for each hand separately). By sending a moderate stimulus, a total of 20 minutes of reflexology session will continue.Since the patient reveals and uses his own internal energy at the end of the session, nobody should talk to the patient until five minutes after the procedure. Survey questions and vital signs would be examined five minutes after the session and the research with the participant would end.
75552390|NCT00328367|Drug|placebo|placebo
75552391|NCT04703088|Drug|Ondansetron 4 MG|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
75712286|NCT02545959|Drug|Rituximab IV|Blood infusion of rituximab (375mg/m2)
75407424|NCT02661828|Other|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
75407425|NCT02662608|Drug|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
75407426|NCT02665260|Drug|Cantharidin|cantharidin 0.7% topical liquid
75407427|NCT02665260|Drug|Placebo|Placebo topical liquid
75407428|NCT02665260|Device|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
75407429|NCT02665728|Drug|BLI400 Laxative|
75407430|NCT02666352|Drug|Uprifosbuvir|A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
75712287|NCT04012528|Other|ERAS program|ERAS program
75712288|NCT04062110|Device|plaster cast|Closed Reduction of Fracture and Application of Plaster Cast
75712289|NCT00747630|Other|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
75552392|NCT04703088|Drug|0.9% Saline|2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
75552393|NCT00328445|Behavioral|Positive Action|See publications
75407431|NCT02666352|Drug|Ruzasvir|A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
75407432|NCT02666508|Other|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
75407433|NCT02666508|Other|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
75407434|NCT02669784|Drug|Low Dose Contrast (Omnipaque) 40mL|The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
75407435|NCT02669784|Drug|Low Dose Contrast (Omnipaque) 50 mL|The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
75407436|NCT02671032|Device|Nucleus CI532 cochlear implant|
75407437|NCT02672514|Device|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
75407438|NCT02672514|Device|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
75407439|NCT02673138|Drug|canagliflozin|basal interruption with canagliflozin
75407440|NCT02673138|Other|basal interruption without canagliflozin|basal interruption
75407441|NCT02673372|Drug|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
75872035|NCT02326558|Procedure|laparoscopic microwave ablation-assisted enucleation|
75407442|NCT02673372|Drug|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
75407443|NCT02673918|Other|Home-based upper-body rehabilitation with online support|"Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes."
75552394|NCT00433875|Drug|AMG 714|
75552395|NCT00328484|Behavioral|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
75552396|NCT00328484|Behavioral|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
75712290|NCT02545647|Device|BRYGB|65 patients undergo a banded RYGB
75552397|NCT00429312|Biological|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
75552398|NCT00328640|Drug|Optimal treatment|
75552399|NCT00328679|Device|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
75872036|NCT02326558|Procedure|conventional laparoscopic partial nephrectomy|
75872037|NCT02331316|Other|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period"
75872038|NCT02331004|Other|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
75552400|NCT00328718|Drug|montelukast (5mg QD)|
75552401|NCT00328718|Drug|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
75552402|NCT00328757|Behavioral|Regular diet as the first postoperative meal|
75552403|NCT01054443|Drug|Placebo|Tablet
75552404|NCT01054443|Drug|Lusutrombopag|Tablet
75552405|NCT00328796|Procedure|acupuncture in 6 specific points|
75552406|NCT00328796|Drug|lidocaine 10mg/ml|
75872039|NCT02331004|Other|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
75552407|NCT01580319|Other|physical exercise|150 minutes per week
75407444|NCT02677428|Behavioral|Remotely-Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
75407445|NCT02677428|Behavioral|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
75407446|NCT02677740|Device|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
75552408|NCT00420134|Procedure|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
75552409|NCT00429390|Behavioral|Ramadan Fasting|
75552410|NCT00420173|Procedure|Laboratory analysis|blood withdrawal
75552411|NCT00429468|Drug|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
76039713|NCT04955977|Other|Physical exercise program|"Step 1 • Diaphragmatic reeducation: • Aerobic capacity: Intensity: zone 2, 60% HRMax, 4-6 / 10 Borg Scale; Charge: 20 m.~Step 2 • Aerobic capacity: Intensity: zone 2, 65% HRMax, 4-6 Borg Scale; Charge: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 3-4 / 10 Omni-Res; Load: 20% 1RM; Series: 3; Reps: 1. • Flexibility and elasticity: Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 3 • Aerobic capacity: Intensity: zone 3, 70% HRMax, 5-6 / 10 Borg scale, Load: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 4-5 / 10 Omni-Res; Load: 30% 1RM; Series: 4; Reps: 10. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 4 •Aerobic capacity: Intensity: zone 3, 75% HRMax, 6-7 / 10 Borg scale, Load: 30 m. • Muscular strength: Intensity: 5-6 / 10 Omni-Res; Load: 40-50% 1RM; Series: 4 s; Reps: 13. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s."
76039714|NCT04955977|Other|Health education in COPD|Week 1-2: Health education: COPD and respiratory care at home. Week 3-4: Importance of daily physical activity in COPD. Week 5-6: Early Signs of COPD Exacerbation and Action Plan Week 7-8: Use and care of respiratory devices at home.
76039715|NCT04956211|Procedure|Periodontal therapy|Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
75552412|NCT00420251|Drug|Genotropin|
75552413|NCT04702698|Drug|Peposertib|Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.
75552414|NCT04702698|Drug|Peposertib|Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
75552415|NCT00328835|Procedure|Brief Elevation of IOP|
75552416|NCT00328874|Drug|Coenzyme Q10|
75712291|NCT00744900|Drug|Pemetrexed, cisplatin|Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
75712292|NCT00727090|Drug|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
75407447|NCT02677740|Device|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
75407448|NCT02678442|Device|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
75407449|NCT02678442|Device|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
75407450|NCT02679690|Behavioral|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
75407451|NCT02679690|Behavioral|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
75407452|NCT02680158|Device|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
75407453|NCT02680158|Device|Sham|Sham device (control), intranasal application for approximately 3 minutes.
75407454|NCT02680158|Device|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
75407455|NCT02681172|Drug|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
75407456|NCT02681172|Procedure|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
75407457|NCT02682030|Device|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
75407458|NCT02682030|Device|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
75407459|NCT02682420|Device|everlinQ endoAVF System|
75407460|NCT02682498|Drug|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
75407461|NCT02682498|Drug|Standard Preparation|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
75407462|NCT02684136|Drug|suvorexant|suvorexant 20 mg taken before sleep
75407463|NCT02684136|Drug|placebo|placebo taken before sleep
75872040|NCT02326480|Other|Identification of genetic causes of obesity|A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
75872041|NCT02331160|Behavioral|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
75872042|NCT02334904|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
75872043|NCT02334904|Drug|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
75407464|NCT02687412|Procedure|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
75407465|NCT02687412|Procedure|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
75712293|NCT00852033|Behavioral|Brief Motivational Intervention (BMI)|Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
75407466|NCT02687412|Procedure|bowel preparation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
75407467|NCT02687412|Procedure|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
75407468|NCT02687412|Procedure|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
75407469|NCT02687412|Procedure|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
75407470|NCT02687412|Procedure|Postoperative glycaemic control|Postoperative glycaemic control;
75407471|NCT02687412|Procedure|postoperative nausea and vomiting (PONV) control;|
75407472|NCT02687412|Procedure|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
75407473|NCT02687412|Procedure|pre-operative fasting at least 8h|
76039716|NCT04949035|Diagnostic Test|Assessment of mental state and quality of life|Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
76039717|NCT04948879|Procedure|Vascular resection/reconstruction|The resection of a major blood vessel with or without reconstruction
76039718|NCT04948957|Drug|Esmolol|
75407474|NCT02687412|Procedure|bowel preparation for traditional surgery|Oral bowel preparations or mechanical bowl until liquid stool
75407475|NCT02687412|Procedure|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
75407476|NCT02693262|Device|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
75407477|NCT02693262|Device|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
75552417|NCT00429546|Behavioral|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
75552418|NCT00429546|Other|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
75407478|NCT02694198|Other|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
75407479|NCT02695290|Drug|Afatinib|
75407480|NCT02695446|Drug|Minocycline|Oral extended release minocycline
75407481|NCT02696070|Device|Provant Therapy System|
75407482|NCT02697240|Drug|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
76039719|NCT04948957|Drug|Nitroglycerin|
75407483|NCT02698566|Drug|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
75407484|NCT02698800|Device|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
75407485|NCT02698800|Device|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
75407486|NCT02701062|Device|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
75407487|NCT02701062|Drug|Anticoagulation Therapy|Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
75407488|NCT02704104|Device|AC5 Topical Hemostatic Device|Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
75407489|NCT02705352|Drug|5-Fluorouracil|Treatment medication
75407490|NCT02705352|Other|Normal saline|Placebo
75407491|NCT02707146|Behavioral|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
75407492|NCT02707146|Other|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
75407493|NCT02707146|Device|iPad|
75407494|NCT02707770|Other|Pulmonary Rehabilitation|
75407495|NCT02708238|Dietary Supplement|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
75407496|NCT02708238|Dietary Supplement|Lactobacillus reuteri DSM 17938 (108 CFU)|
75407497|NCT02708238|Drug|Simethicone|
75407498|NCT02708862|Device|Preoxygenation|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
75407499|NCT02709018|Drug|losartan|Angiotensin receptor blocker (ARB)
75407500|NCT02709018|Drug|Placebo|Placebo
75407501|NCT02713230|Drug|bupivacaine liposome injectable suspension|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
75407502|NCT02713230|Drug|bupivacaine liposome injectable suspension|20 mL EXPAREL (bupivacaine liposome injectable suspension)
75407503|NCT02713230|Drug|Placebo|20 mL normal saline as single-injection
75552419|NCT00328913|Drug|5-hydroxytryptophan (food supplement)|
75552420|NCT00433953|Drug|Mycophenolate Mofetil (CellCept)|
75552421|NCT00433953|Behavioral|Dietary Monitoring|
75552422|NCT00433953|Behavioral|Drug Diary|
75552423|NCT00433953|Procedure|Blood Sampling|
75552424|NCT02957643|Drug|Iron|oral treatment
75552425|NCT00328991|Device|duct tape occlusion therapy|
75552426|NCT02957604|Drug|evolocumab|Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
75552427|NCT00329069|Drug|atorvastatin (drug)|
75552428|NCT00429624|Procedure|Chiropractic manipulation|
75552429|NCT00429624|Drug|acetaminophen|
75552430|NCT00329147|Drug|desvenlafaxine SR|
75552431|NCT00329147|Drug|desipramine|
75552432|NCT00329147|Drug|paroxetine|
75552433|NCT04702503|Drug|WP1220|Topical administration 2x daily for 84 consecutive days
75552434|NCT00329186|Drug|desvenlafaxine SR|
75552435|NCT00329186|Drug|venlafaxine ER|
75552436|NCT00434031|Drug|docetaxel|
75552437|NCT00434031|Drug|cyclophosphamide|
75552438|NCT00434031|Drug|trastuzumab|
75407504|NCT02713698|Drug|Propofol|"The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
75407505|NCT02714400|Drug|Venlafaxine|Venlafaxine 50mg before sleep
75407506|NCT02714400|Drug|Placebo|One piece of placebo before sleep
75407507|NCT02716506|Procedure|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
75552439|NCT00434031|Drug|liposomal doxorubicin|
75407508|NCT02716818|Drug|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
75552440|NCT00329225|Drug|rosiglitazone|
75552441|NCT01050543|Drug|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
75552442|NCT01050543|Drug|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
75552443|NCT00329264|Drug|Quetiapine fumarate|
75552444|NCT00329342|Behavioral|Occupational ergonomic training|Adequate postural habits in activities of daily living
75552445|NCT04703946|Other|observacional|"Analyze the incidence of short sublingual frenulum in newborns of the Hospital Nostra Senyora de Meritxell of the Principat of Andorra.~Association or not of the AG with auxological parameters (weight, height, cranial perimeter) at birth.~Association or not of the AG with sex.~Association or not of the AG with gestational age.~Association or not of the AG with other minor and major malformations."
75552446|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
75552447|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
75552448|NCT00429780|Biological|Alum-ALM + BCG|Alum-ALM + BCG 200 ug per injection
75552449|NCT00329459|Drug|sumatriptan succinate/naproxen sodium|
75552450|NCT00329459|Drug|placebo|placebo to match
75552451|NCT00329498|Drug|L-Ascorbic Acid|
75552452|NCT00434187|Drug|ERB-041|
75552453|NCT00329537|Drug|Sargramostim (Leukine)|Self-subcutaneous injection
75552454|NCT00329537|Drug|Placebo|Self-subcutaneous injection
75552455|NCT00429897|Drug|Bendroflumethiazide 2.5mg - 5mg|
75552456|NCT00429897|Drug|Amiloride 20-40mg|
75552457|NCT00429897|Drug|Spironolactone 50-100mg|
75552458|NCT00429897|Drug|Frusemide 20-40mg|
75552459|NCT00429897|Drug|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
75552460|NCT00329576|Biological|Hepatitis B vaccine|
75552461|NCT00429936|Drug|Fenretinide|Once daily 30 minutes after the evening meal for 24 months
75552462|NCT00429975|Drug|levofloxacin|
75552463|NCT00429975|Drug|ceftriaxone|
75407509|NCT02716818|Drug|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
75552464|NCT00329615|Drug|Insulatard, flexpen|
75552465|NCT00430014|Drug|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
75552466|NCT00329654|Procedure|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
75712294|NCT00852033|Behavioral|Parent Based Intervention plus booster|The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
75712295|NCT00852033|Behavioral|Combined brief motivational intervention and parent based intervention plus boosters for both interventions|A combination of Intervention 1 and 2.
75407510|NCT02719158|Drug|6 mg ciprofloxacin|Single administration of OTO-201
75407511|NCT02719158|Drug|12 mg ciprofloxacin|Single administration of OTO-201
75407512|NCT02719158|Other|Sham|
75712296|NCT00852033|Other|Assessment only|No intervention, assessment only.
75712297|NCT00944944|Behavioral|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
75712298|NCT00944944|Behavioral|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
75407513|NCT02719938|Behavioral|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
75407514|NCT02723916|Behavioral|ezParent Program|Tablet-based behavioral parent training program.
75407515|NCT02723916|Behavioral|Health-e Kids Control App|Tablet based health promotion information App
75407516|NCT02726178|Drug|Advil® Pediatric drops for infants|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
75407517|NCT02726178|Drug|Placebo|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
75407518|NCT02727816|Device|filcon IV I (BC 8.6)|control lens
75552467|NCT00430053|Genetic|gene rearrangement analysis|
75552468|NCT00430053|Genetic|polymerase chain reaction|
75552469|NCT00430053|Genetic|proteomic profiling|
75552470|NCT00430053|Other|flow cytometry|
75552471|NCT00430053|Other|immunohistochemistry staining method|
75552472|NCT00430053|Procedure|biopsy|
75712299|NCT00848835|Device|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
75552473|NCT01056393|Drug|ibalizumab 800mg Q2Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
75552474|NCT01056393|Drug|ibalizumab 2000mg Q4Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
75712300|NCT00950014|Other|Presentation of drug efficacy and side effect data|Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
75407519|NCT02727816|Device|filcon IV I (BC 8.7)|control lens
75407520|NCT02727816|Device|ocufilcon D|test lens
75407521|NCT02727816|Device|methafilcon A (BC 8.6)|control lens
75407522|NCT02727816|Device|methafilcon A (BC 8.7)|control lens
75712301|NCT00855621|Procedure|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
75712302|NCT00689052|Drug|pramipexole ER|
75407523|NCT02727816|Device|somofilcon A|test lens
75407524|NCT02730234|Device|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
75407525|NCT02733588|Drug|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
75407526|NCT02734056|Other|Music|Listening to music that the patient likes
75407527|NCT02734056|Other|Control|Control
75407528|NCT02735382|Behavioral|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
75407529|NCT02735382|Behavioral|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
75407530|NCT02737332|Drug|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
75407531|NCT02737332|Drug|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
75407532|NCT05446428|Other|study of IFNGS expression biomarkers|Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.
75407533|NCT05446116|Procedure|partial splenic artery embolization|embolization of the splenic artery for the treatment of hypersplenism
75407534|NCT05445960|Procedure|Tourniquet|This arm will have a tourniquet placed about the thigh and inflated to 250mmHg for the duration of ankle fracture surgery or 2 hours, whichever is shorter.
75407535|NCT05445180|Behavioral|Contingency management|Contingency management will be used to encourage abstinence
75407536|NCT05445102|Procedure|autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect|after extraction of tooth it will be grinded using hand bone mill and demineralized and placed in intrabony defect
75407537|NCT05444088|Drug|Adebrelimab|intravenous infusion
75407538|NCT05444088|Drug|Bevacizumab|intravenous infusion
75407539|NCT05444088|Drug|SHR-8068|intravenous infusion
75407540|NCT05443854|Drug|Aminoglycosides intervention|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines [3, 28, 50].~Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
75712303|NCT00689052|Drug|placebo|
75712304|NCT04012450|Procedure|Epidural anesthesia|Performing an epidural anesthesia
75712305|NCT04012450|Procedure|spina-epidural anesthesia|Performing a spina-epidural anesthesia
75712306|NCT00945022|Device|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
75712307|NCT02565212|Drug|Montelukast,mometazon froat|
75712308|NCT00848913|Other|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
75712309|NCT00848913|Other|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
75712310|NCT00747708|Drug|Granulocyte-colony stimulating factor|5 days subcutaneous injection
75712311|NCT00747708|Procedure|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
75712312|NCT00747708|Procedure|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
75407541|NCT05443854|Behavioral|Lack of protective isolation intervention|"Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.~Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods.~A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated"
75407542|NCT05443854|Other|No systematic aminoglycosides intervention - standard arm|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines [3, 28, 50].~No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides."
75407543|NCT05443854|Other|Protective isolation intervention - standard arm|"Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide:~High-efficiency air filtration [filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better]~Geographical isolation in an individual room~Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the best available level of isolation in line with recommendation, while not delaying ICU admission and patients' care"
75407544|NCT05443776|Other|Biomaterial implantation|Implant a approved biomaterial by European Regulatory Agencies
75552475|NCT04716491|Device|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.|When they meet the inclusion criteria and accept to participate in the study, the interventionist nurse will explain to the patient the objectives and protocol of the study, apply the consent form and the instruments for assessing sleep (pittsburgh), trait and state anxiety (STAI). Then the software will be randomized and after defining the group, the nurse will guide the patient on the use of the devices from 9:00 am until the final awakening in the morning. Control group participants will only complete the assessment instruments. Noise and brightness will be measured at randomization of participants. The following morning, the visual sleep scale and the sleepiness scale will be applied for both groups, in addition to filling in information regarding the length of time the devices stay with patients at night and the clinical data that will be collected until discharge from the hospital. ICU, when independent of the group, the state anxiety instrument will be applied.
75552476|NCT01055106|Drug|GW05|vaginal gel once daily regimen A
75552477|NCT01055106|Drug|GW05|vaginal gel once daily regimen B
75552478|NCT01055106|Drug|GW05|vaginal gel once daily regimen C
75552479|NCT01055106|Drug|Metronidazole|vaginal gel 0.75% once daily for 5 days
75712313|NCT05602064|Drug|Ibuprofen|Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
75407545|NCT05443308|Diagnostic Test|Cerebral [15O]H2O PET before and after diamox infusion|Cerebral [15O]H2O PET before and after diamox infusion
75407546|NCT05443152|Behavioral|Fetal movement and position tracking training|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
75407547|NCT05442996|Drug|HLX35|The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. It is administered intravenously every 2 weeks on day 1 of each cycle.
75407548|NCT05442996|Drug|HLX10|The dose of HLX10 is fixed at 200 mg. It is administered intravenously once every 2 weeks on day 1 of each cycle.
75407549|NCT05441046|Drug|Genakumab|genakumab plus tislelizumab 200 mg
75407550|NCT05412264|Behavioral|Website intervention|12 week motivational emails, recording pedometer steps and waist circumference
75407551|NCT05394870|Other|manual lymphatic drainage (massage)|Patients will begin treatment with manual lymphatic drainage in the affected extremity. In this context, while the patients are in the supine hook position, lymph drainage will be applied first to the neck and then to the abdomen. After the stimulation of the central lymph nodes, the lymph circulation will be increased by stimulating the axillary lymph nodes of the relevant region. First, the proximal part will be drained and it will be advanced towards the distal. Drainage will be repeated depending on the edema at the distal forearm-wrist level.
75407552|NCT05394870|Other|Splint treatment|The splint routinely given to patients diagnosed with mild to moderate carpal tunnel syndrome will be given to both groups in these patients
75552480|NCT00329693|Drug|Norprolac|Placebo
75552481|NCT00329693|Drug|Norprolac|Quinagolide
75552482|NCT00329693|Drug|Norprolac|Quinagolide
75552483|NCT00329693|Drug|Norprolac|Quinagolide
75552484|NCT00430131|Procedure|Cognitive Orientation to Occupational Performance|
75552485|NCT00430131|Procedure|Contemporary Treatment Approach|
75552486|NCT00329810|Drug|Aripiprazole|Tablets, oral, 15 mg, once daily, 12 weeks.
75712314|NCT05602064|Drug|Paracetamol|Paracetamol is an analgesic that acts peripherally; although its primary site of action is still debatable, it is thought to inhibit prostaglandins in the hypothalamus
75407553|NCT05350332|Device|Negative Pressure Ventilator|The negative pressure ventilator is an off-the-shelf FDA-approved device designed to treat respiratory patients with hypoventilation syndromes. This ventilator places the torso within a fixed container that is connected to a vacuum source, which inflates the lungs by pulling a negative pressure around the chest and abdomen. After the clinically routine DISE, a negative pressure ventilator will be placed on the participant's chest to increase lung volumes and the DISE evaluation will be repeated to observe changes.
75407554|NCT05350332|Device|Pulmonary Function Testing (PFT)|PFT is a routine standardized clinical test to evaluate lung function. PFT is an outpatient procedure that consist of two parts: spirometry and body plethysmography. In spirometry, participants are asked to breathe through a mouthpiece that measures airflow and volume. Several breathing maneuvers are used to determine normal and maximal volume of inspiration/expiration. Body plethysmography is performed to calculate residual lung volumes. Participants are placed in an enclosed chamber where they are asked again to breathe through a mouthpiece. Changes in pressure in the sealed chamber during breathing can be used to calculate the volume of air that remains in the lung after expiration. The combination of values measured on spirometry and body plethysmography allow for calculation of residual lung volumes including the functional residual capacity and expiratory reserve volume.
75552487|NCT00329888|Procedure|Endoscopic papillary balloon dilatation|
75552488|NCT00329888|Procedure|Endoscopic sphincterotomy|
75552489|NCT00430170|Drug|Dipyridamole|Dipyridamole 2x200mg 7day per os
75552490|NCT00430170|Drug|caffeine|caffeine 4mg/kg iv
75552491|NCT00329927|Biological|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
75407555|NCT05350332|Device|Transcutaneous Phrenic Nerve Stimulation|Phrenic nerve stimulation (PNS) will be performed trancutaneously using a commercially available and FDA approved peripheral neurostimulator. (Digitimer DS7A High Voltage Constant Current Stimulators). The neurostimulator consists of a stimulation generating box connected to electrodes that will be placed over the skin of the neck bilaterally over both phrenic nerves where an bipolar electric current will be used to stimulate the phrenic nerve leading to diaphragm contraction.
75552492|NCT00329966|Biological|Surface Antigen, Inactivated, Influenza (form.2006-07)|
75552493|NCT00434265|Behavioral|Physical training|
75552494|NCT00330005|Behavioral|Group Psychotherapy|
75552495|NCT04716530|Other|No intervention is associated with the study.|No intervention is associated with the study.
75552496|NCT00330044|Drug|Premetrexed (Alimta)|
75552497|NCT00330044|Drug|Carboplatin|
75552498|NCT00430326|Drug|Avotermin|
75552499|NCT00330083|Biological|ALK Ragweed Tablet|
75552500|NCT00430365|Drug|lenalidomide|oral drug
75552501|NCT00430365|Drug|placebo|oral placebo
75552502|NCT00330122|Procedure|fore locked plate|
75552503|NCT00330122|Procedure|external radiocarpal fixer|
75552504|NCT00330239|Drug|Paroxetine CR|
75552505|NCT01051557|Other|Laboratory Biomarker Analysis|Correlative studies
75552506|NCT01051557|Drug|Perifosine|Given PO
75552507|NCT01051557|Drug|Temsirolimus|Given IV
75552508|NCT01051557|Procedure|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
75552509|NCT00330278|Drug|Cefazolin|
75552510|NCT00430404|Other|Collaborative care (Intervention)|Structured shared care with treatment protocol & support
75552511|NCT00330317|Drug|letrozole|2.5mg letrozole once-daily
75552512|NCT03270384|Device|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
75552513|NCT00330356|Behavioral|Low Salt Diet versus High salt diet|
75552514|NCT00430443|Drug|Liposomal Annamycin|3-day IV infusion
75552515|NCT00330395|Drug|caspofungin acetate|Duration of Treatment 28 Days
75552516|NCT00330434|Other|Trial Withdrawn 1|Trial Withdrawn 1
75552517|NCT00330434|Other|Trial Withdrawn 2|Trial Withdrawn 2
75552518|NCT00434382|Drug|Sevoflurane|
75552519|NCT00434382|Drug|Isoflurane|
75552520|NCT00434382|Drug|Desflurane|
75552521|NCT00434382|Drug|Propofol|
75552522|NCT00434382|Drug|Fentanyl|
75552523|NCT00434382|Drug|Sufentanil|
75552524|NCT00434382|Drug|Alfentanil|
75552525|NCT00434382|Drug|Remifentanil|
75552526|NCT00434382|Device|Midlatency auditory evoked potentials|
75552527|NCT00430560|Behavioral|cognitive rehabilitation|computer training
75552528|NCT00430560|Procedure|work therapy|opportunity to work in carefully supervised hospital job
75552529|NCT00430560|Behavioral|work therapy|work therapy
75552530|NCT01054170|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
75552531|NCT01054170|Drug|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
75552532|NCT00330629|Behavioral|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
75552533|NCT00330629|Behavioral|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
75552534|NCT00330707|Drug|Bacillus Calmette Guerin and interferon alpha|
75552535|NCT00434460|Behavioral|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
75552536|NCT00330746|Drug|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
75407556|NCT05340270|Drug|PD-1 inhibitor+GP|PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
75407557|NCT05340270|Drug|GP|Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
75407558|NCT05313594|Diagnostic Test|Mixed meal challenge test|Mixed meal consumption followed by postprandial blood sampling
75552537|NCT00330746|Drug|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
75552538|NCT00330746|Drug|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
75407559|NCT05313594|Diagnostic Test|MRI|MRI imaging
75407560|NCT05313594|Diagnostic Test|DEXA|DEXA scan
75407561|NCT05313594|Device|Freestyle Libre|Continuous blood glucose measurement
75407562|NCT05313594|Device|ActivPAL3|Continuous physical activity measurement
75552539|NCT00330746|Drug|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
75552540|NCT01053741|Biological|Radiolabeled autologous seminal fluid|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
75552541|NCT01053741|Biological|Radiolabeled Normosol-R|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
75407563|NCT05289414|Device|Radiofrequency|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency treatment
75552542|NCT04702230|Diagnostic Test|MRI|Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE
75712315|NCT05602064|Other|Placebo|A placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
75712316|NCT02565134|Drug|PAC-14028 cream 0.1%|Topical application
76039720|NCT04948801|Drug|Epclusa (sofosbuvir and velpatasvir)|Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
76039721|NCT04948255|Other|Health and Safety Executive's (HSE) Management Standards Indicator Tool (MSIT) to measure work-related stress|Questionnaire
75407564|NCT05289414|Procedure|Greater occipital nerve block|patients with diagnosis of cervicogenic headache will be subjected to Greater occipital nerve block
75407565|NCT05269368|Procedure|Wicking|Absorbable or non-absorbable wicking
75407566|NCT05269368|Procedure|No wicking|No wicking after surgery
75407567|NCT05266404|Drug|Dapagliflozin/sitagliptin FDC|Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
75407568|NCT05266404|Drug|Sitagliptin|Subjects will receive 100 mg single dose of Sitagliptin orally.
75407569|NCT05266404|Drug|Dapagliflozin|Subjects will receive 10 mg single dose of Dapagliflozin orally.
75407570|NCT05212584|Biological|CD7CAR T cells|CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
75407571|NCT05206188|Behavioral|Mastering the World of Work (MWW)|Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
75407572|NCT05184738|Other|Experimental Treatment, Oligomeric nutritional formula|Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
75407573|NCT05184738|Other|Control Treatment|Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
75407574|NCT05175924|Other|Nanpharmacological method|Virtual Reality
75407575|NCT05150418|Drug|Oxygen gas|Oxygen 15 l/min
75407576|NCT05150418|Drug|Air|Room air 15 l/min
75407577|NCT05146206|Other|Observational|In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
75407578|NCT05127564|Drug|Diroximel fumarate|Administered as specified in the treatment arm
75407579|NCT05122494|Drug|Hemay022+AI|hemay022：orally once daily，A 21-day cycle
75552543|NCT00330785|Drug|Amlodipine/Atorvastatin|
75552544|NCT00330824|Drug|antibiotic/steroid combination|1gtt, 4x/d, 15 days
75552545|NCT00330824|Drug|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
75552546|NCT00434538|Device|BST-DermOn|
75552547|NCT00330902|Drug|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
75552548|NCT00330902|Drug|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
75552549|NCT00434616|Procedure|Autologous bone marrow cell concentrate transplantation|bone marrow aspiration (240 ml), processing and reinjection
75552550|NCT00434616|Biological|saline injection|saline injections
75552551|NCT00430794|Drug|Spironolactone|
75712317|NCT02565134|Drug|PAC-14028 cream 0.3%|Topical application
75712318|NCT02565134|Drug|PAC-14028 cream 1.0%|Topical application
75552552|NCT00330980|Drug|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
75552553|NCT00330980|Drug|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
75552554|NCT00330980|Drug|Placebo|Participants will receive placebo for 6 months.
75552555|NCT00430833|Drug|candesartan|
75552556|NCT00434655|Procedure|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
75552557|NCT00331058|Procedure|Bronchoscopsy|Healthy and Asthmatic Volunteers
75552558|NCT00331058|Procedure|Prednisolone|Asthmatic Volunteers
75712319|NCT02565134|Drug|PAC-14028 cream vehicle|Topical application
75552559|NCT00430872|Behavioral|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
75552560|NCT00331097|Drug|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
75552561|NCT00331097|Drug|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
75552562|NCT00331097|Drug|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
75552563|NCT00331097|Drug|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
75552564|NCT00434694|Procedure|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
75552565|NCT00331175|Drug|Peptide YY3-36|
75552566|NCT00430911|Drug|Radiotherapy|
75552567|NCT00331214|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
75712320|NCT00747942|Behavioral|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
75552568|NCT00331214|Drug|placebo patch|placebo patch replaced every 3-4 days for 6 months
75552569|NCT04702074|Drug|Traditional Chinese medicine granules|"Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months."
75552570|NCT04702074|Drug|Traditional Chinese medicine granules placebo|"Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules ."
75552571|NCT00434733|Biological|Pandemic influenza vaccine|
75552572|NCT00434772|Drug|glucagon|
75552573|NCT04703907|Other|Auricular stimulation|"Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)"
75552574|NCT00331253|Procedure|Indocyanine Green-Mediated Photothrombosis|
75552575|NCT00431028|Device|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
75552576|NCT00431106|Drug|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
75552577|NCT00431106|Drug|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
75712321|NCT00560950|Biological|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
75712322|NCT02562144|Drug|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
75712323|NCT02562144|Drug|Placebo|Cutaneous placebo before intravenous cannulation.
75712324|NCT02562300|Drug|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
75712325|NCT02562300|Drug|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
75552578|NCT00431106|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
75552579|NCT00331370|Behavioral|GP training and Health Education|
75552580|NCT00431145|Drug|Niacin|
75407580|NCT05122494|Drug|Lapatinib+Capecitabine|Take the pills according to the instructions
75407581|NCT05097924|Other|NAN Supreme HypoAllergenic Starter Infant Formula in ready-to-feed format|Post-market observational study with formula feeding administered via standard of care
75407582|NCT05063604|Drug|Citalopram|20 mg tablet one or twice daily for 12 weeks
75407583|NCT05063604|Behavioral|Psychotherapy|One session weekly for 12 weeks
75552581|NCT00431145|Drug|Niacin+Statin|
75712326|NCT00945178|Drug|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
75407584|NCT05051514|Diagnostic Test|Evaluation|To examine the differences in postural stability, anxiety/depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
75407585|NCT04978428|Drug|Cannabidiol|Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)
75407586|NCT04960332|Device|Prevena|RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
75407587|NCT04940364|Drug|Pozelimab|Administered intravenous (IV) or subcutaneous (SC) per protocol
75552582|NCT00331487|Drug|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
75552583|NCT00331487|Drug|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
75407588|NCT04940364|Drug|Cemdisiran|Administered SC per protocol
75407589|NCT04844736|Procedure|CT Simulation|"Patient will undergo routine CT simulation to initiate radiation treatment planning process. For the purposes of this study, the day of CT simulation mapping scan will be counted as day 0. After the patient completes the CT simulation scan, the CT images and plan/structure files will be sent to the treatment planning system. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes."
75407590|NCT04814706|Dietary Supplement|Carbohydrate drinking|Administration of carbohydrate fluid
75407591|NCT04804488|Procedure|nasal polyp surgery|A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out.
75407592|NCT04780464|Drug|Doxorubicin|60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
75552584|NCT00431223|Behavioral|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
75552585|NCT00331526|Biological|aldesleukin|
75552586|NCT00331526|Biological|therapeutic autologous lymphocytes|
75552587|NCT00331526|Procedure|adjuvant therapy|
75552588|NCT00331526|Procedure|conventional surgery|
75552589|NCT00435084|Drug|APO866|
75552590|NCT00331565|Procedure|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
75552591|NCT00431262|Drug|antabuse (disulfiram)|
75552592|NCT00331604|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
75712327|NCT00945178|Drug|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
75712328|NCT00945178|Drug|Naproxen|Tablet, single oral dose, 500mg
75712329|NCT00945178|Drug|Placebo for Naproxen|Tablet, single oral dose
75712330|NCT00749346|Device|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
75712331|NCT05301478|Device|standard of care insole|standard of care diabetic insole
75712332|NCT05301478|Device|3D Printed Insole - pressure based|3D Printed Insole - pressure based
75712333|NCT05301478|Device|3D Printed Insole - FEA|3D Printed Insole - FEA
75407593|NCT04780464|Drug|Doxorubicin|12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
75552593|NCT00331604|Drug|insulin detemir|Injection s.c., 50% of daily dose.
75552594|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
75552595|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
75552596|NCT00435123|Dietary Supplement|Nutritional Supplement ProStat 64 twice a day|
75407594|NCT04780464|Drug|Cyclophosphamide Oral Product|100 mg BD on day 1 to day 7 of each 14 day cycle until PD
75552597|NCT00435123|Dietary Supplement|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
75552598|NCT04716764|Other|3-Day Food Intake Record|Collecting clinical and socio-demographic information, nutritional status, food consumption (dietary intake of advanced glycation end products, dietary total antioxidant capacity, dietary inflammatory index), anthropometric measurements (body weight, height, body composition, handgrip strength, upper-middle arm circumference, waist circumference, hip circumference, triceps skinfold thickness), quality of life, biochemical biomarkers (serum carboxymethyl lysine, advanced glycation end products receptor, the soluble receptor of advanced glycation end products, TNF-α, IL-1β, IL-6, malondialdehyde, 2,4-dinitrophenyl hydrazine, 8-hydroxy-2'-deoxyguanosine, total antioxidant capacity)
75552599|NCT00331643|Drug|ixabepilone|Given IV
75407595|NCT04780464|Drug|Prednisolone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD
75407596|NCT04780464|Drug|Prednisone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
75552600|NCT00331721|Drug|Enecadin|Dose escalating
75552601|NCT00331721|Drug|Placebo|Placebo comparator
75552602|NCT00431340|Drug|PXD101|
75407597|NCT04660422|Other|VitalTalk communication skills training|Clinicians will receive VitalTalk intensive communication skills training via highly structured Zoom conference. They will learn skills relevant to discussions about ACP and COVID-19 including delivering serious news, eliciting goals of care, and managing difficult conversations via telehealth platforms.
75552603|NCT00431379|Drug|Tenecteplase|
75552604|NCT00331838|Drug|Semuloparin sodium|"0.8 mL solution in Type I amber glass vials~Subcutaneous injection"
75552605|NCT00331838|Drug|Placebo (for Enoxaparin sodium)|"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
75552606|NCT00331838|Drug|Enoxaparin sodium|"0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection"
75552607|NCT00331838|Drug|Placebo (for Semuloparin sodium)|"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
75407598|NCT04660422|Other|ACP Decisions Video Program|All clinicians will also be trained remotely on the ACP Decisions Video Program using the ACP app. Training will instruct clinicians on how to: 1. Introduce the COVID-19 videos to patients and caregivers; 2. Select the appropriate video(s) from the entire suite according to patients' needs; and, 3. Prescribe videos for patients and caregivers using the electronic platform. The suite of ACP videos is designed to address common ACP decisions confronting patients at risk or with COVID-19 and the caregivers.
75407599|NCT04660422|Other|Intervention training:|Training will instruct the clinicians on how to: i. more effectively communicate with patients regarding COVID- 19, ii. have ACP conversations with patients, iii. introduce the videos to patients and families, iv. use the videos as an adjunct to ACP counseling by clinicians, v. select the appropriate video(s) from the entire suite as according to patients' needs, and, vi. use the app or electronic platform for prescribing videos to be seen at home (telehealth visits), or to be viewed in clinic with an iPad.
75552608|NCT03277365|Other|Receive genetic risk information|Risk scores are provided by ResearchKit app.
75552609|NCT00331877|Procedure|family conference with bereavement information leaflet|
75552610|NCT00431418|Drug|Sildenafil|Sildenafil oral solution
75552611|NCT00431418|Drug|Placebo|Placebo solution
75552612|NCT00331916|Drug|quinolone|
75552613|NCT00420368|Dietary Supplement|No food supplement|
75552614|NCT00420368|Dietary Supplement|Food supplement: fortified spread|
75552615|NCT00420368|Dietary Supplement|Food supplement: maize-soy flour|
75552616|NCT00420446|Behavioral|Adjusted diet|
75552617|NCT00331955|Drug|doxorubicin hydrochloride|Given IV
75552618|NCT00331955|Drug|vorinostat|Given orally
75552619|NCT00331955|Other|pharmacological study|Correlative studies
75552620|NCT00331955|Other|laboratory biomarker analysis|Correlative studies
75552621|NCT00331994|Drug|Bacillus clausii|3 bacillus clausii vials/day for one month
75552622|NCT00331994|Drug|Metronidazole|3 Metronidazole tablets/day for one week
75552623|NCT00435240|Behavioral|Paleolithic diet|
75552624|NCT00332033|Drug|Pirfenidone|
75552625|NCT00435279|Drug|Eszopiclone|Eszopiclone 3 mg
75552626|NCT00435279|Drug|Placebo|Placebo
75552627|NCT00435279|Drug|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
75552628|NCT00332072|Drug|bimatoprost/timolol fixed combination|
75407600|NCT04660422|Other|Medical Record Review|13,000 (total) patients aged 65 or older for our primary (completed advance care plans) outcome. ACP can include designating a health care proxy, discussion of advance directives, goals-of-care discussions, CPR discussions, palliative care discussions and referrals, as well as hospice. Each of these ACP outcomes will also be compared in secondary analyses using NLP. These data will be obtained from the EHR. All patient participants will only be included for medical record review.
75407601|NCT04601922|Other|Semi-structured interview|The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
75407602|NCT04376658|Other|COVID-19 Severity|Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death
75552629|NCT00431574|Procedure|dosing|
75552630|NCT00431613|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
76039722|NCT04965415|Behavioral|Health Links + Leadership Training|Help businesses undergo transactional (i.e., business management practices) and transformational (i.e., business leadership and culture) change. Transactional change component: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.Transformational change component: The experimental arm includes TWH leadership training for small business owners and other senior leaders. This is a three-month training that includes assessments, in-person training, and virtual training transfer activities. The goal is to help the leader understand their organization's current approach to TWH, identify areas for improvement, and to take action.
76039723|NCT04965415|Behavioral|Health Links|Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - create a culture of both safety and health. Health Links does this by helping businesses incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.
75712334|NCT00945412|Device|Micropolysaccharide Hemospheres (Arista)|"MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.~No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect."
75712335|NCT00945412|Device|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
75552631|NCT00431613|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
75552632|NCT00431613|Drug|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
75552633|NCT00431613|Radiation|Chemoradiotherapy|"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"
75552634|NCT00431613|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
75552635|NCT00435318|Procedure|Iontophoresis|
75712336|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
75712337|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
75712338|NCT00945568|Drug|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
75712339|NCT02562690|Other|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
76039724|NCT04948567|Other|split-dose of Magnesium Sulfate solution|purgative for bowel preparation
76039725|NCT04948567|Other|split-dose of PEG|purgative for bowel preparation
75407603|NCT04352010|Behavioral|Res-Up!|Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
75712340|NCT00950092|Device|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
76039726|NCT04955665|Procedure|bone block procedure|a 20 × 15 × 3 mm3 bone block was cut from the lateral malleolus, rotated backwards 45°, and sutured back to the periosteum of the lateral malleolus using non-absorbable sutures.
76039727|NCT04955665|Procedure|Reattachment of the superior peroneal retinaculum|two suture anchors (Mini Quickanchor,DePuy Mitek) were inserted into the postero-lateral ridge of the lateral malleolus without damaging the cartilaginous ridge, after which the SPR was reattached to the lateral malleolus with the anchored suture. The inner layer of the false pouch was incised, and the outer layer (periosteum) was sutured with the SPR in a pants-over-vest style.
76039728|NCT04965571|Genetic|genetic test|Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA)
76039729|NCT04955509|Other|MRI|conventional MRI and diffusion MRI
75407604|NCT04352010|Behavioral|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
76039730|NCT03060655|Biological|PLGA-Mg material|The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.
75407605|NCT04352010|Other|Wait-Control Group|In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
75407606|NCT04185792|Diagnostic Test|NBSS, Qualiveen and SF-Qualiveen|NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
75407607|NCT04076202|Device|Cementless Vanguard DD RP|Patients treated with the Cementless Vanguard DD RP knee implant
75407608|NCT03947814|Drug|Pimodivir|Participants will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
75552636|NCT00332228|Drug|depot naltrexone|long-acting depot parenteral formulation of naltrexone
75712341|NCT00576758|Drug|obinutuzumab (RO5072759)|1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
75712342|NCT00576758|Drug|rituximab|375 mg/m^2 rituximab IV infusion once a week for 4 weeks.
75712343|NCT00923676|Drug|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
76039731|NCT03060655|Biological|titanium alloy|Traditional fixation was titanium alloy. the clinical outcome was assessed.
76039732|NCT03060187|Other|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
75712344|NCT00923676|Drug|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
75712345|NCT00923676|Drug|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
76039733|NCT04955353|Dietary Supplement|AVC-H2|A total of 2.5g AVC-H2 daily (2 tablets in the morning and 2 in the evening)
76039734|NCT04955353|Dietary Supplement|Placebo|A total of 2.5g placebo daily (2 tablets in the morning and 2 in the evening)
76039735|NCT03060343|Biological|Zeushield Cytotoxic T Lymphocytes|"Three dose levels will be evaluated. Dose Level One: 1.0×10^5 cells/kg, Dose Level Two: 1.0×10^6 cells/kg, Dose Level Three: 1.0×10^7 cells/kg.~At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals."
76039736|NCT04955119|Diagnostic Test|Fusion imaging contrast-enhanced ultrasound|"Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
76039737|NCT04965103|Procedure|SCR|Superior Capsule reconstruction
76039738|NCT04965103|Procedure|Bridging|Tendon repair with graft interposition
76039739|NCT04954963|Diagnostic Test|Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
76039740|NCT03060421|Device|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
76039741|NCT04955041|Other|MRI|T2* MRI
76039742|NCT04954885|Procedure|Biospecimen Collection|Undergo stool sample
76039743|NCT04954885|Other|Physical Performance Testing|Undergo short physical performance battery
76039744|NCT04954885|Other|Physical Performance Testing|Perform 6-minute walk test
75712346|NCT00950326|Procedure|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
75712347|NCT00950326|Procedure|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
75712348|NCT00950326|Procedure|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
75407609|NCT03797586|Other|Electroacupuncture group|Bilateral Tianshu (ST25), Fujie (SP14), Shangjuxu (ST37) will be used in the EA group. With the local skin of the patients was routinely sterilized in a prone position in relaxation, acupuncturists will insert needles into the acupuncture points. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal wall, where participants will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
75712349|NCT00745446|Procedure|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
75712350|NCT00921284|Drug|NaCl 9/00|Same volume as in the dexmedetomidine group
75407610|NCT03797586|Other|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
75712351|NCT00921284|Drug|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
75712352|NCT00748020|Procedure|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
75712353|NCT00748020|Procedure|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
75407611|NCT03770130|Drug|Dexmedetomidine|Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
75712354|NCT00749502|Drug|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
75712355|NCT00560794|Biological|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
75712356|NCT03879330|Device|NIRS monitoring|aSAH patients will be given continuous NIRS and blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring of 4 hours. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
75712357|NCT00749736|Dietary Supplement|cholecalciferol|"4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm."
75407612|NCT03770130|Drug|Saline|Saline, a kind of crystalloid widely used in clinical treatment
75407613|NCT03758664|Drug|ICP-192|"Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,"
75407614|NCT03694626|Device|Pupillography|A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.
75407615|NCT03694626|Device|Ocular Coherence Tomography (OCT)|The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.
75552637|NCT00332228|Behavioral|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
75712358|NCT00749736|Dietary Supplement|doxercalciferol|1 mcg of doxercalciferol per day
75712359|NCT00749736|Dietary Supplement|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm."
75712360|NCT00950404|Drug|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
75712361|NCT00950404|Drug|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
75712362|NCT00950404|Drug|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
75407616|NCT03694626|Device|Wrist-watch sensor device|A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).
75407617|NCT03694626|Device|Videography|"The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next.~After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities.~At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity."
75407618|NCT03694626|Device|Electrophysiology|Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.
75407619|NCT03670914|Diagnostic Test|WatchPAT 200|The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
75407620|NCT03642834|Drug|ICP-105|25mg, 100mg capsule
75407621|NCT03449784|Other|Detection of patients with dyslipidemia|Detection of patients with dyslipidemia
75407622|NCT03447834|Other|Selective intracoronary hypothermia + PPCI|Selective intracoronary hypothermia is a new technique, recently tested for safety and feasibility in the SINTAMI trial. The procedure starts by advancing a guidewire beyond the occlusion in the culprit artery, followed by an OTWB that is inflated at the location of the occlusion, at a low pressure (4 atm), to prevent reperfusion. After that, a pressure/temperature wire will be advanced along the inflated OTWB and is placed in the distal coronary artery. Then the guidewire is removed and the lumen is used for infusion of saline. During the 'occlusion phase', saline at room temperature is infused for 10 minutes with distal coronary temperature 6-8°C below body temperature. After that, the balloon of the OTWB is deflated. Simultaneously, infusion is started with saline of 4°C, the so called 'reperfusion phase'. This is continued for 10 more minutes. After that, the OTWB can be retracted and the procedure can continue not different from routine PPCI.
75407623|NCT03447834|Other|Standard PPCI|PPCI per routine
75407624|NCT03064074|Drug|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
75407625|NCT03012282|Diagnostic Test|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
75407626|NCT02945436|Behavioral|Substance Use Brief Intervention|SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.
75712363|NCT00950404|Drug|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
75712364|NCT00749814|Dietary Supplement|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
75407627|NCT02945436|Behavioral|Standard of Care (SOC)|Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
75407628|NCT02445456|Drug|Sienna+ injection|Endoscopic injection of magnetic tracer
75407629|NCT02445456|Other|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
75552638|NCT00332228|Drug|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
75712365|NCT00749814|Other|Placebo tablets|Placebo
76039745|NCT04954885|Other|Questionnaire Administration|Complete questionnaires
75407630|NCT02445456|Procedure|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
75407631|NCT02445456|Device|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
76039746|NCT04965805|Device|cold plasmaJet kINPen Med|experimental, non-inferiority
75407632|NCT02316132|Drug|Stress|Corticotropin-Releasing Hormone
75407633|NCT02316132|Drug|Control|Saline 0.9%
75407634|NCT01770756|Behavioral|Self-Care Training|
75407635|NCT01276002|Procedure|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
75407638|NCT05452746|Device|Acupuncture|"Unilateral and bilateral acupuncture points:~Du 20 and GV 29,39 MS1, MS2, MS3 and MS4,40~Location of points:~Number of needles: 9~Depth of insertion:~MS1, MS2, MS3: insert the needle obliquely in the frontal direction for 1 cm Du 20: insert the needle obliquely in the frontal direction for 0.5 cm GV 29: insert the needle obliquely and downward for 0.5 cm Needles retained for 20 min Needle type: Han Yi 0.25x25 mm Treatment regimen: once per day for 2 weeks"
75407639|NCT05452746|Other|Treatment as usual|Inpatient psychiatric care for depression
75712366|NCT00950482|Procedure|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
75712367|NCT00950482|Other|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
75712368|NCT00950482|Other|WC|Waiting Group
75712369|NCT00748176|Procedure|spinal anesthesia|spinal anesthesia with bupivacaine
75407640|NCT05452434|Drug|mirabegron|mirabegron 50mg QD for 12 weeks.
75712370|NCT02041936|Device|NanoKnife IRE System|
75712371|NCT00941122|Device|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
75712372|NCT02565758|Drug|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
75712373|NCT04159922|Other|questionnaire|Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
75407641|NCT05451342|Diagnostic Test|Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling|Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.
75407642|NCT05450874|Procedure|hepatectomy|
75407643|NCT05450328|Drug|Combined Epoprostenol Sodium & Milrinone|"One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
75712374|NCT00941200|Biological|Blood collection|
75712375|NCT00945880|Drug|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
76039747|NCT04965805|Device|Best practice wound dressings|comparative,
75712376|NCT04061174|Other|Shoulder stabilization exercises|When participants are able to do the exercise 15 repetitions without difficulty, the exercise will be advanced by modifying or adding the weight.The exercises include chin tulk exercise, shoulder closed chain weight transfer, prone and iso-abdominal exercises, push-up exercise, lower trapezius muscle strengthening exercise, dead bug exercise, ball rolling on the wall, bench press with dumbbell and internal/external rotation (IR / ER) strengthening exercises
75407644|NCT05450328|Drug|Normal saline|"The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
75407645|NCT05450172|Other|QoR-15 questionnaire|The QoR-15 is a 15-item questionnaire on postoperative quality of recovery. The DN4 is a 10-item questionnaire on neuropathic pain. Both questionnaires will be given to the patients preoperatively, on postoperative days 2 and 3, and 1, 3 and 6 months after surgery.
75872044|NCT02331238|Behavioral|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
75407646|NCT05449938|Procedure|Scaling and root planing|Scaling and root planing involves removal of plaque and calculus on tooth surface.
75407647|NCT03018912|Other|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~How many days a week are you satisfied with your sleep?~How many days a week is sleepiness a problem?"
75407648|NCT05449860|Procedure|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes|Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
75407649|NCT05449782|Dietary Supplement|Cocoa flavanol|Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)
75407650|NCT05449782|Other|Placebo|Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
75407651|NCT05449704|Drug|DA-5218|single dose administration (DA-5218 one tablet once a day)
75407652|NCT05449704|Drug|DA-5218-R1 + DA-5218-R2 + DA-5218-R3|single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day)
75407653|NCT05449158|Procedure|left atrial pressure regulation|For patients after atrioventricular node ablation combined with left atrial appendage closure, the regulation of left atrial pressure can be controlled by adjusting the frequency of pacemaker.
75407654|NCT05449080|Diagnostic Test|Karyotype|Patients were subjected to karyotype to determine their genotype
75407655|NCT05448924|Diagnostic Test|Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone
75407656|NCT05447832|Device|Lung function monitoring equipment at home - 2 weeks|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once daily for 2 weeks.
75407657|NCT05447832|Device|Lung function monitoring equipment at home - 4 months|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once weekly for 4 months.
75407658|NCT05447832|Diagnostic Test|Inflammation and remodelling from clinical indicted bronchoscopy|For patients who are undergoing clinically indicated bronchoscopy, consent will be obtained to use any surplus clinical samples for this study. The samples to be collected are broncho-alveolar lavage and endobronchial biopsies. Both of these are taken from the airways during clinical bronchoscopy.
75712377|NCT04061174|Other|Office exercises training|Information will be given in a brochure that includes the appropriate chair height and work table, sitting position, distance between eyes and monitor, and table chair dimensions.approved and standardized office-based stretching and strengthening exercises will be given for workplaces
75407659|NCT05447754|Other|Combined RAGT and TBT|Combined RAGT and TBT: Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
76039748|NCT02624713|Behavioral|obesity treatment|"Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
76039749|NCT03058081|Device|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher&Paykel)
76039750|NCT04430179|Drug|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300 mg every other week for 24 weeks
76039751|NCT04430179|Other|Placebo|No active drug
76039752|NCT04946929|Drug|Ticagrelor Oral Tablet [Brilinta]|Ticagrelor, 2-3mg/kg, 12h, p.o.
75407660|NCT05447754|Other|balance exercises|TBT
75407661|NCT05447364|Drug|Pregabalin 75mg|1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo
75407662|NCT05447364|Drug|Pregabalin 150mg|2 tabs of Pregabalin Brillior 75 mg
75407663|NCT05446974|Other|Nursing Competency Enhancement Training Program in PTSD Intervention|This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
75407664|NCT05446896|Device|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
76039753|NCT04946929|Drug|Low molecular weight heparin|half amount low molecular weight heparin
76039754|NCT04933045|Device|Arthrex InternalBrace|Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
76039755|NCT03058159|Other|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
76039756|NCT02624791|Device|1-DAY ACUVUE® MOIST contact lenses|spherical contact lenses worn during simulated driving tests
76039757|NCT02624791|Device|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|toric contact lenses worn during simulated driving tests
76039758|NCT02624791|Other|No contact lenses|simulated driving tests
76039759|NCT03058237|Drug|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
76039760|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
76039761|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
76039762|NCT03058237|Drug|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
75407665|NCT05446818|Dietary Supplement|Cocoa flavanol (CF)|2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)
75407666|NCT05446818|Other|Placebo (P)|2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)
75407667|NCT05444322|Drug|RD14-01 cell infusion|Autologous CAR T cells
75712378|NCT00950638|Drug|ARC1905|intravitreal injection
75712379|NCT02565290|Dietary Supplement|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
75712380|NCT02565290|Dietary Supplement|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
75712381|NCT00941278|Drug|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
75712382|NCT00619359|Drug|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
75712383|NCT00619359|Drug|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
75712384|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
76039763|NCT04947241|Drug|PD-1 inhibitor+ Gemcitabine + Cisplatin|"Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles"
76039764|NCT04946539|Diagnostic Test|Ultrasonography|Enthesitis assessment via ultrasonography
76039765|NCT03058393|Other|Teach-Back Lesson|A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients
75552639|NCT00431691|Drug|vitamin and mineral supplement|"dose: 4 tablets daily for two weeks~vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg"
75552640|NCT00431691|Drug|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
75552641|NCT00431691|Drug|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
75552642|NCT00431691|Drug|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
75552643|NCT00332267|Procedure|Endotoxin infusion, Normobaric hypoxia|
75407668|NCT05439018|Other|Integrated Neuromuscular inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
75552644|NCT00435357|Device|mobile-bearing TKA|
75552645|NCT00435357|Device|fixed- bearing TKA|
75712385|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
76039766|NCT04944511|Drug|Toripalimab Injection|Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.
75552646|NCT00332306|Drug|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients <60kg, 400mg patients > 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
75552647|NCT00332306|Drug|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients < 60kg, 400 mg OD patients > 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
75552648|NCT00431730|Procedure|flicker light stimulation|
75552649|NCT00332345|Drug|brimonidine/timolol fixed combination|
75552650|NCT00435396|Biological|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
75552651|NCT00332384|Drug|brimonidine/timolol fixed combination|
75552652|NCT00435435|Drug|Disulfiram|
75552653|NCT00435435|Drug|Acamprosate|
75552654|NCT00435435|Drug|Naltexone|
75552655|NCT00420485|Drug|gimatecan|
75552656|NCT00435474|Procedure|Wound treatment|wound treatment (silver product, alginate and foam dressing)
75552657|NCT00435474|Procedure|wound treatment|wound treatment (honey product, alginate and foam dressing)
75872045|NCT03717077|Procedure|learned resourcefulness intervention|The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
76039767|NCT03057925|Device|Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
76039768|NCT04933279|Dietary Supplement|iodine-containg spareribs soup|administrated a 150 ml - 200 ml of iodine-containg spareribs soup delivering ≈ 600 µg or 1200 µg iodine
76039769|NCT04933279|Dietary Supplement|intrinsic iodine in natural kelp|administrated 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine). The natural kelp will be approximately produced in an experimental barn feeding supplementary iodine to reach a final iodine intake of ≈ 600 µg or 1200 µg. The iodine intake of natural kelp will be adjusted to the required dose by determing iodine content in the natural kelp.
75407669|NCT05439018|Other|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
75552658|NCT00435474|Other|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
75552659|NCT00435474|Other|relaxation therapy|relaxation therapy
75552660|NCT00332540|Drug|bimatoprost/timolol fixed combination|
75552661|NCT00332618|Device|OXYGENATED GLYCEROL TRIESTERS|
75552662|NCT04704102|Behavioral|Muscle energy technique (MET)|A manual therapy technique that uses the gentle muscle contractions of the patient to relax and lengthen muscles and normalize joint motion.
75407670|NCT05418036|Drug|Sotalol Oral Tablet|Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
75407671|NCT05392920|Other|assessment study|there is no intervention in this study
75407672|NCT05378178|Drug|HS-10381|Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2…) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
75407673|NCT05316714|Procedure|Nanofat grafing|NANOFAT REGENERATIVE SURGICAL GRAFTING IN PRNILE ALBUGIANEA OF PATIENTS AFFECTED BY PEYRONIES' DISEASE
75552663|NCT04704102|Behavioral|Strain-counterstrain (SCS)|"It's also called the positional release technique, a manual therapy technique that passively positions the hypertonic (spasmed) muscles and dysfunctional joints in positions of shortened or comfort."
75552664|NCT04704102|Behavioral|sham SCS|SCS intervention that position with opposite site limb and direction, and with modified method as consider the easiness of a practitioner to press the tender points
75552665|NCT00332735|Drug|spinal administration of articaine|
75552666|NCT00332735|Drug|spinal administration of bupivacaine|
75552667|NCT00435552|Procedure|Ease-It Spray|
75552668|NCT00332774|Drug|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
75552669|NCT00332774|Drug|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
75552670|NCT00332774|Other|Nepafenac ophthalmic suspension vehicle|
75552671|NCT00431769|Drug|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
75552672|NCT00332813|Behavioral|HIV Risk Behavior Intervention|
75712386|NCT00619359|Drug|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
76039770|NCT03057301|Device|iCare home tonometer|All subjects will be taught to use the home care tonometer.
75552673|NCT00435630|Other|LapSim training|complete curriculum training on LapSim surgical simulator
76039771|NCT04943809|Device|POD 26P AY FT|Routine cataract surgery
75712387|NCT00950716|Behavioral|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
75712388|NCT00950716|Behavioral|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
75872046|NCT02326090|Drug|cis-UCA ophthalmic solution 1.0%|
75872047|NCT02326090|Drug|cis-UCA ophthalmic solution 2.5%|
76039772|NCT04943809|Device|POD 26P AY F|Routine cataract surgery
76039773|NCT04946695|Other|Telefisio India|Implement telephysiotherapy programmes in low-resource areas.
76039774|NCT03058003|Diagnostic Test|Posturography Evaluation|Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended
75407674|NCT05234346|Drug|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
75407675|NCT05234346|Other|Placebo|No Description for the intervention
75407676|NCT05028426|Procedure|Enhanced recovery program|Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.
75407677|NCT05023278|Drug|Venlafaxine 37.5 MG|venlafaxine 37.5mg daily for 7 consecutive days.
75407678|NCT05023278|Drug|Placebo|placebo filled pill daily for 7 consecutive days.
75407679|NCT05021172|Other|Best Practice|Receive usual care
75407680|NCT05021172|Other|Informational Intervention|Receive Passport to Health booklet
75407681|NCT05021172|Other|Questionnaire Administration|Complete ePrognosis
75407682|NCT05021172|Other|Survey Administration|Ancillary studies
75407683|NCT04962048|Device|pulse-synchronized negative pressure (PSNP) device|The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.
75552674|NCT00332852|Drug|Letrozole|2.5 mg/day - oraly
75552675|NCT00435669|Drug|Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME
75552676|NCT00435669|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression
75872048|NCT02326090|Drug|Placebo ophthalmic solution|
75872049|NCT01311011|Procedure|SCT|SCT
75872050|NCT02326246|Other|multi-parametic MRI|
76039775|NCT03058003|Other|Central Sensitization Inventory|Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
76039776|NCT02577029|Drug|ARC-520|ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
76039777|NCT02577029|Drug|entecavir|0.5 mg once daily; oral
76039778|NCT02577029|Biological|pegylated interferon alpha 2a|180 mcg; subcutaneous injection once weekly
76039779|NCT02577029|Drug|tenofovir disoproxil|300 mg once daily; oral
76039780|NCT02577029|Drug|antihistamine|All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
75407684|NCT04962048|Other|Control - no intervention|The other leg serves as non-treated control
75407685|NCT04949568|Behavioral|Diabetes Self-Management Behaviors|The intervention is to be delivered by a diabetes educator.
75872051|NCT03437447|Drug|Cisticid|Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
75407686|NCT04944810|Procedure|Magnetic Gastric Bypass|Perform a gastric bypass with the magnetic grasper to do the liver retraction, upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb and perform the section of the limb and finish the gastric bypass
75407687|NCT04944810|Procedure|Magnetic Sleeve Gastrectomy|Perform a sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach
75407688|NCT04944810|Procedure|Revisional Bariatric Surgery|Perform liver retraction and also steps of the surgery like upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb, upper retraction of the stomach
75407689|NCT04944810|Procedure|Nissen/Sleeve Gastrectomy with Magnetic Assistance|Perform a nissen-sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach, retraction of the stomach to close the hiatal defect and perform a nissen funduplication before do the sleeve gastrectomy
75407690|NCT04944810|Procedure|Mangetic General Surgery|Use the magnetic grasper to do the gallbladder retraction in cholecystectomies and upper retraction of the stomach to close the defect on hiatal hernia cases.
75872052|NCT03437447|Drug|Biltricide|Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
75872053|NCT02459080|Drug|TD-4208|
75552677|NCT00332891|Drug|SR58611A|
75552678|NCT00435708|Behavioral|5 portions fruit and vegetables/day|Participants consume > = 5 portions fruit and veg per day
75552679|NCT00332930|Biological|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
75552680|NCT00332930|Biological|HIV gag-pol antigens and interferon-gamma (IFN-y)|
75552681|NCT00431808|Biological|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
75552682|NCT00431808|Biological|AMA1|50 micrograms of AMA1
75552683|NCT00332969|Drug|Octreotide|
75552684|NCT00333008|Drug|Doxil|
75552685|NCT00333008|Drug|Cyclophosphamide|
75552686|NCT00333008|Drug|Vincristine|
75552687|NCT00333008|Drug|Prednisone|
75552688|NCT00333008|Drug|Rituximab|
75552689|NCT00333008|Drug|Pegfilgrastim|
75552690|NCT00435747|Drug|PARECOXIB SODIUM|
75552691|NCT00333047|Drug|Letrozole|
75552692|NCT00431886|Procedure|64 multi-detector computed tomography|
75872054|NCT02459080|Drug|Placebo|
75872055|NCT03720041|Drug|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged > 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
75552693|NCT00333086|Drug|Letrozole|
75552694|NCT00333125|Drug|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
75552695|NCT00333125|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
75552696|NCT00333125|Other|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
75407691|NCT04914702|Device|Everion®|The Everion® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
75407692|NCT04914702|Device|CORE®|The CORE® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
76023184|NCT05017883|Drug|TAA05 cell injection|"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
75552697|NCT00333164|Drug|Asprin, Cilostazol|
75552698|NCT00333203|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
75407693|NCT04881708|Device|Remote Monitoring|Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
75552699|NCT00333203|Other|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
75712389|NCT00848991|Drug|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
75712390|NCT00848991|Drug|Propofol|evaulation of propofol for emergence from anesthesia
75712391|NCT00941434|Dietary Supplement|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
75712392|NCT02545725|Other|Questionnaire on Quality of Life|The patients were asked to complete a questionnaire on Quality of Life
75407697|NCT04532658|Behavioral|Coaching program|"Charting system for outcomes feedback~Profiling of individual surgeon~Modules of improvement"
75407698|NCT04522206|Drug|Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone|"The study subjects will be assigned to the defined pre-op MMA regimen with standard postop oxycodone based pain control regimen given on an as needed basis. The treatment group outcomes will be compared to patients outside of the study including a historical control group (receiving only post-op pain regimen) prior to the implementation of the new regimen. The studied treatment group will receive within 3 hours before surgery an oral MMA regimen consisting of:~Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release"
75552700|NCT01052493|Drug|PP 1420|Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
75552701|NCT01052493|Drug|Placebo|0.9% saline
75552702|NCT00333242|Drug|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
75712393|NCT00950794|Drug|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
75712394|NCT00950794|Drug|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
75712395|NCT00852189|Drug|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
75552703|NCT04703634|Procedure|erector spinae block (ESP)|Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra
75552704|NCT00333281|Drug|tadalafil|
75552705|NCT00435864|Procedure|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
75552706|NCT00333320|Procedure|postconditioning|patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
75552707|NCT00333320|Procedure|Control group|Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
75407699|NCT04510116|Behavioral|Adults in the Making program|The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
75552708|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
75552709|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
75552710|NCT00333398|Biological|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
75407700|NCT04505592|Drug|Tenecteplase|First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
75552711|NCT00333476|Drug|MSI-1256F (Squalamine Lactate)|
75552712|NCT00435981|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
76023185|NCT05008991|Device|Spirometry|Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity [TLC]) to maximal expiration (residual volume [RV]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
75407701|NCT04505592|Drug|Placebo|Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
75552713|NCT01052103|Drug|LY2140023|40 milligrams (mg), oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg.
75552714|NCT01052103|Drug|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
75552715|NCT01052103|Drug|Standard of Care|United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
75552716|NCT00333515|Drug|Human Butyrylcholinesterase (HuBChE) derived from human plasma|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
75552717|NCT00333515|Drug|Placebo: Normal saline|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
75552718|NCT00333554|Dietary Supplement|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
75552719|NCT00333554|Dietary Supplement|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
75552720|NCT00436020|Device|TMS|Transcranial Magnetic Stimulation
75552721|NCT00436020|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
75552722|NCT00333593|Device|Large pore dialyser|
75552723|NCT00333593|Device|Standard dialyser|
75552724|NCT00432081|Drug|indomethacin|
75552725|NCT00333632|Drug|Dexmedetomidine|
75552726|NCT00333632|Drug|Propofol|
75552727|NCT00333632|Drug|Midazolam|
75552728|NCT00333632|Drug|Fentanyl|
75552729|NCT00333632|Drug|Isoflurane|
75552730|NCT00436059|Drug|bortezomib|
75552731|NCT00420524|Drug|Patupilone/EPO906|
75552732|NCT00432120|Drug|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
75552733|NCT00436098|Behavioral|Motorpedagogic exercise|physical training
75712396|NCT00852189|Drug|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
75712397|NCT00852189|Drug|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
76023186|NCT02700997|Device|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
76039781|NCT04932889|Other|Survey|A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
76039782|NCT04932889|Other|Laboratory parameters|The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
75712398|NCT00951028|Behavioral|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
76039783|NCT04932889|Other|chest computed tomography|Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
75552734|NCT00432198|Drug|Zolpidem (Myslee®)|Oral
75407702|NCT04460508|Drug|Pegylated rhG-CSF|Pegylated rhG-CSF:6mg
75407703|NCT04460508|Drug|rhG-CSF|rhG-CSF:5ug/kg/d
75712399|NCT00951028|Behavioral|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
75712400|NCT00951028|Behavioral|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
75712401|NCT00849069|Biological|GSK2231395A|3 doses intramuscular injections
75712402|NCT00849069|Biological|TwinrixTM|3 doses intramuscular injections
76039784|NCT04946617|Drug|undefined|Rinsing with mouthwashes
76039785|NCT04946383|Drug|Dasatinib plus Quercetin|Dasatinib plus Quercetin
75407704|NCT04415892|Other|Cinnamaldehyde and capsaicin|Topical application of cinnamaldehyde and capsaicin on the fingers
75407705|NCT04256070|Behavioral|education and tele-consultation|education and tele-consultation based on Watson's Human Care Theory
75407706|NCT04226118|Device|Vein Illumintion System device|Spotting veins of a patient by use of a Vein Illumintion System device
75407707|NCT04176354|Drug|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
75407708|NCT04176354|Drug|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
75407709|NCT04176354|Drug|Letrozole|Letrozole monotherapy
75552735|NCT00432198|Drug|placebo|Oral
75552736|NCT01051986|Procedure|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
75552737|NCT01051986|Procedure|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
75552738|NCT00420563|Drug|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
76023187|NCT02407015|Other|Nintendo 3DS gameplay|
75407710|NCT04128540|Drug|Fentanyl|fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
75712403|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
75552739|NCT00420563|Drug|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
75552740|NCT00432315|Drug|Docetaxel + CDDP|"3 cycles chemotherapy : docetaxel + CDDP~Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~3 cycles adjuvant chemotherapy docetaxel"
75872056|NCT03720041|Drug|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~Fit category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~Unfit category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
75552741|NCT00432315|Drug|docetaxel + CDDP|"3 cycles chemotherapy: docetaxel + CDDP~Radiochemotherapy~3 cycles adjuvant chemotherapy docetaxel"
75552742|NCT00333671|Drug|Glycerol|
75552743|NCT00333749|Biological|Drinking or rinsing the mouth 2-3 times for 1 day|
75552744|NCT00333749|Biological|Pasturlized cow milk|Drinking or rinsing the mouth 2-3 times for one day.
76039786|NCT04943653|Drug|Paclitaxel|"intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)"
75552745|NCT00432354|Drug|atorvastatin|
75407711|NCT04128540|Procedure|Erector spinae plane block|"ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.."
75552746|NCT00333827|Drug|optimal therapy for cardiaca failure|optimal therapy for cardiaca failure
75712404|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
75407712|NCT05448612|Other|Active Release Technique and muscle energy technique|74 participants divided into two groups and 37 in each group.
75407713|NCT04104438|Drug|Basiliximab 20 MG|Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30
75552747|NCT00333827|Procedure|cell|stem cell
75552748|NCT03278184|Device|tDCS sham motor cortex|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
75552749|NCT03278184|Device|active prefrontal cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
75712405|NCT04042545|Drug|PPP001|1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
75712406|NCT04042545|Drug|Placebo|1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
75712407|NCT00951106|Drug|Pyrimethamine/sulfdoxine (Fansidar)|
75712408|NCT00852267|Other|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
75712409|NCT00852267|Other|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
75712410|NCT00852267|Other|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
75712411|NCT00372229|Drug|Valganciclovir CMV Prophylaxis|900 mg valganciclovir, taken orally once daily, adjusted to renal function starting within 14 days of transplantation until Day 100 after transplantation.
76039787|NCT04942951|Diagnostic Test|Gynecological examination|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
75407714|NCT04007640|Radiation|MRI with additional sequences|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
75407715|NCT04007640|Radiation|MRI|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
75407716|NCT04007640|Procedure|Left pancreatectomy or pancreaticoduodenectomy|Histological analysis :
75407717|NCT04007640|Radiation|MRI with additional sequences|MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients
75407718|NCT03752970|Drug|Spesolimab|Solution for infusion
75407719|NCT03752970|Drug|Placebo|Solution for infusion
75407720|NCT03703206|Drug|ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)|nerve block for posterior knee pain after a TKA.
75407721|NCT03476928|Drug|Vilaprisan (BAY1002670)|2mg, once daily, oral
75407722|NCT03427320|Drug|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
75407723|NCT03086616|Drug|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
75407724|NCT03026712|Device|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
75712412|NCT00372229|Drug|Valganciclovir (Pre-emptive CMV Therapy)|If plasma polymerase chain reaction (PCR) ≥ 400 CMV copies/millilitre, then 1800 mg valganciclovir per day adjusted to renal function for at least 14 days until the second negative PCR (below 400 copies/ml) followed by secondary prophylaxis for 28 days with 900 mg valganciclovir adjusted to renal function. If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
75407725|NCT03026712|Device|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
75407726|NCT02952924|Drug|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
75712413|NCT00372229|Drug|Ganciclovir|If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
75407727|NCT02952924|Other|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
75407728|NCT02952924|Drug|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
75407729|NCT02823834|Device|PROFEMUR® Gladiator Plasma Femoral Stems|THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
75407730|NCT02770638|Device|Scoop Stretcher|Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
75407731|NCT02770638|Device|Long Back Spinal board|Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
75407732|NCT02509962|Dietary Supplement|Slow sodium tablets|6 g sodium chloride per day over 14 days
75407733|NCT02476500|Procedure|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
75407734|NCT02199366|Procedure|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
75712414|NCT05301010|Drug|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
75407735|NCT02021448|Other|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
75407736|NCT01368666|Device|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
76039788|NCT04942951|Other|Pelvic Organ Prolapse Quantification (POP-Q)|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
75552750|NCT03278184|Device|active motor cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
75407737|NCT00860730|Device|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
75552751|NCT00333905|Procedure|Ischemic exercise training|
75552752|NCT00436137|Behavioral|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
75552753|NCT04716374|Other|Tumor molecular profiling|Tumor tissue processing and all NGS genotyping were performed at the Laboratory of Molecular Oncology (Hellenic Foundation for Cancer Research / AUTH). Paraffin H&E sections from the retrieved tissue blocks were centrally reviewed for tumor histology and tissue adequacy for DNA extraction and were marked for macrodissection along with tumor DNA content [(former tumor cell content (TCC%)] assessment. DNA was extracted from macrodissected tissue fragments with the QIAamp® DNA mini kit (Qiagen, Hilden, Germany), measured in a Qubit fluorometer (Thermo Fisher Scientific, Paisley, UK), and genotyped with NGS in an Ion Torrent Proton sequencer (Thermo Fisher Scientific) by using a previously published custom panel (Kotoula, Lakis et al. 2019). Following stringent variant quality filtering (Kotoula, Chatzopoulos et al. 2021), 500 tumors
75552754|NCT00438009|Drug|Coxsackievirus A21|Two doses of drug, separated by 48 hours
75552755|NCT00333944|Drug|Pralidoxime(drug)|
75552756|NCT04702347|Diagnostic Test|Urine biomarker|Bladder urine samples (> 10 ml) will be collected for cytology and for the methylation test before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the upper urinary tract will be obtained via a ureteral catheter.
75552757|NCT00334022|Drug|enfuvirtide|1ml BID
76039789|NCT04942951|Other|Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire|ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
75712415|NCT05301010|Drug|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
75407738|NCT00677586|Procedure|simultaneous resection of liver metastasis and the rectal primary tumor|simultaneous resection of liver metastasis and the rectal primary tumor
75407739|NCT00677586|Procedure|staged resection of liver metastasis and the rectal primary tumor|Patients received resection of the rectal tumor. 1 months later received resection of liver metastasis
75407740|NCT05454930|Other|Filtered Air|The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
75552758|NCT04701528|Drug|Voclosporin|Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
76039790|NCT04942951|Other|Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire|PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
75552759|NCT04701528|Drug|Tacrolimus|Comparator
75552760|NCT00334100|Behavioral|Exercise|Treadmill exercise
75712416|NCT05301010|Drug|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
76039791|NCT02577887|Device|Patients implanted with a St. Jude Medical pacemakers|
75552761|NCT04701294|Device|Giomer Beautifil flow plusF03 Shofu-Japan|A pair of permanent first molars will be used for each participant homologs The operator will apply in the upper / lower first molars the sealant material in the order assigned according to the previous randomization. For the intervention group, they will be sealed based on a fluid resin with s-prg glass ionomer filling (Giomer F03 Beautiful -Shofu) in association with a bottle of adhesive (Single Bond) . The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
75552762|NCT04701294|Device|Tetric N flow ivoclar vivadent-Germany|And on the contralateral side (control) the first upper / lower molars will be sealed will be sealed with a fluid resin compound (Tetric N-Flow ivoclar vivadent) in association with a bottle of adhesive (Single Bond). Both materials have a similar color. The operator and the child will not be informed about the brand of the material used. The assistant will collect the data in the file. The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
76039792|NCT04943029|Drug|Carrelizumab|Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.
76039793|NCT04943029|Drug|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Nab-paclitaxel: 260mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles.
75552763|NCT00334139|Drug|Zoledronic Acid|every 4 weeks for 4 months
76039794|NCT04943029|Drug|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.
76039795|NCT04943029|Procedure|Surgery|Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)
76039796|NCT05236283|Diagnostic Test|Blood Culture|Blood Culture
76039797|NCT04932499|Other|Standard of Care|Participants randomly assigned to this intervention will receive standard of care given to all patients undergoing total knee arthroplasty at our institution as outlined in the Common Care Pathway for Total Joint Replacement. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.
75552764|NCT00334178|Drug|Laxymig ER (drug)|
75552765|NCT03279978|Drug|BI 730357|BI 730357 film-coated tablet
75552766|NCT03279978|Drug|Placebo|Placebo
75712417|NCT00855699|Drug|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
75552767|NCT03279978|Drug|Midazolam|Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed
75712418|NCT00855777|Drug|etoricoxib|etoricoxib 120 mg/day for 3 days
75712419|NCT00855777|Drug|ibuprofen|ibuprofen 1,800 mg/day for 3 days
76039798|NCT04932499|Other|Mindfulness Meditation|"In addition to standard of care, participants randomly assigned to the treatment group will be given a 45-60 minute teaching session on mindfulness meditation. Upon completion of this session, participants will be given homework recordings of a body scan exercise and asked to listen to the recording daily for the two-week period prior to surgery. Participants will be asked to listen to their recording immediately prior to their surgery and daily while in hospital. In addition, participants assigned to mindfulness intervention will receive standard of care as outlined in the control group. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative."
75407741|NCT05454774|Genetic|Single dose intravenous injection of BBM 002|Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10^13 vg/ kg
75407742|NCT05454540|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|"daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS"
75872057|NCT03720041|Drug|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg*/day on days 1-21, taken orally Placebo: 4mg*/day on days 1, 8 and 15~* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
75407743|NCT05454384|Other|Medical Record Examination|The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.
75407744|NCT05453838|Dietary Supplement|oral intake of one serving of the original and new product|1) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
75407745|NCT05453448|Drug|tenofovir alafenamide|Antiviral therapy
75407746|NCT05453448|Drug|Entecavir|entecavir
75407747|NCT05453214|Drug|Fludrocortisone Acetate 0.1 MG|Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
75407748|NCT05452980|Procedure|reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
75407749|NCT05452980|Procedure|sleeve gastrectomy|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
75407750|NCT05451498|Dietary Supplement|Creatine|Participants were matched according to fat-free mass to consume a placebo, or 5-g dose of creatine monohydrate within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum [1RM]) and endurance (repetitions to fatigue [RTF] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
75712420|NCT04012294|Drug|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
75407751|NCT05451498|Dietary Supplement|Maltodextrin|Participants were matched according to fat-free mass to consume a placebo (maltodextrin) within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum [1RM]) and endurance (repetitions to fatigue [RTF] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
75552768|NCT00334217|Behavioral|Cognitive Remediation|PSS Cogrehab
75407752|NCT05448300|Device|Colonoscopy with water exchange or air insufflation methods|Using computer-aided polyp detection algorithm on colonoscopy with water exchange or air insufflation methods. This computer-aided algorithm does not intervene directly the colonoscopy procedure.
75407753|NCT05354466|Drug|Sugammadex injection|sugammadex as reversal agent
75407754|NCT05354466|Drug|Neostigmine|neostigmine as a reversal agent
75552769|NCT00438048|Procedure|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
75552770|NCT00438048|Drug|Artificial Saliva|5ml 3 times daily
75552771|NCT00334256|Drug|Tenofovir (TDF)|
75552772|NCT00334256|Drug|Emtricitabine (FTC)|
75552773|NCT00438087|Drug|methylprednisolone|methylprednisolone administrated intra and post operatively
75407755|NCT05347602|Dietary Supplement|Gold Factor (Gold Nanoparticles, AuNPs)|AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
75407756|NCT05347602|Dietary Supplement|Placebo|For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.
75407757|NCT05346432|Dietary Supplement|PS23|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
75407758|NCT05236140|Device|Perineal electrical stimulation|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
75712421|NCT00849459|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
75712422|NCT00852345|Drug|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
75407759|NCT05144490|Other|Exercise|A single session of bodyweight exercise
75407760|NCT05137704|Other|No intervention|This is a non-interventional study.
75407761|NCT04971096|Dietary Supplement|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 30 billion CFU (colony forming units) of PS23
75407762|NCT04971096|Dietary Supplement|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 30 billion of PS23 cells.
75407763|NCT04971096|Dietary Supplement|Placebo|The placebo capsule contains microcrystalline cellulose.
75407764|NCT04880616|Drug|NBI-827104|Capsules for oral administration
75407765|NCT04880616|Drug|Placebo|Capsules matching NBI-827104 for oral administration
75407766|NCT04757766|Drug|in daily everyday routine practice|The treatment of patients with chronic venous disease of CEAP classes C6 will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation.
75407767|NCT04720404|Behavioral|Mindfulness-Based Stress Reduction|Participants in the intervention group will follow a 4-week adapted MBSR training. The training consists of biweekly sessions of 1,5 hours. The training is structured based on the Mindfulness-Based Stress Reduction training as originally designed by John Kabat Zinn. The program includes both formal and informal meditation exercises.
75407768|NCT04720404|Other|Self-help mindfulness/compassion exercises|Participants in the self-help group will receive a 4-week program with daily suggestions for mindfulness/compassion exercises of 30 minutes on a YouTube-channel. Participants can schedule the exercises themselves.
75552774|NCT00334334|Biological|Pneumococcal (vaccine)|
75552775|NCT00438126|Behavioral|A lifestyle educational program|
75552776|NCT00334373|Procedure|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
75552777|NCT03279939|Device|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
75552778|NCT03279939|Device|Color Fundus Photography|Non-contact white light photography.
75712423|NCT00698828|Drug|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
75552779|NCT03279939|Device|Fluorescein Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.
75407769|NCT04720404|Other|Support as usual|Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
75552780|NCT03279939|Device|Indocyaine Green Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
75552781|NCT00334412|Drug|Ambisome|
75552782|NCT00334412|Drug|caspofungin|
75552783|NCT00438165|Behavioral|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
75552784|NCT04701879|Other|Spine decompression with core stability exercises|"50 minutes per session~Decompression with core stability on alternate days for 8 visits."
75552785|NCT04701879|Other|Spine decompression|"40 minutes per session~-Decompression therapy on alternate days for 8 visits."
76039799|NCT05535101|Device|Intermittent theta burst transcranial magnetic stimulation (iTBS)|The amphetamine users will undergo a one-month iTBS intervention. From Week 1 to Week 4, subjects will be treated five times a week.
75552786|NCT00334490|Drug|Sildenafil|12.5 mg Sildenafil once with optional second dose
75552787|NCT00334490|Drug|Sildenafil|12.5 mg orally once with optional second dose
75552788|NCT00334490|Drug|Placebo|Oral Placebo in 5 mls distilled water
75552789|NCT00436176|Behavioral|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
75552790|NCT00334529|Drug|Oseltamivir|
75552791|NCT04716218|Procedure|back up head elevated position|The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
75552792|NCT03271281|Drug|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E[c(RGDyK)]2
75552793|NCT03271281|Device|PET/CT|Following injection of 68Ga-NODAGA-E[c(RGDyK)]2 the patients will be subjected to whole body PET/CT
76039800|NCT05535101|Device|Sham stimulation|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
76039801|NCT04943107|Other|no intervention|no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
75712424|NCT00698828|Drug|SUN11031 20 μg/kg|Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
75712425|NCT00698828|Drug|SUN11031 40 μg/kg|Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
75552794|NCT00334568|Drug|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
75552795|NCT00334568|Drug|Placebo|Placebo
75552796|NCT03272451|Procedure|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
75552797|NCT03272451|Procedure|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
75552798|NCT02273544|Drug|Asasantin ER (new formulation - low)|
76039802|NCT03660059|Drug|Peficitinib|Oral
76039803|NCT03660059|Drug|Plaebo|Oral
76039804|NCT03660059|Drug|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
76039805|NCT04943263|Other|Tracheal Temperature|Temperature measured from the endotracheal tube compared with the esophageal temperature
75552799|NCT02273544|Drug|Asasantin ER (new formulation - medium)|
75552800|NCT02273544|Drug|Asasantin ER (new formulation - high)|
75552801|NCT02273544|Drug|Asasantin ER - commercial formulation|
76039806|NCT04932343|Diagnostic Test|cohort study|no intervention
75552802|NCT00334607|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
75552803|NCT00436293|Drug|Docetaxel|75 mg/m²
75552804|NCT00436293|Drug|Cisplatin|75 mg/m²
75552805|NCT00334646|Drug|Oral GW679769|150mg oral, once daily on days 1-3
75552806|NCT00334646|Drug|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
75552807|NCT04701606|Drug|Artecom® (pyronaridine-artesunate)|"* Participant body weight (Artecom® dose)~≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~≥ 45kg and < 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)"
75552808|NCT04701606|Drug|Placebo|"* Participant body weight (Placebo dose)~≥ 65kg (Placebo 4 tablets)~≥ 45kg and < 65kg (Placebo 3 tablets)"
75552809|NCT00334685|Drug|[S,S]-Reboxetine + Pregabalin|[S,S]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
75552810|NCT00334685|Drug|Pregabalin|Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
75552811|NCT00436371|Drug|Amisulpride|Oral tablets
75552812|NCT00334724|Procedure|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
75552813|NCT00334724|Procedure|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
75552814|NCT00436410|Biological|colloidal gold-bound tumor necrosis factor|
75552815|NCT00436410|Other|electron microscopy|
75552816|NCT00436410|Other|pharmacological study|
75712426|NCT00619515|Other|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
76039807|NCT04943185|Device|XEN gel microstent implantation|"Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention"
76039808|NCT04942873|Other|adherence|PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
76039809|NCT03634319|Device|Beacon Aqueous Microshunt|"The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.~Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma."
76039810|NCT04946227|Drug|Pembrolizumab 200mg +Paclitaxel 80mg/m2|Pembrolizumab 200mg +Paclitaxel 80mg/m2
75552817|NCT00436410|Procedure|conventional surgery|
75552818|NCT00334763|Biological|bevacizumab|
75552819|NCT00334763|Drug|carboplatin|
75552820|NCT00334763|Drug|chemoprotection|
75552821|NCT00334763|Drug|paclitaxel|
75552822|NCT00334763|Radiation|radiation therapy|
75552823|NCT00436449|Drug|Avotermin|
75407770|NCT04683900|Other|Standard of care + Mediterranean diet (intervention)|"Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.~Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consume ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fruits; d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish/seafood; f) ≥3 weekly serving of nuts/seeds; g) select white instead of red or processed meats; h) cook at least twice a week with sofrito. Limit consumption of cream, butter, processed meat, sugared beverages, industrial bakery products and desserts, and French fries or chips. For usual drinkers, the main source of alcohol should be wine."
75407771|NCT04683900|Other|Standard of care (control)|Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.
75552824|NCT04716062|Procedure|Open or Laparoscopic-assisted Colorectal surgery|Colorectal surgery
75552825|NCT00436722|Drug|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
75552826|NCT00334880|Drug|NRP104|
75552827|NCT00436761|Biological|anti-thymocyte globulin|
75552828|NCT00436761|Biological|graft-versus-tumor induction therapy|
75552829|NCT00436761|Biological|sargramostim|
76039811|NCT04945525|Other|Care Continuity Program|The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
75407772|NCT04608396|Drug|AXS-05|AXS-05 taken daily for up to 52 weeks, until relapse.
75552830|NCT00436761|Drug|busulfan|
75552831|NCT00436761|Drug|cyclosporine|
75552832|NCT00436761|Drug|melphalan|
76039812|NCT04932187|Drug|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
75552833|NCT00436761|Drug|methylprednisolone|
75552834|NCT00436761|Other|flow cytometry|
75552835|NCT00436761|Other|immunologic technique|
76039813|NCT04931719|Combination Product|PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
75552836|NCT00436761|Other|laboratory biomarker analysis|
75552837|NCT00436761|Procedure|allogeneic hematopoietic stem cell transplantation|
76039814|NCT04931719|Combination Product|PRP+ HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
75552838|NCT00436761|Procedure|umbilical cord blood transplantation|
75552839|NCT00436800|Drug|Gemcitabine|1000mg/m² over 10mg/m²/min
75552840|NCT00436800|Drug|Oxaliplatin|100 mg/m² over 2 hours.
75552841|NCT00334997|Procedure|endoscopic surgery|
75552842|NCT00334997|Procedure|laser surgery|
75552843|NCT00334997|Radiation|radiation therapy|
75552844|NCT00436839|Drug|Docetaxel|75mg/m² intravenously (day 1) every 21 days
75552845|NCT00436839|Drug|Mitoxantrone|12mg/m² intravenously every 21 days
75552846|NCT00436839|Drug|Prednisone|10mg orally given daily
75552847|NCT00335036|Device|ICD lead implant|Randomization of ICD lead type at implant
75552848|NCT00335036|Device|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
75552849|NCT00436878|Behavioral|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
75552850|NCT00335075|Drug|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
75407773|NCT04608396|Drug|Placebo|Placebo taken daily for up to 52 weeks, until relapse.
75407774|NCT04561128|Drug|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels
76039815|NCT04945681|Biological|Pneumococcal conjugate vaccine|Mass campaign offering simultaneous pneumococcal conjugate vaccination to all children aged below 15 years of age living in Digaale camp, Somaliland. Children aged below 12 months receive 2 doses of vaccine, spaced 4 weeks apart. All other children receive one dose.
75407775|NCT04561128|Drug|Placebo|Placebo will be subcutaneously administered with different dose levels
75407776|NCT04095624|Behavioral|Spinal Fusion Preoperative Opioid Taper|Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
75407777|NCT04095624|Other|Non-taper Control|Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
75407778|NCT03745716|Drug|APR-246 + azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
75407779|NCT03745716|Drug|Azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
75407780|NCT03651336|Device|ARGOS-IO Sensor Pressure System|The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
75407781|NCT03395340|Drug|Ruxolitinib 1.5% cream|Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
75712427|NCT00619515|Procedure|implanted fiducial-based imaging|Undergo fiducial placement imaging
75407782|NCT03395340|Drug|vehicle cream|Matching vehicle cream applied as a thin film
75712428|NCT00619515|Radiation|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
76039816|NCT04945291|Behavioral|New way of counting calories using the hands|The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
76039817|NCT04945291|Behavioral|Mobile applications|the participant will use a mobile application to log their calories
75712429|NCT00951184|Behavioral|telephone-based intervention|
75712430|NCT00951184|Other|screening questionnaire administration|
75712431|NCT00951184|Other|study of socioeconomic and demographic variables|
75712432|NCT00951184|Procedure|assessment of therapy complications|
75712433|NCT00951184|Procedure|psychosocial assessment and care|
75407783|NCT03341676|Drug|Dexamethasone|Dexamethasone 3.3 mg/mL solution for injection
75872058|NCT03720041|Drug|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg*/day on days 1-21, taken orally Ixazomib: 4mg*/day on days 1, 8 and 15~* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
75407784|NCT03341676|Drug|Placebo|Sodium Chloride 0.9% w/v solution for injection
75872059|NCT02326168|Drug|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
75552851|NCT00335075|Drug|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
75407785|NCT03121716|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
75407786|NCT03121716|Drug|Gemcitabine|gemcitabine
75407787|NCT03121716|Drug|cis-platinum|cis-platinum
75407788|NCT02714634|Drug|Methotrexate + targeted therapy administration|"Methotrexate or leflunomide + adalimumab or~Methotrexate or leflunomide + certolizumab or~Methotrexate or leflunomide + etanercept or~Methotrexate or leflunomide + golimumab or~Methotrexate or leflunomide + infliximab or~Methotrexate or leflunomide + abatacept or~Methotrexate or leflunomide + rituximab or~Methotrexate or leflunomide + tocilizumab or~Methotrexate or leflunomide + sarilumab or~Methotrexate or leflunomide + filgotinib or~Methotrexate or leflunomide + upadacitinib or~Methotrexate or leflunomide + Tofacitinib or~Methotrexate or leflunomide + baricitinib"
75407789|NCT02714634|Drug|methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration|
75407790|NCT00553800|Drug|bevacizumab|
75872060|NCT02334826|Procedure|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
75872061|NCT02334826|Procedure|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
76039818|NCT04942795|Device|Compliant balloon|Use of a compliant balloon when ADAPT fails to reach the clot site
75407791|NCT00553800|Drug|Erlotinib|
75407792|NCT02747628|Drug|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
75552852|NCT00436995|Drug|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
75552853|NCT00437190|Device|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
75552854|NCT00437190|Device|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
75552855|NCT04716179|Diagnostic Test|Sperm test|The semen sample will be collected and analyzed within an hour after collection.
75552856|NCT04716179|Diagnostic Test|hormone levels (testosterone, FSH, LH, prolactin)|Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.
76039819|NCT04942561|Device|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
75407793|NCT02747628|Drug|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
75407794|NCT02747628|Drug|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
75552857|NCT04716179|Diagnostic Test|SARS-CoV-2 Ig G levels|SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge
75407795|NCT02748096|Procedure|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
75407796|NCT02748096|Procedure|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
75407797|NCT02754570|Drug|Pilocarpine|Pilocarpine will be administered 4 times in addition to latanoprost.
75407798|NCT02756910|Device|iThermonitor (WT701)|Continuously monitor the axillary temperature during surgery
75552858|NCT04716179|Other|Testis pathology samples|Postmortem examination of the testes of patients deceased as a result of COVID-19 infection will be carried out using immunohistochemistry analysis.
75552859|NCT00437229|Drug|Casopitant (GW679769) Oral Tablets|Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.
75552860|NCT00437229|Drug|dexamethasone|Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.
75712434|NCT03469843|Other|Non intervention|patients without intervention
75712435|NCT00941746|Biological|PG110|Single, slow intravenous infusion
75712436|NCT00941746|Biological|PG110|Single, slow intravenous infusion
75712437|NCT00941746|Biological|PG110|Single, slow intravenous infusion
75712438|NCT00941746|Biological|PG110|Single, slow intravenous infusion
75407799|NCT02760264|Drug|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
75712439|NCT00941746|Biological|PG110|Single, slow intravenous infusion
75407800|NCT02760264|Drug|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
75407801|NCT02760264|Drug|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
75407802|NCT02760264|Drug|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
75407803|NCT02764164|Device|Intervention Active tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
75407804|NCT02765256|Drug|Fluconazole|400mg orally once daily (Day 1-14)
75712440|NCT00941746|Biological|PG110|Single, slow intravenous infusion
75407805|NCT02765256|Drug|Vancomycin|500mg oral suspension 4 times daily (Day 1-14)
75407806|NCT02765256|Drug|Neomycin|neomycin 1000 mg orally three times daily (Days 1-3)
75407807|NCT02765256|Drug|Ciprofloxacin|ciprofloxacin 750 mg orally twice daily (Day 4-14)
75407808|NCT02765256|Drug|Polyethylene Glycol 3350|238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2
75407809|NCT02765256|Drug|Promethazine|PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
75407810|NCT02765256|Drug|Fluconazole placebo|Once daily
75407811|NCT02767128|Drug|Triferic|
75407812|NCT02767128|Drug|Fer-In-Sol|
75407813|NCT02767128|Drug|Shohl's solution|
75407814|NCT02769702|Drug|Acthar|Acthar 80 IU SC twice a week
75407815|NCT02770014|Drug|Erlotinib|
75407816|NCT02771340|Biological|ICON-1|Intravitreal injection of ICON-1
75407817|NCT02771574|Drug|Lyo avexitide|Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
75407818|NCT02771574|Drug|Liq avexitide|Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
75407819|NCT02772432|Behavioral|Relaxation Response Resiliency Training for Parents of SPLD|
75407820|NCT02772666|Device|O-Glass|The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
75407821|NCT02772666|Other|Swinging Flashlight Test|The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
75407822|NCT02773758|Other|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
75407823|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
75407824|NCT02773836|Other|Questionnaire|Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
75407825|NCT02774226|Drug|Tetrahydrobiopterin (BH4)|12 week intervention
75407826|NCT02774226|Dietary Supplement|Antioxidant Cocktail|12 week intervention
75407827|NCT02774616|Device|Ilivia ICD Family|pre-defined device programming, measurements and follow-up schedule
75407828|NCT02774616|Device|Plexa ICD lead|predefined follow-up schedule
75407829|NCT02775240|Drug|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
75552861|NCT00437229|Drug|ondansetron|Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
75407830|NCT02775240|Drug|Maribavir|200mg twice a day for 8 days
75407831|NCT02775240|Drug|Dextromethorphan|30 mg oral dose
75407832|NCT02777268|Drug|Infacort|Multi-particulate granules
75407833|NCT02777268|Drug|Hydrocortisone|Tablet
75407834|NCT05350020|Drug|Solu-Cortef 100 MG Injection|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.
75407835|NCT05350020|Drug|Hydrocortisone 100mg/ml|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
75407836|NCT05349942|Device|Intraoral scanning and data acquisition|Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
75407837|NCT05349786|Other|Physical activity program|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. After the data obtained in the pre-test, the pedometers, which were calibrated and checked by the researchers, were delivered to the patients. At the end of each day of walking with pedometer monitoring, they were asked to record data such as the number of steps, walking hour, walking time, distance and complaints encountered during walking on the walking monitoring chart given to the patient by the researchers. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
75552862|NCT00335192|Drug|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
75407838|NCT05349708|Device|THE-FACS|Telehealth home-monitoring tablet and blood pressure cuff
75407839|NCT05349396|Drug|Eszopiclone 3mg Test Drug T-1 Coated Tablets|Participants will receive one tablet of the test formulation T-1 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
75407840|NCT05349396|Drug|Eszopiclone 3mg Test Drug T-2 Coated Tablets|Participants will receive one tablet of the test formulation T-2 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
75407841|NCT05349396|Drug|Eszopiclone 3mg Reference Product Coated Tablets|Participants will receive one tablet of the Rerefence Product containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
75407842|NCT05349162|Device|Implantable cardioverter defibrillator use|Implantation of an implantable cardioverter defibrillator (epicardial or transvenous)
75407843|NCT05348148|Drug|Oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
75712441|NCT00941746|Biological|PG110|Single, slow intravenous infusion
75712442|NCT00941746|Biological|PG110|Single, slow intravenous infusion
76039820|NCT04942561|Device|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
75407844|NCT05348148|Drug|Combined Intranasal Mometasone Furoate with oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
75712443|NCT00941746|Biological|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
76039821|NCT04942171|Procedure|Atrial fibrillation catheter ablation group|"Pulmonary vein isolation~Additional treatment for lesions caused by non-pulmonary veins~Esophageal temperature monitoring to prevent damage to the esophagus~Evaluation of procedure time and radiofrequency ablation time~Evaluation of complications after the procedure~Rhythm follow-up after the procedure is conducted in accordance with the above study design.~Conduct a survey on cognitive function and emotion before and 12 months after the procedure"
75712444|NCT00852423|Drug|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
75712445|NCT00852423|Drug|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
75712446|NCT00852423|Drug|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
75712447|NCT00852423|Drug|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
75407845|NCT05348148|Drug|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
75407846|NCT05348070|Procedure|Laparoscopy/Laparotomy|All patients included in the study were operated patients.
75407847|NCT05266482|Other|Personal report|In the intervention group, in addition to receiving the usual care, patients will receive personal reports on multiple time points. These reports include feedback on their PROs including reference scores of patients who previously underwent total knee replacement surgery.
76039822|NCT04942171|Drug|Medical therapy group|"Use of beta-blockers or calcium channel blockers for pulse rate control~Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure"
75407848|NCT05264688|Diagnostic Test|68Ga-FAPI-04 imaging agent|1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg) intravenously
75407849|NCT05456022|Drug|Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one|"Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying < 4 % _ Purity (HPLC) > 95 %"
75407850|NCT05456022|Drug|Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)|Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
75407851|NCT05456022|Drug|Doxorubicin chemotherapeutic drug as a positive control|Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
75407852|NCT05455866|Device|central venous catheter|collection and descriptionof central venous catheter-related complications
75407853|NCT05455788|Drug|Aminoglycoside|injection of sewing ring of prosthetic valve with aminoglycoside
75407854|NCT05455554|Diagnostic Test|Flowmet-D|Flowmet-D is a non-invasive device that measures blood flow.
75407855|NCT05455554|Diagnostic Test|ABI|ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
75552863|NCT00335192|Drug|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
75712448|NCT00941824|Drug|mycophénolate acid|"Day 0 to Day 7, 720 mg twice daily~Day 8 to Day 30, 540 mg twice daily~Day 30 to Day 90, 360 mg twice daily"
75712449|NCT00849537|Drug|Triamcinolone|Injection of intravitreal Triamcinolone
75712450|NCT03167606|Behavioral|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
76039823|NCT04944823|Other|Clinical follow-up for 24 months|Sampling and clinical follow-up for 24 months
75407856|NCT05455398|Procedure|Surgical treatment of round window niche enlargement via round window for inner ear drug delivery|The round window niche is surgically removed and the hormone is slowly released into the inner ear using a gelatin sponge that has absorbed the hormone in the round window
75552864|NCT00335192|Drug|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
75552865|NCT00437307|Drug|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
75552866|NCT00335231|Drug|gatifloxacin ophthalmic (ZYMAR)|
75552867|NCT00437346|Procedure|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
76039824|NCT04930939|Other|Aerobic training cardiac rehabilitation program|Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
76039825|NCT03597347|Drug|Molgramostim nebulizer solution|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
76039826|NCT03597347|Device|PARI eFlow nebulizer system|PARI eFlow nebulizer system
76039827|NCT04944355|Other|ultrasound|diagnosis of morbid adherent placenta and incidence of urinary tract injuries during surgery
75552868|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
75552869|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
75552870|NCT00335270|Drug|fos-amprenavir calcium, ritonavir|
75552871|NCT00335270|Drug|abacavir/lamivudine as Epzicom|
75552872|NCT00437385|Drug|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
75552873|NCT00437385|Procedure|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
76039828|NCT04942015|Drug|Honghuaruyi Wan|Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
75407857|NCT05455398|Procedure|Drum chamber drug injection|Injection of drugs into the tympanic chamber through the tympanic membrane
75552874|NCT00437385|Behavioral|Cognitive behavioral group therapy|"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."
75552875|NCT00335309|Procedure|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
75552876|NCT00335309|Drug|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
76039829|NCT04942015|Drug|Placebo of Honghuaruyi Wan|Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
76039830|NCT04941859|Behavioral|acupoint massage and application|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
76039831|NCT04942249|Other|No intervention|No intervention
76039832|NCT04431427|Device|Biliary drainage with PC-SEMS|partially covered metallic biliary stent insertion during ERCP
75872062|NCT03487445|Drug|Selatogrel 8 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
76039833|NCT04431427|Device|Biliary drainage with U-SEMS|Uncovered metallic biliary stent insertion during ERCP
76039834|NCT04930627|Drug|Empagliflozin|dosis depending on body weight: <20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; >40 kg 2 x 10 mg
75407858|NCT05455242|Behavioral|Habit formation|Habit formation interventions to promote context-dependent automatic behaviors to support diabetes self-management.
75407859|NCT05455164|Dietary Supplement|Isomalto Oligosaccharide|all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
75407860|NCT05451420|Drug|PegIFN α- 2b|"Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）"
75552877|NCT00437424|Drug|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
75552878|NCT00335348|Drug|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
75552879|NCT00335348|Drug|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
75552880|NCT00435903|Device|Palm Pilot|
75872063|NCT03487445|Drug|Selatogrel 16 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
75872064|NCT02109172|Drug|TD-4208|
75407861|NCT05324124|Drug|Selpercatinib|Administered orally.
75552881|NCT00334919|Behavioral|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
75872065|NCT02109172|Drug|Placebo|
75712451|NCT00951262|Behavioral|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
75712452|NCT01049815|Drug|sevelamer hydrochloride|800-3200 mg with each meal
75872066|NCT02326012|Behavioral|Emotion Regulation Individual Therapy for Adolescents|
75407862|NCT05305092|Device|PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample|Neuroimaging data were collected by integrated PET/MRI machine, and collected the psychobehavioral data, the serum and stool samples of participants.
75872067|NCT02334592|Radiation|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
76039835|NCT03057769|Drug|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
76039836|NCT03057769|Drug|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
76039837|NCT03057769|Drug|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
75407863|NCT05273814|Drug|Tislelizumab|Tislelizumab intravenous infusion 200mg d4
76039838|NCT05508269|Genetic|quantitative polymerase chain reaction(QPCR) for four genes|quantitative polymerase chain reaction(QPCR) for four genes
76039839|NCT05508269|Procedure|Cardiac biopsy, blood sampling|In the studied thirteen peripheral blood subjects, five milliliters blood samples were taken from each patient in potassium EDTA tubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators. All studied thirteen cardiac tissue subjects were underwent cardiac biopsy after PCI in order to take two specimens from the left ventricle using judkin right seven french catheters for femoral access and cardiac bioptome 2.3 mm wide. All cardiac specimens were collected in cryotubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators.
75407864|NCT05273814|Drug|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
75712453|NCT01049815|Drug|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
75712454|NCT00849615|Drug|Docetaxel|50mg/m2 qd15
76039840|NCT05531045|Diagnostic Test|PET/CT|FDG PET/CT assessed after 2 cycles of chemotherapy with PERCIST criteria
75407865|NCT05273814|Drug|Bevacizumab|Pemetrexed intravenous infusion 7.5mg/kg，d1
75552882|NCT00437463|Drug|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
75712455|NCT00849615|Drug|5-Fluorouracil|2600mg/m2 qd15
75712456|NCT00849615|Drug|Oxaliplatin|85mg/m2 qd15
75712457|NCT00849615|Drug|folinic acid|200mg/m2 qd15
75712458|NCT00946036|Drug|Sertraline Hydrochloride|
75712459|NCT00688740|Drug|Docetaxel|intravenous
75712460|NCT00688740|Drug|5-fluorouracil|intravenous
75712461|NCT00688740|Drug|Doxorubicin|intravenous
75712462|NCT00688740|Drug|Cyclophosphamide|intravenous
76039841|NCT04633577|Drug|Lidocaine IV|A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
76039842|NCT04633577|Drug|0.9% normal saline|0.9% normal saline
76039843|NCT04941625|Diagnostic Test|serum cystatin C|blood sampling
76039844|NCT04941625|Diagnostic Test|serum beta-microglubulin|blood sampling
75407866|NCT05215080|Dietary Supplement|Organic Formula Milk|Organic formula milk is given to the infants three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
75552883|NCT00420602|Dietary Supplement|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
75552884|NCT00437502|Biological|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
75407867|NCT05006118|Drug|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
75407868|NCT04963218|Diagnostic Test|AI Algorithm to detect LVEF in ECG|A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.
75712463|NCT01049893|Drug|Compound AC220|Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
75712464|NCT04088942|Other|High-intensity smoking cessation intervention|"Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~A hotline is established which the high-intensity group can call.~Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking."
75712465|NCT04088942|Drug|Low-intensity smoking cessation intervention|Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
75872068|NCT05076916|Behavioral|The effectiveness of the web-based education programme among cancer patients|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
76039845|NCT04941625|Diagnostic Test|urine|neutrophil gelatinase-associated lipocalin
76039846|NCT04944589|Procedure|ROOT CANAL TREATMENT|Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
75407869|NCT04867044|Other|STUDY|One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
75407870|NCT04867044|Other|Control|healthy woman volunteers
76039847|NCT04922125|Combination Product|Pulse flour|Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.
76039848|NCT04922125|Combination Product|Pre-processed pulse flour|Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
75407871|NCT04784208|Diagnostic Test|Blood test for Thyroid stimulating hormone (TSH)|Blood test for Thyroid stimulating hormone (TSH)
75407872|NCT04775004|Other|Bone marrow venting procedure (BMVP)|The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
75407873|NCT04775004|Other|Platelet Rich Plasma (PRP)|The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
75552885|NCT00437502|Biological|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
76039849|NCT04922203|Other|in Situ Simulation|2 sessions of in situ simulation with 4 crisis scenarios and debriefing focused on non technical skills
75552886|NCT00420680|Drug|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
75552887|NCT00420680|Drug|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
75552888|NCT00420680|Drug|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
75407874|NCT04504188|Device|Heart Rate Monitor Enhanced Treatment Optimization|Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.
75407875|NCT04063956|Behavioral|multi-domain internet-based adaptive training program|The training paradigms include a time perception task, visual search task, rapid serial presentation task, delayed match to sample task, paired-associate recall task, attention span task, digit span task, go-no go task, Stroop task, task switching, auditory span task and n-back working memory task. Each task has several difficulty levels. The tasks are grouped in different cognitive domains including: processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Participants in the cognitive training group will complete 40 min of training daily, 4 days a week for 12 weeks. When a high accuracy (80%) is achieved for each task, the level of difficulty will be upgraded for that task.
76023188|NCT02404597|Device|NICOM (non-invasive cardiac output monitor)|"The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure <100 or mean arterial pressure <65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined."
75552889|NCT04701567|Diagnostic Test|Magnetic resonance imaging|Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
75407876|NCT04063956|Behavioral|active-control program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
76039850|NCT04922047|Drug|tislelizumab and BCG|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
76039851|NCT03057535|Drug|Sodium Bicarbonate|
76039852|NCT03057535|Drug|Sodium Chloride|
75407877|NCT04024878|Drug|Nivolumab|Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
75407878|NCT04024878|Biological|NeoVax|"The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity"
75407879|NCT04024878|Procedure|Core Needle Biopsy|Surgical procedure
75407880|NCT04004520|Behavioral|Virtual Reality with Meditation|The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
75407881|NCT04004520|Behavioral|Audio Control|The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
75407882|NCT04004520|Behavioral|Virtual reality Control|The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
75407883|NCT03686514|Biological|FLUARIX QUADRIVALENT|The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
75407884|NCT03004248|Biological|Botulinum Toxins, Type A|Intramuscular Injection
75407885|NCT02529930|Biological|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
75407886|NCT00039780|Drug|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
75552890|NCT00420719|Device|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
75552891|NCT00437541|Device|Insulation retrofitted into house|
75552892|NCT00420758|Dietary Supplement|Food supplement: fortified spread|Provision of fortified spread
75552893|NCT00420758|Dietary Supplement|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
75552894|NCT00437580|Drug|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
75552895|NCT00420797|Drug|10% Phenylephrine hydrochloride gel|
76039853|NCT04407013|Other|Enhanced supportive care based on standardized care pathway|Enhanced supportive care based on standard care pathway is consisted of 1) symptom management (symptom assessment and according management) and 2) coping enhancement (nurse-led counseling). The enhanced supportive care will be provided 5 times, according to the standardized care pathway.
76039854|NCT04407013|Other|Control group with usual care|Control group will receive usual care (symptom monitoring only)
76039855|NCT04941235|Device|ultrasound and nerve stimulator|nerve stimulator and ultrasound guided interscalene brachial plexus block
76039856|NCT04921891|Procedure|Infraclavicular nerve block|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
76039857|NCT04921891|Procedure|Without nerve block|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
76039858|NCT04941079|Other|no intervention|no intervention
76039859|NCT03057457|Device|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
76039860|NCT04921579|Procedure|En masse retraction|Retraction stated on a 0.017''x 0.025'' Stainless steel wire using elastomeric chain ( force applied 200 g per side) extending between the crimpable hooks and the mini-screw.
75552896|NCT00437619|Drug|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a >50% response to Daivobet from weeks 0-4.
75872069|NCT02331082|Other|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
76023189|NCT04481659|Procedure|Lap partial ISR|A direct laparoscopic surgery with completely abdominal approach laparoscopic partial intersphincteric resection
75407887|NCT00039780|Drug|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
75407888|NCT04961034|Procedure|kasai portoenterostomy|surgical creation of stoma between porta hepatis and jejunal loop
75407889|NCT04951518|Other|VAN Stroke Scale|V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
75407890|NCT04945356|Other|upper limb training|The 6-week exercise program will consist of evidence-based exercises covering the breadth and depth of rehabilitation interventions. The therapist will choose the appropriate exercises for each participant's level of function from more than 15,000 exercises implemented within the Physiotec app and developed by rehabilitation experts. Personalized upper limb exercises will be based on the therapist initial assessment of participants, using the TERA+ telerehabilitation platform, and their goals. After each training session, participants will have to rate their perceived level of effort on a Borg scale (/10). The Borg scores will be monitored by the therapist as a precautionary measure to ensure safety and appropriateness of intensity of exercises. Participants will be instructed to train at a target score of around 7/10 (somewhat hard) on the Borg scale.
75552897|NCT00420836|Drug|Tobramycin|
76023190|NCT04481659|Combination Product|NCRT+Lap partial ISR|Preoperative radiation and chemotherapy + laparoscopic completely abdominal approach laparoscopic partial intersphincteric resection
75407891|NCT04902300|Other|Data collection|evaluation of internet addiction
75552898|NCT00437697|Drug|dalteparin|
75552899|NCT00335426|Procedure|Spinal manipulative therapy|
75552900|NCT00437736|Drug|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
75552901|NCT00335465|Drug|Insulin glargine|once a daily, sc injection, 100IU/ml
75552902|NCT00335543|Drug|cisplatin|
75552903|NCT00335543|Drug|gemcitabine hydrochloride|
75552904|NCT00335543|Procedure|adjuvant therapy|
75552905|NCT00335543|Procedure|conventional surgery|
75552906|NCT00335543|Procedure|neoadjuvant therapy|
75552907|NCT00335543|Radiation|radiation therapy|
75552908|NCT00437814|Drug|Ketamine, effect on intracranial pressure|
75552909|NCT00335582|Drug|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
75872070|NCT02331082|Other|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
75407892|NCT04845282|Dietary Supplement|Graded Protein plus Resistance Training|"Participants will be counseled to consume the specific level of dietary protein plus the protein supplement is MusclePharm Combat 100% Whey. Specific values per week are listed below:~Week 1: 25 g of protein supplement (0.8 g protein/kg body weight) Week 2: 25 g of protein supplement (1.0 g protein/kg body weight) Week 3: 50 g of protein supplement (1.2 g protein/kg body weight) Week 4: 50 g of protein supplement (1.4 g protein/kg body weight) Week 5: 50 g of protein supplement (1.4 g protein/kg body weight) Week 6: 75 g of protein supplement (1.6 g protein/kg body weight) Week 7: 75 g of protein supplement (1.8 g protein/kg body weight) Week 8: 75 g of protein supplement (2.0 g protein/kg body weight) Week 9: 75 g of protein supplement (2.2 g protein/kg body weight) Week 10: 100 g of protein supplement (2.2 g protein/kg body weight)"
76039861|NCT04921579|Procedure|Two-Step retraction|Retraction of canine started on a 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 150 g per side) followed by anterior teeth retraction on 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 160 g per side) extending between crimpable hooks and the mini-screw.
76039862|NCT04921657|Drug|Rosuvastatin 10mg|
76039863|NCT04930471|Drug|Metformin|Treatment with Metformin as prescribed by the treating physician.
76039864|NCT04921813|Other|3 dimensional scoliosis exercise|Schroth exercises
76039865|NCT04921813|Other|Balance Exercise|Balance-coordination exercises
75552910|NCT00437853|Drug|Anastrozole|
75712466|NCT02545803|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
75712467|NCT02534857|Procedure|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
75712468|NCT00951340|Other|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
76039866|NCT04921813|Other|Brace treatment|Brace usage
75712469|NCT00951340|Behavioral|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
75872071|NCT02331082|Device|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
75872072|NCT02331082|Device|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
75407893|NCT04845282|Dietary Supplement|RDA Protein plus Resistance Training|Participants will be counseled to consume the RDA level of protein (0.8g/kg/day) utilizing only dietary protein.
75407894|NCT04763226|Drug|BMS-986308|Specified dose on specified days
76039867|NCT04930393|Procedure|Nerve Block - either PECS II or axillary ring|In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
75712470|NCT00951340|Behavioral|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
75407895|NCT04763226|Other|Placebo (for BMS-986308)|Specified dose on specified days
75407896|NCT04763226|Drug|Furosemide|Specified dose on specified days
75407897|NCT04695678|Diagnostic Test|COVID-19 nasal/pharyngeal swab|each study participant receives a nasal/pharyngeal swab
75712471|NCT00748332|Dietary Supplement|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
75712472|NCT00748332|Dietary Supplement|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
75712473|NCT02545569|Device|hearing aid (MD class IIa) - ITE, BTE, RIC|Hearing aid means any wearable instrument or device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing.
75872073|NCT02331082|Behavioral|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
76039868|NCT03057223|Device|3D-printed patient-specific titanium plates|3D-printed patient-specific titanium plates will be used in patients.
76039869|NCT04940923|Diagnostic Test|MRI|"T2 weighted and DTI MRI images of brachial plexus and wrist. Quantitative sensory tests include warm and cold detection and pain thresholds, paradoxical heat sensation, mechanical detection thresholds, mechanical pain sensation and thresholds, wind up ratios, vibration thresholds and pressure pain thresholds.~Clinical tests include standard neurological tests and test for heightened nerve mechanosensitivity.~Blood serum to analyse inflammatory proteins. Questionnaires include neck disability index, painDETECT, PTSD8, pain catastrophising scale, eq-5D-5L, DASS 42 and global perceived recovery"
76039870|NCT02576951|Drug|Galcanezumab|Administered SC
76039871|NCT02576951|Drug|Placebo|Administered SC
76039872|NCT04921501|Device|HD ECG|This experimental procedure is a passive, non-invasive, high-density surface ECG recording using 128 skin electrodes.The electrodes are positioned on strips of 10 electrodes to be prepared with adhesive tape and coated with conductive gel before installation on the patient. The total duration of the acquisition is 10 to 30 minutes.
75407898|NCT04636008|Drug|Sintilimab|Sintilimab+Hypofractionated radiotherapy
75552911|NCT00335621|Drug|Inhaled Tiotropium|
75552912|NCT00437892|Drug|atorvastatin|tablets, 40 mg day, 3 months
76039873|NCT04921501|Device|Conventional 12-lead ECG|This standard 12-lead ECG is defined on the HD ECG, from electrodes F13, G3, G14, H5, H15, H25 corresponding to the precordial electrodes. 4 limb electrodes will be added for the frontal leads. Thus, the HD and 12-lead ECGs will be obtained simultaneously.
76039874|NCT04921267|Behavioral|training|training with filtered speech
76039875|NCT05530811|Drug|Dexamethasone|The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.
76039876|NCT05530811|Drug|Bupivacaine|0.5% bupivacaine
75407899|NCT04636008|Radiation|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy
75407900|NCT04549428|Drug|Atezolizumab|Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.
75552913|NCT00437892|Drug|atorvastatin|tablets, 40 mg once daily
76039877|NCT04940845|Drug|HS-20090-2|Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
76039878|NCT04940845|Drug|Prolia|Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
76039879|NCT05507567|Drug|Neumifil|Liquid for intranasal spray administration
76039880|NCT05507567|Drug|Placebo|Liquid for intranasal spray administration
75407901|NCT06085378|Drug|Urinary Kallidinogenase for injection|The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days
75407902|NCT06085378|Other|Placebo|The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.
75712474|NCT05323058|Drug|tulsi extract|4% topical oral spray
75712475|NCT05323058|Drug|Benzydamine Hydrochloride|0.15% topical oral spray
75712476|NCT02561910|Device|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
76039881|NCT04921111|Drug|SCT1000|Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
76039882|NCT04921111|Drug|Gardasil®9|Recombinant 9 or 4 valent human papillomavirus vaccine
75712477|NCT00552760|Drug|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
76039883|NCT04921111|Drug|placebo|aluminium phosphate
76039884|NCT04921111|Drug|Gardasil®|Recombinant 4 valent human papillomavirus vaccine
76039885|NCT05530733|Procedure|Pacifier|Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.
76039886|NCT05530733|Procedure|Breast milk|For babies assigned to the pacifier with breast milk group, their own breast milk will be applied by dripping 1 ml into the pacifier.
75407903|NCT06085365|Drug|Immunonutrition （Su yusu)|Immunonutrition （Su yusu） 250ml oral twice a day d1-d21
75407904|NCT06085365|Drug|fluorouracil based chemotherapy regimens|fluorouracil based chemotherapy regimens
75552914|NCT00437892|Behavioral|diet|daily
75552915|NCT00437892|Behavioral|diet|daily diet
75552916|NCT00335660|Drug|AV608|
75552917|NCT00437970|Drug|Pioglitazone|15mg of Pioglitazone taken orally twice a day
75552918|NCT00437970|Drug|Metformin|500 mg of Metformin taken orally twice a day
75552919|NCT00335699|Drug|Rosuvastatin|
75552920|NCT03279003|Device|LED light|An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.
75552921|NCT04716140|Procedure|Debridement of the MTP1 cartillage lesion and microfracture|Patients with a MTP1 cartillage lesion > grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture
75552922|NCT00335855|Device|Auto-injector for IM/SC vaccine administration|
75552923|NCT00335894|Drug|hMG-IBSA|
75712478|NCT00552760|Drug|Placebo|one tablet at bedtime for up to 6 months
75712479|NCT01046773|Drug|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
76039887|NCT03057145|Drug|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
76039888|NCT03057145|Drug|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
75552924|NCT00335933|Drug|Gabapentin extended-release tablets|
75552925|NCT00336011|Device|Magnetic resonance imaging|
75712480|NCT01046773|Drug|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
75712481|NCT00745602|Procedure|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
75872074|NCT02331082|Other|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
76039889|NCT04921423|Behavioral|Situational simulation teaching|The intervention included communication theory and skills, aging trend and knowledge, teaching plans for elderly nursing, activities for the elderly and visual experience, application and debriefing of empathy.
75407905|NCT06085352|Drug|TetraLens bandage contact lens|Methafilcon-A contact lens eluding tetracaine ophthalmic solution
75407906|NCT06085352|Device|Control Acuvue Oasys Bandage contact Lens|Standard of care bandage contact lens
75407907|NCT06085287|Device|Electromagnetic therapy|Electromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.
75407908|NCT06085274|Procedure|ICG guided sentinel lymph node biopsy|During sentinel lymph node biopsy the surgeon will inject a volume of 0.1ml divided into 2 doses (0.05ml each) of 2.5mg/mL ICG into the periareolar dermis of the involved breast. Technetium and blue dye will also be administered as per standard of care. The surgeon will assess the axilla with the the SPY-PHI near infrared imaging system to identify and remove ICG-fluorescent nodes; Any other sentinel lymph nodes identified will also be removed as per standard of care. If there is no progression of ICG towards the axilla, or if no ICG sentinel lymph node can be identified, an alternate injection technique involving peritumoural injection at 2-3 locations near the cancer site in the subcutaneous or dermal space of 0.05ml will be utilized.
75407909|NCT06085261|Behavioral|home-based telerehabilitation group|Participants will download the web application in their smartphones in the hospital's outpatient clinic and learn to use the sports wristwatch. Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises. The initial aerobic exercise prescription for walking will be set at 80% of the speed walked during a 6-minute walk test (6MWT) and progressed each 4-week according to patient assessments. Resistance training for the arms and legs will utilize elastic bands, while respiratory training will utilize portable breathing trainer. During each training session, participants will be asked to follow the videos in the web application, wearing the sports wristwatch recording their exercise intensity. At the end of every training session, training data could be uploaded to the web platform automatically, which will be checked by staff in hospital.
75552926|NCT03270111|Behavioral|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
75552927|NCT03270111|Behavioral|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
75552928|NCT03270111|Behavioral|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
75552929|NCT03270111|Behavioral|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
75552930|NCT00336089|Behavioral|exercise intervention|
75552931|NCT00336089|Other|educational intervention|
75712482|NCT00850005|Biological|Intravenous immunoglobulin|2 g/kg divided over five days
75712483|NCT00850005|Biological|Normal Saline|Same volume as experimental arm
75712484|NCT00941980|Biological|Osteocel Plus|biologic
75712485|NCT04060706|Radiation|Radical Image-Guided Radiotherapy|Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
75712486|NCT04012372|Other|ROSA Water|Ad libitum hydration with ROSA oligomineral water
75712487|NCT04012372|Other|Control water|Ad libitum hydration with other waters
75872075|NCT03144154|Behavioral|Self-hypnosis + Self-care|Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
76039890|NCT04425005|Other|Home-based exercise|Home-based exercise training, supervised by videoconference.
76039891|NCT03056989|Drug|SPX-101|Inhalation solution twice daily for 7 days.
76039892|NCT04940455|Other|Educational digital platforms|The digital educational platforms will be implemented through games of questions and answers, simulated cases sent via google forms about the nurse's performance in a critical care unit facing the patient with signs and symptoms of sepsis. The questions in the games will aim to develop clinical judgment and quick decision-making in nursing students in order not to compromise the health care of the patient in sepsis.
76039893|NCT04920877|Other|Infection Prevention|Preventing central catheter-related bloodstream infections in intensive care units
75407910|NCT06085261|Behavioral|center-based traditional rehabilitation group|"Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.~The initial aerobic exercise prescription for cycling will be set at 60% of the peak oxygen uptake (VO2) on a cardiopulmonary exercise test (CPET). Resistance training and respiratory training are similar to the telerehabilitation group."
75407911|NCT06085248|Device|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
75552932|NCT00336089|Procedure|complementary or alternative medicine procedure|
75552933|NCT00336089|Procedure|fatigue assessment and management|
75407912|NCT06085248|Behavioral|Active walking|walking without RAS cue
75552934|NCT00336089|Procedure|management of therapy complications|
75552935|NCT00336089|Procedure|pain therapy|
75552936|NCT00336089|Procedure|quality-of-life assessment|
75552937|NCT00336167|Drug|bezafibrate (drug)|
75552938|NCT00336206|Drug|Alemtuzumab|
75552939|NCT00347334|Behavioral|infant home positioning|
75552940|NCT00336245|Device|Copper T Intrauterine Contraceptive Device|
75552941|NCT00336245|Drug|Hormonal Contraception|
75552942|NCT00336362|Drug|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
75552943|NCT00347373|Drug|Tonalin Conjugated linoleic acid (dietary supplement)|
75552944|NCT00336401|Drug|Sevoflurane or Propofol|
75552945|NCT00336518|Drug|peginterferon alfa-2a|
75552946|NCT00336518|Drug|ribavirin|
75552947|NCT00336557|Procedure|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
75552948|NCT00336596|Procedure|transcranial ultrasound in patients treated with iv t-PA|
75712488|NCT00852501|Other|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
76039894|NCT04929925|Diagnostic Test|serum procalcitonin in acute bacterial meningitis|Serum Procalcitonin estimation will be done by Cobas e411Roch diagnostic,Switzerland apparatus by immunoassay method (electrochemiluminescence immunoassay) by using sample serum or plasma heparin or EDTA with reference range less than 0.5ng/ml ( no sepsis) but 0.5-2ng/ml)follow up is recommended) and more than 2 (sepsis)
75552949|NCT03277872|Device|Laryngoscopy with GlideScope (GVL) Blade|"st Laryngoscopy with GVL Blade~nd Laryngoscopy with MAC Blade~rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
75552950|NCT03277872|Device|Laryngoscopy with MacIntosh (MAC) Blade|"st Laryngoscopy with MAC Blade~nd Laryngoscopy with GVL Blade~rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
75407913|NCT06085235|Behavioral|exercise|cycling exercise for 15min, with 5min warm up
75407914|NCT06085196|Behavioral|Mindful walking activity|Participate in 24 sessions of outdoor mindful walking on a local walking trail over three months
75407915|NCT06085183|Other|Saline Injection 0.9%|Placebo
75552951|NCT00336635|Biological|cell-culture derived smallpox vaccine|
75552952|NCT00347490|Drug|Enoxaparine|
75552953|NCT00336674|Biological|Intranasal insulin|440IU Insulin
75552954|NCT00336674|Other|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
75552955|NCT00444483|Behavioral|Structured diabetes teaching and treatment program|
75552956|NCT00336752|Procedure|non operative treatment|non operative treatment -casting for 6 weeks
75552957|NCT00336752|Procedure|operative treatment of ankle fractures|operative treatment of ankle fractures
75552958|NCT00444522|Drug|Alprazolam thermal aerosol|
75552959|NCT00336791|Drug|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m^2 IV on day 1 and day 4 of 21 day cycle."
75552960|NCT00336791|Drug|Cyclophosphamide|"FAC and FEC Chemotherapy:~500 mg/m^2 IV on day 1 of 21 day cycle."
75552961|NCT00336791|Drug|Doxorubicin|FAC Chemotherapy: 50 mg/m^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
75552962|NCT00336791|Drug|Paclitaxel|80 mg/m^2 by vein (IVPB) over 1 hour every week for 12 weeks
75552963|NCT00336791|Drug|Epirubicin|FEC: 100 mg/m^2 IV on day 1 of 21 day cycle.
75552964|NCT00347529|Biological|pPML7789 with and without pPJV2012 administered by PMED|
75552965|NCT00336830|Behavioral|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
75552966|NCT00336830|Behavioral|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
75407916|NCT06085183|Drug|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
75552967|NCT00444561|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC administration
75552968|NCT00347568|Device|TX-plore|PI has terminated at institution and there is no one available to report.
75552969|NCT00336908|Drug|a combination of MCT, LCT , and Fish Oil|
75407917|NCT06085170|Diagnostic Test|Acoustic Analysis by MDVP|Acoustic measurements: Acoustic analysis using Multidimensional voice program software (MDVP) will be carried out with the sustained /a/vowel for 9 seconds, for measuring frequency, jitter, shimmer and harmonic to noise ratio of the voice
75407918|NCT06085118|Other|Pepticate® Syneo®|Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
75407919|NCT06085105|Behavioral|CPIPE Training|A two day training covering the following topics: understanding stress & burnout and developing positive coping mechanisms, bias awareness & mitigation, person-centered maternity care mindfulness, dealing with difficult situations, emergency obstetric and neonatal care, teamwork and communication, mentorship and peer support.
75407920|NCT06085105|Behavioral|Peer support groups|Groups for healthcare providers to meet with other healthcare providers of their cadre, and discuss issues they are facing, brainstorm solutions, and provide support to one another.
75872076|NCT02334670|Drug|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
75407921|NCT06085105|Behavioral|Mentorship|Mentor-mentee relationships that provide the opportunity to coach junior healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. Mentors develop their mentorship and leadership skills.
75407922|NCT06085105|Behavioral|Leadership engagement|Engagement of County leadership at the onset of the project through a community advisory board, regular updates of the study and findings, and discussing systemic gaps that impact provider stress and bias.
75407923|NCT06085105|Behavioral|Embedded champions|To facilitate ongoing engagement and sustainability at the facility level, we identified facility champions who lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
75552970|NCT00444639|Drug|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
75552971|NCT00336947|Drug|tegafur-gimeracil-oteracil potassium|
75407924|NCT06085079|Drug|Ixekizumab Prefilled Syringe|Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.
75407925|NCT06085027|Procedure|Labor analgesia|Perform epidrual analgesia for parturients between 18 to 45 year-old
75407926|NCT06085014|Other|Standard of care|All patients will undergo, as clinically indicated, AF ablation by pulmonary vein isolation achievable by radiofrequency, cryoenergy, or electroporation. All patients will preliminarily undergo electroanatomic mapping of the atrium by CARTO/Navx/Rhythmia system indifferently. Patients will be given follow-up visits at 3-6-12 months, during which any arrhythmic recurrences will be assessed
75407927|NCT06085014|Other|Data collection|There's no patient involvement. Data of patients who underwent ablative procedures two years before the start of the study will be retrospectively analyzed
75407928|NCT06085001|Diagnostic Test|Lumella finger prick blood test|Finger prick blood test
75407929|NCT06084975|Procedure|Splenic vessels preservation|preservation the splenic vessels
75407930|NCT06084962|Biological|DeepTag-GPRC5D Targeted CAR T-cells|Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion
75407931|NCT06084949|Device|Nordic walking or inspiratory muscle training|Nordic walking is a form of low-impact aerobic exercise that incorporates the use of walking poles. And inspiratory muscle training is a type of exercise that provides resistance during the inhalation phase.
75552972|NCT00336947|Drug|tegafur-uracil|
75552973|NCT00336947|Procedure|adjuvant therapy|
75552974|NCT00347607|Behavioral|community surveillance and re-treatment|
75552975|NCT00444717|Drug|pitavastatin|Pitavastatin (2mg/day) was administered for 12 weeks
75552976|NCT00347646|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
75552977|NCT00337064|Procedure|Radiation Therapy|
75552978|NCT00421278|Drug|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
75552979|NCT00421317|Drug|Imatinib|800 mg/day until disease progression or toxicity
75712489|NCT02562534|Device|MRI compatible ElectroCardioGraph|MRI with ECG control for people with healthy heart or heart diseases
75712490|NCT00852579|Drug|Azithromycin|Daily dose 250mg
75712491|NCT00852579|Drug|Placebo|Placebo
75712492|NCT00942058|Other|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
75712493|NCT02562456|Procedure|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
75407932|NCT06084923|Other|Observation|Patients will be observed after ibrutinib discontinuation and data on ibrutinib discontinuation, reatreatment and outcome will be collected
75407933|NCT06084910|Behavioral|Cultural Pride Reinforcement for Early School Readiness|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR) is based on the nationwide Reach Out and Read (ROR) program adapted to reinforce cultural pride. ROR provides children's books, brief book-sharing advice, and developmental surveillance at pediatric well child visits. Each of the 5 CPR4ESR sessions provides 1 children's book with a cultural pride theme, 1 parent handout, and modeling of book-sharing.
75552980|NCT00337259|Drug|gemcitabine|D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
75712494|NCT02562456|Procedure|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
75712495|NCT00942136|Drug|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
75712496|NCT00942136|Drug|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
75712497|NCT00942136|Drug|Placebo|Placebo Suspension as a single dose.
75712498|NCT00942136|Drug|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
75712499|NCT00748488|Other|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
75407934|NCT06084910|Behavioral|Reach Out and Read|ROR provides children's books and brief book-sharing advice at pediatric well child visits
75407935|NCT06084858|Other|Dialysate bicarbonate modification|Dialysate bicarbonate prescription will be modified from low (27 mmol/l) to high (37 mmol/l) in a step-wise fashion
75407936|NCT06084819|Drug|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"Azacytidine (75mg/m2/day, days 1 to 7).~Cytarabine (75-100mg/m2 q12h, days 1 to 5).~Aclacinomycin(20mg/day, days 1,3,5).~Chidamide(30mg/day , days 1,4,8,11).~Venetoclax (100mg on day 1,200mg on day 2,400mg on days 3-14).~Granulocyte colony stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
75552981|NCT04699734|Diagnostic Test|Xylocaine 1%|Nerve block
75552982|NCT04699734|Diagnostic Test|NaCl 9mg/ml|Nerve block
75552983|NCT00337298|Drug|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
75552984|NCT00337298|Drug|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
75552985|NCT04699851|Behavioral|Tailored recommendations|Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
75712500|NCT00748488|Other|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
75712501|NCT05300932|Drug|Baricitinib|Orally take Baricitinib 4mg everyday for 48 weeks
76039895|NCT04940143|Drug|Botulinum toxin type-A (Onabotulinum toxin type-A)|Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
76039896|NCT04940143|Other|Physical Therapy|After the botulinum toxin-A injection, the patients will be included in the comprehensive physiotherapy program thrice a week for a total of 12 weeks. The physiotherapy program will be consisted of the ankle range of motion and stretching, strengthening of the antagonist muscles, proprioception exercises, functional walking training and static and dynamic balance training.
75552986|NCT04699851|Behavioral|General recommendation|The control group will receive general recommendations by email about health prevention in a pandemic.
75552987|NCT00337337|Behavioral|Multiple grain|
75712502|NCT05300932|Drug|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
75407937|NCT06084819|Drug|Best-Available Therapy(BAT) Regimen|"FLAG regimen:Fludarabine(30mg/m2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~CLAG regimen:Cladribine(5mg/2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~MAE regimen:Mitox(10mg/m2,days 1 to 5)+VP-16(100mg/m2,days 1 to 5)+Cytarabine (100-150mg/m2,days 1 to 7)~DCAG regimen:Decitabine(20mg/m2,days 1 to 5)+Aclacinomycin(20mg/day on days 1,3,5)+Cytarabine (100mg q12h,days 1 to 5)+Granulocyte colony-stimulating factor(300 ug/day,day 0 until agranulocytosi recovery)~HAA regimen:HHT(2mg/m2,days 1 to 7)+Aclacinomycin(20mg/day,days 1 to 7) and Cytarabine (100-200 mg/m2, days 1 to 5);~HAD regimen:HHT(2mg/m2,days 1 to 7)+Daunorubicin(45mg/m2/day,days 1 to 3)+Cytarabine (100-200 mg/m2,days 1 to 5)."
75407938|NCT06084806|Drug|[18F]F-ARAG PET|Two imaging sessions
75552988|NCT00337337|Behavioral|Ordinary Asian- rice|
75552989|NCT00337376|Drug|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
75552990|NCT00337376|Drug|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
76039897|NCT03057067|Procedure|Embolization of pelvic vein varicosities|Embolization of pelvic vein varicosities
76039898|NCT03056911|Drug|Ozone|Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
76039899|NCT04929613|Behavioral|Mindfulness-Based Resilience Training|2.5-day intensive MBRT training sessions.
76039900|NCT04920409|Other|FAWGT diet|Composed of 15% protein, 55% CH and 30% fat of which < 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
76039901|NCT04920409|Other|Usual diet (UD)|Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
75552991|NCT00337415|Drug|MK0354|
75552992|NCT03275688|Diagnostic Test|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
75552993|NCT00337493|Drug|mycophenolate mofetil [CellCept]|Concentration-controlled
75552994|NCT00337493|Drug|mycophenolate mofetil [CellCept]|1g po bid
76039902|NCT04920721|Other|no intervention|no intervention descriptiv study
75552995|NCT00337493|Drug|Cyclosporine or tacrolimus|Reduced
75712503|NCT02545491|Behavioral|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
75712504|NCT02545491|Behavioral|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
75552996|NCT00337493|Drug|Cyclosporine or tacrolimus|Standard, as prescribed
75712505|NCT00942214|Drug|Natalizumab|300mg, IV, every 4 weeks
75712506|NCT00850161|Drug|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
75712507|NCT00850161|Drug|Nasulin™|100 IU(2 puffs in each nostril)
75872077|NCT02330848|Dietary Supplement|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
75872078|NCT02330848|Dietary Supplement|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
76039903|NCT04939675|Drug|Zonisamide 100mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
76039904|NCT04939675|Drug|Levetiracetam 500mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
76039905|NCT04939675|Drug|LamoTRIgine 50mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
75552997|NCT00444756|Procedure|J-tip jet injection of 1% buffered lidocaine|
75712508|NCT00951574|Drug|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
75552998|NCT03275649|Other|Help-seeking for non-motor symptoms|Brief, self-paced, online individually tailored intervention using LifeGuide software. Includes information, videos and exercises.
75712509|NCT00951574|Drug|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
75712510|NCT00686790|Biological|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
75712511|NCT00850239|Drug|dutogliptin|400 mg
75712512|NCT00850239|Drug|placebo|
75712513|NCT00946426|Other|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
75712514|NCT00942292|Dietary Supplement|Lipidem- fish oil emulsion BBraun UK|
75712515|NCT00942292|Procedure|Digital Contrast MRI scan|
75712516|NCT02563392|Procedure|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
75712517|NCT02563392|Procedure|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
75712518|NCT00856089|Drug|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
75712519|NCT00942370|Device|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~EMG and MMG Signals of rectus abdominis of the abdomen,~Respiratory flow,~An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
75552999|NCT04715789|Behavioral|graded exposure and activity|"Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner"
75872079|NCT02334202|Behavioral|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
75553000|NCT00444834|Drug|Carvedilol|50 mg
75553001|NCT00337688|Device|isometric joystick|isometric joystick
75407939|NCT06084780|Procedure|Intestinal, Multivisceral or Modified Multivisceral Transplantation|"Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:~Isolated small bowel transplant (SBT): transplantation of the donor small intestine~Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach~Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach"
75553002|NCT04698486|Other|Hyperinsulinemic euglycaemic clamp|"Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention."
75553003|NCT00337766|Drug|Desmopressin (DDAVP)|
75553004|NCT00337766|Drug|Placebo|
75553005|NCT00444873|Drug|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
76039906|NCT04939285|Procedure|PEEP|The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
75407940|NCT06084780|Drug|Alemtuzumab|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
76039907|NCT04929691|Device|CPAP helmet|helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation
76039908|NCT04929691|Other|Standard of care non-helmet based CPAP ventilation|Standard of care ventilation without helmet-based CPAP
75407941|NCT06084780|Drug|Tacrolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
75407942|NCT06084780|Drug|Sirolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
75407943|NCT06084741|Other|Omitting of usage of intraabdominal drains after repair of peptic ulcer perforations|omitting the intraabdominal drains
75407944|NCT06084741|Other|Using intraabdominal drains|The investigators will put intraabdominal drains
75407945|NCT06084728|Diagnostic Test|Color Doppler ultrasonography|in a longitudinal plane, the dorsal clitoral artery, which is sampled on the outer surface of the clitoral body as previously described. With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) was visualized posterolaterally to the labia majora
75407946|NCT06084715|Other|Nutritional support|The hospitals in Benin already provide nutritional support for patients with pulmonary TB which will continue throughout the study.
76039909|NCT04939129|Diagnostic Test|The research is terminated by calculating the percentage of PVI changes with SAB formed by LRM after fluid challenge.|Measurements will begin after a hemodynamically stable period in the supine position.Heart rate, central venous pressure, systolic, diastolic and mean arterial pressure, peripheral oxygen saturation, PVI and BIS baseline values (baseline 1) will be recorded.LRM will be automatically adjusted in the mechanical ventilator(30 cm H2O/30 seconds) and all hemodynamic parameters where the maximum change at the end of 30 seconds, will be recorded(after LRM), and the differences initial baseline values will be calculated and recorded as percentages.After the recording of the second values, the crystalloid infusion at 10ml/kg will be made to the patient through the peripheral venous line within 15minutes, new baseline values will be taken before the test(baseline 2).After fluid replacement, LRM will be repeated in the same way. The values after LRM(Fluid Challenge-FC) will be recorded and differences between basal 2 values will be calculated and recorded as percentages.
75553006|NCT00337805|Other|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
75553007|NCT01580397|Drug|INNO-206|INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
75553008|NCT04715594|Device|1st-generation drug-eluting stent|Implantation of 1st-generation drug-eluting stent
75553009|NCT04715594|Device|2nd-generation drug-eluting stents|Implantation of 2nd-generation drug-eluting stent
75553010|NCT00444990|Device|Magnetic Flex Pad|
75553011|NCT00337883|Drug|Erlotinib HCl (OSI-774)|
75553012|NCT00451113|Drug|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
75553013|NCT00337922|Drug|Lamivudine / Abacavir Sulfate|
75553014|NCT04699578|Diagnostic Test|Covid-19 positive|All pregnant women at any stage of pregnancy afferent to obstetrics services who tested positive in confirmation tests by nasopharyngeal swab for viral RNA detection through real-time reverse transcriptase - polymerase chain reaction (rRT-PCR) will be included.
75553015|NCT00337961|Procedure|Optic Nerve Sheath Fenestration|
75553016|NCT00451230|Drug|cocaine|
75553017|NCT00451230|Drug|hydrocortisone|
75553018|NCT00338000|Drug|Epoetin alfa|
75553019|NCT00451269|Device|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
75872080|NCT02334202|Other|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
75872081|NCT02334280|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
75553020|NCT00338078|Device|nocturnal oxygen treatment from oxygen concentrators|
75553021|NCT00338117|Drug|Galantamine hydrobromide|
75553022|NCT02956707|Other|No pre-operative steroids|Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
75553023|NCT00338195|Behavioral|Individualized caffeine cessation instructions|Intervention is described in the protocol
75553024|NCT00451308|Procedure|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
75553025|NCT00451308|Procedure|Induction of labor with foley balloon with 30cc|30cc of saline in foley
75553026|NCT00451347|Device|Quadriceps strength training|
75553027|NCT00451347|Device|Taping|
75553028|NCT00451347|Device|Home exercise|
75553029|NCT00338273|Drug|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
75553030|NCT00338273|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
75553031|NCT03277833|Dietary Supplement|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
75553032|NCT03277833|Dietary Supplement|Placebo|Placebo, parallel design
75553033|NCT00338312|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
75553034|NCT00338312|Drug|Placebo patch|placebo patch changed twice a week for one year
75553035|NCT00451386|Drug|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
75553036|NCT00451386|Drug|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
75553037|NCT00420875|Device|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
75553038|NCT02956824|Other|Standard care|Current care
75553039|NCT00338351|Biological|Pneumococcal (vaccine)|
75553040|NCT00451425|Behavioral|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
75553041|NCT00338390|Drug|Abacavir|Change tenofovir to abacavir
75553042|NCT00338390|Drug|Didanosine|Increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
75553043|NCT00338390|Drug|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
75553044|NCT00338429|Behavioral|FHP Sleep Program|Cognitive-Behavioral Intervention
75553045|NCT00338468|Drug|epoetin alfa|
75553046|NCT00338507|Drug|Erdosteine|
75553047|NCT00445185|Biological|Henogen HB vaccine|Month 12, 24 and 36
75553048|NCT00445185|Biological|Fendrix vaccine|Month 12, 24 and 36
75553049|NCT00338546|Drug|Cocaine hydrochloride|
75553050|NCT00338546|Drug|Dexmedetomidine|
75553051|NCT00338546|Procedure|Microneurography|
75553052|NCT00338546|Procedure|Laser doppler velocimetry|
75553053|NCT00338585|Drug|alfimeprase|
75553054|NCT00451503|Device|Middle Ear Implant|surgery
75553055|NCT00338624|Drug|oxybutynin chloride extended release|
75553056|NCT00338663|Device|knee immobilization splint|
75553057|NCT00445419|Biological|PEV2A PEV2B|
75553058|NCT00451581|Procedure|Endoscopic papillary balloon dilation-5 minutes|
75553059|NCT00451581|Procedure|Endoscopic papillary balloon dilation-1 minute|
75553060|NCT00338780|Drug|Lamivudine/ Placebo 100mg daily|
75872082|NCT02974868|Drug|PF-06651600|200 mg QD during induction and 50 mg QD during Maintenance
75872083|NCT02974868|Drug|PF-06700841|60 mg QD during induction and 30 mg QD during maintenance
75872084|NCT02974868|Drug|Placebo|Placebo
75553061|NCT00451620|Drug|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
76039910|NCT04938739|Other|Cognitive Behavioral Therapy|"The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained."
76039911|NCT04938739|Other|Home program exercises|Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
76039912|NCT03055975|Diagnostic Test|Detection of residual vital bacteria in the root canal space|Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
76039913|NCT04929301|Other|Antenatal milk expression|Hand-expression of breast milk in pregnancy
76039914|NCT04929301|Other|Education handouts|Educational breastfeeding handouts
76039915|NCT03055663|Other|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
76039916|NCT03055663|Procedure|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
76039917|NCT03055663|Drug|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
76039918|NCT04928443|Other|Scar dressing group|Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.
75407950|NCT06084637|Biological|Intra-articular injection of autologous microfat|A preparation of autologous microfat (5mL) will be injected intra-articularly.
75407951|NCT06084637|Biological|Intra-articular injection of autologous platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
75407952|NCT06084637|Biological|Intra-articular injection of autologous microfat and platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
75553062|NCT00451620|Drug|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
75553063|NCT00338858|Other|walking and balance performance evaluation|
75553064|NCT00338858|Procedure|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
76039919|NCT04928443|Other|Regular care group|Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
76039920|NCT02621047|Drug|Alectinib|Participants will receive alectinib as per the dosage schedule mentioned in arm description.
75407953|NCT06084624|Drug|Rebamipide mouthwash|Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinone-4-yl]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome
75407954|NCT06084624|Drug|Betamethasone mouthwash|Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers
75407955|NCT06084611|Device|Provox Life|Compliant use of Provox Life HMEs
75553065|NCT00451737|Device|Isokinetic test|
75553066|NCT00338897|Drug|SR123781A|
75553067|NCT00445497|Drug|amoxicillin-clavulanate potassium|
75553068|NCT00445497|Drug|ciprofloxacin|
75407956|NCT06084585|Dietary Supplement|Study Product A (High-dose 2X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
75407957|NCT06084585|Dietary Supplement|Study Product B (Low-dose X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
75407958|NCT06084585|Dietary Supplement|Placebo|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
75407959|NCT06084572|Other|Questionnaires|FSSG & BEDQ
75407960|NCT06084559|Other|Supplemental oxygen therapy|Mobile oxygen via pressurized bottle or mobile oxygen concentrator will be applied
75407961|NCT06084559|Other|Sham Oxygen therapy|Patients will reveice pressurized air via a nasal cannula
75553069|NCT00445497|Procedure|psychosocial assessment and care|
75553070|NCT00445497|Procedure|quality-of-life assessment|
75553071|NCT00451776|Drug|etomidate|patients who received etomidate
76039921|NCT03057691|Other|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
75553072|NCT00451776|Drug|propofol|patients who received propofol
75553073|NCT00338936|Drug|Valsartan + Hydrochlorothiazide|
75553074|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
75553075|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
75553076|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
76039922|NCT03057379|Other|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
76039923|NCT04928365|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 therapy
76039924|NCT04938037|Procedure|US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine|nerve block
76039925|NCT04431271|Procedure|Robot-assisted hernia repair|Inguinal hernia repair was performed using the DaVinci Xi robotic system
76039926|NCT04919785|Device|Deep brain stimulation|Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
75553077|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
75553078|NCT00338975|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
75872085|NCT03144076|Other|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
75407962|NCT06084546|Device|geko™ X-W3|The geko™ X-W3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ W3 device and the new geko™ XW-3 device is the adhesive used to attach each device to the skin.
75407963|NCT06084507|Drug|GST-HG171/ritonavir|Single oral dose of GST-HG171 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
75407964|NCT06084507|Drug|ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to GST-HG171/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours and 24 hours after GST-HG171/ritonavir dosing.
75872086|NCT05076526|Biological|Hyaluronic acid (Synolis VA)|"Synolis VA harbours the following characteristics:~NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~Sorbitol: 40mg/mL~Molecular weight of 2MDa, sterilized in moist heat"
75712520|NCT04041999|Behavioral|Daily Cognition Training Program|"Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc."
75872087|NCT05076526|Biological|Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)|"The CM-PRP-HA tube is under vacuum containing the following:~2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~3g of inert cell-selector gel~0.6mL of anticoagulant (sodium citrate 4%)"
75407965|NCT06084494|Diagnostic Test|analytical determination and interpretation of heat stress using calculation of the Predicted Heat Strain and Wet Bulb Globe Temperature|The temperature inside the climatic chamber was set at 40 C and 31 C at a relative humidity of 20 % and 70 % respectively to count for a WBGT level of 28 C. The subject does walk at 5 km/h and jog at 8 km/h under these conditions for up to 70 minutes. The test includes the measurement of the height and weight of the subjects, heart rate, oxygen consumption, body weight loss (sweat evaporation), skin temperature, and core body temperature under hot environmental conditions. Subjective responses will also be recorded. WBGT was recorded after every ten minutes by heat stress meter and Bruel Kjaer.
75872088|NCT03111784|Other|Fish consumption and lipid profiles|
75872089|NCT02330614|Other|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
75712521|NCT00686712|Drug|1- Insulin glargine QHS|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings <120 mg/dL)
75712522|NCT00686712|Drug|2 - Insulin glargine QAM|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings <120 mg/dL)
75712523|NCT00686712|Drug|3 - NPH insulin QHS|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses <120 mg/dL)
75872090|NCT02330614|Other|Nothing - control group|Only NEO-FFI test , data used as control
75872091|NCT02330692|Other|No intervention|
75872092|NCT03653858|Device|Vercise GEVIA deep brain stimulation (DBS) system|DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)
75872093|NCT05076136|Other|Regional treatment|In reginal treatment patients were given physiotherapy exercises and manual therapies on hip joint as well as on surrounding areas of hip joint such as lumber area and sacroiliac joint.
75872094|NCT05076136|Other|Standard physiotherapy treatment|In this treatment patients were given just hip joint mobilizations and quadriceps and hamstrings stretching.
76039927|NCT04928833|Other|Pilates Training|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all subjects were taught the key elements of Pilates in 1 session. Pilates training started with standing exercises for warming up and centering in the supine position. Training continued with upper and lower extremity movements. The intensity of the exercises was increased using different positions and elastic bands. Stretching exercises and posture exercises were used during the cooling period. All exercises were started with 10 repetitions and then increased to 20. In order for the patients to perform the movements correctly, each movement was first demonstrated by the physiotherapist. The movements that the patients could not do were applied by modifying them in a suitable way.
76039928|NCT04928833|Other|Control group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
75553079|NCT00338975|Behavioral|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
75872095|NCT03654482|Device|SuperSeton|The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
75872096|NCT02330536|Device|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
75872097|NCT03653780|Device|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
75872098|NCT05076058|Dietary Supplement|Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza|"Brand names: BY-HEALTH；~Main contents (per 100g): silibinin 2g, salvianolic acid B 0.72g，Puerarin 0.68g"
76039929|NCT04919473|Biological|Gene Therapy product:vMCO-I|The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
76039930|NCT04937569|Drug|Ivermectin Tablets|4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast
76039931|NCT04937257|Other|Virtual Reality|The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.
75407967|NCT06084442|Procedure|Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia|"Patients will be divided into 2 groups:~Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique."
75407968|NCT06084390|Other|Interdisciplinary care + booster session (intervention)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden + one extra booster-session 3 months after the standard care rehabilitation. At the booster-session, the participant´s individual rehabilitation plan is followed-up and adjusted. This extra period also includes extended access to the team, meaning that the participants have the possibility to contact the team and, if needed, have digital or telephone contact.
75553080|NCT00338975|Behavioral|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
75553081|NCT00338975|Behavioral|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
75712524|NCT00852735|Dietary Supplement|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
75712525|NCT02545257|Other|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
75712526|NCT00852813|Dietary Supplement|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
75872099|NCT05076058|Other|Placebo tablet|"Brand names: BY-HEALTH；~Main contents : starch"
75872100|NCT03143998|Drug|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
76023191|NCT03115645|Other|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
76023192|NCT03218423|Device|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
76023193|NCT02398981|Other|Clinical decision support tool|
76039932|NCT04937257|Other|E-module|The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
76039933|NCT04937335|Other|intratumoral hemorrhage|Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
75407969|NCT06084390|Other|Interdisciplinary care (control)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden.
75553082|NCT00339014|Drug|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
75712527|NCT00748644|Drug|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
75712528|NCT00748644|Drug|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
75407970|NCT06084351|Drug|Convalescent Plasma|"Class: Blood product Physical Description: Opaque yellow fluid within a container labelled with the statement Caution: New Drug - Limited by Federal (or United States) law to investigational use). Container will also be labelled with the International Society of Blood Transfusion format for Blood Components. Label will contain the expiration date and the donor identification number. Label will also contain information pertaining to the ABO typing of the plasma. A copy of the IBST identifier will be placed with the patient chart.~Manufacture: Plasma will be collected via apheresis via collaboration with American Blood Bank Corporation, a FDA-registered blood establishment. The donors will be screened in accordance with the FDA guidance for donor eligibility for COVID-19:"
75712529|NCT04042779|Other|model-based WM training|model-based WM training program: four sessions a week, 45 minutes each; lasting for three weeks
75712530|NCT04042779|Other|single-task WM training|single-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
76023194|NCT04826081|Other|data collection|data collection
75407971|NCT06084351|Other|Standard of Care|Standard of care treatment for hospitalized COVID-19 patients
75553083|NCT00339014|Other|Placebo|Identical placebo
75712531|NCT04042779|Other|multiple-task WM training|multiple-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
75712532|NCT04042779|Other|sham intervention|motor training program: four sessions a week, 45 minutes each; lasting for three weeks
75712533|NCT00748722|Device|CT Angiography|Injection of contrast material (iodine)
75712534|NCT00745836|Drug|statin|
75712535|NCT00853203|Behavioral|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
76023195|NCT02398903|Other|Blood samples for measurement of drug Css|Blood samples for measurement of drug Css
75407972|NCT06084325|Device|Respiration resistance sensitivity task (RRST)|The RRST measures interoception on the domain of the breath and thus allows its (non-invasive) manipulation. The RRST apparatus includes a step motor that moves a wedge piece back and forth to change the obstruction level in the breathing circuit. This fully automated apparatus will change the breathing obstruction level via a computer-controlled algorithm. The patient breath by the month though this device.
75553084|NCT00451854|Procedure|Random, no advanced notice drug and alcohol testing|
76023196|NCT02398903|Other|DXA and impedancemetry|Body composition by DXA and impedancemetry
75553085|NCT04715828|Other|Cryopreserved semen|sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
75553086|NCT04715828|Other|Acute and low irradiation|sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
75553087|NCT04715828|Other|Long and low irradiation|sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
75712536|NCT00853203|Behavioral|Questionnaires|Written survey taking about 1 hour.
75712537|NCT00853203|Other|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
76023197|NCT04923971|Other|Purdue Pegboard|Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
76023198|NCT02398669|Drug|Lorcaserin hydrochloride|A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
76023199|NCT05041751|Procedure|Acupuncture Point Injection|Receive trigger point injections
76023200|NCT05041751|Procedure|Massage Therapy|Perform myofascial release
76023201|NCT05041751|Other|Quality-of-Life Assessment|Ancillary studies
76023202|NCT05041751|Other|Questionnaire Administration|Ancillary studies
76023203|NCT02398591|Drug|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
75712538|NCT00853203|Behavioral|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
75712539|NCT00853203|Behavioral|Written Materials|Written educational materials plus community resource information.
75712540|NCT00748800|Behavioral|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
75407973|NCT06084325|Behavioral|Heartbeat Tracking (HBT)|The HBT measures interoception on the domain of the cardiovascular system, by assessing how accurate participants perceive their own heartbeat. After each time window participants will be asked how many heartbeats they counted, which will be compared to the actual heartbeat measured via electrocardiography (ECG).
75712541|NCT00748800|Behavioral|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
75712542|NCT00856167|Drug|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
75553088|NCT04715828|Other|Long and medium irradiation|sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
75553089|NCT00445614|Behavioral|Effects of trout on CVD risk markers and plasma proteome|
75712543|NCT00856167|Behavioral|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
75553090|NCT00339053|Drug|Immunonutrition ( Impact)|
75553091|NCT00339092|Behavioral|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
75712544|NCT00686634|Drug|Sitagliptin|Sitagliptin 100 mg by mouth once daily
75872101|NCT05075902|Behavioral|Aerobic training|The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
76039934|NCT04919005|Other|Virtual Environment|The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
76039935|NCT04927507|Behavioral|Internet plus nursing home rehabilitation|"The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time."
75553092|NCT00339092|Behavioral|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
75553093|NCT00445731|Behavioral|exercise intervention|
75712545|NCT00856401|Drug|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
75712546|NCT00560404|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
75712547|NCT00560404|Drug|Epoetin alfa|As prescribed
75712548|NCT00751920|Procedure|Enhanced MRI Scan|Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
75712549|NCT00850551|Other|Early Intervention|Twice a week home spirometry and symptom assessment
75712550|NCT00850629|Behavioral|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
75712551|NCT00850629|Behavioral|placebo|no intervention, only follow up
75712552|NCT00951730|Other|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
75712553|NCT02546037|Device|FX100 dialyzer|comparison of dialyzers
75553094|NCT00445731|Procedure|management of therapy complications|
75553095|NCT00445731|Procedure|observation|
75712554|NCT02546037|Device|SOLACEA 21H|comparison of dialyzers
75712555|NCT00942526|Drug|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
75712556|NCT00942526|Other|Water|perioperative gargling with water
75712557|NCT00853281|Other|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
75553096|NCT00420914|Procedure|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
75872102|NCT05075668|Device|CPAP face mask|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
75553097|NCT00420953|Drug|Cordarone|
75553098|NCT00425204|Drug|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
75553099|NCT00425243|Drug|zolpidem-MR (SL800750)|
75553100|NCT00451893|Procedure|Lichtenstein operation with a heavy-weight mesh|Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
75712558|NCT00853281|Other|Standard vector control measures|Insectice-treated net
75712559|NCT04042389|Behavioral|WhatsApp reminder|"The WhatsApp group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
75712560|NCT04042389|Behavioral|Email reminder|"The Email group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
75712561|NCT04042389|Behavioral|Control|No messages sent.
75712562|NCT03967444|Device|Hyaluronic acid|Injectable gel for lip augmentation
75712563|NCT03967444|Device|Hyaluronic acid|Injectable gel. Lip Augmentation and other wrinkles/folds
75712564|NCT00850785|Biological|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
75712565|NCT05300854|Procedure|Standard anesthesia in addition to serratus plane block|a US-guided SPB was performed after induction of general anesthesia with the patient lying supine.
75712566|NCT05300854|Procedure|Standard anesthesia in addition to para-vertebral block|Standard anesthesia in addition to para-vertebral block
75712567|NCT00946504|Drug|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
75553101|NCT00451893|Procedure|Lichtenstein operation with a light-weight mesh|Johnson&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
75712568|NCT00946504|Drug|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
75872103|NCT05075668|Device|High flow nasal cannula (HFNC)|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
75872104|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
75872105|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
75872106|NCT02334046|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
75872107|NCT03486899|Drug|BMS-986036|Specified dose on specified days.
75553102|NCT00425282|Drug|RWJ-333369|
75553103|NCT00339131|Drug|Ultratrace iobenguane I 131|
75553104|NCT00339170|Behavioral|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
75553105|NCT00339170|Behavioral|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
75553106|NCT00451932|Drug|FK778|
75872108|NCT03486899|Other|Placebo|Specified dose on specified days.
75872109|NCT02918552|Drug|sodium nitrite|Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
75553107|NCT00451971|Drug|LEFLUNOMIDE|
75553108|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
75872110|NCT02918552|Drug|Control|Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
76023204|NCT02398591|Drug|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
76023205|NCT02398357|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
75553109|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
75553110|NCT00445926|Device|deep TMS H-coil|
75553111|NCT00339365|Behavioral|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
75553112|NCT00339365|Behavioral|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
75553113|NCT00452049|Procedure|parathyroidectomy|parathyroidectomy
75712569|NCT00619983|Drug|donepezil|Group 1: Will receive donepezil 5mg once a day
75712570|NCT00619983|Drug|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
75712571|NCT00619983|Drug|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
75712572|NCT00619983|Drug|placebo|Group 4: Will receive placebo pills
75407974|NCT06084325|Device|Heartbeat evoked potential (HEP)|The HEP is computed by averaging EEG signals time-locked to specific peaks of simultaneously measured ECG signals. Therefore both an ECG and an EEG will be set up for the participants. The task during the HEP is to simply focus on interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). A further condition of HEP measurement is the cardio-audio synchronization. Hereby, participants will be instructed to passively listen to sounds presented to them via in-ear phones while further fixating the cross.
75407975|NCT06084325|Device|Libet task|Additionally we also link the interoceptive domain of the breath to a well-known and established agency task measuring conscious intention. Participants will do two versions of the Libet taks while simultaneously recording their EEG and breathing signals with a respiratory belt.
75407976|NCT06084299|Biological|Autologous Tumor Infiltrating Lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.
75407977|NCT06084286|Biological|Dual-targeting CLDN18.2 and PD-L1 CAR-T cells|The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
75553114|NCT00452088|Biological|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
75553115|NCT00452088|Biological|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
75553116|NCT00452088|Biological|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
75553117|NCT00452166|Drug|rosiglitazone|
75553118|NCT00446004|Drug|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
75553119|NCT00446004|Drug|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
75553120|NCT00446082|Drug|Pasireotide|
75553121|NCT03275376|Drug|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
75553122|NCT03275376|Drug|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
75712573|NCT00619983|Drug|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
75712574|NCT00946582|Behavioral|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
75712575|NCT00942682|Drug|Sorafenib|Taken orally twice daily
75712576|NCT00942682|Drug|RAD001|Taken orally once daily in the morning
75872111|NCT02330458|Procedure|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall >3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
75872112|NCT05068882|Dietary Supplement|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
75872113|NCT05068882|Dietary Supplement|High-protein nutrition|Oral nutrition with high-protein content
75872114|NCT05068882|Dietary Supplement|Standard nutrition|Oral nutrition with standard ingredients
75872115|NCT02330380|Drug|Methotrexate|"Subjects will receive Methotrexate as detailed in the Group description."
75872116|NCT02330380|Drug|Ustekinumab|"Subjects will receive Ustekinumab as detailed in the Group description."
75872117|NCT02330380|Drug|Etanercept|"Subjects will receive Etanercept as detailed in the Group description."
75872118|NCT02330380|Drug|Adalimumab|"Subjects will receive Adalimumab as detailed in the Group description."
75872119|NCT02330380|Drug|Acitretin|"Subjects will receive Acitretin as detailed in the Group description."
75872120|NCT02330380|Other|UVB Excimer Laser|"Subjects will receive UVB Excimer Laser therapy as detailed in the Group description."
75872121|NCT02330380|Other|Narrowband UVB|"Subjects will receive Narrowband UVB as detailed in the Group description."
75872122|NCT02038348|Device|PET with 18F-FDOPA|
75712577|NCT00853515|Other|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
75712578|NCT00576420|Biological|FS VH S/D 500 s-apr, 60-seconds polymerization time|FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.
75712579|NCT00576420|Biological|FS VH S/D 500 s-apr, 120-seconds polymerization time|Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.
75872123|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
75872124|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
75712580|NCT00576420|Procedure|Manual compression with surgical gauze pads|Treatment of the study suture line with manual compression with surgical gauze pads.
75553123|NCT03275337|Device|Transcranial Direct Current Stimulation|tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
75872125|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
75872126|NCT02333890|Drug|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
75872127|NCT02333890|Drug|Placebo|
75872128|NCT03719963|Device|Cochlear implant|Cochlear implant for hearing process by surgical intervention
75872129|NCT03143686|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
76039936|NCT04937101|Drug|Chlorpheniramine-Codeine|When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
75553124|NCT03275259|Device|THORK Shock Wave® (Extracorporeal shock waves)|Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
75553125|NCT00339872|Drug|IMA-638|
75553126|NCT03275220|Diagnostic Test|2D Echocardiography and 3D Echocardiography|Imaging of right ventricle by 2d echocardiography and 3D echocardiography to assess right ventricular function accurately
75553127|NCT04698447|Dietary Supplement|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS|20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
75712581|NCT00951964|Drug|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
75872130|NCT03485495|Drug|Divaza|Oral administration.
75872131|NCT03485495|Drug|Placebo|Oral administration.
75872132|NCT03652532|Behavioral|Alternate Day Fasting|"During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week."
75712582|NCT00951964|Drug|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
75712583|NCT00942760|Device|3T MRI|The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
75712584|NCT00853983|Drug|[14C] AZD0530|Solution, Oral, once
75712585|NCT02545179|Other|web-based daily care training|12 week interactive web based caring training education
75712586|NCT00749034|Biological|VPM1002|live vaccine
75872133|NCT03652532|Behavioral|Exercise|During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
75872134|NCT02330302|Drug|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
75872135|NCT02330302|Drug|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
75872136|NCT02330224|Other|Hypertension Management Intervention|"The multifaceted intervention consists of three main components:~Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~Telephone based follow-up for all patients by nurses"
75872137|NCT03653624|Other|No intervention|No intervention is involved int his study. Fully anonymised blood pressure data will be collected from the vital signs monitors in the operating room.
76039937|NCT04431505|Other|apoptosis|study of apoptotic changes due to anaesthesia
76039938|NCT04937023|Drug|Ursodeoxycholic acid gel|Following scaling and root planing in intrabony defects UDCA gel will be injected
75553128|NCT04698447|Dietary Supplement|Placebo (without any active ingredients)|20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
75553129|NCT04698447|Dietary Supplement|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS|20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
75407978|NCT06084273|Other|Bobath Exercises|"The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training."
75553130|NCT00340106|Behavioral|Counseling|
75553131|NCT00446238|Behavioral|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
75553132|NCT00446238|Behavioral|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
75553133|NCT00340184|Drug|paclitaxel, carboplatin|
75553134|NCT00446277|Procedure|cataract surgery|
75553135|NCT04698408|Other|high-protein, carbohydrate-reduced diet|the high-protein, carbohydrate-reduced diet will consist of 1.2-1.4 g/kg/d protein, 26-20en% carbohydrates and +/- 50en% fatty acids, with mainly unsaturated fatty acids. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
75553136|NCT04698408|Other|Dutch Nutritional Guidelines|the diet according to the Dutch Nutritional Guidelines will consist of a protein intake of 0.8-1.0 g/kg/d and 50-60en% carbohydrates, and +/-30en% fatty acids, with restriction of saturated fatty acids <10en%. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
75553137|NCT00446316|Drug|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
75553138|NCT00446316|Drug|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
75553139|NCT00446394|Behavioral|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
75553140|NCT00446394|Behavioral|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
75553141|NCT03275181|Diagnostic Test|Transthoracic Echocardiography|Non-invasive assessment of left ventricle structure and function
75553142|NCT03275181|Diagnostic Test|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplethysmography
75553143|NCT03275181|Diagnostic Test|Submaximal Exercise|Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
75553144|NCT00446433|Drug|CC-5013|
76039939|NCT04937179|Procedure|Ischemic Conditioning Low - Sham Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 25mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
75553145|NCT00340574|Drug|AMA1-C1/Alhydrogel + CpG 7909|
76039940|NCT04937179|Procedure|Ischemic Conditioning High - Active Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 225mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
76039941|NCT04936711|Device|Resteck Shiatsu Neck and Back Massager|back massager device sold on the market that can readily be purchased online or in store
76039942|NCT04936711|Drug|Marcaine|Marcaine spray at incision site after closure
75553146|NCT00340613|Drug|glargine insulin|
75553147|NCT03275025|Drug|YRA-1909 low dose|A low dose of YRA-1909; daily oral intake for 12 weeks
75553148|NCT03275025|Drug|YRA-1909 mid dose|A mid dose of YRA-1909; daily oral intake for 12 weeks
75553149|NCT03275025|Drug|YRA-1909 high dose|A high dose of YRA-1909; daily oral intake for 12 weeks
75553150|NCT03275025|Drug|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
75553151|NCT00340691|Drug|Doxycycline|
75553152|NCT00452244|Drug|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
75553153|NCT00452244|Drug|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
75553154|NCT00446472|Drug|Regranex®|Regranex gel will be used for a total of 16 weeks
75553155|NCT00446472|Drug|Hydrogel|Placebo hydrogel will be applied for 16 weeks
75553156|NCT04715711|Other|Forearm coolng|forearm immersion will be performed for active cooling assessment
75553157|NCT04715711|Other|Wet-towel cooling|Wet towels will be wrapped around the participant's arms for active cooling
75553158|NCT04715711|Other|mist-fan|a mist-fan will be placed in front of the participant for active cooling
75712587|NCT00749034|Biological|BCG|commercially available live vaccine BCG
75712588|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
75872138|NCT03143530|Procedure|Pectoralis block|Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
75872139|NCT03143530|Drug|Normal saline injection|Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
75407979|NCT06084273|Other|Breathing Exercises,Breathing Exercises, Bobath Exercises|"The puckered lip breathing exercise aims to prevent the closure of the small airways by creating pressure during expiration. During the exercise, the individual is asked to follow these steps:~Breathe calmly and slowly through the nose.~Pucker the lips as if whistling or inflating a balloon.~Exhale the breath with puckered lips. Relaxation exercises Progressive Muscle Relaxation Technique: Progressive muscle relaxation is one of the easiest methods to learn and apply, developed by Jacobson. It involves voluntarily tensing and relaxing large muscle groups regularly and sequentially. The participant was encouraged to wear comfortable clothing, breathe deeply, and exhale. The technique can be performed in a sitting or lying position. Music can be played to contribute to the participant's relaxation."
75407980|NCT06084221|Behavioral|Data-Driven Decision Making (DDDM)|The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.
75407981|NCT06084221|Behavioral|Overdose-prevention strategies inventory|A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
75407982|NCT06084208|Device|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Cone Beam Computed Tomography (CBCT)
75407983|NCT06084182|Other|Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment|6-minute walk test and 5-time sit-to-stand test (STS-5) were used for functional capacity assessment. For cognitive reserve assessment, the Cognitive Reserve Index questionnaire was used. Reaction time, cognitive function and visiospatial perception were evaluated with the mobile application. In addition, the Fatigue Severity Scale; Beck Depression Questionnaire and Nottingham Health Profile were used.
75407984|NCT06084169|Device|Intra Ocular Lens (IOL) Implant|Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye
75553159|NCT04715711|Other|passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
75553160|NCT00446589|Drug|ibandronate|iv 1mg ibandronate monthly for one year
75872140|NCT03143530|Drug|Ropivacaine Injection|Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
75872141|NCT01065818|Drug|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
76023206|NCT04437641|Other|Tobacco questionnaire|"A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact."
75553161|NCT00446589|Drug|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
75553162|NCT00446628|Behavioral|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
75553163|NCT00452322|Drug|Testosterone Substitution by Testosterone Undecanoate i.m.|
75553164|NCT00452478|Drug|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
75712589|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
75712590|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
75712591|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
75712592|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
75712593|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
75712594|NCT04059510|Procedure|rectovaginal swab|Self taken rectal and vaginal swab
75712595|NCT04059510|Procedure|pregnancy test|Urine pregnancy test
75712596|NCT04059510|Procedure|Menstrual cup|Menstrual cup vaginal fluid collection
75712597|NCT04059510|Procedure|Blood test|Venous blood sample
75712598|NCT04059510|Other|Focus group|Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
75553165|NCT00452517|Procedure|Percutaneous Coronary Intervention|
75553166|NCT00452556|Drug|Docetaxel|Weekly
75712599|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
76023207|NCT02398435|Biological|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients received the study treatment three times a week subcutaneously.
76023208|NCT02398513|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
75407985|NCT06084156|Drug|HSK7653|Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg
75407986|NCT06084156|Drug|Metformin|Part 1: Day 1 to Day 4, 1000mg BID; Part 2: Not take; Part 3: Day 38- day 47, 1000mg BID
75553167|NCT00452556|Drug|Leuprolide Acetate (Eligard®)|2.5 years
75712600|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
75712601|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
75712602|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
75712603|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
75407987|NCT06084130|Drug|Zolpidem|10 milligrams zolpidem contained in white-color opaque medicine capsule
75407988|NCT06084130|Drug|Placebo|corn-starch contained in identical white-color opaque medicine capsule
75407989|NCT06084117|Other|HFNO|Respiratory support with HFNO (as opposed to NIV, as per standard of care)
75407990|NCT06084117|Other|NIV|Respiratory support with Non-invasive ventilation, standard of care
75407991|NCT06084065|Device|CART-I Plus|Photoplethysmography based ring-type blood pressure measurement device
75553168|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
75553169|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
75553170|NCT00446667|Drug|mannitol|400mg BD for 2 days
75553171|NCT03277755|Drug|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
75553172|NCT03277755|Drug|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
75712604|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
76023209|NCT04436939|Device|Dental implant|Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.
76023210|NCT02398279|Dietary Supplement|L-Arginine|Experimental supplement
76023211|NCT02398279|Other|Placebo|Placebo capsules in the same color and shape with the experimental supplement
76023212|NCT04611425|Drug|Remimazolam|Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
76023213|NCT04436471|Biological|Gam-COVID-Vac|adenoviral-based vaccine against SARS-CoV-2
76023214|NCT02398201|Drug|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
75553173|NCT03277755|Drug|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
75553174|NCT03277677|Drug|Normal saline|for resuscitation in sepsis patients
75553175|NCT03277677|Drug|Ringer's Acetate|for resuscitation in sepsis patients
75553176|NCT00452595|Drug|DVS-233 SR (desvenlafaxine sustained release )|
75553177|NCT02956980|Biological|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
75712605|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
76023215|NCT05106179|Drug|Atenolol Pill|Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
76023216|NCT05106179|Drug|Propranolol Pill|Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
75407992|NCT06084052|Device|Path Active|Participant use of Path Active insoles, mobile phone app and clinician's dashboard (where pressure and temperature changes can be reviewed by a clinician). Participants will complete a patient questionnaire relating to use of the device and EuroQol - EQ5D at the beginning and end of the study.
75407993|NCT06083961|Drug|Alirocumab|Initial alirocumab, single dose of 300mg, subcutaneous injection
75407994|NCT06083935|Drug|Daflon|Daflon; two film coated tablets 500 mg daily
75407995|NCT06083935|Drug|Combined oral contraceptive|Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
75407996|NCT06083935|Drug|Metformin|Glucophage ® 500 tablets twice daily
75553178|NCT00341354|Behavioral|Prolonged Mechanical Ventilation|
75407997|NCT06083779|Genetic|low-depth whole-genome sequencing technology|the characteristics of five cfDNA fragments based on low-depth whole-genome sequencing technology (WGS)
75407998|NCT06083740|Device|Granudacyn/Veriforte|Wound irrigation solution for all kinds of wounds (Acute, chronic or contaminated wounds).
75407999|NCT06083727|Other|rate of cesarean section|rate of primary cesarean section in primigravida and multigravida
75408000|NCT06083714|Other|Scapular Stabilization Exercises|Home-based scapular stabilization exercises (Inferior Glide, Low Row, Scapular Clock, Wall Push Up, Wall Slide and Squat Robbery) will be performed once or twice a day, 3 sets x 20 repetitions, 3 days a week for 8 weeks.
75553179|NCT01580436|Procedure|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
75408001|NCT06083714|Other|Schroth Exercises|It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
75553180|NCT02956668|Other|Blindsight Training associated to tDCS|The patient undergo visual rehabilitation while his brain is electrically stimulated with tDCS.
75553181|NCT02956668|Other|Blindsight Training alone|The patient undergo visual rehabilitation
75553182|NCT00341432|Behavioral|Nicotine Replacement Therapy|
75553183|NCT00452634|Drug|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
75712606|NCT00755742|Other|Lifestyle intervention|"The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided."
75712607|NCT00857025|Biological|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
75712608|NCT00857025|Other|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
75553184|NCT00452634|Drug|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
75553185|NCT00452634|Drug|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
75712609|NCT00857025|Other|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
75712610|NCT00857025|Other|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
75712611|NCT00750048|Drug|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
76023217|NCT04480567|Drug|BMN 307|AAV Gene Therapy Infusion
75553186|NCT03277599|Drug|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
75553187|NCT03277599|Drug|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
75553188|NCT03277599|Drug|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
75553189|NCT00341471|Procedure|Risk Behavior Prevention Intervention Program|
75553190|NCT00452712|Procedure|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
75553191|NCT00452751|Procedure|laparoscopy-assisted distal gastrectomy|
75408002|NCT06083701|Drug|Linperlisib in combined with Chidamide|"Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;~Phase 2: dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;"
75408003|NCT06083688|Drug|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).
75408004|NCT06083688|Drug|Chloroquine|"Treatment will be with CQ alone if female and 13 years old or older in all study arms.~Treatment in combination with SP in Arm 2 (females less than 13 years old and all males)."
75408005|NCT06083688|Drug|Sulfadoxine pyrimethamine|"Treatment in combination with CQ in Arm 2 (females less than 13 years old and all males).~Treatment in combination with AQ in Arm 3 (females less than 13 years old and all males)."
75408006|NCT06083688|Drug|Sulfadoxine-pyrimethamine-amodiaquine|Treatment in Arm 3 (females less than 13 years old and all males).
75553192|NCT00452751|Procedure|open distal gastrectomy|
75553193|NCT00452829|Drug|Folic Acid and inositol|Folic Acid and inositol
75553194|NCT00452829|Drug|Folic acid and placebo|Folic acid and placebo
75553195|NCT03277560|Other|No Intervention as it is an observational study|No Intervention as it is an observational study
75553196|NCT03277443|Procedure|Computer guided surgery|Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly
75553197|NCT03277443|Procedure|Conventional model surgery|preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.
75553198|NCT03277443|Device|2D cephalometric radiograph|2D cephalometric radiograph
75553199|NCT03277443|Device|3D computerized tomography|3D computerized tomography
75553200|NCT00452907|Drug|Artesunate|oad, per os, 3 days of treatment
75553201|NCT00452907|Drug|Artesunate + Sulfadoxine-Pyrimethamine|oad, per os
75553202|NCT00452907|Drug|arthemether + lumefantrine|bid, per os. Duration of treatment: 3 days
75712612|NCT00942838|Drug|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
75712613|NCT00942838|Radiation|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
75872142|NCT02333968|Behavioral|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
75872143|NCT03483623|Other|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
75872144|NCT03483623|Other|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
76023218|NCT02406781|Drug|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
75408007|NCT06083636|Other|Single extra blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
75408008|NCT06083636|Other|Single blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
75408009|NCT06083623|Biological|TNM001|single dose intramuscular injection
75408010|NCT06083623|Biological|placebo|single dose intramuscular injection
75553203|NCT00446784|Drug|CE-224,535|
75553204|NCT00446784|Drug|Methotrexate|
75553205|NCT00452985|Drug|Docetaxel|60-75 mg/m²
75553206|NCT00452985|Drug|Carboplatin|AUC 5
75553207|NCT00453024|Procedure|Pericardial graft & tissue glue|
75553208|NCT00453024|Procedure|scleral flap & sutures|
75553209|NCT03277404|Procedure|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
75553210|NCT03277404|Procedure|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
75553211|NCT03277326|Procedure|ISB|ISB block with 0.5% ropivicaine 15mls ( 45mg )
75553212|NCT03277326|Procedure|aSSB|aSSB block with 0.5% ropivicaine 15mls ( 45mg )
75553213|NCT03277326|Procedure|pSSB|pSSB block with 0.5% ropivicaine 15mls ( 45mg )
75712614|NCT04041765|Drug|IgM-enriched IVIG|Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
76039943|NCT04936945|Procedure|Temporomandibular joint arthroscopy plus intra-articular injection|patients with TMJ degenerative joint diseases Wilkes stages IV, V not responding to conservative treatment will undergo operative diagnostic arthroscopic treatment then at the end of the procedure intra-articular injection of platelet rich plasma or hyaluronic acid will be done.
75408011|NCT06083610|Other|miRNA levels analysis from saliva samples|Each participant will be given two 50-mL Falcon tubes and will be asked to expectorate a small amount (about 1 mL) of saliva before and immediately after the end of exercise. Part of each saliva sample will be mixed with an equal volume of denaturing solution included in the mirVanaTM PARISTM kit from Ambion, Foster City, CA, in order to inactivate ribonucleases. Serum samples will be separated by centrifugation at 4000 rpm from the saliva samples taken into the biochemistry tubes of the participants and controls and will be raised to -80 centigrade degrees until the study day. Micro RNA will be isolated from serum samples on the working day. Determination of microRNA expression levels (micro RNA-1 and micro RNA-133a) will be determined by reverse transcriptase polymerase chain reaction (RT-PCR) (Applied Biosystems 7500 Fast Real-Time PCR).
76039944|NCT04936789|Device|IMES|Surgical implantation of IMES
76039945|NCT04936555|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
75408012|NCT06083597|Other|Qualitative interview|Qualitative interviews will be performed on women with chronic pelvic pain of venous origin.
75408013|NCT06083584|Other|RNA sequencing|RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample
75408014|NCT06083545|Behavioral|App|The low-protein diet app introduces the perceived significant efficacy of low-protein diets for patients with chronic kidney disease.
75408015|NCT06083532|Behavioral|PAP induced at an intensity of 70% 1RM combined with complex training|This group of subjects first performed 3 sets of 70% 1RM squats after a routine warm-up, 3 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity & Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity & repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
75712615|NCT00752076|Other|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
75553214|NCT03277287|Radiation|Fractional CO2 laser|Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
76039946|NCT04927273|Other|Survey|Surveyed neurological and orthopedic surgeons
75553215|NCT03277209|Drug|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
75712616|NCT02546271|Behavioral|GPS|
75712617|NCT04057014|Drug|Amoxicillin|Antibiotic given at different dosages and durations.
75712618|NCT04057014|Procedure|Tooth extraction|Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
75712619|NCT00946738|Other|Biofeedback|Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
76039947|NCT03056521|Other|preoperative information about pain|It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
76039948|NCT04431349|Drug|Ticagrelor 180mg|Patient received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
76039949|NCT04431349|Drug|Clopidogrel 75mg|Patient received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
75553216|NCT00342134|Procedure|Stem Cell Transplanataion|
75712620|NCT00946738|Other|Deep oscillation|Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
75712621|NCT00857103|Behavioral|CHOICE|Use of Choice support system as preparation for patient consultations
76039950|NCT03056677|Dietary Supplement|Control|200mls water will be given prior to a mixed carbohydrate meal
76039951|NCT03056677|Dietary Supplement|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
76039952|NCT03056677|Dietary Supplement|Modified whey protein|Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
76039953|NCT04431583|Procedure|Bariatric surgery- single surgeon service|
75408016|NCT06083532|Behavioral|PAP induced at an intensity of 80% 1RM combined with complex training|This group of subjects first performed 3 sets of 80% 1RM squats after a routine warm-up, 2 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity & Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity & repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
75408017|NCT06083532|Behavioral|PAP induced at an intensity of 90% 1RM combined with complex training|This group of subjects first performed 3 sets of 90% 1RM squats after a routine warm-up, 1 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity & Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity & repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
75553217|NCT00453141|Drug|dosing of Betamethasone|
75553218|NCT03277092|Device|VeinViewer®|Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
75553219|NCT03277092|Procedure|Usual care|The blood drawing is performed traditionally
75553220|NCT00453219|Procedure|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
75712622|NCT00364351|Drug|Vandetanib|once daily oral tablet
75712623|NCT00364351|Drug|Erlotinib|oral dose
75553221|NCT00453219|Procedure|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
75553222|NCT00453219|Genetic|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
75712624|NCT00854139|Drug|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
75712625|NCT00854139|Procedure|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
75712626|NCT00854139|Radiation|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
75872145|NCT03483623|Other|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
76039954|NCT04431583|Procedure|Bariatric surgery- multiple surgeon + multidisciplinary team approach|
76039955|NCT04431583|Procedure|Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach|
76039956|NCT04431115|Other|Interviews|Interviews for stakeholders
76039957|NCT03055741|Drug|Donepezil|5mg or 10mg, once a day, 24 weeks
76039958|NCT03055741|Drug|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
76039959|NCT03055741|Drug|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
76039960|NCT04926883|Other|bulk-fill composite resin restorations|bulk-fill composite resin restorations up to 5mm layer thickness
76039961|NCT04414657|Other|blood sampling for biobank|blood sampling for biobank
75553223|NCT00453219|Procedure|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
75712627|NCT00854139|Procedure|Bone marrow transplant from a related donor|• Donor bone marrow (> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is > 60 seconds, the protamine treatment shall be repeated
75712628|NCT00755820|Behavioral|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
75712629|NCT00755820|Behavioral|Exposure Therapy + Placebo|Exposure therapy with placebo medication
75712630|NCT00755820|Behavioral|Supportive Psychotherapy|Supportive psychotherapy
75712631|NCT00952042|Other|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
75712632|NCT00952042|Other|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
75712633|NCT00854217|Procedure|acute normovolemic hemodilution|
75712634|NCT00943228|Drug|mycophenolate mofetil|High dose 4gms daily
75872146|NCT03483623|Other|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
75408018|NCT06083532|Behavioral|Routine warm-up combined with complex training|This group of subjects first completed a 30-minute routine warm-up, then rested for 6 minutes, and then performed complex training consisted of maximum strength training (back squats) and plyometric training (drop jump). Back squat intensity & repetition is 80% 1RM × 4, 4 sets, with an interval of 2 minutes; after resting for 3 minutes, perform a drop jump, Intensity & Repetition is 50cm (height) × 10, 4 sets, with an interval of 2 minutes. Intervention training was conducted twice weekly for 12 weeks, and the intensity was gradually increasing over the 12 weeks.
75408019|NCT06083441|Diagnostic Test|SeeMe|"A video-recorded SeeMe command following assessment by a trained professional once a day Each session involves three command sets that are played from an audio recording 10 times over the course of 8 minutes. These commands are Stick out your tongue, Open your eyes, and Show me a smile Each command set is recorded separately for a total of 3 videos per session. These videos are then analyzed by SeeMe to detect if subjects are responding to commands."
75553224|NCT00453219|Procedure|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
75553225|NCT00421031|Drug|DVS-233 SR|
75553226|NCT03277053|Device|Mobile application|A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
75553227|NCT03277053|Other|Control.|Patient receive an ipad with no application.
75712635|NCT00850941|Behavioral|Questionnaire|Information collection.
75712636|NCT00952198|Drug|ARRY-403, glucokinase activator; oral|multiple dose, escalating
75712637|NCT00952198|Drug|Placebo; oral|matching placebo
75712638|NCT00750126|Drug|Fludarabine, Busulfan, Thymoglobulin|"study :~acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~the effectiveness of the protocol on tumor response~overall survival"
75712639|NCT00851019|Behavioral|DDR|"Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period"
75712640|NCT00851019|Behavioral|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
75712641|NCT00946816|Behavioral|Nutritional Intervention|Nutritional Intervention
75712642|NCT00755976|Drug|epirubicin hydrochloride|
75712643|NCT00755976|Drug|sulindac|
75712644|NCT00755976|Other|immunologic technique|
75712645|NCT04012060|Procedure|Limited access aortic valve replacement.|Limited access aortic valve replacement through partial upper hemisternotomy
75712646|NCT04012060|Procedure|Conventional aortic valve replacement|Aortic valve replacement through full median sternotomy
75712647|NCT00752310|Drug|Darunavir|
75872147|NCT02329990|Dietary Supplement|phosphorus|phosphorus supplement
75872148|NCT03653468|Behavioral|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
75408020|NCT06083441|Diagnostic Test|Coma Recovery Scale-Revised (CRS-R)|A video-recorded CRS-R score assessment by a trained professional once a day. A score of 10 or greater, an auditory score >2, or an arousal score > 0 means that a subject is responding to commands
75553228|NCT00421070|Procedure|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
75553229|NCT03274908|Other|regular medical treatment|regular medical treatment
75408021|NCT06083415|Other|Environmental health measures|MRI will be used to confirm the presence of breast buds, to measure the size of the ovaries and uterus, as well as the fraction of fat mass (abdominal, subcutaneous, liver and bone marrow). The bood and urine tests will allow to measure different biological and metabolic parameters. The presence of endocrine disruptors will be determined in the hair. The bone age x ray will be estimate the maturity of the child's skeletal system.
75408022|NCT06083402|Dietary Supplement|HyaCera™|1 Ritual HyaCera capsule once daily
75408023|NCT06083402|Dietary Supplement|Placebo|1 placebo capsule once daily
75408024|NCT06083389|Behavioral|kabat technique for rehabilitation of facial palsy|To evaluate the comparative effectiveness of the Kabat rehabilitation technique with conventional physical therapy along with electrical stimulation in both, for reducing facial disability in patients with Bell's palsy.
75408025|NCT06083389|Device|electrotherapy|electrical stimulation of facial nerve supplied muscles.3 sessions per week.
75408026|NCT06083350|Dietary Supplement|Yeast beta-glucan|Produced by Angel Yeast Co., LTD
75408027|NCT06083350|Dietary Supplement|Starch|Produced by Angel Yeast Co., LTD
75408028|NCT06083337|Device|CaRi-Heart device|Open-label treatment with atorvastatin +/- low-dose colchicine medications based on CaRi-Heart algorithm management.
75712648|NCT00943462|Radiation|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2-Gy fractions, for a total of 30 fractions
76039962|NCT04936087|Other|The World Health Organization 8 steps for manual wheelchair service delivery|"All study participants were provided with a new wheelchair, a wheelchair cushion, and wheelchair services, delivered by trained wheelchair service providers, according to the WHO 8-step wheelchair service delivery process including assessment, fitting, and a 30-minute individual or group training on 7 wheelchair skills, device care, and pressure injury prevention techniques. Additionally, wheelchair maintenance reminders were sent through a text message service (SMS) to a sub-cohort of participants.~Wheelchair users were provided with one of three different, International Standards Organization (ISO) tested, wheelchair models according to the users' needs and availability: standard, active, and all-terrain models. All wheelchairs were provided with a basic contour cushion made of polyurethane foam. However, whenever a risk of pressure injury was identified for a study participant, wheelchair providers fabricated a pressure-relief cushion."
75408029|NCT06083324|Other|Dose esclated resistance training|All individuals will be engaging in resistance training during and/or after their cancer treatment
76039963|NCT04936165|Procedure|Low-Level Laser Therapy|Use 810-nm-photosource to irradiate the participants' brain and forearm for 10 minutes with a water-cooling radiator to keep it at 25 ± 0.5 ℃.
76039964|NCT04926727|Other|Survey|Observational study
75408030|NCT06083311|Dietary Supplement|Probiotic|Participants in this arm will receive a daily dose of 3x10^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
75408031|NCT06083311|Dietary Supplement|Placebo|Participants in this arm will receive an equivalent placebo for 28 days
75408032|NCT06082817|Drug|Oral Testosterone Undecanoate|50mg oral testosterone undecanoate daily
76039965|NCT04927039|Drug|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
75408033|NCT06082726|Dietary Supplement|SCFA|Participants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours.
75408034|NCT06082232|Drug|Dexmedetomidine|Under strict aseptic conditions, a lumbar puncture will be performed with selective technique in sitting position at L2-3 or L3-4 interspaces with midline approach using a 25-G Quincke's needle. After achieving the free flow of cerebrospinal fluid, the study drug will be injected into the subarachnoid space, immediately after injection the patient will be asked for supine position.
75553230|NCT00421109|Drug|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
75553231|NCT00421109|Drug|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
75553232|NCT00421109|Drug|Placebo|Encapsulated tablet. Once daily for 28 days
75553233|NCT00446823|Device|XCell cellulose wound dressing|
75553234|NCT00446823|Device|Impregnated gauze dressing|
75553235|NCT02273583|Drug|continuous oral cyclophosphamide and methotrexate|
75553236|NCT00446862|Drug|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
75553237|NCT00453258|Other|Eye Examination|Subjects receiving eye examination
76039966|NCT04927039|Drug|20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline|After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
75712649|NCT00943462|Drug|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
75712650|NCT02560974|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
75712651|NCT02560974|Drug|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m^2 on Day 1 of each 3-week cycle for 8 cycles.
76039967|NCT04926493|Biological|microbiological characterization|microbiological characterization of endotracheal tube biofilm
76039968|NCT04918303|Device|SKNA recording|"The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.~It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6"
75712652|NCT00946894|Procedure|Total thyroidectomy|Total thyroidectomy
76039969|NCT03055585|Biological|Wolbachia-infected Aedes aegypti mosquitoes|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
76039970|NCT03055585|Other|standard practice dengue control|standard practice dengue control activities conducted by dengue control program
75553238|NCT00342368|Procedure|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
75712653|NCT00946894|Procedure|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
76039971|NCT04926649|Procedure|Differential ventilation to the non-dependent lung|When the hypoxemia occurs during sing lung ventilation in robot-assisted cardiac surgery, the non-dependent lung will be ventilated with normal tidal volume in conventional ways and the surgery procedure have to be ceased. In this trial, the non-dependent lung will be ventilated with the continuous positive airway pressure (CPAP) or the high-frequency low-volume ventilation (HFLVV) to prevent the hypoxemia.
75408035|NCT06082232|Drug|Midazolam|1 mg midazolam intrathecal administration
75408036|NCT06082232|Drug|Bupivacain|20 mg bupivacaine intrathecal administration
75408037|NCT06082206|Procedure|thoracic paravertebral block (TPVB)|Bupivacaine 0.25% 20 ml was injected between the costotransverse ligament and the parietal pleura.
75408038|NCT06082206|Procedure|PECS group|entering the plane between the pectoralis minor muscle and serratus anterior muscle, and bupivacaine 0.25% 10 ml was deposited in this space
75408039|NCT06081231|Device|AndroidAPS-rt-CGM;|a real-time continuous glucose monitoring, an insulin pump, and an intelligent algorithm.
75408040|NCT06080958|Device|NPWT|the NPWT dressing applied to fasciocutaneous flap
75553239|NCT00446901|Dietary Supplement|Selenium|Selenized yeast, 300 ug/day
75712654|NCT00946894|Procedure|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
75408041|NCT06080958|Other|Conventional dressing|Conventional dressing ( topical care ) applied to fasciocutaneous flap
75553240|NCT00453297|Drug|MF101|
75553241|NCT00453375|Drug|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
75712655|NCT00854451|Drug|omeprazole plus amoxicillin|
75712656|NCT00854451|Drug|omeprazole plus amoxicillin|
75712657|NCT00854451|Drug|omeprazole plus amoxicillin|
75712658|NCT00854451|Drug|omeprazole plus amoxicillin|
75712659|NCT00946972|Drug|JNJ-38431055; Placebo|
75712660|NCT00854529|Drug|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
75712661|NCT00947050|Other|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
75553242|NCT00453375|Drug|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
75553243|NCT00446940|Drug|rosuvastatin|
75553244|NCT00446940|Drug|atorvastatin|
75553245|NCT00453414|Drug|Iloprost Inhalation Solution (Ventavis)|
75553246|NCT00342836|Procedure|Akt levels|
75553247|NCT00446979|Drug|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
75553248|NCT00446979|Drug|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
75553249|NCT00453453|Drug|Nesiritide|Nesiritide given orally in the emergency department
75712662|NCT00861237|Drug|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
75712663|NCT00861237|Drug|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
75872149|NCT03143608|Device|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
75872150|NCT03652844|Procedure|AAM|Subcutaneous injection procedure
75872151|NCT03697408|Drug|Itacitinib|A JAK 1 selective small molecule inhibitor
75872152|NCT03697408|Drug|Everolimus|A mammalian target of rapamycin (mTOR) inhibitor
75553250|NCT00447018|Drug|20% mannitol|
75553251|NCT00447018|Drug|7.45% hypertonic saline solution|
75408042|NCT06079385|Other|Acupuncture treatment|Acupuncture treatment with needles
75408043|NCT06078293|Behavioral|Home-based Exercise Program|12-week home-based exercise program that involves individualized exercise prescription and motivational health coaching calls.
75408044|NCT06077214|Drug|Treatment with liposomal bupivacaine|Patients will randomly be treated with either liposomal bupivacaine (study drug) after undergoing bariatric surgery.
75408045|NCT06077214|Drug|Treatment with standard bupivacaine|Patients will randomly be treated with standard bupivacaine after undergoing bariatric surgery.
75408046|NCT06077032|Drug|garlic extract (15%) solution|•Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
75408047|NCT06077032|Drug|topical chlorhexidine (2%) solution|•Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
75408048|NCT06077032|Drug|Saline|•Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
75408049|NCT06076798|Device|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
75408050|NCT06075654|Other|no intervention it is considered (Epidemiological Study)|It was a survey used Visual Analog Scale and WaLIDD scale to measure the severity of primary dysmenorrhea between both groups
75408051|NCT06074302|Device|RHA Redensity|RHA Redensity will be injected in a microdroplet technique to bilateral cheeks.
75712664|NCT02544867|Behavioral|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
75712665|NCT00952432|Drug|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
75712666|NCT00952432|Procedure|Acupuncture|Acupuncture
76039972|NCT03055351|Behavioral|Stop&Go Intervention|Stop&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
75408052|NCT06073158|Procedure|Esophageal biopsy collection during anastomosis|During the anastomosis, the surgeon will collect an esophageal mucosa biopsy
75712667|NCT00861315|Drug|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
75408053|NCT06071247|Other|3D printed models|3D printed simulation models of the stomach, duodenum, common bile duct, and pancreatic duct structures using a combination of soft and hard materials
75408054|NCT06058572|Drug|Rifaximin with allogeneic stem cell transplant|Tab Rifaximin 200 mg will begiven orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care posttransplant treatment
75408055|NCT06058572|Procedure|Allogeneic stem cell transplant|Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.
75408056|NCT06058260|Other|Pediatric Quality of Life Inventory (questionnaire) and The Stanford-Binet Intelligence Scale fifth edition|Quality of Life Assessment By Pediatric Quality of life Inventory. Cognitive Function Assessment By The Stanford-Binet Intelligence Scale fifth edition.
75408057|NCT06058221|Device|simultaneous videolaryngoscopy|Two specialists perform tracheal intubation, one using a video laryngoscope to expose the vocal cords and the other using a fiberoptic bronchoscope.
75408058|NCT06058221|Device|supraglottic airway|After inserting the supraglottic airway, the specialist performs intubation using a fiberoptic bronchoscope through the supraglottic airway.
75553252|NCT05649033|Other|data collection|Work-related stress evaluation
75553253|NCT00343070|Drug|Oral administration of escitalopram during 8 weeks|
75553254|NCT00453492|Drug|risedronate sodium|
75553255|NCT00447096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS).
75712668|NCT00861315|Drug|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
75408059|NCT06042933|Other|Post operative early oral feeding|To start oral feeding 6 hours after perforated peptic ulcer repairs
75408060|NCT06042933|Other|Traditional delayed oral Feeding Post-perforated Peptic Ulcer Repairs|To start oral feeding after 48 hours
75408061|NCT06034353|Behavioral|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
75408062|NCT06028984|Device|Intervention app|An app-based intervention for depression
75712669|NCT00861315|Drug|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
75712670|NCT00861315|Drug|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
75712671|NCT00388297|Drug|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
75712672|NCT00388297|Drug|Placebo for Levothyroxine|
76039973|NCT02443155|Drug|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
76039974|NCT02443155|Drug|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
75408063|NCT06028984|Other|Control app|An app with non-therapeutic content
75408064|NCT05992181|Other|NEORTHO|early orofacial stimulation
75408065|NCT05985954|Drug|Cetuximab|Given by IV (vein)
75408066|NCT05985954|Drug|Ulixertinib|Given by PO
75408067|NCT05985954|Drug|Encorafenib|Given by PO
75408068|NCT05980169|Device|SensoniQ Treatment Station|The SensoniQ® Treatment Station is a chemotherapy chair with multiple transducers that release low- frequency sound waves to different points on the body in a preset frequency, distribution and time during a chemotherapy infusion.
75408069|NCT05978362|Procedure|Latarjet technique|Realization of a stop according to Latarjet
75553256|NCT00343148|Drug|AVI-4126 Injection (RESTEN-NG®)|
75553257|NCT00343187|Drug|ACZONE (dapsone) Gel, 5%|
75553258|NCT00343187|Drug|Vehicle Control|
75712673|NCT00943540|Drug|raltegravir QD|Raltegravir 800mg QD
75712674|NCT00943540|Drug|atazanavir|atazanavir
75712675|NCT00943540|Drug|lamivudine (or emtricitabine)|lamivudine (or emtricitabine)
75872153|NCT03653312|Device|NMES|Neuromuscular electrical stimulation of the paretic lower limb during exercise
76039975|NCT02443155|Drug|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
76039976|NCT03055117|Behavioral|Group-based exercise rehabilitation|Group- based physiotherapy-led exercise rehabilitation
75712676|NCT00861393|Behavioral|CBT|12 Session CBT group
75712677|NCT00861393|Behavioral|Waitlist CBT|Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
75408070|NCT05958888|Behavioral|Text only sodium label|"Warning: High in sodium. is shown in a black square label on the can of soup."
75408071|NCT05958888|Behavioral|Icon sodium label|"Warning: High in sodium. is shown beneath a yellow triangle icon with an exclamation mark all in a black square label on the can of soup."
75553259|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
75553260|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
76039977|NCT03055117|Behavioral|Individual exercise rehabilitation|Individual physiotherapy-led exercise rehabilitation
75553261|NCT00453570|Biological|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
76039978|NCT03055117|Behavioral|Home exercise|Supervised home exercise
76039979|NCT04935541|Drug|Dexmedetomidine infusion|After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
75553262|NCT00343226|Drug|Basiliximab|
75553263|NCT00447174|Behavioral|Dyadic treatment for parental bereavement|
75553264|NCT00343265|Drug|Vaginal progesterone gel|Vaginal gel once daily
76039980|NCT04935541|Drug|Remifentanil infusion|After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
76039981|NCT04925791|Diagnostic Test|standardized pre-conditioning treatment|3 rounds of 5 minutes of full occlusion alternating with 5 minutes of reperfusion while seated.
76039982|NCT04925791|Diagnostic Test|Partial occlusion|3 rounds of 5 minutes of partial occlusion alternating with 5 minutes of reperfusion while seated.
76039983|NCT04935151|Procedure|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser
76039984|NCT04935151|Procedure|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
76039985|NCT04935073|Drug|Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang|The medicines used in this study including Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 15 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 10 g, Ligusticum wallichii 6 g, Poria cocos 15g, Polygonatum 15g, eclipta 10g. which will be taken for 10-15days.After the ET, the treatment group will continue to take Chinese herbal medicine, changing to Shou Tai pills ( Morinda officinalis 15 g, Teasel 15g，Cuscutae 20 g, Eucommia ulmoides 15 g, Rehmannia 15 g, Cornus officinalis 15 g, loranthus parasiticus 20 g, Ligustrum lucidum 15g, Salvia miltiorrhiza 10g, Scutellaria baicalensis 10g, Atractylodes macrocephala 15g); which will be taken for 14days. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening.
76039986|NCT04935073|Drug|Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for Injection|The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET.
76039987|NCT04934761|Procedure|Fluid challenge strategy|Patients received 2ml/kg of succinylateol gelatin within 10 min for fluid shock therapy after grouping, taking SVV as the management target. If SVV< 13% after shock therapy, the shock therapy was stopped and the infusion was maintained with 4ml/kg/h of crystal solution. If SVV ≥ 13% and ΔSV <10%, the individual would be excluded from the experiment. If SVV ≥ 13% but ΔSV≥10%, 2ml/kg of succinylateol gelatin was given again within 10 min for liquid shock therapy until SVV<13%, and 4ml/kg/h of crystal solution was maintained after reaching the target. If SVV≥ 13% after two shock treatments, they were excluded from the experiment. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
76039988|NCT04934761|Procedure|conventional strategy|4ml/kg/h of crystal solution was maintained. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
76039989|NCT04934605|Procedure|Cochlear implantation|Cochlear implantation
76039990|NCT04934059|Drug|Yuxuebi tablet|0.5g/ tablet
75408072|NCT05958888|Behavioral|Pictorial sodium label|"Warning: High in sodium. is shown beneath an image of a spilled salt shaker, all in a black square label on the can of soup."
75408073|NCT05958888|Behavioral|Barcode label|Barcode is shown in white square label on the can of soup
75553265|NCT00343265|Drug|Placebo gel|once daily
75553266|NCT00453609|Drug|long-lasting injectable naltrexone|
76039991|NCT04934059|Drug|Placebo tablet|0.5g/ tablet
76039992|NCT04917835|Device|PLADUO(PX1000)|Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
75553267|NCT00343304|Device|Robot|
75553268|NCT00343304|Device|Ergometer|
75553269|NCT00447213|Drug|Insulin glargine|Patient specific, injected, daily, 24 weeks
75553270|NCT00447213|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
75553271|NCT00447213|Drug|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
75553272|NCT00343343|Device|NovoFine® needle 6 mm|
75553273|NCT00343343|Device|NovoFine® needle 4 mm|
75553274|NCT00453648|Other|White-fleshed sweet potatoes|
75553275|NCT00453648|Other|Orange-fleshed sweet potatoes (boiled)|
75553276|NCT00453648|Other|Orange-fleshed sweet potatoes (fried)|
75553277|NCT00453648|Other|WFSP and capsule of retinyl palmitate|
75553278|NCT00343421|Biological|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
75553279|NCT00343421|Biological|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
75553280|NCT00343499|Drug|valsartan|
75408074|NCT05955937|Other|Enhanced HF Clinical Care (Core-HF)|All clinical care providers involved in HF care at participating RRHs will be trained in a HF service bundle including a care protocol (treatment algorithm based on global guidelines), self-care training for patients and providers, and medication stock management to ensure supply of HF medications to patients in need.
76039993|NCT04917991|Dietary Supplement|Extra Virgin Olive Oil-enriched chocolate spread|the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.
76039994|NCT04917991|Dietary Supplement|Palm Oil-enriched chocolate spread|the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
76039995|NCT04917757|Diagnostic Test|1mg Dexamethasone test|For each patient a 1mg dexamethasone test has been performed.
76039996|NCT04917289|Drug|Chemotherapy|Started chemotherapy or change the current adjuvant therapy
75408075|NCT05955937|Other|Digital health intervention (Medly Uganda) plus enhanced HF clinical care (Core-HF)|A patient-facing mobile health application designed to improve self-care will be provided to the study participant, which will operate on all mobile devices. This will be introduced after the Core-HF intervention has been delivered.
75553281|NCT00453687|Drug|GSK233705|investigational drug
75553282|NCT00447291|Drug|Supplement: Omega-3 Fish Oil|
75553283|NCT00447291|Behavioral|Multi-Disciplinary Nutrition & Exercise program|
75712678|NCT00943696|Dietary Supplement|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
75712679|NCT00854685|Drug|ART621|3.0mg/kg s.c. - weekly
76039997|NCT04917913|Dietary Supplement|Digestive enzyme blend|Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.
76039998|NCT04917913|Dietary Supplement|Placebo|Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
76039999|NCT04925869|Other|Observational study|Observational study
75553284|NCT04715360|Combination Product|autologous activated platelet-rich plasma|Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
75553285|NCT04715360|Drug|Avigan|Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
75408076|NCT05954702|Procedure|Supercharged TRAM esophagectomy|Esophagectomy, immediately followed by supercharged esophagogastroplasty. Use the transverse rectus abdominis myocutaneous (TRAM) flap transfers to surgically create a new anastomosis in the left gastroepiploic vessels.
75408077|NCT05954702|Procedure|Conventional Esophagectomy|Esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
75408078|NCT05952258|Device|Magnetic stimulation|The magnetic stimulation to the pelvic floor muscle will be provided by the Emsella® chair: which will be activated for 28 minutes at each treatment session. The treatment arm will receive up to 100% intensity at each treatment session.
75553286|NCT00447369|Drug|Pregabalin|
75553287|NCT00447369|Drug|sodium valproate|
75553288|NCT00343616|Procedure|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
75553289|NCT00343616|Procedure|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
75553290|NCT00343616|Procedure|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
75553291|NCT00343616|Procedure|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
75553292|NCT00453726|Procedure|Non invasive mechanical ventilation|
75553293|NCT00343655|Drug|Atorvastatin|
76040000|NCT04925635|Behavioral|experimental group|"The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group. Arteriovenous fistula care mobile health application will be installed in daytime groups during working hours during or at the end of dialysis according to the patient's request. In addition, the information contained in the arteriovenous care mobile health application will be verbally explained to the patients and their relatives, as well as shown in practice. The training results were evaluated by the researcher in the 1st and 3rd months in the Scale for Evaluation of Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients, Final Level of Renal Failure Compliance Scale, Arteriovenous Fistula Care Education Knowledge Level Evaluation Form (Post-Training Section) and  Visual Benchmarking Scale ."
75712680|NCT00854685|Drug|ART621|3.0mg/kg s.c. - fortnightly
76040001|NCT04925635|Behavioral|control group|"Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given. The information contained in the booklet will be explained orally to the patients and their relatives by the researcher, and will also be shown in practice. The results of the training were determined by the researcher at the 1st and 3rd months of the Self-Care Behaviors Scale for Arteriovenous Fistula in Hemodialysis Patients, End Stage Renal Failure Compliance Scale, Arteriovenous Fistula Care Training Information Level Assessment Form (Post-training section) and Visual It will be evaluated with the Comparison Scale."
76040002|NCT03055273|Behavioral|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
76040003|NCT04916899|Drug|Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
76040004|NCT04933981|Diagnostic Test|Nasopharyngeal swab for SARS-CoV-2|in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
76040005|NCT04925245|Other|Clinical Reminder|Clinical reminder in the electronic medical record
75408079|NCT05952258|Device|Sham Magnetic stimulation|The sham arm will receive up to 5% intensity at each treatment session
75408080|NCT05942521|Behavioral|Very brief extinction|"The very brief extinction presents a very short (33ms) repetitive sequence of alcohol cues, followed by a masking stimulus(117ms), which masks the alcohol cues. In the case of repeated exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
75408081|NCT05942521|Behavioral|Clearly visible extinction|"The clearly visible extinction presents a repetitive sequence of alcohol cues(150ms) without a masking stimulus. In the case of repeat exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of conscious processing."
75408082|NCT05942521|Behavioral|Very brief neutral extinction|"The very brief neutral extinction presents a very short (33ms) repetitive sequence of neutral cues, followed by a masking stimulus(117ms), which masks the neutral cues. In the case of repeated exposure to neutral stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
75408083|NCT05942352|Drug|Ligustrazine by intravenously administration|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days
75408084|NCT05942352|Drug|Ligustrazine by mouth|50 mg Ligustrazine tablet by mouth would be maintained for 1 year
75408085|NCT05942352|Drug|Placebo by intravenously administration|Intravenous administration of 250ml saline per day for 15 days
75408086|NCT05942352|Drug|Placebo by mouth|50 mg placebo tablet by mouth would be maintained for 1 year
75408087|NCT05936489|Drug|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
76040006|NCT04933357|Radiation|Dose escalation|Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost
75408088|NCT05936489|Drug|Aceclidine|LNZ100 (Aceclidine) non-preserved ophthalmic solution
75712681|NCT00854685|Drug|ART621|1.5mg/kg s.c. - weekly
75712682|NCT00854685|Drug|ART621|1.5mg/kg s.c. - fortnightly
75712683|NCT00854685|Drug|Placebo|Placebo s.c. - weekly
75712684|NCT00854685|Drug|Placebo|Placebo s.c. - fortnightly
75712685|NCT01864720|Behavioral|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
75408089|NCT05934903|Device|Transcranial Direct Current Stimulation|Cathodal direct current stimulation at 0 or 2mA will be applied to subjects
75408090|NCT05932745|Other|E-liquid coolant (no WS-3) (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
76040007|NCT04933357|Radiation|Standard dose|Standard dose to good responders to achieve dose equivalent of 70 Gy.
75872154|NCT03143764|Behavioral|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
75872155|NCT03622034|Other|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
75408091|NCT05932745|Other|E-liquid coolant (Low WS-3) (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
75408092|NCT05932745|Other|E-liquid coolant (High WS-3) (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
76040008|NCT04916821|Dietary Supplement|propolis|Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules
75553294|NCT00453765|Drug|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
75553295|NCT00453765|Drug|placebo|placebo
75553296|NCT00343733|Drug|OraVescent Fentanyl|
76040009|NCT04916665|Drug|Teduglutide|bridging intestinal failure with teduglutide until reconstruction
75408093|NCT05932745|Other|E-liquid coolant (no WS-3) (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
75553297|NCT00447408|Behavioral|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
75553298|NCT00447408|Behavioral|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
75553299|NCT00343811|Drug|Modafinil|
75553300|NCT00453804|Drug|injectable naltrexone|
75553301|NCT00453804|Drug|oral naltrexone|
75553302|NCT00343850|Drug|Asacol (mesalamine)|
76040010|NCT04933201|Other|Music|Perioperative musical intervention
76040011|NCT04933201|Other|Routine perioperative treatment|Routine perioperative treatment
76040012|NCT04925323|Biological|BLOOD SAMPLES|BLOOD SAMPLES
75408094|NCT05932745|Other|E-liquid coolant (Low WS-3) (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
75408095|NCT05932745|Other|E-liquid coolant (High WS-3) (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
75553303|NCT00447486|Drug|GW842166|
75553304|NCT00343928|Other|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
76040013|NCT04925323|Biological|surgical tissue samples|unused surgical tissue removed during plastic surgeries
76040014|NCT02460159|Drug|EZ 10 mg/Atorva 20 mg FDC|
75408096|NCT05932745|Other|E-liquid coolant (no WS-3) (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
76040015|NCT02460159|Drug|EZ 10 mg/Atorva 10 mg FDC|
76040016|NCT04925011|Drug|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
76040017|NCT04924855|Other|Blood sampling (4 per year)|Blood sampling (4 per year)
76040018|NCT04913155|Radiation|Low-dose CT screening|Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
76040019|NCT02498067|Behavioral|rPlan dual protection waiting room app intervention|
76040020|NCT04916353|Drug|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain
76040021|NCT04916353|Drug|Triamcinolone Acetonide.|Triamcinolone Acetonide 40mg/1ml injection
76040022|NCT02497755|Behavioral|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
76040023|NCT02497755|Device|smartphone|
75553305|NCT00453843|Device|rehabilitation robotics|sequence of intervention
75553306|NCT00453843|Procedure|Movement therapy|sequence of intervention
75553307|NCT00447525|Biological|REVAXIS®|
75553308|NCT00447525|Biological|DT-Polio®|
75553309|NCT00344006|Drug|chlorproguanil-dapsone-artesunate|
75553310|NCT00344006|Drug|artemether-lumefantrine|
76040024|NCT03056599|Drug|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
76040025|NCT03056599|Device|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
76040026|NCT04924465|Other|Follow-up|Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
76040027|NCT04916275|Other|Cognitive tests|Optional tests: Corsi block-tapping task, Stroop test and Iowa gambling task
76040028|NCT02619175|Device|Stroke Subjects Perturbation-Based Balance Training|
76040029|NCT02619175|Device|Stroke Subjects Weight Shifting and Gait training|
76040030|NCT04924231|Behavioral|astigmatism|astigamatism at least 1 month after the cataract surgery
76040031|NCT03056443|Device|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
76040032|NCT04915885|Other|Routine care|Routine contraceptive counseling and routine method availability
75408097|NCT05932745|Other|E-liquid coolant (Low WS-3) (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
75408098|NCT05932745|Other|E-liquid coolant (High WS-3) (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
75408099|NCT05932732|Device|HydraFacial Syndeo System|Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.
75408100|NCT05932732|Drug|ReGen-GF|The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
75408101|NCT05932732|Device|HydraFacial Elite MD System|Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.
75408102|NCT05913050|Other|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
76040033|NCT04915885|Other|Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
75408103|NCT05913050|Other|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
75553311|NCT02273661|Drug|Liposomal amphotericin B (Ambisome®)|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
76040034|NCT04915885|Other|Expanded methods|Expanded range of contraceptive methods as recommended by national policies
76040035|NCT04915963|Dietary Supplement|Vitamin D supplementation|Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
76040036|NCT04915807|Drug|Ramucirumab and paclitaxel|Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started
76040037|NCT04915807|Drug|Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy|Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy
76040038|NCT04915651|Device|Gallbladder Cryoablation|Percutaneous cryoablation of the gallbladder.
75553312|NCT02273661|Drug|placebo|An aerosol of isotonic saline x 1/ week will be administered during 6 months
76040039|NCT01360021|Drug|Symbicort|Breath actuated metered dose inhaler
76040040|NCT01360021|Drug|Symbicort|Actuation counter pressured metered dose inhaler
76040041|NCT01360021|Drug|Budesonide|Actuation counter pressured metered dose inhaler
76040042|NCT04924309|Other|Exposure: donor sperm|One group use donor sperm through the process of assisted reproduction and the other uses husband's semen.
76040043|NCT04915573|Diagnostic Test|Specimen|Sputum will be collected in clean disposable containers
75408104|NCT05902325|Drug|Mepolizumab 100 MG Injection|Patients will receive Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections, no placebo) at the hospital. The IMP will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction. Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas) or the upper arms. Background therapy will be assured with mometasone furoate nasal spray (200µg BID) daily throughout the study.
75408105|NCT05901883|Drug|CEL383|Subjects will receive CEL383
75408106|NCT05901883|Drug|Placebo|Subjects will receive placebo
75408107|NCT05901545|Biological|Panitumumab|Given by IV
75408108|NCT05901545|Other|Indium In 111 Panitumumab|Given by IV
75408109|NCT05901545|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
75408110|NCT05901545|Procedure|Computed Tomography|Undergo SPECT/CT
75408111|NCT05901545|Procedure|Surgical Procedure|Undergo standard of care surgery
75553313|NCT00447642|Drug|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
75408112|NCT05901545|Other|Imaging agent|Receive local injection of optical dye
75408113|NCT05901545|Procedure|Intraoperative Imaging|Undergo Intraoperative Imaging
75408114|NCT05901545|Procedure|Near Infrared Imaging|Undergo Near Infrared Imaging
75408115|NCT05901545|Procedure|Electrocardiography|Undergo Electrocardiography
75553314|NCT00447642|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
75408116|NCT05901545|Procedure|Biospecimen Collection|Undergo blood sample collection
75408117|NCT05876910|Behavioral|Speech Production Tasks|View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
75408118|NCT05856162|Behavioral|ENRICH pilot intervention (full intervention)|The full ENRICH pilot intervention will consist of content related to diet, physical activity, stress/mental health, sleep, tobacco cessation, and child health. The investigators will use an adapted version of the Mothers and Babies stress management intervention to address mental health, an adapted version of the HEALTH curriculum to address diet/physical activity, and an adapted version of the INSIGHT curriculum to address child health.
75408119|NCT05856162|Behavioral|ENRICH pilot intervention (partial intervention: only diet and physical activity)|The partial ENRICH intervention will focus only on diet and physical activity.
75408120|NCT05840302|Device|Activity monitor|Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention
75408121|NCT05840302|Other|Questionnaire|Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
75553315|NCT00344123|Drug|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
75408122|NCT05839457|Behavioral|Empowerment Pilot|The Empowerment Pilot is a school-based program aimed to raise awareness and change attitudes around SRGBV among students and teachers and promote gender equality. This intervention includes training provided by Teacher Mentors to other teachers in school, learning sessions delivered via safe spaces for student learners, and guidance for engaging parent-teacher committees.
75553316|NCT00344123|Drug|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
75553317|NCT00453882|Device|flostat (TM) System|
75553318|NCT00344201|Device|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
75553319|NCT00453960|Dietary Supplement|Genivis|54 mg/day daily for 6 months
75553320|NCT00453960|Drug|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
75408123|NCT05826171|Behavioral|High-Intensity Aerobic Exercise Prior to Balance Training|20-30 minutes of high intensity aerobic exercise followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 weeks (16 sessions total). For the aerobic component, participants will be instructed in a 20-30-minute exercise program, using available equipment already located in the participant's home (eg. stationary cycle, elliptical trainer, etc). Exercise intensity is moderate-to-high (between 50-85% Heart Rate Reserve. Participants will be placed on a ramped protocol which increases in intensity slowly over the course of the intervention period. For the balance training component, exercises will consist of steady state, proative, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.
76040044|NCT04912219|Device|Microneedling|"Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.~Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.~Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.~This will be repeated for a total of four treatments one month apart"
75553321|NCT00453960|Other|placebo|tablets daily for 6 months
76040045|NCT04915339|Behavioral|Physical activity|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
75712686|NCT01864720|Behavioral|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
75408124|NCT05826171|Behavioral|Low-Intensity Exercise Prior to Balance Training|"20-30 minutes of light intensity warm-up type exercises, followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 week (16 sessions total). For the warm-up exercise component, exercises will consist of stretching and core training. For the balance training component, exercises will consist of steady state, proactive, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses throughout. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.~Both groups are matched for time and frequency of intervention components."
75553322|NCT00344240|Behavioral|Functional circuit training with lifestyle behavior|
75553323|NCT00447681|Drug|ILV-094|
75712687|NCT00857571|Drug|150 mg Suspension|Single oral dose of 150 mg of PF-02413873 suspension
75712688|NCT00857571|Drug|30 mg Suspension|Single oral dose of 30 mg of PF-02413873 suspension
75712689|NCT00857571|Drug|400 mg Suspension|Single oral dose of 400 mg of PF-02413873 suspension
75408127|NCT05806385|Device|Cryoablation|Tumor ablation before neoadjuvant chemotherapy
75408128|NCT05806385|Combination Product|Cryoablation combined with PD1 Inhibitor|Combination of cryoablation with PD1 inhibitor before neoadjuvant chemotherapy
75553324|NCT00454038|Device|HYPRO SORB F|resorbable, double layered, collagen membrane
75712690|NCT00857571|Drug|5 mg Suspension|Single oral dose of 5 mg of PF-02413873 suspension
75712691|NCT00857571|Drug|750 mg Suspension|Single oral dose of 750 mg of PF-02413873 suspension
75553325|NCT04715282|Procedure|Epley maneuver|Epley maneuver
75553326|NCT00454077|Procedure|radioiodine therapy after rhTSH|
75712692|NCT00857571|Drug|150 mg Tablet|Single oral dose of 150 mg of PF-02413873 tablets
75712693|NCT00857571|Drug|30 mg Tablet|Single oral dose of 30 mg of PF-02413873 tablets
75712694|NCT00857571|Drug|400 mg Tablet|Single oral dose of 400 mg of PF-02413873 tablets
75712695|NCT00857571|Drug|5 mg Tablet|Single oral dose of 5 mg of PF-02413873 tablets
75712696|NCT00857571|Drug|750 mg Tablet|Single oral dose of 750 mg of PF-02413873 tablets
75712697|NCT00943774|Other|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
75712698|NCT00861627|Biological|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
75712699|NCT00861627|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
75408129|NCT05788185|Biological|RVM-V001 30 µg|For BNT162b2 subjects
75408130|NCT05788185|Biological|RVM-V002 30 µg|For BNT162b2 subjects
75408131|NCT05788185|Biological|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BNT162b2 subjects
75553327|NCT00447720|Behavioral|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
75553328|NCT00344474|Behavioral|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
75553329|NCT00447759|Drug|Celecoxib|200-400mg daily in divided doses
75553330|NCT00447759|Drug|Diclofenac|prescribed medication taken orally
75553331|NCT00344513|Drug|Beta-blockers including Carvedilol|
75553332|NCT00344513|Drug|ACE inhibitors|
75553333|NCT00454155|Drug|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
75553334|NCT00344552|Drug|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
75553335|NCT00447798|Behavioral|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building & strengths based case management
75553336|NCT00447837|Drug|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
75553337|NCT00344591|Behavioral|Structured Ecosystems Therapy (SET)|
75712700|NCT00861627|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
75408132|NCT05788185|Biological|RVM-V001 30 µg|For BBIBP-CorV or CoronaVac subjects
75408133|NCT05788185|Biological|RVM-V002 30 µg|For BBIBP-CorV or CoronaVac subjects
75408134|NCT05788185|Biological|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BBIBP-CorV or CoronaVac subjects
75408135|NCT05785065|Drug|Mycophenolate Mofetil|"The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
75408136|NCT05785065|Other|Placebo|"The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
75553338|NCT00344591|Behavioral|Individually tailored intervention|
75553339|NCT00447915|Drug|ibandronic acid 0.5mg|0.5mg(i.v.)/month for 35 months
75553340|NCT00447915|Drug|RIS placebo|0 mg(p.o.)/day for 36 months
75553341|NCT00447915|Drug|1.0mg ibandronic acid|1.0mg(i.v.)/month for 35 months
75553342|NCT00447915|Drug|ibandronic acid placebo|0mg(i.v.)/month for 35 months
75553343|NCT00447915|Drug|2.5mg RIS|2.5 mg(p.o.)/day for 36 months
75553344|NCT00447915|Dietary Supplement|Calcium and Vitamine D3|Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
75553345|NCT00344630|Device|TAXUS Stent and Cypher Stent|
75553346|NCT00344669|Drug|Albendazole 400 mg, given 6 monthly|
75553347|NCT03274791|Diagnostic Test|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
75712701|NCT00943930|Drug|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
76040046|NCT04915339|Behavioral|cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
75712702|NCT00854763|Drug|olmesartan|olmesartan
75712703|NCT00952666|Device|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
75712704|NCT00854841|Drug|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
75712705|NCT00944008|Drug|DepoCyte|
75712706|NCT00854919|Drug|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
75408137|NCT05784285|Behavioral|Engagement in a 8-week community-based activity program|Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.
76040047|NCT04915339|Behavioral|combined physical and cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
75408138|NCT05779033|Behavioral|scapular stabilization exercises|scapular stabilization exercises 3 times per week for 4 weeks.
76040048|NCT04923373|Other|telerehabilitation|"Procedure for both groups:~I pre surgery evaluation~initial training in hospital~physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation"
75712707|NCT00854919|Behavioral|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
76040049|NCT04923373|Procedure|standard physiotherapy|standard physiotherapy
76040050|NCT04915417|Radiation|Stereotactic Ablative Body Radiotherapy (SABR)|Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.
76040051|NCT04912297|Biological|10-valent pneumococcal conjugate vaccine, PCV10|10-valent pneumococcal conjugate vaccine, PCV10
76040052|NCT02497287|Drug|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 >= 65 years old will start at a dose of 28 mg in Week 5.
76040053|NCT02497287|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
76040054|NCT02497287|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants >= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
76040055|NCT02497287|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
75408139|NCT05779033|Device|ultrasound|Ultrasound 3 times per week for 4 weeks.continuous US operated at a frequency of 1 MHz and at an intensity of 1.5 W/cm2 for 5 minutes
75712708|NCT00861783|Drug|irinotecan and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling."
75408140|NCT05779033|Other|Kinesio Tape|"Kinesiotape 3 times per week for 4 weeks. We will apply taping to two muscles (deltoideus and supraspinatus). A Y' tape was placed over the deltoid muscle using the muscle stimulation (KT strip arms were located by stretching slightly by 15%-25%) and mechanical correction techniques (KT strip arms were located with maximal stretching). Another Y tape was placed over the supraspinatus muscle using the muscle inhibition technique (the starting point of the tape was attached to the sub acromial-greater tubercle with submaximal (75%) stretching and without stretching on strip arms)."
75408141|NCT05779020|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan (dose 0.25ml and 0.50ml)
75408142|NCT05779020|Biological|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage/dose 0.50ml
75408143|NCT05779020|Biological|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage/dose 0.25ml
75408144|NCT05770401|Behavioral|Internet-Behavioral Cough Suppression Therapy|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
75408145|NCT05770401|Behavioral|Sham Treatment|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
75408146|NCT05756803|Device|Low-intensity acoustic shockwave therapy|The study is being done to find out if low-intensity shockwave therapy can improve penile blood flow and restore sexual function in men with impaired erectile function.
75408147|NCT05751096|Device|Low-intensity Focused Ultrasound (LIFU)|repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.
75712709|NCT00861783|Drug|oxaliplatin and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling."
75712710|NCT00947128|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
75408148|NCT05751096|Device|Sham Low-intensity focused ultrasound (LIFU)|Sham application of LIFU.
75408149|NCT05742919|Drug|NNC0194-0499|Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
75408150|NCT05742919|Drug|NNC0194-0499|Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
75408151|NCT05742919|Drug|NC0194-0499|Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
75408152|NCT05722925|Drug|Fluciclovine PET/CT|8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
75408153|NCT05713461|Behavioral|exercise training program|"Adapted Interval Training Intervention, three days a week, 10 weeks.~Warm-up 10': Joint mobility and cardiovascular activation~Main part:~Resistance training circuit for strengthening the main muscle groups.~Cool down Flexibility and CORE"
75408154|NCT05713461|Behavioral|Feeding training|Two workshops on healthy eating habits (Week 1 and week 5). Food Frequency Questionnaires (weekly). Feedback weekly. Mediterranean Diet Adherence Screener (MEDAS). The dietary intervention will be based on the nutritional recommendations based on the Mediterranean diet, according to the evidence from the PREDIMED trial.
75408155|NCT05704751|Device|spinal cord stimulation|EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients
75408156|NCT05669235|Diagnostic Test|Questionnaires|A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
75712711|NCT00947128|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
75408157|NCT05656417|Behavioral|Temporary cessation of all oral hygiene|Participants will refrain from all oral hygiene for 3 weeks.
75408158|NCT05648240|Other|Blood test|Venous blood samples taken at the moment of colonoscopy to test for biomarkers
75408159|NCT05637216|Drug|Losartan 25 milligram capsule|Losartan 25 milligram oral capsule
75408160|NCT05637216|Drug|Placebo|Placebo 25 milligram oral capsule
75408161|NCT05628337|Other|Motivational texting|Health related information relevant to a subject's diagnosis and ongoing treatment
75408162|NCT05628337|Other|Control|Non-motivational text messages containing no specific health information
75408163|NCT05616585|Other|Pharmacokinetic (PK)- Controlled Feeding Diet|Pharmacokinetic- single-day isocaloric meals of beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, and oats with blood and urine samples taken at Time Zero and every hour (blood) or two hours (urine) after eating, over 10 hours; and at 24 hr.
75408164|NCT05616585|Other|Dose Response (DR)- Controlled Feeding Diet|Dose Response-3 level, six days controlled feeding study with assignment to either beef/whole wheat bread, chicken/potato, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for 6 days.
75408165|NCT05612984|Combination Product|Calcium aspirin multiple micronutrients|Women randomized to CAMMS will receive weekly blister cards containing all 3 components: 1 81 mg aspirin tablet, 1 UNIMMAP MMS, and 1 500-mg elemental calcium tablets. Blister packages will be labeled with times of day and days of week when tablets are to be taken. 4 weekly blister cards will be packaged in one unit box.
75408166|NCT05612984|Dietary Supplement|Iron-folic Acid|Women randomized to IFA will receive monthly (28-day) blister cards containing containing 1 combined IFA tablet to be taken each day. 1 4-weekly blister card will be packaged in one unit box.
75408167|NCT05604014|Behavioral|My Health Coach|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
75553348|NCT03274791|Diagnostic Test|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
75553349|NCT03274791|Diagnostic Test|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
75553350|NCT00344708|Procedure|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
75553351|NCT03274713|Device|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
75553352|NCT03274713|Device|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
75712712|NCT00947206|Behavioral|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
75712713|NCT00947206|Behavioral|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
75712714|NCT00857805|Procedure|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
75712715|NCT00857805|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
75553353|NCT00344747|Behavioral|dietary, behavioral, physical activity|
75553354|NCT00344786|Drug|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
75553355|NCT03274674|Other|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
75712716|NCT00947362|Other|Electro-thermo-coagulation|
75712717|NCT00947362|Drug|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
75712718|NCT00947362|Drug|saline|physiological saline
75712719|NCT00861861|Drug|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
75712720|NCT00861861|Drug|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
75712721|NCT01529866|Device|New Abutment Connection implant|New abutment connection implant
75712722|NCT01529866|Device|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
75712723|NCT00857883|Drug|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
75712724|NCT00952900|Behavioral|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
75712725|NCT00952900|Behavioral|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
75408168|NCT05603897|Other|Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)|Upon 1-2 days of admission to inpatient rehabilitation, the MASA will be administered for approximately 20 minutes during initial speech language pathology evaluation. The MASA will be administered at bedside as a cognitive/speech language evaluation as well as oropharyngeal function examination.
75712726|NCT02545413|Drug|Probiotic VSL#3|
76040056|NCT02497287|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants < 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants >= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
76040057|NCT04923607|Drug|TQC2731|TQC2731 injection
75408169|NCT05603897|Other|Non-standardized clinical swallow evaluation|Participants will receive current standard of care for dysphagia screening and treatment.
75408170|NCT05594017|Drug|Scopolamine (5ug/kg)|Patient receives a dose of scopolamine (5ug/kg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
75408171|NCT05594017|Drug|Placebo|Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
75553356|NCT04715165|Drug|USG-STAP with bupivacaine and dexmedetomidine|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline
75712727|NCT02545413|Drug|Placebo|
75712728|NCT00944086|Other|Recruitment Manoeuvre|Recruitment Manoeuvre
75712729|NCT00855075|Device|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
75712730|NCT00944164|Behavioral|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
75712731|NCT00944164|Behavioral|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
75712732|NCT00686166|Biological|cetuximab|"Chemotherapy cycle 1: Cetuximab, 400 mg/m^2, IV, Day 1; Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78"
75712733|NCT00686166|Drug|capecitabine|"Chemotherapy Cycle 1: Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)"
76040058|NCT04923607|Drug|Placebo|Matching placebo with no active ingredients
75553357|NCT04715165|Drug|IP bupivacaine and dexmedetomidine|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
75553358|NCT00454233|Drug|YM543|Oral
75712734|NCT00686166|Drug|oxaliplatin|"Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78"
76040059|NCT04911985|Device|Measurement of the Cardiac Output/ Cardiac Index|Semiinvasive Measurement of the Cardiac Output/ Cardiac Index with the Pulsion device
76040060|NCT04912141|Drug|conestat alfa or placebo|"Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line."
76040061|NCT04915105|Diagnostic Test|Markers data from PBMCs|Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.
75712735|NCT00686166|Procedure|therapeutic surgical procedure|Surgical resection
75712736|NCT00686166|Radiation|radiation therapy|IMRT (intensity-modulated radiation therapy)
75712737|NCT04280536|Drug|Cohort A|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
75712738|NCT04280536|Drug|Cohort B|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
75712739|NCT00944242|Drug|Sertraline|
75712740|NCT00944242|Drug|Sertraline Hydrochloride|
75712741|NCT00363649|Biological|GM-K562 cell vaccine|Given by injection
75712742|NCT00363649|Biological|Interferon alfa|Given by injection
75712743|NCT00363649|Biological|Sargramostim|Given by injection
75712744|NCT00855153|Other|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
75712745|NCT00855153|Drug|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
75712746|NCT00947440|Drug|ABT-072|See arm description for more information
75408172|NCT05591274|Device|SmileyScope Virtual Reality Headset|The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
75408173|NCT05581511|Other|Evaluation of the natural history of cutaneous neurofibromas|Cutaneous neurofibromas (cNFs) are the most common tumors in people with neurofibromatosis type 1 (NF1). Despite their benign histology, they can significantly impact patients' quality of life (QoL). In this project, the natural history of cNFs will be prospectively and systematically studied. To accomplish this, the reproducibility and efficiency of using 3D whole-body photography was evaluated in a small cohort of patients. The study is enrolling patients of all ages with cNFs into groups by epochs of life to characterize the baseline tumor burden and the change in number and morphology of cNFs over five years. In addition, the study will perform next generation sequencing to describe the genetic variations in the NF1 gene and evaluate potential relations between genotype and phenotype. Lastly, the study will validate clinician- and patient-reported severity scales of cNFs developed for this patient population.
75553359|NCT00454233|Drug|Metformin|Oral
75553360|NCT00454233|Drug|Placebo|oral
75553361|NCT04715477|Behavioral|Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
75553362|NCT00448032|Drug|PPM-204|
75408174|NCT05581108|Dietary Supplement|Juice PLUS+® OMEGA|Daily dose of total Omega blend: 925 mg (2 capsules)
75408175|NCT05581108|Dietary Supplement|Placebo|matched placebo (2 capsules)
75408176|NCT05579392|Device|Bright Light Therapy|Device: Bright Light Therapy Retimer
75712747|NCT02545023|Other|Quality-of-Life Assessment|Complete an in-person one-on-one interview
75408177|NCT05579392|Device|Placebo Retimer Device|Device: Placebo Retimer Device with no bright light therapy
75408178|NCT05576038|Drug|L-Tryptophan|L-tryptophan is an essential amino acid responsible for activating the aryl hydrocarbon receptor (AhR). Dietary tryptophan is metabolized by the gut microbiota producing several 'indoles' such as (indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3 propionic acid (IPA), indole-3-acetaldehyde (IAAld), indole-3-lactic acid (ILA) and indole-acrylic acid) and tryptamine, which are ligands for the AhR, a nuclear transcription factor involved in activating target genes responsible for maintaining gut integrity. Prior literature suggests that patients with active celiac disease have a lower functional capacity to produce these AhR ligands, which further impairs the AhR pathway. Hence, the aim of this study is to assess the effects of tryptophan supplementation in patients with celiac disease, non-responsive to a GFD for more than 1 year compared with the effects of an inactive, placebo comparator, L-leucine.
75553363|NCT04714931|Diagnostic Test|Sentinel lymph node detection|Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
75553364|NCT00454272|Drug|Teicoplanin|
75553365|NCT00454272|Drug|Vancomycin|
75553366|NCT00448071|Drug|MTR107|
75553367|NCT00344825|Drug|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
75553368|NCT00448110|Drug|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
75712748|NCT02545023|Other|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
75712749|NCT00952978|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
75712750|NCT00952978|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
75712751|NCT01046851|Drug|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
75712752|NCT01046851|Drug|Placebo|Placebo in a manner similar to the active comparator
75712753|NCT00861939|Drug|Bupropion HCI 300 mg Extended-Release Tablets EON|
75553369|NCT00448110|Drug|Intravenous Ketorolac|Intravenous Ketorolac
75553370|NCT00448110|Drug|placebo|placebo
75553371|NCT00344864|Device|LADARWave|
75553372|NCT00454311|Procedure|Biopsy of Day 3 Embryo|
75553373|NCT00454311|Procedure|· day embryo biopsy|
75553374|NCT00448149|Drug|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
75712754|NCT00861939|Drug|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
75712755|NCT01046929|Dietary Supplement|limonene|oral dosing at 2 gram QD
75712756|NCT00953134|Dietary Supplement|Ferrous fumarate (iron)|60 mg of ferrous fumarate
75872156|NCT02333734|Other|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces ~ 90% of the maximum heart rate. The time spent per session is expected to last ~ 25 minutes.
76040062|NCT04923451|Device|Active Trans-cranial direct current stimulation (tDCS)|5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed
75408179|NCT05576038|Drug|Freedom SimpleCap Powder|Freedom SimpleCap Powder is a high functionality capsule and tablet excipient composite comprised of filler, glidant, disintegrant and lubricant (ingredients include: Microcrystalline Cellulose, Silicon Dioxide Colloidal, Sodium Starch Glycolate, Sodium Stearyl Fumarate). This capsule is dye, lactose and gluten free and will not interfere with the AhR pathway. Freedom SimpleCap Powder makes oral capsule formulation convenient, quick and simple Thus, this SimpleCap Powder will be an appropriate placebo comparator for this study.
75408180|NCT05570916|Device|Zip-stitch(R)|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
75408181|NCT05570916|Device|Reference suture|Standard suture for vaginal cuff closure during laparoscopic hysterectomy
75408182|NCT05529069|Drug|Pirtobrutinib|Given by PO
75408183|NCT05529069|Drug|Venetoclax|Given by PO
75553375|NCT00448149|Drug|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
75553376|NCT00344942|Drug|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
75553377|NCT00344942|Drug|placebo|a double spray into each nostril once daily
75553378|NCT00454350|Drug|Hectorol (doxercalciferol injection)|
75553379|NCT00454350|Drug|Zemplar (Paricalcitol injection)|
75553380|NCT00448188|Procedure|central venous catheter application|
75553381|NCT00454389|Device|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
75712757|NCT00953134|Dietary Supplement|folic acid|400 mcg folic acid
75712758|NCT02544945|Other|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
75712759|NCT02544945|Other|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
75712760|NCT00944398|Dietary Supplement|Zinc fortified food|Daily consumption
75872157|NCT02318277|Drug|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
75872158|NCT02318277|Drug|INCB024360|INCB024360: Oral daily dosing
75553382|NCT00454389|Drug|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
75712761|NCT00944398|Dietary Supplement|Zinc supplement|Liquid supplement containing zinc sulfate
75712762|NCT00944398|Other|Placebo supplement|Liquid placebo supplement
75712763|NCT00944398|Dietary Supplement|Non-fortified food|Non-fortified complementary food.
75712764|NCT00862017|Dietary Supplement|MSg supplementation|
75553383|NCT00344981|Drug|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
75553384|NCT00344981|Drug|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches >400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
75553385|NCT00448266|Drug|Intensified Cyclophophamide, Carboplatin and Thiotepa|2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
75553386|NCT00448266|Drug|dose dense adriamycine and cyclophosphamide|dose dense adriamycine and cyclophosphamide, Q 2 weeks
75553387|NCT00454428|Procedure|pulsatile intra-aortic balloon pump|
75553388|NCT00345020|Procedure|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
75712765|NCT00862017|Dietary Supplement|NaCl supplementation|
76040063|NCT04923451|Device|Sham Trans-cranial direct current stimulation (tDCS)|5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed
76040064|NCT04922385|Other|Cognitive Behavioural Therapy|This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).
75553389|NCT00454545|Drug|Atorvastatin|
75553390|NCT00345059|Drug|docetaxel|
75553391|NCT00345059|Drug|vinorelbine|
75553392|NCT00345059|Drug|gemcitabine|
75553393|NCT00345059|Drug|capecitabine|
75553394|NCT03274635|Behavioral|Desk-based pedaling device and pedaling incentives provided|Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
75553395|NCT00345098|Drug|SR58611A|
75553396|NCT00448305|Drug|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
76040065|NCT04923061|Other|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected four different points will also be applied to the other extremity, a total of 16 minutes of compression will be applied to each point, provided that it is two minutes. Each nurse's session will be approximately 20 minutes, depending on the preparation and compression time on each point.
76040066|NCT04923061|Other|Sham acupressure group|In the sham group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
76040067|NCT03056287|Behavioral|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
76040068|NCT03056287|Other|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
76040069|NCT04911829|Behavioral|Psychotherapy|
75553397|NCT00448305|Drug|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
75553398|NCT00448305|Drug|Paclitaxel|Paclitaxel 90 mg/m² weekly
75553399|NCT00345137|Drug|Ng-monomethyl-L-arginine (drug)|
75553400|NCT00448383|Biological|adalimumab|40mg every other week
75553401|NCT00345215|Behavioral|High Sodium Diet|250-350 mmol
75553402|NCT00345215|Behavioral|Low Sodium Diet|25-35 mmol
75553403|NCT00448461|Drug|heparin|comparison between heparin and bivalirudin
75553404|NCT00448461|Drug|bivalirudin|comparison between heparin and bivalirudin
75553405|NCT00345410|Drug|AVE1625 B|
75553406|NCT00454623|Behavioral|drawing serum adiponectin level|
75553407|NCT00345449|Behavioral|Decision Aid|
75553408|NCT00454662|Drug|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
75712766|NCT00944476|Procedure|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
75712767|NCT00953368|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
75553409|NCT00454662|Drug|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
75712768|NCT00855387|Other|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
76040070|NCT04911595|Diagnostic Test|exercise oximetry|transcutaneous oxygen pressure is measured at the skin level on chest , buttocks and calves during a walking test 3.2 km*:h 10% slope. From the test result the decrease from rest of oxygen pressure (DROP) index is calculated to estimate muscle ischemia
76040071|NCT04911595|Diagnostic Test|thallium scintigraphy|Muscle thallium fixation is measured immediately after a walking test 3.2 km*:h 10% slope and at 4 hours after the test. From the test result the difference of late and early radioactivity is calculated at the buttock and calf level and normalized to total body radioactivity to estimate muscle ischemia
76040072|NCT02458287|Biological|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
76040073|NCT02458287|Biological|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
76040074|NCT02458287|Biological|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
76040075|NCT02458287|Biological|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
76040076|NCT04914715|Device|Non-invasive High Frequency Oscillatory Ventilation|We are planning to use (Medin-CNO) for non-invasive ventilation. This machine has option to deliver NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option.
76040077|NCT04914715|Device|Conventional Invasive Ventilation|Invasive ventilation will be started following endotracheal intubation, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40.
76040078|NCT04914871|Behavioral|Protocol UN Lifeguard Kids in the Tunja version|"The experimental protocol UN Lifeguard Kids in the Tunja version done by the researcher following the guidelines of International organizations such as the American Heart association and European Resuscitation Council.~The intervention consists of 3 sessions of 60 minutes of theoretical and practical exercises on BLS, developed within the usual class schedule."
75712769|NCT00947596|Drug|atropine sulfate|dry powder for inhalation
75712770|NCT00947596|Drug|atropine sulfate|intramuscular injection
75712771|NCT00865059|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
75553410|NCT00345527|Behavioral|Emotion and Behaviour Regulation Treatment (EBRT)|
75553411|NCT00345527|Behavioral|Cognitive Behavioural Therapy|
75408184|NCT05528770|Device|FCL+BPS|The automated insulin delivery system includes the Bolus Priming System, a software automatically analyzing past continuous glucose monitoring values to trigger priming insulin bolus delivery isn the suspected presence of meal like glycemic disturbances
75553412|NCT00345566|Procedure|Nutrition composition|
75553413|NCT00345644|Drug|risedronate|risedronate sodium 35 mg tablets (once a week dose)
76040079|NCT04914871|Behavioral|Educational session accident prevention and wound management|It will be provided to the control group
76040080|NCT02441517|Drug|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
76040081|NCT03688347|Procedure|Nasal Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently inserted less than one inch into the anterior nare (nostril) until resistance is met at turbinate. Then it is rotated several times against nasal wall and repeated in other nostril using the same swab.
76040082|NCT03688347|Procedure|Oral Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently rubbed along the inside of the participant's cheek for 5-10 seconds.
75408185|NCT05528770|Device|FCL|The automated insulin delivery system does not include the Bolus Priming System, and therefore does not automatically command priming boluses.
75408186|NCT05525000|Device|Validation|"The validation protocol consists of the following activities:~Activities of daily living, Exercise test on the treadmill, Exercise test on the cycle ergometer, Free-living session"
75408187|NCT05523596|Drug|ICM20|small molecules
75408188|NCT05523596|Drug|Benznidazole|small molecule
75408189|NCT05482568|Drug|SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316|"Drug: SHR-A1811 & Pyrotinib~SHR-A1811： intravenous Pyrotinib：oral~Drug: SHR-A1811 & SHR-1316~SHR-A1811： intravenous SHR-1316： intravenous"
76040083|NCT03688347|Other|Stool Collection|A stool collection kit will be sent home with each participant. It will include instructions on how to collect the stool specimen and how to return the kit.
75553414|NCT00345644|Drug|risedronate placebo|placebo for risedronate tablets (once a week dose)
75553415|NCT00345722|Procedure|strawberry dietary intervention|
75408190|NCT05478018|Behavioral|High Intensity Interval Training|Supervised high-intensity interval training for 12 weeks three times per week
75553416|NCT00454701|Drug|Alefacept exposure|Observational
75553417|NCT00345761|Drug|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
75408191|NCT05477147|Device|Catheter Ablation|Cardiac catheter ablation for recurrent AF after previous ablation (catheter or surgical).
75553418|NCT00345761|Drug|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
75553419|NCT00345761|Drug|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
75408192|NCT05476796|Drug|Trifluridine/Tipiracil|Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
75712772|NCT00865059|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
75712773|NCT00956410|Biological|CAD106|
75712774|NCT00865137|Drug|Tacrolimus, modified release|Oral
75712775|NCT00947674|Device|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
75712776|NCT00862095|Drug|Placebo|Every month for 3 months
75712777|NCT00862095|Drug|Propranolol|target does 80 mg per day for 3 months
75712778|NCT00862095|Drug|Amitriptyline|Target does of 50 mg per day for 3 months
75712779|NCT00862095|Drug|Topiramate|Target dose 100 mg a day for 3 months
76040084|NCT03688347|Genetic|Microbiome analysis|Study of microbial communities found in and on the human body.
75553420|NCT00345800|Drug|Sodium Oxybate (Xyrem)|"Active Substance: Sodium Oxybate~Pharmaceutical form: Oral Solution~Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~Route of administration: Oral"
75553421|NCT00454740|Drug|solifenacin succinate|Oral
76040085|NCT03688347|Genetic|DNA Banking|Secure, long term storage of an individual's genetic material.
76040086|NCT03688347|Procedure|Skin Swab|Gentle rubbing of the swab will be applied to the skin on the dorsal part of the hand.
75553422|NCT00345917|Device|Retinal transplantation instrument|
75408193|NCT05476796|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
75553423|NCT00345917|Device|Fetal tissue.|
75553424|NCT03276897|Other|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
75553425|NCT00345956|Biological|Human rotavirus liquid vaccine|
75553426|NCT03276858|Drug|CRN00808|Investigational drug
75553427|NCT03276858|Drug|Placebo Oral Solution|Placebo
75553428|NCT03276858|Drug|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
75553429|NCT03276858|Drug|Placebo oral capsule|Placebo
75408194|NCT05476796|Drug|FOLFOX regimen|Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
75553430|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
75553431|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
75712780|NCT04054128|Drug|Sodium Bicarbonate 7.5% Injection|Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
75712781|NCT04054128|Drug|Heparin Sodium, 1000 Units/mL Injectable Solution 1|Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
75712782|NCT00956566|Behavioral|dietary intervention|dietary counseling, group teaching
75553432|NCT00454896|Drug|VESIcare®|Oral
75553433|NCT00454896|Drug|placebo|Oral
75553434|NCT00421226|Drug|ACZ885|
75553435|NCT03276624|Procedure|CABG|surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
75553436|NCT00346112|Procedure|psycho-educational|
75553437|NCT00346190|Drug|Alendronate|
75553438|NCT00454974|Device|Wearable artificial kidney|
75553439|NCT00346229|Biological|filgrastim|
75553440|NCT00346229|Biological|pegfilgrastim|
75553441|NCT00346229|Drug|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
75553442|NCT00346229|Procedure|hyperthermia treatment|
75553443|NCT00455052|Drug|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
75553444|NCT00346385|Drug|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
75553445|NCT00448578|Drug|Quetiapine Fumarate|
75553446|NCT00448578|Drug|Lithium|
75553447|NCT00346424|Drug|Alfimeprase|
75553448|NCT03276507|Diagnostic Test|Pulmonary function studies|
75553449|NCT03276507|Diagnostic Test|Echocardiogram|
75553450|NCT03276507|Diagnostic Test|Electrocardiogram|
75553451|NCT03276507|Diagnostic Test|Chest radiography|
75408195|NCT05476796|Drug|Nivolumab|Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
75553452|NCT03276507|Diagnostic Test|Blood test|
75408196|NCT05456997|Procedure|Muscle biopsy|Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
75408197|NCT05455619|Drug|Evexomostat|Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
76040087|NCT03056131|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
76040088|NCT03056209|Drug|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
76040089|NCT03056209|Drug|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
76040090|NCT03056209|Drug|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
75553453|NCT03276507|Behavioral|Quality of life questionnaire|
76040091|NCT03056209|Drug|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
76040092|NCT03056209|Drug|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
76040093|NCT03056209|Drug|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
76040094|NCT03056209|Drug|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
76040095|NCT03056209|Drug|Placebo|oral administration, placebo
76040096|NCT02457819|Drug|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
75553454|NCT00346463|Drug|Allopurinol|
75553455|NCT00455091|Drug|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/> 105 copies/mL and ALT > 2.0 x UNL
75553456|NCT00346502|Drug|20% betulinic acid ointment|
75553457|NCT00346502|Drug|BA|20% Betulinic Acid Ointment
75553458|NCT04699344|Diagnostic Test|The level of CNV|The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.
75553459|NCT00346580|Drug|Nelfinavir|
75553460|NCT00346619|Drug|Nelfinavir|
76040097|NCT03056053|Drug|Zolpidem|Commercially available tablets of zolpidem (5 or 10 mg) for oral use
76040098|NCT04914325|Combination Product|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
76040099|NCT04922905|Other|NEURO +|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~the Peri traumatic distress inventory (Jehel et al., 2005)~and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed."
75553461|NCT00346658|Drug|magnesium|
75553462|NCT02273700|Drug|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
75553463|NCT02273778|Procedure|MRI Scan|
75553464|NCT02273778|Procedure|PET-CT Scan|
75553465|NCT02273778|Other|No intervention|
75553466|NCT00346736|Procedure|Acupuncture (Procedure)|
75553467|NCT00448656|Procedure|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
75553468|NCT02959658|Drug|Dimethyl fumarate|
75553469|NCT02959658|Drug|Placebo|Manufactured to mimic Dimethyl Fumarate capsules
75553470|NCT04698213|Drug|Axitinib Oral Tablet|"Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect."
75712783|NCT00865215|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under fasting conditions
75712784|NCT00865215|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
76040100|NCT04922905|Other|NEURO -|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~the Peri traumatic distress inventory (Jehel et al., 2005)~and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)"
75553471|NCT04698213|Drug|Avelumab|Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
75408198|NCT05433493|Behavioral|Cognitive stimulation|"The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant."
75553472|NCT00346814|Drug|intravitreal injection|
75553473|NCT02273817|Drug|Ciclesonide nasal spray, 50 μg per actuation.|"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."
75553474|NCT00346853|Drug|4-Methylpyrazole|15 mg/kg dose
75553475|NCT00346853|Other|saline|
76040101|NCT04914559|Other|Oral nutrition supplement - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
76040102|NCT04914559|Other|Oral nutrition supplement - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
75712785|NCT00684060|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
76040103|NCT02496039|Drug|NUEDEXTA®|NUEDEXTA® only
76040104|NCT04911205|Other|Preoperative training program|Patients of intervention group (N=44) followed a 6-week supervised high-intensity preoperative training program. They had a session of preoperative resistance training five days per week for a period of 6 weeks before TKA. Each session was supervised by a physiotherapist specifically trained in progressive resistance training. The duration of each session was approximately 60 minutes. If a participant missed a training session, it was attempted to substitute the session on an alternative day.
76040105|NCT04911283|Other|Brucella serology test|MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.
75408199|NCT05427084|Drug|Canagliflozin|Canagliflozin tablet 300mg PO daily
75408200|NCT05427084|Drug|Placebo|Placebo tablet
75553476|NCT00448695|Procedure|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
75553477|NCT00346892|Biological|Rotavirus (vaccine)|
75553478|NCT00346931|Procedure|Phacoemulsification, implantation of intraocular lens|
75553479|NCT00346931|Procedure|Phacoemulsification, Implantation of IOL, trabeculotomy|
75553480|NCT00346970|Drug|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
75553481|NCT00346970|Drug|Placebo|Placebo tablets
75712786|NCT00684060|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
75712787|NCT00865371|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
76040106|NCT04911283|Other|Medical history for brucellosis|Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
75553482|NCT00455130|Drug|Inhaled mannitol|
76040107|NCT02441283|Drug|ABT-493|ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
76040108|NCT02441283|Drug|ABT-530|ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
75712788|NCT00865371|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
76040109|NCT04922359|Drug|Lidocain|Patients received 1.5mg/kg of intravenous lidocaine during induction of anesthesia and 1.5 mg/kg/h for anesthesia maintenance.
75872159|NCT03653234|Device|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
75872160|NCT02333656|Other|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
76040110|NCT04922359|Drug|normal saline|Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
76040111|NCT03054493|Behavioral|no intervention|no intervention
76040112|NCT04910737|Procedure|extended posterior circumferential decompressive surgery|After the pedicle screws were implanted, laminectomy was performed. Kyphotic correction was done through a temporary rod to reduce the tension of spinal cord. The posterior 1/3 of the vertebral body was resected using a high-speed drill, preserving the anterior wall of the spinal canal to protect the cord from disturbance. The dissection of adhesion at the anterior side of spinal cord was to be done through a posterolateral direction. The region of posterior resection was expanded, including bilateral residual articular processes, transverse processes and pedicles. Slightly press down the ossified lesion, and detach it from the dura mater (perform a sharp dissection if necessary) followed by completely removal. If cerebrospinal fluid leakage was encountered during the process, autologous fat, fascia or gelatin sponge can be applied locally for packaging.
76040113|NCT02495883|Other|Ethanol|50ml of 40% Ethanol
76040114|NCT02495883|Drug|Propranolol|Beta blocker
76040115|NCT04910893|Device|Cytokine Adsorption|Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.
76040116|NCT04910893|Other|Standard of Care|Standard intensive care of patients suffering septic shock
76040117|NCT02495025|Behavioral|Telephone-based developmental screening and care coordination|
76040118|NCT04910659|Other|acupuncture|P6, LI4 and LI 11 stimulation
75408201|NCT05414123|Device|CNSide|The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
75553483|NCT00347048|Drug|tacrolimus|oral
75553484|NCT00347048|Drug|Placebo|oral
75553485|NCT00448773|Behavioral|Online education|
75553486|NCT00455169|Biological|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
76040119|NCT04910347|Drug|Nivolumab|"Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs."
75553487|NCT00347087|Drug|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
75553488|NCT00347165|Drug|bevacizumab intravitreal injection|
75553489|NCT00455208|Drug|Cura-100|
75553490|NCT00455247|Drug|Glutamine|
75553491|NCT00347204|Drug|ketorolac (Acular LS)|
75712789|NCT00865449|Drug|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
75712790|NCT00865449|Drug|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
75712791|NCT00865527|Other|Fecal occult blood test|FOBT
75712792|NCT00865527|Procedure|Virtual colonoscopy|computed tomographic colonography
75712793|NCT00865527|Procedure|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
75712794|NCT00756210|Other|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
75712795|NCT00858195|Drug|Indomethacin 75mg Extended-Release Capsules, Sandoz|
75553492|NCT00347204|Drug|Nepafenac (Nevanac)|
76040120|NCT04914169|Device|ICRS|The ICRS enables a stationary bike to automatically adjust the pedaling resistance (i.e. training intensity) according to the subject's heart rate. The training intensity is determined by monitoring whether the subject is able to maintain a 50-70 cycles/min cadence with 60-80% HRR. Subjects heart rate was detected by a wearable device for heart rate, synching with the stationary bike.
76040121|NCT02439957|Drug|Brincidofovir|
75408202|NCT05394818|Drug|SHR-A2009|The total dosage of SHR-A2009 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
75408203|NCT05391503|Behavioral|Light therapy|Morning bright light for 60 minutes after awakening
75553493|NCT00347243|Procedure|phacoemulsification (cataract surgery)|
75712796|NCT00858195|Drug|Indocin 75mg SR Capsules|
75408204|NCT05391503|Behavioral|Placebo light therapy|Placebo morning bright light for 60 minutes after awakening
75408205|NCT05387317|Biological|Pfizer-BioNTech Standard dose|"Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
75408206|NCT05387317|Biological|AstraZeneca Standard dose|"Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
75872161|NCT03143452|Drug|lidocaine gel|2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
75872162|NCT03143452|Drug|tetracaine eye drop|0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
76040122|NCT02439957|Drug|Valganciclovir|
76040123|NCT04914013|Other|no intervention|no intervention
76040124|NCT02494401|Other|Internet-based self-management program|
76040125|NCT02494401|Other|Scleroderma book|
76040126|NCT03054415|Procedure|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
76040127|NCT04922515|Other|Oral and rectal swabs for microbiome sequencing|Oral swabs and rectal swabs are collected non-invasively.
75408207|NCT05387317|Biological|Pfizer-BioNTech Fractional dose|"Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
75408208|NCT05387317|Biological|AstraZeneca Fractional dose|"Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
75408209|NCT05387317|Biological|Moderna Standard dose|Standard dose (50ug in 0.25ml)
75408210|NCT05387317|Biological|Moderna Fractional dose|Fractional dose (20ug in 0.1ml)
75408211|NCT05384821|Drug|Vincristine|IV, D1-D22-D43 and D64
76040128|NCT04922437|Procedure|Native bladder implantation|Continent catheterizable channel implanted in the detrusor of the native bladder
76040129|NCT04922437|Procedure|Enterocystoplasty implantation|Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
76040130|NCT04913545|Diagnostic Test|using salivary miRNA (412,512)|quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
75553494|NCT00448851|Biological|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
75553495|NCT00455286|Drug|Methotrexate|
75712797|NCT00858351|Behavioral|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
75712798|NCT00858351|Behavioral|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
75712799|NCT03131648|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
75712800|NCT03131648|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
76040131|NCT04913935|Diagnostic Test|Muscle-Skeleton Ultrasonography|postero-anterior radiography
76040132|NCT04910191|Diagnostic Test|Electronic stethoscope|Electronic stethoscope
76040133|NCT02457195|Drug|granisetron|Application granisetron transdermal patch preoperatively
75553496|NCT00455286|Drug|Methylprednisolone|
75553497|NCT00455286|Drug|Temozolomide|
75553498|NCT00455364|Drug|Voriconazole|
75553499|NCT00347321|Procedure|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
75553500|NCT00448929|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
75553501|NCT00347399|Drug|bevacizumab intravitreal injection|
75553502|NCT00347399|Procedure|verteporfin photodynamic therapy|
75553503|NCT00455442|Drug|Mifepristone|
75553504|NCT00347477|Drug|HyperHAES vs. RA-solution/NaCl|
75553505|NCT00347516|Procedure|IOL calculation formula|
75553506|NCT00449085|Procedure|Electrophysiology|
75712801|NCT00618813|Other|radiation therapy|Undergo radiation therapy
75712802|NCT00618813|Other|therapeutic conventional surgery|Undergo surgery
76040134|NCT04913779|Drug|Anti-SARS-CoV-2|Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)
75712803|NCT00618813|Drug|etoposide|Given IV
75712804|NCT00618813|Drug|ifosfamide|Given IV
75712805|NCT00618813|Drug|doxorubicin hydrochloride|Given IV
75712806|NCT00618813|Drug|cyclophosphamide|Given IV
76040135|NCT04913779|Drug|Placebo|Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
76040136|NCT04904497|Behavioral|Early Occupational Therapy|"Occupational therapists will implement the following activities:~Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 2 one session each 24 h.~Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS <2, 6> environmental orientation will be considered~Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~Education: trained family members and health staff about the intervention process"
76040137|NCT04913623|Procedure|Hip Replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
75712807|NCT00618813|Drug|vincristine sulfate|Given IV
75712808|NCT00618813|Drug|topotecan hydrochloride|Given IV
75712809|NCT00618813|Biological|filgrastim|Given SC
75712810|NCT00685698|Drug|TG-873870 (Nemonoxacin)|750 mg
75712811|NCT00858429|Drug|capecitabine|1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
75712812|NCT00858429|Radiation|yttrium Y 90 glass microspheres|The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
76040138|NCT03054259|Drug|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
75408212|NCT05384821|Drug|Irinotecan|Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
75408213|NCT05384821|Drug|Temozolomide|Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
75712813|NCT00756366|Other|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
76040139|NCT03054259|Drug|Methylprednisolone|100mg infusion on days 1 and 15
76040140|NCT03054259|Drug|Normal Saline|250ml infusion on days 1 and 15
75712814|NCT00756366|Other|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
75712815|NCT00756366|Other|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
75712816|NCT02566928|Drug|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
75712817|NCT02566928|Other|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
75712818|NCT02566928|Behavioral|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
75712819|NCT00756522|Other|There is no intervention. Study is observational.|There is no intervention. Study is observational.
75712820|NCT00865605|Drug|Halobetasol Propionate 0.05% Ointment, single exposure|A: Other Subjects received Alpharma/Purepac USHP formulated products
75712821|NCT00865605|Drug|Ultravate® 0.05% ointment, single exposure|Subjects received Bristol-Myers Squibb Company formulated products
75712822|NCT00756756|Drug|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
75712823|NCT00756756|Drug|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
75712824|NCT02565056|Other|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
75712825|NCT00865683|Dietary Supplement|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
75712826|NCT00865683|Dietary Supplement|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
75712827|NCT00953446|Procedure|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
75712828|NCT02560818|Other|collection of a blood sample and breast and ovarian tissue|a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)
75712829|NCT02560818|Other|use of a previous blood collection for patients|
75408214|NCT05384821|Drug|Etoposide|Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
75712830|NCT03058250|Other|Transesophageal echocardiography|
76040141|NCT02456727|Procedure|Group/Community Acupuncture|Acupuncture treatment in a group setting.
75712831|NCT00956644|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
75712832|NCT00956644|Drug|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
75408215|NCT05384821|Drug|Cis-Retinoic acid|Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
75408216|NCT05377723|Device|Neodyne Device|See Arm Description: Neodyne Device
75408217|NCT05369260|Other|Telerehabilitation-based cervical and scapular stabilization exercises|Telerehabilitation based cervical and scapular stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
75408218|NCT05369260|Other|Telerehabilitation-based cervical and core stabilization exercises|Telerehabilitation based cervical and core stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
75712833|NCT00756834|Device|Screening|The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
75712834|NCT03895268|Device|ALiA Analyser|NPS specimens shall be tested with the investigational device
76040142|NCT02456727|Procedure|Individual Acupuncture|Acupuncture treatment in an individual setting.
76040143|NCT03054025|Device|Smart Phone Monitoring Device|Use activity tracker application
76040144|NCT04910035|Other|Exercises Training|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
76040145|NCT03052387|Other|assigned intervention|"* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~Using fissure bur to harvest the graft for the defect.~Closure using vicryl 3-O sutures."
75408219|NCT05368350|Device|Transcranial direct current stimulation|"Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds."
75553507|NCT00449085|Device|CARTO™ XP EP Navigation System V9|
75712835|NCT03895268|Device|Influenza A+B Test Kit|NPS specimens shall be tested with the investigational device
75712836|NCT00858663|Radiation|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
75712837|NCT00858663|Drug|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
75712838|NCT03894488|Diagnostic Test|FilmArray Gastrointestinal (GI) Panel|The FilmArray GI Panel tests for 22 of the most commonly associated pathogens related to gastroenteritis-all from one patient sample, one easy to use reagent, and results are available in about one hour.
75712839|NCT02544789|Drug|Clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
75712840|NCT00956722|Drug|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
75712841|NCT00858741|Radiation|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
75712842|NCT00858741|Radiation|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
75712843|NCT04985864|Device|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
75553508|NCT00347555|Biological|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
75408220|NCT05317455|Drug|Dichloroacetate|Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.
75712844|NCT04985864|Device|Treadmill gait training|Lokomat robot training was applied to stroke patients.
75408221|NCT05293197|Device|SonoCloud® (9 transducers)|SonoCloud®, sonication: dose escalation 6 cycles of sonication
75408222|NCT05281198|Dietary Supplement|tart cherry juice|2, 8oz bottles of Montmorency tart cherry juice daily; 8oz taken in AM, 8oz taken in PM
75408223|NCT05281198|Dietary Supplement|Placebo|2, 8oz bottles of placebo juice daily; 8oz taken in AM, 8oz taken in PM
75408224|NCT05239143|Biological|P-MUC1C-ALLO1 CAR-T cells|P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.
75408225|NCT05239143|Drug|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
76040146|NCT04909879|Biological|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
75408226|NCT05217459|Device|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
75408227|NCT05207085|Drug|Valbenazine Oral Capsule|Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
75408228|NCT05207085|Other|Placebo Oral capsule|Participants randomized to placebo will be given a capsule that is the same shape and color as the active medication and will subject to the same dose escalation requirements as the other arm but will receive placebo during the treatment period.
75553509|NCT00347555|Drug|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
75553510|NCT00347555|Biological|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
75712845|NCT00953602|Other|Genetically modified potato|Genetically modified potato
75712846|NCT00956800|Other|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
75712847|NCT00956800|Other|Normal care|Control group will receive 5 routine office visits in one year
75712848|NCT02565836|Drug|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated"
75712849|NCT02565836|Drug|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated."
75712850|NCT00865761|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
75712851|NCT00865761|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under fasting conditions
75712852|NCT00953758|Drug|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
76040147|NCT04909879|Drug|Placebo|Excipient solution
76040148|NCT04894513|Other|Kabat motor control re-education therapy|Kabat motor control re-education therapy that includes specific movements with predefined patterns of facial muscles exercises, which is spiral and diagonal movements involve the facial muscles, which are brought to train in global patterns. The program of treatment for three times per week for six weeks.
75712853|NCT00947908|Biological|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
75712854|NCT00865839|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
75712855|NCT00865839|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
75712856|NCT00549328|Drug|Pazopanib (GW786034)|Pazopanib monotherapy
75408229|NCT05206695|Behavioral|Multi-condition Pathway Intervention|See Experimental/Arm 1 description
75408230|NCT05201469|Drug|VIB4920|Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
75408231|NCT05201469|Drug|Placebo for VIB4920|Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
75712857|NCT00865917|Drug|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
75712858|NCT00865917|Drug|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
75872163|NCT03693742|Diagnostic Test|18F-DCFPyL PET/CT scan|"Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes."
76040149|NCT04894513|Other|conventional selected program|the conventional selected program in the form of electrical stimulation (Faradic current) of affected muscles, facial muscle exercise program in front of the mirror, and home advices.
76040150|NCT04921137|Other|No endocrine therapy|No endocrine therapy given
76040151|NCT04921137|Other|Endocrine therapy|Endocrine therapy given for at least 5 years
75408232|NCT05199285|Biological|Ipilimumab|Given IV
76040152|NCT04894201|Radiation|Dental Panoramic Radiographs|Exposure to dental panoramic radiographs
75408233|NCT05199285|Biological|Nivolumab|Given IV
75408234|NCT05198518|Device|Microcurrent TENS device|The study device is a handheld micro-current TENS emitter intended to be used for the relief of postoperative pain after FESS. The design of the study device was optimized to provide transcutaneous nerve stimulation to the regional areas associated with the sinuses.
75408235|NCT05198518|Device|Sham Device|The sham device appears and operates identically to the active device, including indicator lights and haptic vibration, however it emits a weak direct current that is non-therapeutic.
75712859|NCT00865917|Drug|Placebo|matching appearance
76040153|NCT03052465|Other|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
76040154|NCT04893889|Diagnostic Test|Shear-wave elastography|Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
76040155|NCT02456103|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
75712860|NCT00696410|Drug|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels ~10-12.
75712861|NCT00865995|Procedure|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
75408237|NCT05175664|Other|Long-term study|No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
75553511|NCT00455598|Drug|ISIS 113715|doses of 100 and 200 mg per week
75712862|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
76040156|NCT04894357|Other|Phenotypic resistance measure|SDM experiments: Reverse transcriptase mutants of HIV-1 will be obtained by site-directed mutagenesis using specific primers introducing the expected mutations into plasmids pNL4.3 and CRF02_AG. HIV-1 stocks will be obtained by transfecting 293-T cells with the various HIV-1 molecular clones. 48 hours after transfection, the viral supernatants will be recovered, quantified for HIV-1p24gag antigen (Vidas BioMérieux) and frozen at -80°C.The single-cycle virus titers will be determined on HeLa-P4 cells in which the expression of b-galactosidase is inducible by the HIV Tat protein. Phenotypic analysis: creation of replication competent chimeric viruses through homologous recombination between patient or laboratory virus-derived PCR fragments and the corresponding NL4-3 vector where the whole Gag-PR, RT-RNaseH or IN coding regions have been deleted through inverse PCR. The susceptibility to Doravirine will be calculated through a single round infection assay in TZM-bl cells.
76040157|NCT04399603|Other|no intervention-mechanistic study|no intervention-mechanistic study
75712863|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
75872164|NCT03693742|Other|Placebo drink|Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
76040158|NCT01653327|Drug|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
76040159|NCT01653327|Drug|Placebo|
75408238|NCT05175664|Other|Short-term study|No intervention. Investigations: blood samples and pupillometry.
75408239|NCT05175664|Other|Cross-sectional study|No intervention. Investigations: cognitive tests, pupillometry and actigraphy.
75408240|NCT05148156|Device|Urolift|Study intervention involves a one-time administration of Urolift in out-patient setting prior to Stereotactic body radiation therapy (SBRT).
75408241|NCT05146700|Drug|Restrictive oxygen|Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
75408242|NCT05146700|Drug|Liberal oxygen|15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
75408243|NCT05138393|Other|Active self-corrective exercises|Scoliosis specific exercises with an Active self-corrective approach. Non-specific physical activity 60 minutes per day.
75408244|NCT05138393|Other|Observation|Non-specific physical activity 60 minutes per day.
75408245|NCT05136976|Drug|Rituximab infusion|2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).
75408246|NCT05136976|Drug|Placebo infusion|2 infusions of placebo at a 2 week interval.
75712864|NCT00947986|Other|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
75408247|NCT05136976|Drug|Premedications|"Premedications prior to rituximab or placebo infusions:~IV Dexchlorpheniramine Maleate IV: 10 mg~IV Methylprednisolone: 40 mg~PO Paracetamol : 1 gram"
75408248|NCT05136352|Procedure|adductor canal block|loco-regional anesthesia using adductor canal block
75408249|NCT05136352|Procedure|iPACK block|loco-regional anesthesia using infiltration between the popliteal artery and the capsule of the posterior knee
75408250|NCT05128838|Other|RISE (Reinvent, Integrate, Strengthen, Expand) Intervention|Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management. In summary, the RISE intervention includes three components: patient education, internalization of self-determination, and habit formation.
75408251|NCT05123222|Other|ZIKV-SJRP/2016-184 Strain|Zika Virus Strain
75408252|NCT05123222|Other|Experimental: ZIKV-Nicaragua/2016 Strain|Zika Virus Strain
75408253|NCT05123222|Biological|Placebo|Not an active strain of Zika
75408254|NCT05107310|Procedure|Pedicle screws insertion by free hand technique|Spinal deformity correction. Pedicle screws are inserted using free hand technique with the help of intraoperative fluoroscopy if needed.
75408255|NCT05107310|Procedure|Pedicle screws insertion using ARSN|Spinal deformity correction. Pedicle screws are inserted using augmented reality surgical navigation (ARSN) with the ClarifEye navigation system and the Philips Allura 2D/3D imaging system.
75408256|NCT05107310|Procedure|Pedicle screws insertion using IRSN|Spinal deformity correction. Pedicle screws are inserted using infra-red surgical navigation (IRSN) with the Brainlab Curve 1.2 navigation system combined with the Medtronic O-arm 2D/3D imaging system.
75408257|NCT05101798|Drug|5-Aminolevulinic acid Hydrochloride|The closure consists of colorless glass vial (Type II, Ph Eur) and bromobutyl-rubber stopper ø 20 mm (Type I, Ph Eur) and flip cap. The powder for oral solution is intended for single (partial) use. To prepare the ready-to-use solution the content of one vial is dissolved in 50 ml of water or apple juice. The concentration of the reconstituted solution is 3%. Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW). The reconstituted solution may be prepared up to 24 hours prior to use if protected from light. It should be given 3 hours (range 3-5 hours) prior to planned induction of anesthesia for surgery, although its effect is present for up to 8-12 hours. This step is critical for an optimal visualization of tumor tissue due to pharmacokinetic properties of Gleolan®.
75408258|NCT05101213|Biological|Virus-specific Cytotoxic T-lymphocytes|Given IV
75408259|NCT05090722|Device|PureWick System|The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
75408260|NCT05073588|Other|Indo Mediterranean diet|Mediterranean diet has been shown to be effective in NAFLD adult patients. In India, it is very difficult to follow Mediterranean diet, so one group will be given Indianized version of mediterranean diet.
75408261|NCT05073588|Other|Calorie restricted diet|One group will be given diet restricted in calories, which most of the patients follow to lose weight
75712865|NCT00862329|Dietary Supplement|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
75408262|NCT05068726|Drug|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
75408263|NCT05041140|Device|29-XeMRI imaging|129-XeMRI scan
75408264|NCT05040282|Device|Implanon NXT|women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.
75408265|NCT05039801|Biological|Bevacizumab|Given IV
75408266|NCT05039801|Drug|Glutaminase-1 Inhibitor IACS-6274|Given by PO
75408267|NCT05039801|Drug|Paclitaxel|Given by IV (vein)
75408268|NCT05039801|Drug|Capivasertib|Given by PO
75712866|NCT00862329|Dietary Supplement|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
75408269|NCT05034198|Behavioral|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
75553512|NCT00347594|Device|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
75553513|NCT00347594|Device|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
75712867|NCT00862329|Dietary Supplement|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
75712868|NCT00862329|Dietary Supplement|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
75712869|NCT00956956|Drug|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
75712870|NCT00956956|Drug|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
75712871|NCT00866073|Drug|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
75712872|NCT00957112|Procedure|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
75872165|NCT03693742|Other|MSG drink|Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
75872166|NCT01063868|Drug|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
75872167|NCT01063868|Drug|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
75872168|NCT04054934|Behavioral|Reversed Circadian Rhythm|Revered day/ night sleep cycle
75872169|NCT04054934|Behavioral|Normal Circadian Rhythm|Normal day/ night sleep cycle
75872170|NCT02333266|Other|Candidemia|
75872171|NCT02692443|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
75872172|NCT02692443|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
75872173|NCT02974088|Device|Neem-based lotion plus louse comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
75872174|NCT02974088|Device|Neem-based lotion plus grooming comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
75872175|NCT02329912|Device|SmartPill|Application of the SmartPill at the end of surgery
75872176|NCT01372683|Other|Dietary Intervention|Comparison of oat based breakfast cereals
75408270|NCT05034198|Behavioral|Cognitive behavioral therapy (CBT) for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
75712873|NCT00957112|Procedure|standard follow-up care|Patients receive standard care
75712874|NCT02544711|Device|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
75712875|NCT02544711|Procedure|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
75712876|NCT00752466|Drug|Topiramate; flunarizine|
75712877|NCT04982588|Device|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~EnVeo™ PRO Delivery Catheter System (DCS)~EnVeo™ PRO Loading System (LS)"
75712878|NCT00957190|Drug|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
75712879|NCT00866229|Drug|Rosuvastatin|10 mg per day for 12 weeks
75712880|NCT00866229|Drug|Simvastatin|20 mg per day
75872177|NCT02333500|Other|olfactory workshop|olfactory workshop
75872178|NCT02333500|Other|other workshop|other workshop: discussion group, dance and body Expression
75872179|NCT02333500|Other|No intervention|control group
75553514|NCT00347672|Biological|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
75553515|NCT02956863|Procedure|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
75553516|NCT02956863|Procedure|Exercises|Exercise for stretching and strength for neck muscles
75553517|NCT00347711|Drug|Intravitreal injection|
75553518|NCT00455637|Biological|Botulinum toxin type A|
75553519|NCT00347750|Drug|Lopinavir pharmacokinetic/pharmacodynamic analysis|
75553520|NCT00455676|Procedure|Chevron osteotomy versus Scarf osteotomy|
75553521|NCT00347789|Procedure|Glaucoma surgery- Bleb revision|
75408271|NCT05034198|Behavioral|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
75553522|NCT03276312|Device|Lipogems|Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
75553523|NCT00347828|Drug|Moxifloxacin ophthalmic solution 0.5%|
75553524|NCT00347828|Drug|Gatifloxacin ophthalmic solution 0.3%|
75553525|NCT00449124|Drug|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
75553526|NCT00449124|Biological|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10^6 PFU, TG4040 10^7 PFU and TG4040 10^8 PFU.
75553527|NCT00347867|Drug|Viagra administration in IUGR/PET pregnancies|
75408272|NCT05032183|Drug|Cyclophosphamide|Given IV
75553528|NCT00347906|Procedure|laser treatment|
75408273|NCT05032183|Drug|Cytarabine|Given IT
75553529|NCT00449202|Drug|oleoyl-estrone (MP 101)|
75553530|NCT00347945|Procedure|Pencil Push-ups|
75553531|NCT00347945|Procedure|Office-based Vision Therapy|
75553532|NCT00347945|Procedure|Placebo Office-based Vision Therapy|
75553533|NCT00455715|Drug|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
75553534|NCT00455754|Drug|Esomeprazole|
75553535|NCT00347984|Other|Systane Lubricant eye drops|
75872180|NCT05193435|Other|Pelvic floor exercises|Pelvic floor exercises for types I and II muscle fibers will be performed
75408274|NCT05032183|Drug|Dexamethasone|Given IV or PO
75553536|NCT00348023|Drug|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
75553537|NCT00348062|Drug|Bimatoprost|
75553538|NCT00449241|Device|Acupuncture|
75553539|NCT00348101|Drug|Combined therapy with enoximone and esmolol|
75553540|NCT00455832|Procedure|peginterferon alpha and ribavirin|sperm collection
75553541|NCT00348179|Procedure|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
75553542|NCT00455871|Drug|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
75553543|NCT00455871|Drug|Lucentis|Lucentis intravitreal injection
75553544|NCT00348218|Device|NeuroVision|
75553545|NCT00449280|Drug|Sorafenib|400mg BID (200 mg twice daily)
75553546|NCT00449280|Drug|Rapamycin|30mg once weekly
75553547|NCT00449280|Drug|Rapamycin|3mg once daily
75553548|NCT00348257|Device|Hair removal by laser/IPL device|
75553549|NCT00455910|Drug|Thalidomide|
75553550|NCT00348296|Drug|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
75553551|NCT00449319|Procedure|Identification of appropriate therapies according to risks factors|
75553552|NCT00449319|Drug|Daunorubicine|
75553553|NCT00449319|Procedure|Transplant|
75553554|NCT00348335|Drug|Cyclosporine 0.05%|
75553555|NCT00348335|Drug|Ocular lubricant|
75553556|NCT00449358|Procedure|apply methyl-ALA cream|
75553557|NCT00348413|Drug|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
75553558|NCT00348452|Drug|tramadol HCl ER; celecoxib|
75553559|NCT00449397|Drug|Quetiapine Fumarate|
75553560|NCT00348491|Drug|Lumiracoxib|
75553561|NCT03274323|Device|iStent and travoprost or latanoprost|2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure
75553562|NCT03274323|Procedure|Trabeculectomy|Standard trabeculectomy
75553563|NCT00348530|Drug|Verapamil|
75553564|NCT00449436|Drug|TRIZIVIR|TRIZIVIR
75872181|NCT05193435|Other|Stabilization exercises|Lumbar spinal stabilization exercises will be performed
76040160|NCT03053869|Drug|Benzodiazepine - limited use strategy|"No routine use of any intraoperative benzodiazepines.~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
75408275|NCT05032183|Biological|Filgrastim-sndz|Given SC
75553565|NCT00449436|Drug|Non-nucleoside reverse transcriptase inhibitor|Non-nucleoside reverse transcriptase inhibitor
76040161|NCT03053869|Drug|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
75408276|NCT05032183|Drug|Leucovorin|Given IV
75408277|NCT05032183|Drug|Mercaptopurine|Given PO
75408278|NCT05032183|Drug|Mesna|Give IV
76040162|NCT03053947|Drug|Intranasal Ketamine|Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
75408279|NCT05032183|Drug|Methotrexate|Given IT
75408280|NCT05032183|Biological|Pegfilgrastim|Given SC
75408281|NCT05032183|Drug|Prednisone|Given PO
75408282|NCT05032183|Biological|Rituximab|Given IV
75553566|NCT00449436|Drug|Boosted Protease Inhibitor|Boosted Protease Inhibitor
75553567|NCT00348569|Device|64 Channel VCT|
75553568|NCT03274284|Combination Product|chemoradiation|chemoradiation in case of T1G3 BC after BCG failure.
75553569|NCT00348608|Drug|iodixanol|
75712881|NCT04051398|Other|transcutaneous nerve electrostimulation (TENS) of acupuncture points|TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
75712882|NCT00953914|Drug|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
75712883|NCT00953914|Drug|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
75712884|NCT00858975|Procedure|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
75712885|NCT03891290|Other|Collecting recorded videos of Colonoscopy screening tests of the general population|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
76040163|NCT04893733|Drug|Vitamin B Complex|"Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI"
76040164|NCT04903483|Other|bispectral index monitoring|intraoperative single-channel electroencephalography monitoring of the depth of anesthesia
75408283|NCT05032183|Biological|Tagraxofusp-erzs|Given IV
75408284|NCT05032183|Drug|Vincristine|Given IV
75408285|NCT05032079|Procedure|cryoablation|single probe ultrasound guided cryoablation
75408286|NCT05026125|Drug|Remifentanil Injection|Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
75408287|NCT05026125|Drug|Remifentanil Injection plus 30%|Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
75408288|NCT05013879|Device|Kinesio(R)Tape for edema control|Kinesio(R)Tape is an elastic, cotton tape with an adhesive backing. When applied for edema management, strips of Kinesio(R)Tape are applied to the lower leg in a criss-cross fashion by a physical therapist who is a Certified Kinesiotape Practitioner.
75408289|NCT05012943|Biological|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
75408290|NCT05012943|Other|Placebo (normal saline)|Normal saline with the same volume as of ARCT-154
75408291|NCT05012943|Biological|Astra Zeneca COVID-19 vaccine|Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
75408292|NCT04997369|Device|Rezum|The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
75408293|NCT04994990|Drug|OnabotulinumtoxinA Standard Dose|Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
75408294|NCT04994990|Drug|OnabotulinumtoxinA Half Standard Dose|Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
75408295|NCT04992260|Biological|Inactivated COVID-19 Vaccine|The inactivated COVID-19 vaccine was manufactured by Sinovac Research& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
75408296|NCT04992260|Biological|Controlled vaccine|The placebo was manufactured by Sinovac Research& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
75408297|NCT04990895|Other|Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires|A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
75408298|NCT04984317|Drug|onabotulinumtoxin A|One-time injection of 100U BOTOX
75408299|NCT04981184|Device|Gait and balance measurement|Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
75408300|NCT04977479|Biological|Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)|mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
75408301|NCT04977479|Other|Placebo|Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.
75408302|NCT04977479|Biological|Pfizer-BioNTech COVID-19 Vaccine, Bivalent|mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.
75408303|NCT04976621|Behavioral|Behavioral Activation|BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. BA protocol components include: goal setting (especially for activities that promote social connectedness), creation of a plan (broken down into steps), strategies for implementation of steps, identification of potential barriers, tactics to overcome them, activity monitoring and scheduling, and emotion regulation strategies. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.
75408304|NCT04976621|Other|Treatment as Usual|Treatment as Usual refers to usual care provided by the VA medical center.
75408305|NCT04974515|Device|eXciteOSA|eXciteOSA is a device for improving genioglossus endurance through electrical stimulation
75408306|NCT04966247|Other|Microdialysis|Monitoring real-time cerebral biomarkers using microdialysis method
75408307|NCT04954690|Behavioral|Structured Program of exercise for Recipients of Kidney Transplantation (WC)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching)
75408308|NCT04954690|Behavioral|Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching + caregiver participation)
75408309|NCT04954690|Behavioral|Usual Care|Usual Care
75408310|NCT04947189|Drug|Seviteronel-D (Seivteronel in combination with dexamethasone)|Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
75408311|NCT04947189|Drug|Docetaxel|Use of docetaxel chemotherapy for solid tumours
75408312|NCT04916678|Other|R-TEP EMDR intervention|"During the intervention period, trained psychologists are available in the ER and will provide preferentially a short early 1-hour R-TEP EMDR intervention for patients selected with high risk of PCLS. Patient's selection will be conducted using a score developed in previous studies. If therapist considers R-TEP EMDR unsuitable, he could provide another type of intervention (such as reassurance) that will be recorded.~When no high-risk patient is identified, the therapist could assess other patients and treat them if judged necessary. In this context, they could provide either a R-TEP EMDR or short intervention such as reassurance according to therapist assessment."
75408313|NCT04912479|Device|connected watch|connected watch that provide to patients with information on their sleep quality and their performed activities
75408314|NCT04896736|Other|Multisite tissue oxygenation-guided care|"The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase >/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity"
75408315|NCT04896736|Other|Usual care|Usual care in this study means the standard perioperative care. Patients who are meant to receive usual care will receive both cerebral and muscular tissue oxygen saturation monitoring; however, the monitor screen will be covered and the monitoring data will not be used to guide clinical care.
75712886|NCT00756912|Drug|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
75712887|NCT00948220|Drug|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
75712888|NCT00756990|Drug|Depot Naltrexone|228mg of injectable naltrexone
76040165|NCT04903405|Other|No intervention|No intervention is involved in this study
75408316|NCT04858620|Drug|Xlear Nasal Spray|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nostrils, every 6 hours
75408317|NCT04858620|Drug|Placebo|Saline nasal spray, 2 puffs per nostrils, every 6 hours
75408318|NCT04854486|Other|GSE and Xylitol|Participants are given the experimental treatment to be used for 7 days.
76040166|NCT04903639|Diagnostic Test|sleep study|The polysomnography consists of electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), electromyogram (EMG), pulse oximetry, thoracic and abdominal straps, body posture sensor, nasal thermistor and nasal cannula to assess respiratory flow and pressure and bipolar channel limb movements (tibialis anterior). Electrodes and sensors were attached to patients by sleep physiologist. Data collection was obtained following signal perception by preprocessed computer (DOMINO Software, ver. 2.6.0; SOMNO Medics GmbH).
76040167|NCT03051139|Behavioral|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
75408319|NCT04854486|Drug|Control Placebo|Saline
75408320|NCT04821310|Drug|Full dose Pantoprazole plus matching placebo|Full healing dose of pantoprazole plus matching placebo
75408321|NCT04821310|Drug|Half Dose Pantoprazole plus matching placebo|Half healing dose of pantoprazole plus matching placebo
75553570|NCT03274245|Behavioral|Intervention Package|"Community Level:~Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~Transect Walk: village walk to identify and mark feces in community;~Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~Wall painting: village map noting households that use latrines always.~Sub-Community level:~Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~Household Level:~Household visits: to those with latrines to motivate use;~Latrine repairs: for households with non-functional latrines to make functional."
75712889|NCT05301244|Other|laughter yoga for nurses|The experimental group was divided into three groups as 17-17-16 people. For four weeks, laughter yoga sessions were held between 20.00 and 21.00, 2 days a week for each group. Laughter yoga sessions were held for the 1st group between 20.00-21.00 on Mondays and Thursdays, for the 2nd group between 20.00-21.00 on Tuesdays and Fridays, and for the 3rd group between 20.00-21.00 on Wednesdays and Sundays. The first sessions lasted 45 minutes, every other session 40 minutes.
76040168|NCT03053323|Behavioral|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
75408322|NCT04810260|Behavioral|Use mobile health app (WellXcel) to increase knowledge|Download the app (WellXcel) to the mobile device
75408323|NCT04805437|Device|3D TLSO|Brace treatment with Boston 3D 20 hours a day until skeletal maturity.
75408324|NCT04805437|Device|Standard TLSO|Brace treatment with standard Boston brace 20 hours a day until skeletal maturity.
75408325|NCT04790487|Drug|CPM|one spray dose (~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
76040169|NCT03053557|Behavioral|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
75408326|NCT04790487|Drug|Placebo|Saline
75408327|NCT04789681|Drug|Canakinumab|Given SC
75408328|NCT04789681|Other|Quality-of-Life Assessment|Ancillary studies
75408329|NCT04789239|Drug|Sodium zirconium cyclosilicate|SZC is an approved drug in Sweden and subsidized for patients with chronic kidney disease in stages 3 to 5, with or without chronic heart failure, for whom treatment with Resonium is not suitable and for patients with chronic heart failure without con-comitant chronic kidney disease
75408330|NCT04789239|Other|Placebo|Treatment with the same dose of placebo medicine as they would have received had they been treated with the interventional drug (SZC).
75408331|NCT04786119|Device|CORI Robotics|Knee arthroplasty with robotics assisted surgery using the CORI Robotics System.
75408332|NCT04745754|Other|Embedded primary care in cancer survivorship model|Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
75408333|NCT04720053|Device|Wearable brain sensing wellness device headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
75408334|NCT04713618|Procedure|Pelvic Examination|Undergo pelvic exam
75408335|NCT04713618|Other|Survey|Complete surveys
75408336|NCT04706793|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
75408337|NCT04706793|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
75408338|NCT04694131|Device|TMS|The intervention of interest will be TMS delivered to the region of the left posterior parietal cortex with the greatest connectivity with the left hippocampus derived from the baseline resting-state fMRI session. This region was chosen because of its dense connections with the hippocampus, allowing stimulation of this location to modulate function of the hippocampal-cortical network. The control intervention target will be vertex, a commonly used active control site which does not influence neural or behavioral activity.
75712890|NCT05301244|Other|laughter yoga for nurses-Deep breathing exercises|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
75408339|NCT04677049|Drug|Niacin CRT|A controlled release technology (CRT) tablet of Niacin
75553571|NCT03274245|Other|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
75553572|NCT00348647|Behavioral|physical training program to prevent injuries|
75553573|NCT00456027|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
75553574|NCT00448734|Drug|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
75553575|NCT00448734|Drug|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
75553576|NCT00348725|Drug|fenofibrate and metformin fixed combination (drug)|
75712891|NCT05301244|Other|laughter yoga for nurses-Warm-up exercises|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
75712892|NCT05301244|Other|laughter yoga for nurses-Childish games|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
75712893|NCT05301244|Other|laughter yoga for nurses-Laughter exercises|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
76040170|NCT04903171|Other|INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN|Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
75408340|NCT04650100|Procedure|ultrasound-guided PENG bloc realized before surgery|ultrasound-guided PENG block realized before surgery. The PENG block, described by Giron-Arebgi is made in the supine position. The ultrasound probe used is a 5 MHz high frequency linear probe placed parallel to the line delimited by the anterior-inferior iliac spine (lateral) and the pubis (medial). The needle used is an 80 mm, 22G, needle inserted in the ultrasound plane. The slow and fractioned injection of 20 ml of Ropivacaine 4.75 mg/ml is performed in the fascia between the psoas tendon and the iliopubic eminence under ultrasound guidance.
75408341|NCT04610801|Drug|Nasal Spray|Randomized to placebo and Xlear
75408342|NCT04607148|Drug|Galegenimab|Intravitreal (ITV) injections of galegenimab
75408343|NCT04603326|Procedure|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
75408344|NCT04560712|Procedure|Acupuncture Therapy|Undergo acupuncture
75408345|NCT04560712|Other|Best Practice|Undergo usual care
75553577|NCT00456066|Device|Export Aspiration System|Patients scheduled for emergency angioplasty
75712894|NCT02561286|Behavioral|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
76040171|NCT03053635|Drug|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
76040172|NCT03053011|Other|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
76040173|NCT04909489|Other|cross-sectional study without intervention|cross-sectional study without intervention
76040174|NCT04893031|Drug|Tocilizumab|400mg or 800 mg IV tocilizumab treatment according to patient clinical severity
76040175|NCT02493855|Drug|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
75553578|NCT00348764|Drug|lauromacrogol|
75553579|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
75553580|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
75872182|NCT05060536|Procedure|Removal of infrapatellar fat pad|"There is no agreed protocol for retaining or excising the infrapatellar fat pad with many surgeons routinely completely removing the fat pad to improve view of the proximal tibia while others opt to retain or minimally excise the tissue.~We are aware of no risks involved in performing this procedure and current practice of many orthopaedic surgeons is either to routinely remove or routinely retain the infrapatellar fat pad when performing total knee arthroplasty.~The potential benefits are that we will understand better whether removing or retaining this tissue does have a role in influencing outcomes after total knee replacement surgery. The results will be disseminated to the wider orthopaedic community to inform practice with the aim or improving outcomes from total knee arthroplasty."
75872183|NCT05060536|Procedure|No removal of infrapatellar fat pad|Retaining the infrapatellar fat pad during total knee replacement- no surgical removal.
76040176|NCT02493855|Drug|Dasabuvir|Dasabuvir tablets
76040177|NCT02493855|Drug|Ribavirin (RBV)|Ribavirin tablets
76040178|NCT04902157|Diagnostic Test|Cycle threshold|cycle threshold number
76040179|NCT04892563|Procedure|Erector Spinae Plane Block|Nerve block with local anesthetic in the erector spinae plane
75408346|NCT04560712|Other|Questionnaire Administration|Ancillary studies
75408347|NCT04551170|Drug|Theophylline|oral theophylline
75408348|NCT04551170|Drug|Placebo|Placebo capsule or elixir
75408349|NCT04542057|Drug|Ensifentrine|"Dosage Formulation:~Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks"
75408350|NCT04542057|Drug|Placebo|"Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks"
75408351|NCT04522570|Device|Laser ablation|Single session with Diode laser ablation system; one or two applicators will be used for treatments; one to three illuminations; fixed output power of 3 watts (W); pullback technique; delivered energy: 1200-1800 Joules (J) varying according to tumor volume; treatment under local anesthesia +- conscious or moderate sedation;
75553581|NCT00456105|Behavioral|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
75553582|NCT03276156|Drug|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
76040180|NCT04892563|Drug|IV Analgesia|IV analgesia, typically Morphine/Opioid medications
76040181|NCT04909255|Drug|mirabegron|use beta-3 agonist for sjogren syndrome patient
76040182|NCT04909255|Drug|oxybutynin, tolterodine, solifenacin|use anti-muscarinic agent for patient with overactive bladder syndrome
75553583|NCT00348842|Procedure|Newcastle Virus|
76040183|NCT03052231|Device|caremessage|Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
75408352|NCT04522570|Device|Cryoablation|Single session with Argon-based cryoablation system; one 17 Gauge (G) V-probe applicator will be used for treatments; fixed gas delivery of 100%; treatment under local anesthesia +- conscious or moderate sedation;
75408353|NCT04522570|Device|Radiofrequency ablation|Single session with radiofrequency generator; one 17 Gauge (G) V-tip applicator with a 1 to 4cm active tip; moving-shot technique or multiple overlapping shot technique with 60 Watts (W) output power; treatment under local anesthesia +- conscious or moderate sedation;
75408354|NCT04520503|Drug|Propofol|The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.
75408355|NCT04520503|Device|EEG monitoring|The processed EEG spectrogram and indices, such as patient status index, 95% spectral edge frequency, and suppression ratio, will be obtained from Sedline monitoring device. The raw pre-induction EEG will be extracted from Sedline at the end of induction and it will be analyzed by an external software to calculate the mean frequency, frequency band power and its distribution.
75408356|NCT04518748|Drug|Yttrium-90|Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)
75408357|NCT04518748|Device|Selective Internal Radiation Therapy|SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres
75408358|NCT04518748|Radiation|Stereotactic Body Radiation Therapy|3-5 fractions over 1-2 weeks, after Y-90 SIRT
75408359|NCT04518748|Diagnostic Test|PET/CT|Within 3 hours of completing Y-90 SIRT
75408360|NCT04518748|Device|Therasphere|Glass microspheres containing Y-90, administered at day 0 by SIRT
75408361|NCT04514757|Device|active tVNS|20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
75408362|NCT04514757|Device|sham tVNS|Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
75408363|NCT04505267|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or intranodally
75408364|NCT04505267|Radiation|Radiation Therapy|Undergo RT
75408365|NCT04482621|Drug|Decitabine|"Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.~Decitabine will be administered via Intravenous Administration 10/mg/m^2/day Dosage: 10mg/m^2/day IV day x 5 days (1 cycle only)"
75712895|NCT02561286|Behavioral|Health Promotion Intervention|"Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals."
75712896|NCT00757068|Behavioral|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
75712897|NCT00757068|Behavioral|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
75872184|NCT04210869|Dietary Supplement|Mixed Nuts|Study volunteers will receive daily 60 g of mixed nuts (15 g walnut, 15 g cashew, 15 g hazelnut, 15 g pistachio) for 16 weeks.
75408366|NCT04482621|Other|Placebo Saline|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
75408367|NCT04447872|Procedure|Timing of injectable gonadotropins|Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)
75408368|NCT04423211|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
75408369|NCT04423211|Drug|Apalutamide|Given PO
75408370|NCT04423211|Procedure|Computed Tomography|Undergo PET/CT
75408371|NCT04423211|Drug|Degarelix|Given SC
75408372|NCT04423211|Radiation|External Beam Radiation Therapy|Undergo EBRT
75408373|NCT04423211|Other|Fluciclovine F18|Given IV
75408374|NCT04423211|Drug|Goserelin Acetate|Given SC
75408375|NCT04423211|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
75408376|NCT04423211|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75408377|NCT04423211|Drug|Leuprolide Acetate|Given IM
75408378|NCT04423211|Procedure|Magnetic Resonance Imaging|Undergo PET/MR
75408379|NCT04423211|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MR
75408380|NCT04423211|Other|Quality-of-Life Assessment|Ancillary studies
75408381|NCT04423211|Other|Questionnaire Administration|Ancillary studies
75408382|NCT04423211|Drug|Relugolix|Given PO
75408383|NCT04423211|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75408384|NCT04423211|Drug|Triptorelin|Given IM
75408385|NCT04423211|Radiation|Volume Modulated Arc Therapy|Undergo VMAT
75553584|NCT00456144|Drug|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
75553585|NCT00456183|Biological|MVA 85A|
75408386|NCT04422951|Behavioral|Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment|Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity
75408387|NCT04422951|Behavioral|Education plus usual care behavioral treatment|6-month health education plus usual care behavioral intervention for weight control in children with obesity
75408388|NCT04410302|Procedure|Biospecimen Collection|Undergo collection of tumor tissue, blood, saliva, and urine samples
75553586|NCT00348920|Procedure|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
75553587|NCT00348959|Behavioral|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
75553588|NCT00449514|Drug|tamoxifen|
75712898|NCT00957346|Drug|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
75712899|NCT00957346|Drug|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
75712900|NCT04061096|Diagnostic Test|Evaluation of cold test|Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
75712901|NCT04061096|Diagnostic Test|Evaluation of electrical pulp test|Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
75712902|NCT04061096|Diagnostic Test|Evaluation of pain during the treatment|Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
75408389|NCT04404088|Drug|Acalabrutinib|Given PO
75408390|NCT04404088|Drug|Lenalidomide|Given PO
75408391|NCT04404088|Biological|Rituximab|Given IV
75712903|NCT00750984|Procedure|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
75712904|NCT00750984|Procedure|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
75408392|NCT04353154|Diagnostic Test|Spartan Cube Point-of Care Covid-19 test|Throat and nasal swab for COVID-19 point-of-care test.
75408393|NCT04340570|Behavioral|Medication management via televisit to home|Pharmacist led home based televisit for medication management
76040184|NCT04891939|Other|Health education lessons (Smart-Kid's program)|The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So & Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
75712905|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
75408394|NCT04335292|Drug|Osimertinib First-Line|Osimertinib, 80 mg, oral, daily
75553589|NCT00449514|Drug|clomiphene citrate|
75553590|NCT00348998|Biological|bevacizumab|
75712906|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
75712907|NCT00954070|Device|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
76040185|NCT04891939|Other|School Health and Education Program (SHEP)|The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
76040186|NCT04892095|Other|No intervention|This is an observational cross-sectional study. No intervention is considered.
76040187|NCT04891861|Drug|Apixaban|Direct Oral Anticoagulation all at label dose and frequency
76040188|NCT04902313|Behavioral|Awareness and insight Modules (AiM)|12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
76040189|NCT04891783|Device|ultrasonography|The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus[26]. Plaque is defined as a focal protrusion in the lumen at least cIMT>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching >0.5 mm [26]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
76040190|NCT03053167|Drug|Irinotecan|Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
75408395|NCT04335292|Drug|Platinum + Pemetrexed Chemotherapy Second-Line|Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
75408396|NCT04335292|Drug|Osimertinib Third-Line|Rechallenge with osimertinib, 80 mg, oral, daily
75408397|NCT04317534|Drug|Pembrolizumab|Pembrolizumab 400mg IV
75553591|NCT00348998|Drug|bicalutamide|
75712908|NCT00752544|Drug|TMC435350|
76040191|NCT03053167|Drug|Raltitrexed|Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
75553592|NCT00348998|Drug|goserelin acetate|
75553593|NCT00348998|Radiation|radiation therapy|
75553594|NCT00456222|Behavioral|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
75553595|NCT00349037|Biological|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
75553596|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
75553597|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
75553598|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
75712909|NCT00957502|Device|ENTact™ Septal Stapler|1 year aged septal staples
75712910|NCT00957502|Device|ENTact™ Septal Stapler|18 Month Aged Staples
75712911|NCT00751062|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
75712912|NCT00751062|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
75712913|NCT04031456|Biological|Autologous Platelet Rich Plasma|Autologous PRP intra ovarian infusion
75712914|NCT04031456|Biological|Placebo-Platelet Free Plasma|Autologous PFP intra ovarian infusion
75712915|NCT00948376|Genetic|IFT80 screening|Natural History
75712916|NCT00752700|Other|Conventional resistance training|Conventional resistance training program (CRT)
75712917|NCT00752700|Other|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
75872185|NCT04993924|Drug|Cetrorelix Acetate, Ganerelix Acetate|3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle
76040192|NCT03052543|Device|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
75712918|NCT00957736|Genetic|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
75712919|NCT00957736|Other|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
75712920|NCT00751374|Drug|gentamicin|topical gentamicin cream on daily basis
75712921|NCT00751374|Drug|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
75712922|NCT02566694|Procedure|Implant|orthopaedic implant
75408398|NCT04312802|Diagnostic Test|Cardiopulmonary exercise test (CPET)|"The participant will undergo a cardio-pulmonary exercise test (CPET) on a cycle ergometer (Ergoline) connected to a 12-lead electrocardiogram, oxygen saturation monitor and continuous non-invasive blood pressure cuff. Respiratory gas exchanged will be measured from a tight fitting facemask. An initial 2-min period of baseline data will be collected at rest before a 180-s period of unloaded cycling. A ramp protocol will then be applied and the participant will be instructed to continue cycling at a constant cadence of 60 rpm as long as they can. The test will be terminated if the participant indicates that:~they cannot continue~cadence falls to <55 rpm due to fatigue or dyspnoea~they develop abnormal cardiac signs or symptoms, such as ischaemia and arrhythmia."
75553599|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
75712923|NCT00954148|Procedure|PET/CT|5 visits with PET/CT as only testing
75712924|NCT00954148|Procedure|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
75712925|NCT03951194|Biological|Autologous Platelet Rich Plasma (PRP) intra ovarian infusion|Autologous PRP intra ovarian infusion
75712926|NCT03951194|Other|Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion|Autologous PFP intra ovarian infusion
75712927|NCT00957814|Behavioral|Nutritional education|Systematic nutritional orientation program
75712928|NCT00757224|Behavioral|Guidance|Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
75712929|NCT00954304|Drug|HM30181AK 1mg|HM30181AK 1mg tablet
75712930|NCT00954304|Drug|HM30181AK 5mg|HM30181AK 5mg tablet
75872186|NCT02330068|Drug|citalopram|Cases
75712931|NCT00954304|Drug|HM30181AK 15mg|HM30181AK 15mg tablet
75872187|NCT04904458|Other|"Experimental group (enfacement illusion)"|Virtual reality enfacement illusion exposure
75872188|NCT04904458|Other|Control Group (Pleasant virtual environment exposure)|Pleasant virtual environment exposure
76040193|NCT04902079|Device|Device for Cardiac Contractility Modulation Therapy (CCM)|Evaluate the effect from CCM Therapy in HF population
75712932|NCT00954304|Drug|HM30181AK 60mg|HM30181AK 60mg tablet
75712933|NCT00954304|Drug|Loperamide 2mg|Loperamide 2mg capsule
75408399|NCT04306315|Biological|Brodalumab|Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.
75553600|NCT00449592|Drug|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
75553601|NCT00449592|Drug|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
75712934|NCT00752778|Other|pet-scan FDG-F18|
75712935|NCT00363415|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
75712936|NCT00363415|Drug|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
76023219|NCT02406781|Drug|Combination of MK3475 with Metronomic CP and G100|"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
76023220|NCT05106023|Drug|SHR-1701|SHR-1701 combined with temozolomide
76023221|NCT05106023|Drug|Temozolomide|SHR-1701 combined with temozolomide
76023222|NCT02398123|Other|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
75712937|NCT00363415|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
75712938|NCT00757302|Device|SLN procedure (CarolIReS camera)|"Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²)."
76040194|NCT04901923|Drug|ACP-196|Participants will receive ACP-196 oral capsule(s) in all parts.
75553602|NCT00349076|Drug|5-FU and oxaliplatin|"Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
75712939|NCT00757380|Procedure|Trypan Blue|Membranepeeling with TB
76040195|NCT04901923|Drug|Itraconazole|Participants will receive itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then 200 mg capsule QD on Day 9 under fasting state.
76040196|NCT04901845|Other|No intervention provided|Study is provided in the usual daily practice of the physicians without interventions made in their practice
75408400|NCT04294901|Behavioral|Direct to patient medication brochure|An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
76040197|NCT04908007|Other|Qualitative analysis for professionals|"3 individual interviews with the different categories of professionals most involved during the crisis in each university hospital. In the first phase, the points of improvement identified will be analyzed In the second phase, good practices and innovations will be analyzed. For these first two phases, the duration of one hour was chosen because it is difficult to mobilize the professionals for longer. Individual interviews are preferred, but group interviews are possible with no more than three people so that everyone can express himself or herself. Finally, individual interviews of 15 to 30 minutes will be conducted with some of the people interviewed previously in order to identify the costs of the dysfunctions or problems encountered during the crisis.~Questionnaires with establishments associated with the crisis management, the ARS AuRA and France Assos Santé AuRA.~Analysis of evidence documents in the university hospitals"
76040198|NCT04908007|Other|Quantitative analysis for Professionals|"A self-assessment of the three phases of the crisis management process (preparation, crisis management, crisis recovery) will be carried out in the participating establishments using the WHO grid with the target persons identified within the establishments.~This step will use the crisis response assessment tool developed by the WHO following the H1N1 pandemic in 2011. This grid will be adapted beforehand to the COVID-19 situation and to the local organization by the study's scientific committee. The dimensions investigated will be : Command and control, Communication, Safety and security, Triage, Surge capacity, Continuity of essential services; Human resources, Logistics and supply management, Post-disaster recovery.~The grids will be sent to the 4 university hospitals to be filled in with the target audience recommended by the WHO methodological guide.~The results of this self-assessment will be linked to and interpreted with the results of the interviews in phase 1."
76040199|NCT04908007|Other|Quantitative analysis for Patients|"A questionnaire of patients' perceptions on the same perimeter (crisis and post-crisis management, from the point of view of points of improvement and good practices) will be constructed and sent by the management of the establishments to all patients hospitalized for 48 hours or more during the first wave and who have left their email address (methods similar to the e-satis survey). The online questionnaire survey is preferred in order to get away from the emotion and for feasibility reasons. This patient experience questionnaire adapted to COVID will be co-constructed with expert/partner patients and user associations.~Four dimensions will be investigated : The perception of the quality of the information received by the patient, The nature of the information on the specific health protection protocol from which the patient benefited, The patient's consideration of the overall context, during and after, The effects of the health context on the overall management of the patient"
75408401|NCT04276922|Behavioral|Visual Arts|"Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
76040200|NCT04908007|Other|Tools development|"Development of tools to prepare for situations of uncertainty : In the third phase of the project, design thinking workshops will be organized (within the HCL) to develop training (in the form of simulation) in order to appropriate virtuous practices in situations of uncertainty. The purpose of these training sessions will be to improve the institution's ability to learn in a situation of uncertainty and thus to develop its reliability.~The aim of these workshops is to provide tools for raising awareness of situations of uncertainty to all hospital staff."
76040201|NCT03050905|Drug|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
75408402|NCT04276922|Behavioral|Music|"Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation."
75408403|NCT04276922|Behavioral|Dance/Movement|"Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
75553603|NCT00349076|Drug|5-FU|"Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
76040202|NCT03050905|Drug|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"
75553604|NCT00349115|Drug|Thalidomide|
75712940|NCT00757380|Procedure|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
75553605|NCT00456339|Drug|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
75553606|NCT00349193|Drug|laquinimod 0.3|laquinimod 0.3mg
75553607|NCT00349193|Drug|laquinimod 0.6|laquinimod 0.6mg
75553608|NCT00349193|Other|Placebo|Blinded Placebo
75408404|NCT04276922|Behavioral|Writing/Poetry|"Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
76040203|NCT03050827|Drug|3% oxybutynin|Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
75408405|NCT04276922|Behavioral|Control|Control Group will only complete surveys at baseline and 12 weeks later.
75408406|NCT04267315|Procedure|Trigger point injection|1mL injections of 1% lidocaine in the muscles identified active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
76040204|NCT03050827|Drug|Placebo|Non-active placebo for 3% oxybutynin
76040205|NCT04891159|Other|Shared decision making|The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
76040206|NCT04900909|Device|Aortic Valve Replacement|Surgical replacement of aortic valves
75408407|NCT04267315|Procedure|Subcutaneous saline injection|0.2mL subcutaneous saline injections superficial to the muscles identified with active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
76040207|NCT04891003|Diagnostic Test|Ultrasonography|The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
75553609|NCT00449709|Drug|GSK221149|
75553610|NCT00421421|Drug|Dutasteride|
75553611|NCT03274206|Biological|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
76040208|NCT04907461|Procedure|LAPTAP|Laparoscopic guided Transverse Abdominus Plane block
75553612|NCT03274206|Drug|Placebo|BLS-ILB-E710c-placebo
75553613|NCT00421460|Drug|Testosterone Undecanoate,1000mg|duration for 4 injections
75553614|NCT00349232|Behavioral|lifestyle intervention (diet and physical activity)|
75553615|NCT00449826|Procedure|Computed Tomographic Angiography|CT scan
75553616|NCT00349271|Procedure|Stem cell|Stem cell
75553617|NCT00349271|Drug|Filgrastime (G-CSF)|Filgrastime (G-CSF)
75553618|NCT00349271|Drug|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
75553619|NCT00456417|Drug|123-I MNI-187 Injection and Imaging Procedures|
75553620|NCT03274167|Drug|Gabapentin 300mg|
75553621|NCT03274167|Drug|Placebo oral capsule|
75553622|NCT00349427|Drug|Rosiglitazone 4 mg|
75553623|NCT00449943|Procedure|Computed Tomographic Angiography|CT scan
75553624|NCT00449943|Procedure|Myocardial Perfusion Imaging Scan|SPECT
75553625|NCT00349505|Procedure|hyper thermic chemo + surgery|
75553626|NCT00349583|Drug|Topical Cyclosporine, Tears|
75553627|NCT00449982|Drug|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
75553628|NCT00349661|Drug|impact on VASP test|
75553629|NCT00456651|Device|CPAP (Continuous Positive Airway Pressure)|
75553630|NCT00349700|Procedure|Compression: 2 weeks four layer bandages, then stockings|
75553631|NCT00349700|Procedure|debridement|
76040209|NCT04907617|Other|FAW|After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of <36.5°C.
76040210|NCT04907617|Other|Warmed fluids|In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
75408408|NCT04267315|Other|Comprehensive Rehabilitation program|Patients in both groups will undergo standard of care rehabilitation delivered by a Physiatrist, which may include Physical Therapy, Occupational Therapy, Exercise Physiologist, Rehabilitation Nurse, Psychologist, as per Physiatrist's prescription. Both the comprehensive rehabilitation program and pain medications will continue to be managed by participant's Physiatrist, who will be blinded to patient's allocation. The researchers will be responsible for TPI and for data collection.
75408409|NCT04260607|Drug|Ketamine Hydrochloride|"Experimental Procedure~Baseline evaluation of suicidal severity (BSSI) & degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect."
75712941|NCT00957970|Device|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
75553632|NCT00349700|Procedure|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
76023223|NCT02398123|Other|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
76023224|NCT02398123|Drug|Bupivacaine|
76023225|NCT05105945|Procedure|Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery|"Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery dissects, dissociates and removes the esophagus in the mediastinum through an inflatable endoscopy. Detailed surgical procedures and related instructions have been published in Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11."
76023226|NCT05105945|Procedure|Thoracoscopy Combined With Laparoscopic Surgery|Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery
76040211|NCT04907617|Other|Combination|"After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of <36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet."
75408410|NCT04260607|Drug|Normal saline|"Experimental Procedure~Baseline evaluation of suicidal severity (BSSI) & degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~Post Normal Saline re-evaluation of outcome measure at one-week post infusion."
75712942|NCT00957970|Device|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
75872189|NCT05193357|Device|home-based intermittent pneumatic compression (IPC) device|During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
75872190|NCT02494869|Behavioral|Nonlinear Aerobic Training|
76040212|NCT04907617|Other|Control|The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
76040213|NCT02438787|Drug|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
76040214|NCT02438787|Drug|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
76040215|NCT02438787|Drug|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
76040216|NCT02438787|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
75408411|NCT04260347|Drug|Alteplase|Intravenous injection
75872191|NCT02494869|Other|Height, Weight, BMI measure|
75872192|NCT02494869|Other|Blood draw|
75872193|NCT02494869|Other|Cardiopulmonary exercise test|
75553633|NCT00450021|Drug|[(11)C] MePPEP|
75872194|NCT02385045|Device|i-scan|i-scan function is located on the head of the Pentax endoscopes
75872195|NCT02385045|Device|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
75553634|NCT00349739|Drug|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
75408412|NCT04259411|Device|MitraClip procedure|MitraClip procedure with MitraClip NTR System or MitraClip XTR System
75408413|NCT04207190|Drug|Gemtuzumab Ozogamicin|Given IV
75408414|NCT04207190|Other|Quality-of-Life Assessment|Ancillary studies
75553635|NCT00456690|Other|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
75553636|NCT00349817|Behavioral|web-based learning, didactic lecture and role-play|
75553637|NCT00450060|Device|lumbar puncture with Quincke-design needles|
75553638|NCT00450060|Device|lumbar puncture with Sprotte-design needles|
75553639|NCT00349856|Device|Biofinity|Soft contact lens
75553640|NCT00456729|Drug|Metronidazole|
75553641|NCT00456729|Procedure|Blood tests|
75872196|NCT02330146|Drug|RCT-01|
75872197|NCT02330146|Drug|Placebo|
75872198|NCT02329444|Procedure|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
75872199|NCT02329444|Procedure|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
75872200|NCT01990521|Procedure|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
76040217|NCT04901065|Drug|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle
75408415|NCT04207190|Other|Questionnaire Administration|Ancillary studies
75408416|NCT04207190|Drug|Talazoparib|Given PO
75408417|NCT04207190|Drug|Talazoparib Tosylate|Given PO
75408418|NCT04198558|Drug|MEDI0618|MEDI0618 A novel human immunoglobulin antibody
75408419|NCT04198558|Drug|Placebo|Placebo
75408420|NCT04197921|Device|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
75553642|NCT00349895|Device|Coronary stent implantation|Percutaneous Coronary Intervention
75553643|NCT00349934|Biological|IMP321|"This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
75553644|NCT00450099|Drug|bupivacaine|0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
75553645|NCT00450138|Drug|ZD6474 (vandetanib)|once daily oral dose
75553646|NCT00450138|Drug|Cisplatin|intravenous infusion
75553647|NCT00450138|Radiation|Radiation|radiation of head and neck
75553648|NCT00350051|Drug|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
75553649|NCT00350090|Drug|Epoetin Alfa|
75553650|NCT04699110|Drug|Adrenaline|Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow
76040218|NCT04901065|Drug|Placebo|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
76040219|NCT04430803|Dietary Supplement|Hydrogen-rich water|A tablet that produces hydrogen dissolved in a glass of water
75553651|NCT04699110|Drug|Adenosine|Control group will receive adenosine (100 to 400 mcg)
75712943|NCT00752934|Drug|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
76040220|NCT04430803|Other|Control Water|A glass of tap water
75712944|NCT00752934|Drug|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
75712945|NCT00948532|Biological|biologic, Osteocel Plus|Osteocel® Plus
76040221|NCT04412005|Other|No intervention|No intervention
75712946|NCT00696020|Drug|BI 1744 CL/tiotropium bromide fixed dose combination|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
76040222|NCT02493777|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
76040223|NCT02493777|Drug|Placebo|
76040224|NCT04890691|Device|Feel Bright Light|During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
75712947|NCT00696020|Drug|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
75712948|NCT00696020|Device|Respimat® Inhaler|
76023227|NCT04480801|Other|Thermal Evaluation and Foot Care|Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.
76023228|NCT04480801|Other|Foot Care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
75408422|NCT04193527|Drug|DaTSCAN™ Ioflupane (123I) Injection|All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie [mCi]) per participant at a maximum volume of 5 milliliter [mL]) intravenously on Day 1.
76040225|NCT04890457|Device|Vagus nerve stimulation via tragus|The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
76040226|NCT04890457|Device|Sham stimulation via earlobe|The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
76040227|NCT03052699|Procedure|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
76040228|NCT04907149|Drug|GLPG3970 film-coated tablet|Participants will receive a single oral dose of GLPG3970.
76040229|NCT04907149|Drug|[14C]GLPG3970 solution for infusion|Participants will receive an i.v. microtracer microdose.
76040230|NCT04907149|Drug|[14]GLPG3970 oral solution|Participants will receive a single oral dose [14C]GLPG3970.
75408423|NCT04191824|Diagnostic Test|APOL1 status|Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.
75408424|NCT04186416|Other|Mostcare® device|The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
75408425|NCT04186416|Other|Transthoracic cardiac ultrasound|Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
75408426|NCT04172259|Drug|Doxorubicin liposome|PLD
75553652|NCT04698759|Other|No Intervention|no Intervention
76040231|NCT04431037|Dietary Supplement|Early oral feeding/Enhanced recovery after surgery protocols|Early oral feeding refers to NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
75408427|NCT04172259|Drug|Cyclophosphamide|CTX
75408428|NCT04172259|Drug|Trastuzumab|H
75408429|NCT04172259|Drug|Docetaxel|DOC
75408430|NCT04172259|Drug|Epirubicin|EPI
75408431|NCT04172259|Drug|Pertuzumab|P
75712949|NCT00751608|Drug|APL180|
75712950|NCT00751608|Drug|APL180|
75712951|NCT00751608|Drug|Placebo|
75712952|NCT00958048|Device|non-invasive ventilation|CPAP, BiPAP
75872201|NCT01990521|Device|MS3TMRI / TRUS Guided Biopsy|"Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.~A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished)."
75872202|NCT02333344|Drug|Zoledronic acid 5mg|two-year Zoledronic acid 5mg infusion treatment
75712953|NCT00751686|Procedure|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
75872203|NCT01312857|Drug|panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles"
75712954|NCT00751686|Other|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
75712955|NCT01047085|Procedure|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
75712956|NCT00576576|Drug|Atorvastatin|Atorvastatin 80 mg a day
75712957|NCT01049971|Device|wound protector|after minilaparotomy, the wound protector is applied
75872204|NCT01312857|Drug|Randomization to No Panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles"
75712958|NCT01049971|Device|no wound protector|use of woven drape instead of wound protector
75712959|NCT04056156|Behavioral|HIV-screening advice|To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail
75712960|NCT04056156|Behavioral|HIV-testing advice plus group-level training|To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
75712961|NCT00751764|Drug|Moxidectin|
75408432|NCT04172259|Drug|Paclitaxel|paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week
75553653|NCT00350168|Drug|valsartan + amlodipine|
76040232|NCT03052621|Procedure|Omental transposition|Harvesting the omentum to cover irradiated defects of breast cancer
75553654|NCT03274089|Device|Kiosk intervention group|"SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~Collects patient information using patient-specific identification~Prompts the user for answers to screening questions for acute conditions~Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~Triages patients based on responses to screening questions, physiological parameters and blood test results~Provides recommendations to the patient on the care plan, self management and lifestyle choices"
75553655|NCT00350246|Procedure|Laser Refractive Surgery|
75553656|NCT00456924|Drug|VA2914|
75553657|NCT00350285|Behavioral|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
75872205|NCT02974010|Drug|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
75553658|NCT00350285|Behavioral|Marijuana education|Information about health and behavioral effects of marijuana use.
75408433|NCT04172259|Drug|Paclitaxel-albumin|albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
75408434|NCT04155424|Drug|Eculizumab|Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
75408435|NCT04128501|Drug|Azacitidine|Given SC
75553659|NCT00105534|Drug|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
75872206|NCT02974010|Drug|Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
75408436|NCT04128501|Drug|Venetoclax|Given PO
75408437|NCT04103216|Other|Nitazoxanide with Lactobacillus Reuteri DSM 17938|Nitazoxanide with probiotics
75553660|NCT00105534|Other|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
75553661|NCT00350441|Drug|Sildenafil Citrate|
75553662|NCT00350480|Drug|Provera|
75553663|NCT00350480|Drug|Combination Birth Control pills|
75553664|NCT00456963|Behavioral|Diet|total fat < 5%, saturated fat < 10%, vegetables, fruit
75553665|NCT00456963|Behavioral|Moderate exercise|30 min at least 5 times/week
75553666|NCT00456963|Drug|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
75872207|NCT02974010|Drug|Ketamine Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
75872208|NCT02974010|Drug|Saline Solution Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
75872209|NCT05193201|Drug|recombinant human thrombopoietin injection|recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
75553667|NCT00456963|Drug|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
75872210|NCT02030938|Device|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
76023229|NCT02397967|Other|Neuropsychological assessments|"Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
76023230|NCT04458077|Behavioral|Discover Learning (SEIL)|This mobile-phone-based intervention will assess the effectiveness of 10 SEIL sessions conducted at the household level with VYAs. Activities were designed to be done individually, with siblings/peers, and with parents/caregivers. This intervention will look at how household composition and types of practice that can enhance SEIL learning.
76023231|NCT02404363|Drug|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --> clopidogrel 150 mg/d x 7days then 75mg/d"
75408438|NCT04103216|Other|Nitazoxanide|Nitazoxanide with placebo
75408439|NCT04079296|Biological|ASP7517|Intravenous (IV)
75408440|NCT04075747|Drug|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
75408441|NCT04075747|Drug|Venetoclax|Will be administered over specified duration during induction and consolidation courses
75408442|NCT04075747|Drug|Midostaurin|Will be administered over specified duration during induction and consolidation courses
75408443|NCT04075747|Drug|Enasidenib|Will be administered over specified duration during induction and consolidation courses
75408444|NCT04061746|Biological|Mesenchymal Stem Cells (MSCs)|Patients in Group A will receive a single MSCs infusion
75553668|NCT00456963|Drug|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
75408445|NCT04061746|Other|Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)|Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
75408446|NCT04022213|Drug|131 I-omburtamab|Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
75712962|NCT00757458|Drug|EDTA without re-filling|Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
75408447|NCT04022213|Radiation|WAP-IMRT|Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
75408448|NCT04013542|Biological|Ipilimumab|Given IV
75553669|NCT00350597|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
75553670|NCT00457080|Device|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
75553671|NCT00350753|Drug|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
75553672|NCT00457119|Drug|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
75712963|NCT00757458|Other|Propofol syringe re-filling with propofol containing EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
75712964|NCT00757458|Other|Target controlled infusion of propofol without EDTA|Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
75712965|NCT00757458|Other|Re-filling of syringe with propofol without EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
76040233|NCT04906681|Device|i-ACT|i-ACT is a Microsoft Kinect-based system that provides individualised exercises based on patients own goalsetting.
76040234|NCT04906915|Drug|Ketamine|The efficacy of ketamine was assessed by calculating oxygen supply and consumption
75553673|NCT00350831|Drug|XL820|
75553674|NCT00350909|Behavioral|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
75408449|NCT04013542|Biological|Nivolumab|Given IV
75408450|NCT04013542|Radiation|Radiation Therapy|Undergo radiation therapy
75408451|NCT03992456|Biological|Panitumumab|Given IV
75408452|NCT03992456|Other|Quality-of-Life Assessment|Ancillary studies
75408453|NCT03992456|Other|Questionnaire Administration|Ancillary studies
75408454|NCT03992456|Drug|Regorafenib|Given PO
75408455|NCT03992456|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
75408456|NCT03960424|Other|Comprehensive Outpatient Management|Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.
75408457|NCT03960424|Behavioral|Diabetes Telemonitoring|Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.
75553675|NCT00350948|Drug|Telcyta|Day 1 of 28 day Cycle.
75553676|NCT00350948|Drug|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
75553677|NCT00450567|Procedure|computed tomography|
75553678|NCT00450567|Procedure|positron emission tomography|
75712966|NCT02919098|Behavioral|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
75712967|NCT02919098|Behavioral|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
75553679|NCT00450567|Radiation|fludeoxyglucose F 18|
75553680|NCT00457158|Device|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
75553681|NCT00350987|Behavioral|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
75553682|NCT00421499|Drug|dark chocolate|
75553683|NCT00421538|Drug|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
75712968|NCT00923247|Drug|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
75553684|NCT00421538|Drug|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
75553685|NCT03276039|Diagnostic Test|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
75553686|NCT04714697|Drug|Cabometyx|Cabometyx 60mg once daily, oral , up to Progression disease
75712969|NCT00923247|Drug|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
75712970|NCT00757536|Procedure|Encircling Band|ppVE and encircling band
75712971|NCT00757536|Procedure|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
75712972|NCT03890354|Procedure|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
75712973|NCT00757614|Genetic|DNA analysis|
75712974|NCT00757614|Genetic|polymorphism analysis|
75712975|NCT00757614|Other|laboratory biomarker analysis|
75408458|NCT03945812|Drug|Granulocyte Colony Stimulating Factor|Filgrastim, Amgen, California, USA 300 mg/1.0 mL
75712976|NCT00757614|Other|questionnaire administration|
75872211|NCT03122535|Device|FS-LASIK 70 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
75872212|NCT03122535|Device|FS-LASIK 110 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
75712977|NCT02866136|Drug|VP16, carboplatin|Systemic treatment : Intravenous injections, 2 cycles (21 days)
75872213|NCT04835818|Diagnostic Test|Provide the panel report to the primary care physician|Point-of-care Multiplex PCR Respiratory Panel (BIOFIRE FilmArray) and Pneumonia Panel results (BIOFIRE FilmArray)
75872214|NCT01061606|Drug|temsirolimus|Given IV
75872215|NCT02329678|Procedure|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
75408459|NCT03945812|Other|Platelet Rich Plasma Arm|Platelet Rich Plasma Arm
75408460|NCT03945812|Other|Saline|Saline 9%
75408461|NCT03927131|Biological|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
75408462|NCT03927131|Biological|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
75408463|NCT03927131|Biological|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
75408464|NCT03927131|Biological|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
75712978|NCT02866136|Drug|Melphalan|intraarterial injections, 3 to 6 cycles (1 month)
75712979|NCT02866136|Drug|VP16, carboplatin, vincristin|Systemic treatment : Intravenous injections, 6 cycles (21 days)
75712980|NCT02866136|Drug|Carboplatin + laser day 1 (chemothermotherapy)|Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
75712981|NCT02866136|Device|Laser (local treatment)|
75712982|NCT02866136|Device|cryoapplication (local treatment)|
75712983|NCT02866136|Radiation|I125 radioactive plaques (local treatment)|
75712984|NCT02866136|Drug|intravitreal Melphalan (local treatment)|
75712985|NCT00757692|Drug|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
75712986|NCT00757692|Drug|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
75408465|NCT03927131|Biological|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
75408466|NCT03927131|Biological|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
75408467|NCT03915470|Drug|XF-73|XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
75408468|NCT03915470|Drug|Placebo|Placebo to match XF-73 nasal gel for colour and viscosity.
75408469|NCT03813381|Behavioral|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
75712987|NCT04041141|Diagnostic Test|CT Scan|An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
75712988|NCT04041141|Device|Experimental Oral Stent Device|Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
75712989|NCT00866385|Drug|AZD8566|Single 6 mg oral solution dose
75408470|NCT03799445|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75712990|NCT00866385|Drug|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
75712991|NCT00757770|Biological|Rotarix|Two oral doses.
75712992|NCT00757770|Biological|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
75712993|NCT04847648|Procedure|Air-polishing|Air-polishing with erythritol powder during non-surgical therapy (at baseline, 5 seconds per surface, and, if necessary, at 3 months).
75712994|NCT04847648|Procedure|Mechanical decontamination|Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
75712995|NCT02544555|Procedure|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
75712996|NCT02544555|Procedure|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
75553687|NCT03275961|Behavioral|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
75553688|NCT00351026|Drug|Methadone|short-term methadone maintenance
75408471|NCT03799445|Biological|Ipilimumab|Given IV
75408472|NCT03799445|Biological|Nivolumab|Given IV
75408473|NCT03799445|Other|Quality-of-Life Assessment|Ancillary studies
75408474|NCT03799445|Other|Questionnaire Administration|Ancillary studies
75408475|NCT03791970|Device|Orchid 035 DCB Catheter|Stents placement for femoropopliteal arterial occlusions following with Orchid 035 DCB Catheter for post-dilation
75553689|NCT00351065|Drug|SK3530|
75872216|NCT04118361|Diagnostic Test|HINTS Test|"The HINTS test is a clinical test composed of 3 oculomotor examinations:~Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging."
75408476|NCT03791970|Device|POBA Catheter|Stents placement for femoropopliteal arterial occlusions following with POBA for post-dilation
75872217|NCT04118361|Diagnostic Test|STANDING Algorithm|The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
75872218|NCT02333578|Procedure|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
75872219|NCT02329522|Device|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
75408477|NCT03784326|Drug|Atezolizumab|Given IV (vein)
75712997|NCT00753168|Drug|OT-730 ophthalmic solution|one eye drop twice daily
75408478|NCT03784326|Procedure|Conventional Surgery|Undergo surgical resection
75408479|NCT03784326|Drug|Fluorouracil|Given IV (vein)
75408480|NCT03784326|Drug|Oxaliplatin|Given IV (vein)
75408481|NCT03784326|Drug|Tiragolumab|Given IV (vein)
75408482|NCT03776487|Drug|Fluorouracil|Given IV
75408483|NCT03776487|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75408484|NCT03776487|Biological|Ipilimumab|Given IV
75712998|NCT00753168|Drug|timolol maleate ophthalmic solution|one eye drop twice daily
75712999|NCT00753168|Drug|OT-730 placebo|one eye drop twice daily
75713000|NCT02565602|Other|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
75408485|NCT03776487|Biological|Nivolumab|Given IV
75408486|NCT03776487|Drug|Oxaliplatin|Given IV
75408487|NCT03776487|Procedure|Therapeutic Conventional Surgery|Undergo partial or total gastrectomy and lymphadenectomy
75408488|NCT03751436|Drug|Enzalutamide|Given PO
75408489|NCT03751436|Drug|Venetoclax|Given PO
75408490|NCT03750903|Behavioral|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
75408491|NCT03750903|Behavioral|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
75408492|NCT03735875|Drug|Quizartinib|Given PO
75408493|NCT03735875|Drug|Venetoclax|Given PO
75408494|NCT03723694|Dietary Supplement|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
75408495|NCT03723694|Dietary Supplement|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
75408496|NCT03697148|Diagnostic Test|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
75408497|NCT03634839|Drug|Flavoring Agents|Flavor of e-liquid - sweet or tobacco
75408498|NCT03634839|Drug|Nicotine|Nicotine level (0, 3, or 12 mg)
75408499|NCT03629327|Drug|ASA 81mg|Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months
75408500|NCT03629327|Other|Control Group|Participants will be randomized to take nothing on a daily basis for a duration of 6 months
75408501|NCT03629327|Drug|ASA 325mg|Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months
75408504|NCT03575793|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.
75553690|NCT00457314|Behavioral|Exercise|Regular exercise training
75713001|NCT02565602|Other|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
75713002|NCT02565602|Dietary Supplement|Vitamin D|One tablet daily (400IU per tablet)
75408505|NCT03575793|Drug|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl[methylene]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).
75408506|NCT03575793|Drug|Ipilimumab|Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
75408507|NCT03575468|Behavioral|Enhanced E-cigarette Coaching|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
75408508|NCT03575468|Behavioral|Quitline treatment as usual|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
75408509|NCT03570801|Other|Expert Panel Review|There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
75408510|NCT03555981|Other|Early Kangaroo Mother Care|Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
75408511|NCT03555981|Other|Standard care|Incubator or radiant heater care until stable, off oxygen and >24h of admission, at which point will start intermittent or continuous kangaroo mother care
75408512|NCT03522324|Drug|Cannabis Edible|Self-Directed Use (ad-libitum)
75553691|NCT04714658|Other|Therapeutic Education|"Each patient will participate in 1 to 3 PTE sessions.~st group collective workshop : allow the patient to better understand autoimmune~nd workshop : fatigue and techniques that enable its best management.~rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges."
75553692|NCT00457353|Drug|Bacillus Clausii|For 5 days
75553693|NCT00457353|Other|Oral rehydration therapy|For 5 days
75553694|NCT00351104|Drug|Ketoprofen Topical Patch 20%|
75553695|NCT03275922|Drug|Placebo ZNS|Placebo Zolmitriptan Nasal Spray
75553696|NCT03275922|Drug|ZNS|Zolmitriptan Nasal Spray
75553697|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training|Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
75713003|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
75713004|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
75713005|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
75713006|NCT04051164|Other|Progressive Muscle Relaxation Technique|"PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week."
75553698|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg|Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
75553699|NCT00457431|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
75713007|NCT04051164|Other|Conventional treatment|Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
75713008|NCT03823118|Drug|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
75713009|NCT00866541|Device|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
75713010|NCT00695864|Drug|Ondansetron and Placebo crossover|
75713011|NCT00684996|Drug|etaracizumab|Given IV
75713012|NCT00684996|Biological|bevacizumab|Given IV
75713013|NCT04841408|Other|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
75713014|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
75872220|NCT02329522|Device|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
75872221|NCT02333422|Other|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
75872222|NCT04729192|Other|ObsQoR-10T Questionnaire|The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
75872223|NCT02329756|Drug|Tranexamic Acid (TXA)|1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
75408513|NCT03513744|Dietary Supplement|human milk oligosaccharides|mixture of five different human milk oligosaccharides
75408514|NCT03491384|Drug|Cannabis (smoked flower, ingested edible)|Self-Directed Use (ad-libitum)
75408515|NCT03488225|Drug|Cyclophosphamide|Given IV
75713015|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
75713016|NCT00751842|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
75713017|NCT05325008|Drug|Immunosuppression reduction/modification + intravenous immunoglobulin|Participants will receive intravenous immunoglobulin along with immunosuppression reduction/modification.
75872224|NCT02329756|Drug|Sodium Chloride 0.9%|"Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia~Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.~The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol."
75872225|NCT04567342|Other|1 automated message|Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
75872226|NCT04567342|Other|2 automated messages|Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
76040235|NCT04900285|Device|Delta Dental Oral Device|"The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described."
75408516|NCT03488225|Drug|Cytarabine|Given IT or IV
75408517|NCT03488225|Drug|Dexamethasone|Given IV or PO
75713018|NCT05325008|Other|Immunosuppression reduction/modification|Participants will receive immunosuppression reduction/modification.
75713019|NCT00684762|Drug|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
75713020|NCT00684762|Drug|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
75713021|NCT00753246|Drug|nimotuzumab|monoclonal antibody
75713022|NCT00695786|Drug|Lenalidomide|Given PO
75872227|NCT04567342|Other|No personal contact attempt|No personal contact attempts will be made.
75713023|NCT00695786|Biological|Rituximab|Given IV
75553700|NCT00351221|Drug|rhIGF-1/rhIGFBP-3|
75553701|NCT00457470|Drug|AG-014699|
75553702|NCT00351260|Procedure|Coronary Angioplasty|
75713024|NCT02561676|Other|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
75713025|NCT02561676|Other|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
75553703|NCT04698642|Drug|CBL-514|Both sides of the abdominal region will receive CBL-514.
75553704|NCT00450606|Procedure|Balneotherapy and hydrotherapy|
75553705|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
75713026|NCT02560740|Dietary Supplement|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
75553706|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
75553707|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
75553708|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
75553709|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
75713027|NCT02560740|Dietary Supplement|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
75713028|NCT03893942|Other|Questionnaires administration|Psychological and quality of life questionnaires
75713029|NCT03893942|Other|Langer Mindfulness Scale (LMS)|The LMS is a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
75713030|NCT03893942|Other|Mindful Attention Awareness Scale (MAAS)|The MAAS is a 15-item questionnaire, designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present
75713031|NCT03893942|Other|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
75553710|NCT00351494|Procedure|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
75872228|NCT04567342|Other|1 personal contact attempt|Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.
75872229|NCT03985072|Drug|Andes-1537 for Injection|Andes-1537 administered subcutaneously five days per week.
75408518|NCT03488225|Drug|Doxorubicin Hydrochloride|Given IV
75553711|NCT00351494|Procedure|embolization|Intervention is described in the case report form for each patient
75408519|NCT03488225|Biological|Inotuzumab Ozogamicin|Given IV
75553712|NCT00450645|Drug|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
75553713|NCT04714307|Diagnostic Test|SCA3/MJD molecular diagnosis|Double-blind molecular diagnosis for determination of the presence of the mutation.
75713032|NCT03893942|Other|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
75713033|NCT03893942|Other|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
75408520|NCT03488225|Other|Laboratory Biomarker Analysis|Correlative studies
75408521|NCT03488225|Drug|Leucovorin Calcium|Given IV
75408522|NCT03488225|Drug|Mercaptopurine|Given PO
75713034|NCT03893942|Other|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
75713035|NCT03893942|Other|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
75408523|NCT03488225|Drug|Methotrexate|Given IT, IV or PO
75408524|NCT03488225|Biological|Ofatumumab|Given IV
75408525|NCT03488225|Drug|Prednisone|Given PO
75408526|NCT03488225|Biological|Rituximab|Given IV
75408527|NCT03488225|Drug|Vincristine Sulfate|Given IV
75408528|NCT03450122|Biological|Aldesleukin|Given SC
75553714|NCT04714307|Diagnostic Test|Cognitive Testing|"Cross-sectional Cognitive evaluation with~CCAS Scale~Trail-Making Test parts A and B~Stroop Color-Word Test"
75872230|NCT02329288|Drug|Triamcinolone Acetonide|
75872231|NCT02329288|Drug|placebo|
75872232|NCT01861353|Other|Cranberry-lingonberry juice|
75553715|NCT04714307|Diagnostic Test|Psychiatric Evaluation|Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.
76040236|NCT03052777|Behavioral|Telephone counselling|The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
76040237|NCT04906837|Diagnostic Test|Trans aortic valve implantation|Measurement of the membranous septum on the pre TAVI scanner and the valve implantation height
75713036|NCT04049838|Procedure|postoperative analgesia for lower abdominal surgery in children|compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
75713037|NCT00753324|Drug|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
75713038|NCT00757926|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
75713039|NCT00757926|Other|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
75713040|NCT02561520|Biological|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
75713041|NCT02561520|Biological|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
75713042|NCT00387127|Drug|Lapatinib oral tablets|Lapatinib is administered orally once daily.
75713043|NCT00387127|Drug|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
75872233|NCT01861353|Other|Placebo juice|Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
75872234|NCT02329054|Drug|Favipiravir|"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight."
75872235|NCT03122457|Drug|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination|At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
76040238|NCT04906291|Other|Toothpaste use|Brushing three times a day
76040239|NCT04900129|Combination Product|Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%|inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.
76040240|NCT02616601|Drug|Generic Fluorouracil Cream|Topical cream, generic formulation of the brand product.
76040241|NCT02616601|Drug|Carac® (Fluorouracil) Cream|Topical cream, brand product.
76040242|NCT02616601|Drug|Vehicle Cream|Topical cream, placebo. Has no active ingredient.
76040243|NCT04927845|Behavioral|StriveWeekly|"The intervention (app.striveweekly.com) delivers content via independent modules. Principles covered in content modules: Psychoeducation; Self-monitoring; Values-based goal-setting; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Relaxation strategies; Maintenance planning. Modules get released week-by-week, and participants are self-guided through content. To facilitate skills practice, every module is accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displays user progress, including self-rating graphs and a history log of skills practice. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity."
75553716|NCT04714307|Diagnostic Test|Clinical Neurological Evaluation|Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.
75713044|NCT00387127|Drug|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
75713045|NCT00683592|Drug|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
75713046|NCT00683592|Drug|placebo|placebo
75713047|NCT00695396|Drug|Placebo|Matching volume 2 mLfor 48 weeks
75713048|NCT00695396|Drug|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
75872236|NCT02328976|Other|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
75872237|NCT02333032|Other|Inclined treadmill training|
75408529|NCT03450122|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
75408530|NCT03450122|Drug|Cyclophosphamide|Given IV
75408531|NCT03450122|Biological|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Given ID
75408532|NCT03382834|Drug|Tamoxifen|20 mg orally
75408533|NCT03382834|Drug|Vorinostat|400 mg orally
75872238|NCT04407988|Drug|Pyrotinib Maleate plus Letrozole|pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
75872239|NCT05192967|Behavioral|Pandemic preparedness via video|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.
76040244|NCT02492997|Device|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
76040245|NCT02492997|Other|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
75408534|NCT03382834|Drug|Antiretroviral drugs|Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
75713049|NCT00695396|Drug|Placebo|Matching volume 1 mL for 48 weeks
75872240|NCT05192967|Behavioral|Pandemic preparedness via classical method|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
75408535|NCT03368742|Genetic|SGT-001|AAV9 vector containing muscle-specific promoter and microdystrophin construct
75408536|NCT03360721|Drug|Abiraterone Acetate|Given PO
75408537|NCT03360721|Drug|Apalutamide|Given PO
75408538|NCT03360721|Drug|Prednisone|Given PO
75408539|NCT03350516|Dietary Supplement|Daily 500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
75408540|NCT03350516|Dietary Supplement|Daily1500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
75408541|NCT03348670|Drug|Abiraterone - Usual|"Oral~Abiraterone Combined Chemotherapy (high dose)"
75713050|NCT00695396|Drug|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
75713051|NCT00753402|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
75713052|NCT00753402|Biological|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes/Epinephrine 30mcg/kg/min
75713053|NCT05434884|Procedure|occlusal veneer restorations|"occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars"
75872241|NCT02329132|Drug|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
75408542|NCT03348670|Drug|Abiraterone - Study|"Oral~Abiraterone Combined Chemotherapy (low dose)"
75408543|NCT03308942|Drug|Niraparib|Niraparib is an orally available, potent, highly selective poly adenosine diphosphate- ribose (poly ADP-ribose) polymerase-1 (PARP-1) and PARP-2 inhibitor. It will be available as 100 milligrams (mg) capsules and will be administered as 2 X 100 mg capsules (200 mg per day) orally once daily (QD).
75553717|NCT04714307|Diagnostic Test|Emotional Attribution Evaluation|Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).
75553718|NCT04714307|Diagnostic Test|Activities of Daily Living|Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.
76040246|NCT03052075|Other|Retrospective Data Review|Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
76040247|NCT04906603|Device|Theta Burst Stimulation|TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
76040248|NCT02437305|Behavioral|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
75872242|NCT03634371|Drug|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
75872243|NCT03634371|Drug|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
75872244|NCT04342078|Dietary Supplement|Vitamin D|To investigate the effect of one year vitamin D supplementation in preterm born adults (4000 IU = 100 micrograms a day if serum concentration is < 30 nmol/l, 2000 IU = 50 micrograms a day if 30-50 nmol/l and 1000 IU = 25 micrograms a day if > 50-80 nmol/l, and no additional supplement if > 80 nmol/l) on health outcomes (bones, teeth, muscles, heart, lungs) . The target level of vitamin D concentration by every 4 months interval is 80 - 120 nmol/l .(Preterm Adult group)
75872245|NCT05192811|Dietary Supplement|Lactobacillus paracasei K56|probiotic K56 capsule, 1capsule/day (10^9cfu) ,for 60days
75713054|NCT05434884|Procedure|endocrown restorations|endocrown restorations
76040249|NCT02437305|Behavioral|ABCDEs of Melanoma|Conventional melanoma educational intervention.
76040250|NCT03051919|Other|observation|
76040251|NCT04393207|Drug|Liposomal bupivacaine (LB)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with liposomal bupivacaine + bupivacaine or with bupivacaine alone.
75408544|NCT03308942|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G-4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands (PD-L1 and PD-L2). It will be available as 50 mg lyophilized powder single-use vials or 100 mg/4 milliliters (mL) (25 mg/mL) solution in a single-dose vial. It will be administered at a dose of 200 mg intravenous (IV) using a 30-minute IV infusion
75553719|NCT00457548|Behavioral|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
75553720|NCT00351572|Procedure|Cell Search Assay|
75553721|NCT00450684|Device|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
75553722|NCT00450684|Device|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
75713055|NCT00758004|Drug|Atorvastatin|A single dose of 80 mg atrovastatin tablet
75713056|NCT00758004|Drug|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
76040252|NCT04393207|Drug|Dexamethasone and methylprednisolone (CG)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with with bupivacaine alone.
75713057|NCT02656706|Drug|Ipilumumab|
75713058|NCT02656706|Drug|Nivolumab|
75713059|NCT00753480|Drug|D4064A|
76040253|NCT04393207|Drug|Control group (Bupivacaine)- (BPG)|Transverse abdominis plane block will be performed with plain bupivacaine
76040254|NCT02492841|Drug|Mineral trioxide aggregate|Mineral trioxide aggregate
75713060|NCT00758082|Device|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
75553723|NCT00351689|Behavioral|dietary supplement|
75553724|NCT04714268|Procedure|Aorto-iliac endovascular procedure|Percutaneous procedure with stent placement
75553725|NCT00457782|Drug|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
76040255|NCT02492841|Drug|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
75408545|NCT03308942|Biological|TSR-042 (Dostarlimab)|TSR-042 (Dostarlimab) is a humanized mAb of the IgG4/kappa isotype that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. It will be administered at a dose of 500 mg for every 3 weeks (Q3W) for first 4 cycles followed by 1000 mg for every 6 weeks (Q6W) for all subsequent cycles using a 30-minute IV infusion. TSR-042 (dostarlimab) will be supplied as a solution of 160 mg (20 mg/mL) or 500 mg (50 mg/mL) in a single-dose vial.
75553726|NCT00351182|Drug|Telithromycin|
75553727|NCT00351182|Drug|Doxycycline|
75553728|NCT00457860|Drug|Immunotoxin therapy|
75553729|NCT00457860|Drug|CAT-8015 immunotoxin|
75553730|NCT00457860|Procedure|Biological therapy|
75553731|NCT00351806|Drug|Erigeron breviscapus injection|
75553732|NCT00351806|Drug|hua tuo zai zao wan (a herbal medicine pill)|
75553733|NCT00351806|Drug|Compound stroke herbal medicine (8 herbal)|
75553734|NCT00457899|Drug|Quetiapine IR (Immediate Release)|oral
75553735|NCT00457938|Other|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
75553736|NCT00457938|Other|Diet|10 % versus 35 % fat in diet
76040256|NCT02492841|Drug|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
75408546|NCT03301857|Drug|Denosumab (Cohort A)|Cohort A: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
76040257|NCT04817917|Biological|Japanese Encephalitis Vaccine (Vero Cell), Inactivated;|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. For participants from Group 1 and Group 2 who haven't completed the JE immunization schedules, a booster dose of JEV-I will be administered at 6 years old.
76040258|NCT04817917|Other|No prospective interventions|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.
76040259|NCT04412161|Procedure|Liver transplantation|Living donor liver transplantation
76040260|NCT02436915|Other|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
76040261|NCT02436915|Other|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
75553737|NCT00351845|Behavioral|Low carbohydrate diet (behavior)|
75553738|NCT00458016|Drug|MB07803|Daily oral administration
75553739|NCT00458016|Drug|Placebo|Daily oral administration
76040262|NCT04815499|Dietary Supplement|Food supplement|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
76040263|NCT04815499|Dietary Supplement|Placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
76040264|NCT04398901|Other|Neurodevelopmental assessments|The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
75553740|NCT00351884|Drug|Vildagliptin AM|
75553741|NCT00351884|Drug|vildagliptin pm|
75553742|NCT00351884|Drug|placebo|
75553743|NCT00458055|Drug|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
75553744|NCT00351923|Biological|MeMuRu-OKA (study vaccine)|
75553745|NCT00450762|Drug|gemcitabine|
75553746|NCT00450762|Drug|carboplatin|
75553747|NCT00351962|Procedure|Fractionated Stereotactic Radiotherapy|
75553748|NCT03275883|Procedure|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
75553749|NCT04698798|Procedure|Muscle Biopsy|Patients will be treated for SARS-CoV-2 symptoms on the intensive care unit. During this treatment two muscle biopsies will be obtained with an interval of seven days between them.
75553750|NCT00352157|Behavioral|Revival Soy Dietary Supplement|
75553751|NCT00450840|Drug|Simvastatin|
75553752|NCT00352196|Drug|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
75553753|NCT00352196|Other|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
75553754|NCT00450879|Drug|Pazopanib Hydrochloride|Given PO
75553755|NCT00450879|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
75553756|NCT00450879|Other|Pharmacological Study|Correlative studies
75553757|NCT00450879|Other|Laboratory Biomarker Analysis|Correlative studies
75553758|NCT00352235|Drug|KRN7000|
75553759|NCT00352313|Drug|ATN-161|Given IV
75553760|NCT00352313|Drug|carboplatin|Given IV
75553761|NCT00352352|Procedure|Tongue Acupuncture (Procedure)|
75553762|NCT00450957|Dietary Supplement|lycopene|Given orally
75553763|NCT00450957|Other|pharmacological study|Correlative studies
75553764|NCT00352391|Other|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
75553765|NCT03275844|Procedure|Physical activity assessment|Assessment of Moderate-to-vigorous physical activity
75553766|NCT00352430|Drug|Nitric Oxide/INP Pulse Delivery|
75553767|NCT00352430|Drug|Nitric Oxide/INO Pulse Delivery|
75553768|NCT00450996|Drug|Topical Steroids|
75553769|NCT00352469|Drug|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
75553770|NCT00451074|Drug|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
75553771|NCT00352508|Behavioral|Dietary advice|
75553772|NCT00465621|Drug|Xalatan|
75553773|NCT00465660|Behavioral|Progressive resistance training|
75872246|NCT05192811|Dietary Supplement|placebo|placebo capsule(maltodextrin) , 1capsule/day ,for 60days
75872247|NCT03143296|Other|Simulated reverberant environment|Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
75872248|NCT02332954|Drug|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
75553774|NCT00465699|Drug|Topical B12 0.07%|
75553775|NCT00352625|Drug|Ketoprofen Topical Patch 20%|
75553776|NCT00465777|Behavioral|Guideline adherence and financial incentive|
75553777|NCT00352703|Drug|Kepivance (Palifermin)|
75553778|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
75553779|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
75553780|NCT00352742|Drug|ATN-224 + bortezomib|ATN-224 and bortezomib dose to be determined in Phase I portion of study
75553781|NCT00465933|Drug|AIDA|
75553782|NCT00352820|Behavioral|Interview|Recorded face-to-face session.
75553783|NCT00352820|Behavioral|Questionnaire|Written survey lasting approximately 30 minutes.
75553784|NCT00352859|Drug|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
75553785|NCT00352859|Drug|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
75553786|NCT00352898|Biological|MeMuRu-OKA (study vac)|
75553787|NCT00352898|Biological|MMR, Varicella vacc (control)|
75553788|NCT00105183|Biological|Placebo|placebo infusion, single
75553789|NCT00105183|Biological|EZ-2053|single IV infusion, 9 mg/kg
75553790|NCT00105183|Biological|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
75553791|NCT00466089|Drug|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
75553792|NCT04714346|Other|no interventions|there is no intervention
75553793|NCT00466128|Drug|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
75553794|NCT00466245|Drug|MVA Smallpox vaccine|Two 0.5mL subcutaneous injections, separated by 28 days
75553795|NCT00466245|Drug|Placebo|Two 0.5mL subcutaneous injections, separated by 28 days
75553796|NCT00353015|Drug|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
75553797|NCT00353015|Drug|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
75408547|NCT03291431|Device|Intermittent theta burst transcranial magnetic stimulation|20 iTBS sessions (active or sham) administered over the course of 2 weeks
75713061|NCT00758082|Device|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
75713062|NCT04049916|Drug|Pyronaridine Tetraphosphate/Artesunate|Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
75713063|NCT04049916|Drug|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
75713064|NCT04049916|Drug|Primaquine Diphosphate|Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
75408548|NCT03289949|Drug|Psilocybine|Oral dose of psilocybine.
75713065|NCT00753558|Drug|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin & polymyxin E, gentamicin & polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel."
76023232|NCT02404363|Drug|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --> placebo 150 mg/d x 7days then 75mg/d"
75408549|NCT03289949|Drug|Ketanserin|Oral dose of ketanserin.
75408550|NCT03283761|Drug|Nab-paclitaxel 150 mg/m^2|Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
75408551|NCT03283761|Drug|Oxaliplatin 85 mg/m^2|Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
75408552|NCT03283761|Drug|5-FU 1200 mg/m^2 x 2 D|Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
75408553|NCT03283761|Drug|Leucovorin 400 mg/m^2|Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
75408554|NCT03261401|Drug|M5717|Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
75408555|NCT03261401|Drug|Placebo|Participants received placebo matched to M5717
75408556|NCT03261401|Drug|M5717|Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
75553798|NCT00466284|Drug|Tarceva (erlotinib)|
75553799|NCT00353054|Drug|Caltrate® 600 + D|
75553800|NCT00353054|Behavioral|Weight loss intervention|
75553801|NCT00466362|Behavioral|The Evje Model|
75553802|NCT00353093|Procedure|Ultrasonography of the deep vein system of the legs|
75553803|NCT00466401|Drug|Simvastatin|
75553804|NCT00466401|Drug|Ezetimibe|
75553805|NCT00353249|Behavioral|Adapted cognitive behavioral therapy (CBT)|Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
75553806|NCT00466479|Drug|brimonidine|
75553807|NCT00466479|Procedure|laser trabeculoplasty|
75553808|NCT03272256|Drug|IM156|Sequential 3+3 design.
75553809|NCT00353288|Biological|MeMuRu-OKA (study vacc)|
75553810|NCT00353288|Biological|MMR, Varicella vacc (control)|
75553811|NCT03272100|Procedure|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
75553812|NCT00353327|Procedure|Plasma infusion|
75553813|NCT00353405|Behavioral|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
75553814|NCT00353405|Behavioral|Mass media|Mass media provides messages that support sexual health skills.
76023233|NCT02404519|Dietary Supplement|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
75553815|NCT00353405|Behavioral|Control|Control group received no social skills training and no media mass media messages.
75553816|NCT00466518|Drug|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
75713066|NCT02561208|Other|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
75713067|NCT02559960|Drug|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
76040265|NCT04814875|Drug|ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)|"Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design."
76040266|NCT02492763|Drug|MK-8521|Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen [60 μg, 120 μg] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen [60 μg, 120 μg, 180 μg] over the first 3 weeks is used to achieve the final dose up to 300 μg.
76040267|NCT02492763|Drug|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
76040268|NCT02492763|Drug|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.
75408557|NCT03191461|Diagnostic Test|Adenosine stress test MRI|Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane
75408558|NCT03166644|Device|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
75408559|NCT03043976|Device|Actigraph GT9X Link device|"Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased"
75408560|NCT03035123|Behavioral|Therapeutic education|Interventional arm
75553817|NCT00458094|Behavioral|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
76023234|NCT02404519|Dietary Supplement|Placebo|1 tablet without MK-7 taken orally every day during 1 year
75408561|NCT02998528|Biological|Nivolumab|Specified dose on specified days
76023235|NCT03173131|Behavioral|Pre-operative opioid counseling|Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
76023236|NCT02398045|Other|Computerised CBT for OCD|Computerised CBT for OCD
76023237|NCT02658149|Drug|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
76023238|NCT02658149|Drug|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
76023239|NCT02658149|Drug|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
76023240|NCT02658149|Drug|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
75408562|NCT02998528|Drug|Cisplatin|Specified dose on specified days
76023241|NCT02658149|Drug|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
75408563|NCT02998528|Drug|Vinorelbine|Specified dose on specified days
75408564|NCT02998528|Drug|Gemcitabine|Specified dose on specified days
75408565|NCT02998528|Drug|Docetaxel|Specified dose on specified days
75408566|NCT02998528|Drug|Pemetrexed|Specified dose on specified days
75408567|NCT02998528|Drug|Carboplatin|Specified dose on specified days
75408568|NCT02998528|Drug|Paclitaxel|Specified dose on specified days
75408569|NCT02998528|Biological|Ipilimumab|This arm is closed and no longer enrolling patients.
75408570|NCT02933255|Biological|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x109 infectious units.
75408571|NCT02933255|Drug|Nivolumab|Nivolumab is to be administered as a flat dose over approximately 60-minutes via IV infusion.
75408572|NCT02897427|Other|Biomarker Analysis|Complete HPV testing
75408573|NCT02897427|Procedure|Biospecimen Collection|Undergo collection of blood and oral gargle samples
75408574|NCT02897427|Procedure|Ultrasonography|Undergo transcervical ultrasonography
75408575|NCT02828917|Device|MedJ-01 Ridaforolimus Eluting Coronary Stent System|
75408576|NCT02768090|Device|Skin Patch|Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
75408577|NCT02736045|Device|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
75408578|NCT02726997|Drug|Carboplatin|Given IV
75408579|NCT02726997|Biological|Durvalumab|Given IV
75408580|NCT02726997|Other|Laboratory Biomarker Analysis|Correlative studies
75408581|NCT02726997|Drug|Paclitaxel|Given IV
75408582|NCT02726997|Other|Pharmacological Study|Correlative studies
75408583|NCT02726997|Other|Quality-of-Life Assessment|Ancillary studies
75408584|NCT02718911|Drug|LY3022855|Administered IV
76023242|NCT03511079|Behavioral|Music|Music will be delivered through Pandora Plus radio via patient's computer or smartphone. The patient will choose a favorite song to create a playlist which will be used for the duration of the entire study. The subgenre of the initial song will be recorded.
75408585|NCT02718911|Drug|Durvalumab|Administered IV
75408586|NCT02718911|Drug|Tremelimumab|Administered IV
75408587|NCT02707887|Behavioral|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
75408588|NCT02707887|Behavioral|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
75408589|NCT02707887|Behavioral|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
75408590|NCT02633943|Other|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term effects of autologous transplant
75408591|NCT02605551|Procedure|Osteopathic Manipulative Therapy|"All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:~OM Occipitomastoid release technique~Sub-Occipital Release Technique~Rib Raising Technique~Rotatory stimulation of posterior Chapman's Reflexes~Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)"
75408592|NCT02605551|Behavioral|Lifestyle Modification|Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
75408593|NCT02573896|Drug|Dinutuximab|17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
75713068|NCT00921596|Procedure|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
75713069|NCT03625544|Procedure|Instrumented posterolateral spinal fusion|Instrumented posterolateral spinal fusion, with or without an additional interbody device
75713070|NCT03625544|Device|MagnetOs™ Granules|8-10cc of MagnetOs™ Granules per spinal level at the randomized allocation side of the spine (left or right)
76040269|NCT02492763|Drug|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
75713071|NCT03625544|Procedure|Autologous bone graft|8-10cc autologous bone graft per spinal level at the control side of the spine (left or right). This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
75872249|NCT01372059|Other|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
75408594|NCT02573896|Biological|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
75408595|NCT02573896|Drug|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
76040270|NCT04899817|Drug|Granisetron|The drug is given after induction of general anesthesia
76040271|NCT04905667|Drug|GB221|6 mg/kg, single dose, intravenous infusion, 90-100 min
76040272|NCT04905667|Drug|Herceptin|6 mg/kg, single dose, intravenous infusion, 90-100 min
76040273|NCT03050749|Device|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
76040274|NCT02491671|Device|Hemopatch|
76040275|NCT02491671|Procedure|standard preventive measures|
76040276|NCT04889677|Drug|Danicopan|
76040277|NCT04889677|Drug|Placebo|
76040278|NCT04397107|Drug|IL-2|Patients were received low dose recombinant human Interleukin-2
75408596|NCT02542267|Device|Gore VIABAHN Endoprosthesis|
75408597|NCT02480283|Procedure|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
75408598|NCT02480283|Radiation|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
76040279|NCT02453841|Drug|Oxymetazoline|
75408599|NCT02480283|Procedure|Venipuncture|To collect blood cells and serum for analyses.
75408600|NCT02480283|Procedure|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
75408601|NCT02477202|Device|Mirena® intra-uterine device (IUD)|In this study, a Mirena® IUD will be inserted into volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing salpingectomy (RRS) at Memorial Sloan Kettering Cancer Center (MSK). Alternatively, women with a Mirena® IUD already in place and who will be scheduled for an RRSO or RRS at MSK can also participate. We are seeking 14 evaluable participants. FTF tissue (and ovarian inclusion cyst tissue, when available) collected at the time of risk-reducing salpingectomy (RRS) will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
75408602|NCT02416128|Drug|Euphrasia|1 drop in the treated eye QID X 10 days
75408603|NCT02416128|Drug|Prednisolone acetate|1 drop in the treated eye QID X 10 days
75408604|NCT02344121|Radiation|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
75408605|NCT02330653|Biological|Fecal Microbiota Transplant (FMT)|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
75408606|NCT02330653|Biological|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
75408607|NCT02218606|Drug|Abiraterone acetate 1000 mg po daily|
75408608|NCT02218606|Drug|Cabazitaxel 25 mg/m2 IV|
76040280|NCT04430647|Procedure|combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)|performing ultrasound ciliary plasty then performing standard phacoemulsification
75408609|NCT02218606|Drug|prednisone 5 mg po BID|
75408610|NCT02096055|Drug|Cladribine|Given IV
76040281|NCT04430647|Procedure|Phacoemulsification alone|standard phacoemulsification for catarct extraction
76040282|NCT04889365|Diagnostic Test|SG Diagnostics COVID-19 Antigen Rapid Test Kit|SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
76040283|NCT04889365|Diagnostic Test|Polymerase chain reaction (PCR) test|Professional collection of a second swab sample, for confirmation by PCR
76040284|NCT04889131|Behavioral|Yoga Program Immediately|free 12 week yoga program, twice a week for 75 minutes each
76040285|NCT04889131|Behavioral|Wait-Listed Control|assigned to take the Yoga Program in 12-weeks
76040286|NCT04889131|Other|Activity Monitor|Garmin VivoSmart activity monitor throughout study
76040287|NCT04888663|Drug|Trastuzumab + Ramucirumab + Paclitaxel|For both Phase Ib and II: Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg on Days 1, 8, 15 and 22, and ramucirumab 8 mg/kg on Days 1 and 15, as well as paclitaxel will be administered intravenously in a 4-week cycle (every 28 days) For Phase Ib, Paclitaxel 80 or 70 mg/m2 (according to dose level) will be administered on Days 1, 8, 15 For Phase II, paclitaxel at RP2D (80 or 70 mg/m2) will be administered on Days 1, 8, 15 of each cycle
76040288|NCT04899427|Drug|orelabrutinib|Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
75408611|NCT02096055|Drug|Guadecitabine|Given SC
76023243|NCT03458195|Other|bio-banking collection|blood samples, biopsies, and surgical specimen collected in addition to usual practice
76023244|NCT05111873|Other|multimodal treatment|combination of medical consultations, psychological therapy, physiotherapy, occupational therapy, disease specific education und progressive muscle relaxation
75408612|NCT02096055|Drug|Idarubicin|Given IV
75408613|NCT02017717|Biological|Nivolumab|specified dose on specified days
75408614|NCT02017717|Biological|Bevacizumab|specified dose on specified days
76023245|NCT05105321|Drug|Berberine|The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
75408615|NCT02017717|Biological|Ipilimumab|specified dose on specified days
75408616|NCT01940094|Drug|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
75408617|NCT01940094|Drug|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
75408618|NCT01761305|Procedure|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
75408619|NCT01761305|Behavioral|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
75408620|NCT01761305|Other|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
75408621|NCT01539863|Other|maintenance care|Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor
75408622|NCT01539863|Other|Treatment as needed|Participants may never receive treatment, there is no upper limit
75408623|NCT01445509|Drug|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
75713072|NCT00575328|Drug|Maca Root|3g/day of Maca Root for 12 weeks.
75713073|NCT00575328|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
75713074|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
75713075|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
75713076|NCT00753792|Drug|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
76023246|NCT05105321|Behavioral|Healthy lifestyle intervention|"Healthy lifestyle intervention will be launched according to the Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019, including health lectures, health information promotion, health manual and so on."
76023247|NCT02698189|Drug|Birabresib Dose 20 mg|Administered as an oral capsule twice a day for 21 consecutive days per cycle.
75408624|NCT01445509|Drug|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
75408625|NCT00942331|Biological|Bevacizumab|Given IV
75408626|NCT00942331|Drug|Cisplatin|Given IV
75408627|NCT00942331|Drug|Gemcitabine Hydrochloride|Given IV
75553818|NCT00458094|Behavioral|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
75553819|NCT04714580|Other|Animal Fun Program|This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
75872250|NCT01372059|Other|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
75408628|NCT00942331|Other|Laboratory Biomarker Analysis|Correlative studies
75872251|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
76023248|NCT03172663|Device|pure tone audiometry|for estimate the type and degree of hearing loss
75408629|NCT00942331|Other|Placebo Administration|Given IV
76023249|NCT02397733|Radiation|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
75408630|NCT00828919|Drug|axitinib|BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
75408631|NCT00828919|Drug|crizotinib|BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
75408632|NCT00827372|Drug|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
75553820|NCT00353561|Drug|Boric|Gelatin capsules filled with 600 mg of boric acid
75553821|NCT00353561|Drug|Fluconazole|150 mg oral fluconazole gives once in 14 days
75553822|NCT00466596|Drug|Gamma Tocopherol|14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
75553823|NCT00458172|Behavioral|Assessment of beliefs and attitudes|
75553824|NCT00466635|Drug|GT267-004 (tolevamer potassium sodium)|
75553825|NCT00353678|Drug|YM150|
75553826|NCT00458250|Procedure|Haploidentical hematopoietic stem cell transplantation|
75553827|NCT00458250|Drug|Busulfan|
75553828|NCT00458250|Drug|Cyclophosphamide|
75553829|NCT00458250|Drug|CAMPATH-1H|
75553830|NCT00458250|Drug|Cyclosporin A|
75553831|NCT00458250|Drug|Methotrexate|
75553832|NCT02959736|Behavioral|MATADOC and CRS-R|Behavioural assessments for Disorders of Consciousness
75553833|NCT00466674|Drug|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
75553834|NCT00353717|Drug|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
75553835|NCT00466713|Drug|Rosiglitazone therapy|
75553836|NCT00353756|Drug|C326, IL-6 Inhibitory Avimer protein|
75553837|NCT00466791|Drug|Methylphenidate Transdermal System|Placebo
75553838|NCT00353912|Drug|valsartan + amlodipine|
75553839|NCT00458289|Drug|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
75553840|NCT00466830|Other|questionnaire administration|
75553841|NCT00466830|Procedure|management of therapy complications|
75553842|NCT00466830|Procedure|psychosocial assessment and care|
75553843|NCT00466830|Procedure|quality-of-life assessment|
75553844|NCT00353990|Drug|Insulin Aspart|
75713077|NCT05434494|Drug|Remimazolam|"Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19."
75872252|NCT00230607|Drug|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
75553845|NCT00458328|Drug|Z-338|
75553846|NCT00354068|Drug|imatinib mesylate|
75553847|NCT00354068|Drug|temozolomide|
75553848|NCT00354068|Other|pharmacological study|
75553849|NCT00466869|Drug|Betahistine|
75553850|NCT00354146|Drug|tipifarnib (R115777)|
75713078|NCT05434494|Drug|remifantanil|25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
75713079|NCT05433792|Device|Myolens CN (Central-Near) soft contact lens|Personal fitting of the Myolens-CN/CF.
75713080|NCT05433792|Device|MiSight® soft contact lens|Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
75713081|NCT00753870|Biological|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
75872253|NCT02328664|Procedure|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
75872254|NCT02332642|Other|Immuno-monitoring|
76023250|NCT02397733|Radiation|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
76023251|NCT04482127|Other|SubEpithelial connective graft|Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
76023252|NCT02397811|Dietary Supplement|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
76023253|NCT02397811|Dietary Supplement|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
75553851|NCT00458367|Drug|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
75553852|NCT00466908|Device|Pentacam and IOL Master|Pentacam and IOL Master
75553853|NCT00354185|Drug|tanespimycin|Given IV
75553854|NCT00354185|Drug|belinostat|Given IV
75553855|NCT00354185|Other|laboratory biomarker analysis|Correlative studies
75553856|NCT00354185|Other|pharmacological study|Correlative studies
75553857|NCT00458445|Drug|SPD465|
75553858|NCT00458445|Other|Placebo|Placebo is a material that may look similar to SPD465, however, contains no active drug.
75553859|NCT00354263|Biological|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
75553860|NCT00354263|Biological|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
75553861|NCT00466986|Drug|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
76023254|NCT02397811|Dietary Supplement|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
76023255|NCT02397811|Dietary Supplement|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
76023256|NCT02397811|Dietary Supplement|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
76040289|NCT04899427|Drug|Sintilimab|Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
76040290|NCT04899427|Drug|Tislelizumab|Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
76040291|NCT02453685|Drug|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
76040292|NCT02453685|Drug|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
76040293|NCT02453685|Drug|insulin aspart|Injected s.c./subcutaneously once daily.
75408643|NCT00687856|Procedure|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
75408644|NCT00590902|Drug|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
75408645|NCT00577122|Drug|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
75408646|NCT00577122|Drug|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
75408647|NCT00419770|Drug|deferasirox|20 mg/kg enterally per day
75408648|NCT00419770|Drug|Placebo|
75408649|NCT00419770|Drug|Liposomal amphotericin B|
75553862|NCT00354302|Dietary Supplement|calcium carbonate|
75408650|NCT00129701|Procedure|Telephone consultation|
75408651|NCT00076310|Drug|Docetaxel|60 mg/m^2 IV repeated every 21 days.
75408652|NCT00076310|Drug|OSI-774|100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
75408653|NCT00076310|Drug|Cisplatin|75 mg/m^2 IV every 21 days.
75408654|NCT04498416|Diagnostic Test|Quantitative and qualitative assessments of mental health|Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale
75553863|NCT00354302|Dietary Supplement|calcium citrate|
75553864|NCT00354302|Dietary Supplement|cholecalciferol|
75553865|NCT00354302|Drug|alendronate sodium|
75553866|NCT00354302|Drug|calcium gluconate|
75553867|NCT00354302|Drug|risedronate sodium|
75553868|NCT00354302|Other|laboratory biomarker analysis|
75553869|NCT00354302|Procedure|dual x-ray absorptometry|
75553870|NCT04714229|Biological|Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
75553871|NCT04714229|Biological|Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
75553872|NCT00458523|Biological|alemtuzumab|
75872255|NCT03111160|Procedure|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
75408655|NCT04350606|Biological|PF-06462700|PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
75408656|NCT04340856|Procedure|colon surgery|There are no guidelines to direct surgical therapy in patients with chronic megacolon. Historically, it is the surgeons individual choice to use one of the above mentioned surgical treatments. Therefore, the aim of this study is to analyze the success and downsides of the different surgical approaches.
75408657|NCT04340856|Drug|Laxatives|There are no guidelines to direct laxative measures in patients with chronic megacolon. Historically, it is the gastroenterologists individual choice to use one of the above mentioned laxative measures. Therefore, the aim of this study is to analyze the success and downsides of the different Laxative measures.
75408658|NCT04335240|Other|Premature family music therapy intervention to support parenting, attachment bond and preterm development|We have structured an integrated psychological and music therapeutic protocol that aims to limit or overcome neonatal long-term developmental morbidities, promote parenting and attachment bond in preterm infants.
75408659|NCT04301154|Biological|HIVIS DNA/MVA-CMDR|HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.
75408660|NCT04301154|Biological|HIVIS DNA + Cervarix and MVA-CMDR|Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
75408661|NCT04301154|Biological|Cervarix|Cervarix by IM needle injection at weeks 0, 4 and 24.
75408662|NCT04239846|Drug|AC-701 Topical Gel 0.3%|AC-701 Topical Gel 0.3%, BID
75408663|NCT04239846|Other|Placebo Gel|Placebo Gel, BID
76023257|NCT02397811|Dietary Supplement|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
75408664|NCT04233060|Drug|CS3005|CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
75408665|NCT04040790|Device|Scleral contact lens without a passive artificial iris|Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment
75408666|NCT04040790|Device|Scleral contact lens with a passive artificial iris with low contrast (<1:5)|Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
75408667|NCT04040790|Device|Scleral contact lens with a passive artificial iris with high contrast (>1:5)|Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
75408668|NCT04040790|Drug|Tropicamide and phenylephrine|Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
75408669|NCT04027998|Diagnostic Test|strain and applied pressure measurement|Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
75408670|NCT03707184|Procedure|Computed Tomography|Undergo PET/CT scan
75408671|NCT03707184|Drug|Fluciclovine F18|Given IV
75713082|NCT00575094|Drug|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
75553873|NCT00458523|Genetic|fluorescence in situ hybridization|
75713083|NCT00553696|Drug|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
75713084|NCT00553696|Drug|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
75713085|NCT00553696|Drug|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
75713086|NCT05430126|Drug|Protein Kinase Inhibitor|This retrospective pharmacovigilance study will include protein kinase inhibitor and exclude those drugs known to cause hepatotoxicities
75713087|NCT05427864|Diagnostic Test|Multiparametric Prostate MRI|Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer
75713088|NCT00553540|Device|Back supports|The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
76023258|NCT04481971|Drug|Prednisolone|Tablets
76023259|NCT04481971|Drug|lactose in capsules gelatin|Tablets
75408672|NCT03707184|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75408673|NCT03556800|Drug|Estrogel|"Each subject will receive the following IMPs in accordance with the randomisation code:~Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~Reference IMP: a single-dose of 1.25g EstroGel"
75408674|NCT03551886|Behavioral|Advanced Emotion App|The app is designed to help TAY better recognize their emotions using enhanced features
75408675|NCT03551886|Behavioral|Basic Emotion App|The app is designed to help TAY better recognize their emotions using basic features
75408676|NCT04741620|Other|Capsaicin 10microM (TRPV1 natural agonist)|10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.
75408677|NCT04741620|Other|Piperine 150microM (TRPV1 & TRPA1 natural agonist)|10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.
75408678|NCT04741620|Other|Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)|10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
75408679|NCT04741620|Other|Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)|10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
75553874|NCT00458523|Genetic|mutation analysis|
75553875|NCT00458523|Other|flow cytometry|
75713089|NCT02559804|Other|survival and late effects|survival and late effects
75713090|NCT03877380|Other|semi-structured interview|Semi-strucured interview to identify the difficulties when first applying for a personalised autonomy allowance by beneficiaries and their relatives
75553876|NCT00467064|Behavioral|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
75553877|NCT00467064|Other|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
75553878|NCT00354380|Drug|Methylene blue|
75553879|NCT00354380|Drug|Artesunate|
75553880|NCT00354380|Drug|Amodiaquine|
75553881|NCT00354419|Radiation|total-body irradiation|Undergo radiotherapy
75553882|NCT00354419|Drug|cyclophosphamide|Given IV
75713091|NCT00958204|Procedure|Light treatment|Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.
75713092|NCT00958204|Procedure|Negative ion therapy|Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks
75713093|NCT00958204|Drug|Placebo|Placebo Pill: one oral tablet each day, for 8 weeks.
75713094|NCT00958204|Drug|Fluoxetine|Fluoxetine: 20 mg oral tablet each day, for 8 weeks
75713095|NCT00954460|Drug|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
75713096|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
75713097|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
76040294|NCT04888975|Device|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
75872256|NCT03111160|Procedure|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
76040295|NCT04918797|Biological|COVAXIN|Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)
76040296|NCT05530187|Device|Electronic Patient-reported Outcomes-based Model of Care|Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
76040297|NCT04905355|Device|Virtual reality|The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
75408680|NCT04741620|Other|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)|10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
75408681|NCT04741620|Other|Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)|10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.
75408682|NCT03034902|Device|Combined EEG and fNIRS|The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
75408683|NCT02952846|Other|Algorithm for tapering og analgosedation|Algorithm for tapering og analgosedation
75408684|NCT00800514|Drug|amantadine|amantadine twice daily
75408685|NCT00800514|Drug|amantadine|amantadine 100 mg twice daily
75408686|NCT02780622|Drug|Oseltamivir|Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.
75408687|NCT02780622|Drug|Warfarin|Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
75408688|NCT02781480|Biological|AAV RPE65|Comparison of different dosages of AAV RPE65
75408689|NCT02783820|Drug|MMV390048 40 mg|
75408690|NCT02783820|Drug|Placebo to match MMV390048 40 mg|
75408691|NCT02783820|Drug|MMV390048 80 mg|
75408692|NCT02783820|Drug|Placebo to match MMV390048 80 mg|
75408693|NCT02783820|Drug|MMV390048 120 mg|
75408694|NCT02783820|Drug|Placebo to match MMV390048 120 mg|
75408695|NCT02783898|Device|AliveCor Heart Monitor|Smart phone based ECG event recorder
76040298|NCT03051841|Drug|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
75408696|NCT02784444|Drug|MSDC-0602K|MSDC-0602K capsules
75408697|NCT02784444|Drug|Placebo|Placebo capsules
75408698|NCT02787564|Behavioral|Intervention Group|The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
75408699|NCT02788188|Biological|SAB-301|SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
75408700|NCT02788188|Other|Normal (9%) Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
75408701|NCT02791308|Drug|Pimecrolimus Cream 1% (Valeant)|
75408702|NCT02791308|Drug|Vehicle cream|
75408703|NCT02791308|Drug|Pimecrolimus Cream, 1%|
75408704|NCT02796144|Drug|Lorcaserin|Max dose of 10 mg BID
75408705|NCT02796144|Drug|Metformin|Max dose of 1,000 mg BID
75408706|NCT02796144|Drug|Placebo|Matching placebos will be administered for each drug.
75408707|NCT02796300|Device|Bioflo Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
75553883|NCT00354419|Biological|anti-thymocyte globulin|Given IV
75553884|NCT00354419|Drug|cyclosporine|Given IV
75408708|NCT02796300|Device|Palindrome Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
75408709|NCT02796924|Device|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
75408710|NCT02798952|Biological|Engerix-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
75408711|NCT02800356|Procedure|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
75408712|NCT02801370|Drug|12 mg ciprofloxacin|Single administration of OTO-201
75553885|NCT00354419|Procedure|umbilical cord blood transplantation|Undergo transplantation
75553886|NCT00354419|Drug|mycophenolate mofetil|Given IV or orally
75408713|NCT02801370|Drug|Sham Control|Simulated, single adminstration
75713098|NCT00617409|Drug|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
75872257|NCT03953859|Genetic|double strand break|an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
75872258|NCT05365191|Procedure|Near infrared fluorescence navigated sentinel lymph node mapping|Participants undergo sentinel lymph node biopsy for breast cancer, and use blue dye/Tc99m radioisotope as primary tracer. Indocyanine green near infrared fluorescence as secondary tracer for mapping.
76040299|NCT04905043|Drug|Acalabrutinib|Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).
75408714|NCT02803164|Device|Wound Vacuum-assisted dressing|The NPWT system (V.A.C. Therapy System, KCI USA Inc.) consisted of a medical-grade non-adherent polyvinyl alcohol white foam applied directly to the infected surface, followed by an open-pore reticulated polyurethane black foam cut to fit the wound and covered by a transparent air-tight adhesive drape. A suction cup with tubing was placed over a small slit on the drape and connected to a suction machine (V.A.C. ULTA Therapy Unit).
75408715|NCT02803164|Other|Control group|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
75408716|NCT02806908|Drug|JZP-110|
75408717|NCT02806908|Drug|Placebo|
75408718|NCT02813070|Drug|[18F] Flutemetamol|PET brain imaging and Magnetic resonance brain imaging
75408719|NCT02815644|Drug|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
75408720|NCT02816346|Biological|Shigella sonnei 53G|"Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)"
75408721|NCT02820324|Drug|Oliceridine|
75408722|NCT02820324|Drug|Placebo|
75408723|NCT02820324|Drug|Morphine|
75408724|NCT02820870|Behavioral|Statin Decision Support Intervention|"The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline."
75553887|NCT00354419|Procedure|bone marrow aspiration|Correlative study
75553888|NCT00354419|Genetic|DNA analysis|Correlative study
75553889|NCT00354419|Biological|filgrastim|Given IV or SC
75872259|NCT02328820|Other|Percutaneous coronary intervention (PCI)|For lesions with both FFR<=0.8 and CFR<2.0
75553890|NCT00458679|Biological|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10^7) of IL-2 secreting B-cells together with (2 x 10^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
75408725|NCT02821338|Drug|Lamotrigine Extended Release|Lamotrigine Extended Release (generic) and Lamictal XR (brand).
75408726|NCT02823600|Device|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
75408727|NCT02829294|Device|E002 - cerumen removal aid|topical treatment
75408728|NCT02830074|Behavioral|Best practices PAP + patient Education +ongoing Support and Training|"This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training"
75408729|NCT02830074|Behavioral|Sleep Education|This program includes non-directive sleep education plus standard treatment of SDB.
75553891|NCT00354458|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
75553892|NCT00354458|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
75408730|NCT02835846|Drug|Estrogen Cream|Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
75553893|NCT00458718|Drug|rimonabant (SR141716)|
75408731|NCT02837328|Drug|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
75872260|NCT02328820|Other|Optimal medical therapy (OMT)|For lesions with FFR>0.8 or CFR>=2.0 or both
75408732|NCT02837328|Drug|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
75408733|NCT02839902|Drug|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
75408734|NCT02839902|Other|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
75408735|NCT02840916|Procedure|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
75408736|NCT02840916|Procedure|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
75408737|NCT02842242|Drug|MYK-461|
75408738|NCT02844582|Drug|Cabazitaxel|Given IV
75553894|NCT00354497|Other|physiologic testing|
75553895|NCT00354497|Other|study of socioeconomic and demographic variables|
75553896|NCT00354497|Procedure|evaluation of cancer risk factors|
75553897|NCT00354497|Procedure|mutation carrier screening|
75553898|NCT00354497|Procedure|study of high risk factors|
75408739|NCT02844582|Drug|Prednisone|Given PO
75408740|NCT02845674|Drug|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
75408741|NCT02845752|Drug|Stiolto Respimat|Oral inhalation spray
75408742|NCT02845752|Drug|Placebo Respimat|Oral inhalation spray
75408743|NCT02849184|Drug|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
75408744|NCT02849184|Other|Placebo|Placebo once daily before bedtime.
75553899|NCT00467181|Drug|Fenoldopam|
75553900|NCT00354536|Drug|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
75553901|NCT00354536|Biological|placebo injection|placebo injection
75553902|NCT00467220|Behavioral|calorie restriction|"Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction."
75553903|NCT00425711|Drug|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
75553904|NCT00467337|Procedure|Medial-Wedge Insole intervention|
75553905|NCT00425789|Procedure|Treatment with Hyperbaric oxygen|
75553906|NCT00425867|Behavioral|PAR1 polymoprhisms and placental invasion|
75553907|NCT03274011|Drug|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
75553908|NCT00425906|Drug|nicotine|
75553909|NCT00425906|Other|Placebo|
75553910|NCT00425906|Procedure|Quality of life|
75553911|NCT00425984|Procedure|Adult male circumcision|
75553912|NCT00467376|Drug|Insulin Glulisine|3 times a day before each meal
75553913|NCT00467376|Drug|Lispro|3 times a day before each meal
75872261|NCT01372761|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
75408745|NCT02849418|Drug|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
75408746|NCT02849418|Drug|Placebo|Placebo injection contains sodium chloride (0.9 milligrams [mg]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
75408747|NCT02856828|Device|DIE|digital image enhancement
75872262|NCT01372761|Drug|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
75872263|NCT03866512|Behavioral|Forearm immobilization|Two days of forearm immobilization
75408748|NCT02861118|Other|No Intervention|
75408749|NCT02862912|Drug|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
75872264|NCT03634527|Behavioral|Auricular Point Acupressure|Light touch using vaccaria seeds on specific points of the ear
75872265|NCT03634527|Behavioral|Control Auricular Point Acupressure-|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
75872266|NCT03778606|Dietary Supplement|Potato starch|Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
75553914|NCT00467376|Drug|Insulin Glargine|once daily
75553915|NCT00426023|Drug|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
75553916|NCT00426023|Drug|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
75553917|NCT00467415|Behavioral|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
75553918|NCT00467415|Behavioral|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
75553919|NCT00467454|Drug|Naltrexone|daily
75553920|NCT00467454|Drug|Placebo|daily
75553921|NCT00426101|Drug|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days"
75553922|NCT00426101|Drug|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk"
75553923|NCT00426101|Drug|Cyclosporin|"WK 1-8:~- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~- Aim for around 200 microgram/L. Monitor GFR."
75408750|NCT02862912|Drug|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
75408751|NCT02862912|Drug|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
75408752|NCT02862912|Drug|Saline|Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml
75408753|NCT02864706|Drug|Everolimus|"All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used."
75408754|NCT02864706|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
75408755|NCT02864706|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
75408756|NCT02864706|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
75408757|NCT02865720|Drug|CINRYZE 500 U|IV infusion administered twice weekly
75408758|NCT02865720|Drug|CINRYZE 1000 U|IV infusion administered twice weekly
75408759|NCT02867202|Device|Intrauterine balloon|After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.
75408760|NCT02867202|Device|Intrauterine Contraceptive Device Plus Foley Catheter|After the completion of hysteroscopic adhesiolysis, Intrauterine Contraceptive Device Plus Foley Catheter were inserted into the uterine cavity. Foley Catheter was removed after three days and Intrauterine Device was removed at the second time of hysteroscopy.
75408761|NCT02871570|Drug|Rivipansel|A single dose of IV Rivipansel over 20 minutes
75408762|NCT02873286|Biological|MVA-BN-RSV|MVA-mBN294B
75408763|NCT02873286|Other|Placebo|Tris Buffered Saline, sterile
75408764|NCT02874066|Drug|PTV/r/OBV/DSV|Viekirax/Exviera for 12 weeks
75408765|NCT02874846|Drug|Netarsudil ophthalmic solution 0.02%|Once daily in both eyes (OU) in the evening (PM) for 7 days
75553924|NCT00426101|Procedure|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: <1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, >3 yrs 12 mg. Prednisolone: <1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, >3 yrs 10 mg."
75553925|NCT00426101|Procedure|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
75872267|NCT03873675|Diagnostic Test|parathyroid hormone|10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
75408766|NCT02874846|Other|Netarsudil Ophthalmic Solution Vehicle|Once daily in both eyes (OU) in the evening (PM) for 7 days
75408767|NCT02880228|Drug|Dexamethasone|Given PO
75408768|NCT02880228|Other|Laboratory Biomarker Analysis|Correlative studies
75408769|NCT02880228|Drug|Lenalidomide|Given PO
75408770|NCT02880228|Biological|Pembrolizumab|Given IV
75408771|NCT02880852|Drug|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
75553926|NCT00426140|Drug|Patupilone|
75553927|NCT00467493|Drug|Anastrozole|
75553928|NCT00426179|Drug|Imatinib|
75872268|NCT03111706|Procedure|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
75713099|NCT00617409|Biological|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
75713100|NCT00617409|Drug|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
75713101|NCT00695318|Drug|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
75713102|NCT00695318|Drug|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
75713103|NCT00754104|Drug|ABT-869|0.25 mg/kg. daily.
75408772|NCT02886234|Behavioral|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
75408773|NCT02886234|Behavioral|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
75408774|NCT02887404|Other|Spine surgery analgesic pathway|Enhanced pain management care
75408775|NCT02887404|Other|Usual Care|Standard of pain management care
75408776|NCT02889510|Drug|liraglutide|7-week subcutaneous liraglutide once daily
75408777|NCT02889510|Drug|placebo|7-week subcutaneous placebo once daily
75408778|NCT02893878|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
75408779|NCT02899650|Other|exercise|acute downhill running
75408780|NCT02899884|Other|No Intervention|
75408781|NCT02902146|Device|Bougie|
75408782|NCT02902146|Device|Endotracheal tube|
75408783|NCT02902770|Drug|Lidocaine|1.5 mg/kg IV lidocaine drip (given over 10 minutes)
75408784|NCT02902770|Drug|Ketorolac Tromethamine|IV ketorolac 30mg push
75408785|NCT02902770|Drug|Normal Saline Drip|Normal Saline Drip Placebo given over 10 minutes
75408786|NCT02902770|Drug|Normal Saline Push|Normal Saline Push Placebo
75408787|NCT02903394|Device|mLCI Device|imaging of cervical epithelium using mLCI device
75408788|NCT02907918|Drug|Palbociclib|Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.
75408789|NCT02907918|Drug|Letrozole|Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.
75713104|NCT00754104|Drug|Tarceva|150mg, daily.
75713105|NCT00386425|Drug|Drotrecogin alfa (activated)|intravenous
75408790|NCT02907918|Biological|Trastuzumab|"Or FDA approved biosimilar~Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery."
75408791|NCT02907918|Drug|Goserelin|Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.
75408792|NCT02907918|Procedure|Breast surgery|Standard of care
75408793|NCT02907918|Procedure|Research tumor biopsy|Baseline, cycle 1 day 15, and surgery
75408794|NCT02907918|Procedure|Research bone marrow (OPTIONAL)|Baseline and surgery
75408795|NCT02907918|Procedure|Research blood sample|Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
75408796|NCT02907918|Genetic|Research blood for germline DNA|Baseline
75408797|NCT02907918|Procedure|Blood for detection of circulating tumor cells|Baseline
75408798|NCT02908620|Combination Product|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
75408799|NCT02908620|Drug|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
75408800|NCT02908620|Combination Product|Two sprays CTY-5339-A|Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
76040300|NCT04905043|Drug|SmartPill®|Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
75408801|NCT02908620|Drug|One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)|A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
75553929|NCT00458874|Behavioral|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
75553930|NCT00426218|Drug|ACZ885|
75553931|NCT00458913|Drug|bortezomib|
75553932|NCT00458913|Drug|cisplatin|
75553933|NCT00458991|Drug|Dextromethorphan and Caffeine|"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
75553934|NCT01059617|Biological|GSK Biologicals' FluLaval®|Intramuscular injection
75408802|NCT02910102|Drug|RVT-101 35 mg|RVT-101 once daily, oral, 35-mg tablets
75408803|NCT02910102|Drug|Placebo|Placebo once daily, oral
75553935|NCT01059617|Biological|Placebo (saline)|Intramuscular injection
75713106|NCT05300230|Device|Neuro Zti cochlear implant and Neuro 2 sound processor|"The study will consist in 3 visits:~Visit 1: it will be carried out the first contact and learning the measurement procedure.~Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters."
75713107|NCT00758238|Other|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
75713108|NCT05352412|Behavioral|Shared Decision Making Aid|Patients will be randomized to the shared decision making aid intervention.
75713109|NCT05352412|Behavioral|Baseline Counseling As usual|Patients will be randomized to the baseline counseling as usual.
75713110|NCT00859365|Procedure|Real Acupuncture|Real acupuncture treatment in real acupuncture points
75408804|NCT02911818|Behavioral|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
75408805|NCT02911818|Drug|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
75408806|NCT02911818|Other|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
75408807|NCT02911818|Drug|Placebo Oral Tablet|
75408808|NCT02911818|Drug|Phentermine 15 MG|
75408809|NCT02911818|Behavioral|Extension Study CMS-recommended lifestyle counseling|4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
75553936|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
75553937|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
75553938|NCT03271944|Device|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
75553939|NCT03273933|Device|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
75553940|NCT03273933|Device|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
75553941|NCT00459030|Other|educational intervention via internet|additional cancer screening information via password protected internet site
75713111|NCT00859365|Procedure|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
75408810|NCT02912364|Drug|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
75408811|NCT02912364|Drug|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
75553942|NCT00459030|Other|educational intervention mailed|
75553943|NCT00459030|Other|No additional educational intervention|
75713112|NCT00859365|Procedure|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
75713113|NCT00948844|Device|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
75713114|NCT05402592|Dietary Supplement|Carbonhydrate rich drink|It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.
75408812|NCT02913924|Drug|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
76040301|NCT03050983|Device|IPI|Enable the IPI algorithm and IPI alarm algorithm
75408813|NCT02913924|Drug|Placebo|
76040302|NCT02436759|Drug|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
75408814|NCT02916498|Device|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
75408815|NCT02917122|Device|active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
75408816|NCT02917122|Drug|Sertraline|Patients will take Sertraline.
75553944|NCT04705337|Drug|Levosimendan|administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
75553945|NCT04705337|Other|Placebo|administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
75553946|NCT00459069|Biological|Dendritic Cell Tumor Fusion Vaccine|Vaccine administered on weeks 0, 3 and 6
75553947|NCT00426257|Procedure|Secondary debulking|Secondary debulking
75713115|NCT05402592|Other|Water|A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
75713116|NCT02544477|Device|High-flow Nasal Cannula Oxygen (HFNCO)|
75408817|NCT02917122|Device|sham tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
75408818|NCT02917278|Dietary Supplement|Meals|High Protein renal-specific meals
75408819|NCT02921412|Device|fanfilcon A|contact lens
75408820|NCT02921490|Device|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
75408821|NCT02922582|Drug|DepoTXA|
75408822|NCT02922582|Drug|Tranexamic Acid|
75408823|NCT02922738|Other|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
75408824|NCT02925078|Device|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with <2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
75408825|NCT02925858|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Normal saline infusion mimicking infusion rate of ketamine for a given weight
75713117|NCT02544477|Device|Conventional oxygen treatment|
75713118|NCT00949000|Device|ICD Implantation|Implantation of a commercially available AnalyST or AnalyST Accel ICD
76040303|NCT02436759|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
76040304|NCT04888819|Drug|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
75408826|NCT02925858|Drug|Ketamine Hydrochloride|Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
75408827|NCT02933034|Drug|Manganese-enhanced MRI contrast reagent|MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
75553948|NCT00426257|Procedure|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
76040305|NCT04888819|Drug|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
76040306|NCT02436681|Device|MIROMESH|
76040307|NCT03052153|Other|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
75553949|NCT00467571|Drug|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
75553950|NCT00467688|Device|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
75553951|NCT00426296|Drug|atazanavir (Reyataz)|
75553952|NCT00426296|Drug|ritonavir (Norvir)|
75553953|NCT03271905|Drug|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
76040308|NCT03051685|Drug|DFN-15 Dose 1|
76040309|NCT03051685|Drug|DFN-15 Dose 2|
76040310|NCT03051685|Drug|DFN-15 Dose 3|
76040311|NCT03051685|Drug|Active Comparator|
75408828|NCT02933034|Drug|Gadolinium-enhanced MRI contrast reagent|MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
75408829|NCT02933502|Drug|DSXS topical product|treatment daily for 28 days
75408830|NCT02935062|Behavioral|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
75408831|NCT02935062|Behavioral|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
75408832|NCT02935062|Behavioral|Placebo Therapy|No intervention to improve speech.
75408833|NCT02936076|Other|Exercise intervention|
75408834|NCT02936076|Other|Delayed exercise intervention|
75408835|NCT02937168|Drug|Reslizumab|Reslizumab will be administered as per the dose and schedule specified in the arm.
75408836|NCT02937168|Drug|Fludeoxyglucose F 18 (FDG)|FDG will be administered by IV infusion prior to each PET/CT scan.
75408837|NCT02937168|Drug|Placebo|Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
75408838|NCT02937558|Drug|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
75408839|NCT02937558|Other|Placebo|Isotonic saline
75408840|NCT02938494|Drug|IDP-123 Lotion|Lotion
75408841|NCT02938494|Drug|Tazorac Cream|Cream
75408842|NCT02938494|Drug|Vehicle Lotion|Lotion
75408843|NCT02938494|Drug|Vehicle Cream|Cream
75408844|NCT02941614|Behavioral|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
75408845|NCT02941692|Drug|Oxytocin|
75408846|NCT02941692|Drug|Placebo|Placebo for Oxytocin
75408847|NCT02942160|Biological|Collagenase Clostridium Histolyticum|
75408848|NCT02953860|Drug|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
75408849|NCT02956044|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
75408850|NCT02956044|Drug|Metformin|1000 mg metformin
75408851|NCT02956044|Drug|Glimepiride|4 mg glimepiride
75408852|NCT02956044|Drug|Sitagliptin|100 mg sitagliptin
75408853|NCT02956122|Biological|GLASSIA|GLASSIA [Alpha1-Proteinase Inhibitor (Human)]
75408854|NCT02956122|Drug|methylprednisolone or equivalent steroid|The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
75408855|NCT02956122|Biological|Albumin|The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
75408856|NCT02956746|Biological|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
75408857|NCT02956746|Biological|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
75408858|NCT02956746|Biological|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
75408859|NCT02956746|Biological|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
75408860|NCT02961894|Device|Revolution™ Peripheral Atherectomy System|The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
75408861|NCT02963376|Drug|0.05 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).
75408862|NCT02963376|Drug|0.05 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).
75713119|NCT03993145|Behavioral|Web-based lifestyle intervention|Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
75713120|NCT00859599|Device|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
75713121|NCT00859599|Device|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
75713122|NCT05396898|Drug|LCP-tacrolimus|Prophylaxis of transplant rejection in liver and kidney allograft recipients
75713123|NCT05396898|Drug|twice-daily tacrolimus|Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients
75872269|NCT03863769|Other|Lumbar Spinal Stenosis|Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
76040312|NCT04888351|Other|Comparison of complications between mastectomies with IBR and mastectomies without IBR|"Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.~Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain."
76040313|NCT04888351|Other|To analyze variations of number of patients eligibles to IBR|Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past
76040314|NCT04904731|Other|Prone position|Patients were assisted in NIV in supine position that was switched in prone position for clinical purpouse
76040315|NCT04904887|Procedure|phacoemulsification|phacoemulsification with implantation of EYEHANCE IOL
75408863|NCT02963376|Drug|0.10 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
75408864|NCT02963376|Drug|0.10 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
75408865|NCT02963376|Drug|0.17 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
76040316|NCT04078243|Device|CardioMEMS HF System|The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
75408866|NCT02963376|Drug|0.17 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
75408867|NCT02967354|Radiation|Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan|Estimation of islet mass by PET using the tracer [11C]5-hydroxy-tryptophan
75408868|NCT02967510|Drug|Estriol|
75408869|NCT02967510|Drug|Placebo|
75408870|NCT02968134|Drug|Posaconazole|A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
76040317|NCT04898881|Other|Breast Human Milk|Interventional drug is given to the neonates 2 minutes before the heel lance
76040318|NCT04898881|Other|24 % Sucrose|0.5 ml of sucrose given once 2 minutes prior to procedure
75553954|NCT03271905|Device|Mesh nebulization|Nebulization with Mesh device.
75553955|NCT00426374|Procedure|echocardiography and blood test|
75553956|NCT00459225|Drug|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
75408871|NCT02968368|Drug|Ferric maltol|
75713124|NCT00694304|Drug|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
75713125|NCT05352334|Diagnostic Test|self-report Emotional Intelligence test (SSCEIT)|The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
75713126|NCT00371839|Procedure|Audiological Evaluation|Tests of hearing, cognition, and speech perception
75713127|NCT00866853|Drug|TMC435|
75713128|NCT05386836|Device|Pulse oximeter validation population|Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
75408872|NCT02968368|Other|Placebo|
75408873|NCT02968758|Device|Comparison between GenePOC PCR and Reference Method|Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
75408874|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
75408875|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
75408876|NCT02970006|Device|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
75408877|NCT02970162|Drug|Amifampridine Phosphate|
75408878|NCT02970162|Drug|Placebo Oral Tablet|
75408879|NCT02970552|Drug|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
75408880|NCT02970552|Drug|Placebo|Indistinguishable placebo vaginal suppository
75408881|NCT02971488|Other|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
75553957|NCT00426413|Drug|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
75872270|NCT03111472|Other|Self-management guide for people with Parkinson's who fall and their informal caregivers|The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.
75408882|NCT02973438|Device|Intermittent Hypoxia (IH)|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.
75553958|NCT00459264|Drug|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
75872271|NCT02328898|Device|Cre8 Stent|Comparison of the Resolute Integrity stent with the Cre8 stent.
75553959|NCT00459264|Drug|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
75553960|NCT00426452|Drug|Vatalinib|
75553961|NCT00467727|Other|Phase Contrast Mammography|Standard and magnification views
75553962|NCT00426491|Drug|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
75408883|NCT02973438|Device|SHAM|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
75408884|NCT02973516|Drug|P03277 at 0.1 mmol/kg|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
75553963|NCT03273777|Procedure|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
75408885|NCT02973516|Drug|P03277 at 0.05 mmol/kg|P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
75408886|NCT02974296|Device|transcranial magnetic stimulation|non invasive brain stimulation approach
75408887|NCT02978508|Drug|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
75408888|NCT02978508|Drug|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
75713129|NCT00949156|Procedure|Different surgical approach and techniques being used to treat three subtype of CP|According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
75713130|NCT02544399|Other|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
76040319|NCT04904185|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
75408889|NCT02979054|Device|T4020|
75408890|NCT02979054|Device|Placebo|
75408891|NCT02979444|Behavioral|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
75408892|NCT02881008|Drug|Entecavir|
75408893|NCT02881008|Drug|Myrcludex B|
75408894|NCT02987868|Drug|Amino acid supplement first day|An orally administered supplement of the proprietary amino acid derivative
75408895|NCT02987868|Drug|Placebo first day|A non-active orally administered supplement of the proprietary amino acid derivative
75713131|NCT01044511|Behavioral|Home visits|home visits by specialist nurse 2 times and 1 phonecall
75713132|NCT01044511|Behavioral|standard|hotline
75553964|NCT00426530|Drug|everolimus (RAD001)|
75553965|NCT00459420|Drug|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
75553966|NCT00459420|Drug|placebo|placebo
75553967|NCT00467766|Behavioral|Psychosocial information, counseling, and support|
75553968|NCT00467766|Drug|Donepezil (Aricept)|
75553969|NCT00459459|Procedure|Fine needle aspiration of the thyroid|
75553970|NCT00467805|Procedure|Light therapy|
75553971|NCT00467883|Drug|Liposomal Amphotericin B|high dosage
75553972|NCT00426608|Drug|metyrapone|Metyrapone will be available as 250 mg dose capsule.
75553973|NCT00426608|Drug|alprazolam|Alprazolam capsules will be available with dose strength of 0.25mg
75553974|NCT00426608|Drug|placebo|GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
75553975|NCT00426608|Drug|GSK561679|GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
75713133|NCT04011904|Other|Cross-over study|Traditional Inuit Diet vs Westernized Diet
76040320|NCT04904185|Drug|Fludarabine Phosphate|Fludarabine Phosphate 30 mg/m2 is administered on day -4 and -3
76040321|NCT04904185|Biological|Multiple Antigen Specific Endogenously derived T cells|Antigen specific, ex vivo expanded T cells derived from peripheral blood T cells
76040322|NCT04904185|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered on day -1 and on day 21. The medicine is administered over 30 minutes
76040323|NCT04887961|Drug|PLD and Trabectedin rechallenge|Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments
75408896|NCT02987868|Drug|Amino acid supplement second day|An orally administered supplement of the proprietary amino acid derivative
75408897|NCT02987868|Drug|Placebo second day|A non-active orally administered supplement of the proprietary amino acid derivative
75408898|NCT02988882|Drug|Dexamethasone|
75408899|NCT02988882|Other|Placebo Vehicle|
75408900|NCT02992236|Drug|VAS203|Infusion of NO-Synthase inhibitor VAS203
75408901|NCT02992236|Drug|Saline|Infusion of saline
75408902|NCT02994732|Drug|[14C]-BVD-523|[14C]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
75713134|NCT04040517|Diagnostic Test|Evoked potential audiometer|The ASSR [ steady state response] test stimuli are modulated pure tones with insert earphone..
76040324|NCT04887883|Behavioral|Resistance exercise|Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.
75408903|NCT03001674|Device|Conductance catheterization|CD Leycom Conductance Catheter
75408904|NCT03002454|Drug|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
75408905|NCT03004638|Drug|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
75408906|NCT03004638|Drug|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
75408907|NCT03004638|Drug|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
75408908|NCT03004638|Drug|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
75408909|NCT03004638|Drug|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
75408910|NCT03004638|Drug|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
75408911|NCT03009162|Drug|Lasmiditan|200 mg, single oral tablet
75553976|NCT00467922|Drug|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
75553977|NCT00467922|Drug|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
75553978|NCT00426647|Drug|Buprenorphine|
75553979|NCT00426647|Drug|Tramadol|
75713135|NCT00682890|Drug|placebo|placebo birth control pill daily
75713136|NCT00682890|Drug|metformin|2000 mg per day for 3 months daily birth control pill
75713137|NCT02565368|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
75713138|NCT02565368|Drug|CKD-395 0.5/1000mg|single oral administration
75713139|NCT00949390|Behavioral|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
76040325|NCT04887649|Drug|Morphine|morphine 3 mg
76040326|NCT04887649|Drug|saline solution|4 cc of saline solution in epidural cateter in postpartum
75713140|NCT04040595|Procedure|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
75713141|NCT03992365|Drug|Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)|"The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets."
75872272|NCT02328898|Device|Resolute Integrity stent|
75872273|NCT02332408|Radiation|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
75408912|NCT03009396|Drug|RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)|For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
75408913|NCT03010488|Behavioral|Morning Light Therapy|10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
75408914|NCT03010488|Behavioral|Assigned Sleep Times|Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
75408915|NCT03010488|Device|Goggles|Subjects will wear goggles during saliva collection and Bright Light Therapy
75408916|NCT03010800|Device|With Yoni.Fit|Abbreviated Pad Test with Yoni.Fit first, then without Yoni.Fit.
75408917|NCT03010800|Device|Without Yoni.Fit|Abbreviated Pad Test without Yoni.Fit, then with Yoni.Fit.
75408918|NCT03012594|Drug|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
75408919|NCT03014700|Biological|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
75408920|NCT03014700|Biological|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
75408921|NCT03017508|Drug|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
75408922|NCT03017508|Drug|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
75408923|NCT03020004|Drug|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
75408924|NCT03020004|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
75408925|NCT03020004|Drug|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
75408926|NCT03020004|Drug|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)
75408927|NCT03020082|Drug|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
75408928|NCT03020082|Drug|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
75408929|NCT03020082|Drug|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
75408930|NCT03020082|Drug|RBV|RBV administered orally 500mg (5 tablets)( body weight <75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
75408931|NCT03020472|Biological|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist vaccine delivered intranasally
75408932|NCT03026556|Drug|Dabigatran vs. Rivaroxaban|observed for 6 years
75408933|NCT03026556|Drug|Dabigatran vs. Apixaban|Observed for 6 years
75408934|NCT03028974|Biological|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
75408935|NCT03028974|Biological|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
75408936|NCT03029988|Drug|Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Drug: Technetium Tc 99m tilmanocept
75408937|NCT03029988|Procedure|SPECT/CT Imaging|4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
75408938|NCT03033108|Drug|Emixustat|Once daily, tablet for oral administration
75408939|NCT03035760|Drug|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
76040327|NCT04887649|Drug|Morphine|morphine 2 mg for epidural cateter in postpartum
76040328|NCT03050437|Drug|Cisplatin|cisplatin is added to Pem/cis arm
75553980|NCT00468078|Procedure|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
75553981|NCT00468078|Drug|F-18 FPCIT|5mCi, intravenous injection
75713142|NCT03992365|Drug|Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl|"The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes."
75408940|NCT03036384|Drug|HB Prilocaine 2% (varying dose)|Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
75408941|NCT03036384|Drug|HB Prilocaine 2%|The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
76040329|NCT03050437|Drug|Pemetrexed|Pem is applied to both arms
75408942|NCT03036384|Drug|Sufentanil|2.5µg sufentanyl
75408943|NCT03036384|Drug|Morphine|100 µg Morphine
75713143|NCT04011514|Behavioral|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
75713144|NCT00921804|Drug|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
75408944|NCT03040362|Drug|[14C]-lasmiditan|[14C]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
76040330|NCT03050593|Diagnostic Test|MRI scan, Echo scan|
75408945|NCT03041298|Procedure|MR mammography with Dotarem|
76040331|NCT02436135|Drug|Idelalisib|Idelalisib tablets administered orally for 24 weeks
76040332|NCT02436135|Drug|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
75408946|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
75408947|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
75408948|NCT03044028|Device|CyMedica Orthopedics QB1 e-vive™ system|a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
75553982|NCT00468156|Behavioral|written materials only|related to fruit/vegetable servings/day
75553983|NCT00468156|Behavioral|written materials|related to fruit/vegetable servings/day
75553984|NCT00468156|Behavioral|telephone support|related to fruit/vegetable servings/day
75553985|NCT00426725|Device|EasyLabour|According to the trial protocol
75713145|NCT00921804|Drug|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
75713146|NCT00921804|Drug|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
75713147|NCT00921804|Drug|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
75713148|NCT02534779|Other|Placebo Vaginal Insert|Placebo insert
75713149|NCT00867399|Drug|ABT-126|See arm for details
75713150|NCT00758316|Other|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
76040333|NCT04898569|Drug|Ferinject|Ferric carboxymaltose injection
76040334|NCT04898569|Drug|Normal Saline Flush|placebo
76040335|NCT03050515|Biological|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
76040336|NCT02489799|Behavioral|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
75408949|NCT03044418|Other|Application of ET laser tube in propofol anesthesia|The special ET laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
75408950|NCT03046212|Device|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
75408951|NCT03046212|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
75408952|NCT03048006|Procedure|MRI with Dotarem|
75408953|NCT03051672|Drug|Pembrolizumab|Pembrolizumab (formerly MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD1 and its ligands, PD-L1 and PD-L2.
75553986|NCT01059344|Drug|Mesalamin|4.8g/day, 800 mg tablets
75553987|NCT00459615|Drug|Artesunate for Injection|
75553988|NCT00468351|Procedure|Intravitreal Injection of 1,5 mg of bevacizumab|
75553989|NCT00468351|Procedure|Intravitreal injection of 4 mg of Triamcinolone acetonide|
76040337|NCT02489799|Behavioral|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
76040338|NCT05457699|Radiation|SABR|SBAR to PSMA-PET visible disease at maximal systemic therapy response.
76040339|NCT05457699|Other|no RT|no SABR, continued systemic therapy per SOC
76040340|NCT04391257|Device|geko™|Assess if cardiac pacemakers detect geko™ electrical output pulse.
75553990|NCT00459654|Drug|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
76040341|NCT04884841|Other|Patients diagnosed with postoperative complications|Patients diagnosed with postoperative complications (Acute kidney injury, Chronic Kidney disease, Infection, Delirium, MACCE, Myocardial infarction, Postoperative pulmonary complications, major bleeding, ECMO, IABP....)
76040342|NCT04884841|Other|Patients without postoperative complications|Patients without postoperative complications
76040343|NCT04884529|Behavioral|Chair-yoga program|8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
76040344|NCT04884217|Drug|Pro-ocular™ Topical Gel|Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
76040345|NCT04884217|Drug|Placebo Topical Gel|Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
75408954|NCT03051672|Radiation|Palliative radiotherapy|Palliative radiotherapy aims to shrink cancer, slow down its growth or control symptoms.
76040346|NCT03050281|Other|Simulation/Cadaver lab|The primary focus of this study is to determine whether the use of a comprehensive, combined, and simplified approach of using cadavers and simulation laboratories to train third-year medical students will have a beneficial effect on student performance in the OB-GYN and surgical clerkships.
76040347|NCT03050281|Other|Lectures|Standard Anatomy lectures were offered.
75408955|NCT03052530|Device|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
75408956|NCT03055650|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
75553991|NCT00459654|Drug|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
75553992|NCT00468429|Drug|Subconjunctival Bevacizumab|
75713151|NCT00758316|Procedure|Thoracoscopy|Talc poudrage
75713152|NCT00859755|Drug|ARRY-403, glucokinase activator; oral|single dose, escalating
76040348|NCT02435277|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
76040349|NCT02435277|Drug|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
76040350|NCT02435277|Drug|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
76040351|NCT02435277|Drug|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
76040352|NCT04898335|Device|Tendyne Mitral Valve System|Tendyne Mitral Valve System for mitral valve disease in a commercial setting
76040353|NCT02420223|Drug|Propranolol|
76040354|NCT02433483|Drug|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
76040355|NCT02433483|Drug|Intrathecal Triples|given IT.
76040356|NCT02433483|Biological|HPC-A|Given IV.
76040357|NCT02419755|Drug|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
75408957|NCT03057132|Device|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
75408958|NCT03057366|Drug|Pevonedistat|Pevonedistat intravenous infusion.
75408959|NCT03057366|Drug|[14C]-Pevonedistat|[14C]-Pevonedistat intravenous infusion.
75408960|NCT03057366|Drug|Docetaxel|Docetaxel intravenous infusion.
75408961|NCT03057366|Drug|Carboplatin|Carboplatin intravenous infusion.
75553993|NCT00468468|Behavioral|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
75713153|NCT00859755|Drug|Placebo; oral|matching placebo
75713154|NCT00754182|Device|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
76040358|NCT02419755|Drug|Vorinostat|Vorinostat should be taken orally (PO) with food.
76040359|NCT02419755|Drug|Mitoxantrone|Given by intravenous (IV) injection.
76040360|NCT02419755|Drug|Cytarabine|Given by intravenous (IV) injection.
76040361|NCT02419755|Drug|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
76040362|NCT02419755|Drug|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
75553994|NCT00468507|Dietary Supplement|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
75553995|NCT00426803|Drug|activated recombinant human factor VII|
75713155|NCT00754182|Device|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
75713156|NCT00859911|Dietary Supplement|Multiple micronutrients|A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
75713157|NCT00954694|Device|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
75713158|NCT00385723|Dietary Supplement|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
75713159|NCT00385723|Dietary Supplement|Placebo|matching placebo capsule daily for 4 months
75713160|NCT00698516|Drug|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
75713161|NCT00859989|Behavioral|behavioral dietary intervention|
75408962|NCT03057366|Drug|Paclitaxel|Paclitaxel intravenous infusion.
75408963|NCT03060486|Device|HYBENX®|"The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.~Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle."
75408964|NCT03061812|Drug|Rovalpituzumab tesirine|Powder for solution for infusion in vials.
75408965|NCT03061812|Drug|Topotecan|Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.
75408966|NCT03061812|Drug|Dexamethasone|Oral tablet.
75408967|NCT03063294|Other|Online Toolkit|The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
75553996|NCT00459771|Drug|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
75553997|NCT00459771|Drug|Placebo|Placebo, 32 mg, oral QD
75713162|NCT00859989|Behavioral|exercise intervention|
75713163|NCT00859989|Behavioral|telephone-based intervention|
75713164|NCT00859989|Other|counseling intervention|
75713165|NCT00859989|Other|educational intervention|
75713166|NCT00859989|Other|immunoenzyme technique|
75553998|NCT01058369|Drug|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
75553999|NCT00459849|Procedure|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
75554000|NCT03271788|Other|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
75554001|NCT01057433|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
75713167|NCT00859989|Other|laboratory biomarker analysis|
75713168|NCT00859989|Other|questionnaire administration|
75408968|NCT03063294|Other|Distance-based coaching|The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
75408969|NCT03064152|Device|Rotational Thromboelastometry|ROTEM is a point-of-care coagulation assay.
75408970|NCT03066102|Other|muscle fatigue|"Modified push-up plus exercise:~the participants first supported by both knees and the single elbow, and then performed sustained scapular protraction for three minutes with ten repetitions in males and two minutes with five repetitions in females with forty-five seconds rest between."
75408971|NCT03067506|Other|No intervention|No intervention
75408972|NCT03070470|Drug|Ranolazine|Ranolazine 1500 mg orally two times per day for 2.5 days
75408973|NCT03070470|Drug|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
75408974|NCT03070470|Drug|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
75408975|NCT03070470|Drug|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
75408976|NCT03070470|Drug|Placebo|Placebo (administered orally)
75408977|NCT03070470|Drug|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
75408978|NCT03070548|Drug|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
75713169|NCT00859989|Other|study of socioeconomic and demographic variables|
75713170|NCT00859989|Procedure|evaluation of cancer risk factors|
75713171|NCT00859989|Procedure|support group therapy|
75713172|NCT00679302|Drug|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
75713173|NCT00679302|Drug|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
75713174|NCT04011124|Drug|Fluzoparib|single dose on Day 1 and Day 12
75713175|NCT04011124|Drug|Rifampicin|QD on Day 5-14 for 10 days
75408979|NCT03072186|Device|near-infrared light nasal endoscope used with ICG|Using the near-infrared light nasal endoscope with ICG will identify anatomical landmarks and and tumor characteristics to provide a clear demonstration of the blood supply.
75408980|NCT03072732|Device|u-Cor System|Monitoring System
75408981|NCT03072732|Device|ZOE Fluid Status Monitor|Monitoring System
75408982|NCT03074682|Device|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
75408983|NCT03074682|Device|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
75408984|NCT03074682|Device|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
75408985|NCT03078504|Device|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
75408986|NCT03080142|Drug|Exparel|Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
75408987|NCT03080142|Drug|Ropivacaine|Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
75408988|NCT03085836|Drug|TAK-438|TAK-438 tablets.
75408989|NCT03088800|Drug|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
75408990|NCT03088800|Drug|APAP|Oral APAP at 15mg/kg dose
75408991|NCT03092934|Drug|LY3295668|Oral capsules
75408992|NCT03094806|Device|Acapella Vibratory PEP Therapy Device plus usual care|The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
75554002|NCT01057433|Drug|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
75554003|NCT00459888|Device|PolarCath Peripheral Dilatation System (Boston Scientific)|
75408993|NCT03094806|Device|Sham Acapella Vibratory PEP Device plus usual care|The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
75408994|NCT03095976|Procedure|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
75554004|NCT01057394|Device|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
75408995|NCT03096444|Drug|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
75554005|NCT01057394|Device|RF PVI Ablation|Radiofrequency ablation
75713176|NCT00862797|Other|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
75713177|NCT01047397|Drug|1278863A|25mg, 50mg, 100mg
75408996|NCT03096444|Drug|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
75408997|NCT03096444|Drug|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
75408998|NCT03096444|Combination Product|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
75713178|NCT01047397|Drug|Placebo|matching placebo
75713179|NCT02564822|Procedure|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
75713180|NCT00862875|Drug|Detemir or Glargine|Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
75713181|NCT02566616|Device|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
75713182|NCT00867477|Procedure|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
76040363|NCT02419755|Drug|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
75408999|NCT03096444|Drug|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
75409000|NCT03100500|Drug|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
75409001|NCT03100968|Procedure|Palpation|Traditional epidural methods used for the identification of the midline using palpation prior to procedure
75409002|NCT03100968|Device|Ultrasound|Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
75409003|NCT03104322|Other|patientMpower platform|electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
75409004|NCT03104322|Other|usual care|usual care
75409005|NCT03107754|Drug|Lidocaine|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
75409006|NCT03107754|Drug|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
75409007|NCT03118596|Device|I-gel|Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
75554006|NCT00459927|Device|Floseal tonsillectomy|
75554007|NCT00459927|Device|Coblation tonsillectomy|
75554008|NCT00459966|Procedure|Preoperative rehabilitation|
75554009|NCT01058642|Drug|ADL5747|
75554010|NCT01058642|Drug|Placebo|
75554011|NCT01058642|Drug|Pregabalin|
75554012|NCT00426881|Behavioral|Exercise Training|Twice weekly resistance training for 52 weeks.
75554013|NCT00426881|Behavioral|Exercise training|Once weekly resistance training for 52 weeks.
75554014|NCT00426881|Behavioral|Exercise training|Twice weekly resistance training for 52 weeks.
75713183|NCT00867477|Behavioral|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
75713184|NCT00867477|Procedure|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
75554015|NCT03271437|Behavioral|PC-based Flash|Progressive counting with Flash technique
75713185|NCT00867555|Dietary Supplement|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
76040364|NCT02419755|Drug|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
76040365|NCT02419755|Drug|Dexamethasone|Given orally (PO) or intravenously (IV).
76040366|NCT02419755|Drug|Mercaptopurine|Given orally (PO).
75554016|NCT03271437|Behavioral|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
76040367|NCT02419755|Drug|Doxorubicin|Given intravenously (IV).
76040368|NCT04913025|Drug|Nivolumab|60-minute IV infusion, as a flat dose of 480mg
75554017|NCT00426920|Drug|Insulin|
75713186|NCT00955006|Biological|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
75713187|NCT00955006|Biological|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
75713188|NCT02378246|Dietary Supplement|Iodine|
75713189|NCT02378246|Dietary Supplement|Placebo|
75713190|NCT02544165|Dietary Supplement|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
76040369|NCT04913025|Drug|Pembrolizumab|60-minute IV infusion, as a flat dose of 400mg
76040370|NCT02488551|Device|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
76040371|NCT02488551|Other|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
76040372|NCT02488239|Device|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
76040373|NCT02488005|Device|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
76040374|NCT02487771|Drug|DHA|600 mg DHA capsule
76040375|NCT02487771|Drug|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
76040376|NCT01359943|Biological|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
75409008|NCT03118596|Device|LMA Protector|Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
75409009|NCT03124368|Drug|Danicopan|Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).
75409010|NCT03124602|Device|Red Diamond Disposable Pulse Oximeter Sensor|Noninvasive Pulse Oximeter Sensor
75409011|NCT03124758|Device|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
75409012|NCT03124836|Device|Pulse Oximeter Sensor|
76040377|NCT01359943|Drug|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
76040378|NCT04898101|Drug|Acalabrutinib|Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
76040379|NCT04898101|Drug|Microtracer [14C]ACP-196|Participants in Cohort 1 will receive a single microtracer (<10 μg; ≤1 μCi) IV solution dose of [14C]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (<10 μg; ≤1 μCi) of [14C]ACP-196 on Day 1.
76040380|NCT04884451|Behavioral|Lifestyle modification|Diet and physical activity modification and behavioral approach
76040381|NCT02432703|Drug|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
76040382|NCT02432703|Drug|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
75409013|NCT03125226|Device|Polyethylene Glycol Hydrogel|Given TracelT hydrogel via injection
75409014|NCT03127956|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
75409015|NCT03132246|Diagnostic Test|Blood draws|The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
75409016|NCT03138330|Other|this study is observational, it is not an intervention|
75554018|NCT03271710|Device|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
75554019|NCT00426959|Device|Image Guided Dynamic Dosimetry|Image Guided Dynamic Dosimetry
75554020|NCT00468624|Drug|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
75554021|NCT00468624|Procedure|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
75554022|NCT00468624|Procedure|blood sampling before and after pegvisomant/placebo|
76040383|NCT04887727|Dietary Supplement|Crystalline amino acids to assess myofibrillar protein synthesis rates|Amino acid dose = 0.25g/kg bodyweight
76040384|NCT04887727|Dietary Supplement|Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance|Amino acid dose = 0.25g/kg bodyweight
76040385|NCT04887493|Drug|Misoprostol|Misoprostol 25µg will be used for both the study arms
75554023|NCT00468624|Procedure|arginine stimulation test after each limb|
75554024|NCT00426998|Drug|Verteporfin|
75554025|NCT00426998|Drug|Bevacizumab|
75554026|NCT00427076|Drug|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR<30.
75554027|NCT00427076|Drug|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR <10 1gr Q 4-7 days.
75554028|NCT00427115|Behavioral|Multimodal exercise and psychosocial program|
75713191|NCT02544165|Other|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
75554029|NCT00427232|Drug|BQ-123 and BQ-788|
75554030|NCT00468702|Device|CoaguChek S|
76040386|NCT04898257|Dietary Supplement|Multistrain probiotic|After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).
76040387|NCT02486757|Drug|micronized progesterone|
76040388|NCT02486757|Drug|transdermal estradiol|
76040389|NCT04887103|Other|Hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
76040390|NCT04887181|Other|Teethmate Desensitizer|Powder and liquid contained in the material were mixed. It was applied to the buccal surface of the sensitive tooth. then it was washed away from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
76040391|NCT04887181|Other|Gluma Desensitizer|The material was applied to the buccal surface of the tooth with sensitivity. It was washed with water and removed from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
75409017|NCT03138798|Device|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
75409018|NCT03138876|Device|EEG Cap|Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
75409019|NCT03138876|Drug|Anti-seizure medication|Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
75713192|NCT02544165|Other|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
75713193|NCT00955084|Drug|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
75554031|NCT00427271|Drug|aspirin|
75713194|NCT05343156|Drug|Dexamethasone nanoparticles eye drops|DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks
75713195|NCT00955162|Drug|Buprenorphine (Subutex)|Sublingual tablet
75713196|NCT00955162|Drug|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
75872274|NCT02332408|Radiation|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
76040392|NCT04887181|Other|Hybrid Bond|It was applied to the buccal surface of the sensitive tooth with an applicator. It was cured with a LED light device. Dentin sensitivity was checked with evaporative air application. The process was repeated until the sensitivity disappeared.
76040393|NCT04883515|Dietary Supplement|Oral glutamine supplementation|patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
76040394|NCT04883515|Dietary Supplement|Oral protein powder supplementation|patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
76040395|NCT04883515|Procedure|Insulin-resistance evaluation|Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
76040396|NCT04883515|Procedure|Functional intestinal disorders evaluation|Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
75554032|NCT00460083|Drug|Elidel(R) (pimecrolimus 1%)|
75554033|NCT00460083|Device|EpiCeram(R) -ceramide based barrier repair cream|
75554034|NCT00427310|Drug|fluorouracil|
75554035|NCT00427310|Other|Observation|
75554036|NCT00427310|Drug|sodium heparin|
75554037|NCT00468741|Behavioral|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
75554038|NCT00468741|Behavioral|CHESS|informational services of CHESS available to subject
75554039|NCT00468741|Behavioral|CHESS|CHESS informational services and social support available to subject
75554040|NCT00427388|Drug|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
75554041|NCT00427388|Other|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
76040397|NCT04883593|Drug|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
75872275|NCT03775785|Dietary Supplement|Tailored enteral nutrition|"The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d."
76040398|NCT04883593|Drug|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
75872276|NCT05174715|Other|BIA|nutritional status was evaluated using BIA
76040399|NCT04883203|Drug|Vit-D 0.2 MG/ML Oral Solution [Calcidol]|ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
76040400|NCT04883203|Drug|Physiological Irrigating Solution|ARM 2 : placebo
76040401|NCT04883047|Other|holistic birth support strategies|"Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy."
75409020|NCT03138876|Procedure|Standard EEG|An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
75409021|NCT03139032|Drug|APD334|APD334 active treatment for 12 weeks.
75409022|NCT03139578|Device|Test 8.5BC|senofilcon A contact lenses with 8.5 base curve
75409023|NCT03139578|Device|Test 9.0BC|senofilcon A contact lenses with 9.0 base curve
75409024|NCT03139578|Device|Control 8.5BC|narafilcon A contact lenses with 8.5 base curve
75409025|NCT03139578|Device|Control 9.0BC|narafilcon A contact lenses with 9.0 base curve
75409026|NCT03141372|Device|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
75409027|NCT03141528|Other|Self-learning|Training without supervision
75409028|NCT03141528|Other|Instructor-led learning|Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
75409029|NCT03145818|Other|VD-HCBS|Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
75409030|NCT03147690|Drug|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
75409031|NCT03148236|Drug|Vitamin C|200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
75409032|NCT03148236|Other|Placebo|50mL infused over 30 minutes
75409033|NCT03148470|Device|Sham iTBS|Placebo stimulation for the iTBS group
75409034|NCT03148470|Device|Sham cTBS|Placebo stimulation for the cTBS group
75409035|NCT03148470|Device|intermittent theta burst stimulation (iTBS)|Excitatory theta burst stimulation
75409036|NCT03148470|Device|continuous theta burst stimulation (cTBS)|inhibitory theta burst stimulation
75409037|NCT03149172|Device|Equimatrix®|Ridge preservation bone grafting after tooth extraction
75713197|NCT00742664|Behavioral|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
75713198|NCT00742664|Behavioral|Wait-list control|The subject will not receive active treatment during this interval.
75713199|NCT00862953|Dietary Supplement|Normal protein energy-restricted|Normal protein diet energy restricted
75409038|NCT03149172|Device|Bio-Oss®|Ridge preservation bone grafting after tooth extraction
76040402|NCT04897555|Device|LLLT|This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
76040403|NCT04882969|Device|Fractionated Thulium laser|LaseMD Lutronic Laser is a 1927-nm fractionated thulium laser, which is better absorbed by water than non-ablative 1,540-nm erbium glass laser energy. The laser energy and power can be customized to target a specific penetration depth and achieve selective photothermolysis in skin while mitigating injury to surrounding tissue. The thermal energy generated by the laser has been shown to facilitate the delivery of kerafactor, which contain hair growth factors to stimulate follicular progenitor cell proliferation and differentiation into follicular keratinocytes to promote hair growth.
76040404|NCT03051529|Other|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
76040405|NCT02418819|Drug|PF-06412562 3mg BID|PF-06412562
76040406|NCT02418819|Drug|PF-06412562 9mg BID|PF-06412562
75409039|NCT03149172|Device|Endobon®|Ridge preservation bone grafting after tooth extraction
76040407|NCT02418819|Drug|PF-06412562 45mg BID|PF-06412562
76040408|NCT02418819|Other|Placebo|Placebo
76040409|NCT04886869|Dietary Supplement|caffeine|oral consumption
76040410|NCT04886947|Procedure|stem cell transplantation|After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
75409040|NCT03150108|Drug|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
76040411|NCT04897477|Drug|Azacytidine, Bendamustine and Piamprizumab|Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
76040412|NCT04886713|Diagnostic Test|Adipose and myocardial tissue sampling|After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.
75409041|NCT03150108|Drug|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
75409042|NCT03150108|Drug|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
75409043|NCT03154710|Device|MOOVCARE|web-mediated follow up
75409044|NCT03160170|Device|SISTER device|Use of the Suction-Integrated Surgical Tissue Elevator & Retractor (SISTER) device during surgery
75409045|NCT03162354|Other|Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool|"The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture."
75409046|NCT03163134|Device|Lumbar Drain|
75409047|NCT03163758|Device|real Repetitive Transcranial Magnetic Stimulation|The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
75409048|NCT03163758|Device|sham Repetitive Transcranial Magnetic Stimulation|The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
75409049|NCT03164538|Behavioral|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
75554042|NCT01056653|Behavioral|Standard Dose|Two intevention home visits
75554043|NCT01056653|Behavioral|High Dose|Four intervention home visits
75554044|NCT01056653|Behavioral|Comparison Group|One home visit, information only
75554045|NCT01056536|Behavioral|Structured intervention for the prevention of sexually transmitted infections (STI).|The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
75554046|NCT01056536|Device|Free condoms|Subjects will be proposed free condoms at the end of the pre-travel consultation.
75554047|NCT00427427|Drug|Trastuzumab|
75409050|NCT03164538|Behavioral|Diabetes Education|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
75554048|NCT04704947|Drug|nonselective beta blocker|nonselective beta blocker
75554049|NCT04704947|Drug|cardio-selective beta blocker group|cardio-selective beta blocker group
75713200|NCT00862953|Dietary Supplement|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
75713201|NCT00949546|Drug|etanercept|etanercept 50 mg sc twice weekly
75554050|NCT04704947|Drug|alendronate sodium|alendronate sodium
75554051|NCT04705142|Drug|MgSo4|Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
75554052|NCT04705064|Diagnostic Test|Prediction of postoperative acute kidney injury using an artificial intelligence|The performance of an artificial intelligence model to predict postoperative acute kidney injury will be tested prospectively.
75713202|NCT00742742|Behavioral|healthy life style education|healthy life style education
75713203|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
75713204|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
75713205|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
75713206|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
75713207|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
75713208|NCT00949624|Drug|Docetaxel|Intravenous 100 mg/m2 every three weeks
76040413|NCT04886713|Diagnostic Test|Cardiac magnetic resonance imaging|"Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.~The following imaging parameters will be acquired:~Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume~Biventricular mass, wall thickness~T1 mapping; native and > 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume~Late enhancement for detection of regional fibrosis and scar~Myocardial feature tracking for analysis of deformation/motion~Epicardial fat volume"
75554053|NCT00460161|Procedure|acupuncture|2 treatments/week for 4 weeks
75554054|NCT00460161|Other|placebo/sham acupuncture|2 treatments/week for 4 weeks
75554055|NCT00427466|Drug|Pemetrexed|
75554056|NCT00468897|Drug|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
75713209|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
75713210|NCT00949624|Drug|AG-013736|Oral tablet 5 mg BID continuous
75713211|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
75554057|NCT00427505|Drug|Deferasirox|
75554058|NCT00427544|Drug|PRA-027|
75554059|NCT00460200|Genetic|polymorphism analysis|
75554060|NCT00460200|Other|laboratory biomarker analysis|
75554061|NCT00460200|Other|physiologic testing|
75554062|NCT00460200|Other|questionnaire administration|
75554063|NCT00460200|Procedure|conventional surgery|
75713212|NCT02560272|Biological|Minhai-HIB|0.5ml, intramuscular
75713213|NCT02560272|Biological|Act-HIB®|0.5ml, intramuscular
75713214|NCT04019379|Other|Low Calcium/High Phosphorus Diet|Controlled research diet of low calcium/high phosphorus
75713215|NCT04019379|Other|High Calcium/Low Phosphorus Diet|Controlled research diet of high calcium/low phosphorus
75713216|NCT00690482|Drug|AZD1981|Oral tablet, twice daily
75713217|NCT00690482|Drug|Placebo|Placebo Oral tablet, twice daily
75713218|NCT00385255|Biological|Fluarix®|GSK Biologicals' inactivated influenza split virus vaccine.
75713219|NCT00385255|Biological|Boostrix®|GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
75554064|NCT00460200|Procedure|fatigue assessment and management|
75554065|NCT00460200|Procedure|psychosocial assessment and care|
75554066|NCT00427583|Drug|imatinib mesylate|
75554067|NCT00468936|Drug|Myfortic|enteric coated Cellcept pills in applicable dose for patient
76040414|NCT04886713|Diagnostic Test|Cardiopulmonary exercise testing|After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.
75554068|NCT00427622|Other|physiologic testing|
75554069|NCT00469053|Drug|Buprenorphine|
75554070|NCT00427739|Procedure|Cardiac CT|64 slice spiral computerized tomography
75554071|NCT00460278|Drug|XL418|
75554072|NCT00460356|Other|Laboratory Biomarker Analysis|Correlative studies
75554073|NCT00460356|Procedure|Lymphadenectomy|Undergo lymphadenectomy
75554074|NCT00428012|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
75554075|NCT00428012|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
75554076|NCT00469131|Drug|tacrolimus + steroid|
75554077|NCT00469131|Drug|tacrolimus + mycophenolate mofetil|
75554078|NCT00428051|Other|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
75554079|NCT00460395|Procedure|Surgery|
75554080|NCT00460395|Procedure|Stereotactic radiosurgery|
75554081|NCT02956356|Dietary Supplement|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
75554082|NCT02956356|Dietary Supplement|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
75554083|NCT02956356|Dietary Supplement|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
75554084|NCT02956356|Dietary Supplement|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
75554085|NCT00428129|Drug|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
75554086|NCT03271515|Biological|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
75554087|NCT00428168|Drug|Betahistine|Betahistine 24mg BID
76040415|NCT04897243|Drug|Biktarvy|B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.
76040416|NCT04897243|Behavioral|Patient Experience|To capture and integrate the patient experience, this study will collect patient-reported experience measures, conduct qualitative interviews, and engage patients as well as providers.
75554088|NCT00428285|Procedure|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
75554089|NCT00428363|Device|Cataract surgery with implantation of an intraocular lens|
75554090|NCT00428402|Behavioral|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
75554091|NCT00469170|Device|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
75554092|NCT00469248|Device|Intra-aortic balloon pump counterpulsation|
75554093|NCT00428480|Behavioral|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
75554094|NCT00428480|Behavioral|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
75554095|NCT00460473|Drug|Dexmedetomidine|
75554096|NCT00460473|Drug|Placebo|
75554097|NCT00428519|Drug|Placebo|Placebo for 14 days
75554098|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
75554099|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
75554100|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
75554101|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
75554102|NCT00460512|Drug|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
75554103|NCT01056380|Drug|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
75554104|NCT01056380|Drug|Placebo|Tablet, twice daily with food for 5 days
75554105|NCT00460590|Biological|MVA 85A|ID vaccine
75713220|NCT04009005|Behavioral|Therapeutic diet and lifestyle|Educational videos, 1 individual support call from RD follwed by monthly support group meetings conducted via an internet based audio/ video conference platform. Patients will be trained on a low lectin modified paleolithic elimination diet; breathing meditation practice, and walking sessions to increase daily moderate to vigorous physiscal activity
75713221|NCT05299996|Procedure|flexible ureterorenoscopy|stone disintegration stricture dilation tumor resection access guidance
75409051|NCT03169062|Device|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
75409052|NCT03170388|Drug|IDP-126 Gel|Gel
75409053|NCT03170388|Drug|IDP-126 Component A|Component A
75409054|NCT03170388|Drug|IDP-126 Component B|Component B
75713222|NCT02560506|Device|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
75713223|NCT04005339|Drug|Nanoliposomal Irinotecan|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days
75713224|NCT04005339|Drug|Leucovorin|Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
75409055|NCT03170388|Drug|IDP-126 Component C|Component C
75409056|NCT03170388|Drug|IDP-126 Vehicle Gel|Vehicle Gel
75713225|NCT04005339|Drug|Fluorouracil|Fluorouracil 2,400 mg/m IV over 46 hours.
75713226|NCT00949780|Drug|Chloral Hydrate|
75713227|NCT02560350|Other|no intervention|no intervention
75713228|NCT02544243|Drug|Vinorelbine|
75713229|NCT02544243|Drug|Gemcitabine|
75713230|NCT02544243|Drug|Cisplatin|
75713231|NCT04061408|Radiation|Fractionated stereotactic radiotherapy(FSRT)|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
75409057|NCT03172884|Drug|Copanlisib (ALIQOPA, BAY80-6946)|12mg single dose, intravenous on Day 0
75409058|NCT03174366|Drug|Denosumab|Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
75409059|NCT03177798|Drug|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
75409060|NCT03177798|Drug|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
75713232|NCT04011670|Other|200 mg caffeine tablet|"Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
75713233|NCT04011670|Other|Non-active tablet|"Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
75713234|NCT01581073|Drug|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
75409061|NCT03178344|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
75554106|NCT01055834|Drug|Eszopiclone 3 mg|"Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting >=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast & the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
75554107|NCT01055834|Drug|Eszopiclone 1 mg|"Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
75554108|NCT00469326|Drug|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
75554109|NCT01055639|Behavioral|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
75713235|NCT00742820|Drug|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
76040417|NCT04886557|Procedure|L4-L5 decompression and dynamic instrumentation|All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
75409062|NCT03178344|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
75554110|NCT01055639|Behavioral|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
75554111|NCT00460629|Procedure|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
75713236|NCT00742820|Drug|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
75713237|NCT00742820|Dietary Supplement|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
75713238|NCT00860145|Procedure|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
75872277|NCT02328742|Biological|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study."
76040418|NCT04897087|Other|patient safety event|This study will explore the perceptions of patients, carers and relatives who have experienced a patient safety event. Telephone interviews will be undertaken lasting up to 60 minutes This study involves NHS patients, their carers or relatives. We will ask participants about their experience of being involved a patient safety event and the barriers and enablers to participation in the review. We will ask what 'good' patient involvement in patient safety reviews should look like from those with lived experience. This is because we wish to understand from their perspective what matters to them when things go wrong and how best to involve them.
75409063|NCT05364216|Behavioral|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
75554112|NCT00460668|Behavioral|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
75554113|NCT04704713|Drug|Afamelanotide|
75554114|NCT04704713|Drug|Placebo|
75554115|NCT00469365|Behavioral|pharmacist contact with the patient via telephone|
75409064|NCT05364216|Procedure|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
75409065|NCT05364216|Behavioral|The assessment of cognitive function|Participants were assessed for MMSE and MoCA at the same period as the group C
75713239|NCT00860145|Procedure|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
75713240|NCT00754728|Device|JACTAX DES|Drug Eluting Stent
75713241|NCT05301166|Behavioral|Technology Based Motivation Education Program|Technology-Based Motivation Education Program consists of web-based education, motivation program and individual motivation interviews. This program will be prepared according to the Health Belief Model (HBM). It will be applied for 4 months. Participants will take a pre-test before starting the program and a post-test at the end of the program. Individual motivation interviews will be 6 sessions in total. A website will be prepared for the Technology Based Motivation Education Program. This website consists of two parts, a web-based education and motivation program for obesity. The motivation program will enable the participant to follow the program and receive motivational messages.
75713242|NCT05301166|Other|Web Based Education|Students in the control group will participate in web-based educations on obesity prepared only according to the Health Belief Model in the Technology-Based Motivation Education Program. Individual interviews supporting web-based education will be held with the control group once a month.
75713243|NCT00742898|Other|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
75409066|NCT05353920|Other|Cognitive training|cognitive related training bu virtual reality system
75409067|NCT05304000|Behavioral|Mindfulness Meditation|Participants are informed they should sit down in a chair or, if they preferred, to lie down, and then to set a timer for 5 minutes. Then they are told to close their eyes and to start breathing while focusing their mental attention on their forehead region between their two eyes. They are told that if their focus drifted from that location to re-recenter their attention by focusing back first on their breath and then on the forehead region between their eyes. They are told that as thoughts arise, to recognize that as normal, refocus their attention back to their forehead region and to continue the practice until time has elapsed.
75713244|NCT04040283|Procedure|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
75872278|NCT02328742|Other|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study."
75554116|NCT00469365|Behavioral|Pharmacist contact with the patient's physician via fax|
75554117|NCT00469365|Behavioral|Usual care|
75554118|NCT02957513|Behavioral|Text Messaging (TM)|As specified in the arm description above
75554119|NCT02957513|Behavioral|Health Coaching (HC)|As specified in the arm description above
75554120|NCT02957513|Behavioral|Enhanced Usual Care (EC)|As specified in the arm description above
75554121|NCT00460707|Drug|Casopitant 150 mg|Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
75554122|NCT00460707|Drug|Ketoconazole|Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
75554123|NCT00460707|Drug|Casopitant 150 mg matching placebo|Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
75554124|NCT00460707|Drug|Casopitant 50 mg|Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
75554125|NCT00460707|Drug|Casopitant 50 mg matching placebo|Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
75554126|NCT00428636|Procedure|ileostomy|
75554127|NCT00469404|Drug|Buprenorphine|
75713245|NCT05435430|Other|PERSPECTIVE, MULTICENTRIC and observational|we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.
75713246|NCT01324843|Drug|EMLA Cream|
76040419|NCT03049891|Other|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
76040420|NCT03049891|Other|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
76040421|NCT03049891|Other|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
76040422|NCT02576639|Drug|CNP520|
76040423|NCT02576639|Drug|Placebo|Matching placebo to CNP520 was supplied in capsules.
76040424|NCT03049579|Dietary Supplement|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
75713247|NCT01324843|Drug|Aveeno Daily Moist|
75554128|NCT01055132|Device|Etafilcon A toric contact lens|contact lens to correct astigmatism
75554129|NCT01055132|Device|Nelfilcon A toric contact lens|contact lens to correct astigmatism
75554130|NCT00460785|Drug|Opioid|
75554131|NCT01054976|Drug|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
75554132|NCT00469443|Drug|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
75554133|NCT00469443|Drug|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
75554134|NCT00469443|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
75554135|NCT00469443|Drug|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
75872279|NCT02328742|Biological|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study."
76040425|NCT03049579|Dietary Supplement|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
75554136|NCT00469443|Drug|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
75554137|NCT00469443|Drug|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
75554138|NCT00469443|Drug|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
76040426|NCT02418585|Drug|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
75554139|NCT00460863|Procedure|using cool versus warm dialysate during hemodialysis|
75554140|NCT00428870|Procedure|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
75554141|NCT00469482|Other|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
75713248|NCT01324843|Device|Derma Vax|
75713249|NCT01324843|Procedure|Intradermal Electroporation|
75713250|NCT01324843|Procedure|Visual Analogue Scale|
75713251|NCT01324843|Procedure|Present Pain Intensity|
75713252|NCT01324843|Procedure|McGill Pain Questionnaire|
75713253|NCT01324843|Procedure|Skin Assessment|
76040427|NCT02418585|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
75409068|NCT05304000|Behavioral|Cyclic Sighing Breathing|Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 minutes. Then they are told to inhale slowly, and that once their lungs are expanded, to inhale again once more to maximally fill their lungs -- even if the second inhale was shorter in duration and smaller in volume than the first, and then to slowly and fully exhale all their breath. They are told to repeat this pattern of breathing for 5 minutes. They are also informed that ideally, both inhales would be performed via their nose and the exhale would be performed via their mouth, but that if they preferred, they are welcome to do the breathing entirely through their nose. They are also informed that it is normal for the second inhale to be briefer than the first.
75409069|NCT05304000|Behavioral|Box Breathing|"Participants are informed they should sit down in a chair or lie down, and to get a timer. Then they are told to take the CO2 tolerance test as follows: Take 4 breaths through the nose. Then take a maximally deep breath and once your lungs are full, exhale as slowly as possible through your nose or mouth. Time how long it takes to empty your lungs; this will be your C02 discard duration. Use your discard duration to determine how long your inhales, exhales, and breath holds should be (CO2 discard time) by using this table: <20 sec = 3 - 4 sec, 25 - 45 sec = 5 - 6 sec, 50 - 75+ sec = 8 -10 sec. They are then told to inhale, hold, exhale, hold (for the duration determined by the C02 discard table) and to repeat this pattern for the entire 5 minutes. If at any point they had to strain to reach these times, they should simply reduce the duration of inhales, exhales, and breath holds. We ask participants to perform all breathing through their nose, if possible."
75409070|NCT05304000|Behavioral|Cyclic Hyperventilation with Retention|"Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 min. Then they are told to inhale deeply (ideally through their nose but if that is not possible, to inhale through their mouth) and then exhale by passively letting the air fall out from the mouth. We inform them that for sake of this protocol, that pattern of a deep inhale through the nose and passively letting the air fall out from the mouth = 1 breath.~Then they are instructed to perform 30 breaths (in and out) in this manner, and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds."
75409071|NCT05192772|Device|NPi200|Digital pupillometry performed during cardiopulmonary resuscutation (CPR) every CPR cycle end in case of not intubated patient, or every 2 minutes in case of intubated patient
75409072|NCT05133882|Drug|Clifutinib Besylate|The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
75409073|NCT05037474|Procedure|TLE group|all patients underwent a transvenous lead extraction/explantation (TLE) procedure
75409074|NCT05015400|Other|Plain Water|To increase water fluid intake, an additional 1.89 L, during phase 1 of the menstrual cycle (days 1-5).
75713254|NCT02566460|Other|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
75554142|NCT00469482|Other|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
75713255|NCT00863031|Behavioral|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
75713256|NCT00863031|Behavioral|Video-viewing|Three sessions of viewing health educational videos.
76040428|NCT02418585|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
75554143|NCT00428909|Drug|Imatinib/Acetaminophen|
75554144|NCT00469521|Drug|Refresh Tears, 9582X|
75554145|NCT00429065|Drug|Rituximab|
75713257|NCT00949936|Device|CAdisc™-L (Total Disc Replacement)|
75713258|NCT00742976|Drug|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
75554146|NCT02956941|Behavioral|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
75554147|NCT00429221|Behavioral|Tailored Medication Messages for Parents|
75554148|NCT00460902|Device|Transcranial Magnetic Stimulation (TMS)|
75554149|NCT04704206|Other|Children will perform activities on interactive tablet|"The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions."
75554150|NCT06189742|Biological|Tezepelumab|Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).
75554151|NCT06189729|Behavioral|Text reminder|Participants will receive trimonthly text reminders through instant messaging mobile applications or short message service.
75409075|NCT04936074|Procedure|Muscle preserving selective laminectomy|Muscle-preserving selective laminectomy differ from traditional laminectomy by the spinous process split that preserves the deep extensor muscles. The bilateral facet joints are not exposed. After the laminectomy is finished the split fragments of the spinous process are sutured together so that the deep extensor muscles are restored.
75554152|NCT06189729|Behavioral|HIV self-test|Participants will receive trimonthly text messages asking them to choose a pickup point run by the delivery company to collect the free HIV self-test. Upon receiving the delivery instruction, the self-test kit with bilingual (Chinese and English) instructions would be delivered to the designated location.
75554153|NCT06189703|Device|tRNS|transcranial random noise stimulation applied to the right IFG and the left DLPFC
75554154|NCT06189690|Device|rTMS|Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
75554155|NCT06189677|Other|Observation of biological characteristics of fertile men|Sampling in outpatient settings, after biopsy or after surgery and collection of biological samples in fertile subjects
75713259|NCT00742976|Drug|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
75713260|NCT04040985|Procedure|Total Knee Arthroplasty using Legion Total Knee System|Primary Total Knee Arthroscopy using Legion Total Knee System
75713261|NCT00955240|Biological|cetuximab|
75713262|NCT00955240|Drug|cisplatin|
75409076|NCT04936074|Procedure|Laminectomy with instrumented fusion|A traditional laminectomy is complemented with lateral mass and/or pedicle screws connected with rods.
75713263|NCT00955240|Drug|fluorouracil|
75713264|NCT00955240|Other|laboratory biomarker analysis|
75409077|NCT04933344|Other|patients having had BJI or PJI treated with daptomycin|patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK
75409078|NCT04847544|Drug|ADX-629|ADX-629 administered orally twice daily (BID) for up to 28 days.
75409079|NCT04847544|Drug|Placebo|Placebo administered orally BID for up to 28 days.
75713265|NCT00955240|Radiation|radiation therapy|
75713266|NCT02566382|Procedure|arthroscopy arthrodesis of the shoulder|The shoulder surgery will be realized under arthroscopy only
75713267|NCT03844893|Procedure|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
75713268|NCT05261100|Other|Core stability exercises|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises.."
75409080|NCT05406804|Behavioral|Olfactory stimulation|1) For the premature infants who use non-invasive ventilation, place a single layer of gauze soaked in breast milk on the air outlet of the non-invasive ventilator. When inhaling oxygen with a high-flow nasal cannula, the same measure is performed, and the breast milk and sterile gauze soaked in breast milk are replaced every 4 hours. 2) For the premature infants who withdrawn from assisted ventilation, place the breast pad near the infants' nose, and replace the breast milk pad every 4 hours. Acquisition of breast milk pads: use the same brand of breast milk pads; put the breast milk pads used between 00:00 and 07:00 every day (use time > 2 hours) into the same brand of milk storage bags, and use two left and right at the same time. 3) If the premature infants don't have any ventilation support, the breast milk stimulation method is the same as 2). This intervention will continue until premature infants discharge from hospital.
75409081|NCT05406804|Behavioral|Routine nursing care|Nursing is performed according to existing nursing practices. Nasal feeding is generally used.
75713269|NCT05261100|Other|Conventional Physical Therapy|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform."
75409082|NCT05406648|Other|Morus nigra concentrate|The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.
75409083|NCT05406492|Other|Residual blood|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
75409084|NCT05406336|Other|Predicted uncontrolled BP status (yes/no) at follow up visit, derived using a machine learning algorithm|The investigators have created a machine learning algorithm to predict uncontrolled blood pressure (BP) status (yes/no) at a follow up visit among adults with uncontrolled BP at their current visit. The investigators will determine whether adding this information to a vignette describing a patient will increase the likelihood that a clinician will intensify antihypertensive medication treatment.
75409085|NCT05406180|Biological|VaxigripTetra inj.|Suspension for injection in a pre-filled syringe Injection intramuscular
75409086|NCT05406024|Device|Digital platform|The digital platform consists of 84 exercise sessions of progressive intensity. Each day, the tool offers 8 exercise sessions of about 5 to 10 minutes each, spaced out over an hour. One session can represent several exercises. The patient is asked to perform them daily.
75409087|NCT05405946|Behavioral|Computerized Cognitive Remediation Therapy|"Sessions of 45 minutes will be developed 2 times a week, for 4-5 months (performing a total of 40 sessions). The sessions will be led by an experienced clinician with psychotic patients, and trained for the management of CCRT. Each intervention session will be individualized according to the results of the evaluation tests and the computerized program itself will adapt the difficulty of the tasks according to the performance of each patient.~The cognitive remediation NeuroPersonalTrainer platform includes two rehabilitation modules: the cognition module that includes attention, memory and executive functions with different levels of complexity and the Social Cognition module which allows working on different aspects of emotional processing, theory of mind and cognitive biases through 43 tasks based on multiple multimedia materials."
75409088|NCT05405946|Other|Treatment as Usual|Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.
75409089|NCT05405712|Behavioral|Mobile Phone App|App-based peer support program, used in conjunction with standard outpatient treatment
75409090|NCT05405478|Drug|Omalizumab|subcutaneous injection every 2 or 4 weeks, depending on the pretreatment serum total IgE level and body weight
75409091|NCT05405478|Diagnostic Test|SNOT22 score|score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110)
75409092|NCT05333952|Procedure|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
75554156|NCT06189664|Diagnostic Test|Frozen section|Frozen section analysis
75713270|NCT00867867|Drug|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
75713271|NCT00867867|Drug|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
75713272|NCT00867867|Drug|Placebo|9.3 mg once per day, 6 days per week, for 9 months
75713273|NCT00955318|Drug|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
75713274|NCT01044667|Behavioral|GI and Quality of Life Assessment|
75713275|NCT01766492|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
75713276|NCT00860223|Drug|Digoxin|
75554157|NCT06189651|Device|wrist splint|The same type of wrist splint to be used for at least 8 hours at night for 4 weeks, to be worn in a neutral position and in accordance with the wrist as described in previous studies to restrict movement in the wrist. Patients who did not sleep for 8 hours were asked to complete 8 hours of wrist splint use before going to sleep or after waking up.
75554158|NCT06189651|Procedure|5% dextrose injection using USG-guided nerve hydrodissection method|2 ml each of 5% dextrose injection was administered once at the proximal wrist level above the median nerve separating the median nerve from the flexor retinaculum and below the median nerve separating the median nerve from the flexor tendons by nerve hydrodissection method in the transverse inplane plane under ultrasound guidance. After the application, the spread of the injectate was observed by looking longitudinally at the median nerve.
75713277|NCT00860223|Drug|Neratinib|HKI-272
76040429|NCT02418585|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
76040430|NCT02418585|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
76040431|NCT02418585|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
76040432|NCT04896853|Biological|ProTrans®|Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells
75409093|NCT05333952|Procedure|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
76040433|NCT05530031|Procedure|trabeculotomy ( angle glaucoma surgery )|a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.
75409094|NCT05276310|Biological|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
75409095|NCT05233254|Behavioral|Abdominal Hollowing exercise|Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
75554159|NCT06189638|Drug|Antimicrobial Peptide PL-5 Topical Spray and Placebo|Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
75554160|NCT06189612|Other|Clinical reasoning based physiotherapy + cervical movement control training|An individualized cervical motor control training based on the positive tests of the test battery introduced by Patroncini et al. (2014).
75554161|NCT06189612|Other|Clinical reasoning based physiotherapy + orofacial movement control training|An individualized orofacial motor control training based on the positive tests of the test battery introduced by von Piekartz et al. (2017).
75554162|NCT06189612|Other|Clinical reasoning based physiotherapy + standard exercises|A generalized training regimen based on exercises which are taught in physiotherapy training for the neck and scapula region preventing the overlap with exercises of the test batteries.
75713278|NCT05223504|Device|Continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
75409096|NCT05169918|Other|Core stabilization|"The progressive core stabilization exercise approach created by Kumar et al. will be used.~Stage 1; Isolation and facilitation of target muscles~Stage 2; Trunk stabilization training with increased load under static conditions~Stage 3; Development of trunk stabilization during slow controlled movement of the lumbar spine.~Stage 4 and 5; Lumbar stabilization during high speed and dexterous movements. The exercises will last 20-30 minutes in each sessions and twice a week for 10 weeks. The level of stage will be increased when the patients reach the aim of the stage where he/she is at. The duration of the each stage will change depending on the days the patients' need to achieve the aim of the level. For each level, at least four exercise is described."
75409097|NCT05169918|Other|Sensorial Discrimination Training|Training group will be participate in core stabilization exercises (as describe in Control Group). Additionally, Sensorial Discrimination Training (SDT) will be applied on the low back of the patients for 20 minutes before the 20 minutes of core stabilization exercises. SDT is defined as the ability to correctly interpret the characteristics of the stimulus made to a part of the body by the patient. It aims to reverse the cortical reorganization observed in patients with chronic pain. It consists of tactile localization and graphesthesia training, which includes determining the localization and type of stimulus and recognizing the letter/number that drawn in a body part, by the patient. The training consists of five stages progressively, each stage lasting two weeks. As the participants complete the sensory tests at each stage with 90% accuracy, the next stage will be passed. If this accuracy rate is not achieved within two weeks, the stage can be extended for one week.
76040434|NCT04897165|Other|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants received access to three online lectures at the start of the first, third, and forth training week (each lasting 60 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
75713279|NCT01044823|Other|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
75409098|NCT05083806|Device|Multispectral Optoacoustic Tomography|Non-invasive optoacoustic imaging of muscular structure
75409099|NCT05023512|Behavioral|Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health|Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.
75409100|NCT04890366|Drug|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
75554163|NCT06189586|Drug|aerosol inhalation of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
75713280|NCT02564276|Procedure|Sentinel lymph node biopsy|
75713281|NCT00860301|Other|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
75872280|NCT02328742|Biological|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study."
76023260|NCT03170791|Device|vagal nerve stimulation intervention|During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
76023261|NCT03172741|Drug|Medical Marijuana|1-gram marijuana cigarette smoked once per day for 3 months
76023262|NCT03172741|Drug|Placebo|Matching 1 gram placebo cigarette smoked once per day for 3 months
76023263|NCT02702011|Drug|empagliflozin medium dose|
76023264|NCT02702011|Drug|empagliflozin low dose|
76023265|NCT02702011|Drug|empagliflozin high dose|
76023266|NCT02702011|Drug|placebo|
76023267|NCT03170713|Drug|arveles|800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
76023268|NCT03170713|Drug|intrafen|800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
76023269|NCT03170713|Other|placebos|150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
76023270|NCT02404207|Other|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
76023271|NCT02404207|Other|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
75409101|NCT04723368|Device|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=5 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 14 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
76040435|NCT04897165|Other|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants attended three live lectures at the start of the first, third, and forth training week (each lasting 90 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
75409102|NCT04601532|Device|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin.
76040436|NCT05529875|Drug|Propofol|intravenous propofol using target-controlled infusion (TCI) devices.
76040437|NCT05529875|Drug|sevoflurane|inhalator sevoflurane using sevoflurane vaporizer sevoflurane vaporizer.
76040438|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Group A will receive metformin 1000 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
75409103|NCT04601532|Drug|Silver Sulfadiazine|Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
75409104|NCT04520256|Behavioral|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
75409105|NCT04520256|Behavioral|Virtual Reality for Behavioral Weight Loss Skills Training|This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
75409106|NCT04520256|Behavioral|Tailored Interactive Video Feedback|Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
75409107|NCT04520256|Behavioral|Tailored Intervention for Structured Physical Activity|Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
75409108|NCT04520256|Behavioral|Skills Training for Dysregulated Eating|Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
75409109|NCT04520256|Behavioral|Platform for Social Support & Friendly Competition|An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
75409110|NCT04098978|Other|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
75409111|NCT03811470|Other|Standard diabetes management model in each MMC center|Standard diabetes management model in each MMC center
75409112|NCT03780426|Device|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
76023272|NCT02404207|Other|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
76023273|NCT02404207|Other|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
76023274|NCT02657369|Drug|Lenvatinib 24 mg|
76023275|NCT02397421|Drug|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
76023276|NCT02397421|Drug|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
76023277|NCT04862507|Other|Telephone call on day 90|telephone call on day 90 to assess the primary outcome (mRs 90)
76023278|NCT04862507|Diagnostic Test|Quantification of lesion water uptake by CT densitometry|Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
75409113|NCT03780426|Device|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
75409114|NCT03192774|Device|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
76040439|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Group B will receive metformin 1700 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
76040440|NCT03051451|Drug|Placebo Oral Tablet|Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
76040441|NCT02417961|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
76040442|NCT03049657|Device|Angiolite|Percutaneous coronary intervention
75409115|NCT03137160|Biological|Ixekizumab|Injection
75409116|NCT03058614|Drug|CEUS|In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
75554164|NCT06189586|Drug|intravenous injection of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
76040443|NCT03049657|Device|Xience|Percutaneous coronary intervention
75409117|NCT03058614|Diagnostic Test|Non-contrast CT scan|The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
75409118|NCT03058614|Diagnostic Test|Capping trial|Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
75409119|NCT03048240|Device|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
75409120|NCT03048240|Drug|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
75713282|NCT01047631|Behavioral|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~Measure general fitness levels such as walking, strength and balance.~Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~Blood and urine tests and a heart ultrasound.~Questionnaires & activity measures.~Group assignment for 12 weeks:~-Exercise classes & activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
76040444|NCT05529719|Other|Clinical Pilates Exercises|Participants in the experimental group were included in the clinical Pilates intervention, which consisted of three weekly sessions for 50 minutes for 12 weeks. Clinical pilates sessions were performed by a clinically Pilates-certified instructor and a physiotherapist. The intervention was divided into three sections. Each session started with the warm-up section. The warm-up part started with breathing exercises, pelvic tilt centering, activation of deep trunk and pelvic floor muscles, and joint mobility. The Clinical Pilates exercises section consisted of matte level strength and flexibility exercises involving the trunk, upper and lower extremities. Finally, a cooling part was done that included some flexibility exercises.
76040445|NCT03050047|Biological|BCD-100|Anti-PD1 monoclonal antibody
76040446|NCT04886089|Device|Pleth variability index for prediction of post-induction hypotension|The use of the baseline Pleth variability index values for prediction of occurrence of post-induction hypotension
76040447|NCT04896463|Radiation|Abdominal ultrasound (US)|abdominal examination with US device
76040448|NCT04885933|Diagnostic Test|sarcopenia measurement|BIA for fat free muscle mass hand grasp strength
76040449|NCT04883125|Drug|Pioglitazone 15mg|pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
76040450|NCT04882423|Other|grilled hamburger (7 oz) with no vegetables|Test meal 1: grilled hamburger (7 oz) with no vegetables
75713283|NCT01047631|Behavioral|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~Measure general fitness levels such as walking, strength and balance.~Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~Blood and urine tests and a heart ultrasound.~Questionnaires & activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
76040451|NCT04882423|Other|grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)|Test meal 2: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
76040452|NCT04882423|Other|grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)|Test meal 3: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
75409121|NCT02893800|Device|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
75872281|NCT05296239|Other|SimpleC Wellness Platform with Social Robot Interaction|"Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia."
75409122|NCT02856126|Procedure|Hepatic arterial infusion chemotherapy|
75409123|NCT02856126|Procedure|Transarterial chemoembolization|
75409124|NCT02856126|Drug|TACE regimen|infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
75872282|NCT05256459|Other|Long term follow-up|No extra intervention.
75409125|NCT02856126|Drug|HAIC Regimen|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
75409126|NCT02856126|Drug|Oral Sorafenib|Oral Sorafenib, 400mg, Bid
75409127|NCT04682574|Drug|Vitamin C|mega dose is given to the selected critically ill patients
75409128|NCT04589364|Drug|Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)|injection of toxin on facial muscle
75409129|NCT04553484|Diagnostic Test|Measuring cardiovascular performance and blood flow|Measuring cardiovascular performance and blood flow
75409130|NCT04492488|Drug|MRG002|Administrated intravenously
75409131|NCT04473924|Drug|Mycophenolate Mofetil|Body surface area-based dosing of mycophenolate
75409132|NCT04473924|Drug|Mycophenolate Mofetil|Standard (fixed) dosing of mycophenolate
75409133|NCT04426500|Drug|Bupivacain|Direct injection of 0.25% bupivacaine into surgical wounds
76040453|NCT04882423|Other|grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).|Test meal 4: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
76040454|NCT05529563|Procedure|LSG|LSG
76040455|NCT04882267|Behavioral|Team and Technology|Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
76040456|NCT04430413|Biological|Platelet Rich Plasma|Autologous PRP obtained via double centrifugation process of the participant's blood sample. PRP was prepared by the double Spain strategy.
76040457|NCT04882345|Drug|Almonertinib|"Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day."
76040458|NCT05529485|Procedure|Cataract surgery by phacoemulsification|Cataract surgery by phacoemulsification
75409134|NCT04426500|Drug|Ultrasound-guided transversus abdominus plane block|bilateral TAP using ultrasound guidance in prostatectomies
75409135|NCT04426500|Drug|Laparoscopic-guided transversus abdominus plane block|bilateral TAP using laparoscopic guidance in prostatectomies
75409136|NCT04251546|Diagnostic Test|p2PSA|p2PSA test(for calculation of PHI)
75409137|NCT04251546|Diagnostic Test|Ultrasonic parameters|Ultrasonic parameters(TPV)
75409138|NCT04251546|Diagnostic Test|Transperineal prostate biopsy|Transperineal prostate biopsy for confirmation of prostate cancer or benign disease
76040459|NCT04882033|Drug|Concurrent chemoradiotherapy plus anlotinib|"Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy."
75409139|NCT04131192|Drug|Z650|250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
75872283|NCT02328586|Other|Group Acupuncture|
75409140|NCT04131192|Drug|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
75409141|NCT04123626|Drug|QR-1123|unilateral IVT injection
75409142|NCT04123626|Other|Sham procedure|Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
75409143|NCT03925116|Other|COntraceptive pathway|alternative way of aiding patients in deciding contraception method
75409144|NCT03923868|Drug|D-0120|D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
75409145|NCT03883074|Device|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate|Melt in mouth tablets (1100 mg)
75409146|NCT03883074|Device|Placebo|tablets with the same aspect of the active device
75409147|NCT03708900|Drug|LCI699|osilodrostat (LCI699) is in the form of tablets for oral administration and comes in the following tablet strengths: 1 milligram (mg), 5 mg, and 10mg.
75409148|NCT03670836|Device|Dilapan|Dilapan-S® is a mechanical method for cervical ripening using rods made of a patented hydrogel Aquacryl, it is marketed in form of rods of 3 and 4 mm diameter. It is FDA approved for cervical ripening.
75409149|NCT03670836|Drug|Misoprostol|"25mcg of Misoprostol will be administered orally every 2 hours (maximum of 6 doses)~Misoprostol is a prostaglandin E1 analog approved for treatment and prevention of gastric ulcers. The use of Misoprostol appears to be safe and effective for induction of labor when used in low dose."
75409150|NCT03449628|Dietary Supplement|L.casei DG|"(At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
75409151|NCT03449628|Dietary Supplement|PLACEBO|1 capsule, b.i.d. for 12 weeks
75409152|NCT03409614|Drug|REGN2810|REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
75409153|NCT03409614|Drug|REGN2810/chemo/ipi|REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
75409154|NCT03409614|Other|Chemotherapy|Platinum-based doublet chemotherapy Part 1
75409155|NCT03409614|Drug|Placebo|Matching placebo Part 2
75409156|NCT03320382|Device|Multiple breath washout testing|Multiple breath washout testing will be completed on different devices over time
75409157|NCT02767830|Behavioral|Excercise and Nutrition Program|
75409158|NCT02651844|Drug|Mifepristone|"At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).~Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file."
75409159|NCT02341716|Procedure|WA|Walk advice with Nordic Poles and best medical treatment
75409160|NCT02341716|Procedure|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
75409161|NCT02341716|Procedure|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
75409162|NCT02155452|Procedure|ALA|"Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation"
75409163|NCT01952340|Dietary Supplement|Flaxseed|Milled flaxseed
75409164|NCT01952340|Dietary Supplement|Placebo|Wheat germ/wheat bran and mixed dietary oils
75409165|NCT01463670|Drug|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
75409166|NCT00682032|Dietary Supplement|beta-glucan|AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
75409167|NCT00151398|Drug|lecozotan SR|"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."
75409168|NCT00151398|Drug|Donepezil|10 mg donepezil QD dosed up to 40 weeks
75409169|NCT03181308|Drug|Carotuximab (TRC105)|Anti Endoglin Antibody
75409170|NCT03181308|Drug|OPDIVO|Programmed Death Receptor-1
75409171|NCT03184428|Other|Postoperative observation and survey|For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
75409172|NCT03187002|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
75409173|NCT03187002|Drug|Moderate IV Sedation|IV sedation with fentanyl and versed
75409174|NCT03187002|Other|SHAM: Transcutaneous electrical nerve stimulation (TENS)|Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
75409175|NCT03187002|Other|SHAM: Moderate IV Sedation|Sham IV to ensure blinding
75409176|NCT03193398|Drug|BTRX-246040 oral capsule(s)|BTRX-246040 administered once daily to patients with MDD for 8 weeks
75409177|NCT03193398|Drug|Placebo oral capsule(s)|administered once daily to patients with MDD for 8 weeks
75409178|NCT03194334|Behavioral|Vegetarian diet|
75409179|NCT03194334|Dietary Supplement|creatine|1g creatine/day
75409180|NCT03194334|Dietary Supplement|Placebo|pills
75872284|NCT03604107|Genetic|Preimplantation Genetic Testing-Aneuploidy|trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined
75409181|NCT03194334|Dietary Supplement|Beta-alanine|0.8g beta-alanine per day
75409182|NCT03199872|Biological|RV001V|Sc injection
75409183|NCT03202134|Other|opioid free anesthesia|general anesthesia blocking reflexes without using an opioid
75409184|NCT03204942|Device|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
75409185|NCT03204942|Device|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
76040460|NCT05474183|Drug|Ketamine|drug
75409186|NCT03204942|Drug|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
76040461|NCT04885777|Drug|Lidocaine|"Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution."
76040462|NCT04885777|Other|Placebo|"Initially, a nasopharyngeal swab was performed on placebo group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, the Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril). The second samples were collected after waiting 5 minutes following the administration of the solution."
76040463|NCT05529407|Device|Simple Vaginal Tampon|Use of single use vaginal tampons
76040464|NCT05529407|Device|Glass Vaginal Trainer|Use of glass vaginal trainers
76040465|NCT04885855|Drug|Sofosbuvir 400 MG|Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
75409187|NCT03207438|Drug|Quetiapine 50 MG Extended Release Oral Tablet|OD
75409188|NCT03207438|Drug|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
75409189|NCT03207438|Drug|Placebos|Placebo
75409190|NCT03218592|Drug|Maraviroc Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
75409191|NCT03218592|Drug|Dolutegravir Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
75409192|NCT03218592|Drug|Truvada Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
75409193|NCT03219294|Drug|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
75409194|NCT03219294|Drug|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
75872285|NCT02332486|Drug|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
75872286|NCT05173857|Device|Advance PTX|PTA in Dysfunctional Haemodialysis Access
76040466|NCT04885855|Drug|Ravidasvir 200mg|Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
75872287|NCT05173857|Device|Advance LP (Low Profile)|Plain Old Balloon Angioplasty (POBA)
75872288|NCT05173857|Drug|Paclitaxel (PTX)|Paclitaxel (PTX)
75872289|NCT03111238|Drug|REX-001|REX-001 is administered through an intra-arterial catheter.
75554165|NCT06189573|Procedure|Anterior cruciate ligament Reconstruction with autologous quadriceps tendon graft|Surgical reconstruction of anterior cruciate ligament with autologous quadriceps tendon graft
75554166|NCT06189573|Procedure|Anterior cruciate ligament Reconstruction with autologous bone patellar tendon bone graft|Surgical reconstruction of anterior cruciate ligament with autologous bone patellar tendon bone graft
75713284|NCT04018287|Other|HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)|"HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation."
75409195|NCT03219840|Drug|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
75713285|NCT00698204|Drug|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
75713286|NCT00698204|Drug|placebo|Subject was asked to take placebo each day that radiation therapy was given.
75713287|NCT02560194|Procedure|Flexible Sigmoidoscopy|Examination of the rectal and distal colon by means of a flexible endoscope
75713288|NCT02560194|Other|Fecal occult blood test|Test for hemoglobin in faeces
75713289|NCT00549718|Drug|Lurasidone HCl|Once daily
75872290|NCT03111238|Drug|Placebo|Placebo is administered through an intra-arterial catheter.
76040467|NCT05196659|Behavioral|Integrated comprehensive cardiovascular disease management|"Electronic Health Record-Decision Support Software (EHR-DSS):~Electronic patient health record storage~Management prompts to the clinical team (following algorithms)~Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~Non-physician health worker-led continuity of care:~- individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~Text-message based reminders for a healthy lifestyle~Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~Quarterly audit and feedback to the clinical team"
76040468|NCT04895683|Behavioral|Text message content|Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
75409196|NCT03219840|Drug|Xylitol only chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
75713290|NCT00863187|Biological|rituximab|b cell depletion
75713291|NCT00754884|Drug|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
75713292|NCT00754884|Drug|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
75872291|NCT01372137|Drug|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
76040469|NCT05534555|Diagnostic Test|FebriDx|Testing of finger-prick blood sample using FebriDx
75409197|NCT03222414|Device|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
75409198|NCT03222414|Device|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
75409199|NCT03222414|Other|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
75409200|NCT03223272|Drug|Reserpine|Open label reserpine 0.1 mg pill orally
76040470|NCT05534399|Procedure|Intra-vesical BoNTA injections|"Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure."
76040471|NCT03051295|Other|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
76040472|NCT02632721|Drug|Decitabine|
76040473|NCT02632721|Drug|BI 836858|
75409201|NCT03224520|Behavioral|Recommender CTHC|Enhanced Messaging
75409202|NCT03224520|Behavioral|Standard CTHC|Standard Messaging
75409203|NCT03224520|Other|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
75409204|NCT03224520|Other|Standard Online Recruitment|Search Engine and Social Media Advertisements
76040474|NCT05529095|Drug|Apomorphine Sublingual Film|Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
76040475|NCT05529095|Drug|Placebo|Placebo (sugar pill)
75409205|NCT03237156|Drug|TAK-906|TAK-906 capsules.
75409206|NCT03237156|Drug|TAK-906 Placebo|Placebo capsules.
75409207|NCT03239106|Drug|Apremilast|Apremilast 30 mg BID daily
75409208|NCT03239574|Device|MightySat|MightySat - investigational pulse oximeter that will be placed on the subject's right index finger for the duration of the study
75872292|NCT01372137|Other|Glucose 5%|Placebo
76040476|NCT01596127|Drug|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
76040477|NCT03051373|Drug|nanoparticle albumin-bound paclitaxel, S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
76040478|NCT03051373|Drug|Gemcitabine, cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
76040479|NCT04881331|Other|Analysis of electrosurgical smoke.|Patients undergo standard of care surgical removal of the malignant breast tumor. Electrosurgical knife is used to cut tissues according to standard practice. Fraction of the surgical smoke is captured for analysis and video record of the point of view of the surgeon is captured with a head-mounted camera.
75409209|NCT03242148|Device|Toffee Nasal Pillows Mask|Participants will be placed on this intervention for a total 14 ± 5 days from Visit 2. Participants will be using the Toffee nasal pillows mask during this treatment arm.
75409210|NCT03257202|Drug|Clindamycin 1% Gel|topical clindamycin
75409211|NCT03257202|Drug|Benzoyl peroxide 5% gel|topical benzoyl peroxide
75409212|NCT03257202|Drug|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
75409213|NCT03260790|Biological|PCV13|Single 0.5 ml dose of PCV13 administered via intramuscular injection
75409214|NCT03260790|Biological|PPSV23|Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
75409215|NCT03261960|Drug|BLI4700|Oral bowel preparation
75409216|NCT03261960|Drug|Magnesium bowel preparation|Oral bowel preparation
75409217|NCT03273270|Radiation|transcranial magnetic stimulation|transcranial magnetic stimulation
75409218|NCT03273426|Procedure|Minimally-invasive biopsy|Intervention (core needle biopsy (14G) or vacuum-assisted biopsy(10G)) for complete clinical response (cCR) or near-cCR predicted by MRI.
75409219|NCT03273426|Procedure|wide excision|Surgical wide excision of the biopsied area.
75713293|NCT00743210|Drug|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
75713294|NCT00743210|Drug|Placebo|Placebo, 3 grams once per day for 3 weeks.
75713295|NCT00371761|Biological|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
75713296|NCT00371761|Drug|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
75713297|NCT05435274|Drug|HS-10376|HS-10376 will be administered orally once daily in a continuous regimen
75554169|NCT06189547|Other|different prior cancer history type|different types of prior cancer history
75713298|NCT03888794|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging on pregnant women after 18 weeks of pregnancy with US diagnosis of congenital CNS fetal abnormality.
75713299|NCT05351398|Drug|PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
75713300|NCT05351398|Drug|Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
75713301|NCT00860613|Other|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
75713302|NCT00754962|Drug|protriptyline|10 mg tablet
75713303|NCT02564666|Other|telephone counseling|regular telephone counseling for compliance and advese event
75872293|NCT03620097|Dietary Supplement|EuPoly-3 DHA Infant|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
76040480|NCT04895059|Drug|Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose|Form: Tablets Dosage: 20 mg Adminstration way: Oral
76023279|NCT03168451|Behavioral|Culturally Tailored Text Messages|Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
76023280|NCT05110859|Other|in-depth individual interviews|in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
76023281|NCT02397343|Drug|Hyperbaric oxygen|
76023282|NCT04850339|Biological|ANXV|Intravenous infusion
76040481|NCT04895059|Drug|Rosuvastatin 20mg|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
75554170|NCT06189534|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy-based interventions were used to manage social media addiction and; to address associated problems with it. Psychoeducation, problem conceptualization, cognitive distortions and belief identification,Time management,Stress and distress management, Emotional and beliefs modification,Priority and Goal setting, Problem solving skills, Social skill training, Emotional and behavioral activation and Relapse prevention are techniques that will be used in the intervention.
75554171|NCT06189521|Other|Extracorporeal shock wave group|In addition to the ten-day of physiotherapy program, in the first group one day for a week a total of 3 sessions of ESWT was applied at 1.8 bar, 10.0 Hz, 2000 beats (Elmed Vibrolith Ortho).
75554172|NCT06189521|Other|ultrasound group|In addition to the ten-day of physiotherapy program,In the second group, ten days of ultrasound applied at 1.5 watt/cm2 continuous mode to the painful area for 5 minutes, 5 days a week for two weeks (Chattanooga Intelect Advanced).
76023283|NCT04850339|Other|Placebo|Intravenous infusion
76023284|NCT02403973|Other|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
76040482|NCT04895059|Drug|Ezetimibe 10mg|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
75554173|NCT06189521|Other|dexamethasone iontophoresis group|In addition to the ten-day of physiotherapy program, In the third group ten days of dexamethasone iontophoresis therapy was applied. 10 days for 10 minutes. 0,1% dexamethasone ophthalmic pomade was applied to the anodal electrode and placed on the lateral epicondyle and 0.1-0.2 milliampere/cm2 galvanic current was applied in each session (ES-522; ITO Physiotherapy and Rehabilitation).
75554174|NCT06189495|Drug|GenSci048|1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
75713304|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
75713305|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
76040483|NCT04391413|Device|Use of OCT to guide the angioplasty procedure|OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
75713306|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
75409220|NCT03274518|Device|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
75409221|NCT03274518|Device|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
75409222|NCT03275766|Other|DLPFC facilitatory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
75409223|NCT03275766|Other|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
75409224|NCT03275766|Other|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
75409225|NCT03275766|Other|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
76040484|NCT05467475|Drug|BI 1819479|BI 1819479
75713307|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
75713308|NCT00868023|Drug|Placebo|Placebo
75713309|NCT05300386|Drug|Escitalopram|We use Escitalopram 5~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder
75713310|NCT01050127|Drug|ABT-436|See Arm Description for details.
75409226|NCT03278886|Drug|Low dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks
75409227|NCT03278886|Drug|Nalmefene|18 mg of nalmefene taken once daily for 8 weeks
75409228|NCT03281538|Drug|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
75409229|NCT03285984|Other|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
75713311|NCT01050127|Drug|Placebo|See Arm Description for details.
75409230|NCT03285984|Other|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
75713312|NCT00955396|Drug|GSK1014802|Tablets
75713313|NCT00955396|Drug|Placebo|Tablets
75713314|NCT00863499|Drug|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
75713315|NCT00863499|Drug|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
75872294|NCT03620097|Other|Placebo|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
75409231|NCT03285984|Other|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
75409232|NCT03285984|Other|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
75554175|NCT06189495|Drug|GenSci048 placebo|"1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)"
75554178|NCT06189456|Device|BLUgel A|BLUgel A: Hyaluronic Acid Eye Drops 0.30%
75554179|NCT06189456|Device|BLUyal A|BLUyal A:Hyaluronic Acid Eye Drops 0.15%
75554180|NCT06189443|Other|Group administered to individual telemedicine|A brochure containing incontinence patient information will be prepared and given, web-based training will be implemented, and informative/reminder messages will be sent via short messages every day.
75713316|NCT04061642|Device|Clinical Decision Aid|The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
75713317|NCT03992053|Other|sacroiliac joint injection|Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
75713318|NCT00755118|Drug|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
75409233|NCT03287310|Drug|GSK3511294|GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
75713319|NCT00755118|Drug|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
75713320|NCT00755118|Drug|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
76040485|NCT05467475|Drug|Esomeprazole|Esomeprazole
76040486|NCT05528705|Biological|LAENNEC|Subacromial spatial administration
75409234|NCT03287310|Drug|Placebo|Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
75409235|NCT03287310|Drug|Salbutamol/albuterol|Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
75409236|NCT03292614|Diagnostic Test|Measurements of the postoperative refraction|"The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)"
75409237|NCT03292692|Behavioral|OurRelationship|Online intervention with coach support
75409238|NCT03295266|Drug|MK-3866|Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
75409239|NCT03301272|Drug|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
75713321|NCT00755118|Drug|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
75872295|NCT05078086|Other|No intervention|No intervention
75409240|NCT03301272|Other|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
75409241|NCT03303144|Drug|Triferic|ferric pyrophosphate citrate
75409242|NCT03306420|Drug|M4112|All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
75409243|NCT03312348|Device|Infrared imaging|Infrared image image acquisition of study participants
75713322|NCT00755118|Drug|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
75409244|NCT03315702|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
75409245|NCT03315780|Drug|Dulaglutide|Administered SC
75409246|NCT03315780|Drug|Placebo|Administered SC
75409247|NCT03319134|Device|active anodal HD-tDCS|1) active anodal HD-tDCS with memory task
75713323|NCT00755118|Drug|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
75713324|NCT00755352|Drug|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
75713325|NCT00755352|Drug|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
75409248|NCT03319134|Device|sham HD-tDCS|2) sham HD-tDCS with memory task
75409249|NCT03319134|Device|active cathodal HD-tDCS|3) active cathodal HD-tDCS with memory task
75409250|NCT03329352|Device|F&P Full-Face Mask|The F&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
75409251|NCT03330834|Biological|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
75409252|NCT03334734|Drug|PBTZ169|Once a day for 14 days
75554181|NCT06189430|Other|Yoga|Yoga practice was standardized throughout the study to avoid the risk of intervention variability. The basic structure of each yoga session is meditation, breathing exercises (pranayama), and after a warm-up, yoga practice includes asanas (postures) for strength, balance and mobility, and finally ends with relaxation. The yoga intervention we recommend was created within the framework of the asanas that the elderly can do in the literature and by taking the expert opinion of a sports physician.
75554182|NCT06189430|Other|Standard exercise|It is a type of exercise similar in intensity to vinyasa yoga. (50-70% MHR: maximum pulse rate)
75713326|NCT00549640|Drug|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
75713327|NCT00549640|Drug|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
75713328|NCT00868335|Device|Activ C disc prosthesis|cervical disc prosthesis
75713329|NCT00868335|Procedure|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
75409253|NCT03334734|Drug|Isoniazid|Once a day for 14 days
75409254|NCT03334812|Biological|LNA043|LNA043 Single dose
75409255|NCT03334812|Biological|placebo to LNA043|placebo to LNA043 single dose
75409256|NCT03336450|Drug|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
75409257|NCT03336450|Drug|MHOS/SHP615|MHOS/SHP615
75409258|NCT03338556|Drug|PrEP-001|
75409259|NCT03338556|Other|Placebo|
76040487|NCT05528705|Other|0.9% normal saline|Subacromial spatial administration
75554183|NCT06189417|Behavioral|Health Extension Led club based Intervention|The Health Extension Workers-led club-based intervention primarily focuses on equipping individuals with the necessary knowledge and skills to enhance their self-management behavior. The intervention encompasses education on adopting healthy eating habits, promoting regular exercise, effectively managing weight, and supporting smoking cessation. It emphasizes the importance of regular blood sugar level monitoring, limiting alcohol intake, and reducing sedentary behavior. The intervention also includes counseling to provide guidance and support in adopting and maintaining healthy behaviors. Additionally, it highlights the significance of adhering to medication regimens for optimal health outcomes. If additional medical attention is required, the intervention provides referral services to nearby health facilities.
75554184|NCT06189404|Drug|Tigulixostat|300 mg oral dose
75554185|NCT06189404|Drug|Theophylline|400 mg oral dose
75409260|NCT03606408|Drug|osilodrostat|osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
75554186|NCT06189352|Other|Positive feeding of the preterm infant|Feeding strategy for the preterm infant with description of nutritional needs and based on the infants development and cues.
75554187|NCT06189339|Diagnostic Test|non-cancerous cyst|For patients who have a pancreatic cyst bigger than 2cm found during a radiology exam, they will undergo an Endoscopic ultrasound exam to check the cyst and fluid will be collected for testing, including glucose, CEA (carcinoembryonic antigen), and amylase. A biopsy will be done if possible. We will analyze how well the glucose level in the fluid can tell us if the cyst is cancerous or not, using CEA level, EUS findings, and amylase level as the standard. This is an observational study, and patients will receive standard medical treatment.
75554188|NCT06189339|Diagnostic Test|cancerous cyst.|For patients who have a pancreatic cyst bigger than 2cm found during a radiology exam, they will undergo an Endoscopic ultrasound exam to check the cyst and fluid will be collected for testing, including glucose, CEA (carcinoembryonic antigen), and amylase. A biopsy will be done if possible. We will analyze how well the glucose level in the fluid can tell us if the cyst is cancerous or not, using CEA level, EUS findings, and amylase level as the standard. This is an observational study, and patients will receive standard medical treatment.
75409261|NCT03256968|Drug|Ataluren|ataluren
75409262|NCT03339570|Procedure|Orthopedic treatment for a proximal humeral fracture|Orthopedic treatment consisting in inmobilization of the arm in a sling for the first three weeks, followed by physical therapy.
75409263|NCT03340350|Drug|Minocycline|Minocycline capsule
75409264|NCT03340428|Behavioral|Transition Community Adherence Club (TCAC)|A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
75409265|NCT03341910|Drug|DFD-03 Lotion, 0.1%|DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
75713330|NCT00860691|Procedure|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
75872296|NCT05078008|Procedure|Physiotherapy modalities|parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
75554189|NCT06189326|Procedure|non-penetrating deep sclerectomy|Non-penetrating deep sclerectomy (NPDS) is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma. This procedure was developed in an attempt to avoid many of the postoperative complications of trabeculectomy
75713331|NCT00860691|Procedure|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
75872297|NCT05078008|Procedure|Balneotherapy modalities|Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
75409266|NCT03341910|Drug|Tazorac Cream, 0.1%|Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
75409267|NCT03341910|Drug|DFD-03 Vehicle Lotion 0%|Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
75409268|NCT03341910|Drug|Tazorac Vehicle Cream 0%|Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
75409269|NCT03343080|Drug|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
75409270|NCT03343080|Other|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
75554190|NCT06189326|Procedure|primary combined trabeculotomy-trabeculectomy|Combining trabeculotomy with trabeculectomy is one of the preferred surgical options, which showed favorable results in congenital glaucoma, and is advised mainly for treating moderate to severe forms of the disease, as the procedure provides dual pathways for aqueous drainage
75554191|NCT06189300|Other|Education and counseling intervention|In addition to standard training, training and consultancy will be provided to individuals with stoma intermittently within a month.
75554192|NCT06189274|Other|Anatomy-Based Electrode Array Selection|Use of pre-operative imaging to select the appropriate length electrode vs standard of care
75554193|NCT06189274|Other|Standard of Care Electrode Array Selection|Use of standard of care electrode which is the FLEX 28 electrode
75872298|NCT03417999|Drug|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
75409271|NCT03345108|Device|Denture Adhesive Cream (Conventional Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05g for the maxillary and 0.60±0.05g for the mandibular dentures.
75409272|NCT03345108|Device|Denture Adhesive (Continuous Strip Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05 g for the maxillary and 0.60±0.05 g for the mandibular dentures.
75409273|NCT03345108|Other|No Adhesive|No adhesive applied.
75409274|NCT03346902|Drug|EB-001|Injection of EB-001 into area of scarring (forehead)
75409275|NCT03346902|Drug|0.9% Sodium Chloride Injection|Injection of Saline into area of scarring (forehead)
75409276|NCT03349632|Device|verofilcon A contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
75872299|NCT02328430|Device|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
75872300|NCT03142516|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
75872301|NCT03142516|Drug|Irinotecan|Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
75409277|NCT03349632|Device|senofilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
75409278|NCT03349632|Device|stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
75409279|NCT03349632|Device|etafilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
75409280|NCT03350724|Device|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
75409281|NCT03350724|Device|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
75409282|NCT03365154|Device|Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment|Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.
75409283|NCT03365154|Device|Balloon Angioplasty|Low pressure balloon angioplasty may be used following atherectomy
75554194|NCT06189261|Other|Holistic needs assessment based on the use of patient-reported outcome measures|During the study, two intervention consultations will take place 1 and 3 months after the initial clinical team meeting, where each participant's case will be discussed. At the start of each intervention consultation, participants will be asked to complete the intervention patient-reported outcome measure (i.e. Distress Thermometer and Problem Checklist, and Supportive Care Needs Survey-Melanoma Module). The recorded information will be passed to their nurse specialist, who will identify the participant's needs and offer tailored advice and support to meet these needs.
75554195|NCT06189248|Behavioral|Resourcefulness intervention|Teaching personal and social resourcefulness skills.
75554196|NCT06189235|Other|Biofeedback training|The target of additional biofeedback training is to provide hints which are related to the essential aspects during hand therapy such as the stress on the tissue and the distance of tendon gliding.
75713332|NCT00860691|Other|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
75409284|NCT03365778|Other|Patient Educational Intervention|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.
75409285|NCT03365778|Other|Usual Care|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.
75409286|NCT03365778|Other|Ophthalmologist Educational Intervention|Responses to online survey regarding beliefs and attitudes towards selective laser trabeculoplasty (SLT) before and after educational slide presentation were recorded and compared between physician specialty groups.
75409287|NCT03369756|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Wound cleansing using Prontosan solution and gel
75409288|NCT03373890|Behavioral|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
75713333|NCT04444804|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Dosage at the discretion of the treating physician
75713334|NCT04444804|Drug|LMWH and Phenprocoumon|Dosage at the discretion of the treating physician
75409289|NCT03375294|Drug|Nitrous Oxide|One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
75713335|NCT05226741|Device|Head protection device|The participants are fitted with a form of head protection over the craniectomy and provide feedback on design, use, and comfort
75713336|NCT04010890|Behavioral|Culturally adapted CBT|Culturally adapted CBT for South Asian Canadians
75872302|NCT03142516|Drug|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
75872303|NCT03142516|Drug|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
75872304|NCT03482453|Drug|TAK-788|TAK-788 capsules.
75872305|NCT03482453|Drug|Placebo|TAK-788 placebo-matching capsules.
75409290|NCT03377244|Behavioral|HBHS|Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.
75409291|NCT03377244|Behavioral|HBHS Policy|Church-level policy changes that encourages participants to engage in healthy behaviors.
75409292|NCT03377244|Behavioral|WORD DPP|Faith based diabetes curriculum that teaches participants to connect faith and health.
75409293|NCT03379662|Device|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
75409294|NCT03379662|Device|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
75409295|NCT03379740|Other|E-cigarette|Subject's own e-cigarette
75409296|NCT03379740|Other|P4M3-1.7%|P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
75409297|NCT03379740|Other|P4M3-1.7%LA|P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
75409298|NCT03379740|Other|P4M3-3%LA|P4M3 e-liquid concentration of 3% nicotine with lactic acid
75409299|NCT03379740|Other|P4M3-4%LA|P4M3 e-liquid concentration of 4% nicotine with lactic acid
75409300|NCT03390114|Behavioral|SHUTi|SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.
75409301|NCT03391986|Device|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
75409302|NCT03391986|Procedure|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
75409303|NCT03392532|Device|Lotrafilcon B toric contact lenses with HYDRAGLYDE|Silicone hydrogel soft contact lenses for astigmatism
75409304|NCT03392532|Device|Lotrafilcon B toric contact lenses|Silicone hydrogel soft contact lenses for astigmatism
75409305|NCT03395808|Drug|Tramadol|IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
75409306|NCT03395886|Drug|Remifentanil|The noninvasive ventilation intolerated patients was sedated by remifentanil.
75409307|NCT03395886|Drug|Dexmedetomidine|The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
75409308|NCT03396432|Device|Video Laryngoscopy for ET placement|Tracheal intubation performed with the Storz C-Mac Video Laryngoscope
75409309|NCT03396432|Device|Direct Laryngoscopy for ET Placement|Tracheal Intubation performed with the Miller Blade
75409310|NCT03398928|Other|Acupuncture|Acupuncture added to usual care
75872306|NCT03482453|Drug|TAK-788|TAK-788 DiC.
75872307|NCT05077930|Biological|Convalescent plasma|The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.
75409311|NCT03400800|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
75409312|NCT03400800|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
75409313|NCT03410628|Device|gammaCore|Non-invasive vagal nerve stimulator
75409314|NCT03410862|Drug|Elderberry Extract|Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)
75409315|NCT03410862|Drug|Placebos|Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
75409316|NCT03415152|Drug|Omacor (Omega-3-acid ethyl esters)|Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
75409317|NCT03416946|Device|Visionaire|Custom cutting block using MRI to create patient specific instrumentations
75409318|NCT03416946|Other|Traditional|Traditional cutting method
75409319|NCT03418662|Device|EndoRings device|Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
75409320|NCT03423186|Drug|SOBI003|Weekly i.v.infusion
75409321|NCT03426228|Diagnostic Test|HbA1C|"After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:~At baseline (second day of the menstrual period)~Triggering phase (post-egg retrieval procedure)~Embryo transfer phase (post-transfer procedure)~Week 4 (positive bHCG)~4. Week 8 of pregnancy"
75713337|NCT00921882|Procedure|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
75713338|NCT00863577|Drug|Oral bemiparin|Bemiparin tablets and bemiparin tablets into hard gelatine capsules
75872308|NCT05077930|Drug|Standard of care|The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
75409322|NCT03429270|Device|TDOC 5Fr|A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
75409323|NCT03429348|Other|Sauna Rehabilitation|Firefighters selected for sauna rehabilitation will spend time in a sauna
75409324|NCT03430050|Drug|Progesterone|Progesterone capsule
75409325|NCT03430050|Drug|Placebo|Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
75409326|NCT03430206|Device|High-flow nasal cannula|While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
75713339|NCT05351320|Drug|WX-0593 Tablets|WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily
75872309|NCT05077696|Other|Drawing a tube of blood (serum)|dosage of neurofilaments and comparison with a final diagnosis one year after sampling.
75409327|NCT03433794|Behavioral|Alcohol 101 Plus (TM)|It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
75409328|NCT03433794|Behavioral|Booster|Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
75713340|NCT05351320|Drug|chemotherapy|Platinum-based chemotherapy
75713341|NCT05351320|Radiation|Thoracic Radiation Therapy（TRT）|Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy
75713342|NCT00868413|Drug|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
75872310|NCT05077618|Other|sampling of dental plaque and blood sample during the treatment|sampling of dental plaque and blood sample analysed on day 1
76040488|NCT04430491|Diagnostic Test|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
75713343|NCT00868413|Drug|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
75713344|NCT00868413|Drug|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
75713345|NCT05351008|Other|Cognitive physical therapy|Cognitive therapy techniques, TENS, ultrasound, massage
75713346|NCT05351008|Other|Physical therapy|TENS, ultrasound, massage, exercise
76040489|NCT05534165|Drug|Tecovirimat|600 mg po BID
76040490|NCT05534165|Drug|Placebo|identical placebo 600 mg po BID
75554197|NCT06189222|Device|virtual reality glasses|The population of the study consisted of children who were aged between 7- 12 and were on treatment using an intravenous catheter in the pediatric emergency unit of a state hospital in Turkey.Participants were divided into two groups, namely experimental and control groups, by using simple randomization software. The design and implementation of the study were based on the principles in the CONSORT list (Consolidated Standards of Reporting Studies). Descriptive data form for children,this form was prepared to collect information about the children included in the sample. It consists of seven questions on children's sociodemographic characteristics and previous intravenous catheter insertion experience.The Children's Emotional Manifestation Scale (CEMS), this scale was developed by Li & Lopez (2005) to measure children's emotional responses during stressful medical procedures. The VR glasses we used in our study were connected to a mobile phone.
75554198|NCT06189209|Drug|Tenalisib|Tenalisib will be administered 800mg BID, orally
75409329|NCT03433794|Behavioral|Lilly for Better Health|This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
75554199|NCT06189196|Device|BLOW BOTTLE|Blow Bottle PEP' is the cost-effective device comparative to other PEP devices. Treatment (CPT) along with BBPEP twice a day. Therapist made a cost-effective BBPEP which generates 10 cm of H2O PEP and it was given for 10 breaths, 3 sets with 5 second hold.
75554200|NCT06189196|Other|ACBT|Active cycle of breathing technique (ACBT) is an alternative airway clearance technique. A typical ACBT cycle consists of breathing control, three to four thoracic expansion exercises, and a forced expiratory technique (huffing). ACBT has been shown to improve short-term secretion clearance in patients with chronic lung disease. It is also flexible, tolerated, and accepted well by patients. Although ACBT is widely used in patients with respiratory conditions characterized by chronic sputum production.
75554201|NCT06189183|Radiation|Adjuvant Hypofractionation Radiotherapy|Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
75554202|NCT06189157|Biological|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells
75554203|NCT06189144|Other|Emollient cream treatment|Rilastil Difesa Sterile cream
75409330|NCT03440424|Drug|Lemborexant|oral tablet
75554204|NCT06189144|Other|no treatment|no treatment
76023285|NCT04832009|Drug|Dextrose 20 % in 500 ML Injection|Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
75554205|NCT06189131|Device|Ventriject|Ventriject is a non-exercise method for estimating V02Max
75554206|NCT06189118|Behavioral|Online Mindfulness Based Cognitive Therapy or Health Education Program|12 hours of online group training of Mindfulness Based Cognitive Therapy OR 12 hours of online group training of Health Education Program will be provided via teleconferencing. Additional both groups will perform daily home practice.
75554207|NCT06189105|Other|miss alice face it you love me serum|Facial serum with niacinamide, plant-based collagen and peptides will be applied by each participant to the treatment site according to randomization protocol every evening
75554208|NCT06189105|Other|No treatment (usual skincare rutine)|No treatment (usual skincare rutine)
75554209|NCT06189092|Drug|Bleomycin|Using electroporation to infuse bleomycin in the lesion
75554210|NCT06189040|Drug|BNT162b2 30µg|intramuscular administration of 30µg
75554211|NCT06189040|Drug|BNT162b2 20µg|intramuscular administration of 20µg
75554212|NCT06189040|Drug|BNT162b2 6µg|intradermal administration of 6µg
75554213|NCT06189040|Drug|mRNA-1273 100µg|intramuscular administration of 100µg
75554214|NCT06189040|Drug|mRNA-1273 50µg|intramuscular administration of 50µg
75554215|NCT06189040|Drug|ChAdOx1-S [Recombinant]|intramuscular administration of not less than 2.5 x 10^8 infectious units
75554216|NCT06189027|Drug|MDMA|Adjunctive administration of MDMA to assist psychotherapeutic process
75554217|NCT06189027|Behavioral|Psychotherapy|Psychotherapy aimed at assisting with PTSD symptom reduction
75554218|NCT06189001|Drug|Oxytocin|Intravenous oxytocin 0.2 IU/min during experimental days
75554219|NCT06189001|Other|Placebo (saline)|Intravenous saline during experimental days
75554220|NCT06188975|Drug|DRUG: ABBV-CLS-484|
75554221|NCT06188962|Behavioral|CBT-informed school-based counselling|Knowledge Insight Tools (KIT) is a CBT-based model of one-to-one therapy for secondary school pupils who are struggling with low mood and/or anxiety. KIT incorporates the key features of CBT (e.g., agenda setting, formulation around maintenance cycles, inter-session work involving exposure and/or behavioural activation) but is delivered in a semi-structured way that meets the young person's needs and pace of learning. Whilst there is an emphasis on symptom reduction, the primary focus is on the young person's goals for living and co-producing an understanding of how symptoms can interfere with these goals. Practitioners are encouraged to incorporate different therapeutic tools and modalities that complement the young person's strengths and ways of learning, including non-verbal forms of expression like arts and crafts, music, and dance. By being flexible, person-led, goal-focused, and integrative, KIT was designed to suit the needs of secondary school students.
75409331|NCT03444090|Procedure|Colon polypectomy|"For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size <10 mm are removed as they are identified on insertion and withdrawal. Polyps with size >10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum."
75409332|NCT03448068|Drug|Ketamine|"Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated."
75554222|NCT06188936|Device|ExSeed®|"In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of normal or below normal, as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email."
75554223|NCT06188936|Other|Survey|Surveys will be completed on a hard copy or electronically.
75554224|NCT06188923|Drug|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
75872311|NCT03480425|Diagnostic Test|Measuring extubation force|Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
76040491|NCT04885387|Device|chest CT|chest CT pectus deformities diagnostic
75554225|NCT06188923|Drug|Placebo|Same as active comparator, except placebo dispensed
75554226|NCT06188910|Other|Neurofeedback|Conducting neurofeedback sessions guided by a researcher
75554227|NCT06188910|Other|Health education|Health education on mobile phone addiction
75554228|NCT06188897|Other|Self-stretching of the masticatory musculature|"If the subject belonged to the Treatment group, he was instructed to self-stretch the masticatory muscle.~This stretch consisted of introducing three knuckles of the non-dominant hand between the incisors for two minutes while sitting."
75554229|NCT06188897|Other|Control group intervention|The control group was asked to introduce only two knuckles in the oral cavity and perform a mandibular occlusion, an intervention that serves as a simulated stretch in said group.
75872312|NCT03719729|Drug|Rifaximin|Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
75872313|NCT05077462|Drug|C52R1M Tab. and C52R2 Tab.|Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
76040492|NCT04885387|Device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device pectus deformities diagnostic
75872314|NCT05077462|Drug|AJU-C52H|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
75872315|NCT03719651|Behavioral|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
75872316|NCT03719651|Behavioral|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
75409333|NCT03448068|Drug|Standard therapy|"Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care"
75409334|NCT03453060|Drug|E-WE Thrombin- Dose 1|Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
75409335|NCT03453060|Drug|E-WE Thrombin- Dose 2|Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
75872317|NCT03719651|Behavioral|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
75872318|NCT03719651|Behavioral|TF-CBT|TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
75872319|NCT02328508|Device|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
76040493|NCT04885309|Procedure|Nerve Stimulator-guided Obturator Nerve Block|Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.
75409336|NCT03453060|Drug|E-WE Thrombin- Dose 3|Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
75409337|NCT03453060|Drug|E-WE Thrombin- Dose 4|Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
75409338|NCT03453060|Other|Placebo|Participants received a single intravenous dose of placebo.
75409339|NCT03457116|Drug|Norco|20 tablets of Hydrocodone 5mg-Acetaminophen 325mg (Norco)
75409340|NCT03457116|Drug|NSAID|Ibuprofen 400mg for post-operative pain
75409341|NCT03459612|Drug|Lasmiditan|Administered orally
75409342|NCT03459612|Drug|Placebo|Administered orally
75409343|NCT03459612|Drug|Diphenhydramine|Administered orally
75409344|NCT03463512|Drug|Racecadotril plus ORS|Racecadotril plus ORS
75872320|NCT03714113|Diagnostic Test|Anti-HLA donor-specific antibodies monitoring|Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
75409345|NCT03463512|Drug|ORS|ORS
75409346|NCT03467412|Drug|FOL-005|intradermal injection
75409347|NCT03467412|Drug|Placebo|intradermal injection
75409348|NCT03468816|Device|Sensor activation (on DryMax Extra Soft)|Study profile of sensor activation
75409349|NCT03473184|Drug|Diacerein 1% ointment|Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.
75409350|NCT03473886|Behavioral|Intervention arm: PP-MI|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
75554230|NCT06188871|Drug|Dupilumab|Two injections of 300mg dupilumab, subcutaneous 14 days apart
75554231|NCT06188845|Other|Kinesio taping|Kinesio taping is a non-invasive physical treatment, which is breathable, hypoallergenic and elastic. Because of the mechanical properties and physiological effects, Kinesio taping has been thought to relieve pain, reduce swelling, support and relax soft tissue, promote motor performance, and correct posture or abnormal movement patterns.
75554232|NCT06188832|Dietary Supplement|glucomannan, inulin, and psyllium|the subjects recieved fiber supplement containing glucomannan, inulin, and psyllium
75554233|NCT06188832|Other|placebo|the subjects recieved placebo
75409351|NCT03475992|Device|Low-power microwave breast imaging system|Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
75409352|NCT03476850|Procedure|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
75409353|NCT03476850|Procedure|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
75409354|NCT03477006|Biological|Whole blood|Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood
75409355|NCT03478254|Biological|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
75409356|NCT03478254|Biological|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years.~One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
75554234|NCT06188819|Procedure|Explantation of a previous aortic graft or endograft and reconstruction by arterial allograft or rolled pericardium|In situ reconstruction with explantation of the infected graft or endograft and reconstruction by allograft or pericardium
75713347|NCT00860769|Behavioral|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
75713348|NCT00860769|Behavioral|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
76040494|NCT04880941|Behavioral|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
75713349|NCT04010500|Device|no mouthguard|Control (not using mouthguard)
75713350|NCT04010500|Device|'boil and bite' mouthguard|KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.
76040495|NCT04880551|Radiation|Fluoroscopy|In this study the patient will be exposed to radiation during the fluoroscopy for lungs. There is a small chance of alopecia. There is a rare chance that the patients skin may turn red or be damaged.
76040496|NCT05528627|Other|Pectoral Nerve (PECs) block|Pectoral Nerve (PECS) blocks were performed on the side of surgery, using the ultrasound-guided technique 30 min before the implantable cardiac electronic device (pacemaker, implantable cardioverter defibrillator) insertion procedure
75409357|NCT03478254|Biological|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
75409358|NCT03480048|Behavioral|Breastfeeding and weight loss support|The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.
75713351|NCT04010500|Device|custom-fitted mouthguard|The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
75713352|NCT04040829|Behavioral|Cognitive remediation therapy (CR)|Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
75713353|NCT04040829|Behavioral|Supported education (SE)|Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
75713354|NCT04040829|Other|Treatment as usual (TAU)|Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
76040497|NCT04880005|Behavioral|Clinical decision support|"Based on the phenotyping and algorithms developed by the hospital specialists at Odense University Hospital and Holbæk Hospital in collaboration with GPs, the individual GPs and their patients will receive individualized recommendations on lifestyle interventions and pharmacological treatments.~The GPs will receive specific clinical decision support (CDS) recommendations on what drugs to prescribe to each patient based on the phenotyping in accordance with a clinical decision support tool (Cambio) and the updated guidelines at all times (Sparrow 2019). The treatment advice to the GPs will be adjusted annually based on treatment effect, re-phenotyping, and updated knowledge of the treatment of T2D. Furthermore, psychiatric, socioeconomic and/or cultural challenges and other determinants for frailty will be a part of the individualized intervention provided to patients by the GPs, again based on the specialist advice."
76040498|NCT04880005|Behavioral|Digital Lifestyle Coaching|As part of DICTA, the patients are offered a personal health coach (dietician, nurse, occupational therapist, or physiotherapist) through the complex eHealth intervention (Liva). Patients will receive personalized empathic, relation driven coaching on healthy lifestyle on the individual patient's preferences (e.g. increased physical activity, healthier diet, weight loss, smoking cessation, personal goal setting, tailored information, peer to peer support), including optimal pharmacological treatment (Komkova 2019). The collaborative eHealth tool will give health coaches access to patient registered outcome measurements (PRO), information. This forms the basis of the individual coaching and is partly supported by artificial intelligence (AI) to improve the coaching by the health coaches (Holzinger 2016).
75713355|NCT03897348|Drug|Placebo|Oral medication
75713356|NCT03897348|Drug|Lacosamide 100 mg|Oral medication
75872321|NCT03111004|Other|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
75872322|NCT03472547|Drug|diacerein 1% ointment|All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
75409359|NCT03485976|Drug|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
75409360|NCT03486990|Drug|TIMP-GLIA|intravenous infusion.
75409361|NCT03490110|Behavioral|State regulation skill training|Participants complete seven supervised training sessions. Training sessions last 2 hours, and participants are requested to complete approximately 2.5 hours of additional skill practice over the course of each week outside of session (total ~4.5 hours per week).
75409362|NCT03490110|Other|Treatment-as-usual|Participants receive clinical care as usual over a matched time period.
75409363|NCT03495648|Behavioral|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
75409364|NCT03496428|Device|Dental implant impressions- Different Techniques|Assessment of soft tissues changes with different techniques
75409365|NCT03496974|Drug|Bermekimab Monoclonal Antibody 200 mg|200 mg subcutaneous injection
75409366|NCT03496974|Drug|Bermekimab Monoclonal Antibody 400 mg|400 mg subcutaneous injection
75409367|NCT03498300|Biological|Tdap vaccine|A single dose of Tdap vaccine at GA 27 - 36 weeks
75713357|NCT03897348|Drug|Lacosamide 200 mg|Oral medication
75409368|NCT03501264|Behavioral|Online Game|LGBTQ Bullying game
75554235|NCT06188806|Other|ADDUKTOR CANAL BLOCK|All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.
75554236|NCT06188806|Other|CONTROL GROUP|No nerve block procedure is applied to patients.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia) tramadol 50 mg at 10 mg / hour basal rate after loading (20 mg bolus dose + 30 minutes lock time) and paracetamol 10 mg / kg iv (8 hours apart) will be given.
75872323|NCT00799396|Drug|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
75872324|NCT00799396|Drug|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
75872325|NCT05077306|Other|music therapy group|individual bedside single session of receptive music therapy (RMT) by a certified Music therapist- GIM fellow in presence. STAI Y-1 was administered 5 min. before session (STAI Y-1 PRE) and 15 min. after session (STAI Y-1 POST) in paper form. HR and O2Sat were recorded from the bedside monitor 3 times: start session (T0), 10 min. (T1), end session (T2).Participants i were asked to fill in an optional open-ended question concerning their experience with music therapy.
75872326|NCT03143062|Diagnostic Test|NEWS|NEWS
75872327|NCT03469349|Drug|Actovegin|Actovegin intravenous infusion and tablets.
76040499|NCT04880005|Behavioral|Integration to Standard Electronic Health Record|Data on physical activity, steps, diet goal fulfillment, smoking status etc., are being provided for GPs in a web-based solution integrated into the GPs' health record system. Integration with the GP system XMO (covering 52% of all Danish GPs) has been finalized.
75409369|NCT03501264|Behavioral|LGBTQ Resources|This group receives LGBTQ Resources
75409370|NCT03503292|Drug|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
75409371|NCT03503292|Drug|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
75409372|NCT03506724|Drug|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
75409373|NCT03506724|Drug|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
75409374|NCT03507036|Device|Profound system|Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
75409375|NCT03509766|Device|Histamine skin testing|skin testing using histamine
75409376|NCT03511638|Device|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
75409377|NCT03511638|Device|Alcon VISCOAT®|Ophthalmic viscosurgical device
75409378|NCT03519282|Device|comfilcon A multifocal toric lens|contact lens
75409379|NCT03519282|Device|omafilcon A Multifocal Toric Lens|contact lens
75409380|NCT03520998|Drug|GRF6019|GRF6019 for IV infusion
75409381|NCT03525210|Biological|9-valent HPV vaccine|Vaccination
75409382|NCT03532308|Drug|Fermented Soy|Two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.
75409383|NCT03532308|Other|Placebo|A placebo compliment to the active intervention with identical packaging and labeling will be used.
75409384|NCT03532776|Drug|Podofilox Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
75409385|NCT03532776|Drug|Condylox Topical Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
75872328|NCT03469349|Drug|Placebo|Actovegin placebo-matching intravenous infusion and tablets.
75872329|NCT03639233|Behavioral|YESS!|Web based self-management education
75872330|NCT03467945|Drug|Metformin/Gliclazide Fixed Combination|Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
75872331|NCT03467945|Drug|Metformin|Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
75872332|NCT03467945|Drug|Gliclazide|Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
76040500|NCT05377697|Other|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
76040501|NCT05528393|Diagnostic Test|Blood sampling|blood sampling
76040502|NCT01595581|Drug|Testosterone|8 weeks of testosterone administration beginning 2 weeks before ACL surgery
76040503|NCT01595581|Drug|Placebo|8 weeks of saline administration beginning 2 weeks before ACL surgery
76040504|NCT05534009|Other|Follow up of the first known immunization event|"The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved.~HCWs can be enrolled in the category of:~(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection."
76040505|NCT03050125|Device|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
76040506|NCT03050125|Device|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
75409386|NCT03532776|Drug|Placebo Gel|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
75409387|NCT03533244|Drug|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
75409388|NCT03533244|Drug|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
75409389|NCT03533244|Drug|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
75409390|NCT03541356|Combination Product|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device
75409391|NCT03541356|Combination Product|L-dopa 35 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
75409392|NCT03541356|Combination Product|L-dopa 70mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
75409393|NCT03541356|Combination Product|L-dopa 140 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
75409394|NCT03541356|Combination Product|L-dopa 70mg/carbidopa 7mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
75872333|NCT03719261|Drug|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
75872334|NCT03719261|Drug|Sodium Hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
75872335|NCT00069238|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
75872336|NCT00069238|Drug|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
75872337|NCT03435497|Behavioral|Game Changers|Game Changers is an intervention that aims to empower and mobilize PLHA to be agents for HIV prevention and behavioral change in their social networks.
75872338|NCT03143140|Other|PAFA|percutaneous ablation of tumor feeding artery
75872339|NCT03143140|Other|tumor ablation|ablation of tumor area directly
75872340|NCT03639155|Drug|vadadustat reference tablets|oral tablet
75713358|NCT04010734|Procedure|Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography|"The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH)."
75409395|NCT03545412|Device|Microfocused ultrasound with visualization|Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
75713359|NCT00868491|Drug|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
75713360|NCT00868491|Radiation|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
75872341|NCT03639155|Drug|vadadustat test tablets|oral tablet
75409396|NCT03546270|Behavioral|Swimming|This group completed 20-weeks of swimming
75409397|NCT03549234|Drug|Erector Spinae (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
75409398|NCT03549234|Drug|Paravertebral (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
75409399|NCT03557658|Drug|Bexagliflozin|Single oral dose of bexagliflozin tablet, 20 mg
75409400|NCT03564444|Biological|Bivalent influenza vaccine|A single dose of bivalent vaccine (10^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.
75713361|NCT00868491|Drug|cetuximab, cisplatin|"cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)"
75872342|NCT03145324|Other|Collection of vaccine histories|
75409401|NCT03564444|Other|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
75713362|NCT00955630|Drug|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
75713363|NCT00955630|Drug|ranibizumab|prn injections of ranibizumab throughout the study
75872343|NCT02328274|Procedure|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
75409402|NCT03567252|Behavioral|Walking Group|Participants will walk 1 kilometer to a Farmer's Market.
75713364|NCT00868569|Procedure|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4"
75872344|NCT05080348|Procedure|Ropivacaine iPACK Injection|Injection of 20mL of 0.25% Ropivacaine with 1:400,000 Epinephrine between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
75872345|NCT05080348|Procedure|Normal Saline iPACK Injection|Injection of 20mL of 0.9% Normal Saline between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
75872346|NCT02328196|Behavioral|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
75409403|NCT03569748|Device|IQOS|IQOS USE FOR 12 WEEKS
75409404|NCT03569748|Device|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
76040507|NCT03050125|Device|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
76040508|NCT05373563|Procedure|cesarean section women|The test will be applied to women who have had a cesarean section and the Turkish validity and reliability of the scale will be determined according to the answers given.
75409405|NCT03572478|Drug|Rucaparib|600 mg taken by mouth twice daily.
75409406|NCT03572478|Drug|Nivolumab|480 mg given by intravenous (IV) infusion every 4 weeks.
75409407|NCT03574818|Drug|Necitumumab-Gemcitabine-Cisplatin|"Gemcitabine 1250mg/m2 IV on D1, D8~Cisplatin 75mg / m2 IV on D1~Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
75554237|NCT06188793|Device|Virtual reality-directed BGBT|Enrolled participants will receive up to 3-days of VR-directed BGBT through several modules including distraction games, mindfulness meditation, breathing exercises, and cognitive behavioral therapy based coaching. Participants will complete questionnaires at various time points and be asked to complete a semi-structured interview post-intervention.
75713365|NCT00868569|Procedure|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4"
75713366|NCT00863733|Drug|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
75713367|NCT00549562|Drug|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
76040509|NCT03048955|Device|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
76040510|NCT03048955|Procedure|Direct decompression Surgery|A surgical procedure - the control
75409408|NCT03574818|Diagnostic Test|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
75409409|NCT03575754|Device|Percutaneous Ultrasound Gastrostomy|A balloon catheter is inserted into the stomach and used to appose tissue between anterior stomach and skin. Fluid fills the balloon, enabling ultrasound visualization. Then a guidewire is inserted, and pulled out through the mouth to create wire-to-wire (through and through) access. At that point, a gastrostomy tube is placed over it using over-the-wire (push) technique.
75409410|NCT03593538|Drug|Metformin|Metformin capsule
75554238|NCT06188780|Diagnostic Test|urine/blood analysis with IA and LC-GCMS analysis|urine/blood analysis with IA and LC-GCMS analysis
75713368|NCT00860925|Drug|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
75713369|NCT00860925|Drug|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
75713370|NCT00860925|Drug|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
75872347|NCT03073200|Drug|Ixekizumab|Administered SC
76040511|NCT04885153|Drug|Fenofibrate|Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.
75409411|NCT03593538|Drug|Placebo|Sucrose filler in gel capsules
75409412|NCT03610464|Drug|Amphetamine Extended Release Suspension [Dyanavel]|1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
75872348|NCT03073200|Drug|Placebo|Administered SC
76040512|NCT04885153|Drug|Placebo|Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
75872349|NCT03073200|Drug|Etanercept|Administered SC
76040513|NCT04302311|Diagnostic Test|Holter monitoring|Use of smart device application and technologies to assess for arrhythmias
76040514|NCT04302311|Diagnostic Test|Kardia/AliveCor monitoring|Kardia/AliveCor monitoring
76040515|NCT03048643|Behavioral|Outpatient parenteral antibiotic therapy|Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
76040516|NCT04884997|Drug|toripalimab|toripalimab 3mg/kg, Q2w;
76040517|NCT04884997|Drug|Temozolomide Injection|Temozolomide 150mg/m2,d1-5,Q4w
76040518|NCT03048721|Procedure|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
75554239|NCT06188767|Drug|Testosterone Undecanoate|Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.
75713371|NCT00860925|Drug|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
75409413|NCT03613818|Behavioral|eCHECKUP TO GO|eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
75554240|NCT06188754|Behavioral|Time restricted eating|Limiting food intake to 10 hours per day
75409414|NCT03614130|Device|LID011121 contact lens|Investigational silicone hydrogel contact lens
75554241|NCT06188754|Behavioral|Mediterranean diet|Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and the use of olive oil.
75554242|NCT06188702|Drug|S095035|S095035 will be taken orally once daily in 28-day cycle.
75872350|NCT03142126|Device|Early ambulation with Angioseal closure device|To reaffirm safety and efficacy of using Angioseal for early ambulation by patients after femoral artery arteriotomy
75409415|NCT03614130|Device|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
75409416|NCT03618030|Drug|PRC-063 oral capsules|Daily dose
75409417|NCT03618030|Drug|Placebo oral capsules|Daily dose
75409418|NCT03619590|Other|Data Collection|When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
75409419|NCT03623334|Radiation|Image-Guided Radiation Therapy|Radiotherapy to a potent tumorcidal dose
75409420|NCT03630198|Drug|Corticosteroid with lidocaine|Intralesional corticosteroid injection
75554243|NCT06188689|Diagnostic Test|Pacing|"Ventricular 10 beat burst at 500ms (120bpm)~Ventricular 10 beat burst at 400ms (150bpm)~Atrial 10 beat burst at 500ms (120bpm)~Atrial 10 beat burst at 400ms (150bpm)."
75554244|NCT06188676|Drug|Cyclophosphamide|Ciclofosfamida
75554245|NCT06188676|Drug|Doxorubicin Hydrochloride|Adriamycin
75554246|NCT06188676|Drug|Etoposide Phosphate|Etopophos
75872351|NCT05080114|Procedure|Modified Bakay technique (MT)|The conventional standard technique for laparoscopic hysterectomy was followed until the colpotomy. The remaining steps were as follows: A 0-Monocryl™ violet (poliglecaprone-25) or a 0-PDS-II (polydioxanone) suture with a 36-mm needle (Ethicon Inc., NJ, USA) was placed first on the right USL, proximal to the ischial spine and 1-3 cm away from its uterine insertion, then helically proceeded by 1 to 3 bite(s) (depending on the length of the ligament) for suspension/plication. The suture continued circumferentially in counter clockwise direction on the line between the cervicovaginal junction and the bladder in a full-thickness purse string fashion, at least 1 cm away to the bladder. This suture symmetrically ended in the left USL, with forming nearly an Ohm sign (Ω). Colpotomy was performed circumferentially using laparoscopic cold scissors and/or knife, maintaining a safe distance from the suture line. Following removal of the uterus, both ends of the prior suture line were knotted.
76040519|NCT03048721|Procedure|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
76040520|NCT04879771|Procedure|Receive gastrointestinal endoscopy|patients receive gastrointestinal endoscopy in the morning or afternoon
76040521|NCT03048565|Behavioral|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
76040522|NCT04879693|Device|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
76040523|NCT04885075|Drug|IV diazepam|inj.diazepam 0.2mg/kg/dose stat
76040524|NCT04885075|Drug|I/N Midazolam|intranasal midazolam 0.2mg/kg/dose stat
76040525|NCT01610687|Drug|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
76040526|NCT04884919|Device|Regular Gauze|Regular gauze
76040527|NCT04884919|Device|Chitosan Dressing|Dressing made of chitosan material
76040528|NCT04879303|Behavioral|Robot-assisted social skill intervention|Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
76040529|NCT04879303|Behavioral|Human-only instruction programme on social skill training|The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
75409421|NCT03630198|Drug|Corticosteroid with normal saline|Intralesional corticosteroid injection
75409422|NCT03633084|Drug|RBM-007 Injectable Solution|(No additional description)
76040530|NCT05533931|Other|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
76040531|NCT05533931|Other|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
76040532|NCT04879381|Other|Sputum samples|During consultation, one expectoration will be performed.
76040533|NCT05528237|Device|Flocked swab paired with Roche Cobas 4800|Consenting individuals will insert the sterile flocked swab into the vagina, rotate at least once, and store in the provided dry tube. The sample will be stored at ambient temperature and routed to the lab for HPV testing with Roche Cobas 4800.
75409423|NCT03637296|Other|Critical time intervention|Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
75409424|NCT03637842|Drug|Lorcaserin|Lorcaserin XR 20mg per day
75409425|NCT03637842|Drug|Placebo oral capsule|Placebo
75409426|NCT03638622|Combination Product|Photodynamic Therapy|Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
75554247|NCT06188676|Drug|Prednisolone|Prednisolonum
75554248|NCT06188676|Drug|Rituximab|Chimeric Anti-CD20 Antibody
75554249|NCT06188676|Drug|Vincristine Sulfate|Oncovin
75554250|NCT06188676|Drug|Filgrastim|G-CSF
75554251|NCT06188676|Drug|Pegfilgrastim|PEG-filgrastim
75554252|NCT06188676|Drug|Nivolumab 40 mg in 4 ml Injection|Opdivo
75713372|NCT00681564|Procedure|One-Stage Full-Mouth Disinfection|"Scaling and root planing, four quadrants in one session~Tongue brushing with a 1% chlorhexidine gel (1 minute)~Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~Subgingival chlorhexidine (1%) irrigation in all pockets~Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~Basic oral hygiene instructions~Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
76040534|NCT05533853|Other|Posture corrective exercises|The exercises are of two types strengthening exercises and starching exercise ,). The strengthening exercises are to be done for 15 repetitions in 2 sets, Progression will be by increasing to 3 sets and adding 1 Kilogram of resistance in dumbbells exercises, the targeted muscles are teres minor, infraspinatus, medial and lower trapezius, rhomboids, and cervical flexor muscles. On the other hand, stretching exercises are to be hold for 30 seconds for 2 sets then progressed to 3 sets, the targeted muscles are pectoralis minor, sternocleidomastoid and levator scapulae.
76040535|NCT05533853|Other|Denneroll extension traction|The participants will be instructed to lie supine and keep their legs extended. Based on the apex of each participant's cervical curvature on the initial radiograph, the therapist will position the apex of the denneroll in one of two regions (mid cervical placement or lower cervical placement). The duration of the traction session will start at 2-3 min and increased 1 min per session until reaching the goal of 20 min, the traction will repeated three times per week for 6 weeks
76040536|NCT03048409|Other|Enteral Formula|Enteral feeding with a peptide-based formula.
76040537|NCT05528081|Other|Phone interview|Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
76040538|NCT04879147|Diagnostic Test|Evalution of thyroid function|Determination of TSH, free T4, free T3, SPINA-GT, SPINA-GD and Jostel's TSH index
76040539|NCT04878835|Biological|intralesional ranibizumab|Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL
75872352|NCT05080114|Procedure|Standard technique (ST)|"The conventional standard total laparoscopic hysterectomy technique was used in this control group.~All operations were performed under general anaesthesia with nasogastric intubation and a bladder catheter in place. Cefazolin 2 g was administered to all patients for prophylaxis 30 min prior to surgery. Operations were performed with a 10-mm laparoscope (Karl Storz, Germany) through the trocar placed usually in the umbilicus. Two lateral 5-mm trocars and one midline 10-mm trocar were used. The placement of trocars varied according to the uterine size. Haemostasis was usually performed using bipolar forceps (Karl Storz Robi, Germany), whereas dissection was performed using the LigaSure™ (Covidien, Medtronic, USA). Maryland jaw laparoscopic sealer/divider, bipolar forceps and scissors. Colpotomy was performed with electrocautery devices and sutured intracorporeally."
75872353|NCT05079958|Behavioral|cognitive-behavioral education|four-week cognitive-behavioral education course
76040540|NCT05528003|Procedure|Commercialized single-access port devices|Two kinds of commercialized single-access port devices were used.
76040541|NCT03049423|Device|MRI scans|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
75713373|NCT00681564|Procedure|Periodontal care|"Basic oral hygiene instructions~Supragingival plaque removal"
75713374|NCT05350852|Biological|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
75713375|NCT00955786|Drug|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
75713376|NCT04237012|Drug|Dextenza 0.4Mg Intracanalicular Insert|all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
75554253|NCT06188650|Drug|Anlotinib|After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
75554254|NCT06188637|Drug|Ozanimod Oral Capsule|open label ozanimod
75554255|NCT06188624|Drug|TQB2922 for injection|TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
75554256|NCT06188611|Drug|Huazhi Rougan Granule Placebo granule|Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
76040542|NCT03049423|Diagnostic Test|MRI scans and general physical examination|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
76040543|NCT04878523|Dietary Supplement|multi berries juice|Testing product
76040544|NCT04878523|Dietary Supplement|Placebo drink|Blank
75554257|NCT06188559|Drug|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
75554258|NCT06188546|Drug|Propofol|trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
76040545|NCT05527925|Device|MRI|Brain testing of patients using MRI
76040546|NCT04872283|Procedure|great toe (1st metatarsophalangeal joint) fusion|Great Toe joint fusion surgery
76040547|NCT04872283|Drug|IV Ketorolac|Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
76040548|NCT04872283|Drug|Ketorolac Pill|Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
75554259|NCT06188533|Other|Urinary activin A in AKI|Urinary activin A in AKI patient
75554260|NCT06188507|Drug|GSK4347859|GSK4347859 will be administered
76040549|NCT04872283|Drug|5/325mg Oxycodone-Acetaminophen|Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
75554261|NCT06188507|Drug|Placebo|Placebo will be administered
75554262|NCT06188468|Diagnostic Test|18F-FDG PET/CT, 68Ga-THP-Trop2 VHH PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-THP-Trop2 VHH, and undergoes PET/CT imaging within the specified time.
75713377|NCT04237012|Other|Over the counter Artificial tears|over the counter artificial tears PRN at patient discretion
76040550|NCT04872283|Drug|Aspirin 81Mg Ec Tab|Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
76040551|NCT05182385|Drug|Blinatumomab|"All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type."
76040552|NCT05182385|Drug|Venetoclax|"In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type."
76040553|NCT04871581|Device|NTI-tss|FDA cleared device for prophylactic treatment of medically diagnosed migraine pain
76040554|NCT04871581|Device|Placebo|Similar to Device, but having no influence on clenching intensity
76040555|NCT04871347|Drug|TWP-101|IV infusion
76040556|NCT04589533|Other|educational program|The educational program will be based on: a outreach visit (a 3-h face-to-face meeting between a trained diabetes specialist from outside the Center and the staff of the Center itself) and a distance learning (FAD).The educational programme will be focused on current Diabetes Guidelines recommendations and based on possible deviations from the best clinical practice observed during phase1
75554263|NCT06188455|Drug|Fluzoparib Capsules|Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily
75554264|NCT06188455|Drug|Apatinib Mesylate Tablets|Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)
75554265|NCT06188442|Drug|DoxyODPrEP|Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex
75554266|NCT06188442|Drug|DoxyPEP|Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
75554267|NCT06188429|Diagnostic Test|DSM-5|Using DSM-5 for diagnostic testing of the children in the study group.
75554268|NCT06188403|Procedure|Orthognathic surgery (lefort1)|Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
75554269|NCT06188390|Procedure|Ultrasound guided median nerve hydrodissection injection with Hyaluronic acid|Hyaluronic acid was injected under ultrasound guidance around median nerve at the wrist
75554270|NCT06188390|Procedure|Ultrasound guided median nerve hydrodissection injection with Dextrose water|Dextrose water was injected under ultrasound guidance around median nerve at the wrist
75713378|NCT00863889|Drug|Depomedrol injection|1 cc of Depomedrol 80
76040557|NCT05524805|Device|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
76040558|NCT04466761|Dietary Supplement|Monosaccharide Powder|Monosaccharide powder dissolved in water.
76040559|NCT04466761|Other|Placebo Comparator|Placebo (cellulose powder).
76040560|NCT04425083|Other|no intervention|no intervention
76040561|NCT05527613|Other|whatsapp application with oral hygiene reminder for orthodontic patients|Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
76040562|NCT04878133|Diagnostic Test|OCT - optical coherence tomography|"The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds.~In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console."
76040563|NCT05527535|Diagnostic Test|Diabetic retinopathy screening by artificial intelligence|Screening diabetic patients' eyes with AI through digital health platform
76040564|NCT05527535|Diagnostic Test|Diabetic retinopathy screening by healthcare personnel|Screening diabetic patients' eyes by conventional method (healthcare personnel)
75713379|NCT00863889|Drug|Lidocaine, Marcaine|4 cc of each local anesthetic
76040565|NCT04877899|Device|EchoGo|"EchoGo Core is a stand-alone software application. Echocardiograms should be acquired under the supervision of a physician and standard clinical protocols which includes focused apical 2, 3 and 4 chamber views. The results contain calculated measurements that will be returned to the interpreting physician. These results are intended as an additional input to standard diagnostic pathways and should only be used by a board-certified cardiologist/physician.~EchoGo Core is intended to be used for the quantification and reporting of results of cardiovascular function to support physician diagnosis. EchoGo Core is indicated for use in adult populations."
75409427|NCT03643692|Device|ARISES|The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
75713380|NCT05299450|Dietary Supplement|Beet It shots|In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
76040566|NCT05533385|Other|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
75872354|NCT05079958|Behavioral|12-week brisk walking|12-week brisk walking
75409428|NCT03645954|Procedure|Femoral Nerve Block|"Procedure: Femoral Nerve Block~The femoral nerve block will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 50 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral nerve block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral nerve block."
75554271|NCT06188364|Other|Standard of Care|The usual Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge, so the the delivery of traditional CHW outreach services such as finding health, community and social determinants referrals, problem-solving, and connecting care partners to long-term supports/services
75872355|NCT02328352|Procedure|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
75872356|NCT02328352|Procedure|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
76040567|NCT04389073|Drug|Vinorelbine 40mg|Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
76040568|NCT04389073|Biological|Toripalimab 240mg|Toripalimab 240 MG IV infusion every 3 weeks. Toripalimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
76040569|NCT04389073|Biological|Bevacizumab 5 mg/kg|Bevacizumab 5 mg/kg IV infusion every 3 weeks. Bevacizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
75713381|NCT05299450|Behavioral|Exercise|In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
75554272|NCT06188364|Other|Experimental|"Novel aspects of the CHW experimental intervention for TBI care partners include:~CHW services begin prior to inpatient rehabilitation discharge;~care partners get timely, useful health management materials;~encounters focus on unlimited, brief, situation-focused calls to help care partners assess and resolve pressing concerns; and~long-term support capacity for care partners is built by establishing a reliable referral network of medical, community, and social services that become foundational resources beyond study completion."
75554273|NCT06188351|Device|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
75554274|NCT06188351|Device|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using traditioanl two-dimensional atrial septal puncture kit using traditional method.
76040570|NCT04389073|Drug|Cyclophosphamide 50 mg|50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
75554275|NCT06188338|Combination Product|Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.
75713382|NCT05299450|Other|Control group|Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
75713383|NCT00861003|Device|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
75872357|NCT02328352|Procedure|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
76040571|NCT04389073|Drug|Capecitabine 500Mg Oral Tablet|500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
75554276|NCT06188338|Combination Product|Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.
75872358|NCT02328352|Procedure|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
75872359|NCT02030860|Drug|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
76040572|NCT04389073|Drug|Cisplatin|Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
76040573|NCT05175443|Other|Exercise|Participants will be trained, by a physical therapist, to perform a set of four daily exercises requiring 1 sets of 2 minutes for each exercise totaling 8 minutes of targeted exercise per day for 8 weeks of the intervention. These exercises will be progressed or modified every 2-4 weeks to assure the participant is receiving maximal benefit for their exercise intervention.
76040574|NCT04371445|Drug|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
75554277|NCT06188325|Drug|Eliglustat|Pharmaceutical form:Capsule-Route of administration:Oral
75554278|NCT06188299|Other|Restricted Fluid Administration|Restrictive fluid administration generally consists of partial or no replacement for the intravascular expansion from anesthesia, in which case vasopressors are usually administered, no replacement for the third space loss, and only partial replacement for deficits from preoperative fasting.
75554279|NCT06188221|Drug|Lidocaine|The group with the lidocaine will get a combined injection with a corticosteroid and lidocaine. The dosages depend on the disease.
75872360|NCT02030860|Drug|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
75872361|NCT02030860|Drug|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
75872362|NCT03290781|Drug|Ontamalimab|Participants will receive 1 milliliter (mL) of ontamalimab sterile aqueous buffered solution at an appropriate oncentration to provide an intended dose of drug (25 or 75 mg).
75872363|NCT03290781|Other|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
75554280|NCT06188221|Drug|Corticoids|The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
75713384|NCT01563250|Device|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
75713385|NCT00677352|Drug|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
75713386|NCT00677352|Drug|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
75409429|NCT03645954|Procedure|Femoral Triangle & Adductor Canal Blocks|"Procedure: Femoral Triangle & Adductor Canal Blocks~These two blocks will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 100 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral triangle block and adductor canal block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral triangle block and adductor canal block (10 mL for each block)."
75554281|NCT06188208|Drug|VVD-130850|Oral tablets
75554282|NCT06188208|Drug|Pembrolizumab|IV infusion
75554283|NCT06188195|Drug|Dexamethasone|ACS intervention were used in the experimental group
75554284|NCT06188169|Procedure|Increasing the inspiratory pressure if atelectasis detected by US|The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.
76040575|NCT04371445|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
75554285|NCT06188156|Procedure|Anethesia|To assess the effectiveness of thoracic epidural blockage versus ultrasonic guided PECS II block versus ultrasound guided serratus anterior plane block for postoperative pain management in modified radical mastectomy.
75554286|NCT06188143|Combination Product|Ibuprofen-Paracetamol|Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, in study group 30minutes before hysteroscopic procedure
75713387|NCT00861081|Behavioral|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
76040576|NCT05524337|Behavioral|white noise|"Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db."
76040577|NCT05524337|Behavioral|therapeutic touch|In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.
76040578|NCT05524337|Behavioral|white noise and therapeutic touch|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
76040579|NCT04230577|Device|Real LED Intervention|A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
76040580|NCT04230577|Device|Sham LED Intervention|A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
76040581|NCT05533307|Diagnostic Test|observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth|ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
75409430|NCT03647046|Device|Customized Scleral Lens|A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
75554287|NCT06188130|Other|active rTMS|Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed dominant side abductor pollicis brevis (APB).The patient received robotic therapy for lower extremity just after each active TMS sessions.
75554288|NCT06188130|Other|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for lower extremity just after each sham TMS sessions.
75554289|NCT06188130|Other|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the Cz central (International 10/20 Electroencephalogram System) area, corresponding to the location of the dominant hemisphere lower extremity motor cortex and cathodal to the contralateral supraorbital region. The patient received robotic therapy for lower extremity just after each active tDCS sessions.
76040582|NCT03049267|Drug|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
76040583|NCT03049267|Drug|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
76040584|NCT02615509|Radiation|Imaging on experimental tomo device|The system used for imaging in the experimental arm is the Philips MicroDose tomography system. The system used for imaging in the active comparator is a standard FFDM system
76040585|NCT05524259|Dietary Supplement|Myo-inositol and routinely recommended folic acid|Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
76040586|NCT05524259|Dietary Supplement|Routinely recommended folic acid|The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
76040587|NCT03047317|Biological|MABp1|Single dose of intravenous MABp1
75409431|NCT03649932|Dietary Supplement|Enteral L-citrulline|"L-Citrulline as 10 % solution (100 mg/ml) will be provided to the bedside nurse by the Investigational Pediatric Pharmacy. The drug will be given via gavage feeding by bolus infusions followed by a 0.5 ml water flush twice daily (0900 and 2100). Bolus dosing will be needed due to the small volumes (0.5-1.5 ml per dose in most infants). The volume of nasogastric tubing used in preterm infants (Ameritus 4.0 Fr 50 cm) is 0.48 ml, therefore we will follow the administration with 0.5 ml of saline/water flush to ensure all the study drug is delivered to the patient.~Administration of study drug - Will be given via gavage feeding tube twice daily (0900 +/- 30 mins, 2100 +/- 30 mins). L-citrulline will be given by the bedside nurse as a bolus followed by 0.5 ml water flush. L-citrulline will be given separate from feeds to avoid any confusion.~Study drug will be started when infant has been off of TPN for at least 3 days so that IV arginine in TPN does not interfere."
75713388|NCT00861081|Behavioral|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
76040588|NCT05533151|Device|Respiratory muscle training|All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
76040589|NCT04112095|Drug|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
76040590|NCT05257993|Drug|JPI-547|"Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~Capsules should be swallowed whole and should not be chewed, crushed or split."
76040591|NCT05257993|Drug|modified FOLFIRINOX|"After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~Repeated administration every 2 weeks on a 14-day cycle"
75554290|NCT06188130|Other|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for lower extremity just after each sham tDCS sessions
75409432|NCT03655080|Radiation|Radiation therapy|Using the View Ray System
75409433|NCT03655080|Drug|nab-Paclitaxel|"Dose 15 mg/m^2~Should be administered by IV over 30 minutes"
75409434|NCT03663816|Device|experimental foot device|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
75554291|NCT06188104|Drug|Trichloroacetic acid|Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
75713389|NCT04010110|Diagnostic Test|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
76040592|NCT05257993|Drug|Gemcitabine-nab-paclitaxel|"After IV administration of nab-paclitaxel 100 mg/m2 for 30 minutes~IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~Administration on Days 1, 8, and 15 on a 28-day cycle"
76040593|NCT05533073|Drug|A1: Etoricoxib / Tramadol Fixed dose combination|Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral
76040594|NCT05533073|Drug|A2: Etoricoxib|Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
75554292|NCT06188091|Behavioral|Exercise|Physiotherapeutic instructions to patients to do active exercise to improve the mobility of knee joint post-surgical
75554293|NCT06188078|Other|Control|Babies in the control group will be fed only breast milk or formula, and a urine bag will be inserted after 10 minutes and they will be expected to urinate. The success of the transaction and the processing time will be recorded.
75713390|NCT00864045|Drug|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
76040595|NCT05533073|Drug|A3: Tramadol|Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
75713391|NCT00864045|Drug|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
76040596|NCT04050553|Drug|Tirzepatide|Administered SC
76040597|NCT04050553|Drug|Placebo|Administered SC
76040598|NCT03946891|Drug|Inhaled Furosemide|Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.
75713392|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
76040599|NCT03946891|Drug|Intravenous Furosemide|Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
76040600|NCT05524103|Drug|ALMB-0166|A single dose of ALMB-0166 injection.
76040601|NCT05257915|Drug|Perampanel|"For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients <12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
76040602|NCT05257837|Behavioral|Gun handling behavior|Children will play in an observed room for 20 minutes. Aside from a selection of toys, two real handguns will be placed in a drawer. The handguns have been modified so they cannot fire. Inside the magazine, the handgun contains no bullets. Instead, it contains a sensor that counts the number of times the trigger is pulled with sufficient force to discharge the gun. This allows us to distinguish reliably the children who pull the trigger from those who handle the gun but do not pull the trigger
76040603|NCT05257837|Other|Debriefing|Children and their parents will be debriefed on the actual purpose of the study, including the role of the safety video and how the movie clips were edited.
76040604|NCT04870723|Behavioral|eHealth for Covid-19 prevention and support|3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
76040605|NCT05527145|Procedure|Minimally invasive surgery|Surgery with decompression. Central decompression of the stenotic segment with undercutting of the lateral recesses.
75409435|NCT03674970|Drug|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
75409436|NCT03679494|Other|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
75409437|NCT03685968|Device|Video laryngoscopes|Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
75409438|NCT03687450|Behavioral|RISE yoga-based program|The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga & Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
75409439|NCT03687684|Drug|TAK-831|TAK-831 Tablets.
75409440|NCT03687684|Drug|Placebo|TAK-831 Matching Placebo Tablets.
75872364|NCT01569984|Radiation|Stereotactic body radiotherapy|Avastin 7.5 mg/kg IV x 2 doses 14 days apart
75713393|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
75713394|NCT00755508|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
76040606|NCT05527145|Procedure|Percutaneous Spacer|percutaneous image guided outpatient procedure that enables interspinous spacer insertion and fusion
76040607|NCT04870879|Procedure|Liver Transplant|Liver Transplant from cadaveric donors
76040608|NCT04870879|Drug|Chemotherapy|Chemotherapy
76040609|NCT03849625|Drug|aspirin, NSAIDs, paracetamol|Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
75409441|NCT03688542|Other|Quality Circle Deprescribing Module|The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..
76040610|NCT03046849|Other|next-generation sequencing|Use next-generation sequencing to test germline mutation.
75409442|NCT03697122|Device|Heated Humidified Breathing Circuit and Forced Air Blanket|"Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.~Forced air warming blankets will be set at 42C for duration of rewarming."
75409443|NCT03704376|Drug|30 ml of 0.2% ropivacaine|
75409444|NCT03704376|Drug|15 ml of 0.2% ropivacaine|
76040611|NCT03046693|Drug|Group A Citicoline 1000 mg oral tablet|Citicoline 1000 mg will be repackaged and given to Group A for 60 days
75409445|NCT03704376|Drug|100 mcg clonidine|
75409446|NCT03704376|Device|High-frequency linear ultrasound transducer|
75409447|NCT03711396|Behavioral|Advance Care Planning Group Visits|Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
75554294|NCT06188078|Other|The bladder stimulation technique|"Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. A urine bag will be inserted 10 minutes after the feeding.~The newborn will be held under the armpit by the nurse, male infants will be held with their legs hanging down, and female infants will be held in the hip flexion position.~Newborns with spontaneous voiding during the period from the beginning of the investigation procedure to positioning the newborn will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until voiding begins.The success of the transaction and the processing time will be recorded."
76040612|NCT03046693|Drug|Group B placebo oral tablet|Placebo will be repackaged and given to Group B for 60 days
76040613|NCT05257369|Device|Blue-Green LED photoherapy|Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
75409448|NCT03715452|Device|DyeVert Plus Contrast Reduction System|The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.
75409449|NCT03716076|Drug|Carbetocin|50 mcg or 100 mcg bolus of carbetocin
75409450|NCT03835728|Drug|Ocrelizumab|Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
75409451|NCT03835728|Drug|Saline|This will be the matching placebo used in the study.
76040614|NCT04632329|Device|Negative Pressure Treatment via the Mercury Multi-Pressure Dial|Negative Pressure Treatment via the Mercury Multi-Pressure Dial
75713395|NCT00755508|Drug|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
76040615|NCT03327493|Diagnostic Test|Biological|"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~Lymphocytes Th1/Th2 pattern by flow cytometry~Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~Hemodynamic parameters~Cumulated doses of catecholamines~Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)"
76040616|NCT05523791|Dietary Supplement|Fortiral|Twice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
76040617|NCT05523791|Dietary Supplement|Mg++|Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water
75713396|NCT00755508|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
75713397|NCT02544087|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
76040618|NCT03049345|Procedure|Sentinel Lymph Node Sampling|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.
76040619|NCT03049345|Drug|Radioactive Tracers|see above
75713398|NCT02544087|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
75713399|NCT02544087|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
75713400|NCT03680352|Drug|cefepime/AAI101|Fixed dose combination of cefepime and AAI101
76040620|NCT03049345|Drug|Methylene Blue 20 MG/ML|see above
76040621|NCT02575079|Device|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
76040622|NCT05526911|Drug|TBAJ-876|"Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
76040623|NCT05526911|Drug|TBAJ-876|"Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~Day 20: 200 mg TBAJ-876 oral suspension, fasting~Day 21 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
76040624|NCT05526911|Drug|Midazolam|Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
75409452|NCT03848910|Device|Investigational device - Sound Processor|"At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator."
75409453|NCT03861780|Drug|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
75409454|NCT03861780|Drug|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
75409455|NCT03861780|Drug|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
75409456|NCT03889158|Biological|Typhoid Vaccine|All participants will receive the typhoid vaccine.
75409457|NCT03889158|Dietary Supplement|Ascorbic Acid|All participants will receive ascorbic acid.
75409458|NCT04018794|Device|Behavioral/organizational skills intervention augmented with digital health application|Behavioral/organizational skills intervention with digital health application augmentation
75409459|NCT04096482|Device|Peregrine Drivable ENT Scope|Peregrine, developed by 3NT Medical, is a single-use disposable handheld endoscope, which is thinner and more flexible than other endoscopes. The endoscope includes a camera at its end and a working channel. The thin endoscope provides a means to visualize the nasal cavity and paranasal sinus space and to deliver irrigation to treat the sinus ostia (drainage openings) and spaces within the paranasal sinus cavities
75409460|NCT04096482|Device|Standard 30° 4mm Endoscope|The Standard 30° 4mm endoscopic sinus evaluation is the standard procedure that would normally be used to evaluate the condition of each participant.
75409461|NCT04138758|Drug|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
75409462|NCT04138758|Drug|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
75409463|NCT04323852|Drug|Vitamin D|Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
75409464|NCT04323852|Drug|Placebo|Placebo
75409465|NCT04381728|Device|Womed Leaf|Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.
75409466|NCT04420572|Drug|ozone injection|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
76040625|NCT05526911|Drug|Digoxin|Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
76040626|NCT05526911|Drug|TLD|Day 1 and Day 20: fixed dose combination of dolutegravir 50 mg + tenofovir disoproxil fumarate 300 mg + lamivudine 300 mg, fasted
76040627|NCT03046771|Behavioral|Transport PLUS group|The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
76040628|NCT03048175|Procedure|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
76040629|NCT04870489|Combination Product|Isotretinoin and CO2 laser|Patients must complete at least 2 months of Isotretinoin prior to starting the study and then continue it for the duration of the 3 months of treatment with the CO2 laser.
75713401|NCT00955942|Dietary Supplement|flaxseed|Given orally
75713402|NCT00955942|Other|placebo|Given orally
75713403|NCT00864201|Drug|bosentan|bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
75713404|NCT00864279|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
75409467|NCT04420572|Drug|betamethasone|1ml betamethasone will be used for steroid injection.
75409468|NCT04709484|Drug|USG-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
76040630|NCT04870489|Device|Co2 laser|After 6-12 months of no treatment for acne the patient comes to do second side of face only laser treatment
76040631|NCT05526677|Device|x-guide dynamic navigation system|One implant placement is assisted with x-guide dynamic navigation system. The other implant placement is assisted with static surgical guide
75554295|NCT06188078|Other|Bath|Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. Babies in the bath group will be given a bath under running water for no longer than 5 minutes before feeding. After the bath, the baby will be fed, and a urine bag will be inserted 10 minutes after the feeding. The success of the transaction and the processing time will be recorded.
76040632|NCT05532761|Other|self-administered questionnaires|"In order to describe the experience of CAR-T cell therapy of DLBCL patients, a pharmaceutical follow-up is carried out the day before the injection (baseline) and at 1, 3, 6, 9, 12 and 18 months. These follow-ups consist of interviews with the patient and the delivery of self-administered questionnaires. The interviews will investigate drug consumption, the use of self-medication and complementary alternative therapies and the adverse effects of interest. The self-questionnaires will focus on exploring multidimensional quality of life, social and professional life, anxiety-depression or uncertainty tolerance through internationally validated questionnaires.~No supplementary visits will be needed : interviews with the research team will occur at the end of hematologic consultations."
75554297|NCT06188052|Drug|Tranexamic acid|Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
75409469|NCT04709484|Drug|Palpation-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
75554298|NCT06188000|Dietary Supplement|Extra Virgin Olive Oil|The patients was given extra virgin olive oil, an unrefined (not processed with chemicals or heat) for of olive oil
75554299|NCT06188000|Dietary Supplement|Olive Oil|The patients was given olive oil.
75554300|NCT06188000|Dietary Supplement|Placebo|The patients was given empty capsule
75554301|NCT06187987|Device|Mechanical thrombectomy|Aspirational mechanical thrombectomy
76040633|NCT04301453|Other|Maternal Scent|Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
76040634|NCT02614183|Drug|Galcanezumab|Administered SC
76040635|NCT02614183|Drug|Placebo|Administered SC
75409470|NCT03541980|Drug|Acetaminophen|Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
75409471|NCT03541980|Drug|Normal saline|Normal saline volume equivalent
75409472|NCT04511520|Other|Physical training program|
75409473|NCT04511520|Drug|Trimetazidine|
75409474|NCT04491240|Drug|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.
75409475|NCT04491240|Drug|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.
75409476|NCT04491240|Drug|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
75554302|NCT06187987|Drug|Intravenous thrombolysis|Intravenous thrombolysis with tissue-type plasminogen activator (tPA)
75554303|NCT06187974|Other|observation|observation
75554304|NCT06187961|Procedure|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
75554305|NCT06187961|Drug|Lenvatinib plus cadonilimab|lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
76040636|NCT05523011|Drug|Exosome ointment|100 µg MSC exosomes/g ointment
76040637|NCT05522933|Other|4 weekly musculoskeletal health promotion workshops with stretching and muscle-strengthening exercise|The modified online multidimensional musculoskeletal health promotion program will consist of 4 weekly workshops for 90-minute each for a group size of 8-12 participants. The topics of the workshop are: (1) exercise and health & work; (2) prevention of musculoskeletal problems; (3) musculoskeletal health and traditional Chinese medicine; and (4) mental health and community resources. Each workshop will consist of stretching and muscle strengthening exercises (30 minutes), a health education topic (about 45 minutes), and a question-and-answer period (about 15 minutes).
75554306|NCT06187948|Other|Video|All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
75554307|NCT06187922|Drug|Pregabalin 75mg|Group pregabalin will receive cap pregabalin 75mg as premedication and will continue as B.D dose for 72 Hrs.
75554308|NCT06187922|Procedure|adductor canal block|Both group will receive ultrasound guided Adductor canal block with bupivacaine 0.2% 20-30ml and dexmedetomidine 1mcg/Kg
76040638|NCT05526209|Procedure|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
75554309|NCT06187909|Procedure|PECS II BLOCK|The linear probe will be placed transversely between the clavicle medially and above . After identifying the pectoralis major and minor muscles , the probe will be angled caudally to look for the pulsating pectoral branch of the thoraco-acromial artery. The block needle will be inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine will be administered. Then probe will be moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The third and fourth ribs will be detected. The needle will target the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 20 ml bupivacaine.
75713405|NCT00864279|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
76040639|NCT04870567|Radiation|Stereotactic ablative radiotherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
75409477|NCT04463004|Drug|Mavrilimumab|Treatment infusion
75409478|NCT04463004|Drug|Placebos|Placebo infusion
75713406|NCT02559648|Drug|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
75872365|NCT02328118|Drug|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
76040640|NCT04870567|Radiation|High dose rate brachytherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
75409479|NCT04430634|Other|Myblu variant A|Use of Myblu e-cigarette with flavor A 2.4% nicotine
75409480|NCT04430634|Other|Myblu variant B|Use of Myblu e-cigarette with flavor B 3.6% nicotine
76040641|NCT05526131|Other|Questionare|"Assessing the presence or the absence of depression:~By structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders."
75409481|NCT04430634|Other|Myblu variant C|Use of Myblu e-cigarette with flavor C 2.5% nicotine
75409482|NCT04430634|Other|Myblu variant D|Use of Myblu e-cigarette with flavor D 4.0% nicotine
75409483|NCT04430634|Other|Myblu variant E|Use of Myblu e-cigarette with flavor E 3.6% nicotine
75409484|NCT04430634|Other|Myblu variant F|Use of Myblu e-cigarette with flavor F 2.4% nicotine
75409485|NCT04430634|Other|Myblu variant G|Use of Myblu e-cigarette with flavor G 4.0% nicotine
75409486|NCT04430634|Other|Myblu variant H|Use of Myblu e-cigarette with flavor H 3.6% nicotine
75409487|NCT04429932|Other|Myblu flavor A_2.4|Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
75409488|NCT04429932|Other|Myblu flavor B_2.4|Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
75872366|NCT02328118|Drug|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
75713407|NCT02559648|Drug|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
76040642|NCT05256433|Other|Group-A|IASTM Certified IASTM practitioner will be performing the technique with emollient lubricant in which brushing and sweeping stroke will be applied for plantar fascia and fanning and sweeping stroke technique for calf muscles for the duration of 10 minutes to eliminate the inflammation. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury. The frequency stretching will be 5 repetitions for each with 10 seconds hold.
76040643|NCT05256433|Other|Group-B|Manual massage includes transverse friction massage for plantar fascia, flexor digitorum brevis, and deep massage for calf muscle for the duration of 10 minutes to eliminate the tightness and increase the blood flow. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury.
75713408|NCT05299372|Other|Telemonitoring via Careportal®|The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
76040644|NCT05522621|Drug|TJAOA102|Once enrolled, participants will be administrated TJAOA102
75713409|NCT00870285|Radiation|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
76040645|NCT05256043|Diagnostic Test|Diabetes Diagnosis|HbA1c > 6.5%
75872367|NCT03466073|Drug|Recombinant Human Plasma Gelsolin|Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water
75409489|NCT04429932|Other|Myblu flavor C_2.4|Use of Myblu e-cigarette with flavor C at 2.4% nicotine
76040646|NCT05532527|Drug|Microwave ablation combined with Camrelizumab and chemotherapy|Microwave ablation combined with Camrelizumab and chemotherapy
75409490|NCT04429932|Other|Myblu flavor D_2.4|Use of Myblu e-cigarette with flavor D at 2.4% nicotine
76040647|NCT05231941|Drug|Lidocaine IV|Bolus and infusion of lidocaine will be administered
75713410|NCT00755586|Procedure|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 * 10e8 cells in the m. biceps brachii.
75409491|NCT04429932|Other|Myblu flavor E_1.2|Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine
75409492|NCT04429932|Other|Myblu flavor F_1.2|Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
75713411|NCT00755586|Procedure|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 * 10e8 cells in the m. biceps brachii.
76040648|NCT05231941|Drug|Ropivacaine|Bilateral TAP block will be given to these patients
76040649|NCT05217745|Dietary Supplement|MLCT Oil|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
76040650|NCT05217745|Dietary Supplement|LCT Oil (Corn Oil)|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
76040651|NCT05216575|Drug|Administration of Almitrine|Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
75872368|NCT03466073|Other|Normal Saline Placebo|Normal saline in volume equivalent to drug
75872369|NCT02602314|Drug|Imatinib|
75872370|NCT02602314|Drug|Nilotinib|
75872371|NCT03412019|Other|Music|Selections of Mozart piano sonatas
76040652|NCT05522543|Other|Conventional treatment with Passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
75409493|NCT04429932|Other|Myblu flavor G_2.4|Use of Myblu e-cigarette with flavor G at 2.4% nicotine
75409494|NCT04429932|Other|Myblu flavor H_2.4|Use of Myblu e-cigarette with flavor H at 2.4% nicotine
75409495|NCT04409886|Biological|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
75409496|NCT04399980|Drug|Mavrilimumab|Treatment infusion
75409497|NCT04399980|Drug|Placebos|Placebo infusion
75409498|NCT04397094|Drug|Theracal LC|pulpotomy
75409499|NCT04397094|Drug|Formocresol|Pulpotomy
75409500|NCT04385238|Other|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
75409501|NCT04383132|Device|Abdominal Binder|abdominal binder is a kind of elastic abdominal compression device
75713412|NCT00755586|Procedure|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
75713413|NCT00864357|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
75713414|NCT00864357|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
76040653|NCT05522543|Other|Conventional treatment with manual segmental lumbar traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
75713415|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
75409502|NCT04335552|Other|Standard of care|Standard of care
75409503|NCT04335552|Drug|Hydroxychloroquine|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
75409504|NCT04335552|Drug|Azithromycin|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
75713416|NCT02559492|Drug|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
75713417|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
75713418|NCT02559492|Drug|INCB050465|INCB050465 tablets will be administered orally once daily.
75713419|NCT00864435|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
75409505|NCT04321980|Drug|OP-101|Subcutaneous injection of OP-101 in healthy volunteers
75713420|NCT00864435|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
75713421|NCT00755664|Dietary Supplement|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
75713422|NCT00956098|Drug|oltipraz|60mg bid 90mg qd
75713423|NCT00956098|Drug|placebo|
75713424|NCT00864591|Procedure|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
75872372|NCT05079880|Drug|300 mg of caffeine citrate infusion|At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
75409506|NCT04288752|Device|VR101 Lubricating Intravaginal Ring|VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.
75409507|NCT04288752|Device|Sham Ring|Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
75409508|NCT04287036|Device|JJVC Investigational Contact Lens|TEST
75409509|NCT04287036|Device|1-DAY ACUVUE® DEFINE® Radiant Sweet™|CONTROL
75409510|NCT04284930|Drug|Depobupivacaine|surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.
75409511|NCT04284930|Drug|OnQ pump|group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.
75409512|NCT04284930|Drug|0.25% Bupivacaine|group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
75409513|NCT04267770|Drug|Insulin (circadian)|Participant's own insulin adjusted to circadian infusion rates
75409514|NCT04267770|Drug|Insulin (flat rate)|Participant's own insulin set to flat basal rates
75409515|NCT04252092|Other|Sensory training|15 session,20 minutes sensory training program
75409516|NCT04252092|Other|Electrical stimulation|15 session,20 minutes electrical stimulation program
75409517|NCT04204200|Dietary Supplement|liposomal vitamin C|The intake of liposomal vitamin C at 500 mg, in the morning and evening, one week before surgery, one during the day of surgery and lastly, during the first 21 post operation days.
75554310|NCT06187909|Procedure|MTP BLOCK|The block will be performed with the patient in a sitting position ,High frequency linear probe will be placed in a vertical orientation 3 cm lateral to the midline at T2 level in parasagittal plane. We will identify the midpoint between the transverse process and parietal pleura, and the distance from this point to the skin will be measured which will be the measured depth of insertion and will be marked in the block needle. The block needle will be inserted out of plane to the probe and advanced till the marked depth till the point is confirmed, 10 ml of 0.25% bupivacaine will be injected. Similar two injections will be made at T4, T6 levels sonographic identification and level determination by counting from the second rib.
75554311|NCT06187896|Drug|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
75554312|NCT06187896|Drug|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
75554313|NCT06187870|Other|Collection of biological data|Biological samples will be collected from the patient at the time of their access to the Hospital
75554314|NCT06187857|Behavioral|Ecologically Oriented Neurorehabilitation of Memory (EON-Mem)|Feasibility study of a virtually-delivered adaptation of an ecologically oriented neurorehabilitation of memory (EON-Mem) in improving memory for healthy older adults
75554315|NCT06187844|Procedure|Inguinal exploration|Inguinal exploration will be done for all the included patients.
75713425|NCT00864591|Procedure|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
75713426|NCT05350384|Drug|Methylprednisolone|1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days
75409518|NCT04204200|Dietary Supplement|standard vitamin C|The intake of traditional vitamin C with a daily intake of 500 mg in the morning and evening for 28 days (starting 7 days before the operative procedure, on the day of the surgery and ending twenty-one days after surgery).
75409519|NCT04204200|Dietary Supplement|placebo|The intake placebo was taken daily in the morning and the evening for 28 days (7 days before surgery, on the day of surgery and twenty-one days after the surgical procedure).
75409520|NCT04179474|Drug|Ubrogepant|Oral administration of 100 mg ubrogepant tablet once daily [Intervention A=single dose and Intervention D=repeated daily dose].
75409521|NCT04179474|Drug|Erenumab|Single dose subcutaneous (SC) injection of erenumab 140 mg [Intervention B].
75409522|NCT04179474|Drug|Galcanezumab|2 SC injections of galcanezumab 120 mg [Intervention C].
75409523|NCT04174638|Other|Motivational Interviewing and Education Based on Watson's Theory of Human Caring|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
75409524|NCT04152642|Device|Marketed Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
75409525|NCT04152642|Other|Water control|negative control
75409526|NCT04152642|Device|Experimental Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
75409527|NCT04150224|Drug|PBTZ169 640 mg OD|Two administrations once a day with a wash-out period: food effect
75409528|NCT04150224|Drug|PBTZ169 640 mg BiD|Twice a day fasted; 1 day of administration
75409529|NCT04150224|Drug|PBTZ169 960 mg SD|Once a day fasted
75554316|NCT06187844|Procedure|Laparoscopy|All patients will have abdominal laparoscopy first to assess the location of the impalpable testis, the inguinal canal and the cord structures.
75554317|NCT06187818|Drug|Crocin|According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group [experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period]
75713427|NCT00870441|Drug|ASP2151|Oral
75409530|NCT04150224|Drug|PBTZ169 1280 mg SD|Once a day fasted
75409531|NCT04150224|Drug|PBTZ169 1280 mg MD|Once a day after meal, 14 doses
75409532|NCT04116684|Device|Withings Digital Blood Pressure Monitor|This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
75409533|NCT04102956|Drug|Kallikrein|HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
75554318|NCT06187779|Other|Lower segment measurment|Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
75409534|NCT04086576|Device|Alcohoot|Alcohoot branded smartphone-paired breathalyzer
75409535|NCT04086576|Device|BACtrack Mobile Pro|BACtrack Mobile Pro branded smartphone-paired breathalyzer
75554319|NCT06187766|Diagnostic Test|Social Media Addiction|Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
75409536|NCT04086576|Device|DRIVESAFE Evoc|DRIVESAFE Evoc branded smartphone-paired breathalyzer
75409537|NCT04086576|Device|BACtrack Vio|BACtrack Vio branded smartphone-paired breathalyzer
75409538|NCT04086576|Device|Drinkmate|Drinkmate branded smartphone-paired breathalyzer
75409539|NCT04086576|Device|Floome|Floome branded smartphone-paired breathalyzer
75409540|NCT04086576|Device|Intoxilyzer 240|Intoxilyzer 240 police grade breathalyzer
75409541|NCT04075812|Device|Neuromuscular Stimulator|
75554320|NCT06187753|Diagnostic Test|Sensory Profile|The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.
75554321|NCT06187727|Drug|Henagliflozin|After primary PCI, Henggliflozin or Placebo was administered within 24 hours, followed by daily oral administration until 6 months post-acute myocardial infarction.
75554322|NCT06187714|Procedure|caudal block rate|optic nerve sheath diameter measurement according to caudal block rate
75713428|NCT00870441|Drug|Valacyclovir|Oral
75409542|NCT04061694|Procedure|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
76040654|NCT05522387|Drug|XPro1595|Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
75554324|NCT06187688|Other|Questionnaire|Patients to complete a questionnaire on measurement of pain intensity.
75554325|NCT06187675|Behavioral|Nutrition and Exercise Lifestyle Intervention Program|Nutrition and Exercise components for pregnancy
75554326|NCT06187662|Behavioral|Checklist|This intervention consists of a checklist to guide blood culture decisions, that a clinician in a site randomized to Arm A will be asked to consult and complete prior to ordering or not ordering a blood culture; as the relevant clinical scenario occurs. Meaning, if a clinician in Arm A is faced with a scenario in which it is customary or usual care to consider a blood culture, the clinician will be asked to first review this checklist. The checklist is not a binding or absolute process - the clinician should use both the checklist and typical clinical judgment to decide if the blood culture test is needed or not. The checklist is based on prototypes used in the completed parent study, BrighT STAR and the earlier preliminary studies at Johns Hopkins.
75713429|NCT00870441|Drug|Placebo|Oral
75713430|NCT04786704|Diagnostic Test|Stool-based SDC2 DNA methylation test|A diagnostic device measuring syndecan 2(SDC2) methylation status in stool DNA to detect colorectal cancer
75713431|NCT04786704|Diagnostic Test|quantitative Fecal immunochemical test|A diagnostic device using immunoturbidimetric methods to measure fecal hemoglobin concentration
75872373|NCT05079880|Drug|Placebo|At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
76040655|NCT05532449|Drug|Intravenous dizocine|Intravenous dizocine (0.03mg/kg diluted to 5 ml)
76040656|NCT05532371|Other|Aerobic exercise training combined with lower limb strengthening|The participants performed aerobic exercise training and lower limb strengthening during this intervention.
75713432|NCT04079452|Drug|Doravirine|Doravirine 100 mg tablet
75713433|NCT04079452|Drug|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
75713434|NCT00864669|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
76040657|NCT05532371|Other|Dual-task training combined with lower limb strengthening group (DG)|The participants performed dual-task training combined with lower limb strengthening during this intervention.
76040658|NCT05532371|Other|Aerobic exercise training combined with dual-task training and lower limb strengthening|The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
76040659|NCT05532371|Other|Only lower limb strengthening group (CG)|The participants performed only lower limb strengthening group during this intervention.
76040660|NCT02352103|Procedure|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
76040661|NCT02352103|Procedure|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
75409543|NCT04061694|Procedure|Immediate loading|Only subjected to immediate loading. Conventional procedure.
75409544|NCT04057248|Device|Dario Blood Glucose Monitoring System|Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
75409545|NCT04057248|Behavioral|CDE|Certified Diabetes Educator Sessions
75409546|NCT04053270|Drug|Afamelanotide|16mg subcutaneous implant
75409547|NCT04053270|Drug|Placebo|Placebo subcutaneous implant
76040662|NCT02352103|Device|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
75554327|NCT06187662|Behavioral|Targeted Messaging|This intervention consists of targeted messaging and education that the primary study team will create and ask the Arm B sites to deliver to the PICU clinicians, which focuses on the importance of diagnostic stewardship and the current evidence for the benefit/low risk nature of the stewardship program to date.
75554328|NCT06187649|Procedure|breast reconstruction|breast expander/implant insertion for breast reconstruction following mastectomy
75554329|NCT06187623|Other|Clinic based exercise|"15 patients and their parents in the clinic-based group will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 3 days a week (24 sessions) with a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 4 days of the week."
75554330|NCT06187623|Other|Home based exercise|"15 patients in the home-based group and their parents will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 1 day a week (8 sessions) accompanied by a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 6 days of the week."
75554331|NCT06187610|Behavioral|Digital education|Patients assigned to the experimental group will learn about symptom self-management in a digital learning environment.
75409548|NCT04051710|Drug|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
76040663|NCT05146037|Other|CO2 and saline flushing|TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.
75409549|NCT04051710|Drug|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
76040664|NCT05146037|Other|Saline flushing|TAVI valves will be flushed with saline only as per IFU.
75409550|NCT04051710|Drug|Placebo|Placebo Product
75409551|NCT04047342|Behavioral|Welcome email|Email
75409552|NCT04047342|Behavioral|Loss frame|Email
75409553|NCT04022694|Behavioral|Exposure to beverage health information|Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information
75409554|NCT04022694|Behavioral|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
75409555|NCT04015440|Behavioral|HBMT|Individual is presented with words with some letters missing and told to complete the word.
75554332|NCT06187584|Drug|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen 0.15mg/kg PO q6
75554333|NCT06187584|Drug|Acetaminophen|15mg/kg PO q6 hours
75554334|NCT06187584|Drug|Ibuprofen|10mg/kg PO q6 hours
76040665|NCT04870021|Biological|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs
76040666|NCT04870021|Behavioral|Short text messages and calls to parents for compliance to routine immunization schedule|After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
75554335|NCT06187571|Other|CT+MWM|The MWM technique was applied to the MWM group in addition to the CT. The MWM technique was applied in flexion, abduction, internal rotation, and external rotation directions. The MWM technique was performed with 3 sets of 10 repetitions.
75554336|NCT06187571|Other|CT|Cold packs, electrotherapy modalities, scapular mobilization, stretching, and strengthening exercises were applied to the CT group.
75713435|NCT00864669|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
75713436|NCT00760890|Dietary Supplement|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
75713437|NCT00760890|Dietary Supplement|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
75409556|NCT04015440|Behavioral|Other Training|Alternative to HBMT training
75409557|NCT04030104|Device|Reader Study - Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of Reader study
76040667|NCT04144387|Procedure|Myelogram|Two additional myelograms will be performed comparing to standard of care.
75409558|NCT04030104|Device|Reader Study Imagio Ultrasound + Optoacoustic Imaging|Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study
75409559|NCT04030104|Device|Mammography|Mammography as available per standard of care
75409560|NCT04027218|Device|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
75409561|NCT04027218|Device|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
75409562|NCT04027218|Device|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
75554337|NCT06187558|Procedure|Pelvic and abdominal organ suspension technique|The intervention involves a unique organ suspension technique tailored for minimally invasive gynecologic surgeries. A fragment of a Foley catheter (2 cm of a 1 Fr/Ch) is tied at the end of an absorbable 2-0 Polyglactin suture with a straight needle to create the suspension device. This suture is introduced into the pelvic cavity via an ancillary port. It's designed to penetrate organs such as the ovary, posterior peritoneum, vesico-uterine peritoneum, or bowel. Once the suture is retrieved by passing it through the abdominal wall and pulled so that the Foley segment faces the organ's surface, it's secured using a Kelly clamp. This setup eliminates the need for a knot and offers the surgeon the flexibility to adjust the suspension tension as required.
75554338|NCT06187545|Device|Minimum viable prototype|Deep sedation in critical ill patients using minimum viable prototype
75554339|NCT06187545|Device|Usual care|Deep sedation without minimum viable prototype
75554340|NCT06187519|Device|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|The intervention tested is the system (patch and mobile device/phone for reporting) that provides patients with better knowledge (test results) about the impact of their daily dietary choices on their uric acid levels.
75554341|NCT06187506|Drug|Disitamab vedotin|2.0 mg/kg, administered intravenously every three weeks
75713438|NCT00864747|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
75713439|NCT00864747|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
75713440|NCT05279716|Drug|Eybelis ophthalmic solution 0.002%|Ophthalmic eye drop
75713441|NCT04619628|Biological|COVI-VAC|intranasal, live attenuated vaccine against SARS-CoV-2
75872374|NCT05021146|Other|usual care and topical essential copaiba oil|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
76040668|NCT05525897|Other|Psychoeducational|The focus of the course is to teach students the fundamental theories, and practices of soft skills, as well as providing cases and material that give students the opportunity to learn from real life experiences.
75713442|NCT04619628|Other|Placebo|normal saline
75713443|NCT02543853|Other|direct trocar entry|direct trocar entry to provide pneumoperitoneum
75872375|NCT05021146|Other|usual care and placebo treatment|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
75713444|NCT02543853|Other|veres needle entry|veres needle entry to provide pneumoperitoneum
75713445|NCT02543931|Drug|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
75713446|NCT02543931|Drug|placebo|Placebo capsules containing inert ingredients
75713447|NCT04604652|Drug|HTD1801 (BUDCA)|HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
75713448|NCT05350228|Diagnostic Test|CNN based model|It is an automatic detector model based on convolution neural network created by computer science expert
75713449|NCT00870519|Drug|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
75872376|NCT05021146|Other|usual care|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay.
76040669|NCT04877509|Biological|Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization|Micronutrient assays on heparinized plasma.
76040670|NCT05525819|Drug|Control group|The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
75554342|NCT06187506|Drug|Bacillus Calmette Guerin Vaccine|Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
75554343|NCT06187493|Drug|lisinopril, enalapril|"Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
75554344|NCT06187493|Drug|dapagliflozin, empagliflozin|"Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
75554345|NCT06187480|Procedure|total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)|The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.
75554346|NCT06187467|Other|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires to quantify cortical and motor activities using portable EEG and lower limb sensors during dynamic balance and gait activities.
75713450|NCT00870519|Drug|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
75713451|NCT02559102|Drug|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
76040671|NCT05525819|Drug|Intrathecal group|The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
75409563|NCT04026750|Drug|Pitolisant|Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
75409564|NCT04020822|Device|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
75409565|NCT03979872|Diagnostic Test|MC1R Genetic Testing|[See arm/group descriptions]
75409566|NCT03979872|Other|Skin Cancer Education|[See arm/group descriptions]
75409567|NCT03979872|Device|UV Photo|[See arm/group descriptions]
75409568|NCT03993210|Device|Magnetic Resonance Fingerprinting (MRF)|In MRF, multiple tissue properties are acquired simultaneously.
75409569|NCT03993210|Device|Q-space Trajectory Imaging (QTI)|By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.
75713452|NCT02559102|Drug|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
75713453|NCT02559102|Procedure|Caudal anaesthesia|single shot caudal anaesthesia
75713454|NCT02559102|Procedure|Inguinal hernia surgery|Infant inguinal hernia repair.
75872377|NCT03714035|Other|no intervention|no intervention
75409570|NCT03993210|Device|Magnetic Resonance Imaging Machine (MRI)|MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.
75409571|NCT03988374|Drug|Dentifrices|Dentifrice on plaque, gingivitis, and bleeding.
75409572|NCT03976752|Drug|Genvoya|"Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic."
75409573|NCT03974802|Device|somofilcon A contact lens|Contact Lens
75409574|NCT03974802|Device|fanfilcon A contact lens|Contact Lens
75409575|NCT03966924|Device|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
75409576|NCT03965754|Behavioral|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
75554347|NCT06187454|Device|Active Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a method for noninvasive brain stimulation, where a weak electrical current is delivered through two scalp electrodes by a portable battery-powered stimulator.
75409577|NCT03965754|Behavioral|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
75409578|NCT03965754|Behavioral|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
75409579|NCT03962634|Drug|Kovanaze Nasal Spray|Intra-nasal local anesthetic
75409580|NCT03962634|Drug|Articaine Injection|Local anesthetic
75409581|NCT03933774|Drug|Tretinoin 0.05% cream|Stieva-A Cream 0.05%, 25g, GSK
75409582|NCT03933774|Drug|Placebo cream|Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
75409583|NCT03933618|Drug|Anastrozole 1mg|
75554348|NCT06187454|Device|Sham Transcranial direct current stimulation|For sham tDCS, the electrode positions and stimulation parameters will be the same as that used for anodal stimulation except that the current will be delivered only for the initial 30 seconds.
75554349|NCT06187441|Drug|Daratumumab Injection|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
75554350|NCT06187441|Drug|Dexamethasone|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
75554351|NCT06187441|Drug|Lenalidomide capsule|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
75554352|NCT06187415|Behavioral|Mobile app to reduce harm of chemsex|Access to the mobile app which includes PrEP diary, demistification of chemsex urban legends, information on the location of needle and syringe services program, and alert sending to emergency contact.
75409584|NCT03933618|Drug|Clomiphene Citrate 25mg|
75409585|NCT03933618|Drug|Placebo - Cap|
75409586|NCT03930264|Drug|Azathioprine 50Mg Tab|tablet
75409587|NCT03930264|Drug|Azathioprine 10mg/mL oral suspension|oral suspension
75409588|NCT03919422|Procedure|T2 paravertebral block|Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
75409589|NCT03919422|Procedure|interscalene brachial plexus block and superficial cervical plexus block|An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
75554353|NCT06187389|Other|1 Grups|This methodological study was conducted using a cross-sectional observational approach at a leading teaching and research hospital. The study duration was from March to June 2023
75554354|NCT06187376|Drug|Chinese Herbal Medicine (CHM) supplement|Dropper of tincture by mouth for 12 weeks.
75554355|NCT06187376|Drug|Placebo|Matching placebo tincture.
75409590|NCT03926208|Procedure|Soak and Scrub|Betadine soak and scrub in addition to standard clorhexadine scrub (standard of care).
75409591|NCT03926208|Procedure|Clorhexadine scrub|Clorhexadine scrub (standard of care).
75409592|NCT03901092|Drug|flortaucipir F 18|No study drug will be administered.
75409593|NCT03887286|Device|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
75554356|NCT06187363|Procedure|TIP Procedure|Tubularized incised plate procedre
75554357|NCT06187363|Procedure|Other proceudres|other procedures than TIP procedure
75713455|NCT05348668|Drug|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
75409594|NCT03887286|Device|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
75554358|NCT06187350|Device|AI cancer detection system|The AI system Transpara (Screenpoint Medical, The Netherlands) will be implemented for triaging two-image mammography examinations based on the probability of malignancy. Transpara assigns a score from 1 to 10 to each examination, indicating the risk of malignancy. A score between 1 and 7 indicates a low risk of cancer, 8-9 indicates an intermediate and 10 an elevated risk of cancer. Examinations with an AI score between 1 and 7 will be reviewed by only one radiologist, while examinations with an AI score > 7 will be double-reviewed as normal.
75554359|NCT06187337|Device|Maxillary expansion device|The maxillary expansion device is a orthodontic appliance that is used to expand the maxilla in children.
75554360|NCT06187324|Diagnostic Test|biomarkers|by th use of perio paper GCF was collected and Biomarkers level was estimated
75554362|NCT06187272|Behavioral|Listening to music|Students listened to background music during a practical examination of 60 bpm.
75554363|NCT06187259|Device|caries removal by carbide bur|caries was removed using a slow-speed handpiece and round carbide burs in sizes #12, #14, and #16, based on the lesion's size. When hard dentin was found using a dental probe, carious dentin removal was stopped.
75554364|NCT06187259|Device|caries removal by polymer bur II|carious tissue was removed utilizing smart polymer burs of sizes #4, #6, and #8, depending on the cavity's size, running at a slow speed without water coolant, in circular motions from the center of the lesion outward. Carious dentin removal ceased when the instrument became macroscopically abraded and sharpened and could no longer remove tooth tissues.
75409595|NCT03882528|Biological|Plasmodium falciparum malaria parasite|Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
75554365|NCT06187246|Behavioral|Avatar-based intervention|"Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.~It was delivered via a metaverse: Second Life."
75554366|NCT06187246|Other|Individual informative talks|Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
75554367|NCT06187233|Other|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied during the procedure.
75554368|NCT06187220|Device|Therapeutic Plasma Exchange (PEX)|Therapeutic plasma exchange with treatment sessions >=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma
75554369|NCT06187181|Procedure|implant overdenture|. Videofluoroscopy swallowing evaluation was done using 10 ml of thin liquid bolus at three different oral conditions: Without dentures (WOD), with the conventional complete denture (CDs) and with mandibular implant retained overdenture (IODs).
75554370|NCT06187181|Radiation|videofluroscopy|videofluroscopy evaluation of swallowing function
75713456|NCT05309044|Behavioral|Planetary Health Diet Group|This group includes a diet proportional to the EAT-Lancet reference diet (2500 kcal), with a caloric intake of 1200 to 1800 kcal, in addition to a behavioral change protocol during the time of the study (4 months).
75713457|NCT05309044|Other|Low-fat diet group|This group includes a low-fat, low-calorie diet (1200-1800 kcal), in addition to a behavioral change protocol
75872378|NCT05018338|Device|Brain shift monitoring|For use to monitor brain shift during craniotomy
75409596|NCT03881670|Device|Lotrafilcon B|commercially available contact lens
75409597|NCT03881670|Device|lotrafilcon B with Hydraluxe|commercially available contact lens
75409598|NCT03861000|Drug|[C-11]T-1650|radio-labeled drug
75409599|NCT03861000|Drug|BPN14770|selective compound
75409600|NCT03863496|Procedure|Scoliosis surgery|All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
75409601|NCT03856944|Device|ReSTOR Toric|ReSTOR Toric bilateral IOL implantation
75409602|NCT03865446|Drug|Dacomitinib|anti-cancer agent
75409603|NCT03868254|Device|XEN Group|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
75409604|NCT03868254|Procedure|Phacoemulsification|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
75409605|NCT03862482|Device|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Brånemark® implant placed at sites 2 (left medial) and 5 (right distal), Swede-Vent® implant placed at sites 1 (left distal) and 4 (right medial), Screw-Vent® implant placed at site 3 (para symphysis)
75409606|NCT03862482|Device|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Brånemark® implant placed at site 3 (para symphysis), Swede-Vent® implant placed at sites 2 (left medial) and 5 (right distal), Screw-Vent® implant placed at sites 1 (left distal) and 4 (right medial)
75554371|NCT06187142|Behavioral|Initial phase: Personalized Chat Support (PCS)|Participants will receive three months of personalized chat support through WeChat. A total of 24 pre-set messages will be sent with the schedule of 3 times a week for 2 weeks, twice a week for the next 8 weeks and once a week for the last 2 weeks. These messages cover generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and hazards of smoking for chronic diseases experienced by different participants. Counsellors will respond to the participants' messages instantly. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PCS (subgroup PCS-1). Incomplete responders (smokers) will be randomly assigned to continue PCS (subgroup PCS-2) or receive PCS and MOS (subgroup PCS-3).
75554372|NCT06187142|Behavioral|Second phase: Multi-component Optional Support (MOS)|For incomplete responders (subgroup PCS-3) randomized to MOS, the available intervention options include phone counseling, family/peer support group and financial incentive for nicotine replacement therapy. Participants will be guided by cessation counsellors at 1-month follow-up to choose any combination of MOS based on their prefer choice or combination of MOS. If MOS participants cannot be followed up at 1-month, they will continue PCS by default.
75554373|NCT06187142|Behavioral|Initial phase: Group Chat Support (GCS)|Participant will receive three months of group chat support through WeChat. In this group, participants can send 'No Smoking' and the smart quit-smoking assistant will record it. A smoking cessation clinic doctor in the group will respond to participants' questions about smoking cessation. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive GCS (subgroup GCS-1). Incomplete responders (smokers) will be randomly assigned to continue GCS (subgroup GCS-2) or receive GCS and PCS (subgroup GCS-3).
75554374|NCT06187142|Behavioral|Second phase: Personalized Chat Support (PCS)|For incomplete responders (subgroup GCS-3) randomized to PCS, participants will receive the same intervention as Group PCS delivered at the initial stage. Participants will receive two months of personalized messages through WeChat. Please refer to Intervention Group 'Initial phase: Personalized Chat Support (PCS) for details.
75713458|NCT05309044|Other|Waiting list group|This group will only receive digital information with recommendations on healthy eating. When the study has finished, this group will receive a behavioral change protocol with a low-fat, low-calorie diet.
75713459|NCT00864825|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
75713460|NCT00870597|Procedure|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
75713461|NCT00870597|Procedure|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
75872379|NCT03716765|Dietary Supplement|locally injected vitamin D|locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
75872380|NCT03716687|Device|Prophylactic negative pressure wound dressing after laparotomy|Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
75409607|NCT03862482|Device|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Brånemark® implant placed at sites 1 (left distal) and 4 (right medial), Swede-Vent® implant placed at site 3 (para symphysis), Screw-Vent® implant placed at sites 2 (left medial) and 5 (right distal)
75409608|NCT03848208|Drug|cytisine|cytisine film-coated oral tablet
75409609|NCT03848208|Drug|placebo|matching placebo oral tablet
75409610|NCT03858894|Drug|DE-117 Ophthalmic Solution QD|DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye
75409611|NCT03858894|Drug|DE-117 Ophthalmic Solution BID|DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye
75409612|NCT03856164|Drug|Tranexamic Acid|Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
75409613|NCT03856164|Drug|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
75713462|NCT00956176|Drug|Cidofovir|Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
75713463|NCT00864981|Drug|Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.|
75713464|NCT00864981|Drug|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|
75713465|NCT00371683|Drug|Enoxaparin + Placebo|Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
75713466|NCT00371683|Drug|Apixaban + Placebo|Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
75713467|NCT05286580|Behavioral|Morbidity and mortality conference toolkit|"Standardized slide deck~Code of conduct~Conference planning checklist~Case documentation form"
75713468|NCT00876057|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy
75872381|NCT05017324|Device|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation
75409614|NCT03849690|Drug|TAK-906|TAK-906 capsules.
75554375|NCT06187142|Behavioral|5A's / 5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
75554376|NCT06187142|Behavioral|health warning leaflet|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
75554377|NCT06187142|Behavioral|Self-help booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
75554379|NCT06187116|Other|Physiotherapist consultation|The consultation with the PT is 40-45 minutes long according to usual care and includes patient history, assessment and management according to an assessment template. If the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to general practitioner (GP) for new tests/assessments/medication. If the patient is found to be appropriate for surgery, and wishes to undergo surgery, or if the PT in the study wants a second opinion, the patient is 4) referred for orthopaedic consultation for surgical consideration.
75554380|NCT06187116|Other|Orthopaedic surgeon consultation|The consultation with the OS is 20-30 minutes long and includes medical history, assessment and management plan, all according to usual care. It the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to GP for new tests/assessments/medication. If the patient is found appropriate for surgery, and wishes to undergo surgery, the patient is 4) scheduled for surgery.
75554381|NCT06187103|Device|HyperSight Imaging|Patients undergo 2 HyperSight CBCT acquisitions in addition to the standard imaging for treatment guidance. The HyperSight CBCT images will be acquired at the start of treatment, and approximately halfway through treatment. If the patient is sent for mid-treatment re-planning, a third HyperSight CBCT will be acquired on the same day as their re-simulation.
75409615|NCT03849690|Drug|Esomeprazole|Esomeprazole capsules.
75409616|NCT03843372|Device|High flow nasal cannula|All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
75713469|NCT00876057|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
75713470|NCT05276128|Dietary Supplement|lipids|Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
76040672|NCT05525819|Drug|Intravenous group|The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
75409617|NCT03822078|Drug|Placebo|Administered by subcutaneous injection
75409618|NCT03822078|Biological|Denosumab|Administered by subcutaneous injection
75713471|NCT05226273|Other|no intervention|no intervention
75713472|NCT00956332|Biological|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
75713473|NCT00956332|Biological|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
75713474|NCT00870753|Behavioral|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
76040673|NCT03044743|Drug|Fludarabine|To modify immune micro-environment
75409619|NCT03806556|Drug|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
75409620|NCT03806556|Drug|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
76040674|NCT03044743|Drug|Cyclophosphamide|To modify immune micro-environment
75409621|NCT03809052|Drug|GB1211|Hard capsules for oral use
75409622|NCT03809052|Drug|Placebo|Hard capsules for oral use
76040675|NCT03044743|Drug|Interleukin-2|To sustain the survival of infused T cells
75409623|NCT03812328|Drug|SelK2|I.V., single-dose
75409624|NCT03812328|Biological|Enoxaparin|SC, QD for up to 10 ± 2 days
75409625|NCT03816696|Drug|GSK3640254|GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
75409626|NCT03816696|Drug|DTG|DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
75713475|NCT03825718|Biological|GC007F|GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
76040676|NCT05532293|Drug|MSP008-22|MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro & in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
75409627|NCT03815292|Drug|MMH-MAP|Oral administration
75409628|NCT03815292|Drug|Placebo|Oral administration
75409629|NCT03809910|Device|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
75409630|NCT03809910|Device|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
75409631|NCT03809910|Device|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
75554382|NCT06187090|Dietary Supplement|Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form|Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
75554383|NCT06187051|Device|FEVAR|Relining the EVAR with FEVAR
75554384|NCT06187051|Device|Explantation|open surgery to explant the previous EVAR
75713476|NCT00876135|Drug|Ventolin|Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
75409632|NCT03809910|Device|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
75713477|NCT05214742|Other|Diagnostic Test|Molecular diagnosis carried out in the context of care
75713478|NCT00870831|Other|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
75872382|NCT01311323|Procedure|PCI|Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging
75409633|NCT03806790|Drug|LEO 90100 foam|Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
75409634|NCT03806790|Drug|Dovobet® ointment|Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
75409635|NCT03805386|Drug|Physician directed opioid prescribing|Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
75409636|NCT03805386|Drug|Patient directed opioid prescribing|Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
75409637|NCT03802344|Drug|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
75554385|NCT06187025|Other|Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)|Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)
75554386|NCT06187025|Other|Ecological Momentary Assessment (EMA)|Daily EMA evaluations during 12 weeks
75554387|NCT06187012|Other|Hypertensive pregnancy|Participants will attend one visit lasting approximately 3-4 hours on a single day or split over multiple visits to complete all measures. Participants will first be asked to provide written informed consent for the study. Participants' anthropometric measures (waist-to-hip ratio, height and weight, hip and waist circumference and left arm circumference and resting blood pressures will then be taken. After this, the participants will undergo cardiopulmonary exercise testing, followed by magnetic resonance imaging, echocardiography, retinal imaging and vascular imaging of the ear. The study visit will conclude with participants being provided with a wrist-worn physical activity monitor to wear for 7-9 days following the visit. These monitors will provide objective measures of physical activity while people go about their normal activities.
75554388|NCT06186986|Drug|Brentuximab vedotin|5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
75554389|NCT06186973|Other|Monitoring with Neobeat heart rate meter|"At the designated time for cord clamping as per clinical indication, a 10 cm segment of the umbilical cord will be double-clamped and 5 ml of preferably arterial blood will be obtained.~In infants brought to the resuscitation table, six ECG electrodes will be placed on the skin and cardiac output will be measured with a hemodynamic monitor (PhysioFlow®) for at least 10 min, or until the end of resuscitation/stabilization."
75554390|NCT06186973|Other|Maternal arterial blood gases|Arterial blood gases will be drawn from a radial artery line and analyzed at the end of a contraction at pre-specified time points during labor.
75872383|NCT01311323|Procedure|CABG|Coronary Artery Bypass Graft
75872384|NCT05079646|Other|class 1 and class 2 cavity preparation and restored with contemporary materials|class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
76040677|NCT05532293|Other|Placebo|Placebo tablets identical in appearance, taste and smell to the tablets of MSP008-22
76040678|NCT03044665|Drug|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
75409638|NCT03802344|Drug|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
75409639|NCT03802344|Drug|Vehicle|Vehicle cream
75409640|NCT03799614|Device|RMBand lower dose|Light-weight portable device that delivers low dose vibration to the arm
75409641|NCT03799614|Device|RMBand higher dose|Light-weight portable device that delivers higher dose vibration to the arm
75409642|NCT03796260|Drug|Entrectinib Test Formulation (F1)|Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.
75409643|NCT03796260|Drug|Entrectinib Reference Formulation (F06)|Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
75713479|NCT03588286|Procedure|Electrophysiology study (EPS)|EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting > 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
76040679|NCT03044665|Drug|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
75409644|NCT03796182|Drug|Metformin|Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
75554391|NCT06186973|Other|Amniotic fluid lactate|Amniotic fluid will be collected (2mL) and analyzed at pre-specified time points after rupture of the membranes.
75554392|NCT06186960|Device|Tandem Virtual Reality|Hospice patients and their primary caregiver will each wear virtual reality headsets and will experience a customized and synchronized 5-15min virtual reality experience.
75554393|NCT06186947|Other|No intervention|Participants are not subjected to any specific intervention.
75409645|NCT03796182|Drug|PF-04965842|PF 04965842 100 mg tablets
75409646|NCT03779724|Other|exercises|
75713480|NCT03588286|Other|Standard Care|The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
75872385|NCT03070002|Biological|Denosumab|Given SC
75872386|NCT03070002|Other|Laboratory Biomarker Analysis|Correlative studies
76040680|NCT03046537|Diagnostic Test|Breath test|Collecting breath test from participants
76040681|NCT03046615|Device|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
75409647|NCT03786744|Biological|ASD CB-MNC injection.|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
75409648|NCT03786744|Other|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
75409649|NCT03790878|Behavioral|Mindful Breathing|Training in a mindful breathing skill that reduces emotional distress
75409650|NCT03790878|Behavioral|Habituation|An exposure procedure that reduces emotional distress through habituation
75554394|NCT06186921|Drug|Dexamethasone|After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.
75554395|NCT06186908|Diagnostic Test|Saliva obtaining|Full-mouth clinical periodontal measurements recorded and saliva obtained.
75554396|NCT06186895|Drug|Dexmedetomidine|received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
75554397|NCT06186895|Drug|Fentanyl|fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
76040682|NCT03046615|Device|Standard Needles|Needles are placed in the muscles surrounding the eye to measure eye movements.
76040683|NCT04877353|Device|NIV|NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
75409651|NCT03790878|Behavioral|Control|No emotion regulation intervention, placebo
75409652|NCT03789474|Device|HUNTLEIGH FLOWTRON ACS900|
75554398|NCT06186882|Behavioral|Action Video-Game|Thanks to their specific characteristics (presentation of multiple peripheral, rapidly moving, spatio-temporally unpredictable stimuli), Action Video-Games improve reading skills through their effects on the Magnocellular-Dorsal stream. Training will consist of 20 days of Action Video-Games sessions of 1 hour each, three times per week.
75554399|NCT06186869|Behavioral|Aerobic Exercise and diet intervention|subjects randomized and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform moderate-intensity aerobic exercises
75554400|NCT06186869|Behavioral|Hiit and diet intervention|subjects randomised and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform high-intensity interval exercises in the gym
75713481|NCT03588286|Procedure|Cardiac Magnetic Resonance (CMR)|CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) <30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
76040684|NCT05521841|Procedure|Erector Spinae Plane Block(Bilateral Ultrasound Guided Erector Spinae Plane Block)|"Bilateral USG guided Erector Spinae Plane Block:~Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg Ultrasound transducer will be placed in a cephalocaudal orientation over the back at 10th thoracic vertebral level.~The probe will then slowly be moved laterally until the transverse process is visible The trapezius muscle and erector spinae muscle will be identified as superficial to the transverse process.~A 25-gauge Quincke spinal needle (Romsons spinal needle, Quincke type)will be inserted using an in-plane approach in the cephalad to the caudal direction and towards the transverse process.~A 5ml bolus of local anesthetic will be given. Erector spinae muscle plane is then visualized separating from the transverse process.~The local anesthetic is then injected in 5 ml increments, with aspiration after every 5 ml to avoid intravascular injection Same procedure will be repeated on the other side"
75872387|NCT02327728|Procedure|Botulinum toxin A injection (5 sites: 12.5U)|
75409653|NCT03765996|Other|Decongestive Physiotherapy|This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
75409654|NCT03765996|Other|Decongestive Physiotherapy plus taping|This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
75409655|NCT03765762|Drug|GRF6019|GRF6019 for IV infusion
75409656|NCT03765762|Other|Placebo|Placebo for IV infusion
75409657|NCT03756012|Device|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
75554401|NCT06186869|Behavioral|Diet|subjects randomised and assigned to this intervention group will follow the low-glycaemic index Mediterranean diet
75554402|NCT06186843|Behavioral|Plant-based diet|A two week training program will be completed which consists of information, resources and activities that will help participants transition to a plant-based diet. Each day of the program, participants will engage with material that provides information about how a plant-based diet can improve health outcomes, how to cook plant-based meals, what to shop for when eating plant-based, and other information that will help participants become comfortable with this dietary change. In addition, each participant will have a virtual, weekly check-in with one of the investigators. Finally, participants will be encouraged to attend a once monthly group session with all participants.
75554403|NCT06186830|Other|Validity and reliability analyses|Validity and reliability analyses will be performed using Cognitive Exercise Therapy Approach Biopsychosocial Questionnaire, Patient Health Questionnaire-9, Patient Health Questionnaire-15, Generalized Anxiety Disorder-7, Short Form-36, Craniomandibular Pain and Disability Inventory, and Mandibular Function Impairment Questionnaire.
75554404|NCT06186817|Procedure|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
75554405|NCT06186817|Procedure|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
75554406|NCT06186817|Behavioral|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
75713482|NCT00876291|Dietary Supplement|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
75713483|NCT00876291|Dietary Supplement|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
75713484|NCT03563482|Diagnostic Test|PET scan|Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
75713485|NCT00870909|Procedure|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
75713486|NCT00870909|Procedure|sham tDCS|sham condition as delivered by the stimulator
75409658|NCT03748992|Drug|gNO|"This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires."
75409659|NCT03748758|Combination Product|Drug: OP0201|Drug OP0201
75409660|NCT03748758|Combination Product|Drug: Placebo|Placebo
75409661|NCT03745092|Device|normobaric oxygen|Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
75554407|NCT06186817|Procedure|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
75713487|NCT04039815|Drug|Ascorbic acid-Vitamin B1-Hydrocortisone|intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
75713488|NCT04039815|Drug|Placebo|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
75713489|NCT00870987|Biological|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
75713490|NCT00870987|Biological|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
75872388|NCT02327728|Procedure|Botulinum toxin A injection (4 sites: 10U)|
75872389|NCT02327728|Drug|Botulinum toxin A 12.5U|
75872390|NCT02327728|Drug|Botulinum toxin A 10U|
75872391|NCT03142672|Procedure|pulpotomy|vital endodontic procedure
75872392|NCT03142672|Procedure|tooth filling|tooth filling
75409662|NCT03745092|Device|room air|The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
75554408|NCT06186804|Drug|ABSK021|Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.
75554409|NCT06186778|Procedure|secondary colonoscopy|After the routine colonoscopy, a repeat colonoscopy of the sigmoid colon is performed
76040685|NCT05521841|Procedure|Transversus abdominis plane block(Bilateral Ultrasound-guided bilateral Transversus abdominis plane block)|"Bilateral Ultrasound-guided bilateral Transversus abdominis plane block Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg The linear transducer will be placed in the transverse plane at the lateral abdominal wall in the mid-axillary line, between the lower costal margin and the iliac crest.~Abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized.~Bowel movement and visualization of hypoechoic peritoneum would further guide the block.~The needle will be inserted in-plane and advanced until the tip is between the internal oblique and the transversus abdominis muscle.~After negative aspiration, 20 mL of 0.25% bupivacaine is injected in a 5ml increment ,aspirating after every 5ml injection.~Same procedure will be repeated on the other side."
76040686|NCT05525351|Device|Bispectral index (BIS) or Patient State Index (PSI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI). BIS is maintained between 40 - 60 and PSI between 25 - 50. The vital signs, BIS or PSI are recorded automatically and continuously through computerized software. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
76040687|NCT05525351|Drug|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Propofol is given via target control pump with typical target effect-site propofol concentration 1-5 ug/mL according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
76040688|NCT05525351|Drug|Alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0~1000mcg according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
75409663|NCT03744780|Behavioral|ACT Workshop for Emotional Eating|"This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
75409664|NCT03730116|Drug|bisoprolol/perindopril FDC|the first and only single-pill combination of beta-blocker and ACE inhibitor
75409665|NCT03729960|Other|LENA recorder|The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
75554410|NCT06186778|Procedure|conventional colonoscopy|It starts from the rectum and progresses forward to the cecum, with observations made during withdrawal: from the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon to the rectum.
75872393|NCT02918318|Drug|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
75409666|NCT03729024|Device|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments
75409667|NCT03728790|Device|Remote Patient Monitoring|Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
75409668|NCT03727854|Dietary Supplement|Premeal protein enriched bar|Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
75409669|NCT03727854|Behavioral|Dietary modification|Subjects in this group will follow diabetes diet education.
75409670|NCT03544242|Other|Control|A saline infusion will be administered during the pre-isolation and post-isolation phases.
75872394|NCT02918318|Drug|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
75872395|NCT02918318|Drug|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
75872396|NCT02918318|Drug|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
75409671|NCT03544242|Drug|Pre-Isolation Infusion|A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
75409672|NCT03544242|Drug|Post-Isolation Infusion|A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
75554411|NCT06186752|Behavioral|MyIBD|MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.
75554412|NCT06186739|Behavioral|home-based motor rehabilitation training participated by caregivers|The knowledge provider was a multi-disciplinary home-based rehabilitation nursing team, which is composed of advanced practice nurse (APN) who engaged in professional rehabilitation of stroke, neurologists, rehabilitation doctors and physical therapists. Among them, APN mainly carry out and supervise family rehabilitation education and all members are collectively responsible for the adjustment and optimization of the program content. After the assessment is completed, the patient's current functional status will be confirmed. based on this, team members recommend home-exercise items that match the patient's motor function state . In this intervention programme, the content of the intervention was developed based on the recommendations of internationally published guidelines related to the rehabilitation of ischemic patients, with some adjustments to consider the cultural appropriateness of implementation in China.
75409673|NCT03500406|Device|RestoreX|Penile traction therapy in the straight position
75554413|NCT06186739|Behavioral|routine self-care|the patients in this group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
75409674|NCT03500406|Other|Control|No treatment
75554414|NCT06186713|Other|This was an observational study, and no Intervention was given to the patients.|This was an observational study, and no Intervention was given to the patients.
75554415|NCT06186700|Drug|Pentoxifylline|Pentoxiphylline tablets three times per day for the treatment period of neoadjuvant chemotherapy cycles of doxorubicin/ cyclophosphamide
75554416|NCT06186700|Drug|Placebo|Placebo tablets three times per day for the treatment period of neoadjuvant chemotherapy cycles of doxorubicin/ cyclophosphamide
75554417|NCT06186674|Diagnostic Test|sorensen test for back endurance|• Biering-Sorensen test will be utilized to gauge the trunk extensor muscles' isometric endurance. The patient will be lying on a treatment couch, prone. The top half of the body will be permitted to rest on a chair prior to the test starting. The patient will be told to elevate their upper trunks off of the chair at the start of the test. the examiner determined how long the individual could hold this position.
75872397|NCT03713957|Drug|GRF6021|GRF6021 for IV infusion
75872398|NCT03713957|Other|Placebo|Placebo for IV infusion
75872399|NCT01374321|Drug|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
75872400|NCT01374321|Drug|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
75872401|NCT04960150|Device|Press tack needle|"Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm"
76040689|NCT05525351|Drug|Dexmedetomidine|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical Dexmedetomidine ranged from 0.5-1 ug/kg/hr according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
76040690|NCT04869865|Dietary Supplement|9-day detoxification cleanse and 1 week of pre-cleanse transition|Subjects will participate in the full 9-day Springtime Home Cleanse, including the week prior to a pre-cleanse transition period. The cleanse includes a transition week, 9 days of a monodiet, internal oleation with ghee, external oleation, herbs, purgation, and an enema. During this time, subjects will also attend daily online meetings on Facebook Live throughout the cleanse and on AyurPrana's AyurLearn online portal to participate in guided mediation and yoga. Subjects will also use these platforms to access daily cleanse instructions and journaling topics.
76040691|NCT04869475|Drug|Arsenic trioxide|This is a single-arm study with all patients receiving arsenci trioxide.
76040692|NCT05521763|Behavioral|ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness|"The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention."
76040693|NCT03044821|Procedure|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
76040694|NCT02612155|Biological|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
75409675|NCT03423654|Other|Spatial Training|Spatial Training using a 5x5 grid
75409676|NCT03423654|Other|Letter number matching|Letter number matching
75409677|NCT03370536|Device|CardioInsight ECGI Mapping System|The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
75409678|NCT03370536|Procedure|AF ablation|Empiric ablation (CFAE or linear ablation) is not permitted
75409679|NCT03370536|Drug|Ibutilide|Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
75409680|NCT03161964|Drug|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
75409681|NCT03161964|Drug|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
75409682|NCT03078270|Drug|botulinum toxin A|Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
75409683|NCT03078270|Other|Placebo|single treatment visit for 5 injections of normal saline
76040695|NCT02612155|Biological|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
75409684|NCT03042780|Drug|FOLFIRINOX|The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
75872402|NCT04960150|Device|Plesterin|Plesterin
75409685|NCT03042780|Drug|Granulocyte colony-stimulating factor (G-CSF)|The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
75409686|NCT03017040|Device|CT scan|A CT scan of the wrist
75409687|NCT03017040|Device|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
75409688|NCT02985840|Drug|Ondansetron|Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
75409689|NCT02985840|Drug|Dexamethasone|Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
75872403|NCT02327806|Device|pulsed electromagnetic field therapy|
76040696|NCT05100251|Drug|WBC100|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, patients take WBC100 once on cycle 0. After a washout period of 2 days, patents start subsequent 4 weeks cycles until progression disease or intolerable toxicity. In each cycle, patient was on WBC100 every for 3 weeks and off for 1 week.~The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage enroll 12 pancreatic patients with positive c-myc expression."
76040697|NCT04876885|Other|Educational video|Three two-minute educational videos about COVID-19 vaccine development and dissemination
76040698|NCT04865185|Diagnostic Test|Xylocaine spray 100mg/ml|Topical application
76040699|NCT04865185|Diagnostic Test|Ethanol|Topical application
76040700|NCT05518565|Other|No intervention|No intervention
76040701|NCT04865107|Biological|UC-MSCs|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
76040702|NCT04865107|Biological|Placebo|PlasmaLyte A and 5% Human Albumin
76040703|NCT05531903|Device|Description of Slow pathway signals to facilitate ablation|3D endocardial mapping in order to identify slow pathway signals and abolish or modificate them after radiofrequency ablation
76040704|NCT03046459|Biological|BNZ132-1-40|pegylated peptide inhibiting IL-2, IL-9 and IL-15
76040705|NCT03046381|Drug|Tocilizumab|Tocilizumab 162mg 1x weekly s.c.
76040706|NCT05521373|Device|ultrasound cervical selective nerve root block|"A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance"
76040707|NCT05521373|Device|ultrasound and fluoroscopy-guided cervical selective nerve root block|The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
76040708|NCT05521295|Other|no intervention|no intervention in this study
76040709|NCT04876807|Drug|ACP-196|In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
76040710|NCT04876807|Drug|Omeprazole|Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
76040711|NCT05518409|Biological|Detection of cytof in peripheral PBMC|Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.
76040712|NCT05518409|Drug|Donepezil for patients with AD and DLB|The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
75409690|NCT02974686|Drug|Everolimus|
75409691|NCT02974686|Drug|Mycophenolic Acid|
75409692|NCT02966184|Drug|preservative free albuterol|Preservative free albuterol for nebulization
75409693|NCT02950896|Other|observational fetal heart rate monitoring|Patients will have fetal heart rate monitoring
75409694|NCT02877732|Device|EYE-SYNC eye-tracking|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
75554418|NCT06186674|Diagnostic Test|6 minute walk test|"It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace.~It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace."
75554419|NCT06186674|Diagnostic Test|c7-s1 SVA|Subjects will obtain standardized lateral views radiographs in a neutral standing position for the whole spine. The C7- S1 SVA will be measured as the distance from the plumb line dropped from the center of the C7 vertebral body to the most posterior edge of the upper sacral endplate surface.
75554420|NCT06186661|Other|neurophysiological exercise|The content of the treatment program consisted of neurophysiological exercises based on Bobath.
75554421|NCT06186661|Other|cognitive rehabilitation|Cognitive rehabilitation sessions of the experimental group included 30 minutes of remedial and functional adaptive approaches and 30 minutes of implementation of Multicontextual treatment intervention.
75554422|NCT06186648|Drug|Glofitamab + Obinutuzumab|Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
75554423|NCT06186635|Other|Traditional yoga|This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.
75713491|NCT03951766|Behavioral|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
75554424|NCT06186635|Other|AI-Assisted Yoga|This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
75554425|NCT06186609|Drug|PD-1 inhibitor 200mg per three to four weeks, for one year|"PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction."
76040713|NCT02614729|Other|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
75409695|NCT02877732|Other|SCAT-3 subtests|Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
75554426|NCT06186596|Device|Triamcinolone delivered via injection assistance device|0.1mL of 1% to 2% triamcinolone solution will be delivered to up to 3 facial inflammatory acne lesions
75713492|NCT00876603|Procedure|ACDF|Anterior cervical decompression and fusion
75713493|NCT00876603|Procedure|Cervical laminoplasty|Cervical laminoplasty
75713494|NCT00371137|Drug|Xyrem®|two doses
75713495|NCT00371137|Drug|Placebo|Oral Solution
76040714|NCT02614729|Other|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
76040715|NCT02614729|Other|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
76040716|NCT02614729|Other|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
75409696|NCT02877732|Other|DEM|Participant will be asked to read list of numbers out loud from a card
75409697|NCT02877732|Other|Simple Reaction Time subtest of ANAM-SRT|Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
75409698|NCT02877732|Other|Level of Alertnesss|Participants will answer questions. This assessment is to assess their alertness level.
75409699|NCT02808390|Drug|GED-0507-34-Levo 80 mg|GED-0507-34-Levo 80 mg BID for 8 Weeks
75409700|NCT02808390|Drug|GED-0507-34-Levo 160 mg|GED-0507-34-Levo 160 mg BID for 8 Weeks
75409701|NCT02808390|Drug|Placebo|Placebo BID for 8 Weeks
75409702|NCT02744352|Drug|20ml bolus of 0.5% ropivicaine|Local anesthetic
75409703|NCT02744352|Drug|0.2% of ropivacaine at 8 milliliter/hour|Local anesthetic
75409704|NCT02745210|Diagnostic Test|13C magnetic resonance spectroscopy|acquisition of 13C MR spectroscopy in the brain
75409705|NCT02679066|Device|Sugar-tong splint|Plaster immobilization including the elbow
75409706|NCT02679066|Device|Short forearm cast|Fiberglass immobilization with elbow free
75409707|NCT02590068|Drug|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
75713496|NCT01050283|Procedure|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
76040717|NCT05531825|Device|A device for detecting arteriovenous fistula vascular function|An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels
76040718|NCT05518331|Drug|avatrombopag|Avatrombopag, 40-60 mg (body weight < 80 kg, 40 mg per day; body weight > 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
75713497|NCT00961870|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
75713498|NCT05175417|Other|MRI|3 tesla (T) MRI to provide higher resolution and quality brain images.
75713499|NCT01047787|Other|Polysomnography|examination for sleep disorders
75409708|NCT02587650|Drug|Capmatinib|Given PO
75713500|NCT00871299|Behavioral|Mindfulness Based Cognitive Therapy|"Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression."
75713501|NCT00871299|Behavioral|Health Enhancement Program and medication management|The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
75713502|NCT02534545|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
75713503|NCT02534545|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
75713504|NCT00962026|Drug|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
76040719|NCT04876573|Drug|Cyproheptadine Hydrochloride 4 MG|"Phase 1: Cyproheptadine 4 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~Phase 2: Cyproheptadine 8 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~The dose will be adjusted according to the renal function."
76040720|NCT05521139|Diagnostic Test|drug sensitivity results|drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
76040721|NCT03046147|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
75409709|NCT02587650|Drug|Ceritinib|Given PO
75409710|NCT02587650|Drug|Entrectinib|Given PO
75409711|NCT02587650|Other|Laboratory Biomarker Analysis|Correlative studies
75409712|NCT02587650|Drug|Regorafenib|Given PO
75713505|NCT03753789|Device|Microwave Ablation|NEUWAVE microwave ablation of soft tissue liver lesions will be performed percutaneously by an interventional radiologist while the patient is under general anesthesia or deep conscious sedation.
75554427|NCT06186583|Drug|Pimicotinib（ABSK021）|A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
75554428|NCT06186570|Behavioral|Online-Based Self-Help Intervention|See the description above.
75554429|NCT06186557|Other|No intervention|No intervention
75554430|NCT06186531|Dietary Supplement|PhytoSERM|PhytoSERM, a formulated dietary supplement, will be an ovalized tablet measuring 8.51 mm x 15.49 mm. Each pill will contain a white PEG coating and an equal mixture of, daidzein, genistein, and S-equol.
75554431|NCT06186531|Drug|Placebo|Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
75409713|NCT02514252|Drug|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
75713506|NCT00876681|Procedure|Popliteal catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
75409714|NCT02514252|Behavioral|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
75409715|NCT02514252|Behavioral|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
75409716|NCT02514252|Behavioral|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
75409717|NCT02434146|Drug|Topical Phenylephrine Solution|Given topically via spray
75409718|NCT02431494|Device|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
75554432|NCT06186518|Other|PİKSEÇ|"In designing the PİKSEÇ application, the Turkish validity and reliability version of the 'Difficult Intravenous Access Score' and a literal translation of the miniMAGIC instructions were utilized. The application serves as a guideline for nurses during peripheral intravenous catheter insertion, taking into account parameters such as the patient's age, urgency status, anxiety, and vein characteristics, providing tailored suggestions.~By utilizing the application, nurses can follow evidence-based guidelines more efficiently, ensuring a faster and more practical adherence to the PIVC intervention procedure, ultimately contributing to a safer peripheral intravenous catheter insertion process."
75554433|NCT06186518|Other|Routine care|The pediatric unit's PIVC insertion process will be routinely performed in routine care.
75554434|NCT06186505|Device|AirGlove|AirGlove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intraveneous drugs by gently heating the patients arm up as it forces warm air through a double walled polythene glove. In this study, the device will be used on the leg of the participants as means of encouraging circulation to the area.
75554435|NCT06186492|Drug|WVE-006|RNA editing oligonucleotide
75554436|NCT06186479|Drug|Aconite pain oil|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
75554437|NCT06186479|Drug|Placebo|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
75713507|NCT05299840|Diagnostic Test|Oncogramme results available|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
75713508|NCT05299840|Diagnostic Test|Oncogramme results unavailable|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
75713509|NCT03991897|Dietary Supplement|Ketogenic diet|Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.
75713510|NCT03991897|Dietary Supplement|Isocaloric diet|Patients will follow an isocaloric diet
75713511|NCT00616239|Drug|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
75713512|NCT00616239|Drug|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
75713513|NCT03234166|Other|Non interventional study|Only data will be taken of patient's file.
75713514|NCT01045213|Other|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
75713515|NCT00876759|Radiation|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
75409719|NCT02431494|Device|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
75554438|NCT06186466|Other|Observational Survey and Analysis|This study does not involve a clinical or medical intervention. Instead, it employs an observational survey method to gather data from family members of patients who visited the Health Sciences University Van Training and Research Hospital's emergency department between December 1, 2023, and June 1, 2024. The study aims to use logistic regression analysis to identify factors influencing the intent of violence against healthcare professionals. The survey includes structured questionnaires and scales developed based on theoretical frameworks and previous research. The gathered data will be statistically analyzed using the G*Power software to assess the significance and impact of various factors on the propensity for violence.
75554439|NCT06186440|Drug|Cisplatin Plus Temozolomide|Cisplatin Plus Temozolomide . Cisplatin 20mg/mCisplatin days 1-5
75554440|NCT06186440|Drug|Temozolomide|Temozolomide
75409720|NCT02431494|Device|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
75554445|NCT06186388|Diagnostic Test|TEMPO iMOvifa|Screening test with 28 testing points
75554446|NCT06186375|Other|Patients with planned biotherapy|Single additional volume of blood (10 ml) to be collected using the PAXgene system at the same time as the routine blood test before starting biotherapy.
75554447|NCT06186349|Genetic|Genomic sequencing|Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
75554448|NCT06186336|Other|Deep Learning-based Vulnerable Plaque Detection and Assessment Tool|"Scanning requirements for the clinically indicated CCTA and ICA with OCT will be performed according to current site(s) guidelines and procedures. Administration of medications (such as contrast agents and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational product. The tool's use is intended for research purposes and is not intended as a substitute for required medical care. The CCTA and ICA with OCT will be processed in real-time using the site's locally available post-processing tools in order to guide the subject's medical care. Once the ICA with OCT is complete, the de-identified CCTA data will be inputted in the investigational tool.~The clinically indicated CCTA and the ICA with OCT will both take approximately 1 hour and will take place within 10 days. No additional imaging is needed as part of the study."
75554449|NCT06186323|Behavioral|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
75554450|NCT06186323|Behavioral|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales | Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years. Used to evaluate children's motor development with separate tests and rating scales for both gross motor skills and fine motor skills"
75713516|NCT00876759|Radiation|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
75713517|NCT01045291|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
75713518|NCT05167539|Procedure|Aortic valve surgery|mechanical aortic valve replacement versus ross procedure and stentless bioprothesis
75713519|NCT01047943|Drug|Topical application of STA-21 ointment for treatment of psoriasis|
75713520|NCT00547534|Drug|bortezomib|1.3 mg/m^2 on days 1, 4, 8, 11
75713521|NCT00547534|Drug|bendamustine|90 mg/m^2 days 1 and 4
75713522|NCT00547534|Drug|rituximab|375 mg/m^2 day 1
75713523|NCT00871455|Drug|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
75713524|NCT00962182|Drug|STAN1|3-4 capsules/day at meals
75713525|NCT00962182|Drug|Placebo enzyme|3-4 capsules/day at meals
75713526|NCT00962182|Drug|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
75554451|NCT06186323|Behavioral|Test Of Sensory Functions In Infants (TSFI)|his test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
75713527|NCT00871533|Drug|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
75554452|NCT06186310|Other|Aquatic Therapy Group|After the initial evaluations, patients will be given aquatic exercises including personalized strengthening, balance and breathing exercises accompanied by a physiotherapist 3 days a week for total 5 weeks. At the same time, the exercises taught as a home program will be asked to be repeated every day for 5 weeks.
75713528|NCT00871533|Drug|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
75713529|NCT00871533|Drug|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
75713530|NCT00871533|Drug|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
75713531|NCT05157022|Device|ESWT|Extracorporeal Shock-wave Therapy
75713532|NCT00962260|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
75713533|NCT00877149|Drug|telbivudine/LDT600|
75713534|NCT00877227|Drug|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
75713535|NCT05149846|Procedure|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
75713536|NCT00871767|Drug|AZD5672|40 mg tablet (Test formulation)
75713537|NCT00871767|Drug|AZD5672|40 mg tablet (Reference formulation)
75713538|NCT00871767|Drug|AZD5672|100 mg tablet (Test formulation)
75713539|NCT00871767|Drug|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
75713540|NCT05279248|Biological|HPV+MMR（0d），HPV（6m）|Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.
75409721|NCT02382588|Drug|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
75409722|NCT02382588|Drug|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
75409723|NCT02345460|Drug|Irinotecan Hydrochloride|Given IV
75409724|NCT02345460|Drug|Oxaliplatin|Given IV
75409725|NCT02345460|Drug|Leucovorin Calcium|Given IV
75409726|NCT02345460|Drug|Fluorouracil|Given IV
75409727|NCT02345460|Other|Laboratory Biomarker Analysis|Correlative studies
75409728|NCT02345772|Drug|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
75409729|NCT02345772|Drug|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
75409730|NCT02345772|Drug|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
75409731|NCT02345772|Drug|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
75409732|NCT02280252|Drug|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
75409733|NCT02280252|Radiation|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
75409734|NCT02266914|Device|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
75409735|NCT02262000|Radiation|Image Guided Stereotactic Ablative Radiotherapy|
75554453|NCT06186310|Other|Conventional Physical Therapy Group|After the initial evaluations, patients in the control group will be taught passive, active, actively assisted or resistant upper and lower extremity exercises as a home program, appropriate to each patient's functional level and muscle strength. Subjects will be asked to perform the exercises every day for 5 weeks, not exceeding an average of 45 minutes, 5 to 10 repetitions of each exercise, depending on fatigue.
75554454|NCT06186297|Dietary Supplement|Cranberry extract|polyphenol PAC-1
75554455|NCT06186232|Procedure|guided bone regeneration (GBR).|guided bone regeneration (GBR) using polymethylmethacrylate (PMMA) polymer as membrane.
75409736|NCT02248740|Procedure|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
75409737|NCT02242578|Device|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
75409738|NCT02242578|Device|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
75409739|NCT02133534|Drug|Atorvastatin|
75409740|NCT02009982|Procedure|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
75554456|NCT06186219|Drug|Rituximab|"Rituximab is a monoclonal antibody that targets cluster of differentiate 20 (CD20) present on B-cells and lowers humoral immunity. Rituximab has been used successfully as a desensitization agent to treat Highly Human Leukocyte Antigens (HLA)-sensitized patients planning renal transplant. All cases of antibody-mediated rejection were seen in the placebo group, none in the Rituximab group. Rituximab has been safely used with Methotrexate in the treatment of Rheumatoid Arthritis, where co-administration of Methotrexate and Rituximab results in better outcomes than either medication alone.~We propose this safety and feasibility open-label trial that will examine if Rituximab pre-treatment before Standard-of-Care Methotrexate-Pegloticase will result in recapture of Pegloticase efficacy as measured by serum urate (SU) < 6 mg/dL throughout the trial and up to 6-months of Methotrexate-Pegloticase administration."
75554457|NCT06186167|Procedure|Chest Wall Fat Tissue Collection|As part of routine cardiac device implantation, chest wall fat tissue is collected for histopathological analysis. This tissue, which is typically discarded, will be used to identify amyloid deposits in high-risk cardiac patients. No additional surgical intervention is performed beyond the standard procedure for device implantation.
75554458|NCT06185933|Drug|Lidocaine Spray|Pharyngeal anesthesia using a topical lidocaine spray was administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
75554459|NCT06185933|Drug|Lidocaine Viscous+Lidocane spray|Pharyngeal anesthesia using topical viscous lidocaine solution + lidocaine spray were administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
75554460|NCT06185894|Procedure|Uterovesical tourniquet before uterine devascularization steps|Insertion of a Foley catheter tourniquet through broad ligament apertures & tightening it immediately before hysterotomy in cases of conservative management of placenta accreta spectrum
75409741|NCT02009982|Device|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
75409742|NCT02013414|Device|3D ultrasound-guided biopsy|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
75554461|NCT06185894|Procedure|Conventional conservative surgery|Conventional conservative surgery
75554462|NCT06185647|Other|No intervention. Observational retrospective study|No intervention.
75554463|NCT06185439|Behavioral|Prenatal Pilates Assisted Childbirth Preparation Training|Training was given twice a week for two hours a day (one hour of theory, one An hour of exercise = 45 minutes of pregnant plates and 15 minutes of breathing exercises) total eight weeks.
75554464|NCT06185426|Drug|Methyprednisolon and low level laser theraphy|All rats will be anesthetized with ketamine hydrochloride at a dose of 50 mg/kg (i.p) (Ketalar ®, Eczacıbaşı Parke-Davis, İstanbul, Türkiye) and Xylazine HCl (Alfazyne ®, Alfasan International B.V. Woerden, Hollanda) at a dose of 10 mg/kg (intraperitoneal). A right postauricular incision will made under general anesthesia, and an external trunk of the facial nerve will be found. In the DCG and other experimental groups, the facial nerve was dissected, and it will be clamped with an average force of 150 g for about 1 minute. Afterward, the surgical area will be sutured in all rats in the DCG, L, S, and LSG groups. At the end of the 4 weeks of study, tissue samples will be taken from the facial nerve trunk in the control and experimental groups with a second surgical procedure preserved in formalin solution and sent for histopathological and biochemical examination.
75554465|NCT06185179|Drug|Metformin|Metformin will be distributed in 500mg pills.
75554466|NCT06185179|Other|Placebo|Placebo will be distributed in pill form
75554467|NCT06185140|Other|cardiac rehabilitation program|Cardiac rehabilitation program
75409743|NCT02015910|Drug|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
75409744|NCT02015910|Drug|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
75409745|NCT01996410|Device|Acupuncture|
75409746|NCT01980342|Drug|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
75409747|NCT01881984|Drug|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
75409748|NCT01878786|Drug|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
75409749|NCT01878786|Drug|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
76040722|NCT05521061|Dietary Supplement|2-fucosyllactose|Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
75409750|NCT01878786|Drug|Mycophenolate mofetil (MMF/MPA)|Control Drug
75409751|NCT01851174|Drug|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m^2) IV over 30 minutes after nab-paclitaxel infusion
75409752|NCT01851174|Drug|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m^2) IV over 30 minutes before Gemcitabine infusion
75409753|NCT01846182|Drug|Duloxetine|serotonin norepinephrine reuptake inhibitor
75409754|NCT01846182|Drug|Pregabalin|alpha-2-alpha subunit calcium channel ligand
75409755|NCT01846182|Drug|Placebo|Placebo
75409756|NCT01800162|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
75409757|NCT01800162|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
75409758|NCT01800162|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
75409759|NCT01794936|Device|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
75409760|NCT01756560|Drug|dexamethsone|
75409761|NCT01756560|Drug|Bupivacaine|
75409762|NCT01738698|Drug|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
75409763|NCT01738698|Drug|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
75409764|NCT01738698|Drug|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
75409765|NCT01738698|Drug|Placebo|Oral administration once-daily for 12 weeks
75409766|NCT01717482|Drug|Metformin|
75409767|NCT01717482|Other|Placebo Comparator|Standard of Care Observation
75409768|NCT01702896|Drug|Interleukin-2|Interleukin-2
75409769|NCT01682928|Drug|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs"
75409770|NCT01682928|Other|Hydrotherapy|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
75409771|NCT01683864|Drug|positive cytology with HIPEC|HIPEC with mytomycin and cisplatin
75409772|NCT01648296|Drug|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
75409773|NCT01608906|Drug|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
75409774|NCT01608906|Drug|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
75409775|NCT01602198|Drug|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
75409776|NCT01602198|Drug|Placebo transdermal patch|Placebo transdermal patch 1/day for 6 months
75409777|NCT01577628|Drug|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
75409778|NCT01550562|Device|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
75409779|NCT01545648|Drug|Denosumab|"Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
75409780|NCT01527942|Drug|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
75409781|NCT01527942|Drug|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
75409782|NCT01507584|Device|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
75409783|NCT01483872|Drug|NAC/Tigecycline/Heparin combination lock solution|
75409784|NCT01483872|Drug|Standard anticoagulant (Heparin or Citrate)|
75409785|NCT01385280|Biological|therapeutic estradiol|Given orally (PO)
75409786|NCT01385280|Drug|exemestane|Given PO
75409787|NCT01385280|Other|laboratory biomarker analysis|Correlative studies
75409788|NCT01385280|Other|enzyme-linked immunosorbent assay|Correlative studies
75409789|NCT01365156|Procedure|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
75409790|NCT01365156|Radiation|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
75409791|NCT01350258|Drug|Fludarabine|Part of the conditioning regimen
75409792|NCT01350258|Drug|Thiotepa|Part of the conditioning regimen
75409793|NCT01350258|Radiation|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
75409794|NCT01350258|Biological|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
75554468|NCT06185140|Other|TELEA platform|TELEA platform
75409795|NCT01350258|Drug|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
75409796|NCT01350258|Device|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
75409797|NCT01319760|Device|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
75409798|NCT01319760|Other|Standard of care (Control)|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
75409799|NCT01302444|Drug|Tadalafil|Tadalafil 40mg for 12 weeks
75409800|NCT01302444|Drug|Placebo|Placebo for 12 weeks
75409801|NCT01292070|Biological|Intradermal Human Fcγ1-Fel d1 fusion protein|"Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm."
75409802|NCT01292070|Biological|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
75409803|NCT01292070|Biological|Positive Control - Histamine Prick|1.0 mg/mL
75409804|NCT01292070|Biological|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
75409805|NCT01284504|Drug|Celecoxib|200 mg tablet oral
75409806|NCT01284504|Other|placebo|Placebo, tab
75713541|NCT05279248|Biological|HPV（0d），HPV（6m），MMR（7m）|Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.
75409807|NCT01204788|Procedure|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
76040723|NCT03046069|Other|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
76040724|NCT03046069|Other|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
75409808|NCT01204788|Procedure|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
75409809|NCT01183416|Drug|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are ~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
75409810|NCT01169610|Drug|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
76040725|NCT03046069|Other|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
75409811|NCT01166724|Drug|Sirolimus|Tacrolimus to Sirolimus
75409812|NCT01166724|Drug|Tacrolimus|dosage per trough level
76040726|NCT03046069|Other|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
75409813|NCT01151904|Drug|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
75409814|NCT01151904|Drug|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
75409815|NCT01110174|Diagnostic Test|HD PET/CT|imaging
75409816|NCT01115244|Drug|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
76040727|NCT03046069|Other|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
75409817|NCT01079598|Device|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
75409818|NCT01031550|Drug|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
75409819|NCT01031550|Drug|propofol|standard of care
75409820|NCT00986310|Drug|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
75409821|NCT00986310|Drug|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
75409822|NCT00907218|Drug|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
75409823|NCT00895284|Procedure|Robotic hysterectomy|Robotic hysterectomy.
75409824|NCT00895284|Procedure|Standard Hysterectomy|Standard hysterectomy.
76040728|NCT04864873|Diagnostic Test|Metagenomic next generation sequencing using Oxford Nanopore|See previous.
75554469|NCT06185010|Other|One Resistance Training Set (Single Session)|The participants will perform a resistance training session with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions at 55% 1RM in the chest press, iv) 1 set of 10 repetitions in the sit-to-stand exercise, v) 1 set of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
75554470|NCT06185010|Other|Three Resistance Training Sets (Single Session)|The participants will perform a resistance training session with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions at 55% 1RM in the chest press, iv) 3 sets of 10 repetitions in the sit-to-stand exercise, v) 3 sets of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
75554471|NCT06185010|Other|One Resistance Training Set (8 Weeks)|The participants will perform eight weeks of resistance training with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions between 40-60% 1RM in the chest press, iv) 1 set of 6-12 repetitions in the sit-to-stand exercise, v) 1 set of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
75713542|NCT05279248|Biological|MMR（0d），HPV（1m），HPV（7m）|Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).
75713543|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
75713544|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75713545|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75713546|NCT00877305|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
75713547|NCT00877305|Other|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
75713548|NCT04039659|Device|Negative-pressure wound therapy (PICO)|After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
75409825|NCT00903396|Drug|palonosetron hydrochloride|Given IV
75713549|NCT02715388|Device|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
75409826|NCT00903396|Other|placebo|Given IV
75409827|NCT00875394|Drug|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
75409828|NCT00875394|Drug|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
75409829|NCT00875394|Drug|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
75409830|NCT00875394|Drug|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
75713550|NCT05119894|Drug|Brexpiprazole LAI: Dose 1|Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1
75409831|NCT00832572|Drug|Ranolazine|Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
75409832|NCT00832572|Drug|Placebo|Placebo to match ranolazine administered twice a day for 6 weeks
75713551|NCT05119894|Drug|Brexpiprazole LAI: Dose 2|Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2
75713552|NCT05119894|Drug|Brexpiprazole LAI: Dose 3|Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3
75713553|NCT05119894|Drug|Brexpiprazole LAI: Dose 4|Cohort 4: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 4
75713554|NCT00877539|Drug|PF-03526299|Inhaled, two doses 4 hours apart
75713555|NCT00877539|Drug|Placebo|Inhaled, two doses 4 hours apart
75713556|NCT00877539|Drug|Fluticasone propionate|Inhaled
75713557|NCT04039737|Drug|Qingpeng Ointment|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
75872404|NCT04926454|Drug|Dexmedetomidine|"Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia"
75554472|NCT06185010|Other|Three Resistance Training Sets (8 Weeks)|The participants will perform eight weeks of resistance training with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions between 40-60% 1RM in the chest press, iv) 3 sets of 6-12 repetitions in the sit-to-stand exercise, v) 3 sets of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
75554473|NCT06185010|Other|Control (8 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
75713558|NCT00872157|Drug|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
75713559|NCT00872235|Drug|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
75713560|NCT00877617|Behavioral|QOL Questionnaire|Mailed survey.
75872405|NCT03196167|Drug|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
75872406|NCT03196167|Other|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
76040729|NCT04864873|Diagnostic Test|Standard microbiological diagnostic pathway|See previous.
76040730|NCT04864717|Drug|Doxycycline 100mg po once daily x 6 months|active intervention
76040731|NCT04864717|Drug|Isotretinoin 40 mg po once daily x 6 months|active intervention
76040732|NCT04876495|Dietary Supplement|Whey protein isolate|"Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the whey protein shake:~Tropicana Trop50 Orange Juice 207mL~Water 43 mL~Sucralose 0.5g~The total energy 233.47Kcal.~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
76040733|NCT04876495|Dietary Supplement|Potato protein isolate|"Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.~Other ingredients in the potato protein shake:~Tropicana Trop50 Orange Juice 250mL~Sucralose 0.5g~The total energy 233.46Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
75713561|NCT00877695|Behavioral|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
75713562|NCT00872391|Radiation|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
75713563|NCT00872469|Drug|Tranexamic acid|1-2 grams by intravenous injection
75713564|NCT00872469|Drug|Placebo [Saline]|Matched to active comparator
75713565|NCT00872547|Device|DePuy ASR™ Hip System|Resurfacing system
75713566|NCT00872547|Device|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
75872407|NCT03652376|Drug|Benralizumab|Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
75872408|NCT04875988|Procedure|Butterfly iQ+ Ultrasound|ultrasound will be used in the intervention group for IV access
75872409|NCT04875988|Procedure|Traditional|ultrasound will not be used in the traditional IV placement group
75872410|NCT03411863|Device|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
75409833|NCT00811590|Drug|Everolimus|"Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~directly on the tumor cells by inhibiting tumor cell growth and proliferation~indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells."
75409834|NCT00749658|Drug|Bupropion|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
75409835|NCT00749658|Drug|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
75409836|NCT00738972|Drug|valsartan|80 mg valsartan. Duration: 12 months. Tablets
75554474|NCT06184672|Other|dry needling|"the area is disinfected by the use of 0.5% chlorhexidine digluconate alcohol solution. The physiotherapist in charge of the intervention uses sterile nitrile gloves, using dry needling needles with dimensions of 0.30 x 50 mm is used. This technique, designed by Hong, applies speed both at the entrance, in order to provoke the local spasm response and at the exit. The inputs and outputs are performed until the REL disappears or until the tolerance threshold of the patient is reached.~Immediately after performing the puncture, ischemic compression is performed on the treated muscle, in order to decrease the duration and intensity of post-puncture pain. For this, a digital pressure is made to the point where the patient's sensation ceases to be pressure and becomes pain. Once the patient is noted that pain is repeated again the art up to a total of 2 minutes"
75554475|NCT06184542|Biological|DTacP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on Day 0
75554476|NCT06184542|Biological|DTacP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on the M3-M4-M5, M2-M3-M4, or M2-M4-M6 immunization schedule
75554477|NCT06184542|Biological|DT (one-dose booster)|Diphtheria-Tetanus Combined Vaccine of 0.5mL on Day 0
75554478|NCT06184542|Biological|DTaP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on Day 0
75872411|NCT03411863|Device|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
76023286|NCT04832009|Drug|Intralipid|Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
75409837|NCT00738972|Drug|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
75409838|NCT00738972|Drug|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
75409839|NCT00738972|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
75409840|NCT00726180|Drug|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
75409841|NCT00704496|Drug|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
75554479|NCT06184542|Biological|PENTAXIM (one-dose booster)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on Day 0
75554480|NCT06184542|Biological|DTaP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on an M3-M4-M5immunization schedule
75554481|NCT06184542|Biological|PENTAXIM (three-dose primary vaccination)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on the M3-M4-M5 or M2-M3-M4 immunization schedule
76023287|NCT04832009|Drug|Saline|Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
76023288|NCT04832009|Drug|Ascorbic acid|"(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant."
75409842|NCT00692094|Biological|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
75554482|NCT06184451|Other|Therapeutic exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
75409843|NCT00692094|Biological|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
75713567|NCT05225883|Genetic|GWAS|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
75713568|NCT00878007|Drug|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
76023289|NCT03115957|Other|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
76040734|NCT04876495|Dietary Supplement|Rice protein isolate|"Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the rice protein shake:~Tropicana Trop50 Orange Juice 183mL~Water 67mL~Sucralose 0.5g~The total energy 233.43Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
76040735|NCT04876261|Dietary Supplement|Oliphenolia® bitter|"ingredients: concentrated watery extract of olives 94%, lemon juice 6%~35 mg hydroxytyrosol, 0,24 mg Oleuropein"
76040736|NCT04876261|Dietary Supplement|Oliphenolia®|"ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~38 mg hydroxytyrosol, 0,28 mg Oleuropein"
75713569|NCT00878007|Behavioral|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness & vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
75713570|NCT00878007|Other|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
76040737|NCT04876261|Dietary Supplement|La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol|"extra virgin olive oil~5 mg hydroxytyrosol"
75713571|NCT00872625|Drug|cyclophosphamide|
75713572|NCT00872625|Drug|docetaxel|
75713573|NCT00872625|Drug|epirubicin hydrochloride|
75713574|NCT00872625|Drug|fluorouracil|
75713575|NCT00872625|Procedure|neoadjuvant therapy|
75713576|NCT00872625|Procedure|therapeutic conventional surgery|
75713577|NCT00872625|Radiation|hypofractionated radiation therapy|
75713578|NCT00872625|Radiation|image-guided radiation therapy|
75409844|NCT00692094|Biological|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
75409845|NCT00692094|Biological|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
75713579|NCT00872625|Radiation|radiation therapy|
75713580|NCT00872625|Radiation|stereotactic radiosurgery|
75713581|NCT00878085|Device|Robot Therapy Device|3x a week for 4 weeks
75713582|NCT00878085|Behavioral|Occupational Therapy|3x a week for 4 weeks
76023290|NCT03129113|Drug|Maraviroc|1:1:1:1 randomisation to one of four arms for 48 weeks
76023291|NCT03129113|Drug|Metformin|1:1:1:1 randomisation to one of four arms for 48 weeks
76023292|NCT03116035|Other|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
76023293|NCT03116035|Other|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
76040738|NCT05518097|Other|Conventional physical therapy program|Patients with knee osteoarthritis underwent a total of 15 sessions of conventional physical therapy program including hotpack, US, TENS, and exercise 5 days a week, for 3 weeks. Hot pack was applied for 10 minutes, ultrasound was applied continuously at 1 MHz, 1.0 W/cm2 for 10 minutes, and TENS was applied for 30 minutes according to the patient's tolerance. The exercise program consisted of an active, active-assisted range of motion and isometric quadriceps strength training.
75554483|NCT06184451|Device|Transcutaneous electrical nerve stimulation|"TENS will be applied with a portable device, Neurodyn Portable System from Ibramed, while carrying out the entire therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. The application time will be proportional to the time of the exercise session, approximately 60 minutes. The researcher will evaluate the need to adjust the current intensity through the pulse amplitude regularly so that the stimulus does not accommodate."
75554484|NCT06184451|Device|Placebo transcutaneous electrical nerve stimulation|"The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this."
75409846|NCT00676026|Drug|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
75409847|NCT00676026|Drug|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
75713583|NCT00878241|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
76040739|NCT05518019|Dietary Supplement|The Daily Supplement|"Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol"
75409848|NCT00676026|Drug|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
75409849|NCT00679926|Drug|Once daily|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
75409850|NCT00680316|Drug|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
75409851|NCT00680316|Drug|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
75409852|NCT00656916|Drug|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
75409853|NCT00629850|Device|Powerlung Performer|Inspiratory/Expiratory muscle trainer
75409854|NCT00619242|Drug|sorafenib|2 tablets with water by mouth twice a day for two weeks.
76040740|NCT02613871|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
75409855|NCT00601848|Drug|chemotherapy|
76040741|NCT05531747|Other|Skin biopsy|A maximum of 2 superficial skin biopsies (epidermis/dermis), allowing 10 hair follicles to be obtained, at the edge of the affected area, in healthy territory (excluding the face and folds but not excluding the pubic region), at initiation visit.
76040742|NCT05531747|Other|Blood sample|42mL of blood (6 tubes of 7mL) sampled at initiation visit
76040743|NCT04425161|Other|Fluid challenge (0.9 % NaCl)|500 ml Fluid challenge of (0.9 % NaCl) will be given
76040744|NCT04875949|Procedure|Immunoabsorption/plasmapheresis procedure|
75409856|NCT00601848|Drug|porfimer sodium|
75409857|NCT00601848|Other|immunohistochemistry staining method|
75409858|NCT00601848|Other|laboratory biomarker analysis|
75409859|NCT00601848|Procedure|spectroscopy|
75409860|NCT00601848|Procedure|therapeutic conventional surgery|
75409861|NCT00586716|Drug|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
75409862|NCT00571194|Drug|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study"
75409863|NCT00570258|Drug|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
75409864|NCT00570258|Drug|erlotinib|150 mg PO QD
75409865|NCT00570258|Drug|Fulvestrant|250 mg IM Q 4 weeks
75409866|NCT00570258|Drug|Placebo|Placebo 150 mg PO QD
75713584|NCT00878319|Procedure|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using dynamic compression plate
76040745|NCT05520671|Other|Gamified online quizzing platform|"TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days."
75409867|NCT00568698|Drug|Hydroxyurea|
75409868|NCT00568698|Drug|Placebo to match hydroxyurea|
75554485|NCT06184295|Device|TBI - Intervention Group|The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
75409869|NCT00577356|Drug|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
75409870|NCT00577356|Biological|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
75409871|NCT00569868|Drug|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
75554486|NCT06184282|Drug|MEBO|MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
75554487|NCT06184282|Drug|Lidocaine|Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
75554488|NCT06184217|Other|Experimental group (MSPE programme group).|Experimental group. MSPE Programme. This group will receive a face-to-face mindfulness MSPE programme for 6 weeks, once a week for 1h 50min-2 hours. In addition to doing mindfulness activities at home. Each session contains the following exercises: (1) intention meditation, sultana exercise, diaphragmatic breathing and sitting meditation with a focus on breath, body and sound; (2) diaphragmatic breathing, Body Scan; (3) sitting meditation, dynamics of emotions, Mindful Yoga on the floor; (4) letting go of attachments, mindful Yoga on the floor walking meditation; (5) sports meditation, sitting meditation with a focus on breath, body and sound; (6) intention meditation, body scan analysis and review of sports meditation.
75554489|NCT06184217|Other|Control group (relaxation group).|These instructions included a combination of tension-relaxation of specific muscles and simple breathing techniques. They were recommended to do this on a daily basis, with a minimum of 4 sessions per week.
75713585|NCT00878319|Other|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
75409872|NCT05599854|Procedure|vitrectomy and silicone oil injection|Parsplana vitrectomy and silicone oil injection
75409873|NCT05599542|Other|Solution-oriented approach|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order. The Eliciting, Amplifying, Reinforcing and Start Over technique reminds the counselor of the basic concepts of solution-oriented approach and its explanation is as follows;
75409874|NCT05599542|Other|Hypno-breastfeeding|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
75409875|NCT05599230|Drug|Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening|Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
75554490|NCT06184204|Drug|Trombix® (Rivaroxaban)|20mg or 15 mg as per the doctor's prescription
75554491|NCT06184152|Diagnostic Test|CEUS vs aMRI|Comparison between CEUS and aMRI
75713586|NCT00872781|Drug|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
75713587|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
75713588|NCT00384085|Drug|Insulin Glargine|Subcutaneous injection once-a-day
75713589|NCT00384085|Drug|Premixed Insulin|Subcutaneous injection twice-a-day.
75713590|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
75713591|NCT00878397|Device|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
75713592|NCT00872859|Procedure|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
75409876|NCT05573256|Behavioral|Lavender oil inhalation|Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.
75409877|NCT05573256|Behavioral|Sleep hygiene education|Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.
76040746|NCT05520671|Other|Conventional quizzing platform|"The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days."
75409878|NCT05533476|Behavioral|Multi Sensory Stimulation and Priming|In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
75409879|NCT05533476|Behavioral|Intensive Usual Care (Upper Limb)|The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
75409880|NCT05403762|Other|ESENTA™ Skin Barrier Spray (ConvaTec, UK)|The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.
75409881|NCT05403762|Other|Hydrophobes Basisgel DAC|The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.
75409882|NCT05381376|Diagnostic Test|Hysteroscopy|Hysteroscopy for CSGE, AFS, and endometrial receptivity assessment
75409883|NCT05381376|Diagnostic Test|Ultrasonography|Ultrasonography for Uterus size and endometrial thickness
75409884|NCT05330442|Behavioral|Written Exposure Therapy (WET)|The WET protocol for primary care settings consists of six, 30-minute sessions. The first session consists of psychoeducation of PTSD and treatment rationale. Written narratives are conducted in sessions 2-6, following specific writing instructions and 20 minutes of writing in each session.
75713593|NCT00361231|Drug|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
75554492|NCT06184113|Procedure|Aortic valve replacement surgery|Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.
75554493|NCT06184113|Diagnostic Test|Computed tomography|All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.
75554494|NCT06184113|Diagnostic Test|Echocardiography|All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.
75554495|NCT06184061|Combination Product|Herbal Supplement|Herbal supplement will be the mixture of strawberry, black mulberry, blueberry, raspberry, ginseng, ashwagandha, honey, water
75554496|NCT06183619|Procedure|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
75554497|NCT06183619|Procedure|Pulmonary vein isolation|Pulmonary vein isolation only
75409885|NCT05288946|Other|local segmental control and closed kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then closed kinetic chain exercise in the form of Stand-up position on unstable surface, Closed chain lunge exercises, with the addition of hand weights, Bridge in prone position, Bridge in supine position, Lateral Bridge
75554498|NCT06183177|Other|Whole-Body Vibration|10 minutes of whole-body vibration when performing semi-squatting or forward lunges (12-16 Hz, varying intensity from low to high depending on patients' tolerance
75409886|NCT05288946|Other|local segmental control and open kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then open kinetic chain in the form of Lower limb abduction, Knee extension in a supine position on a roller, Open chain exercise of the upper limb after co-contraction of transversus abdominis and multifidus.
75409887|NCT05288946|Other|traditional therapy|the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
75409888|NCT05164614|Combination Product|RT-102 (80 μg)|RaniPill capsule containing PTH with doses of 20 and 80 μg
75409889|NCT05164614|Drug|Forteo|A commercial formulation of PTH for SC control (20 µg)
75409890|NCT05164614|Combination Product|RT-102 (20 μg)|RaniPill capsule containing PTH with dose of 20μg
75554499|NCT06183177|Other|Exercise|Four to five sessions of a physiotherapist-led exercise program with education talk (20 minutes), group exercises (30 minutes) and individual exercises (30 minutes) per week supplemented with home exercises
75409891|NCT05001048|Drug|Phenylephrine Hydrochloride|Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.
75409892|NCT05001048|Other|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
75554500|NCT06183138|Genetic|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
75554501|NCT06182306|Procedure|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
75554502|NCT06182267|Drug|L Arginine|toothpaste
75554503|NCT06182267|Drug|Sodium Fluoride|toothpaste
75554504|NCT06181825|Behavioral|COMET-BA (Common Elements Toolbox- Behavioral Activation)|COMET-BA includes 4 online weekly modules which focus on elements of behavioral activation, including positive activity scheduling, avoidance reduction, values, and change plans.
75554505|NCT06180824|Drug|Gelafundin|"Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment."
75554506|NCT06180694|Other|Reminiscence therapy|In the research, reminiscence therapies will be carried out once a week for 8 weeks, in sessions of approximately 45 minutes.
75554507|NCT06180499|Drug|T-reg depleted DLI|Treg depleted Donor Lymphocytes Infusion
76023294|NCT05105165|Diagnostic Test|Enzyme linked immunosorbent assay|Determination of serum β 1-aa content
76023295|NCT03170635|Behavioral|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
76023296|NCT05110547|Biological|blood collection|2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.
75409893|NCT05001048|Other|Isocapnic Acute Hypoxia|During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.
75409894|NCT05001048|Other|Hyperoxia|During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.
75409895|NCT04954638|Other|endodontic desinfection|"outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~using microbiological methods~outcome assessed by radiological method and clinical evaluation"
75409896|NCT04906200|Other|Best Practice|Receive usual care
75409897|NCT04906200|Other|Internet-Based Intervention|Receive access to YES portal
75409898|NCT04906200|Other|Survey Administration|Complete survey
75409899|NCT04848870|Other|Salivary samples|collection of salivary samples from Sjögren patients on routine care in the oral medicine department.NA
75409900|NCT04810572|Dietary Supplement|Composition with Silymarin|"Volunteers will receive supplementation for 90 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30 and 90 days from the beginning of supplementation."
75409901|NCT04810572|Dietary Supplement|Low-mineral composition without Silymarin|"Volunteers will receive supplementation for 90 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30 and 90 days from the beginning of supplementation."
75409902|NCT04772742|Drug|Placebo|Placebo - solution for infusion
75409903|NCT04772742|Drug|Eptinezumab|Eptinezumab - 100 mg, solution for infusion
75409904|NCT04702386|Behavioral|Focus groups|Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF
75554508|NCT06180486|Other|Mindfulness Meditation Intervention|The mindfulness intervention is a scripted, ~12min audio recording based on core tenets of mindfulness meditation and contextualized for patients undergoing total knee arthroplasty. It teaches sustained attention on the present, body awareness, acceptance of the body's current state, and transformational strategies to cope with emotional or physical stimuli as they arise. It has been created by the study team based on the teachings of Jon Kabat Zinn (founder of mindfulness meditation) and the PI's history teaching yoga and meditation. Patients will be encouraged to review the audio recording once a week.
75713594|NCT00361231|Drug|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
75713595|NCT00361231|Drug|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
75554510|NCT06180330|Other|Aquatic baby class|The intervention will consist of exercises for infants. They will be in the water together with parents
75554511|NCT06180161|Behavioral|multidomain intervention|"Integrating exercise cognitive training with nutrition, chronic disease management, oral health, fall prevention, traffic safety, psychosocial well-being, and sleep to enhance the effectiveness of improving cognitive function in the elderly community."
76023297|NCT02397577|Other|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
76040747|NCT04869709|Drug|Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
76040748|NCT05021081|Device|TRP-200|JJVC Investigational Contact Lens
76040749|NCT05021081|Device|ACUVUE Oasys 1-Day|JJVC Marketed Contact Lens
75409905|NCT04702386|Behavioral|Individual interviews|Interview led by the psychologist about being the child of a parent with CF
75409906|NCT04575090|Drug|Simvastatin|Simvastatin 40 mg daily.
75409907|NCT04302948|Other|HCV RNA screening|The Cepheid Xpert testing requires a fingerstick to obtain blood spots which are then tested for HCV RNA. Results available within one to two hours, facilitating counseling for patients to link to care.
75554512|NCT06179082|Combination Product|Botox then threads|patients in which Botox injection then threads insertion were used
75554513|NCT06179082|Procedure|threads only|patients in which threads insertion only was used
75554514|NCT06179030|Diagnostic Test|serum samples|The serum samples were taken from the patients at the 3rd month (switch point)
75554515|NCT06179030|Drug|dexamethasone implant versus ranibizumab|dexamethasone implant versus ranibizumab will be studied as a secondary outcome
76023298|NCT05105009|Drug|Furosemide|"Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~Oral creatinine load using 5 grams of creatinine"
76023299|NCT03168529|Drug|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
75554516|NCT06178614|Drug|JNJ-87890387|JNJ-87890387 will be administered.
75554517|NCT06178367|Drug|Low molecular weight hyaluronic acid|Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle
75554518|NCT06178367|Drug|High molecular weight hyaluronic acid|Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle
75554519|NCT06178367|Drug|Vehicle|Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
75554520|NCT06177977|Device|SS-HH-OCT|The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University. OCT systems are non-contact, in-vivo optical imaging technology. The OCT system creates real-time, non-invasive images of ocular microstructure. OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image. These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information. Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
75554521|NCT06177652|Other|Paravertebral Block|Ultrasound (US) -guided paravertebral block (PVB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the PVB group.
75554522|NCT06177652|Other|Serratus Plane Block|Ultrasound (US) -guided serratus plane block (SPB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the SPB group.
75713596|NCT01050361|Procedure|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
75713597|NCT01048021|Procedure|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
75713598|NCT01050439|Procedure|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
75713599|NCT01050439|Other|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
75713600|NCT00676650|Drug|Prednisone|5 mg BID, oral
75872412|NCT04262726|Behavioral|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and monitoring/modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as an add-on to treatment as usual (TAU), which is psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
75409908|NCT04234152|Other|Photo-protection|The MV solution is delivered from producing companies in amber vials. The MV will be sampled by the pharmacy technician in a syringe that is photo-protected with a white label indicating the subject study name, protocol number and the infusion rate. The MV will be transported to the unit in the same photo-protected syringe. In the neonatal unit, this syringe will be installed in the pump and connected to photo-protected extension duration.
75409909|NCT04234152|Other|Standard Care|This group will receive the standard practice of PN compounding in the pharmacy followed by infusion in standard infusion kit available in Sainte-Justine's Hospital.
75409910|NCT04100772|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular other name:PCV13i
75409911|NCT04100772|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular other name:Prevnar
75409912|NCT04012008|Other|Comprehensive care|"Regular follow-up by nephrologists every 1-3 month~Multidisciplinary team consisting pharmacists, nurses, and dieticians"
75409913|NCT04012008|Other|Standard care|"Regular follow-up by internists every 3 month~May consult nephrologists case-by-case"
75409914|NCT03472872|Drug|Ketorolac|15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
75409915|NCT03472872|Drug|Acetaminophen|1,000mg acetaminophen IVPB
75409916|NCT02836470|Drug|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
75409917|NCT02836470|Drug|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
75409918|NCT02808702|Behavioral|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
75409919|NCT02411526|Drug|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
75409920|NCT02411526|Drug|Risperdal Consta|Risperdal Consta administered as a IM injection
75409921|NCT02411526|Drug|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
75409922|NCT02400060|Behavioral|Telephone-Based Intervention|Receive text messaging
75409923|NCT02400060|Other|Survey Administration|Ancillary studies
75409924|NCT02400060|Other|Laboratory Biomarker Analysis|Correlative studies
75713601|NCT00676650|Drug|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
75713602|NCT00676650|Drug|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
75713603|NCT00676650|Drug|Prednisone|5 mg BID, oral
75872413|NCT04262726|Behavioral|TAU|Treatment as usual (TAU) refers to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern. Psychotherapy at the outpatient clinic is based on Psychological Therapy (Grawe, 1998) principles, which are largely rooted in academic psychology and which mainly draw on interventions from Cognitive Behavior Therapy. Individual case conceptualization are key in Psychological Therapy, along with general therapeutic factors and a focus on the therapeutic relationship.
75872414|NCT03719027|Diagnostic Test|Study population|Dyspnea assessment (NYHA functional class) EKG Echocardiography
75713604|NCT01045369|Drug|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
75409925|NCT00564876|Drug|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
75409926|NCT00558870|Drug|Morphine|"Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
75409927|NCT00558870|Drug|Methadone|"1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain."
76040750|NCT04864327|Behavioral|Brief smoking cessation advise|The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
75554525|NCT06175962|Behavioral|TRAINING AND EXERCISE|"Menopause health training will take place in 2 sessions each week and will be completed in 4 sessions. Each session duration is 45 minutes. Baduanjin exercise training will take place in 2 sessions per week, each session lasting 30 minutes. It will be completed in 8 sessions in total. Relaxing music will be played during the Baduanjin exercise and relaxation will be encouraged. During the Baduanjin exercise, proper posture, conscious breathing and focus of the mind will be prioritized. While the movements are being implemented, their symbolic meanings will be explained to the participants. Women will be asked to perform baduanji 3 times a week for 8 weeks.~During this process, reminder messages will be sent to women via WhatsApp."
75554526|NCT06174402|Drug|Fenofibrate|Fenofibrate 200 mg/day
75409928|NCT00548886|Drug|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
75409929|NCT00538980|Drug|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
75409930|NCT00529464|Procedure|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
75409931|NCT00529464|Procedure|Colposcopy|A standard colposcopy will be performed.
75409932|NCT00529464|Procedure|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
75409933|NCT00519090|Drug|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
75409934|NCT00519090|Drug|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
75554527|NCT06174402|Drug|Placebo|1 tablet/ day
75554528|NCT06174402|Drug|UDCA|UDCA 13-15mg/kg/day
75713605|NCT00573183|Behavioral|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
75713606|NCT00573183|Behavioral|Treatment as Usual|
75713607|NCT00615459|Drug|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
75713608|NCT00615459|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
75713609|NCT00615459|Drug|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
75713610|NCT04048902|Device|Pilates and Shortwave placebo|Pilates exercises and application of the device without produce thermal effects
75713611|NCT04048902|Device|Pilates and Shortwave active|Pilates exercises and application of the device producing thermal effects
75872415|NCT04256876|Device|TTNS|See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
75872416|NCT04256876|Device|TTNS Sham|See section 'arms'
75409935|NCT00506064|Drug|Melatonin|0.15 mg/kg by mouth (PO) Daily
75409936|NCT00506064|Drug|Placebo|Two, three, or four starch tablet or capsules before bed
75409937|NCT00506064|Behavioral|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
75554529|NCT06172413|Device|transcranial alternating current stimulation (tACS)|"Three conductive electrodes will be applied to the scalp: one 4.45 × 9.53 cm electrode placed over the forehead (Fpz, Fp1, and Fp2 in the 10/20 international placement system) and two 3.18 × 3.81 cm electrodes over the mastoid areas.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~Each subject will receive 40 sessions of tACS intervention during 4 consecutive weeks at a fixed day time twice per day (once in morning and afternoon, respectively) from Monday through Friday. Each session lasts 40 min."
75554530|NCT06172413|Device|Sham tACS|Sham tACS
75554531|NCT06171945|Behavioral|AYA Connect intervention|Participants will receive a smart scale, activity tracker, an individual kickoff videochat session with a health coach, and access to a mobile smartphone app that includes weekly behavioral lessons, dietary tracking log, daily weight-related behavioral goals, tailored feedback summaries, and in-app health-related messages.
75554532|NCT06171945|Behavioral|Positive Psychology (PP) intervention|Participants will receive lessons about positive psychology (PP) strategies, weekly goals for PP exercises, and in-app health-related messages that include reminders to practice PP exercises.
75554533|NCT06171945|Behavioral|Positive Psychology Plus (PP+) intervention|Participants will receive weekly individual videochat sessions with a health coach.
75554534|NCT06171854|Drug|Cabozantinib|cabozantinib in patients with refractory mCRC
75713612|NCT03839511|Procedure|Hyperinsulinemic-hypoglycemic clamp|Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.
75872417|NCT04808284|Device|Transcranial direct-current stimulation|A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
75409938|NCT00475332|Drug|Iodine I -01 Tositumomab (Bexxar)|"Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed dosimetric dose, involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm^3) total body radiation dose can be calculated."
75554535|NCT06168539|Other|Emboless|Emboless has the US patent number 8894749 is compared to standard dialysis See also reference Jonsson et al 2023 referred to in the main text.
75554536|NCT06168539|Other|Standard|Standard dialysis set is used as comparative
75554537|NCT06168383|Drug|HSK31679 80mg|once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
75554538|NCT06168383|Drug|HSK31679 160mg|once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
75554539|NCT06168383|Drug|Placebo|once daily, oral administration of placebo from Day 1 to Week 52.
75713613|NCT03876366|Other|online survey|Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP.
75872418|NCT04808284|Device|Transcranial direct-current stimulation|A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
76023300|NCT03168529|Drug|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
76023301|NCT03115879|Other|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
75409939|NCT00475332|Procedure|External Beam Radiation Therapy|All patients are to receive 20 Gy in 10 fractions of 200 cGy to the PTV
75409940|NCT00478062|Biological|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
75409941|NCT00478062|Procedure|adjuvant therapy|
75409942|NCT00470574|Biological|QS21|
75409943|NCT00470574|Biological|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
75409944|NCT00470574|Other|immunoenzyme technique|
75409945|NCT00470574|Other|immunologic technique|
75409946|NCT00470574|Other|laboratory biomarker analysis|
75409947|NCT03053700|Drug|Bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
75554540|NCT06168019|Other|Exposures|COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn
75409948|NCT03053700|Device|Intense Pulsed Light (M22)|Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
75409949|NCT00442260|Drug|DOXIL|
75409950|NCT00442260|Drug|Abraxane|
75554541|NCT06166485|Other|take a bath|The effects of two different bathtub bath methods on physiological parameters will be compared in babies divided into 2 different groups.
75554542|NCT06166225|Behavioral|Internet-based weight loss program|12-month, automated and behaviorally-based, Internet-delivered weight loss and weight loss maintenance program
75713614|NCT03876366|Other|focus group meeting|Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine.
75713615|NCT00383149|Drug|Ixabepilone|Intravenous Infusion (IV), 32 mg/m^2 every 21 days.
75713616|NCT00383149|Drug|Cetuximab|Initial dose of 400 mg/m^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m^2 IV over 1 hour.
75713617|NCT03364296|Other|Blood Samples|Blood sample retrieved for biological assessment and biobanking
76023302|NCT03115879|Other|Hip manipulation simulation|Hip manipulation simulation
76023303|NCT05104931|Drug|Nanoformed Piroxicam IR Tablet|Orally delivered Nanoformed Piroxicam
75409951|NCT00386724|Device|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
75409952|NCT00386724|Device|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
75409953|NCT00325572|Drug|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
75409954|NCT00325572|Other|oral Placebo|Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
75409955|NCT00333762|Device|Smart Power Assistance Module (SPAM)|Experimental Power wheelchair utilized to traverse prescribed course
75409956|NCT00333762|Device|Smart Wheelchair Component System (SWCS)|Experimental power wheelchair utilized to traverse prescribed course
75409957|NCT00145704|Drug|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
75554543|NCT06166225|Behavioral|Yoga|9-month Iyengar yoga program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12, and self-guided yoga practice recommendations.
75554544|NCT06166225|Behavioral|Health and Wellness|9-month health and wellness program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12.
75713618|NCT00878631|Drug|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
75554545|NCT06165900|Drug|adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.
75554546|NCT06165900|Drug|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
75554547|NCT06165575|Device|Press needle|Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.
75554548|NCT06165575|Device|Sham press needle|Sham press needle is a surgical adhesive patch placed on acupuncture points
75554549|NCT06165471|Behavioral|Online and offline blended teaching|The Chaoxing app is an interventional tool, a professional mobile learning platform for smartphones, tablet computers, and other mobile terminals. They will learn the online course on the Chaoxing app and carry out offline classroom learning. The online courses focus on teaching design to make teaching PowerPoint, teaching videos, micro-lessons, homework library, and so on.
75554550|NCT06165471|Behavioral|Traditional teaching|The researchers will implement the traditional teaching intervention of a surgical nursing practice course to the control group, and the teacher will demonstrate the operation procedure to the students face to face offline, and the students will practice. The whole intervention time is two months.
75713619|NCT00878631|Drug|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
75409958|NCT00145704|Dietary Supplement|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
75554551|NCT06163287|Dietary Supplement|Supplement|Dietary supplement containing molecular hydrogen
75554552|NCT06163287|Dietary Supplement|Placebo|Inert substance
75713620|NCT00921960|Other|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
75713621|NCT00878787|Device|Transcranial magnetic stimulation|
75713622|NCT00382993|Drug|Placebo|Matching placebo tablet
76023304|NCT05104931|Drug|Felden (piroxicam) Tablets|orally delivered Felden (reference) tablets
76023305|NCT05104931|Drug|Brexidol (piroxicam) Tablets|orally delivered Brexidol (reference) tablets
75554553|NCT06161805|Drug|Esketamine hydrochloride|Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour). This dosage regimen is similar to that used earlier by Sigtermans et al. [1].
75554554|NCT06161805|Drug|Placebo|8 hour infusion with saline (NaCl 0.9%)
75554555|NCT06161012|Device|Senofilcon A contact lenses (TEST)|Rotationally stabilized astigmatic soft contact lenses in senofilcon A containing a chromophore to filter High-Energy Visible Light (HEVL)
75554556|NCT06161012|Device|Delefilcon A contact lenses (CONTROL)|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
75713623|NCT00382993|Drug|Combination Product (sumatriptan succinate/naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
75554557|NCT06160895|Drug|TQ-A3334 tablets|TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
75554558|NCT06160895|Drug|TQ-A3334 placebo tablets|TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
75554559|NCT06157177|Drug|Metaxalone 640 mg Oral Tablet|Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.
75554560|NCT06156644|Device|PFA|Ablation to treat trail fibrillation
75713624|NCT04585464|Drug|EDG-5506|EDG-5506 is administered orally as a single dose or once daily
75872419|NCT04808284|Device|Sham Transcranial direct-current stimulation|A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
75554561|NCT06154278|Drug|Imdusiran (AB-729)|60mg subcutaneously, every 8 weeks, for a total of 4 doses
75554562|NCT06153537|Drug|Insulin degludec|Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
75554563|NCT06153264|Other|neurodynamic mobilization exercise|Upper extremity neurodynamic mobilization exercises and upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
75713625|NCT04585464|Drug|Placebo|Placebo is administered orally as a single dose or once daily
75409959|NCT00145704|Dietary Supplement|Calcium|calcium supplement given to patients with growth hormone deficiency
75409960|NCT00108342|Drug|Nicotine gum - 2 mg and 4 mg|
75409961|NCT00108342|Drug|Nicotine lozenges - 2 mg and 4 mg|
75409962|NCT00108342|Drug|"Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing"|can yield 4 mg from 10 mg device - infrequent and frequent puffing
75409963|NCT00108342|Other|Computer learning|
75409964|NCT00090870|Biological|PEG-interferon alfa-2b|Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
75409965|NCT00090870|Biological|GM-CSF|GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
75409966|NCT00090870|Drug|thalidomide|200mg daily by mouth
75554564|NCT06153264|Other|strengthening exercises|upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks
75554565|NCT06152328|Other|Virtual reality applications based on mirror therapy|Mirror therapy-based games will be played for 30 minutes every day for eight weeks, three days a week, for the VR group.
75554566|NCT06152328|Other|Conventional treatment|Bobath therapy, walking exercises, upper extremity active exercises, and proprioceptive neuromuscular facilitation techniques will be applied three days a week for eight weeks.
75554567|NCT06152328|Other|Mirror therapy|In conventional mirror therapy, the unaffected extremities of the individuals will be positioned outside the mirror, while the affected extremities will be placed inside the mirror so that the patient cannot see them. In this way, the image of the intact hand will be transferred to the affected side and activities will be performed three days a week for eight weeks.
75554568|NCT06152328|Other|Placebo virtual reality|For 8 weeks, watching the uninteractive virtual environment for 10 minutes
75409967|NCT00074724|Procedure|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
75409968|NCT00074724|Drug|Modern medical management|Therapies with evidence-based recommendations.
75409969|NCT00074724|Device|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
75409970|NCT00074724|Drug|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
75554569|NCT06151717|Other|Non-Interventional Study|Non-interventional study
75554570|NCT06150144|Drug|5-Fluorouracil|The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.
75554571|NCT06150144|Other|SURGERY|Total excision of the lesion
75713626|NCT00873405|Procedure|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
75554572|NCT06148337|Dietary Supplement|unhydrolyzed eggshell membrane|an unhydrolyzed, minimally processed chicken eggshell membrane powder.
75554573|NCT06148337|Dietary Supplement|Placebo|psyllium husk fiber powder
75713627|NCT00873405|Procedure|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
75554574|NCT06147336|Device|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, fixated within the inter-atrial septum.
75554575|NCT06146088|Biological|EV71 Vaccine|Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
75713628|NCT04049682|Behavioral|Delayed School Start Time|Francis Parker High School implemented 45-minute later school start time.
75872420|NCT05197803|Device|Hearing aid model|Amplification
75872421|NCT04054700|Device|distal upper rehabilitation robot|Intervention with distal upper rehabilitation robot
75872422|NCT04054700|Device|proximal upper rehabilitation robot|Intervention with proximal upper rehabilitation robot
75409971|NCT00058188|Dietary Supplement|cholecalciferol|Given orally
75409972|NCT00058188|Drug|calcium gluconate|Given orally
75409973|NCT00058188|Drug|zoledronic acid|Given IV
75409974|NCT00003726|Biological|lepirudin|lepirudin
75409975|NCT02595996|Drug|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
75409976|NCT03198156|Device|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
75409977|NCT03198156|Device|Sham stimulation|Sham stimulation
75409978|NCT04422210|Drug|Venetoclax|Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
75554576|NCT06145906|Procedure|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
75872423|NCT05387044|Radiation|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
75872424|NCT03142828|Drug|Chlorhexidine|Healing abutment with Clorhexidine
75872425|NCT03142828|Other|Placebo|Healing abutment without any antiseptic
76023306|NCT02397499|Drug|LIPO-202|
76023307|NCT02397499|Drug|Placebo|
76023308|NCT02847689|Behavioral|Language Treatment|Recording of a mother's voice reading a children's storybook.
76023309|NCT02847689|Behavioral|Control Treatment|Standard of Care
76023310|NCT02406703|Drug|Chloroprocaine|
76023311|NCT02406703|Drug|Mepivacaine|
76023312|NCT02682641|Drug|IBRUTINIB|Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
76023313|NCT02682641|Drug|Rituximab|Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
76040751|NCT05520515|Other|Aquatic Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention is performed at the thermal pool sector of Clube Brilhante in Pelotas city. The pool water temperature is maintained between 30-32°C, with participants immersed in the depth level between the xiphoid process and shoulders. The aquatic training group performs the following water aerobics exercises: stationary running, frontal kick, cross-country skiing, and butt kick during the stimulus and jumping jacks during the active recovery. The training session is collective, with 3 to 6 participants, supervised by two experienced instructors, one outside and one inside the pool. The group also receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
75409979|NCT04422210|Drug|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
75554577|NCT06145906|Procedure|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
75554578|NCT06144762|Biological|Biological/Vaccine: Blood sample and tissue sample|"During the surgery :~Tissus sample : primary tumor and metastasis blood sample : 3 EDTA tubes ex vivo MRI data"
75554579|NCT06144385|Biological|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204 . During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injection.
76040752|NCT05520515|Other|Land Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention occurs at the School of Physical Education, Federal University of Pelotas. Depending on weather conditions, the land training group will perform aerobic training with walking/running exercises in a flat outdoor environment or inside a multi-sport gym. The training session will be collective, with 3 to 6 participants, supervised by two experienced instructors, one at the starting point and the other following the movement of the participants. In addition, the group receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
75554580|NCT06144099|Biological|fresh frozen plasma|transfusion of fresh frozen plasma
75554581|NCT06144099|Biological|prothrombin complex concentrate|prothrombin complex concentrate administration
75554582|NCT06143436|Diagnostic Test|Constitution in Chinese Medicine Questionnaire|Using questionnaire to collect data from new lung cancer patients.
75713629|NCT00760968|Drug|TAK-783 and methotrexate|TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
75713630|NCT00760968|Drug|Methotrexate|TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
75713631|NCT00369967|Drug|NuvaRing|Initiation of NuvaRing for contraception
75713632|NCT00878865|Drug|Alprazolam|1 mg tablet one oral dose
75409980|NCT04422210|Drug|Carboplatin|Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
75409981|NCT04422210|Drug|Etoposide|Etoposide will be administered via IV infusion at a dose of 100mg/m^2 as per the dosing schedules described above.
75409982|NCT00000108|Behavioral|Exercise|
75409983|NCT00000126|Procedure|Surgery|
75409984|NCT00000132|Drug|Betaxolol|
75409985|NCT00000132|Procedure|Argon Laser Trabeculoplasty|
75409986|NCT00000138|Drug|Prednisolone Phosphate|
75409987|NCT00000138|Drug|Acyclovir|
75409988|NCT00000162|Procedure|Macular Argon Laser Photocoagulation|
75409989|NCT00000162|Procedure|Peripheral Scatter Argon Laser Photocoagulation|
75409990|NCT00000162|Procedure|Scatter Argon Laser Photocoagulation|
75409991|NCT00000174|Drug|Rivastigmine|
75409992|NCT00000192|Drug|Lamotrigine|
75409993|NCT00000198|Drug|Piracetam|
75409994|NCT00000204|Drug|Buprenorphine|
75409995|NCT00000210|Drug|Buprenorphine|
75409996|NCT00000222|Drug|Buprenorphine|
75409997|NCT00000228|Drug|Buprenorphine|
75409998|NCT00000234|Drug|Buprenorphine|
75713633|NCT00878865|Drug|Alprazolam|1 mg tablet
75713634|NCT00873483|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 3 cycles
75713635|NCT01050517|Drug|albendazole + ivermectin + praziquantel|albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
75713636|NCT01050517|Drug|albendazole + ivermectin + (1 week later) praziquantel|albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
75554583|NCT06143020|Procedure|Erector spinae plane block|In the ESPB group, the patients were placed in the lateral decubitus position. The ultrasound probe was located in longitudinal orientation at the level of the T4 spinous process and then placed 3 cm laterally from the midline to the side involved in the surgery. The ultrasound landmarks, T4 transverse process, and the overlying trapezius, rhomboideus, and erector spinae muscles, were identified. Under aseptic conditions, an 80-mm 21-gauge block needle was inserted in-plane at an angle of 30-40° in the cranial-to-caudal direction until the tip contacted the T4 transverse process.After the hydrodissection with 2-3 mL of isotonic saline solution confirmed the correct needle tip position, the intermixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Local anesthetic spread in a fascial longitudinal pattern deep to the erector spinae muscle was visualized using ultrasound guidance.
75713637|NCT02534467|Drug|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
75713638|NCT01050595|Drug|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance <30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
75409999|NCT00000240|Drug|Buprenorphine|
75410000|NCT00000246|Drug|Flumazenil|
75410001|NCT00000264|Drug|30% Nitrous oxide|
75713639|NCT01050595|Drug|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
75713640|NCT00616629|Drug|AZD1305|Intravenous infusion
75872426|NCT01372839|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
75872427|NCT01372839|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
76023314|NCT02397031|Behavioral|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
76023315|NCT02397031|Behavioral|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
76023316|NCT05110469|Drug|Magnesium sulfate|"IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
75410002|NCT00000264|Other|0.35 g/Kg ethanol|
75410003|NCT00000264|Other|0.7 g/Kg ethanol|
76023317|NCT05110469|Drug|Meperidine|"IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
75410004|NCT00000264|Other|0 g/Kg ethanol|
75410005|NCT00000270|Drug|Cocaine|
75410006|NCT00000276|Drug|Bupropion|
75410007|NCT00000282|Drug|Pemoline|
75410008|NCT00000288|Drug|Cotinine fumarate|
75410009|NCT00000294|Drug|Carvedilol|
75410010|NCT00000300|Drug|LAAM|
75410011|NCT00000306|Drug|Dextroamphetamine|
75554589|NCT06141460|Drug|RRG001|Administered via Subretinal injection. Dosage form: injection solution.
75554590|NCT06140966|Drug|Daratumumab|Given by vein: days 1 and 8 of each Induction cycle; days 1 and 15 of each Consolidation cycle; and day 1of each Maintenance cycle.
75410012|NCT00000312|Drug|M-CPP|
75410013|NCT00000318|Drug|Buprenorphine|"Experimental Maintenance treatment with daily medication~Experimental Maintenance treatment with thrice-weekly medication"
75410014|NCT00000330|Drug|Opioid-Related Disorders|
75410015|NCT00000336|Drug|Selegiline|
75410016|NCT00000342|Drug|Risperidone|
75410017|NCT00000348|Drug|Dihydrexidine|
75410018|NCT00000354|Drug|Lofexidine|
75410019|NCT00000372|Drug|D-cycloserine|
75410020|NCT00000372|Drug|Glycine|
75410021|NCT00000372|Drug|Clozapine|
75410022|NCT00000372|Drug|Placebo|
75410023|NCT00000384|Behavioral|Cognitive Behavior Therapy|
75410024|NCT00000384|Behavioral|Educational Support|
75410025|NCT00000384|Drug|Sertraline|
75410026|NCT00000390|Drug|Imipramine hydrochloride|
75410027|NCT00000396|Behavioral|Patient self-care education|
75410028|NCT00000402|Drug|Calcium|
75410029|NCT00000438|Drug|naltrexone (Revia)|
75410030|NCT00000444|Drug|nicotine replacement patch|
75410031|NCT00000450|Drug|Naltrexone Tablet|
75554591|NCT06140966|Drug|Carfilzomib|Given by vein: days 1,2,8 and 9 of each Induction cycle; days 1, 2, 8, 9,15, and 16 of each Consolidation cycle; days 1, 2,15, and 16 of each Maintenance cycle.
75554592|NCT06140966|Drug|Lenalidomide|Given by mouth: days 1-7 of each Induction cycle; days 1-14 of each Consolidation cycle.
75554593|NCT06140966|Drug|Dexamethasone|Given by mouth or by vein: days 1, 8, 15, and 22 of each Induction cycle; days 1, 8, 15, and 22 of each Consolidation cycle; and days 1 and 15 of every cycle during Maintenance
75554594|NCT06140966|Drug|Cisplatin|Given by vein: days 1-4 of each Induction cycle
75554595|NCT06140966|Drug|epirubicin|Given by vein: days 1-4 of each Induction cycle
75554596|NCT06140966|Drug|Cyclophosphamide|Given by vein: days 1-4 of each Induction cycle
75554597|NCT06140966|Drug|Etoposide|Given by vein: days 1-4 of each Induction cycle
75554598|NCT06140966|Drug|Melphalan|Given by vein: day -1 of Transplant
75554599|NCT06140966|Procedure|ASCT|day 0 of Transplant
75713641|NCT03991975|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
75713642|NCT03991975|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
75713643|NCT04039269|Other|Preoperative video information|
75410032|NCT00000450|Drug|Matched Placebo Tablet|
75410033|NCT00000486|Procedure|coronary artery bypass|
75410034|NCT00000510|Drug|aspirin|
75410035|NCT00000510|Drug|dipyridamole|
75410036|NCT00000510|Procedure|angioplasty, transluminal, percutaneous coronary|
75410037|NCT00000546|Behavioral|meditation|
75410038|NCT00000570|Drug|pulmonary surfactant|
75410039|NCT00000582|Drug|factor ix|
75410040|NCT00000600|Drug|Vitamin E|
75410041|NCT00000600|Drug|Vitamin C|
75410042|NCT00000630|Biological|HIVAC-1e|
75410043|NCT00000630|Biological|gp160 Vaccine (MicroGeneSys)|
75410044|NCT00000636|Drug|Isoniazid|
75410045|NCT00000636|Drug|Pyrazinamide|
75410046|NCT00000636|Drug|Pyridoxine hydrochloride|
75410047|NCT00000636|Drug|Rifampin|
75410048|NCT00000648|Drug|Penicillin G potassium|
75410049|NCT00000648|Drug|Ceftriaxone sodium|
75410050|NCT00000654|Drug|Fialuridine|
75410051|NCT00000660|Drug|Etoposide|
75410052|NCT00000702|Drug|Zidovudine|
75410053|NCT00000714|Drug|Trimetrexate glucuronate|
75410054|NCT00000714|Drug|Leucovorin calcium|
75410055|NCT00000732|Drug|Sulfamethoxazole-Trimethoprim|
75410056|NCT00000732|Drug|Zidovudine|
75410057|NCT00000738|Drug|Nimodipine|
75410058|NCT00000738|Drug|Zidovudine|
75554600|NCT06140966|Drug|bortezomib|given by subcutaneous injection: days 1, 4, 8, and 11 of pretrial induction chemotherapy
75554601|NCT06139107|Drug|Abemaciclib|150mg twice a day for 3 cycles prior to radiation.
75554602|NCT06139107|Drug|Letrozole|Letrozole 2.5mg daily
75554603|NCT06136832|Behavioral|Pneumococcal Vaccine Education|Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia
75554604|NCT06136455|Drug|Listerine Clinical Solutions Teeth Strength|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
75554605|NCT06136455|Drug|Listerine Total Care Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
75554606|NCT06136455|Other|Listerine Cool Mint Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.
75554607|NCT06136455|Drug|Colgate Cavity Protection Toothpaste|Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
75554608|NCT06134804|Biological|ExPEC9V|ExPEC9V will be administered as an IM injection.
75554609|NCT06134804|Biological|Placebo|Placebo will be administered as an IM injection.
75554610|NCT06134804|Biological|HD quadrivalent influenza vaccine|HD quadrivalent influenza vaccine will be administered as IM injection.
75713644|NCT02534311|Drug|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
75713645|NCT00873561|Drug|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
75713646|NCT04039425|Procedure|Hair cut|Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
75410059|NCT00000750|Drug|Zidovudine|
75872428|NCT01065350|Drug|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
75872429|NCT01065350|Drug|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
75872430|NCT03434249|Dietary Supplement|Bifidobacterium, BB-12® (Bifidolactis Infant)|
76040753|NCT05520515|Other|Health Education|The intervention occurs at the School of Physical Education, Federal University of Pelotas. The intervention consists of an educational program with weekly lectures of approximately 30 min. The lectures are led by a qualified health professional, using expository and interactive approaches on topics that cover basic knowledge related to breast cancer and complementary therapies. Additionally, each participant receives a self-care booklet containing information about the topics addressed during the meetings. Qualified professionals give lectures on the following topics: 1) fatigue and quality of life; 2) anxiety and depressive symptoms; 3) body image and sexual function; 4) self-esteem; 5) self-care; 6) sleep; 7) cognitive function; 8) symptoms in the arm and breast; 9) pain and arthralgia; 10) body composition and bone health; 11) eating habits; 12) physical activity.
76040754|NCT05520437|Dietary Supplement|Omega-3 fatty acids|Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).
76040755|NCT05520437|Dietary Supplement|Placebo|Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.
75410060|NCT00000756|Drug|Lymphocytes, Activated|
75872431|NCT03434249|Dietary Supplement|Bifidolactis Infant Placebo|
76040756|NCT02612077|Other|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
75713647|NCT02534389|Dietary Supplement|omega-3 fish oil|2,4g of EPA + DHA
75410061|NCT00000774|Biological|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
75410062|NCT00000774|Biological|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
75410063|NCT00000774|Biological|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
75410064|NCT00000774|Biological|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
75410065|NCT00000804|Drug|Indinavir sulfate|
75410066|NCT00000810|Drug|Delavirdine mesylate|
75410067|NCT00000810|Drug|Zidovudine|
75410068|NCT00000810|Drug|Didanosine|
75410069|NCT00000834|Drug|Lamivudine|
75410070|NCT00000834|Drug|Methotrexate|
75410071|NCT00000834|Drug|Zidovudine|
75410072|NCT00000846|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
75410073|NCT00000846|Biological|HIV-1 Peptide Immunogen, Multivalent|
75410074|NCT00000852|Procedure|Allogeneic lymphocyte transfer|
75410075|NCT00000864|Drug|Abacavir sulfate|
75410076|NCT00000864|Drug|Zidovudine|
75410077|NCT00000876|Drug|CD4-IgG2|
75713648|NCT00878943|Drug|Sildenafil citrate|20 mg tablet to be taken thrice daily for 1 year
76040757|NCT02612077|Drug|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
75410078|NCT00000894|Drug|Cidofovir|
75410079|NCT00000894|Drug|Probenecid|
75410080|NCT00000894|Drug|Ganciclovir|
75410081|NCT00000912|Drug|Indinavir sulfate|
75410082|NCT00000912|Drug|Abacavir sulfate|
75410083|NCT00000912|Drug|Amprenavir|
75410084|NCT00000912|Drug|Nelfinavir mesylate|
75410085|NCT00000912|Drug|Efavirenz|
75410086|NCT00000912|Drug|Levocarnitine|
75410087|NCT00000912|Drug|Adefovir dipivoxil|
75410088|NCT00000912|Drug|Saquinavir|
75410089|NCT00000918|Drug|Indinavir sulfate|
75410090|NCT00000918|Drug|Lamivudine/Zidovudine|
75410091|NCT00000918|Drug|Ritonavir|
75410092|NCT00000918|Drug|Amprenavir|
75410093|NCT00000918|Drug|Efavirenz|
75410094|NCT00000918|Drug|Saquinavir|
75410095|NCT00000918|Drug|Lamivudine|
75410096|NCT00000918|Drug|Stavudine|
75410097|NCT00000918|Drug|Zidovudine|
75410098|NCT00000918|Drug|Didanosine|
75410099|NCT00000924|Drug|Ritonavir|
75410100|NCT00000924|Drug|Nelfinavir mesylate|
75410101|NCT00000924|Drug|Nevirapine|
75410102|NCT00000924|Drug|Stavudine|
75410103|NCT00000924|Drug|Didanosine|
75410104|NCT00000936|Drug|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
75410105|NCT00000936|Drug|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
75713649|NCT00873639|Drug|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
75713650|NCT00873639|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
75713651|NCT00879021|Drug|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
75554611|NCT06133699|Procedure|Orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye.|Study participants will undergo orchofuniculectomy through an inguinal or laparoscopic approach. After completion of the orchofuniculectomy, indocyanine green (ICG) dye with or without methylene blue dye will be injected into the spermatic cord stump. Next step is detection with a gamma detector the sentinel lymph nodes and follow removing of one or more (up to 4) lymph nodes during laparoscopy. These lymph nodes will be sent for histological examination.
76040758|NCT04622735|Combination Product|nefopam hydrochloride 30mg / paracetamol 500mg X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
76040759|NCT04622735|Drug|Paracetamol 500 Mg Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
75713652|NCT00879021|Drug|matching placebo|150 mg by mouth ,twice a day for 49 weeks
75713653|NCT00879099|Drug|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
75554612|NCT06133699|Diagnostic Test|Radiopharmaceutical administration (Technetium/methylene blue)|24 hours before surgery, a radiotracer (RP) will be injected into the spermatic cord followed by SPECT to identify the regional sentinel lymph node(s).
75554613|NCT06132126|Drug|LY3938577|Administered SC.
75713654|NCT00879099|Drug|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
75713655|NCT00879099|Drug|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
75713656|NCT00879099|Drug|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
75713657|NCT00369655|Biological|ziv-aflibercept|
75713658|NCT00615069|Device|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
75713659|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
75713660|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
76040760|NCT04622735|Drug|Nefopam HCl 30 MG Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
76040761|NCT03045991|Behavioral|aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
75554614|NCT06132126|Drug|Placebo|Administered SC.
75554615|NCT06132126|Drug|Insulin degludec|Administered SC.
75554616|NCT06131866|Other|Psychoeducation based on Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
75410106|NCT00000936|Drug|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
75554617|NCT06131840|Drug|SGN-CEACAM5C|Given into the vein (IV; intravenous)
75554618|NCT06131788|Behavioral|Educational hand hygiene intervention|The intervention combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB
75410107|NCT00000942|Drug|Nevirapine|
75554619|NCT06129890|Device|Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.
75554620|NCT06129890|Device|Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.
75554621|NCT06129175|Biological|Neuroncell-EX|Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.
75554622|NCT06129175|Other|Placebo|Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
75554623|NCT06129058|Device|At-home transcranial direct current stimulation (tDCS)|30 minutes session 5 days/week for 3 weeks.
75554624|NCT06129058|Device|Sham at-home tDCS|30 minutes session 5 days/week for 3 weeks.
75554625|NCT06128304|Other|Core Implementation strategies|"Core Implementation Strategies~Ongoing consultation~Educational meetings~Strengthen referral system~Prepare patients to be active participants"
75554626|NCT06128304|Other|Core+ Enhanced Implementation Strategies|"Includes all of the Core implementation strategies and adds:~5. Community engagement using Health Beginning Initiative Model~6. Smart Cards to facilitate patient engagement"
75554627|NCT06128239|Behavioral|Caring Contacts|Text message version of Motto's Caring Contacts intervention. The study will compare two versions of text-based Caring Contacts: two-way messages, to which participants can respond to receive text-based support from follow-up specialists, and one-way text messages, to which participants cannot respond.
75554628|NCT06127823|Behavioral|Dietary treatment|Dietary counselling
75554629|NCT06126861|Drug|[14C]LP-168|single dose of 150 mg/100 μCi [14C] LP-168, orally suspension at fasted state
75554630|NCT06126562|Drug|Lanifibranor|Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
75554631|NCT06122116|Other|Physical Therapy|The PT treatment participants receive in this study will be standard of care; that is, the PT treatment regimen will not be standardized across study participants and/or dictated by study-specific criteria. Participants will be referred to the Physical Therapy Department at the Madigan Army Medical Center (MAMC). Number of PT treatments will be documented on a follow-up Chart Review.
75554632|NCT06122116|Biological|Platelet-Rich Plasma Injection|PRP injection procedures will follow current clinical recommendation and standard operating procedures. Prior to the injection, the area will be sterilely prepared and anesthetized with either ethyl chloride spray or lidocaine (limited to the cutaneous and subcutaneous layer, so as not to alter the synovial contents). Then, the participant will receive LP-PRP injection in the affected knee area under ultrasound guidance. Qualified study providers will inject 2-5cc LP-PRP using an 18-gauge 1/5-inch needle for both aspiration and subsequent injection. Study providers will select the injection portal they are most comfortable with, in order to achieve an accurate intra-articular injection. The PRP injection procedure is expected to take approximately one hour.
75713661|NCT00879177|Drug|Varenicline|Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
76040762|NCT03045991|Behavioral|control training|The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.
75410108|NCT00000948|Drug|Aldesleukin|Il-2
75410109|NCT00000948|Drug|ART|antiretroviral therapy for the treatment of HIV
75410110|NCT00000954|Drug|Bleomycin sulfate|
75410111|NCT00000954|Drug|Vincristine sulfate|
75410112|NCT00000954|Drug|Doxorubicin hydrochloride|
75410113|NCT00000954|Drug|Zalcitabine|
75410114|NCT00000954|Drug|Didanosine|
75410115|NCT00000960|Drug|Zidovudine|
75410116|NCT00000984|Drug|CD4 Antigens|
75410117|NCT00000990|Drug|Zidovudine|
75410118|NCT00000996|Drug|Doxorubicin hydrochloride|
75410119|NCT00001026|Biological|gp160 Vaccine (Immuno-AG)|
75410120|NCT00001026|Biological|rgp120/HIV-1IIIB|
75410121|NCT00001026|Biological|rgp120/HIV-1MN|
75410122|NCT00001026|Biological|rgp120/HIV-1 SF-2|
76040763|NCT03045991|Behavioral|cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
76040764|NCT04615559|Diagnostic Test|Contrast enhanced ultrasound|CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
75554633|NCT06122116|Device|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. PBMT will be delivered at 6 J/cm^2 and applied in a circular pattern to the knee area.
76040765|NCT05517629|Other|It is an observational cross-sectional study|It is an observational cross-sectional study
76040766|NCT03046303|Procedure|ERAS|optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
75410123|NCT00001026|Biological|HIVAC-1e|
75410124|NCT00001044|Biological|Aluminum hydroxide|
75410125|NCT00001044|Biological|QS-21|
75410126|NCT00001044|Biological|rgp120/HIV-1MN|
75410127|NCT00001056|Biological|gp160 Vaccine (Immuno-AG)|
75554634|NCT06119165|Behavioral|Environmental nudges|Participants will view protein, frozen meal, and snack products with eco-labels applied. For each category, they will then be instructed to select 1 item from that category they wish most to purchase. Categories will be shown in random order. If a participant selects a product with a red eco-label, they will be shown a peer comparison message and will be given an opportunity to switch to a product with a yellow or green eco-label.
75554635|NCT06118411|Drug|Upadacitinib|Oral Tablets
75554636|NCT06118411|Drug|Placebo|Oral Tablets
75554637|NCT06117969|Drug|Tibolone|1.25mg po qd
75554638|NCT06117969|Drug|Xiangshao granules|4g po tid
75554639|NCT06117969|Drug|Tibolone plus Xiangshao granules|Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid
75554640|NCT06116708|Device|Kalogon AF Prototype Smart Cushion|The Kalogon cushion is a dynamic smart cushion that utilizes a combination of foam and 5 adjustable air cells to intelligently redistribute weight and increase comfort for users. The air cells are used to modulate interface pressures and adjust where support or pressure reductions are provided based on input from the controller's pressure sensing system.
76040767|NCT04875637|Diagnostic Test|WAI-MEMR|Using wideband acoustic reflectance for middle-ear muscle reflex.
76040768|NCT05531669|Behavioral|PLAY Project|PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.
75410128|NCT00001062|Drug|Ganciclovir|
75410129|NCT00001068|Drug|Lamivudine|
75410130|NCT00001080|Biological|Influenza Virus Vaccine|
75554641|NCT06116708|Device|Standard Seat Cushion from Air Force|This is the standard seat cushion that was provided by the United States Air Force to use for this study. It is a high-density, molded polyurethane foam.
75713662|NCT00879177|Behavioral|behavioral therapy|confirmed negative smoking status at different time points
76040769|NCT05531669|Behavioral|Parental Education|Each study center provides welcome course and parent guide for families with ASD children monthly.
75410131|NCT00001080|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
75410132|NCT00001080|Drug|Lamivudine|
75410133|NCT00001104|Drug|Zidovudine|
75410134|NCT00001110|Procedure|Bronchoalveolar lavage|
75410135|NCT00001122|Drug|Nelfinavir mesylate|
75410136|NCT00001122|Drug|Efavirenz|
75410137|NCT00001122|Drug|Stavudine|
75410138|NCT00001122|Drug|Didanosine|
75410139|NCT00001128|Drug|Interleukin-12|
75410140|NCT00001128|Drug|Paromomycin sulfate|
75410141|NCT00001128|Drug|Azithromycin|
75410142|NCT00001182|Procedure|current standard of care treatments|
75410143|NCT00001188|Procedure|radiation therapy following surgery|
75410144|NCT00001272|Drug|taxol|
75410145|NCT00001296|Drug|melphalan|
75410146|NCT00001296|Drug|tumor necrosis factor|
75410147|NCT00001296|Drug|interferon-gamma|
75410148|NCT00001296|Procedure|hyperthermic isolated limb perfusion|
75410149|NCT00001338|Drug|FLAC chemotherapy with GM-CSF|
75410150|NCT00001422|Drug|fludarabine|
75410151|NCT00001428|Drug|5-fluorouracil|
75410152|NCT00001440|Procedure|Autologous T cells|
75410153|NCT00001440|Drug|Interleukin-2|
75410154|NCT00001446|Drug|thalidomide|
75410155|NCT00001512|Drug|Id-KLH Vaccine|
75410156|NCT00001512|Drug|GM-CSF|
75410157|NCT00001572|Drug|Id-KLH Vaccine|
75554642|NCT06113887|Other|psychoeducation based on acceptance and commitment therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
75554643|NCT06113341|Drug|IDegLira|Pre-filled pen injection.
75713663|NCT01050829|Drug|Gadobutrol (Gadovist, BAY86-4875)|Single administration at a dose of 0.1 mmol/kg
75713664|NCT01050829|Drug|Gadopentetate Dimeglumine (Magnevist, BAY86-4882)|Single administration at a dose of 0.1 mmol/kg
75410158|NCT00001572|Drug|QS-21 (Stimulation-QS-21) Drug|
75410159|NCT00001614|Drug|Chicken type II collagen|
75713665|NCT00873717|Other|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
75713666|NCT00873717|Other|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
75410160|NCT00001626|Drug|antithymocyte globulin|antithymocyte globulin
75410161|NCT00001626|Drug|cyclophosphamide|cyclophosphamide
75410162|NCT00001626|Drug|cyclosporine|cyclosporine
75410163|NCT00001680|Drug|Thalidomide|
75410164|NCT00001698|Drug|Ketorolac Rinse|
75410165|NCT00001716|Drug|Nitric Oxide|
75410166|NCT00001716|Drug|Nitroglycerin|
75410167|NCT00001812|Drug|Nystatin|
75410168|NCT00001830|Drug|Th2 cells in allo HSCTT|
75410169|NCT00001830|Drug|Th2 Cells|
75410170|NCT00001842|Drug|Granulocyte colony-stimulating factor|
75410171|NCT00001842|Drug|Dexamethasone|
75410172|NCT00001848|Drug|Raloxifene|
75410173|NCT00001854|Drug|Ribavirin|
75410174|NCT00001860|Drug|Sandostatin LAR Depot versus transsphenoidal surgery|
75410175|NCT00001866|Procedure|horizontal muscles of the eye will be cut and then reattached in the same position|
75410176|NCT00001890|Drug|Estrogen therapy|
75410177|NCT00001926|Drug|O15|
75410178|NCT00001926|Device|Cadwell rTMS|
75410179|NCT00001944|Drug|Vinorelbine|
75410180|NCT00001944|Drug|XR9576|
75410181|NCT00001956|Procedure|Blood draw|
75410182|NCT00001956|Procedure|Oral surgery|
75410183|NCT00001956|Procedure|Tissue biopsy|
75410184|NCT00001968|Drug|Amprenavir|
75410185|NCT00001968|Drug|Ritonavir|
75410186|NCT00001968|Drug|Abacavir|
75410187|NCT00001968|Drug|Lamivudine|
75410188|NCT00001986|Drug|1-Octanol|
75410189|NCT00001992|Biological|rgp120/HIV-1IIIB|
75410190|NCT00001998|Drug|Nystatin|
75410191|NCT00002004|Drug|CD4 Antigens|
75410192|NCT00002010|Drug|Fluconazole|
75410193|NCT00002016|Drug|Sevirumab|
75410194|NCT00002022|Drug|Epoetin alfa|
75410195|NCT00002028|Drug|Didanosine|
75410196|NCT00002034|Drug|Zidovudine|
75410197|NCT00002034|Drug|Ganciclovir|
75410198|NCT00002040|Drug|Fluconazole|
75410199|NCT00002046|Drug|Zidovudine|
75410200|NCT00002052|Drug|Ceftriaxone sodium|
75410201|NCT00002052|Drug|Ampicillin sodium|
75410202|NCT00002052|Drug|Amoxicillin trihydrate|
75410203|NCT00002058|Drug|Clofazimine|
75410204|NCT00002064|Drug|Pyrimethamine|
75410205|NCT00002064|Drug|Clindamycin|
75410206|NCT00002070|Drug|Sargramostim|
75410207|NCT00002070|Drug|Ganciclovir|
75410208|NCT00002076|Drug|Fluconazole|
75554644|NCT06111040|Other|Measurement|The only interventions are at the measurement level and consist of two behavioral protocols designed to assess children's eating behavior, where food stimuli are provided and children's behavioral responses are recorded.
75410209|NCT00002082|Drug|Azithromycin|
75554645|NCT06110793|Drug|Lenvatinib|20mg orally PO daily
75554646|NCT06110793|Drug|Pembrolizuma|400mg IV Q6W
75554647|NCT06110793|Drug|Fulvestrant|500mg IM Q4W
75554648|NCT06108479|Drug|DF6215|Immunotherapy (cytokine) targeting effector cells.
75554649|NCT06102174|Drug|Placebo|Placebo
75554650|NCT06102174|Drug|Active|Sisunatovir
75554651|NCT06101628|Other|Gel nail application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the gel nail is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
75554652|NCT06101212|Other|survey|After obtaining the informed consent form, a 10-15 minute questionnaire will be applied to the patients included in the study.
75554653|NCT06101173|Biological|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
75554654|NCT06101173|Biological|Inactivated poliomyelitis vaccine (IPOL)|1 dose of IPOL vaccine (0.5ml) on Visit 1
75554655|NCT06101173|Biological|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
75554656|NCT06101173|Biological|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
75554657|NCT06101173|Biological|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
75554658|NCT06101173|Biological|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
75554659|NCT06100653|Drug|BCG for therapeutic use|The 10 patients were infused with BCG 120mg dissolved in 40 ~ 50 mL normal saline once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.
75554660|NCT06098755|Behavioral|Transcendence Research: Holistic Education|With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.
75554661|NCT06098612|Drug|C11-SY08|a PET imaging agent
75554662|NCT06097676|Drug|Placebo|Placebo
75554663|NCT06097676|Drug|Alprazolam 2 mg|Oral dose of alprazolam 2 mg
75554664|NCT06097676|Drug|Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg|Oral dose of GE-IR 200 mg
75554665|NCT06097676|Drug|Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg|Oral dose of GE-IR 450 mg
75554666|NCT06097676|Drug|Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg|Oral dose of GE-IR 700 mg
75554667|NCT06095089|Drug|JNJ-78278343|JNJ-78278343 will be administered.
75554668|NCT06095089|Drug|JNJ-87189401|JNJ-87189401 will be administered.
75410210|NCT00002088|Drug|Saccharomyces boulardii|
75410211|NCT00002094|Drug|Atevirdine mesylate|
75410212|NCT00002100|Drug|Curdlan sulfate|
75410213|NCT00002106|Drug|Ranitidine hydrochloride|
75554669|NCT06089239|Other|High Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
75410214|NCT00002112|Drug|Nystatin|
75410215|NCT00002112|Drug|Fluconazole|
75410216|NCT00002118|Drug|Zalcitabine|
75410217|NCT00002124|Drug|Delavirdine mesylate|
75410218|NCT00002124|Drug|Lamivudine|
75410219|NCT00002124|Drug|Zidovudine|
75410220|NCT00002130|Drug|Vesnarinone|
75410221|NCT00002136|Drug|Tecogalan sodium|
75410222|NCT00002142|Drug|Cidofovir|
75554670|NCT06089239|Other|Low Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
75554671|NCT06088030|Drug|Arsenic trioxide|Patients should be treated with the corresponding first-line chemotherapy regimen first, for example: Neuroblastoma: CAV (cyclophosphamide, pinarubicin, vincristine), PVP (cisplatin, etoposide) ,CT (cyclophosphamide, topotecan).If patients was evaluted as PD/SD after treatments, arsenic trioxide (ATO) will be administered 0.18mg/kg per day over six hours IV daily for ten days in combination with previous chemotherapy regimen on the third day of each treatment cycle. Other pediatric tumors with TP53 mutations not mentioned above will have similar treatment regimens. If the efficacy of the conventional standard chemotherapy regimen is evaluated as PD/SD, then the next course of treatment will be combined with ATO on the basis of the standard chemotherapy regimen.
75554672|NCT06085339|Behavioral|Social Media|The social media arm participants will receive a diabetes curriculum designed to address diabetes self-efficacy and independence with diabetes management over the course of 6 months. Participants will have the option to engage with the study team and other participants through Instagram posts and direct messaging.
75554673|NCT06084403|Drug|20 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine (Buvasin %5 flakon) 20ml will be injected here.
75554674|NCT06084403|Drug|30 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 30ml will be injected here.
75713667|NCT00873717|Other|Dentary + Nutrition|"trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat."
75713668|NCT00676338|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
75410223|NCT00002142|Drug|Probenecid|
75410224|NCT00002148|Drug|OPC 14117|
75410225|NCT00002154|Drug|Thioctic acid|
75410226|NCT00002154|Drug|Selegiline hydrochloride|
75410227|NCT00002160|Drug|Ziconotide|
75410228|NCT00002166|Drug|Nevirapine|
75410229|NCT00002172|Biological|HIV-1 Immunogen|
75410230|NCT00002178|Drug|Ritonavir|
75410231|NCT00002178|Drug|Nelfinavir mesylate|
75410232|NCT00002178|Drug|Saquinavir|
75410233|NCT00002178|Drug|Delavirdine mesylate|
75410234|NCT00002184|Drug|Nelfinavir mesylate|
75410235|NCT00002184|Drug|Levocarnitine|
75410236|NCT00002184|Drug|Adefovir dipivoxil|
75410237|NCT00002184|Drug|Saquinavir|
75554675|NCT06084403|Drug|40 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 40ml will be injected here.
75554676|NCT06084195|Biological|Blood sample and tissue sample|"During the surgery :~Tissus sample : primary tumor and metastasis~blood sample : 3 EDTA tubes~ex vivo MRI data"
75554677|NCT06080906|Biological|IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero Cells) of 320EU/0.5ml on Day 0, 28
75872432|NCT03142906|Diagnostic Test|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
75872433|NCT03033693|Other|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
75872434|NCT03033693|Other|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
75872435|NCT05079490|Behavioral|motor intervention|gross motor skill intervention combined with fitness training
75872436|NCT02914977|Drug|Daunorubicin|"Agent: Daunorubicin~Dose: 6.75 mg/m2/day~Route: IV~Schedule: Days 1-5~Duration: One cycle"
76040770|NCT02613481|Drug|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
75410238|NCT00002184|Drug|Lamivudine|
75713669|NCT00676338|Drug|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
75713670|NCT00676338|Drug|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
75410239|NCT00002184|Drug|Stavudine|
75410240|NCT00002184|Drug|Zidovudine|
75410241|NCT00002190|Drug|Saquinavir|
75410242|NCT00002190|Drug|Lamivudine|
75713671|NCT00676338|Drug|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
75872437|NCT03718715|Drug|Metformin|Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
75872438|NCT05053347|Dietary Supplement|Flaxseed oil capsule|The participants were asked to take flaxseed oil capsule 5d/day(ALA 2.5g/d). The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
76040771|NCT04864015|Device|Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable|Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
76040772|NCT05298917|Device|silicone hydrogel contact lens|silicone hydrogel contact lens
75410243|NCT00002190|Drug|Zidovudine|
75410244|NCT00002196|Drug|CI-1012|
75410245|NCT00002202|Drug|Indinavir sulfate|
75410246|NCT00002202|Drug|Amprenavir|
75410247|NCT00002208|Drug|Indinavir sulfate|
75410248|NCT00002208|Drug|Lamivudine|
75410249|NCT00002208|Drug|Stavudine|
75410250|NCT00002208|Drug|Zidovudine|
75410251|NCT00002214|Drug|Capravirine|
75410252|NCT00002220|Drug|Indinavir sulfate|
75410253|NCT00002220|Drug|Efavirenz|
75410254|NCT00002220|Drug|Levocarnitine|
75410255|NCT00002220|Drug|Adefovir dipivoxil|
75410256|NCT00002226|Drug|SU5416|
75410257|NCT00002232|Biological|APL 400-003|
75410258|NCT00002238|Drug|Interferon beta-1b|
75410259|NCT00002238|Drug|Zidovudine|
75410260|NCT00002244|Drug|WF10|
75410261|NCT00002250|Drug|CD4-IgG|
75410262|NCT00002256|Drug|Zalcitabine|
75410263|NCT00002262|Drug|Tumor Necrosis Factor|
75713672|NCT02534623|Procedure|Spinal anesthesia|
75713673|NCT02534623|Procedure|General anesthesia|
75713674|NCT02534623|Drug|bupivacaine|
75713675|NCT02534623|Drug|fentanyl|
75713676|NCT02534623|Drug|propofol|
75713677|NCT02534623|Drug|sevoflurane|
76040773|NCT04385251|Other|Data Collection|"DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 & 28:~Vital and hospitalization status; Symptoms and health status"
76040774|NCT04864093|Diagnostic Test|muscular ultrasound|respiratroy and muscular ultrasound
75410264|NCT00002268|Drug|Sevirumab|
76040775|NCT04384705|Other|research specific blood sample|"one blood sample before the epidemic phase~one blood sample during epidemic phase~one blood sample after epidemic phase"
76040776|NCT05517551|Procedure|robotic assisted radical prostatectomy|Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery
76040777|NCT05520125|Biological|Mesenchymal stem cells enriched by extracellular vesicles|Mesenchymal stem cells enriched by extracellular vesicles
75872439|NCT05053347|Dietary Supplement|Corn oil capsule|The participants were asked to take corn oil capsule 5d/day. The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
76040778|NCT05520125|Other|Standard treatment of bone defects|Standard surgical treatment of bone defects
76040779|NCT04297319|Procedure|Laser diiodo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.
76040780|NCT04297319|Procedure|Laser Placebo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.
76040781|NCT05517395|Behavioral|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
76040782|NCT05517395|Behavioral|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
76040783|NCT05048615|Drug|Venetoclax 100 MG|Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.
75872440|NCT05079022|Drug|Furmonertinib|Furmonertinib at 80mg dose will be administered orally once daily.
75410265|NCT00002274|Drug|Didanosine|
75410266|NCT00002280|Drug|Didanosine|
75410267|NCT00002286|Drug|Zidovudine|
75410268|NCT00002292|Drug|Pentamidine isethionate|
75410269|NCT00002298|Drug|Ribavirin|
76040784|NCT05048615|Drug|Itraconazole capsule|Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.
76040785|NCT05048615|Drug|Azacitidine Injection|Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.
76040786|NCT05531435|Drug|local anaesthetic injection|Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
76040787|NCT05517317|Combination Product|Autologous BMMC transplantation|One administration of autologous bone marrow mononuclear cells via the hepatic artery
75410270|NCT00002304|Drug|Ketoconazole|
75410271|NCT00002304|Drug|Fluconazole|
75410272|NCT00002310|Drug|Crofelemer|
75410273|NCT00002316|Drug|Lobradimil|
75410274|NCT00002316|Drug|Amphotericin B|
75410275|NCT00002322|Drug|Atevirdine mesylate|
75410276|NCT00002322|Drug|Zidovudine|
75410277|NCT00002328|Drug|Azithromycin|
75410278|NCT00002334|Drug|Saquinavir|
75410279|NCT00002334|Drug|Zidovudine|
75410280|NCT00002334|Drug|Zalcitabine|
75410281|NCT00002340|Drug|Atovaquone|
75410282|NCT00002340|Drug|Pentamidine isethionate|
75410283|NCT00002346|Drug|Adefovir dipivoxil|
75410284|NCT00002352|Drug|Lobucavir|
75410285|NCT00002358|Drug|Sorivudine|
75410286|NCT00002364|Drug|Abacavir sulfate|
75410287|NCT00002370|Drug|Itraconazole|
75410288|NCT00002376|Drug|Indinavir sulfate|
75410289|NCT00002376|Drug|Lamivudine|
75410290|NCT00002376|Drug|Stavudine|
76040788|NCT05517239|Drug|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
76040789|NCT05519813|Drug|Metformin|Use Metformin for 3 months to treat PCOS
76040790|NCT05519813|Drug|Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
75554678|NCT06080906|Biological|IRV on a 0-, 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on Day 0, 28, 56
75554679|NCT06080906|Biological|Placebo on Day 0, 28|Two doses of placebo at the vaccination schedule of Day 0, 28
75872441|NCT05078788|Procedure|Laser uretherotomy|Holmium YAG Laser with pulse energy from 1-2 Joule, frequency from 10-15 Hertz and total power from 3.0 to 30.0 Watt were set up, respectively, based on the extent of the lesions. Scar tissue was incised at the position of 12-o'clock under the guidance of guidewire or ureteric catheter till fresh mucosa appeared.
75872442|NCT05078788|Procedure|Laser uretherotomy with triamcinolone|After laser urethrotomy, 80 mg of triamcinolone (diluted with normal saline to 10 ml) will be injected by using an injection needle (5 F size and 23 G needle size) at 10 sites, 1 ml each, along the site of urethrotomy and circumferentially.
75872443|NCT02032654|Drug|Flucloxacillin|
76040791|NCT05517005|Dietary Supplement|Hype Bites Supplement|"The ingredients of the vitamin supplement are:~Chocolate liquor Sugar Cocoa butter Vanilla extract Vitamin B12 (as methylcobalamin) Tapioca Gum arabic Coloring (radish, apple, black currant) Carnauba Wax"
76040792|NCT05519657|Other||
76040793|NCT05082311|Other|Observational study|This is an observational study
75872444|NCT02032654|Drug|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
75872445|NCT04737694|Dietary Supplement|Ketone ester|Oral ketone ester + glucose supplement
75872446|NCT04737694|Dietary Supplement|Glucose|Glucose supplement
75872447|NCT04734886|Dietary Supplement|L. reuteri DSM 17938 + vitamin D|1 * 10^8 CFU of L. reuteri DSM 17938 + 10 ug vitamin D3, two capsules per day for 6 months
75872448|NCT04734886|Dietary Supplement|Placebo + vitamin D|Placebo tablet + 10 ug vitamin D3, Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
76040794|NCT05519501|Device|SyntrFuge System|Microsized Adipose Tissue
75713678|NCT00873795|Drug|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
75713679|NCT00879489|Biological|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
75872449|NCT03142282|Drug|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
75872450|NCT03142282|Radiation|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
75872451|NCT03114969|Device|Relvar ELLIPTA|ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
75872452|NCT03114969|Device|Symbicort TURBUHALER|TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
75872453|NCT03114969|Device|Seretide DISKUS|DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
76040795|NCT05519501|Procedure|Standard of Care|Offloading
76040796|NCT02613403|Drug|MK-3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
75713680|NCT00382291|Drug|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
75713681|NCT00382291|Drug|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
76040797|NCT02613403|Drug|Ribavirin|Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
75410291|NCT00002376|Drug|Zidovudine|
75410292|NCT00002376|Drug|Didanosine|
75410293|NCT00002382|Drug|Saquinavir|
76040798|NCT05531279|Drug|PEG-rhG-CSF|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
75410294|NCT00002388|Drug|Abacavir sulfate|
75410295|NCT00002394|Drug|Terbinafine hydrochloride|
75410296|NCT00002400|Drug|Indinavir sulfate|
75410297|NCT00002400|Drug|Delavirdine mesylate|
75410298|NCT00002400|Drug|Lamivudine|
75410299|NCT00002400|Drug|Zidovudine|
75410300|NCT00002406|Drug|Indinavir sulfate|
75410301|NCT00002412|Drug|Emivirine|
75410302|NCT00002412|Drug|Hydroxyurea|
75410303|NCT00002412|Drug|Stavudine|
75410304|NCT00002412|Drug|Didanosine|
76040799|NCT04875403|Other|Inspiratory muscle trainning|linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).
76040800|NCT04875403|Other|Exercise|exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
76040801|NCT05267093|Procedure|Acupuncture|Sterile single-use stainless steel needles (size 0.3 mm × 25 mm) will be utilized. After local skin disinfection with 75% alcohol wipes, acupuncturists will insert needles perpendicularly into the Ashi points to a depth of approximately 2-3 mm; horizontally into the Baxie points toward the wrist to a depth of 5-10 mm; and perpendicularly into Houxi (SI3) and Waiguan (TE5) to a depth of approximately 5-10 mm. The depth of needling will vary based on the participant's body sizes. After insertion, all needles except those in the Ashi points will be manually manipulated to achieve De qi sensations. All the needles will be retained for 30 min and then gently removed. Participants will take acupuncture treatment three times per week for a total of 12 sessions in 4 consecutive weeks.
76040802|NCT05267093|Procedure|Sham acupuncture|The sham needles with blunt tips (size 0.3 mm × 25 mm) will be used in the control group. Acupuncturists will gently lift and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Acupuncturist will firstly sterilize the areas of acupoints, then apply the adhesive pads on the surface of Ashi points, Baxie points, Houxi (SI3) and Waiguan (TE5) and insert the sham needles without penetrating. The duration and frequency of treatment sessions will be the same as in the acupuncture group.
76040803|NCT05519267|Behavioral|MBSWSC|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory (Maddock et al. 2019a). This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
75410305|NCT00002418|Drug|Emivirine|
75410306|NCT00002418|Drug|Hydroxyurea|
75410307|NCT00002418|Drug|Nevirapine|
75410308|NCT00002418|Drug|Stavudine|
75410309|NCT00002418|Drug|Didanosine|
75554680|NCT06080906|Biological|Placebo on Day 0, 28, 56|Three doses of placebo at the vaccination schedule of Day 0, 28, 56
75554681|NCT06075576|Diagnostic Test|Intervention|No test articles will be used in the study. However, while taking measurements, the subject's eye will be exposed to light or light flashes that are about the same or lesser intensity than those in a routine eye exam in an eye care provider's office.
75410310|NCT00002424|Drug|L-756423|
75410311|NCT00002424|Drug|Indinavir sulfate|
75410312|NCT00002424|Drug|Lamivudine|
75410313|NCT00002424|Drug|Stavudine|
75410314|NCT00002430|Drug|Indinavir sulfate|
75410315|NCT00002430|Drug|Nelfinavir mesylate|
75410316|NCT00002430|Drug|Lamivudine|
75410317|NCT00002430|Drug|Stavudine|
75410318|NCT00002436|Drug|Lamivudine|
75410319|NCT00002436|Drug|Zidovudine|
75410320|NCT00002436|Drug|Zalcitabine|
75410321|NCT00002442|Drug|Indinavir sulfate|
75410322|NCT00002442|Drug|Nelfinavir mesylate|
75410323|NCT00002442|Drug|Lamivudine|
75410324|NCT00002442|Drug|Stavudine|
75410325|NCT00002448|Drug|Ritonavir|
75410326|NCT00002448|Drug|Efavirenz|
75410327|NCT00002448|Drug|Saquinavir|
75410328|NCT00002454|Biological|autologous tumor cell vaccine|
75410329|NCT00002460|Drug|goserelin acetate|
75410330|NCT00002460|Drug|tamoxifen citrate|
75410331|NCT00002460|Procedure|ablative endocrine surgery|
75410332|NCT00002460|Procedure|oophorectomy|
75410333|NCT00002466|Drug|cyclophosphamide|
75410334|NCT00002466|Drug|doxorubicin hydrochloride|
75410335|NCT00002466|Drug|etoposide|
75410336|NCT00002466|Drug|ifosfamide|
75410337|NCT00002466|Drug|vincristine sulfate|
75410338|NCT00002466|Procedure|conventional surgery|
75410339|NCT00002466|Radiation|radiation therapy|
75410340|NCT00002472|Drug|cisplatin|
75410341|NCT00002472|Drug|etoposide|
75410342|NCT00002472|Procedure|conventional surgery|
75410343|NCT00002472|Procedure|neoadjuvant therapy|
75554682|NCT06074627|Dietary Supplement|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
75554683|NCT06074627|Dietary Supplement|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
76040804|NCT05519267|Behavioral|MBSC|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
76040805|NCT03044119|Biological|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
75554684|NCT06074627|Dietary Supplement|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
75554685|NCT06074627|Dietary Supplement|Energy Active Study Product 1.3 Usage|Participants will use their Radicle Energy Active Study Product 1.3 as directed for a period of 6 weeks.
75713682|NCT00382291|Drug|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
75554686|NCT06072794|Drug|VL-PX10|VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.
76040806|NCT03044119|Biological|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
75713683|NCT00873951|Other|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
76040807|NCT04863937|Device|Distal Thigh Compression Garment, Knee Sleeve|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
76040808|NCT03044275|Other|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
75554687|NCT06068959|Device|Photobiomodulation using LED|Photobiomodulation Using a Cluster of LEDs in the Red and Infrared Wavelengths in the Cervical Spine Region and Over the Masticatory Muscles
75554688|NCT06068959|Device|Placebo|Photobiomodulation Placebo
75713684|NCT00873951|Dietary Supplement|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
75713685|NCT00873951|Dietary Supplement|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
75713686|NCT00873951|Dietary Supplement|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
75713687|NCT00874107|Biological|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
75713688|NCT00874107|Biological|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
75872454|NCT03114969|Device|Spiriva HANDIHALER|HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
75872455|NCT03114969|Device|BREEZHALER|BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
75872456|NCT03114969|Device|Incruse ELLIPTA|ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
75872457|NCT03114969|Device|Anoro ELLIPTA|ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
76040809|NCT03044275|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
76040810|NCT04640597|Device|BioMimics 3D Vascular Stent System|Patients with BioMimics 3D Vascular Stent System
76040811|NCT04874701|Drug|Capsimax|Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
76040812|NCT04874701|Other|Energy restriction|Personalised diet plan targeting a 500 kcal/day energy restriction
76040813|NCT03045835|Device|BASKA mask|Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
75410344|NCT00002472|Radiation|radiation therapy|
75872458|NCT05078710|Drug|Telitacicept|160mg once a week for 24 weeks
75410345|NCT00002478|Drug|etoposide|
75410346|NCT00002484|Radiation|radiation therapy|
75410347|NCT00002490|Biological|BCG vaccine|
75410348|NCT00002490|Drug|mitomycin C|
75872459|NCT05078632|Other|Montreal-Toulouse Test adapted in eye tracking|participant pass an eye tracking test to evaluate comprehension
75872460|NCT03144778|Biological|Durvalumab|Given IV
75872461|NCT03144778|Biological|Tremelimumab|Given IV
75872462|NCT02046096|Device|Günther Tulip® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
75872463|NCT02046096|Device|Cook Celect® Vena Cava Filters|Temporary or permanent filter placement for the prevention of pulmonary embolism
75872464|NCT03142360|Drug|Beraprost sodium (Berasil)|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
75872465|NCT05124678|Drug|Isoniazid Tablets|High dose of isoniazid
76040814|NCT03045835|Device|Endotracheal intubation|Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
76040815|NCT05516693|Other|Myofacial muscle training protocol.|Muscle training for orofacial motricity stimulation
75410349|NCT00002490|Radiation|radiation therapy|
75410350|NCT00002496|Drug|chemotherapy|
75410351|NCT00002496|Drug|cisplatin|
75410352|NCT00002496|Drug|fluorouracil|
75410353|NCT00002496|Procedure|conventional surgery|
75410354|NCT00002496|Radiation|low-LET cobalt-60 gamma ray therapy|
75410355|NCT00002496|Radiation|low-LET electron therapy|
75410356|NCT00002496|Radiation|low-LET photon therapy|
75410357|NCT00002502|Drug|busulfan|
75410358|NCT00002502|Drug|cyclophosphamide|
75410359|NCT00002502|Drug|cytarabine|
75713689|NCT00874107|Drug|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
75713690|NCT00874107|Drug|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
75713691|NCT00761358|Drug|Z-338|Oral
75713692|NCT00761358|Drug|Placebo|Oral
75713693|NCT05213637|Biological|Expanded Activated Lymphocytes (EAL)|12~20 doses of EAL (1×10^9~2×10^10 cells per dose) will be infused into patients.
76040816|NCT04874779|Other|non|follow up investigations
75713694|NCT05213637|Procedure|transarterial chemoembolization (TACE)|After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
75713695|NCT03992989|Device|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
75410360|NCT00002502|Procedure|allogeneic bone marrow transplantation|
75410361|NCT00002508|Drug|carboplatin|
75410362|NCT00002508|Drug|etoposide|
75713696|NCT03992989|Device|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
75872466|NCT04668820|Diagnostic Test|video Pediatric Gait, Arms, Legs and Spine (V-pGALS)|The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
75410363|NCT00002508|Procedure|autologous bone marrow transplantation|
75410364|NCT00002508|Procedure|peripheral blood stem cell transplantation|
75410365|NCT00002526|Biological|filgrastim|
75410366|NCT00002526|Drug|doxorubicin hydrochloride|
75410367|NCT00002526|Drug|ifosfamide|
75410368|NCT00002532|Biological|filgrastim|
76040817|NCT05002127|Drug|Evorpacept (ALX148)|IV Q2W
76040818|NCT05002127|Drug|Trastuzumab|IV Q2W
75713697|NCT00879723|Dietary Supplement|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
75713698|NCT00874341|Other|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
75713699|NCT00874419|Drug|erlotinib|erlotinib 150 mg oral, once a day
76040819|NCT05002127|Drug|Ramucirumab|IV Q2W
76040820|NCT05002127|Drug|Paclitaxel|IV Days 1, 8, and 15 of a 28-day cycle
75410369|NCT00002532|Drug|asparaginase|
75410370|NCT00002532|Drug|cytarabine|
75713700|NCT00874419|Drug|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
75410371|NCT00002532|Drug|daunorubicin hydrochloride|
75713701|NCT00547378|Device|InterStim|
75713702|NCT00547378|Drug|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
76040821|NCT04863547|Other|Data collection|Data collection
75410372|NCT00002532|Drug|dexamethasone|
75410373|NCT00002532|Drug|etoposide|
75410374|NCT00002532|Drug|idarubicin|
75410375|NCT00002532|Drug|ifosfamide|
75410376|NCT00002532|Drug|leucovorin calcium|
75410377|NCT00002532|Drug|methotrexate|
75410378|NCT00002532|Drug|prednisolone|
75410379|NCT00002532|Drug|vindesine|
75410380|NCT00002538|Procedure|laparoscopic surgery|
75410381|NCT00002544|Drug|docetaxel|
75410382|NCT00002544|Drug|mitoxantrone hydrochloride|
75410383|NCT00002550|Drug|cisplatin|
75410384|NCT00002550|Drug|etoposide|
75410385|NCT00002550|Procedure|conventional surgery|
75410386|NCT00002550|Radiation|radiation therapy|
75410387|NCT00002556|Drug|vincristine sulfate|Given IV
75410388|NCT00002556|Drug|carmustine|Given IV
75410389|NCT00002556|Drug|melphalan|Given PO
75410390|NCT00002556|Drug|cyclophosphamide|Given IV
75410391|NCT00002556|Drug|prednisone|Given PO
75410392|NCT00002556|Biological|recombinant interferon alfa-2b|Given SC
75410393|NCT00002556|Other|laboratory biomarker analysis|Correlative studies
75554689|NCT06065527|Behavioral|Map Our Life|The intervention takes participants through the process of planning using the Preparation for Future Care Model stages: care expectation, awareness, information gathering, decision making, and concrete planning. The intervention has 8 modules: (1) Letter of Intent for Your Loved One, (2) Caregiver Support and Well-Being, (3) Medical Decision Making for Your Loved One, (4) Daily Routines and Medical Management, (5) Medicaid Waiver for Your Loved One, (6) Financial Planning for Your Loved One, (7) Emergency Planning for Your Loved One, and (8) Managing Jobs, Day Programs, and Transportation. Map Our Life takes users - the caregiver alongside the individual with intellectual disability - through the stages of planning in each of the 8 modules until a concrete care plan is developed. The last component of the intervention is that this Care Plan is subsequently saved and shared with others such as care managers, clinicians, friends or family members.
75554690|NCT06065527|Behavioral|Attention Control|The control group will have access to a CDC Website, CDC Healthy Living with a Disability.
75554691|NCT06064890|Procedure|Intrathalamic AAV.PGRN administration|One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain
75410394|NCT00002562|Drug|paclitaxel|
75554692|NCT06064890|Genetic|Intrathalamic AVB-101|AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
75554693|NCT06064097|Procedure|Biopsy|Undergo tissue biopsy
75554694|NCT06064097|Procedure|Biospecimen Collection|Undergo blood and stool sample collection
75713703|NCT00381043|Drug|Acamprosate (Campral)|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
75713704|NCT02534701|Device|ERIC® and SOFIA™|a self-expanding clot retrieval system
75713705|NCT00962338|Behavioral|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
75713706|NCT01050985|Drug|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
75713707|NCT04010656|Procedure|PVR-based self-catheterization|Home self-catheterization based on standard of care
75872467|NCT03463577|Other|Safety assessment following routine immunization with Boostrix|Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
75872468|NCT04667884|Dietary Supplement|Prebiotics or Probiotics|All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.
75410395|NCT00002568|Drug|cisplatin|
75872469|NCT05761002|Biological|the Quadrivalent Vaccine (Gardasil)|• Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions.
75872470|NCT03424824|Drug|BP1.3656 low dose|Tablet, once daily oral administration at the low dose
75554695|NCT06064097|Procedure|Chest Radiography|Undergo chest x-ray
75554696|NCT06064097|Drug|Cisplatin|Given IV
75554697|NCT06064097|Procedure|Computed Tomography|Undergo CT
75554698|NCT06064097|Procedure|Echocardiography|Undergo ECHO
75554699|NCT06064097|Other|Electronic Health Record Review|Ancillary studies
75554700|NCT06064097|Other|Fluciclovine F18|Given IV
75554701|NCT06064097|Drug|Gemcitabine|Given IV
75554702|NCT06064097|Procedure|Magnetic Resonance Imaging|Undergo MRI
75554703|NCT06064097|Procedure|Multigated Acquisition Scan|Undergo MUGA
75554704|NCT06064097|Biological|Nivolumab|Given IV
75554705|NCT06064097|Procedure|Positron Emission Tomography|Undergo PET
75872471|NCT03424824|Drug|BP1.3656 intermediate dose|Tablet, once daily oral administration at the intermediate dose
75872472|NCT03424824|Drug|Placebo|Tablet, once daily oral administration
75410396|NCT00002568|Drug|paclitaxel|
75410397|NCT00002568|Procedure|conventional surgery|
75410398|NCT00002574|Biological|recombinant interferon alfa|
75410399|NCT00002574|Drug|omacetaxine mepesuccinate|
75410400|NCT00002580|Drug|cyclophosphamide|
75410401|NCT00002580|Drug|fluorouracil|
75410402|NCT00002580|Drug|goserelin acetate|
75410403|NCT00002580|Drug|leuprolide acetate|
75410404|NCT00002580|Drug|methotrexate|
75410405|NCT00002580|Drug|tamoxifen citrate|
75410406|NCT00002580|Procedure|conventional surgery|
75410407|NCT00002580|Procedure|laparoscopic surgery|
75410408|NCT00002580|Procedure|oophorectomy|
75410409|NCT00002580|Radiation|radiation therapy|
75410410|NCT00002586|Drug|13-cis retinoic acid|
75872473|NCT03424824|Drug|BP1.3656 high dose|Tablet, once daily oral administration at the high dose
75872474|NCT04661956|Procedure|Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)|Transbronchial lung biopsy by cryoprobe or by forcep
76040822|NCT04874389|Diagnostic Test|Multimodal Assessment|Participants will complete BISQ/health questionnaire and proceed to each testing station with 15 minute rest breaks in between randomly ordered assigned stations.
75410411|NCT00002586|Dietary Supplement|Tocopherol|
75410412|NCT00002592|Biological|c-myb antisense oligonucleotide G4460|
75872475|NCT05060172|Device|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data."
75410413|NCT00002592|Biological|filgrastim|
75410414|NCT00002592|Drug|busulfan|
75713708|NCT00962416|Device|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
75713709|NCT00962416|Device|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
75410415|NCT00002592|Drug|cyclophosphamide|
75410416|NCT00002592|Procedure|autologous bone marrow transplantation|
75410417|NCT00002592|Procedure|in vitro-treated bone marrow transplantation|
75410418|NCT00002598|Biological|recombinant interferon alfa|
75410419|NCT00002598|Biological|sargramostim|
75410420|NCT00002598|Drug|cyclophosphamide|
75410421|NCT00002598|Drug|cytarabine|
75410422|NCT00002598|Drug|etoposide|
75554706|NCT06064097|Other|Quality-of-Life Assessment|Ancillary studies
75554707|NCT06064097|Other|Questionnaire Administration|Ancillary studies
75554708|NCT06064097|Radiation|Radiation Therapy|Receive radiation therapy
75554709|NCT06064097|Procedure|X-Ray Imaging|Undergo dental x-ray
76040823|NCT04873921|Other|sterile kinesio taping|Application area will be cleaned and dried prior to application to increase the adhesiveness of the tape and application will be done by an experienced physiotherapist during ACLR surgery.
76040824|NCT04869241|Diagnostic Test|surface EMG|Carrying backpacks forward or backward
76040825|NCT04429867|Drug|Hydroxychloroquine|Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
76040826|NCT04429867|Drug|Placebo|Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
75410423|NCT00002598|Drug|methotrexate|
75410424|NCT00002598|Drug|mitoxantrone hydrochloride|
75410425|NCT00002598|Procedure|bone marrow ablation with stem cell support|
75410426|NCT00002598|Radiation|radiation therapy|
75410427|NCT00002604|Drug|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
75410428|NCT00002604|Drug|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
75410429|NCT00002604|Drug|chemosensitization/potentiation therapy|
75410430|NCT00002610|Biological|dactinomycin|
75410431|NCT00002610|Biological|filgrastim|
75410432|NCT00002610|Drug|carboplatin|
75410433|NCT00002610|Drug|cyclophosphamide|
75410434|NCT00002610|Drug|doxorubicin hydrochloride|
75410435|NCT00002610|Drug|etoposide|
75410436|NCT00002610|Drug|vincristine sulfate|IV
75410437|NCT00002610|Procedure|conventional surgery|
75410438|NCT00002610|Radiation|radiation therapy|
75410439|NCT00002616|Biological|aldesleukin|
75410440|NCT00002616|Biological|filgrastim|
75410441|NCT00002616|Drug|carboplatin|
75410442|NCT00002616|Drug|cyclophosphamide|
75713710|NCT00614991|Drug|Raltegravir|400mg BID
75713711|NCT00614991|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
75713712|NCT00614991|Drug|Ritonavir|100 mg BID or QD
75713713|NCT00962494|Behavioral|Cancer: Thriving and Surviving Online Workshop|
75713714|NCT04010032|Device|Programmed intermittent epidural bolus|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device
75713715|NCT04010032|Device|Continuous epidural infusion|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
75713716|NCT00360529|Drug|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
75872476|NCT04983927|Device|cASPECTS|Clinical decision support system for scoring ASPECTS score
75872477|NCT01477008|Device|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
75872478|NCT01477008|Procedure|Marrow Stimulation|Microfracture or Subchondral Drilling
76040827|NCT03044041|Drug|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
75713717|NCT04858971|Other|Perception of information source|Participants will see the same health advice, with no source or one of three other sources indicated
75713718|NCT02247388|Behavioral|Computerized Alcohol Screening|iPad based automated alcohol screening
75410443|NCT00002616|Drug|thiotepa|
75713719|NCT02247388|Behavioral|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
75713720|NCT00874575|Dietary Supplement|Placebo|
75410444|NCT00002616|Procedure|peripheral blood stem cell transplantation|
75713721|NCT00874575|Dietary Supplement|Vitamin D|
75713722|NCT00874575|Dietary Supplement|Beta-hydroxy-Beta-methylbutyrate|
75713723|NCT00874575|Drug|Beta-hydroxy-Beta-methylbutyrate and Vitamin D|
75713724|NCT02009800|Biological|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
75410445|NCT00002622|Drug|talc|4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
75410446|NCT00002622|Drug|Talc|4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
75410447|NCT00002634|Biological|filgrastim|
75410448|NCT00002634|Biological|monoclonal antibody 3F8|
75713725|NCT05205213|Other|Surgical Technique (lateral retromuscular preperitoneal)|Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
75713726|NCT05205057|Other|Saliva|Unstimulated whole saliva is collected
75713727|NCT00874653|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
75713728|NCT00369577|Drug|Inhaled Placebo|Inhaled Placebo, single dose
75713729|NCT00369577|Drug|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
75713730|NCT00369577|Drug|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
75713731|NCT02559336|Other|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
75713732|NCT00879957|Drug|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
75410449|NCT00002634|Drug|cisplatin|
75713733|NCT00879957|Drug|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
75713734|NCT00874809|Device|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
75410450|NCT00002634|Drug|cyclophosphamide|
75410451|NCT00002634|Drug|doxorubicin hydrochloride|
75410452|NCT00002634|Drug|etoposide|
75410453|NCT00002634|Drug|mesna|
75410454|NCT00002634|Drug|perfosfamide|
75410455|NCT00002634|Drug|vincristine sulfate|
75410456|NCT00002634|Procedure|autologous bone marrow transplantation|
75410457|NCT00002634|Procedure|in vitro-treated bone marrow transplantation|
75410458|NCT00002634|Radiation|low-LET cobalt-60 gamma ray therapy|
75410459|NCT00002634|Radiation|low-LET photon therapy|
75410460|NCT00002634|Radiation|radioisotope therapy|
75410461|NCT00002646|Drug|fenretinide|
75410462|NCT00002646|Drug|tamoxifen citrate|
75410463|NCT00002652|Drug|suramin|
75713735|NCT02534155|Device|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
75713736|NCT02534155|Procedure|Mitral valve Surgery|Repair or replace mitral valve
75713737|NCT00880035|Device|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
75713738|NCT00761436|Biological|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
75713739|NCT00880113|Procedure|Non-contrast CT, CT-perfusion and CT-angiography|Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
75872479|NCT01374399|Behavioral|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
75713740|NCT00880347|Device|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
75713741|NCT00874965|Device|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
75713742|NCT00874965|Device|Sham stimulation|30 min; 5 times / week
75713743|NCT00875199|Behavioral|contingency management|Prize-based contingency management for weight loss
75713744|NCT00875199|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
75713745|NCT00875355|Drug|temozolomide|Given orally
75713746|NCT00875355|Radiation|radiation therapy|Patients undergo radiotherapy
75713747|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
75713748|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
75713749|NCT04772859|Behavioral|Online Lifestyle Intervention|"The intervention will be based on the Planet Nutrition program. This program was previously designed by the present research group and has a handbook that includes nutrition topics, framed by different behavior change strategies. The nutrition education and physical activity sessions will be offered 3 days a week, in the same 1-hour class: 30 minutes for each.~Nutrition education: presentations based on the Planet Nutrition program, a dedicated website, and the Zoom application, will be used to deliver the intervention. The website will be used to upload the nutrition materials and the recorded sessions. Participants will work on self-monitoring of different health behaviors.~Physical activity: The classes will be delivered by the Physical Activity team through the Zoom application. A website will be used to upload the recorded sessions.~Parents participation. The same website and a private Facebook group will be used to upload nutrition information once a week."
76040828|NCT03047941|Diagnostic Test|Determination of optimal cutoff values.|The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
76040829|NCT04863391|Diagnostic Test|Referrable versus Non Referral AMD diagnostic test|Artificial intelligence read reports Referrable versus Non Referral AMD
75410464|NCT00002658|Biological|filgrastim|
75410465|NCT00002658|Drug|amsacrine|
75410466|NCT00002658|Drug|cyclophosphamide|
75410467|NCT00002658|Drug|cytarabine|
75713750|NCT04772859|Other|Control Group|They will receive one digital brochure with general information on a healthy diet, at the beginning of the program.
75713751|NCT00880659|Behavioral|Soap|Promotion of handwashing with soap
76040830|NCT04869007|Device|hysterosonography|Isthmocele mesured by hysterosonography before ART procedure
76040831|NCT05029427|Other|High molecular weight β-glucan oat cookies|Two cookies that contains 4g beta glucan made from oats will be consumed per day.
76040832|NCT05029427|Other|Control wheat based cookies|Two cookies that made from cream of wheat without beta glucan will be consumed per day.
76040833|NCT04429789|Behavioral|Active-Alert Hypnosis|Participants in this arm will receive four one-hour weekly sessions that will include training in a rapid self-hypnosis method. Participants will learn how to use waking hypnosis to manage fatigue using exercises with sensory experiences.
75410468|NCT00002658|Drug|daunorubicin hydrochloride|
75410469|NCT00002658|Drug|etoposide|
75410470|NCT00002658|Drug|idarubicin|
75410471|NCT00002658|Drug|mitoxantrone hydrochloride|
75410472|NCT00002658|Drug|thioguanine|
75713752|NCT04038879|Diagnostic Test|MRI|MRI of the heart
75410473|NCT00002658|Drug|tretinoin|
75410474|NCT00002658|Procedure|allogeneic bone marrow transplantation|
75410475|NCT00002658|Procedure|autologous bone marrow transplantation|
75410476|NCT00002658|Procedure|peripheral blood stem cell transplantation|
75410477|NCT00002658|Radiation|radiation therapy|
75410478|NCT00002664|Biological|edrecolomab|
75554710|NCT06061003|Other|Clinical Anatomical Education with Fractured Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. In the practical session, anatomical structures, their relationships, and arrangements will be demonstrated to the practice group using a model of a fractured wrist.
75410479|NCT00002664|Biological|sargramostim|
75554711|NCT06061003|Other|Clinical Anatomical Education with Standard Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. The control group will receive the same practical session using a standard anatomical model.
75713753|NCT00880815|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
75713754|NCT00880815|Biological|Anti-Thymocyte Globulin|Given IV
75713755|NCT00880815|Drug|Bendamustine|Given IV
75713756|NCT00880815|Biological|Filgrastim|Given IV
75713757|NCT00880815|Drug|Fludarabine|Given IV
75713758|NCT00880815|Drug|Methotrexate|Given IV
75410480|NCT00002670|Drug|chemotherapy|
75410481|NCT00002670|Drug|cisplatin|
75713759|NCT00880815|Biological|Rituximab|Given IV
75713760|NCT00880815|Drug|Tacrolimus|Given IV and PO
75713761|NCT00369343|Drug|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
75713762|NCT00369343|Drug|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
75713763|NCT00880971|Radiation|Postoperative 3D-CRT or IMRT|Postoperative radiotherapy using 3D-CRT or IMRT techniques, 2 Gy per fraction, total 25 fractions (50Gy) over 5 weeks.
76023318|NCT02404129|Other|Turn 180 test|"The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor."
75713764|NCT03992599|Procedure|Laparoscopic modified complete mesocolic excision|First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
75410482|NCT00002670|Radiation|low-LET cobalt-60 gamma ray therapy|
75410483|NCT00002670|Radiation|low-LET electron therapy|
75410484|NCT00002670|Radiation|low-LET photon therapy|
75410485|NCT00002676|Drug|carmustine|
75410486|NCT00002676|Drug|cyclophosphamide|
75410487|NCT00002676|Drug|cytarabine|
75410488|NCT00002676|Drug|dexamethasone|
75410489|NCT00002676|Drug|doxorubicin hydrochloride|
75410490|NCT00002676|Drug|methotrexate|
75410491|NCT00002676|Drug|vincristine sulfate|
75410492|NCT00002676|Radiation|low-LET cobalt-60 gamma ray therapy|
75410493|NCT00002676|Radiation|low-LET photon therapy|
75410494|NCT00002682|Drug|Amoxicillin|
75410495|NCT00002682|Drug|Bismuth Subsalicylate|
75410496|NCT00002682|Drug|Clarithromycin|
75410497|NCT00002682|Drug|Metronidazole Hydrochloride|
75713765|NCT00881049|Drug|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
76040834|NCT04429789|Behavioral|Traditional Hypnosis|Participants in this arm will receive four one-hour weekly sessions where participants will learn how to use hypnosis along with relaxation. The exercises and suggestions included in the training will be adapted from the protocol used in a series of studies on the efficacy of self-hypnosis training for the management of chronic pain in persons with disabilities, and from a therapist guide of procedures and hypnotic suggestions for chronic pain.
75410498|NCT00002682|Drug|Omeprazole|
75410499|NCT00002682|Drug|Tetracycline Hydrochloride|
75410500|NCT00002688|Drug|cyclosporine|
75410501|NCT00002688|Drug|etoposide|
75410502|NCT00002688|Drug|mitoxantrone hydrochloride|
75410503|NCT00002700|Drug|asparaginase|
75410504|NCT00002700|Drug|cyclophosphamide|
75713766|NCT00881127|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
75554712|NCT06058013|Drug|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
75410505|NCT00002700|Drug|cytarabine|
75554713|NCT06058013|Drug|Placebo|Placebo will be administered orally
75713767|NCT00881127|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
75713768|NCT00369265|Drug|Lansoprazole|Lansoprazole 30mg twice daily
75713769|NCT00369265|Dietary Supplement|Sugar pill|placebo twice daily
76040835|NCT05518955|Behavioral|Virtual reality and eye mask|Participates will receive a virtual reality program 30 min before their sleep and combine with the sleep routine program for consecutive 2 nights in the ICU.
75554714|NCT06057571|Drug|TT-00420 (tinengotinib)|TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
75554715|NCT06057038|Biological|GEN1042|Intravenous
75554716|NCT06057038|Drug|Pembrolizumab|Intravenous
75554717|NCT06057038|Drug|Cisplatin|Intravenous
75713770|NCT00875745|Drug|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
75713771|NCT00368875|Drug|vorinostat|Given orally
76040836|NCT04863235|Behavioral|Control Group|Eight week behavioural change program aimed to increase physical activity plus information on general health topics among individuals with prediabetes.
76040837|NCT04863235|Behavioral|Intervention Group|Eight week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes.
76040838|NCT03048097|Drug|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
76040839|NCT03048097|Drug|Rubidium|used in PET scans
75410506|NCT00002700|Drug|daunorubicin hydrochloride|
75410507|NCT00002700|Drug|dexamethasone|
75410508|NCT00002700|Drug|doxorubicin hydrochloride|
75410509|NCT00002700|Drug|leucovorin calcium|
75410510|NCT00002700|Drug|mercaptopurine|
75410511|NCT00002700|Drug|methotrexate|
75410512|NCT00002700|Drug|mitoxantrone hydrochloride|
75410513|NCT00002700|Drug|prednisolone|
75410514|NCT00002700|Drug|prednisone|
75410515|NCT00002700|Drug|therapeutic hydrocortisone|
75410516|NCT00002700|Drug|vincristine sulfate|
75410517|NCT00002700|Procedure|allogeneic bone marrow transplantation|
75410518|NCT00002700|Procedure|autologous bone marrow transplantation|
75410519|NCT00002700|Radiation|radiation therapy|
75554718|NCT06057038|Drug|Carboplatin|Intravenous
75554719|NCT06057038|Drug|5-Fluorouracil|Intravenous
75554720|NCT06056245|Procedure|Preoperative step|"Explanation of the surgery and use of the IV-PCA pump.~Signed informed consent."
75554721|NCT06056245|Drug|Intraoperative|Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
75554722|NCT06056245|Drug|Post-operative|Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
75713772|NCT00368875|Drug|paclitaxel|Given IV
75713773|NCT00368875|Biological|bevacizumab|Given IV
75713774|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
75713775|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
75713776|NCT00614055|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
75713777|NCT00614055|Drug|metformin|Tablets, 1500-2000 mg/day
75713778|NCT01051141|Behavioral|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
75410520|NCT00002706|Procedure|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
75713779|NCT01051141|Behavioral|Intervener-delivered Brief Intervention (IBI)|"The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
75713780|NCT01051141|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|The AMET session will have a similar general outline (~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
75713781|NCT04040127|Biological|Cord blood stem cells|Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
75713782|NCT04040127|Other|Saline solution|saline solution used to rinse the canal.
76040840|NCT03048097|Diagnostic Test|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
76040841|NCT03048253|Biological|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
75410521|NCT00002706|Other|Quality-of-Life Assessment|Ancillary studies
75410522|NCT00002706|Procedure|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
76040842|NCT05516303|Genetic|Genetic polymorphism|One blood tube will be taken for genetic testing
75410523|NCT00002718|Biological|anti-thymocyte globulin|
75410524|NCT00002718|Biological|filgrastim|
75410525|NCT00002718|Drug|cyclophosphamide|
75410526|NCT00002718|Drug|cytarabine|
75410527|NCT00002718|Drug|methylprednisolone|
75713783|NCT04039971|Procedure|ACL Reconstruction|Surgical techniques
75713784|NCT00613821|Drug|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
75713785|NCT00613821|Drug|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
75713786|NCT04038723|Behavioral|High-intensity interval training|Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
75713787|NCT00882765|Dietary Supplement|genistein|Given orally
75410528|NCT00002718|Drug|thiotepa|
75410529|NCT00002718|Procedure|in vitro-treated bone marrow transplantation|
75410530|NCT00002718|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75410531|NCT00002718|Radiation|radiation therapy|
75410532|NCT00002730|Drug|buthionine sulfoximine|
75410533|NCT00002730|Drug|melphalan|
75410534|NCT00002742|Drug|amphotericin B deoxycholate|
75410535|NCT00002742|Drug|nystatin|
75410536|NCT00002748|Biological|gene-modified tumor cell vaccine therapy|
75410537|NCT00002748|Biological|interleukin-2 gene|
75410538|NCT00002754|Biological|monoclonal antibody Me1-14 F(ab')2|
76040843|NCT05516303|Diagnostic Test|Measurement of fingolimod and fingolimod-phosphate concentrations|Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time
75554723|NCT06054256|Behavioral|Group CBT-I|The group-based intervention will consist of 6 weekly sessions (90-min, 5-8 pregnant women in each group). The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia with the followings: psycho-education about sleep and sleep hygiene (e.g., psychoeducation about sleep during pregnancy and normal development and patterns of infant sleep, psychoeducation on ways of improving infant sleep, strategies to limit the development of unwanted sleep associations, etc.), stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
75554724|NCT06054256|Behavioral|App-based CBT-I|The smartphone app-based intervention will consist of 6 weekly sessions. The app-based intervention will involve a self-paced, fully automated digital programme with interactive components. The structure of the app involves six sequential modules (comparable to the six treatment sessions delivered in groups) with different elements to engage the users, such as animated videos, case vignettes, narration, quizzes, and homework assignment. Each module will be unlocked and released to the participants every week after the previous module has been completed. Personalised feedback will be provided by the app following the completion of sleep diary each week. Automated messages will be sent to the participants regularly via phone to remind them of implementing learned strategies after each module, as well as timely completing the treatment modules and sleep diaries.
75554725|NCT06054256|Other|Health related psychoeducation|The control group will receive 6 sessions of group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components.
75554726|NCT06053281|Drug|Cholecalciferol|Daily Cholecalciferol 1000 IU in 24 weeks
75554727|NCT06053281|Other|Placebo|Placebo
75713788|NCT04543695|Combination Product|Concurrent Chemoradiotherapy|"Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
76040844|NCT04863079|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.
75713789|NCT04543695|Drug|XELOX|"Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course"
75713790|NCT04543695|Drug|mFOLFOX|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
75713791|NCT04543695|Procedure|TME|Total mesorectal excision
75410539|NCT00002760|Drug|ketoconazole|400 mg PO tid for as long as treatment is effective
75410540|NCT00002760|Drug|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
75410541|NCT00002760|Other|Withdrawal of antiandrogen therapy|no drugs given
75410542|NCT00002772|Biological|filgrastim|
75410543|NCT00002772|Drug|carboplatin|
75410544|NCT00002772|Drug|carmustine|
75410545|NCT00002772|Drug|cisplatin|
75410546|NCT00002772|Drug|cyclophosphamide|
75410547|NCT00002772|Drug|doxorubicin hydrochloride|
75410548|NCT00002772|Drug|paclitaxel|
75410549|NCT00002772|Drug|tamoxifen citrate|
75410550|NCT00002772|Drug|thiotepa|
75410551|NCT00002772|Procedure|autologous bone marrow transplantation|
75410552|NCT00002772|Procedure|peripheral blood stem cell transplantation|
75410553|NCT00002772|Radiation|radiation therapy|
75410554|NCT00002778|Biological|sargramostim|
75410555|NCT00002778|Biological|therapeutic allogeneic lymphocytes|
75410556|NCT00002778|Procedure|allogeneic bone marrow transplantation|
75410557|NCT00002778|Procedure|in vitro-treated bone marrow transplantation|
75410558|NCT00002784|Biological|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
75410559|NCT00002784|Drug|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
75410560|NCT00002784|Drug|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
75410561|NCT00002784|Drug|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
75410562|NCT00002784|Drug|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
75410563|NCT00002784|Drug|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
75410564|NCT00002784|Drug|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
75554728|NCT06052319|Device|Care4Today® Connect CAD-PAD Mobile Application|Participants will not receive any drug intervention in this study. Participants will use Care 4Today® Connect CAD-PAD mobile application for 3 months. The study will assess participant engagement and usefulness.
75554729|NCT06052176|Drug|Albumin Infusion|Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
75554730|NCT06048133|Drug|Gemcitabine|Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days
75410565|NCT00002784|Drug|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
75554731|NCT06048133|Drug|Cisplatin|Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.
75554732|NCT06048133|Drug|Zimberelimab|Zimberelimab IV: Day 1 and 22 every 42 days
75713792|NCT00548548|Drug|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
75713793|NCT00548548|Drug|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
75713794|NCT00548548|Drug|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
75410566|NCT00002784|Drug|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
75410567|NCT00002784|Procedure|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
75713795|NCT00548548|Drug|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
75713796|NCT00548548|Drug|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
75713797|NCT00613509|Biological|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
75410568|NCT00002784|Radiation|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
75410569|NCT00002784|Radiation|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
75410570|NCT00002790|Drug|cyclosporine|
75410571|NCT00002790|Drug|methotrexate|
75410572|NCT00002790|Drug|sirolimus|
75410573|NCT05752578|Other|Neuropsychological testing|During the session the patient will be administered the Memory for Intentions Screening Test (MIST; Raskin et al., 2010) with the purpose of investigating prospective memory ability. Then during the same meeting the following tests will be offered to the patient: Montreal Cognitive Assessment (MOCA; Nasreddine. Translation Pirani et al 2006) investigating global cognitive performance; - Interpersonal Reactivity Index (IRI; Davis, 1980;1983- Italian version edited by Bonino et al, 1998) with the purpose of assessing cognitive and affective empathy (Hot cognition); Modified Five Point Test (Ruffi et al 1987) aimed at assessing figurative fluency (Cold cognition).
75554733|NCT06048133|Drug|Quemliclustat|Quemliclustat IV: Day 1, 15, 29 every 42 days
75554734|NCT06046274|Biological|Pembrolizumab|Pembrolizumab intravenous (IV) infusion
75554735|NCT06046274|Biological|Acasunlimab|Acasunlimab IV infusion
75554736|NCT06041204|Drug|Letrozole 2.5mg|Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.
75713798|NCT00613509|Biological|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
75410574|NCT05752422|Device|Niraxx G1 Headband Device including sham|Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
75713799|NCT00881439|Drug|Aliskiren|Oral, 300 mg, once daily, 6 months
75410575|NCT05752344|Other|Counseling|Professional Counseling is an activity that aims to improve the client's quality of life. Supporting his strengths and his ability to self-determination, Counseling offers a space for listening and reflection in which to explore difficulties, related to evolutionary processes, transition phase, states of crisis and reinforcement of the ability to choose or change.
75410576|NCT05752188|Other|Multimarker approach in acute coronary syndrome|The main objective of the study is to evaluate the prognostic role of the biochemical marker sST2 in patients attending the Emergency Department of our hospital with acute chest pain with suspected acute coronary syndrome.
75410577|NCT05751954|Radiation|Postero-anterior weight-bearing full-leg radiograph|Full leg standing X ray of the involved lower extremity (postero-anterior direction)
75410578|NCT05751954|Device|Pedobarographic analysis|Foot pressure analysis during gait on pedobarographic device
76040845|NCT05512325|Drug|Gene evolution and molecular response under Bevacizumab treatment|Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) * 150mg/m2/day BSA(Body Surface Area)=[weight (kg)* height (cm)/3600]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes
75410579|NCT05751876|Drug|Dienogest|Dienogest 2mg was prescribed once per day orally
75713800|NCT00881439|Drug|Placebo|Matching Placebo once daily, 6 months
75713801|NCT00881517|Drug|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
75713802|NCT00881517|Drug|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
75713803|NCT00881595|Drug|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
75713804|NCT00881595|Radiation|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
75713805|NCT00881595|Procedure|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
75713806|NCT00883155|Drug|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
75713807|NCT00883155|Drug|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
76040846|NCT04868383|Behavioral|Use of smart phone technology to support medication adherence and uptake|Use of smart phone technology to support medication adherence and uptake
76040847|NCT05518643|Procedure|ERAS protocol|ERAS protocol as described above
76040848|NCT03047863|Drug|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
76040849|NCT03047863|Drug|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
75410580|NCT05751798|Drug|OSE-279 100mg|Human IgG4 mAb against PD-1
75410581|NCT05751798|Drug|OSE-279 300mg|Human IgG4 mAb against PD-1
75410582|NCT05751798|Drug|OSE-279 500mg|Human IgG4 mAb against PD-1
75410583|NCT05751564|Biological|"Ready to inject Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product"|Cryopreserved thaw & inject MSC intra-articular therapy
75713808|NCT01505062|Drug|SAR421869|"Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
75713809|NCT00881673|Drug|AL38583 Ophthalmic Solution|Topical ophthalmic
75713810|NCT00881673|Drug|Maxidex|Topical ophthalmic
75713811|NCT00881673|Drug|Vehicle|AL38583 Vehicle
75713812|NCT00881829|Device|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
76023319|NCT04831775|Behavioral|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice and will be held over 8 weeks. The classes will be taught by a GRA. Classes 1 & 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 & 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. Each online class will follow the same format: (1) introduction/revisiting content from the previous class; (2) review of progress on computer exercises; (3) practicing cognitive strategies in class; and (4) a weekly topic. The GRA will also prescribe exercises for the following weeks.
76023320|NCT04831775|Behavioral|Brain Games|The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Participants will only need a computer, smart phone, or tablet with Internet access to securely log onto the website. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on.
76023321|NCT02404051|Drug|Everolimus|10 mg daily tablets
76040850|NCT04868227|Dietary Supplement|FULTIUM D3 VITAMIN D3|VITAMIN D3 SUPPLEMENT
75410584|NCT05751564|Biological|Resuspended Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product|Cryopreserved resuspended MSC intra-articular therapy
76040851|NCT04863001|Drug|Antiarrhythmic drug|all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university
75713813|NCT01293448|Device|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
75713814|NCT00961714|Device|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
75713815|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
75713816|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
75713817|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
75713818|NCT04487925|Drug|A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation|CFA will be administered in combination with Follitropin beta.
75713819|NCT04487925|Drug|Up to three modified natural cycles with Follitropin beta.|Follitropin beta in a low dose will be given.
75713820|NCT00547300|Drug|Metoprolol ER|Metoprolol ER once daily, oral administration
75713821|NCT00547300|Drug|Nebivolol|Nebivolol once daily, oral administration
75410585|NCT05751486|Biological|Toripalimab injection(subcutaneous)/JS001sc|JS001sc Q3W combination with gemcitabine and cisplatin.
75410586|NCT05751486|Biological|Toripalimab injection(subcutaneous)/JS001sc|JS001sc long period combination with gemcitabine and cisplatin.
75713822|NCT04386759|Other|Cohort|None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.
75713823|NCT00958516|Drug|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
75713824|NCT00881985|Device|continuous positive airway pressure|Use CPAP whenever sleep
75410587|NCT05751486|Biological|Toripalimab /JS001|JS001 IV (if applicable) .
75410588|NCT05751486|Biological|Toripalimab injection(subcutaneous)/JS001sc|Additional cohort (if applicable)
75713825|NCT00962572|Behavioral|Patient management|"Aggressive patient management will be implemented by a corps of patient manager volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged."
75713826|NCT00612807|Behavioral|Weekly marital therapy|Weekly marital therapy for 6 months.
76023322|NCT02404051|Drug|Exemestane|25 mg daily tablets
75410589|NCT05751408|Procedure|gait analysis using 3D (Vicon) and IMU (Movella)|Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
75410590|NCT05751330|Procedure|Transcatheter ablation of cardiac ganglionated plexi|"The ablative procedure involves applying radiofrequency deliveries in the two~Right atrium anatomical sites close to the two main ganglionic plexuses of the right atrium:~Inferior-posterior area (site of first ablation) corresponding to the right inferior atrial ganglion located between the inferior vena cava, coronary sinus ostium and near the atrioventricular node~Upper-posterior area (site of second ablation) corresponding to the right superior atrial ganglion located between the superior vena cava and the posterior surface of the right atrium"
75410591|NCT05751252|Drug|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.0625 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
75410592|NCT05751252|Drug|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.025 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
75410593|NCT05751174|Other|pediatric patients affected by severe burns|All patients admitted to the pediatric intensive care unit affected by severe burns involving more than 10% of the body surface will be enrolled.
75410594|NCT00002628|Biological|filgrastim|
75410595|NCT00002628|Drug|carboplatin|
75410596|NCT00002628|Drug|cyclophosphamide|
75410597|NCT00002628|Drug|mesna|
75554737|NCT06041204|Drug|Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet|Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
75554738|NCT06041048|Drug|Modafinil|Single dose (200 mg) of medication versus placebo given to healthy control subjects
75554739|NCT06039189|Drug|Guselkumab|Guselkumab will be administered as subcutaneous injection.
75554740|NCT06039189|Drug|Placebo|Placebo will be administered as subcutaneous injection.
76023323|NCT02404051|Drug|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
76023324|NCT05102357|Procedure|Conservative Treatment (splint)|splint 6 weeks
76023325|NCT02406547|Device|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
76023326|NCT02406547|Device|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
75713827|NCT00612807|Drug|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|"Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)"
75713828|NCT00962806|Behavioral|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
75554741|NCT06032013|Other|Cardiac rehabilitation program (PROMs)|"The program is multidisciplinary with the following components:~Medical assessment~Physical training and counselling on physical activity~Identification and control of risk factors~Nutritional assessment and counselling~Psychological assessment and intervention~Education and information"
75554742|NCT06030141|Other|sesame oil application|sesame oil application
75554743|NCT06030141|Other|nigella sativa oil application|nigella sativa oil application
75713829|NCT00962806|Behavioral|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
75554744|NCT06028438|Drug|Placebo|Placebo will be administered intravenously.
75554745|NCT06028438|Drug|Nipocalimab|Nipocalimab will be administered intravenously.
75554746|NCT06028438|Drug|Certolizumab|Certolizumab will be administered subcutaneously.
75554747|NCT06025292|Other|Lean Pork vs Plant Based|Participants will eat pre prepared study meals for three days that have either protein sourced from lean pork or plant sources.
75554748|NCT06020274|Behavioral|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF. Upon logging on to the iCF-PWR, the viewer will see two paths (i.e., child with CF or sibling) and will be encouraged by program narrator to choose the appropriate path. Each pathway (i.e., child with CF or sibling) is comprised of five text/voice-delivered, animated, interactive modules: (1) CF education, (2) CF health, (3) emotions and CF, (4) cognitive behaviour model of emotions, and (5) coping strategies. Each module takes 15-20 minutes to complete.
75554749|NCT06020157|Other|Simple Suture Technique|The half of the full arch flap will be closed by the simple suture technique.
75554750|NCT06020157|Other|Continuous Suture Technique|The half of the full arch flap will be closed by the continuous suture technique.
75554751|NCT06019975|Diagnostic Test|FDG-PET|Brain FDG-PET
75554752|NCT06018844|Other|NUDGE|NUDGE is a brief mHealth text messaging intervention designed to promote activity in adolescents by allowing them to set, monitor, and receive feedback on daily PA goals through text message.
75554753|NCT06018129|Biological|GEN3017|Subcutaneous injection
75554754|NCT06016842|Drug|Elafibranor|Duration: up to an estimated 84-month (7-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily
75554755|NCT06016842|Other|Matched 80 mg placebo|Duration: up to an estimated 84-month (7-year) double-blind treatment period during which matching placebo tablet will be administered once daily
75554756|NCT06016348|Procedure|Endovascular treatment|This procedure is instrumental in restoring cerebral blood flow by addressing the clot-induced obstruction within brain-supplying blood vessels.
75554757|NCT06015789|Other|Questionnaire|Administration of questionnaires for the evaluation of self-care
75713830|NCT05299684|Other|EVALUATION|The level of addiction was assessed with the Smartphone Addiction Scale Short Form (SAS-SF). The posture of participants was evaluated by New York Posture Rating Chart (NYPRC), mostly usage smartphone posture, forward head and myofascial trigger points were questioned according to Simon and Travel criteria. Mann-Whitney U test Pearson's chi-squared test were used for analyzing the data.
75713831|NCT04038801|Procedure|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed by assortment of manuel periodontal curettes over four visits at 1-weekly intervals.
75713832|NCT04038801|Procedure|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
75713833|NCT04038801|Procedure|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
75410598|NCT00002628|Drug|paclitaxel|
75410599|NCT00002628|Procedure|peripheral blood stem cell transplantation|
75410600|NCT05751018|Drug|Pyrotinib|Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
75410601|NCT05750940|Diagnostic Test|31Phosphor Magnetic Resonance Spectroscopy|Measurement of skeletal oxidative metabolism with 31phosphor magnetic resonance spectroscopy
75410602|NCT05750784|Procedure|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
75410603|NCT05750706|Other|observation of invasive fungal infections|observation of invasive fungal infections during chemotherapy
75410604|NCT05750394|Procedure|Uterine layers closed|Uterus closed with 1, 2 or 3 layers
75410605|NCT05750394|Device|Suture Type|Barbed or smooth
75410606|NCT05750394|Procedure|Endometrium|Included or excluded
75554758|NCT06014008|Other|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
75554759|NCT06012084|Behavioral|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF.
76040852|NCT04873531|Drug|Neostigmine|"For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
75554760|NCT06011876|Other|Acute Intermittent Hypoxia (AIH)|AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
75554761|NCT06011876|Other|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).
75554762|NCT06011876|Other|Sham AIH|A single session of sham AIH with episodes of normal room air (21% O2).
75554763|NCT06010628|Drug|Tenecteplase|intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
75554764|NCT06009614|Dietary Supplement|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
75713834|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
75713835|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
76040853|NCT04873531|Drug|Normal saline|"For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
76040854|NCT03045601|Diagnostic Test|CT-FFR|Invasive FFR and CCTA With CT-FFR
75554765|NCT06009614|Dietary Supplement|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
75554766|NCT06009614|Dietary Supplement|Radicle GI Health Placebo Control Form 2|Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.
75554767|NCT06009614|Dietary Supplement|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
75713836|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
76040855|NCT03045601|Diagnostic Test|Stress echocardiography|Stress echocardiography and invasive FFR
76040856|NCT02572817|Biological|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
76040857|NCT02572817|Biological|Low-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
76040858|NCT04862845|Drug|Duloxetine and Pregabalin|will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.
76040859|NCT04862845|Drug|pregabalin|received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.
76040860|NCT04862845|Drug|sham|received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
75410607|NCT05750238|Other|no intervention|no intervention, survey was applied to the participants
75410608|NCT05749614|Drug|Lidocaine cream|Group 1 was given 1 ml of 5% lidocaine cream on demand. They were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. The treatment lasted for a total of 4 weeks.
75410609|NCT05749614|Drug|Lidocaine cream|Group 2 had a penile biological vibration threshold test performed to detect loci with a lower threshold. They were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks.
75410610|NCT05749380|Drug|AmBisome|Reference, dose of 3 mg/kg.
75410611|NCT05749380|Drug|DKF-5122|Test, dose of 3 mg/kg
75410612|NCT05749302|Drug|Al18F-NOTA-FAPI|Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
75554768|NCT06009614|Dietary Supplement|Radicle GI Health Active Study Product 2.2 Usage|Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.
75554769|NCT06009614|Dietary Supplement|Radicle GI Health Placebo Control Form 3|Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.
75554770|NCT06009614|Dietary Supplement|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
75554771|NCT06005675|Device|Intervention|No study treatments will be administered during this study.
75554772|NCT06005480|Drug|Mepivacaine|Injection of 1.5% Mepivacaine in nerve block
75554773|NCT06003218|Drug|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
75554774|NCT06003218|Drug|Remifentanil|Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
75713837|NCT00962962|Behavioral|Exercise and Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
75713838|NCT00882063|Drug|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
75713839|NCT00958672|Other|Endoscopic capsule|Endoscopic capsule
75410613|NCT05749224|Diagnostic Test|Helkimo Index|Helkimo Index is comprised of five items, with each assessment having three possible answers, scored as 0, 1 or 5. The first item is related to the limitation in the range of jaw movement. The second item evaluates the alterations of joint function that produce deviations, sounds and/or joint locks or blockages; the third item evaluates the presence of pain when performing some movements; the fourth item evaluates muscular pain in the masticatory muscles; and the fifth item evaluates the presence of discomfort or pain in the prearticular area of the temporomandibular joint (TMJ) through palpation. From the sum of the 5 items, we identify no TMJ involvement if the score is 0, mild TMJ involvement when the score ranges from 1 to 9, moderate TMJ involvement if the score ranges between 10 and 19 and severe TMJ involvement for a score between 20 and 25.
75410614|NCT05749068|Device|CapScan intestinal sampling device|CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.
75554775|NCT06003218|Drug|Oxycodone|Oxycodone will be injected intravenously 10-15 min before puncture.
75713840|NCT00958750|Drug|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
75713841|NCT00882141|Behavioral|Diet modification|Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
75713842|NCT00882141|Behavioral|Aerobic exercise|Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
75410615|NCT05748912|Procedure|Therapeutic bronchoscopy for removal of mucus plugs|Research participants that meet the study inclusion criteria will undergo a research bronchoscopy to remove airway mucus plugs from 1 lung for the first 5 participants, and, if single lung mucus removal is well tolerated, on both lungs for the next 5 participants.
75713843|NCT04902274|Other|Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the tDCS group will complete a 20-minute tDCS session while performing the warm-up.
75713844|NCT04902274|Other|Sham Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the sham tDCS group will complete a 20-minute sham-tDCS session while performing the warm-up, but the app will discontinue the treatment after 30 seconds.
76040861|NCT04873609|Behavioral|Patient portal message|Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory
75410616|NCT05748756|Other|Enucleation and filling by Bone marrow aspirate|"The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique."
75410617|NCT05748756|Other|Conventional enucleation only|patients were treated conventionally by enucleation and plain collagen sponge only.
75410618|NCT05745246|Behavioral|e-health training program|"Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information."
75410619|NCT05743374|Other|Normal diet|These patients will be given advice about a normal healthy diet.
75410620|NCT05743374|Dietary Supplement|E400 elimination|Patients in the intervention group will be given advice how to eliminate E440 additives with regard to carragenan, CMC and polysorbates.
75554776|NCT06002607|Other|Antibiotic duration|The patient will be enrolled in a 48-hour course of antibiotics.
76040862|NCT04873141|Drug|Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)|Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
75554777|NCT06002607|Other|Antibiotic duration|The patient will be enrolled in a 7 day course of antibiotics.
75554778|NCT05999305|Other|Teaching the critical care nursing course with an Escape Room game|A teacher will begin with a 1.5-hour lecture, followed by an escape room game to reinforce learning through case studies for another 1.5 hours. The first section of the game will be a ten-minute pre-brief. The game will then begin promptly at a designated time and will be played in groups of six to seven students, with each group seated separately in a classroom. The game will last up to fifty minutes, during which all groups will be assisted to complete puzzles within the time limit. After the game, a fifteen-minute debriefing session will be held by the teacher, during which the students will reflect on their performance and what they learned about the cases and related topics. The teacher will finally provide feedback and support to the groups during this session.
76023327|NCT04436549|Procedure|Stab Avulsion of varicose veins|Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.
76023328|NCT04436549|Diagnostic Test|Histopathologic evaluation of varicose veins|Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
76040863|NCT04862377|Drug|Poractant Alfa Intratracheal Suspension [Curosurf]|"Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg."
76040864|NCT04862377|Drug|Budesonide 0.5 MG/ML|"Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide."
76040865|NCT05516225|Drug|PBCLN-003|Human Milk Oligosaccharide Concentrate
75410621|NCT05739396|Other|core stabilization|The treatment session lasted one hour with short breaks of around 10 minutes and will be conducted three times per week for twelve successive weeks
75410622|NCT05739240|Procedure|Osteosynthesis|Osteosynthesis of distal radius fractures
75410623|NCT05688228|Other|questionnaire|Female Sexual Function Index (FSFI) and self-administrative questionnaires on sexuality just after abortion and repeated at 1, 3 and 6 months
75410624|NCT05682300|Procedure|peripheral nerve block|After signing the informed consent by the patient, specific for this observational study, the peripheral regional anesthesia technique will be performed following the usual practice of the anesthesiologist responsible for the surgery. Under standard monitoring and taking into account the necessary aseptic measures, either peripheral nerve blocks (for surgeries involving extremities) or fascial blocks (for surgeries involving the chest wall, abdomen, or spine) will be performed.
75554779|NCT05999305|Other|Teaching the critical care nursing course with a case-based learning|Students in the comparison group will also receive a 1.5 hour lecture which is the same as those in the intervention group. Another 1.5 hour is a case-based learning session, with six sessions in total over six weeks. The case-based learning sessions will include a pre-brief, teamwork, and debrief, and will be facilitated by the same teacher and teaching assistant and will primarily be provided with paper-based case studies.
75410625|NCT05677698|Other|Lemon oil|Lemon oil with massage
76040866|NCT04867993|Drug|Amikacin|15 mg/kg/36h
76040867|NCT04873219|Device|manufacturing a complete dental prosthesis|dental treatment to replace missing teeth
75554780|NCT05997420|Behavioral|STAR Program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
76040868|NCT04988009|Other|Electronic Health Record Review|Review of medical chart
75410626|NCT05677698|Other|peppermint oil|peppermint oil with massage
75410627|NCT05677698|Other|Almond oil|Almond oil massage
75410628|NCT05667168|Procedure|physiotherapy approach|The therapy will take place 2-3 times a week; the therapeutic unit will last 45 minutes and will be oriented towards one therapeutic approach from the above list. The total number of therapy sessions will be limited to 3 months (i.e. three months, 2-3 times a week). After completion of the 3-month therapy, a follow-up examination will be performed again by kinesiological analysis, questions about the intensity of tinnitus according to a numerical scale and quality of life by a selected questionnaire.
76023329|NCT03172585|Other|High resolution computed tomography|High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
76040869|NCT04988009|Other|Survey Administration|Complete survey
75410629|NCT05636358|Other|Home-based hypnotherapy|The home-based hypnotherapy package contains five standard hypnosis exercises. They consist of one breathing exercise, and four visualisation exercises. Two separate sets adjusted to the child's age will be used: one for children younger than 12 years and one for children of 12 years and older. The children will be asked to listen to the exercises at least 5 times per week, for approximately 15-20 minutes per day, during a period of 3 months. A workbook will provide children and/or parents with the instructions and planning of the exercises.
75410630|NCT05628870|Drug|HRS-1358|HRS-1358 will be administered daily orally in continuous dosing over 28-day cycles.
75410631|NCT05625282|Procedure|Weil osteotomy|Open, oblique, distal osteotomy of the metatarsal bone, with screw fixation.
75410632|NCT05625282|Procedure|Plantar plate repair|Plantar plate reconstruction at metatarsophalangeal area, using sutures.
76023330|NCT03172585|Other|trans thoracic ultrasonography|Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
76040870|NCT04872985|Drug|Pyrotinib|400 mg orally once per day
76040871|NCT04872985|Drug|Epirubicin|100 mg/m2,q3W*4
76040872|NCT04872985|Drug|Doxorubicin Hydrochloride Liposome Injection|30mg/m2, q3w*4
76040873|NCT04872985|Drug|Cyclophosphamide|600 mg/m2, q3w*4
76023331|NCT05094323|Drug|Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine|Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
76023332|NCT05094323|Drug|Local wound infiltration with isobaric bupivacaine|Patients will receive local wound infiltration with isobaric bupivacaine.
76040874|NCT04872985|Drug|Docetaxel|100 mg/m2, q3w*4
76040875|NCT04872985|Drug|Nab paclitaxel|120mg/m2 qw*12
75410634|NCT05623254|Other|no comparator - TAU (Treatment-as-usual)|"Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) [Time Frame: At Three-six months]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)"
75410635|NCT05612022|Procedure|AVF creation|AVF is surgically created in the forearm by an anastomosis between a vein and an artery
75410636|NCT05612022|Procedure|AVG creation|Surgery is done using an artificial plastic tube that connects an artery to a vein
75410637|NCT05595876|Procedure|stent retriever thrombectomy|The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
75410638|NCT05595876|Procedure|contact aspiration thrombectomy|A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
75410639|NCT05574582|Procedure|Graft reconstruction and internal fixation with compression screw|Patients suffering from scaphoid nonunion are treated surgically by debridement, graft reconstruction and internal fixation with compression screw
75713845|NCT04902274|Other|Physical Therapy|After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
75713846|NCT00958906|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
76040876|NCT04872985|Drug|Placebo|400 mg orally once per day
76040877|NCT04872907|Device|adhesive system|adhesive system G-BOND. It will be applied to healthy temporary anterior and posterior teeth The adhesive system (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
75410640|NCT05544162|Dietary Supplement|Nutrition supplement - Ensure shakes|Ensure shakes will be take up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
75410641|NCT05516628|Procedure|Surgical Resection|Resection of Primary Hepatocellular Cancer Tumour.
76040878|NCT04872907|Device|fluoride varnish|The reference drug is a fluoride varnish at 22,600 ppm of the brand Duraphat 50 mg / ml, dental suspension. The varnish is applied to healthy temporary anterior and posterior teeth, on the three sides of the teeth. The reference treatment (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
76040879|NCT04872907|Drug|flowable composite|"Composite Essentia HiFlo. It will be applied on healthy temporary molar grooves (on side defined by randomization).~Complete or partial renewal of the fluid composite in the grooves of the molars in the event of total or partial loss at 6, 12, 18 months"
75410642|NCT05516628|Drug|Adjuvant Atezolizumab-Bevacizumab Therapy|Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for a year following resection of hepatocellular cancer tumour.
75410643|NCT05497674|Drug|Rongliflozin|oral administration, single dose on Day 1 and Day 11
76040880|NCT02566109|Diagnostic Test|Fast MRI|The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
76040881|NCT04868071|Behavioral|Physical Exercise|Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).
75410644|NCT05497674|Drug|Rifampin|QD for 10 days
75410645|NCT05497674|Drug|Rongliflozin|oral administration, single dose on Day 1 and Day 6
75410646|NCT05497674|Drug|Probenecid|twice a day, for 5 days
75410647|NCT05485740|Other|cognitive multisensory rehabilitation|sensorimotor rehabilitation approach, in which the patient is asked to solve sensory discrimination exercises with closed eyes or to solve multisensory discrimination exercises, e.g., by comparing feeling shapes with seeing shapes.
75410648|NCT05485740|Other|the selected exercise program|Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise
75410649|NCT05437926|Device|Arrhythmia Analysis Software (software) which runs on a mobile application (Huawei Phone) and uses input from a wearable device (smart watch or smart band).|Subjects with or without cardiac arrhythmias and of light skin tone (melanin index <150) or dark skin tone (melanin index >350). Subjects will be divided based on their heart rhythm in three groups: approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
75410650|NCT05437068|Other|Oral Nutritional Supplement (ONS)|ONS plus dietary counseling
75410651|NCT05435508|Other|Pain Neuroscience Education|A total of 1 PNE sessions (Neuroscience pain education) will be carried out, in addition medical treatment similar to control group (Usual care). The PNE sessions will be conducted by an experienced PNE certified proffesional in 35 minute face-to-face sessions. In PNE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
75410652|NCT05435508|Other|Usual care|The control group (Usual care) is treated with pre-anesthetic assessment + usual treatment, management for analgesic medication pre, during and post hysterectomy. Depending on the medical needs and criteria of patients´s care physician.
75410653|NCT05435352|Procedure|Core needle biopsy|An additional core needle biopsy is taken to run the Pear Bio test. Test results are not used to inform treatment. Approved neoadjuvant therapy regimens are given to the patient as per standard of care to observe response.
75410654|NCT05403372|Device|PAS-C System|The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
75410655|NCT05400252|Behavioral|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
75410656|NCT05400252|Behavioral|Health and Wellness|Health & Wellness is an educational wellness intervention
75410657|NCT05377164|Behavioral|food choices|Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.
75713847|NCT00882219|Device|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
75713848|NCT00959062|Drug|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
75713849|NCT00959062|Drug|placebo|Preparation visually identical to clonidine.
75872480|NCT04598386|Other|PR Lotion - AMP Human Performance|Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers >2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.
76040882|NCT04861909|Device|AT LISA tri 839MP|Non interventional study
75872481|NCT04598386|Other|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
75872482|NCT02861820|Device|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
76040883|NCT03047707|Diagnostic Test|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
75713850|NCT04296981|Other|video-based patient information|explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
75410658|NCT05370300|Diagnostic Test|Blood test|Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
75410659|NCT05360628|Drug|D-0120 in combination with Allopurinol|noted above
75713851|NCT04009564|Dietary Supplement|Date coffee|45 g of date seeds coffee in 280 ml of water
75713852|NCT04009564|Dietary Supplement|Normal coffee|6 g of normal coffee in 280ml of water
75713853|NCT04009564|Dietary Supplement|Placebo|water, food colouring and coffee flavouring
75872483|NCT03122145|Drug|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
75713854|NCT04038411|Drug|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
76023333|NCT05094323|Drug|Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine|Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
75410660|NCT05326932|Procedure|Mechanical thrombectomy|Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
75410661|NCT05312112|Drug|Venetoclax|Observational study of venetoclax in AML
75410662|NCT05312112|Drug|Gilteritinib|Observational study of gilteritinib in AML
75410663|NCT05269758|Behavioral|activity-based resistance training of ingestive skills (ACT-ING-program)|The ACT-ING program is based on a task-oriented approach within motor behavior theories and combines resistance training principles with goal-directed and task-specific swallowing exercises in eating and drinking activities through a client-centered procedure informed by self-determination theory.
75713855|NCT04009642|Other|Surely observational based on disease state|Metabolism in T2DM vs non diabetic
75713856|NCT00882297|Procedure|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
76023334|NCT03170323|Drug|Mycophenolate Mofetil|steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
76023335|NCT03170323|Drug|Cyclosporins|steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
76023336|NCT05087225|Biological|polyethelyene glycol|the excipients at covid-19 vaccines
76040884|NCT02566031|Drug|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
76040885|NCT02566031|Drug|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
75410664|NCT05268432|Procedure|Surgery with intraoperative imaging|laparoscopic, robot-assisted or other intraoperative imaging (ultrasound, CT, MRI)
75410665|NCT05266170|Device|aerobic and anaerobic exercises|"[aerobic]~Aerobic treadmill walking program without EX1~Aerobic treadmill walking program with EX1~High-intensity interval exercise (HIIT) program with EX1~[anaerobic]~1. Fitness exercise program with EX1"
75554781|NCT05997420|Behavioral|Usual Care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
75554782|NCT05994963|Drug|sisunatovir|Administered as either capsules in fasted state or tablet in fasted or fed state.
76040886|NCT04861753|Other|Reiki and back massage|In the current study, at the beginning of the treatment, the researcher held his hands 2-3 cm above the patient sand adjusted the aura of the patient by making circular movements from the head to the feet. After this process of aura attunement, the researcher placed his hands directly on the patient's body. In the areas where the practitioner had placed his hands for an average of three minutes, starting from between the eyes, the researcher felt various degrees of warmth and tingling in his palms. Only the back was left exposed to prevent the patient becoming cold. The researcher took a little non-aromatic baby oil in hand and heated it, then began a 20-minute-long massage. The massage consisted of 6.5 minutes of effleurage (stroking), 3.5 minutes of petrissage (kneading), 13 minutes of effleurage and seven minutes of petrissage.
76040887|NCT04861675|Procedure|Full mouth rehabilitation under general anaesethia|Assessment of change in oral health related quality of life , body growth status and oral hygiene status for children with special health care needs after full mouth rehabilitation under general anesethia,
76040888|NCT04901039|Other|Lung ultrasound|Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging
76040889|NCT04901039|Other|Echocardiography|Comprehensive echocardiography with evaluation of filling pressures
76040890|NCT04901039|Other|Peripheral venous pressure|Assessment of peripheral venous pressure
75410666|NCT05259462|Behavioral|Intervention|Participants will utilize low-cost, consumer available head-mounted displays to meet with peers and coaches online. The program will last 4 weeks and include 2 x 1-hour sessions per week of supervised peer-to-peer gaming. The coaches will utilize behavioral change and mindfulness techniques to promote autonomy, competence, and relatedness through a respectful, cohesive, and positive atmosphere. These strategies will be framed by the Self-Determination Theory and learned from the National Center on Health, Physical Activity, and Disability (NCHPAD) mindfulness coaching workshops. Some of the mindfulness-based strategies will include guided breathing focused exercises, body scanning, meditation, and acceptance of social anxiety and shyness
75410667|NCT05257746|Procedure|Rectal resection|Open or minimally invasive rectal resection with total mesorectal excision
76040891|NCT04901039|Other|Magnetic resonance imaging|Cardiac magnetic resonance imaging
76040892|NCT04901039|Other|Pulmonary scintigraphy|Assessment of pulmonary perfusion with scintigraphy
75410668|NCT05251428|Procedure|Excision of the A1 pulley|Participants will undergo excision of the A1 pulley. Wounds will then be irrigated and closed in the standard fashion.
75410669|NCT05251428|Procedure|Incision of the A1 pulley in the standard fashion|Participants will undergo incision of the A1 pulley in the standard fashion. Wounds will then be irrigated and closed in the standard fashion.
75554783|NCT05992350|Other|Garmin physical activity tracker|The Garmin physical activity tracker is worn like a watch on the user. The tracker assesses several physical states, indicates when the body is at optimal time for activity or when the body needs to rest. The tracker also monitors stress levels and prompts relaxation when appropriate. The tracker sets goals with participants based on previously completed activity. The tracker alerts participants after a period of inactivity, encourages regular movement throughout the day, and decreases the amount of time spent sedentary.
75554784|NCT05991960|Device|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
75713857|NCT00883467|Procedure|preconditioning|3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
75713858|NCT00883467|Procedure|no preconditioning|no preconditioning
75713859|NCT00963118|Dietary Supplement|plant based nutrition bar|Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
75713860|NCT00882375|Drug|Nicotine|Nicotine administered using novel NRT user instructions
75713861|NCT00882375|Drug|Placebo|Placebo administered using novel NRT user instructions
76040893|NCT04861519|Other|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
76040894|NCT04769765|Other|Definition of the Individualized Care Pathway|Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient's general practitioner (with or without a consultation with the clinical pharmacist).
75554785|NCT05989048|Drug|Zavegepant|The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
75554786|NCT05989048|Drug|Placebo|Single dose of matching placebo taken within Treatment Phase.
75554787|NCT05987956|Drug|Alectinib - Usual|"Usual Alectinib Chemotherapy (NDC...01)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
75554788|NCT05987956|Drug|Alectinib - Study|"Study Alectinib Chemotherapy (NDC...86)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
75410670|NCT05248854|Other|Sensorimotor exercise training|The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.
75554789|NCT05985538|Behavioral|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28. Each vaping prevention text message will focus on one of six topics: nicotine addiction, monetary costs of vaping, chemical exposures from e-cigarette vapor, cosmetic effects of vaping, mental and physical use symptoms of vaping, and health impact on organs from vaping. Some text messages will ask participants for a reply (i.e., two-way messages).
75554790|NCT05985538|Behavioral|Wellness behaviors text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28. Each wellness text message will focus on one of six topics: sleep hygiene, safe driving, sun safety, study habits, nutrition, and exercise. This attention control condition is matched with the intervention condition in that participants will receive the same number of text messages over the same number of days, the same intervention structure (e.g., 6 topics), and the same number and types of two-way messages.
75554791|NCT05985434|Procedure|Surgical treatment|decompression with or without stabilization; stabilization only; debulking; en bloc resection
75554792|NCT05981235|Biological|AZD6422 CLDN18.2 CAR-T product|AZD6422 CAR-T product infusion after pre-conditioning
75554793|NCT05981118|Drug|Betamethasone dipropionate 0.05%|0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
75554794|NCT05981118|Drug|Tapinarof|1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
75554795|NCT05973448|Other|Novel Lighting Condition|Horizontal and vertical lights over a doorway visible from the bed
75554796|NCT05973448|Other|Control Lighting Condition|Standard night light plugged into wall socket
75554797|NCT05971693|Device|OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator|Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping [stimulating and recording] and, when used with a Generator, for cardiac ablation).
75554798|NCT05970120|Device|NUVISION NAV Ultrasound Catheter|Participants will be scheduled to have a clinically-indicated ablation procedure using NUVISION NAV ultrasound catheter for management of atrial procedure.
75554799|NCT05968456|Other|Data collection|Observational study in patients undergoing thoracic, cardiac and vascular surgery.
75554800|NCT05963438|Procedure|anterior retraction|After placement of mini-implants and extraction of maxillary first premolar, retraction of anterior either simultaneously or separately depending on the allocated group will be done
75554801|NCT05961410|Drug|Eltrombopag olamine|Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.
76040895|NCT03045523|Drug|GLPG2222 150 mg q.d.|GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
76040896|NCT03045523|Drug|GLPG2222 300 mg q.d.|GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
76040897|NCT03045523|Drug|Placebo|Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
75554802|NCT05956769|Drug|Tranexamic Acid|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
75554803|NCT05956769|Diagnostic Test|thromboelastography|thromboelastography (TEG6)
75554804|NCT05956769|Drug|Placebo|Normal saline injection
75554805|NCT05956665|Behavioral|Shed-MEDS deprescribing intervention|See single arm description
75554806|NCT05956587|Drug|BL-B01D1|Administration by intravenous infusion
75554807|NCT05956587|Drug|SI-B003|Administration by intravenous infusion
76040898|NCT04984967|Device|Insertion of peripheral venous catheter with micro-guide|After antisepsis, the vein is punctured using a needle. Then the micro-guide is inserted to the first landmark, which indicates the passage of the micro-guide beyond the end of the needle. After the needle removed, the peripheral venous catheter is placed on the micro-guide. The guide is then removed, the peripheral venous catheter can be used.
76040899|NCT04984967|Other|Classic insertion of peripheral venous catheter, without micro-guide|After antisepsis, the catheter is introduced into the vein by a needle which is subsequently removed while the catheter remains in place.
75713862|NCT00963196|Dietary Supplement|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
76040900|NCT04872829|Device|cataract surgery|"All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D."
76040901|NCT03045211|Device|Dynamic Standing Table|The dynamic standing table is a height-adjustable standing table which gives periodic cues to the user to make stepping movements.
76040902|NCT04872361|Procedure|Low PEEP|Patients will be ventilated with a PEEP of 4 cm H2O and no RMs throughout the study
76040903|NCT04872361|Procedure|High PEEP|PEEP of 10 cm H2O will be applied
76040904|NCT04872361|Procedure|High PEEP/RM|PEEP of 10 cm H2O and RM (30 cm H2O for 30 s) immediately after the second lung ultrasonographic examination and repeated every 30 minutes till emergence
76040905|NCT04872361|Device|Lung ultrasonogrphy assessment|"The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~three or more B lines~coalescent B lines~consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss"
75410671|NCT05248854|Other|Core stabilization exercise training|Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
75554808|NCT05955729|Behavioral|On-duty Nap|For 12 weeks, an opportunity for a 30-minute nap during the night shift, between 1 a.m. and 4 a.m., in a quiet room with facilities for lying down.
75554809|NCT05955729|Behavioral|Control condition (30-min rest)|For 12 weeks, an opportunity for a 30-minute rest during the night shift, between 1 a.m. and 4 a.m., in a quiet room without facilities for lying down or napping.
76040906|NCT03045367|Procedure|Phacoemulsification, intraocular lens implant, vitrectomy.|Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
76040907|NCT04763681|Behavioral|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson & Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
75713863|NCT00963196|Drug|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
75713864|NCT00882453|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
75713865|NCT04860778|Dietary Supplement|BDNF Essentials|Participants will take two capsules, twice daily with water for 84 days.
75713866|NCT00883545|Other|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
75713867|NCT00883545|Other|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
75713868|NCT04812340|Other|High intensity circuit training|6 series with 3 minutes rest between the series. each series will consist of 30 seconds each of burpees, skipping, lunges, 1- legged squat, leg levers, and push-ups with 30 seconds rest in between. the volume of exercise will be increased progressively over a period of 8 weeks.
75713869|NCT04812340|Other|Low intensity interval training|4 series with 3 minutes rest in between. each series will consist of 10 minutes of jogging and 5 minutes walking with 30 seconds recovery in between. the volume of exercise will be increased progressively over a period of 8 weeks.
75713870|NCT00882531|Drug|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
75713871|NCT00882531|Drug|placebo|
75410672|NCT05244174|Device|Pancreatic stent|Insertion of a pancreatic stent during ERCP to improve pancreatic secretion
75410673|NCT05241522|Diagnostic Test|Tc-99m-Tilmanocept|Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.
75410674|NCT05226858|Diagnostic Test|Transesophageal echocardiography (TEE)|Sensitivity and specificity of TEE in identification of BTAI
75713872|NCT00923403|Dietary Supplement|plant sterol enriched soymilk|plant sterol enriched soymilk
75713873|NCT00923403|Dietary Supplement|control dairy milk|control dairy milk
75713874|NCT00963274|Drug|Bortezomib|Starting dose: 1.3 mg/sq m
75713875|NCT00963274|Drug|Romidepsin|Starting dose: 8 mg/sq m
75554810|NCT05955729|Device|EndoPAT|"The EndoPAT device® measures vascular reactivity after a 5-minute occlusion on one arm.~This device measures changes in vascular tone induced by the endothelium at fingertip level using a pair of plethysmographic sensors. The measurement consists of performing a reference recording for 5 minutes on the 2 arms, then a test arm is chosen to perform an occlusion for 5 minutes while continuing the recording."
75554811|NCT05955729|Device|Popmeter®|The tool is connected to the caregiver's finger and toe via photodiode sensors. Its simple operation enables reproducible measurement of the propagation speed of the pulse wave in 14 seconds.
75554812|NCT05955729|Device|Panasonic EW3109|Diastolic and systolic blood pressure measured 3 times in succession using an automatic blood pressure monitor (Panasonic EW3109) in the sitting position on the left arm.
75554813|NCT05955729|Device|ECG Holter|The Holter takes an ECG during the subject's daily activities at home.
76040908|NCT04861129|Procedure|Bowen therapy|Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
76040909|NCT04861129|Procedure|Sham Bowen therapy|Sham Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
76040910|NCT05507489|Drug|Jinzhen oral liquid or Jinhuaqinggan granules|Jinzhen oral liquid, for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day.The dosage and usage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition. The drugs were medicated for 14 days.
75554814|NCT05955729|Biological|Fasting blood sample|A 5 ml blood sample (venous sampling) will be taken to measure inflammatory biomarkers (hsCRP, IL-6 TNF-α, IL-1β) and blood markers of endothelial function (NO, CRP, SOD, IL-18).
75554815|NCT05955729|Other|Pichot fatigue scale|The Pichot fatigue scale is an 8-item questionnaire, with a score above 22 indicating excessive fatigue.
75554816|NCT05955729|Other|French version of the Recovery Needs Scale (BRD)|BRD questionnaire consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.
75713876|NCT00882609|Device|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
75713877|NCT00883623|Drug|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
75713878|NCT00959218|Drug|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
75713879|NCT00959218|Drug|Placebo|oral solution
76040911|NCT04761341|Drug|NUTROF TOTAL|1 per day over a course of 3 months
76040912|NCT05507411|Radiation|Neoadjuvant Radiotherapy|41.4Gy/23F
76040913|NCT05507411|Drug|Neoadjuvant Chemotherapy|Paclitaxel for Injection （Albumin Bound): 50mg/m^2 QW Carboplatin: AUC=2 QW
75410675|NCT05218668|Drug|Fasudil (WP-0512)|Oral fasudil up to 240 mg/day
76040914|NCT05507411|Drug|Immunotherapy|Camrelizumab 200mg Q3W
76040915|NCT05515913|Other|Nutritional status|Nutritional status of children as analyzed by anthropometric indices was under study
76040916|NCT05515913|Behavioral|Eating behavior|The eating behavior of ASD children as analyzed by frequency of refusal of new food, sensitivity to food, food allergy and gastrointestinal systems was under study
76040917|NCT05515913|Other|Urine iodine concentration|the 24 urine iodine concentration of all subjects was under study
76040918|NCT05515913|Other|Nutrient intake|The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study
76040919|NCT05515913|Other|Dietary assessment|The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study
76040920|NCT05515913|Other|Childhood autism rating scale|The autistic severity of ASD diagnosed children was under study as analyzed by childhood autism rating scale diagnosis
76040921|NCT04603625|Other|postural management|postural management in sitting position
76040922|NCT02569853|Drug|DFN-11|
76040923|NCT02569853|Other|Placebo|
76040924|NCT04894643|Radiation|Proton Ions|According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
75410676|NCT05211882|Other|Immediate ENABLE nurse coaching, on top of usual care|Participants in the intervention arm will start on the ENABLE program at point of randomization
75410677|NCT05211882|Other|Usual Care|Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
75410678|NCT05118360|Drug|ASC41 2 mg|2mg of ASC41 orally once daily for 52 weeks
75410679|NCT05118360|Drug|ASC41 4 mg|4mg of ASC41 orally once daily for 52 weeks
75410680|NCT05118360|Drug|Placebo|Matching placebo orally once daily for 52 weeks.
75410681|NCT05096364|Biological|AK111/Placebo|After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
75410682|NCT05048940|Biological|Janssen vaccine|0.5 ml millilitre(s) Intramuscular use
75410683|NCT05048940|Biological|Spikevax (Moderna) vaccine|0.5 ml millilitre(s) Intramuscular use
75410684|NCT05046990|Diagnostic Test|Regular Arrangement of Collecting Venules|This is a prospective, multicentre, international study without a control group.
75410685|NCT04987164|Dietary Supplement|Feminabiane CBU|EXTRACTS OF CRANBERRY, CINNAMON AND MICROBIOTIC STRAINS
75410686|NCT04985682|Biological|ADVATE|Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
75410687|NCT04945590|Behavioral|Virtual Intervention Program|Four separate virtual individual and group interviews (via telephone or online), which will be scheduled with the help of champions and leaders of the Latino community who will collaborate as companions to improve the commitment and experience of families.
75554817|NCT05955729|Other|The Short-Form 36 (SF-36)|The SF-36 questionnaire is used to assess quality of life. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).
76040925|NCT04894643|Drug|Nab-PACLitaxel|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes."
75554818|NCT05955729|Other|Pittsburgh Sleep Quality Index (PSQI)|24-question sleep quality assessment scale, a score > 5 indicates poor sleep quality
75554819|NCT05955729|Other|Epworth questionnaire|8-question sleepiness assessment scale, a score above 10 indicates excessive sleepiness
75554820|NCT05955729|Other|The Karolinska Sleepiness Scale|The Karolinska Sleepiness Scale measures daytime sleepiness on a 9-point scale, based on 5 states and 4 intermediate states that are not verbally indicated.
76040926|NCT04894643|Drug|Gemcitabine|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel."
75554821|NCT05955729|Device|Dreem Headband|A connected sleep band (Dreem Headband), which measures sleep duration, sleep patterns and sleep quality, will be worn during night-time sleep at home and naps at work.
75554822|NCT05955729|Device|Actimeter|An actimeter will be worn on the non-dominant wrist, uninterrupted day and night, for 7 consecutive days.
75713880|NCT04009954|Other|Fecal and blood samples collection for analysis|"Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs)."
75713881|NCT00678210|Drug|CP-690,550|tablets, 2 mg BID for 12 weeks
76040927|NCT04894643|Drug|Capecitabine|Concomitant to proton-radiotherapy (on the same days, within week 14-19)
75713882|NCT00678210|Drug|CP-690,550|tablets, 5 mg BID for 12 weeks
75713883|NCT00678210|Drug|CP-690,550|tablets, 15 mg BID for 12 weeks
75713884|NCT00678210|Drug|Placebo|tablets, BID for 12 weeks
76040928|NCT04894643|Procedure|Surgical resection of the pancreas (when feasible)|Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
76040929|NCT05511857|Behavioral|Self-distancing, third-person self-talk.|The participants will engage in self-distancing, third-person self-talk.
76040930|NCT05511857|Behavioral|Self-immersed, first-person self-talk.|The participants will engage in self-immersed, first-person self-talk.
75554823|NCT05955508|Drug|Linvoseltamab|Administration by intravenous (IV) infusion
75554825|NCT05945212|Device|Vibration|The program will take place over 40 sessions : 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during the hospitalization in the department); this group will benefit from an effective vibration of a frequency of 100Hz
75554826|NCT05945212|Device|Sham vibration|The program will take place over 40 sessions: 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during hospitalization in the department); this group will not benefit from effective vibration.
75554827|NCT05945212|Other|10 meters Walk Test|Short-distance ambulation speed is measurement between 2 markers on the ground 10 meters apart in a corridor with flat ground, the patient starting his walk 3 meters before to have a launched march disregarding markers, and ends 3 meters After. The stopwatch is started when the markers are crossed.
75713885|NCT00959296|Device|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
76040931|NCT05511857|Behavioral|Distraction|The participants will engage in a distraction task.
75554828|NCT05945212|Other|2 Minute Walk Test (2MWT)|Long-distance ambulation speed is measured from a standing start and the test involves asking the patient to walk as far as possible in 2 minutes.
75554829|NCT05945212|Other|Fugl-Meyer (FMA-LE)|The Fugl-Meyer (FMA-LE) assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination. Score from 0 to 34
75713886|NCT00611715|Drug|erlotinib hydrochloride|OSI-774 150 mg/day
75713887|NCT00611715|Drug|letrozole|Letrozole 2.5 mg/day
75713888|NCT00611715|Genetic|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
75713889|NCT00611715|Other|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
75713890|NCT00611715|Other|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
75713891|NCT04722718|Drug|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
75872484|NCT03122145|Device|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
75872485|NCT05081830|Behavioral|Transdiagnostic online intervention|Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.
75872486|NCT05081830|Behavioral|TCC online intervention|This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
75872487|NCT05150535|Radiation|Hypofractionation Radiotherapy.|Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.
75872488|NCT05150535|Radiation|Ultra-hypofractionation radiotherapy|Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.
75872489|NCT03140800|Device|intrauterine device|a method of contraception inserted in the uterus
75554830|NCT05945212|Other|Modified Ashworth scale|The modified Ashworth scale allows the measurement of spasticity, that is to say the measurement of muscle tone by mobilizing the segment of the lower limb and by evaluating the resistance to stretching of the muscles. Score from 0 to 4
75554831|NCT05945212|Other|ABILOCO questionnaire|The ABILOCO questionnaire evaluate the autonomy in the walking capacities of the patients (13-items)
75554832|NCT05945212|Other|Barthel index|The Barthel index measure autonomy in daily life.
75554833|NCT05945212|Other|isometric ergometer|Evaluate voluntary maximum force in isometric ankle dorsiflexion by Cybex isometric ergometer results.
75554834|NCT05945212|Other|Electromyograms (EMG)|Assessment of neuromuscular fatigue by electromyograms (EMG). Surface electrodes is place on the tibial muscle anterior to non-invasively collect electromyograms (EMG). The intensity of stimulation will be gradually increased until a plateau in mechanical (strength) and electromyograms (EMG) responses is obtained.
75554835|NCT05945212|Other|Traditional quantified gait analysis|Gait kinematics will be recorded on a force platform (90 x 90 cm, Model 9287C, Kistler, Winterthur, Switzerland) to determine: joint angles, net joint moments and powers at the ankle, knee and hip.
75554836|NCT05945212|Other|SPM - Statistical Parametric Mapping|Addition of a temporal component to the traditional quantified gait analysis, allowing the focus to be on time series parameters.
75554837|NCT05945212|Other|FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)|A short questionnaire consisting of 13 questions to which the patient answers on a scale from 0 to 4. The scores are simply added up, inverting the scale for negative sentences, to give a result out of 52 points. The lower the score, the greater the fatigue.
75554838|NCT05943977|Drug|MB-102 DMID|130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
75554839|NCT05943977|Drug|MB-102 OMID|130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
75713892|NCT04649710|Biological|BMS-986036|Specified dose on specified days
75713893|NCT04649710|Other|Placebo|Specified dose on specified days
75713894|NCT00885573|Device|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
75713895|NCT00761670|Drug|amisulpride and risperidone|amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
75554840|NCT05943977|Device|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.
75410688|NCT04935684|Drug|Fecal Microbiota Transplantation|"Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes."
75554841|NCT05936138|Drug|LY3502970|Administered orally.
75554842|NCT05931601|Drug|Noradrenaline|See arm description
75554843|NCT05930093|Dietary Supplement|Placebo|Placebo matching LivPhcD cap.
75554844|NCT05930093|Dietary Supplement|2 cap.LivPhcD/per day|2 caps. LivPhcD cap. after meal, once a day
75554845|NCT05930093|Dietary Supplement|4 cap.LivPhcD/per day|4 caps. LivPhcD cap. after meal, BID
75554846|NCT05930093|Dietary Supplement|6 cap.LivPhcD/per day|6 caps. LivPhcD cap. after meal, TID
75554847|NCT05929885|Drug|Low Dose OXIRI (LD-OXIRI)|"The LD-OXIRI regimen will be administered in the following sequence:~metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1*6 and UGT1A1*28 genotype status."
75713896|NCT00963664|Drug|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
75872490|NCT02327650|Procedure|The examinations for bones in joints of OA and RA patients|
75410689|NCT04927806|Device|Silver Knight|"Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:~Staphyloccus epidermis~Pseudomonas aeruginosa~Klebsiella pneumoniae~Acinetobacter calcoaceticus~Escherichia coli"
75554850|NCT05929378|Procedure|Lightweight mesh fixation|Lightweight mesh fixation in 3 points
75554851|NCT05923073|Drug|Guselkumab|Guselkumab will be administered either intravenously or subcutaneously.
75554852|NCT05923073|Drug|Placebo|Week 12 induction responders will be administered placebo (matching guselkumab up to Week 48) SC at protocol specified time points to maintain the blind.
75554853|NCT05918978|Drug|Efgartigimod|Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
75554854|NCT05918029|Drug|Potassium citrate|Oral potassium citrate
75554855|NCT05918029|Drug|Placebo|Placebo capsule identical to active ingredient
75554856|NCT05917548|Device|Teledentistry oral health promotion|Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)
75554857|NCT05917548|Behavioral|Face-to-Face oral health promotion|Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
75713897|NCT00963664|Drug|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
75713898|NCT00677820|Biological|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
75713899|NCT00677820|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
75713900|NCT00611559|Biological|Infanrix™ penta|Subjects received a booster dose
75713901|NCT00611559|Biological|Infanrix™ hexa|Subjects received a booster dose
75872491|NCT03144856|Drug|Apatinib|Apatinib 500mg, po, qd, every 4 weeks.
75410690|NCT04911894|Drug|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
75410691|NCT04896372|Other|ACT comprehensive of standard care|"The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement."
75410692|NCT04896372|Other|TAU only|adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
75410693|NCT04848402|Device|On-Body Delivery System (OBDS)/Multiple Bolus Injector|Used to administer placebo SC.
75410694|NCT04848402|Device|Single Auto Injector|Used to administer placebo SC.
75410695|NCT04848402|Drug|Placebo|Administered SC.
75410696|NCT04836780|Drug|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
75410697|NCT04793724|Device|Simeox|"A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~clearance of the upper airways before the physiotherapy session~correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~comfortable, relaxed sitting position with straightened spine~controlled cough, which will be encouraged only when it is productive"
75554858|NCT05913973|Drug|Pvs230D1-EPA/Matrix-M|Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.
75554859|NCT05912517|Drug|Nipocalimab|Nipocalimab will be administered as an intravenous infusion.
75554860|NCT05912517|Drug|Placebo|Placebo will be administered as an intravenous infusion.
75554861|NCT05909332|Drug|Antivascular therapy|BP102 (anti VEGFR)
75554862|NCT05909332|Drug|Chemotherapy|ddEC-P
75554863|NCT05908734|Drug|Cetrelimab|Cetrelimab will be administered as IV infusion.
75554864|NCT05908734|Drug|Amivantamab|Amivantamab will be administered as IV infusion.
75554865|NCT05908656|Procedure|Investigational procedure|Subjects that consent will have a single blood draw either via a finger stick or via venous blood draw (blood will be placed on a 5 spot blood card) used to determine whether they have Gaucher Disease or ASMD
75713902|NCT00963742|Device|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
75713903|NCT00963898|Device|Target controlled infusion(TCI), Bispectral index(BIS)|Using TCI and BIS or not
75713904|NCT00761904|Behavioral|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
75713905|NCT00963976|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
75713906|NCT00964054|Other|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
75554866|NCT05908383|Drug|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
75554867|NCT05908383|Other|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
75713907|NCT00964054|Other|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
75713908|NCT02559258|Drug|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
75713909|NCT02559258|Drug|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
75410698|NCT04793724|Device|PARI O PEP|"ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~horizontal;~low;~transition of the device from the low position to the horizontal position;~upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum."
75410699|NCT04782492|Procedure|graft configuration in coronary artery bypass grafting|Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
76040932|NCT05511545|Other|Patient Education Booklet|Excretory system organs, signs and symptoms to be seen in kidney and ureteral stones, treatment methods, ureteroscopy procedure, what to do before and on the morning of surgery, and surgery, using the training booklet prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. An average of 25-30 minutes of training was given in the patient's room in an encouraging language, allowing the patient to ask questions about the situations he would encounter in the clinic after the surgery. She started asking questions she didn't understand. Afterwards, the questions of the patients were answered and the patient was given a training booklet.
75410700|NCT04779138|Behavioral|Increasing Willingness and Uptake of COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 vaccine hesitancy and increase willingness and uptake in COVID-19 vaccination.
76040933|NCT05506865|Drug|Indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
76040934|NCT05506865|Drug|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
76040935|NCT05506709|Device|Seawater nasal spray|Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
75713910|NCT02559258|Drug|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
75713911|NCT02559258|Drug|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
75713912|NCT02559258|Drug|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
75872492|NCT05080894|Device|Virtual reality|Embodiment of a healthy virtual body in virtual reality and action observation/motor imagery of the subject's virtual body performing high-level lower limb exercises.
76040936|NCT05506553|Device|Intervention arm - Eyhance Toric II Intraocular Lens|Bilateral cataract extraction and insertion of Eyhance Toric II Intraocular Lens
75713913|NCT00964132|Drug|NRX194204|Once Daily, Oral
75713914|NCT02558868|Drug|Irinotecan|
75713915|NCT02558868|Drug|Oxaliplatin|
75713916|NCT00611247|Drug|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"
75713917|NCT04038177|Behavioral|Superset strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.
75713918|NCT04038177|Behavioral|Traditional strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
75872494|NCT04949022|Device|Medronic 780G insulin pump|Commercial hybrid closed loop system Medronic 780G
76040937|NCT05506553|Device|Control Arm - Alcon IQ Toric Intraocular lens|Bilateral cataract extraction and insertion of Alcon IQ Toric Intraocular Lens
76040938|NCT05506397|Other|Acupressure|Acupressure is a technique based on stimulating certain points on the body with stimulation methods such as hands and fingers.
76040939|NCT04140773|Dietary Supplement|D-serine|Capsule D-serine
76040940|NCT04140773|Other|Placebo|Capsule D-serine
75410701|NCT04772898|Behavioral|Hippotherapy|The hippotherapy involves occupational therapy while being on a horse.
75410702|NCT04740294|Drug|Magnesium Sulfate|Randomized to receive either magnesium sulfate or normal saline placebo.
75713919|NCT00885651|Drug|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
75713920|NCT00885651|Drug|Placebo|
76040941|NCT05506319|Other|Norepinephrine|"The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).~Interruption means suspension for at least 24 hours."
75410703|NCT04723680|Other|Qualitative interview|Qualitative semi structured interview
75410704|NCT04705818|Drug|Durvalumab|Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
75410705|NCT04705818|Drug|Tazemetostat|Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
75410706|NCT04703712|Procedure|Lens extraction combined with goniosynechialysis|The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
75713921|NCT00885729|Procedure|stem cells|Stem cells or chondrocytes under a commercial available membrane
75713922|NCT00885729|Procedure|Chondrocytes|Implantation of chondrocytes
75713923|NCT00885729|Other|Rehabilitation program|Strength exercises, neuromuscular exercises
75713924|NCT00883935|Drug|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
75713925|NCT00883935|Drug|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
75713926|NCT00883935|Drug|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
75713927|NCT00883935|Drug|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
75713928|NCT00675948|Drug|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
76023337|NCT04480489|Other|VR|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
76040942|NCT05506319|Other|Vasopressin|"The patients will be randomized for the initial suspension of vasopressin (vasopressin group).~Interruption means suspension for at least 24 hours."
76040943|NCT05506007|Drug|DA-5216|"During the cross-over [Part A], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
76040944|NCT05506007|Drug|DA-5216-R|"During the cross-over [Part A], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
75410707|NCT04703712|Procedure|Trabeculectomy surgery|The patients enrolled underwent trabeculectomy surgery
75554868|NCT05901909|Behavioral|Educational intervention based on the Precede-Proceed Model for individuals caring for stroke home care patients|Home visits will be made to 70 stroke patients identified during the implementation phase of the research, and training based on the Precede-Proceed model will be given to 70 individuals who care for these patients in the meeting room of the hospital where the research will be conducted. In the research, pre-education evaluation will be collected at the hospital before the training for the caregivers and home visits for the patients. In the second stage, the training program planned for the caregivers will be implemented in the meeting room of the hospital. After the training program reaches all of the caregivers in the determined number, the first evaluation will be made for the caregivers and the patient in the 8th week after the training is over. The third stage is the 16th week after the completion of the training, and the final evaluation will be made for the patients and caregivers.
76040945|NCT05506007|Drug|DA-5216|"During the cross-over [Part B], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
75554869|NCT05901649|Drug|Apalutamide|No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.
76040946|NCT05506007|Drug|DA-5216|"During the cross-over [Part B], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
76040947|NCT05515757|Behavioral|Mobile-app based contingency management|We are adapting an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with stimulant use disorders requiring prolonged hospitalization. Participants will be enrolled into an 8-week mobile-app based contingency management intervention.
75554870|NCT05901649|Drug|Enzalutamide|No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.
75554871|NCT05901636|Biological|INFLUENZA G1 mHA|INFLUENZA G1 mHA will be administered intramuscularly.
75554872|NCT05901636|Biological|Placebo|Placebo will be administered intramuscularly.
76040948|NCT04591067|Other|Testing of physical capacity|"This cross-sectional study will involve evaluation of physical capacity by assessment of:~Gait function~Muscle activity during walking~Endurance during walking~Hip muscle strength~Hip range of motion~Hip and muscle-tendon-related groin pain~Hip and groin related patient-reported outcome measures (PROMs)"
76040949|NCT05515133|Other|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
76040950|NCT05505851|Other|Control|Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
76040951|NCT05505851|Other|Sequential Core Stability Corrective Exercise Approach|"Corrective Exercises~Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~Core Stability exercises~Beginning~Progressing~Advanced"
76040952|NCT04969445|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
75410708|NCT04637724|Device|transcranial direct current stimulation (tDCS)|10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
75554873|NCT05901636|Biological|Al(OH)3|Al(OH)3 will be administered intramuscularly.
75554874|NCT05896839|Procedure|Biopsy|Undergo tumor biopsy
75554875|NCT05896839|Procedure|Biospecimen Collection|Undergo blood sample collection
75554876|NCT05896839|Procedure|Computed Tomography|Undergo CT scan
75554877|NCT05896839|Biological|Ipilimumab|Given IV
75554878|NCT05896839|Procedure|Kidney Biopsy|Undergo kidney biopsy
75554879|NCT05896839|Procedure|Magnetic Resonance Imaging|Undergo MRI
75554880|NCT05896839|Biological|Nivolumab|Given IV
75554881|NCT05896839|Drug|Prednisone|Given PO
75554882|NCT05896839|Drug|Sirolimus|Given PO
75713929|NCT00675948|Drug|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
76040953|NCT05505695|Other|Brace and Exercise Treatment|Schroth exercises, which are a specific exercise method for scoliosis, were given to the experimental group for 8 weeks, different from the control group.
75554883|NCT05896592|Diagnostic Test|Invasive electrophysiological study|Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
75554884|NCT05896592|Diagnostic Test|Extracardiac vagal stimulation|"Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia."
75554885|NCT05896592|Procedure|Cardioneuroablation|CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
75554886|NCT05896592|Procedure|Redo cardioneuroablation|It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
75554887|NCT05896592|Procedure|Implantation of the implantable loop recorder|Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
75554888|NCT05896592|Diagnostic Test|Pacemaker check|It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
76040954|NCT05505695|Other|Brace Treatment|Among the patients included in the study, those who wore braces but did not agree to exercise constituted the ''Brace Group'' of the study.
75554889|NCT05896592|Diagnostic Test|Implantable loop recorder check|Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
75554890|NCT05896592|Diagnostic Test|Holter ECG|24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
75410709|NCT04626804|Other|Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community|testing the usability, perceptions, and acceptability of R/S among dyads of older adults with early Alzheimer's disease and other related dementias
75410710|NCT04610736|Drug|Temozolomide Oral Suspension|One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
75410711|NCT04610190|Device|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
75410712|NCT04591236|Device|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
75410713|NCT04591236|Device|Treadmill gait training|Treadmill gait training was applied to Parkinson patients.
76040955|NCT04945187|Other|Nurse-led consultations based on electronic patient-reported outcomes|The patients will weekly answer electronic patient-reported outcomes during chemotherapy and the answers will be used proactive in nurse-led consultations.
76040956|NCT05505539|Drug|5-fluorouracil|Given intralesionally by injection
76040957|NCT04588103|Other|Heat therapy|Lower limb warm water immersion (42 degrees C)
76040958|NCT04588103|Other|Exercise training|Moderate-intensity cycling exercise (~40-59% VO2 reserve)
76040959|NCT04943315|Procedure|Monolithic zirconia|posterior crowns
76040960|NCT04943315|Procedure|Metal-ceramic|posterior crowns
76040961|NCT05514977|Procedure|Erector spine plane block|Thoracic ESPB
75410714|NCT04575324|Behavioral|Telemedicine Linkage Intervention|Participants will be immediately linked to telemedicine care provided by an FQHC provider waivered to prescribe buprenorphine and naltrexone or able to refer patients to methadone treatment. Participants will have their vitals checked and be virtually connected to the provider. The research assistant will share the vitals with the provider, and the provider will provide personalized care during which they discuss treatment options with the participant. If a medication for opioid use disorder is prescribed or if a methadone referral is made, transportation assistance will be provided to the participant as part of the intervention. Transportation to pick up the prescription or complete the first appointment will be provided via a HIPAA compliant ride-share company, and a bus pass will be provided to the participant for the return trip.
75554891|NCT05896592|Diagnostic Test|Anamnesis|Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
75554892|NCT05893940|Procedure|Low Intensity Vibration Therapy|Undergo LIMS vibration therapy
75554893|NCT05893940|Procedure|Dual X-ray Absorptiometry|Undergo DEXA scan
75554894|NCT05893940|Procedure|Biospecimen Collection|Undergo blood sample collection
75554895|NCT05893758|Device|The Cera™ PFO Occluder|The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
75554896|NCT05891093|Drug|Fluzoparib|Fluzoparib 50mg bid orally for 1 year.
76040962|NCT04140539|Biological|OTL-101|Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
75554897|NCT05891093|Drug|Anastrozole|1mg, qd orally
75554898|NCT05891093|Drug|Letrozole|2.5mg, qd orally
75554899|NCT05891093|Drug|Exemestane|25mg, qd orally
75554900|NCT05891093|Drug|Tamoxifen|10mg, bid orally
76040963|NCT05505461|Drug|neoadjuvant Radiation plus SOX and PD-1 antibody|"Patients will be given the perioperative treatment as below once recruited:~First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.~The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.~SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery."
76040964|NCT05505383|Other|Exercise training|People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
75554901|NCT05891093|Drug|Toremifene|60mg, qd orally
75554902|NCT05891093|Drug|Abemaciclib|150mg/100mg/50mg, bid orally for 2 years
75554903|NCT05891093|Drug|LHRH agonist|Leuprorelin acetate, goserelin acetate
75554904|NCT05889793|Drug|Emetine Hydrochloride|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
75554905|NCT05889793|Drug|Placebo|Participant takes a placebo for 10 consecutive days.
75554906|NCT05884398|Drug|Apalutamide|Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.
75554907|NCT05884398|Drug|Androgen-deprivation Therapy (ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
75713930|NCT02659878|Procedure|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
75410715|NCT04529538|Biological|Novel Oral Polio Vaccine Type 1 (nOPV1)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10^6.5 CCID50.
75713931|NCT02529696|Device|Accelerometer|Measures patient movement
76040965|NCT05514743|Procedure|6 minute walk test , Blood pressure monitoring|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day &in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days."
76040966|NCT05511311|Procedure|Resistance Training|Resistance training developed by the researcher (SCR-RSCM) for 12 weeks
76040967|NCT05511311|Procedure|Standard Therapy|Standard therapy for 12 weeks
76040968|NCT05514665|Device|Diffuse Optical Tomography|Neonates once hemodynamically stable will undergo diffuse optical tomography measurements of functional brain connectivity at the bedside within 3-7 days after birth.
75410716|NCT04529538|Biological|Novel Oral Polio Vaccine Type 3 (nOPV3)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10^6.5 CCID50.
75410717|NCT04529538|Biological|Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)|The Sabin mOPV1 control vaccine contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
75410718|NCT04529538|Biological|Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)|the Sabin mOPV3 control vaccine contains ≥ 10^5.8 CCID50 per 0.1 mL (2 drops) dose.
75410719|NCT04522596|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day
75410720|NCT04522596|Other|Placebo|Placebo inhaled once a day
75410721|NCT04521114|Drug|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
75410722|NCT04521114|Drug|leronlimab 700 mg|700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
75410723|NCT04521114|Drug|leronlimab 350 mg|350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
75410724|NCT04510272|Other|Aloud Real-time Reading of ICU Diaries|Standard ICU diaries will be read aloud in real time daily to patients by ICU nurses/therapists/family members
75410725|NCT04494360|Other|No intervention|No investigational medicinal product will be administered as a part of this study.
75410726|NCT04471974|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
75410727|NCT04471974|Drug|Enzalutamide|Given PO
75410728|NCT04471974|Biological|Pembrolizumab|Given IV
75410729|NCT04470648|Diagnostic Test|blood test for SARS-COV2 serology|each person who will accept to participate will have a bood test for a SARS-COV2 serology
75713932|NCT00885885|Drug|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
75554908|NCT05879926|Drug|Ovarian Function Suppression + Aromatase Inhibitor|Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
75554909|NCT05879926|Drug|Adjuvant Chemotherapy + Ovarian Function Suppression|Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
75554910|NCT05878691|Drug|GRC 54276|"Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm."
75554911|NCT05878691|Drug|GRC 54276 + Pembrolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
75554912|NCT05878691|Drug|GRC 54276 + Atezolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
75554913|NCT05872282|Device|ZIPPER aortic arch stentgraft system|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
75410730|NCT04461678|Diagnostic Test|HPV Genotyping Nucleic Acid Assay Kit|The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.
75554914|NCT05868629|Other|Non-investigational|Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
75554915|NCT05868122|Drug|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
75554916|NCT05868122|Drug|Placebo|Placebo will be administered orally.
75410731|NCT04452084|Radiation|HA-WBRT|The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.
75554917|NCT05864560|Device|Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System|Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
76023338|NCT04480489|Other|Traditional|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
76023339|NCT02396797|Behavioral|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
76023340|NCT02396797|Behavioral|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
76023341|NCT04788875|Procedure|Small bite suturing Technique|Small bite suturing technique with PDS 2.0
75410732|NCT04452084|Radiation|HA-SIB-WBRT|The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.
75410733|NCT04389216|Device|Cool-tip electrode for Radiofrequency Ablation|Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
75554918|NCT05859477|Drug|Nivolumab|360 mg, i.v., every 3 weeks
75554919|NCT05859477|Drug|Capecitabine|capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle
75554920|NCT05859477|Drug|Oxaliplatin|130 mg/m², i.v., day 1, every 3 weeks
75554921|NCT05857397|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
75554922|NCT05855200|Biological|Dostarlimab|Dostarlimab will be administered.
75554923|NCT05855200|Drug|CAPEOX|CAPEOX will be administered.
75554924|NCT05855200|Drug|FOLFOX|FOLFOX will be administered.
76040969|NCT05514275|Drug|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
76040970|NCT04877249|Behavioral|Split-belt treadmill training|1. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg
76040971|NCT05510999|Other|Placebo|One capsule of placebo will be taken twice daily for 24 weeks.
76040972|NCT05510999|Dietary Supplement|Water soluble pollen extract fraction|Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
76040973|NCT05510999|Dietary Supplement|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
76040974|NCT05510999|Dietary Supplement|Lipid soluble pollen extract fraction|Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
76040975|NCT05510999|Dietary Supplement|Water soluble pollen extract fraction + cranberry powder|Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
75410734|NCT04360824|Drug|Intermediate dose thromboprophylaxis|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
75554925|NCT05851924|Drug|NALIRIFOX|"Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 46 hours (±60 minutes) on days 1 and 15 of every 4-week cycle"
75410735|NCT04360824|Drug|Standard of Care thromboprophylaxis|Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI <30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
75554926|NCT05851924|Combination Product|AD-XRT and Capecitabine|The interval between completion of induction chemotherapy and initiation of AD-XRT will be 2-6 weeks. The patient will be concurrently treated with capecitabine (1000-1500 mg flat BID PO Monday to Friday) with radiation, as per standard dosing regimens at MSK.
75554927|NCT05851872|Procedure|Coronary angiogram|Being done per standard of care
75554928|NCT05851872|Procedure|Right heart catheterization|Being done per standard of care
75554929|NCT05851183|Drug|Vitis Vinifera seed extract medication plus therapeutic lifestyle change|Administer 150mg of Vitis Vinifera seed extract (Entelon®) orally twice a day
75554930|NCT05851183|Behavioral|Therapeutic lifestyle change only|Implementing TLCs is a critical component of a comprehensive treatment plan for varicose veins. A key aspect of TLCs is the optimization of postural habits. Patients are advised to avoid extended sitting or standing periods, which exert additional pressure on the venous system in the lower extremities and exacerbate venous insufficiency. During rest periods, elevating the legs closer to the heart is recommended because this simple yet effective adjustment promotes venous return and reduces the gravitational burden on the venous valves of the legs. The use of graduated compression stockings during waking hours is another therapeutic lifestyle intervention that is often prescribed for patients with varicose veins. Additional TLCs include maintaining optimal body weight and engaging in regular physical exercise Walking or cycling are often recommended because of their effectiveness in promoting lower limb venous return.
75554931|NCT05850546|Drug|Rituximab|Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy
75554932|NCT05850546|Drug|Corticosteroid|guideline-recommended corticosteroid therapy
75410736|NCT04331652|Procedure|Polypectomy without anesthesia or analgo-sedation|"Premedication: paracetamol 1g oral. Patient will undergo polypectomy without anesthesia. During the procedure, pain will be monitored using a pain assessment scale from 0 to 10 (0 meaning no pain and 10 meaning maximum pain imaginable). At any time, if the patient express a pain strictly superior to 4 an analgo-sedation will be proposed and/or general anesthesia.~Pulse and blood pressure will be monitored. Assessment of patient satisfaction after the intervention."
75554933|NCT05845008|Drug|Acetaminophen/Naproxen Sodium Fixed Combination|Acetaminophen/naproxen sodium fixed combination tablets, oral.
75554934|NCT05844995|Drug|Acetaminophen/Naproxen Sodium|Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
75554935|NCT05844267|Behavioral|Experimental led booster breaks|Participants in this group will receive interventions in the form of active breaks, administered by professionals in the relevant field, such as Physical Education teachers, for a period of 12 weeks. The active breaks will comprise exercises of light-to-moderate intensity, based on the guidelines provided by the Chilean safety association (ACHS), with an average duration of 14-16 minutes per day from Monday to Friday. The exercise types and progression will be elaborated in our protocol and published as supplementary material.
75554936|NCT05844267|Behavioral|Experimental unled computer-prompts|"Participants in this group will receive interventions in the form of active breaks, facilitated through an application called Ponte de pie por tu salud, proposed by the Chilean Ministry of Health. This off-line application will be configured to generate breaks every hour, lasting for 2 minutes per break, over the course of 8 hours. This ensures that an average of 14-16 minutes of active breaks are accumulated throughout the day. Our research team will install the application on the participants' work computers and collect data from these computers weekly. At the end of the intervention period, the application will be uninstalled if necessary."
75554937|NCT05841290|Procedure|Primary local anesthesia|Tooth will be anaesthetized using Local anesthesia containing Articaine with epinephrine 1:100,000.
75554938|NCT05841290|Procedure|Supplemental local anesthesia|if needed
75554939|NCT05841290|Procedure|Removal Of Caries and Access Cavity|• Access cavity will be performed using a carbide round steel bur and tapered diamond stone until complete deroofing.
75410737|NCT04288128|Procedure|Lumbar puncture|Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)
75410738|NCT04288128|Other|Magnetic Resonance Imaging (MRI)|Each participant will undergo scanning at 3 visits (M0, M6 and M12)
75554940|NCT05841290|Procedure|Rubber dam isolation of tooth|Rubber dam isolation of tooth using certain clamps .
75554941|NCT05841290|Procedure|Bleeding control|bleeding is controlled by using excavator for the removing the pulp tissue . using a piece of cotton soaked with Sodium hypochlorite. using local anesthesia with vasoconstrictor if needed and if suitable for the patient.
75554942|NCT05841290|Procedure|Canal negotiation|Coronal patency of the coronal and the Middle part of the canal using file #10 Apical patency of the apical part of the canal using #10
75554943|NCT05841290|Procedure|Coronal flaring|Coronal flaring using Orifice opener of a certain Rotary system in and out motion first then brushing motion touching all the canal walls
76023342|NCT04788875|Procedure|Standardised Large Bites Technique|Standardised large bite suturing technique with PDS 2.0
76023343|NCT02396875|Procedure|Blood sampling and exercise protocol pre and post CRT implant|
75554944|NCT05841290|Procedure|Working Length Determination (W.L)|Working length determination (W.L) using #10 K File , working length is recorded using apex locator and confirmatory radiograph.
76023344|NCT02396875|Procedure|Peripheral blood sampling|
76023345|NCT02396875|Procedure|Central blood sampling pre and post CRT implant|
75554945|NCT05841290|Procedure|Glide path|Glide path of the canal Using #10 ,15 ,20 ,25 K files till becoming Super-Loose Inside the Canal at the recorded w.l to create a path for the rotary file .
75713933|NCT00885885|Drug|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
76040976|NCT05505149|Other|physiotherapy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
76040977|NCT05505071|Device|DANTE SPACE sequence|investigational MRI sequence less than 15 minutes
76040978|NCT05504993|Other|Frequency of AECOPD|No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
76040979|NCT05514041|Drug|Varenicline solution|OC-01 nasal spray 0.03 mg
76040980|NCT05514041|Drug|Placebo nasal spray (OC-01 Vehicle Nasal Spray)|Placebo nasal spray (OC-01 Vehicle Nasal Spray)
76040981|NCT04691531|Device|The use of classical Gauge 22 needle|After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
75410739|NCT04261296|Other|dry needling|In this treatment, depending on the thickness of the adipose tissue under the skin, 13 mm, 25 mm or 30 mm long; 0.20 mm thick acupuncture needle is used
75410740|NCT04261296|Other|balneotherapy|"This treatment method; An alert-fit performed in a certain time interval and in a cure style by using the methods and doses of hot mineral waters, gases and peloids (sludge) from natural underground, determined in detail, repeatedly in series as bath, drinking and inhalation treatments. treatment can be defined as. There are studies showing that the effect of balneotherapy is mechanical, thermal, chemical, anti-inflammatory and immunological."
75410741|NCT04261296|Other|dry needling +balneotherapy|Both of these methods will be applied to patients in the third group.
75410742|NCT04243590|Behavioral|Hand-Use-at-Home Questionnaire (HUH)|The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).
75410743|NCT04243590|Behavioral|Pediatric Outcome Data Collection Instrument (PODCI)|The PODCI is designed to assess different aspects of daily living in children with musculoskeletal disorders. It has excellent psychometric properties, and it is a widely accepted instrument to provide parent/patient-reported information about upper extremity functioning. A Dutch version is available and it is validated for children with neonatal brachial plexus palsy. It consists of 85 questions and five scale scores and one total score can be calculated (range for all scales and total score 0-100, higher scores indicating better functioning/quality of life). Only the Upper Extremity and Physical Function Scale (8 items) were used in this study since this scale provides information about difficulties performing activities using the arms/hands (score 0-100; lower score, more difficulties).
75554946|NCT05841290|Procedure|Irrigation|Irrigation using 5.25% sodium hypochlorite introduced using side vented needle
75713934|NCT04077762|Procedure|Radial Access|Radial Access
76040982|NCT04691531|Device|The use of classical Gauge 27 needle|After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
76040983|NCT05513963|Behavioral|Clairity|Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.
76040984|NCT05510765|Behavioral|Transportation service|Improved transportation assets applied to all aspects of subjects life
76040985|NCT05504759|Other|splint|Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
76040986|NCT05504759|Other|steroid|Betamethasone Dipropionate + Betamethasone Sodium Phosphate-1 ml will be administered once at the beginning of the study to patients who will receive steroid injection, one of the local injection treatments. Steroid injection will be applied to the most sensitive point on the lateral epicondyle. Afterwards, patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during daytime hours for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
75410744|NCT04243590|Behavioral|Children's Hand-Use Experience Questionnaire (CHEQ)|"The CHEQ is a questionnaire for children (aged 6-18) with unilateral functional limitations of hand use and is well validated for children with unilateral cerebral palsy. It was only partially validated for use in children with neonatal brachial plexus palsy and has not yet been used in studies. Therefore, it was not used in this group. The questionnaire consists of 29 bimanual activities, typically requiring the use of both hands. It assesses the child's experience using their affected hand when performing the activities and counts how many of the activities are executed independently (with and without using the affected hand).~In the mini-version of the CHEQ some items were deleted or replaced (with more age-appropriate activities for children aged three to eight years) and this version was used for all unilateral cerebral palsy children <six years in this study."
75554947|NCT05841290|Procedure|Cleaning and shaping using rotary system|Cleaning and shaping using rotary system plus irrigation and apical patency between every rotary file .
75554948|NCT05841290|Procedure|Second w.l determination|Second w.l determination using electronic apex locator before using final finishing rotary file .
76040987|NCT05504759|Other|dry needling|The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x30 mm needles will be used for dry needling. Dry needle treatment will be applied to the painful trigger points in the forearm extensor group muscles with the stick-pull technique, 1 session per week, for a total of 2 sessions. Afterwards, the patients will be given a 2 weeks rest protocol (works that may strain the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The purpose of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. During the treatment of lateral epicondylitis, home exercises will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
76040988|NCT02570711|Drug|ACP-196|ACP-196 capsule
76040989|NCT02570711|Drug|Nab-paclitaxel|Nab-paclitaxel infusion
76040990|NCT02570711|Drug|Gemcitabine|Gemcitabine infusion
76040991|NCT05513729|Drug|Canagliflozin|According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
75410745|NCT04198350|Procedure|Islet implantation|Transplantation of allogeneic pancreatic human islets will be performed into the anterior chamber of a single eye with the poorest visual acuity (see inclusion/exclusion criteria below). Up to 40 000 IEQ of islets in a maximum volume of 350µl will be transplanted.
75410746|NCT04174716|Drug|IDX-1197|Until progression or unacceptable toxicity develops
75410747|NCT04159740|Other|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
75410748|NCT04122924|Other|Abdominal muscle training|The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
75554949|NCT05841290|Procedure|Apical gauging|"Establish the depth of apical constriction - this is the zero reading on your apex locator. your working length will be 0.5mm - 1mm short of this.~After cleaning and preparing the canal system to your working length, passively insert 02 taper hand files, starting from #15. If the file goes past the apical constriction (your working length + 0.5-1mm), then choose the next largest file and repeat.~When a file passively binds short of the apical constriction, that will be the upper limit of the apical constriction diameter. The smaller file before that would be the lower limit.~Apical gauging helps with:~Choosing the best master cone that closely matches canal length and taper Achieving true tug back - as opposed to false tug back! Minimising gutta percha extrusions during obturation"
75554950|NCT05841290|Procedure|Activation of the irrigant|Activation of the irrigant using Manual Dynamic Agitation and Ultra x or eddy tips for activation
75554951|NCT05841290|Procedure|Master cone check|Master cone check Clinically and confirmatory radiograph
75554952|NCT05841290|Drug|application of resin based sealer inside the canal in the resin based sealer group|application done by inserting inside the canal by spreader or master cone
75713935|NCT04077762|Procedure|State-of-the-art femoral access with 18 gauge needle|State-of-the-art femoral access with 18 gauge needle
76040992|NCT05513729|Drug|Pioglitazone|According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
75410749|NCT04055298|Device|SMASS-Triage|SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
75410750|NCT04049214|Other|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
75410751|NCT04042038|Behavioral|Cognitive-behavior therapy (psychological treatment)|Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
75410752|NCT03990792|Behavioral|e-predictD intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.
75410753|NCT03990792|Other|Brief psychoeducational intervention|The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)
75410754|NCT03952338|Other|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
75410755|NCT03952338|Other|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
75410756|NCT03941106|Device|Accelerated repetitive transcranial magnetic stimulation|Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
75410757|NCT03915366|Drug|Valganciclovir Oral Solution [Valcyte]|Treatment for CMV
75410758|NCT03915366|Drug|Tuberculostatic Agents|Treatment for tuberculosis
75410759|NCT03903666|Other|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
75410760|NCT03892746|Device|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
75410761|NCT03892746|Device|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
76023346|NCT02396875|Procedure|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
76023347|NCT02396641|Other|Best Supportive Care Checklist|
75554953|NCT05841290|Diagnostic Test|application of the sillicon based sealer inside the canal in the sillicon based group|application done by injection inside the canal
75554954|NCT05841290|Procedure|Obturation|done by lateral condensation technique
75554955|NCT05841290|Diagnostic Test|Visual Analogue Scale (VAS)|"Pain is evaluated using visual analogue scale (VAS) which is a pain rating scale. Scores are based on measures that are self-reported of symptoms that are recorded through a single handwritten mark placed at one point along the length of a 10-cm line representing a continuum between the two ends of the scale; on the left end of the scale (0 cm) means no pain and the on the right end of the scale (10 cm) worst pain"
75554956|NCT05841277|Drug|LY3819469|Administered SC.
75554957|NCT05841030|Other|No Intervention|There is no interventional treatment administered to the participants as a part of this study.
75554958|NCT05840224|Biological|GS-4528|Administered intravenously
75554959|NCT05840224|Drug|Zimberelimab|Administered intravenously.
76023348|NCT05109923|Dietary Supplement|Multi-Ingredient Herbal Supplement|Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.
76023349|NCT05109923|Dietary Supplement|Placebo Supplement|Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
75410762|NCT03853356|Device|Orthoss|Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
75410763|NCT03846570|Drug|Formoterol-beclomethasone|formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler
75713936|NCT04077762|Procedure|State-of-the-art femoral access with 21 gauge needle|State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
76023350|NCT02396563|Procedure|epidural analgesia|
75554960|NCT05837923|Dietary Supplement|Relief Active Study Product 1.1 Usage|Participants will use their Radicle Relief Active Study Product 1.1 as directed for a period of 6 weeks.
75410764|NCT03846570|Drug|Placebo|Matching placebo (identically package) administered BID
75554961|NCT05837923|Dietary Supplement|Relief Active Study Product 1.2 Usage|Participants will use their Radicle Relief Active Study Product 1.2 as directed for a period of 6 weeks.
75554962|NCT05837923|Dietary Supplement|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
75554963|NCT05837923|Dietary Supplement|Relief Active Study Product 2.1 Usage|Participants will use their Radicle Relief Active Study Product 2.1 as directed for a period of 6 weeks.
75554964|NCT05837923|Dietary Supplement|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
76023351|NCT02396563|Drug|Ropivacaine|
75410765|NCT03838848|Drug|KN046|3mg/kg, Q2W, intravenous injection (IV)
75410766|NCT03838848|Drug|KN046|5mg/kg, Q2W, intravenous injection (IV)
75410767|NCT03838848|Drug|KN046|5mg/kg, Q3W, intravenous injection (IV)
75410768|NCT03838848|Drug|Carboplatin|AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
75410769|NCT03838848|Drug|Pemetrexed|500 mg/m2, Q3W, intravenous injection (IV)
75410770|NCT03838848|Drug|Ningetinib|Oral, QD
75410771|NCT03787602|Drug|KRT-232|KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
75410772|NCT03787602|Drug|Avelumab|Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
75410773|NCT03778164|Other|Fast Track Partner Services-Sexual Health Intervention|The Partner Services-Sexual Health Intervention enhances the current standard of care by introducing four service innovations to the DOHMH Partner Services program: (1) enhanced field-based combination HIV and STI testing; (2) immediate field-based ARV/PrEP start; (3) navigation to a sexual health clinic for test results and treatment; and (4) enhanced linkage support to facilitate ongoing PrEP or HIV care.
75554965|NCT05837923|Dietary Supplement|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
75554966|NCT05837923|Dietary Supplement|Relief Active Study Product 3.1 Usage|Participants will use their Radicle Relief Active Study Product 3.1 as directed for a period of 6 weeks.
75554967|NCT05837923|Dietary Supplement|Relief Active Study Product 3.2 Usage|Participants will use their Radicle Relief Active Study Product 3.2 as directed for a period of 6 weeks.
75713937|NCT00610935|Drug|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
75713938|NCT00610935|Drug|Placebo|Single intramuscular injection
75713939|NCT00761982|Procedure|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
75554968|NCT05837923|Dietary Supplement|Relief Active Study Product 3.3 Usage|Participants will use their Radicle Relief Active Study Product 3.3 as directed for a period of 6 weeks.
75410774|NCT03778164|Other|Partner Services Standard of Care|Participants in neighborhoods that have not yet been assigned to the intervention condition in the stepped wedge trial will receive standard Partner Services components, including field-based HIV testing and referral to clinical sites for HIV prevention or treatment.
75554969|NCT05837910|Dietary Supplement|Calm Active Study Product 1.1 Usage|Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
75554970|NCT05837910|Dietary Supplement|Calm Active Study Product 1.2 Usage|Participants will use their Radicle Calm Active Study Product 1.2 as directed for a period of 6 weeks.
75554971|NCT05837910|Dietary Supplement|Calm Active Study Product 1.3 Usage|Participants will use their Radicle Calm Active Study Product 1.3 as directed for a period of 6 weeks.
75554972|NCT05837910|Dietary Supplement|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
75410775|NCT03745170|Drug|Sintilimab|Weight<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
75410776|NCT03745170|Drug|Oxaliplatin|130 mg/m^2 Q3W on Day 1 by IV infusion
75410777|NCT03745170|Drug|Capecitabine|1000 mg/m^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
75410778|NCT03745170|Drug|placebo|Weight<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
75554973|NCT05837910|Dietary Supplement|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
75554974|NCT05837910|Dietary Supplement|Calm Active Study Product 2.1 Usage|Participants will use their Radicle Calm Active Study Product 2.1 as directed for a period of 6 weeks.
75554975|NCT05837910|Dietary Supplement|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
75554976|NCT05837910|Dietary Supplement|Calm Active Study Product 3.1 Usage|Participants will use their Radicle Calm Active Study Product 3.1 as directed for a period of 6 weeks.
75554977|NCT05837910|Dietary Supplement|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
75410779|NCT03737370|Drug|Docetaxel|Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
75554978|NCT05837910|Dietary Supplement|Calm Active Study Product 4.1 Usage|Participants will use their Radicle Calm Active Study Product 4.1 as directed for a period of 6 weeks.
75554979|NCT05837481|Behavioral|Meditation|Guided meditation utilizing breath awareness, body scan and visualization techniques
75554980|NCT05830968|Device|Morpheus8 Applicator Radiofrequency device|Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is ~6 months, depending on subject recruitment rate.
75554981|NCT05830058|Procedure|Biospecimen Collection|Undergo blood collection
75554982|NCT05830058|Procedure|Computed Tomography|Undergo CT or PET/CT
75554983|NCT05830058|Procedure|Positron Emission Tomography|Undergo PET
75554984|NCT05830058|Other|Questionnaire Administration|Ancillary studies
75554985|NCT05830058|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75554986|NCT05829343|Procedure|Laparoscopic Left colectomy|Patients are treated with a laparoscopic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
75554987|NCT05829343|Procedure|Robotic left colectomy|Patients are treated with a robotic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
75554988|NCT05826847|Procedure|Prone Positioning|Prone positioning will be performed according to ICU local protocol with trained provider teams.
75554989|NCT05826847|Procedure|Thoracoabdominal Binding|Thoracoabdominal binding will be used in semi-recumbent position (supine at 45º) and titrated to obtain a 20-30% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing
75554990|NCT05826847|Procedure|Control|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
75554991|NCT05825963|Dietary Supplement|Psyllium|The participants select hamburgers randomly by themselves, with or without (control) 12 g of psyllium, each containing 85 g of hamburger bread, 160 g of 20% fat beef, 2.56 g of salt, and 1.28 g of pepper, and asked to consume them with 200 ml of water.
75713940|NCT04049448|Drug|ABX464|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
75410780|NCT03737370|Radiation|Radium 223|Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
75554992|NCT05825469|Behavioral|Nutrition Algorithm|A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
75713941|NCT02303028|Drug|Topotecan and Pazopanib|Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
75713942|NCT02287818|Drug|Placebo|Placebo twice daily from Day 1 to Week 12
75713943|NCT02287818|Drug|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
75410781|NCT03711786|Other|Basic implementation package|The basic implementation package will involve identifying an internal coordinator who is one of the full-time on-site providers at the clinic. The internal coordinator provides mentoring to peers and support to leadership in implementing the treatment program and aligning it with clinic priorities.
75410782|NCT03711786|Other|Enhanced implementation package|The enhanced implementation package will combine the internal coordinator with an external quality assurance committee. This committee will complete quarterly audits at the facility to evaluate compliance with the depression treatment protocol as well as providing high-level support in implementing the treatment program through clinical expertise and limited on-site presence.
75410783|NCT03701490|Drug|Progesterone subcutaneous|25 mg/twice a day.
75410784|NCT03701490|Drug|Progesterone Vaginal Product|200 mg three times a day.
75410785|NCT03723720|Device|Colonoscopy|Endoscopic examination of large bowel
75410786|NCT03694392|Biological|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
75410787|NCT03694392|Biological|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
76023352|NCT05109767|Device|Virtual reality|The Virtual Reality Glass game application reduces anxiety by distracting attention..The virtual reality glass game was played to intervention group for 15 minutes before surgery.
75713944|NCT02287818|Drug|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration <6 mg/dL
75410788|NCT03691974|Drug|Fasinumab|Subcutaneous (SC) every four weeks (Q4W)
75410789|NCT03691974|Other|Placebo|Subcutaneous (SC) every four weeks (Q4W)
75410790|NCT03675360|Behavioral|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
75713945|NCT02542449|Dietary Supplement|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
75713946|NCT02542449|Dietary Supplement|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
76023353|NCT05109767|Device|Smartphone|The Smartphone game application reduces anxiety by distracting attention. Smartphone game was played to intervention group for 15 minutes before surgery.
76023354|NCT03170245|Diagnostic Test|Interleukin-6|serum samples used for doing the test by ELISA
76023355|NCT03170245|Diagnostic Test|HsC-RP|serum samples used for doing the test by ELISA
76023356|NCT03170245|Diagnostic Test|Adiponectin level|serum samples used for doing the test by ELISA
75410791|NCT03652428|Drug|Gemcitabine|see arm description
75410792|NCT03652428|Radiation|Hypofractionated Ablative Proton Therapy|see arm description
75410793|NCT03592290|Diagnostic Test|Lower body negative pressure|We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
75410794|NCT03580044|Combination Product|ATM-AVI|ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
75410795|NCT03580044|Drug|BAT|The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
75410796|NCT03571776|Procedure|Surgery|Laparoscopic ovarian cystectomy
75410797|NCT03571776|Procedure|Sclerotherapy|US-aspiration and alcohol sclerosis
75410798|NCT03398304|Other|Graded Exercise|Study arm 1 (Graded Exercise) participants will complete either 20 minutes of mild or moderate intensity at 2 different study visits. The third study visit will consist of 20 minutes of sitting.
75410799|NCT03398304|Other|Marathon participation|Study arm 2 (Marathon participation) participants will take part in a marathon. On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
75410800|NCT03351270|Other|Standardized strength, respiratory and motor function assessments|Standardized assessments will be adjusted by the age, the ambulant status and the respiratory status of the patient. The visit frequency will also be adjusted according to the age and to the time spent in the study varying between quarterly to yearly.
75410801|NCT03306576|Device|ELS Extra composite|One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
75410802|NCT03306576|Device|ELS composite|the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
75410803|NCT03207984|Procedure|Root coverage surgery|Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM
75713947|NCT00762060|Device|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
75713948|NCT00762060|Drug|Patient controlled analgesia|IV opioids delivered via PCA
75713949|NCT00884169|Drug|M518101|Proper quantity twice a day
75713950|NCT00884169|Drug|placebo|Proper quantity twice a day
75713951|NCT00886041|Procedure|laparoscopy|subjected to laparoscopy
76023357|NCT03170245|Diagnostic Test|Carotid intima media thickness|Done by carotid doppler
75410804|NCT03030066|Drug|DS-1001b|Generic not assigned
75554993|NCT05823480|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo HCT per standard of care
75554994|NCT05823480|Drug|Azacitidine|Given IV
75410805|NCT02972034|Drug|MK-8353|PO capsule
75554995|NCT05823480|Procedure|Biospecimen Collection|Undergo blood sample collection
75554996|NCT05823480|Procedure|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
76040993|NCT05504603|Drug|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1,8,15,22. Other name: Part A
75554997|NCT05823480|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
75554998|NCT05823480|Procedure|Echocardiography|Undergo ECHO
75872495|NCT05762562|Other|Telerehabilitation with open source platforms|"Telerehabilitation with opensource platforms. Patients enrolled were dived into three groups based on their score in SPPB. Each group corresponded to a Program (Pr): • Pr. A is for patients with capable motor skills, Pr. B is for patients with reduced motor skills, • Pr. C is for patients who didn't show having sufficient motor skills to support a TR program. Patients who were included in TrP.A and TrP.B underwent a TR program using OS platforms for 8 consecutive weeks. A specific exercise program for the parkinsonian patients was structured in relation to the individual residual motor skills based on the FITT - frequency/intensity/type/time - protocol.~Twice a week, the activity was performed with the support of a physiotherapist through OS TR platform.~Subjects included in TmP.C participated in an 8-weeks program. A video-call was scheduled once a week to monitor the patient's clinical condition without any exercise program."
76040994|NCT05504603|Drug|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1. Other name: Part B
75554999|NCT05823480|Biological|Magrolimab|Given IV
75555000|NCT05823480|Procedure|Multigated Acquisition Scan|Undergo MUGA
75555001|NCT05823480|Other|Questionnaire Administration|Ancillary studies
75555002|NCT05823012|Drug|levothyroxine sodium|Levothyroxine sodium 10 mg/mL
75555003|NCT05819372|Procedure|Zygomaticomaxillary fracture repair|"A cone beam CT (CBCT) scan of the patient will be used to create a 3D scanned image of zygomaticomaxillary complex fracture (ZMC)~3D images will be introduced to finite element (FA) software to evaluate Stresses (MPa), Micromotion (microns), and Life time (cycle) For each model and determine which point of fixation is the best~After application this point of fixation on the patient~Finite element analysis will be done again to verify the previous results"
75555004|NCT05818683|Drug|JNJ-78278343|JNJ-78278343 will be administered subcutaneously.
75555005|NCT05818683|Drug|Cetrelimab|Cetrelimab will be administered by intravenous infusion.
76040995|NCT05504603|Drug|BEAM pretreatment|semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.
75555006|NCT05817084|Procedure|medial opening wedge high tibial osteotomy|medial opening wedge valgus high tibial osteotomy
75555007|NCT05817084|Procedure|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
75555008|NCT05816850|Diagnostic Test|EZH2 mutations/CNAs by droplet digital PCR (ddPCR)|Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment
75410806|NCT02972034|Biological|Pembrolizumab|IV infusion
75410807|NCT02882802|Behavioral|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
75410808|NCT02882802|Behavioral|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
75410809|NCT02795988|Biological|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
75555009|NCT05816850|Diagnostic Test|EZH2-derived gene expression signature by RNA-Seq|Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples
75555010|NCT05816057|Biological|semaglutide injection|The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.
75555011|NCT05811351|Drug|JNJ-81201887|JNJ-81201887 will be administered as intravitreal injection.
75555012|NCT05811351|Drug|Prednisone|Prednisone will be administered as oral capsule.
75555013|NCT05811351|Other|Placebo|Prednisone matching placebo will be administered as oral capsule.
75555014|NCT05811351|Drug|Triamcinolone|Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.
75555015|NCT05811351|Other|Sham Procedure|Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.
75410810|NCT02795988|Drug|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.|Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
75555016|NCT05807594|Behavioral|HMZ 2.0 Intervention|The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.
75555017|NCT05807594|Behavioral|Attention Control Intervention|Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
75555018|NCT05806346|Drug|TXA administration|Tranexamic acid intravenous administration
75555019|NCT05806346|Drug|Placebo administration|Placebo (normal saline) intravenous administration
75555020|NCT05803850|Drug|HNC1058 Capsules|HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
75713952|NCT00886041|Other|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
75872496|NCT04457752|Biological|Dual Layer Amniotic Membrane (DLAM). Artacent®|"Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers."
76040996|NCT05504603|Drug|zanubrutinib maintenance|zanubrutinib 160mg PO BID.
76040997|NCT05510609|Device|BK 5000 Ultrasound Machine|Both 2D and 3D ultrasound is being used. 3D using optical tracking.
76040998|NCT04863131|Biological|EXG-5003|COVID-19 self-replicating mRNA vaccine
75555021|NCT05801614|Other|Low carb diet|Low calori diet
75555022|NCT05797519|Device|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System.
75713953|NCT05278923|Device|SALAD simulation device|An airway CPR manikin was modified to simulate regurgitation during CPR . A manual pump was fixed on the bottom of the torso to simulate the stomach. A clear vinyl tube was connected the manikin's oesophagus and the outflow port of the pump. A water container outside the manikin was filled with simulated gastric content and connected to the inflow port of the pump through another vinyl tube. The manikin's left main bronchus was occluded using a red cap provided by the manufacturer. The lung was simulated by an anaesthesia breathing bag placed outside the manikin and connected to the manikin's right main bronchus via a breathing circuit. A compression pad was attached to the bottom of the manikin's compression plate. During chest compression, the compression pad squeezed the pump to regurgitate gastric contents into the oropharynx
75872497|NCT02327338|Device|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
75872498|NCT02327338|Drug|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
75872499|NCT05080816|Dietary Supplement|Parenteral nutrition (PN)|Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
76040999|NCT04863131|Biological|Placebo|placebo solution
76041000|NCT05504369|Other|Magnetic tape|Tape with magnetic nanoparticles applied to the skin
76041001|NCT05504369|Other|Placebo tape|Tape without nano particles applied to the skin
76041002|NCT05513495|Other|The effect of drip versus intermittent feeding on splanchnic oxygenation|After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
76041003|NCT05513417|Device|Bloom Pod|Pelvic floor program consisting of exercise performed while using the device, education and behavioural change
76041004|NCT05504213|Drug|HS-10352 combined with fulvestrant (Stage 1)|"Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
76041005|NCT05504213|Drug|HS-10352 combined with fulvestrant (Stage 2)|"Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
76041006|NCT04424771|Behavioral|Maslach Burnout Inventory (MBI)|The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
75410811|NCT02782104|Drug|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
75410812|NCT02454972|Drug|lurbinectedin (PM01183)|
75713954|NCT00610857|Drug|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
75713955|NCT00672984|Drug|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
75410813|NCT02025270|Biological|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
75713956|NCT00672984|Drug|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
75872500|NCT05080816|Dietary Supplement|Enteral nutrition|Oral nutrition drink. 2 * 200 ml on the night before operation. 1* 200 ml on the morning of operation day.
75872501|NCT05080816|Other|Control|Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
75872502|NCT02327416|Drug|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
75410814|NCT01821690|Drug|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
75872503|NCT02327416|Drug|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
75872504|NCT02327416|Drug|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
75872505|NCT05080582|Behavioral|Mother-Scented Simulated Hand|Preterm neonates wrapped with a warm Mother-Scented Simulated Hand during the invasive procedures
75410815|NCT01821690|Drug|Placebo|The placebo tablets taste and look identical to buspirone.
75410816|NCT01649388|Biological|FCR001|Enriched hematopoietic stem cell infusion
75410817|NCT01394016|Drug|LY2835219|Administered orally, daily for 28-day cycles for two planned cycles. For Part G only in addition to LY2835219 as above, fulvestrant is administered as specified in the label. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
75410818|NCT01394016|Drug|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks as specified in the label in Part G only.
75713957|NCT00672984|Drug|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
75713958|NCT02543697|Radiation|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
75872506|NCT05080582|Behavioral|NICU Standard Care|Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture.
75872507|NCT03114657|Drug|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
75872508|NCT03114657|Drug|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
76041007|NCT02570165|Drug|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
75713959|NCT00762138|Device|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
75713960|NCT02543775|Procedure|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
75713961|NCT00758472|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
76041008|NCT02570165|Drug|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
76041009|NCT02570165|Drug|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
76041010|NCT04661813|Other|EXTRA-CVD Virtual Care|"The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination."
76041011|NCT05513339|Device|WHOOP strap 4.0|Subjects will wear the WHOOP strap 4.0 for continuous physiologic monitoring.
75410819|NCT00978822|Drug|Clevidipine butyrate injectable emulsion|Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
75410820|NCT00577200|Drug|Midazolam|Midazolam
75713962|NCT00886275|Drug|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
75410821|NCT00577200|Drug|Sufentanil|Sufentanil
75410822|NCT00577200|Drug|Propofol|Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
75410823|NCT00063882|Radiation|Brachytherapy (100/110)|100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
75410824|NCT00063882|Radiation|Brachytherapy (125/145)|125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
75713963|NCT00886275|Drug|Midazolam|The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
75410825|NCT00063882|Radiation|External Beam Radiation Therapy|Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
75410826|NCT00002796|Drug|fluorouracil|Given IV
75410827|NCT00002796|Drug|sodium phenylbutyrate|Given IV
75713964|NCT00886275|Drug|Dexmedetomidine, Midazolam|The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
75713965|NCT02543619|Other|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
75713966|NCT00886353|Biological|APN01|APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
75713967|NCT00886353|Other|Placebo|Physiological saline administrated i.v.
76041012|NCT05510453|Other|Low-intensity online intervention (LiON)|"The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills.~Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for 45 minutes. Participants will attend these sessions once a week.~The control group will receive the intervention after a waiting period of 4 weeks."
75410828|NCT00002796|Drug|indomethacin|Given orally
75410829|NCT00002796|Biological|recombinant interferon gamma|Given subcutaneously
75410830|NCT00002802|Drug|carboplatin|
75410831|NCT00002802|Drug|cisplatin|
75410832|NCT00002802|Drug|cyclophosphamide|
75410833|NCT00002802|Drug|dacarbazine|
75410834|NCT00002802|Drug|doxorubicin hydrochloride|
75410835|NCT00002802|Drug|etoposide|
75410836|NCT00002802|Drug|ifosfamide|
75410837|NCT00002802|Drug|melphalan|
75713968|NCT02543463|Device|Trident X3 Insert with Navigation system|
75713969|NCT02543463|Device|Trident X3 Insert with conventional instrumentation|
75410838|NCT00002802|Drug|mesna|
75410839|NCT00002802|Drug|vincristine sulfate|
75410840|NCT00002802|Drug|vindesine|
75410841|NCT00002802|Procedure|autologous bone marrow transplantation|
75410842|NCT00002802|Procedure|conventional surgery|
75410843|NCT00002802|Radiation|low-LET cobalt-60 gamma ray therapy|
75555023|NCT05796687|Behavioral|My Future Self|My Future Self is based upon the Theory of Possible Selves, which promotes the capacity of young people to construct goals for a successful adulthood. Youth who hold a balanced set of negative and positive images of their future have both a) a positive goal to strive for and b) awareness of the personally relevant consequences of not meeting that goal. My Future Self also includes two new supportive gaming elements that reinforce learning of relevant knowledge and skills as well as provide opportunities for youth to individually practice these skills in a personalized virtual environment. Gaming interventions using interactive technology can significantly increase self-reported abstinence and lower reports of diagnosed STD in young women, as well as reduce risky sex in high-risk young men who have sex with men. Youth will participate in these gaming elements on tablets provided by CHLA. My Future Self will be implemented as a ninety-minute small group 5-week program.
75872509|NCT05071456|Other|Collects of skin's hydration|Collects of skin's hydration will be made by using patch using electrochemistry.
75872510|NCT02926950|Drug|Sotagliflozin (SAR439954)|Pharmaceutical form: tablet. Route of administration: oral.
75872511|NCT02926950|Drug|Placebo|Pharmaceutical form: tablet. Route of administration: oral.
75410844|NCT00002802|Radiation|low-LET electron therapy|
75410845|NCT00002802|Radiation|low-LET photon therapy|
75410846|NCT00002802|Radiation|radioisotope therapy|
75410847|NCT00002814|Biological|filgrastim|
75410848|NCT00002814|Drug|paclitaxel|
75410849|NCT00002814|Drug|topotecan hydrochloride|
75410850|NCT00002832|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
75410851|NCT00002832|Drug|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
75410852|NCT00002832|Drug|Decitabine|IV for 6 hours every 12 hr for 5 days.
75410853|NCT00002832|Procedure|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
75872512|NCT02926950|Drug|Metformin|Pharmaceutical form: tablet. Route of administration: oral.
75410854|NCT00002832|Procedure|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
75555027|NCT05792696|Behavioral|PPI guided strategies|For targeted MAP or lower, if PPI<1, more fluid therapy. if PPI>3, vasoconstriction therapy. For MAP<65mmHg and 1<=PPI<3, test bolus of 250 ml crystalloid fluid.
75872513|NCT03410693|Drug|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
75872514|NCT03410693|Drug|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
75872515|NCT01064414|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
75872516|NCT01064414|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
75872517|NCT04254172|Device|Activity Monitor|Wrist and ankle sensors to be worn continuously for 2-week intervals.
75872518|NCT04944849|Diagnostic Test|Reaction Time Tests|While doing our research, the reaction time test in the Human Benchmark application, where the reaction time to many different stimuli on the computer can be evaluated, the Aim Trainer test and the auditory reaction time tests at https://playback.fm/audio-reaction-time will be applied.
75872519|NCT03433703|Drug|Lenvatinib|"Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW <60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)"
75410855|NCT00002838|Biological|Filgrastim (G-CSF)|
75410856|NCT00002838|Drug|Cyclophosphamide|
75410857|NCT00002838|Drug|Fludarabine Phosphate|
75410858|NCT00002838|Procedure|Peripheral Blood Stem Cell Transplantation|
75410859|NCT00002844|Drug|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
75410860|NCT00002844|Procedure|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
75872520|NCT03652766|Behavioral|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
75872521|NCT05202600|Procedure|Appendectomy|Surgical removal of the vermiform appendix.
75872522|NCT04904601|Dietary Supplement|Kale supplement|Kale (blanched freeze-dried Kale) group1
75872523|NCT04904601|Dietary Supplement|Peas supplement|placebo (Blanched Freeze-dried Peas) group2
75872524|NCT03653078|Device|Three dimensional printed digital guide|A CAD/CAM printed plate with a channel for mini-screw insertion
75410861|NCT00002844|Procedure|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
75410862|NCT00002844|Radiation|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
75713970|NCT04017897|Drug|The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)|Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
76041013|NCT05513105|Diagnostic Test|Iron study of neonates|Blood sambles
75410863|NCT00002862|Drug|perillyl alcohol|
75410864|NCT00002880|Drug|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
75410865|NCT00002892|Biological|recombinant interferon alfa|
75713971|NCT02543541|Behavioral|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
75713972|NCT02543541|Behavioral|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
75713973|NCT02542137|Radiation|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
75713974|NCT02542137|Drug|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
75713975|NCT00886431|Other|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
75872525|NCT03713723|Device|NICaS bioimpedance system|NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
75872526|NCT05202444|Procedure|Osteotomy using piezoelectrical device|"osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla."
76041014|NCT05510375|Dietary Supplement|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
76041015|NCT05510375|Dietary Supplement|Multivitamin|Multivitamin
76041016|NCT05510375|Dietary Supplement|Cocoa extract placebo|Cocoa extract placebo
76041017|NCT05510375|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
75410866|NCT00002898|Biological|dactinomycin|
75410867|NCT00002898|Drug|carboplatin|
75713976|NCT00886509|Biological|pegfilgrastim|s.c. administration of pegylated G-CSF over 6 months
75410868|NCT00002898|Drug|cyclophosphamide|
75410869|NCT00002898|Drug|epirubicin hydrochloride|
75713977|NCT00886509|Other|Placebo|Placebo control Arm 1: Collateral promotion; PCI after 6 months
75713978|NCT00886665|Drug|placebo|placebo, 4 g, powder, oral, 3 times a day
75713979|NCT00886665|Drug|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
75713980|NCT02543385|Drug|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
75713981|NCT00886977|Drug|YAM80|Oral administration, 2 to 6 mg, once a day.
75713982|NCT00884481|Other|Natalizumab|Participants treated with Tysabri
76041018|NCT05512715|Procedure|radioactive iodine|radioactive iodine 15mci
75410870|NCT00002898|Drug|etoposide|
75410871|NCT00002898|Drug|ifosfamide|
75410872|NCT00002898|Drug|vincristine sulfate|
75410873|NCT00002898|Procedure|adjuvant therapy|
75410874|NCT00002898|Procedure|conventional surgery|
75410875|NCT00002898|Procedure|neoadjuvant therapy|
75410876|NCT00002898|Radiation|brachytherapy|
75410877|NCT00002898|Radiation|radiation therapy|
75410878|NCT00002904|Drug|trabectedin|
75410879|NCT00002916|Biological|human papillomavirus 16 E7 peptide|
75410880|NCT00002916|Biological|synthetic human papillomavirus 16 E6 peptide|
75410881|NCT00002916|Procedure|adjuvant therapy|
75410882|NCT00002916|Procedure|surgical procedure|
75410883|NCT00002916|Radiation|radiation therapy|
75410884|NCT00002928|Drug|paclitaxel|
75410885|NCT00002940|Drug|hydroxyurea|
75410886|NCT00002946|Drug|penclomedine|
75410887|NCT00002952|Biological|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
76041019|NCT05510219|Drug|intravenous rapid infusion of obinutuzumab|This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
75872527|NCT01374633|Drug|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
75872528|NCT03652922|Drug|Reactivation Mismatch|"Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative."
75410888|NCT00002952|Biological|recombinant MAGE-3.1 antigen|
75410889|NCT00002952|Biological|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
75410890|NCT00002964|Drug|porfimer sodium|
75410891|NCT00002964|Other|fluorophotometry|
75410892|NCT00002970|Drug|nelarabine|Given IV
75410893|NCT00002970|Drug|methotrexate|Given IT
75410894|NCT00002970|Drug|cytarabine|Given IT
75410895|NCT00002970|Drug|therapeutic hydrocortisone|Given IT
75410896|NCT00002976|Drug|conjugated estrogens|
75410897|NCT00002982|Biological|filgrastim|
75410898|NCT00002982|Drug|carboplatin|
75410899|NCT00002982|Drug|carmustine|
75410900|NCT00002982|Drug|cytarabine|
75410901|NCT00002982|Drug|etoposide|
75410902|NCT00002982|Drug|ifosfamide|
75410903|NCT00002982|Drug|melphalan|
75410904|NCT00002982|Procedure|autologous bone marrow transplantation|
75555028|NCT05792696|Behavioral|Empirical strategies|Fluid therapy or vasoconstriction depended on experiences of anesthetic staffs.
75410905|NCT00002982|Procedure|peripheral blood stem cell transplantation|
75410906|NCT00002982|Radiation|radiation therapy|
75410907|NCT00002988|Drug|carmustine|
75410908|NCT00002988|Drug|irinotecan hydrochloride|
75410909|NCT00002994|Biological|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
75410910|NCT00002994|Biological|rhuMAb|90 min IV infusion day 7 of each cycle
75410911|NCT00003000|Drug|fentanyl citrate|
75410912|NCT00003000|Drug|morphine sulfate|
75410913|NCT00003006|Genetic|reverse transcriptase-polymerase chain reaction|
75410914|NCT00003006|Other|immunohistochemistry staining method|
75410915|NCT00003012|Drug|CMF regimen|
75410916|NCT00003012|Drug|cyclophosphamide|
75410917|NCT00003012|Drug|epirubicin hydrochloride|
75410918|NCT00003012|Drug|fluorouracil|
75410919|NCT00003012|Drug|methotrexate|
75410920|NCT00003048|Drug|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
75410921|NCT00003054|Drug|paclitaxel|
75410922|NCT00003060|Biological|filgrastim|
75410923|NCT00003060|Drug|busulfan|
75410924|NCT00003060|Drug|cyclophosphamide|
75410925|NCT00003060|Drug|cyclosporine|
75410926|NCT00003060|Drug|methotrexate|
75410927|NCT00003060|Procedure|allogeneic bone marrow transplantation|
75410928|NCT00003066|Drug|docetaxel|
75410929|NCT00003066|Drug|estramustine phosphate sodium|
75410930|NCT00003072|Drug|amifostine trihydrate|
75410931|NCT00003072|Drug|carboplatin|
75410932|NCT00003072|Drug|paclitaxel|
75410933|NCT00003078|Drug|cisplatin|
75410934|NCT00003078|Drug|fluorouracil|
75410935|NCT00003078|Radiation|brachytherapy|
75410936|NCT00003078|Radiation|radiation therapy|
75410937|NCT00003084|Drug|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
75410938|NCT00003084|Drug|Estramustine phosphate sodium|"Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle."
75410939|NCT00003084|Drug|Etoposide|Oral etoposide twice daily on days 1-14.
75410940|NCT00003084|Drug|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
75555029|NCT05784246|Drug|Mirikizumab IV|Administered IV
75555030|NCT05784246|Drug|Mirikizumab SC|Administered SC
75410941|NCT00003084|Drug|Paclitaxel|IV over 1 hour on day 2.
75713983|NCT02543307|Procedure|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
75872529|NCT03713567|Behavioral|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
75872530|NCT01178814|Drug|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
75555031|NCT05784181|Device|bipolar transurethral resection and Laser enaculation by holmium: YAG laser|Laser enaculation by holmium: YAG laser
75555032|NCT05782361|Drug|Tepotinib|Tepotinib hydrochloride hydrate will be supplied as film coated tablets. The 250 mg oval, white-pink film-coated tablets contain the excipients mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry II pink. All formulations are intended for oral administration. Refer to pharmacy manual for formulation and strength information.
75410942|NCT00003084|Drug|Vinblastine|IV on days 8, 22, and 36.
75410943|NCT00003090|Biological|aldesleukin|
75555033|NCT05782361|Drug|Pembrolizumab|"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
75555034|NCT05778578|Behavioral|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
75555035|NCT05773040|Drug|JV-213|Given by (IV) vein
75713984|NCT02543151|Procedure|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
75713985|NCT02543229|Drug|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
75410944|NCT00003096|Genetic|DNA ploidy analysis|
75713986|NCT02543229|Drug|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
75713987|NCT02543073|Biological|MSCs|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 weeks as one cycle treatment.
75713988|NCT02543073|Drug|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
75872531|NCT04053920|Behavioral|Low Load Resistance exercise|leg extension, leg press, leg curl and calf press
75872532|NCT04053920|Behavioral|High Load Resistance exercise|leg extension, leg press, leg curl and calf press
75872533|NCT03713489|Procedure|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
75872534|NCT04053686|Behavioral|Breaks|3-min breaks every half hour at work
75555036|NCT05773040|Procedure|Leukapheresis|Given by IV (vein)
75555037|NCT05772065|Behavioral|CDC/NTCA guidelines only|The control group will have a link to US guidelines only.
75713989|NCT02543073|Drug|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
75872535|NCT05202288|Biological|Ervebo|Administration of r-VSV-ZEBOV vaccine
75872536|NCT05202288|Drug|Inmazeb|Administration of Inmazeb
75410945|NCT00003096|Genetic|comparative genomic hybridization|
75410946|NCT00003096|Genetic|cytogenetic analysis|
75410947|NCT00003096|Genetic|fluorescence in situ hybridization|
75410948|NCT00003108|Drug|bryostatin 1|
75410949|NCT00003108|Drug|cisplatin|
75410950|NCT00003114|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42.The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
75410951|NCT00003114|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
75410952|NCT00003114|Drug|etoposide|Oral etoposide on days 1-3. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
75410953|NCT00003114|Drug|lomustine|Patients receive oral lomustine on day 1.
75555038|NCT05772065|Behavioral|LTBI ASSIST and CDC/NTCA guidelines only|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool.
75555039|NCT05770921|Device|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
75555040|NCT05768711|Drug|Venetoclax|Combination of Azacitidine and Venetoclax
75713990|NCT02542995|Other|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
75713991|NCT00887055|Device|CRT device|
75713992|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
75410954|NCT00003114|Drug|procarbazine hydrochloride|Oral and procarbazine on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
75410955|NCT00003114|Radiation|radiation therapy|Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy.
75410956|NCT00003120|Drug|paclitaxel|135 mg/m2 IV every 28 days
75410957|NCT00003126|Drug|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
75410958|NCT00003132|Drug|bryostatin 1|
75410959|NCT00003132|Drug|cisplatin|
75555041|NCT05765851|Drug|DS-1103a|One IV infusion Q3W on Day 1 of each 21-day cycle
75713993|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
75713994|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
75713995|NCT00884559|Other|instruction|Debriefing
75713996|NCT00546364|Drug|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
75410960|NCT00003144|Drug|amifostine trihydrate|
75410961|NCT00003144|Drug|cisplatin|
75555042|NCT05765851|Drug|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
75555043|NCT05761574|Drug|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
75555044|NCT05761574|Drug|Naproxen Sodium|Naproxen Sodium will be administered orally.
75555045|NCT05761574|Drug|Acetaminophen|Acetaminophen will be administered orally.
75410962|NCT00003144|Drug|gemcitabine hydrochloride|
75410963|NCT00003150|Biological|rituximab|
75410964|NCT00003150|Drug|CHOP regimen|
75410965|NCT00003150|Drug|cyclophosphamide|
75410966|NCT00003150|Drug|doxorubicin hydrochloride|
75410967|NCT00003150|Drug|prednisone|
75410968|NCT00003150|Drug|vincristine sulfate|
75410969|NCT00003156|Drug|topotecan hydrochloride|
75410970|NCT00003162|Procedure|pain therapy|
75410971|NCT00003162|Radiation|radiation therapy|
75410972|NCT00003174|Drug|bryostatin 1|
75410973|NCT00003174|Drug|cladribine|
75410974|NCT00003186|Drug|isosulfan blue|
75410975|NCT00003186|Procedure|lymphangiography|
75410976|NCT00003186|Procedure|sentinel lymph node biopsy|
75410977|NCT00003192|Drug|aminocamptothecin|
75410978|NCT00003018|Drug|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
75410979|NCT00003018|Drug|fluorouracil|200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle
75410980|NCT00003018|Drug|leucovorin calcium|30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle
75410981|NCT00003018|Drug|mitomycin C|10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
75410982|NCT00003198|Drug|ifosfamide|
75410983|NCT00003198|Drug|topotecan hydrochloride|
75410984|NCT00003204|Drug|cyclophosphamide|Given IV
75410985|NCT00003204|Drug|fludarabine phosphate|Given IV
75410986|NCT00003204|Drug|vincristine sulfate|Given IV
75410987|NCT00003204|Drug|prednisone|Given PO
75410988|NCT00003204|Biological|rituximab|Given IV
75410989|NCT00003204|Other|laboratory biomarker analysis|Correlative studies
75410990|NCT00003210|Biological|recombinant interleukin-12|Given subcutaneously
75410991|NCT00003210|Other|laboratory biomarker analysis|Correlative studies
75410992|NCT00003216|Drug|fluorouracil|
75410993|NCT00003216|Drug|gemcitabine hydrochloride|
75410994|NCT00003216|Radiation|radiation therapy|
75410995|NCT00003234|Drug|vinorelbine tartrate|
75410996|NCT00003240|Drug|cisplatin|
75410997|NCT00003240|Drug|ifosfamide|
75410998|NCT00003240|Drug|mitomycin C|
75713997|NCT00546364|Drug|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
75713998|NCT00546364|Drug|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
75713999|NCT00887211|Device|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
75714000|NCT00887211|Device|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
75410999|NCT00003240|Drug|vinblastine sulfate|
75411000|NCT00003240|Drug|vindesine|
75411001|NCT00003240|Drug|vinorelbine tartrate|
75411002|NCT00003240|Procedure|conventional surgery|
75411003|NCT00003240|Radiation|radiation therapy|
75411004|NCT00003252|Drug|amifostine trihydrate|
75411005|NCT00003264|Drug|cisplatin|
75411006|NCT00003264|Drug|gemcitabine hydrochloride|
75411007|NCT00003276|Drug|irinotecan hydrochloride|
75411008|NCT00003282|Drug|EF5|Given IV
75411009|NCT00003282|Procedure|therapeutic conventional surgery|Undergo resection
75411010|NCT00003282|Procedure|biopsy|Undergo biopsy
75411011|NCT00003282|Other|pharmacological study|Correlative studies
75411012|NCT00003288|Biological|filgrastim|
75411013|NCT00003288|Drug|cyclophosphamide|
75411014|NCT00003288|Drug|tirapazamine|
75411015|NCT00003294|Biological|filgrastim|
75411016|NCT00003294|Drug|amifostine trihydrate|
75411017|NCT00003294|Drug|carboplatin|
75411018|NCT00003294|Drug|paclitaxel|
75411019|NCT00003312|Radiation|iodine I 125|
75411020|NCT00003324|Procedure|conventional surgery|
75411021|NCT00003324|Radiation|radiation therapy|
75411022|NCT00003330|Biological|recombinant interleukin-12|
75411023|NCT00003336|Biological|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
75411024|NCT00003336|Drug|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
75411025|NCT00003336|Drug|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
75411026|NCT00003336|Drug|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
75555046|NCT05761574|Drug|Placebo|Placebo will be administered orally.
75411027|NCT00003336|Drug|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
75411028|NCT00003336|Procedure|bone marrow ablation with stem cell support|
75555047|NCT05760924|Device|Cardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The new CRT-D will be connected with leads and placed back into the pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture.
75555048|NCT05760924|Device|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. RV and LV pacing will be inactivated and only LBB pacing will be switched on.
75555049|NCT05760924|Device|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. LBB and LV pacing will be switched on.
75555050|NCT05759338|Device|Revian Red All LED cap|"The cap is a dual-band LED light therapy wireless smart cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women."
75555051|NCT05758168|Procedure|Addition of Tie-Over Bolster Dressing|Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.
75555052|NCT05757869|Drug|Milvexian|Milvexian will be administered orally.
75555053|NCT05757869|Drug|Apixaban|Apixaban will be administered orally.
75714001|NCT00887367|Drug|GSK598809|Two 175 mg doses of GSK598809 will be given.
75411029|NCT00003336|Procedure|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
75714002|NCT00887367|Other|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
75714003|NCT00887445|Drug|SLV341|5 - 1000mg once daily
75411030|NCT00003336|Radiation|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
75411031|NCT00003342|Biological|filgrastim|
75411032|NCT00003342|Drug|carboplatin|
75411033|NCT00003342|Drug|doxorubicin hydrochloride|
75411034|NCT00003342|Drug|gemcitabine hydrochloride|
75714004|NCT00887445|Drug|placebo|
75411035|NCT00003342|Drug|paclitaxel|
75411036|NCT00003348|Drug|O6-benzylguanine|
75411037|NCT00003348|Drug|carmustine|
75411038|NCT00003354|Procedure|conventional surgery|
75411039|NCT00003354|Procedure|laparoscopic surgery|
75411040|NCT00003360|Radiation|iodine I 131 monoclonal antibody A33|
75411041|NCT00003372|Drug|topotecan hydrochloride|
75411042|NCT00003378|Drug|carboplatin|
75411043|NCT00003378|Drug|gemcitabine hydrochloride|
75411044|NCT00003378|Drug|paclitaxel|
75411045|NCT00003384|Other|Cervical Papanicolaou Test|Undergo Pap smear
75555054|NCT05757869|Drug|Placebo|Milvexian matching milvexian placebo will be administered orally.
75555055|NCT05757869|Drug|Apixaban Placebo|Apixaban matching apixaban placebo will be administered orally.
75555056|NCT05756621|Drug|Ketamine|"Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight > 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight < 50 kg), followed by gradual reduction according to clinical evolution."
75555057|NCT05756621|Drug|Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel|Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
75555058|NCT05755347|Other|General health survey questionnaires|Patient-reported outcome survey will be offered at baseline.
75555059|NCT05755347|Other|PROMIS Cancer Function Brief 3D profile questionnaires|Patient-reported outcome survey will be offered at baseline.
75555060|NCT05755347|Other|FACT-G questionnaires|Patient-reported outcome survey will be offered at baseline.
75714005|NCT00964210|Drug|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
75411046|NCT00003384|Procedure|Conization|Undergo cone biopsy
75411047|NCT00003384|Other|Laboratory Biomarker Analysis|Correlative studies
75411048|NCT00003390|Drug|irofulven|
75411049|NCT00003396|Biological|anti-thymocyte globulin|
75714006|NCT00964288|Drug|GSK1014802 low dose|oral tablet
75714007|NCT00964288|Drug|Lidocaine|positive control
76041020|NCT05503745|Other|CBT-F+MIT|The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.
75411050|NCT00003396|Biological|graft-versus-tumor induction therapy|
75411051|NCT00003396|Drug|cyclophosphamide|
75411052|NCT00003396|Drug|melphalan|
75411053|NCT00003396|Procedure|peripheral blood stem cell transplantation|
75411054|NCT00003396|Radiation|radiation therapy|
75411055|NCT00003402|Drug|carmustine|
75411056|NCT00003402|Drug|cisplatin|
75411057|NCT00003402|Drug|cyclophosphamide|
75411058|NCT00003402|Drug|dexamethasone|
75411059|NCT00003402|Drug|etoposide|
75411060|NCT00003402|Drug|melphalan|
75714008|NCT00964288|Drug|GSK1014802 high dose|oral tablet
75714009|NCT00964288|Drug|Placebo|To match GSK drug and positive control
75411061|NCT00003402|Drug|paclitaxel|
75411062|NCT00003402|Procedure|bone marrow ablation with stem cell support|
75411063|NCT00003402|Procedure|peripheral blood stem cell transplantation|
75411064|NCT00003408|Biological|aldesleukin|
75411065|NCT00003408|Biological|recombinant interferon alfa|
75411066|NCT00003408|Biological|sargramostim|
75411067|NCT00003414|Biological|aldesleukin|
75411068|NCT00003414|Biological|recombinant interferon gamma|
75411069|NCT00003414|Drug|busulfan|
75411070|NCT00003414|Drug|cyclophosphamide|
75411071|NCT00003414|Drug|cyclosporine|
75411072|NCT00003414|Procedure|peripheral blood stem cell transplantation|
75411073|NCT00003414|Radiation|radiation therapy|
75411074|NCT00003420|Procedure|computed tomography|
75411075|NCT00003426|Drug|gemcitabine hydrochloride|
75411076|NCT00003426|Radiation|radiation therapy|
75411077|NCT00003432|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
75411078|NCT00003450|Biological|Ad5CMV-p53 gene|
75411079|NCT00003462|Drug|busulfan|
75411080|NCT00003486|Drug|antineoplaston A10|
75411081|NCT00003486|Drug|antineoplaston AS2-1|
75411082|NCT00003486|Procedure|alternative product therapy|
75411083|NCT00003486|Procedure|biological therapy|
75411084|NCT00003486|Procedure|biologically based therapies|
75411085|NCT00003486|Procedure|cancer prevention intervention|
75411086|NCT00003486|Procedure|complementary and alternative therapy|
75555061|NCT05755347|Other|Godin Leisure-Time Exercise Questionnaire|Patient-reported outcome survey will be offered at baseline.
75555062|NCT05755347|Other|REAP-S questionnaires|Patient-reported outcome survey will be offered at baseline.
75555063|NCT05754957|Drug|Milvexian|Milvexian will be administered orally.
75555064|NCT05754957|Other|Placebo|Placebo will be administered orally.
75555065|NCT05752487|Device|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|Participants will undergo catheter ablation with the PF /RF ablation system consisting of the TRUPULSE Generator (delivers RF or PF energy through the study catheter) and the THERMOCOOL SMARTTOUCH SF (STSF) Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a Generator, for cardiac ablation).
75555066|NCT05738083|Diagnostic Test|machine learning models|Area under the curve (ROC), accuracy, precise, sensitivity, specificity indicators to show the prediction performance of machine learning models
75714010|NCT00964522|Other|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
75714011|NCT05955001|Drug|Tadalafil 5mg|Patients after Endoscopic Enucleation of Prostate will receive single daily dose of Tadalafil for 3 months
75714012|NCT05954975|Combination Product|BabyCheck and pulse oximetry|"The BabyCheck is a validated scoring system to grade the severity of acute systemic illness in infants up to six months of age. Severity of illness is graded by using a weighted score of a combination of nineteen signs and symptoms. The higher the score, the higher the chance of severe illness.~Nellcor PM10N is a pulse oximeter which is cleared for use in young infants. A sensor for infants will be used, so reliable oxygen saturation and heart rate can be obtained."
75714013|NCT05954923|Other|Amino acid bolus infusion|Equimolar bolus infusions of amino acids or saline (placebo)
75411087|NCT00003486|Procedure|differentiation therapy|
75411088|NCT00003516|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
75411089|NCT00003522|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75411090|NCT00003528|Drug|raltitrexed|Given IV
75411091|NCT00003534|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75411092|NCT00003540|Drug|gemcitabine hydrochloride|
75411093|NCT00003546|Drug|gemcitabine hydrochloride|given IV
75411094|NCT00003546|Radiation|radiation therapy|1.8 Gy to tumor bed
75411095|NCT00003552|Drug|allogeneic lymphocytes|
75411096|NCT00003552|Drug|anti-thymocyte globulin|
75411097|NCT00003552|Drug|cyclophosphamide|
75555067|NCT05734729|Device|EFFIDRAIN|. Effidrain is a progammable, light-weight, portable drain regulator that can control the rate and volume of body fluid being drained, while empowering the user with information on dynamic changes of pressure within the body cavity being drainged. It is able to adapt to existing drainage systems via a standard medical luer taper connector, and comes with a failsafe system to alert users of drainage irregularities.
75714014|NCT05954897|Drug|Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC|RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
75411098|NCT00003552|Drug|fludarabine|
75411099|NCT00003558|Drug|carboplatin|
75411100|NCT00003558|Drug|etoposide|
75411101|NCT00003558|Drug|fluorouracil|
75411102|NCT00003558|Drug|leucovorin calcium|
75411103|NCT00003558|Drug|paclitaxel|
75411104|NCT00003564|Drug|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
75411105|NCT00003564|Drug|Procarbazine Hydrochloride|"Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses."
75411106|NCT00003576|Drug|cisplatin|
75411107|NCT00003576|Drug|fluorouracil|
75411108|NCT00003576|Procedure|surgical procedure|
75555068|NCT05734729|Device|Manual drainage system|drainage systems required manual control and are unautomated; consequent unintended rapid intravascular and extravascular fluid shifts may result in clinical instability.
75555069|NCT05731492|Drug|Macitentan|Macitentan will be administered orally.
75555070|NCT05730712|Procedure|Biopsy|Undergo biopsy
75555071|NCT05730712|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
75555072|NCT05730712|Procedure|Computed Tomography|Undergo CT
75555073|NCT05730712|Procedure|Echocardiography|Undergo ECHO
75555074|NCT05730712|Drug|Enzalutamide|Given PO
75555075|NCT05730712|Drug|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
75411109|NCT00003576|Radiation|radiation therapy|
75714015|NCT05954884|Other|Telemedicine-based WHO HEARTS package|"Interventions in this study will include-~Community- and team-based model of hypertension care delivery~Opportunistic hypertension screening at Community Clinic (CC) by Community Health Care Provider (CHCP)~Use of a hypertension treatment protocol with amlodipine and losartan and standardized approach to measuring and monitoring BP, retaining participants in care, and promoting adherence~Use of Simple App to document BP readings and medications/dosage and to monitor hypertension care delivery at the CC through utilities including dashboards~Establishment of telemedicine service between CC and Upazila Health Complex (UHC)~Community-based, multi-month prescription refills from CC~Training of clinic and research staff on BP measurement following standard techniques~Site monitoring and mentorship to ensure screening and patient enrollment/registration~Use of text messages to promote follow-up visits and medication adherence"
75872537|NCT03652298|Other|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
75872538|NCT03652298|Other|support and attention (usual care)|support and attention (usual care)
75872539|NCT03463031|Drug|GSP 301 NS|1 spray in each nostril twice daily for 14 days
75872540|NCT03463031|Drug|GSP 301 Placebo NS|1 spray in each nostril twice daily for 14 days
75872541|NCT04054388|Behavioral|LINE re-education|
75872542|NCT05202132|Diagnostic Test|Questionnaire|A 3 item validated questionnaire assessing masticatory function
75872543|NCT05202132|Diagnostic Test|Chewing gum test|The test is based on the ability of a subject of mixing a two colour chewing gum with 20 masticatory cycles. Mixing of the two colour chewing gum will be assessed as variance of hue in a scanned image of the flattened chewing gum. The method has been validated in independent studies.
75872544|NCT03652688|Behavioral|Three 0's|A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.
75872545|NCT03652688|Behavioral|Fire Safety|Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
75411110|NCT00003582|Drug|amifostine trihydrate|
75411111|NCT00003582|Drug|cisplatin|
75411112|NCT00003582|Drug|fluorouracil|
75411113|NCT00003582|Drug|paclitaxel|
75411114|NCT00003582|Procedure|quality-of-life assessment|
75411115|NCT00003582|Radiation|radiation therapy|
75411116|NCT00003588|Biological|Ad5CMV-p53 gene|
75411117|NCT00003588|Procedure|laparoscopic surgery|
75411118|NCT00003594|Drug|irinotecan|
75411119|NCT00003594|Drug|fluorouracil|
75411120|NCT00003594|Drug|leucovorin calcium|
75411121|NCT00003594|Drug|oxaliplatin|
75411122|NCT00003600|Biological|epoetin alfa|
75411123|NCT00003600|Other|placebo|
75411124|NCT00003606|Drug|cisplatin|
75411125|NCT00003606|Drug|cyclophosphamide|
75411126|NCT00003606|Drug|epirubicin hydrochloride|
75411127|NCT00003606|Drug|etoposide|
75411128|NCT00003606|Radiation|radiation therapy|
75411129|NCT00003612|Biological|trastuzumab|
75411130|NCT00003612|Drug|carboplatin|
75555076|NCT05730712|Procedure|Magnetic Resonance Imaging|Undergo MRI
75555077|NCT05730712|Other|Questionnaire Administration|Ancillary studies
75555078|NCT05728333|Drug|Tirofiban|Intravenous tirofiban before endovascular thrombectomy.
75555079|NCT05728333|Drug|Alteplase|Intravenous alteplase before endovascular thrombectomy.
75555080|NCT05727072|Drug|LY3848575|Administered IV.
75555081|NCT05727072|Drug|LY3848575|Administered SC.
75555082|NCT05727072|Drug|Placebo|Administered IV.
75555083|NCT05727072|Drug|Placebo|Administered SC.
75555084|NCT05726591|Device|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
75411131|NCT00003612|Drug|paclitaxel|
75555085|NCT05726383|Drug|Iscador*P|Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
75555086|NCT05723562|Biological|Dostarlimab|Dostarlimab will be administered.
75872546|NCT05762484|Procedure|Nd:YAG laser hair removal|Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.
75872547|NCT05762484|Drug|Clindamycin 1 % Topical Lotion|Clindamycin 1% lotion if needed
75872548|NCT03462641|Drug|Flumazenil|1mg in 10cc normal saline
76041021|NCT05503745|Other|CBT-E|In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
76041022|NCT02564471|Drug|Chloroquine|FDA approve dosing schedule
76041023|NCT02564471|Drug|Atovaquone and Proguanil|FDA approve dosing schedule
75411132|NCT00003624|Drug|amifostine trihydrate|
75411133|NCT00003624|Drug|cisplatin|
76041024|NCT02564471|Drug|Doxycycline|FDA approve dosing schedule
76041025|NCT02564471|Biological|Rabies Vaccine|FDA approve dosing schedule
76041026|NCT05503667|Drug|Furmonertinib|Furmonertinib 80 mg/day for 16 weeks
75411134|NCT00003624|Drug|paclitaxel|
75411135|NCT00003630|Drug|arsenic trioxide|
75411136|NCT00003636|Drug|carboplatin|
75411137|NCT00003636|Drug|cisplatin|
75411138|NCT00003636|Procedure|conventional surgery|
75411139|NCT00003636|Procedure|neoadjuvant therapy|
75411140|NCT00003642|Drug|cisplatin|
75555087|NCT05720520|Other|Technological education method|Students in the experimental group will play the mobile application developed for stoma and peristomal skin care and are expected to learn the skill in this way. The students in the control group, on the other hand, will learn stoma and peristomal skin care on a model in the traditional skill laboratory and are expected to learn the skill in this way. Afterwards, the knowledge and skill scores of the two groups will be compared and the results will be reported.
75714016|NCT05954858|Procedure|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
75714017|NCT05954806|Drug|Antivenom Snakes|No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
75714018|NCT05954780|Drug|Selinexor|Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
75714019|NCT05954767|Drug|IS-001|IV injection of IS-001 drug substance with near infrared (NIR) imaging
75872549|NCT03462641|Drug|Placebo|10 cc normal saline
75872550|NCT04150796|Procedure|Ventral Hernia Repair|Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.
75872551|NCT05206968|Radiation|pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph
76041027|NCT05503667|Drug|Bevacizumab|bevacizumab 400 mg/4 weeks i.v. for 4 times
76041028|NCT04411979|Other|treatment-as-usual plus aerobic walking|aerobic walking
75411141|NCT00003642|Drug|fluorouracil|
75411142|NCT00003642|Radiation|radiation therapy|
75411143|NCT00003648|Genetic|DNA stability analysis|
75411144|NCT00003648|Genetic|gene rearrangement analysis|
75411145|NCT00003654|Drug|patent blue V dye|
75411146|NCT00003654|Procedure|lymphangiography|
75411147|NCT00003654|Procedure|radionuclide imaging|
75411148|NCT00003654|Procedure|sentinel lymph node biopsy|
75411149|NCT00003654|Radiation|technetium Tc 99m sulfur colloid|
75411150|NCT00003666|Drug|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
75411151|NCT00003678|Drug|tamoxifen citrate|
75411152|NCT00003678|Procedure|adjuvant therapy|
75411153|NCT00003684|Drug|theophylline|
75411154|NCT00003684|Procedure|quality-of-life assessment|
75411155|NCT00003690|Drug|alvocidib|
75411156|NCT00003690|Drug|carboplatin|
75411157|NCT00003690|Drug|cisplatin|
75411158|NCT00003696|Drug|carboplatin|
75411159|NCT00003696|Drug|cyclophosphamide|
75411160|NCT00003696|Drug|doxorubicin hydrochloride|
75411161|NCT00003696|Drug|etoposide|
75411162|NCT00003696|Drug|paclitaxel|
75714020|NCT05954754|Other|Diaphragmatic Breathing Exercises|Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
76041029|NCT05512637|Diagnostic Test|Step 1 - Screening ; Step 2 - Clinical interview|"Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview.~Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process."
75714021|NCT05954689|Other|Femoral artery block|Injection on the antero-medial side of the femoral artery of 10mL 0.5% ropivacaine with ultrasound guidance.
75714022|NCT05954650|Behavioral|Rehabilitation|Physical therapy and multisensory stimulation adjusted to the needs of each patient.
75714023|NCT05954611|Biological|GR2002 injection|one single dose of GR2002 injection
75872552|NCT04858074|Drug|Hypoestoxide|Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
76041030|NCT02563067|Drug|QAW039|QAW039 150 mg once daily
75411163|NCT00003708|Drug|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
75411164|NCT00003714|Drug|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
75411165|NCT00003720|Drug|semaxanib|
75411166|NCT00003732|Drug|carboplatin|
75872553|NCT04856202|Behavioral|Advance Care Planning interview|The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
75872554|NCT02974634|Other|Ostomy self management training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
75411167|NCT00003732|Drug|paclitaxel|
75714024|NCT05954611|Biological|Placebo|one single dose of placebo
76041031|NCT02563067|Drug|QAW039|QAW039 450 mg once daily
76041032|NCT02563067|Drug|Placebo|Placebo once daily
75714025|NCT05954598|Dietary Supplement|probiotic|This study was designed as a randomized double-blind controlled study. The enrolled subjects were randomized into two groups: intervention group and waiting intervention group. The intervention group received 12 weeks of probiotic intervention from the start of the study, and the waiting group received 12 weeks of placebo intervention from the start of the study. At the start of the study, both groups received 12 weeks of probiotic intervention.
75411168|NCT00003732|Drug|topotecan hydrochloride|
75411169|NCT00003744|Drug|gemcitabine|
75411170|NCT00003750|Biological|hu14.18-IL2 fusion protein|
75411171|NCT00003762|Drug|docetaxel|
75411172|NCT00003762|Drug|gemcitabine hydrochloride|
75411173|NCT00003768|Drug|fosbretabulin disodium|
75411174|NCT00003780|Biological|tumor infiltrating lymphocyte therapy|
75411175|NCT00003780|Drug|gemcitabine hydrochloride|
75411176|NCT00003786|Drug|irofulven|
75411177|NCT00003792|Biological|MART-1 antigen|
75714026|NCT05954572|Diagnostic Test|standardized skin surface biopsy (SSSB)|This technique is applied in four facial localizations, including the forehead, cheeks, and nose. The surface biopsy procedure is performed as follows: one cm² area was marked on a glass slide using a fine ruler. The designated skin area for sampling is gently swabbed with a dry gauze pad to create mild irritation. Subsequently, one drop of cyanoacrylate adhesive is applied to the marked area on the glass slide. The glass slide is carefully pressed onto the skin, allowing the adhesive to adhere. After approximately one minute, the glass slide is gently lifted. The sampled area on the glass slide is examined under x10 and x40 magnification. Immersion oil is applied to enhance visualization and determine the number of Demodex parasites within the marked area. An increased demodicosis is defined as the presence of five or more Demodex parasites per square centimeter of skin.
75714027|NCT05954520|Device|Tympan|Participants will wear a prototype hearing aid (called the Tympan)
75411178|NCT00003792|Biological|filgrastim|
75714028|NCT05954429|Drug|serplulimab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10"
75714029|NCT05954429|Drug|Fruquintinib|5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
75714030|NCT05954390|Dietary Supplement|Undenatured beta-glucan solution|The active comparator is a solution containing undenatured beta-glucans
75714031|NCT05954390|Other|Placebo|The placebo comparator is the same solution as the active therapy except it does not contain any undenatured beta-glucans
75714032|NCT05954286|Drug|Upamostat|Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.
75872555|NCT04814316|Diagnostic Test|Blood and urine specimens|Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.
75872556|NCT04113122|Diagnostic Test|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
75872557|NCT04113122|Diagnostic Test|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
75872558|NCT05201352|Drug|trifluridine/tipiracil + XB2001|trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
75872559|NCT05201352|Drug|trifluridine/tipiracil + placebo|trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
75411179|NCT00003792|Biological|flu matrix peptide p58-66|
76041033|NCT02568683|Drug|Entospletinib|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
76041034|NCT02568683|Drug|Vincristine|VCR administered intravenously
75411180|NCT00003792|Biological|gp100 antigen|
75411181|NCT00003792|Biological|recombinant MAGE-3.1 antigen|
75411182|NCT00003792|Biological|tyrosinase peptide|
75411183|NCT00003792|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75411184|NCT00003798|Drug|motexafin gadolinium|
75411185|NCT00003798|Radiation|radiation therapy|
75411186|NCT00003804|Biological|dactinomycin|
75411187|NCT00003804|Drug|vincristine sulfate|
75411188|NCT00003804|Procedure|conventional surgery|
75411189|NCT00003822|Drug|apomine|
75411190|NCT00003828|Drug|vinorelbine|
75411191|NCT00003834|Drug|fluorouracil|
75411192|NCT00003834|Drug|leucovorin calcium|
75411193|NCT00003834|Drug|oxaliplatin|
75411194|NCT00003840|Biological|DTGM fusion protein|
75411195|NCT00003846|Biological|filgrastim|
75411196|NCT00003846|Drug|carboplatin|
75411197|NCT00003846|Drug|cyclophosphamide|
75411198|NCT00003846|Drug|thiotepa|
75411199|NCT00003846|Drug|vincristine sulfate|
75411200|NCT00003846|Procedure|bone marrow ablation with stem cell support|
75411201|NCT00003846|Procedure|peripheral blood stem cell transplantation|
75411202|NCT00003846|Radiation|radiation therapy|
75411203|NCT00003852|Biological|filgrastim|
75411204|NCT00003852|Drug|carboplatin|
75411205|NCT00003852|Drug|cyclophosphamide|
75411206|NCT00003852|Drug|epirubicin hydrochloride|
75714033|NCT05954286|Drug|Placebo (PO)|Oral Capsules
75714034|NCT05954260|Diagnostic Test|Blood sampling|We will collect blood samples from the patients included in the study on ICU days 1, 3 and 5. We will measure gene expression (mRNA) and plasma levels of various elements involved in the immunological synapse.
75714035|NCT05954234|Other|Postural re-education|"Each session of the experimental approach will be composed of 40 minutes of postural exercise. Participants will be asked to maintain two different postures to stretch both the anterior and posterior muscle chains. The first posture will consist of lying on the back maintaining the extension of the legs to release the respiratory diaphragm and stretch the anterior muscle chain. For the second posture, participants wiil be asked to lie on their back with their legs flexed to stretch the posterior chai. For each posture, the physical therapist will use verbal commands and manual contact to maintain alignment and make the necessary postural corrections to optimize the stretching and discourage compensatory movements.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
75872560|NCT04804332|Procedure|Operative hysteroscopy|Operative hysteroscopy is performed without or under local, regional or general anesthesia according to the local protocol preferably within 2 to 3 weeks after randomization. In case of highly vascularized RPOC, a repeat sonogram is performed 2 to 4 weeks after randomization to check for persistence of vascularity and to optimize operative timing. Operative hysteroscopy is then performed within 2 to 3 weeks after the repeat sonogram. Removal of the RPOC is performed by an experienced gynecologist using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) and according to the local protocol.
76041035|NCT05502731|Drug|Filgotinib|Filgotinib is a small molecule that reversibly inhibits Janus kinases (JAK, selectively JAK 1), thereby inhibiting downstream signalling events induced by various pro-inflammatory and regulatory cytokines.
76041036|NCT05502731|Drug|Adalimumab|Adalimumab is a monoclonal antibody selectively inhibiting the pro-inflammatory cytokine TNF-alpha.
76041037|NCT05502497|Other|Observational|No application will be made to the control group.
75411207|NCT00003852|Drug|etoposide|
75411208|NCT00003852|Drug|ifosfamide|
75411209|NCT00003852|Drug|paclitaxel|
75411210|NCT00003852|Drug|thiotepa|
76041038|NCT05502497|Other|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
76041039|NCT05503277|Device|LTSD|measuring seal pressure
76041040|NCT05503277|Device|i-gel|measuring seal pressure
75411211|NCT00003852|Procedure|bone marrow ablation with stem cell support|
75411212|NCT00003852|Procedure|peripheral blood stem cell transplantation|
75411213|NCT00003858|Drug|mitoxantrone hydrochloride|
75411214|NCT00003870|Drug|cyclophosphamide|
75411215|NCT00003870|Drug|methotrexate|
75411216|NCT00003870|Procedure|allogeneic bone marrow transplantation|
75411217|NCT00003870|Radiation|iodine I 131 monoclonal antibody BC8|
75411218|NCT00003870|Radiation|radiation therapy|
75411219|NCT00003876|Drug|polifeprosan 20 with carmustine implant|
75411220|NCT00003876|Procedure|surgical procedure|
75411221|NCT00003876|Radiation|iodine I 125|
75411222|NCT00003882|Drug|anhydrovinblastine|
75411223|NCT00003888|Drug|cisplatin|
75411224|NCT00003888|Drug|docetaxel|
75411225|NCT00003888|Drug|fluorouracil|
75411226|NCT00003888|Radiation|radiation therapy|
75411227|NCT00003894|Drug|thalidomide|
75411228|NCT00003900|Drug|docetaxel|
75411229|NCT00003900|Drug|irinotecan hydrochloride|
75411230|NCT00003906|Drug|Raloxifene|60 mg/day plus placebo for 5 years
75411231|NCT00003906|Drug|Tamoxifen|20 mg/day plus placebo for 5 years
75411232|NCT00003912|Drug|carboplatin|
75411233|NCT00003912|Drug|cisplatin|
75411234|NCT00003912|Drug|doxorubicin hydrochloride|
75411235|NCT00003912|Procedure|conventional surgery|
75411236|NCT00003924|Biological|recombinant interferon alfa|
75411237|NCT00003930|Drug|cisplatin|
75411238|NCT00003930|Drug|gemcitabine hydrochloride|
75411239|NCT00003930|Drug|paclitaxel|
75411240|NCT00003930|Procedure|conventional surgery|
75411241|NCT00003930|Radiation|radiation therapy|
75411242|NCT00003936|Drug|bryostatin 1|
75411243|NCT00003942|Biological|RevM10 gene|
75411244|NCT00003942|Biological|RevM10/polAS gene|
75411245|NCT00003942|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75411246|NCT00003942|Procedure|peripheral blood stem cell transplantation|
75411247|NCT00003954|Drug|melphalan|Given IV
75411248|NCT00003954|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
75411249|NCT00003954|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
75555088|NCT05719363|Device|Inogen Rove 6 Portable Oxygen Concentrator|"The Inogen Rove 6 POC is designed to provide a flow of high-purity oxygen. Inogen Rove 6 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen Rove 6 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient."
75555089|NCT05719285|Drug|Single-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 1: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure~Second line:~Arm 1: cefalexin 500 mg once pre-procedure~Third line:~Arm 1: nitrofurantoin 100 mg once pre-procedure~Fourth line:~Arm 1: ciprofloxacin 500 mg once pre-procedure"
75714036|NCT05954234|Other|Spinal mobilization|"This approach will consist of 40 minutes of thoracolumbar spine mobilization. Two different mobilizations will be carried out. In the first one the patient will be in sitting position with both legs out of the bed and a mobilization in antero-posterior direction will be provide by the physiotherapist; the second one will consist in rotational mobilisation provide with the patient in lateral decubitus position.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
75714037|NCT05954234|Other|Perineal Exercises|Perineal Exercises will be performed in both the allocated approach. The protocol will consist in 10 minutes of perineal contraction and relaxation and 10 minutes of stretch-reflex for a total of 20 minutes of perineal exercises.10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks.
75714038|NCT05954221|Procedure|Red cell lysis buffer (RCLB) application|The tissue is lysed with 50% concentration of RCLB for 15 min on a shaking device. If the lysis is judged to be insufficient, it can be repeated one more time. Finally, the treated tissue will be fixed with 10% formalin.
75714039|NCT05954221|Procedure|Conventional processing|The tissue is fixed with 10% formalin.
75872561|NCT04804332|Other|Expectant management|No treatment will be offered. Patients will be given telephone numbers to contact a doctor. In case of severe complaints, defined as heavy uterine bleeding and/or severe abdominal pain, not responding to conservative treatment, an emergency curettage or operative hysteroscopy may be performed.
75872563|NCT04737876|Biological|BX002-A|bacteriophage cocktail
75872564|NCT04737876|Other|Placebo|Placebo
75872565|NCT04128956|Drug|Aspirin 100mg|Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
75872566|NCT05206578|Drug|AGT2, AGZ|Tablet, q.d.
75872567|NCT05206578|Drug|AGT2|Tablet, q.d.
75872568|NCT05206578|Drug|AGT4, AGZ|Tablet, q.d.
75872569|NCT05206578|Drug|AGT4|Tablet, q.d.
76041041|NCT05502419|Procedure|Neural slump mobilization|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
75411250|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
75411251|NCT00003954|Radiation|total-body irradiation|Undergo TBI
75411252|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo donor PBSCT
75411253|NCT00003954|Drug|cyclosporine|Given IV and PO
75411254|NCT00003954|Drug|mycophenolate mofetil|Given PO
75411255|NCT00003954|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
75411256|NCT00003960|Drug|busulfan|
75411257|NCT00003960|Drug|cyclophosphamide|
75411258|NCT00003960|Drug|methylprednisolone|
75411259|NCT00003960|Procedure|allogeneic bone marrow transplantation|
75411260|NCT00003960|Procedure|in vitro-treated bone marrow transplantation|
75411261|NCT00003966|Drug|defibrotide|
75411262|NCT00003972|Biological|filgrastim|
75411263|NCT00003972|Biological|sargramostim|
75411264|NCT00003972|Drug|busulfan|
75411265|NCT00003972|Drug|carboplatin|
75411266|NCT00003972|Drug|cyclophosphamide|
75411267|NCT00003972|Drug|melphalan|
75411268|NCT00003972|Drug|paclitaxel|
75714040|NCT05954208|Other|Vısual Arts Group Therapy Based On Watson's Human Care Model|VAGT-WHCM was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups.
76041042|NCT05502419|Procedure|Conventional Physical Therapy|Moist heat with hydro collator pack, Maitland Mobilization for Lumbar spine, Therapeutic exercise: Core stability exercises
76041043|NCT05503121|Diagnostic Test|3D motion analysis, muscle activation, biomarker analysis|Participants with nonspesific low back pain and control group will be analysed with 3D motion analysis sistem, sEMG and will be checked the biomarkers. Then the data will be compared.
76041044|NCT05503043|Drug|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
76041045|NCT05503043|Drug|Normal saline|Patients are received equal volumes of saline intravenously until the end of the surgery
75411269|NCT00003972|Drug|tamoxifen citrate|
75411270|NCT00003972|Drug|thiotepa|
76041046|NCT04579211|Diagnostic Test|urine lipoarabinomannan (LAM)|Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
75411271|NCT00003972|Procedure|peripheral blood stem cell transplantation|
75872570|NCT03651908|Procedure|Conventional Flap Surgery|"After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back."
76041047|NCT02563925|Radiation|Brain radiotherapy or Stereotactic Radiosurgery|
76041048|NCT02563925|Drug|Tremelimumab|
75872571|NCT05206032|Other|Raman spectroscopy|Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
76041049|NCT02563925|Drug|HER2 directed therapy|
76041050|NCT02563925|Drug|Durvalumab|
75714041|NCT05954208|Other|Ongoing treatment|The control group participated only in the routine follow-up, treatment and practices in the institution.
76041051|NCT01663727|Drug|Bevacizumab [Avastin]|Intravenous repeating dose
76041052|NCT01663727|Drug|Paclitaxel|Intravenous repeating dose
76041053|NCT01663727|Drug|Placebo|Intravenous repeating dose
76041054|NCT02614261|Drug|Galcanezumab|Administered SC
76041055|NCT02614261|Drug|Placebo|Administered SC
76041056|NCT04859023|Diagnostic Test|saliva sample combined to an anterior nare self-swabbing (Self-samples)|Tested by antigenic test.
75411272|NCT00003972|Radiation|radiation therapy|
75411273|NCT00003984|Biological|lintuzumab|
75411274|NCT00003996|Drug|carmustine|
75411275|NCT00003996|Drug|chemotherapy|
75411276|NCT00003996|Drug|cisplatin|
75411277|NCT00003996|Drug|etoposide|
75411278|NCT00003996|Radiation|radiation therapy|
75411279|NCT00004002|Drug|bortezomib|
75411280|NCT00004008|Drug|bryostatin 1|
75411281|NCT00004014|Drug|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
75411282|NCT00004026|Drug|CT-2584|
75411283|NCT00004026|Drug|chemotherapy|
75411284|NCT00004032|Biological|ALVAC-hB7.1|Given IP
75411285|NCT00004032|Biological|recombinant interferon gamma|Given IP
75411286|NCT00004032|Other|laboratory biomarker analysis|Correlative studies
75411287|NCT00004038|Biological|Ad5CMV-p53 gene|
75411288|NCT00004038|Drug|chemotherapy|
75714042|NCT05954195|Other|high intensity interval training|high intensity interval training through ergometer, with whole treatment session between 20 - 30 minutes divided into 3 parts, the 1st is warming up (40% of HRmax intensity for 2/3/5 minutes then the active training part (intervals of 85-90% of HRmax for 1 minute then rest period of 1 minute of 40 % of HRmax and so on for nearly 20 minutes ) then the last part is cooling down (30 % of HRmax for 3/5 minutes).
76041057|NCT04859023|Diagnostic Test|saliva sample (Self-sample)|Tested by RT-PCR.
76041058|NCT04859023|Other|Survey of SARS-COV-19 knowledge|collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.
75555090|NCT05719285|Drug|Multi-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses"
75555091|NCT05713253|Device|ELITA System|Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
75555092|NCT05712720|Drug|Experimental: Group 1|RZ402 50 mg oral tablet, once daily for 3 months
75411289|NCT00004050|Biological|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
75411290|NCT00004056|Biological|filgrastim|
75555093|NCT05712720|Drug|Experimental: Group 2|RZ402 200mg oral tablet, once daily for 3 months
75555094|NCT05712720|Drug|Experimental: Group 3|RZ402 400mg oral tablet, once daily for 3 months
75555095|NCT05712720|Other|Placebo: Group 4|Placebo, once daily for 3 months
75555096|NCT05708144|Diagnostic Test|ICG-SG incubation solution|The fresh excision breast cancer tissues were completely soaked in the incubation solution and performed fluorescence imaging.
75555097|NCT05705401|Radiation|Standard of Care Adjuvant Breast Radiation|adjuvant breast radiotherapy per the current standard of care
75872572|NCT05201274|Behavioral|Baduanjin sequential therapy|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
76041059|NCT04859023|Other|Survey of acceptability of the different self-samples.|collection of : assessment and acceptability of the tolerance of self-samples.
76041060|NCT03043261|Behavioral|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
76041061|NCT03043417|Behavioral|CHC's given the intervention|CHC's NOT given the intervention
75411291|NCT00004056|Drug|asparaginase|
75411292|NCT00004056|Drug|cytarabine|
75411293|NCT00004056|Drug|daunorubicin hydrochloride|
75411294|NCT00004056|Drug|melphalan|
75555098|NCT05705401|Drug|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
75555099|NCT05702034|Drug|Milvexian|Milvexian will be administered orally.
75411295|NCT00004056|Drug|thioguanine|
75411296|NCT00004056|Procedure|peripheral blood stem cell transplantation|
76041062|NCT03042325|Drug|Alogliptin|Alogliptin tablets
76041063|NCT03045445|Diagnostic Test|Double Low-Dose protocol CT|Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
75411297|NCT00004062|Drug|azacitidine|
75411298|NCT00004062|Drug|liothyronine sodium|
75411299|NCT00004062|Radiation|iodine I 131|
75411300|NCT00004068|Drug|irinotecan hydrochloride|
75411301|NCT00004068|Drug|temozolomide|
75411302|NCT00004068|Procedure|conventional surgery|
75411303|NCT00004068|Radiation|radiation therapy|
75411304|NCT00004074|Biological|recombinant interleukin-12|Given IV
75411305|NCT00004074|Biological|ABI-007/carboplatin/trastuzumab|Given IV
75411306|NCT00004080|Biological|recombinant adenovirus-p53 SCH-58500|
75411307|NCT00004080|Procedure|conventional surgery|
75411308|NCT00004086|Biological|filgrastim|
75411309|NCT00004086|Drug|cisplatin|
75411310|NCT00004086|Drug|cytarabine|
75411311|NCT00004086|Drug|etoposide|
75411312|NCT00004086|Drug|ifosfamide|
75411313|NCT00004086|Procedure|autologous bone marrow transplantation|
75411314|NCT00004086|Procedure|peripheral blood stem cell transplantation|
75411315|NCT00004086|Radiation|indium In 111 LL2 IgG|
75411316|NCT00004086|Radiation|yttrium Y 90 epratuzumab|
75411317|NCT00004104|Biological|liposomal interleukin-2|
75411318|NCT00004104|Biological|polyvalent melanoma vaccine|
75411319|NCT00004104|Biological|recombinant interferon alfa|
75411320|NCT00004110|Biological|monoclonal antibody 3F8|
75411321|NCT00004110|Drug|etoposide|
75411322|NCT00004110|Drug|isotretinoin|
75411323|NCT00004122|Biological|BCG vaccine|
75411324|NCT00004122|Biological|recombinant interferon alfa|
75555100|NCT05702034|Drug|Placebo|Placebo will be administered orally
75555101|NCT05698407|Drug|Dexmedetomidine|loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine.
75714043|NCT05954156|Other|injectable composite|The introduction of injectable composites, according to available literature, offers a simple and efficient solution for the cementation of veneers. This versatile, injectable restorative composite unites easy handling, high physical properties and excellent aesthetics. Generally used as a restorative material, it can also be used for the cementation of veneers and some inlays/onlays, thus considered as good alternative to preheated composite. (Alajrash MM et al., 2020)
75411325|NCT00004128|Biological|aldesleukin|
76041064|NCT03045445|Diagnostic Test|Standard protocol CT|standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
75411326|NCT00004128|Biological|filgrastim|
76041065|NCT01594411|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score (ASGES)
75411327|NCT00004128|Drug|busulfan|
75411328|NCT00004128|Drug|cyclophosphamide|
75555102|NCT05698407|Drug|Sufentanil|loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
75555103|NCT05697939|Diagnostic Test|NSite 3D Scanning|"Three separate users will enter the exam room and use the NSite application to scan the patient in the bending position. These users may include research coordinators, physicians, or other authorized staff.~The NSite application will have a user tutorial on how to scan patients that users are instructed to watch prior to conducting a scan.~All participants are asked to remove clothing above the waist but may keep a bra or tight-fitting shirt on during the scanning procedures. The patient will be asked to assume a forward bending position. One user will capture a scan of the patient's back in this position. The user will calibrate the device and then walk around the patient while scanning per app directions. Once this user captures the scan, it will be processed by the application. New scans will then be obtained by the two other users. Once all users have captured a scan, the scanning process and patient participation will be completed."
75555104|NCT05694013|Device|Roche DPM Module|Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support
75872573|NCT05201274|Behavioral|Aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.
75555105|NCT05694013|Drug|Atezolizumab SC|Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)
75555106|NCT05694013|Other|Local SOC support|Participants will receive local SOC support
75714044|NCT05954130|Other|Education|Sexual Health in Pregnancy
75714045|NCT05954117|Procedure|Adipose tissue biopsies|"During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory."
75714046|NCT05954091|Drug|OH2 Injection|OH2 injection will be given intratumorally, and Q2W.
75714047|NCT05954078|Drug|mFOLFIRINOX adjuvant chemotherapy|mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
75872574|NCT03629496|Other|Arts-based intervention|6x1 hourly facilitated art sessions during haemodialysis. Participants will be provided with an option of visual art or creative writing, the artistic materials used will include graphite pencils, colouring pencils, water colour paints and graphic pens. Participants will be provided with their own art supplies for infection control purposes. During each session participants will be allowed to self-select a subject matter or be provided with binary prompts to facilitate decision making. Participants will also have an option of displaying completed work in the reception area of the unit during their haemodialysis sessions.
75872575|NCT05762406|Device|Respiratory protective mask|"Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)"
76041066|NCT01594333|Drug|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
76041067|NCT01594333|Drug|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
76041068|NCT04860895|Diagnostic Test|AP-23|AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
76041069|NCT04860583|Other|Renal ultrasound|
76041070|NCT03042247|Diagnostic Test|FDG PET/TC and FDG PET/MRI|Combined assessment with FDG PET/TC and PET/MRI
75411329|NCT00004128|Drug|cytarabine|
75411330|NCT00004128|Drug|daunorubicin hydrochloride|
75411331|NCT00004128|Drug|etoposide|
75411332|NCT00004128|Procedure|autologous bone marrow transplantation|
75411333|NCT00004128|Procedure|peripheral blood stem cell transplantation|
75411334|NCT00004128|Radiation|radiation therapy|
75411335|NCT00004152|Drug|iodinated contrast dye|
75872576|NCT05761704|Drug|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
75872577|NCT05761704|Drug|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
75411336|NCT00004152|Procedure|computed tomography|
75872578|NCT05205798|Behavioral|Food consumption using plates with a diameter of 23 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.
75872579|NCT05205798|Behavioral|Washout period|No interventional food consumption for 1 week
75872580|NCT05205798|Behavioral|Food consumption using plates with a diameter of 31 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
75872581|NCT01060670|Device|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
75411337|NCT00004152|Procedure|positron emission tomography|
75411338|NCT00004152|Radiation|fludeoxyglucose F 18|
76041071|NCT03042403|Other|Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
76041072|NCT04858633|Drug|Hydroxychloroquine (HCQ)|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg )
76041073|NCT04858633|Other|Standard care|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
75411339|NCT00004158|Drug|melphalan|
75411340|NCT00004158|Procedure|peripheral blood stem cell transplantation|
75872582|NCT01060670|Other|Conventional Wound Therapy|Conventional Wound Therapy
75872583|NCT05205642|Device|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
76041074|NCT04858633|Other|Placebo|Tablet placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
76041075|NCT04867291|Dietary Supplement|Pizza|Portion equivalent to 200 µg of iodine (half a pizza), consumed with ~450mL of water.
76041076|NCT04867291|Dietary Supplement|Seaweed Sheets|Portion equivalent to 200 µg of iodine (~10g), consumed with two slices of white bread and ~450mL of water.
75411341|NCT00004158|Radiation|holmium Ho 166 DOTMP|
75411342|NCT00004164|Biological|filgrastim|
75411343|NCT00004164|Drug|cisplatin|
75411344|NCT00004164|Drug|docetaxel|
75411345|NCT00004164|Drug|fluorouracil|
75411346|NCT00004164|Drug|leucovorin calcium|
75411347|NCT00004164|Radiation|radiation therapy|
75411348|NCT00004176|Drug|amifostine trihydrate|
75411349|NCT00004176|Drug|cisplatin|
75411350|NCT00004176|Drug|etoposide|
75411351|NCT00004176|Radiation|radiation therapy|
75411352|NCT00004188|Biological|filgrastim|Given IV
75411353|NCT00004188|Drug|carboplatin|Given IV
75411354|NCT00004188|Drug|cisplatin|Given IV
75411355|NCT00004188|Drug|cyclophosphamide|Given IV
75411356|NCT00004188|Drug|doxorubicin hydrochloride|Given IV
75411357|NCT00004188|Drug|etoposide|Given IV
75411358|NCT00004188|Drug|isotretinoin|Given IV
75411359|NCT00004188|Drug|melphalan|Given IV
75411360|NCT00004188|Drug|topotecan hydrochloride|Given IV
75411361|NCT00004188|Drug|vincristine sulfate|Given IV
75411362|NCT00004188|Procedure|autologous bone marrow transplantation|
75411363|NCT00004188|Procedure|bone marrow ablation with stem cell support|
75411364|NCT00004188|Procedure|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
75411365|NCT00004188|Procedure|peripheral blood stem cell transplantation|
75411366|NCT00004188|Radiation|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
75411367|NCT00004194|Drug|fludarabine phosphate|
75411368|NCT00004200|Drug|prinomastat|
75411369|NCT00004200|Drug|temozolomide|
75411370|NCT00004206|Drug|FOLFOX regimen|
75411371|NCT00004206|Drug|fluorouracil|
75411372|NCT00004206|Drug|leucovorin calcium|
75411373|NCT00004206|Drug|oxaliplatin|
75555107|NCT05691790|Behavioral|MMA and patient activation intervention scheme|"Design of booklet for older people's preventive care: We propose that the booklet will include 8 main topics based on what experts and current academic literature believe are important for encouraging older people's preventive care utilization. To add the social norms-related cues for the later three topics of the booklet, one qualitative study on older adults who are active in preventive care is needed. Therefore, we will interview ~20 older adults aged 70 years or above who are active in taking preventive care. We will conduct one-to-one in-depth interview to explore how participants overcome difficulties during decision making for vaccination and their positive feelings after making achievements. We will also explore and identify older adults who have a positive future perspective.~Patient activation sections: . Four undergraduate medical students will be trained as the coaches to deliver the patient activation sections over six weeks. Each section will be around 20 min."
75714048|NCT05954078|Drug|mFOLFOX6/XELOX adjuvant chemotherapy|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles
75714049|NCT05954052|Drug|Glutathione|Giving supplement orally
75714050|NCT05954039|Dietary Supplement|Wheat Polar Lipid Complex|The study foresees the intake of 2 capsules per day during 84 days
75714051|NCT05954039|Dietary Supplement|Placebo|The study foresees the intake of 2 capsules per day during 84 days
76041077|NCT04867291|Dietary Supplement|Seaweed Powder|Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and ~450mL of water.
75411374|NCT00004212|Biological|filgrastim|
75411375|NCT00004212|Drug|exatecan mesylate|
76041078|NCT04867291|Dietary Supplement|Potassium iodide|Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and ~450mL of water.
76041079|NCT03043495|Procedure|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
75411376|NCT00004218|Drug|chlorambucil|
76041080|NCT03043495|Drug|Dexamethasone|Various doses of Dexamethasone (2, 4 & 8 mg) to be used as an Adjuvant to Local anesthetic drugs
75411377|NCT00004218|Drug|cyclophosphamide|
75411378|NCT00004218|Drug|doxorubicin hydrochloride|
75411379|NCT00004218|Drug|fludarabine phosphate|
75411380|NCT00004218|Drug|prednisolone|
75714052|NCT05954013|Behavioral|PD_Pal intervention|The PD_Pal intervention will be delivered by a nurse that is specifically trained to deliver the PD_Pal intervention, i.e. the PD_Pal nurse. In the PD_Pal intervention, the patient, family caregiver and PD_Pal nurse complete four steps wherein they discuss and compose a: 1) Individual care plan; 2) Proactive care plan; 3) Quality of life and end-of-life plan and; 4) Coordination and revision plan. Together these steps lead to the Parkinson Support Plan. To facilitate patients in taking these steps, all patients receive a Parkinson Support Plan workbook. This workbook consists of information and questions aligned with the four steps. Patients can utilize this workbook before, during, or after the conversations with the PD_Pal nurse.
75411381|NCT00004218|Drug|vincristine sulfate|
75411382|NCT00004224|Drug|cyclophosphamide|
75411383|NCT00004224|Drug|etoposide|
75411384|NCT00004224|Drug|vincristine sulfate|
75411385|NCT00004224|Procedure|adjuvant therapy|
75411386|NCT00004224|Procedure|conventional surgery|
75411387|NCT00004224|Radiation|radiation therapy|
75411388|NCT00004236|Drug|pegylated liposomal doxorubicin hydrochloride|
75411389|NCT00004242|Drug|fluorouracil|
75411390|NCT00004242|Drug|gemcitabine hydrochloride|
75411391|NCT00004242|Drug|oxaliplatin|
75411392|NCT00004248|Biological|aldesleukin|
75411393|NCT00004248|Drug|doxorubicin hydrochloride|
75411394|NCT00004254|Drug|raltitrexed|
75411395|NCT00004260|Biological|recombinant interleukin-12|
75411396|NCT00004260|Biological|rituximab|
75411397|NCT00004266|Drug|Lisinopril|
75411398|NCT00004266|Drug|Nifedipine|
75411399|NCT00004266|Drug|Simvastatin|
75411400|NCT00004278|Drug|ganciclovir|
75411401|NCT00004284|Drug|potassium citrate|
75411402|NCT00004284|Drug|potassium phosphate|
75411403|NCT00004314|Drug|aminomidazole carboxamide riboside|
75411404|NCT00004338|Drug|zinc acetate|
75411405|NCT00004344|Drug|leuprolide|
75411406|NCT00004344|Drug|testosterone|
75411407|NCT00004368|Drug|colchicine|
75411408|NCT00004380|Drug|relaxin|
75411409|NCT00004386|Genetic|recombinant adenovirus containing the ornithine transcarbamylase gene|
75411410|NCT00004398|Drug|heme arginate|
75872584|NCT05205642|Device|Peripheral Arterial Tonography (PAT) using the EndoPAT™ device|A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
75872585|NCT05205642|Diagnostic Test|Endothelin|For Endothelin levels we will use the Endothelin ELISA kit from R&D company, and for measurement 1 cc of serum will be needed.
75411411|NCT00004398|Drug|tin mesoporphyrin|
75872586|NCT03652142|Other|Biomarker Research|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.
75872587|NCT03652142|Drug|Nivolumab|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
75411412|NCT00004404|Drug|clotrimazole|
75411413|NCT00004404|Drug|hydroxyurea|
75411414|NCT00004410|Drug|tauroursodeoxycholic acid|
75872588|NCT04656678|Device|Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance|Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.
76041081|NCT03043183|Procedure|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
75411415|NCT00004416|Drug|botulinum toxin type A|
75411416|NCT00004422|Drug|immune globulin|
76041082|NCT03042949|Device|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
76041083|NCT03042949|Device|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
76041084|NCT03043027|Drug|liposomal bupivicaine|local anesthetic
75411417|NCT00004428|Drug|CPX|
75411418|NCT00004440|Drug|ibuprofen|
75411419|NCT00004446|Drug|fluoxetine|
75411420|NCT00004464|Drug|cyclophosphamide|
75411421|NCT00004464|Drug|filgrastim|
75411422|NCT00004482|Drug|Cyclosporine|
75872589|NCT01176578|Other|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
76041085|NCT03043027|Drug|Bupivacaine|local anesthetic
76041086|NCT03043027|Drug|Saline Solution|saline injection
76041087|NCT04861207|Drug|Cladribine|The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
75411423|NCT00004482|Drug|methylprednisolone|
75411424|NCT00004482|Drug|Muromonab-CD3|
75411425|NCT00004482|Drug|prednisone|
75411426|NCT00004488|Drug|alendronate sodium|
75411427|NCT00004488|Drug|calcium carbonate|
75411428|NCT00004488|Drug|cholecalciferol|
75411429|NCT00004554|Drug|naltrexone (Revia)|100mg/day
75411430|NCT00004554|Drug|sertraline (Zoloft)|200mg/day
75411431|NCT00004554|Drug|Placebo|Placebo
75411432|NCT00004560|Device|defibrillator|
75411433|NCT00004572|Procedure|Sustacal challenge|
75411434|NCT00004578|Drug|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
75411435|NCT00004578|Drug|Lamivudine|150 mg, every 12 hours
75411436|NCT00004578|Drug|Stavudine|40 mg every 12 hours
75411437|NCT00004638|Procedure|pathogenesis study|
75411438|NCT00004644|Drug|acyclovir|
75411439|NCT00004650|Drug|conjugated estrogens|
75411440|NCT00004650|Drug|Medroxyprogesterone|
75411441|NCT00004656|Procedure|Metabolic assessment with body composition evaluation|
75411442|NCT00004662|Drug|dehydroepiandrosterone|
75411443|NCT00004686|Drug|methotrexate|
75411444|NCT00004686|Drug|prednisone|
75411445|NCT00004728|Drug|Warfarin|
75411446|NCT00004728|Drug|Aspirin|
75411447|NCT00004734|Drug|pyridoxine|
75411448|NCT00004734|Drug|cyanocobalamin|
75411449|NCT00004734|Drug|folic acid multivitamin|
75411450|NCT00004740|Drug|isoniazid|
75411451|NCT00004758|Drug|carbamazepine|
75411452|NCT00004758|Drug|corticotropin|
75411453|NCT00004758|Drug|nitrazepam|
75411454|NCT00004758|Drug|pyridoxine|
75411455|NCT00004758|Drug|valproic acid|
75411456|NCT00004758|Procedure|Surgery|
75411457|NCT00004770|Drug|thioctic acid|
75411458|NCT00004776|Drug|topiramate|
75411459|NCT00004794|Drug|cidofovir|
75411460|NCT00004800|Biological|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
75411461|NCT00004800|Biological|diphtheria-tetanus vaccine|
75555108|NCT05691790|Behavioral|Control Group|"Participants in the control group will receive a pamphlet about recommendation for influenza, pneumococcal, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. As a control for the patient activation interviews, the control group will also be informed that they will join our telephone-based elderly care project by the end of the baseline assessment but instead of receiving the patient activation interviews, this group will receive six control telephone care visits over six weeks. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health."
75555109|NCT05690087|Drug|Lidocaine|intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation
75555110|NCT05690087|Drug|sodium chloride 0.9% solution|intravenous sodium chloride 0.9% solution volume matched bolus and infusion.
75555113|NCT05681143|Other|Crisis Prevention Arm|The crisis prevention program involves a 3-session model. Each session lasts up to 60 minutes. They take place via telehealth with a licensed clinical therapist. Sessions involve case formulation, provision of prevention strategies, connecting with professional and lay resources, what to do if a crisis occurs, and strategies to prevent the re-occurrence of a crisis, should one occur. Each session involves use of checklists, a community resource guide, and homework. Implementation is standardized using two different manuals, one for the parent and the other for the provider.
76041088|NCT04858165|Procedure|MY GERYFS PROTOCOL|The MY GERYFS will be introduced through a guideline document, dissemination through the department of nursing, notices on the intranet and provision of large signs indicating that MY GERYFS are in progress and the times of meals for each ward. The developed protocol in phase 1 and 2 will be tested in single-centre in a before and after study for its feasibility and safety. In the pre-study, patients will be given usual care. In the post-study, patients will care according to the developed protocol. Clinical outcomes such as malnutrition risk, medical background, anthropometry data, nutrition-focused physical findings, dietary intake, mealtime barrier, Hospital Foodservices satisfaction will be recorded.
75872590|NCT02971670|Biological|rTSST-1 Variant Candidate Vaccine|Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
76041089|NCT04858321|Procedure|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature ~38.5 °C and <39 °C) sessions over a period of 14 days.
76041090|NCT04858087|Other|Screening and treatment|Students were screened by mRDTs and treated with artemether-lumefantrine if positive
75714054|NCT05953987|Other|aerobic combined with diaphragmatic breathing exercise (EXDB)|The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added
75872591|NCT04629378|Drug|Meropenem Injection|Meropenem IV 6 grams
75872592|NCT04629378|Drug|Amoxicillin Clavulanate|Amx/CA oral 1000/62.5mg 2 tablets
75872593|NCT04629378|Drug|Pyrazinamide|Pyrazinamide 20-30mg/kg
75872594|NCT04629378|Drug|Bedaquiline|Bedaquiline 400mg
76041091|NCT03041935|Procedure|Ilioinguinal/iliohypogastric nerve block|See arm description
76041092|NCT03041935|Procedure|Caudal-epidural nerve block|See arm description
76041093|NCT03041935|Drug|Acetaminophen|See arm description
76041094|NCT03041935|Drug|Sevoflurane|See arm description
75411462|NCT00004806|Genetic|Cystic fibrosis transmembrane conductance regulator|
75411463|NCT00004812|Behavioral|Exercise|
75411464|NCT00004842|Drug|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
75411465|NCT00004854|Drug|Carvedilol|
75411466|NCT00004866|Drug|exatecan mesylate|
75411467|NCT00004872|Biological|recombinant human endostatin|
75411468|NCT00004878|Biological|therapeutic allogeneic lymphocytes|
75411469|NCT00004878|Drug|cytarabine|
75411470|NCT00004878|Drug|fludarabine phosphate|
75411471|NCT00004878|Drug|idarubicin|
75411472|NCT00004878|Drug|methotrexate|
75411473|NCT00004878|Drug|tacrolimus|
75411474|NCT00004878|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75411475|NCT00004878|Procedure|peripheral blood stem cell transplantation|
75411476|NCT00004884|Drug|cisplatin|
75411477|NCT00004884|Drug|docetaxel|
75411478|NCT00004884|Drug|gemcitabine hydrochloride|
75555114|NCT05681143|Other|Control|The control condition will involve sending families the Autism Speaks Challenging Behavior Toolkit. It offers a complimentary set of recommendations. It is freely available and can be found here: https://www.autismspeaks.org/tool-kit/challenging-behaviors-tool-kit. There is no interaction with the clinician in the controlcondition. After the study observation period, we will provide them with the crisis manual (for parents) used in the active treatment arm.
75555115|NCT05677256|Biological|nOPV2|Vaccination
75555116|NCT05676112|Drug|nintedanib|nintedanib
75555117|NCT05676112|Drug|pirfenidone|pirfenidone
75555118|NCT05674396|Radiation|Stereotactic body radiotherapy|Participants will receive radiation as per the schedule discussed with the study doctor.
75555119|NCT05674396|Radiation|Traditional Palliation|Participants will receive radiation as per the schedule discussed with the study doctor.
75555120|NCT05674188|Behavioral|Augmented Reality Headset|Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
75555121|NCT05672368|Device|Robot-Assisted Surgery|Undergo surgery using the da Vinci SP device
75555122|NCT05672342|Drug|Cannabidiol|Given PO
75555123|NCT05672342|Drug|Delta-8-Tetrahydrocannabinol|Given PO
75555124|NCT05672342|Drug|Placebo Administration|Given PO
75555125|NCT05672342|Other|Questionnaire Administration|Ancillary studies
75555126|NCT05668650|Drug|Pembrolizumab|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
75555127|NCT05668650|Drug|Pembrolizumab biosimilar|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
75555128|NCT05663866|Drug|Dexamethasone|Dexamethasone will be administered orally.
75555129|NCT05663866|Drug|Montelukast|Montelukast will be administered orally.
75555130|NCT05663866|Drug|Methotrexate|Methotrexate will be administered subcutaneously.
75555131|NCT05663866|Drug|Amivantamab|Amivantamab will be administered intravenously.
75555132|NCT05663866|Drug|Lazertinib|Lazertinib tablets will be administered orally.
75714055|NCT05953987|Other|aerobic exercise (EX)|The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
75714056|NCT05953987|Other|sedentary control (CON)|The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
75714057|NCT05953948|Other|Intelligent Case Manage Platform (ICMP) and self-management program|This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
75555133|NCT05661604|Other|No Intervention|This is an observational study to assess the incidence and key disease characteristics of symptomatic acute respiratory viral infections in a high-risk population at risk for poor outcomes. Duration of each participant will be up to 12 months.
75555134|NCT05660967|Biological|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.
75714058|NCT05953922|Other|core stability exersises|core stability exercises and transcutaneous electrical nerve stimulation for four week three session per week
75714059|NCT05953909|Drug|Eribulin-Based Regimen|Eribulin Mesylate will be administered as a 1.4 mg/m^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
75714060|NCT05953909|Drug|nab-paclitaxel based regimen|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.
75872595|NCT04629378|Drug|Rifafour|Rifafour (HRZE) Standard dose
75872596|NCT04615806|Drug|Indocyanine green solution|ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.
75555135|NCT05660967|Drug|Lenalidomide|Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.
75555136|NCT05657808|Dietary Supplement|Rest Study Active Product 1.1 Usage|Participants will use Radicle Rest Active Product 1.1 as directed for a period of 6 weeks.
75555137|NCT05657808|Dietary Supplement|Rest Study Active Product 1.2 Usage|Participants will use Radicle Rest Active Product 1.2 as directed for a period of 6 weeks.
75555138|NCT05657808|Dietary Supplement|Rest Study Active Product 2.1 Usage|Participants will use Radicle Rest Active Product 2.1 as directed for a period of 6 weeks.
75555139|NCT05657808|Dietary Supplement|Rest Study Active Product 2.2 Usage|Participants will use Radicle Rest Active Product 2.2 as directed for a period of 6 weeks.
75555140|NCT05657808|Dietary Supplement|Placebo Control Form 1|Participants will use Placebo Control Form 1 as directed for a period of 6 weeks.
75555141|NCT05657808|Dietary Supplement|Placebo Control Form 2|Participants will use Placebo Control Form 2 as directed for a period of 6 weeks.
76041095|NCT03041935|Drug|Remifentanil|See arm description
76041096|NCT03041935|Drug|Propofol|See arm description
75411479|NCT00004890|Biological|aldesleukin|
75411480|NCT00004890|Drug|Biomed 101|
75555142|NCT05657808|Dietary Supplement|Placebo Control Form 3|Participants will use Placebo Control Form 3 as directed for a period of 6 weeks.
76041097|NCT03041935|Drug|Morphine|See arm description
75411481|NCT00004920|Drug|cisplatin|
75555143|NCT05657808|Dietary Supplement|Rest Study Active Product 3.1 Usage|Participants will use Radicle Rest Active Product 3.1 as directed for a period of 6 weeks.
75555144|NCT05657808|Dietary Supplement|Placebo Control Form 4|Participants will use Placebo Control Form 4 as directed for a period of 6 weeks.
75555145|NCT05657808|Dietary Supplement|Rest Study Active Product 4.1 Usage|Participants will use Radicle Rest Active Product 4.1 as directed for a period of 6 weeks.
75714061|NCT05953909|Drug|Other Chemotherapy Regimen|"TX：Docetaxel 75mg/ m^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m^2, D1,8 Q3W+Cisplatin 75mg/m^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m^2 D1 Q3W (or paclitaxel 175mg/ m^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)"
75714062|NCT05953896|Combination Product|Hyaluronic acid gel|For the Hyaluronic acid gel group: HA gel was injected 2-3mm apical to the coronal tip of the involved papillae and the needle was directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically until papilla became blanched. The injection was given at each papilla at the following intervals baseline, one week and two weeks.
75714063|NCT05953896|Combination Product|Multilayer L-PRF membranes|For the multilayer L-PRF group: A single semilunar incision is made in the buccal vestibule, apical to the muco-gingival junction in the mid interproximal area of the papilla to be treated.Tunneling of the incisions has maintained the full height and thickness of the gingiva. Multilayer L-PRF membranes were prepared according to Pinto's protocol immediately prior to the surgery and placed in the tunnel then incision was closed with simple interrupted sutures.
75714064|NCT05953883|Procedure|Tumor and blood sample|Analyzing proteogenomic profiles in order to find individual platinum-induced modifications on tumor tissue of HGSOC according to chemotherapy response score (CRS). Whole genome sequencing (WGS), transcriptomic (RNAseq) and proteomics analyses on OC tissue samples before and after a standard platinum-based chemotherapy will be carried out and correlated to clinical variables.
75872597|NCT03651674|Device|ECT treatment|Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks
75872598|NCT03651674|Drug|Drug treatment|Patients only have antipsychotic drugs
76041098|NCT03041935|Drug|Ondansetron|See arm description
76041099|NCT03041935|Drug|Dexamethasone|See arm description
76041100|NCT03041935|Drug|Ketorolac|See arm description
75411482|NCT00004920|Drug|raltitrexed|
75411483|NCT00004926|Dietary Supplement|vitamin D3 analogue ILX23-7553|
75411484|NCT00004932|Drug|imatinib mesylate|
75411485|NCT00004938|Drug|fluconazole|
75411486|NCT00004986|Drug|Nitazoxanide|
75411487|NCT00004992|Behavioral|Intensive lifestyle|
75411488|NCT00004992|Drug|Metformin|
76041101|NCT03041935|Drug|Ropivacaine|See arm description
76041102|NCT03042013|Drug|ASP8273|Oral
76041103|NCT04857853|Other|Exercise Without Rest Break|"Participants in the exercise group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Exercises include shoulder shrugs, neck tilts, wrist and forearm stretch, back and hip stretch, upper body stretch, hamstring stretch, upper back stretch, hand/finger stretch. Side stretch and neck stretch.~Follow up 3 times a week for 5 weeks."
75411489|NCT00004992|Drug|Placebo|
75411490|NCT00004998|Drug|Lamivudine/Zidovudine|
75411491|NCT00004998|Drug|Capravirine|
75411492|NCT00004998|Drug|Nelfinavir mesylate|
75411493|NCT00005010|Drug|Irbesartan|
75411494|NCT00005010|Drug|Pravastatin|
75411495|NCT00005022|Drug|cisplatin|
75411496|NCT00005022|Drug|etoposide|
75411497|NCT00005022|Radiation|radiation therapy|
75411498|NCT00005028|Drug|bryostatin 1|
75411499|NCT00005028|Drug|paclitaxel|
75411500|NCT00005040|Drug|arsenic trioxide|
75411501|NCT00005046|Drug|chemotherapy|
75411502|NCT00005046|Drug|paclitaxel|
75411503|NCT00005052|Biological|GM2-KLH vaccine|
75411504|NCT00005052|Biological|QS21|
75411505|NCT00005052|Procedure|adjuvant therapy|
75555146|NCT05657808|Dietary Supplement|Rest Study Active Product 4.2 Usage|Participants will use Radicle Rest Active Product 4.2 as directed for a period of 6 weeks.
75555147|NCT05657808|Dietary Supplement|Rest Study Active Product 4.3 Usage|Participants will use Radicle Rest Active Product 4.3 as directed for a period of 6 weeks.
75714065|NCT05953792|Procedure|Select the vertebra above sagittal stable vertebra as the distal fusion level|The surgeries were performed by the same surgical team. Multi-level Ponte osteotomies were performed across the apex of the kyphosis after complete exposure of the spine, with resection of supra- and inter-spinous ligaments, ligamentum flavum, and the whole facet joints. After placement of the pedicle screws at the expected fusion levels, pre-contoured rods were attached to the screws followed by segmental compression. During rod placement, two to three rounds of compression in the area with Ponte osteotomies were employed to enhance kyphosis correction. Satellite rods were routinely added to long rods and implanted with duet screws. The final tightening was performed, and the posterior fusion was completed with a mixture of local and allogeneic bone. Due attention was given to preserving the posterior ligamentous structures at the upper and lower junctional areas.
76041104|NCT04857853|Other|Exercise With Rest Break|"Participants in the exercise with rest break group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Participants will also receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation Follow up 3 times a week for 5 weeks."
75872599|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
75411506|NCT00005058|Procedure|ultrasound imaging|
75411507|NCT00005064|Drug|bortezomib|Given IV
75411508|NCT00005070|Drug|irofulven|
75411509|NCT00005076|Biological|cetuximab|
75872600|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
75411510|NCT00005076|Drug|irinotecan hydrochloride|
75872601|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
76041105|NCT04857853|Other|Rest Break|"Participants in the rest breaks group will receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours.~Follow up 3 times a week for 5 weeks. During the rest breaks, participants will not perform any exercises."
75411511|NCT00005082|Procedure|biopsy|
75411512|NCT00005082|Procedure|magnetic resonance imaging|
76041106|NCT03042793|Biological|PD-L1 peptide vaccine|PD-L1 peptide given subcutaneously with Montanide ISA-51
75411513|NCT00005088|Drug|cisplatin|
75411514|NCT00005088|Radiation|radiation therapy|
75411515|NCT00005094|Drug|celecoxib|Given orally
75411516|NCT00005094|Other|placebo|Given orally
75411517|NCT00005106|Drug|Lamivudine/Zidovudine|
75411518|NCT00005106|Drug|Abacavir sulfate|
75411519|NCT00005106|Drug|Nelfinavir mesylate|
75411520|NCT00005106|Drug|Lamivudine|
75411521|NCT00005106|Drug|Stavudine|
75411522|NCT00005118|Drug|Indinavir sulfate|
75411523|NCT00005118|Drug|Ritonavir|
75411524|NCT00005520|Drug|Hydrochlorothiazide|
75411525|NCT00005520|Drug|Candesartan|
75411526|NCT00005574|Drug|Gentamicin|
75555148|NCT05657743|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
75411527|NCT00005580|Drug|bryostatin 1|
75555149|NCT05656599|Drug|Letermovir|Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
75714066|NCT05953779|Behavioral|Clinician-administered Need-focused Single Session Intervention|All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. They will also meet with the therapist for a 10-minute remote check-in two weeks following the single session. All interventions include standard psychoeducational components. Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology. The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models.
75411528|NCT00005580|Drug|fludarabine phosphate|
76041107|NCT03042871|Drug|0.5mg intravitreal ranibizumab|Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
75411529|NCT00005586|Drug|L-leucovorin|
75411530|NCT00005586|Drug|fluorouracil|
75411531|NCT00005586|Procedure|adjuvant therapy|
75411532|NCT00005592|Biological|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
75411533|NCT00005592|Biological|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
75411534|NCT00005592|Radiation|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
75411535|NCT00005598|Drug|amifostine trihydrate|
75411536|NCT00005598|Drug|azacitidine|
75872602|NCT01569906|Radiation|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
75872603|NCT03651440|Other|PNF|PNF
75411537|NCT00005604|Biological|recombinant interleukin-12|Given IV
75411538|NCT00005604|Biological|aldesleukin|Given SC
75411539|NCT00005604|Other|laboratory biomarker analysis|Correlative studies
75411540|NCT00005610|Biological|sargramostim|
75411541|NCT00005616|Procedure|conventional surgery|
75411542|NCT00005616|Procedure|neoadjuvant therapy|
75411543|NCT00005616|Procedure|radionuclide imaging|
75411544|NCT00005616|Radiation|iodine I 131 monoclonal antibody F19|
75411545|NCT00005622|Drug|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
75411546|NCT00005622|Radiation|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
75411547|NCT00005628|Biological|vitespen|
75411548|NCT00005634|Drug|vorinostat|
75411549|NCT00005640|Procedure|Preoperative Endoscopy|
75411550|NCT00005640|Radiation|Technetium Tc 99m Sulfur Colloid|
75411551|NCT00005640|Procedure|Gamma Probe|
75411552|NCT00005640|Procedure|Biopsy of Sentinel Lymph Nodes|
75411553|NCT00005646|Drug|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
75555150|NCT05652725|Dietary Supplement|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
75555151|NCT05652725|Dietary Supplement|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
75555152|NCT05652725|Dietary Supplement|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
75555153|NCT05652725|Dietary Supplement|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
75555154|NCT05652725|Dietary Supplement|Clarity Active Study Product 4.2 Usage|Participants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks.
75411554|NCT00005652|Drug|rituximab|
75411555|NCT00005658|Drug|Glycine|
75411556|NCT00005724|Behavioral|Computer Program Intervention Group|A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
75411557|NCT00005724|Other|Minimal Intervention Group|Dietary Information pamphlets.
75411558|NCT00005724|Behavioral|Health Counselor Intervention Group|Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
75411559|NCT00005766|Drug|Creatinine|
76041108|NCT03042637|Drug|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
75411560|NCT00005772|Device|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
75555155|NCT05652725|Dietary Supplement|Clarity Active Study Product 4.3 Usage|Participants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks.
75714067|NCT05953727|Other|Low level laser therapy with proprioceptive stimulation|10 minutes of low level laser therapy and 10-15 minutes of proprioceptive stimulation and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
75714068|NCT05953727|Other|Low level laser therapy without proprioceptive stimulation|10 minutes of low level laser therapy and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
75872604|NCT03651440|Other|lumbar stabilization training|lumbar stabilization training
75411561|NCT00005772|Device|Control|Control group: standard care
75411562|NCT00005778|Drug|High-dose immunoablative therapy|"High dose cyclophosphamide for 4 days.~NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."
75411563|NCT00005790|Other|laboratory biomarker analysis|
75411564|NCT00005790|Procedure|biopsy|
75411565|NCT00005790|Procedure|magnetic resonance imaging|
75411566|NCT00005790|Radiation|gadopentetate dimeglumine|
75411567|NCT00005796|Procedure|filgrastim|GCSF is given after chemo administration
75411568|NCT00005796|Biological|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
75555156|NCT05652725|Dietary Supplement|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
75555157|NCT05652725|Dietary Supplement|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
75555158|NCT05652725|Dietary Supplement|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
75555159|NCT05652725|Dietary Supplement|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
75555160|NCT05652725|Dietary Supplement|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
75872605|NCT03651440|Other|Physical Therapy|Physical Therapy
75872606|NCT03651440|Other|Control|Control group
76041109|NCT03045133|Drug|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
76041110|NCT03045133|Drug|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
75411569|NCT00005796|Drug|lomustine|chemotherapy is administered every 21 days
75411570|NCT00005796|Drug|procarbazine hydrochloride|chemotherapy is administered every 21 days.
75411571|NCT00005796|Drug|vincristine sulfate|chemotherapy is administered every 21 days
75411572|NCT00005796|Procedure|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
75411573|NCT00005802|Biological|aldesleukin|
75411574|NCT00005802|Biological|filgrastim|
75411575|NCT00005802|Biological|therapeutic allogeneic lymphocytes|
75411576|NCT00005802|Drug|cytarabine|
75411577|NCT00005802|Drug|etoposide|
75411578|NCT00005802|Drug|fludarabine phosphate|
75411579|NCT00005802|Drug|methotrexate|
75411580|NCT00005802|Drug|mitoxantrone hydrochloride|
75411581|NCT00005802|Drug|therapeutic hydrocortisone|
75555161|NCT05652725|Dietary Supplement|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
75555162|NCT05652725|Dietary Supplement|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
75555163|NCT05652335|Drug|JNJ-79635322|JNJ-79635322 will be administered as SC injection.
75555167|NCT05642078|Biological|Investigational Vaccine(0.25ml/vial)|Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
75555168|NCT05642078|Biological|Investigational Vaccine(0.5ml/vial)|Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
75555169|NCT05642078|Biological|Active compared Vaccine|Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
75555170|NCT05641246|Drug|(CARBAMIDE®)|Urea is used to treat dry/rough skin conditions (such as eczema, psoriasis, corns, callus) and some nail problems (such as ingrown nails). It may also be used to help remove dead tissue in some wounds to help wound healing. Urea is known as a keratolytic. It increases moisture in the skin by softening/dissolving the horny substance (keratin) holding the top layer of skin cells together. This effect helps the dead skin cells fall off and helps the skin keep more water in.
75555171|NCT05641246|Drug|(VOLTAREN®) Emulgel 1%|(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has a cooling effect.
75555172|NCT05640193|Biological|Lifileucel (LN-144)|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
75555173|NCT05639569|Device|Ankura™ TAA Stent Graft Systems|All patients will be implanted with Ankura™ TAA Stent Graft Systems in accordance with the instructions for use (IFU).
75555174|NCT05638295|Procedure|Biopsy|Undergo tumor biopsy
75555175|NCT05638295|Procedure|Biospecimen Collection|Undergo collection of blood
75555176|NCT05638295|Procedure|Computed Tomography|Undergo CT scan
75555177|NCT05638295|Procedure|Magnetic Resonance Imaging|Undergo MRI
75555178|NCT05638295|Biological|Panitumumab|Given IV
75555179|NCT05638295|Drug|Sotorasib|Given PO
75555180|NCT05634408|Device|ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management (A1D)|TEST Lens
75411582|NCT00005802|Radiation|radiation therapy|
75411583|NCT00005808|Drug|motexafin lutetium|Given IV
75411584|NCT00005808|Drug|photodynamic therapy|Undergo laser therapy
75411585|NCT00005808|Procedure|loop electrosurgical excision procedure|Undergo LEEP
75411586|NCT00005808|Other|laboratory biomarker analysis|Correlative studies
75411587|NCT00005814|Biological|cetuximab|
75411588|NCT00005814|Drug|cisplatin|
75411589|NCT00005814|Radiation|radiation therapy|
75411590|NCT00354666|Drug|GSK159797|
75411591|NCT00354822|Drug|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts>150x10^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
75411592|NCT00354900|Drug|Aprotinin|
75411593|NCT00355212|Procedure|percutaneous ablation of hepatocellular carcinoma|
75411594|NCT00355290|Behavioral|Changes on Oral Vitamin K Intake|
75411595|NCT00355446|Drug|Bimatoprost 0.03%|
75555181|NCT05633407|Drug|Efgartigimod|Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
75555182|NCT05633407|Drug|Placebo|"Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively"
75555183|NCT05632718|Other|Exercise|Resistance and endurance supervised exercise-training. The training programme will last for 16 weeks. Training sessions will be held at Porto Faculty of Sports, 3 times per week with the duration of 1 hour.
75555184|NCT05628103|Drug|SEP-363856|SEP-363856 flexibly dosed
75555185|NCT05627362|Drug|Elafibranor 80 mg|Oral Tablet
75555186|NCT05627362|Drug|Elafibranor 120 mg|Oral Tablet
75555187|NCT05627362|Drug|Placebo Matched to Elafibranor 80 mg|Oral Tablet
75411596|NCT00355524|Drug|TMC114|TMC114 will be administered as oral tablets (75 milligram [mg] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
75411597|NCT00355524|Drug|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
75555188|NCT05627362|Drug|Placebo Matched to Elafibranor 120 mg|Oral Tablet
75555189|NCT05626569|Drug|PD-1 combined with SBRT|Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
75555190|NCT05624372|Diagnostic Test|hearing and cognitive assessment|psychiatric assessment, hearing assessment and brief cognitive assessment
75555191|NCT05620888|Behavioral|Walk behavior change: Tailored messages (TM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days."
75555192|NCT05620888|Behavioral|Walk behavior change: Non tailored messages (NTM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days."
75555193|NCT05619926|Drug|STSP-0601 for Injection|Intravenous Injection
75555194|NCT05618145|Other|Clinical information|The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
75555195|NCT05611736|Other|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
75555196|NCT05611736|Other|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
75555197|NCT05609565|Drug|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
75555198|NCT05609565|Drug|spinal anesthesia with bupivacaine|spinal anesthesia with bupivacaine
75555199|NCT05608902|Other|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis
75872607|NCT02971202|Drug|Hyperinsulinemic, euglycemic clamp|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts."
75411598|NCT00355602|Drug|Cefuroxime|
75411599|NCT00355602|Drug|Ciprofloxacin|
75411600|NCT00355602|Drug|Clarithromycin|
75411601|NCT00355602|Drug|Cotrimoxazole|
75411602|NCT00355602|Drug|Coamoxiclav|
75411603|NCT00355602|Drug|metronidazole|
75411604|NCT00355602|Drug|neomycin|
75411605|NCT00355602|Drug|rifaximin|
75411606|NCT00355602|Drug|Vancomycin|
75411607|NCT00355602|Drug|Doxycycline|
75411608|NCT00355680|Device|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
75411609|NCT00355680|Device|Green Laser (Iridex)|Already available green laser
75411610|NCT00356070|Drug|Strattera|
76041111|NCT04866745|Device|Magnetotherapy plus exercise|The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.
75555200|NCT05607108|Drug|ZEN003694|ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
75555201|NCT05605730|Other|Maitland mobilization for thoracic spine|The thoracic spine mobilization will be consisting of oscillations to the thoracic vertebrae from the prone positions for repeated 30 times with 1 min interval between each 4 sets for 15 minutes. For central posterio-anterior mobilization, a grade III large amplitude rhythmic oscillation in the postero-anterior direction will be applied to the joint sign segment which is defined as the patient's most painful or hardest to move segment. It will be detected through a passive accessory intervertebral motion (PAIVM) test. T6,7 will be used as a site for application if the joint sign can't be detected. The frequency of treatment sessions will be 3 sessions per week for 4 weeks.
75555202|NCT05605730|Other|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Verbal instructions will be provided for the patient to move into thoracic extension and do over-pressure at the end of ROM while a transverse glide is maintained by the therapist for a set of 10 repetitions. The significance of performing a pain-free movement will be emphasized to the patient all the time. There will be 3 sets of 10 repetitions with one minute rest between each set.
75411611|NCT00356226|Drug|clonidine|
75411612|NCT00356382|Drug|Lactobacillus (L.) casei|
75411613|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
75411614|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
75872608|NCT02971202|Drug|20% dextrose|A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
75872609|NCT05761548|Diagnostic Test|ultrafast ultrasound power Doppler imaging|ultrafast ultrasound power Doppler imaging for neonatal brain microvessels
75872610|NCT00702494|Biological|TB-403|Multiple IV
75872611|NCT02926638|Drug|Erlotinib Hydrochloride|Given PO
75872612|NCT02926638|Other|Laboratory Biomarker Analysis|Correlative studies
76041112|NCT04866745|Device|Microwave plus exercise|The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.
76041113|NCT04866745|Device|Sham Magnetotherapy plus exercise|The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.
75872613|NCT02926638|Biological|Rilotumumab|Given IV
75411615|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
75411616|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
75872614|NCT00641420|Procedure|Fractionated Laser Resurfacing|
75872615|NCT03651596|Behavioral|mHealth Messaging Intervention Group|The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.
75411617|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
75411618|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
75411619|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
75872616|NCT03651596|Behavioral|Standard mHealth Messaging Group|Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
75555203|NCT05605730|Other|Traditional exercise management|"Prone back extension. Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
75411620|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
75411621|NCT00356616|Drug|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
75714069|NCT05953714|Other|incision side cleaning with antiseptic products|A pilot study was conducted with six pregnant women to clarify the use of the data collection tools and the implementation plan during the study process. After that, the data collection forms were finalized. In the 6 operating room, two different solutions (PI and CG) were applied, according to the preference of the physician, to clean the surgical field. The study was carried out by adding a CG shower application to the physician's preferred solution (for a total of 3 groups). Pregnant women who were admitted to the obstetrics clinic were informed about the purpose, scope, duration, and method of the study by one of the researchers. Follow-up of the women was done for 7 day duration following postnatal to assess postoperative for comfort, pain, wound complications by the nurse researcher. At discharge, cultures were taken from the abdominal wounds of the participants
76041114|NCT04860115|Procedure|Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)|"PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered.~PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes."
75411622|NCT00356616|Drug|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
75411623|NCT00356772|Drug|Azithromycin|
75411624|NCT00356850|Drug|Azithromycin|
75411625|NCT00356928|Drug|Cyclophosphamide|50 mg/kg/day intravenously (IV) on Days -2 and -1.
75411626|NCT00356928|Biological|Donor T cells|"CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells"
75411627|NCT00357084|Drug|methotrexate|
75411628|NCT00357084|Drug|methylprednisolone|
76041115|NCT02609659|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
75411629|NCT00357084|Drug|prednisone|
75411630|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
75555204|NCT05602623|Device|Adaptive Optics System (AO)|Subjects will have their higher and lower order aberrations corrected with the AO system.
75714070|NCT05953675|Drug|Ethanol 70%|Once a week, the catheter will be closed with 3 mL ethanol 70% lock-solution after a completed hemodialysis. The fluid will stay in the catheter until next hemodialysis (ca. 48 hours). The fluid will be aspirated before the hemodialysis. Standard lock-solution of isotonic saline with heparin will be used for the remaining two hemodialysis procedures of the week.
75714071|NCT05953675|Drug|Isotonic saline with heparin|Standard procedure of isotonic saline used as lock-fluid after completed hemodialysis.
75872617|NCT03650582|Drug|Glucagon|Intranasal glucagon
76041116|NCT02609659|Drug|ribavirin|Tablet
76041117|NCT04856995|Other|exposure to surgical smoke during surgery|No intervention was made. During the surgery, complaints and throat cultures were taken before and after exposure to surgical smoke. Simultaneously, 45 air samples are taken in the operating room before, during and after the operation.
75411631|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
75411632|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
75411633|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
75411634|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
75411635|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
75555205|NCT05601492|Drug|Otezla - Standard Care|The participant will be given their medication with the electronic adapter cap on it and asked to return for the follow-up visit
76041118|NCT04859881|Other|No intervention|No intervention
76041119|NCT04429711|Drug|Ivermectin Oral Product|3mg Capsules, 12-15mg/ day for 3 days
76041120|NCT04429633|Drug|Candesartan|If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
76041121|NCT04856839|Diagnostic Test|high throughput sequencing and electromyography|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
76041122|NCT03042091|Drug|Polyethylene Glycol|Given orally
75411636|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
75411637|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
75411638|NCT00357318|Drug|sunitinib malate|Given PO
75411639|NCT00357318|Biological|bevacizumab|Given IV
75411640|NCT00357318|Other|pharmacological study|Correlative studies
75411641|NCT00357318|Other|laboratory biomarker analysis|Correlative studies
75411642|NCT00357474|Procedure|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
75411643|NCT00357474|Procedure|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
75411644|NCT00357630|Drug|gemcitabine hydrochloride|
75411645|NCT00357630|Procedure|quality-of-life assessment|
75411646|NCT00357708|Drug|decitabine|Given IV
75411647|NCT00357708|Drug|vorinostat|Given orally
75411648|NCT00357708|Other|laboratory biomarker analysis|Correlative studies
75411649|NCT00357708|Other|pharmacological study|Correlative studies
75411650|NCT00357786|Drug|Replagal agalsidase alfa|
75411651|NCT00357786|Drug|Replagal|
75411652|NCT00357864|Drug|carbachol|
75411653|NCT00357942|Drug|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
75411654|NCT00357942|Drug|Placebo|Placebo mouthwash
75411655|NCT00357942|Drug|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
75411656|NCT00357942|Drug|Placebo|Placebo solution for injection every 3 hour for 24 hours
75411657|NCT00358020|Drug|THALIDOMIDE|
75411658|NCT00358020|Drug|BORTEZOMIB|
75411659|NCT00358176|Drug|Risedronate (HMR4003)|
75411660|NCT00358410|Drug|GW679769 oral tablets|2x GW679769 60mg tablets
75411661|NCT00358410|Drug|Placebo|Placebo oral tablets to match experimental intervention
75411662|NCT00358488|Drug|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
75411663|NCT00358488|Drug|salbutamol|salbutamol
75411664|NCT00358488|Drug|salmeterol 50mcg|salmeterol 50mcg
75411665|NCT00358488|Drug|placebo|placebo
75411666|NCT00358566|Biological|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
75411667|NCT00358566|Drug|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
75411668|NCT00358800|Device|REMStar Auto with C-Flex|
75411669|NCT00359112|Drug|metformin|
75411670|NCT00359112|Drug|sulphonylurea|
75411671|NCT00359112|Drug|Avandamet|
75411672|NCT00359190|Drug|lapatinib|GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
75411673|NCT00359658|Drug|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
75411674|NCT00359658|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
75411675|NCT00359658|Drug|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
75411676|NCT00359814|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
75411677|NCT00359814|Drug|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
75411678|NCT00359892|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
75411679|NCT00359970|Drug|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
75411680|NCT00359970|Drug|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
75411681|NCT00359970|Drug|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
75411682|NCT00359970|Other|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
75411683|NCT00360048|Drug|oxytocin|
75411684|NCT00360204|Behavioral|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
75411685|NCT00360438|Drug|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
75411686|NCT00360516|Behavioral|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
75411687|NCT00360594|Drug|Acamprosate|3 pills (666 mg) for 1998mg/day
75411688|NCT00360594|Drug|Placebo|3 pills (666mg) for 1998mg/day
75411689|NCT00360750|Drug|carboplatin|
75411690|NCT00360750|Drug|cytarabine|
75411691|NCT00360750|Drug|etoposide|
75411692|NCT00360750|Drug|vincristine sulfate|
76041123|NCT03042091|Drug|Neomycin|Given orally
76041124|NCT03042091|Drug|Metronidazole Hydrochloride|Given orally
76041125|NCT03042091|Procedure|Therapeutic Conventional Surgery|Undergo colorectal resection
76041126|NCT04859569|Drug|LY01011|subcutaneously (SC) once every 4 weeks (Q4W)
76041127|NCT04859569|Drug|Xgeva®|subcutaneously (SC) once every 4 weeks (Q4W)
76041128|NCT04859959|Diagnostic Test|Gallium-68 Pentixafor PET/CT|Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
75411693|NCT00360750|Other|clinical observation|
75555206|NCT05601492|Behavioral|Reminder Text Intervention with apremilast|Participants will receive a weekly electronic text/email-based intervention that is designed to promote better adherence to treatment in addition to receiving their medication with the electronic adapter cap on it.
75714072|NCT05953662|Procedure|Reduced-port laparoscopic surgery|compare different operational styles of colon and upper rectal cancer
75714073|NCT05953662|Procedure|conventional laparoscopic surgery|conventional laparoscopic surgery
75714074|NCT05953649|Device|Extracorporeal Diaphragm Pacing|In the EDP group, a pacer using the extracorporeal diaphragm pacemaker provided by Guangzhou Xueliang Biotechnology Developing Co., Ltd., the pacing electrode is pasted on the body surface closest to the phrenic nerve at the outer edge of the lower end of the sternocleidomastoid muscle under ultrasound guidance, and the auxiliary electrode is placed between the second intercostal of the midline of the clavicle. The intensity of treatment parameters was set from low to high, and the intensity of treatment was increased when the patient could tolerate it, pacing 12-18 times/min at a frequency of 40 hertz (Hz)/30min/time, and performed every 12 hours for a week.
75714075|NCT05953649|Device|Tilt Table Verticalization|VitalGo bed (VitalGo Systems Ltd., Fort Lauderdale） is used for verticalization. Verticalization was set to minimum 30°, depending on cardiopulmonary parameters (respiratory rate, heart rate, blood pressure, oxygen saturation), vertical position was gradually increased (in 5° steps) to a maximum of 90°, as long as the above-named cardiopulmonary parameters of the patient remained stable and remain this position for 30 minutes simultaneously with extracorporeal diaphragm pacing for a week.
75714076|NCT05953649|Other|Conventional Physiotherapy|Patients receive early mobilization, which refers to a series of clinical intervention protocols (such as passive movement or active exercises, etc.) that confers physical benefits at an early period in collaboration with a multidisciplinary team (intensive care physicians, rehabilitation physicians, physical therapists, occupational therapists, respiratory therapists, and nurses). The study intervention take place during working time between 8 a.m. and 17 p.m. Patients of all three study groups receive this rehabilitation program until they transfer out of ICU.
75872618|NCT03650582|Drug|Placebo|Intranasal placebo
75411694|NCT00360750|Procedure|adjuvant therapy|
75411695|NCT00360750|Radiation|radiation therapy|
75411696|NCT00360906|Drug|Triomar™ (omega-3 fatty acids)|
75411697|NCT00360984|Drug|insulin glargine|
75411698|NCT00360984|Device|continuous subcutaneous insulin infusion|
76041129|NCT04856605|Procedure|surgery|regular surgery
76041130|NCT04856371|Drug|CYH33|Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
75411699|NCT00361062|Behavioral|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
75411700|NCT00361452|Drug|nebulized epinephrine and nebulized albuterol|
75411701|NCT00361530|Drug|Statin|
75411702|NCT00361608|Device|EarlySense ES 16|
75411703|NCT00361686|Drug|tramadol|
75411704|NCT00361686|Drug|remifentanyl|
75411705|NCT00361686|Device|patient contolled analgesia|
75411706|NCT00361920|Drug|prednisone|
75411707|NCT00361998|Drug|NITROFURANTOIN MACROCRYSTALS|
75411708|NCT00362310|Drug|indinavir|
75411709|NCT00362388|Procedure|Intramyocardial injection of autologous bone marrow cells|
75411710|NCT00362544|Drug|Ambisome|
75411711|NCT00362700|Drug|Clevudine|
75411712|NCT00362778|Drug|Insulin|intravenous continuous insulin infusion for 48 hours
75411713|NCT00362856|Drug|larazotide acetate|capsule
75411714|NCT00362856|Drug|Placebo|capsule
75411715|NCT00362934|Drug|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
75411716|NCT00362934|Drug|Atorvastatin|Atorvastatin 10 mg and 20mg
75411717|NCT00355836|Behavioral|Mental Imagery|
75411718|NCT00363090|Biological|alemtuzumab|
75411719|NCT00363090|Drug|cyclophosphamide|
75411720|NCT00363090|Drug|doxorubicin hydrochloride|
75411721|NCT00363090|Drug|prednisone|
75411722|NCT00363090|Drug|vincristine sulfate|
75411723|NCT00363090|Other|flow cytometry|
75411724|NCT00363090|Other|pharmacological study|
75411725|NCT00363324|Procedure|intracoronary injection of bone marrow cells|
75411726|NCT00363402|Procedure|PET-CT|
75411727|NCT00363714|Drug|AGN211745|100microgram single intravitreal injection
75411728|NCT00363714|Drug|AGN211745|200microgram single intravitreal injection
75411729|NCT00363714|Drug|AGN211745|400microgram single intravitreal injection
75411730|NCT00363714|Drug|AGN211745|800microgram single intravitreal injection
75411731|NCT00363714|Drug|AGN211745|1200microgram single intravitreal injection
75411732|NCT00363714|Drug|AGN211745|1600microgram single intravitreal injection
75411733|NCT00363792|Drug|Glyceryl trinitrate, azetazolamide|
75411734|NCT00363870|Biological|Fluarix vaccine|
75411735|NCT00363948|Drug|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
75411736|NCT00363948|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
75411737|NCT00364026|Drug|darusentan|
75411738|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
76041131|NCT04856371|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
75411739|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
75555207|NCT05601492|Behavioral|Extended Consultation for apremilast|Participants will be given their medication with the electronic adapter cap on it and will receive an initial patient consult intervention, which will focus on medication education and setting expectations of what to anticipate with usage of the prescribed medication
75555208|NCT05598320|Drug|TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
75555209|NCT05598320|Drug|Placebo for TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
75555210|NCT05596747|Drug|LY3209590|Administered SC.
75555211|NCT05596747|Drug|Insulin Glargine|Administered SC.
75555212|NCT05596162|Other|Blood Flow Restriction Therapy|Exercise with Blood Flow Restriction
75411740|NCT00364104|Drug|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
75555213|NCT05596162|Other|Standard Physical Therapy|Exercise without Blood Flow Restriction
75411741|NCT00364104|Drug|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
75555214|NCT05590793|Drug|Triptorelin pamoate (embonate) salt|Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.
75555215|NCT05586321|Biological|GEN1056|GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1.
75555216|NCT05582434|Drug|Adapalene Gel|Single topical treatment arm topical to be applied daily to area affected
76041132|NCT04856371|Drug|Letrozole|Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
75411742|NCT00364260|Drug|epoetin alfa|
75411743|NCT00364338|Behavioral|gourment cooking workshop|
75411744|NCT00364416|Other|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
75411745|NCT00364494|Procedure|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht>25% bleed or not
75411746|NCT00364572|Drug|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
75411747|NCT00364572|Drug|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
75411748|NCT00364650|Drug|Probiotic Supplement|2 capsules twice daily
75411749|NCT00364650|Other|Placebo|placebo
75411750|NCT00364806|Drug|Prochlorperazine|
75411751|NCT00364806|Drug|Metoclopramide|
75411752|NCT00364884|Drug|ketoaminoacid|
75411753|NCT00365040|Procedure|Prk with mitomycin vs Lasik|
75555217|NCT05582434|Drug|Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel|Two topical treatments will be dispensed and instructions to apply daily to affected area
75555218|NCT05582434|Drug|adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.|Three topical treatments will be dispensed and instructions to apply daily to affected area arm.
75555219|NCT05580237|Procedure|Simultaneous right and left heart catheterization|Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.
75555220|NCT05575063|Device|Investigational Healon Endocoat|Ophthalmic Viscoelastic device
75555221|NCT05575063|Device|Control Healon EndoCoat|Ophthalmic Viscoelastic device
75555222|NCT05574959|Device|investigational IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the investigational IOL Model DEN00V in both eyes for the duration of the study.
75555223|NCT05574959|Device|control IOL Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model ZCB00/DCB00 in both eyes for the duration of the study.
75555224|NCT05572515|Drug|Teclistamab|Teclistamab will be administered subcutaneously.
75555225|NCT05572515|Drug|Pomalidomide|Pomalidomide will be administered orally.
75555226|NCT05572515|Drug|Bortezomib|Bortezomib will be administered subcutaneously.
75555227|NCT05572515|Drug|Dexamethasone|Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
75555228|NCT05572515|Drug|Carfilzomib|Carfilzomib will be administered intravenously.
75872619|NCT02903030|Drug|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
76041133|NCT04856371|Drug|Palbociclib|Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
76041134|NCT04866277|Other|Fast-track referral for reference services|Activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study.
76041135|NCT03041779|Drug|Diclofenac Sodium 50Mg Suppository|
75411754|NCT00365118|Device|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
75411755|NCT00365196|Behavioral|CBT Hostility Reduction Program|
75411756|NCT00365430|Behavioral|safety program|Education, patient involvement, tailored implementation and a computerized registration system
75411757|NCT00365586|Drug|Ketoprofen Topical Patch , 20%|
75411758|NCT00365742|Drug|simvastatin|
75411759|NCT00365742|Drug|red yeast rice|
75411760|NCT00365742|Drug|pharmaceutical grade fish oil|
75411761|NCT00365742|Behavioral|therapeutic lifestyle changes|
75411762|NCT00365820|Drug|Tegaserod|
75411763|NCT00365898|Drug|Hydromorphone Hydrochloride Extended-Release|
75555229|NCT05571644|Drug|mFOLFOXIRI + Cadonilimab|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
75714077|NCT05953636|Dietary Supplement|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )
75714078|NCT05953623|Biological|Albumin|This is a 3 + 3 dose-escalation study with 5 doses (0.25g/kg, 0.35g/kg, 0.40g/kg, 0.45g/kg, 0.5g/kg). Intra-arterial albumin infusion will be applied after successful recanalization of the culprit artery in the anterior circulation.
75714079|NCT05953571|Procedure|Dismembered Pyeloplasty|dismembered Anderson-Hynes repair was performed using 5/0 absorbable suture.
75714080|NCT05953558|Device|Patients implanted with Micra AV|The first 1000 patients implanted by the device in France
75714081|NCT05953519|Behavioral|Unified Protocol|The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety.
75714082|NCT05953506|Drug|HS-10506|HS-10506 will be administered orally once on Day 1.
75872620|NCT02903030|Drug|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
76041136|NCT03041779|Drug|Paracetamol 500Mg Suppository|
75411764|NCT00366210|Behavioral|Constraint-Induced Movement (CI) Therapy|
75411765|NCT00366210|Behavioral|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
75411766|NCT00366288|Drug|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
75411767|NCT00366366|Biological|Infanrix-Hexa|
75411768|NCT00366522|Drug|LXR-623|
75411769|NCT00366600|Drug|neratinib|HKI-272
75714083|NCT05953506|Drug|HS-10506 Placebo|Matching placebo will be administered orally once on Day 1.
75714084|NCT05953467|Other|No intervention, observational.|None, observational study
75714085|NCT05953454|Other|Pain neuroscience Education|A pain neuroscience education session geared towards fear-avoidance beliefs
75411770|NCT00366834|Drug|Casopitant (GW679769) oral tablets|
75411771|NCT00366834|Drug|Casopitant (GW679769) intravenous|
75411772|NCT00366834|Drug|Dexamethasone intravenous|
75411773|NCT00366834|Drug|Ondansetron oral tablets|
75411774|NCT00366834|Drug|placebo|casopitant placebo
75411775|NCT00366912|Device|non-invasive ventilation|
75411776|NCT00366990|Behavioral|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics with a focus on lowering sodium intake.
75872621|NCT03650504|Procedure|Above Artery Catheter Placement|Nerve catheter placed between superficial femoral artery and sartorial muscle
76041137|NCT02612779|Drug|Elotuzumab|
76041138|NCT02612779|Drug|Pomalidomide|
76041139|NCT02612779|Drug|Dexamethasone|
76041140|NCT02612779|Drug|Nivolumab|
75411777|NCT00366990|Behavioral|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics.
75411778|NCT00367068|Drug|baclofen, intrathecal|
75411779|NCT00367068|Device|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
75411780|NCT00367146|Drug|MMF|
75411781|NCT00367224|Procedure|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
75411782|NCT00367224|Procedure|Skin biopsies|4 mm punch biopsies of the skin
75411783|NCT00367302|Drug|buprenorphine|maintenance
75411784|NCT00367302|Drug|methadone|maintenance
75411785|NCT00367536|Drug|bazedoxifene/conjugated estrogens combination tablet|
75411786|NCT00367614|Drug|pantoprazole|
75411787|NCT00367692|Drug|PSI-697|
75411788|NCT00367926|Drug|American ginseng root / polysaccharides|
75411789|NCT00368160|Drug|Eszopiclone|eszopiclone 3 mg
75411790|NCT00368160|Drug|Placebo|Placebo tablet
75411791|NCT00368238|Drug|Recombinant human erythropoietin alfa (drug)|
75411792|NCT00368238|Drug|Aspirin (drug)|
76041141|NCT02612623|Drug|Gefapixant|Gefapixant tablets administered by mouth twice daily for 8 weeks
75714086|NCT05953441|Other|AI-powered doctor|AI-powered virtual doctor
75714087|NCT05953441|Other|Human-controlled doctor avatar|Virtual doctor avatar controlled by the medical student.
76041142|NCT02612623|Drug|Placebo (for gefapixant)|Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
75411793|NCT00368238|Drug|Clopidogrel (drug)|
75411794|NCT00368394|Drug|Insulin glulisine|
76041143|NCT03041857|Radiation|Observational use of fluoroscopy|
75411795|NCT00368628|Procedure|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
75411796|NCT00368706|Drug|solifenacin succinate|Oral
75411797|NCT00368706|Drug|tolterodine|oral
76041144|NCT04809961|Other|I-care app|A smart phone app to enable healthcare worker peer support for improved workplace wellbeing.
75411798|NCT00368862|Drug|Ebixa (memantine hydrochloride)|
75411799|NCT00368862|Drug|Cipralex (escitalopram)|
75411800|NCT00369018|Drug|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
75714088|NCT05953389|Drug|Pitolisant|histamine H3 receptor antagonist/inverse agonist
75714089|NCT05953389|Drug|Placebo|Matching placebo of pitolisant tablets
75714090|NCT05953376|Drug|Calcium Gluconate|There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
76041145|NCT04808011|Device|Intelligent Dialysis Assistant (IDA)|The IDA is intended for home dialysis for subjects who are stage 5 kidney diease patients and who perform Peritoneal Dialysis. The system is used deveral times a day for approximately 20 minutes for each cycle. During the interventional period, subjects will use only the investigational IDA system for their in/out exchanges.
75411801|NCT00369096|Drug|bemiparin 3500 IU/day|
75411802|NCT00369174|Drug|rosiglitazone maleate|Given orally
75555230|NCT05571644|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycels before surgery
76041146|NCT04866355|Other|Lumbar spine manipulation|Lumbar spine manipulation
76041147|NCT04866355|Drug|Hyoscine and Ibuprofen|hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
76041148|NCT04866121|Procedure|Acupuncture|A standardized acupuncture protocol will be administered
76041149|NCT04849819|Drug|Corticosteroids, immunosuppressors, biological agents|We do not prescribe new medications to patients but only observe their adverse effects on the eye.
75555231|NCT05571644|Drug|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
75555232|NCT05568719|Diagnostic Test|Testing of hepatic AAV Vector integration|Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated
75555233|NCT05567185|Drug|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
75411803|NCT00369174|Other|laboratory biomarker analysis|Correlative studies
75411804|NCT00369252|Drug|Nimotuzumab (TheraCIM h-R3)|
75411805|NCT00369330|Device|external electrical cardioversion|
75411806|NCT00369408|Drug|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
75555234|NCT05564052|Drug|Ibrutinib|Ibrutinib capsules will be administered orally.
75555235|NCT05564052|Drug|Lenalidomide|Lenalidomide capsules will be administered orally.
76041150|NCT02607865|Drug|semaglutide|Oral administration once-daily
76041151|NCT02607865|Drug|sitagliptin|Oral administration once-daily
75411807|NCT00369408|Drug|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
75411808|NCT00369642|Behavioral|Cognitive-behavioral therapy|
75411809|NCT00369720|Procedure|Titration of oxygen in delivery room|
75411810|NCT00369798|Procedure|PET scan|
75411811|NCT00369798|Drug|Rolipram|
75411812|NCT00369954|Drug|carboplatin|
75411813|NCT00369954|Drug|gemcitabine hydrochloride|
75411814|NCT00370110|Drug|Itopride 100 mg|100 mg three times daily
75411815|NCT00370110|Other|Placebo|
75411816|NCT00370110|Drug|Itopride 200 mg|200 mg three times daily
75411817|NCT00370188|Drug|Topiramate|
75411818|NCT00370266|Drug|Triamcinolone|
75411819|NCT00370344|Procedure|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
76041152|NCT02607865|Drug|placebo|Oral administration once-daily
76041153|NCT04856137|Drug|Rituximab Paclitaxel Ruxolitinib|Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
75411820|NCT00370344|Procedure|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
75411821|NCT00370422|Drug|Triamcinolone, Bevacizumab|
75411822|NCT00370500|Drug|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
75411823|NCT00370578|Device|repeated thrombus aspiration during primary PCI|
75411824|NCT00370656|Drug|Pregabalin|capsule, 150mg bd, 300mg bd
75411825|NCT00370656|Drug|Duloxetine|Capsule, 60mg on, 60mg bd
75411826|NCT00370656|Drug|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
75411827|NCT00370734|Drug|Botulinum toxin A injection|
75411828|NCT00370812|Procedure|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
75411829|NCT00370968|Drug|Zinc sulphate|
75411830|NCT00371046|Procedure|Transvaginal ultrasound cervical length|
75411831|NCT00371046|Procedure|Cervicovaginal fetal fibronectin|
75555236|NCT05564052|Drug|Rituximab|Rituximab will be administered IV.
75555237|NCT05564052|Drug|Bortezomib|Bortezomib will be administered either intravenously or subcutaneously.
75411832|NCT00371124|Drug|Atropine Eye drops|
75411833|NCT00371202|Procedure|keratoplasty|
75411834|NCT00371280|Procedure|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
75555238|NCT05563961|Drug|Panadol®|Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
75555239|NCT05563961|Drug|SafeTynadol®|"Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)"
75555240|NCT05558501|Other|Mild Intermittent Hypoxia|The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2)= 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
75411835|NCT00371592|Drug|Acyclovir|800 mg tablet taken orally twice daily
75555241|NCT05558501|Other|Sham MIH|"During sham MIH the participants will be exposed to compressed air (the equivalent of room air)."
75555242|NCT05552963|Device|Multi-Channel Irreversible Electroporation (IRE) Generator|The multi-channel IRE Generator is intended for use during cardiac Pulsed Field Ablation (PFA) therapy. This device is used in conjunction with a compatible ablation catheter to create a closed electrical circuit capable of delivering pulsed electrical field energy.
75714091|NCT05953350|Drug|600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib|hydroxychloroquine group of 600mg bid combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.
75872622|NCT03650504|Procedure|Between Artery and Vein Placement|Nerve catheter placed between superficial femoral artery and femoral vein
75411836|NCT00371592|Drug|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
75411837|NCT00371670|Drug|balicatib (AAE581)|
75411838|NCT00371748|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
75411839|NCT00371748|Device|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
75411840|NCT00371748|Device|Express2|Coronary Stent System
75411841|NCT00371904|Drug|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
75411842|NCT00371904|Drug|Standard Care|Standard care
75411843|NCT00371982|Drug|Fish oil (Maxepa)|
75411844|NCT00372138|Procedure|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
75411845|NCT00372216|Drug|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
75411846|NCT00372294|Drug|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
75411847|NCT00372294|Drug|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
75555243|NCT05552963|Device|Multi-Channel Circular IRE Catheter|The multi-channel circular IRE Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and when used with an IRE Generator, for cardiac ablation.
75555244|NCT05552794|Diagnostic Test|Optic nerve Sheath Diameter (ONSD)|ONSD and rSO2 monitoring will perform when the patients arrived in ICU.
75555245|NCT05552222|Drug|Teclistamab|Teclistamab will be administered as SC injection.
75555246|NCT05552222|Drug|Daratumumab|Daratumumab will be administered as SC injection.
76041154|NCT03041545|Device|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
76041155|NCT04849195|Other|No intervention|No intervention
75555247|NCT05552222|Drug|Lenalidomide|Lenalidomide will be administered orally.
76041156|NCT04849351|Drug|HMPL-689|All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
76041157|NCT03044899|Procedure|All surgeries in adult patients|All surgeries in adult patients
75555248|NCT05552222|Drug|Dexamethasone|Dexamethasone will be administered either orally or intravenously (IV).
75714092|NCT05953350|Drug|RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.|After the exploration of 600mg bid dose of hydroxychloroquine combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of 600mg bid dose of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
76041158|NCT03045055|Device|Remote ischemic conditioning.|The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
76041159|NCT03045055|Procedure|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
76041160|NCT03045055|Device|Sham remote ischemic conditioning|The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
75555249|NCT05552222|Drug|Talquetamab|Talquetamab will be administered as SC injection.
76041161|NCT04849117|Procedure|Ultrasound guided Bilateral Transversus Thoracis Muscle Plane block|"In the TTMP block group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal. Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected single-shot in the tranversus thoracis muscle plane. The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously."
76041162|NCT04848493|Biological|COVID-19 vaccines|This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.
76041163|NCT04855591|Drug|SHR-1703|SHR-1703 will be administered subcutaneously
76041164|NCT04855591|Drug|Placebo|Placebo of SHR-1703 will be administered subcutaneously
76041165|NCT04848649|Other|Study arm|Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
75555250|NCT05550532|Drug|Aticaprant|Aticaprant tablet will be administered orally.
75555251|NCT05550532|Other|Placebo|Placebo tablet will be administered orally.
75714093|NCT05953324|Other|Kiwifruit|2 kiwifruit for 6 weeks
75714094|NCT05953311|Other|Blood analysis|Blood analysis for neurological biomarkers measurements
76041166|NCT04855279|Other|neutral sodium fluoride|Topically applied
76041167|NCT04855279|Other|ACP-CCP gel|Topically applied
76041168|NCT04855279|Other|nano-hydroxyapatite solution|Topically applied
76041169|NCT04855279|Other|glycerine|Topically applied
76041170|NCT04848259|Drug|Normal saline|Saline will be applied after surgery
75411848|NCT00372372|Drug|risedronate|
75411849|NCT00372450|Procedure|management of therapy complications|
75411850|NCT00372450|Procedure|quality-of-life assessment|
75411851|NCT00372606|Behavioral|Online MiDieta Diet and Weight Management Program for Hispanics|
75411852|NCT00372684|Genetic|with severe malaria hospitalized in ICU|with severe malaria hospitalized in ICU
75411853|NCT00372684|Genetic|with uncomplicated malaria|with uncomplicated malaria
75411854|NCT00372762|Drug|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
75411855|NCT00372762|Drug|Bumetanide|Equivalent dose to pre-existing furosemide will be used
75411856|NCT00372762|Drug|furosemide|20mg to 80mg orally once or twice daily
75411857|NCT00372762|Drug|bumetanide|0.5mg to 2mg orally once or twice daily
75411858|NCT00372840|Other|educational intervention|
75411859|NCT00372840|Procedure|psychosocial assessment and care|
75411860|NCT00372840|Procedure|quality-of-life assessment|
75411861|NCT00372918|Procedure|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
75411862|NCT00373074|Other|Epidural Blood Patch|Use 15 cc of blood
75411863|NCT00373074|Other|Epidural Blood Patch|Inject 20 cc of blood into epidural space
75411864|NCT00373074|Other|Epidural Blood Patch|Inject 30 cc of autologous blood
75411865|NCT00373152|Procedure|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
75411866|NCT00373152|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
75411867|NCT00373152|Procedure|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
75411868|NCT00373152|Radiation|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
75411869|NCT00373230|Behavioral|telemedicine|One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
75411870|NCT00366132|Device|Extracorporeal Shockwaves|
75714095|NCT05953311|Other|Cognitive tests|Questionnaires assessing cognitive function
75714096|NCT05953298|Device|Electrical impedance tomography (EIT)|Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level
75872623|NCT03650426|Procedure|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
76041171|NCT04848259|Drug|Dexamethasone|Dexamethason will be given IV before surgery
76041172|NCT04848259|Drug|Honey|Honey will be applied locally after surgery
76041173|NCT04848259|Drug|Dexamethasone and honey|Dexamethason will be given IV before surgery and then Honey will be applied locally after surgery
75555254|NCT05545137|Drug|Pivmecillinam hydrochloride tablets|400mg tablet
75872624|NCT03650426|Procedure|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
75872625|NCT02969408|Drug|Albuterol Sulfate|Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
75872626|NCT03462563|Device|INTERCEED™|when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
76041174|NCT03040609|Behavioral|Visual-behavioral Scale at day 1|To perform the classification with the scale by caregiver.
76041175|NCT03040609|Behavioral|Test-retest at the end of 2 weeks|To perform the classification with the scale by orthoptist at the end of 2 weeks
75411871|NCT00373464|Drug|etoricoxib|
75411872|NCT00373620|Drug|paclitaxel|
75411873|NCT00373776|Drug|miltefosine 2.5 mg/kg/day for 28 days|
75411874|NCT00373932|Behavioral|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
75411875|NCT00373932|Behavioral|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
75555255|NCT05545137|Drug|Fosfomycin Tromethamine Granules|3g/pack
75555256|NCT05543915|Device|Active tDCS|The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
75555257|NCT05539027|Drug|Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)|patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
76041176|NCT03040609|Behavioral|Test at 6 months|To perform the classification with the scale by orthoptist at the end 6 months.
76041177|NCT04848571|Combination Product|Fetal Protection Pill|A Chinese medicine used in pregnant women for fetal protection, including mainly radix polygoni multiflori, Rehmannia glutinosa.
76041178|NCT04840537|Procedure|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage
76041179|NCT03038971|Biological|Dose Level 1|Short and Tall Ragweed Mix
76041180|NCT03038971|Biological|Dose Level 2|Short and Tall Ragweed Mix
76041181|NCT03038971|Biological|Placebo|Saline with 0.4% Phenol
75555258|NCT05539027|Drug|Branched-chain amino acids (BCAA), enriched solution (Aminoleban)|patients will receive BCAA enriched solution (Aminoleban)
75555259|NCT05538910|Other|Placebo Nicotine Patch|Comparator
75555260|NCT05538910|Drug|Nicotine Patch|Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
75872627|NCT03462563|Device|Placebo|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
76041182|NCT03039127|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
76041183|NCT03039049|Drug|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
75555261|NCT05537246|Procedure|PWV|All cases were evaluated in the service before surgery. Pulse wave velocity measurement was performed with the MOBİL-O-GRAPH device, which is one of the noninvasive methods. Before measuring from patients; It was confirmed that there was no coffee/cigarette consumption within 30 minutes. After resting for 5 minutes in a quiet room, the cuff of the appropriate size was tied to the arm in such a way that it came to the brachial artery. The data recorded by the tonometer was transferred to the computer program. Care was taken that the patient did not move or talk during the measurement.
76041184|NCT03038893|Diagnostic Test|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
76041185|NCT03038893|Diagnostic Test|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
75555262|NCT05535972|Drug|FF/UMEC/VI|FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
75555263|NCT05531292|Device|Model C0002|Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.
76041186|NCT03040453|Device|Microwave ablation|
75555264|NCT05531292|Device|Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.
75555265|NCT05531097|Drug|HSK31679|Single or multiple oral doses of HSK31679
75555266|NCT05531097|Drug|Placebo|Matching placebo
75555267|NCT05528510|Drug|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered as SC injection.
75555268|NCT05528510|Drug|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered as SC injection.
75555269|NCT05528510|Drug|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered as SC injection.
75555270|NCT05528510|Other|Placebo|Placebo will be administered as SC injection.
75555271|NCT05522075|Behavioral|Exercise Training|Subjects will be asked to perform exercise training (high-intensity interval training) under supervision, 3 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
75555272|NCT05522075|Behavioral|Alcohol Abstinence Intervention|Subjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.
75555273|NCT05521087|Drug|JNJ-75276617|JNJ-75276617 will be administered orally.
75555274|NCT05521087|Drug|Fludarabine|Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
76041187|NCT03040453|Device|Irreversible electroporation|
76041188|NCT04848181|Drug|cyproterone acetate|two weeks Cyproterone acetate administration before TURP
75872628|NCT03716453|Procedure|Standard protocol|Give narcotic according to vital signs
75872629|NCT03716453|Procedure|ANI protocol|"ANI score 50-70 indicates optimal narcotic effect. ANI score > 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score < 50 indicates inadequate narcotic and narcotic should be given."
75872630|NCT05180214|Drug|Bupivacain|analgesic
75872631|NCT05180214|Drug|Ketorolac|analgesia
76041189|NCT04848181|Drug|finasteride|two weeks finasteride administration before TURP
76041190|NCT04848181|Drug|no treatment received|no treatment received before TURP
75714097|NCT05953272|Other|EMG Biofeedback therapy and Bobath therapy|"EMG Biofeedback therapy will be used to up-train the ankle dorsiflexors in stroke patients. It will be given for 15 minutes. Patient will practice 2 blocks of Tibialis Anterior muscle contraction trials (holding for 10 seconds per trial with 10 seconds of rest, 20 trials per block with 1 minute 40 seconds of rest in between the blocks) with the heel contacts the floor for a total of 40 trials.~In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
76041191|NCT04848415|Other|Point-of-Care Ultrasound|Patients admitted to the ED with abdominal pain and suspicion of bowel obstruction : realization of a Point-of-Care Ultrasound after clinical exam by the Emergency Physician in charge as a standard of care. Beside usual findings, the investigators will search for signs of bowel obstruction: dilated and incompressible small bowel loop, back-and-forth peristalsis sign. Determination of probability of small bowel obstruction. Realization of a computed tomography in search of small bowel obstruction.
76041192|NCT04847791|Dietary Supplement|Bovine lactoferrin|Oral Administration of Bovine Lactoferrin -fixed dose 800 mg / day for 30 days
76041193|NCT04847791|Dietary Supplement|Placebo administration|capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
75411876|NCT00374010|Behavioral|Patient-Centered Advance Care Planning|"The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:~Representational assessment (10 - 15 minutes);~Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);~Creating conditions for conceptual change (5 minutes);~Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and~Summary (3 - 5 minutes)"
75555275|NCT05521087|Drug|Cytarabine|Cytarabine chemotherapy will be administered as IV infusion for participants with AML.
75714098|NCT05953272|Other|Bobath therapy|"In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
75555276|NCT05521087|Drug|Intrathecal Chemotherapy|Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.
75555277|NCT05521087|Drug|Dexamethasone|Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.
75555278|NCT05521087|Drug|Vincristine|Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.
75555279|NCT05521087|Drug|Pegaspargase|Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.
76041194|NCT04848103|Behavioral|Radial extracorporeal shockwave therapy|Radial extracorporeal shockwave therapy group include Therapeutic modality(Transcutaneous electrical nerve stimulation [TENS], Microwave thermotherapy, and Superficial heat therapy), Range of motion exercise(Continuous passive motion and Active range of motion exercise).
75555280|NCT05519215|Device|ECHELON 3000 Stapler|There is no intervention, beyond necessary clinical care, in this study. Echelon 3000 Stapler is used for transection and resection in LSG or lung surgical procedure per its IFU.
75872632|NCT01060124|Drug|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
76041195|NCT04847869|Device|Ellex Integre NIR laser|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
76041196|NCT03041389|Behavioral|CCBT-I Group|Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
76041197|NCT03041389|Behavioral|Control Group|Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
75411877|NCT00374478|Drug|Scopolamine|
75411878|NCT00374634|Drug|rFSH drug dose|"Individual rFSH dose (50, 75 or 100 IU rFSH/day)"
75411879|NCT00374634|Drug|"Standard rFSH dose"|"Standard rFSH dose was 75 IU/day"
75555281|NCT05518149|Drug|Aticaprant|Aticaprant 10 mg tablet will be administered orally.
75555282|NCT05511246|Drug|Venous ethanol|Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
75555283|NCT05511246|Procedure|Catheter ablation|Endocardial catheter ablation of VT substrate
75555284|NCT05498948|Dietary Supplement|Probiotic mixture|orally take .
75555285|NCT05498935|Other|CPB time|Cardiopulmonary bypass time
75555286|NCT05498428|Drug|Amivantamab|Amivantamab will be administered subcutaneously by manual injection.
75411880|NCT00374790|Drug|Ferrous sulfate|
75411881|NCT00374946|Device|THA|
76041198|NCT04847713|Other|extraction of blood samples|Two blood samples (3.5 ml each) will be collected directly into purple K2-EDTA tubes and stored at 4°C for up to 24 hours for analysis
76041199|NCT03041155|Behavioral|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
75411882|NCT00375024|Procedure|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
75411883|NCT00375024|Procedure|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
75555287|NCT05498428|Drug|Lazertinib|Lazertinib will be administered as an oral tablet.
75555288|NCT05498428|Drug|Carboplatin|Carboplatin will be administrated by IV infusion.
76041200|NCT03041233|Other|Observation / Data Collection|"The following data will be reviewed / collected:~BASELINE VISIT: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.~ABLATION PROCEDURE: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).~6 and 12 MONTH FOLLOW-UP (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
76041201|NCT04375813|Drug|eRapa|0.5mg eRapa (encapsulated rapamycin) oral capsules
76041202|NCT04375813|Drug|Placebos|placebo capsules visually identical to eRapa oral capsules
76041203|NCT03041077|Dietary Supplement|Instaflex Advanced|Joint function
76041204|NCT03041077|Dietary Supplement|Placebo|Placebo
75411884|NCT00375102|Procedure|Acupuncture|
75411885|NCT00375102|Behavioral|Relaxation Response|
75411886|NCT00373542|Drug|ropinirole CR-RLS|
75411887|NCT00375258|Drug|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
75411888|NCT00375258|Drug|Sodium Chloride 0.9%|Visual matched placebo
75411889|NCT00375414|Procedure|PEG-Gastropexy|
76041205|NCT04847245|Drug|Pregabalin 75mg tid + Duloxetine|Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.
75411890|NCT00375570|Drug|ME-609|Topical treatment 5 times daily for 5 days
75411891|NCT00375648|Drug|Zoledronic acid|
75411892|NCT00375726|Biological|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
75411893|NCT00375726|Biological|Placebo|Placebo for rDEN3/4delta30(ME)
75411894|NCT00375882|Procedure|hypothermia|
75411895|NCT00375882|Procedure|cochlear implantation with mild hypothermia|
75411896|NCT00375960|Drug|V3381|
75411897|NCT00375960|Drug|Placebo|
75411898|NCT00376038|Drug|GSK189075 oral tablets|
75411899|NCT00376038|Drug|metformin tablets|
75555289|NCT05498428|Drug|Pemetrexed|Pemetrexed will be administered by IV infusion.
75411900|NCT00376116|Device|Cardiac resynchronisation therapy|
75411901|NCT00376116|Device|Implantable cardioverter-defibrillator|
75411902|NCT00376194|Drug|DMSA|
75411903|NCT00376272|Drug|Valsartan|
76041206|NCT04847245|Drug|Intravenous administration of esketamine 0.125 mg/kg+Duloxetine|Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
76041207|NCT04847245|Drug|Intravenous administration of esketamine 0.25 mg/kg +Duloxetine|Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
75411904|NCT00376272|Drug|Placebo|
75411905|NCT00376350|Procedure|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
75555290|NCT05498428|Drug|Direct Oral Anticoagulant (DOAC)|DOAC will be administered orally.
75555291|NCT05498428|Drug|Low Molecular Weight Heparin (LMWH)|LMWH will be administered subcutaneously.
75714099|NCT05953259|Device|Combination of STERN FIX and wires|Closure of the median sternotomy using a combination of at least one STERN FIX device and wires for a total of 5 fixation points.
75411906|NCT00376350|Procedure|Light Massage|light pressure massage of the low back.
76041208|NCT04847245|Drug|Intravenous administration of esketamine 0.50 mg/kg+Duloxetine|Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
75555292|NCT05495815|Drug|6 months of SAT|6 months of oral suppressive antibiotic therapy
75555293|NCT05495815|Drug|12 months of SAT|12 months of oral suppressive antibiotic therapy
75714100|NCT05953259|Device|Wires|Closure of the median sternotomy using the standard of care with steel wires.
76041209|NCT04840225|Other|Measurement of biomarkers for inflammation and anemia|Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements
76041210|NCT04839913|Diagnostic Test|Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM
76041211|NCT04839835|Other|waiting room enriched with music, paintings and artificial plants|waiting room enriched with music, paintings and artificial plants
75411907|NCT00376350|Procedure|Pulsed Ultrasound|5 minutes pulsed ultrasound
75411908|NCT00376428|Drug|Gentamicin|
75411909|NCT00376584|Drug|MK-0524A|
75411910|NCT00376584|Drug|ER Niacin|
75411911|NCT00376584|Drug|Placebo|
75714101|NCT05953220|Other|Exclusive tobacco smoking|No intervention, participants own tobacco products
76041212|NCT04847401|Diagnostic Test|H. pylori stool antigen|using H. pylori antigen kits in stool
76041213|NCT04846699|Procedure|per-cutaneous stone extraction|percutaneous nephrolithotripsy for renal stones by different renal access
75411912|NCT00376662|Drug|Hormone Replacement Therapy and Etidronate|
75411913|NCT00376740|Drug|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
75411914|NCT00376818|Behavioral|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
75411915|NCT00376818|Other|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
75411916|NCT00376818|Other|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
75411917|NCT00376818|Other|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
75411918|NCT00376818|Behavioral|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
75555294|NCT05495815|Drug|Indefinite SAT|Indefinite oral suppressive antibiotic therapy
75555295|NCT05492175|Other|robotic practice|According to the group assignment, participants will start from the BMT proximal mode (i.e., forearm pronation-supination movement), and then the distal mode (i.e., wrist flexion-extension movement), and vice versa. Each participant is expected to complete approximately 400 to 600 repetitions of the proximal mode session (i.e., forearm movements) and another 400 to 600 repetitions of the distal mode session (i.e., wrist movements), respectively.
75714102|NCT05953220|Other|Exclusive e-cigarette use|No intervention, participants own e-cigarette products
76041214|NCT04847089|Device|Motor imagery BCI training|Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
76041215|NCT04846621|Drug|Potassium Channel Opener|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
76041216|NCT04846621|Drug|Calcium channel blocker|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
75714103|NCT05953220|Other|Dual use of e-cigarettes and tobacco smoking|No intervention, participants own tobacco and e-cigarette products
75714104|NCT05953220|Other|No use of e-cigarettes or tobacco smoking|No intervention
75714105|NCT05953181|Procedure|Active surveillance|Patients enrolled in the active surveillance arm will undergo diagnostic evaluations every 3 months in the first year after completion of neoadjuvant treatment, every 4 months in the second year, every 6 months in the third year and yearly in the 4th and 5th year of follow up, or when symptoms or results of any diagnostic test require shorter assessment intervals. In the active surveillance arm, surgical resection will be offered only to those patients, in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination.
75714106|NCT05949034|Device|JUUL E-Cigarette Device|We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.
75714107|NCT05947578|Drug|CLZ-2002|Low dose group (6×10^6 cells), Mid dose group (12×10^6 cells), High dose group (24×10^6 cells)
75714108|NCT05945472|Other|Positive reinforcement method|"A 30-minute talk based on mindfulness, positive thinking and teaching for the application of the cosmetic through positive messages (Ayuna method). Adapts the teachings of mindfulness to the field of beauty and stimulates the skin-brain connection through self-care. By applying cosmetics through intentional massages, with this technique is stimulated the brain in a positive positively in the general wellbeing.~The cosmetic is applied with a massage aimed at loving oneself, a ceremony for the skin and an invitation to enjoy the moment; positive messages are included during the application. In addition to favoring the penetration of the products, these maneuvers help to disconnect and achieve, in the long term, a healthier appearance. The technique consists of slow, intentional movements to create an ideal space to become aware of the present moment and draw a love story with oneself."
75411919|NCT00376818|Procedure|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
75411920|NCT00376896|Drug|GW876008 200mcg|GW876008
75411921|NCT00376896|Drug|GW876008 20mcg|GW876008 20mcg
76041217|NCT04846777|Device|Mindfulness ecological momentary intervention|Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
76041218|NCT04846777|Device|Self-monitoring placebo|Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
76041219|NCT04846543|Other|MRI Scan|MRI scan
76041220|NCT04854655|Other|Conventional resin composite|nanofilled resin composite
75411922|NCT00376896|Other|Placebo|placebo
75411923|NCT00376974|Behavioral|American Academy of Ophthalmology Glaucoma Educational Tape|
75411924|NCT00377130|Other|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
75411925|NCT00377208|Behavioral|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
75411926|NCT00377286|Dietary Supplement|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
75411927|NCT00377286|Other|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
75411928|NCT00377442|Drug|GK Activator (2)|100mg po
75411929|NCT00377442|Drug|Simvastatin|80mg po
75714109|NCT05945472|Other|Standard method|"A 30-minute talk based on how to administer it according to the guidelines of general cosmetology, related to the use and application of the cream, following conventional techniques of the cosmetic industry, which focus on the application of the product in the areas of wrinkles or with more treatment needs: anti-aging anti-stain anti-sagging anti-sagging product, anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging product. rejuvenating results to try to reduce the skin years, reduce wrinkles, loss of firmness, flaccidity and spots."
75411930|NCT00377598|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
75714110|NCT05942833|Procedure|Sigmoid resection|Timing of sigmoid resection
75714111|NCT05937113|Biological|RABIVAX-S|"1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).~Pre-exposure prophylaxis regimens for two groups~Intramuscular 1ml on days D0, D7 and D21+7~Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28"
75714112|NCT05937074|Other|Weight loss (%)|Change in body weight from cancer diagnosis to study enrollment
75714113|NCT05936944|Other|Exposure to totally artificial lighting|The second group of patients will be admitted to an ICU without windows and with a totally artificial lighting
75714114|NCT05928312|Drug|Fruquintinib Combined With Chemotherapy|"1.Security introduction period:~[1] Safety introduction period (N=6), fruquintinib combined with three-week regimen:~1. Fruquintinib: Three-week regimen of combined chemotherapy: 4mg/d, orally, once a day, taking the drug for 2 weeks and stopping the drug for 1 week, 3 weeks as a treatment cycle.~[2] Safety introduction period (N=6), fruquintinib combined 2-week regimen:~Fruquintinib: two-week combination chemotherapy regimen: 4mg/d, orally, once a day, taking the drug for 3 weeks and stopping the drug for 1 week, 4 weeks as a treatment cycle.~Dose expansion phase design(N=60) Cohort 1 (30 patients) : Fruquintinib combined with oxaliplatin. Cohort 2 (30 patients) : Fruquintinib combined with irinotecan ."
75714115|NCT05926687|Behavioral|Social Communication|Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour twice/week
75714116|NCT05926687|Behavioral|Disruptive Behavior|Intervention: Disruptive Behavior Who: Parent & Therapist only Frequency: 1-hour once/week
75714117|NCT05926687|Behavioral|Social Communication + Reduce Frequency|Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour once/week
75714118|NCT05926687|Behavioral|Social Communication + Add Tools|Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour twice/week
75714119|NCT05926687|Behavioral|Disruptive Behavior + Reduce Frequency|Intervention: Disruptive Behavior Who: Parent & Therapist only Frequency: 1-hour every other week
75714120|NCT05926687|Behavioral|Disruptive Behavior + Add Tools|Intervention: Disruptive Behavior Who: Parent & Therapist only Frequency: 1-hour once/week
75872633|NCT03461003|Other|NICHE method|Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.
75872634|NCT03461003|Other|Usual care|Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.
75872635|NCT03461003|Drug|Amlodipine|Calcium-channel blocker; antihypertensive
75872636|NCT03461003|Drug|Lisinopril|Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive
75872637|NCT03461003|Drug|Hydrochlorothiazide|Thiazide diuretic; antihypertensive
75872638|NCT03461003|Drug|Losartan|Angiotensin II receptor blocker (ARB); antihypertensive
75872639|NCT05177172|Other|High beta glucans|higher dose betaglucans
75411931|NCT00377598|Drug|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
75411932|NCT00377598|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
75872640|NCT05177172|Other|Low beta glucans|lower dose beta glucans
75872641|NCT05177172|Other|Low beta glucans + low polar lipids|low dose betaglucans in a combination with low dose of polar lipids
75872642|NCT05177172|Other|Polar lipids|low dose polar lipids
75872643|NCT05177172|Other|Control|No beta glucans or polar lipids
75411933|NCT00377598|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
75411934|NCT00377598|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
75411935|NCT00377910|Drug|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
75411936|NCT00377988|Drug|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
75411937|NCT00377988|Drug|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
75714121|NCT05924009|Procedure|Transcranial Magnetic Stimulation, TMS|"The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot."
75411938|NCT00378066|Drug|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
75411939|NCT00378144|Drug|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime [Paracetamol (500 mg) and Pseudoephedrine (30 mg)]
75411940|NCT00378222|Procedure|Autologous Stem Cell Transplantation|
75411941|NCT00378300|Drug|Oral Probiotics|
75411942|NCT00378456|Drug|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
75555296|NCT05492175|Other|kinetic exergaming|All of the participants in experimental and comparison groups will practice on the exergaming for 30 minutes per session. To avoid fatigue, the four domains of programs will be provided alternately. Each program will be executed for approximately 5 minutes with warm-up, followed by a 2-minute break between programs, and cool-down. The games will be selected and adapted according to the personal capacity, the occupational role, and the rehabilitation goal of each participant. The investigators will illustrate and guide the participants to play the games and stand next to them to prevent falls from occurring. To increase security, we will place a handrail in front of the participant for support as needed.
75411943|NCT00378456|Drug|Folinic acid|
75411944|NCT00378456|Drug|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
75411945|NCT00378456|Drug|Placebo|
75411946|NCT00378612|Device|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
75555297|NCT05492175|Other|conventional therapy|Participants in control group will receive 30 minutes of therapist-mediated conventional therapy per session. The training protocols of the conventional therapy will use occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their personal needs. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The content of the functional tasks will be decided together by participants and therapists, such as picking up and putting down items in a box, lifting two soft drink bottles, and so on.
75555298|NCT05491317|Biological|GEN1042|Intravenous
75555299|NCT05491317|Drug|Pembrolizumab|Intravenous
75555300|NCT05491317|Radiation|Radiotherapy|Radiotherapy
75555301|NCT05490771|Procedure|Biopsy|Undergo tumor biopsy
75555302|NCT05490771|Procedure|Computed Tomography|Undergo CT
75555303|NCT05490771|Drug|Copanlisib Hydrochloride|Given IV
75555304|NCT05490771|Procedure|Magnetic Resonance Imaging|Undergo MRI
75714122|NCT05922774|Device|Cervical VEMP testing|cervical vestibular evoked myogenic potentials
75872644|NCT03650348|Drug|PRS-343 in Combination with Atezolizumab|HER2/4-1BB Bispecific
75714123|NCT05919602|Other|Visualization of an image catalogue|Participants in the intervention group will be shown a catalog consisting of 8 images, each for 8 seconds, 25 minutes before entering the operating room. The images shown will be landscapes and/or objects of nature as an expression of neutrality, with light and soft colors, and will be chosen by over 50% of the research team from a gallery of 20 possible images that meet the aforementioned requirements.
76041221|NCT04854655|Other|Activa Presto|calcium and phosphate hybrid material
76041222|NCT04854655|Other|Giomer|fluoride releasing hybrid material
75555305|NCT05488314|Drug|Capmatinib|Capmatinib will be administered orally.
75555306|NCT05488314|Drug|Amivantamab|Amivantamab will be administered as IV infusion.
75555307|NCT05486169|Procedure|Sleeve Gastrectomy|surgery of laparoscopic sleeve gastrectomy
75411947|NCT00378690|Drug|leuprorelin acetate|LHRH antagonist
75411948|NCT00378768|Biological|anti-thymocyte globulin|
75411949|NCT00378846|Procedure|infrared thermography|
75411950|NCT00379158|Drug|Micronutrient supplements|
75411951|NCT00379314|Procedure|TVT and TVT-O minimally invasive surgical procedures|
75411952|NCT00379314|Procedure|Surgery for female stress urinary incontinence|
75411953|NCT00379392|Behavioral|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
75411954|NCT00379392|Procedure|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
75555308|NCT05486065|Drug|Semaglutide|Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
75555309|NCT05486065|Drug|Placebo|Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
75411955|NCT00379470|Device|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
75555310|NCT05483595|Drug|Chinese herbal medicine FYTF-919|Oral liquid 10ml
75411956|NCT00379548|Behavioral|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
75411957|NCT00379626|Drug|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
75411958|NCT00379782|Other|Navigation|Navigation and escourt
75411959|NCT00379860|Drug|LXR-623|
75555311|NCT05480514|Device|TEST LENS|etafilcon A with cosmetic pattern
75411960|NCT00380016|Procedure|Percutaneous Transluminal Angioplasty|
75411961|NCT00380172|Device|Rheopheresis blood filtration|
75411962|NCT00380328|Drug|neratinib|HKI-272
75411963|NCT00380406|Drug|Leuprolide acetate|
75555312|NCT05480514|Device|CONTROL LENS|Acuvue 1-Day Define Fresh Honey
75555313|NCT05478304|Device|AtriClip LAA Exclusion System|LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery
75555314|NCT05478252|Drug|Semaglutide J|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
75714124|NCT05919147|Drug|Pioglitazone 45 mg|The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.
75714125|NCT05919147|Drug|Placebo|Placebo will have the same appearance as the active drug.
75411964|NCT00380484|Drug|Budesonide|200µg daily
75411965|NCT00380484|Drug|Montelukast|5 mg daily
75555315|NCT05478252|Drug|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
75555316|NCT05476926|Drug|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
75555317|NCT05476926|Combination Product|Port Delivery System with Ranibizumab|The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
75555318|NCT05468242|Drug|Neoadjuvant chemo-immunotherapy|The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab [200 mg, once every 3 weeks (Q3W)].
75555319|NCT05468242|Drug|Bevacizumab|The Bevacizumab was administrated concurrently with neoadjuvant chemo-immunotherapy (7.5mg/kg) once every 3 weeks (Q3W).
75714126|NCT05919030|Radiation|Intensity-modulated radiotherapy (IMRT)|Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy
75555320|NCT05468242|Radiation|Radiotherapy|Hypofractionated radiation technique was used to deliver a definitive radiation dose to the thoracic lesions.
75714127|NCT05919030|Drug|Tislelizumab|200 mg IV Q3W
75714128|NCT05919030|Drug|Cisplatin|During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
75714129|NCT05919030|Drug|Nab paclitaxel|During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
75872645|NCT05761470|Drug|Camrelizumab|"Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle."
75872646|NCT05761470|Drug|Fluzoparib|Fluzoparib
75714130|NCT05917509|Drug|DTG/3TC|DTG/3TC FDC will be administered as an oral once daily tablet.
75872647|NCT05761470|Drug|Nab-paclitaxel|Nab-paclitaxel
75872648|NCT01372293|Drug|oral contraceptive pill|ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
75872649|NCT05205096|Biological|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (CoronaVac), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
75872650|NCT05759598|Other|Rehabilitation protocol + guided spontaneous breathing exercises|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
75411966|NCT00380562|Behavioral|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
75411967|NCT00380640|Drug|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
75411968|NCT00380640|Drug|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
75411969|NCT00380796|Drug|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
75411970|NCT00380952|Device|Dune Device|
75411971|NCT00381030|Drug|carvedilol plus nurse management|
75411972|NCT00381108|Drug|Placebo Tablet|Two tablets, twice daily.
75411973|NCT00381108|Drug|Pomegranate Tablet|Two tablets, twice daily.
75411974|NCT00381186|Behavioral|diet- and exercise intervention|
75411975|NCT00381264|Drug|Cesamet™ (nabilone)|
75411976|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
75411977|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
75411978|NCT00381342|Drug|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
75411979|NCT00381420|Device|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
75411980|NCT00381420|Device|bare-metal stent|un-coated Bx VELOCITY Stent
76041223|NCT03038737|Other|bre.flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
75411981|NCT00381576|Behavioral|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
75411982|NCT00381654|Drug|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
75411983|NCT00381732|Drug|tadalafil|2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
75411984|NCT00381732|Drug|placebo|Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
75411985|NCT00382044|Drug|Eprex; Neorecormon; Aranesp|
75411986|NCT00382278|Procedure|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
75555321|NCT05468242|Drug|Tislelizumab|Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.
75555322|NCT05467800|Drug|Canakinumab|Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
75555323|NCT05458856|Drug|Triptorelin embonate 22.5 mg|A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
75555324|NCT05455684|Drug|Aticaprant|Aticaprant will be administered orally as tablets.
75555325|NCT05455684|Other|Placebo|Placebo will be administered orally as tablets.
75555326|NCT05455541|Diagnostic Test|AI augmented POCUS examination|Internists will perform POCUS studies as they consider appropriate for patient management. Interpretation of the POCUS exams will be aided by machine learning based analysis of the videos.
75714131|NCT05917509|Drug|Cabotegravir (CAB) LA|CAB LA will be administered as an intramuscular injection once every 2 months in combination with RPV LA.
75714132|NCT05917509|Drug|Rilpivirine (RPV) LA|RPV LA will be administered as an intramuscular injection once every 2 months in combination with CAB LA.
75714133|NCT05902520|Biological|DP CD8 TIL|intravenous infusion of T cell suspension
75411987|NCT00382356|Drug|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
75411988|NCT00382434|Procedure|presence of an emergency pharmacist in the ED|
75411989|NCT00382512|Drug|Raptiva (efalizumab)|
75411990|NCT00382668|Drug|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
75411991|NCT00382668|Drug|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
75411992|NCT00382668|Drug|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
75411993|NCT00382746|Device|EarlySense monitoring device|
75411994|NCT00382902|Device|OptiFree Multi-Purpose Disinfecting Solution|
75411995|NCT00382980|Biological|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
75411996|NCT00382980|Biological|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
75411997|NCT00382980|Drug|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
75411998|NCT00383058|Drug|the extract of green tea|
75411999|NCT00383136|Drug|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
75412000|NCT00383136|Drug|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
75412001|NCT00383214|Drug|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
75412002|NCT00383214|Other|Placebo|Intravenous
75412003|NCT00383370|Drug|VEGF Trap|VEGF Trap formulation 1, ITV-1
75412004|NCT00383370|Biological|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
75412005|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
75412006|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
75872651|NCT05759598|Other|Rehabilitation protocol + specific respiratory muscle training program|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects
75412007|NCT00383682|Drug|morphine and mexiletine|
75412008|NCT00383838|Behavioral|brief, voluntary substance use intervention|
75412009|NCT00383916|Drug|pantoprazole|
75412010|NCT00383994|Drug|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
75412011|NCT00383994|Drug|Rituximab|375 mg/m^2 by vein followed by 1000 mg/m^2 weekly for 3 weeks for a total of 4 doses.
75412012|NCT00383994|Biological|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
75412013|NCT00384072|Drug|bazedoxifene BZA-20|
75412014|NCT00384228|Drug|Nilotinib|
75412015|NCT00384306|Drug|prednisolone|
75412016|NCT00384384|Drug|oral 18B Glycyrrhetinic acid versus placebo|
75412017|NCT00384540|Procedure|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
75412018|NCT00384618|Drug|pravastatin|
75412019|NCT00384618|Drug|vitamin E|
75412020|NCT00384696|Drug|Nicotine Replacement Therapy|4 Weeks of nicotine patch. Patch therapy for participants who smoke >10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
75412021|NCT00384696|Behavioral|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
75412022|NCT00385086|Drug|TNF blocker|Treatment with TNF-alpha blocker
75412023|NCT00385086|Drug|Placebo|Treatment with placebo
75412024|NCT00385164|Procedure|PET/CT scan for RT planning|
75412025|NCT00385242|Procedure|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
75412026|NCT00385242|Other|PET imaging|PET viability imaging
75412027|NCT00385320|Biological|HRV vaccine|
75412028|NCT00385398|Drug|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
75412029|NCT00385398|Drug|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
75412030|NCT00385398|Radiation|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
75872652|NCT02904902|Drug|adalimumab|Subcutaneous Injection
75412031|NCT00385476|Behavioral|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
75412032|NCT00385554|Drug|UC-781 carbomer gel, 0.1% and 0.25%|
75412033|NCT00385632|Drug|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
75412034|NCT00385710|Drug|valproic acid|Depakine
75412035|NCT00385710|Drug|Placebo|Placebo
75412036|NCT00385866|Behavioral|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
75412037|NCT00385866|Behavioral|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
75412038|NCT00386178|Drug|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
75412039|NCT00421590|Drug|SMC021|
75412040|NCT00421668|Drug|Zinc|zinc
75412041|NCT00421668|Drug|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
75412042|NCT00421668|Drug|Placebo|Placebo
75412043|NCT00421746|Drug|Piboserod|
75412044|NCT00421824|Drug|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
76041224|NCT03038737|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
76041225|NCT04854421|Device|VBC|Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
75555327|NCT05455320|Drug|Talquetamab|Talquetamab will be administered subcutaneously.
75714134|NCT05902520|Biological|DP CD8 TIL KD|intravenous infusion of T cell suspension
76041226|NCT04846153|Other|Human-based Quantification of Airway Stenosis|Human-based Quantification of Airway Stenosis From Bronchoscopic Images.
76041227|NCT04846153|Device|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
76041228|NCT04854577|Procedure|Opioid Free Anesthesia|Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
76041229|NCT04854577|Procedure|Traditional Anesthetic Regimen|Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
75412045|NCT00421824|Drug|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
75412046|NCT00421902|Procedure|Acupuncture|Patients will be have acupuncture (with electro stimulation)
75412047|NCT00421980|Drug|Etanercept|
75412048|NCT00422214|Drug|Quetiapine fumarate (Seroquel) SR|
75412049|NCT00422370|Device|lipid based additives based on vegetable oil & lecithin|
75412050|NCT00422526|Drug|Micronised progesterone (Utrogestan)|
75412051|NCT00422604|Drug|salmeterol|
75412052|NCT00422604|Drug|tiotropium|
75412053|NCT00422604|Drug|GSK233705|
75714135|NCT05902520|Biological|Low dose IL-2|Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
75714136|NCT05895201|Drug|Sitagliptin|600 or 400 (or MTD) mg PO every 12 hours on days -1 to +14 depending on dose level assignment.
76041230|NCT04846465|Other|Screening in picture archiving and communication system (PACS) .|Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.
75412054|NCT00422682|Drug|bsi-201 + topotecan|21 day cycle
75412055|NCT00422682|Drug|bsi-201 + temozolomide|28 day cycle
75412056|NCT00422682|Drug|bsi-201 + gemcitabine|28 day cycle
75412057|NCT00422682|Drug|bsi-201 + carboplatin/paclitaxel|21 day cycle
75412058|NCT00422838|Procedure|fine-needle aspiration biopsy|aspiration of intrahepatic cells
75412059|NCT00422916|Behavioral|behavioral intervention|
75412060|NCT00422994|Drug|ropinirole dosing for up to 28 days|
75555328|NCT05455320|Drug|Daratumumab|Daratumumab will be administered subcutaneously.
75555329|NCT05455320|Drug|Pomalidomide|Pomalidomide will be administered orally.
75555330|NCT05455320|Drug|Dexamethasone|Dexamethasone will be administered orally or intravenously.
75555331|NCT05454709|Drug|Dasiglucagon|Use of dasiglucagon in the AP system.
75555332|NCT05454709|Drug|GlucaGen|Use of GlucaGen in the AP system.
75555333|NCT05454189|Device|Reduced IPD Flush Schedule|IPD flush every 12 weeks
75555334|NCT05454189|Device|Standard IPD Flush Schedule|IPD flush every 4 weeks
75412061|NCT00423228|Drug|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
75555335|NCT05454176|Device|Libre 2|"The unblinded FreeStyle Libre 2 CGM will be placed every two weeks during months 0-12 for the CGM Cohort. Patients will be taught to insert the sensor themselves.~They will be given a 1 month supply at each monthly clinic visit and extra sensors in case a sensor falls out early. Patients will be given SMBG test strips to test capillary glucose for confirmation of any CGM glucose level <=60mg/dl. They will keep track of the number of times this is necessary. Patients will return used sensors at each clinic visit. The study team will upload the data to a study website. Patients and care providers will have access to unblinded sensor data for clinical use."
75555336|NCT05454176|Device|Device for SMBG and Libre Pro|"A glucose meter and sufficient teststrips for fingerpoke glucose monitoring 3x/day will be provided for months 1-6. This is standard-of-care in Uganda. Glucose meters will be downloaded monthly in clinic as per usual clinical practice.~DeviceBlinded CGM device: Libre Pro (blinded data collection device, not an intervention) The blinded FreeStyle Libre Pro CGM will be inserted at each monthly clinic visit to provide control data, months 0-6 for the Control Group. They will return all used sensors at each clinic visit. The study team will upload the data to a study website. Neither patients nor the local research teams will have access to the blinded sensor data for clinical use until the end of months 0-6 so as not to influence standard diabetes management. They will instead rely on SMBG values as per usual routine.~After the first 6 months they will receive Libre 2 CGM systems as described above for the intervention group."
75555337|NCT05453903|Drug|JNJ-75276617|Participants will receive JNJ-75276617.
75555338|NCT05453903|Drug|Venetoclax (VEN)|Participants will receive VEN.
75555339|NCT05453903|Drug|Azacitidine (AZA)|Participants will receive AZA.
75555340|NCT05453903|Drug|Cytarabine|Participants will receive cytarabine
75555341|NCT05453903|Drug|Daunorubicin or Idarubicin|Participants will receive daunorubicin or idarubicin
75555342|NCT05447650|Device|i-Lumen(TM) AMD|Transpalpebral microcrurrent stimulation
75555343|NCT05447650|Device|i-Lumen(TM) AMD Sham|Transpalpebral sham stimulation
75555344|NCT05444530|Biological|VAC85135|Participants will receive VAC85135 as IM injection.
75872653|NCT03650270|Drug|Phenobarbital|Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
75412062|NCT00423228|Drug|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
75412063|NCT00423306|Drug|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
75412064|NCT01799382|Other|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
75412065|NCT01799382|Device|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
75555345|NCT05444530|Drug|Ipilimumab|Participants will receive Ipilimumab as IV infusion.
75555346|NCT05441501|Drug|JNJ-80038114|JNJ-80038114 will be administered.
75714137|NCT05895201|Drug|Bortezomib|1.3 or 1.0 mg/m2 (or MTD) IV push 6 hours after graft infusion completion (day 0), and 72 hours thereafter depending on dose level assignment.
75714138|NCT05895201|Drug|Cyclophosphamide|50 mg/kg IV over 1 hour on days +3 and +4
75714139|NCT05891106|Device|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
75714140|NCT05887895|Drug|INS062 injection、INS068 injection、HR20014 injection|"INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects."
75872654|NCT03621722|Other|Elequil Aromatabs|There will be a variety of different Aromatabs such as orange/peppermint or lavender
75872655|NCT04425720|Device|LifeSignals Biosensor 1AX*|Shared-clinical decisions will be made based on the monitored data and patient diary. Two devices will be used to monitor data, LifeSignals Biosensor 1AX* and a pulse oximeter.
75872656|NCT04425720|Other|Standard of Care|This group will be treated based on standard of care at our institution.
76041231|NCT04846075|Behavioral|Ramadan fasting, praying, and welfare for poor|Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
76041232|NCT04860427|Device|trapezoidal condylar plate|trapezoidal condylar plate open reduction and fixation
76041233|NCT04860427|Device|two miniplates|two miniplates open reduction and fixation
76041234|NCT04839445|Procedure|General anesthesia + TAP block|Post induction TAP block for intra and postoperative analgesia.
76041235|NCT04839445|Procedure|General anesthesia + ESP block|Pre induction ESP block for intra and postoperative analgesia.
76041236|NCT04845607|Drug|Amiodarone Injection|Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
76041237|NCT04142515|Other|no intervention|no intervention
75412066|NCT01799616|Drug|Pamidronate|
75412067|NCT01799616|Other|Placebo|
75412068|NCT01799772|Behavioral|Comprehensive Behavioral Intervention|"Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.~Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.~Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.~Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c."
75412069|NCT01799772|Other|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
75412070|NCT01799850|Drug|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
75412071|NCT01799850|Drug|placebo|placebo assigned randomly, double blind
75412072|NCT01792050|Drug|Docetaxel|Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
75412073|NCT01792050|Other|Placebo|Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
75555347|NCT05438719|Device|MOTUS Total Joint Replacement|The MOTUS Total Joint Replacement is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level from L1/L2 to L5/S1 for skeletally mature patients due to symptomatic lumbar degeneration with or without foraminal or recess spinal stenosis confirmed by radiographic imaging (CT, MRI, X-rays), with no more than a Grade 1 spondylolisthesis at the involved level.
75555348|NCT05438043|Drug|Daratumumab|Daratumumab will be administered either intravenously or subcutaneously.
75555349|NCT05438043|Drug|Carfilzomib|Carfilzomib will be administered intravenously.
75555350|NCT05438043|Drug|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
75555351|NCT05438043|Drug|Lenalidomide|Lenalidomide will be administered orally.
75555352|NCT05438043|Drug|Pomalidomide|Pomalidomide will be administered orally.
76041238|NCT04845763|Other|FQoR-15 questionnaire|The FQoR-15 questionnaire (French version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. In the case of ambulatory surgery, the patient is contacted by telephone to answer the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
75555353|NCT05436249|Device|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~Overt finger tapping in time with a flashing cue.~Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
75555354|NCT05436249|Behavioral|At-home therapy|"Participants are assigned to groups where they will practice each day for 3 weeks at-home.~Group 1: Imagery only.~Group 2: Overt finger tapping only.~Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
75555355|NCT05435339|Biological|GEN1053|GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
75555356|NCT05431088|Drug|GBT021601|Tablets which contain GBT021601 drug substance
75555357|NCT05430477|Device|Electrical impedance imaging using Non-Significant Risk device (EII probe)|novel small field-of-view Non-Significant Risk device (EII probe)
75714141|NCT05880368|Other|Patient partnership tools|The intervention consists of two patient partnership tools: (1) a one-page 'visit prep guide' given to relevant patients by clinic staff before seeing the primary care provider, with the intention to improve communication and shared decision-making; and (2) a series of short educational videos that clinic staff can encourage patients to watch. The interventions will be included in the workflow of the clinics during the intervention periods (i.e., clinics either do not use the intervention or use them for all relevant patients depending on study period).
75714142|NCT05876494|Diagnostic Test|serum lactate|assessment of serum lactate and mean platelets volume
76041239|NCT04853797|Drug|Ivabradine|To investigate the role of ivabradine on levcromakalim-induced migraine in patients with migraine without aura.
76041240|NCT04853797|Drug|Calcium|To investigate the role of calcium on levcromakalim-induced migraine in patients with migraine without aura.
75555358|NCT05429892|Behavioral|Smoking cessation counseling and food delivery|"The community health workers will delivery five 30-minute sessions during intervention months 1 through 5 to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Smokers enrolled in the TRTsocialmot1 arm will be provided with monthly delivery of food boxes in accordance with the number of persons in the household and caloric intake needed to support one week's worth of family meals. Healthy meal preparation instructions will be included and delivery by project staff will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
75714143|NCT05873387|Device|Use of Eko DUO stethoscope (paired ECG/PCG)|Auscultation of heart sounds using electronic stethoscope
75714144|NCT05870956|Drug|Nintedanib|Nintedanib
75714145|NCT05870527|Device|Electrical stimulator|Electrical stimulation will be used to stimulate the Arnold's nerve and measure pupil dilation. The electrical stimulator is part of the standard facial nerve monitoring unit that we utilize in cochlear implantation and will be setup prior to surgery in standard fashion. The device allows for constant current stimulation, with stimulus range between 0-30 mA.
75872657|NCT03649568|Other|Pork|1 oz lean pork
75714146|NCT05870384|Behavioral|Group Interpersonal Psychotherapy|Ten sessions of IPT-G, which focuses on the common problem area of patient relatives, will be applied.
75714147|NCT05865535|Biological|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
75714148|NCT05848908|Other|Telehealth Visit|telemedicine visit and follow-up surveys
75714149|NCT05847348|Drug|68Ga-PSMA-11|A single dose of 111 - 259 MBq administered intravenously over 3 -5 minutes
75714150|NCT05847348|Other|PET/CT or PET/MRI|PET/CT or PET/MRI will be acquired no sooner than 50 minutes post injection and not later than 100 minutes post injection with 68Ga-PSMA-11
75872658|NCT03649568|Other|Egg|1 large whole egg
75872659|NCT03649568|Other|Black beans|0.5 cups cooked black beans
75872660|NCT03649568|Other|Almonds|1 oz almonds
75872661|NCT03629574|Procedure|Ventilation during cardiopulmonary bypass|Mechanical ventilation during cardiopulmonary bypass
76041241|NCT04845529|Device|transcranial direct current stimulation (tDCS)|We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.
75714151|NCT05843383|Drug|Ciprofol|Ciprofol group will be started and maintained total intravenous anesthesia with ciprofol and remifentanil
75714152|NCT05843383|Drug|Propofol|Propofol group will be started and maintained total intravenous anesthesia with propofol and remifentanil
76041242|NCT04845295|Other|resistance training|Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.
75412074|NCT01792050|Drug|Indoximod|Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
75555359|NCT05429892|Behavioral|Smoking cessation counseling|"The community health workers will delivery five 30-minute sessions during intervention months 1 through 5 to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Participants will receive educational materials."
75555360|NCT05429892|Behavioral|Food delivery|"Smokers enrolled in the TRTsocial2 arm will be provided with monthly delivery of food boxes in accordance with the number of persons in the household and caloric intake needed to support one week's worth of family meals. Healthy meal preparation instructions will be included and delivery by project staff will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
75555361|NCT05427162|Drug|Prostacyclin Receptor Agonist|Prostacyclin receptor agonist will be administered.
75555362|NCT05424822|Drug|JNJ-80948543|JNJ-80948543 will be administered as SC injection.
75555363|NCT05419856|Drug|4P-004|single intraarticular administration in the knee joint
75555364|NCT05419856|Drug|Placebo|single intraarticular administration in the knee joint
75555365|NCT05417165|Biological|Pneumococcal 20-valent Conjugate Vaccine|Given IM
75555366|NCT05417165|Biological|Pneumococcal Polyvalent Vaccine|Given IM
75555367|NCT05416333|Drug|azelaic acid|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months
75555368|NCT05416333|Other|usual medication for CCCA|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months
76041243|NCT04845373|Other|Mediterranean diet|Diet intervention:Mediterranean diet
75555369|NCT05411497|Biological|Autologous MUC1-activated T-cells|Given IV
75555370|NCT05411497|Drug|Cyclophosphamide|Given IV
75555371|NCT05407805|Other|Electronic Diary|Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
75714153|NCT05842668|Behavioral|ESWL Group|Increasing comfort and reducing pain during ESWL
75714154|NCT05836753|Drug|Sarecycline Tablet|Each tablet contained 100 mg of Sarecycline.
75714155|NCT05836753|Drug|Placebo tablets of Sarecycline tablets|Each tablet contained 0 mg of Sarecycline.
75412075|NCT01792050|Drug|Paclitaxel|Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
75412076|NCT01790256|Device|Cereve Sleep System at 30 degrees C|
75412077|NCT01790256|Device|Cereve Sleep System at 14-16 degrees C|
75412078|NCT01790100|Drug|VX-135|12 weeks of VX-135
75412079|NCT01790100|Drug|Ribavirin|12 weeks of ribavirin
75412080|NCT01791660|Device|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
75555372|NCT05403996|Behavioral|Activa-Mente|Active break program
75555373|NCT05403879|Procedure|fixation of greater tuberosity fractures|deltopectoral approach for shoulder, then open reduction and fixation of displaced greater tuberosity fractures using hooked Kirshner wires
75714156|NCT05831280|Behavioral|Laughter Yoga|"Warm-up exercises (5 minutes),~Deep breathing exercises (5 minutes),~Childlike playfulness (5 minutes),~Laughter exercises (15 minutes)."
75714157|NCT05830123|Drug|HS-20093|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
75714158|NCT05827211|Procedure|Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive systemic antibiotics
75714159|NCT05827211|Procedure|Non-Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive placebo
75714160|NCT05822063|Drug|Lidocaine topical|lidocaine spray
75714161|NCT05822063|Other|cold packs|ice packs
75714162|NCT05822063|Device|flash lights|flash lights by camera
75872662|NCT05204628|Drug|XZP-3621|XZP-3621 tablets will be administered orally at a dose of 500 mg QD until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
75872663|NCT05204628|Drug|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
75412081|NCT01793220|Other|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
75412082|NCT01797588|Procedure|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
75412083|NCT01797588|Procedure|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
76041244|NCT04845373|Other|Control diet: Low fat diet|Low fat diet
76041245|NCT03040531|Dietary Supplement|Genistein aglycone|27mg bid in tablets
75555374|NCT05400070|Drug|Neoadjuvant therapy 1|Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.
75555375|NCT05390177|Behavioral|Video type|One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
76041246|NCT03040531|Drug|Alendronate Oral Tablet|70 mg/week in tablets
76041247|NCT03040531|Dietary Supplement|Calcium + vitamin D3 tablet|500mg Calcium + 200 IU Vitamin D3 bid in tablets
75555376|NCT05388669|Drug|Lazertinib|Lazertinib tablets will be administered orally.
75555377|NCT05388669|Drug|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Amivantamab injection will be administered subcutaneously by manual injection
75714163|NCT05820503|Procedure|Ultrasound-guided lower abdominis rectus sheath block|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally
75714164|NCT05820503|Procedure|Local anesthesia infiltration|Local anesthesia drugs were injected into the peri-umbilicus cord
75714165|NCT05817097|Drug|Dipeptidyl peptidase-4 inhibitor|The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
75714166|NCT05815420|Device|Non invasive ventilation|Treatment by non invasive ventilation
75714167|NCT05814354|Drug|SHR-A1811|SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.
75714168|NCT05814354|Drug|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization).
76041248|NCT03040375|Behavioral|Peer counselling|
75555378|NCT05388669|Drug|Amivantamab Intravenous|Amivantamab will be administered by IV infusion
75555379|NCT05388058|Drug|Cannabidiol|Applied topically
76041249|NCT04839055|Drug|Coenzyme A Combined With Abiraterone|Abiraterone 4 pieces per day. Coenzyme A 200U
76041250|NCT04839055|Drug|Abiraterone|Abiraterone
76041251|NCT04838821|Biological|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
76041252|NCT04838821|Biological|placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
76041253|NCT04838665|Drug|0.5% cyclopentolate and 2.5% phenylephrine|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses
76041254|NCT04838665|Drug|0.5% tropicamide + 0.5% phenylephrine|Single instillation of 0.5% tropicamide + 0.5% phenylephrine
76041255|NCT04838665|Drug|0.5% tropicamide + 0.5% phenylephrine with a cotton wick|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
76041256|NCT03038659|Device|Penile Duplex|Measuring intima media thickness
76041257|NCT04845061|Drug|Nebivolol Tablets|cardio selective beta-1 blocker
76041258|NCT03040765|Drug|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
76041259|NCT03040765|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
75412084|NCT01799460|Drug|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|"①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily."
75555380|NCT05388058|Drug|Placebo Administration|Applied topically
75412085|NCT01799460|Drug|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
75412086|NCT02994966|Device|Surrosense|
75412087|NCT02994966|Other|Standard care|
76041260|NCT04853953|Other|Incidence of bleeding complications in ARDS patients on veno-venous ECMO|All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment
75412088|NCT02992080|Other|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
75412089|NCT02995434|Device|Virtual Reality Headset|"The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe_Lucem__Seize_The_Light_VR/"
75412090|NCT02995434|Other|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/"
75412091|NCT02999880|Procedure|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
75412092|NCT02999724|Drug|Gabapentin|Gabapentin 300-600 mg 1 hour preop
75555381|NCT05388058|Other|Quality-of-Life Assessment|Ancillary studies
75555382|NCT05388058|Other|Questionnaire Administration|Ancillary studies
75555383|NCT05379920|Behavioral|High Volume Aerobic Exercise|Aerobic exercise is completed for 30 minutes, 5 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
75555384|NCT05379920|Behavioral|Low Volume Aerobic Exercise|Aerobic exercise is completed for 20 minutes, 3 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
75555385|NCT05379595|Drug|Amivantamab|Amivantamab will be administered as intravenous infusion.
75555386|NCT05379595|Biological|Fluorouracil|Fluorouracil will be administered as intravenous infusion.
75555387|NCT05379595|Biological|Leucovorin|Leucovorin will be administered as intravenous infusion.
75555388|NCT05379595|Biological|Oxaliplatin|Oxaliplatin will be administered as intravenous infusion.
76041261|NCT01668667|Drug|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
76041262|NCT01668667|Drug|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
76041263|NCT01668667|Drug|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
76041264|NCT01668667|Drug|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
75412093|NCT02999724|Other|placebo|placebo capsule(s) 1 hour preop
75412094|NCT02999490|Radiation|18F-FDG|18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
75555389|NCT05379595|Biological|Irinotecan|Irinotecan will be administered as intravenous infusion.
75555390|NCT05379101|Diagnostic Test|Cardiac magnetic resonance image (CMR)|A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
75555391|NCT05379101|Diagnostic Test|Transthoracic Echocardiogram (TTE)|An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
75555392|NCT05379101|Diagnostic Test|Six-minute Walk Test|A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
76041265|NCT04852939|Other|Bowen's technique|"Initially, cup move is performed which requires a vertically rolling Bowen move over the posterior border of the deltoid muscle above the axillary crease.~The subject's arm is held flexed at 90 degrees at mid-chest height. Then, the elbow is slowly and passively moved in the direction of the opposite shoulder.~After maximal adduction of the arm, the therapist firmly taps the lateral aspect of the shoulder with the heel of his/her hand.~The arm is then carried back to the original start position, where the therapist gently moves superiorly and slightly laterally over the anterior fibers of the deltoid. The arm is then carefully lowered.~The therapist strives to undertake a minimum of moves and procedures to trigger the body's own self-healing powers and assess how much pressure to use and where and when to perform a move to release the build-up of stress.~40-minute sessions thrice a week for 6 weeks."
75412095|NCT02999568|Other|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
75412096|NCT02999256|Dietary Supplement|Montmorency Tart Cherry Juice|
75412097|NCT02999256|Other|Placebo|
76041266|NCT04852939|Other|Conventional physical therapy|"Hot pack and transcutaneous electrical nerve stimulator (TENS) for 15 minutes.~Pendulum stretch, 10 revolutions.~Cross body stretch, 4 repetitions.~Towel stretch/hand behind the back, 4 repetitions.~Isometric internal and external rotation exercises. 40-minute sessions thrice a week for 6 weeks."
75412098|NCT02999334|Behavioral|Group Antenatal Care|To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
75412099|NCT02998866|Procedure|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI [means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
75412100|NCT02998632|Procedure|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
75412101|NCT02998632|Procedure|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
75412102|NCT02998242|Drug|Apatinib|
75412103|NCT02998242|Radiation|SBRT to symptomatic bony metastatic bony site(s)|
76041267|NCT03040219|Drug|Folic Acid|Tablets
76041268|NCT03038503|Drug|Methylene Blue|after defined refractory shock (need NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
75412104|NCT02998398|Other|Switch from REMICADE® to INFLECTRA®|Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months
75412105|NCT02998320|Drug|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
75412106|NCT02998086|Behavioral|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
75412107|NCT02997696|Drug|ONO-4474|
75412108|NCT02997696|Drug|Placebo matching ONO-4474|
75412109|NCT02997852|Behavioral|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
76041269|NCT03038503|Drug|Terlipressin|after defined refractory shock (need NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
75555393|NCT05370911|Drug|Psilocybin|"The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms"
75555394|NCT05370287|Other|oxygen inhalation|Subjects will breath 100% oxygen through a mask.
76041270|NCT02608879|Procedure|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
75714169|NCT05812222|Behavioral|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
75714170|NCT05796674|Device|Clareon UVA IOL|Clareon UVA IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery to replace the natural crystalline lens. Models CC60WF and CCA0T0 are indicated for the visual correction of aphakia. Models CCW0T3, CCW0T4, CCW0T5, and CCW0T6 are indicated for the visual correction of aphakia and preexisting corneal astigmatism.
75714171|NCT05796674|Device|WaveTec Optiwave Refractive Analysis (ORA) System|Intra-operative system used during refractive cataract surgery to capture wavefront images of the patient's eye for the purpose of optimizing IOL implantation
75714172|NCT05796674|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon UVA IOL
76041271|NCT02608879|Procedure|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
76041272|NCT02608879|Procedure|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
76041273|NCT02608879|Other|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
75412110|NCT02997930|Behavioral|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
75555395|NCT05370287|Device|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
75555396|NCT05370105|Other|blood withdrawal|"10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies."
75714173|NCT05794659|Biological|AST-201|i.d. (3-week interval, 3 cycles in total)
75412111|NCT02997930|Behavioral|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
75714174|NCT05794659|Drug|Paclitaxel|3-week interval, 6 cycles in total
75872664|NCT05078190|Other|Social Determinants of Health|The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
75872665|NCT05285072|Radiation|PET-CT scan|PET-CT scan using 68Ga-DFO
75412112|NCT02997930|Behavioral|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
75412113|NCT02997930|Behavioral|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
75714175|NCT05794659|Drug|Carboplatin|3-week interval, 6 cycles in total
75714176|NCT05794659|Drug|Placebo|i.d. (3-week interval, 3 cycles in total)
75714177|NCT05794659|Drug|rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)|i.d. (3-week interval, 3 cycles in total)
75714178|NCT05793645|Device|personalized care plan|Algorithm that defines personalized care plan
75714179|NCT05785650|Diagnostic Test|osteopathic palpation|comparaison of ultrasound caracteristics of areas with ad without TP
75872666|NCT05204394|Drug|VM-1500A-LAI|Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
75872667|NCT05204394|Other|Standard of Care|Any oral 1st line approved HIV treatment regimen
75872668|NCT03650972|Other|Samarin|Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
75872669|NCT05065398|Drug|HLX208|450mg bid, take orally
75412114|NCT02997930|Behavioral|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
75412115|NCT02997930|Behavioral|General Depression Scale (GDS)|A measure of the of presence of depression.
75872670|NCT02904512|Device|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
75714180|NCT05784857|Other|Touch Methods|"The Yakson touch method continue for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In this method, the palms of the practitioner and all fingers keep in close contact so that the babies don't feel pressure.~Gentle human touch refers to steady contact of the skin without caressing or massaging. While the practitioner place one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was place on the lower abdomen covering the waist and hip of the infants."
75872671|NCT02904512|Other|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
75412116|NCT02997774|Other|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
75412117|NCT02997774|Other|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
75412118|NCT02997618|Behavioral|Community based exercise programme|20 week community (home or gym based) exercise programme
75412119|NCT02997618|Other|Control|Usual care consisting of advice.
75412120|NCT02997384|Other|Information|information of women about their risk of breast cancer and the screening methods recommended for them
75412121|NCT02997306|Procedure|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
75412122|NCT02997306|Procedure|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
75412123|NCT02996916|Drug|Olmesartan|10-40mg daily
75412124|NCT02996916|Drug|Amlodipine|2.5-10mg daily
75412125|NCT02997150|Drug|IL-2 Low dose|"Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection"
75872672|NCT05065008|Other|Cranberry juice|The responders and non-responders will drink 20-30 oz of (590-885 mL) 27% cranberry juice daily for 3 weeks.
75872673|NCT05065008|Other|Apple juice|The participants will drink apple juice with matching sugar content and calories for 3 weeks
75412126|NCT02996838|Drug|TQ-B3234|TQ-B3234 p.o. qd
75412127|NCT02996604|Other|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
75412128|NCT02996370|Other|papilla fill index|The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
75412129|NCT02996370|Other|crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
75412130|NCT02996370|Other|probing depth|The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
75412131|NCT02996370|Other|Modified sulcus bleeding index|Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
75412132|NCT02996370|Other|Modified plaque index|Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
75412133|NCT02996214|Drug|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
75412134|NCT02996214|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.
75412135|NCT02996214|Drug|Cisplatin|Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
75555397|NCT05367999|Diagnostic Test|initial Paroxysmal Event Profile|The initial Paroxysmal Event Profile (iPEP) was derived from the paroxysmal event profile (PEP) and paroxysmal event observer (PEO) to provide a diagnostic tool aiming to differentiate between the most common underlying reasons for TLOC presentations: syncope, epilepsy, and dissociative seizures. The iPEP is a 35-item questionnaire developed from the PEP and PEO.5,25 The 5-point frequency scales used in response to each symptom in the PEP and PEO have been replaced with a binary 'present'/'not present' classification in recognition of the fact that the target patient group may have experienced only one or a few episodes of TLOC.
75412136|NCT02996058|Drug|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
75412137|NCT02996058|Drug|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
75412138|NCT02996136|Device|Flu Symptoms|Flu Symptoms
75412139|NCT02995512|Drug|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
75412140|NCT02995590|Drug|Hyperpolarized He3|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
75412141|NCT02995278|Other|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
75412142|NCT02995200|Behavioral|Accelerometer Based Feedback|
75412143|NCT02995044|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-180)
75412144|NCT02995044|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75555398|NCT05357443|Procedure|Gastric bypass with transection of vagal nerves|Vagal nerve interruption above the level of the stomach is a known treatment for complicated peptic ulcer disease. It is not commonly performed during routine gastric bypass. The vagi are, however, interrupted part-way down the stomach to create the gastric pouch. This is the pars flaccida technique.
75872674|NCT03713333|Diagnostic Test|Digital Health Device Diagnostics|"Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.~Handheld imaging - focused echocardiographic examination (Butterfly IQ)~Smartphone iECG for cardiac rhythm assessments (Alivecor)~Blood Pressure (CloudDX)~Oxygen Saturation (CloudDX)~Weight (CloudDX)~Point-of-Care Genetic Testing (Phosphorous)"
75872675|NCT05031624|Drug|CDX-0159|Single subcutaneous dose of one of four dosages of CDX-0159
75872676|NCT05031624|Drug|Normal saline|Single subcutaneous dose of normal saline
75412145|NCT02995122|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z43-090)"
75412146|NCT02995122|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75412147|NCT02994888|Drug|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
75412148|NCT02994810|Other|Breastfeeding guidance|Breastfeeding guidance
75412149|NCT02994342|Device|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
75412150|NCT02994186|Procedure|Bariatric Surgery|These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
75412151|NCT02994186|Other|Medical Weight Loss Program|These are patients who will be starting a structured medical weight loss program.
75872677|NCT03650738|Drug|Apatinib|Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
75412152|NCT02993952|Device|Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
75412153|NCT02993952|Device|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
75412154|NCT02994264|Radiation|adjuvant concurrent chemoradiation|
76041274|NCT04852549|Other|Oculomotor exercise|"While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions."
76041275|NCT04852705|Biological|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
76041276|NCT04852705|Biological|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
75872678|NCT04053530|Other|restorative materials|glass ionomer and bulk fill flowable composite
75872679|NCT02904200|Device|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
76041277|NCT03040297|Device|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
75412155|NCT02993874|Dietary Supplement|Creatine|The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
76041278|NCT03040297|Device|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
75412156|NCT02993874|Dietary Supplement|Placebo|The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
76041279|NCT03040297|Device|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
75412157|NCT02993718|Drug|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
75412158|NCT02993718|Drug|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
76041280|NCT04852315|Dietary Supplement|Caffeine|Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
75555399|NCT05357443|Procedure|Gastric bypass without transection of vagal nerves|Dissection between the neurovascular bundle and the stomach, spareing the vagus nerves. This is the perigastric technique.
75412159|NCT02993640|Drug|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
75412160|NCT02993562|Drug|Levothyroxine|Normal treatment with levothyroxine.
75412161|NCT02993484|Drug|Dimethyl Malonate|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
75555400|NCT05356403|Drug|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
75555401|NCT05356403|Drug|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
75555402|NCT05355415|Device|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
76041281|NCT04852315|Dietary Supplement|Placebo|Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
76041282|NCT03038425|Drug|Normal Saline|This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
76041283|NCT03038425|Drug|Ropivacaine|This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
75555403|NCT05351385|Procedure|Hematolgy and Chemistry analysis|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
75555404|NCT05351385|Procedure|Real Time PCR|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
75872680|NCT02904200|Device|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
75872681|NCT03432533|Drug|romosozumab HCP administration with PFS|210 mg romosozumab SC QM by HCP administration with 2 PFS
75872682|NCT03432533|Device|romosozumab self-administration with AI/Pen|210 mg romosozumab SC QM by self-administration with 2 AI/Pens
75412162|NCT02993484|Biological|Ischemic preconditioning|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
75555405|NCT05351385|Procedure|PROS assay COVID+|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
75412163|NCT02993484|Other|Ischemia reperfusion|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
75555406|NCT05351385|Procedure|Sflt1 assay COVID+|Samples will be collected at Day 0 and Day 10
75555407|NCT05351385|Procedure|PROS assay CONTROL|Samples will be collected at Day 0 (+5)
75555408|NCT05351385|Procedure|Sflt1 assay CONTROL|Samples will be collected at Day 0 (+5)
75555409|NCT05347095|Drug|Guselkumab|Guselkumab will be administered subcutaneously/IV infusion.
75555410|NCT05347095|Drug|Placebo|Matching placebo will be administered subcutaneously/IV infusion.
76041284|NCT03038191|Device|Neuroelectrics Enobio 8(R)|Monitoring
75412164|NCT02993484|Other|Sham|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
75412165|NCT02993328|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
75412166|NCT02993328|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
75412167|NCT02993094|Drug|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
75555411|NCT05344339|Procedure|Distal gastrectomy|Reconstruction after Distal Gastrectomy
75555412|NCT05342623|Drug|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
75555413|NCT05342623|Drug|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
75555414|NCT05338775|Drug|Talquetamab|Talquetamab will be administered as a subcutaneous (SC) injection.
75555415|NCT05338775|Drug|Teclistamab|Teclistamab will be administered as a SC injection.
75555416|NCT05338775|Drug|PD-1 Inhibitor|The PD-1 inhibitor will be administered as an intravenous injection.
75555417|NCT05336565|Other|Electronic medical record analysis|"Medical information system (MIS) BARS will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. Incidence rates and patterns of PIM prescription, polypharmacy, and PDDIs in the time of COVID-19 pandemic will be studied."
75555418|NCT05335733|Diagnostic Test|Intraoral examination, saliva, dental plaque and serum collection.|"Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit."
75714181|NCT05775133|Device|ICG|"Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting."
75714182|NCT05771584|Drug|AST-301|100 μg
75714183|NCT05771584|Drug|rhuGM-CSF|100 μg
75714184|NCT05761041|Drug|Sodium Fluoride Varnish (5%)|Applied at baseline
76041285|NCT04844047|Other|Exercise|refer to arm descriptors
76041286|NCT04844047|Other|Exercise|refer to arm descriptors
76041287|NCT04843969|Behavioral|Stress induction|Exposure to a psychosocial stressor
76041288|NCT04843969|Behavioral|Control stress exposure|Exposure to a control task (no stress)
76041289|NCT04843969|Behavioral|Cue induction|Exposure to a smoking-related task
76041290|NCT04843969|Behavioral|Neutral cue exposure|Exposure to neutral cues
75555419|NCT05328622|Behavioral|Aqueduct Contingency Management Platform|"All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care."
75555420|NCT05328297|Drug|JNJ-55308942|JNJ-55308942 capsules will be administered orally.
75555421|NCT05328297|Drug|Placebo|Matching placebo capsules will be administered orally.
75555422|NCT05327816|Biological|RSV preF-based Vaccine|RSV preF-based vaccine will be administered as intramuscular injection.
75555423|NCT05327816|Drug|Placebo|Placebo will be administered as intramuscular injection.
75555424|NCT05327114|Drug|Nipocalimab|Nipocalimab will be administered intravenously.
75412168|NCT02993094|Drug|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
75412169|NCT02993016|Procedure|patient-specific instruments|
75412170|NCT02993016|Device|The Signature™ Vanguard|
76041291|NCT04851769|Drug|PCSK9 inhibitor plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
75872683|NCT03621800|Other|Menthol popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
75555425|NCT05327114|Drug|Placebo|Placebo will be administered intravenously.
75872684|NCT05285462|Behavioral|VR Pain Education|pain education delivered via VR headset, up to 12 sessions
75555426|NCT05318937|Drug|SAGE-718|Softgel capsules
75555427|NCT05318937|Drug|SAGE-718-matching placebo|Softgel capsules
75555428|NCT05316311|Device|CERENOVUS ENTERPRISE 2 Intracranial Stent|CERENOVUS ENTERPRISE 2 Intracranial Stent will be used to treat severe symptomatic intracranial artery stenosis.
75555429|NCT05316155|Drug|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
75555430|NCT05315973|Device|Testing sensor vs glucometer|Will test accuracy of this sensor; there will be no intervention.
75555431|NCT05313334|Behavioral|GAMBIT Task|The GAMBIT task is a novel inhibitory control task. Participants in the Healthy Control group will receive the GAMBIT intervention repeatedly over the study period.
75555432|NCT05306288|Other|Blood Sample Collection|Subjects enrolled in DELFI-L201 will have blood specimens collected (~30 mL) at enrollment or up to 30 days from enrollment.
76041292|NCT04851769|Drug|standard statin therapy|Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
76041293|NCT04851769|Procedure|Coronary imaging follow-up|coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
76041294|NCT04843813|Dietary Supplement|Lutein|Participants will consume daily soft gels containing the lutein supplement.
76041295|NCT04843813|Dietary Supplement|Placebo|Participants will consume daily soft gels containing the safflower oil.
75714185|NCT05761041|Behavioral|Motivational Interviewing|Two MI sessions: face-to-face at baseline and phone call at 3 months
75714186|NCT05761041|Drug|SDF|Applied bianually
76041296|NCT04843189|Procedure|Da Vinci Robotic Surgery|Da Vinci Robotic Surgery
76041297|NCT04843267|Drug|Tislelizumab|Tislelizumab in first-line treatment of Hodgkin's lymphoma
76041298|NCT04843657|Behavioral|Observation for symptom distress|Observation for symptom distress
76041299|NCT04838899|Radiation|Stereotactic Body Radiation Therapy (SABR)|SABR to oligoprogressive metastases while continuing abiraterone therapy
75412171|NCT02993016|Procedure|conventional instruments|
75412172|NCT02993016|Device|Vanguard PS(posterior stabilized)|
75555433|NCT05299606|Device|Transbronchial Microwave Ablation|Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
75714187|NCT05760339|Behavioral|Time-restricted feeding|Subjects in the will be instructed to follow a TRF regimen consisting of a daily 8h ad libitum eating period and 16h water fasting period during the last 2 weeks before surgery. Participants will be encouraged to begin their eating period at 08:00h and end it at 16:00h, since the metabolic benefits of TRF appear to be considerably more pronounced when the eating period starts early in the day.
75872685|NCT05285462|Behavioral|Usual Care Physical Therapy|Normal course of PT without influence by study team on frequency or duration
75872686|NCT03649334|Drug|ketamine-ketorolac|The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
76041300|NCT03037957|Device|ARIES Group A Strep Assay|
76041301|NCT04852081|Drug|Palbociclib|Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
76041302|NCT04852081|Drug|Ribociclib|Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
76041303|NCT04852081|Drug|Abemaciclib|Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
75555434|NCT05295940|Drug|LY3841136|Administered SC.
75555435|NCT05295940|Drug|Placebo|Administered SC.
75555436|NCT05294302|Behavioral|eSCCIP/eSCCIP-SP|eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.
75555437|NCT05294302|Behavioral|Coping Space|Coping Space is a psychosocial informational website for PCCC.
75555438|NCT05293639|Device|Pulse Field Ablation|PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
75714188|NCT05760339|Dietary Supplement|Carbohydrate loading|Subjects will continue their usual diet and will receive two quantities of a clear beverage containing 12.5 g/100 mL maltodextrin (50 kCal/100 mL, pH 5.0); 800 mL at 22.00h on the evening before surgery and 400 mL two hours before anaesthesia induction.
76041304|NCT04852081|Drug|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
75412173|NCT02992860|Drug|JNJ-56022473|JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by > 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
75714189|NCT05756946|Procedure|periodontal dressing (coe-pak)|Guided tissue regeneration and periodontal dressing
75714190|NCT05756946|Procedure|Guided Tissue Regeneration|Regeneration of lost periodontal tissues
76041305|NCT04852081|Drug|Anastrozole|Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
76041306|NCT04852081|Drug|Tamoxifen|Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
76041307|NCT04852081|Drug|Fulvestrant|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
76041308|NCT04852081|Drug|Exemestane|Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
76041309|NCT04852081|Drug|Alpelisib|Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
76041310|NCT04851067|Other|Dry Needling and Therapeutic Exercises (DNTEx)|Already included in arm/group descriptions.
75412174|NCT02992860|Procedure|Bone marrow analyses and CBC with differential|Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
75555439|NCT05280093|Device|AtriCure ISOLATOR Synergy Surgical Ablation System|Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
75714191|NCT05753436|Dietary Supplement|Puritans Pride Turmeric curcumin® 500 mg|Turmeric curcumin 500 mg per oral capsule of Puritans Pride company supplement composed of Turmeric (curcuma longa) root 450mg and Turmeric extract (curcuma longa root 50mg ) standardized to contain 95%curcuminoids.It is added because of its possibility to reduce the risk of ASCVD by lowering blood pressure, lipid profile, blood glucose, inflammation, and oxidative stress.
75714192|NCT05751590|Device|comined use of gliddescope and fiberoptic broncscopy|endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
75714193|NCT05751590|Device|fiberoptic bronscopy|endotrachotreal intubation will be done by Fiberoptic broncscopy
75714194|NCT05750966|Drug|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)|The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
76041311|NCT04851067|Other|Manual Therapy and Therapeutic Exercises (MTTEx)|Already included in arm/group descriptions.
76041312|NCT04838509|Other|no intervention|retrospective descriptive without intervention
76041313|NCT04843033|Drug|SH3809 tablet|Starting dose 2mg,oral administered once daily. If tolerated subsequent cohorts will test increasing doses (4mg,6mg,8mg,10mg,12mg) of SH3809.
76041314|NCT02608099|Drug|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
76041315|NCT02608099|Drug|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
75555440|NCT05279118|Dietary Supplement|Ketogenic diet|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
75412175|NCT02992860|Other|Flow cytometry analyses|Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
75555441|NCT05279118|Drug|ACTH|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
75555442|NCT05272852|Device|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
75555443|NCT05272618|Diagnostic Test|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
75714195|NCT05750966|Drug|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)|The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
75714197|NCT05737901|Other|Education Booklet|"Training titles and contents were created by listing the most common complications and needs of patients after CABG surgery. In the General Information section of the booklet, the definition of CAD, how CABG surgery is performed, the length of hospital stay, and what can be experienced in the hospital after surgery and in the home environment after discharge were discussed. In the Postoperative Self-Care Practices section, information about the healing process of the breastbone, pain management, medication, respiratory exercises, early nutrition, personal hygiene, protection from coronavirus-19, pulse control, postoperative heart attack, conditions to be reported, compression stockings use for varicose veins, physical activity, travel, sleep and rest, sexual life, and coping with stress and depression was presented. In the Postoperative Life section, training topics on exercise, nutrition, smoking, and alcohol use were included."
75714198|NCT05737901|Other|Mobile application|"The logo and content of the Bypass e-Discharge application was visually designed, and the software was developed. In-app transactions were secured with end-to-end encryption by entering the username and password, and internet access was not required to use the application. The application was presented for expert opinion (3 patients, 1 academician, 2 nurses, 2 physicians) in order to investigate the user experience, and edits were made on its interface (such as adding the acceleration feature in videos, an additional button for stopping and starting videos, displaying video total time on the screen, and magnification of all buttons)."
75872687|NCT03649334|Drug|fentanyl- ketorolac|The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
76041316|NCT04842877|Drug|Valemetostat tosylate|200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
76041317|NCT04842565|Drug|Sintilimab|Sintilimab (200mg ivdrip D1 Q3W)
75412176|NCT02992860|Other|Central biobanking|Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
75412177|NCT02992860|Procedure|Histopathology analysis|A bone marrow biopsy is taken whenever it seems necessary to the investigator.
75412178|NCT02992860|Genetic|Cytogenetic analysis|The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
75412179|NCT02992860|Procedure|Serum chemistry|For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
75412180|NCT02992860|Procedure|Automated CBC|For CBC a minimum of 3 ml of peripheral blood have to be collected.
76041318|NCT04842565|Device|TACE|TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.
75555444|NCT05272150|Drug|Guselkumab|Participants will receive guselkumab as subcutaneous injection.
75555445|NCT05272150|Drug|Placebo|Participants will receive placebo as subcutaneous injection.
75555446|NCT05271513|Device|non invasive repetitive magnetic stimulation (real Transcranial + real trans-spinal )|repetitive transcranial magnetic stimulation and trans-spinal magnetic stimulation
75412181|NCT02992860|Procedure|Pregnancy Test|Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
75412182|NCT02992938|Drug|Acetazolamide|
75412183|NCT02992938|Drug|Placebo Oral Tablet|
75412184|NCT02992704|Drug|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
75412185|NCT02992470|Dietary Supplement|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
75555447|NCT05271513|Device|non invasive repetitive magnetic stimulation (real Transcranial + sham trans-spinal )sham trans-spinal magnetic stimulation|sham trans-spinal magnetic stimulation
75555448|NCT05269004|Drug|Ocrelizumab|Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
75555449|NCT05268679|Other|Biospecimen Collection|A blood of a sample of 2 x 7 mL will be collected for the analysis of the anti-SARS-CoV-2 T-cell response during a scheduled check-up as part of their routine follow-up
75555450|NCT05268679|Other|Questionnaire|Patients who have received SARS-CoV-2 vaccination will be asked to complete the Vaccine tolerance questionnaire
75555451|NCT05268679|Other|Electronic Health Record Review|For heart transplant recipients who were offered vaccination against SARS-CoV-2 medical records will be reviewed retrospectively.
75555452|NCT05265273|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
75555453|NCT05263804|Other|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection|No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
75555454|NCT05263804|Other|Cardiac MRI with gadolinium injection - Ancillary Study|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
75412186|NCT02992470|Dietary Supplement|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
75412187|NCT02992548|Drug|Pravastatin|
75412188|NCT02992626|Other|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
75555455|NCT05259033|Drug|IcoSema|"IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month."
75555456|NCT05259033|Drug|Semaglutide 1 mg|Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.
75555457|NCT05257759|Other|Usual care|Standard management offered in the intensive care unit
75555458|NCT05257759|Other|Electrostimulation|The patients included will receive throughout their stay, in addition to the standard care offered in the department, electrical nerve stimulation. The ES will be applied to the tibial nerve to allow contraction of the plantar flexors. The protocol will be applied twice a day, 5-7 days a week and will have the following characteristics: stimulation frequency 100Hz, pulse width 1ms, intensity allowing the development of 5-10% of the maximum tetanic force obtained during the force-frequency relation, contraction time 20s, recovery time 20s, for a total of 25 contractions per session.
75555459|NCT05257759|Other|Evaluation of the neuromuscular system|"Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition."
75555460|NCT05253053|Drug|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
75555461|NCT05253053|Drug|Combination Product: Atezolizumab|Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
75555462|NCT05253053|Drug|Combination Product: Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
75555463|NCT05252533|Drug|Ustekinumab|This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
75714199|NCT05730374|Behavioral|Benson's Relaxation technique|Each child in the study group had an individual interview with researchers, who demonstrated the Benson relaxation technique while teaching them. The child was then asked to demonstrate it. sit quietly in a comfortable position in separate room., close eyes, deeply relax all muscles, beginning at the feet and progressing up to the face and breathe through nose. Become aware of breathing pattern. As breathes out, say the word one silently to child. For example, breathe in, and then out, say one, in and out, and repeat one. Breathe easily and naturally. It is Continue for 10 minutes and repeated two times.
75412189|NCT02992626|Other|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
75412190|NCT02992392|Drug|Liposic|one eye of the participant recieved Lipoic
75714200|NCT05730374|Behavioral|Music therapy|"The child lessen to a Mozart's music, which is played before and throughout the blood transfusion procedure. Ambient noise can be reduced by using headphones. As a result, it is easier to see how the intervention has succeeded.~This intervention was done using an MP3 player during the blood transfusion procedure and immediately following the completion of the intervention to prevent the transmission of infections headphones were cleaned with disinfectant after each -use."
76041319|NCT04850755|Drug|Selinexor in combination with nivolumab and ipilimumab|Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity
75412191|NCT02992392|Drug|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
75412192|NCT02992314|Device|Metaqil™ Oral Rinse|Metaqil™ is a proprietary formulation of GRAS ingradients
75412193|NCT02992314|Device|Placebo|Placebo formulation with out the active ingredients
75412194|NCT02992002|Other|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
75412195|NCT02992158|Behavioral|behavioral activation|
75412196|NCT02992158|Behavioral|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
75412197|NCT02991768|Drug|Entocort|A corticosteroid that decreases levels of inflammatory cytokines.
75412198|NCT02991768|Drug|Placebos|Placebo is matched to the study drug.
75412199|NCT02991612|Drug|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
75412200|NCT02991534|Behavioral|CV Toolkit Components|"Patient completes a CV self screener.~Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
76041320|NCT03038035|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
76041321|NCT03038035|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
76041322|NCT03037801|Device|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
76041323|NCT04850131|Procedure|Desarda repair|Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
76041324|NCT04842487|Drug|R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)|Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
76041325|NCT03040063|Procedure|Combined endovascular approach (EVAR)|"puncture of SFA in orthograde position if possible~DSA through 4F dilator, proof of occlusion~wire test~Heparin 70-80 IU/kg i.a.~implantation of peripheral stent graft VIABAHN~implantation of peripheral stent SUPERA into stent graft~insertion of strait flush catheter for local thrombolysis~administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~control angiography in 12 hrs or earlier according to clinical status and symptoms~repeated angiography in 24 hrs"
75412201|NCT02991378|Behavioral|Children's emotional and stress coping program|Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
75714201|NCT05725096|Diagnostic Test|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
75412202|NCT02991222|Drug|SPARC001 type I|Treatment type I
75412203|NCT02991222|Drug|SPARC001 type II|Treatment type II
75412204|NCT02991222|Drug|Reference001 type I|Hydrocodone-Acetaminophen
75412205|NCT02991222|Drug|Reference001 type II|Hydrocodone-Acetaminophen
75412206|NCT02990832|Device|Exciton|"Exsalt® Wound Dressings will be applied by the physician/nursing staff.~The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.~Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.~Maximum treatment course will be 28 days (end of study) or until wound closure."
75412207|NCT02990754|Behavioral|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
75412208|NCT02990676|Behavioral|Computerised cognitive training|Computerised cognitive training regime
75555464|NCT05252312|Behavioral|Psycho-acoustic tests|"Listeners' cognitive and biological responses to vocal stimuli will be tested using psycho-acoustic tests. After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?).~These stimuli might be human voices, animal voices or synthetic voices Physiological measures will be simultaneously taken using an array of complimentary, non-invasive techniques such as the Nociception Level (NOL) Index or video pupillometry"
75555465|NCT05250973|Drug|Daratumumab|Daratumumab will be administered subcutaneously.
75555466|NCT05250973|Drug|Cyclophosphamide|Cyclophosphamide will be administered either orally or IV.
75412209|NCT02990442|Device|rTMS|repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R_DLPFC)
75412210|NCT02990286|Drug|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
75412211|NCT02990286|Drug|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
75412212|NCT02990286|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
75412213|NCT02990208|Behavioral|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens & Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
75412214|NCT02990208|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger & Pauli, 2011)
75555467|NCT05250973|Drug|Bortezomib|Bortezomib will be administered by SC injection.
75555468|NCT05250973|Drug|Dexamethasone|Dexamethasone will be administered orally or IV.
75412215|NCT02990052|Procedure|Volar plating|Open reduction and volar fixed-angle plate fixation of distal radius fracture
75555469|NCT05248516|Dietary Supplement|Simplified dose of ready-to-use therapeutic food (RUTF)|"In the simplified arm all children receive the same dose: 1 sachet of RUTF/day. This until discharge from treatment.~Recovery from treatment will be defined as WAZ>= -3 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
75714202|NCT05725096|Other|No Intervention|Chinese guidelines for lipid management (2023)
75714203|NCT05722587|Other|Pain science education|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
75714204|NCT05721274|Behavioral|Community mobilization and Conditional community incentives|Non-cash, incentives would be given to clusters which improve the polio vaccine coverage and reduce the refusals and these incentives would be decided with consensus by community and costs would be shared
75872688|NCT02901548|Drug|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
75412216|NCT02990052|Procedure|Conservative treatment|Closed reduction & casting of distal radius fracture
75412217|NCT02991300|Device|BioPoly RS Partial Resurfacing Patella Implant|
75412218|NCT02999958|Biological|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
75412219|NCT02995746|Drug|Dexamethasone|"On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant~Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant~Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan~Anticipated duration of the study: 6 months"
75412220|NCT02990364|Drug|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
75555470|NCT05248516|Dietary Supplement|Standard dose of ready-to-use therapeutic food (RUTF)|"In the standard arm, children will receive different doses of RUTF depending on their WHZ category and weight.~children with a WHZ<-3 will receive the equivalent of 200kcal/kg/d of RUTF until discharge.~children with a WHZ between -3 and -2 will receive 1 sachet (500kcal) of RUTF per day until discharge.~children with a WHZ>=-2 will receive no nutritional treatment.~Recovery from treatment will be defined as WHZ>= -2 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
75555471|NCT05248516|Dietary Supplement|No nutritional treatment|no nutritional treatment will be provided to children in the control arm.
75555472|NCT05242484|Biological|Guselkumab|Guselkumab will be administered as subcutaneous injection.
75412221|NCT02990364|Drug|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
75555473|NCT05242484|Biological|Golimumab|Golimumab will be administered as subcutaneous injection.
75555474|NCT05242484|Biological|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
75555475|NCT05242484|Drug|Placebo|Placebo will be administered as subcutaneous injection.
75555476|NCT05242471|Biological|Guselkumab|Guselkumab will be administered as subcutaneous injection.
75555477|NCT05242471|Biological|Golimumab|Golimumab will be administered as subcutaneous injection.
75555478|NCT05242471|Biological|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
75412222|NCT02990364|Drug|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
75412223|NCT01270074|Drug|Azithromycin|azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
75412224|NCT01270074|Drug|Placebo control|inert liquid preparation will be given three times per week from three months of age to three years of age
75555479|NCT05242471|Drug|Placebo|Placebo will be administered as subcutaneous injection.
75555480|NCT05236673|Drug|JARDIANCE®|JARDIANCE® film-coated tablets 10mg
75555481|NCT05231278|Device|nCLE aided RANB biospy|nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.
75555482|NCT05230589|Drug|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75555483|NCT05227027|Behavioral|Game Module|Receive access to the the game module through the free, 'Smoke Free' smartphone application
75714205|NCT05713370|Dietary Supplement|high fat meal|A high fat meal (milkshake) will be administered on the morning after the intervention of no exercise and no SR the night before.
75714206|NCT05711953|Other|Egyfil Pain Lotion|"Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1.~The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product."
75714207|NCT05709964|Other|Self-reported|Self-reported height, weight, and neck circumference
75714208|NCT05709964|Other|Measured|Height, weight, and neck circumference measured by the investigator.
76041326|NCT03040063|Procedure|Standard optimal therapy (OPT)|"puncture of SFA in orthograde position if possible~DSA through 4F dilator, proof of occlusion~wire test~Unfractionated heparin 70-80 IU/kg i.a.~insertion of strait flush catheter for local thrombolysis~administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~control angiography in 12 hrs or according to clinical status and symptoms~repeated angiography in24 hrs~Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
76041327|NCT04841941|Device|G4 Multifocal soft contact lens with a 54% water content for presbyopia|"The participants must agree to wear lenses from a trial set with the fit assessed according to the Fitting Guide. Prescription lenses will then be ordered from the manufacturer."
75412225|NCT01270230|Behavioral|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
75555484|NCT05227027|Behavioral|Smoke Free smartphone application|Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
75555485|NCT05221294|Drug|Modified Del Nido Versus Custodiol Cardioplegia|Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
75714209|NCT05709769|Other|There are no interventions.|There are no interventions.
75714210|NCT05703542|Drug|BXCL701|Tablet, taken Orally
75714211|NCT05701293|Procedure|Endovascular implantation of Renzan Stent|Endovascular treatment of LEAD patients with Renzan Stent
75714212|NCT05697757|Other|Dynamic Lighting|This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.
75714213|NCT05697757|Other|Placebo Lighting|We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
75714214|NCT05688397|Dietary Supplement|Experimental 1|L. gasseri oral capsule once a day (1 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over
75714215|NCT05688397|Dietary Supplement|Experimental 2|L. gasseri and L. crispatus oral capsule once a day (1.5 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over
76041328|NCT04841863|Device|MyPlan digital health platform|Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
76041329|NCT04841863|Other|Satndard care|Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
76041330|NCT04833673|Behavioral|PMR: Progressive Muscle Relaxation|tensing and relaxing the body muscles accompanied with deep breathing
76041331|NCT04833673|Behavioral|BRT:Benson Relaxation Technique|relaxation using mental imagery and mediation
75714216|NCT05688397|Dietary Supplement|Placebo|One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
75714217|NCT05683327|Dietary Supplement|UltraHA® 75 mg/capsule|Take 2 capsules per day at any time.
75714218|NCT05683327|Dietary Supplement|UltraHA® 40 mg/capsule|Take 2 capsules per day at any time.
75714219|NCT05683327|Dietary Supplement|Placebo|Take 2 capsules per day at any time.
76041332|NCT04837885|Procedure|Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection|Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
75412226|NCT01270230|Behavioral|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
75412227|NCT01270308|Drug|Lansoprazole|Lansoprazole DR Capsules 30 mg
75412228|NCT01270386|Drug|apatinib|Apatinib 750 mg p.o. once daily
75412229|NCT01270386|Drug|placebo|placebo p.o. once daily
75412230|NCT01270698|Drug|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
75714220|NCT05679921|Drug|pembrolizumab, pazopanib|Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.
75714221|NCT05675878|Behavioral|Dietary Intervention|This is a whole food, nutrient-dense diet that aims to remove exposure to specific food additives thought to have negative neurological effects, while also optimizing micronutrient intake.
75872689|NCT02901548|Procedure|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
75412231|NCT01270854|Other|Plasmalyte A|Intravenous fluid
75412232|NCT01270854|Other|Normal Saline|Intravenous fluid
75412233|NCT01270932|Drug|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
75412234|NCT01271088|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
75412235|NCT01271166|Drug|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
75412236|NCT01271556|Drug|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
75412237|NCT01271556|Procedure|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
75412238|NCT01271556|Other|Placebo|placebo, inhalatory (MDI) once
75412239|NCT01272024|Behavioral|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
75412240|NCT01272024|Behavioral|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
75412241|NCT01272258|Drug|PRO 140|SC injection
75412242|NCT01272258|Drug|Placebo|SC injection
75412243|NCT01272336|Drug|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
75412244|NCT01272336|Other|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
75412245|NCT01272414|Drug|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
75412246|NCT01272414|Drug|Saline injection|Injection of 0.4cc 0.9% normal saline
75412247|NCT01272492|Other|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
75412248|NCT01272648|Behavioral|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
75412249|NCT01273116|Other|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~will be discussed at least once in a multidisciplinary meeting;~a structured medication review will be carried out by a geriatrician;~is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~may receive a consult of a geriatrician, if judged necessary;~will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
75412250|NCT01273272|Behavioral|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
75412251|NCT01273272|Behavioral|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
75555486|NCT05217628|Drug|Basimglurant|"Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability.~Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo.~OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1."
75555487|NCT05217628|Other|Placebo|Participant randomized to receive matching placebo once daily.
75555488|NCT05214716|Diagnostic Test|FilmArray Pneumonia panel|A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
75555489|NCT05201794|Drug|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
75714222|NCT05673317|Other|"Breastfeeding at AU Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
75714223|NCT05673304|Radiation|SBRT anticipated boost|24 Gy in 3 fractions to the tumour
75714224|NCT05672797|Other|Wellth app|The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.
76041333|NCT04837885|Procedure|Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection|intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
75555490|NCT05201794|Drug|Placebo|Matching placebo for each dose level as tablet will be administered orally.
75555491|NCT05201781|Drug|Cilta-cel|Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
75555492|NCT05197049|Drug|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
75555493|NCT05197049|Drug|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered by SC injection.
75714225|NCT05672797|Behavioral|Habit training|"Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue)."
75412252|NCT01273350|Device|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
76041334|NCT04837885|Drug|LUTATHERA® by intra-arterial hepatic (IAH) injection|"One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.~The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations"
75714226|NCT05667129|Drug|XEN-101|Capsule formulation
76041335|NCT04837885|Procedure|Scan|Scans after completion of LUTATHERA® treatment injection
75412253|NCT01273428|Drug|HP011-101|
75412254|NCT01273428|Device|HP-828-101|
75412255|NCT01273428|Other|Standard Care|
75412256|NCT01273506|Drug|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
75412257|NCT01273506|Drug|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
75555494|NCT05197049|Drug|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered by SC injection.
75555495|NCT05197049|Drug|Placebo|Placebo will be administered by SC injection.
75555496|NCT05192447|Behavioral|Exercise treatment|Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.
76041336|NCT03039829|Dietary Supplement|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
76041337|NCT03039829|Dietary Supplement|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
76041338|NCT03039829|Dietary Supplement|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
75555497|NCT05192200|Drug|Anti-Beta Interferon (PF-06823859)|IV infusion
75714227|NCT05667129|Drug|Placebo|capsule formulation
75714228|NCT05661500|Other|Creative Darama Group|Postmortem care training given by creative drama method
75714229|NCT05661500|Other|Classical Education Group|Postmortem care training given by classical education method
75714230|NCT05658380|Drug|atropine|patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
76041339|NCT04833595|Behavioral|Mindfulness practice|Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
76041340|NCT03039907|Procedure|Total Knee Arthroplasty|Total knee arthroplasty
76041341|NCT04833205|Drug|Nimotuzumab|Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
76041342|NCT03036475|Device|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
76041343|NCT03037645|Drug|SNS-062|SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
76041344|NCT04371913|Radiation|600cGY x 5 fractions|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
75412258|NCT01273662|Drug|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
75412259|NCT01273740|Procedure|External support|Bypass surgery with externally supported graft
75714231|NCT05658380|Drug|Isotonic saline|patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
75714232|NCT05653531|Other|Blood sample|Liver blood tests (AST, ALT, PAL, GGT, bilirubin, PT) will be performed before each ICI injection during the first three injections and again at 6 months.
76041345|NCT04370665|Device|Exablate BBBD with Cerezyme|"Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.~Other Names:~Exablate Neuro"
76041346|NCT04312243|Drug|Inhaled nitric oxide gas|Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
76041347|NCT04841551|Drug|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
75412260|NCT01273974|Biological|intradermal influenza vaccine|0.25ml ,intradermal
75412261|NCT01273974|Biological|intramuscular influenza vaccine|0.5ml,intramuscular
75412262|NCT01274130|Drug|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
75412263|NCT01274364|Other|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
75412264|NCT01274364|Other|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
75412265|NCT01274598|Biological|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10^10 CFU by mouth twice daily for 28 days
75412266|NCT01274676|Device|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
75412267|NCT01274676|Device|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
75412268|NCT01274910|Dietary Supplement|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
75872690|NCT03649256|Diagnostic Test|Thickness of lower uterine segment scar|Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
75412269|NCT01274910|Dietary Supplement|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
75555498|NCT05187624|Drug|RO7428731|Participants will receive RO7428731 as described.
75555499|NCT05185089|Drug|Orvepitant Maleate|Orvepitant tablets 30mg or 10mg
75555500|NCT05185089|Drug|Placebo|Placebo tablets to match orvepitant 30mg and 10mg tablets
75555501|NCT05184504|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
75555502|NCT05184361|Behavioral|Intermittent energy restriction (IER)|"Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.~Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.~In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.~The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks."
75555503|NCT05184361|Behavioral|Continuous energy restriction (CER)|A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
75555504|NCT05181735|Drug|Luspatercept Injection [Reblozyl]|All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg
75714233|NCT05647902|Diagnostic Test|Serum samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum samples will be collected from both groups for biochemical analysis.
75714234|NCT05646251|Device|Heart Ultrasound|A wand is placed on the chest to use soundwaves to make a picture of the heart and shows how the muscle and valves work. This helps with device placement.
75714235|NCT05642052|Dietary Supplement|low carb diet|low carb meals will be 50% less carbs than the regular meals
75555505|NCT05181735|Drug|Eprex|Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
75714236|NCT05642052|Dietary Supplement|Regular diet|Regular diet
75714237|NCT05631171|Behavioral|Adhera® Fatigue Digital Program|"Adhera® Fatigue Digital Program, that includes an application and a smartwatch, is a digital health solution based on emotional and behavioral change techniques. Patient adaptative self-management content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 3 months to detect biometric and psychometric (patient-reported outcomes) information."
75872691|NCT04053374|Other|Blood sampling|Blood sampling +/- CSF sampling
75872692|NCT03650660|Other|Trans-thoracic ultrasound|Trans-thoracic ultrasound performed by an expert and a non-expert
75872693|NCT02903966|Drug|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
75412270|NCT01275378|Behavioral|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
75412271|NCT01275378|Behavioral|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
75412272|NCT01275456|Procedure|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
75412273|NCT01275612|Biological|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
75555506|NCT05180474|Biological|GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.|GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
75872694|NCT02903966|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
75412274|NCT01275768|Procedure|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
75412275|NCT01275924|Device|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
75412276|NCT01275924|Device|Syndesmotic screw|Quadricortical syndesmotic screw
75412277|NCT01276080|Drug|Donepezil|10 mg tablets
75412278|NCT01276158|Procedure|Ultrasound|Ultrasound used to place arterial line
75412279|NCT01276158|Procedure|Doppler|Doppler used to place arterial line
75412280|NCT01276548|Drug|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
75412281|NCT01276548|Drug|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
75412282|NCT01276626|Dietary Supplement|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
75412283|NCT01276626|Other|Maltodextrin|Powder containing only maltodextrin
75412284|NCT01276782|Drug|Levothyroxine|It is FDA approved drug for thyroid disease
75412285|NCT01276938|Radiation|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
75555507|NCT05179876|Drug|Macitentan|Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (>=) 2 year to less than (<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.
75555508|NCT05179876|Drug|Selexipag|Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms.
75714238|NCT05629221|Other|TreC Diabete App|Participants can download the App from Google Play or Apple Store and activate the App as soon as the clinician provides them a unique activation code, created through an online medical dashboard. The dashboard allows the interaction between healthcare staff and the participant through the use of a chat or a video-chat. Participants are asked to register some information in the App at set times (e.g. blood pressure). Reminders are periodically sent to remember the participants to perform some tasks. Clinicians will periodically check the information entered by the participant (min frequency 45 days).
75714239|NCT05625295|Other|data collection protocol in clinical history|collection of data from the clinical history according to the established protocol
75555509|NCT05179876|Drug|Macitentan/Tadalafil FDC|Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.
75714240|NCT05624684|Diagnostic Test|Multiplex respiratory PCR|The BIOFIRE® FILMARRAY® Pneumonia plus Panel
75714241|NCT05617066|Behavioral|Cognitive behavioral therapy|With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
76041348|NCT03037567|Behavioral|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
76041349|NCT04833049|Drug|TAK-994 Oral Tablet|TAK-994 tablet.
75412286|NCT01276938|Radiation|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
75412287|NCT01277094|Drug|Placebo|Oral daily doses for 12 weeks
75412288|NCT01277094|Drug|RO5093151|Oral daily doses for 12 weeks
75412289|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
75412290|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
75412291|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
75412292|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
75412293|NCT01277406|Drug|4SC-201(Resminostat)|oral administration
75412294|NCT01277406|Drug|FOLFIRI|i.v. administration
75412295|NCT01277640|Drug|dapivirine|"dosage form: gel 0.05%~dosage: 2.5g~frequency: once daily~duration: 7 days"
75412296|NCT01277640|Drug|matched placebo|"dosage form: gel, no api~dosage: 2.5g~frequency: once daily~duration: 7 days"
75412297|NCT01277640|Drug|universal placebo|"dosage form: gel, HEC-based~dosage: 2.5g~frequency: once daily~duration: 7 days"
75412298|NCT01277796|Device|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
75555510|NCT05176366|Biological|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
75555511|NCT05175131|Drug|Mebeverine+Simethicone|fixed-dose combination, film-coated tablets, 135 mg + 80 mg
75714242|NCT05603819|Device|EDIT-B|To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.
76041350|NCT04833049|Drug|[14C]TAK-994 Intravenous Infusion|[14C]TAK-994 intravenous infusion.
76041351|NCT04833049|Drug|[14C]TAK-994 Oral Suspension|[14C]TAK-994 oral suspension.
75555512|NCT05175131|Drug|Mebeverine|Duspatalin®, coated tablets 135 mg
75555513|NCT05175131|Drug|Simethicone|Espumisan® capsules 40 mg
75555514|NCT05174169|Device|Signatera test|Central ctDNA testing for all patients
75714243|NCT05601115|Procedure|Robot assisted therapy|In addition to the conventional treatment for 60 minutes in the RYT group, it was planned to perform robotic rehabilitation with a hand-finger robot [Amadeo (Tyromotion, Graz, Austria)] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience
75872695|NCT03457727|Drug|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
75872696|NCT03457727|Drug|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
75412299|NCT01277874|Device|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
75412300|NCT01277874|Device|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
75412301|NCT01277952|Device|Deep Brain Stimulation|Brain pace maker, implanted in the brain
75555515|NCT05174169|Drug|mFOLFOX6 3-6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles
75555516|NCT05174169|Drug|CAPOX 3 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
75714244|NCT05601115|Procedure|Conventional Therapy Group|An exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) and 15 minutes of NMES was planned, accompanied by a physiotherapist experienced for at least 5 years in stroke rehabilitation, in the conventional therapy group.
75872697|NCT03647618|Other|Ultrasound|Ultrasound-guided regional anaesthesia
75872698|NCT03431441|Device|JJVC Marketed Contact Lens|Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
75872699|NCT03648554|Drug|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
75872700|NCT03648554|Other|reinforced dietary monitoring|moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
75872701|NCT03457103|Device|Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.
75872702|NCT03457103|Device|Pulmonary Rehabilitation (PR)|Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
75872703|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
75872704|NCT03648320|Other|Peanut oral immunotherapy|Daily doses of peanut flour (with 2-weekly incremental interval)
75872705|NCT05284994|Drug|TQ-B3525 Tablets, Osimertinib Mesylate Tablets|TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
75872706|NCT03649100|Procedure|Implant placement|Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
75872707|NCT03649022|Device|Catheter ablation|Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)
75412302|NCT01278108|Drug|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
75412303|NCT01278108|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
75412304|NCT01278108|Drug|GLPG0778|multiple dose, capsule, 7 days
75555517|NCT05174169|Drug|mFOLFIRINOX|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
75555518|NCT05174169|Drug|mFOLFOX6 6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
75555519|NCT05174169|Drug|CAPOX 6 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
75555520|NCT05172843|Procedure|Surgical knee arthroplasty|"Surgery will be performed 3 months from inclusion in the trial (at week 13). The procedure and type of prosthesis and postoperative program will be at the discretion of the involved surgeon and the participating department.~Post-surgical care and rehabilitation will follow current clinical standards."
75412305|NCT01278108|Drug|placebo|multiple dose, capsule, 7 days
75412306|NCT01278420|Device|Tecnis MF|30 subjects will be implanted with the Tecnis MF
75412307|NCT01278420|Device|ReSTOR|30 subjects will be implanted with ReSTOR
75412308|NCT01278576|Drug|BOTOX-A®|200 units, single treatment only
75412309|NCT01278654|Behavioral|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
75555521|NCT05172843|Behavioral|Supervised weight loss|"The supervised intensive dietary weight loss program will be initiated 3 months from inclusion in the trial (at week 13) and lasts for 12 weeks.~The program includes full meal replacement by a standard liquid energy intake in a supervised dietary program. Participants will attend the nutrition department weekly. They will be weighed on a decimal scale, given nutritional and dietetic instructions by an experienced dietitian and formula diet products are handed in sessions of 1-2 h. The participants will be taught to make diet plans.~Following the 12 weeks intensive dietary weight loss program participants will be scheduled for two booster follow-up sessions with a dietician at weeks 39 and 51."
75555522|NCT05172596|Biological|PHE885|Intravenous (IV) infusion
75412310|NCT01278810|Drug|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
75872708|NCT04053296|Other|Observational study|We follow up the results of patients.
75872709|NCT03648944|Other|Accelerated Rehabillitation|
76041352|NCT04841161|Behavioral|Balance function, gait ability, weight- distribution and weight-shifting|Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.
76041353|NCT04841161|Behavioral|Weight- distribution and weight-shifting training program|The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
76041354|NCT04841239|Other|Herbal topical formulation|
76041355|NCT04841395|Diagnostic Test|Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)|Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.
75714245|NCT05598047|Behavioral|Executive Functioning Training|Those in the Executive Functioning Training Group will engage in exercises requiring one to set shift; that is, to maintain at least two sets of rules and decide which is appropriate to determine the response. In using these training exercises in the TOPS study, the effects size was quite large (d=-0.89). Dosage of 20 hours of training is considered an upper range on how much training is needed to produce an optimal therapeutic effect.
75714246|NCT05595122|Device|EUS-CDS|EUS-CDS with FCSEMS through LAMS
76041356|NCT03036241|Device|Conventional angioplasty|Angioplasty with conventional balloon
75714247|NCT05577065|Dietary Supplement|Probiotic|Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
76041357|NCT03036241|Device|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
75714248|NCT05577065|Dietary Supplement|Placebo|Matching placebo in the form of a sachet once daily for 26 weeks
75714249|NCT05571969|Drug|2X-121 and dovitinib|"The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;"
75872710|NCT03648944|Other|Non-Accelerated Rehabillitation|
75872711|NCT03455543|Device|Active Provant Therapy System|Treatment with active Provant Therapy System
75412311|NCT01278966|Other|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
75412312|NCT01279122|Device|Nanoflex IOL|Patients who were implanted with the Nanoflex IOL
75412313|NCT01279278|Other|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
75872712|NCT03455543|Device|Inactive (sham) Provant Therapy System|Treatment with inactive Provant Therapy System
76041358|NCT03037333|Procedure|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
76041359|NCT03037333|Procedure|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
76041360|NCT03039517|Device|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
75412314|NCT01279278|Other|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
75412315|NCT01279434|Drug|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
76041361|NCT03039517|Device|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
76041362|NCT03039361|Behavioral|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
75555523|NCT05172557|Behavioral|Wellness Program|Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation
75555524|NCT05172557|Behavioral|Wellness Coaching|Wellness coaching sessions throughout 12 months of study participation
76041363|NCT04840771|Procedure|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
75555525|NCT05167825|Drug|Macitentan|Macitentan will be administered orally as a tablet.
75555526|NCT05166798|Behavioral|Cognitive control training|The five intervention groups will receive either 1, 5, 10, 15 or 20 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT).
76041364|NCT04837651|Device|Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test|Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.
75555527|NCT05162976|Biological|Nivolumab|Given IV
75555528|NCT05162976|Drug|Oral Azacitidine|Given PO
75555529|NCT05160584|Other|No intervention|There is no interventional treatment component for participants with RRMM in this study.
75555530|NCT05157919|Behavioral|ICU-Care|The mobile app intervention, ICU-CARE, will consist of 3 separate education modules, each approximately 5-7 minutes in length: (Module #1) ICU orientation, (Module #2) Symptom Assessment, (Module #3) Symptom Management
76041365|NCT04837651|Device|T-Detect COVID T-cell blood test|A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.
76041366|NCT04832581|Behavioral|The Self-Care Behavior Development Program|This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
76041367|NCT04832191|Device|CE-SM|contrast enhanced spectral mammography &contrast enhanced magnetic resonance imaging
76041368|NCT03039205|Drug|Clopidogrel|Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
76041369|NCT03039205|Drug|Ticagrelor|Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
75412316|NCT01279434|Drug|Vitamin E|Vitamin E 400 mg BD daily for 12 months
75412317|NCT01279512|Drug|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
75412318|NCT01279512|Drug|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
75412319|NCT01279668|Drug|Montelukast|10mg tablets, once per day for 28 days.
75412320|NCT01279668|Drug|Placebo|tablets, once per day for 28 days.
75412321|NCT01279746|Device|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
75555531|NCT05156671|Biological|Adrecizumab (HAM 8101)|Drip infusion over 60 minutes.
75555532|NCT05156671|Drug|Placebo|Drip infusion over 60 minutes
75555533|NCT05155163|Behavioral|SC-POWR|Patients assigned to SC-POWR receive 12 Cognitive Behavioral Therapy (CBT) sessions over 24 weeks.
75555534|NCT05153161|Device|Memesto|Edgewater plans to develop the next generation Memesto, a wearable device able to sense increasing agitation in ADRD sufferers and automatically deliver agitation-reducing personalized voice messages and music most effective at calming the individual based on past interventions. This innovative product will be the first wearable ADRD device to track agitation via body-worn sensors and automatically deploy agitation-reducing voice and music therapy without any caregiver interaction. The new system will use analytics to track the effectiveness of the various media and update the calming 'play list' over time.
75555535|NCT05151640|Drug|Nintedanib|Nintedanib
75555536|NCT05147571|Device|Responsive stimulation|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
76041370|NCT04837261|Drug|Propranolol|3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
76041371|NCT04837261|Drug|Flecainide|80 mg/m2/d
75555537|NCT05147571|Device|Sham stimulation|For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.
75714250|NCT05566015|Other|questionnaire|self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.
75714251|NCT05560529|Behavioral|DBT|Applying DBT modules in group format over 20 weeks
75714252|NCT05560529|Drug|TAU|Giving TAU (usual pharmacotherapy in BED) over 20 weeks
75714253|NCT05560529|Diagnostic Test|Plasma Ghrelin|Measuring fasting plasma ghrelin pre and post treatment in both arms
75714254|NCT05551104|Drug|Oral Nifedipine|Administration of oral nifedipine to control postpartum hypertension.
75714255|NCT05551104|Drug|Oral Labetalol|Administration of oral labetalol to control postpartum hypertension.
76041372|NCT04837261|Drug|Amiodarone|Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
76041373|NCT04832035|Other|"coordinated and peer supported mental health care"|Health services, coordination of services, method to support utilization
76041374|NCT04832035|Behavioral|"standard psychotherapeutic care in the public healthcare system"|Psychotherapeutic services that are financed by the public health insurance system.
76041375|NCT04792177|Behavioral|Emotion regulation skills training|The intervention will involve an online emotion-regulation skills training for individuals with sexual problems. It will last for 8 weeks, encompassing psycho-educational and emotion-regulation skills components. Every week participants will gain access to a different intervention module of the training, containing videos, presentation slides, written support material and a recommendation of activities to be completed until the following week of training. Participants are expected to dedicate 30 minutes to one hour per week to complete each module.
75412322|NCT01279902|Drug|Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
75555538|NCT05142202|Radiation|Breast Irradiation after Breast-Conserving Surgery|All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.
76041376|NCT04832347|Other|Exercise|Exercise Group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
76041377|NCT04832347|Other|Vagus Nerve Stimulation|Vagus therapy will be applied for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
75714258|NCT05534191|Other|Experimental, comparator and control|"To quantify the effect of a strength intervention for footballers on improved range of motion, balance, speed, jump height, and technical football skills compared to a training group from the Danish football strength and conditioning concept Fodboldperformance and a control group."
75412323|NCT01279044|Behavioral|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
75412324|NCT01279044|Behavioral|Standard HIV testing with information only|Standard HIV testing with information only
75412325|NCT01278342|Drug|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
76041378|NCT04428697|Procedure|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .
76041379|NCT04831489|Radiation|Imaging|pre and postoperative CT scan of lung
76041380|NCT04831879|Device|GONDOLA AMPS|The Gondola device is composed of two units, one per foot, each having two motors that activate rounded stimulation tips that interact with the target points. It delivers mechanical, pressure-based stimulations, sequentially in each of the four points, for the duration of 6 seconds per point. This treatment cycle is repeated 4 times, for an overall treatment duration of less than 2 minutes
76041381|NCT04831645|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
76041382|NCT04831645|Procedure|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
76041383|NCT04824937|Drug|Telaglenastat|Capsule, taken by mouth
76041384|NCT04824937|Drug|Talazoparib|Capsule, taken by mouth
75412326|NCT01278342|Drug|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
75412327|NCT01278342|Drug|cabergoline|"Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~st week: 0.25 mg twice a week (0.50 mg/week)~nd week: 0.50 mg/week twice a week (1 mg/week)~rd week: 0.50 mg four times a week (2 mg/week)~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
75412328|NCT01278030|Procedure|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
75555539|NCT05141227|Procedure|Two-stage Open reduction and internal fixation ( ORIF) using plates & screws|Two stage ORIF using initially temporary spanning fixator then conversion to plates & screws
75555540|NCT05141227|Procedure|single-stage external fixation (EX.FIX.) with minimal internal fixation using cannulated screws if needed|Single stage Ex.Fix. Using illizarov & minimal fixation of the articular surface using cannulated screws through mini open approaches
76041385|NCT03037099|Behavioral|Enhanced GI Concept Education|
75555541|NCT05139875|Drug|Betamethasone Dipropionate / Betamethasone Sodium Phosphate|Single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate (Diprospan) injections to affected knee
76041386|NCT04836949|Device|Shear Wave Elastography of prostate|A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
75412329|NCT01277718|Drug|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
75412330|NCT01277718|Drug|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
75555542|NCT05139875|Drug|Triamcinolone Acetonide 40mg/mL|Single intra-articular Triamcinolone Acetonide injections to affected knee
75555543|NCT05139810|Drug|Donidalorsen|Donidalorsen will be administered by SC injection.
75555544|NCT05139810|Drug|Placebo|Donidalorsen-matching placebo will be administered by SC injection.
76041387|NCT04836949|Device|Conventional Prostate Ultrasound|A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
76041388|NCT04836793|Other|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
75714259|NCT05533970|Procedure|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 ~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.
75714260|NCT05527418|Drug|Dasatinib|Dasatinib monotherapy 70 mg/day, during 16 weeks.
75714261|NCT05527418|Drug|Placebo|Placebo during 16 weeks.
75714262|NCT05520333|Behavioral|BIPAS Alcohol|Weekly text messages for three months.
75714263|NCT05515614|Dietary Supplement|Targeted Fortification|Mother's breast milk will be fortified in modular fashion based on the level of macronutrients (protein, carbohydrate, and fat) found from analysis using the Miris Human Milk Analyser. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. Mother's breast milk will be fortified in modular fashion. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. For lipid supplementation, safflower oil will be utilized. We will set our goal energy level between 110 - 135 kcal/kg/day, protein level between 3.5 - 4.5 g/kg/day, lipid level between 4.8 - 6.6 g/kg/day, and carbohydrate level between 11.6 - 13.2 g/kg/day. We will regard daily fluid volume to be between 150 to 180 mL/kg/day.
75714264|NCT05515614|Dietary Supplement|Enfamil Liquid Human Milk Fortifier|Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier as per standard feeding protocol defined by LLUCH NICU manual.
75714265|NCT05512481|Drug|Camrelizumab|"NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year"
75714266|NCT05493293|Drug|NBI-921352|Tablets for oral administration
75714267|NCT05492110|Device|Coronary sinus reducer|The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
75714268|NCT05492110|Other|Sham-procedure|Implantation procedure with no device implanted
75714269|NCT05492110|Diagnostic Test|Invasive coronary physiology|Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
75714270|NCT05482412|Device|transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve|Direct superficial auricular sensory branch of Cr X [Cranial Nerve Ten Vagus]
75714271|NCT05481424|Other|Biodynamic|This will be a nine-hour lighting scheme that includes three modes: morning, noon, and afternoon. It mimics natural lighting by providing blue-enriched bright lighting in the morning and yellowish dimmed lighting in the afternoon. The lighting scheme is designed to satisfy the visual lighting needs of office workers while maintaining a robust circadian clock.
75714272|NCT05481424|Other|Active Placebo|"We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness during working hours. This condition is designed to serve to requirements: (1) to simulate a conventional, well-lit office lighting in compliance with the WELL standard V1 recommendations for circadian lighting design, and (2) to provide an Equivalent Melanopic Lux (EML) equal to the geometric average of EML delivered by the Biodynamic condition. Participants will receive a similar dose of lighting under both the Placebo and Biodynamic conditions; however, the time factor is ignored in the Placebo, and hence the method of delivery is different (constant versus dynamic)."
75714273|NCT05473273|Drug|Endometrin 100Mg Vaginal Insert|Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
75714274|NCT05473273|Drug|Estradiol Valerate|Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).
75412331|NCT01276236|Drug|Maraviroc|"FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.~Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.~Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions."
75714275|NCT05472831|Behavioral|BAILAMOS dance program plus MIND diet|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute MIND diet session per week.
75714276|NCT05472831|Behavioral|BAILAMOS dance program plus Health Education|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute Health Education session per week.
75714277|NCT05467163|Device|Biventricular pacemaker implantation|Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.
75714278|NCT05467163|Device|Conduction system pacing device implantation|Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.
75714279|NCT05467163|Procedure|AV node ablation|Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
76041389|NCT04428073|Biological|Covax-19™|Therapeutic vaccine for SARS-CoV-2 infection
75412332|NCT01275222|Drug|RAD001|RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
75412333|NCT01275222|Drug|Imatinib 600mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.
75555545|NCT05133336|Drug|Saroglitazar Magnesium 1 mg|Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment until the optimal dose (1 or 2 mg) is selected at interim analysis, after which these subjects will receive Saroglitazar Magnesium Optimal Dose (1 or 2 mg) up to Week 52. If the selection of optimal dose is inconclusive at the interim analysis, all subjects in this arm will continue to receive Saroglitazar Magnesium 1 mg as per the initial treatment assignment for the entire treatment period up to Week 52.
75555546|NCT05133336|Drug|Saroglitazar Magnesium 2 mg|Subjects randomized to Saroglitazar Magnesium 2 mg arm will receive Saroglitazar Magnesium 2 mg treatment until the optimal dose (1 or 2 mg) is selected at interim analysis, after which these subjects will receive Saroglitazar Magnesium Optimal Dose (1 or 2 mg) up to Week 52. If the selection of optimal dose is inconclusive at the interim analysis, all subjects in this arm will continue to receive Saroglitazar Magnesium 2 mg as per the initial treatment assignment for the entire treatment period up to Week 52.
75555547|NCT05133336|Drug|Placebo|Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
76041390|NCT04824313|Diagnostic Test|Chest CT|Chest CT without intravenous contrast material
75412334|NCT01275222|Drug|Imatinib 800mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
75412335|NCT01275144|Drug|LY2216684|Administered orally
75412336|NCT01275144|Drug|Placebo|Administered orally
75412337|NCT01275144|Drug|Lorazepam|Administered orally
75412338|NCT01275066|Drug|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
75412339|NCT01275066|Drug|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
75555548|NCT05132790|Drug|SHR-1316 at a dose 20mg/kg q3w|Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin
75555549|NCT05132790|Drug|SHR6390 at a dose of 150mg orally, daily|SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT
75555550|NCT05132790|Radiation|SBRT|radiation therapy for breast cance before surgery.
75555551|NCT05130983|Biological|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
76041391|NCT04824313|Diagnostic Test|Chest CTA|Chest CT with intravenous contrast material
76041392|NCT04824235|Other|Amniotic Chorion Membrane and Bio-Oss xenograft|Bioxclude Amniotic Chorion Membrane with xenograft (Bio-Oss) for ridge preservation
75412340|NCT01275066|Drug|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
75412341|NCT01273038|Device|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
75555552|NCT05125302|Drug|Ubrogepant|Oral Tablet
75555553|NCT05125302|Drug|Placebo-Matching Ubrogepant|Oral Tablet
75555554|NCT05124210|Biological|Sotrovimab|Sotrovimab will be administered.
75555555|NCT05123599|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
76041393|NCT04824235|Other|Amniotic Chorion Membrane only|Bioxclude Amniotic Chorion Membrane only
76041394|NCT04824157|Other|Non|Follow up
75555556|NCT05123599|Biological|JNJ-64300535|JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.
75555557|NCT05123599|Drug|ETV monohydrate|ETV monohydrate film-coated tablets will be administered orally.
75555558|NCT05123599|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
75555559|NCT05123599|Drug|TAF|TAF film-coated tablets will be administered orally.
75555560|NCT05121103|Drug|EZM0414|Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)
75555561|NCT05118932|Behavioral|Mindful Movement Intervention|"There are five components that together make-up the Mindful Movement Intervention: Biomechanical Warm-ups, Yoga postures, modified Tai Chi sequence, Imaginative Play, and Reflection. During the year, participants will learn a Simplified Form of a classic Tai Chi sequence. Yoga movements will be used to prepare participants for the nuanced movements of Tai Chi practice, with both Yoga and Tai Chi providing a physical framework in which participants can track their own progress and begin to understand how to better regulate their attention, behavior and emotional responses. Imaginative Play and Reflection Activities are used to stimulate a deeper curiosity in participants about the everyday use and employment of mindfulness practice and to engage participants."
75555562|NCT05112939|Drug|RPV LA|RPV LA will be administered at different formulations.
76041395|NCT04824001|Other|exercise stress echocardiography|Stress echocardiography test. The standardized exercise test was conducted by 50-W semi-recumbent cycling for 3 min. Stress echocardiograph images were acquired at the third minute of cycling to ensure that subjects had reached a steady-state HR.
76041396|NCT03036085|Drug|Liposomal bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
76041397|NCT03036085|Drug|Bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
75412342|NCT01273038|Device|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
75412343|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
75555563|NCT05112939|Drug|CAB LA|CAB LA will be administered at formulation 3.
75555564|NCT05112627|Procedure|Biospecimen Collection|Undergo blood collection
75555565|NCT05104723|Drug|XELJANZ (tofacitinib)|The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
75555566|NCT05102370|Drug|Enasidenib|Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
75555568|NCT05092269|Drug|Ustekinumab|Ustekinumab will be administered as a SC injection.
76041398|NCT03036085|Drug|Epinephrine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
75555569|NCT05092035|Diagnostic Test|single high-fidelity expiratory CO2 analysis|in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
75555570|NCT05090826|Device|Model ZFR00V|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
75555571|NCT05090813|Device|Model ICB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
75555572|NCT05090787|Device|Investigational mDCB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
75555573|NCT05090787|Device|Control DCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes
75872713|NCT03648242|Behavioral|Interruptive Clinical Decision Support|"An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~One-click addition of elevated BMI to problem list~Reminder to utilize Suggested PowerPlan~One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~Links to existing, evidence-based childhood obesity screening and management guidelines"
75555574|NCT05090475|Behavioral|Academic detailing intervention|Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
75555575|NCT05089695|Device|Noninvasive respiratory support|Treatment of acute hypoxemic respiratory failure
75555576|NCT05089604|Drug|Tacrolimus, Immediate Release, Oral|Twice Daily Tacrolimus
75555577|NCT05089604|Drug|Tacrolimus Extended Release Oral Tablet|Once Daily Tacrolimus
75555578|NCT05088681|Other|Rehabilitation program|The exercise intervention will consist of an individualized prescription of resistance training, balance training and cardiovascular exercises delivered for 20 session, one-hour, two/three times per week.
75555579|NCT05087498|Biological|autologous cord blood mononuclear cells|preterm neonates less than 32 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (2-10×107cells/kg) within 24 hours after birth
75555580|NCT05087498|Biological|normal saline|preterm neonates less than 32 weeks are assigned to receive normal saline within 24 hours after birth
75555581|NCT05083182|Drug|Ustekinumab|Ustekinumab will be administered as subcutaneous injection.
75555582|NCT05083182|Drug|Guselkumab|Guselkumab will be administered as subcutaneous injection.
75555583|NCT05083169|Drug|Daratumumab|Daratumumab will be administered SC injection.
75714280|NCT05464680|Other|blood sample and bronchoalveolar lavage|"These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60."
75872714|NCT03068754|Drug|Acthar|Repository corticotropin for subcutaneous injection
75872715|NCT03068754|Drug|Placebo|Matching placebo for subcutaneous injection
75412344|NCT01272180|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
75412345|NCT01272180|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
75412346|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
75555584|NCT05083169|Drug|Pomalidomide|Pomalidomide will be administered orally.
75555585|NCT05083169|Drug|Dexamethasone|Dexamethasone will be administered orally or intravenously.
75412347|NCT01271712|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
75555586|NCT05083169|Drug|Bortezomib|Bortezomib will be administered SC injection.
75872716|NCT02965820|Device|Opti-Free® PureMoist® contact lens solution|
75872717|NCT02965820|Device|Habitual Multi-Purpose Contact Lens Solution|
75872718|NCT02965820|Device|Habitual Contact Lenses|Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
75555587|NCT05083169|Drug|Teclistamab|Teclistamab will be administered SC injection.
75555588|NCT05081609|Drug|TransCon IL-2 β/γ|TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
75555589|NCT05081609|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion
75714281|NCT05463068|Drug|NVX-Cov2373|Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
75714282|NCT05453513|Other|MRI study - everyone scanned.|This is an observational study without an intervention.
75714283|NCT05453175|Other|Interrupting sitting with Physical activity|Participants will engage in three minutes of walking, five sit to stands and five calf raises every thirty minutes
75714284|NCT05441033|Other|Group-FHB|This is the group where pregnant women and their spouses listen to the fetal heartbeat.
76041399|NCT03036085|Drug|Normal saline|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
75714285|NCT05441033|Other|Group-GIT|This is the group in which the guided imagery technique is applied to pregnant women and their spouses.
75714286|NCT05440604|Other|Fortified milk|Commercially available milk-based fortified beverage that has an updated profile of key micronutrients along with appropriate levels of protein and other macro- and micro- nutrients, in accordance with global and local nutritional recommendations
75714287|NCT05438004|Other|Ambulatory nice birth|discharge from the maternity ward from the 2nd hour and before the 24th hour following an uncomplicated delivery
75714288|NCT05433246|Behavioral|Massage therapy group|Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
75714289|NCT05425290|Behavioral|Single-session emotion regulation training|The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
75714290|NCT05425238|Other|Blood flow restriction|"strengthening protocol but with Blood flow restriction technique~.Standard BFR Application: a standard pressure (used for all patients) for e.g. 180~mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.40% cuff pressure as percentage of LOP.(4) And performing BFR-RE with low load exercises. So 30% of 1 RPM would be enough 4 times a week for 6 week"
75714291|NCT05425238|Other|Conventional physical therapy|Resistance exercise 75 repetitions across four sets of exercises, with30 repetitions in the first set and 15 repetitions in each subsequent set. 4 times a week for 6
75872719|NCT03713099|Device|Microwave ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound (EBUS) to confirm disease staging.
75872720|NCT03716375|Drug|Intrapleural Medications|urokinase
76041400|NCT04823767|Other|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
76041401|NCT04836481|Other|Serum Sample Collection|Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.
76041402|NCT04831333|Other||
76041403|NCT04831255|Drug|triamcinolone acetonide extended-release injectable suspension|ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
76041404|NCT04831177|Procedure|Laser in situ keratomileusis|Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
76041405|NCT02432235|Drug|Camidanlumab tesirine|Intravenous (IV) infusion.
76041406|NCT02431533|Dietary Supplement|PX0612|PX0612 is a probiotic contained in a veggie capsule.
76041407|NCT02431533|Dietary Supplement|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
76041408|NCT02416791|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
76041409|NCT02416791|Device|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
75412348|NCT01271712|Drug|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
75555590|NCT05081609|Drug|Chemotherapy drug|SOC chemotherapy will be administered as an intravenous (IV) infusion
76041410|NCT02416791|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
76041411|NCT02416791|Other|Physical Therapy|Physical therapy will be administered for 40 minutes.
75555591|NCT05081609|Drug|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
75714292|NCT05420090|Behavioral|Banana arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied.Food consumption frequency and food-based follow-up will be carried out.Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
75714293|NCT05420090|Behavioral|Milk arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. Food consumption frequency and food-based follow-up will be carried out. Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
75714294|NCT05420090|Behavioral|No intervention|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. The frequency of food consumption will be taken from the participants each week.Participants are expected not to make any changes in their diet. As in other groups, the frequency of food consumption will be taken from the participants every week in this group. In order to observe the possible changes in the experimental arms, the individuals in the control arm will be asked not to consume bananas and whole milk after 16:00 and they will be informed about this.
75872721|NCT04021472|Behavioral|Text message|Two months of daily text messages to support meeting a health goal
76041412|NCT02416791|Other|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
75412349|NCT01271712|Drug|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
76041413|NCT02414841|Drug|Vonapanitase|
76041414|NCT02414841|Drug|Placebo|
76041415|NCT02413593|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
76041416|NCT02413593|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75555592|NCT05081609|Procedure|Surgery|Surgery will take place 4-6 weeks after last dose of study treatment.
76041417|NCT04942275|Drug|Pre-therapeutic imaging test|The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
76041418|NCT01652703|Biological|Evolocumab|Administered by subcutaneous injection
76041419|NCT01652703|Other|Placebo|Administered by subcutaneous injection
76041420|NCT01652469|Drug|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
76041421|NCT01652469|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
75412350|NCT01271010|Drug|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle.
76041422|NCT02429427|Drug|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
76041423|NCT02429427|Other|Placebo|Two capsules once daily with food
75412351|NCT01271010|Drug|Fludarabine|Participants received fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle.
75412352|NCT01271010|Drug|Rituximab|Participants received 375 mg/m^2 IV on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle.
75412353|NCT01270620|Drug|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
75555593|NCT05081011|Device|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily custom insulin titration instructions.
75555594|NCT05081011|Device|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily generic insulin reminders.
75555595|NCT05072964|Device|FARAPULSE Pulsed Field Ablation System|A pulmonary vein isolation will be performed using catheter ablation
75555596|NCT05071664|Drug|Guselkumab|Guselkumab will be administered as a SC injection.
75555597|NCT05071664|Drug|Golimumab|Golimumab will be administered as a SC injection.
75555598|NCT05071664|Drug|Placebo|Placebo will be administered as a SC injection.
75555599|NCT05069545|Drug|Insulin degludec|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
75412354|NCT01270620|Drug|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
75412355|NCT01270464|Drug|Reslizumab|3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
75412356|NCT01270464|Drug|Placebo|Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
75555600|NCT05069545|Drug|Fast-acting insulin aspart|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
75555601|NCT05068960|Drug|Liposomal bupivacaine|Addition of liposomal bupivacaine to the interscalene block for extended pain control following total shoulder arthroplasty
75714295|NCT05411692|Other|Functional electrical stimulations and motor priming exercise|"One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion. The third pair of electrodes is placed on the subject's skin, above the extensor digitorum muscle, to generate finger extension. Motor priming exercises will be done (functional task practice, FTP) for 20 minutes. Participants will be asked to spend at least 20 minutesDuration of training will be 4 weeks, 5 days per week, one session per day, and one hour per session."
75412357|NCT01279590|Drug|PPD10558|"PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks"
75714296|NCT05411692|Other|Functional electrical stimulations|"Stimulation parameters are (1) balanced, biphasic, current-regulated electrical pulses; (2) pulse amplitude from 8 to 50 mA (typical values 17- 26 mA); (3) pulse width 250 ms; and (4) pulse frequency from 20 to 70 Hz (18). Trancutaneous stimulation will be delivered bilaterally with surface electrodes placed on the volar aspect of each wrist targeting the distribution of the median nerve. One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion for 20 minutes"
75555602|NCT05068960|Drug|Bupivacaine|Interscalene block with bupivacaine for pain control following total shoulder arthroplasty
75555603|NCT05067972|Drug|PF-07260437|B7-H4 x CD3 bi-specific mAb
75555604|NCT05067972|Diagnostic Test|B7-H4 IHC|B7-H4 expression
75714297|NCT05411692|Other|Conventional physical therapy|a structured exercise protocol targeting strength (2 days/week) and endurance (3days/week) training
76041424|NCT05370573|Other|No intervention|Observational - no interventions
76041425|NCT02412735|Drug|Rexlemestrocel-L|Rexlemestrocel-L injection
76041426|NCT02412735|Drug|Rexlemestrocel-L + HA Mixture|Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
75555605|NCT05064553|Device|Study CT/MRI Imaging|Subjects with negative ultrasound will be sent for a study CT/MRI.
75555606|NCT05064553|Device|Standard of Care CT/MRI Imaging|Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.
75555607|NCT05064553|Diagnostic Test|Oncoguard™ Liver Test|Subjects will have a blood sample collected for the Oncoguard™ Liver Test.
75555610|NCT05056402|Biological|3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 1 and 6 month.
75555611|NCT05056402|Biological|2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Two doses administered intramuscularly at 0 and 6 month.
75555612|NCT05054140|Drug|IMU-838|IMU-838 tablets
75555613|NCT05054140|Drug|Placebo matching IMU-838|Placebo matching IMU-838 tablets
76041427|NCT02412735|Drug|Placebo|Saline control solution
75555614|NCT05053399|Device|Model Series ZXT|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
75555615|NCT05051059|Other|Functional outcome|3D-motion analysis and strength assessment
75555616|NCT05051059|Other|Health related quality of life (HRQoL) assessment|Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
75555617|NCT05050097|Drug|Talquetamab|Talquetamab will be administered subcutaneously.
75555618|NCT05050097|Drug|Carfilzomib|Carfilzomib will be administered as an IV infusion.
76041428|NCT02412657|Drug|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
75555619|NCT05050097|Drug|Daratumumab SC|Daratumumab will be administered subcutaneously.
75555620|NCT05050097|Drug|Lenalidomide|Lenalidomide will be self-administered orally.
75555621|NCT05050097|Drug|Pomalidomide|Pomalidomide will be self-administered orally.
75555622|NCT05049798|Drug|Guselkumab|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
75714298|NCT05409430|Device|Neurothrombectomy|"The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction.~The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion."
75714299|NCT05402137|Behavioral|Weight stigma intervention|Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
75714300|NCT05396391|Drug|IAP0971|IAP0971 should be subcutaneous injected，q2w
75714301|NCT05396352|Device|Transcranial direct current stimulation|TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.
75714302|NCT05389813|Drug|Oxycodone 20 Mg Oral Tablet|Oxycodone is a semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.
76041429|NCT02412657|Drug|Normal Saline|
76041430|NCT02428413|Device|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
75412358|NCT01279590|Drug|Atorvastatin|"Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then~Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks"
75555623|NCT05049798|Drug|IL-17i|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
75555624|NCT05048394|Device|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
75555625|NCT05048394|Device|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
76041431|NCT02428413|Device|Standard oxygen mask|Provide supplemental oxygen
76041432|NCT02412111|Drug|Ivacaftor|
76041433|NCT02412111|Drug|Tezacaftor/Ivacaftor|
76041434|NCT02427477|Device|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
76041435|NCT02427477|Device|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
76041436|NCT02427399|Other|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
76041437|NCT02427399|Other|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
75412359|NCT01279590|Drug|Placebo|2 placebo capsules twice daily for 12 weeks
75412360|NCT01271790|Drug|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
75412361|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
75555626|NCT05047094|Device|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
75555627|NCT05047094|Drug|Pembrolizumab|200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
75412362|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
76041438|NCT02427399|Other|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
76041439|NCT02427399|Other|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
75555628|NCT05043584|Device|Fluobeam LX, Fluoptics, Grenoble, France|See arm description
75555629|NCT05041062|Drug|Nivolumab|Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
75555630|NCT05041062|Drug|Ipilimumab|Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
75555631|NCT05040126|Drug|Linezolid|"Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment"
75555632|NCT05040126|Drug|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms
75555633|NCT05040126|Drug|Pretomanid|Pretomanid is administered as one tablet once a day for 26 weeks in all three arms
75555634|NCT05039645|Behavioral|Patient specific, clinician determined Intervention|Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of >2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment).
75555635|NCT05039515|Drug|IPN60130|Immediate-release capsule containing high dose of the drug substance.
75555636|NCT05039515|Drug|IPN60130|Immediate-release capsule containing low dose of the drug substance.
75872722|NCT05203848|Procedure|Community Dance Intervention|The main dance instructor for the CDP is Yarra Ileto, who is the Artistic Director for NUS Dance Synergy. Yarra was trained at LASALLE College of the Arts, graduating with a First Class BA (Hons) Dance in 2008. Also, she has experience with crafting and conducting Community Dance Programs (CDP) for Seniors. Yarra will be developing the dance lesson plan and also training selected students from NUS Dance Synergy to guide the seniors during the dance sessions. Older adults will learn and practice the basic steps together for the first few weeks. Then, the student dance instructors will start teaching the dance formation. During each session, participants will need to warm up first to prevent injuries before practicing dance steps. Small group practicing is reserved for older adults to interact with each other. All the participants will do relaxation exercises before ending the session to cool down their bodies and release muscle tensions.
76041440|NCT02426541|Drug|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
75555637|NCT05039515|Drug|Placebo|Placebo will be supplied as powder filled hard capsules
75555638|NCT05039021|Device|HARMONIC 1100 Shears|HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
75555639|NCT05038800|Biological|MK-0482|IV infusion
75555640|NCT05037422|Procedure|STARR surgery|"This intervention is carried out under general anesthesia or spinal anesthesia. It consists of the circular resection of the surplus of rectal mucosa. Rectal resection and suturing is performed using automatic mechanical forceps introduced through the anus."
75555641|NCT05036343|Device|InPen®|A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
75555642|NCT05036070|Device|Model C0001|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
75555643|NCT05036070|Device|Model ZCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
75555644|NCT05029921|Drug|Ustekinumab|Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.
75555645|NCT05027802|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day.
75555646|NCT05022849|Drug|JNJ-75229414|JNJ-75229414 infusion will be administered intravenously.
75872723|NCT05203848|Other|Control group|Control group
76041441|NCT02426541|Drug|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
76041442|NCT02484651|Drug|Sugammadex|Reversal of deep neuromuscular block
76041443|NCT02484651|Drug|Rocuronium|Maintenance of deep neuromuscular block
76041444|NCT02410551|Drug|Pacritinib|200 mg by mouth twice a day for 60 days.
75555647|NCT05022849|Drug|Bridging Therapy|Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
75555648|NCT05020743|Other|No intervention|Not applicable for a Natural History Study
75555649|NCT05016245|Combination Product|TheraSphere™ Yttrium-90 Glass Microspheres|"TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit"
75555650|NCT05016245|Procedure|conventional Transarterial Chemoembolization(cTACE)|conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
75555651|NCT05016011|Biological|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Human umbilical cord-derived mesenchymal stem cells
75555652|NCT05016011|Procedure|Marrow cellution|Patients will undergo marrow cellution surgical procedure.
75555653|NCT05013970|Other|Clinical assessment|Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire
75555654|NCT05013970|Other|Radiographic imaging|MRI of the knee
75555655|NCT05013229|Drug|IcoSema|Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
75555656|NCT05013229|Drug|Insulin glargine|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
75555657|NCT05013229|Drug|insulin aspart|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
75714303|NCT05389813|Drug|Pregabalin 150mg|Pregabalin is a gabapentinoid and acts by inhibiting certain calcium channels. Specifically it is a ligand of the auxiliary α2δ subunit site of certain voltage-dependent calcium channels (VDCCs), and thereby acts as an inhibitor of α2δ subunit-containing VDCCs. There are two drug-binding α2δ subunits, α2δ-1 and α2δ-2, and pregabalin shows similar affinity for (and hence lack of selectivity between) these two sites. Pregabalin is selective in its binding to the α2δ VDCC subunit. Despite the fact that pregabalin is a GABA analogue. r synthesizing GABA, and hence may have some indirect GABAergic effects by increasing GABA levels in the brain. In accordance, inhibition of α2δ-1-containing VDCCs by pregabalin appears to be responsible for its anticonvulsant, analgesic, and anxiolytic effects.
76041445|NCT02410551|Drug|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
75555658|NCT05012657|Device|Point Partial|The Point Partial partial finger prosthetic system consists of 1-4 ratcheting mechanical partial digits and mounting brackets
75555659|NCT05009511|Behavioral|Learning through feedback|The goal of this investigation is to examine the influence of feedback timing on learning and brain function.
76041446|NCT02410551|Behavioral|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
75555660|NCT05003804|Biological|STMC-103H|STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
75555661|NCT05003804|Biological|Placebo|Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
75555662|NCT05003271|Other|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.
75555663|NCT04998136|Drug|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
75555664|NCT04998136|Drug|Placebo (semaglutide 2.4 mg)|Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
75555665|NCT04992312|Drug|Glucagon Nasal Powder [Baqsimi]|Administered intranasally
75555666|NCT04989218|Drug|Novel combination of chemotherapy and immunotherapy|This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
75555667|NCT04988295|Drug|Lazertinib|Lazertinib will be administered orally.
75555668|NCT04988295|Drug|Amivantamab|Amivantamab will be administered as an IV infusion.
75555669|NCT04988295|Drug|Pemetrexed|Pemetrexed will be administered as an IV infusion.
75555670|NCT04988295|Drug|Carboplatin|Carboplatin will be administered as an IV infusion.
75555671|NCT04987281|Procedure|Computed Tomography|Undergo CT
75555672|NCT04987281|Drug|Indocyanine Green Solution|Given via injection
75555673|NCT04987281|Device|Therapeutic Bronchoscopy|Undergo bronchoscopy using Ion robotic bronchoscope
75555674|NCT04985916|Biological|Vehicle|topical liniment without investigational product
75555675|NCT04985916|Biological|botulinum toxin, Type A|ET-01 topical liniment
75555676|NCT04982653|Other|Quality-of-Life Assessment|Ancillary studies
75555677|NCT04982653|Procedure|Surgical Procedure|Undergo hepatectomy using small bites fascial method for abdominal wall closure
75555678|NCT04982653|Procedure|Surgical Procedure|Undergo hepatectomy using conventional fascial method for abdominal wall closure
75412363|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
75714304|NCT05389813|Drug|Multivitamin with Minerals|Vit A 3000 IU, Vit B1 2.5mg, Vit B2 2.0mg, Vit B12 10mcg, Vit C 150mg, Vit D3 400 IU, Vit E10 IU, Biotin 25mcg, Nicotimamide 30mg, Calcium Pantothenate 3mg, Folic acid 800mcg, Iron Fumarate 18mg, Calcium 125mg, Magnesium Oxide 10mg, Iodine Potassium 150mcg, Manganese sulfate 0.5mg, Phosphorus 23.8mg, Copper sulfate 1.0mg, Molybdinium Sodium 0.10mg, Zinc Sulfate 5.0mg.
76041447|NCT02410551|Behavioral|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
75714306|NCT05387512|Drug|Camrelizumab|Patients with EGFR-mutation-negative and ALK-negative advanced non-squamous non-small cell lung cancer were treated with first-line chemotherapy in combination with camrelizumab.
76041448|NCT02410551|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
76041449|NCT02410551|Drug|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
76041450|NCT02424591|Drug|Ketamine|Infusion at a rate of 10 mcg/kg/min
76041451|NCT02424591|Other|Placebo|Placebo IV
75412364|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg QD
75412365|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
75412366|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
75412367|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
75555686|NCT04977154|Other|Primary prevention|The primary prevention that the trainers put in place for the hockey players
75555687|NCT04973345|Drug|Terbutaline|management of asthma symptoms
75555688|NCT04967417|Drug|Pemetrexed, Carboplatin, Pembrolizumab|"Pemetrexed 500mg/m2~Carboplatin AUC 5.0~Pembrolizumab 200mg"
75555689|NCT04967417|Drug|Paclitaxel, Carboplatin, Pembrolizumab|"Paclitaxel 200mg/m2~Caboplatin AUC 6.0~Pembrolizumab 200mg"
75555690|NCT04963725|Drug|Ustekinumab|No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
75555691|NCT04963192|Device|Connected actimeter to measure physical activity in OSA patients|Connected actimeter worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for OSA patients
75555692|NCT04963192|Device|Connected BORA Band to measure physical activity in COPD patients only|Connected BORA Band worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for COPD patients only
75555693|NCT04963192|Other|IPAQ to evaluated physical activity|Physical activity evaluated by IPAQ (International Physical Activity Questionnaire) at the inclusion, M3 and M6
75555694|NCT04963192|Device|Connected scale to measure weight|Weight measured by a connected scale, before CPAP or NIV treatment, at M3 and M6
75555695|NCT04963192|Device|Connected tensiometer to measure arterial pressure|Arterial pressure measured by a connected tensiometer, before CPAP or NIV treatment, at M3 and M6
75555696|NCT04963192|Device|Connected BORA Band to measure oxygen saturation in COPD patients only|Daily oxygen saturation measured by the connected BORA Band for COPD patients only during 6 months
75555697|NCT04963192|Device|Connected BORA Band to measure heart rate in COPD patients only|Daily heart rate measured by the connected BORA Band for COPD patients only during 6 months
75714307|NCT05371106|Other|exposure to mycotoxins|self-report eating questionnaire
75872724|NCT03648164|Other|CHAT-CS Survey|Students will complete a computer-based survey
75872725|NCT03430895|Drug|durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.
75872726|NCT03648086|Other|intestinal microbiota transplantation|Participants in Exprerimental group take 6 times IMT with 2-week intervals
76041452|NCT02408523|Drug|Lacosamide Tablet|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated Tablet~Concentration: 50 mg~Route of Administration: Oral use"
76041453|NCT02408523|Drug|Lasosamide Oral Solution|"Active Substance: Lacosamide~Pharmaceutical Form: Oral Solution~Concentration: 10 mg/ml~Route of Administration: Oral use"
76041454|NCT02408523|Other|Placebo Tablet|"Active Substance: Placebo~Pharmaceutical Form: Film-coated Tablet~Concentration: 50 mg~Route of Administration: Oral use"
75412368|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
75412369|NCT01271790|Drug|GS-9451 placebo|placebo matching GS-9451 tablet QD
75412370|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
75555698|NCT04963192|Device|Connected BORA Band to measure respiratory rate in COPD patients only|Daily respiratory rate measured by the connected BORA Band for COPD patients only during 6 months
76041455|NCT02408523|Other|Placebo Oral Solution|"Active Substance: Placebo~Pharmaceutical Form: Oral Solution~Concentration: 10 mg/ml~Route of Administration: Oral use"
75555699|NCT04963192|Other|EXASCORE to evaluated COPD severity|COPD severity evaluated by the EXASCORE questionnaire at inclusion, M3 and M6 for COPD patients only
76041456|NCT04830319|Other|Pilates Method|includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.
75412371|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
75555700|NCT04963192|Other|Epworth scale to evaluate sleepiness|Sleepiness evaluated by the Epworth scale at baseline, M3 and M6
75412372|NCT01270152|Drug|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
75412373|NCT01274988|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
76041457|NCT04830319|Other|task-oriented training protocol|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
75714308|NCT05365997|Other|Default Nudge|For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
75412374|NCT01274988|Other|methadone maintenance treatment|methadone maintenance treatment
75412375|NCT01278498|Drug|Escitalopram|first week:5mg 2nd week~12 week:10mg
75412376|NCT01278498|Drug|sugar pill|first week:5mg 2nd week~12 weeks:10mg
75412377|NCT01279980|Other|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
75412378|NCT01279980|Other|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
75412379|NCT00249834|Drug|Gonal-f|GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
75555701|NCT04963192|Other|Pichot scale to evaluate fatigue|Fatigue evaluated by the Pichot scale at inclusion, M3 and M6
75555702|NCT04963192|Other|Usability questionnaire|Subjective assessment of each device by means of usability questionnaire at M6
75555703|NCT04963192|Other|SF36 questionnaire|Quality of life evaluated by the SF36 questionnaire at inclusion and M6
75555704|NCT04955301|Behavioral|Priming intervention|The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.
75714309|NCT05363943|Procedure|double plating|open reduction and internal fixation by using lateral and medial plates.
75555705|NCT04954898|Device|Study Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT|Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.
76041458|NCT04836403|Other|Sinus and nasal quality of life survey questionnaire (SN-5)|"The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)"
76041459|NCT04836091|Behavioral|Waitlist|From day 31 to day 60 (ie., during month 2) of the trial, participants in the waitlist arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
76041460|NCT04836091|Behavioral|Intervention|From day 1 to day 60 (ie., entire 2 month duration) of the trial, participants in the intervention arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
76041461|NCT04836169|Device|InCaveo's EOA system with integrated mobile CBT|integrated pain management therapeutic and tapering system including a software apt that manages and tracks patient-reported outcomes, including pain levels, medication use, quality of life
75555706|NCT04951622|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
75555707|NCT04951622|Drug|Placebo|Matching placebo will be administered as an IV infusion.
76041462|NCT04836013|Dietary Supplement|combined Lactobacilli|1 oral stick per day for 30 days starting the day of antibiotic treatment
75412380|NCT00249834|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
75412381|NCT00249444|Drug|Mirtazapine|Mirtazapine
75412382|NCT00249444|Drug|Placebo|placebo
75555708|NCT04951609|Drug|Seltorexant|Participants will receive a single oral dose of seltorexant.
75555709|NCT04951609|Drug|Placebo|Participants will receive matching placebo orally.
75555710|NCT04940039|Drug|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
75555711|NCT04940039|Drug|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
75412383|NCT00249288|Drug|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
75412384|NCT00249288|Drug|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
75412385|NCT00247962|Drug|etanercept|50 mg
75412386|NCT00247962|Drug|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
75872730|NCT03712709|Diagnostic Test|Truenat MTB|The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
75872731|NCT04312386|Other|OPTIMAT|Baseline menue, not optimized
76041463|NCT04836013|Other|Placebo|1 oral stick per day for 30 days starting the day of antibiotic treatment
75555712|NCT04940039|Drug|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
75555713|NCT04940039|Drug|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
75555714|NCT04940039|Drug|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
76041464|NCT04822909|Drug|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study"
76041465|NCT04831099|Drug|Testosterone gel|The route of administration is transdermal.
75555715|NCT04940039|Drug|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
75714310|NCT05363943|Procedure|Distal femoral replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
75412387|NCT00247416|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 intravenously over 30 minutes on days 5 and 12.
75714311|NCT05363293|Drug|AL 001|a crystal engineered lithium-salicylate-proline lithium delivery product
75714312|NCT05363293|Drug|Placebo|matching placebo formulation
75412388|NCT00247416|Drug|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
75412389|NCT00247416|Drug|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
75412390|NCT00246090|Drug|E7389|E7389 1.4 mg/m^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
75412391|NCT00246012|Drug|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
75872732|NCT03718481|Other|ARCP Process|One Annual Review of Competence Progression (ARCP) cycle. In the U.K., doctors, across all specialities, undergo an Annual Review of Competence Progression (ARCP) to evaluate performance during each training year and determine progression to the next year of training. Similar processes exist in the Republic of Ireland. The process and requirements for ARCP in the UK are specified in the Gold Guide, the Reference Guide for Postgraduate Specialty Training [1]. It defines ARCP as a formal process that uses evidence collected by trainees to review and record performance, demonstrate competencies achieved and inform decisions regarding progression in training
75872733|NCT03452189|Drug|Vancomycin|Oral vancomycin 250mg capsules
75412392|NCT00246012|Drug|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
75412393|NCT00246012|Drug|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
75872734|NCT03452189|Other|Placebo|"Placebo Pills distributed by Research Pharmacy labeled placebo."
75555716|NCT04940039|Drug|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
75555717|NCT04940039|Drug|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
75872735|NCT04306380|Other|no intervention, database study|data collection from EMR for database
75872736|NCT03451721|Device|ImageReady™ MR Conditional Defibrillation System|Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
75872737|NCT00603954|Drug|Conditioning regimen: TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
75872738|NCT00603954|Drug|Conditioning regimen:TLI (8 Gy) + ATG|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
75872739|NCT03712631|Procedure|tunneling technique bone augmentation|horizontal ridge augmentation using mixture of xenograft,autogenous bone
75872740|NCT03712553|Behavioral|Opt-Out|Opt-In messaging prompts participants to contact their primary care provider to receive Hepatitis C screening whereas Opt-Out messaging includes a signed laboratory order for Hepatitis C screening.
75872741|NCT03712553|Behavioral|Letter|Participants receive messaging prompting them to contact their primary care provider to receive Hepatitis C screening, either as a letter or an electronic message on the MyPennMedicine patient portal.
76041466|NCT04831099|Drug|Placebo|The route of administration is transdermal
76041467|NCT04830085|Procedure|Hysterectomy|Hysterectomy (abdominal, vaginal or laparoscopic)
76041468|NCT04822831|Behavioral|45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The experimental group was given 45 degree Semi-sitting 2 hrs and upper-limb exercise training 10 mins once a day, and this intervention kept 4 weeks.
76041469|NCT04822831|Behavioral|no 45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The control group was with usual treatment.
75412394|NCT00245856|Drug|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
75412395|NCT00245856|Drug|Warfarin|Titrated to INR 2-3 through study month 3
75872742|NCT03712553|Behavioral|Behavioral Economic Messaging|Participants receive standard messaging about HCV and ways to get screened and messaging that incorporates behavioral economic principles such as norms, reciprocity, anticipated regret, and pre-commitment to get screening.
75872743|NCT03712553|Behavioral|Usual Care Messaging|Participants receive standard messaging about HCV and ways to get screening.
76041470|NCT04830241|Drug|Antidepressant|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
75412396|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
76041471|NCT04302337|Procedure|Curettage adenoidectomy with transoral endoscopic ablation|Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.
76041472|NCT04302337|Procedure|Conventional cold curettage adenoidectomy|Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
75412397|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
76041473|NCT03036943|Radiation|Fluciclovine|Fluciclovine (18F) PET/CT scan completed >= 48 hours prior to surgical resection for breast cancer
76041474|NCT03036865|Drug|BOS161721|Single dose administered IV or SC
75412398|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
75412399|NCT00244764|Drug|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
76041475|NCT03036865|Drug|Placebo|Single dose administered IV or SC
76041476|NCT04835389|Biological|AlloGen Liquid|Amniotic fluid
76041477|NCT04835389|Drug|Placebo|0.9% normal saline
76041478|NCT04832893|Diagnostic Test|steady intensity aerobic test of 30 minutes long|the use of different type of masks during an aerobic exercise
75412400|NCT00244764|Drug|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
75412401|NCT00244374|Biological|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects>18 years of age will receive the Twinrix vaccine and subjects<18 years of age will receive the Engerix-B vaccine. Cohort subjects>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
75412402|NCT00244374|Behavioral|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
76041479|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
76041480|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
76041481|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
75412403|NCT00244374|Behavioral|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
75872744|NCT04285242|Other|Observational assessments|Clinical assessments
75872745|NCT04271748|Other|Time Restricted Feeding|The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
75872746|NCT03427619|Drug|OK432|OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
76041482|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
76041483|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
76041484|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
75872747|NCT03407729|Other|Magnetic Resonance Imaging|MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.
76041485|NCT04367935|Drug|Pentoxifylline|Pentoxifylline tablets 400mg three times daily for 2 months
76041486|NCT04829773|Drug|Palovarotene|oral capsules
76041487|NCT04829773|Drug|midazolam|oral syrup
76041488|NCT04822285|Behavioral|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition& follow up).
75714313|NCT05358236|Other|Episiotomy Wound Care and Genital Hygiene Training|"Episiotomy wound healing and genital hygiene training were given face-to-face by researchers to the mothers assigned to the training group. The trainings were given to each mother individually in their rooms. The total training lasted an average of one hour. At the end of the training, the mothers were given a written and illustrated training brochure.~Training content~Primarily, external reproductive organs were shown to mothers through pictures.~Urethra, Vagina, Anus, Perineum areas were mentioned.~The definition of Episiotomy was made; and where and how it was applied was explained with visual materials. It was explained how to care for the episiotomy area to heal more rapid and healthier.~Information was given on how to change their menstrual pads.~Information was provided on what to look for when using underwear~What to watch out while taking a bath:~What to pay attention to in your stitch area"
76041489|NCT04822285|Behavioral|Routine psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
76041490|NCT04829695|Drug|Artesunate-amodiaquine drug combination|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
75412404|NCT00244374|Behavioral|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
75412405|NCT00242658|Behavioral|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
75412406|NCT00242580|Drug|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
75412407|NCT00242580|Drug|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
76041491|NCT04829695|Drug|Artemether-lumefantrine drug combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
76041492|NCT03035539|Other|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
75412408|NCT00242580|Drug|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
75412409|NCT00241644|Biological|Rotarix™|Two or Three doses, oral administration
75555718|NCT04940039|Drug|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
76041493|NCT03035539|Other|Standard treatment|Standard treatment
76041494|NCT04821973|Device|Radius PPG Tetherless Pulse Oximetry (Masimo)|continuous monitoring by a portable, wireless and stand-alone device
75872748|NCT03407729|Other|Cognitive Performance Testing|For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.
76041495|NCT04821973|Device|usual monitoring|usual nurse respiratory monitoring
75714314|NCT05345743|Procedure|Surgery|All types of surgery requiring general anesthesia
75872749|NCT03712475|Drug|Pregabalin|pharmacokinetic study under fasting conditions
75872750|NCT02435433|Drug|Ramucirumab|Administered IV
75872751|NCT02435433|Drug|Placebo|Administered IV
75872752|NCT01372371|Biological|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
76041496|NCT04822207|Procedure|acupuncture|Patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. Every acupuncture lasts 20 minutes.
76041497|NCT03035695|Device|Axiostat®|
76041498|NCT03035695|Device|Cotton Gauze|
76041499|NCT04822051|Other|The Uncertainty Management Psychoeducation Program|The program is conducted in the form of individual psychoeducation. The training was planned to include a total of five sessions, with 60 minutes for each session once a day, and at least two sessions a week. At least two days of a gap was decided between two consecutive sessions.
75714315|NCT05341167|Device|HPI algorithm using Edwards device https://www.edwards.com/gb/devices/decision-software/hpi|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
75872753|NCT01372371|Biological|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
76041500|NCT04821427|Behavioral|Brief mhealth intervention + mobile messaging to reduce sexual risk behavior and heavy drinking|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages to reduce heavy episodic drinking and sexual risk behavior (condomless anal intercourse) among Black/African American and Hispanic/Latino men who have sex with men
75412410|NCT00241644|Biological|Placebo|One or three doses, oral administration.
75412411|NCT00245622|Biological|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
75412412|NCT00245622|Biological|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
75412413|NCT03800784|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
75412414|NCT03809754|Procedure|Percutaneous Coronary Intervention under OCT|After randomization, subjects receive primary PCI under the guiding of OCT
75412415|NCT03809754|Procedure|Percutaneous Coronary Intervention under Angiography|After randomization, subjects receive primary PCI under the guiding of angiography
75412416|NCT03809676|Other|periodontal examination|clinical measurements were recorded
75412417|NCT03809832|Diagnostic Test|Microbiological sampling|An microbiological sampling of the ventilator humidifier will be performed.
75412418|NCT03808974|Other|Educational video|Short educational video describing the mid-urethral sling procedure
75412419|NCT03808974|Other|Educational leaflet|Standard educational leaflet describing the mid-urethral sling procedure
75412420|NCT03808896|Procedure|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
75412421|NCT03808896|Device|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
75412422|NCT03809130|Other|Internet-Based Intervention|Use Untire application after baseline up to 6 months
75555719|NCT04939662|Drug|Olaparib+Bevacizumab to SCLC patients|"Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
75412423|NCT03809130|Other|Internet-Based Intervention|Use Untire application after 3 months up to 6 months
75412424|NCT03809130|Other|Quality-of-Life Assessment|Ancillary studies
75412425|NCT03809130|Other|Questionnaire Administration|Ancillary studies
75412426|NCT03808428|Device|Ankle Group|Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
75412427|NCT03808116|Device|SmartBx|"he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~To preserve sample unity, including core fragments in their original location along the needle notch.~Avoid sample damaging during sample removal from the needle and the following pathology process."
75555720|NCT04936542|Biological|AboBoNT-A|AbobotulinumtoxinA for injection: 500 Unit vial. Dose: 900 Units (3.6 mL)
75555721|NCT04936542|Biological|OnaBoNT-A|OnabotulinumtoxinA for injection: 200 Unit vial. Dose: 360 Units (3.6 mL)
75872754|NCT01372371|Biological|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
75872755|NCT05167383|Device|VRH (Virtual Reality Hypnosis)|Hypnosis is delivered as a standardized therapeutic intervention through virtual reality, using a digital sedation software (AQUA ®, Onfomfort SA).
76041501|NCT04821583|Drug|Hydrocortisone|Hydrocortisone is orally administered.
76041502|NCT04821583|Drug|Placebo|Placebo is orally administered.
75555722|NCT04936308|Drug|Guselkumab|Participants will receive guselkumab as SC injection.
75555723|NCT04936308|Drug|Placebo|Participants will receive matching placebo as SC injection.
75555724|NCT04935203|Behavioral|Priming intervention|The priming manipulation will be embedded in one computerized experiment to test the effect of three priming interventions on people's emotional reaction and their subsequent sustainable food selection. The priming conditions include priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively. The cueing manipulation will be achieved by asking participants to complete a word-search exercise. Brief introduction will be provided to guide participants to choose words/statements that can indicate having a health and sustainable diet can have one of the three benefits: health benefits, environmental benefits or both benefits. The exercise will take ~2 min.
75555725|NCT04929210|Drug|Guselkumab|Guselkumab will be administered as subcutaneous injection.
75555726|NCT04929210|Drug|Placebo|Matching placebo will be administered as subcutaneous injection.
75555727|NCT04928807|Combination Product|Short course radiotherapy sequential camrelizumab and chemotherapy|Short course radiotherapy, 5 * 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
75555728|NCT04923893|Drug|Bortezomib|Bortezomib will be administered SC.
75555729|NCT04923893|Drug|Dexamethasone|Dexamethasone will be administered orally.
75555730|NCT04923893|Drug|Lenalidomide|Lenalidomide will be administered orally.
75555731|NCT04923893|Drug|Cilta-cel|Cilta-cel infusion will be administered.
75714316|NCT05341167|Drug|Vasoactive Agent|Hypotensive episodes will be treated with vasoactive agents and fluids. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
75555732|NCT04923893|Drug|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
75714317|NCT05339555|Other|Instructions for IUD Self-Removal Provided to Participant|The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
75714318|NCT05325047|Procedure|Intensive speech rehabilitation|Combination an e-health device allowing the patient to self-rehabilitate with a face-to-face approach of accompaniment and support of the patient by the speech therapist.
75555733|NCT04923893|Drug|Fludarabine|Fludarabine will be administered intravenously.
75555734|NCT04922164|Behavioral|Cue intervention|"Around 30 pieces of narrative information about how a mother behaves in specific decision context will be derived from our qualitative study to construct social normative cues.~For goal-related cues, words relating to each category of breastfeeding-related values, benefits and goals will be identified and used to construct the messages (e.g. attractive body shape, smart baby, natural, strong immunity and etc.). Each goal-priming message will be presented with brief priming words and a picture of an image of the desirable goal."
75555735|NCT04921969|Drug|Ruxolitinib|The study cream will be applied topically twice a day for up to 52 weeks.
75714319|NCT05319054|Device|Sacral NeuroModulation|Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.
75555736|NCT04921969|Drug|Vehicle Cream|Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
75714320|NCT05319054|Device|Trans-Anal Irrigation|Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.
75714321|NCT05319054|Other|Optimised Conservative Management|Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.
75555737|NCT04920578|Drug|JNJ-69095897|JNJ-69095897 will be administered orally in Parts 1, 2 and 3.
75555738|NCT04920578|Other|Placebo|Matching placebo will be administered orally in Parts 1 and 3.
75412428|NCT03808038|Other|None- Observational Study|None- Observational Study
75412429|NCT03807960|Other|written form|The written form which include PCA usage information.
75714322|NCT05318027|Device|ChatBot|The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits. The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups. High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video. Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day. Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV). If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.
75714323|NCT05311007|Other|Evaluation of the incidence and nature of adverse events|Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
75714324|NCT05301751|Drug|AG-73305|AG-73305 Ophthalmic Solution
75714325|NCT05293132|Drug|Montelukast Sodium 10 mg|Film coated tablets containing 10 mg montelukast
75412430|NCT03807960|Other|video|The video about PCA usage
75412431|NCT03807960|Other|routine care|The routine description about PCA usage
75412432|NCT03807726|Behavioral|Simulation breastfeeding education|The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy.
75412433|NCT03807570|Dietary Supplement|Morus Alba L. Extract|Morus Alba L. Extract 30 ml/day for 12 weeks.
75555739|NCT04919642|Drug|TT-00420|TT-00420 tablet, administered orally once daily
75714326|NCT05293132|Drug|Co-Enzyme Q10|Capsules contain 210 mg Co-Enzyme Q10
75714327|NCT05293132|Drug|Standard Treatment|Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
75412434|NCT03807570|Dietary Supplement|Placebo|Placebo 30 ml/day for 12 weeks.
75555740|NCT04919512|Drug|TAR-200|TAR-200 will be administered.
75555741|NCT04919512|Biological|Cetrelimab|Cetrelimab will be administered.
75412435|NCT03807258|Other|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
75714328|NCT05288361|Diagnostic Test|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|"Patients presenting with symptomatic ischemic heart disease (including chronic stable angina or unstable angina) without evidence of myocardial infarction who require elective or urgent cardiac catheterization, and who meet all eligibility criteria will be enrolled.~Participants will undergo routine coronary angiography as well as comprehensive physiologic assessment with intracoronary acetylcholine provocation for diagnosis of vasospastic angina (VSA), coronary thermodilution to evaluate for coronary microvascular dysfunction (CMD), and intracoronary imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) to evaluate for the presence of atheroma, plaque burden, and myocardial bridging."
75412436|NCT03807180|Other|Tai Chi (exercise)|Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
75555744|NCT04912830|Procedure|Tension-free vaginal tape|female incontinence surgery with polypropylene tape applied
75555745|NCT04912375|Behavioral|Priming intervention|The pilot RCT will ask participants to complete a simple word-searching exercise as a goal-priming of healthy eating and can be completed in 5 min.
75412437|NCT03806712|Other|multi method questionary (developped by De Rosa, in 1995 and 2014)|questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
75412438|NCT03807024|Diagnostic Test|Bladder diary|3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
75412439|NCT03806868|Other|voucher for ordering foods (ONLY omega-3 rich foods)|A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.
75714329|NCT05281627|Other|Emergency Laparotomy|All patients undergoing Emergency Laparotomy
75714330|NCT05265949|Behavioral|diet and physical activity intervention|Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
75872756|NCT05167383|Behavioral|Standard care|The standard treatment (ST) for labor pain as used in our hospital contains massage, aquatherapy and postural exercises. This is always available for any woman in labor.
75872757|NCT01374711|Drug|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
75412440|NCT03806868|Other|voucher for ordering foods in general (any type of foods)|A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
75412441|NCT03806478|Drug|APH-1105|The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
75412442|NCT03806478|Other|Placebo|The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
75412443|NCT03806010|Procedure|Quantitative sensory testing|Quantitative sensory testing
75714331|NCT05259774|Device|Relizema cram|Relizema cream is a CE marked, Class IIa medical device, dermatological cream for topical use indicated for symptomatic treatment of dermatitis and erythema. Relizema cream is indicated for the treatment of itching and flushing associated with different types of dermatitis, including atopic dermatitis.
75714332|NCT05237908|Device|Transforaminal Lumbar Interbody Fusion|Interbody Fusion means the operative immobilization or ankylosis of two or more vertebrae by fusion of the vertebral bodies with a short bone graft or often with diskectomy or laminectomy. (From Blauvelt and Nelson, A Manual of Orthopaedic Terminology, 5th ed, p236; Dorland, 28th ed
75714333|NCT05234892|Device|ALTO endograft implantation|Implantantion of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
75872758|NCT01374711|Drug|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
75872759|NCT01374711|Other|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
75872760|NCT05167071|Drug|HBM4003|Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
75872761|NCT05167071|Drug|Toripalimab|Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
75872762|NCT03120351|Drug|Lidoderm 5 % Topical Patch|Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
75412444|NCT03805776|Other|Fasting (diet restruction for specific period)|12-14 hours fasting
75412445|NCT03805620|Other|Combined physical-cognitive training|combined physical-cognitive training
75412446|NCT03805620|Other|Physical training|Multi-component physical exercise
75412447|NCT03805620|Other|Cognitive training|cognitive training
75555746|NCT04910607|Other|Questionnaire|"Questionnaire with 4 axes:~sociological, reflexive medical, prospective medical, transversal"
75555747|NCT04910607|Other|Interview|Interview concerning health pathways, experience of confinement, consequences of confinement on health, representations of obesity.
75412448|NCT03805542|Combination Product|0.5% Iodophors|Before lithotripsy, 0.5% iodophor 40 ml(depending on the degree of hydronephrosis) was used to perfuse the calculous side pelvis under low pressure for 5 minutes.
75714334|NCT05231980|Dietary Supplement|Alpha lipoic acid (ALA)|ALA is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect.
75412449|NCT03805152|Drug|Neuronox(R)|Injection botulinum toxin intramuscular for affected neck muscle
75412450|NCT03805152|Drug|Dysport (R)|Intramuscular injection
75412451|NCT03804840|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication (Broyd et al, 2016; Hartman and Huestis, 2013).
75555748|NCT04899362|Device|BB-RIC-D1/LAPUL Medical Devices Co, Ltd, China|The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.
75714335|NCT05231980|Drug|Pentoxifylline (PTX)|Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
75714336|NCT05231980|Drug|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
75872763|NCT03120351|Drug|Placebo patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
75872764|NCT05165355|Drug|Furmonertinib|Furmonertinib (80 mg orally, once daily) for 3 years.
76041503|NCT04834921|Device|Ultraflux® EMiC®2|Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
76041504|NCT04829149|Other|Observational|Statin therapy group and Rosuzet tablet group
76041505|NCT01668355|Other|Patient Aligned Care Team (PACT)|An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
76041506|NCT01667731|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
76041507|NCT01667731|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
76041508|NCT05618119|Drug|[18F]MC225|[18F]MC225 PET scan
76041509|NCT04828759|Behavioral|VR-treatment|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
75412452|NCT03804840|Drug|Placebo|Placebo
75555749|NCT04899362|Procedure|Intravenous blood collection|Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
76041510|NCT04828759|Behavioral|Treatment as usual|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
76041511|NCT04828525|Drug|Dexamethasone|adjuvant dexamethasone treatment
75555750|NCT04899362|Device|dCA measurement|Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
75714337|NCT05225675|Biological|ARGX-117|Intravenous administration of ARGX-117
75714338|NCT05225675|Other|Placebo|Intravenous administration of placebo
75714339|NCT05223166|Drug|Pitolisant|Wakix tablet
75872765|NCT01374789|Drug|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
76041512|NCT04828525|Drug|normal saline|placebo
76041513|NCT04821505|Behavioral|Health Education|didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.
76041514|NCT04821505|Behavioral|Transcendental Meditation|TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
75555751|NCT04898634|Drug|JNJ-78278343|JNJ-78278343 will be administered subcutaneously (injection or infusion) or via intravenous infusion.
75555752|NCT04894344|Behavioral|Education group|Is taught to choose low-sodium foods
76041515|NCT04835155|Procedure|Premature Infant Oral Motor Intervention (PIOMI)|The Premature Infant Oral Motor Intervention (PIOMI), developed by Dr. Brenda Lessen Knoll, was chosen for this study because it is the only oral motor program designed specifically for preterm babies as young as 29 weeks post menstrual age (PMA) and is the only program with a standardized training method and published intervention fidelity. The 5 minute therapy offers assisted movement to activate muscle contraction and movement against resistance to build strength in the perioral structures. The PIOMI has 8 steps where a provider uses a pinky finger to provide gentle stroking and pressure on the cheeks, lips, tongue, gums and palate to strengthen the oral sensory-motor functions and improve feeding efficiency. PIOMI ends with 2 minutes of NNS. NNS and oral stimulation have been found to mature the oral motor sensory system, and improve not only bottle feeding, but also breastfeeding.
75412453|NCT03804762|Procedure|the third space robotic and endoscopic cooperative surgery|This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.
75412454|NCT03804450|Procedure|Regenerative endodontic procedures (REPs)|Instrumentation using rotary Pro-Taper Next, disinfection using sodium hypochlorite and calcium hydroxide as intracanal medication followed by induction of blood and application of Biodentine as a cervical plug.
75412455|NCT03804372|Drug|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
75412456|NCT03804372|Drug|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
75412457|NCT03804372|Drug|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
75412458|NCT03803982|Procedure|Deep Neuromuscular Blockade|The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
75412459|NCT03803982|Drug|Sugammadex|Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
75412460|NCT03804216|Other|Multimodal Imaging Analysis|The patients are seen in consultation ophthalmological before and the 1 hour after their session of dialysis. THE OCT angiography and other not invasive ophthalmological examinations will be realized during the follow-up
75412461|NCT03803670|Diagnostic Test|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
75412462|NCT03803514|Drug|Recombinant EPO|Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
75412463|NCT03803358|Other|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
75412464|NCT03803358|Other|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
75412465|NCT03803124|Drug|Tolvaptan|1 tablet before renography
75555753|NCT04893811|Biological|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
75555754|NCT04892264|Biological|Belantamab Mafodotin|Given IV
76041516|NCT04828915|Other|Machine learning|Machine learning on vital parameters, clinical symptoms and underlying diseases
75412466|NCT03803124|Drug|Placebo|1 tablet before renography
75412467|NCT03802734|Device|Mindful meditation phone app|Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
75412468|NCT03802500|Diagnostic Test|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is < 2,5 mV."
75412469|NCT03802032|Drug|Lidocaine Gel|topical lidocaine gel
75555755|NCT04892264|Biological|Daratumumab|Given IV
75555756|NCT04892264|Drug|Dexamethasone|Given PO
75555757|NCT04892264|Drug|Lenalidomide|Given PO
75555758|NCT04892264|Other|Quality-of-Life Assessment|Ancillary studies
75555759|NCT04890613|Drug|CX-5461|150 mg sterile lyophilized powder containing 1% sucrose
75555760|NCT04889989|Device|Microwave Ablation|Percutaneous microwave ablation using the NeuWave Microwave Ablation System for non-small cell lung cancer or oligometastatic lung tumors
75714340|NCT05223166|Drug|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
75714341|NCT05210998|Other|Gradual Aerobic exercise training AND Respiratory muscle training|Combined Exercise Group
75555761|NCT04886531|Drug|Neratinib|120mg for 7 days; 160mg for 7 days ; 240mg for 7 days. 240 mg (up to a maximum of 24 weeks) orally daily*.
75412470|NCT03802032|Drug|KY jelly|topical KY jelly
75412471|NCT03802266|Device|Electromagnetic Navigation guided transthoracic needle aspiration|Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
75412472|NCT03802266|Device|CT-guided Transthoracic Needle Aspiration|Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
75714342|NCT05210998|Other|Gradual Aerobic exercise training|Aerobic exercise Group
75714343|NCT05205980|Behavioral|Perturbation training|Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
75872766|NCT01374789|Drug|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
75872767|NCT05164809|Device|Application of novel electrodes|Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics
75714344|NCT05202938|Diagnostic Test|ultrasound cardiography|Ultrasound to check heart functions and systolic ejection fraction.
75872768|NCT05101083|Device|New Receiver-in-Canal Device|Successor of previous device generation
75555762|NCT04886531|Drug|Letrozole (L) or Anastrozole (A)|L: (2.5 mg) OR A: (1 mg) orally daily (up to a maximum of 24 weeks)*
75555763|NCT04886531|Drug|Trastuzumab|All Arms 8mg/kg loading dose followed by 6mg/kg every 3 weeks administered every 3 weeks by IV starting wk 4. Trastuzumab biosimilars may be used per institutional guidelines.
75714345|NCT05202938|Diagnostic Test|FDG PET scan|FDG venous injection and positron emission tomography scan.
75555764|NCT04883619|Other|Placebo|Placebo will be administered intravenously.
75555765|NCT04883619|Drug|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
75555766|NCT04883619|Drug|Standard-of-care treatment|Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
75555767|NCT04882878|Other|Placebo|Placebo will be administered intravenously.
75555768|NCT04882878|Drug|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
75555769|NCT04882878|Drug|Standard-of-care treatment|Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
75555770|NCT04882098|Drug|Guselkumab|Participants will receive guselkumab as SC injection.
75555771|NCT04882098|Drug|Placebo|Participants will receive matching placebo as SC injection.
75714346|NCT05202938|Diagnostic Test|Palmitate PET scan|C11-Palmitate venous injection and positron emission tomography scan.
75714347|NCT05202938|Diagnostic Test|Acetate PET scan|C11-Acetate venous injection and positron emission tomography scan.
75714348|NCT05202938|Diagnostic Test|Blood sampling|Collecting 20ml of venous blood.
75412473|NCT03801798|Drug|GC1102|NAs antivirals+GC1102 180,000 IU
75412474|NCT03801798|Other|GC1102 Placebo|NAs antivirals+GC1102 Placebo
75412475|NCT03801252|Drug|Cefazolin|intravenous drugs used as prophylactic antibiotics
75412476|NCT03801252|Drug|Placebo|Intravenous saline
75555772|NCT04879849|Drug|Pembrolizumab|IV infusion.
75555773|NCT04879849|Drug|TAK-676|IV infusion.
75555774|NCT04879849|Radiation|Image-guided radiation therapy|Radiation therapy.
75555775|NCT04870606|Drug|Proxalutamide (GT0918)|Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
75714351|NCT05186233|Behavioral|Phototherapy|Light exposure recommendations provided by SHIFT mobile application
75872769|NCT05101083|Device|Legacy Receiver-in-Canal Device|Receiver-in-canal device available on the market
75872770|NCT02354703|Drug|Ondansetron|Ondansetron (0.33 mg) bid+ BBCET counseling
75872771|NCT02354703|Drug|Placebo|Placebo + BBCET counseling
75872772|NCT00740181|Drug|chemotherapy|
75872773|NCT00384111|Drug|Zevalin Therapeutic Regimen|Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
75872774|NCT00384111|Drug|R-CVP|Standard R-CVP
75872775|NCT05008887|Drug|Methotrexate|Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
75872776|NCT05008887|Drug|5-fluorouracil|Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
75872777|NCT05008887|Device|Fractional CO2 laser|Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo
75872778|NCT01376115|Drug|Nelarabine|
75555776|NCT04870606|Drug|Placebo|Placebo+Standard of care determined by PI and local regulatory
75555777|NCT04864054|Biological|ECT204 T cells|ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.
75412477|NCT03801252|Drug|Azithromycin|prophylactic antibiotic
75412478|NCT03801018|Other|Questionnary and Interviews|"An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation."
75412479|NCT03801096|Behavioral|Narrative Based Therapuetic Assessment (NbTa)|The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry & Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White & Epston, 1990).
75714352|NCT05182632|Behavioral|Group pelvic floor telerehabilitation|Multimodal group physiotherapy: 12 weeks of weekly group physiotherapy treatments including education and pelvic floor muscle exercises delivered online + home exercise program
75412480|NCT03801096|Behavioral|Health Education Control Condition (HE)|The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
75555778|NCT04862923|Drug|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to treat the participant with a given product is independent of the decision to include him/her in the study.
75555779|NCT04861337|Drug|Remimazolam|Remimazolam is infused at a rate of 0.25 mg/kg/h from end of anesthesia induction until 15 minutes before the end of surgery.
75714353|NCT05182476|Drug|Placebo|Oral tablets
75714354|NCT05182476|Drug|Luvadaxistat|Oral tablets
75714355|NCT05180227|Device|DS8R|transcutaneous stimulation of the spinal cord.
75714356|NCT05180227|Diagnostic Test|Orthostatic tilt|perform an orthostatic tilt without and with stimulation.
75714357|NCT05173051|Other|Solid Medication intake vs. crushed medication intake|The swallowing ability for solid and crushed medications in stroke patients is evaluated.
75555780|NCT04861337|Drug|Placebo|Normal saline is infused at a rate same as in the remimazolam group from end of anesthesia induction until 15 minutes before the end of surgery.
75555781|NCT04857463|Other|Nutritional supplement drink|At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.
75714358|NCT05171062|Drug|bexmarilimab (FP-1305)|standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
75714359|NCT05171062|Drug|Pembrolizumab|Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
75714360|NCT05168384|Combination Product|Extracorporeal Photopheresis|"ECP procedures will be performed using a Therakos Cellex integrated, closed photopheresis system (Therakos, Inc., a Mallinckrodt Pharmaceuticals Company).~ECP will administered according to the following schedule (Group A):~Weeks 1-8: Twice per week (16 sessions). Weeks 9-16: Once per week (8 sessions). Weeks 17-24: Once every 2 weeks (4 sessions). Total: 28 sessions (within 24 weeks)."
75714361|NCT05168384|Combination Product|MS standard of care|Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN, excluding B cells therapies
75714362|NCT05164471|Genetic|verbrinacogene setparvovec|FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
75714363|NCT05148962|Biological|GRT-R910 10 mcg Dose (after AZ)|10 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
75412481|NCT03800706|Drug|TQB2450|TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
75412482|NCT03800628|Other|qualitative study|semi-structured interviews
75412483|NCT03800550|Drug|Bedaquiline|Bedaquiline tablet will be administered, orally.
75412484|NCT03800550|Drug|Clarithromycin|Clarithromycin tablet will be administered, orally.
75412485|NCT03800472|Drug|GLPG3312 IR|GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
75412486|NCT03800472|Drug|Placebo|Placebo tablets
75714364|NCT05148962|Biological|GRT-R910 30 mcg Dose (after AZ)|30 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
75714365|NCT05148962|Biological|GRT-R910 10 mcg Dose (After Adenovirus based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
75714366|NCT05148962|Biological|GRT-R910 10 mcg Dose (after mRNA based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
75714367|NCT05140941|Drug|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet|One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
75714368|NCT05130840|Diagnostic Test|MRI|MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks).
75714369|NCT05130840|Diagnostic Test|Lumbar puncture|LP at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA.
75714370|NCT05119842|Device|APrevent® VOIS-Implant|To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
75412487|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
75555782|NCT04857463|Other|Nutritional education|At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
75555783|NCT04856891|Drug|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
75555784|NCT04856891|Other|Placebo|Placebo
75555785|NCT04853810|Other|CUTADIAB questionnaire|During a regular diabetes follow-up consultation, the patient is asked to complete the CUTADIAB questionnaire on a tablet, entirely dedicated to the study
75555786|NCT04851145|Diagnostic Test|Mass spectrometry-based proteomics of FFPE biopsies and urine samples|"The biopsy and urine samples will be processed by the OncoProt platform (University of Bordeaux) for proteomic analysis by tandem mass spectrometry (label-free quantification) as follows:~Biopsies: laser microdissection of the renal cortex, fixation reversion, protein extraction and electrophoretic migration, tryptic digestion.~Urines: samples concentration by centrifugation/filtration and tryptic digestion according to a protocol adapted from the FASP method (Filter-Aided Sample Preparation)"
75714371|NCT05108441|Other|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris|In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
75714372|NCT05101902|Other|Pre-Screening|No intervention given
75412488|NCT03800472|Drug|GLPG3312 FE MR|GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
75714373|NCT05094882|Procedure|pulmonary lobectomy|resection of lung lobe
75412489|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
75412490|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).
75714374|NCT05072574|Other|Specific dietary treatment and follow-up using coaching techniques|Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
75714375|NCT05070988|Other|Semi-structured interview|Semi-structured interview with the investigating doctor of the study lasting 30 minutes to an hour
75714376|NCT05068440|Drug|Zanubrutinib|administered orally as capsules
75412491|NCT03800472|Drug|Placebo|Placebo optimized tablets
75412492|NCT03800316|Device|Video Consultation|Video consultation with emergency medicine physicians for patients that are critically ill prior to arrival in the ED
75412493|NCT03809286|Device|active rTMS|rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.
75412494|NCT03809286|Behavioral|Inpatient admission|All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.
75714377|NCT05059938|Behavioral|MyFitnessPal user|Patients will be counseled on how to use the MyFitnessPal application to help with the patient's weight loss goals. The physician will monitor the patient's weight, blood pressure, and waist circumference over up to a six month period with visits at 1, 3, and 6 months. Patients will be asked about the patient's use of the application at the end of the study.
75714378|NCT05050305|Drug|Marizomib|Intravenous Infusion
75872779|NCT01376193|Drug|Naratriptan|Collection of safety data
75872780|NCT01373073|Other|Experimental human milk fortifier|Human milk fortifier to be added to human milk feedings
75872781|NCT01373073|Other|Control human milk fortifier|Control human milk fortifier to be added to human milk
75412495|NCT03809286|Device|sham rTMS|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
75412496|NCT03805698|Device|Platelet-rich Plasma (PRP)|The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
75412497|NCT03805698|Other|Standard Arthroscopic Debridement|Standard arthroscopic debridement. No PRP injection.
75714379|NCT05050305|Drug|Pomalidomide|Taken orally
75714380|NCT05050305|Drug|Dexamethasone|Taken orally
75872782|NCT04944771|Drug|Capivasertib|Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
75872783|NCT04944771|Drug|Rabeprazole|Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
75412498|NCT03804684|Diagnostic Test|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.
75412499|NCT03804684|Diagnostic Test|visuALL Field Analyzer|visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.
75555787|NCT04850781|Behavioral|Bi-weekly frozen meal home delivery|All participants randomized to this arm will receive 10 frozen meals that are mailed to their home every two weeks from a MOW vendor, TRIO foods.
75555788|NCT04850781|Behavioral|Daily home meal delivery|All participants randomized to this arm will receive meals delivered to their home multiple times per week from a MOW program employee/volunteer with a wellness check and socialization.
75714381|NCT05048667|Device|Shock Wave therapy (SWT)|Each SWT will administer 720 shocks in the treatment arm. Total of 3600 shocks are given over 5 weeks treatment period.
75714382|NCT05048667|Drug|Platelet Rich Plasma (PRP)|5 mL PRP will be administered via intracavernous injection
75714383|NCT05048667|Other|Sham SWT|Sham Shockwave Therapy will be administered in the sham arm.
75714384|NCT05048667|Other|Placebo Saline|5 mL Placebo saline will be administered via intracavernous injection in the sham arm.
75714385|NCT05044104|Device|Consumer-facing wearable smart watch|Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
75714386|NCT05036616|Device|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
75714387|NCT05034276|Other|MORE-VR|Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
75714388|NCT05030571|Device|DPMAS|DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China)
75872784|NCT01374945|Device|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
75872785|NCT05197413|Dietary Supplement|Arrae bloat supplement|The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
75412500|NCT05318430|Device|Subcutaneous closed-suction drainage device|This subcutaneous closed-suction drainage device was designed to be placed subcutaneously when surgeons have completed all intra-abdominal operations and are about to suture subcutaneous layer and skin
75412501|NCT05744154|Behavioral|Audit & feedback with educational outreach and facilitation|As in arm descriptions
75412502|NCT05744154|Behavioral|Simple audit & feedback (usual practice)|As in arm descriptions
75555789|NCT04844775|Biological|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.~CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
75555790|NCT04844775|Biological|DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)|"Drep-HIV-PT1 1mg (see above)~Drep-HIV-PT1 1mg (see above)"
75714389|NCT05030571|Other|standard treatment|standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.
75872786|NCT01375023|Radiation|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
75872787|NCT01375023|Biological|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
75872788|NCT05197101|Procedure|balloon catheter combined with oxytocin induction|Balloon catheter for 12 hours and oxytocin for up to 3days.If failed , they will be treated ceacrean.
75412503|NCT05743920|Behavioral|Self-help Forest Bathing|The self-help forest bathing includes two sessions (i.e., participants will perform the first intervention within week 1 to 3, and the second intervention within week 4 to 6) that are related to the following forest bathing activities : (a) forest meditation, (b) forest walking, (c) calling attention to sensory experiences of the forest, including seeing, hearing, touching, and smelling, and (d) building connection to the nature by partnership invitation. Each session will last for 45 minutes.
75412504|NCT05743530|Device|TENS - transcutaneous electrical nerve stimulation|Pre-operative day 1 till postoperative day 14.
75412505|NCT05743530|Other|Placebo|Pre-operative day 1 till postoperative day 14.
75412506|NCT05743452|Device|GBR with CS@Mg|The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
75412507|NCT05743218|Other|electropuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675."
75412508|NCT05742906|Device|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
75412509|NCT05742750|Drug|Camrelizumab and Apatinib Plus GP|"Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.~Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks.~GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason."
75412510|NCT05742516|Dietary Supplement|Bimuno Daily|Galactooligosaccharide supplement within Bimuno Daily
75412511|NCT05742516|Dietary Supplement|Placebo|Maltodextrin powder
75412512|NCT05742360|Device|CPAP therapy|CPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype
75412513|NCT05740878|Dietary Supplement|immunonutrients oral nutritional supplements|1 serving of ONS immunonutrients which is 57 grams of ready-to-brew powder yields 200 ml of a liquid formula containing 251 kcal energy (1.26 kcal/ml), 9 grams protein (14%), 94 mg omega-3, and 20 mg anthocyanins.
75714390|NCT05029154|Behavioral|High intensity interval exercise|Patients in the exercise group will perform interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Patients will undergo 2 initial training sessions at the exercise physiology core lab. All exercise will consist of stationary cycling to avoid discomfort associated with abdominal surgery as well as stress to the incision and help reduce fall risk. Study investigators will check in weekly with participants and remotely track exercise data and compliance via the Fitbit app.
75412514|NCT05740878|Dietary Supplement|standard oral nutritional supplements|1 serving of standard ONS which is 57 grams of ready-to-brew powder yields 200 ml of liquid formula containing 258 kcal energy (1.26 kcal/ml), 5 g (7.5%) protein , 7 g (24%) fat, 43 g (68%) carbohydrate
75412515|NCT05740332|Drug|Alcohol hand sanitizer foam|"1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)"
75412516|NCT05737992|Other|Exercise in water|"Participants will do some exercises in water for 30-60 minutes. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg Rate of Perceived (RPE) Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
75412517|NCT05557266|Behavioral|Mindfulness-based intervention|An mindfulness instructor will conduct meditations lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have audio files designed ad hoc with the practice of the week so they can do it individually at home.
75412518|NCT05557266|Behavioral|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have video files designed ad hoc with the practice of the week so they can do it individually at home.The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
75714391|NCT05029154|Behavioral|Attention control|Patients in the control group (physical activity education and physical activity monitoring) will receive counseling regarding the benefits of physical activity during chemotherapy treatment. During the intervention, participants will receive a weekly phone call to discuss their physical activity and remind them to engage in physical activity. Patients will be given a goal of working up to 30 minutes of exercise daily. Subjects will be urged to increase daily step counts by 250-500 steps/day. Physical activity will be objectively assessed and made available to the participant using a Fitbit.
75714392|NCT05026554|Genetic|Tape stripping|Optional genetic analysis for chronic hand eczema
75555791|NCT04844775|Biological|DNA-HIV-PT123 4mg and CN54gp140/MPLA-L|"DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef~CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
75555792|NCT04844203|Diagnostic Test|Polygraphy with surface electrodes|Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG
75555793|NCT04842591|Diagnostic Test|exercise echocardiography|All patients will undergo exercise echocardiography during a symptom-limited cardiopulmonary exercise test.
75714393|NCT05020327|Drug|Graded Oral Amoxicillin Challenge|Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval
75872789|NCT05039775|Device|EROS device|Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.
75872790|NCT05039775|Behavioral|Psychosexual support|Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.
75872791|NCT05197023|Drug|SHR-1819 injection or placebo|Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week
75872792|NCT03633669|Diagnostic Test|Fecal calprotectin|Testing every 3 months
75872793|NCT03633669|Other|Routine care|As per treating gastroenterologist
75872794|NCT01375101|Drug|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
75872795|NCT01375101|Drug|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
76041517|NCT04828915|Other|Machine based evaluation|Quantification of the prediction power and identification of the most relevant predictive parameters
75714394|NCT05020327|Other|De-labelling in electronic medical record|Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
76041518|NCT04427683|Behavioral|Brief mindful parenting program|Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
76041519|NCT04828213|Device|Rapid Maxillary Expansion Treatment with Tooth-borne RME appliance (Hyrax)|The patients were treated with a expansion appliance containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
75714395|NCT05020327|Other|Referral to Allergy Immunology/Retention of Allergy Label|Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
76041520|NCT04828213|Device|Rapid Maxillary Expansion Treatment with Hybrid hyrax RME appliance|The patients were treated with a Hybrid hyrax RME appliance containing a Hyrax expansion screw positioned parallel to the second premolars and mini-screws. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
75412519|NCT05543928|Drug|CTAP101|CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
75412520|NCT05543928|Drug|Placebo|Placebo
75555794|NCT04836559|Drug|JNJ-40411813|JNJ-40411813 will be administered orally.
75555795|NCT04836559|Drug|Placebo|Placebo will be administered orally.
75555796|NCT04829994|Device|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures subjects would receive as part of SOC.
75714396|NCT04994704|Drug|Propfol group|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
75714397|NCT04994704|Drug|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
75555797|NCT04829357|Device|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures the subjects would receive as part of SOC.
76041521|NCT04821193|Drug|Skin antisepsis with 5% NaHCO3 water solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
75714398|NCT04990817|Other|Average American Diet With SoFAS Replaced With Avocado|Replacing energy from solid fats and added sugars (SoFAS) with Avocado as part of an average American diet
76041522|NCT04821193|Drug|Skin antisepsis with 2% Chlorhexidine Gluconate solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
75714399|NCT04990817|Other|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
75714400|NCT04988451|Behavioral|ASL Services|ASL specialist meets with participants and provides ASL instruction
76041523|NCT04821037|Behavioral|ACT|Acceptance and Commitment Therapy
75412521|NCT05502978|Behavioral|Blended education of Infant and Young Child Feeding|Blended education is an intervention about IYCF consisting of 3 components: Education via WhatsApp group, counselling face to face, Consultation with nutritionist via WhatsApp call. In the intervention group, participants will get blended education about IYCF provided by trained cadres. Education via WhatsApp group. The implementation of this educational program was carried out for 3 meeting sessions, where previously trained cadres had distributed videos and digital booklets for IYCF material and opened a discussion session at the end of the meeting in WhatsApp group. Face to face Counselling (Home visit). The cadres conduct home visits every month when the participants have given birth until the child is 7 months old. Consultation with nutritionist via WhatsApp call. Consultations were carried out via WhatsApp calls about IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months.
75412522|NCT05441124|Behavioral|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
75412523|NCT05435742|Biological|SON-080|Recombinant human interleukin-6 (rhIL-6)
75555798|NCT04829318|Drug|Esketamine|Esketamine will be self-administered as nasal spray.
75714401|NCT04981951|Drug|Dexmedetomidine|Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.
75714402|NCT04977063|Device|Atmo gas capsule|The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
75714403|NCT04977063|Device|SmartPill|The SmartPill measures the capsules location and motility/transit times through pH sensing
75714404|NCT04947527|Drug|Test varnish|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
75714405|NCT04947527|Drug|Placebo|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
75714406|NCT04939935|Drug|Metformin XR|Extended release metformin.
75714407|NCT04939935|Other|Control|Placebo is inactive tablets that is identical to the intervention Metformin tablets.
76041524|NCT04820725|Diagnostic Test|Plantar pressure and gait|Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated using Win-Track platform (MEDICAPTEURS Technology, France).
75555799|NCT04829318|Drug|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
75555800|NCT04829175|Device|Intervention|There is no intervention, beyond necessary clinical care, in this registry. The surgical procedures being performed within the registry are identical to the surgical procedures patients would receive as part of SOC.
75555801|NCT04829058|Device|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures that were performed in subjects within this study are identical to the surgical procedures the subjects would have received as part of SOC.
75412524|NCT05343468|Device|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
75714414|NCT04909827|Procedure|3D-printed endocrown|pulpotomy and restoration with 3D-printed microfilled hybrid composite endocrown
75412525|NCT05311800|Other|Physical activity|Comparison of HIIT mode (running vs cycling)
75714415|NCT04909827|Procedure|Zirconia crown|pulpotomy and restoration with prefabricated zirconia crown
75714416|NCT04908722|Biological|Ad26.COV2.S|Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
75555802|NCT04823858|Procedure|Lumbar Interbody Fusion|The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
75555803|NCT04822272|Device|MRI thermometry|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
75714417|NCT04907214|Drug|Empagliflozin 25 MG|Oral empagliflozin daily
75555804|NCT04821622|Drug|talazoparib plus enzalutamide|experimental arm
75714418|NCT04907032|Drug|Mirabegron 50 MG|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
75555805|NCT04821622|Drug|Placebo plus enzalutamide|Active comparator arm
75555806|NCT04821154|Device|Persona Revision Knee System|Patients in this cohort will have been previously implanted with the Persona Revision Knee system in the described configuration per standard of care. The Persona Revision knee system is a total knee system that is widely available for use in the United States and is designed for use in primary and revision knee surgical interventions.
75714419|NCT04907032|Device|Posterior Tibial Nerve Stimulation (PTNS)|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
75714420|NCT04904809|Device|Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System|The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
75714421|NCT04897633|Device|transcranial electric stimulation|Simon's task assessment when under tDCS
75412526|NCT05045898|Other|plantar massage|The patients will be given a classical massage, known as Swedish massage, consisting of euflorage and petrissage. While the patient is lying in the supine position, a classical massage will be applied to the plantar face, dorsum and toes of both feet, which will take approximately 20 minutes in total. It will last for 6 weeks, 3 days a week.
75714422|NCT04883918|Biological|ASC930|4 intravenous doses of ASC930
75714423|NCT04882930|Procedure|Functional Near-Infrared Spectroscopy (fNIRS)|All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
75714424|NCT04882917|Drug|M4076|M4076 will be administered orally, in Part 1A and Part 1B.
75555807|NCT04816591|Device|Experimental: Interventional Cohort: Treatment Arm|Standard of Care Surgery + Embolization
75555808|NCT04816591|Other|Active Comparator: Interventional Cohort: Control Arm|Standard of Care Surgery Only (Control)
75714425|NCT04876950|Combination Product|Virtual care with remote automated monitoring|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
75714426|NCT04866563|Drug|AX-8|orally disintegrating tablets, BID
75714427|NCT04866563|Drug|Placebo|orally disintegrating tablets, BID
75714428|NCT04864418|Drug|AST-021p|3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization
75714429|NCT04861051|Drug|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
75714430|NCT04846127|Device|CanGaroo Envelope|Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.
76041525|NCT04828291|Behavioral|Benign Behavioral Interventions|This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
75555809|NCT04816591|Device|Experimental: Observational Cohort: Treatment Arm|Standard of Care Medical Management + Embolization
75555810|NCT04816591|Other|Active Comparator: Observational Cohort: Control Arm|Standard of Care Medical Management Only (Control)
75555811|NCT04814992|Behavioral|Computer-Assisted Preoperative CBT Intervention (PAINTrainer)|Subjects will be asked to complete eight (8) 30- to 45-minute educational sessions during the 4 weeks prior to your surgery. In addition to the computer based training sessions, there is a motivational interviewing component that requires subjects to meet with a member of the study team weekly for a total of four (4) 30- to 45-minute meetings to help manage opioid medication use. It is expected that subject participation in this arm of the study will be a total of 12 hours over the course of the entire study.
75555812|NCT04811560|Drug|JNJ-75276617|JNJ-75276617 is administered orally.
75555813|NCT04802161|Procedure|Biospecimen Collection|Undergo collection of blood samples
75555814|NCT04802161|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
75555815|NCT04802161|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
76041526|NCT04820803|Other|ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE|one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds
75555816|NCT04802161|Drug|Pomalidomide|Given PO
75555817|NCT04800315|Drug|CC-93538|Specified dosages on specified days
76041527|NCT04820803|Other|PLACEBO|one mouthwash containing distilled (placebo) water for 60 seconds
75555818|NCT04800315|Other|Placebo|Specified dosages on specified days
75555819|NCT04799054|Drug|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT injection
75714431|NCT04842409|Radiation|Whole breast irradiation|Whole breast irradiation using an ultra-hypofractionated schedule (26 Gy in 5 fractions)
75714432|NCT04839575|Drug|Latiglutenase|Administered orally (daily)
76041528|NCT03036787|Behavioral|family based intervention|behavioural advises to family for normal motor development
75714433|NCT04839575|Drug|Placebo|Administered orally (daily)
75714434|NCT04834375|Drug|Weight-based dexamethasone dose|Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
75714435|NCT04812964|Dietary Supplement|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
75714436|NCT04812964|Dietary Supplement|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
75872796|NCT05196711|Drug|MAX-40070|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days."
75872797|NCT05196711|Drug|Placebo|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo"
75412527|NCT05045898|Other|textured insoles|"Textured insoles will be prepared in accordance with the principles stated by Waddington et al. in 2003. In the studies of Waddington et al., ethyl vinyl acetate (EVA) textured insoles with 4 hemispherical protrusions per cm² were used. The height of each hemispherical protrusion from the EVA floor is 2 mm; The height of the insoles from the ground is 3 mm.~The textured insoles will be prepared by an orthotic prosthesis center by cutting the EVA layer with the above-mentioned features in accordance with the patient's shoe/home shoe insoles and placing them on the shoe/home shoe insoles. Insoles will be provided free of charge to patients. Patients will be asked to wear their shoes/house shoes with insoles while performing activities inside and outside the home for 6 weeks."
75555820|NCT04799054|Drug|Pembrolizumab|Pembrolizumab will be administered IV
75555821|NCT04793360|Device|LiverCare|The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.
75555822|NCT04789252|Biological|Bioinformatics analysis of single cell transcriptomics data|"Sample collection: Myeloid cell purification + Single cell sequencing~Primary analysis: QC sequencing data + Reads alignment + UMI quantification~Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification)~Validation: FACS analysis + immunohistochemistry"
75872798|NCT04878003|Drug|KRT-232|KRT-232, administration by mouth
76041529|NCT04834843|Other|Observational study, no intervention|Observational study, no intervention
76041530|NCT04827511|Other|Refraction measurement with auto-ref-keratometer Canon|Refractive measurement and vitamin D level dosing
75555823|NCT04778527|Drug|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
75555824|NCT04778527|Drug|PrEP tablet and a COC as two separate tablets|PrEP tablet and a COC as two separate tablets
75714437|NCT04788745|Drug|Trimetazidine Dihydrochloride|Oral tablet, twice-daily
75714438|NCT04782869|Device|transcranial direct current stimulation|Patients will be treated using Starstim 8 device, a device allowing to perform transcranial direct current stimulation. The position of electrodes will be personalized based on the localization of the epileptogenic zone.
75872799|NCT04878003|Drug|TL-895|TL-895, administration by mouth
75872800|NCT03633591|Drug|Tolcapone|Multiple doses of tolcapone tablets in the fasted state
75872801|NCT03633591|Drug|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype in the fasted state
75872802|NCT03633591|Drug|Tolcapone Divided Dose|Tolcapone (suspension) in equal divided doses in the fasted state
76041531|NCT04827667|Diagnostic Test|bronchoalveolar lavage|Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.
76041532|NCT04834609|Procedure|Injection of autologous adipose tissue in anal fistula|
76041533|NCT04834531|Drug|Zhuli capsule|This capsule is made from the exact of Phyllostachys glauca McClure or Phyllostachysnuda McClure, which has the expectorant effects. It is oral used,2 capsules for once, three times a day, for 7 days.
75714439|NCT04770519|Genetic|whole genome sequencing or whole exome sequencing|Whole genome sequencing or whole exome sequencing will be performed for all enrolled participants.
75872803|NCT03633591|Drug|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
75714440|NCT04752579|Other|Pilates exercise program|"The program will be individually supervised and will be conducted twice a week at the physiotherapy center.~• Slow execution of 7-10 repetitions of the following Pilates exercises: Pelvic Curl, Pilates Single Legs Lifts & Leg Change, Twist Supine Pilates exercise, Chest Lifts Pilates Exercise, Chest Lift with Rotation Pilates exercise, 100's Prep Pilates Exercise, Single Leg Stretch Pilates Exercise, Front Support Pilates Exercise and Basic Back Extension Pilates Exercise. After the 6th week, while the person will be familiar with the basic exercises of the Pilates method the following exercises will be added: Leg Pull Front, Side Bend Pilates Exercise, Sphinx - Abdominal Lift Pilates Exercise, Shoulder Bridge Prep Pilates and Shoulder Bridge Pilates Exercise. Each session will be completed with breathing exercises and stretching exercises of the torso and lower limbs for 5 minutes."
75714441|NCT04741672|Behavioral|Providing guidance after discharge routine procedure and calling one week after discharge.|Guidance will be given to mothers after routine discharge. After one week, she will be called by phone and her questions about infant care will be answered.
75412528|NCT04741074|Drug|Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution|Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.
75412529|NCT04741074|Drug|Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution|Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
75714442|NCT04741672|Behavioral|Discharge routine procedure.|Discharge routine procedure.
75714443|NCT04739709|Drug|APP13007, 0.05%|APP13007 eye drop, 0.05%
75412530|NCT04601454|Device|Spinal Cord Stimulation System|Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
75714444|NCT04739709|Drug|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
75714445|NCT04717479|Other|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
75872804|NCT01376271|Drug|Paroxetine|
75872805|NCT05196555|Procedure|Repair of cleft palate with intravelar veloplasty (IVVP)|A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
75412531|NCT04581408|Drug|Lumacaftor / Ivacaftor, Orkambi® Oral Tablet|"Total daily dose: 800 mg of Lumacaftor and 500 mg of Ivacaftor.~Duration of treatment: according to the clinical conditions of the patient and based on the response to the drugs: up to a maximum of 7 days"
75555825|NCT04776486|Drug|Iohexol|"Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).~Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose."
75555826|NCT04776005|Other|Data collection|Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
75714446|NCT04712903|Drug|Durvalumab|Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
75872806|NCT04885881|Procedure|Ozone therapy|Patients in the ozone therapy group will be treated with ozone (O2-O3) in a volume of 5 ml and a dose of 10 µg / ml for three consecutive weeks in a weekly session to the most painful trigger point.
75412532|NCT04544748|Biological|GNR-051|Anti-PD1 monoclonal antibody
75412533|NCT04509726|Drug|EBV-specific TCR-T cell with cytokine auto-secreting element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with cytokine auto-secreting element
75412534|NCT04446078|Device|PEEK- acrylic resin prosthesis supported by 4 dental implants|Patients rehabilitated for edentulism of one or both arches through an implant supported fixed prosthesis
75412535|NCT04384302|Other|Visual training|Pre-defined visual training protocol including the optometrical unit exercises
75412536|NCT04295772|Drug|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
75412537|NCT04160286|Other|Electroconvulsive therapy|"Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)"
75714447|NCT04712903|Drug|Cisplatin|Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
76041534|NCT04834531|Drug|Placebo|The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.
76041535|NCT04834531|Other|Standard medical treatment|"Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks."
76041536|NCT04360135|Drug|Acetaminophen|Preemptive acetaminophen the day before surgery
75555828|NCT04773522|Drug|Talquetamab|Talquetamab will be administered subcutaneously.
76041537|NCT04360135|Drug|Placebo|Preemptive placebo the day before surgery
76041538|NCT04827823|Other|Retrospective evaluation of amalgam and composite restorations|Multi-surface restorations that were performed by dental students and that are in function for the last five years will be clinically evaluated with mirrors and probes according to the modified USPHS criteria.
75555829|NCT04769362|Drug|Discontinuation of β-blocker|Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
76041539|NCT04827589|Drug|Tirabrutinib|Tablets administered orally
76041540|NCT04827589|Drug|Placebo|Tablets administered orally
75555830|NCT04769219|Other|Secondary prevention training|Secondary prevention training will be given after acute myocardial infarction
75714448|NCT04712903|Drug|Etoposide|Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
75714449|NCT04712903|Drug|Carboplatin|Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
75714450|NCT04710927|Device|Silver Diamine Fluoride|A single application of SDF 38% (Riva Star) on dry affected molar for 1 minute and immediately restored using HVGIC
75872807|NCT04885881|Procedure|Lidocaine injection group|Patients in the lidocaine injection group will be applied to the most painful trigger point in a volume of 2 ml of 1% lidocaine for three consecutive weeks, once a week.
76041541|NCT04834687|Behavioral|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
76041542|NCT04834687|Behavioral|Diet|"Diet interventions include ten-hour time-restricted eating and a high-fiber diet.~Participants will be instructed to take food from 7:30 AM until 5:30 PM and completely abstain from caloric intake for the remainder of the day (14 hours fast:10 hours eat). Only noncaloric beverages were permitted outside of the eating widow.~According to the dietary recommendation proposed by Chinese Government and the existing dishes in the canteen , participants are instructed to eat following a high-diet recipe weekly from Monday to Friday which includes whole grain wheat rice, vegetables, fruits, and other foods rich in dietary fiber ."
76041543|NCT04827277|Procedure|Reverse Total Shoulder Replacement|Participants will be randomized to a reverse total shoulder replacement
76041544|NCT04827277|Procedure|Anatomic Total Shoulder Replacement|Participants will be randomized to an anatomic total shoulder replacement
76041545|NCT02605837|Drug|Oral Budesonide Suspension (OBS)|Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
76041546|NCT02605837|Drug|Placebo|Oral dose of 10 ml of placebo matched with the experimental drug.
76041547|NCT04820569|Procedure|Resection and chemotherapy|
75412538|NCT04148430|Drug|Anakinra|100mg subcutaneous
75412539|NCT03888066|Drug|Patiromer|The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
75412540|NCT03888066|Drug|Placebos|The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
75412541|NCT03467256|Biological|Chimeric Antigen Receptor T-Cell Therapy|anti-CD19 chimeric antigen receptor - transduced T-cell given IV
75555831|NCT04768114|Behavioral|Genetically-Informed RiskProfile|"Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~This is a fully remote trial, with intervention delivered via video conferencing."
75555832|NCT04768114|Other|Brief Cessation Advice|"Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~This is a fully remote trial, with brief cessation advice delivered via video conferencing."
75555833|NCT04767672|Dietary Supplement|Non digestible carbohydrates|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
75714451|NCT04710927|Device|Papain-Based Gel|Papain based Gel (Papacare Duo) will be applied to the MIH affected molar for 60 seconds and repeated if required. The molar will be treated with SDF and restored using HVGIC
75714452|NCT04710927|Device|High Viscosity Glass Ionomer Cement (HVGIC)|The molar will be restored with HVGIC
75714453|NCT04709601|Drug|Hiprex|Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
75412542|NCT03467256|Drug|Fludarabine|given IV
75412543|NCT03467256|Drug|Cyclophosphamide|given IV
75412544|NCT03467256|Drug|Tocilizumab|given IV
75714454|NCT04694976|Biological|25-OH Vitamin D measure|As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.
75412545|NCT03467256|Drug|Cytarabine|given IV
75412546|NCT03467256|Drug|Etoposide|given IV
75412547|NCT03467256|Drug|Dexamethasone|given IV
75412548|NCT03326388|Drug|Selumetinib|Selumetinib Intermittent Dosing
75412549|NCT03265080|Biological|ADXS-NEO|Intravenous infusion
75412550|NCT03265080|Biological|Pembrolizumab|Intravenous infusion
75714455|NCT04694313|Device|OPM|Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
75872808|NCT01375179|Drug|KRP203|
75872809|NCT01375179|Drug|Placebo matching KRP203|
75412551|NCT02554500|Procedure|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
75872810|NCT05196321|Other|sessions with ENF (Electro Neuro Feedback).|The study evaluates patients with clinical evidence of post-surgical hematoma / seroma after hip replacement surgery. These patients will undergo ultrasound evaluation in the 4th (+/- 2) day post surgery, in which triaxial parameters of the hematoma will be measured. This evaluation will then be repeated after 5 treatment sessions with ENF (Electro Neuro Feedback).
75412552|NCT02439060|Other|Acellular Cadaveric Dermal Matrix|Undergo intraperitoneal prophylactic mesh placement
75412553|NCT02424084|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy
75872811|NCT01373307|Behavioral|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
75412554|NCT05310318|Procedure|Surgical treatment with and without fertility-sparing procedures|Patients accepted surgeries for LGESS and relevant adjuvant therapy if indicated.
75555834|NCT04767672|Dietary Supplement|Placebo|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
75714456|NCT04692701|Device|Pulvinar deep brain stimulation|Stimulation of the medial pulvinar
75714457|NCT04691596|Behavioral|Non-cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day
75714458|NCT04691596|Behavioral|Cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue
75714459|NCT04691596|Behavioral|Habit Coaching|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
75714460|NCT04691596|Behavioral|App use instructions|Received a basic training with the StepUp app
75714461|NCT04691011|Other|Muscular MRI|MRI (1.5T)
75714462|NCT04691011|Other|Electrophysiological exam|MUNIX
75714463|NCT04691011|Other|Brain MRI|MRI (7T)
75555835|NCT04763200|Device|Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®|Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI <20 kg/m2 or body weight <60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.
75555836|NCT04763200|Device|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
75555837|NCT04753138|Device|TotalFill Bioceramic Sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
75555838|NCT04753138|Device|AH+ Sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
75714464|NCT04691011|Other|Spinal cord MRI|7T and 3T MRI
75872812|NCT04820205|Drug|Intranasal dexmedetomidine and ketamine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
75872813|NCT04820205|Drug|Oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
75872814|NCT01375257|Drug|Oral treatment with antibiotics for endocarditis|
75555839|NCT04752774|Biological|IPN10200|Powder and solvent for solution for injection
75555840|NCT04752774|Drug|Placebo|Powder and solvent for solution for injection
75555841|NCT04752774|Biological|Dysport|Powder for solution for injection
75555842|NCT04742959|Drug|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
75555843|NCT04742959|Combination Product|Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle
75555844|NCT04742673|Drug|Guanfacine|Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
75555845|NCT04742673|Drug|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
75555846|NCT04740372|Other|No intervention. Method study. Psychometric testing|Patients will fill in the questionnaire followed by an interview (phase IIIA) or a debriefing questionnaire (Phase IIIB)
75555847|NCT04739852|Other|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
75555848|NCT04732052|Device|Transcranial Direct Current Stimulation|non-invasive brain stimulator
75555849|NCT04730271|Device|Total Knee Replacement|Subjects will be implanted with an ATTUNE Primary total knee replacement.
75555850|NCT04722146|Drug|Teclistamab|Participants will receive teclistamab.
75555851|NCT04722146|Drug|Daratumumab|Participants will receive daratumumab.
75555852|NCT04722146|Drug|Pomalidomide|Participants will receive pomalidomide.
75555853|NCT04722146|Drug|Lenalidomide|Participants will receive lenalidomide.
75555854|NCT04722146|Drug|Bortezomib|Participants will receive bortezomib.
75555855|NCT04722146|Drug|Nirogacestat|Participants will receive nirogacestat.
75714465|NCT04690998|Other|Blood Samples|Genetic, proteomic, neurofilament analysis
75714466|NCT04690998|Other|MRI|Spinal and muscular MRI
75714467|NCT04689997|Behavioral|cSBI|The standard CRAFFT SU screen has additional questions about reasons to use or not use, SU expectancies of effect and embedded education. The teens of enhanced care PCPs will also complete a Strengths and Goals tool. Data from both will be used by the PCP in counseling regarding continued abstention, reduction or cessation of SU or referral. Teens will also get monthly text messages about goals.
75714468|NCT04689035|Drug|AVLX-144|Test drug
75714469|NCT04689035|Drug|Placebo|Placebo
75555856|NCT04718844|Drug|SLN124|SLN124 for subcutaneous (s.c.) injection
75555857|NCT04718844|Drug|Placebo|Sodium chloride for s.c. injection
75555858|NCT04706715|Other|89Zr-DFO-REGN3767|Anti-LAG-3 PET imaging tracer
75555859|NCT04706715|Drug|Cemiplimab|Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
76041548|NCT05619133|Device|PBM|"In this study, the health benefits of the addition of NIR to the light spectrum of a desk lamp already available in the market will be investigate; Ikea Ypeperlig, to which a module with high power Lumileds NIR-Leds will be attached with beam angle of 90 degrees. They will be attached in such a way that, when the lamp is installed in the right place, a 1sr beam that covers the users face, neck and hands and lower arms on the desk with the required intensity of 5mW/cm2 of NIR at the skin surface.~The device will be equipped with 3 sensors:~A distance sensor connected to the driver of the NIR-leds, such that when the user leans forward or backward, the intensity of the NIR is automatically adjusted such that the intensity on the skin remains 5mW/cm2 (see figure below).~a presence sensor~ambient vertical lux sensor by which amount of light that enters the users' eye will be measured since it is known that these have an effect sleep, mood and performance."
75714470|NCT04684862|Device|Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)|This infusion system is composed of a Medtronic SynchroMed II programmable pump connected to a Intera tapered catheter. Specifically, the Medtronic pump comes with a small connector that ends in a metal flange. During the operation, under sterile conditions, the distal 1 cm of the flange is severed using a scissor. Then, using a Intera connector pin, the end of the Medtronic catheter is connected to the Intera catheter . Two 2-0 silk ties secure the catheters to the pin. The pump and catheter are then inserted into the patient into the abdominal wall or into the chest wall. The catheter is inserted into an artery within the abdomen (usually the gastroduodenal artery but it depends on the exact arterial branching in the individual patient) that feeds the liver.
75714471|NCT04683627|Drug|Diclofenac sodium active topical patch|A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
76041549|NCT04819789|Other|Fermotein™ dry powder porridge|At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
76041550|NCT04819789|Other|Fermotein™ wet porridge|At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
75714472|NCT04683627|Drug|Placebo patch|A placebo patch without diclofenac sodium was used for the placebo arm.
76041551|NCT04819789|Other|Fermotein™ modified wet porridge|At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
76041552|NCT04819789|Other|Mycoprotein porridge (matching control)|At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
76041553|NCT04833985|Procedure|LAAC combined with radiofrequency ablation|Each patient received the same group of patients with simple radiofrequency ablation and LAAC
76041554|NCT04827121|Procedure|Fascial iliac compartment block|Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
75555860|NCT04706598|Drug|Camrelizumab|Solution for Infusion (Intravesical)
75714473|NCT04657666|Drug|Nabiximols|oromucosal spray
75714474|NCT04657666|Drug|Placebo|oromucosal spray
75714475|NCT04652687|Biological|VIA Disc NP|VIA Disc NP - Allograft tissue injection
75714476|NCT04646967|Drug|Bupivacain|See active comparator description
75714477|NCT04646967|Drug|Sevoflurane|See active comparator description
75714478|NCT04646967|Drug|Acetaminophen|See active comparator description
75714479|NCT04646967|Drug|Ibuprofen|See active comparator description
75714480|NCT04646967|Drug|Ketorolac|See experimental arm description
75714481|NCT04636307|Other|Biomarkers|To identify biomarkers obtained using non-invasive procedures that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in NPDR.
75714482|NCT04633512|Device|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted intestinal anastomoses and patients undergoing laparoscopic or robot assisted cholecystectomy.
75714483|NCT04614324|Device|RhinAer ARC Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).
75714484|NCT04606355|Diagnostic Test|Visual Acuity|autostereoscopic, monocular dynamic force choice test
75714485|NCT04606355|Diagnostic Test|stereopsis|autostereoscopic dynamic forced-choice depth perception test
75412555|NCT05310006|Other|Exercise|Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
76041555|NCT04827121|Procedure|Quadratus lumborum block|Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
76041556|NCT04820101|Drug|Dexmedetomidine|administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure
76041557|NCT04826887|Other|SOLTIVE Thulium Laser|Use of SOLTIVE Thulium laser for HoLEP
75412556|NCT05313282|Combination Product|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 8th day 30minutes after meals, once a day, for continuous medication.~3. On the 22nd day of treatment, namely the second session of HAIC, intravenous infusion of Camrelizumab 200mg every 3 weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
75412557|NCT05313282|Combination Product|Apatinib combined with Camrelizumab|Drug: Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally 30minutes after meals, once a day, for continuous medication 2. Intravenous infusion of Camrelizumab 200mg every 2 weeks.
75412558|NCT05315622|Other|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
75714486|NCT04606355|Diagnostic Test|Color vision|autostereoscopic forced choice monocular or binocular color vision tests
75714487|NCT04589286|Behavioral|Pack Health's Digital Life Coaching (DLC)|Pack Health smartphone-based DLC platform
75714488|NCT04589286|Other|Electronic Handouts|Generic wellness-related electronic handouts
76041558|NCT04826887|Other|Standard of Care (Holmium Laser)|Use of Holmium laser for HoLEP
76041559|NCT04328311|Other|Watermelon Juice|500 mL watermelon juice (What a Melon), containing ~1 g of L-citrulline.
76041560|NCT04328311|Other|Water|500 mL low nitrate water
76041561|NCT04428463|Procedure|Tachosil|tympanic membrane perforation repair using Tachosil patch under local anesthesia
76041562|NCT04428463|Procedure|fascia and cartilage|tympanic membrane perforation repair using fascia and cartilage under general anesthesia
76041563|NCT04819633|Other|Determination of serum sestrin levels|Serum sestrin levels will be determined using venous blood samples obtained from the subjects.
76041564|NCT04819867|Drug|Propolis|propolis is an extract derived from bee hives
76041565|NCT04819867|Drug|Gluma Desensitizer|Gluma is a desensitizer agent
76041566|NCT04827043|Combination Product|Ultrasound guided quadratus lumborum block|prospective randomized comparative study between Group (1) : quadratus lumborum block
76041567|NCT04827043|Combination Product|Ultrasound guided thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
76041568|NCT02423343|Drug|Galunisertib|Administered orally
76041569|NCT02423343|Drug|Nivolumab|Administered IV
76041570|NCT04909515|Drug|Naxitamab|3.0 mg/kg/day = 9.0 mg/kg/cycle
76041571|NCT04909515|Drug|GM-CSF|250 - 500 microgram/m2/day
76041572|NCT04909515|Drug|Isotretinoin|160 mg/m2/day
75412559|NCT05315622|Other|Placebo|"Manual tension without reaching the manipulation thrust"
75714489|NCT04563754|Diagnostic Test|mHRME (Mobile High resolution microendoscope)|"SOC (standard of care) HRA with Lugol's iodine will be performed. Unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis:~contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)).~The mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.~This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging."
75714490|NCT04563754|Drug|Proflavine Hemisulfate|Contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)) to use with the mHRME
75714491|NCT04563754|Diagnostic Test|High resolution anoscopy|SOC (standard of care) HRA with Lugol's iodine will be performed.
75714492|NCT04557111|Device|remote monitoring|CIED monitoiring with remote monitoring device
75714493|NCT04539249|Drug|Magnesium sulphate|"1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
75714494|NCT04539249|Drug|Pentazocine|"Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
75714495|NCT04513002|Dietary Supplement|Triheptanoin|Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.
75555863|NCT04704999|Drug|Tafenoquine|Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
75714496|NCT04495829|Device|Phorcides Analytical Engine|Surgery planning using the Phorcides analytical engine.
76041573|NCT02605447|Drug|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
76041574|NCT02605447|Device|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
75714497|NCT04492891|Drug|Cyclosporine|2.5 mg/kg PO BID 7 days
75714498|NCT04492891|Other|Standard of Care Treatment|Standard of Care Treatment, N= 25 Patients, 7 days
75714499|NCT04449198|Drug|Resveratrol|500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
75412560|NCT05318274|Radiation|Hypofractionated radiotherapy|Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
75555864|NCT04704999|Drug|Chloroquine|Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
75555865|NCT04704999|Drug|Artemether 20 mg-Lumefantrine 120 mg|Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
75714500|NCT04449198|Other|Placebo|placebo for 12 weeks
75872815|NCT01375257|Drug|Guideline treatment with parenteral antibiotics|
75872816|NCT01375335|Drug|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
76041575|NCT05617729|Other|Saline applied via swab|sterile saline applied via swab
76041576|NCT05617729|Other|Povidone-iodine based gel|gel applied via swab
76041577|NCT02485899|Biological|BMN 190|300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
76041578|NCT02485899|Device|Intracerebroventricular (ICV) access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
76041579|NCT04362553|Device|wearable vital signs sensor|vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
76041580|NCT05619055|Other|Routine treatment|Antibiotics, intravenous fluids and symptomatic supportive treatment.
76041581|NCT04818931|Drug|Cefazolin Injection|cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
76041582|NCT02423109|Device|fanfilcon A|contact lens
76041583|NCT02423109|Device|enfilcon A|contact lens
76041584|NCT02420691|Other|Laboratory Biomarker Analysis|Correlative studies
75555866|NCT04700722|Diagnostic Test|Skin Biopsy|Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
75714501|NCT04446559|Procedure|Sitting in chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
75714502|NCT04432337|Procedure|The role of the activation of the NLRP3 inflammasome after cardiac surgery|Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
75412561|NCT05312034|Behavioral|Implementation of the predictive model for an antimicrobial management program|"Firstly it will be used the predictive model as a simulation tool to educate physicians. For three months, physicians will use the model to understand the main factors associated with Gram-positive infection. They will test the model using real-case data previously collected at the hospitals. The model will provide them information such as the probability of that patient having a Gram-positive infection and the proportion of infected patients in that ICU and hospital.~This model will be embedded in an app and a web page to provide real-time guidance on the predicted probability of infection due to Gram-positive agents.~The intervention will be implemented in two selected hospitals, aiming at monthly decreasing the use of broad-spectrum antibiotics while maintaining or reducing the ICU standardized mortality ratio and the standardized resource use."
75714503|NCT04417595|Drug|Fish Oil (Containing Omega-3 Acids)|Fish Oil Supplement
75714504|NCT04417595|Drug|Olive Oil|Olive Oil Supplement
75714505|NCT04385082|Drug|Active Cannabis|Smoked cannabis with THC
75714506|NCT04385082|Drug|Placebo Cannabis|Placebo smoked cannabis (no THC)
75714507|NCT04353960|Diagnostic Test|electrocardiograph|electrocardiograph monitor during strabismus surgery
75714508|NCT04342481|Other|Educational Screening tool|Educational Screening tool
75412562|NCT05311722|Drug|Dexmedetomidine|Inj dexmedetomidine, will be given in infusion over 10 mins and their effect on post spinal shivering will be assessed.
75714509|NCT04312945|Other|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
75714510|NCT04312945|Other|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
75714511|NCT04299659|Diagnostic Test|Landolt C entry method|Four different methods for entering the Landolt C gap position are compared
75412563|NCT05311722|Drug|Ketamine|Ketamine
75412564|NCT05311722|Drug|Tramadol|Tramadol
75714512|NCT04271189|Drug|Metformin-Sitagliptin-Empaglifozin-Pioglitazone|1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
75714513|NCT04271189|Drug|Standard of care|Usual medical care to treat diabetes.
75714514|NCT04243551|Drug|Latiglutenase|Administered orally (daily)
76041585|NCT02420691|Other|Pharmacological Study|Correlative studies
75412565|NCT05311644|Other|Telephone survey|All participants are interviewed by telephone, and are asked to answer a survey.
75412566|NCT05310552|Other|No interventions - observational study|No interventions - observational study
75412567|NCT05314062|Dietary Supplement|FeSO4|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
75412568|NCT05314062|Dietary Supplement|Ao iron|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
75412569|NCT05317884|Behavioral|Reminder|Email
75412570|NCT03215940|Drug|Delta-9-Tetrahydrocannabinol|An oral dose of Delta-9-Tetrahydrocannabinol (THC) will be given once a day for five day with pain ratings taken before and after each dose every day.
75412571|NCT03215940|Drug|Cannabidiol|An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.
75714515|NCT04243551|Other|Placebo|Administered orally (daily)
75714516|NCT04221945|Biological|Pembrolizumab|IV infusion
75412572|NCT03215940|Drug|Placebos|An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
75412573|NCT03219762|Drug|Nabpaclitaxel|Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
75412574|NCT03219918|Device|EndoRings II Distal Attachment|Colonoscopy cap
75555867|NCT04696809|Drug|Teclistamab|Teclistamab will be administered subcutaneously.
75714517|NCT04221945|Drug|Placebo for pembrolizumab|IV infusion
75714518|NCT04221945|Drug|Cisplatin|IV infusion
75714519|NCT04221945|Radiation|External Beam Radiotherapy (EBRT)|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
75714520|NCT04221945|Radiation|Brachytherapy|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
75872817|NCT05195307|Other|Music Group|Pregnant women included in the practice group were given 20 minutes of music every day for ten days. Anxiety and stress levels of pregnant women were measured before and after the intervention.
76041586|NCT02420691|Drug|Ribociclib|Given PO
75555868|NCT04691297|Other|Escape|The ESCAPE intervention consists of five components:1) behavioral counseling, 2) the use of NRT, 3) digital SNC 4) decision aid about LDCT screening, and 5) a letter and educational materials sent to the primary care provider.
75555869|NCT04691297|Other|Standard Care|Participants in the standard care arm (brief advice and referral to quit line), will be referred to the MA Quitline which provides free NRT by the study team and will receive an educational brochure related to lung cancer screening.
75555870|NCT04683029|Drug|Guselkumab Dose 1|Guselkumab Dose 1 will be administered intravenously.
75555871|NCT04683029|Drug|Guselkumab Dose 2|Guselkumab Dose 2 will be administered subcutaneously.
76041587|NCT02406651|Drug|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
75714521|NCT04206501|Device|Medtronic ICD with Opti Vol-Monitor|Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.
75714522|NCT04199325|Dietary Supplement|Probiotics|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
75714523|NCT04199325|Drug|uric-acid-lowering drug|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
75714524|NCT04189133|Drug|Lutropin alfa|daily increasing dosages of lutropin alfa
75412575|NCT03219996|Other|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
75555872|NCT04683029|Drug|Placebo|Placebo will be administered intravenously or subcutaneously.
75555873|NCT04673357|Drug|Ustekinumab|Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.
75555874|NCT04673357|Drug|Placebo|Matching placebo will be administered as SC injection.
75555875|NCT04670874|Other|Quality-of-Life Assessment|Complete quality of life questionnaire
75412576|NCT03219606|Other|Organized education course of Modified Rodnan Skin Scoring|"Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).~Demonstration: Master instructor demonstrate the patient assessment without revealing his score.~Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course."
75412577|NCT03219684|Diagnostic Test|serum protein ,kidney function ,liver function.,serum cholesterol|monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients
75714525|NCT04189133|Drug|Human chorionic gonadotropin|human chorionic gonadotropin increasing administration
76041588|NCT02406651|Drug|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
76041589|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
76041590|NCT02406261|Drug|Simvastatin|20 mg simvastatin will be administered orally as 1 × 20-mg tablet
75555876|NCT04670874|Other|Questionnaire Administration|Complete quality of life questionnaire
75555877|NCT04669288|Drug|Azithromycin|"oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging."
75714529|NCT04158804|Diagnostic Test|procalcitonin|accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection
75555878|NCT04669288|Drug|Placebo|"oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging."
75872818|NCT05194527|Other|Biomarker validation and VOC profile identification|Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
75555879|NCT04666987|Drug|Insulin degludec and liraglutide (IDegLira)|Paricipants will be treated with commercially available Xultophy® according to routine clinical practice at the discretion of the treating physician, following approved label in Italy. The decision to initiate treatment with commercially available Xultophy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
75555880|NCT04666454|Drug|Adenosine|Adenosine infusion 70 µg/kg/min for 3 hours.
75555881|NCT04666454|Drug|Dipyridamole 200 mg|200 mg b.i.d
75555882|NCT04666454|Drug|Apixaban 5 mg Oral Tablet|5mg b.i.d
75555883|NCT04666454|Other|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome|This treatment will vary depending on local routines and the degree of adherence to the recommendations.
75555885|NCT04663347|Drug|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
75555886|NCT04663347|Drug|rituximab and lenalidomide|28-day cycles
75412578|NCT03218904|Dietary Supplement|Glucose intake|Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
75412579|NCT03218904|Dietary Supplement|Carbohydrates intake|Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3- single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
75872819|NCT01375413|Behavioral|physical therapy|Physical therapy consisting of gait training 3 times a week for 6 weeks
75412580|NCT03219138|Device|Acceleromyography|Use of an uncalibrated acceleromyography
75555887|NCT04663347|Drug|rituximab and bendamustine|28-day cycles
75555888|NCT04663347|Drug|rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin|21-day cycles
75555889|NCT04663347|Drug|gemcitabine and oxaliplatin|28-day cycles
75555890|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
75555891|NCT04663347|Drug|rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone|21-day cycles
75555892|NCT04663347|Drug|Lenalidomide|28-day cycles
75555893|NCT04663347|Drug|rituximab, ifosfamide, carboplatin, and etoposide phosphate|21-day cycles
75555894|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
75872820|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
75872821|NCT01373463|Drug|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
75555895|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until disease progression or unacceptable toxicity.
75555896|NCT04663347|Biological|Epcoritamab|Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
75555897|NCT04663347|Biological|Epcoritamab|Every week in cycle 1 and then every 8 weeks for a total of 2 years.
75555898|NCT04663347|Biological|Epcoritamab|Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
75555899|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
75555900|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until transplant or disease progression.
75555901|NCT04658862|Biological|Cetrelimab|Participants will receive intravenous Cetrelimab.
75555902|NCT04658862|Drug|TAR-200|Participants will receive intravesical TAR-200.
75555903|NCT04658862|Drug|Cisplatin|Participants will receive cisplatin intravenously.
75555904|NCT04658862|Drug|Gemcitabine|Participants will receive gemcitabine intravenously.
75555905|NCT04658862|Radiation|Conventional radiation therapy|Participants will receive conventional radiation therapy for bladder (64 gy).
75872822|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
75872823|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
75872824|NCT01373463|Drug|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
75872825|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
75872826|NCT01373463|Procedure|Lobectomy|Surgery
75872827|NCT01373463|Procedure|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
75412581|NCT03219060|Behavioral|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
75555906|NCT04658862|Radiation|Hypo-fractioned radiation therapy|Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).
75555907|NCT04657991|Drug|Encorafenib|Encorafenib
75714530|NCT04157725|Drug|mild stimulation protocol: oral Clomiphene Citrate|Group A (mild stimulation protocol) will receive oral Clomiphene Citrate (Clomid®) 150 mg/day for 5 days (starting on the 2nd of menses), followed by FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting from the 6th day of the menstrual cycle. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
75714531|NCT04157725|Drug|Conventional Stimulation Protocol: will receive FSH/HMG|Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
76041591|NCT02406261|Drug|Midazolam|500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
75412582|NCT03219060|Behavioral|Brief advice|Brief advice based on 5As
75412583|NCT03218514|Drug|Dalteparin|
75412584|NCT03218436|Procedure|CAP treatment|Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
75412585|NCT03218280|Drug|Vitamin C|
75555908|NCT04657991|Drug|Binimetinib|Binimetinib
76041592|NCT02406261|Drug|Midazolam|250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
76041593|NCT02406261|Drug|Donepezil|5 mg donepezil will be administered orally as 1 × 5-mg tablet
75412586|NCT03218124|Other|Remifentanil Effect site concentration|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
75412587|NCT03217578|Other|SMA Newborn Screening|
75555909|NCT04657991|Drug|Pembrolizumab|Pembrolizumab
75555910|NCT04657224|Drug|JNJ-64264681|JNJ-64264681 capsules will be administered orally.
75555911|NCT04657224|Drug|JNJ-67856633|JNJ-67856633 capsules or tablets will be administered orally.
75555912|NCT04648254|Drug|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
75555913|NCT04640623|Drug|TAR-200|TAR-200 will be administered transuretherally.
75412588|NCT03217500|Procedure|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
75412589|NCT03217500|Procedure|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
75412590|NCT03217500|Procedure|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
75412591|NCT03217500|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
75412592|NCT03217500|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
75714532|NCT04145518|Drug|Naproxen Sodium|Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
75714533|NCT04140903|Drug|Early transition to oral antibiotics|Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
75412593|NCT03217734|Biological|Adalimumab|Subcutaneous Injection
76041594|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
75714534|NCT04140903|Drug|Standard treatment of intravenous antibiotics|Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
75714535|NCT04130126|Behavioral|Taking cold showers|Showering behaviour
75714536|NCT04118998|Behavioral|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
75714537|NCT04118998|Behavioral|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
75714538|NCT04109079|Procedure|Axillary lymph node dissection|Participants will undergo removal of at least level I and II axillary lymph nodes.
75412594|NCT03217734|Drug|Methotrexate|Oral Tablet
75412595|NCT03217734|Drug|Placebo|Oral Tablet
75412596|NCT03217032|Biological|YUVA-GT-F801|Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
75412597|NCT03216876|Drug|Ursolic acid|Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
75412598|NCT03216642|Diagnostic Test|bacterial culture and analysis|Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.
75412599|NCT03216330|Other|No Intervention|There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
75412600|NCT03216408|Drug|Neuronox|
75555914|NCT04640623|Biological|Cetrelimab|Cetrelimab will be administered.
75714539|NCT04109079|Radiation|Axillary radiotherapy|Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
75714540|NCT04109079|Radiation|Breast or chest wall radiotherapy|Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
75412601|NCT03216408|Drug|Botox|
76041595|NCT04421001|Device|I-port use|patient will use I-port device fo 2 months
75412602|NCT03216564|Drug|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
75412603|NCT03216174|Procedure|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
75412604|NCT03215862|Drug|Lactated Ringer|This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.
75412605|NCT03215862|Drug|Normal Saline 0.9% Infusion Solution Bag|This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
75412606|NCT03216018|Behavioral|"Prevention program: In Favor of Resilient Self"|"Prevention program: In Favor of Resilient Self"
75555915|NCT04634552|Drug|Talquetamab|Talquetamab will be administered SC until disease progression.
75555916|NCT04633447|Drug|Guselkumab|Guselkumab will be administered subcutaneously.
75555917|NCT04633447|Drug|Placebo|Matching placebo will be administered subcutaneously.
75714541|NCT04101721|Drug|aflibercept|Administered IVT
75714542|NCT04101721|Procedure|laser photocoagulation|Transpupillary conventional laser will be administered according to standard local procedures.
75714543|NCT04057872|Procedure|Therapeutic plasma exchange|The removed plasma is 'exchanged or replaced' with either IV fluids, albumin, and/or Fresh frozen plasma
75714544|NCT04055012|Drug|Metformin|500mg tabs of Metformin Extended Release
75714545|NCT04055012|Drug|Placebo|Placebo Tabs
75714546|NCT03995368|Other|Electroencephalography|The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.
76041596|NCT04420767|Device|tDCS|Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
76041597|NCT04420767|Device|Sham brain stimulation|Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
75555918|NCT04633005|Drug|Polypill|Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.
75555919|NCT04633005|Drug|Control Rx|Typical prescriptions of guideline-directed therapies for heart failure with reduced ejection fraction.
75412607|NCT03215472|Other|DASH Cloud|With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.
75555920|NCT04630145|Drug|Bedaquiline|Participants will receive BDQ tablets only/
75714547|NCT03977129|Device|QFR-guided strategy|In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR > 0.80, then no CABG revascularization of target blood vessels will be carried out.
76041598|NCT04420767|Behavioral|Go-No GO task|During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
76041599|NCT02405091|Drug|NBI-98854|
76041600|NCT02485353|Drug|Vosaroxin and Cytarabine|
75412608|NCT03215472|Other|Nutritionix Track app|DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
75412609|NCT03216096|Drug|Placebo ophthalmic solution and 3% DE-089 ophthalmic solution|Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
75412610|NCT03215082|Other|Vestibular-Visual Intervention|vestibular-visual exercises
75412611|NCT03215082|Behavioral|standard care|standard care
75412612|NCT03214926|Device|Moving Through Glass intervention|
75555921|NCT04630145|Drug|Clarithromycin|Participants will receive CAM 400 or 500 mg twice a day.
75555922|NCT04630145|Drug|Ethambutol|Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram [g]) or 15 mg/kg once a day.
75555923|NCT04630145|Drug|Rifampicin|Participants will receive daily dose is 450 mg (maximum 600 mg) RFP capsule once a day.
75555924|NCT04630145|Drug|Rifabutin|Participants will receive daily dose of RBT 300 mg or 150 mg capsules once a day.
75555925|NCT04630028|Drug|Ustekinumab Dose Based on BSA and Body Weight|As per BSA and body weight Ustekinumab will be administered SC and IV.
75555926|NCT04630028|Drug|Matching Placebo|Placebo will be administered subcutaneously.
75555927|NCT04628494|Biological|Epcoritamab|Following mandatory pre-medication subject will be administered epcoritamab as a subcutaneous injection.
75555928|NCT04628494|Drug|Investigator's Choice Chemotherapy|Following mandatory pre-medication subject will be administered intravenously either BR or R-GemOx.
75714548|NCT03977129|Other|CAG-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
75872828|NCT04573647|Drug|Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]|Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
76041601|NCT02603107|Drug|RTV|100 mg capsule coadministered orally with ATV or DRV once daily with food
76041602|NCT02603107|Drug|ATV|300 mg capsule administered orally once daily with food
76041603|NCT02603107|Drug|DRV|800 mg tablet administered orally once daily with food
75555929|NCT04627103|Device|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.
75872829|NCT05194371|Radiation|definitive radiotherapy or definitive chemoradiotherapy|A total dose of radiation therapy should be more than 50Gy
76041604|NCT02603107|Drug|COBI|150 mg tablet coadministered orally with ATV or DRV once daily with food
76041605|NCT02603107|Drug|ATV/co|300/150 mg FDC tablet administered orally once daily with food
76041606|NCT02603107|Drug|DRV/co|800/150 mg FDC tablet administered orally once daily with food
75412613|NCT03214848|Behavioral|Contraceptive education prior to abortion|Contraceptive education script will be delivered over the phone prior to abortion visit.
76041607|NCT02603107|Drug|FTC/TDF|200/300 mg FDC tablet administered orally once daily without regard to food
75412614|NCT03214692|Dietary Supplement|Gum Arabic|Oral intake of GA in powder from30 grams per day
75412615|NCT03214458|Device|Nasal high flow|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
75412616|NCT03214536|Procedure|erector spinae block|bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process
75412617|NCT03214536|Drug|Ropivacaine|injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block
75412618|NCT03214536|Procedure|Spine surgery|Surgery of lumbar spine
75555930|NCT04623541|Biological|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
75555931|NCT04623541|Biological|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 21 days (Cycle 1-6) and 28 days for Cycle 7 and beyond.
75872830|NCT05194215|Device|Ada WRA|The Ada WRA is a study-only device based on the Ada mobile app. The patient will use this device to answer questions regarding their symptoms but will not be given any feedback by the app.
75872831|NCT03113409|Drug|Buprenorphine|Buprenorphine will be administered daily
76041608|NCT02603107|Drug|ABC/3TC|600/300 mg tablet administered orally once daily with or without regard to food
76041609|NCT02603107|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
76041610|NCT04826263|Other|Home Exercise Program|All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.
76041611|NCT04826263|Other|Low-Level Laser Therapy (LLLT)|Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.
76041612|NCT04826263|Other|Extracorporeal Shockwave Therapy (ESWT)|Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
75872832|NCT03113409|Drug|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
75872833|NCT03113409|Drug|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
75872834|NCT05193747|Other|Anesthesia depth monitoring|BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention.
75412619|NCT03214536|Procedure|anesthesia|general anesthesia
75412620|NCT03214770|Drug|TheraCal|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
75412621|NCT03214770|Drug|light-cured calcium hydroxide|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
75412622|NCT03214614|Drug|GLPG2451 multiple dose|GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
75412623|NCT03214614|Drug|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
75412624|NCT03214614|Drug|GLPG2451/GLPG2222 multiple dose|GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
75412625|NCT03214614|Drug|Combined Placebo multiple dose|Combined Placebo, oral suspension, daily for 14 days
75412626|NCT03214146|Biological|HYNRCS-Allo inj|The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10^6 cells/kg according to the protocol design.
75412627|NCT03213834|Procedure|Chest thoracoscopy|Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
75412628|NCT03213834|Procedure|Chest fibrinolytic therapy|A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
75555932|NCT04623541|Drug|rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|R-CHOP will be administered intravenously in cycles of 21 days for the first 6 cycles.
75872835|NCT05193513|Device|hybrid expanders|tow maxillary hybrid expanders supported anteriorly with tow miniscrews
75555933|NCT04623541|Drug|Venetoclax|Venetoclax tablets will be administered orally once daily during the 5-week ramp up period and during Cycle 1-26 of 28 or 35 days each.
75872836|NCT03634293|Drug|Alirocumab Injectable Product|Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
75872837|NCT03634293|Drug|Saline Solution|The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
75412629|NCT03213834|Drug|tPA|tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
75412630|NCT03213834|Drug|DNase|DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
75555934|NCT04623541|Biological|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
75555935|NCT04623541|Drug|Lenalidomide|Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days up to 12 cycles.
75555936|NCT04622527|Other|Random assigned paradigm viewing order|Participants experience the paradigm in a random order
75555937|NCT04616534|Procedure|Biopsy|Undergo biopsy (dose expansion cohort only)
75872838|NCT01373541|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
75872839|NCT01373541|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
75872840|NCT03633747|Drug|Propranolol Hydrochloride|Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
75412631|NCT03213756|Device|Isometric exercises using Hand grip and elastic bands|"Isometric exercises using hand-grip. This exercise consists of two sets of 30 hand-grip contractions with the hand of the upper arm candidate for AVF (in case of doubts about the most appropriate arm for AVF the exercise will be performed with both arms). The patient will rest one minute every 10 contractions and 5 minutes between both sets. The patient will repeat this protocol twice a day, morning and night (Approximately 15 minutes each session). The contraction intensity will start with half of the maximum force obtained by dynamometry and will be increased or decreased to be placed on an effort intensity 2-3 in the Borg scale.~Isometric exercise using elastic bands. At noon the patient will perform a slow contraction session using elastic band with 20 slow repetitions with the arm in flexion and 20 repetitions with the arm in extension. (Total duration: less than 10 minutes)"
76041613|NCT02484729|Drug|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
75872841|NCT01376739|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
76041614|NCT02484729|Drug|Placebo, oral suspension|Matching placebo
76041615|NCT02484729|Drug|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
76041616|NCT04941729|Device|OR3O™ - Dual Mobility System|OR3O™ Dual Mobility System is comprised of a diffusion-hardened, oxidized zirconium acetabular liner (OR3O™ Liner), and an insert of highly cross-linked polyethylene (OR3O™ XLPE Insert).
76041617|NCT04941729|Device|Conventional|A conventional, single-bearing design Total Hip System comprised of R3™ Acetabular Shell with XLPE liner and a Smith & Nephew Oxinium (Ox) femoral head.
76041618|NCT02601625|Drug|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
75872842|NCT05190783|Drug|Formocresol|mixture of formalin, cresol and glycerine used for fixation of pulp tissues
76041619|NCT02601625|Drug|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
75412632|NCT03213444|Drug|adjuvant chemotherapy with 5-FU isolated|Patients submitted to adjuvant chemotherapy with 5-FU isolated
75412633|NCT03213444|Drug|adjuvant chemotherapy with 5-FU associated with oxaliplatin|Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
75872843|NCT05190783|Drug|MTA|material used for pulp regeneration, direct and indirect pulp capping
76041620|NCT02601625|Drug|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
75555938|NCT04616534|Procedure|Biospecimen Collection|Undergo collection of blood samples
75555939|NCT04616534|Procedure|Diagnostic Imaging|Undergo medical imaging scans
76041621|NCT02601625|Drug|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
75555940|NCT04616534|Drug|Elimusertib|Given PO
75872844|NCT05190783|Drug|TheraCal|light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping
76041622|NCT02601625|Drug|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
76041623|NCT02601625|Drug|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
76041624|NCT04819087|Behavioral|Questionnaires and Rehabilitation Programs|Questionnaires and Rehabilitation Programs
76041625|NCT04819165|Other|COVID-19|Impact of covid-19 on infections associated with health care devices.
76041626|NCT04819321|Device|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
75555941|NCT04616534|Drug|Gemcitabine|Given IV
76041627|NCT03036553|Other|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
75555942|NCT04612244|Device|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
75412634|NCT03213600|Device|transcranial Direct Current Stimulation tDCS|75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
75412635|NCT03213522|Procedure|Pelvic Floor Physical Therapy|Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
75412636|NCT03213522|Procedure|Craniosacral Therapy|Modified Upledger Institute 10-step protocol.
75555943|NCT04612244|Device|RadioFrequency and Cryoballoon Ablation|Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
75872845|NCT05190783|Procedure|pulpotomy|removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.
75872846|NCT05190783|Procedure|partial pulpotomy|complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.
75872847|NCT01375647|Biological|IPV|Administered per protocol
75872848|NCT01375647|Biological|Rotarix|Administered per protocol
75412637|NCT03213054|Biological|OBP-301|OBP-301 administration on the Day 1, Day 18 and Day 32
75412638|NCT03213054|Radiation|Radiation|Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
75412639|NCT03213288|Dietary Supplement|Delphinidin type anthocyanins|Bilberry extract containing Delphinidin type anthocyanins
75412640|NCT03213288|Dietary Supplement|Cyanidin type anthocyanins|Black rice extract containing Cyanidin type anthocyanins
75412641|NCT03213288|Dietary Supplement|Placebo|No anthocyanins
75412642|NCT03212820|Procedure|Drilling at low speed|
75412643|NCT03212820|Procedure|Drilling at conventional or high speed|
75555944|NCT04609826|Drug|JNJ-74856665|JNJ-74856665 will be administered orally.
75555945|NCT04609826|Drug|AZA|AZA will be administered IV infusion or SC injection.
75555946|NCT04609826|Drug|VEN|VEN tablet will be administered orally.
75555947|NCT04606381|Drug|Ami-LC-MD|Participants will receive amivantamab admixed with rHuPH20 SC infusion.
75555948|NCT04606381|Drug|Ami-LC|Participants will receive amivantamab SC infusion.
75555949|NCT04606381|Drug|Ami-HC|Participants will receive amivantamab SC infusion.
75555950|NCT04606381|Drug|Ami-HC-CF|Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
75872849|NCT01373619|Drug|Ivabradine|ivabradine titrated to 7.5 mg BID
75412644|NCT03212664|Other|exercise|physical therapy exercises
75555951|NCT04606381|Drug|Lazertinib|Participants will receive lazertinib orally as a film-coated tablet.
75555952|NCT04601753|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75555953|NCT04599855|Drug|Esketamine 56 mg|Esketamine 56 mg will be self administered as nasal spray.
75555954|NCT04599855|Drug|Esketamine 84 mg|Esketamine 84 mg will be self administered as nasal spray.
75555955|NCT04599855|Drug|Placebo|Matching placebo will be self administered as nasal spray.
75555956|NCT04589754|Drug|Sintilimab plus chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.
75555957|NCT04589754|Drug|Adriamycin-based chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.
75412645|NCT03212898|Other|anticoagulation care|Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
75412646|NCT03212586|Drug|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
75412647|NCT03212586|Drug|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
75412648|NCT03212430|Drug|L-kynurenine|intravenous infusion of L-kynurenine to healthy individuals.
75412649|NCT03211806|Behavioral|Sedentary Behavior|Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
75412650|NCT03211806|Device|Bluetooth-enabled activity monitor|Monitoring activity using a Bluetooth-enabled activity monitor
75412651|NCT03212040|Diagnostic Test|needle biopsy|breast biopsy using different needle gauges
75412652|NCT03211962|Other|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
75412653|NCT03211884|Behavioral|Problem-Solving Thearpy|"The problem-solving therapy (PST)-based intervention consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet & greet session, participants received written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7-steps to solve at least one problem together before ending the training. Participants keep a record of their problem-solving efforts between sessions and questions they had related to the application of PST. These records were used as a basis for discussion during the PST training sessions."
75412654|NCT03211728|Drug|pregabalin|The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
75412655|NCT03211728|Drug|placebo|The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
75872850|NCT01376817|Drug|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
75872851|NCT01376817|Drug|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
75872852|NCT01375803|Dietary Supplement|Novel dietary fiber|oral consumption in beverage
75412656|NCT03211572|Drug|Tamoxifen|Participants will take endocrine therapy for 2 weeks prior to surgery.
75872853|NCT01375803|Dietary Supplement|Novel dietary fiber|Oral consumption in beverage
75872854|NCT01375803|Other|Placebo|Oral consumption in beverage
75872855|NCT01373697|Drug|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
75872856|NCT01373697|Drug|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
76041628|NCT04834141|Other|FlexiCurve ruler method to assess thoracic kyphosis angle|The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
75555958|NCT04586426|Drug|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
75714549|NCT03968640|Dietary Supplement|CoQ10|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
75412657|NCT03211494|Device|INTELLiVENT-ASV|INTELLiVENT-ASV, with software 2.60
75714550|NCT03968640|Dietary Supplement|Placebo|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
75412658|NCT03211494|Other|Conventional lung protective ventilation|Lung protective ventilation according to the ARDSnet guidelines
75412659|NCT03211650|Drug|hyaluronic Acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
75412660|NCT03211650|Drug|hyaluronic acid|Intra-articular injections of hyaluronic acid
75412661|NCT03211650|Drug|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
75412662|NCT03211182|Behavioral|lifestyle modification intervention|healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
75412663|NCT03211260|Device|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
75412664|NCT03211026|Other|No intervention|No intervention
75412665|NCT03211104|Dietary Supplement|curcumin|
75412666|NCT03211104|Dietary Supplement|Placebo|
75412667|NCT03210636|Device|LapSpace|use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery
75412668|NCT03210792|Device|Application of Rib Splint|Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
75412669|NCT03210870|Behavioral|nutritional education classes|The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
75412670|NCT03210948|Device|RTE-guided EUS-FNA|Fine needle aspiration with 25 gauge needle under RTE-guidance
75412671|NCT03210948|Device|Conventional EUS-FNA|Fine needle aspiration with no RTE guidance
75412672|NCT03210402|Device|Elevated night pacing on|Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
75412673|NCT03210402|Device|Elevated night pacing off|Device will be programmed to normal lower rates
75714551|NCT03962504|Behavioral|trauma-focused treatment|cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
75714552|NCT03948074|Drug|Cannabis|Medicinal Cannabis Oil
75872857|NCT01375881|Drug|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
75872858|NCT03427073|Drug|ALM201|Drug: ALM201 administered subcutaneously
75412674|NCT03210168|Other|BioFe Medical Food|BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
75412675|NCT03210246|Drug|Vilaprisan (BAY 1002670)|Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
75412676|NCT03210246|Drug|Vilaprisan Placebo|Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
75412677|NCT03210246|Drug|Microgynon|Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
75555959|NCT04586426|Drug|Teclistamab|Teclistamab will be administered by SC injection.
75555960|NCT04586426|Drug|Daratumumab|Daratumumab will be administered by SC injection.
75555961|NCT04585789|Drug|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
75555962|NCT04585789|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
75555963|NCT04585789|Drug|Entecavir (ETV)|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
75412678|NCT03210246|Drug|Microgynon Placebo|For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
75412679|NCT03210324|Drug|Mifepristone tablets|Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
75412680|NCT03210480|Drug|Lithium sulphate prolonged-release 660 mg|Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
75412681|NCT03210480|Drug|Lithium carbonate immediate-release 150 mg and 300 mg|Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
75555964|NCT04585789|Drug|Tenofovir disoproxil|Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
75555965|NCT04585789|Drug|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
75555966|NCT04585789|Drug|PegIFN-alpha-2a (Optional)|PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
75412682|NCT03210012|Diagnostic Test|Transthoracic echocardiography|Diagnostic test done prior and after the dive
75412683|NCT03210012|Diagnostic Test|Blood samples|Diagnostic test done prior and after the dive
75412684|NCT01830114|Behavioral|Web app|The Checkup and Choices web application
75412685|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
75555967|NCT04585763|Device|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
75555968|NCT04581512|Drug|EP0042|EP0042 Oral 20 mg 50 mg capsules
75555969|NCT04581473|Drug|CT041 autologous CAR T-cell injection|Up to 3 times CT041 autologous CAR T-cell injection infusion
75555970|NCT04581473|Drug|Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）|Physician's choice of any BSC listed above
75555971|NCT04577833|Drug|Niraparib|Niraparib will be administered orally.
75714553|NCT03939104|Drug|Artemether-lumefantrine+amodiaquine|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: Amodiaquine is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
75714554|NCT03939104|Drug|Artemether-lumefantrine+placebo|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
75412686|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
75872859|NCT05760885|Behavioral|Balance training with sensory augmentation|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.
76041629|NCT04826497|Drug|nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
75412687|NCT01830348|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
75412688|NCT01830348|Drug|placebo vehicle gel|
75412689|NCT01830582|Procedure|Advanced MR Imaging|
75555972|NCT04577833|Drug|Abiraterone Acetate (AA)|Abiraterone Acetate will be administered orally.
75555973|NCT04577833|Drug|Prednisone|Prednisone will be administered orally.
75555974|NCT04572165|Drug|Ozempic®|Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75412690|NCT01830660|Drug|Hetrombopag Olamine Tablets|
75412691|NCT01830660|Drug|placebo|
75412692|NCT01830738|Procedure|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
75412693|NCT01830738|Procedure|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
75412694|NCT01830894|Device|MRI|3 MRI on different times during the study for each arm.
75412695|NCT01831128|Device|ASV Treatment|
75412696|NCT01831206|Procedure|Collagen cross-linking|"Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication."
75412697|NCT01831284|Procedure|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
75714555|NCT03939104|Drug|Artesunate-mefloquine+piperaquine|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately~24 mg/kg/day in patients <25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
75412698|NCT01831362|Behavioral|Mindfulness-Based Cognitive Therapy|
75872860|NCT05760885|Behavioral|Balance training|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
75872861|NCT03716219|Other|Exercise Training|Physical activity in children and adults with asthma.
75872862|NCT04690023|Procedure|Pericapsular nerves group (PENG) block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block with injection 20 ml of ropivacaine 0,75%, between the anterior hip articular capsule, the ilii-psoas muscle, the ileo-pubic eminence and the antero-inferior iliac spine.
75412699|NCT01831362|Behavioral|Focused Attention (FA)|
75412700|NCT01831362|Behavioral|Open- Monitoring|
75412701|NCT01831518|Device|CRT Implant|
75412702|NCT01831518|Device|Body Surface ECG Mapping|
75872863|NCT04690023|Procedure|Supra-inguinal fascia-iliaca compartment block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block with injection over de inguinal ligament of 40 ml of ropivacaine 0,375%, between de ilio-psoas muscle and internal oblique muscle.
75872864|NCT04690023|Drug|Ropivacaine 0,75% in PENG block|20 ml injection of ropivacaine 0,75%
75872865|NCT04690023|Drug|Ropivacaine 0,375% in SFICB block|40 ml injection of ropivacaine 0,375%
75412703|NCT01831674|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
75412704|NCT01831674|Drug|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
75412705|NCT01831830|Behavioral|The Veterans' In-home Program|VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
75412706|NCT01832064|Behavioral|Mailed Chronic Disease Self-Management Program|materials are mailed to participants
75412707|NCT01832298|Drug|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
75412708|NCT01832376|Procedure|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
75412709|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
75412710|NCT01832844|Procedure|"Group  with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
75412711|NCT01832844|Procedure|"Group  without scan "|
75714556|NCT03939104|Drug|Artesunate-mefloquine+placebo|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
75412712|NCT01832922|Drug|Bendamustine|
75412713|NCT01832922|Drug|Rituximab|
75412714|NCT01833000|Device|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
75872866|NCT03066804|Drug|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
75412715|NCT01833156|Device|MoistureMeterD|measuring erythema size and the dielectric constant values
75412716|NCT01833234|Other|Interviews and questionnaires|
76041630|NCT04826497|Drug|Placebo（normal saline）|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
75412717|NCT01833312|Device|Hypothermia|In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.
76041631|NCT04834219|Procedure|On-Pump CABG|Patients who have undergone on-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
75412718|NCT01833312|Drug|Buspirone|anti-shivering treatment
75412719|NCT01833312|Drug|Pethidine|anti-shivering treatment
75412720|NCT01833390|Drug|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
75412721|NCT01833624|Dietary Supplement|Peptamen® AF|Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
75412722|NCT01833624|Dietary Supplement|Sondalis® HP|
75714557|NCT03932318|Biological|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
75872867|NCT03066804|Drug|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
76041632|NCT04834219|Procedure|Off-Pump CABG|Patients who have undergone off-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
76041633|NCT04819243|Drug|Pabociclib, Endocrine, Talazoparib, Atezolizumab|"Palbociclib 125mg~AI~GnRH agonist~Talazoparib~Atezolizumab"
76041634|NCT04819243|Drug|Pabociclib, Endocrine, Talazoparib,|"Palbociclib 125mg~AI~GnRH agonist~Talazoparib"
76041635|NCT05618821|Drug|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
75412723|NCT01834014|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75872868|NCT03066804|Drug|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
76041636|NCT04818619|Diagnostic Test|flow cytometry test|Blood samples will be stained with TIGIT by flow cytometry test
76041637|NCT02601469|Drug|DSXS|twice daily for 28 days
76041638|NCT05618743|Procedure|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
76041639|NCT04826107|Drug|DP303c treatment|DP303c injection, every 3 weeks.
75714558|NCT03932318|Drug|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
75714559|NCT03932318|Drug|Azacitidine|75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
75714560|NCT03926949|Other|Parenteral Nutrition|Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
75714561|NCT03926949|Other|Standard Nutrition Care|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
75714562|NCT03923725|Drug|Artemether-lumefantrine+ Amodiaquine (AL+AQ)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
75714563|NCT03923725|Drug|Artemether-lumefantrine + placebo (AL+PBO)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
75714564|NCT03923725|Drug|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately.~24 mg/kg/day in patients <25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
75714565|NCT03923725|Drug|Artesunate-mefloquine+placebo (AS-MQ+PBO)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
75714566|NCT03918603|Other|ventral décubitus|Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus
75872869|NCT03066804|Drug|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
75872870|NCT03066804|Drug|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
75872871|NCT03066804|Drug|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
75872872|NCT03633357|Drug|JNJ-18038683|"JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days."
76041640|NCT04826107|Drug|DP303c treatment（second-line of HER2-positive）|DP303c injection, every 3 weeks.
75412724|NCT01834014|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
76041641|NCT04826107|Drug|DP303c treatment （third-line of HER2-positive）|DP303c injection, every 3 weeks.
75714567|NCT03912155|Other|Multi-scale analysis of physiological brain networks|It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
76041642|NCT04826107|Drug|DP303c treatment（≥second-line of HER2 low expressing）|DP303c injection, every 3 weeks.
75714568|NCT03896347|Other|ViBone®|Viable bone allograft
75714569|NCT03896347|Other|Demineralized Bone Matrix|Demineralized Bone Matrix
75714570|NCT03896347|Other|Bone Morphogenetic Protein|Bone Morphogenetic Protein
75714571|NCT03864926|Drug|Envarsus XR|"Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR."
75714572|NCT03864926|Drug|Tacrolimus|Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
75872873|NCT03633357|Drug|Placebo|Participants will take two placebo tablets daily, for seven days.
76041643|NCT04826107|Drug|DP303c + PD-1/PD-L1 treatment|DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
76041644|NCT04816435|Diagnostic Test|Ultrasound test|Ultrasound evaluation of airway
76041645|NCT05617417|Other|Local applied injectable platelet-rich fibrin in women with stress urinary incontinence|Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
76041646|NCT02604589|Drug|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
76041647|NCT02604589|Procedure|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
76041648|NCT02604589|Drug|bupivicaine 0.25%|Low Dose analgesia
76041649|NCT02604589|Drug|bupivicaine 0.5%|High dose analgesia
76041650|NCT04825249|Procedure|traditional suture bridge technique|(A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique
76041651|NCT04825249|Procedure|modified suture bridge technique|(A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
76041652|NCT04356859|Drug|Albumin Human|Addition of albumin during acute resuscitation following burn injury
75412725|NCT01834014|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75412726|NCT01834014|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75412727|NCT01834014|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75412728|NCT01834014|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75412729|NCT01834092|Other|Plasma|2 Units of plasma transfused equvilant to 2 times 275ml
75412730|NCT01834170|Drug|Gemcitabine|"Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist"
75412731|NCT01834482|Dietary Supplement|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
75412732|NCT01834482|Dietary Supplement|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
75412733|NCT01834638|Drug|ABT-126|capsule(s)
75412734|NCT01834794|Behavioral|MET/CBT/CM plus NRT|Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
75412735|NCT01834950|Other|Blood test|
75412736|NCT01835106|Procedure|Epidural catheter is used postoperatively|
75412737|NCT01835106|Procedure|Fascia iliaca compartment catheter is used postoperatively|
75412738|NCT01835184|Drug|cabozantinib-s-malate|Given PO
75412739|NCT01835184|Drug|vemurafenib|Given PO
75412740|NCT01835184|Other|laboratory biomarker analysis|Correlative studies
75412741|NCT01835184|Other|pharmacological study|Correlative studies
75555975|NCT04572165|Drug|Active Comparator|Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75555976|NCT04572165|Drug|Rybelsus®|Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75555977|NCT04569240|Device|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor will be applied to the upper outer arm before cardiovascular surgery. Data will be collected for 10 days or upon discharge from the ICU.
75714573|NCT03855735|Behavioral|TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)|The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
76041653|NCT04818307|Other|Macquarie Injury Management group|Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.
75412742|NCT01835340|Device|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
75555978|NCT04567602|Drug|PAH medication|There will be no specific interventions.
75555979|NCT04567303|Drug|Zifibancimig|"Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant."
75555980|NCT04567303|Drug|Ranibizumab|Participants will receive ranibizumab 100 mg/mL through the PD implant
75412743|NCT01835574|Behavioral|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete >=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
75412744|NCT01835652|Other|Active Exercise|
75412745|NCT01835652|Other|Passive Exercise|
75412746|NCT01835730|Drug|PE0139 Injection|
75412747|NCT01835730|Drug|Placebo|
75412748|NCT01835886|Other|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
75412749|NCT01836120|Drug|Raltitrexed plus Docetaxel|"Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d~1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)"
75412750|NCT01836120|Drug|Docetaxel|Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
75555981|NCT04567303|Device|Port Delivery Platform|Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
75555982|NCT04565990|Drug|Selexipag|Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily.
75555983|NCT04563871|Drug|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
75714574|NCT03853434|Procedure|Embolization|Angiographic embolization
75714575|NCT03836261|Drug|Acalabrutinib|Acalabrutinib,
75714576|NCT03836261|Drug|Venetoclax|Venetoclax
75714577|NCT03836261|Drug|Chemoimmunotherapy|fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
75714578|NCT03836261|Drug|Obinutuzumab|Obinutuzumab
75714579|NCT03809533|Drug|sofosbuvir/velpatasvir|12-week, oral, fixed-dose
75714580|NCT03808922|Drug|DAS181|DAS181 4.5mg nebulized qd x 7 OR 10 days
75714581|NCT03808922|Drug|Placebo|Placebo nebulized qd x 7 OR 10 days
75714582|NCT03808922|Drug|DAS181 COVID-19|DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
75714583|NCT03808922|Drug|DAS181 OL|DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days < 40kg
76041654|NCT04818307|Other|Mulligan Mobilization with Movement|Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
76041655|NCT02601001|Drug|Omecamtiv mecarbil|Omecamtiv mecarbil tablets for oral administration
75412751|NCT01836588|Procedure|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
75412752|NCT01836822|Procedure|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
75412753|NCT01836822|Procedure|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
75412754|NCT01836822|Procedure|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
75555984|NCT04563325|Drug|Oral co-amoxiclav or oral dicloxacillin only|High dose oral treatment followed by standard dose oral treatment
75555985|NCT04563325|Drug|IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin|IV treatment followed by standard dose oral treatment
75555986|NCT04559815|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75555987|NCT04557098|Drug|Teclistamab|Teclistamab will be administered SC.
75714584|NCT03796793|Procedure|Wound Edge Debridement|Wound debridement is performed using a sharp, circular disposable curette to remove the slough, non-viable tissue and any fibrous tissue down to the vascular base.
75412755|NCT01836822|Procedure|Bronchoalveolar lavage (BAL)|
75412756|NCT01836822|Procedure|Endobronchial forceps biopsy|
75555988|NCT04557059|Radiation|Radiotherapy|Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.
76041656|NCT02601001|Drug|Placebo|Matching placebo tablets
75555989|NCT04557059|Drug|LHRHa|Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
75555990|NCT04557059|Drug|Apalutamide|Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
75714585|NCT03796793|Other|Standard of Care Treatment|Standard of Care treatment will include foam dressing and 4 layer compression therapy, changed weekly.
75714586|NCT03763864|Other|Skin Biopsy|Skin Biopsy
75412757|NCT01836900|Device|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
75412758|NCT01836978|Other|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
75412759|NCT01837368|Other|observational research|It is a observational research, no intervention are performed
75555991|NCT04547192|Other|Improving initial care of the injured|Improvement in Care Processes
75714587|NCT03760016|Behavioral|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
75714588|NCT03760016|Behavioral|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
75714589|NCT03756870|Procedure|Percutaneous coronary intervention (PCI)|A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
75714590|NCT03718234|Drug|Subcutaneous hydrocortisone|Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.
75412760|NCT01837836|Behavioral|Health education|Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.
75412761|NCT01837992|Drug|Primaquine|
75412762|NCT01837992|Drug|delayed primaquine|
75412763|NCT01838382|Device|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
75412764|NCT01838460|Drug|sublingual nicotine tablets|6 mg = 3 tablets
75412765|NCT01838460|Other|Smokeless tobacco|Swedish type moist snuff
75412766|NCT01838538|Drug|Bevacizumab|
75412767|NCT01838538|Drug|TC:paclitaxel + carboplatin|
75412768|NCT01838772|Drug|Pegylated-Interferon and Ribavirin|This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
75412769|NCT01838928|Drug|Bupivacaine|
75714591|NCT03718234|Drug|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
75714592|NCT03717519|Diagnostic Test|Measurement of platelet count at diagnosis|Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
75714593|NCT03708276|Other|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
75714594|NCT03689439|Diagnostic Test|bone scintigraphy|bone scintigraphy
75714595|NCT03685110|Device|CoreHip Total Hip Arthroplasty|Replacement of the Hip Joint
75714596|NCT03667248|Device|Sorin Perceval ® Sutureless Valve (Sorin Group Italia Srl, 13040 Saluggia, Italy), available in different sizes (S 19-21mm, M 21-23mm, L 23-25mm, XL 25-27mm)|Sizing of the valve by preoperative CT scan of the heart and comparison of this measurement with the standard procedure (Sizing intraoperatively using the measuring devices provided by the product manufacturer)
75555996|NCT04543903|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
75555997|NCT04542824|Biological|epcoritamab (monotherapy)|Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
75555998|NCT04542824|Biological|epcoritamab|Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
75555999|NCT04542824|Drug|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
75556000|NCT04542824|Drug|gemcitabine and oxaliplatin|28-day cycles
75556001|NCT04542824|Biological|epcoritamab (maintenance)|28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
75556002|NCT04542824|Drug|rituximab and lenalidomide|28-day cycles.
75714597|NCT03643107|Drug|Irofulven|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
75412770|NCT01839006|Procedure|dismembered pyeloplasty|Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
75412771|NCT01839084|Drug|Xenon|general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
75412772|NCT01839084|Drug|Isoflurane|general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
75412773|NCT01839162|Procedure|Coronary angiography|Diagnostic coronary angiography
75412774|NCT01839162|Procedure|PCI|Percutaneous coronary intervention
75412775|NCT01839162|Procedure|Right approach|Right transradial access
75412776|NCT01839162|Procedure|Left approach|Left transradial access
75412777|NCT01839240|Drug|azacitidine|Given IV or SC
75412778|NCT01839240|Drug|cytarabine|Given IV
75412779|NCT01839240|Drug|mitoxantrone hydrochloride|Given IV
75412780|NCT01839240|Other|laboratory biomarker analysis|Correlative studies
75412781|NCT01839474|Device|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
75412782|NCT01839552|Drug|Fentanyl Citrate Nasal Spray (FCNS)|
75412783|NCT01839630|Drug|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
75556003|NCT04540796|Drug|JNJ-75348780|Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
75556004|NCT04540692|Drug|Docetaxel or Paclitaxel|Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks
75556005|NCT04540692|Drug|Cyclophosphamide + Doxorrubicin|Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles
75556006|NCT04538664|Drug|Amivantamab|Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
75556007|NCT04538664|Drug|Pemetrexed|Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.
75556008|NCT04538664|Drug|Carboplatin|Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
75714598|NCT03643107|Combination Product|Prednisolone 10 mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
75714599|NCT03641703|Biological|FLT180a|FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
75714600|NCT03623243|Drug|Siponimod|Siponimod 2mg tablets taken once daily
76041657|NCT04825405|Procedure|hand motor coordination in a sitting position after use TipStim Glove|The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.
76041658|NCT05618665|Other|Asthma Education|Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.
75412784|NCT01839864|Behavioral|Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count|Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
75412785|NCT01839942|Procedure|hernia gap closure|type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal
75714601|NCT03619707|Drug|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
75714602|NCT03611673|Other|Smell Test|Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.
75714603|NCT03603717|Behavioral|Cognitive Behavioral Therapy for Insomnia|The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
75714604|NCT03603717|Behavioral|Sleep Hygiene|The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
76041659|NCT05618665|Other|Delivery of booklets|The booklets, prepared by the researchers, included information about the content of the education.
76041660|NCT04818151|Drug|Warfarin|Warfarin treatment for VTE
76041661|NCT04818151|Drug|Apixaban|Apixaban treatment for VTE
75412786|NCT01839942|Procedure|extracorporal suturing of gap|ventral hernia gap is sutured extracorporally
75412787|NCT01834248|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
75412788|NCT01834248|Drug|Decitabine|Given IV
75412789|NCT01834248|Other|Laboratory Biomarker Analysis|Correlative studies
75556009|NCT04538664|Drug|Pemetrexed|Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
76041662|NCT04817527|Drug|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
76041663|NCT04357795|Drug|CequaTM (Cyclosporine 0.09%) ophthalmic solution|One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
75556010|NCT04537624|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75556011|NCT04537039|Diagnostic Test|Frailty screening for people over 65 living at home.|The home care services will carry out the SEGA-A test.
75556012|NCT04535544|Drug|JNJ-73763989|JNJ-73763989 will be administered as a SC injection.
75556013|NCT04535544|Drug|Placebo|Matching placebo to JNJ-73763989 will be administered as a SC injection.
75556014|NCT04535544|Drug|Entecavir (ETV) monohydrate|ETV monohydrate film coated tablet will be administered orally.
75556015|NCT04535544|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
75412790|NCT01834248|Drug|Poly ICLC|Given SC
75556016|NCT04535544|Drug|Tenofovir alafenamide (TAF)|TAF film coated tablet will be administered orally.
75556017|NCT04533529|Drug|Seltorexant|Seltorexant tablet will be administered orally once daily.
76041664|NCT05617339|Behavioral|I am (internet approach to migraine)|I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
75556018|NCT04533529|Drug|Placebo|Matching placebo tablet will be administered orally once daily.
75556019|NCT04532372|Other|Best Practice|Receive standard of care drugs
75556020|NCT04532372|Drug|Leflunomide|Given PO
76041665|NCT02604199|Drug|ARC-520 Injection|ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
75556021|NCT04532372|Drug|Placebo Administration|Given PO
75412791|NCT01833858|Drug|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
75412792|NCT01833858|Drug|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
75556022|NCT04532307|Behavioral|Standard of Care SOC|Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
75556023|NCT04532307|Behavioral|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples are collected at enrolment. Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
75556024|NCT04532307|Behavioral|Peer-support (Thetha-Nami)|The research assistants refer the participant to a Thetha Nami peer-navigator in their community. Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need. The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
75556025|NCT04532307|Behavioral|SOC + SRH + peer-support|A combination of interventions 2 and 3, to include both self-collected STI testing, nurse led testing and counseling, and referral to a Thetha Nami peer navigator to encourage clinic attendance and sexual health promotion.
75556026|NCT04514510|Drug|Isoquercetin|"Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.~Isoquercetin given at 1000 mg, once daily by mouth for 28 days."
75556027|NCT04514510|Drug|Placebo|"Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days."
75556028|NCT04514497|Procedure|Biopsy|Undergo tumor biopsy
75556029|NCT04514497|Procedure|Biospecimen Collection|Undergo collection of blood samples
75556030|NCT04514497|Procedure|Computed Tomography|Undergo CT
75412793|NCT01834872|Device|Amigo|
75412794|NCT01834872|Device|Manual ablation|
75412795|NCT01836432|Drug|FOLFIRINOX|FOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours
75412796|NCT01836432|Biological|Algenpantucel-L Immunotherapy|Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection
75412797|NCT01836432|Radiation|5-FU Chemoradiation|5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
75556031|NCT04514497|Drug|Elimusertib|Given PO
75556032|NCT04514497|Drug|Irinotecan Hydrochloride|Given IV
75556033|NCT04514497|Procedure|Magnetic Resonance Imaging|Undergo MRI
75872874|NCT02954237|Device|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
75872875|NCT03629262|Drug|Dexmedetomidine|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
75714605|NCT03597568|Dietary Supplement|Resveratrol|Oral supplementation for 6 weeks
75714606|NCT03597568|Other|Placebo|Oral supplementation for 6 weeks
75714607|NCT03593408|Drug|Dexmedetomidine|Administered for sedation management per hospital protocol
75872876|NCT03629262|Drug|Placebo|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
75872877|NCT04224090|Diagnostic Test|Echocardiographic assessment of coronary arteries origin and proximal course|Echocardiographic assessment of CAA utilizing 4 specific echocardiographic acoustic windows: parasternal short-axis (PSAX), parasternal long-axis (PLAX), apical 4/5-chambers views.
75556034|NCT04514497|Drug|Topotecan Hydrochloride|Given IV
75556035|NCT04509752|Other|Survey|An online survey will be sent to each clinic to answer the survey questions.
75556036|NCT04507854|Other|Strength, range of motion and functional tests + Questionnaire|Patients undergoing instability surgery will perform amplitude, strength, functional tests and a questionnaire at 6 months of the operation. Then they will be contacted at 12, 18 and 24 months to find out if they have regained their performance level or if they have injured their shoulder again.
75556037|NCT04505956|Device|Holmium laser lithotripsy with Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned on.
75556038|NCT04505956|Device|Holmium laser lithotripsy without Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.
75714608|NCT03593408|Drug|Fentanyl|Administered for sedation management per hospital protocol
75714609|NCT03593408|Drug|Midazolam|Administered for sedation management per hospital protocol
75714610|NCT03593408|Drug|Morphine|Administered for sedation management per hospital protocol
75714611|NCT03591445|Device|Flexible Bronchoscopy|Flexible Bronchoscopy
75714612|NCT03572582|Drug|Nivolumab|Nivolumab therapy combined with standard TACE treatment
75714613|NCT03572582|Drug|TACE|TACE is performed by using drug eluting beads
75714614|NCT03562832|Drug|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
75714615|NCT03492164|Drug|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one also known as [18F]FluorThanatrace or [18F]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
75714616|NCT03432871|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
75714617|NCT03399942|Procedure|Deep brain Stimulation of cingulum anterior|The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
75714618|NCT03399318|Drug|Acetaminophen|"30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments"
75714619|NCT03399318|Drug|Ibuprofen|10 mg/kg Q6 hours for the Aggressive Antipyretic Arm
75714620|NCT03399318|Drug|placebo for acetaminophen|"placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo"
76041666|NCT02604199|Other|placebo|Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
76041667|NCT02604199|Drug|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
76041668|NCT02604199|Drug|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
76041669|NCT02604199|Drug|antihistamine|All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
76041670|NCT04807699|Other|Data collection|Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
76041671|NCT04817215|Drug|ORMD-0801|Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
75556039|NCT04502576|Device|Noninvasive respiratory support|"In both arms, the treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge.~Patients will have to undergo the allocated treatment within 1 hour from the moment of randomization and within 24 hours from admission in the intensive care unit"
75556040|NCT04497844|Drug|Niraparib|Participants will receive Niraparib 200 mg once daily.
75556041|NCT04497844|Drug|Abiraterone acetate (AA)|Participants will receive AA 1000 mg once daily.
75714621|NCT03399318|Drug|placebo for ibuprofen|placebo for ibuprofen
75714622|NCT03389139|Device|Near infrared spectroscopy (spinal anesthesia)|effect of spinal anesthesia on regional renal and cerebral oxygen saturation in newborns
75714623|NCT03389139|Device|Near infrared spectroscopy (general anesthesia)|effect of general anesthesia on regional renal and cerebral oxygen saturation in newborns
75714624|NCT03382938|Drug|Dexmedetomidine|WOUND INFILTRATION IN CESAREAN SECTION
75714625|NCT03382938|Drug|Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
75714626|NCT03382938|Drug|Dexmedetomidine - Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
75714627|NCT03382938|Other|0,9% saline|placebo WOUND INFILTRATION IN CESAREAN SECTION
75714628|NCT03380468|Drug|cisplatin plus pemetrexed|cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
75714629|NCT03356366|Other|MRI 3T|Magnetic Resonance Imaging 3 Tesla
75714630|NCT03356366|Other|MRI 1,5T|Magnetic Resonance Imaging 1,5 Tesla
75714631|NCT03356366|Other|MRI 7T|Magnetic Resonance Imaging 7 Tesla
75714632|NCT03322774|Behavioral|digital Cognitive Behavioral Therapy for Insomnia|"Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment."
76041672|NCT04817059|Device|Caseforge headcase|We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
76041673|NCT04816903|Diagnostic Test|Gyni|Vaginal discharge collection
75412798|NCT01836432|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
75872878|NCT05208372|Diagnostic Test|CTC test|Circulating tumor cells test of ascites and blood for patients with gastric cancer.
75714633|NCT03322774|Behavioral|face-to-face Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.
75714634|NCT03322774|Behavioral|Sleep Hygiene Education Control|Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
75714635|NCT03304483|Other|246-km running|Spartathlon 2017
75714636|NCT03284892|Behavioral|SOC program|A once-daily, 7-day SOC program, including oral-motor exercise, sensory stimulation and lubrication, and safe-swallowing education.
75714637|NCT03279952|Drug|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
75714638|NCT03271242|Other|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
75412799|NCT01836432|Drug|Capecitabine|Capecitabine consisting of 825 mg/m^2 PO BID M-F concurrently with external beam radiation
75714639|NCT03271242|Other|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
75872879|NCT05208372|Diagnostic Test|ctDNA test|Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
75872880|NCT05213988|Dietary Supplement|Intermittent Fasting|Intermittent fasting meal pattern
75872881|NCT05213988|Drug|Fibrates|Bezafibrate 400 mg/day
75872882|NCT05213988|Dietary Supplement|Low-Carbohydrate/High-Protein diet|Low-calorie, low-carbohydrate, high-protein diet
75872883|NCT05207904|Drug|Tislelizumab, paclitaxel, Carboplatin|Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
75872884|NCT05207826|Diagnostic Test|Cystometrogram|Serial cystometrogram every 3 days for acute traumatic spinal cord injured patients
75872885|NCT04150692|Biological|Dara-SC|-Subcutaneous daratumumab and hyaluronidase-fihj
75872886|NCT04150692|Procedure|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
75412800|NCT01836432|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes
75412801|NCT01720056|Drug|Verapamil|
75412802|NCT01720056|Drug|Kenalog 10|
75412803|NCT01720212|Drug|YM178|oral
75412804|NCT01720290|Drug|repaglinide|Dose individually adjusted
75412805|NCT01720290|Drug|metformin|Dose individually adjusted
75412806|NCT01720290|Drug|metformin|Dose at 1000 mg/day
75412807|NCT01720680|Radiation|Low dose multislice CT thorax|"All patients will have 2 low dose multi-slice CT's at visit 2: one CT pre-dose and one CT 1 to 3 hours post-dose."
75412808|NCT01720680|Device|AlphaCore® device|All patients will receive a stimulation therapy of 90 seconds delivered by the AlphaCore.
75556042|NCT04497844|Drug|Prednisone|Participants will receive prednisone 5 mg once daily.
75556043|NCT04497844|Drug|Placebo for Niraparib|Participants will receive matching placebo for Niraparib once daily.
75556044|NCT04496219|Device|Acupuncture Therapy|Undergo acupuncture therapy
75556045|NCT04496219|Biological|BCG Solution|Given by intravesical injection
75556046|NCT04496219|Other|Best Practice|Receive standard of care symptom management
75556047|NCT04496219|Other|Quality-of-Life Assessment|Ancillary studies
75872887|NCT04150692|Procedure|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
75556048|NCT04496219|Other|Questionnaire Administration|Ancillary studies
75714640|NCT03258853|Device|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
75714641|NCT03258853|Other|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
75872888|NCT05715450|Procedure|Falciformopexy for Treatment Perforated Peptic Ulcer|use the falciform ligament on perforated peptic ulcer
75412809|NCT01720992|Other|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
75412810|NCT01721148|Drug|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
75412811|NCT01721304|Other|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
75556049|NCT04495946|Behavioral|Sepsis Transition and Recovery (STAR) program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
75556050|NCT04495946|Behavioral|Usual care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
75556051|NCT04494412|Drug|Zanamivir|Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.
75412812|NCT01721382|Drug|Sitagliptin|
75556052|NCT04487080|Drug|Amivantamab|Participants will receive amivantamab intravenously.
75556053|NCT04487080|Drug|Osimertinib|Participants will receive osimertinib capsules orally.
75556054|NCT04487080|Drug|Lazertinib|Participants will receive lazertinib tablets orally.
75556055|NCT04487080|Drug|Placebo|Participants will receive matching placebo orally.
75714642|NCT03236155|Drug|opioid pain pills|patient will receive their pain pill prescription
75714643|NCT03216551|Diagnostic Test|Intra-operative frozen section|Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
75714644|NCT03192202|Drug|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
75714645|NCT03177122|Drug|Myo-inositol|Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
75714646|NCT03169166|Drug|Triptorelin|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
75412813|NCT01721538|Other|Weight reduction program|
75412814|NCT01721538|Other|Lecture on healthy nutrition|
75556056|NCT04482556|Device|Q-NRG+ Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
75556057|NCT04482556|Device|V(max) Encore Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
75872889|NCT05213754|Procedure|Endovascular Treatment|Re-open the occluded cerebral artery using endovascular treatment
75872890|NCT05207514|Drug|Nanoxel M|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
75872891|NCT05207514|Drug|Taxotere|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
75556058|NCT04471532|Behavioral|Behavior change intervention|"It is a 3-month, multimodal, minimal contact, pedometer-driven, behavior change intervention to promote and support physical activity, that is initiated 3 months after THA. There is one initial, physiotherapist-led, face-to-face, physical activity counselling including 1) a brief motivational interviewing regarding physical activity, 2) patient education regarding physical activity after THA including recommendations and safety based on an orthopedic surgeon guided video and leaflet, 3) handling out pedometer and educational material i.e. a practice-oriented leaflet with advice on how to use a pedometer, a step-calendar and goal setting as well as strategies to incorporate physical activity into daily life. This initial counselling is followed by two, physiotherapist-led, telephone-assisted counselling after respectively three and seven weeks."
75556059|NCT04464993|Behavioral|Device-based feedback, self-monitoring, and education: CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
75714647|NCT03140735|Other|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
75714648|NCT03140735|Other|Control group without heart disease|Control group without heart disease
75714649|NCT03068780|Drug|Oleogel-S10|10% birch bark extract in 90% sunflower oil
75714650|NCT03068780|Drug|Control gel|Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
75714651|NCT03006848|Drug|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
75872892|NCT05207514|Drug|Doxorubicin|60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
75412815|NCT01721616|Drug|Azithromycin|
75412816|NCT01721616|Drug|Cefazolin|
75412817|NCT01721694|Drug|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
75412818|NCT01721694|Drug|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
75714652|NCT03006848|Other|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
75714653|NCT02981069|Drug|Dapagliflozin|10mg
75714654|NCT02981069|Drug|Exenatide|Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
75714655|NCT02981069|Drug|Placebo|Placebo for Dapagliflozin
75714656|NCT02980991|Drug|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
75412819|NCT01722006|Behavioral|Pairing condition|
75412820|NCT01722006|Behavioral|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
75412821|NCT01722084|Behavioral|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|"TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process."
75412822|NCT01722396|Dietary Supplement|Vitamin D|
75412823|NCT01722630|Drug|Dopamine|
75412824|NCT01722942|Procedure|ICD implantation|ventricular ICD implantation
75412825|NCT01722942|Drug|amiodarone hydrochloride|amiodarone prescription
75412826|NCT01723020|Drug|AMG 232|Given an an oral tablet in escalating doses.
75714657|NCT02980991|Drug|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
75714658|NCT02958462|Other|follow up|
75714659|NCT02923128|Drug|Dexmedetomidine|Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
75714660|NCT02923128|Drug|Sufentanyl|Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
75714661|NCT02923128|Drug|Saline|Saline is used to dilute other drugs
75714662|NCT02839642|Drug|Rivastigmine|
75556060|NCT04464993|Behavioral|Sedentary Screen Time lockout: LOCKOUT|Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
75556061|NCT04464993|Behavioral|Context-based prompts: TEXT|The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
75412827|NCT01723098|Behavioral|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
75714663|NCT02839642|Drug|Placebo|
75714664|NCT02810444|Biological|IgG Next Generation (BT595)|
75714665|NCT02672748|Other|Garden|Two years of financial and technical home gardening support for new gardeners
75412828|NCT01723176|Procedure|Echocardiography|
75714666|NCT02612311|Biological|Obinutuzumab|Obinutuzumab: IV infusion
75714667|NCT02612311|Biological|Ublituximab|Ublituximab: IV infusion
75714668|NCT02612311|Drug|TGR-1202|TGR-1202: Oral daily dose
75872893|NCT05207514|Drug|Cyclophosphamide|600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
75872894|NCT04250337|Biological|Lebrikizumab|Subcutaneous injection
75872895|NCT04250337|Other|Placebo|Subcutaneous injection
75872896|NCT04250337|Other|Topical Corticosteroid|Topical Corticosteroid
75412829|NCT01723332|Behavioral|Educational|"The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions."
75412830|NCT01723332|Behavioral|Self management|"The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions."
75412831|NCT01723410|Behavioral|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
75412832|NCT01723410|Other|Writing about places, objects|
75714669|NCT02612311|Drug|Chlorambucil|Chlorambucil: Oral dose
75714670|NCT02607319|Drug|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
75714671|NCT02596191|Other|Clinical evaluation|
75714672|NCT02596191|Other|electrophysiological record|
75714673|NCT02596191|Other|Muscle MRI|
75714674|NCT02596191|Other|blood samples analysis|
75872897|NCT04011540|Behavioral|Digital data|Receiving digital data prior to a scheduled mental health session
75872898|NCT04687059|Biological|PQ Grass|Suspension for injection
75412833|NCT01723488|Radiation|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
75412834|NCT01723644|Other|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
75412835|NCT01723644|Other|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
75412836|NCT01723800|Drug|PI3K inhibitor BKM120|Given PO
75412837|NCT01723800|Drug|pemetrexed disodium|Given IV
75412838|NCT01723800|Drug|carboplatin|Given IV
75412839|NCT01723800|Other|laboratory biomarker analysis|Correlative studies
75412840|NCT01723800|Other|pharmacological study|Correlative studies
75412841|NCT01723800|Procedure|quality-of-life assessment|Ancillary studies
75412842|NCT01723956|Procedure|Cryotherapy|This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
75412843|NCT01723956|Procedure|LEEP|The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
75412844|NCT01724034|Other|Abolish Lung Sliding|If there is no lung sliding, the patient will be promptly evaluated for pneumothorax or mainstream intubation.
75412845|NCT01724034|Other|Normal Lung Ultrasound|If the patient fails the spontaneous breathing trial and the lung ultrasound examination is normal - researchers will investigate venous thrombosis (deep vein thrombosis and/or pulmonary embolism) and rule out reversible airway obstruction. If the patient has the previous diagnosis of COPD, non invasive mechanical ventilation is indicated for facilitate weaning.
75412846|NCT01724034|Other|Pulmonary Interstitial Syndrome|"If lung ultrasound shows B pattern - cardiogenic pulmonary edema will be differentiated from Acute Respiratory Distress Syndrome (ARDS). If cardiogenic edema is a possibility, diuretics will be administrated (at least 40 mg of furosemide) or ultrafiltration will be performed. The main target is a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to titrate vasodilators (at least a 20% reduction in the systolic blood pressure) before the next spontaneous breathing trial."
75872899|NCT04687059|Drug|Placebo Option 1|Suspension for injection
75872900|NCT04687059|Drug|Placebo Option 2|Solution for injection
75412847|NCT01724034|Other|Asymmetrical Lung Ultrasound|If lung ultrasound shows asymmetrical findings, the occurence of new or uncontrolled infection (pulmonary or extrapulmonary) will be investigated.
75412848|NCT01724034|Other|Simple Pleural Effusion|If the patient has pleural effusion without ultrasonographic signs of complications (any hyperechoic pattern or complex septated pattern), researchers will administrate diuretics (at least 40 mg of furosemide in 24 hours) or increase ultrafiltration - to achieve a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to perform pleural drainage.
75412849|NCT01724034|Other|Complex Pleural Effusion|If there is pleural effusion with hyperechoic or septated pattern, another image exam will be performed and evaluated by the surgical team.
75412850|NCT01724190|Drug|Vitamin D|
75412851|NCT01724190|Drug|Placebo|
75412852|NCT01724268|Drug|Pred + Meth|PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
75412853|NCT01724268|Drug|Anti TNF + Meth|
75412854|NCT01724424|Drug|Melatonin|20 mg oral single dose
75412855|NCT01724424|Drug|Melatonin|30 mg oral single dose
75412856|NCT01724424|Drug|Melatonin|50mg oral single dose
76041674|NCT04816045|Procedure|Electrochemotheraoy|Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin
75412857|NCT01724424|Drug|Melatonin|100mg oral single dose
75412858|NCT01724502|Behavioral|Exercise and muscle biopsies|Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.
75412859|NCT01724736|Drug|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
76041675|NCT04816045|Procedure|Electroporation with saline (placebo)|Electroporation in the control group is performed endoscopically with saline
75714675|NCT02582021|Procedure|Coronary Angiography|"A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography."
75714676|NCT02582021|Procedure|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
75412860|NCT01724736|Drug|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
75412861|NCT01724814|Drug|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
75412862|NCT01724814|Drug|Placebo|Singe dose SC administration of Placebo
75412863|NCT01724970|Device|ProSeal|Patients will be ventilated with PLMA
75412864|NCT01724970|Device|Supreme LMA|Patients will be ventilated with SLMA
75714677|NCT02582021|Procedure|Cardiac Magnetic Resonance Imaging|"Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.~Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI."
76041676|NCT04816123|Drug|[14C]Donafenib|Each volunteers received a single 300 mg dose of [14C]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
75412865|NCT01725048|Drug|Mirtazapine|7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
75412866|NCT01725048|Drug|Citalopram|Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
75412867|NCT01725204|Drug|Dasatinib + PegIFN|
75412868|NCT01725360|Drug|montelukast|Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
75412869|NCT01725516|Procedure|Myofascial release technique|
75556062|NCT04464993|Behavioral|Earn sedentary screen time through moderate-vigorous physical activity: EARN|Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a >5 min continuous bout of exercise (as defined by Fitbit minutes >4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
75556063|NCT04461639|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice
75872901|NCT04682145|Drug|Turoctocog alfa pegol|Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
75872902|NCT05760729|Diagnostic Test|Cognitive testing|Cognitive tests will be carried: MOCA, trail making test, digit symbol substitution, forward and backward digit testing.
75412870|NCT01725594|Drug|CAT 2003|
75412871|NCT01725594|Drug|Placebo|
75412872|NCT01725672|Drug|Metformin, 500 mg extended release tablet|In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
75412873|NCT01725672|Drug|Metformin, 1000 mg extended release tablet|In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
75412874|NCT01725672|Drug|Glimepiride, 1 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
75412875|NCT01725672|Drug|Glimepiride, 2 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
75412876|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
75556064|NCT04461509|Drug|18F-PSMA|"Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-PSMA)~Other Names:~18F-DCFPyL Injection prostate-cancer-specific radiotracer"
75556065|NCT04459507|Other|No intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
75556066|NCT04443907|Biological|OTQ923|Single intravenous infusion of OTQ923 cell suspension
75556067|NCT04443907|Biological|OTQ923|Single intravenous infusion of OTQ923, based on review of data from Part A by Health agencies after a formal interim analysis
75872903|NCT01373775|Other|Patient charts reviewing|Reviewing chart and identifying risk factors
75412877|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
75412878|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
75412879|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
75556068|NCT04439539|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
75556069|NCT04439539|Drug|PegIFN-alpha-2a|PegIFN-alpha-2a injection will be administered subcutaneously.
75556070|NCT04439539|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
75556071|NCT04439539|Drug|Tenofovir alafenamide|Tenofovir alafenamide film-coated tablet will be administered orally.
75714678|NCT02582021|Procedure|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
76041677|NCT04807465|Device|G-Premio Bond in etch&rinse mode|The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.
75412880|NCT01725906|Drug|empirical therapy|"Nexium (esomeprazole), 40mg, bid, 14 days, plus~Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
75556072|NCT04439539|Drug|JNJ-56136379|JNJ-56136379 will be administered orally.
75556073|NCT04439123|Drug|Capivasertib|Given PO
75556074|NCT04434729|Device|Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils|The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.
75556075|NCT04429542|Drug|BCA101|EGFR/TGFβ fusion monoclonal antibody
75556076|NCT04429542|Drug|Pembrolizumab|anti-PD-1
75556077|NCT04421573|Procedure|BCPHD with D5W|D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
75556078|NCT04421573|Procedure|Waiting period with usual care|Same as previous group description
75714679|NCT02582021|Procedure|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
75872904|NCT03118947|Drug|Pimavanserin|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
75872905|NCT03983733|Other|Dietary Intervention|To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
75872906|NCT03953079|Drug|Drug: GB-102|Intravitreal injection of GB-102
75872907|NCT03953079|Drug|Aflibercept|Intravitreal injection of aflibercept (2 mg dose)
75872908|NCT04572399|Device|UV Light Treatment|UV light therapy administered while patient is mechanically ventilated
75872909|NCT03885999|Device|Fecobionics|Fecobionics is a new device for studying defecation
76041678|NCT04807465|Device|G-Premio Bond in selective-etch mode|The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.
76041679|NCT04807465|Device|G-Premio Bond in self-etch mode|The adhesive system was applied to the enamel and dentin surfaces.
75556079|NCT04418154|Drug|epirubicin hydrochloride|Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
75556080|NCT04418154|Drug|Cyclophosphamide|Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
75556081|NCT04418154|Drug|Albumin bound paclitaxel|Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
75556082|NCT04418154|Drug|Toripalimab|Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
75556083|NCT04404985|Procedure|Surgical AVF|"Surgical fistula creation is standard surgical procedures, where a small cut through the skin is made to create a channel directly between a vein and artery .~The study procedures are standard clinical practice, and not considered an experimental procedure."
75556084|NCT04404985|Procedure|Endo-vascular AVF|Endovascular fistula creation is a minimally invasive procedure used to create a canal between close artery and vein at the forearm. A magnet attached to a catheter is passed over a guidewire into the artery while another magnet passed over the guidewire into the vein. The two magnets are aligned close to each other, then the radiofrequency electrode is released from the venous catheter and energized for 2 seconds, creating a channel between the vein and the artery.
75714680|NCT02582021|Procedure|Rest-Stress Millar Testing|"Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.~Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging."
75412881|NCT01725906|Drug|Genotypic resistance guided therapy|"Nexium (esomeprazole), 40mg, bid, 14 days, plus~Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
75412882|NCT01726062|Behavioral|Motivational Interviewing plus Incentives|"Two hospital-based, face-to-face MI+ sessions~Two home-based MI+ sessions~Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge"
75412883|NCT01726062|Behavioral|Conventional Care (CC)|Participants in this arm will receive brochures and a brief information meeting in the NICU.
75714681|NCT02582021|Procedure|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
75714682|NCT02581085|Drug|Tocotrienol (TCT)|TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.
75714683|NCT02581085|Other|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
75556085|NCT04397276|Drug|JNJ-70218902|JNJ-70218902 will be administered.
75556086|NCT04397263|Drug|Guselkumab|Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
75556087|NCT04389294|Diagnostic Test|SARS-CoV2 serum antibody testing|Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.
75556088|NCT04388163|Drug|Gentian Violet|Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration.
75556089|NCT04384341|Radiation|Bone densitometry (BMD)|"Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements."
75714684|NCT02575963|Drug|Cytarabine (Phase 1 only)|Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
75714685|NCT02575963|Biological|Lintuzumab-Ac225|In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
75714686|NCT02575963|Drug|Furosemide (Phase 1 only)|40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
75714687|NCT02575963|Drug|Spironolactone|25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
75714688|NCT02541305|Other|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
75872910|NCT03879525|Other|EMR-based-interventional method|Questionnaire delivery method. Participants will complete standard care anxiety and depression screening and quality of life assessment directly into the patient entered section of the EMR, administered on arrival in the clinic.
75412884|NCT01726140|Procedure|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be >200, the patient will stop the treatment.
75872911|NCT03879525|Other|Telephone-based-standard method|Questionnaires delivered via phone. Participants will complete standard care anxiety and depression screening and quality of life assessment via phone. Standard delivery method.
75872912|NCT03108027|Drug|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
75872913|NCT03108027|Drug|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
75872914|NCT03108027|Drug|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
75412885|NCT01726140|Procedure|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be >200, the patient will stop the treatment.
75714689|NCT02541305|Other|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
75714690|NCT02507284|Drug|SRX246|
75714691|NCT02507284|Drug|Placebo|
75714692|NCT02501096|Drug|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
75714693|NCT02501096|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
75872915|NCT03812601|Procedure|Simultaneous bi-atrial electroanatomic mapping and ablation|Simultaneous bi-atrial electroanatomic mapping during atrial fibrillation and during pacing from 3 different vectors at varying cycle lengths followed by pulmonary vein isolation and AcQMap guided ablation of non-pulmonary vein mechanisms.
75872916|NCT03794427|Other|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
75872917|NCT03794427|Other|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
75872918|NCT03794427|Other|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
75872919|NCT03794427|Other|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
76041680|NCT04807621|Biological|Platelet transfusion|Platelets (10 ml/kg body weight) is transfused.
76041681|NCT04807621|Biological|Fibrinogen concentrate|Fibrinogen concentrate (300 mg/kg body weight) is administered.
75412886|NCT01726296|Other|educational intervention|Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
75412887|NCT01726296|Other|medical chart review|Complete patient medical chart audit
75556090|NCT04384341|Biological|Blood sampling for patients only|For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.
75714694|NCT02455622|Drug|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
75872920|NCT03606291|Radiation|isotoxic hypofractionation|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
75872921|NCT03427827|Drug|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
75872922|NCT03633513|Diagnostic Test|LBT-3627|Immunomodulatory agent
75872923|NCT03633513|Diagnostic Test|Immunological profiling|Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
75714695|NCT02432248|Drug|Dehydroepiandrosterone|75mg/day, PO for 90 days
75714696|NCT02432248|Other|placebo(medical starch)|75mg/day, PO for 90 days
75872924|NCT03410901|Biological|Anti-OX40 Antibody BMS 986178|Given IV, intratumoral
75872925|NCT03410901|Other|Laboratory Biomarker Analysis|Correlative studies
75872926|NCT03410901|Radiation|Radiation Therapy|Undergo radiation therapy
75872927|NCT03410901|Drug|TLR9 Agonist SD-101|Given intratumorally
75412888|NCT01726374|Drug|BEP(500)|"One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15"
75412889|NCT01726530|Drug|transdermal fentanyl patch (50 mcg/hour)|
75412890|NCT01726530|Drug|Placebo|
75412891|NCT01726608|Procedure|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
75714697|NCT02418143|Device|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
75714698|NCT02370797|Radiation|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
75872928|NCT01373853|Procedure|Lens Fragmentation by means of a femtosecondlaser|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
75872929|NCT01373853|Procedure|Manual Phacoemulsification|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
75412892|NCT01726686|Drug|Ropivacaine|100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
75412893|NCT01726686|Drug|Placebo|
75412894|NCT01726764|Other|St John's Wort|
75872930|NCT03357939|Drug|HLX03|A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
75412895|NCT01726764|Drug|Metformin|
75714699|NCT02364089|Procedure|Laparoscopic surgical removal of the adrenal tumor|
75872931|NCT03357939|Drug|adalimumab|A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
75872932|NCT05759403|Diagnostic Test|Cortical excitability using transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.
75412896|NCT01726842|Device|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
75412897|NCT01726920|Drug|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
75556091|NCT04381117|Drug|Previously Treated with EN3835|No treatment to be administered - Observational only
75556092|NCT04367116|Procedure|Spinal Cord Stimulation|Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.
76041682|NCT04807543|Drug|17-hydroxyprogesterone caproate|intramuscular injection weekly
75412898|NCT01726920|Drug|naratriptan|Tablets containing naratriptan 2,5 mg
75412899|NCT01726920|Drug|naproxen|Tablets containing naproxen 500 mg
75412900|NCT01726998|Other|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
75412901|NCT01726998|Other|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
75412902|NCT01727076|Other|Laboratory Biomarker Analysis|Correlative studies
75412903|NCT01727076|Other|Pharmacological Study|Correlative studies
75412904|NCT01727076|Biological|Recombinant Human Interleukin-15|Given SC
75714700|NCT02364089|Drug|Standardized medical treatment of hypertension by SAHR|"Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~step 4: Add-on of Indapamide LP 1.5 mg~step 5: Add-on of Spironolactone 25 mg~step 6: Add-on of Bisoprolol 10 mg~step 7: Add-on of Prazosine LP 5mg/day."
75872933|NCT03713073|Device|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
75412905|NCT01727388|Procedure|lateral decubitus|
75412906|NCT01727388|Procedure|supine decubitus|
75872934|NCT03713073|Device|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
75412907|NCT01727466|Behavioral|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
75412908|NCT01727544|Procedure|cartilage cap occlusion surgery|placement of a cartilage cap over the dome of the superior semicircular canal through a combined transmastoid and tegmen mini- craniotomy approach.
75412909|NCT01727622|Drug|FDG-PET|Diagnostic: FDG-PET imaging to examine neuronal health
75412910|NCT01727622|Other|ASL-MRI|Arterial-Spin Labeled MRI to examine cerebral blood flow
75412911|NCT01727622|Procedure|Lumbar Puncture|Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
75412912|NCT01727856|Device|Rehabilitation Measurement Tool|The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
75412913|NCT01727934|Drug|Miravirsen sodium|Subcutaneous injection
75872935|NCT05760495|Other|blood sampling|Blood sampling for evaluation of oxidative stress markers
75872936|NCT03633435|Procedure|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
76041683|NCT04807543|Drug|Castor Oil|intramuscular injection weekly
75412914|NCT01728090|Other|hand sanitizer|alcohol-based, hydroalcoholic gel
75412915|NCT01728480|Drug|entolimod|Given SC
75412916|NCT01728480|Radiation|intensity-modulated radiation therapy|Undergo IMRT
75412917|NCT01728480|Drug|cisplatin|Given IV
75412918|NCT01728480|Other|pharmacological study|Correlative studies
75412919|NCT01728480|Other|laboratory biomarker analysis|Correlative studies
75412920|NCT01728558|Other|Early goal Directed Sedation|
75412921|NCT01728558|Other|Standard care sedation|
75412922|NCT01728948|Drug|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
75412923|NCT01729104|Drug|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."
75412924|NCT01729104|Drug|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
75412925|NCT01729104|Drug|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
75412926|NCT01729260|Drug|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
75412927|NCT01729416|Other|Water Exchange Colonoscopy|"We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.~We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.~On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn."
75412928|NCT01729416|Other|Air Colonoscopy|Air will be infused into the colon during colonoscopy.
75412929|NCT01729572|Other|Tele-medicine monitoring of medication adherence|
75412930|NCT01729650|Behavioral|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
75412931|NCT01729806|Biological|Ipilimumab|Given IV
75412932|NCT01729806|Other|Laboratory Biomarker Analysis|Correlative studies
75412933|NCT01729806|Biological|Rituximab|Given IV
75412934|NCT01721850|Other|control formula|commercial stage 1 infant formula
75556093|NCT04361825|Drug|Durvalumab|Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects > 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.
75556094|NCT04345913|Procedure|Biopsy|Undergo biopsy
75872937|NCT03107715|Behavioral|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
75412935|NCT01721850|Other|intervention formula 1|infant formula with hydrolyzed protein (type I) and pre- and probiotics
75412936|NCT01721850|Other|intervention formula 2|infant formula with hydrolyzed protein (type II) and pre- and probiotics
75412937|NCT01729884|Biological|HER-2/neu peptide vaccine|Given ID
75412938|NCT01724112|Drug|LY2940094|Administered orally
75412939|NCT01724112|Drug|Placebo|Administered orally
75412940|NCT01722864|Drug|COV155|COV155 tablets
75412941|NCT01724658|Drug|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week
75412942|NCT01724658|Drug|placebo|placebo orally twice a week with progynova 1 mg oral daily
75412943|NCT01049334|Drug|Placebo|Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
75556095|NCT04345913|Procedure|Biospecimen Collection|Undergo blood sample collection
75556096|NCT04345913|Procedure|Computed Tomography|Undergo CT scan
75556097|NCT04345913|Drug|Copanlisib Hydrochloride|Given IV
75556098|NCT04345913|Drug|Eribulin Mesylate|Given IV
75556099|NCT04345913|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556100|NCT04345601|Biological|Mesenchymal Stromal Cells|Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10^8 MSCs.
75872938|NCT03107715|Behavioral|Positive Messaging|iPad based behavioral intervention facilitated by researcher
75714701|NCT02347995|Other|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
75412944|NCT01049334|Drug|Flurbiprofen|Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
75412945|NCT01048944|Drug|Bupropion SR|150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
75412946|NCT01048944|Drug|Nicotine Patch|Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
75412947|NCT01048944|Drug|Placebo Patch and Placebo Pill|150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
75412948|NCT01048866|Drug|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
75872939|NCT03567057|Drug|ADS-5102, 274 mg|Oral capsules
76041684|NCT05616559|Combination Product|Treatment Package for First-Episode Depression|The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
75412949|NCT01048866|Drug|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
75412950|NCT01048866|Drug|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
75412951|NCT01048788|Drug|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
75412952|NCT01048242|Drug|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
75412953|NCT01048242|Drug|Placebo|placebo
75714702|NCT02347995|Other|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
75714703|NCT02186418|Genetic|ARU-1801|"Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells."
75714704|NCT02122562|Drug|Ketamine|Treatment
75714705|NCT02122562|Other|Alcohol Infusion|Biomarker
75412954|NCT01047306|Other|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
75412955|NCT01046682|Drug|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
75412956|NCT01044732|Device|Third Eye Retroscope|Device used with colonoscope to provide second, retrograde view of the colon
75412957|NCT01044498|Drug|Tocilizumab|Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
75412958|NCT01044498|Drug|Ortho-Novum® 1/35|Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
75714706|NCT02121873|Device|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
75714707|NCT02121873|Device|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
75714708|NCT02121873|Device|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
75412959|NCT01043874|Drug|Nilotinib|400 mg BID
75412960|NCT01042938|Drug|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
75412961|NCT01042938|Drug|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
75412962|NCT01042158|Drug|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
75412963|NCT01046916|Drug|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
75412964|NCT03408912|Diagnostic Test|FFR|FFR from CMR compared to invasive FFR
75412965|NCT03405870|Drug|Smoflipid|Administration of lipid injectable emulsion
75412966|NCT03409302|Behavioral|ALGEApp (Brief iACT intervention)|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.
75412967|NCT03409302|Behavioral|Active control group|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
75412968|NCT03409146|Device|Monica Novii Wireless Patch System|The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
75412969|NCT03409068|Procedure|C2-C4 compartment anesthetic block|C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
75412970|NCT03409068|Procedure|Costagliola block|Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
75412971|NCT03408834|Other|pulse variability index|fluid management with pulse variability index or conventional
75412972|NCT03408600|Other|Management|To evaluate vital signs in a global cohort of patients with acute peritonitis, determining which parameters are statistically significant to predict in-hospital mortality and ICU admission.
75412973|NCT03408288|Other|Hemapoche|Use of Hemapoche scale to assess hematuria in reference samples
75714709|NCT02115724|Dietary Supplement|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
75714710|NCT02115724|Other|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
75714711|NCT02115724|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
75412974|NCT03408288|Other|Hemastick|Use of Hemastick scale to assess hematuria in reference samples
75412975|NCT03408288|Other|Color description|Describe color of reference sample
75412976|NCT03408210|Radiation|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
75556101|NCT04345601|Other|Supportive Care|Patients will receive supportive care per their treating physician
75556102|NCT04344470|Device|EMG|EMG will be recorded from two electrodes placed on both extensor carpi radialis (ECR) muscles
75556103|NCT04344470|Device|EEG|EEG electrodes will be positioned according to 10-20 International System, with every impedance kept under 5 kOhm. EEG data will be amplified, filtered (DC-100 Hz), digitized at 1000 Hz, and stored on a computer for offline analysis.
75556104|NCT04341246|Device|LiverMultiscan|The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation
75556105|NCT04337554|Device|Exoskeleton footwear|Assistive footwear
75556106|NCT04336722|Drug|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
75556107|NCT04336722|Drug|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
75714712|NCT02115724|Drug|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
75412977|NCT03408210|Radiation|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
75556108|NCT04330313|Procedure|Traction|Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.
75556109|NCT04330313|Procedure|Laser therapy|Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.
75556110|NCT04330313|Procedure|Hot pack|The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.
75556111|NCT04330313|Procedure|Stretching|Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
75556112|NCT04325828|Drug|Apalutamide|Apalutamide 240 mg (4*60-mg tablets) will be administered orally once daily with or without food.
75556113|NCT04325828|Drug|GnRH Agonist|A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.
75556114|NCT04322708|Other|Placebo|Placebo
75556115|NCT04322708|Drug|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
75556116|NCT04322604|Drug|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
75714713|NCT02036372|Drug|Liraglutide|
75714714|NCT02036372|Drug|Insulin bolus|
75714715|NCT02036372|Drug|GIK infusion|continuous infusion
75714716|NCT01965249|Device|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HR48 mm
75714717|NCT01965249|Device|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
75714718|NCT01807936|Procedure|Lymphadenectomy|
75714719|NCT01633541|Drug|AT-101|Patients will receive AT-101 40 mg orally two times a day.
75714720|NCT01633541|Drug|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
75714721|NCT01633541|Drug|Cisplatin|Cisplatin 100 mg/m2
75412978|NCT03408132|Drug|FE203799|FE203799 5 mg subcutaneous once weekly
75556117|NCT04322604|Other|Placebo|Placebo
75556118|NCT04317807|Drug|Levetiracetam Pill|Levetiracetam is an anticonvulsant that is frequently used to treat epilepsy in children and adults due to its superior tolerability, ease of use and excellent safety profile. It is rapidly absorbed and rapidly crosses the blood-brain barrier. Levetiracetam does not affect metabolism of antipsychotic drugs and may normalize hippocampal hyperactivity by decreasing excessive glutamatergic and dopaminergic transmission, thereby making it an ideal agent to test the hypothesis that reducing excessive hippocampal activity may enhance treatment of early psychosis and prevent antipsychotic toxicity. Levetiracetam will be administered in 500 mg capsules twice a day.
75556119|NCT04317807|Other|Placebo|The placebo pill (sugar pill) will look just like the levetiracetam pill but does not contain levetiracetam. Placebo will be taken along with optimal antipsychotic medication selected by either the outpatient provider or the hospital staff responsible for the participant's care. Participants will be instructed to take the placebo pill twice daily for 12 weeks.
75556120|NCT04317105|Procedure|Biopsy|Undergo a tumor biopsy
75556121|NCT04317105|Procedure|Biospecimen Collection|Undergo blood sample collection
75556122|NCT04317105|Procedure|Computed Tomography|Undergo a CT scan
75412979|NCT03408054|Drug|Oxytocin|Oxytocin 10-5M solution
75412980|NCT03408054|Drug|Nitroglycerin|Nitroglycerin 25-1000mcg
75412981|NCT03407976|Drug|Apatinib|Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
75412982|NCT03407976|Drug|Pembrolizumab|200 mg Q3 weeks IV
75412983|NCT03407898|Other|intubation time|intubation attempt number and intubation time
75556123|NCT04317105|Drug|Copanlisib Hydrochloride|Given IV
75556124|NCT04317105|Procedure|Echocardiography|Undergo ECHO
75556125|NCT04317105|Biological|Ipilimumab|Given IV
75556126|NCT04317105|Biological|Nivolumab|Given IV
75556127|NCT04317105|Procedure|X-Ray Imaging|Undergo an x-ray
75412984|NCT03407820|Procedure|Absorbable Chromic gut sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received absorbable Chromic sutures are treated recording to the standard protocol and they are advised that they can start to gently rub the scab and suture line to encourage the sutures to fall off starting 10-14 days postoperatively.
75556130|NCT04289480|Device|ENTERPRISE 2 device|The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
75556131|NCT04284839|Drug|DOAC|Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
75556132|NCT04284839|Drug|VKA|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
75714722|NCT01633541|Drug|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
75412985|NCT03407820|Procedure|Non-absorbable Nylon sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received Nylon sutures are treated recording to the standard protocol and sutures are removed after the usual time (10-14 days) of the received procedure.
75556133|NCT04283461|Biological|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
75556134|NCT04278560|Device|Transcranial direct current stimulation (tDCS)|tDCS will be delivered via six gel electrodes with placement and current parameters optimized based on a standard brain to maximize the average normal component of the generated electric field over the left dlPFC. Current delivered by anyone electrode will never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
75556135|NCT04278560|Device|Sham stimulation|An 'active' sham will be used in which very low-level currents are transferred between the same electrodes used in the active condition throughout the 20-minute session. However, currents will be designed to mimic the cutaneous sensations induced by tDCS yet not significantly influence cortical tissue.
75412986|NCT03407742|Behavioral|CAPAS Youth|9-week parenting intervention
75714723|NCT01466036|Drug|Cabozantinib|60 mg QD orally in cycles of 28 days
75714724|NCT01399372|Biological|Rituximab|One 28-day cycle = 500 mg/m^2 intravenously on day 1 and day 5.
75714725|NCT01399372|Drug|Cytarabine|One 28-day cycle = 3 g/m^2 intravenously on day 1 and day 2.
75714726|NCT01399372|Drug|Methotrexate|One 28-day cycle = 3.5 g/m^2 intravenously (standard hydration/leucovorin support) on day 2.
75714727|NCT01399372|Drug|Procarbazine|One 28-day cycle = 100 mg/m^2 orally on days 2-8.
75412987|NCT03407664|Other|this field is not applicable|We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
75556136|NCT04278560|Behavioral|Behavioral intervention to increase physical activity|Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
75556137|NCT04276441|Device|Heart healthy Engagement Program with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.
75556138|NCT04276441|Device|Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.
75556139|NCT04273945|Drug|Macitentan 10 mg|Participants will receive macitentan 10 mg film-coated tablets orally.
75556140|NCT04273945|Drug|Macitentan 37.5 mg|Participants will receive macitentan 37.5 mg film-coated tablets orally.
75412988|NCT03407586|Diagnostic Test|Point-of-care STI testing|All participants underwent point-of-care STI testing (GeneXpert), and if diagnosed with a STI were offered immediate therapy, and expedited therapy, if indicated.
75556141|NCT04273945|Drug|Macitentan 75 mg|Participants will receive macitentan 75 mg film-coated tablets orally.
75556142|NCT04273945|Drug|Placebo|Participants will receive matching placebo film-coated tablets orally.
75714728|NCT01399372|Drug|Vincristine|One 28-day cycle = 1.4 mg/m^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
75412989|NCT03407508|Dietary Supplement|Comparison of Diets|Okinawan-based Nordic Diet and Control Diet
75412990|NCT03407352|Behavioral|Active Video Game Play|60 minutes of active video game play at a moderate intensity
75556143|NCT04272294|Device|Optical Spectroscopy|Using oral spectroscopy device to characterize treatment response in tumors
75556144|NCT04272073|Other|High-Protein Mediterranean Diet|As in arm/group descriptions
75556145|NCT04272073|Other|Resistance Exercise|As in arm/group descriptions
75714729|NCT01399372|Radiation|low-dose whole-brain radiation therapy|Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
75714730|NCT01267604|Drug|Recombinant FSH (rFSH)|225IU
75714731|NCT01267604|Dietary Supplement|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
75714732|NCT01244399|Dietary Supplement|Inositol|
75714733|NCT01087125|Drug|No Interventions|No Interventions
75714734|NCT01063517|Drug|olaparib|100mg BID oral tablet continuous
75556146|NCT04272073|Other|Standard Dietary Advice|As in arm/group descriptions
75556147|NCT04272073|Other|Standard Cardiac Rehabilitation Exercise|As in arm/group descriptions
75556148|NCT04271475|Drug|Macitentan|Participants will receive Macitentan film-coated tablets orally od.
75412991|NCT03407352|Behavioral|Passive Video Game Play|60 minutes of passive video game play
75412992|NCT03407196|Drug|Forxiga|Oral antidiabetics
75714735|NCT01063517|Drug|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
75714736|NCT01063517|Drug|Placebo|100mg BID oral tablet to match olaparib tablet
75714737|NCT01047111|Procedure|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
75714738|NCT00920621|Dietary Supplement|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
75714739|NCT00920621|Dietary Supplement|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
75714740|NCT00903591|Other|questionaire, blood or saliva sample|Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
75714741|NCT00832702|Procedure|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
75714742|NCT00820430|Other|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
75714743|NCT00311324|Behavioral|Special Intervention|
75714744|NCT00311324|Behavioral|Delayed Intervention|
75714745|NCT00964600|Procedure|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
75714746|NCT00964756|Genetic|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
75714747|NCT00964756|Drug|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
75714748|NCT00964834|Drug|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
76041685|NCT04815811|Other|Blood collection|Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.
75714749|NCT00964834|Drug|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
75714750|NCT00964834|Drug|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
75714751|NCT00612105|Drug|Retigabine|150mg/day up to 900mg/day
75714752|NCT00612105|Drug|Placebo|daily
76041686|NCT04815811|Other|Stool collection|Fecal sample collection to delineate microbiome contribution, we will study the gut microbiota in faecal samples obtained from the recruited patients.
75412993|NCT03406416|Device|44Ch Bionic Eye Device|Prototype wide view suprachoroidal retinal prosthesis
75412994|NCT03406026|Other|Balance System Protocol Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. One session consists of 45 minutes of regular physiotherapy and 15 minutes in which exercises will be carried out focused on the balance systems, following the program that is detailed below.
75412995|NCT03406026|Other|Control Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. The control group will perform, during the 60 minutes that the session lasts, the usual physiotherapy treatment.
75556149|NCT04271475|Drug|Placebo|Participant will receive matching placebo tablets orally od.
75556150|NCT04263922|Drug|Huaiqihuang granules|Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
75556151|NCT04263922|Drug|Valsartan capsule|Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
75556152|NCT04261556|Device|Real tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, real anodal tDCS and CCT will be provided simultaneously."
75556153|NCT04261556|Device|Sham tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of apparent (sham) tDCS.~In the first 20 min of the 40 min-intervention, sham tDCS and CCT will be provided simultaneously."
76041687|NCT04815655|Procedure|Cartilage tympanoplasty|is the reconstruction of the tympanic membrane (TM) by using catilage
75412996|NCT03405948|Drug|Intra muscular injection of Botulinum toxin|posture and gait analysis were performed before injection and 4 to 6 weeks after injection
76041688|NCT02600845|Device|ACCU-CHEK|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.
75556154|NCT04253392|Device|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
75556155|NCT04251377|Device|Defensive Antiadhesive Coating DAC®, Novagenit SRL|"DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.~The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture."
75556156|NCT04248920|Behavioral|Clinic to Community Education Program|The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
75412997|NCT03405636|Device|Xeltis Pulmonary Valved Conduit|RVOT reconstruction
75412998|NCT03405402|Procedure|Blood sampling|Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
75556157|NCT04241835|Drug|Tazemetostat|"Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle.~Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity."
75556158|NCT04240704|Drug|JBH492|Anti-CCR7 antibody-drug conjugate (ADC)
75556159|NCT04232280|Biological|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
75556160|NCT04232280|Other|Placebo|0.9% sodium chloride (normal saline) injection
75556161|NCT04226313|Diagnostic Test|Self-sampling by Evalyn Brush|Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
75556162|NCT04226313|Diagnostic Test|Self sampling by Evalyn Brush home or in GP´s clinic|Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush
75556163|NCT04224740|Drug|Pembrolizumab|Patients will receive pembrolizumab at the dose of 200mg IV Q3W with maximum duration of 2 years (34 cycles-counting the part combined with chemotherapy)
75714753|NCT04017741|Drug|Combined Depo-Medrone and Lidocaine|"Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm."
75872940|NCT03508557|Behavioral|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
75412999|NCT03405324|Device|tDCS|a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
75556164|NCT04224740|Drug|Standard of care therapy|Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
76041689|NCT04427995|Device|OMNI surgical system|GATT + viscodilation
76041690|NCT04806997|Diagnostic Test|Vascular occlusion test|The VOT procedure was conducted twice in each patient, before and 15 min after intrathecal injection. An NIRS sensor (INVOSTM 5100C Cerebral/Somatic Oximeter; Medtronic, Minneapolis, MN, USA) was attached to the patient's gastrocnemius muscle. A tourniquet (A.T.S ® 3000 Automatic Tourniquet System; Zimmer Inc., Warsaw, IL, USA) was applied to the thigh and inflated to a pressure value 50 mmHg over the patient's baseline systolic blood pressure in the leg and maintained for 5 min. After a 5-min ischemic period, the tourniquet was rapidly deflated to 0 mmHg. The StO2 data was continuously recorded during the VOT procedure. After confirmation of spinal anesthesia using cold sensitivity, the VOT procedure was repeated in the same manner as mentioned above. The occlusion slope and recovery slope were calculated based on the measured StO2 data.
75413000|NCT03405324|Device|sham tDCS|sham tDCS
75413001|NCT03405246|Behavioral|KIDFIT HEALTHY|KIDFIT Healthy intervention combines traditional in-person and electronic participant contacts.
75556165|NCT04224493|Drug|Tazemetostat|"Stage 1 (Phase 1b):~Tazemetostat will be escalated from a starting dose of 400 mg orally twice daily to 600 mg orally twice daily to 800 mg PO twice daily in 28-day cycles as tolerated in a standard 3 + 3 design. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
75556166|NCT04224493|Drug|Tazemetostat|"Stage 2 and Optional Stage 3 (Phase 3):~Tazemetostat 800 mg administered orally twice daily in continuous 28-day cycles for 12 cycles. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
75413002|NCT03405246|Behavioral|KIDFIT SAFE|KIDFIT Safe group will be referred to the KIDFIT Safe website for monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms.
75556167|NCT04224493|Drug|Placebo oral tablet|Placebo administered orally twice daily in continuous 28-day cycles. Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy.
75556168|NCT04224493|Combination Product|Lenalidomide|Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
75556169|NCT04224493|Combination Product|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
75556170|NCT04213079|Device|re-adaptation of the vestibulo-ocular reflex|The VOR will be readapted by activating velocity storage with full-field optokinetic motion at 5°/s in a set direction while the head is oscillated with a set frequency and direction. The readaptation training will be conducted in repeated modules, each lasting for 1-5 min. The expected duration of daily sessions varies from 30 to 90 min. A day's session will be terminated if patient no longer feel symptoms of MdDS.
75413003|NCT03405168|Drug|Moxifloxacin Hydrochloride 400mg Tablet|Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.
75413004|NCT03404934|Device|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
75556171|NCT04213079|Device|Habituation of velocity storage of the vestibulo-ocular reflex|The central (velocity storage) time constant will be reduced by inducing cancellation of two velocity storage-mediated responses: OKN and the VOR. Sinusoidal rotation at 0.017 Hz (1 revolution/min) in darkness advances the slow phase eye velocity of the VOR by 32º. In contrast, the OKN at this frequency has no phase advancement. Thus, to counteract the VOR by OKN, the optokinetic stimulus should be set to 32º phase advance the out of phased head rotation stimulus. Since the conflict stimulus is expected to be overwhelming to patients at higher chair velocities, subjects will be first trained with a 10°/s stimulus. In a previous study, no complaints were reported when subjects were tested at such low velocities. Preliminary testing show signs of symptom improvement when the peak velocity reached 30°/s to 40°/s.
75556172|NCT04210219|Drug|JNJ-64264681|JNJ-64264681 capsule will be administered orally.
75413005|NCT03404856|Drug|ORL-1G - D-galactose|Oral ORL-1G - D-galactose
75714754|NCT04017741|Drug|Sodium Chloride 0.9% Inj|Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
75714755|NCT00546052|Drug|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
75714756|NCT00887601|Drug|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
76041691|NCT04798105|Behavioral|Effects of tDCS of dlPFC on Probabilistic Selection Task|Predictors of Probabilistic Selection Task Performance including anodal tDCS of dlPFC, eye blink rate, extraversion and impulsiveness
75714757|NCT00887601|Drug|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
75714758|NCT00887601|Drug|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
75714759|NCT00887601|Drug|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
75714760|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
76041692|NCT04798183|Diagnostic Test|3-dimensional scan|Facial 3-dimensional scan according to posture
75714761|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
76041693|NCT04806763|Device|Menicon Z Night|To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children
76041694|NCT04806763|Device|Control|Distance, single-vision glasses were used as control
75413006|NCT03404622|Drug|IUCD|IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
75714762|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
76041695|NCT05617261|Other|Conscious sedation|Conscious sedation is a combination of medications to help you relax (a sedative, for example nitrous gas) and to block out pain (commonly known as freezing, for example lidocaine).
76041696|NCT04797949|Drug|Low-dose aspirin|Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
76041697|NCT04797793|Drug|Adapalene Gel 0.1%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
75413007|NCT03404466|Drug|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks
75556173|NCT04209595|Drug|PLX038|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. PLX038 (PEGylated SN38) will be administered as a 1 hour (-10 minutes / +30 minutes) intravenous (IV) infusion on Day 1 of each cycle (21 days).
75556174|NCT04209595|Drug|Rucaparib|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. Rucaparib will be given orally at designated dose twice a day on days 5 to 19 of every 21-day cycle.
75413008|NCT03404232|Device|Dynesys DTO device (Zimmer Spine, Inc.)|All patients receive posterior hybrid instrumentation.
75413009|NCT03404154|Diagnostic Test|3D ultrasound|it describes the diagnostic test which is 3D us to diagnose the cause of postmenopausal bleeding
75556175|NCT04209595|Drug|Ondansetron|Participants will be recommended to have 8 mg of ondansetron taken with a small meal or snack to prevent nausea and vomiting approximately 30 minutes prior to each dose of rucaparib.
75556176|NCT04208529|Biological|CTX001|CTX001 infusion.
75714763|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
75714764|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
75714765|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
75714766|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
75714767|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
75714768|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
76041698|NCT04797793|Drug|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
75413010|NCT03404154|Procedure|Dilatation and curretage|it describes the surgical maneuver that will be made to diagnose cause of bleeding
75556177|NCT04208477|Procedure|one site blockade of the stellate ganglion|Ultrasound guided one site blockade of the stellate ganglion.
75556178|NCT04204941|Drug|Tazemetostat|400 mg, 600 to 800 mg of Tazemetostat will be administered twice daily.
75714769|NCT00964912|Drug|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
75714770|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
75872941|NCT03316833|Device|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score <33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
75872942|NCT05760417|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
75413011|NCT03403920|Other|Questionnaire|Profile Fitness Mapping Low Back Questionnaire
75413012|NCT03403764|Other|Wellness Intention|
75556179|NCT04204941|Drug|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
75714771|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
75714772|NCT00887757|Drug|ABT-263|"150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study."
75714773|NCT00887757|Drug|gemcitabine|Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
75714774|NCT00965068|Other|Cholesterol|
75714775|NCT02542527|Procedure|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
75413013|NCT03403530|Drug|IgM rich Immunoglobin|the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
75413014|NCT03403452|Drug|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
75556180|NCT04204941|Drug|Tazemetostat|800 mg administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.
75556181|NCT04204941|Drug|Placebo|Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond
75556182|NCT04204941|Drug|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
75714776|NCT00965224|Biological|dendritic cell vaccination (active specific immunotherapy)|
75556183|NCT04202640|Procedure|Mechanical Stimulation|The technique of mechanical stimulation alternates between compression and decompression of the treated area. It aims to reestablish a good blood circulation and lymphatic drainage.
75413015|NCT03403296|Genetic|nProfiler I Stomach Cancer Assay Kit|qPCR by nProfiler I Stomach Cancer Assay Kit
75413016|NCT03403140|Drug|Etanercept|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
75413017|NCT03402984|Drug|Acotiamide|Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
75413018|NCT03402984|Drug|Placebo Oral Tablet|Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
75556184|NCT04202640|Procedure|Massages|"Massages will be carried out according to a specific regime as specified in the study protocol. The massages will be done in 15 sessions of 30 minutes each, done twice a week and will consist of:~One part muscle exercise~One part skin work (drainage)"
75556185|NCT04200898|Device|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
75556186|NCT04200443|Drug|Cabozantinib|Given PO
75556187|NCT04200443|Other|Quality-of-Life Assessment|Ancillary studies
75714777|NCT00887835|Device|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
75714778|NCT04392921|Drug|Amiodarone|"Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:~• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first)."
76041699|NCT04797793|Drug|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
76041700|NCT04806529|Drug|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
75413019|NCT03402828|Drug|Any topical drug treatment|Any treatment strategy used to prevent relapse of psoriasis symptoms
75413020|NCT03402672|Other|self-administered, e-health application|"AWAITS is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT when they were actively using. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
75413021|NCT03402594|Device|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
75413022|NCT03402594|Device|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
76041701|NCT04806529|Drug|Comparator|Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
75413023|NCT03402516|Device|18.5 resector|hysteroscopic myomectomy with a 18.5 Fr resector after cervical dilatation until Hegar bougie number 7
75413024|NCT03402516|Device|26Fr resector|hysteroscopic myomectomy with a 26Fr resector after cervical dilatation until Hegar bougie number 10
75413025|NCT03402438|Drug|Fulacimstat (BAY1142524)|single oral dose of 25 mg immediate-release tablet BAY1142524
75413026|NCT03402360|Other|Virtual Reality rehabilitation group|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training"
75413027|NCT03402360|Other|Control group rehabilitation|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training"
75413028|NCT03402204|Drug|Simvastatin 10 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
75413029|NCT03402204|Drug|Simvastatin 40 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
75413030|NCT03402048|Drug|Carboplatin|
75413031|NCT03402048|Drug|Gemcitabine|
75413032|NCT03402048|Drug|Pemetrexed|
75714779|NCT04392921|Drug|Placebo|"Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first)."
76041702|NCT04796857|Drug|PD-1 Antibody|Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
76041703|NCT04796857|Drug|Lenalidomide|"Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase"
75413033|NCT03402048|Drug|Docetaxel|
75413034|NCT03402048|Drug|Vinorelbine|
75413035|NCT03401892|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
75413036|NCT03401892|Device|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
76041704|NCT04796623|Drug|TQB3616 capsules|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
76041705|NCT04796623|Drug|Fulvestrant injection|Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
76041706|NCT04815421|Other|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.
75413037|NCT03401892|Device|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
75556188|NCT04200443|Other|Questionnaire Administration|Ancillary studies
75413038|NCT03401814|Other|Magnetic Resonance Elastography|rapidly developing technology for quantitatively assessing the mechanical properties of tissue, using externally applied mechanical waves
75556189|NCT04200443|Drug|Temozolomide|Given PO
75556190|NCT04199221|Behavioral|Stress Innoculation Training (SIT)|1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.
75714780|NCT00959530|Procedure|lingualized occlusion|occlusal surface arranged by lingualized occlusion
75714781|NCT00959530|Procedure|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
75714782|NCT00959608|Behavioral|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
75714783|NCT00959608|Behavioral|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
75714784|NCT00673920|Drug|Methotrexate|Oral or parenteral repeating dose
75714785|NCT00673920|Drug|Ocrelizumab|"Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate."
75714786|NCT00673920|Drug|Placebo|Intravenous repeating dose
75714787|NCT00959686|Drug|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
75714788|NCT00379795|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
76041707|NCT04815421|Other|the meridian group|Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
76041708|NCT04815265|Drug|Remimazolam|Remimazolam is used for sedation
76041709|NCT04815265|Drug|Dexmedetomidine|Dexmedetomidine is used for sedation
75413039|NCT03401658|Device|Sensor light detector|The intervention is based on a sensor technology that gathers data and transmit it to another location for processing. The monitoring utilises an LED light source, an integral detector set which has variance from device to device and chromatic based algorithms for extraction of information from the detectors. The integration of these components into a system provides robustness and stability for operation. The availability of smartphones which possess high quality cameras and constant internet connectivity provides an ideal platform for multimedia clinical data collection and real-time patient-provider communication.
75556191|NCT04199221|Behavioral|Extra attempt|an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
75556192|NCT04190446|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75556193|NCT04190446|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
75556194|NCT04190446|Other|Quality-of-Life Assessment|Ancillary studies
75556195|NCT04190446|Other|Questionnaire Administration|Ancillary studies
75556196|NCT04190446|Procedure|Computed Tomography|Undergo CT scan
75556197|NCT04190446|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556198|NCT04190446|Procedure|Biospecimen Collection|Undergo blood sample collection
75556199|NCT04182672|Drug|FX006|Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
75556200|NCT04181827|Drug|JNJ-68284528|Cilta-cel infusion will be administered at a target dose of 0.75 * 10^6 CAR-positive viable T cells/kilogram (kg).
75413040|NCT03401580|Drug|Viena II 160/10|once daily
75556201|NCT04181827|Drug|Pomalidomide|Pomalidomide 4 mg will be administered orally.
75556202|NCT04181827|Drug|Bortezomib|Bortezomib 1.3 milligram per meter square (mg/m^2) will be administered subcutaneously (SC).
75556203|NCT04181827|Drug|Dexamethasone|Dexamethasone 20 mg/day (10mg/day for participants >75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants >75 years of age) in DPd treatment.
76041710|NCT04796389|Other|Music|Preferred music of the participant administered using headphones.
76041711|NCT04806841|Behavioral|Motivational intervention|Three group meeting of 60 minutes to help create effective goals and methods on maintaining motivation to exercise regularly. These meetings will help participants create effective goals and methods on maintaining their motivation to exercise regularly. They will then receive a monthly phone call follow-up at months 4-6.
76041712|NCT04806841|Other|Control intervention|Participants in the control group will be simply encouraged to exercise at the EPIC center and complete the online surveys. Participants in the control group will receive the skills/tactics at the end of the study.
76041713|NCT04815187|Drug|Montelukast|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
76041714|NCT04815187|Drug|Placebo|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
76041715|NCT05616481|Procedure|Laparoscopic Burch colposuspension|The original Burch procedure will be performed
76041716|NCT05616481|Procedure|Modefied Burch (TOT - like)|more lateral fixation to avoid post-operative voiding dysfunction
76041717|NCT02599129|Drug|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
75413041|NCT03401580|Drug|Viena II 190/10|once daily
76041718|NCT02599129|Drug|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
76041719|NCT04796077|Other|Pop-Up Book|Patients spent 5-10 minutes reading an illustrated pop-up book that promoted active learning about the process of general anesthesia induction.
76041720|NCT04806061|Drug|Sodium bicarbonate|sodium bicarbonate 8.4% to achieve urinary pH >7.5
75413042|NCT03401580|Drug|Viena II 160/12|once daily
75413043|NCT03401580|Drug|Viena II 190/12|once daily
75413044|NCT03401502|Drug|Ranolazine|Oral, b.i.d
75413045|NCT03401502|Drug|Placebos|Oral, b.i.d
75413046|NCT03401424|Procedure|improved Warren-type style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision plus modified Warren cholangiobiliary reconstruction.
75556204|NCT04181827|Drug|Daratumumab|Daratumumab 1800 mg will be administered SC.
76041721|NCT04806061|Drug|standard care|standard care
75413047|NCT03401424|Procedure|Roux-en-Y style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision Roux-en-Y cholangiobiliary reconstruction.
75413048|NCT03401346|Combination Product|INP104|Dihydroergotamine Mesylate (DHE) administered via I123 Precision Olfactory Delivery (POD) Device
75413049|NCT03401346|Drug|Dihydroergotamine Mesylate (DHE)|Dihydroergotamine Mesylate (DHE) injection (intravenous)
75413050|NCT03401346|Combination Product|Migranal Nasal Spray|Dihydroergotamine Mesylate (DHE) delivered via Migranal Nasal Spray pump
75413051|NCT03401268|Drug|subcutaneous immunoglobulin|24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
75413052|NCT03400878|Biological|BCG-Japan|One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
75413053|NCT03400878|Biological|BCG-Russia|One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
75556205|NCT04179864|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
75556206|NCT04179864|Drug|Abiraterone/prednisone|1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
75556207|NCT04179864|Drug|Enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
75413054|NCT03400722|Drug|Pergoveris|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
75556208|NCT04175600|Drug|Selexipag|Selexipag tablet will be administered orally.
75556209|NCT04175600|Drug|Placebo|Matching placebo tablets will be administered orally.
75556210|NCT04175431|Procedure|Positron Emission Tomography|Undergo fluciclovine PET/CT
75413055|NCT03400722|Drug|Clomiphene|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
75714789|NCT04588948|Drug|Intravitreal Aflibercept|Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
76041722|NCT04805749|Other|Manual Therapy: osteopathy|"Osteopathic protocol applied at week 0, 1, 2 and 3:~Spinal mobilisation of L1, L2 and L3 vertebrae to stimulate the arterial supply of mesenteric attachments of the colon and small intestine.~Visceral osteopathic therapy to address adhesions/ fixations in the presacral fascia, Toldt fascia, posterior peritoneum and caudal peritoneum.~Circulatory techniques to stimulate the celiac plexus, the superior and inferior ganglia.~Cranial osteopathy techniques to address the vagus parasympathetic nerves."
75413056|NCT03400644|Device|Cervical collar|Cervical neck collar which is routinely made for post-laminoplasty patients
75413057|NCT03400566|Behavioral|Narrative|Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).
75413058|NCT03400566|Behavioral|Experiential|Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.
75413059|NCT03400488|Drug|AZD5718 oral suspension|In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
75556211|NCT04175431|Procedure|Lymphadenectomy|Undergo lymphadenectomy
75714790|NCT00758628|Drug|Bromefenac|Bromfenac BID 3 months
76041723|NCT04814797|Other|Capnography data included in Lung Clearance Index measurement|Capnography data included in Lung Clearance Index measurement (a pulmonary function test included in routinely yearly follow-up of cystic fibrosis children) will be collected and analyzed
75413060|NCT03400488|Other|Placebo matching AZD5817 oral suspension|In all cohorts, randomized subjects will receive orally placebo matching AZD5718 oral suspension on Day 1 and from Days 3 to 10. On Day 2, no dose will be given.
75556212|NCT04175431|Radiation|Radiation Therapy|Undergo radiation therapy
75556213|NCT04175431|Drug|Abiraterone Acetate|Given PO
75556214|NCT04175431|Drug|Prednisone|Given PO
75556215|NCT04175431|Procedure|Computed Tomography|Undergo fluciclovine PET/CT
75556216|NCT04175431|Drug|Abiraterone|Given PO
75714791|NCT00758628|Drug|Blink|Blink BID for 3 months
75714792|NCT00959998|Other|Self-administered Acupressure|
75714793|NCT01048411|Drug|Naja-comp.|homeopathic remedy
75714794|NCT01048411|Drug|Placebo|s.c. injection of NaCl-solution three times a week
76041724|NCT04814641|Biological|hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit|Serum phosphorus level < 1.55 mmol/L at any time between admission and the 5th day.
76041725|NCT04814719|Drug|Pentosan Polysulphate Sodium|Subcutaneous Injection (100mg/ml)
75556217|NCT04175431|Procedure|PSMA PET Scan|Undergo PSMA PET scan
75714795|NCT00765024|Drug|Ivermectin|single dose of 200 mcg/kg
75556218|NCT04172675|Drug|Erdafitinib|Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.
75556219|NCT04172675|Drug|Investigator Choice (Gemcitabine)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
75556220|NCT04172675|Drug|Investigator Choice (Mitomycin C)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
75556221|NCT04171037|Procedure|Oxygen Therapy|Receive oxygen via Optiflow THRIVE
75556222|NCT04171037|Procedure|Oxygen Therapy|Receive oxygen via non-rebreather
75714796|NCT00765024|Drug|ivermectin|two single dose of 200mcg/kg in 2 weeks
75714797|NCT00765024|Drug|Albendazole|Albendazole 7 days
75714798|NCT01743391|Procedure|Office-hysteroscopy with biopsy|
75413061|NCT03400254|Drug|Hydroxychloroquine (HCQ)|All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
75413062|NCT03400254|Drug|Gedatolisib|"Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC >1.0 x 109/L and platelet count > 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to <grade 1 then any further treatment with GED should be stopped."
75714799|NCT05279638|Diagnostic Test|serum ATG5|This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
76041726|NCT04814719|Drug|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
75413063|NCT03400098|Drug|Inotersen|Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm
75556223|NCT04171037|Other|Questionnaire Administration|Ancillary studies
75556224|NCT04171037|Device|Optiflow THRIVE|Oxygen Administration
76041727|NCT04795609|Other|Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).|"Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).~Trunk control.~Orthostatism.~Walk training.~Aerobic exercises.~Muscle strengthening."
75556225|NCT04154774|Drug|Apalutamide|Apalutamide will be administered orally.
75556227|NCT04133636|Drug|JNJ-68284528|Participants in Cohorts A,B,C, D, E, F, G, and H will receive JNJ-68284528 intravenously.
75556228|NCT04133636|Drug|Lenalidomide|Some participants in Cohort D and all participants in Cohorts E, G, and H will also receive lenalidomide capsules orally.
75556229|NCT04133636|Drug|Daratumumab|Participants in Cohorts E, G, and H will also receive daratumumab subcutaneous (SC) injection.
75556230|NCT04133636|Drug|Bortezomib|Participants in Cohorts E and H will also receive bortezomib subcutaneously.
75556231|NCT04133636|Drug|Dexamethasone|Participants in Cohorts E, G, and H will also receive dexamethasone orally or intravenously.
75556232|NCT04124315|Other|Accelerometry|Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
75714800|NCT02557932|Drug|Standard triple therapy|Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
75714801|NCT02557932|Drug|Bismuth quadruple therapy|Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
75714802|NCT00965614|Other|MCG|Cardiac Arrhythmia,Heart Disease
75714803|NCT00762684|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
75714804|NCT00762684|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
75714805|NCT00960232|Drug|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
75714806|NCT00960232|Drug|placebo|placebo
75714807|NCT00765180|Device|TRE vs. NBI|TRE NBI
75714808|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
75714809|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
75714810|NCT00610155|Drug|Placebo|BID
75556233|NCT04124315|Other|Daynamica app|Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
75556234|NCT04119050|Drug|M281|M281 injection administered as intravenous infusion
75556235|NCT04119050|Drug|Placebo|Placebo administered as intravenous infusion
75413064|NCT03400020|Other|Ascorbic acid|Ascorbic acid 500 Mg in normal saline IV two hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
75556236|NCT04117295|Device|Carmat Total Artificial Heart|Heart replacement therapy
75556237|NCT04115163|Drug|Gemcitabine|Given IV
75714811|NCT00610155|Drug|Pregabalin|Dose 75 mg titrated to 150 mg, bid
75413065|NCT03400020|Other|Normal Saline|Normal saline IV two hours before the operation and thereafter for three days.
75413066|NCT03408444|Device|EMO-114|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
75556238|NCT04115163|Drug|Nab-paclitaxel|Given IV
75714812|NCT00610155|Drug|Tramadol SR|Dose 50mg titrated to 200 mg, bid
75413067|NCT03408444|Device|EMO-116|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
75556239|NCT04113759|Behavioral|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain <2/10 on VAS and RPE <5 on 0-10 scale. (Heerey et al), and no break down in form."
75556240|NCT04113759|Behavioral|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
75714813|NCT00960466|Behavioral|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
75714814|NCT00960466|Behavioral|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
75413068|NCT03408444|Device|EMO-118|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
75413069|NCT03408444|Device|EMO-117|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
75413070|NCT03401190|Drug|CM4620 Injectable Emulsion (Low Dose)|CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
75556241|NCT04108208|Drug|Apalutamide|Apalutamide 240 mg (4*60 mg tablets) will be administrated orally once daily.
75556242|NCT04108208|Drug|Placebo|Matching placebo will be administered orally.
75556243|NCT04108208|Drug|Androgen-deprivation Therapy (ADT)|Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
75556244|NCT04108195|Drug|Daratumumab|Participants will receive daratumumab.
75556245|NCT04108195|Drug|Talquetamab|Participants will receive talquetamab.
75556246|NCT04108195|Drug|Teclistamab|Participants will receive teclistamab.
75556247|NCT04108195|Drug|Pomalidomide|Participants will receive pomalidomide.
75714815|NCT00758940|Device|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
75413071|NCT03401190|Drug|CM4620 Injectable Emulsion (High Dose)|CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
75413072|NCT03406728|Other|PDSAFEX|PDSAFEX is a week by week, progressive, exercise protocol that is followed. It lasts 12 weeks.
75413073|NCT03406728|Other|CONTROL|Participants will be asked to maintain their day to day life as consistently as possible for the 12 week duration of the study.
75413074|NCT03406728|Device|VIRTUAL REALITY|WorldViz Oculus Rift Move package (headset and software).
75714816|NCT00759018|Biological|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
75714817|NCT00965770|Device|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
75413075|NCT03403218|Behavioral|Case group|assessment of quality on posture, transfers and displacement
75413076|NCT03400956|Drug|Vilaprisan (BAY1002670)|Orally, coated tablet 2 mg, once daily
75413077|NCT03400956|Drug|Placebo|Orally, coated tablet, once daily
75413078|NCT00012012|Drug|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
75413079|NCT00012012|Drug|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
75714818|NCT02541825|Device|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
75714819|NCT02541825|Device|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
75714820|NCT00884871|Procedure|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
75714821|NCT00765414|Biological|Myozyme|30 mg/kg qow f and 40 mg/kg qow
75714822|NCT00960544|Drug|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
75413080|NCT00012012|Radiation|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
75413081|NCT00012012|Radiation|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
75556248|NCT04107766|Device|Microwave Ablation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.
75556249|NCT04102189|Drug|Semaglutide|Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
75556250|NCT04102189|Other|Placebo|Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks
75556251|NCT04090268|Other|Sport Therapy|Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
75556252|NCT04087317|Drug|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
75556253|NCT04087317|Drug|Ibuprofen 400Mg Tab|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
75714823|NCT00888147|Dietary Supplement|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
75413082|NCT00010374|Device|NeuRx DPS|Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.
75413083|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
75413084|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
75413085|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner
75714824|NCT04049136|Diagnostic Test|NT-proBNP|Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
75714825|NCT04037631|Diagnostic Test|Diagnostic device|Diagnostic test
75413086|NCT02240004|Device|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
75413087|NCT02240082|Behavioral|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
75556254|NCT04087317|Drug|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
75556255|NCT04087317|Drug|Ibuprofen 400 mg|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
75714826|NCT00762840|Device|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
75714827|NCT00762840|Procedure|Conventional endodontic procedure|Standard root canal treatment
75714828|NCT00888225|Procedure|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
75714829|NCT00888225|Procedure|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
75714830|NCT00765492|Drug|AZD8529|oral
75714831|NCT00765492|Drug|Placebo|oral
75714832|NCT00960700|Device|Visual Acuity|Assessment of visual acuity
75714833|NCT00960700|Device|Contrast sensitivity|Assessment of contrast sensitivity
75714834|NCT00960700|Device|Reading Speed|Assessment of reading speed
75413088|NCT02240160|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
75413089|NCT02240238|Drug|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
75413090|NCT02240238|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
75413091|NCT02240550|Device|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
75556256|NCT04087317|Drug|MIR|At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
75556257|NCT04083976|Drug|Erdafitinib|Participants will receive erdafitinib oral tablets.
75556258|NCT04083599|Biological|GEN1042|Intravenous
75714835|NCT00960700|Procedure|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
75714836|NCT02541747|Behavioral|massage|massage
75714837|NCT04488952|Device|nerve block combined with general anesthesia|Patients in this group receive nerve block combined with general anesthesia.
75714838|NCT04488952|Device|spinal anesthesia|Patients in this group receive spinal anesthesia.
75714839|NCT00888303|Drug|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
75872943|NCT04388787|Device|Stochastic resonance (SR) wraps|SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
75556259|NCT04083599|Drug|Pembrolizumab|Intravenous
75556260|NCT04083599|Drug|Cisplatin|Intravenous
75714840|NCT00888303|Drug|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
75714841|NCT00888303|Procedure|Thyroidectomy, total or partial|Surgical standard intervention
75714842|NCT00967642|Drug|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
75714843|NCT02541591|Other|Neuroprotective goal directed hemodynamic optimization|
75714844|NCT02541591|Other|MAP > 65mmHg|MAP > 65mmHg
75556261|NCT04083599|Drug|Carboplatin|Intravenous
75556262|NCT04083599|Drug|5-FU|Intravenous
75413092|NCT02240550|Device|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
75556263|NCT04083599|Drug|Gemcitabine|Intravenous
75556264|NCT04083599|Drug|Nab paclitaxel|Intravenous
75556265|NCT04083599|Drug|Pemetrexed|Intravenous
75714845|NCT00961012|Procedure|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
75714846|NCT00674700|Drug|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
75413093|NCT02240940|Device|Parachute Implant|CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
75413094|NCT02241096|Drug|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
75413095|NCT02241174|Drug|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
75556266|NCT04083599|Drug|Paclitaxel|Intravenous
75556267|NCT04083235|Drug|Irinotecan Liposomal Injection|Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).
75556268|NCT04083235|Drug|Oxaliplatin|Oxaliplatin injection, USP is supplied in single-dose vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.
75714847|NCT00674700|Drug|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
75714848|NCT00674700|Drug|Placebo tablet|One sublingual tablet daily for one year
75714849|NCT00888537|Other|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
75714850|NCT00888537|Other|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
75714851|NCT02542371|Other|Arterial Imaging|
75872944|NCT03477357|Device|Geratherm non Contact thermometer|Temperature taken from subject using non-contact device as per manufacturers instructions
76041728|NCT04805905|Other|FACE-Q patient reported outcome|"As both interventions of treatment are gold standards and clinical equipoise exists if one intervention is superior to the other, there is no true control group. However, for the purpose of the application, the local flap group will be chosen as the control group.~Skin graft (Experimental): Participants in the experimental group will receive a skin graft and receive the FACE-Q skin cancer questionnaire pre- and post-treatment. There will also be photos taken of the patient's face along with the distributed questionnaires.~Local flap (Control): Participants in the experimental group will receive a local flap and receive the FACE-Q questionnaire pre- and post-treatment."
76041729|NCT04805827|Drug|Gabapentin|1 tablet contains 600 mg Gabapentin
76041730|NCT04805827|Drug|Neurontin|2 capsule contains 2*300 = 600 mg Gabapentin
75413096|NCT02241252|Device|iPhone ECG|Please see detailed description for additional information.
75413097|NCT02241330|Dietary Supplement|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
75413098|NCT02241330|Dietary Supplement|Fortification|Wheat flour is fortified before testmeal preparation
75413099|NCT02241330|Dietary Supplement|Control|wheat flour is used as control comparator.
75556269|NCT04083235|Drug|5Fluorouracil|Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.
75714852|NCT00762918|Dietary Supplement|cholecalciferol|cholecalciferol 5000 IU capsule by mouth daily for 3 months
76041731|NCT04805359|Behavioral|Normoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
76041732|NCT04805359|Behavioral|Hypoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
76041733|NCT02596711|Drug|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
75413100|NCT02241564|Other|Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|
75714853|NCT00546910|Drug|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
75714854|NCT00546910|Drug|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
75714855|NCT00763074|Behavioral|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.~----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30~35kcal/day"
75714856|NCT00763074|Behavioral|Diet restriction|"Education for diet and exercise every 2 weeks~----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
75714857|NCT00763074|Behavioral|Exercise|"Education for diet and exercise every 2 weeks~----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
76041734|NCT02596711|Behavioral|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
75413101|NCT02241564|Drug|Switch from calcineurin inhibitor to an mTOR inhibitor|
75714858|NCT00763074|Behavioral|Diet and exercise|"Education for diet and exercise every 2 weeks~----------- Exercise education like as exercise group and diet education like as diet group"
75714859|NCT02541513|Drug|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
76041735|NCT02596711|Other|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
75413102|NCT02241642|Device|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
75413103|NCT02241798|Other|oxygen|O2 by nasal prongs
75413104|NCT02241876|Drug|N-acetylcysteine|
75714860|NCT00888693|Drug|ABT-288|See Arm Description for details.
75714861|NCT00888693|Drug|Placebo|See Arm Description for details.
75714862|NCT02558712|Other|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
75714863|NCT05278767|Other|E-Mobile Education and Counselling|The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
75714864|NCT00961168|Other|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
76041736|NCT02596711|Behavioral|Health Education and Handouts|Participants receive general health education and handouts.
76041737|NCT02596711|Behavioral|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
75714865|NCT00961168|Other|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
75413105|NCT02241954|Device|Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)|
75413106|NCT02242032|Drug|P-321 Ophthalmic Solution|
75413107|NCT02242032|Drug|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
75413108|NCT02242344|Drug|Telmisartan|
75714866|NCT00885183|Procedure|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
75714867|NCT00763152|Other|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
75714868|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
75714869|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
75714870|NCT00759720|Drug|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
75714871|NCT04037319|Diagnostic Test|24 Hour Holter Monitor|24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
75714872|NCT00888069|Drug|CTAP101 Capsules|Single dose oral administration
75714873|NCT00888069|Drug|CTAP101 Injection|single IV injection
75413109|NCT02242344|Drug|Placebo|
75413110|NCT02242500|Procedure|Coronally Advanced Flap|
75413111|NCT02242500|Device|Mucograft|
75413112|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
75556270|NCT04083235|Drug|Leucovorin|Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.
75714874|NCT00763230|Device|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
76041738|NCT02596711|Behavioral|Counseling Sessions|Participants attend 3 counseling sessions during the study.
75413113|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
76041739|NCT04805281|Other|monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.|wear of the new material of monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime in posterior teeth
75413114|NCT02242812|Drug|Telmisartan|
75413115|NCT02242812|Drug|Metoprolol succinate|
75413116|NCT02242812|Drug|Placebo|
75413117|NCT02242890|Behavioral|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
75413118|NCT02243124|Drug|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
75872945|NCT03057600|Drug|Paclitaxel|standard weekly paclitaxel in 28-day cycles
75413119|NCT02243124|Drug|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
75413120|NCT02243436|Drug|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
75413121|NCT02243436|Drug|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
75413122|NCT02243436|Drug|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
76041740|NCT04805281|Other|Lithium Dislicate IPS e.max crown|wear of lithium disilicate IPS e.max crown in posterior teeth
76041741|NCT05616403|Other|No intervention|This is an observational study without any intervention
76041742|NCT04814251|Other|Observationnal cohort|data collection
76041743|NCT04814485|Drug|SHR-1020+albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
75413123|NCT02243436|Drug|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
75413124|NCT02243436|Drug|Ara C|Intravenous use, 2g/m2, day 5
75413125|NCT02243670|Device|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®. If a participant misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by research staff or the AiCure study team through automated SMS text or by phone.
75413126|NCT02243748|Other|Palliative Therapy|Receive individualized palliative care
75413127|NCT02243748|Other|quality-of-life assessment|Ancillary studies
76041744|NCT04288141|Other|Acquisition of blood samples and tumour tissue samples (biopsies)|Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.
76041745|NCT04280887|Device|MyPad|Ultrasound bed wetting alarm
75413128|NCT02243748|Other|questionnaire administration|Ancillary studies
75556271|NCT04083235|Drug|Nab-paclitaxel|Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.
75556272|NCT04083235|Drug|Gemcitabine|Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.
75556273|NCT04079361|Diagnostic Test|Blood samples|Bood samples during prenatal and postnatal visits
75556274|NCT04077723|Drug|RO7227166|RO7227166 will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
75556275|NCT04077723|Drug|Obinutuzumab|A fixed dose of obinutuzumab will be administered seven days prior to first does of RO7227166 and glofitamab and then Q3W in combination with RO7227166 in Part I
75714875|NCT00379639|Drug|Romidepsin|7, 10 or 12 mg/m^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
75413129|NCT02243826|Drug|50:50 mixture of nitrous oxide/oxygen|
75556276|NCT04077723|Drug|Glofitamab|A fixed dose of glofitamab will be administered Q3W in combination with RO7227166 in Part II and Part III
75556277|NCT04077723|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
75556278|NCT04077463|Drug|Lazertinib|Lazertinib will be administered orally.
75714876|NCT00379639|Drug|Gemcitabine|800 or 1000 mg/m^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
75714877|NCT03948334|Drug|ZPL389 30mg|30mg of ZPL389; once daily
75714878|NCT03948334|Drug|ZPL389 50mg|50mg of ZPL389; once daily
75714879|NCT03948334|Drug|TCS and/or TCI|Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
75413130|NCT02244060|Other|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
75413131|NCT02244138|Behavioral|Adolescent CDSS|computer decision support system (CDSS) for health care providers of adolescents in primary care
75413132|NCT02244216|Drug|Berotec® N 100 µg Metered-dose Inhaler|
75413133|NCT02244294|Drug|FLOMAX® capsules|
75413134|NCT02244294|Drug|Placebo capsules|
75413135|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 0.76 g|
75556279|NCT04077463|Drug|Amivantamab|Amivantamab will be administered as an intravenous (IV) infusion.
75556280|NCT04077463|Drug|Carboplatin|Carboplatin will be administered as IV infusion.
75556281|NCT04077463|Drug|Pemetrexed|Pemetrexed will be administered as IV infusion.
75556282|NCT04075591|Device|iDesign Refractive Studio with STAR S4 IR® Excimer laser System|Surgeons will perform wavefront-guided monovision LASIK for the treatment of myopic subjects with presbyopia based upon measurements obtained with an iDesign Refractive Studio.
75556283|NCT04071925|Procedure|Urethroplasty|Open reconstructive surgery to restore urethral patency in case of urethral stricture disease.
75556284|NCT04068103|Drug|Capecitabine|Given PO
75556285|NCT04068103|Drug|Fluorouracil|Given IV
75556286|NCT04068103|Drug|Leucovorin|Given IV
75556287|NCT04068103|Drug|Leucovorin Calcium|Given IV
75556288|NCT04068103|Drug|Oxaliplatin|Give IV
75556289|NCT04068103|Other|Patient Observation|Undergo active surveillance
75413136|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 1.15 g|
75413137|NCT02244372|Dietary Supplement|Placebo|
75413138|NCT02244528|Drug|Sildenafil|
75556290|NCT04061226|Device|Overnight polysomnography|Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
75556291|NCT04054167|Drug|Low Dose Radiation Therapy|Undergo ultra low dose radiation
75556292|NCT04042376|Drug|Ibrutinib|Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg*3 capsules taken together at one time).
75556293|NCT04040634|Drug|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP <120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine
75556294|NCT04040634|Drug|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
75556295|NCT04038515|Drug|Nicotine 0 mg/mL|E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
75556296|NCT04038515|Drug|Nicotine 6 mg/mL|E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
75714880|NCT00609765|Drug|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
75714881|NCT00609765|Drug|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m^2 iv bolus daily days 1-5
75714882|NCT00609765|Drug|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m^2 iv bolus day 1
75413139|NCT02245074|Other|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
75413140|NCT02245386|Radiation|transperineal pelvic floor ultrasound|"Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
75413141|NCT02245464|Drug|Telmisartan|
75714883|NCT00609765|Drug|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
75714884|NCT00609765|Drug|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
75714885|NCT00609765|Drug|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
75714886|NCT00763308|Behavioral|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
75413142|NCT02245542|Drug|ALNA®OCAS®|
75413143|NCT02245698|Biological|Stem cell|Intrathecal autologous bone marrow mononuclear cell transplantation
75413144|NCT02245776|Biological|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
75413145|NCT02246244|Drug|Escitalopram|
75413146|NCT02246244|Other|Placebo|
75413147|NCT02246322|Device|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
75413148|NCT02246322|Device|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
75413149|NCT02246400|Behavioral|eCMP|eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.
75413150|NCT02246556|Device|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
75413151|NCT02246556|Other|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
75413152|NCT02246556|Device|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
75413153|NCT02246712|Drug|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
75413154|NCT02246712|Other|CYP2D6 phenotype|"Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato"
75413155|NCT02246712|Other|CYP3A phenotype|"A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance."
75413156|NCT02246712|Genetic|CYP2B6 genotype|The single nucleotide polymorphism 516G>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
75413157|NCT02246790|Procedure|Biatrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
75413158|NCT02246790|Procedure|Left atrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
75714887|NCT01051219|Drug|Losartan|50 milligrams to be taken orally, daily
76041746|NCT04280029|Device|SELUTION SLR™ DEB|The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal angioplasty (PTA) balloon catheter coated with a drug (Sirolimus). The drug coating is formulated with Sirolimus microspheres suspended in a phospholipid blend. The balloon catheter component of the SELUTION SLR™ DEB is a conventional single use, sterile, rapid exchange catheter to dilate vascular lesions. The semi-compliant balloon is inflated for 60 seconds (minimum of 30 seconds) to transfer the Sirolimus loaded microspheres to the target vessel wall. The balloon is then deflated and removed from the body.
76041747|NCT04280029|Device|Control|The treating physician may chose to implant a commercially available DES or alternatively may use POBA only to treat the patient. Choice of DES is at the treating physician's discretion, but is limited to ZES and EES devices
75413159|NCT02246868|Biological|Optivate® (Human Coagulation Factor VIII)|
75714888|NCT00885417|Drug|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
75714889|NCT00766272|Device|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
75413160|NCT02246946|Device|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
75413161|NCT02246946|Other|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
75413162|NCT02246946|Procedure|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
75714890|NCT00961246|Behavioral|general health information|participants received general health information
75714891|NCT00961246|Behavioral|individually-tailored intervention|participants received individually-tailored intervention
75872946|NCT03057600|Drug|CB-839|CB-839 administered as oral tablets twice daily (BID)
75872947|NCT04382937|Drug|P1101 + Ribavirin|P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
75872948|NCT04382937|Drug|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
75872949|NCT04355169|Drug|Naldemedine|Oral tablet
75872950|NCT04355169|Drug|Placebo|Oral tablet
76041748|NCT04262401|Behavioral|Standard health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
76041749|NCT04262401|Behavioral|Habit-focused health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
75556297|NCT04038515|Drug|Nicotine 12 mg/mL|E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
75556298|NCT04038515|Drug|Nicotine 24 mg/mL|E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
75413163|NCT02247102|Dietary Supplement|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
75556299|NCT04038515|Other|'Menthol' flavor|E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
75413164|NCT02247102|Dietary Supplement|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
76041750|NCT04795063|Procedure|Total Robotic Distal Gastrectomy|All the surgical procedures are performed using the robot system.
75413165|NCT02247180|Behavioral|cognitive rehabilitation|
75413166|NCT02247180|Behavioral|standardized cognitive training|
75413167|NCT02247258|Drug|Azathioprine|See arm/group descriptions
75413168|NCT02247258|Drug|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
75413169|NCT02247258|Procedure|Ileocolonoscopy|See arm/group descriptions
75413170|NCT02247258|Procedure|Small bowel follow trough|See arm/group descriptions
75413171|NCT02247414|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
75556300|NCT04038515|Other|'Menthol/Mint' flavor|E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
75556301|NCT04038515|Other|'Green Apple' flavor|E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
75556302|NCT04038515|Other|'Watermelon' flavor|E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
75556303|NCT04038515|Other|'Unflavored'|E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
75556304|NCT04035278|Biological|Dengusiil|Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.
75413172|NCT02247414|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
75413173|NCT02247414|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
75556305|NCT04035278|Biological|Placebo|Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.
75872951|NCT05206890|Drug|fluzoparib monotherapy or combination therapy|patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
75872952|NCT05212974|Other|Questionnaires|The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
76041751|NCT04795063|Procedure|Robotic-Assisted Distal Gastrectomy|After finishing the lymphadenectomy, the digestive tract reconstruction is performed extracorporal.
76041752|NCT04804501|Device|Blue Light Glasses|Participants will be randomized into an experimental group (blue light glasses) or a control group (no glasses). Participants will perform a computer reading task while either wearing, or not wearing the glasses.
76041753|NCT04804501|Other|Computer Reading Task|Participants will read on a computer until concussion symptoms increase by a score of 3 or more (reading task termination criteria). One or more points will be assigned for each increase in symptom severity, and one point will be assigned for each new symptom that appears.
75413174|NCT02247414|Drug|Low Molecular Weight Heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
75413175|NCT02247570|Procedure|Vestibular Rehabilitation|Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
75413176|NCT02247648|Drug|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
75413177|NCT02247648|Drug|Placebo|"Patients from control group received a shame tramadol pill on day one, two, and 3"
75556306|NCT04034927|Procedure|Biospecimen Collection|Undergo blood sample collection
75556307|NCT04034927|Procedure|Computed Tomography|Undergo CT
75556308|NCT04034927|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556309|NCT04034927|Drug|Olaparib|Given PO
75556310|NCT04034927|Biological|Tremelimumab|Given IV
75872953|NCT03371823|Other|Normotensive|FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.
76041754|NCT04814017|Procedure|Radial Shock-Wave Therapy|Radial shock-wave therapy was applied in 1.0-4.0 bar intensity, 10-15 hz frequency interval. 300-700 pulse for a trigger point, 1500-3000 pulse for a muscle. Intensity, frequency and pulse increased every session regularly beginning from minimal taking patients tolerance into consideration. Trigger points in the upper, middle and lower trapezius, supraspinatus, infraspinatus and levator scapula muscles were treated. Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
75556311|NCT04034095|Drug|Androgen-deprivation Therapy (ADT)|Participants enrolled in this study will continue to receive ADT (example- Leuprorelin, Goserelin and Degarelix) alone or in combination with other therapies in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
75556312|NCT04034095|Drug|Bicalutamide|Participants enrolled in this study will continue to receive bicalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
75556313|NCT04034095|Drug|Abiraterone|Participants enrolled in this study will continue to receive abiraterone in combination with prednisolone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
75556314|NCT04034095|Drug|Prednisolone|Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
75556315|NCT04034095|Drug|Docetaxel|Participants enrolled in this study will continue to receive docetaxel along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
75556316|NCT04034095|Drug|Enzalutamide|Participants enrolled in this study will continue to receive enzalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
75714892|NCT01048489|Behavioral|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
75413178|NCT02247882|Other|Patient Education|"The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.~The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain."
75413179|NCT02247882|Other|Aquatic Physical Therapy|The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
75413180|NCT02248038|Procedure|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
75413181|NCT02248038|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
75556317|NCT04034095|Drug|Apalutamide|Participants enrolled in this study will continue to receive apalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
75556318|NCT04033926|Drug|KZR-616|Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
75714893|NCT00961324|Drug|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
75413182|NCT02248116|Drug|Talsaclidine|
75556319|NCT04033926|Drug|Placebo|Subcutaneous injection for 16 weeks
75714894|NCT00961324|Drug|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
75714895|NCT00766350|Drug|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
75413183|NCT02248194|Device|Tactile electrosurgical ablation probe|
75556320|NCT04033445|Drug|Placebo|Participants will receive matching placebo IV or SC.
75556321|NCT04033445|Drug|Guselkumab|Participants will receive guselkumab IV or SC.
75413184|NCT02248194|Device|Hysteroscopic endometrial ablation|
75714896|NCT00766350|Drug|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
75714897|NCT00889161|Drug|Curcumin|Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
76041755|NCT04814017|Procedure|Control|Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
76041756|NCT04804657|Dietary Supplement|Sage extracts Cognivia|Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
75413185|NCT02248272|Other|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
76041757|NCT04804657|Dietary Supplement|Placebo|Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
75413186|NCT02248272|Other|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
75556322|NCT04025606|Drug|Thoracic epidural|Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.
75714898|NCT03992755|Drug|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
75714899|NCT01563328|Drug|DTG|50 mg q24h
75714900|NCT01563328|Drug|BCV|800 mg q8h
75714901|NCT01563328|Drug|TVR|750 mg q8h
75714902|NCT00889239|Other|lithia-disilicate-based crown|all-ceramic crown
76041758|NCT04804423|Drug|38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)|38% silver fluoride will be applied to the surface of the isolated hypersensitive carious lesion followed by application of potassium iodide solution and according to manufacturer's instructions.
76041759|NCT04804423|Drug|Sodium fluoride varnish (generic name; Duraphat®)|22,600 ppm sodium fluoride varnish will be applied on the surface of the affected hypersensitive active carious lesions.
75413187|NCT02248350|Behavioral|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
75413188|NCT02248350|Behavioral|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
75556323|NCT04025606|Drug|Paravertebral block|Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
75714903|NCT00760032|Drug|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
75714904|NCT00760032|Drug|Placebo|Placebo capsules, one capsule per day during four weeks.
75714905|NCT00961480|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
75714906|NCT00961480|Drug|Comparator: metformin 500mg|A single dose of metformin 500 mg tablet
75714907|NCT00961480|Drug|Comparator: sitagliptin|A single dose of 50 mg sitagliptin tablet
75714908|NCT00961480|Drug|Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
75714909|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
75714910|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
75714911|NCT00961480|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablet
75714912|NCT00961480|Drug|Comparator: metformin 850 mg|A single dose of metformin 850 mg tablet
75714913|NCT00760110|Device|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
75714914|NCT00608829|Device|GORE TAG® Thoracic Endoprosthesis|Implant
76041760|NCT04804111|Drug|arm 0|placebo group
76041761|NCT04804111|Drug|arm 1|3 mg of the URC102 group
76041762|NCT04804111|Drug|arm 2|6 mg of the URC102 group
76041763|NCT04804111|Drug|arm 3|9 mg of the URC102 group
76041764|NCT04804111|Drug|arm 4|Febuxostat 80 mg
76041765|NCT04794673|Other|brain damage|Have or not have the brain damage and the location of the damage
75556324|NCT04025580|Biological|Flucelvax|Seasonal influenza vaccine
75556325|NCT04025580|Biological|Fluvirin|Seasonal influenza vaccine
75556326|NCT04025580|Biological|Fluzone High Dose|Seasonal influenza vaccine for adults ages 65 and older
75556327|NCT04021277|Drug|20 uL/kg PS101|20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
76041766|NCT04794049|Drug|Lactulose|In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
75714915|NCT04462393|Other|Admission to ICU for COVID-19|All patients admitted to Swedish ICUs with COVID-19 between 6 Mar - 6 May 2020
76041767|NCT04794049|Drug|Polyethylene Glycol (PEG)|In control cohort, patients use the standard split-dose bowel preparation regimen,
75714916|NCT04049370|Other|No intervention|"Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit."
75714917|NCT00961558|Procedure|Varicocelectomy|Varicocelectomy
75714918|NCT00889317|Device|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
75714919|NCT00763464|Procedure|stress-echocardiography|stress-echocardiography will be performed once using Adenosin (140 µg/kg/min over 6 Minutes) and a contrast agent (SonoVue)
75714920|NCT00763464|Procedure|stress-MRI|stress-MRI will be performed once using Adenosin (140 µg/kg/min over 6 Minutes)and a contrast agent (Gadovist)
76041768|NCT04794127|Drug|Trabectedin|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
75413189|NCT02248428|Drug|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
75413190|NCT02248428|Drug|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
75413191|NCT02248428|Drug|Cyclophosphamide|300mg/m^2 intravenously daily on day 1-3,repeated every 28 days
75556328|NCT04021277|Drug|40 uL/kg PS101|40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
75556329|NCT04021277|Device|Ultrasound|Ultrasound activation and enhancement
75556330|NCT04020913|Drug|Somatropin injection|"Boys with short stature will be studied for measures of:~skeletal muscle strength, power, and endurance~muscle agility~lean body mass accrual~bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration"
75714921|NCT00973492|Other|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later."
75714922|NCT00760188|Device|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
75714923|NCT00973570|Behavioral|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
75714924|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
75413192|NCT02248428|Drug|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
75714925|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
75413193|NCT02248506|Other|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
75714926|NCT00766662|Drug|Sulfadoxine pyrimethamine|
75413194|NCT02248584|Dietary Supplement|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
75714927|NCT00965926|Drug|YM178|oral
75714928|NCT00889395|Behavioral|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
75714929|NCT02557776|Genetic|Germline genetic testing of BRCA1 and BRCA2|
75714930|NCT00966004|Drug|YM178|oral
75413195|NCT02248896|Drug|Telmisartan|
75413196|NCT02248896|Drug|Other angiotensin-receptor blockers (ARBs)|
75413197|NCT02248896|Drug|Angiotensin-converting enzyme inhibitors (ACEIs)|
75413198|NCT02248896|Drug|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
75413199|NCT02249130|Drug|Tipranavir (TPV)|
75714931|NCT00966004|Drug|Placebo|oral
75714932|NCT00966004|Drug|tolterodine|oral
75413200|NCT02249130|Drug|Ritonavir (RTV)|
75413201|NCT02249130|Drug|Delavirdine (DLV)|
75413202|NCT02249130|Drug|Zidovudine (ZDV)|
75413203|NCT02249130|Drug|Lamivudine (3TC)|
75413204|NCT02249130|Drug|Stavudine (d4T)|
75413205|NCT02249208|Device|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
75413206|NCT02249208|Device|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
75413207|NCT02249208|Device|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
75413208|NCT02249286|Behavioral|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
75413209|NCT02249286|Other|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
75413210|NCT02249364|Procedure|Control|Routine practice
75413211|NCT02249364|Procedure|Hypnosis|Hypnosis session before induction of anesthesia
75413212|NCT02249364|Drug|propofol|Closed-loop administration of propofol for anesthesia induction
75714933|NCT00892671|Other|Simulation|simulation of airway management and vascular access
75714934|NCT04048590|Other|Skilled Nursing Facility at Home|We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
75714935|NCT00966082|Procedure|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
75714936|NCT00966082|Procedure|endoscopic band ligation+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
75413213|NCT02249442|Drug|Tipranavir (TPV)|
76041769|NCT04794127|Drug|Pioglitazone Oral Product|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
75413214|NCT02249442|Drug|Ritonavir (r)|
75413215|NCT02249598|Biological|lactamica|
75413216|NCT02249598|Biological|Placebo|
75413217|NCT02249676|Biological|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
75413218|NCT02249754|Behavioral|Nutrition education|This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
75413219|NCT02249754|Behavioral|Routine health education|This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
75413220|NCT02249988|Drug|ABX203 therapeutic Hepatitis B vaccine treatment arm|
75413221|NCT02244762|Drug|20 mg HC-ER|1-72 hours
75413222|NCT02244762|Drug|20 mg HC-ER|1-72 hours
75413223|NCT02244762|Drug|20 mg HC-ER|1-72 hours
75413224|NCT02242734|Drug|20 mg HC-ER|1-72 hours
75413225|NCT02242734|Drug|20 mg HC-ER|1-72 hours
75413226|NCT02242734|Drug|20 mg HC-ER|1-72 hours
75413227|NCT02240862|Device|Carotid Artery Stent|Placement of a stent within the carotid artery
75413228|NCT02244606|Drug|SCY-078|
75413229|NCT02244606|Drug|Fluconazole|
75413230|NCT02244606|Drug|Micafungin|
75413231|NCT02245308|Drug|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
75413232|NCT02245308|Behavioral|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
75413233|NCT02245308|Behavioral|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
75714937|NCT00766740|Device|thrombectomy devices|mechanical or manual devices able to remove thrombus from the coronary arteries.
75714938|NCT00766740|Device|angioplasty|percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
75714939|NCT00892749|Drug|ASP1585|oral
76041770|NCT04804267|Drug|Linaclotide|Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
76041771|NCT04804267|Drug|LINZESS®|Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
76041772|NCT04804267|Drug|Placebo|Drug: Placebo orally once daily
75413234|NCT02245308|Drug|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
75413235|NCT02245308|Drug|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
75413236|NCT02243358|Drug|Folfox6|
75413237|NCT02243358|Drug|Gemcitabine|
75413238|NCT02243358|Radiation|Radiation Therapy|
75413239|NCT02243358|Procedure|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
75413240|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
75413241|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
75413242|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
75413243|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
75413244|NCT00559962|Drug|placebo|3 capsules each evening for each 4-week period
75714940|NCT00763542|Behavioral|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
75714941|NCT00763542|Behavioral|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
75714942|NCT00889629|Drug|Doxercalciferol|Active group receives doxercalciferol (Hectorol) 1mcg
75714943|NCT00889629|Drug|placebo|Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
75714944|NCT00889629|Drug|25-OH Vitamin D3|All groups received cholecalciferol
75714945|NCT00966160|Drug|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
75413245|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
75413246|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
75714946|NCT00966160|Drug|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
75714947|NCT00766818|Drug|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
75714948|NCT04009252|Behavioral|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
75714949|NCT04036383|Other|vestibular exercise training|The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
75714950|NCT04036383|Other|Balance training with computerized balance system|Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
75413247|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
75413248|NCT00559962|Drug|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
75413249|NCT00559962|Drug|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
75413250|NCT00559962|Drug|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
75413251|NCT00559104|Drug|carmustine|Unique to the Carmustine in Conditioning arm
75413252|NCT00559104|Drug|cyclophosphamide|Used in Both Arms
75413253|NCT00559104|Drug|etoposide|Used in Both Arms
75714951|NCT04036383|Other|square step exercises|Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
75714952|NCT02558556|Device|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
75714953|NCT02558556|Other|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
75714954|NCT00966316|Drug|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
75714955|NCT00889785|Behavioral|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
75714956|NCT00889785|Behavioral|Usual Care|Will receive usual care and monthly phone calls as an active control.
75413254|NCT00559104|Procedure|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
75413255|NCT00559104|Procedure|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
75413256|NCT00559104|Radiation|total-body irradiation|Unique to the Radiation in Conditioning Arm
75413257|NCT00559104|Drug|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
75413258|NCT00558636|Drug|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
75556331|NCT04008368|Device|CliniMACS CD34 Reagent|Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
75413259|NCT00558636|Drug|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
75413260|NCT00558558|Drug|Haelan|4 oz orally twice daily for 8 Weeks
75413261|NCT00557622|Drug|paroxetine|BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
75413262|NCT00557622|Other|placebo|placebo
75413263|NCT00557466|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
75413264|NCT00557466|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
75556332|NCT03999827|Other|Low Glycaemic Index Diet|Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
75556333|NCT03998020|Other|scale of severity|assessment of the severity of the sleep disorders by scale
75556334|NCT03998020|Genetic|blood sample|Genetical study, serum and sample
75556335|NCT03996837|Other|Intra uterine infusion of platelet rich plasma|Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
75556336|NCT03993327|Biological|Iodine I 124 Monoclonal Antibody M5A|Given IV
75556337|NCT03993327|Procedure|Positron Emission Tomography|Undergo PET scan
75556338|NCT03982368|Drug|rhNGF 20 μg/ml|one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
75556339|NCT03982368|Drug|rhNGF 20 μg/ml + vehicle|"one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon."
75714957|NCT04049292|Other|Better and safer return to sport (BEAST)|The RTS assessment includes a Lachman test, modified stroke test, side hop test, triple hop test, and quadriceps muscle power test. The sport-specific progression plans have 6 participation levels in practice and 6 participation levels in match play. A minimum of 2 weeks and 4 training sessions without pain or effusion must be completed before the athlete progresses to the next level. Criteria for full, unrestricted participation in practice: (1)at least 9 months from ACLR, (2)modified stroke test grade 0, (3)completed previous levels in the sport-specific progression plan, (4)negative Lachman test, (5)side hop test limb symmetry at least 90%, (6)triple hop test limb symmetry at least 90%, (7)quadriceps power symmetry at least 90%. The strength training and knee control exercise protocols each have 3-4 different exercises of 3-4 sets that are performed 3 days per week.
75413265|NCT00557466|Drug|placebo to indacaterol|Placebo TWISTHALER® device
75413266|NCT00557466|Drug|placebo to formoterol|Placebo AEROLIZER® device
75413267|NCT00557466|Drug|short acting β2- agonist|100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
75413268|NCT00557310|Drug|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
75413269|NCT00555438|Drug|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
75556340|NCT03982368|Other|Vehicle|one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
75413270|NCT00553644|Drug|Bortezomib|Given IV
75413271|NCT00553644|Other|Laboratory Biomarker Analysis|Correlative studies
75413272|NCT00553644|Drug|Lenalidomide|Given PO
75413273|NCT00553332|Drug|selumetinib|Given orally
75413274|NCT00553332|Other|laboratory biomarker analysis|Correlative studies
75413275|NCT00552396|Drug|Anti-KIR (1-7F9)|human monoclonal antibody
75413276|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
75556341|NCT03969446|Drug|Decitabine|Given IV
75413277|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
75413278|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
75413279|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
75413280|NCT00552240|Drug|Nevirapine 200 mg BID|200 mg BID
75413281|NCT00552240|Drug|Atazanavir 300 mg|300 mg QD
75413282|NCT00552240|Drug|Ritonavir 100 mg|100 mg QD
75413283|NCT00552084|Drug|Fish oil|Fish oil supplements 4 gms will be taken daily for 24 weeks.
75413284|NCT00552084|Drug|Placebo|Placebo supplements will be taken daily for 24 weeks.
75413285|NCT00550836|Biological|panitumumab|Given IV
75413286|NCT00550836|Drug|erlotinib hydrochloride|Given orally
75413287|NCT00550836|Drug|gemcitabine hydrochloride|Given IV
75556342|NCT03969446|Biological|Pembrolizumab|Given IV
75556343|NCT03969446|Drug|Venetoclax|Given PO
75413288|NCT00550680|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
75413289|NCT00559650|Drug|Placebo|Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
75413290|NCT00559650|Drug|Cinaciguat (BAY58-2667)|Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
75413291|NCT00556920|Drug|COREG CR|
75413292|NCT00554190|Device|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
75413293|NCT00554190|Device|Merogel Injectable|Bioresorbable hyaluronic acid product
75413294|NCT00552708|Drug|COREG CR|
75556344|NCT03968068|Procedure|Exercise Procedure|Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.
75556345|NCT03968068|Procedure|Remote Ischaemic Conditioning|Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
75714958|NCT04049292|Other|Usual care|Usual care is determined by the treating health care professional
75413295|NCT00552708|Drug|Lisinopril|
75413296|NCT00556374|Drug|Placebo|
75413297|NCT00556374|Biological|Denosumab|Administered as a subcutaneous injection
75413298|NCT00556374|Drug|Non-steroidal aromatase inhibitor therapy|An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
75413299|NCT00556374|Drug|Zoledronic Acid|5 mg zoledronic acid administered at a constant infusion rate
75413300|NCT00556374|Other|Standard of Care|Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
75413301|NCT03029910|Other|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)
75413302|NCT03029910|Other|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
75413303|NCT03029754|Procedure|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
75556346|NCT03960840|Biological|Rapcabtagene autoleucel single agent|Single infusion of rapcabtagene autoleucel
75413304|NCT00555204|Drug|ABT-089|10 mg - capsules once daily for 12 weeks
76041773|NCT04427059|Procedure|Transversus Abdominis Plane (TAP) block|"The laparoscopic-assisted Transversus Abdominis Plane (TAP) block will be done just after the optic trocar placement as follow: as landmarks we use the anterior axillary line, in the middle between the iliac crest and the costal margin. After insertion of the optic trocar the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. Laparoscopy allows to confirm that the needle did not pass the peritoneum.~A solution of 20 ml of Ropivacaine (0.25%) is then injected, observing the formation of a bulge posterior to the transversus abdominis muscle.~The procedure is then repeated identically on the contralateral side."
75413305|NCT00555204|Drug|ABT-089|5 mg - capsules once daily for 12 weeks
75413306|NCT00555204|Drug|ABT-089|15 mg - capsules once daily for 12 weeks
75413307|NCT00555204|Drug|ABT-089|20 mg - capsules once daily for 12 weeks
75413308|NCT00555204|Drug|ABT-089|30 mg - capsules once daily for 12 weeks
75872954|NCT03371823|Drug|Hypertensives|ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
75872955|NCT03879642|Behavioral|REDCHiP|10 week video-based telemedicine intervention to reduce hypoglycemia fear
75872956|NCT05212896|Drug|BC006|BC006 monoclonal antibody injection
75872957|NCT03619980|Other|No intervention|Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
75872958|NCT03125967|Other|Philips GoLite Blu HF3429/60|Exposure to daily morning colored light in the 440-485 nm wavelength range
75872959|NCT03125967|Other|Philips LivingColor Aura 70998/60/48|Exposure to daily morning colored light in the 625-740 nm wavelength range
75872960|NCT04308603|Diagnostic Test|NON-IMMUNE HYDROPS FETALIS diagnosis|Amniotic liquid of each selected patients will be tested by both technic to describe and detect etiological information. Each patient will be tested using the current procedure with a defined panel of genes as well as with the NGS procedure. The results of both procedures will be compared.
76041774|NCT04427059|Procedure|Port-Site Infiltration (PSI)|The Port-Site Infiltration (PSI) will be performed by infiltrating the subcutis and the skin at the trocar site before the trocar placements with a solution of local anesthetic (Ropivacaine 0.25%), a total of 40 ml will be administered.
76041775|NCT04793971|Procedure|percutaneous paratenon release|percutaneous paratenon release for chronic midportion Achilles tendinopathy
76041776|NCT04794439|Drug|Dentifrices|Dentifrice on plaque
76041777|NCT02596009|Device|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
76041778|NCT02596009|Device|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
75413309|NCT00555204|Drug|ABT-089|35 mg - capsules once daily for 12 weeks
75413310|NCT00555204|Drug|placebo|placebo - capsules once daily for 12 weeks
75413311|NCT03029676|Drug|benzodiazepines|sedative
75413312|NCT03029676|Drug|opioid|analgetic, sedative
75413313|NCT03029676|Procedure|spinal anesthesia|
75413314|NCT03029520|Other|Root canal obturation with iRoot SP sealer|Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
75413315|NCT03029520|Other|Root canal obturation with AH Plus Sealer|Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
75413316|NCT03029130|Device|Catheter extension|Foley transurethral catheter placed to allow continuous drainage of urine.
75413317|NCT03029052|Behavioral|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
75413318|NCT04270344|Drug|Pitavastatin 4mg|combination therapy with pitavastatin/valsartan (LivaloV)
75413319|NCT04279548|Device|Deep Brain Stimulation|Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
75413320|NCT04270032|Diagnostic Test|ABUS and HHUS|Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images
75413321|NCT04277910|Drug|MT2004|MT2004 oral capsules
75413322|NCT04277910|Drug|Placebo|Placebo oral capsules
75714959|NCT00892827|Drug|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
76041779|NCT02596009|Device|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
76041780|NCT02590939|Device|CEFALY Active|Active external trigeminal nerve stimulation
76041781|NCT02590939|Device|CEFALY Placebo|Placebo external trigeminal nerve stimulation
76041782|NCT04793503|Other|conventional complete denture|the complete denture constructed by packing technique
76041783|NCT04793503|Other|CADCAM 3D printed denture|The files from the laser-scan will be translated into stereolithography (STL) files and the CDs are virtually designed in ExoCad software
75413323|NCT04275570|Behavioral|Motivational interview|The motivational interview is integrated in a structural theoretical mark. This method is a person-centered counseling style that increases the intrinsic motivation of the patient to behavioral changes through spirit, acceptance, compassion and evocation.
75413324|NCT04278846|Drug|Depofoam bupivacaine|The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
75413325|NCT04278846|Drug|Bupivacaine hydrochloride (HCl)|The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
75556347|NCT03960840|Drug|Ibrutinib|Tablets or capsules for oral daily use
75714960|NCT00766896|Drug|Aspirin (platelet sensitive versus platelet hyperreactivity)|"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."
75714961|NCT00889941|Procedure|LASIK|laser-assisted in situ keratomileusis
75714962|NCT00766974|Device|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
76041784|NCT04793503|Other|CAD/CAM milled denture|Once the complete denture has been virtually designed in CAD software (ExoCad software) a preview will be sent for evaluation using 3D viewing software
76041785|NCT04793113|Other|FreshlyFit Meals|FreshlyFit meals are low carbohydrate, high protein meals
75413326|NCT04277988|Device|Ultrasonography|Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
75413327|NCT03832374|Other|Descriptive|
75413328|NCT03838770|Device|Active tDCS|Active target 2.0mA tDCS (n=60)
75413329|NCT03838770|Device|sham tDCS|sham left-anodal dorsolateral prefrontal cortex (DLFPC) montage
75413330|NCT03839862|Drug|TNF-inhibition|Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
75556348|NCT03960372|Behavioral|ICT activities|Public education activities using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
75556349|NCT03954574|Diagnostic Test|assessment of pulmonary hemodynamics during exercise by right heart catheterization|all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
75556350|NCT03945773|Drug|Cabozantinib|Oral tablets of 60mg, 40mg and 20 mg.
76041786|NCT04813471|Drug|Endothelial Protocol|Endothelial Protocol
76041787|NCT04813393|Other|Questionnaire Development|To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
76041788|NCT04803175|Drug|Sacubitril-Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
75413331|NCT03839550|Combination Product|Apatinib Mesylate +SHR-1210|"Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection."
75413332|NCT03839550|Procedure|Hepatic Arterial Infusion(HAI)|Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
75413333|NCT03839160|Procedure|Serratus anterior plane block|Serratus anterior plane block was applied in Group S. It was performed at the end of the operation following the skin closure, while the patient lay on his side with his arm above the head. After proper site cleaning, the first and second ribs were identified with a linear probe in the midclavicular line. The USG probe was advanced caudally in the sagittal plane, and the fourth and fifth ribs were visualized. The USG probe was then directed posteriorly and the serratus, latissimus dorsi and intercostal muscles were visualized. Bupivacaine 0.25% 30 mL was administered to the lower plane of the serratus muscle through an inserted catheter under the guidance of USG through the in-line technique. Afterwards, 0.12% bupivacaine hydrochloride was maintained at the rate of 0.1ml/kg/hr.
75413334|NCT03839160|Drug|Intravenous patient-controlled-analgesia morphine|Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
75556351|NCT03944304|Drug|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
75556352|NCT03934684|Drug|Drug: Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~Carfilzomib will be administered as a 30-minute infusion.~Dexamethasone will be taken by mouth or intravenously."
75556353|NCT03934684|Drug|Drug: Carfilzomib + Lenalidomide + Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~Carfilzomib will be administered as a 10 minute infusion.~Lenalidomide will be taken orally.~Dexamethasone will be taken by mouth or intravenously."
75714963|NCT00766974|Device|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
75714964|NCT00890019|Biological|AdCh63 ME-TRAP|"A:Intradermal injection 1x10^8 vp at day 0~A:Intradermal injection 1x10^9 vp at day 0~A:Intradermal injection 1x10^10 vp at day 0~A:Intradermal injection 5x10^10 vp at day 0~5:Intramuscular injection 1x10^10 vp at day 0~6A:Intramuscular injection 5x10^10 vp at day 0~7A: Intramuscular injection 2x10^11 vp at day 0"
75714965|NCT00890019|Biological|AdCh63 ME-TRAP; MVA ME-TRAP|"B: AdCh63 ME-TRAP intradermally at dose of 1x10^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 1x10^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 1x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)"
75714966|NCT00973726|Other|Glucose test|Subjects ingest an oral glucose tolerance test.
75872961|NCT05212506|Biological|vaccinated and unvaccinated|the vaccinated :Male patients who received more than 2 injections of the covid-19 vaccine;the unvaccinated :Male patients who did not receive the covid-19 vaccine
76041789|NCT04803175|Drug|Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
76041790|NCT04793347|Device|shock master (shock waves device)|device produces shock waves
76041791|NCT04793425|Behavioral|Mobile application (afterAMI)|"The rehabilitation process of the patients in the intervention group will be supported by the mobile application (afterAMI) with synchronized, dedicated web page.~Patients in the intervention group will be given an access to educational data regarding their individualized diseases. Additionally every patient will receive regularly messages with notifications regarding lifestyle and adherence to the therapy. All reported vital signs (blood pressure, heart rate, weight and many more) will be analyzed every day and in case of need a short message will be sent to the patient with indication to go to the primary healthcare clinic/hospital.~Additionally, application will send notifications with reminders to take drugs."
75556354|NCT03932201|Drug|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
75556355|NCT03927768|Diagnostic Test|Predictive Model|Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
75413335|NCT03839238|Biological|hESC derived MSC like cell|Different dosage of hESC derived MSC like cell for the meniscus injured patients
75556356|NCT03927768|Diagnostic Test|Breast Imagers|Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
75556357|NCT03914326|Drug|Semaglutide|Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
75556358|NCT03914326|Drug|Placebo (semaglutide)|Placebo tablets to be taken with water at the same time every morning in a fasting state
75556359|NCT03912207|Biological|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
75556360|NCT03912207|Other|Saline placebo|Saline is a routinely used placebo.
75714967|NCT00763620|Device|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
75714968|NCT00973804|Drug|EPOCH-F/R|
75714969|NCT00973804|Drug|FLAG|
75556361|NCT03901963|Drug|Daratumumab|Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
75556362|NCT03901963|Drug|Lenalidomide|Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
75556363|NCT03899467|Drug|GT0918|anti-tumor activity
75556364|NCT03899402|Drug|Insulin|Standard of care insulin for pump or injection and serves as a control
75714970|NCT00973804|Drug|Transplant Preparative Regimen (Flu/Cy/Mes)|
75714971|NCT00973804|Drug|GVHD Prophylaxis (tacrolimus and sirolimus)|
75714972|NCT00973804|Procedure|Double Cord Blood Transplantation|
75714973|NCT04018131|Drug|Cimetidine|Antihistamine 2 antagonist
75714974|NCT04018131|Drug|Placebos|Placebo drug
75714975|NCT00767052|Drug|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
75714976|NCT00767052|Drug|Placebo|Placebo tablet matching to the active in multiple dose part.
75714977|NCT00767052|Drug|AZD1236|75mg single dose will be administered in relative bioavailability part.
75714978|NCT00767052|Drug|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
75413336|NCT03838926|Drug|Trichostatin A|Intravenous Infusion
75413337|NCT03839004|Behavioral|Integrated approach to pregnancy|Yoga classes, mindfulness classes, coaching, nutrition counselling and osteopathy
75556365|NCT03899402|Drug|Semaglutide|Injectable weekly GLP-1RA given as open label experimental drug
75714979|NCT00973882|Drug|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
76041792|NCT04351087|Device|Platelet Rich Plasma|"Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance."
75556366|NCT03899402|Drug|Dapagliflozin|Oral daily SGLT2 Inhibitor given as experimental drug
75556367|NCT03899402|Drug|Placebo to Dapagliflozin|Placebo to Dapagliflozin given as a control to the experimental drug
75556368|NCT03885531|Device|Total knee arthroplasty with Journey II CR Total Knee System|TKA with Journey II CR Total Knee System
75556369|NCT03880019|Procedure|Computed Tomography|Undergo CT
75556370|NCT03880019|Procedure|Core Biopsy|Undergo tumor biopsy
75413338|NCT03838380|Other|Smartphone application|Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
75413339|NCT03838614|Behavioral|Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)|The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
75413340|NCT03838614|Behavioral|Rhythmical auditory stimulation gait training (RAS)|The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
75413341|NCT03838614|Behavioral|Muscle power training (MPT)|The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
75556371|NCT03880019|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556372|NCT03880019|Drug|Olaparib|Given PO
75556373|NCT03880019|Drug|Temozolomide|Given PO
75556374|NCT03876769|Biological|CTL019|"Based on the subject's weight, one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
75556375|NCT03864419|Biological|Rituximab and Hyaluronidase Human|Given SC
75556376|NCT03864419|Drug|Cyclophosphamide|Given IV
76041793|NCT04803253|Device|ORTHOPUS prosthetic accessory: 0109 - Universal Wrist|"The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools)."
76041794|NCT04803253|Device|ORTHOPUS prosthetic terminal device: 0112 - Hook|The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.
75556377|NCT03864419|Drug|Vincristine|Given IV
75556378|NCT03864419|Drug|Methotrexate|Given IV
75556379|NCT03864419|Drug|Doxorubicin|Given IV
75556380|NCT03864419|Drug|Doxorubicin Hydrochloride|Given IV
75556381|NCT03864419|Drug|Prednisone|Given PO
75556382|NCT03864419|Drug|Etoposide|Given IV
75556383|NCT03864419|Biological|Rituximab|Given IV
75556384|NCT03850795|Drug|HC-1119|oral once daily 80 mg
75556385|NCT03850795|Drug|Enzalutamide|oral once daily 160 mg
75556386|NCT03847844|Biological|Umbilical cord derived mesenchymal stem cell|Umbilical cord derived mesenchymal stem cell
75556387|NCT03847844|Other|Placebo|Normal saline
75556388|NCT03842189|Drug|M281|Participants will receive once weekly intravenous (IV) infusions of M281
75556389|NCT03829111|Drug|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
75556390|NCT03829111|Biological|Ipilimumab|Given IV
75556391|NCT03829111|Biological|Nivolumab|Given IV
75714980|NCT00973882|Drug|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
75714981|NCT02558322|Other|Primary medical care|All study participants receive primary care as usual in the respective region
75714982|NCT03666819|Device|Carbon Dioxide Fractional Laser|Undergo CO2RE laser therapy
76041795|NCT04803253|Device|ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand|The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.
75413342|NCT03838614|Other|Controls|Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
76041796|NCT04803253|Device|ORTHOPUS prosthetic accessory: 0104 - body powered harness|The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
75413343|NCT03838224|Other|dry needling|"Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves. The needle will be moved up and down within the muscle, using a fast-in and fast-out technique. Needle insertions will be repeated 12 times."
76041797|NCT04792723|Drug|Sublingual aspirin|Vita Green Health Products sublingual aspirin 80 mg tablet
75413344|NCT03838224|Other|Sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
76041798|NCT04792723|Drug|Oral aspirin|Synco (HK) oral aspirin 80mg tablet
75413345|NCT03838302|Procedure|Transvaginal tissue retrieval via a posterior colpotomy|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
75556392|NCT03828227|Drug|OPTIMOX-bevacizumab|"Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks [q2w]),~Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~Bevacizumab: 5 mg/kg IV (day 1, q2w),~FA: 400 mg/m² IV/2h (day 1, q2w),~5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~No 5-FU bolus"
75556393|NCT03828227|Drug|Capecitabine plus bevacizumab|"Bevacizumab: 7.5 mg/kg intravenous infusion [IV] (day 1; q3w),~Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w)."
75556394|NCT03822897|Radiation|Radiation|"35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy"
75556395|NCT03822897|Drug|Cisplatin|100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
75556396|NCT03819049|Biological|ExPEC10V|Participants will receive a single IM injection of ExPEC10V (1 of 3 doses [low or medium or high]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
75556397|NCT03819049|Biological|ExPEC4V|Participants will receive a single IM injection of ExPEC4V on Day 1.
75556398|NCT03819049|Biological|Prevnar 13|Participants will receive a single IM injection of Prevnar 13 on Day 1.
75556399|NCT03819049|Biological|Placebo|Participants will receive single IM injection of matching placebo on Day 1.
75714983|NCT03666819|Other|Questionnaire Administration|Ancillary studies
75714984|NCT05278455|Behavioral|Lifestyle Medicine|A smartphone-delivered application with a series of lifestyle medicine components, including lifestyle psychoeducational, physical activity, dietary recommendations, stress management, sleep management, and motivation and goal-setting techniques.
76041799|NCT04813081|Procedure|Free Gingival Graft|In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.
75413346|NCT03838302|Procedure|Transabdominal retrieval via trocar|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
75413347|NCT03837834|Other|Functional Electrical Stimulation Leg Cycling Exercise|FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.
75556400|NCT03818035|Drug|Guselkumab|Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
75413348|NCT03837210|Drug|Pylorin|Poly Herbal formulation
75413349|NCT03837288|Procedure|Cerclage|Cervical cerclage under effect of spinal anaesthesia
75413350|NCT03837366|Behavioral|Activity tracker and health coaching|Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.
75413351|NCT03837054|Biological|Blood collection and Micronuclei assay on binucleate lymphocytes in culture|"The activity of the oncology Department of the North Hospital ensures the quick and easy recruitment of 30 patients over the 10-month inclusion period. The collection of samples will be done in a forward-looking manner during chemotherapy and at different times. The patients will have 4 blood samples of 10 mL carried out during their chemotherapy with a sampling at T0 (before the initiation of chemotherapy), then to T1 (after the first 3 cures), to T2 (after the 6th cure) and to T3 is 5 weeks after the end of the chemo And before the onset of radiation therapy. The samples will be carried out within the Medical Oncology Department of the hospital Nord of Marseille.~We will also perform micronuclei testing on Binucleate lymphocytes in culture. The lymphocyte Micronuclei test reveals structure and number chromosomal damage and allows to reveal clastogenic or eugènes exposures."
75556401|NCT03818035|Drug|Placebo Injection|Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
75556402|NCT03809793|Other|Exercise Program|12-week walking based intervention (3 sessions per week)
75556403|NCT03809793|Diagnostic Test|DXA|Participants will undergo an assessment of body composition (DXA)
76041800|NCT04427215|Other|Complementary and alternative medicines|Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
76041801|NCT04813237|Other|n a|the participants are not subjected to any type of intervention
76041802|NCT04427449|Biological|CD44v6-specific CAR gene-engineered T cells|4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10^6 cells/kg body weight
76041803|NCT04803487|Other|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.
76041804|NCT04803487|Other|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the da Vinci surgical robot.
76041805|NCT04803097|Diagnostic Test||We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
76041806|NCT05616169|Device|Easy Flype/EasyHiFlype|Patients with stenosis or occlusion of the iliac artery, femoral artery and first third of the popliteal artery, implanted with at least one study device, the Easy Flype or the Easy Hi Flype.
76041807|NCT04812769|Device|eCARE-ID|The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel
76041808|NCT04812769|Other|Standard of Care|Standard of care will be delivered to the control home.
76041809|NCT04792333|Drug|firibastat|Single oral dose of 500 mg administration on Day 1
75413352|NCT03836742|Procedure|Hemofiltration with regional citrate anticoagulation|To reduce risk of metabolic alkalosis during hemofiltration treatment, ACD-A citrate solution was proposed instead of most commonly used trisodium citrate solution and relatively low target citrate concentration (2.8 mmol/L) was adopted. In case of pH increase above 7.5 or bicarbonate concentration above 40 mmol/L filtrate flow was decreased from initial 35 ml/kg/hour down to 25 ml/kg/hour which reduced bicarbonate delivery by 25%. If metabolic alkalosis persisted, the second step involved reduction of blood flow from initial 5 times down to 4 times filtrate flow, which reduced citrate flow by the same factor.
75556404|NCT03809793|Diagnostic Test|MRI|used to measure fat stored in the liver
75714985|NCT02558088|Drug|Salmeterol|
75714986|NCT05279482|Other|observation for outcome of methylprednisolone dose|no intervention as it is retrospective study for outcome
75714987|NCT00890175|Drug|Inhaled loxapine @ 0 & 10 h|10 mg, 2 doses, 10 hours apart
76041810|NCT04803019|Combination Product|DEB-TACE|"The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F).~TANDEM® embozene microspheres are available in three different sizes, in 2 ml and 3 ml volumes of product and are supplied in preloaded vials and syringes.The maximum loadable amount on the hydrospheres 50 mg of Doxorubicina for ml. The maximum injectable dose of Doxorubicin for each treatment is 150 mg and therefore the maximum amount of microspheres that can be used for each treatment is 3 ml. The size of microspheres that will be used in this study is up to 100 ± 25 μm."
75413353|NCT03836898|Device|Presbyopic posterior chamber phakic intraocular lens IPCL|Presbyopic posterior chamber phakic intraocular lens IPCL (EyeolUK, United Kingdom) has a refractive optic and diffractive trifocal pattern on its anterior optical surface to correct both distance and near refractive errors. Presbyopic addition is manufactured in a range of +1.0 to + 4.0 diopters (D) in 0.5 D steps.
75556405|NCT03809793|Diagnostic Test|Hyperinsulinaemic Euglycaemic Clamp|Participants will arrive at the laboratory after an overnight fast (>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
75714988|NCT00890175|Drug|Inhaled placebo @ 2 & 10 hours|placebo, 2 doses, 10 hours apart
75556406|NCT03809793|Diagnostic Test|VO2 Max|Assessment of maximum aerobic capacity.
75556407|NCT03809793|Diagnostic Test|Continuous Glucose Monitor|CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
75556408|NCT03809793|Procedure|Muscle Biopsies|Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
75714989|NCT00966472|Drug|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
75556409|NCT03809793|Drug|Acipimox 250 MG|Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
75556410|NCT03804892|Diagnostic Test|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
75556411|NCT03804892|Diagnostic Test|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
75556412|NCT03804892|Diagnostic Test|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
75556413|NCT03804892|Other|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
75714990|NCT00767208|Other|oral glucose load|oral ingestion of 13C labeled glucose
75714991|NCT00892983|Behavioral|FAB|Standard well child care plus 7 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, and 3, 4, 7, 9, 13, and 18 months post-partum.
75872962|NCT03012789|Procedure|Surgery|Surgical excision
75872963|NCT02966301|Drug|Arsenic Trioxide Injectable Solution|"Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).~Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.~The study duration will be 2 years (12 months recruitment + 12 months follow-up)."
75413354|NCT03836118|Procedure|Homologous intrauterine insemination (IUI)|"Patients were treated with HMG/rFSH according to classic protocols of therapy and monitoring. An injection of uHCG 5000 IU/ rHCG 250 mg was given to trigger ovulation. On the day of insemination, the semen sample was obtained through masturbation after a 2-5 day abstinence period and collected in a sterile cup. TMSC was determined by multiplying grade A or grade A + B sperm motility percentages by sperm volume and concentration. To evaluate sperm viability Eosin and Nigrosin (E&N) staining was carried out according to WHO standards. Sperm capacitation was performed using density gradient centrifugation or swim-up procedure in order to remove seminal fluids and enhance sperm quality for IUI.~IUI was performed a t36 hours post-HCG. A fraction of the washed motile spermatozoa was inserted up to the uterine fundus and expelled into the uterine cavity. Daily treatment with micronized progesterone was prescribed for 14 days after IUI. Serum ß-HCG was determined 14 days after IUI."
75413355|NCT03836274|Dietary Supplement|AYMES MONACO|AYMES MONACO is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
75556414|NCT03804892|Other|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
75556415|NCT03798093|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
75556416|NCT03798093|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
75556417|NCT03794921|Other|Every Step Counts|Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
75556418|NCT03789669|Device|Cheetah femtosecond laser and Cheetah patient interface|Ophthalmic laser surgical system
75556419|NCT03789669|Device|IntraLase iFS iFS femtosecond laser and patient interface|Commercial ophthalmic laser surgical system
75556420|NCT03789669|Device|Cheetah femtosecond laser and cheetah patient interface|Ophthalmic laser surgical system
75556421|NCT03783871|Device|Microwave ablation|Subjects will be treated with microwave ablation.
75556422|NCT03767244|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
75556423|NCT03767244|Drug|Androgen Deprivation Therapy (ADT)|Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter [ng/dL]).
75556424|NCT03767244|Drug|Placebo|Participants will receive matching placebo oral tablets daily.
75556425|NCT03758742|Behavioral|High-Fruit Diet|Participants will consume a diet rich in whole fruit. During Phase I (Weeks 1-4; supervised controlled feeding), participants will gradually increase the amount of whole fruit they consume, eventually reaching 50% of calories from whole fruit. In Phase II (Week 5-12; supervised controlled feeding), participants will consume a whole fruit-rich, eucaloric diet that provides 50% of calories in the form of whole fruit. The non-fruit portion of the diet will be styled as a Mediterranean Diet. Participants will be required to approximately keep their weight stable during Phases I and II. In the Follow-Up Phase (Months 4-12; free-living), participants will be instructed to continue consuming at least one-third of their diet as whole fruit and to make healthy food choices.
75556426|NCT03755128|Other|No intervention|No investigational drugs will be administered as part of the study
75556427|NCT03750227|Procedure|Conventional Surgery|Undergo surgery
75556428|NCT03750227|Other|Quality-of-Life Assessment|Ancillary studies
75556429|NCT03750227|Other|Questionnaire Administration|Ancillary studies
75556430|NCT03750227|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
75556431|NCT03749057|Drug|Rivaroxaban|Rivaroxaban 15-20 mg daily
75556432|NCT03748641|Drug|Niraparib|Participants will receive niraparib 200 mg capsules once daily.
75556433|NCT03748641|Drug|Abiraterone Acetate|Participants will receive AA 1000 mg tablets once daily.
75556434|NCT03748641|Drug|Prednisone|Participants will receive prednisone 10 mg tablets daily.
75556435|NCT03748641|Drug|Placebo|Participants will receive matching placebo once daily.
75556436|NCT03748641|Drug|New Formulation of Niraparib and Abiraterone Acetate (AA)|Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
76041811|NCT04803019|Device|TAE|"The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F). This medical device is available in various sizes; in this study, to avoid that the particle size exceeds the one used for the treatment of arm A, it will be possible to use microspheres with dimensions up to 100 μm (range 75 ± 125 μm).~Embozene microspheres are offered in vials containing 1 ml of suspended product in physiological saline solution for apyrogenic sterile transport. The total volume of the Embozene microspheres, including the transport solution, is about 7 ml. To this product it is necessary to add an appropriate amount of non-ionic contrast medium in order to obtain a homogeneous suspension and with good visibility during the injection under fluoroscopy."
75556437|NCT03744104|Biological|Quadrivalent influenza vaccine|0.5 mL, intramuscular, one dose
76041812|NCT04802785|Drug|Citicoline|Citicoline 500 mg (Vitaae®) per os
75413356|NCT03835962|Device|NeuroCatch™ Platform|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
75413357|NCT03835806|Other|Elastikon|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.
75556438|NCT03744104|Biological|Trivalent influenza vaccine A|0.5 mL, intramuscular, one dose
75556439|NCT03744104|Biological|Trivalent influenza vaccine B|0.5 mL, intramuscular, one dose
75413358|NCT03835806|Other|Rocktape|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.
75413359|NCT03835572|Other|CircaHealth: a course on circadian rhythms and health|Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.
75413360|NCT03835572|Other|Sleep hygiene materials|Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
75556440|NCT03737994|Drug|Alectinib|Given PO
75556441|NCT03737994|Drug|Brigatinib|Given PO
75556442|NCT03737994|Drug|Carboplatin|Given IV
75556443|NCT03737994|Drug|Ceritinib|Given PO
75556444|NCT03737994|Drug|Cisplatin|Given IV
75556445|NCT03737994|Drug|Crizotinib|Given PO
75556446|NCT03737994|Drug|Ensartinib|Given PO
75556447|NCT03737994|Drug|Lorlatinib|Given PO
75556448|NCT03737994|Drug|Pemetrexed|Given IV
75556449|NCT03736304|Device|AKI alert|An AKI alert will send to the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
75556450|NCT03736304|Other|Usual care|Patients will receive standard clinical care by the doctor in charge.
75556451|NCT03729999|Device|Portable, Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
75556452|NCT03706482|Biological|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
75556453|NCT03698019|Procedure|Biospecimen Collection|Undergo collection of blood
75556454|NCT03698019|Procedure|Computed Tomography|Undergo CT
75556455|NCT03698019|Procedure|Magnetic Resonance Imaging|Undergo MRI
75714992|NCT00892983|Behavioral|Sleep|"Standard well child care plus 2 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), and sleep problem prevention at 3 weeks. A sleep problem intervention starting at 6 months was possible for those indicating their child had a sleep problem at 6 months of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying."
75714993|NCT00760422|Device|NIR|Thermometer
75714994|NCT00890253|Drug|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
75714995|NCT00890253|Drug|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
76041813|NCT04802785|Drug|Cytochrome C6|Cytochrome10 mg per os
76041814|NCT04802785|Drug|Sodium Chloride Oral Product|Sodium Chloride (NaCl) 2.6 g. per os
75413361|NCT03835494|Other|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
75413362|NCT03835104|Device|CRP point-of-care testing|CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
75556456|NCT03698019|Biological|Pembrolizumab|Given IV
75556457|NCT03698019|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75556458|NCT03685578|Device|EmboTrap® Revascularization Device|EmboTrap® Revascularization Device
75556459|NCT03685578|Device|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
76041815|NCT04802785|Drug|Potassium Chloride Oral Product|Potassium Chloride 1.5 g per os
76041816|NCT04802785|Drug|Sodium Citrate Oral Product|Sodium Citrate 2.90 g per os
76041817|NCT04802785|Drug|Dextrose Oral Tablet, Chewable|Dextrose 13.5 g per os
75413363|NCT03834636|Procedure|Restorations with nanoparticulated composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanoparticulated composite (Z350, 3M ESPE)
75413364|NCT03834636|Procedure|Restorations with nanoparticulated composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanoparticulated composite (Z350, 3M ESPE)
75556460|NCT03685175|Drug|Formal study using hyperpolarized 13C-pyruvate injection|Administration at two visits 1) after completion of cardiotoxic therapy and 2) 1 to 6 months after the first time point following medical therapy (SOC)
75556461|NCT03685175|Drug|Feasible study using hyperpolarized 13C-pyruvate injection|Administration at two visits: 1) baseline MRI before administration of cardiotoxic therapy and 2) after completion of cardiotoxic therapy
75413365|NCT03834636|Procedure|Restorations with nanohybrid composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
75413366|NCT03834636|Procedure|Restorations with nanohybrid composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
75556462|NCT03674112|Drug|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).
75556463|NCT03674112|Drug|Pertuzumab IV|Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
75556464|NCT03674112|Drug|Trastuzumab IV|Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
75556465|NCT03673501|Drug|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
75556466|NCT03673501|Drug|Sunitinib|Oral receptor tyrosine kinase (RTK) inhibitor
75556467|NCT03668340|Drug|AZD1775|AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
75714996|NCT00890253|Drug|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
76041818|NCT04802785|Drug|Domperidone Oral Product|Domperidone 1 tablet per os
75714997|NCT00890253|Drug|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
75714998|NCT00760500|Other|Nasopharyngeal Swab|Nasopharyngeal Swab
76041819|NCT04802785|Drug|Simethicone|3-4 capsules per os
76041820|NCT04802785|Drug|Acetylsalicylic acid|Acetylsalicylic acid 150 mg per os
76041821|NCT04802785|Drug|Magnesium hydroxide|magnesium hydroxide 30 mg per os
76041822|NCT04802785|Drug|Probiotic Formula|1 capsule per os.
76041823|NCT04802785|Drug|Melatonin 5 mg|Melatonin 5 mg per os.
76041824|NCT04802941|Device|Neoadjuvant Chemotherapy by CDSS (MedicBK)|CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.
75413367|NCT03834480|Other|Ultrasound guided Sacroiliac intra-articular injection|At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
75714999|NCT00545818|Device|OsseoSpeed™ length 6 mm|OsseoSpeed™ dental implant, length: 6 mm
75872964|NCT03262623|Other|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
76041825|NCT04802941|Drug|General practice|General practice
75413368|NCT03834558|Other|Mixed exercise program|"A progressive program of high intensity strength and myofascial conditioning will be carried out in 2 non-consecutive weekly sessions (24 weeks). Each session will include:~A) Warm up on a cycle ergometer~B) Strength circuit: 6 exercises will be included to strengthen different muscle groups (2 in the upper extremities, 2 in the trunk and 2 in the lower extremities). 3 sets of 10-15 repetitions until the failure. The load will be set to 70% of 1 maximal resistance.~C) Self-myofascial conditioning: 10 repetitions, in the direction of the fibres of each muscle group, with different materials. 7 muscle groups will be worked (quadriceps, hamstrings, abductors, gluteus, pectoralis, full back and trapezius).~D) At the end, static stretches will be performed"
75413369|NCT03834324|Device|FES|Functional Electrical Stimulation during cycling with Virtual Reality Feedback
75413370|NCT03834012|Drug|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 µg HFA per day
75413371|NCT03834012|Drug|Placebo|Intervention: Drug: placebo
75413372|NCT03834012|Drug|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg HFA per day
75413373|NCT03834012|Drug|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day
75556468|NCT03661840|Behavioral|Acceptance and Commitment Therapy|Intervention group participants will attend eight weekly, 90-minute, in person, group-based ACT sessions. Groups will be initiated with no more than 10 participants and no fewer than 6 participants. Sessions will include key theoretical ACT constructs and strategies as they relate to chronic pain. A licensed clinical psychologist or licensed clinical social worker trained in ACT will facilitate all sessions. Participants in the ACT intervention group will also continue to receive medication management and other behavioral management interventions that they would get as usual treatment.
75715000|NCT00545818|Device|OsseoSpeed™ length 11 mm|OsseoSpeed™ dental implant, length: 11 mm
75715001|NCT00674154|Drug|Cholecalciferol|2800 IE daily in 52 weeks
75715002|NCT00974038|Behavioral|psychotherapy|1) cognitive-behavioral therapy or 2) supportive psychotherapy
75715003|NCT00967954|Drug|antiandrogen therapy|
75715004|NCT00967954|Drug|releasing hormone agonist therapy|
75872965|NCT03262623|Other|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
75413374|NCT03834090|Device|rESWT|rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.
75715005|NCT00967954|Genetic|DNA analysis|
75715006|NCT00967954|Genetic|RNA analysis|
75715007|NCT00967954|Genetic|comparative genomic hybridization|
75715008|NCT00967954|Genetic|gene expression analysis|
75715009|NCT00967954|Other|laboratory biomarker analysis|
75715010|NCT00967954|Procedure|diffusion-weighted magnetic resonance imaging|
75872966|NCT05759169|Other|Foot Bath Tub|A foot bath is generally a form of rest and care where feet are put in water. Feet are body areas where fatigue is most felt as organs that carry the body's total weight. This study uses a specially designed foot bath bath bath bath to give the patients in the experimental group foot bath. The cuvette has four-stage water heating (35-45°C). It has a magnetic field and operates at 390 Watts. It has a splash guard. The sole features non-slip rubber feet. It has a heat shield feature because it has a double wall construction for heat isolation.
75872967|NCT03107091|Drug|Terlipressin acetate continuous infusion|Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
76041826|NCT02598193|Drug|Nintedanib|Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
76041827|NCT02598193|Drug|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
76041828|NCT04791631|Procedure|Epiretinal membrane surgery|Surgery for epiretinal membrane i.e. standard 3-port pars plana vitrectomy and epiretinal membrane and internal limiting membrane peel. Phakic patients will undergo cataract surgery.
75872968|NCT03849768|Drug|HS-10296|Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
75872969|NCT03849768|Drug|Gefitinib|Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
75413375|NCT03834090|Other|Supervised exercises|A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
75413376|NCT03833466|Drug|metformin and chemotherapy|"Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle."
75413377|NCT03833388|Drug|TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
75556469|NCT03661840|Other|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management. This includes continued medication management for cancer related chronic pain by prescribing providers, and access to supportive oncology services. It may also include other behavioral pain management such as physical therapy, acupuncture, or massage.
75556470|NCT03654547|Drug|TT-00420|"TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg."
75556471|NCT03650764|Drug|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
75556472|NCT03650764|Drug|Pembrolizumab|Pembrolizumab is commercially available
75413378|NCT03833388|Drug|Placebo to TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
75413379|NCT03833310|Diagnostic Test|Osteoprotegerin marker in serum in inflammatory bowel disease|I will measure Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand markers in serum of patient with inflammatory bowel disease
75413380|NCT03832608|Other|No intervention|There is not intervention to be administered, only collection of data through various tests and questionnaires.
75872970|NCT03189693|Other|PVB|nerve stimulator-guided PVB will be performed at two levels
75872971|NCT03189693|Other|Placebo|nerve stimulator-guided PVB containing placebo will be performed at two levels
75872972|NCT03189693|Other|GA|All patients will receive general anesthesia.
75872973|NCT03189693|Other|Anesthetic injections|4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
75872974|NCT03065400|Drug|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
75413381|NCT03830658|Behavioral|Structured Intervention on Self-care with AVF (SISC-AVF)|"Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions."
75556473|NCT03650764|Other|EORTC QLQ-30|-Screening, start of cycle 2, start of cycle 5
75556474|NCT03650764|Other|FACT H&N|-Screening, start of cycle 2, start of cycle 5
75872975|NCT05200065|Procedure|Thulium laser enucleation of the prostate|Using the thulium laser to achieve complete endoscopic enucleation of the prostate.
75872976|NCT05200065|Procedure|Bipolar enucleation of the prostate|Using the bipolar plasma energy to achieve complete endoscopic enucleation of the prostate.
75872977|NCT05734989|Diagnostic Test|BP|Blood pressure measurements and HbA1c tests will be conducted to identify participants with or at risk for high blood pressure and/or Type 2 Diabetes. Those identified will be referred to PCP for follow up/treatment.
75556475|NCT03650764|Procedure|Peripheral blood|-Baseline
75556476|NCT03644485|Drug|Tacrolimus immediate-release formulation|oral
75556477|NCT03644485|Drug|Tacrolimus prolonged-release formulation|oral
75872978|NCT05734989|Diagnostic Test|HbA1c|HbA1c will screen to identify patients with Type 2 diabetes
75872979|NCT05734989|Behavioral|PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD|Guidelines will be developed and provided to PCPs to use with their Hispanic/Latinx patients with or at risk for CKD.
75413382|NCT03830580|Other|Positive stimulation (singing)|A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
75413383|NCT03830424|Procedure|Pain stimulus|Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure
75413384|NCT03830424|Dietary Supplement|Non-pharmacological pain relief|Administration of sucrose/mother milk during pain stimulus
75413385|NCT03830346|Other|Instrument-assisted|instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).
75413386|NCT03830112|Behavioral|Pilates exercise with Theraband|The experimental group will perform all the exercises with Theraband® in the same manner than active comparator group.
75413387|NCT03830112|Behavioral|Pilates exercise|The active comparator group will perform all the exercises without Theraband®
75413388|NCT03830034|Drug|Amino Acid chelated iron tab 15 mg|"Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins & milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline & then 4, 8 & 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
75556478|NCT03644485|Drug|Induction therapy|All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
75556479|NCT03644485|Drug|Mycophenolic acid drugs|All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
75556480|NCT03644485|Drug|Corticosteroids|All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
75556481|NCT03642639|Device|MICRUSFRAME and GALAXY coils|MICRUSFRAME and GALAXY Coils
75556482|NCT03641092|Behavioral|CenteringParenting Intervention|The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.
75556483|NCT03641092|Behavioral|Routine Well Child Care|The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site [when recruited families will be ineligible for CenteringParenting groups that will start in control sites]. They will receive anticipatory guidance and handouts that are standard for the clinic.
75715011|NCT00967954|Procedure|magnetic resonance spectroscopic imaging|
75413389|NCT03830034|Drug|Ferrous Fumarate tab 350 mg( 115 mg elemental iron)|"75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins & milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline & then 4, 8 & 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
75872980|NCT05212350|Procedure|Total pancreatectomy|Patients randomized to receive total pancreatectomy at the time of transection of the pancreas will undergo completion total pancreatectomy according to each Institution's operative standards.
76041829|NCT04791397|Procedure|Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
76041830|NCT04791397|Procedure|Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
76041831|NCT04802239|Other|Medical hypnosis group|"Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~State of calm at rest of 3 minutes.~Hypnotic induction by catalepsy of the eyes guided by breathing.~The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques."
75556484|NCT03631940|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
75413390|NCT03837132|Behavioral|Palliative care assessment|Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
75872981|NCT05212350|Procedure|Pancreatic anastomosis|Patients randomized to receive pancreatic anastomosis at the time of transection of the pancreas will undergo pancreatico-jejunosomy or pancreatico-gastrostomy according to each Institution's operative standards.
75872982|NCT04165863|Procedure|total knee replacement surgery|total knee replacement surgery
76041832|NCT04802239|Other|calm wake group|healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
76041833|NCT04802551|Other|Sensory integration therapy|Sensory integration disorder is defined as the inability of a person to use the information he / she receives through his / her senses properly in order to continue his daily life properly. Intervention group have some therapy sessions which include sensory integration therapy exercises.
76041834|NCT02595073|Drug|DSXS|Active treatment
76041835|NCT02595073|Drug|Placebo|Placebo treatment
76041836|NCT04791007|Drug|OB-002|vaginal or rectal administration
76041837|NCT04791007|Drug|Placebo|vaginal or rectal administration
76041838|NCT04802083|Biological|Eculizumab|Eculizumab 900-1200 mg will be administered intravenously.
76041839|NCT02593825|Behavioral|START-Play intervention|The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.
76041840|NCT02593825|Behavioral|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
75413391|NCT03832062|Other|Leftover surgical tissue homogenization|Leftover surgical tissue homogenization
75413392|NCT03831360|Behavioral|Yoga|Hatha yoga for depressed adolescents
75413393|NCT03831360|Behavioral|Group CBT|Group cognitive behavioral therapy for depressed adolescents
75413394|NCT03838068|Biological|Biodentine|Biodentine is considered a calcium silicate cement
75413395|NCT03838068|Biological|mineral trioxide aggregate|calcium based silicate cement
75413396|NCT03838068|Procedure|cervical pulpotomy|coronal pulp tissue was removed till the orifice
75556485|NCT03631940|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
75556486|NCT03625986|Other|Nicotine-Containing Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The experimental group in this project will receive a SREC device with liquid containing 58 mg/mL of nicotine."
75413397|NCT03838068|Drug|Local Anesthetics Procaine|40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance
75413398|NCT03836508|Device|Medium cut-off|"All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
75715012|NCT04048980|Behavioral|CARExDEM|CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
75413399|NCT03836508|Device|High-Flux|"All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
75715013|NCT00974116|Behavioral|MEND Childhood Obesity Program|The number of children who are obese in the UK is steadily increasing with both short and long term consequences for health. The aim of this study is to determine whether the MEND Programme (a new national initiative for the treatment of childhood obesity) is a successful and sustainable treatment for childhood obesity and obesity related health problems.
75715014|NCT00974116|Behavioral|Control Group|No intervention
75715015|NCT00767286|Drug|flutamide|
75715016|NCT00767286|Drug|goserelin acetate|
75715017|NCT00767286|Radiation|low-LET cobalt-60 gamma ray therapy|
75715018|NCT00767286|Radiation|low-LET photon therapy|
76041841|NCT04790929|Device|Muse|Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.
75413400|NCT03832530|Behavioral|Safer conception counseling inclusive of periconception PrEP|Observational evaluation of factors associated with uptake of and adherence to daily, oral TDF/FTC PrEP and other safer conception methods (including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive during follow-up) over 9 month. Maximum 19 month follow-up period (through pregnancy outcome).
75556487|NCT03625986|Other|Non-Nicotine Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The placebo group in this project will receive a SREC device with liquid containing 0 mg/mL of nicotine."
75715019|NCT00966628|Drug|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
75556488|NCT03625037|Biological|Epcoritamab|Administered as specified in the treatment arm.
75715020|NCT00966628|Drug|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
75715021|NCT00968110|Drug|omalizumab|Dosing table established for omalizumab
75715022|NCT00608517|Biological|anti-thymocyte globulin|Given IV
75715023|NCT00608517|Drug|cyclophosphamide|Given IV
75556489|NCT03621943|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
75556490|NCT03621943|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
75556491|NCT03598270|Drug|Placebo|Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1
75556492|NCT03598270|Drug|Carboplatin|Intravenous. Day 1
75556493|NCT03598270|Drug|Paclitaxel|175 mg/m². Intravenous. Day 1
75556494|NCT03598270|Drug|Niraparib|200 mg or 300 mg. Oral. From day 1 to 21
75556495|NCT03598270|Drug|Gemcitabine|1000 mg/m². Intravenous. Day 1 and day 8.
75715024|NCT00608517|Drug|fludarabine phosphate|Given IV
75715025|NCT00608517|Drug|methylprednisolone|Given IV
75715026|NCT00608517|Radiation|total-body irradiation|Given daily for 1-4 days
75413401|NCT03832296|Behavioral|Weight-Loss Maintenance|Over the course of the first 6-months, participants will build their self-efficacy to maintain weight loss on their own, empowered to do what is needed to achieve personal goals and long-term behavior change (months 7-18). The first 6 months of I-CAN will prepare participants for successful independent weight-loss maintenance in months 7-18. During the 12-month independent weight-loss maintenance phase participants exercise on their own and maintain their weight loss (or increase weight loss if they choose) with the only contact from interventionists being two newsletters at months 9 and 15.
75413402|NCT03832296|Behavioral|Health Education (Attention Control)|Participants in the control group will attend an individual session during month 1, and a monthly face-to-face group meeting during months 2-6. The sessions will provide attention, social interaction, and physician-based health education. Participants will receive a newsletter during months 9 and 15.
75413403|NCT05440734|Drug|Melatonin|2 Mg Oral Tablet, slow release
75413404|NCT05440734|Drug|Placebo|placebo pill identical to the treatment pill
75413405|NCT05447208|Drug|Growth Hormone|Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
75413406|NCT05447208|Drug|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
75556496|NCT03598270|Drug|Pegylated liposomal doxorubicin (PLD)|30 mg/m². Intravenous. Day 1
75556497|NCT03598270|Drug|Atezolizumab|1200 mg. Intravenous. Day 1
75556498|NCT03596671|Device|RENOVA iStim™ System|Tibial implantable neuromodulation device
75556499|NCT03596645|Drug|Golimumab|Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
75556500|NCT03596645|Drug|Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
75556501|NCT03593317|Drug|Spironolactone|The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
75556502|NCT03593317|Drug|Placebo|Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
75556503|NCT03582176|Drug|Lactose Placebo|One capsule by mouth twice per day
75556504|NCT03582176|Drug|Ketotifen Fumarate 2mg|2 mg tablets (over-encapsulated into one capsule) by mouth twice per day
75556505|NCT03582176|Drug|Ketotifen Fumarate 5mg|5 mg tablets (over-encapsulated into one capsule) by mouth twice per day
75556506|NCT03581214|Other|No oxygen|No facemask, room air only
75556507|NCT03581214|Other|Oxygen|10Liters/minute oxygen by facemask
75556508|NCT03578367|Drug|Asciminib add-on|Asciminib 60 mg or 40 mg taken orally once daily.
75556509|NCT03578367|Drug|Imatinib|Imatinib 400 mg taken orally once daily
75556510|NCT03578367|Drug|Nilotinib|Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
75556511|NCT03578367|Drug|Asciminib single agent|Asciminib 80 mg taken orally once daily
75715027|NCT00966706|Drug|capecitabine|Given systemically
75715028|NCT00966706|Drug|cisplatin|Given systemically
75556512|NCT03573310|Drug|JNJ-64619178|JNJ-64619178 capsules to be administered orally.
75556513|NCT03571763|Other|SWI sequence|Acute ischemic stroke patient confirmed by SWI sequence
75556514|NCT03568058|Drug|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
75556515|NCT03568058|Drug|Pembrolizumab|200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
75715029|NCT00966706|Drug|docetaxel|Given systemically
75715030|NCT00966706|Drug|epirubicin hydrochloride|Given systemically
75715031|NCT00966706|Drug|gemcitabine hydrochloride|Given systemically
75715032|NCT00763776|Device|clamp crushing technique|Liver transection during hepatectomy by clamp crushing technique
75715033|NCT00763776|Device|ultrasonic dissector|Liver transection during hepatectomy by the ultrasonic dissector
75715034|NCT00966784|Other|Dietary Fibers|
75556516|NCT03556839|Drug|Atezolizumab|Intravenous Infusion
75556517|NCT03556839|Drug|Bevacizumab|Intravenous Infusion
75715035|NCT00893061|Drug|anastrozole|Given orally
75715036|NCT00893061|Drug|exemestane|Given orally
75715037|NCT00893061|Drug|letrozole|Given orally
75413407|NCT05444556|Drug|Imlunestrant|Administered orally.
75413408|NCT05444556|Drug|Repaglinide|Administered orally.
75413409|NCT05444556|Drug|Omeprazole|Administered orally.
75413410|NCT05444556|Drug|Dextromethorphan|Administered orally.
75413411|NCT05444556|Drug|Quinidine|Administered orally.
75413412|NCT05444556|Drug|Rosuvastatin|Administered orally.
75413413|NCT05444556|Drug|Digoxin|Administered orally.
75413414|NCT05444400|Other|Strengthening|Strengthening
75413415|NCT05444400|Other|Conventional protocol|Conventional protocol
75556518|NCT03556839|Drug|Cisplatin/Carboplatin|Intravenous Infusion
75556519|NCT03556839|Drug|Paclitaxel|Intravenous Infusion
75556520|NCT03534700|Procedure|parasacral flap reconstruction|parasacral flap reconstruction
75556521|NCT03534700|Procedure|open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
75715038|NCT00893061|Drug|tamoxifen citrate|Given orally
75715039|NCT00763932|Biological|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
75413416|NCT05443542|Device|Virtual Reality|Game to be played is a commercially available VR game
75413417|NCT05443542|Other|Control intervention|Sodoku, crossword puzzles
75413418|NCT05442294|Behavioral|Juego de Llaves|The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values
75413419|NCT05441904|Drug|PXL770|A single dose of 500 and 750 mg was administered to each subject.
75413420|NCT05441436|Procedure|Allogeneic hematopoietic stem cell transplantation|Allogeneic hematopoietic stem cell transplantation
75413421|NCT05441436|Procedure|Solid organ transplantation|Solid organ transplantation
75413422|NCT05441358|Procedure|Open Heart Surgery|Blood collection at 4 timepoints (prior to anesthesia induction, immediately post-protamine, 1-2 hours post protamine, and up to 48 hours post-surgical completion) to assess platelet function.
75413423|NCT05441202|Device|transdermal therapy|transdermal therapy with Chinese medicine
75413424|NCT05440578|Drug|olaparib plus bevacizumab maintenance therapy|First-line olaparib plus bevacizumab maintenance therapy initiated from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required).
75413425|NCT05446662|Other|music therapy|Patients participating in the study will be informed about the application of music therapy in the preoperative period. The patients who will take part in the music group are given 30 minutes the day before the surgery, and 30 minutes a day on the 1st and 2nd days after the surgery. Music that is selected by the researcher and grouped as relaxing music, classical music, sufi music and Turkish folk music will be played. The patients will be listened to the music with headphones that cover the whole ear, and the music will be adjusted to make them feel comfortable.
75413426|NCT05446662|Other|aromatherapy|Patients participating in the study will be informed about the application of aromatherapy in the preoperative period. During this period, patients undergo elbow test (1 drop of lavender oil will be dripped onto the inside of the patient's elbow, after 20 minutes, it will be evaluated whether an allergic reaction has developed). Lavender oil as aromatic oil will be administered to the patients in the aromatherapy group in the form of inhalation. Lavender oil inhalation (1 drop of 0.1 cc) It will be applied by inhalation with gauze on which 3-4 drops of lavender oil are poured. 30 minutes before surgery. Aromatherapy will be applied four times with an interval of 30 seconds on the 1st and 2nd days before and after the surgery.
75413427|NCT05446662|Other|Progressive Relaxation Exercises|Patients participating in the study will be informed about relaxation exercises in the preoperative period. Progressive relaxation training will be applied to the patients for 30 minutes once a day, on the day before the operation and on the 1st and 2nd days after the operation.
75413428|NCT05446662|Other|Hand massage|Patients participating in the study will be informed about the application of massage therapy in the preoperative period. 10-15 minutes once in the preoperative period. And in the postoperative period, the 1st and 2nd days are 10-15 minutes. application will be carried out. Lavender oil (Lavandula Angustifolia) will be used in hand massage, sweet almond oil (Prunus Amygladus Sativa) will be used as essential oil.
75413429|NCT05448690|Procedure|Two different approaches|Please refer to Groups
75556522|NCT03523442|Drug|Apalutamide|The participants will receive apalutamide 240 mg once daily orally.
75715040|NCT00966862|Other|Other: Dietary Fibers|
75556523|NCT03517969|Drug|Berzosertib|Given IV
75556524|NCT03517969|Drug|Carboplatin|Given IV
75556525|NCT03517969|Drug|Docetaxel|Given IV
75556526|NCT03517969|Other|Laboratory Biomarker Analysis|Correlative studies
75556527|NCT03517722|Drug|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
75556528|NCT03517722|Drug|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
75556529|NCT03517722|Drug|Ustekinumab 90 mg|Participants will receive 90 mg ustekinumab via SC route.
75556530|NCT03507491|Drug|Gemcitabine|Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
75413430|NCT05445570|Diagnostic Test|Non-Interventional|This is an observational, non interventional study
75413431|NCT01689402|Device|MRI Scan with the specified sequences below:|"Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.~Susceptibility weighted imaging (SWI)~Chemical Shift Imaging (CSI) multivoxel spectroscopi~Post contrast 3D box reconstruction"
75413432|NCT01689480|Other|FSHD training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
75556531|NCT03507491|Drug|Nab-paclitaxel|Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
75556532|NCT03503370|Drug|Chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
75556533|NCT03503370|Drug|Placebo|Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
75556534|NCT03484884|Diagnostic Test|Cerenkov luminescence imaging.|Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
75556535|NCT03474718|Biological|Platelet-rich Plasma Left Side|Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
75556536|NCT03474718|Biological|Platelet-rich Plasma Right Side|Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
75556537|NCT03466411|Drug|Guselkumab Dose 1|Guselkumab will be administered by IV infusion.
75556538|NCT03466411|Drug|Guselkumab Dose 2|Guselkumab will be administered by SC injection.
75556539|NCT03466411|Drug|Guselkumab Dose 3|Guselkumab will be administered by IV infusion.
75413433|NCT01689558|Drug|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
75413434|NCT01689870|Drug|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
75556540|NCT03466411|Drug|Guselkumab Dose 4|Guselkumab will be administered by IV infusion.
75556541|NCT03466411|Drug|Guselkumab Dose 5|Guselkumab will be by SC injection.
75556542|NCT03466411|Drug|Guselkumab|Guselkumab will be administered by IV infusion and SC injection.
75556543|NCT03466411|Drug|Ustekinumab|Ustekinumab will be administered by IV infusion and SC injection.
75556544|NCT03466411|Drug|Placebo|Placebo will be administered as IV infusion.
75556545|NCT03465696|Behavioral|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
75715041|NCT00890331|Behavioral|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
75413435|NCT01689870|Drug|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
76041842|NCT04790929|Behavioral|Meditation Coaching|Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
76041843|NCT04802005|Other|Aerobic Interval Training|The aerobic interval training group
75556546|NCT03465696|Behavioral|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~Stelara® acts in an almost all-natural way to help control psoriasis.~Stelara® blocks one of the genetic causes of psoriasis.~Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
75556547|NCT03451851|Drug|Guselkumab|Participants will receive a weight-based dose of guselkumab subcutaneously.
75715042|NCT00890331|Behavioral|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
75556548|NCT03451851|Drug|Placebo for guselkumab|Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
75556549|NCT03451851|Drug|Etanercept|Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
75715043|NCT00974194|Procedure|Single Trocar CCK|CCK using Triport
75715044|NCT00974194|Procedure|Standard CCK|CCK using three or four ports
75715045|NCT00974272|Drug|Exenatide|Single subcutaneous injection (10 μg)
76041844|NCT04790383|Other|Advanced Self-Adhesive resin composite hybrid restorations (Surefil one (Dentsply Sirona)).|Hybrid resin composite that doesn't need bonding system and releases calcium and flouride.
75715046|NCT00974272|Other|Normal Saline|Single subcutaneous injection
75715047|NCT02558478|Genetic|blood sampling|
75715048|NCT00974428|Dietary Supplement|Wobenzym® N|4 tablets TID, 6 weeks
75413436|NCT01689948|Behavioral|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
75413437|NCT01689012|Behavioral|Facial Exercise|
75413438|NCT05768828|Diagnostic Test|Nociceptive Blink Reflex|Noxious trigeminal electrical stimulation at different interstimulus intervals using 1.5x the pain threshold in order to provoke a release of trigeminal CGRP
75413439|NCT05768750|Other|Rehabilitation|X
75715049|NCT00974428|Dietary Supplement|Placebo|4 tablets TID
76041845|NCT04790383|Other|Conventional resin composite restoration. (Sphere Tec, (Dentsply Sirona|Conventional Nanohybrid resin composite
76041846|NCT04790461|Other|Pre-post test|Adult Caregiver Quality of Life Questionnaire (AC-QoL) Perceived Stress Scale (PSS) The Stress Coping Styles Questionnaire (SCSQ)
76041847|NCT04790461|Behavioral|face-to-face training + PMR exercise|4 weeks Roy adaptation-based face-to-face training + PMR exercises to be taught, 4 weeks exercise counseling
75413440|NCT05768724|Behavioral|intervention diet|"The Resmena diet: It was characterized by a higher meal frequency, consisting of seven meals/d (including breakfast, lunch, dinner, and two snacks in the morning and two snacks in the afternoon), and by a different macronutrient distribution; 40% total energy value from CHO, 30% from proteins and 30% from lipids. This pattern tried to reinforce high n-3 polyunsaturated FA (n-3 PUFA) and high natural antioxidant food consumption and promoted low GL CHO intake as well as a high adherence to the Mediterranean diet. It also maintained a healthy FA profile and a cholesterol content of less than 300 mg/day.~Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked."
75413441|NCT05768724|Behavioral|control diet|"Control diet: It was based on the American Heart Association (AHA) guidelines, including 3-5 meals per day, a macronutrient distribution of 55% total energy value from carbohydrates, 15% proteins, and 30% lipids, a healthy fatty acids (FA) profile and a cholesterol consumption lower than 300 mg/day.~- Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked"
75413442|NCT05768698|Diagnostic Test|Software algorithm|Validation of a software package based on an artificial intelligence algorithm for automated non-invasive estimation of LVFP against invasively measured ones by left and right heart catheterization
75413443|NCT05768685|Behavioral|Affective touch paradigm|Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm. After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness. As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch inclose relationships.
75413444|NCT05768672|Behavioral|Experimental Task|The main task is an olfactory version of a traditional Go/No-Go task (Albayay et al., 2019): it includes the delivery of either an odour or clean air prior to the presentation of a visual target Moreover, all participants will be assessed with the italian version of the Stroop color and word test (Caffarra et al., 2004) to evaluate inhibition, together with selective and sustained attention. This neuropsychological test consists of three tables, showing color words (W), colored circles (C), and color words printed in incongruent ink (i.e., red printed in blue ink, CW), respectively. The Stroop effect consists of a delayed response when words have to be named according to the color of the ink, ignoring the meaning of the printed word.
75413445|NCT05768659|Behavioral|Fear Conditioning|"It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered."
75413446|NCT05768646|Behavioral|Neuropsychological instruments|Neuropsychological instruments assessing cognitive (including counterfactual abilities), behavioural and psychopathological features
75556550|NCT03441282|Drug|Fentanyl|"After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia."
75556551|NCT03439462|Drug|nab-sirolimus|nab-sirolimus combined with mFOLFOX6 + bevacizumab
75556552|NCT03432936|Device|MRI guided procedure software evaluation|MRI guided ablation/biopsy using standard MR imaging along with Philips Interventional iSuite software tools.
75715050|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
75715051|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
75556553|NCT03427099|Behavioral|Rehabilitation with a biopsychosocial focus|Rehabilitation with a biopsychosocial focus
75556554|NCT03427099|Behavioral|Control group|usual care
75556555|NCT03414502|Drug|Methotrexate|Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg. daily.
75556556|NCT03414502|Drug|Abatacept|Starting dose which may be adjusted as needed at the discretion of the investigator
75556557|NCT03414502|Drug|Adalimumab|Starting dose which may be adjusted as needed at the discretion of the investigator
75556558|NCT03414502|Drug|Azathioprine|Starting dose which may be adjusted as needed at the discretion of the investigator
75715052|NCT00974506|Other|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
75413447|NCT05768633|Behavioral|Counterfactual Inference Test|All participants will be asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
75413448|NCT05768581|Other|Concurrent Training|Participants should perform strength training and aerobic exercises
75413449|NCT05768581|Other|Strength Training|Participants should perform strength exercises
75413450|NCT05768581|Other|Aerobic training|Participants should perform aerobic exercises
75715053|NCT00974506|Other|Routine care therapy|Routine care therapy by general practitioner
75715054|NCT00764010|Dietary Supplement|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
75715055|NCT00764010|Dietary Supplement|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
75556559|NCT03414502|Drug|Baricitinib|Starting dose which may be adjusted as needed at the discretion of the investigator
75556560|NCT03414502|Drug|Certolizumab|Starting dose which may be adjusted as needed at the discretion of the investigator
75556561|NCT03414502|Drug|Etanercept|Starting dose which may be adjusted as needed at the discretion of the investigator
75715056|NCT00764010|Dietary Supplement|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
75715057|NCT00968188|Behavioral|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
75715058|NCT00968188|Behavioral|Information only|Medically fact based HIV information delivered online.
75715059|NCT00974584|Drug|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\n\n\n\n\n\n
75556562|NCT03414502|Drug|Golimumab|Starting dose which may be adjusted as needed at the discretion of the investigator
75715060|NCT00974584|Drug|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
75715061|NCT00974584|Drug|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter*minute (mg/mL*min).\n
75715062|NCT00974584|Drug|cisplatin|Cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of every 3-week cycle.\n
75556563|NCT03414502|Drug|Hydroxychloroquine|Starting dose which may be adjusted as needed at the discretion of the investigator
75715063|NCT00974584|Drug|paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of every 3-week cycle.\n\n
75715064|NCT00974584|Drug|pemetrexed|Pemetrexed 500 mg/m^2 IV on Day 1 of every 3-week cycle.
75715065|NCT00608205|Drug|cisplatin|Given IV
75715066|NCT00608205|Drug|fluorouracil|Given IV
75556564|NCT03414502|Drug|Infliximab|Starting dose which may be adjusted as needed at the discretion of the investigator
75556565|NCT03414502|Drug|Leflunomide|Starting dose which may be adjusted as needed at the discretion of the investigator
75556566|NCT03414502|Drug|Minocycline|Starting dose which may be adjusted as needed at the discretion of the investigator
75556567|NCT03414502|Drug|Rituximab|Starting dose which may be adjusted as needed at the discretion of the investigator
75556568|NCT03414502|Drug|Sarilumab|Starting dose which may be adjusted as needed at the discretion of the investigator
75556569|NCT03414502|Drug|Sulfasalazine|Starting dose which may be adjusted as needed at the discretion of the investigator
75556570|NCT03414502|Drug|Tofacitinib|Starting dose which may be adjusted as needed at the discretion of the investigator
75556571|NCT03410615|Radiation|Radiation|70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
75556572|NCT03410615|Drug|Cisplatin|100 mg/m2 days 1, 22, 43 concurrently with RT
75556573|NCT03410615|Drug|Durvalumab|Given in concurrent and adjuvant phase
75715067|NCT00608205|Radiation|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
75715068|NCT00974662|Drug|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 & 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
75556574|NCT03410615|Drug|Tremelimumab|ARM CLOSED TO ACCRUAL - 2019
75556575|NCT03409263|Other|Observational study|Not applicable (observational registry study)
75556576|NCT03399799|Drug|Talquetamab|Participants will receive IV infusion or SC injection of Talquetamab.
75556577|NCT03390504|Drug|Erdafitinib|Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
75413451|NCT05768568|Device|Manual Toothbrush and Powered Toothbrush|Manual Toothbrush will be mechanically (hand) driven Powered Toothbrush will be battery operated
75556578|NCT03390504|Drug|Vinflunine|Participants will receive vinflunine 320 mg/m^2 as a 20-minute intravenous infusion.
75413452|NCT05768542|Drug|Metoprolol Injection|If heart rate below 60, give 5 mg IV. If heart rate above 60, give 5 mg IV and repeat until heart rate below 65 or 20 mg given in total or systolic blood pressure below 110 mmHg.
75556579|NCT03390504|Drug|Docetaxel|Participants will receive docetaxel 75 mg/m^2 as a 1 hour intravenous infusion.
75413453|NCT05768542|Drug|Saline|5 ml given IV
75556580|NCT03390504|Drug|Pembrolizumab|Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
75413454|NCT05768503|Drug|Experimental drug|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
75556581|NCT03390504|Device|Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)|FGFRi CTA will be used to determine molecular eligibility.
75556582|NCT03389230|Biological|HER2(EQ)BBζ/CD19t+ T cells|Given via catheter
75556583|NCT03389230|Other|Laboratory Biomarker Analysis|Correlative studies
75556584|NCT03389230|Procedure|Leukapheresis|Undergo leukapheresis
75556585|NCT03384914|Biological|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
75556586|NCT03384914|Biological|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
75556587|NCT03384641|Drug|Bedaquiline 200 mg|Participants will receive bedaquiline 200 mg (2*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
75413455|NCT05768503|Drug|Control Rx|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
75556588|NCT03375762|Other|Remote ischemic perconditioning|Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score >0 and RACE motor item>0
75556589|NCT03375762|Other|Sham remote perconditioning|Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score >0 and RACE motor item>0
75556590|NCT03375320|Drug|Cabozantinib S-malate|Given PO
75556591|NCT03375320|Procedure|Computed Tomography|Undergo CT
75556592|NCT03375320|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556593|NCT03375320|Other|Placebo Administration|Given PO
75556594|NCT03375320|Other|Quality-of-Life Assessment|Ancillary studies
75556595|NCT03375320|Procedure|X-Ray Imaging|Undergo x-ray
75556596|NCT03374982|Device|DentalVibe|The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
75556597|NCT03371498|Drug|Methylprednisolone|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
75556598|NCT03371498|Drug|Methylprednisolone placebo|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
75556599|NCT03368729|Drug|Niraparib|Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
75556600|NCT03368729|Drug|Trastuzumab|Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
75715069|NCT00974740|Drug|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
75413456|NCT05768490|Radiation|brain radiotherapy|Patients were randomly divided into two groups, experimental group (early intervention group of brain radiotherapy) : the brain radiotherapy started within 1 month of TKI treatment, the brain radiotherapy here specifically refers to stereotactic radiotherapy; Control group (brain radiotherapy late intervention group) : Brain radiotherapy was given within 3 months after brain progression during TKI treatment.
75556601|NCT03366636|Behavioral|Project Legacy|"Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~1. Thinking about the future~2. Present actions to achieve future success~3. Safeguarding one's future~4. Creating a Healthy Life Plan~5. Navigating service systems"
75556602|NCT03325101|Procedure|Cryosurgery|Undergo cryosurgery
75556603|NCT03325101|Biological|Pembrolizumab|Given IV
75556604|NCT03325101|Procedure|Pheresis|Undergo apheresis
75556605|NCT03325101|Biological|Therapeutic Autologous Dendritic Cells|Given IT
75556606|NCT03310918|Other|Palliative Care|Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family
75556607|NCT03310918|Other|Standard Leukemia care|Standard care per the hospital guideline
75556608|NCT03302494|Device|Coherex WaveCrest® Left Atrial Appendage Occlusion System|Percutaneous left atrial appendage closure
75556609|NCT03302494|Device|Watchman® LAA Closure Device|Percutaeous left atrial appendage closure
75556610|NCT03301220|Drug|Daratumumab SC: daratumumab + rHuPH20|Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 [2000 U/mL]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
75556611|NCT03287544|Other|Combined rehabilitation|Linguistic training as well as communication training.
75556612|NCT03287544|Other|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
75556613|NCT03260569|Drug|Inhaled Nitric Oxide|Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
75556614|NCT03260569|Drug|Placebo|Nitrogen plus oxygen
75556615|NCT03258593|Drug|Durvalumab|Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
75556616|NCT03258593|Drug|Vicineum|Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
75556617|NCT03258593|Drug|Acetaminophen|Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
75556618|NCT03258593|Drug|Antihistamine|Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
75556619|NCT03258593|Procedure|Bladder Biopsy|Bladder biopsy at screening and every 3 months before each cystoscopy per schema.
75413457|NCT05768490|Drug|Almonertinib|almonertinib po 110mg QD
75413458|NCT05768464|Drug|Toripalimab|240mg intravenously every 3 weeks
75413459|NCT05768464|Drug|Axitinib|5mg orraly twice daily
75413460|NCT05768451|Other|Ultrasonic image analysis|Preoperative conventional ultrasound (US), elastic ultrasound (UE) and contrast-enhanced ultrasound (CEUS) images were analyzed. Histopathological results were used as the gold standard. The cases were randomly divided into training set and test set with a ratio of 7:3. The US image, UE image and CEUS image of the maximum long-axis section of each lesion were selected, and the region of interest (ROI) of the lesion was manually delineated.
75413461|NCT05768438|Other|Mulligan with upper limb movement|Group A subjects will receive mulligan mobilizations with upper limb movement of the involved side. The patient will be in a sitting position and the therapist will stand beside the patient. The therapist will place one thumb overlapped by the other on one of the selected cervical and then the therapist will push down the spinous process of that specific vertebrae, the pressure will be sustained and the patient will actively abduct his/her arm, assistance will be provided if needed. Initially it will start from 10 repetitions and 1 set which will further progress up to 2 or 3 sets as per patient's tolerance with 60 seconds rest in between each set.
75556620|NCT03258593|Procedure|TURBT|Transurethral resection of a bladder tumor (TURBT) at screening and every 3 months before each cystoscopy per schema.
75556621|NCT03258593|Procedure|Cystoscopy|Urine cytology at screening and every 3 months before each cystoscopy per schema.
75715070|NCT00974740|Drug|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
75556622|NCT03258593|Diagnostic Test|Urine cytology|Urine cytology at baseline and every 3 months before each cystoscopy per schema.
75715071|NCT00967096|Drug|Rifaximin|Rifaximin for Bone marrow transplant patients
75715072|NCT04037163|Diagnostic Test|Fractional flow reserve, Coronary CT angiography|Coronary CT angiography was performed as part of routine clinical practice for patients with suspected coronary artery disease and the decision to perform coronary CT angiography before invasive angiography was at the judgment of the physicians in charge.
75715073|NCT05227300|Drug|Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
75556623|NCT03258593|Diagnostic Test|Electrocardiogram|Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.
75556624|NCT03258593|Diagnostic Test|CT|Computed tomography (CT) at screening and every 12 months while on study.
75556625|NCT03258593|Diagnostic Test|MRI|Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
75556626|NCT03250663|Behavioral|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
75556627|NCT03250663|Drug|EUCRISA|Participants are given EUCRISA (crisaborole) ointment 2%.
75715074|NCT05227300|Drug|2% lidocaine with 1:100,000 epinephrine|Septodont's standard formulation of 2% lidocaine with epinephrine
75715075|NCT00890487|Other|hyaluronic acid pill|pill, 220 mg, once a day, three months
75715076|NCT02541357|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
75556628|NCT03241615|Other|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
75556629|NCT03234972|Drug|Daratumumab|Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.
75556630|NCT03234972|Drug|Velcade|Velcade will be administered at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
75556631|NCT03234972|Drug|Dexamethasone|Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
75556632|NCT03223090|Behavioral|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
75556633|NCT03223090|Behavioral|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
75556634|NCT03218488|Drug|Ustekinumab|Participants will not receive any intervention as part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab in clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development.
75556635|NCT03217812|Drug|Velcade|Participants will receive velcade 1.3 mg/m^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
75715077|NCT02541357|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
75715078|NCT00890565|Drug|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
75715079|NCT00890643|Drug|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
75715080|NCT00890643|Drug|placebo|placebo
75715081|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
75715082|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
75715083|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
75715084|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
75715085|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
75556636|NCT03217812|Drug|Melphalan|Participants will receive melphalan 9 mg/m^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
76041848|NCT04790461|Behavioral|mobile health education + PMR exercise|To provide awareness and exercise with 8 weeks Roy adaptation model-based training and mobile application access with PMR exercise content
75556637|NCT03217812|Drug|Prednisone|Participants will receive prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
75715086|NCT00670800|Drug|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
76041849|NCT04790461|Behavioral|face-to-face and mobile health education + PMR exercise|4 weeks face-to-face training based on Roy adaptation model + teaching PMR exercises and 4 weeks based training on Roy adaptation model and mobile application access with PMR exercise content
75556638|NCT03217812|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as IV infusion or daratumumab SC, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
75715087|NCT00764166|Drug|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:~To D1 of every cycle in the dose of 70 mg/m²,~Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
76041850|NCT04790539|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
76041851|NCT04790149|Other|Conventional Rehabilitation|Motor Imagery Training combined with Active functional exercises
76041852|NCT04790149|Other|NEUROM + tDCS|NEUROM combined to tDCS
76041853|NCT04790149|Other|NEUROM|protocol to induce motor recovery
75556647|NCT03212742|Drug|Olaparib|We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously
75556648|NCT03212742|Drug|Temozolomide (TMZ)|TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
75556649|NCT03212742|Radiation|IMRT (Intensity Modulated Radiation Therapy)|Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
75556650|NCT03201458|Drug|Atezolizumab|Given IV
75556651|NCT03201458|Procedure|Biopsy|Undergo tumor biopsy
75556652|NCT03201458|Procedure|Biospecimen Collection|Undergo collection of blood samples
75556653|NCT03201458|Drug|Cobimetinib|Given PO
75556654|NCT03201458|Procedure|Computed Tomography|Undergo CT
75556655|NCT03201458|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556656|NCT03193814|Drug|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
75556657|NCT03191916|Device|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
75556658|NCT03191916|Device|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
75556659|NCT03178149|Drug|ASP7317|subretinal injection
75556660|NCT03178149|Drug|tacrolimus|oral
75556661|NCT03178149|Drug|trimethoprim-sulfamethoxazole|oral
75556662|NCT03178149|Drug|Acyclovir|oral
75556663|NCT03178149|Drug|Nystatin|oral
75556664|NCT03168672|Device|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
75556665|NCT03164785|Drug|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
75556666|NCT03153553|Other|Ischemic Preconditioning|Ischemic preconditioning (IPC) is an experimental technique for producing resistance to the loss of blood supply, and thus oxygen, to tissues of many types. In the heart, IPC is an intrinsic process whereby repeated short episodes of ischaemia protect the myocardium against a subsequent ischaemic insult
75715088|NCT00764166|Drug|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
76041854|NCT04789993|Other|No intervention.|There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient.
76041855|NCT04812301|Radiation|Egg-white sandwich|1 mCi of Tc-99m sodium phytate is added into the egg-white sandwich
75556667|NCT03153553|Other|Sham Intervention|Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
75556668|NCT03153475|Device|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
75556669|NCT03153449|Device|ATTUNE Revision Knee System in Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
75556670|NCT03145181|Drug|Teclistamab (IV)|Participants will receive IV infusion of Teclistamab.
75556671|NCT03145181|Drug|Teclistamab(SC)|Participants will receive SC injection of Teclistamab.
75715089|NCT00770406|Drug|botulinum toxin type A|100 or 200 units intravesically
75715090|NCT02557542|Other|One Stop Vein Clinic|Same day diagnosis and treatment
76041856|NCT04812301|Radiation|Abbott Vital®|1 mCi of Tc-99m sodium phytate is added into the Abbott Vital®
76041857|NCT04427371|Other|the levels of pyroptosis|Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
75556672|NCT03136887|Device|JOURNEY II XR Total Knee System|JOURNEY II XR Total Knee System
75556673|NCT03135652|Radiation|adjuvant SBRT|adjuvant SBRT of liver lesions
75715091|NCT02557542|Device|Radiofrequency ablation|Venous ablation
75715092|NCT02557542|Device|Endovenous laser ablation|Venous ablation
75715093|NCT02557542|Drug|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
75715094|NCT00767754|Drug|Paxil CR|12 week treatment of Paxil(20-40mg)
76041858|NCT04812145|Radiation|Chemoradiation|Hypofractionated radiotherapy with concurrent Gemcitabine
76041859|NCT04801069|Device|Nocturnal Ventilation|AirCurve 10CS PaceWave (Resmed)
76041860|NCT04426903|Other|webFitForAll|PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
76041861|NCT04426903|Other|BrainHQ|CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
75715095|NCT00607893|Device|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
75413462|NCT05768438|Other|McKenzie exercises with neural mobilizations|The subjects of Group B will receive McKenzie exercises. Initially, it will start with retraction exercises. The frequency of exercises will be 10 to 15 repetitions followed by three to four sets with one second hold. On the second or third day, the cervical extension will be added. While in the second week the same set of exercises will be administered with the patient in a sitting position combined with application of over pressure at the end range by therapist. In the third week, extension and retraction exercises will be performed along with traction which will be applied by the therapist. Finally, in the fourth week all retraction and lateral flexion then neck rotation and the last one retraction with neck flexion will be added. Neural mobilizations will be given to patients in group B in supine lying. From proximal to distal, 20 oscillations (1 oscillation/ 1 second)
75413463|NCT05768412|Procedure|Radial Artery Access|The radial artery is stabilized between the thumb and forefinger of the left hand and 1 to 2 mL of subcutaneous lidocaine is used to create a wheal over the zone of planned entry.
75556674|NCT03135652|Drug|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
75556675|NCT03130244|Device|Magnet Anastomosis System|The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.
75556676|NCT03130244|Drug|Best Medical Management|The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
75715096|NCT00607893|Device|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
75715097|NCT00571038|Behavioral|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
75715098|NCT00571038|Behavioral|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
76041862|NCT04812223|Procedure|Delayed umbilical cord clamping|The umbilical cord will be clamped 60 seconds after the baby is born.
75556677|NCT03125928|Drug|Atezolizumab|Monoclonal antibody
75556678|NCT03125928|Drug|Paclitaxel|Chemotherapy
75715099|NCT00764244|Procedure|Vitrectomy|Vitrectomy
76041863|NCT04812223|Procedure|Early umbilical cord clamping|The umbilical cord will be clamped 15 seconds after the baby is born.
76041864|NCT04812223|Procedure|Milking of the umbilical cord|The cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
76041865|NCT04789759|Device|Socket Preservation - Bond Apatite synthetic bone substitute|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth. If 1/3 of the buccal plate is missing, considered a class 2 alveolar socket.~Extraction of tooth and place 2/3 biphasic calcium sulfate cement matrix's with Hydroxyapatite (HA granules) , condensed , and covered with a resorbable membrane suture to the adjacent tissue.~At implant placement ,take bone for histological preparation and histomorphometric analysis of the healing pattern.~At T0, T1 and T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements, will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.~Primary and secondary stability will be measured by ISQ units with a RFA machine, that will include the machine to measure and the magnetic tip to be screwed in the implant platform."
75556679|NCT03125928|Drug|Trastuzumab|Monoclonal antibody
75556680|NCT03125928|Drug|Pertuzumab|Monoclonal antibody
75556681|NCT03114319|Drug|TNO155|TNO155 for oral administration
75556682|NCT03114319|Drug|TNO155 in combination with EGF816 (nazartinib)|TNO155 for oral administration; EGF816 (nazartinib) for oral administration
75413464|NCT05768308|Behavioral|Internet CBT-UP intervention iCBT-UP|The self-helped internet intervention for students experiencing emotional difficulties, especially adjustment disorder. This intervention is based on transdiagnostic cbt principles - unified protocol (Barlow et al., 2018). It is a modular intervention consisting of six modules teaching different skills of dealing with emotions. Intervention is interactive and contains of video materials, quizes, texts and audio materials.
75413465|NCT05768308|Behavioral|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR) (Bernstein, Borkovec, Hazlett-Stevens, 2000). It is also a modular intervention and, similar to the i-cbt condition, consists of 5 modules. During the intervention, participants learn how to progressively tighten and relax different muscle groups.The first module is planned for two weeks and the rest of them for one week each. Intervention consists of video materials and audio guided relaxations. Participants are encouraged to train these relaxations once a day.
75413466|NCT05768243|Drug|Hyaluronic acid|hyaluronic acid is used as an adjunctive treatment to scaling and root planing
75413467|NCT05768243|Procedure|red injectable platelet rich fibrin (i-prf)|injecting red i-prf into the pocket after scaling and root planing
75413468|NCT05768230|Drug|levosimendan|Levosimendan 12.5mg was injected intravenously in a 5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
75715100|NCT00764244|Drug|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
75715101|NCT00764244|Procedure|Laser photocoagulation|Laser photocoagulation
76041866|NCT04789759|Procedure|Socket healing - No Filler|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth, at extraction day, no flap opening , atraumatic extraction, no biomaterial filler, At T0, T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements will include an intramural scanner from all the stages , we will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material."
76041867|NCT04789525|Other|High-intensity aerobic training with high protein diet|High-intensity aerobic training was given with 50 to 70 % of the maximum heart rate. the intervention started with 10 mins of warm-up exercise through stretching of upper and lower limb muscles. Subsequent to stretching, the subjects were asked to do 30 mins of exercises; consisting of 20 mins on the treadmill and 10 mins of cycle ergometer at 50 to 70 % of MHR, then with 10 mins of cool down.
75715102|NCT00770640|Drug|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
75715103|NCT00770640|Drug|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
75413469|NCT05768230|Drug|5% glucose injection|5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
75413470|NCT05768204|Drug|Prednisolone Acetate|The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.
75413471|NCT05768204|Other|placebo|A placebo consistent in appearance with the prednisolone acetate.
75556683|NCT03113487|Biological|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
75556684|NCT03113487|Biological|Pembrolizumab|Given IV
75715104|NCT00764400|Behavioral|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
75413472|NCT05768152|Device|RLRL|RLRL will be performed twice per day with an interval of at least 4 hours, each treatment last 3 minutes, in addition to single vision spectacles with power for correcting distance refraction.
75413473|NCT05768126|Drug|Rivastigmine Transdermal Product|The patches will be administered when a patient is starting ECT treatment (first four weeks 4.6 mg and then 9.5. mg). When the ECT treatment is completed, the administration of rivastigmine patches will be halted.
75556685|NCT03109197|Other|Biospecimin Collection|
75556686|NCT03107780|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
75556687|NCT03107780|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556688|NCT03107780|Drug|Navtemadlin|Given PO
75556689|NCT03107780|Radiation|Radiation Therapy|Undergo radiation therapy
75556690|NCT03103971|Biological|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
75556691|NCT03103971|Drug|Cyclophosphamide|Given IV
75413474|NCT05768126|Other|Sham|The sham patches will be administered when a patient is starting ECT treatment. When the ECT treatment is completed, the administration of rivastigmine patches will be halted.
75413475|NCT05768074|Other|Qualitative Interview|Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews
75413476|NCT05768022|Other|Cura Kensio-tapping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length.
75556692|NCT03103971|Drug|Fludarabine|Given IV
75556693|NCT03103971|Other|Laboratory Biomarker Analysis|Correlative studies
75556694|NCT03103971|Procedure|Leukapheresis|Undergo leukapheresis
75556695|NCT03103971|Other|Pharmacological Study|Correlative studies
75413477|NCT05768022|Other|placebo|placebo taping
75413478|NCT05767983|Other|Fat-free milk|Fat-free milk (500 mL, skim, 0%, Lactantia PurFiltre) will provide 180 kcal, 0 g fat, 26 g carbohydrate, and 18 g protein. Treatments matched for calories (180 kcal).
75413479|NCT05767983|Other|Fat-free yogurt|Fat-free yogurt (242 g, vanilla, 0% Greek, Oikos) will provide 180 kcal, 0 g fat, 23.5 g carbohydrate, and 19.4 g protein. Treatments matched for calories (180 kcal).
75413480|NCT05767983|Other|Low-fat cheese|Low-fat cheese (60 g, mild marble cheddar, 40% less fat, Selection) will provide 180 kcal, 10 g fat, 2 g carbohydrate, and 16 g protein. Treatments matched for calories (180 kcal).
75556696|NCT03090165|Drug|ribociclib|400mg PO
75556697|NCT03090165|Drug|ribociclib|600mg PO
75556698|NCT03090165|Drug|Bicalutamide|150mg PO
75413481|NCT05767983|Other|Fruit juice|Fruit juice (450 mL, Fruité® Fruit Punch) will provide 180 kcal, 0 g fat, 46.8 g carbohydrate, and 0 g protein. Treatments matched for calories (180 kcal).
75413482|NCT05767983|Other|Snack skipping|Water control treatment (no caloric contribution). Matched for volume (500 mL) to fat-free milk treatment.
75413483|NCT05767957|Other|Rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist using conventional technique alone.
75413484|NCT05767957|Other|Cognitive-behavioral therapies in addition to rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist according to conventional technique, with the addition of techniques from cognitive-behavioral therapies.
75413485|NCT05767879|Drug|Encorafenib + Binimetinib|"In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated."
76041868|NCT04801147|Biological|Dendritic Cells Vaccine|"Right after the surgical resection of the tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Immunotherapy will follow radiochemotherapy and will comprise 4 vaccinations every second week (injections I, II, III, IV), 2 further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) 2 months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only. In correspondence to the third vaccine injection (week 13), mTMZ will start.~Vaccine doses will be injected in the forearm of the patient."
75413486|NCT05767853|Other|Immune-phenotyping of tissue and peripheral blood myeloid compartment|"Peripheral blood sampling and bronchoalveolar lavage fluid collection based on the clinical indication at baseline (T0) and peripheral blood sample at the time of clinical worsening/improvement during the follow-up (T1). Moreover, after complete recovery and discharge from the hospital peripheral blood sampling in the outpatient clinical assessment will be performed (T2).~BALF and peripheral blood will be processed for immune-phenotyping of the myeloid compartment using single-cell RAN sequencing analysis."
76041869|NCT02388165|Biological|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
76041870|NCT02388165|Other|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
76041871|NCT04811755|Behavioral|Surgical timing from ED admission to surgery|the impact of delay of time between patient admission to ED and surgery for source control on 90-d mortality and postoperative outcomes in patients with gastrointestinal perforation with or without septic shock
76041872|NCT04800679|Drug|receive 4 monthly IVB injections and then rescue IVB|IVB group that receive 4 monthly IVB injections and then rescue IVB
76041873|NCT04800679|Drug|PRP group|PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
76041874|NCT04800679|Drug|IVB injections and a modified laser|Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
76041875|NCT04811911|Radiation|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
76041876|NCT04811911|Drug|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
76041877|NCT04789291|Drug|BI 1595043|BI 1595043
76041878|NCT04789603|Other|6-min-walk surgical mask|To walk as fast as possible without running for 6 minutes with surgical mask
76041879|NCT04789603|Other|6-min-walk Fpp2|To walk as fast as possible without running for 6 minutes with Fpp2 mask
75413487|NCT05767827|Drug|ropivacaine, lidocaine with adrenaline|Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
75413488|NCT05767827|Drug|Dexmedetomidine, ropivacaine, lidocaine with adrenaline|Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
75413489|NCT01689792|Drug|MOVIPREP|
75715105|NCT00770718|Drug|Recombinant Activated Factor VII (rFVIIa)|Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
76041880|NCT04789603|Other|6-min-walk without mask|To walk as fast as possible without running for 6 minutes without mask
75413490|NCT01689792|Drug|CitraFleet|
75413491|NCT05767814|Other|Phenotyping of synovial immune and stromal cells|Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.
76041881|NCT04789135|Drug|Ozone|Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
76041882|NCT04348669|Other|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
76041883|NCT04800445|Diagnostic Test|Salivary CRP|Salivary C reactive protein in neonatal sepsis
76041884|NCT02404545|Device|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
76041885|NCT04788979|Drug|Melatonin 5Mg Oral Tablet|"control without treatment~obese periodontitis patients treated only by scaling and root planning~obese periodontitis patients treated with scaling and root planning with daily dietary supplementation of 5 mg melatonin (NOW-USA)"
76041886|NCT04811209|Other|1.Baseline Measurements Before Surgery|"Baseline demographic data~Baseline physiological variables (blood pressure, heart rate, respiratory rate, oxygen saturation)~Baseline investigations (hemoglobin, coagulation profile, serum electrolytes) if appropriate.~Preoperative pain state using NRS (0-10)~Preoperative functional state using the QoR-15 questionnaire~Pain expectation - patients will be asked preoperatively with the question In a scale from 0 to 10 (where 0 = no pain and 10 = worst pain imaginable), what do you consider is an acceptable pain score for your first (and second) day after surgery?... Two weeks after surgery?~Pain castastrophizing scale"
76041887|NCT04811209|Other|2.Intraoperative Anesthetic Management|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
75715106|NCT00770718|Drug|Prothrombin Complex Concentrate|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
76041888|NCT04811209|Other|3.Postoperative Analgesic Management|"postoperative pain will be managed on the ward using a multimodal analgesic regimen as appropriate. This includes:~acetaminophen 650 - 1,000 mg given orally every 6 hours around the clock~NSAIDs e.g., celecoxib or other agents given orally around the clock per clinical guideline; omit if contraindicated or per surgeon's preference~Opioids e.g., hydromorphone 1-2 mg or oxycodone 15-30 mg given orally every 1-2 hours as required by the patient per standard nurse administered analgesic protocol.~In the event of severe pain refractory to the above treatments, the patient will be offered IV opioid e.g., intermittent doses of 0.2-0.4 mg hydromorphone IV every 10 minutes until pain becomes tolerable"
76041889|NCT04811209|Other|4.Postoperative NRS Pain Assessment|Pain assessment using NRS pain scores (0 = no pain and 10 = worst possible pain) will be performed by an independent research staff, starting immediately in the PACU and serially over the first 48 hours after surgery or until hospital discharge.
76041890|NCT04811209|Other|5.Postoperative Global Rating Scale (GRS) Pain Assessment|Also, the degree of pain relief after treatment is assessed using a subjective 15-point Global Rating Scale (GRS) as mentioned above (Background). This is performed at the same time of each NRS assessment and a minimum of twice daily
76041891|NCT04811209|Other|6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain|"During each NRS pain assessment before or after an analgesic intervention on POD 0, 1 and 2, the patient will also be asked this question- In your opinion, do you consider your current pain state satisfactory after your operation? Patients giving a positive response are considered having an acceptable pain state. The PASS is the 75th centile for the pain NRS score in those with a satisfactory pain state."
76041892|NCT04811209|Other|7.Postoperative Quality of Recovery Assessment|The quality of recovery 15 questionnaire (QoR-15) to measure the dimension of quality of recovery will be administered once in the morning of POD 1 and POD 2. The MCID and PASS for QoR are determined in the same way as for NRS score. The final MCID value will be average of 4 values, 1 generated by the anchor based method and 3 generated by the distribution based method. The PASS for QoR is the 75th centile of the QoR-15 score in those patients who rated their recovery as good.
76041893|NCT04811209|Other|8.Other Postoperative Assessments|Additionally, opioid related adverse effects e.g., nausea, vomiting, itchiness, constipation, sedation (RASS + Ramsay)/ and respiratory depression will be assessed daily.
76041894|NCT04800211|Other|Experimental: Test Product 1|Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
76041895|NCT04800211|Other|Experimental: Test Product 2|Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
76041896|NCT04811443|Drug|Empegfilgrastim|Extimia®
75413492|NCT05767801|Procedure|Evaluation of subclinical inflammation|Minimally invasive synovial tissue biopsy for the semiquantitative and qualitative assessment of synovial immune and stromal cells; Peripheral blood collection for MBDA assessment and phenotyping of immune cells;
75556702|NCT03073382|Other|Chart review|This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.
75556703|NCT03057002|Drug|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized [1-13C]pyruvate flux during magnetic resonance spectroscopic imaging.
75556704|NCT03049033|Other|Neurologic Music Therapy|Neurologic Music Therapy uses rhythms to change brain activity and function.
75715107|NCT00770718|Biological|Fresh Frozen Plasma|Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
75715108|NCT00770796|Drug|Atorvastatin|80 mg die
75715109|NCT00770796|Drug|Placebo|
75715110|NCT00767988|Dietary Supplement|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
75715111|NCT00767988|Other|Placebo|Capsule once daily at approximately the same time each day for 6 months.
75715112|NCT00545740|Drug|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
75715113|NCT00545740|Drug|SPD476 (2.4 g)|2.4g SPD476 QD orally
75715114|NCT00545740|Drug|SPD476 (4.8 g)|4.8g SPD476 QD orally
75715115|NCT00545740|Drug|Placebo|QD orally
75413493|NCT05767788|Other|Movement with Mobilization (MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
75413494|NCT05767788|Other|Sham Movement with Mobilization (Sham MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior light-touch glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
75556705|NCT03049033|Other|Occupational Therapy|Occupational Therapy uses traditional motor training.
75556706|NCT03049033|Other|Music Supported Therapy|Music Supported Therapy uses musical instruments to train fine motor movements.
75556707|NCT03033225|Procedure|Endoscopic Ultrasound|Undergo EUS-guided PDT
75556708|NCT03033225|Procedure|Fluorescence Imaging|Undergo fluorescence imaging
75556709|NCT03033225|Drug|Photodynamic Therapy|Undergo EUS-guided PDT
75715116|NCT05208190|Drug|Clozapine|treatment will occur naturalistically, as per standard clinical guidelines
75715117|NCT05208190|Drug|treatment as usual|naturalistic treatment with any other antipsychotic medication except clozapine
75715118|NCT00609609|Procedure|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
75715119|NCT00609609|Drug|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
75715120|NCT00968422|Drug|ABT-384|3 escalating doses will be administered daily for 21 days
75715121|NCT00968422|Drug|Matching placebo to ABT-384|Doses will be administered daily for 21 days
75715122|NCT00673452|Drug|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
75715123|NCT00673452|Drug|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
75715124|NCT00890799|Device|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
75715125|NCT00890799|Procedure|surgery|Patient in this group received open surgical repair of pmVSD.
76041897|NCT04810897|Other|Exercise|Exercise programme is reported in the clinical trial registration number is NCT03473834.
76041898|NCT04788355|Drug|Control group (standard hospital treatment)|Medications defined by the hospital involved in the study
75413495|NCT05767775|Other|Assessment of synovial- and adipose tissue-derived inflammatory biomarkers|"Parafﬁn-embedded synovial tissue (ST) specimens will be stained for H&E and other sections will be stained for CD68, CD21, CD20, CD3, CD31 and Masson Trichrome Goldner with light green to assess the microanatomical organization of resident synovial inflammatory cells. Some synovial samples will be used for tissue resident macrophages subpopulations analysis using FACS gated on their expression of the CD64+/CD11b+/MHC-ClassII+/CD206+/-/Lineage-.~Each RA patient reaching a stable clinical (DAS<1.6 for at least two different evaluations 6 months apart) and imaging (PDUS negative signal) remission under Tofacitinib treatment will undergo synovial biopsy and each synovial tissue sample will be processed as above.~Plasma levels of adipokines will be tested through ELISA method at baseline, 3, 6 and 12 months of follow-up in all patients."
75413496|NCT05767723|Drug|Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel|Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
75413497|NCT05767723|Drug|Monotherapy: Ticagrelor alone OR Prasugrel alone|Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)
75556710|NCT03033225|Other|Quality-of-Life Assessment|Ancillary studies
75556711|NCT03033225|Other|Questionnaire Administration|Ancillary studies
75556712|NCT03033225|Drug|Verteporfin|Given IV
75556713|NCT03030118|Drug|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
75556714|NCT03030118|Drug|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
75556715|NCT03011567|Drug|Acetaminophen|Participants will receive acetaminophen for postpartum mild pain relief
75556716|NCT03011567|Drug|Ibuprofen|Participants will receive ibuprofen for postpartum mild pain relief
75715126|NCT00967174|Drug|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
76041899|NCT04788355|Drug|Group Hydroxychloroquine|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.
76041900|NCT04788355|Drug|Group Hydroxychloroquine and apixaban|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
75413498|NCT05767710|Behavioral|AI telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
75413499|NCT05767710|Behavioral|general telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
75413500|NCT05767710|Behavioral|traditional rehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
75413501|NCT05767710|Behavioral|AI telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
75556717|NCT03006302|Drug|Epacadostat|50, 100, 300, or 600 mg taken by mouth twice a day, every day of each cycle
75556718|NCT03006302|Drug|Pembrolizumab|200 mg IV on Day 1 of each cycle
75556719|NCT03006302|Biological|CRS-207|1x10^9 CFU given IV on Day 2 of Cycles 3-6 (Arm A) or Day 2 of Cycles 1-6 (Arm B)
75556720|NCT03006302|Drug|CY|200 mg/m^2 given IV on Day 1 of Cycles 1-2 (Arm A only)
76041901|NCT04788355|Drug|Group Apixaban|Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
76041902|NCT04800289|Other|questionnaires|questionnaires about disease and satisfaction of patient
75556721|NCT03006302|Biological|GVAX|5x10^8 cells given as 6 intradermal injections on Day 2 of Cycles 1-2 (Arm A only)
75556722|NCT03000439|Drug|In open-label phase: treatment with tofacitinib|Treatment with investigational drug
75556723|NCT03000439|Drug|In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio|Treatment with investigational drug or placebo
76041903|NCT02420379|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
75556724|NCT02997293|Other|Enhanced Recovery protocol|The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.
75556725|NCT02988609|Device|fMRI|fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
76041904|NCT04799743|Drug|Resveratrol|Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.
75556726|NCT02962973|Device|CARMAT TAH|
75556727|NCT02962973|Procedure|Surgical intervention|
75556729|NCT02932553|Device|BVS+OMT|bioresorbable vascular scaffold implantation plus optimal medical treatment
75556730|NCT02924129|Device|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
75556731|NCT02919592|Device|MemoryShape® Breast Implants|MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
75556732|NCT02919592|Device|MemoryGel® Breast Implants|MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. MemoryGel Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
75556733|NCT02919592|Procedure|Other Aesthetic Surgery|Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
75556734|NCT02911103|Procedure|DBS surgery|Unilateral thalamic DBS therapy
75556735|NCT02891824|Drug|atezolizumab + avastin + platinum-based chemotherapy|"atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
75556736|NCT02891824|Drug|placebo + avastin + platinum-based chemotherapy|"placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
75556737|NCT02875548|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.
75556738|NCT02824263|Other|CPAP withdrawal|CPAP is discontinued for 3 nights.
75556739|NCT02814838|Drug|Ladarixin|Ladarixin oral capsule
75556740|NCT02814838|Drug|Placebo|Placebo oral capsule
75556741|NCT02783690|Radiation|Hypofractionation|40 Gy (RBE) in 15 daily fractions
75556742|NCT02737046|Drug|Belinostat|Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.
75715127|NCT00967174|Drug|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
76041905|NCT04799743|Drug|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
75556743|NCT02737046|Drug|Zidovudine|Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
75715128|NCT00967174|Drug|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
75715129|NCT00890877|Drug|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
75715130|NCT00967252|Drug|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
75715131|NCT00967252|Drug|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
75715132|NCT00967252|Drug|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
76041906|NCT04788199|Other|Closure of mesenteric defects using glue|Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
76041907|NCT04788121|Drug|Tranexamic acid|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
75715133|NCT00967252|Drug|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
75715134|NCT00967252|Other|Control|No statin being taken
76041908|NCT04788121|Other|Standard of care|For management, initial priority will be given to secure airway, breathing and circulation. To ensure hemodynamic stability, crystalloids infusion will be given as and when required. Blood transfusion will be initiated at the threshold hemoglobin (Hb) of 7g/dl, to maintain the target Hb of 7-9g/dl or with signs of hemodynamic instability despite fluid resuscitation. Intra venous (IV) PPI and antibiotic will be started promptly in all cases and IV splanchnic vasoconstrictor will be given in all suspicious case of Variceal hemorrhage before definitive therapeutic and diagnostic endoscopic procedure is done.
76041909|NCT04811053|Drug|HR021618|Treatment group A: HR021618 injection
75413502|NCT05767710|Behavioral|general telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
75556744|NCT02737046|Drug|Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
75556745|NCT02737046|Drug|Pegylated Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
75556746|NCT02724878|Drug|Bevacizumab|
75556747|NCT02724878|Drug|Atezolizumab|
75556748|NCT02724371|Device|Mentor Larger Size MemoryGel Ultra High Profile Breast Implant|The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
75556749|NCT02713607|Drug|Doxycycline|Given doxycycline to acne subjects
75413503|NCT05767710|Behavioral|traditional rehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
76041910|NCT04811053|Drug|Placebo|Treatment group B: Saline injection
75413504|NCT05767710|Behavioral|AI telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
76041911|NCT04810819|Drug|Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;|Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
76041912|NCT04810819|Drug|Placebo|Placebo
76041913|NCT04799509|Procedure|VATS lobectomy|VATS lobectomy
75556750|NCT02699606|Drug|Erdafitinib|Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.
75556751|NCT02698254|Biological|Bevacizumab|
75556752|NCT02698254|Other|Quality-of-Life Assessment|Ancillary studies
75556753|NCT02698254|Radiation|Radiation Therapy|Undergo radiation therapy with conventional fractionation
75556754|NCT02688894|Other|No treatment is included in this protocol.|"Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.~Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists."
75556755|NCT02669173|Drug|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
75556756|NCT02669173|Drug|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
75556757|NCT02661464|Biological|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
76041914|NCT04810663|Radiation|Radiotherapy|Adjuvant Radiotherapy in operated gastric cancer
76041915|NCT04810507|Drug|Anagliptin BID Treatment|Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
76041916|NCT04810585|Drug|Aflibercept + FOLFIRI|"Day 1. Aflibercept + FOLFIRI~aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)~Folinic acid: 400 mg/m2 IV infusion for over 2 hours~Irinotecan: 150 mg/m2 IV infusion for over 1 hours~5-FU: 400 mg/m2 IV bolus injection for over 5 minute~5-FU: 2400 mg/m2 IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity"
76041917|NCT04787887|Drug|Abcertin|60IU/kg Single Intravenous Administration
75556758|NCT02661464|Biological|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
76041918|NCT04787887|Drug|EU-sourced Cerezyme|60IU/kg Single Intravenous Administration
75413505|NCT05767710|Behavioral|general telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
75413506|NCT05767710|Behavioral|traditional rehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
75556759|NCT02650401|Drug|Entrectinib|TRKA/B/C, ROS1, and ALK inhibitor
75556760|NCT02647203|Drug|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
75715135|NCT00890955|Drug|Amrubicin|"Dose Level -1: 20mg/m2~Dose Level 1: 25mg/m2~Dose Level 2: 30mg/m2~Dose Level 3: 35mg/m2~Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
75715136|NCT00890955|Drug|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
75715137|NCT00974896|Drug|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
75715138|NCT04008550|Procedure|Right Heart Catheterization|A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
75715139|NCT00893295|Other|informational intervention|
75715140|NCT00893295|Other|medical chart review|
75556761|NCT02647021|Behavioral|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
75556762|NCT02647021|Behavioral|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
75715141|NCT00893295|Other|screening questionnaire administration|
75715142|NCT00893295|Other|study of socioeconomic and demographic variables|
75556763|NCT02618408|Drug|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
75715143|NCT00893295|Procedure|barium enema injection|
75715144|NCT00893295|Procedure|colon imaging study|
75715145|NCT00893295|Procedure|screening colonoscopy|
75715146|NCT00893295|Procedure|sigmoidoscopy|
75715147|NCT00975052|Drug|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
75715148|NCT00975052|Drug|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
75715149|NCT00975052|Drug|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
75715150|NCT00975052|Drug|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
75715151|NCT00891033|Drug|Bortezomib (Velcade)|During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
75715152|NCT00891033|Drug|Panobinostat|During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
75715153|NCT00770952|Drug|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
76041919|NCT04799041|Drug|GTX 2/3|There were 15 patients in this group. Each one received only one treatment.
76041920|NCT04799041|Drug|Placebo|There were 15 patients in this group. Each one received only one treatment.
76041921|NCT02347761|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
76041922|NCT02347761|Drug|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
76041923|NCT02347761|Drug|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
76041924|NCT04798807|Diagnostic Test|Nutritional screening|
76041925|NCT04798963|Procedure|On-clamp partial nephrectomy|Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)
76041926|NCT04798963|Procedure|Off-clamp partial nephrectomy|Partial nephrectomy will performed without renal artery clamping
75556764|NCT02618408|Drug|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
75413507|NCT05767671|Other|Non-Bronchoscopic Mini Bronchoalveolar Lavage|"A minimally invasive technique frequently used in the ICU to obtain alveolar fluid samples from mechanically ventilated patients. The technique uses a commercially available telescoping catheter with a curved distal tip that allows the operator to direct the catheter into the right or left lung. The catheter is passed through an air-tight adapter on the distal end of the endotracheal tube and gently advanced to the desired lung until resistance is encountered. The inner catheter is then advanced until resistance is again encountered, signifying that the distal catheter tip is wedged. 20ml of sterile saline is instilled into the catheter followed by 5 ml of air, and the fluid aspirated. Two additional 20ml aliquots of sterile saline are injected and aspirated in a similar fashion. Specimens are pooled and on average provide a combined volume of 10ml."
75715154|NCT00770952|Drug|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
75715155|NCT00891111|Behavioral|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
75413508|NCT05767632|Drug|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg & 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
75715156|NCT00891111|Behavioral|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
75715157|NCT00764556|Drug|Insulin|Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
75715158|NCT00968578|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
75413509|NCT05767632|Drug|Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)|1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg & Mirabegron 50 mg orally administrated followed by 240 ml of water
75413510|NCT05767632|Drug|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg & 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
75715159|NCT00968578|Drug|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
75715160|NCT00893373|Drug|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
75715161|NCT00893373|Drug|placebo|Standard AML chemotherapy plus placebo
75715162|NCT00891267|Drug|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
75715163|NCT00891267|Drug|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
75715164|NCT00891267|Drug|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
75413511|NCT05767593|Device|Wearing Samsung smartwatch and filling out daily surveys|Participants will wear a Samsung smartwatch and fill out daily surveys about their mood and depressive symptoms.
75413512|NCT05767580|Other|evaluation|The Timed Get Up and Go test to assess dual-tasking, the 4m Walk Test to assess gait, and the Footprint Method to assess cadence
75715165|NCT04036617|Drug|NaQuinate|SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
75715166|NCT04036617|Drug|Placebo|SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
76041927|NCT04798729|Device|Digital Occlusal Recording with T-Scan|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the T-Scan (T-Scan III, version 9.1, Tekscan Inc., South Boston, USA).
75715167|NCT00891345|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
76041928|NCT04798729|Device|Digital Occlusal Recording with Cerec Omnicam|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the CEREC Omnicam™ (version 4.2, Sirona Dental Systems, New York, USA).
76041929|NCT04787263|Biological|CD19-CAR_Lenti T cell|Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10^6 CAR+ cells/kg.
76041930|NCT04810039|Other|Predict the outcome of the Glasgow Outcome Scale|Predict the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
76041931|NCT04809727|Procedure|Cervical biopsy|4 quadrant biopsy
76041932|NCT04798417|Dietary Supplement|Probiotic supplement|Use of a probiotic sachet
76041933|NCT04798417|Dietary Supplement|Prebiotic supplement|Prebiotic sachets
75413513|NCT05767541|Other|Pilates exercises|The Pilates technique consist of hundred, swimming, prone leg lift, single leg stretch, spine stretch forward, arm circles, imprint and release, one leg circles and mini squat.
75413514|NCT05767541|Other|Resistance exercises|Resistance training include leg press, shoulder press, bench press, back arm press, seated row, knee extension, leg curl and seated calf raise
75413515|NCT05767528|Diagnostic Test|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing|Conducting the neoadjuvant therapy of FDA-approved drugs for patients with muscle-invasive bladder carcinoma, culturing the patient-derived tumor-like cell clusters for drug sensitivity testing simultaneously, then assess the accuracy of the diagnostic test by combination and analysis of these results
75413516|NCT05767515|Drug|metformin|Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
75715168|NCT02541279|Procedure|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
75715169|NCT00545584|Drug|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
75715170|NCT00545584|Behavioral|Comparator: Diet|Diet
75715171|NCT00545584|Behavioral|Comparator: Physical Activity|Physical Activity
75715172|NCT00378703|Biological|Bevacizumab|Given IV
76041934|NCT04798417|Dietary Supplement|Maltodextrin|Placebo comparator
76041935|NCT04426747|Other|No intervention|No intervention
76041936|NCT04809649|Drug|SUBA-itraconazole|Participant will receive treatment with SUBA-itraconazole
76041937|NCT04354831|Biological|anti-SARS-CoV-2 convalescent plasma|"SARS-CoV-2 convalescent plasma (1-2 units; ~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~Study drug will be administered as a single intravenous infusion"
76041938|NCT04787185|Radiation|Valutation of toxicity|"Observation of toxicity~All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy"
76041939|NCT04786795|Drug|Compound Azintamide Enteric-coated Tablets|the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
75556765|NCT02618408|Drug|Placebo|Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
75715173|NCT00378703|Other|Laboratory Biomarker Analysis|Correlative studies
75715174|NCT00378703|Other|Pharmacological Study|Correlative studies
75715175|NCT00378703|Drug|Sorafenib Tosylate|Given PO
75715176|NCT00378703|Drug|Temsirolimus|Given IV
75715177|NCT00893451|Drug|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
76041940|NCT04786795|Drug|Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets|the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
75872983|NCT05199675|Behavioral|Digital Peer Support Training Program|The digital peer support training program will consist of bite size modules on the four active ingredients of youth mental well-being, which will be delivered through training workshops, simulation activities, and homework assignments. The training will be conducted over 8 sessions, each lasting for 45-60 minutes following the typical duration of a school lesson on Character and Citizenship Education. The training workshops will be conducted as part of the school's Character and Citizenship Education lessons. The proficiency of participants in applying these digital support skills will be evaluated through simulation and homework activities, in which they apply the four active ingredients in their responses to mock letters that are adapted from actual cases of peer emotional disclosure. At the end of the training, adolescents are expected to apply the four active ingredients to the homework assignments on peers' emotional experiences.
75872984|NCT05109156|Other|This is an observational study|This is an observational study
75413517|NCT05767502|Diagnostic Test|GCS-Pupil score|"GCS+attributed verbal score- Step 1 to obtain pupillary score:~Patients with a motor (M) and eye-opening response (E) total score between 2 and 6 are assigned a verbal score of +1~Patients with an M+E score of 7 are assigned a verbal score of +2~Patients with an M+E score of 8-9 are assigned a verbal score of +4~Patients with an M+E score of 10 are assigned a verbal score of +5~GCS+attributed verbal score- Step 2 to obtain the pupillary score:~The total score is obtained by subtracting the pupil score from the score obtained in the 1st step. Pupil score is scored as follows;~0 points if both pupils react to light,~1 point if a pupil does not react to light and has anisocoria,~2 points if both pupils do not react to light"
75715178|NCT00893451|Drug|Placebo|Placebo orally twice daily
75715179|NCT00893529|Dietary Supplement|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
75413518|NCT05767489|Combination Product|electroencephalogram (EEG) and magnetic resonance (MR)|"High-resolution 3D T1 and T2 sequences, acquired in the sagittal plane and MR reconstructed in the remaining orthogonal planes, for morphological assessment of different cortical and subcortical.~EEG tracing involving recording channels such as eye tracking (eye-tracking: electrooculogram, pupillometry, saccades, fixation times on areas predefined areas), performance measures (response times), electrocardiogram and electromyogram proper to clinical acquisition"
75413519|NCT05767476|Diagnostic Test|Clinical and instrumental neurological assessment|"Participants will be involved in serial assessment:~Neonatal Cranial Ultrasonography~Brain magnetic resonance imaging~Neurological assessment~Neurodevelopmental and cognitive assessment~Electroencephalogram (EEG)~Motor performance assessment"
75715180|NCT00893529|Dietary Supplement|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
75715181|NCT00967408|Drug|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
76041941|NCT04375189|Other|High Risk Clinic|"Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations"
75715182|NCT00967408|Drug|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
75715183|NCT00967408|Other|Rehabilitative treatment|Rehabilitative treatment
75715184|NCT00891423|Drug|Meropenem short infusion|
75715185|NCT00891423|Drug|Meropenem extended infusion|
75715186|NCT04035382|Procedure|Labor induction|The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
75556766|NCT02611453|Other|"Air contrast cholangiography using carbon dioxide gas"|Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
75556767|NCT02609776|Drug|Amivantamab|The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
75556768|NCT02609776|Drug|Amivantamab|Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
75715187|NCT00891501|Procedure|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
75413520|NCT05767450|Dietary Supplement|Probiotic Vivomixx®|The correct number of Vivomixx® sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
75715188|NCT00891501|Procedure|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
75715189|NCT00967564|Other|epidemiologic study|QoL assessment
75715190|NCT02541045|Drug|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
75715191|NCT02541045|Other|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
75715192|NCT05131282|Diagnostic Test|Blood test of PE risk|A blood test is applied to women at the 1st or early 2nd trimester to evaluate risk of developing PE
75413521|NCT05767450|Dietary Supplement|Placebo|The correct number of Placebo sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
75413522|NCT05767385|Procedure|Single Arm|"Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care.~Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete.~Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline."
76041942|NCT04809337|Other|Exercise|After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
75413523|NCT05767385|Procedure|Neonatal Neurobehavioral Scale|Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) evaluation: All neonates with CHD expected to undergo neonatal cardiac intervention or surgery have pre-operative NNNS assessment as PCH as standard of care. The NNNS takes approximately 30 minutes to complete. It is administered by a licensed physical, speech, or occupational therapist who has completed training and additional certification. The NNNS therapist will be blinded to the results of the fetal echocardiogram and MCA-PI.
75413524|NCT05767320|Procedure|open repair(exploration)|repair of defect of perforated peptic ulcer and peritoneal decontamination by exploration
75413525|NCT05767320|Procedure|abdominal laparoscopy|repair of defect of perforated peptic ulcer and peritoneal decontamination by laparoscopy
75413526|NCT05767281|Behavioral|prevention program|introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
75715193|NCT00968656|Radiation|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
75715194|NCT00968656|Other|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
75715195|NCT00968656|Other|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
75715196|NCT00968656|Other|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
76041943|NCT04808635|Other|no intervention, this is a cross sectional questionnaire based study.|no intervention, this is an observational cross sectional study
75413527|NCT05767268|Device|Lokomat|gait rehabilitation
75413528|NCT05767255|Drug|insulin degludec + liraglutide|The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent and safe drug that reduces the risk of hypoglycemia.
75715197|NCT00968656|Drug|F-18-ISO|Patients receive F-18-ISO-1 i.v.
75715198|NCT04036149|Device|Intraocular lens|Implantation as part of cataract surgery
76041944|NCT05614219|Other|Biochemistry interpretive comment on elevated LDL-C levels|The interpretive comment on LDL-C will encourage for excluding secondary dyslipidemia (measuring Hba1C, TSH and checking current drugs and talk about diet). If secondary dyslipidemia ca be excluded we encourage to referral to lipid clinic. Familial hypercholesterolemia should be suspected if LDL-C > 4 mmol/L in persons under the age of 40, or LDL-C > 5 mmol/L in persons over the age of 40. The biochemistry interpretive comment will thus be released to the referring physician if the blood sample meet the criteria above. We advice that in pregnant women to control elevated LDL-C after childbirth.
75715199|NCT00975442|Other|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
75715200|NCT00975442|Device|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
75715201|NCT00975442|Device|Forearm band|All patients were instructed to use a forearm band during all daily activities.
75413529|NCT05767255|Drug|Insulin Glargine - Insulin Aspart|The insulin dose of the basal group will be adjusted according to the blood glucose reports presented by the patients.
75715202|NCT00891579|Drug|Pemetrexed (Alimta)|treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
75715203|NCT00891579|Drug|Gefitinib (IRESSA)|treatment of Gefitinib will be applied until discontinued conditions are met
75715204|NCT00968734|Dietary Supplement|colecalciferol|50.000UI single oral dose
75715205|NCT03620643|Drug|Crizotinib Oral Capsule [Xalkori]|Crizotinib 250 mg Crizotinib 200mg
75715206|NCT03620643|Drug|Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]|Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
75715207|NCT04008316|Drug|Colchicine|colchicine 1mg/day
75715208|NCT00893607|Drug|NRL001|10mg NRL001 was administered as a slow release suppository
75715209|NCT00969046|Drug|EPO906 (patupilone)|
75715210|NCT05011708|Device|I-DROP MGD|I-DROP MGD are eye drop produced by I-MED PHARMA for the management of moderate to severe Dry Eye Disease.
75413530|NCT05767242|Other|Electrophysiological recording|Investigation of early neural markers using electrophysiology at 6-12-24 months
75413531|NCT05767242|Behavioral|Behavioral assessment|Individual behavioral assessment at later ages (3, 4.5, 6, and 8 years)
75413532|NCT05767229|Drug|Carvedilol|Carvedilol 0.2 mg/kg for 1.5 hrs
75413533|NCT05767216|Other|Biological sampling|Blood, skin and stool samples for laboratory analysis
75715211|NCT05011708|Device|Thealoz Duo|I-DROP MGD are eye drop produced by Laboratoires Thea for the management of Dry Eye Disease.
75715212|NCT00893685|Device|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
75715213|NCT05008354|Drug|Pyridoxine|Pyridoxine tablet 40mg once daily
75715214|NCT05008354|Drug|Placebo|Placebo tablet once daily
75715215|NCT00975754|Drug|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
75715216|NCT00975754|Drug|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
75715217|NCT00975754|Drug|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
75413534|NCT05767203|Other|Biological samplings|Blood and/or skin samples
75413535|NCT05767164|Procedure|cervical single open-door surgery|The patients were operated by the cervical single open-door surgery, which were used with the Centerpiece titanium plate to internal fixation.
75413536|NCT05767138|Behavioral|HPV Vaccine Acceptance Survey|
76041945|NCT04241575|Diagnostic Test|Simple fibrosis scores and electronic reminder messages|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
75413537|NCT05767125|Device|APRV|Patients with moderate-to-severe ARDS were supported with APRV.
75413538|NCT05767125|Device|LTV|Patients with moderate-to-severe ARDS were supported with LTV.
75413539|NCT05767112|Other|Supplement administation|HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.
75413540|NCT05767099|Diagnostic Test|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
75715218|NCT00975754|Drug|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
75715219|NCT01045681|Drug|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
75715220|NCT00868647|Procedure|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
75715221|NCT00868725|Other|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
75715222|NCT00975910|Drug|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
75715223|NCT00975910|Drug|saline|Saline arm: infused at the same rate as lidocaine
75715224|NCT01048567|Other|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
75413541|NCT05767060|Drug|BAT7104 injection|According to the protocol, each dose group is given intravenous infusion at the rate of mg/kg, and the recommended infusion time is ≥ 60 minutes. Once every two weeks (Q2W), on the first day of each cycle.
75715225|NCT01048567|Other|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
76041946|NCT02596945|Drug|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
75715226|NCT00969202|Radiation|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
75715227|NCT01051375|Behavioral|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
75715228|NCT03617913|Drug|Avelumab|Given IV
75715229|NCT03617913|Drug|Cisplatin|Given IV
75715230|NCT03617913|Drug|Fluorouracil|Given IV
75715231|NCT03617913|Drug|Mitomycin|Given IV
75715232|NCT03617913|Other|Quality-of-Life Assessment|Ancillary studies
75715233|NCT03617913|Radiation|Radiation Therapy|Undergo RT
75715234|NCT05073328|Other|COVID-19 required hospitalisation|Patients who contracted a COVID19 required hospitalisation
75413542|NCT05765968|Procedure|Double Stimulation Protocol|cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle
75413543|NCT05765968|Procedure|Antagonist Stimulation Protocol|cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
75413544|NCT05765955|Drug|POLB 001|Investigational Medicinal Product
75413545|NCT05765955|Drug|Placebo|Matching Placebo
76041947|NCT04761523|Behavioral|Dietary intervention: reduced fat diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
75556769|NCT02609776|Drug|Lazertinib|Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
76041948|NCT04761523|Behavioral|Dietary intervention: standard healthy diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
76041949|NCT04786483|Other|Laughter Theraphy|"Laughter therapy will be applied for 60 minutes, 10 sessions, 2 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality. The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
75413546|NCT05765214|Behavioral|Intervention Group (IG)|"In general, the education will cover:~(i) Colorectal cancer - knowledge, perceptions, self-care, and social norms (CRC-KPSS): Knowledge; Perceptions (perceived susceptibility, perceived severity, perceived benefits, perceived barriers); Self-care; and Social norms; and information on colorectal cancer screening (ii) Healthy nutrition colorectal for cancer risk reduction and complementary to diabetes guideline (increasing consumption of fiber, fruits, vegetables, whole grains, and calcium; reducing red and processed meat, fat, added sugars and alcohol)"
75413547|NCT05764694|Other|bullied children|A questionnaire will be answered by parent to measure the primary outcome of the study, which is Presence, duration, and frequency of Oral habits (Bruxism, Nail biting) in addition to a questionnaire answered by child to measure the secondary outcome which is Prevalence of Bullying and victimization.
75556770|NCT02609776|Drug|Carboplatin|Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
75413548|NCT05764031|Other|Clinical pilates exercise|Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.
75413549|NCT05764031|Other|Aerobic exercise|Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
75556771|NCT02609776|Drug|Pemetrexed|Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
76041950|NCT04786327|Procedure|Minimal invasive flap technique|contained defect treated with Minimally invasive flap
76041951|NCT04786327|Procedure|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
76041952|NCT04786327|Combination Product|minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S|contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
76041953|NCT05614141|Device|Lokomat Augmented Performance Feedback|All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.
76041954|NCT05614141|Other|Conventional Physiotherapy|Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
76041955|NCT04153435|Drug|Calcium Chloride|Calcium chloride 5 mmol
76041956|NCT04153435|Drug|Sodium chloride 0.9%|Placebo
75556772|NCT02601950|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
75556773|NCT02592317|Drug|JNJ 56021927|JNJ 56021927 will be administered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
75556774|NCT02592317|Drug|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.
75413550|NCT05763641|Procedure|Target Axillary Dissection|TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
75413551|NCT05762965|Dietary Supplement|GOS 1|1 sachet each morning
75413552|NCT05762965|Dietary Supplement|GOS 2|1 sachet each morning
75413553|NCT05761691|Procedure|Dental treatment|Children treated for ECC under general (DGA) and local anesthesia (LA).
75556775|NCT02592317|Drug|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
75556776|NCT02592317|Drug|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
75556777|NCT02568267|Drug|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
75556778|NCT02531516|Drug|Apalutamide|
75556779|NCT02531516|Drug|Bicalutamide|
75556780|NCT02531516|Drug|Bicalutamide Placebo|
75556781|NCT02531516|Drug|Apalutamide Placebo|
75556782|NCT02531516|Drug|GnRH (agonist)|
76041957|NCT04121845|Device|Coronary Sinus Reducer device|Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
76041958|NCT04121845|Other|Sham procedure|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
76041959|NCT02404389|Drug|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
76041960|NCT02404389|Drug|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
76041961|NCT01667419|Drug|Vemurafenib|4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
76041962|NCT01667419|Drug|Placebo|Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
76041963|NCT04786015|Other|Active Surveillance Reporting System|A system to actively record change in symptoms older adult patients experience following a chiropractic visit.
76041964|NCT04089709|Behavioral|Well-arm Exercise|Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
76041965|NCT04808791|Drug|Irinotecan|"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."
76041966|NCT04808791|Drug|Oxaliplatin|"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."
75413554|NCT05759741|Drug|MIYAIRI 588|4 tablets of MIYAIRI 588 were inserted into the distal ileostomy once a week for 6 months
75413555|NCT05759533|Procedure|Corrected carotid flow time, IVC diameter|Corrected carotid flow time correction: is the carotid systole time, with heart rate correction applied IVC Collapsibility Index measurement is a reliable predictor of intraoperative hypotension within 30 minutes of spinal anesthetic administration
75413556|NCT05759065|Behavioral|Tele-Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) comprises of up to five weekly intervention visits by phone, delivered by a variety of practitioners without formal training in sleep.
75413557|NCT05759065|Behavioral|Tele-Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) is a multicomponent strategy delivered by trained mental health clinicians over 6 to 12 weeks.
75413558|NCT05758220|Device|MRI|Structural MRI volumetry, resting functional MRI & MR spectroscopy
75413559|NCT05757427|Device|Wavelia #2|Patients who are eligible and consent to have an MBI breast scan procedure will be asked to confirm their willingness to participate on the day of the breast scan. The patient will first have an OBCD scan, to reconstruct the external surface of the breast with high-precision, measure the total volume and the vertical extent of the breast before the MBI scan. The MBI scan will be performed on both breasts. The process will include optimization of breast positioning and breast cleaning to remove any transition liquid remaining on the skin.
75556783|NCT02531516|Radiation|74-80 Grays (units of radiation)|
75556784|NCT02502786|Biological|humanized anti-GD2 antibody|
75556785|NCT02502786|Drug|GM-CSF|
75556786|NCT02499172|Biological|Shanchol|
75556787|NCT02494986|Drug|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
75556788|NCT02478099|Drug|MPDL3280A|Anti-PD-L1 antibody
75556789|NCT02455687|Drug|Hi-dose iv MgSO4|
75556790|NCT02455687|Drug|Nebulized budesonide|
75556791|NCT02455687|Drug|Std-dose iv MgSO4|
75556792|NCT02455687|Drug|Nebulized normal saline|
75556793|NCT02446964|Procedure|Bone Marrow Transplantation|Undergo bone marrow transplant
75556794|NCT02446964|Drug|Cyclophosphamide|Given IV
75556795|NCT02446964|Drug|Fludarabine Phosphate|Given IV
75556796|NCT02446964|Other|Laboratory Biomarker Analysis|Correlative studies
75556797|NCT02446964|Drug|Mycophenolate Mofetil|Given PO or IV
75556798|NCT02446964|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
75556799|NCT02446964|Drug|Tacrolimus|Given IV and PO
75413560|NCT05753267|Drug|Mesalamine|Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC
75413561|NCT05753267|Drug|Fenofibrate 160mg|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.
75556800|NCT02446964|Radiation|Total Marrow Irradiation|Undergo TMLI
76041967|NCT04808791|Drug|TAS 102 (Trifluridine/Tipiracil)|"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"
76041968|NCT04808557|Other|Biorepair Total Protection|Volunteers will use Biorepair Total Protection for home oral hygiene for the following 30 days from the bonding procedure.
76041969|NCT04808557|Other|Sensodyne Repair & Protect|Volunteers will use Sensodyne Repair & Protect for home oral hygiene for the following 30 days from the bonding procedure.
75413562|NCT05751343|Drug|TACE-HACI, plus atezolizumab-bevacizumab|transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
75413563|NCT05750914|Device|Broadband Light|Broadband Light treatment using standard protocol
75556801|NCT02446600|Procedure|Biospecimen Collection|Undergo blood sample collection
75556802|NCT02446600|Drug|Carboplatin|Given IV
75556803|NCT02446600|Drug|Cediranib Maleate|Given PO
75556804|NCT02446600|Procedure|Computed Tomography|Undergo CT
75556805|NCT02446600|Procedure|Echocardiography|Undergo ECHO
75556806|NCT02446600|Drug|Gemcitabine|Given IV
75556807|NCT02446600|Drug|Gemcitabine Hydrochloride|Given IV
75556808|NCT02446600|Other|Laboratory Biomarker Analysis|Correlative studies
75556809|NCT02446600|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556810|NCT02446600|Procedure|Multigated Acquisition Scan|Undergo MUGA
75556811|NCT02446600|Drug|Olaparib|Given PO
75556812|NCT02446600|Drug|Paclitaxel|Given IV
75413564|NCT05742373|Other|Exercise training in the fasted state|Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal
75413565|NCT05742373|Other|Exercise training in the fed state|Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal
75413566|NCT05737134|Other|MA_PESAN MOBILE APPLICATION|The intervention group was given a mobile application consisting of video, and educational material that information was provided regarding the prevention of child sexual abuse.
75413567|NCT05736900|Diagnostic Test|Blood sampling|One samples of 5 mL blood is taken into a Serum tube for measurement of the RAAS-Biomarkers. After allowing to coagulate between 30 min and 60 min at room temperature, samples are centrifuged at 3000g for 10 min at room temperature.
75556813|NCT02446600|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75556814|NCT02446600|Other|Pharmacological Study|Correlative studies
75556815|NCT02446600|Other|Quality-of-Life Assessment|Ancillary studies
75556816|NCT02395367|Procedure|resection|This is an observational study. And we are interested in observing the outcome of different treatment methods.
75556817|NCT02395367|Radiation|adjuvant radiotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
75556818|NCT02395367|Drug|neoadjuvant chemotherapy or adjuvant chemotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
75556819|NCT02354014|Drug|Bedaquiline (TMC207)|TMC207 oral tablet adult formulation (containing 100 mg TMC207 per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg TMC207. Bedaquiline (TMC207) tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of TMC207 8 mg/kg qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4, TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3.
75715235|NCT00975988|Drug|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
75413568|NCT05708417|Behavioral|Lifestyle Intervention|"The intervention in SDOI has the predominantly focus on each individual reflection and realisation and is built upon ACT' six core processes: 1) Acceptance, 2) Cognitive defusion 3) Being present, 4) Self as context, 5) Values, and 6) Committed action.~The program is based on up to 13 times attendance within the 12 months intervention period."
75556820|NCT02354014|Drug|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
75556821|NCT02351063|Drug|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
75556822|NCT02346396|Device|tDCS (use at home)|During 4 weeks (every week : 20 minutes / day during 5 days)
75556823|NCT02323880|Other|Pharmacological Study|Correlative studies
75556824|NCT02323880|Drug|Selinexor|Given PO
75556825|NCT02316106|Drug|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
75556826|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
75556827|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
75413569|NCT05708417|Other|Placebo|No lifestyle intervention within the study, only test/datacollection
75413570|NCT05700227|Radiation|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
75413571|NCT05683275|Other|IASTM|IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute.
75413572|NCT05683275|Other|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application.
75556828|NCT02298959|Procedure|Biopsy|Undergo tumor biopsy
75556829|NCT02298959|Procedure|Biospecimen Collection|Undergo blood sample collection
75413573|NCT05683275|Other|Home Exercise|Special static stretching and eccentric strengthening exercises for the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks.
75556830|NCT02298959|Procedure|Computed Tomography|Undergo CT scan
75556831|NCT02298959|Procedure|Magnetic Resonance Elastography|Undergo MRI
75556832|NCT02298959|Biological|Pembrolizumab|Given IV
75556833|NCT02298959|Biological|Ziv-Aflibercept|Given IV
75413574|NCT05679752|Other|Facial PNF technique|Stimulation techniques used to facilitate the weak muscle groups
75413575|NCT05679752|Other|Massage therapy|frictional massage to stimulate the weak muscle groups
75556834|NCT02270814|Drug|nab-paclitaxel|
75556835|NCT02270814|Drug|Cisplatin|
75556836|NCT02270814|Drug|Carboplatin|
75556837|NCT02270814|Biological|Cetuximab|
75413576|NCT05677568|Device|Carillon Mitral Contour System|"The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components:~A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly~A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation."
75556838|NCT02228681|Drug|Everolimus|10mg daily by mouth
75556839|NCT02228681|Drug|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
75556840|NCT02228681|Drug|Letrozole|2.5mg once a day by mouth
75556841|NCT02228681|Drug|Medroxyprogesterone Acetate|200 mg daily by mouth
75556842|NCT02213107|Drug|Enzalutamide and Dutasteride or finasteride|"Use of either two oral drugs together~Enzalutamide by mouth daily and dutasteride by mouth daily or~Enzalutamide by mouth daily and finasteride by mouth daily"
75556843|NCT02143414|Procedure|Biopsy|Undergo a biopsy
75556844|NCT02143414|Procedure|Biospecimen Collection|Undergo a blood sample collection
75556845|NCT02143414|Biological|Blinatumomab|Given IV
75556846|NCT02143414|Procedure|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
75556847|NCT02143414|Procedure|Computed Tomography|Undergo a CT scan
75556848|NCT02143414|Drug|Dasatinib|Given PO
75556849|NCT02143414|Procedure|Echocardiography|Undergo ECHO
75556850|NCT02143414|Procedure|Lumbar Puncture|Undergo a lumbar puncture
75556851|NCT02143414|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556852|NCT02143414|Drug|Mercaptopurine|Given PO
75556853|NCT02143414|Drug|Methotrexate|Given PO
75556854|NCT02143414|Drug|Methotrexate Sodium|Given PO
75556855|NCT02143414|Drug|Prednisone|Given PO
75556856|NCT02143414|Drug|Vincristine|Given IV
75556857|NCT02143414|Drug|Vincristine Sulfate|Given IV
75556858|NCT02143414|Procedure|X-Ray Imaging|Undergo an x-ray
75556859|NCT02123758|Drug|Abiraterone Acetate|Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
75556860|NCT02123758|Drug|Prednisone|Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
75556861|NCT02123758|Drug|JNJ-56021927|Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
75556862|NCT02115282|Procedure|Biospecimen Collection|Undergo collection of blood and archived tissue samples
75556863|NCT02115282|Procedure|Computed Tomography|Undergo CT
75556864|NCT02115282|Drug|Entinostat|Given PO
75556865|NCT02115282|Drug|Exemestane|Given PO
75413577|NCT05668663|Diagnostic Test|Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample|"If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.~The blood sample will be collected up to 3 days after admission"
75413578|NCT05668208|Device|E-CUBE i7 ultrasound system (Alpinion Medical Systems, Seoul, Republic of Korea)|ONSD measurement will be made using the E-CUBE i7 ultrasound system.
75413579|NCT05655442|Procedure|early APM|early APM within 3 and 6 month knee pain symptoms
75413580|NCT05655442|Procedure|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
75556866|NCT02115282|Drug|Goserelin|Given PO
75556867|NCT02115282|Drug|Goserelin Acetate|Given SC
75556868|NCT02115282|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556869|NCT02115282|Other|Placebo Administration|Given PO
75556870|NCT02115282|Other|Quality-of-Life Assessment|Ancillary studies
75556871|NCT02111941|Other|Laboratory Biomarker Analysis|Correlative studies
75556872|NCT02111941|Biological|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
75556873|NCT01998971|Drug|Daratumumab|Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.
75556874|NCT01998971|Drug|Velcade|Administered subcutaneously in accordance with product labeling and local standards.
75556875|NCT01998971|Drug|Pomalidomide|Administered orally in accordance with product labeling and local standards.
75556876|NCT01998971|Drug|Dexamethasone|Administered intravenously or orally in accordance with product labeling and local standards.
75556877|NCT01998971|Drug|Melphalan|Administered orally in accordance with product labeling and local standards.
75556878|NCT01998971|Drug|Prednisone|Administered intravenously or orally in accordance with product labeling and local standards.
75556879|NCT01998971|Drug|Thalidomide|Administered orally in accordance with product labeling and local standards.
75556880|NCT01998971|Drug|Diphenhydramine|Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
75556881|NCT01998971|Drug|Acetaminophen|Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
75556882|NCT01998971|Drug|Carfilzomib|Administered intravenously in accordance with product labeling and local standards.
75556883|NCT01998971|Drug|Lenalidomide|Administered orally in accordance with product labeling and local standards.
75556884|NCT01998971|Drug|Montelukast|Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
75556885|NCT01991977|Procedure|Diffusion Weighted Imaging|Undergo DTI
75556886|NCT01991977|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET
75556887|NCT01991977|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75556888|NCT01991977|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
75556889|NCT01991977|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET
75556890|NCT01991977|Other|Quality-of-Life Assessment|Ancillary studies
75556891|NCT01991977|Drug|Temozolomide|Receive temozolomide
75556892|NCT01989585|Procedure|Biopsy|Undergo biopsy
75556893|NCT01989585|Procedure|Biospecimen Collection|Undergo collection of blood samples
75556894|NCT01989585|Procedure|Computed Tomography|Undergo CT
75872985|NCT05059314|Other|Brisk walking (moderate physical activity)|"Warm up and cool down~Brisk walk (30 mintues each session per week 5 days)~Week 1 to 6"
75556895|NCT01989585|Drug|Dabrafenib|Given PO
75556896|NCT01989585|Other|Laboratory Biomarker Analysis|Correlative studies
75556897|NCT01989585|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556898|NCT01989585|Biological|Navitoclax|Given PO
75556899|NCT01989585|Other|Pharmacological Study|Correlative studies
75556900|NCT01989585|Drug|Trametinib|Given PO
75556901|NCT01941277|Behavioral|Current Recommendations Exercise Group|
75556902|NCT01941277|Behavioral|Intensive Exercise Group|
75556903|NCT01938261|Drug|paracetamol|
75556904|NCT01938261|Drug|0.45 % saline solution|Placebo
75556905|NCT01934582|Drug|UT-15C SR|
75556906|NCT01934582|Drug|treprostinil diethanolamine|Open label study drug.
75556907|NCT01922076|Drug|Adavosertib|Given PO
75556908|NCT01922076|Other|Laboratory Biomarker Analysis|Correlative studies
75872986|NCT05734716|Drug|Erythropoietin|use of erythropoietin to stimulate red blood cell development prior to ascent to altitude
75556909|NCT01922076|Other|Pharmacological Study|Correlative studies
75413581|NCT05655429|Procedure|physical therapy|The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 day per week.
75413582|NCT05655429|Procedure|arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy surgery procedure
75556910|NCT01922076|Radiation|Radiation Therapy|Undergo radiation therapy
75556911|NCT01894854|Procedure|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
75715236|NCT00976066|Drug|Part A Assessing GSK1521498|"Each participant will receive up to three [11C]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan."
75872987|NCT05734716|Drug|Iron sucrose (Venofer)|use of iron sucrose to stimulate red blood cell development prior to ascent to altitude
75872988|NCT05734716|Drug|Sterile Sodium Chloride|sham treatment with sterile saline
76041970|NCT04808089|Other|Health Lung App. of mobile phone+ezOxygen mobile spirometry|"Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~The physicians can get the information about control status, lung function, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
76041971|NCT04808089|Other|Usual care|The research assistant assess/ teach inhaler technique, offering advice on adherence, delivering patient self-management asthma action plan and education the meaning of asthma control accessed by ACT.
75413583|NCT05647681|Drug|Douloff|topic gel
75413584|NCT05647681|Drug|paracetamol|tablets
75413585|NCT05644314|Device|The drug-eluting stent|Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials.
75413586|NCT05644171|Device|RESToration Of Rehabilitative function with Epidural spinal Stimulation|Three patients with chronic motor SCI will be recruited in total for this study. The recruited patients will not be randomized nor blinded due to the nature of this study. Pre-op rehabilitation session will take place over 4 weeks. 1 month post-surgical implants, patients will undergo 24 weeks of rehabilitation. The training sessions may continue to take place after the stipulated 24 weeks as long the electrode remains implanted, and the patient is available.
75556912|NCT01854554|Radiation|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
75556913|NCT01854554|Radiation|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
75556914|NCT01854554|Behavioral|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
75556915|NCT01854554|Behavioral|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
75556916|NCT01817959|Drug|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.
75556917|NCT01817959|Drug|Placebo|Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
75413587|NCT05644145|Biological|Serological study after yellow fever vaccination|It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.
75413588|NCT05642858|Behavioral|Digital Educational Messaging|Education via mobile phone text messages for up to 6 months.
75413589|NCT05642416|Drug|Continuous Infusion of ropivacaine|Continuous infusion of ropivacaine
75413590|NCT05642416|Drug|Intermittent bolus of ropivacaine|Intermittent bolus of ropivacaine
75413591|NCT05636826|Drug|atherolive-drug|placebo
75413592|NCT05632263|Diagnostic Test|EHMRGscore|validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
75413593|NCT05631028|Drug|Dexmedetomidine|Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
76041972|NCT04785937|Diagnostic Test|Ultrasound and Magnetic Resonance|liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
76041973|NCT04785313|Biological|Retrievable Inferior Vena Cava Filters (IVCF)|Analysis anatomopathology of Retrievable Inferior Vena Cava Filters (IVCF) (ALN CF model).
75413594|NCT05631028|Drug|Remimazolam tosilate|Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
75556918|NCT01804686|Drug|Ibrutinib|Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
75556919|NCT01792687|Drug|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
75556920|NCT01792687|Drug|Abiraterone acetate|1,000 mg, oral, daily
75556921|NCT01792687|Drug|Prednisone|5 mg, oral, daily
75556922|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 5 Gy x 5 (over 1-2 weeks)*
75556923|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 6.6 Gy x 5 (over 1-2 weeks)*
75556924|NCT01755195|Drug|Cabozantinib|Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
75556925|NCT01697384|Drug|histrelin acetate|52 week implant
75413595|NCT05625685|Other|Quitbuddy|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD EMA/GPS smoking data collection. GPS guided NRT usage prompts, via hotspot algorithms, will be provided to participants in the Quitbuddy Arm. Participants will contribute four weeks of post-TQD EMA/GPS data to capture lapses and NRT use in real-time. Carbon Monoxide (CO) levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
75413596|NCT05625685|Other|Control|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD smoking data collection. Participants will contribute four weeks of post-TQD data to capture lapses and NRT use. CO levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
75556926|NCT01637987|Procedure|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
75556927|NCT01637987|Procedure|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
75715237|NCT00976066|Drug|Part B Assessing GSK1521498|"The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three [11C]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2)."
75715238|NCT00976066|Drug|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three [11C]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
75715239|NCT00976144|Drug|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
75715240|NCT04008472|Other|Telemedecine|Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
75413597|NCT05625685|Other|SDoH Augmentation|The SDoH intervention is based on the findhelp.org online platform, with customization to meet the specific needs of the study and communities being served: includes validated SDoH assessments, personalized social needs searching based on priorities, access to the most comprehensive social service database, and a streamlined closed loop referral system that integrates with workflows.
75413598|NCT05625685|Other|SDoH Control|No SDoH intervention
75413599|NCT05623228|Combination Product|The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia|The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia.
75413600|NCT05622877|Drug|Qushi Formula|Qushi Formula are decoction granules composed 8 traditional Chinese medicines, such as poria cocos, Macrocephalae Rhizoma, Polyporus, cassia twig, dried ginger and licorice, Etc.
75715241|NCT00969592|Drug|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
75715242|NCT00969592|Drug|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
75715243|NCT00368641|Drug|Extraneal|Periotneal Dialysis
75556928|NCT01637987|Procedure|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein & surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
75556929|NCT01604512|Diagnostic Test|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
75556930|NCT01541709|Drug|imatinib|The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
75556931|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
75556932|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
75556933|NCT01450020|Other|educational intervention|Receive ACS material
75556934|NCT01450020|Other|questionnaire administration|Ancillary studies
75556935|NCT01450020|Other|counseling intervention|Undergo PN session
75556936|NCT01450020|Other|survey administration|Ancillary studies
75556937|NCT01450020|Procedure|quality-of-life assessment|Ancillary studies
75556938|NCT01394263|Drug|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
75556939|NCT01394263|Drug|Zoladex goserelin implant|goserelin implant injection.
75556940|NCT01347567|Other|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
75556941|NCT01263769|Drug|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
75556942|NCT01154764|Drug|CG100649|I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time
75556943|NCT01154764|Drug|Ketoconazole|I period: ketoconazole + CG100649 II period: CG 100649
75715244|NCT00976222|Drug|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
75715245|NCT00979888|Other|educational intervention|
76041974|NCT04785313|Other|Demographics data collection|Demographics data : age, gender, thromboembolic risk factors, Retrievable Inferior Vena Cava Filters (IVCF) (indication, dates of insertion and removal), and anticoagulant management during the period with filter.
76041975|NCT04785235|Procedure|Non-Surgical Periodontal Therapy|
75413601|NCT05622877|Drug|Zhu's Wenban Formula|Zhu's Wenban granules are decoction granules composed of leech, panax notoginseng, Atractylodes Lancea and rhizome
76041976|NCT04807855|Device|The cMLP device|There is only one medical device we are testing, so only one intervention.
76041977|NCT03843853|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1
76041978|NCT03843853|Drug|S-1|S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14
75413602|NCT05622877|Drug|placebo|The placebo was composed of dextrin, powdered sugar, starch, and liquid caramel in the same color as the other two groups.
75556944|NCT01153035|Device|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
75556945|NCT01035983|Drug|Frovatriptan 2.5 mg|
75556946|NCT01013025|Procedure|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
75556947|NCT01004978|Drug|Cisplatin|Undergo TACE
75556948|NCT01004978|Procedure|Computed Tomography|Undergo CT scan
76041979|NCT03843853|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg d1
75556949|NCT01004978|Drug|Doxorubicin Hydrochloride|Undergo TACE
75556950|NCT01004978|Drug|Doxorubicin-Eluting Beads|Undergo TACE
75556951|NCT01004978|Other|Laboratory Biomarker Analysis|Correlative studies
75556952|NCT01004978|Procedure|Magnetic Resonance Imaging|Undergo MRI
75556953|NCT01004978|Drug|Mitomycin|Undergo TACE
75556954|NCT01004978|Other|Pharmacological Study|Correlative studies
75556955|NCT01004978|Other|Placebo Administration|Given PO
75556956|NCT01004978|Drug|Sorafenib Tosylate|Given PO
75556957|NCT00947531|Drug|Cerebrolysin|
75556958|NCT00947531|Drug|0.9% Saline Solution|
75556959|NCT00937001|Procedure|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
75556960|NCT00904540|Drug|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (<6 weeks) LBP, subacute (6 weeks to <3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (>12 months LBP)
76041980|NCT04784767|Biological|25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
76041981|NCT04784767|Drug|Sodium chloride, USP, for injection (0.9% NaCl)|Normal saline will be provided in a sterile, single-use 10 mL vial
76041982|NCT04784767|Biological|50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
76041983|NCT04784611|Behavioral|Our Peers - Empowerment and Navigational Support (OP-ENS) Peer Health Navigator Intervention|Disability peer health navigator mentored and manualized process of barriers identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
75556961|NCT00904202|Drug|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
75556962|NCT00904202|Drug|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
75556963|NCT00904202|Drug|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
75556964|NCT00904202|Drug|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
75556965|NCT00904202|Drug|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
75413603|NCT05622877|Other|Basic treatment|Basic diseases except hyperlipidemia were treated in accordance with the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack. Basic treatment includes conventional treatment such as comprehensive prevention and treatment (actively controlling basic diseases such as hypertension and diabetes and suggesting a good lifestyle), drug therapy (anti-inflammatory, lipid-regulating, anti-platelet aggregation, calcium channel blockers) and so on according to individual conditions of patients.
76041984|NCT04337749|Drug|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
76041985|NCT04337749|Device|ZnO-NPs socks|ZnO-NPs socks were given to patients for 2 weeks
76041986|NCT04337749|Combination Product|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks were given to patients for 2 weeks
75556966|NCT00904202|Drug|Gabapentin 1800 mg/day + Lidoderm patch|
75556967|NCT00904020|Drug|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
75556968|NCT00903110|Drug|Increlex®|Increlex® (mecasermin [rDNA origin] injection), 10 mg/ml solution for injection, 40-120mcg/kg BID or 0,04 to 0,12 mg/kg BID, as prescribed by physician
75556969|NCT00719966|Drug|anastrozole|Patients receive aromatase inhibition therapy.
75556970|NCT00719966|Drug|exemestane|Patients receive aromatase inhibition therapy.
75556971|NCT00719966|Drug|letrozole|Patients receive aromatase inhibition therapy.
75556972|NCT00719966|Procedure|assessment of therapy complications|Endothelial function is measured
75556973|NCT00671008|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
76041987|NCT04337749|Device|Placebo socks|Placebo socks were given to patients for 2 weeks
75556974|NCT00671008|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75556975|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
76041988|NCT05054179|Drug|Ropivacaine 0.2% Injectable Solution Bolus|20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side
76041989|NCT05054179|Other|Normal Saline Infusion|3 mL/hour infusion of normal saline for 48 hours via parasternal multi-orifice catheters on each side of the sternum
75413604|NCT05611047|Other|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
75413605|NCT05611047|Other|Classical cognitive evaluation of several domains:|Information processing speed (IPS) Working memory (WM) Executive functions (EF) Episodic memory (EM) Premorbid intelligence quotient (IQ) Multidomain or complex task
75413606|NCT05611047|Other|Ecological evaluation|Virtual reality task : Urban DailyCog©
75556976|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
75556977|NCT00644033|Drug|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
75556978|NCT00643604|Drug|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
75556979|NCT00606346|Biological|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
75556980|NCT00606346|Drug|No Biologics|Treatments will be prescribed according to investigator judgement.
75556981|NCT00585559|Drug|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
75556982|NCT00585559|Drug|APAP 1 gm every 6 hours and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
75556983|NCT00585559|Drug|NAC IV infusion at 0.5 gm hourly and APAP placebo|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
75556984|NCT00585559|Drug|APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
75556985|NCT00585559|Drug|APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
75556986|NCT00486356|Drug|capecitabine|
75556987|NCT00486356|Drug|carboplatin|
75556988|NCT00486356|Drug|epirubicin hydrochloride|
75556989|NCT00486356|Genetic|microarray analysis|
76041990|NCT05054179|Drug|Ropivacaine 0.2% Injectable Solution Infusion|3 mL/h infusion of Ropivacaine 0.2% for 48 hours via parasternal multi-orifice catheters on each side of the sternum
76041991|NCT03688945|Procedure|Art Therapy|Attend art viewing sessions
76041992|NCT03688945|Other|Best Practice|Receive standard of care
76041993|NCT03688945|Other|Questionnaire Administration|Ancillary studies
76041994|NCT05612113|Behavioral|Live Supervision + Session Goal Formulation|"Read under Arms"
76041995|NCT05612113|Other|Session Goal Formulation|"Read under Arms"
76041996|NCT05014477|Procedure|Removal or leaving of LAA occluders|After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
75556990|NCT00486356|Genetic|polymorphism analysis|
75715246|NCT00979888|Other|informational intervention|
76041997|NCT03679585|Other|Internet-Based Intervention|Undergo Talking Pictures social media intervention
76041998|NCT03679585|Other|Quality-of-Life Assessment|Ancillary studies
76041999|NCT03679585|Other|Questionnaire Administration|Ancillary studies
75556991|NCT00486356|Other|pharmacological study|
75413607|NCT05611047|Behavioral|Patent reported outcomes (PRO's)|"Patent reported outcomes (PRO's) : Beck Depression Inventory (BDI), European Quality of Life-5 Dimensions (EQ-5D-5L) for Health-Related Quality of Life (HRQOL), Multiple Sclerosis Impact Scale-29 Items (MSIS-29), French version of the Modified Fatigue Impact Scale (EMISEP) and State trait anxiety inventory (STAI).~Subjective cognitive deficits: Perceived Deficits Questionnaire (PDQ) and Cognitive Activities Questionnaire (DCAQ)"
75556992|NCT00475514|Drug|Frovatriptan 2.5mg QD|
75556993|NCT00475514|Drug|Frovatriptan 2.5 mg BID|
75556994|NCT00475514|Drug|placebo|
75556995|NCT00471601|Behavioral|counseling intervention|
75556996|NCT00471601|Behavioral|questionnaire administration|
75413608|NCT05611047|Other|Telerehabilitation : active procedure|The Cognitive rehabilitation (CR) consists of weekly 45 minutes online individual session with the unblinded Speech Therapist.
75413609|NCT05611047|Other|Telerehabilitation : comparator procedure|Once per week over a 12-week period completed by daily online exercises performed by the patient 4 days a week.
75556997|NCT00471601|Behavioral|psychosocial assessment and care|
75556998|NCT00471601|Behavioral|quality-of-life assessment|
75556999|NCT00447382|Drug|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
75557000|NCT00447382|Drug|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
75557001|NCT00447382|Drug|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
75557002|NCT00439946|Drug|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
75557003|NCT00439946|Device|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
75557004|NCT00383877|Drug|insulin detemir|
75557005|NCT00383877|Drug|insulin NPH|
75557006|NCT00325403|Drug|Oral treprostinil (UT-15C) Sustained Release Tablets|Sustained release oral tablet, twice daily
75557007|NCT00325403|Other|Placebo|Placebo oral tablet twice daily
75557008|NCT00278785|Behavioral|Brief Motivational Interview|10-20 minute brief motivational interview
75557009|NCT00226421|Drug|Oxymorphone Extended Release|
75557010|NCT00226395|Drug|Oxymorphone immediate release|
75557011|NCT00225797|Drug|Oxymorphone Extended Release|
75557012|NCT00147199|Drug|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
75557013|NCT00147199|Drug|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
75557014|NCT00135668|Drug|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS (Interactive Voice Response System).
75715247|NCT00979888|Other|psychosocial support for caregiver|
75715248|NCT00979888|Other|questionnaire administration|
75715249|NCT00979888|Procedure|dyspnea management|
75715250|NCT00979888|Procedure|management of therapy complications|
75715251|NCT00976300|Drug|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
76042000|NCT04972825|Behavioral|Mind the Gap|This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.
76042001|NCT03588637|Other|No intervention|No intervention
76042002|NCT05472727|Other|reaction time test|Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.
76042003|NCT05472727|Other|Physical fitness test|The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.
76042004|NCT05472571|Other|Forest bathing|The intervention consists of 11 consecutive sessions of forest bathing (one session per week), each one lasting about 2 hours. Each session involves an easy walk through a forest area, interspersed with non-intrusive activities of contact with the surrounding nature aimed at fostering mindfulness and the use of the five senses.
75557015|NCT00135668|Drug|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
75557016|NCT00135668|Drug|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
75557017|NCT00135668|Drug|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS
75413610|NCT05605704|Drug|atherolive|In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
75557018|NCT00066703|Drug|exemestane|
75557019|NCT00066703|Drug|tamoxifen|
75557020|NCT00066703|Drug|triptorelin|
75557021|NCT00066690|Drug|Exemestane|Exemestane 25mg orally daily for 5 years plus ovarian function suppression
75557022|NCT00066690|Other|Laboratory Biomarker Analysis|Correlative studies
75715252|NCT00976300|Drug|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
75715253|NCT00976378|Drug|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
75557023|NCT00066690|Procedure|Oophorectomy|Undergo bilateral surgical oophorectomy
76042005|NCT03529669|Device|Cytosponge™|Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
75413611|NCT05604599|Drug|Intranasal dexmedetomidine|45 -60 min before the operation, patients will receive dose of dexmedetomidine 1microgram/kg diluted in 10ml 0.9% saline administered to each naris as drops + infusion saline
75557024|NCT00066690|Other|Quality-of-Life Assessment|Ancillary studies
75557025|NCT00066690|Radiation|Radiation Therapy|Undergo ovarian irradiation
75557026|NCT00066690|Drug|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
75715254|NCT00976378|Drug|NOX-A12|single IV dose, at efficacious dose level
76042006|NCT05472493|Biological|[18-F]CETO|PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, ~3 mm). CETO (~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from ~0-90 minutes.
76042007|NCT02588833|Drug|Pegcetacoplan|Complement (C3) Inhibitor
76042008|NCT05472415|Other|cognicise|"a combination of cognition and exercise training"
75413612|NCT05604599|Drug|Intravenous dexmedetomidine|patients will receive loading dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia, followed by continuous infusion of (0.4 µ g/kg/h) + intranasal saline.
75557027|NCT00066690|Drug|Triptorelin|3.75 mg by im injection q28 days for 5 years
75557028|NCT00469560|Drug|Deferasirox|
75557029|NCT04704167|Other|fixation of double barrel vascularised fibula|3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
75557030|NCT00469599|Drug|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
75557031|NCT00469599|Drug|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
75715255|NCT00976534|Drug|AZD1386|90 mg, capsules, oral, during 3 weeks
75557032|NCT00429260|Drug|Saredutant|
75715256|NCT00976534|Drug|Placebo|capsules, oral, during 3 weeks
75715257|NCT00979966|Drug|Temsirolimus|25 mg intravenously, once weekly infusion
75715258|NCT00979966|Drug|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
75715259|NCT00969826|Drug|GCPGC, Neulasta, Placebo|A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
75715260|NCT04007926|Behavioral|Aerobic exercise programme|Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
75413613|NCT05603793|Behavioral|Knowledge, Attitude & Practices|The objective the of the KAP intervention is to explore key aspects related to child health and nutrition to better understand the community's knowledge, perception and practices. In addition to child health, we are also tracking the transition of health from urban to rural areas in terms of the prevalence of adult non-communicable diseases.
76042009|NCT05472415|Device|arch support insoles|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
75557033|NCT00460980|Behavioral|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
76042010|NCT04884373|Diagnostic Test|Gastric ultrasound|An ultrasound exam will be performed before induction of anaesthesia. GUS results from selected patients will be systematically acquired and assessed following an algorithm (Appendix Ia). The ultrasound results will be collected on a standardized form (Appendix IIa). The technique is performed in the supine and right lateral decubitus position (Appendix Ib) and only by anesthesiologists with sufficient experience with ultrasound and the technique. The patient will be asked to indicate his/her satiety on a predetermined ten-point scale.
75557034|NCT00429338|Procedure|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
75413614|NCT05599646|Behavioral|traditional pedometer based walking intervention|Participants were recommended to monitor their step count using traditional pedometer and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
75413615|NCT05599646|Behavioral|gamified pedometer based walking intervention|Participants were recommended to monitor their step count using gamified pedometer, earn money, compete friends and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
75413616|NCT05594511|Procedure|Muscle-energy mandibular technique|A single session will be used with the mandibular musculoenergy technique. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
75557035|NCT00429338|Procedure|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
75557036|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
75557037|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
75557038|NCT00429377|Drug|tacrolimus|
75557039|NCT00469716|Drug|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
75557040|NCT00429455|Behavioral|Survey|3-Part Questionnaire
76023358|NCT05109689|Behavioral|ACT-P|ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).
76042011|NCT05613673|Other|No intervention - observational study only|No intervention - observational study only
76042012|NCT05472103|Behavioral|ergonomics surgical workshop|ergonomics surgical workshop
75557041|NCT00461019|Procedure|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
75557042|NCT00429533|Drug|Dapsone|
75413617|NCT05594511|Procedure|Sham technique|A single session with a sham technique simulating the suboccipital muscle inhibition technique will be used. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
75872989|NCT05044884|Other|Otago Exercise training|"Warm-up exercises. Chair March, Arm swings ( 30 second), Head movement, neck movement, back extension, trunk movement, ankle movement (repeat 5 times).~Back of thigh stretch, calf stretch, (hold for 8 seconds).~Strengthening exercises Front knee strengthening, back knee strengthening, side hip strengthening (2 or more sets of 10 reps) Calf raises, toe raises (repeat this exercises 10 to 20 times)~Balance improvement exercises Knee bends, heel-toe standing, heel toes walking, one leg stand ( start with 5 sec move up to 10 sec) Side walk, heel walking, sit to stand, backwards walking, heel toes walking backwards, walking and turning around, stair walking (10 steps).~Cool-down session Back of thigh stretch, calf stretches ( 10 to 20 sec hold, 1 to 3 reps)~Pulmonary rehabilitation program~Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~Stretch exercise for major respiratory muscles."
75557043|NCT00461058|Drug|Actos|Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
75872990|NCT05044884|Other|Circuit training|"Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~Sit on floor and stand up with assistance and then without assistance.~Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~Pulmonary rehabilitation program~Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~Stretch exercise for major respiratory muscles"
75872991|NCT05211258|Device|a novel portable upper gastrointestinal endoscopy system|Patients arrived at the hospital in the morning after an overnight fast (>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
75872992|NCT05733000|Procedure|Biospecimen Collection|Undergo blood sample collection
75872993|NCT05733000|Procedure|Computed Tomography|Undergo CT
75872994|NCT05733000|Drug|Devimistat|Receive IV
75872995|NCT05733000|Drug|Fluorouracil|Receive IV
75872996|NCT05733000|Drug|Gemcitabine Hydrochloride|Receive IV
75872997|NCT05733000|Drug|Hydroxychloroquine|Receive PO
75872998|NCT05733000|Procedure|Magnetic Resonance Imaging|Undergo MRI
75872999|NCT05210946|Drug|Pemigatinib|"Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0."
75413618|NCT05576220|Device|IDION iTempShield|Subject is being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
75413619|NCT05572840|Other|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (powerpoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (powerpoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
75413620|NCT05554874|Other|Pulsed electromagnetic fields|receiving Pulsed electromagnetic fields 3 times, immediately after the onset of delayed muscle soreness, 24 and 48 hours later.
75557044|NCT00461058|Drug|aleglitazar|Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
75557045|NCT00429611|Procedure|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
75557046|NCT00461136|Drug|Aliskiren|
75557047|NCT02957708|Other|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
75557048|NCT02957708|Other|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
75557049|NCT00469794|Procedure|stress test|
75557050|NCT00429650|Behavioral|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
75557051|NCT00429650|Behavioral|diet|Use a prescribed diet to maintain weight loss
75557052|NCT00429650|Behavioral|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
75557053|NCT00461214|Other|Participation in laparoscopic training curriculum|General Surgery Training Outcome
75557054|NCT00429689|Procedure|Saliva sample|
75557055|NCT00469872|Procedure|Context-focused compared to child-focused interventions|
75557056|NCT00429728|Drug|GW876008|
75557057|NCT03271476|Behavioral|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
75413621|NCT05554874|Other|Sham Pulsed electromagnetic fields|Sham application will be applied with the same device without applying magnetic current.
75557058|NCT03273738|Diagnostic Test|folate level measurement|the level of folate measured in plasma with homocysteine
75715261|NCT04007926|Behavioral|Resistance exercise programme|Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
75715262|NCT00969904|Drug|N-acetylcysteine|600 mg TID for 12 weeks
75715263|NCT00969904|Drug|placebo|placebo tablet TID for 12 weeks
75715264|NCT00976612|Drug|Nilotinib|Nilotinib 400mg bid daily
75715265|NCT00976690|Drug|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
75413622|NCT05543837|Drug|Capsaicin|Patients will receive a fixed dose of capsaicin
75413623|NCT05534867|Other|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 1 month, 2 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
75413624|NCT05519982|Behavioral|Sleep Treatment Education Program (STEP-1)|Video conference instruction on behavioral changes to improve sleep.
75557059|NCT03273738|Diagnostic Test|B12|B12 measurement in blood
75557060|NCT04704245|Drug|epidermal growth factor (EGF)-containing ointment|The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
75557061|NCT04704245|Drug|Vehicle ointment|To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
75715266|NCT00976768|Drug|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
76042013|NCT05613595|Behavioral|Positive Psychotherapy|"Positive Psychotherapy is an effective treatment for many mental disorders and depression is primary empirical target. Its primary goal is to build positive emotion, engagement, and meaning in life that will alleviate depression and other mental health disorders. Thus PPT may offer a new way to treat and prevent mental health issues.~Interventions sessions included, Session Records Session One: Positive Introduction and Gratitude Journal Session Two: Character Strengths and Signature Strengths Session Three: Practical Wisdom , Session Four: A Better Version of Me , Session Five: Open and Closed Memories, Session Six: Forgiveness Session Seven: Maximizing versus Satisficing, Session Eight: Gratitude ,Session Nine: Hope and Optimism, Session Ten: Posttraumatic Growth, Session Eleven: Slowness and Savoring, Session Twelve: Positive Relationships, Session Thirteen: Positive Communication, Session Fourteen: Altruism , Session Fifteen: Meaning and Purpose"
76042014|NCT05613595|Behavioral|Counseling Group|Caregivers in control group only regular counseling will be provided (psychoeducation). it will be based upon the insight of cerebral palsy and training based on Adaptive skill functioning of the CP child of the caregivers
75873000|NCT05210868|Drug|CM355|"Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug"
76042015|NCT05471869|Diagnostic Test|Aneurysm diagnosis|Intelligent detection and diagnosis of aneurysm diagnosis by CTA
76042016|NCT05613439|Procedure|Day-surgery|Standard surgical procedure but with planned discharge on day of surgery
76042017|NCT05613439|Procedure|High-risk patient|Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.
76042018|NCT05613439|Procedure|Main Group|Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
76042019|NCT05471713|Other|Autonomic dysfunction|Autonomic dysfunction
76042020|NCT04789057|Drug|Atorvastatin 40 Mg Oral Tablet|p.o., once daily
76042021|NCT04789057|Drug|Placebo|p.o., once daily
75413625|NCT05519982|Behavioral|Enhanced Usual Care|Video conference instruction on relaxation techniques to improve sleep.
75413626|NCT05514769|Procedure|Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty|The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure
75413627|NCT05514561|Diagnostic Test|Fecal calprotectin|To calculate the diagnostic accuracy of fecal calprotectin in the diagnosis of significant ileocolonic lesions
75715267|NCT00608985|Drug|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
76042022|NCT05611723|Other|Exposure to disability|Disability status assessed by functional measures
76042023|NCT05611645|Radiation|Hypofractionated Stereotactic Radiotherapy|Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
76042024|NCT05611645|Drug|Bevacizumab|Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
76042025|NCT05611567|Procedure|POSE2.0 procedure|The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
76042026|NCT05611567|Behavioral|Life style and behavioral intervention|The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
75715268|NCT00608985|Drug|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
75715269|NCT00608985|Drug|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
75413628|NCT05514561|Diagnostic Test|Fecal immunochemical test|To calculate the diagnostic accuracy of the fecal immunochemical test in the diagnosis of significant ileocolonic lesions
75413629|NCT05512000|Behavioral|Feedback with massed trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
75715270|NCT00608985|Drug|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
75715271|NCT00969982|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
75715272|NCT00969982|Drug|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
75715273|NCT00976846|Device|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
75413630|NCT05512000|Behavioral|Feedback with spaced trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
75557062|NCT04704245|Procedure|Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening."
75557063|NCT03271671|Other|NAVA during Non invasive ventilation|NIV during respiratory failure
75873001|NCT03417180|Drug|Remifentanil|a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
76042027|NCT05611489|Procedure|Open appendectomy|performed With the patient in supine position.incision made lateral to McBurney's point.layers of the abdomen is exposed. If the cecum can be visualized, it can be mobilized and used to identify the appendix. Once the appendix is identified, the mesoappendix should be dissected and the appendiceal vessels divided between clamps. The appendiceal vessels are then ligated with silk sutures. A silk purse-string suture can then be placed around the appendiceal base.A 15-blade knife is then used to excise the appendix proximal to the right angle clamp.The appendiceal stump mucosa can be obliterated using electrocautery. Then good haemostasis and layered closure is done.
75557064|NCT03271671|Other|PSV during Non invasive ventilation|PSV during respiratory failure
75557065|NCT04703933|Other|EVALUATION OF THE LEVEL OF KNOWLEDGE AND ATTITUDE OF THE OPERATING ROOM NURSES|This descriptive study was conducted with 100 nurses working in the operating room of two university hospitals in Istanbul
75557066|NCT03271632|Biological|CAR T cells|Infusion of multi-CAR T cells
75557067|NCT00429806|Drug|DHEA|DHEA
75557068|NCT00429806|Drug|Placebo|Placebo
75715274|NCT00976924|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
76042028|NCT05611489|Procedure|Conventional Lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
75715275|NCT00970060|Behavioral|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
75715276|NCT00970138|Drug|apatinib tablet|"A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent"
75715277|NCT00892125|Drug|paliperidone ER; Carbamazepine|
75715278|NCT00977002|Other|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
75715279|NCT00977002|Other|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
75715280|NCT00869037|Drug|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
75715281|NCT00869037|Drug|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
75715282|NCT00980356|Drug|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
75715283|NCT00869115|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
75715284|NCT00869115|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
75715285|NCT00869115|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
75413631|NCT05512000|Behavioral|No feedback with massed trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
75873002|NCT03417180|Device|surgical pleth index|every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
75873003|NCT03085095|Drug|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
75413632|NCT05512000|Behavioral|No feedback with spaced trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
75413633|NCT05512000|Behavioral|No teaching control|The words in this set are not taught, only assessed.
75873004|NCT03085095|Drug|Leuprolide Acetate|Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
76042029|NCT04426513|Other|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
75413634|NCT05497999|Other|Proactive Outreach|"The treatment is proactive outreach that sought to enroll individuals in a VBID program available to all enrollees that provided: 1) large reductions in cost-sharing for maintenance inhalers, and 2) telephone-based COPD medication management services.~Proactive outreach for those randomized to the treatment arm included, at a minimum, a phone call and letter in the mail from Humana. Proactive outreach could also have included an email, text message, and/or provider referral."
75413635|NCT05497999|Other|No Proactive Outreach|Control group participants received no proactive outreach but could call to enroll themselves in the VBID program if they learned about it through traditional means, such as the benefits description manual.
75557069|NCT03273660|Device|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
75557070|NCT00429845|Behavioral|Nutritional|
75557071|NCT03271593|Other|No intervention|No intervention
75557072|NCT00469950|Behavioral|exercise training|Exercise training in groups
75557073|NCT00429962|Drug|intravitreal ranibizumab|intraocular injection
75557074|NCT00429962|Drug|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
75557075|NCT03273504|Other|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
75557076|NCT03273504|Other|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
75557077|NCT00430001|Drug|docetaxel|
75557078|NCT00430001|Drug|vinorelbine|
75557079|NCT00430001|Drug|trastuzumab|
75557080|NCT00461370|Drug|SRX251|
75557081|NCT04703894|Dietary Supplement|AYMES 'CARDIFF'|AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
75557082|NCT00461448|Dietary Supplement|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
75557083|NCT00430079|Drug|etanidazole|Given IV
75557084|NCT00430079|Procedure|conventional surgery|Undergo surgery
75557085|NCT00430079|Other|pharmacological study|Correlative studies
75557086|NCT00430079|Other|laboratory biomarker analysis|Correlative studies
75557087|NCT00469989|Procedure|Infection with hookworm larvae|
75557088|NCT00430118|Drug|asparaginase|
75557089|NCT00430118|Drug|cyclophosphamide|
75557090|NCT00430118|Drug|cytarabine|
75557091|NCT00430118|Drug|daunorubicin hydrochloride|
75557092|NCT00430118|Drug|dexamethasone|
75557093|NCT00430118|Drug|doxorubicin hydrochloride|
75557094|NCT00430118|Drug|etoposide|
75557095|NCT00430118|Drug|ifosfamide|
75557096|NCT00430118|Drug|mercaptopurine|
75557097|NCT00430118|Drug|methotrexate|
75557098|NCT00430118|Drug|prednisone|
75557099|NCT00430118|Drug|thioguanine|
75557100|NCT00430118|Drug|vincristine sulfate|
75557101|NCT00430118|Drug|vindesine|
75557102|NCT00430118|Radiation|radiation therapy|
75715286|NCT00869115|Drug|Istaroxime|Placebo continuous i.v. infusion for 24 hours
75715287|NCT00368251|Other|Placebo|"Pharmaceutical Form: Tablet~Concentration: 2.5 mg, 25 mg and 50 mg~Route of Administration: Oral use"
75715288|NCT00368251|Drug|BRV 2.5 mg|"Pharmaceutical Form: Tablet~Concentration: 2.5 mg~Route of Administration: Oral use"
75715289|NCT00368251|Drug|BRV 25 mg|"Pharmaceutical Form: Tablet~Concentration: 25 mg~Route of Administration: Oral use"
75715290|NCT00368251|Drug|BRV 50 mg|"Pharmaceutical Form: Tablet~Concentration: 50 mg~Route of Administration: Oral use"
75715291|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
75557103|NCT00461487|Behavioral|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
75715292|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
75715293|NCT00893841|Drug|placebo|placebo
75413636|NCT05496647|Other|Virtual Reality|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Preferred video will be watched with Virtual Reality Glasses for approximately 20 minutes during the process, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form, Visual Comparison Scale will be filled.~2. Measurements After Daily Gynecological Surgery; At the 1st hour after the procedure, Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale and Satisfaction Evaluation Form will be filled."
75413637|NCT05496647|Other|Music Therapy|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; During the procedure, the preferred music for Music Therapy will be played for approximately 20 minutes, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
75715294|NCT00893841|Drug|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
75715295|NCT02541123|Other|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
75715296|NCT00980512|Behavioral|Parent Training|16 weeks of parent training led by trained group facilitator
75715297|NCT02534077|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
75715298|NCT02534077|Drug|Omegaven|Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
75715299|NCT02534077|Drug|Omegaven|If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
75715300|NCT00977158|Procedure|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
75715301|NCT00977236|Device|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
75715302|NCT00977236|Device|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
75715303|NCT00378079|Other|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
75715304|NCT00378079|Drug|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
75715305|NCT00378079|Drug|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
75715306|NCT00970450|Drug|Paracetamol|Paracetamol 1 g i.v. once
75715307|NCT00970450|Drug|Tropisetron|Tropisetron 5 mg i.v. once
75715308|NCT00970450|Drug|Placebo|Saline
75715309|NCT00970528|Drug|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
75715310|NCT00970528|Drug|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
75715311|NCT00977392|Behavioral|compliance monitoring|
75715312|NCT00977392|Other|cervical Papanicolaou test|
75715313|NCT00977392|Other|educational intervention|
75715314|NCT00977392|Other|screening questionnaire administration|
75715315|NCT00977392|Other|survey administration|
75557104|NCT00461487|Behavioral|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
75557105|NCT00461526|Drug|crofelemer|125 mg crofelemer vs. placebo
75413638|NCT05496647|Other|Stress Ball Application|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Stress ball will be played for approximately 20 minutes during the process.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
75557106|NCT00430157|Drug|GSK256066|
75557107|NCT00461565|Drug|Sildenafil|A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
75557108|NCT00461565|Drug|Placebo|A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
75557109|NCT00461565|Drug|Vardenafil (Levitra, BAY38-9456)|B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
75557110|NCT00461565|Drug|Placebo|B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
75557111|NCT00430196|Drug|BOTOX®|
75557112|NCT00430196|Drug|Zanaflex®|
75557113|NCT00470028|Device|Transcranial Magnetic Stimulation|
75557114|NCT00430235|Drug|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
75715316|NCT00977392|Procedure|colposcopy|
75715317|NCT03936244|Device|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
75715318|NCT04009486|Device|Whole Body Vibration|"Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)"
75715319|NCT05279404|Other|electroacupuncture|Electroacupuncture at Neiguan and Jianshi acupoint
75715320|NCT05191576|Other|Children's sleep habits questionnaire (CSHQ)|"Children's Sleep Habits Questionnaire is a validated tool to screen sleep behavior in young children's assessment of pediatric sleep problems.~DSM-V Level II Sleep Disturbance- Child Report. is retrospective, 8-item self-report used to assess the pure domain of sleep disturbances in children and adolescents age of 11-17 years in the past seven days.Higher scores indicate more severe sleep disorders. High scores on a particular domain might indicate significant and problematic areas for the child that may warrant further assessment.~DSM -V Sleep Disturbance -Adult Report. is used to assess the pure domain of sleep disturbances in adults for the past seven days.~SDQ).is used to screen emotional and behavioral problems in children.~SDQ is used to screen emotional and behavioral problems in children."
75557115|NCT00470145|Drug|SB-568859|
75715321|NCT00970762|Drug|Rocuronium 0.6 mg/kg intubating dose|Rocuronium 0.6 mg/kg intubating dose
75715322|NCT00970762|Drug|Rocuronium 0.9 mg/kg intubating dose|0.9 mg/kg intubating dose of rocuronium
75715323|NCT00970762|Drug|Rocuronium 0.1 mg/kg maintenance dose|Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
75715324|NCT00970762|Drug|Rocuronium 0.15 mg/kg maintenance dose|Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
75715325|NCT00970762|Drug|Rocuronium 0.2 mg/kg maintenance|Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
75715326|NCT00970762|Drug|Vecuronium 0.1 mg/kg intubating dose|Vecuronium 0.1 mg/kg intubating dose
75557116|NCT04697979|Other|Questionnaire|"Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary."
75557117|NCT00430391|Other|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
75715327|NCT00970762|Drug|Vecuronium 0.025 mg/kg maintenance dose|Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
75557118|NCT00430391|Other|Routine Control|Participants are assigned to the routine, standard consent.
75557119|NCT00470340|Drug|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
75557120|NCT00430430|Procedure|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
75557121|NCT00430430|Procedure|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
75715328|NCT00980824|Behavioral|Cognitive behavioural therapy|Six sessions brief CBT.
75557122|NCT00430469|Drug|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
75413639|NCT05496647|Other|Control|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; Women in the control group will not undergo any intervention other than routine surgery.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure, the Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
75413640|NCT05486026|Drug|Duloxetine 30 MG|patient in first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. The for 13 weeks
75715329|NCT00980824|Other|Standard treatment|Referral to NHS services appropriate to patient's needs
75715330|NCT00977626|Drug|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
75715331|NCT00977626|Drug|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
75715332|NCT00977626|Drug|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
75715333|NCT00970840|Dietary Supplement|LNS-20gM or LNS-P&L|Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
75715334|NCT00978172|Drug|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
75715335|NCT00970918|Procedure|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
75413641|NCT05486026|Drug|Nonsteroidal Antiinflammatory Drug|patient in this second group will receive NSAID for 3 weeks
75413642|NCT05468099|Other|Chlorhexidine mouthwash and Povidone-Iodine|Chlorhexidine mouth rinse which participants use for 20 seconds before procedure. Moreover, Povidone-Iodine nasal swabs are used to disinfect nostrils
75413643|NCT05468099|Device|High volume evacuator|High volume evacuator held by assistant to capture dental spray
75413644|NCT05468099|Device|High volume evactuator and saliva ejector|High volume evacuator and saliva ejector held by assistant to capture dental spray
75715336|NCT00970918|Biological|Blood sample testing for hs-CRP|one time, blood sample taking
75715337|NCT03923530|Drug|Eplerenone|Eplerenone 50 mg daily
75413645|NCT05468099|Device|Local Exhaust System|Local exhaust system hovers above patient head to capture dental spray
75557123|NCT00461643|Drug|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
75557124|NCT00430547|Drug|Carbimazole, radio-active iodine (I131)|
75557125|NCT00430586|Drug|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
75557126|NCT00430586|Drug|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
75413646|NCT05463549|Other|Informative video|An informative instructional film regarding the amniocentesis procedure including answers to frequently asked questions.
75557127|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
75873005|NCT04097301|Drug|MLM-CAR44.1 T-cells at day 0 Single intravenous infusion|Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
75413647|NCT05449587|Other|MRI and PRO|MRI as a standard of care for the analysis of silent rupture. BREAST-Q Postoperative Augmentation module scales to record patients for satisfaction: Satisfaction with breasts; Satisfaction with outcome; Psychosocial well-being; Physical well-being
75413648|NCT05445596|Behavioral|Functional communication training|Functional communication training (FCT) is a behavioral approach to treating problem behavior. During FCT, children learn to use communication to access reinforcers, instead of using problem behavior.
75413649|NCT05438654|Diagnostic Test|Point of care ultrasound|"Abdominal PoCUS use according to the following protocol:~PoCUS assessment of the right lung base PoCUS assessment of Morrison's pouch PoCUS assessment of gallbladder PoCUS assessment of right kidney (comparison to left kidney acceptable) PoCUS assessment of small bowel"
75413650|NCT05438251|Drug|Fespixon Cream|"Name: Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (approximately 2 mm in thickness)~Dosing schedule: Apply twice a day~Duration: up to 12 weeks"
75413651|NCT05432570|Procedure|Group A - Muscle Relaxants Used|Induction will be achieved with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium stored at 4 degrees. After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
75413652|NCT05432570|Procedure|Group B - No Muscle Relaxants|Induction will be provided with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol. After ventilation, vocal cords will be seen with a Macintosh laryngoscope, and 2cc of 2% lidocaine will be applied to the vocal cords as a spray with the help of a 5 ml injector. After ventilation, laryngoscopy will be performed with a Macintosh laryngoscope by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
75413653|NCT05406830|Device|verum acupuncture|The special type of acupuncture needles will be inserted into the skin of standard acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
75413654|NCT05406830|Behavioral|health education|According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.
75413655|NCT05406830|Device|sham acupuncture|We will use a non-insertive sham control. Sham points are located at 5 cun lateral to the seventh, eighth, ninth, tenth, eleven and twelve thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.
75557128|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
75557129|NCT01053962|Drug|SP-304 0.3 mg|SP-304 0.3 mg
75557130|NCT01053962|Drug|SP-304 1.0 mg|SP-304 1.0 mg
75557131|NCT01053962|Drug|SP-304 3.0 mg|SP-304 3.0 mg
75557132|NCT01053962|Drug|SP-304 9.0 mg|SP-304 9.0 mg
75557133|NCT01053962|Drug|Placebo|Placebo
75557134|NCT00461799|Drug|orlistat|
75873006|NCT05199363|Other|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
75873007|NCT05199363|Other|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
75557135|NCT00430664|Procedure|Pleurodesis with either talc or iodopovidone|
75557136|NCT00461838|Procedure|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
75557137|NCT00461838|Other|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
75557138|NCT00430703|Behavioral|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
75557139|NCT00470379|Drug|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
75557140|NCT00430742|Drug|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
75557141|NCT00430742|Drug|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
75557142|NCT00430820|Procedure|per intervention|per intervention
75557143|NCT00470457|Biological|Allergen specific immunotherapy|
75557144|NCT00430859|Drug|Alkaline Phosphatase|Intravenous over a period of 24 hours
75557145|NCT00430859|Drug|Placebo|Saline over a period of 24h
75557146|NCT03271320|Other|appearance scales|appearance scales : AVS; ASWAP; DAS 59
75557147|NCT03271164|Device|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
75557148|NCT03271164|Other|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
75557149|NCT00430898|Drug|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
75557150|NCT00470613|Genetic|SGT-53|For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
75557151|NCT00461916|Drug|Half-Dose Depot Triptorelin|
75557152|NCT00461916|Drug|Reduced-Dose Daily Buserelin|
75557153|NCT00430976|Behavioral|Minds in Motion|
75557154|NCT03273465|Other|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
75557155|NCT02957409|Drug|sacubitril/valsartan|This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
75557156|NCT01053221|Drug|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
75557157|NCT01053221|Drug|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
75557158|NCT02956551|Biological|DC vaccine|subcutaneous administration
75413656|NCT05390645|Drug|MFA-370|MFA-370 is a treatment with a combination of two approved pharmaceuticals
75557159|NCT00431054|Drug|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
75557160|NCT00431054|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour every 4 weeks
75715338|NCT00608907|Drug|bortezomib|1.3 mg/m^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
75715339|NCT00608907|Drug|bortezomib, rifampicin|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
75715340|NCT00608907|Drug|bortezomib, dexamethasone|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
75715341|NCT00970996|Drug|Temozolomide|250 mg/m^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
75413657|NCT05384964|Other|Questionnaire|Questionnaire completed by ICU nurses
75413658|NCT05380401|Dietary Supplement|Enfamil® DHA & ARA Supplement for Special Dietary Use|Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe
75557161|NCT00470652|Device|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was >4/10. After a 10-day test period, the post-intervention data collection started.
75557162|NCT00431171|Drug|Lithium carbonate|
75557163|NCT02956395|Other|Integrated care intervention|"Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.~The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m"
75557164|NCT00431210|Biological|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
75715342|NCT00970996|Drug|Abraxane|100 mg/m^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m^2 given on day 5 of each 21-day cycle.
75715343|NCT00970996|Drug|Cisplatin|20 mg/m^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
75715344|NCT00970996|Biological|Interleukin-2|9 MIU/m^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
75873008|NCT05199363|Other|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers"
76042030|NCT02977195|Drug|NP137 DL and RP2D|"DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
76042031|NCT04340167|Biological|Autologous humanized anti-CD22 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
76042032|NCT02907697|Behavioral|Life Steps-Drug Use|
76042033|NCT02907697|Behavioral|General Health Education|
75413659|NCT05366582|Device|Macintosh Laryngoscope|"After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal carbon dioxide (CO2). Failed intubation will be considered if not achieved within 2 minutes"
75557165|NCT00470691|Procedure|plaster cast|complete circular plaster cast
75557166|NCT00470691|Procedure|dorsal splint|dorsal plaster splint
75557167|NCT00431249|Drug|Cilostazol|
75557168|NCT00470769|Procedure|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
75557169|NCT00470808|Drug|POMx|
75557170|NCT00461955|Procedure|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
75557171|NCT00470886|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
75715345|NCT00970996|Biological|Interferon alpha 2b|5 MIU/m^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
75715346|NCT00869193|Dietary Supplement|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
75873009|NCT05760105|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
75557172|NCT00431483|Behavioral|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
75557173|NCT00461994|Behavioral|diet|
75557174|NCT00461994|Behavioral|exercise|
75557175|NCT00461994|Behavioral|diet and exercise|
75557176|NCT00431522|Drug|Valproic acid, sodium salt|
75557177|NCT00462111|Drug|Indometacin|
75557178|NCT00431561|Drug|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
75413660|NCT05366582|Device|Video Laryngoscope|"After the induction, laryngoscopy will be performed with a Video laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2. Failed intubation will be considered if not achieved within 2 minutes"
75557179|NCT00431561|Drug|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
75557180|NCT00431561|Drug|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
75557181|NCT00431561|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
75557182|NCT00431561|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
75557183|NCT00462150|Behavioral|home-based emotional disclosure|
75557184|NCT00462150|Behavioral|time management control condition|
76042034|NCT02906215|Behavioral|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
75557185|NCT00462189|Drug|Immunotoxin therapy|
76042035|NCT02835079|Drug|Tamoxifen|
75557186|NCT00462189|Drug|CAT-8015 Immunotoxin|
75557187|NCT00462189|Procedure|Biological therapy|
75557188|NCT00431600|Other|100% Oxygen|100% Oxygen- breathing over 30 minutes
75557189|NCT00431639|Behavioral|Animal Assisted Therapy|Every subject will be exposed to both treatment and comparison conditions.
75557190|NCT00470925|Drug|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
75557191|NCT00470964|Procedure|Titanium Sapphire laser trabeculoplasty|
75715347|NCT00869193|Dietary Supplement|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
76042036|NCT02474095|Other|Quality-of-Life Assessment|Ancillary studies
76042037|NCT02474095|Procedure|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
76042038|NCT05455567|Diagnostic Test|OCTA|Choriocapillary vessel density calculated with OCTA
75413661|NCT05352386|Diagnostic Test|Coronary computed tomography angiography (CCTA)|Participants undergo coronary computed tomography angiography (CCTA)
75557192|NCT00431678|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
75557193|NCT00431678|Drug|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
75557194|NCT00471003|Drug|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
75557195|NCT04704128|Other|Salivic sample|Collection of total saliva not stimulated
75557196|NCT00462267|Behavioral|Enriched lifestyle intervention|Multi-component lifestyle intervention
75557197|NCT00471042|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
75557198|NCT00471120|Other|P2x7 assay|compare P2X7 assay to biopsy
75557199|NCT02957669|Behavioral|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
75557200|NCT02957669|Behavioral|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
75557201|NCT00462540|Drug|Formoterol Fumurate inhalation solution 20 mcg|
75557202|NCT00462540|Drug|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
75557203|NCT04703972|Behavioral|clinical assessment (mood relapses identification)|clinical assessment via psychometric scales physiological data acquired automatically via the connected device (wristwatch, wristband)
75557204|NCT04703465|Drug|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25mg for 48 weeks will be delivered
75557205|NCT00471159|Drug|docetaxel|
75557206|NCT00471159|Drug|PF-3512676|
75557207|NCT04703582|Diagnostic Test|Activated clotting time|Relationship between elongated baseline activated clotting time and comorbidity
75715348|NCT04009018|Other|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
75715349|NCT00869271|Procedure|tac + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again."
75873010|NCT02811783|Drug|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
75557208|NCT00462618|Drug|Quetiapine|
75557209|NCT00462618|Behavioral|Cogntive behavioral therapy|
75557210|NCT00431795|Drug|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m^2 IV every 4 weeks for 6 consecutive cycles
75557211|NCT00431795|Drug|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m^2 IV every 3 weeks for 6 consecutive cycles
75557212|NCT03271203|Other|Michigan Hand Outcomes Questionnaire|The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
75557213|NCT03271203|Other|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
75715350|NCT00869271|Procedure|Folfox4|"folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle"
75715351|NCT00971074|Drug|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
75715352|NCT00971074|Other|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
75873011|NCT02811783|Drug|Placebo Lotion|Topical TID for 2 weeks
76042039|NCT05446285|Other|Clinical assessment|All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)
75413662|NCT05335421|Behavioral|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
75413663|NCT05334472|Other|Kesimpta|There is no treatment allocation. Patients administered Kesimpta by prescription that have started before inclusion of the patient into the study will be enrolled.
75413664|NCT05333926|Device|MHNA-001|3-month digital therapy program designed to reduce the severity of IBS symptoms
75413665|NCT05332067|Drug|Omalizumab|"Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe"
75557214|NCT00431912|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
75557215|NCT00462657|Genetic|polymerase chain reaction|
75557216|NCT00462657|Other|bronchoalveolar lavage|
75557217|NCT00462657|Other|immunoenzyme technique|
75557218|NCT00462657|Other|laboratory biomarker analysis|
75557219|NCT00462657|Procedure|bronchoscopy|
75557220|NCT00462657|Procedure|management of therapy complications|
75557221|NCT00431990|Drug|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
75557222|NCT00431990|Drug|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
75557223|NCT00431990|Drug|dexamethasone|20mg for 2 days with each dose of bortezomib
75557224|NCT00462696|Drug|docetaxel|
75557225|NCT00462696|Drug|epirubicin hydrochloride|
75715353|NCT00971152|Drug|menotropins for injection|comparison of different dosages
75715354|NCT00971152|Drug|urofollitropin for injection|comparison of different dosages
75715355|NCT00893919|Drug|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
75715356|NCT00981136|Procedure|Single Incision Laparoscopic Appendectomy|A single incision through the umbilicus to remove the appendix
75557226|NCT00462696|Procedure|conventional surgery|
75557227|NCT00462696|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
75557228|NCT00462696|Procedure|neoadjuvant therapy|
75557229|NCT00462696|Procedure|radiomammography|
75557230|NCT00462774|Procedure|Intramyocardial injection of autologous CD133+ marrow cells|
75873012|NCT03632811|Other|A structured interview with every patient|The comprehension test will be done through structured interviews in which the principal investigator will ask if the patient has had difficulty understanding the recommendations and questions, will check the interpretation of all items and the understanding of each word by the patient. In case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives.
75715357|NCT00981136|Procedure|3 port laparoscopic appendectomy|Standard 3 port laparoscopic appendectomy with intracorporeal stapling
75413666|NCT05332067|Drug|Placebo|Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
75413667|NCT05323890|Drug|Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy|Patients received tislelizumab at a fixed dose of 200 mg every three weeks (q3w, 21 days) for 2 cycles.
75413668|NCT05323318|Other|Neuropsychological Sequelae|Neuropsychological Sequelae after SARS-CoV-2 symtomatic infection
75413669|NCT05312554|Device|Iris FIT™ PFO closure system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Iris Patent foramen ovale occluder according to the INSTRUCTIONS for Use (IFU)
75413670|NCT05312437|Other|Interruptive Alert, CDS|"Experimental: CDS Intervention Adult patients in the highest predicted risk tier (>=2% predicted risk) at the time visit registration (aka check-in).~The Intervention would then be described as:~Physicians review a Best Practice Advisory describing the patient's risk and choose from the following options:~Document face-to-face suicide risk screening with the Columbia Suicide Severity Rating Scale (CDS complete once the CSSRS is complete)~Agree to screen using an alternative method chosen at the clinician's discretion (CDS complete)~Disagree with alert and provide a rationale for disagreement (CDS complete)~Indicate suicide risk face-to-face screening has already occurred (CDS complete)~Dismiss the alert. The alert will be available in Epic Storyboard persistently until acted on further. The Storyboard functionality after dismissal is identical to the Passive Prompt, CDS intervention (below)"
75413671|NCT05312437|Other|Passive Prompt, CDS|"Adult patients in the highest predicted risk tier (>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm."
75413672|NCT05308199|Other|thoracic manipulation|thoracic manipulation for unlocking of facet joints
75557231|NCT00462813|Drug|oral microencapsulated diindolylmethane|
75715358|NCT05278689|Other|No intervention|No intervention
75413673|NCT05308199|Other|muscle enegy technique|to release muscle spasm of cervical musces
75413674|NCT05303233|Procedure|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anaesthetics around the nerve.
75413675|NCT05303233|Procedure|IPACK|The IPACK will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where twenty mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anaesthetics will be observed above the posterior capsule.
75715359|NCT00377611|Biological|Fluarix™|
75715360|NCT00978328|Drug|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
75715361|NCT00869427|Drug|vitamin C|vitamin C 1g bid for 1 year
75715362|NCT00971230|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
75715363|NCT00971230|Drug|Placebo|Placebo
75715364|NCT00892359|Drug|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
75557232|NCT00462813|Genetic|polymerase chain reaction|
75557233|NCT00462813|Other|cervical Papanicolaou test|
75557234|NCT00462813|Other|cytology specimen collection procedure|
75557235|NCT00462813|Procedure|colposcopic biopsy|
75557236|NCT01052012|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; SABER-Bupivacaine /Once
75715365|NCT00892515|Behavioral|exercise intervention|
75715366|NCT00892515|Other|counseling intervention|
75715367|NCT00892515|Other|gas chromatography|
75715368|NCT00892515|Other|immunoenzyme technique|
75715369|NCT00892515|Other|immunologic technique|
75873013|NCT02746029|Other|Clinical examination|
75557237|NCT01052012|Drug|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
75557238|NCT01052012|Drug|SABER-Placebo|Injectable Solution; SABER-Placebo/Once
75557239|NCT00462852|Drug|dalteparin|
75715370|NCT00892515|Other|laboratory biomarker analysis|
75715371|NCT00892515|Other|mass spectrometry|
75715372|NCT00892515|Other|physiologic testing|
75715373|NCT00892515|Other|questionnaire administration|
75715374|NCT00892515|Other|survey administration|
75715375|NCT00892515|Procedure|dual x-ray absorptometry|
75557240|NCT00462852|Drug|gemcitabine hydrochloride|
75557241|NCT00462852|Other|diagnostic laboratory biomarker analysis|
75413676|NCT05301179|Other|Protein quantity and quality|Participants will ingest Lacto-vegetarian and vegan diets providing different daily protein quantities. The parallel design will test for protein quantity and the cross-over design will compare the effects of the quality of the protein sources in the diet.
75413677|NCT05295992|Device|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
75413678|NCT05293223|Biological|Ad5-nCov|Participants enrolled in Group A with only the 1st dose of Sputnik V will receive Ad5-nCoV vaccine at least 21 days but no more than 180 days after the first dose. They will be followed to evaluate the immunogenicity and safety of Ad5-nCoV vaccine during 6 months
75413679|NCT05284019|Drug|Eptinezumab|Concentrate for solution for IV infusion
75413680|NCT05284019|Drug|Erenumab|Solution for SC Injection
75413681|NCT05284019|Drug|Onabotulinumtoxin-A|Solution for IM Injection
75557242|NCT00471393|Drug|1.5% diclofenac in 45.5% DMSO (topical treatment)|
75557243|NCT00471393|Drug|45.5% DMSO (topical placebo)|
75715376|NCT00892515|Procedure|magnetic resonance imaging|
75715377|NCT00892515|Procedure|study of high risk factors|
75715378|NCT00978484|Behavioral|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
75715379|NCT00978484|Behavioral|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
75715380|NCT01051531|Drug|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
75715381|NCT00971308|Drug|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
75873014|NCT05198973|Behavioral|Bumblebee Breath|"Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face.~this will applied half an hour daily for ( 1 month)"
75413682|NCT05284019|Drug|Fremanezumab|Solution for SC Injection
75557244|NCT00432029|Procedure|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
75557245|NCT00432029|Device|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
75557246|NCT03273348|Procedure|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
75557247|NCT00432068|Drug|Octreotide pamoate|
75715382|NCT00971308|Drug|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
75413683|NCT05284019|Drug|Galcanezumab|Solution for SC Injection
75413684|NCT05263336|Drug|Verdye Green|intraoperative iv application of indocyanic green for visualisation of blood supply to the anastomosis after rectal cancer recection
75413685|NCT05250804|Other|Helfer Skin Tap Technique|Helfer Skin Tap Technique is a technique in which the researcher taps the Dorso gluteal muscle by counting 1-15 with the palmar aspect of fingers (non-dominant hand) in rhythmic manner before inserting the injection intra muscularly at 90 degree and remove the needle quickly again by tapping and counting 1-3.
75413686|NCT05249634|Drug|Jatenzo Pill|oral tablet daily
75413687|NCT05244980|Drug|TDM-105795|TDM-105795 topical solution
75413688|NCT05244980|Drug|Placebo|Placebo for TDM-105795 topical solution
75557248|NCT03273309|Other|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
75715383|NCT00971308|Drug|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
75413689|NCT05232604|Other|Aerobic exercise|30-45 minutes of aerobic exercise in a cycle ergometer will be applied in three different intensities (low, moderate and high) along 12 weeks of treatment.
75413690|NCT05232604|Other|Neck motor control exercise|An specific neck motor control exercise targeted to the neck flexor and extensor muscles supervised by a physical therapist will be applied during 12 weeks of treatment.
75715384|NCT00971308|Drug|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
75715385|NCT00971308|Drug|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
75557249|NCT03273309|Other|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
75557250|NCT00432107|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
75557251|NCT03273231|Drug|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
75557252|NCT03273231|Drug|Saline|0.9% saline solution
75557253|NCT00432146|Drug|lugol's solution|
75557254|NCT00462891|Other|IT System|
75413691|NCT05228366|Other|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
75413692|NCT05228366|Other|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
75557255|NCT00432224|Procedure|photodynamic therapy|
75557256|NCT00432263|Drug|Genotropin (PN-180,307) Somatropin|
75557257|NCT00462969|Procedure|Sonohysterography|Sonohysterography
75557258|NCT00432302|Drug|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg [14C]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
75557259|NCT00463008|Drug|methotrexate|
75557260|NCT00463008|Other|pharmacological study|
75557261|NCT00432419|Procedure|autologous peripheral blood cell transplantation|
75557262|NCT00463086|Drug|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
75557263|NCT00463086|Drug|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
75557264|NCT02957435|Drug|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
75557265|NCT03271359|Behavioral|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
75557266|NCT03271359|Behavioral|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
75557267|NCT02957591|Dietary Supplement|Vivomixx®|Streptococcus thermophilus Bifidobacterium breve Bifidobacterium longum Bifidobacterium infantis Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus paracasei Lactobacillus delbrueckii subsp. bulgaricus
75557268|NCT02957591|Other|Placebo|Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
75413693|NCT05228366|Other|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
75413694|NCT05222581|Device|Prototypes of breast shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump.
75715386|NCT00869583|Behavioral|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents [METS]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
75715387|NCT02533843|Procedure|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
75413695|NCT05217342|Drug|Diuretic therapy|Standard diuretic therapy according to the current guidelines
75413696|NCT05211245|Device|therapeutic ultrasound|Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain & muscle spasm by altering nerve conduction velocity & changes in cell membrane permeability along with increased rate of tissue repair & wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons & joint capsules, thus leading to decrease in the pain & muscle spasm, stiffness of the joint & temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central & peripheral sensitization.
75557269|NCT00432536|Other|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
75557270|NCT03271125|Behavioral|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
75715388|NCT00971386|Behavioral|Slow breathing|The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
75413697|NCT05194618|Dietary Supplement|Valerian - lavender|1 tablet per day, half hour before bedtime, day 1 to day 28
75413698|NCT05194618|Dietary Supplement|Placebo|1 tablet per day, half hour before bedtime, day 1 to day 28
75413699|NCT05193370|Drug|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
75413700|NCT05193370|Drug|Vasopressin|Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.
75413701|NCT05172947|Drug|Resveratrol|This group received resveratrol with the conventional therapy
75715389|NCT00971464|Behavioral|eccentric viewing (EV) training|Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.
75413702|NCT05172947|Drug|Placebo|This group received placebo with the conventional therapy
75557271|NCT03271125|Behavioral|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
75557272|NCT00471471|Biological|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
75557273|NCT00471471|Biological|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
75557274|NCT00471471|Biological|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
75557275|NCT02273492|Drug|Asasantin ER|
75557276|NCT02273492|Other|Standardized breakfast|
75715390|NCT00971464|Device|Closed circuit television (CCTV)|A CCTV is an electro-optical device mainly used for reading.
75715391|NCT03992911|Drug|Simmtecan, 5-FU and l-LV|Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.
75715392|NCT03992911|Drug|Toripalimab|Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.
75715393|NCT03992911|Drug|Etoposide, Cisplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.
75715394|NCT03992911|Drug|Etoposide, Carboplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
75557277|NCT00471510|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
75557278|NCT02273531|Drug|Asasantin ER, new formulation|
75557279|NCT02273531|Drug|Asasantin ER, present commercial formulation|
75715395|NCT00895479|Procedure|Graft placement surgery plus Trinam therapy|"Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.~Control arm: graft placement surgery"
75715396|NCT01324765|Behavioral|TARGET|12-session group therapy twice weekly 6 weeks
75715397|NCT01324765|Behavioral|SGT|12 sessions supportive group therapy twice weekly 6 weeks
75715398|NCT02541201|Dietary Supplement|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
75413703|NCT05172947|Other|Resveratrol plus Pharmaceutical care|This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy
75413704|NCT05172947|Other|Placebo+Pharmaceutical care|This group received placebo with Pharmaceutical care in addition to the conventional therapy
75413705|NCT05170607|Diagnostic Test|Proteomic analysis by antibody microarrays|Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer
75413706|NCT05167591|Diagnostic Test|Drug concentration measurement|Measurement of paracetamol concentration in capillary, venous plasma and saliva samples after standard premedication with paracetamol
75413707|NCT05151367|Behavioral|Text message reminder|Receipt of text messages notifying when the next HPV vaccine dose is due (either first or second)
75557280|NCT01580345|Dietary Supplement|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.
75557281|NCT01580345|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.
75557282|NCT00463203|Drug|Bevacizumab|10 mg/kg every 2 weeks
75557283|NCT00463203|Drug|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
75557284|NCT00471549|Drug|Statin (simvastatin)|
75557285|NCT00432575|Drug|surinabant (SR147778)|oral administration
75557286|NCT00432575|Drug|placebo|oral administration
75557287|NCT00432614|Drug|SR58611A|oral administration
75557288|NCT00432614|Drug|escitalopram|oral administration
75557289|NCT00432614|Drug|placebo|oral administration
75557290|NCT00463320|Drug|Pazopanib eye drops and Allergen Refresh Plus eye drops|
75557291|NCT00432653|Drug|rituximab|
75557292|NCT00471588|Drug|Pramipexole, Amisulpride|Study Drug
75557293|NCT00432692|Procedure|Falls Prevention Program|
75557294|NCT00463359|Drug|Imiquimod cream|
75557295|NCT00463359|Procedure|curettage and cautery|
75557296|NCT00432731|Biological|VARIVAX®|
75557297|NCT00432731|Biological|M-M-RTM II|
75715399|NCT02541201|Dietary Supplement|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
75557298|NCT00432770|Drug|ARC1779|
75557299|NCT00471627|Procedure|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
75557300|NCT00432887|Drug|caffeine administration|
75557301|NCT00471744|Drug|Treatment with levetiracetam or sulthiame over a six-month period.|
75557302|NCT01051817|Drug|AIN457|infusion 10 mg/Kg
75557303|NCT01051817|Drug|Placebo|infusion
75557304|NCT00471783|Procedure|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
75557305|NCT04703660|Procedure|cervical mobilization|3 types of cervical mobilization at the level of C 5- 6
75557306|NCT01327846|Drug|Canakinumab|
75557307|NCT01327846|Drug|Placebo|
75557308|NCT01327846|Drug|Standard of care|Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
75557309|NCT00463515|Drug|carboplatin/gemcitabine|
75557310|NCT00463515|Procedure|cisplatin/radiation therapy|
75557311|NCT00432926|Behavioral|EDGE counseling, no maintenance|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
75557312|NCT00432926|Behavioral|EDGE counseling, plus maintenance|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
75715400|NCT00545272|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
75715401|NCT00545272|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
75715402|NCT00545272|Drug|placebo to indacaterol|Placebo TWISTHALER® device
75715403|NCT00545272|Drug|placebo to formoterol|Placebo AEROLIZER® device
75557313|NCT00432926|Behavioral|Attention control|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
75557314|NCT00433043|Drug|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
75557315|NCT00433043|Procedure|CRT (cardiac resynchronization therapy)|Both arms
75557316|NCT00433082|Behavioral|Ramadan Fasting|
75557317|NCT01051739|Procedure|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
75557318|NCT03273075|Drug|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
75557319|NCT03273075|Drug|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
75557320|NCT03273075|Drug|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
75557321|NCT03273075|Drug|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
75715404|NCT00545272|Drug|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
75715405|NCT00869739|Behavioral|telephone-based intervention|
75715406|NCT00869739|Other|educational intervention|
75715407|NCT00869739|Other|partner-assisted coping skills training|
75715408|NCT00869739|Other|questionnaire administration|
75715409|NCT00869739|Procedure|psychosocial assessment and care|
75715410|NCT00869739|Procedure|quality-of-life assessment|
75715411|NCT00377455|Drug|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
75715412|NCT00377455|Drug|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
75557322|NCT00471900|Drug|dehydroepiandrosterone (DHEA)|
75557323|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
75557324|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
75557325|NCT01051661|Biological|Placebo|Intramuscular injection, one dose
75557326|NCT00471939|Drug|I-020502|1 mcg/mL TG-PDGF.AB
75557327|NCT04448548|Other|blood sample taking|For study purposes, blood sample was taken during the first medical examination from patients with suspected infection.
75557328|NCT04448782|Diagnostic Test|Asynchronies detection|Asycnhronies detection
75557329|NCT01051466|Drug|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
75413708|NCT05127902|Diagnostic Test|Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)|"Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG_max) for comparison with normalization signal processing program in Noraxon System."
75557330|NCT04448197|Other|Chinese Medicine|Dialectical treatment of traditional Chinese medicine according to different constitution
75557331|NCT04446793|Drug|Onvansertib|15 mg/m^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
75557332|NCT04446793|Biological|Bevacizumab|5 mg/kg will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
75557333|NCT04446793|Drug|FOLFIRI|FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil [5-FU], and 2400 mg/m^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
75557334|NCT04446247|Diagnostic Test|Owlet Smart Sock Sensor 3rd Generation|Pulse Oximetry
75557335|NCT00463125|Drug|Platelet Gel|
75557336|NCT01051349|Biological|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
75557337|NCT01051349|Biological|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
75557338|NCT04329208|Device|Transcranial doppler|"TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH."
75557339|NCT04444336|Behavioral|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms
75557340|NCT00472017|Drug|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
75557341|NCT02894203|Behavioral|Mindfulness|
75557342|NCT02894203|Behavioral|Yoga|
75557343|NCT00433121|Drug|Risperidone|
75557344|NCT00433121|Drug|Olanzapine|
75557345|NCT00433121|Drug|Haloperidole|
75557346|NCT00433121|Drug|Quetiapin|
75557347|NCT00433121|Drug|Escitalopram|
75715413|NCT00895557|Drug|chantix|.5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
75715414|NCT01051609|Other|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
75413709|NCT05122832|Diagnostic Test|Blood test|Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
75557348|NCT00433121|Drug|Citalopram|
75557349|NCT00433121|Drug|Sertralin|
75557350|NCT00463671|Drug|N-acetylcysteine|
75557351|NCT04442659|Diagnostic Test|pre hospital triage tool|EMS workers fill in an application containing 10-13 vclinical items
75557352|NCT04442386|Other|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout
75557353|NCT04703543|Device|Pilot evaluation study on use PSMA and Cu-PET/CT|This study aims at assessing the detection rate of both PSMA and Cu-PET/CT on tissue relapse, study whether this method is equivalent to mpMR
75557354|NCT00591526|Drug|Arac|Ommit ARAC in the chemotherapy
75413710|NCT05122832|Diagnostic Test|STEPwise Approach to NCD Risk Factor Surveillance (STEPS)|The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
75715415|NCT01051609|Other|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
75413711|NCT05122832|Diagnostic Test|Spirometry|Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
75413712|NCT05121415|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
75413713|NCT05118997|Device|IRRAflow|IRRAflow consists of a control unit and disposables (dual-lumen catheter and tube set) to offer an integrated and synchronized active fluid exchange system. Active fluid exchange is the combination of traditional gravity-driven drainage with periodic, controlled irrigation of the catheter probe to exchange any pathological fluid collection with neutral physiological fluids.
75413714|NCT05118997|Device|EVD|An external ventricular drain (EVD), also known as a ventriculostomy or extraventricular drain, is a device used in neurosurgery to treat hydrocephalus and relieve elevated intracranial pressure when the normal flow of cerebrospinal fluid inside the brain is obstructed.
75413715|NCT05095181|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
75715416|NCT01051609|Behavioral|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
75715417|NCT01051609|Other|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
75715418|NCT01051609|Procedure|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
75413716|NCT05095155|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
75413717|NCT05095142|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
75413718|NCT05095129|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
75557355|NCT04440397|Other|xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined
75557356|NCT00463710|Drug|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
75715419|NCT00869895|Drug|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
75715420|NCT00978640|Other|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
76042040|NCT05436145|Behavioral|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
76042041|NCT01667107|Drug|Posaconazole|
75413719|NCT05090644|Genetic|DNA analysis|GWAS
75413720|NCT05090631|Genetic|DNA analysis|GWAS
75413721|NCT05090618|Genetic|DNA analysis|GWAS
75557357|NCT02894008|Drug|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
75557358|NCT04440124|Other|Incremental shuttle walk test|All patients were reviewed by a physiotherapist during their pre-assessment clinic one week prior to surgery to complete an incremental shuttle walk test (ISWT). The ISWT was completed according to a standardised protocol and involved patients walking around 2 cones set up 9 metres apart. Patients were asked to cover the distance between the cones in time to auditory cues. Oxygen levels and heart rate were recorded during the assessment with the use of a portable pulse oximeter. The test was stopped when patients could no longer keep pace with the auditory cues or were too breathless to continue. The total distance mobilised was recorded.
75715421|NCT00978640|Other|exercise|exercise 1 h 50% VO2max
75715422|NCT02533687|Procedure|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
75715423|NCT02533687|Procedure|Bipolar TURP-2|Bipolar TURP
75413722|NCT05090605|Genetic|DNA analysis|GWAS
75413723|NCT05090436|Other|Schroth Exercise|two month (three session per week)
75413724|NCT05090436|Other|Functional Electrical Stimulation (physiotherapy techniques)|two month (three session per week)
75413725|NCT05088512|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
75413726|NCT05088499|Genetic|DNA analysis|GWAS
75715424|NCT02533687|Procedure|Monopolar TURP|Monopolar TURP
75715425|NCT00869973|Drug|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
76042042|NCT01667107|Drug|Calogen®|
75413727|NCT05088486|Genetic|DNA analysis|GWAS
75413728|NCT05078827|Drug|Test Product (A): Fluorouracil Cream, 5% topical cream|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
75715426|NCT00869973|Drug|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
75715427|NCT01048645|Drug|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
75715428|NCT01048645|Other|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
75715429|NCT04008784|Drug|Crisaborole 2% Topical Application Ointment [EUCRISA]|Ointment
75557359|NCT02893735|Other|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
76042043|NCT04412239|Behavioral|Patient-centred advice on Telephone Consultation in TB Patients:|The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
75413729|NCT05078827|Drug|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
75715430|NCT04008784|Drug|Triamcinolone Acetonide 0.1% Ointment|Topical Corticosteroid
75715431|NCT03544905|Drug|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
75715432|NCT04008394|Genetic|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
75715433|NCT00895635|Behavioral|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
75715434|NCT00895635|Behavioral|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
75715435|NCT00895635|Behavioral|Usual Care|Usual care for PAD
76042044|NCT02410213|Drug|Ferric Carboxymaltose (FCM)|
76042045|NCT04411615|Drug|Omega 3|rTG form Omega-3
76042046|NCT01802203|Device|truFreeze Spray Cryotherapy|spray cryotherapy
76042047|NCT04685551|Behavioral|Change in knowledge, motivation, skills, and resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to improve survivorship outcomes.
76042048|NCT04638673|Device|Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
75413730|NCT05078827|Drug|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
75413731|NCT05076981|Drug|human chorionic gonadotropin|once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
75413732|NCT05076422|Drug|BI 3006337|BI 3006337
75413733|NCT05076422|Drug|Placebo|Placebo
76042049|NCT04638673|Device|Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group|Participants will receive sham taVNS stimulation for weeks 1&2 and active stimulation for weeks 3&4 of the stimulation portion of this study.
75413734|NCT05074979|Other|telerehabilitation|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
75413735|NCT05074979|Other|home exercise program|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
75715436|NCT01051687|Drug|Botulinum toxin A|"Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit."
75715437|NCT00978718|Dietary Supplement|high-selenium baker's yeast|Given orally
75413736|NCT05074979|Other|informed program|will informed after COVID 19
75557360|NCT02893735|Other|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
75715438|NCT00978718|Dietary Supplement|selenium|Given orally
75715439|NCT00978718|Other|placebo|Given orally
76042050|NCT05240131|Drug|GB1211|GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
75715440|NCT00894153|Drug|chemotherapy plus p53|chemotherapy plus p53
76042051|NCT05240131|Drug|Placebo|Placebo is administered orally twice a day.
75715441|NCT00894153|Drug|chemotherapy|chemotherapy
76042052|NCT05240131|Drug|Atezolizumab|Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
75715442|NCT00894153|Radiation|radiotherapy|radiotherapy
76042053|NCT05220943|Behavioral|Video|This 5-minute video presents clips with voiceover narration summarizing and highlighting the key safety points in the Center for Surgical Innovation (CSI) location.
76042054|NCT05475145|Procedure|Resin based sealing [RBS]|
76042055|NCT05614999|Other|Endoscopy training curriculum|Eight sessions training in endoscopic tip control using Varix trainer model I.
76042056|NCT05188339|Drug|4% sodium citrate|"Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.~A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months."
76042057|NCT05188339|Drug|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
76042058|NCT04393909|Behavioral|Diagnostic Uncertainty Educational Curriculum|"A Diagnostic Uncertainty Educational Curriculum will consist of an interactive, one-hour teach-the-teacher workshop delivered to resident-attending pairs early on during their inpatient medicine rotation. During the workshop, we will discuss the motivation behind teaching diagnostic uncertainty, review factors that may predict risk of diagnostic error during hospitalization, introduce the framework. Each resident-attending pair will work through a case-based exercise focused on managing learners' diagnostic uncertainty during rounds. Our research team will also conduct Training for clinical staff working on intervention units and will provide at-the-elbow support during the intervention period of the main trial."
76042059|NCT04393909|Behavioral|Diagnostic Timeout|"A Diagnostic Timeout is a structured pocket guide that clinicians may use to address uncertainty in a step-wise approach for patients who have risk factors for diagnostic error. This tool can be used during or after clinical rounds, inside or outside of a patient's room if the patient is agreeable. The Diagnostic Timeout will be introduced as part of the Diagnostic Uncertainty Educational Curriculum as well as Training."
75413737|NCT05065164|Drug|Denosumab Only Product|denosumab subcutaneous injection /6 months, twice a year
75413738|NCT05062122|Other|vibration group|Hand skills were evaluated before and after 10 minutes of vibration application.
75413739|NCT05062122|Other|kinesiology tape group|Dexterity was assessed before and after kinesiology tape application.
75413740|NCT05062122|Other|control group|Manual dexterity was assessed before and after traditional physiotherapy.
75413741|NCT05057819|Drug|Empagliflozin 25 MG|Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days
75413742|NCT05057819|Drug|Placebo|Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
75715443|NCT01048801|Device|Rapid diagnostic test|Use of rapid daignostic tests for diagnosis of malaria
75715444|NCT01048801|Other|presumptive malaria treatment|Treatment of malariabased on clinical diagnosis without use of diagnostic test
75557361|NCT03271086|Behavioral|The StressEraser|The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.
75413743|NCT05046834|Other|cold application|Oral paracetamol 10 mg/kg, which is administered as standard 60 minutes before the procedure, will be given to patients who have decided to remove the chest tube by the physician and comply with the limitations of the study. After that, initial pain severity and vital signs of the patient will be recorded using FLACC 15 minutes before the start of the chest tube removal process (1.MEASURE). After this measurement, the cold gel package will be wrapped in gauze and placed directly on the skin, covering the area around the chest tube with a radius of about 5 cm. The cold gel package will remain on the skin surface for about 20 minutes. After 15 minutes, the cold package will be removed and the chest tube will be removed by the doctor.
75557362|NCT03271086|Behavioral|Breathe2Relax|Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.
75557363|NCT03271086|Behavioral|Reminder text messages|Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
75557364|NCT00433238|Behavioral|Participants will be screened for depression and cognitive impairment, then receive screening results.|
75557365|NCT00463749|Drug|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
75557366|NCT00463749|Drug|Placebo|NaCl as placebo
75557367|NCT00433277|Drug|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
75557368|NCT00463827|Drug|Atorvastatin|
75557369|NCT00463827|Drug|atorvastatin|atorvastatin 40mg
75557370|NCT00463827|Drug|matched placebo|Matched placebo
75557371|NCT00433316|Drug|ropivacaine|1% ropivacaine
75557372|NCT00433316|Device|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
75557373|NCT00472095|Other|Fotonovela|
75557374|NCT00472095|Other|Placebo Fotonovela|
75557375|NCT00433394|Procedure|cancer prevention intervention|
75715445|NCT00971542|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
75715446|NCT00895713|Drug|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
75715447|NCT01051765|Drug|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
75715448|NCT00978796|Drug|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
75557376|NCT00433394|Procedure|educational intervention|
75715449|NCT00978796|Drug|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
75715450|NCT00894231|Drug|levocetirizine (Xyzal)|5mg po QD
75557377|NCT00472134|Drug|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
75557378|NCT00472134|Device|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
75557379|NCT00433433|Drug|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
75557380|NCT00433433|Drug|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes>1.0x109/l
75557381|NCT00433433|Radiation|IN-RT 30 Gy (+ boost 6 Gy residual)|
75557382|NCT00433433|Procedure|FDG-PET scan|
75557383|NCT00463905|Procedure|Clinical assessment +/- radiography|Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
75557384|NCT00433472|Device|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI
75557385|NCT00463944|Behavioral|Effect of an electronic voting system|
75557386|NCT00433667|Drug|RWJ-333369|
75557387|NCT00463983|Drug|octreotide|
75715451|NCT00894231|Drug|placebo|sugar tablet
75715452|NCT00870207|Behavioral|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
75715453|NCT05030974|Biological|mRNA-1273|SARS-CoV-2 vaccination
75715454|NCT05030974|Biological|Ad26.COV2.S vaccine|SARS-CoV-2 vaccination
75557388|NCT03270813|Behavioral|Relaxation training plus RAGE-Control|RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
75413744|NCT05046834|Other|cold application until 13.6 C|After measurements, the cold gel package, which rotates with one end open and forms a circle, will be wrapped in gauze and placed directly on the skin in a radius of about 5 cm, covering around the chest tube. 10 of the app. After the minute, the skin temperature will be measured with an infrared thermometer if the heat falls below 13.6 o C, the process will be terminated. If the skin temperature does not fall below 13.6 0 C, the application will continue, the application will be terminated when the heat falls below the specified temperature. After the cold package is removed, the chest tube will be removed by the doctor.
75557389|NCT03270813|Behavioral|Relaxation training plus Sham Videogame|The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
75715455|NCT00377299|Drug|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
75715456|NCT00377299|Drug|Placebo|Placebo matching active medication in all other physical aspects
76042060|NCT04393909|Behavioral|Patient Diagnostic (Dx) Questionnaire|"We will administer a survey, the Dx Questionnaire, to patients which asks a series of questions on communication regarding diagnosis with the care team. Patients admitted to inpatient units within the prior 24 hours will be approached after asking the patient's nurse to determine whether it is the appropriate time to approach for enrollment. Upon explaining the objectives of the survey and obtaining verbal informed consent, patients will be asked to complete the Dx Questionnaire via REDCap on an iPad. Alternatively, the research assistant administering the survey will go through the Dx Questionnaire with the patient and record their answers in REDCap on their behalf. If patients' answers indicate a gap in communication (i.e., an answer of No on a question), the Research Assistant will ask for permission to follow-up within the next few days and will relay the gap in communication to the patients' care team (i.e., nurse)."
76042061|NCT04393909|Behavioral|Enhancements to Epic-integrated Quality & Safety Dashboard|"Epic-integrated Quality and Safety Dashboard, currently in operational use at BWH, will be enhanced to include a new diagnostic safety column. Clinical staff will receive Training and at-the-elbow support by the research team upon implementation."
75413745|NCT05035693|Device|MOVE®-C|Momo- or bisegmental implantation of MOVE®-C cervical prothesis.
75557390|NCT00464022|Device|Carbon dioxide|
75557391|NCT01050998|Biological|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
75557392|NCT01050998|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
75557393|NCT01050998|Biological|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
75557394|NCT01050998|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
75557395|NCT01050998|Other|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
75557396|NCT00472173|Drug|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
75557397|NCT00472173|Drug|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
75557398|NCT00472329|Procedure|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
75557399|NCT00472329|Drug|fludarabine|
75715457|NCT00981604|Procedure|SILS|Single Incision Laparoscopic Cholecystectomy
75715458|NCT00981604|Procedure|Standard Laparoscopic Cholecystectomy|4 port technique
75715459|NCT03472365|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
75715460|NCT03472365|Drug|Capecitabine|1000 mg/m^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
75557400|NCT00472329|Procedure|TBI|
75557401|NCT00464139|Procedure|Laparoscopy|Laparoscopy
75557402|NCT00464217|Drug|ARA-C|
75557403|NCT00464217|Drug|Idarubicin|
75557404|NCT00464217|Drug|Leucomax|
75715461|NCT03472365|Drug|Oxaliplatin|130 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle.
75715462|NCT03472365|Drug|Apatinib|375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
75557405|NCT00433706|Procedure|Control position by 3DOBI before the fraction|
75557406|NCT00433706|Procedure|Standard imaging|
75715463|NCT03200977|Other|Non-Interventional|Non-Interventional
75715464|NCT00971776|Device|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
75715465|NCT00978952|Device|Large Diameter Advanta™ V12 Covered Stent|Stent placement
76042062|NCT05474911|Device|Negative pressure therapy|The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.
75413746|NCT05029375|Behavioral|PEERS® for Preschoolers|P4P is a 16-week manualized social skills treatment program, adapted from an existing empirically supported social skills intervention for young children with autism
75413747|NCT05027074|Drug|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion
75557407|NCT03270852|Device|Enhanced reality|"This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.~The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro."
75413748|NCT05027074|Drug|Placebo|Normal saline administered via IV infusion
76042063|NCT05474911|Other|Conventional wound care|The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.
75413749|NCT05024487|Diagnostic Test|Clinical Examination|Given the most frequent causes of AD, the above-mentioned trigger stimuli will be used. All these procedures are commonly used in SCI people.
75413750|NCT05022095|Other|Questionnaires|Diverse questionnaires have to be filled in.
75413751|NCT05011006|Diagnostic Test|NT3 blood draw|blood draw
75413752|NCT05004389|Diagnostic Test|MRI|white matter integrity and brain structural connectivity metrics
75715466|NCT00896259|Other|home based exercise and education program|Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
75715467|NCT00971854|Procedure|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
75715468|NCT00894621|Drug|Norepinephrine|Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
75715469|NCT00894621|Drug|Placebo|
76042064|NCT05614765|Drug|Statin+Ezetimibe compound|Crezet Tablet, Litorvazet Tablet
76042065|NCT05613127|Biological|Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL|Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
76042066|NCT05613127|Biological|HAVRIX 720 Junior 0.5 mL|Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
76042067|NCT05610865|Other|Control; Standard-of-care management|Patients will undergo conventional wound care management.
76042068|NCT05610865|Biological|Only PRP injection|Only PRP injected / cm2 intradermally at the border zone & inside of wound surface bed.
75413753|NCT05004389|Diagnostic Test|blood draw|post-stroke serum/plasma levels of BDNF, VEGF, IL-6, IL-10, CRP, TNFalpha, MMPs, IGF-1, cGP
75557408|NCT03270852|Other|No Enhanced reality|Identical rehabilitation without enhanced reality
75557409|NCT00433784|Drug|Clopidogrel|
75557410|NCT00433784|Procedure|Blood sampling - platelet aggregation|
75557411|NCT00433784|Procedure|Blood sampling - genotyping|
75413754|NCT05004389|Other|Clinical assessments|measures of strength, balance, and mobility
75413755|NCT04981821|Behavioral|GO-EXCAP Mobile App|A mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©®) is a progressive walking and resistance exercise program
75413756|NCT04981821|Behavioral|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
75413757|NCT04975763|Other|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
75413758|NCT04975763|Other|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
75413759|NCT04962165|Device|Mandibular Advancement Device|The device maintain opened upper airway by moving the lower jaw slightly forward while sleeping.
75413760|NCT04947033|Drug|TJ210001 Injection|The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
75413761|NCT04934124|Drug|ITI-333|ITI-333 oral solution
76042069|NCT05610865|Biological|PRP + SVF injection|Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone & inside of wound surface bed.
76042070|NCT05610865|Biological|PRP + ASCs injection|Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone & inside of wound surface bed.
75715470|NCT00901095|Behavioral|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
75413762|NCT04934124|Other|Placebo|Matching placebo
75557412|NCT00464256|Drug|rimonabant|
75557413|NCT00433823|Drug|Atorvastatin, Ezetimibe|
75557414|NCT00464295|Drug|Capecitabine in HCC|
75557415|NCT03273036|Drug|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
75557416|NCT03273036|Drug|Placebos|no injected agent
75715471|NCT00979108|Other|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
75715472|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
75557417|NCT00433901|Behavioral|Targeted parental instruction for positive lifestyle change with follow-up calls.|
75557418|NCT03270735|Drug|Snake venom thrombin (Treatment)|Snake venom thrombin
75715473|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
75413763|NCT04928196|Other|Microperimtery and optical coherence tomography angiography OCTA|observational: Investigations are done to assess the retinal microvasculature and function before and after silicone oil removal
75413764|NCT04924920|Diagnostic Test|SIGH|To add the Sigh35 to PSV, the ventilator is set in pressure controlled synchronized intermittent mandatory ventilation plus PSV [SIMV (PC) + PS mode], with SIMV rate set a 1/min and inspiratory time of 4 seconds. SIMV (PC) = 35 cmH20 of total inspiratory support (PEEP + PS).
75413765|NCT04924920|Diagnostic Test|EEOT|• The EEOT is performed by interrupting the mechanical ventilation for 15 seconds, by using and end-expiratory hold on the ventilator. The ventilator trigger is set at 2 L/min.
75557419|NCT03270735|Drug|Placebo|No snake venom thrombin
75557420|NCT04702841|Drug|Chimeric antigen receptor modified γδ T cells|Dosage: the total dosage of reinfusion is 0.2-5 × 10^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
75557421|NCT04703114|Diagnostic Test|Blood count|Blood count at each visit
75557422|NCT04703114|Diagnostic Test|Blood collection|Blood collection to understanding of the immunological profile at each visit
75557423|NCT04703114|Diagnostic Test|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR at day 8 and day 15
75557424|NCT04703114|Diagnostic Test|Saliva samples|Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)
75557425|NCT04703114|Diagnostic Test|Faeces samples|Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90
75557426|NCT04703114|Genetic|Genetic blood collection|Collection to further research at each visit
75413766|NCT04924010|Behavioral|Cognitive Behavioural Therapy (CBT)|The CBT intervention will be delivered by a Senior Psychologist with seventeen years of hospital psychology experience, six in the treatment of chronic pain patients. Sessions are delivered in one hour, individual therapy appointments to patients, and there is an emphasis on relaxation training, cognitive restructuring, exercise and pacing, behavioral activation, improving sleep, and anger management. Standardized worksheets and homework assignments are an important part of CBT-CP and these will be given (post or email) to patients who will be asked to read and complete in terms of complementing the consultations. This intervention has been developed with reference to two sources: A successful national implementation of CBT for chronic pain (CBT-CP) using video teleconferencing format [Connolly KS et al] AND an evidence-based CBT manual specifically designed to treat chronic pain [Murphy JL et al].
75557427|NCT04703114|Other|Data collection|Demographics, symptoms, biological constants
75557428|NCT04053153|Device|Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)|exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
75557429|NCT04702685|Drug|Ropivacaine|Local anesthetic for injection
75557430|NCT04702685|Other|Placebo|Bandage will be placed in the presumed injection site while patients in under general anesthesia
75557431|NCT00464373|Drug|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
75557432|NCT00464373|Drug|Placebo|4ml NaCl 0.9%
75557433|NCT00472368|Drug|LBH589|
75557434|NCT00106028|Drug|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
75557435|NCT00106028|Drug|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
75557436|NCT00464412|Behavioral|Education|
75557437|NCT00464451|Drug|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
75715474|NCT00376675|Drug|methylphenidate hydrochloride|Given orally
75715475|NCT00376675|Other|placebo|Given orally
75715476|NCT02539875|Behavioral|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
75715477|NCT00979186|Device|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
75715478|NCT04017663|Other|Application of questionnaires|Application of questionnaires to identify characteristics and main barriers of patients
75715479|NCT00979264|Behavioral|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
75557438|NCT00464451|Drug|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
75557439|NCT00464529|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
75557440|NCT00433940|Drug|Prednisolone|Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
75557441|NCT00433979|Drug|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
75557442|NCT01050764|Drug|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~T-reg: 1 x 10e5/kg~T-con: 3 x10e5/kg~Cohort 2~T-reg: 3 x 10e5/kg~T-con: 1 x 10e6/kg~Cohort 3~T-reg: 1 x 10e6/kg~T-con: 3 x 10e6/kg~Cohort 4~T-reg: 3 x 10e6/kg~T-con: 1 x 10e7/kg"
75557443|NCT01050764|Drug|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
75557444|NCT01050764|Drug|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
75557445|NCT01050764|Drug|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
75557446|NCT01050764|Device|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
75557447|NCT01050764|Drug|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
75873015|NCT05410353|Behavioral|Active Intervention Group|"The 3 major intervention components are diet, physical activity, and the behavioral modification curriculum. Scheduled interactions are educational podcasts (a series of audiovisual, digital media files) paired with a follow-up phone counseling session with a trained behavioral interventionist. A patient portal message will be sent to participants when a new podcast is posted. Interactive sessions will be weekly (weeks 1-16), biweekly (weeks 17-24), and monthly (weeks 25-52). The goal for weight loss is ≥ 7% of initial weight over the course of 12 months. Participants will restrict caloric intake with the goal of 1,200-1,500 kcal/day for those weighing < 114 kg and 1,500-1,800 kcal/day for those weighing ≥ 114 kg. The physical activity goal will be for participants to gradually increase to 175-200 minutes of moderate-intensity activity per week by the 24th week. Participants will also be asked to self-monitor their dietary intake and physical activity using the Lose It! app."
75873016|NCT05410353|Behavioral|Comparison Group|All participants in the Comparison Group will receive a mandatory 13 contacts per year including 3 informational sessions on nutrition, physical activity and social support and 10 contacts via patient portal or email regarding intervention topics. The Look AHEAD Comparison Group was designed to be realistic, achievable, and an acceptable intervention that encouraged optimal study retention.
75873017|NCT05198661|Biological|Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.|"Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.~2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection"
75873018|NCT02364843|Dietary Supplement|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
75413881|NCT04395430|Behavioral|online KKH Sports Singapore Program with Usual Care|"Participants will receive standard care and basic sports equipment and cooking materials for the online programme.~The online programme will be available up to 4 days per week (Weekdays evenings and Weekends mornings or early afternoons) and all household family members are invited to participate. The majority of the programming will be run by trained research coordinator and volunteers from KKH and Sports Singapore coaches. A regular rotation of comprehensive programming is provided, which includes online fitness, cooking, nutrition, and peer support classes. Every session includes up to 60 minutes of exercise and/or active play, and each session has an additional special 'theme.' For example, one to two sessions per week includes nutrition related programming (e.g., cooking classes), parent specific activities (e.g., a yoga class), peer support sessions (e.g., small group discussions around issues such as weight stigmatization), and fitness classes (e.g., soccer classes)."
75441366|NCT01633840|Other|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
75558233|NCT03279354|Behavioral|"HK FitNuts app intervention"|"The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics & Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week."
75558234|NCT02957045|Procedure|Cough pressure measurement|
75413882|NCT04344262|Drug|Atracurium Besylate regular dose|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
75413883|NCT04344262|Drug|Atracurium Besylate minial dose|atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
75413884|NCT04333875|Device|TAVR or SAVR|Patients with critical aortic stenosis as defined by an AVA <0.6 cm2 or a transvalvular mean gradient of >60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR.
75413885|NCT04330638|Other|Usual Care|Usual Care
75413886|NCT04330638|Drug|Anakinra|Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first
75413887|NCT04330638|Drug|Siltuximab|Siltuximab will be given via single IV infusion at a dose of 11 mg/kg
75558235|NCT02957045|Device|Pcough|
75873021|NCT03633123|Drug|D_PLEX|D_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
75558236|NCT00479583|Drug|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
75441367|NCT01633840|Other|Elemental E028|Elemental E028 with no added food allergens
75441368|NCT01633879|Behavioral|audio-CD parent education|audio CD stories in English and Spanish that support positive parenting practices
75441369|NCT01633879|Behavioral|health and success parent and school|Parenting education and school intervention
75441370|NCT01633918|Behavioral|Internet-supported FeetEnergy approach|Three health education lessons and two homework's about increasing physical activity and reducing screen time
75441371|NCT01633918|Behavioral|Usual health education|Usual health education lessons
75441372|NCT01633957|Other|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
75441373|NCT01633957|Other|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
75441374|NCT01633970|Drug|5-FU|Participants will receive 5-FU 400 mg/m^2 IV q2w.
75441375|NCT01633970|Drug|Atezolizumab|Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
75441376|NCT01633970|Drug|Bevacizumab|Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.
75873022|NCT03633123|Other|Standard of Care (SoC)|"Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure"
75558237|NCT00479583|Drug|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
75873023|NCT02276547|Device|Mitral valve replacement|Transcatheter mitral valve replacement
75873024|NCT05296083|Dietary Supplement|G3P-01|G3P-01 is a food-grade pectic product derived from squash.
75873025|NCT01917903|Behavioral|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
75413888|NCT04330638|Drug|Tocilizumab|Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection
75441377|NCT01633970|Drug|Carboplatin|Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
75441378|NCT01633970|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV q2w.
75441379|NCT01633970|Drug|Nab-paclitaxel|Participants will receive nab-paclitaxel 100 mg/m^2 IV qw.
75558238|NCT04699643|Drug|EVER4010001|Please refer to information in arm/group descriptions.
75558239|NCT04699916|Other|EEG based protocol for deep sedation|Protocol established to guide sedation drug dosification to maintain the patient with a Suppression Rate (SR) less than 1% and a Spectral Edge Frequency 95 over 10 Hz
75558240|NCT02274090|Drug|Placebo gel|Placebo gel consist of drug without the active component.
75558241|NCT02274090|Drug|1% Metformin gel|Metformin gel consist of active component.
75558242|NCT03278327|Procedure|Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.|Endoscopic resection treatment
75558243|NCT03278327|Device|Endoscopic resection at month 2 and month 4|"System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.~The device the most used in this case is the system COOK Medical Duett of Laboratories.~The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.~The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane."
75558244|NCT04700748|Radiation|Brain metastases radiation|Brain metastases radiation according to clinical practice.
75413889|NCT04325321|Other|Stress reactivity test|"The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP.~Resting Baseline (BL - 10 min). The participant is instructed to rest quietly.~Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked.~Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP."
75413890|NCT04322006|Drug|TJ004309|Antibody to CD73
75558245|NCT04699955|Behavioral|Deviance Regulation Theory|In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.
75413891|NCT04322006|Drug|Toripalimab|Humanized monoclonal antibody to PD-1
75413892|NCT04315610|Other|Access to mobile phone application|Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application. After discharge, assessments using the application are performed if necessary.
75558246|NCT03279315|Dietary Supplement|iodized table salt, non-iodized table salt|During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
75558247|NCT00444743|Drug|MM-093|60 mg, administered subcutaneously, weekly
75558248|NCT00444743|Other|Placebo|Placebo
75558249|NCT00479622|Drug|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
75558250|NCT00444782|Biological|GV1001|
75558251|NCT03279159|Other|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
75413893|NCT04315610|Other|Treatment as usual|Active comparator group, based on traditional information and follow-up.
75558252|NCT03279159|Other|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
75873026|NCT01917903|Behavioral|Identification of at risk variables|Participants will complete walking under three conditions: walking alone for six minutes; standing from a chair, walking 3 meters, turning, and returning to a seated position (TUG); and standing from a chair, walking 3 meters turning and returning to a seated postion while subtracting numbers (TUG Cognitive). Spatiotemporal measures of gait will be collected.
75873027|NCT02966834|Drug|Placebo|GSK2330672 matching placebo will be supplied as white film-coated tablets.
75873028|NCT02966834|Drug|GSK2330672|GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
75413894|NCT04304131|Diagnostic Test|Earlytect Colon Cancer|A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer
75413895|NCT04298879|Drug|IBI376|IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily
75413896|NCT04298554|Other|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration
75413897|NCT04298554|Other|Hemp Oil|CBD PURE HEMP OIL
75413898|NCT04291521|Drug|Ketamine|Administering ketamine as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
75413899|NCT04291521|Drug|Etomidate|Administering etomidate as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
75413900|NCT04291521|Drug|Propofol|Administering propofol as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
75441380|NCT01633970|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV q2w.
75441381|NCT01633970|Drug|Paclitaxel|Participants will receive paclitaxel 200 mg/m^2 IV q3w.
75441382|NCT01633970|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV q3w.
75441383|NCT01633983|Drug|Methotrexate|7.5 mg per week p.o. escalating up to 15 mg per week
75441384|NCT01633983|Drug|Delayed treatment|Methotrexate 7.5 mg per week per os escalating to 15 mg per week
75558253|NCT00444860|Biological|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
75873029|NCT03106077|Biological|Mirvetuximab Soravtansine|Given IV
75441385|NCT01633996|Procedure|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
75441386|NCT01634009|Dietary Supplement|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
75441387|NCT01634022|Procedure|Acupuncture|5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (-) to GV24.5 (+).
75558254|NCT00479661|Drug|Dexmedetomidine|Continuous infusion
75558255|NCT00479661|Drug|Propofol|Continuous infusion
75734908|NCT03583190|Other|Thoracic Manipulation|Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.
75558256|NCT00444899|Behavioral|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
75558257|NCT00444899|Other|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
75558258|NCT04700670|Biological|measurement of anti-Xa activities|"The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~STA-Liquid anti-Xa (STAGO) (not containing dextran)~Biophen Heparin LRT (Hyphen) (reactive containing dextran)~Berichrom (Siemens) with dextran~Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits."
75558259|NCT00444938|Device|H1 -coil TMS device|
75715504|NCT04035993|Other|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
75715505|NCT00367237|Drug|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
75715506|NCT00367237|Drug|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
75715507|NCT04006912|Procedure|phacoemulsification and Toric intraocular lens implantation|A clear corneal incision is made in a different position
75715508|NCT02540889|Behavioral|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
75413901|NCT04288427|Drug|Finasteride|Patients who are candidates to receive 5ARI therapy, Finasteride, for clinical medical management of lower urinary tract symptoms will begin treatment once deemed eligible. They will be assess every 6 months for changes in urinary symptom scores and their responsiveness to the Finasteride treatment will be assessed at the 12-month time point. MRIs of prostate taken at the start of study and at the 3 year time point will assess prostate size and changes in size as well as degree of inflammatory changes. Gene expression of SRD5A2 as well as methylation pattern will be tested on prostate tissue samples, where hormonal androgen/estrogen levels will also be assessed as they are in blood samples.
75413902|NCT04280601|Dietary Supplement|vitamin D|Patients with insufficient and/or deficient vitamin D status (<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months
75715509|NCT00894855|Behavioral|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
75715510|NCT00894855|Behavioral|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
75715511|NCT00894855|Other|dermatologist skin exam|Full body skin exam.
75558260|NCT00441870|Drug|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
75558261|NCT00441870|Drug|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
75558262|NCT00444977|Behavioral|Case-management linkage intervention|dental care
75413903|NCT04271501|Procedure|Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB)|Application of melanocytes (aka melanocyte-keratinocyte transplantation procedure or MKTP) to surgically prepared depigmented areas
75413904|NCT04271501|Device|RECELL 1:5 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
75413905|NCT04271501|Device|RECELL 1:10 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
75413906|NCT04271501|Device|RECELL 1:20 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
75558263|NCT04700592|Other|Gabapentin versus Ketamine|A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
75558264|NCT04699526|Other|Universal Prevention Curriculum Training for Schools|School administrators and teachers participated in UPC training and formed prevention leadership action teams
75558265|NCT00441909|Drug|UC-781|0.1% UC-781 Vaginal Gel
75558266|NCT00441909|Drug|UC-781 placebo|Vaginal Gel Placebo
75558267|NCT00445016|Procedure|peripheral regional anesthesia|evaluation and description of adverse effects
75558268|NCT00445055|Drug|Droperidol|Intravenous injection
75558269|NCT00479700|Drug|SAM-531|
75558270|NCT02957201|Other|Blood samples|Blood samples at baseline and 3 timepoints for EPC analysis
75558271|NCT00479739|Drug|Salmeterol/fluticasone propionate or formoterol/budesonide|
75558272|NCT03277820|Dietary Supplement|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
75413907|NCT04266964|Procedure|Manual examination|"With the patient in a supine position, squeeze the skinfold between your thumb and pointfinger on the inner aspect of the middle third of the thigh and on the inner aspect of the middle third of the calf.~Place your hand under the proximal calf and the heel and move the leg into maximum flexion at the hip and knee joints. After the response, if any, is completed, move the limb back into full extension. Each of these movements lasts for one second."
75413908|NCT04264013|Behavioral|Exercise|Participants will exercise in a supervised facility twice weekly and consume their habitual diet.
75558273|NCT00441948|Device|Peterio|
75558274|NCT00445094|Drug|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
75558275|NCT00445094|Drug|Comparator: amikacin / Duration of Treatment: 3 Days|
75558276|NCT00445094|Drug|Comparator: tazocin / Duration of Treatment: 3 Days|
75558277|NCT00445094|Drug|Comparator: vancomycin / Duration of Treatment: 3 Days|
75413909|NCT04264013|Behavioral|Exercise plus diet (egg)|Participants will exercise in a supervised facility twice weekly and consume an addiitonal 4 eggs per day.
75413910|NCT04263064|Drug|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine) caudal block
75413911|NCT04263064|Drug|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
75413912|NCT04261751|Other|Clinician Questionnaire|Nurses will take the Clinician Questionnaire electronically
75413913|NCT04258449|Device|DOvEEgene Fleur Sampling|Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.
75413914|NCT04249466|Other|Questionnaire|"During this consult, several parameters will be measured :~nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage."
75413915|NCT04248764|Other|Foam roller application|Following the fatigue protocol, foam roller application will be applied to the quadriceps femoris muscle for five minutes in the prone position.
75413916|NCT04248764|Other|Massage application|Following the fatigue protocol, sports massage will be applied to the quadriceps femoris muscle for five minutes.
75413917|NCT04231669|Behavioral|Anzansi Family Program|"the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG). Family EE includes: 1) Workshops on asset building, future planning, and protection from risks; 2) Child Development Account (CDA); and 3) Family income-generating/microenterprise promotion (IGA) component:~MFG a family-centered, group-delivered, evidence-informed intervention designed for children and adolescents whose families struggle with poverty and associated stressors. The MFG is based on building family support through opportunities for parents and children to communicate in a safe setting with other families who have shared experiences, and allow each family to learn from one another. MFG builds protective factors for healthy parent-child relationships while addressing familial, social and community stressors and barriers to adolescent girls' well-being. Both adolecsnt girls and their caregivers will receive the intervention."
75413918|NCT04228107|Device|Medication monitoring|This is an observational study of medication use patterns. The propeller health device has reminders for controller medication use and gives feedback regarding medication use to the participant, their guardian and their asthma provider
75413919|NCT04215692|Diagnostic Test|Pulmonary ultrasound|Pulmonary ultrasound is a basic application of critical ultrasound, defined as a loop associating urgent diagnoses with immediate therapeutic decisions.
75413920|NCT04210778|Behavioral|Cognitive orientation to daily occupational performance (CO-OP)|The CO-OP is a client-centered, goal directed approach aimed at enabling individuals to identify strategies that will improve daily function. A Weekly (1hr) session is delivered remotely via video conferencing.
75558278|NCT00479778|Drug|Bazedoxifene/conjugated estrogens|
75558279|NCT00445133|Device|Magnetic Sleep Pad|
75558280|NCT00442026|Drug|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
75558281|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
75558282|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
75558283|NCT00479895|Drug|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
75558284|NCT00445250|Drug|Calcipotriol|
75558285|NCT00442065|Device|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
75558286|NCT00445289|Device|SmartCare/PS|
75558287|NCT00442143|Procedure|Stem cell implantation|
75558288|NCT02957006|Device|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
75558289|NCT03279120|Drug|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
75558290|NCT03279120|Drug|Placebo|Used for 90 days (Continuous or Interrupted)
75558291|NCT04699760|Dietary Supplement|Fish Oil|8 weeks, 2.2 G EPA/day
75558292|NCT04699760|Dietary Supplement|Placebo|Placebo
75558293|NCT00479934|Drug|imatinib mesylate|6 month treatment with 400mg/day (per os)
75558294|NCT03274778|Drug|Ruxolitinib 20 MG|tablets
75558295|NCT00442182|Drug|ITF2357|
75558296|NCT03274700|Drug|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
75558297|NCT03274700|Drug|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
75558298|NCT00442221|Drug|Sumatriptan and Naproxen sodium|
75715512|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
75413921|NCT04210778|Behavioral|Computerized Cognitive Training (BrainHQ, posit science)|The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
75413922|NCT04208048|Device|FLXfit 15TM device|In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
75413923|NCT04204135|Procedure|LLIF or ALIF procedures|LLIF or ALIF procedures
75413924|NCT04194541|Device|Cutimed Sorbact Hydroactive B wound dressing|Wound dressing applied and changed as needed.
75413925|NCT04194541|Device|Cutimed Siltect wound dressing|Wound dressing applied and changed as needed.
75413926|NCT04194541|Device|Sorbion Sana multi-star wound dressing|Wound dressing applied and changed as needed.
75558299|NCT00479973|Dietary Supplement|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
75558300|NCT00479973|Dietary Supplement|Placebo|Placebo. 2 capsules after the two largest meals of the day
75558301|NCT00454259|Drug|Fentanyl/Placebo injection|Ultra low dose intravenous injection
75715513|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
75558302|NCT00454298|Drug|AGG-523 (Aggrecanase Inhibitor)|
75558303|NCT03279042|Procedure|Flapless corticotomy surgical intervention will be conducted|Piezocision will be used to perform the procedure
75558304|NCT03279042|Procedure|Traditional corticotomy|Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
75558305|NCT00454337|Drug|FTC/TDF + EFV or LPV/R +T20|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
75715514|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
75715515|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
75558306|NCT00454337|Drug|FTC/TDF + EFV or LPV/R|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
75558307|NCT00480012|Device|rTMS|repetitive transcranial meagnetic stimulation of the brain
75558308|NCT00454376|Other|questionnaire administration|
75558309|NCT00454376|Procedure|quality-of-life assessment|
75715516|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
75715517|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
75715518|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
75715519|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
75715520|NCT00984646|Drug|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
75413927|NCT04190706|Other|bioactive components fortified food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
75715521|NCT03991585|Behavioral|Musical Contour Regulation Facilitation (MCRF)|MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
75715522|NCT00901407|Drug|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
75715523|NCT00901407|Drug|placebo|placebo: 1-2 tablets bid; 10 weeks
75715524|NCT00901407|Drug|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
75715525|NCT01052155|Other|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
75413928|NCT04190706|Other|control food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
75413929|NCT04185532|Other|Rebound ACL brace and physioterapy|Usage of rebound ACL brace and physioterapy supervised by physioterapist
75413930|NCT04185532|Other|Physioterapy|Physioterapy supervised by physioterapist
75441388|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
75558310|NCT00480051|Device|Cardiac Resynchronization Pacing|
75558311|NCT00454493|Drug|Omacor (omega-3-acid ethyl esters)|
75558312|NCT00454610|Behavioral|FLOW|
75558313|NCT00454610|Behavioral|SelfHelp|
75558314|NCT00454688|Drug|Asimadoline|Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
75558315|NCT00454688|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
75558316|NCT03278808|Drug|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
75558317|NCT03278808|Drug|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
75715526|NCT00896883|Device|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
75558318|NCT03278808|Drug|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
75715527|NCT00984724|Behavioral|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
75715528|NCT00984724|Behavioral|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
75715529|NCT00984724|Behavioral|Quitline|Letter referring participants to a Quitline providing quit smoking services.
75715530|NCT00984724|Behavioral|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
75558319|NCT00480090|Drug|Cytarabine|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
75558320|NCT00454766|Behavioral|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
75558321|NCT00480129|Behavioral|Probiotic or placebo yogurt consumed daily|
75441389|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
75441390|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
75558322|NCT00480129|Device|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
75558323|NCT00480129|Procedure|Blood sample|
75558324|NCT00480129|Procedure|Nasal lavage|
75558325|NCT03274622|Behavioral|Impact Parent Training|
75558326|NCT03274622|Behavioral|No Impact|
75558327|NCT00442299|Device|Fractionated Plasma Separation and Adsorption (FPSA)|
75715531|NCT04035915|Procedure|Limited driving pressure|Keep driving pressure <15 cmH2O
75715532|NCT04035915|Procedure|Conventional mechanical ventilation strategies|Keep tidalvolume </= 8
75558328|NCT00454883|Drug|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
75558329|NCT00442377|Procedure|exposure to malaria sporozoites|
75558330|NCT00454922|Behavioral|standard of care|no intervention
75441391|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
75441392|NCT01634126|Behavioral|1 FIT kit|Patient receives 1 FIT
75441393|NCT01634126|Behavioral|2 FIT kit|Patient receives 2 FIT kits
75441394|NCT01634204|Other|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
75558331|NCT00454922|Other|education|meet with trained glaucoma educator 6 times over life of study
75558332|NCT03278652|Other|Consumption of drugs for analgesic use|"Regular assessment of pain~Drug data will be collected (name, dosage, route of administration, time of delivery)"
75715533|NCT00972400|Genetic|protein analysis|
75413931|NCT04153396|Drug|The Treatment group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection(betamethasone propionate 5mg and betamethasone sodium phosphate 2mg per 1ml) added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
75558333|NCT00454961|Drug|artemether-lumefantrine|
75558334|NCT03278574|Procedure|Mitral valve repair|Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
75558335|NCT03278574|Device|Ring annuloplasty with posterior band|Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
75558336|NCT03278574|Device|Ring annuloplasty with complete ring|Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
75558337|NCT00455000|Biological|PF-04360365|Monoclonal antibody
75558338|NCT00455000|Drug|Placebo|Placebo
75558339|NCT00455078|Procedure|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
75558340|NCT00455078|Other|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
75558341|NCT00455078|Procedure|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
75558342|NCT00455078|Procedure|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
75558343|NCT00455078|Procedure|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
75715534|NCT00972400|Other|laboratory biomarker analysis|
75558344|NCT00480207|Dietary Supplement|folic acid|
75558345|NCT00480207|Dietary Supplement|omega-3|
75558346|NCT00480207|Dietary Supplement|vit B12|
75558347|NCT00480207|Other|folic acid placebo|
75558348|NCT00480207|Other|omega-3 placebo|
75558349|NCT03274583|Diagnostic Test|Smartphone seismographic recording|A short recording of heart rhythm using a smartphone.
75558350|NCT00442455|Drug|Erlotinib chlorhydrate|150 mg/day for 7 weeks
75558351|NCT00442455|Drug|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
75558352|NCT00442455|Procedure|Radiation therapy|63 Gy, five days a week, for 7 weeks
75558353|NCT02956655|Other|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
75715535|NCT00972400|Other|mass spectrometry|
75715536|NCT00972400|Other|questionnaire administration|
75715537|NCT00972400|Procedure|assessment of therapy complications|
75558354|NCT02956655|Drug|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
75558355|NCT02956655|Other|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
75558356|NCT02956655|Behavioral|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
75558357|NCT02956655|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
75558358|NCT00480246|Drug|BL 1020|
75558359|NCT00480246|Drug|Perphenazine|
75558360|NCT00455117|Drug|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
75558361|NCT00442494|Drug|intravenous hydrocortisone|
75715538|NCT00972400|Procedure|cognitive assessment|
75558362|NCT03274427|Device|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
75558363|NCT03274427|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
75558364|NCT03274427|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
75715539|NCT00972400|Procedure|quality-of-life assessment|
75715540|NCT00896961|Drug|EF5|
75715541|NCT00896961|Other|diagnostic laboratory biomarker analysis|
75715542|NCT00896961|Other|pharmacological study|
75558365|NCT03274388|Procedure|nutritional therapy|protein-rich nutritional therapy and counseling, during study period of 12 weeks
75558366|NCT03274388|Procedure|WB-EMS combined with nutritional therapy|protein-rich nutritional therapy and counseling plus whole body electromyostimulation exercise training, twice a week for 20 min., during study period of 12 weeks
75558367|NCT00480285|Procedure|Laparoscopic Nissen Fundoplication|
75558368|NCT00480285|Procedure|Laparoscopic anterior partial fundoplication|
75715543|NCT00984802|Drug|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
75715544|NCT00984802|Drug|Placebo control|Vehicle solution for IV administration single dose.
75715545|NCT00901563|Drug|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
75413932|NCT04153396|Drug|The Control group|The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
75558369|NCT03274349|Procedure|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
75558370|NCT03274349|Procedure|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
75558371|NCT00442650|Drug|Efalizumab|
75715546|NCT00901563|Other|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
75558372|NCT02273687|Device|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
75413933|NCT04148521|Behavioral|Behavioral Health - Virtual Patient Navigation|Patients are identified by a clinician in the ED as needing psychiatric evaluation and a referral is made to a tele-psych provider for a virtual consult. Patients can be enrolled to the intervention arm based on a randomization scheme that randomly allocates days that navigators are available. The psychiatrist will make a recommendation to admit or discharge the patient. For patients that have a discharge recommendation on days that BH-VPN is available, patients will be offered the BH-VPN program. Enrolled patients are followed for up to 45 days. On days where the navigator is available, all patients who meet eligibility criteria will be considered exposed to the intervention.
75413934|NCT04131309|Drug|Daratumumab|As of Protocol Amendment 1, all new subjects are dosed with daratumumab subcutaneous injection (SC) co-formulated with recombinant human hyaluronidase rHuPH20. Subjects who already began treatment with daratumumab intravenous (IV) infusion (i.e., prior to Am 1) switch to SC on the next administration date according to the protocol schedule. Subjects receive daratumumab IV at a dose of 16 mg/kg and daratumumab SC at a fixed dose of 1800 mg for the first 8 weeks (Cycles 1 and 2) of treatment and then every 2 weeks for 4 cycles (Cycles 3 to 6) and then every 4 weeks until progression of disease (according to MOD-PFS), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total. All treatment cycles are 4 weeks (28 days) in length.
75413935|NCT04131309|Drug|Bortezomib Injection|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib at a dose of 1.3 mg/m2 weekly for a maximum of 6 cycles as a subcutaneous injection
75558373|NCT00442728|Device|ELECTRICAL STIMULATION|
75558374|NCT00455234|Drug|Intramuscular Olanzepine 10 mg|
75558375|NCT00455234|Drug|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
75558376|NCT00480363|Procedure|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
75558377|NCT00442806|Drug|Injection of ADRC's|ADRC's are injected
75558378|NCT00442806|Other|Injection of Placebo|Placebo is injected
75558379|NCT00455390|Procedure|Post-immediate Psychotherapeutic Intervention|
75558380|NCT00442845|Drug|Atorvastatin (Lipitor)|
75558381|NCT00455468|Procedure|Day-care treatment vs. hospital care|
75558382|NCT00455507|Drug|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
75558383|NCT00455507|Drug|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
75558384|NCT00455507|Drug|Placebo|Two placebo tablets orally once daily for 12 weeks
75558385|NCT00442884|Behavioral|Trier Social Stress Test (TSST)|
75558386|NCT00455546|Drug|A-002|
75558387|NCT00442923|Drug|Coreg|
75558388|NCT00480402|Drug|200 mg of Progesterone|Administration of 200 mg of Progesterone
75558389|NCT00480402|Drug|400 mg Progesterone|Administration of 400 mg Progesterone
75558390|NCT00480402|Drug|Placebo|Administration of a Placebo
75558391|NCT00455585|Drug|nevirapine, stavudine, lamivudine|
75715547|NCT00901641|Device|CogniFit Personal Coach®|The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
75558392|NCT00455624|Drug|Androgen deprivation therapy|According to standard medical care
75558393|NCT01240005|Biological|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
75413936|NCT04131309|Drug|Dexamethasone oral tablet|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab low dose dexamethasone at a maximum total dose of 20 mg weekly.
75413937|NCT04119778|Behavioral|Aerobic Exercise, Tai chi|They are aerobic and mind-body exercise respectively.
75413938|NCT04108767|Behavioral|Answer to standardized questionnaires in quality of life, health, lifestyle and behaviors|"The cross-sectional study will be conducted in all students in health sciences in 3rd year enrolled at the University Claude Bernard Lyon 1 (UCBL) and participating at the required medical consultation at the college Health Department of UCBL, over a period of 9 months.~The self-questionnaires will be completed by the students during the mandatory medical preventive visit at the university health center.~All dimensions investigated by the questionnaire are usually questioned by the caregivers during the consultation as part of the usual follow-up of students."
75413939|NCT04100486|Other|Standing-Squatting-Standing Test|The participant will begin by actively standing for one minute, followed by a transition to a squat for one minute, and one last transition to one minute of standing.
75413940|NCT04100486|Other|Deep Breathing Test|The participant will be asked to lay down for seven minutes and take long, controlled breaths at a rate within 4 to 10 breaths per minute.
75413941|NCT04100486|Other|Cold Pressor Test|The participant will be asked to immerse their hand into ice water (1- 10°C) for up to three minutes, followed by removal of the hand from the bath and continuation for recording for a further three to five minutes. The participant will be informed that he or she can remove his or her hand at any point if there is discomfort.
75413942|NCT04100486|Other|Cold Face Test|The cold stimulus will be applied with refrigerated gel-filled compresses places on the forehead and cheeks of the participant for one minute.
75413943|NCT04100486|Other|Valsalva Maneuver|The participant will be asked to inhale deeply, pinch his or her nose, close his or her mouth, and forcibly exhale, while bearing down with tight chest and stomach muscles, for approximately 10 to 15 seconds. The sensors will continue recording as the participant recovers to normal breathing over the next one minute.
75413944|NCT04100486|Device|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The participant will receive electrical stimulation applied to their ear for five minutes. The threshold for stimulation will be determined before the test begins at a level that may elicit sensation (tickling, vibrating, pricking), but no pain. There is a possibility that the participant will receive sham stimulation, or inactive stimulation, for this test.
75413945|NCT04078594|Other|sepsis e-alert|At 2-each month interval, the e-alert will be activated in five new randomly selected wards, until all wards eventually will have active alert
75413946|NCT04077970|Biological|Intrauterine flushing of follicular fluid with granulosa cells|All patients in case and control groups will receive agonist and antagonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
75413947|NCT04067427|Other|Mental training|App-based mental training
75413948|NCT04056221|Other|Acupuncture|Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.
75413949|NCT04056221|Other|Sham acupuncture|The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.
75413950|NCT04043442|Device|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P|rTMS device
75715548|NCT00972556|Drug|Gray Mineral Trioxide Aggregate (GMTA)|Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
75715549|NCT00972556|Drug|Diluted (20%) Formocresol (DFC)|After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
75715550|NCT00897039|Other|flow cytometry|
75413951|NCT04040959|Drug|Nicotinamide riboside|Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
75413952|NCT04035031|Drug|Forxiga 10mg|Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)
75413953|NCT04035031|Drug|Placebo|Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
75413954|NCT04018638|Other|B-FREE|Blood flow-restriction exercise enhancement (B-FREE) will be performed at home 3x/wk for 10 weeks. A blood pressure cuff will be inflated to partially occlude blood to the limb during light weight exercises involving knee extension, body weight squats, and walking.
75413955|NCT04014907|Procedure|Frozen Elephant Trunk Technique|Endovascular technique forTAA repair
75413956|NCT04006392|Device|Erchonia FX-635|The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.
75413957|NCT04006392|Device|Placebo Laser|Non-therapeutic output.
75413958|NCT04000568|Other|Respiratory support: NAVA -NIV and PC-NIV|The infants enrolled will receive respiratory assistance by NAVA-NIV and PC-NIV in a randomized order
75558394|NCT00455819|Procedure|home treatment|
75413959|NCT03997617|Diagnostic Test|Personalized Functional Profiling|During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
75413960|NCT03959423|Device|AHCL insulin pump system|670G 4.0 system with GS3; 780G system with G4S (continued access phase);
75558395|NCT00443157|Biological|Meningococcal B Vaccine NZ|
75558396|NCT00455897|Drug|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
75558397|NCT00455897|Drug|CHOP|Administered as part of standard care
75558398|NCT00455897|Drug|Rituximab|Administered as part of standard treatment
75558399|NCT00480480|Behavioral|Trauma and Grief Component Therapy for Adolescents (Group Version)|
75558400|NCT00455936|Drug|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
75558401|NCT00455936|Procedure|chemotherapy|gemcitabine(1250mg/m2 iv on D1 & 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
75558402|NCT00443196|Procedure|MiCK Assay|Physician determined treatment
75715551|NCT00897039|Other|immunohistochemistry staining method|
75715552|NCT00984880|Drug|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
75715553|NCT02540499|Radiation|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
75715554|NCT00972634|Other|computer-assisted intervention|symptom assessment
75715555|NCT00972634|Other|questionnaire administration|Symptom assessment
75715556|NCT00972634|Procedure|assessment of therapy complications|Symptom assessment
75715557|NCT00972634|Procedure|quality-of-life assessment|Symptom assessment
75715558|NCT00901719|Drug|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
75558403|NCT03274310|Behavioral|Educational text messages|Educational text message about ways to decrease household transmission of influenza and other respiratory infections
75558404|NCT00443235|Drug|Melphalan/Prednisone/Velcade|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
75558405|NCT00443235|Drug|Thalidomide/Prednisone/Velcade|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
75558406|NCT03274232|Device|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
75558407|NCT00456053|Drug|FG2216|
75558408|NCT00456131|Behavioral|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
75413961|NCT03934697|Behavioral|imaginal exposure therapy|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
75413962|NCT03907462|Behavioral|SMART 2.0|SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
75558409|NCT00480519|Procedure|Meatotomy|
75558410|NCT00456170|Procedure|Performing Vaginal hysterectomy with Harmonic Scalpel|
75873030|NCT04052984|Procedure|Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section|Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
75413963|NCT03900910|Other|Gastric cancer prevention|Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.
75413964|NCT03900910|Other|Execution of the program|Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .
75558411|NCT03278535|Diagnostic Test|CAREN-based gait analysis|subjects only walk at CAREN at different speed
75558412|NCT04700943|Procedure|Regional awake anesthesia|We want to assess the impact of regional anesthesia on diaphragmatic function in patients undergoing Video-assisted thoracoscopic surgery pulmonary biopsy in interstitial lung disease
75558413|NCT00456248|Drug|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
75558414|NCT00480558|Biological|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10^7
75558415|NCT00456287|Device|CPAP (Continuous Positive Airway Pressure)|
75558416|NCT04700709|Drug|Sirolimus Tab.|Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~8ng/ml.
75558417|NCT04700709|Drug|Mycophenolate Mofetil Cap./Tab.|Up to 1g BID(total 2g daily), PO
75413965|NCT03879304|Other|multimodal physiotherapy program with RV|Physiotherapy Programm includes: respiratory physiotherapy, stretching, resistance training, aerobic training and adaptation and training with virtual reality glasses and relaxation.
75413966|NCT03879304|Other|traditional physiotherapy program|Multimodal physiotherapy Programm includes: traditional physiotherapy, stretching, massage.
75413967|NCT03869957|Dietary Supplement|Intervention group|0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
75413968|NCT03860285|Other|Short form 36 quality of life survey|Prospective non-comparative observational study of cohorts
75413969|NCT03852147|Procedure|: hemodynamic management|"Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.~Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine."
75413970|NCT03844607|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
75413971|NCT03844607|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
75413972|NCT03835065|Procedure|Closed Reduction|The primary goal of closed reduction is to maintain appropriate bony alignment and angulation to allow for appropriate healing.
75558418|NCT04698317|Procedure|open flap debridement|Open flap for removal of diseased periodontal tissues and necrotic cementum
75558419|NCT04698317|Other|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate plus concentrated growth factors|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate incorporating Concentrated Growth Factors in Periodontal Defect
75558420|NCT04698317|Other|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone in the Intrabony Periodontal Defect
75558421|NCT04700475|Device|low level laser|"Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland ."
75558422|NCT04700475|Drug|citric acid solution|citric acid solution applied as a mouth rinse
75413973|NCT03835065|Other|Long Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
75558423|NCT00456404|Drug|peppermint water|
75558424|NCT04700436|Drug|Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)|"IP~Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)"
75558425|NCT00456443|Procedure|Historical records|
75413974|NCT03835065|Other|Short Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
75413975|NCT03801837|Dietary Supplement|Macadamia Nut|Participants will be provided with the appropriate portion of macadamia nuts [15% of daily calories or 30-45 grams based on kcal requirement of the individual]
75413976|NCT03801837|Dietary Supplement|Control Diet|Participants will continue with their Habitual Diet during this part of the intervention
75413977|NCT03790150|Other|Evidence-based practices|Implementation of evidence-based practices
75558426|NCT00480597|Drug|gemcitabine|
75558427|NCT00480597|Drug|cisplatin|
75558428|NCT00480597|Drug|vinorelbine|
75873031|NCT03648866|Other|interview|"Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds"
75873032|NCT03648788|Other|NA (Observation study)|NA (Observation study)
75873033|NCT03647540|Procedure|fluorescent laparoscopic radical gastrectomy|The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
75413978|NCT03786783|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
75558429|NCT00480597|Drug|capecitabine|
75558430|NCT00456482|Drug|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
75558431|NCT00456482|Drug|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
75558432|NCT00480675|Procedure|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
75558433|NCT00480675|Procedure|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
75558434|NCT00456560|Drug|AV650|
75558435|NCT00456560|Drug|Fluvoxamine|
75558436|NCT00456560|Drug|Paroxetine|
75558437|NCT04700358|Other|Blood sampling|"Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)"
75558438|NCT00456638|Drug|Depodur|Depodur vs. traditional management
75558439|NCT04700085|Device|ReMotion Knee|The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
75558440|NCT00480714|Biological|BCG (SSI Strain)|
75558441|NCT00456677|Drug|minocycline|addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
75558442|NCT00456677|Drug|Placebos|Addition of oral placebo capsule in addition to standard of care regimen
75558443|NCT03278496|Behavioral|Recovery Housing plus Counseling|Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.
75873034|NCT03647540|Procedure|traditional laparoscopic radical gastrectomy|The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
75873035|NCT04009382|Other|Baduanjin Exercise|Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
75873036|NCT04009382|Other|Cognitive Fitness Program|Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
75873037|NCT03648008|Drug|Hydromorphone|0.002 mg*kg-1 bolus with 0.002 mg*kg-1 background infusion for group BH 0.002 mg*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.
75873038|NCT03648008|Drug|Morphine|0.015 mg*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
75873039|NCT03647930|Device|Microporous Polysaccharide Hemospheres (MPH)|Microporous Polysaccharide Hemospheres (MPH)
75413979|NCT03786783|Drug|Carboplatin|Given IV
75413980|NCT03786783|Drug|Cisplatin|Given IV
75413981|NCT03786783|Drug|Cyclophosphamide|Given IV
75413982|NCT03786783|Drug|Dexrazoxane|Given IV
75413983|NCT03786783|Biological|Dinutuximab|Given IV
75413984|NCT03786783|Drug|Doxorubicin|Given IV
75413985|NCT03786783|Drug|Etoposide|Given IV
75413986|NCT03786783|Radiation|External Beam Radiation Therapy|Undergo EBRT
75413987|NCT03786783|Drug|Isotretinoin|Given PO
75413988|NCT03786783|Drug|Melphalan|Given IV
75413989|NCT03786783|Biological|Sargramostim|Given SC
75413990|NCT03786783|Drug|Thiotepa|Given IV
75715559|NCT00901719|Drug|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
75715560|NCT00901719|Drug|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
75558444|NCT03278496|Behavioral|Usual Care Referral|Participants are referred to an outpatient program of their choosing with an appointment made for them.
75558445|NCT03278496|Behavioral|Recovery Housing Only|Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
75558446|NCT00456716|Drug|sorafenib|400mg po bid
75715561|NCT00901719|Drug|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
75715562|NCT00972712|Drug|Bortezomib and Tipifarnib|"Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)"
75715563|NCT00984958|Device|Bulkamid|injection of Bulkamid in the urethra
75413991|NCT03786783|Drug|Topotecan|Given IV
75413992|NCT03786783|Drug|Vincristine|Given IV
75413993|NCT03785587|Drug|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
75413994|NCT03761680|Dietary Supplement|MEDPass mode of administration|Allocation of 50 ml of ONS four times per day distributed with the medication rounds
75413995|NCT03761680|Dietary Supplement|Control Intervention|Patients receive ONS between meals or at their request as usual
75715564|NCT00984958|Device|Bulkamid expectation|expectance
75715565|NCT00897273|Genetic|comparative genomic hybridization|
75715566|NCT00897273|Genetic|gene expression analysis|
75715567|NCT00897273|Other|study of socioeconomic and demographic variables|
75715568|NCT00897273|Procedure|evaluation of cancer risk factors|
75715569|NCT00897273|Procedure|study of high risk factors|
75413996|NCT03720080|Device|OpenAPS|A self-constructed OpenAPS system will be worn contemporaneously to a Medtronic Minimed 670G hybrid closed loop system. Both systems will calculate recommended basal rate insulin adjustments but only the Minimed 670G system will inject insulin. The maximum treatment period will be 2 weeks per patient
75413997|NCT03670056|Drug|Combination immunotherapy with Ipilimumab and Nivolumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
75413998|NCT03661073|Behavioral|Assessment of motor imagery ability|The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.
75715570|NCT04007302|Other|measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)|measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
75715571|NCT04007302|Other|completion of questionnaires|igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
75413999|NCT03661073|Behavioral|Assessment of motor imagery ability of healthy subject|The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
75414000|NCT03654833|Drug|Rucaparib|PARP inhibitor
75414001|NCT03654833|Drug|Abemaciclib|CDK4/6 inhibitor
75414002|NCT03654833|Drug|pembrolizumab & bemcentinib|PD1 checkpoint inhibitor, AXL inhibitor
75414003|NCT03654833|Drug|Atezolizumab & Bevacizumab|PDL1 checkpoint inhibitor, VEGF inhibitor
75715572|NCT04007302|Other|completion of questionnaires for pain|analogical visual and numerical scale and Borg scale
75414004|NCT03654833|Drug|Dostarlimab and Niraparib|IG Antibody, PARP Inhibitor
75558447|NCT04700397|Diagnostic Test|Nitroglycerine|We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
75558448|NCT00456794|Drug|Istradefylline (KW-6002)|
75558449|NCT00456833|Drug|RAD001|
75414005|NCT03653455|Behavioral|Email reminders|Patients will receive email reminders until their PROs are completed.
75414006|NCT03653455|Behavioral|Pre- and Post-operative discussion|Patients will discuss with their provider the importance of PROs pre-operatively, as well as their post-operative progression in comparison to established norms.
75414007|NCT03653455|Behavioral|Incentive|Patients will receive up to $30 in amazon gift cards upon the completion of their PROs.
75715573|NCT00901797|Procedure|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
75414008|NCT03520751|Drug|scAAV1.tMCK.NTF3|gene vector
75414009|NCT03519451|Other|Internet-Based Intervention|Given KickAsh smartphone mobile application
75414010|NCT03519451|Other|Internet-Based Intervention|Given Breathe2Relax smartphone mobile application
75414011|NCT03519451|Other|Questionnaire Administration|Ancillary studies
75414012|NCT03432494|Device|Transcaval closure device (TCD)|Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
75414013|NCT03426904|Drug|Neoadjuvant FOLFOX|4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy
75414014|NCT03426904|Drug|Conventional adjuvant FOLFOX|12 cycles of postoperative FOLFOX chemotherapy
75558450|NCT00456833|Drug|erlotinib|
75558451|NCT04700319|Drug|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T,Infusion,iv,0.2×10^6-5×10^6γδT /kg,once
75558452|NCT00456872|Drug|lidocaine|
75558453|NCT00480753|Drug|Nitroglycerin|
75558454|NCT00456911|Behavioral|Fat and carbohydrate controlled diet|
75558455|NCT03274154|Dietary Supplement|Pre-Hyaluron 465 Innēov|Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
75558456|NCT03274115|Device|BLI (Blue Laser Imaging)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
75558457|NCT04700241|Dietary Supplement|Potassium nitrate|Acute intervention (5.5 hours)
75558458|NCT04700241|Dietary Supplement|Placebo|Acute intervention (5.5 hours)
75558459|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
75558460|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
75558461|NCT00480792|Biological|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
75558462|NCT00457067|Drug|Ranibizumab|
75715574|NCT00901797|Procedure|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
75414015|NCT03420482|Drug|Fecal Microbiota Transplant (FMT) oral capsules|Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
75414016|NCT03420482|Drug|Placebo oral capsule|Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
75414017|NCT03375827|Other|IGCDG|The IGCDG reviews topics of concern for patients with metastatic breast cancer.
75441395|NCT01634204|Other|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
75558463|NCT00480870|Drug|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
75558464|NCT00480870|Drug|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
75558465|NCT00457106|Drug|Paroxetine|
75558466|NCT00457106|Drug|Risperidone|
75558467|NCT00480948|Behavioral|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing ~49% of C16:0 at sn-2 position), 24 wk
75558468|NCT00480948|Dietary Supplement|Control|Standard vegetable oil based infant formula
75558469|NCT00457145|Drug|Ranibizumab|
75558470|NCT00443469|Device|magnetic stimulation|SMS was delivered with a repetitive magnetic stimulator connected to a figure of eight coil capable of delivering a maximum output of 2 Tesla per pulse. The coil measured 90 mm in each wing and was centered over the surface landmark corresponding to the cauda equina region. SMS was performed with the patient lying comfortably in the prone position and a soft pillow supported the lower abdomen. The coil was placed flat over the back with the handle pointing cranially. Each patient on active treatment received 200 trains of 5 pulses delivered at 10 Hz, at an interval of 5 s between each train. As this was a pilot study, each only received 1000 pulses in a single session.
75558471|NCT00443469|Device|Magnetic Stimulation with tilted coil|The placebo arm consisted of 'sham' SMS delivered with the coil angled vertically and one of the wing edges in contact with the stimulation point. As this coil type allows maximum magnetic flux at the center of the intersection, we believe minimum or no stimulation was effected at the edge of the coil in contact with the patient. Stimulation parameters and duration were unchanged in this arm.
75558472|NCT00457184|Procedure|Blood tests|
75558473|NCT01240044|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
75715575|NCT02539641|Radiation|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
75715576|NCT02539641|Other|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
75414018|NCT03362372|Behavioral|Mediterranean diet counseling|"The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog."
75414019|NCT03361072|Dietary Supplement|Oral immunotherapy|Milk, peanut or egg oral immunotherapy
75414020|NCT03303963|Diagnostic Test|Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line|"Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:~Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)~Validating the Molbio Truenat test as a point of care test (Study 1 - phase 2)~Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)"
75414021|NCT03303963|Diagnostic Test|Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis|"Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:~FDA microscopy~Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin~Measurement of pre-rRNA synthesis"
75414022|NCT03302611|Behavioral|Physical Activity-based Interventions|Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
75414023|NCT03292315|Drug|Semaglutide 1MG Injection [Ozempic]|Once weekly injection of 1mg of Semaglutide.
75558474|NCT01240044|Procedure|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
75558475|NCT00457223|Procedure|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
75558476|NCT00443508|Drug|adding Certican to therapy|
75715577|NCT00544882|Drug|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
75715578|NCT00544882|Drug|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
75715579|NCT00544882|Drug|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
75558477|NCT00443508|Drug|reducing Tacrolimus|
75558478|NCT00457262|Procedure|soy consumption|
75558479|NCT03278418|Procedure|Tricuspid Valve Repair|It will be performed according to the surgeon preference
75558480|NCT03278418|Procedure|Left-sided valve surgery|It will be performed according to the surgeon preference
75558481|NCT00457340|Drug|Atorvastatin 80mg|
75558482|NCT03278379|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
75715580|NCT04035603|Drug|D-Cycloserine|50 mg d-cycloserine given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
75715581|NCT04035603|Drug|Placebo oral tablet|matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
75558483|NCT00457379|Behavioral|physical exercise|
75414024|NCT03292315|Other|No Intervention|No injection will be administered
75558484|NCT01240083|Device|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
75558485|NCT01240083|Device|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
75414025|NCT03287830|Behavioral|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
75558486|NCT01240083|Device|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
75558487|NCT02956538|Drug|Thalidomide|
75558488|NCT02956538|Drug|placebo(for thalidomide)|sugar pill manufactured to mimic thalidomide 100mg tablet
75558489|NCT01240161|Drug|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
75558490|NCT00457496|Behavioral|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
75558491|NCT00443586|Behavioral|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
75558492|NCT00443586|Behavioral|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
75558493|NCT00443586|Behavioral|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
75873040|NCT03105297|Device|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
75414026|NCT03287778|Dietary Supplement|Pyridoxine|Max dose of 400 mg QD PO
75558494|NCT00443586|Behavioral|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
75558495|NCT00457574|Drug|GMX1777|
75558496|NCT00443625|Drug|SK3530|
75558497|NCT00457613|Drug|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
75414027|NCT03287778|Dietary Supplement|Placebo|Matching placebos will be administered.
75414028|NCT03273413|Drug|Pravastatin|Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
75558498|NCT00481026|Device|transcranial direct current stimulation (tDCS)|tDCS
75558499|NCT00481026|Device|active tDCS|Active tDCS
75558500|NCT00457652|Drug|Rosuvastatin|7 day treatment rosuvastatin 20mg
75558501|NCT00443664|Device|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
75558502|NCT00457769|Drug|Donepezil and self-generated memory training|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
75558503|NCT00457769|Drug|Donepezil and experimenter-administered memory training|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
75558504|NCT00481104|Drug|Tesofensine|
75558505|NCT00457808|Drug|Rapamycin, sirolimus|
75558506|NCT00443742|Procedure|Validation|
75558507|NCT03278301|Device|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
75558508|NCT00457925|Drug|GSK221149A|
75558509|NCT00481143|Drug|ICL670/Deferasirox|
75558510|NCT00457964|Drug|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
75873041|NCT03105297|Other|No strip|
75873042|NCT03647384|Drug|Gulingji capsules|Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
75414029|NCT03273413|Drug|Placebo|Inactive tablet
75414030|NCT03266484|Dietary Supplement|Probiotic Mixture|The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.
75414031|NCT03266484|Dietary Supplement|Placebo|A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
75414032|NCT03242824|Drug|Fluorine F 18 Fluorodopa|Contrast used in PET
75414033|NCT03242824|Radiation|Intensity-Modulated Radiation Therapy|Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
75558511|NCT01240395|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|"MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course."
75414034|NCT03242824|Procedure|Positron Emission Tomography|imaging test
75414035|NCT03233750|Behavioral|Stress Inoculation Training|see description in arm/group descriptions
75414036|NCT03233750|Behavioral|Crisis Resource Management|During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
75558512|NCT00458042|Drug|treprostinil sodium|
75558513|NCT00458081|Drug|Rimonabant|20 mg once per day + slightly reduced calorie diet
75558514|NCT00458081|Drug|Placebo|placebo once per day + slightly reduced calorie diet
75558515|NCT00458120|Biological|rDEN1delta30|Live attenuated 10^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
75558516|NCT00458120|Biological|rDEN2/4delta30(ME)|Live attenuated 10^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
75558517|NCT00458120|Biological|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
75558518|NCT00481182|Drug|fosamprenavir + ritonavir + methadone|
75558519|NCT00458159|Drug|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, & 50mg, taken once daily, orally.
75873043|NCT03647384|Drug|Ginko Biloba Extract tablet|Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
75873044|NCT05284916|Behavioral|liver diseases admissions|The different patterns of liver disease related admissions after the era of DAAS
75414037|NCT03227458|Other|DHEA|Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.
75414038|NCT03227458|Other|Placebo|Participants will take placebo daily for 36 weeks.
75414039|NCT03227458|Behavioral|Exercise|bone-loading exercise on 3 days per week for 38 weeks
75414040|NCT03181633|Drug|ACH-0144471|ACH-0144471 will be administered to all participants enrolled in the study.
75414041|NCT03141983|Drug|Anakinra|Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). It is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) but differs from human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. It is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.
75558520|NCT00443937|Drug|enteric-coated mycophenolate sodium|oral
75558521|NCT00443937|Drug|everolimus|oral
75558522|NCT00455780|Behavioral|Weight Loss Phase|Weight loss using CBT and meal replacements
75558523|NCT00455780|Behavioral|Continued CBT|Using CBT during weight loss maintenance
75558524|NCT00455780|Behavioral|reduced energy density education|Additional nutritional learning
75558525|NCT00455780|Behavioral|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
75715582|NCT04035603|Behavioral|Open Phase CBT that preceeds the randomization phase|Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).
75558526|NCT00458198|Behavioral|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
75558527|NCT00487929|Device|nasal CPAP|Nocturnal
75558528|NCT00487929|Device|Sham CPAP|Nocturnal
75558529|NCT00458315|Drug|Cisplatin|
75558530|NCT00458315|Drug|Paclitaxel|
75558531|NCT00458315|Drug|Gemcitabine|
75558532|NCT00458315|Drug|Avastin (Bevacizumab)|
75558533|NCT00458354|Device|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
75558534|NCT00458354|Procedure|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
75558535|NCT00444015|Drug|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
75558536|NCT00444054|Behavioral|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
75558537|NCT00458471|Device|Insertion of a urinary catheter coated with benign E. coli|
75558538|NCT00487968|Drug|eltrombopag|
75558539|NCT00458510|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
75414042|NCT03141983|Drug|Placebo|Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
75558540|NCT00488007|Device|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
75558541|NCT00458549|Dietary Supplement|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
75558542|NCT00458549|Procedure|biopsy|
75558543|NCT00458588|Other|physiologic testing|
75558544|NCT00458588|Other|questionnaire administration|
75558545|NCT00458588|Procedure|breast imaging study|
75558546|NCT00458588|Procedure|dual x-ray absorptometry|
75558547|NCT00458588|Procedure|evaluation of cancer risk factors|
75558548|NCT00458588|Procedure|magnetic resonance imaging|
75414043|NCT03122223|Biological|ALVAC-HIV (vCP2438)|expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10^6 cell culture infectious dose (CCID)50 and less than 1 × 10^8 CCID50 (nominal dose of 10^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.
75558549|NCT00488046|Biological|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
75558550|NCT00444132|Drug|clopidogrel|
75558551|NCT03274037|Diagnostic Test|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
75558552|NCT02956733|Procedure|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
75558553|NCT02956733|Procedure|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
75558554|NCT00458744|Drug|talotrexin|
75558555|NCT00458744|Procedure|chemotherapy|
75558556|NCT00444171|Procedure|insulin infusion rate controled by computer algorithm|
75558557|NCT00444171|Procedure|insulin infusion rate guided by in-house glucose management protocol|
75414044|NCT03122223|Biological|Bivalent subtype C gp120/MF59|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered IM as a single 0.5 mL dose.
75414045|NCT03122223|Biological|Bivalent subtype C gp120/AS01(B)|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.
75414046|NCT03122223|Biological|Placebo|Sodium Chloride for Injection, 0.9%, administered IM.
75414047|NCT03077087|Device|thin Integra® (125 cm2)|125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
75414048|NCT03074539|Drug|Riociguat|Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
75414049|NCT03074539|Procedure|Pulmonary Endarteriectomy|Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.
75414050|NCT03074539|Procedure|Ballon Pulmonary Angioplasty|Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
75414051|NCT03030131|Drug|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
75414052|NCT03011021|Drug|Liraglutide|Dose escalation of Liraglutide starts from 0.6 mg up to 1.2 mg per day.
75414053|NCT03011021|Biological|UCB-Treg|Receive Treg infusion: 1~5*10^6/kg b.w. in 100ml normal saline
75414054|NCT03011021|Drug|Insulin|Receive insulin following clinician's instruction.
75414055|NCT02995252|Other|Blood draws|
75414056|NCT02995252|Drug|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
75414057|NCT02995252|Other|Knowledge Index Questionnaire|
75414058|NCT02995252|Other|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
75414059|NCT02995252|Procedure|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
75414060|NCT02990793|Device|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/ECG resonance therapy (MeRT) treatment that is tailored specifically to each participant's EEG intrinsic alpha frequency (IAF). rTMS is applied at the participant's IAF.
75558558|NCT00458900|Drug|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
75414061|NCT02990793|Device|Sham MeRT Treatment|rTMS coil does not emit magnetic stimulation.
75414062|NCT02989948|Device|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
75414063|NCT02970513|Other|Psychiatric evaluation|The purpose of this study is to determine whether the presence of pathogenic Escherichia coli in colon is associated with psychiatric disorders.
75414064|NCT02932826|Biological|Umbilical Cord Blood Regulatory T cells Therapy|Receive Treg infusion: 1~5*10^6/kg b.w. in 100ml NS
75715583|NCT04035603|Drug|Open phase smoking cessation pharmacotherapy that proceeds the randomization phase|Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
75414065|NCT02932826|Drug|Insulin|Treated according to routine clinical practice at the discretion of the treating physician
75414066|NCT02874131|Behavioral|Behavioral Activation|Behavioral activation
75414067|NCT02874131|Behavioral|Cognitive Processing Therapy|Cognitive processing therapy
75414068|NCT02853604|Drug|ADXS11-001|
75414069|NCT02853604|Drug|Placebo|
75414070|NCT02843191|Drug|Chemotherapy|5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
75414071|NCT02817360|Drug|RAS-antagonist and beta-blocker up-to maximal dosages|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
75414072|NCT02817360|Other|RAS-antagonist and beta-blocker none or at stable dose|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
75414073|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 8 Gy|
75414074|NCT02811250|Radiation|Stereotactic radiotherapy 5 x 8 Gy|
75414075|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 10 Gy|
75414076|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 12 Gy|
75414077|NCT02799706|Drug|Degarelix|a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
75414078|NCT02799706|Drug|approved GnRH agonist|A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
75715584|NCT00606801|Drug|Galantamine|Galantamine 8 mg/day
75715585|NCT00606801|Drug|placebo|sugar pill
75715586|NCT00972790|Procedure|Bilateral Scalp Nerve Blocks|Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
75414079|NCT02799706|Radiation|Radiotherapy|.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
75414080|NCT02770599|Other|IBD multidisciplinary team model including IBD nurse|IBD multidisciplinary team model including IBD nurse
75414081|NCT02759458|Device|Smith & Nephew Healicoil Anchor|
75558559|NCT00488124|Drug|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
75558560|NCT00459017|Device|Portable blood pressure wrist manometer|
75414082|NCT02759458|Device|Smith & Nephew Twinfix Anchor|
75414083|NCT02689778|Drug|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
75414084|NCT02689778|Drug|Placebo|Identical tablets without active substance
75414085|NCT02678377|Drug|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
75414086|NCT02678377|Drug|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
75414087|NCT02659384|Drug|Bevacizumab|
75414088|NCT02659384|Drug|atezolizumab|
75414089|NCT02659384|Drug|acetylsalicylic acid|
75414090|NCT02659384|Drug|placebo|
75414091|NCT02659306|Drug|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
75414092|NCT02632552|Behavioral|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
75414093|NCT02632552|Behavioral|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
75414094|NCT02591147|Device|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
75414095|NCT02591147|Device|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
75558561|NCT00444210|Device|DL6049 (injectable poly-L-lactic acid)|
75558562|NCT03273959|Other|Exercise protocol|Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
75558563|NCT00488163|Drug|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
75558564|NCT00459173|Drug|rimonabant (SR141716)|
75873045|NCT05702541|Device|Lehfilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses
75414096|NCT02588872|Biological|Platelet-rich Plasma (PRP)|
75558565|NCT00444249|Procedure|White Alcon IOL|Implantation of white Alcon IOL
75558566|NCT00444249|Procedure|Yellow Alcon IOL|Implantation of yellow Alcon IOL
75558567|NCT00444249|Procedure|White Hoya IOL|Implantation of white Hoya IOL
75558568|NCT00444249|Procedure|Yellow Hoya IOL|Implantation of yellow Hoya IOL
75873046|NCT05702541|Device|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses
75558569|NCT00459212|Drug|GTI-2040|Given IV
75873047|NCT05702541|Device|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
75414097|NCT02588872|Biological|Hyaluronic Acid|
75414098|NCT02525562|Device|Triathlon Total Knee System with X3 insert|Total knee replacement
75414099|NCT02525562|Device|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
75414100|NCT02525562|Device|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
75414101|NCT02525562|Procedure|Total Knee Replacement|Total Knee Replacement
75414102|NCT02525562|Procedure|Partial Knee Resurfacing|Partial Knee Resurfacing
75414103|NCT02456233|Procedure|Conventional AF Ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone
75414104|NCT02456233|Procedure|FIRM-guided ablation plus PVI|Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will also be performed.
75414105|NCT02448485|Procedure|Aortic Valve Intervention (surgical or transcatheter)|Surgical or interventional aortic valve implantation
75558570|NCT00459212|Procedure|pharmacological study|Correlative study
75558571|NCT00459212|Procedure|laboratory biomarker analysis|Correlative study
75558572|NCT00459329|Behavioral|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
75558573|NCT00459407|Dietary Supplement|defined green tea catechin extract|Given orally
75558574|NCT00459407|Drug|placebo|Given orally
75558575|NCT00459407|Other|immunohistochemistry staining method|Correlative studies
75558576|NCT00459407|Other|immunoenzyme technique|Correlative studies
75558577|NCT00459407|Other|laboratory biomarker analysis|Correlative studies
75558578|NCT00459407|Procedure|biopsy|Undergo biopsy
75558579|NCT00459407|Other|mass spectrometry|Correlative studies
75558580|NCT00459407|Other|high performance liquid chromatography|Correlative studies
75558581|NCT03278262|Drug|Aflibercept (Eylea, BAY86-5321)|Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
75558582|NCT03273803|Diagnostic Test|Heart sound recording using smartphone application|Heart sound recording and analysis using android smartphones (Samsung Galaxy S5, Galaxy S6, and LG G3)
75558583|NCT00488280|Behavioral|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
75558584|NCT00459446|Drug|MS-325 Injection (Gadofosveset Trisodium)|
75873048|NCT05198037|Device|Bihemispheric tDCS|The anode and cathode are placed over the ipsilesional and contralesional primary motor cortex (C3 or C4 based on 10-20 system), respectively. The size of the electrode is 5x5 cm.
75558585|NCT04698044|Diagnostic Test|Hospital Anxiety Depression Scale|HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).
75414106|NCT02387203|Drug|PrevPac (Prevacid, Amoxicillin, Clarithromycin)|30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
75558586|NCT00459485|Dietary Supplement|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
75414107|NCT02381353|Drug|Bupivacaine|Intraoperative orbital injection of local pain medication
76042071|NCT05134051|Device|Shockwave® Intravascular Lithotripsy System (Shockwave Medical Inc)|IVL is a novel balloon catheter-based device that utilises pulsatile mechanical energy to disrupt calcified lesions. IVL differs from other types of lithotripsy with respect to depth of penetration. It is a single-use, sterile, disposable balloon catheter. The emitters convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within plaque. The balloon catheter is connected to the generator, which is programmed to deliver the specified dosage of pulses. The IVL balloon, sized 1:1 to the reference artery ratio, is inflated low pressure (4 atm) with 10 pulses of ultrasound energy of 10s delivered per balloon. The procedure is repeated to provide a minimum of 20 pulses in the target lesion, with interval deflation to allow distal perfusion. Each catheter can emit a max of 80 pulses at a rate of one pulse per second. If the lesion exceeds the 12mm balloon length, the balloon can be repositioned and the IVL repeated.
75558587|NCT00459485|Dietary Supplement|Placebo|Daily placebo for 3 weeks
76042072|NCT02590003|Drug|Carboplatin|
76042073|NCT02590003|Drug|Nab-paclitaxel|
75558588|NCT00459524|Behavioral|Questionnaire|Questionnaires taking about 30 minutes to complete.
75558589|NCT00459524|Behavioral|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
76042074|NCT05474521|Device|CODTimer test|The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.
75414108|NCT02310061|Procedure|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
75715587|NCT04007458|Behavioral|Letter|MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.
75715588|NCT04007458|Behavioral|Community Health Worker Phone Call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
75715589|NCT00897351|Genetic|mutation analysis|
75715590|NCT00897351|Genetic|polymorphism analysis|
75715591|NCT00897351|Genetic|protein expression analysis|
75715592|NCT00897351|Other|immunohistochemistry staining method|
75715593|NCT00897351|Other|laboratory biomarker analysis|
76042075|NCT05614531|Genetic|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
76042076|NCT04134325|Biological|Nivolumab|Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
76042077|NCT04134325|Biological|Pembrolizumab|Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
75558590|NCT03278145|Genetic|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
75558591|NCT00459563|Drug|Vitamin D|200,000 IU once weekly for 3 weeks (600,000 IU total dose)
75414109|NCT02310061|Other|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
75414110|NCT02305537|Behavioral|McLean Anxiety Mastery Program|Cognitive-Behavioral Therapy with Exposure and Response Prevention
75558592|NCT00459563|Drug|calcitriol|calcitriol 0.5 mcg twice a day for 1 week
75558593|NCT00459563|Drug|Placebo|Placebo once a week for 3 weeks
75558594|NCT01242384|Device|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
75558595|NCT00488397|Other|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
75558596|NCT00459641|Drug|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
75558597|NCT00459641|Other|Standard of Care|Bone marrow aspirate or steroids
75558598|NCT00488436|Drug|Antithymocyte globulin|
75558599|NCT00488436|Drug|Cyclosporine|
75558600|NCT00459680|Device|Laser acupoint treatment|Laser
75873049|NCT05225025|Behavioral|ROSE|"The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based intervention that has been proven to reduce cases of post-partum depression among low-income and racially and ethnically diverse women.~ROSE is administered to pregnant women in small group settings, typically in the same location that prenatal care is being provided (in this study, a hospital setting). It is divided into four 90-minute group sessions and teaches interpersonal psychotherapy-based skills that mitigate identified risk factors for PPD such as social support, stress management skills and communication.~ROSE curriculum will be implemented using groups in a continuous cycle, with patients entering into the intervention curriculum at the time of their enrollment and continuing through until all 4 total sessions have been accomplished."
75873050|NCT05225025|Other|Standard of Care|Usual hospital care with no behavioral intervention
75414111|NCT02296307|Other|Blood test: CA-125 biomarker|"CA-125 biomarker blood test at visit 1, day 1.~CA-125 biomarker blood test at visit 2, week 6."
75414112|NCT02296307|Other|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 1, day 1.
75414113|NCT02296307|Other|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
75414114|NCT01992653|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
75558601|NCT00459680|Procedure|Acupuncture|Needle acupuncture on ST36 and LI11.
75558602|NCT03277950|Other|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
75558603|NCT03277950|Other|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
75558604|NCT03277950|Other|Healthy|Healthy do not play game
75558605|NCT00488553|Behavioral|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
75558606|NCT00459719|Drug|Tacrolimus modified-release|oral
75414115|NCT01992653|Drug|Doxorubicin|Doxorubicin will be administered at 50 mg/m^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
75414116|NCT01992653|Drug|Obinutuzumab|Obinutuzumab will be administered at 1000 milligrams (mg) IV on Cycle 1 Days 1, 8, and 15 and on Day 1 of Cycles 3-8.
75414117|NCT01992653|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at escalating doses (at a starting dose of 1 mg/kg) IV every 3 weeks, for 6 or 8 cycles.
75441396|NCT01634217|Biological|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
75558607|NCT00459719|Drug|Prograf|oral
75558608|NCT00495144|Drug|TH-302|
75558609|NCT00459758|Device|Hans unit|
75558610|NCT00495183|Drug|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
75558611|NCT00495183|Drug|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
75558612|NCT00495183|Drug|Placebo|Placebo
75558613|NCT00459797|Device|Conventional (reusable) Glidescope|
75558614|NCT00459797|Device|Single-use Glidescope videolaryngoscope|
75558615|NCT00488670|Drug|Escitalopram|See Detailed Description.
75558616|NCT00459836|Drug|PR-104|
75558617|NCT00459836|Drug|docetaxel|
75558618|NCT00459836|Drug|gemcitabine hydrochloride|
75558619|NCT00459836|Other|laboratory biomarker analysis|
75558620|NCT00459836|Other|pharmacological study|
75558621|NCT00495261|Behavioral|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
75558622|NCT00495261|Behavioral|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
75715594|NCT04008862|Behavioral|Partnership-based nursing practice|Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
75414118|NCT01992653|Drug|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
75414119|NCT01992653|Drug|Prednisone|Prednisone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
75414120|NCT01992653|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
75414121|NCT01924247|Behavioral|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
75414122|NCT01924247|Behavioral|Standard treatment by family physician|Standard treatment by family physician.
75715595|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
75715596|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|
75414123|NCT01881659|Other|HPV screening|Women who signed informed consent will be screened with HPV testing.
75414124|NCT01850303|Drug|Pemetrexed|
75414125|NCT01850303|Drug|Gemcitabine|
75414126|NCT01850303|Drug|Induction chemotherapy|4 cycles of carboplatin-paclitaxel
75558623|NCT00459914|Device|cpap treatment during sleep|CPAP
75558624|NCT00488709|Drug|Topotecan|
75558625|NCT00488709|Drug|Fludarabine|
75734909|NCT03583190|Other|Exercise|Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.
75734910|NCT03583190|Other|Patient Education|Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.
75414127|NCT01763671|Drug|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
75414128|NCT01763671|Drug|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
75414129|NCT01763671|Drug|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
75414130|NCT01696435|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
75441397|NCT01634230|Drug|OCR-002|daily dose: 10 g infused over 24 hours
75558626|NCT00488709|Drug|Cytarabine|
75558627|NCT00459992|Drug|Betahistine Hydrochloride|
75558628|NCT00495339|Drug|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
75414131|NCT01696435|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
75414132|NCT01696435|Dietary Supplement|Fish oil placebo|Fish oil placebo
75414133|NCT01696435|Dietary Supplement|Vitamin D placebo|Vitamin D placebo
75414134|NCT01681264|Drug|Morphine|
75414135|NCT01681264|Drug|Guanfacine 1mg|
75414136|NCT01681264|Drug|Guanfacine 2mg|
75414137|NCT01681264|Drug|Placebo|
75558629|NCT00460148|Drug|Ropinirole|
75558630|NCT01242423|Device|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
75558631|NCT00460187|Device|Percutaneous intervention of the carotid artery|
75558632|NCT00460226|Drug|lamotrigine|lamotrigine treatment for 12weeks
75558633|NCT00495378|Drug|epoetin alfa|
75558634|NCT00460304|Drug|pramlintide|
75558635|NCT00460304|Procedure|continuous glucose monitoring|
75558636|NCT01242462|Procedure|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 & Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
75558637|NCT01242462|Other|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is >/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH >/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
75558638|NCT00460343|Other|extensive implementation programme|experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
75558639|NCT00460343|Other|control|pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
75558640|NCT00495417|Biological|AFFITOPE AD01|s.c. injection
75558641|NCT00495417|Biological|AFFITOPE AD01 adjuvanted|s.c. injection
75715597|NCT00972868|Device|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
75715598|NCT00897429|Procedure|laboratory biomarker analysis|Correlative studies
75558642|NCT00460382|Drug|raltegravir potassium|400 mg twice a day
75414138|NCT01654276|Drug|Febuxostat|One 40 mg tablet once a day for 6 months
75414139|NCT01527591|Biological|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
75414140|NCT01399658|Procedure|Image-guided brachytherapy|MRI-guided application of brachytherapy
75414141|NCT01399658|Drug|3'-Deoxy-3'-18f-Fluorothymidine|Assessing tumor proliferation in Gynecologic cancer
75414142|NCT01296113|Drug|Chemotherapy|"Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total"
75441398|NCT01634282|Drug|OPC-262|Orally administered once daily
75441399|NCT01634295|Drug|CKD-828 2.5/40mg|"Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~With the others investigation product placebo 4 tabs QD 2 weeks."
75715599|NCT00982306|Behavioral|Brief intervention|20 minute one to one counseling session
75558643|NCT00460382|Drug|darunavir/ritonavir|2 pills of 300 mg twice a day
75558644|NCT00460382|Drug|etravirine|2 pills of 100 mg twice a day
75558645|NCT00460382|Drug|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
75558646|NCT01242501|Behavioral|60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling.|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
76042078|NCT04131439|Diagnostic Test|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
75414143|NCT00690196|Behavioral|Tai Chi Chih|"Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up."
76042079|NCT05474443|Other|Myofascial gun with conventional therapy|"MYofascial gun was applied for the duration of 5 minutes over upper trapezius muscle. every week, on first two sessions frequency was set to 1-2 then for next two 3-4 and so on conventional therapy Hot Pack applied at the beginning of session for 10 minutes Muscle stretching of Upper Trapezius, Levator Scapulae and Pectoralis Major applied with holding time 20 seconds and 4 repetitions.~Cold pack was applied at the end of the session for few minutes"
76042080|NCT05474443|Other|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool was applied over upper trapezius muscle from its origin to insertion kept at the angle of 45 Conventional Therapy Hot pack 10mins Upper Trapezius, Levator scapule and Pectoralis major muscle stretching(20s hold and 4 reps) Cold pack for few minutes
76042081|NCT04116697|Other|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
75558647|NCT01242501|Behavioral|20-Min education session|Patients receive a single 20 min education session for STI/HIV informationSingle brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
75558648|NCT00460460|Drug|AZD4877|
75558649|NCT01242579|Drug|Maraviroc/Dapivirine Gel|Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
75558650|NCT01242579|Drug|Dapivirine Vaginal Gel|Dapivirine vaginal gel containing 2.5g
75558651|NCT01242579|Drug|Maraviroc Vaginal Gel|Maraviroc vaginal gel containing 2.5g
75558652|NCT01242579|Drug|Matching Placebo Gel|Matching placebo gel containing 2.5g
75558653|NCT00460499|Drug|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
75558654|NCT00460499|Drug|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
75558655|NCT00460499|Drug|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
75558656|NCT00495573|Drug|acyclovir|400 mg acyclovir, orally three times a day for 5 days
75558657|NCT00460538|Dietary Supplement|Lectranal|"Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
75558658|NCT00460538|Dietary Supplement|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
75558659|NCT00488787|Drug|intranasal ketamine|low dose
76042082|NCT04116697|Other|Aromatherapy|Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
75558660|NCT00488787|Drug|intranasal ketamine|medium dose
75558661|NCT00488787|Drug|intranasal ketamine|high dose
75558662|NCT00488787|Drug|placebo|placebo
75558663|NCT00460616|Drug|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
75558664|NCT00495651|Drug|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
75558665|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
75558666|NCT00495651|Drug|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
75558667|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
75558668|NCT00460694|Biological|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
75558669|NCT01244841|Procedure|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
75558670|NCT00460733|Drug|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
75715600|NCT00985036|Procedure|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
75715601|NCT00972946|Biological|Administration of autologous Endorem-labelled mononuclear cells intravenously|single dose
75414144|NCT00690196|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
75414145|NCT00590122|Drug|Parcopa|at subjects current stable dose of comparator
75558671|NCT00460733|Drug|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
75558672|NCT00488904|Dietary Supplement|supportan|2 sip feed pr. day
75558673|NCT00488904|Dietary Supplement|supportan placebo|2 sip feed pr. day
75715602|NCT00972946|Drug|Administration of Endorem|single dose, intravenous
75414146|NCT00590122|Drug|carbidopa-levodopa (Sinemet)|at subjects current stable dose
75558674|NCT00460850|Drug|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
75715603|NCT00973180|Other|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
75715604|NCT00606177|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
75558675|NCT00495690|Drug|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
75558676|NCT00460889|Procedure|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
75558677|NCT00495729|Drug|SB-649868|Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
75558678|NCT00495729|Drug|Placebo|Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
75558679|NCT00495729|Drug|Simvastatin|Subjects will receive Simvastatin 10 mg tablets orally.
75558680|NCT00460928|Drug|intravenous immune globulin (IVIG)|
75715605|NCT00606177|Drug|placebo|oral, 0mg(4tablets)/day
75715606|NCT00985270|Drug|Rifampicin|
75715607|NCT00985270|Drug|Placebo|
75715608|NCT00359281|Drug|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
75715609|NCT00359281|Drug|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
75558681|NCT00495768|Behavioral|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
75414147|NCT00309192|Drug|Triamcinolone Acetonide|Intravitreal Injection 4mg single dose
75414148|NCT00309192|Procedure|Grid laser|Grid laser as specified in ETDRS
75414149|NCT00309192|Procedure|Sham Injection|Simulation procedure for triamcinolone injection
75414150|NCT00110591|Drug|PRO 140|Monoclonal antibody to CCR5
75558682|NCT00460967|Device|Rheopheresis|8 rheopheresis treatments over 10 wks.
75715610|NCT00359281|Drug|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
75715611|NCT00359281|Drug|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
75715612|NCT00359281|Drug|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
75715613|NCT00359281|Drug|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
75715614|NCT00982384|Other|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
75715615|NCT00982384|Other|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
75734911|NCT03582514|Radiation|Preoperative brain irradiation (single fraction)|Dose and volume escalation of preoperative single-fraction radiotherapy.
75414151|NCT01689246|Drug|TRx0237 150 mg/day|TRx0237 75 mg tablets will be administered twice daily.
75414152|NCT01689246|Drug|TRx0237 250 mg/day|TRx0237 125 mg tablets will be administered twice daily.
75414153|NCT01689246|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
75414154|NCT01685268|Drug|AT13387|Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
75414155|NCT01685268|Drug|abiraterone acetate|1000 mg PO daily.
75734912|NCT03581487|Biological|Durvalumab|Given IV
75734913|NCT03581487|Drug|Selumetinib|Given PO
75734914|NCT03581487|Biological|Tremelimumab|Given IV
75734915|NCT03576859|Other|blood sample|Peripheral venous blood is collected before liver transplantation and after restoration of liver function
75734916|NCT03557619|Drug|Venetoclax|tablet; oral
75734917|NCT03557619|Drug|ethinyl estradiol/levonorgestrel|tablet; oral
75734918|NCT03556007|Drug|LY3471851|LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
75558683|NCT00460967|Device|Rheopheresis|Sham treatment
75414156|NCT01685268|Drug|Prednisone|5 mg PO twice daily.
75734919|NCT03556007|Drug|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
75734920|NCT03550911|Other|Biological Collection From Samples From The Gut Microbiota|The aim of this study is just to constitute a biological collection from samples from the Gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
75734921|NCT03539705|Other|There is no intervention|There is no intervention
75734922|NCT03524573|Procedure|Appendectomy|Appendectomy is the surgical removal of the appendix.
75414157|NCT01683786|Drug|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day
75414158|NCT01684956|Procedure|Intradermal injection|
75414159|NCT01684956|Procedure|Subcutaneous injection|
75414160|NCT01683084|Drug|Telmisartan|
75414161|NCT01683084|Drug|Placebo|
75414162|NCT04823442|Drug|Mirabegron|Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
75414163|NCT04823442|Drug|Bisoprolol Fumarate|a single dose of 10 mg (2 tablets of 5 mg)
75414164|NCT04827108|Other|PeNAT validation|Children will be required to fill in a set of questionnaires including the Chinese version of the Pediatric Nausea Assessment Tool (PeNAT), the Chinese version of the Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0), and the Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC)
75414165|NCT04820244|Other|No intervention|No intervention
75414166|NCT04820634|Other|Virtual Reality Job Interview Training|The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills & concepts of job interviews. Sessions are approximately 90 minutes long.
75414167|NCT04820634|Other|Wonderworks|The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
75414168|NCT04825470|Procedure|Liver Transplantation|Liver Transplantation
75873051|NCT05054751|Drug|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side."
75414169|NCT04821648|Drug|RJV001|Subcutaneous injection in the abdomen
75414170|NCT04821648|Drug|Placebo|The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
75414171|NCT04829682|Behavioral|ACT for Life|ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.
75414172|NCT04829682|Behavioral|Present Centered Therapy|PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
75414173|NCT02270892|Device|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
75715616|NCT00982462|Dietary Supplement|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
75715617|NCT00982462|Dietary Supplement|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
76042083|NCT05474365|Other|Stepwise training|The protocol of stepwise training is mentioned in Detailed description in Study Description.
75715618|NCT03992287|Dietary Supplement|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
75715619|NCT03992287|Dietary Supplement|Placebo|Placebo for 12 weeks
75715620|NCT02540343|Other|questionnaires|fill out all questionnaires twice
75715621|NCT00973258|Dietary Supplement|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
75414174|NCT01384396|Drug|KW-3357|Intravenous infusion once a day
75414175|NCT01384409|Drug|KW-3357|Intravenous infusion once a day
75414176|NCT01384422|Drug|GLPG0634|
75414177|NCT01384435|Drug|KPS-0373|
75558684|NCT00461084|Drug|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
75558685|NCT00461084|Drug|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
75715622|NCT00973258|Other|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
75715623|NCT00973258|Other|Cognitive Training|"The proposed cognitive training intervention program comprises:~Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors."
75715624|NCT00973258|Other|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
75414178|NCT01384435|Drug|KPS-0373|
75414179|NCT01384435|Drug|KPS-0373|
75558686|NCT00495807|Behavioral|No Words|Without any words was given during pain management
75558687|NCT00495807|Behavioral|Positive words|Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
75558688|NCT00495807|Behavioral|Partially Negative Words|Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
75558689|NCT00495807|Behavioral|Totally Negative Words|Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
75558690|NCT00461162|Behavioral|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
75715625|NCT00973258|Other|Placebo|Participants will receive their usual diet and placeboes.
75715626|NCT00902031|Drug|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
75715627|NCT00902031|Drug|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
75715628|NCT03991039|Radiation|Gamma knife|Microvascular decompression
75715629|NCT00897663|Genetic|gene expression analysis|
76042084|NCT05474209|Other|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes"|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months"
75414180|NCT01384435|Drug|KPS-0373|
75414181|NCT01384435|Drug|Placebo|
75414182|NCT01384448|Procedure|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
75441400|NCT01634295|Drug|CKD-828 5/40mg|"Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~With the others investigation product placebo 4 tabs QD 2 weeks."
75414183|NCT01384448|Procedure|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
75715630|NCT00897663|Genetic|microarray analysis|
75873052|NCT05054751|Drug|Placebo+Fulvestrant|"Placebo: The dose of Placebo is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side."
75715631|NCT00897663|Genetic|protein expression analysis|
75414184|NCT01384474|Other|Diffusion of a surgical safety checklist|"Assistance by a local caregiver investigator (i.e., surgeon, anaesthetist, nurse,...) responsible for the implementation of surgical safety checklist within the operatory rooms of his department ;~A two-step CRM training of surgical teams (i.e., surgeons, anaesthetists, nurses,...) conducted by advisors from the world of air company using video support:~First month following randomization: a course about the implementation of surgical safety checklist (using online-available WHO short movies and other videos of surgical teams) and core concepts of CRM adapted to the operating room;~Sixth month following randomization: a feedback to surgical teams aiming at identifying and solving barriers related to the checklist implementation and interpersonal communication~Written reminders including the systematic presence of an unfilled surgical safety checklist in the patient's medical report, stickers and wall posters in operatory rooms"
75414185|NCT01384500|Other|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
75414186|NCT01384552|Other|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
75414187|NCT01384552|Other|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
75414188|NCT01384565|Drug|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
75414189|NCT01384565|Drug|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
75414190|NCT01384578|Drug|pentoxiphylline and Vitamin E|Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
75414191|NCT01384578|Drug|Vitamin E|Patients in control group will receive vitamin E 800 IU/day
75414192|NCT01384617|Procedure|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
75715632|NCT00897663|Other|diagnostic laboratory biomarker analysis|
75715633|NCT00897663|Other|immunohistochemistry staining method|
75715634|NCT00985348|Drug|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
76042085|NCT05474053|Drug|Ticagrelor 90mg (Brilique)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
75715635|NCT00973336|Drug|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
75715636|NCT00902109|Device|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
75715637|NCT00902109|Device|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
75715638|NCT00902109|Device|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
75414193|NCT01384617|Procedure|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
75414194|NCT01384643|Drug|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
75558691|NCT00461162|Behavioral|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
75558692|NCT00461162|Behavioral|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
75715639|NCT03991273|Other|Y-M2M©|The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
75558693|NCT00495846|Drug|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
75558694|NCT00495846|Other|Locoregional treatments|
75558695|NCT00461201|Procedure|Nurse practitioner care of patients|
75558696|NCT04697316|Device|Transcranial Direct Current Stimulation|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.
75558697|NCT04697316|Device|Sham|For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
75558698|NCT00495924|Procedure|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
75558699|NCT00461279|Behavioral|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
75558700|NCT00461279|Behavioral|Interpersonal Psychotherapy|Established psychotherapy for depression
75715640|NCT03991273|Other|B-M2M©|The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
75715641|NCT00973414|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
75715642|NCT00973414|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
75715643|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
75715644|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
75715645|NCT01052233|Procedure|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
75715646|NCT01052233|Procedure|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
75734923|NCT03518099|Biological|blood sampling|Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
75734924|NCT03505229|Radiation|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30-45 gray in 5 fractions over 2 weeks will be given to all eligible patients.
75734925|NCT03503110|Other|electrocorticography with electrostimulation|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
75734926|NCT03503110|Other|dRMI|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
75734927|NCT03498521|Drug|Alectinib|Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
75734928|NCT03498521|Drug|Vismodegib|Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
75414195|NCT01384656|Drug|GIK solution|Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
75414196|NCT01384682|Drug|Maraviroc|Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
75558701|NCT04697082|Procedure|Open surgery|Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
75558702|NCT04697082|Procedure|Minimal invasive surgery|In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured
75558703|NCT04697082|Other|Platelet rich plasma administration|Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
75558704|NCT00105482|Drug|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
75558705|NCT00105482|Drug|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
75558706|NCT00105482|Behavioral|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
75414197|NCT01384695|Drug|Fluorescein|fluorescent contrast agent, Fluorescein 5ml
76042086|NCT05474053|Drug|Ticagrelor 90mg (Ticaloguard)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
75414198|NCT01384695|Drug|Proflavine hemisulfate|3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
75414199|NCT01384708|Drug|proflavine|1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
75414200|NCT01384747|Drug|Fimasartan|60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
75414201|NCT01384747|Drug|Placebo|60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
75558707|NCT00495963|Procedure|bronchoaleolar lavage|
75558708|NCT00495963|Procedure|Bronchoscopy|
75558709|NCT00489021|Procedure|sub-acute hospitalization|
75558710|NCT00496002|Drug|Clevudine|
75558711|NCT00496002|Drug|Adefovir|
75558712|NCT03273725|Other|Dental examination including taking a saliva sample.|The main focus of the dental examination is enamel defects and caries. Saliva samples (stimulated) will also be taken.
75558713|NCT03273686|Procedure|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
75558714|NCT00489060|Procedure|Cryoablation and External Beam Radiation|
75558715|NCT03273647|Radiation|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
75558716|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot A|
75558717|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot B|
75558718|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot C|
75558719|NCT00489099|Biological|V232 Current Process Hepatitis B Vaccine|
75414202|NCT01384799|Drug|CUDC-101|CUDC-101 will be administered as a 1 hour intravenous infusion three times per week for a one week run-in (week -1) and then as part of the combination treatment on weeks 1-7. If the 225 mg/m2 dose is tolerated in the first cohort, the dose will be increased to 275 mg/m2. If the 225 mg/m2 dose is not tolerated, the dose will be decreased to 175 mg/m2. If 175 mg/m2 is not tolerated the dose will be further decreased to 150 mg/m2.
75414203|NCT01384799|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 100 mg/m2 on days 2, 23 and 44 of the seven week combination treatment course.
75558720|NCT03273569|Procedure|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
75558721|NCT00496158|Drug|Clevudine|
75558722|NCT00496158|Drug|Adefovir|
75715647|NCT00902343|Procedure|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
75414204|NCT01384799|Radiation|Radiation Therapy|The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions per week. The gross disease sites will receive 70 Gy in 35 fractions over seven weeks and the subclinical disease sites will receive 56 Gy in 35 fractions, again over seven weeks.
75715648|NCT00902343|Procedure|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
75715649|NCT01052311|Drug|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
75715650|NCT01052311|Drug|Placebo|Placebo tablets once daily
75414205|NCT01384812|Drug|dinoprostone|intravenous injection 0.4 μgr/kg/min for 25 min
75414206|NCT01384812|Drug|isoton sodium chloride|intravenous injection for 25 min
75414207|NCT01384838|Behavioral|Counseling|Nutritional, lifestyle and sports counseling
75414208|NCT01384838|Behavioral|physical activity|counseling and controlled physical activity
75414209|NCT01384851|Drug|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
75414210|NCT01384851|Drug|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
75414211|NCT01384851|Drug|Refresh Contacts|One drop both eyes four times daily for two weeks
75414212|NCT01384864|Drug|proflavine|2-6 ml of 0.01% proflavine
75414213|NCT01384890|Radiation|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
75414214|NCT01384890|Radiation|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
75414215|NCT01384903|Drug|KW-3357|Intravenous infusion once a day
75414216|NCT01384903|Drug|Plasma-derived antithrombin|Intravenous infusion once a day
75414217|NCT01384916|Behavioral|Yoga|2x weekly
75414218|NCT01384916|Behavioral|Healthy Living Workshop|2x weekly
75414219|NCT01384942|Behavioral|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
75558723|NCT03273530|Other|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
75558724|NCT00489138|Drug|Ertapenem|1g a day by drip of 30 min
75558725|NCT00461396|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
75558726|NCT00489177|Device|A|QuickOpt intra-cardiac electrogram optimization
75414220|NCT01384942|Behavioral|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
75414221|NCT01384968|Dietary Supplement|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
75414222|NCT01384981|Procedure|pulmonary rehabilitation|
75558727|NCT00489177|Device|B|Single optimization in initial month post-implant
75414223|NCT01384994|Drug|Folic Acid|400 mg/m2, 2h infusion, d1, q2w
75414224|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
75414225|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
75414226|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
75414227|NCT01384994|Drug|Panitumumab|6 mg/kg BW every 2 weeks
75414228|NCT01384994|Drug|Panitumumab|Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
75414229|NCT01384994|Drug|Folic Acid|400 mg/m2, 2-h infusion, d1, q2w
75414230|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
75414231|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
75414232|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
75414233|NCT01385007|Behavioral|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
75414234|NCT01385020|Drug|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
75414235|NCT01385046|Behavioral|Project Fit|physical activity and nutrition education
75558728|NCT00461435|Procedure|hyperbaric oxygen therapy|
75558729|NCT01327651|Drug|Daily dosing|A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
75558730|NCT01327651|Drug|Time-driven dosing|TDF/FTC twice weekly with a post-exposure dose
75414236|NCT01385072|Biological|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
75558731|NCT01327651|Drug|Event-driven dosing|TDF/FTC as needed with a post exposure dose
75558732|NCT00496236|Drug|TNFerade biologic|
75558733|NCT00461474|Behavioral|Shoulder strengthening exercises|
75558734|NCT00461474|Behavioral|Movement Optimization|
75558735|NCT00496275|Drug|Zactima (ZD6474)|
75558736|NCT00496275|Drug|Vinorelbine plus cisplatin|
75558737|NCT00496275|Drug|Gemcitabine plus cisplatin|
75558738|NCT03273491|Behavioral|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
75558739|NCT03273491|Behavioral|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
75414237|NCT01385111|Procedure|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
75558740|NCT04329169|Other|Virtual Implant Planning|According to the virtual implant plan, a CAD/CAM tooth supported surgical guide will be fabricated to place the dental implant with a fully guided surgical protocol.The surgical guide will be manufactured from a photopolymer resin using a 3D printing machine. A hex- shaped metal sleeve will be inserted in the surgical guide with the flat surface located buccally so that it will help in orientation of the implant hex during the implant placement.
75558741|NCT00461669|Procedure|ultrasound examination of the hip|
75715651|NCT01052311|Drug|Tredaptive|Tredaptive 1 g [Laropiprant 20 mg(LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
75715652|NCT00988078|Drug|Placebo|Capsule (without biologic action) administered three times a day for six months
75715653|NCT00988078|Drug|Metformin|Metformin 500mg three times a day for six months
75558742|NCT00489294|Drug|Syntropin|
75558743|NCT00591604|Drug|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
75558744|NCT00591643|Procedure|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
75715654|NCT00895089|Drug|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
75558745|NCT00591643|Radiation|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
75558746|NCT00461747|Drug|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
75558747|NCT00461747|Drug|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
75558748|NCT00461747|Drug|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
75715655|NCT00895089|Drug|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
75414238|NCT01385111|Procedure|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
75414239|NCT01385124|Drug|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
75558749|NCT00489333|Drug|ProAlgaZyme|
75715656|NCT00982540|Drug|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
75715657|NCT00897741|Genetic|microarray analysis|
75715658|NCT00897741|Other|laboratory biomarker analysis|
75715659|NCT04674358|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
75715660|NCT04674358|Drug|Vehicle Opthalmic Solution|Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
75715661|NCT00897819|Genetic|DNA methylation analysis|
75715662|NCT00897819|Genetic|loss of heterozygosity analysis|
75715663|NCT00897819|Genetic|microsatellite instability analysis|
75715664|NCT00897819|Other|laboratory biomarker analysis|
75414240|NCT01385150|Genetic|mutation analysis|
75414241|NCT01385150|Genetic|protein analysis|
75414242|NCT01385150|Other|laboratory biomarker analysis|
75414243|NCT01385150|Other|liquid chromatography|
75414244|NCT01385150|Other|mass spectrometry|
75414245|NCT01385215|Drug|Fluzone|0.5 ml/15 micrograms
75414246|NCT01385215|Drug|Fluzone|0.5 ml/60 micrograms
75414247|NCT01385228|Drug|Pazopanib|"Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg."
75414248|NCT01385228|Drug|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
75414249|NCT01385228|Drug|Pazopanib|"Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg."
75414250|NCT01385228|Drug|Prednisone|5mg Prednisone given twice daily days 1-21.
75558750|NCT04328935|Behavioral|WET|The manual is based on established CBT interventions in trauma such as exposure. In short, the treatment is that the participant should be able to approach their intrusive memories and by doing this repeatedly, the memory will give rise to less discomfort.
75558751|NCT00496314|Device|e2TM Cervical Cell Collector|
75558752|NCT00461825|Drug|Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups|
75558753|NCT00461825|Drug|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
75558754|NCT00461825|Drug|Group B: CsA + CellCept(500 mg x 2/day)|
75558755|NCT00461825|Drug|Group C: CsAm|
75558756|NCT04433026|Diagnostic Test|N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I|Biomarkers detected in the serum of patients
75558757|NCT00489372|Drug|Se-methyl-seleno-L-cysteine|Given orally
75558758|NCT00489372|Other|placebo|Given orally
75558759|NCT00489372|Other|pharmacological study|Correlative studies
75558760|NCT00489372|Other|laboratory biomarker analysis|Correlative studies
75558761|NCT04431739|Device|MRI including conventional MRI, DWI with multiple ADC values|The utility of apparent diffusion coefficient obtained in diffusion-weighted MR imaging for the differentiation between benign and malignant vertebral lesions
75414251|NCT01385228|Drug|Pegfilgrastim|
75414252|NCT01385241|Behavioral|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
75414253|NCT01385267|Procedure|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
75558762|NCT04430686|Other|Questionaires|Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (if available)
75558763|NCT00461864|Procedure|ultrasound examination of the hip|
75558764|NCT04430023|Other|epidemiological and demographic characteristics|Patients' age, gender, BMI, medical history, symptoms at admission (e.g., cough, fever, myalgia, gastrointestinal symptoms, headache), concomitant diseases (e.g., diabetes mellitus, hypertension, chronic lung disease, cerebrovascular disease, kidney disease, heart disease, cancer, smoking
75558765|NCT00496353|Drug|MK2461|MK2461 treatment, bid, 28-day
75558766|NCT04429477|Device|Cerebral compliance and hemodynamics monitoring|Noninvasive devices are been used to assess cerebral circulation and compliance.
75558767|NCT00461318|Procedure|Individual placement and support (vocational rehabilitation)|
75558768|NCT04428229|Other|Optic nerve sheath diameter|Pre and post-trendelenburg optic nerve sheath diameter will be measured
75558769|NCT00461903|Drug|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
75715665|NCT00366535|Drug|Placebo|4 tabs b.i.d.
75558770|NCT00591682|Drug|MSX-122|"Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort."
75558771|NCT00496392|Drug|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
75558772|NCT04329013|Other|Left lateral Position during intervention|Left lateral position during EGD
75558773|NCT04329013|Other|Prone Position during intervention|Prone position during EGD
75558774|NCT02893696|Other|Various sitting time|Various sitting time
75715666|NCT00366535|Drug|Neurotropin|4 tabs b.i.d.
75715667|NCT00982618|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
75558775|NCT00496509|Drug|ZD6474 (Zactima) 100mg|
75558776|NCT00496509|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
75558777|NCT00496509|Procedure|Biomarker Draws|
75558778|NCT00496509|Drug|ZD6474 (Zactima) 300mg|
75558779|NCT04136197|Diagnostic Test|Manual palpation for incidence determination|The patients are positioned in a sitting and prone lying posture. Trigger points are discrete, local, hypersensitive spots located in a taut band of muscles. Palpation of the trigger point will cause elicitation pain over the affected area and radiation of pain toward a zone of reference and a local twitch response.
75558780|NCT00496548|Procedure|Fecal calprotectin|Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.
75558781|NCT00496548|Procedure|Urinary PGE-M Level|Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
75715668|NCT00982618|Procedure|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
75715669|NCT00982618|Drug|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
75715670|NCT00895167|Dietary Supplement|curcumin|one oral dose of 12 caplets = 12 g curcumin
75715671|NCT00988234|Procedure|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
75715672|NCT00988234|Procedure|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
75715673|NCT00988234|Procedure|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
75715674|NCT00988234|Procedure|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
75715675|NCT00902421|Drug|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
75715676|NCT00902421|Drug|Antimuscarinics|Antimuscarinics for 3 months
75414254|NCT01385319|Device|Bare metal stent implantation|"After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
75414255|NCT01385319|Device|zotarolimus eluting stent|"After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
75414256|NCT01385332|Procedure|Early luteal phase|We will administer in the tenth day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
75558782|NCT04135222|Diagnostic Test|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
75873053|NCT04791735|Procedure|Laparoscopy|"Installations of the patient: the position of the patient will depend on both extent of resection and location of the lesion.~Absence of laparotomy with the exception of the extraction of the resected specimen and absence of costal retractors.~Use of laparoscopic specific devices:~Use of multiple (3-7) ports depending on the operator's preference and technical difficulty (mainly 5-6 ports for major liver resection).~Use of a laparoscopic camera system with 0° or 30°~Use of a dedicated laparoscopic ultrasound probe.~Use of specific laparoscopic devices for coagulation, parenchymal transection and sealing.~Placement of the resected specimen in a plastic bag and extraction without fragmentation, depending on the surgeon's preferenceand the diameter of the resected specimen"
75558783|NCT02893618|Drug|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
75558784|NCT03273452|Drug|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
75558785|NCT00496665|Drug|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
75558786|NCT00496665|Drug|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
75558787|NCT00496665|Drug|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
75558788|NCT04423003|Procedure|Endoscopic intervention|All endoscopic interventions in COVID-19 positive tested patients were included
75558789|NCT00496704|Drug|capecitabine|
75558790|NCT00496704|Drug|gemcitabine hydrochloride|
75558791|NCT00496704|Drug|oxaliplatin|
75715677|NCT00985660|Drug|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
75715678|NCT00985660|Drug|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
75715679|NCT00350545|Drug|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
75715680|NCT00350545|Drug|Prednisone|1 mg/kg; po per day with taper
75558792|NCT04420117|Other|Perioperative assessment of physical capacity|Evaluation of physical capacity with the Short Physical Performance Battery (SPPB) questionaire
75558793|NCT04698005|Dietary Supplement|25g Ketone monoester without added salts|oral supplementation of ketone monoester
75715681|NCT00350545|Drug|Cyclosporine A|trough 200-300 or lower; po
75715682|NCT00350545|Drug|tacrolimus|trough 5-10 or lower; po
75715683|NCT04006054|Drug|Dexmedetomidine|When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .
75715684|NCT04006054|Drug|Midazolam|When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .
75715685|NCT00897975|Dietary Supplement|red yeast rice|600 mg 3 capsules bid
75715686|NCT00897975|Drug|phytosterol|phytosterol 450 mg 2 tabs bid with food
75715687|NCT00897975|Behavioral|therapeutic lifestyle program|TLC - 12 weeks
75715688|NCT00897975|Drug|placebo|placebo
75715689|NCT00985816|Dietary Supplement|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
75715690|NCT00985816|Dietary Supplement|Placebo|Placebo
75558794|NCT04698005|Other|Placebo|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
75558795|NCT00496743|Device|Low-dose total skin electron beam therapy (4 Gy)|
75558796|NCT04419064|Diagnostic Test|Point of care ultrasound|Tracheal and lung ultrasonography
75558797|NCT04418050|Procedure|Shoulder arthroplasty|Surgery consisting in replacement of gleno-humeral joint by a shoulder prosthesis
75558798|NCT04417426|Other|Survey|A survey was conducted, which was filled voluntarily and completely anonymously; the demographic data asked were: sex, age, religion, and semester. We included questions about their sexual behavior: if they considered having enough knowledge about STDs, sexual intercourse onset, number of sexual partners in the last year, the total number of sexual partners, sexual orientation, the use of condoms and contraceptives, exclusive or non-exclusive sexual intercourses, frequency of STDs screening, and then if they know the location of STD testing centers.
75558799|NCT02893852|Behavioral|standard CO-OP Approach|The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems and to support generalization and transfer of skills.
75558800|NCT02893852|Behavioral|standard CO-OP Approach plus coaching parents|CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
75558801|NCT00496821|Drug|ALN-RSV01|
75414257|NCT01385332|Procedure|Late follicular phase -COH-|We will administer in the 20th day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
75414258|NCT01385345|Drug|Vitamin D3 cholecalciferol|High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
75558802|NCT00461942|Drug|Green Tea Polyphenols (EGCG/ECG)|
75558803|NCT04416022|Diagnostic Test|Ultrasound examination|Women that are planned for labour induction, will undergo a routine ultrasound examination prior to the initiation of the induction process.
75715691|NCT01052389|Drug|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
75715692|NCT01052389|Drug|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
75414259|NCT01385358|Procedure|Thoracoscopically Assisted Surgical Ablation|Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
75414260|NCT01385358|Procedure|Catheter Ablation|In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
75441401|NCT01634295|Drug|CKD-828 5/80mg|"Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~With the others investigation product placebo 4 tabs QD 6 weeks."
75441402|NCT01634295|Drug|S-amlodipine 2.5mg|"S-amlodipine 2.5mg QD 4 weeks~With the others investigation product placebo 4 tabs QD 4 weeks."
75441403|NCT01634295|Drug|S-amlodipine 5mg|"S-amlodipine 2.5mg QD 6weeks~With the others investigation product placebo 4 tabs QD 6 weeks."
75441404|NCT01634308|Drug|Novosis(bongros/BMP-2)|
75441405|NCT01634308|Drug|Bio-oss|
75441406|NCT01634321|Drug|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
75441407|NCT01634334|Behavioral|Real-Time Intervention|Lights and Sound Brief Coaching
75558804|NCT00462059|Behavioral|Treatment|
76042087|NCT04027465|Dietary Supplement|Egg allergy oral desensitization|Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
75558805|NCT00591877|Procedure|Acupuncture|"Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~CV-12: 4 finger breadths superior to the umbilicus."
75558806|NCT00591877|Procedure|Sham Acupuncture|"The acupoints for SAC are:~LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae."
75558807|NCT00591877|Other|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
75558808|NCT00591916|Drug|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
75558809|NCT00591916|Procedure|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
75558810|NCT00591916|Procedure|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
75558811|NCT00496938|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
75558812|NCT04413916|Diagnostic Test|miRNA expression|Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.
75414261|NCT01385384|Device|NeuRx RA/4 diaphragmatic pacemaker|"Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.~The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.~Sites that provide the optimal response (greater region and magnitude) are noted.~Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed."
75414262|NCT01385397|Other|Preceptorship and virtual community|
75558813|NCT00462098|Device|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
75558814|NCT00462098|Device|non-treated control group|no change from routine care, no HBO
75558815|NCT00462137|Procedure|Sleep Studies|
75558816|NCT04413487|Other|Extra echocardiogram|Subjects will receive an extra echocardiogram after 2 cycles of chemotherapy
75558817|NCT04412902|Drug|adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy
75558818|NCT00462176|Procedure|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
75558819|NCT00462176|Other|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
75558820|NCT02893969|Behavioral|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
75558821|NCT02893969|Behavioral|Rest|Complete physical rest until asymptomatic.
75715693|NCT01052389|Drug|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
75715694|NCT02539485|Other|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
75558822|NCT04328896|Other|CGM-Tele-monitoring|"Baseline Visit-Visit 0~Obtain informed consent~Administer questionnaires~Measure A1C~Start study Dexcom CGM device (those already on CGM will change to the study device).~The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~14 days worth of data will be downloaded from the patient's CGM device.~Systems will be checked to be sure they are functioning~Remote monitoring program will be activated.~Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~Administer questionnaires~Measure A1C.~Collect CGM data and compare to baseline~Testing and Assessments:~Continuous glucose monitoring~Tidepool cloud upload~HbA1c~T1D REDEEM diabetes distress questionnaire~Hypoglycemia Fear Survey~Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis"
75558823|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
75558824|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
75558825|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
75715695|NCT01052467|Drug|Xamiol® Gel|Once daily application for about 4 weeks
75715696|NCT05277987|Drug|HEC-016(0.5×10^6 CAR-T Cells)|The initial dose is set to 0.5 × 10^6 car-t cells / kg, and 3 ~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
75715697|NCT05277987|Drug|HEC-016(0.5×10^6.5 CAR-T Cells)|The Second dose is set 0.5 × 10^6.5 car-t cells / kg, and 3 ~ 6 subjects are expected to be included in the dose group.
75715698|NCT05277987|Drug|HEC-016(0.5×10^7 CAR-T Cells)|The Third dose is set 0.5 × 10^7 car-t cells / kg, and 3 ~ 6 subjects are expected to be included in the dose group.
75715699|NCT00895323|Other|enzyme-linked immunosorbent assay|
75414263|NCT01385410|Behavioral|Peer mother support for continued exclusive breastfeeding|Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
75414264|NCT01385423|Drug|Preparative Regimen|Fludarabine 25 mg/m^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (*if < 4 months from prior transplant, omit day -4 dose)
75414265|NCT01385423|Biological|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
75414266|NCT01385449|Procedure|interscalene catheter|interscalene catheter
75414267|NCT01385449|Procedure|interscalene block|interscalene block
75558826|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
75715700|NCT00895323|Other|pharmacological study|
75715701|NCT00895323|Procedure|whole-body scintigraphy|
75715702|NCT00895323|Radiation|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
75715703|NCT00898053|Other|laboratory biomarker analysis|Correlative studies
75715704|NCT00349921|Drug|clonidine|Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
75414268|NCT01385475|Behavioral|RT|8 week RT Intervention
75414269|NCT01385488|Behavioral|self-monitor arm volume|bioelectrical impedance
75441408|NCT01634334|Behavioral|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
75715705|NCT00349921|Drug|adenosine|Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
75414270|NCT01385501|Other|Video intervention along with educational hand out|The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
75715706|NCT00349921|Drug|placebo|inactive substance
75715707|NCT00349921|Drug|placebo|inactive substance
75715708|NCT00902655|Drug|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
75715709|NCT01052623|Drug|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
75715710|NCT00902733|Other|medical chart review|
75715711|NCT00902733|Other|questionnaire administration|
75715712|NCT00902733|Procedure|fatigue assessment and management|
75715713|NCT00902733|Procedure|psychosocial assessment and care|
75715714|NCT00902733|Procedure|quality-of-life assessment|
75715715|NCT01058785|Biological|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
75414271|NCT01385527|Behavioral|Weekly Internet survey|Parents will complete a weekly online survey about medication use.
75414272|NCT01385527|Drug|Topical Triamcinolone|Topical triamcinolone to all affected areas once daily
75715716|NCT00898209|Genetic|protein expression analysis|Blood and exhaled breath condensate will be collected.
75715717|NCT00898209|Genetic|proteomic profiling|Blood and exhaled breath condensate will be collected.
75715718|NCT00898209|Other|biologic sample preservation procedure|Blood and exhaled breath condensate will be collected.
75715719|NCT00898209|Other|laboratory biomarker analysis|Blood and exhaled breath condensate will be collected.
75873054|NCT04791735|Procedure|Laparotomy|"Installation of the patient: patients will be placed in supine position, the surgeon operating on the right side of the patient and the assistant standing on the left side.~Incision: the type of incision will depend on both the nature of the resection and the operator's preference. Various incisions such as bi subcostal incision, J-shaped incision, right subcostal incision and midline incision can be used.~Use of open surgical instruments and devices for coagulation and parenchymal transection. These may include the crush-clamp technique or ultrasonic dissection for parenchymal transection, bipolar coagulation, clips, sutures or open vascular stapler for hemostasis and biliostasis.~Methylene blue injection through the cystic drain to rule out biliary leakage will be performed depending on the surgeon's preference."
75873055|NCT00604617|Procedure|Interferon-Gamma Release Assay|IGRAs
75414273|NCT01385540|Behavioral|Task-Based Functional Magnetic Resonance Imaging (fMRI)|Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
75873056|NCT00604617|Drug|RT-23|TST - tuberculin skin test
75873057|NCT05573295|Other|Diagnostic Test: Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
75873058|NCT05573295|Other|Diagnostic Test: Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
75414274|NCT01385553|Behavioral|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
75414275|NCT01385553|Behavioral|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
75873059|NCT05573295|Other|Diagnostic Test: London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
75414276|NCT01385631|Drug|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
75414277|NCT01385631|Drug|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
75873060|NCT05007249|Procedure|Use of the Chalaxie pedagogical evaluation tool|Use of the Chalaxie pedagogical evaluation tool during two visits
75873061|NCT03426995|Drug|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
75414278|NCT01385657|Drug|Placebo|A total of 4 doses were administered.
75414279|NCT01385657|Drug|Dupilumab|A total of 4 doses were administered.
75414280|NCT01385657|Other|Background treatment|Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.
75873062|NCT03426995|Drug|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
75558827|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
75414281|NCT01385670|Device|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
75414282|NCT01385683|Drug|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
75558828|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
75558829|NCT04410640|Other|survey|Members chosen for this study group are general surgery residents. A quintet with stations composed of normal pancreaticobiliary anatomy, common bile duct tumor, stony cholecystitis, pancreatic head cancer and cholelithiasis was assembled for the study. Each station contained CT, 3D-STL images and 1:1 solid models of cases. Each imaging method associated with the scenarios of the quintet is observed by the residents of the study. An explanatory assessment measure is being used as data collection method where the perception of each imaging method is being evaluated based on their effectiveness in problem identification as well as their efficiency in diverse diagnosis and pre-surgery organization. Participants' perception of residency training was evaluated with a multi-entry survey. The focus of the survey, which was applied by our team was by domains, self determined decision-making, diverse diagnosis, academic scholarship, and scientific appraisal.
75558830|NCT00462254|Drug|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
75558831|NCT00462254|Drug|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
75558832|NCT00496977|Procedure|annual CT screening|
75558833|NCT04410172|Diagnostic Test|Mirror and prope|Mirror and probe will be used for each patient. Mirrors for proper visualization especially for maxillary teeth, explorers will be used to aid in tactile sensation.
75715720|NCT00898209|Other|matrix-asst laser desorption/ionization time flight mass spectrometry|Blood and exhaled breath condensate will be collected.
75715721|NCT00898209|Other|questionnaire administration|Questionnaire will be completed.
75715722|NCT01325077|Other|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
75715723|NCT00902811|Drug|AM(FDC)|Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
75715724|NCT00902811|Drug|AM(LT)|Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
75414283|NCT01385683|Drug|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
75414284|NCT01385735|Drug|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
75414285|NCT01385735|Drug|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
75558834|NCT04328545|Device|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
75558835|NCT04328545|Device|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
75558836|NCT04328545|Device|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
75414286|NCT01385761|Device|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
75715725|NCT00902811|Drug|AL|Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
75715726|NCT00902811|Drug|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group <6yrs of age, a subdivision according to weight is made
75873063|NCT03426995|Biological|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
75414287|NCT01385761|Device|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
75414288|NCT01385774|Procedure|Percutaneous Transluminal Angioplasty|The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
75414289|NCT01385774|Other|Supervised Exercise Therapy|Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
75414290|NCT01385800|Biological|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
75715727|NCT00902811|Drug|AA(FDC)|Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
75715728|NCT04035681|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
75414291|NCT01385800|Biological|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
75558837|NCT00462371|Device|Insulin pump (CSII)|
75715729|NCT04035681|Other|Stroke-Related Health Education|The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
75558838|NCT00497016|Drug|atorvastatin 80 mg|
75715730|NCT02539173|Other|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
75873064|NCT03426995|Biological|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
75873065|NCT03426995|Other|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
75873066|NCT05200533|Other|Task-sharing and shifting model between family physicians and physiotherapists|Medical consultations for acute low back pain patients are shifted from family physicians to physiotherapists.
75873067|NCT05200533|Other|Usual care|Medical consultations for acute low back pain patients are performed by family physicians
75558839|NCT04406701|Other|Ceres|This will be a self-administered survey on eating habits and their relationship to coping strategies and economic level among nurses.
75873068|NCT05560815|Procedure|Any surgical procedure|Might differ for substudies.
75558840|NCT00462410|Other|counseling intervention|
75558841|NCT00462410|Procedure|psychosocial assessment and care|
75558842|NCT02893891|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
75558843|NCT02893891|Procedure|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
75558844|NCT02893891|Procedure|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
75558845|NCT02893891|Device|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
75873069|NCT05200299|Drug|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)
75873070|NCT05200299|Drug|mFOLFOX6 OR CapeOx|"mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)"
75873071|NCT03940989|Other|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
75414292|NCT01385826|Drug|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
75414293|NCT01385826|Drug|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
75414294|NCT01385839|Procedure|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
75414295|NCT01385839|Procedure|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
75414296|NCT01385852|Procedure|microcoaxial phacoemulsification|conventional longitudinal ultrasound
75558846|NCT04405414|Other|Form|Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD
75558847|NCT00462566|Device|motor cortex stimulation|
75558848|NCT00497094|Device|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
75558849|NCT00222872|Drug|Parathyroid Hormone-related Protein|PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
75558850|NCT00222872|Drug|Placebo|Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
75558851|NCT00497172|Device|CYPHER Sirolimus-eluting stent|drug-eluting stent
75558852|NCT00497172|Device|Bx SONIC bare metal stent|bare-metal stent
75558853|NCT03273296|Drug|Amoxicillin|Amoxicillin (po) 500 mg x 3 per day for 3 days.
75558854|NCT03273296|Drug|Azithromycin|Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
75558855|NCT03273296|Drug|Vancomycin|Vancomycin (po) 125 mg x 4 per day for 3 days.
75558856|NCT00497211|Procedure|Intracoronary mononuclear cell infusion|
75873072|NCT04867499|Other|No intervention|Descriptive study. No intervention.
75873073|NCT03424265|Dietary Supplement|EAA mixture|Dietary supplement intervention for 12-weeks
75873074|NCT03424265|Dietary Supplement|Placebo (whey protein)|Dietary supplement intervention for 12-weeks
75558857|NCT00497250|Drug|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
75558858|NCT00497250|Device|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
75414297|NCT01385865|Dietary Supplement|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
75414298|NCT01385865|Dietary Supplement|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
75414299|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through small clear corneal incision
75414300|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through clear corneal incision
75414301|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial Phacoemulsification through 1.8mm incision
75414302|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial phacoemulsification through 2.2mm incision
75414303|NCT01385891|Drug|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
75873075|NCT05181423|Other|Biomarkers|Different serum and radiological biomarkers neonates undergoing abdominal surgery.
75414304|NCT01385930|Behavioral|Lifestyle counseling|Lifestyle counseling
75414305|NCT01385956|Drug|SOM 230 LAR|We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
75414306|NCT01385956|Drug|Gemcitabine|Fixed dose: 1000mg/m^2 weekly x3 then 1 week off
75414307|NCT01385969|Device|Standard inflation of LMA cuff|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.
75414308|NCT01385969|Device|Pressure check with syringe recoil|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil
75414309|NCT01385969|Device|Pressure check by pressure transducer|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
75414310|NCT01385982|Other|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
75558859|NCT00462878|Drug|Meropenem|antibiotic
75558860|NCT00462878|Drug|Vancomycin|Antibiotic
75558861|NCT00462878|Drug|Teicoplanin|Antibiotic
75558862|NCT01242618|Biological|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
75558863|NCT00222911|Device|dorsiflexion night splint|
75441409|NCT01634347|Drug|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
75441410|NCT01634347|Drug|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
75558864|NCT00222911|Device|medial arch support|
75558865|NCT01242696|Procedure|Coronary artery stenting|Coronary artery stenting with drug eluting stents
75558866|NCT00462956|Drug|Tykerb|lapatinib 1500mg daily
75558867|NCT01242735|Behavioral|Aerobic exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.
75558868|NCT01242735|Behavioral|Health and Wellness|12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
75558869|NCT00462995|Drug|Erlotinib|150mg once a day for 28 days
75558870|NCT00462995|Drug|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
75558871|NCT00489450|Drug|SK3530|
75873076|NCT04934319|Behavioral|Balance and Proprioceptive Training|"Step-by-step training (5 levels)~30 minute per training~3 times per week~Four weeks"
75873077|NCT03322566|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
75873078|NCT03322566|Drug|Epacadostat|Epacadostat administered orally twice daily.
75414311|NCT01386034|Drug|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-[1-13C]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
75558872|NCT00489528|Drug|Somatropin; Recombinant human growth hormone (r hGH)|
75558873|NCT00463034|Genetic|microarray analysis|
75558874|NCT00463034|Genetic|polymerase chain reaction|
75558875|NCT00463034|Genetic|polymorphism analysis|
75558876|NCT00463034|Other|high performance liquid chromatography|
75558877|NCT00463034|Other|immunohistochemistry staining method|
75558878|NCT00463034|Other|laboratory biomarker analysis|
75558879|NCT00463034|Other|questionnaire administration|
75734929|NCT03498521|Drug|Ipatasertib|Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
75414312|NCT01386047|Other|Integrated Clinical Prediction Rule (iCPR)|Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
75414313|NCT01386060|Other|Mindfulness Meditation Training|One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
75414314|NCT01386073|Drug|FreshKote|Three times a day for three months
75414315|NCT01386073|Drug|Systane|three times a day for three months
75414316|NCT01386086|Drug|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
75558880|NCT01242852|Procedure|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS & hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions & endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
75414317|NCT01386099|Drug|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
75558881|NCT03273140|Device|Gamification Diabetes Education Program (GDEP)|"Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform."
75558882|NCT01242891|Device|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
75558883|NCT00463073|Drug|Cetuximab|
75558884|NCT00463073|Drug|Bevacizumab|
75558885|NCT00463073|Drug|Irinotecan|
75558886|NCT00222989|Drug|PPI|
75558887|NCT00489567|Procedure|Blood sample collection|
75558888|NCT00463112|Drug|Sibutramine|
75558889|NCT00489606|Drug|SK3530|
75558890|NCT00223028|Drug|sirolimus, mycophenolat mofetil, fluvastatin|
75558891|NCT00489645|Drug|placebo|placebo SC during euglycemia
75558892|NCT00489645|Drug|pramlintide|pramlintide SC during eglycemia
75558893|NCT00489645|Drug|placebo|placebo during hyperglycemia
75414318|NCT01386099|Drug|Placebo|Placebo twice a day for 12 weeks.
75558894|NCT00489645|Drug|pramlintide|pramlintide SC during hyperglycemia
75558895|NCT00465686|Device|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
75558896|NCT00465686|Device|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
75558897|NCT01243008|Drug|Application of SHB001|"Cohort 1: Application of SHB001 on the skin of right thigh~Cohort 2:~Application of SHB001 on the skin of right thigh~punch biopsies of treated skin areas"
75558898|NCT04697199|Drug|Lactobacillus Reuteri Oral Drops|Subgingival delivery of probiotic suspension
75558899|NCT04697199|Procedure|Scaling and root planing|Scaling and root planing using hand and ultrasonic instruments
75558900|NCT00463190|Drug|Biothree|
75558901|NCT00463268|Drug|alendronate|alendronate 70 mg every 2 weeks
75558902|NCT00463268|Dietary Supplement|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
75558903|NCT00463268|Drug|placebo|identical placebo every 2 weeks
75558904|NCT00489723|Drug|tamsulosin 0.4mg|
75558905|NCT00463424|Device|NeuFlex metacarpophalangeal implant|
75558906|NCT00463424|Device|Swanson metacarpophalangeal implant|
75558907|NCT04697433|Device|Myotonometry|The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
75414319|NCT01386112|Drug|EUR-1100|Active oral medication
75414320|NCT01386112|Drug|placebo|matching placebo
75414321|NCT01386138|Behavioral|Psycho-education|Receive RBT education and peer-support in a group format.
75414322|NCT01386138|Behavioral|Experimental|Receive RBT education and a pro-active counseling method
75558908|NCT00489762|Procedure|Installation of an energy efficient heater|
75558909|NCT00105443|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.
75558910|NCT00105443|Drug|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid).
75558911|NCT00489801|Other|Exercise|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
75558912|NCT01243047|Drug|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
75558913|NCT00489840|Drug|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
75414323|NCT01386151|Drug|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
75414324|NCT01386151|Drug|Saline placebo|Normal (0.9%) saline will be used as a placebo.
75414325|NCT01386164|Biological|Gardasil|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
75414326|NCT01386164|Biological|Cervarix|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
75558914|NCT00489840|Drug|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
75414327|NCT01386177|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
75734930|NCT03498521|Drug|Olaparib|Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
75414328|NCT01386177|Drug|Doxazosin|"3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os."
75414329|NCT01386177|Drug|placebo|capsules identical to MDMA or doxazosin
75414330|NCT01386190|Other|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
75441411|NCT01634373|Drug|Torrent's Quetiapine Fumarate Tablets|
75441412|NCT01634386|Drug|Torrent's Quetiapine Fumarate Tablets|
75558915|NCT00463463|Drug|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
75558916|NCT00489879|Device|Mobile Health Care System (DrUB)|
75873079|NCT03322566|Drug|Platinum-based chemotherapy|Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
75873080|NCT03322566|Drug|Placebo|Matching placebo administered orally twice daily.
75715731|NCT00898287|Drug|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
75414331|NCT01386216|Device|Magellan®|Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
75414332|NCT01386229|Drug|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
75414333|NCT01386229|Drug|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
75414334|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
75414335|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
75414336|NCT01386242|Other|Saline Injection|Saline Injection, 1mL, im,three times per week
75414337|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
75873081|NCT03822975|Drug|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is <225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is >225 seconds.
75558917|NCT00465725|Drug|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
75558918|NCT00463502|Drug|Metformin|
75558919|NCT00489996|Drug|gemcitabine|
75558920|NCT00489996|Drug|cisplatin|
75715732|NCT00898287|Drug|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
75873082|NCT03822975|Drug|unfractionated Heparin|Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT <225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is >225 seconds.
75558921|NCT00465764|Other|Alternate protein infant formula|Feed as per HCP directions
75558922|NCT00465764|Other|Standard infant formula|Feed as per HCP directions
75558923|NCT00490074|Biological|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
75558924|NCT00490074|Biological|NYVAC-C|NYVAC-C 1 ml IM
75414338|NCT01386255|Drug|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
75414339|NCT01386255|Drug|placebo|placebo. No other names
75414340|NCT01386268|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
75414341|NCT01386281|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
75414342|NCT01386294|Drug|Tenofovir gel|Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
75414343|NCT01386294|Drug|Universal placebo gel|The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
75558925|NCT04696926|Other|Edwards Intuity TM Valve implantation|aortic valve replacement with an Edwards Intuity TM bioprosthesis
75414344|NCT01386320|Procedure|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
75414345|NCT01386320|Procedure|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
75414346|NCT01386333|Drug|oxytocin|Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
75414347|NCT01386333|Drug|Saline Nasal Mist|Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
75414348|NCT01386346|Drug|Azacitidine|Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
75558926|NCT00463541|Drug|solifenacin succinate|oral
75558927|NCT00490113|Drug|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
75558928|NCT00463619|Drug|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
75558929|NCT01243164|Other|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
75558930|NCT00465881|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
75558931|NCT01243203|Drug|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
75558932|NCT03273101|Device|Mechanical assisted sit-to-stand training group|Mechanical assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
75715733|NCT02539251|Behavioral|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
75873083|NCT05543733|Behavioral|Home exercise program|Participants will complete a 6-month prescription telemedicine-based structured home exercise program. Baseline information will be used to develop a personalized home exercise program. This program will involve downloading the MyDataHelps application on a mobile device to securely collect wearable device information like step counts, activity minutes, and heart rate. Additionally, participants will have multiple virtual visits as well as the 2 in-person visits.
75873084|NCT05732532|Drug|Bupivacaine|2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
75873085|NCT05732532|Drug|Lidocaine|0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
75414349|NCT01386346|Drug|Oxaliplatin|130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
75414350|NCT01386346|Drug|Epirubicin|50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
75558933|NCT03273101|Other|Manual assisted sit-to-stand training group|Manual assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
75715734|NCT04034823|Biological|KN035|KN035 5 mg/kg s.c. Q3W
75715735|NCT04034823|Biological|Trastuzumab|8 mg/kg IV loading followed by 6 mg/kg Q3W IV
75715736|NCT04034823|Drug|Docetaxel|100 mg/m2 Q3W IV
75715737|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
75715738|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
75414351|NCT01386346|Drug|Capecitabine|625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
75414352|NCT01386372|Drug|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
75441413|NCT01634399|Drug|Torrent's Quetiapine Fumarate Tablets|
76042088|NCT05473819|Drug|Buffered Local Anesthesia|"Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe [Tyco Healthcare, tyco.com] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present."
76042089|NCT05473819|Drug|Conventional Unbuffered Local Anesthesia|The control group will receive the unbuffered conventional anaesthetic solution
75414353|NCT01386372|Other|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
75414354|NCT01386398|Drug|bortezomib|
75414355|NCT01386398|Drug|vorinostat|
75414356|NCT01386398|Other|laboratory biomarker analysis|
75558934|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
75558935|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
75558936|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
75558937|NCT00465920|Behavioral|modified cognitive behavioural therapy (mCBT)|
75558938|NCT01245036|Drug|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.<50 kg and 600 mg/day if wt. >50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
75558939|NCT00466037|Biological|Influenza vaccine|
75558940|NCT00490191|Drug|Somatropin|
75558941|NCT00463658|Other|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
75558942|NCT00497328|Drug|N-acetylcysteine|
75558943|NCT00497328|Drug|Sodium Bicarbonate|
75558944|NCT00466076|Drug|Copaxone (Glatiramer acetate)|
75558945|NCT01245075|Other|Deep brain stimulation|Deep brain stimulation on
75558946|NCT01245075|Other|Placebo|deep brain stimulation off
75558947|NCT00463697|Drug|GW642444H (100mcg)|H salt
75558948|NCT00463697|Drug|placebo|placebo
75558949|NCT00463697|Drug|GW642444M (25, 100 & 400 mcg)|M salt
75558950|NCT00490230|Drug|WR 279396|
75558951|NCT00466154|Drug|Aspirin|
75873086|NCT05732532|Drug|Dexamethasone|0.5 mL of dexamethasone (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
76042090|NCT04842721|Drug|Hypertonic Saturated Saline Mouth Rinse Active Arm|Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
75414357|NCT01386411|Genetic|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
75558952|NCT00490308|Drug|Treatment with estradiol valerate|
75558953|NCT00463736|Drug|Magnesium sulfate|
75558954|NCT00490347|Device|VentrAssist Left Ventricular Assist Device|
75558955|NCT00490425|Drug|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
75558956|NCT00497367|Device|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
75414358|NCT01386489|Biological|VRC-HIVDNA016-00-VP|
75414359|NCT01386489|Biological|VRC-HIVADV014-00-VP|
75414360|NCT01386502|Biological|p53: 264-272 peptide|
75414361|NCT01386502|Drug|CT-011|
75414362|NCT01386541|Drug|BYK324677|capsules, administered orally
75414363|NCT01386567|Drug|Androxal (enclomiphene citrate)|"capsules oral 1x a day~1 year"
75414364|NCT01386567|Drug|Testim (topical testosterone)|"topical~1 tube~1x a day~1 year"
75414365|NCT01386580|Drug|2B3-101|IV every 21 days
75414366|NCT01386580|Drug|Trastuzumab|IV every 21 days
75414367|NCT01386580|Drug|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
75558957|NCT00497406|Procedure|Salivary gland transfer|Retrograde flow method
75558958|NCT00497406|Procedure|Helical Tomotherapy treatment|total of 30 fractions
75715739|NCT00895401|Dietary Supplement|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
75414368|NCT01386580|Drug|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
75414369|NCT01386593|Drug|Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)|
75558959|NCT00497445|Procedure|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
75558960|NCT00497445|Procedure|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
75558961|NCT00497484|Drug|recombinant human somatotropin|
75558962|NCT00490464|Drug|Nicardipine and Nipride|
75558963|NCT00497523|Drug|Beclomethasone dipropionate|
75558964|NCT00497523|Drug|Beclomethasone dipropionate/Salbutamol combination|
75558965|NCT00497523|Drug|Salbutamol|
75558966|NCT00463775|Drug|Topiramate|SSRI plus topiramate SSRI plus placebo
75558967|NCT00463853|Procedure|Autologous stem cell therapy|
75558968|NCT00463853|Procedure|CABG|
75558969|NCT00463853|Radiation|CMRI|
75558970|NCT00490620|Drug|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
75558971|NCT00490620|Drug|Placebo|placebo BID for 6 months
75558972|NCT00466232|Drug|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
75558973|NCT00466232|Drug|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
75558974|NCT00490659|Drug|gemcitabine|
75414370|NCT01386593|Drug|"Basel Cocktail"|
75414371|NCT01386593|Drug|Basel cocktail + Rifampicin|
75414372|NCT01386619|Biological|CD3-depleted/CD56+ selected natural killer cells collected from apheresis products|NK DLI products containing >1 10e7 NK cells/kg bodyweight (BW) and < 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
75414373|NCT01386658|Drug|icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
75414374|NCT01386671|Drug|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
75558975|NCT00490659|Drug|cisplatin|
75558976|NCT00490659|Procedure|radical surgery|
75558977|NCT00490659|Procedure|chemoradiotherapy|
75558978|NCT00463892|Procedure|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
75558979|NCT00490737|Drug|daptomycin|6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
75558980|NCT00497562|Drug|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
75558981|NCT00497562|Drug|amitriptyline, fluoxetine and tramadol alone (control group)|
75558982|NCT00497601|Drug|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 & 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 & 5 mg/kg on day 1 & 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 & 2.5 mg/kg on day 1 & 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
75558983|NCT00497601|Drug|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
75558984|NCT00497601|Drug|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
75558985|NCT00466388|Drug|Cevimeline|
75558986|NCT00497640|Procedure|Artificial Neural Network|Use of a predicted optimal CPAP
75558987|NCT00497679|Drug|AZD1152|7-day continuous intravenous infusion
75558988|NCT00466466|Drug|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
75558989|NCT00490854|Drug|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
75715740|NCT00895401|Other|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
75715741|NCT00606021|Drug|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
75715742|NCT00606021|Drug|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
75414375|NCT01386671|Drug|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
75414376|NCT01386723|Drug|Discontinuation of eltrombopag|Observation of subjects as they discontinue the use of eltrombopag
75414377|NCT01386736|Drug|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
75414378|NCT01386736|Drug|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
75558990|NCT00490854|Drug|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
75558991|NCT00463970|Behavioral|Brief Intervention|Physical examination, education and follow up by a physiotherapist
75558992|NCT00463970|Behavioral|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
75558993|NCT00463970|Dietary Supplement|Seal oil|20 capsules per day for 3 months
75558994|NCT00463970|Dietary Supplement|Soy oil|20 capsules per day for 3 months
75558995|NCT00497718|Procedure|Chiropractic Manipulation|
75715743|NCT00337675|Drug|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
75715744|NCT00337675|Drug|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
75715745|NCT00337675|Drug|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
75734931|NCT03498521|Drug|Erlotinib|Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
75414379|NCT01386749|Procedure|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
75414380|NCT01386762|Other|Exercise training|6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
75414381|NCT01386827|Biological|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml > 2 years later
75414382|NCT01386827|Biological|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml > 2 years later
75414383|NCT01386827|Biological|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
75414384|NCT01386827|Biological|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
75414385|NCT01386840|Other|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
75558996|NCT00464009|Behavioral|Continuing medical education|"Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist."
75558997|NCT00464048|Procedure|controlled physical exercise|
75558998|NCT00490893|Drug|Detemir|
75558999|NCT00464126|Other|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
75559000|NCT00464126|Other|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
75559001|NCT00490932|Drug|Hypo-osmolar ORS|
75559002|NCT03272399|Other|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
75559003|NCT00491010|Procedure|radiofrequency catheter ablation|
75559004|NCT03272126|Drug|Vitamin D|vitamin D given as bolus versus daily dosing
75734932|NCT03498521|Drug|Bevacizumab|Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
75414386|NCT01386853|Drug|Pitavastatin|2 mg QD
75559005|NCT03272126|Drug|Placebo|identical looking as vitamin D
75559006|NCT00491049|Drug|0.5% levofloxacin eye drops|
75559007|NCT00464165|Drug|rimonabant|
75559008|NCT00497913|Drug|NaCl 0.9%|
75559009|NCT00497913|Drug|Botulinum Toxin A|
75559010|NCT00497991|Drug|AZD1152|
75559011|NCT03272321|Drug|Oxytocin|Syntocinon nasal spray
75559012|NCT03272321|Drug|Placebo|Placebo nasal spray
75559013|NCT00491088|Device|CPAP|CPAP for 12 weeks
75559014|NCT00466544|Device|Plasmaknife|
76042091|NCT04842721|Other|Placebo Plain Water Mouth Rinse Arm|Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
75414387|NCT01386853|Drug|Atorvastatin|10 mg QD
75559015|NCT00466544|Device|Monopolar|
75559016|NCT00491127|Drug|gemcitabine|
75559017|NCT00491127|Drug|cisplatin|
75559018|NCT00491127|Drug|dexamethasone|
75559019|NCT00491166|Drug|Bromfenac ophthalmic solution|
75559020|NCT00491283|Device|Swab Specimen Collection (QuickVue)|
75873087|NCT05732532|Drug|Normal saline|0.5 mL of normal saline 0.9% injected at the origin of each bilateral greater and lesser occipital nerves
75873088|NCT05732532|Procedure|Greater/lesser occipital nerve blocks|Subjects will receive a total of 12 mL injectate divided equally between the 4 injection sites of the bilateral greater and lesser occipital nerves using the landmark-based technique.
75559021|NCT00498069|Device|Harvest Smartprep2 BMAC System|injection of 40cc bmac
75559022|NCT00498069|Device|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
75441414|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
75414388|NCT01386866|Drug|AMG 706|Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of [14C]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
75414389|NCT01386879|Drug|methylene blue|A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
75559023|NCT00498069|Biological|placebo|injection of placebo into ischemic tissue of the lower extremity
75414390|NCT01386892|Other|No intervention|There is no intervention for this study
75414391|NCT01386905|Device|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
75734933|NCT03498521|Drug|Vemurafenib|Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
75734934|NCT03498521|Drug|Cobimetinib|Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
75873089|NCT05178225|Dietary Supplement|ubiquinol (reduced coenzyme Q10)|supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg. one morning after breakfast, and second dose after dinner.
75873090|NCT05178225|Other|mountain spa rehabilitation|special spa rehabilitation in the mountain High Tatras; Functional capacity of the lungs (6MWT) at before and after 16-18 days of rehabilitation, Borg scale for dyspnea and oxygen saturation SpO2 (%) were monitored.
75873091|NCT05178225|Diagnostic Test|2x14 ml of peripheral blood collected in a tube with anticoagulant|2x14 ml of peripheral blood collected in a tube with anticoagulant
75414392|NCT01386918|Device|repetitive Transcranial Magnetic Stimulation|The treatment involves the administration of a magnetic field applied to a specific area of the brain.
75414393|NCT01386931|Procedure|EUS-guided FNA performed with on-site Cytopathologist|Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
75414394|NCT01386931|Procedure|EUS-guided FNA performed without on-site Cytopathologist|In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
75414395|NCT01386996|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
75559024|NCT03273062|Drug|Tolcapone 200 MG|Tolcapone 200 MG TID
75559025|NCT03273062|Other|Placebo|Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
75559026|NCT00498108|Drug|Rotigotine|
75414396|NCT01386996|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
75414397|NCT01387048|Drug|skinoren|gel 15%, twice daily, 36 weeks
75414398|NCT01387048|Drug|differin|0.1% gel, once daily in the evening
75414399|NCT01387048|Drug|skinoren|12 weeks treatment, the following 24 months only observation
75414400|NCT01387061|Procedure|hepatic resection|surgical resection of the liver for multiple HCC
75414401|NCT01387087|Drug|ASP015K|oral
75414402|NCT01387087|Drug|Placebo|oral
75414403|NCT01387100|Behavioral|Vocational Rehabilitation Intervention|Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
75414404|NCT01387126|Dietary Supplement|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
75414405|NCT01387165|Drug|Treatment|were receiving an oral hypoglycemic agent (OHA) or insulin
75414406|NCT01387191|Drug|Epoprostenol|
75559027|NCT00464321|Biological|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
75559028|NCT00464321|Biological|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
75414407|NCT01387204|Drug|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
75559029|NCT00464321|Biological|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
75414408|NCT01387217|Drug|GSK2018682|GSK2018682
75559030|NCT00464321|Biological|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
75559031|NCT03272984|Procedure|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
75559032|NCT03272984|Procedure|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
75559033|NCT00498147|Other|ADEC Program|Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
75559034|NCT00466583|Drug|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
75559035|NCT00498225|Drug|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
75559036|NCT00498225|Drug|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
75734935|NCT03498521|Drug|Trastuzumab Subcutaneous (SC)|Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
75734936|NCT03498521|Drug|Pertuzumab|Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
76042092|NCT05614375|Procedure|endoscopic surgery|transnasal endoscopic surgery
75414409|NCT01387217|Drug|Placebo|Matched Placebo
75414410|NCT01387243|Drug|Orlistat|60 mg
75414411|NCT01387256|Drug|medical abortion|pregnancy termination with drugs
75414412|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
75414413|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 3, single dose
75414414|NCT01387308|Drug|Fostamatinib|Oral tablets, 100 mg, single dose
75414415|NCT01387308|Drug|Fostamatinib|Oral tablets, 150 mg, single dose
75414416|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
75414417|NCT01387321|Drug|BYL719|
75414418|NCT01387334|Behavioral|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
75441415|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
76042093|NCT05612893|Other|pathogen|"The patients were divided into groups according to the pathogen(bacteria or virus).~The influenza upper respiratory tract infection cohort will be grouped mainly according to age."
76042094|NCT03882307|Drug|sofosbuvir and daclatasvir|oral tablets
75414419|NCT01387360|Device|Supracor|"The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.~The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances."
75414420|NCT01387373|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
75414421|NCT01387399|Procedure|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|"Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)"
75414422|NCT01387425|Drug|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
75414423|NCT01387425|Drug|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
75414424|NCT01387477|Drug|Lactate|Infusion of 66 mmol of lactate
75414425|NCT01387477|Drug|Glucose|Infusion of 33 mmol of glucose
75414426|NCT01387490|Behavioral|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
75414427|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
75559037|NCT00498225|Drug|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
75559038|NCT00466622|Drug|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
75734937|NCT03498521|Drug|Atezolizumab|Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
76042095|NCT03858517|Device|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
75414428|NCT01387503|Procedure|Liver transplantation|Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
75414429|NCT01387555|Biological|JX-594 recombinant vaccina GM-CSF|Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
75559039|NCT00466622|Drug|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
75414430|NCT01387555|Other|Best Supportive Care|Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
75414431|NCT01387568|Drug|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg-1.h-1. and were continued up to 6 hours postoperatively
75734938|NCT03498521|Drug|Carboplatin|Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
75873092|NCT05210244|Dietary Supplement|Beetroot Juice (BJ) acute supplementation|One serving of 70 mL of BJ (6.4 mmol of NO3) 3h before initiating the testing session
76042096|NCT04803799|Other|Training Programme|Cognitive-motor dual task exercises corresponding to associations between different motor tasks and different cognitive tasks.
76042097|NCT04800601|Other|Rehabilitation program 1|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~In addition to this conventional rehabilitation, the experimental group will receive an ankle isokinetic program, 5 times a week, for 6 weeks (with a minimum of 25 sessions)"
75414432|NCT01387568|Drug|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
75441416|NCT01634412|Drug|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
75559040|NCT00498264|Behavioral|walking program, resistance muscular exercise|
75559041|NCT01327612|Drug|Modified FOLFOX6|The mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m² administered as a 2-hour intravenous (IV) infusion on day 1 and leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1, followed by a loading dose of 5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1, then 5-FU 2400 mg/m² via ambulatory pump administered for a period of 46 to 48 hours every 14 days.
75559042|NCT01327612|Biological|Conatumumab|Administered by intravenous infusion Q2W or Q3W.
75734939|NCT03498521|Drug|Paclitaxel|Paclitaxel will be administered intravenously, 175 mg/m^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
75414433|NCT01387620|Drug|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
75414434|NCT01387633|Other|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact|For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist
75414435|NCT01387633|Other|Educational intervention group for people with diabetes through Diabetes Conversation Maps|For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
75414436|NCT01387646|Behavioral|Project IMAGE|Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
75414437|NCT01387659|Procedure|Gastric emptying test|Gastric emptying tests will be performed at baseline, 6 months and 12 months
75414438|NCT01387711|Drug|PEP005 (Ingenol mebutat Gel, 0.05 %)|All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
75414439|NCT01387724|Genetic|RNA analysis|
75414440|NCT01387724|Genetic|polymerase chain reaction|
75414441|NCT01387724|Genetic|protein expression analysis|
75414442|NCT01387724|Genetic|proteomic profiling|
75414443|NCT01387724|Genetic|western blotting|
75414444|NCT01387724|Other|enzyme-linked immunosorbent assay|
75414445|NCT01387724|Other|immunohistochemistry staining method|
75414446|NCT01387724|Other|laboratory biomarker analysis|
75414447|NCT01387724|Other|liquid chromatography|
75414448|NCT01387724|Other|mass spectrometry|
75414449|NCT01387750|Other|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
75414450|NCT01387750|Other|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
75414451|NCT01387828|Procedure|Laparoscopic splenic aneurysm repair, eventual splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach
75414452|NCT01387828|Procedure|Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
75414453|NCT01387841|Behavioral|yoga|Postures,relaxation techniques
75414454|NCT01387841|Behavioral|Jacobsons PMRT group|jacobsons Progressive muscle relaxation training involving 16 muscle groups
75559043|NCT01327612|Biological|Ganitumab|Administered by intravenous infusion Q3W or Q4W.
75559044|NCT01327612|Biological|Bevacizumab|Administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle.
75559045|NCT01243281|Drug|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
75559046|NCT00464399|Drug|everolimus|
75559047|NCT04132882|Drug|Sodium Thiosulfate (STS)|
75734940|NCT03498521|Drug|Cisplatin|Cisplatin will be administered intravenously, 60-75 mg/m^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
75559048|NCT01243359|Drug|sunitinib malate|Given PO
75559049|NCT01243359|Biological|bevacizumab|Given IV
75414455|NCT01387867|Procedure|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
75559050|NCT01243359|Other|pharmacological study|Correlative studies
75559051|NCT01243359|Other|laboratory biomarker analysis|Correlative studies
75559052|NCT01243359|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
75559053|NCT01243359|Procedure|positron emission tomography|Undergo FLT PET/CT
75559054|NCT01243359|Procedure|computed tomography|Undergo FLT PET/CT
75559055|NCT04403581|Other|Questionnaire|Questionnaire for assessing stresses, knowledge and attitudes of doctors in COVID-19 pandemic
75559056|NCT02893579|Behavioral|Early SR intervention|Self-directed stress reduction program delivered through a smart-phone application
75559057|NCT02893579|Behavioral|Delayed SR intervention|Activity tracking only for the first month
75559058|NCT00498303|Biological|trivalent split influenza vaccine|
75559059|NCT04402567|Other|No Intervention|Not Apply
75559060|NCT01243398|Procedure|quality-of-life assessment|
75559061|NCT04400812|Other|questionnaire|Arabic questionnaire focused on knowledge, perception and attitude
75559062|NCT04400461|Other|Data collection and clinical testing of subjects|"Clinical Testing: muscle strength. Muscle strength, as a component of physical function, will be assessed with the Medical Research Council sum score (MRC- SS) at discharge from the ICU and at discharge from the hospital.~Clinical testing: physical function. The Functional Status Score for the ICU (FSS-ICU) will be used to evaluate 5 functional tasks at discharge from hospital."
75559063|NCT00498342|Drug|N-acetylcysteine|
75559064|NCT04399174|Device|US|
75559065|NCT00466856|Drug|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres~<10% Administer full dose of SIR-Spheres~10% to 15% Reduce dose of SIR-Spheres by 20%~16% to 20% Reduce dose of SIR-Spheres by 40%~>20% Do not give SIR-Spheres"
75559066|NCT00466856|Radiation|yttrium Y 90 resin microspheres|radiation
75559067|NCT04398979|Procedure|Thoracoscopic Atrial fibrillation Ablation|After blunt dissection of the oblique and transverse sinus, an AtriCure Lumitip Dissector was introduced around the pulmonary veins. Pulmonary vein isolation was achieved with an AtriCure Isolator Synergy ablation clamp around the pulmonary vein antrum at least six times for each side. Ganglionated plexus identification and ablation were performed using an AtriCure Synergy ablation pen. The additional superior and inferior ablation lines connecting the bilateral pulmonary vein isolations were created by applying the AtriCure Synergy ablation pen. Following completion of the ablation on the right side, ablation on the left side was accomplished in a similar manner. The ligament of Marshall was dissected by electrical cautery. Conduction block was confirmed upon completion of the ablation procedure on the left side.
75559068|NCT02893189|Genetic|Infusion of modified CAR19 T-cells (4G7-CARD T-cells)|The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.
75559069|NCT00498381|Device|CPAP|
75734941|NCT03498521|Drug|Gemcitabine|Gemcitabine will be administered intravenously, 1000 mg/m^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
75414456|NCT01387867|Procedure|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
75414457|NCT01387867|Procedure|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
75414458|NCT01387880|Drug|Everolimus|"Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan."
75559070|NCT00464516|Drug|placebo|once daily for 14 days orally
75559071|NCT00464516|Drug|Estetrol|once daily for 14 days orally
75559072|NCT01243437|Drug|ciprofloxacin|"For adults and children aged > 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
75559073|NCT01243437|Drug|doxyxcycline|"For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
75559074|NCT00591994|Drug|piribedil|50 mg once a day, after lunch 3 month therapy
75559075|NCT00464594|Behavioral|Standard lifestyle guidance|
75559076|NCT00464594|Drug|Lifestyle guidance and monotherapy with acarbose|
75559077|NCT00464594|Drug|Lifestyle guidance and monotherapy with metformin|
75559078|NCT00464594|Drug|Lifestyle guidance and monotherapy with gliclazide|
75559079|NCT00592033|Other|oxygen from a portable concentrator|2 l/minute during exercise
75559080|NCT02893345|Behavioral|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
75559081|NCT02893345|Other|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
75559082|NCT04397302|Diagnostic Test|Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction|Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study
75559083|NCT03272945|Procedure|Linked-color imaging|Linked-color imaging colonoscopy
75559084|NCT04396210|Other|Questionnaire|Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
75559085|NCT04395898|Procedure|pancreaticoduodenectomy|Whipple's procedure
75559086|NCT00466895|Drug|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
75559087|NCT04395664|Device|C3+ Holter Monitor|ECG monitoring
75559088|NCT04395313|Other|no intervention carried out|no intervention was done
75559089|NCT00498459|Behavioral|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
75559090|NCT04132258|Other|survey|(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
75559091|NCT03272087|Device|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
75559092|NCT03272087|Device|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
75559093|NCT02893306|Biological|MSCs|origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
75734942|NCT03498521|Drug|Entrectinib|Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
76042098|NCT04800601|Other|Rehabilitation program 2|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~The control group will have a supplement in conventional rehabilitation equal to the additional time of the experimental group."
75559094|NCT02893540|Drug|Capecitabine|we are going to compare two maintenance treatment models with capecitabine in this study
75559095|NCT04393090|Other|eHealth platform CANKADO|The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.
75559096|NCT01327573|Drug|eculizumab|"Eculizumab Induction 600mg IV every 7 days for 4 doses~Eculizumab 900mg IV 7 days later~Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
75414459|NCT01387880|Drug|Everolimus|1.66 mg per day up to 7½ mg per day
75441417|NCT01634412|Drug|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
75559097|NCT04328428|Other|acupuncture|Use one acupuncture needle insert in a acupoint.
75559098|NCT02893384|Drug|Local Anesthetic Injection above the serratus anterior|This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
75559099|NCT02893228|Procedure|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
75734943|NCT03498521|Drug|Ivosidenib|Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
75441418|NCT01634425|Device|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
75441419|NCT01634438|Drug|unfractionated heparin|unfractionated heparin
75559100|NCT02893228|Drug|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
75559101|NCT00466973|Device|Dry bipolar radiofrequency (RF) clamp|Specified device used for ablation during standard surgical procedure
75559102|NCT00466973|Device|Unipolar microwave antenna|Specified device used for ablation during standard surgical procedure
75559103|NCT00466973|Device|Unipolar cryothermic probe|Specified device used for ablation during standard surgical procedure
75559104|NCT00466973|Device|Irrigated unipolar RF antenna|Specified device used for ablation during standard surgical procedure
76042099|NCT04762771|Drug|Colchicine|"Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase > 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral"
75559105|NCT00466973|Device|Irrigated bipolar RF clamp|Specified device used for ablation during standard surgical procedure
75559106|NCT00466973|Device|Hi-intensity focused ultrasound wand|Specified device used for ablation during standard surgical procedure
75559107|NCT00498537|Drug|spironolactone|
75559108|NCT04387747|Other|SARCOPENIA IN STROKE PATIENTS|Demographic characteristics, duration of stroke, sarcopenia presence,thigh circumference , Hand grip strength , TANITA BIA analysis
75559109|NCT04387513|Procedure|Cardiac surgery|Cardiac surgery, if indicated, delayed or not by neurological complications
75559110|NCT00464750|Device|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
75559111|NCT00491478|Drug|sertraline|
75559112|NCT03272204|Behavioral|No pubic hair|Natural pubic hair to fully removed pubic hair
75559113|NCT03272204|Behavioral|Pubic Hair|Removed pubic hair to natural pubic hair
75559114|NCT00491517|Drug|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
76042100|NCT04339465|Behavioral|CARE-FAM|CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.
75441420|NCT01634451|Other|Bespoke on-line sedation education package|A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
75559115|NCT00491517|Drug|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
75559116|NCT00464789|Drug|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
75559117|NCT00491595|Drug|High Dose Soy isoflavones|
75559118|NCT00467012|Drug|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
75559119|NCT00467012|Drug|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
75715746|NCT00898521|Drug|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area."
75441421|NCT01634451|Other|Sedation specific outcome process feedback|Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
75441422|NCT01634451|Device|Responsiveness monitoring; novel sedation monitor|Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
75559120|NCT03272867|Dietary Supplement|ProManna|
75559121|NCT00498654|Biological|Ty800 (Salmonella typhi) Oral Vaccine|
75559122|NCT01327495|Other|placebo acyline|Placebo acyline subcutaneous injection every 2 weeks
75559123|NCT01327495|Other|placebo gel|daily placebo testosterone gel applied transdermally x 12 weeks
75559124|NCT01327495|Drug|Testosterone 1% gel 1.25 g|testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
75559125|NCT01327495|Drug|Testosterone 1% gel 2.5 g|Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
75559126|NCT01327495|Drug|Testosterone 1% gel 5.0 g|Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
75559127|NCT01327495|Drug|testosterone 1% gel 10 g|Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
75559128|NCT01327495|Drug|testosterone 1% gel 15 g|Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
75559129|NCT01327495|Drug|Acyline|300 ug/kg subcutaneous injection every 2 weeks
75559130|NCT00491634|Drug|treosulfan|12 g/m2 x 3 days
75715747|NCT03985579|Other|Kinesiology taping application|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
75559131|NCT00491634|Drug|Treosulfan|12 g/m2 x 3
75559132|NCT04328155|Procedure|Hotpack Group|Hotpack Group received 20 minutes hotpack to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
75715748|NCT00902967|Drug|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
75715749|NCT00902967|Drug|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
75715750|NCT01324921|Other|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
75715751|NCT01324921|Other|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
75715752|NCT01324921|Other|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
75715753|NCT00898599|Dietary Supplement|Prebiotic|Inulin type fructooligosaccharides
75715754|NCT00898599|Dietary Supplement|Placebo|Maltodextrin as placebo
75715755|NCT01055665|Other|cognitive behavior therapy|6 cognitive behavior therapy groups
75873093|NCT05210244|Dietary Supplement|Placebo Juice (PLA) acute supplementation|One serving of 70 mL of juice (0.005 mmol of NO3) 3h before initiating the testing session
75873094|NCT02969018|Drug|PF-06700841|
75873095|NCT02969018|Other|Placebo|
75414460|NCT01387893|Behavioral|the Digital Repetitive Infrapubic Pressure maneuver|The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
75414461|NCT01387906|Drug|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
75559133|NCT04328155|Procedure|Infrared Group|Infrared Group received 20 minutes infrared to hamstring muscles region at prone position and participants stretchted the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15. seconds .
75559134|NCT04328155|Procedure|Ultrasound Group|Ultrasound Group received 5 minutes 1 M-Hz, 1,5 watt/cm2 ultrasound therapy to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
75559135|NCT04328155|Procedure|Control|Control Group participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
75559136|NCT01327339|Drug|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
75715756|NCT00903045|Drug|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
75715757|NCT00903045|Drug|Placebo|Identical placebo twice a day
75873096|NCT04624620|Behavioral|Teaching Kitchen Collaborative Curriculum|This is a referral-based teaching kitchen intervention that synergistically provides basic cooking skills, an evidence-based nutrition curriculum, mindfulness skills, activity tracking, and support for behavior change to augment weight management and lifestyle change in the primary care setting.
75559137|NCT01243515|Device|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
75559138|NCT01243515|Procedure|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
75559139|NCT03272789|Other|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
75414462|NCT01387919|Behavioral|Prolonged fasting|48 hours of fasting
75414463|NCT01387945|Behavioral|HBPM+website+patient navigator|In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
75559140|NCT01327300|Drug|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
75715758|NCT02539095|Device|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
75715759|NCT02539095|Device|Normal saline|"Supplementation of fluid and electrolytes (sodium or chlorine deficiency)~Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity."
75715760|NCT00337285|Drug|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
75414464|NCT01387958|Drug|LCQ908|
75414465|NCT01387958|Drug|Placebo|
75559141|NCT01327300|Other|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
75559142|NCT00491673|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
75715761|NCT03991117|Behavioral|resistance exercise|unilateral knee extensions until fatigue with varying load and speeds of contraction
75734944|NCT03498521|Drug|Pemigatinib|Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
75734945|NCT03489291|Genetic|AAV5-hFIXco-Padua (AMT-061)|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
75441423|NCT01634503|Genetic|GX-188E administered by electroporation|Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
75441424|NCT01634516|Behavioral|Dietary support|Face to face intervention plus subsequent telephone support
75441425|NCT01634516|Behavioral|No dietary support|No face to face intervention or subsequent telephone support
75441426|NCT01634529|Drug|V158866|Single ascending oral doses of V158866 and Placebo
75559143|NCT00491673|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
75559144|NCT00467129|Genetic|microarray analysis|
75559145|NCT00467129|Genetic|mutation analysis|
75559146|NCT00467129|Genetic|polymerase chain reaction|
75559147|NCT00467129|Genetic|polymorphism analysis|
75559148|NCT00467129|Other|laboratory biomarker analysis|
75559149|NCT00467129|Other|questionnaire administration|
75559150|NCT04381273|Other|No intervention|questionnaire-based assessment
75559151|NCT00464828|Procedure|Internal jugular vein cannulation|
75559152|NCT00464828|Device|ultrasound|
75559153|NCT00467168|Behavioral|Diet|
75734946|NCT03483038|Drug|Liposomal Irinotecan|Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
75734947|NCT03483038|Drug|FOLFOX regimen|Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
75734948|NCT03479515|Device|Ultrasound|Ultrasound, ADP, bioimpedance measurements
75559154|NCT04379245|Other|Data research, database analysis|"Extraction of virological data at the virology laboratory (date, SARS-COV2 PCR result, identification number, sex, date of birth) (Excel file)~Extraction of demographic and viro-immunological data from patients infected with HIV and on PrEP followed at the Hospices Civils de Lyon, France, over the period concerned (Access extraction)~Data crossing (Excel / Access) and statistical analysis~Calculation of the positivity rate per calendar period (= number of diagnosed cases / number of patients tested) and the attack rate per calendar period (number of diagnosed cases / number of people exposed (= active file of patients followed reduced by the number already known to be positive))."
75559155|NCT04328389|Behavioral|electric toothbrush|Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque
75414466|NCT01387997|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
75559156|NCT04328389|Procedure|Professional oral hygiene|Professional oral hygiene using ultrosound scaling and root planing
75559157|NCT00467207|Drug|Botulinum Toxin A|
75414467|NCT01388010|Other|1-Fermented Probiotic Dairy Product (test)|
75559158|NCT00467207|Behavioral|Resistance training|
75559159|NCT04378855|Other|Questionnaire|Quality of life assessment
75559160|NCT00592111|Drug|COPP/ABV|4 courses of COPP/ABV hybrid
75559161|NCT00592111|Drug|COPP/ABV|6 courses of COPP/ABV hybrid
75715762|NCT04035525|Dietary Supplement|MaxSimil® fish oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
75715763|NCT04035525|Dietary Supplement|Rice bran oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
75559162|NCT00592111|Drug|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
75559163|NCT00592150|Drug|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
75559164|NCT00592150|Drug|Placebo|Placebo infusion for 3 hours
75559165|NCT00464867|Biological|Whole cell killed cholera vaccine & probiotic|The oral cholera vaccine Dukoral will be administered to all study participants in two doses,two weeks between doses.Each dose of the formalin inactivated whole cell vaccine contains one mg of recombinant B subunit of cholera toxin(rCTB).The vaccine will be administered in bicarbonate-tartaric acid buffer to counteract the effect of low pH in the stomach.
75734949|NCT03472742|Drug|Mesenchymal Stem Cell|As this is a follow-up and an observation study, ADR-001 was administered in the previous study, not in this study.
75734950|NCT03457948|Procedure|Arterial Embolization|Undergo TAE
75734951|NCT03457948|Biological|Pembrolizumab|Given IV
75734952|NCT03457948|Biological|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate|Given IV
75734953|NCT03457948|Device|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere RE
75734954|NCT03444701|Drug|E7130|Starting dose of 25 μg/m^2 on Day 1 and Day 15 of Cycle 1.
75734955|NCT03444701|Drug|E7130|Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.
75414468|NCT01388010|Other|2-Milk-based non-fermented dairy product(control)|
75414469|NCT01388023|Dietary Supplement|herbal formula for fresh breath|composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
75559166|NCT00592189|Procedure|blood draw|blood collection
75559167|NCT00592228|Device|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~FFR group: if FFR<0.75~Routine DES group"
75559168|NCT00592306|Drug|thymoglobulin (intraoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses."
75559169|NCT00592306|Drug|thymoglobulin (postoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin."
75559170|NCT00467246|Drug|Levemir|
75559171|NCT00592345|Radiation|Proton Beam Radiation|Administered over a period of 12 weeks.
75414470|NCT01388036|Drug|esmolol|consecutive infusions of esmolol and normal saline (placebo)
75559172|NCT00592345|Radiation|Photon Beam Radiation|Administered over a period of 12 weeks.
75559173|NCT00592345|Radiation|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
75559174|NCT00498732|Device|CPAP|CPAP treatment for 4 weeks
75559175|NCT04377295|Drug|Ranibizumab 0.5Mg/0.05Ml Oph Inj|All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography
75559176|NCT00491712|Procedure|Glaucoma drainage implant with/without triamcinolone|
75559177|NCT00467324|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
75559178|NCT02893111|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
75559179|NCT00498771|Behavioral|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
75715764|NCT04035525|Dietary Supplement|CoQ10 as powder form|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
75734956|NCT03444324|Biological|BT524|BT524 is administered intravenously, patient specific dosage calculated based on body weight and fibrinogen level.
75414471|NCT01388049|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
75414472|NCT01388062|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
75559180|NCT00464984|Behavioral|Lifestyle intervention|Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
75559181|NCT04328272|Drug|Hydroxychloroquine 200 Mg Oral Tablet|Hydroxychloroquine administered orally with water
75559182|NCT04328272|Drug|Azithromycin 500Mg Oral Tablet|Azithromycin administered orally with water
75559183|NCT04328272|Dietary Supplement|Glucose tablets|administered orally with water
75559184|NCT04328194|Diagnostic Test|Serum Autotaxin|Marker
75559185|NCT04328194|Radiation|chest x-ray|chest x- ray will be done for the study group
75559186|NCT04328194|Diagnostic Test|Breast ultrasound or mammography|Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer
75559187|NCT04328194|Diagnostic Test|Histopathological examination of breast mass specimens|by True cut or fine needle aspiration cytology
75734957|NCT03444324|Biological|FFP/Cryo|FFP/Cryo is administered intravenously; dosage according to local standards in mL per kg body weight.
75559188|NCT04328194|Radiation|Magnetic Resonance Imaging ( MRI) and Bone scan|will be done for the study group
75414473|NCT01388075|Drug|Rifampicin|oral, 450 mg/day , 7 days
75559189|NCT04328194|Diagnostic Test|Peripheral haemogram|blood sample will be taken from the patients
75559190|NCT04328194|Diagnostic Test|Renal and liver functions|to exclude any other morbidity
75559191|NCT04328194|Diagnostic Test|Prothrombin time and concentration|blood sample will be taken from the patients
75559192|NCT04328194|Diagnostic Test|Cancer Antigen 15-3 (CA15-3).|will be done for the 2 groups
75559193|NCT04328194|Other|Full medical history|full medical history will be taken from all patients
75715765|NCT04035057|Other|Behaviorally Enhanced Training|Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.
75715766|NCT04035057|Other|Standard Didactic Training|Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
75414474|NCT01388088|Drug|Spironolactone|25 mg twice a day
75414475|NCT01388088|Drug|Amiloride|5 mg twice a day
75414476|NCT01388088|Drug|Placebo|twice a day
75559194|NCT04328194|Other|Full clinical examination|full clinical examination will be done for the patients
75715767|NCT04034979|Behavioral|decision aid|One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
75715768|NCT00905853|Procedure|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
75715769|NCT00905853|Drug|Escalated Antiarrhythmic Therapy|"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"
75559195|NCT03272750|Dietary Supplement|Bioscalin® new formulation with Galeopsis Segetum|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
75559196|NCT03272750|Dietary Supplement|Reference product|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
75559197|NCT03272750|Dietary Supplement|Placebo|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
75414477|NCT01388101|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
75441427|NCT01634529|Drug|V158866|Multiple ascending oral doses of V158866 and Placebo
75441428|NCT01632956|Behavioral|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
75559198|NCT00498810|Procedure|complete repair|
75559199|NCT00498810|Procedure|partial repair of the abdominal wall|
75559200|NCT04374682|Other|exercises|stretching exercises - physiotherapy modalities - self care instructions
75559201|NCT04374370|Biological|SARSCoV2 Convalescent Plasma|Provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.
75559202|NCT00465023|Procedure|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
75559203|NCT00491790|Drug|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
75559204|NCT00491790|Other|Sterile water|Sterile water
75873097|NCT03255096|Drug|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
75873098|NCT03255096|Drug|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
75873099|NCT03255096|Drug|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
75441429|NCT01632956|Behavioral|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
75873100|NCT01319721|Procedure|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
75873101|NCT01319721|Procedure|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
75873102|NCT01319721|Procedure|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
75441430|NCT01634568|Drug|V81444|"Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo"
75441431|NCT01634594|Drug|Group R|
75441432|NCT01634594|Drug|Group N|
75414478|NCT01388114|Device|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
75414479|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
75414480|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
75414481|NCT01388153|Drug|Acarbose (Glucobay, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
75414482|NCT01388179|Device|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
75414483|NCT01388205|Behavioral|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
75414484|NCT01388231|Behavioral|CBT-Manualized Intervention|Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
75414485|NCT01388231|Behavioral|CBT-Treatment as Usual|Cognitive-behavioral therapy for social phobia following no specific model.
75414486|NCT01388257|Procedure|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
75414487|NCT01388257|Procedure|Simple seton drain removal|Patients are simply followed after seton drain removal.
75414488|NCT01388270|Device|a pre-heparin-coated hemodialysis filter; Hepran|Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
75414489|NCT01388322|Drug|Enoxaparin|40 mg (4000 IU) women <80 kg at the time of randomization or 60 mg (6000 IU) women> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
75715770|NCT00905931|Drug|Lycopene|30 mg oral, daily, for 21 days
75715771|NCT00905931|Drug|placebo|starch
75414490|NCT01388348|Device|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
75414491|NCT01388374|Other|Other, care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
75414492|NCT01388400|Other|conventional occupational therapy|upper limb exercises
75414493|NCT01388400|Device|video capture virtual reality|virtual reality delivered uppe limb exercises
75414494|NCT01388413|Drug|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
75414495|NCT01388426|Device|7eye( Panoptx)™ moisture chamber glasses|moisture chamber glasses
75441433|NCT01634594|Drug|Group D|
75559205|NCT02892994|Other|ultrasound|
75715772|NCT02540187|Other|blood specimen|
75559206|NCT04371328|Other|RECOP unit patient|"All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.~30 days after inclusion, virological status and mortality will be collect"
75559207|NCT04371211|Behavioral|Telemedicine Brain Injury Coping Skills|"BICS is a 12 session (one session per week), manualized, cognitive-behavioral treatment group designed to provide support, coping skills, and psychoeducation aimed to improve perceived self-efficacy (PSE) and emotional functioning. PSE has been found to be strongly linked to social participation, increased positive regard toward the caregiving role, and was found to be the greatest contributing factor to predicting life satisfaction.~For this study, the Brain Injury Coping Skills (BICS) group intervention will be administered electronically in a web-based group telemedicine platform, BICS-T. The purpose of this phase is to test the feasibility, participant training protocol, and ease of use of equipment and technology."
75559208|NCT00498849|Device|CPAP|
75559209|NCT04369261|Drug|Synovian®|Synovian® Inj.
75559210|NCT03272009|Drug|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
75559211|NCT03272009|Drug|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
75559212|NCT03272009|Drug|Entecavir|Tablets administered orally
75559213|NCT03272009|Drug|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
76042101|NCT04339465|Behavioral|WEP-CARE|WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform
75414496|NCT01388439|Drug|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants < 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants > 38 weeks PMA. Dosing in infants < 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants > 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants > 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
75414497|NCT01388452|Device|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
75414498|NCT01388465|Behavioral|Mobile phone text messaging|Daily assessment followed by feedback
75414499|NCT01388504|Drug|sodium nitrite|sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
75414500|NCT01388504|Other|Placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
75414501|NCT01388517|Drug|Tacrolimus|0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
75414502|NCT01388517|Drug|Calcitriol|0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
75414503|NCT01388517|Drug|Petrolatum|Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
75559214|NCT04327882|Diagnostic Test|Point-of-care ultrasound|performance of a POCUS: lung and cardiac ultrasound mainly
75559215|NCT00498888|Procedure|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
75414504|NCT01388556|Behavioral|Tango dancing|Twice weekly tango dance classes
75414505|NCT01388569|Other|flow cytometry|
75414506|NCT01388569|Other|immunologic technique|
75414507|NCT01388569|Other|laboratory biomarker analysis|
75414508|NCT01388582|Device|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
75414509|NCT01388582|Device|Implanon|60 mcg/day contraceptive implant
75414510|NCT01388582|Drug|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
75414511|NCT01388582|Device|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
75414512|NCT01388582|Device|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
75414513|NCT01388595|Drug|FLUTICASONE PROPRIONATE|1. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
75414514|NCT01388595|Drug|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
75414515|NCT01388595|Drug|PLACEBO|4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported & QP release tested in UK : DHP Clinical supplies, Powys, UK
75414516|NCT01388621|Drug|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
75414517|NCT01388621|Drug|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
75414518|NCT01388621|Drug|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
76042102|NCT05466409|Other|Visualization of the hyoid bone|Visualization of the hyoid bone using POCUS of upper airway (probe positioning: transverse plane). Hyoid bone visualization will be assessed as a binary outcome (yes/no).
75414519|NCT01388621|Drug|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
75414520|NCT01388621|Drug|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
75414521|NCT01388621|Drug|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
75414522|NCT01388660|Drug|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I & II Day 1 (crossover manner)
75414523|NCT01388660|Drug|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I & II Day 1 (crossover manner)
75414524|NCT01388673|Procedure|BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy|The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
75414525|NCT01388712|Dietary Supplement|Lactobacillus reuteri DSM 17938|Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10^8CFU).
75414526|NCT01388712|Dietary Supplement|Placebo|Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
75414527|NCT01388738|Drug|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg*3 times per day) per os
75414528|NCT01388738|Drug|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
75414529|NCT01388738|Drug|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
75414530|NCT01388751|Procedure|night splinting|splint finger at night for 4 weeks
75414531|NCT01388764|Drug|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
75414532|NCT01388829|Drug|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
75414533|NCT01388829|Drug|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
75414534|NCT01388842|Drug|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
75414535|NCT01388842|Drug|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
75715773|NCT04035291|Other|exercise|exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
75414536|NCT01388855|Drug|Cholecalciferol|Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
75414537|NCT01388855|Drug|Placebo|Pills made to look like vitamin D but have no medication in them
75414538|NCT01388868|Other|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
75414539|NCT01388868|Other|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
75414540|NCT01388868|Other|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
75414541|NCT01388881|Other|Music Education|"The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music."
75414542|NCT01388959|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
75414543|NCT01388998|Other|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
75559216|NCT00498888|Procedure|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
75559217|NCT00498888|Procedure|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
75559218|NCT00498888|Procedure|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
75559219|NCT02893072|Behavioral|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
75559220|NCT04369105|Other|Prone position|The patients will be put in prone position while receiving invasive mechanical ventilation and the investigators will monitor changes in mechanical power applied to the respiratory system and compare with supine position
75559221|NCT04368754|Other|Questionnaire|Patients evaluated with different questionnaire.
75559222|NCT00491868|Drug|R744|100μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
75559223|NCT00491868|Drug|R744|150μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
75715774|NCT00898833|Other|laboratory biomarker analysis|
75715775|NCT04035135|Drug|ANX005|investigational drug
75414544|NCT01389037|Behavioral|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
75414545|NCT01389037|Behavioral|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
75414546|NCT01389063|Drug|Maraviroc|HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
75559224|NCT00491868|Drug|rHuEPO|2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
75559225|NCT00491868|Drug|rHuEPO|4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
75559226|NCT00491868|Drug|R744 placebo|0 μg/4week for 24 weeks
75559227|NCT00491868|Drug|rHuEPO placebo|0 IU 2 or 3 times/week for 8 weeks, then 1~3 times/week for 16 weeks
75715776|NCT04035135|Drug|Intravenous immunoglobulin|investigational drug
75715777|NCT00898911|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
75715778|NCT04034745|Drug|telotristat ethyl|250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
75715779|NCT00903279|Drug|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
75559228|NCT04367896|Other|Survey Group|"The survey sought to elucidate equity principles that are influencing transplant decision making. The group of respondents included solid organ transplant doctors (surgeons, referring doctors, transplant physicians, transplant coordinators, ICU transplant doctors), COVID-doctors (ICU doctors, Infectious Disease Doctors, Pulmonologists, Internists), and Ethicists with experience of transplant related issues.~Respondent identification:~A. The e-mail addresses of corresponding authors from Scopus January 1, 2017 and march 20, 2020:~All (surgery) AND subj (medi) and key (transplantation), All (critical care) AND subj (medi) and key (transplantation), All (ethics) AND subj (medi) and key (transplantation). B. Emailing through the mailing list of scientific societies. C. The link to the survey published online. D. The link to the survey circulated through personal contacts and via social media sites."
75559229|NCT02893033|Device|repetitive transcranial magnetic stimulation|rTMS
75559230|NCT00491907|Drug|folic acid 5mg/day|
75559231|NCT03271931|Behavioral|Active choice|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
75559232|NCT03271931|Behavioral|Passive choice|EHR passive alert to cardiologists about prescribing a statin
76042103|NCT05466409|Other|Visualization of vocal cords|Visualization of the vocal cords through the cricoid cartilage using POCUS of upper airway (probe positioning: transverse plane). Vocal cords visualization will be assessed as a binary outcome (yes/no).
75559233|NCT00467441|Drug|VSF-173|
75559234|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100microgram
75559235|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100micgrams
75414547|NCT01389154|Procedure|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
75559236|NCT00465140|Drug|creatine supplementation|
75559237|NCT00465140|Behavioral|aerobic exercise training|
75715780|NCT00903279|Drug|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
75715781|NCT00903435|Other|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
76042104|NCT05466409|Other|Localization of thyrohyoid membrane|Localization of thyrohyoid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Thyrohyoid membrane visualization will be assessed as a binary outcome (yes/no).
76042105|NCT05466409|Other|Visualization of epiglottis and pre-epiglottic space|Visualization of epiglottis and pre-epiglottic space using POCUS of upper airway (probe positioning: midsagittal plane). Epiglottis and pre-epiglottic space visualization will be assessed as a binary outcome (yes/no).
75414548|NCT01389167|Drug|Vivitrol|An extended release naltrexone formulation for intramuscular injection
75414549|NCT01389167|Drug|Naltrexone (oral)|Naltrexone 50 mg pills, daily
75559238|NCT04327765|Combination Product|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
75559239|NCT04327765|Combination Product|1mg AZ-010|Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo
75559240|NCT04327765|Combination Product|3mg AZ-010|Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo
75559241|NCT04362163|Device|Snorkel-based improvised personal protective equipment|An improvised PPE design based on a full face snorkel mask mated to a heat-and-moisture exchange filter via a 3D printed adaptor.
75559242|NCT00491946|Drug|Actinomycin-D|
75559243|NCT00491946|Drug|Vincristine|
75715782|NCT02539017|Drug|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
75715783|NCT02539017|Biological|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
75559244|NCT03272048|Behavioral|Lethal Means Counseling|Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, & Rudd, 2011; Jin, Khazem, & Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, & Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
75559245|NCT04361344|Biological|blood samples|Clinical examination and blood samples will be done at inclusion (day 0), at day 7 (between day 4 and exit from intensive care) and at day 60.
75715784|NCT04034667|Other|No intervention|No intervention
75715785|NCT00605865|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
75715786|NCT00899145|Other|Laboratory Biomarker Analysis|Correlative studies
75414550|NCT01389167|Behavioral|BDRC|Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
75414551|NCT01389167|Behavioral|Medical Management|Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
75414552|NCT01389180|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
75715787|NCT00922467|Drug|NaCl 9/00|Same volume as in the esmolol group
75715788|NCT00922467|Drug|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
75414553|NCT01389180|Behavioral|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
75715789|NCT00903747|Drug|prucalopride|2-10 mg prucalopride
75715790|NCT00903747|Drug|moxifloxacin|400 mg moxifloxacin (Group 2a)
75715791|NCT00903747|Drug|placebo|placebo (Group 2b)
75414554|NCT01389180|Behavioral|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
75414555|NCT01389193|Drug|Ibudilast|Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
75414556|NCT01389193|Drug|Placebo|Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
75414557|NCT01389206|Drug|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
75559246|NCT04358848|Device|X-PLO2R|Portable Oxygen Concentrator (POC)
75715792|NCT02538627|Drug|MM-151|MM-151
75559247|NCT01245231|Genetic|protein expression analysis|
75715793|NCT02538627|Drug|MM-121|MM-121
75715794|NCT02538627|Drug|MM-141|MM-141
75715795|NCT02538627|Drug|trametinib|trametininb
75715796|NCT00899457|Genetic|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
75715797|NCT00899457|Other|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
75715798|NCT00899457|Other|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
75715799|NCT00899457|Procedure|bronchoscopy|Collection of breath condensate.
75715800|NCT00906321|Behavioral|Web-Based Decision Support|
76042106|NCT05466409|Other|Visualization of cricothyroid membrane|Visualization of cricothyroid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Cricothyroid membrane visualization will be assessed as a binary outcome (yes/no).
76042107|NCT05466409|Other|Visualization of thyroid gland|Visualization of thyroid gland using POCUS of upper airway (probe positioning: transverse plane). Thyroid gland visualization will be assessed as a binary outcome (yes/no).
75715801|NCT00903825|Procedure|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
75715802|NCT00903825|Procedure|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
75715803|NCT00899535|Genetic|DNA analysis|
76042108|NCT05466409|Other|Hyoid bone to skin distance|Measurement of hyoid bone to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
76042109|NCT05466409|Other|Anterior commissure to skin distance|Measurement of anterior commissure to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
76042110|NCT05466409|Other|Epiglottis to skin distance|Measurement of epiglottis to skin distance (mm) using POCUS of upper airway (probe positioning: midsagittal plane).
76042111|NCT05466409|Other|Thyroid isthmus to skin distance|Measurement of thyroid isthmus to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
75414558|NCT01389219|Other|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron & vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
76042112|NCT05614297|Diagnostic Test|Knee joint laxity test|Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
75559248|NCT01245231|Genetic|western blotting|
75414559|NCT01389271|Drug|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
75414560|NCT01389297|Behavioral|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
75715804|NCT00899535|Genetic|RNA analysis|
75715805|NCT00899535|Genetic|microarray analysis|
75715806|NCT00899535|Genetic|mutation analysis|
75715807|NCT00899535|Genetic|polymorphism analysis|
75715808|NCT00903981|Drug|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
75715809|NCT00903981|Drug|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
75873103|NCT05284682|Diagnostic Test|Right hearted catheterization|Right hearted catheterization and collection of blood sampels in the coronary sinus, arterial blood and central venous blood for analysis of energy substrate metabolites.
76042113|NCT04754737|Other|No antibiotic|No antibiotics will be given prior to intravesical injection of onabotulinumtoxinA
76042114|NCT04754737|Other|Prophylactic antibiotic|This is the current standard of care, this group of patients will be given a single dose of prophylactic antibiotic prior to the injection of onabotulinumtoxinA via cystoscopy
76042115|NCT04754737|Procedure|cystoscopic injection of onabotulinumtoxinA|cystoscopic injection of onabotulinumtoxinA
75715810|NCT00903981|Drug|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
76042116|NCT04705363|Behavioral|Dialectal Features Varied|Participants will randomized to interact with a VHA that speaks either Standardized American English, a low level of African American English, or a high level of African American English
75414561|NCT01389297|Behavioral|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
75414562|NCT01389349|Other|Acupuncture|Battlefield acupuncture protocol
75414563|NCT01389349|Other|Sham Control|Sham control acupuncture
75414564|NCT01389362|Drug|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
75559249|NCT01245231|Other|flow cytometry|
75559250|NCT01245231|Other|laboratory biomarker analysis|
75559251|NCT01245231|Other|medical chart review|
75559252|NCT03272672|Other|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
75559253|NCT00592423|Other|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
75715811|NCT00899613|Other|laboratory biomarker analysis|
75715812|NCT00899613|Procedure|study of high risk factors|
75715813|NCT00899691|Genetic|protein expression analysis|
75715814|NCT00899769|Genetic|protein expression analysis|
75715815|NCT00899769|Genetic|proteomic profiling|
75715816|NCT00899769|Other|immunoenzyme technique|
75414565|NCT01389362|Drug|Placebo comparator|2 sachets to be taken daily
75559254|NCT00592462|Procedure|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
75559255|NCT00592540|Procedure|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
76042117|NCT04705363|Behavioral|Video Intervention|Participants will randomized to either receive a video introduction from the voice actor or receive no introduction
76042118|NCT04705363|Behavioral|VHA with no voice|virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
76042119|NCT05612737|Procedure|Horizontal bone augmentation|"After taking six 9 mL tubes of blood from the patient, advanced (A-PRF) and liquid (S-PRF) PRFs were prepared. A-PRF was chopped, added to the xenogeneic bone substitute (THE Graft; Purgo Biologics Inc.), and then impregnated with the liquid S-PRF, which enabled the particulate bone substitute to become moldable and turned into a block (sticky bone). After local anesthesia, a midcrestal incision was made with one vertical releasing incision at the flap's mesial end. After full-thickness flap elevation, a periosteal releasing incision was made at the flap's apical portion. The alveolar bone was decorticalized on the buccal aspect with surgical burs. Next, the prepared bonded graft matrix was adapted to the ridge. Then, tenting screws (Pro-fix; Osteogenics) were placed to maintain the periosteum in an elevated and tension-free position The bone augmentation material was covered with A-PRF membranes. Finally, tension-free wound closure was performed."
76042120|NCT04608721|Other|Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI) with a score ≥40 serving as a positive screen.
76042121|NCT04426357|Drug|JNJ-64417184|Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
75559256|NCT00491985|Biological|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
75715817|NCT00899769|Other|laboratory biomarker analysis|
75715818|NCT00899769|Other|liquid chromatography|
75715819|NCT00899769|Other|mass spectrometry|
76042122|NCT04603417|Diagnostic Test|Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI|This cross-sectional study will present the participants with an instrumental pain avoidance learning task, while we record continuous Magnetoencephalography (MEG) brain signals, and other autonomic measurements. All patients will complete behavioral, neuropsychological and pain assessments to rate their current pain, disability, fear, anxiety, and depression using standardized scales.
75414566|NCT01389375|Device|FemoSeal®|Closure device for femoral artery access closure
75414567|NCT01389375|Device|ExoSeal®|Closure device for femoral artery access closure
75414568|NCT01389375|Other|Manual compression|Conventional manual compression
75414569|NCT01389388|Drug|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
75414570|NCT01389401|Drug|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
75414571|NCT01389414|Drug|Panitumumab plus GEMOX chemotherapy|panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
75414572|NCT01389414|Drug|GEMOX chemotherapy|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
75559257|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
75559258|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
75559259|NCT04355884|Diagnostic Test|Standard 12-lead ECG, NT-proBNP, echocardiography|Cardiac assessment
75559260|NCT03272594|Other|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
75559261|NCT03272594|Drug|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
75559262|NCT02892916|Drug|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
75559263|NCT02892916|Drug|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
75559264|NCT01245309|Procedure|scratching|endometrial scratching before COH in IVF
75715820|NCT00904059|Drug|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
75414573|NCT01389427|Drug|Torisel dose 15 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414574|NCT01389427|Drug|Torisel dose 15 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75559265|NCT01245309|Procedure|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
75559266|NCT04354792|Diagnostic Test|Serum SARs COV 2 IGg screening in health care workers|Blood samples will be collected from the enrolled HCWs. Sample collection, processing, and laboratory testing will follow guidance from the World Health Organization
75559267|NCT04354285|Other|Observational|Observational
75559268|NCT02956304|Other|PMv stimulation (iTBS)|PMv stimulation (iTBS)
75559269|NCT02956304|Other|PMv inhibition (cTBS)|PMv inhibition (cTBS)
75559270|NCT02956304|Other|Control (SHAM)|Control (SHAM)
75559271|NCT04354753|Other|No Intervention|No intervention
75559272|NCT00492102|Drug|Montelukast|One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing >1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
75559273|NCT00465218|Procedure|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
75559274|NCT00499044|Other|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
75715821|NCT00904059|Drug|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
75715822|NCT00904059|Drug|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
75715823|NCT00904059|Drug|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
75715824|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
75715825|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
75715826|NCT00904137|Procedure|Cast|
75715827|NCT00904137|Procedure|Splint|
75715828|NCT00904137|Procedure|Tape|
75734958|NCT03442569|Drug|Panitumumab|6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
75734959|NCT03442569|Drug|Nivolumab|240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
75734960|NCT03442569|Drug|Ipilimumab|1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
75734961|NCT03422848|Dietary Supplement|Water|Increased daily water intake with 1.5 L of water on top of habitual water intake.
75734962|NCT03422848|Behavioral|general life style advice|oral and written advice on diet and physical activity
75734963|NCT03420963|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
75734964|NCT03420963|Drug|Cyclophosphamide|Given IV
75734965|NCT03420963|Drug|Etoposide|Given IV
75734966|NCT03414463|Behavioral|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
75734967|NCT03412227|Behavioral|Individual Behavioral Activation Therapy (IBAT)|IBAT is a manual-based, individual behavioral activation plus exposure therapy aimed at treating youth with anxiety, depression, and anger. The program consists of 10-14 weekly 60 minute sessions. It uses behavioral activation (BA) strategies to target avoidance by helping youth identify stuck points in their lives through functional assessment of numerous life domains, including family and peer interactions, school, extracurricular activities, and health and self-care.
75734968|NCT03412227|Behavioral|The PASCET Program for Youth Depressive Disorders|The Primary and Secondary Control Enhancement Therapy (PASCET; Weisz, Southam-Gerow, Gordis, & Connor-Smith, 2003; Weisz, Southam-Gerow et al., 2009; Weisz, Thurber, Sweeney, Proffitt, & LeGagnoux, 1997) is a brief (usually 11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of, and beneficial treatments for, youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, & Snyder, 1982; Weisz et al., 1984a,b).
75715829|NCT00906477|Procedure|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
75715830|NCT03987607|Device|neuromuscular blockade monitoring|Neuromuscular blockade monitoring via two different types of monitoring devices
75715831|NCT00900003|Genetic|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
75715832|NCT00900003|Other|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
75715833|NCT00906555|Procedure|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
75715834|NCT00337207|Biological|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
75715835|NCT01052857|Procedure|acupuncture|acupuncture application
75873104|NCT05210010|Device|CA-4F|"The study intervention is the CA-4F algorithm developed by Ensho Health.~The algorithm is a process for converting input parameters to a CA-4F Risk Score intended to facilitate clinical prioritization of patients suitable for follow-up investigation for ATTR-CM.~The algorithm is applied using the CA-4F Likelihood Estimator which encodes it in software and records its outputs. The CA-4F Likelihood Estimator is controlled through a graphical user interface called the CA-4F Controller.~The CA-4F Likelihood Estimator and its Controller are Class I medical devices in Canada registered under the Medical Device Establishment License of Ensho Health (license 16208)."
75873105|NCT03015324|Drug|Hydroxychloroquine|Hydroxychloroquine
75414575|NCT01389427|Drug|Torisel dose 15 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414576|NCT01389427|Drug|Torisel dose 25 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414577|NCT01389427|Drug|Torisel dose 50 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
76055847|NCT05886010|Device|prototypes 2 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75873106|NCT05754450|Drug|AVTX-803|L-fucose crystalline powder
75414578|NCT01389427|Drug|Torisel dose 75 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414579|NCT01389427|Drug|Torisel dose 25 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414580|NCT01389427|Drug|Torisel dose 50 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414581|NCT01389427|Drug|Torisel dose 75 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414582|NCT01389427|Drug|Torisel dose 25 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414583|NCT01389427|Drug|Torisel dose 50 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414584|NCT01389427|Drug|Torisel 75 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
75414585|NCT01389440|Drug|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
75414586|NCT01389453|Procedure|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
75414587|NCT01389466|Biological|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
75414588|NCT01389466|Biological|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
75414589|NCT01389479|Biological|Fluviral™|Intramuscular, single dose
75414590|NCT01389479|Biological|Fluzone®|Intramuscular, single dose
75414591|NCT01389492|Other|frozen meat cutlets meal|250 g of meat cutlets
75414592|NCT01389492|Other|meat meals|250 g of meat meal for 4 days
75414593|NCT01389505|Procedure|Panretinal photocoagulation|Three episodes of panretinal photocoagulation with one week of interval
75414594|NCT01389505|Procedure|Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab|Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP
75414595|NCT01389518|Drug|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
75414596|NCT01389518|Drug|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
75414597|NCT01389531|Procedure|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
75414598|NCT01389544|Drug|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
75414599|NCT01389544|Drug|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
75414600|NCT01389544|Drug|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
75414601|NCT01389557|Drug|Dihydroartemisinin-piperaquine with primaquine|"P. falciparum : Treated with fixed doses of 40 mg dihydroartemisinin and 320 mg piperaquine based on weight for 3 days (D0, D1 and D2) with max dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets. The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.~P. vivax: DHP (3 days) + primaquine (14 days)"
75414602|NCT01389570|Procedure|Acupressure wrist band|Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
75414603|NCT01389583|Drug|AUY922|70 mg/m2 60-min i.v. infusion weekly
75414604|NCT01389609|Drug|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
75414605|NCT01389609|Drug|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
75414606|NCT01389609|Drug|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
75873107|NCT04605744|Behavioral|Smoking cessation counseling|"Patients will be given a briefing on the benefits of smoking cessation in the peri-procedural period around their interventional pain procedure. They will also be provided an informational sheet from the American Society of Anesthesiologists promoting cessation. The sheet will contain the 1-800-QUITNOW national hotline phone number.~Additional an enrollment folder will provided that contains referral information to Cooper's Tobacco Cessation program. This service, free of charge to Cooper Health patients consists of 5 tobacco cessation counselors who use personalized cessation plans, individual and group counseling cessations, Chantix, and education to promote smoking cessation."
75414607|NCT01389622|Other|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
75414608|NCT01389622|Other|acupuncture|random points + digital pressure
75414609|NCT01389648|Other|Pre Operative|Pre operative chest physiotherapy treatment
75414610|NCT01389661|Biological|MSV treatment|Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
75414611|NCT01389674|Procedure|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
75414612|NCT01389687|Biological|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
75414613|NCT01389713|Drug|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
75559275|NCT00499044|Other|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
75559276|NCT02892838|Device|mobile bearing knee system for total knee arthroplasty|
75559277|NCT02892838|Device|fixed bearing total knee prosthesis|
75414614|NCT01389713|Drug|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
75414615|NCT01389726|Behavioral|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
75414616|NCT01389726|Behavioral|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
75559278|NCT00467636|Procedure|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
75715836|NCT01055743|Procedure|Radical resection|Radical resection of hepatocellular carcinoma
75715837|NCT01055743|Drug|Fluorouracil Implants|Implanted during the surgical treatment
75715838|NCT00604695|Drug|Tenecteplase|Intracoronary injection of IV tenecteplase.
75715839|NCT00604695|Drug|Sterile Saline|Intracoronary injection of IV sterile saline
75414617|NCT01389726|Behavioral|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader & 1 peer leader over the course of 11 weeks.
75414618|NCT01389739|Other|Multi-faceted intervention to improve continuity of care|Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
75414619|NCT01389778|Drug|Metformin ER|Metformin ER 1500 mg for 12 weeks
75414620|NCT01389778|Drug|Metformin|
75414621|NCT01389791|Drug|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
75414622|NCT01389791|Drug|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
75414623|NCT01389791|Drug|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
75559279|NCT00467636|Drug|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI < 30 = 0.1 unit/kg. BMI > 30 = 0.2 unit/kg)
75715840|NCT01055821|Drug|pegylated interferon and ribavirin|48 weeks
75715841|NCT01055821|Biological|TG4040 + SOC|6 injections
75715842|NCT01055821|Biological|TG4040 + SOC|13 injections
75715843|NCT00900081|Other|immunohistochemistry staining method|
75715844|NCT00900081|Other|laboratory biomarker analysis|
75715845|NCT00900081|Other|medical chart review|
75414624|NCT01389830|Behavioral|Telephone Survey|Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
75559280|NCT00492141|Drug|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
75559281|NCT00492141|Drug|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
75559282|NCT04350112|Other|Clinical assessment|Clinical assessment (history, examination) is gold standard for diagnosing constipation - gold standard will be compared with simple question about constipation, Rome IV diagnostic criteria for OIC, and common definitions of constipation for constipation / OIC
75414625|NCT01389869|Biological|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
75559283|NCT00467675|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
75559284|NCT04350151|Behavioral|no intervention|no intervention
75414626|NCT01389869|Biological|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
75414627|NCT01389869|Biological|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
75414628|NCT01389869|Biological|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
75559285|NCT04327726|Drug|Dexmedetomidine Nebulization|ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment
75559286|NCT04327726|Other|0.9% Saline Nebulization|nebulization of 4mL 0.9% saline
75559287|NCT00499161|Behavioral|New model of nursing care|
75559288|NCT04349254|Device|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision.
75559289|NCT00492219|Device|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
75559290|NCT00492219|Device|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
75414629|NCT01389895|Drug|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
75559291|NCT00465257|Drug|artesunate + amodiaquine|
75559292|NCT04131127|Device|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
75559293|NCT01245465|Other|Profermin|Medical Food (food for special medical purposes)
75715846|NCT03990727|Diagnostic Test|Retina Analysis-mosaic|Fundus retina pattern study
75715847|NCT03990727|Diagnostic Test|Autofluorescence|Fundus reflectance-functionality
75715848|NCT03990727|Diagnostic Test|OCT- 1 micra|Fine tomography fundus retina
75414630|NCT01389895|Drug|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
75414631|NCT01389908|Drug|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
75414632|NCT01389921|Other|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
75414633|NCT01389986|Behavioral|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
75414634|NCT01389999|Other|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
75414635|NCT01390012|Drug|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
75715849|NCT03990727|Procedure|Genotype analysis|Molecular target retina dystrophy analysis
75414636|NCT01390012|Drug|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
75414637|NCT01390025|Biological|TCN-032|TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.
75414638|NCT01390025|Biological|Placebo|Placebo - 0.9% Sodium Chloride for Injection, USP
75414639|NCT01390051|Drug|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
75414640|NCT01390051|Drug|tinzaparin|Dose 4,500 IE daily
75414641|NCT01390103|Other|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
75414642|NCT01390116|Dietary Supplement|Aged garlic extract|2 aged garlic extract capsules taken twice daily
75414643|NCT01390116|Dietary Supplement|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
75414644|NCT01390129|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
75414645|NCT01390129|Procedure|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
75414646|NCT01390142|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
75414647|NCT01390142|Procedure|RIPer|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
75414648|NCT01390142|Procedure|RIPer + IPost|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
75715850|NCT02540031|Drug|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
75873108|NCT05174871|Behavioral|Lifestyle intervention|Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.
76055848|NCT05886010|Device|prototypes 3 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75414649|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
75414650|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
75414651|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
75414652|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
75414653|NCT01390168|Behavioral|Tailored Internet-administrated CBT-Treatment|"This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
75414654|NCT01390168|Behavioral|Waitlist|active waitlist
76042123|NCT05421481|Other|home visit, health education, mobile application, group walk, message|"Home visit: Elderly individuals will be visited once at home. During the home visit, training will be given on the slide about physical activity. A brochure will be provided for general health promotion awareness. Counseling will also be provided during the home visit process.~Google Fit Application: During the home visit, the application will be downloaded to the phone of the elderly, and a document will be given about the use of the application after the usage is explained. The researcher will support those who have problems with the application in the following weeks.~Group walking: The walk, which will be done once, will be done in a light paced manner, and the purpose of the walk is to see the number of steps in the mobile application and to increase their motivation with the group.~Message: Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be."
76042124|NCT04580563|Drug|OctaplasLG®|Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
76042125|NCT04580563|Drug|0.9% NaCl|Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
76042126|NCT04481035|Drug|N-acetylcysteine (NAC)|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the experimental phase/arm will receive 70 mg/kg/dose (max dose 900 mg) three times per day of NAC for eight (8) weeks.
76042127|NCT04481035|Other|Placebo|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the placebo phase/arm will receive placebo (non-drug) three times per day for eight (8) weeks.
75414655|NCT01390207|Other|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
75414656|NCT01390285|Device|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
75715851|NCT02540031|Drug|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
75715852|NCT00904293|Other|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
75715853|NCT00904293|Other|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
75715854|NCT00900549|Device|CRT on|12 months
75414657|NCT01390285|Device|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
75414658|NCT01390311|Drug|Azacitidine|
75414659|NCT01390311|Drug|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
75414660|NCT01390311|Biological|Donor Leukocyte Infusion (DLI)|
75414661|NCT01390324|Drug|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
75414662|NCT01390324|Drug|Naratriptan|Tablets containing naratriptan 2,5 mg
75414663|NCT01390324|Drug|Naproxen|Tablets containing naproxen 500 mg
75414664|NCT01390337|Drug|AC220|Oral Liquid
75414665|NCT01390337|Drug|daunorubicin|Intravenous Infusion
76042128|NCT04427137|Device|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single LFR treatment, with 360 pulses of LFR delivered in one continuous train of 6 minutes at 1Hz at 120% of the patient's resting motor threshold.
75414666|NCT01390337|Drug|cytarabine|Intravenous Infusion
76042129|NCT02404311|Biological|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and < 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
76042130|NCT02404311|Biological|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
75414667|NCT01390350|Drug|Canakinumab|150mg subcutaneous injections on day 0
75414668|NCT01390350|Drug|Placebo|150mg subcutaneous injections on day 0
75414669|NCT01390363|Other|Parent Only Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
75559294|NCT04130776|Diagnostic Test|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from <1% to >95% of a man having aggressive cancer in a prospective biopsy.
75559295|NCT00492258|Drug|sorafenib tosylate|
75559296|NCT00492258|Procedure|adjuvant therapy|
75559297|NCT04327648|Device|Social interaction treatment|Children in social interaction treatment group will have 30min social interaction each day for 3 months.
75559298|NCT04327648|Device|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months.
75559299|NCT04327648|Other|Routine treatment|Children in routine treatment group will keep the same initial treatment.
75559300|NCT00467714|Procedure|rhinoplasty|COLUMELLA STRUT PLACEMENT
75559301|NCT03272438|Device|Accelerometer|Participants use an accelerometer to monitor their steps activity
76042131|NCT02404311|Biological|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
76042132|NCT02404311|Biological|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
75559302|NCT03272438|Behavioral|Step goal|Participants are given a daily step goal to aim for
75559303|NCT03272438|Behavioral|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
75559304|NCT03272438|Behavioral|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
75559305|NCT02955810|Drug|Daratumumab|
75559306|NCT02955810|Drug|Cyclophosphamide|
75559307|NCT02955810|Drug|Bortezomib|
75559308|NCT02955810|Drug|Dexamethasone|
75559309|NCT04342468|Other|non-interventional|No intervention
75559310|NCT04339855|Other|CAD with LCI for colorectal polyp detection|Polyps within fully recorded endoscopy videos with LCI mode, covering the whole spectrum of adenomatous histology, are used to evaluate the efficacy of CAD with LCI for polyp detection.
75559311|NCT00465296|Drug|rosiglitazone|
75559312|NCT00492414|Drug|Paroxetine CR|
75559313|NCT04337983|Device|Transpulmonary thermodilution|Obtained by averaging the results of three thermodilution measurements. Each thermodilution is performed by injecting a bolus (15 mL) of cold saline (less than 10°C)
75559314|NCT04337983|Device|Echocardiography|Daily echocardiography evaluation
75559315|NCT04337320|Other|newborns from covid 19 positive mothers|Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers
75559316|NCT03272555|Other|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
75414670|NCT01390363|Other|Parent and Adolescent Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
75414671|NCT01390376|Drug|DAAOI-1|DAAOI-1 1g
75414672|NCT01390376|Drug|DAAOI-1|DAAOI-1 2g
75414673|NCT01390376|Drug|placebo|starch pill
75414674|NCT01390454|Procedure|Ultrasound of the elbow 1, days 7 to 15|The primary endpoint is evaluated a first time via an ultrasound exam.
75414675|NCT01390454|Procedure|Ultrasound of the elbow 2, days 7 to 15|The primary endpoint is evaluated a second time by a second practitioner.
76042133|NCT03032107|Drug|T-DM1|-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
75414676|NCT01390454|Procedure|Ultrasound of the elbow 3, days 45 to 90|A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
75559317|NCT00499200|Drug|SRA-444|
75559318|NCT04327492|Diagnostic Test|Biomarker - FGF 23; troponin I; PCR - high sensitivity; BNP|peak wave velocity; gray weale plaque classification
75559319|NCT00499278|Behavioral|Rehabilitation after joint replacement surgery|
75559320|NCT04334395|Procedure|primary tumor resection group|resection of cancer at colon
75873109|NCT05174871|Behavioral|TRF intervention|Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.
76042134|NCT03032107|Drug|Pembrolizumab|-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
76042135|NCT02841163|Drug|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
76042136|NCT02841163|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
75414677|NCT01390467|Drug|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
75414678|NCT01390480|Drug|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
75414679|NCT01390493|Behavioral|neurofeedback training|training of individual alpha frequency, 10 sessions, each 15 min
75414680|NCT01390506|Drug|Sodium-selenite|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
75414681|NCT01390506|Drug|Placebo|0,9% sodium chloride is administered intravenously
75414682|NCT01390519|Other|everolimis|
75414683|NCT01390532|Device|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|"Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (>85% PHR).~Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA)."
75414684|NCT01390558|Procedure|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
75414685|NCT01390571|Drug|olaparib|
75414686|NCT01390571|Drug|temozolomide|
75414687|NCT01390571|Genetic|gene expression analysis|
75414688|NCT01390571|Genetic|protein expression analysis|
75414689|NCT01390571|Other|laboratory biomarker analysis|
75414690|NCT01390571|Other|pharmacological study|
75414691|NCT01390571|Procedure|diffusion-weighted magnetic resonance imaging|
75414692|NCT01390571|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
75559321|NCT04333186|Other|Data from ultrasound measurements|Data from ultrasound measurements and from the electronic patient record will be obtained / analyzed. One additional blood sample will be obtained within 24 hours after inclusion, during planned blood collection (from arterial line or venous puncture).
75559322|NCT01243632|Drug|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
75559323|NCT00467909|Behavioral|micronutrients|
75414693|NCT01390571|Procedure|therapeutic conventional surgery|
75414694|NCT01390597|Genetic|DNA analysis|
75559324|NCT04327375|Other|Observational|Observational
75559325|NCT00499356|Device|pressure reducing insole|
75559326|NCT00499356|Device|GlideSoft®|
75559327|NCT04327453|Device|double antibiotic paste with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of double antibiotic paste
75559328|NCT04327453|Device|double antibiotic paste with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in removal of double antibiotic paste
75715855|NCT00900549|Device|CRT off|12-month
75715856|NCT00904449|Drug|Oxymorphone ER|10mg, 20mg, and 40mg PO
75715857|NCT00904527|Behavioral|relaxation (Schultz)|Patients have relaxation consultations during 2 months
75715858|NCT00348595|Drug|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
75715859|NCT02538939|Drug|Sodium thiosulfate|
75559329|NCT04327453|Device|double antibiotic paste with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of double antibiotic paste
75559330|NCT04330105|Device|ECG, HolterECG ,Echocardiography|ECG, HolterECG ,Echocardiography to determine any type of arrythmia,ischaemic heart disease,valvular heart disease,systolic and diastolic dysfunction
75559331|NCT00467948|Drug|cefazolin|
75559332|NCT01245504|Other|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
75559333|NCT00592579|Drug|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
75414695|NCT01390597|Genetic|cytogenetic analysis|
75414696|NCT01390597|Genetic|gene mapping|
75414697|NCT01390597|Genetic|mutation analysis|
75414698|NCT01390597|Genetic|polymerase chain reaction|
75414699|NCT01390597|Other|laboratory biomarker analysis|
75414700|NCT01390623|Drug|Ceftriaxone|"Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.~The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria."
75559334|NCT04327414|Behavioral|Intervention group|Standing desks
75715860|NCT00904605|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
75715861|NCT00904605|Drug|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
75715862|NCT00904761|Other|exercise training|The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
75715863|NCT00337129|Drug|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
75414701|NCT01390662|Dietary Supplement|Vitamin D3|one tablet of vitamin D3 70 µg pr. day, for 24 weeks.
75414702|NCT01390662|Dietary Supplement|placebo|one tablet of sugar pill pr. day, for 24 weeks.
75414703|NCT01390701|Device|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
75414704|NCT01390701|Drug|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
75414705|NCT01390714|Drug|E3710|"Arm A:~E3710 40 mg→RPZ 10 mg→E3710 20 mg~RPZ 10 mg→E3710 20 mg→E3710 40 mg~E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration."
75414706|NCT01390714|Drug|E3710|"Arm B:~E3710 40 mg→E3710 80 mg→EPZ 40 mg~E3710 80 mg→EPZ 40 mg →E3710 40 mg~EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration."
75559335|NCT00592618|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
75559336|NCT00465374|Procedure|Change ventilatory parameters with stress index monitoring|
75559337|NCT01243710|Device|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
75559338|NCT00622843|Biological|pneumococcal conjugate vaccine|"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."
75715864|NCT00905073|Drug|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
75715865|NCT02538705|Drug|Neovasculgen|
75715866|NCT00905229|Drug|Phytonadione|2.5 mg po
75715867|NCT00905229|Drug|Phytonadione|0.5 mg IV
75715868|NCT01052935|Biological|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
75414707|NCT01390727|Device|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
75559339|NCT00622843|Biological|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
75559340|NCT03271736|Behavioral|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
75559341|NCT03271736|Device|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
75715869|NCT00605085|Biological|Japanese Encephalitis purified inactivated vaccine (IC51)|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
75559342|NCT00592735|Procedure|laparoscopic gastric banding|standard surgical procedure
75715870|NCT00605085|Biological|Placebo|Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
75715871|NCT00905463|Procedure|Lung transplantation|Lung transplantation
75414708|NCT01390727|Other|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
75414709|NCT01390753|Dietary Supplement|Human donor milk|
75715872|NCT00905541|Drug|simvastatin|40 mg/day
75414710|NCT01390766|Drug|Azathioprine|
75414711|NCT01390792|Drug|Zanamivir hydrate|
75715873|NCT00905541|Drug|simvastatin|80 mg simvastatin acute-on-chronic
75414712|NCT01390805|Drug|Valaciclovir Hydrochloride.|
75715874|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
75873110|NCT05193474|Behavioral|integrated palliative care|shared decision making with patient, and timely integrated palliative care according to patient's preference
75873111|NCT04793841|Other|self-sampling kits for STI testing in laboratory|participants in both groups will receive self-sampling kits and deliver the collected samples to laboratory for testing
75873112|NCT02985138|Procedure|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
75414713|NCT01390831|Device|THERMOCOOL® Catheter|Catheter-based renal denervation
75414714|NCT01390883|Drug|Fondaparinux Sodium|
75414715|NCT01390896|Drug|Fondaparinux Sodium|
75414716|NCT01390922|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
75715875|NCT00348283|Biological|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
75715876|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
75715877|NCT00905697|Procedure|Living donor lung transplantation|Living donor lung transplantation
75715878|NCT01055899|Biological|REGN88|Single SC Dose
75559343|NCT00592813|Behavioral|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
75715879|NCT01055899|Biological|REGN88|Single SC Dose
75715880|NCT01055899|Biological|REGN88|Single SC Dose
75873113|NCT02985138|Procedure|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
75414717|NCT01390935|Other|guideline adherence|guideline adherence of physician
75873114|NCT02985138|Device|Pedicle screw and cage|Pedicle screw and cage
76042137|NCT02841163|Procedure|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
75414718|NCT01390961|Drug|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
75559344|NCT00592813|Behavioral|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
75559345|NCT01245543|Drug|AC480IV|AC480IV will be administered as an infusion using a dose escalation design.
75559346|NCT01245543|Drug|Docetaxel|Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
75559347|NCT00592891|Drug|Hyperbaric oxygen therapy|Total body pressurized oxygen
75559348|NCT00592930|Drug|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
75559349|NCT00592930|Drug|placebo|
75559350|NCT00468026|Device|ProstaPlant Stent|
75414719|NCT01391039|Drug|Perflutren lipid microsphere|Intravenous injection of 10 microL/kg once prior to ultrasound examination
75414720|NCT01391052|Drug|Norethindrone acetate pretreatment|5 mg tablets, three times a day for 21 days for 2 menstrual cycles.
75414721|NCT01391052|Other|No pretreatment|LVN IUS is placed withour Norethindrone acetate pretreatment.
75414722|NCT01391065|Radiation|MR PET Guided Brachytherapy|
75414723|NCT01391078|Device|Sensimed Triggerfish Sensor|IOP will be monitored for 24 hours
75414724|NCT01391078|Device|Goldmann Applanation Tonometry, Perkins Tonometry|IOP will be measured every two hours within 24 hours
75414725|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
75414726|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
75414727|NCT01391104|Drug|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
75414728|NCT01391104|Drug|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
75414729|NCT01391117|Drug|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
75414730|NCT01391117|Drug|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
75414731|NCT01391117|Drug|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
75414732|NCT01391117|Drug|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
75414733|NCT01391117|Drug|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
75414734|NCT01391117|Drug|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
75559351|NCT00592969|Drug|metformin|
75559352|NCT00592969|Drug|biphasic insulin aspart|
75559353|NCT01245582|Drug|oxaliplatin (SR96669)|"Pharmaceutical form:injection~Route of administration: intravenous"
75559354|NCT01245582|Drug|capecitabine|"Pharmaceutical form:tablet~Route of administration: oral"
75559355|NCT01245582|Drug|sorafenib|"Pharmaceutical form:tablet~Route of administration: oral"
75559356|NCT00593008|Drug|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
75559357|NCT00593008|Drug|Gemcitabine|Given intravenously every other week of each 28-day cycle.
75559358|NCT00593047|Drug|KB2115|tablet formulation given once daily for 12 weeks
75559359|NCT00465413|Device|Small volume spacer and/or Rinsing the mouth with water|
75559360|NCT00593086|Procedure|Pain management|Pain mamagement for burn care procedures.
75559361|NCT00593086|Other|Standard of care/no virtual reality game|no intervention for standard of care
75559362|NCT02956200|Drug|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
75559363|NCT00593125|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
75559364|NCT00593164|Device|Cooling with ThermoSuit with Magnesium Sulfate Infusion|Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
75414735|NCT01391117|Drug|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
75414736|NCT01391117|Drug|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
75414737|NCT01391117|Drug|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
75414738|NCT01391117|Drug|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
75414739|NCT01391156|Drug|3%Minoxidil lotion|3% Minoxidil lotion apply two times a day
75414740|NCT01391156|Drug|3% Minoxidil with 0.1% Finasteride lotion|3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
75414741|NCT01391169|Other|seromuscular flap enforcement|seromuscular flap enforcement
75414742|NCT01391182|Other|EACA|EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
75715881|NCT00336895|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
75559365|NCT00593164|Device|Cooling with ThermoSuit with Normal Saline Infusion|Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
75559366|NCT01316107|Drug|ipragliflozin|oral
75559367|NCT01316107|Drug|nateglinide|oral
75559368|NCT00492453|Procedure|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
75559369|NCT01316185|Drug|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
75559370|NCT05654194|Drug|Azacitidine Combined With Venetoclax and ATRA group|AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
75559371|NCT05654155|Other|auricular acupressure|Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
75559372|NCT00468065|Device|VeinViewer|Veinveiwer is used to view veins subQ
75559373|NCT00468065|Device|Veinviewer|near infrared light reveals veins subcutaneously
75559374|NCT00492492|Procedure|trans-styloid and intrafocal pinning on the one side|
75559375|NCT00492492|Procedure|volar fixed-angle plating on the other side|
75559376|NCT05653453|Device|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields until disease progression or for a maximum of 30 months.~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months."
75559377|NCT05653453|Drug|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months.
75559378|NCT00468182|Drug|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
75559379|NCT05653375|Other|Mindfulness-based psychoeducation program|In this study, a mindfulness-based psychoeducation program was applied to the experimental group, 2 times a week for 4 weeks, with a total of 8 sessions, including methods such as meditation, body scanning, mindful eating, and breathing work. Measurement tools were applied to the experimental and control groups before and after the program.
75559380|NCT05653375|Other|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
75559381|NCT05653297|Device|Vacuum-Assisted Closure|NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
75559382|NCT05649163|Drug|Disitamab Vedotin|Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
75559383|NCT00499395|Procedure|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
75559384|NCT00499395|Procedure|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
75559385|NCT00465452|Drug|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
75414743|NCT01391182|Other|Placebo arm|Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
75414744|NCT01391195|Device|Phototherapy by low level laser therapy|Phototherapy by low level laser therapy during 9 weeks
75414745|NCT01391208|Drug|GI heptapeptide|GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Chemical Formula: Ala1-Ser2-Tyr3-Asn4-Tyr5-Asp6-Ala7-Gly8- Gly9-Gly10-Ser11-Lys12 (5-FITC) -NH213.Investigational Agent Manufacturer: CPC Scientific, 1245 Reamwood Ave, Sunnyvale, CA 94089 Investigational Agent information: Lot Number: 10031701, M.W. 1577.6, 97.2% pure. Stored at -20C Yellow, lyophilized powder in single use amber vials. 5-FITC is light-sensitive, therefore stored protected from light. Manufactured under cGMP with Certificate of Analysis (COA) provided.
75559386|NCT05652010|Device|Iris - new coupling|"SenSura Mio Click maxi bag (open, wide outlet), 50mm Ø with new coupling and lock ring~Baseplate flat: SenSura Mio, click base plate with belt ears, 50 mm, 10-45 mm with improved weld-ing bead~Baseplate Concave: Item 18510 SenSura Mio Concave, click base plate with ears size Ø50, 10-45 mm"
75559387|NCT05652010|Device|Sensura Mio Click|"SenSura Mio Click 2p bag, item #11472. Open, wide outlet, maxi, neutral grey. 50mm with inspection window and circle filter 430~Baseplate flat: Item #10512 SenSura Mio Click Base Plate with belt ears, 50 mm, 10-45 mm~Baseplate concave: Item #18510 SenSura Mio Concave, click base plate with ears size Ø50, 10-45 mm"
75559388|NCT05650684|Other|data collection|continuation of exclusive breastfeeding until the post-natal visit (6 to 8 weeks after birth)
75559389|NCT00465491|Drug|picoplatin|IV picoplatin 150mg/m2 q3wk
75559390|NCT00465491|Other|best supportive care|best supportive care
75414746|NCT01391221|Drug|Duloxetine|Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
75414747|NCT01391260|Other|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
75715882|NCT01059019|Dietary Supplement|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
75715883|NCT00336583|Drug|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
76042138|NCT02841163|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
75414748|NCT01391338|Drug|ASP3652|Oral
75414749|NCT01391338|Drug|Placebo|Oral
75414750|NCT01391351|Other|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy :~On Day 1 of the first course of chemotherapy~On Day 1 of the second course of chemotherapy~Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~At the end of chemotherapy"
75414751|NCT01391351|Other|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:~On Day 1 of the first course of chemotherapy~On Day 1 of the second course of chemotherapy~Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~At the end of chemotherapy"
75414752|NCT01391377|Drug|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
75414753|NCT01391377|Drug|Sugar pill|Placebo
75414754|NCT01391390|Drug|Melatonin|10mg/day, 12-week treatment
75414755|NCT01391390|Drug|Placebo|10mg/day, 12-week treatment for TD
75414756|NCT01391403|Drug|Artemisinin|400 mg/day
75559391|NCT00499512|Behavioral|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
75559392|NCT00468221|Drug|Ozone Exposure|Low dose ozone exposure in chamber
75559393|NCT01379521|Drug|everolimus|
75559394|NCT01379521|Drug|everolimus placebo|
75559395|NCT00499551|Device|Iontophoresis second generation Eyegate II device|
75559396|NCT00468260|Drug|Patupilone|
75559397|NCT01371994|Drug|solifenacin succinate|oral
75559398|NCT01371994|Drug|Placebo|oral
75715884|NCT00336505|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
75715885|NCT00336505|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
75414757|NCT01391403|Other|Placebo|400mg/day
75414758|NCT01391429|Behavioral|Video Decision Support Tool|Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
75414759|NCT01391442|Biological|blood and urine samples|58 ml of blood 120 ml of urine
75414760|NCT01391442|Genetic|blood sample|11 ml of blood
75414761|NCT01391442|Other|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
75559399|NCT00465608|Drug|propranolol|propranolol by mouth (per os)
75559400|NCT01245777|Drug|ferric carboxymaltose|20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
75559401|NCT00468338|Device|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
75559402|NCT01371877|Drug|High Dose Vitamin D3|Vitamin D 4000 IU per day for 3 months
75559403|NCT01371877|Drug|Low Dose Vitamin D3|Vitamin D 600 IU per day
75559404|NCT00468416|Device|Compression Anastomosis Ring (CAR)|
75559405|NCT01245816|Drug|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
75559406|NCT01245816|Drug|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
75559407|NCT01245816|Drug|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
75559408|NCT00468455|Procedure|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
75559409|NCT00492687|Drug|carboplatin|
75559410|NCT00492687|Drug|tamoxifen citrate|
75559411|NCT00492687|Drug|temozolomide|
75559412|NCT00492687|Procedure|adjuvant therapy|
75559413|NCT00492687|Radiation|radiation therapy|
75559414|NCT01371838|Drug|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
75559415|NCT01371838|Drug|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
75559416|NCT01245855|Drug|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
75559417|NCT00473603|Drug|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
75559418|NCT00492765|Drug|Interferon-beta-1a|dosage and frequency as per label
75559419|NCT00492765|Drug|Simvastatin|dosage and frequency as per Biogen Idec protocol
75559420|NCT00492765|Drug|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
75559421|NCT00468533|Drug|Aripiprazole|
75715886|NCT00357877|Drug|10% w/v chlorhexidine acetate coating FDA IND #45466|Dental coating topically applied by dental professional supragingivally to the full dentition
75715887|NCT00357877|Other|Placebo|
75715888|NCT03990337|Device|Ultrasound|Ultrasonography of cricoid cartilage.
75414762|NCT01391442|Other|Stanislas ancillary study : MRI examination with GRICS technique|
75414763|NCT01391455|Procedure|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
75414764|NCT01391481|Drug|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
75414765|NCT01391481|Drug|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
75414766|NCT01389934|Drug|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
75414767|NCT01389934|Drug|Placebo|Women of this group be infused saline 2 ml / h for 48h.
75414768|NCT01391494|Biological|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
75559422|NCT00473681|Behavioral|Self-Help Intervention Program-High Blood Pressure|
75559423|NCT00499629|Drug|FXR 450|capsule, single oral doses from 10 mg to 450 mg
75559424|NCT00499629|Drug|placebo|capsule similar to active drug
75559425|NCT01371721|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
75559426|NCT00473720|Drug|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
75559427|NCT00473720|Drug|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
75559428|NCT00492804|Procedure|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
75559429|NCT00492804|Procedure|Neurectomy|Neurectomy
75559430|NCT01605448|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
75559431|NCT00468572|Behavioral|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
75715889|NCT03987529|Other|sevoflurane|volatile anesthetic
75715890|NCT03987529|Other|propofol|intravenous anesthetic
75559432|NCT00468572|Behavioral|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
75414769|NCT01391494|Biological|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
75414770|NCT01391494|Biological|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
75414771|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
76042139|NCT02841163|Procedure|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
75414772|NCT01391494|Biological|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
75414773|NCT01391494|Biological|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
75414774|NCT01391494|Biological|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
75414775|NCT01391494|Biological|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
75559433|NCT00499668|Drug|aprepitant|125 mg orally for 7 days
75559434|NCT00499668|Drug|ondansetron hydrochloride|24 mg orally for 7 days
75559435|NCT00499707|Drug|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
76042140|NCT05388175|Device|Rigid catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
76042141|NCT05388175|Device|Soft catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
75559436|NCT00468611|Drug|MBP8298|500mg MBP8298 IV every six months for a period of two years
76042142|NCT05700955|Drug|Pembrolizumab and Temozolomide|Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
76042143|NCT01650519|Drug|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
75414776|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
75414777|NCT01391494|Biological|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
75414778|NCT01391494|Biological|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
75414779|NCT01391494|Biological|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
75414780|NCT01391494|Biological|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
75414781|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
75414782|NCT01391494|Biological|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
75559437|NCT03270995|Behavioral|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
75559438|NCT03270995|Behavioral|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
75559439|NCT01366534|Biological|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
75559440|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
75559441|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
75559442|NCT01366534|Other|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
75559443|NCT00492843|Drug|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
75414783|NCT01391520|Drug|deferiprone|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
75559444|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
75559445|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
75559446|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
75715891|NCT03990259|Other|Running the CSP Mountain Race|The runners completed a 107,6 km mountain race
76042144|NCT01650519|Drug|IV ketorolac|30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) administered intravenously over no less than 15 seconds
75414784|NCT01391520|Drug|Placebo|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
75414785|NCT01391533|Drug|SAR125844|"Pharmaceutical form:solution~Route of administration: intravenous"
75414786|NCT01391572|Radiation|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
75559447|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
75715892|NCT00335959|Drug|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
75715893|NCT00335959|Drug|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
76042145|NCT01650285|Drug|Cabazitaxel|"Dose Level Day 1, 22, 43~5.0 mg/m2~10.0 mg/m2~15.0 mg/m2~20.0 mg/m2"
76042146|NCT05612503|Other|Traditional physical therapy program|resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.
75414787|NCT01391572|Radiation|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
75414788|NCT01391572|Drug|cisplatin|
75414789|NCT01391572|Drug|fluorouracil|
75414790|NCT01391585|Other|Text Message prompts|In this single armed intervention, patients will receive text message prompts
75559448|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
75559449|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
75559450|NCT03271775|Other|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
75715894|NCT00335959|Procedure|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
75715895|NCT00335959|Radiation|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
75715896|NCT01056133|Other|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
76042147|NCT05612503|Other|Virtual reality-based exercises|Virtual reality exercise using Nintendo Wii systems. As game interfaces, the Nintendo Wii systems employ haptic sensor-based controllers and a balance board.
76042148|NCT02347527|Behavioral|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
76042149|NCT02347527|Behavioral|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
75715897|NCT01059097|Procedure|Pancreaticoduodenectomy|
75414791|NCT01391598|Drug|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
75559451|NCT03271775|Other|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
75559452|NCT00499824|Behavioral|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
75559453|NCT01365910|Drug|linifanib|Given PO
75559454|NCT00473798|Behavioral|Questionnaire|Questionnaire
75559455|NCT01605526|Drug|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
75559456|NCT01605526|Drug|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
75559457|NCT00492882|Drug|usual administration of exogenous recombinant FSH|
75559458|NCT00468689|Drug|SB-751689 oral tablets (100 and 400 ng)|
75559459|NCT00468689|Drug|Ketoconazole (NIZORAL) oral tablets (200 mg)|
75559460|NCT02274480|Device|cardiac MRI with DWI|
76042150|NCT02197039|Drug|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
75414792|NCT01391598|Drug|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
75559461|NCT00473915|Drug|fluticasone furoate|corticosteroid nasal spray
75559462|NCT00499902|Drug|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
75559463|NCT00473954|Genetic|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
75559464|NCT00468767|Drug|Vernakalant Injection 20 mg/mL|
75559465|NCT00493077|Drug|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
75559466|NCT00474071|Drug|Remifentanil|See Detailed Description.
75559467|NCT00468884|Drug|Increasing doses of GLP-1|
75559468|NCT00468884|Drug|PYY3-36|
75559469|NCT00474110|Drug|Ketamine & hydromorphone|See Detailed Description
75559470|NCT00500058|Drug|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
75559471|NCT00500058|Drug|Rituximab|Rituximab 375 mg/m^2 will be administered by IV infusion.
75559472|NCT00468923|Drug|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
75559473|NCT00468923|Drug|Rosuvastatin|Rosuvastatin 10 mg once daily
75559474|NCT00500097|Device|Digital retina image|
75559475|NCT00500097|Device|direct ophthalmoscopy|
75559476|NCT00500097|Procedure|comprehensive eye exam|
75559477|NCT01365481|Drug|Valsartan|week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
75559478|NCT01365481|Drug|amlodipine|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
76042151|NCT02197039|Procedure|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
76042152|NCT02028559|Device|Propulse 1|Move kidney stones with Propulse 1 device.
76042153|NCT05557903|Biological|Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection|Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
76042154|NCT04335097|Device|Biosensors|Sensor that detect vital signs
75414793|NCT01391624|Drug|Flaxseed oil|3 g (3 capsules/day) of flax oil for a period of 8 weeks
75559479|NCT01365481|Drug|Hydrochlorothiazide|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
75414794|NCT01391624|Drug|Paraffin + # 2 dye|3 capsules of mineral oil (ineffective) for 8 weeks.
75559480|NCT03271619|Other|Surface current measurement|Measurement of surface current between electrodes placed on the chest wall during defibrillation
76042155|NCT02386839|Drug|rhIGF-1/rhIGFBP-3|"Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study."
76042156|NCT01718041|Drug|Experimental: VRS-317|Active treatment arm
76042157|NCT05557669|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is a procedure of removal of the gallbladder and a gold standard in treatment of gallstone disease.
76042158|NCT05347459|Drug|Dapagliflozin|usual and customary doses for type 2 diabetes management
76042159|NCT05347459|Drug|Empagliflozin|usual and customary doses for type 2 diabetes management
76042160|NCT05347459|Drug|Canagliflozin|usual and customary doses for type 2 diabetes management
75559481|NCT01605604|Behavioral|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
76042161|NCT05347459|Drug|Sitagliptin|usual and customary doses for type 2 diabetes management
76042162|NCT05347459|Drug|Saxagliptin|usual and customary doses for type 2 diabetes management
76042163|NCT05347459|Drug|Linagliptin|usual and customary doses for type 2 diabetes management
76042164|NCT05347459|Drug|Vildagliptin|usual and customary doses for type 2 diabetes management
76042165|NCT05346445|Drug|Fluoxetine 20 MG|Participants received non-hormonal treatment with fluoxetine.
76042166|NCT05346445|Drug|Citalopram 20mg|Participants received non-hormonal treatment with citalopram.
76042167|NCT05334121|Dietary Supplement|Beta-alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
76042168|NCT05334121|Other|Control product consumption|Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
76042169|NCT05612269|Diagnostic Test|interleukin 6|follow up of type 2 diabetes with SGLT2 inhibitors like empagliflozin, canagliflozin, and dapagliflozin for measurement of inflammatory factors like interleukin-6, CRP
76042170|NCT05557201|Biological|Lymphocyte immunophenotyping|If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
76042171|NCT05557123|Device|MEDI-app|MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
75559482|NCT00493116|Drug|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
76042172|NCT05557123|Device|conventional treatment|conventional treatment with rivoxaban
75414795|NCT01391637|Biological|HuCNS-SC transplant in the lead-in phase|Long-term safety follow-up study
75414796|NCT01391650|Procedure|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
75414797|NCT01391676|Procedure|trabeculectomy|postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
75414798|NCT01391689|Dietary Supplement|diindolylmethane|Given PO
76042173|NCT01649271|Drug|Herceptin|3-weekly
76042174|NCT01649271|Drug|afatinib|at MTD level
75414799|NCT01391689|Dietary Supplement|placebo|Given PO
75414800|NCT01391715|Drug|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
75414801|NCT01391715|Drug|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
75414802|NCT01391728|Behavioral|Active Lifestyle all your Life|"Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves."
75414803|NCT01391741|Other|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
75414804|NCT01391741|Other|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
75414805|NCT01391754|Behavioral|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
75414806|NCT01391754|Other|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
75414807|NCT01391754|Behavioral|Services As Usual|Home based services not using the SafeCare model
75414808|NCT01391754|Other|Uncoached|No in vivo coached quality control or fidelity monitoring
75414809|NCT01391767|Device|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
75414810|NCT01391845|Drug|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
75715898|NCT01053091|Behavioral|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
75715899|NCT03987061|Device|MOTIV BVS|MOTIVS BVS in below-the-knee artery disease
75414811|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
75414812|NCT01391845|Drug|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
75414813|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
75414814|NCT01391871|Device|OCT|Optical coherence tomography
75414815|NCT01391871|Device|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
75414816|NCT01391897|Behavioral|psychotherapy|"multimodal complex psychotherapy"
75715900|NCT01053169|Biological|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
75715901|NCT01053169|Biological|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
75715902|NCT01053169|Other|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
75715903|NCT01059253|Other|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
75715904|NCT01059331|Drug|Pregabalin|150 mg x 2 daily for 2 days
75715905|NCT01059331|Drug|Sugar pill|1 tablet x 2 daily, for 2 days
75715906|NCT03985345|Device|intravaginal device (probe) EMY|Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
76042175|NCT01649271|Drug|trastuzumab|3-weekly
75414817|NCT01391923|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
75414818|NCT01391936|Procedure|Tension Band Wiring|AO technique of TBW for fixation of fracture.
75414819|NCT01391936|Procedure|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
75414820|NCT01391975|Procedure|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
75715907|NCT01059409|Procedure|Meniscal Allograft|Meniscal Allograft
75715908|NCT01059487|Other|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
76042176|NCT01649271|Drug|Herceptin|weekly
76042177|NCT01649271|Drug|afatinib|at MTD level
76042178|NCT01649271|Drug|afatinib|escalating dose
75559483|NCT00493116|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
75559484|NCT00468962|Drug|FACOS (functional food)|
75559485|NCT01605682|Dietary Supplement|Fresh berry extract.|Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
75715909|NCT01059721|Procedure|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
76042179|NCT05700877|Other|CAC-based treatment strategy|The intervention is a combination of screening with a heart CT scan and multifactorial intervention based on the screening results. Participants randomized to CAC-based treatment and with screening results showing high risk of CVD, will receive a multifactorial intervention including the combination of two open label investigational medical products: dapagliflozin 10mg/day and semaglutide 0.25 /week or 0.5 /week or 1.0 /week.
76042180|NCT05700877|Other|Standard treatment|Participants randomized to standard treatment are recommended to follow updated guidelines for CVD prevention.
75414821|NCT01392014|Drug|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
75414822|NCT01392014|Drug|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
75414823|NCT01392027|Procedure|Blood Draw|Blood draw for research specimens only
75559486|NCT00493155|Drug|RG1530|Administered po at escalating doses (10 cohorts)
75559487|NCT01357915|Procedure|Blood sampling|"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
75559488|NCT01357915|Biological|GSK149203A|GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
75559489|NCT00474227|Behavioral|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
75559490|NCT00493194|Drug|sirolimus|
75559491|NCT00493194|Drug|cyclosporine|
75715910|NCT03985111|Device|Central Venous Catheter|Insertion of a central venous catheter insertion pre-operatively (electively)
75715911|NCT03742063|Drug|first-line chemotherapy|patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
76042181|NCT05558917|Procedure|PECS BLOCK 2|With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.
76042182|NCT05558917|Procedure|ESP BLOCK|Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.
76042183|NCT05558839|Behavioral|A 12-week weekly sports and cognitive training intervention.|A 12-week weekly sports and cognitive training intervention was provided to the participants. The training, 2 hours each week, involved 1 hour of sports training and 1 hour of cognitive training.
75559492|NCT00493194|Drug|daclizumab|
75559493|NCT01350973|Drug|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
75559494|NCT01350973|Drug|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
75715912|NCT03741985|Behavioral|The handgrip exercise|The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
76042184|NCT04334239|Other|Oncological certification|Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.
75559495|NCT00500136|Procedure|mortality salience|
76042185|NCT02385669|Drug|Ipilimumab|Checkpoint blockade inhibitor
75559496|NCT03270722|Device|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
75715913|NCT03741985|Behavioral|The dumbbell exercise|The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
75559497|NCT03270722|Procedure|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
75559498|NCT01350544|Behavioral|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
75559499|NCT01350505|Behavioral|White light exposure|~200 lux of broad spectrum white light
75559500|NCT01350505|Behavioral|Dim white light exposure|~28 lux of broad spectrum white light
75559501|NCT01350505|Behavioral|Very dim white light exposure|<0.5 lux of broad spectrum white light
75559502|NCT01350505|Behavioral|Dim orange light exposure|~28 lux of orange light
75559503|NCT00500175|Device|TempTouchRM|
75559504|NCT00500175|Device|Offloading|
75559505|NCT00469001|Procedure|Treatment according NT Pro BNP level|
75559506|NCT01605721|Device|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"
76042186|NCT02385669|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
75414824|NCT01392066|Behavioral|questionnaire|"Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up."
75414825|NCT01392079|Drug|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
75559507|NCT01605760|Drug|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
75715914|NCT01059955|Drug|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
76042187|NCT05255965|Diagnostic Test|level of IL-8+ initial T cells|5ml peripheral venous blood was taken before surgery or biopsy, and the levels of initial T cell with IL-8+, PLXND1+, PTK7+ or CR2+ were detected and recorded within 6 hours, respectively.
76042188|NCT05558683|Other|Randomized clinical trial.|Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.
75414826|NCT01392105|Drug|Mesenchymal stem cell|Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention
75414827|NCT01392105|Drug|Control group|No additional treatment of mesenchymal stem cells
75414828|NCT01392131|Dietary Supplement|Oncoxin|20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
75414829|NCT01392131|Other|Supportive treatment|patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
76042189|NCT02402907|Device|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
76042190|NCT02402907|Device|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
75559508|NCT00469040|Drug|GW642444M for 14 days|M salt
75414830|NCT01392144|Procedure|Nitric oxide breath test|Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
75414831|NCT01392144|Behavioral|Questionnaires|On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
75559509|NCT01350271|Drug|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
75559510|NCT01350271|Drug|Mebendazole polymorph C|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
75414832|NCT01392157|Device|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
75414833|NCT01392157|Device|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
75414834|NCT01392157|Device|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
75414835|NCT01392157|Device|LNG-IUS|100 women will receive an LNG-IUS
75559511|NCT01350271|Drug|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
75559512|NCT00469118|Device|DRX9000™|Nonsurgical spinal decompression
75559513|NCT00474305|Behavioral|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
75559514|NCT00493233|Drug|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."
75559515|NCT00493233|Drug|main antipsychotic medication and placebo|"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."
75559516|NCT00469157|Drug|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
75559517|NCT00500214|Procedure|elective ilioinguinal nerve excision|
75559518|NCT03270410|Other|Data collection|"After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.~At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care."
75559519|NCT00493272|Drug|Fibrinogen|Fibrinogen behandling
75559520|NCT00500253|Device|exhaled nitric oxide measurement|exhaled nitric oxide measurement
75559521|NCT00500253|Procedure|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
75559522|NCT00500253|Procedure|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
75559523|NCT00469196|Procedure|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
75559524|NCT03270566|Device|Domestic ion-exchange water softener|Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
75559525|NCT00469235|Drug|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
75559526|NCT01243788|Drug|Salmeterol/Fluticasone Propionate|Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
75559527|NCT03270605|Procedure|Myomectomy|Surgical removal of uterine fibroid
75559528|NCT01243827|Drug|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
75559529|NCT01243827|Drug|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
75559530|NCT00500409|Drug|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
75559531|NCT00500409|Drug|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
75559532|NCT00469352|Drug|Ranibizumab|Ranibizumab as needed
75559533|NCT01243866|Other|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
75559534|NCT01243866|Other|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
75559535|NCT00469430|Drug|cefotaxim and metronidazol|iv administration for at least 24 h
75559536|NCT00500487|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
75559537|NCT00500487|Behavioral|HIV Prevention Skills|12-session group intervention including sexual health skills training.
75559538|NCT00500487|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of health topics.
75559539|NCT00474422|Behavioral|Proactive assignment to attend a breastfeeding clinic|
75559540|NCT01243905|Other|Family psychoeducational therapy plus TAU|Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians
75559541|NCT01243905|Other|Treatment as usual|Treatment as usual administered by physicians
75559542|NCT00474461|Biological|Treatment group|Intracoronary injection of cardiac stem cells
75559543|NCT00500526|Other|Singing practice|
75559544|NCT00500526|Other|Singing classes|
76042191|NCT05254093|Other|Quadratus lumborum block|quadratus lumborum block, anterior approach using a curvilinear (5-8MHz) transducer. The transducer will be positioned transverse above the iliac crest at the posterior axillary line and slided posteriorly till the Shamrock sign is identified (the transvers process represent the stem and the attached erector spinae, QL and Psoas major muscles represent the three leaves). A 22 G, 100 mm needle will be advanced in-plane from lateral to medial through the QL muscle to reach the inter-fascial plane between the QL and psoas major muscles, posterior to the transversalis fascia. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected anterior to the QL muscle. The procedure will be repeated on the opposite side of the back
75873115|NCT05139849|Drug|Vasopressin; Methylprednisolone; Hydrocortisone|"Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow.~Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury."
75559545|NCT00500526|Other|Hand craft classes|
75559546|NCT03270488|Other|Laser|Laser (power of 3.0w).
75559547|NCT03270488|Other|Placebo|Laser (power 0,0w)
75559548|NCT00493350|Procedure|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
75559549|NCT00469469|Drug|Bevacizumab|
75873116|NCT05139849|Drug|Sodium chloride|Sodium chloride 9 mg/ml
75873117|NCT02905032|Behavioral|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
75873118|NCT05504187|Drug|KP104|KP104 will be administered.
75559550|NCT00500565|Drug|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
75559551|NCT00500565|Drug|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
75559552|NCT03270293|Device|Profhilo|
75559553|NCT01243983|Drug|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"
75559554|NCT00469547|Other|62% ethanol in emollient gel|62% ethanol in emollient gel used as a topical male microbicide
75559555|NCT00469547|Drug|Placebo|15% ethanol in emollient gel used as a topical male microbicide
75559556|NCT00469547|Other|15% ethanol in emollient gel|15% ethanol in emollient gel used as a topical male microbicide
75559557|NCT00500604|Drug|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
75559558|NCT00500604|Drug|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
75559559|NCT00500604|Drug|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
75559560|NCT03270215|Procedure|Computed tomography|The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
75559561|NCT01348828|Device|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
75559562|NCT00493389|Drug|Adrenocorticotrophic hormone|
75559563|NCT03270254|Device|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
75559564|NCT01348789|Device|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
75559565|NCT01605994|Drug|BMS-933043|
75559566|NCT01605994|Drug|Placebo matching with BMS-933043|
75559567|NCT01605994|Drug|Antacid Buffer Predose Solution|
75559568|NCT01606033|Other|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
75559569|NCT01606033|Other|questionnaire|understanding of the implications of participating in a clinical trial
75559570|NCT00500721|Drug|HCV-796|HCV-796 500mg BID x 14 days
75873119|NCT05191368|Other|No intervention|No intervention
75873120|NCT02799186|Procedure|blood sample for genetic analysis|
75873121|NCT02767518|Behavioral|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
75559571|NCT00500721|Drug|Desipramine|"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."
75559572|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
75559573|NCT00469586|Drug|metformin|Tablets, 2000 mg/day.
75873122|NCT03351075|Other|Standard physical therapy program|"Mobilisations, stretching, scar tissue treatment and exercises~Start immediately after surgery, sessions are individual and take 30 minutes~Intensive phase (4 months): 1-2x/week~Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery"
75873123|NCT03351075|Other|Modern educational program|"This modern neuroscience educational approach is suited to explain more complex issues associated with pain such as the involvement of peripheral and central mechanisms, neuroplasticity and pain behaviour.~Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
76042192|NCT05254093|Other|erector spinae plane block|the block will be given at the level of the 9th thoracic transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T9) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected below the muscle. The procedure will be repeated on the opposite side of the back
76042193|NCT02345889|Device|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
76042194|NCT02345889|Device|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
76042195|NCT02345889|Device|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
76042196|NCT02345889|Device|Standard Colonoscopy|Current standard of care colonoscopy
76042197|NCT05556421|Diagnostic Test|uterocervical angle|uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
76042198|NCT04328623|Procedure|Hypnosis|"conversational hypnosis technique call the magic glove"
76042199|NCT04328623|Procedure|Infiltration|Ultrasound-guided hand infiltration
75414836|NCT01392209|Other|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
75559574|NCT00469586|Drug|glimepiride|Tablets, 4 mg/day.
75559575|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
75559576|NCT01606111|Drug|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
75559577|NCT01606111|Drug|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
75873124|NCT03351075|Other|Traditional biomedical educational program|"Traditional educational interventions are applied according to the biomedical model. This means that the patient's pain experience is explained from a tissue (injured versus healthy tissue) and biomechanics perspective~Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
75873125|NCT05312229|Behavioral|Critical Time Intervention|An evidence-based, structured, and time-limited case management practice
76042200|NCT02345811|Device|Sapphire|silicone-hydrogel contact lens
75559578|NCT01606267|Other|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
76042201|NCT02345811|Device|senofilcon A|contact lens
75559579|NCT00493428|Drug|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
75559580|NCT01342510|Drug|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
75559581|NCT01342510|Drug|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
75559582|NCT01342510|Drug|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
75715915|NCT01059955|Drug|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
75715916|NCT01060033|Device|MR Spectroscopy|
75873126|NCT05312229|Other|External Facilitation|Site-specific support to help sites develop tailored plans to implement CTI.
75873127|NCT05312229|Other|Replicating Effective Programs|A stakeholder-informed training and technical assistance implementation strategy
76042202|NCT05549869|Diagnostic Test|serum leptin|Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators
76042203|NCT05556109|Diagnostic Test|Inflammatory serum biomarkers|Measuring inflammatory serum biomarkers by ELISA
76042204|NCT02586493|Drug|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
75414837|NCT01392222|Behavioral|Focus groups|"The focus groups will cover the following issues~Perceptions of thyroid cancer and disease status~Sources of information used in papillary microcarcinoma treatment decision-making~Treatment decision-making processes and influential factors~Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~Views about how to improve acceptability of active surveillance as a disease management option"
76042205|NCT02586493|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
76042206|NCT05543395|Behavioral|Domestic Violence Questionnaire|Domestic Violence Questionnaire
76042207|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
76042208|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
75414838|NCT01392222|Behavioral|Focus groups|"The focus groups will cover the following issues:~Perceptions of thyroid cancer and disease status~Sources of information used in papillary microcarcinoma treatment decision-making~Treatment decision-making processes and influential factors~Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~Views about how to improve acceptability of active surveillance as a disease management option"
75414839|NCT01392235|Drug|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
75559583|NCT01342510|Drug|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
75559584|NCT01606345|Drug|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
75559585|NCT01244022|Procedure|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
75559586|NCT00474500|Drug|Coca, Cola, Diet Coke|
75559587|NCT01245894|Drug|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
75559588|NCT01245894|Drug|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
75559589|NCT00469625|Drug|paricalcitol (initial dose 1 mcg orally per day)|
75715917|NCT01060033|Device|Fat-Saturation and Diffusion-Weighted Imaging|
75715918|NCT01060033|Device|Dynamic Contrast Enhancement MRI (MR-DCE)|
75715919|NCT01060033|Device|Diffusion Tensor Imaging (DTI)|
75715920|NCT01060189|Drug|Ulinastatin|
75715921|NCT01060189|Drug|Tranexamic Acid|
76042209|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
76042210|NCT02400333|Drug|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
76042211|NCT02399475|Drug|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
75414840|NCT01392287|Drug|Memantine|"Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
75414841|NCT01392313|Dietary Supplement|Carnitine|Carnitine Ingestion
75414842|NCT01392313|Dietary Supplement|Placebo|Carnitine placebo
75414843|NCT01392339|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
75559590|NCT01316367|Behavioral|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
75559591|NCT01316367|Behavioral|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
75559592|NCT00469664|Drug|Guanfacine/Tenex|
75559593|NCT00469703|Drug|Thalidomide|
75559594|NCT01244100|Drug|PL2200 fasted|Fasted state
75715922|NCT01060189|Drug|Saline Solution|
75715923|NCT03984877|Diagnostic Test|Diagnosis of amyloidosis|Scintigraphy and protein electrophoresis
75715924|NCT01060267|Drug|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
75715925|NCT01060267|Drug|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
75715926|NCT01060423|Drug|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
75414844|NCT01392352|Drug|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
75414845|NCT01392391|Procedure|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
75715927|NCT01060423|Drug|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
75715928|NCT01060423|Device|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
75715929|NCT03984721|Diagnostic Test|Amyloidosis typing using mass spectrometry-based proteomics|Amyloidosis typing using nanoLC-MS/MS method
75873128|NCT03315741|Drug|Pirfenidone 267 MG [Esbriet]|Tolerability of drug
75414846|NCT01392391|Procedure|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
75414847|NCT01392430|Other|Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin|Discontinuation of prophylaxis for opportunistic infections
75414848|NCT01392456|Procedure|Insertion of two screw type dental implants|Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
75414849|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
75559595|NCT01244100|Drug|PL2200 fed|Fed state
75559596|NCT04697888|Drug|Omegaven|Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
75559597|NCT01340872|Drug|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
75559598|NCT01340872|Drug|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
75559599|NCT00474656|Device|High-frequency oscillation|
75715930|NCT01060501|Drug|Folinic Acid, interferon-alpha|5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
76042212|NCT02399475|Drug|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
76042213|NCT02399475|Drug|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
75559600|NCT00474656|Device|Conventional lung-open mechanical ventilation|
75559601|NCT00469781|Drug|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
76042214|NCT04420377|Dietary Supplement|Carnipure|Supplement contains L-carnitine tartrate.
76042215|NCT04420377|Other|Resistance Training|5 weeks of whole-body resistance training, performed 2 times per week.
76042216|NCT02399163|Drug|Fluoride free toothpaste|Brushing with fluoride free toothpaste
76042217|NCT02399163|Drug|Fluoride toothpaste|Brushing with fluoride containing toothpaste
76042218|NCT02399163|Drug|Fluoride mouthwash|"Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm"
75414850|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
75414851|NCT01392534|Drug|Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)|Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
75414852|NCT01392586|Procedure|upfront breast surgery|surgery of primary tumor, lumpectomy or mastectomy
75414853|NCT01392586|Other|systemic therapy|chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)
75559602|NCT00469781|Drug|1. Pred Forte|"Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks."
75559603|NCT01244139|Drug|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
75559604|NCT01244139|Drug|Placebo|IV infusion dummy drug
75559605|NCT01340794|Other|Laboratory Biomarker Analysis|Correlative studies
75559606|NCT01340794|Drug|Pazopanib Hydrochloride|Given PO
75559607|NCT00469820|Biological|autologous tumor cell vaccine|
75559608|NCT00469820|Biological|peripheral blood lymphocyte therapy|
75559609|NCT00500838|Device|Transthoracic Impedance|Impedance measures will be automatically collected via the device
75559610|NCT00474695|Drug|Lucentis|0.05 mg intravitreal injection
76042219|NCT02398227|Behavioral|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
76042220|NCT02398227|Behavioral|PCT|Present Centered Therapy for PTSD
76042221|NCT02397915|Drug|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
76042222|NCT02397915|Drug|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
75559611|NCT00500877|Behavioral|Mood Management Phone Counseling for Smoking Cessation|Phone counseling addressed mood management and smoking cessation
75559612|NCT00474734|Device|Intravascular ultrasound of the liver|
75414854|NCT01392599|Procedure|SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)|After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
75414855|NCT01392612|Drug|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
75414856|NCT01392638|Other|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
76042223|NCT02397837|Drug|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
76042224|NCT02397837|Drug|Placebo|placebo match study drug
75559613|NCT00500916|Device|ProSeal LMA|GEB vs digital vs introducer tool
75559614|NCT03271502|Procedure|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
76042225|NCT02586415|Procedure|Endovascular Thrombectomy|Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
76042226|NCT02586415|Device|Trevo Retriever|Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
75414857|NCT01392638|Drug|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
75414858|NCT01392690|Behavioral|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
75414859|NCT01392716|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
75414860|NCT01392755|Drug|danoprevir|oral doses of danoprevir
75559615|NCT03271502|Procedure|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
75559616|NCT00500955|Drug|Rosiglitazone|
75559617|NCT00474773|Drug|Celecoxib|
75559618|NCT00474890|Drug|cetericine and pseudoephedrine|
75559619|NCT00501033|Device|Mechanical induction of labor|
76042227|NCT02586415|Device|Solitaire™ FR Revascularization Device|Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
75559620|NCT00501033|Device|Double Balloon|
75559621|NCT00501033|Device|Foley Catheter|
75559622|NCT03271463|Behavioral|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
75559623|NCT00501072|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
75414861|NCT01392755|Drug|omeprazole|oral doses of omeprazole
75715931|NCT00670488|Drug|MK-2206|MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
75715932|NCT00671658|Drug|Rituximab|375 mg/m2 by vein
75715933|NCT00671658|Drug|Cyclophosphamide (CTX)|300 mg/m2 by vein
75715934|NCT00671658|Drug|Doxorubicin|50 mg/m2 by vein
75414862|NCT01392755|Drug|ranitidine|oral dose of ranitidine
75414863|NCT01392755|Drug|ritonavir|oral doses of ritonavir
75414864|NCT01392768|Drug|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
75559624|NCT01340482|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
75715935|NCT00671658|Drug|Vincristine|2 mg by vein
75715936|NCT00671658|Drug|Dexamethasone|40 mg by vein or by mouth (P.O.)
75715937|NCT00671658|Drug|Methotrexate (MTX)|"12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8"
75715938|NCT00671658|Drug|Cytarabine|"100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8"
75715939|NCT00671658|Drug|G-CSF|10 ug/kg subcutaneous injection
75414865|NCT01392768|Drug|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
75414866|NCT01392794|Drug|YM060|oral, without water
75414867|NCT01392807|Drug|NKTR-118|25 mg Oral tablets, single dose
75414868|NCT01392820|Drug|TC-5214|Tablet, Oral, twice daily
75414869|NCT01392820|Drug|Placebo|Tablet, Oral, twice daily
75559625|NCT03271697|Drug|Astragalus Membranaceus|This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
75715940|NCT00671658|Drug|Mesna|600 mg/m2 a day by vein
75715941|NCT00671658|Drug|Pegylated asparaginase|2000 International units/m2 by vein
75715942|NCT00671658|Drug|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
75715943|NCT00671658|Drug|Solumedrol|40 mg by vein for Courses 2,4,6,8
75715944|NCT00768378|Device|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
75715945|NCT00764712|Drug|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
75715946|NCT00768456|Drug|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
75715947|NCT00768456|Drug|Isotonic NaCl|Local Infiltration with NaCl
75715948|NCT00542386|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
75715949|NCT00542386|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
75715950|NCT00768612|Drug|SCA-136 50mg/day|
75715951|NCT00768612|Drug|SCA-136 150 mg/day|
75414870|NCT01392833|Drug|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
75414871|NCT01392833|Drug|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
75414872|NCT01392833|Drug|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
75414873|NCT01392872|Other|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
75414874|NCT01392898|Drug|liraglutide|liraglutide 1.8 mg q.d.
75414875|NCT01392898|Drug|Insulin|insulin dosed according titration scheme
75559626|NCT03271697|Drug|Placebo|as a comparator comparing with AM group
75559627|NCT00501111|Drug|AZD3480|3 oral doses
75559628|NCT00501111|Drug|Donepezil|
75559629|NCT00475007|Device|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
75559630|NCT03271541|Drug|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
75559631|NCT00501189|Biological|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
75715952|NCT00768612|Drug|SCA-136 300mg/day|
75559632|NCT01340209|Drug|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
75715953|NCT00768612|Drug|Risperidone 4mg/day|
75559633|NCT01340209|Drug|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
75559634|NCT01340209|Drug|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
75559635|NCT00475046|Behavioral|Motivational Interviewing|
75559636|NCT01246089|Drug|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
75715954|NCT00604383|Drug|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
75715955|NCT00604383|Drug|placebo|1 tablet, orally, daily, up to 42 months
75715956|NCT00771108|Behavioral|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
75715957|NCT04048200|Drug|Fentanyl|Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
75715958|NCT04048200|Drug|Dexmedetomidine Ketamine|No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
75559637|NCT00598897|Drug|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
75559638|NCT04697732|Other|General anesthesia|Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
75559639|NCT00501267|Drug|solabegron and oxybutynin|
75715959|NCT00985894|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
75414876|NCT01392911|Drug|Rifampicin|High dose rifampicin
75559640|NCT00598936|Device|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
75559641|NCT04326244|Diagnostic Test|blood test|High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
75559642|NCT04326244|Diagnostic Test|genetic test|FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
75559643|NCT04326244|Diagnostic Test|Constitution in Chinese Medicine Questionnaire|Constitution in Chinese Medicine Questionnaire
75559644|NCT04326244|Diagnostic Test|Epworth Sleepiness Scale|Epworth Sleepiness Scale
75559645|NCT04326244|Diagnostic Test|cephalometry|Evaluation of craniofacial morphology in OSA patients
75559646|NCT04326244|Diagnostic Test|polysomnography|to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
75715960|NCT00985894|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
75715961|NCT04034589|Drug|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
75715962|NCT04048434|Device|Cytosorb|extracorporeal cytokine adsorption
75414877|NCT01392924|Drug|SAR245408|Pharmaceutical form: tablet Route of administration: oral
75559647|NCT00599209|Other|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
75559648|NCT01326910|Drug|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
75414878|NCT01392937|Device|All-in-One Light multipurpose|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
75414879|NCT01392937|Device|Aquify care|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
75559649|NCT01326910|Device|Topical Cream|Topical cream applied twice daily (or as needed)
75715963|NCT00988312|Biological|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
75715964|NCT00906867|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
75715965|NCT00906867|Procedure|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
75715966|NCT00768690|Drug|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
75715967|NCT00768690|Drug|ketoconazole|Tablet, see arms for intervention description
75715968|NCT00768690|Drug|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
75414880|NCT01392950|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
75559650|NCT00469937|Drug|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
75559651|NCT00469937|Procedure|cognitive assessment|cognitive assessment
75559652|NCT00469937|Procedure|quality-of-life assessment|quality-of-life assessment
75559653|NCT00469937|Radiation|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
75559654|NCT00599287|Drug|Haloperidol|Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
75559655|NCT00599287|Drug|Methylphenidate|Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
75559656|NCT00599287|Drug|Rivastigmine|Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
75715969|NCT02538549|Behavioral|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
75715970|NCT00982774|Biological|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
75414881|NCT01392950|Device|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
75715971|NCT00775008|Behavioral|electronic health information|Participants will receive weight loss information via 1 of 2 different mediums.
75715972|NCT00985972|Behavioral|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
75414882|NCT01392976|Drug|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
75559657|NCT00599365|Other|Pharmacy care arm|"The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.~You will need to give a complete list of medications to the pharmacist.~You will need to describe how you take these medications.~The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.~The pharmacist will give you a medication schedule, and other papers about your medications."
75715973|NCT02539953|Device|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
75414883|NCT01392976|Drug|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
75414884|NCT01393015|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
75414885|NCT01393015|Device|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
75414886|NCT01393028|Other|Cardiac CT|Cardiac CT: calcium scan and CT coronary angiography
75414887|NCT01393028|Other|Standard care|Standard care according to international guidelines
75414888|NCT01393041|Device|Angio-Seal VIP|Vascular Closure Device
75414889|NCT01393054|Drug|Nigella sativa|Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
75414890|NCT01393067|Device|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
75559658|NCT00599404|Drug|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
75559659|NCT00475124|Device|Home Monitoring of pacemaker|Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.
75559660|NCT00475124|Device|Home Monitoring of pacemaker deactivated|No Home Monitoring data transmission.
75559661|NCT04326166|Drug|Evogliptin|Evogliptin
75559662|NCT04326166|Drug|Evogliptin|Evogliptin
75559663|NCT04326166|Drug|Metformin and Evogliptin|Metformin and Evogliptin
75715974|NCT00768768|Other|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
75715975|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
75414891|NCT01393067|Device|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
75414892|NCT01393080|Drug|Nimotuzumab and TP regimen|"TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
75414893|NCT01393080|Drug|TP regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
75414894|NCT01393093|Procedure|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
75414895|NCT01393119|Drug|GTx-758|
75414896|NCT01393119|Drug|GTx-758|
75414897|NCT01393119|Drug|GTx-758|
75559664|NCT00599443|Biological|Seasonal cell-derived influenza vaccine|0.5 mL im, single dose
75414898|NCT01393119|Drug|GTx-758|
75414899|NCT01391988|Procedure|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
75414900|NCT01391988|Procedure|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
75414901|NCT01393145|Drug|Combination Fluticasone /Formoterol 12/250 μg|Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
75414902|NCT01393145|Drug|Seretide Diskus (salmeterol/fluticasone) 50/250 μg|Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
75414903|NCT01393184|Drug|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
75414904|NCT01393197|Other|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
75414905|NCT01393210|Dietary Supplement|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
75414906|NCT01393210|Other|low-calorie diet|low-calorie diet only for 12 weeks.
75414907|NCT01393223|Drug|LP-08 80mg|Intravesical instillation of 80mg LP08
75414908|NCT01393223|Drug|Normal saline|Intravesical instillation of normal saline
75414909|NCT01393223|Drug|LP-08 20mg|Intravesical instillation of 20mg LP08
75559665|NCT00599443|Biological|Placebo Comparator|0.5 mL im, single dose
75559666|NCT00501384|Drug|satavaptan (SR121463B)|
75715976|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
75414910|NCT01393275|Other|rehabilitation exercise intervention|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
76042228|NCT02586415|Device|Penumbra thrombectomy system|"Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:~• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System [026, 032, 041] Penumbra System Separator Flex [026, 032, 041, 054] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 & ACE68"
75559667|NCT00599482|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
75559668|NCT00599560|Genetic|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
75559669|NCT00599599|Behavioral|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
75559670|NCT02891668|Drug|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
75715977|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
75873129|NCT05307393|Behavioral|Positioning|Upon admission to labor and delivery, following an initial ultrasound to confirm fetal OP position, women in this study will be randomly assigned to one of three groups; one control (Group A), and two experimental (Groups B and C) groups. Those assigned to Group A will be allowed to remain in any position they chose during their labor and delivery course. Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement. Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
75414911|NCT01393275|Other|placebo control group|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
75414912|NCT01393288|Drug|Ondansetron|8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
75414913|NCT01393288|Drug|Lorazepam|1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.
75414914|NCT01393288|Drug|Aprepitant|40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
75873130|NCT03632967|Device|Tricinch Coil System Implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
75414915|NCT01393327|Behavioral|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
75559671|NCT02956343|Device|Five minutes pulse wave recording|Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
75559672|NCT00599677|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
75559673|NCT00599677|Drug|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
75559674|NCT00599716|Drug|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
75559675|NCT00599716|Drug|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
75559676|NCT01246284|Drug|Triamcinolone acetonide|Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
75559677|NCT01246284|Other|Normal saline|
75715978|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
75715979|NCT00988390|Behavioral|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
75559678|NCT00599833|Biological|cetuximab|
75715980|NCT00775086|Drug|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
75715981|NCT00908427|Procedure|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
75715982|NCT00908427|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
75715983|NCT00988468|Procedure|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
75715984|NCT00988468|Behavioral|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
75715985|NCT00988468|Behavioral|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
75715986|NCT02557854|Drug|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
75559679|NCT00599833|Radiation|3-dimensional conformal radiation therapy|
75559680|NCT00469976|Drug|bevacizumab|
75559681|NCT00469976|Drug|carboplatin|
75559682|NCT00469976|Drug|enzastaurin hydrochloride|
75559683|NCT00469976|Drug|gemcitabine hydrochloride|
75559684|NCT00599911|Drug|Lu AA24530|per oral, once daily for 6 weeks
75559685|NCT00599911|Drug|Duloxetine|per oral, once daily for 6 weeks
75559686|NCT00599911|Drug|Placebo|per oral, once daily for 6 weeks
75559687|NCT00501462|Drug|GSK189075|single 250 mg dose of drug
75559688|NCT00599950|Drug|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
75559689|NCT00475163|Behavioral|Behavior modification|
75559690|NCT00600145|Drug|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
75715987|NCT02557854|Device|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
75715988|NCT00908505|Procedure|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
75715989|NCT00988546|Other|Computer based template for exam documentation|exam documentation performed using computer based template
75559691|NCT00600145|Other|Placebo|Placebo
75559692|NCT00501501|Procedure|Cesarean section|
75559693|NCT00501501|Procedure|Vaginal delivery|
75559694|NCT00600223|Behavioral|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
75715990|NCT00988546|Other|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
75715991|NCT02557386|Drug|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
75559695|NCT00470015|Biological|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
75559696|NCT00470015|Biological|IL-2|0.5x10^6/m^2
75715992|NCT02557386|Drug|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
75414916|NCT01393340|Drug|Omalizumab|"Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab."
75414917|NCT01393340|Drug|Placebo|Placebo
75414918|NCT01393353|Other|Cognitive Training|
75414919|NCT01393353|Other|computer game|
75414920|NCT01393366|Other|Telephone Intervention|Only for arm AMA, patient will have one phone every week to evaluate physical conditions.
75559697|NCT00470015|Biological|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
75559698|NCT00470015|Biological|GM-CSF|300mcg
75559699|NCT00470015|Biological|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
75559700|NCT00600262|Drug|intravitreal bevacizumab|
75559701|NCT00600301|Drug|Triamcinolone Acetonide and Bevacizumab|
75559702|NCT04325971|Other|Neuroimaging|MR, EEG recordings
75559703|NCT04326127|Device|Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)|Data were recorded overnight by both devices simultaneously
75715993|NCT02557386|Drug|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
75715994|NCT02557386|Drug|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
75715995|NCT02557386|Drug|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
75559704|NCT00501579|Drug|Difluprednate|
75715996|NCT02557386|Drug|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
75715997|NCT00986050|Drug|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
75715998|NCT00986050|Device|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
75715999|NCT00986050|Device|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
75716000|NCT00986128|Drug|topiramate|100 mg tablet twice daily for 3 weeks
75716001|NCT00986128|Drug|topiramate|One 100 mg and one 200 mg tablet twice daily for 3 weeks
75414921|NCT01393366|Other|Usual Practice|None, only usual practice.
75414922|NCT01393418|Other|Cardiac Surgery|
75414923|NCT01392196|Procedure|Renal Denervation|Renal Denervation using the Symplicity Catheter in Heart Failure Population
75414924|NCT01393470|Procedure|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
75414925|NCT01393496|Other|red blood cell transfusion|"Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants"
75414926|NCT01393496|Other|red blood cell transfusion|"Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants"
75414927|NCT01393548|Drug|brompheniramine + phenylephrine|"Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient."
75559705|NCT00501579|Drug|Prednisolone Acetate|
75559706|NCT00600379|Device|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
75716002|NCT00771342|Drug|Nitric Oxide|1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
75716003|NCT00771342|Drug|Nitrogen|Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
75716004|NCT00775164|Drug|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
75716005|NCT00775164|Drug|Metformin|Metformin XR; 1000 mg once daily
75716006|NCT00988624|Drug|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
75716007|NCT00988624|Drug|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
75716008|NCT00988624|Drug|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
75414928|NCT01393548|Drug|Brompheniramine + pseudoephedrine|Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
75414929|NCT01393561|Drug|Group 1|Brompheniramine + phenylephrine
75414930|NCT01393561|Drug|Group 2|Placebo
75414931|NCT01393574|Drug|Melatonin|3 mg for body weight <40kg, 6 mg for body weight >40kg, once a day 30-60 minutes before sleep
75414932|NCT01393574|Drug|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
75414933|NCT01393587|Procedure|Taking blood samples|
75414934|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
75414935|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
75414936|NCT01393652|Drug|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
75559707|NCT02891707|Device|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
75559708|NCT00501618|Drug|Fazaclo|single-arm
75559709|NCT00600457|Device|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
75414937|NCT01393665|Drug|PENNEL capsule|"hard capsule DDB 25mg & GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D"
75414938|NCT01393665|Drug|Placebo|Placebo
75414939|NCT01393678|Drug|NISSEL|Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
75414940|NCT01393678|Drug|PENNEL|Biphenyl Dimethyl Dicarboxylate 25mg & garlic oil 50mg ............. 1cap
75414941|NCT01393691|Behavioral|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
75414942|NCT01393691|Behavioral|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
75414943|NCT01393769|Drug|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
75414944|NCT01393782|Drug|Angiotensin II|All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
75414945|NCT01393808|Drug|Paricalcitol|1-month Paricalcitol 2mcg/day
75414946|NCT01393808|Other|placebo|1-month Placebo Treatment
75559710|NCT02891434|Device|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
75559711|NCT02891434|Device|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
75559712|NCT02891434|Device|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
75716009|NCT00988624|Drug|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
75716010|NCT00988624|Drug|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
75716011|NCT00771420|Drug|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
75716012|NCT00771420|Drug|CAM-3001|Dosed at 0.1mg/kg.
75716013|NCT00771420|Drug|CAM-3001|Dosed at 0.3mg/kg
75716014|NCT00771420|Drug|CAM-3001|Dosed at 1.0 mg/kg.
75414947|NCT01393834|Procedure|Delayed cord clamping|Delay cord clamping for 30 seconds after birth
75414948|NCT01393834|Procedure|Milking of the cord|Milking of the cord 4 times in 10 seconds
75559713|NCT00600535|Drug|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
75559714|NCT00600535|Drug|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
75559715|NCT00600535|Drug|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
75716015|NCT00771420|Drug|CAM-3001|Dosed at 3.0 mg/kg.
75559716|NCT00600535|Drug|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
75559717|NCT00600535|Drug|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
75559718|NCT00600535|Drug|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
75559719|NCT00600535|Drug|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
75559720|NCT00600574|Other|physical therapy|weekly pool physiotherapy with muscle stretching
75716016|NCT00771420|Drug|CAM-3001|Dosed at 10 mg/kg.
75716017|NCT00771420|Other|Placebo|Active: Placebo 5:1 for arms 2-6
75873131|NCT05077449|Drug|XZP-3287+Fulvestrant|XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
75873132|NCT05077449|Drug|Placebo + Fulvestrant|Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
75873133|NCT03632733|Drug|Tetracycline|Tetracycline cream
75716018|NCT00983008|Behavioral|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
75414949|NCT01393886|Procedure|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
75414950|NCT01393912|Drug|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
75414951|NCT01393925|Drug|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
75414952|NCT01393938|Other|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
75414953|NCT01393951|Biological|ASP7374|subcutaneous and intramuscular
75414954|NCT01393977|Procedure|rehabilitation of limb function|only receive rehabilitation of limb function
75414955|NCT01393977|Procedure|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
75414956|NCT01394029|Drug|deferasirox|
75414957|NCT01394042|Device|Proxiscan device|All patients will be imaged with the device
75414958|NCT01394055|Drug|RM-131|100 μg subcutaneously once
75559721|NCT00600574|Other|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
75559722|NCT00470171|Drug|Ursodesoxycholic acid|
75414959|NCT01394055|Drug|Placebo|Matching placebo volume subcutaneously once
75414960|NCT01394094|Behavioral|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
75414961|NCT01394120|Drug|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
75414962|NCT01394120|Drug|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
75559723|NCT00600691|Drug|Finasteride|one tablet (5mg) of finasteride
75559724|NCT00623077|Biological|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) > 1,000/mm^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
75873134|NCT03632733|Drug|Clotrimazole|Clotrimazole cream
75873135|NCT03632733|Drug|Tetracycline and Clotrimazole|Combination cream
75873136|NCT03632733|Other|Placebo|Placebo cream without active drug ingredients
75414963|NCT01394133|Drug|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
75414964|NCT01394146|Other|Research diet|Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
75414965|NCT01394224|Drug|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
75559725|NCT00623077|Drug|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age),every 6 hours on Days -8 through -6.
75559726|NCT00623077|Drug|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m^2/day intravenous (IV) over 1 hour for 5 days.
75559727|NCT00623077|Drug|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day intravenous (IV) over 1 hour on for 5 days.
75414966|NCT01394224|Drug|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
75414967|NCT01394237|Other|Examination|Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
75414968|NCT01394289|Biological|Lolium allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
75414969|NCT01394341|Drug|Liraglutide|Daily sc. injection, individual dosage
75414970|NCT01394354|Drug|Vorinostat|"Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.~The dose level of Vorinostat will be escalated in each new cohort:~if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o."
75414971|NCT01394354|Drug|Bortezomib|1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles
75414972|NCT01394354|Drug|Doxorubicin|18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
75414973|NCT01394354|Drug|Dexamethasone|40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
75559728|NCT00623077|Drug|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m^2 intravenous (IV) over 30 min on Days -5 through -4.
75559729|NCT00623077|Drug|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m^2 intravenously (IV) over 2 hrs on Days -3 through -2.
75559730|NCT00623077|Procedure|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
75559731|NCT00623077|Radiation|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate)."
75559732|NCT00623077|Radiation|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
75559733|NCT00623077|Drug|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day divided in every 6 hrs dosing for 5 days.
75716019|NCT04767256|Drug|Dexamethasone and dexmedetomidine|General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.
75716020|NCT04767256|Drug|Dexmedetomidine|Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.
75716021|NCT04767256|Other|Ultrasound-guided lumbar erector spinae plane block|The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
75414974|NCT01394367|Other|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
75414975|NCT01394380|Other|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
75559734|NCT00623077|Radiation|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
75559735|NCT00475358|Drug|Duloxetine|
75716022|NCT04767256|Other|PCIA|Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
75559736|NCT00475358|Drug|Placebo|
75559737|NCT00623116|Drug|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
75559738|NCT00623155|Drug|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
75716023|NCT00771498|Drug|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
75716024|NCT00986206|Diagnostic Test|Biomarker LPA and HE4|Non Interventional Trial
75716025|NCT00986284|Drug|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
75716026|NCT00768846|Device|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
75716027|NCT00768846|Device|Xience V Stent|Everolimus-eluting Xience V Stent
75559739|NCT00600730|Procedure|Hyperinsulinemic euglycemic clamp with fMRi|Hyperinsulinemic euglycemic clamp on day 1 with morning fMRi
75559740|NCT00600730|Procedure|Hyperinsulinemic hypoglycemic clamp study with fMRi|Hyperinsulinemic hypoglycemic clamp on day1 with fMRi in morning
75559741|NCT00600769|Drug|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
75559742|NCT00600808|Drug|BPLG-003|
75716028|NCT00988702|Behavioral|Dan Tian Breathing|Dan Tian Breathing for one month
75716029|NCT00988702|Behavioral|Progressive muscle training|Progressive muscle training for one month
75716030|NCT00988780|Drug|maraviroc|"Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
75716031|NCT00988780|Drug|Placebo|"Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
75716032|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
75716033|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
75716034|NCT00986518|Biological|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
75716035|NCT00769158|Drug|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
75716036|NCT00769158|Other|Placebo|Placebo Comparator
75441434|NCT01634646|Dietary Supplement|Lyzme5|"Dietary Supplement (or placebo):~Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).~Week one:~A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;~Week two:~Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;~Week three through the end of the study:~Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day."
75873137|NCT03259425|Drug|Nivolumab|Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then participant will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
75441435|NCT01634685|Radiation|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
75441436|NCT01634685|Drug|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
75441437|NCT01634685|Drug|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
75441438|NCT01634698|Dietary Supplement|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
75559743|NCT00470210|Drug|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
75559744|NCT00470210|Drug|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
75559745|NCT00470210|Drug|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
75559746|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 20mg
75559747|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 5 mg
75559748|NCT00600847|Drug|placebo|single dose for 7 days, oral
75414976|NCT01394393|Behavioral|Experiential-Cognitive Therapy for Obesity|Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, & Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
75414977|NCT01394393|Behavioral|Behavioral cognitive Treatment|Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive-behavioral treatment approach described by Cooper and colleagues (Cooper & Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
75559749|NCT04325932|Drug|Urinary Kallikrein|
75414978|NCT01394393|Dietary Supplement|Nutritional groups (NT)|5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
75414979|NCT01394406|Drug|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
75559750|NCT00501657|Drug|Sitagliptin|100mg mane for 2 days
75414980|NCT01394406|Drug|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
75414981|NCT01394419|Drug|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
75559751|NCT00501657|Drug|Placebo|100mg mane for 2 days
75559752|NCT00600964|Drug|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
75414982|NCT01394419|Drug|Saline|Equal volume of normal saline
75559753|NCT00600964|Drug|GX15-070MS|GX15-070MS at various doses and schedules
75559754|NCT00475397|Drug|Duloxetine|
75559755|NCT00475397|Drug|Placebo|
75716037|NCT00983086|Drug|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
75716038|NCT00775320|Procedure|FLT-PET scan|Imaging test
75716039|NCT00983164|Dietary Supplement|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
75559756|NCT02891512|Other|ELF|Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
75716040|NCT00769236|Other|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
75716041|NCT00769236|Other|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
75559757|NCT02891512|Other|Xinepa®|2 tablets of Xinepa daily (morning and evening) for 1 month.
75559758|NCT02891512|Other|Placebo Xinepa®|2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
75559759|NCT00601042|Other|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
75559760|NCT00601042|Other|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
75559761|NCT00501696|Drug|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
75559762|NCT00501696|Drug|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
75559763|NCT00601120|Procedure|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
75559764|NCT00475436|Drug|GSK573719|
75559765|NCT04326322|Dietary Supplement|Methionine Intake|Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
75559766|NCT04326088|Other|Reconstruction group|Patients with primary tumor which underwent free flap reconstruction group.
75559767|NCT04326088|Other|Recurrent group|Patients with recurrent tumor which underwent free flap reconstruction group.
75559768|NCT00601237|Behavioral|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
75559769|NCT00601237|Behavioral|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
75559770|NCT00475475|Behavioral|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
75559771|NCT00475475|Behavioral|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
75559772|NCT00475475|Behavioral|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
75559773|NCT00601276|Drug|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
75559774|NCT00601276|Drug|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
75559775|NCT00601315|Drug|Clarithromycin|
75559776|NCT02274714|Other|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
75559777|NCT00601393|Behavioral|Cognitive behavioral therapy (CBT)|CBT treatment is delivered via the Internet. Adaptations to the CBT program will include the addition of content of particular relevance to mothers of young children and the incorporation of instructional design principles to promote self-learning. The treatment program will take advantage of the unique properties of the Internet, including multimedia presentations and interactive components with professional and moderated peer social support.
75414983|NCT01394432|Procedure|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
75559778|NCT00601393|Other|Treatment as usual (TAU)|Participants receiving TAU will be offered the CBT treatment after a wait-list period. During the wait-list period, participants will be offered facilitated referrals to treatment provided in the community.
75559779|NCT00470249|Drug|Carboplatin|At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
75716042|NCT00769236|Other|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
75414984|NCT01394445|Drug|Physostigmine|continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
75559780|NCT00470249|Drug|Gemcitabine Hydrochloride|1500 mg/m2 on day 2 of every 2-week cycle
75559781|NCT04325893|Drug|Hydroxychloroquine|First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
75559782|NCT04325893|Drug|Placebo|TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
75559783|NCT00601432|Drug|levofloxacin oral solution|
75559784|NCT00501813|Procedure|Hepatectomy|irregular Hepatectomy
75559785|NCT00501813|Procedure|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
75559786|NCT00601471|Other|proximal tibiofibular manipulation|proximal tibiofibular manipulation
75559787|NCT00601471|Other|distal tibiofibular manipulation|distal tibiofibular manipulation
75559788|NCT00601471|Other|no intervention|no intervention / control
75716043|NCT00988936|Drug|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with [F-18]RGD-K5
75414985|NCT01394445|Drug|Placebo|"continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg"
75414986|NCT01394458|Other|30 % ethanol / 4% sodium citrate catheter locking solution|This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
75414987|NCT01394458|Drug|Heparin 1000 u / ml|In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
75414988|NCT01394471|Drug|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
75559789|NCT00601510|Drug|capecitabine|
75559790|NCT00601510|Drug|cisplatin|
75559791|NCT00601510|Drug|imatinib mesylate|
75716044|NCT00333775|Drug|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
75559792|NCT00501930|Drug|GSK189075|
75559793|NCT00470288|Procedure|bladder flap during cesarean section|
75559794|NCT00601549|Procedure|Laparoscopic surgery|Laparoscopic surgery
75414989|NCT01394484|Other|Intervention I|Four servings of dairy foods (milk and yogurt) per day for 42 days.
75414990|NCT01394484|Dietary Supplement|Intervention II|1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
75441439|NCT01634724|Drug|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
75559795|NCT00601549|Procedure|Traditional open surgery|Open surgery
75559796|NCT00601588|Drug|Sertraline|
75559797|NCT00601666|Drug|Zolpidem|
75559798|NCT00601744|Behavioral|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
75559799|NCT00601744|Behavioral|Questionnaire|5-10 minute questionnaire to be completed after the interview.
75559800|NCT01246362|Drug|Control|Given placebo
75559801|NCT01246362|Drug|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
75559802|NCT04325854|Procedure|I and II level ART procedure|I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
75414991|NCT01394497|Drug|N-acetylcystein|15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco-regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross-clamping.
75441440|NCT01634750|Drug|ManNAc|Single dose
75441441|NCT01634763|Drug|LDK378|
75441442|NCT01634776|Dietary Supplement|Flaxseed oil|Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
75441443|NCT01634776|Dietary Supplement|corn oil|
75441444|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
75441445|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
75441446|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
75559803|NCT00470405|Drug|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
75559804|NCT00470405|Drug|pemetrexed disodium|a novel antifolate with multiple targets.
75559805|NCT04207372|Dietary Supplement|whey protein isolate|whey protein isolate
75559806|NCT04207372|Dietary Supplement|Zein|zein protein
75559807|NCT04207372|Other|protein-free|protein free
75559808|NCT00601822|Behavioral|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
75559809|NCT00601822|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
75559810|NCT00502008|Drug|Coccinia Cordifolia (herbal extract)|
75559811|NCT00601861|Drug|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
75716045|NCT00333775|Drug|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
75716046|NCT00333775|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
75716047|NCT00771732|Device|light therapy|6 minute light therapy
75716048|NCT00771732|Device|light therapy|combination of wavelengths
75716049|NCT03860428|Drug|Ibuprofen|In the medical treatment arm the in-tention is to close the ductus arteriosus.
75716050|NCT03860428|Drug|Paracetamol|In the medical treatment arm the in-tention is to close the ductus arteriosus.
75716051|NCT03860428|Other|Expectant Management|Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
75716052|NCT02557074|Drug|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
75441447|NCT01634789|Drug|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
75441448|NCT01634802|Other|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
75441449|NCT01634802|Other|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
75441450|NCT01634815|Procedure|The Edge|measuring blood lactate
75441451|NCT01634841|Dietary Supplement|Walnuts|30 to 60g (1 to 2 oz) per day of walnuts
75441452|NCT01634841|Other|habitual diet|Dietary information will be provided
75441453|NCT01634880|Drug|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
75559812|NCT00470444|Procedure|Transfusion with Red Blood Cells|Units of donated Red blood cells
75559813|NCT00470444|Biological|1 unit of donated red blood cells|Units of red blood cells
75559814|NCT00470444|Biological|1 unit of donated red blood cells|Units of donated red blood cells
75559815|NCT00601978|Drug|carbidopa/levodopa|
75559816|NCT00601978|Drug|Carbidopa/Levodopa/Entacapone|
75716053|NCT02557074|Drug|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
75716054|NCT00771888|Drug|lanreotide|lanreotide
75716055|NCT00989170|Behavioral|Family Program for the Prevention of Weight Gain|The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
75716056|NCT00989170|Behavioral|Control Group|This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
75716057|NCT00771966|Procedure|Standard therapy|Standard therapy
75716058|NCT00771966|Procedure|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
75716059|NCT00605475|Drug|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
75414992|NCT01394536|Device|Battery-operated electroacustimulation device (Inactive)|In the sham arm, this device will not be turned on. The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
75559817|NCT00601159|Drug|gemcitabine and cisplatin|Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
75559818|NCT00502047|Drug|Plantago ovata husk|
75716060|NCT00605475|Drug|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
75559819|NCT00602017|Drug|Amlodipine|
75559820|NCT00470483|Drug|Placebo treatment during 8 weeks|comparator
75559821|NCT00470483|Drug|Paroxetine treatment during 8 weeks|treatment drug
75716061|NCT00605475|Drug|Metformin|Participants continued on their stable daily dose of metformin throughout the study
75559822|NCT00602056|Other|Redesigned immunization card|A low cost nad simplified redesigned immunization card
75559823|NCT00602056|Other|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
75559824|NCT00602056|Other|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
75559825|NCT00602095|Drug|misoprostol|0.025mg tablet vaginally every 4 hour until progress
75559826|NCT00602095|Drug|dinoprostone|2mg vaginal gel every 6 hours until progress
75559827|NCT00602095|Device|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
75716062|NCT00986596|Dietary Supplement|vitamin D3|4000 IU once daily by mouth for 4 months
75716063|NCT00986596|Dietary Supplement|Placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
75716064|NCT00772044|Device|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
75716065|NCT00772044|Device|Sham Device|Sham device will be applied
75716066|NCT00333619|Behavioral|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
75716067|NCT00333619|Behavioral|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
75716068|NCT00986752|Device|Stenting (Smart Stent)|Nitinol stent
75716069|NCT00986752|Device|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
75716070|NCT00986752|Procedure|Atherectomy (SilverHawk device)|Atherectomy
75559828|NCT00502086|Dietary Supplement|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
75716071|NCT00772122|Drug|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
75414993|NCT01394536|Device|Battery-operated electroacustimulation device (Active)|The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
75414994|NCT01394562|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
75414995|NCT01394562|Other|Standard of Care|Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
75414996|NCT01394575|Radiation|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
75559829|NCT00502086|Other|Placebo|Placebo three sachets daily during 96 weeks
75559830|NCT00475553|Other|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
75559831|NCT00475553|Other|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
75559832|NCT01326481|Drug|TRC105|IV
75414997|NCT01394588|Device|Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)|Use of continuous glucose monitor during surgery.
75559833|NCT01326481|Drug|Capecitabine|oral
75559834|NCT00502125|Procedure|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
75559835|NCT03271346|Behavioral|intensive trauma-focused therapy|
75559836|NCT00502164|Drug|AZD2171|
75716072|NCT00772122|Drug|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
75559837|NCT00475592|Device|Esophageal Capsule Endoscopy|
75559838|NCT00475592|Device|Upper Gastrointestinal Endoscopy|
75559839|NCT00502281|Drug|highly purified urinary FSH|
75559840|NCT00502281|Behavioral|timed intercourses, intrauterine insemination|
76042229|NCT02586415|Device|Covidien MindFrame Capture Revascularization Device|Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
75414998|NCT01394653|Drug|YM060|oral, with water
75559841|NCT00470522|Drug|Methotrexate and folic acid|
75559842|NCT00502359|Device|capillary blood glucose measurement|
75559843|NCT00475748|Procedure|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
75716073|NCT04006678|Procedure|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
75414999|NCT01394679|Drug|(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
75415000|NCT01394679|Drug|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
75415001|NCT01394731|Drug|Acetaminophen|
75415002|NCT01394731|Drug|Meperidine|
75415003|NCT01394757|Drug|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
75415004|NCT01394770|Drug|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
75415005|NCT01394783|Device|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
75415006|NCT01394783|Device|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
75559844|NCT01244178|Drug|Insulin|Intravenous Hyperinsulinemic therapy
75559845|NCT01244178|Drug|Insulin|Standard Intravenous Insulin Therapy
75716074|NCT00769470|Biological|trastuzumab|Given IV
75559846|NCT00470561|Drug|Aspirin|Two 325 mg doses of aspirin per day for 6 months
75559847|NCT00470561|Drug|Placebo|Two placebo pills per day for 6 months
75559848|NCT00502398|Procedure|Blood test|
75559849|NCT00475826|Drug|Statins and Ezetimibe|
75559850|NCT00493506|Drug|ProAlgaZyme|
75559851|NCT00502437|Drug|GRANISETRON|
75559852|NCT00470678|Drug|ranibizumab|
75559853|NCT00502476|Procedure|Bathing with Chlorhexidine Impregnated Washcloths|
75559854|NCT00470756|Other|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
75559855|NCT00470795|Other|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
75559856|NCT00470795|Procedure|placebo/sham acupuncture|acupuncture at sham points without skin penetration
75559857|NCT00493545|Biological|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
75559858|NCT00470873|Drug|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
75559859|NCT00493584|Procedure|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
75716075|NCT00769470|Drug|carboplatin|Given IV
75716076|NCT00769470|Drug|docetaxel|Given IV
75716077|NCT00769470|Drug|lapatinib ditosylate|Given orally
76042230|NCT02383017|Dietary Supplement|Shroom Tech Sport|STS will be given every day in accordance to company guidelines for 12 weeks.
76042231|NCT02383017|Dietary Supplement|Placebo|Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
76042232|NCT05556031|Other|Standard care|Standard clinical care
75559860|NCT00493584|Procedure|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
75559861|NCT00493623|Drug|Placebo|Placebo i.v. single dose
75716078|NCT04854382|Behavioral|Tailored information|Tailored information about coronavirus for patients with chronic kidney disease by information videos followed by a teach back procedure
75559862|NCT00493623|Drug|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
75559863|NCT02955849|Device|SLT laser|Patients will be offered initial SLT laser by doctors
75559864|NCT00476099|Drug|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
75716079|NCT00605319|Drug|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
75415007|NCT01394796|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
75415008|NCT01394796|Drug|Placebo|No active treatment is given.
75415009|NCT01394809|Behavioral|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
75415010|NCT01394835|Drug|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
75415011|NCT01394835|Drug|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
75415012|NCT01394835|Drug|AAT|Inhalation twice daily' 160mg
75415013|NCT01394848|Device|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
75415014|NCT01394848|Device|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
75415015|NCT01394848|Drug|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
75415016|NCT01394848|Drug|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
75415017|NCT01394861|Device|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
75415018|NCT01394874|Behavioral|TLC|Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
75415019|NCT01394887|Drug|Metformin|850 mg of metformin twice daily over 12 weeks
75415020|NCT01394887|Drug|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
75415021|NCT01394913|Drug|Reumatocept (etanercept)|50mg each week for 30 weeks
75415022|NCT01394913|Drug|Enbrel (etanercept)|50mg each week for 30 weeks
75415023|NCT01394965|Procedure|ECG electrodes|Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
75415024|NCT01395069|Drug|Nepafenac 0.1%|1 drop QID for 1 month
75559865|NCT00476099|Drug|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
75559866|NCT00476099|Drug|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
75716080|NCT04006834|Other|No intervention involved|No intervention involved
75716081|NCT00922038|Behavioral|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
75716082|NCT00983320|Drug|quetiapine|flexible dosage (50 to 300 mg)
75415025|NCT01395069|Drug|Ketorolac 0.5%|1 drop QID for 1 month
75415026|NCT01395069|Other|Placebo (sterile saline drops)|1 drop QID for 1 month
75559867|NCT00493662|Drug|Polyethylene Glycol 400 0.4%|
75559868|NCT00493662|Drug|Propylene Glycol 0.3%|
75716083|NCT00983320|Drug|placebo|placebo
75716084|NCT00908661|Device|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
75559869|NCT00493662|Drug|0.15% sodium Hyaluronate|
75559870|NCT00493662|Drug|sodium chloride|
75559871|NCT00493662|Drug|sodium phosphate monobasic|
75559872|NCT00470912|Drug|sunscreen RV 2547C|
75559873|NCT02274519|Other|Tai Chi|Arm 1
75559874|NCT02274519|Other|Education|Arm 2
75559875|NCT00476138|Drug|Epigallocatechin-gallate|
75716085|NCT00989248|Other|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
76042233|NCT05549791|Drug|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
75415027|NCT01395095|Other|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
75559876|NCT02955888|Drug|PBI4050|Investigational Medicinal Product
75559877|NCT02955888|Drug|Placebo|Comparator
75559878|NCT00470951|Procedure|open rectal resection|open rectal resection
75559879|NCT00470951|Procedure|laparoscopic rectal resection|laparoscopic assisted rectal resection
75559880|NCT02956083|Other|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
75559881|NCT02956083|Other|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
75559882|NCT02956083|Other|saline|Saline - no brand name
75559883|NCT00470990|Drug|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
75559884|NCT01246440|Drug|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
75559885|NCT03271112|Other|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
75559886|NCT00493740|Procedure|chocolate cake|
75559887|NCT00471029|Drug|esomeprazole|
75559888|NCT00476177|Biological|Infusion of donor dendritic cells|Given in the outpatient setting
75559889|NCT00476177|Biological|Infusion of donor lymphocytes|Given in outpatient setting
75559890|NCT00493818|Drug|GSK690693|
75716086|NCT00983398|Drug|Carboplatin|Given IA
75716087|NCT00983398|Drug|Mannitol|Given IA
75716088|NCT00983398|Drug|Melphalan|Given IA
75716089|NCT00983398|Other|Quality-of-Life Assessment|Ancillary studies
75716090|NCT00983398|Other|Questionnaire Administration|Ancillary studies
75716091|NCT00983398|Drug|Sodium Thiosulfate|Given IV
75716092|NCT00333229|Drug|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
75716093|NCT00333229|Drug|Placebo|Matching Placebo
75716094|NCT00769548|Drug|flutamide|Drug used for TAS.
75716095|NCT00769548|Drug|goserelin acetate|Drug used for TAS.
75716096|NCT00769548|Radiation|low-LET photon therapy|radiation therapy
76042234|NCT02382939|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
76042235|NCT02382939|Drug|somatropin|Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
76042236|NCT05549557|Drug|IMM40H|IMM40H is a monoclonal antibody with a molecular generated from ImmuneOnco's antibody platform. IMM40H targets CD70 (a tumor cell marker).
75415028|NCT01395095|Other|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
75415029|NCT01395095|Other|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
75415030|NCT01395108|Drug|Nemonoxacin|oral once daily
75415031|NCT01395121|Drug|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
76042237|NCT05543005|Other|maternal voice intervention|maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time after routine care period
76042238|NCT05542927|Diagnostic Test|urine chloride|Serum chloride, urinary chloride & serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride & urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI & mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours
76042239|NCT04425889|Diagnostic Test|COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)|a blood sample is drained for detection of IgG and IgM antibody
75415032|NCT01395134|Device|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
75559891|NCT00476216|Drug|Combination of Arixtra with chemotherapy|"Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 & 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy."
75559892|NCT00502632|Drug|Urokinase and Dornase alfa|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
75559893|NCT00502632|Drug|Urokinase|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~25ml normal saline, twice daily for 4 days"
75559894|NCT00471185|Drug|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
75559895|NCT01325701|Drug|ibrutinib|ibrutinib is an inhibitor of BTK
75559896|NCT00493857|Drug|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
75559897|NCT00493857|Drug|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
75559898|NCT00476255|Behavioral|Enhanced Standard Care (ESC)|Reading material
75559899|NCT00476255|Behavioral|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
75716097|NCT05277675|Drug|Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab|Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
75415033|NCT01395147|Drug|Lu AA21004|Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
75559900|NCT00476294|Other|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
75559901|NCT01325623|Device|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
75559902|NCT00494052|Behavioral|Heart to Heart (Web-Based Decision Aid)|Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
75559903|NCT00494052|Behavioral|Physician Education Session|A physician education session will be included in the program.
75559904|NCT00476333|Device|APOS biomechanical gait system|
75559905|NCT01246518|Drug|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
75559906|NCT01325584|Drug|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
75559907|NCT04207294|Other|Pork arm|The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
75559908|NCT04207294|Other|Chicken arm|The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
75559909|NCT00502749|Behavioral|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
76042240|NCT05555563|Other|MTAD irrigation|Final irrigation protocol was performed using 5 ml MTAD (n=50).
75716098|NCT05277675|Procedure|RFA|RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
75716099|NCT00769626|Other|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
75415034|NCT01395173|Procedure|Position change|Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
75415035|NCT01395173|Procedure|Standard|Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
75415036|NCT01395186|Procedure|varicocelectomy|varicocelectomy for painful varicocele
75559910|NCT00502749|Behavioral|Questionnaires|Questionnaires taking 15 minutes to complete.
76042241|NCT04426435|Drug|honey based (HB) syrup|"honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO)."
76042242|NCT05549245|Device|high-flow nasal cannula oxygen therapy,|Patients were treated with high-flow nasal cannula oxygen therapy for three nights
76042243|NCT05549245|Device|CPAP|Patients were treated with CPAP for three nights
75559911|NCT02891473|Other|Mézières Method|10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
75873138|NCT03259425|Drug|HF10|1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
75873139|NCT03259269|Other|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
75873140|NCT04923555|Behavioral|Vegetable proteins (VP) rich in leucine, cystein, arginine|33 volunteers will consume 400 ml of yogurt with vegetable proteins (VP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of vegetable proteins.
75873141|NCT04923555|Behavioral|Animal proteins (AP)|33 volunteers will consume 400 ml of yogurt with animal proteins (AP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
75415037|NCT01395199|Drug|Amlodipine|5mg PO initially; may be reduced to 2.5mg PO if side effects
75415038|NCT01395238|Behavioral|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
75415039|NCT01395251|Drug|Prednisolone|prednisolone 20 mg once a day per os for 3 subsequent days
75559912|NCT02891473|Other|Home based exercise program|1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
75415040|NCT01395290|Drug|cholecalciferol|20.000 IU per week, oral
75415041|NCT01395342|Other|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
75415042|NCT01395355|Behavioral|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
75559913|NCT04126915|Genetic|Whole Exome Sequencing|Whole Exome Sequencing of the patient's primary tumor, metastases
75559914|NCT00502788|Drug|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
75559915|NCT00502788|Drug|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight > 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
75559916|NCT00602134|Drug|6-Mercaptopurine|
75559917|NCT00471224|Other|Observational Trial|No intervention is being used in this study.
75415043|NCT01395355|Behavioral|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
75559918|NCT02891590|Drug|DTRMWXHS-12|
75559919|NCT00502827|Behavioral|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
75559920|NCT00502827|Other|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
75559921|NCT00494208|Drug|Testosterone|Testosterone ester
75559922|NCT00471341|Drug|Celecoxib|
75415044|NCT01395381|Drug|Placebo|placebo given once
75415045|NCT01395381|Drug|Albendazole|single dose albendazole given at the time of enrollment
75415046|NCT01395407|Radiation|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~21 18 15~23 20 17~25 22 19"
75559923|NCT00471341|Drug|placebo|
75559924|NCT01325428|Drug|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
75559925|NCT01325428|Drug|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
75559926|NCT00502983|Behavioral|Interview|Interview lasting approximately 50 minutes.
75559927|NCT00476411|Biological|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
75559928|NCT00494247|Device|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
75559929|NCT00471419|Drug|Rimexolone|
75415047|NCT01395420|Drug|CAZ104|IV Infusion
75559930|NCT01325350|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
75415048|NCT01395420|Drug|CAZ104|IV Infusion
75559931|NCT01325350|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
75873142|NCT04923555|Behavioral|No protein (T)|33 volunteers will consume 400 ml of yogurt without any protein (T) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
75415049|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
75415050|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
75415051|NCT01395433|Drug|Escitalopram|1 x 20 mg, single dose
75559932|NCT01325350|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
75415052|NCT01395459|Behavioral|IVR only|As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.
75415053|NCT01395459|Behavioral|IVR+PCC|Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR
75415054|NCT01395472|Behavioral|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
75415055|NCT01395472|Behavioral|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
75415056|NCT01395485|Drug|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
75415057|NCT01395498|Other|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
75415058|NCT01395511|Device|Acupuncture|"Tool : Acupuncture Seirin SJ 0.16 * 40 (mm) / SJ 0.18 * 50 (mm) L-type needles were used for the study.~Made from stainless steel needle SEIRIN JAPAN"
75559933|NCT01325350|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
75559934|NCT01325350|Drug|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
75559935|NCT01324999|Drug|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
75559936|NCT00503022|Drug|ACZ885|
75559937|NCT02891356|Device|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
75559938|NCT03273335|Device|Millipore biomarker assay plate|Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
75559939|NCT00494286|Behavioral|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
75559940|NCT00494286|Behavioral|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
75873143|NCT03101241|Drug|CX-8998|T-type calcium channel blocker
75873144|NCT03101241|Drug|Placebo|Placebo comparator
75415059|NCT01395563|Behavioral|strength training|strength training, high intensity, twice up to 3 times per week
75415060|NCT01395576|Device|Genu Neurexa orthosis|Knee orthosis for the prevention of knee hyper extension
75415061|NCT01395589|Drug|Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
75415062|NCT01395602|Drug|Cabergoline|cabergoline 0.5 mg twice weekly
75415063|NCT01395602|Other|placebo|1 pill twice weekly
75415064|NCT01395628|Drug|in vitro sensitivity-directed chemotherapy|
75559941|NCT03271385|Diagnostic Test|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
75559942|NCT01324570|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
75559943|NCT05645653|Behavioral|Motivational tteaching|A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
75559944|NCT03271229|Biological|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
75559945|NCT03271229|Biological|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
75559946|NCT04325698|Drug|PF-06439535 (CN)|15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
75559947|NCT04325698|Drug|Bevacizumab-EU|15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
75716100|NCT00769626|Other|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
75716101|NCT03984409|Dietary Supplement|Kroger low calorie orange juice beverage|Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
75716102|NCT00900939|Behavioral|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
75873145|NCT03061188|Other|Laboratory Biomarker Analysis|Correlative studies
75415065|NCT01395628|Other|cell proliferation assay|
75415066|NCT01395628|Other|fluorescence activated cell sorting|
75415067|NCT01395628|Other|laboratory biomarker analysis|
75559948|NCT04325698|Drug|Paclitaxel|175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
75559949|NCT04325698|Drug|Carboplatin|AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
75415068|NCT01395628|Other|microscopy|
75415069|NCT01395654|Drug|isoniazid, rifampin, pyrazinamide|rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
75415070|NCT01395667|Other|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
75415071|NCT01395693|Device|Salt Lake mask system|Study participants will Salt Lake mask system for 1 week in place of their current mask system.
75415072|NCT01395706|Procedure|ICG Fluorescence technique|"This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated"
75415073|NCT01395719|Other|Remote ischemic conditioning|Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
75415074|NCT01395732|Drug|Bosentan|2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
75415075|NCT01395745|Drug|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
75415076|NCT01395745|Drug|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
75415077|NCT01395771|Behavioral|Phone call intervention, no phone call intervention|Biweekly phone call intervention +routine service will be assigned to intervention group of new cases and old cases. Only routine service will be assigned to the control group of abovementioned two kind of cases.
75415078|NCT01395849|Drug|Salmeterol and Fluticasone|
75415079|NCT01395862|Drug|Salmeterol and Fluticasone|
75415080|NCT01395875|Drug|Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)|COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
75415081|NCT01395875|Drug|Anticholinergics (AC)|COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium [IPR]).
75415082|NCT01395927|Drug|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
75559950|NCT00503100|Device|Thermal stimulation|Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
75559951|NCT01324141|Drug|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).
75559952|NCT01324141|Drug|5-Fluorouracil|5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.
75559953|NCT01324141|Drug|Mitomycin-C|Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29
75559954|NCT01324141|Procedure|Radiation Therapy|Radiation therapy (RT) will be delivered to a total dose of 50-54 Gray (Gy) based on tumor characteristics.
75559955|NCT00471575|Procedure|ultra sound examination|
75559956|NCT00503217|Drug|Tryptorelin|
75559957|NCT01324102|Behavioral|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
75559958|NCT00503256|Behavioral|Questionnaire|Questionnaires each taking 60 minutes to complete.
75559959|NCT01324024|Drug|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
75559960|NCT01324024|Drug|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
75559961|NCT00476528|Behavioral|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
75559962|NCT00476528|Behavioral|Reality Orientation|A quasiexperimental study
75559963|NCT00494520|Procedure|Errorful training condition|"Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended."
75415083|NCT01395927|Drug|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
75415084|NCT01395940|Drug|KLH-2109|
75415085|NCT01395940|Drug|KLH-2109|
75415086|NCT01395953|Drug|Buspirone|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
75559964|NCT00494520|Procedure|Errorless training condition|"Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended."
75559965|NCT00476567|Other|standard|standard antenatal care
75559966|NCT00476567|Behavioral|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
75559967|NCT00502554|Procedure|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
75559968|NCT00503295|Biological|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
75415087|NCT01395953|Drug|Placebo|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
75415088|NCT01395979|Behavioral|Cognitive Processing Therapy for Sexual Risk|Eight weekly sessions, 4 modules.
75415089|NCT01395979|Behavioral|Supportive Psychotherapy|Eight weekly sessions
75559969|NCT00471614|Drug|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
75716103|NCT00900939|Behavioral|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
75716104|NCT00775554|Other|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
75415090|NCT01395979|Behavioral|Sexual Risk Reduction Intervention|Two weekly sessions.
75415091|NCT01395992|Drug|asenapine|asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days
75415092|NCT01395992|Drug|asenapine|asenapine 10 mg tablet, SL BID for 182 days
75415093|NCT01396031|Behavioral|Physical Therapy|Standard of care
75559970|NCT01244217|Drug|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
75415094|NCT01396109|Procedure|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
75415095|NCT01396109|Procedure|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
75415096|NCT01396122|Procedure|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
75415097|NCT01396135|Drug|CP-601,927|Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
75559971|NCT00471653|Drug|temozolomide|
75716105|NCT00775554|Other|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
75559972|NCT00471653|Genetic|comparative genomic hybridization|
75559973|NCT00471653|Genetic|polymorphism analysis|
75559974|NCT00471653|Other|laboratory biomarker analysis|
75559975|NCT00471653|Other|pharmacological study|
75559976|NCT00471653|Radiation|radiation therapy|
75559977|NCT00471692|Drug|Ropivicaine|
75559978|NCT01244295|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
75559979|NCT01244295|Behavioral|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
75559980|NCT00476684|Procedure|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
75716106|NCT04005820|Other|Radiologic Centralized Review|The patient's imaging will be examined in one of the examination centers
75716107|NCT04005820|Other|Tissue sample (tumor, sung, urine)|all the samples will be made during the patients care
75415098|NCT01396135|Drug|CP-601,927|Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
75415099|NCT01396135|Drug|CP-601,927|Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
75415100|NCT01396135|Drug|Placebo|Single dose of placebo given as a matching number of oral tablets
75415101|NCT01396135|Drug|CP-601,927|Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
75415102|NCT01396135|Drug|Placebo|Multiple doses of placebo given as a matching number of oral tablets
75873146|NCT03061188|Biological|Nivolumab|Given IV
75873147|NCT03061188|Other|Pharmacological Study|Correlative studies
75873148|NCT03061188|Drug|Veliparib|Given PO
75415103|NCT01396174|Behavioral|prosocial online support group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
75415104|NCT01396174|Behavioral|Standard Online Support Group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
75415105|NCT01396200|Drug|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
75415106|NCT01396200|Drug|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
75415107|NCT01396252|Drug|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
75415108|NCT01396252|Drug|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
75415109|NCT01396252|Drug|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
75415110|NCT01396252|Drug|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
75415111|NCT01396252|Drug|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
75415112|NCT01396291|Drug|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
75415113|NCT01396291|Drug|placebo|asenapine-matched placebo, sublingual tablets, BID
75415114|NCT01396304|Device|Restore Calcium Alginate Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
75873149|NCT03449147|Drug|Placebo|Placebo tablet administered orally BID
75873150|NCT03449147|Drug|Gefapixant 15 mg BID|Gefapixant 15 mg tablet administered orally BID
75415115|NCT01396304|Device|AquaCel Ag Wound Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
75415116|NCT01396330|Behavioral|stress|3 professional safe drive training courses each lasting 30 minutes
75415117|NCT01396356|Procedure|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
75873151|NCT03449147|Drug|Gefapixant 45 mg BID|Gefapixant 45 mg tablet administered orally BID
75873152|NCT03628638|Other|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
75873153|NCT04031040|Device|Genio(TM) system therapy|Hypoglossal nerve stimulation system
75873154|NCT05588453|Biological|Natural Killer Cell Therapy|Given UD TGFbi NK cell IV
75873155|NCT05588453|Drug|Temozolomide|Given PO
75873156|NCT01311401|Other|NONE intervention|NONE intervention
75559981|NCT00476684|Procedure|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
75559982|NCT00494559|Drug|Pioglitazone|Actos 15mg once a day before breakfast
75559983|NCT00494559|Drug|Placebo|Placebo drug with the same appearance as actos
75559984|NCT00503334|Dietary Supplement|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
75559985|NCT00494598|Drug|Sufentanil|200 mcg intra-arterial one time bolus
75559986|NCT00503412|Drug|AZD2171|oral 14C
75559987|NCT00503451|Drug|LBH589|
75716108|NCT02538159|Device|CVC|The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.
75716109|NCT02538159|Device|PICC|The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
75716110|NCT00983554|Drug|Anastrazole|Arimidex 1mg daily
75873157|NCT03716141|Other|Autologous Platelets Rich Plasma Treatment|For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.
75873158|NCT03716141|Other|Conventional Saline dressing|saline dressing of diabetic wounds will be done
75415118|NCT01396369|Drug|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
75441454|NCT01634893|Drug|Sorafenib combined with Hydroxychloroquine|"dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
75441455|NCT01634906|Drug|Temporary discontinuation of statin therapy|All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
75441456|NCT01634919|Device|chronic hepatitis C|acoustic radiation force impulse ultrasonography
75559988|NCT00471809|Drug|Budesonide + Salmeterol + Azithromycin|
75716111|NCT00983554|Drug|Testosterone|Testim 10g daily
75716112|NCT00983554|Drug|Dutasteride|Avodart 2.5mg daily
75716113|NCT00983554|Drug|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
75873159|NCT02366520|Device|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
75559989|NCT00471809|Drug|Budesonide + Salmeterol + Montelukast|
75559990|NCT00471809|Drug|Budesonide + Salmeterol + Placebo|
75559991|NCT00503490|Drug|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
75559992|NCT00503490|Drug|placebo|BID
75559993|NCT00476801|Device|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
75559994|NCT04696965|Other|Correct/recheck strategy|One month after recruitment and every 3 months. 1. Check the inhaler step errors of patients by research assistant; 2.Demonstrate the right way by research assistant; 3. give the inhaler check list with marks of the wrong step(s) patients made to patients and 4. confirm the patients do the right way of the previous wrong step(s).
75559995|NCT04696965|Other|Usual verbal instruction|One month after recruitment and every 3 months.1. Check the inhaler step errors of patients by research assistant; 2. Verbal instruction with a physical demonstration will be given by educational nurse in usual care.
75559996|NCT00494637|Drug|sodium bicarbonate|isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
75873160|NCT05186454|Drug|Morphine Sulfate|analgesia
75873161|NCT05186454|Drug|Bupivacaine|Analgesia
75873162|NCT05186454|Drug|dexamethasone, morphine, midazolam|1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
75873163|NCT05177640|Drug|99mTc-Duramycin|This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
75415119|NCT01396369|Drug|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
75415120|NCT01396460|Other|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
75559997|NCT00471965|Drug|Oxaliplatin + 5-Fluorouracil/Leucovorin|"Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
75716114|NCT00908739|Genetic|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
75441457|NCT01634932|Other|Regular iron|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
75559998|NCT00471965|Drug|Doxorubicin|Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
75559999|NCT00472004|Drug|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
75560000|NCT00472004|Drug|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
75716115|NCT00908739|Other|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
75716116|NCT00908739|Other|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
75873164|NCT02113878|Drug|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
75560001|NCT00494715|Drug|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
75873165|NCT02113878|Drug|Cisplatin|Cisplatin is a chemotherapy drug
75873166|NCT02113878|Radiation|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
75415121|NCT01396473|Behavioral|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
75873167|NCT05162898|Drug|toripalimab|240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.
75873168|NCT05162898|Drug|Lenvatinib|12mg (weight ≥60kg) or 8mg (weight <60kg) orally, once a day
75415122|NCT01396499|Drug|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
75415123|NCT01396564|Drug|Metformin|850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
75415124|NCT01396564|Drug|Pioglitazone|15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
75415125|NCT01396577|Drug|perampanel|3 x 2 mg perampanel once per day
75415126|NCT01396577|Drug|perampanel|6 mg perampanel once per day
75415127|NCT01396590|Drug|Perampanel|6 x 2 mg perampanel once per day
75415128|NCT01396590|Drug|Perampanel|12 mg perampanel once per day
75415129|NCT01396616|Device|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
75415130|NCT01396629|Procedure|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
75716117|NCT00908817|Drug|triamcinolone acetonide|paste applied over tracheal tube for lubrication
75716118|NCT00908817|Drug|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
75716119|NCT04005898|Device|Near-infrared fluorescence cholangiography|Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
75873169|NCT05162898|Device|Radiofrequency ablation|ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma
75560002|NCT00494715|Drug|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
75415131|NCT01396642|Other|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
75560003|NCT00494715|Drug|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
75560004|NCT00472043|Procedure|PDT with Metvix 160 mg/g cream and Placebo cream|
75560005|NCT00503529|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
75560006|NCT02273999|Device|RecoveryRx™|Appliance of the device after surgery
75560007|NCT01323946|Biological|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
75415132|NCT01396655|Drug|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
75560008|NCT03271073|Drug|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
75560009|NCT01246557|Drug|Lenalidomide|"Lenalidomide - Revlimid®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 ́-aminoisoindoline-1 ́ona)-1- piperidine-2,6-dione.~REVLIMID® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
75560010|NCT01246557|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
75441458|NCT01634932|Other|Iron biofortified millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
75560011|NCT00476879|Drug|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
75560012|NCT00472121|Device|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
75560013|NCT00494793|Procedure|VAWC and mesh mediated fascial traction|"The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed"
75560014|NCT00476918|Drug|Intravitreal injection (triamcinolone acetonide)|
75560015|NCT01246635|Device|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
75560016|NCT01246635|Procedure|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
75560017|NCT00472160|Procedure|Non Invasive Ventilation|Non Invasive Ventilation
75560018|NCT00472238|Behavioral|endurance training|control group.
75415133|NCT01396668|Drug|gemcitabine, cisplatin, capecitabine|Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)
75415134|NCT01396681|Drug|gemcitabine and cisplatin|The study consists of three phases; Induction chemotherapy phase:Starting 4~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
75415135|NCT01396694|Other|Questionnaire|Questionnaire
75415136|NCT01396707|Drug|Herceptin+XELOX|"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~Oxaliplatin 130 mg/m2 i.v. on day 1"
75415137|NCT01396720|Drug|fluvoxamine|Fluvoxamine 100mg daily, 7 days
75415138|NCT01396720|Drug|citalopharm|Citalopharm 20mg daily, 7 days
75415139|NCT01396733|Drug|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
75560019|NCT00472238|Behavioral|exercise training|Treadmill exercise training to optimize physical endurance
75560020|NCT01323790|Drug|NKTR-118|12.5 mg oral tablet once daily
75560021|NCT01323790|Drug|NKTR-118|25 mg oral tablet once daily
75560022|NCT01323790|Drug|Placebo|Placebo to NKTR-118
75560023|NCT00477035|Drug|CIK cells|2x10e8 cells/kg
75560024|NCT00477035|Drug|etoposide|60 mg/kg
75560025|NCT00477035|Drug|bcnu|15 mg/kg
75560026|NCT00477035|Drug|cyclophosphamide|100 mg/kg
75560027|NCT00477035|Drug|gemcitabine|1250 mg/m2
75560028|NCT00477035|Drug|vinorelbine|30 mg/m2
75560029|NCT00477035|Drug|melphalan|200 mg/m2
75560030|NCT00494832|Drug|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
75873170|NCT03628872|Procedure|Scaling and root planing|"A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis."
75560031|NCT00494832|Drug|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
75560032|NCT00477074|Procedure|bronchoalveolar lavage, blood analysis|
75560033|NCT01323673|Drug|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
75560034|NCT01323673|Drug|Vehicle / Placebo|2 times a day, 14 total days of study treatment
75560035|NCT00494949|Drug|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
75560036|NCT00494949|Drug|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
75560037|NCT00472316|Behavioral|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
75560038|NCT01246752|Biological|Human Stem Cell Transplantation|Human allogenic stem cells
75560039|NCT01246752|Drug|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
75560040|NCT01323634|Drug|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
75560041|NCT01323634|Drug|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
75560042|NCT05645302|Drug|Lidocaine Cataplasms|The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.
75560043|NCT00494988|Drug|insulin aspart|
75560044|NCT00494988|Drug|insulin NPH|
75560045|NCT01323478|Drug|Vortioxetine (Lu AA21004)|15 or 20 mg/day; tablets; orally
75560046|NCT00472355|Drug|apomorphine|
75560047|NCT04325581|Drug|Liraglutide 6 MG/ML|Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
75560048|NCT04325581|Drug|Placebos|Normal Saline SC daily
75560049|NCT02956161|Device|Stimulation of up-phase of sleep slow oscillation|
75560050|NCT02956161|Device|Random stimulation of up phase of sleep slow oscillation|
75560051|NCT02956161|Device|No stimulation|
75560052|NCT05645263|Other|dieting Coca-cola|The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
75560053|NCT00623272|Other|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
75415140|NCT01396759|Procedure|Bubble continuous positive airway pressure|All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
75560054|NCT04325776|Drug|AL2846|AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
75441459|NCT01634932|Other|Post-harvest iron-fortifed millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
75560055|NCT04325776|Drug|Zoledronic Acid Injection|Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
75560056|NCT03276845|Diagnostic Test|Ultrasound of the breast|Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
75560057|NCT01322386|Drug|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
75560058|NCT00495027|Behavioral|Internet-delivered Stress Innoculation Training|
75716120|NCT00332839|Drug|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
75560059|NCT03275909|Behavioral|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
75560060|NCT00495066|Drug|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
75560061|NCT00477308|Procedure|salvage therapy|
75560062|NCT01246908|Drug|Placebo|Placebo administered twice per day for six weeks.
75560063|NCT01246908|Drug|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
75560064|NCT00472433|Drug|Alemtuzumab|
75560065|NCT00495105|Behavioral|Two Servings of Dairy Snacks|2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
75560066|NCT00472472|Device|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
75560067|NCT01247025|Other|No intervention|This study will not contain a specific intervention
75560068|NCT00477347|Device|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
75560069|NCT00477347|Device|Manual administration|intraoperative manual administration of propofol and remifentanil
75560070|NCT01244568|Behavioral|Prostate cancer treatment DESI|DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
75560071|NCT00503568|Biological|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10^7 cells twice weekly, maximum 36 vaccines/patient
75716121|NCT00332839|Drug|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
75716122|NCT00332839|Drug|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
75560072|NCT00472550|Drug|esomeprazole 20 mg|
75415141|NCT01396759|Procedure|Humidified high flow air / O2 mix at 2 l/kg/min|Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
75415142|NCT01396759|Procedure|Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min|Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
75415143|NCT01396772|Behavioral|PREPARE education program|"PREPARE stands for Prediabetes Research and Education Promoting Activity and Responsible Eating and is a 6-month community-based prediabetes lifestyle and behaviour change intervention program. It includes a series of six interactive education sessions of two hours each on healthy eating and physical activity."
75415144|NCT01396772|Other|standard of care presentation|A one-time 2-hour group prediabetes education session, offered as the standard for individuals referred for prediabetes in London, Ontario (Canada)
75415145|NCT01396824|Other|No intervention|No intervention
75560073|NCT01244607|Drug|Placebo|single i.v. administration
75560074|NCT01244607|Drug|NI-0801|single i.v. administration
75560075|NCT00503607|Drug|BLI-800|
75560076|NCT00503607|Drug|Polyethylene glycol 3350 based bowel preparation|
75560077|NCT00477503|Drug|Gallium-67 Citrate (Ga-67)|"Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
75560078|NCT00477503|Drug|In-111 DTPA (In-111 pentetate)|"Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
75560079|NCT00472628|Procedure|Blood samples collected|
75560080|NCT00503646|Other|communication intervention|
75560081|NCT00503646|Other|counseling intervention|
75716123|NCT00332839|Drug|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
75560082|NCT00503646|Other|questionnaire administration|
75560083|NCT00503646|Procedure|psychosocial assessment and care|
75560084|NCT01244334|Drug|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
75560085|NCT01244334|Drug|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
75560086|NCT00477542|Drug|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~3-6 30~3-6 40~3-6 50~3-6 60~6-10 70"
75560087|NCT00503724|Drug|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
75560088|NCT00472667|Procedure|Procalcitonin guided strategy|Procalcitonin guided strategy
75716124|NCT00332839|Drug|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
75716125|NCT00983632|Procedure|Selective vagus nerve stimulation|"Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.~For details see detailed study description"
75560089|NCT00503763|Drug|Simvastatin|
75716126|NCT00983632|Device|selective vagus nerve stimulation|electrical vagus stimulation
75415146|NCT01396863|Procedure|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
75415147|NCT01396863|Procedure|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
75560090|NCT00477581|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
75560091|NCT00477581|Drug|sitagliptin|oral administration (100mg), once a day in the morning
75415148|NCT01396876|Behavioral|clown|a distraction technique is performed by a clown during venipuncture
75560092|NCT00503802|Procedure|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
75716127|NCT00927147|Radiation|BNCT|Boronophenylalanine infusion followed by neutron irradiation
75415149|NCT01396889|Drug|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
75560093|NCT00503802|Procedure|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
75560094|NCT00477620|Behavioral|Wearing of reading glasses during prolonged near work|
75560095|NCT00477737|Drug|Sevoflurane|
75560096|NCT00477737|Drug|propofol|
75716128|NCT00927147|Drug|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
75560097|NCT01247103|Drug|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
75560098|NCT01247103|Drug|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
75560099|NCT01247103|Other|Placebo|Placebo to match AZD4316
75560100|NCT00477776|Drug|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
75560101|NCT00477776|Drug|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
75560102|NCT00504699|Procedure|Ovarian stimulation in vitro fertilization cryopreservation|Letrozole 5 mg/day during ovarian stimulation
75560103|NCT00477815|Biological|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
75415150|NCT01396889|Drug|Placebo|Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
75415151|NCT01396902|Behavioral|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
76042244|NCT05699005|Drug|Packed Red Blood Cells (PRBCs)|"Patient will recieve PRBCs transfusion only in case of ScVO2 level<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature >38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia >4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level <7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement."
75415152|NCT01396902|Behavioral|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
75415153|NCT01396915|Dietary Supplement|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
75415154|NCT01396928|Procedure|Colonic reservoir|Type of reservoir to be performed
75415155|NCT01396941|Behavioral|Sleep restriction|Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
75560104|NCT00477815|Drug|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
75716129|NCT05712616|Drug|Strontium Ranelate|Dual mode of action, anabolic and anti-resorptive
75716130|NCT05712616|Drug|Lacto-N-Hexaose|Placebo look alike drug
75415156|NCT01396967|Device|surgery|cataract surgery
75415157|NCT01396993|Procedure|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
75415158|NCT01396993|Procedure|Breast Surgery|Breast conserving therapy without defect correction
75415159|NCT01397006|Drug|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
75415160|NCT01397019|Drug|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
75560105|NCT00477815|Biological|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
75560106|NCT00477815|Biological|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
75716131|NCT00927225|Drug|ropivacaine 0.2%, 50 mL|
75716132|NCT00927225|Drug|normal saline|
75716133|NCT00357097|Drug|Ropinirole|
75415161|NCT01397032|Behavioral|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
75560107|NCT00477815|Radiation|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
75716134|NCT00983710|Behavioral|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
75415162|NCT01397032|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
75415163|NCT01397045|Other|VATS|Video-assisted lung segmentectomy
75415164|NCT01397045|Procedure|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
75415165|NCT01397097|Drug|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
75415166|NCT01397097|Drug|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
75560108|NCT00477815|Biological|111In Zevalin|5.0 mCi by IV
75560109|NCT01247181|Other|Mobile phone text message|Weekly message with motivational content
75560110|NCT01247181|Other|Usual care|Usual care provided at clinic
75415167|NCT01397123|Other|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
75560111|NCT01244685|Device|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
75716135|NCT00983710|Behavioral|Usual care|Booklet on coping with localized prostate cancer
75716136|NCT00927303|Device|Cirrus-Spectralis|512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
75716137|NCT00927303|Device|Spectralis-Cirrus|retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
75716138|NCT00983788|Drug|Bezafibrate|3 x 200 mg/ day
75415168|NCT01397149|Drug|Placebo|Dosage form, frequency and duration exactly as experimental arm.
75415169|NCT01397149|Drug|Eltrombopag|"Phase I:~Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to > 400,000/µl).~Phase II:~Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I."
75560112|NCT00477854|Drug|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
75716139|NCT00983788|Other|Placebo|Placebo
75560113|NCT01247259|Drug|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
75415170|NCT01397175|Device|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
75560114|NCT00477893|Drug|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
75560115|NCT00477893|Drug|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
75415171|NCT01397175|Device|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
75415172|NCT01397175|Device|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
75415173|NCT01397188|Device|PiCCO|transpulmonary thermodilution technique
75415174|NCT01397188|Other|sham, no intervention|no intervention
75415175|NCT01397214|Drug|Megace F|Megace F oral suspension
75560116|NCT01245426|Drug|GW870086 2mg|oral inhalation
75560117|NCT01245426|Drug|GW870086 4mg|oral inhalation
75560118|NCT01245426|Drug|GW870086 Placebo|oral inhalation
75560119|NCT01245426|Drug|GW870086 1mg|oral inhalation
75560120|NCT01245426|Drug|GW870086 3mg|oral inhalation
75415176|NCT01397214|Drug|Megace OS|Megace oral suspension
75415177|NCT01397240|Drug|Albis Tab|2 Tab, twice a day, 12 weeks
75415178|NCT01397240|Drug|Placebo|2 Tab, twice a day, 12 weeks
75560121|NCT00478010|Other|counseling intervention|
75560122|NCT00478010|Other|study of socioeconomic and demographic variables|
75560123|NCT00478010|Procedure|psychosocial assessment and care|
75415179|NCT01397266|Procedure|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
75415180|NCT01397266|Procedure|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
75415181|NCT01397305|Drug|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
75415182|NCT01397305|Drug|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
75415183|NCT01397331|Drug|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
75415184|NCT01397331|Drug|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
75560124|NCT00478010|Procedure|quality-of-life assessment|
75560125|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
75560126|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
75560127|NCT00478049|Drug|Gefitinib|250 mg oral tablet
75560128|NCT00478049|Drug|Docetaxel|intravenous infusion
75560129|NCT01248975|Drug|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
75560130|NCT01248975|Drug|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
75560131|NCT01248975|Drug|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
75560132|NCT01248975|Drug|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
75560133|NCT01248975|Drug|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
75560134|NCT01248975|Drug|Placebo capsule (PM)|Placebo capsule (PM)
75560135|NCT02955927|Drug|0.01% atropine eye drops|
75560136|NCT02955927|Device|ortho-k|
75560137|NCT00478283|Other|survey administration|
75560138|NCT01247454|Behavioral|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
75560139|NCT01247454|Behavioral|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
75415185|NCT01397357|Other|Cardiac magnetic resonance - CINE MRI stress test.|Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
75415186|NCT01397370|Drug|GLPG0492|Oral solution
75415187|NCT01397370|Drug|Placebo|Oral solution
75415188|NCT01397396|Procedure|Inspiratory Muscle Training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
75415189|NCT01397474|Other|PPTFM|Peripheral Perfusion Targeted Fluid Management
75415190|NCT05269290|Drug|Ingavirin®, syrup, 30 mg/5 ml|A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.
75415191|NCT05269290|Drug|Placebo|Placebo will be administered once a day on top of standard therapy.
75415192|NCT05269251|Device|Near Infrared Spectroscopy (NIRS)|After the brachial plexus block, the regional oxygen saturation (rSO2) was monitored for 30 minutes with the Regional Oximetry System (O3™, Masimo, Irvine, CA) and the radial artery diameter with ultrasound in the same period.
75415193|NCT05268952|Other|Liquid biopsies|Blood/urine sampling and scans are done at regular intervals
75415194|NCT05268952|Other|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
75560140|NCT01247454|Behavioral|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
75560141|NCT00478322|Drug|Placebo|Matching placebo of 100 mg BID
75560142|NCT00478322|Drug|INCB013739|INCB013739 100 mg BID
75560143|NCT01322347|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
75873171|NCT03628872|Device|Er:YAG Laser|This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
75415195|NCT05268913|Diagnostic Test|MRI scan|Participants will undertake a magnetic resonance imaging scan.
75415196|NCT05268913|Biological|Blood test|Participants will undertake a fasting blood test.
75415197|NCT05268900|Device|Volume control ventilation group|Volume control ventilation mode
75415198|NCT05268900|Device|Pressure control ventilation-volume guaranteed group|Pressure control ventilation-volume guaranteed mode
75415199|NCT05268861|Behavioral|Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. Subjects will receive an elbow flexion error of 15 degrees to encourage elbow extension.
75415200|NCT05268861|Behavioral|No Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. In this case, subjects that do not receive EA feedback will act as sham comparators.
75415201|NCT05268848|Other|Thermographic photo|Barefoot patient, thermographic photo of the sole of the feet is taken
75415202|NCT05268835|Drug|Dalacin C|The objective of the intervention is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars
75415203|NCT05268718|Drug|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.
75873172|NCT03628872|Device|Hand instruments|11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
75873173|NCT05113290|Drug|Recombinant Human Adenovirus Type 5 injection|Intratumoral injection of lesions with dose of 3 vials (1.5 × 10^12 vp) if the sum of the maximum lesion diameters was > 10 cm, 2 vials (1.0 × 10^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
75415204|NCT05268718|Drug|Voriconazole eye drops|Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)
75415205|NCT05268718|Other|Normal saline|To be placebo, normal saline were administrated to infectious eye
75415206|NCT05268692|Drug|GS|drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (< 1.25 m2, 60 mg/d; ≥ 1.25 to < 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
75415207|NCT05268692|Drug|GnP|"drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle."
75873174|NCT05113290|Drug|Sorafenib|Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
76042245|NCT05549167|Drug|Sirolimus|Sirolimus 0,8 mg/m2, but <2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
75415208|NCT05268627|Drug|Liraglutide|endoscopy
75415209|NCT05268601|Drug|Bamlanivimab|Administration of monoclonal antibody against SARS-CoV-2
75415210|NCT05268601|Drug|Bamlanivimab and Etesevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
75415211|NCT05268601|Drug|Casirivimab and Imdevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
75415212|NCT05268601|Drug|Sotrovimab|Administration of monoclonal antibody against SARS-CoV-2
75415213|NCT05268536|Other|core stabilization exercise|Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
75415214|NCT05268536|Other|resistance exercise|resistance exercise
75560144|NCT01322347|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
76042246|NCT05542693|Biological|RNA MCTI CIMATEC HDT 5µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
76042247|NCT05542693|Biological|RNA MCTI CIMATEC HDT 10µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
75560145|NCT01247493|Drug|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
76042248|NCT05542693|Biological|Covishield® - AstraZeneca|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)
75560146|NCT00478439|Dietary Supplement|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
75560147|NCT00478439|Dietary Supplement|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
75716140|NCT00983866|Behavioral|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
75716141|NCT00983944|Biological|bleomycin sulfate|Given IV
75716142|NCT00983944|Biological|rituximab|Given IV
75716143|NCT00983944|Drug|EPOCH regimen|Given IV or orally
75415215|NCT05268523|Behavioral|Education and Strategies Intervention|Sessions will be led by registered therapists and clinicians in the fields of psychology, rheumatology, cardiology and neurology. The sessions will be comprised of educational presentations on the nature of persisting symptoms after COVID-19 and associated recommendations for self-management.
75415216|NCT05268523|Behavioral|Mindfulness Skills Intervention|The Mindfulness Skills Intervention is an 8-week program designed to provide an introduction to some basic mindfulness skills. Each session begins with a brief breath focus practice followed by discussion of the experience and sharing/discussion of the previous week including participants' experiences. Each session also includes some didactics, and a new, related mindfulness skill is introduced and practiced, followed by another discussion.
75441460|NCT01634945|Drug|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
75441461|NCT01634945|Dietary Supplement|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
75560148|NCT04325425|Drug|FOLFOXIRI Protocol|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
75716144|NCT00983944|Drug|cyclophosphamide|Given IV or orally
75716145|NCT00983944|Drug|doxorubicin hydrochloride|Given IV or orally
75716146|NCT00983944|Drug|etoposide|Given IV or orally
76042249|NCT05542693|Biological|Comirnaty® - Pfizer|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).
76042250|NCT05549089|Device|Insignia™ twin brackets|it is metal orthodontic twin brackets with customized base and individual arch-wires for each patient
76042251|NCT05549089|Device|Maestro® 3D Ortho Studio software (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and 3D printing indirect bonding tray
76042252|NCT05549089|Device|Ray set® device (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and double-layer vacuum-formed thermoplastic indirect bonding tray
75716147|NCT00983944|Drug|prednisone|Given IV or orally
75716148|NCT00983944|Drug|vincristine sulfate|Given IV or orally
75716149|NCT00927459|Drug|PRO-040201|Single dose IV infusion
76042253|NCT04323553|Diagnostic Test|Pulsed-field gel electrophoresis and whole genome sequencing|Comparison of the two different techniques
75415217|NCT05268484|Device|Perturbation-based Training with visual cues using Neurocom|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
75415218|NCT05268354|Other|6-week neuromuscular training program|Training program consisting of three neuromuscular training sessions per week
75415219|NCT05268211|Diagnostic Test|urinary oxygen partial pressure|measuring urinary oxygen partial pressure and measuring US Doppler renal resistive index
75560149|NCT04325425|Drug|Cisplatin injection|"Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 [the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3"
75560150|NCT02891395|Drug|Imatinib Mesylate and Nilotinib|"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
75560151|NCT00478478|Procedure|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
75560152|NCT05645185|Diagnostic Test|Diagnosis test|Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
75560153|NCT01247532|Behavioral|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
75560154|NCT00478517|Drug|Erythropoetin (rHuEPO, EPREX®)|
75415220|NCT05268068|Drug|Risankizumab|Intravenous (IV) Infusion
75415221|NCT05268068|Drug|Risankizumab|Subcutaneous (SC) Injection
75560155|NCT03273218|Device|Tiger catheter|
75560156|NCT03273218|Device|Judkins catheter|
75560157|NCT01321879|Drug|Telavancin|10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
75560158|NCT03271853|Device|Sentinel BreastScan II|The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
75560159|NCT01321723|Drug|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
75716150|NCT00927459|Drug|Placebo|placebo
75415222|NCT05267977|Drug|Cephalosporin 1St Generation|
75415223|NCT05267977|Drug|Aminoglycosides|
75560160|NCT01321723|Drug|Placebo|
75560161|NCT01321723|Drug|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
75560162|NCT01247649|Device|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
75560163|NCT00478634|Drug|RAD001, Cetuximab, Irinotecan|
75560164|NCT01247688|Drug|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
75560165|NCT01247688|Drug|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
75560166|NCT01247688|Radiation|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
75560167|NCT01247688|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
75560168|NCT01321606|Dietary Supplement|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10^10 organisms
75560169|NCT01321606|Dietary Supplement|sugar pill (placebo)|Placebo identical to the active product will be given
75560170|NCT00503919|Procedure|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
75560171|NCT00478790|Device|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
75560172|NCT02956187|Behavioral|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
75415224|NCT05267964|Procedure|Epping resection arthroplasty|Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
75560173|NCT02956187|Dietary Supplement|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
75415225|NCT05267964|Procedure|CMC I prosthesis|Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
75415226|NCT05246891|Other|rehabilitation nursing|Functional respiratory rehabilitation and motor exercise plan.
75415227|NCT05246748|Other|Human Caring Theory based Education|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
75415228|NCT05246748|Other|Standard Education|The control group received solely standard education program for one sessions in prenatal period.
75441462|NCT01634945|Drug|SP/Amodiaquine + FeFum fortified porridge|"One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months."
75560174|NCT04517682|Diagnostic Test|RT-PCR|The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples
75560175|NCT01320943|Drug|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
75560176|NCT01320943|Other|Stop TDF|Participants will stop TDF therapy
75560177|NCT04519008|Device|Mobile app|Medical device for improving emotion dysregulation
75560178|NCT04519008|Combination Product|Treatment as usual|Bimonthly individual psychotherapy and psychostimulant medications
75560179|NCT04325347|Other|Virtual Reality application|Virtual Reality application with a VR goggle
75560180|NCT00472706|Procedure|excision|excision 3 mm margin
75560181|NCT00472706|Procedure|Photodynamic therapy|Photodynamic therapy
75560182|NCT02955459|Drug|VNRX-5133|
75560183|NCT02955459|Drug|Placebo|
75560184|NCT00478907|Drug|KETAMINE, PROPOFOL, THIOPENTAL|
75560185|NCT02275377|Other|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
75560186|NCT02275377|Other|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
75560187|NCT00478946|Drug|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
75560188|NCT00478946|Drug|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
75560189|NCT00478946|Drug|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
75560190|NCT01247844|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
75560191|NCT01247961|Drug|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
75560192|NCT01247961|Other|Placebo|Normal saline
75415229|NCT05238090|Other|Passive and active analytical stretching exercises|"For each stretching technique described, 3 repetitions of 15 seconds duration will be performed of 15 seconds duration each, within the patient's tolerance threshold. In any case, the impossibility of performing any technique due to exacerbation of pain shall be recorded in a patient record created for this study, noting the technique in question and the reason for its technique in question and the reason for its non-application. Passive stretches shall be applied in the same order for all subjects.~The physiotherapists in charge of applying the treatments will be trained in advance in the different techniques to be applied and will not in the different techniques to be applied and shall not intervene at any time in the two previous phases.~Both the control group and the study group will receive their respective treatments two days a week for four weeks. In no case will any other type of treatment be associated treatment during the whole process."
75415230|NCT05238090|Other|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
75415231|NCT05207696|Other|retrospective data analysis|The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)
75415232|NCT05186558|Drug|penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin|"Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~lenalidomide: 10 mg, po, for 18 months."
75415233|NCT05175456|Other|Bedjet|Bedjet is a sleep cooling system. All participants will be provided a Bedjet system as part of the study.
75415234|NCT05175456|Device|FitBit|Each participant will receive a FitBit device to track sleep quality and related information.
75560193|NCT01248000|Procedure|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
75560194|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
75415235|NCT05113810|Drug|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
75415236|NCT05113810|Other|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
75415237|NCT05101135|Drug|JT-001|Subjects take the investigational products once a day for 24 weeks.
75415238|NCT05101135|Drug|JT-001 Placebo|Subjects take the investigational products once a day for 24 weeks.
75415239|NCT05092698|Dietary Supplement|Vitamin D (cholecalciferol)|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of cholecalciferol weekly and 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
75415240|NCT05092698|Dietary Supplement|Herbal oil|Patients will receive 45 ml of herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of pure herbal oil weekly and two drops of herbal oil daily until discharge or death.
75415241|NCT05051254|Other|Esogastric pressure measurement|"Measurement of work of breathing and respiratory muscles strength using an esogastric catheter.~One measurement or before and after (6 months and 1 year) the initiation of a pharmacological treatment in order to assess the effect of the treatment on respiratory muscle function."
75415242|NCT05009355|Drug|Vitamin C|antioxidant
75415243|NCT05003661|Behavioral|Parents' Voice|the intervention is recording of parents voice of reading children's book.
75441463|NCT01634945|Dietary Supplement|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
75560195|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
75560196|NCT01248078|Drug|saline solution|100cc administered before skin incision
75560197|NCT00472823|Dietary Supplement|Vitamin D3|Orally for one year
75560198|NCT00472823|Dietary Supplement|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
75560199|NCT02275416|Drug|Ipilimumab|
75560200|NCT02275416|Biological|UV1 vaccine|
75560201|NCT02275416|Biological|GM-CSF|
75415244|NCT04986449|Behavioral|nutritional and culinary intervention|"Each family will attend a total of 4 culinary-nutritional workshops between April and June 2021. Workshops 1 and 2 will be held in the kitchen located at the Science Building of the University of Navarra and will be given individually to each family.~Workshops 3 and 4 will be online (Zoom) and will be held in groups of 5 families. These workshops will be held from 5.30 pm to 7.30 pm on Fridays or from 11.30 am to 1.30 pm on Saturdays.~Finally, a meeting will be organized with all the families (parents and children) where the recipes prepared by the children for the n-CHEF challenge will be shared and prizes will be awarded."
75415245|NCT04981587|Procedure|Strength exercise|Strength exercise protocol for upper and lower limbs, using weights and elastic bands
75415246|NCT04981587|Other|Usual treatment|The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
75560202|NCT00472862|Behavioral|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
75560203|NCT00472901|Drug|Afamelanotide (CUV1647)|16mg implant
75560204|NCT00479024|Drug|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
75560205|NCT02482233|Behavioral|ENDD (NJOY)|As described above.
75560206|NCT02482233|Drug|NRT (NicoDerm CQ)|As described above.
75560207|NCT02482233|Behavioral|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
75560208|NCT02482233|Behavioral|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
75560209|NCT02482233|Behavioral|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf"
75415247|NCT04980014|Drug|NesinaAct® Tablet|NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.
75716151|NCT00356863|Behavioral|Increasing awareness to cardiac rehabilitation programs|Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
75560210|NCT02489526|Drug|VVZ-149 Injections|Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
75560211|NCT02489526|Drug|Placebo|Placebo group will receive the corresponding amount of placebo.
75560212|NCT00473018|Behavioral|standard versus enhanced risk reduction counseling|
75560213|NCT00479102|Drug|Ferripel-3 - iron polysaccharide complex for prevention|
75560214|NCT01248117|Drug|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
75560215|NCT00479141|Behavioral|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
75716152|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
75716153|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
75716154|NCT00987064|Device|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
75716155|NCT00987064|Device|Placebo TLA|TLA treatment with disabled filtration function
75716156|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
75560216|NCT00479141|Behavioral|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
75560217|NCT00479180|Biological|Vascugel|One time implant on the day of surgery
75560218|NCT00479180|Biological|Placebo Comparator|One time implant on the day of surgery
75716157|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
75716158|NCT03760744|Procedure|CDT with Negative Pressure|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) in conjunction with manual intervention of graded negative pressure application for lymphatic stimulation/ tissue clearance
75716159|NCT03760744|Procedure|CDT alone|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) for lymphatic stimulation/ tissue clearance
75716160|NCT00909129|Drug|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
75716161|NCT00909129|Drug|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
75716162|NCT01053325|Drug|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
75873175|NCT03628794|Device|D-SCAN|"Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks"
75415248|NCT04975204|Drug|TQB3909 Tablets|TQB3909 is an inhibitor targeting BCL-2 protein
75560219|NCT01248234|Drug|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
75560220|NCT01248234|Drug|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
75560221|NCT01248234|Drug|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
75560222|NCT00479219|Drug|GSI-953|
75560223|NCT00479219|Other|Placebo|
75560224|NCT00479297|Drug|SAM-531|
75873176|NCT03461952|Drug|Nivolumab|240mg
75415249|NCT04965870|Drug|Trifluridine/Tipiracil|Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
75415250|NCT04954807|Dietary Supplement|human milk fortified|HMF will be given 6 scoops a day
75415251|NCT04954807|Dietary Supplement|placebo|Placebo will be given six scoops a day
75415252|NCT04944745|Other|Myofascial Release|Moderate pressure manual treatment to the pectoral fascia.
75415253|NCT04944745|Other|Soft-touch Control|No pressure manual treatment to the pectoral fascia.
75415254|NCT04856436|Drug|Benzodiazepine|Exposure to benzodiazepine during early pregnancy
75415255|NCT04853212|Procedure|Biopsy|Biopsy during recto-coloscopy
75415256|NCT04685902|Device|One-way speaking valve|One-way speaking valve is a small device that attaches to the tracheostomy tube, to allows tracheostomy patient to breathe in through his or her trach tube. After the inhalation, the speaking valve closes. Air is breathed out (exhaled) up through the vocal cords, then through the mouth and nose.
75415257|NCT04641091|Device|Multispectral Optoacustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
75560225|NCT00503958|Genetic|DNA methylation analysis|
75560226|NCT00503958|Genetic|DNA stability analysis|
75560227|NCT00503958|Genetic|gene expression analysis|
75560228|NCT00503958|Other|epidemiologic study|
75560229|NCT00503958|Other|study of socioeconomic and demographic variables|
75560230|NCT00503958|Procedure|biopsy|
75560231|NCT00503958|Procedure|evaluation of cancer risk factors|
75560232|NCT00503958|Procedure|study of high risk factors|
75560233|NCT00473057|Other|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
75716163|NCT01053325|Drug|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
75716164|NCT04733404|Device|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
75873177|NCT03461952|Drug|Ipilimumab|1mg/kg
75873178|NCT03423173|Biological|TAK-003|TDV subcutaneous injection
75873179|NCT03423173|Biological|Placebo|TDV Placebo-matching normal saline (0.9% NaCl) subcutaneous injection
75415258|NCT04600674|Procedure|Delayed cord clamping|DCC performed at 60 sec after birth
75415259|NCT04600674|Procedure|Early cord clamping|ECC performed at 15 sec after birth
75415260|NCT04598087|Behavioral|Prehabilitation|The multi-phasic prehabilitation intervention involves three phases: Phase 1: Before surgery (typically ~25 days); Phase 2: The in-hospital phase (typically 10-14 days); Phase 3: Discharge to 6-weeks after surgery.
75415261|NCT04593784|Drug|Ciraparantag|Ciraparantag: 180 mg, intravenous
75415262|NCT04593784|Drug|Placebo|Placebo: 0.9% sodium chloride, intravenous
75415263|NCT04593784|Device|Point-of-Care Coagulometer (investigational device)|Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.
75415264|NCT04576910|Biological|vaccinated with Sabin IPV|the 4th dose of polio vaccination
75415265|NCT04576910|Biological|vaccinated with bOPV|the 4th dose of polio vaccination
75415266|NCT04503603|Drug|Lanadelumab|Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
75716165|NCT05277363|Other|None (Observational study)|No investigational intervention, marketed product, or placebo will be administered to study participants in this study.
75716166|NCT03990181|Dietary Supplement|meal matrix & NPPS|Test meal consumed with the natural polyphenol supplement
75415267|NCT04503603|Other|Placebo|Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.
75415268|NCT04500366|Behavioral|Socialization|Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.
75415269|NCT04500366|Behavioral|Virtual Group Exercise|Participants will receive twice-weekly (one hour per class) virtual exercise via small-group physiotherapy sessions for a total of 12 weeks. All exercise sessions will occur virtually via a videoconferencing system. The classes will focus on functional movements specifically designed for seniors with frailty and mobility challenges, and will include modifications for gait aids such as canes or walkers. Class sizes will be small to allow for tailoring of exercises based on challenging, safe, progressive, evidence-based exercises. In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults, participants will also be provided with tailored supplemental home exercises developed by the study physiotherapist to gain an additional 1 hour of physical activity.
75415270|NCT04500366|Combination Product|Nutrition Consult and Protein Supplementation|"Nutrition Consult: Participants will be scheduled for a one-on-one virtual nutrition consult. During the consultation, study staff will assess the nutritional status of the participant and will provide them with counselling and coaching to improve their nutrition.~Protein Supplementation: Oral nutrition supplements commercially available from Nestle will be provided unless contraindicated. The oral nutrition supplement contains 360 calories and 14 grams of protein per serving. Participants are advised to take this with a meal or within 3 hours of exercise on activity days."
75415271|NCT04500366|Behavioral|Medication Review|A study pharmacist will review the participant's medication list and will utilize Beers and/or START/STOPP criteria to provide recommendations to optimize/update their medications to the participant's healthcare provider. Study geriatricians will be listed as contacts on the primary care provider recommendations and available for consultation.
75415272|NCT04466540|Drug|Hydroxychloroquine|Hydroxychloroquine pharmaceutical form will be tablets of 400 mg.
75415273|NCT04466540|Drug|Placebo|Hydroxychloroquine placebo
75415274|NCT04454918|Drug|TAK-906 Oral Capsule|TAK-906 capsule.
75415275|NCT04454918|Drug|[14C]-TAK-906 Intravenous Infusion|[14C]-TAK-906 intravenous infusion.
75415276|NCT04454918|Drug|[14C]-TAK-906 Oral Solution|[14C]-TAK-906 oral solution.
75415277|NCT06105606|Device|AveCure Flexible Microwave Ablation Probe|Consists of a handheld, surgical device which delivers microwave energy from its microwave antenna. The flexible probe has a 3cm active microwave field that radiates from the tip.
75415278|NCT06105541|Device|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
75415279|NCT06105515|Procedure|Laparoscopic and Endoscopic Collaborative Surgery (LECS)|Minimal invasive surgery in collaboration between endoscopy and laparoscopic surgery, to locally remove the tumor
75560234|NCT00473096|Behavioral|Informed breast cancer surgical treatment|
75560235|NCT00473135|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10^3 PFU
75560236|NCT00473135|Biological|Placebo|Placebo for rDEN1delta30
75716167|NCT03990181|Dietary Supplement|meal matrix & CS|Test meal consumed with the control supplement
75415280|NCT06105502|Behavioral|Psychotherapy education|Psychotherapy education, including supervision, lectures, and workshops
75415281|NCT06105489|Procedure|Lateral Sinus Lift using tunnel flap technique|"The surgical procedure will involve the following steps:~A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~The door will be removed.~The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~The flaps will be meticulously sutured."
75415282|NCT06105489|Procedure|Lateral Sinus Lift using crestal incision flap|"The surgical procedure will involve the following steps:~A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~The door will be removed.~The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~The flaps will be meticulously sutured."
75415283|NCT06105437|Other|BE-EMPOWERed program|The BE-EMPOWERed program entails a group program for older people, workshops for healthcare professionals and a 6-steps implementation plan for primary care areas. The group program for older people is based on the main principles of the Australian multifactorial falls prevention program 'Stepping On'. The workshops for healthcare professionals focus on the multifactorial falls prevention approach, reimbursement of healthcare costs, referrals to other healthcare professionals and motivational interviewing. The Implementation plan consists of 6-steps: 1. enable support, 2. map baseline situation, 3. define objectives and priorities, 4. plan implementation, 5. implementation and 6. evaluation, adjust and work towards sustainability. Last, to support the primary care areas, implementation facilitators were trained.
75415284|NCT06105424|Procedure|Lung Permeability Assessment|A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.
75415285|NCT06105398|Other|clinical evaluation|clinical evaluation tests
75560237|NCT01248273|Biological|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
75560238|NCT00479375|Procedure|Adding Human Papillomavirus testing to organised cervical screening|
75415286|NCT06105385|Other|Suboccipital Myofascial Release Technique|With the patient in a supine position, the therapist sits behind the patient with his or her forearms on the treatment table. The therapist places his fingers between the occiput and axis, with his fingers in semi-flexion (2nd, 3rd and 4th fingers), and continues to hold his hands on the occiput until relaxation is achieved in the suboccipital muscles. A light traction is applied at the end of the technique. Average application time is 4-5 minutes.
75441464|NCT01634945|Other|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
75560239|NCT01248312|Device|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
75560240|NCT01248312|Device|sentec monitor|transcutaneous monitoring
75560241|NCT01248351|Other|autologous stored platelets|Administration of autologous stored platelets
75560242|NCT01248351|Other|administration of autologous stored platelets|administration of autologous stored platelets
75716168|NCT03990181|Dietary Supplement|no-matrix & NPPS|Test drink consumed with the natural polyphenol supplement
75716169|NCT03990181|Dietary Supplement|no-matrix & CS|Test drink consumed with the control supplement
75716170|NCT05712148|Biological|Stem cell implantation|Suprachoridal mesenchymal spheroidal stem cell implantation
75716171|NCT00909207|Behavioral|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
75560243|NCT01248351|Biological|autologous stored platelets|transfusion of autologous stored platelets
75560244|NCT00473174|Drug|Ramipril|Dosing on awakening versus bedtime
75560245|NCT00473174|Device|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
75716172|NCT01053403|Drug|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
75716173|NCT00987142|Drug|CX501|Cultured chimeric skin
75560246|NCT01248390|Behavioral|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
75560247|NCT00473213|Drug|Interferon Beta 1|
75441465|NCT01634958|Biological|Depigoid Phleum|Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
75560248|NCT02274831|Other|Email Reminder of need to follow up with primary physician|
75560249|NCT01320202|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
75560250|NCT01320202|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
75560251|NCT00479531|Device|AirCast Sequential Compression Device|
75560252|NCT00479570|Drug|PF-00446687|Single 200mg dose
75560253|NCT00479570|Drug|Placebo|
75716174|NCT00987142|Device|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
75716175|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intracoronary)
75560254|NCT01319383|Drug|Vorinostat|Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
75560255|NCT05645029|Other|glass ionomer-chlorhexidine|chlorhexidine will be added to glass ionomer
75560256|NCT05645029|Other|glass ionomer-titanium dioxide powder|titanium dioxide will be added to glass ionomer
75560257|NCT05645029|Other|glass ionomer|glass ionomer will be used without any additives
75873180|NCT03348228|Dietary Supplement|Hydroxycitrate (HCA)|Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
75560258|NCT00479609|Drug|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
75560259|NCT00479609|Drug|Placebo|Placebo gel
75560260|NCT04325113|Drug|levobupivacaine|Patient satisfaction and pain score using a visual anagogic scale (VAS)
75560261|NCT02275104|Device|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
75716176|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intravenous)
75873181|NCT05062746|Other|Matrix-Rhythm Therapy|One session Matrix-Rhythm Therapy will be applied to affected body parts.
75716177|NCT03990103|Drug|S1|80-120 mg/day, PO, D1-14, every 21 days
75716178|NCT03990103|Drug|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
75716179|NCT03990103|Drug|Bevacizumab|200 mg, IP, D1, every 21 days
75716180|NCT03990103|Drug|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
75441466|NCT01634971|Procedure|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
75441467|NCT01635010|Procedure|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
75560262|NCT02275104|Device|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
75560263|NCT02275104|Device|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
75716181|NCT00927693|Other|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
75716182|NCT00987220|Drug|Placebo|Oral
75716183|NCT00987220|Drug|donepezil (Aricept)|5mg oral
75415287|NCT06105333|Procedure|standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline|CrSO2 (Cerebral regional oxygen saturation) monitoring was visible to the clinical team with the same SpO2 target as in the control group. If SpO2 (oxygen saturation) remained between the 10th and 90th centiles and within local limits, and crSO2 was <10th centile according to published reference ranges, FiO2 (fraction of inspired oxygen) was increased by 10-20% every 60 seconds or respiratory support was started or increased. If crSO2 remained >10th centile for >60 seconds or if rSO2 was >90th centile,FiO2 was reduced by 10-20% or respiratory support was adjusted accordingly. If there was a history of blood loss or clinical signs of blood loss, intravenous fluids (10 mL/kg) were considered.
75415288|NCT06105320|Other|LCHF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%"
75716184|NCT01581151|Drug|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
75716185|NCT01581151|Drug|Monthly Ranibizumab|30 days between treatments
75716186|NCT00909285|Device|TMS stimulation|TMS stimulation and cognitive training
75716187|NCT00909285|Device|Sham comparator|Sham comparator
75716188|NCT00909285|Behavioral|Cognitive training|TMS stimulation and cognitive training
75716189|NCT01053481|Dietary Supplement|vitamin D|Vitamin D supplement
75716190|NCT01053481|Behavioral|exercise program (rebounding on a trampoline)|40 days at 30 min/d
75716191|NCT05712070|Behavioral|App-guided lifestyle modification|Smart watch and smartphone application-based life style modification for 12 weeks
75716192|NCT05712070|Behavioral|A book-based self-education of lifestyle modification|A take-home book-based self-education for lifestyle modification
75716193|NCT00927771|Drug|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
75716194|NCT00927771|Drug|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
75873182|NCT05062746|Other|Conventional physiotherapy and rehabilitation|Hemiparetics wil receive one session conventional physiotherapy and rehabilitation.
75873183|NCT03192540|Other|Exercise|Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
75415289|NCT06105320|Other|HCLF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%"
75415290|NCT06105294|Behavioral|time-restricted eating|Restrict eating to a 10-hour window.
75716195|NCT01053559|Drug|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
75716196|NCT00987298|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
75415291|NCT06105281|Behavioral|The consultation with a pain specialist nurse|When the participant receives a consultation with the pain specialist nurse ,there will be assessed if the patient knows what the procedure involves and what they can expect of it. To meet de expectations of the patient the nurse will explain the procedure and what they can expect. Further there will be an short education about what pain is and the physiology of chronic pain. Because chronic pain has a lot of influencing factors the nurse will explain the main factors.
75415292|NCT06105268|Other|flipped learning training group|flipped learning training group. Applying a flipped learning model in addition to routine training in a fully equipped simulation
75415293|NCT06105255|Drug|D-1553|D-1553 is a novel, targeted KRASG12C inhibitor.
75415294|NCT06105203|Procedure|Robotic-assisted total mesorectal excision|TME will be performed with the assistance of robot in rectal cancer
75415295|NCT06105203|Procedure|laparoscopic-assisted total mesorectal excision|TME will be performed with the assistance of laparoscopy in rectal cancer
75415296|NCT06105164|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher."
75716197|NCT00909441|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
75716198|NCT00984100|Procedure|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
75716199|NCT01053637|Drug|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
75716200|NCT01053637|Drug|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
75873184|NCT03619824|Drug|Sintilimab|Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
75873185|NCT03619824|Drug|Gemcitabine|Gemcitabine 1g/m2, d1 & 8 of every cycle, every 3 weeks for 3 cycles before radiation.
75873186|NCT03619824|Drug|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
75873187|NCT03619824|Radiation|intensity-modulated radiotherapy|Definitive IMRT of 66-70Gy will be given in six to seven weeks.
75873188|NCT01759836|Drug|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
75873189|NCT03447821|Drug|400 mg Rifamycin SV dosage|
75873190|NCT03447821|Drug|800 mg Rifamycin SV dosage|
75873191|NCT03447821|Drug|1200 mg Rifamycin SV dosage|
75415297|NCT06105164|Device|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
75415298|NCT06105112|Device|Hyaluronic acid|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Application of cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) hyaluronic acid (hyaDent BG, Regedent, Germany) through a syringe over a bone xenograft (Smartgraft, Regedent, Germany). The mixture will be then compacted within the intrabony component of the defect.
75415299|NCT06105112|Device|Enamel matrix derivatives|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Enamel matrix derivatives gel (Emdogain, Straumann, Switzerland) will be applied on the dry root surfaces and left in place for at least 1 minute avoiding blood contamination. Subsequently, a bone xenograft (Smartgraft, Regedent, Germany) will be compacted within the intrabony component of the defect.
75716201|NCT00928005|Behavioral|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
75415300|NCT06105099|Behavioral|Motor-phonetic intervention|"Children will receive phonetic articulation therapy treating consonants in a phoneme-by-phoneme basis, emphasizing phonetic placement and shaping techniques.~Phonetic articulation therapy includes a progression of the target consonant from isolated level, syllable level, word level, sentence level, spontaneous speech level in five different steps:~identification of the target consonant using visual, tactile, and auditory feedback techniques, discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 90% of the time with minimal cues from the therapist."
75716202|NCT00928005|Behavioral|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
75441468|NCT01635023|Drug|AZD6244 Dosing Period 1|Treatment A, B, or C depending on randomization assignment
76042254|NCT04323553|Other|Data collection|Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
76042255|NCT05542537|Behavioral|Brighter Bites (BB) Produce Distribution|For 16 weeks in the school year, teachers in participating program schools will receive distributions of 8-10 different types of produce items.
76042256|NCT05542537|Behavioral|Brighter Bites (BB) Nutrition Education|Brighter Bites Nutrition Education will consist of recipes, food preparation and storage ideas, and tips and tools to budget and plan meals. Teachers will be trained in a nutrition education curriculum, which will be implemented in the program schools as part of the BB program.
76042257|NCT05542537|Behavioral|Create Healthy Futures (CHF) Weekly Wellness Groups|Peer-facilitators will lead virtual weekly group discussions. Penn State Better Kid Care will train the wellness facilitators.
76042258|NCT05542537|Behavioral|Create Healthy Futures (CHF) Web-Based Module|Create Healthy Futures Web-Based Module is self-paced and focuses on the following topics: 1) Introduction, 2) Challenges of the food environment, 3) Nutrition and your health, 4) Food culture reform, and 5) Providers' role in creating healthy futures. The Create Healthy Futures module utilizes several educational methods to increase interactivity and engagement, including video footage of content experts, reflection activities, downloadable handouts, and action planning. Each chapter takes approximately 30-40 minutes to complete. The program is delivered on the Better Kid Care On Demand platform, an asynchronous learning management system that provides professional development training for teachers in all 50 states and 69 countries.
76042259|NCT04320667|Diagnostic Test|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
75560264|NCT02275104|Device|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
75716203|NCT00928161|Drug|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
75716204|NCT00909519|Drug|naproxcinod|naproxcinod 750 mg bid
75716205|NCT00909519|Drug|Naproxen|Naproxen 500 mg bid
75716206|NCT00909519|Drug|placebo|placebo
76042260|NCT05548933|Procedure|non-surgical periodontal therapy|supragingival scaling,subgingival scaling
76042261|NCT05542459|Drug|Biologics|Infliximab, adalimumab, vedolizumab, ustekinumab, and other biologics approved for IBD
76042262|NCT05698849|Other|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
75441469|NCT01635023|Drug|AZD6244 Dosing Period 2|Treatment A, B, or C depending on randomization assignment
75441470|NCT01635023|Drug|AZD6244 Dosing Period 3|Treatment A, B, or C depending on randomization assignment
75441471|NCT01635023|Drug|AZD6244 Dosing Period 4|Treatment B
75716207|NCT00909519|Drug|furosemide|furosemide
75716208|NCT00928239|Procedure|laparoscopic sacropexy with mid vaginal attachment|"supracervical hysterectomy for uterine prolapse~exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~dissection up to ventrolateral part of the levator ani muscle~Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment~suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
75734969|NCT03412227|Behavioral|The Coping Cat Program for Youth Anxiety Disorders|"The Coping Cat program (Kendall & Hedtke, 2006; Kendall, Choudhury, Hudson, & Webb, 2002) has received substantial empirical support for its efficacy in both children (9-13 years old) and teens (12 - 17 years old) (Kendall, 1994; Kendall et al., 1997; Kendall et al., 2008) and involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward."
75560265|NCT02275104|Procedure|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
75873192|NCT03079284|Other|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
75873193|NCT05630339|Dietary Supplement|Magnesium chloride|Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.
76042263|NCT05700175|Diagnostic Test|Transcriptomic, epigenetic and proteomic analysis|"Next-generation sequencing will be used to identify differences in expression of circulating transcripts (protein-coding and not) in patients affected by Marfan Syndrome (MFS), subdivided based on the presence or absence of thoracic aortic aneurysms (TAA) and indication of TAA-surgery (TAA_MFS_signature).~The obtained TAA_MFS_signature will be correlated to fundamental biological parameters by analysing:~Blood-levels of cytokines and chemokines relevant for inflammation. Transcriptomic and epigenetic (Cytosine methylation) changes in aortic aneurysms tissue by Next-generation sequencing.~Progression of biomarkers in surgical-patients before and at 6 and 12 months after surgery."
76042264|NCT05554783|Diagnostic Test|Trendelenburg position|Positioning the patient with head 15 degrees down
76042265|NCT05698615|Behavioral|Chess training|"The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises."
75415301|NCT06105099|Behavioral|Phonological intervention|"The phonological approach consists of two phases. In the first phase, the child's attention is drawn to the contrastive features of the speech sound system which are relevant to the target consonants. Terms that describe the sound features will be introduced using words on the child's level, e.g. in the case of active nasal fricatives the words 'nose' and 'mouth' will be used. Child-friendly games will be played to illustrate the contrast between the concepts followed by activities that focus on the contrasts in non-speech sounds, in which child and therapist will alternate between being listener and speaker. At the end of this phase, minimal word pairs (e.g. tap/cap), only produced by the therapist, will be used to facilitate the child's awareness of sounds in words and meaningful differences based on distinctive features.~In the second phase, the child will produce minimal pairs providing the opportunity to monitor his/her speech and to make self-corrections."
75415302|NCT06105099|Behavioral|Combined phonetic-phonological intervention|Children will receive motor-phonetic articulation therapy supplemented with phonological principles. Therapy will be provided following the same five steps as the 'motor-phonetic group'. However, articulation errors will not be treated in a phoneme-by-phoneme basis. In contrast, multiple errors will be targeted simultaneously by focusing on a process. For example, if the child produces glottal stops for the /t/ and the /p/, these sounds will be treated simultaneously as sounds requiring oral front placements. Exercises will be embedded in meaningful language contexts such as minimal pairs
75415303|NCT06105086|Other|Semi-structured interview|Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
75441472|NCT01635036|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
75441473|NCT01635075|Behavioral|Exercise|1-mile treadmill walk
75441474|NCT01635075|Behavioral|passive control|20 min inactivity
75441475|NCT01635088|Drug|Mometasone furoate 220|dry powder inhaler QD for 28-43 days
76042266|NCT05542225|Procedure|Strength training|Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.
75441476|NCT01635088|Device|KoKo Spirometry|
75441477|NCT01635088|Drug|Mometasone furoate 440|dry powder inhaler QD for 28-43 days
75441478|NCT01635088|Device|Oscillometry|
75560266|NCT05644717|Drug|Ertugliflozin 5 mg, 15mg|Ertugliflozin 5/15mg once daily in addition to standard of care
75560267|NCT01248429|Biological|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
75873194|NCT05630339|Dietary Supplement|Vitamin D|Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.
75441479|NCT01635114|Dietary Supplement|resveratrol|150 mg resVida per day for 12 weeks
75873195|NCT05630339|Dietary Supplement|Inert placebo|Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.
75873196|NCT03447353|Drug|Xanax 1Mg Tablet|Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
75873197|NCT03447353|Drug|Norco 10Mg-325Mg Tablet|Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
75873198|NCT03447353|Drug|Placebo Oral Tablet|Single dose on two of the four study visits, double dose on one of the four study visits
75716209|NCT00928239|Procedure|laparoscopic sacropexy with caudal vaginal attachment|"supracervical hysterectomy for uterine prolapse~exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~dissection up to ventrolateral part of the levator ani muscle~Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment~suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
75716210|NCT00928317|Drug|ART621|3.0mg/kg s.c.
75716211|NCT00928317|Drug|ART621|1.5mg/kg s.c.
75716212|NCT00928317|Drug|ART621|0.75mg/kg s.c.
76042267|NCT05542225|Procedure|Flexibility training|Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.
76042268|NCT05542225|Procedure|Standard therapy|TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
75441480|NCT01635114|Dietary Supplement|Placebo|Placebo for 12 weeks
75441481|NCT01635127|Drug|Canakinumab|150mg s.c.
76042269|NCT02587819|Drug|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
75716213|NCT00928317|Drug|Placebo|Placebo s.c.
75716214|NCT00355615|Drug|Rosuvastatin|oral
75441482|NCT01635127|Drug|Placebo|Constituent of canakinumab
75441483|NCT01635140|Radiation|Hypofractionated radiotherapy|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
75716215|NCT00355615|Drug|Placebo|oral
75716216|NCT00907179|Drug|LBH 589|"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"
75716217|NCT00907179|Drug|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
75716218|NCT00347269|Behavioral|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
75716219|NCT00347269|Drug|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
75716220|NCT00347269|Behavioral|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
75873199|NCT03055884|Device|tDCS|active tDCS versus sham tDCS
75873200|NCT03055884|Behavioral|Verbal paired-associate learning task|with or without repeated retrieval practice
75560268|NCT01248429|Other|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
75716221|NCT00928473|Behavioral|A family-centered, multidisciplinary obesity treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
75716222|NCT01053793|Other|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
75716223|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
76042270|NCT04426045|Procedure|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.
76042271|NCT04426045|Procedure|Supra-inguinal fascia iliaca compartment block|"A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected."
75716224|NCT01056211|Procedure|treatment without laser|Starlux 300 Lux 1540nm Fractional laser hand piece
75716225|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
75716226|NCT00924105|Drug|CYT013-IL1bQb|s.c. injection
75716227|NCT00924105|Drug|Placebo|s.c. injection
75716228|NCT00544648|Drug|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
75716229|NCT00544648|Drug|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
75716230|NCT00544648|Radiation|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
75873201|NCT03718169|Behavioral|questionnaires|Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
75873202|NCT03446885|Drug|Lisdexamfetamine Dimesylate 40 MG|Lisdexamfetamine Dimesylate 40 MG administered orally
75873203|NCT03446885|Drug|Placebo|Placebo capsule administered orally
75716231|NCT00924183|Other|Treatment-as-usual|
76042272|NCT05548465|Drug|Remifentanil Hydrochloride|Subjects will receive remifentanil anesthesia for operative analgesia.
76042273|NCT05548465|Drug|Sufentanil Citrate|Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
75441484|NCT01635140|Radiation|Conventional arm|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
75441485|NCT01635166|Device|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
75441486|NCT01635179|Procedure|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
75441487|NCT01635192|Biological|VSL#3|"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."
75441488|NCT01635192|Biological|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
75441489|NCT01635205|Procedure|paraspinous anesthetic block|Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
75441490|NCT01635205|Procedure|subcutaneous puncture with no anesthetic effect|Subcutaneous puncture with injection needle (no substance will be injected)
75441491|NCT01635231|Other|hypertonic saline|hypertonic saline 3.0% 7 ml/kg
75441492|NCT01635257|Other|Ultrasound scan|A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
75441493|NCT01635270|Radiation|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
75716232|NCT00346333|Drug|Lutein|12mg/d
75415304|NCT06105073|Procedure|Pulmonary Rehabilitation Program|"Consecutive patients who attend with a confirmed diagnosis of Systemic Sclerosis associated Interstitial Lung disease, at the Dr. Antonio Fraga Mouret from the Centro Medico Nacional La Raza del IMSS. The anxiety and depression questionnaire will be applied to them. Goldberg, as well as the SF-36 questionnaire to evaluate quality of life and the SySQ questionnaire to evaluate functionality, to include these data in the analysis, these questionnaires are validated in our population and have been widely used. All participants (T0) will undergo Forced Spirometry, Carbon Monoxide Diffusion Capacity and Cardiopulmonary Exercise Test. Then they will enter a supervised pulmonary rehabilitation program that consists of 36 sessions, which is equivalent to 12 weeks. At the end of this period (T1), again the respiratory function tests (spirometry, DLCO and Cardiopulmonary Exercise Test) as well as the Goldberg, SF-36 and SySq questionnaires."
75415305|NCT06105021|Drug|AFNT-211|Engineered TCR T-Cell
75415306|NCT06105008|Drug|Disitamab Vedotin|2.0 mg/kg intravenous (lV) infusion every 2 weeks
75415307|NCT06105008|Drug|Toripalimab|3.0 mg/kg intravenous (lV) infusion every 2 weeks
75415308|NCT06104995|Other|Interventional video|The educational video comprises of health care professionals explaining the durability of the back against the popular belief that the back is fragile and the multifactorial nature of back pain.
75716233|NCT00346333|Dietary Supplement|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
75716234|NCT00924261|Other|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
75415309|NCT06104995|Other|Control video|The control video is a neutral video with no content addressing back beliefs (fragility and need for protection).
75441494|NCT01635270|Radiation|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
75716235|NCT00924261|Other|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
75716236|NCT00928551|Drug|vabicaserin|
75716237|NCT01053871|Drug|propofol|conscious sedation using propofol
75716238|NCT01053871|Drug|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
75716239|NCT00984178|Other|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
75716240|NCT00984178|Other|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
75716241|NCT04034277|Other|Lee Silverman Voice Therapy|LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
75716242|NCT04034277|Other|Conventional Treatment|"speech rehabilitation protocol comprehend:~Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation."
75716243|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
75716244|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
75716245|NCT00928629|Procedure|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
75716246|NCT04005508|Diagnostic Test|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
75716247|NCT00987376|Device|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
75716248|NCT00924339|Dietary Supplement|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
75716249|NCT00924339|Dietary Supplement|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
75716250|NCT00987454|Drug|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
75716251|NCT00987454|Drug|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
75716252|NCT03986983|Device|Shockwave therapy|Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
76042274|NCT04882735|Drug|Acoramidis|TTR stabilizer administered orally twice daily (BID)
75415310|NCT06104982|Device|NeuroTrac MyoPlus Pro single-channel electromyography biofeedback electrotherapy devices|Neuromuscular electrical stimulation (NMES) is applied to intact second motor neurons and target muscles of patients with SCI and provides functional and therapeutic benefits in neurological rehabilitation. Functional electrical stimulation (FES) is a type of NMES that is used for electrical stimulation during exercises such as crunches. Newly used SiFES is a method in which the biofeedback-enabled FES device detects muscle contractions, and this electromyography (EMG) signal triggers the muscle stimulant mode of the device.
75716253|NCT03986983|Other|Aerobic exercise|Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
75716254|NCT00924417|Behavioral|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
76042275|NCT05548309|Device|HFNC|High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher & Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.
76042276|NCT05548309|Device|Oxygen face mask|Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
76042277|NCT05554471|Device|MYNX CONTROL™ Venous Vascular Closure Device 6F-12F|Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.
76042278|NCT05542069|Device|Threshold IMT (Inspiratory muscle trainer) by Philips|Apply a resistive load with the IMT device according the maximal inspiratory pressure of each subject.
75716255|NCT00924417|Behavioral|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
76042279|NCT05541991|Dietary Supplement|single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a single dose of standardised rhubarb extract
75716256|NCT04015245|Drug|Stronger Neo-Minophagen C|intravenous injection after TACE
75716257|NCT03983785|Other|Pilates|In pilates group: Pilates training twice a week for 6 weeks.
75716258|NCT03983785|Other|Elastic taping|Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List
75716259|NCT00924495|Device|transcranial magnetic stimulation|rTMS therapy daily for two weeks, five times per week each lasting for half an hour
75716260|NCT04005664|Drug|Phenylephrine|Prophylactic phenylephrine infusion as part of fluid coload
75716261|NCT00928785|Biological|REPEVAX|1 dose of 0.5 mL at Day 0
75716262|NCT00928785|Biological|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
75716263|NCT00330967|Drug|20% Intralipid|lipid infusion
75716264|NCT00928863|Other|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
75716265|NCT03983629|Other|Collection of data and genetic analysis|Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
75873204|NCT03712319|Behavioral|REM Volver a casa|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
76042280|NCT05541991|Dietary Supplement|placebo coated tablet|coated tablet without active principle
76042281|NCT05541991|Dietary Supplement|double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a double dose of standardised rhubarb extract
76042282|NCT05700097|Drug|Dengzhanxixin Injection|Experimental arms for low, and high dose for the standard protocol
76042283|NCT05700097|Drug|Placebo injection|placebo control arm for the standard protocol
76042284|NCT05541835|Diagnostic Test|sampling|venous sampling of patient
76042285|NCT05554081|Device|Peezy urine collection device|use peezy collection to obtain urine sample
75415311|NCT06104982|Other|Isometric strengthening exercises|Isometric abdominal strengthening exercises are part of the standard rehabilitation program for individuals with spinal cord injuries.
75415312|NCT06104956|Drug|HFNO weaning protocol|Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
75415313|NCT06104956|Drug|Standard of care|Weaning methods will be left to the free choice of the practitioner.
75415314|NCT06104943|Other|Heredity for cardiovascular disease|First degree relatives with a diagnosis of Cardiovascular disease.
75716266|NCT00987610|Device|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
75716267|NCT00924573|Drug|Metformin|oral administration
75716268|NCT00924573|Drug|placebo|oral administration
75716269|NCT00924573|Drug|Glimepiride (HOE490)|oral administration
75716270|NCT01054027|Drug|1% phenylephrine and 0.2% cyclopentolate|given as drops, prior to eye exam
75716271|NCT00928941|Behavioral|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
75716272|NCT00928941|Behavioral|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
75716273|NCT01054105|Drug|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
75716274|NCT00987688|Other|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
76042286|NCT05700643|Dietary Supplement|Montmorency cherry supplement|Montmorency cherry supplement
75415315|NCT06104943|Other|Heredity for pancreatitis|First degree relatives with a diagnosis of pancreatitis.
75415316|NCT06104943|Other|Heredity for type 2 diabetes|First degree relatives with a diagnosis of type 2 diabetes.
75415317|NCT06104943|Other|Heredity for hypertriglyceridemia|First degree relatives with hypertriglyceridemia
75415318|NCT06104917|Drug|High Dose Maolactin|Once daily dose of 2 capsules (250mg per capsule)
75415319|NCT06104917|Drug|Low Dose Maolactin|Once daily dose of 2 capsules (125mg per capsule)
75415320|NCT06104917|Drug|Maltodextrin|Once daily dose of 2 capsules
75415321|NCT06104852|Other|Survey|Participants will be surveyed on demographics, medical history, and current memory and cognitive concerns. Vitals signs, urine drug screen, blood draw may be collected.
75560269|NCT01316614|Device|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
75560270|NCT00479648|Biological|CSL412|
75873205|NCT03712319|Behavioral|Mindfulness-Based Stress Reduction program|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
76042287|NCT05700643|Dietary Supplement|Control|Placebo
76042288|NCT05554003|Drug|Temozolomide capsule|Metronomic temozolomide 60 mg/die continuously
75415322|NCT06104852|Other|Optional Medication Washout|Participants taking memory medications which require a down-taper per the judgment of the study physicians may participate in a medication washout period during study screening.
75415323|NCT06104839|Drug|NXC736|oral administration
75415324|NCT06104839|Drug|Placebo|oral administration
75415325|NCT06104813|Other|Interviews|Interview with volunteer, to ask them a series of open questions about sexual health in the deaf male population.
75415326|NCT06104800|Other|Calorie-restricted diet with red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
75415327|NCT06104800|Other|Calorie-restricted diet without red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
75441495|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
75560271|NCT00479648|Biological|Inactivated trivalent influenza vaccine|
75560272|NCT01316575|Device|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
75560273|NCT01316575|Device|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
75560274|NCT02955771|Combination Product|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
75716275|NCT05277597|Diagnostic Test|The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.|Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
75716276|NCT05277597|Diagnostic Test|The same exercise training program without the sauna treatments|The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
76042289|NCT05541757|Drug|In vitro heparin|In vitro heparin and in vitro LMWH
76042290|NCT05541601|Other|Blood and Urine samples|The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.
75560275|NCT02955771|Combination Product|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
75415328|NCT06104774|Behavioral|Tai Chi Exercise|The experimental group will receive Tai Chi exercise and routine treatment after the operation, and after discharge from the hospital, they will perform Tai Chi exercise three times a week, 50 minutes each time, for a total of eight weeks after discharge.
75415329|NCT06104761|Other|Release group|i will make release for these muscles ( upper trapizius , levator scapulae , strenomastoid ) in addition to sub occipital fascia , then I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
76042291|NCT05547997|Other|Stretching exercises|Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times
75415330|NCT06104761|Other|strength exercises and stretching for upper crossed syndrome|I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
75415331|NCT06104722|Other|High-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
75415332|NCT06104722|Other|Low-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
75560276|NCT02955771|Device|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
75560277|NCT00473408|Device|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
75560278|NCT00473408|Procedure|Blood sample|See protocol.
75560279|NCT00473408|Procedure|Tumor sample|See protocol.
75560280|NCT02891161|Drug|durvalumab|1500 mg Q4 weekly
75560281|NCT02891161|Radiation|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
75560282|NCT00478985|Behavioral|Imatinib ending|Interruption of the treatment by Imatinib
75415333|NCT06104696|Procedure|Functional geriatric assessment|Examination of physical and mental status using standardized tests.
76042292|NCT05547997|Other|Two way traction|During the traction, the head halter will be fixed posteriorly to cause slight distraction, retraction, and slight extension and at the same time a front anterior strap had weight will be applied over a pulley that allows transverse traction load to be applied to the apex of the participants cervical curve alteration. Weights will start at 15 lbs. (6.8 Kg) on the anterior strap and will increase over consecutive visits to patient tolerance or a maximum of 35 lbs. (15.9 Kg).
76042293|NCT05700565|Other|Extracorporeal photopheresis|ECP consists of the three steps of leukapheresis, photoactivation and reinfusion and has immunomodulatory effects (modulation of dendritic cells, change in cytokine profile, induction of T cell subpopulations). Indications are currently the treatment of Sézary syndrome, Graft-versus-host disease (GvHD), organ transplant rejection and systemic scleroderma.
75560283|NCT02955732|Device|Dexmedetomidine|A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
75415334|NCT06104644|Drug|Deucravacitinib|Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics
75716277|NCT00907413|Procedure|ERCP and Photodynamic Therapy|Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
76042294|NCT05700565|Other|Other immunosuppressive or immunomodulatory drugs|Other immunosuppressive or immunomodulatory drugs
76042295|NCT05541523|Behavioral|cognitive behavioural therapy|The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.
75415335|NCT06104631|Other|BK003|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.
75415336|NCT06104631|Other|Placebo|The placebo product has the same composition in excipient, same form and same posology as BK003.
75560284|NCT00473447|Behavioral|Modified Constraint-induced movement therapy|
75716278|NCT00907413|Procedure|ERCP only|Endoscopic retrograde cholangiopancreatography and stenting.
75716279|NCT00330343|Drug|naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
75716280|NCT00987766|Drug|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
75716281|NCT00987766|Drug|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
75716282|NCT00987766|Drug|oxaliplatin|Given through a vein in the arm 1 time every other week.
75716283|NCT00987766|Other|laboratory biomarker analysis|Blood and tissue collection.
75415337|NCT06104592|Radiation|Comprehensive Ablative Bridging Irradiation (CABI)|Participants will receive radiation therapy to all pretreatment lesions that are able to be feasibly and safely treated.
75415338|NCT06104592|Biological|Chimeric Antigen Receptor T-Cell Therapy|Yascarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
75415339|NCT06104501|Device|RadiHeart|The participants' blood pressure will be measured multiple times by both the mercury sphygmomanometer and RadiHeart, by using the same arm sequential method.
75415340|NCT06104488|Drug|Avutometinib|Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
75415341|NCT06104475|Other|CT scan|A CT scan will be requested for every patient in addition to the chest X-ray
75441496|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
75441497|NCT01635296|Drug|cytarabine|20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
75441498|NCT01635296|Drug|cytarabine|1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
75441499|NCT01635309|Other|Coronary CT Angiogram|pre-operative coronary CTA
75716284|NCT00984412|Procedure|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
75716285|NCT00330187|Drug|Bupropion SR|Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
75560285|NCT01315678|Drug|Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
76042296|NCT05541523|Behavioral|mindfulness-based therapy|The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
75560286|NCT01315678|Drug|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~Nebulization time is approximately 20 minutes for each administration.~Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
76042297|NCT05541445|Drug|Pembrolizumab|The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
75716286|NCT00330187|Behavioral|Contingency Management|Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.
75415342|NCT06104462|Device|Intermittent theta burst stimulation (iTBS)|"The iTBS protocol consists of 20 trains of stimulation. Each train comprises ten 3-pulse bursts, delivered at an intra-burst frequency of 50 Hz, with a 5 Hz overall frequency, followed by 8 seconds of rest. A total of 600 pulses (10*3*20) will be administered in this 3-minute iTBS protocol. Concurrent TBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% of the resting motor threshold (RMT), which is considered appropriate to ensure compliance and elicit robust DLPFC activation.~Considering that the fNIRS optode beneath the coil increases the distance between the TMS coil and the skull by 10 mm, we will use the equation AdjMT% = MT + 2.8 * (Dsitex - Dm1). Therefore, 2.8 * 10 = 28% will be added to the normal intensity. The stimulation site over the DLPFC will be determined by the MNI coordinate (x-38, y+44, z+26) reported in previous studies."
75415343|NCT06104436|Behavioral|Individualized music playlist|Individualized music playlist composed of preferred music genres sequenced according to the ISO-Principle. It will be played at the state of agitation.
75415344|NCT06104436|Behavioral|Preferred music|Preferred music is composed of the genres selected by the participants, and to be played at random sequence.
75415345|NCT06104436|Behavioral|Usual care|Usual technique for calming agitated older adults with dementia
75415346|NCT06104423|Drug|Nebivolol 5 mg|1 tablet of study medication to be administered orally according to instructions of Investigator.
75716287|NCT00330187|Other|Placebo|Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
75716288|NCT00987844|Drug|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
75716289|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
75415347|NCT06104423|Drug|Ramipril 2.5/5/10 mg|1 tablet of study medication to be administered orally according to instructions of Investigator.
75716290|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
75716291|NCT04006132|Device|Fitting of Ponto 3 SuperPower|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
75716292|NCT03986905|Drug|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
75716293|NCT03986905|Other|Placebo|placebo nasal gel + placebo patch
75441500|NCT01635322|Device|Polyaxial posterior spinal fusion system|posterior correction and fusion of the thoraco-lumbar or lumbar spine
75560287|NCT02955693|Drug|LAS41008 120 mg / Fumaderm® 120 mg|Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
75560288|NCT00479726|Drug|duloxetine hydrochloride|
76042298|NCT05699863|Behavioral|Lifestyle intervention|"Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months."
76042299|NCT05541289|Biological|BBV152|Single Arm; BBV152 (COVAXIN™)
76042300|NCT05699785|Other|plasma inflammatory markers|Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)
75415348|NCT06104397|Other|Written exercise guidance by neurologist|Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease during neurologist visits and/or in after visit summary in the patient's EMR patient portal. The research team will facilitate the development of the written exercise guidance with input and feedback from each site's neurology, clinical, and administrative teams.
76042301|NCT05699785|Other|CD4/CD8 ratio|Evolution of CD4/CD8 ratio
75560289|NCT04697121|Dietary Supplement|Combined Bergamot phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract. Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
75560290|NCT04697121|Combination Product|Placebo|Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
75560291|NCT03270761|Other||
75560292|NCT01315249|Drug|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
75560293|NCT01315249|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
75560294|NCT01315249|Drug|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
75441501|NCT01635335|Behavioral|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
75560295|NCT01315249|Drug|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
75560296|NCT03270800|Biological|CTA control|Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
75560297|NCT03270800|Biological|IMX101 vaccine|Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
75560298|NCT04207411|Drug|Bupivacaine|Injection of anesthetics blocks once a week during 4 weeks.
75560299|NCT04207411|Drug|Lidocaine|Injection of anesthetics blocks once a week during 4 weeks.
75415349|NCT06104397|Other|Physical therapy|A consultative model of physical therapy - a lower dose of physical therapy focused on physical activity and exercise promotion and coaching - will be implemented into each site. In the consultative model of physical therapy, visits are scheduled around needs of the patient, however will involve 1-4 additional visits within 3 months of evaluation and is based on personal factors that influence their exercise prognosis such as self-efficacy, readiness to change, fitness level, age, health literacy, comorbidities, and Parkinson's Disease-related motor and non-motor impairments.
75415350|NCT06104384|Behavioral|Behavioral and supportive therapy|Behavioral and supportive therapy
75415351|NCT06104267|Behavioral|7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients|"The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group."
75415352|NCT06104241|Biological|BGT007 Injection|BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10^7 cells,1.0 ×10^8 cells, 3.0× 10^8 cells,1.0 × 10^9 cells,3.0 ×10^9 cells.
75415353|NCT06104215|Biological|BGT007H Injection|BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10^8 cells,5.0 ×10^8 cells, 1.0× 10^9 cells,3.0 × 10^9 cells,6.0 ×10^9 cells.
75415354|NCT06104189|Diagnostic Test|MRI|MRI based classification of breast cancer histological factors and subtypes
75415355|NCT06104150|Other|Intervallic submaximal exercise test|Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.
75415356|NCT06104137|Other|course (MOOC) patient education|this is a massive open online course created by us for patient education. Patients will be given a login and password to access the MOOC from their own computer. The MOOC has 3.5 hours of content and patients will be given 3 weeks to complete.
75560300|NCT01248663|Procedure|antecolic reconstruction|see study arm description
75560301|NCT01248663|Procedure|retrocolic reconstruction|see study arm description
75560302|NCT00473486|Drug|pemetrexed, carboplatin, sorafenib|"Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1"
75560303|NCT00473486|Drug|pemetrexed, carboplatin, placebo|Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
75716294|NCT04713280|Procedure|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion
75716295|NCT00987922|Device|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
75716296|NCT03595774|Dietary Supplement|Beet root juice|Beet root juice
75716297|NCT04914286|Drug|GFH018|Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.
75716298|NCT04914286|Drug|Toripalimab|Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
75716299|NCT03914950|Diagnostic Test|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas."
75716300|NCT00329797|Dietary Supplement|Calcium|A single dose of 500 mg of elemental calcium orally each day for 3 years.
75560304|NCT05644483|Drug|Remimazolam|Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)
75560305|NCT05644483|Drug|Propofol|Propofol: target controlled infusion: 2-3mcg/mL
75716301|NCT00329797|Dietary Supplement|Zoledronic acid|Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
75716302|NCT00329797|Radiation|radiation therapy|Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
75560306|NCT01315132|Device|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
75415357|NCT06104137|Other|standard patient consent process|standard consenting and shared decision making in the clinic
75415358|NCT06104111|Dietary Supplement|Vitamin D3|Vitamin D3 bolus at days 0, 28 and 56. Blood samples taken at days 0, 1, 28, 29, 56, 57 ad 84
75415359|NCT06104085|Diagnostic Test|99mTc-MY6349 SPECT/CT scan|Triple-negative breast cancer patients underwent 99mTc-MY6349 SPECT/CT imaging to observe the binding ability of this tracer to Trop2 in the tumor and the uptake of the drug by the tumor, combined with the pathological expression level of Trop2 in the patient's lesions and 18F-FDG PET/CT imaging uptake to evaluate the efficacy of 99mTc-MY6349 in the diagnosis of triple-negative breast cancer; at the same time, combined with the treatment effect of patients using the anti-Trop2 targeted antibody gosatuzumab, the analysis of 99mTc-MY6349 SPECT/CT imaging prediction of prognosis in patients with triple-negative breast cancer treated with gosatuzumab.
75415360|NCT06104072|Device|REHACOM Software|"It is a computer-based cognitive rehabilitation test that includes 32 cognition training tasks for attention/concentration, reaction behavior, memory , logical reasoning & executive functioning with graded difficulty . It is composed of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel & printer .The Rehacom software version is (patientenpult (1990-1997) EN/ISO-13485-certified).~For each Cognitive training domain there is one hundred levels of difficulty.~Each patient is evaluated from level one(1) ang gradually increase the difficulty till we reach the level that will be used in the treatment sessions as the patient's performance improve we can proceed to the next level.~The period of the session was chosen to be maximum (60 minutes) for each patient with five minutes rest in between each level."
75415361|NCT06104072|Other|Designed Physical Therapy Program|a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises.
75415362|NCT06104059|Device|Nociception level index (NOL™)|If a NOL value >25 persists for >1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.
75415363|NCT06104059|Other|Fentanyl|Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.
75415364|NCT06104033|Device|drug-coated balloon|For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.
75415365|NCT06104033|Device|drug-eluting stent|When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.
75415366|NCT06104020|Other|Intraoperative fluid management stratigies.|"Regimens of different intraoperative fluid management The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.~The other group of patients, the liberal group (LG), will receive a 10 ml/kg bolus at anesthesia induction,followed by an intraoperative crystalloid infusion at a rate of 8 ml/kg/hr."
75560307|NCT00479804|Device|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
75560308|NCT00479804|Device|spirometry|spirometry for testing the ventilatory function
75560309|NCT00479804|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
75560310|NCT00504036|Device|inflatable intra-gastric balloon|inflatable intra-gastric balloon
75716303|NCT00329797|Drug|LHRH|LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
75560311|NCT01248702|Other|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
75560312|NCT00479843|Behavioral|Nutritional programme|
75560313|NCT01248819|Drug|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
75716304|NCT00329797|Dietary Supplement|Vitamin D|400 IU (10μg), orally each day for 3 years.
75716305|NCT00541450|Drug|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
75716306|NCT00541450|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
75716307|NCT00541450|Drug|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
75873206|NCT00710970|Drug|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
75415367|NCT06104007|Device|Genoss® DCB|This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
75560314|NCT01248819|Drug|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
75560315|NCT01313767|Drug|Botulinum toxin type A|Botulinum toxin type A
75560316|NCT01313767|Drug|Botulinum Toxin type A|Botulinum Toxin type A
75560317|NCT00479921|Biological|Trivalent influenza subunit vaccine|
75415368|NCT06103981|Other|Acute Liver Injury|To evaluate the impact of acute liver injury in patients with pneumonia on hospital stay and outcome.
75560318|NCT01248858|Drug|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
75415369|NCT06103968|Device|LMA BLOCKBUSTER|In this study we wish to evaluate weather gastric tube inserted through LMA helps in maintaining the LMA blockbuster placement by comparing fibreoptic bronchoscope (FOB) scores recorded immediately after LMA placement and at the end of the surgical procedure.
75560319|NCT00481286|Behavioral|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
75560320|NCT00481286|Behavioral|Standard of Care|Standard of care for diabetes patients
75415370|NCT06103942|Diagnostic Test|CO2 angiography|A supplemental CO2 angiography will be performed before and after the stent graft placement.
75415371|NCT06103916|Other|Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.|From all included patients, prospective data will be collected of the ultrasound(s) performed, the performed treatment and in case of surgery also the final pathological diagnosis. Participating patients will not be subjected to acts or additional procedures or examinations in this study, nor will rules of conduct be imposed.
75560321|NCT01313728|Drug|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
75560322|NCT01313728|Drug|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
75716308|NCT00541450|Drug|Matching placebo to pioglitazone|"matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks."
75415372|NCT06103903|Behavioral|Questionnaire|Questionnaire according to age (6-13;14-17); the parents for minors and adults
75415373|NCT06103825|Drug|Solriamfetol|solriamfetol : QD，PO，Day 1-Day 84；
75415374|NCT06103825|Drug|Placebo|Placebo :QD，PO，Day 1-Day 84
75415375|NCT06103812|Device|Hyalo4 Skin Gel|The evaluation of performance and safety of Hyalo4 Skin Gel in the amelioration of bed wound appearance after 14 days of treatment.
75415376|NCT06103799|Behavioral|IMB model-based continuity of care|The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.
75415377|NCT06103773|Drug|TollB-001 tablets|TollB-001 treatment
75560323|NCT01248897|Other|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
75716309|NCT00541450|Drug|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
75716310|NCT00541450|Drug|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
75716311|NCT03989635|Drug|QAW039|QAW039 450mg
75716312|NCT03986827|Behavioral|Cool Kids Anxiety Program - Social Enhanced|Specific G-CBT intervention for adolescents with social anxiety disorder
75873207|NCT03716063|Drug|Jianpi Huatan dispensing granule|once a day in the morning and evening, every month for a course of treatment, a total of three courses
75415378|NCT06103773|Drug|TollB-001 placebo|TollB-001 Placebo
75415379|NCT06103747|Drug|Metformin / Vildagliptin Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of test drug
75560324|NCT00481364|Drug|atorvastatin|atorvastatin 40 mg/day
75560325|NCT00481364|Drug|placebo|1 tb/day
76042302|NCT05547763|Procedure|surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates|under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
75415380|NCT06103747|Drug|Galvumet® Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of reference drug
76042303|NCT05540977|Drug|Donepezil|Donepezil 5mg QN
76042304|NCT05540977|Other|Usual care|Usual care
75415381|NCT06103695|Drug|Tapinarof|Add on Vtama (tapinarof) to biololgic therapy
75560326|NCT05661331|Device|Transjugular intrahepatic portosystemic shunt|The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.
75560327|NCT00479960|Behavioral|commercially available omega-3 fatty acids supplementation|
75560328|NCT01249014|Other|Warmed fluids|IV fluids warmed by a Belmont fluid warmer
75560329|NCT01249014|Other|Fluid warmer and warming blanket|Warm are blown into a Bair hugger warming blanket covering the patient
75560330|NCT01249014|Device|Belmont fluid warmer|Belmont fluid warmer used to warm fluids
76042305|NCT05553535|Diagnostic Test|MRI|retrospective review of shoulder MRI
75415382|NCT06103669|Device|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
75415383|NCT06103630|Other|Oropharyngeal Exercises|Oropharyngeal Exercises
75415384|NCT06103630|Other|Mandibular advancement device|Mandibular advancement device
75415385|NCT06103591|Device|The EmStop Embolic Protection System (EmStop System)|The EmStop Embolic Protection System (EmStop System) is a catheter-based filter system that captures and removes debris dislodged during transcatheter aortic valve replacement (TAVR) procedures.
75560331|NCT01249014|Device|Bair hugger warming blanket|Bair hugger warming blanket laid on body
75560332|NCT01240460|Drug|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
75716313|NCT03986827|Behavioral|Cool Kids Anxiety Program|Generic G-CBT intervention for adolescents with anxiety disorders
75716314|NCT01054261|Drug|avanafil|200 mg avanafil tablet QD
75716315|NCT01056679|Drug|Doxorubicine|50mg/m2 day 1 + 15
75716316|NCT01056679|Drug|DTIC|375mg/m2 day 1 + 15
75716317|NCT01056679|Drug|Lenalidomide|day 1 - 21
75716318|NCT01056679|Drug|Vinblastine|6mg/m2 day 1 + 15
76042306|NCT05547685|Diagnostic Test|Methylene blue intradermal injection|Methylene blue intradermal injection
76042307|NCT05553379|Diagnostic Test|FeNO measurement|FeNO measurement at each visit
75415386|NCT06103578|Diagnostic Test|GCF and saliva analysis|ELISA
75560333|NCT01240460|Drug|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
75560334|NCT01249170|Behavioral|First year program|Information on group that underwent new educational program
75560335|NCT01249170|Other|Control comparison|Information from group that did not undergo new first year program
75560336|NCT00479999|Drug|VRC-HIVADV027-00-VP|
75560337|NCT00479999|Drug|VRC-HIVADV038-00-VP|
75560338|NCT01249209|Device|lifestyle advice|
75560339|NCT00481442|Drug|Phenylephrine|
75716319|NCT03989791|Dietary Supplement|absolute diet|Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
75716320|NCT03989791|Dietary Supplement|normal diet|Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
75716321|NCT00355147|Behavioral|Physician stroke guideline adherence|Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors
75560340|NCT01249248|Device|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
76042308|NCT05540821|Diagnostic Test|Hysterosalpingo-contrast sonography and sonoPODography|"Before operation, phloroglucinol 40mg of antispasmolysis was injected intramuscular, and then cervical dilation was performed according to aseptic operation requirements. A 12G double-lumen catheter was inserted into the uterine cavity, and 1.5-1.8ml of normal saline was injected into the sacculus.~Transvaginal 2/3/4D hysterosalpingo-contrast sonography: One operator extracted 2ml of Sonovue and injected 18ml of normal saline through a dual-lumen catheter, and the other operator started the four-dimensional ultrasound mode to collect dynamic volume data.~sonoPODography: Sterile saline was injected into the intrauterine cavity, with an upper limit of 20ml. The normal saline flowed from the intrauterine cavity into the pelvic cavity through the bilateral fallopian tubes, forming a good acoustic window. Pelvic observation was then performed."
75560341|NCT00480038|Other|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
76042309|NCT05540587|Drug|Edoxaban|"Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~CrCl 15-50mL/min~Body weight ≤ 60kg~Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)"
75560342|NCT04697537|Drug|Ultrasound guided regional anesthesia|Applied perineurally preoperatively ultrasound guided regional anesthesia
75560343|NCT04697537|Drug|Local infiltration analgesia|Applied in the wound intraoperatively from the orthopedics
75716322|NCT00355147|Behavioral|Stroke Self Management|Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
75716323|NCT00355147|Other|Attention Control Group|Received Phone Calls from Staff to Control for Attention
75873208|NCT04957524|Device|iStim TENS unit and Transvaginal Probe|"iStim TENS unit and Transvaginal Probe are both commercially available products. TENS units work by delivering small electrical impulses through electrodes either attached to the skin or through a transvaginal probe.~iStim transvaginal probe will be inserted vaginally to provide transvaginal electrical stimulation."
75560344|NCT01249326|Other|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
75560345|NCT01313650|Drug|62.5/25mcg|GSK573719/GW64244
75560346|NCT01313650|Drug|62.5mcg|GSK573719
75560347|NCT01313650|Drug|25mcg|GW642444
75560348|NCT01313650|Drug|Placebo|Placebo
75560349|NCT02274909|Other|TRAINING PROGRAM|Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
75560350|NCT04697615|Device|Algometry|The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
75560351|NCT00504114|Procedure|ACL Reconstruction Surgery|
75873209|NCT03718013|Device|accelerated deep TMS|subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
75873210|NCT03718013|Device|standard deep TMS|standard deep TMS treatment: once a day, during 4 weeks
75415387|NCT06103565|Other|Clinical Decision Support Tool|Clinical decision support tool to enable pharmacists to monitor adherence to guideline-directed medical therapy for patients with heart failure with reduced ejection fraction
75415388|NCT06103188|Drug|Placebo|The placebo pill will be given to the patients 1 hour prior to their planned surgery.
75415389|NCT06103188|Drug|Diazepam|Diazepam will be given to the patients 1 hour prior to their planned surgery.
75415390|NCT06103188|Drug|Melatonin|Melatonin will be given to the patients 1 hour prior to their planned surgery.
75560352|NCT00504114|Procedure|Cartilage Resurfacing Surgery|
75560353|NCT00504114|Procedure|Total Knee Replacement|
75560354|NCT00481481|Drug|tacrolimus|immunosuppression
75560355|NCT04516317|Other|None (Observational study Group intravenous artesunate)|Retrospective descriptive study of Group intravenous artesunate
75560356|NCT04516317|Other|None (Observational study Group intravenous quinine)|Retrospective descriptive study of Group intravenous quinine
75560357|NCT02891239|Device|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
75560358|NCT02891083|Drug|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
75560359|NCT02891083|Radiation|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d"
75560360|NCT02891083|Other|Control group (Surgery alone)|
75560361|NCT02890966|Drug|SHR4640|Day1~Day7:oral administration
75560362|NCT02890966|Drug|placebo|Day1~Day7:oral administration
75415391|NCT06103006|Other|Telerehabilitation|The structured telerehabilitation program focused on 4 specific objectives: breathing, stretching, posture, and stability. The duration was between 20-30 minutes. Exercises involving the major muscle groups (upper, lower extremity, and trunk muscle groups) were applied by the physiotherapists. Strengthening and stretching sets and repetitions were started with 1 set of 8-15 reps (progress to >1 set).
75415392|NCT06102889|Diagnostic Test|liquid biopsy|Taking blood samples (liquid biopsy) for multiple analysis in genomics, proteomics, and metabolomics
75415393|NCT06102408|Other|second line investigations for uveitis etiological workup|Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
75415394|NCT06101979|Device|Fortiva Tissue Matrix|Acellular Dermal Matrix used in hernia surgery
75560363|NCT02890927|Other|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:~Low risk patients are expected to do well and will not receive co-management.~Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
75560364|NCT05644405|Diagnostic Test|FloTrac Vigileo|A dedicated transducer (FloTrac TM, Edwards Lifesciences, LLC, Irvine, CA, USA) was connected to the radial arterial line on one side and to the Vigileo System (Vigileo TM Edwards Lifesciences, LLC, Irvine, CA, USA) on the other side
75560365|NCT02891005|Device|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
75560366|NCT02891005|Device|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
75716324|NCT05711368|Behavioral|Distress tolerance training|It consisted of seven sessions. A 90-minute session will be conducted twice a week for four weeks. The first introductory session will be concerned with helping the student learn how to engage in distress tolerance training and define goals of distress tolerance. At the end of the 1st session, a written plan for every session (time, duration and setting) will be scheduled individually with each student.The next six training sessions will cover three core skills which comprised three sets: Crisis Survival Skills, the skills of Reality Acceptance; and the Skills When the Crisis Is Addiction. The distress tolerance training methods will include individualized interactions, demonstration, and rehearsal, psychoeducation, practice exercises and homework assignments. Follow up between sessions will done using telephone calling and messaging in order to encourage performance homework assignments, and provide help and support when needed particularly at the time of stress. .
75716325|NCT03983551|Drug|Dipeptidyl Peptidase 4 Inhibitor|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
75415395|NCT06101160|Drug|onaBoNT-A|injection under ultrasonography
75560367|NCT02891044|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-040)
75560368|NCT00481559|Drug|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
75560369|NCT00504816|Drug|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
75560370|NCT00504816|Drug|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
75560371|NCT00623350|Other|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
75716326|NCT03983551|Drug|Sulfonylurea|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
75716327|NCT05709574|Drug|Tadalafil 20 MG|Tadalafil 20 mg tablets will be taken daily for 2 weeks alone and then for 8 weeks in combination with neoadjuvant chemotherapy in the window between gastric/GEJ adenocarcinoma diagnosis and interventional surgery.
75560372|NCT00623350|Other|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
75873211|NCT02868528|Genetic|chromosome screening with NGS technology|
75560373|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
75716328|NCT04767100|Device|Social telepresence robot|Use of a social telepresence robot at home, during three months with the aim of reducing the feeling of loneliness and social isolation among the elderly.
75716329|NCT05706142|Other|Motor Imagery Education|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
75873212|NCT04945746|Procedure|AF ablation|"AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability)."
75873213|NCT05209542|Procedure|Hysterosalpingo-Foam Ultrasonography|"Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection"
76042310|NCT05540587|Drug|Warfarin|Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
75415396|NCT06100887|Drug|EDG-5506 Dose 1|EDG-5506 is administered orally once per day
75560374|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
75560375|NCT00480116|Biological|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
75560376|NCT00504855|Other|Casting using Gortex (waterproof) cast padding materials|
75716330|NCT04697212|Behavioral|Healthcare team- + patient-directed intervention|"Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities, and will also complete a patient prompt list that elicits strategies that they prefer the healthcare team to use during their visit."
75873214|NCT05209542|Procedure|Laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
75560377|NCT00504855|Other|Casting using cotton/cotton-poly cast padding materials|
75560378|NCT00481598|Procedure|magnet resonance spectroscopy|magnet resonance spectroscopy
75560379|NCT00504933|Drug|bilastine|20 mg (encapsulated) tablets QD/14days
75560380|NCT00504933|Drug|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
75560381|NCT00504933|Drug|Placebo|(encapsulated) Tablets QD/14 days
75873215|NCT03421379|Drug|Glucagon Nasal Powder|Administered intranasally
75873216|NCT03421379|Drug|Glucagon Hydrochloride Solution|Administered IM
75873217|NCT03712241|Drug|K-285|Topical
75873218|NCT03712241|Drug|Indomethacin|Capsule
75716331|NCT04697212|Behavioral|Healthcare team-directed intervention|Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
75716332|NCT04690504|Other|dim light melatonin onset (DLMO)|A series of saliva samples will be collected and assayed for melatonin so that the timing of melatonin secretion onset can be determined.
76042311|NCT05540509|Behavioral|Community-based intervention|Mothers were given physical activity goals and coping resources to practice at home and were asked to record their experiences on an activity log. Course content was taught from a detailed training manual and was based on concepts and strategies from social cognitive theory that have been effective in increasing physical activity and fitness levels among mothers. In the first month, mothers attended group exercise sessions twice per week (total of eight group sessions) and exercised on their own once per week. In the second month, mothers attended group exercise sessions once per week (total of four group sessions) and exercised on their own twice per week. In the third month, mothers exercised on their own three times per week.
76042312|NCT05540509|Behavioral|Home-based intervention|The HBI group received information on building social support and reducing physical activity barriers based on materials from the Diabetes Prevention Program. Participants were also given activity logs to record their physical activity each week, which was collected by research staff at each monthly assessment time point to assess how participants were progressing with their physical activity goals. Mothers exercised on their own for three months with the goal of meeting national physical activity guidelines
76042313|NCT05540431|Drug|Activated Charcoal|RCT
76042314|NCT05540431|Dietary Supplement|Probiotic|RCT
75415397|NCT06100887|Drug|EDG-5506 Dose 2|EDG-5506 is administered orally once per day
76042315|NCT05540431|Other|No intervention|RCT
76042316|NCT05700409|Behavioral|Intensive lifestyle consultations|detailed above
75415398|NCT06100887|Drug|Placebo|Placebo is administered orally once per day
75415399|NCT06100497|Drug|Pembrolizumab|Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment
75415400|NCT06100497|Drug|Cisplatin|Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy
75415401|NCT06100497|Drug|Paclitaxel-albumin|Mainly used for neoadjuvant treatment
75415402|NCT06099652|Drug|611 300 mg Q2W|611 subcutaneous (SC) injection
75415403|NCT06099652|Drug|611 450 mg Q2W|611 subcutaneous (SC) injection
75415404|NCT06099652|Drug|Matching placebo|placebo subcutaneous (SC) injection
75415405|NCT06097195|Device|BioEP|When a consenting participant has their first electroencephalogram (EEG), they will be assigned with a unique participant study identifier before being uploaded. The centre will convert the EEG to European Data Format (EDF) format (or upload the total file) and upload this to the Neuronostics platform. The EEG will be stored on the Neuronostics database management system, within which the computational and mathematical analysis will be carried out. This study involves data analysis and mathematical modelling of the EEG recordings of each patient individually to generate a computational analysis score (BioEP).
75415406|NCT06096727|Behavioral|Energize!|Energize! is 3 month online physical activity program which consists of weekly physical activity goals, video lessons, action planning, and homework.
75560382|NCT01313299|Biological|Botulinum toxin type A|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
75560383|NCT01313299|Biological|Botulinum toxin type A|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
75560384|NCT01313299|Drug|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
75560385|NCT00480155|Biological|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
75560386|NCT00480155|Other|Placebo|
75560387|NCT00504972|Drug|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
75560388|NCT01313221|Biological|etanercept|Administered by subcutaneous injection
75716333|NCT00540124|Drug|Tadalafil|5 mg once a day
75716334|NCT00540124|Drug|Placebo|once a day
75415407|NCT06096584|Procedure|Triple Injection Perisartorius block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone.~Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata"
75415408|NCT06096584|Procedure|Dual sub sartorial block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone~Patients will receive a combination of femoral triangle block and distal ACB."
75415409|NCT06096584|Procedure|Femoral triangle block|Femoral triangle block will be given just (1-2 cm) proximal to the apex of the femoral tringle which is the point at which the medial border of the sartorius muscle (STM) meets the medial border of the adductor longus muscle (ALM). Ten ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected just below the STM.
75415410|NCT06096584|Procedure|Distal adductor canal block|Another 20 ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected in the lower one-third of the adductor canal.
75560389|NCT01313221|Drug|Topical agents|"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~hydrocortisone 2.5%~betamethasone valerate 0.1%~betamethasone dipropionate 0.05%~clobetasol 0.05%~calcitriol~calcipotriol plus betamethsone dipropionate 0.05%"
75716335|NCT00540124|Drug|Tamsulosin|0.2 mg once a day
75716336|NCT00540046|Device|Copper T 380A IUD|Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
75415411|NCT06096584|Procedure|Suprasartorial plane block|Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata
75415412|NCT06094075|Other|Resistance training based on DSI value|The intervention consist of modifying the ongoing resistance exercises. Those with low DSI values will perform ballistics, explosive exercises. Those with high DSI will perform heavy-load training. The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
75415413|NCT06094075|Other|Normal training group|The participants will do a general training program (not based on DSI values). The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
75415414|NCT06093256|Device|Fixed orthodontic appliances|Taste sensation will be checked before and after fixed orthodontic therapy.
75716337|NCT04613830|Drug|Bupivacaine Hydrochloride|The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride
75716338|NCT04613830|Drug|Tramadol hydrochloride|Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic
75716339|NCT04599166|Behavioral|Who Would You Choose: Serious Fun|"Who Would You Choose: Serious Fun is a conversation activity that prompts players (using scenarios and metaphors) to choose a spokesperson whose qualities are best suited to the role. At the end of the activity, players identify a real-life spokesperson based on the qualities considered during gameplay."
75716340|NCT05676892|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed, and the skin was sutured"
76042317|NCT05553067|Genetic|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.
75415415|NCT06092411|Behavioral|Cognitive Behavioural Therapy for Depression|Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
75560390|NCT01313182|Drug|mupirocin calcium ointment, 2%|"Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares."
75560391|NCT01313182|Drug|3M Skin and Nasal Antiseptic|The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
75560392|NCT04516512|Biological|Blood draw|For each participants to the research a peripherical blood draw will be performed
75560393|NCT04512495|Other|Blood samples will be collected at two times :|"at Baseline,~after surgery or at the time of post-chemotherapy evaluation."
75560394|NCT00505050|Other|Disease Program Management|"This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.~After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms."
75415416|NCT06092411|Device|Bright Light Therapy|Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
75415417|NCT06090071|Device|LaseMD Laser|The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.
75560395|NCT00480194|Drug|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
75560396|NCT00505089|Drug|ACZ885|
76042318|NCT04319809|Device|Object recognition subsystem|The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
76042319|NCT05547139|Other|Protocolized weaning of respiratory support|The protocolized weaning aims to keep babies on CPAP for a longer period of time and will measure how long it takes babies to wean to 2L nasal cannula support or come off all support (room air, RA).
75415418|NCT06090071|Device|Sciton Laser|The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.
75415419|NCT06090071|Drug|Phyto A+ Brightening Treatment|Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
75415420|NCT06089057|Behavioral|Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This is a 16-week power-training and physical activity-focused intervention that contains group in-center and individual at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
75560397|NCT00505089|Drug|ACZ885|
75560398|NCT00505089|Drug|ACZ885|
75560399|NCT00505089|Drug|ACZ885|
76042320|NCT05547061|Drug|Lu-177-DGUL|Lu-177-DGUL(150mCi, 200mCi) intravenous 4 doses, 6weeks apart
75716341|NCT00689936|Drug|Lenalidomide and low-dose dexamethasone|"Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression"
75716342|NCT00689936|Drug|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|"lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles"
76042321|NCT05547061|Drug|Ga-68-NGUL|Ga-68-NGUL(2MBq/kg) intravenous during screening and every 12 weeks after the first administration of Lu-177-DGUL
75415421|NCT06089057|Behavioral|Attention Control for Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
75415422|NCT06088563|Other|Vaccine injection|Injection of the vaccine in renal transplant patients.
75560400|NCT00481715|Behavioral|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
75560401|NCT00481715|Behavioral|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
75560402|NCT00505128|Procedure|Endoscopic sphincterotomy|procedure
75560403|NCT00505167|Drug|Memantine|Patients randomized to receive either memantine or donepezil
75560404|NCT00505167|Drug|Donepezil|Patients randomized to receive either memantine or donepezil
75560405|NCT00480272|Drug|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
75560406|NCT00480272|Drug|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
75560407|NCT04517058|Other|psychology therapy|If the symptoms are mild, patients will get the psychology therapy. If it's necessary according to patients' willings, patients will be given SSRIs antidepressant therapy.
75560408|NCT00480311|Other|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
75560409|NCT04519788|Drug|AT-301B|Nasal Spray
75716343|NCT00689936|Drug|Melphalan, Prednisone and Thalidomide|Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
75716344|NCT04528576|Device|Dragonfly mitral valve repair system|With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
75415423|NCT06087991|Behavioral|Implementation of the BINDeR-Tx service model|ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.
75415424|NCT06087484|Behavioral|Mindfulness Intervention for Emotional Distress and Insomnia (MIED-I)|The MIED-I program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs).Also, a portion of the CBT-I will be added to the course to provide psychoeducation for insomnia. Variables that have been shown to be effective in interventions for insomnia in past studies, such as awareness, non-responsiveness, and self-compassion, will also be added to better alleviate insomnia symptoms
75560410|NCT04519788|Drug|AT-301A|Nasal Spray
75560411|NCT00480350|Behavioral|rice based food supplement|
75560412|NCT04519593|Procedure|Laparoscopic myomectomy with prior temporary uterine blood supply occlusion|Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
75560413|NCT04519593|Procedure|Conventional laparoscopic myomectomy|Laparoscopic myomectomy without prior temporary uterine blood supply occlusion
75716345|NCT05279170|Other|MAVEPPIC: MAsk VEntilation with Paratracheal Pressure In Children|"Pressure will be applied with two fingers in the area located between the trachea and the sternal head of the sternocleidomastoid muscle on the left side to compress the cervical esophagus.~The force applied (after measuring the equivalent force applied on a precision scale) will be about 10 - 15 N. This force will be adapted according to the child's body weight : 10 N below 20 kgs and 15 N between 20 kgs and 40 kgs"
75716346|NCT01563718|Drug|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
75716347|NCT05485714|Other|Reviewing records retrospectively of patients undergoing screening endoscopy|Reviewing records retrospectively of patients undergoing screening endoscopy to assess Baveno VI, expanded Baveno VI, Platelet count/spleen diameter and other non-invasive predictors of esophageal varices or varices needing treatment
75560414|NCT00480389|Drug|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
75560415|NCT04519554|Device|Endometrial sampling|Endometrial sampling with 2 different forceps
75716348|NCT05473234|Drug|Azithromycin|Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
76042322|NCT04318249|Behavioral|Assisted Relaxation Therapy|This intervention includes using a smartphone application that helps with breathing techniques and sleep.
75560416|NCT04519710|Biological|o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B|to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
75560417|NCT00482027|Biological|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
75560418|NCT02275455|Behavioral|real life situations|Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
75560419|NCT03272243|Procedure|short segment posterior spine fixation|
75560420|NCT03272243|Procedure|long segment posterior spine fixation|
75716349|NCT05473234|Drug|Amoxicillin|Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
75716350|NCT04500418|Drug|Cenicriviroc (CVC)|Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).
75716351|NCT04500418|Drug|Placebo|Optically identical pills without CVC.
75716352|NCT05473156|Drug|AP203|"Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D[s]).~Participants will be administered by intravenous (IV) infusion, every week (Q1W [± 1days]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W [± 3 days]) for all the following doses."
75415425|NCT06087107|Other|High Intensity Spinal Decompression Exercises|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes with 8-10 repetitions of each exercise.
75716353|NCT05473156|Drug|AP203|The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
75415426|NCT06087107|Other|Eldoa|The duration of the intervention will be 4 weeks, 3 sessions a week, and a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes.
75716354|NCT04005196|Diagnostic Test|EEG|Data recording will continue up until a maximum of 120 hours after emergence from sedation or at CVICU discharge. This study period is informed by baseline data from our institution where the median duration of delirium following emergence from coma was 2 days, allowing sufficient time to capture transitions from coma to wakefulness with and without delirium. EEG recordings will be divided in to epochs corresponding to coma, wakefulness, and delirium if present.
75716355|NCT00671034|Drug|Calaspargase Pegol-mknl|Given IV
75716356|NCT00671034|Drug|Cyclophosphamide|Given IV
75716357|NCT00671034|Drug|Cytarabine|Given IV, IT, PO, or SC
75716358|NCT00671034|Drug|Daunorubicin Hydrochloride|Given IV
75716359|NCT00671034|Drug|Dexamethasone|Given PO or IV
75716360|NCT00671034|Drug|Doxorubicin Hydrochloride|Given IV
75716361|NCT00671034|Other|Laboratory Biomarker Analysis|Correlative studies
75716362|NCT00671034|Drug|Mercaptopurine|Given PO
75716363|NCT00671034|Drug|Methotrexate|Given IV, IT, or PO
75716364|NCT00671034|Drug|Pegaspargase|Given IV
75560421|NCT03270137|Device|repetitive transcranial magnetic stimulation- IDLPFC|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
75560422|NCT03270137|Device|repetitive transcranial magnetic stimulation - Six regions|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
75560423|NCT04519398|Genetic|Complete thrombophilic profile testing by multiplex PCR|"Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~Factor V Leiden~Factor V 4070 A>G (Hr2)~Factor II G20210A~Methylenetetrahydrofolate reductase (MTHFR) C677T~MTHFR A1298C~Cystathionine β-synthase (CBS) 844ins68~PAI-1 4G/5G~Glycoprotein IIIa T1565C (HPA-1a/b)~ACE-DEL/INS~Apolipoprotein E (ApoE)~AGT M235T~Angiotensin II type 1 receptor (ATR-1) A1166C~Fibrinogen - 455 G>A~Factor XIII Val34Leu"
75716365|NCT00671034|Other|Pharmacological Study|Correlative studies
75716366|NCT00671034|Drug|Prednisone|Given IV or PO
75716367|NCT00671034|Radiation|Radiation Therapy|Some patients undergo RT
75716368|NCT00671034|Drug|Thioguanine|Given PO
75716369|NCT00671034|Drug|Vincristine Sulfate|Given IV
75716370|NCT04483648|Other|Exercise|Home exercises were performed three times in a week for six weeks. Home exercises included range of motion exercises, coordination exercises and strengthening exercises. Repeats and durations of the exercises increased every week to provide progression.
75716371|NCT04432792|Other|Questionnaire|Study survey participants will be administered 3 online surveys.
75415427|NCT06086717|Other|Kinesio Taping|"One Y-shaped strap with 25% stretch was applied from the mid third of the thigh over the rectus femoris, then its ends directed toward the tibial tuberosity by enwrapping the patella from lateral and medial sides. In 45° knee flexion one eye strap from medial to lateral was applied through the collateral medial and lateral ligaments.~For the facilitation of VMO 1 eye strap with 25% stretch from medial aspect of thigh to quadriceps tendon. Lastly, 1 eye strap with 25% stretch from tibial tuberosity to lateral aspect of thigh for inhibition of Vastus lateralis"
75415428|NCT06086717|Other|Dry Needling|"Following a protocol according to patient and limb, the tensor fasciae latae, hip adductors, hamstrings, quadriceps, gastrocnemius, and popliteus muscles were properly examined in each subject. These muscles are frequently involved in muscle-related knee pain.~Patients with knee OA who had at least one active MTrP that produced pain were recruited. Patients received a total of 8 DN sessions (2 sessions per week for 4 weeks) at all MTrPs of the lower limbs using the fast-in and fast-out technique (the needle was moved up and down within the muscle)."
75415429|NCT06085885|Device|Cochlear implant|Cochlear implant
75415430|NCT06085534|Drug|LNK01001|Capsules for oral use
75415431|NCT06085534|Drug|Placebo|Capsules for oral use
75415432|NCT06085521|Drug|LNK01001 Dose A|Capsules taken orally
75415433|NCT06085521|Drug|LNK01001 Dose B|Capsules taken orally
75415434|NCT06085521|Drug|placebo|Capsules taken orally
75415435|NCT06079931|Drug|Babaodan Capsule|The patient received 66-66Gy/30-33F radiation therapy. During radiation therapy, concurrent chemotherapy includes receiving 45mg/m2 paclitaxel and carboplatin (AUC 2) once a week; From the start of radiation therapy to 2 months after the completion of CCRT, the patient takes 2 capsules of Babaodan orally every day, tid (1.8 g/day), and systemic corticosteroids can be used for acute radiation pneumonia patients with G ≥ 2.
75716372|NCT00743522|Device|ICD/ CRT-D|Cardiac device
75716373|NCT05623462|Device|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
76042323|NCT04318249|Behavioral|Modified Assisted Relaxation Therapy|This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
75716374|NCT05623462|Other|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program includes the following:~- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
75716375|NCT00743600|Other|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
75716376|NCT00743600|Other|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
75716377|NCT04425070|Combination Product|ICE [ifosfamide+carboplatin+etoposide]|"• Combined with ICE chemotherapy regimen:~Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;~Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;~Etoposide l00 mg/m2, iv infusion, on Days 1-3;~ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
75716378|NCT04425070|Combination Product|GEMOX [gemcitabine+oxaliplatin]|"• Combined with GEMOX chemotherapy regimen:~Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;~Oxaliplatin 130 mg/m2, iv infusion, on Day 1;~ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
75716379|NCT04425070|Combination Product|Tislelizumab|Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle
75716380|NCT00743678|Drug|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
75415436|NCT06074055|Other|FET Protocol|Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol
75415437|NCT06073184|Drug|Ozempic|Semaglutide injection, 2mg once weekly.
75415438|NCT06073184|Drug|Mirena|Levonorgestrel-releasing Intrauterine System (52mg) to deliver up to 20 mcg levonorgestrel per day
75415439|NCT06071845|Device|Cytosponge Procedure|Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.
75415440|NCT06071845|Diagnostic Test|Endoscopic Assessment|Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
75716381|NCT00743756|Dietary Supplement|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
75716382|NCT00743756|Dietary Supplement|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
75716383|NCT00743756|Behavioral|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
75716384|NCT05604508|Other|Many posters with prices|No poster number or price restrictions
75873219|NCT01311479|Procedure|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
76042324|NCT05540119|Procedure|Surgery|Patients who undergo surgery are separately assessed
76042325|NCT05552677|Other|Multicomponent Training|Participants will perform a multicomponent training that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 12 weeks
76042326|NCT05539885|Procedure|Pre-incisional Ultrasound guided (PIFP) block|Patients in group P will be injected with 0.4 mL/kg of 0.25 bupivacaine in the fascial plane between the internal intercostal and pectoralis major muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
75560424|NCT00482066|Drug|Abatacept (Orencia)|"500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v."
75560425|NCT04519047|Biological|PRP|Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
75560426|NCT00482105|Other|EGIR Tape|Tape stripping is a non-invasive method that allows the recovery of cells
76042327|NCT05539885|Procedure|Post-incisional Surgeon delivered parasternal block group|"After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
75560427|NCT04519242|Procedure|Surgery|"ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.~PA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).~Type and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon."
76042328|NCT05552599|Procedure|woolen blanket|Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
75560428|NCT00482144|Procedure|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
75560429|NCT00482144|Procedure|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
75560430|NCT04519359|Other|Stop NAs therapy|Stop NAs therapy
75560431|NCT00482183|Drug|Pioglitazone|
76042329|NCT05552521|Diagnostic Test|Echocardiography|Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission
75560432|NCT04518774|Biological|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
75560433|NCT01312909|Drug|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
75560434|NCT01312909|Drug|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
75560435|NCT01312909|Drug|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
75716385|NCT05604508|Other|Many posters, no prices|No poster number restrictions, but price restrictions
76042330|NCT04426123|Drug|Botulinum toxin type A|Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.
76042331|NCT04426123|Other|saline solution|Intramuscular injection with NaCl in m.masseter and m.temporalis.
76042332|NCT05539651|Drug|RBD5044|Subcutaneously Administered RBD5044 in Healthy Subjects
76042333|NCT05539651|Drug|Placebo|Subcutaneously Administered Placebo in Healthy Subjects
75560436|NCT00482222|Biological|cetuximab|
75560437|NCT00482222|Drug|capecitabine|
75716386|NCT05604508|Other|Fewer posters, no price restrictions|Poster number restrictions, but no price restrictions
75716387|NCT00772278|Procedure|carotid artery stenting|carotid artery angiography, angioplasty and stenting
75716388|NCT00772278|Procedure|carotid endarterectomy|open surgery including endarterectomy
75716389|NCT02679508|Drug|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
75716390|NCT02679508|Drug|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
75560438|NCT00482222|Drug|fluorouracil|
75716391|NCT00775632|Drug|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
75716392|NCT00775632|Drug|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
75716393|NCT04047654|Drug|Non vitamin K oral anticoagulants|Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
75415441|NCT06067516|Other|Fluid resuscitations|In line with the recommendations in the Surviving Sepsis Guide, fingertip capillary refill time (CRT) will be measured by applying pressure to the index finger for 15 seconds in the T1 time period after 30 mL/kg/3 hours crystalloid infusion.
75415442|NCT06066905|Drug|chidamide and azacitidine|"chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally."
75415443|NCT06056518|Other|AI-based risk prediction for kidney graft loss|Implementation of AI-based risk prediction tool for the 1-year risk of kidney graft loss.
75560439|NCT00482222|Drug|leucovorin calcium|
75560440|NCT00482222|Drug|oxaliplatin|
75560441|NCT00482222|Other|study of socioeconomic and demographic variables|
75560442|NCT00482222|Procedure|adjuvant therapy|
75560443|NCT00482222|Procedure|neoadjuvant therapy|
75560444|NCT00482222|Procedure|quality-of-life assessment|
75560445|NCT01312129|Drug|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
75560446|NCT01312129|Drug|Placebo|Placebo capsule x 3 doses 12 hours apart
75560447|NCT00480467|Drug|SAM-315|
75560448|NCT04518852|Combination Product|TACE combined with sorafenib and PD-1 mAb|the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
75560449|NCT02955615|Drug|ILT-101|"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ..."
75873220|NCT05208996|Drug|siCoV/KK46|"The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg."
75560450|NCT02955615|Drug|Placebo|"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ..."
75560451|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
75560452|NCT01311661|Drug|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
75560453|NCT01311661|Drug|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
75560454|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
75560455|NCT01311661|Drug|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
75415444|NCT06049576|Procedure|Biospecimen Collection|Undergo blood and stool sample collection
75560456|NCT01311661|Drug|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
75415445|NCT06049576|Procedure|Bone Scan|Undergo bone scan
75560457|NCT04518735|Other|Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19|Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
75560458|NCT00482261|Drug|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
75560459|NCT00482261|Drug|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
75560460|NCT00482261|Drug|aspirin|100mg/day
75560461|NCT04518618|Drug|Fentanyl|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
75560462|NCT04518618|Drug|Naloxone|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
75560463|NCT00480584|Drug|gemcitabine|Levels 1 through 4: 1000 mg/m^2
75560464|NCT00480584|Drug|capecitabine|Level 1: 500 mg/m^2; Level 2: 825 mg/m^2; Level 3: 1000 mg/m^2; Level 4: 1250 mg/m^2
75560465|NCT00480584|Drug|erlotinib|Levels 1 through 4: 100 mg
75560466|NCT01311505|Drug|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
75415446|NCT06049576|Procedure|Computed Tomography|Undergo CT
75415447|NCT06049576|Biological|Ipilimumab|Given IV
75415448|NCT06049576|Procedure|Magnetic Resonance Imaging|Undergo MRI
75415449|NCT06049576|Drug|Myrciaria dubia Prebiotic Supplement|Given PO
75415450|NCT06049576|Biological|Nivolumab|Given IV
75415451|NCT06048809|Other|Stannous Fluoride Toothpaste (Sensodyne Repair and Protect)|Sensodyne Repair and Protect toothpaste containing 1100 ppm fluoride as SnF2.
75560467|NCT01311505|Drug|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
75560468|NCT05644366|Other|Postural Control Balance Assessment|Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
75560469|NCT05644327|Behavioral|Cardiovascular training (CT)|12 weeks of CT
75560470|NCT05644327|Behavioral|Resistance training (RT)|12 weeks of RT
75560471|NCT05644327|Behavioral|Multimodal training (MT)|12 weeks of MT
75560472|NCT01240538|Biological|wild-type reovirus|Given IV
75560473|NCT01240538|Drug|cyclophosphamide|Given PO
75560474|NCT01240538|Other|laboratory biomarker analysis|Correlative studies
75560475|NCT01240538|Other|pharmacological study|Correlative studies
75560476|NCT04518579|Procedure|thoracic epidural|undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections
75873221|NCT02739750|Other|No intervention|There is no intervention for this study. It is a MRS.
76042334|NCT04425811|Other|kinesiological taping|The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
75560477|NCT01310803|Drug|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
75716394|NCT04404478|Behavioral|B-SWELL: Midlife Black Women's Stress Reduction Wellness Program|Stress reduction and culturally tailored information on healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on per support, goal setting, stress reduction, and culturally relevant information.
76042335|NCT01666951|Drug|LCP-Tacro tablets|Tacrolimus
76042336|NCT01666951|Drug|Prograf|Tacrolimus
76042337|NCT05699395|Diagnostic Test|Non interventional|No intervention
76042338|NCT05539339|Other|Individualized intervention based on genomic alterations|Specialized tumor board recommended agents that target the specific recurrence-driving genomic alterations that are determined by serial TISF ctDNA analysis.
76042339|NCT05539261|Device|magnetic resonance image|Imaging data were collected in a strong magnetic field
75560478|NCT01310803|Other|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
75560479|NCT01240577|Drug|IPdR|
75716395|NCT04404478|Behavioral|WE: Wellness program for Midlife Black Women|Culturally tailored information will be provided about healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on peer support and culturally relevant content.
76042340|NCT05539261|Diagnostic Test|Neuropsychological scale|Multi dimensional neuropsychological test
76042341|NCT05539183|Procedure|Blood withdrawal|Blood withdrawal
76042342|NCT05539105|Procedure|Double tract reconstruction|Double tract reconstruction would be applied after radical proximal gastrectomy.
75873222|NCT02675946|Drug|CGX1321|
75873223|NCT02675946|Drug|Pembrolizumab|
75873224|NCT02675946|Drug|encorafenib|
75873225|NCT02675946|Drug|cetuximab|
75873226|NCT02900378|Drug|LCZ696 (Sacubitril/Valsartan)|LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
75873227|NCT02900378|Drug|Placebo of LCZ696 (Sacubitril/Valsartan)|Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
75415452|NCT06048809|Other|Regular Fluoride Toothpaste (Colgate Cavity Protection)|Colgate Cavity Protection containing 1100 ppm fluoride as SMFP.
75560480|NCT04518540|Drug|lipoic acid group|"The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day."
75560481|NCT04518540|Drug|control group|The patients will take domestic riluzole tablets 50mg orally, twice a day.
75560482|NCT00480623|Drug|Satraplatin plus radiation therapy|
75560483|NCT00505323|Device|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :~Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
75560484|NCT01240655|Drug|LCL161|
75873228|NCT02900378|Drug|Enalapril|Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets
75873229|NCT02900378|Drug|Placebo of Enalapril|Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
75873230|NCT03058692|Biological|Influenza Multimeric-001 Vaccine|The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
75873231|NCT03058692|Other|Placebo|Placebo is saline injection
75873232|NCT03058692|Biological|Quadrivalent Recombinant Seasonal Influenza Vaccine|Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
75873233|NCT03647228|Drug|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
75415453|NCT06044896|Procedure|Supine Positioning|The participant will be guided to the Multicare bed and will be positioned supine with the headboard not tilted. At this point, the participant will already have the EIT electrode belt and head, trunk and lower limb cushions around it, providing stability. After the participant has been correctly positioned, ventilatory monitoring will begin using the EIT. The environment must be fully controlled, that is, with adequate lighting, all collection members in silence, as well as the devices in the place, air-conditioned environment, without exposing the participant to heat or cold. Before starting the collection, the volunteer will be asked to try not to sleep or talk, making it clear that any discomfort can be reported at any time. To keep the volunteer awake, visual and sound stimuli can be performed. Furthermore, if you cough or sigh, the collection will restart. The intervention will last 5 minutes and will be repeated twice, with intervals between body lateralization.
75716396|NCT00772356|Device|Accu-Chek Spirit Insulin Pump|
75716397|NCT00772356|Device|Comparator insulin pump|
75716398|NCT04360096|Drug|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
75716399|NCT04360096|Drug|Placebo|Normal Saline Inhalation
75716400|NCT04360096|Device|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
75716401|NCT04005040|Procedure|Mobile X-ray|Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
75716402|NCT04048044|Device|Exposure to GHz electromagnetic energy (RejuvaMatrix)|75 decibels of 54 to 78 GHz daily for 60 minutes
75716403|NCT00775710|Device|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
75415454|NCT06044896|Procedure|Body Lateral Positioning|The participant will start from the bench press to the 30-degree lateral position. The cushions placed at the beginning of the collection will provide stability so that the inclination does not compromise the correct positioning of the participant, preventing them from sliding on the bed. Furthermore, it is also a safety measure for the participant. The environment will be controlled throughout the intervention and visual and sound effects will also be performed in lateral positioning. The volunteer will remain in this position for five minutes and shortly after will be placed in the supine position again. To start the protocol for the second and final time, the participant will have a washout time of thirty minutes.
75415455|NCT06044623|Drug|CDK 4/6 inhibitors|Either Palbociclib, Ribociclib or Abemaciclib
75415456|NCT06044623|Drug|Endocrine therapy|Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
75415457|NCT06044142|Drug|Curcumin|Curcumin and low laser therapy will be used on patients undergoing chemotherapy
75716404|NCT04047888|Other|Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message|60 minute educational message at each visit
75716405|NCT04047888|Other|Non nutrition-based educational message|No nutrition-based education on infant feeding and practices
75716406|NCT04004650|Procedure|Gluteal turnover flap|Link to procedure: https://www.youtube.com/watch?v=u7_vH2_1ZZc
75415458|NCT06044142|Device|Laser|Low level laser therapy
75415459|NCT06043986|Device|novel nurse call system|"Inavya Ventures Ltd (Inavya) has developed a medical-grade artificial intelligence enabled mobile system (AVATR) to support out-of-hospital healthcare. AVATR is approved as a UK Government official supplier of healthcare technology on the UK Digital Marketplace for cloud-based solutions (G Cloud). AVATR in hospital, will connect to the existing AVATR outpatient service building on existing AVATR technology, which is regulated CE-mark Grade 1 (EU/UK). The research team will create, deploy and test a novel ward-based AI technology innovation to transform current nurse call systems to patient-centred mobile technology assets at bedside, thus reducing the need for unproductive visits by nurses to the bedside, which takes away time and attention where it is otherwise best served.~Having mobile connection to the patients, would improve patient experience and saving nursing staff time, thereby improving quality of care, and saving money."
75415460|NCT06043011|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
75560485|NCT01240655|Drug|Paclitaxel|
75560486|NCT01240031|Other|Individualised nutritional therapy|"Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:~Thorough sensory and nutrition assessment (questionnaire).~Nutrition plan adjusted daily according to the assessment.~Serving appetising, energy- and protein-dense meals, snacks and drinks."
75560487|NCT01240031|Other|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
75560488|NCT04518189|Drug|lidocaine patch|lidocaine patch applied 3 hours before the procedure
75560489|NCT04518189|Drug|Sham patch|Sham patch applied 3 hours before the procedure
75716407|NCT03730792|Behavioral|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
75560490|NCT00482300|Procedure|Systematic pelvic lymphadenectomy|
75560491|NCT00505401|Biological|recombinant HIV-1 Tat protein|
75560492|NCT00505440|Behavioral|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
75560493|NCT00505440|Behavioral|Usual care|Usual care with mailed screening results
75560494|NCT00482378|Drug|Pamidronate|90 mg by IV monthly.
75560495|NCT00482378|Drug|Zoledronic acid|4 mg by IV monthly.
75716408|NCT04394182|Radiation|Ultra-Low-dose radiotherapy|The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
75716409|NCT04394182|Device|ventilatory support with oxygen therapy|Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
75716410|NCT04394182|Drug|Lopinavir/ritonavir|100/400 mg/12h; 7-10 days
75560496|NCT00482378|Radiation|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
75560497|NCT04517955|Device|Transcatheter Aortic Valve Implantation (TAVI)|Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro
75560498|NCT00480818|Drug|SAM-531|
75560499|NCT01310413|Biological|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
75560500|NCT01310413|Biological|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
75560501|NCT02275572|Procedure|Pharmacist Intervention|
75560502|NCT00482417|Drug|MK0359|
75873234|NCT03647228|Drug|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
75873235|NCT04052594|Drug|LY3475766 - IV|Administered IV
75873236|NCT04052594|Drug|LY3475766 - SC|Administered SC
76042343|NCT05539105|Procedure|Gastric conduit reconstruction|Gastric conduit reconstructionn would be applied after radical proximal gastrectomy.
76042344|NCT05539105|Procedure|Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after radical proximal gastrectomy.
75415461|NCT06038487|Procedure|Immediate loading of maxillary implant overdenture|The denture will be immediately connected to the implants. The abutment screw will be torqued at 15 Ncm. The Novaloc cap attachments will be picked up intra-orally using cold curing resin. To avoid contact of the resin with the surgical wound, a circular portion of a sterile rubber dam sheet will be adapted on the cap attachment once placed on the abutment during the pickup procedure. Occlusion is then checked and adjusted if necessary as well as the adaptation on the residual ridges and the patient dismissed. The patients in the test group will be instructed not to remove the prosthesis for one week.
75560503|NCT02275689|Procedure|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
76042345|NCT05546203|Other|Ischemic compression|"IC was applied over the detected MTrPs and the participant was asked to describe the pressure and pain she felt . It was started with moderate tolerable pressure (7/10) and then severity was increased. The color of the thumb pulp was observed to control the pressure. The pressure was continued for 90 sec. The patient's pain sensation continued to be questioned and the pressure was controlled to a level at comfortable pain"
76042346|NCT05546203|Device|Low-level laser therapy|LLLT was applied for 90 sec at each MTrPs with a frequency of 2000 Hz (3 J) using a GaAs diode laser instrument (Roland Serie Elettronica Pagani, wavelength 904 nm, the frequency range of 5-7000 Hz and maximum peak power of 27, 50 or 2764 W) . The laser probe was held perpendicular to the MTrPs in skin contact without pressure.
75560504|NCT02275689|Procedure|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
75560505|NCT00482456|Drug|Nitrous oxide|
75560506|NCT00480896|Drug|tacrolimus ointment|Topical application
75560507|NCT00480896|Drug|Placebo ointment|Topical application
75560508|NCT01309828|Drug|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
75560509|NCT01309828|Drug|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
75560510|NCT00482820|Behavioral|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
75560511|NCT00482495|Biological|bevacizumab|
75560512|NCT00482495|Genetic|gene expression analysis|
75560513|NCT00482495|Genetic|protein expression analysis|
75560514|NCT00482495|Other|laboratory biomarker analysis|
75560515|NCT00480935|Drug|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
75560516|NCT02955264|Dietary Supplement|D-Galactose|D-Galactose is an oral powdered dietary supplement to be taken by mouth.
75560517|NCT00480974|Other|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
75560518|NCT04518150|Device|Bakri balloon|the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
75560519|NCT04518150|Procedure|Bilateral Uterine Artery Ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
75873237|NCT04052594|Drug|Placebo - IV|Administered IV
75873238|NCT04052594|Drug|Placebo - SC|Administered SC
75873239|NCT03621566|Other|No intervention|Routine care (registry)
75560520|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution with epinephrine 1:100,000~infusion of 1,8 mL (one cartridge)~Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
75560521|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution without vasoconstrictor~infusion of 1,8 mL (one cartridge)~Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
75415462|NCT06038487|Procedure|Delayed loading of maxillary implant overdenture|A cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as described for the test group. The abutment screw will be torqued at 35 Ncm. As post-surgical instructions, the patients will be asked not to brush the operated areas and to rinse instead with 0,12% chlorhexidine solution twice a day for 1 minute for 14 days. Pain control is provided with 400 mg ibuprofen, as needed. Soft diet is recommended for 2 weeks. The patients in the control group will be asked not to wear the denture for 7 days.
75560522|NCT00482898|Drug|MK0359|
75560523|NCT00482937|Drug|CD-NP|
75560524|NCT00482651|Radiation|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
75560525|NCT00482651|Procedure|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
75560526|NCT00482651|Procedure|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
75560527|NCT00482651|Procedure|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
75415463|NCT06037876|Drug|IVM (200 µg/kg) + ALB (400 mg)|World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
75415464|NCT06037876|Drug|ALB (400mg)|Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
76042347|NCT05546203|Behavioral|Standardized exercise program|The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.
75415465|NCT06037590|Combination Product|Levodopa Cyclops™|Orally inhaled dry powder levodopa from the Cyclops™ dry powder inhaler
75415466|NCT06037590|Combination Product|INBRIJA®|Orally inhaled dry powder levodopa from the ARCUS® dry powder inhaler
75560528|NCT00482976|Drug|Ruboxistaurin|
75716411|NCT04394182|Drug|Hydroxychloroquine|200 mg/12h
75716412|NCT04394182|Drug|Azithromycin|500 mg/24h, 3 days
75716413|NCT04394182|Drug|Piperacillin/tazobactam|4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
75716414|NCT04394182|Drug|Low molecular weight heparin|prophylactic doses
75716415|NCT04394182|Drug|Corticosteroid injection|250mg x 3 boluses
75415467|NCT06035601|Device|EHR-integrated texting platform|"An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI~Evidence-based prevention education material on recurrent UTIs~5 standing orders for urinalysis and urine culture in the EHR upon enrollment~Standard-of-care management for recurrent UTI"
75415468|NCT06035601|Other|Usual care|• Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms, and 3 to 6 month in-person visits for check-ins and prevention treatment discussion)
75415469|NCT06032247|Behavioral|Resistance exercise program- UL|"Unilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include single-leg squats, split squats, single-leg deadlifts, single-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
75560529|NCT00482976|Drug|Placebo|
75560530|NCT00481013|Drug|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
75560531|NCT00481013|Drug|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
75560532|NCT00483015|Behavioral|smoking|
75560533|NCT00482768|Behavioral|Practice Facilitation|Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
75716416|NCT04394182|Drug|Tocilizumab|600mg single dose
75873240|NCT04052750|Behavioral|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
75873241|NCT04379154|Device|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air by electronic noses
75716417|NCT05386576|Drug|Venetoclax|"During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42."
75415470|NCT06032247|Behavioral|Resistance exercise program- BL|"Bilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include double-leg squats, double-leg deadlifts, double-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
75415471|NCT06029907|Other|Smoking cessation and pain management intervention|Patients will receive a behavioral smoking cessation and pain management intervention
75415472|NCT06029907|Drug|Varenicline|Patients will receive varenicline prescribed by their oncologist
75415473|NCT06028802|Diagnostic Test|CT Clock Tool measurement|Ratio of CT attenuation measurements acquired from within the visible ischaemic lesion (or estimated location if not visible) ÷ CT attenuation measurements acquired from within the equivalent normal brain.
75415474|NCT06026436|Biological|Blood samples|12-24 hours after P2Y12 ADP receptor loading dose (LD)
75415475|NCT06026436|Biological|Blood samples|1 month after Percutaneous Coronary Intervention (PCI)
75415476|NCT06022510|Device|Fetoscopy Sets for Anterior and Posterior Placentas|Patients who choose to undergo fetoscopic surgery for a complicated monochorionic-diamniotic pregnancy will be offered participation in this study. All patients will undergo selective laser photocoagulation with the use of the fetoscopes in this study.
75415477|NCT06017882|Other|Partial sleep deprivation|
75415478|NCT06011798|Drug|Aflibercept|Anti-VEGF control
75415479|NCT06011798|Drug|foselutoclax|Experimental drug
76042348|NCT05551507|Drug|IN10018 in combination with PLD|IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
75415480|NCT06011291|Drug|SYH2051 tablets|Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
75415481|NCT06011291|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Radical or adjuvant radiotherapy
75415482|NCT06008613|Device|3D Holographic Guidance, Navigation, and Control (3D GN&C)|"Using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of:~experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS),~FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system, and~3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2."
75415483|NCT06008158|Radiation|Accelerated Partial Breast Irradiation|Undergo APBI
75873242|NCT04052438|Diagnostic Test|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
75873243|NCT03647150|Drug|amoxicillin|At enrollment the child will receive a 1 week course of amoxicillin
75873244|NCT03647150|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
75873245|NCT03647150|Behavioral|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
75873246|NCT04373226|Behavioral|Magnitude comparison tasks and neuropsychological testing|neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
75873247|NCT04708158|Biological|Novaferon|a novel recombinant antiviral protein drug
75873248|NCT04708158|Biological|Placebo|Saline
75873249|NCT02964338|Drug|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
75873250|NCT02964338|Drug|Placebo|Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
75873251|NCT03056352|Drug|Metoclopramide|Intravenous medication drip
75873252|NCT03056352|Drug|Diphenhydramine|Intravenous medication drip
75873253|NCT04360980|Drug|Colchicine Tablets|1.5 mg loading then 0.5 mg BID P.O
75873254|NCT03645278|Drug|SHR0532|Ascending dose oral adminstration
75873255|NCT03645278|Drug|Placebo|Ascending dose oral administration
76042349|NCT05538559|Other|Chemomechanical caries removal by Carie-Care|caries in primary teeth will be removed using Carie-Care™ the chemomechanical agent.
75873256|NCT03647072|Drug|CHOP|CHOP only
75415484|NCT05988710|Drug|Buccal Buprenorphine 300 mcg|buprenorphine for 300mcg buccal administration
75415485|NCT05988710|Drug|Buccal Buprenorphine 600 mcg|buprenorphine for 600mcg buccal administration
75415486|NCT05988710|Drug|Buccal Buprenorphine 900 mcg|buprenorphine for 900mcg buccal administration
75415487|NCT05988710|Drug|Buccal Placebo|Placebo for buccal administration
75415488|NCT05988710|Drug|Oral Placebo|Placebo for oral administration
75415489|NCT05988710|Drug|Oral immediate-release oxycodone 10mg|Immediate-release oxycodone for 10 mg oral administration
75415490|NCT05977686|Device|Masimo Root Radical 7 Pulse CO-Oximeter|The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.
75716418|NCT05376124|Other|original therapy|Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
75415491|NCT05977686|Device|HemoCue Hb 801|The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.
75415492|NCT05977556|Behavioral|Combined neuromuscular exercise training and 'sit less, move more' program|"Neuromuscular strength training: The experimental group will receive up to 24 sessions of neuromuscular strength training led by a physical therapist with expertise in geriatrics and movement behaviors. The program includes exercises such as pelvic lifts, lunges, step-ups, squats, and sit-stands. The difficulty level will progressively increase using techniques like manual resistance, dumbbells, and unstable surfaces.~Sedentary behavior intervention: The experimental group will also undergo a sedentary behavior intervention based on social cognitive theory. It involves weekly coaching sessions to enhance self-efficacy in reducing sedentary time and increasing light-intensity activity throughout the day. Participants will be provided with a wrist-worn Fitbit activity monitor for daily feedback and to track adherence to the intervention. The aim is to encourage participants to sit less and move more throughout their waking hours."
75415493|NCT05969808|Other|baseline therapy and conventional therapy|These activities included were warm-up activities, general playtime, basic gross motor activities, and free play with toys three times a week for 45 minutes for a period of 12 weeks.
75560534|NCT01309243|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
75560535|NCT01309243|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
75873257|NCT03647072|Drug|CHOP Plus Lanzoprazole|CHOP plus Lanzoprazole 60 mg
75560536|NCT01240070|Other|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
75873258|NCT03647072|Drug|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
76042350|NCT05538559|Other|Mechanical caries removal by Atraumatic Restorative Technique|caries in primary teeth will be removed using the mechanical caries removal by ART method.
75716419|NCT05376124|Other|rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
75716420|NCT04244890|Device|Uninterrupted CPAP for the first hours of life|Directly at birth the infant will be supported with PPV with PEEP as needed, followed by nasal CPAP. Support will be provided with a single device for up to four hours.
75716421|NCT04223206|Dietary Supplement|NATURLENS|Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
75716422|NCT03472768|Diagnostic Test|Plasma Haptoglobin Concentration|N/A, comparison of haptoglobin concentration between groups
75716423|NCT05325580|Drug|Magnesium sulfate|"magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum"
75873259|NCT05284136|Dietary Supplement|Crohn's disease exclusion diet (CDED)|16-week course of CDED+Partial Enteral Nutrition. During the first 6 weeks (phase 1 of CDED), patients will be prescribed the CDED and oral Modulen 1 liter (1000kcal) daily. Between week 6 and 16 (phase 2 of CDED), patients will be prescribed CDED and oral Modulen (500 mL).
75716424|NCT04144348|Biological|mRNA-1653|Sterile liquid for injection
75716425|NCT04144348|Biological|Placebo|Sterile liquid for injection
75716426|NCT00539734|Drug|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
75873260|NCT05284136|Drug|Oral prednisolone|oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
75716427|NCT03907072|Drug|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
75716428|NCT03907072|Drug|Placebo|Buffered saline solution
75716429|NCT04004338|Drug|Kyprolis|Patients receiving kyprolis (carfilzomib)
75716430|NCT04209322|Procedure|pulsed Radiofrequency|Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging
75716431|NCT04209322|Procedure|Transforaminal Epidural Steroid Injection|Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
75716432|NCT04004572|Drug|LEAP regimen|Patients will be given LEAP regimen every 3 weeks for 8 cycles.
75716433|NCT04050436|Drug|Cemiplimab|Cemiplimab administered intravenously
75716434|NCT04050436|Biological|RP1|RP1 administered intratumorally
75716435|NCT04045912|Other|AGYW-Friendly Services|"Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW."
75716436|NCT04045912|Other|HIVST|Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
75716437|NCT01093976|Drug|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
75560537|NCT04517409|Procedure|Goal-directed hemodynamic therapy|Eligible patients were equally randomized into two study groups: 1) Standard perioperative (Control group ) and 2) hemodinamic management based using radial artery pulse contour analysis (GDHT group). Randomization was performed the day before surgery by the study member responsable for anesthesia delivery using sealed opaque envelope technique stored in non-transparent containers with group allocation in a 1:1 ratio. Only patients were blinded to group allocation. Care providers and investigators could not be blinded due to the presence of the cardiac index trending monitor
75560538|NCT04517409|Procedure|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment."
75560539|NCT01240109|Drug|Remifentanil|"propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
75560540|NCT04517526|Drug|pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
75560541|NCT01309204|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
75560542|NCT01309204|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
75560543|NCT01309204|Drug|Brinzolamide 1% ophthalmic suspension|
75415494|NCT05969808|Other|baseline treatment and adaptive physical activity|The experimental group's intervention plan had the following 12 elements . Each of which was completed for 10 minutes with two-minute breaks. Warm-up activities, puzzles and manipulatives, e.g., interlocking blocks or shape sorting toys, Balloon Badminton, Obstacle course (crawl in Tunnel ), Peg board play, Tactile sensory bin exploration filled with sand, Ball roll and catch, Tracing shapes, Play dough and clay activities, Cutting and pasting.
75560544|NCT01309204|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
75560545|NCT01309165|Behavioral|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
75560546|NCT01309165|Behavioral|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
75560547|NCT01308853|Device|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
75560548|NCT02890888|Other|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
75560549|NCT04517331|Procedure|Thoracic paravertebral block-single injection|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
75716438|NCT04597346|Device|Bronchoscopic Transparenchymal Nodule Access|Bronchoscopic Transparenchymal Nodule Access (BTPNA) is locating the lesion in the lung tissue guided by the bronchoscope navigation system (LungPro) in the natural lumen (bronchus), and automatically calculates the best point of entry (POE) and the best route to avoid blood vessels. An opening is made from the POE under the endoscope, and is extended with a balloon dilator. Combined with X-ray fluoroscopy, a sheath with a blunt-tip core is used in the lung parenchyma to reach the lesion site, and then biopsy diagnosis or treatment.
76042351|NCT05698303|Drug|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
75415497|NCT05965258|Diagnostic Test|Cardiac magnetic resonance (CMR)|Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.
75560550|NCT04517331|Procedure|Thoracic paravertebral block-double injection|The blocks were performed at both T2-T3 and T4-T5 levels bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
75415498|NCT05952271|Other|Hospitalization|Population of patients hospitalized for Herpes Zoster (ICD9-CM 053.xx)
75415499|NCT05950594|Radiation|Radiotherapy|Standard of care pre-operative radiotherapy
75415500|NCT05950594|Other|Surgery|Standard of care definitive surgery
75415501|NCT05944770|Other|DIY portable air cleaner with a highly effective filter|"A portable air filtration device that can be homemade (DIY), constructed by attaching a highly effective air filter (MERV13 rating or higher) to a 20 inch box fan to filter air pollutants including particulate matter of size 2.5 micrometers diameter or greater."
75415502|NCT05944770|Other|DIY portable air cleaner with sham filtration|"A portable air filtration device that can be homemade (DIY) by attaching an air filter to a 20 inch box fan. The portable air cleaner with sham filtration with have a filter that is not effective for filtration of fine particulate matter, including that in wildfire smoke."
75415503|NCT05936255|Behavioral|Give to Others Module|Negative interpersonal beliefs are targeted via cognitive-behavioral strategies, including evaluation of cognitive distortions, and activity planning and tracking.
75415504|NCT05921045|Other|modification of clinical approach in clinical practice at time 0|evaluation of modification in clinical approach after training
75415505|NCT05921045|Other|modification of clinical approach in clinical practice at 6 months|evaluation of modification in clinical approach after retraining
75415506|NCT05916885|Other|short-intensity modified CIMT and conventional therapy|an experimental group receiving short-intensity modified CIMT and conventional therapy
75560551|NCT01240148|Drug|AZD3161|Single dose, intradermal injection
75560552|NCT01240148|Drug|Lidocaine|Single dose, intradermal injection
75560553|NCT01240148|Drug|AZD3161 Placebo|
75716439|NCT00329719|Procedure|Conventional Surgery|Undergo surgery
75716440|NCT00329719|Other|Laboratory Biomarker Analysis|Correlative studies
75716441|NCT00329719|Drug|Sorafenib Tosylate|Given PO
75716442|NCT00329719|Drug|Temsirolimus|Given IV
75716443|NCT04008628|Drug|Nitrous Oxide|Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
75716444|NCT04004806|Device|Hill Rom tracking device|Location tracking devices from Hill Rom company.
75716445|NCT00743834|Drug|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
75716446|NCT00743834|Behavioral|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
75560554|NCT04325191|Dietary Supplement|Melatonin|Daily consumption of a high sodium diet and melatonin for 10 days
75716447|NCT00743912|Drug|rifaximin|550 mg TID
75415507|NCT05916885|Other|conventional therapy alone|a control group receiving conventional therapy alone.
75415508|NCT05916872|Other|experimental group|Patients will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique with EMS
75415509|NCT05916872|Other|control group|Patients will receive conventional therapy.
75415510|NCT05915247|Drug|HER-096|Administered as a single dose via s.c. injection
75415511|NCT05915247|Drug|Placebo|Administered as a single dose via s.c. injection
75415512|NCT05902546|Other|High intensity interval training|Patients will receive interval training exercise of high intensity. This includes several rounds that alternate between several minutes of high intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of rest
75560555|NCT04325191|Other|Placebo|aily consumption of a high sodium diet and placebo for 10 days
75560556|NCT04324879|Drug|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
75560557|NCT04517292|Drug|Eribulin,cisplatin|Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
75873261|NCT03646916|Drug|Dexamethasone|Gluco-corticosteroid
75415513|NCT05902546|Other|moderate intensity aerobic exercise|Patients will receive moderate intensity continuous aerobic exercise (walking) for 40 minutes (preceded by 10 minutes warming up and followed by 5 minutes cooling down)
75415514|NCT05896423|Behavioral|PrEP awareness materials|Community-designed PrEP awareness materials - developed in the formative portion of this study
75716448|NCT02563886|Other|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
75560558|NCT04517292|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
75716449|NCT02563886|Other|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
75716450|NCT05306080|Drug|Tadekinig alfa (IL-18BP)|"Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~Injection #1/Day 1:~o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS."
75560559|NCT02890849|Other|Liquid biopsy|
75873262|NCT03646916|Other|No dexamethasone|Nothing
76042352|NCT05551351|Diagnostic Test|Cardiac CT with photon counting detector|Cardiac CT including the coronary arteries. The cardiac CT is performed in routine care for the included patients.
75415515|NCT05888662|Procedure|Endo-epicardial ablation|Endo-epicardial ablation of ventricular tachycardia
75415516|NCT05888662|Procedure|endocardial ablation only|endocardial-only catheter ablation of ventricular tachycardia
75716451|NCT04060472|Drug|albumin-bound paclitaxel + oxaliplatin|Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
75873263|NCT04305756|Drug|Enoxaparin|Low molecular weight heparin
75873264|NCT02898662|Drug|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
75873265|NCT02898662|Drug|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
75873266|NCT04437810|Biological|Albumin|- Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)
75415517|NCT05882357|Drug|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
75415518|NCT05882357|Drug|IVA|Granules for oral administration
75560560|NCT00482846|Biological|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
75415519|NCT05879653|Drug|MK-3475|During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.
75560561|NCT00482846|Drug|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
75415520|NCT05879653|Drug|ASG-22CE|During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.
75415521|NCT05879653|Procedure|maximal TURBT|All participants who were not determined to have PD on imaging during the induction phase should have had a maximal TURBT performed at 13 (± 1week) weeks after the first dose of trial drug.
75415522|NCT05879653|Radiation|Radiation therapy|Radiotherapy will be initiated no later than 8 weeks after maximal TUR-BT. In this trial, a total dose of 56 Gy will be delivered using 2 Gy per dose. 40 Gy/20 fr (2 Gy/fr) to the small pelvis followed by 16 Gy /8 fr (2 Gy/fr) to the whole bladder 5 times a week for 5 consecutive days using Three-Dimensional Conformal Radiation Therapy (3D-CRT).
75415523|NCT05878288|Drug|Cemiplimab|Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
75560562|NCT00482846|Other|questionnaire administration|Day -5 to Day +28
75560563|NCT00482846|Procedure|autologous peripheral blood stem cell transplantation|Day 0
76042353|NCT02586805|Drug|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
75415524|NCT05877586|Other|CLARE app|"CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge."
75415525|NCT05876273|Device|Neural-net Artificial Pancreas|NAP is a neural-net implementation of the previously tested UMPC algorithm (below).
75415526|NCT05876273|Device|University of Virginia Model Predictive Control|A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.
75415527|NCT05874713|Biological|aH5N8c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
75560564|NCT00482846|Other|quality-of-life assessment|Day -5 to Day +28
75560565|NCT01308736|Drug|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
75560566|NCT01308736|Drug|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
75560567|NCT04517214|Drug|Toripalimab|PD-1 inhibitor
75560568|NCT04517214|Radiation|IMRT to the nasopharynx and neck|IMRT to the nasopharynx and neck
75560569|NCT04517214|Drug|Gemcitabine and Cisplatin Chemotherapy|Systemic chemotherapy
75560570|NCT04517214|Drug|Adjuvant chemotherapy with Capecitabine|Adjuvant chemotherapy after radiation
75560571|NCT01240187|Drug|perampanel|Single dose of 6 tablets 2 mg orally
75560572|NCT01240187|Drug|perampanel|Single dose of 1 tablet 12 mg orally
76042354|NCT02586805|Drug|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
75415528|NCT05874713|Biological|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
75415529|NCT05874713|Biological|aH5N8c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
75415530|NCT05874713|Biological|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
75415531|NCT05874713|Biological|aH5N8c on Day 202|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
75560573|NCT00483054|Drug|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
75560574|NCT00483054|Drug|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
75560575|NCT01240226|Drug|GDC-0941|Oral repeating dose
75560576|NCT01240226|Drug|GDC-0941|Oral repeating dose
75716452|NCT02563730|Procedure|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
75716453|NCT00329641|Drug|carboplatin|Given IV
75716454|NCT00329641|Drug|paclitaxel|Given IV
76042355|NCT02586805|Drug|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
76042356|NCT02586805|Drug|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
75716455|NCT00329641|Drug|sorafenib tosylate|Given orally
75716456|NCT02566070|Other|Continuous Gastric Feeding|
75415532|NCT05864950|Device|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
75560577|NCT01240226|Drug|ketoconazole|Oral repeating dose
75560578|NCT01240824|Drug|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
75560579|NCT00482924|Other|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
75560580|NCT01240941|Drug|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
75560581|NCT01240941|Drug|Exemestane|25 mg orally daily
75560582|NCT01240941|Drug|Goserelin|3.6 mg orally monthly
75716457|NCT02566070|Other|Bolus Gastric Feeding|
75716458|NCT02533219|Drug|18 F-DOPA|Subjects will undergo PET imaging with [18F]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of [18F]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
75873267|NCT04437810|Other|Standard Medical Treatment|standard medical therapy
75716459|NCT03366220|Drug|Plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
76042357|NCT05545423|Other|instrumented assisted soft tissue mobilization|the appropriate Graston technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and invested the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sternocleidomastoids and upper fibers of trapezius muscles. The IASTM technique was applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, following immediately by an additional 20-seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds.
75716460|NCT03366220|Drug|Balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
75716461|NCT00743990|Other|Ointment containing camphor, eucalyptus oil, and menthol|One time use
75716462|NCT00743990|Other|Petroleum jelly|One time use
75716463|NCT00329407|Drug|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
75716464|NCT04595006|Other|Cold Stimulation (CS)|Subject wear cooling vest to stay cool
75560583|NCT04517097|Biological|blood sample|one blood sample and one questionnaire to each patient and salaried staff included
75560584|NCT00482963|Drug|levonorgestrel, efavirenz|
75560585|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.1 mg, once daily, 1 day
75560586|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
75560587|NCT01240980|Drug|BMS-903452|Suspension, Oral, 3.0 mg, once daily, 1 day
75716465|NCT04595006|Other|Browning Nutraceutical (BN)|Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root
75873268|NCT04368156|Device|gammaCore® (Vagus nerve stimulation)|Vagus nerve stimulation using the gammacore neurostimulation device
75560588|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
75560589|NCT01240980|Drug|BMS-903452|Suspension, Oral, 30 mg, once daily, 1 day
75560590|NCT01240980|Drug|BMS-903452|Suspension, Oral, 60 mg, once daily, 1 day
75560591|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
75716466|NCT04595006|Other|Cold Stimulation and Browning Nutraceutical (CSBN)|Subject wear a cooling vest and consume 2000mg of curcumin
75716467|NCT04004728|Procedure|1064 Nd:YAG laser|1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
75415533|NCT05864001|Behavioral|STAR-C mobile app|Digital coaching intervention for healthy lifestyle
75415534|NCT05859152|Other|Zona Pellucida-Bound Sperm Selection for ICSI|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.
75873269|NCT04354272|Other|Questionnaire|Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
75873270|NCT03645980|Drug|DKN-01 300 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
75415535|NCT05859152|Other|Routine Embryologist Selected Sperm|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
75415536|NCT05849207|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
75560592|NCT01240980|Drug|Placebo|Solution, Oral, 0 mg, once daily, 1 day
75560593|NCT01240980|Drug|Placebo|Suspension, Oral, 0 mg, once daily, 1 day
75560594|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
75560595|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
75560596|NCT01240980|Drug|Placebo|Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
75716468|NCT01056757|Drug|Ribavirin|1000 mg bid, po, q28days
75873271|NCT03645980|Drug|DKN-01 600 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
75415537|NCT05845541|Behavioral|Technology Supported Meditation and Biofeedback|"Patient's in the treatment arm will participate in technology based meditation using the iom2 and Journeys app at least 3 times/ week. This will involve placing a probe on their ear attached to the iom2 and following the guidance provided by the Journeys App.~During and following each session, participants will be shown their average heart rate variability (HRV) score, average HRV, and time spent on the session. Patients will be able to review sessions and keep track of their progress. Participants in the intervention arm will be asked to complete the outcome measures prior to their hospital discharge. As well, an informal discussion about the patient's experience using technology based meditation will be transcribed."
75415538|NCT05845541|Other|Standard Treatment|Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
75415539|NCT05838183|Diagnostic Test|The relationship between imaging and ROSE and NGS|The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed
75415540|NCT05835856|Device|Virtual coach with NAO robot|The coaching device used is the softbank NAO 5 and NAO 6 humanoid interactive mobile robot. These robot platform allows multimodal natural language interaction and robot autonomous movement.
75415541|NCT05835856|Device|Virtual coach with Google Nest Hub (2e generation) group|The coaching device used is Google Nest Hub (2e generation). This is a connected speaker enriched with a 7-chip touch screen. It has a loudspeaker and 3 microphones, making interaction possible.
75560597|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
75560598|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
75560599|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
75560600|NCT01240772|Device|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
75560601|NCT01240772|Device|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
75560602|NCT01241019|Drug|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
75560603|NCT01240928|Drug|MSK-2206|Level 1: MK-2206 135mg weekly
75560604|NCT01240928|Drug|Exemestane|Level 1: Exemestane - 25mg daily
75560605|NCT01240928|Drug|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
75560606|NCT04517175|Diagnostic Test|Flow cytometry|Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
75560607|NCT00481169|Drug|Bazedoxifene Acetate (TSE-424)|
75560608|NCT04516980|Other|Questionnaires administration|"Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints."
75560609|NCT01240421|Drug|Eribulin Mesylate|At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
75560610|NCT04516863|Diagnostic Test|German Autobiographical Memory Interview short-form|Diagnostic Test
75560611|NCT01240967|Drug|TC-5214|Oral tablets, single dose
75415542|NCT05835856|Device|Virtual coach with Gatebox device|The coaching device used is the Gatebox, a hologram like device which the user can interact. There are internal sensors such as a camera and a microphone allow the user to converse with the projected character. It connects to the Internet via a wireless LAN. With infrared rays and Bluetooth, it can also be connected to household appliances and other devices.
75415543|NCT05835856|Device|virtual coach with CelesTE robot|"The coaching device used is the CelesTE robot, a prayer companion designed for Christian Catholic users.The intended main function of CelesTE is to be a guardian angel, especially thought for elderly people. It can be a prayer companion, and contains a vast number of teachings, including the whole Bible. Its AI is capable of keeping a short conversation, in which the user may ask and receive an answer about a sensitive topic (such as happiness, death, faith, etc.). It can also printout a selection of contents.~The coaching device CelesTE will be substituted by DarumaTO for the Japanese centers."
75560612|NCT04517019|Device|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
75560613|NCT00483093|Drug|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
75560614|NCT00483093|Drug|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
75560615|NCT00487916|Drug|AMA1-C1/ISA 720|
75560616|NCT00483132|Drug|interferon alpha 2a|
75415544|NCT05835856|Other|booklet|Participant in the control group will receive a booklet containing information and activities on well-being
75560617|NCT00483080|Drug|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
75560618|NCT00483210|Drug|Fenofibrate|
75560619|NCT00487955|Procedure|Resting Energy Expenditure examination|
75560620|NCT00483288|Other|educational intervention|
75560621|NCT00483288|Other|questionnaire administration|
75560622|NCT00483288|Other|study of socioeconomic and demographic variables|
75560623|NCT00483288|Other|survey administration|
75560624|NCT00487994|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
75560625|NCT00487994|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
75716469|NCT00744068|Behavioral|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
75716470|NCT01056835|Drug|prostaglandin I2 analogue|
75716471|NCT03989323|Other|Estimation of the incidence of the irAE|Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
75560626|NCT00487994|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
75560627|NCT04516824|Procedure|Orthopaedic Surgical Procedures|Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
75415545|NCT05834244|Drug|Azacitidine|Given by IV (vein)
75415546|NCT05834244|Drug|Venetoclax|Given by PO
75415547|NCT05834244|Drug|NK Cells|Given by IV (vein)
75415548|NCT05831046|Other|ED management software|Patients utilize software after being screened, but prior to being re-evaluated by physician
75560628|NCT02955342|Other|no intervention|no intervention
76042358|NCT05545423|Other|traditional therapy|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises
75560629|NCT00483158|Drug|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
75560630|NCT00488111|Other|Ringer's Lactate|Ringer's Lactate was used 15min before operation
75560631|NCT00488111|Other|6% Starch|6% Starch was used 15min before operation
75560632|NCT02955381|Device|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
75560633|NCT02955381|Device|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
75560634|NCT00483197|Device|VentrAssistTM Left Ventricular Assist Device|
75560635|NCT02955420|Drug|BC 007|
75560636|NCT02955420|Drug|NaCl 0.9 %|
75560637|NCT02955303|Other|TECH: Tablet Enhancement of Cognition and Health|cognitive training using touchscreen tablet gaming applications
75560638|NCT01308580|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
75560639|NCT01308580|Drug|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
75560640|NCT00483275|Drug|Alfacalcidol|
75560641|NCT00483275|Behavioral|Balance, gait and strength training|
75560642|NCT00483275|Behavioral|Patient education|
76042359|NCT05545345|Procedure|tympanostomy tube placement|An incision will be made in the the tympanic membrane, through which a ventilation tube will be inserted.
75560643|NCT00483444|Behavioral|Scheduled telephone follow-up|Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
75560644|NCT02890810|Other|Real Acupuncture with Electrical Stimulation|Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
75560645|NCT02890810|Other|Simulated Acupuncture with Electrical Stimulation|This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
75560646|NCT00483314|Drug|N-acetylcysteine|2 g p.o. BID x 60 days
75560647|NCT04516629|Diagnostic Test|heart rate variability, pulse diagnosis device|check heart rate and pulse rate
75560648|NCT01308463|Device|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
75560649|NCT04324918|Drug|HCP1102|The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
75716472|NCT03986515|Drug|apatinib plus SHR-1210|apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
75560650|NCT04324918|Drug|HGP1408|The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
75716473|NCT03989479|Behavioral|Brushing demonstration using T shaped toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
75716474|NCT03989479|Behavioral|Brushing demonstration using conventional toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
75415549|NCT05819021|Device|SAINT® Neuromodulation System (NMS)|The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.
75415550|NCT05816330|Biological|L9LS (VRC-MALMAB0114-00-AB)|Administered one time via subcutaneous route.
75560651|NCT00483353|Procedure|Intra-nasal allergen challenge with Phleum pratense.|
75716475|NCT01056991|Other|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
75560652|NCT00483353|Procedure|Collection of nasal effluent using filter paper.|
75716476|NCT01056991|Other|warming blanket|
75716477|NCT00328783|Device|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
75716478|NCT00328783|Radiation|Radiation Therapy|
75716479|NCT00567489|Drug|Physioneal|Physioneal 40 or Physioneal 35
76042360|NCT05545345|Procedure|adenoidectomy|The adenoid is resected transorally under a 70° endoscope with microdebrider or coblator until torus tubarius and choanae are completely revealed.
75415551|NCT05816330|Other|Normal Saline|Administered one time via subcutaneous route.
75415552|NCT05806060|Drug|VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
75415553|NCT05806060|Drug|nab-paclitaxel, with maintenance of capecitabine|Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
75415554|NCT05806060|Drug|Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1|TPC
75415555|NCT05806060|Drug|VEGFR and TPC|VEGFR bevacizumab and TPC
75415556|NCT05802927|Other|DSF|Diabetes-specific formula
75415557|NCT05802927|Other|Breakfast 1|Noodle Soup
75560653|NCT00483353|Procedure|Measurement of nasal congestion using acoustic rhinometry.|
75560654|NCT00483483|Behavioral|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
75716480|NCT00567489|Drug|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
75716481|NCT00567489|Drug|Extraneal|7.5% Icodextrin
75716482|NCT00567489|Drug|Nutrineal|Amino Acids 1.1%
75873272|NCT03645980|Drug|Sorafenib|For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
75716483|NCT00669942|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
75873273|NCT04315038|Procedure|spinal anesthesia|Plan to enroll 200 health volunteers and 40 neurodegenerative diseases patients with received spinal anesthesia. Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
75873274|NCT03645200|Drug|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
75415558|NCT05802927|Other|Breakfast 2|Glutinous rice
75560655|NCT00483483|Behavioral|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
75560656|NCT01308424|Drug|BTL TML HSV|Sublingual micro-dosing for 7 days
75560657|NCT01308424|Drug|Matching placebo|sublingual dosing for 7 days
75716484|NCT00669942|Drug|Placebo|Placebo to AIN457
75716485|NCT00929019|Biological|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
75716486|NCT00907491|Device|pulmonary sounds analyzer|Cough counting device based on the WIM Technology
75716487|NCT00929097|Other|Implementation aids|"Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~Clinicians receive the guidelines and a risk communication tool, as well as education"
75716488|NCT00929097|Other|Control|Dissemination of guidelines
75716489|NCT00769938|Device|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
75873275|NCT03645902|Diagnostic Test|Magnetic resonance imaging|
76042361|NCT05545267|Procedure|Angioplasties|Transluminal angioplastie
75415559|NCT05795647|Drug|Pentoxifylline+Tocopherol|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
75415560|NCT05784194|Procedure|Intervention for correct discharge medication list|As above
75415561|NCT05775809|Drug|selective serotonin reuptake inhibitors|"Research Treatment Drug treatment The patient did not take antidepressant treatment at least 14 days before enrollment (the patients treated with fluoxetine before enrollment should stop using it for at least 28 days). During 8 weeks, all subjects with major depressive disorder received effective dosages of selective serotonin reuptake inhibitors, and all subjects with major depressive disorder were limited to a single class of antidepressants. If the treatment of selective serotonin reuptake inhibitors is not effective after eight weeks, the drugs can be considered for replacement. The drugs for replacement include but are not limited to selective serotonin reuptake inhibitors.~Other treatment Settings Psychotherapy and TMS are allowed. The method, frequency, and duration of therapy should be recorded."
75415562|NCT05775809|Device|TMS|TMS are allowed. The method, frequency, and duration of therapy should be recorded.
75415563|NCT05770804|Behavioral|Face to face education|Face-to-face training was provided and supported by booklets.
75415564|NCT05769855|Drug|HR18034|HR18034 380mg
75415565|NCT05769855|Drug|ropivacaine HCl|ropivacaine HCl 75mg.
75415566|NCT05769855|Drug|Sodium Chloride Physiological Solution|Sodium Chloride Physiological Solution 20ml
75415567|NCT05759221|Procedure|Bronchoscopy with airway biopsy|Forceps biopsy of peripheral airways under direct endoscopic visualisation.
75716490|NCT00907569|Radiation|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
75415568|NCT05745883|Drug|DISC-0974|DISC-0974 is administered subcutaneously
75415569|NCT05745883|Drug|Placebo|Placebo is administered subcutaneously
75415570|NCT05733091|Behavioral|Standard of Care|Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
75415571|NCT05727059|Device|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
75560658|NCT05644288|Other|Help eNursing|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation.~Over the 36 weeks of the HELPeN Program, each volunteer is expected to provide intervention to 2 seniors, making 1 call per week to each subject lasting approximately 30 minutes. Students will perform physical and psychosocial assessments of the elders and create individualized care plans based on each subject's needs."
75415572|NCT05714514|Drug|Imlifidase administered in the ConfIdeS study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
75415573|NCT05714514|Other|Best available treatment administered in the ConfIdeS study|Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
75415574|NCT05714293|Radiation|CT scan with contrast medium|Multi-detector CT scan (if possible with prospective-ECG gated sequential scan) with contrast medium injection of nonionic contrast agent. All CT datasets will be analysed for the qualitative and quantitative assessment of the aortic root. The coronary height will be assessed at baseline in relation to the aortic annulus and in relation to the stent of the bioprostheses after aortic valve replacement.
75415575|NCT05711420|Behavioral|Gamification method group|Gamification method group
75415576|NCT05711420|Behavioral|Flipped learning group|Flipped learning group
75415577|NCT05703113|Behavioral|Web 2.0 tools|Education with Web 2.0 tools
75415578|NCT05702749|Procedure|Microsurgical resection of VS|Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.
75415579|NCT05702749|Radiation|Stereotactic radiosurgery|Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.
75560659|NCT00483522|Behavioral|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
75716491|NCT02538393|Drug|Sorafenib (BAY43-9006) Film-coated tablet|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state in Treatment A
75716492|NCT02538393|Drug|Sorafenib (BAY43-9006) Oral suspension|Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.
75716493|NCT00770016|Drug|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
75415580|NCT05702749|Other|PREHAB|A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).
75716494|NCT00924963|Device|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
75560660|NCT00483392|Drug|metformin, rosiglitazone|
75560661|NCT00483431|Dietary Supplement|Placebo|
75560662|NCT00483431|Dietary Supplement|MK7|
75560663|NCT00483600|Drug|fondaparinux|injections of 2.5mg every other day for 4 weeks
75560664|NCT00488189|Drug|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
75560665|NCT04516551|Biological|anti-CD19 allo-CAR-T cells|The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
75560666|NCT00488228|Behavioral|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
75716495|NCT00924963|Device|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
75716496|NCT00924963|Drug|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
75716497|NCT00770094|Device|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
75560667|NCT00483639|Other|Medical chart review|medical chart review
75560668|NCT00483639|Other|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
75560669|NCT00483639|Procedure|management of therapy complications|management of therapy complications
75560670|NCT00483639|Procedure|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
75560671|NCT00483639|Other|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
75560672|NCT02956421|Biological|RABIPUR®|Biological rabies vaccine
75560673|NCT02956421|Biological|PIKA rabies vaccine|Biological rabies vaccine
75560674|NCT04516239|Device|THA|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. For the THA, the standard techniques proposed by the manufacturer for insertion of the stem were followed. Neck sleeve adapters and three different prosthetic neck-shaft angles (125, 135, and 145) were available to adjust leg length and femoral offset with the large-diameter head THA system.
75716498|NCT00770094|Device|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
75415583|NCT05692635|Diagnostic Test|MRI of the Brain|An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
75415584|NCT05692635|Other|Blood draws|Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
75560675|NCT04516239|Device|HR|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. In the HR group, the capsulotomy was completed circumferentially, and the gluteus tendinous insertion on the femur was released in all men, but only when needed in women, to improve femur mobilization.
75716499|NCT00770094|Device|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
75716500|NCT00925041|Device|Vedera KXS|one treatment with the Vedera KXS
75716501|NCT00775788|Procedure|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
75716502|NCT00929175|Device|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
75716503|NCT00929175|Device|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
75716504|NCT00929409|Drug|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
75716505|NCT00929409|Drug|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
75415585|NCT05692635|Other|Quality of Life Questionnaires|Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.
75415586|NCT05692635|Drug|Gadolinium|Given intravenously
75415587|NCT05686122|Behavioral|PainPac|Patient-focused behavioral pain intervention delivered via mobile application.
75560676|NCT00483470|Biological|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
75560677|NCT00483470|Biological|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
75560678|NCT00483678|Other|counseling intervention|
75560679|NCT00483678|Other|questionnaire administration|
75716506|NCT00772512|Drug|PF-04802540|5 mg capsule, single dose
75716507|NCT00772512|Drug|PF-04802540|15 mg capsule, single dose
75716508|NCT00772512|Drug|Placebo|Placebo capsule, single dose
75415588|NCT05673005|Device|MED3000 topical gel|Topical gel that has been shown to improve erectile dysfunction when used as needed.
75415589|NCT05656911|Drug|Zabedosertib (BAY1834845)|Oral administration, two times a day
75415590|NCT05656911|Drug|Placebo to zabedosertib (BAY 1834845)|Oral administration, two times a day
75415591|NCT05645523|Drug|Indocyanine Green|Given in to the vein (IV)
75415592|NCT05635032|Other|Comprehensive clinical assessment and biological samples collection|To establish the first Portuguese registry and biobank of PF-ILDs, comprising both extensive patient-level data, and systematic biological sampling (DNA, RNA, plasma, serum, bronchoalveolar lavage, lung tissue) at baseline and repeated biological sampling of blood and pharyngeal swabs performed at 6, 12 and 18 months, or whenever progression criteria are met or an acute exacerbation occurs. Participants will have regular visits at maximum intervals of 6 months, when their clinical condition and lung function tests are reassessed. A high resolution computed tomography (HRCT) scan of the lung will be performed every 12 months. Progressive fibrosis will be diagnosed based on meeting at least two of the following three criteria, occurring within the last year: (i) worsening of symptoms; (ii) absolute decline in FVC ≥5% predicted or absolute decline in DLCO (corrected for Hb) ≥10% predicted; (iii) increased extent of fibrotic changes on HRCT.
75415593|NCT05621733|Other|ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.
75415594|NCT05619991|Other|Group watching video|The video will include preparation for the surgery, the operating room environment and the post-operative process.
75415595|NCT05619991|Other|Scheduled training group|The scheduled training will include preparation for the surgery, the operating room environment and the post-operative process.
75415596|NCT05619874|Behavioral|HIFCT-S|"A functional circuit training of 30 sessions will be carried out as follows:~Sessions 1 to 6: General circuit (two series) composed of four blocks of three exercises.~Sessions 7 to 14: Concentrated circuit (two sets) composed of four blocks of three exercises of greater complexity than the exercises of the general circuit.~Sessions 15 to 22: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~Sessions 23 to 30: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
75560680|NCT00483678|Procedure|psychosocial assessment and care|
75560681|NCT00483587|Drug|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
75560682|NCT04516590|Other||There was no intervention in this observational study
75560683|NCT00488306|Drug|tigecycline|
75560684|NCT01307800|Drug|LY2140023|Administered orally
75560685|NCT01307800|Drug|Placebo|Administered orally
75560686|NCT04516044|Behavioral|Video games|See arm description
75560687|NCT00483626|Drug|oral sildenafil|
75560688|NCT00483795|Drug|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
75560689|NCT05644210|Drug|Telitacicept|160mg once a week for 24 weeks
75560690|NCT05644210|Drug|Rituximab|Patients received 200mg of rituximab intravenously at week 0 and week 2.
75560691|NCT05644210|Drug|Aspirin|50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
75560692|NCT05644210|Drug|Warfarin|Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it
75560693|NCT05644210|Drug|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period
75560694|NCT05644210|Drug|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
75560695|NCT00488384|Drug|Chemopreventive application (Acitretin)|Chemopreventive application (Acitretin)
75560696|NCT04325074|Other|Mental practice|During each of the 12 treatment sessions, the patient was asked to select two tasks from a list of MP activities, graded by level. Once the task was selected, patients received the specific visual or audio instructions and subsequently performed the task. The recording was viewed three times and the audio instructions were repeated two times. To listen to the audio instructions, the participants were requested to close their eyes in order to aid concentration. After listening to the recordings, the patient was asked to perform the task once again, practicing what had been learnt. After the process was completed, the participant completed a questionnaire and scored each task.
75716509|NCT00925197|Other|INR self-testing program|
75716510|NCT00775866|Procedure|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
76042362|NCT05550883|Other|Aerobic exercise|The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.
75415597|NCT05619874|Behavioral|HIFCT-P|"A functional circuit training of 30 sessions will be carried out as follows:~Sessions 1 to 6: General circuit (two series) composed of two blocks of 6 exercises.~Sessions 7 to 14: Concentrated circuit (two sets) composed of two blocks of 6 exercises of greater complexity than the exercises of the general circuit.~Sessions 15 to 22: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~Sessions 23 to 30: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
75415598|NCT05605379|Biological|Next Generation Sequencing (DNA and RNA)|Targeted Next Generation Sequencing (DNA and RNA)
75415599|NCT05597878|Drug|Oxycodone|Given after surgery 5 mg every 6 hours as needed for severe pain.
75415600|NCT05597878|Drug|Acetaminophen|Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
75415601|NCT05597878|Drug|Ketamine|Given before and during surgery 1.5 mg/kg intravenously
75415602|NCT05597878|Drug|Ketorolac|Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
75415603|NCT05597878|Drug|Acetaminophen|Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
75415604|NCT05594589|Drug|Lemborexant|Lemborexant oral tablet.
75415605|NCT05594589|Other|PBO|Lemborexant-matched PBO tablet.
75415606|NCT05591846|Behavioral|Face-to-face training|Face-to-face training
75415607|NCT05591846|Behavioral|web-based training|web-based training
75415608|NCT05589701|Radiation|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
75415609|NCT05589363|Drug|ABC block with bupivacaine/liposomal bupivacaine|Patients will be randomized to receive an ABC block using bupivacaine/liposomal bupivacaine solution
75415610|NCT05589363|Drug|ABC block with saline|Patients will be randomized to receive an ABC block using normal saline
75415611|NCT05584657|Drug|Sulopenem etzadroxil/probenecid|Oral sulopenem twice daily for 5 days
75415612|NCT05584657|Drug|Amoxicillin/clavulanate|Oral Augmentin twice daily for 5 days
75716511|NCT00669864|Drug|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
76042363|NCT05550883|Drug|Fibromyalgia Agents|tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
75716512|NCT00669864|Drug|metformin|Tablets, 1000 - 2000 mg daily
75415613|NCT05580770|Drug|Mirdametinib|Mirdametinib administered orally
75415614|NCT05580770|Drug|BGB-3245|BGB-3245 administered orally
75415615|NCT05568615|Drug|MT-1186|Suspension
75415616|NCT05547425|Device|Blur Obfuscation|Blurring is applied to objects and people in the background of images.
75415617|NCT05547425|Device|Edge Obfuscation|Objects and people in the background of images are replaced with an outline of the object.
75415618|NCT05547425|Device|Cartoon Obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
75415619|NCT05547425|Device|Raw images|No editing is performed on images.
75415620|NCT05529511|Other|Phase 1 - semi-structured interviews|Semi-structured face-to-face or virtual interviews.
75415621|NCT05529511|Other|Phase 2 - consensus meeting|Face-to-face or virtual meeting(s)
75716513|NCT00770172|Biological|filgrastim|Given subcutaneously
75716514|NCT02557620|Drug|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
75560697|NCT04325074|Other|Mental practice + skill training|In this option, six sessions of MP were alternated with six sessions of skills training (ST). The MP protocol was the same as in group A: selecting, performing, visualizing, listening to and scoring the selected tasks. The activities performed in the skills training were based on the Kamm et al. (2015) protocol and bimanual tasks. After the performance of each task, the patients were allowed to rest for 1 or 2 minutes to avoid the appearance of fatigue.
75716515|NCT02557620|Drug|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
75716516|NCT00776022|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
75716517|NCT00772824|Dietary Supplement|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
75560698|NCT04325074|Other|Control group|The control group only received their usual physical therapy and occupational therapy treatments provided by their association. The treatment mainly consisted of the application of the Bobath concept and the Vojta method, dry needling, myofascial induction therapy, passive mobilizations, training of gross and fine motor coordination of the upper limbs, resistance training and static and dynamic balance training.
75716518|NCT00772824|Dietary Supplement|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
75716519|NCT03875040|Behavioral|kinesiophobia|patients who have a high-level or low-level kinesiophobia have been evaluated.
75716520|NCT04047732|Biological|KB105|KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel
75415622|NCT05528692|Diagnostic Test|Magnetic resonance imaging (MRI)|MRI is a non-invasive imaging modality capable of producing precise soft-tissue images in all body areas. In contrast to CT scanning, MRI does not rely on ionizing radiation. There are no known risks associated with MRI as long as patients with contraindications such as pacemakers are identified and excluded. The MRI scans in this study will be performed without use of contrast media.
75415623|NCT05509634|Drug|HR20013 for injection；dexamethasone|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
75560699|NCT00483834|Drug|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
75716521|NCT00772902|Drug|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
75716522|NCT00772902|Drug|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
75415624|NCT05509634|Drug|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|"fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
75560700|NCT00483834|Drug|Irinotecan|200mg/m^2, IV, day 1 each cycle
75716523|NCT02557152|Device|GentleWave System Treatment|
75716524|NCT00779220|Drug|placebo|Intravenous repeating dose
75716525|NCT00779220|Drug|methotrexate|Oral repeating dose
75716526|NCT00779220|Drug|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
75716527|NCT00779220|Drug|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
75716528|NCT00779220|Drug|ocrelizumab 500mg|Intravenous repeating dose (500mg)
75716529|NCT00776256|Dietary Supplement|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
75716530|NCT00779376|Drug|Zidovudine 300mg tablets|
75716531|NCT00779454|Drug|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
75415625|NCT05505760|Behavioral|Quality-Based Digital Messaging|"The impact of MomConnect's models will be evaluated using a randomized controlled trial (RCT). Randomization will be at the individual level, where an individual refers to the unique user, which is defined by the unique phone number used at the time of registration to MomConnect at health facilities. Randomizing control and treatment allocations ensures that the study groups will be comparable in terms of observable and unobservable characteristics in expectation. Therefore, statistical inference can shed light on the likelihood that any differences in outcome variables at the end of the intervention were caused by the intervention as compared to chance. We will also study the treatment effects on different outcomes between the different arms of the experiment - comparing outcomes across different treatment arms or outcomes in the control to outcomes in treatment arms will help us answer the aforementioned research questions."
75415626|NCT05503095|Genetic|Genetic analysis for PCSK9 polymorphisms|Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
75415627|NCT05499000|Behavioral|Emotional freedom technique|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the 2nd session, post-test data will be taken with SUE, PMSS."
75415628|NCT05489718|Biological|IBI324|Dose 2 IBI324 of multiple IVT injection
75560701|NCT00483834|Drug|Capecitabine|1000mg/m^2 or 750mg/m^2 for patients over 65yrs old PO BID, day 1-14 each cycle
75560702|NCT04324801|Other|Homeostatic plasticity induction using transcranial direct current stimulation|Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
75560703|NCT01307449|Biological|PNEUMOVAX|1 dose of PNEUMOVAX
75560704|NCT01307449|Biological|Prevnar|1 dose of Prevnar
75716532|NCT00779454|Drug|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
75716533|NCT00772980|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
75560705|NCT00483665|Procedure|Computed tomography angiography|Computed tomography angiography
75560706|NCT00483665|Procedure|Magnetic resonance imaging|Magnetic resonance imaging after injection of Vasovist
75560707|NCT00483912|Device|Molecular adsorbent recirculating system|
75560708|NCT00488423|Procedure|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test & hyperglycemic clamp to assess insulin secretion & sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp & mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting & specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass & gastric banding.
75716534|NCT00772980|Drug|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
75716535|NCT00773058|Drug|hydrocortisone|hydrocortisone 100mg q8h
75716536|NCT00773058|Drug|placebo|normal saline 100ml q8h
75716537|NCT00776334|Drug|Fosinopril 40mg Tablets|
75716538|NCT00779610|Procedure|Vibration with flexion|Vibration with forearm flexion (active contraction)
75716539|NCT00779610|Procedure|Vibration without flexion|Vibration without forearm flexion (passive)
75716540|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
75716541|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
75716542|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
76042364|NCT05545189|Diagnostic Test|colonoscopy,polypectomy|polyp removal during colonoscopy
75415629|NCT05489718|Biological|IBI324|Dose 2 IBI324 of single IVT injection
75415630|NCT05489718|Biological|IBI324|Dose 1 IBI324 of single IVT injection
75415631|NCT05489718|Biological|IBI324|Dose 3 IBI324 of single IVT injection
75415632|NCT05489718|Biological|IBI324|Dose 3 IBI324 of multiple IVT injection
75415633|NCT05475925|Drug|DR-01|DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
75415634|NCT05470218|Other|Meal|Liquid mixed meal with different amounts of protein and leucine
75415635|NCT05469464|Drug|Orismilast modified release tablets|"Orismilast modified release is a next generation PDE4 inhibitor with high selectivity for the PD4 subtypes linked to inflammation.~Other Names:~UNI50001~LEO32731"
75415636|NCT05469464|Drug|Placebo|Placebo matching tablets
75415637|NCT05464524|Other|Main questionnaire|10-15 minute questionnaire asking about environmental factors (i.e daily lifestyle questions), quality of life, comorbidities among others.
75415638|NCT05464524|Other|Optional 12-week follow up questionnaire|A 5-minute questionnaire asking about changes to the quality of life and DFU status since the initial questionnaire.
75415639|NCT05464498|Device|MD-Tissue Collagen Medical Device|"MD-Tissue (GUNA, Milan-Italy) Composition per 2 ml: collagen 100 micrograms Excipients: Ascorbic acid, Magnesium gluconate, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, NaCl, Water for injection.~Subjects will be treated with No. 6 peri-tendon injections (2 infiltrations per week for three weeks)."
75560709|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
75560710|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
75716543|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
75716544|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
75716545|NCT00667992|Drug|Budesonide HFA|standard daily inhaled dose
75716546|NCT00667992|Drug|Budesonide CFC|standard daily inhaled dose
75716547|NCT02556294|Behavioral|Self-acceptance based intervention|The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
75716548|NCT02556294|Behavioral|HIV/STI counseling and testing|The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
75716549|NCT00779688|Device|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
75716550|NCT00776490|Drug|Glimepiride 1mg Tablets|
75716551|NCT00779844|Procedure|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
76042365|NCT05537779|Device|CT examination|Administration of contrast medium using the power injector
76042366|NCT05698225|Other|Streptococcus pneumoniae serotype 6B|A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
75415640|NCT05464498|Other|eccentric strengthening protocol|Group B which, will implement only physiotherapy (eccentric strengthening protocol)
75415641|NCT05438225|Behavioral|Automated text message reminder|Participants in the intervention group will receive monthly automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
75415642|NCT05432167|Drug|CIN-107|Patients will take CIN-107 tablets by mouth once daily.
75415643|NCT05432167|Drug|Placebo|Patients will take placebo tablets by mouth once daily.
75415644|NCT05430230|Drug|Naproxen 500 Mg|naproxen tablets
75415645|NCT05430230|Drug|Placebo|lactose NF
75415646|NCT05414097|Other|Semi-structured focus group discussions - Women|Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.
75560711|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
75560712|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
75560713|NCT01307020|Drug|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
75560714|NCT01307020|Drug|Placebo|Placebo, oral film-coated table, once
75415647|NCT05414097|Other|semi-structured focus groups discussions - Men|Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening.
75716552|NCT00779844|Procedure|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
75716553|NCT00773214|Behavioral|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
75716554|NCT00776568|Procedure|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
75716555|NCT00776568|Drug|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
75716556|NCT00779922|Drug|lenalidomide|
75716557|NCT00776646|Drug|hydrochlorothiazide 50 mg tablet|
75716558|NCT00780078|Procedure|extubation|extubation failure in patients intubated orotracheally
75716559|NCT00773448|Device|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
76042367|NCT04736017|Device|TSB Axo|The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
75560715|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
75560716|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
75560717|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
75560718|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
75560719|NCT00483743|Drug|TPI 1020|250 mcg/caps 2 caps BID x 42 days
75716560|NCT00773448|Other|Limited Malignancy Screening|"1) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if > 18 and < 70 years old and not performed during the past year),a mammogram (> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (>40 years old) will be performed if not conducted in the past year."
75560720|NCT00483743|Drug|Budesonide|400mcg mcg capsules- 2 capsules BID
75560721|NCT00483743|Drug|Placebo|2 caps BID x42 days
75560722|NCT04515654|Other|IDEAS (Identity Evolution and Sharing) Performance|60 minute webinar depicting first-hand stories of transgender and gender non-conforming individuals followed by expert panel/talk-back
75560723|NCT04324996|Biological|NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells|The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
75716561|NCT00776724|Drug|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
75716562|NCT00776724|Drug|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
76042368|NCT05545033|Device|Virtual reality|5 to 15 minutes of virtual reality exposure
75415648|NCT05414097|Other|In-depth key stakeholders interviews|In-depth interviews to contextualise findings from women and men focus group discussions.
75415649|NCT05414097|Other|Discrete Choice Experiment - Women|Discrete Choice Experiment to determine preferences to different cancer screening models.
75415650|NCT05414097|Other|Development and User Pre-testing Workshops|Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 &2.
75415651|NCT05405569|Other|CPR Arms Angle 90º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.
75415652|NCT05405569|Other|CPR Arms Angle 60º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.
75415653|NCT05400655|Drug|L9LS|Administered subcutaneously.
75560724|NCT00483782|Biological|bevacizumab|
75560725|NCT00483782|Drug|carboplatin|
75560726|NCT00483782|Drug|paclitaxel|
75560727|NCT00483782|Other|questionnaire administration|
75560728|NCT00483782|Other|study of socioeconomic and demographic variables|
75560729|NCT00483782|Procedure|quality-of-life assessment|
75560730|NCT00483951|Device|Toshiba Aquilion ONE CT|The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.
75415654|NCT05400655|Other|Normal Saline|Administered subcutaneously.
75415655|NCT05397912|Diagnostic Test|Uterine Elastography|Shear wave elastography data will be obtained at the transvaginal ultrasound visit the day prior to frozen embryo transfer
75560731|NCT00483951|Device|SWiemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
75415656|NCT05390398|Behavioral|Behaviour change guided lifestyle intervention|Participants in the intervention group receive personalized coaching from a lifestyle coach on adhering to the World Cancer Research Fund cancer prevention guidelines. The lifestyle coach is specialized in behaviour change techniques and uses these as the core of the lifestyle coaching. For each participant behavioural determinants will be assessed and targeted with specific applicable behaviour change techniques.
75560732|NCT00488462|Device|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
75560733|NCT04516005|Procedure|foot reflexology|Acupressure was applied at the plantar side of the right foot at the first metatarsal bone, around 1-1.5 centimeters proximal to the first metatarsophalangeal joint. (Figure 2) Approximately 3-kilogram pressure was applied by using a knuckle of the right index finger (dorsal part of the proximal interphalangeal joint in flexing position) in a perpendicular manner and held for 15 seconds (sec) then released for 5 sec. This hold-release cycle was done 5 times over the course of 2 min. This method was recommended by the Department of Thai Traditional and Alternative Medicine in accordance with the Zone theory and the Meridian theory.
75560734|NCT02890732|Device|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
75415657|NCT05383079|Drug|Lutetium-177 PSMA-I&T|Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
75560735|NCT02890771|Procedure|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
75716563|NCT00773526|Drug|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
75415658|NCT05383079|Drug|Radium-223|During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
75415659|NCT05381155|Behavioral|A single-session behavioral intervention composed of a brief evocation of the childbirth memory followed by a Tetris gameplay|"The intervention is composed of two tasks:~The childbirth narration task (8-10 min.): To trigger the malleability of the traumatic childbirth memory through memory reactivation, a psychologist will ask the participants to briefly narrate their childbirth and the moment associated with their most frequent or distressing CB-ITM. This intervention part will take place on the maternity ward to use this context as a reactivation cue.~The visuospatial task (3 min. practice + 20 min. gameplay): Participants will be instructed to engage in a Tetris gameplay for 20 minutes on a handheld gaming device (Nintendo 3DS), which is assumed to disrupt memory reconsolidation. This part of the intervention will take place in a neutral room."
75415660|NCT05370820|Drug|Tranexamic acid|IV 2 minutes, IV 10 minutes, IM
75415661|NCT05367544|Behavioral|Health Education|All participants will receive education regardless of randomization status. On the day of enrollment, participants will be invited to attend education modules focused on HTN risk, diet, physical activity, stress management, and goal setting. Participants will also have access to culturally relevant, weekly online sessions, alternating between cooking shows and exercise
75415662|NCT05367544|Behavioral|Individual-Level Peer Support|Participants will receive bi-weekly peer support calls for 6 months, followed by monthly calls for another 6 months.
75415663|NCT05367544|Behavioral|Community-Level Peer Support|Church Leadership in churches randomized to intervention will identify 2-3 Peer Health Advocates from the church who will receive training on ways to promote a culture of health, encouraging church members to attend on-line cooking shows and exercise sessions. After training, these individuals will also work with Church Leadership to form a committee that will develop a project (e.g., community food pantry, farmer's market, Zumba instruction, small church gym) aimed at overcoming structural barriers to healthy behaviors. Each church will receive a small stipend for their project. Churches randomized to education alone will receive the community-level intervention after 12 months of participation in the study (delayed intervention)
75716564|NCT00776802|Drug|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
75716565|NCT00776802|Drug|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
75716566|NCT00780312|Other|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
75716567|NCT00776880|Other|ASA scale|ASA scale evaluation before operation
75716568|NCT00776880|Other|PPS scale|PPS scale evaluation before operation
75873276|NCT04844567|Device|COVVR_Synch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Synch provided synchronous feedback: participants receive real-time feedback of their respiration."
75873277|NCT04844567|Device|COVVR_Asynch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration."
75560736|NCT02890771|Procedure|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
75873278|NCT03055338|Drug|MK-8189|Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
75415664|NCT05341011|Behavioral|PEERS® Social Skills Training|"The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session."
75415665|NCT05329220|Biological|ABNCoV2|ABNCoV2 100μg single dose
75415666|NCT05329220|Biological|Comirnaty|Comirnaty
75560737|NCT02890771|Procedure|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
75560738|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
75560739|NCT01306162|Drug|Dabigatran etexilate|150 mg as single dose
75560740|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
75560741|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
75560742|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
75716569|NCT00780390|Other|Autonomic Function Assessment|
75716570|NCT00780468|Behavioral|Existing diet plan|
75716571|NCT00780468|Behavioral|New diet plan|
75716572|NCT00773682|Other|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
75716573|NCT00773760|Other|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
75415667|NCT05328258|Drug|Triptorelin Embonate|"11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug."
75415668|NCT05328258|Drug|Sodium Chloride solution 0.9%|One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
75415669|NCT05324358|Drug|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (~0.9% NaCl) adjusted to a pH of ~7.4. Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL of NTM-001).
75415670|NCT05324358|Drug|Morphine Sulfate|Morphine single use vials at 4 mg/mL, filled with 1 mL.
75415671|NCT05324358|Other|Intravenous Placebo for NTM-001|Placebo alcohol free saline solution (~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).
75415672|NCT05324358|Other|IV Placebo for Morphine|Placebo single use vials with saline (matching active morphine).
75415673|NCT05312645|Drug|Diclofenac 1% Topical|2 grams topically four times daily for 2 weeks to posterior cervical spine
75415674|NCT05312645|Other|Petroleum Jelly|2 grams topically four times daily for 2 weeks to posterior cervical spine
75415675|NCT05311969|Other|cognitive evaluations and non cognitive evaluations|"Cognitive evaluations with executive functions evaluations :~Mini Mental State Examination~Stroop Victoria Test~Hayling test~Frontal Assessment Battery test mental flexibility:~Trial Making Test (TMT) A and B~Connection test~Alphaflex test~Verbal and visuospatial working memory~Wechsler Adult Intelligence Scale (WAIS) span~Visuo-spatial span~Visuo-spatial span simplified version~Month Of the Year Backwards (MOTYB) Planning~Tinker Toy test~Clock Test~Non-cognitive evaluations:~The Katz Autonomy Scale Neuropsychiatric Inventory version Care team Geriatric Depression Scale 15-item version Apathy inventory"
75415676|NCT05301556|Other|Experimental Product|"Before the surgery: FSMP provides daily target energy needed by participants~1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~6th to 11th day after surgery. FSMP provides daily target energy needed by participants"
75560743|NCT04327960|Diagnostic Test|Cardiac troponin (cTn)|Cardiac troponin (cTn) will be measured with the Dimension RxL-HM analyzer .The one-step enzyme immunoassay is based on cTn specific monoclonal antibodies, performed on a separate module of the analyzer, assay-time is 17 minutes.
75560744|NCT00483821|Other|medical chart review|medical chart review
75560745|NCT04515732|Drug|Apremilast Oral Tablet|As in description
75873279|NCT03055338|Drug|Risperidone|Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
75716574|NCT00773916|Drug|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
75560746|NCT01305577|Drug|Deoxycholic acid injection|
75716575|NCT00773994|Other|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
75716576|NCT00774072|Drug|Tobramycin (Gernebcin®)|1 ml / day in each nostril
75716577|NCT00774150|Behavioral|Cognitive Behavioral Therapy|16 sessions of CBT
75716578|NCT00774150|Behavioral|Client Centered Therapy|16 sessions of CCT
75716579|NCT02556996|Biological|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
75415677|NCT05301556|Other|Control Product|"Before surgery: TPF-T provides daily target energy needed by participants~1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~6th to 11th day after surgery. TPF-T provides daily target energy needed by participants"
75415678|NCT05301322|Biological|RSVpreF Vaccine|RSV Vaccine
75560747|NCT01305577|Drug|Placebo|Phosphate buffered saline placebo for injection
75560748|NCT00483990|Drug|PSD502|
75560749|NCT05644054|Drug|Cannabis oil|The participants will receive 0.15 mg/kg of the drug
75560750|NCT01304329|Drug|BI 10773|Medium dose oral administration
75560751|NCT01304329|Drug|simvastatin|Medium dose oral administration
75560752|NCT01304329|Drug|simvastatin|Medium dose oral administration
75560753|NCT01304329|Drug|BI 10773|Medium dose oral administration
75716580|NCT02556996|Other|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10^11 heat-killed bacteria per dose)
75560754|NCT04515420|Drug|noradrenaline|noradrenaline infusion
75716581|NCT00774228|Device|I-ZIP Ocular Bandage|
75716582|NCT00774228|Device|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
75716583|NCT00780624|Device|NIPPV|Ventilator is Bird VIP.
75716584|NCT00780624|Device|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
75415679|NCT05301322|Other|Placebo|Placebo
75415680|NCT05301322|Biological|Seasonal Inactivated Influenza Vaccine|SIIV
75415681|NCT05286528|Drug|Bosutinib|Bosutinib as prescribed in real world
75415682|NCT05286528|Drug|Imatinib|Imatinib as prescribed in real world
75415683|NCT05286528|Drug|Nilotinib|Nilotinib as prescribed in real world
75716585|NCT00780624|Device|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
75716586|NCT04047498|Device|Alternating DBS|Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
75716587|NCT00780702|Drug|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
75716588|NCT00780702|Drug|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
75415684|NCT05286528|Drug|Dasatinib|Dasatinib as prescribed in real world
75560755|NCT00488540|Drug|Paracetamol|Suppository
75560756|NCT00488540|Drug|Placebos|Suppository
75560757|NCT00484068|Drug|enalapril|
75560758|NCT00484068|Procedure|chicken diet|
75560759|NCT00483860|Drug|Topotecan|once a day
75560760|NCT01241097|Drug|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
75560761|NCT00483899|Drug|GW870086X|Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
75560762|NCT00483899|Drug|Placebo|Placebo matching GW870086X will be administered by subjects
75560763|NCT01303861|Drug|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
75560764|NCT01303861|Drug|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
75560765|NCT01303861|Drug|Nicotine patches|"Nicotine Replacement Therapy Groups:~For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~For smokers with high baseline CO: 42 mg/24 h for 1 week~For smokers with low baseline CO: 21 mg/24 h for 1 week"
75560766|NCT01303861|Drug|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
75560767|NCT05661136|Device|Warm air blower|Lower body blanket with warm air blower set at 44 deg c started after spinal anesthesia when patient placed in supine/left lat position
75560768|NCT05661136|Other|Control: Lower body blanket not attached to warm air blower|Control: Lower body blanket placed, not attached to warm air blower
75716589|NCT00780780|Drug|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
75716590|NCT00780780|Drug|triamcinolone intravitreal injection|triamcinolone intravitreal injection
75716591|NCT00780858|Drug|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
75716592|NCT00780936|Procedure|femoral nerve block|
75716593|NCT00776958|Other|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
75415685|NCT05286528|Drug|Ponatinib|Ponatinib as prescribed in real world
75560769|NCT01241136|Procedure|open wide-excision pilonidal cystectomy|traditional open wide-excisional pilonidal cystectomy
75560770|NCT01241136|Procedure|minimal invasive pilonidal cystotomy|unroofing the cyst cavity and curettage the cyst
75560771|NCT00488579|Drug|Two policies of iron prophylaxis|60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb>9g/dl only folic acid, Hb<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
75560772|NCT01303627|Drug|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
75560773|NCT01303510|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
75560774|NCT00505557|Procedure|Transaxillary dual plane technique|
75560775|NCT00488657|Device|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
75716594|NCT00774384|Biological|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
75716595|NCT00777114|Drug|bortezomib, tositumomab|"0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
75716596|NCT00669396|Drug|Copper T380 IUD|Copper T380 IUD
75716597|NCT00669396|Drug|levonorgestrel|1.5 mg
75716598|NCT00774462|Drug|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
75560776|NCT02890654|Other|First time measure|"Initial Interview~Initial Survey,~Quality of life Scale~Kinesitherapy Review~Anxiety Scale"
75560777|NCT02890654|Other|Second time measure|"Kinesitherapy review~Second survey including numeric scale of pain~Anxiety scale~Scoliosis Research Society 22 quality of life scale"
75560778|NCT02890654|Other|Third time measure|"Scoliosis Research Society 22 quality of life Scale~Anxiety scale~Numeric scale of pain~Kinesitherapy review"
75873280|NCT03055338|Drug|Placebo matching MK-8189|Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.
75873281|NCT03055338|Drug|Placebo matching risperidone|Oral placebo capsule(s) matching the risperidone capsule, administered QD.
75560779|NCT02890576|Other|telemedicine|Monitoring of patients with cochlear implant with sessions of telemedicine
75560780|NCT01241175|Drug|Magnesium Sulfate|
75560781|NCT01241175|Drug|normal saline|
75560782|NCT02890615|Behavioral|Depression self-care|Toolkit and coaching
75560783|NCT05644015|Other|escape room game|Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
75560784|NCT04324723|Behavioral|WhatsApp message|"The experimentally evaluated part of the intervention is a WhatsApp message.~The message translated from Arabic to English appears below. Dear [First name], Your BP reading during Beirut Marathon was [reading]. This indicates that you have elevated blood pressure. You should seek medical attention at your earliest convenience. Your wellbeing matters to us. Nudge Lebanon team"
75560785|NCT05643937|Behavioral|Routine health education|The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
75716599|NCT00777192|Behavioral|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
75716600|NCT00669318|Biological|alemtuzumab|
75716601|NCT00669318|Biological|rituximab|
75716602|NCT00669318|Drug|pentostatin|
75716603|NCT00669318|Drug|sargramostim|
75716604|NCT00781092|Other|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
75716605|NCT00781092|Other|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
75716606|NCT00781170|Procedure|allogeneic hematopoietic SCT|
75716607|NCT00774540|Drug|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
75716608|NCT00774540|Drug|Placebo|Saline
75716609|NCT00777270|Procedure|repair of episiotomy or second degree tears|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
75716610|NCT00777270|Procedure|repair of episiotomy or second degree tears|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
75734970|NCT03412227|Other|14-week waitlist (WL) condition|Youth assigned to the 14-week WL will receive no specific therapeutic services from study therapists during the 14-week WL period. However, participants will be assigned a WL Liaison whom families can contact in the event of clinical deterioration. The Liaison will also be responsible for sending links to, and monitor completion of, weekly and mid-WL online surveys (Qualtrics). Independent Evaluators will conduct post-WL diagnostic interviews at the completion of the 14-week WL. WL participants will receive compensation for completion of assessments. After completion of the WL, participants will be invited to continue in the study and be randomly assigned to one of the three behavioral treatments (IBAT, PASCET, or Coping Cat).
75873282|NCT03913130|Drug|QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
75716611|NCT00774618|Device|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
76042369|NCT05550649|Procedure|embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
76042370|NCT05544955|Dietary Supplement|isolate whey protein prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
75716612|NCT00669240|Drug|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
75716613|NCT00669162|Drug|Docetaxel|20mg/m2 IV weekly for 7 weeks
76042371|NCT05544955|Dietary Supplement|isolate whey protein 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
75415686|NCT05265026|Behavioral|High Intensity Interval Training|A training session consists of 40 minutes as follows: 4x4 minutes at > 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-79% of HRmax) and 5- minute cool-down at ~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: >85% of HRmax).
75873283|NCT03645746|Drug|REGN5069|REGN5069 will be administered by IV infusion or SC injection
75873284|NCT03645746|Drug|Placebo|Placebo-matching REGN5069
75873285|NCT03715907|Behavioral|Financial Incentives|Incentives for gap closure.
75873286|NCT03715907|Behavioral|Information|Information on care gap and closure process.
75873287|NCT03628482|Procedure|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
75873288|NCT03628482|Procedure|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
76042372|NCT05544877|Behavioral|Integrated 5-day Gratitude Exercise and Behavioral Activation Program|The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
76042373|NCT05550415|Drug|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
75415687|NCT05256537|Other|Omission of the drug mycophenolate mofetil|Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
76042374|NCT05550415|Drug|Placebo|The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
75560786|NCT05643937|Behavioral|Routine health education + precise health education|On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
75560787|NCT02955498|Drug|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
75560788|NCT02955498|Drug|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
75560789|NCT05643898|Behavioral|Mamá, te entiendo (Mom, I get you)|"Mamá, te entiendo is a guided 8-week cognitive-behavioral app-based intervention that targets postpartum women with minor and major depression. The development of the intervention followed the CeHRes Roadmap. It includes some elements from attachment and mentalization theories.~The intervention consists of six main sequential modules and three optional modules. All modules except the two psychoeducational ones include homework. Participants will receive feedback from an e-coach. They also can contact the e-coach to solve doubts about the app content and exercises. Other sections of the app include infographics about other relevant topics (for example, How to strengthen the couple relationship), a shareable document with reading about how to support a loved one struggling with depression and a resources section with links to websites and documents of interest."
75716614|NCT00669162|Radiation|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
75716615|NCT00669162|Drug|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
75716616|NCT00774696|Drug|clarithromycin 500mg tablets|
75716617|NCT00774774|Device|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
75873289|NCT03645668|Drug|Meropenem Injection|Different administration types between two groups
76042375|NCT05699161|Genetic|Adipose-derived stromal vascular fraction cells|Published minimal clinically important differences (MCID) for PDQ-39; MDS-UPDRS; and levo-dopa equivalent dose and changes in the levels of blood proteins (L-1beta, IL-2, IL-6, IL-10, and TNF-alpha) in 10 patients after 12 months of treatment with SVF cells.
75415688|NCT05253573|Drug|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
75415689|NCT05253573|Behavioral|Self-help materials (to support smoking cessation)|"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help material in this study."
75560790|NCT01303159|Device|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
75560791|NCT00484107|Drug|Conjugated Estrogen Cream (Premarin®)|
75560792|NCT00505596|Behavioral|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
75560793|NCT00488735|Behavioral|Cognitive-behavioral rehabilitation|
75560794|NCT00488735|Behavioral|Traditional primary care|
75441502|NCT01635348|Behavioral|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
75560795|NCT01302964|Drug|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
75560796|NCT01302964|Drug|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
75560797|NCT04515381|Other|Therapeutic Touch|Therapeutic Touch
75716618|NCT00774774|Device|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~during the night,~when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
75560798|NCT04515381|Other|Control group|Making measurements at the beginning of the research and 4 weeks
75560799|NCT04515381|Other|Sham Therapeutic Touch|Sham Therapeutic Touch
75560800|NCT00484055|Drug|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
75716619|NCT02556060|Drug|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
75716620|NCT02556060|Drug|Placebo|Same dosing schedule as study drug
75716621|NCT00354770|Drug|Placebo|daily
75716622|NCT00354770|Drug|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
75716623|NCT00741494|Device|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
75716624|NCT00744146|Biological|Protexia|Single 50 mg IM dose
75716625|NCT00744146|Biological|Protexia|Single 100 mg dose
75716626|NCT00744146|Biological|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
75716627|NCT00744146|Biological|Protexia|Single 500 mg dose, IM
75716628|NCT00744146|Biological|Protexia|Single 750 mg dose, IM
75716629|NCT00744224|Drug|Placebo|Single dose of placebo with saline infusion
75716630|NCT00744224|Drug|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
75716631|NCT00744224|Drug|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
75716632|NCT00744302|Drug|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
75560801|NCT00484055|Procedure|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
75716633|NCT00666588|Drug|idarubicin|Given IV
75716634|NCT00666588|Drug|cytarabine|Given IV or IT
75560802|NCT01302691|Drug|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
76042376|NCT05537155|Procedure|Buccal acupuncture in addition to routine care|"Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed."
75716635|NCT00666588|Drug|bortezomib|Given IV
75716636|NCT00666588|Drug|etoposide|Given IV
75716637|NCT00666588|Other|laboratory biomarker analysis|Correlative studies
75716638|NCT00689390|Biological|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
75716639|NCT00689390|Biological|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
76042377|NCT05537155|Other|Routine care|Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
76042378|NCT05550259|Procedure|protocolized postextubation support|The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
76042379|NCT05537077|Other|Prolotherapy|DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
75716640|NCT00689390|Biological|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
75716641|NCT00689390|Drug|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
75716642|NCT00689390|Other|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
75716643|NCT00781248|Device|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
75716644|NCT00567879|Drug|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
75716645|NCT00567879|Drug|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
75716646|NCT00781404|Drug|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
75716647|NCT00777504|Drug|usage oral angiogenesis inhibitor|see under 'study arms'
75716648|NCT00777504|Drug|stop oral angiogenesis inhibitor|see under 'study arms'
75716649|NCT00781482|Drug|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
75560803|NCT01302691|Drug|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
75560804|NCT01302691|Drug|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
75873290|NCT05628779|Device|TriClip TTVr system (Abbott Vascular)|Edge-to-edge leaflet approximation for the tricuspid valve
76042380|NCT05537077|Other|Home based exercise program|Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.
75415690|NCT05253573|Behavioral|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 12-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
75415691|NCT05252845|Biological|R21/Matrix-M vaccination|R21/Matrix-M is the standard formulation of the vaccine (Once prepared, a standard dose of R21/Matrix-M contains approximately 5 µg of R21 antigen, in 0.5 mL of liquid adjuvant containing 50 µg MatrixM). The reconstituted vaccine will be administered by slow IM injection on Day 0 at Study Months 0, 1 and 2.
75415692|NCT05252845|Drug|DHA-PIP|Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.
75415693|NCT05252845|Drug|PQ|Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.
75415694|NCT05242380|Other|Kettlebell Exercise|"The exercise training plan for this group consists of 4 stages. Each stage lasts 2 weeks and consist of 5 kettlebell (KB) exercises. These exercises will continue from basic (single movement training) to advanced (comprehensive movement training) and is geared towards functional training. Participants will perform 2 sets of 12 repetitions of each exercise. Each training session is planned to last 45 minutes.~The following exercises will be used in KB training: biceps curl, triceps extension, kettlebell swing (two-handed), kettlebell dead lift, kettlebell goblet squat, suitcase carry, waiter carry, bottoms up carry, farmer's walk, overhead carry, lunge, kettlebell row."
75415695|NCT05235464|Other|Standard meal|Standard meal
75415696|NCT05235464|Other|High animal protein meal|Meal with high animal protein content
75415697|NCT05235464|Other|High plant protein meal|Meal with high plant protein content
75415698|NCT05235464|Other|High plant protein meal with additional leucine|Meal with high plant protein content and additional leucine
75415699|NCT05234112|Behavioral|Community mobilisation for hrHPV self-testing|use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
75873291|NCT05628779|Device|PASCAL TTVr system (Edwards Lifesciences)|Edge-to-edge leaflet approximation for the tricuspid valve
76042381|NCT05537077|Other|Hotpack therapy|Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.
76042382|NCT05544643|Device|Medtronic Extended Mio 30 Infusion Set|Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
75415700|NCT05234112|Diagnostic Test|hrHPV self-testing|use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.
75415701|NCT05234112|Behavioral|Follow-up after testing|based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up
75415702|NCT05234112|Diagnostic Test|VIA|Test offers insight into existence of dysplasia of the cervix by colouring the transition area
75415703|NCT05234112|Procedure|Thermo-ablation or cryotherapy for dysplasia|Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix
75415704|NCT05234112|Diagnostic Test|Pap smear cytology|Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions
75873292|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 1)|Single dose Norketotifen
75873293|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 2)|Single dose Norketotifen
75873294|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 3)|Single dose Norketotifen
75873295|NCT03712163|Drug|Norketotifen Oral Capsule (Multiple Dose Cohort)|Multiple dose Norketotifen
75873296|NCT03712163|Drug|Placebo Oral Capsule|Placebo
75873297|NCT04052360|Drug|Cenerimod|A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
75560805|NCT01302691|Drug|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
75560806|NCT01302691|Drug|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
75560807|NCT01302691|Drug|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
75716650|NCT00925275|Drug|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
75716651|NCT00907725|Other|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
75415705|NCT05201898|Other|control:usual medical management|with regular doctor visits every 3 months
75415706|NCT05201898|Behavioral|intervention 1:usual medical management+individual dieting consultation|with regular doctor visits every 3 months and dietitian visits every 3 months
75415707|NCT05201898|Behavioral|intervention 2:usual medical management+individual dieting consultation+ daily tea drinking|with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
75415708|NCT05201248|Drug|Epcoritamab|Subcutaneous Injection (SC)
75415709|NCT05201248|Drug|Cyclophosphamide|IV Injection
75415710|NCT05201248|Drug|Rituximab|Intravenous (IV) Infusion
75415711|NCT05201248|Drug|Doxorubicin|IV Infusion
75415712|NCT05201248|Drug|Vincristine|IV Infusion
75415713|NCT05201248|Drug|Prednisone|Oral; Tablet
75415714|NCT05201248|Drug|Lenalidomide|Oral; Capsule
75415715|NCT05179954|Other|Metabolic testing|Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
75415716|NCT05166785|Other|DPP Tailored for Older Adults and delivered via Telehealth|Diabetes Prevention Program (DPP) Tailored for Older Adults and delivered via Telehealth (DPP-TOAT) will be composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions
75560808|NCT01241084|Dietary Supplement|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
75560809|NCT01241084|Dietary Supplement|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
75560810|NCT05643820|Drug|Permethrin 5% topical lotion|patients in group A prescribed with 5% topical permethrin lotion two overnight applications seven days apart
75560811|NCT05643820|Drug|Ivermectin|patients in group B and weighing more than 15 kgs were given oral ivermectin 200 microgram/kg two doses seven days apart
75560812|NCT01302418|Device|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
75560813|NCT01241123|Procedure|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
75560814|NCT01241123|Drug|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
75716652|NCT00907725|Other|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
75716653|NCT00603915|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) day 1 and day 8
75716654|NCT00603915|Drug|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m^2 (Cisplatin) intravenous (IV) day 1
75716655|NCT00603915|Drug|erlotinib|150mg daily (post GC therapy)
75873298|NCT04052360|Drug|Matching Placebo|A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
75873299|NCT01311167|Drug|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
76042383|NCT05550025|Drug|camrelizumab& apatinib|"TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
75415717|NCT05166785|Other|In-Person Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP) is composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions over 12 months in person approved by the Centers for Disease Control and Prevention (CDC)
75716656|NCT00929487|Device|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
75716657|NCT00929487|Other|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
75716658|NCT00929487|Device|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
75716659|NCT00603837|Device|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
76042384|NCT05544409|Device|MAKv1|1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
76042385|NCT05700253|Device|Cooled Radiofrequency Ablation|Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF* CRFA; Avanos Medical).
76042386|NCT05700253|Device|Hyaluronic Acid Injection|Synvisc-One ([Hylan G-F 20]; Sanofi) will be administered as a single intra-articular dose (6 mL).
75560815|NCT01241123|Radiation|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
75560816|NCT01241123|Device|pedometers|to record the amount of ambulation
75560817|NCT00484263|Drug|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
75716660|NCT00603837|Device|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
75716661|NCT04015089|Dietary Supplement|Partially hydrolyzed formula (pHF)|Infant formula with partially hydrolyzed protein
75716662|NCT04015089|Dietary Supplement|Standard formula (SF)|Infant formula with intact protein
75716663|NCT00925509|Procedure|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
75716664|NCT00925665|Device|Glidescope|Patients are to be intubated using the Glidescope technique
76042387|NCT05536765|Procedure|Surgical exposure of impacted tooth|"The therapeutic approach of surgical exposure of impacted teeth is performed by preparing a flap and removing the cortical bone around the crown of the teeth.~This procedure provides optimal conditions for the orthodontist. In fact, surgical exposure allows the orthodontist to bond the impacted tooth in the correct position depending on the intended direction to apply the correct traction forces for alignment."
75415718|NCT05154058|Procedure|Medial Subperiosteal Release with Sharp Dissection|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery
75415719|NCT05154058|Procedure|Medial Subperiosteal Release with Electrocautery|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
75560818|NCT01242449|Drug|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
75560819|NCT01242449|Drug|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
75560820|NCT00484302|Behavioral|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
75560821|NCT00484302|Behavioral|Non-manualized standard treatment|Treatment by case-manager
75560822|NCT01241162|Biological|Autologous dendritic cell vaccine with adjuvant|"Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination"
75560823|NCT04515303|Other|Diverse Intervention Participation in DASH|A qualitative examination of barriers and facilitators of the DASH dietary pattern, and quantitative investigation of the types of recruitment methods effective for black adults entering a digital DASH-promoting intervention.
75560824|NCT00484133|Drug|Dopamine|
75716665|NCT00925665|Device|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
75716666|NCT00925743|Drug|cabazitaxel (XRP6258)|"administered by IV infusion~in addition to cisplatin treatment"
75716667|NCT00925821|Procedure|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
75716668|NCT00925821|Drug|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
75415720|NCT05140551|Device|COMPASS: digital CBT|COMPASS is an evidence based digital CBT intervention with guided therapist support, tailored to treat anxiety and/or depression in long term conditions (LTCs). The intervention consists of eleven modules/sessions in which CBT techniques are taught. Users of COMPASS receive guided therapist support from a trained therapist. The guided support aims to help patients identify and apply the CBT skills outlined in COMPASS to meet their individual needs and experiences of living with LTC(s). The support can occur through in-site messaging or via the telephone.
75415721|NCT05129098|Device|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath
75415722|NCT05129098|Device|Right ventricular active fixation lead|Active fixation lead (standard)
75415723|NCT05086692|Drug|MDNA11|MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the Recommended Dose for Expansion (RDE).
75560825|NCT00484133|Drug|dobutamine|
75716669|NCT00925977|Drug|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
75716670|NCT00925977|Drug|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
75716671|NCT00926055|Drug|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
75716672|NCT00926055|Drug|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
75716673|NCT04015635|Other|None involved|NO intervention
75560826|NCT00484133|Drug|enoximone|
75716674|NCT00926133|Other|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
75716675|NCT00907959|Drug|BZL101|Oral BZL101 20 grams/day (10 grams BID).
75560827|NCT00484133|Drug|nitroglycerine|
75560828|NCT00484133|Drug|noradrenaline|
75560829|NCT00484341|Drug|low-dose NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
75560830|NCT00484341|Drug|high-dose NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
75560831|NCT00484341|Drug|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
75560832|NCT01242566|Drug|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
75560833|NCT04515225|Other|Blood Sample|Blood Sample
76042388|NCT05536687|Device|FeetMe|"Healthy volunteers will wear the insoles at 2 visits in hospitals (D0 and D8) and 2 visits at home (D1 and D7). The visits at the hospital will be composed of 3 tests of 6 min. in various conditions in a hospital environment :~In degraded conditions, i.e. a 10m corridor, evaluated simultaneously by the FeetMe® system and an evaluator~In degraded condition, a 10m corridor, evaluated simultaneously by the FeetMe® system and an odometer and evaluator~Under the conditions recommended for the 6-minute test (ref), i.e. a 30m corridor, evaluated simultaneously by the FeetMe® system and the evaluator A rest time of 15 min minimum will be respected between each test. The visits at home will be composed of a 6-minute test at home or outdoors (quiet place, flat, hard surface, few or no passages, ideally no obstacles, covered if weather conditions are not suitable) with a 10-meter track that you can define simply with equipment provided by the promoter."
75560834|NCT00484172|Procedure|blood draws|
75716676|NCT00667602|Biological|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
75716677|NCT00667602|Biological|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
75716678|NCT00667602|Biological|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
75716679|NCT00667602|Biological|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
75716680|NCT00667602|Biological|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
75716681|NCT04034199|Drug|Denosumab|Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
75873300|NCT01311167|Drug|Placebo|Daily administration of 2 mg of placebo for 4 days
75415724|NCT05086692|Drug|Pembrolizumab|MDNA11 will be administered in combination with pembrolizumab, IV
75415725|NCT05082649|Other|Face to Face Exercise|Face to face (in clinic) progressive spinal stabilization exercises.
75415726|NCT05082649|Other|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
75415727|NCT05073809|Diagnostic Test|Photoacoustic Imaging Scan|A relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid.
76042389|NCT05544331|Behavioral|Exercise group (written form)|The exercise program will be structUred with core stabilization exercises. Patients will be given the written form of exercises and will be applied as home exercises. Exercise progression will be provided by position changes.
75873301|NCT05691192|Behavioral|Cognitive Leisure Activities|Participants in the active phase of the study will be asked to increase engagement in certain cognitive leisure activities. The activities are chosen on the basis of previous research and measures of cognitive reserve-building activities.
75716682|NCT04034199|Drug|Zoledronic Acid|Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
76042390|NCT05544331|Behavioral|Exercise group (video based)|The exercise program will be structUred with core stabilization exercises. Patients will be given the exercise videos, which provide visual and auditory feedback, and will be applied as home exercises. Exercise progression will be provided by position changes.
76042391|NCT05535673|Drug|ThisCART19A|In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
75441503|NCT01635348|Behavioral|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
75716683|NCT02538237|Drug|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
75716684|NCT02538237|Drug|Ibuprofen 2% mouthwash|
75716685|NCT00691028|Drug|TA-650 3 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
75716686|NCT00691028|Drug|TA-650 6 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
75716687|NCT00691028|Drug|TA-650 10 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
75873302|NCT03628326|Other|Pulmonary arterial tree|The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
75873303|NCT03419741|Device|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
75873304|NCT04233840|Drug|P1101 (Ropeginterferon alfa-2b)|solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks
76042392|NCT05544253|Procedure|mitomycin C-based hyperthermic intraperitoneal chemotherapy|The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
76042393|NCT05535517|Other|CeraVe SA Smoothing Cleanser|The CeraVe Salicylic Acid (SA) Smoothing Cleanser is formulated with salicylic acid to help exfoliate the skin and remove dirt and dead skin cells on the skin without compromising or striping moisture from the skin's natural barrier, leaving the skin feeling clean, smooth and hydrated. This salicylic acid cleanser is also formulated to include hyaluronic acid to hydrate and retain moisture and 3 essential ceramides to moisturise and help support the skin's barrier.
76042394|NCT05535517|Other|CeraVe SA Smoothing Cream|The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.
75560835|NCT04514835|Drug|Cisplatin+Capecitabine+Sintilimab|"The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months."
75560836|NCT00484211|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
75560837|NCT00488813|Drug|Third generation cephalosporins|
75560838|NCT00484380|Procedure|Coronary scanner|multislice spiral computed tomography coronary angiography
75560839|NCT00484250|Drug|metronidazole,doxycycline|
75560840|NCT00484458|Device|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
75560841|NCT00484458|Device|Total Disc Replacement|Total disc
75560842|NCT00488891|Drug|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
75560843|NCT00488891|Drug|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
75560844|NCT00484497|Drug|cyclamax|
75560845|NCT00484328|Drug|Ribavirin|different dosing regimes of Ribavirin
75560846|NCT04514640|Behavioral|The Calm app|"All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention."
75560847|NCT00488930|Other|Observational|data collection ONLY
75560848|NCT00484575|Drug|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
75560849|NCT00484575|Drug|propofol|propofol given intravenously for sedation in control group
75560850|NCT04697342|Behavioral|strategy of education|"one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education"
75560851|NCT04514796|Drug|Adalimumab|SB5 (adalimumab), 40 mg, single-dose
75560852|NCT00484367|Behavioral|Adolescent group therapy|Adolescent group therapy
75560853|NCT00484367|Behavioral|Transitional family therapy|Transitional family therapy
75560854|NCT00484614|Procedure|Positron Emission Mammography|Molecular Imaging Device
75560855|NCT00484614|Procedure|Magnetic Resonance Imaging|Imaging Device
75560856|NCT00488969|Drug|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
75560857|NCT00488969|Drug|Placebo|
75560858|NCT00484653|Procedure|cervical smear|biological analysis
75560859|NCT04697108|Other|Shoulder reproduction teste assisted by laser pointer|In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
75560860|NCT00484692|Drug|sustained-release bupropion (Zyban(R))|
75560861|NCT00484692|Behavioral|Psychodynamic Model Training (R) = PDM(R)|
75560862|NCT00489008|Procedure|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 & 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
75873305|NCT04233840|Drug|Nivolumab|"Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101"
75873306|NCT03787758|Drug|SAGE-718|SAGE-718
75560863|NCT00484731|Procedure|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
75873307|NCT02896400|Behavioral|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
76042395|NCT05535517|Other|Propaira 20% Lactic Acid Exfoliating Lotion|For smoothing rough skin.
75560864|NCT00484731|Procedure|Infiltration with Bupivacaine|
75716688|NCT05277441|Diagnostic Test|Novel severity grading system of unexpected events in pediatric surgery|Classification of unexpected events according to the Clavien-Madadi classification for pediatric surgical patients and simultaneously the non-modified Clavien-Dindo classification in more than 10.000 patients who have been treated at a single center from 2017 to 2022.
75716689|NCT05280327|Other|Virtual Reality Application|The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
75716690|NCT00929721|Procedure|Blood draw|culture for Streptococcus pneumoniae Frequency-1
75716691|NCT00929721|Procedure|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
75716692|NCT00929721|Procedure|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
75716693|NCT00929721|Procedure|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
75716694|NCT00929721|Procedure|sputum|culture for Streptococcus pneumoniae Frequency-1
75716695|NCT04533230|Behavioral|Educational intervention with prescription feedback|Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
75873308|NCT02896400|Drug|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
76042396|NCT05535517|Other|Propaira 30% Urea Exfoliating Emollient|30% Urea, 7% Glycerin to smoothen rough skin.
75415728|NCT05066347|Device|Cardiophone Plus|Cardiophone Plus (Bittium Faros 360 Mobile event recorder, Bittium Biosignals Ltd., Finland., an external loop recorder with 3 leads for 2 channels. Cardiophone Plus evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need for any patient intervention (device-triggered transmission). This transmission occurs through the cell phone that comes with the device. The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call.
75560865|NCT04515069|Procedure|traditional technique of tooth preparation|"Depth cutter wheels of predetermined depths (Komet, Germany) were used to perform the preparation directly on the tooth structure.~Depth cuts were performed on the labial surface using depth cutter wheels (Komet, Germany) with radius of 0.3 mm and 0.5 mm which is directly related to the thickness of the laminate veneers in the cervical and incisal one thirds respectively. Then islands of tooth structure between depth orientation grooves were removed.~Proximal reduction:~The interproximal reduction was completed just labial to the contact areas using a round end tapered diamond stone (Mani, Japan), and polishing was performed using polishing strips (Sof-Lex, 3M ESPE, Seefeld, Germany).~Incisal reduction:~Vertical depth grooves were created. Then, the round end tapered diamond stone (Mani, Japan)was used to create 1.5 mm incisal butt joint preparation.~Then, finishing and polishing of tooth preparation was performed."
75560866|NCT04515069|Procedure|aesthetic preevaluative temporary technique for tooth preparation|"The data obtained from digital smile design was used for construction of the diagnostic wax-up. The wax-up was then be transferred to the mouth using a silicone index, creating the aesthetic pre-evaluative temporary (APT). The APT was tested esthetically and functionally. Once approved by the operator and the patient, tooth preparation was performed through the APT. Depth cuts were performed similar to those performed in the traditional preparation with the difference of being prepared on the aesthetic pre-evaluative temporary instead of directly on the dental structure. Using tapered stone with round end (Mani, Japan), islands of tooth structure between depth orientation grooves were removed.~Proximal reduction, Incisal reduction Finishing and polishing of tooth preparation were carried out using the same technique as in the Group T with the difference of being performed through the APT, resulting in minimal tooth preparation"
75415729|NCT05062343|Device|Dilapan-S|Osmotic dilator
75560867|NCT00484484|Drug|Ketamine|Ketamine
75560868|NCT00484523|Procedure|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
76042397|NCT05535517|Other|KPAI|The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.
75560869|NCT04514601|Other|Standard Operating Protocol|This was a written protocol on how the handover process should be conducted.
75560870|NCT00484562|Device|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
76042398|NCT05535517|Other|KP-IGA|A standard 5-point IGA score (0-4) defined specifically for KP
76042399|NCT05698069|Diagnostic Test|Pain Modulation Index|A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.
75415730|NCT05062343|Device|Cook Cervical Ripening Balloon|Double balloon catheter for cervical ripening
75415731|NCT05048212|Drug|Nivolumab|Given by IV
75560871|NCT00484562|Device|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
75560872|NCT00484562|Device|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
75560873|NCT00484562|Device|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
75560874|NCT00484601|Drug|Ifosfamide|
75560875|NCT00484601|Drug|Doxorubicin|
75560876|NCT00484640|Drug|Coumadin|
76042400|NCT05698069|Other|Pain Detect|A questionnaire that was validated for the assessment of neuropathic pain
75415732|NCT05048212|Drug|Ipilimumab|Given by IV
75560877|NCT04514718|Device|Holmium laser|low energy holmium laser
75560878|NCT00489125|Other|physiologic testing|physical testing of range of motion, grip strength etc.
75560879|NCT00484757|Drug|Orexine A|
75716696|NCT04533230|Behavioral|Information on treatment guidelines|Written information on treatment guidelines.
75415733|NCT05048212|Drug|Cabozantinib|Given by IV
75560880|NCT04514406|Device|APERTO OTW DCB|Drug Coated Balloon Angioplasty
75560881|NCT00489164|Device|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
75560882|NCT00484809|Drug|Enbrel (Etanercept)|
76042401|NCT05698069|Other|Central sensitization inventory|A questionnaire developed for the detection of central sensitization.
76042402|NCT05536531|Device|Neuromuscular electrical stimulation (NMES)|Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
75415734|NCT05046964|Device|Masimo Radical-7 Pulse CO-Oximeter|The Radical-7 Pulse CO-Oximeter uses photospectroscopy to non-invasively measure the total hemoglobin (SpHb) in a patient's blood throughout their C-section.
75560883|NCT00489242|Procedure|Procedure / Percutaneous angioplasty|
75560884|NCT04514094|Drug|SDF|SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
75560885|NCT04514094|Procedure|ART|The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.
75560886|NCT00489320|Device|Cypher Stent|
75415735|NCT05025280|Other|Adolescent/Adult Sensory Profile Questionnaire|"The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking."
75560887|NCT00484848|Device|Vortex port and Celsite port|
75560888|NCT00484796|Procedure|MED-SEP|intraoperative neurophysiological monitoring
75560889|NCT00484796|Procedure|TRI-SEP|intraoperative neurophysiologic monitoring
75560890|NCT00484796|Procedure|neuropsychological tests|neurological short- and longterm outcome
75560891|NCT04514289|Drug|Indocyanine green solution|Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
75560892|NCT00484835|Procedure|Performing abdominal hysterectomy using gyrus electrocoagulation forceps|
75560893|NCT00484913|Procedure|abdominal hot compress|
75560894|NCT00484926|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
75560895|NCT00484926|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
75560896|NCT01242683|Behavioral|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
75560897|NCT01242722|Device|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
75560898|NCT00484965|Procedure|Coronary stenting|
75560899|NCT02275806|Drug|Irinotecan|
75560900|NCT02275806|Drug|Cisplatin|
75716697|NCT00908193|Device|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
75716698|NCT00908193|Procedure|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
75560901|NCT01241409|Drug|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
75560902|NCT01241409|Drug|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
75560903|NCT01241409|Drug|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
75716699|NCT03885050|Other|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
75716700|NCT00781638|Device|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
75560904|NCT01242839|Device|CACICOL20|CACICOL20 is a solution of dextran & poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
75415736|NCT05020821|Procedure|Single-shot superior trunk block with intravenous dexmedetomidine|During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 0.5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot superior trunk block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.
75560905|NCT01242839|Device|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
75560906|NCT02275845|Drug|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
75560907|NCT02275845|Other|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
75415737|NCT05020821|Procedure|Continuous superior trunk block|During surgery, an equivalent volume of the placebo solution was administered in a similar manner as dexmedetomidine. The superior trunk block catheter will be inserted under ultrasound guidance using 15 mL of 0.5% ropivacaine after the operation and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 5 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.
75415738|NCT05010772|Drug|Decitabine and Cedazuridine|Given PO
75415739|NCT05010772|Drug|Enasidenib|Given PO
75560908|NCT01241201|Dietary Supplement|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
75560909|NCT02275884|Dietary Supplement|Dark chocolate (85% cocoa)|
75560910|NCT02275884|Dietary Supplement|White chocolate (0% cocoa)|
75716701|NCT00781716|Device|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
75716702|NCT05461586|Device|Refractive Technique (MR #1)|Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.
75716703|NCT05461586|Device|Refractive Technique (MR #2)|Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths
75716704|NCT00690794|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
75560911|NCT00489398|Drug|epinastine HCL and olopatadine HCL|
75560912|NCT01241357|Device|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
75560913|NCT00485004|Device|Cutting balloon|Cutting balloon
75560914|NCT00485004|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
75560915|NCT01241396|Other|Any MMY treatment|Any line of treatment for MMY
75560916|NCT00485043|Behavioral|Modified T'ai Chi: T'ai Chi for Arthritis|
75560917|NCT00484991|Drug|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
75560918|NCT00485121|Drug|Ezetimibe|
75716705|NCT00690794|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
75873309|NCT02896400|Other|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
75560919|NCT00489437|Device|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
75560920|NCT00489437|Procedure|Clinical Prediction Score-HIT Score Card|"clinical prediction rule~rapid immunoassay"
75716706|NCT00741650|Behavioral|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
75415740|NCT05010772|Drug|Gilteritinib|Given PO
75415741|NCT05010772|Drug|Ivosidenib|Given PO
75415742|NCT05010772|Drug|Venetoclax|Given PO
75560921|NCT00485160|Drug|Continuous indomethacin|
75560922|NCT00485160|Drug|ibuprofen|
75560923|NCT00485030|Device|Cypher|sirolimus-eluting stent
75560924|NCT00485030|Device|Xience-V|everolimus-eluting stent
75560925|NCT00485199|Procedure|Pneumatic Retinopexy|
75560926|NCT00485199|Procedure|Vitrectomy with Gas|
75560927|NCT04514172|Device|Passive industrial exoskeleton for back support|The goal is to compare the human response to the simulated industrial tasks
75716707|NCT00741650|Behavioral|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,"
75415743|NCT05010265|Other|Clinician Questionnaire|Surveys will serve to identify preferences, expectations and concerns among clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through investigative neurotechnologies which will then be systematically evaluated.
75441504|NCT01635361|Other|New Medicine Service|The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
75560928|NCT04514172|Other|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
75560929|NCT04513821|Drug|Mino-Lok Therapy (MLT)|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
75560930|NCT00485108|Drug|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
75560931|NCT00485108|Drug|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
75560932|NCT00485108|Drug|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
75560933|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
75560934|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
75560935|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
75873310|NCT02896400|Other|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
75415744|NCT05010265|Other|Semi Structured Interviews|Semi-structured interviews will further serve to identify preferences, expectations and concerns among patients, surrogates, clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through these investigative neurotechnologies which will then be systematically evaluated.
75560936|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
75560937|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
75560938|NCT04513704|Drug|Oral Semaglutide|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
75873311|NCT03405935|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
75415745|NCT05007873|Drug|Dasatinib|Given PO
75415746|NCT05007873|Drug|Decitabine and Cedazuridine|Given PO
75415747|NCT05005910|Drug|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours)
75415748|NCT05005910|Drug|PPIs IV infusion|Pantoprazole 80 mg IV loading then 8 mg/hr
75560939|NCT01241474|Dietary Supplement|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
75560940|NCT01241474|Dietary Supplement|Maize (corn) oil|6 x 1g capsules per day for 9 months
75560941|NCT00485238|Procedure|Argon laser Iridoplasty|
75560942|NCT00485238|Drug|Intravenous acetazolamide|
75560943|NCT00485277|Biological|MVA-BN-HER2|Experimental vaccine, subcutaneous injection q3weeks x 3
75560944|NCT01242956|Behavioral|verum group|video-based training after stroke
75873312|NCT03644888|Other|Cycle ergometer training|Already in arm/group descriptions
76042403|NCT05536063|Procedure|bilateral erector spinae plane block in pediatric cardiac surgeries|The ESPB will be performed after induction of anesthesia, endotracheal tube insertion and before the start of operation, with the child in a right lateral decubitus position under aseptic precautions. A high frequency linear ultrasound transducer will be placed over the T4 transverse process lateral to the spinous process. After identifying the muscles above the hyperechoic transverse process image, a 5-cm 22 gauge needle will be inserted in-plane in a cephalo-caudad direction. The endpoint is defined as the needle pointing to the tip of transverse process piercing the erector spinae muscle. The local anesthetic will be deposited at this position, After careful negative aspiration, local anesthetic, according to study groups , The process will be repeated on thecontralateral side
76042404|NCT05535985|Device|acupuncture|treatment of pain or disease by inserting the tips of needles at specific points on the skin
76042405|NCT05535985|Device|placebo acupuncture|placebo acupuncture
75415749|NCT05004285|Drug|[F-18]Florastamin|A single dose of [F-18]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and [F-18]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.
75716708|NCT00666276|Drug|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
75560945|NCT01242956|Behavioral|Placebo group|non-video group
75560946|NCT00485316|Procedure|Laparoscopic assisted resection of colorectal carcinoma|
75716709|NCT00567255|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
75716710|NCT00567255|Drug|Placebo|
75716711|NCT00567255|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
76042406|NCT05544097|Other|Recording of the bowel sounds|Recording of the bowel sounds before and after enteral feeding three times a week with an electronical stethoscope
75415751|NCT04983901|Drug|Cefepime|Given IV
75560947|NCT00485147|Procedure|Recording of GPS during a free walking in a public park|Analyse the clinical change after surgery from GPS measurements and compare it with laboratory measurement.
75560948|NCT00485355|Procedure|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
75560949|NCT00485355|Procedure|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
75415752|NCT04983901|Drug|Imipenem/cilastatin-relebactam|Given IV
75415753|NCT04983901|Drug|Daptomycin|Given IV
75415754|NCT04983901|Drug|Linezolid|Given IV or PO
75415755|NCT04983901|Drug|Meropenem|Given IV
75415756|NCT04983901|Drug|Piperacillin-Tazobactam|Given IV
75415757|NCT04983901|Drug|Vancomycin|Given IV
76042407|NCT05592535|Procedure|Coronary revascularization|Coronary revascularization performed by PCI in a vessel investigated with FFR or indication for surgery
75560950|NCT04513509|Drug|Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin|Start with empirical lower dose for 3 months, and then titrate up
75560951|NCT00485342|Drug|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
75716712|NCT00744458|Other|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
75415758|NCT04983199|Device|Hexoskin Medical System|Hexoskin is a smart shirt that can detect heart rates, lung function and physical activity of patients before and after radiotherapy.
75415759|NCT04980404|Drug|Inqovi|Tablet combination of drugs decitabine and cedazuridine, given orally.
76042408|NCT05699083|Other|Body Image/Self-Esteem Questionnaires|Pre-operation and post-operation questionnaires to assess factors including but not limited to body image, quality of life, and self-esteem.
75716713|NCT00744458|Other|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
75716714|NCT00744458|Other|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
75716715|NCT00781794|Drug|NSA-789 at 2 different doses|
76042409|NCT05697913|Other|Continued treatment adapted to the response|Instead of receiving a pre-specified number of treatment cycles, regardless of the result obtained, in the MRDI-driven treatment group patients continue receiving treatment until reaching a complete remission with negative MRD and Image, changing the therapeutic line if it is not obtained with the line current therapy. In this group of the patients the treatment was stopped only when this degree of deep response was achieved.
76042410|NCT05543941|Device|XPERIENCE Advanced Surgical Irrigation|The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.
75415760|NCT04960579|Biological|P-BCMA-ALLO1 CAR-T cells|Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
75415761|NCT04960579|Drug|Rimiducid|Safety switch activator
75415762|NCT04957992|Other|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
75415763|NCT04957992|Other|Control Toddler Drink|~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
75415764|NCT04957992|Other|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
75415765|NCT04957992|Other|Experimental Toddler Drink|~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
75415766|NCT04957992|Other|Human Milk|Ad libitum or as instructed by HCP
75415767|NCT04957992|Other|Human Milk Supplemental Formula|Ad libitum if consuming supplemented formula; feeding period up to 12 months of age
75415768|NCT04957992|Other|Human Milk Toddler Drink|~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
75415769|NCT04956575|Biological|mRNA-1010|Sterile liquid for injection
75415770|NCT04956575|Biological|Placebo|0.9% sodium chloride solution for injection
75415771|NCT04956575|Biological|Active Comparator|0.5 milliliter (mL) intramuscular (IM) injection
75716716|NCT00746174|Drug|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
75560952|NCT00485342|Drug|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
75560953|NCT00485394|Drug|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
75415772|NCT04949087|Procedure|Glenohumeral Injection|Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
75415773|NCT04948294|Device|Channeled blade|In the present group, a tracheal tube was launched in the channel of the blade before tracheal intubation
75560954|NCT00485394|Drug|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
75560955|NCT00485394|Drug|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
75560956|NCT01242995|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
75560957|NCT04513587|Behavioral|CBT-based weight loss model|Methods of cognitive behavioral psychotherapy
75560958|NCT04513587|Behavioral|Control|Treatment as usual
75560959|NCT00489593|Drug|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
75560960|NCT01241487|Drug|valsartan/amlodipine|160/10 mg
76042411|NCT05543941|Device|Dilute Betadine|The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.
75415774|NCT04948294|Device|Non-channeled blade|In the present group, a tracheal tube was not launched in the videolaryngoscope blade before tracheal intubation
75560961|NCT00489632|Behavioral|Questionnaire|Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
75560962|NCT00505791|Drug|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure > 100 mmHg.
75560963|NCT00485420|Other|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
76042412|NCT04425733|Drug|MK-5475|MK-5475 administered at a dose of 180 µg or ≤360 µg QD via inhalation
76042413|NCT04425733|Drug|Placebo|MK-5475-matching placebo administered QD via inhalation
76042414|NCT05543863|Diagnostic Test|Platelet function testing|platelet function testing (Platelet function analyzer-100 (PFA-100) collagen epinephrine closure time, VerifyNowⓇ Assays (aspirin, P2Y12)) before surgery and 5 days, 3 months after surgery
75560964|NCT02955108|Procedure|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
75560965|NCT02955108|Procedure|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
75415775|NCT04943380|Diagnostic Test|Cxbladder|The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
75560966|NCT04697303|Other|anorectal function test|anorectal function test
75560967|NCT02274207|Device|NPWT application|NPWT mode is cyclic mode : -125~-50 mmHg
75560968|NCT00485459|Drug|Atomoxetine Hydrochloride|
75560969|NCT00485459|Drug|Placebo|
76042415|NCT05543473|Other|Vestibular Rehabilitation Therapy|an exercise-based treatment program designed to promote vestibular adaptation and substitution. The goals of VRT are to enhance gaze stability, to enhance postural stability, to improve vertigo, and to improve activities of daily living. VRT facilitates vestibular recovery mechanisms: vestibular adaptation, substitution by the other eye-movement systems, substitution by vision, somatosensory cues, other postural strategies, and habituation
76042416|NCT05696041|Other|Static strength training program or/and Dynamic strength training program of the hand|Four of the five exercises included in the static or dynamic training program were based on holding the weight over the edge of the table and maintaining the position for 10 seconds, then resting briefly and changing to the next position. The training was performed in the following assumed positions, pronation, supination, radial and ulnar position. In the fifth and final exercise, you would squeeze an exercise ball as hard as possible without pain. The starting weight was 0.5 kilogram, and each exercise (1-4) was performed in three sets in the first week. The training increased by one set per week for up to eight sets/week if pain or paresthesia got worsened. If the training worked, the OT and the subject could choose to increase the weight to 1 kilogram and start over with three sets/day and gradually increase the training or switch to a dynamic training program.
76042417|NCT05498701|Drug|Tafamidis free acid tablet (Test)|12.2 mg tafamidis free acid tablet (Test)
76042418|NCT05498701|Drug|Tafamidis meglumine capsule (Reference)|Commercial 20 mg tafamidis meglumine capsule (Reference)
76042419|NCT05695807|Device|Carboxytherapy|Device generating CO2 gas
76042420|NCT02580877|Drug|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
75415776|NCT04942379|Other|Asthma Link|Providers enroll patients in school nurse supervised daily controller asthma medication delivery
75415777|NCT04942379|Other|Enhanced Usual Care|Providers counsel patients on behavioral strategies to improve medication adherence. Patients also receive an asthma workbook outlining behavioral strategies for asthma medication adherence.
75560970|NCT04513431|Biological|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
75560971|NCT02274246|Drug|gadobutrol|Gadobutrol administration in healthy volunteers
75560972|NCT01241630|Procedure|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
76042421|NCT02580877|Drug|500mg oral insulin crystals every other week|human insulin crystals in capsules
75560973|NCT00489749|Procedure|Protected early weightbearing/Achilles tendon surgery|
75560974|NCT04513275|Drug|non-medicine intervention|rating by MCCB only one time
75560975|NCT02274194|Device|Nasal CPAP|use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment
75560976|NCT02274194|Device|Oronasal CPAP|use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
75560977|NCT00505830|Other|questionnaires|"Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score"
75415778|NCT04940130|Biological|Sanaria® PfSPZ Vaccine|non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).
75415779|NCT04940130|Other|Normal Saline|placebo control- saline
75415780|NCT04938427|Drug|Soticlestat|Soticlestat mini-tablets or tablets.
75415781|NCT04938427|Drug|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
75415782|NCT04925414|Drug|oxygenotherapy|High concentration mask delivering 15L/min of oxygen
75415783|NCT04925414|Drug|placebo air aerosol|High concentration mask delivering 15L/min of air
75415784|NCT04920708|Drug|Ipatasertib 300mg|Ipatasertib 300mg once daily. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
75415785|NCT04920708|Drug|Fulvestrant 500g|Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
75415786|NCT04920708|Drug|Palbociclib 75mg-125mg|Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
75415787|NCT04920708|Drug|CDK4/6 Inhibitor|CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.
75415788|NCT04904796|Other|CIMT|CIMT : Constraint-Induced Movement Therapy (CIMT) is a deviation from traditional treatments, used to treat hemiplegia. Its aim is to stimulate the functional use of the affected limb and reverse the process developmental is disregard. In this method, the unaffected or less affected limb is restrained, so the person has to use the affected limb.
75415789|NCT04904796|Other|H-HABIT|H-HABIT : Hand-Arm Bimanual Intensive Therapy (HABIT) in children with hemiplegia is a new intervention developed at Columbia University. HABIT aims to improve the use and coordination of both arms in daily function. Unlike CIMT, HABIT focuses on improving the ability to perform bimanual activities. Participants will be monitored via webcam-based software (i.e. ZOOM) while they performed the activities in their own home.
75415790|NCT04895111|Diagnostic Test|Endobronchial ultrasound strain elastography|Measurement of tissue elasticity of hilar and mediastinal lymph nodes through strain elastography measured during an endonbronchial ultrasound examination
75415791|NCT04889274|Biological|COVID-19 vaccine|COVID-19 vaccine as offered by NHS England
75560978|NCT02274233|Drug|SP-420|
75560979|NCT04697511|Drug|Midazolam|Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.
75560980|NCT04697511|Drug|M2951|Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.
75560981|NCT00485511|Drug|Hydroxyurea|
75560982|NCT02274272|Other|ADR-1|two ADR-1 capsules, once daily, QD
75560983|NCT02274272|Other|GMNL-263|two GMNL-263 capsules, once daily, QD
75560984|NCT02274272|Other|placebo|two placebo capsules, once daily, QD
75560985|NCT04512963|Drug|Progerinin|100 mg/g nano-suspension for oral use
75560986|NCT04512963|Drug|Placebo|A substance that has no therapeutic effect, used as a control in testing Progerinin
75560987|NCT00485498|Drug|Olanzapine Hydrochloride|
75560988|NCT00485498|Drug|Risperidone|
76042422|NCT05688163|Other|programme based on everyday cognition|Will carry out a programme based on everyday cognition, As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above. Each day one of these tasks will be worked on.
75415792|NCT04889274|Biological|Concentrate beetroot Juice|Beetroot juice containing approximately 5mmol/l nitrate
75560989|NCT01302067|Drug|Fesoterodine 8mg|Oral, 1 tablet per day, 12 weeks duration, 8mg/day
75415793|NCT04889274|Biological|Nitrate-deplete beetroot juice|Beetroot juice with nitrate removed
75560990|NCT01302067|Drug|Fesoterodine 4mg|Oral, 1 tablet per day, 12 weeks duration, 4mg/day
75560991|NCT01302067|Drug|Placebo|Oral, 1 tablet per day, 12 weeks duration
75873313|NCT03644888|Other|Airway clearance program|Already in arm/group descriptions
75873314|NCT03644888|Device|Vibration therapy|Already in arm/group descriptions
75873315|NCT03644888|Device|Sham vibration therapy|Already in arm/group descriptions
76042423|NCT05688163|Other|traditional cognitive stimulation|Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
75415794|NCT04865770|Drug|Semaglutide|Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
75415795|NCT04865770|Drug|Placebo (Semaglutide)|Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
75415796|NCT04843683|Radiation|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
75560992|NCT00485550|Drug|Atomoxetine Hydrochloride|
75560993|NCT00485550|Drug|Methylphenidate Hydrochloride|
75560994|NCT00485550|Drug|Placebo|
75560995|NCT04697147|Behavioral|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
75560996|NCT00485537|Procedure|oocyte retrieval and ICSI procedure|
75560997|NCT00485628|Drug|Atomoxetine Hydrochloride|
75560998|NCT00485576|Drug|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
75415797|NCT04832698|Other|Survey Administration|Complete survey
75415798|NCT04812015|Device|transcutaneous auricular vagus nerve stimulation (taVNS) 15 minutes|Sham 60 minutes and taVNS active stimulation for 15 minutes
75415799|NCT04812015|Device|taVNS 30 minutes|Sham 45 minutes and taVNS active stimulation for 30 minutes
75415800|NCT04812015|Device|taVNS 45 minutes|Sham 30 minutes and taVNS active stimulation for 45 minutes
75415801|NCT04812015|Device|taVNS 60 minutes|Sham 15 minutes and taVNS active stimulation for 60 minutes
75415802|NCT04812015|Device|taVNS 75 minutes|Sham 0 minutes and taVNS active stimulation for 75 minutes
75415803|NCT04812015|Device|taVNS 0 minutes|Sham taVNS 75 minutes
75415804|NCT04811040|Drug|Oral Lenacapavir|Tablets administered without regard to food
75415805|NCT04811040|Drug|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
75415806|NCT04811040|Drug|Teropavimab|Administered intravenously
75415807|NCT04811040|Drug|Zinlirvimab|Administered intravenously
75560999|NCT00485667|Drug|SKY0402|Subects received either 300mg or 450mg
75561000|NCT00485667|Drug|Moxifloxacin 400mg|
75561001|NCT00485667|Drug|Placebo injection|
75561002|NCT00485667|Drug|Placebo tablet|
75561003|NCT01301950|Other|Custom Patient Instrumentation|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
75716717|NCT00746174|Drug|Placebo|Placebo 1 tablet PO daily for 16 weeks
75716718|NCT00784446|Drug|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
75716719|NCT00744536|Drug|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
75716720|NCT05028972|Other|Personal Amplifier|The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED
75716721|NCT05028972|Other|No Personal Amplifier|The control group will not receive personal amplifiers while they receive care in the ED
75873316|NCT03055260|Device|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
76042424|NCT04316923|Diagnostic Test|ECG|ECG will be performed during each visit in the study group.
76042425|NCT04316923|Diagnostic Test|24-hour ECG monitoring|24-hour ECG monitoring will be performed during each visit in the study group.
76042426|NCT04316923|Diagnostic Test|Cardio-pulmonary exercise test (CPET)|CPET will be performed during the first and the last visit in the study group.
75415808|NCT04808479|Behavioral|imFREE mCBT|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
75561004|NCT01301950|Other|Conventional Instruments|Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
76042427|NCT04316923|Diagnostic Test|Cardiac biomarkers|Cardiac biomarkers will be assessed during each visit in the study group.
75415809|NCT04808479|Behavioral|mHealth ED|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
75561005|NCT00489905|Drug|Zolderonic acid (Zometa)|
75561006|NCT00485615|Drug|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
75716722|NCT00744614|Procedure|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
75716723|NCT00929799|Drug|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
75415810|NCT04803058|Biological|TCD601|Investigational Product
76042428|NCT05697523|Other|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
75561007|NCT00489944|Drug|cisplatin|
75415811|NCT04803006|Biological|TCD601|Investigational Product
75415812|NCT04799587|Other|Magnet at P6|Magnet applied at P6 and attached with adhesive tape. The P6 pressure point is 2 inches proximal to the flexor retinaculum, between the flexor carpi radialis and palmaras longus.
75716724|NCT00777738|Drug|BORTEZOMIB|"Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).~For responding patients : up to 6 cycles~For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days"
75873317|NCT03055260|Device|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
76042429|NCT04425499|Other|Learning running subcuticular sutures on the Gamified Educational Network|Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
75415813|NCT04799587|Other|Magnet applied to arm not at P6 pressure point.|Magnet applied to arm not at P6 pressure point and affixed with adhesive tape.
75415814|NCT04796896|Biological|mRNA-1273|Sterile liquid for injection
75415815|NCT04796896|Biological|Placebo|0.9% sodium chloride (normal saline) injection
76042430|NCT01905631|Drug|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
76042431|NCT05679115|Behavioral|Lifestyle tool|Regular use of the digital Lifestyle tool
76042432|NCT01808989|Other|Exercise oxymetry|
75415816|NCT04796896|Biological|mRNA-1273.214|Sterile liquid for injection
75415817|NCT04789720|Behavioral|Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)|Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.
75415818|NCT04777305|Other|Physical activity training|Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
75415819|NCT04774471|Diagnostic Test|Evaluation of BIT-Motion software|Software program to discern benign versus malignant breast lesions.
75561008|NCT00489944|Drug|sunitinib malate|
75561009|NCT00489944|Drug|tamoxifen citrate|
75561010|NCT00489944|Procedure|adjuvant therapy|
75561011|NCT00485706|Procedure|high calcium dialysate|
75561012|NCT00505869|Behavioral|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
75561013|NCT00505869|Behavioral|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
75561014|NCT00505869|Behavioral|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
75561015|NCT00505947|Drug|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
75716725|NCT00744770|Drug|TMC278|
75716726|NCT00926523|Other|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
75716727|NCT00926523|Other|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
76042433|NCT05591521|Other|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
75415821|NCT04732065|Drug|ONC206|Given orally (PO)
75716728|NCT00926523|Other|Spirometry|To assess subjects lung function
75716729|NCT00926523|Other|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
75716730|NCT00781872|Biological|Injection of autologous bone marrow derived mesenchymal stem cells|60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
75873318|NCT03404843|Drug|Fasudil Hydrochloride|10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
75873319|NCT03404843|Other|Saline|100 mL saline bag.
75873320|NCT05283902|Biological|ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine|In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.
75415822|NCT04732065|Radiation|Standard of Care Radiation Therapy|Undergo RT
75415823|NCT04723862|Drug|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
75415824|NCT04723862|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
75415825|NCT04720105|Drug|Duobrii®|Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
75415826|NCT04714723|Behavioral|Programmed smartphone intervention|Interactive programmed lifestyle education based on smartphone for six month
75561016|NCT00505947|Drug|placebo|placebo 5 mg/Kg body weight by intravenous infusion
75561017|NCT00489983|Drug|pemetrexed|
76042434|NCT05591287|Procedure|Contrast enhanced harmonic Endoscopic Ultrasound|Solid pancreatic masses suspected for PDAC detected by cross-sectional imaging and confirmed at EUS will be enrolled. The
75561018|NCT00489983|Drug|gemcitabine|
75873321|NCT05284448|Drug|pentoxifylline (Trental SR®)|400 mg three times daily
76042435|NCT05535205|Other|Digital preoperative assessment|a digital preoperative assessment for patient requiring surgery
75415827|NCT04714723|Behavioral|Programmed smartphone plus dietitian intervention|Interactive programmed lifestyle education based on smartphone plus dietitians support for six month
75415828|NCT04693234|Drug|Tislelizumab|Administered as specified in the treatment arm
75415829|NCT04693234|Drug|Ociperlimab|Administered as specified in the treatment arm
75415835|NCT04664179|Biological|Dose Level 1A: 2 x 10^7 cells/m2|2 x 10^7 cells/m2
75415836|NCT04664179|Biological|Dose Level 2A: 6 x 10^7 cells/m2|6 x 10^7 cells/m2
75415837|NCT04664179|Biological|Dose Level 2B: 6 x 10^7 cells/m2|6 x 10^7 cells/m2
75873322|NCT03627936|Drug|Lorcaserin manufactured at Zofingen|Lorcaserin XR tablets manufactured at Zofingen.
75873323|NCT03627936|Drug|Lorcaserin manufactured at Kawashima|Lorcaserin XR tablets manufactured at Kawashima.
75561019|NCT01241682|Biological|DC + CTX|3x 50x10e6 DC + cyclophosphamide
75561020|NCT01241669|Drug|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
75561021|NCT01241669|Drug|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
75561022|NCT00505986|Procedure|endometrial biopsy|
75561023|NCT01241825|Other|Trident sugarless chewing gum.|Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
75561024|NCT01241825|Other|One control group (these do not chew gum).|The control group will not chew chewing gum while undergoing capsule endoscopy
75561025|NCT01241721|Device|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
75561026|NCT01241942|Device|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
75716731|NCT00741728|Other|Spider flash EKG, echocardiography tracking, step test|cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
76042436|NCT05535205|Other|Face-to-face preoperative assessment|a face-to-face preoperative assessment for patient requiring surgery
75415838|NCT04664179|Biological|Dose Level 3B: 2 x 10^8 cells/m2|2 x 10^8 cells/m2
75415839|NCT04664179|Biological|Dose Level 3A: 2 x 10^8 cells/m2|2 x 10^8 cells/m2
75716732|NCT00784680|Drug|Anastrozole|1mg, orally, once daily
75716733|NCT00784680|Drug|Tamoxifen|20mg, orally, once daily
75716734|NCT00908271|Drug|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
75716735|NCT02556840|Other|insulin therapy|
75716736|NCT00741806|Biological|GHB04L1|single dose intranasal administration of GHB04L1
75716737|NCT00741806|Other|Placebo|SPGN buffer
75716738|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
76042437|NCT05679037|Other|Placebo|Inactive capsules
76042438|NCT05679037|Drug|Alpha Lipoic Acid 600 MG Oral Capsule|Universal antioxidant
76042439|NCT05587465|Device|Lobster Device|The intervention is performed percutaneously using the dedicated instrument set.
76042440|NCT05695651|Diagnostic Test|triglyceride glucose index and HOMA IR|"TyG index was calculated as formula: ln[fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2].~an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance)."
75415840|NCT04649177|Device|Ocular surface optical coherence tomography|EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
75415841|NCT04625205|Biological|NEO-PTC-01|Administered via intravenous infusion.
75415842|NCT04625205|Drug|IL-2|Administered via intravenous infusion.
75415843|NCT04625205|Drug|αPD-1 therapy|Administered via intravenous infusion.
75415844|NCT04594278|Behavioral|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
75415845|NCT04585542|Drug|Polyethylene Glycol 3350|Nonspecific laxative comparison group.
76042441|NCT05678881|Drug|High dose RLS103|8 mg CBD inhaled powder
76042442|NCT05678881|Drug|placebo inhaled powder|placebo inhaled powder
75415846|NCT04585542|Drug|Sodium Polystyrene Sulfonate Oral Suspension [SPS]|Potassium binder to treat hyperkalemia.
76042443|NCT05678881|Drug|Low dose RLS103|4 mg CBD inhaled powder (open label)
75415847|NCT04585542|Drug|Patiromer|Potassium binder to treat hyperkalemia.
75415848|NCT04585542|Drug|Sodium zirconium cyclosilicate|Potassium binder to treat hyperkalemia.
75415849|NCT04585334|Drug|Tricortin 1000|Tricortin 1000 [2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
75561027|NCT01241942|Other|Conventional Lung Transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
75561028|NCT00490178|Drug|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
75561029|NCT01241799|Procedure|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
75716739|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
76042444|NCT05678725|Device|tACS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.
76042445|NCT05678725|Device|tDCS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.
75561030|NCT01241799|Procedure|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
75716740|NCT00929877|Drug|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
75716741|NCT00741884|Drug|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
76042446|NCT05678725|Device|sham|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 0mA for 20 minutes with the ramp up and down time of 40 seconds.
76042447|NCT05678569|Diagnostic Test|Dual Energy Xray Absorptiometry|DXA for diagnosis of osteoporosis
76042448|NCT02582983|Drug|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
75415850|NCT04585334|Drug|Itami|Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).
75415851|NCT04585334|Drug|Placebo|Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
75415852|NCT04574960|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, IV infusion on days 1 and 8 of each 3-week cycle
75415853|NCT04574960|Drug|Cisplatin|Cisplatin 70 mg/m^2, IV infusion on day 1 of each 3-week cycle
75415854|NCT04574960|Drug|Carboplatin|Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
75415855|NCT04574947|Drug|Intravenous lidocaine|Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
75561031|NCT01241838|Device|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
75561032|NCT00485771|Drug|Olanzapine|
75561033|NCT00485771|Drug|Fluoxetine|
75716742|NCT00741884|Drug|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
75716743|NCT00741884|Drug|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
75716744|NCT00741884|Drug|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
75716745|NCT00741884|Drug|Placebo|Placebo BID for 7 weeks
75716746|NCT00777816|Drug|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
75415856|NCT04574947|Drug|Intravenous placebo|During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
75415857|NCT04574947|Procedure|Intra-cuff lidocaine|The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
75415858|NCT04574947|Procedure|Intra-cuff placebo|The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
75415859|NCT04573309|Drug|ALXN1840|Administered orally as tablets.
75415860|NCT04571541|Device|Stenting|Effect of endoscopic stenting on healing of esophageal wall defects
75415861|NCT04554693|Drug|Metronidazole Oral|250 mg oral three times a day for 14 days
75561034|NCT00485771|Drug|Lamotrigine|
75415862|NCT04554693|Drug|Placebo|Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
75415863|NCT04511845|Drug|SPYK04|SPYK04 capsule
75415864|NCT04507568|Other|Quality of Life Questionnaires|Quality of Life questionnaires will be administered to both arms at baseline, and at the first and last day of treatment.
75561035|NCT01241877|Dietary Supplement|astaxanthin|astaxanthin
75415865|NCT04488198|Other|Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with acupuncture needles.
75415866|NCT04488198|Other|Placebo-Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with placebo-needles.
75415867|NCT04475523|Drug|CI-8993|CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
75415868|NCT04474925|Procedure|Brain Surgery|Surgery to remove brain metastases
75415869|NCT04474925|Radiation|Stereotactic Radiosurgery|SRS uses many focused radiation beams to treat tumors within the brain
75415870|NCT04473911|Drug|FLUDARABINE|predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles
75561036|NCT01241877|Dietary Supplement|placebo|placebo
75561037|NCT04512729|Diagnostic Test|Colonoscopy|"For all patients, either moderate sedation with intravenous midazolam or conscious sedation with intravenous propofol will be administered in a standard fashion prior to undergoing colonoscopy.~The colonoscope will be inserted and cecum will be intubated. Photo documentation of the cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of the colonoscope.~The time spent in inspecting the mucosa during withdrawal of the colonoscope will be documented as the withdrawal time. Meticulous technique will be employed during the withdrawal phase with special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral folds, flexures and valves.All polyps detected will be documented: size, location, and morphology. Photo documentation of the polyps will be performed."
75561038|NCT00485784|Other|Blood test|Blood test
75873324|NCT03717779|Diagnostic Test|lung ultrasound|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
76042449|NCT02582749|Drug|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
76042450|NCT02582749|Drug|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
76042451|NCT02582749|Radiation|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
76042452|NCT05461261|Drug|Docetaxel|Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.
75561039|NCT00485810|Drug|Olanzapine Hydrochloride|
76042453|NCT05461261|Drug|Prednisolone Acetate|5mg Prednisolone Acetate will be given orally twice a day during treatment.
75415871|NCT04473911|Drug|CYCLOPHOSPHAMIDE|◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
75415872|NCT04473911|Radiation|TBI|Total body irradiation (TBI) once per cycle.
75415873|NCT04473911|Drug|Melphalan|Melphalan, infusion, determined dosage, once per cycle
75415874|NCT04473911|Drug|Sirolimus|Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism
75415875|NCT04473911|Drug|Mycophenolate mofetil|◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
75415876|NCT04473911|Drug|RGI-2001|IV, predetermined dose, weekly to 6 total doses
75716747|NCT00777816|Drug|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
75716748|NCT00931437|Dietary Supplement|vitamin K-rich dairy product|several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
75716749|NCT00741962|Dietary Supplement|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
75716750|NCT00741962|Dietary Supplement|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
75873325|NCT03646682|Procedure|vitrectomy with membrane peeling|during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
75873326|NCT03032250|Other|Communication Intervention|Attend interventionist sessions
75873327|NCT03032250|Other|Watch video|Watch video on a DVD
76042454|NCT05461261|Drug|Platinum-based drugs|Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.
76042455|NCT05383729|Other|learning-curve-based training modality|It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.
75415877|NCT04473911|Drug|CYCLOPHOSPHAMIDE|◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
76042456|NCT05383729|Other|fixed-training-time training modality|It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.[1]
75415878|NCT04446312|Drug|Bowel Prep|Orally ingested liquid bowel preparation
75415879|NCT04439409|Device|Holter electrocardiogram|Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
75561040|NCT04512651|Other|Tibiotarsal Thrust Manipulation|The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.
75561041|NCT04512651|Other|Simulation Tibiotarsal Thrust Manipulation|Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
75561042|NCT00490373|Drug|pemetrexed|
76042457|NCT05339815|Device|SMR shoulder arthroplasty|Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres
75415880|NCT04410406|Drug|Ivermectin|Ivermectin (IVM) 200 µg/kg
75415881|NCT04410406|Drug|Diethylcarbamazine|Diethylcarbamazine (DEC) 6mg/kg
75415882|NCT04410406|Drug|Albendazole|Albendazole (ABZ) 400 mg
75415883|NCT04410406|Drug|Moxidectin|Moxidectin (Mox) 8 mg
75415884|NCT04403074|Procedure|Celiac Plexus Neurolysis|When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
75415885|NCT04359888|Other|Multi-Component Exercise Training (MCET)|Three one-hour training sessions per week for six weeks in Multi-Component Exercise Training (MCET). (See Study Design)
75415886|NCT04359888|Other|Balanced Reach Training (BRT)|Three one-hour training sessions per week for six weeks in the Balanced Reach Training Protocol (BRTP) (See Study Design).
75415887|NCT04359784|Biological|Anakinra|Given SC
75415888|NCT04350125|Biological|Autologous Platelet Rich Plasma|One 4-5mL platelet rich plasma injection administered to each side of the intracavernosal space on the right and left side of the corpus cavernosum at the base of the penis, every two weeks for 6 weeks.
75415889|NCT04342546|Device|NovaGray RILA Breast® test|The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
75415890|NCT04338269|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.
75415891|NCT04338269|Drug|Cabozantinib|Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
75415892|NCT04323189|Drug|Sitagliptin 100mg|Sitagliptin will be administered daily for 7 days, with a study day on day 7.
75415893|NCT04323189|Drug|Placebo Oral Tablet|Placebo will be administered daily for 7 days, with a study day on day 7.
75561043|NCT00485823|Drug|Olanzapine Hydrochloride|
75415894|NCT04321330|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
75415895|NCT04287985|Drug|Dose-Placebo|Unit Dose Strength - 0.9%.
75415896|NCT04287985|Drug|Low Dose-VIS649|Dose Level = Low
75561044|NCT00485823|Procedure|Weight Management Program|
75561045|NCT00485849|Drug|Atomoxetine Hydrochloride|
75561046|NCT04512417|Drug|Camrelizumab+Radiotherapy|The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.
75415897|NCT04287985|Drug|Medium Dose-VIS649|Dose Level = Medium
75415898|NCT04287985|Drug|High Dose-VIS649|Dose Level = High
75415899|NCT04270149|Biological|ESR1 peptide vaccine|ESR1 peptides plus Montanide and GM-CSF
75415900|NCT04268914|Device|Oculus Go VR|The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.
75561047|NCT04512417|Drug|Camrelizumab|Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
75561048|NCT00485888|Drug|Cipralex|10-20mg; one per day
75561049|NCT00485888|Drug|Placebo|Matched to Cipralex
75561050|NCT00485862|Drug|Atomoxetine Hydrochloride|
75561051|NCT00485862|Drug|Sertraline|
75561052|NCT00485862|Drug|Placebo|
75561053|NCT00485927|Behavioral|stress|
75561054|NCT00485901|Drug|Olanzapine Hydrochloride|
75561055|NCT00485901|Drug|Haloperidol|
75561056|NCT00490412|Dietary Supplement|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
75561057|NCT00490412|Other|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
75561058|NCT01241955|Behavioral|video decision aid|video of CPR
75561059|NCT00485966|Drug|CX-3543|360 mg/m2 daily x 5 q 21 days
75561060|NCT00485940|Drug|Prucalopride|2 mg o.d.
75561061|NCT00485940|Other|Placebo|Placebo o.d.
75561062|NCT00485940|Drug|Prucalopride|4 mg o.d.
75561063|NCT00486005|Drug|Olanzapine Hydrochloride|
75561064|NCT00486005|Drug|Nizatidine|
75561065|NCT00486005|Drug|Placebo|
75561066|NCT00485979|Drug|larotaxel (XRP9881)|intravenous administration
75561067|NCT00485979|Drug|docetaxel|intravenous administration
75561068|NCT00485979|Drug|trastuzumab|intravenous administration
75561069|NCT00486083|Drug|Atomoxetine Hydrochloride|
75561070|NCT00486083|Drug|Methylphenidate Hydrochloride|
75561071|NCT04512027|Other|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19
75561072|NCT04512027|Other|Standard of Care|Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.
75561073|NCT00490685|Drug|Sorafenib (BAY-43-9006)|
75561074|NCT00486122|Drug|Atomoxetine Hydrochloride|
75561075|NCT00486122|Drug|Placebo|
75561076|NCT04511715|Drug|Intravitreal Bevacizumab IVB|Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment
75561077|NCT04511715|Other|Follow-up with regular examination for determination of DR progression|regular examination for determination of DR progression
75561078|NCT00486135|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
75561079|NCT00486135|Drug|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
75561080|NCT00486317|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
75561081|NCT04511910|Procedure|Early Laparoscopic Cholecystectomy|
75561082|NCT00490880|Drug|gemcitabine|
75561083|NCT00490880|Drug|cisplatin|
75561084|NCT00490880|Procedure|radical cystectomy|
75561085|NCT00490880|Procedure|radiotherapy|
75415901|NCT04268914|Device|Mira Prism VR|The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
75415902|NCT04268901|Device|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE to be used in this study is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
75561086|NCT01241994|Other|AASD dialysis technique|
75561087|NCT01242033|Dietary Supplement|red raspberries|single serving of one, two or four cups red raspberries
75561088|NCT01242033|Dietary Supplement|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
75561089|NCT00486174|Drug|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
75561090|NCT04511793|Device|Medtronic Synchromed II pump|The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
75561091|NCT00490958|Drug|telmisartan|
75561092|NCT00486213|Dietary Supplement|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
75561093|NCT00486213|Other|Placebo|
75561094|NCT00486395|Device|CPAP|"CPAP administered via Bubble method or Infant Flow Driver"
75561095|NCT00486395|Device|Mechanical ventilation|Volume guarantee strategy
75561096|NCT00486369|Drug|Oral salmon calcitonin|
75561097|NCT00490997|Drug|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
75561098|NCT00490997|Drug|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
75561099|NCT04511949|Diagnostic Test|COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)|"The rapid test is performed using a drop of blood obtained at the fingertip (10 microliters) using a lancet.~The dropper pipette, held vertically, collects the drop of whole blood up to the sample line~Place 1 drop of whole blood (10 μL in the sample well (S) of the cassette.~Immediately add 2 drops (80μL) of buffer to the well (B) of the cassette.~Avoid air bubbles; if there is an air bubble, add a 3rd drop of buffer.~The reading is taken after 10 minutes at most by the healthcare professional under medical supervision.~In case of sepositivity of the rapid test, it may be offered to index cases and adult contacts, a blood sample of 5 ml of blood for a serothèque allowing a characterization of the antibodies and in particular of the neutralizing antibodies."
75561100|NCT00486473|Drug|Multihance|0.5 Molar at a single dose injection
75561101|NCT00486473|Drug|Magnevist|0.5M at a single dose injection
75561102|NCT00486408|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5x10^10 Ad vg
75561103|NCT00486590|Procedure|Prolact-Plus Human Milk Fortifier|
75561104|NCT04511637|Drug|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|15 mg as 1 x 15 mg orally disintegrating tablet (ODT)
75561105|NCT04511637|Drug|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|15 mg as 1 x 15 mg film-coated tablet
75561106|NCT00491036|Device|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
75561107|NCT00486486|Drug|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
75561108|NCT00486486|Drug|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
75561109|NCT04511481|Other|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
75561110|NCT00491114|Drug|Gemcitabine|
75561111|NCT00486564|Drug|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
75561112|NCT00486668|Drug|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
75561113|NCT00486668|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
75561114|NCT00486668|Drug|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
75561115|NCT00486668|Drug|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
75561116|NCT00486668|Drug|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
75561117|NCT04511598|Device|"Bellus 3D Face Camera"|The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.
75415903|NCT04268901|Device|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
75561118|NCT04511598|Device|"Planmeca ProMax 3D Proface"|The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
75561119|NCT00486681|Device|Accu Chek Inform and Cobas IT 1000|period II (warning activated)
76042458|NCT05285761|Behavioral|Provision of extended information on the conduct of complementary feeding|"Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child."
76042459|NCT05285761|Behavioral|Provision of current official information on complementary feeding|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
76042460|NCT05204875|Radiation|X-ray Velocimetry|X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
75561120|NCT00486707|Behavioral|Questionnaire|A questionnaire will be completed.
75561121|NCT04510935|Procedure|general anesthesia|the patient will receive general anesthesia during surgery in this group.
75561122|NCT04510935|Procedure|local anesthesia|the patient will receive local anesthesia during surgery in this group.
75561123|NCT00491192|Drug|Diclofenac|
75561124|NCT04510974|Other|Spinal Cord Injury|Spinal Cord Injury
75561125|NCT00486746|Behavioral|Lifestyle intervention (physical activity and dietary counseling)|One-year intervention
75561126|NCT00486746|Behavioral|General information on healthy lifestyle habits|A single session
75561127|NCT04510896|Other|InheRET|Primary Appropriate Referral Rates 6-months pre-intervention vs post-intervention Compare appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention vs post- intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
75561128|NCT04510896|Other|Patient Acceptance|Acceptance by Patients Over the course of the study Acceptance measures will include completion rates and levels of ease of use of InheRET by the patient. Impact measures will include uptake of advised risk management interventions. We will qualitatively describe why patients do not follow up with their referral. We will explore patterns of acceptance and impact levels by demographic and clinical data using correlation, t- tests, ANOVA, or their non-parametric equivalents.
75716751|NCT00782028|Other|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
75561129|NCT04510896|Other|Physician Acceptance Survey|Secondary Acceptance by Physicians Over the course of the study Acceptance by physicians will measure the physician effort required to deploy and use InheRET in their respective clinics, and overall satisfaction. Impact measures will include appropriate referral rates and rates of genetic testing. We will qualitatively describe why patients are not referred for genetic counseling if indicated. We will explore patterns in acceptance and impact levels by demographic and clinical data using correlations, t-tests, ANOVA, or their non-parametric equivalents.
76042461|NCT05678413|Procedure|DVIU with paclitaxel injection|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
75561130|NCT00486798|Drug|Quetiapine|
75415904|NCT04268901|Device|Oculus Go|Participants 7-21 years can use the Oculus Go. The visual a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a handheld remote. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
75561131|NCT00486798|Procedure|Rating Scales|
75561132|NCT00486798|Procedure|Self Assessment Form|
75561133|NCT00486798|Procedure|Blood and urine samples|
75561134|NCT00486798|Procedure|Sleeping pattern|
75561135|NCT01301833|Drug|teneligliptin|
75561136|NCT01301833|Drug|glinide|
75561137|NCT01301833|Drug|biguanide|
75561138|NCT01301833|Drug|alpha-glucosidase inhibitor|
75561139|NCT00486785|Drug|Alfuzosin|Alfuzosin 10mg Once Daily for 24 weeks
75561140|NCT04324411|Drug|sirolimus and ATRA|sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
75561141|NCT04324489|Drug|DAS181|Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
76042462|NCT05678413|Procedure|DVIU|DVIU
75561142|NCT00486876|Drug|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
75561143|NCT05643703|Procedure|Suture method|One-layered Suture: Single layer intermittent suture; Two-layered Suture:Single layer intermittent suture plus U type reinforcement stitching
75561144|NCT00491270|Device|VS Sense|An applicator to diagnose pH increase above 5.2
75561145|NCT05643586|Drug|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
75561146|NCT05643586|Drug|Prasugrel|Patient treated with 60 mg prasugrel 12 hours before the procedure
75561147|NCT01242059|Dietary Supplement|yellow pea protein|Served in a tomato soup
75561148|NCT01242059|Other|yellow pea fiber|Served in a tomato soup
75561149|NCT01242059|Dietary Supplement|Control|Served in a tomato soup
75561150|NCT01242072|Drug|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
75415905|NCT04221724|Other|Multicomponent physical exercise program|"The intervention consists of a combined multicomponent exercise program (EP) carried out for 6 months that includes strength, balance, flexibility and functional exercises aimed to improve functioning on daily life activities. The EP will be divided into two parts:~The first 3 months the EP aims to restore the physical condition through the multicomponent exercise program. This program will comprise of upper and lower body strengthening exercises, using external weights for 2-3sets of 8-12repetitions at a progressive intensity of 30-50% of 1RM. In addition, static balance and flexibility exercise will be performed.~From 3th to 6th months, the objective will be to improve autonomy through the functional EP. Strength exercises intensity will be increased to 60-70% of 1-RM, 2-3sets of 8-12repetitions. Attention tasks, temporal space dissociation and dynamic balance exercises will be added to increase the intensity in balance exercises. Flexibility and fine handle will be also performed"
75415906|NCT04220866|Drug|Ulevostinag|IT injection
75415907|NCT04220866|Biological|Pembrolizumab|IV infusion
75415908|NCT04197297|Diagnostic Test|CT and MRI Scans|CT and MRI scans will occur before and after radiation therapy.
75415909|NCT04179136|Dietary Supplement|lignan capsules contain 300 mg flaxseed (SDG) extract|lignan capsules contain 300 mg flaxseed (SDG) extract
75415910|NCT04179136|Dietary Supplement|Placebo treatment matching intervention|Placebo treatment matching intervention
75561151|NCT05643352|Procedure|Barbed reposition pharyngoplasty|Barbed reposition pharyngoplasty was performed in all patients
75561152|NCT00491348|Drug|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
75561153|NCT01242098|Drug|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
75561154|NCT01242098|Drug|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
75561155|NCT01301092|Biological|LY2189265|administered intravenous, subcutaneous or intramuscular
75716752|NCT00782028|Other|Standard Care|
75716753|NCT04014621|Device|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
75561156|NCT01242150|Device|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow >40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
75561157|NCT01242150|Device|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
75561158|NCT05643157|Device|Adaptive optics imaging|adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
75561159|NCT04510623|Other|ARBs and/or ACE inhibitors|This is an observational study only.
75561160|NCT04510623|Other|Usual Care|This is an observational study only.
75561161|NCT05643040|Other|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral block in patients who will have knee surgery.
75561162|NCT05643040|Other|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
75716754|NCT00742040|Drug|Captopril|A rapid 3-day up-titration protocol
75716755|NCT00742040|Drug|Captopril|A slower 9-day up-titration protocol
75734971|NCT03410498|Other|Incremental shuttle walk test|"In the incremental shuttle walk test, participants will have to walk between two cones (10m distance) several times. The time they will have to cover the distance between the two cones (signified by 'bleeps') will become increasingly shorter, until they cannot get to the next cone before the next 'bleep'. This test will last a maximum of 20 minutes.~In the Stroop test, the words of four colours, but written with a different colour, will be projected on the wall in front of participants and they will need to identify the colour of the text and ignore the word itself."
75873328|NCT03032250|Other|Module completion of the Prepare to Care kit|Complete modules of the Prepare to Care kit
75415911|NCT04170946|Other|Talazoparib in Combination with Low Dose Radiotherapy (RT)|Dose escalation model to determine the safety and MTD of talazoparib in combination with low dose RT.
75415912|NCT04170283|Drug|Zanubrutinib|Participants will receive zanubrutinib at a dose of 160 mg twice daily (for a total daily dose of 320 mg), or the last dose level received in the BeiGene parent study.
75415913|NCT04170283|Drug|Tislelizumab|Patients in Australia who participated in a parent study that involved combination therapy of zanubrutinib and tislelizumab will receive tislelizumab at a dose of 200mg every 3 weeks..
75415914|NCT04160052|Drug|Azacitidine|Given SC or IV
75415915|NCT04160052|Drug|Venetoclax|Given PO
75561163|NCT05643040|Other|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
75415916|NCT04152018|Drug|PF-06940434|PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
75561164|NCT05367622|Behavioral|Self-regulation health education|"Insert the continuous blood glucose monitor~Give self-regulation model of health education to assist patients in making a judgmental decision on how to modify health promotion behaviors to reach a good glucose control~Use Telecommunications on the modifications of health promotion behaviors for 7 days"
75561165|NCT05367622|Behavioral|Usual diabetes health education|"Practice self-monitoring of blood glucose~Give usual diabetes health education"
75716756|NCT00777894|Radiation|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
75734972|NCT03409458|Drug|PT-112|"The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15."
76042463|NCT05678335|Drug|Hydroxychloroquine|Oral hydroxychloroquine 200mg twice daily for 12weeks.
76042464|NCT05678335|Drug|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
76042465|NCT02582671|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
76042466|NCT02582671|Drug|Dasabuvir|Tablet
75415917|NCT04152018|Drug|PF-06801591|PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
75415918|NCT04149574|Drug|nivolumab|Specified Dose on Specified Days
75415919|NCT04149574|Other|Placebo|Specified Dose on Specified Days
75415920|NCT04149574|Biological|Bacillus Calmette-Guérin (BCG)|Specified Dose on Specified Days
75415921|NCT04147559|Device|Total Hip Arthroplasty Implant|Single study group either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with other Wright Medical Technology (WMT) or MicroPort Orthopedics Inc (MPO) THA components including acetabular shells, liners and femoral heads.
75415922|NCT04139577|Biological|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
76042467|NCT02582671|Drug|Ribavirin|Tablet
76042468|NCT05696899|Other|STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents|A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
75415923|NCT04121325|Device|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
76042469|NCT05154721|Device|experimental Group - Mila-Learn|Eight tasks are used in Mila-Learn.
76042470|NCT05154721|Device|control Group - Mila-Placebo|Eight tasks similar to Mila-Learn are used in the placebo group
75415924|NCT04115384|Drug|Novolin-R insulin|Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
75561166|NCT02274350|Radiation|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
76042471|NCT02585713|Drug|Apixaban|Given PO
76042472|NCT02585713|Drug|Dalteparin|Given SC
76042473|NCT02585713|Other|Questionnaire Administration|Ancillary studies
76042474|NCT05032495|Other|Surveys|Surveys to evaluate prior experience, opinions and intervention acceptability.
76042475|NCT05032495|Other|Focus group|To answer any questions and discuss topics covered in the standard presentation.
76042476|NCT05078671|Drug|Olaparib|olaparib treatment
76042477|NCT05078671|Drug|Cobicistat|Pharmacokinetic booster
76042478|NCT02579863|Biological|Pembrolizumab|IV infusion
76042479|NCT02579863|Drug|Lenalidomide|oral capsules
76042480|NCT02579863|Drug|Dexamethasone|oral tablets
75415925|NCT04113733|Other|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
75415926|NCT04075149|Drug|Spironolactone|Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if > 60 kg, 100 mg twice daily.
75415927|NCT04060199|Drug|Viltolarsen|IV infusion
75415928|NCT04060199|Drug|Placebo|IV infusion
75415929|NCT04039113|Biological|Tezepelumab|Tezepelumab subcutaneous injection
75415930|NCT04039113|Other|Placebo|Placebo subcutaneous injection
75561167|NCT04510818|Drug|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
75561168|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
75415931|NCT04028570|Radiation|Varying Doses of Background and Boost RT|3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
75415932|NCT04025554|Drug|Anakinra|100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.
75415933|NCT04025372|Drug|Bicalutamide|Bicalutamide is categorized as an antiandrogen. Antiandrogens are substances that block the effects of testosterone. Cancer of the prostate depends on the male hormone testosterone for its growth. If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.
75561169|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
75873329|NCT03032250|Other|Quality-of-Life Assessment|Ancillary studies
75561170|NCT01243307|Drug|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
75561171|NCT00486941|Behavioral|Exercise and diet - based on DPS and DPP|
75561172|NCT05642689|Other|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
75561173|NCT05642689|Other|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
75415934|NCT04025372|Drug|GnRH Agonist|In men, GnRH agonists cause the testicles to stop making testosterone. Some GnRH agonists are used to treat prostate cancer.
75415935|NCT04025372|Radiation|Radiation Therapy|Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
75415936|NCT04025372|Drug|Darolutamide|Darolutamide belongs to a class of drugs called androgen receptor inhibitors. In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
75415937|NCT04019002|Drug|Hyperpolarized 13C Pyruvate|Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
75415938|NCT04017351|Other|Artificial Intelligence Virtual Assistant|Virtual assistance application for subjects to ask questions and get information regarding planned surgery
75415939|NCT04004611|Drug|Mirikizumab|Administered IV and SC
75415940|NCT04004364|Other|Coordinated Specialty Care (CSC)|CSC is an integrated and team-based treatment model for first episode psychosis elements include psychotherapy, supported employment and education, family education and support, and pharmacotherapy.
75415941|NCT03994770|Diagnostic Test|Balanced Reach Assessment and Training Protocol|Three one-hour training sessions for one week in the Balanced Reach Training Protocol
75415942|NCT03951259|Drug|SM934|In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
75561174|NCT00486915|Procedure|Left Atrial Appendage Ligation|
75561175|NCT01243502|Drug|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
75561176|NCT01243502|Drug|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
75734973|NCT03409458|Biological|avelumab|Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.
75734974|NCT03406897|Drug|Cholecalciferol|Oral Administration
75734975|NCT03406897|Drug|Omega 3 fatty acid|Oral Administration
75873330|NCT03032250|Other|Survey Administration|Ancillary studies
75561177|NCT01300819|Other|Placebo|"Placebo patches of 2, 4, 6 & 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
75873331|NCT03032250|Other|Salivary cortisol collection|Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
75873332|NCT03645512|Behavioral|Corporate Athlete Resilience (CAR) Training Program|A 1-day training program developed by the J&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
75415943|NCT03951259|Drug|Placebos|The placebo pills are made identical to the investigating SM934 in appearance.
75873333|NCT03444155|Dietary Supplement|Natural Panmol-B-Complex|Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
75415944|NCT03949660|Device|Stimulation for blood pressure without stand|Consists of 80 daily training sessions using epidural stimulation optimized for blood pressure for up to 6 hours of stimulation a day.
75415945|NCT03949660|Device|Stimulation for blood pressure with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
75415946|NCT03949660|Device|Stimulation for trunk and core without stand|Consists of 80 daily training sessions using epidural stimulation optimized for trunk/core/voluntary function for up to 6 hours of stimulation a day.
75415947|NCT03949660|Device|Stimulation for trunk or core with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
75415948|NCT03948061|Other|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
75415949|NCT03948061|Other|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
75415950|NCT03939767|Drug|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
75415951|NCT03918447|Drug|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
75415952|NCT03918447|Drug|Placebo oral capsule|Capsule containing an inert placebo
75415953|NCT03918382|Other|Electronic Patient-Reported Outcome|Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
75415954|NCT03914820|Procedure|HIPEC CO2 surgery|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
75415955|NCT03914820|Procedure|Standard surgery|Standard surgery without HIPEC CO2
75415956|NCT03914820|Drug|Mitomycin|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
75415957|NCT03907046|Drug|Apixaban|Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.
75415958|NCT03907046|Drug|Aspirin|Aspirin is an oral antiplatelet drug.
75415959|NCT03895359|Radiation|Stereotactic Body Radiation|For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
75415960|NCT03895359|Drug|Transarterial Chemoembolization|Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
75561178|NCT01300819|Drug|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
75561179|NCT00486980|Drug|Peramivir 150mg|
75561180|NCT00486980|Drug|Peramivir 300mg|
75716757|NCT00777894|Radiation|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
75415961|NCT03891966|Procedure|Rigid Splint|50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
75415962|NCT03891966|Procedure|Soft Dressing|50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
75415963|NCT03884439|Drug|Infliximab [infliximab biosimilar 3]|<Crohn's disease> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. <Ulcerative colitis> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
75561181|NCT00486993|Behavioral|Dietary and nutritional modification|
75561182|NCT00486993|Behavioral|Stop smoking|
75561183|NCT00486993|Behavioral|Regular physical activities|
75561184|NCT00486993|Behavioral|Weight reduction to normal ranges|
75561185|NCT00486993|Behavioral|Regular intake of polyphenols, esp. from Ilex paraguayensis|
75561186|NCT01300741|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
75561187|NCT01300741|Device|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
75561188|NCT01300741|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
75561189|NCT02275962|Drug|K-877|
75561190|NCT02275962|Drug|Rifampin|
75561191|NCT00487058|Drug|Gimatecan|
75561192|NCT00487032|Drug|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
75561193|NCT00487032|Drug|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
75561194|NCT00487032|Drug|Prazosin hydrochloride|Prazosin 1mg one dose only
75561195|NCT00487032|Drug|Placebo to Prazosin|Placebo 1 tablet one dose only
75561196|NCT05642377|Drug|HGR4113|Once-daily oral administration
75561197|NCT05642377|Drug|Placebo|Once-daily oral administration
75561198|NCT00491426|Drug|Ampicillin|Drug prescribed per routine medical care.
75561199|NCT00491426|Drug|Metronidazole|Drug prescribed per routine medical care.
75561200|NCT00491426|Drug|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
75415964|NCT03859427|Drug|Carfilzomib|Once weekly IV over 30 minutes on day 1, 8 and 15 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 day 1 and 56 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
75415965|NCT03859427|Drug|Carfilzomib|Twice weekly IV over 10 minutes on day 1, 2, 8, 9, 15 and 16 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 27 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
75415966|NCT03859427|Drug|Lenalidomide|Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
75415967|NCT03859427|Drug|Dexamethasone|Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
75415968|NCT03832855|Biological|pING-hHER3FL|Plasmid vaccine containing HER3
75415969|NCT03824938|Drug|Aspirin 650mg Oral Capsule|A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
75415970|NCT03824938|Drug|Acetaminophen Tablet 650mg|A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
75415971|NCT03824938|Other|Placebo|A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
75415972|NCT03766425|Drug|Aflibercept|subconjunctival injection
75415973|NCT03766425|Drug|Mitomycin|subconjunctival injection
75415974|NCT03749447|Drug|Bardoxolone methyl|Bardoxolone methyl capsules
75561201|NCT00491426|Drug|Acyclovir|Drug prescribed per routine medical care.
75415975|NCT03705806|Radiation|Radiation combined with immunotherapy|The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
75415976|NCT03674047|Drug|ruxolitinib|Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
75415977|NCT03638167|Biological|EGFR806-specific chimeric antigen receptor (CAR) T cell|Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
75415978|NCT03636373|Drug|Etanercept|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
75415979|NCT03636373|Drug|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
75415980|NCT03631706|Drug|M7824|Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
75415981|NCT03631706|Drug|Pembrolizumab|Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
75561202|NCT00491426|Drug|Amphotericin B|Drug prescribed per routine medical care.
75561203|NCT00491426|Drug|Ambisome|Drug prescribed per routine medical care.
75561204|NCT00491426|Drug|Anidulafungin|Drug prescribed per routine medical care.
75561205|NCT00491426|Drug|Caspofungin|Drug prescribed per routine medical care.
75561206|NCT05642338|Diagnostic Test|WATS3D|the WATS3D brush samples the esophagus by abresing the tissue. the brush is directed through the workingchanel of endoscope into the oesophagus
75561207|NCT05642299|Device|MBCI-SR|Participants will be asked to wear and EEG+NIRS cap and a soft robotic glove on their stroke-impaired hand. The participant will be instructed to ask to imagine to picture moving the stroke-imparied hand in the mind. The brain signal (EEG and NIRS data) will be recorded as a reference. When the participant pictures this move again, upon detection of such imagined move by MBCI-SR system, the glove will be activated and assists the participants to perform a specific upper limb task based on individual ability. There are six different activities of daily living (ADL)-oriented tasks enacted through a virtual arm and virtual objects, which formed the visual feedback for the participants. These tasks include scanning goods, moving an object upward to a cabinet, using two hands to move a towel, pouring of water into a cup, eating action and fine motor movement of picking up a small block using two fingers. Training intensity is 1.5 hours for 3 times a week for 6 weeks, a total of 18 sessions.
75561208|NCT02274363|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
75716758|NCT00777894|Radiation|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
75873334|NCT03444155|Dietary Supplement|Synthetic Vitamin B-Complex|Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
75415982|NCT03579030|Drug|Placebo oral capsule|Placebo capsule matched to an RTA 1701 capsule
75415983|NCT03579030|Drug|RTA 1701 capsules|Capsule containing RTA 1701, multiple dosages
75415984|NCT03560310|Drug|Ticagrelor 90mg twice daily and ASA 75-100 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
75415985|NCT03560310|Drug|ASA 75-160 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
75561209|NCT00487097|Dietary Supplement|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
75873335|NCT03644810|Diagnostic Test|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
75873336|NCT03644810|Diagnostic Test|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
75415986|NCT03470675|Drug|Epidural saline + IV saline|Sterile saline injection in the epidural catheter and in the intravenous catheter
75415987|NCT03470675|Drug|Epidural morphine 3 mg + IV saline|Morphine 3 milligrams injection in the epidural catheter and sterile normal saline intravenous catheter
75561210|NCT01300546|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
75716759|NCT00926757|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
76042481|NCT05677945|Drug|3Mixtatin paste: Simvastatin mixed with modified triple antibiotic|"Drying the mucosa with gauze,topical anesthesia will be applied.~Administration of local anesthesia with vasoconstrictor.~Rubber dam isolation.~Caries removal & access cavity using a round bur mounted on a high-speed contra with coolant.~Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~Radicular section will be kept untouched,no instrumentation.~Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~Drying the access cavity with sterile cotton pellets.~Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier & condensed over orifices using a moist cotton pellet.~Cavity sealing with RMGI capsules.~Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
75415988|NCT03470675|Drug|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
75415989|NCT03456063|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase"
75415990|NCT03456063|Drug|Placebo Comparator|Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
75415991|NCT03456063|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
75561211|NCT01300546|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
75561212|NCT00487071|Device|Anal fistula plug|
75561213|NCT05642104|Drug|Neoadjuvant therapy|all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
75561214|NCT00487110|Drug|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
75561215|NCT00487110|Drug|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
75561216|NCT00487136|Drug|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
75716760|NCT00926757|Drug|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
75415992|NCT03456063|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
75415993|NCT03456063|Drug|Carboplatin|Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
75561217|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
75561218|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
75561219|NCT02276001|Drug|K-877|
75415994|NCT03456063|Drug|Cisplatin|Cisplatin 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
75561220|NCT02276001|Drug|Cyclosporine|
75561221|NCT00491543|Drug|ALT-2074|
75561222|NCT02276118|Device|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
75561223|NCT02276118|Device|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
75561224|NCT00491582|Drug|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
75561225|NCT00491621|Procedure|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
75561226|NCT04510155|Behavioral|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 1 day
75561227|NCT00487175|Drug|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
75561228|NCT00487227|Drug|caffeine|
75561229|NCT00487227|Drug|Placebo|
75561230|NCT00487266|Other|Acupuncture|Acupuncture of low back and legs.
75415995|NCT03456063|Drug|Gemcitabine|Gemcitabine 1250 mg/m^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
75415996|NCT03448796|Procedure|HTO|Group that receives high tibial osteotomy combined with supervised physiotherapy as treatment.
75415997|NCT03448796|Other|Supervised physiotherapeutic program|Group that receives only supervised physiotherapy as treatment.
75415998|NCT03418818|Drug|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after their radiation treatment.
75415999|NCT03418818|Drug|Pimonidazole|Pimonidazole is a drug that will attached to areas in the tumour that are low in oxygen. When this occurs, the areas of the tumour that are low in oxygen can be more easily found and studied after surgical removal.
75416000|NCT03417284|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo HSCT
75561231|NCT00491660|Behavioral|supine positioning|
75561232|NCT00491660|Behavioral|lateral positioning|
75561233|NCT00487344|Procedure|Non-Personalized Meal Planning|
75561234|NCT00487344|Procedure|Personalized Meal Planning and Dietetic Consultation|
75561235|NCT01300351|Drug|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
75561236|NCT01300351|Drug|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
75561237|NCT00487253|Drug|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
75561238|NCT00487253|Drug|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
75561239|NCT04510233|Drug|Ivermectin nasal|Ivermectin nasal spray one ml in each nostril two times daily
75561240|NCT04510233|Drug|Ivermectin oral|Ivermectin oral (one tablet 6 mg three times daily)
75561241|NCT04510233|Other|standard care|oxygen via masks or ventilators
75561242|NCT00487292|Behavioral|naps and pulses of bright light|
75561243|NCT05641909|Drug|Remifentanil|Remifentanil
75561244|NCT05641909|Drug|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
75561245|NCT00487331|Other|Acupuncture|Acupuncture sessions 1-3 times per week.
75416001|NCT03417284|Biological|Filgrastim-sndz|Given SC
76042482|NCT05677945|Drug|3Mix: Modified triple antibiotic mix in propylene glycol|"Drying the mucosa with gauze,topical anesthesia will be applied.~Administration of local anesthesia with vasoconstrictor.~Rubber dam isolation.~Caries removal & access cavity using a round bur mounted on a high-speed contra with coolant.~Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~Radicular section will be kept untouched,no instrumentation.~Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~Drying the access cavity with sterile cotton pellets.~Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier & condensed over orifices using a moist cotton pellet.~Cavity sealing with RMGI capsules.~Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
75561246|NCT00487331|Behavioral|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
75561247|NCT05639452|Other|Data collection for developing an algorithm for an Early Warning Score|Data collection of patient parameters (heart rate, respiratory rate, clinical outcomes (death, transfer to intensive care unit, adverse events like sepsis, infection, heart attack))
75561248|NCT05639179|Biological|UCAR-T Cells|"UCAR-T Cellswill be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one:1×10^6 cells/kg;Dose level two:2×10^6 cells/kg;Dose level three:5×10^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of UCAR-T Cells at the best dose verified in the first portion."
75561249|NCT04510077|Behavioral|SmartQuit Smoking and Tobacco Cessation Program|Use SmartQuit program
75416002|NCT03417284|Drug|Melphalan Hydrochloride|Given IV
75416003|NCT03383133|Drug|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
75416004|NCT03350607|Other|Non interventional study|Non interventional study (collect of data)
75416005|NCT03281369|Drug|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
75561250|NCT04510077|Other|Survey Administration|Ancillary studies
75561251|NCT05637892|Other|No intervention|This is a prospective observational study with no intervention
75561252|NCT02274389|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
75561253|NCT05637619|Device|Monolithic Zirconia|Maxillary or/and mandibular screw retained zirconia monolithic prostheses supported by at least 4 implants
75561254|NCT05637619|Device|Hybrid-Acrylic|Maxillary or/and mandibular screw retained hybrid prostheses supported by at least 4 implants;
75561255|NCT05637619|Behavioral|Dentate Patients|Dentate Patients with natural dentition or tooth supported crowns
75561256|NCT02276196|Drug|Lixisenatide|GLP-1 receptor agonist
75416006|NCT03281369|Drug|Leucovorin|Leucovorin: 100 mg/m^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
75416007|NCT03281369|Drug|Oxaliplatin|Oxaliplatin: 100 mg/m^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
75416008|NCT03281369|Drug|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
75416009|NCT03281369|Drug|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
75416010|NCT03281369|Biological|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
75561257|NCT02276196|Drug|Insulin glulisine|Insulin analogue
75561258|NCT00487370|Procedure|Implantation of gold beads around a knee through needles|
75561259|NCT00487370|Procedure|Sham implantation: Insertion of needles around a knee|
75561260|NCT00487422|Drug|prucalopride|2 mg o.d.
75561261|NCT00487422|Drug|Prucalopride|4 mg o.d.
75561262|NCT00487422|Other|Placebo|o.d.
75561263|NCT00491699|Drug|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
75561264|NCT05620615|Other|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
75873337|NCT03644810|Procedure|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
75416011|NCT03281369|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
75416012|NCT03281369|Biological|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
75416013|NCT03281369|Drug|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
75416014|NCT03281369|Drug|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
75416015|NCT03281369|Drug|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
75416016|NCT03281369|Drug|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
75416017|NCT03281369|Drug|Cisplatin|Cisplatin: 80 mg/m^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
75416018|NCT03281369|Drug|Tiragolumab|Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
75416019|NCT03281369|Drug|5-Fluorouracil (5-FU)|5-FU 800 mg/m^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
75561265|NCT00506181|Drug|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
75561266|NCT00506181|Drug|Placebo|
75561267|NCT00487409|Procedure|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
75561268|NCT00487409|Procedure|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
75561269|NCT00623662|Other|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
75561270|NCT00623662|Other|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
75561271|NCT02274402|Biological|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
75416020|NCT03264079|Drug|Bardoxolone methyl capsules 10 mg|One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
75561272|NCT00491777|Device|Noninvasive Hemodynamic Patient Monitor|
75561273|NCT04327531|Behavioral|turkish physicians|turkish physicians, who work active in pandemic hospital.
75561274|NCT04697355|Dietary Supplement|naringenin and beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
75561275|NCT00491816|Drug|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
75561276|NCT00487500|Device|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
75561277|NCT00491855|Drug|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
75561278|NCT00491855|Drug|Oxaliplatin|Starting dose level 25 mg/m^2 given intraperitoneally on day 2.
75873338|NCT03017898|Procedure|Laser Coagulation|Laser coagulation of anal fistula
75416021|NCT03264079|Drug|Itraconazole capsules 100 mg|Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
75561279|NCT00491855|Drug|Paclitaxel|Starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
75561280|NCT04697277|Drug|Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section|
75561281|NCT00487448|Drug|Fludarabine|
75416022|NCT03263130|Other|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
75416023|NCT03262974|Diagnostic Test|PCR|PCR
75416024|NCT03262974|Diagnostic Test|HPLC-UV|HPLC-UV
75561282|NCT00487448|Drug|Cytarabine|
75561283|NCT00487448|Drug|G-CSF|
75561284|NCT00487448|Drug|Idarubicin|
75873339|NCT03715673|Diagnostic Test|von willebrand antigen and activity|Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
75873340|NCT02962128|Dietary Supplement|High Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a high [10% energy] LA-containing diet for 12 weeks.
75873341|NCT02962128|Dietary Supplement|Low Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a low [2.5% energy] LA-containing diet for 12 weeks.
75416025|NCT03195478|Drug|Nivolumab|Specified dose on specified days
75416026|NCT03195478|Drug|Ipilimumab|Specified dose on specified days
75416027|NCT03042156|Radiation|Palliative Radiation Therapy|
75416028|NCT03016871|Drug|Carboplatin|Given IV
75416029|NCT03016871|Drug|Etoposide|Given IV
75416030|NCT03016871|Drug|Ifosfamide|Given IV
75416031|NCT03016871|Other|Laboratory Biomarker Analysis|Correlative studies
75416032|NCT03016871|Biological|Nivolumab|Given IV
75561285|NCT00487448|Procedure|Peripheral blood stem cell transplantation|
75561286|NCT00487448|Procedure|Bone marrow transplantation|
75561287|NCT00506259|Drug|dTR Melatonin (NIH CC PDS)|
75561288|NCT00506259|Device|Phototherapy (Bright Light)|
75561289|NCT00506259|Drug|Melatonin CR|
75561290|NCT00506298|Drug|bezafibrate + diflunisal|bezafibrate + diflunisal
75561291|NCT00506298|Drug|bezafibrate + placebo|bezafibrate + placebo
75561292|NCT01242215|Device|ipragliflozin|oral
75561293|NCT01242215|Drug|Placebo|oral
75561294|NCT01242215|Drug|Sulfonylurea|oral
75561295|NCT00487617|Procedure|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
75561296|NCT00491933|Procedure|Quantiferon-TB Gold assay|
75561297|NCT00491933|Procedure|Tuberculin skin test|
75561298|NCT01242228|Drug|ipragliflozin|oral
75561299|NCT01242228|Drug|DPP-4 inhibitor|oral
75561300|NCT02274428|Drug|pneumostem|human umbilical cord blood derived mesenchymal stem cells
75716761|NCT00746408|Other|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
75716762|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
75873342|NCT02898116|Drug|Ensartinib|Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
75873343|NCT02898116|Drug|Durvalumab|During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
75561301|NCT00506337|Drug|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
75561302|NCT01316354|Other|Bread types|Bread with 50 g available carbohydrate
75561303|NCT00487526|Procedure|duodenal jejunal bypass|
75561304|NCT00491465|Behavioral|Intensive Physical activity|
75561305|NCT00491465|Behavioral|Control- regular physical activity|
75561306|NCT01242306|Drug|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
75561307|NCT01242345|Device|Capnography|Monitoring of the capnography curve for early detection of apnea
75561308|NCT04511364|Other|Clinical imaging is performed during the 24 and 60 month follow-up visits|X-ray and DXA scan
75716763|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|"IV infusion of IGIV, 10% to determine pharmacokinetics~Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
75716764|NCT00929955|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
75716765|NCT00929955|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
75716766|NCT00929955|Drug|Placebo|Placebo added to TAU
75416033|NCT03004443|Drug|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
75416034|NCT03004443|Drug|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
75416035|NCT02869841|Drug|Levobupivacaine continuous infusion|Levobupivacaine continuous infusion to rectus sheath catheters
75716767|NCT00742118|Procedure|Colic biopsies|colic biopsies and analysis
75716768|NCT00784914|Drug|temsirolimus|Receive temsirolimus IV
75416036|NCT02869841|Drug|levobupivacaine bolus dosing|Levobupivacaine bolus dosing to rectus sheath catheters
75416037|NCT02869841|Drug|single bolus of levobupivacaine|Levobupivacaine single dose to rectus sheath catheters
75716769|NCT00784914|Other|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
75716770|NCT00784914|Other|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
75873344|NCT03717701|Drug|metformin|Patients will take metformin single dose of 1000 mg orally once a day
75416038|NCT02869841|Other|Placebo|No rectus sheath analgesia
75416039|NCT02861755|Behavioral|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
75416040|NCT02861755|Behavioral|5-week Emotion Reporting|
75561309|NCT00492011|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
75561310|NCT00492011|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
75561311|NCT00492011|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
75561312|NCT00492011|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
75416041|NCT02798029|Radiation|Frameless Fractionated Stereotactic Radiation Therapy|
75416042|NCT02793492|Device|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
75416043|NCT02701699|Biological|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
75873345|NCT03717701|Drug|esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day
75416044|NCT02666963|Drug|RTA 901 Capsules, 10 or 40 mg|
75561313|NCT01242254|Biological|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
75561314|NCT04513353|Device|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to total knee arthroplasty post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 3 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 3 to 12 weeks post surgery."
75561315|NCT04513353|Other|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
75561316|NCT00492128|Drug|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
75561317|NCT00487734|Radiation|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level <500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
75561318|NCT00487734|Drug|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
75416045|NCT02666963|Drug|Placebo|
75416046|NCT02629692|Drug|Vodobatinib (K0706) capsules|"Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily."
75416047|NCT02596490|Behavioral|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
75561319|NCT01242293|Other|0.9% Saline with glucose 5%|intravenous hydration at a rate of 125 ml per hour during labor
75716771|NCT04060238|Diagnostic Test|Anomaloscope (colour vision test)|"The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)"
75716772|NCT00784992|Procedure|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
75873346|NCT03717701|Drug|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
75873347|NCT04114110|Other|RTLS data|data extraction from RTLS
75873348|NCT03931902|Device|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
75873349|NCT03931902|Device|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
75416048|NCT02596490|Behavioral|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
75561320|NCT01242293|Other|Ringer lactate|intravenous hydration at a rate of 250 ml per hour during labor
75561321|NCT01242293|Other|Ringer lactate - Controls|intravenous hydration at a rate of 125 ml per hour during labor
75561322|NCT01300234|Drug|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
75873350|NCT03712085|Other|Abdominal acupuncture|Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.
75416049|NCT02596490|Behavioral|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
75416050|NCT02402920|Drug|Carboplatin|Given IV
75561323|NCT01300234|Drug|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
75561324|NCT04510701|Other|videoscope|a videoscope will be used to evaluate the integrity of the membrane while doing lateral maxillary sinus elevation surgery
75561325|NCT01242332|Drug|Pregabalin|75 mg po 2 hrs before surgery
75561326|NCT00487773|Drug|budesonide|budesonide
75561327|NCT00487773|Drug|D3 vitamin|D3 vitamin
75561328|NCT00487773|Drug|montelukast sodium|montelukast sodium
75561329|NCT00487773|Drug|salbutamol|salbutamol
75561330|NCT01299961|Drug|abatacept|125 mg once a week up to 12 months.
75561331|NCT00487643|Procedure|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
75561332|NCT04327297|Dietary Supplement|Amino acid-based formula|Amino acid based formula is formula which is used as dietary supplement instead of dairy products in cow's milk allergic infants
75561333|NCT00492245|Procedure|PTK with mitomycin in Adenoviral Opacities|
75716773|NCT00745004|Drug|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
75716774|NCT00745004|Drug|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
75416051|NCT02402920|Drug|Cisplatin|Given IV
75416052|NCT02402920|Drug|Etoposide|Given IV
75416053|NCT02402920|Other|Laboratory Biomarker Analysis|Correlative studies
75416054|NCT02402920|Biological|Pembrolizumab|Given IV
75416055|NCT02402920|Procedure|Radiation Therapy|Undergo radiation therapy
75873351|NCT03712085|Other|Sham abdominal acupuncture|Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
75716775|NCT00745160|Other|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
75716776|NCT04060550|Biological|Xolair|This is in vitro mechanistic study. No drug will be given in vivo to patients.
75716777|NCT00921674|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
75716778|NCT00667446|Drug|Leuprolide Acetate 3 Month Depot|
75716779|NCT00742430|Procedure|PCI|percutaneous coronary intervention in stable coronary artery disease
75561334|NCT00487812|Procedure|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
75561335|NCT01299805|Drug|Vortioxetine|Encapsulated tablet
75561336|NCT01299805|Drug|Placebo|Vortioxetine placebo-matching capsules.
75561337|NCT00487682|Drug|ASP2151|oral
75561338|NCT00487682|Drug|Valacyclovir hydrochloride|oral
75416056|NCT02315521|Procedure|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
75561339|NCT00487851|Procedure|surgery|hepaticojejunostomy and gastroenterostomy
75561340|NCT00487851|Procedure|endoscopic strategy|Stent insertion
75561341|NCT01299766|Behavioral|Behavioral Activation (BA)|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
75561342|NCT01299766|Behavioral|Supportive Therapy (ST)|ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
75561343|NCT04512261|Drug|Tucatinib|Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
75561344|NCT04512261|Drug|Pembrolizumab|Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
75561345|NCT04512261|Drug|Trastuzumab|Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
75561346|NCT00492362|Behavioral|ergometer exercise during hemodialysis|
75561347|NCT00492362|Behavioral|pedometer activity outside of hemodialysis|
75416057|NCT02277028|Behavioral|priming and task specific training|This task specific training protocol has been used in several clinical trials.
75561348|NCT04519515|Device|Allergan Vollure|Injection of Allergan Vollure into Atrophic Scars
75561349|NCT00487799|Drug|Ularitide|
75716780|NCT03873168|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in gynecological, urological, vascular, ENT and head and neck surgeries.
75416058|NCT02273375|Drug|MEDI4736|
75416059|NCT02273375|Drug|Placebo|
75416060|NCT02266212|Procedure|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
75561350|NCT04516785|Diagnostic Test|FIT and VOC|Stool sample (FIT) analysed for blood in faeces and urine sample (VOC) analysed for the presence of volatile organic compounds
75561351|NCT05149248|Biological|Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]|HPV vaccination in an alternative schedule for MSM of 1 dose (M0).
75561352|NCT05149248|Biological|Two dose|HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6)
75561353|NCT05149248|Other|Control group|HPV vaccination at 12 months
75561354|NCT05149248|Biological|2 dose vaccination over 6 month|2-dose HPV vaccination regimen over a 6-month period (M0,6)
75561355|NCT01243541|Procedure|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
75561356|NCT01243541|Other|questionnaire administration|Ancillary studies
75561357|NCT01243541|Procedure|quality-of-life assessment|Ancillary studies
75716781|NCT00688844|Drug|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
75716782|NCT02555670|Other|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
75416061|NCT02117063|Behavioral|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
75416062|NCT02113202|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
75416063|NCT02113202|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
75416064|NCT02064764|Device|Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter|
75416065|NCT02064764|Device|Arctic Front Advance™ Cardiac Cryoablation System|
75416066|NCT02029729|Drug|omaveloxolone|
75416067|NCT02029716|Drug|RTA 408 Lotion 0.5%, 1%, 3%|
75716783|NCT00777972|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
75416068|NCT02029716|Drug|Lotion vehicle/placebo|
75416069|NCT01999062|Other|IMRT + CT + MR scan|
75716784|NCT00745238|Other|withdrawal of non-invasive ventilation|Four weeks withdrawal of non-invasive ventilation
75416070|NCT01811043|Behavioral|Guided Meditation|
75416071|NCT01811043|Behavioral|Music|
75416072|NCT01811043|Behavioral|Supportive Dialogue|
75416073|NCT01803542|Radiation|Stereotactic Radiation|Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
75416074|NCT01781468|Drug|armodafinil 150 mg|given orally
75416075|NCT01781468|Other|Placebo|given orally
75416076|NCT01781468|Drug|armodafinil 250 mg|given orally
75416077|NCT01709045|Other|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
75416078|NCT01709045|Radiation|Dual-Energy Computed Tomography (DECT)|
75416079|NCT01709045|Other|Ultrasound|
75416080|NCT01709045|Other|Transcranial doppler|
75873352|NCT03628170|Other|platelet rich fibrin|platelet rich fibrin will be prepared from patient's venous blood and inserted in the centrifuge at 2000 r.p.m. for 12 minutes Then, the Platelet rich fibrin plug will be placed in the socket after extraction for socket preservation covered by platelet rich fibrin membrane.
75416081|NCT01689116|Drug|Bardoxolone Methyl 20mg|Oral
75416082|NCT01689116|Drug|Bardoxolone Methyl 80mg|Oral
75416083|NCT01689116|Drug|Bardoxolone Methyl Placebo|Oral
75416084|NCT01689116|Drug|Moxifloxacin 400mg|Oral
75416085|NCT01689116|Drug|Moxifloxacin Placebo|Oral
75416086|NCT01655186|Drug|Bardoxolone Methyl|
75416087|NCT01655186|Drug|Placebo|
75416088|NCT01598363|Drug|Digoxin|Oral, Day 1 and Day 10
75416089|NCT01598363|Drug|Rosuvastatin|Oral, Day 1 and Day 10
75416090|NCT01576887|Drug|Bardoxolone Methyl 20 mg|Oral, once daily
75416091|NCT01576887|Drug|Placebo|Oral, once daily
75416092|NCT01563562|Drug|Bardoxolone Methyl|Oral, Single dose
75416093|NCT01551446|Drug|Bardoxolone Methyl|Oral, once daily
75416094|NCT01549769|Drug|Bardoxolone Methyl|Oral, once daily
75416095|NCT01545141|Drug|Chemokin Modulatory Regimen (5 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
75416096|NCT01545141|Drug|Chemokin Modulatory Regimen (10 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
75416097|NCT01545141|Drug|Chemokin Modulatory Regimen (20 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
75416098|NCT01503866|Drug|bardoxolone methyl|oral, single dose
75416099|NCT01500798|Drug|20 mg bardoxolone methyl|20 mg, oral, once daily
75416100|NCT01500798|Drug|Placebo|Oral, once daily
75416101|NCT01461161|Drug|bardoxolone methyl|oral, single dose
75416102|NCT01428895|Procedure|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
75416103|NCT01428895|Other|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
75873353|NCT03628170|Other|Free gingival graft|Free gingival graft will be taken from the palate to cover the socket after extraction of the tooth for socket preservation.
75716785|NCT00782262|Dietary Supplement|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
75416104|NCT01422759|Drug|Spironolactone|50-100 mg PO BID (X 12 weeks)
75416105|NCT01421797|Drug|Dexamethasone|1 mg PO
75561358|NCT01243541|Procedure|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
75416106|NCT01421797|Drug|Cortrosyn|single IV bolus of 0.25 mg will be administered
75416107|NCT01404741|Procedure|allogeneic stem cell transplantation|donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
75416108|NCT01404741|Procedure|5-azacytidine until progress|if no donor available 5-azacytidine until progress or toxicities
75416109|NCT01335022|Behavioral|lecture|6 lectures on cardiovascular disease covering obesity, diet & exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
75561359|NCT01243541|Procedure|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
75561360|NCT04518033|Device|Various commercially available face coverings|Various commercially available face coverings
75561361|NCT05149209|Procedure|cervical restoration|A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.
75416110|NCT01279408|Other|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
75416111|NCT00944528|Radiation|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
75416112|NCT00937248|Device|prone pillow and simple ankle fixation device|Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
75416113|NCT00937248|Device|Customized Vacuum Immobilization Device (CVID)|This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
75716786|NCT00778050|Drug|Amoxicillin 600mg|
75873354|NCT03658304|Drug|Mitomycin c|All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
75873355|NCT03422159|Drug|Ascorbic Acid|Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
75416114|NCT00881660|Device|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
75416115|NCT00857662|Device|Onyx|Embolization
75561362|NCT00487877|Device|SenseWear Pro3 Armband|
75561363|NCT00487877|Device|i-button DS2191 H|
75561364|NCT00495209|Other|Qigong|EQT daily for 5 consecutive days prior to surgery.
75561365|NCT05149170|Drug|Anti-PD-1 monoclonal antibody|inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT
75716787|NCT00746486|Drug|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
75416116|NCT00857662|Device|TRUFILL|Embolization
75716788|NCT00746486|Drug|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
75716789|NCT00785148|Drug|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
75716790|NCT00745550|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
75873356|NCT03422159|Drug|Thiamine|Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
75873357|NCT03422159|Drug|Hydrocortisone|Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
75561366|NCT02956226|Drug|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
75561367|NCT02956226|Drug|Placebo|Olive oil and flavors solution.
75716791|NCT00778128|Drug|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
75416117|NCT00777998|Procedure|Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI|"*Multiple myeloma~-> Induction Therapy (max. 8 cycles)~-> Registration of patient, stem cell mobilization, start of donor search~-> Melphalan (200mg/qm) plus autologous PBSCT~-> 2 months later: Melphalan plus allogeneic PBSCT~-> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)~-> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10^6 (MRD) or 5 x 10^5 (MUD) CD3+ cells per kg BW)~-> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)~-> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)~-> Further DLI depending on MRD-measurement"
75416118|NCT00777998|Procedure|auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide|"*Multiple myeloma~-> Induction Therapy (max. 8 cycles)~-> Registration of patient, stem cell mobilization, start of donor search~-> Melphalan (200mg/qm) plus autologous PBSCT~-> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT~-> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)"
75561368|NCT02956226|Drug|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
75561369|NCT04516473|Procedure|Abdominal Body Contouring|These are surgeries that correct for excess skin and its adverse consequences. The surgeries that focus on central area to remove a large hanging pannus is usually called panniculectomies or abdominoplasties; the former is focused on the excision of excess tissue to relieve impairment while the latter is generally considered a cosmetic surgery. The form of the surgery is case dependent and can range from removing apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button.
75561370|NCT00492440|Biological|recombinant interleukin-7|
75561371|NCT00492440|Genetic|gene expression analysis|
75561372|NCT00492440|Genetic|polymerase chain reaction|
75561373|NCT00492440|Genetic|protein expression analysis|
75561374|NCT00492440|Other|flow cytometry|
75873358|NCT03422159|Drug|Sodium Chloride 0.9%|"Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days)."
75416119|NCT00550849|Drug|RTA 402|5 mg oral capsules
75416120|NCT00550849|Drug|RTA 402|25 mg oral capsules
75416121|NCT00550849|Drug|RTA 402|50 mg oral capsules
75416122|NCT00538343|Drug|berubicin hydrochloride (RTA 744)|
75416123|NCT00535314|Drug|RTA 402 Dose1|
75416124|NCT00535314|Drug|RTA 402 Dose2|
75416125|NCT00529438|Drug|Bardoxolone methyl|
75416126|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
75561375|NCT00492440|Other|immunoenzyme technique|
75561376|NCT00492440|Other|immunologic technique|
75561377|NCT00492440|Other|laboratory biomarker analysis|
75416127|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
75416128|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
75416129|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
75416130|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
75561378|NCT00492440|Other|pharmacological study|
75561379|NCT04518501|Drug|Arsenic trioxide Tablet +Fuzuloparib Capsules|Arsenic trioxide Tablet : 0.27*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
75561380|NCT00495248|Behavioral|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
75561381|NCT00495248|Behavioral|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
75416131|NCT00529113|Drug|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
75416132|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
75416133|NCT00529113|Drug|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
75416134|NCT00529113|Drug|Placebo|Placebo capsules x 28 days
75561382|NCT05149053|Dietary Supplement|Hydrolyzed Collagen|Active product was composed of Hydrolyzed Collagen, lemon flavoring, anhydrous citric acid (acidifier), calcium ascorbate (vitamin C), sucralose (sweetener) and stevia (sweetener). One 10.728 g dose provides 10 g of HC and 80 mg of vitamin C.
75561383|NCT05149053|Other|Placebo|Placebo packet contained sucralose (sweetener) and stevia (sweetener) in identical proportions to the active preparation.
75561384|NCT00495287|Drug|cytosine arabinoside|"Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin."
75561385|NCT00495326|Drug|Nevirapine based therapy|"Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"
75561386|NCT00495326|Drug|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
75416135|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
75416136|NCT00527410|Drug|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
75416137|NCT00526812|Drug|RTA 744|Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
75416138|NCT00526812|Drug|RTA 744 injection|Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
75416139|NCT00188539|Procedure|Pre-treatment tumour oxygen measurements (under anesthesia)|
75416140|NCT04453449|Drug|Midazolam|Midazolam given as a sedative during diagnostic lumbar medial branch block
75416141|NCT04366336|Procedure|Blood Flow Restriction Training|Same as Standard PT with the exception that BFRT involves placing the pressure cuff before the start of therapeutic exercises
75561387|NCT00495326|Drug|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|"Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~Continuation phase: 4 months daily H(RMP).~Patients with meningitis will receive Streptomycin instead of E during intensive phase."
75561388|NCT00492479|Drug|Kinerase Pro+Therapy Line day repair, serum, night repair|
75561389|NCT00492479|Drug|Kinerase Pro+Therapy Line Ultra rich day repair|
75561390|NCT00492479|Drug|LubriDerm|
75561391|NCT00506766|Behavioral|Bladder Health Class consisting of 6 weekly group sessions|1 time
75561392|NCT00506766|Behavioral|Practice PFMT and BT|As needed for 4 years
75561393|NCT00506766|Behavioral|Clinic examination for pelvic muscle function|1/year for 4 years
75561394|NCT00506766|Behavioral|Record keeping in 3-day voiding diary|Every 6 months for 4 years
75561395|NCT00495365|Drug|Epoetin alfa|
76042483|NCT05650177|Behavioral|blended Mindfulness-Based Intervention (bMBI)|The blended Mindfulness-Based Intervention (bMBI) is a 24-week online course 'blended' with therapist support via video link. The entire course is completed online and requires no in person contact. The bMBI follows the general structure of Mindfulness-Based Cognitive Therapy (MBCT) with an added emphasis on the cultivation of self-compassion. The bMBI comprises of 9-themed sessions spread out over the 24-weeks. Each session involves: video instructions, written information, psycho-educational exercises, and guided meditation practices. Participants meditate for 30-minutes each day. Additional homework involves short daily activities designed to incorporate mindfulness into daily life and keeping a journal about experiences within and around the practices and exercises. The therapist sessions are every two weeks and last for 45-minutes and help participants overcome any problems they experience.
75416142|NCT04366336|Procedure|Standard Physical Therapy|Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
76042484|NCT05677789|Diagnostic Test|Medical observation|Likely suitable for home treatment
75416143|NCT04364867|Drug|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
75416144|NCT04364867|Drug|Pain Pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the PACU infusing at 4cc/hr. The patient will go home with that device until it runs out.
76042485|NCT05677789|Diagnostic Test|Supportive treatment (BSC)|Consider hospital supervised treatment
76042486|NCT05677789|Diagnostic Test|Intensive care management|Manage in hospital as severe pneumonia
75441505|NCT01635374|Procedure|Per-Oral Endoscopic Esophagomyotomy|In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
76042487|NCT02582515|Drug|D-cycloserine|
76042488|NCT02582515|Drug|Placebo|
75561396|NCT04515927|Drug|JS002|Biological: JS002 Administered by subcutaneous injection
75561397|NCT00492518|Drug|Acetylcysteine|
75561398|NCT00492518|Drug|Theophylline|
75561399|NCT00492518|Drug|Placebo|
76042489|NCT02579629|Drug|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
75561400|NCT05148936|Other|COVID-19 Testing Home-based (Aim 1)|Implementation of Antigen and PCR testing at participant homes
75561401|NCT05148936|Other|COVID-19 Testing Mobile (Aim 1)|Implementation of Antigen and PCR testing at mobile test sites
75561402|NCT05148936|Other|COVID-19 Testing Mobile Approach 1 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - active outreach
75561403|NCT05148936|Other|COVID-19 Testing Mobile Approach 2 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
75561404|NCT00495404|Behavioral|Physician Treatment Guidelines|
75561405|NCT04513860|Drug|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
75561406|NCT00495443|Device|Peterio|
75561407|NCT04510545|Diagnostic Test|Endobrain, Computer Aided Diagnosis (CAD)|Artificial intelligence
75716792|NCT00778128|Drug|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
75716793|NCT00778284|Drug|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
75716794|NCT02563418|Device|Eye-tracking|
75561408|NCT00506805|Drug|SNX-5422|dose escalated, tablets every other day; undetermined duration until disease progression
75561409|NCT00495560|Drug|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
75561410|NCT00506376|Behavioral|Interview|Interview that will take about 20 minutes to complete.
75561411|NCT00495599|Procedure|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
75561412|NCT00506844|Drug|Cetuximab, Irinotecan, Capecitabine|
75716795|NCT00749060|Other|conventional treatment|with our without brace
75716796|NCT00749060|Procedure|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
75416145|NCT04347343|Procedure|Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction|"Subjects will begin a standardized protocol on post-op day 2. Outpatient visits will be 2x/wk for weeks 0-4 and then 1x/wk for weeks 5-8.~Subjects will utilize NMES on the quadriceps in the home setting 2x/day for the first 3-4 weeks during isometric contractions at their highest tolerated intensity. Total treatment will begin at 10 minutes.~At the end of post-op week 2, subjects will be exposed in clinic to BFR on the surgical limb increasing to 80% limb occlusion pressure over weeks 3-4 as tolerated. Initially, BFR and NMES will be performed simultaneously. BFR will then be progressed using active exercises. After completing a safety checklist, subjects will be issued a home BFR unit for use 2x/week (3x total including clinic visit) at which time NMES will be discontinued. BFR exercise intensity will be progressed as tolerated to maintain 20-30% of 1RM."
75716797|NCT00749060|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
75416146|NCT04340739|Other|online patient education teach mindfulness based stress reduction|This is an online self management chronic pain curriculum that presents adapted Mindfulness Based Stress Reduction through videos, audios, and written materials
76042490|NCT02579629|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
75416147|NCT04333888|Behavioral|Neurofeedback|fMRI neurofeedback training of amygdala downregulation
75416148|NCT04283071|Device|Boxed infrared gross kinematic assessment tool|An optical motion capture system, which records the movements of infrared emitting diodes (IREDs) in three-dimensional (3D) space by triangulating images from a pair of infrared cameras
75416149|NCT04233814|Drug|Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)|LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
75416150|NCT04233814|Drug|Placebo|Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
75441506|NCT01635387|Drug|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
75441507|NCT01635400|Drug|Irinotecan|irinotecan 180mg/m2 i.v. over 30 min d1,q2w
75441508|NCT01635413|Behavioral|Exercise Intervention|Undergo strength training classes
75561413|NCT04515693|Other|6 Minutes Walking Test|A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.
75561414|NCT00495833|Behavioral|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
75561415|NCT00495833|Behavioral|Promotional gift|half of participants who go to a fire station will receive a gift card.
75561416|NCT00506961|Drug|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
75561417|NCT00506961|Drug|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
75716798|NCT00749138|Drug|tamoxifen|giving drug tamoxifen
75716799|NCT05001906|Behavioral|Exercise group|The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
75716800|NCT02563340|Other|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
75716801|NCT02563340|Other|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
75441509|NCT01635413|Behavioral|Exercise Intervention|Undergo tai chi classes
75441510|NCT01635413|Behavioral|Exercise Intervention|Undergo stretching and relaxation classes
75441511|NCT01635413|Other|Questionnaire Administration|Ancillary studies
75441512|NCT01635530|Drug|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
75441513|NCT01635530|Drug|Ceftriaxone|2 g intravenous once a day, three weeks
75441514|NCT01635556|Behavioral|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
75441515|NCT01635582|Other|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
75441516|NCT01635582|Other|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
75561418|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
75561419|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
75716802|NCT00782652|Drug|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
75561420|NCT00492635|Drug|Placebo|9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
75561421|NCT00492674|Device|APOS biomechanical gait system|
75561422|NCT00492674|Procedure|Physical Therapy|
75716803|NCT00782652|Drug|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
76042491|NCT02579629|Drug|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
76042492|NCT02579629|Device|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
76042493|NCT05677555|Drug|Colchicine 0.5 MG|A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.
76042494|NCT05677555|Drug|Placebo|A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
75716804|NCT00746642|Device|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
75716805|NCT02562092|Behavioral|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
75716806|NCT02562092|Behavioral|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
75716807|NCT00745706|Device|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
75716808|NCT00785382|Drug|Placebo|Lactulose Placebo
76042495|NCT05696821|Diagnostic Test|Educational intervention|The educational intervention includes a 3-months training program in the use of point-of-care ultrasound tailored to meet the educational needs of general practitioners. The training programs consists of three teaching seminars over a three month time period, a curriculum of 10 POCUS applications, and an online learning platform providing educational support before, during and after the teaching sessions.
76042496|NCT04874857|Other|Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.|Massage application
75441517|NCT01635595|Procedure|Subtotal esophagectomy and gastric pull up|Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
75441518|NCT01635595|Procedure|Subtotal esophagectomy at the azygos vein, total gastrectomy|Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
75441519|NCT01635608|Drug|Acetaminophen|administration of 500 mg paracetamol
75441520|NCT01635608|Drug|Talinolol|administration of 50 mg talinolol
75441521|NCT01635608|Drug|Amoxicillin|administration of 500 mg amoxicillin
75441522|NCT01635608|Other|non-caloric water|administration of 240 ml water
75441523|NCT01635608|Other|caloric water|administration of 240 ml caloric water (containing 25.5 g sucrose)
75441524|NCT01635621|Drug|Olokizumab (OKZ)|"Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~OKZ 120 mg every 2 weeks~OKZ 240 mg every 2 weeks~OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0."
75716809|NCT00785382|Drug|Pregabalin 150 mg|150 mg Q12H x 2 doses
76042497|NCT04874857|Other|Baby oil|Massage application
75716810|NCT00745784|Behavioral|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
75716811|NCT00745862|Behavioral|questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided|This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
75716812|NCT00667368|Drug|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
75716813|NCT00785460|Drug|Benfotiamine|
75716814|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
75716815|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
76042498|NCT05677477|Other|simulation training|A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
75873359|NCT04538040|Drug|Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch|Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.
76042499|NCT05677399|Other|aquatic exercise and peloidotherapy|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
76042500|NCT02343939|Drug|Entospletinib|Tablet(s) administered orally every 12 hours
76042501|NCT02343939|Drug|Daunorubicin|60 mg/m^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles
75416151|NCT04232059|Device|cerebral oximetry|evaluation of the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.
75416152|NCT04212286|Diagnostic Test|Diagnostic CEUS and EOB-MRI|Undergo Sonovue-CEUS and EOB-MRI
75416153|NCT04155216|Behavioral|Relaxation and guided imagery program|Listening to a relaxation and guided imagery program for 25 minutes during hemodialysis treatments.
75416154|NCT04023162|Behavioral|Graded Activity|Active participation of participants, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.
75416155|NCT04023162|Behavioral|Group-based Therapy Exercise|Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise
75561423|NCT00507000|Drug|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
75561424|NCT00507000|Drug|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
75561425|NCT00495872|Drug|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
75561426|NCT00495872|Drug|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
75716816|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
75716817|NCT05264844|Other|Masking tape|IV catheters will be fixed with masking tape
75716818|NCT00785616|Other|MEMS cap monitoring|Electronic monitoring of medication adherence using MEMS caps
75716819|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time signature of each bottle opening.
75873360|NCT04033692|Device|JuggerKnot Mini Soft Anchor|Patient who have been implanted with one or more JuggerKnot Mini Soft Anchor(s) who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc.
75873361|NCT03950024|Diagnostic Test|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
76042502|NCT02343939|Drug|Cytarabine|100 mg/m^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles
76042503|NCT02343939|Drug|Decitabine|20 mg/m^2 administered intravenously
76042504|NCT02343939|Drug|Azacitidine|75 mg/m^2 administered intravenously or subcutaneously
76042505|NCT02397447|Drug|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
76042506|NCT02397447|Drug|Placebo|Placebo: 2000 mg per day for three months
75416156|NCT04023162|Behavioral|Back School|Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
75416157|NCT04002388|Behavioral|activity monitor group|will receive a FitBit and will be asked to wear this for one year
76042507|NCT02397057|Drug|Injectafer|
75561427|NCT00495872|Drug|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
75561428|NCT00495872|Drug|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
75561429|NCT00495872|Drug|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
75561430|NCT00495872|Drug|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
75561431|NCT00495872|Drug|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
75561432|NCT00507039|Procedure|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
75561433|NCT00507078|Procedure|Surgical treatment for OSA|
75561434|NCT00492713|Other|dark chocolate|dark chocolate
75416158|NCT04002388|Behavioral|usual care group|will NOT receive a FitBit
75416159|NCT03993821|Drug|Burosumab|Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.
75561435|NCT00492713|Other|Milk chocolate 1|Milk chocolate 1
75561436|NCT00492713|Other|Milk chocolate 2|Milk chocolate 2
75561437|NCT00507117|Drug|Lunesta|Lunesta 3mg prior to PSG
75873362|NCT03964506|Drug|Hyperbaric oxygen|Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
75416160|NCT03964545|Behavioral|neurofeedback|Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
75416161|NCT03871751|Behavioral|Safe and Sound Protocol|The auditory intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
75416162|NCT03735849|Biological|VRC07-523LS|Administered by intravenous (IV) infusion
75441525|NCT01635621|Drug|Placebo|Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
75561438|NCT00507117|Drug|Placebo control|matching placebo
75561439|NCT00492791|Device|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
75561440|NCT00492830|Drug|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
75561441|NCT01299727|Biological|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
75561442|NCT01299727|Biological|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
75561443|NCT01299727|Biological|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
75561444|NCT00492908|Device|Helistent Titan2 (Titanium coated stent)|Titan2
75441526|NCT01635634|Other|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
75561445|NCT00492908|Device|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
75561446|NCT01299571|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
75716820|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time/date signature of each bottle opening.
75873363|NCT03403751|Drug|Reltecimod 0.5 mg/kg|Single IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL) over approximately 10 minutes
75873364|NCT03403751|Drug|Placebo|Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
75873365|NCT02297412|Drug|Minocycline Hydrochloride|Given PO
75873366|NCT02297412|Other|Placebo|Given PO
75416163|NCT03708159|Device|active tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
75416164|NCT03708159|Other|sham tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
75416165|NCT03691857|Procedure|Ultrasound algorithm (EMERALD-US)|Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
75416166|NCT03663361|Other|SMART Intervention|Ankle rehabilitation with the addition of sensorimotor components
75416167|NCT03663361|Other|Standard of Care Intervention|Ankle rehabilitation focused on restoring range of motion, strength and balance
75441527|NCT01635647|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 1 x 10^8 pfu heterologous prime-boost immunisation
75561447|NCT01243736|Drug|Combination Prep|"combination bowel preparation, which consists of:~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
75561448|NCT02274467|Device|Trans-catheter electric stimulation test|
75561449|NCT01299376|Drug|L50/H12.5/A5|
75716821|NCT00567567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
75716822|NCT00567567|Drug|Carboplatin|Given IV
75716823|NCT00567567|Drug|Cisplatin|Given IV
75716824|NCT00567567|Drug|Cyclophosphamide|Given IV
75716825|NCT00567567|Drug|Doxorubicin Hydrochloride|Given IV
75716826|NCT00567567|Drug|Etoposide|Given IV
75716827|NCT00567567|Radiation|External Beam Radiation Therapy|Undergo EBRT
75873367|NCT02297412|Other|Quality-of-Life Assessment|Ancillary studies
76042508|NCT02397057|Other|Placebo|
75441528|NCT01635647|Biological|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
75441529|NCT01635660|Device|Intubation|Tracheal Intubation with the assigned video laryngoscope
75561450|NCT01299376|Drug|L50/H12.5|
75561451|NCT01299376|Drug|Placebo to L50/H12.5/A5|
75561452|NCT01299376|Drug|Placebo to L50/H12.5|
75561453|NCT04324450|Device|MRI|"The MRI protocol is composed of:~T1-weighted anatomical sequences~DTI sequences~resting functional MRI~3D MR spectroscopic imaging"
75561454|NCT04324450|Behavioral|Cognitive assessment|Battery of neuropsychological tests
75716828|NCT00567567|Biological|Filgrastim|Given IV or SC
75716829|NCT00567567|Drug|Isotretinoin|Given orally
75716830|NCT00567567|Other|Laboratory Biomarker Analysis|Correlative studies
75716831|NCT00567567|Drug|Melphalan|Given IV
75873368|NCT02297412|Other|Questionnaire Administration|Ancillary studies
76042509|NCT02343549|Device|NovoTTF100A|
76042510|NCT02343549|Drug|Bevacizumab|
75561455|NCT02890537|Drug|Core decompression/PREOB® implantation|All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
75716832|NCT00567567|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
76042511|NCT02343549|Drug|Temozolomide|
76042512|NCT02343159|Drug|dimethyl fumarate|120 mg and 240 mg delayed release capsules
76042513|NCT02343159|Device|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
76042514|NCT02343159|Behavioral|Adherence counseling|A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
76042515|NCT02395653|Drug|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
75416168|NCT03572621|Other|Therapeutic education|"Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid."
75416169|NCT03572621|Other|Collection of data concerning their sexuality|Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
75561456|NCT02890537|Drug|Core decompression/BMC implantation|All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
75561457|NCT00492947|Biological|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
75561458|NCT02890225|Procedure|3 days after|in 3 days after RIRS.
75561459|NCT02890225|Procedure|10days after|in10 days after RIRS.
75561460|NCT02890225|Procedure|EPVL performed in30days after RIRS|Patients in Group C undergo EPVL in630days after RIRS.
75561461|NCT01299025|Other|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
75561462|NCT00492986|Drug|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
75561463|NCT04324528|Device|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
75716833|NCT00567567|Other|Pharmacological Study|Correlative studies
75716834|NCT00567567|Drug|Thiotepa|Given IV
75716835|NCT00567567|Drug|Topotecan Hydrochloride|Given IV
75716836|NCT00567567|Drug|Vincristine Sulfate Liposome|Given IV
75716837|NCT00666198|Drug|SILDENAFIL|"Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration."
75716838|NCT00778596|Drug|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
76042516|NCT01664923|Drug|Enzalutamide|160 mg, daily, by mouth.
76042517|NCT01664923|Drug|Bicalutamide|50 mg, daily, by mouth
76042518|NCT04743583|Device|Endosonography B-mode examination|Endobronchial ultrasound (EBUS) or Endoscopic with bronchoscope (EUS-B) B-mode examination and sampling, when indicated, of lymphadenopathy
76042519|NCT05696665|Other|conventional therapy|Patients will be kept on conventional therapy and no added drugs will be given
75716839|NCT00778596|Drug|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
75561464|NCT04324528|Device|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
75716840|NCT00785694|Drug|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
75716841|NCT00778674|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
75734976|NCT03404895|Device|Conventional Therapy|Local wound care consists of at least once daily dressing Occasionally, a limited bedside debridement is indicated to excise small quantity of devitalized tissues and to provide better drainage. Antibiotic therapy including both gram-positive and gram-negative coverage when the DFU appears infected is guided by wound cultures and when necessary, Infectious Disease consultation. Debridement and amputation will be performed as clinically indicated. To promote healing after the more acute processes have been addressed, pressure offloading is frequently helpful in the healing of DFU. Pressure offloading treatment ranges from special dressings and devices to special diabetic foot wares. Offloading will be utilized as indicated.
75873369|NCT03644576|Drug|ozanimod|ozanimod
76042520|NCT05696665|Drug|Saffron and Chamomile|Patients will be given saffron and chamomile in capsule formulation twice daily
75416170|NCT03572621|Other|Participation|Participation in a therapeutic education day.
75416171|NCT03564067|Device|Soterix Medical tDCS mini-Clinical Trials system (mini-CT)|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.
75416172|NCT03564067|Behavioral|Computerized CBT (cCBT)|Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
75416173|NCT03552393|Drug|Mircera|The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.
75561465|NCT01298596|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
75561466|NCT01298596|Procedure|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
75561467|NCT02890108|Dietary Supplement|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
75561468|NCT02890108|Dietary Supplement|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
76042521|NCT05696665|Drug|Crocin and Apigenin|Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
75561469|NCT00493259|Behavioral|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
75734977|NCT03404895|Device|Venous Stent(s)|After PVOO is confirmed by venography and IVUS, and patient subject is randomized to conventional therapy and stent placement, stent placement is performed immediately at the same sitting.
75734978|NCT03403894|Behavioral|Asking caregivers in their practice|A questionary is given to caregivers
75873370|NCT03644576|Drug|Pseudoephedrine|Pseudoephedrine
75873371|NCT03644576|Drug|ozanimod placebo|ozanimod placebo
75873372|NCT04812821|Other|questionnaire|questionnaire post delivery
76042522|NCT04465201|Device|Impella CP with Smart Assist (Circulatory Support System)|Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
75561470|NCT00493259|Behavioral|Depression Scale for Children (CES-DC)|questionnaire
75561471|NCT04324138|Drug|Jianpi Qinghua granules|3 times a day and 1 hour after a meal, for 4 weeks
75416174|NCT03524170|Drug|Bintrafusp Alfa|Given IV
75416175|NCT03524170|Radiation|Radiation Therapy|Undergo radiation therapy
75416176|NCT03490331|Other|Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)|Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
75416177|NCT03336983|Drug|Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid
75416178|NCT03336983|Drug|Enzalutamide|Patients from both arms will be treated with LHRH-A + Enzalutamide
75416179|NCT03333382|Device|Plastic biliary stent|Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.
75416180|NCT03333382|Device|FCSEMS|FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.
75416181|NCT03301493|Other|Genomic testing|Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice
75416182|NCT03283813|Dietary Supplement|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
75416183|NCT03283813|Drug|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
75561472|NCT04324138|Drug|Jianpi Qinghua placebo granules|3 times a day and 1 hour after a meal, for 4 weeks
75561473|NCT00493337|Behavioral|advanced adherence counseling+reminder|
75561474|NCT00493337|Device|Compliance Card|
75561475|NCT01243814|Device|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
75561476|NCT01243814|Device|placebo injection|joint injection with saline solution for placebo
75561477|NCT01243853|Dietary Supplement|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
75561478|NCT01298518|Drug|PF-04620110|5 mg of PF-04620110 given once daily
75561479|NCT01298518|Drug|PF-04620110|2.5 mg of PF-04620110 given twice daily
75561480|NCT01298518|Drug|Placebo|Matching placebo giving for 4 weeks
75873373|NCT03418727|Drug|Brimonidine|Two products delivered in sequence twice daily.
75873374|NCT03418727|Drug|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
75873375|NCT03418727|Drug|sodium carboxymethylcellulose|Placebo given twice daily.
75873376|NCT03418727|Drug|Corticosteroid Eye Drop|Eye drop to be administered after Brimonidine in treatment arm 1
75873377|NCT01180374|Drug|Cannabidiol|Active Cannabidiol 5mg.
75561481|NCT01243970|Drug|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg *~* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
75561482|NCT01243970|Drug|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. *~* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
75561483|NCT04515576|Drug|LY3493269|Administered SC
75561484|NCT04515576|Drug|Dulaglutide|Administered SC
75561485|NCT04515576|Drug|Placebo|Administered SC
75561486|NCT01298362|Drug|Aromatase Inhibitors|
75716842|NCT00778752|Drug|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
76042523|NCT04403347|Dietary Supplement|Innovative Dietary Formulation (Patent ID: CN110250417A)|In addition to regular diets and usual care of hypertension, additional innovative natural dietary formulation derived from tartary buckwheat will be orally taken 3 times per day.
75561487|NCT01298362|Drug|Chemotherapy|
75561488|NCT00493376|Procedure|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
75561489|NCT00493376|Procedure|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
75561490|NCT00493376|Procedure|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
75716843|NCT00926835|Drug|paroxetine|6 weeks, 20-50mg/day
76042524|NCT04403347|Drug|Losartan 50mg per day|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
76042525|NCT05677009|Device|BUFEO system|In the BUFEO Condition, the subject will receive oxygen through the BUFEO system.
75561491|NCT00493376|Procedure|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
75561492|NCT00493415|Drug|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
75561493|NCT00493415|Drug|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
75561494|NCT01244009|Drug|MK-4827|MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
75716844|NCT00926835|Drug|Escitalopram|10-20mg/day for 6 weeks
76042526|NCT05677009|Other|Standard of Care|Standard Condition is the baseline apparatus utilized by the subject at the time of enrollment in the study. In the hospital setting, the supplemental oxygen delivery may come from compressed oxygen cylinders or liquid oxygen and is often delivered through a port in the facility wall at the bedside.
75561495|NCT04511832|Drug|Diclofenac|Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
75416184|NCT03283813|Drug|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
75561496|NCT00495950|Behavioral|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
76042527|NCT05675761|Drug|Azorubine|Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
76042528|NCT05674357|Behavioral|Individualized Evidence-Based Therapy in Cancer (Patients)|"The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~Cognitive Behavioral Therapy (CBT)~Acceptance Commitment Therapy (ACT)~Mindfulness-Based Cognitive Therapy (MBCT)~Mindfulness-Based Stress Reduction (MBSR)~Meaning-Centered Psychotherapy (MCP)~Cognitive Behavioral Therapy for Insomnia (CBT-I)~CBT for pain~CBT for fatigue~CBT for nausea"
75416185|NCT03283657|Behavioral|DiRECT|DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.
75416186|NCT03283657|Behavioral|Usual care (UC)|Standard care with routine medical care.
75416187|NCT03262519|Diagnostic Test|Computer based neurocognitive testing|Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
75716845|NCT00926835|Drug|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
75716846|NCT00926835|Drug|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
76042529|NCT05674357|Behavioral|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
76042530|NCT01664533|Drug|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
76042531|NCT04661293|Biological|Autologous Muscle Derived Cells (AMDCs)|
76042532|NCT05673655|Drug|intraoral trigger point injection by botox|intraoral injection of trigger point of masseter muscle by botulinum toxin
76042533|NCT05673655|Drug|transcutaneous trigger point injection by botox|transcutaneous injection of masseter muscle by botulinum toxin
76042534|NCT05692297|Drug|Denosumab|The patients in the denosumab group received subcutaneous injection of denosumab 60mg once every 6 months for 24 months.
76042535|NCT05692297|Drug|Non-denosumab|Taken other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc.
76042536|NCT05696587|Other|Multimodal rehabilitation|"The multimodal rehabilitation program included comprehensive therapy 5 times a week during the 4 weeks between assessments. The therapy consists of:~Individual physical therapy focused on improving range of motion and alleviating pain in the affected limb;~Mechanical desensitization;~Transcutaneous electric nerve stimulation (TENS) electrotherapy;~Aquatherapy (arm or leg whirlpool bath of the affected extremity);~Graded Motor Imagery, including the Recognise™ app and mirror therapy;~Psychoeducation on relaxation and coping with chronic pain."
76042537|NCT05696509|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.
75716847|NCT00926835|Drug|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
76042538|NCT05696509|Drug|Isoflurane|Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC
76042539|NCT05696509|Drug|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
76042540|NCT02584855|Drug|Ixekizumab|Administered SC
76042541|NCT02584855|Drug|Placebo|Administered SC
76042542|NCT05654935|Radiation|Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center."
75716848|NCT00926835|Drug|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
75716849|NCT00926835|Drug|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
75716850|NCT00926835|Drug|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
76042543|NCT05654935|Radiation|Telerobotic Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet)."
75716851|NCT00926835|Drug|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
76042544|NCT04523857|Drug|Abemaciclib|Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
75416188|NCT03245827|Drug|Clomiphene|clomiphene capsule 25mg twice a week
75416189|NCT03245827|Drug|Placebo|placebo capsule 25mg twice a week
75416190|NCT03169231|Biological|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
75416191|NCT03169231|Other|Placebo|Intravenously delivered
75416192|NCT03129321|Drug|Econazole Nitrate Cream, 1%|
75416193|NCT03129321|Drug|Placebo|
75416194|NCT03107611|Drug|Pimecrolimus Cream, 1%|
75561497|NCT05148507|Device|PROKERA|Amniotic membrane is the sac that encloses the baby during pregnancy. Amniotic membrane has been used to treat many ocular (eye) diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States food and drug administration (FDA) in 2001. PROKERA is considering it investigational for the study
75561498|NCT00495989|Procedure|saliva sampling + dental calculus collection|
75561499|NCT05148273|Behavioral|telenursing|7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
75561500|NCT01244204|Dietary Supplement|Vitamin D|Daily dose of 800IU of vitamin D
75416195|NCT03107611|Drug|Placebo Cream|
75716852|NCT00930033|Procedure|Nephrectomy|Current surgery
75716853|NCT00930033|Other|Sunitinib alone|Sunitinib alone without nephrectomy
75716854|NCT00931593|Device|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):~Subject selection~Obtaining of written informed consent~Visit V1 (day 0):~Fasting subject~Randomization to determine the examination order~Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study"
75416196|NCT03107611|Drug|Pimecrolimus Cream, 1%|
75416197|NCT02988544|Procedure|Artificial shrinkage|Artificial shrinkage of blastocyst
75441530|NCT01635673|Other|Exercise intervention|Whole body vibration exercise 3 times per week
75441531|NCT01635686|Drug|DWP422 25mg|
75441532|NCT01635686|Drug|ENBREL 25MG PFS INJ.|
75441533|NCT01635712|Drug|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
75441534|NCT01635738|Biological|LP GMNL-133 capsule|One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
75561501|NCT01244204|Dietary Supplement|Placebo|Identically appearing capsules
75561502|NCT00496028|Drug|AZD0530|oral tablet
75561503|NCT00496028|Drug|Carboplatin|intravenous infusion
75561504|NCT00496028|Drug|Paclitaxel|intravenous infusion
75561505|NCT00493493|Procedure|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
75416198|NCT02880774|Other|mandibular nonspecific mobilization|The mobilization will be held with the individual in supine position, by a trained and experienced therapist, where using disposable gloves, will position the first finger on the last molar, performing intermittently mobilization during 1 minute, will be held five repetitions. Going on a break during the repetition, in that the individual will carry out 15 times language exercises on the palate. With regard to mobilizing joint side, this will be previously set by means of the RDC/TMD and may be unilateral or bilateral basis, depending on the diagnosis. The therapist will remain in orthostatic in opposite side the mobilization to prevent any pressure on the jaw. The treatment will last for 4 weeks, 3 times a week, for a total of 12 sessions.
76042545|NCT04523857|Drug|Hydroxychloroquine|Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
75416199|NCT02880774|Other|Ultrasound detuned,|Will be held the identical positioning to group A with the individual supine on the stretcher, used ultrasound equipment detuned on the region of the face with the presence of TMD. The procedures of this group will have a duration of 4 weeks, 3 times a week, for a total of 12 sessions.
75416200|NCT02801136|Behavioral|ReACT|
75416201|NCT02801136|Behavioral|Supportive Therapy|
75441535|NCT01635738|Biological|LF GM-090 capsule|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
75561506|NCT00496067|Device|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
75441536|NCT01635738|Biological|LP GMNL-133 +LF GM-090 capsule|One capsule with 4x10^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO
75441537|NCT01635738|Biological|Placebo|Placebo
75561507|NCT04516278|Biological|bevacizumab|1.25 mg, intravitreal injection
75561508|NCT04516200|Device|transcranial direct current stimulation and traditional physical therapy program|Transcranial stimulation will be applied only for the study group.
75561509|NCT04516200|Other|designed physical therapy program|sensory training and balance training
75561510|NCT00493532|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
75561511|NCT01297465|Drug|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
75561512|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
75561513|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
76042546|NCT02581345|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
76042547|NCT02581345|Biological|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
75561514|NCT01297465|Drug|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles >= 18 mm).
75561515|NCT02276508|Drug|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
75561516|NCT00496106|Behavioral|Telephone counseling|6 telephone counseling sessions
75561517|NCT00496106|Behavioral|Telephone interview|telephone interview
75561518|NCT04511286|Behavioral|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
75561519|NCT00493571|Drug|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
75561520|NCT02276586|Procedure|Horizontal Tooth preparation|Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
75561521|NCT02276586|Procedure|Vertical Tooth preparation|Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
75561522|NCT00496145|Behavioral|Spanish Diabetes Self-Management Program|small-group self management education program
76042548|NCT05579509|Drug|Midazolam and Fentanyl|Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
76042549|NCT05579509|Behavioral|Educational Reassurance|Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
75561523|NCT01297309|Drug|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
76042550|NCT04314661|Biological|Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
76042551|NCT04314661|Biological|Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
75416202|NCT02798588|Radiation|PET-MRI|18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)->8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
76042552|NCT04314661|Biological|Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
75561524|NCT04518462|Drug|Exparel|EXPAREL (bupivacaine liposome injectable suspension)
75416203|NCT02720016|Behavioral|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
75561525|NCT04518462|Drug|Bupivacaine Hydrochloride|0.25% bupivacaine
75561526|NCT00496184|Drug|Nifedipine cream topical application|
75561527|NCT00493610|Drug|N-acetylcysteine(Mucomyst)|
75561528|NCT02274506|Drug|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
75561529|NCT02274506|Drug|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
75561530|NCT02274506|Procedure|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
75561531|NCT04519632|Other|Qualitative study|Qualitative interviews
75561532|NCT00496223|Drug|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
75561533|NCT00496223|Drug|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
75561534|NCT02593422|Behavioral|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
75441538|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
75441539|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
75561535|NCT02593422|Behavioral|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
75561536|NCT00496301|Drug|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
75561537|NCT00493688|Other|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
75561538|NCT02597985|Other|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
75416204|NCT02720016|Behavioral|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
75416205|NCT02720016|Behavioral|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
75561539|NCT02597985|Other|Usual Care|
75416206|NCT02607956|Drug|DTG|50 mg tablets administered orally, once daily
75416207|NCT02607956|Drug|F/TAF|200/25 mg tablets administered orally, once daily
75416208|NCT02607956|Drug|B/F/TAF|50/200/25 milligrams (mg) FDC tablets administered orally, once daily
75416209|NCT02607956|Drug|DTG Placebo|Tablets administered orally, once daily
75416210|NCT02607956|Drug|F/TAF Placebo|Tablets administered orally, once daily
75561540|NCT00496418|Device|Mesh in permanent colostomy|
75561541|NCT05141838|Drug|Vitamin D|Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state
75561542|NCT05141838|Dietary Supplement|Oral nutritional supplement|Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition
75561543|NCT00493727|Drug|N-acetylcysteine(Mucomyst)|
75561544|NCT05143788|Procedure|Awake craniotomy|The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.
75561545|NCT00493766|Drug|LBH589|
75561546|NCT05140005|Diagnostic Test|GlowTest COVID-19 Antigen Home Test|diagnostic testing for Covid 19
75561547|NCT00496457|Drug|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
75561548|NCT00496457|Drug|Placebo comparator|4 Capsules of PBO per day before noon meal
75416211|NCT02607956|Drug|B/F/TAF Placebo|Tablets administered orally, once daily
75561549|NCT02598648|Other|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
75416212|NCT02564523|Biological|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles)
75561550|NCT02598648|Other|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
75561551|NCT00493844|Other|Exercise testing|Exercise testing
75561552|NCT00493844|Other|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
75561553|NCT05146479|Procedure|Fluoride varnish and pit and fissure sealants onto first permanent molars|Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
75561554|NCT01297270|Drug|BI201335|QD BI 201335
75561555|NCT01297270|Drug|PegIFN/RBV|
75561556|NCT01297270|Drug|BI201335|QD (once daily) BI 201335
75416213|NCT02564523|Biological|MVA-BN-Filo|One 0.5 mL IM injection of (1x10*8 infectious units)
75416214|NCT02564523|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline
75561557|NCT01297270|Drug|Placebo|
75441540|NCT01635751|Drug|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
75441541|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 12 weeks
75441542|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 8 weeks
75561558|NCT00496535|Drug|TNFerade biologic|
75561559|NCT05145621|Drug|Fingolimod 0.5 mg capsules- Test drug|An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
75561560|NCT00493883|Device|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
75561561|NCT01296568|Drug|LY2603618|Administered intravenously
75561562|NCT01296568|Drug|Pemetrexed|Administered intravenously
75561563|NCT01296568|Drug|Gemcitabine|Administered intravenously
75561564|NCT05140668|Device|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
75561565|NCT00496574|Biological|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
75561566|NCT02598999|Drug|ALX-009|Solution for inhalation administered through nebulization
75561567|NCT02598999|Drug|OSCN-|Solution for inhalation administered through nebulization
75561568|NCT02598999|Drug|bLF|Solution for inhalation administered through nebulization
75561569|NCT02598999|Drug|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
75561570|NCT00493922|Procedure|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
75716855|NCT00664560|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
75716856|NCT00664560|Drug|celebrex|200 mg celecoxib qd
75416215|NCT02560961|Other|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
75416216|NCT02560961|Other|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
75416217|NCT02499666|Procedure|Percutaneous Coronary Intervention|As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
75441543|NCT01635790|Drug|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
75561571|NCT00493922|Procedure|Microscopy|Microscopy for diagnosis of malaria
75561572|NCT00493922|Procedure|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
75561573|NCT01296412|Drug|sitagliptin|100 mg tablet, orally, once daily.
75561574|NCT01296412|Drug|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
75561575|NCT01296412|Drug|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
75561576|NCT01296412|Drug|metformin|metformin tablets at a dose of ≥1500 mg per day
75561577|NCT05605561|Other|Digital Story|It is the standard of care given according to the hospital's policies and procedures.
75561578|NCT05146128|Other|Strengthening exercises|The participants had to perform specific exercices 3 times a week during 8 weeks
75561579|NCT00496652|Radiation|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
75561580|NCT00496652|Drug|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
75561581|NCT01295905|Device|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
75561582|NCT01295905|Device|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
75716857|NCT00664560|Drug|Placebo|sugar pill bid
75716858|NCT00664560|Drug|Rescue Antacid|Antacid Tablets
75716859|NCT00566709|Procedure|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
75716860|NCT00785850|Drug|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
75716861|NCT00931671|Other|Exercise training|aerobic exercise training
75716862|NCT00931749|Device|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
75561583|NCT02956148|Radiation|Radioligand [18F]MNI-659|The effective radiation dose for the injection of [18F]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
75561584|NCT02597634|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
75716863|NCT00931749|Device|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
75716864|NCT00783042|Drug|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
75716865|NCT00783042|Drug|Placebo|Tablet, oral, once daily for 1 month (double blind)
75716866|NCT02556528|Behavioral|Health Coaching|
75716867|NCT00688688|Drug|Mirabegron|Tablets
75716868|NCT00688688|Drug|Tolterodine|Extended release capsules
75416218|NCT02499666|Device|Coronary stent|As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
75561585|NCT02597634|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
75561586|NCT00494039|Procedure|Radioactive seed implant to prostate|
75561587|NCT05148429|Other|Ultrasound exam|Ultrasound exam
76042553|NCT04314661|Biological|Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
75716869|NCT00688688|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
75416219|NCT02499666|Drug|Clopidogrel|As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
75416220|NCT02474017|Drug|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
75416221|NCT02474017|Device|CRC749 inhaler|
75416222|NCT02420912|Drug|Ibrutinib|Given PO
75416223|NCT02420912|Other|Laboratory Biomarker Analysis|Correlative studies
75416224|NCT02420912|Biological|Nivolumab|Given IV
75416225|NCT02094716|Drug|Permethrin Foam 4%|Topical application, whole-body treatment
75561588|NCT05148429|Other|Fetal MRI|Fetal MRI
75561589|NCT05148429|Other|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
75716870|NCT00688688|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
75716871|NCT00926991|Other|No intervention|No intervention; observation only
75716872|NCT00930189|Drug|intravitreal injection of ranibizumab|
75716873|NCT00930189|Drug|intravitreal injection of triamcinolone|
75716874|NCT00930189|Procedure|photodynamic therapy|
75416226|NCT02094716|Drug|Permethrin Foam 5%|Topical application, whole-body treatment
75416227|NCT02094716|Drug|Vehicle Foam|Topical application, whole-body treatment
75416228|NCT01868139|Device|Liquid nitrogen spray cryotherapy with the truFreeze device|Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
75416229|NCT01762605|Other|Supportive Care|
75561590|NCT05148429|Other|Pediatric Follow up|Pediatric Follow up
75561591|NCT00496691|Behavioral|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
75561592|NCT05145972|Other|Ultrasound Guided Superior Hypogastric Plexus|The division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography , and the body of the fifth (5th) Lumbar vertebra will be identified by placing the transducer transversely. A skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. A 15-cm Long 22-G Chiba needle will be used with out of plane technique, and the needle will be advanced under USG-guidance to reach the anterior- most point of the fifth Lumber vertebral body avoiding the vascular structures. The needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. After confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. The uniform spread of the drug will be confirmed under real-time sonography.
75561593|NCT00496847|Drug|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
75561594|NCT00496847|Drug|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
75716875|NCT00936819|Biological|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
75716876|NCT00936819|Biological|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
75716877|NCT00936819|Biological|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
75716878|NCT00937053|Other|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
75716879|NCT00937053|Other|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
75716880|NCT00937053|Other|Platelet transfusion|Patients whose platelets fall below 10 x 10*9 will be transfused with platelets
75416230|NCT01762605|Procedure|Cast|
75561595|NCT02591199|Drug|URG101|
75561596|NCT02591199|Drug|Placebo|
75561597|NCT02591199|Drug|Lidocaine|
75561598|NCT02591199|Drug|Heparin|
75561599|NCT00494078|Device|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
75561600|NCT00494078|Drug|intensive insulin therapy|intensive insulin therapy according to an algorithm
75561601|NCT02596035|Drug|Nivolumab|
75716881|NCT04013997|Device|EksoGT|The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
75716882|NCT00931827|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
75716883|NCT00931827|Drug|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
75716884|NCT00664326|Drug|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
75716885|NCT04015323|Device|Interferential current|An electrotherapy current with different carrier frequencies
75716886|NCT00778908|Radiation|Late-course accelerated hyperfractionated IMRT|"IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
76042554|NCT05696431|Other|Universal adhesives application|The adhesive will be used according to their manufacturer's instructions. Selective etching for enamel will be applied for 15 seconds, followed by rinsing and gentle air drying. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
75416231|NCT01620658|Device|0.5mm XPF cap|"Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
75416232|NCT01620658|Device|0.3mm XPF cap|"Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
75416233|NCT01620658|Device|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
75561602|NCT00494117|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
75561603|NCT05147883|Behavioral|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks
75561604|NCT00494156|Drug|heparin|
75561605|NCT00494156|Drug|aspirin and clopidogrel|
75561606|NCT02595489|Dietary Supplement|vitamin D3|Daily oral supplement provided by study investigators
75561607|NCT00494195|Genetic|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
75416234|NCT01460810|Other|1000CsK Silicon Oil Tamponade|Details covered in arm description
75416235|NCT01447628|Drug|Saline|intravenous, no active drug
75416236|NCT01447628|Drug|Ferinject or CosmoFer|Intravenous, 1000 mg iron
75561608|NCT00494195|Genetic|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
75561609|NCT00497003|Drug|Treatment with either metoprolol or carvedilol|
75561610|NCT00494273|Behavioral|Cognitive Behavioral and Standard Care with Healthy Living|
75561611|NCT00494312|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
75416237|NCT00744484|Behavioral|Training in water|45 minutes interval training in water, submaximal intensity, twice a week
75561612|NCT00494312|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
75561613|NCT05145348|Biological|Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)|The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, <2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.
75561614|NCT00494351|Procedure|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
75561615|NCT02595372|Drug|Omeprazole|
75561616|NCT00497042|Device|Self Adjusting File|
75561617|NCT05142969|Other|2% Chlorhexidine bathing|Eight chlorhexidine-impregnated cloths are used in sequential order to wipe the body surfaces from neck to toe to avoid exposure of chlorhexidine to the mucous membranes of the eyes, ears and mouth.
75561618|NCT01244867|Biological|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
75561619|NCT01244867|Biological|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
75561620|NCT01244867|Biological|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
75561621|NCT01244867|Biological|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
75873378|NCT01180374|Drug|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
76042555|NCT05696431|Other|universal adhesive with bioactive properties|The adhesive will be used according to their manufacturer's instructions. Enamel and dentin will be cleaned using clean and boost for 10 seconds, rinsed and gently dried. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
75873379|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
76042556|NCT05696431|Other|Fluoride-releasing universal adhesive|Fluoride-releasing universal adhesive
75416238|NCT00744484|Behavioral|Training on land|45 minutes interval training on land, submaximal intensity, twice a week
75416239|NCT00667329|Drug|2CdA|1.5 mg/m^2 subcutaneous injection three times daily x 7 days.
75561622|NCT01244867|Biological|Placebo|2 doses given 21 days apart of the placebo
75873380|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
75873381|NCT03418571|Biological|ALX-0171 1.5 mg/kg|ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
75873382|NCT03418571|Other|Placebo|Placebo was administered via a single inhalation once daily for 3 consecutive days.
75873383|NCT03887520|Diagnostic Test|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
76042557|NCT05696275|Behavioral|exercise|20-30 minutes of walking and elastic band exercise per day
76042558|NCT05575453|Other|Kvatchii Portal|Online education portal
75416240|NCT00667329|Drug|Cyclophosphamide|40 mg/m^2 PO twice daily x 7 days.
75416241|NCT00667329|Drug|Rituximab|375 mg/m^2 IV once weekly x 4 weeks.
75416242|NCT00515853|Behavioral|Biofeedback|Biofeedback sessions or biofeedback exercises
75416243|NCT00492167|Biological|beta-glucan|
75416244|NCT00492167|Biological|monoclonal antibody 3F8|
75416245|NCT00492167|Other|immunohistochemistry staining method|
75416246|NCT00492167|Other|laboratory biomarker analysis|
75416247|NCT00003458|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
75416248|NCT05274724|Diagnostic Test|No teleconsultation during the ambulance journey|Standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty
75441544|NCT01635790|Drug|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
75441545|NCT01635803|Drug|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
75441546|NCT01635803|Drug|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
75441547|NCT01635816|Biological|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
75561623|NCT02596503|Drug|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
75873384|NCT03715595|Other|SSDM group|The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
75416249|NCT05274724|Diagnostic Test|Teleconsultation during the ambulance journey|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
75561624|NCT02596503|Drug|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
75873385|NCT05545943|Other|2-days of zero calorie restriction and whole-body cold-water immersion|The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.
75873386|NCT05545943|Other|6-days of calorie restriction|The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
75561625|NCT02596503|Other|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
75873387|NCT05545943|Other|2-days of zero calorie restriction without whole-body cold-water immersion|2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .
75873388|NCT05545943|Other|2-days of usual diet with whole-body cold-water immersion|Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.
76042559|NCT05629351|Other|Observational Group|"Demographic Data (Blood pressure, subcutaneous fat tissue, height, waist and hip circumference, and body weight, BMI (body mass index) and double product)~International Physical Activity Questionnaire (IPAQ)~Godin-Shephard Leisure-Time Physical Activity Questionnaire~The Dutch Eating Behavior Questionnaire~Pittsburg Sleep Quality Questionnaire~Perceived Stress Scale and Beck Depression Scale"
75873389|NCT03717545|Other|second allogeneic stem cell transplantation|"Change another donor~conditioning regimen: FLU/CY/anti-CD25 moAb"
75873390|NCT03715517|Procedure|Continuous thoracic epidural analgesia|"Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose"
75873391|NCT03715517|Procedure|Spinal anesthesia with intrathecal morphine|"Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in <5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid"
75873392|NCT03715517|Drug|Bupivacaine 0.75% in Dextrose Inj 8.25%|0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%
75873393|NCT03715517|Drug|Morphine|3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
75873394|NCT03715517|Drug|Bupivacaine 0.25% Preservative-Free Injectable Solution|0.25 mg⋅kg-¹ bupivacaine 0.25%
75873395|NCT03715517|Drug|Bupicavaine 0.125% epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
75873396|NCT03715517|Drug|Hydromorphone 10 mcg/mL epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
75561626|NCT00494429|Drug|Morphine|Gestational Age< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
75561627|NCT00494429|Drug|Morphine|Gestational Age>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
75873397|NCT03402893|Drug|ONEXTON Topical Gel|Onexton gel applied once daily to face
75873398|NCT03715361|Diagnostic Test|SL-ECG|additional SL-ECG measurement
75561628|NCT01245023|Procedure|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
75561629|NCT01245023|Procedure|Placebo-surgery|skin incisions without laparoscopy or related procedures
75561630|NCT00497120|Drug|acetazolamide|
75561631|NCT00497120|Drug|placebo|
75561632|NCT00497120|Procedure|uvulopalatopharygoplasty|
75561633|NCT02276352|Drug|Treatment 1|
75416250|NCT05274685|Procedure|haemodialysis|continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
75416251|NCT05274594|Radiation|Radiotherapy|Patients who are candidate for radiotherapy and received neoadjuvant chemotherapy for breast cancer were evaluated after neoadjuvant chemotherapy. Cases that do not have clinical response received radiotherapy before surgery in order to increase complete response.
75873399|NCT03717467|Drug|isotonic saline|100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
75873400|NCT03717467|Drug|Magnesium Sulfate|40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
75873401|NCT03717389|Other|presence of soft tissue calcification in head and neck|soft tissue calcifications of the head and neck region in the Egyptian population
75416252|NCT05274568|Drug|[18F]UCB-2897|"Investigational Agent:~[18F]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product [18F]UCB2897is delivered in normal saline (0.9 % sodium chloride [NaCl]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. [18F]UCB2897 will be stored at ambient temperature in its original container."
75416253|NCT05274490|Procedure|intubation and mechanical ventilation|patients who were in need were intubated and mechanically ventilated
75416254|NCT05274438|Drug|JS001+Imatinib mesylate|"This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered."
75561634|NCT02276352|Drug|Treatment 2|
75561635|NCT02276352|Drug|Treatment 3|
75561636|NCT00494468|Drug|Zolpidem|
75561637|NCT00497237|Drug|Beclomethasone plus formoterol fixed combination|100+6 pMDI
75873402|NCT04464954|Device|Auricular semi-permanent (ASP gold) needles|ASP semi-permanent Battlefield Acupuncture needles are semi-permanent needles that will remain in subject ears for 2-8 days and will be allowed to fall out on their own
75561638|NCT00497237|Drug|Fluticasone plus salmeterol fixed combination|diskus 250/50
75561639|NCT05144061|Drug|HRS2398 Tablets|Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
75561640|NCT01244282|Procedure|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
75716887|NCT00778908|Drug|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
75716888|NCT00778908|Radiation|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
75716889|NCT00931905|Drug|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
75716890|NCT00931905|Other|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
75716891|NCT02561468|Drug|Nefopam|
75873403|NCT04464954|Device|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|Intradermal (long) needles will remain in subject ears for 15-30 minutes and will be removed by a member of the study staff.
75873404|NCT04464954|Device|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|Pyonex needles will remain in subject ears for 2-21 days and allowed to fall out on their own.
75873405|NCT03628248|Procedure|embolization of the inferior mesenteric artery|proximal occlusion of the inferior mesenteric artery, before its divisional branches, by coils or plug 3-4 weeks prior to surgery.
75561641|NCT00494546|Procedure|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
75561642|NCT00497276|Procedure|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
75561643|NCT00497315|Drug|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
75873406|NCT03628248|Procedure|Inferior mesenteric artery ligation|Endovascular ligation of Inferior mesenteric artery
75416255|NCT05274386|Device|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours.
75416256|NCT05274386|Device|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours.
75416257|NCT05274386|Device|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours.
75561644|NCT00497315|Radiation|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
75416258|NCT05274360|Behavioral|Mobile evidence-based aphasia therapy|Use of mobile application to practice language for 2 weeks with a recommendation of 2 sessions per day of 20 minutes. The Android application, which is a Unity-based 2D game, will be installed on the patient's own phone, and they will play individually with the support of a family member if needed. The patients are free to start and stop using the application at any time. The application is safe to use, and it consists of therapeutic training methods such as object-matching, word search, writing, and manual voice recordings.
75561645|NCT05142072|Drug|Vitamin D3|intranasal film
75561646|NCT00497354|Drug|Variation in volume of local anesthetic|
75716892|NCT02561468|Drug|Saline|
75416259|NCT05274360|Behavioral|Conventional aphasia rehabilitation|Control Group (conventional aphasia rehabilitation). No therapy as patients are in the chronic stage, where they do not receive healthcare rehabilitation training.
75416260|NCT05274256|Procedure|implant placement with simultaneous soft tissue augmentation|implant placement with simultaneous soft tissue augmentation using De-epithelialized free gingival graft and immediate temporization in the maxillary aesthetic zone .
75416261|NCT05274191|Drug|Pyrotinib Maleate|Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
75416262|NCT05274191|Other|standard regimen|standard regimen
75441548|NCT01635816|Biological|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
75561647|NCT00497354|Procedure|Ultrasound-guided interscalene brachial plexus block|
75716893|NCT02555748|Drug|Pazopanib|
75561648|NCT00497393|Behavioral|Clinical Decision Unit|a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
75561649|NCT05140785|Diagnostic Test|Advanced MRI sequences|Advanced MRI sequences which look to a) determine structure of a primary brain tumour and b) metabolism within a primary brain tumour
75561650|NCT00494624|Drug|prednisolone|
75561651|NCT00507156|Procedure|Standard primary PCI|Acute re-opening of the occluded coronary artery
75561652|NCT00507156|Procedure|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
75561653|NCT00494663|Drug|DIO-902|150mg tablet once per day for 16 weeks
75561654|NCT00494663|Drug|DIO-902|300mg tablet once per day for 16 weeks
75716894|NCT02555748|Drug|Sunitinib|
75561655|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
75561656|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
75561657|NCT00494663|Drug|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
75561658|NCT00494663|Drug|DIO-902|300mg DIO-902 tablet daily for 16 weeks
75561659|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet for 16 weeks
75561660|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
75716895|NCT04014933|Diagnostic Test|LASER SPECKLE FLOWGRAPHY|Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
75716896|NCT00751946|Behavioral|Trauma Adaptive Recovery Group Education and Therapy|"Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis & Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing."
75873407|NCT03442985|Drug|Palovarotene 2.5 mg|Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
75873408|NCT03442985|Drug|Palovarotene 5.0 mg|Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
75716897|NCT00751946|Behavioral|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, & Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
75873409|NCT03442985|Other|Placebo|Subjects received placebo, once daily, for up to 24 months.
76042560|NCT05575219|Drug|Clonidine (without protocolized initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
76042561|NCT05575219|Drug|Clonidine (protocolized initiation)|"Observe participants without initiating clonidine with dexmedetomidine infusion time of 72-119 hours. To wean off dexmedetomidine, decrease the infusion by 25% of the starting dose every 6 hours.~Begin clonidine at 1 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of 120-167 hours. Decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours).~Begin clonidine at 2 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of >/= 168 hours or with infusion time of 120-167 hours at doses >/= 1.1 mcg/kg/min. Decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours)."
75873410|NCT03715283|Other|Home Ankle Strengthing Program|Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
75416263|NCT05274139|Drug|HD-MTX-Ara-C regimen|"HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles"
75416264|NCT05274139|Drug|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
75873411|NCT03715283|Other|Standard of Care|Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
75416265|NCT05274113|Drug|Dexamethasone 4mg|4 mg of Dexamethasone will be given before surgery
75873412|NCT01311635|Drug|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
75873413|NCT01311635|Drug|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
75416266|NCT05274113|Drug|Ropivacaine|Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery
75873414|NCT01311635|Drug|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
75873415|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
75416267|NCT05274100|Drug|Risankizumab|Subcutaneous Injection via prefilled syringe (PFS)
75416268|NCT05274100|Drug|Risankizumab|Intravenous Infusion
75416269|NCT05274100|Drug|Risankizumab|Subcutaneous Injection via on-body delivery system (OBDS)
75873416|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
75416270|NCT05274087|Drug|Risankizumab|Subcutaneous autoinjector
75416271|NCT05273957|Other|Case Manager|Patients are followed up by a nurse specialist in parkinsonism (case manager) who interacts with the treating neurologist and a multidisciplinary team
75416272|NCT05273957|Other|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
75873417|NCT02954159|Drug|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
75416273|NCT05273944|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
75416274|NCT05273866|Other|Virtual reality|Virtual Reality video application reduces pain by distracting. The intervention group was watched video during the procedure, starting before the procedure.
75416275|NCT05273853|Procedure|Partial Adenoidectomy|Partial removal of adenoid
75561661|NCT05146674|Drug|Tadalafil 5mg|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
75561662|NCT00494702|Procedure|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
75561663|NCT00494702|Procedure|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
75716898|NCT02555592|Procedure|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2~4 weeks after adjuvant chemotherapy.
75716899|NCT04059614|Procedure|HFNC; COT|"HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy"
75416276|NCT05273801|Device|Heart Rate Recording from Multiple Participants, No visual feedback|Heart rates are recorded from multiple participants during the group sessions. However during this intervention, it will not be cast to a TV for feedback to the participant or clinician.
75561664|NCT00507195|Drug|Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam|
75716900|NCT00930345|Drug|Sunitinib (SUTENT)|"Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).~Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.~At the end of the treatment period patients will be treated at the discretion of the Investigator."
75416277|NCT05273801|Device|Visual Feedback of Multiple Participant Heart Rates|Visual feedback of HR is provided through a TV monitor. Multiple heart rates can be displayed and recorded simultaneously allowing for group encouragement, continuous monitoring and adjustment of all participants to ensure reaching appropriate target intensity.
75416278|NCT05273593|Device|Confocal Laser Endomicroscopy (CLE)|Administration of fluorescein, intravesically and intravenously. CLE measurements with flexible and rigid probe of papillary bladder tumour and rigid probe-measurement of resection bed.
75561665|NCT00497471|Drug|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
75561666|NCT00497471|Drug|iron (2 mg/kg/daily)|
75561667|NCT05146635|Drug|Intravesical Bcg|Patients will receive induction and maintenance BCG after complete TURBT.
75561668|NCT05146635|Drug|Intravesical chemotherapy (epirubicin)|Patients will receive induction and maintenance epirubicin after complete TURBT.
75561669|NCT00494741|Drug|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
75416279|NCT05273528|Biological|Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
75416280|NCT05273489|Procedure|Hepatectomy|Neoadjuvant treatment
75416281|NCT05273398|Drug|nasal diazepam|Nasal administration of diazepam
75561670|NCT00494741|Drug|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight > 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
75561671|NCT00507234|Drug|formoterol fumarate inhalation solution|
75416282|NCT05273372|Other|Placebo|Placebo treatment with the food white rice flour. 1,000 mg BID
75416283|NCT05273372|Other|Medical Food - Anhydrous Enol-Oxaloacetate|Active treatment with oxaloacetate. 1,000 mg BID
75416284|NCT05273333|Device|Ultra-gyn®|Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.
75416285|NCT05273294|Device|Portable color Doppler ultrasound system|In the ultrasound group, the catheter type was selected according to the results of ultrasonic measurement of transverse diameter of cricoid cartilage after induction of general anesthesia, and tracheal intubation was performed with ordinary laryngoscope after measurement
75416286|NCT05273229|Other|Virtual Gait|Virtual Gait: the patient will be placed in a standing position (with an ad-hoc designed help system) in front of a mirror (from the waist up) and a screen (from the waist down) where a video of legs walking on a treadmill will be projected and overcoming obstacles. Projected legs will be customized based on height, using the tibia length method.
75416287|NCT05273229|Other|Physical exercise|"PE: it will be divided into two parts: in the first one, a gait technique training will be carried out and, in the second, a leg strength training, for 30 min. Exercises:~Coordination exercises: normal and lateral parallel walking and walking with obstacles.~Functional exercises such as climbing stairs, etc.~Lower limb strength exercises. Strength exercises will be prescribed according to the guidelines of the American College of Sports Medicine (ACSM). Progression will be customized based on individual abilities."
75716901|NCT00786006|Drug|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
75716902|NCT00786006|Drug|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
75716903|NCT02562326|Drug|BioChaperone insulin lispro|Injection immediately before the start of the individualised standard meal
75716904|NCT02562326|Drug|Humalog®|Injection immediately before the start of the individualised standard meal
75716905|NCT00930501|Biological|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
75873418|NCT02954159|Drug|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
75873419|NCT02954159|Other|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
75873420|NCT01311245|Behavioral|Stage-tailored intervention|Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.
75416288|NCT05273229|Other|Sham Virtual Gait|only the placebo virtual gait.
75441549|NCT01635816|Biological|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
75716906|NCT00783120|Other|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
75716907|NCT00783120|Other|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
75716908|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
75716909|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
75873421|NCT01311245|Behavioral|Non-stage-tailored Intervention|Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
75873422|NCT03442829|Behavioral|Sweet food consumption|Sweet food consumption at breakfast
75873423|NCT03442829|Behavioral|Non-sweet food consumption|Non-sweet food consumption at breakfast
75873424|NCT05218512|Other|WB-EMS|"The group has been submitted to 2 experimental conditions:~At rest with superimposed WB-EMS.~During uphill walking exercise with superimposed WB-EMS."
75873425|NCT03442595|Other|Intensive diabetes education and medication management|Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
75873426|NCT03717311|Other|Nutritional Intervention|The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
75873427|NCT03763422|Drug|Temozolomide|Oral Administration of Temozolomide
75716910|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
75716911|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
75716912|NCT00783276|Drug|SYN115|100 mg single dose
75416289|NCT05273073|Dietary Supplement|Probiotics|Each sachet consists of 30 billion colony-forming units (CFU) of six viable probiotic strains (Lactobacillus acidophilus BCMC® 12130 (107 mg), Lactobacillus casei subsp. BCMC® 12313 (107 mg), Lactobacillus lactis BCMC® 12451 (107 mg), Bifidobacterium bifidum BCMC® 02290 (107 mg), Bifidobacterium infantis BCMC® 02129 (107 mg), and Bifidobacterium longum BCMC® 02120 (107 mg).
75416290|NCT05273073|Dietary Supplement|Placebo|Placebo samples were identical to the probiotics in term of taste and texture without live microbial cells.
75416291|NCT05273021|Diagnostic Test|TAPS|all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
75873428|NCT03763422|Radiation|Radiotherapy|50.4 Gy in 28 fractions over 6 weeks
75873429|NCT03763422|Procedure|Surgery|Surgery
75873430|NCT05658029|Drug|ARINA-1|Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
75716913|NCT00783276|Drug|PLACEBO|PLACEBO
75716914|NCT00932061|Other|Traditional Acupuncture|"Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
75873431|NCT05520281|Behavioral|Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS)|A short-term psychodynamic therapy that focuses on the special inner and outer situation of patients with a serious physical illness, especially with regard to the importance of relationships in a limited lifetime.
75873432|NCT03715049|Procedure|Fraxel Laser Treatment|The device to be used in this study is a FDA approved device [510(k) approval] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
75441550|NCT01635816|Biological|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
75441551|NCT01635829|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
75441552|NCT01635829|Drug|Phenytoin|Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
75441553|NCT01635829|Drug|Carbamazepine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
75441554|NCT01635894|Behavioral|Training|Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
75441555|NCT01635946|Drug|Isavuconazole|oral
75873433|NCT03667716|Drug|COM701|COM701 monotherapy.
75873434|NCT03667716|Drug|COM701 with Opdivo (Nivolumab).|COM701 in combination with Opdivo (Nivolumab).
75441556|NCT01635946|Drug|atorvastatin|oral
75441557|NCT01635972|Drug|Isavuconazole|oral
75441558|NCT01635972|Drug|bupropion hydrochloride|oral
75441559|NCT01635985|Drug|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
75441560|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
76042562|NCT05568745|Device|Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)|Balloon catheter is inserted by a resident or a physician under visual control. The expected volume injected in the balloon probe is 60 mL. No traction is performed on the catheter. The catheter is left in place for a maximum of 12 hours.
75416292|NCT05272982|Diagnostic Test|Thoracic fluid content by electrical cardiometry group|Thoracic fluid content will be measured using electrical cardiometry device (ICON ® Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). The ICON device will be connected to four electrocardiogram electrodes which will be placed over patients' skin after cleaning with alcohol at the neck below the left ear, just above the left clavicular midpoint, and two electrodes at left mid-axillary line one at the level of the xiphoid process, and the other electrode 5 cm below this point. The thoracic fluid content will be observed for 30 s and the average of the highest and lowest values will be recorded.
76042563|NCT05568745|Drug|Oxytocin|Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
75416293|NCT05272982|Diagnostic Test|Ultrasound examination group|The 12-region technique for lung assessment will be performed using Philips ® (CX50 - Extreme edition) equipped with phased array transducer. B-line will be defined as laser like vertical hyperechoic artefact which extends between the pleural line and the bottom of the screen and moves with respiratory movements. Two types of B-lines will be evaluated.
75716915|NCT00932061|Other|Sham Treatment|"Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
75716916|NCT02562170|Device|TiLoop Bra|
75716917|NCT02562170|Device|Protexa|
76042564|NCT05568745|Drug|Misoprostol Oral Tablet|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
76042565|NCT04302493|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course of MBSR taught by a psychologist trained in the MBSR protocol and encouraged to engage in additional individual mindfulness sessions using a cell phone application.
75416294|NCT05272904|Procedure|Quilting|Following mastectomy and/or axillary lymph node dissection, the subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin.
76042566|NCT04302493|Behavioral|Stroke Support Group (SSG)|As a control group, participants randomized to the SSG arm will participate in 8 weeks of weekly Stroke Support Group sessions to experience activity and socialization without additional mindfulness training.
75716918|NCT03538197|Other|clinical and biological correlates|"To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.~To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors"
75716919|NCT00686972|Drug|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
75716920|NCT00937287|Other|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
75716921|NCT00665652|Drug|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
76042567|NCT02581189|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
76042568|NCT02581189|Drug|Dasabuvir|Tablet
76042569|NCT02581189|Drug|Ribavirin|Tablet
76042570|NCT05569681|Drug|Bemiparin 3500|"Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
76042571|NCT05569681|Drug|Bemiparin 5000 IU|"Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
75716922|NCT00937365|Behavioral|Exercise|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
76042572|NCT05535127|Diagnostic Test|"Palpation with  laryngeal handshake technique"|Information alredy included
76042573|NCT05535127|Diagnostic Test|Palpation strategy plus sequential ultrasound|Information alredy included
76042574|NCT05535127|Diagnostic Test|Identification of the cricothyroid membrane with routine ultrasound|Information alredy included
76042575|NCT05595655|Behavioral|Motivational Interviewing|Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.
75716923|NCT00937365|Procedure|Spinal Manipulation|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
75716924|NCT00937365|Procedure|Neuroemotional Technique (NET)|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
75716925|NCT00783588|Biological|ISF35|Subjects participating in this study will receive up to two doses of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.
75716926|NCT02561390|Procedure|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
75716927|NCT02561390|Other|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
76042576|NCT04425265|Procedure|Plasma radiofrequency ablation|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.
76042577|NCT04425265|Procedure|Electrocautery block resection|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the soft palate under the inferior margin, investigators horizontally cut the mucosa of the posterior wall of the nasopharynx, and completely frees the entire soft tissue of the posterior wall of the nasopharynx.
76042578|NCT05594641|Other|Remote ischaemic preconditioning|A tourniquet will be applied to the right arm and it will be inflated (3 cycles, each lasting 5 minutes, at a pressure of 200 mmHg); each cycle is followed by 5 minutes of resting
76042579|NCT05594641|Other|Control|The tourniquet will be applied to the right arm but the cuff will be not inflated
75716928|NCT00937443|Other|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
75416295|NCT05272904|Procedure|Conventional wound closure|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
75716929|NCT00937443|Biological|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
75716930|NCT00752024|Device|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
75716931|NCT00752024|Drug|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
75416296|NCT05272839|Dietary Supplement|Hypoglycemic food group|A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).
75416297|NCT05272839|Dietary Supplement|Control group|The control group will receive only lifestyle and dietary recommendations.
75416298|NCT05272449|Device|Sleep apnea diagnosis|Split-night
75416299|NCT05272436|Device|Virtual Reality Upper Limb Motor Impairment Rehabilitation|Patients wore a VR headset while undergoing their physical rehabilitation at home
75873435|NCT03714971|Behavioral|WhatsApp embedded in smoking cessation service|The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
75416300|NCT05272371|Combination Product|Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)|Dinutuximab beta in combination with chemotherapy.
75416301|NCT05272358|Other|NETSARC network|MDTB and/or surgery in NETSARC network
75416302|NCT05272215|Procedure|Bariatric surgery|Pre- and post-bariatric surgery (3, 6, 12 months postoperative and yearly)
75416303|NCT05272215|Procedure|Body contouring surgery|Pre- and post body contouring surgery (3, 6, 12 months postoperative and yearly)
75416304|NCT05272189|Behavioral|Simulated Second Reader AI|In this experiment, in some conditions, the participant makes their decision in the presence of information about a simulated artificial intelligence decision.
75416305|NCT05272189|Behavioral|Target Prevalence|The frequency with which targets are presented varies from 10% to 90%
75416306|NCT05272163|Behavioral|Stimulus Type|Targets can be specific or categorical
75416307|NCT05272163|Behavioral|Target Presence|There is or is not a target present on each trial
75416308|NCT05272163|Behavioral|Checklist|In fact, there is a checklist on every trial but these results will be compared to a non-checklist condition from another experiment
75561672|NCT00507273|Other|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
75873436|NCT03712007|Device|MAMP therapy with MARPE expander|Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
75416309|NCT05272124|Other|Hip Abductor Strengthening|"Elastic resisted training of Hip Abductors (5-10 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
75716932|NCT04046952|Device|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
75716933|NCT04046952|Device|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
75416310|NCT05272124|Other|Traditional Physical Therapy|"Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
75416311|NCT05272020|Diagnostic Test|CPET, 6MWT, QOL assessment|Preoperative and postoperative (6 months + 18 months) assessment
75441561|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
75561673|NCT00497510|Procedure|Chiropractic manipulation|
75561674|NCT00507312|Device|HD medical device (ViScope)|Device
75561675|NCT00507312|Device|CSIRO device|device
75873437|NCT03712007|Device|MAMP therapy with Hyrax expander|Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
75416312|NCT05271968|Procedure|Global management of scabies|"For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC service, but the patient will have to come back the following day to take a shower at the BOPC service and will receive new clothes.~The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC service and to receive again new clothes"
75416313|NCT05271942|Procedure|Tilt and Tumble|The Tilt and Tumble technique is used to remove the human lens.
75873438|NCT05218122|Other|cross-sectional study without intervention|cross-sectional study without intervention
76042580|NCT04686253|Other|not appliable|not appliable
76042581|NCT05551039|Other|Retrospective patient chart review|Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).
75416314|NCT05271942|Procedure|Divide and Conquer|The Divide and Conquer technique is used to remove the human lens.
75416315|NCT05271877|Procedure|Laparoscopy|Diagnostic/operative laparoscopic procedure
75416316|NCT05271838|Dietary Supplement|Magnesium acetate mixture (30 mmol/ml)|Patients with a magnesium retention test >25% and randomized to intervention receive magnesium acetate oral mixture (30 mmol/ml) 20 ml x 3/day for a period of three weeks.
75416317|NCT05271838|Dietary Supplement|High-protein diet (2 g/kg/day)|Nutritional counseling and protein supplementation to establish an intake of 2 g protein kg/day during admission and three weeks after discharge.
75416318|NCT05271786|Other|Decannulation|retrospective evaluation of decannulation
76042582|NCT04685941|Drug|Drug-mediated hyperemia|Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.
76042583|NCT04685941|Other|Flow-mediated hyperemia|Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.
76042584|NCT02576977|Biological|Pembrolizumab|pembrolizumab 200 mg IV infusion
76042585|NCT02576977|Drug|Pomalidomide|pomalidomide 4 mg capsules
76042586|NCT02576977|Drug|Dexamethasone|dexamethasone 40 mg tablets
76042587|NCT04421755|Other|Produce delivery|weekly home delivery of fresh fruits and vegetables
75416319|NCT05271539|Drug|Lucentis alone group|The Lucentis alone group received 3 monthly intravitreal injections of lucentis alone or less than 3 injections if the central foveal thickness reached 250 microns
75416320|NCT05271539|Drug|Lucentis dexamethasone group|Lucentis dexamethasone group received intravitreal injections of combination of both lucentis and commercial dexamethasone. the second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN). Treatment was stopped when CMT improved below 250 µ.
75416321|NCT05271500|Device|laser acupuncture|gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks
75416322|NCT05271487|Other|Multi-Step Botanical Skin Care Regimen|"The intervention includes 7 different topical products:~Cleanser~Toner~Oil Control Cream~Exfoliating Facial Scrub~Clay Mask~Acne Spot Treatment~Body Scrub"
75416323|NCT05271461|Radiation|Low level laser Therapy|Pin pointed application of low level laser on 15 acupuncture points each point 1 min time of application 15 min.
75416324|NCT05271461|Other|Circulatory exercises|"Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails.~If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position.~The subject will have A 3 min rest period to acclimatize themselves to each position.~The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals:~repeated dorsiflexion and planter-flexion with no rest (no rest exercise).~repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise).~repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise).~Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure."
75416325|NCT05271422|Device|Real Pulse Electrical Stimulation (NuEyne 01)|Patients wear our clinical trial device 15~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
75441562|NCT01635985|Drug|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
75716934|NCT00937599|Dietary Supplement|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
76042588|NCT04421755|Other|Cooking classes|weekly home delivery of fresh fruits and vegetables participants will be invited to participate in a Culinary Medicine cooking series. The OU Culinary Medicine cooking curriculum will involve a 3-part class series designed to build nutrition knowledge and cooking self-efficacy for preparing fresh F/Vs. Each session is ~2 hr. Core nutrition guidelines for blood pressure and blood sugar management will also be emphasized informed by an evidence-based Conceptual Model of Healthy Cooking. Classes will be conducted in small groups (~16 participants) in an established teaching kitchen used by the culinary medicine program. Classes will be facilitated by a professional chef, a healthcare professional (dietitian, medical doctor, or trained medical student), and other support staff, including trained medical, dietetic, and public health students.
75873439|NCT03695406|Behavioral|Mind-Body Program for Fear of Recurrence|An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
75416326|NCT05271422|Device|Sham Pulse Electrical Stimulation|Patients wear our clinical trial device 15~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
75416327|NCT05271396|Other|Clinical Assessment|The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.
75416328|NCT05271370|Drug|PRO 140 350|Pro140 SC injection 350 mg
75416329|NCT05271370|Drug|PRO 140 525|525 mg
75416330|NCT05271370|Drug|PRO 140 700|700 mg
75416331|NCT05271253|Drug|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.
75716935|NCT00937677|Drug|Tysabri|"Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.~Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.~TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial."
75716936|NCT00786162|Other|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
75716937|NCT00786162|Other|BP cuff at workplace|Provided BP cuff for communal use at the worksite
75561676|NCT00497549|Procedure|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
75716938|NCT00778986|Device|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
75716939|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
76042589|NCT05213845|Procedure|Spine flexion/extension active range of motion exercises|Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
75716940|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
76042590|NCT05867290|Behavioral|Mindful music-listening with sleep hygiene|5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
75416332|NCT05271253|Drug|bupivacaine|0.25% bupivacaine is injected in the caudal epidural space
75416333|NCT05271253|Drug|normal Saline|injection of normal Saline
75441563|NCT01635985|Drug|AZD5423|dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
75441564|NCT01635985|Drug|AZD5423|dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
75441565|NCT01636011|Other|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
75441566|NCT01636011|Other|Light Touch sham|Light Touch sham
75441567|NCT01636024|Drug|AZD7594|Suspension inhaled via Spira nebuliser
75441568|NCT01636024|Drug|Placebo to match|Matching placebo inhaled via Spira nebuliser
75441569|NCT01636037|Drug|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
75716941|NCT04498923|Drug|Bupivacaine, dexamethasone, epinephrine|Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
75716942|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
75716943|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
75716944|NCT04046874|Drug|Usual Care|Pain Medication, imaging, referrals to other health services, other health care appointments
75716945|NCT04046874|Other|SPLIT Stratified Model of Care|Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
75716946|NCT00932217|Drug|filgrastim|subcutaneous filgrastim administration
75561677|NCT00497549|Procedure|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
75561678|NCT05148546|Drug|Neoadjuvant nivolumab|Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.
75561679|NCT05148546|Drug|Neoadjuvant ipilimumab|Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.
75561680|NCT05148546|Drug|Neoadjuvant relatlimab|Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.
75561681|NCT00507351|Behavioral|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
75561682|NCT00497588|Procedure|surgery|
75561683|NCT00497588|Radiation|radiotherapy|
75561684|NCT00506532|Drug|Surfactant (calfactant)|
75561685|NCT00494858|Behavioral|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
75561686|NCT00494858|Behavioral|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
75561687|NCT05143983|Behavioral|Positive valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excerpts, with positive valence characteristics (fast tempo, major key). They will be told to listen carefully in order to then answer a short questionnaire. The listening will be followed by an liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
75716947|NCT00932217|Drug|lenograstim|subcutaneous lenograstim administration
75441570|NCT01636050|Other|squat exercise training|Intervention may include squat exercise for 8 weeks
75441571|NCT01636089|Drug|bicarbonates|sodium bicarbonates 1,4%
75441572|NCT01636089|Drug|saline|sodium chloride 0,9%
75716948|NCT00786318|Drug|ziprasidone|ziprasidone 20mg IM
75441573|NCT01636128|Drug|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
75441574|NCT01636128|Drug|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
75441575|NCT01636141|Drug|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
75441576|NCT01636141|Drug|Placebo gel|
75561688|NCT05143983|Behavioral|Neutral valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excepts with neutral valence. They will be told to listen carefully in order to then answer to a short questionnaire. The listening will be followed by a liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
75716949|NCT00786318|Drug|Standard therapy|Haldol 5mg/ Ativan 2mg IM
75716950|NCT00783666|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
75716951|NCT00566631|Drug|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
75441577|NCT01636154|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
75561689|NCT05149560|Drug|Ticagrelor 90mg|All patients will be prescribed ticagrelor as monotherapy
75561690|NCT00494897|Drug|Asparaginase|
75716952|NCT00932295|Other|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
75716953|NCT00932295|Other|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
75716954|NCT00932295|Other|CROWN SEVEN|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
75716955|NCT00932295|Other|NJOY|"10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)"
76042591|NCT05867277|Other|music|The students in the intervention group listened to music for 15 min before and during the peripheral intravenous catheter placement skill practice.
75416334|NCT05271227|Other|Transthoracic echocardiography and Carotid artery doppler (PHILIPS HD11 XE ultrasound device) before and after PLR test.|VTI-LVOT was measured by echo by placing the pulsed wave Doppler sample gate in the LVOT diameter in apical-5-chamber window. VTI-LVOT was obtained by manually tracing the Doppler velocity spectrum. LVOT velocity time integral was recorded before and after PLR test within 2 minutes. Carotid blood flow was measured by using two-dimensional image, the optimal image of the long-axis view was obtained at the common carotid artery. The sample volume was placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination,The angle correction cursor was placed parallel to the direction of blood flow. A PLR will be performed in 2 sequential steps, first step patient is seated in the semi recumbent position (45°) then using an automatic bed elevation technique, the lower limbs will be then raised to a 45° angle while the patient's trunk will be lowered in supine position. Thus, the angle between the trunk and the lower limbs will remain unchanged (135°).
75416335|NCT05271201|Other|treadmill exercise (mild)|mild intensity treadmill training.
75416336|NCT05271201|Other|treadmill exercise (moderate)|moderate-intensity treadmill training
75441578|NCT01636154|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
75441579|NCT01636154|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
75441580|NCT01636167|Device|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
75561691|NCT00494897|Drug|Cyclophosphamide|
75561692|NCT00494897|Drug|Cytarabine|
75561693|NCT00494897|Drug|Daunorubicin|
75716956|NCT04014699|Procedure|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
75561694|NCT00494897|Drug|Mercaptopurine|
75561695|NCT00494897|Drug|Prednisone|
75561696|NCT00494897|Drug|Vincristine|
75561697|NCT00494897|Drug|Methotrexate|
76042592|NCT05867264|Other|Early drinking water|"After passing the evaluation by the anesthesiologist team in PACU, the EOF1 group drank 200ml of water.~The evaluation criteria for the anesthesiologist team are:~Steward's awakening score is ≥ 6 points.~Level of sobriety ≥ 3.~There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
75561698|NCT00494897|Procedure|Intrathecally treatment|
75561699|NCT05148624|Procedure|embryo transfer|immediate ambulation after embryo transfer
75561700|NCT00497666|Drug|Rosiglitasone (retrospective observation)|
75716957|NCT04014699|Procedure|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
75716958|NCT00937911|Drug|YM150|oral
75716959|NCT00937989|Other|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
75716960|NCT00937989|Other|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
75716961|NCT00937989|Other|medical chart review|Baseline, 3, 6 and 9 months after starting the study
75716962|NCT00937989|Other|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
75716963|NCT00937989|Other|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
75716964|NCT00937989|Procedure|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
75561701|NCT05144919|Behavioral|Promotion of a biodiverse diet|"Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~Where to locally source inputs and expected price~How/when to prepare plots using organic inputs~Planting and best-practice management practices~Seed saving and storage~Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices"
75561702|NCT05144568|Other|Nutrition education|Nutrition education will be given to improve PMS
75561703|NCT05144217|Drug|Placebo|1 capsule per day of placebo
75561704|NCT05144217|Drug|2x 140 mg per day|2 capsule per day of silimarit
75561705|NCT05144217|Drug|3x 280 mg per day|3 capsule per day of silimarit
75561706|NCT05144217|Drug|1x 1120 mg|8 capsule per day of silimarit
75561707|NCT00497744|Drug|Intraperitoneal Cefepime|
75561708|NCT00495053|Drug|hMaxi-K|Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
75416337|NCT05271188|Procedure|Infiltration of local anaesthetic between popliteal artery and posterior knee capsule|Adductor canal block (ACB) is a popular peripheral nerve block that has been shown to decrease pain significantly and thereby opioid consumption with minimal effect on quadriceps function [8]. Though ACB provides analgesia to the peripatellar and intra-articular aspect of knee joint, it does not relieve posterior knee pain which is moderate to severe in intensity [9, 10]. The recent technique of an ultrasound (US)-guided local anesthetic infiltration of the interspace between popliteal artery and the capsule of posterior knee (IPACK) has shown to provide significant posterior knee analgesia without affecting the common peroneal nerve (CPN) [11]. We postulated that IPACK will provide better pain relief and improve knee function in the immediate postoperative period compared to ACB
75416338|NCT05271149|Other|Routine Physical Therapy|Routine physical therapy and orthosis
75561709|NCT00495053|Other|Placebo|Matching placebo (PBS-20% sucrose)
75561710|NCT00497783|Drug|Lactoserum|
75716965|NCT00938067|Behavioral|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
75873440|NCT03633786|Procedure|standard laparoscopic surgery|removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung & Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm
75416339|NCT05271136|Other|Anti-aging Serum|Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers
75416340|NCT05271136|Other|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after serum
75561711|NCT05143515|Behavioral|PACE label|There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
75716966|NCT00938223|Biological|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
75716967|NCT04014777|Biological|NGM621|NGM621 Dose 1
75416341|NCT05271136|Other|Cleansing Lotion|Facial cleansing lotion to be used by study participants
75416342|NCT05271136|Other|Sunscreen|Sunscreen to be applied after application of serum in the morning. Participants were asked to reapply every 2 hours
75416343|NCT05271136|Other|Sunscreen|Sunscreen to be applied after application of facial moisturizer in the morning. Participants were asked to reapply every 2 hours
75416344|NCT05271123|Diagnostic Test|Assessment of respiratory function and growth motor function classiffication level|Assessment of respiratory function using spirometer and assessment of growth motor function classiffication level using GMFCs
75716968|NCT04014777|Biological|NGM621|NGM621 Dose 2
75416345|NCT05271110|Procedure|Liver resection (ablation)|Treatment of liver metastases from pancreatic cancer by surgery or ablation
75716969|NCT04014777|Biological|NGM621|NGM621 Dose 3
75716970|NCT04014777|Biological|NGM621|NGM621 Dose 4
75416346|NCT05271058|Other|Control group|23 eyes that didn't receive any intraoperative steroids
75416347|NCT05271058|Drug|Dexamethasone group|23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.
75416348|NCT05271058|Drug|Triamcinolone (TA) group|23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
75716971|NCT00930891|Drug|Standard Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles"
75716972|NCT00930891|Drug|Experimental Treatment (PCDE or PE + bevacizumab)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression"
75716973|NCT00930891|Drug|Prerandomization Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles"
75716974|NCT00938301|Drug|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
75716975|NCT00938301|Drug|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
75416349|NCT05271045|Dietary Supplement|fortified canola oil with vitamins A and D and γ-oryzanol|30 g fortified canola oil with vitamins A and D and γ-oryzanol
75416350|NCT05271045|Dietary Supplement|Active comparator|30 g fortified canola oil with vitamins A and D
75416351|NCT05271045|Dietary Supplement|Placebo|30 g fortified sunflower oil with vitamins A and D
75561712|NCT00495092|Drug|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
75716976|NCT00938379|Drug|20% deet insect repellent|skin-applied repellent lotion
75716977|NCT00938379|Drug|placebo control|Identical base formulation of lotion but without any deet active
75561713|NCT00495092|Drug|Biperiden|Biperiden 2-4 mg/d p.o.
75561714|NCT00495092|Drug|Placebo|Placebo + Placebo
75561715|NCT05143359|Diagnostic Test|Wharfe and Pederson difficulty index|Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.
75416352|NCT05270967|Diagnostic Test|F-18 FDG PET/CT imaging|Oncological imaging
75416353|NCT05270967|Biological|Pfizer/biontech mRNA vaccine|COVID-19 vaccine
75416354|NCT05270954|Biological|Betuvax-CoV-2|Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)
75416355|NCT05270954|Drug|Placebo|Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
75441581|NCT01636180|Drug|Clopidogrel|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
75441582|NCT01636180|Drug|Clopidogrel|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
75441583|NCT01636193|Biological|Oral Rotarix®|2 doses administered orally.
75561716|NCT05143359|Diagnostic Test|Winters difficulty index|Efficiency of Winters Difficulty index in extraction of third molars.
75561717|NCT00497822|Procedure|Aerobic exercise training|
75416356|NCT05270941|Procedure|COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT|In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.
75561718|NCT00497861|Procedure|Activator Methods Chiropractic Technique|
75416357|NCT05270915|Behavioral|Family supportive care in EOLC|The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
75416358|NCT05270889|Drug|Tislelizumab+Zanidatamab|"Zanidatamab will be administered at a flat dose as follows:~Subjects with body weight <70 kg: 1800 mg IV on Day 1 of each 21-day cycle~Subjects with body weight ≥70 kg: 2400 mg IV on Day 1 of each 21-day cycle Tislelizumab will be administered at a dose of 200 mg IV on Day 1 of each cycle."
75416359|NCT05270824|Combination Product|radical surgery after neoadjuvant immunotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
75561719|NCT01244360|Dietary Supplement|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
75561720|NCT01244360|Other|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
75561721|NCT00506571|Drug|S-1, irinotecan, oxaliplatin|
75561722|NCT00497900|Drug|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
75716978|NCT00938535|Behavioral|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
75416360|NCT05270824|Combination Product|radical surgery after neoadjuvant chemotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
75441584|NCT01636193|Other|Data collection|Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
75561723|NCT05143125|Biological|Decitabine combined with NK cell infusion|Decitabine combined with NK cell infusion
75561724|NCT01244555|Other|ultrasound|Twice weekly ultrasound sessions for 6 weeks
75561725|NCT01244555|Other|massage|Twice weekly massage sessions for 6 weeks
75561726|NCT05143008|Behavioral|SMART Intervention|Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.
75561727|NCT00497939|Drug|Saw palmetto and sanmiaoshan capsule|
75561728|NCT05142930|Other|Intermittent ultrasound|Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region
75561729|NCT05142930|Other|Continuous ultrasound|Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region
75716979|NCT00661830|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
75561730|NCT01244594|Other|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
75561731|NCT00497978|Dietary Supplement|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
75561732|NCT00497978|Dietary Supplement|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
75716980|NCT00661830|Drug|Placebo|Placebo
75416361|NCT05270772|Biological|CAR-T-19 Cells|T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10^6/kg,1.5×10^6/kg, 5.0×10^6/kg CAR+ cells.
75416362|NCT05270720|Biological|dendritic cell|"Biological: Dendritic Cell Immunotherapy Adult patients with histopathologically diagnosed Ovarian Cancer will be eligible for this novel, personalized dendritic cell vaccine during course of standard of care chemotherapy.~If unacceptable side effects are observed at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 2.5x106.~If no unacceptable side effects are identified at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1X107."
75416363|NCT05270681|Other|Movement to Music|Participants will be educated on how to access prerecorded Move to Improve classes conducted by a professional dance instructor which will be accessible by computer or tablet 24/7 via a hyperlink. Classes last 45 minutes, and participants will be instructed to participate in the activity at least twice weekly, for 12 weeks. Each class uses movement to music combinations across different dance genres that build in intensity and sequence complexity, accompanied by music with faster beats, to encourage participants to achieve a moderate-vigorous level of physical and cognitive activity. Care partners will be present during each class to ensure safety and will also participate in the Move to Improve exercise program. The care partner and participant will be instructed to stand at a counter or behind a chair for safety during exercise.
75561733|NCT00506610|Drug|T-62|
75561734|NCT01244672|Procedure|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
75561735|NCT01244672|Procedure|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
75561736|NCT05142852|Device|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
75561737|NCT05142852|Other|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
75561738|NCT00498056|Biological|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
75716981|NCT00661830|Drug|Sorafenib|Sorafenib 400 mg bid orally continuously
75716982|NCT00932529|Drug|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
75716983|NCT00932529|Drug|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
76042593|NCT05867264|Combination Product|Early consumption of carbohydrates|"After passing the evaluation by the anesthesiologist team in PACU, the EOF2 group had a drinking capacity of 200ml of 12.5% carbohydrates (100ml containing 12.5g of maltodextrin, fructose, and glucose).~The evaluation criteria for the anesthesiologist team are:~Steward's awakening score is 6 points.~Level of sobriety ≥ 3.~There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
75716984|NCT00932529|Drug|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
75716985|NCT00932529|Drug|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
75716986|NCT00783744|Drug|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
75716987|NCT00783744|Drug|Glimepiride|Glimepiride 3 or 4 mg
75716988|NCT00783744|Drug|Metformin|At least 850 mg od
75416364|NCT05270642|Procedure|Microwave Thermal guided by Plan for Microwave Thermal Field system|When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.
75561739|NCT00498056|Biological|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
75561740|NCT00498056|Biological|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
76042594|NCT05867264|Other|Late feeding group|After observing the vital signs for 30 minutes after surgery, patients in Group C were sent back to the ward to continue fasting and drinking for at least 6 hours. After the anus exhausts, they began to gradually drink and eat
76042595|NCT05867212|Drug|Cabotegravir Injection [Apretude]|People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.
75416365|NCT05270629|Other|Antegrade and retrograde anastomoses|Patients who had received both antegrade and retrograde anastomoses.
75416366|NCT05270629|Other|Antegrade-only anastomoses|Patients who had received antegrade-only anastomoses.
75561741|NCT00498056|Biological|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
75561742|NCT00498095|Procedure|Renal biopsy|
75561743|NCT05141331|Device|piezoelectric|Comparing Piezoelectric split-crest technique versus expansion using Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
75716989|NCT00783744|Drug|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
75416367|NCT05270616|Procedure|robotic surgery|minimally invasive surgery using the Davinci robotic system
75416368|NCT05270616|Procedure|uniport surgery|VATS minimally invasive surgery under the uniportal status
75561744|NCT00498134|Drug|Triple therapy for H. pylori infection|
75561745|NCT00498134|Drug|Cox-2 inhibitor|
75561746|NCT05146557|Other|Dental examination|In this cross sectional observational study only Dental examination and a self response survey was applied.
75561747|NCT00502580|Behavioral|Interview|Interview taking about 10 minutes to complete.
75873441|NCT03633786|Procedure|robot-assisted surgery|"removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console."
75561748|NCT05146518|Behavioral|Supportive and Dignified Maternity Care|"The core components of intervention would include: capacity-building of a typical maternity team comprising clinical staff (gynaecologists, doctors, nurses) and support staff (ward boys/porters and maids); collaborative care, a team-driven approach, led by gynaecologists (ward in-charge), attempts to integrate care and behaviour practices of staff according to the principles of measurement-guided care-plans, quality improvement and accountability, with a focus on meeting SDMC needs; staff and patient feedback: a complaints register will be maintained by designated staff; and brief exit interviews will elicit, and record, the degree to which care has been supportive and respectful; Accountability and governance (performance review): reports of non-respectful care will be discussed, and remedial actions decided, in periodic meetings.~Note: Since it is a behavioural intervention being administered at health system level so LSHTM has exempted this study to have a sponsor."
75561749|NCT00498251|Drug|inhalation of salbutamol (5 mg)|
75716990|NCT00932607|Drug|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
75716991|NCT00783822|Other|RGCT|rapid genetic counseling and testing
75716992|NCT00932685|Drug|Midazolam|Midazolam 0.5mg/kg
75716993|NCT00932685|Device|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
75716994|NCT05000346|Drug|Drug, inhalation|Solution administered by inhalation
75716995|NCT00931125|Drug|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
75716996|NCT00931125|Procedure|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
75716997|NCT00789984|Device|noncontact specular microscopy|
75716998|NCT00932763|Drug|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
75716999|NCT00932763|Drug|Norvasc|10 mg dose (Pfizer, USA)
75416369|NCT05270616|Procedure|multiple- port surgery|VATS minimally invasive surgery under the multiple- port status
75416370|NCT05270590|Procedure|minimally invasive rheumatic mitral valve surgery|First, venous and arterial access was established. Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ). The thoracoscope was inserted. Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made. Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently. After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0. Weaning from bypass start
75416371|NCT05270577|Other|Prehabilitation|prehabilitation
75416372|NCT05270577|Other|Standard care|No intervention
75416373|NCT05270564|Procedure|Drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
75416374|NCT05270564|Procedure|No drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
75416375|NCT05270551|Procedure|ACL Reconstruction|All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program
75416376|NCT05270538|Device|Mask Zero Seam Virus Bac-Off Lupo® 98% Polyamide and 2% Elastane|The 26 participants allocated as G2 had to perform the physical exercise using the Zero Sewing Virus Bac-Off Virus® 98% Polyamide and 2% Elastane, in order to totally seal the nose and mouth.
75416377|NCT05270486|Procedure|Electromagnetic navigation system|The aim of this study is to assess the safety and efficacy of TELD assisted by electromagnetic navigation for treating lumbar disc herniation (LDH).
75441585|NCT01636245|Biological|three consecutive lots of EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
75441586|NCT01636245|Biological|placebo|placebo, two doses, 28 days interval
75561750|NCT00498251|Drug|ipratropium|
75717000|NCT00786396|Behavioral|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
75717001|NCT04014543|Other|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
75717002|NCT00783900|Other|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
75717003|NCT00932841|Other|Placebo|One packet PO daily x 8 weeks.
75717004|NCT00932841|Drug|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
75416378|NCT05270447|Other|Massage and patient education|"Connective tissue manipulation: The patients were informed about CTM and its mechanism of action before starting the CTM application. CTM was performed by a trained physiotherapist as the patient was in a sitting position.~Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off."
75561751|NCT05146401|Other|Plasma fatty acid concentration|Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
75561752|NCT00502619|Procedure|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
75416379|NCT05270447|Behavioral|Routine care and advising|Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
75416380|NCT05270434|Procedure|time interval between ESWL and ERCP is 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12h.
75416381|NCT05270434|Procedure|time interval between ESWL and ERCP is 12-36h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12-36h.
75561753|NCT00502619|Other|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
75561754|NCT00498290|Procedure|enhanced recovery after surgery (ERAS) protocol|An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
75561755|NCT00498290|Procedure|control|normal recovery protocol as usually
75561756|NCT00502658|Behavioral|Dietary supplement containing vitamins, minerals, and herbs|
75561757|NCT00502658|Behavioral|Shakes with nutrients and herbs|
75561758|NCT00502658|Behavioral|Control dietary supplement|
75416382|NCT05270434|Procedure|time interval between ESWL and ERCP is greater than 36h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP >36h.
75416383|NCT05270434|Drug|morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
75416384|NCT05270421|Drug|Furosemide 40 mg|Standard ESWL + Furosemide 40 mg
75416385|NCT05270421|Other|Conventional Treatment|Standard ESWL
75416386|NCT05270382|Other|cetylpyridinium chloride|The mouthwash is used to see the effects on wound healing and the oral microbiome.
75441587|NCT01636271|Drug|darapladib|darapladib enteric coated tablets 160 mg
75441588|NCT01636271|Drug|placebo|placebo
75561759|NCT00502658|Behavioral|Isocaloric, isonitrogenous control shakes without herbs|
75561760|NCT00502658|Behavioral|Personal energy tracking tool|
75561761|NCT00502736|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
75561762|NCT02954679|Other|Online self-administrated and anonymous survey questionnaire|The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.
75561763|NCT01246505|Device|CTO Crossing and Percutaneous transluminal angioplasty|Crossing of the CTO with the BridgePoint Medical System and subsequent treatment of the CTO via PTA (specific devices to be used for PTA at investigators' discretion)
75561764|NCT05146089|Other|Hypoxic exposure|30 minutes of intermittent hypoxia achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask.
75561765|NCT05146089|Other|modified Oxford test|An intravenous bolus of sodium nitroprusside (100 μg) will be given to decrease blood pressure, followed 1 minute later by a bolus of phenylephrine (150 μg) to increase blood pressure, occurring before and after intermittent hypoxia exposure.
75561766|NCT05146089|Drug|Oral Bosentan 62.5 mg|Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.
75416387|NCT05270343|Drug|Cholecalciferol (Vit D3) 400Unit Cap|Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml[125-200nmol/L], ≤100ng/ml[≤250nmol/L]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
75416388|NCT05270330|Other|This is an observational study, we don't have any interventions.|No intervention
75416389|NCT05270252|Other|Learning and Care|"The educational intervention lasted 10 hours: six face-to-face and four for personal study. Three educational methodologies were combined.~The first: flipped classroom. Students received training material in their email: articles on the needs of families / cancer survivors and family nursing according to the Calgary Model (Wright & Leahey, 2013) and experiential videos of survivors and family members. In the classroom, a week later, a nurse promoted students' self-learning and reflection.~The second: simulation clinical case. The students received by email a summary of the case and material for their personal work. Students in groups of three performed the entire clinical scenario.~The third: round table. The components were advanced practice nurse, medical oncologist, cancer survivor and a family member. The content revolved around personal experience in caring for family members and cancer survivors and the interdisciplinary work required for this care."
75561767|NCT05146089|Other|Hypoxic ventilatory response test|Hypoxia will be achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask. This will be repeated 4-5 times per test, occurring before and after intermittent hypoxia exposure.
75561768|NCT02955030|Biological|NSV0001|sublingual
75561769|NCT02955030|Biological|"Influenza HA vaccine Biken HA"|subcutaneous
75561770|NCT02955030|Biological|Placebo|sublingual
75717005|NCT00932841|Drug|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
75717006|NCT00783978|Other|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
75717007|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
75717008|NCT00938613|Drug|Placebo|nasal spray, one spray per nostril at time 0
75717009|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
75717010|NCT00786552|Drug|pemetrexed + paclitaxel|Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
75717011|NCT00938691|Procedure|Intradermal Suture|
75717012|NCT00938691|Procedure|Intradermal Suture|
75717013|NCT04046640|Device|Infrared thermal imaging|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a NEC InfRec R450 infrared thermal imaging camera~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
75873442|NCT03633786|Diagnostic Test|assessment of sexual function|assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery
75873443|NCT03633786|Diagnostic Test|assessment of bowel symptoms|assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery
75441589|NCT01636310|Other|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
75561771|NCT00498407|Drug|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
75561772|NCT02954913|Procedure|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
75561773|NCT00498524|Device|ICD|Received an ICD
75561774|NCT00498524|Device|ICD|Have not received an ICD
75561775|NCT02954757|Procedure|HIFU treatment|High intensity focused ultrasound
75873444|NCT03633786|Diagnostic Test|assessment of urinary symptoms|assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
75561776|NCT00502814|Procedure|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
75561777|NCT00502814|Procedure|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
75873445|NCT03421392|Other|non interventional study|non interventional study
75561778|NCT00502814|Procedure|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
75717014|NCT00938769|Other|Self-Efficacy Training for Caregivers|"The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.~2-hour in-person instruction of home care issues for caregivers of patients with cancer."
75717015|NCT00938769|Other|Comparison Conditions for Caregivers|"Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.~2-hour counseling session for cancer caregivers to locate community support resources"
75717016|NCT04047186|Drug|Nivolumab Injection|Nivolumab 3mg/kg on day-28 and day-14 prior to planned surgical resection
75561779|NCT00502814|Procedure|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
75561780|NCT02954640|Biological|Blood sampling|Additional blood sampling for the realization of the test on the gene panel
75561781|NCT00498563|Procedure|altitude exposure in hypobaric chamber|
75717017|NCT00931203|Drug|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
75717018|NCT00784056|Drug|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
75873446|NCT05217732|Drug|ZX-7101A|tablet
75561782|NCT02954796|Drug|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
75561783|NCT00502892|Drug|Topotecan|0.5 mg/m^2 IV Daily x 3 Days
75561784|NCT00502892|Drug|Ifosfamide|1.8 grams/m^2 IV Over 1 Hour x 5 Days
75561785|NCT00502892|Drug|Carboplatin|AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days [for patients > 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days]
75873447|NCT05217732|Drug|Placebo|Tablet
75873448|NCT05217576|Device|NBM-200|Finger Prick and Venipuncture
75873449|NCT03440411|Drug|Pomalidomide|4 mg/daily as oral administration (PO) on days 1-21.
75873450|NCT03440411|Drug|Cyclophosphamide|50 mg every other day as oral administration (PO) on days 1-28
75873451|NCT03440411|Drug|Dexamethasone|40 mg as oral administration (PO) on days 1, 8, 15, 22.
75873452|NCT03714893|Device|Sensor wrist watch|Participants will wear a sensor wrist watch which will collect data
75873453|NCT03717233|Device|Exoskeleton|Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
75416390|NCT05270226|Behavioral|The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)|"The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists)."
75561786|NCT02954835|Device|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
75561787|NCT02954835|Device|Traditional Dressing|Sterile gauze dressing secured by tape.
76042596|NCT05867199|Behavioral|Motor Imagery and Action Observation Training|The training consists of watching videos of actions performed with the hand. At the end of the video the subject is subsequently asked to imagine performing the action just seen
75561788|NCT00502970|Drug|16 weeks Interferon Tiw with Ribavirin|16 weeks Interferon Tiw
75561789|NCT00502970|Drug|24 weeks Interferon|24 weeks Interferon Tiw with Ribavirin
75561790|NCT00506649|Other|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
75416391|NCT05270187|Other|Photobiomodulation therapy (laser therapy)|The Multiwave Locked System Laser will treat both the scan and point application groups. M6 laser equipment (ASA, Arcugnano, Italy) is used in this study in the physiotherapy and rehabilitation department, Faculty of Applied Medical Science, Umm Al-Qura University. It provides synchronized and overlapping continuous and pulsed emissions of Ga-Al-Ar laser emitted in a single hand piece. M6 has a continuous emission of a wavelength of 808 nm with peak power of 1000 mW, mean power of 500mW, spot diameter of 2 cm, and spot area of 3.14 cm2. Pulsed emission has a wavelength of 905 nm, peak power of 25 W, and mean power of 54mW with frequency of 1500 Hz.
75873454|NCT03714737|Biological|experimental vaccine|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
75873455|NCT03714737|Biological|Positive control vaccine 1|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
76042597|NCT05867160|Other|ASM as adjunctive therapy|ASM approved as adjunctive therapy
76042598|NCT05867134|Behavioral|Removal of postoperative lifting restrictions|"Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to return to activity as tolerated/comfortable and stop activity if pain present."
76042599|NCT05867095|Procedure|Surgical navigation|Patients will be operated with assistance of a navigation system
76042600|NCT05867095|Procedure|Conventional|Patients will be operated using the conventional technique
75561791|NCT00498641|Procedure|computer program and patching|
75561792|NCT05140980|Other|Data collection|evaluation of women's knowledge concerning sexuality
75561793|NCT00498680|Drug|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
75561794|NCT00498680|Drug|Sildenafil|100mg
75561795|NCT00498680|Drug|Vardenafil|20mg
75561796|NCT00498680|Drug|Sildenafil & Vardenafil|50mg & 10 mg
75561797|NCT05146011|Procedure|Gatsric balloon insertion|Insertion of Gastric balloon prior to laparoscopic gastric bypass surgery
75561798|NCT00498719|Behavioral|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
75561799|NCT00498719|Other|Control Group|Standard educational support.
75561800|NCT00498758|Device|APOS System - biomechanical wedge shoe|
75561801|NCT00507390|Dietary Supplement|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
75561802|NCT00507390|Dietary Supplement|olive oil|1 capsule day
75561803|NCT00503087|Procedure|Saline Injection|
75561804|NCT00503087|Device|Pneumatic Skin Flattening (PSF)|
76042601|NCT05867082|Other|Neural Mobilization|Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization
75561805|NCT00498953|Drug|carboplatin|
75416392|NCT05270187|Other|Facial massage and facial expression exercises|Facial massage and facial expression exercises will be applied for all patients in the three treatment groups. It includes simple facial expression exercises, active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
76042602|NCT05866978|Behavioral|Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA)|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish context among blue-collar workers.
75561806|NCT00498953|Drug|cisplatin|
75561807|NCT00498953|Drug|docetaxel|
75561808|NCT00498953|Drug|fluorouracil|
76042603|NCT05866965|Other|PRF|centrifuge patient's blood to collect 1 block of yellowish condensed fibrin, which is platelet-rich fibrin
75561809|NCT00498953|Drug|lapatinib ditosylate|
75561810|NCT00498953|Genetic|cytogenetic analysis|
75561811|NCT00498953|Genetic|fluorescence in situ hybridization|
75873456|NCT03714737|Biological|Positive control vaccine 2|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
75416393|NCT05270161|Procedure|Tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The incision was extended to the adjacent tooth on both sides of the multiple recessions. Dissection of the entire buccal aspect was performed as a partial-thickness flap using sharp tunnel elevators preserving the papillae. The flap was extended beyond the mucogingival junction and under each papilla allowing a tension-free flap mobilization in the coronal direction. The connective tissue graft was placed in the tunnel and was stabilized using absorbable suspensory sutures. The mobilized mucous flap was advanced coronally to the cemento enamel junction, and suspensory sutures were stitched.
75561812|NCT00498953|Genetic|in situ hybridization|
75561813|NCT00498953|Genetic|polymerase chain reaction|
75561814|NCT00498953|Genetic|reverse transcriptase-polymerase chain reaction|
75561815|NCT00498953|Other|immunohistochemistry staining method|
75873457|NCT03438539|Behavioral|Normative Feedback|Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
75873458|NCT03438539|Behavioral|Inhibitory Control Training|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control.
75561816|NCT00498953|Other|laboratory biomarker analysis|
75561817|NCT00498953|Procedure|conventional surgery|
75561818|NCT00498953|Procedure|neoadjuvant therapy|
75561819|NCT00498953|Radiation|fludeoxyglucose F 18|
75561820|NCT00498953|Radiation|radiation therapy|
75561821|NCT00506688|Drug|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
75561822|NCT00506688|Drug|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
75561823|NCT00503126|Drug|bivalirudin|anticoagulation
75561824|NCT05145894|Device|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
75561825|NCT00503165|Biological|Menitorix (MenC and Hib conjugate)|
75561826|NCT05145543|Drug|Saline 0.9%|0.9 NaCl % (Saline) (5 ml) will be applied
75561827|NCT05145543|Drug|Levobupivacaine Hydrochloride|0.25 % levobupivacaine (5 ml) will be applied.
75561828|NCT05145543|Drug|Fentanyl|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
75561829|NCT05145543|Drug|Dexamethasone|Dexamethasone plus levobupivacaine (5 ml) will be applied.
75561830|NCT00503204|Drug|Cediranib|oral tablet
75561831|NCT00503204|Drug|Lomustine|oral capsule
75873459|NCT03438539|Behavioral|Working Memory Training|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task.
75873460|NCT05657639|Drug|CAV Regimen|Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
76042604|NCT05866965|Other|standard third molar surgical removal|standard third molar surgery following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
76042605|NCT05866926|Drug|FAB122|FAB122 Daily dose 100 mg
76042606|NCT05866900|Device|MiniMed 780G with SmartGuard activated|The MiniMed 780G system consists of a MiniMed 780G Insulin Pump connected to Guardian 4 Sensor or Guardian 3 Sensor, using an automated insulin delivery algorithm called SmartGuard.
76042607|NCT05866861|Drug|CUG252|CUG252 will be administered by subcutaneous injection.
76042608|NCT05866861|Drug|Placebo|Placebo will be administered by subcutaneous injection.
76042609|NCT05866848|Other|Placebo|Flour capsules as a placebo.
76042610|NCT05866848|Other|Anhydrous caffeine (45mg)|Capsules dosed with 45mg of anhydrous caffeine.
76042611|NCT05866848|Other|Anhydrous caffeine (120mg)|Capsules dosed with 120mg of anhydrous caffeine.
76042612|NCT05866822|Other|APA|24 APA sessions
76042613|NCT05866822|Other|PAE|8 individuals sessions of PAE
76042614|NCT05866796|Diagnostic Test|GlycoTransplantTest|Determination of serum glycomics in the early posttransplant stage, using an optimal cutoff based on statistic modeling.
75561832|NCT05145504|Diagnostic Test|Evaluation of IL-6 biomarkers in synovial fluid|Evaluation of IL-6 biomarkers in synovial fluid in obese and normal weight patients with gonarthrosis
75873461|NCT05657639|Drug|MEC Regimen|Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
75561833|NCT00503243|Drug|Delayed and extended release mesalazine|
75873462|NCT05656625|Other|descriptive|The block performed (distal peripheral nerve block and/or brachial nerve block) and the volume applied, block performance time, first analgesia times, surgery times, surgery types, discharge times, presence of additional complaints will be recorded. The data obtained by grouping the patients according to the type of anesthesia applied (brachial plexus block and distal nerve blocks) will be subjected to statistical analysis.
76042615|NCT05866783|Diagnostic Test|HCCRecurrencePrognosticScore|Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling
76042616|NCT05866783|Diagnostic Test|HCCRecurrenceDiagnosticScore|Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
76042617|NCT05866744|Other|Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow an early 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 08:00-18:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
75416394|NCT05270161|Procedure|Laterally closed tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The tunnel elevators were mobilized apically beyond the mucogingival line and extended medially and distally from the recession defect by undermining the facial surface of the interdental papillae. The insertion of muscles and fibers must be removed until a tension-free flap is obtained in the mesial, apical and distal directions. The preparation of the flap will be done carefully to avoid rupture of the papillae and perforation of the flap. As a result of this procedure, the mesial and distal margins of the flap must be brought together without tension to cover the exposed part of the root surface. The connective tissue graft was placed in the tunnel and was fixed mesially and distally at the inner aspect of the flap. Margins of the flap were pulled together over the graft and sutured with interrupted sutures.
75561834|NCT05145465|Other|Telerehabilitation group|"All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not."
75561835|NCT00498992|Dietary Supplement|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
75873463|NCT03400787|Device|Latera Implant|Treatment with implant
75873464|NCT03400787|Device|Sham Procedure|Sham procedure where the Latera delivery device is inserted but no implant delivered.
75873465|NCT03639077|Device|Allograft bone alone|The subject will receive an allograft as graft material of choice for sinus augmentation
75873466|NCT03639077|Device|Allograft and xenograft mixture|The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
75873467|NCT03417245|Drug|fitusiran|by SC injection
75873468|NCT03417245|Drug|factor concentrates|by intravenous (IV) injection
75873469|NCT03711851|Behavioral|Self-help Acceptance and commitment therapy (Web-based)|9 week program with minimal contact with therapist (predominantly self-help)
75873470|NCT03711851|Behavioral|Self-help Acceptance and commitment therapy (bibliotherapy)|9 week program with contact with therapist (predominantly self-help)
75416395|NCT05270161|Procedure|Free gingival graft|In the recipient area, a marginal horizontal linear incision will be made in the mucogingival junction with a n°15 C blade, creating a partial thickness flap, keeping the periosteum intact. The horizontal dimension of the receiving area will be determined according to the mesiodistal extension of the area without keratinized gingiva. All mobile soft tissues, including epithelium, connective tissue and muscle fibers will be removed from the donor area using scissors to ensure stability in the recipient area. The connective tissue graft will be obtained by the free gingival graft technique and will be sutured in the recipient area.
75416396|NCT05270161|Procedure|Gingival graft - donor area|The connective tissue graft will be obtained by the free gingival graft technique for all groups (T1, T2, T3 and T4). The mold of the prepared receiving area will be performed using sterile aluminum foil. The mold will be transferred to the donor area on the palate and the edges of the mold delimited with a scalpel blade. Deeper incisions will be made on the edges with the scalpel perpendicular to the palate, aiming to obtain a graft approximately 1.5 mm thick. With the scalpel blade parallel, the graft will be removed (epithelium and connective graft) maintaining its uniform thickness. For T1 and T2, the free gingival graft will be de-epithelialized. In donor area, a hyaluronic acid gel and green tea will be applied by the participant 3 times a day for 7 days (gel group) or no material will be placed in the donor area and the clot will be kept in position by means of sutures (clot group).
75561836|NCT04696107|Behavioral|Psychoeducative intervention|"This workshop is centred in psychoeducational and training action in emotional self-regulation in a group modality and participatory character, aimed at patients with mCNCP to acquire basic knowledge in:~Neurology and psychoneuroimmunology.~The role of beliefs in our manifestation of the disease.~Body language and modulation of pain perception.~Relaxation body-mind techniques.~Creative visualization for pain management.~Mirror feed-back.~The workshop will take place at the Hospital San Juan de Dios del Aljarafe, in four weeks, once a week, three hours each. Until now, the attendance was 24 patients per workshop. After the pandemic, we will reduce to 15 to increase safety distance. We will also conduct a telephone survey of each patient on symptoms of Covid infection in the 24 hours prior to the workshop."
75561837|NCT02276391|Drug|Telmisartan/HCTZ combination|
75561838|NCT02276391|Drug|Telmisartan|
75561839|NCT05145270|Dietary Supplement|Escitalopram+Sulforaphane|Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day .
75561840|NCT05145270|Device|Escitalopram+rTMS|Escitalopram(No-specified) 10-20mg/d, once per day; rTMS: rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day.
75561841|NCT05145270|Drug|Escitalopram|Escitalopram(No-specified) 10-20mg/d, once per day.
75561842|NCT02276625|Biological|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
75561843|NCT02276664|Behavioral|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
75561844|NCT02276664|Behavioral|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
75561845|NCT01245296|Procedure|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
75561846|NCT04695990|Drug|Wenyang Huoxue Decoction|Wenyang Huoxue granules
75561847|NCT04695990|Drug|Wenyang Huoxue placebo|Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
75561848|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
75561849|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
75561850|NCT02276703|Device|Skin Conductance Monitor|monitors skin conductance values
75561851|NCT00499070|Genetic|polymerase chain reaction|
75717019|NCT00540592|Biological|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
75717020|NCT00540592|Biological|Fluarix|Single dose, Intramuscular injection
75717021|NCT03970395|Other|Osteopathic manipulative therapy (OMTh)|The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
75717022|NCT03970395|Other|Light Touch Therapy (LTT)|The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
75561852|NCT00499070|Other|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
75416397|NCT05270135|Behavioral|ASAP|ASAP is an intervention geared toward increasing non-stigmatized syringe sales to people who inject drugs to prevent bloodborne illnesses.
75416398|NCT05270070|Other|Appointment booking system|Patients were sent an email to book an appointment using the telephone/email versus a online booking system.
75561853|NCT00499070|Other|immunologic technique|
75561854|NCT00499070|Procedure|biopsy|
75561855|NCT00503360|Drug|SAD448|
75561856|NCT05147844|Drug|Toripalimab|"Toripalimab: 240mg, iv. Q3W for 1 year or until disease progression/intolerable toxicity~Radiotherapy:~Newly diagnosed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 70 Gy, pGTVnd 99Gy, pCTV1, 60 Gy, pCTV2, 54 Gy, 33 times, completed in 7 weeks.~Relapsed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 60Gy, pGTVnd 60Gy, 20-25 times, completed in 4-5 weeks.~Newly diagnosed and relapsed patients: SBRT for oligometastatic lesions, pGTV 25-40 Gy, 3-5 times, completed in 1-2 weeks."
75561857|NCT00503477|Drug|AZD2171|oral tablet
75561858|NCT00499148|Other|herbal extract; root of woody shrub grown in India/Sri-Lanka|
75873471|NCT03711851|Other|Self-help Education pamphlets on pain (active control group)|9 week program with contact with therapist (predominantly self-help)
76042618|NCT05866744|Other|Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow a late 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 12:00-22:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
75416399|NCT05270018|Drug|Bacterial Lysates|14mg once a day
75416400|NCT05270018|Other|normal saline|14.0ml once a day
75416401|NCT05270005|Diagnostic Test|Ultrasound-based flow imaging|Ultrasound-based flow imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
75416402|NCT05270005|Diagnostic Test|Ultrasound-based strain imaging|Ultrasound-based strain imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
75416403|NCT05270005|Diagnostic Test|Conventional duplex|Conventional duplex measurements of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
75416404|NCT05269979|Behavioral|Prevention of hip fractures|Physical exercise and lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
75416405|NCT05269940|Drug|ZX-101A|oral dosing, once daily
75416406|NCT05269927|Diagnostic Test|EEG|resting state EEG
75561859|NCT05144295|Drug|Lubiprostone Pill|Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.
75416407|NCT05269927|Diagnostic Test|DNA samples|genotypings of twelve CNTNAP2 SNPs from DNA obtained by saliva samples
75561860|NCT05144295|Drug|Lactulose Oral Liquid Product|"Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)"
75561861|NCT05144295|Drug|Bisacodyl 5 MG|Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for < 12 years or 3 tab/day for > 12 years
75561862|NCT05144295|Drug|Sodium Picosulfate|Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
75561863|NCT01245452|Drug|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
75561864|NCT01245452|Drug|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
75561865|NCT00503516|Drug|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
75561866|NCT00503516|Drug|Placebo|1 sachet of 160 mg of placebo b.i.d.
75561867|NCT05148195|Drug|Envofolimab|300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
75561868|NCT05148195|Drug|BD0801|2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
75561869|NCT05148195|Drug|Docetaxel|75mg/m2，Q3W
75561870|NCT05148195|Drug|Irinotecan|180 mg/m2，Q2W
75561871|NCT05148195|Drug|Leucovorin calcium|400mg/m2，Q2W
75561872|NCT05148195|Drug|5-Fluorouridine|2400 mg/m2，Q2W
75561873|NCT04696991|Behavioral|The postpartum discharge education with PechaKucha Method.|The postpartum discharge training in which the PechaKucha method was applied via the smartphones was offered to the mothers in the experimental group whereas the mothers in the control group had solely the routine discharge training. The postpartum training was offered as per the Postpartum Care Management Guideline of the Ministry of Health of Turkey. The discharge training was offered to the experimental group by using the PechaKucha presentation technique.
76042619|NCT05866744|Other|Hypocaloric Mediterranean Diet Without Time Restriction In Feeding|18 patients with NAFLD will be asked to follow an individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) without time restriction in feeding (eating throughout the day) for 12 weeks
76042620|NCT05866614|Drug|Remsima IV|Patient will be treated with Remsima IV as per the SmPC or
75561874|NCT05146869|Drug|DBPR108 tablets|DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
75561875|NCT01245491|Other|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
75416408|NCT05269927|Diagnostic Test|clinical data|"standardized scales measuring the infants' cognitive, motor and linguistic development administered at 6, 12 and 18. Measures available at 6 and 12 months: a) Bayley Scales of Infant and Toddler Development- Third Edition; b) Griffiths mental development scales (0-2) (GMDS-R); Measures available at 18 months: c) Language Development Survey (LDS); d) Il PRIMO VOCABOLARIO DEL BAMBINO (PVB); e) CHILD BEHAVIOR CHECKLIST (CBCL); (f) Modified Checklist for Autism in Toddlers (M-CHAT)."
75416409|NCT05269927|Other|environmental data|questionnaires administered to parents related to the following environmental factors: a) information about the presence of a clinical diagnosis of neurodevelopmental disorders within first-degree relatives; b) gestational age; c) birth weight; d) parental age and education; e) socio-economic status
75416410|NCT05269914|Other|Autologous anti-CD19 CAR-T cell injection|"According to preclinical research, existing preliminary clinical data and similar approved therapeutic products (kte-c19 of Kate company, the trade name is yescarta ®） According to the clinical trial results, three doses (the number of cells per unit body weight) were selected as the therapeutic dose of this study. Among the patients who increased the dose according to the 3 + 3 design, the number of target cells in each dose group was: (1) the first dose group was 1.00 × 106 Car + T cells / kg, 20% dose error is allowed. (2) the second dose group is 3.00 × 106 Car + T cells / kg, 20% dose error is allowed. (3) the third dose group is 9.00 × 106 Car + T cells / kg, 20% dose error is allowed."
76042621|NCT05866614|Drug|Remsima SC|Patient will be treated with Remsima SC as per the SmPC
75416411|NCT05269719|Procedure|Suture of digital nerve|The digital nerves were sutured according to the discretion of the treating surgeon and the standard procedure was three epineural sutures 8.0 or 9.0 nylon under loop magnification. Concomitant tendon injuries were also sutured according to the discretion of the treating surgeon, most commonly with two loop sutures (four strand core) and a peritendinous PDS suture.
75561876|NCT05143827|Other|Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
75561877|NCT05143827|Other|Pasta manufactured with current wheat varieties (Claudio)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
75561878|NCT00499187|Procedure|Blood Draws|A single whole blood sample was collected for genomic analysis.
75561879|NCT05147259|Drug|HR011408 injection|Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
75416412|NCT05269693|Other|Brief Hope Intervention|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions
75561880|NCT00499265|Drug|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
75561881|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
76042622|NCT05866588|Behavioral|Physical, psychological and spiritual nursing care (Nursing Therapeutics)|"Follow-up: To make a presentation about the physiological and psychological changes during pregnancy. do dream work~Follow-up: Providing education and counseling for childbirth.~Follow-up: Training and role rehearsal on mother-infant interaction, breastfeeding and infant care.~Follow-up: To provide counseling on the issues needed with the approaching of the birth.~Follow-up: Teaching about conscious parenting and mother-infant, father-infant interaction.~Tracking. To provide education, counseling and social support on the other roles of the mother in life such as wife role, working woman role, social role.~Follow-up: To evaluate the transition to motherhood.~Follow-up: To evaluate the outcomes of transition to motherhood and adjustment to motherhood according to expected completion time."
75416413|NCT05269654|Device|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
75416414|NCT05269654|Other|Normal Saline|Sham Comparator
75561882|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
75561883|NCT05147064|Procedure|minimally invasive surgery|using (tubular dilators, surgical microscope, and/ or endoscope). the other group will be operated by conventional inter laminar decompression.
75561884|NCT05147064|Procedure|conventional open surgery|open interlaminar lumbar decompression
75561885|NCT01246622|Drug|cytarabine|Given IV
75561886|NCT01246622|Drug|lenalidomide|Given PO
75561887|NCT01245530|Drug|Aricept|Aricept Comparator Intervention: Drug: Aricept 5~10 mg orally every day for 24weeks
75561888|NCT01245530|Drug|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600~1200 mg orally every day for 24weeks
75717023|NCT03970395|Other|Repositioning therapy|"It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed."
75561889|NCT00499382|Procedure|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
75561890|NCT00499382|Procedure|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
75561891|NCT05148312|Drug|Budesonide Inhalant Product|Single-dose of budesonide solution administered by nebulization.
75561892|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
75561893|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
75416415|NCT05269641|Other|Food: whole almonds|60g of whole almonds will be consumed daily.
75561894|NCT05142306|Biological|COVID-HIG|Anti-SARS-CoV-2 Immunoglobulin (Human) [COVID-HIG] is a purified liquid immunoglobulin G (IgG) preparation
75416416|NCT05269641|Other|Food: non-nut snack|A non-nut snack will be consumed daily.
75717024|NCT00790140|Dietary Supplement|Prosure|This is an enteral tube feed with 125 kcals & 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
75416417|NCT05269524|Behavioral|Internet-delivered tailored cognitive behavior therapy|Therapists-supported tailored 10-week treatment for depression in older adults.
75416418|NCT05269485|Radiation|High-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f with one-year immunotherapy maintenance.
75416419|NCT05269485|Radiation|Low-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/15-12f with one-year immunotherapy maintenance.
75416420|NCT05269420|Procedure|SAS-J|Single Anastomosis Sleeve Jejunal Bypass
75561895|NCT05143437|Behavioral|Love Together Parent Together|A brief, low-intensity writing intervention adapted for parents of young children, designed to reduce conflict-related distress, prevent relationship deterioration and encourage the use of conflict reappraisal strategies designed to reduce conflict-related distress, etc.
75561896|NCT00499499|Drug|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
75561897|NCT05148663|Diagnostic Test|CCM Hemorrhagic Panel|Biomarker
75561898|NCT01246817|Drug|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
75717025|NCT00790140|Dietary Supplement|Ensure Plus|This is a standard enteral tube feed with 150 kcals & 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
75416421|NCT05269342|Behavioral|nurse-led counseling and after intervention|the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC
75416422|NCT05269329|Drug|XC8, film-coated tablets, 20 mg/day|20 mg/day (1 tablet twice a day)
75416423|NCT05269329|Drug|XC8, film-coated tablets, 40 mg/day|40 mg/day (2 tablets twice a day)
75416424|NCT05269329|Drug|XC8, film-coated tablets, 80 mg/day|80 mg/day (4 tablets twice a day)
75717026|NCT00565773|Drug|Belatacept|Belatacept will be given within 24 hours of transplantation via a peripheral intravenous catheter at a dose of 10mg/kg (actual body weight) infused over 30 mins. The dose will be repeated on study days 4 (post op day 3) and 8 (post op day 7), then every 2 weeks for 5 additional doses. Thereafter, belatacept will be given once every 4 weeks (+/- 3 days) at 10mg/kg through 6 months then at 5mg/kg indefinitely.
76042623|NCT05866575|Other|escitalopram|Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
75416425|NCT05269329|Drug|Placebo|1, 2, or 4 tablets twice a day
75416426|NCT05262673|Biological|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
75416427|NCT05254392|Device|Digital BP monitor (Chidalex®)|Interventions were provided in groups of 4 - 10 participants after data collection at baseline while reinforcing individualized interventions were provided during subsequent visits to the research clinic for follow-up at 6 months and 12 months. Medication reminder text messages were delivered to each participant biweekly.
75561899|NCT04696341|Procedure|Matrix Rhythm Therapy|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.
76042624|NCT05866575|Other|vortioxetine|Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
76042625|NCT05866562|Drug|Dupilumab|every other week 200 mg or 300 mg (weight-based) SC injections
76042626|NCT05866562|Drug|Placebo|Placebo comparator
75717027|NCT00565773|Drug|Sirolimus|Sirolimus will be started on postoperative day 1 at a dose of 2 mg per day orally. Doses will be adjusted to maintain 24-hour trough levels of 8-10ng/ml until the drug is weaned. Toxicity attributable to sirolimus (e.g., mouth ulcers, arthralgias) will prompt dose reduction to address clinical concerns in this regard. If sirolimus trough levels need to be reduced below 4ng/ml to control drug side effects, the patient will be considered intolerant to the drug and will be changed to other medications.
76042627|NCT05866510|Drug|Utidelone and anlotinib|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days."
76042628|NCT05866497|Diagnostic Test|clinical periodontal measurements|"Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.~The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop"
76042629|NCT05866497|Diagnostic Test|CAVI measurements|"Arterial stiffness of the participants included in this study were assessed by CAVI index using VaSera (VS-1500N) CAVI device (Fukuda Denshi Co. Ltd., Tokyo, Japan) between both arms and ankles in a supine position.~Right and left CAVI values were calculated separately."
76042630|NCT05866393|Behavioral|Clean Hands Accessible and Manageable for Patients|Use of a patient-smart hand sanitation dispenser that provides reminders that are non-beeping reminders.
76042631|NCT05866380|Other|heart failure risk factors|observational study with diabetes patient with heart failure risk factors
76042632|NCT05866289|Other|Prone position|Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
75416428|NCT05253625|Other|Listening to a recorded lullaby.|A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.
75561900|NCT04696341|Procedure|Control|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
75561901|NCT05147025|Other|Revascularization|Regain pulp vascularity for young permenant teeth
75717028|NCT00565773|Drug|Alemtuzumab|All participants will receive a single dose of 30 mgs of alemtuzumab on the day of transplantation.
75416429|NCT05252897|Procedure|Endoscopic necrosectomy with step up approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, step up approach will be adopted.
75416430|NCT05252897|Procedure|Endoscopic necrosectomy with direct approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, the direct approach will be adopted.
75416431|NCT05252468|Device|TaffiX™|Personal nasal powder spray.
75416432|NCT05251961|Procedure|operative deformity correction|"The participants will be subjected to surgical correction using growing rods as a novel technique for their long bone deformities.~Procedure will be done under anaesethia~Osteotomy , fracture reduction , deformity correction will be done , then introduction of the growing rod"
75561902|NCT00499538|Drug|SKI-606|
75561903|NCT01245803|Drug|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
75561904|NCT01245803|Drug|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
75561905|NCT05148975|Diagnostic Test|Bronchoalveolar lavage fluid diagnostics|Bronchoalveolar lavage fluid diagnostics for superinfection in patients with COVID-19 pneumonia.
75561906|NCT01246934|Other|ASR METHOD|
75561907|NCT05146947|Device|near infrared spectroscopy|near infrared spectroscopy monitoring on kidney after reperfusion
75561908|NCT01247012|Dietary Supplement|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
75561909|NCT01247012|Dietary Supplement|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
75561910|NCT03454191|Procedure|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
75561911|NCT03454191|Procedure|No injection|No injection
75561912|NCT00499577|Biological|CMV pp65 peptide|Given intramuscularly
75561913|NCT00499577|Biological|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
75717029|NCT00932919|Behavioral|Thought field therapy|5 sessions with Thought field therapy
75717030|NCT00932919|Behavioral|Cognitive therapy|12 sessions of Cognitive therapy
75717031|NCT00932919|Behavioral|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
75416433|NCT05250739|Other|Strength training|Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.
75561914|NCT00499577|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
75561915|NCT00499577|Biological|survivin Sur1M2 peptide vaccine|Given subcutaneously
75561916|NCT03450096|Other|LPB|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
75561917|NCT02274740|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
75561918|NCT02274740|Drug|metformin|Pharmaceutical form:tablet Route of administration: oral
75561919|NCT00499733|Drug|cyclophosphamide|500 mg/m^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
75561920|NCT00499733|Device|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
75561921|NCT03452202|Device|Soterix 1x1 line tDCS low-intensity stimulator|Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
75561922|NCT03452202|Device|Sham|Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
75561923|NCT06155825|Behavioral|no intervention|Group 4 will receive no intervention
76042633|NCT05866263|Other|green walking and intelligence gam|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
75561924|NCT06155825|Drug|nonnutritive suckling|Group 1 will receive nonnutritive suckling
76042634|NCT05866224|Other|Telerehabilitation program|The supervised telerehabilitation program will be performed in the home of each patient and supervised by an experienced physiotherapist with more than 4 years of clinical experience in therapeutic exercise for chronic diseases.
76042635|NCT05866211|Other|Previous exposure to SARS-CoV-2|This is an observational study in which no intervention will be applied.
76042636|NCT05866172|Procedure|HAIC|hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)
75561925|NCT06155825|Drug|oral glucose 25%|Group 2 will receive oral glucose 25%
75561926|NCT06155825|Behavioral|facilitated tuckling|Group 3 will undergo facilitated tuckling
76042637|NCT05866172|Drug|Zoledronic acid|Zoledronic acid 4mg iv.drip
75561927|NCT06155812|Other|Simultaneous administration of vasopressors|Early, simultaneous administration of norepinephrine, angiotensin II, and vasopressin.
75561928|NCT06155812|Other|Successive administration of vasopressors|Administration and titration of norepinephrine and administration of additional vasoactive drugs (epinephrine, methylene blue, angiotensin II, dobutamine, or dopamine) as per clinical team.
75561929|NCT06155799|Device|Freehand zygomatic implant placement|Zygomatic implants will be placed without any guidance after preoperative virtual planning has been performed.
75561930|NCT06155760|Drug|Prednisolone|10mg of prednisolone plus standard medical therapy for 60 days
75561931|NCT06155760|Other|Standard Medical therapy|IV Albumin, Diuretics, Multi vitamins as per clinicians decision
75561932|NCT06155760|Drug|Placebo|Placebo
75717032|NCT00932997|Behavioral|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
75561933|NCT06155734|Drug|Fluorescence guided identification using indocyanine green|During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas
75561934|NCT06155682|Device|repetitive transcranial magnetic stimulation|non-invasive repetitive stimulation applied to the scalp surface
75561935|NCT06155630|Other|mandibular implant-overdenture|Mandibular overdentures fabricated over two implants will be delivered to the patients. In the first group, the 3D printed overdentures will be given for 3 months, followed by 3-month wear of traditional overdentures. The second group will wear traditional overdenture first followed by 3 months of 3D printed overdenture.
75717033|NCT00932997|Other|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
75717034|NCT00932997|Other|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
75717035|NCT00932997|Other|questionnaire administration|Baseline and 9 months after enrollment and intervention
75717036|NCT00932997|Procedure|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
75717037|NCT00932997|Procedure|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
75416434|NCT05250739|Other|Neuromuscular training|consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
75416435|NCT05250583|Biological|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
75416436|NCT05250193|Device|DK ScoreTM Coronary Scoring Balloon|After pre-dilation balloon is used (if any), DK Score is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
75561936|NCT06155617|Other|Upper Extremity Rehabilitation|Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
75561937|NCT06155604|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily
75717038|NCT00570492|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
75717039|NCT00570492|Drug|Placebo nasal spray|Placebo nasal spray
75717040|NCT00931281|Drug|ABT-450|capsules, QD or BID, 14 days, ascending doses
75717041|NCT00931281|Drug|ritonavir|capsules, QD or BID, 14 days, ascending doses
75561938|NCT06155604|Drug|Standard maintenance therapy|Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (<=1.5 g/D) or Azathioprine (<=150 mg/D)
75717042|NCT00931281|Drug|Placebo for ABT-450|capsule, QD or BID, 14 days
76042638|NCT05866146|Other|Interprofessional rehabilitation program|The interprofessional rehabilitation program includes a comprehensive assessment, intensified physical activities and exercises, pain education, psychotherapy, occupational therapy, ergonomic interventions, and psychosocial counselling in addition to the current treatment standards. The interprofessional rehabilitation program will be delivered in a combination of individual (one-to-one) and group sessions (in groups of 6 - 10 patients). Care providers will apply a combination of lectures and discussions, individual exercises, and group-based exercises and education. All sessions will be delivered face-to-face (in person). The intervention will be provided by a team of healthcare providers with different professional backgrounds and training. The interprofessional team may include experienced physicians (GPs), neurosurgeons, physiotherapists, nurses, occupational therapists, and clinical psychologists.
75416437|NCT05250193|Device|Non-Slip Element Coronary Dilatation Catheter|After pre-dilation balloon is used (if any), NSE is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
76042639|NCT05866146|Other|Usual standard care|Participants in this group will receive the usual care currently implemented mainly pharmacological treatment (pain medication), and back pain advice. The usual care in rare occasions may also include physical therapy such as exercise and massage.
76042640|NCT05866120|Other|Physiotherapy on the ground|Physical therapy will be performed on the ground, in 12 weeks, twice a week. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
75416438|NCT05250141|Drug|Levodopa 250mg and Carbidopa 25mg Test Drug tablet|Investigational Medicinal Product
75416439|NCT05250141|Drug|Levodopa 250mg and Carbidopa 25mg Referent Product tablet|Sinemet (Savio Industrial S.R.L, Brazil)
75561939|NCT06155578|Drug|Topical 25% sodium metabisulfite (SM) in pediatric cold cream|Topical 25% sodium metabisulfite (SM) in pediatric cold cream will be applied twice daily on hand calcinosis.
75717043|NCT00931281|Drug|Placebo for ritonavir|capsule, QD or BID, 14 days
76042641|NCT05866120|Other|Aquatic physiotherapy|Aquatic physiotherapy will be performed in 12 weeks, twice a week, in shallow water. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
75416440|NCT05254769|Device|Neurofeedback Equipment (Cygnet) by BEE Medic GmbH Technologies, Baden-Wurttemberg, Germany.|The EEG NeuroAmp (Electroencephalogram Amplifier) is a user-friendly high-performance interface between client and clinician computer. It can be used in two different functionalities: In an EEG/ERP (Event related potential) measurement and in an EEG biofeedback (neurofeedback) and/or peripheral biofeedback setting.
75416441|NCT05248724|Combination Product|periarticular infiltration (50ml) with Ropivacaine Hydrochloride 10 MG/ML (200 mg) + ketorolac tromethamine 30 mg/ml (30 mg) + adrenaline 1mg/ml (300 microgram) + morphine hydrochloride 10mg/ml (5 mg)|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride ,150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride , 30 mg of ketorolac tromethamine, 300 micrograms of adrenaline and saline 0.9% till reaching 50 ml of volume. Half of the solution was injected into the proximal hamstring stump. The surgical team closed the wounds and injected the other half of the intervention into the subcutaneous tissue in the distal wound and portals. There was not any medication introduced inside the articulation. Patients of the placebo group were treated in the same way, but the solution injected was 50 ml of saline 0.9%.
75416442|NCT05248724|Drug|placebo|50 ml of 0.9 saline
75416443|NCT05246241|Device|magnetic resonance imaging|Preoperative magnetic resonance imaging
75416444|NCT05237310|Device|Standard Colonoscopy|Standard Colonoscopy using a standard Fujifilm colonoscope
75416445|NCT05237310|Device|G-EYE Colonoscopy|G-EYE Colonoscopy performed using SMART Medical G-EYE Colonoscope
75416446|NCT05237310|Device|CAD-EYE|Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence
75561940|NCT06155578|Drug|Placebo|Pediatric cold cream will be applied twice daily on hand calcinosis.
75561941|NCT06155539|Other|No intervention|No intervention
75717044|NCT00933075|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
75717045|NCT04014855|Drug|Iron Supplement|in iron deficiency anemia
75717046|NCT00933153|Dietary Supplement|Ensure Plus|Ensure plus supplement with meals
75717047|NCT00933153|Dietary Supplement|Meals on Wheels|Two Meals on Wheels twice daily
75717048|NCT00571922|Drug|Acamprosate|2 gr/day (333 mg, TID)
75717049|NCT00571922|Drug|placebo|matching placebo
75717050|NCT00786630|Behavioral|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
75561942|NCT06155526|Other|Activity|patients taking an active rest after swimming sets
75561943|NCT06155487|Drug|AJH-2947 100 mg (SAD)|Oral Tablet, Single dose of AJH-2947 100 mg
75561944|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 100 mg
75561945|NCT06155487|Drug|AJH-2947 200 mg (SAD)|Oral Tablet, Single dose of AJH-2947 200 mg
75416447|NCT05235893|Procedure|Reflexology|Reflexology was applied to soles of the babies in the second study group during 5-7 minutes, three minutes before the painful procedure was started by a physiotherapist, certificated in reflexology.
75561946|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 200 mg
76042642|NCT05866120|Other|Power training|The individuals will be submitted to the same exercises as the therapy protocol on the ground, but with a focus on power training, with fewer repetitions of the exercises and greater speed of movement in the concentric phase of the movement. As with other therapies, participants will be accompanied by therapists in small activity groups.
76042643|NCT05866068|Drug|Clomiphene|Clomiphene citrate 100mg daily during IVF stimulation
75416448|NCT05235893|Procedure|Sucrose %24|The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
75416449|NCT05235893|Procedure|Kangaroo care|The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
75416450|NCT05235893|Procedure|Music|"Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music"
75416451|NCT05232006|Drug|Niraparib|Niraparib, once daily
75416452|NCT05231447|Other|Environmental survey|"Exposure to environmental factors, drugs or individual toxicity during the periconceptional period and at the beginning of the pregnancy will be investigated by means of a questionnaire administered to the parents. This questionnaire, drawn up by the Aquitaine Reproduction Enfance Maternité et Impact Santé-environnement (ARTEMIS) centre and completed by both members of the couple, will constitute an initial assessment that will make it possible to collect environmental exposures for the parents of cases identified by the register."
75416453|NCT05228548|Other|Perioperative blood transfusion|Perioperative blood transfusion
75416454|NCT05225051|Other|skin biopsy|skin biopsy
75561947|NCT06155487|Drug|AJH-2947 300 mg (SAD)|Oral Tablet, Single dose of AJH-2947 300 mg
75561948|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 300 mg
75873472|NCT03389555|Drug|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
75561949|NCT06155487|Drug|AJH-2947 400 mg (SAD)|Oral Tablet, Single dose of AJH-2947 400 mg
75561950|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 400 mg
75561951|NCT06155487|Drug|AJH-2947 600 mg (SAD)|Oral Tablet, Single dose of AJH-2947 600 mg
75561952|NCT06155487|Drug|Placebo|Oral Tablet,Single dose of Placebo 600 mg
75561953|NCT06155487|Drug|AJH-2947 800 mg (SAD)|Oral Tablet, Single dose of AJH-2947 800 mg
75561954|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 800 mg
75561955|NCT06155487|Drug|AJH-2947 200 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
75561956|NCT06155487|Drug|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 200 mg
75561957|NCT06155487|Drug|AJH-2947 400 mg (MAD)|Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg
75416455|NCT05224583|Procedure|Simultaneous Liver-Kidney Transplant|Simultaneous Liver-Kidney Transplant
75416456|NCT05224297|Radiation|external beam photon therapy|Patients receive external beam photon therapy for different tumor locations (groups).
75416457|NCT05214885|Diagnostic Test|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
75561958|NCT06155487|Drug|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 400 mg
75561959|NCT06155487|Drug|AJH-2947 600 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg
75561960|NCT06155487|Drug|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 600 mg
75561961|NCT06155474|Dietary Supplement|Prebiotic galacto-oligosaccharide (GOS) Powder|"Prebiotic GOS Powder is a galacto-oligosaccharide ingredient low in mono-sugars. Scientific studies have shown positive effects of oligosaccharides, among which galacto-oligosaccharides, on growth of bifidobacterial, stool consistency bowel function and transit time, support of natural defenses and mineral absorption.~The product mainly consists of 97% dry matter with 69% prebiotic GOS, 23% lactose and 5% glucose and galactose as monosaccharides. These prebiotics have β-(4) glycosidic linkages and have been proven as safe product"
75873473|NCT03389555|Drug|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
75416458|NCT05211362|Biological|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
75561962|NCT06155474|Dietary Supplement|Starch Only|The Starch Solution is a low-fat diet.
75561963|NCT06155474|Dietary Supplement|RUTF + Starch|ready-to-use therapeutic food and The Starch Solution is a low-fat diet.
75561964|NCT06155461|Procedure|Preoperative Ultrasonographic Evaluation of Caval Aorta Diameter Index|to evaluate the ability of preoperative ultrasound measurements of IVC to aorta diameter index and the inferior vena cava collapsibility index (IVCCI) for predicting post induction hypotension after general anesthesia in geriatric patients.
75561965|NCT06155448|Other|Perennial Malaria Chemoprevention effect|Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.
75873474|NCT03714581|Device|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
75561966|NCT06155422|Drug|Cadonilimab|recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
75717051|NCT00786630|Behavioral|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
75717052|NCT00933231|Drug|tacrolimus|Standard dose, Oral
75561967|NCT06155370|Other|construction of organoids from gynecological tumor|organoids construction
75561968|NCT06155305|Procedure|Biopsy|Before initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
75561969|NCT06155279|Drug|Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab|"The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery."
75717053|NCT00933231|Drug|tacrolimus|Low dose, Oral
75717054|NCT00933231|Biological|Simulect|IV
75717055|NCT00933231|Drug|Cellcept|Oral
75717056|NCT00933231|Drug|Corticosteroids|IV and Oral
75561970|NCT06155253|Procedure|Erector spinae plane block|"ESP block is a paraspinal fascial plane block that involves injection of local anesthetic underneath the anterior fascia of the erector spinae muscles.~Local anaesthetic mixture (lignocaine 2% with adrenaline, bupivacaine 0.25%) will be delivered with insulated needle in bolus(es) to above-mentioned levels (L1 in 1ESP group, T12 & L1 in 2ESP group)"
75717057|NCT00933231|Drug|Ramipril|Oral
75717058|NCT00933231|Drug|Irbesartan|Oral
75717059|NCT00746876|Device|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
75416459|NCT05211362|Biological|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
75416460|NCT05209841|Drug|Low dose heparin|Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)
75561971|NCT06155240|Behavioral|Therapeutic yoga|Yoga interventions include yoga poses, breathing, and meditation
75561972|NCT06155201|Behavioral|functional training|Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.
75561973|NCT06155201|Other|Observation|Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.
75416461|NCT05209841|Drug|Normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
75416462|NCT05203978|Procedure|colonoscopy|Colonoscopy
75416463|NCT05202899|Drug|sugammadex|The use of sugammadex
75561974|NCT06155188|Procedure|applying of FLU+CY post-HSCT|The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
75561975|NCT06155162|Behavioral|The HuggyPuppy Intervention|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
75561976|NCT06155149|Other|Mobile application|"Mobile application: The content of the mobile application that can be used continuously after the presentation in the education of families will consist of three parts.~In the first section: There will be short information notes and visuals on burn diagnosis and types.~Second part: Frequently seen burns as a result of home accidents will be introduced and the precautions to be taken will be included through visuals.~Third Section: First aid applications specific to each type of burn (scalding, fire-flame, hot contact, electrical, chemical) will be presented with visuals and information notes."
76042644|NCT05866042|Device|tDCS|TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.
75561977|NCT06155149|Other|Family Information Training|Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
75416464|NCT05191537|Other|Sustained Natural Apophyseal Glides|The patient sits well supported in a chair. The cervical spine and head are set in a neutral position. A painless passive posterior to anterior (PA) glide is applied in the plane of the facets on either the spinous process or the articular pillar/cervical lamina. While the glide is sustained the patient actively moves their neck in the direction that previously produced the symptoms. If symptom-free, the patient applies over-pressure further into the movement restriction. 3-6 repetitions are performed
75416465|NCT05191537|Other|shoulder Mobilization with arm movement|The patient is seated. The therapist contacts the length of the spinous process with the medial aspect of the thumb. A transverse glide is applied by the therapist's index finger against the thumb contacting the spinous process. The direction of the glide is to the contralateral side of the pain. While the mobilisation is sustained the patient moves their arm through a pain-free abduction range. 3-5 sets of 6-10 repetitions may be performed.
75416466|NCT05189834|Dietary Supplement|Gelsectan|Xyloglucan, vegetable protein and xylooligosaccharides
75416467|NCT05186922|Biological|CM326|CM326 injection
75416468|NCT05186922|Other|Placebo|Placebo
75416469|NCT05182827|Other|Tactile stimulation|"The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness."
75416470|NCT05182346|Procedure|Manual therapy|"Acupressure of acupoints is manipulation of classic acupoints by pressure.~Ischemic compression release is applying pressure to the myofascial trigger points until release of these points."
75561978|NCT06155110|Drug|cardiomyopeptidin|cardiomyopeptidin intervention group will accept cardiomyopeptidin (Dalian Zhenao Pharmaceutical Co., Ltd., approval number: National Drug Approval No. H20052173, specification: 20 mg/tube) 3 mg/(kg·d)；
75561979|NCT06155084|Drug|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
75561980|NCT06155084|Drug|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
75561981|NCT06155084|Drug|HP518 -Dose Expansion|Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
75561982|NCT06155058|Procedure|SYREBO|Serial ADL training of upper extremities with robotic aid
75561983|NCT06155058|Procedure|Conventional Mirror Method|Serial ADL training of upper extremities assisted by physical therapist
75416471|NCT05175911|Other|golden hour : an initial standardized stabilization|"This is a quality improvement project to evaluate the implementation of Golden hour, a standardized stabilization during the first hour of life in inborn preterm infants younger than 31 weeks of gestational age or weighting less than 1300 g in the NICU of the University of Liege.~There is no comparative arm."
75416472|NCT05173142|Drug|HMPL-453|HMPL-453 administered orally.
75717060|NCT00746876|Device|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
75717061|NCT00790374|Drug|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
75717062|NCT00790374|Drug|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
75717063|NCT00790374|Drug|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
76042645|NCT05865951|Other|Isometric Exercises|Isometric (same length) strengthening exercises of the neck muscles will be performed.
75873475|NCT03711461|Device|endotracheal tube (double lumen)|patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
75873476|NCT03711461|Device|nonintubated|patients receiving nonintubated anesthetic plan while they have received thoracoscopy
75416473|NCT05173142|Drug|gemcitabine and cisplatin|Gemcitabine and Cisplatin administered intravenously.
75416474|NCT05173142|Drug|toripalimab|Toripalimab administered intravenously.
75416475|NCT05173142|Drug|Docetaxel|Docetaxel administered intravenously.
75416476|NCT05167929|Behavioral|Self-determination Enhancement Group|The self-determination enhancement group - Each group has eight participants. There will be 10 sessions per group and each session will last 1.5 hours.
75416477|NCT05167929|Behavioral|Self-determination Enhancement Plus Group|The self-determination enhancement PLUS group - Each group has eight participants and their caregivers. There will be 10 sessions per group and each session will last 1.5 hours. Meanwhile, their caregivers will attend four sessions separately and each session will last 1.5 hours.
75416478|NCT05167929|Behavioral|Leisure activity group|Leisure activity group - Leisure activity group is the comparison group. Each group will consist of eight adults with mild intellectual disability. There will be 10 sessions for the group and each session will last for 1.5 hours.
75416479|NCT05167435|Other|Myofascial Release Experimental|Myofascial release is a gentle sustained pressure that elongates fascial adhesions so that tissue can return to proper realignment.
75416480|NCT05167435|Other|Posterior-Anterior Glide|Posterior-anterior mobilization is a standard assessment and treatment technique for most clinicians. It is a mobilization technique that involves passive oscillatory movements applied to a vertebral segment in a posteroanterior direction (Back to front).
76042646|NCT05865951|Other|Isotonic Exercises|Isotonic strengthening exercises for the neck muscles will be performed.
76042647|NCT05865938|Device|PASCAL vs. MitraClip|"transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device."
76042648|NCT05865925|Drug|LY010616|IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
75416481|NCT05165875|Drug|Hydrocortisone-Lidocaine|"Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
75416482|NCT05165875|Other|Splint|"Intervention will be done on the same day based on the randomization. For the splint group, a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks. Subsequently, the splint will be weaned and passive range of motion exercises taught.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
75416483|NCT05163860|Other|Survey|Participants will complete an online survey.
75416484|NCT05163457|Other|Data collection|frailty evaluation
75416485|NCT05162313|Device|confirmation of endotracheal tube positioning|After performing the tube insertion by direct laryngoscopy, videolaringoscopy or fiberoptic technique, the attending neonatologist will connect both the colorimetric capnometer and the proximal flow-sensor to the tracheal tube. If the flow sensor is not proximal but incorporated into the mechanical ventilator, the care provider will connect the capnometer only. During the procedure, the information given by the capnometer will be evaluated by the care provider performing the intubation, while the flow sensor information will be monitored only by a study investigator, who will not reveal any details to the care provider. In particular, the yellow color change by the capnometer and the presence of exhalation flow curves on the ventilator screen will be considered as confirmation of correct tracheal tube positioning, respectively.
75561984|NCT06155006|Diagnostic Test|rapid diagnostic test HCV Ab Plus Rapid test|The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes. This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
75416486|NCT05162118|Drug|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab|Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.
75416487|NCT05159310|Procedure|Cast vs Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast.
75416488|NCT05158556|Other|Myofascial Release Technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. Deep pressure will be applied and glided medially towards the thoraco-lumbar region.
75416489|NCT05158556|Other|Instrument Assisted Soft tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
75416490|NCT05155917|Drug|Insulin Glargine 300 UNT/ML [Toujeo]|insulin glargine sc (0.25 U/kg body weight)
75416491|NCT05153291|Procedure|Bachmann's bundle lead placement|Atrial lead placement at Bachmann's bundle area
75416492|NCT05153291|Procedure|Right atrial appendage lead placement|Atrial lead placement in the right atrial appendage
75717064|NCT04054466|Behavioral|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
75416493|NCT05150041|Device|Guardian connect|"Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
75416494|NCT05150041|Device|iPro2|"Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
76042649|NCT05865912|Combination Product|Mindfulness training + real tDCS|"The MT is an established app-based programme delivered by Headspace®. During MT, participants complete guided meditation sessions which focus on mindful eating and on coping with cravings. Each MT session lasts 15 min. Participants in the MT+ real tDCS and MT+ sham tDCS groups will be given instructions to practice daily mindfulness for 3 weeks. During 10 of these sessions, MT and real/sham tDCS will be delivered concurrently.~TDCS: During tDCS, a constant weak direct current is applied via electrodes (anode and cathode) placed on the scalp. In this study, the anode will be placed over the right dorsolateral prefrontal cortex (dlPFC) and the cathode will be placed over the left dlPFC. In the real tDCS condition, stimulation will be delivered at a constant current of 2 mA with a 10 second fade in/fade out for 20 minutes. In sham tDCS, the stimulator will deliver 60 seconds of active stimulation at the start (ramping up) and end (ramping down) of the 20 minute period."
75416495|NCT05138029|Drug|Ranibizumab Injection [Lucentis]|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
75416496|NCT05138029|Procedure|Inner limiting membrane stripping|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
75416497|NCT05138029|Drug|Dexamethasone intravitreal implant|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
75416498|NCT05135039|Drug|Canagliflozin|Canagliflozin 100mg/day/patient
75416499|NCT05135039|Drug|Placebo|Placebo 100mg/day/patient
75416500|NCT05128591|Drug|Rivaroxaban 18mg Oral Tablet|AD-109 (Rivaroxaban 18mg) Oral Tablet
75416501|NCT05128591|Drug|Rivaroxaban 20 MG Oral Tablet|AD-1091 (Rivaroxaban 20mg) Oral Tablet
75416502|NCT05127408|Procedure|Interventional Endoscopy|correct defects of the gastrointestinal tract.
75416503|NCT05123560|Other|Anonymous online questionnaire|A QR code qill be provided to access the online questionnaire
75416504|NCT05121701|Device|Videolaryngoscope|C-MAC PM-Karl Storz
75416505|NCT05121701|Device|Macintosh Laryngoscope|Laryngoscope
75416506|NCT05111327|Other|Structured guideline|Students in the intervention group will receive more learning materials before study. The structured guideline will be used to facilitate students' learning in simulation by the facilitator.
75416507|NCT05109806|Behavioral|problem prevention therapy with CHD|The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
75717065|NCT04054466|Behavioral|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
75416508|NCT05096052|Drug|Galactomannan|Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
75416509|NCT05096052|Drug|PLACEBO|A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
75416510|NCT05093595|Device|SFC|The lubricated SFC passed nasally into the oropharynx under the visual guidance of visual laryngoscope to ensure that the cuff had passed through the posterior choanae and reached the oropharynx. The guide wire is removed and the balloon inflated with 5 ml normal saline. The catheter is then pulled slightly until the balloon is fixed and concealed by the soft palate . The ETT is anchored to the SFC with a cable tie .
75561985|NCT06154993|Other|static opening with slider+ Conventional PT|"Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
75561986|NCT06154993|Other|dynamic opener with slider + Conventional PT|"Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
76042650|NCT05865912|Combination Product|Mindfulness training + sham tDCS|Mindfulness training + sham tDCS
75416511|NCT05088928|Drug|Apixaban|Direct Acting Oral Anti coagulant
75416512|NCT05088928|Drug|Rivaroxaban|Direct Acting Oral Anti coagulant
75416513|NCT05078762|Other|Immersive Virtual Reality|Training in an iVR environment with Virtual Reality Goggles while using the bronchoscopy simulator, while the control group will train without VR goggles.
75416514|NCT05075122|Biological|UV1|UV1 vaccination (300 μg) UV1 vaccination will be applied in a dense schedule with three vaccinations during one week before initiation of pembrolizumab, followed by 5 additional vaccinations every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14)
76042651|NCT05865899|Procedure|valgus producing medial opening wedge high tibial osteotomy|Valgus producing Opening wedge high tibial osteotomy will be performed through a medial incision at the proximal tibia and stabilized with a plate and screws. Hardware will be removed within 10-12 months to avoid soft tissue irritation.
75561989|NCT06154967|Radiation|tereotactic body radiotherapy|In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used
75561990|NCT06154954|Diagnostic Test|Semen analysis|Semen analysis for extracellular matrix proteins analysis
75561991|NCT06154941|Procedure|Giomer Varnish|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession
75561992|NCT06154941|Procedure|CPP-ACP varnish|CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. CPP-ACP Varnish delivers bioavailable calcium and phosphate ions to occlude dentinal tubules treating dentin hypersensitivity
75717066|NCT03489525|Biological|Dose Escalation, MEDI2228, ADC (antibody drug conjugate)|Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
75717067|NCT03489525|Biological|Dose Expansion, MEDI2228, ADC (antibody drug conjugate)|Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
75717068|NCT00784212|Drug|BGG492|
75717069|NCT00784212|Drug|BGG492|
75717070|NCT00784212|Drug|Placebo|
75416515|NCT05075122|Drug|Sargramostim for Injection|75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
75416516|NCT05075122|Drug|Pembrolizumab injection|200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
75717071|NCT00752180|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
75561993|NCT06154928|Other|Drinking Warm Water Intervention|Patients in the Warm Water Group (WG) received a warm water drinking intervention post-laparoscopic cholecystectomy. Before intake, the bed head was elevated to 45°C, and gagging and swallowing reflexes were assessed using an Abeslang to touch the oropharynx. Nausea indicated a positive reflex. Two patients with negative reflexes were excluded from WG. To maintain water temperature, individual insulated cups with thermal features were used, preventing infection transmission. Water was boiled in a clinic kettle, cooled to 37-38°C, and given to patients to drink within 15 minutes. Swallowing ability was monitored after the first sip; successful swallowing allowed the patient to continue. Patients were observed for 15 minutes with an aspirator on standby for aspiration risks. No complications occurred during the water drinking process in WG.
75717072|NCT00752180|Biological|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
75416517|NCT05067439|Drug|Abrocitinib|200 mg once daily (QD)
75416518|NCT05067439|Drug|Omeprazole|single doses of 10 mg
75717073|NCT00784290|Drug|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
75717074|NCT00752336|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
75717075|NCT00752414|Drug|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
75717076|NCT00752414|Drug|Placebo|same frequency as MP-376
75717077|NCT00790530|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
75717078|NCT00790530|Other|Usual Care|Usual Care
75416519|NCT05067439|Drug|Caffeine|single dose of 100 mg
75416520|NCT05067439|Drug|Efavirenz|single doses of 50 mg
75416521|NCT05064176|Other|Usual care|"Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~week 3-4: start physical therapy, 2 days/ week: exercises, skin care & manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care & MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up"
75717079|NCT03396562|Other|Assessments of Development and Growth|Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years.
75717080|NCT02554266|Device|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
75717081|NCT00786942|Procedure|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
75561994|NCT06154915|Other|medical treatments|All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding) according to the best standard of care
75416522|NCT05064176|Procedure|Reconstructive lymphatic surgery|"For the procedure of LVA:~- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~- Aim:~Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~Placed lymph nodes induce lymphangiogenesis"
75416523|NCT05064137|Drug|Monomeric self - assembling peptide P11-4|Monomeric self - assembling peptide P11-4 ( Curodont Repair ) is a remineralizing agent applied on tooth surface after treating it with 3% sodium hypochlorite for 20 seconds then etching it with 37% phosphoric acid for 20 seconds followed by rinsing then dryness.
75416524|NCT05064137|Drug|Tricalcium phosphate fluoride varnish, 5% F-|Tricalcium phosphate fluoride varnish, 5% F- ( Clinpro White Varnish ) is a remineralizing agent applied on tooth surface after mixing it with a brush onto the dosage guide.
75416525|NCT05064137|Drug|fluoride varnish (5% sodium fluoride)|fluoride varnish (5% sodium fluoride) ( Voco-profluorid ) is a remineralizing agent applied on tooth surface then area is allowed to become wet (either by gentle rinsing or natural salivary flow) to ensure setting of VOCO Profluorid Varnish.
75416526|NCT05059743|Drug|[14C]-Larotinib|Patients will receive single dose of orally [14C]-Larotinib on Day 1.
75416527|NCT05057364|Other|Heart Smart Virtual Self-Management Group|The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
75416528|NCT05055986|Device|Semiautomatic segmentation of open-source software|Semiautomatic segmentation of open-source software is accurate as of the manual segmentation of commercial software.
75416529|NCT05052528|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19 CAR T cells IV
75416530|NCT05052528|Drug|Cyclophosphamide|Given IV
75416531|NCT05052528|Drug|Fludarabine Phosphate|Given IV
75416532|NCT05052528|Biological|Rituximab|Given IV
75416533|NCT05051150|Drug|Epinephrin 0.03|epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
75416534|NCT05051150|Drug|Epinephrin 0.05|epinephrine infusion rate of 0.05 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
75561995|NCT06154902|Drug|Idecabtagene vicleucel|According to approved product label in France
75561996|NCT06154902|Other|Not treated|Eligible for idecabtagene vicleucel treatment but not treated
75561997|NCT06154889|Other|consultations with a psychologist|Consultations with a sports psychologist to decrease kinesiophobia
75561998|NCT06154889|Other|Conventional reeducation|Conventional reeducation
75717082|NCT00786942|Procedure|higi tibial osteotomy|the gap of the tibia is unfilled
75717083|NCT02193958|Drug|FF-10501-01|FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
76042652|NCT05865873|Behavioral|Health education|Health education will be delivered for six months, two times per month; one session will take one hour, and an overall 12 sessions will be conducted. One health education session consists of key messages on normal pregnancy and childbirths, ODS during pregnancy, delivery, and the postpartum period, the practice of BPCR, and the benefits of MHSU. The other actions executed by WDT facilitators will be the motivating mother and their families to utilize MHS. One hour will be allocated for each session, from this 20 minutes will be allowed for the pre-recorded an audio-based lecturer and the remaining 40 minutes will be allowed for raising questions and responses (discussion). After the session, some of the women will be selected to carry out role play which is basic to demonstrate the important messages and share experiences.
75561999|NCT06154876|Device|Cough assist device|"Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise."
75562000|NCT06154863|Drug|RAI|Radioactive iodine
75717084|NCT00686894|Procedure|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
75717085|NCT00686894|Drug|Infliximab|"5 mg/kg~IV~Frequency : weeks 0,2,6"
75416535|NCT05051150|Drug|Epinephrin 0.07|epinephrine infusion rate of 0.07 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
75416536|NCT05045313|Drug|Warfarin sodium tablets|Drug: Warfarin sodium, tablet, oral
75416537|NCT05045313|Drug|Digoxin tablet|Drug: Digoxin, tablet, oral
75416538|NCT05045313|Drug|Probenecid tablets|Drug: Probenecid, tablet, oral
75717086|NCT00328627|Drug|Alogliptin|Alogliptin tablets.
75717087|NCT00328627|Drug|Alogliptin placebo|Alogliptin placebo-matching tablets.
75717088|NCT00328627|Drug|Pioglitazone|Pioglitazone tablets.
75717089|NCT00328627|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets.
76042653|NCT05865847|Other|Not applicable, this is an observational study|Not applicable, this is an observational study
75416539|NCT05045313|Drug|DBPR108 tablets|Drug: DBPR108, tablet, oral
75416540|NCT05044572|Other|Open chain kinetic exercises|Group A will perform open chain kinetic exercises Before the intervention all the participants will perform 20 minutes of warm up and 10 minutes of cool down. The Open kinematic chain exercises(Three sets of each exercise while one set of each exercise will be performed at the setup and remaining two sets will be guided to the patient as a home plan)-:Blackburn exercises ( 20 repetitions ) , Dynamic hug( 10 repetitions), W exercise(10 repetitions), lunges with dumbbells-forward(10 repetitions with half kg dumbbell), upward and diagonal, and Pectoralis minor stretching(3 to 5 stretches)will be performed
75416541|NCT05044572|Other|Forward head posture correction exercises|PatienGroup B participants will perform forward head correction exercise(22) Chin tuck Patient will Stand with upper back against a wall, feet shoulder-width apart. • Face forward, tuck your chin down, and pull head back until it meets the wall. • t
75562001|NCT06154850|Other|Immersive virtual reality|Oculus Quest 2 will be used with NatureTrek application for 10 minutes.
75562002|NCT06154850|Other|Non-immersive virtual reality|Patients will watch a video including scenes from NatureTrek application on a screen.
75562003|NCT06154837|Drug|GSK3862995B|GSK3862995B will be administered.
75562004|NCT06154837|Drug|Placebo|Placebo will be administered.
75562005|NCT06154798|Behavioral|World Digital Detox Women's Health Program|World Digital Detox Women's Health Program incorporates gradual steps, including mindfulness exercises, setting boundaries on digital usage, decluttering digital spaces, promoting offline connections, and encouraging mindful technology use.
75562006|NCT06154759|Other|Watson Human Caring Model-based psychoeducation|It is a psychoeducation program based on the Watson human care model, one of the theories of the nursing profession, that includes healing processes, and consists of sessions that address the hopelessness, death anxiety and care burden of individuals.
76042654|NCT05865834|Other|A smartphone application|app will have 2 modules: Chill zone and sleep; Chill zone has 9 sub-modules which are meditation, breathing techniques, family time, art time, funny sayings, reframe stress and relax, diet and cooking tips, mini courses and how to become better. The sub-modules of sleep are: wind down, sleep music, storytelling, nature sounds and beautiful nature. These modules will be approved by a clinical psychologist to help people with symptoms of depression and anxiety. Skills learned include emotion recognition, emotional management, behavioral activation (being active), recognizing and challenging unhelpful thoughts and cognitive restructuring to plan for their future.
75416542|NCT05044156|Other|salivary sample|salivary sample
75562007|NCT06154746|Diagnostic Test|slit lamb & OCT|"The Slit lamb is a biomicroscope. It emits a beam of light that can be varied in height and width. It allows visualization of the anterior segment of the eye. With auxiliary lenses, the examiner can also view the posterior segment. These lenses are simple, affordable, and portable. Although high-end devices like fundus cameras and optical coherence tomography have revolutionized how practitioners detect eye diseases, they can never replace these handheld lenses.~OCT is a noninvasive method that yields a cross-section image of the retina by exposing the eye to near-infrared light. Specifically, an emitted light beam is scattered and reflected back by the retinal surface as well as its different layers."
75562008|NCT06154733|Procedure|Photobiomodulation usinf low level laser therapy|Diode laser will be used (SIROLaser Blue®, Sirona, Germany) at a wavelength of 660 nm and a power of 100 mW for 10 sec, corresponding to an energy dose of 1 J. Irradiation will be performed at the hypomineralized area: two irradiations scanning the surface in the mesiodistal direction and two in the occlusogingival direction (perpendicular to the tooth surface) precisely over the lesion, in a uniform scanning motion with relative isolation. Treatment will be performed in 3 sessions with a 72-hour interval between sessions.
75562009|NCT06154733|Procedure|Resin-based sealant|Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
75562010|NCT06154733|Procedure|Glass ionomer sealant|"Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.~For the duration of the study, children will be instructed to undergo regular tooth brushing and flossing. Any other needed treatment will be done for the child."
75717090|NCT02562248|Other|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
76042655|NCT05865834|Other|Pictorial educational leaflets|the control group will receive self-reading educational leaflets, the majority of which are pictorial. These leaflets will be approved by a clinical psychologist to help people with symptoms of depression and anxiety.
75416543|NCT05032872|Behavioral|Social Exergame Treatment Group|"Physical activity tracking, walk to grow flowers and plant their own garden~Follow workout tutorials~Daily steps tracked by Fitbit and workout log tracked by the app~Daily reminders to wear Fitbit, use the app, and share stories to unlock new flowers to grow~Includes social features: like, reply, and see other's stories, and share their stories; Access to other people's gardens~In-app rewards (unlock new flowers to grow each week) if participants post stories"
75416544|NCT05032872|Behavioral|Control Group|"Physical activity tracking, walk to grow flowers and plant their own garden~Follow workout tutorials~Daily steps tracked by Fitbit and workout log tracked by the app~Daily reminders to wear Fitbit and use the app"
75416545|NCT05007561|Drug|Naltrexone Hydrochloride|oral naltrexone
75416546|NCT05007561|Drug|Placebo|oral sugar pill
75416547|NCT04983394|Other|Virtual Realty Exercises|motion-controlled video game
75717091|NCT02562248|Other|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
75717092|NCT03977727|Drug|Fiasp®|Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
75717093|NCT03977727|Drug|Novolog®|Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
75416548|NCT04983394|Other|Aerobic exercises|cycling activity
75416549|NCT04983394|Other|conventional exercises|stretching, strengthening and endurance exercises
75416550|NCT04981002|Other|Telemedicine Consultation with self orthopedic exam|Brief telemedicine consultation, with self orthopedic exam,blinded to subsequent face-to-face evaluation.
75416551|NCT04981002|Other|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
75416552|NCT04970914|Drug|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
75416553|NCT04970914|Drug|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
75416554|NCT04968418|Device|APDM OPAL system wearable IMU|The OPAL system contains wearable IMUs with a sampling rate of 128 Hz and a resolution of 17.5 bits. Each IMU has a size of about 44mm 40mm 14mm × × and weighs less than 25 gm.
75562011|NCT06154694|Radiation|Stereo Radiographic EOS Measurements|"Healthy control will undergo a stereo radiographic EOS exam with their arm in various positions.~Relaxed standing (0 degree of abduction)~45 degree of abduction in the coronal plane~90 degree of abduction in the coronal plane~120 degree of abduction in the coronal plane~45 degree anterior flexion in the sagittal plane~90 degree anterior flexion in the sagittal plane~120 degree of anterior flexion in the sagittal plane~45 degree extension in the sagittal plane"
75562012|NCT06154681|Other|World Digital Detox Family Program|The Self-Help World Digital Detox Family Program spans four weeks and offers a structured approach to tackle the rising issues associated with the overuse of screens, social media, and digital devices within families. This intervention provides practical tools and strategies to be implemented on a weekly basis.
75562013|NCT06154655|Other|E-zine|Health education will be delivered through an electronic magazine
75416555|NCT04965402|Drug|BMS-986166|Specified dose on specified days
75562014|NCT06154642|Diagnostic Test|Determination of arterial compliance using blood pressure waveform analysis|Measurement of arterial stiffness using a non-invasive pressure transducer placed on the skin of the wrist, which records the pulse wave at the level of the radial artery in order to analyze the characteristics of the arterial wall. The parameters of interest are the arterial stiffness of large- and small-caliber arteries (ml/mmHg).
75562015|NCT06154642|Diagnostic Test|Measurement of plasma Vascular Endothelium Growth Factor|Measurement of plasma Vascular Endothelium Growth Factor levels by ELISA
75562016|NCT06154642|Diagnostic Test|Skin temperature gradient|Measurement of skin surface temperature gradient, defined as the difference in temperature between the skin surface of the forearm and that of the fingertip (forearm-to-fingertip)
75562017|NCT06154642|Diagnostic Test|Vaso-occlusion test|Measurement of endothelial function by a vaso-occlusion test performed by inflating a cuff on the arm to occlude arterial flow for 3 min. Reactive hyperemia on deflation of the cuff is measured by photoplethysmography placed on the index finger, and tissue oxygen saturation (StO2) by near-infrared spectroscopy (NIRS). The amplitude of the reperfusion flow corresponding to the peak of the perfusion index (ΔPI Peak) and the time to reach this peak (time to peak) are the parameters recorded by photoplethysmography. Tissue resaturation rate (rStO2) is the parameter recorded by NIRS.
75562018|NCT06154642|Diagnostic Test|Transthoracic echocardiography|The diameter of the left ventricular outflow tract is measured in the tele systolic parasternal long-axis view. The pulsed Doppler flow profile is acquired at the level of the left ventricular chamber in the apical five-chamber view. The time-velocity integral of the aortic flow is then calculated. Left ventricular end-diastolic and end-systolic volumes are also measured using Simpson's method in the 4-cavity monoplane view. Measurements of vena cava diameter and respiratory variability of vena cava diameter provide an estimate of right atrial pressure. These measurements estimate cardiac output and systemic vascular resistance.
75562019|NCT06154642|Diagnostic Test|Photoplethysmography|The perfusion index (PI) is derived from the signal and represents the ratio between the absorbance or reflectance of pulsatile and non-pulsatile light of the photoplethysmography signal. PI is measured non-invasively using a photoplethysmographic sensor placed on the earlobe or finger.
75717094|NCT03977727|Device|670G hybrid closed loop continuous subcutaneous insulin infusion system|CSII
75717095|NCT02563184|Biological|Fluzone|
75416556|NCT04965402|Other|Placebo|Specified dose on specified days
75717096|NCT00663858|Drug|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
75717097|NCT00663858|Drug|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
75416557|NCT04961801|Drug|Acalabrutinib, tacrolimus, methotrexate|For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
75416558|NCT04954131|Biological|Candidate Vaccine, SCB-2019|30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants
75717098|NCT00663858|Other|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
75717099|NCT00749372|Other|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
75416559|NCT04954131|Other|Placebo|Saline solution (0.9%)
75416560|NCT04938388|Drug|Semaglutide Pill|All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.
75416561|NCT04938388|Dietary Supplement|Fresh organic vegetables|Prescriptions of organic vegetables
75416562|NCT04935723|Other|Reiki|The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.
75717100|NCT05223400|Drug|Clindamycin Injection|it is a clindamycin use evaluation study
75562020|NCT06154642|Procedure|Transcatheter aortic valve insertion (TAVI)|TAVI is a treatment for aortic valve stenosis. A new valve is inserted with minimally invasive procedure without removing the old, damaged valve.
75562021|NCT06154603|Procedure|Surgical treatment type|This observational design will study the clinical outcome for each type of upper gastrointestinal perforation in relation to surgical or non-surgery treatment and in relation to treatment centre.
75562022|NCT06154590|Drug|Method(s)1 Attribution|"Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
75717101|NCT00790608|Drug|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
75717102|NCT02562014|Other|Glucose|75g glucose
75717103|NCT02562014|Other|Inulin|75g glucose plus 24g inulin
75416563|NCT04935008|Diagnostic Test|The recruitment maneuver|In patients with ARDS, 30 cm H2O positive pressure support and 30 seconds recruitment maneuver will be applied. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver. Optic nerve diameter will be evaluated with a linear probe on the eyeball before and after the collection maneuver, taking a value of 3 mm from the eyeball.
75717104|NCT02562014|Other|Resistant Starch|75g glucose plus 28.2g resistant starch
75717105|NCT00787098|Other|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
75416564|NCT04930406|Other|Physical therapy|Had to receive 10 or more visits of physical therapy during the cancer treatment period to qualify for intervention group.
75416565|NCT04931264|Diagnostic Test|YuWell YE660D Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE660D Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer
75416566|NCT04910932|Other|Breathing Exercises|Breathing exercises including diaphragmatic breathing, thoracic expansion and breathing control exercises
75416567|NCT04910932|Other|Information on COVID-19|"Information about COVID-19 based on the advices in COVID-19 advice for the public section of World Health Organization website."
75441590|NCT01636323|Other|Nicotine|Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
75717106|NCT00749450|Drug|capecitabine|Given orally
75717107|NCT00749450|Drug|fluorouracil|Given IV
75717108|NCT00749450|Drug|oxaliplatin|Given IV
75717109|NCT00795444|Drug|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
75717110|NCT00790686|Procedure|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
75717111|NCT02561936|Drug|Rilpivirine Oral Tablet|Rilpivirine formulated as 25 mg oral tablet.
75717112|NCT02561936|Drug|Rilpivirine formulation G007|Rilpivirine G007 formulation as 10*2.5 mg tablets.
75717113|NCT02561936|Drug|Rilpivirine formulation G009-01|Rilpivirine G009-01 formulation as 10*2.5 mg tablets.
75562023|NCT06154590|Drug|Method(s)2 Attribution,|"Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
75416568|NCT04909372|Behavioral|Labelling|"Food products in the virtual supermarket will display an environmental label on their packaging, from A (lowest impact) to E (highest impact). The label categories are based on the Product Environmental Footprint, a score recommended by the European Commission that evaluates the environmental impact of a food product based on 16 indicators calculated throughout the life cycle of the products (e.g., climate change in kg carbon dioxide eq, marine eutrophication in kg N eq, land and water use or acidification in mol H+ eq).~Instructions will introduce and explain the environmental label to the participants as In the virtual supermarket, each product will have an environmental label. This label describes whether a product had a negative impact on the environment (green house gaz emissions, water resources depletion, etc.) from A, lowest impact, to E, highest impact."
75562024|NCT06154577|Diagnostic Test|Ultrasonography|Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)
75562025|NCT06154551|Diagnostic Test|Paxillin biomarker|Paxillin used as a salivary biomarker
75562026|NCT06154538|Drug|Cadonilimab|PD-1/CTLA-4 bi-specific antibody
75562027|NCT06154538|Drug|FOLFOX regimen|FOLFOX chemotherapy
75416569|NCT04908826|Procedure|Indocyanine Green (ICG) administration|Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.
75562028|NCT06154499|Procedure|Radical prostatectomy|Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
75562029|NCT06154486|Drug|semaglutide use|patient using semaglutide for at least 7 days
75562030|NCT06154473|Procedure|Open heart surgery group.|Patients undergoing open heart surgery.
75562031|NCT06154473|Procedure|Percutaneous cardiovascular surgery group.|Patients undergoing percutaneous cardiovascular surgery.
75562032|NCT06154460|Procedure|Laterjet Surgery|The laterjet procedure is an operation in which the coracoid process is transferred to the glenoid rim with a screw.
75562033|NCT06154460|Procedure|Reimplissage Surgery|"Reimplissagge operation, which means to fill, is an open procedure designed to limit the engagement of Hill-Sachs deformity by passing the infraspinatus into the Hill-Sachs defect."
75562034|NCT06154460|Procedure|Capsular Reconstruction|Allografts or autografts are used for capsular reconstruction. In the procedure performed with capsular repair and grafts, the capsule is strengthened and stabilization is attempted
75717114|NCT02561936|Drug|Rilpivirine formulation G002|Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
75717115|NCT02561936|Dietary Supplement|Standardized Breakfast|It will consist of (or its equivalent) 4 slices of bread, 2 slices of ham and/or cheese, butter, fruit preserve and 1 or 2 cups (up to 480 milliliter [mL]) of decaffeinated coffee or decaffeinated tea with milk and/or sugar, if desired (containing approximately fat: 21 gram (gm), carbohydrates: 67 gm, proteins: 19 gm; calories 533 kilocalorie (kcal) [189 kcal from fat, 268 kcal from carbohydrates, and 76 kcal from proteins]).
75416570|NCT04897425|Device|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"Hardware and software for myoelectric pattern recognition and sensory training developed at the Center for Bionics and Pain Research.~tES by Neuroelectrics"
75562035|NCT06154395|Procedure|OCT-guided PCI|The OCT guidance team routinely conducts OCT examinations on patients after standard angiography and/or thrombus aspiration. The OCT examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on OCT image features. After stent implantation, a follow-up OCT examination of the stent segment, as well as angiographic examination, is performed. Based on the OCT results, the operator decides whether post-dilation is necessary.
75562036|NCT06154395|Procedure|60 MHz HD-IVUS-guided PCI|The IVUS guidance team routinely conducts IVUS examinations on patients after standard angiography and/or thrombus aspiration. The IVUS examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on IVUS image features. After stent implantation, a follow-up IVUS examination of the stent segment, as well as angiographic examination, is performed. Based on the IVUS results, the operator decides whether post-dilation is necessary.
75562037|NCT06154395|Procedure|Angiography-guided PCI|After routine angiography and/or thrombus aspiration, the operator assesses the lesion based on treatment standards to determine whether stent implantation is necessary. For patients undergoing stent implantation, a follow-up angiography is performed postoperatively, and the decision for post-dilation is made by the operator based on experience.
75562038|NCT06154382|Drug|Eltroxin administration|eltroxin administration
75562039|NCT06154369|Behavioral|JoyPop|Participants will be asked to use the app at least twice daily for the first 4 weeks with no further instructions on feature usage or time spent using the app.
76042656|NCT05865821|Procedure|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
76042657|NCT05865821|Other|No pressure drain|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
76042658|NCT05865782|Behavioral|Schoolyard reconstruction|The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. By using the stepped-wedge study design, with internal control schools, will enable the control for the seasonal variation in children's physical activity levels and for the age-related decline in physical activity throughout childhood. That is, without control schools we would be unable to attribute a change in physical activity to the reconstruction of the schoolyards - as any difference in physical activity before and after the schoolyard reconstruction in the intervention group could be explained by the natural change in physical activity over time.
76042659|NCT05865769|Other|Balance|measuring pulmonary and vestibular functions in all subjects
76042660|NCT05865730|Other|Live Bacterial Product - Akkermansia muciniphila|Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
75416571|NCT04894786|Other|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization (MIRM) Sleeper Stretch The therapist places a web of his one hand around patient's axilla and thumb of another hand in the bent elbow and the glide will be applied to the head of the humerus down in the glenoid fossa using thumb while stabilizing the scapula with another hand. Therapist will ensures that the other hand is stabilizing up and inwards. While this distraction is taking place the patient internally rotated his shoulder with the help of another hand, at the same time his affected upper arm will abduct by therapist abdomen distracting the head of the humerus laterally. The hand in axilla acts as a fulcrum. Mulligan MWM will be applied for 3 days alternate days by following the rule of 3
75416572|NCT04894786|Other|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique (PIRT) Sleeper Stretch The subject will be positioned supine on the treatment table with the shoulder and elbow, at 90 degree of abduction and flexion. The shoulder will be stabilized at the acromion process with one hand, and the other hand will be used to passively move the arm into internal rotation until the first barrier of motion will reached. The subject will be then instructed to perform a 5second isometric contraction of approximately 25% maximal effort in the direction of external rotation, against an opposing force provided at the distal forearm. Following the contraction, the subject will be instructed to internally rotate the arm toward the ground as a 30-second active assisted stretch will be applied. The subject will be instructed to relax, and a new movement barrier will then engage.
75416573|NCT04891835|Other|Data extraction from medical files|Data extraction from medical files
75416574|NCT04886908|Other|Data extraction from medical files|Data extraction from medical files
75416575|NCT04886817|Behavioral|Pilot Intervention to reduce SSB consumption in children and families|"A 6-month intervention based on the use of 4 components: an educational video, provision of a water-promotion toolkit, a mobile phone application (app), and a series of 14 computerized interactive voice response (IVR) phone calls to parents to compare families' SSB's consumption behaviors"
75562040|NCT06154343|Drug|GQ1005|an antibody drug conjugate
75562041|NCT06154304|Drug|Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)|90 mcg
75562042|NCT06154304|Drug|Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1|90 mcg
75562043|NCT06154304|Drug|Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2|180 mcg
75717116|NCT00790764|Biological|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
75717117|NCT00790764|Other|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
75717118|NCT00752492|Other|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
75717119|NCT02554968|Other|Questionnaires|
75717120|NCT00752648|Drug|TMC435350|
75717121|NCT00790920|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
75717122|NCT00790920|Drug|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
75717123|NCT02563262|Other|body angles measurements during weightlessness|
75717124|NCT04053218|Combination Product|Exercise plus omega-3 supplement|Supervised aerobic exercise and omega-3 supplement
75717125|NCT04053218|Dietary Supplement|Placebo|Olive oil placebo
75717126|NCT00659880|Other|BioCleanse Meniscus|Subjects will undergo routine meniscal allograft transplant surgery.
75717127|NCT00752882|Drug|ceftazidime|
75717128|NCT01060735|Dietary Supplement|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
75562044|NCT06154304|Drug|Placebo|Placebo
75562045|NCT06154265|Device|TEE probe|Transesophageal echocardiography, ultrasound probe
75562046|NCT06154200|Drug|Testosterone gel 4.5%|Testosterone gel applied to eyelids twice per day
75562047|NCT06154200|Drug|Vehicle gel|Vehicle gel applied to eyelids twice per day
75562048|NCT06154187|Drug|PBK_L2201|Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.
75562049|NCT06154187|Drug|Placebo|Placebo was formulated similar to abaloparatide-SC.
75562050|NCT06149299|Procedure|Greater occipital nerve block|Greater occipital nerve block using ultrasound guidance
75562051|NCT06149234|Behavioral|Fruit leather on the tongue|The patient holds a fruit leather strip on the tongue while being exposed.
75562052|NCT06149234|Behavioral|Chewing gum strip|The patient holds a banana-tasting gum strip on the tongue while being exposed.
75562053|NCT06149234|Behavioral|Celluloid matrix group|The patient holds a celluloid matrix stirp gum strip on the tongue while being exposed.
75562054|NCT06149182|Behavioral|Life stress interview according to EAET|This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.
75562055|NCT06149182|Behavioral|"Psychiatric interview according to region stockholm - basutredning"|This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders
75562056|NCT06148818|Other|Progressive neck motor control exercise therapy|The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.
75416579|NCT04886284|Drug|Ertapenem|Adjunctive ertapenem
75416580|NCT04886284|Drug|Placebo|Saline placebo
75562057|NCT06148818|Other|Patient education|The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
75562058|NCT06148636|Drug|[212Pb] VMT-α-NET|Up to 2 infusions with [212Pb] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.
75562059|NCT06148636|Diagnostic Test|[203Pb] VMT-α-NET SPECT/CT|The [203Pb] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . [203Pb] VMT-α-NET, a radioactive tracer drug.
75562060|NCT06145360|Drug|Empagliflozin 10 MG|the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM
75562061|NCT06145360|Drug|Insulin+Metformin+DPP4 inhibitor (DPP4I)|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
75562062|NCT06143644|Other|Serial ctDNA monitoring|Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
75562063|NCT06127810|Device|CE MRI on 0.064T Scanner|Pt will undergo contrast enhanced images using Gadopiclenol on Hyperfine MRI
75562064|NCT06127810|Drug|Gadopiclenol|Subjects will receive Gadopiclenol instead of standard of care contrast
75562065|NCT06126419|Drug|High-Dose Insulin Therapy|A baseline blood glucose value will be obtained. Two units of insulin will be administered IV if the blood glucose is > mmol/L. An insulin infusion of 0.12 units/kg/hr will be started. Ten minutes after starting the insulin, and when the blood glucose is < 6 mmol/L, dextrose 20% supplemented with phosphate (30 mmol/L) will be infused. Blood glucose levels will be measured every 15 minutes, and the dextrose infusion rate adjusted to maintain glycemic levels between 4 and 6 mmol/L for a duration of 6 hours. At the end of the 6 hour period, the insulin will be stopped and the dextrose will be weaned off.
75562066|NCT06117761|Other|Attention Placebo|Telephone follow-up focused on information provision and brief counselling relating to their health conditions. They will also receive routine care from the healthcae system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.
75562067|NCT06117761|Other|Home-based exercises combined with cognitive training|An 8-week, home-based, exercise with cognitive training intervention. 3 sessions per week, and 80 minutes per session.It comprises of 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.
75416581|NCT04876703|Device|Multichannel Functional electrical stimulation|The Xcite system is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education.
75717129|NCT00747032|Drug|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
75416582|NCT04876703|Other|Standard motor training|Standard motor training is the conventional rehabilitation treatment
75416583|NCT04871815|Drug|sodium pyruvate nasal spray|Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
75717130|NCT00747032|Drug|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
75717131|NCT01057303|Genetic|RNA analysis|
75717132|NCT01057303|Genetic|gene expression analysis|
75562068|NCT06117761|Other|Home-based exercises|An 8-week, home-based, exercise-only intervention. Weeks 1 and 2 will be the induction phase, all sessions will be supervised with two home visit sessions and one online session in real-time. Weeks 3 to 6 will be the maintenance phase. For participants with a higher functional performance level (Level 3 or 4), the mode of delivery will change to one home visit and two online training sessions. Weeks 7 and 8 will be the consolidation phase, consisting of two online sessions and one unsupervised self-practice session. They will not receive any structured cognitive training.
75562069|NCT06115993|Drug|AHB-137 injection|AHB-137 injection will be administered subcutaneously.
75416584|NCT04870333|Drug|Niclosamide|140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
75416585|NCT04870333|Drug|Placebo|140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
75562070|NCT06115993|Drug|Placebo|Placebo will be administered subcutaneously. CHB patients not receiving any NA therapy will not receive placebo.
75562071|NCT06107335|Drug|Human Albumin (colloid)|Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to >13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).
75562072|NCT06107335|Drug|Lactated Ringer's Injection (crystalloid)|Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.
75562073|NCT06107335|Device|Edwards HemoSphere monitor with ClearSight-Acumen finger cuff|Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device. The Edwards HemoSphere monitor with ClearSight-Acumen (CSA) finger cuff is a hemodynamic monitoring system that obtains continuous blood pressure readings from a cuff on the finger. In study participants, the finger cuff will be placed on the middle finger of one of the hands. The Edwards device can be used to predict impending intraoperative hypotension before its occurrence. The device has the ability to assess vasodilatory status using systemic vascular resistance (SVR), volume status using stroke volume variation (SVV) and stroke volume (SV) and the use of Carbon Monoxide (CO) to assess for underlying cardiac suppression. It also incorporates the hypotension prediction index (HPI), an algorithm that uses the arterial waveform to predict early phases of intraoperative hypotension.
75562074|NCT06101290|Device|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
75562075|NCT06100549|Other|No intervention|No intervention will be provided.
75562076|NCT06099691|Behavioral|Qualitative Interviews|Participants will take part in one 90-minute interview (or two 45-minute interviews if preferred). The interview will have two sections. The first section will include discussion of what matters to participants. The second section will introduce PROMs which may be pertinent to measuring what matters. The participants will be helped to reflect on their relevance and usefulness to them.
75562077|NCT06097871|Dietary Supplement|Skin Nutraceutical Supplement|The Skin Nutraceutical Supplement is made with Nutrafol's patented Synergen Skin Complex®, which is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties combined to synergistically combat the multiple underlying factors that compromise skin health. These ingredients include Holy Basil, Maca, Curcumin, and Berberine in combination with other nutrients used to support skin health such as olive extract (20% hydroxytyrosol), konjac root (3% ceramides), vitamin A, B vitamins, and vitamin C.
76042661|NCT05865717|Behavioral|Quantitative sampling|A questionnaire asks about demographics, lifestyle (including cigarette smoking) & desk job hours, eating habits, sleep patterns, mental health, and motivation. Data on the frequency and size of regular food consumption will be gathered by completing a survey. Physical activity will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University (Lifestyle Assessment Short Form, 2018).
75416586|NCT04870333|Drug|Ciclesonide|"Participants will be prescribed ciclesonide once daily, administered as follows:~Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
75562078|NCT06097871|Other|Placebo pill|A placebo pill containing non-active ingredients
75562079|NCT06095687|Behavioral|Mindfulness Meditation|Five, 20-minute audio-recorded training sessions of mindfulness of breath and body meditation, practiced over consecutive days, delivered remotely via Qualtrics.
75717133|NCT01057303|Genetic|reverse transcriptase-polymerase chain reaction|
76042662|NCT05865717|Other|Qualitative interviews|Thematic analysis will be done dividing into 4 different themes Personal life, professional life, Concept of Healthiness, Improving Lifestyle
76042663|NCT05865691|Other|biomarker assay|blood sample on the day of inclusion
75416587|NCT04870333|Drug|Placebo|"Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose.~Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
75416588|NCT04870333|Drug|Sotrovimab|"There will be a single infusion of sotrovimab administered at the beginning of the study.~500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter."
75562080|NCT06095687|Behavioral|Clinical Hypnosis|Five, 20-minute audio-recorded training sessions of clinical hypnosis with suggestions targeting pain management, practiced over consecutive days, delivered remotely via Qualtrics.
75717134|NCT01057303|Other|laboratory biomarker analysis|
76042664|NCT05865639|Behavioral|Aerobic Exercise|Three weekly, supervised exercise sessions with aerobic exercise. Each session will last for 60-65 minutes, each period will be consist of 5 min warm up, 45 min formal training and 5-10 min relaxation training. Intervention period will be eight weeks.
75717135|NCT00683774|Drug|diazoxide|100mg orally three times per day for 10 days
75717136|NCT03741907|Procedure|FAUCS|extraperitoneal cesarean with a paramedian left section
76042665|NCT05865639|Behavioral|Time Restricted Fasting|Restricted daily window of caloric intake to maximum 8 hours. Intervention period will be eight weeks.
76042666|NCT05865626|Other|VOT with and without cash incentive|Here we are interested in the remote monitoring of TB treatment, and the impact that financial motivation can have on compliance with this monitoring. the cross-over here means that participants in each intervention group will at some point receive VOT without motivation and then VOT with motivation, depending on whether they start with one or the other combination
76042667|NCT05865613|Device|Pulsed electromagnetic field|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
76042668|NCT05865600|Other|Optimization of guideline-directed medical therapy|Consultation every second week with optimization of guideline-directed medical therapy according to 2019 ESC guidelines on chronic coronary syndrome. Focus will be on risk-factor modification and anti-anginal medication with the treatment aim to achieve freedom from angina and dyspnea with a heart rate at rest ≤ 60 beats/min and systolic blood pressure > 100 mmHg.
76042669|NCT05865600|Diagnostic Test|Immediate referral for invasive coronary angiography|Immediate referral for invasive coronary angiography
75416589|NCT04870333|Drug|Placebo|There will be a single infusion placebo, in the form of 50mL 0.9% sodium chloride, administered at the beginning of the study.
75416590|NCT04861610|Behavioral|Brief mindfulness based program|An intervention promotes the acceptance and emotion regulation in caregiving for frail older adults
75416591|NCT04861610|Behavioral|Psychoeducation|An intervention promotes the coping and problem solving in caregiving for the frail older adults
75416592|NCT04860271|Procedure|Manual Acupuncture|Manual acupuncture treatment using different types of needle
75416593|NCT04857099|Other|Data extraction from medical files|Data extraction from medical files
75562081|NCT06091969|Dietary Supplement|Active multi-ingredient supplement (Fertility Enhancer, FE)|Consuming a multi-ingredient supplement targeting multiple cell pathways daily for 3 months.
75562082|NCT06091969|Dietary Supplement|Inactive placebo (Placebo; PLA)|Consuming an inactive placebo that is calorie-matched to the active supplement daily for 3 months.
75562083|NCT06077227|Behavioral|virtual reality therapy|4 weekly sessions of 30-minute VR therapy in the office with pre- and post-intervention surveys
75717137|NCT03741907|Procedure|MLC|Gold standard
75717138|NCT00787410|Drug|ZD1839|250mg tablet, once daily, orally administered
76042670|NCT05865600|Diagnostic Test|3-months delayed referral for invasive coronary angiography|3-months delayed referral for invasive coronary angiography
75416594|NCT04856696|Diagnostic Test|PGT-A|trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
75416595|NCT04856696|Diagnostic Test|non-invasive PGT-A|cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
75416596|NCT04853459|Procedure|Border modeling..Measurement|By using light cure to make border modeling in complete denture.
75562084|NCT06077227|Other|matched control group|taking the same surveys as the VR intervention group on a weekly basis for 4 weeks
75717139|NCT02555124|Drug|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
75717140|NCT02555124|Drug|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
75717141|NCT02555124|Drug|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
75717142|NCT02555124|Drug|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
75717143|NCT03989557|Drug|Aspirin and clopidogrel/Ticagrelor|The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
75717144|NCT03989557|Device|Light transmittance aggregometry|point-of-care method to assess platelet function by light transmittance aggregometry.
75416597|NCT04851847|Device|Guided Tissue Regeneration (GTR)|Use of resorbable collagen membrane to treat periodontal intrabony defects.
75562086|NCT06066359|Drug|Fludarabine phosphate|Given by (IV) vein
75562087|NCT06066359|Drug|Cyclophosphamide|Given by (IV) vein
75717145|NCT03989557|Drug|Aspirin and clopidogrel/Ticagrelor|maintenance dose of aspirin, clopidogrel and ticagrelor.
75717146|NCT00787488|Device|Hyperthermia|Every 3 weeks
75416598|NCT04839172|Diagnostic Test|Dual-energy X-ray Absorptiometry (DXA) scan|Longitudinal changes in body composition are examined over four consecutive seasons (2017-2018, 2018-2019, 2019-2020, 2020-2021), four times per season in the following stages: start-preseason, start-season, mid-season and end-season.
75562088|NCT06066359|Drug|NY-ESO-1 TCR/IL-15 NK|Given by (IV) vein
75562089|NCT06049199|Other|Speech Enhancer|Speech Enhancer is an adaptive feature which increases the amplitude of speech signal when speech is detected. Speech Enhancer will be switched on and off for the Intervention
76042671|NCT05865600|Other|Standard of care|Standard of care
76042672|NCT05865574|Drug|BAT1706 Injection|1 vial/carton, 400 mg/16 mL/vial
75562092|NCT06039566|Drug|IV N-acetylcysteine|N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure
75717147|NCT01054495|Drug|Acupuncture|"The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes."
75717148|NCT01054495|Device|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
75717149|NCT01054495|Device|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
76042673|NCT05865548|Drug|Aspirin 150 mg|Aspirin 150 mg PO daily
76042674|NCT05865548|Procedure|Standard of care|Surgery with or without radiation, palliative chemo as per investigators choice
75416599|NCT04837534|Behavioral|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
75416600|NCT04837534|Behavioral|SMS and phone call reminder group|In this group after the children have been examined, treatment plan, and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol.
75416601|NCT04835402|Drug|Pembrolizumab|400mg every 6 weeks
75416602|NCT04835402|Device|Irreversible electroporation|Percutaneous ablation of one liver metastasis
75562093|NCT06039566|Drug|IV Placebo|Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
75717150|NCT00790998|Drug|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
75717151|NCT00790998|Drug|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
75562094|NCT06030622|Drug|C3 (Metformin, Simvastatin, and Digoxin)|Combination treatment of Metformin, Simvastatin and Digoxin, with standard of care Gemcitabine.
75873477|NCT03395639|Drug|Edoxaban|Edoxaban 15 mg or 30 mg tablets for participants 12 to <18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
75562095|NCT06029010|Drug|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
76042675|NCT05865509|Other|Escape room|Students were given training on stress response using the escape room method.
75562096|NCT06025253|Device|Negative Pressure Wound Therapy|Application of negative-pressure wound therapy (NPWT) post major lower extremity amputation
75562097|NCT06025253|Device|Standard Wound Dressing|Application of standard wound dressing post major lower extremity amputation
75562098|NCT06023433|Device|Elastomeric powerchain|Canine distalization by engaging the elastomeric power chains onto the canine brackets.
75562099|NCT06018727|Drug|Hydrocortisone|Hydrocortisone 20 mg capsule will be administered orally.
75717152|NCT01057459|Other|laboratory biomarker analysis|Correlative studies
75717153|NCT02555046|Procedure|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
75717154|NCT00787878|Drug|somatropin|SGA previously treated with Norditropin®
75717155|NCT00787878|Drug|No treatment given|Untreated SGA
75717156|NCT00787878|Drug|No treatment given|AGA (Average gestational age)
75717157|NCT00787956|Behavioral|Internet Chronic Disease Self-Management Program (ICDSMP)|
75873478|NCT03395639|Drug|Standard of Care (SOC)|Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
75873479|NCT03353922|Drug|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
75873480|NCT03353922|Drug|Placebo Oral Tablet|sugar pill
75416603|NCT04834648|Behavioral|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
75717158|NCT00354679|Biological|bevacizumab|
75873481|NCT05677932|Device|Bright light therapy|Exposure to bright light therapy for 30mins a day for two weeks
75416604|NCT04831762|Behavioral|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
75873482|NCT05677932|Device|Dim red light therapy|Exposure to 50lux dim red light therapy for 30mins a day for two weeks
76042676|NCT05865509|Other|Storytelling|Students were given training on stress response using the storytelling method.
75416605|NCT04831762|Behavioral|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
75416606|NCT04831762|Behavioral|Laby 5-12|Test of motor planning using labyrinths
75416607|NCT04831762|Behavioral|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
75416608|NCT04831762|Behavioral|Stroop animals|Stroop test for preK children using animals instead of words
75416609|NCT04817579|Device|Digital photography combined with eLABor_aid shade analyzing software|ELABor_aid is a new approach to objective shade communication and shade reproduction in dentistry, based on numeric quantification obtained from standardized RGB (red-green-blue) images, and the formulation of a patient personal shade recipe using trichromatic subtractive color mixing laws, thus abandoning the use of visual assessment and shade guides entirely. This approach is currently enjoying increasing popularity for its ease of use, reliability as well as for its practically oriented features like its imaging ability or the digital try-in.
75562100|NCT06018727|Dietary Supplement|Yohimbine|Yohimbine 20 mg capsule will be administered orally.
75562101|NCT06018727|Drug|Placebo|Two placebos will be administered orally.
75562102|NCT06015724|Drug|Daratumumab|anti-CD38 monoclonal antibody (mAb)
75562103|NCT06015724|Biological|KRAS vaccine|Stimulon QS-21 and Targovax TG01
75562104|NCT06015724|Drug|Nivolumab|anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)
75717159|NCT00354679|Drug|cisplatin|
75717160|NCT00354679|Drug|irinotecan hydrochloride|
75873483|NCT03711383|Dietary Supplement|Inulin and Resistant Starch|12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
75562105|NCT05994924|Behavioral|Educational Handout|Educational handout describing responsive feeding practices.
75562106|NCT05994924|Behavioral|Video Series|Videos geared toward responsive feeding practices.
75717161|NCT00354679|Genetic|proteomic profiling|
75717162|NCT00354679|Other|diagnostic laboratory biomarker analysis|
75717163|NCT00354679|Other|mass spectrometry|
75717164|NCT00354679|Procedure|adjuvant therapy|
75717165|NCT00354679|Procedure|neoadjuvant therapy|
75717166|NCT00354679|Procedure|therapeutic conventional surgery|
75717167|NCT00354679|Radiation|radiation therapy|
75562107|NCT05994924|Behavioral|Group Discussion Sessions|Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
75562108|NCT05989763|Device|Transcutaneous Electrical Acustimulation (TEA)|TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
75562109|NCT05989763|Device|Sham-TEA|Sham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
75562110|NCT05986370|Procedure|lumbar spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
75562111|NCT05986370|Procedure|sham spinal manipulative therapy|Sham spinal manipulative therapy (sham SMT), was designed to be structurally equivalent to SMT, i.e., to attend to the same body regions with the same amount of contact as well as to have the same number, frequency and length of sessions. SMT and sham SMT will be provided by the same treatment provider and will appear to be similarly tailored to the participants' condition. Sham SMT does not share the component of interest of SMT, i.e., the activation of deep high-threshold mechanoreceptors via high-velocity, low-amplitude thrusts applied to the spine. Yet, it shares all the other components not of interest in this study that may contribute to the placebo response, such as therapeutic alliance, contextual factors, physical touch, and expectations. Furthermore, deception will be used to balance expectations and enhance blinding.
76042677|NCT05864079|Diagnostic Test|Platelet count|Platelet count in study groups
75562112|NCT05986370|Procedure|full spine spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
75416610|NCT04817579|Device|Spectrophotometer|Spectrophotometric measurement methods employing computer calculations, based on color science and theories, allow quantitative evaluation which is objective and appears to be more accurate.
76042678|NCT05864079|Diagnostic Test|Developmental endothelial locus-1 (DEL-1)|Serum DEL-1 in study groups
75562113|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 150mg at 0 Day 1, Day 8, Day 15
75562114|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 300mg at 0 Day 1, Day 8, Day 15
75562115|NCT05980065|Drug|Placebo|Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
75562116|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 600mg at 0 Day 1, Day 8, Day 15
75717168|NCT00683696|Device|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
75717169|NCT00345631|Other|Manual Compression|Manual compression
75562117|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 900mg at 0 Day 1, Day 8, Day 15
75562118|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 1200mg at 0 Day 1, Day 8, Day 15
75562119|NCT05977036|Device|DiviTum® TKa assay|Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions
75717170|NCT00345631|Device|Vascular Closure Device|Investigational vascular closure device
75717171|NCT00540514|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
75717172|NCT00540514|Drug|Paclitaxel|Administered by intravenous infusion.
75717173|NCT00540514|Drug|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate [GFR] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
75873484|NCT03711383|Dietary Supplement|Inulin|12g per inulin in combination with maltodextrin per day the day before the CID
76042679|NCT05864079|Diagnostic Test|soluble P-selectin (sP-sel)|Serum sP-sel in study groups
75717174|NCT00663702|Drug|Abatacept|Subcutaneous injection, 125 mg/mL, once weekly, 48 months
75717175|NCT03986281|Other|Omron Wearable Device|Omron wearable device compared to arterial line readings
75416611|NCT04817579|Device|Conventional visual shade matching|Visual shade matching is the most common method, in which a color standard from a commercially available dental shade guide is compared to and matched with the target tooth.
75416612|NCT04805255|Radiation|Hypofractionated Stereotactic Radiotherapy|A course of hypofractionated stereotactic radiotherapy (HF-SRT) is delivered within 2 weeks with a cumulative dose of 3000 - 3500 cGy in 5 fractions.
75562120|NCT05977036|Drug|CDK4/6 + Endocrine therapy|FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
75562121|NCT05974488|Device|McMurray Enhanced Airway|The MEA is non-sterile. It can be used in inpatient or outpatient surgery, in hospital or clinic settings, or in an emergency setting. The MEA has five parts: an optional 15 mm connector, flange (color-coded for size), elongated cushioned bite block, flexible cannula, and distal tip, and a channel to allow for passage of air and a suction catheter. The MEA is designed to open and maintain a patient's upper airway. Oxygen will be delivered through the breathing circuit with the following parameters: 40% oxygen at 6 liters/min flow throughout the procedure time. The MEA will be placed in the participant's oropharyngeal airway one time during an in-person visit.
75562122|NCT05974488|Device|Nasal Cannula|Participants in this group will use the nasal cannula to deliver oxygen as per standard of care one time during the in-person visit.
75562123|NCT05973435|Other|Blood sampling|Blood sample would be taken from the participants in the study for these analyses on three occasions in 3 test tubes (before cesarean section, during cesarean section and after cesarean section).
75562124|NCT05970094|Other|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
75717176|NCT03986281|Other|Standard Arterial Line|Omron wearable device compared to arterial line readings
75717177|NCT02022592|Drug|Lormetazepam|
75717178|NCT02022592|Drug|Midazolam|
75873485|NCT03711383|Dietary Supplement|Placebo|isocaloric maltodextrin before test day
75873486|NCT03387683|Drug|dapagliflozin|dapagliflozin 10mg
75562125|NCT05968963|Behavioral|Mindfulness-based Music Therapy (MBMT)|Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment.
75562126|NCT05968963|Behavioral|Mindfulness Meditation (MM)|Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually.
75717179|NCT03990025|Diagnostic Test|Linked Color Imaging|Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.
75873487|NCT03387683|Drug|placebo|placebo to match dapagliflozin
75717180|NCT03990025|Diagnostic Test|White Light Imaging|White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
75416615|NCT04800718|Other|Intervention Arm|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
75416616|NCT04800276|Other|muscle strengthening targeted on ischemic areas|muscle strengthening targeted on ischemic areas
75416617|NCT04800276|Other|global muscle strenghtening|global muscle strenghtening
75416618|NCT04791813|Other|Alginate impressions , Photographic data and panoramic radiographs .|Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.
75441591|NCT01636336|Other|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
75562127|NCT05967663|Device|PCI-immediate complete revascularisation|In patients allocated to the immediate complete revascularisation group, PCI of the culprit lesion was attempted first and followed by all other lesions deemed to be clinically significant by the operator during the index procedure.
75562128|NCT05967663|Device|PCI-staged complete revascularisation|In the staged complete revascularisation group, only the culprit lesion was treated during the index procedure and PCI of all non-culprit lesions deemed to be clinically significant by the operator was planned at a later stage through an elective re-admission within 15-45 days after randomisation.
75562129|NCT05966896|Device|implanted epidural stimulator|implantable multi-programmable neurostimulation system to deliver electrical stimulation to neural targets in the spinal cord
75717181|NCT00683618|Drug|Rosuvastatin|Capsule/Tablet, oral, qd, 6 or 12 weeks
75717182|NCT00683618|Drug|Atorvastatin|Capsule/Tablet, 10mg, oral, qd, 6 weeks
75717183|NCT01057537|Drug|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
75717184|NCT01057537|Drug|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
75717185|NCT00795678|Drug|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
75717186|NCT00795678|Drug|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
75873488|NCT03714347|Device|cerebral oxygen monitoring|probes will be placed on eyebrows on forehead
75873489|NCT03714347|Device|routine monitoring|We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
75873490|NCT05467553|Drug|Ursodeoxycholic acid|Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
75873491|NCT05467553|Drug|Ropeginterferon alfa-2b|P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
75873492|NCT05467553|Drug|Tenofovir Alafenamide|TAF 25 mg PO QD for 60 weeks
75562130|NCT05949047|Behavioral|Cognitive Emotion Regulation Training via Psychological Distancing|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Psychological Distancing group, participants will be asked to down-regulate negative emotion by reappraising an emotional stimulus as an objective, impartial observer.
75717187|NCT00795678|Drug|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
75717188|NCT00795678|Drug|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
75873493|NCT03387059|Device|Forielle|Participants randomized to receive Forielle endometrial washing (an intrauterine solution) following oocyte retrieval on Study Day 0 (Randomisation).
75873494|NCT02942004|Drug|Placebo|Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
75873495|NCT02942004|Drug|SAGE-547 60 μg/kg/h|Intravenous infusion of SAGE-547.
75873496|NCT02942004|Drug|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547.
75873497|NCT03394391|Behavioral|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
75416619|NCT04783376|Drug|: Insulin, lispro and regular insulin|"A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~C: the same as intervention B but the 40% of the total dose will be given as regular insulin."
75416620|NCT04783285|Behavioral|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 32 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants with psychotic disorders.
75416621|NCT04772560|Device|Precision1 for Astigmatism|Daily disposable soft toric contact lens
75416622|NCT04772560|Device|Precision1 Sphere|Daily disposable soft spherical contact lens
75873498|NCT03394391|Behavioral|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
75416623|NCT04768829|Drug|Moringa oleifera leaf 10mg/100ml|ear drops
75416624|NCT04768829|Drug|Ear Drop|plain ear drop formulation without moringa
75416625|NCT04760912|Drug|Rocuronium|Rocuronium used for neuromuscular blokade during anesthesia and anesthesia without rocuronium
75416626|NCT04760912|Procedure|General anesthesia for surgery|General anesthesia with standard anesthetic monitoring,
75416627|NCT04758208|Diagnostic Test|Hematology Parameters|Measurement of hematology parameters on BC-6800Plus
75562131|NCT05949047|Behavioral|Cognitive Emotion Regulation Training via Reinterpretation|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Reinterpretation group, participants will be asked to down-regulate negative emotion by imagining a better outcome (when engaging with an emotional stimulus) than what initially seemed apparent.
76042680|NCT05863247|Other|Patient Reported Outcomes / Biometric data revision|Multivariate statistical analysis will be done to identify the reported biomarkers to characterize patients into the following categories: satisfied without dysphotopsias, unsatisfied with dysphotopsias, satisfied with dysphotopsias, unsatisfied without dysphotopsias.Main outcome measures will be photic phenomena at 6 months of follow-up in correlation with the following pre-surgical parameters: macular ganglion cell complex thickness and/or total ocular and corneal higher-order aberrations (coma, trefoil, spherical aberration). Patients with known contributing factors for the development of dysphotopsias (such as residual refractive error, IOL decentration, posterior capsular opacification) will be excluded from the analyzis.
75416628|NCT04738448|Behavioral|Art Therapy Group|The art therapy intervention will be executed by the same Medical University of South Carolina (MUSC) board-certified art therapist for each group. The art therapist is a masters-level, licensed practitioner who has experience working in the healthcare system and treating providers. The same art therapy practices that are utilized in daily practice at MUSC will be employed in this study, with a focus on reducing burnout symptoms. Pilot testing of the intervention has been performed informally at MUSC with positive feedback reported by healthcare providers.
75416629|NCT04738201|Other|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
75416630|NCT04734613|Behavioral|Tai Chi exercise|Yang style Tai Chi 16 movements
75416631|NCT04734613|Behavioral|self management|health education and dietary counseling
75416632|NCT04732481|Procedure|passive leg lift test|passive leg lift test
75416633|NCT04729816|Other|Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food.|"Phase 1: Participants will be provided with a high fat/low fiber diet in the form of packed out meals and snacks for 10 days in total (days 2-11 and days 54-63)~Phase 2: Participants will be provided with the high fat/low fiber diet, plus 1 daily fiber-blend snack serving from days 12-25~Phase 3: Participants will receive 2 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 26-39.~Phase 4: Participants will receive 3 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 40-53.~Phase 5: Participants will return to the unsupplemented high fat/low fiber diet for days 54-63"
75562132|NCT05940584|Device|Tele-Reha provided with EvoPads|Exercises and cognitive training provided on an EvoPad
75873499|NCT03711695|Device|iBeat wristwatch device|The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
75416634|NCT04717401|Procedure|Strain-Counterstrain|Strain-counterstrain will be applied to four muscle which are . Tender point of each muscle will be identified then the muscle will be positioned passively in the most relaxed position which will be held for 90 sec. This procedure will repeated 3 times for each muscle
75416635|NCT04717401|Procedure|Muscle Energy Technique|Muscle energy technique will be applied to four muscles which are quadratus Lumborum, iliacus, piriform and erector spinae. Each muscle will be positioned passively in stretched position the patient asked to push against the therapist isometrically while holding breath for 5-10sec. After exhalation, the muscle will be moved into a new barrier. This procedure will repeated 3 times for each muscle
75562133|NCT05940584|Other|Paper-based exercises with option to do tele-reha afterwards|Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards
75562134|NCT05940584|Other|Only paper-based exercises|Same exercises and cognitive training as Group 2 provided on paper only.
75873500|NCT01311791|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
75873501|NCT01311791|Drug|Standard medical therapy|as defined per protocol
75873502|NCT03714269|Other|measurement evaluated with an isokinetic dynamometer|measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
75717189|NCT00795678|Drug|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
75416636|NCT04715516|Behavioral|alcohol brief intervention|Nested within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive an alcohol brief intervention. The strong evidence-base for alcohol brief intervention, amplified by Co-Investigators' Smith and Bragge's (BehaviourWorks) approaches to applied behaviour change, has provided the framework for the development of the alcohol brief intervention used in this study. This intervention comprises personalised feedback on alcohol consumption levels, comparison to gender/age drinking norms, and information and behaviour-change content regarding alcohol consumption (i.e. negative-framed messaging around alcohol risks and harms, positive-framed messaging on the health benefits of reducing alcohol intake, alcohol harm reduction strategies).
75717190|NCT00795678|Drug|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
75416637|NCT04715516|Behavioral|lifestyle health promotion|Lifestyle health promotion specific to physical activity and maintaining a healthy weight, developed to be relevant to women attending breast screening services, will be provided.
75562135|NCT05939492|Behavioral|Mindfulness-Based Intervention|"Participants in the mindfulness-based intervention (MBI) group will be asked to use the Headspace app to sequentially complete the Basics, Basics 2, and Basics 3 courses. Each of these courses lasts 10 days, and participants have the ability to choose how long daily sessions last. Participants can choose between 3, 5, or 10-minute sessions for the Basics course; 10 or 15-minute sessions for the Basics 2 course; and 10, 15, or 20-minute sessions for the Basics 3 course. These daily sessions are audio recordings that prompt users to engage in a variety of mindfulness techniques, including focusing on their body and breathing, as well as acknowledging thoughts and emotions in a non-judgmental manner."
75717191|NCT00795678|Drug|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
75717192|NCT00795678|Drug|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
75717193|NCT00753038|Biological|REOLYSIN®|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
75717194|NCT00753038|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
75416638|NCT04712604|Behavioral|My Sleep Our Sleep (MSOS) Program|MSOS Program is a weekly one-hour Zoom session that focuses on psychoeducation on sleep health for both patients and their sleep partners.
75562136|NCT05932589|Other|EEG and Auditory and Visual Evoked Potentials (AEP and VEP)|Through up to seven standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.
75717195|NCT00753038|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
75717196|NCT00753116|Device|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
75717197|NCT00795756|Drug|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
75717198|NCT00795756|Drug|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
75717199|NCT04058522|Other|Rotator cuff rehabilitation classes|
75717200|NCT04058522|Other|Individual Physiotherapy|
75717201|NCT04058522|Drug|Triamcinolone Injection|Subacromial Injection 40mg/1ml
75717202|NCT04004026|Other|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
75562137|NCT05932589|Other|Clinical assessment|Established clinical measures for RTT will be collected for RTT participants
75717203|NCT00795834|Dietary Supplement|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
75717204|NCT00795834|Dietary Supplement|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
75717205|NCT00791232|Drug|extended-release (ER) OROS paliperidone|
75717206|NCT00749840|Behavioral|Questionnaire|Questionnaire taking 60-90 minutes.
75717207|NCT01563952|Device|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
75717208|NCT01563952|Device|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
75717209|NCT01563952|Device|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
75717210|NCT01563952|Device|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
75717211|NCT00795912|Drug|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
75717212|NCT02562794|Behavioral|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
75717213|NCT05360134|Drug|Carica Papaya Leaf Extract|Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
75717214|NCT05360134|Other|Placebo|Placebo will be given in a similar manner
75416639|NCT04706767|Drug|Co-administration Lidocaine and Dexmedetomidine|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg) and dexmedetomidine (0.5 µg/kg) over 10 min before the induction of anesthesia, and then lidocaine and dexmedetomidine were infused at a rate of 1.5 mg/kg/h and 0.4 µg/kg/h until close of the pneumoperitoneum, respectively.
75416640|NCT04706767|Drug|Dexmedetomidine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until close of the pneumoperitoneum.
75416641|NCT04706767|Drug|Lidocaine infusion|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg over 10 min before the induction of anesthesia), and then lidocaine was infused at a rate of 1.5 mg/kg/h until close of the pneumoperitoneum.
75416642|NCT04706767|Drug|Saline infusion|Patients received the same volume of normal saline 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume until close of the pneumoperitoneum.
75717215|NCT00788034|Drug|Lu AA21004|5 or 10 mg/day
75717216|NCT00788034|Drug|Placebo|Once daily
75416643|NCT04706481|Procedure|Specimen Collection|Specimens obtained from surgical, phlebotomy or other non-invasive procedure
75416644|NCT04706468|Drug|TG-1000|Capsules taken orally
75562138|NCT05929664|Biological|Cemiplimab|Given IV
75562139|NCT05929664|Procedure|Computed Tomography|Undergo CT scan
75562140|NCT05929664|Procedure|Biospecimen Collection|Undergo collection of blood samples
75562141|NCT05929664|Other|Quality-of-Life Assessment|Ancillary studies
75562142|NCT05929235|Drug|FX-909|FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.
75562143|NCT05927519|Device|airtraq video laryngoscope|airtraq video laryngoscope will be used for intubations
75562144|NCT05918861|Drug|Dalcetrapib|Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
75562145|NCT05918861|Drug|Placebo|matching placebo tablets
75416645|NCT04705298|Dietary Supplement|Prebiotic|Oligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
75717217|NCT04058444|Combination Product|ERAS protocol|No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
75416646|NCT04705298|Dietary Supplement|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
75416647|NCT04700215|Device|BiPAP|To give bilevel positive airway pressure to the lungs
75717218|NCT05208814|Drug|TPN171H single dose|10 mg TPN171H taken once
75717219|NCT04004884|Drug|Ulipristal Acetate|Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
75717220|NCT00688064|Drug|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
75717221|NCT00688064|Drug|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
75717222|NCT00788112|Drug|vorinostat|
75717223|NCT00788112|Genetic|protein expression analysis|
75717224|NCT00788112|Other|immunohistochemistry staining method|
75717225|NCT00788112|Other|laboratory biomarker analysis|
75717226|NCT00788112|Procedure|neoadjuvant therapy|
75717227|NCT00788112|Procedure|therapeutic conventional surgery|
75717228|NCT04058600|Behavioral|Virtual Reality Software|Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
75717229|NCT00788190|Procedure|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
75562146|NCT05918757|Other|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day via enteral/parenteral nutrition
75562147|NCT05918757|Other|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day via enteral/parenteral nutrition
75562148|NCT05915104|Drug|Budesonide MMX®|9 mg delayed and extended-release tablet once daily
75562149|NCT05915104|Drug|Budesonide controlled ileal release (CR) capsules|three 3 mg capsules daily oral administration for 8 weeks
75562150|NCT05898230|Device|Mitral Valve Replacement|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
75416648|NCT04700215|Device|Incentive spirometry|IS for 15 minutes after every 4 hours
75416649|NCT04699656|Drug|Plazomicin Injection|single dose of plazomicin
75441592|NCT01636336|Other|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
75717230|NCT00788190|Other|Conservative Management|Conservative management of Distal Radius Fractures
75717231|NCT00749918|Dietary Supplement|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
75717232|NCT00791310|Drug|Flucis|FDG injected i.v
76042681|NCT05862363|Dietary Supplement|Microbiota-directed complementary food (MDCF)-2|Prototypes for nutritional interventions that are composed of locally available, affordable, culturally acceptable complementary foods commonly consumed in Bangladesh have recently been developed.
76042682|NCT05862363|Dietary Supplement|Ready-to-use supplementary food (RUSF)|RUSF is composed of rice, lentil, sugar, soybean oil, and skimmed milk powder mixed with vitamin-mineral premix. MDCF-2 is composed of chickpea flour, peanut flour, soy flour, green banana pulp, sugar, soybean oil, and vitamin-mineral premix. The results from previous studies support the notion that repair of impaired gut microbial community development could represent a new therapeutic concept for restoring healthy growth6. RUSF will be given to one arm of low-BMI women of reproductive age and low-BMI pregnant women.
75416650|NCT04698304|Procedure|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.
75416651|NCT04693364|Other|Decision Aid|Use 3D printed breast model
75717233|NCT04058132|Drug|Sildenafil Citrate 50Mg Tab|sildenafil citrate (Viagra®, Pfizer. Inc., NY, NY). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo[4,3-d]pyrimidin-5-yl)-4- ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate. Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. For this study, we will use 50 mg tablets for the single dose studies.
75734979|NCT03403361|Device|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study. These additional scans will be acquired utilizing the FDA-approved workflow and scanner operating modes. Sinogram data will be exported in raw, minimally processed form utilizing proprietary data export and processing tools provided to the investigators by the scanner vendors. In no case, will the additional local imaging dose (in terms of CTDIvol) given to the patients by the two or three additional scans exceed 6 cGy per session
76042683|NCT05862363|Procedure|Esophagogastroduodenoscopy (EGD)|Aim 1A consists of performing EGD to women with low-BMI and normal BMI women with function dyspepsia. In order to enroll 30 participants with normal duodenal mucosal histology, we are planning to perform EGD on 100 healthy women (BMI 20-24.9 kg/m2) of childbearing age who have been referred for evaluation of functional dyspepsia. Undernourished low-BMI (<18.5kg/m2; 18-30 years) women of childbearing age will be enrolled from Bauniabadh and adjacent slum area of Mirpur, Dhaka and EGD will be performed among 60 women. A total of 6-8 biopsy samples from SI and a dry duodenal aspirate will be collected for biopsy, histochemical and immunocytochemical analysis.
75416652|NCT04693364|Procedure|Discussion|Participate in consultation
75416653|NCT04693364|Other|Questionnaire Administration|Complete questionnaires
75441593|NCT01636349|Other|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
75441594|NCT01636388|Biological|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
75717234|NCT04058132|Device|functional Near-infrared Spectroscopy (fNIRS)|Functional Near-Infrared Spectroscopy (fNIRS): Functional near-infrared spectroscopy (fNIRS) a noninvasive technique that can measure cerebrovascular reactivity (CVR) will be used to measure regional cerebral blood flow and cerebrovascular reactivity in the brain. The device (fNRIS100, fNIR Device LLC), uses laser emission diodes (730nm and 850nm)which in a headband that is worn on the front of the scalp and forehead. Surrounding detectors a few centimeters away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes. fNIRS will be performed twice at each study visit, once before and once about 45 minutes after single dose administration of sildenafil 50 mg.
76042684|NCT05862363|Behavioral|Counselling and follow-up|Normal BMI pregnant women will be counseled and followed up as per standard guidelines and will be provided routine antenatal care
76042685|NCT05862012|Drug|ISB 2001|Participants will receive escalating doses of ISB 2001
76042686|NCT05862012|Drug|ISB 2001|Participants will receive injection of ISB 2001 at 2 putative recommended Phase 2 doses as determined in Part 1.
76042687|NCT05861440|Drug|Prednisolone|adjunct steroid per study protocol
76042688|NCT05861440|Drug|standard anti-tuberculosis agents|standard anti-tuberculosis agents
76042689|NCT05860894|Device|Implantable ECG holter device (Biomonitor3, Biotronik)|Subcutaneous implantation of ECG holder device to monitor ECG
76042690|NCT05858814|Biological|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
75562151|NCT05897021|Behavioral|Expressive Writing on Minority Stressors|The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
75717235|NCT04058132|Other|Carbon Dioxide (CO2) 5%|"Carbon Dioxide (CO2) 5% mixed with room air. Both the fNIRS procedure and one Magnetic Resonance Imaging (MRI) session at visits that include imaging will be done with a hypercapnia challenge for comparison.~CO2 (hypercapnia) challenge is similar to holding one's breath. Participant will wear a nose clip and a mouth breathing apparatus while in the MRI scanner or sitting in a chair during the fNIRS procedure.~During the 7-minute hypercapnia procedure, participants will breathe room air and then switch to room air mixed with 5% CO2, from one to the other for one minute each."
75717236|NCT04058132|Other|Neuropsychological Assessments|TBI Neuropsychological Assessments: Study participants will be administered a set of Neuropsychological Tests designed by the NINDS Common Data Elements (CDEs) initiative for TBI, in order to provide a comprehensive and broad assessment of deficits commonly found after TBI. We anticipate that the neuropsychological battery will require approximately 1 hour to complete. The measures (pencil and paper exercises, questionnaires, and interview by the examiner) to be administered are: Glasgow Outcome Scale-Extended (GOS-E). Learning trials portion of the California Verbal Learning Test (CVLT-II): The Trail Making Tests A and B (TMT): Subsets of the Wechsler Adult Intelligence Scale (WAIS-IV) (Digit Symbol and Symbol Search): Behavioral Symptoms Inventory-18: Satisfaction with Life Scale (SWLS): Word Reading subtest of Wide Range Achievement Test (WRAT)-4: Rivermead Post-Concussion Symptom Questionnaire.
75717237|NCT04058132|Drug|Gadolinium contrast infusion|Gadolinium contrast infusion: Brain MRI with gadolinium contrast: Dynamic contrast-enhanced (DCE) MRI with intravenous gadolinium-based contrast agents (GBCAs) to measure their transfer rate between intravascular and extravascular compartments as a marker of blood-brain barrier (BBB) permeability. For the DCE sequence, the participant is injected with the contrast agent through a heplock/iv in the scanner and the sequence takes about 15 min. Half-life of gadolinium is about 1 ½ hours and 90-98% clearance from the body in 24 hours in people with normal kidney function.
75441595|NCT01636401|Drug|aclidinium bromide 400 μg|
75441596|NCT01636401|Drug|aclidinium bromide placebo|
75441597|NCT01636440|Device|Conditioned Pain Modulation|Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation
75873503|NCT03714269|Other|measurement evaluated with an 2D ultrasound|"simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction."
75873504|NCT03714269|Other|assessment of the level of discomfort|visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
75717238|NCT04058132|Procedure|Blood sample collection for research purposes|Serum and plasma (5 ml each) will be collected at at each study visit 10 m or 2 tsp. per visit or up to 40 ml or 8 tsp. over the 180 day course of the study). Samples will be collected by study personnel.
75717239|NCT04058132|Other|Structural brain Magnetic Resonance Imaging (MRI|"Structural brain Magnetic Resonance Imaging (MRI): The scanner used is a 3.0 Tesla MR (Model 750, General Electric Healthcare), which is equipped with a high-performance gradient subsystem and a 32-channel head coil (General Electric Healthcare). These scans involve lying still in a scanner for several minutes at a time which is tube shaped, using magnetism to take images of the brain. There is no radiation in MRI. The participants will have up to 3 research brain MRIs. Healthy controls will have 1 MRI session.~Common TBI MRI techniques will be performed. Block-design BOLD fMRI during which there will be a 7 minute hypercapnia challenge will be done to assess brain blood flow and measure cerebral vascular reactivity (CVR)."
75416654|NCT04690686|Device|LW-02 device immunopheresis combined with atezolizumab|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with standard dose immunotherapy (atezolizumab) to potentially enhancing its cytotoxic effect.
75717240|NCT03050476|Drug|bRESCAP|intravenous application before, during, and for 24, 48, or 96 hours after heart surgery
75717241|NCT03050476|Drug|placebo|intravenous application before, during, and for 24, 48, or 96 hours after heart surgery
75717242|NCT00791544|Drug|AVE1642|intravenous infusion
75873505|NCT01311869|Dietary Supplement|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
75873506|NCT01311869|Dietary Supplement|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
75873507|NCT03386435|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
76042691|NCT05858125|Other|Social Media Navigation Aid Kit|"The Social media Navigation Aid Kit (SNAK) was created by using search terms, urinary incontinence, urinary leakage, and urogynecology, and querying various websites/blogs, Facebook, Instagram, and YouTube. These social media platforms were chosen based on the top three social media platforms used in Americans aged 50 to >65 years old according to Pew Research Analytics (Pew paper). The experienced reviewer evaluated each platform for users that provided relevant, accurate, and specific content. The department of Urogynecology at UNM independently reviewed the curated pages and users for approval. Once approved, the various users and pages were then collected and a flyer was created. The flyer will be available via hardcopy, email, or text per patient preference."
75441598|NCT01636440|Device|Conditioned Pain Modulation|Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
75562152|NCT05897021|Behavioral|Neutral Writing|To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker & Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
75562153|NCT05895747|Drug|Low Dose 5-hydroxytryptophan|5-hydroxytryptophan 100mg PO BID
75717243|NCT00791544|Drug|sorafenib|oral intake
75717244|NCT00791544|Drug|erlotinib|oral intake
75416655|NCT04690686|Device|LW-02 device immunopheresis combined with weekly paclitaxel|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy to potentially enhancing its cytotoxic effect.
75416656|NCT04690686|Device|LW-02 device immunopheresis|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
75717245|NCT00753350|Device|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
75873508|NCT03714191|Other|Patient Outcomes|The intervention includes different versions of the BPA design and message.
75873509|NCT03714191|Other|Billing documentation|The intervention includes different versions of the BPA design and message.
75873510|NCT03714191|Other|Regulatory|The intervention includes different versions of the BPA design and message.
75416657|NCT04685369|Other|Medical Data extraction|Medical Data extraction
75441599|NCT01636479|Drug|SAR405838|Pharmaceutical form: Capsule Route of administration: Oral
75441600|NCT01636492|Drug|bitopertin|Single oral dose
75441601|NCT01636492|Drug|placebo|Single oral dose
75562154|NCT05895747|Drug|High Dose 5-hydroxytryptophan|5-hydroxytryptophan 200mg PO BID
75562155|NCT05895747|Drug|Low Dose Creatine Monohydrate|Creatine monohydrate 5g PO qday
75562156|NCT05895747|Drug|High Dose Creatine Monohydrate|Creatine monohydrate 10g PO qday
75562157|NCT05895747|Drug|Placebo|Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
75562158|NCT05893225|Drug|Metformin Hydrochloride 850 mg Oral Tablet|Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.
75562159|NCT05893225|Drug|Placebo|Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.
75562160|NCT05887141|Behavioral|Double Standards|We created a VR intervention based on the Cognitive Behavioral Therapy (CBT) technique 'double standards'. In the intervention the participants have to respond to a virtual character they imagine as their friend, who expresses similar self-criticism as they struggle with themselves. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with the virtual friend (second person perspective).
75562161|NCT05887141|Behavioral|Self-criticism avatar|We created a VR intervention called 'Self-criticism avatar' that has common ground with two-chair dialogue. Participants have to assertively respond to their inner critic who criticizes them using their own self-critical thoughts. After responding assertively (for example: 'Go away, I don't need you', 'Good is good enough'), the virtual character becomes weaker until they give up. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with a bystander (third person perspective).
75562162|NCT05881252|Procedure|Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP >= 160 mmHg.
75562163|NCT05881252|Procedure|Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP >= 180 mmHg.
75562164|NCT05880160|Other|Phased withdrawal of heart failure medications|As per arm/group description
75717246|NCT00753428|Other|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
75717247|NCT00990028|Drug|Rosuvastatin|20 mg oral, for 10 days
75717248|NCT00990028|Drug|Placebo|20 mg vehicle
75416658|NCT04682977|Other|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning)|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning) is an intervention designed to be delivered in primary care settings by an on-site occupational therapist. Based on the premise of preventing the physical and cognitive decline that is associated with aging and chronic disease, the 12-week intervention includes a comprehensive assessment of ADL functioning and ten intervention sessions addressing disease management, physical activity and executive functioning.
75416659|NCT04682977|Other|Usual primary care services|Usual primary care services might include monitoring of vitals and other relevant laboratory testing, prescription of medications for chronic disease management, as well as counseling for lifestyle changes.
75416660|NCT04682626|Dietary Supplement|Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.|Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
75416661|NCT04665622|Other|Eye-Tracking / Neuropsychological evaluations|Use of Eye-Tracking / Neuropsychological évaluations in 4 groups
75717249|NCT04052906|Other|Training|Planned Inhaler Medication Trainning
75717250|NCT05361226|Other|Accuracy measurement|"Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters."
75416662|NCT04656236|Biological|3-hydroxybutyrate|3-hydroxybutyrate is a metabolite, produced in the human body.
75441602|NCT01636505|Drug|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
75441603|NCT01636505|Drug|gnrh agonist (suprefact)|suprefact 5.5 ml
75441604|NCT01636518|Procedure|Standard of Care|Standard of care procedure as determined by treating physician for Atrial Fibrillation
75562165|NCT05870982|Behavioral|Early TRE|Participants will be instructed to eat only during an 8-hour window starting 1-2 hours after waking.
75562166|NCT05870982|Behavioral|Late TRE|Participants will be instructed to eat only during an 8-hour window starting 5-6 hours after waking.
76042692|NCT05854654|Diagnostic Test|Air Leaks|"The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing an hermetic closure proximal to the balloon.~This setting will allow us to perform several different endoscopic and RAB procedures in emulated physiologic conditions to complete the study."
75562167|NCT05870982|Behavioral|DCR|Participants will be instructed to reduce caloric intake by 25%.
76042693|NCT05853094|Procedure|Ileostomy|Protective loop ileostomy after low anterior resection
75416663|NCT04647513|Device|Intradermal injection (superficial dermis for Art Filler Fine Lines / moderately deep to deep dermis for Art Filler Universal and Art Filler Lips)|The function of injectable fillers for the treatment of dermal contour deformities is to smooth dermal depressions formed by the loss of volume and the aging process. These fillers (also known as soft tissue augmentation medical devices) can correct the skin depressions/wrinkles, balance the disproportions or correct topographical anomalies.
75416664|NCT04645576|Device|Face correction with injectable fillers|Injection of hyaluronic acid-based fillers
75562168|NCT05863520|Behavioral|Zones of Regulation|ZOR is rooted in CBT principles and uses a metacognitive framework to increase awareness of feelings and to build regulation, prosocial skills, and overall wellness.
76042694|NCT05853094|Procedure|Transverse colostomy|Protective loop transverse colostomy after low anterior resection
75562169|NCT05863520|Behavioral|Facing Your Fears - School Based|FYF-SB is a CBT program for managing anxiety in autistic youth.
75562170|NCT05861076|Other|Moringa Powder - Low Dose|1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
75562171|NCT05861076|Other|Moringa Powder - Medium Dose|2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
75562172|NCT05861076|Other|Moringa Powder - High Dose|3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
75717251|NCT00663234|Drug|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
75717252|NCT00683384|Drug|Etanercept (Enbrel)|
76042695|NCT05834491|Device|minimal shoes and foot strengthening and flexibility exercises|Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
76042696|NCT05834491|Device|Supportive Footwear, foot orthotic device and foot flexibility exercises|sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
75717253|NCT00753662|Device|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
75416665|NCT04623372|Procedure|suture|suture by separated knots using a non-absorbable 4.0 wire and application of a dry dressing after the punch skin-biopsy
75416666|NCT04623372|Procedure|directed wound healing|application of a dry dressing without any prior suture after the skin biopsy.
75441605|NCT01636531|Drug|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
75562173|NCT05851508|Drug|Methylprednisolon|Intratympanal injection with Methylprednisolon 62.5 mg/ ml
75562174|NCT05851508|Drug|Placebo|Intratympanal injection with saline, natriumchloride 0.9%
75562175|NCT05844436|Drug|Pritelivir|Participants receive a loading dose of 400 mg (4 x 100 mg tablet) pritelivir on first day followed by continuous dose of 100 mg per day.
75562176|NCT05838196|Diagnostic Test|Point-of-care ultrasound|Point-of-care ultrasound performed during clinic appointment
75717254|NCT00753662|Device|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
75717255|NCT00753662|Device|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
75717256|NCT04003714|Device|Repetitive Transcranial Magnetic Stimulation|Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
75717257|NCT04003714|Device|Sham Repetitive transcranial Magnetic Stimulation|Control group received sham r-TMS.
75717258|NCT02561312|Other|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
76042697|NCT05828992|Other|No intervention administered|Survey only to gather people's experiences, opinions and needs.
75416667|NCT04621682|Other|Non technical skills and checklist training in simulation|using structured debrifing, in three random medical simulation crises, training in non-technical skills will be carried out
75416668|NCT04621682|Other|Checklist training simulation|using structured debrifing, in three random medical simulation crises, training in checklist will be carried out
75562177|NCT05830643|Behavioral|Social skills group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
75562178|NCT05830643|Behavioral|Adult interest group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
75562179|NCT05823220|Behavioral|Homeless diversion (HD)|Participants will receive services from specialty-trained community health workers and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
75562180|NCT05823220|Behavioral|Treatment-as-usual (TAU)|Participants will receive a list of community resources they can contact to receive services and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
75562181|NCT05822297|Device|Neuromuscular electrical stimulation|NMES will consist of a 12 week electrical stimulation program, three times a week. Electrical stimulation will be done on the quadriceps muscles of both legs simultaneously. For each leg, one electrode is placed on the proximal side and one on the distal side of the quadriceps muscle. Electrical stimulation sessions will take 30min, at a stimulation frequency of 50Hz, an intensity where we can at least see a visible or palpable contraction with a maximum intensity of 100mA (we will choose the highest intensity that is easily supported by the participant without inducing discomfort) and a pulse width of 400μs. The activation within the activation-rest cycle consists of a 1s ramp-up, 7s full activation and 1s ramp-down, followed by 18s rest. Every 4 weeks the rest period will be diminished with 3s until a total of 9s.
75562182|NCT05816369|Other|Taste session of five ONS flavors|Patients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).
76042698|NCT05820295|Behavioral|Care coordination delivered based on perceived need|If patients in intervention group report on the survey that they experience difficulty coordinating care among their providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
76042699|NCT05820295|Behavioral|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
76042700|NCT05819502|Drug|Restylane line of injectable|Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
76042701|NCT05816304|Behavioral|Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)|Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
76042702|NCT05805345|Device|Delefilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
76042703|NCT05805345|Device|Lehfilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
76042704|NCT05805345|Device|Lotrafilcon B toric soft contact lens|Commercially available silicone hydrogel contact lens
75416669|NCT04616846|Diagnostic Test|Peripheral venous ultrasound|Screening for VTE from D7 to 42
75416670|NCT04614597|Biological|Sabin strain inactivated polio vaccine|Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.
75416671|NCT04614142|Drug|Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]|The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
75441606|NCT01636531|Drug|gantenerumab|Lyophilized formulation (LyoF), single dose sc
75441607|NCT01636557|Drug|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
75441608|NCT01636557|Drug|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
75441609|NCT01636557|Drug|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
75441610|NCT01636557|Drug|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
75717259|NCT02561312|Other|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
75873511|NCT02912208|Drug|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
75873512|NCT02912208|Other|Placebo|The administration is the same of eltrombopag
75873513|NCT02793258|Device|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
75873514|NCT02726880|Behavioral|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
75562183|NCT05809011|Drug|Dexamethasone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
75562184|NCT05809011|Drug|Prednisone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
75717260|NCT05361148|Other|no interventions will be used|This is a cohort study with no interventions.
75717261|NCT00788346|Behavioral|Computerized alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
76042705|NCT05805345|Device|Verofilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
75717262|NCT00788346|Behavioral|Alerts Plus Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
75717263|NCT00753740|Drug|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
75717264|NCT00753740|Drug|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
75717265|NCT00753740|Drug|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
75717266|NCT00796380|Drug|Xingnaojing|injection
75717267|NCT00326911|Biological|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
75717268|NCT00326911|Biological|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
75717269|NCT00326911|Drug|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
75873515|NCT02726880|Behavioral|Referral for care|Referral for mental health issues and family support services
75873516|NCT03275389|Biological|D-SUIV cH8/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
75717270|NCT00326911|Biological|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
76042706|NCT05793450|Drug|IBI362|2.0mg, SC, single dose
76042707|NCT05782062|Device|Cleaner XT|Wire like device that rotates to allow for wall to wall disruption of thrombus.
75441611|NCT01636557|Drug|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
75441612|NCT01636557|Drug|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
75441613|NCT01636570|Drug|Placebo Comparator: Sugar Pill|Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
75441614|NCT01636570|Drug|Vitamin D3 (cholecalciferol)|10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
75873517|NCT03275389|Biological|D-SUIV cH5/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
76042708|NCT05782062|Device|Balloon|Use of balloon for disrupting thrombus.
76042709|NCT05771025|Procedure|Hepatectomy|Patients in the hepatectomy group receive liver resection.
76042710|NCT05866029|Drug|Denosumab|Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
76042711|NCT05866029|Drug|Teriparatide|Teriparatide was sequentially treated with Denosumab
75562185|NCT05801419|Device|RETI-port/scan 21|Pattern visual event-related potential and pattern electroretinogram on right eye (non-dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
75416672|NCT04613739|Behavioral|insurance navigation|Intervention subjects will be offered access to AAFA's chat bot and navigation services. The chat bot is an artificial intelligence-enabled interactive online tool that can answer clinical and insurance-related questions and provide information on coverage options and how to find lower-cost alternatives for asthma care. Intervention participants will be given a link to access the chat bot. They will also be provided with information about AAFA's insurance navigation program, how it can help with finding coverage and managing asthma costs, and how to access it within AAFA's asthma community platform. Subjects can access AAFA's community platform and join the private group where they can ask questions and share resources, with moderation by AAFA staff. They will be able to send private messages to an AAFA navigator who can provide support about insurance issues, access to asthma care, and assistance with asthma costs. The navigator will offer telephonic follow-up as needed.
75562186|NCT05801419|Device|Zilia Ocular|Eye fundus tissue oximetry measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
75562187|NCT05801419|Device|OCT-A|Optical coherence tomography angiography measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
75562188|NCT05801419|Combination Product|Electronic cigarette without nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial without nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
75562189|NCT05801419|Combination Product|Electronic cigarette with nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial with nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
75416673|NCT04609124|Diagnostic Test|Abdominal ultrasound evaluation of antral area|ultrasound assessment of antral cross sectional area
75416674|NCT04605172|Other|hospitalization for premature birth|Number of inborn and outborn infants prematurely born during a specific period of time
75562190|NCT05789069|Drug|HFB200603|Participants will be administered HFB200603 as described in the experimental arm.
75562191|NCT05789069|Drug|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
75562192|NCT05775978|Behavioral|Más Presente, the UGRComp program|Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life.
75562193|NCT05775978|Behavioral|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
75562194|NCT05775978|Behavioral|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
76042712|NCT05764278|Other|exercise|exercise group: first bed exercise after 0~24hr onset ; sit at bed after 24~48hr onset control group: first bed exercise after 24~48hr onset ; sit at bed after 48~72hr onset
75562195|NCT05769647|Device|Virtual Reality Glasses|3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.
75562196|NCT05769647|Device|Stress Ball|Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The patient will continue to squeeze the ball throughout the IV catheter insertion attempt.
75562197|NCT05763810|Other|Erector Spinae Plane Block|Erector Spinae Plane Block
75562198|NCT05763810|Other|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
75562199|NCT05763693|Drug|Azithromycin at Baseline|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
76042713|NCT05762705|Behavioral|Multilevel Gaming Adherence Intervention|Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages
75562200|NCT05763693|Drug|Azithromycin at Day 21|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
75562201|NCT05763693|Other|Placebo at Baseline|this group will be randomized to receive Placebo at baseline
76042714|NCT05762705|Behavioral|Treatment as Usual +|non-PrEP related mobile gaming application
76042715|NCT05751473|Behavioral|Prolonged Exposure for Primary Care (PE-PC)|"Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study."
75416675|NCT04604691|Drug|Blinatumomab for Injection|Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
75416676|NCT04594525|Other|Low-Intensity Psychosocial Interventions through Telemental health|Low-Intensity Psychosocial Interventions through Telemental health (Thinking healthy): The intervention will include six sessions. Each session may last to 45 min as a max, and it will be provided through telehealth. The first session will be an introduction, while the other five sessions will be covering the period from the second pregnancy trimester to the first year of the infant's life.
75416677|NCT04580381|Drug|Natalizumab Injection [Tysabri]|Natalizumab infusion interval according to local practice defining the patient's group
75416678|NCT04575792|Behavioral|Practicing oral habits|children who practice one or more of the specified oral habits ( mouth breathing, object sucking, or tongue thrusting) are considered exposed.
75416679|NCT04575649|Other|Gastrointestinal anomalies|Infants born late preterm (at or above 35 weeks gestation) and term infants admitted to the NICU with congenital gastrointestinal anomalies, including gastroschisis, omphalocele, esophageal and bowel artesias, tracheoesophageal fistulas, Hirschsprung's disease, or congenital diaphragmatic hernias.
75416680|NCT04561154|Other|questionnaire|three months after hospitalization, a questionnaire will be sent to patients. If necessary, patient will be seen in consultation of geriatry, otorhinolaryngology, pneumology, neuropsychology
75416681|NCT04561050|Other|Comparison of score performances (Overall performance, discrimination and calibration)|"Our Study is an observational non-interventional study based on a multicentric anonymized registry. It's an external validation of pre-existing prognostic scores of traumatic haemorrhages at different times of care (Scene of Injury, admission at the trauma room) in order to assess their overall performance, discrimination and calibration in the prediction of massive transfusion and haemorrhagic death.~The statistic intervention will be a comparison of score performances (Overall performance, discrimination and calibration)."
75416682|NCT04548245|Device|EEG|EEG
75562202|NCT05763693|Other|Placebo at Day 21|This group will be randomized to receive Placebo at the day 21 visit
75416683|NCT04542564|Device|telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
75562203|NCT05758857|Behavioral|Experimental: Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
75873518|NCT03275389|Biological|D-SUIV cH11/1N1+AS03|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
75416684|NCT04542564|Other|usual care|These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments
75416685|NCT04537884|Drug|UBX1325|Investigational drug intravitreal injection
75416686|NCT04535349|Diagnostic Test|Whole-body & CZT bone tracer imaging (SPECT)|Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras
75562204|NCT05758857|Behavioral|Experimental: Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
76042716|NCT05751473|Behavioral|EAP Treatment as Usual (TAU)|"Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study."
75562205|NCT05758857|Behavioral|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
75562206|NCT05750264|Drug|Ibuprofen|800 mg of IV ibuprofen
75562207|NCT05746754|Radiation|CSI|30 Gy in 10 fractions to CNS
75562208|NCT05742685|Behavioral|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
75562209|NCT05736848|Device|OviTex® PRS|OviTex® PRS is a reinforced tissue matrix intended to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
75562210|NCT05736679|Device|In2Care EaveTube|In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
75562212|NCT05730335|Device|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
75873519|NCT03275389|Biological|D-SUIV cH8/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
75873520|NCT03275389|Biological|D-SUIV cH5/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
75441615|NCT01636583|Device|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
75441616|NCT01636583|Device|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
75441617|NCT01636583|Other|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
75562213|NCT05726123|Device|The Exopulse Mollii Suit on a Fibromyalgia patient|The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
75562214|NCT05715281|Biological|Atezolizumab|Given IV
75562215|NCT05715281|Procedure|Biopsy|Undergo tumor biopsy
75562216|NCT05715281|Procedure|Biospecimen Collection|Undergo blood sample collection
75562217|NCT05715281|Procedure|Computed Tomography|Undergo CT scan
75873521|NCT03275389|Biological|D-SUIV cH11/1N1+AS01|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
75562218|NCT05715281|Procedure|Echocardiography|Undergo ECHO
75873522|NCT03275389|Biological|D-SUIV cH8/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
75562219|NCT05715281|Drug|Tiragolumab|Given IV
75416687|NCT04534686|Behavioral|CogXergaming|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
75416688|NCT04534686|Behavioral|Matter of Balance Training|The program emphasizes practical coping strategies that include group discussions, mutual problem solving, exercises to improve strength, coordination and balance, and, a home safety evaluation.
75873523|NCT03275389|Biological|D-SUIV cH5/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
76042717|NCT05747105|Behavioral|Sleep Extension|The 16-week protocol includes 11 total individual visits that integrate applicable elements of Cognitive Behavioral Therapy for Insomnia (CBT-I) and health behavior change theory. The first 6 weeks include weekly sessions (~45 minutes each) focused on psychoeducation about sleep, goal-setting and self-monitoring, stimulus control, addressing cognitive and somatic arousal, sleep hygiene, and challenging negative thoughts about sleep. Sleep restriction will also be used in specific cases where sleep efficiency is low (<85%). The remaining 10 weeks include briefer biweekly visits (5 visits, ~15-20 minutes each) to reinforce health behavior change strategies through topics such as problem-solving barriers, utilizing social support, identifying setbacks and creating an action plan, and relapse prevention. Self-reported sleep diary data and subjective sleepiness will be collected at each visit.
76042718|NCT05740618|Drug|Mannitol Inhalant Product|A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.
75416689|NCT04526925|Device|Respiratory filter in-line placed with the standard mouthpiece|The respiratory filter is a device that removes solid/large particles from gas
75416690|NCT04526925|Other|Standard mouthpiece|The mouthpiece is the interface that is placed on participant's face in order to measure all the breathing physilogic responses
75441618|NCT01636596|Drug|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
75562220|NCT05713630|Drug|GD-Tranexamic Acid 500 MG Oral Tablet|Tranexamic acid film-coated oral tablet.
75562221|NCT05713630|Drug|Sandoz-Tranexamic Acid 100 MG/ML|Sandoz-Tranexamic acid 100 milligram/millilitre (mg/mL) via nasogastric tube.
75441619|NCT01636609|Drug|Azacitidine|Given IV or SC
75441620|NCT01636609|Drug|Cytarabine|Given SC
75441621|NCT01636609|Drug|Tosedostat|Given PO
75562222|NCT05713630|Drug|Sandoz-Tranexamic Acid 100 Mg/mL Solution for Injection|Sandoz-Tranexamic acid 100 mg/mL solution for injection via intravenous (IV).
75562223|NCT05713630|Drug|Placebo|The placebo 500 mg will consist of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed. Placebo 100 MG/ML via nasogastric tube and placebo 100 Mg/mL solution for injection via intravenous (IV). The solution form of the placebo will consist of 0.9% sodium chloride (saline).
75562224|NCT05712538|Drug|ARCT-032|ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
75562225|NCT05712538|Other|Placebo|Normal saline
75562226|NCT05707871|Drug|SPECTRUM cigarettes|SPECTRUM cigarettes have varying amount of nicotine content
75562227|NCT05707871|Other|usual brand of Cigarettes|Usual Brand of Cigarettes
75562228|NCT05705115|Drug|Ringer acetate|Ringer acetate 5 ml/kg.
75562229|NCT05705115|Other|Lower body negative pressure|Lower body negative pressure, 40 mmHg. Experimental hypovolemia.
75873524|NCT03275389|Biological|D-SUIV cH11/1N1|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
76042719|NCT05736718|Behavioral|Champion Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the champion arm, vaccine champions will deliver the training using slides and a standardized script. They will also conduct outreach and sustainability planning.
75562230|NCT05703152|Other|Combined Exercise|Therapeutic exercise program will be applied that will include two modalities: aerobic and resistance exercise. The duration will be 8 weeks with a frequency of 3 sessions per week, with a duration per session of 60 minutes.
75562231|NCT05701072|Procedure|Oocyte Pick Up|The screening questionnaire will be filled by the Physician doing the OPU. The screening questionnaire will be informed by the participant's history. Cervix will be visualized during routine vaginal cleansing for OPU, and its appearance (size, and deviation) will be recorded in the screening questionnaire after the OPU procedure. Finally, a screenshot of the ultrasound used for OPU, showing the cervix and cervical canal in the sagittal plane will be taken during routine procedure and saved in electronic chart.
76042720|NCT05736718|Behavioral|Traditional Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the traditional arm, outside experts will deliver the training using the same slides and script.
76042721|NCT05698290|Other|HELP Pain Training Program|A training program to teach school providers nonpharmacologic (e.g., cognitive behavioral and mindfulness meditation) strategies to use with students with pain symptoms.
75717271|NCT00990262|Radiation|Cardiac Computed Tomography|"Localization of the heart position in a projectional topographic scan of the chest.~Determination of contrast agent transit time: 10 ml contrast agent.~CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
75873525|NCT03275389|Biological|Placebo|1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
75873526|NCT03275389|Biological|Fluarix Quadrivalent|1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
76042722|NCT05691387|Behavioral|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
75717272|NCT00791622|Drug|Paliperidone ER|
75717273|NCT00747110|Drug|budesonide|3x 3mg budesonide capsules once daily
75717274|NCT00747110|Drug|mesalazine|3x 1000mg mesalazine onc daily
75717275|NCT00796458|Drug|docetaxel|Given IV
75717276|NCT00796458|Drug|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
75717277|NCT00753818|Other|DHA and ARA|various levels of DHA and ARA
75441622|NCT01636622|Drug|Vemurafenib|Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
75441623|NCT01636622|Drug|Carboplatin|Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
75441624|NCT01636622|Drug|Paclitaxel|Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
75717278|NCT00753818|Other|Control|
75717279|NCT05359744|Diagnostic Test|Performance testing|Performance testing on a bicycle ergometer.
75441625|NCT01636635|Other|Calorie Restriction|Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
75717280|NCT00747188|Behavioral|PBL|
75717281|NCT04046016|Drug|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
75717282|NCT01057615|Dietary Supplement|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
75717283|NCT01057615|Dietary Supplement|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
75717284|NCT01057615|Dietary Supplement|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
75441626|NCT01636648|Device|Aortic Valve Replacement|Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000
75717285|NCT01057615|Dietary Supplement|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
75717286|NCT04046718|Device|electro-acupuncture stimulation|stimulation of acupoints of the liver meridian of lv3 lv14
75717287|NCT02561858|Other|acid load test|
75717288|NCT05124418|Diagnostic Test|palatal masticatory mucosa thickness measurement|Measure the thickness of palatal masticatory mucosa by a dynamic navigation system (Navident®, ClaroNav Inc., Toronto, Canada) and periodontal probe piercing.
75873527|NCT03414359|Drug|2% Lidocaine|2% Lidocaine using a combined spinal-epidural (CSE)
75873528|NCT03414359|Drug|3% Chloroprocaine|3% Chloroprocaine using a combined spinal-epidural (CSE)
76042723|NCT05691387|Behavioral|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
75873529|NCT03285295|Device|Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay|For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
75416691|NCT04519320|Diagnostic Test|Pulmonary function testing|"D0: date of first symptoms of SARS-COV-2~M3: D0 + 3 months~Blood test~Blood gases~Clinical examination~CT Scan~Pulmonary function testing (PFT)~6-minute walk test (6MWT)~MOS SF-36 Questionnaire~HADS scale~Ventilatory polygraphy~M6: D0 + 6 months~Clinical examination~PFT~6MWT~MOS SF-36 Questionnaire~HADS scale~M12: D0 + 12 months~Blood test~Blood gases~Clinical examination~CT Scan (If anomaly found at M3)~PFT~Pulmonary Exercise Stress Test~6MWT~MOS SF-36 Questionnaire~HADS scale~Subsequent follow-up will be performed only in patients with an alteration defined by a DLCO <LLN and / or an abnormality objectified at CT-Scan attributable to SARS-CoV-2.~M24, M36, M48 and M60: D0 + 24, 36, 48, 60 months~Clinical examination~PFT~6MWT~MOS SF-36 Questionnaire~HADS scale"
75416692|NCT04496245|Drug|Broncho-Vaxom®|Broncho-Vaxom adult capsules® (OM85)
75562232|NCT05701072|Procedure|Embryo Transfer|When the participants comes back for ET during her routine treatment, ET will be done in exactly the same way in routine treatment. Participant will not undergo any additional manipulation, intervention, nor the procedure will take longer. The Embryologist assisting the procedure will record the duration of the procedure, from the moment the Physician takes the outer ET catheter to his/her hand until he/she passes the cervix and calls for the inner catheter loaded with the embryo. Up on completion of the ET procedure as routine practice, the Physician will fill a questionnaire about the procedure.
75717289|NCT00788424|Drug|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
75717290|NCT00747422|Device|Ulthera™ System|ultrasound treatment
75717291|NCT04003870|Device|CASO|Customized arch support orthoses (CASO)
75873530|NCT03285295|Device|Alinity s HTLV I/II Assay|For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
75717292|NCT04003870|Device|HL|Orthotic Heel Lift (HL)
75416693|NCT04492410|Other|rapid serological test|screening using a rapid serological test with a drop of blood from a finger prick
75416694|NCT04476745|Dietary Supplement|Vitamin D3|Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
75416695|NCT04471545|Procedure|Pectoral nerve block type II|A pectoral nerve block type II will be given to the patient after induction. This is performed ultrasound guided
75416696|NCT04469140|Device|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
75717293|NCT00796536|Behavioral|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
75717294|NCT00796536|Behavioral|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
75717295|NCT04057274|Other|Exercise assessment|The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
75717296|NCT02686060|Device|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
75873531|NCT03285295|Device|Alinity s Anti-HCV Assay|For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
76042724|NCT05684198|Device|subcutaneous NPWT|Following fascia closure, NPWT system will be inserted into subcutaneous tissue, continuous negative pressure of 120 mmHg will be applied.
75416697|NCT04468971|Biological|CK0802|Cryopreserved, off the shelf, cord blood derived T regulatory cells
75416698|NCT04468971|Drug|Placebo|Expicient
75717297|NCT00791856|Drug|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
75562233|NCT05685927|Drug|6-months of medically assisted glycemic improvement|Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark
75562234|NCT05685927|Procedure|Bariatric surgery|Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark
75717298|NCT00791856|Drug|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
75562235|NCT05681858|Diagnostic Test|CT coronary angiography and [12N] NH3 PET-MR|Advanced coronary artery plaque analysis, myocardial ischemia and coronary flow reserve
75416699|NCT04466449|Diagnostic Test|stool sample|A stool sample will be collected from each patient for diagnosis of Entamoeba
75416700|NCT04458805|Drug|NX-13 250 mg|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
75416701|NCT04458805|Drug|Placebo|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
75416702|NCT04458753|Other|Lumbar focused exercises|Transersus abdominis activation Multifidus activation Back extension exercise Curl up abdominal exercise
75416703|NCT04458753|Other|Knee focused exercises|Strengthening of quadriceps Stretching of calf and Hamstring muscles
75717299|NCT02561780|Behavioral|Curriculum|A mental health educational resource delivered in the classroom by trained educators
75717300|NCT02561780|Behavioral|eLearning Follow-up|An online mental health education module that students access individually
75416704|NCT04458441|Other|warm group/cold group|sequential randomization
75416705|NCT04450888|Other|The strategic use of messages in risk communication|The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
75416706|NCT04445207|Biological|Convalescent Plasma|One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.
75416707|NCT04433390|Drug|Naloxegol|one naloxegol 12.5 mg tablet will be administrated 2 hours before surgery. One 25 mg naloxegol tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
75416708|NCT04433390|Drug|inert tablet|one inert tablet will be administrated 2 hours before surgery. One inert tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
75416709|NCT04432272|Biological|COVID-19 convalescent plasma|Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit
75416710|NCT04408222|Other|Awake proning|Prone positioning of awake, as tolerated, for up to 24 hours daily.
75717301|NCT00796692|Drug|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
75562236|NCT05673993|Biological|Telitacicept 80 mg|Telitacicept 80 mg subcutaneously once a week.
75562237|NCT05673993|Biological|Telitacicept 160 mg|Telitacicept 160 mg subcutaneously once a week.
75717302|NCT00796692|Drug|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
75717303|NCT00540436|Drug|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
75873532|NCT03285295|Device|Alinity s HIV Ag/Ab Combo Assay|For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
75562238|NCT05673993|Drug|Placebo|Subjects will be given subcutaneous placebo once a week.
75562239|NCT05673148|Procedure|Stereotactic Ablative Radiotherapy|Undergo SABR
75562240|NCT05673148|Procedure|Resection|undergo surgical resection
75562241|NCT05673148|Procedure|Microwave Ablation|undergo microwave ablation
76042725|NCT05684146|Device|Emboliner Embolic Protection|Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
75562242|NCT05673148|Drug|Chemotherapy|Receive SOC chemotherapy
75562243|NCT05673148|Procedure|Computed Tomography|Undergo CT scan
75562244|NCT05673148|Procedure|Magnetic Resonance Imaging|Undergo MRI
75562245|NCT05673148|Procedure|Positron Emission Tomography|Undergo PET scan
75717304|NCT00754286|Other|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
76042726|NCT05684146|Device|Sentinel Cerebral Protection|The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
76042727|NCT05682846|Drug|Sodium glycerophosphate pentahydrate solution|Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
76042728|NCT05682222|Drug|EDP1815|EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.
76042729|NCT05682222|Drug|EDP2939|EDP2939 is a pharmaceutical preparation of extracellular vesicles.
76042730|NCT05682222|Drug|Placebo oral capsule|Placebo.
76042731|NCT05677295|Drug|duloxetine|Duloxetine 30 mg per day
75416711|NCT04407806|Device|Continous Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation throughout hospitalization
76042732|NCT05677295|Drug|Imipramine|Imipramine 25 mg per day
76042733|NCT05664750|Drug|TNM002|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
76042734|NCT05664750|Drug|Human tetanus immunoglobulin (HTIG)|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
76042735|NCT05623514|Combination Product|Trans-vaginal ultrasound|Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum
76042736|NCT05608304|Behavioral|Formal mindfulness induction|The formal mindfulness induction will consist of a 10-minute audio recording of a sitting meditation, guiding the participant to consciously and repeatedly bring their attention to their breath and inner experience with nonjudgmental acceptance.
76042737|NCT05608304|Behavioral|Informal mindfulness induction|The informal mindfulness induction will consist of on-screen instructions guiding participants through the completion of four routine tasks (washing hands, drinking water, laying down, listening to music) with mindful awareness and acceptance over the course of 10 minutes.
75416712|NCT04407806|Device|Intermittent Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation intermittently during hospitalization
75562246|NCT05649579|Drug|Dupilumab|Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.
75562247|NCT05646459|Drug|cannabidiol|This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
75562248|NCT05646459|Device|floss|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
75562249|NCT05646459|Device|proxabrush|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
75416713|NCT04399746|Drug|Ivermectin|6mg once daily in day 0,1,7 and 8
75416714|NCT04399746|Drug|Azithromycin|500mg once daily for 4 days
75416715|NCT04399746|Drug|Cholecalciferol|400 IU twice daily for 30 days
75416716|NCT04391608|Drug|Switching to Tenofovir Alafenamide|Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
75562250|NCT05638633|Drug|Prednisolone 20 mg/ 5 mg|Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.
75562251|NCT05638633|Drug|Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)|Administration of vitamin B compound for 28 days.
75416717|NCT04383756|Biological|Donor Blood|Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood
75717305|NCT00754286|Other|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
75717306|NCT00796770|Biological|Dendritic Cell Vaccine|"Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~an opportunistic infection~a CDC class C-defining event (defined in appendix 2)~a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48."
75873533|NCT03285295|Device|Alinity s Anti-HBc Assay|For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
75717307|NCT00788580|Drug|pazopanib hydrochloride|
75416718|NCT04383756|Biological|Banked Blood|Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)
75416719|NCT04368299|Other|Telemedicine|Videoconferencing for follow-up
75416720|NCT04368299|Other|Standard care|Standard in-person outpatient follow-up
75416721|NCT04368091|Device|Xtreme Touch - Neo sirolimus coated PTA balloon catheter|The Xtreme Touch (Magic Touch PTA) - Neo Sirolimus PTA Balloon Catheter is the world's first sirolimus coated PTA balloon. The purpose of the X-TOSI all-comers registry is to collect short and long-term clinical performance data on the Xtreme Touch (Magic Touch PTA) -Neo sirolimus PTA balloon catheter in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in real world daily clinical practice.
75416722|NCT04362436|Radiation|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Single-photon emission computed tomography (SPECT) imaging will assess 99mTc-MAA (MAA being macro aggregated albumin) deposition in the tumour bed to estimate the dose of radiation to tumour and healthy tissue, before administration of TheraSpheres to eligible patients
75416723|NCT04353115|Device|Training with Serious game|training the gaze stability with a serious game, 20 minutes a day, 2 days a week for 5 weeks in the presence of a doctor or physiotherapist, at the hospital to avoid addiction at home.
75717308|NCT00788580|Drug|temsirolimus|
75717309|NCT00788580|Procedure|immunoenzyme technique|
75717310|NCT00788580|Procedure|laboratory biomarker analysis|
75717311|NCT00788580|Procedure|pharmacological study|
75717312|NCT00788658|Behavioral|Diet modifications|Diet consultation
75416724|NCT04331379|Device|Nasal Elevator|A device aiming to elevate the clefted nostril extraorally and fixed on the forehead.
75873534|NCT03285295|Device|Alinity s Chagas Assay|For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
75416725|NCT04331379|Device|Taping Alone|Horizontal tape alone.
75416726|NCT04329715|Behavioral|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
75416727|NCT04329715|Behavioral|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
75873535|NCT02583048|Drug|Bedaquiline|Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.
75416728|NCT04328090|Other|Computer based Antimicrobial stewardship (AMS) intervention system|"Re-evaluation alerts and decision support for the duration of antimicrobial treatment.~Re-evaluation alerts and decision support for the choice of antimicrobial.~Quality control audit and feedback."
75416729|NCT04325919|Other|No intervention|No intervention
75416730|NCT04324021|Biological|Emapalumab|I.v. infusion every third day
75416731|NCT04324021|Biological|Anakinra|Daily i.v. infusion
75717313|NCT00788658|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
75562252|NCT05638633|Drug|Placebo for Vitamin B compound|Administration of placebo for vitamin B compound placebo for 28 days.
75562253|NCT05638633|Drug|Placebo for Prednisolon|Administration of placebo for prednisolone 20 mg for 5 days, followed by placebo for prednisolone 5 mg for 23 days.
75562254|NCT05635604|Drug|Eptinezumab|Eptinezumab or ALD403 is a humanized anti-calcitonin gene-related peptide IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). It selectively binds human CGRP ligand to prevent activation of the CGRP receptor and blocks its binding to the receptor for the prevention of migraine.
76042738|NCT05608304|Behavioral|Active control task|Participants assigned to the active control condition will be prompted to download a single-page document containing 100 letters, numbers, and symbols, and a grid of 100 boxes. Following along with a guided audio, participants will be instructed to place all of the characters in the grid in a specific order over the course of 10 minutes. A version of this task has been used in previous studies by our team (Carsley & Heath, 2019; Petrovic et al., 2022) and has been shown not to impact mindfulness levels, and was thus deemed an appropriate neutral attention task for this study.
75717314|NCT03878498|Other|therapeutic management|therapeutic management of anal fistula in Crohn Disease
75416732|NCT04322487|Diagnostic Test|Lung ultrasound|A proposal of a standardized approach in order to optimize the use of lung ultrasound in COVID-19 patients. We focus on equipment, procedure, classification and data-sharing.
75562255|NCT05635604|Drug|PACAP-38|PACAP-38 is a naturally occurring peptide diffusely expressed throughout the body. The Danish Headache Center has used infusion of PACAP-38 for several years and the first time in 2007 where infusion of PACAP-38 triggered headaches and migraines in migraine patients.
75416733|NCT04320797|Diagnostic Test|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
75562256|NCT05630378|Behavioral|outpatient clinic with multimodal integrative medicine and naturopathy for post-COVID-19 patients|Patients receive multimodal integrative medicine and naturopathy applications with focus on mind-body-medicine and whole body hyperthermia to reduce fatigue and improve quality of life.
75562257|NCT05630378|Other|waiting group|Patients receive no intervention
75562258|NCT05625490|Drug|Ga-68 Galmydar|Two intravenous injection of the PET radiotracer 68Ga-Galmydar.
75562259|NCT05625490|Drug|13N-ammonia|Two intravenous Injection of PET radiotracer 13N-Ammonia.
75562260|NCT05625425|Behavioral|LabyrinthVR software|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.
75562261|NCT05625425|Behavioral|Placebo Games software|Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.
75562262|NCT05625425|Behavioral|Labyrinth Tablet software|Tablet computer playing Labyrinth spatial wayfinding game in 2.5D
75717315|NCT00792012|Radiation|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
75416734|NCT04318821|Procedure|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
75562263|NCT05625425|Behavioral|Labyrinth VR wireless|Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
75562264|NCT05621772|Other|Meridian Activation Remedy System for Parkinson's Disease (MARS-PD)|MARS-PD is a complex therapy developed by researchers to enhance the synergistic effects of acupuncture and exercise.
75562265|NCT05619302|Drug|[68Ga]CBP8 PET/MRI|Simultaneous cardiac PET/MRI images will be obtained following injection of [68Ga]CBP8
75717316|NCT00792012|Drug|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
75717317|NCT00990418|Drug|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
75717318|NCT02562950|Drug|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
75717319|NCT02562950|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
75717320|NCT02562950|Drug|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
75717321|NCT02599948|Other|no intervention|
75717322|NCT00788814|Behavioral|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
75717323|NCT00796848|Device|Navigator Continuous Glucose Monitor|
75562266|NCT05618782|Drug|LEVI-04|Intravenous infusion
75562267|NCT05618782|Other|Placebo:|Placebo dose intravenous infusion
75562268|NCT05615285|Other|PERCS Triage and Referral System|Participants will undergo an assessment of physical function and psychosocial wellbeing. Researchers will apply a triage algorithm, based on findings of assessment. Participants will be referred to one of three exercise-based rehabilitation pathways which will best meet their rehabilitation needs. Participants will be re-assessed after 12 weeks. System will be evaluated using RE-AIM framework.
75873536|NCT02583048|Drug|Delamanid|Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
75562269|NCT05613803|Drug|Fish oil|6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.
75562270|NCT05613803|Other|Placebo|Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
75717324|NCT00754754|Procedure|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
75717325|NCT00792090|Other|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
75717326|NCT00792090|Other|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
75562271|NCT05612295|Behavioral|MBPP|"MBPP program consist of three fundamental principles (i.e., attention monitoring, acceptance, sport-specific rationale) and six performance-related core mental attributes including three behavioral and three neurocognitive components.~Each session will start with a brief homework discussion and recap of the preceding session, and instructors will deliver a topic-related brief story or group activity to participants, followed by a theoretical introduction and practice of mindfulness. Finally, at the end of each session, instructors will guide participant to discuss mindfulness applications related to specific sports performances. At the end of the session, participants will be assigned homework to increase the effectiveness of MBPP, and participants will be encouraged to practice daily for at least 10-15 min between the sessions."
75873537|NCT02583048|Drug|Dolutegravir|For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)
75873538|NCT02583048|Drug|Multidrug Background Treatment (MBT) for TB|A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
75873539|NCT02939599|Drug|QCC374|0.015mg and 0.06mg
75416735|NCT04318808|Procedure|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
75416736|NCT04311437|Procedure|Self-acupressure therapy|The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.
75717327|NCT00792168|Drug|venlafaxine (Effexor)|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
75717328|NCT00792168|Other|placebo|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
75717329|NCT02554188|Biological|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine~Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
75873540|NCT05217186|Diagnostic Test|Measurements|All infants wirth high risk of cp will be assessed by neuroimaging and Hammersmith Neonatal Neurological Examination (HNNE) at term age, Prechtl's General movements (GMs) assessments form birth up to 3-5 months, and will be assesed by Hammersmith Infant Neurological Examination (HINE) at 2,3,6,9 and 12th months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at the 3rd, 6th, and 12th months.
75873541|NCT05198622|Procedure|Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
75416737|NCT04311437|Procedure|Combined Valsalva and Toynbee maneuvers|Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
75416738|NCT04310956|Device|Y-Knot all-suture anchor|Y-knot all-suture anchor will be implanted to participants
75416739|NCT04310956|Device|Biocomposite suture anchor|Biocomposite suture anchor will be implanted to participants
75416740|NCT04309513|Behavioral|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device. Their devices and an accompanying app will provide them with an ongoing real time calculation of the PAI score.
75416741|NCT04309513|Behavioral|Step Counter to motivate physical activity|Step Counter to motivate physical activity
75717330|NCT02554188|Other|Diet|A 5-day low calorie fasting-mimicking diet
75416742|NCT04300738|Device|CCS wit CT Scann measurement|Measurement with 2 devices
75717331|NCT00687440|Drug|Pegylated Liposomal Doxorubicin|"Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks."
76042739|NCT05580640|Procedure|OMT|For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system
76042740|NCT05569122|Diagnostic Test|Cardiopulmonary Exercise Testing|"Testing with an exercise bicycle that is considered standard of care for determination of exercise capacity. Participants will complete about 20 minutes of pedaling in a stationary exercise bike"
75717332|NCT00687440|Drug|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
76042741|NCT05569122|Device|pGz Bed|Participants will lay down on a passive exercise (pGz) bed for 45 minutes during which the bed will administer passive exercise through periodic acceleration
75717333|NCT00687440|Drug|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
75717334|NCT02554734|Drug|levodopa, carbidopa, ODM-104|
76042742|NCT05569122|Device|Gentle Jogger|Participants will have passive exercise delivered through the gentle jogger device for 45 minutes. This may be sitting down (aim 1 participants) or laying down (aim 2 participants)
75441627|NCT01636674|Other|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
75441628|NCT01636700|Drug|Tramadol 2mg/kg|2mg/kg
75717335|NCT02554734|Drug|levodopa, carbidopa, entacapone|
76042743|NCT05569122|Device|Exercise Pedal|Participants will exercise while laying down for 20 minutes with an exercise pedal that attaches to the bed
76042744|NCT05569122|Drug|Lumason® contrast agent|Contrast agent used during a vascular ultrasound of the upper leg. Will occur at each study visit twice before and after pGz bed, gentle jogger, exercise pedal or CPET. Drug Administration will be through an IV line and take about 5 - 10 minutes.
76042745|NCT05526001|Biological|ELIXCYTE|ELIXCYTE, a new investigational product developed by UnicoCell Biomed, contains allogenic Adipose-derived stem cells (ADSCs). The ADSCs of ELIXCYTE for subjects were obtained from donors, and the Sponsor followed the manufacturing and testing procedures described in chemistry, manufacturing and control (CMC) information in order to assure the quality of final products.
76042746|NCT05526001|Drug|Saline|Placebo control used in the study.
76042747|NCT05499741|Device|Forehead Temperature-Regulating Therapy|A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
75717336|NCT00990496|Drug|Fludarabine|30 mg/m2
75717337|NCT00990496|Drug|Cyclophosphamide|600 mg/m2
75717338|NCT00990496|Biological|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
75717339|NCT00754910|Drug|porfimer sodium|Given IV
75717340|NCT00754910|Procedure|bronchoscopy|Patients undergo bronchoscopy
75717341|NCT00755066|Drug|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
76042748|NCT05476991|Drug|Colchicine 0.5 MG|Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
76042749|NCT05476991|Drug|Ticagrelor 90mg|Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.
75717342|NCT00755066|Drug|Placebo|Placebo intranasal spray
75562272|NCT05612295|Behavioral|Self-talk|self-talk sessions include: Session 1 & 2. The concepts, types, and the importance of self-talk will be introduced; Session 3. Researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific instructional scripts for specific sports performance (e.g., running); Session 4. practice of sport-specific instructional self-talk; Session 5. researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific motivational self-talk scripts for specific sports performances; Session 6. practice of sport-specific motivational self-talk; and Session 7 & 8. general practice for learned self-talk techniques.
76042750|NCT05476991|Drug|Aspirin 75-300mg|Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
75562273|NCT05601583|Device|Continuous Glucose Monitor (CGM)|FDA-cleared FreeStyle Libre Glucose Monitoring System manufactured by Abbott. Integrated continuous glucose monitoring system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts.
76042751|NCT05471323|Biological|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
75562274|NCT05600907|Biological|JSP191|A monoclonal antibody that targets human CD117
75717343|NCT00990574|Device|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
75717344|NCT00990574|Device|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
75717345|NCT00659490|Drug|AZD1940|800ug oral administration
76042752|NCT05465226|Drug|Oliceridine|see arm description
76042753|NCT05465226|Drug|Historical opioid use|Historical matched, control group in 2:1 ratio
75416743|NCT04265365|Device|rTMS+rPMS_iTBS_R|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
75441629|NCT01636700|Drug|Saline solution|saline solution- 1 dose
75441630|NCT01636726|Drug|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
75717346|NCT00659490|Drug|Naproxen|500mg oral administration
75717347|NCT00659490|Drug|Placebo|Placebo given pre-surgery
76042754|NCT05464134|Radiation|x-ray|plain radiographs of lower limb anteroposterior and lateral views , lumbar spine plain radiographs (anteroposterior, lateral, lateral in flexion and lateral in extension views )
75441631|NCT01636739|Biological|Oral Rotarix®|2 doses administered orally.
75717348|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
75873542|NCT05198622|Procedure|Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
75717349|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
75717350|NCT00539500|Drug|Carboplatin|Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
75562275|NCT05588570|Behavioral|CAT|Treatment includes 12 sessions: 2 caregiver teach sessions, 4 caregiver coach sessions in the child-directed interaction (CDI) phase, and 6 caregiver coach sessions in the DADS (Describe situation, Approach situation, give Direct command for child to join situation, provide Selective attention based on child's performance) phase. Throughout the 12 sessions, caregivers are coached through exposures in which the child is given the opportunity to slowly encounter anxiety-provoking factors. In the first session, caregivers are provided psychoeducation on anxiety and parenting practices and taught PRIDE (praise, reflect, imitate, describe, enjoy) skills, which are aimed at increasing approach behaviors and decreasing avoidant behaviors. In the CDI phase, caregivers are coached live via Bluetooth headset through the PRIDE and active ignoring skills. In the last 5 sessions, caregivers are coached through the DADS protocol while working up the Fear Hierarchy with the child.
75562276|NCT05566873|Behavioral|PA Education plus human and planetary health information|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail, email, and through online scientific video presentations and exploration of freely available citizen science mobile applications
75717351|NCT00539500|Drug|Etoposide|300 mg/m^2 by vein over 24 hours for 4 days
75717352|NCT00539500|Drug|Melphalan|70 mg/m^2 Intravenous Bolus for 3 Days
76042755|NCT05461599|Device|SparkRx Mobile App|The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
76042756|NCT05455710|Device|VigiApp|mobile application containing a patient identification module; post-discharge surveillance questionnaire with questions related to signs and symptoms of SSI previously validated; possibility of attaching and sending a photograph of the surgical wound; field for exchanging messages between professional and patient; issuing an alert / reminder to fill in the data in the application; in addition to establishing interoperability with the system used by the hospital's SCIH, containing a login for each health professional, which allows access to the answers, images and messages sent by surgical patients, categorizing risk and issuing alerts in suspected cases of SSI.
76042757|NCT05451693|Behavioral|Outreach-ER|The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
76042758|NCT05450003|Device|Irrigation activation using xp endo finisher file , new sonic eddy tip and conventional needle syringe irrigation|irrigation activation using 3 different irrigation activation systems including xp endo finisher file , new sonic eddy system and conventional needle syringe irrigation
76042759|NCT05443321|Other|Health Information Exchange (HIE) platform|An improved health information exchange (HIE) platform will be developed at the start of the study with key stakeholder input. This platform will be implemented for use after baseline data collection, and will allow for improved data exchange between transferring and accepting hospital. We will allow for a 6-month wash-in period prior to intervention data collection.
76042760|NCT05437380|Diagnostic Test|peritumoral microbubbles and contrast-enhanced ultrasonography|Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.
76042761|NCT05402436|Other|A diagnosis of atypia as part of the English screening programme|An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
76042762|NCT05382806|Drug|Flumazenil|During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
76042763|NCT05379972|Drug|Pembrolizumab|Pembrolizumab 200mg IV every 3 weeks starting C2D1
76042764|NCT05379972|Drug|Olaparib|Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab
75873543|NCT05186766|Device|Video-Assisted Operating Room Introduce Program|Video demonstration about operation room
76042765|NCT05379972|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib
76042766|NCT05369494|Other|Hydrolyzed protein infant formula with oligosaccharides|Hydrolyzed protein infant formula with oligosaccharides
75416744|NCT04265365|Device|rTMS+rPMS_cTBS_R|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
75441632|NCT01636739|Other|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
75441633|NCT01636752|Behavioral|Deprexis|Online self-help with and without e-mail-support
75717353|NCT00539500|Procedure|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10^8 TNC cells/kg CD133+ selected) on Day 0.
75717354|NCT00539500|Device|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
75717355|NCT00662532|Drug|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
75717356|NCT00686036|Drug|vandetanib|300 mg orally, once daily for up to 18 months
75717357|NCT00686036|Drug|Placebo|
75562277|NCT05566873|Behavioral|PA Education plus Our Voice citizen science|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail and email, plus participatory citizen science activities involving neighborhood audits of the walking environment using a mobile app and remote group discussion and problem-solving around physical activity barriers
76042767|NCT05366400|Diagnostic Test|ECHO|Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
75717358|NCT00788970|Behavioral|Acupressure adjuvant therapy|Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
76042768|NCT05362435|Behavioral|Physical activity-based wellness programs|Each MKS+ program has 20-25 participants and consists of the following: 12 Week INTENSE PHASE: 1) pre-program information and orientation session, and data collection/testing; 2) core weekly programming with the following three components: a) 45-60 minute exercise class, b) 15-20 minute nutrition and wellness education, and c) 15-30 minute sharing circle; 3) end of program celebration; 4) urban poling sessions; 5) introduction to local healthcare providers as identified as relevant for the group; 6) ongoing online support via private Facebook group; 7) daily pedometer tracking to provide immediate motivational feedback to participants. 6-12 Week FOLLOW-UP PHASE: 1) Program Facilitator contacts participants weekly to encourage healthy activities, address concerns as needed, and record weekly step counts; 2) encourages continued engagement in private Facebook group; 3) 15-30 minute nutrition and wellness education, and c) 15-45 minute sharing circle.
76042769|NCT05358366|Behavioral|Infeccion de Amor (Love Infection)|"Love Infection is a filmed dramatized story (telenovela/soap opera) Infección de Amor (IA), or Love Infection - culturally tailored for US Latinas and delivered online. IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
75416745|NCT04265365|Device|rTMS +sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at radial nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
75416746|NCT04265365|Device|rTMS+rPMS_iTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
75441634|NCT01635426|Drug|Aspirin|Aspirin 75 mg daily for 2 months after meals
75441635|NCT01635426|Drug|Clopidogrel|Clopidogrel 75 mg daily for 2 months after meals
75562278|NCT05555732|Drug|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
75562279|NCT05555732|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
75562280|NCT05555732|Drug|Pemetrexed|Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
75717359|NCT00792324|Drug|Etravirine|Four 100mg tablets daily for 12-24 weeks
75717360|NCT00792324|Drug|Efavirenz|One 600mg tablet daily
75717361|NCT00747734|Drug|MNRP1685A|Escalating intravenous dose
76042770|NCT05336188|Device|Smartphone|Adjunctive Smartphone app for improving MAT outcomes
75562281|NCT05555732|Drug|Carboplatin|Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
75562282|NCT05555732|Drug|Cisplatin|Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
75562283|NCT05555264|Behavioral|Self-Guided|Clients who select or are assigned the self-guided condition will be able to contact the Online Therapy Unit regarding any technical issues through the secure treatment platform; monitoring staff will respond by secure message to messages received however, no psychological intervention will be provided by monitoring staff as part of the ACCE treatment intervention. If there is a significant clinical issue requiring attention (e.g., a sudden increase in symptoms) monitoring staff will make a telephone call and crisis support will be provided if necessary.
75717362|NCT00990808|Drug|anacetrapib|[Intervention Name: MK0859] MK0859 100 mg tablet once daily for 8 weeks.
75717363|NCT00990808|Drug|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
75717364|NCT00990808|Drug|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
75717365|NCT00990808|Drug|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
75717366|NCT00750230|Dietary Supplement|NEM|see Treatment Arm
75717367|NCT00797082|Device|MRI|MRI = Myocardial Perfusion Stress
75717368|NCT00797082|Device|MPS|MPS = Myocardial Perfusion Scintigraphy
75717369|NCT00755144|Device|LCS Knee|Cementless total knee arthroplasty with LCS Knee
75717370|NCT00755144|Device|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
75416747|NCT04265365|Device|rTMS+rPMS_cTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
76042771|NCT05335187|Device|micro-macro electrode implantation|One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
75562284|NCT05555264|Behavioral|Therapist-Guided|Therapists will spend ~15 minutes/week communicating with each client who selects the therapist-guided condition, primarily using secure messages. Phone calls will only be made if there is a significant clinical issue requiring attention that the therapist does not feel can be addressed in a message (e.g., a question about the materials that cannot be easily addressed in a text format, a sudden increase in symptoms, increased suicide risk).
75717371|NCT00797160|Drug|propofol|2mg/Kg IV in bolus before tracheal intubation
76042772|NCT05334420|Behavioral|Healthy Dads Healthy Kids|Group based lifestyle behavioral intervention for weight loss for fathers and increased physical activity for their child. The program meets weekly 90-minute sessions over 10 weeks. Mothers/partners are invited to one session (Week 4). Each meeting consisted of a brief review session with Dads and Kids together (15 minutes), separate break-out discussion for Dads (Dad's Club) and Kids (Kid's Club) (30 minutes); and a joint physical activity component for Dads and Kids (Sports Club) (45 minutes). Each week covers different topics for fathers and a corresponding session for kids. The program encourages fathers to be healthy, positive role models for their children, and teaching fathers weight loss strategies, authoritative parenting strategies and to encourage healthy behaviors in their kids. Fathers and kids are encouraged to eat healthy, reduce their screen time and be more active. If the COVID pandemic prevents in-person meetings, the program will be delivered virtually.
75416748|NCT04265365|Device|sham-rTMS+sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve/nervus ulnaris on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
75562285|NCT05547191|Device|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
75717372|NCT00682448|Drug|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
75717373|NCT00682448|Drug|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
75717374|NCT00797238|Other||No intervention in this study
75717375|NCT04003792|Drug|oxaliplatin|intra-arterial oxaliplatin administration
75717376|NCT04003792|Drug|FOLFIRI Protocol|systemic FOLFIRI chemotherapy
75717377|NCT04003792|Drug|Bevacizumab|systemic bevacuzimab therapy
76042773|NCT05334420|Other|Standard of care control|Families will receive handouts on healthy eating, physical activity and screen media use to promote healthy weight status. Fathers will attend one group session with a focus on dietary changes and increased physical activity to promote healthy weight loss.
76042774|NCT05312008|Drug|Intranasal oxytocin|Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart
76042775|NCT05312008|Drug|Intranasal placebo|Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
75416749|NCT04265365|Device|rTMS + optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
75416750|NCT04265365|Device|sham-rTMS+optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
75416751|NCT04261153|Other|Cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
75717378|NCT00747890|Procedure|Modified tonsillectomy|"Tonsillectomy~Uvulectomy~Soft palatal resection~Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
75717379|NCT00747890|Other|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
76042776|NCT05307900|Other|Confirmation of feeding tube placement in critically ill patients|Confirmation of feeding tube placement using ultrasonography
76042777|NCT05296252|Behavioral|mind-wandering intervention|"Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)"
76042778|NCT05296252|Behavioral|mind-wandering comparison|Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
76042779|NCT05281874|Behavioral|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
76042780|NCT05281874|Behavioral|A healthy lifestyles attention control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
75562286|NCT05546723|Biological|Autologous CAR-T cell therapy expressing the BAFF-ligand.|LMY-920
75717380|NCT00789048|Other|radiograph|One radiograph with the patient lying on his contralateral side
75717381|NCT00990886|Drug|Placebo|Once daily for 12 weeks
75717382|NCT00990886|Drug|Oxybutynin chloride|15 mg once daily for 12 weeks
75717383|NCT00755300|Procedure|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
75717384|NCT00789126|Drug|VX-509|
75717385|NCT00755378|Drug|AZD8529|Oral
75717386|NCT00755378|Drug|Placebo|Oral
75873544|NCT05160714|Radiation|Real-time ADC-guided response adaptive Boost in HNC|"40 Gy in 20 fractions over 5 weeks (Monday to Thursday) to the adjuvant neck, simultaneous integrated boost with 56 Gy in 20 fractions in 5 weeks to the low-risk macroscopic tumor.~Once weekly Dose-escalated SBRT adaptive boost to an ADC-based high risk subvolume with graduated dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy"
75416752|NCT04260945|Biological|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
76042781|NCT05281874|Behavioral|Positive Change (+Change) Plus Booster|Positive Change (+Change) Plus Booster
75416753|NCT04260932|Biological|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
75416754|NCT04246008|Other|Neuromuscular training|The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.
75562287|NCT05530642|Behavioral|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of PSP trainers from each of the PSP pilot sectors (i.e., CanOps, Regina Fire & Protective Services, Regina Police Service, Saskatoon Police Service, Regina Emergency Medical Services, Ottawa Emergency Medical Services) during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
75562288|NCT05530330|Diagnostic Test|Platelet/Endothelial proteomics|Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
75562289|NCT05529693|Dietary Supplement|Experimental: Bif-038 arm, high dose|Active trial product with minimum 10 billion CFU daily dose
75562290|NCT05529693|Dietary Supplement|Experimental: Bif-038 arm, low dose|Active trial product with minimum 1 billion CFU daily dose
75562291|NCT05529693|Dietary Supplement|Placebo Comparator: Placebo arm|Similar product to trial product but without Bif-038
75717387|NCT00789204|Other|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
75717388|NCT00789204|Other|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
75717389|NCT01899976|Device|X-Suit NIR Covered Biliary Stent|
75717390|NCT00797394|Dietary Supplement|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
76042782|NCT05280639|Device|Wooden block|Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.
76042783|NCT05280639|Other|Formal physical therapy or Home Exercise Program|Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
75416755|NCT04246008|Other|Conventional strength training|The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes
75416756|NCT04245644|Behavioral|use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins|enrolled patients will be asked details regarding their daily drug use, before and after diagnosis of pancreatic cancer
75416757|NCT04238845|Drug|AQSP Administration|Three days treatment of all children with AQSP for SMC
75717391|NCT00797394|Dietary Supplement|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
75873545|NCT02816658|Other|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
75873546|NCT02816658|Other|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
75562292|NCT05521958|Procedure|Acute injury without compartment syndrome|"Acute tibial shaft or tibial plateau fractures who do not have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
75562293|NCT05521958|Procedure|Acute injury with compartment syndrome|"Acute tibial shaft or tibial plateau fractures who have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
75562294|NCT05521958|Procedure|Exertional compartment syndrome|For patients with exertional compartment syndrome, a muscle biopsy will be obtained from affected extremity.
76042784|NCT05268276|Other|1-perineal ice-gel pad application|For the study group Immediately after delivery (within 30 minutes to one hour after delivery), an ice gel pad will be applied to perineal trauma. each gel pad will have fixed standardized diameter (an approximately 5 cm width, 23 cm length, and 1.5 cm thickness) and approved by Egyptian ministry of health. It will be kept in the freezer for 45-60 minutes and will be removed when frozen. Then, it will be wrapped in a sterile pad and applied to cover the perineum and anal region.The investigator will provide a clear and concise information through oral and written instructions about the following; 1) The ice gel pad's purpose, benefits, anticipated effects and how to apply it, 2) Apply the ice gel pad on perineum after birth within 30 minutes to an hour, 3) Instruct the women to apply the ice gel pad for about 20 minutes every two hours during the first 24 hours postpartum only
75562295|NCT05514132|Drug|Ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
75562296|NCT05514132|Drug|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
75416758|NCT04238845|Dietary Supplement|Supplementation with Plumpy'Doz|Daily supplementation of children with Plumpy'Doz
75416759|NCT04238845|Dietary Supplement|Supplementation with Vitamin A|Single dose supplementation with Vitamin A to all children
75416760|NCT04238845|Dietary Supplement|Supplementation with Zinc|Daily supplementation with Zinc
75416761|NCT04232202|Device|Er:YAG and Nd:YAG lasers|Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.
75416762|NCT04232202|Procedure|Standard extraction|Standard extraction procedure
75416763|NCT04228822|Other|Low carbohydrate diet|25-35% of carbohydrates from total energy intake
75416764|NCT04223037|Biological|Japanese Encephalitis Vaccine produced by IMBCAMS|Dosage form: 0.5mL/vial
75562297|NCT05504707|Biological|HER2 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million"
75416765|NCT04223037|Biological|Japanese Encephalitis Vaccine produced by Liaoning Chenda|Dosage form: 0.5mL/vial
75416766|NCT04213365|Other|Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
75416767|NCT04211753|Behavioral|Treatment as usual (schema therapy)|weekly group psychotherapy and bimonthly individual psychotherapy
75416768|NCT04211753|Device|Mobile app|Medical device for crisis intervention
75562298|NCT05504707|Biological|HER3 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million"
75873547|NCT05142774|Drug|Tapinarof cream, 1%|Tapinarof cream, 1%, applied daily
75416769|NCT04210661|Other|prediction software with spell checker|test with prediction software with spell checker
75562301|NCT05497089|Drug|Temelimab 54mg/kg|Temelimab 54mg/kg will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
76042785|NCT05268276|Other|2-performance of pelvic floor exercises (Kegel exercises)|women will receive instructions to practice pelvic floor exercises (Kegel exercises) and will be asked to perform these exercises from 6 hours postpartum and continue at home till one week. Before applying the technique, the investigator will teach the women how to recognize the accurate muscle, whereby she imagines holding passing gases or trying to stop the flow of urine midstream at the same time. The women will be taught to insert a clean finger into the vagina before practicing the exercises and if the women feeling pressure around her finger, she is on the right track, . The investigator will perform vaginal examination while the woman is doing the pelvic floor exercises (Kegel exercises) to ensure correct use of muscles. The investigator will instruct the women to continue contracting the muscles for about 5 seconds and then to loosen them for 5 seconds and repeat it for five times each set, perform at least five sets per day
76042786|NCT05268276|Other|3- perineal warm compresses application|women will be instructed to apply warm compresses on perineal trauma 48 hours postpartum at home. This will be done by using a clean pad soaked in warm water and squeezed to remove excess water then placed gently on the perineum, the warm compresses will be applied for 15 minutes three times per day (every 8 hours), and water in the bowl will be replaced with every application. Women will be asked to apply warm compresses on perineal trauma from 48 hours postpartum till one week.
75416770|NCT04209621|Drug|Duvelisib|twice daily as tolerated until disease progression
75562302|NCT05497089|Drug|Placebo|Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
75562303|NCT05491538|Behavioral|Social Cognition and Interaction Training-Work Edition (SCIT-WE)|Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.
76042787|NCT05242432|Biological|Ad26/protein preF RSV Vaccine|Ad26/protein preF RSV vaccine will be administered as an IM injection.
75562304|NCT05483296|Other|Low light condition|"During the Dim light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (<5 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of ~100 lx melanopic EDI at the participants' eye level."
75562305|NCT05483296|Other|Moderate light condition|"During the Moderate light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (~100 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of ~100 lx melanopic EDI at the participants' eye level."
75562306|NCT05483296|Other|High light condition|"During the High light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (>1000 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of ~100 lx melanopic EDI at the participants' eye level."
75562307|NCT05480111|Drug|Local anesthesia at incision site|20 ml of 0.25% Bupivacaine will be given at incision site
75562308|NCT05480111|Drug|Sham QL|20 mls of normal saline given at QL.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
75562309|NCT05480111|Drug|Sham Local|20 mls of normal saline given at incision site
76042788|NCT05242432|Other|Placebo|Matching Placebo will be administered as an IM injection
75562310|NCT05480111|Drug|QL|QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
75562311|NCT05454150|Device|balloon-expandable valve|Sapien 3/Ultra, Edwards Lifesciences©
75562312|NCT05454150|Device|self-expanding valve|Evolut R/Pro, Medtronic©
75562313|NCT05439005|Drug|Dexmedetomidine|Dexmedetomidine+Lidocaine
75562314|NCT05437263|Drug|Brepocitinib|Oral Brepocitinib
75562315|NCT05437263|Drug|Placebo|Oral Placebo
75562316|NCT05436613|Device|Transcranial Direct Current Stimulation|tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.
75562317|NCT05434442|Other|simulation model training|"Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator."
75416771|NCT04209621|Drug|Ibrutinib|daily for the first six 28-day cycles
75416772|NCT04207983|Combination Product|EYS606|EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
75416773|NCT04205175|Drug|Feiba|This is a single center, open label, dose escalation study of in vivo administration of Feiba in congenital hemophilia A patients with inhibitors who are on emicizumab.
75416774|NCT04186663|Drug|Silver Diamine Fluoride|38% aqueous silver diamine fluoride [Ag(NH3)]2F, CAS RN 33040-28-7
75416775|NCT04180267|Device|Low-magnitude High-frequency Vibration|35Hz, 0.3g, 20min/day, at least 3 times/week
75416776|NCT04179734|Drug|Bremelanotide|Melanocortin-4 receptor agonist subcutaneous injection.
75562318|NCT05434442|Other|mobile app training|"An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher."
75562319|NCT05434442|Other|control group|Clinical routine training will be given to caregivers in this group.
75416777|NCT04179734|Drug|Placebo|Placebo subcutaenous injection.
75562320|NCT05432024|Device|Catheter ablation|An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.
75562321|NCT05429580|Drug|Tranexamic acid|given intravenous tranexamic acid
75562322|NCT05429580|Other|5% Dextrose|given placebo.
75562323|NCT05426993|Other|Complex decongestive physiotherapy|CDT is a treatment approach consisting of manual lymph drainage, skin care, compression bandage and exercises.
75562324|NCT05401565|Drug|Balovaptan|Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period
76042789|NCT05220982|Behavioral|Conversation Training Therapy|Training clear speech in conversation with new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
75416778|NCT04176302|Device|Parkinson Holter|The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)
75416779|NCT04176302|Diagnostic Test|Motor fluctuations diary|The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).
75416780|NCT04176302|Other|Traditional clinical practice|The neurologists will receive the patient & caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).
75416781|NCT04158219|Behavioral|Behavioral activation for health and depression (BA-HD)|Consistent with successful BA manuals, we plan to conduct up to 10 sessions of treatment over 12 weeks (the recommendation will be at least 8 sessions; scheduling of sessions will be flexible and conform to patient preference). The initial two sessions will be about 50 minutes long and later sessions will be 20-30 minutes long. Sessions can be done on site or over the phone; home visits will be offered for sessions 1-2 if a participant cannot travel. Treatment sessions will use behavioral activation techniques to assess participant values and link these values to behavior change. Goal-setting will focus on sequential, idiographic behavior change (tobacco use, medication adherence, physical activity, and diet) and be accompanied by educational materials and commercially available tools (e.g. activity trackers, pillboxes).
75416782|NCT04156217|Biological|EBV-TCR-T cells|EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
75562325|NCT05401565|Drug|Placebo|Matching placebo
75562326|NCT05397106|Device|CODMAN CERTAS Plus Programmable Valve|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
75562327|NCT05389670|Device|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
75562328|NCT05389670|Device|Sham Continuous Theta-burst stimulation (cTBS)|Sham cTBS, inhibitory-like patterned form of TMS.
75562329|NCT05385783|Drug|CYB003|CYB003 is a synthetic psilocybin analog.
75562330|NCT05385783|Behavioral|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
75562331|NCT05385783|Drug|Placebo|Placebo
75562332|NCT05385783|Behavioral|Psychological Support|Manualized psychological support performed by facilitators
75562333|NCT05382598|Procedure|Renal replacement therapy|Renal replacement therapy (RRT) will be initiated in the early group for patients who have stage 2 AKI according to KDIGO classification. The late group will have RRT when they develop any of the absolute indications for RRT
75562334|NCT05365672|Biological|MIC|Single intravenous infusion of 1.5x10exp8 MIC per kg of body weight
75562335|NCT05365672|Other|Standard of Care|No application of the investigational medicinal product MIC
75562336|NCT05362318|Drug|Nicotine patch and lozenges|Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke >10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke <10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
75562337|NCT05362318|Behavioral|Telephone counseling sessions|Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
75562338|NCT05362318|Behavioral|Access to a web-based video|"Participants will be given web-based access to the relapse prevention video Surviving Smokefree."
75416783|NCT04155853|Procedure|Interposition Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
75562339|NCT05362318|Behavioral|Florida Tobacco Quitline|Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
75562340|NCT05350046|Device|Ear-worn prototype devices|Hearing instrument including sensors to track movement and estimations of biological information.
76042790|NCT05220982|Behavioral|Global Voice Prevention and Therapy Model|Training of four new voices (i.e., resonant voice in connected speech, falsetto for quiet talking, oral twang for talking over noise, and belt for healthy yelling) defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with new vs other or old voice at each step. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
75441636|NCT01636791|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
75562341|NCT05336370|Behavioral|Hypnosis|The hypnosis will be conducted by clinical psychologists who have the formal competence and training in hypnosis. We will be using a tailored hypnosis script designed for this particular study, with a duration of 10-15 minutes. The script involves a hypnotic induction (relaxation-based), imagery (suggestions for pleasant visual imagery), a deepening procedure, and symptom-specific suggestions. The introduction begins by having the hypnotist debunk many of the common myths and misconceptions that patients may hold about hypnosis, and provide a description of hypnosis. Hypnosis is described as focused attention and concentration - like being so lost in a book or movie that it is easy to lose track of what is going on around you. Once the patient is deeply hypnotized, the therapist offers suggestions to reduce distress and improve pain tolerance.
75562342|NCT05336370|Device|Vagus nerve stimulation|A CE approved tVNS device will be used to stimulate the afferent auricular branch of the vagus nerve located medial of the tragus at the entry of the acoustic meatus [36]. A standardized intensity of 10 mA with a pulse width of 250 μs and a consistent stimulation frequency of 25 Hz will be used for optimal stimulation. The stimulation will constantly alternate between active stimulation for 30 seconds, followed by a break of 30 seconds [37], and will have a duration of 15 minutes. Active tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing downward. The bipolar stimulation electrode is placed correctly within the concha of the left ear. Participants are instructed to breathe normally while not talking or making any movements during their session.
75562343|NCT05336370|Device|Sham control|Sham tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing upward. The bipolar stimulation electrode is placed correctly within the concha of the left ear, but no actual stimulation will be performed. The electrode will be left on for 15 minutes. Participants are instructed to breathe normally while not talking or making any movements during their session
75873548|NCT03274687|Radiation|Hypofractionated radiation therapy|66.6 Gy in 37 daily fractions of 1.8 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
75873549|NCT03274687|Radiation|Conventional radiation therapy|62.5 Gy in 25 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
75441637|NCT01636791|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
75562344|NCT05333627|Behavioral|Wellbeing Course for Students (Fast Track)|The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
75562345|NCT05333627|Behavioral|Wellbeing Course for Students (5 weeks)|The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
75562346|NCT05333627|Behavioral|Wellbeing Course (8 weeks)|The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
75562347|NCT05321784|Other|Dermoscopy|Take digital dermoscopy images (DDI)
75562348|NCT05321784|Other|Digital Photography|Take smartphone clinical images (SCI)
75873550|NCT03274687|Drug|Optional androgen deprivation therapy|Any luteinizing hormone-releasing hormone (LHRH) agonist/antagonist with or without an oral antiandrogen can be used up to a six-month administration dose, starting 7-9 weeks before radiation therapy and may begin as early as 42 days prior to or any time after screening. An oral antiandrogen alone is not allowed.
76042791|NCT05220982|Behavioral|Modified Conversation Training Therapy|Training clear speech in conversation with no use of new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
75562349|NCT05321784|Procedure|Self-Skin Examination|Perform self-skin exam (SSE)
75562350|NCT05321784|Device|Skin Examination with Sklip|Apply Sklip System
75562351|NCT05321784|Procedure|Skin Examination|Undergo in-person full body skin examination (FBSE)
75562352|NCT05321784|Other|Survey Administration|Ancillary studies
75562353|NCT05312801|Drug|BAFF CAR-T|Autologous CAR-T cell therapy expressing the BAFF-ligand.
75441638|NCT01636804|Device|Quicksite|St. Jude Medical produced lead called Quicksite
75562354|NCT05292313|Procedure|Single distal femur implant|Single implant fixation
75562355|NCT05292313|Procedure|Dual distal femur implants|Dual implant fixation
75873551|NCT03909750|Procedure|Lipoaspiration|Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells
75873552|NCT03909750|Procedure|AD-cSVF|Isolation of AD-cSVF
75441639|NCT01636804|Device|Quickflex|St. Jude Medical produced lead called Quickflex
75441640|NCT01636830|Device|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
76042792|NCT05220982|Behavioral|Modified Global Voice Prevention and Therapy Model|Training of a new resonant voice in connected speech defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with no use of new vs old voice. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
76042793|NCT05213923|Procedure|ED Sepsis Tracking Sheet|Implementation of an ED Sepsis Tracking Sheet. This sheet will track time of patient presentation, time of High-Acuity Medical Response (HAMR) page, time of bilateral 18g or larger IV access, time of initial lactate, time two sets of blood cultures were sent, time antibiotics were administered as well as which antibiotics and what dose, time initial IV fluid bolus was completed, time repeat lactate was sent, timing of post-IV-fluid bolus vital signs, as well as the presence of persistent hypotension following this IV fluid bolus and whether or not vasopressors were applied.
75416784|NCT04155853|Procedure|Hematoma and Distraction Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
75416785|NCT04155437|Behavioral|Health Facility Level Interventions|"Intensified counseling on maternal dietary diversity and quality using job aids~Counseling on purpose of IFA supplementation, managing side effects, and importance of adherence to daily consumption~Distribution/prescription of IFA tablets at each ANC visit~Use of pill card/reminders for pregnant women and their spouses~Monthly IFA tablet stock monitoring to assure sufficient supplies~Measurement of weight gain during each ANC visit and advise on healthy weight gain~Checks for functioning scales and use of monitoring sheets~Intensified counseling on early initiation of breastfeeding and exclusive breastfeeding using job aids~Reminder on importance of early ANC attendance and 4+ visits"
75441641|NCT01636856|Behavioral|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
75441642|NCT01636856|Behavioral|Respiratory exercises, nasal dilator, nasal lavage|Respiratory exercises, nasal dilator, nasal lavage
75873553|NCT03909750|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
75873554|NCT04651218|Behavioral|exericse|participants perform aerobic exercise until they expend 500 kcal
75873555|NCT05114382|Procedure|EP Procedure|Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
75873556|NCT02542956|Drug|Exparel|receive Exparel by injection
75873557|NCT02542956|Drug|Marcaine|receive Marcaine in a pain pump
76042794|NCT05209243|Radiation|SBRT|SBRT (all metastatic lesions)
76042795|NCT05209243|Radiation|STANDARD OF CARE|ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
76042796|NCT05203237|Biological|VK2735|Administered SC
76042797|NCT05203237|Biological|Placebo|Administered SC
75873558|NCT02542956|Drug|Marcaine|receive Marcaine by injection
75873559|NCT03274453|Drug|Ketamine|0.12 mg/kg/hr of ketamine post surgery
75873560|NCT03274453|Drug|Saline|Saline will be administered at the same rate as the ketamine infusion.
75873561|NCT02313870|Drug|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
75416786|NCT04155437|Behavioral|Community Level Interventions|"Advocacy among community leaders (traditional and religious leaders, local associations, etc.) about ANC~Gatherings among grandmothers, husbands, and other influencers about ANC and their roles~Promotion of ANC service utilisation and the importance of early ANC visit during the first trimester.~Early identification of pregnant women~Support women's group discussions~2-3 home visits per pregnant woman by community health workers (Agent de santé a base communautaire; ASBC) which will include counseling on diet quality, breastfeeding, importance on adherence to daily IFA consumption and side effect management, etc."
76042798|NCT05203237|Drug|VK2735 Placebo|Administered orally
75562356|NCT05275166|Behavioral|Induction of alcohol craving|Presentation of images that may induce craving for alcohol. Recording of brain activity
75562357|NCT05275166|Other|Questionnaires|Questionnaires related to alcohol, quality of life, anxiety and depression
75416787|NCT04155437|Behavioral|Health System Level Interventions|"Training on nutrition interventions during ANC for all ANC providers and community health workers~Semi-annual supervision by the Regional Health Directorate (Direction Regionale de la Santé; DRS)~Quarterly supportive supervision of health facility staff by the health district management team~Monthly supportive supervision of ASBCs~Monthly review between health facilities and ASBCs~Training and use of data registers~Training and use of mother's cards to record up to 8 ANC visits and nutrition services~Training on data utilization to improve coverage and quality"
75562358|NCT05258305|Device|AuraGen 1-2-3 with AuraClens|Autologous fat transfer (AFT) is a minimally invasive medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen 1-2-3 with AuraClens is a lipoaspirate wash system designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister.
75562359|NCT05246527|Behavioral|Physical Exercise|30 min of cycling on an ergometer, moderate or high intensity
76042799|NCT05203237|Drug|VK2735 Drug|Administered orally
76042800|NCT05195931|Diagnostic Test|preload challenge|reduction in preload by head-up tilt and increase in preload with saline infusion
76042801|NCT05195931|Diagnostic Test|afterload challenge|reduction in afterload with nitroprusside and increase in afterload with phenylephrine
76042802|NCT05195931|Diagnostic Test|contractility assessment|heart rate changes will be made by increasing heart rate with external pacemaker/defibrillator. Contractility will be adjusted by dobutamine infusion. Patients will exercise at a constant pump speed and also with pump speed increases.
76042803|NCT05163496|Drug|Psilocybin (Usona Institute)|PAP + psilocybin 25 mg
75562360|NCT05246527|Behavioral|Control Intervention|30 min of watching a movie
75562361|NCT05242822|Drug|KIN-3248|KIN-3248 will be administered orally once daily in 28-day cycles
75562362|NCT05235958|Other|non-linear periodized exercise (NLPE)|Aerobic training derived from professional sports, that is characterized by variable periodization of training frequency, volume and intensity according to individual factors, such as physical and mental readiness, training progress and performance level
75717392|NCT00792480|Behavioral|Dietary and lifestyle counseling|"The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise."
75562363|NCT05235958|Other|Exercise counselling|Standard recommendations for exercise and physical activity, that are individualized according to a medical health and fitness profile
75562364|NCT05229042|Drug|Ricolinostat|Oral
75562365|NCT05220566|Behavioral|Reserved Therapeutic Space|The main objective of the 'Reserved Therapeutic Space' intervention is to enhance the therapeutic bond of trust, to enable the agreement of objectives and interventions in a shared manner in relation to their recovery process in the unit. The intervention is carried out through individual meetings between the nurse and the patient in a comfortable and intimate space, where there are no interruptions and which is also chosen by the person who is hospitalized. The content of the spaces must be constructed individually according to the patients' concerns at each moment of the process.
75717393|NCT00681824|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
76042804|NCT05163496|Drug|Active placebo|PAP + niacin 250mg
76042805|NCT05162443|Drug|adagrasib (MRTX849)|adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
76042806|NCT05150964|Device|Phonak Audeo hearing aid|receiver in the canal devices with custom earmolds
76042807|NCT05135533|Device|Portable Neuromodulation Stimulation|The PoNS group will receive electrical stimulation. Net direct current to the tongue electrode less than 1 µA (micro ampere) will be administered three times a week for four weeks in-lab setting, followed by three times a week for eight weeks at-home setting.
76042808|NCT05135533|Device|Sham|The Sham group will not receive electrical stimulation.
76042809|NCT05135533|Other|Gait and balance training|During each session participants will receive gait training exercises for 20 minutes, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for four weeks in-lab setting. This will be followed by 20 minutes of gait training exercises, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for eight weeks at-home setting
76042810|NCT05114668|Drug|EVT801|"Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study."
75717394|NCT00681824|Procedure|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
75873562|NCT02313870|Drug|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
75873563|NCT02847949|Biological|IGN002|IGN002 is a monoclonal antibody fusion protein
76042811|NCT05112432|Device|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. Exercises continuously adjust difficulty level to user performance to maintain an approximately 80% current performance rate. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
75562366|NCT05207345|Other|Interventional programme|"90-minute session divided into:~45 minutes of core stability treatment~45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
75562367|NCT05207345|Other|General exercise programme|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
75562368|NCT05200325|Other|Educational materials for TissueCypher|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
75717395|NCT00797472|Drug|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
75717396|NCT00797472|Drug|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
75717397|NCT00991042|Other|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
75717398|NCT00789282|Other|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
75873564|NCT01942122|Drug|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
75873565|NCT01942122|Drug|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
75416788|NCT04154423|Other|Glow! Group Prenatal Care|Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.
75416789|NCT04154423|Other|Individual Prenatal Care with CPSP|Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
76042812|NCT05112432|Behavioral|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
75416790|NCT04154371|Device|Electromyography-controlled virtual and augmented reality using serious gaming|Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
75416791|NCT04152824|Behavioral|Resilience-Supportive Leadership Training (RESULT)|Leaders will receive a training addressing supportive supervisor behaviors and resilience
75416792|NCT04131959|Device|CytoSorb 300 mL device|Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass
75416793|NCT04121559|Behavioral|School Interventions|"Classroom lessons on nutrition, dietary diversity, healthy food choices and handwashing.~Principals provide messages on nutrition, dietary diversity, healthy food choices and handwashing at flag events or school assemblies.~Selected adolescent girls are mentored by science teachers as peer mentors and hold weekly group discussions with other girls to discuss nutrition, dietary diversity, healthy food choices and handwashing.~Trained science teachers take anthropometric measurements of adolescent girls to calculate BMI and provide nutrition counseling.~Parent-teacher meetings to inform and encourage parents about adolescent nutrition, dietary diversity, healthy snacks, and handwashing."
75562369|NCT05197608|Other|System Navigator|Participants will be connected to a System Navigator, who is a trained staff embedded within their primary health clinic to support and help navigate biological, psychological and social needs in proactively identified vulnerable patients.
75562370|NCT05197608|Other|Tailored list of resources|Control group will be provided a tailored list of resources
75562371|NCT05196620|Other|Endoanal Ultrasound (EAUS)|Endoanal Ultrasound pre- and postpartum
75416794|NCT04121559|Behavioral|Community Interventions|"Home visits by HEWs and/or community volunteers to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing.~Community gatherings by HEWs and meetings with religious leaders to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing."
75562372|NCT05196607|Other|Survey|A dedicated survey on the use of mobile applications to all patients who were to be operated on a scheduled basis in our Surgery Service
75562373|NCT05195710|Drug|Yttrium-90 (Y-90) resin microspheres|Given by scan
75562374|NCT05194488|Device|Low level laser therapy|Patients will receive low-level laser therapy on the temporomandibular joint disc
75873566|NCT01942122|Drug|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
75562375|NCT05194488|Drug|Botulinum toxin type A|Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.
75562376|NCT05194488|Device|Anterior repositioning appliance|Patients will receive hard maxillary anterior repositioning appliance.
75562377|NCT05187182|Drug|CA-4948|Provided by Curis, Inc.
75562378|NCT05187182|Biological|Nivolumab|240 mg IV on Day 1 of each cycle
75717399|NCT00789282|Other|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
75717400|NCT00789282|Other|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
75717401|NCT00681668|Drug|Quetiapine|150-800 mg, oral, twice a day (bid)
75873567|NCT04297345|Device|Hemodialysis|"Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances."
75873568|NCT01816932|Procedure|Home Visit|The intervention is the location of the insertion visit.
75873569|NCT01816932|Procedure|Office visit|
76042813|NCT05112432|Other|Early Psychosis Coordinated Specialty Care|Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.
75416795|NCT04121559|Behavioral|School System Interventions|"Workshop on the adolescent nutrition interventions for school principals, science teachers, HEWs, supervisors, and woreda officers.~Biweekly supportive supervision on adolescent nutrition activities for schools and HEWs by school supervisors or woreda health/education office."
75416796|NCT04112654|Procedure|Conventional pressure laparoscopy|Conventional pressure laparoscopy using conventional insufflator AirSeal®
75416797|NCT04112654|Procedure|Low pressure laparoscopy|Low pressure laparoscopy using pressure-controlled insufflator AirSeal®
75416798|NCT04098406|Drug|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.
75416799|NCT04098406|Drug|Placebo|Placebo is liquid with identical color and taste
75416800|NCT04095104|Drug|Phentermine|Phentermine tablet
75562379|NCT05187182|Biological|Pembrolizumab|400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,…) and dosing may continue for a max of 2 years
75562380|NCT05187182|Drug|Trastuzumab|6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
75562381|NCT05187182|Drug|mFOLFOX7|Standard of care
75562382|NCT05174559|Other|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.
75562383|NCT05167669|Device|HIFU-MRI guided|HIFU application under MRI guiding to deliver hypothermia to eligible bone metastases before clinical indicated radiotherapy
75562384|NCT05146739|Drug|Cytarabine|Given IV and IT
75562385|NCT05146739|Drug|Fludarabine|Given IV
75562386|NCT05146739|Drug|Leucovorin|Give PO or IV
75562387|NCT05146739|Drug|Triple Intrathecal Chemotherapy|Given IT
75562388|NCT05146739|Drug|Uproleselan|Given IV
75562389|NCT05137327|Behavioral|Classroom Behavior Support (CBS) Condition|An individualized teacher consultation program that includes observation and performance feedback and techniques borrowed from Motivational Interviewing and Cognitive Behavioral Therapy (CBS). It is designed to address barriers to implementation and improve teacher practices and student outcomes.
75717402|NCT00792558|Drug|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
75717403|NCT00539188|Drug|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
75717404|NCT00539188|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
75717405|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|400 IU daily (low dose)
75717406|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|2000 IU daily (high dose)
75717407|NCT04980456|Device|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
75717408|NCT04980456|Device|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
75717409|NCT04980456|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
75717410|NCT05359432|Drug|Empagliflozin|Receiving allocated drug dosage as per clinical needs
75717411|NCT05359432|Drug|Vildagliptin|Receiving allocated drug dosage as per clinical needs
75717412|NCT00755456|Drug|PD solution containing glucose|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
75717413|NCT00755456|Drug|PD solution containing glucose and L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
76042814|NCT05107960|Drug|Azilsartan (TAK-536)|Azilsartan Tablets, Azilsartan Granules
75562390|NCT05137327|Behavioral|Standard Problem Solving Consultation|A standard problem solving approach to teacher consultation that includes observation and brief performance feedback. It represents current best practice in teacher consultation.
75562391|NCT05135715|Drug|RC48-ADC|2.0 mg/kg IV every 2 weeks
75562392|NCT05126758|Biological|CAP-1002|Cohort A: CAP-1002A manufactured in Los Angeles, CA; Cohort B: CAP-1002B manufactured in San Diego, CA
75562393|NCT05126758|Biological|Placebo|Placebo
75562394|NCT05122325|Device|Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device|"Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable)."
75416801|NCT04095104|Drug|Immediate Release Topiramate|Topiramate tablet
75562395|NCT05122325|Device|Genital vibration with Ferticare 2.0® vibrator|Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
75562396|NCT05122325|Device|TENS® EMS NMS60 device_sham intervention|"Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment."
75562397|NCT05118802|Other|Interview|Attends Interviews
75562398|NCT05118802|Other|Survey Administration|Complete Survey
75562399|NCT05111002|Drug|Lefamulin|600mg tablet orally twice daily
75562400|NCT05111002|Drug|Doxycycline|100mg tablet orally twice daily
75562401|NCT05105373|Behavioral|Parenting for Respectability|"The programme addresses main challenges of Parenting and builds skills in 4 main areas~Poor parental bonding and child attachment;~Harsh parenting~Inequitable socialisation by gender~Parental conflict."
75562402|NCT05091346|Drug|E7386|E7386 tablet.
75562403|NCT05091346|Drug|Pembrolizumab|Pembrolizumab IV infusion.
75562404|NCT05091346|Drug|Lenvatinib|Lenvatinib capsule.
75562405|NCT05088655|Drug|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
75562406|NCT05054790|Biological|"Neo-Bladder Construct"|Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo. After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
75562407|NCT05051124|Behavioral|Peer Delivery of Medications|The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities
75562408|NCT05051124|Behavioral|Health Information Technology (HIT) Platform|To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
75562409|NCT05048433|Behavioral|implementation strategy for active learning to promote physical activity|The experimental arm includes using a multifaceted implementation strategy to support the use of active learning approaches. The strategy will consist of a series of skills-based staff trainings, identifying program champions to help lead efforts within the school, establishing an audit and feedback system to monitor the use of active learning, and a reinforcement system to recognize staff who are successfully implementing.
75717414|NCT00991120|Device|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
75717415|NCT00755534|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
75416802|NCT04095104|Drug|Placebo for Phentermine|Compounded tablet to mimic phentermine 8mg tablet
75416803|NCT04095104|Drug|Placebo for Immediate Release Topiramate|Compounded tablet to mimic immediate release topiramate 25mg tablet
75416804|NCT04086966|Drug|[68Ga]PSMA-PET/MRI or PET/CT|[68Ga]PSMA-PET/MRI or PET/CT
75416805|NCT04084990|Device|S9 VPAP Adapt|Auto-titrated positive airway pressure
75416806|NCT04067622|Device|Exersides|A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
75416807|NCT04067284|Behavioral|Nutrition education|"Nutrition Education on~Continued breastfeeding until two years of age~Food groups~Balanced diet~Introduction to locally available nutritious and low-cost foods~Amount and frequency of complementary feeding~Safe water, and~Handwashing with soap before feeding"
75562410|NCT05048433|Behavioral|Usual Implementation support|Usual support consists of the potential to access general resources from the district wellness department. These resources include access to funds to send staff to external trainings and general guidance for how to use active learning approaches.
75416808|NCT04067284|Dietary Supplement|Homemade yogurt supplementation|The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding.
75416809|NCT04067284|Other|Usual care|No intervention/ control group
75562411|NCT05039216|Biological|Blood sampling|4 tubes of 7 mL will be sampled
75717416|NCT00755534|Drug|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
75717417|NCT00755534|Drug|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
75717418|NCT00755534|Drug|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
75717419|NCT00326599|Drug|carboplatin|Given IV
75717420|NCT00326599|Drug|cediranib maleate|Given orally
75416810|NCT04061564|Device|Vagal nerve stimulation|The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
75416811|NCT04045405|Drug|CDR132L|i.v. administration
75416812|NCT04044729|Drug|Cannabidiol|500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding
75416813|NCT04044729|Drug|Placebo|Placebo
75416814|NCT04009356|Procedure|bariatric surgical procedures|gastric bypass, sleeve, banding,biliopancreatic diversion
75717421|NCT00326599|Drug|gemcitabine hydrochloride|Given IV
75717422|NCT00797550|Biological|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
75717423|NCT00797550|Procedure|Autologous bone graft|
75416815|NCT04008082|Drug|Lenvatinib|Lenvatinib capsule.
75416816|NCT03997526|Device|3C Patch|A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process
75562412|NCT05037812|Drug|Saline injection|Saline
75562413|NCT05037812|Drug|Multimodal injections|"5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection)."
75562414|NCT05019638|Drug|Regional anesthesia group|bupivacaine 0.25% with epinephrine 1:400,000.
75562415|NCT05019638|Drug|Local multimodal analgesia group|5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
75717424|NCT05004688|Biological|Biological/Vaccine: Bacillus Calmette-Guerin (BCG)|Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
75717425|NCT00797628|Behavioral|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
75717426|NCT00797628|Behavioral|Smoking Coach|"Control Patients will be referred by paper prescription to the control- Smoking Coach website."
75717427|NCT00750386|Drug|Paclitaxel|175 mg/m2, I.V, every 2 weeks
75562416|NCT05019430|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.
75717428|NCT00750386|Drug|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
75717429|NCT04972266|Device|AcumenTM Hypotension Prediction Index software|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
75717430|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75717431|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75717432|NCT00797706|Drug|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
75717433|NCT00685802|Drug|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
76042815|NCT05091255|Procedure|Cryotherapy|The procedure involves general or peripheral anesthesia and percutaneous treatment under CT control with probes capable of forming ice spheres of up to 3 cm that will be used in sufficient number to treat the neoplasm completely.
75717434|NCT00685802|Drug|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
75717435|NCT00991198|Drug|Topical oxygen|0.5% concentration of Topical oxygen
76042816|NCT05085756|Behavioral|Puma|One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.
76042817|NCT05013190|Other|No intervention|This is a non-interventional study.
76042818|NCT04952402|Biological|Study-provided Moderna mRNA-1273 COVID-19 vaccine|Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
76042819|NCT04952402|Biological|Community-provided Moderna mRNA-1273 COVID-19 Vaccine|Participants received a two-dose series.
75416817|NCT03995589|Other|Walking|Technology-guided semi-supervised walking therapy
75416818|NCT03995589|Other|Control|Go Home and Walk advice
75416819|NCT03979937|Procedure|Arthrocentesis|Arthrocentesis to determine the nature of the effusion (septic or aseptic).
75562417|NCT05019430|Drug|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
75717436|NCT00991198|Drug|Topical oxygen|0.25% concentration topical oxygen
75717437|NCT00991198|Drug|placebo|no O2
75717438|NCT01054651|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
75717439|NCT01054651|Drug|Praziquantel|
75717440|NCT00792714|Drug|Mannitol|400mg twice daily for 7 days
76042820|NCT04952402|Biological|Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine|Participants received a two-dose series.
75416820|NCT03979547|Behavioral|Exercise intervention|"Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down."
75562418|NCT05019430|Drug|Zolmitriptan|The pharmacodynamic effects of zolmitriptan maintenance will be determined.
75562419|NCT05013749|Procedure|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
76042821|NCT04941144|Biological|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
76042822|NCT04938895|Behavioral|Black Respondents Exposure to a Photo|Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
76042823|NCT04930055|Biological|COVID-19 Vaccination|Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
76042824|NCT04890535|Drug|TBAJ-587|oral suspension
76042825|NCT04890535|Drug|Placebo|matching placebo oral suspension for TBAJ-587
76042826|NCT04849000|Drug|SHR-1209|SHR-1209
76042827|NCT04849000|Drug|SHR-1209 Placebo|SHR-1209 Placebo
75416821|NCT03979534|Other|low protein diet|Patients will be managed with a restricted protein intake (controlled protein diets with a mean target at 0.6 g / kg / day of protein, according to a choice of dietary approaches, adapted to the situation of each patient).
75416822|NCT03978000|Drug|IBP-9414|Oral suspension
75562420|NCT05013749|Procedure|Partial Myometrial Resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesico-uterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
75562421|NCT05008965|Biological|FB825|A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on human B lymphocytic cells expressing membrane-bound IgE (mIgE).
75562422|NCT05008965|Other|Placebo|Formulation buffer
75416823|NCT03978000|Drug|Placebo|Sterile water
75562423|NCT05005078|Drug|WST-057|WST-057 topical solution
75562424|NCT05005078|Drug|Placebo|WST-057 Matching placebo
75562425|NCT04994327|Other|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
75562426|NCT04978454|Biological|Influenza RG-A/Texas/71/2017 (H3N2) Challenge|RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.
75562427|NCT04978454|Other|Placebo|Sucrose phosphate glutamate (SPG) inoculum
75562428|NCT04973956|Other|Relaxation|This group will perform the APMR. This intervention consists of a standardized 20 min session in which subjects are asked to sequentially tense and relax various muscle groups. To do so, participants will listen to an audio with relaxation instructions while seated in a reclining seat and dimmed lighting.
75416824|NCT03977779|Device|Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography|The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography
75416825|NCT03974243|Drug|Chiauranib|"In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."
75416826|NCT03974243|Drug|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle
75416827|NCT03970109|Drug|ANS-6637|200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
75416828|NCT03970109|Drug|Placebo oral tablet|Placebo oral tablet
75416829|NCT03967925|Drug|Belimumab|Sub-cutaneous injection
75416830|NCT03967925|Drug|Rituximab|IV infusion 1g x 2
75562429|NCT04973956|Other|Control|No intervention
75562430|NCT04964830|Device|Orthodontic treatment with functional appliance (MAD)|Expansion plate and z-activator (MAD)
75562431|NCT04951219|Drug|Resmetirom|Tablet
75562432|NCT04949399|Drug|OnabotulinumtoxinA|Injection
75562433|NCT04949399|Drug|Placebo|Injection
75562434|NCT04942626|Drug|Kineret 100 MG in 0.67 ML Prefilled Syringe|Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.
75562435|NCT04942626|Drug|Capecitabine|Capecitabine will be administered using a 3+3 dose escalation design (500 mg/m2 bid, 650 mg/m2 bid and 825 mg/m2 bid po, respectively) from day 1 to day 40 of RT including weekends.
75562436|NCT04942626|Radiation|Radiotherapy|PTV: 1.8 Gy to 45 Gy (#28 fractions) to the primary tumor and pelvic lymph nodes; followed by a sequential boost of 1.8 Gy to 9 Gy (#5 fractions) to the gross tumor volume
76042828|NCT04843319|Drug|VERU-100|GnRH antagonist
75416831|NCT03967925|Drug|Prednisolone|20mg prednisolone tapering dose
75416832|NCT03954743|Biological|PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
75416833|NCT03954743|Biological|Lyophilized formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
75717441|NCT04961554|Other|loco-regional anesthesia|demonstrate that the mouth opening (measured in millimeters) of a patient treated for mandibular surgery with a very limited opening (defined by a threshold less than 20mm, not allowing the passage of a video laryngoscope blade per route buccal) is more important after locoregional anesthesia of the V3 than before anesthesia.
75717442|NCT04059692|Other|Cervical manipulation intervention|Cervical manipulative technique
76042829|NCT04842045|Drug|Psilocybin and Midazolam|"The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight."
75416834|NCT03954223|Behavioral|Low sugar and carbohydrate diet|Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day)
75562437|NCT04942626|Procedure|Watch and Wait (cCR) or TME surgery (non-cCR)|Restaging to evaluate tumor response will be conducted 10 weeks after completion of CRT. For patients achieving a clinical complete response (cCR), a Watch and Wait (W&W) option with close follow-up is scheduled. In case of non-cCR, immediate total mesorectal excision (TME) surgery is recommended. According to the current German S3-guidelines, adjuvant chemotherapy is optional.
75562438|NCT04922554|Drug|Omadacycline Oral Tablet|omadacycline 300 mg orally, once daily (150 mg tablets x 2)
75562439|NCT04922554|Drug|Placebo|placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
75562440|NCT04916002|Drug|vidutolimod|Participants will receive vidutolimod 10 mg IT weekly for 7 doses after which vidutolimod will be administered every 3 weeks (Q3W). The first dose of vidutolimod may be administered subcutaneously (SC) or IT at the discretion of Investigator. All subsequent doses will be IT. The initial 7 doses of vidutolimod, delivered on a weekly dosing schedule, must be completed before starting the Q3W vidutolimod dosing schedule.
75562441|NCT04916002|Drug|cemiplimab|Participants will receive cemiplimab 350 mg IV over 30 minutes at week 1 dose 1 (W1D1) and Q3W thereafter.
75717443|NCT04059692|Other|Placebo intervention|Sham intervention
76042830|NCT04839302|Drug|Indocyanine green solution|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
75717444|NCT00789594|Behavioral|laboratory monitoring alerts|laboratory monitoring alerts
75717445|NCT00789594|Behavioral|Result management module|Result management module
75717446|NCT00354601|Drug|capecitabine|oral capecitabine twice daily on days 1-21
75717447|NCT00354601|Drug|docetaxel|docetaxel IV over 30 minutes on days 1, 8, and 15
75734980|NCT03403361|Device|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study. These additional scans will be acquired utilizing the FDA-approved workflow and scanner operating modes. Sinogram data will be exported in raw, minimally processed form utilizing proprietary data export and processing tools provided to the investigators by the scanner vendors. In no case, will the additional local imaging dose (in terms of CTDIvol) given to the patients by the two or three additional scans exceed 6 cGy per session
75734981|NCT03386045|Radiation|Optimal SBRT|Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)
75416835|NCT03954223|Behavioral|Time Limited Eating|16-hour fast/8-hour feed for 3 days per week
75416836|NCT03954223|Device|Continuous Glucose Monitor|CGM (used to monitor adherence and glycemic outcomes without real time feedback)
75416837|NCT03952663|Procedure|inferior alveolar nerve lateralization and dental implant placement.|inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
75416838|NCT03952663|Procedure|platelet rich fibrin membrane around the nerve|platelet rich fibrin membrane is prepared from the patient's blood and placed around the nerve.
75416839|NCT03925584|Other|Music Therapy|Standardized music playlist will be played centrally at the subjects head or feet for a period of 20 minutes once during a 12-hour shift for 14 days or until mechanical ventilation has been discontinued, whichever is first
75416840|NCT03920969|Behavioral|Sports activity|Evaluation of physical activity using the International Physical Activity Questionnaire (IPAQ) short version.
75416841|NCT03915327|Drug|Intravenous iron isomaltose anhydride|Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
75717448|NCT05360914|Other|Hospital at Home (HaH) treatment|The intervention is a new pathway of providing acut treatment for elderly acute ill patients in their own home. If the patient is randomized to the intervention group, the municipalities acute teams start the treatment. The acute team can take venous blood tests, ECG and bladder scan at home. The acute team handles the treatment at home and follows the patient closely. During the treatment course, the acute team and the ED specialist discuss the treatment process either over the phone or virtually on an iPad, where the patient is also involved. If the specialist would like to see the patient for assessment or send the patient for an X-ray, the specialist informs the acute team that the patient must go to a short check-up in the ED. Here, the specialist examines the patient himself and assesses whether the patient can continue to be treated at home, or whether the patient must be admitted to the hospital due to deterioration of the condition.
75717449|NCT05360914|Other|Standard hospital admission|The active comparator is the standard hospital admission for elderly acute ill patients.
75717450|NCT00792792|Device|Modulated Imaging|Modulated Imaging Spectroscopy
75717451|NCT01563640|Other|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
75717452|NCT01563640|Other|washing|normal washing of school uniforms, without permethrin insecticide impregnation
75717453|NCT00792870|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
75717454|NCT00750620|Drug|YM178|oral
75717455|NCT03827473|Drug|Abiraterone Acetate|Given PO
75717456|NCT03827473|Drug|Antiandrogen Therapy|Given per standard of care
75717457|NCT03827473|Drug|Docetaxel|Given IV
75873570|NCT01783704|Dietary Supplement|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
75416842|NCT03911830|Other|Exercise followed cold water immersion|Rehabilitation program of 17 sessions with 30 minutes of exercise followed by 15 minutes of submerged recovery at 17 ° C (3 sessions per week / 6 weeks).
75717458|NCT03827473|Drug|Prednisone|Given PO
75416843|NCT03883594|Behavioral|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
75416844|NCT03880565|Device|Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation|Early use of ECMO
75416845|NCT03880565|Device|Standard Advanced Cardiac Life Support (ACLS) Resuscitation|Standard life support resuscitation
75416846|NCT03876652|Device|Pacemaker with Closed Loop Stimulation (CLS)|In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
75717459|NCT03827473|Other|Quality-of-Life Assessment|Ancillary studies
75717460|NCT03827473|Other|Questionnaire Administration|Ancillary studies
75717461|NCT00800592|Drug|sildenafil|10 mg sildenafil bolus
75717462|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
75717463|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
75717464|NCT00755690|Behavioral|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
75717465|NCT00991354|Biological|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
75717466|NCT00991354|Biological|IL-12 DNA plasmids|Adjuvant for HIV vaccines
75717467|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
75717468|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
75416847|NCT03876080|Other|Dry needling|The use of a solid filiform needle to treat trigger points
75416848|NCT03876080|Other|Sham needling|Simulated needling
75416849|NCT03874988|Behavioral|Portion-Controlled Meals|Participants will receive portion-controlled meals with the aim of encouraging weight loss and healthier eating.
75416850|NCT03874988|Behavioral|Enhanced Self-Monitoring|Participants will be encouraged to track their physical activity, food intake, and weight using technology that will be provided as part of the study.
75717469|NCT00755768|Behavioral|additional review by dietician|
75717470|NCT05360836|Other|Conservative treatment via telerehabilitation|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks."
75416851|NCT03874988|Behavioral|GLB-SCI|Participants will take part in a lifestyle intervention program (tailored for spinal cord injury needs) that encourages steady weight loss through increased physical activity and healthier diet patterns.
75416852|NCT03874988|Behavioral|GLB-SCI+|Participants will receive a combination of the prior interventions studied, with the goal of showing that a multi-component intervention will be the most effective in encouraging weight loss among participants with a spinal cord injury.
75717471|NCT05360836|Other|Conservative treatmen + motor imagery|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images."
75717472|NCT00797784|Drug|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
76042831|NCT04810650|Other|Mobility Dynamic Treatment Intervention|"1) Access to a mobility coordinator who will assist with transfers, rescheduling, and out-of-facility refills; 2) Provision of a travel pack with alternative ART packaging options (e.g. ziplock bags, envelopes, pill boxes), a packing list and mobility coordinator phone contact for unplanned travel; 3) Screening at every clinic visit for planned mobility; 4) Mobile number and mobile minutes for unexpected travel; 5) Provision of longer refills (up to 6-months) for planned travel"
76042832|NCT04810650|Other|Health Living Intervention for Heavy Alcohol Users|1) Two in-person alcohol counseling sessions with support from a clinical psychologist; 2) Monthly booster phone calls
76042833|NCT04810650|Other|Hypertension Linkage|1) Travel voucher (financial incentive) conditional on linkage to hypertensive care; 2) Phone call reminders for missed visits
75416853|NCT03873467|Behavioral|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting, and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems. The GLB curriculum used in this study has been adapted for people with stroke.
75416854|NCT03873467|Other|Usual Care|Participants randomized to the wait-list control group will receive usual care for 6 months before beginning the modified GLB program.
75416855|NCT03867643|Biological|hepatitis B vaccine(HepB)|Children with anti-HBs at a low level (<10mIU/mL and [10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.
75416856|NCT03861533|Other|survey|Cross-Reference
75416857|NCT03858621|Drug|fentanyl NOL guided|Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
75416858|NCT03857984|Other|Blood sampling|blood sample before and after a single HD
75416859|NCT03857074|Device|Green Light Exposure|To test whether exposure to a narrow band of green light (520-540 nm) at low intensities (1-10 cd/m2) decreases interictal epileptiform discharges in patients with epilepsy. The overall hypothesis for this open-label trial is based on findings in patients with migraine that indicate an engagement of thalamocortical inhibitory circuits by green light.
75441643|NCT01636869|Drug|Bupivacaine|"20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block."
75416860|NCT03815370|Device|Experimental: ABRO™ Binder Arm|ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.
76042834|NCT04810650|Other|PrEP/PEP at Outpatient Clinics|Intervention delivered at Outpatient Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
75562442|NCT04915079|Behavioral|Promoting Resilience in Stress Management (PRISM)|"PRISM is a novel resilience resource intervention consisting of five, one-on-one sessions lasting 30-50 minutes targeting specific teachable resilience skills: stress management, problem solving, goal setting, benefit finding, and meaning making. Sessions will occur at a time convenient to the patient with the first session to occur within 1 week of enrollment either while inpatient or if the patient is discharged, in the outpatient setting in-person or by HIPPA-compliant Zoom. After completion, participants will receive weekly booster contacts (invitations to practice reviewing certain skills) until the occurrence of a planned patient-clinician conversation, facilitated and arranged by study staff during the 5th session. All participants will receive paper worksheets to practice skills between sessions, plus access to a free, digital PRISM app (available only for patients enrolled in PRISM)."
75562443|NCT04914403|Biological|UMC119-06-05|Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05
75717473|NCT03983395|Biological|ISB 1302 250 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
75416861|NCT03815370|Device|Placebo Comparator: Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
75416862|NCT03799588|Device|Biphasic Chest Cuirass|Patients will have a esophageal manometer placed after intubation and before initiation of negative pressure ventilation.
75562444|NCT04893174|Biological|UMC119-06-05|"Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05"
75562445|NCT04893174|Device|Hyaluronic acid|IA injection of hyaluronic acid.
75562446|NCT04858503|Other|internet-based cardiac rehabilitation enhancement intervention|Participants in the intervention group will receive a 12-week i-CARE intervention, which will be designed to cover the core elements of CAD self-care: self-care maintenance, self-care monitoring and self-care management. The intervention will comprise: 1) a single individualized face-to-face session and 2) an internet-based intervention through a mobile application. Various behaviour change techniques will be used to increase the self-efficacy of CAD patients in enacting self-care behaviours.
75562447|NCT04838600|Device|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
75562448|NCT04835467|Device|Dual-modal OCT-FLIm|Intracoronary imaging using dual-modal OCT-FLIm catheter
75562449|NCT04829916|Drug|RMC-035|Multiple dosing during 48 hours following cardiac surgery
75562450|NCT04829916|Drug|Placebo|Multiple dosing during 48 hours following cardiac surgery
76042835|NCT04810650|Other|PrEP/PEP at Antenatal Clinics|Intervention delivered at Antenatal Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
76042836|NCT04810650|Other|PrEP/PEP at Community Households|Intervention delivered in community by village health team: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
76042837|NCT04810650|Other|Standard of Care|Local country standard of care protocols
75441644|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
75441645|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
75441646|NCT01636908|Drug|Sunitinib|50 mg once daily, oral use, 14 days
75562451|NCT04825860|Drug|SEP-363856 50 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
75562452|NCT04825860|Drug|SEP-363856 75 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
75562453|NCT04825860|Drug|Placebo|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
76042838|NCT04810650|Other|Hypertension Community|Hypertension care delivered at home with clinician telehealth, facilitated by lay health worker to measure blood pressure and deliver medications
76042839|NCT04795895|Diagnostic Test|ultrasonography (US)|US evaluation was performed after insertion of the tube via subxiphoid approach for tube passing esophagogastric (EG) junction. The tube insertion procedure will be repeated no more than three attempts if no visualization by US.
76042840|NCT04795895|Diagnostic Test|Standard routine (SR)|Standard routine (SR)
75441647|NCT01636908|Drug|Sorafenib|400 mg, twice daily, oral use, 14 days
75717474|NCT03983395|Biological|ISB 1302 325 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
75717475|NCT03983395|Biological|ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
75441648|NCT01636908|Drug|Erlotinib|150 mg once daily, oral use, 14 days
75441649|NCT01636908|Drug|Everolimus|10 mg once daily, oral use, 14 days
75717476|NCT03983395|Biological|ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
75717477|NCT03983395|Biological|ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
75717478|NCT03983395|Biological|ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
76042841|NCT04780815|Other|myBluTM Formulation 1|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs
76042842|NCT04780815|Other|myBluTM Formulation 2|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs
76042843|NCT04754945|Drug|Bortezomib|Given SC
76042844|NCT04754945|Drug|Cyclophosphamide|Given IV or PO
75441650|NCT01636908|Drug|Lapatinib|1250 mg once daily, oral use, 14 days
75441651|NCT01636908|Drug|Dasatinib|100 mg once daily, oral use, 14 days
75441652|NCT01636908|Drug|Pazopanib|800 mg once daily, oral use, 14 days
75441653|NCT01636908|Drug|Vemurafenib|960 mg twice daily, oral use, 15-21 days
75441654|NCT01636908|Procedure|tumor biopsy|
75562454|NCT04816812|Behavioral|Exercise intervention|A 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level. This includes two supervised exercise sessions of 60 minutes per week, combined with one weekly home training session. The type of exercise is planned by a physiotherapist to fit each patient during sessions. We monitor the intervention by training diaries including frequency, intensity, time, and type of exercise (FITT) and the verbal BORG 15-point scale and heart rate monitors. We will also monitor the overall seven days' physical activity level by accelerometry using the AX3 device from the company Axivity at weeks 0 and 12.
75717479|NCT03983395|Biological|ISB 1302 escalating doses,1200 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
75873571|NCT01783704|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
76042845|NCT04754945|Drug|Dexamethasone|Given IV or PO
75416863|NCT03788993|Other|Blue-depleted evening light condition|"A 20-bedded ward with tunable light emitting diode (LED) lamps. At 18:00h the lighting undergoes a 30-minute transition during which the green and blue LEDs are dimmed to produce blue-depleted amber colored lighting. At 06:50h a new 10-minute transition changes the light color to ordinary indoor lighting. From 07:00h to 18:00h, there is ordinary indoor lighting (3000K colour temperature). The light intensity is dimmed to 20% of the maximum from 23:00h to 6:50h.~Blue-blocking window filters are deployed also in the evening. All TV sets have permanent blue-blocking filters and individuals are provided with blue-blocking screens that can be attached to the front of personal electronic devices. If the patients leave the blue-depleted unit after 18:30 they are offered blue-blocking glasses to wear. The light spectrum in the ward was assessed prior to commencing the RCT and is well-matched to what has been shown in laboratory settings to minimally suppress melatonin."
75416864|NCT03788993|Other|Normal light condition|"The other half of the unit (20 patient rooms and their corresponding bathrooms and common areas) have ordinary indoor light installed (Glamox, Norway). This has a 3000K color temperature. The light is dimmed to 20% of max in the night, similar to the blue-depleted condition.~The light in the normal light condition and the blue-depleted light condition have similar levels of photopic lux throughout the 24h cycle, but different levels of melanopic lux between 1830h and 0700h."
75416865|NCT03788421|Device|LIGASURE|Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
75717480|NCT03983395|Biological|ISB 1302 at the MTD and/or RP2D dose|ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
75717481|NCT00747968|Drug|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol*kg-1*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
75717482|NCT00793026|Drug|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
75717483|NCT00755924|Dietary Supplement|Vinegar|Apple cider vinegar 2 TBlsp/day
75717484|NCT00755924|Other|Placebo|Water placebo colored with balsamic vinegar
76042846|NCT04754945|Biological|Isatuximab|Given IV
76042847|NCT04754776|Biological|ChAdOx1 RVF|Single dose of ChAdOx1 RVF
75873572|NCT01783704|Behavioral|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
75873573|NCT03273907|Device|CyPass Micro-Stent implanted with CyPass 241-S applier|CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
75416866|NCT03788421|Procedure|Clamping and suturing|Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
75873574|NCT03273907|Procedure|Cataract surgery|Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit
75873575|NCT03627780|Diagnostic Test|DNA extraction|DNA will be extracted from white cells
75416867|NCT03782792|Drug|Spesolimab|Solution for infusion
75416868|NCT03782792|Drug|Placebo|Solution for infusion
75873576|NCT04246021|Drug|Ferric carboxymaltose (FCM)|intravenous iron formulation
75416869|NCT03762161|Drug|TAS 102|Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
75416870|NCT03758170|Drug|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
75416871|NCT03752762|Dietary Supplement|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study will not include sugar.
75873577|NCT03627702|Radiation|Irradiated VIP (Visible Incoherent Polarized)|20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
75562455|NCT04816812|Behavioral|Lifestyle - online lesson intervention|The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.
75562456|NCT04790903|Drug|Venetoclax|Participants will self-administer Venetoclax, as described in the Arm Descriptions.
75562457|NCT04790903|Drug|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.
75562458|NCT04790903|Drug|Rituximab|Participants will receive Rituximab at a dose of 375 mg/m^2 by IV infusion on Day 1 of Cycles 1-6.
75562459|NCT04790903|Drug|Cyclophosphamide|Participants will receive Cyclophosphamide at a dose of 750 mg/m^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
75562460|NCT04790903|Drug|Doxorubicin|Participants will receive Doxorubicin at a dose of 50 mg/m^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
75562461|NCT04790903|Drug|Prednisone|Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.
75562462|NCT04786405|Behavioral|Mindfulness meditation|Participants in the mindfulness meditation condition will practice a breath and body focused meditation.
75562463|NCT04786405|Behavioral|Clinical hypnosis|Participants in clinical hypnosis will be guided in a hypnosis practice with suggestions tailored towards shifting pain appraisals.
75562464|NCT04779424|Other|POCT|Capillary blood sample antibody point of care test
75873578|NCT02236806|Drug|Bisoprolol|5 mg daily
75873579|NCT02236806|Drug|Ramipril|5 mg daily
75873580|NCT02236806|Drug|Placebo|1 capsule daily
75873581|NCT01578954|Drug|Lenalidomide|"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"
75873582|NCT00659646|Drug|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
75873583|NCT00659646|Drug|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
75416872|NCT03752762|Behavioral|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits and group sessions.
75416873|NCT03746756|Behavioral|SBIRT|"As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study."
75441655|NCT01636908|Procedure|skin biopsy (optional)|
75441656|NCT01636973|Procedure|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
75416874|NCT03746756|Behavioral|SBIRT+RMC-PC|In addition to SBIRT, those randomly assigned to the experimental condition will also receive Recovery Management Checkups for Primary Care (RMC-PC) at the time of referral/study enrollment and quarterly for 12 months. RMC-PC involves a linkage manager reviewing the assessment data and using motivational interviewing to encourage the person to go to treatment and identify barriers to entering or staying in treatment. It also involves problem solving on how to address common issues (e.g., transportation, scheduling), staying in regular contact for the first two weeks to make sure they stay in treatment, and checking in on continuing care compliance at later checkups.
75562465|NCT04779294|Diagnostic Test|STAN ( St wave analysis) and fetal blood sample-lactate|The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
75416875|NCT03740035|Device|eHealth for Sedentary Behavior|Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
76042848|NCT04728841|Genetic|Injection of GS001|"Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is < 5 IU/dL.The dose levels are as follows:~2×10^12 vg/kg~6×10^12vg/kg or other recommended doses~2×10^13 vg/kg or other recommended doses"
75416876|NCT03739034|Behavioral|Lifestyle Medicine|Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
75562466|NCT04772040|Dietary Supplement|Fish oil supplementation|Fish oil capsules.
75562467|NCT04768881|Drug|Selinexor|Dose and formulation: 80 mg (4 tablets of 20 mg)
75562468|NCT04768881|Drug|Pembrolizumab|Dose and formulation: 400 mg (25 milligrams per milliliter [mg/mL]) Solution
75562469|NCT04768790|Other|multidisciplinary program|multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
75562470|NCT04768790|Other|General program|exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
75562471|NCT04761822|Biological|Moderna COVID-19 Vaccine|Intramuscular injection
75562472|NCT04761822|Biological|Pfizer-BioNTech COVID-19 Vaccine|Intramuscular injection
75562473|NCT04761822|Biological|Placebo|Intramuscular injection
75416877|NCT03736954|Behavioral|positive suggestion|humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
75416878|NCT03733119|Drug|Akt/ERK Inhibitor ONC201|Given PO
75416879|NCT03733119|Dietary Supplement|Methionine-Restricted Diet|Given PO
75416880|NCT03724669|Behavioral|waiting list|After the study ends, they will have access to receive the educational texts and view the online lectures.
75416881|NCT03724669|Behavioral|benzodiazepines related knowledge intervention|participants receiving 11 articles pushing and 3 online lectures through the electronic interventions App, once a week, last for 3 months
75416882|NCT03719183|Diagnostic Test|Conventional Cytogenetics Studies|Metaphase cytogenetic studies will be performed in all cases according to standard methods. Chromosome preparations will be G-banded using trypsin and Giemsa, and karyotypes will be described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016.
75416883|NCT03719183|Diagnostic Test|Fluorescent in Situ Hybridization (FISH) Panels|"AML Panel includes:~t(8;21) (RUNX1-RUNX1T1).~inv(16), t(16;16) (CBFB-MYH11).~t(9;22) (BCR-ABL).~11q23 KMT2A rearrangements.~inv(3) MECOM rearrangements.~DEK-NUP214 rearrangements.~Del(5q) Deletion~Del(7q) Deletion~Acute Promyelocytic Leukemia panel includes:~t(15;17) (PML-RARA).~17q RARA rearrangements"
75416884|NCT03719183|Diagnostic Test|Multiplex FISH (M-FISH)|24-color karyotyping
75562474|NCT04743765|Other|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
75717485|NCT00797940|Drug|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
75416885|NCT03717935|Dietary Supplement|Essential Amino Acid (EAA) Supplement|Powder supplement
75416886|NCT03717935|Other|Placebo|Powder that will be similar to the essential amino acid supplement
75416887|NCT03715751|Other|ASV|Adaptive Support Ventilation
75416888|NCT03715751|Other|Lung Protective Ventilation|Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
75416889|NCT03709368|Other|Hardware|Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
75562475|NCT04729543|Biological|Adoptive therapy with autologous MC2 TCR T cells|Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP
75562476|NCT04709692|Drug|(+)-SJ000557733 (SJ733)|Anti-Malarial
75562477|NCT04706962|Drug|TH1902|Intravenous infusion
75562478|NCT04692285|Drug|Zolpidem|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
75562479|NCT04692285|Drug|Placebo|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
75717486|NCT00800748|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
76042849|NCT04723667|Behavioral|13-week multimodal intervention|The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
75873584|NCT02236572|Drug|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~Anastrozole 1 mg~Letrozole 2.5 mg~Exemestane 25 mg"
75416890|NCT03709368|Behavioral|CLTS|CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch & smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
75873585|NCT03054870|Drug|Xe-133|Xe-133 ventilation scintigraphy
76042850|NCT04723667|Behavioral|5-week health education programme|The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
76042851|NCT04702178|Biological|COVAC-2|Intramuscular vaccine against SARS-CoV-2
76042852|NCT04702178|Biological|Saline Placebo|Intramuscular injection of saline placebo
75562480|NCT04690855|Drug|Talazoparib|Talazoparib 1 mg Orally Day 1 to Day 28
75562481|NCT04690855|Drug|Atezolizumab|Atezolizumab 840 mg IV over 60 minutes Day 15 of Cycle 1 then Day 1 and Day 15 of subsequent Cycles
75562482|NCT04690855|Radiation|Radiation|Radiation 8 Gy will be given in 3 fractions QOD beginning Day 12, 13 or 14 of Cycle 1 but 24-72 hours prior to 1st dose of Atezolizumab
75562483|NCT04676100|Other|Cardiac rehabilitation|"A CR program is defined as one that offers initial assessment, structured exercise (can be supervised or unsupervised) and at least one other strategy to control risk factors. The registry pertains to phase II CR.~Quality of care and patient outcomes are benchmarked with other countries anonymously, through 2 registry dashboards (real-time). The dashboards will also show change over time in 6-month increments; Sites will be encouraged to continue to provide data on new patients until all indicators show quality as possible.~Sites will be supported in quality improvement by the ICRR user sub-committee. High-performing programs will be recognized on ICRR's website and ICCPR's social media accounts. This mechanism may be used in future to support program accreditation."
75562484|NCT04663100|Other|Patient-reported outcome measure|Participants will complete a patient-reported outcome measure for their oral anticancer agent at two timepoints over 2 months, to assess patient symptoms and adherence to their oral anticancer agent.
75717487|NCT00800748|Drug|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
75717488|NCT00345397|Device|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
75873586|NCT03054870|Drug|Technegas|Technegas ventilation scintigraphy
75873587|NCT03414047|Drug|Prexasertib|Administered IV
75873588|NCT03711227|Diagnostic Test|Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
75416891|NCT03709368|Behavioral|PHAST|PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
75416892|NCT03709368|Behavioral|RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
75416893|NCT03709368|Behavioral|mini-RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
75717489|NCT00793260|Behavioral|Enhanced Support|"The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness."
76042853|NCT04698967|Behavioral|Purposeful Pathways|Purposeful Pathways is a manualized intervention to assist veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.
75416894|NCT03709368|Other|Placebo poster|One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
75416895|NCT03705338|Device|Electroencephalography|Measure the appearance and disappearance of frontal alpha wave with EE, when them loss and recovery of consciousness under general anesthesia with propofol.
75562485|NCT04663100|Other|Comprehensive Medication Review|Following the first patient-reported outcome measure, participants will be contacted by the community pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. A follow-up CMR will take place after the second patient-reported outcome measure.
75562486|NCT04663100|Other|Pharmacist communication|Throughout the study, the oncology and community pharmacists will communicate about medications through the electronic medical record.
75562487|NCT04643015|Diagnostic Test|MRI|"Briefly, new MRI sequences will be used on a patient who is undergoing a scheduled, clinically necessary MRI exam. Any new research sequence will be scanned in addition to the clinically required sequences and will not interfere with the clinical scan other than requiring five to ten minutes of additional table time. There will be no invasive measures under this protocol."
75562488|NCT04634539|Drug|Gemcitabine|Gemcitabine will be administered at 600, 800, or 1000 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Gemcitabine will be administered immediately after the infusion of nab-paclitaxel. Pre-medication with may be administered per institutional standard practice at the investigator's discretion with gemcitabine.
75562489|NCT04634539|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered at 75, 100, or 125 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Nab-paclitaxel will be given first, before infusion of gemcitabine. Pre-medication for nab-paclitaxel may be administered per institutional standard practice at investigator's discretion.
76042854|NCT04698967|Behavioral|Transitional Work Experience|Provides Veterans with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TWE is time-limited. TWE is staffed by vocational rehabilitation specialists (VRS).
75873589|NCT03709901|Other|Active Allograft|Injection of viable allograft into the nucleus pulposus of the degenerated disc
75416896|NCT03705338|Drug|Propofol|Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
75416897|NCT03704285|Drug|Propofol|Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
75416898|NCT03704285|Device|BIS|GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
75416899|NCT03697395|Diagnostic Test|Lung transplant recipient without MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant, but without consenting to be evaluated by hyperbolized gas MRI. Bronchoscopy sampling will be performed per usual lung transplant team protocol.
75562490|NCT04634539|Drug|L-glutamine|The dose levels of L-glutamine in this study will be 0.1, 0.2, and 0.3 g/kg oral twice daily (rounded to nearest 5 g with an upper limit of 15 g twice daily (30 g/day) for any dose level) taken at the same time each day during the treatment period. L-glutamine will be administered for 1 week (+/-1 day) prior to addition of gemcitabine/nab-paclitaxel. Each dose of L-glutamine should be mixed immediately before ingestion with 8 oz. (240 mL) of a cold or room temperature beverage, such as water, milk or apple juice, or 4 oz. (120 mL) to 6 oz. (177 mL) of food such as applesauce or yogurt. L-glutamine is formulated in 5 gram packets as a white crystalline powder in paper-foil-plastic laminate. Complete dissolution is not required prior to administration.
75562491|NCT04624113|Drug|Tazemetostat|Epizyme will supply the study agent, which will be provided free of charge to the patient.
75562492|NCT04624113|Drug|Pembrolizumab|Pembrolizumab is commercially available
75562493|NCT04619264|Drug|Papacarie|First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
75873590|NCT03709901|Other|Placebo|Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
75873591|NCT05448677|Drug|Ezurpimtrostat|Patients in the experimental arm will be instructed to take their assigned oral dose every day.
75873592|NCT05448677|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
75873593|NCT05448677|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
75873594|NCT04858932|Device|Continuous Glucose Monitor|a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
75873595|NCT04858932|Device|Wrist Actigraphy Device|a watch like wearable sensor
75416900|NCT03697395|Drug|Lung transplant recipient with MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant and with consenting to be evaluated by hyperbolized has MRI. Bronchoscopy sampling will be guided by the results of the hyper polarized gas MRI, different from the usual lung transplant team protocol. Administration of hyper polarized gas MRI is under FDA regulation by IND #129769 (PI, Yun Michael Shim, MD)
75416901|NCT03696537|Drug|Fludarabine|Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen
75416902|NCT03696537|Radiation|Total Marrow Irradiation (TMI)|TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
75416903|NCT03688243|Device|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
75416904|NCT03682250|Device|FreeStyle Libre Pro|A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
75416905|NCT03682250|Device|Holter monitor|A Holter monitor will be used to measure heart's activity
75416906|NCT03664765|Other|UA and RMT|daily oropharyngeal and respiratory muscle exercises
75873596|NCT04858932|Device|Food Weight Scale|a scale to measure food weight
75562494|NCT04619264|Procedure|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
75416907|NCT03664765|Other|Sham exercise|Daily sham exercises
75416908|NCT03663829|Other|Non-Interventional|Non-Interventional
75416909|NCT03663829|Other|Non-Interventional|Non-Interventional
75416910|NCT03662672|Procedure|Rib raising and lumbar release|Rib raising per protocol described in arm description.
75562495|NCT04615819|Other|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
75562496|NCT04615819|Other|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
75562497|NCT04611854|Behavioral|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
75562498|NCT04611854|Behavioral|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
75717490|NCT00793260|Behavioral|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
75873597|NCT04858932|Device|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
76042855|NCT04588740|Drug|concentrated beet root juice|On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.
75416911|NCT03662672|Procedure|Sham procedure|Sham procedure per protocol described in arm description
75416912|NCT03661996|Drug|CNTX-4975-05|Osteoarthritis (OA) intra-articular injection of CNTX-4975-05
75416913|NCT03661996|Drug|Lidocaine without epinephrine|15 mL lidocaine intra-articular injection
75416914|NCT03661996|Device|ElastoGel|Cooling Device
75416915|NCT03661996|Device|Breg Ice Water Pump|Cooling Device
75416916|NCT03645759|Behavioral|I'm Whole|I'm whole will provide 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration.
75416917|NCT03645759|Other|Education + usual care|Will receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
75562499|NCT04604873|Other|Hospital day care follow-up|Regular follow up every month in hospital day care
75562500|NCT04602611|Other|Oncology Nurse Navigation|Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
75562501|NCT04596267|Drug|Pitolisant|8.9mg Pitolisant for 5 days
75562502|NCT04596267|Drug|Placebo|Inert ingredients
75562503|NCT04557878|Drug|Hypertonic Dextrose Solution|Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
75562504|NCT04557878|Biological|Liquid Phase Concentrated Growth Factor (LPCGFs)|Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
75562505|NCT04538742|Drug|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
75562506|NCT04538742|Drug|Durvalumab|Durvalumab: administered as an IV infusion
75562507|NCT04538742|Drug|Paclitaxel|Paclitaxel: administered as an IV infusion
75717491|NCT00756080|Drug|citrulline|0.06 G/kg three times/day during 7 days
75717492|NCT00756080|Drug|placebo|placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
75873598|NCT05216718|Procedure|Mini-flap|Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
75873599|NCT05216718|Procedure|Conventional flap|Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
75873600|NCT03351335|Device|Microfocused ultrasound with visualization|All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.
75416918|NCT03639064|Drug|Cannabis Oil|"Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil."
75416919|NCT03633461|Drug|OC-02 (simpinicline) nasal spray|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
75416920|NCT03633461|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
75416921|NCT03628560|Device|RespirAct Step-Wise Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
75416922|NCT03628560|Device|RespirAct Slope Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
75416923|NCT03628560|Device|RespirAct Step-Wise Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
75416924|NCT03628560|Device|RespirAct Slope Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
75416925|NCT03628560|Device|ROBD Step-Wise desaturation sequence|Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
75416926|NCT03622658|Biological|Placebo|Placebo solution for subcutaneous injection.
75416927|NCT03622658|Biological|Namilumab|Namilumab solution for subcutaneous injection
75416928|NCT03621475|Device|Novel restraint|Use of a novel arm restraint
75416929|NCT03620968|Other|cognitive training|15 minutes day of brain training by an APP
75416930|NCT03615521|Other|Hotpack|Hotpack applied 20 minutes for knee 3 session for 6 weeks
75416931|NCT03615521|Other|Ultrasound|Ultrasound applied 10 minutes for knee 3 session for 6 weeks
75717493|NCT00798252|Drug|Capecitabine|Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
75416932|NCT03615521|Other|Combine Exercise|Proprioceptive Neuromusculer Facilitation Technique İnclude eccentric and concentric contractions 3 session for 6 week
75416933|NCT03615521|Other|Repeated Contraction Exercise|Proprioceptive Neuromusculer Facilitation Technique include concentric contractions 3 session for 6 week
75717494|NCT00798252|Drug|Doxorubicin|IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
75717495|NCT00798252|Drug|Ixabepilone|IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
75562508|NCT04538742|Drug|Pertuzumab|Pertuzumab: administered as an IV infusion
76042856|NCT04588740|Drug|Placebo beet root juice|This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
75416934|NCT03615521|Other|Standart Exercise Therapy|"Quadriceps, hamstring and hip muscle strength exercise. Hamstring stretch exercise.~3 session for 6 week"
75416935|NCT03600142|Behavioral|Mashia|Maisha is a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. The intervention will be developed in a formative phase and includes 1) a video and counseling session prior to HIV testing that addresses HIV stigma, and 2) two post-test HIV counseling sessions for HIV-infected individuals, building on the video content to provide emotional support, address stigma, and reinforce the value of care engagement.
75416936|NCT03526510|Radiation|Conventionally Fractionated versus Hypofractionated Boost|
75416937|NCT03517098|Procedure|The ERAS group|"ERAS pathway for orthopedic surgeons:~Shortened preoperative fasting from intake.~Preoperative tranexamic acid administration.~No indwelling catheters.~No tourniquet used for TKA.~No drainage tube.~Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~Intravenous 20 mg of dexamethasone before anesthetic induction.~Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~Laryngeal mask for airway.~Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied."
75416938|NCT03517098|Procedure|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
75416939|NCT03499314|Device|Active RS-tDCS +At-Home Manual Dexterity Training|Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes
75562509|NCT04538742|Drug|Tucatinib|Tucatinib administered orally (tablet) twice daily
75562510|NCT04537416|Other|No intervention|No intervention
75562511|NCT04517266|Radiation|omit of IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
75562512|NCT04517266|Radiation|IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
75562513|NCT04513912|Drug|Seltorexant|Participants will receive seltorexant over-encapsulated tablet orally.
75562514|NCT04513912|Drug|Matching placebo to Seltorexant|Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
75562515|NCT04513912|Drug|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
75562516|NCT04513912|Drug|Matching placebo to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
75416940|NCT03499314|Device|Sham RS-tDCS +At-Home Manual Dexterity Training|"Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds"
76042857|NCT04580498|Drug|SHR-1701+Paclitaxel+carboplatin|Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5
76042858|NCT04580498|Drug|SHR-1701|Drug: SHR-1701 30mg/kg
75416941|NCT03499314|Other|Manual dexterity training|Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
75416942|NCT03496597|Procedure|Retinal imaging assessment|"OCT-angiography~Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~Eye fundus photography: macular image~Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus"
75416943|NCT03496597|Procedure|blood glucose holter|for 40 subjects, implantation of a blood glucose holter monitor for 7 days
75416944|NCT03478215|Biological|Mesenchymal Stromal Stem Cells (MSCs) Infusion|"Investigational infusion bag containing autologous mesenchymal stromal cells wrapped to cover contents to maintain the blind.~Mesenchymal Stromal Stem Cells Infusion."
75416945|NCT03478215|Other|Normal Saline (Placebo) Infusion|"Matching infusion containing normal saline wrapped to cover contents to maintain the blind.~Normal Saline (Placebo) Infusion."
75562517|NCT04510311|Drug|3-[18F]Fluoro-para-hydroxyphenethylguanidine|Single IV injection of 12.0 mCi (+/- 10%) [18F]3F-PHPG
75562518|NCT04510311|Drug|[123I] metaiodobenzylguanidine|Single IV injection of 10.0 mCi [123I]MIBG
75562519|NCT04510311|Diagnostic Test|Positron emission tomography/computed tomography scan|Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of [18F]3F-PHPG
75562520|NCT04510311|Diagnostic Test|Planar scintigraphy scan|Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of [123I]MIBG
75717496|NCT00798252|Drug|Docetaxel|IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
75717497|NCT00798252|Drug|Paclitaxel|IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
76042859|NCT04574843|Procedure|Embolization of MMA|embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)
75416946|NCT03477084|Biological|ESBL-producing enterobacteriaceae carriage|Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
75717498|NCT00798252|Drug|Brivanib alaninate|Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
75416947|NCT03468556|Drug|SNP-610|Subjects will take 2 tablets once a day orally for 12 weeks
75416948|NCT03468556|Drug|Placebo Oral Tablet|Subjects will take 2 tablets once a day orally for 12 weeks
75416949|NCT03465384|Behavioral|Comet|The intervention is a behaviorally based and manualized parent training program.
75562521|NCT04510311|Diagnostic Test|Single photon emission computed tomography/computed tomography scan|SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of [123I]MIBG
75562522|NCT04508764|Other|Families Accelerating Cascade Testing Toolkit|-Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
75562523|NCT04504253|Dietary Supplement|Creatine monohydrate|Creatine monohydrate loose powder
75562524|NCT04504253|Drug|Placebo|Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
75562525|NCT04484337|Drug|Cabotegravir sodium (Oral Lead In)|CAB will be available as 30 mg tablets for oral administration.
75562526|NCT04484337|Drug|Cabotegravir 400 mg/mL|CAB 400 mg/mL will be available for administration by IM injection or SC Injection.
75562527|NCT04484337|Drug|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be available for administration by IM injection or SC Injection.
75717499|NCT00748046|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
75717500|NCT00326209|Drug|Encapsulated Mesalamine Granules (eMG)|eMG capsules will be administered per dose and schedule specified in the arm.
76042860|NCT04560075|Behavioral|Text2Connect|The T2C intervention aims to increase mental health self-efficacy though psychoeducation, self-monitoring of symptoms and stressors, and cues to action for college-bound youth.
76042861|NCT04560075|Behavioral|Psychoeducational Videos (PE) Only|Participants in this group will receive psychoeducation through the PE video library.
76042862|NCT04544462|Other|M2 Test|DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
76042863|NCT04528498|Other|Preimplantation Genetic Testing|Embryo biopsies will undergo preimplantation genetic testing for aneuploidies as per standard of care, and polygenic disease risk (PGT-P) will be computed for these samples.
75416950|NCT03441958|Biological|ECT-001 (UM171) expanded cord blood|ECT-001 expanded cord-blood will be produced and infused on site
75416951|NCT03424343|Other|Questionnaire bundle|Questionnaires on identity formation and psychosocial functioning, assessed and reported at baseline, one year later, two years later, and five years later.
75416952|NCT03424343|Other|Obtaining information from survivors' medical file|After obtaining informed consent, we will access the medical file of participants to obtain information on the diagnosis, time of diagnosis, treatment duration, type of treatment, and relapse (when applicable).
75416953|NCT03416088|Behavioral|Beverage consumption|The participants drink 300ml wine (alcohol concentration:12.5%)or 300ml coffee (caffeine concentration 72 mg), or water.
75416954|NCT03416088|Behavioral|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading for 8 hours.
75562528|NCT04484337|Drug|Topical non-steroidal anti-inflammatory drug|Non-steroidal anti-inflammatory drug will be available for topical application
75562529|NCT04484337|Drug|Topical steroid|Steroid will be available for topical application
75717501|NCT00537940|Drug|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
75416955|NCT03416088|Behavioral|Body motion|Exercise or body postural changes
75562530|NCT04484337|Drug|Placebo creams/gels|Placebo creams/gels will be available for topical application
75562531|NCT04484337|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|rHuPH20 will be available for administration by SC Injection
75717502|NCT00537940|Drug|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
75717503|NCT00661362|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
75717504|NCT00661362|Drug|Placebo|oral tablet, once daily for 24 weeks
75717505|NCT00661362|Drug|Metformin|oral tablet, once daily for 24 weeks
76042864|NCT04523337|Behavioral|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services. Patients will receive 2 hours of MISSION-CJ services per week during and after their stay in the mental health residential rehabilitation program (total of 6-months). Services are delivered using a Critical Time Intervention stepdown approach.
76042865|NCT04523337|Behavioral|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking Peer Support|The MISSION Peer Support Curriculum is rolling entry, and includes 24, one-hour exercises focused on co-occurring substance use and mental health disorders, recovery, and community integration.
76042866|NCT04483414|Drug|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
76042867|NCT04483414|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
75416956|NCT03410355|Procedure|BMAC/PRP Injection|Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.
75416957|NCT03410355|Procedure|Cortisone Injection|An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.
75416958|NCT03399617|Dietary Supplement|Micronutrient Powders|Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
75717506|NCT00991432|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
75717507|NCT00748202|Drug|C1-Esterase Inhibitor|1000 I.E.
76042868|NCT04469569|Behavioral|HPV-PROTECT|HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
75416959|NCT03399617|Behavioral|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.
75416960|NCT03399617|Dietary Supplement|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
75416961|NCT03395366|Other|Multifaceted Educational / Cognitive Behavioral Intervention|The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts & worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
75416962|NCT03386162|Drug|Alpelisib|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
75416963|NCT03386162|Drug|Chemotherapy|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
75562532|NCT04473053|Drug|Nafamostat Mesilate|Nafamostat has been shown to have potential antiviral effects against MERS CoV and is thought to possibly inhibit SARS CoV2 infection via inhibition of viral entry due to inhibition of TMPRSS2. In addition, nafamostat has potent anticoagulant properties which may provide benefit in patients with DIC, a common finding in serious cases of COVID-19. Nafamostat has been broadly well tolerated in clinical trials in patients with DIC and acute pancreatitis.
75562533|NCT04473053|Drug|TD139|TD139 is a specific inhibitor of galectin-3 which has been investigated in healthy volunteers and patients with IPF. No serious drug related serious adverse events have been reported to date. TD139 had no impact on cardiac, haematological or biochemical measures of safety during trials in humans to date. Beneficial effects on biomarker measures of lung inflammation were observed in patients with IPF. It is the purpose of this investigation to examine the potential for delivery of this inhibitor in pre-ventilator patients hospitalised with COVID-19 to examine whether this may lead to detectable changes in blood biomarkers, reduce viral load and also reduce disease severity such as time to ventilation.
75562534|NCT04473053|Other|Standard care|Patients will receive standard care.
75873601|NCT05216640|Device|High Flow Oxygen Therapy|• The patient will be allocated into 2 groups, patients who will require ventilatory support via HFNC and those who will require HVNI
75873602|NCT03711149|Other|Activity monitor feedback loop|The intervention arm will test if the feedback system (i.e., activity monitor, real-time feedback, and art tours) increases daily step count, decreases length of stay, and improves patient and provider communication, patient awareness of step count goals, and patient confidence in accomplishment of daily goals.
75873603|NCT00472680|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
75873604|NCT00472680|Behavioral|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
75873605|NCT00472680|Behavioral|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
75873606|NCT05670912|Drug|Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
75873607|NCT05670912|Drug|Placebo Comparator of Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
75416964|NCT03373071|Biological|CD19-CAR T cell|"Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment"
75562535|NCT04473053|Biological|Allogeneic SARS-CoV-2 VSTs|The allogeneic SARS-CoV-2 VSTs are manufactured in a single stage process directly from the starting material procured from suitable post COVID-19 recovered individuals. This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs.
75562536|NCT04469452|Device|Apollo Device|Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
76042869|NCT04428385|Other|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
75416965|NCT03369431|Dietary Supplement|Vivomixx|Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
75416966|NCT03369431|Dietary Supplement|Placebo|4.4 grams of maltose and silicon dioxide per sachet
75416967|NCT03360214|Drug|Bupivacaine Hydrochloride|For active drug, 0.25% marcaine, will be used.
75416968|NCT03360214|Other|Placebo Drug|For sham drug, 0.9% saline, will be used.
75717508|NCT00325897|Drug|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
75416969|NCT03360214|Device|Pulsed Electromagnetic Field (PEMF) Device|The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.
75717509|NCT00325897|Drug|Placebo|Placebo taken on a daily basis
75717510|NCT00800826|Drug|dexmedetomidine|
75416970|NCT03360214|Other|Placebo Device|Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.
75416971|NCT03360214|Drug|Ropivacaine Hydrochloride|For active drug, 0.25% naropin, will be used.
75416972|NCT03359239|Drug|Atezolizumab|1200 mg administered by IV infusion every 3 weeks (21 [+/-2] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.
75416973|NCT03359239|Biological|PGV001|"PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)"
75416974|NCT03359239|Drug|Poly ICLC|1.4 mg (0.7 mL, 2 mg/mL)
75562537|NCT04466228|Device|non-invasive transcranial electrical stimulation|Non-invasive transcranial electrical stimulation across the prefrontal cortex.
75717511|NCT04926142|Device|Implantation of Holter device|Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
75416975|NCT03359239|Drug|Normal saline|0.19 mL
75562538|NCT04461080|Behavioral|Community Health Worker|Trained Community Health Worker
75717512|NCT04926142|Procedure|Percutaneous PFO closure|Patients will undergo percutaneous closure of patent foramen ovale
75717513|NCT00756392|Procedure|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
75734982|NCT03386045|Radiation|Optimal Booster|"Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach|) and one third will get the standard treatment (60 Gy in 20 treatments)"
76042870|NCT04428385|Other|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
76042871|NCT04378010|Drug|EDP-305 1.5 mg|Tablet
75562539|NCT04455750|Drug|Enzalutamide|Given PO
75562540|NCT04455750|Drug|Rucaparib camsylate|Given PO
75562541|NCT04455750|Drug|Placebo|Given PO
75562542|NCT04455750|Drug|Leuprolide Acetate|Given IM
75562543|NCT04455750|Drug|Goserelin Acetate|Given SC
76042872|NCT04378010|Drug|EDP-305 2 mg|Tablet
76042873|NCT04378010|Drug|Placebo|Tablet
76042874|NCT04365114|Diagnostic Test|Breast Screening Mammography with single reader|One clinician examined each woman's mammograms for signs of cancer
75562544|NCT04455750|Drug|Degarelix|Given SC
75562545|NCT04455750|Other|Quality-of-Life Assessment|Ancillary studies
75562546|NCT04455750|Other|Questionnaire Administration|Ancillary studies
75562547|NCT04439903|Other|Web-based Simulation Tool|Glucose, insulin and meal data from the participants' insulin pump will be collected and entered into the WST, which will generate personalized models of the participants' glucose metabolism to enable replay simulations.
75562548|NCT04427384|Device|GammaTile|Surgically Targeted Radiation Therapy
75562549|NCT04410107|Diagnostic Test|Lung Function tests|Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)
75873608|NCT03619746|Behavioral|POCUS Educational Intervention|Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
75416976|NCT03350594|Behavioral|Systemic Family Therapy|Patient will have 10 sessions of Systemic Family Therapy during 12 months with his/her family.
75562550|NCT04410107|Diagnostic Test|Exercise capacity|6-minute walk test (6MWT distance)
75873609|NCT05216406|Dietary Supplement|5-HTP|CLEANMOOD is an organic 5-Hydroxytryptophan (5-HTP) ingredient.
75873610|NCT05216406|Other|Placebo|Maltodextrin capsule
75562551|NCT04410107|Diagnostic Test|Exercise physiology|Cardiopulmonary exercise test (CPET)
75562552|NCT04410107|Diagnostic Test|Health-related quality of life|Short-Form Health Survey Questionnaire (SF-36)
75873611|NCT04811898|Biological|LNA-i-miR-221|LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)
76042875|NCT04365114|Diagnostic Test|Breast screening mammography with two readers|Two clinicians seperately examined each woman's mammograms for signs of cancer
76042876|NCT04365114|Diagnostic Test|Test threshold|Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled
75416977|NCT03350594|Behavioral|Multiple Family Therapy|Patient and his/fer family will have 10 sessions of Multiple Family Therapy during 12 months.
75416978|NCT03336866|Drug|Placebo|Normal saline
75416979|NCT03336866|Drug|IXT-m200|IXT-m200 is an anti-methamphetamine monoclonal antibody
75416980|NCT03336411|Behavioral|mHealth|Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet.
75416981|NCT03336411|Behavioral|Personalized mHealth|Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response.
75416982|NCT03335345|Other|maintaining calorie intake|Maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube.
75416983|NCT03335345|Other|maximum gastric vacuity|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its caliber permits) continuously for 6 hours before extubation
75416984|NCT03332173|Drug|Zanubrutinib|Oral administration using 80 mg capsules
75562553|NCT04410107|Diagnostic Test|Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening|"Adapted translation American Thoracic Society respiratory symptoms questionnaire;~Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~Questionnaire for screening for post-traumatic stress symptoms (PTSD)."
75562554|NCT04396860|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced brain MRI
75562555|NCT04396860|Biological|Ipilimumab|Given IV
75873612|NCT05223270|Other|wound dressing under the NIMV mask|wound dressing under the NIMV mask
75416985|NCT03332030|Diagnostic Test|Collection of Stem Cells|One time collection of a 20 ml blood sample
75416986|NCT03328676|Drug|Cannabis|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
75562556|NCT04396860|Biological|Nivolumab|Given IV
75562557|NCT04396860|Device|NovoTTF-100A Device|Wear Optune device
75562558|NCT04396860|Other|Quality-of-Life Assessment|Ancillary studies
75562559|NCT04396860|Other|Questionnaire Administration|Ancillary studies
75562560|NCT04396860|Radiation|Radiation Therapy|Undergo radiation therapy
75562561|NCT04396860|Drug|Temozolomide|Given PO
75562562|NCT04387201|Drug|Cyanocobalamin|Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
75562563|NCT04387201|Drug|Dulaglutide|Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
75562564|NCT04373330|Behavioral|Intensive Lifestyle Intervention|There will be 14 sessions delivered over the course of 6 months; materials consist of CHW lesson plans, participant workbooks, and the DVD series. These materials will be adapted for use in HELP-VM and will include information on migraine and its management as well as mental health resources available to Veterans for common illnesses like depression and post-traumatic stress disorder and modifying physical activity recommendations for Veterans with limited mobility.
75873613|NCT05669898|Behavioral|Pain scores (numerical rating scale at rest and motion): will be assessed with numerical rating scale at both rest and motion on both knees.|Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
75873614|NCT05669898|Other|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale|For the functional assessment both before and after TKA surgery.
75873615|NCT05669898|Behavioral|Rehabilitation physiotherapy|Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.
75873616|NCT05223114|Other|Not applicable (N/A)|Not applicable to this study
75873617|NCT05222958|Device|Gestob App|Gestop App is a mobile app that aims to help pregnant women quit smoking through gamification. It also allows you to obtain information about tobacco and pregnancy.
75873618|NCT04641156|Other|Exercise Therapy program added to laser therapy|a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release
75416987|NCT03328676|Drug|Placebo oil|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
75562565|NCT04369066|Diagnostic Test|Blood samples (collection of 5 mL of blood in a dry tube)|"A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.~The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion.~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The serum samples will be extracted and collected prospectively from the blood samples.~For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie."
75717514|NCT03989089|Drug|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
75873619|NCT04618614|Device|HD-tDCS 1 mA to S1|Anodal high definition transcranial direct current stimulation of the right primary somatosensory cortex with an intensity of 1 mA
75416988|NCT03324711|Diagnostic Test|"Antillanisée Mini Mental State Examination (MMSEa)"|"Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture."
75416989|NCT03322293|Drug|Aminolevulinic Acid Topical 20% Topical Solution|PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
75416990|NCT03322293|Device|BLU-U blue light phototherapy illuminator|Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.
75416991|NCT03322033|Device|Valiant PS-IDE Stent Graft|Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
75416992|NCT03315039|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
75873620|NCT04618614|Device|HD-tDCS 1 mA to M1|Anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1 mA
75416993|NCT03308045|Biological|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
75416994|NCT03295773|Diagnostic Test|3DRA|
75717515|NCT00756626|Behavioral|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
75717516|NCT00793338|Drug|Sildenafil|Sildenafil 20mg three times a day for 3 months.
75717517|NCT00756704|Behavioral|Smoking cessation guideline implementation|"a tutorial on brief cessation counseling for ED nurses and physicians~use of an ED algorithm that includes recommended tobacco counseling items~fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~group feedback to ED staff"
75873621|NCT04618614|Device|Sham control|Sham stimulation of the right primary somatosensory cortex
75873622|NCT05222646|Drug|Metoclopramide|Will receive single dose of 10mg of Metoclopramide intramuscularly
75873623|NCT05222568|Behavioral|Lateral positioning|After the DLT intubation, the patient is placed in lateral decubitus position
75873624|NCT05222568|Device|Cuff pressure measurement|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning
75873625|NCT05222490|Device|Thermal Camera images acquisition - FeetSee|Thermal images will be collected according to the instructions for use of the Feetsee device.
76042877|NCT04361006|Device|Radiofrequency (RF)|Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
75416995|NCT03291652|Diagnostic Test|DSA/3DRA|DSA/3DRA
75873626|NCT05222490|Device|Thermal Camera images acquisition - Reference|After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer
75873627|NCT05222412|Drug|Iptacopan|Patients receive Iptacopan
76042878|NCT04361006|Device|Cryotherapy (CRYO)|Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
76042879|NCT04349072|Drug|Mavacamten|Mavacamten Capsules Other names: MYK-461
76042880|NCT04349072|Drug|Placebo|Placebo
75562566|NCT04369066|Diagnostic Test|Nasopharyngeal swabs|"The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs.~The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers).~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total."
76042881|NCT04319354|Diagnostic Test|Analysis of cfDNA|Analysis of cfDNA through liquid biopsy
76042882|NCT04313868|Drug|GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)|GEN2 is an investigational drug combining cytotoxic and immunotherapy.
75562567|NCT04349839|Device|Acrodat software|Acrodat is a newly developed software medical device to access disease activity in acromegaly based on five parameters: IGF-I, tumour size, comorbidities, symptoms and quality of life.
75562568|NCT04347967|Biological|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
75562569|NCT04331288|Drug|PT150|Intervention 1 includes PT150 with alcohol consumption
75562570|NCT04331288|Other|Beverage|The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
75734983|NCT03383458|Biological|Nivolumab|Specified dose on specified days
75734984|NCT03383458|Other|Placebo|specified dose on specified days
75562571|NCT04329156|Other|Digitally Flip Technique|A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
75562572|NCT04329156|Other|Stock Healing Abutment|After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
75562573|NCT04324762|Behavioral|targetted implementation strategies|strategies at the individual and institutional level to promote implementation of an evidenced based innovation and de-implementation of an unnecessary, low value diagnostic test.
75717518|NCT00798408|Dietary Supplement|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
75416996|NCT03276533|Drug|Saline|Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
75873628|NCT05222334|Procedure|Intrafascial interscalene brachial plexus block|"After sterilization of skin with povidone-iodine (betadine) and skin infiltration with 1-3ml lidocaine 1%, interscalene brachial plexus block will be performed using an ultrasound machine (Phillips Cx-50,Amsterdam, Netherlands) with a linear probe (L12-3 MHz) will be used in both groups. The US transducer will be placed under aseptic fashion on the lateral side of the neck at the cricoid cartilage level to view three hypoechoic structures, that represent the roots of the brachial plexus.~The two outermost nerve roots (C5 and C6) between the anterior and the middle scalene muscles will be identified and the local anesthetic (10 ml 0.5% bupivacaine) is then injected, so that spread will be seen immediately between the C5 and the C6 nerve roots."
75873629|NCT05222334|Procedure|Extrafascial interscalene brachial plexus block group|Final needle tip position will be 4 mm lateral to the brachial plexus sheath, at a level equidistant between C5 and C6 roots. The distance of 4 mm is chosen according to the calculated success rate over 90% reported. the local anesthetic (10 ml 0.5% bupivacaine) is then injected
75416997|NCT03276533|Drug|Lidocaine|Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
75873630|NCT05222334|Drug|Bupivacaine|bupivacaine
75717519|NCT00798408|Dietary Supplement|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
75717520|NCT00344773|Drug|Gefitinib|250mg tablet oral tablet once daily
75717521|NCT02561546|Drug|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
75717522|NCT02561546|Drug|Trans-catheter embolization|Trans-catheter embolization alone
75717523|NCT00991588|Procedure|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
75416998|NCT03276533|Drug|Dexmedetomidine|Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
76042883|NCT04312191|Other|Mantra Meditation|Mantra-based meditation will be taught using a standard one-word mantra (Om). Om is a non-English word that will help with focus as opposed to an English word which may cause distraction based on the word itself.
75416999|NCT03276533|Drug|Lidocaine plus Dexmedetomidine|Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
76042884|NCT04277559|Other|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery.
76042885|NCT04277559|Other|Classical music|Patients will listen to classical music through headphones before surgery.
76042886|NCT04277559|Other|No music|Patients will not listen to music.
75562574|NCT04317820|Behavioral|Deep Brain Reorienting (DBR)|Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm.
75562575|NCT04303715|Procedure|No SLNB|BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients
75562576|NCT04303715|Procedure|SLNB|BCS with SLNB(+/-ALND)
75417000|NCT03258996|Procedure|Modified vestibular incision subperiosteal tunnel access|"Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured."
75417001|NCT03258996|Procedure|Coronally advanced flap|"Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area."
75562577|NCT04298970|Dietary Supplement|Intervention|Freeze-dried Brassica oleracea var. acephala
75717524|NCT02554344|Drug|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
76042887|NCT04275700|Procedure|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma. Up to seven different sites will be injected under ultrasound guidance. The patient will be under IV sedation.
75717525|NCT00750854|Dietary Supplement|NEM Formulation X|see Treatment Arms
75717526|NCT00750854|Dietary Supplement|NEM Formulation Y|see Treatment Arms
75562578|NCT04298970|Dietary Supplement|Placebo|Placebo product
75717527|NCT01054963|Behavioral|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
75717528|NCT02554422|Device|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
75873631|NCT04465266|Drug|Tolperisone|tablets
76042888|NCT04242277|Device|Investigational WF-OCT device|Excised lumpectomy tissue will be imaged on an investigational WF-OCT device
76042889|NCT04240886|Drug|fosmanogepix|IV and oral fosmanogepix
76042890|NCT04240665|Behavioral|Digital Memory Notebook (DMN) Application|Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
76042891|NCT04223154|Device|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
76042892|NCT04223154|Device|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
76042893|NCT04173065|Drug|VK2809|Capsule
76042894|NCT04173065|Drug|Placebos|Capsule
76042895|NCT04173026|Other|Provider-level intervention|Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
75562579|NCT04293055|Behavioral|Maintenance program|1-year weight loss maintenance program, consisting of monthly newsletters
76042896|NCT04173026|Other|Patient-level intervention|50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
76042897|NCT04099511|Behavioral|Usual Care Occupational Therapy-Outpatient|The control group in the proposed study will receive usual care occupational therapy services. The dosage between the experimental group and usual care will be identical with each group receiving ten 45- minute treatment sessions. The treating therapists will be unfamiliar with the experimental group intervention to avoid contamination. Each therapist will be instructed to provide care in the same manner as they typically provide in day-to-day practice for patients with similar characteristics as those in the study. The therapists will be encouraged to provide home action plans to participants. Usual care services will be monitored through a log of number of sessions, time spent in each session, and what activities were the focus of each session. The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
75417002|NCT03254394|Drug|Lidocaine Hydrochloride|"Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study."
75562580|NCT04293055|Behavioral|Phone coaching|Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
76042898|NCT04099511|Behavioral|Cognitive Orientation to daily Occupational Performance|The Cognitive Orientation to daily Occupational Performance (CO-OP) approach was developed within the field of occupational therapy and is a performance-based, problem-solving approach to address activity performance limitations. Subjects will be taught to use the global problem-solving strategy of Goal-Plan-Do-Check: identifying a specific goal (Goal), outlining a practical plan for reaching that goal (Plan), accurately performing the plan (Do), and analyzing whether the plan led to achievement of the goal and altering the plan accordingly (Check). The Goal-Plan-Do-Check process will be iteratively applied to each of the activity goals. Therapists will use guided discovery to allow the subject to self-identify their own potential solutions within an activity (develop the plan). The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
76042899|NCT04092660|Behavioral|Behaviour change Intervention Based on Health Action Process Approach Model|"The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~Health Pamphlet at the initial screening~Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~Booster phone calls in between the follow-up visits"
75417003|NCT03254394|Drug|Placebo|Dextrose 5% in water will be administered as active comparator.
75417004|NCT03254394|Drug|FOLFOX regimen|"Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
75562581|NCT04292496|Procedure|Introperative leak testing|After anastomosis was completed. We test the integrity of anastomosis intraoperatively.
75562582|NCT04280783|Behavioral|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
75562583|NCT04280783|Behavioral|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
75562584|NCT04272268|Device|Nasal High flow Oxygen|If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
75873632|NCT04434300|Drug|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
75873633|NCT04434300|Drug|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
75873634|NCT05214690|Drug|DW1809-T2|pelubiprofen 25mg
75873635|NCT05214690|Drug|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
75873636|NCT03055806|Drug|IX-01 400 mg|IX-01 400 mg caplet
75562585|NCT04250922|Drug|LAM561|"Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment."
75562586|NCT04250922|Drug|TMZ|"TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles."
75562587|NCT04250922|Radiation|RT|During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
75562588|NCT04230759|Drug|Chemotherapy|"Patients recieve chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32"
75562589|NCT04230759|Radiation|Radiation|PTV_A (primary tumor): T1-T2<4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV_A (primary tumor): T2>=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week
75562590|NCT04230759|Drug|Durvalumab|1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses
75562591|NCT04222790|Drug|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
75873637|NCT03055806|Drug|Placebo|Placebo caplet(s)
75873638|NCT03055806|Drug|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
75417005|NCT03253809|Device|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
75417006|NCT03252314|Device|Second-generation hydrogel coils|Hydrogel coils 90% by length
75717529|NCT01055041|Drug|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
75717530|NCT01055041|Drug|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
75873639|NCT03055806|Drug|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
75873640|NCT05194644|Other|Routine physical therapy+ Sensorimotor stimulation|Gustatory, Tactile, Olfactory, Visual and Auditory Stimulation will be applied in sensory stimulation and in motor stimulation strengthening, Proprioceptive neuromuscular facilitation techniques, Balance exercises will be performed
75873641|NCT05194644|Other|Routine physical therapy|Active and passive Range of motion exercise of upper and lower limb, Transfer from bed to chair, Sit to stand practice
75873642|NCT04397796|Biological|BM-Allo.MSC|BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
75873643|NCT04397796|Biological|Placebo|plasmalyte and human albumin
75873644|NCT04315896|Drug|Hydroxychloroquine|hydroxychloroquine 400mg day for 10 days
75873645|NCT04315896|Drug|Placebo oral tablet|Placebo oral tablet
75873646|NCT04311216|Other|3D movement analysis with surface electromyography|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements
75873647|NCT03628092|Device|CO2 Fractional Ablative Laser|Vaginal / vulval laser treatment
75873648|NCT03628092|Device|Placebo|Sham Device
75873649|NCT03628014|Other|Inpatient-care program|"Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~Daily orientation and visiting program~Basic active movements~Meal assistance~Recreational activities"
75417007|NCT03247205|Behavioral|HipERS|This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
75417008|NCT03227081|Behavioral|Sleep Deprivation|Sleep Deprivation
75417009|NCT03203876|Biological|Lirilumab|Specified dose on specified days
75417010|NCT03203876|Biological|Nivolumab|Specified dose on specified days
75417011|NCT03203876|Biological|Ipilimumab|Specified dose on specified days
75417012|NCT03191240|Drug|Vasopressins|Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
75417013|NCT03191240|Drug|Normal saline|Placebo
75562592|NCT04222790|Other|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
75562593|NCT04219917|Other|Kinesio Tape|Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
75562594|NCT04219826|Drug|CK-3773274 (5 - 15 mg)|CK-3773274 tablets administered orally
75562595|NCT04219826|Drug|CK-3773274 (10 - 30 mg)|CK-3773274 tablets administered orally
75562596|NCT04219826|Drug|Placebo for CK-3773274|Placebo administered orally
75562597|NCT04216342|Biological|Fx-5A peptide complex|subject will receive a slow I.V. infusion of the Fx-5A peptide complex as described in Table 1. Five to 10 mL of blood will be collected at 30min (+/- 5min*), 1h (+/- 10min*), 2h (+/- 10min*), 4h (+/- 15min*), 8h (+/- 30min*), 12h (+/- 30min*), and 24h (+/- 30min*) for laboratory tests and to be stored for research tests. The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.
75562598|NCT04214041|Other|Autologous fat grafting|A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.
75562599|NCT04214041|Other|Sub-epithelial connective tissue graft|A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
75717531|NCT01055041|Drug|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
75717532|NCT02561624|Behavioral|Behaviour change communication via text message|
75417014|NCT03180294|Drug|Bupropion 150 mg XL|By mouth
75417015|NCT03180294|Drug|Placebo|By mouth
75417016|NCT03147222|Behavioral|Fracture Care at Home|This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
75417017|NCT03122743|Procedure|Biospecimen Collection|Undergo collection of serum samples
75562600|NCT04206007|Biological|UMC119-06|Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
75562601|NCT04200365|Drug|Itacitinib|Itacitinib will be administered orally once daily for up to 24 months.
75562602|NCT04186260|Behavioral|NAFLD-specific weight loss intervention|This is a 12-month NAFLD-specific weight loss intervention that is explicitly tailored for Mexican-American men. It will include recommendations for diet, physical activity, and will utilize risk for NAFLD as a mechanism to engage men in lifestyle modification.
76042900|NCT04092660|Device|Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard|"Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances [MAA] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device."
76042901|NCT04074161|Drug|Semaglutide|Dose gradually increased to 2.4 mg administered once weekly for 68 weeks
76042902|NCT04074161|Drug|Placebo (semaglutide)|Administered once weekly for 68 weeks
75417018|NCT03122743|Other|Laboratory Biomarker Analysis|Correlative studies
75717533|NCT01060813|Dietary Supplement|Leucine supplements|leucine supplements
75717534|NCT00793416|Device|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
75717535|NCT00748280|Procedure|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
75417019|NCT03122743|Other|Questionnaire Administration|Ancillary studies
75562603|NCT04186260|Other|Wait-list control|Participants in this condition will not receive treatment for 12-months until study comparisons have been made. After 12-months, participants will receive the 12-month NAFLD-specific weight loss intervention.
75734985|NCT03361852|Drug|Rituximab|Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
75562604|NCT04177095|Diagnostic Test|Allosure|Monthly monitoring of dd-cfDNA levels in blood
75734986|NCT03361852|Biological|Neo Vax|"Neo Vax is an experimental viral mimic and an activator of immunity."
75734987|NCT03361852|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
76042903|NCT04074161|Drug|Liraglutide|Dose gradually increased to 3.0 mg administered once daily for 68 weeks
75417020|NCT03111030|Behavioral|ProacTive SCI|"Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:~An assessment of motivated the participant is to be physically active~A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.~B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.~Progress and barriers will be reassessed and discussed."
75562605|NCT04177095|Drug|Immunosuppression reduction|Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results
76042904|NCT04074161|Drug|Placebo (liraglutide)|Administered once daily for 68 weeks
76042905|NCT04066075|Behavioral|Low Vision Rehabilitation|Low Vision Rehabilitation for use of magnification devices for near reading tasks
76042906|NCT04062981|Drug|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
75417021|NCT03098797|Drug|Elamipretide|40 mg daily subcutaneous injection for 12 weeks
76042907|NCT04044456|Behavioral|Goal Management Training|"GMT: is a 10-session intervention to improve planning and problem solving. Interactive Power Point modules are administered by a cognitive therapist. Each session builds on the steps of a five-stage planning and problem-solving strategy. Veterans will be taught to generate and verbalize the following five-steps: stop-what am I doing?, define the goal, list the steps, learn the steps; then, check-am I doing what I planned? The five-stage strategy is then incorporated into a variety of activities in the laboratory and in-home assignments."
75417022|NCT03096067|Other|Heavy slow resistance training|Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
75562606|NCT04177095|Diagnostic Test|Trugraf|Monthly monitoring of Trugraf result
75562607|NCT04170153|Drug|M1774|M1774 will be administered orally throughout the study.
76042908|NCT04044456|Behavioral|Attention Training|"Attention Process Training (APT-III) will be administered for a second weekly session in addition to the GMT session. Each session will be 2 hours/ week for 10 weeks. Veterans will also engage in BrainHQTM attention training at home for one-hour, five days/ week comprised of selected components of BrainHQ from Posit Science Corporation. This web-based computerized CRT modality of cognitive training is a restorative or bottom-up approach that targets basic cognitive skills such as arousal and vigilance processes, attention and information processing, and directly engages fundamental attention-control skills through repetitive graded exercises."
76042909|NCT04044456|Behavioral|Brain Health Workshop|. BHW was developed specifically for consistency with GMT session length and contact with the facilitator49. BHW is an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered. To match time and contact of attention training, control participants will meet with the therapist for a separate two-hour session from BHW
75417023|NCT03096067|Other|Moderate slow resistance training|Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
75417024|NCT03095313|Other|18F-NaF|"At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol [Omnipaque™]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves."
76042910|NCT04044456|Behavioral|National geographic movies|participants will select movies to watch and answer a few questions about to equate the time and therapist interaction to attention training in arm 1.
76042911|NCT04006652|Drug|ApoGraft|ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
76042912|NCT03997903|Drug|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
75417025|NCT03090295|Device|Palpation and Accuro|Identify placement for spinal
75417026|NCT03071601|Drug|Lidocaine-Prilocaine Cream 2.5-2.5%|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture
75417027|NCT03071601|Drug|Lidocaine 1% Epinephrine 0.005mg/mL solution|Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
75562608|NCT04170153|Drug|Niraparib|Niraparib will be administered orally throughout the study.
76042913|NCT03982212|Drug|Copaxone|"Agent: Glatiramer acetate (Copaxone®)~Dose: 40 mg~Route: Intratumoral injection~Schedule: At least 1 dose, up to 3 doses, with each dose being at least 48 hours apart and last dose within 96 hours of standard of care surgery."
76042914|NCT03966157|Device|Nasal Bridle|Feeding tube secured with nasal bridle
75417028|NCT03061903|Device|Prevena|"Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device."
75417029|NCT03061903|Device|Aquacel|"Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device."
75562609|NCT04168203|Drug|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
75562610|NCT04168203|Drug|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
75562611|NCT04158050|Drug|IL5 Antagonist or anti-IL5R-antibody or Omalizumab|mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma
75562612|NCT04150731|Radiation|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
75562613|NCT04142996|Device|Theta burst stimulation|Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
75562614|NCT04119271|Other|Breathe Easy at Home Kit Products|HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
75562615|NCT04118062|Behavioral|Questionnaires|Questionnaires
76042915|NCT03888898|Other|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
75417030|NCT03061643|Drug|Docetaxel|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
75562616|NCT04118062|Behavioral|Semi-structured individual interviews|Semi-structured individual interviews
75562617|NCT04118062|Other|Focus Group|Focus Group
75562618|NCT04118062|Other|DELPHI Consensus Method|DELPHI Consensus Method
75562619|NCT04110379|Behavioral|Virtual Reality (VR)|All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
76042916|NCT03888898|Other|Control fit test evaluation|control comparator for fit testing time threshold
76042917|NCT03843528|Drug|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
76042918|NCT03843528|Drug|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
76042919|NCT03837691|Device|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
76042920|NCT03837691|Behavioral|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
76042921|NCT03827824|Device|Hysteroscopy & virtual reality glasses|Hysteroscopy. Virtual reality glasses. VAS. STAI scale.
75417031|NCT03061643|Other|Androgen-Deprivation Therapy (ADT)|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
75417032|NCT03061630|Drug|Gemcitabine|D1.8.15 : GEMCITABINE 1000MG/M2
75417033|NCT03061630|Drug|Cisplatin|D1: CISPLATIN 60G/M2
76042922|NCT03827824|Device|Hysteroscopy|Hysteroscopy. VAS. STAI scale.
76042923|NCT03827460|Behavioral|Abstinence from alcohol|Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
75417034|NCT03055390|Drug|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
75417035|NCT03055390|Drug|placebo|2ml of saline intravenous
75417036|NCT03039140|Other|Educational Intervention|Attend weekly educational sessions
75417037|NCT03039140|Behavioral|Exercise Intervention|Participate in CR program
75417038|NCT03039140|Other|Quality-of-Life Assessment|Ancillary studies
75417039|NCT03039140|Other|Questionnaire Administration|Ancillary studies
75417040|NCT03033056|Behavioral|Test of fear conditioning|Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
75417041|NCT03015142|Device|New image-guidance software|Patients in this group had spine surgery with new image-guidance software application
75417042|NCT03012672|Drug|Cladribine|Given IV
75417043|NCT03012672|Drug|Cytarabine|Given IV
75417044|NCT03012672|Biological|Granulocyte Colony-Stimulating Factor|Given SC
75417045|NCT03012672|Drug|Mitoxantrone Hydrochloride|Given IV
75562620|NCT04110379|Behavioral|Conventional Behavior Management Techniques|Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
75562621|NCT04097652|Biological|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
75562622|NCT04083183|Biological|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given IV
75562623|NCT04083183|Drug|Fludarabine|Given IV
75562624|NCT04083183|Drug|Cyclophosphamide|Given IV
75562625|NCT04083183|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
75417046|NCT03012672|Other|Quality-of-Life Assessment|Ancillary studies
75417047|NCT03012672|Other|Questionnaire Administration|Ancillary studies
75417048|NCT03011775|Drug|Pioglitazone 15 mg Tablet|Pioglar (Ranbaxy India):1 tablet per day in the morning for 6 months
75562626|NCT04083183|Radiation|Total-Body Irradiation|Undergo TBI
75417049|NCT03011775|Drug|Isosorbide Dinitrate 10Mg Tablet|1-2 tablets 2 times a day
75562627|NCT04083183|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
75417050|NCT03011775|Drug|Acetylsalicylic Acid 75Mg Tablet|1 tablet per a day
75562628|NCT04083183|Drug|Mycophenolate Mofetil|Given PO or IV
75417051|NCT03011775|Drug|Bisoprolol Fumarate 2.5 MG Oral Tablet|1 tablet per a day
75717536|NCT00748280|Procedure|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
75717537|NCT00798642|Behavioral|Hypnotherapy|8 weeks of gut-directed hypnotherapy
75717538|NCT00798642|Behavioral|Standard care|8 weeks of standard of care
75717539|NCT00798642|Behavioral|Mind Body Therapy|8 weeks of mind-body therapy
75717540|NCT00325819|Drug|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
75717541|NCT00325819|Other|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
75734988|NCT03329677|Other|Transference-focused Psychotherapy (TFP)|Participants receive 18 months of bi-weekly TFP. Each sessions lasts 45 minutes. During sessions, a therapist employs assorted psychodynamic techniques tailored specially for symptoms and relational difficulties associated with BPD. A participant processes interpersonal experiences with her therapist in sessions alongside her therapist and gains therapeutic insight into her problematic ways of relating to her self and others.
75734989|NCT03320122|Other|Telemedicine|Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.
75734990|NCT03320122|Other|In-Person Pediatric Physiatrist|UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.
75734991|NCT03320122|Other|In-Person Non-Pediatric Physiatrist|A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
75734992|NCT03319745|Biological|Pembrolizumab|Given IV
75417052|NCT03011775|Drug|Rosuvastatin Calcium 20 MG Oral Tablet|1 tablet per a day
75417053|NCT03011775|Drug|Ramipril 5 MG|1 tablet per a day
75417054|NCT03011346|Device|Symetis ACURATE neo/TF transfemoral TAVI system|Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.
75417055|NCT03011346|Device|Edwards Sapien 3 Transcatheter Heart Valve|Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
75417056|NCT03007485|Other|Telehealth Pulmonary Rehabilitation|Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
75562629|NCT04083183|Drug|Sirolimus|Given PO
75562630|NCT04069273|Drug|Pembrolizumab Monotherapy|Pembrolizumab 200 mg IV
75562631|NCT04069273|Drug|Ramucirumab|Ramucirumab 10 mg/kg IV
75562632|NCT04069273|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV
75562633|NCT04060849|Drug|Nozin|Given via nasal single-use popswabs or single-use cotton tipped applicators
75562634|NCT04060849|Other|Best Practice|Receive standard of care
75562635|NCT04052334|Drug|TIL|Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
75562636|NCT04052334|Drug|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
75734993|NCT03309150|Drug|M6620|Participant will either receive M6620 intravenously as a monotherapy on Day 1, 8 and 15 OR as a combination therapy on Day 2 and 9 of the study.
75734994|NCT03309150|Drug|Carboplatin|Participant will receive carboplatin intravenous infusion as a combination therapy on Day 1 of the study.
75417057|NCT02998476|Drug|Parsaclisib|Parsaclisib once daily for 8 weeks followed by once weekly
75417058|NCT02960997|Drug|Sirolimus, 2%|
75562637|NCT04052334|Drug|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
75562638|NCT04052334|Drug|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
75562639|NCT04044794|Behavioral|Standard Care|Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
75562640|NCT04044794|Behavioral|Daily Self-Weighing|Participants will receive a wireless digital scale and will be asked to keep the scale in their home, weigh daily at the same time, and view their weight trajectory on the scale's digital display.
75717542|NCT00801216|Drug|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
75717543|NCT00756782|Drug|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
75717544|NCT00756782|Drug|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
76042924|NCT03827460|Behavioral|Usual drinking|Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
75417059|NCT02960997|Drug|Vehicle|
75417060|NCT02951104|Device|Ultrasonic Cardiac Output Monitor (USCOM) system|
75417061|NCT02947217|Biological|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
75417062|NCT02947217|Other|Sterile Saline|0.5 mL of sterile Saline administered im
75417063|NCT02924480|Procedure|Cystectomy|
75562641|NCT04004416|Other|Placebo and fMRI|A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
75717545|NCT00748358|Drug|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
75417064|NCT02924480|Drug|Lidocaine|Patients will receive lidocaine infusion during surgery
75417065|NCT02924480|Drug|Saline|Patients will receive saline infusion during surgery
75417066|NCT02924064|Drug|Teneligliptin 20mg|
75417067|NCT02924064|Drug|Placebo|
75417068|NCT02924064|Drug|Metformin ≥ 1000 mg|
75417069|NCT02916706|Drug|Teneligliptin 20mg|
75417070|NCT02916706|Drug|Placebo|
75417071|NCT02889900|Drug|cediranib and olaparib|"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"
75417072|NCT02882022|Device|Continuous positive airway pressure|A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
75417073|NCT02879942|Other|Ultrasound study of the placenta|The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
75417074|NCT02879942|Other|Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test|
75417075|NCT02873819|Drug|GL-0817|GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
75417076|NCT02873819|Drug|Hiltonol|Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
75562642|NCT04004416|Drug|Lorazepam and fMRI|A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
75562643|NCT04003363|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
76042925|NCT03779789|Drug|Vortioxetine|"Antidepressant classified under the category other antidepressants according to the ATC/DDD index [ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day)."
75562644|NCT03972202|Diagnostic Test|MRI|Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
75562645|NCT03972202|Device|TMS|Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
75417077|NCT02873819|Drug|Sargramostim|Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
75417078|NCT02873819|Drug|cyclophosphamide|cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
75734995|NCT03309150|Drug|Paclitaxel|Participant will receive paclitaxel intravenous infusion as a combination therapy on Day 1, 8 and 15 of the study.
75417079|NCT02873819|Drug|Placebo|Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
75417080|NCT02866695|Drug|ingenol mebutate gel 0.015%|ingenol mebutate gel 0.015% to be applied on treatment area
75417081|NCT02862964|Other|identify L4/L5|"For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.~The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.~The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure"
75417082|NCT02834793|Drug|Placebo|Participants will receive matching placebo in Randomization phase.
75562646|NCT03972202|Behavioral|Speech-motor behavioral testing|Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
75734996|NCT03302663|Diagnostic Test|MRI scan|Addition of advanced imaging sequences for fetal MRI
75734997|NCT03297060|Other|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
75734998|NCT03296709|Device|PPC z|Installation of a preformed pediatric zircona crown
75734999|NCT03296709|Device|PPC m|Installation of a preformed pediatric metal crown
75735000|NCT03282292|Procedure|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
75735001|NCT03263572|Biological|Blinatumomab|Given IV
75417083|NCT02834793|Drug|Perampanel|Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
75562647|NCT03964116|Other|Questionnaires set all 3 months|"This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview."
75562648|NCT03964090|Drug|TEDD-R|Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
75717546|NCT00751088|Procedure|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
75717547|NCT00751088|Procedure|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
75717548|NCT00751088|Procedure|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
75717549|NCT00751088|Procedure|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
75717550|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
76042926|NCT03779789|Drug|Sertraline|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day)."
75417084|NCT02810457|Drug|FKB238 (bevacizumab)|
75417085|NCT02810457|Drug|Avastin (bevacizumab)|
75417086|NCT02810457|Drug|Paclitaxel|
75417087|NCT02810457|Drug|Carboplatin|
75417088|NCT02803242|Other|Patient Reported Outcomes|
75417089|NCT02745535|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|
75417090|NCT02730312|Biological|XmAb14045|Administered IV weekly up to 8 weeks, with or without step-up dosing
75417091|NCT02729701|Drug|Duavee|Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
75417092|NCT02723305|Other|No intervention|
75417093|NCT02717650|Other|A-STEP|"Study A) Study A) Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).~Feasibility/safety of a newly designed, incremental, maximal, standardised step test in adults with Cystic Fibrosis."
75562649|NCT03964090|Drug|TEDDI-R|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
75562650|NCT03964090|Drug|Ibrutinib|For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4
75562651|NCT03964090|Drug|Cytarabine|Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable
75417094|NCT02717650|Other|A-STEP (New Protocol)|Study B) Validation Study (random allocation of test order). Validity of an incremental, maximal, standardised incremental step test with breath-by-breath gas analysis using portable metabolic measurement equipment against CPET.
75417095|NCT02717650|Other|Comparator: CPET cycle ergometer (Gold Standard)|"Study B) Validation study (random allocation of test order) Gold standard CPET. An incremental, maximal standardised cycle ergometer exercise test (performed as per published protocol) using portable metabolic measurement equipment."
75417096|NCT02684253|Drug|Nivolumab|
75717551|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
75717552|NCT00748436|Drug|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
75717553|NCT00751244|Behavioral|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
75717554|NCT00751244|Behavioral|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
75717555|NCT00751244|Other|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
75717556|NCT00751322|Other|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
75717557|NCT00751322|Other|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
75717558|NCT00756860|Drug|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
75417097|NCT02684253|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
75417098|NCT02683356|Other|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
75417099|NCT02683356|Other|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
75417100|NCT02681406|Behavioral|ACHESS|Smartphone based additions focused application, encouraging social support
75562652|NCT03964090|Drug|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently
75562653|NCT03964090|Drug|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
75562654|NCT03963843|Behavioral|Guided ICBT|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
75717559|NCT00756860|Drug|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
75417101|NCT02681406|Behavioral|TMC|Brief telephone monitoring and counseling
75417102|NCT02666794|Drug|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
75735002|NCT03263572|Drug|Cytarabine|Given intrathecally via spinal tap
75717560|NCT00757016|Drug|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
75717561|NCT00757016|Drug|Saline solution|Saline solution
75417103|NCT02666794|Drug|Epidural sufentanil|20 mcg
75417104|NCT02666794|Procedure|Placement of the epidural catheter|Placement of the epidural catheter
75417105|NCT02666794|Drug|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
75417106|NCT02666794|Drug|Intrathecal morphine|60 mcg
75417107|NCT02666794|Procedure|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
75417108|NCT02666794|Drug|Intrathecal sufentanil|5 mcg
75562655|NCT03963843|Other|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
75417109|NCT02656550|Procedure|Uterine Transplant|Transplant of a uterus from either a living donor or a deceased donor.,
75417110|NCT02655055|Procedure|high frequency voluntary apheresis blood donation|
75417111|NCT02625090|Drug|UCB0942|"Active Substance: UCB0942~Pharmaceutical form: Film-coated tablet~Concentration: 25 mg, 100 mg or 200 mg~Route of Administration: oral"
75417112|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
75417113|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
75417114|NCT02619552|Drug|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
75417115|NCT02612038|Device|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
75417116|NCT02612038|Device|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
75417117|NCT02598492|Other|arterial blood gas|Just record clinical lab data
75417118|NCT02573376|Behavioral|Directly Observed Therapy|
75417119|NCT02573376|Behavioral|Wirelessly Observed Therapy|
75717562|NCT00687362|Biological|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
75717563|NCT00757250|Drug|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
75717564|NCT00751478|Drug|ALO-01|ALO-01 capsules
75717565|NCT00751478|Drug|MSIR|immediate release morphine sulfate
75717566|NCT00751478|Drug|Placebo|Placebo
75717567|NCT00751556|Drug|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
75717568|NCT00751556|Drug|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
75717569|NCT00748592|Drug|Placebo|Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
75717570|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
75717571|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
75717572|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
75717573|NCT00748670|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
75717574|NCT00757640|Procedure|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
75417120|NCT02566018|Procedure|treatment/medical device|The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards
75417121|NCT02566018|Procedure|standard|The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
75417122|NCT02563691|Radiation|stereotactic radiotherapy|"Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.~The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT."
75417123|NCT02556450|Drug|Spironolacton|Administration of Spironolacton 25 mg per day
75417124|NCT02539225|Drug|Ramucirumab|Administered IV
75417125|NCT02539225|Drug|Placebo|Administered IV
75417126|NCT02539225|Drug|S-1|Administered PO
75717575|NCT00325195|Other|placebo|placebo by intravenous infusion every 2 weeks
75717576|NCT00325195|Biological|pegloticase|8 mg pegloticase by intravenous infusion
75717577|NCT02562560|Behavioral|Neuropsychological tests|
75717578|NCT02562560|Device|Cerebral imaging (MRI, PET-FDG)|
75717579|NCT03976401|Drug|EFX|Administered by subcutaneous injection
75717580|NCT03976401|Drug|Placebo|Administered by subcutaneous injection
76042927|NCT03779789|Drug|citalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day)."
75717581|NCT00757718|Device|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
75717582|NCT00757718|Device|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
75417127|NCT02539225|Drug|Oxaliplatin|Administered IV
75417128|NCT02539225|Drug|Paclitaxel|Administered IV
75417129|NCT02535650|Drug|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
75417130|NCT02526017|Biological|Cabiralizumab|Solution for IV administration
75417131|NCT02526017|Biological|Nivolumab|Solution for IV administration
75417132|NCT02516657|Drug|Liraglutide|Liraglutide 0.6 mg
75417133|NCT02479919|Device|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
75417134|NCT02479919|Device|Magstim® Sham TBS|Sham stimulation
75717583|NCT00748748|Biological|Culturelle|10^10 Lactobacillus rhamnosus GG per capsule
75717584|NCT02532907|Procedure|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
75735003|NCT03263572|Drug|Methotrexate|Given intrathecally via spinal tap
75735004|NCT03263572|Drug|Ponatinib|Given PO
75735005|NCT03243058|Biological|ILT-101 (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin-2 (ILT-101) for two years
76042928|NCT03779789|Drug|Escitalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day)."
75417135|NCT02459067|Biological|ImmuniCell®|Autologous γδ T Lymphocytes
75417136|NCT02427581|Biological|Personalized synthetic long peptide vaccine (Poly ICLC)|
75417137|NCT02427581|Drug|Poly ICLC|
75717585|NCT00751712|Device|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
75717586|NCT00938847|Device|PCI|Stent implantation after acute myocardial infarction
75717587|NCT02562638|Other|Non-fasting|Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
75717588|NCT04013607|Dietary Supplement|fructo- and galacto-oligosaccharides|A NDC drink rich in fructo- and galacto-oligosaccharides
76042929|NCT03779789|Drug|Paroxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day)."
76042930|NCT03779789|Drug|Fluoxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day)."
76042931|NCT03779789|Drug|Fluvoxamine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day)."
75417138|NCT02423525|Drug|Afatinib|
76042932|NCT03737539|Diagnostic Test|Multigene methylation detection|Colorectal tumor-specific plasma ctDNA methylation markers detection
75417139|NCT02417415|Other|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at ~44ºC continuously for 2 hr.
75417140|NCT02417415|Other|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
75417141|NCT02369653|Drug|Apixaban|
75417142|NCT02369653|Other|No systemic anticoagulant prophylaxis|
75417143|NCT02356861|Device|Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on|"The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec"
75417144|NCT02333708|Other|Blood sample|
75417145|NCT02293109|Drug|carfilzomib|Given IV
75417146|NCT02293109|Drug|cyclophosphamide|Given IV
75417147|NCT02293109|Drug|vincristine sulfate|Given IV
75417148|NCT02293109|Drug|doxorubicin hydrochloride|Given IV
75417149|NCT02293109|Drug|dexamethasone|Given PO
75417150|NCT02293109|Drug|methotrexate|Given IV
75417151|NCT02293109|Drug|cytarabine|Given IV
75562656|NCT03947515|Procedure|prostate biopsy|All patients included, will report to the urology department on the date previously agreed with the surgeon. The patient will be seen by the nurse and urologist on duty as part of outpatient care or, more rarely, in ambulatory care. After verification of the patient's identity, the signature of informed consent, the absence of immediate contraindications to biopsy (haemorrhagic and infectious) and the patient's proper preparation (antibiotic prophylaxis and possible enema), the patient will be installed for the taking of samples covered by the protocol (rectal swabbing and prostate biopsies, see paragraph IX). If the patient has not taken the antibiotic prophylaxis or performed the enema, he or she will be reconvened at a later date for the biopsies. After the prostatic biopsies have been performed, the patient's participation in the study ends and his follow-up resumes according to the recommendations adapted to his pathology.
75562657|NCT03947515|Other|Urinary sampling|It will be collected after the prostate massage performed by the surgeon in charge of the patient during his clinical examination for prostate cancer screening. After elimination of the first draft, the urine will be collected in 2 tubes with borated preservative
75562658|NCT03947515|Other|Rectal swabbing before biopsies are performed|A rectal swab will then be taken by the urologist on the day the prostate biopsies are taken. The analysis of the digestive microbiota will eliminate contamination of prostate biopsies by bacteria from the faecal flora during transrectal sampling
75562659|NCT03933202|Drug|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
75417152|NCT02293109|Drug|leucovorin calcium|Given IV or PO
75562660|NCT03906422|Device|3M Unitek 0.016 orthodontic archwire|Placement of 3M Unitek 0.016 archwire for orthodontic treatment
75417153|NCT02293109|Drug|methylprednisolone|Given IV
75717589|NCT04875156|Other|measurement of range of motion and strength|measurement of range of motion (goniometer) and strength (dynamometer) of the metacarpophalangeal joint of the thumb
75717590|NCT00685334|Drug|Olanzapine|Participants will take olanzapine daily for 12 weeks.
75717591|NCT00685334|Drug|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
76042933|NCT03733210|Drug|Panitumumab-IRDye800|30 mg administered intravenously (IV)
75562661|NCT03906422|Device|"Device: 0.016 Ormco 27oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 27oC NiTi orthodontic archwire"
75562662|NCT03906422|Device|"Device: 0.016 Ormco 35oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 35oC NiTi orthodontic archwire"
75562663|NCT03906175|Device|Whole-body hyperthermia|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
76042934|NCT03733210|Drug|89-Zirconium (Zr-89) Panitumumab|0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
76042935|NCT03733210|Device|Pinpoint IR IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
76042936|NCT03733210|Device|SPY-PHI IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
76042937|NCT03733210|Device|Explorer Air camera|Fluorescence camera manufactured by SurgVision
75417154|NCT02293109|Biological|rituximab|
75417155|NCT02293109|Other|laboratory biomarker analysis|Correlative studies
75417156|NCT02284568|Drug|Placebo|Placebo
75417157|NCT02284568|Drug|Laquinimod|Laquinimod capsules in 0.5 mg and 0.6 mg strengths
75417158|NCT02284568|Drug|Placebo|Placebo capsules
75417159|NCT02228525|Drug|selinexor (KPT-330)|
75562664|NCT03871361|Drug|Abatacept 125 MG/ML Prefilled Syringe|Abatacept 125 MG/ML Prefilled Syringe [Orencia] weekly
75562665|NCT03870334|Drug|BT-11 880 mg|Oral once daily tablet
75562666|NCT03870334|Drug|Placebo|Oral once daily tablet
75562667|NCT03799718|Biological|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
75562668|NCT03795701|Drug|Saxenda®|Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
75562669|NCT03795701|Other|Placebo|Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
75562670|NCT03786471|Other|Health System-based Dementia Care|Active comparator
75417160|NCT02195986|Drug|Estradiol Vaginal Cream, 0.01%|Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
75417161|NCT02195986|Drug|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
75417162|NCT02195986|Drug|Placebo Vaginal Cream|Placebo Vaginal Cream ( 1 x 2 g for 7 days)
75417163|NCT02078206|Other|Neurocognitive stimulation|
75441657|NCT01636999|Drug|50% Nitrous Oxide/50% Oxygen|The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
75441658|NCT01637012|Procedure|Implantation|index angioplasty with ALEX stent implatation
76042938|NCT03733210|Device|PDE-NEO II camera|Medical infrared camera manufactured by Hamamatsu Photonics KK
76042939|NCT03733210|Device|FIS-00 fluorescence imaging system (FIS)|Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
75562671|NCT03786471|Other|Community-based Dementia Care|Active comparator
75562672|NCT03786471|Other|Usual Care|Control
75562673|NCT03781791|Drug|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
75717592|NCT00325039|Procedure|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
75717593|NCT00325039|Procedure|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
75717594|NCT00801294|Drug|BIBF 1120 and BIBW 2992|
75717595|NCT04013919|Drug|Multiple Daily Injections of Insulin|Basal/ Bolus insulin injections
75417164|NCT02061319|Behavioral|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
76042940|NCT03733210|Device|Da Vinci Firefly Imaging System|Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
76042941|NCT03733210|Device|IGP-ELVIS-v4 Macroscopic Specimen Imager|Macroscopic specimen imager manufactured by LI-COR Biosciences
76042942|NCT03733210|Device|Vevo 3100 LAZR-X|Photoacoustic ultrasound imaging system manufactured by VisualSonics
75441659|NCT01637025|Device|Oxidized cellulose strip|Single use, intra-operative application to the target bleeding site
75441660|NCT01637025|Device|Oxidized regenerated cellulose strip|A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
75441661|NCT01637038|Other|RIPC|Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
75441662|NCT01637064|Drug|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
75717596|NCT04013919|Drug|Single insulin injections|Basal insulin injections only
75717597|NCT00938925|Procedure|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
75717598|NCT00938925|Procedure|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
75735006|NCT03243058|Other|Treatment-Placebo Arm|Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.
75735007|NCT03243058|Other|Placebo Arm|Participants in this group will receive a placebo injection for two years.
76042943|NCT03733210|Device|Pearl Triology Imaging System|Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
76042944|NCT03733210|Device|Odyssey CLx Imaging System|Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
76042945|NCT03733210|Device|Leica fluorescence microscope|Fluorescence microscope manufactured by Leica
76042946|NCT03733132|Drug|Metformin Hydrochloride|Metformin treatment of 2500mg for 10 months in the Metformin group
75562674|NCT03781791|Drug|Placebo Treatment|Placebo will be administered in tablet form, once daily.
75562675|NCT03776643|Drug|ILT-101 ld-(IL2)|Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
75562676|NCT03775187|Biological|Burosumab|
75562677|NCT03775174|Drug|Mepsevii|
75562678|NCT03773770|Drug|Triheptanoin|Liquid for oral (PO) or enteral tube administration
76042947|NCT03733132|Drug|Placebo Oral Tablet|Placebo treatment of identical tablets to metformin group
76042948|NCT03667820|Drug|Osimertinib|Osimertinib 80mg tablet to be taken once daily.
76042949|NCT03667820|Radiation|SABR|Stereotactic Ablative Radiation (SABR)
76042950|NCT03648840|Behavioral|Aversive cue|Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol
76042951|NCT03648840|Behavioral|Neutral cue|Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
76042952|NCT03635073|Drug|Soticlestat|Soticlestat tablets or mini-tablets.
76042953|NCT03627468|Drug|Sofpironium Bromide Gel, 5%|Sofpironium Bromide Gel, 5%
75417165|NCT02027948|Other|nutritional and functional assessments|"Patients will undergo nutritional & functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, & baseline weight loss. Patients will receive chemotherapy & radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) & radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, & post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, & Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished & receive the appropriate intervention."
75417166|NCT02013297|Radiation|SBRT treatment|"For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy."
76042954|NCT03627468|Drug|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
75417167|NCT02000635|Other|Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day|
75417168|NCT01987973|Procedure|Partial Rotator Cuff Repair|This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
75417169|NCT01987973|Procedure|Partial Rotator Cuff Repair with Allograft Augmentation|Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
75417170|NCT01982630|Drug|MK-8521|
75417171|NCT01982630|Drug|Liraglutide|
75417172|NCT01982630|Drug|Placebo|
75417173|NCT01951469|Drug|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) or Pemetrexed (D1) + nedaplatin (D1) chemotherapy, every 28 days
75417174|NCT01951469|Drug|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
75417175|NCT01940809|Drug|Dabrafenib|Given PO
75417176|NCT01940809|Biological|Ipilimumab|Given IV
75735008|NCT03235544|Drug|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food.
76042955|NCT03613116|Dietary Supplement|Vitamin D3|One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
76042956|NCT03595176|Device|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
75735009|NCT03228940|Drug|RVX000222|oral, BID
75417177|NCT01940809|Other|Laboratory Biomarker Analysis|Correlative studies
75417178|NCT01940809|Biological|Nivolumab|Given IV
75417179|NCT01940809|Drug|Trametinib|Given PO
75735010|NCT03217305|Device|NAVA|Neurally Adjusted Ventilatory Assist is a fairly new ventilation mode
76042957|NCT03588039|Drug|Oraxol|Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
76042958|NCT03588039|Biological|Pembrolizumab|Intravenously administered
75717599|NCT04864548|Biological|SARS-CoV-2 virus|The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
75562679|NCT03763838|Other|Acupressure|Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
75562680|NCT03763838|Other|Sham acupressure|Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.
75562681|NCT03763838|Other|Standard of Care|Fatigue management provided by participants' health care providers.
75717600|NCT03743181|Other|pharmaceutical care services|detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
75717601|NCT04045938|Other|Low Glycemic Index or Glycemic Load|Dietary pattern focused on low glycemic index foods or on a low glycemic load
76042959|NCT03570021|Procedure|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|"total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].~- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection [Hartl DM, Ann Surg 2012], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons [Hartl DM, World J Surg 2012]."
75417180|NCT01937247|Procedure|Patients will be inducted in the induction room|The patients will be inducted in the induction room
75417181|NCT01937247|Procedure|Redesigned process|The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room
75417182|NCT01937247|Drug|patient will be reversed with sugammadex 4mg/kg IV|The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR
75417183|NCT01937247|Procedure|STANDARD PROCESS|standard process
75417184|NCT01879228|Drug|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
75417185|NCT01879228|Drug|Placebo|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
75441663|NCT01637103|Behavioral|Cognitive therapy of depression|Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
75562682|NCT03749499|Other|HTN Educational Video|The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.
75562683|NCT03749499|Other|Visual Echocardiogram Image Clips|Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.
75562684|NCT03749499|Other|Mobile Health and Remote BP monitoring|All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
75717602|NCT00344461|Drug|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
75717603|NCT00939081|Behavioral|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
75735011|NCT03196011|Other|TKR with mechanical alignment method|TKR implanted using traditional mechanical alignment methods
75735012|NCT03196011|Other|TKR with alternative alignment method|TKR implanted using alternative alignment methods
75735013|NCT03191760|Behavioral|Behavioral Activation|Participants will be asked to attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
76042960|NCT03570021|Procedure|total thyroidectomy alone without neck dissection|This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
76042961|NCT03553004|Drug|Niraparib Treatment|Niraparib treatment by mouth (oral)
75417186|NCT01813370|Other|No intervention|No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
75417187|NCT01779557|Drug|Huaren Peritoneal Dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
75417188|NCT01779557|Drug|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
75417189|NCT01740297|Drug|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
75417190|NCT01740297|Drug|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
75417191|NCT01738009|Other|Induction of flow limitation|
75717604|NCT00939081|Behavioral|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
75717605|NCT00685178|Drug|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"
76042962|NCT03488667|Drug|Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
75417192|NCT01729754|Drug|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
75417193|NCT01729754|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
75417194|NCT01729754|Drug|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
75417195|NCT01729754|Drug|Etanercept Placebo|Matching placebo to etanercept administered SC
75417196|NCT01729754|Drug|Etanercept 50 mg|Etanercept 50 mg administered SC
75417197|NCT01658683|Behavioral|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
75417198|NCT01622998|Drug|NicoDerm Patch|"Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable."
75417199|NCT01622998|Drug|Nicorette Inhaler|Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
75417200|NCT01599741|Radiation|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
75417201|NCT01599741|Radiation|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
75417202|NCT01597583|Behavioral|Use of MobileMedMinder|Use of an intervention to remind patients to take their medications.
75417203|NCT01595620|Other|Thermal|Thermal sensation/pain testing
75417204|NCT01595620|Other|Electrical|Electrical sensation/pain testing
75717606|NCT00685178|Behavioral|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
76042963|NCT03488667|Drug|Adjuvant Treatment - mFOLFOX & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
76042964|NCT03416959|Procedure|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment for long bone metastases with intramedullary nail or endoprosthetic reconstruction
75417205|NCT01595620|Other|Capsaicin|Intradermal Capsaicin
75417206|NCT01595620|Drug|THC|Active THC (0.01 mg/kg) administered over 10 minutes
75417207|NCT01595620|Drug|THC|Active THC (0.03 mg/kg) administered over 10 minutes
75562685|NCT03749499|Other|Post-Acute Care HTN Transition consultation (PACHT-c)|All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
75417208|NCT01595620|Drug|Placebo|Control: small amount of alcohol with no THC, administered over 10 minutes
75417209|NCT01593852|Radiation|Advanced image processing|Acquisition of x-ray images with reduced X-ray dose and advanced image processing
75417210|NCT01593852|Radiation|Regular image processing|Acquisition of x-ray images with regular X-ray dose and regular image processing
75417211|NCT01591629|Drug|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
75417212|NCT01591629|Drug|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
76042965|NCT03406247|Drug|Nivolumab|"Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~- nivolumab 240 mg every 2 weeks during 6 months"
75562686|NCT03744871|Other|N95 Respirator|SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
75562687|NCT03735212|Behavioral|Enhanced Services|Participants receive enhanced services over a period of 6 months to support substance abuse recovery, referral to treatment, and parenting skills.
75417213|NCT01591629|Drug|Placebo|Placebo
75417214|NCT01536275|Other|Late parenteral nutrition|Withholding parenteral nutrition during the first 7 days of ICU stay
75562688|NCT03733067|Drug|abatacept|Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.
75562689|NCT03733067|Other|Placebo|Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
75562690|NCT03729544|Behavioral|On-screen computerized decision support alert|On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
75562691|NCT03711929|Drug|DE-109 Intravitreal Injections|440 ug of DE-109 Injectable Solution
75562692|NCT03711929|Other|Sham Procedure|The sham procedure mimics an intravitreal injection without penetrating the eye.
75562693|NCT03711929|Drug|DE-109 Intravitreal Injections|Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
75417215|NCT01515306|Biological|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
75417216|NCT01515306|Drug|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
75417217|NCT01515098|Dietary Supplement|Freeze-dried blueberries|Wild blueberries, freeze-dried and pulverized
75417218|NCT01515098|Dietary Supplement|Dextrose Placebo|Placebo developed to closely match blueberry powder.
75417219|NCT01513187|Drug|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
75417220|NCT01433965|Drug|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
75417221|NCT01431157|Procedure|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
75562694|NCT03711929|Drug|DE-109 Intravitreal Injections (Open Label)|After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
75717607|NCT00685178|Drug|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
75717608|NCT00537394|Drug|Enfuvirtide|90mg subcutaneously twice daily
75717609|NCT00537394|Drug|Raltegravir|400 mg twice daily
75417222|NCT01431157|Other|No nasal oxygen|Patients will have no intervention for sleep apnea
75417223|NCT01423851|Drug|NS-018|Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
75441664|NCT01637103|Behavioral|Bright light therapy|Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
75417224|NCT01360593|Drug|Gemcitabine|"Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles."
75417225|NCT01360593|Drug|Capecitabine|"Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles."
75417226|NCT01360593|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day."
75417227|NCT01354977|Drug|Resveratrol|1,000mg twice daily for 28 days
75417228|NCT01334606|Device|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
75417229|NCT01334606|Device|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
76042966|NCT03406247|Drug|Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~- ipilimumab 1mg/kg IV every 6 weeks during 6 months"
75562695|NCT03697980|Device|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
75562696|NCT03664895|Drug|Leuplin or zoladex|OFS(Leuplin or zoladex) add on to TMX
75562697|NCT03658395|Procedure|Laparoscopic Sacrocolopopexy|The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
75562698|NCT03658395|Procedure|Posterior repair|The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
76042967|NCT03399175|Drug|Early high-dose corticosteroid and immunosuppressive therapy|Early high-dose corticosteroid and immunosuppressive therapy
75417230|NCT01317875|Drug|Ruxolitinib|"Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)~Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count"
75562699|NCT03631420|Biological|Human Umbilical Cord Derived-Mesenchymal Stem Cells|Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
75562700|NCT03599544|Behavioral|Robot-Assisted Therapy (RT)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
76042968|NCT03317535|Procedure|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
76042969|NCT03317535|Procedure|Local anesthesia/concious sedation|Patients will be injected with propofol and remifentanil.
76042970|NCT03317535|Procedure|Spontaneous breath|Patients will be kept spontaneous breath.
75417231|NCT01226732|Drug|Capecitabine|Taken orally twice daily on Days 1 through 14 of 21 day cycle.
75417232|NCT01226732|Drug|Hsp90 Inhibitor AUY 922|IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
75417233|NCT01003496|Behavioral|Treatment as Usual (TAU)|Outpatient substance abuse treatment
75441665|NCT01637129|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation, repetitive at 1Hz
75441666|NCT01637129|Device|Sham Magnetic Stimulation|Sham Magnetic Stimulation
75417234|NCT01003496|Behavioral|TAU + Long-Term Recovery Management|Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
75417235|NCT00962988|Drug|Cost-Free Pharmacotherapy Group|"Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months."
75562701|NCT03599544|Behavioral|Robot + Active Learning Program(RT-ALPS)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
75717610|NCT00537394|Drug|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
75417236|NCT00962988|Other|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
75717611|NCT00537394|Drug|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
75417237|NCT00949312|Genetic|RNA marker analysis of lymph node and primary tumors|
75417238|NCT00949312|Genetic|microarray profiling of primary tumors|
75417239|NCT00949312|Genetic|reverse transcriptase-polymerase chain reaction of lymph node specimens|
75417240|NCT00949312|Other|diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|
75562702|NCT03592368|Device|IBT|Interpretation bias training
75717612|NCT00537394|Drug|Etravirine|Two 100-mg tablets twice daily
75717613|NCT00537394|Drug|Maraviroc|Dosage dependent on regimen in which maraviroc is included
75717614|NCT00793494|Other|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
75717615|NCT00793494|Other|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
75717616|NCT03187977|Behavioral|Cognitive training|Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
75717617|NCT03986359|Device|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
75417241|NCT00949312|Procedure|regional lymph node dissection|
75417242|NCT00949312|Other|lymph node staining for H&E and pancytokeratin IHC|
75417243|NCT00828308|Drug|Ixabepilone|Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
75417244|NCT00828308|Procedure|Prostatectomy|Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study**
75417245|NCT00824252|Behavioral|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
75417246|NCT00768820|Drug|methylphenidate, fluoxetin, risperidone|first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
75417247|NCT00678730|Drug|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
75417248|NCT00654264|Procedure|Water immersion|Subjects will sit in tub for four hours.
75873650|NCT05221788|Procedure|Goal-directed hemodynamic therapy|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased >10%, 200 ml of electrolyte solution was continued until SV increased <10%. After fluid shock, if SV increases <10% but mean arterial pressure (MAP) <65 mmHg and/or cardiac index (CI) <2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output <0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
75873651|NCT05178654|Drug|[14C]PF-07321332|Single oral dose of 300 mg [14C]PF-07321332 containing approximately 100 µCi [14C]PF-07321332 coadministered with 100 mg ritonavir.
75873652|NCT04108962|Drug|Fasenra, 30 Mg/mL Subcutaneous Solution|Anti-IL5 receptor alpha monoclonal antibody
75873653|NCT04015362|Procedure|Sub-threshold intermittent pulsed magnetic stimulation|Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord
75417249|NCT00600015|Drug|Erlotinib + Sorafenib|Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
75417250|NCT00600015|Drug|Erlotinib + Placebo|Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
75417251|NCT00500071|Drug|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
75417252|NCT00447122|Drug|Gemcitabine 1000mg/m2 30 minutes|1000mg/m2 30 minutes
75417253|NCT00447122|Drug|Lapatinib 1000mg/d|1000mg/d
75417254|NCT00447122|Drug|Lapatinib 1500mg/d|1500mg/d
75562703|NCT03559413|Biological|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod|Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
75717618|NCT02554110|Device|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
75717619|NCT02554110|Device|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
75717620|NCT00933309|Drug|Exemestane|25 mg tablets orally once a day
75417255|NCT00447122|Drug|Gemcitabine 1000mg/m2 100minutes|1000mg/m2 100minutes
75417256|NCT00447122|Drug|Oxaliplatin 100mg/m2|100mg/m2
75417257|NCT00430040|Drug|carvedilol|carvedilol
75417258|NCT00430040|Drug|lisinopril|lisinopril
75417259|NCT00382252|Procedure|computed tomography|
75417260|NCT00382252|Procedure|positron emission tomography|
75417261|NCT00382252|Procedure|radiofrequency ablation|
75417262|NCT00290251|Drug|ulipristal acetate 20 mg|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
75417263|NCT00290251|Drug|ulipristal acetate 10 mg|10 mg given daily for three menstrual cycles or 90 - 102 days
75417264|NCT00290251|Drug|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
75417265|NCT00133835|Procedure|Extracorporeal shock wave lithotripsy|
75417266|NCT00133835|Procedure|Endoscopic drainage of the main pancreatic duct|
75417267|NCT00066963|Device|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
75562704|NCT03546335|Drug|89Zr-DFO-CZP|89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
75562705|NCT03495427|Drug|F-DCFPyL Injection|F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.
75562706|NCT03495427|Diagnostic Test|PSMA PET|PSMA PET imaging (for men with high GC >0.45) will be done after 2 years post-treatment, then yearly up to 5 years.
75562707|NCT03467867|Drug|Venetoclax|Venetoclax will be administered as described in the reporting arm.
75562708|NCT03467867|Drug|Rituximab|Rituximab (IV) will be administered as described in the reporting arm.
75562709|NCT03467867|Drug|Rituximab/Hyaluronidase Human|Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
75562710|NCT03458728|Drug|Copanlisib (BAY806946)|Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
75562711|NCT03432806|Other|blood draws|Patients will have 10 mL of peripheral venous blood drawn immediately prior to surgery, in the post anesthesia care unit (PACU), and at the first postoperative clinic visit for a total of 30 mL.
75562712|NCT03432806|Procedure|colectomy or hepatectomy|"Three small pieces of otherwise normal-appearing liver of 0.5-1 cm3 collected intraoperatively from patients in all four groups (including Group D). Because liver biopsy is less frequently performed during operations for benign colon lesions or Stage I-III colon cancers, this single aspect of the protocol can be made optional at the discretion of the surgical attending or the patient, however bloods and tissue from pathology will still be collected."
75562713|NCT03432806|Diagnostic Test|Fibroscan test|This may be done either at a preoperative clinic setting or immediately prior to surgery.
75562714|NCT03352765|Drug|rituximab|rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
75562715|NCT03352765|Drug|bendamustine|bendamustine 160 mg/m2 intravenously on days -3 and -2
75717621|NCT00933309|Drug|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
75717622|NCT00352885|Drug|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
75717623|NCT00352885|Drug|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
75562716|NCT03352765|Drug|melphalan|melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
75562717|NCT03352765|Procedure|Autologous Stem Cell Transplantation (ASCT)|reinfusion of autologous stem cells on day 0.
75562718|NCT03289923|Device|Sham TMS + Cognitive therapy|Placebo Transcranial Magnetic Stimulation with cognitive therapy
75717624|NCT00352885|Drug|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
75873654|NCT04015362|Procedure|Sham|Application of sham magnetic stimulation to spinal cord
76042971|NCT03317535|Procedure|Controlled ventilation|Patient will be kept with controlled ventilation.
75562719|NCT03289923|Device|Active TMS + Cognitive therapy|Active Transcranial Magnetic Stimulation with cognitive therapy.
75562720|NCT03271372|Drug|Avelumab|Given IV
75417268|NCT01397487|Procedure|Blastomere biopsy|The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
75562721|NCT03271372|Other|Peripheral Blood Collection|Correlative studies
75562722|NCT03271372|Other|Placebo|Given IV
75562723|NCT03252249|Other|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
75562724|NCT03252249|Other|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
75417269|NCT01397500|Drug|Genotropin|Genotropin administered sc once a day by patient or caregiver.
75562725|NCT03241732|Other|Anti-inflammatory Diet|Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
75417270|NCT01397500|Drug|Testosterone undecannoate|Testosterone undecannoate administered twice (6 week Interval) im by investigator.
75417271|NCT01397513|Drug|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
75562726|NCT03241732|Dietary Supplement|N-acetyl Cysteine|Intravenous and Oral n-acetyl cysteine
75562727|NCT03241732|Behavioral|Neuro Emotive Technique|Neuro Emotive Technique sessions
75873655|NCT05221710|Behavioral|electroacupuncture|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group."
75873656|NCT04002102|Other|OLP treatment|Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.
75417272|NCT01397539|Drug|BIIB037|Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
75417273|NCT01397539|Other|Placebo|Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
75417274|NCT01397565|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
75417275|NCT01397565|Procedure|Minilaparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using minilaparoscopic instruments
75562728|NCT03220035|Other|Laboratory Biomarker Analysis|Correlative studies
75562729|NCT03220035|Drug|Vemurafenib|Given PO
75562730|NCT03215706|Biological|Ipilimumab|Specified dose on specified day
75562731|NCT03215706|Biological|Nivolumab|Specified dose on specified day
75562732|NCT03215706|Drug|Carboplatin|Specified dose on specified day
75562733|NCT03215706|Drug|Paclitaxel|Specified dose on specified day
75562734|NCT03215706|Drug|Pemetrexed|Specified dose on specified day
75562735|NCT03215706|Drug|Cisplatin|Specified dose on specified day
75417276|NCT01397604|Drug|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
75417277|NCT01397604|Drug|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
75562736|NCT03214354|Drug|Alemtuzumab|Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
75562737|NCT03214354|Radiation|Total Body Irradiation|TBI 300 cGy on Day -2
75562738|NCT03214354|Drug|Sirolimus|Sirolimus is used for GVHD prophylaxis
75562739|NCT03213691|Other|Laboratory Biomarker Analysis|Correlative studies
75562740|NCT03213691|Drug|Selumetinib|Given PO
75562741|NCT03213691|Drug|Selumetinib Sulfate|Given PO
75562742|NCT03213665|Drug|Tazemetostat|Given PO
75562743|NCT03184038|Procedure|Cognitive Assessment|Undergo assessment of neurocognitive function
75562744|NCT03184038|Radiation|Stereotactic Radiosurgery|Undergo SRS
75562745|NCT03184038|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75562746|NCT03184038|Other|Quality-of-Life Assessment|Ancillary studies
75562747|NCT03177460|Biological|Daratumumab|Given IV
75562748|NCT03177460|Drug|FMS Inhibitor JNJ-40346527|Given PO
75562749|NCT03177460|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
75562750|NCT03151005|Drug|Metformin-GLP-1 Receptor Agonist|metformin oral with exenatide/liraglutide subcutaneous injection.
75562751|NCT03151005|Drug|Metformin-Oral Contraceptive(OC)|metformin with Diane 35 oral intake.
75562752|NCT03143153|Biological|Nivolumab|Specified dose on specified days
75562753|NCT03143153|Biological|Ipilimumab|Specified dose on specified days
75562754|NCT03143153|Drug|Cisplatin|Specified dose on specified days
75562755|NCT03143153|Drug|Fluorouracil|Specified dose on specified days
75562756|NCT03106779|Drug|Asciminib|40 mg tablets was taken orally twice a day (BID)
75562757|NCT03106779|Drug|Bosutinib|500 mg tablets was taken orally once daily (QD)
75417278|NCT01397604|Other|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
75417279|NCT01397630|Drug|Oxytocin|Accelerated Oxytocin Titration
75562758|NCT03084757|Diagnostic Test|research of druggable molecular alterations on tumor biopsy|The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations
75562759|NCT03076242|Other|GEM Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
75562760|NCT02979574|Procedure|Electro-Acupuncture (EA)|Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.
75417280|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
75417281|NCT01397643|Other|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
75417282|NCT01397708|Biological|INXN-2001|"approximately 1.0 x 1012 viral particles (vp) per injection~one intratumoral injection of INXN-2001 per study cycle~maximum of 6 study cycles"
75562761|NCT02979574|Procedure|Battle Field Acupuncture (BFA)|Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.
75562762|NCT02979574|Device|Wait List Control (WLC)|After the waiting period (12 weeks from randomization), participants in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
75562763|NCT02927392|Drug|Leuprolide acetate|A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
75562764|NCT02914067|Other|Neurocognitive testing|
75562765|NCT02914067|Device|rsfcMRI|The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross
75562766|NCT02902757|Procedure|Computed Tomography|Undergo FDG PET/CT
75562767|NCT02902757|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
75873657|NCT04002102|Other|Usual care|Remain in standard care after randomization and educational materials.
75873658|NCT04002102|Other|Expectancy Group|Educational materials and positive expectancy orientation via Zoom or telephone
75417283|NCT01397708|Drug|INXN-1001|"4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~7 oral daily doses of INXN-1001 per study cycle~maximum of 6 study cycles~1 Expansion cohort at a single dose level at or below MTD (160mg/day)"
75417284|NCT01397734|Drug|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
75562768|NCT02902757|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
75562769|NCT02872116|Drug|Nivolumab|Specified dose on specified days
75562770|NCT02872116|Drug|Ipilimumab|Specified dose on specified days
75562771|NCT02872116|Drug|Oxaliplatin|Specified dose on specified days
75562772|NCT02872116|Drug|Capecitabine|Specified dose on specified days
75417285|NCT01397799|Drug|KX2-391|Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
75417286|NCT01397812|Device|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
75417287|NCT01397812|Device|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
75417288|NCT01397838|Drug|Pro-Bone|500 mg Capsules of Pro-Bone twice daily
75562773|NCT02872116|Drug|Leucovorin|Specified dose on specified days
75562774|NCT02872116|Drug|Fluorouracil|Specified dose on specified days
75562775|NCT02867384|Drug|Obinutuzumab|B cell depletion
75562776|NCT02867384|Drug|Placebo|Placebo
75562777|NCT02859337|Drug|UPA-ECx1|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
75562778|NCT02859337|Drug|UPA-ECx2|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
75562779|NCT02852486|Drug|Pioglitazone 30 Mg Oral Tablet|30 mg/day, orally, for 3 months, before imatinib discontinuation
75562780|NCT02852486|Other|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
75562781|NCT02828358|Drug|Azacitidine|Given IV
75562782|NCT02828358|Drug|Cyclophosphamide|Given IV
75562783|NCT02828358|Drug|Cytarabine|Given IV, SC, IT
75562784|NCT02828358|Drug|Daunorubicin|Given IV
75562785|NCT02828358|Drug|Daunorubicin Hydrochloride|Given IV
75562786|NCT02828358|Drug|Dexamethasone|Given PO, NG, IV
75717625|NCT00933387|Drug|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
75873659|NCT04989582|Other|The trauma recovery nursing intervention program|The trauma recovery nursing intervention program was for adults who had experienced trauma and consisted of eight sessions, each lasting 30 min. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-help guidelines for clients to develop their mental and physical well-being.
75417289|NCT01397864|Drug|rhC1INH or pdC1INH|C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
75417290|NCT01397942|Other|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
75417291|NCT01397955|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
75417292|NCT01397981|Behavioral|Gait retraining|Changing the kinematics of walking
75417293|NCT01397994|Drug|Nicorandil|Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
75417294|NCT01397994|Drug|Atenolol|Patients in the control arm would be advised atenolol 50 mg od
75417295|NCT01398007|Procedure|Camouflage syringe|Dental anesthesia is administered using the camouflaged syringe.
75417296|NCT01398020|Drug|Standard Bowel Prep|Subjects will be asked to take 4L of Peglyte the day prior to procedure.
75417297|NCT01398020|Drug|2L Bi-Peglyte Bowel Prep|Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
75417298|NCT01398033|Device|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
75562787|NCT02828358|Drug|Hydrocortisone Sodium Succinate|Given IT
75562788|NCT02828358|Other|Laboratory Biomarker Analysis|Correlative studies
75562789|NCT02828358|Drug|Leucovorin|Given PO, IV
75562790|NCT02828358|Drug|Leucovorin Calcium|Given PO, IV
75562791|NCT02828358|Drug|Mercaptopurine|Given PO, NG
75562792|NCT02828358|Drug|Methotrexate|Given IT, IV, PO
75562793|NCT02828358|Drug|Pegaspargase|Given IV
75562794|NCT02828358|Other|Pharmacological Study|Correlative studies
75562795|NCT02828358|Drug|Prednisolone|Given PO, NG
75562796|NCT02828358|Drug|Thioguanine|Given PO, NG
75562797|NCT02828358|Drug|Vincristine|Given IV
75562798|NCT02828358|Drug|Vincristine Sulfate|Given IV
75562799|NCT02721732|Other|Laboratory Biomarker Analysis|Correlative studies
75562800|NCT02721732|Biological|Pembrolizumab|Given IV
75562801|NCT02721732|Other|Questionnaire Administration|Ancillary studies
75717626|NCT00660660|Drug|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
75717627|NCT00660660|Drug|Placebo|once daily
75717628|NCT02560766|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
75717629|NCT02560766|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
75717630|NCT02560766|Drug|Placebo|Placebo once daily
75717631|NCT00933465|Drug|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
75562802|NCT02679430|Device|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
75562803|NCT02676050|Other|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
75562804|NCT02676050|Device|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
75562805|NCT02676050|Device|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
75562806|NCT02641145|Radiation|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan
75562807|NCT02641145|Device|MRI|Cardiac MRI with gadolinium contrast.
75562808|NCT02641145|Radiation|N-13 ammonia PET|N-13 ammonia PET scan following supine bicycle stress.
75562809|NCT02598219|Drug|Pre-operative SN mapping with radionucleide|"Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.~Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.~Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available."
75562810|NCT02598219|Drug|Intra-operative SN mapping with patent V blue dye|"Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.~Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.~SN are detected by direct visualization of blue colored lymphatics and node"
75717632|NCT00933465|Drug|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
76042972|NCT03313206|Drug|Pembrolizumab|"Neo-adjuvant therapy :~Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
75717633|NCT00757874|Drug|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
75717634|NCT00757874|Drug|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
75717635|NCT00933621|Procedure|Autologous bone marrow intracoronary infusion|Percutaneous intracoronary mononuclear bone marrow cell infusion
75717636|NCT04050254|Device|Real tDCS|Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
75717637|NCT04050254|Device|Sham tDCS|Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
75873660|NCT04928040|Diagnostic Test|Measurement of optic nerve sheath diameter|The fluid challenge effects of optic nerve sheath diameter
75562811|NCT02598219|Drug|Intra-operative SN mapping with indocyanin green|"1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.~2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible~3- SN detection by near-infrared fluorescence imaging"
75562812|NCT02598219|Procedure|Full bilateral laparoscopic lymphadenectomy and Hysterectomy|"Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)~Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)~Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)"
75562813|NCT02598219|Procedure|Current initial staging protocols|Current French initial staging protocols
75562814|NCT02592824|Drug|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
75562815|NCT02592824|Drug|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
75562816|NCT02551068|Other|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
75562817|NCT02551068|Other|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
75417299|NCT01398033|Device|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
75562818|NCT02519140|Drug|Cook Medical EMR Gel|Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
75417300|NCT01398046|Drug|Dasatinib|dasatinib (100mg) PO x1
75417301|NCT01398046|Drug|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
75417302|NCT01398046|Drug|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
75417303|NCT01398072|Drug|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
75562819|NCT02446262|Behavioral|Instructions|In sub-study 1, half the participants are instructed about outcomes, half learn through experience.
75562820|NCT02446262|Behavioral|Attention|In sub-study 4, participants learn about outcomes and we manipulate attention toward or away from the pain.
75717638|NCT04050254|Device|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
75417304|NCT01398072|Drug|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
75417305|NCT01398072|Drug|Doxycycline|An oral dose of 100 mg once daily.
75417306|NCT01398072|Drug|Placebo|Oral dose of one table once daily.
75417307|NCT01398098|Drug|Sodium phosphate|32 tablets
75417308|NCT01398111|Drug|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
75417309|NCT01398111|Drug|Glycopyrrolate|glycopyrrolate pMDI
75417310|NCT01398111|Drug|Formoterol|formoterol pMDI
75562821|NCT02446262|Behavioral|Thermal Pain|In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.
75562822|NCT02446262|Behavioral|Placebo instructions|In sub-study 5, we test whether placebo effects and expectancy cues modulate pain through similar mechanisms.
75717639|NCT00933699|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
75717640|NCT00344305|Biological|Trivalent influenza virus vaccine live, intranasal|A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains.
75417311|NCT01398111|Drug|Placebo|placebo pMDI
75417312|NCT01398124|Biological|Cyclin B1 Peptide|vaccine
75417313|NCT01398150|Dietary Supplement|Beverage made to look like the cranberry beverage|one 15 ounce bottle of beverage consumed daily
75417314|NCT01398150|Dietary Supplement|Beverage made from cranberry compounds|one 15 ounce bottle consumed daily for 70 days
75417315|NCT01398163|Other|1-Fermented Dairy Product (test)|Arm 1 - Intervention 1 (probiotics)
75417316|NCT01398163|Other|2-Milk-based non-fermented dairy product(control)|Arm 2 - Intervention 2 (control)
75417317|NCT01398189|Drug|clozapine|C-11 clozapine
75417318|NCT01398202|Dietary Supplement|vitamin D3|20 micrograms per day for 10 weeks
75417319|NCT01398202|Dietary Supplement|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
75417320|NCT01398202|Dietary Supplement|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
75417321|NCT01398202|Dietary Supplement|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
75417322|NCT01398215|Procedure|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
75417323|NCT01398228|Behavioral|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
75417324|NCT01398241|Drug|RO5267683|Multiple ascending doses
75417325|NCT01398241|Drug|placebo|Multiple ascending doses
75562823|NCT02414399|Drug|Azithromycin|oral administration of Azithromycin
75417326|NCT01398254|Procedure|Primary Percutaneous Coronary Intervention (PPCI)|Participants will be randomly assigned an access site, radial or femoral, for PPCI.
75417327|NCT01398267|Drug|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
75417328|NCT01398267|Drug|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
75417329|NCT01398267|Drug|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
75873661|NCT04907292|Other|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
75417330|NCT01398293|Drug|danoprevir|100 mg single dose orally
75417331|NCT01398293|Drug|danoprevir|400 mg single dose orally
75417332|NCT01398293|Drug|danoprevir placebo|single oral dose
75417333|NCT01398293|Drug|moxifloxacin|400 mg single dose orally
75417334|NCT01398293|Drug|moxifloxacin placebo|single oral dose
75417335|NCT01398293|Drug|ritonavir|100 mg single dose orally
75417336|NCT01398293|Drug|ritonavir placebo|single oral dose
75562824|NCT02414399|Drug|Placebo|5 days of taste/appearance/bottle-matched inactive substance
75417337|NCT01398306|Other|Blood sampling by vena punction.|We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.
75417338|NCT01398345|Behavioral|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
75417339|NCT01398371|Drug|Withdrawal of digoxin|Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
75417340|NCT01398371|Drug|Digoxin|Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
75417341|NCT01398384|Drug|Nitric Oxide|MI size at 48-72 hours
75417342|NCT01398384|Drug|MI size at 48-72 hours|Placebo gas
75417343|NCT01398423|Drug|Active Control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
75562825|NCT02363374|Drug|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
75562826|NCT02363374|Radiation|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
75417344|NCT01398423|Drug|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
75417345|NCT01398436|Procedure|central venous catheter positioning in right atrium|A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
75417346|NCT01398449|Radiation|Elective nodal irradiation (ENI)|
75417347|NCT01398449|Other|Adjuvant chemotherapy only|
75562827|NCT02363374|Radiation|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
75562828|NCT02363374|Drug|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
75717641|NCT00933777|Drug|Combination of sorafenib and everolimus|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
76042973|NCT03313206|Procedure|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
75417348|NCT01398462|Drug|CWP232291|IV Infusion
75417349|NCT01398488|Behavioral|Patient education|Patient education by health care professional compared to education via tablet PC
75417350|NCT01398501|Drug|Sorafenib|Oral, 200 to 400 mg QD or BID
75417351|NCT01398527|Other|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
75417352|NCT01398540|Biological|IXIARO|2 immunizations (0,5ml) with a 28 day interval
75417353|NCT01398553|Device|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
75417354|NCT01398553|Other|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
75417355|NCT01398579|Procedure|Gastroscopy|"20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE."
75562829|NCT02363374|Procedure|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
75562830|NCT02348112|Device|Altis Single Incision Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
75562831|NCT02348112|Device|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
75562832|NCT02314481|Drug|MPDL3280A|Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy
75562833|NCT02314481|Drug|Vemurafenib|Film coated tablet
75562834|NCT02314481|Drug|Alectinib|capsule
75562835|NCT02314481|Drug|Trastuzumab emtansine|Powder for concentrate for solution for infusion
75562836|NCT02307630|Biological|124I-Humanized 3F8|
75717642|NCT00757952|Other|Fourier transform ion cyclotron resonance mass spectrometry|
75717643|NCT00757952|Other|chromatography|
75717644|NCT00757952|Other|diagnostic laboratory biomarker analysis|
75717645|NCT00757952|Other|questionnaire administration|
75717646|NCT01564030|Other|Empty|overnight fast
75717647|NCT01564030|Other|Fluid|250mL apple juice
75717648|NCT01564030|Other|Solid|breakfast
75417356|NCT01398592|Drug|Vildagliptin|50mg vildagliptin bid
75417357|NCT01398592|Drug|Sitagliptin|100mg sitagliptin po qd
75417358|NCT01398605|Other|Exercise training|Different dose of exercise training
75417359|NCT01398618|Drug|4-month rifampin vs. 9-month isoniazid|In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
75417360|NCT01398644|Other|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
75417361|NCT01398657|Drug|Adjuvant Androgen-Deprivation Therapy|Short-term adjuvant androgen-deprivation therapy
75417362|NCT01398670|Biological|Insulin Lispro|"a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50~The drugs would be administered subcutaneously"
75417363|NCT01398670|Biological|Insulin Lispro|"Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50~The drugs would be administered subcutaneously"
75717649|NCT00801450|Drug|Triamcinolone acetonide|4 mg
75717650|NCT00801450|Drug|Triamcinolone acetonide|40 mg
75417364|NCT01398696|Procedure|Patient Information Leaflets|Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
75417365|NCT01398696|Procedure|usual consultation|No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
75417366|NCT01398709|Other|Slow rewarming strategy|Rewarming rate:0.24 degrees C/min.
75417367|NCT01398709|Other|Fast rewarming strategy|Rewarming rate:0.5 degrees C/min.
75417368|NCT01398722|Other|Intensive insulin therapy|Titration of the IV insulin rate for glucose goal 110-150 mg/dL
75417369|NCT01398722|Other|Conventional insulin therapy|Titration of the IV insulin rate for glucose goal 150-180 mg/dl
75417370|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
75417371|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
75417372|NCT01398748|Drug|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
75562837|NCT02286726|Other|Laboratory Biomarker Analysis|Correlative studies
75417373|NCT01398761|Other|Signout tool|Electronic signout tool
75417374|NCT01398865|Procedure|PET scan and MRI scan|"PET: The PET Scan is manufactured by Siemens and the model is the Exact HR+ .rCMRglu data will be gathered over a 30 minute resting period using a Siemens HR+ PET camera (4.5 mm in-plane and axial resolution). The total time for an individual PET session, will thus be one hour and a half (30 minutes for serum pregnancy test and 30 minute uptake period followed by 30 minutes of scanning).~MRI: High-resolution scans will be acquired using a Seimens (manufacturer) 1.5T Avonta system at MGH, to be coregistered with subsequently acquired PET images, and used for A) delineation of regions of interest (ROIs), and B) facilitation of optimal transformation to MNI space."
75417375|NCT01398878|Behavioral|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
75417376|NCT01398891|Other|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
75562838|NCT02286726|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
75562839|NCT02217540|Other|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
75417377|NCT01398917|Procedure|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
75417378|NCT01398917|Procedure|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
75417379|NCT01398930|Other|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
75417380|NCT01398969|Biological|Fresh FMT|Participants will receive fresh FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
75562840|NCT02217540|Other|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
75562841|NCT02205034|Drug|oxytocin|Intranasal administration
75562842|NCT02174666|Dietary Supplement|Red clover extract|Aglycone isoflavones 80mg/d
75562843|NCT02174666|Dietary Supplement|Supplementation (placebo)|
75562844|NCT02074631|Drug|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
75873662|NCT05221476|Other|retrospective|The investigators retrospectively analyzed the short- and long-term outcome in polytraumatized patients and the possible influence of RDW values on admission as well as preexisting comorbidities on these outcomes.
76042974|NCT03313206|Radiation|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
76042975|NCT03313206|Drug|Lenvatinib|up to 26 evaluable patients will be treated with pembrolizumab combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
76042976|NCT03250377|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablet~Concentration: 25 mg and 50 mg~Route of administration: Oral use"
75417381|NCT01398969|Biological|Frozen-and-Thawed FMT|Participants will receive frozen-and-thawed FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
75417382|NCT01398995|Other|Reduction of basal insulin infusion to 50% of normal|Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
75417383|NCT01399021|Other|Early Drain Removal|Drain will be removed prior to patient's discharge on the day of the surgery
75417384|NCT01399021|Other|Late Drain Removal|Patient will be seen on the day following the surgery to have the drain removed
75417385|NCT01399073|Behavioral|virtual reality setup|testing for neglect in a virtual reality setup
75417386|NCT01399073|Behavioral|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
75417387|NCT01399073|Other|c-mri|structural and functional (resting state) imaging
75417388|NCT01399086|Drug|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
75735014|NCT03187353|Drug|Lisdexamfetamine|Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.
76042977|NCT03107520|Diagnostic Test|Intraoperative contrast-enhanced ultrasound (CEUS)|An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
76042978|NCT03107520|Drug|Lumason|Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
76042979|NCT03052816|Drug|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
76042980|NCT03052816|Drug|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
75417389|NCT01399112|Behavioral|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
75417390|NCT01399151|Dietary Supplement|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
75417391|NCT01399151|Dietary Supplement|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
75417392|NCT01399151|Dietary Supplement|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
75417393|NCT01399164|Other|14C-B12 fortified bread|A single serving of 14C-B12 fortified bread
75417394|NCT01399216|Dietary Supplement|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
75417395|NCT01399216|Dietary Supplement|Placebo|for 8 weeks
75417396|NCT01399242|Drug|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
75417397|NCT01399255|Biological|Insulin lispro|Dosage form- Subcutaneous Injection
75417398|NCT01399307|Procedure|Liposuction|Elective Liposuction
75417399|NCT01399320|Procedure|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
75417400|NCT01399333|Dietary Supplement|Group 1 Meal Replacement|4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
75735015|NCT03187353|Drug|Placebo oral capsule|The placebo capsule will be filled with microcellulose.
75873663|NCT04865796|Other|Lactoferrin products|Patiens will use a toothpaste and 2 tablets per day (between foods) for home oral care.
75873664|NCT04865796|Other|Probiotics products|Patiens will use a toothpaste and a chewing-gum (for 10 minutes a day) for home oral care.
75873665|NCT04865796|Other|Standard home oral care|Patiens will use a normal toothpaste for home oral care.
75873666|NCT04811118|Drug|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous infusion
75873667|NCT04811118|Drug|Taxotere|Taxotere
75417401|NCT01399333|Dietary Supplement|Group 2 Protein Supplement|4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
75417402|NCT01399333|Dietary Supplement|Group 3|4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
75417403|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
75417404|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
75417405|NCT01399359|Behavioral|Counseling session|
75417406|NCT01399359|Other|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
75417407|NCT01399359|Other|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
75417408|NCT01399359|Other|online questionnaire|
75417409|NCT01399398|Procedure|Brain Scan-PET|
75417410|NCT01399398|Procedure|Brain Scan-MRI|
75417411|NCT01399398|Procedure|Arterial Line|
75417412|NCT01399398|Procedure|Venous Line|
75417413|NCT01399398|Procedure|Blood Sampling|
75417414|NCT01399424|Drug|CP|Immunization
75417415|NCT01399450|Drug|paliperidone|paliperidone augmenting on ongoing medication
75417416|NCT01399463|Device|Angioplasty performed via Paclitaxel Eluting Balloon catheter|
75417417|NCT01399463|Device|Angioplasty via DES|Angioplasty performed via commonly used Drug Eluting Stents
75417418|NCT01399476|Procedure|Endoscopic Myotomy|Patients will receive the surgical procedure described in the summary (POEM).
75417419|NCT01399476|Procedure|Endoscopic Myotomy for treatment of achalasia|Surgical procedure
75562845|NCT02074631|Drug|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
76042981|NCT03029156|Device|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
75417420|NCT01399489|Behavioral|Exercise training|Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
75417421|NCT01399502|Behavioral|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
75417422|NCT01399515|Drug|Valproic Acid|One 500mg tablet by mouth daily
75417423|NCT01399554|Behavioral|Motivational Enhancement Therapy plus Contingency Management|A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
75417424|NCT01399567|Behavioral|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
75417425|NCT01399606|Drug|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
75417426|NCT01399632|Behavioral|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
75417427|NCT01399632|Behavioral|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
75417428|NCT01399645|Drug|Liraglutide-metformin vs insulin-metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."
75417429|NCT01399671|Other|vestibular stimulation|vestibular stimulation
75417430|NCT01399710|Procedure|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
75417431|NCT01399710|Procedure|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
75562846|NCT02061423|Biological|HER-2 pulsed Dendritic Cell Vaccine|Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
75562847|NCT02004691|Drug|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion"
76042982|NCT03029156|Device|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
75417432|NCT01399710|Device|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
75417433|NCT01399749|Other|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
75562848|NCT02004691|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.~Route of administration: intravenous infusion"
75717651|NCT05434988|Procedure|appendectomy|Open or Laparoscopic appendectomy procedure is typically performed under general anaesthesia. in the laparoscopic approach, the main principle is the triangulation of instrument ports to visualize and expose the appendix clearly. The first trocar (10 mm) for the optical device is introduced peri-umbilically, followed by two 5 mm trocars, one in the right lower quadrant just above the pubis (to grasp the appendix) and the other in the left iliac fossa (for the (right-handed) surgeon's right hand), assuming the appendix is in its normal anatomic position. The locations of the 5 mm trocars can be changed based on the anatomic position of the appendix as determined before to surgery (for example a subhepatic appendix could lead to placing the trocars as for cholecystectomy)
75717652|NCT00989326|Other|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
75717653|NCT00933855|Behavioral|Questionnaires and training workshop|"We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment"
75717654|NCT02554578|Other|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
75717655|NCT03988777|Device|Preoperative localisation technique|Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
76042983|NCT02955940|Drug|Ruxolitinib|5 mg BID
75417434|NCT01399762|Device|mechanical recanalization|Endovascular thrombus extraction by mechanical recanalization devices
75417435|NCT01399775|Procedure|immediate implantation|Immediately after tooth extraction, a dental implant is inserted
75717656|NCT00660816|Drug|erlotinib hydrochloride|Given orally once daily on days 2-19.
75717657|NCT00660816|Drug|pemetrexed disodium|Given IV over 10 minutes on day 1
76042984|NCT02955940|Drug|Capecitabine|Capecitabine at the same dose provided in the parent study at the time of the rollover.
76042985|NCT02955940|Drug|Regorafenib|Regorafenib at the same dose provided in the parent study at the time of the rollover.
75417436|NCT01399775|Procedure|Delayed implantation|Four months after extraction, a dental implant is inserted and measurements are recorded.
75417437|NCT01399814|Behavioral|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000~1500ml crystalloid was administered on the days following operation
75562849|NCT01991379|Drug|MEK162|Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
75562850|NCT01991379|Drug|Imatinib Mesylate (Gleevec®; STI571; NSC #716051)|
75562851|NCT01991379|Other|Blood draws|
75417438|NCT01399814|Behavioral|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000~2500ml crystalloid was administered on the days following operation
75417439|NCT01399840|Drug|BMN 673|Oral capsule with multiple dosage forms given once daily
75417440|NCT01399853|Biological|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
75417441|NCT01399853|Biological|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
75417442|NCT01399853|Biological|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
75417443|NCT01399853|Biological|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
75417444|NCT01399853|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
75417445|NCT01399879|Other|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
75417446|NCT01399892|Dietary Supplement|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
75417447|NCT01399970|Other|Mobile Teleconsultation Arm (MTA)|"In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines."
75417448|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
75417449|NCT01400009|Drug|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
75417450|NCT01400009|Drug|Placebo|Standard Placebo made of Lactose 100 mg
75417451|NCT01400022|Other|UVA1 phototherapy|The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
75417452|NCT01400022|Other|Cortisone|Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
75417453|NCT01400048|Dietary Supplement|Aloe vera effervescent tablet (AVH200)|250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
75417454|NCT01400048|Dietary Supplement|Placebo control|60mg Ascorbic acid
75417455|NCT01400074|Drug|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
75417456|NCT01400087|Device|Cap-attached Colonoscopy Versus Regular Colonoscopy|Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
75417457|NCT01400100|Drug|Intraarterial application of Octreotide|500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
75417458|NCT01400100|Drug|sterile NaCl (sodium chloride) 0,9% solution|a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
75417459|NCT01400152|Device|Additional active warming|Chemical heat pad applied to the upper torso
75417460|NCT01400165|Drug|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
75417461|NCT01400165|Drug|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
75417462|NCT01400165|Drug|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
75417463|NCT01400165|Procedure|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
75417464|NCT01400191|Drug|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
75417465|NCT01400217|Drug|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
75562852|NCT01991379|Procedure|biopsy|Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
75562853|NCT01936935|Other|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
75717658|NCT00660816|Drug|docetaxel|IV over 60 minutes on day 1.
75717659|NCT00991666|Procedure|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
75873668|NCT04979988|Drug|Lortlatinib|as provided in real world practice
75873669|NCT05221164|Drug|Aspirin 162 mg|Daily aspirin 162 mg during pregnancy to prevent preeclampsia
75417466|NCT01400217|Drug|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
75417467|NCT01400230|Procedure|diagnostic procedures CCTA, CAG, IVUS and FFR|Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
75417468|NCT01400256|Drug|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
75417469|NCT01400282|Device|High frequency spinal cord stimulation|
75417470|NCT01400308|Drug|Mupirocin + Chlorhexidin|"Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)"
75417471|NCT01400308|Device|Prontoderm MRSA Kit|"Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.~Prontoderm® is a Class III medical device"
75417472|NCT01400334|Radiation|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine [HED, 20 mCi (740 MBq)] to quantify sympathetic nerve function, b) 13N-ammonia [NH3, 20 mCi (740 MBq)] for regional perfusion, and c) 18F-2-deoxyglucose [FDG; 6.5 mCi (241 MBq)] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
75417473|NCT01400360|Other|Combination of TBA and intraarterial application of vasodilators|In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
75562854|NCT01936935|Other|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
75562855|NCT01893710|Procedure|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
75562856|NCT01859858|Dietary Supplement|curcumin|
75562857|NCT01859858|Drug|Irinotecan|
75562858|NCT01739062|Genetic|Genetic risk assessment|
75562859|NCT01613118|Drug|RE-021 (Sparsentan)|Oral, once-daily
75562860|NCT01613118|Drug|Irbesartan|Oral, once-daily
75562861|NCT01470105|Other|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
75717660|NCT00801528|Drug|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
75717661|NCT01060891|Drug|colimycin|
75717662|NCT04003402|Drug|ASP8062|oral
75717663|NCT04003402|Drug|Alcohol|oral
75717664|NCT04003402|Drug|ASP8062 Placebo|oral
75717665|NCT04003402|Drug|Alcohol Placebo|oral
75717666|NCT04045860|Procedure|Complete Decongestive Therapy|A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen
75717667|NCT04045860|Other|Observation|Standard of care is currently observation
75717668|NCT00576056|Drug|Sorafenib|Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.
75717669|NCT00576056|Drug|TACE|TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.
75562862|NCT01416077|Other|fluid optimisation|"Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised~Crystalloid infusion (2,5 ml/kg/t) throughout surgery~3 ml/kg Volulyte (synthetic colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase > 10% is observed. A new dose is given if SV decreases more than 10% from the last value.~If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI > 2,5.~If despite CI > 2,5 Mean Arterial Pressure <65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65."
75562863|NCT01300962|Drug|BMK120|BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
75717670|NCT00798798|Device|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
75717671|NCT05360602|Dietary Supplement|Alpha Lipoic Acid plus the standard care for post-PCI MI|Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
75717672|NCT05360602|Drug|The standard care for post-PCI MI|will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
75717673|NCT00793728|Procedure|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
76042986|NCT02742922|Behavioral|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
75562864|NCT01300962|Drug|Capecitabine|875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
75717674|NCT00991744|Drug|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
75717675|NCT00991744|Drug|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
75717676|NCT00575510|Behavioral|Intervention|Multiple component intervention based in the unified theory of behavior
75717677|NCT00575510|Behavioral|Active control|Partial intervention (full intervention minus cultural-specific component)
75417474|NCT01400373|Device|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
75417475|NCT01400386|Other|Coffee bioavailability trial|Coffee bioavailability trial
75417476|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
75417477|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
75417478|NCT01400464|Drug|Prednisone therapy and pharmacokinetic|Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
75562865|NCT01300962|Drug|BYL719|BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
75562866|NCT01300962|Drug|Trastuzumab|trastuzumab infusion on day 1 of each cycle.
75562867|NCT01300962|Drug|Lapatinib|lapatinib daily for 21 days in each cycle.
75562868|NCT01107340|Device|AMIStem Hip System|
75562869|NCT00752479|Biological|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|"Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
75562870|NCT00752479|Drug|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|"Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
75562871|NCT00732212|Device|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
75562872|NCT00732212|Other|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage & visual cues for risk stratification and completion of endoscopic treatment.
75562873|NCT00647387|Device|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
75562874|NCT00592280|Drug|Two-Layer Method pancreas preservation system drug|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
75873670|NCT03627546|Drug|Sofosbuvir and Velpatasvir|Sofosbuvir/velpatasvir (Epclusa) is an FDA-approved treatment for HCV. It is provided in the intervention arm as part of a rapid treatment strategy,
75417479|NCT01400490|Dietary Supplement|EPA-DHA Study|6 weeks of dietary supplementation
75562875|NCT00592280|Device|Two-Layer Method pancreas preservation system device|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
75417480|NCT01400542|Device|CPAP Treatment|Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.
75417481|NCT01400542|Device|No treatment|no treatment
75417482|NCT01400555|Drug|Cohort 4|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
75417483|NCT01400555|Drug|Cohort 3|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
75717678|NCT00798876|Dietary Supplement|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
75417484|NCT01400555|Drug|Cohort 2|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
76042987|NCT02702596|Other|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
75417485|NCT01400555|Drug|Cohort 1|Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
75417486|NCT01400568|Drug|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
75417487|NCT01400568|Drug|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
75417488|NCT01400581|Behavioral|Collaborative Care Intervention|See description of Intervention arm
75417489|NCT01400607|Biological|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
75417490|NCT01400607|Other|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
75417491|NCT01400620|Drug|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
75417492|NCT01400633|Drug|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
75417493|NCT01400646|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
75417494|NCT01400646|Drug|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
75417495|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
75562876|NCT00589875|Biological|CAN-2409|Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.
75417496|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
75417497|NCT01400646|Drug|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
75417498|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
75417499|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
75417500|NCT01400659|Procedure|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
75417501|NCT01400659|Procedure|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
75417502|NCT01400672|Biological|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
75417503|NCT01400672|Drug|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
75417504|NCT01400672|Radiation|Radiation therapy|"Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy."
75562877|NCT00589875|Drug|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
75562878|NCT00589875|Drug|Temozolomide|Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.
75717679|NCT00798876|Dietary Supplement|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
75717680|NCT00798876|Dietary Supplement|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
75417505|NCT01400685|Drug|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
75417506|NCT01400685|Drug|Bendamustine|90 mg/m^2 IV days 1-2 of each cycle for 6 cycles
75417507|NCT01400685|Drug|Rituximab|375 mg/m^2 IV day 1 (cycle 1), 500 mg/m^2 day 1 (cycles 2-6)
75417508|NCT01400711|Other|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
75417509|NCT01400711|Other|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
75417510|NCT01400724|Dietary Supplement|Inofolic NRT|Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
75717681|NCT00798876|Dietary Supplement|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
75717682|NCT00798876|Other|Medical Examination|Subjects will have a routine medical exam.
75562879|NCT00589875|Radiation|Radiation therapy|Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.
75417511|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
75417512|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
75417513|NCT01400750|Drug|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
75417514|NCT01400750|Drug|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
75417515|NCT01400763|Dietary Supplement|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
75417516|NCT01400763|Dietary Supplement|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
75417517|NCT01400763|Dietary Supplement|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
75562880|NCT00503594|Drug|Methotrexate and temozolomide|Methotrexate and temozolomide
75562881|NCT00503594|Drug|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
75562882|NCT04696302|Behavioral|Focus of attention|Individuals were asked to laterally weight shift while seated with either internal focus or external focus instructions.
75417518|NCT01400763|Dietary Supplement|Placebo beverage|Placebo beverage
75417519|NCT01400789|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
75417520|NCT01400802|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
75417521|NCT01400828|Drug|Bilastine|20 mg (encapsulated) tablets QD/14 days
75417522|NCT01400828|Drug|Desloratadine|5 mg (encapsulated) tablets QD/14 days
75417523|NCT01400828|Drug|Placebo|(encapsulated) Tablets QD/14 days
75562883|NCT05146791|Procedure|Inlay Bristow|A modified Bristow procedure
75562884|NCT05146791|Procedure|Bristow|Traditional Bristow procedure
75417524|NCT01400854|Drug|Effentora®|prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
75717683|NCT00798876|Other|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
75417525|NCT01399996|Dietary Supplement|Yogurt smoothie without probiotic|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
75417526|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added post fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
75417527|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added pre-fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
75417528|NCT01399996|Dietary Supplement|A capsule containing the probiotic|A capsule taken daily will provide between 10x^y9 and 10x^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
75873671|NCT04620798|Behavioral|Immediate vs. delayed provision of antibody test results|The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
75873672|NCT04940208|Other|Pain and neuropsychological questionnaires|Patient-reported outcomes, listed in the Secondary Outcome Measure Section
75417529|NCT01400867|Drug|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects < 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
75417530|NCT01400867|Drug|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
75417531|NCT01400867|Drug|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
75417532|NCT01400945|Drug|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
75417533|NCT01400984|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
75417534|NCT01400997|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
75417535|NCT01401036|Device|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
75562885|NCT00499811|Drug|vorinostat|Given orally
75562886|NCT00499811|Other|pharmacological study|Correlative studies
75562887|NCT05146752|Device|extremely low frequency electromagnetic fields|extremely low frequency electromagnetic fields
75562888|NCT05146752|Other|routine care|routine care
75717684|NCT00798876|Other|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
75717685|NCT00798876|Procedure|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
75717686|NCT00989404|Drug|Zanamivir|Rotahaler placebo 10mg BID 5 days
75562889|NCT00503711|Drug|Vandetanib|100 mg every other day, 100mg once daily
75562890|NCT00503711|Drug|Vandetanib 300 mg|300mg once daily
75562891|NCT03451188|Device|Cerecare compression garments|all Cerecare compression garments
75717687|NCT00989404|Drug|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
75717688|NCT00989404|Drug|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
75717689|NCT00758030|Drug|Paliperidone ER OROS|
75717690|NCT02636439|Behavioral|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
75562892|NCT00499850|Drug|ZD6474 (vandetanib)|once daily oral dose
75717691|NCT02636439|Behavioral|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
75873673|NCT04940208|Diagnostic Test|Quantitative Sensory testing|Summation pain threshold test and Heat pain threshold skin test
75717692|NCT00343915|Biological|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, & 6)
75717693|NCT00343915|Biological|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 & 6)
75717694|NCT00343915|Biological|placebo|In the primary study: 1 deep intramuscular injection (month 1)
75873674|NCT05685966|Other|no intervention|no intervention
76042988|NCT02702596|Behavioral|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
75417536|NCT01401036|Procedure|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
75417537|NCT01401075|Drug|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
75417538|NCT01401075|Drug|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
75417539|NCT01401088|Device|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
75417540|NCT01401114|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
75417541|NCT01401140|Drug|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
75417542|NCT01401140|Drug|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
75562893|NCT00499850|Drug|5-Fluorouracil|intravenous infusion
75562894|NCT00499850|Drug|Leucovorin|intravenous infusion
75562895|NCT00499850|Drug|Oxaliplatin|intravenous infusion
75717695|NCT00751868|Drug|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
75717696|NCT00991822|Drug|Dorzolamide 2%|
75562896|NCT05146713|Dietary Supplement|Propolis nanoparticles extract solution|20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.
75562897|NCT05146713|Drug|sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
75562898|NCT00503789|Procedure|fecal bacteria analysis|ad lib feeding
75717697|NCT00991822|Drug|Timolol 0.5%|
76042989|NCT02702596|Behavioral|Standard Education|The the use of a pamphlet to educate people about depression.
76042990|NCT02682238|Drug|BBI-4000, 15%|
76042991|NCT02682238|Other|Vehicle gel|
75717698|NCT00798954|Device|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
75717699|NCT00798954|Device|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
75417543|NCT01401179|Drug|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
75417544|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
75417545|NCT01401192|Drug|pemetrexed plus cisplatin|Pemetrexed 500mg/m2 & cisplatin 70mg/m2 D1 every 3 weeks
75417546|NCT01401192|Drug|pemetrexed plus cisplatin|pemetrexed 500mg/m2 & cisplatin 70mg/m2 every 3 weeks
75417547|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
75417548|NCT01401205|Other|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
75717700|NCT02560064|Procedure|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
75717701|NCT00989482|Behavioral|Computer kiosk Education|computerized patient education; guidelines for physicians
75562899|NCT05149989|Device|Proning Pillow System|Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
75562900|NCT00499928|Drug|SB-751689|
75562901|NCT00503828|Drug|Derris scandens Benth extracts|Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
75562902|NCT00503828|Drug|naproxen|Naproxen 500 mg/day for 4 weeks
75562903|NCT05149677|Behavioral|Music therapy|Music therapy intervention + Standard of Care for labor pain
75562904|NCT03455478|Device|spectacles|dispending spectacles for uncorrected refractive error
75717702|NCT04348981|Device|Wearable fitness tracking device|Patients having a wearable fitness tracking device will be monitored for their level of activity after surgery. Declines in activity level will prompt a phone call from the surgical provider.
75717703|NCT00934011|Other|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
75417549|NCT01401218|Other|Electronic Medical Record (EMR) Review|"measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.~potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,"
75417550|NCT01401231|Behavioral|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
75417551|NCT01401231|Other|Usual care|Continued usual care (could include referral for medication or psychotherapy)
75417552|NCT01401270|Behavioral|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
75417553|NCT01401296|Behavioral|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
75562905|NCT00499967|Drug|GS-9191 ointment|GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
75562906|NCT00499967|Drug|GS-9191|GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
75562907|NCT00499967|Drug|Placebo|Placebo matching GS-9191 ointment
75562908|NCT00500006|Drug|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
75562909|NCT00500006|Drug|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
75562910|NCT01247051|Procedure|Precoating|preoperative filling of heart lung machine with patients blood
75562911|NCT01247051|Procedure|Standard priming|preoperative filling of heart lung machine with colloids
75562912|NCT00506727|Drug|Mixed amphetamine salts (ADDERALL XR)|
75562913|NCT00506727|Drug|Atomoxetine hydrochloride|
75562914|NCT01247168|Drug|AZD2461|oral capsules, continuous dosing and intermittent dosing
75562915|NCT00500162|Behavioral|Tri-Luma Maintenance regimen|
75562916|NCT00500201|Drug|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
75562917|NCT00500201|Drug|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
75562918|NCT00500201|Drug|Placebo|Placebo tablets will be administered orally by subjects.
75562919|NCT01247246|Drug|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
75562920|NCT01247246|Drug|Placebo|Placebo
75717704|NCT00934011|Other|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
75873675|NCT05220618|Behavioral|Autobiographical Memory Specificity Training PESCAR|An autobiographical memory specificity training has been developed by authors, based on previous training within the frame of Cognitive Bias Modification Interventions (CBM-I; Barry et al., 2019; Hitchcock et al., 2017). The training group will receive a self-guided intervention, which consists of an initial session (lasting 30 minutes approximately) and two-week training, conducted online. Participants will be provided with an online platform for following the intervention in a self-guided modality. The first session aims to give information about autobiographical memory functioning, to train in specificity recall through concrete processing steps and to explain the functioning of the self-guided modality. Then, during the next two weeks, participants will use the online platform once a day for practising the recall of autobiographical memories during 15-20 min approximately.
75562921|NCT04696536|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate cavity protection toothpaste for brushing teeth twice daily.
75562922|NCT04696536|Other|American Dental Association (ADA) Referenced Toothbrush|Participants will brush teeth at least one minute with provided toothbrush twice daily.
75562923|NCT04696536|Other|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse as negative control for 30 sec twice a day after brushing.
75562924|NCT04696536|Other|REACH Dental Floss|Participants after brushing, rinse mouth with water and floss using Reach dental floss once a day.
75562925|NCT04696536|Other|Alcohol-containing Essential Oil (AEO) Mouth Rinse (Listerine Cool Mint, marketed)|Participants after brushing, rinse with 20mL of the AEO mouth rinse for 30 seconds twice a day.
75417554|NCT01401296|Behavioral|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
75717705|NCT02554032|Procedure|Axillary artery cannulation|The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
75417555|NCT01401335|Behavioral|Questionnaires|questionnaires at entry, month 4, 8 and 12
75417556|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
75417557|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
75417558|NCT01401413|Drug|ramelteon|8 mg nightly for 30 nights
75417559|NCT01401413|Drug|placebo|placebo control i pill nightly for 30 nights
75417560|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
75417561|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
75417562|NCT01401491|Drug|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
75417563|NCT01401491|Drug|clozapine plus placebo|clozapine 300 mg/day plus placebo
75417564|NCT01401504|Drug|ASP3026|oral
75562926|NCT00500279|Drug|Celecoxib|
75562927|NCT03459651|Behavioral|ANS training|In-home computer-based ANS training
75562928|NCT00500396|Procedure|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
75417565|NCT01401569|Behavioral|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
75562929|NCT00507468|Procedure|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
75717706|NCT02554032|Procedure|Innominate artery cannulation|After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
75417566|NCT01401608|Device|RF Ablation|Ablation of arrhythmogenic ventricular tissue
75417567|NCT01401621|Behavioral|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
75562930|NCT01245881|Device|Non-ablative fractional photothermolysis laser|"Wavelength: 1,550 nm;~Energy: 15 mJ/MTZ;~Total coverage: 20%;~Total density: 1,048 MTZs/cm2;~Density per pass: 131 MTZ/cm2;~Number of passes: 8."
75417568|NCT01401621|Behavioral|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
75417569|NCT01401621|Behavioral|Control|No scratch-off element
75417570|NCT01401634|Other|Oral water|2 Liters of water given orally
75417571|NCT01401634|Other|Intravenous normal saline|2 Liters Intravenous normal saline
75417572|NCT01401660|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
75417573|NCT01401673|Drug|Indantadol|Titration
75417574|NCT01401712|Procedure|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
75417575|NCT01401712|Procedure|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
75417576|NCT01401725|Behavioral|Electronic Order Entry System + CDSS|Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
75417577|NCT01401725|Behavioral|Electronic Order Entry System Only|Physicians at this hospital will use an Electronic Order Entry System
75417578|NCT01401725|Other|Usual Care|Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
75717707|NCT04040504|Device|ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.
75873676|NCT05684328|Procedure|WLI Then NBI Withdrawal|Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed by cold snare. Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.
75417579|NCT01401751|Device|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
75417580|NCT01401764|Other|Formulation buffers|Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
75417581|NCT01401790|Device|Telehomecare (Intelligent Distance Patient Monitoring)|"Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~Automatic download of blood glucose levels~Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~Changes in treatment plan by the diabetes professionals~E mail exchanges between families and health care professionals~Reinforcement of teaching program"
75417582|NCT01401790|Other|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
75562931|NCT01245881|Other|broad-spectrum sunblock (SPF 50+)|
75562932|NCT00500435|Procedure|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
75562933|NCT01247402|Device|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
75562934|NCT01247402|Device|standard balloon angioplasty|standard balloon angioplasty
75562935|NCT01247441|Other|Clinical data|
75562936|NCT00508170|Behavioral|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
75562937|NCT00500474|Procedure|endolymphatic sac drainage with steroids|
75562938|NCT03458247|Drug|Abiraterone acetate standard dose|1000 mg/day
75717708|NCT04040504|Device|ERCP procedure with Pentax ED-34i10T Duodenoscope|ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
76042992|NCT02674711|Behavioral|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
75717709|NCT01055119|Dietary Supplement|Omega-3 fatty acids|duration: 4 month
75717710|NCT00934167|Biological|heparin sodium - Hipolabor|5.000 UI/0,25mL
76042993|NCT02657356|Drug|Placebo capsules|
75417583|NCT01401803|Drug|Dysport|Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
75562939|NCT03458247|Drug|Abiraterone acetate escalated dose|2000 mg/day
75562940|NCT01247519|Other|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
75717711|NCT00934167|Biological|Heparin sodium - APP|5.000 USP/mL
75562941|NCT03453216|Behavioral|neuropsychological tests|"Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone)."
75562942|NCT00500513|Procedure|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
75717712|NCT00801606|Drug|Zinc|Zinc 20 mg/day
75717713|NCT00801606|Drug|Micronutrient without zinc|Multimineral 2 RDA
75717714|NCT00801606|Drug|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
75717715|NCT00801606|Drug|Placebo|Placebo
76042994|NCT02657356|Drug|Bardoxolone methyl capsules|
76042995|NCT02606201|Other|Peri sphincter injection Autologous myofibers|"The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control."
76042996|NCT02577978|Device|Medacta GMK posterior stabilized prosthesis|
76042997|NCT02577978|Device|Medacta GMK Sphere prosthesis|
76042998|NCT02564705|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|
75417584|NCT01401816|Other|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
75417585|NCT01401829|Behavioral|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
75562943|NCT00500513|Procedure|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
75562944|NCT00500513|Radiation|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
75562945|NCT02954718|Other|activity training|
75562946|NCT01247558|Other|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for >120 days
75562947|NCT01247558|Other|Not treated with Metanx®|Non-treated comparative cohort
75717716|NCT05408806|Other|Exercise Interventions|Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.
75717717|NCT00934245|Biological|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
76042999|NCT02564705|Procedure|Posterior Fusion|"Posterolateral Fusion (PLF)~Posterior Lumbar Interbody Fusion (PLIF)~Transforaminal Lumbar Interbody Fusion (TLIF)"
76043000|NCT02539771|Other|Polysomnography and blood sample|"Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic "
76043001|NCT02393625|Drug|Ceritinib (LDK378)|
75717718|NCT00934245|Biological|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
75717719|NCT05394532|Other|Education|Common Education
75717720|NCT02560688|Drug|DS-1040b|20 mg single 12-hour intravenous infusion
75717721|NCT02560688|Drug|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
76043002|NCT02393625|Drug|Nivolumab|
75717722|NCT00939549|Drug|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
75717723|NCT00799032|Device|PCI|coronary stent implantation
75717724|NCT00758186|Procedure|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
75717725|NCT00758186|Procedure|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
75717726|NCT00989560|Procedure|endoscopy|patients receive best treatment and care with an additional endoscopy
75717727|NCT00934323|Drug|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
76043003|NCT02294032|Drug|Immunosuppressive Agents|standard of care for patients post-transplant
76043004|NCT02168829|Drug|Rivaroxaban|
76043005|NCT02168829|Drug|Acetylsalicylic acid|
75417586|NCT01401829|Behavioral|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
75417587|NCT01401829|Behavioral|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
75417588|NCT01401868|Drug|ME-143|"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
75417589|NCT01401920|Other|leg elevation|bilateral passive leg elevation for 30 seconds
75873677|NCT05684328|Procedure|NBI Then WLI Withdrawal|Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed by cold snare. Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.
75873678|NCT05220228|Drug|Prucalopride|1mg prucalopride x 2d, 2mg prucalopride x 5-8d
76043006|NCT01732120|Procedure|Off-clamp partial nephrectomy|
75417590|NCT01401920|Other|Trendelenburg position|Trendelenburg position (15 degrees) for 30 seconds
76043007|NCT01719562|Procedure|Magnetic resonance imaging|Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
76043008|NCT01719562|Other|Physical Activity|Tailored aerobic exercise program onsite and at home.
76043009|NCT01719562|Other|Healthy Living|Healthy living presentations at a centralized meeting place and over the phone.
76043010|NCT01719562|Device|Cardiopulmonary Exercise Testing (CPET)|Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
75417591|NCT01401920|Other|Trendelenburg position + passive leg elevation|Trendelenburg position + passive leg elevation
75417592|NCT01401920|Other|control group|supine position without passive leg elevation or trendelenburg position
75417593|NCT01401933|Drug|Linifanib|QD on Days 1 and 13
75417594|NCT01401933|Drug|Rifampin|QD on Days 5-16
75417595|NCT01401946|Drug|soy isoflavones|
75417596|NCT01401946|Drug|Placebo|
75417597|NCT01402024|Drug|Aprepitant|"The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg"
75417598|NCT01402024|Drug|Placebo|"Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule)."
75417599|NCT01402037|Drug|Glucose|Glucose 20% intravenous
75417600|NCT01402037|Device|Continuous glucose monitoring|Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
75417601|NCT01402076|Drug|Tasimelteon|20mg daily dosing, Days 4-20
76043011|NCT01719562|Other|Questionnaire Administration|A self-administered 13-item scale to assess fatigue in participants
76043012|NCT01700439|Device|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
76043013|NCT01647698|Behavioral|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
76043014|NCT01647698|Behavioral|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
76043015|NCT01647698|Behavioral|No training|No training during the experiment.
75417602|NCT01402076|Drug|Rosiglitazone|4mg, single dose, Days 3 and 20
75417603|NCT01402076|Drug|Midazolam|10mg, single dose, Days 1 and 18
75417604|NCT01402089|Drug|Sunitinib|Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)
75417605|NCT01402089|Drug|Erlotinib|Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.
75417606|NCT01402089|Drug|Midazolam|For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.
75417607|NCT01402089|Drug|Caffeine|For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
75417608|NCT01402154|Biological|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
75417609|NCT01402154|Biological|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
75417610|NCT01402167|Procedure|Kyphoplasty|Patients will be treated via a balloon kyphoplasty surgical procedure
75417611|NCT01402167|Procedure|Vertebroplasty|Patients will be treated via a transcutaneous vertebroplasty procedure.
75417612|NCT01402180|Biological|Nimotuzumab|
75417613|NCT01402180|Radiation|Radiation therapy|
75417614|NCT01402180|Radiation|radiation therapy|
75417615|NCT01402180|Drug|chemotherapy|
75417616|NCT01402180|Drug|chemotherapy|
75417617|NCT01402193|Drug|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
75873679|NCT05220228|Drug|Placebo|Lactose / sucrose placebo
75873680|NCT05220150|Device|FFC-MRI scan|Undergo one FFC-MRI scan.
75417618|NCT01402193|Drug|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
76043016|NCT01433289|Drug|Polyphenon E|There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
75417619|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
75417620|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
76043017|NCT01433289|Drug|Placebo|
75417621|NCT01402206|Behavioral|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention)."
75417622|NCT01402219|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
75417623|NCT01402219|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
75417624|NCT01402245|Biological|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
75417625|NCT01402245|Biological|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
75417626|NCT01402297|Drug|Apocynin and placebo nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
75417627|NCT01402310|Other|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
75417628|NCT01402323|Other|time point of tooth extraction|
76043018|NCT01345552|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
76043019|NCT00995475|Drug|Fluticasone propionate|
76043020|NCT00995475|Drug|Placebo|
76043021|NCT00945529|Drug|inhaled nitric oxide (iNO)|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
75417629|NCT01402336|Drug|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
75417630|NCT01402336|Drug|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
75417631|NCT01402388|Behavioral|Group lifestyle programme|
75417632|NCT01402414|Radiation|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
75717728|NCT00934323|Drug|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
75717729|NCT00793962|Radiation|hypofractionation radiotherapy|radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
75417633|NCT01402414|Radiation|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
75417634|NCT01402414|Radiation|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
75417635|NCT01402440|Drug|AEB071|
75417636|NCT01402453|Behavioral|Monetary Incentives|Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
75417637|NCT01402453|Behavioral|Intrinsic Motivation|A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
75562948|NCT02954445|Biological|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
75717730|NCT00793962|Radiation|conventional fractionation radiotherapy|50Gy/25/f/5w
75717731|NCT00575666|Drug|Insulin or Placebo|intranasal, 40IU, 4 times daily
75417638|NCT01402466|Behavioral|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
75417639|NCT01402466|Behavioral|Project Bridge|Arm 2
75717732|NCT05378230|Dietary Supplement|Probiotic preparation of three Lactobacillus plantarum strains (CECT 7527, CECT 7528, CECT 7529)|"All subjects were submitted to 4 weeks intervention consisting on a dose-dependent regime of Lactobacillus plantarum AB-B (strains CECT 7527, CECT 7528, CECT 7529; AB-LIFE). Before starting the intervention period, all subjects were submitted to a 2-weeks run-in period. During the wash-in and intervention-periods, participants were instructed to maintain their habitual dietary habits and to continue their normal pattern of physical activity throughout the study period.~Treatments during the intervention period were: Week 1: 1 capsule/day taken during breakfast; Week 2: 2 capsules / day at- breakfast; Week 3: 2 capsules at breakfast and 1 at dinner; Week 4: 2capsules at breakfast and 2 capsules at dinner. Each capsule contains 1.2x10^9 cfu (colony forming units) in a 1: 1: 1 ratio of the three strains."
75417640|NCT01402479|Drug|Ramipril|ramipril 2.5mg twice a day
75717733|NCT00934479|Drug|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
75717734|NCT00658632|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
75717735|NCT00658632|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
75417641|NCT01402505|Procedure|Transvaginal NOTES sleeve gastrectomy|transvaginal NOTES sleeve gastrectomy
75417642|NCT01402518|Procedure|Per-oral enodscopic myotomy|
75717736|NCT05408650|Other|Aromatherapy Massage|"The PI will dilute pure lavender essential oil (Lavandula angustifolia) with almond oil at a dilution rate of 2.5% and apply it to the hands and feet of the patient.~The massage technique including effleurage, petrissage, friction and lymphatic drainage on hands and feet will be adapted from Salvo, (2015) and Youssef and Hassan, (2017).~The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position."
75717737|NCT00677534|Drug|Cholecalciferol|50,000 Units PO Twice weekly for 8 weeks
75417643|NCT01402557|Behavioral|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
75417644|NCT01402557|Behavioral|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
75441667|NCT01637155|Drug|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
75562949|NCT00500552|Drug|Perhexiline/Placebo|
75717738|NCT00940173|Device|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
75717739|NCT00940173|Device|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
76043022|NCT00921115|Drug|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
75417645|NCT01402557|Behavioral|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
75562950|NCT02954250|Behavioral|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
76043023|NCT00921115|Drug|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
76043024|NCT00130351|Device|formoterol|
76043025|NCT04130893|Behavioral|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
75417646|NCT01402583|Drug|PEG IFN/Ribavirin|PEG IFN/Ribavirin
75417647|NCT01402596|Drug|Midazolam|0,4 mg per kg - intranasal midazolam - once
75417648|NCT01402596|Drug|Chloral Hydrate|50 mg per kg, rectal
75417649|NCT01402609|Device|electronic discharge communication tool|The intervention will consist of discharges being conducted with the use of the electronic discharge communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.
75417650|NCT01402609|Device|Usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
75441668|NCT01637168|Drug|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin|A tablet, 2 times daily (12/12 hours).
75441669|NCT01637168|Drug|Ginkgo Biloba (Tebonin®)|A tablet, 2 times daily (12/12 hours).
75562951|NCT00500591|Behavioral|Questionnaire|Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
76043026|NCT04130893|Behavioral|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
75562952|NCT02954289|Behavioral|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets"
75417651|NCT01402622|Drug|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
75562953|NCT00500630|Device|Body fixed 3D sensors|
75717740|NCT00940173|Device|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
75717741|NCT00940173|Device|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
75717742|NCT02559284|Other|A postoperative care after ethmoid sinus surgery|"A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~Gentle blowing of the nose~Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing)."
76043027|NCT03906565|Drug|utidelone injection|utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
76043028|NCT05534659|Device|Programmable valve|Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
76043029|NCT05534659|Device|Non-programmable valve|Non-programmable valve used in the study was Medtronic CSF-flow control valve.
75417652|NCT01402635|Device|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
75417653|NCT01402648|Dietary Supplement|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
75717743|NCT00801762|Device|Fibered confocal microscope|
75717744|NCT00989716|Drug|Transdermal glyceryl trinitrate patch|5mg per day
75717745|NCT00989716|Drug|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
76043030|NCT05530681|Diagnostic Test|Questionnaire|The survey consists in standardized and validated questionnaires on urinary function (ICIQ-SF, 4 items), bowel function (SMIS, 7 items and PAC-SYM, 12 items), symptoms of prolapse (POPDI, 6 items) and sexual function (Female Sexual Function Index FSFI, 19 items and Female Sexual Distress Scale - Revised FSDS-R, 13 items). questionnaire will be used at recruitment, at the postpartum visit, at the first annual follow-up visit.
76043031|NCT05530681|Diagnostic Test|Pelvic floor ultrasound|Pelvic floor ultrasound is the preferred imaging modality for documenting pelvic floor anatomy during pregnancy or after delivery. This examination is routinely performed in the outpatient clinic during patient visits (including the one year check-up after delivery). The technique used to assess the pelvic floor is described in detail in the 2019 practice parameters issued by IUGA.
75417654|NCT01402648|Dietary Supplement|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
75417655|NCT01402674|Drug|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
75417656|NCT01402713|Biological|GC1107|GC1107-T5.0: low dose, GC1107-T7.5: high dose
75417657|NCT01402713|Biological|TD_PUR INJ / SK Td vaccine|step 1(phase 2)-TD_PUR INJ step 2(phase 3)-SK Td vaccine
75417658|NCT01402726|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
75417659|NCT01402739|Other|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
75417660|NCT01402739|Other|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
75417661|NCT01402752|Biological|Blood flow to the tracheo-bronchial mucosa|Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
75417662|NCT01402765|Device|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
75562954|NCT00508209|Drug|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
75562955|NCT04696913|Diagnostic Test|Exposure: Positive COVID-19 infection|Exposure: Positive COVID-19 infection as determined by RT-PCR
75562956|NCT04696913|Diagnostic Test|Exposure: Negative COVID-19 infection|Exposure: Negative COVID-19 infection as determined by RT-PCR
75562957|NCT02954016|Device|ePass|Subject is implanted with the device for up to 3 years.
75562958|NCT00500669|Drug|Betadine|Topically
75417663|NCT01402765|Device|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
76043032|NCT05530525|Diagnostic Test|The Computerized Adaptive Testing system of the Functional Assessment of Stroke|The Computerized Adaptive Testing system of the Functional Assessment of Stroke comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper limb, 11 items from the Fugl-Meyer Assessment-Lower limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. Results are automatically reported as Rasch scores (i.e., the minimum and maximum values are negative and positive infinity, respectively). A higher score indicates greater physical functions.
76043033|NCT05530525|Diagnostic Test|The Barthel Index|The Barthel Index has 10 items, and the total score ranges from 0 to 100. Higher score indicates less disability on activity of daily living functions.
75417664|NCT01402791|Other|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
75417665|NCT01402830|Other|Visual analogue scales (EVAs)|This scale measures the pain intensity.
75417666|NCT01402843|Drug|pitavastatin, valsartan, placebo|pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
75417667|NCT01402856|Other|Education|An educational program targeting HS students on the risks of distracted driving that was 60-min long & utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, & interactive games simulating distracted driving.
75417668|NCT01402882|Drug|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
75562959|NCT00507585|Drug|Fluorouracil|300 mg/m^2 IV over 10 Minutes, then 600 mg/m^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
75562960|NCT00507585|Drug|Avastin|10 mg/m^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
75562961|NCT00507585|Drug|Leucovorin|200 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
75562962|NCT00507585|Drug|Oxaliplatin|60 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
75717746|NCT00660348|Drug|morphine sulfate|This is morphine given in the traditional methods.
75717747|NCT00660348|Device|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
76043034|NCT05530525|Diagnostic Test|The National Institutes of Health Stroke Scale|The National Institutes of Health Stroke Scale comprises 11 items and was used to monitor the severity in the patients with stroke. The total score ranges from 0 to 42, with a higher score indicating greater severity. A National Institutes of Health Stroke Scale score of 1-5 indicates mild severity; 6-14, mild to moderate severity; 15-24, severe severity; and equal to or greater than 25, very severe severity.
76043035|NCT04425187|Drug|Gefitinib|gefitinib 250mg (1 tablet), once a day，PO
76043036|NCT04425187|Drug|Bevacizumab Combined With Gefitinib|Bevacizumab Combined With Gefitinib
76043037|NCT03756649|Procedure|Blood Draw|50 ml will be collected
75417669|NCT01402895|Other|Exercise|Transversus abdominus exercise
75417670|NCT01402895|Other|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
75417671|NCT01402921|Device|V0322 BC|"Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~3 months duration daily treatment"
75417672|NCT01402934|Procedure|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
75441670|NCT01637181|Procedure|Endovenous laser ablation (EVLA)|EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
75562963|NCT01247636|Other|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
75717748|NCT05408416|Procedure|preoperative group and intraoperative group|ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
75717749|NCT00940251|Drug|Mersina|capsule, 3g/day, 3 months
75717750|NCT04013373|Device|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
75717751|NCT03734198|Drug|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
75873681|NCT05220072|Drug|Carbon-14 BIA 28-6156|Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14
75873682|NCT05672862|Device|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
76043038|NCT03756649|Procedure|Urine Collection|50 ml will be collected
75441671|NCT01637194|Drug|everolimus|Given PO
75562964|NCT01247636|Other|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
75562965|NCT00508248|Dietary Supplement|omega 3 fatty acids|1g daily
75717752|NCT03734198|Drug|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
75873683|NCT05219682|Other|electroencephalographic measurement|recording brain activity in mirror therapy, haptic and tactile stimulation and in mirror therapy using virtual reality
75873684|NCT03822780|Drug|Hydroxychloroquin|Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.
75873685|NCT04765644|Drug|Celecoxib|Two 200 mg capsules per day (400 mg/day) for 7 days
75441672|NCT01637194|Biological|cetuximab|Given IV
75441673|NCT01637194|Other|pharmacological study|Correlative studies
75562966|NCT00508248|Dietary Supplement|placebo|olive oil capsule
75562967|NCT01247714|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
75562968|NCT01247714|Dietary Supplement|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
75562969|NCT01247714|Dietary Supplement|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
75562970|NCT01247714|Dietary Supplement|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
75717753|NCT00660192|Drug|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
75717754|NCT00660192|Other|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
75873686|NCT04765644|Other|Placebo|2 capsules/day for 7 days
75873687|NCT04765644|Other|L-arginine + placebo|L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
75873688|NCT04765644|Other|L-arginine + celecoxib|L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
75873689|NCT05216874|Device|Oclusal Splint|"Cl III Laterognati volunteer group using occlusal stabilization splint before orthognathic surgery~-Splint will be used for at least two months"
75717755|NCT01564108|Drug|Ranibizumab|Series of intravitreal injections of Ranibizumab
75441674|NCT01637194|Other|laboratory biomarker analysis|Correlative studies
75441675|NCT01637220|Biological|Blood volume collected specifically for this study|"case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.~Control patients: 20 ml following neuromuscular blocking drug injection"
75441676|NCT01637233|Drug|Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors|NRTI+PI
75873690|NCT04720872|Other|Manual therapy and vestibular rehabilitation treatment|The experimental group received manual therapy and vestibular rehabilitation treatment.
75873691|NCT05649774|Procedure|Therapy|Only Myofascial Release will be provided
75873692|NCT05649774|Procedure|Taping technique|Only Kinesiotaping will be provided
75873693|NCT05649774|Procedure|Therapy with taping|Myofascial release will be provided followed by Kinesiotaping
75873694|NCT05649774|Procedure|SHAM|Placebo Treatment will be given
76043039|NCT03756649|Procedure|Stool Collection|Three 25 ml tubes will be collected
76043040|NCT04425109|Behavioral|meal test response|soy fermented versus non fermented meal test
76043041|NCT05530447|Drug|Samelisant|Tablet
76043042|NCT03730207|Device|Xpede™ Bone Cement|Xpede™ Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
75417673|NCT01402960|Device|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|"Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)"
75417674|NCT01402973|Other|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
75717756|NCT00801918|Drug|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
75417675|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
75417676|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
75417677|NCT01402999|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
75417678|NCT01403012|Other|Withdrawal of venous blood samples|"Withdrawal of venous blood samples (approx. 20 ml) and 2 skin biopsies (5 mm)~Laboratory measurements:~Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids Genome-wide expression profiles generated from RNA derived from peripheral leukocytes"
75417679|NCT01403025|Drug|liraglutide|Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
75417680|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 1 for 84 days
75417681|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 2 for 84 days
75417682|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 3 for 84 days
75417683|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
75417684|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 5 for 84 days
75562971|NCT00507663|Drug|Atenolol|Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
75717757|NCT00801918|Drug|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
75417685|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 6 for 84 days
75417686|NCT01403038|Drug|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
75417687|NCT01403077|Device|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
75417688|NCT01403103|Dietary Supplement|cholecalciferol|Given PO
75417689|NCT01403103|Procedure|biopsy|Correlative studies
75417690|NCT01403103|Genetic|protein expression analysis|Correlative studies
75417691|NCT01403103|Other|enzyme-linked immunosorbent assay|Correlative studies
75417692|NCT01403103|Other|laboratory biomarker analysis|Correlative studies
75562972|NCT00508287|Drug|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
75417693|NCT01403103|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
75417694|NCT01403129|Procedure|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
75562973|NCT00508287|Drug|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
75562974|NCT00508287|Drug|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
75717758|NCT00799188|Drug|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
75717759|NCT00799344|Device|Catania Stent|coronary stent implantation
76043043|NCT03730207|Device|Mendec Spine Bone Cement|Mendec Spine Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
76043044|NCT03693547|Drug|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
75562975|NCT00507702|Procedure|phlebotomy|Standard of care
75417695|NCT01403129|Procedure|Optical Coherence Tomography (OCT) Exam|OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
75562976|NCT00500747|Biological|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
75562977|NCT00500747|Drug|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
75562978|NCT00508326|Drug|Paclitaxel|Starting dose 150 mg/m^2 HAI once every 4 weeks
75562979|NCT01247753|Behavioral|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
75562980|NCT00507780|Drug|GnRH antagonist|
75562981|NCT00500786|Biological|CYT006-AngQb|
75717760|NCT00571688|Drug|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score > 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
75417696|NCT01403155|Biological|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
75417697|NCT01403168|Other|OSTEOPATHY + conventional analgesic treatments|"5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment."
75717761|NCT00571688|Drug|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
75717762|NCT00989794|Device|GelrinC|Applied once during surgery
75562982|NCT00507858|Drug|Pemetrexed|Starting dose of 500 mg/m^2 IV Once Over 10 Minutes Every 3 Weeks
75562983|NCT00507858|Drug|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
75562984|NCT01245920|Biological|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
75417698|NCT01403168|Other|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
75417699|NCT01403181|Drug|Boceprevir|"In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data."
75441677|NCT01637233|Drug|Arm 2 Maraviroc and Protease Inhibitors|maraviroc + PI
75417700|NCT01403207|Other|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
75562985|NCT01245920|Other|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
75562986|NCT00500825|Procedure|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
75562987|NCT00508365|Drug|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
75717763|NCT00794274|Drug|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
75717764|NCT00989872|Drug|EDP-322|
75717765|NCT02560610|Drug|OC000459|
75717766|NCT02560610|Drug|Placebo|
75717767|NCT00799500|Other|Screening|Weekly vaginal pH
75717768|NCT05590546|Other|No intervention|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
75417701|NCT01403220|Procedure|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
75417702|NCT01403220|Procedure|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
75417703|NCT01403233|Dietary Supplement|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
75417704|NCT01403233|Dietary Supplement|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
75417705|NCT01403233|Dietary Supplement|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
75417706|NCT01403259|Drug|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
75417707|NCT01403272|Device|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
75717769|NCT02560532|Drug|Clazosentan|Concentrated solution for intravenous injection
75717770|NCT00799656|Drug|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
75417708|NCT01403285|Drug|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
75417709|NCT01403285|Biological|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
75417710|NCT01403285|Biological|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
75717771|NCT00799656|Drug|placebo|oral administration once daily for 28 days
75417711|NCT01403285|Drug|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
75417712|NCT01403298|Behavioral|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
75417713|NCT01403298|Other|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
75562988|NCT00508365|Drug|Placebo|Placebo capsules to match each dose level will be provided.
75562989|NCT00508365|Drug|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
75562990|NCT01316393|Other|XER2020|mucoprotective product
75562991|NCT00500864|Drug|Magnesium Sulfate 2 grams|
75562992|NCT00508560|Behavioral|Contingency Management|"Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value."
75562993|NCT00508560|Behavioral|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
75417714|NCT01403311|Drug|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
75417715|NCT01403324|Drug|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
75417716|NCT01403337|Other|Ischemic preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
75417717|NCT01403337|Other|Control|A Blood Pressure cuff inflated to 40-50 mmHg
75417718|NCT01403363|Drug|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
75417719|NCT01403389|Drug|Eculizumab|1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
75417720|NCT01403389|Drug|Placebo|240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
75717772|NCT05408182|Procedure|Robotic colorectal resection with ERAS (or eRCS) perioperative care|All patients will undergo robotic colorectal resections using the Da Vinci xi system. All common colorectal procedures will be included: right/left colectomy, sigmoid colectomy, anterior resection with PME/TME/TaTME. Patient will undergo an enhanced recovery pathway perioperatively ensuring prompt recovery and early discharge. Most ERAS guidelines will be followed including preoperative nutrition, behavioral training, avoidance of drains, NG tubes, catheters, opioids, patient based volume repletion, wound local anesthetic infiltration, early mobilization, early postoperative feeding, spirometry and physiotherapy.
75717773|NCT04050020|Biological|Platelet-Rich Plasma (PRP)|All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
75873695|NCT05214846|Behavioral|Education and counseling|After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
75873696|NCT03052764|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
75417721|NCT01403415|Drug|Dexamethasone|Given PO or IV
75417722|NCT01403415|Other|Laboratory Biomarker Analysis|Correlative studies
75417723|NCT01403415|Drug|Methotrexate|Given IT
75417724|NCT01403415|Drug|Mitoxantrone Hydrochloride|Given IV
75417725|NCT01403415|Drug|Pegaspargase|Given IV
75417726|NCT01403415|Other|Pharmacological Study|Correlative studies
75417727|NCT01403415|Drug|Temsirolimus|Given IV
75417728|NCT01403415|Drug|Vincristine Sulfate|Given IV
75417729|NCT01403428|Other|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
75417730|NCT01403454|Behavioral|Interactive Health Communication Application|web-based application
75417731|NCT01403467|Device|Continuous positive airway pressure|CPAP 8 cmH2O
75417732|NCT01403493|Behavioral|Patient education|
75417733|NCT01403506|Drug|N-acetyl Cysteine|600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
75417734|NCT01403532|Drug|Traditional intervention for HH using HCG and FSH|Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
75441678|NCT01637233|Drug|Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors|maraviroc + NRTI
75417735|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH|Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
75417736|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH plus zinc|Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
75417737|NCT01403545|Drug|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
75417738|NCT01403545|Other|Placebo|5% glucose infusion over 120 minutes
75417739|NCT01403558|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
75417740|NCT01403571|Dietary Supplement|Salba (Salvia hispanica L.)|30g/1000kcal/day over 24 wks
75417741|NCT01403571|Dietary Supplement|Oat-based Control|Placebo: 36g/1000kcal/day over 24 weeks
75562994|NCT01247831|Procedure|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
75562995|NCT00507975|Drug|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
75562996|NCT01247909|Drug|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
75562997|NCT02954328|Device|tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
75717774|NCT04050020|Biological|Normal saline injection|All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
75717775|NCT05408104|Drug|tolvaptan|LVAD recipients with post-operative hyponatremia (Na < 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
75717776|NCT00802152|Other|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
75717777|NCT00343291|Biological|Cetuximab|Administered intravenously
75717778|NCT00343291|Biological|Bevacizumab|Administered intravenously
75717779|NCT00343291|Drug|Paclitaxel|Administered intravenously
75417742|NCT01403597|Device|Refirme ST Applicator and Matrix RF Applicator|5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
75417743|NCT01403623|Procedure|Resuscitation and post resuscitation care with plastic bag|Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
75417744|NCT01403623|Procedure|Resuscitation- no plastic bag for temperature regulation|Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
75441679|NCT01637259|Drug|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
75441680|NCT01637259|Drug|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
75417745|NCT01403649|Behavioral|Private/public collaboration to increase flu vaccination|Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
75417746|NCT01403649|Other|Usual care|This group will continue administering influenza vaccine to their patients in their practice as they normally do.
75417747|NCT01403662|Drug|Minocycline|Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
75562998|NCT01247948|Procedure|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
75562999|NCT01247948|Procedure|traditional spine surgery|traditional spine surgery without navigation assist
75563000|NCT02954211|Device|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
75563001|NCT02954211|Behavioral|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
75873697|NCT03052764|Drug|Placebo (saline)|Placebo (saline) injection into the bladder.
75873698|NCT05638698|Biological|TG01 Vaccine|used to assess molecular disease control rate when combined with other interventional methods.
75873699|NCT05638698|Drug|QS-21|used to assess molecular disease control rate when combined with other interventional methods.
75873700|NCT05638698|Drug|Balstilimab|used to assess molecular disease control rate when combined with other interventional methods.
75873701|NCT05637138|Device|tcpCO2 measure|Measurement of tcpCO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
75873702|NCT05637138|Device|tcpO2 measure|Measurement of tcpO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
75873703|NCT05637138|Device|measurement of tissue conductivity to CO2: KS|measurement of tissue conductivity to CO2: KS by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
75873704|NCT05637138|Device|measurement of microcirculation|measurement of microcirculation by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
75873705|NCT05707338|Procedure|Gastrectomy with lymph node dissection|"prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group)."
75441681|NCT01637259|Drug|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
75441682|NCT01637285|Biological|PF-04856883|Dose A
75563002|NCT01245998|Drug|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
75717780|NCT00343291|Drug|Carboplatin|Administered intravenously
75441683|NCT01637285|Biological|PF-04856883|Dose B
75441684|NCT01637285|Biological|PF-04856883|Dose C
75441685|NCT01637285|Biological|PF-04856883|Dose D
75441686|NCT01637311|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
75441687|NCT01637337|Procedure|laparoscopic pyelolithotomy|laparoscopy
75717781|NCT00799734|Drug|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
75563003|NCT01245998|Drug|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
75717782|NCT05407870|Drug|Etomidate Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
75717783|NCT05407870|Drug|Propofol Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
75717784|NCT03988231|Drug|Receipt of enoxaparin|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
75717785|NCT03988231|Drug|Placebo|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
75717786|NCT03988465|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
75717787|NCT03742219|Behavioral|Lifestyle Modification|"Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters."
75717788|NCT00658788|Drug|clobetasol propionate spray 0.05%|clobetasol propionate spray, 0.05%, applied topically twice daily
75417748|NCT01403675|Procedure|Ovarian autotransplantation|There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
75417749|NCT01403688|Procedure|RPFNA|"Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).~Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment~Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding"
75417750|NCT01403701|Behavioral|Physical therapy|pelvic floor physical therapy
75417751|NCT01403714|Procedure|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
75563004|NCT02954484|Drug|pregabalin|see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.
75563005|NCT02954484|Drug|Placebo|Placebo capsule containing lactose and MCC (no active ingredients).
75563006|NCT02954484|Drug|Etoricoxib|Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
75563007|NCT02954484|Drug|paracetamol|Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia
75563008|NCT02954484|Drug|Morphine|"patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany"
75563009|NCT02954484|Drug|Ropivacaine|Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
75717789|NCT00658788|Drug|calcitriol ointment|calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
75717790|NCT05407402|Behavioral|laughter yoga practice|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
75563010|NCT01247987|Procedure|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
76043045|NCT05534113|Drug|Almonertinib Envafolimab|"Subjects will receive Almonertinib treatment for 6-8 weeks after enrollment, and receive ctDNA detection and radiography assessment again.~If the EGFR mutation is positive, according to the patient's condition and clinical actual situation, subjects will receive combination therapy scheme, follow-up once every 6 weeks. The treatment will continue until the disease progress assessed by radiography.~If the EGFR mutation turns negative and stable radiographically deep response, stop Almonertinib treatment and receive the relevant assessment before immunotherapy and receive Envafolimab treatment，and follow-up once every 6 weeks. The treatment of Envafolimab will continue until the EGFR mutation is positive again or disease progress assessed by radiography."
75717791|NCT05407402|Behavioral|watching funny videos|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
75717792|NCT01060969|Drug|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
76043046|NCT05534035|Biological|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
76043047|NCT05534035|Biological|Vaxzevria®|The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6. One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S* recombinant) 5 × 1010 viral particles (vp) (corresponding to not less than 2.5 × 108 ifu).
76043048|NCT05530057|Drug|Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|"Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~Dose reductions for eribulin, but not for SB3, is permitted.~Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa."
75717793|NCT01060969|Drug|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
75873706|NCT05707260|Behavioral|CKD SMS|The intervention begins with a face-to-face or digitally assisted session, entry into improving the knowledge and self-management of CKD through, using the four sources of manipulation of self-efficacy (achievement of performance, indirect experience, verbal persuasion, and self-evaluation). In this session, participants will be asked to identify their problems related to CKD and establish, based on these two goals, that they are real and achievable according to their priorities. These goals will be recorded in the monitoring format and will be monitored in the telephone or WhatsApp follow-ups. This using the performance achievement manipulation source, said session lasts 60 minutes, as does the final session at week 16.
75873707|NCT05197374|Drug|Estradiol Valerate 4mg|Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
75417752|NCT01403740|Drug|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
75417753|NCT01403779|Radiation|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
75417754|NCT01403792|Drug|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
75417755|NCT01403818|Drug|ASP1941|oral
75417756|NCT01403818|Drug|Mitiglinide calcium hydrate|oral
75417757|NCT01403831|Other|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
75417758|NCT01403844|Other|Carotenoid Depletion|Depletion of carotenoids using a restricted food list
75563011|NCT01247987|Procedure|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
75563012|NCT02954367|Dietary Supplement|PROTEIN|Immediately (<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
75717794|NCT05407246|Drug|Hemay005|Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
75717795|NCT01061047|Drug|Ertapeneme|
75717796|NCT00799890|Drug|Sunphenon EGCG|200-800mg (1-4 capsules)
75717797|NCT00799890|Drug|Placebo|1-4 capsules
75717798|NCT01057771|Behavioral|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
75563013|NCT02954367|Dietary Supplement|CARBOHYDRATE|Immediately (<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
76043049|NCT05530057|Drug|Eribulin Mesylate|"Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation."
75563014|NCT01248026|Other|Buttermilk|"Consumption of the 2 experimental periods~buttermilk (45 g/d)~placebo (45 g/d,)"
75417759|NCT01403844|Other|Carotenoid Repletion|Carotenoid repletion with provided diet based on dietary guidelines.
75417760|NCT01403844|Other|Carotenoid Depletion|Carotenoid depletion using a restricted food list.
75563015|NCT02954133|Device|Invisalign (7 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.
75563016|NCT02954133|Device|Invisalign (5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
75563017|NCT02954133|Device|OrthoPulse|Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
75563018|NCT02954133|Device|Invisalign (3.5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 3.5 days.
75563019|NCT00500942|Behavioral|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
75717799|NCT01057771|Behavioral|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
75717800|NCT00799968|Drug|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
76043050|NCT05533957|Other|Application of different dosages of oxygen therapy|To evaluate the response (vasodilation, neuromuscular fatigue and muscle oxygenation) of the administration of different dosages of oxygen therapy (ie. FiO2) in patients with COPD associated with CRF and LTOT
75417761|NCT01403844|Other|Natural Repletion|Resumption of usual personal diet regimen. No restrictions.
75417762|NCT01403857|Other|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
75717801|NCT00799968|Drug|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
75717802|NCT01061125|Other|TTM and Holter monitor|Standard of care visits recordings reviewed during clinical visits
75717803|NCT01055275|Device|Implantation with a Cook Iliac Branch Graft|Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
75717804|NCT00800046|Device|AccuCinch® Ventriculoplasty System|Mitral valve repair due to functional disease
75717805|NCT04002544|Drug|NTG patch|A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
76043051|NCT04310917|Other|blood lipoprotein (a) test|research specific blood sample
76043052|NCT02576587|Other|Continuous Positive Airway Pressure|For cases, those found to have moderate sleep apnea (AHI >=15) will be place on CPAP therapy.
76043053|NCT05519839|Drug|CIC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
75717806|NCT04002544|Other|gauze cover|A gauze will be applied near the radial artery pulsation to ensure blinding
75717807|NCT04829214|Drug|OTO-313|Single intratympanic injection
75717808|NCT04829214|Drug|Placebo|Single intratympanic injection
75417763|NCT01403857|Other|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
75563020|NCT00500981|Procedure|Volume challenge|
75563021|NCT00500981|Procedure|Ultrasound evaluation of internal jugular vein|
75563022|NCT00501020|Drug|Rosiglitazone|
75563023|NCT00508014|Other|Usual Care|Usual Care with primary care provider during time period
75563024|NCT00508014|Behavioral|Concurrent Peer Review visit|Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
75717809|NCT00802308|Drug|Morphine sulphate|Extended release tablet combined with alcohol or water
75717810|NCT00562965|Drug|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
75717811|NCT00562965|Drug|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
75563025|NCT00501098|Drug|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
75563026|NCT00508053|Procedure|Small stitches|
75563027|NCT00508053|Procedure|Mass closure|
75563028|NCT00501137|Biological|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
75563029|NCT00508131|Other|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
75563030|NCT01248260|Dietary Supplement|Folic Acid|4mg of higher strength folic acid once a day until delivery
75563031|NCT00508950|Procedure|Large volume blood draw|Large volume blood draw
75563032|NCT00503945|Device|Nasal continuous positive airway pressure (nCPAP)|
75563033|NCT01246037|Drug|Bisoprolol|In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
75563034|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
75563035|NCT00501215|Behavioral|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
75563036|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
75563037|NCT00501215|Behavioral|Polysomnography (PSG)|"2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
75563038|NCT00509184|Drug|Rituximab|375 mg/m^2, weekly (4 weeks), repeated after 4 weeks gap
75563039|NCT00508599|Other|Study 2 (48 hours of complete bed rest)|Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
75563040|NCT00501254|Drug|Slow release acetyl salicylic acid|
75717812|NCT00562965|Drug|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
75717813|NCT00562965|Drug|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
75717814|NCT00562965|Drug|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
75717815|NCT00562965|Drug|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
75717816|NCT00562965|Drug|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
75417764|NCT01403870|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
75417765|NCT01403883|Behavioral|Standard Care|Psychological & enterostomal therapy clinics on demand only
75417766|NCT01403883|Behavioral|Optimal care (Psychological and enterostomal therapy clinics)|Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
75417767|NCT01403896|Drug|Plerixafor (Mozobil)|They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
75417768|NCT01403896|Drug|Plerixafor + G-CSF|They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
75563041|NCT00501254|Behavioral|Antithrombotic effect|
75563042|NCT00509301|Drug|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
75717817|NCT00562965|Drug|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
75717818|NCT00562965|Drug|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
75717819|NCT05358496|Diagnostic Test|Data collection|Clinical data collection
75717820|NCT05407090|Dietary Supplement|probiotic supplementation|Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.
75717821|NCT05407090|Dietary Supplement|placebo|Participants enrolled in the placebo group will receive a placebo instead of probiotics.
76043054|NCT05519839|Drug|CIC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV, SARS-CoV-2 rS, and 75 μg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
76043055|NCT05519839|Drug|qNIV Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV and 75 μg Matrix-M1 Adjuvant (Influenza Vaccine) on Day 0.
75417769|NCT01403909|Device|Intermittent pneumatic compression|Intermittent pneumatic venous compression is applied to the lower limbs of patients during surgery.
75417770|NCT01403909|Procedure|Standard care|Intermittent pneumatic venous compression is not applied to the lower limbs of patients during surgery.
75417771|NCT01403922|Drug|TC-5214|Tablet oral bid days 1 to 7
75417772|NCT01403922|Drug|TC-5214|Tablet oral bid days 8 to 14
75417773|NCT01403948|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
75417774|NCT01403974|Drug|BI 836845|Intravenous infusion once every week
75563043|NCT01248338|Drug|metoprolol succinate|once daily 50 or 100 mg for one year
75717822|NCT00802620|Procedure|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
75417775|NCT01404000|Drug|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
75417776|NCT01404013|Drug|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
75563044|NCT01248338|Drug|Nebivolol|once daily 5 mg capsule for one year
75717823|NCT05406934|Biological|Infliximab|obseravation with investigation
75717824|NCT00800124|Procedure|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
75563045|NCT01248377|Procedure|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
75563046|NCT01246154|Other|EXERCISE TRAINING|EXERCISE TRAINING
75563047|NCT02953743|Drug|Lenvatinib|Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
75563048|NCT01246193|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
75717825|NCT00940329|Drug|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
75717826|NCT00940329|Drug|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
75417777|NCT01404013|Drug|Montelukast|Montelukast 10mg ,every night, for 8 weeks
75417778|NCT01404013|Drug|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
75417779|NCT01404026|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
75417780|NCT01404052|Device|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
75717827|NCT00794898|Biological|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
75417781|NCT01404065|Procedure|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
75563049|NCT01246193|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
75717828|NCT00934557|Drug|ATG Fresenius|
75717829|NCT00934557|Drug|ATG Fresenius|
75717830|NCT00934557|Drug|ATG Fresenius|
75717831|NCT00934557|Drug|ATG Fresenius|
75873708|NCT05707104|Other|Pilates Exercises|"NO. Exercises Targeted muscles Repetitions~Pelvic curl Abdominals, Hamstrings & Quadriceps Femoris, Gluteus Maximums. 05~Chest lift Rectus Abdominus, Internal & External Oblique Muscles 10~Leg lift supine Quadriceps Femoris, Internal & External Oblique Muscles 10~Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal & External Oblique Muscle 10~Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~Spine twist supine Abdominals,Quadriceps & Hamstring group of Muscles 10~Chest lift with rotation Internal & External Oblique, Rectus & Transverses Abdominus Muscles 5 on each side~Back extension BACK EXTENSION Abdominal group, Gluteus Maximus & Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds"
75873709|NCT05707104|Other|plyometrics exercises|"SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6"
75563050|NCT00509340|Behavioral|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
75717832|NCT00934557|Drug|ATG Fresenius|
75717833|NCT00934557|Drug|ATG Fresenius|
75717834|NCT00934557|Drug|ATG Fresenius|
75563051|NCT02274935|Other|Exercise|Balance and gait exercise twice a week for an hour
75717835|NCT00934557|Drug|ATG Fresenius|
75717836|NCT05357092|Device|Appliance. Orthodontic appliance to carry out dentoalveolar movement|"A digital 3D model obtained with a 3D scanner: (T1,baseline), (T2, aprox 8 weeks), and at the end of othopedic treatment previous to primary lip surgery (T3, aprox 16 weeks).~Once a week, clinical check."
75717837|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
75717838|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
75717839|NCT00800280|Drug|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
75717840|NCT04014153|Procedure|Iodinated contrast media|Percutaneous coronary intervention with iodinated contest media
75417782|NCT01404091|Drug|LY2940094|Administered orally
75417783|NCT01404104|Drug|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
75563052|NCT00509379|Drug|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
75563053|NCT00509379|Drug|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
75717841|NCT04996576|Procedure|infrazygomatic approach sphinopalatine ganglion block|"A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
75717842|NCT04996576|Procedure|intranasal injection approach of sphinopalatine ganglion block|method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
75717843|NCT00800358|Drug|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
75717844|NCT00800358|Drug|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
75873710|NCT02951819|Drug|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
75563054|NCT00509418|Dietary Supplement|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
75563055|NCT00509418|Other|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
75717845|NCT00934713|Drug|montelukast|montelukast 4mg once per day for 8 weeks period
75873711|NCT02951819|Drug|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m^2 ) on Days 1, 8, 15, and 22 for every 28 days.
75873712|NCT02951819|Drug|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
75873713|NCT02951819|Drug|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
75873714|NCT03707717|Drug|Bimekizumab|Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
75417784|NCT01404117|Drug|Laquinimod 0.6|Laquinimod 0.6 capsule
75417785|NCT01404117|Drug|Laquinimod 1.2|Placebo
75417786|NCT01404117|Other|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
75417787|NCT01404130|Drug|Isotretinoin|0.5-1mg/kg daily for 4-6 months
75417788|NCT01404143|Procedure|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
75563056|NCT02274974|Drug|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
75563057|NCT02274974|Drug|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
75563058|NCT00509457|Biological|GV 1001 Telomerase peptide|
75563059|NCT02274545|Biological|H7N9 Anhui 2013/AA ca|10^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
75563060|NCT02274545|Biological|Inactivated subvirion H7N9 vaccine|30 mcg
75563061|NCT02953470|Behavioral|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
75563062|NCT02953470|Behavioral|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
75717846|NCT00802698|Device|Transcorneal electric stimulation|central artery occlusion
75717847|NCT00802698|Device|Transcorneal stimulation|new waveform
75717848|NCT00802698|Device|transcorneal electric stimulation|Novel waveform central artery occlusion
75563063|NCT02275013|Drug|Levosimendan|
75717849|NCT00935025|Drug|AZD1305|single and multiple oral doses, extended-release capsule
75717850|NCT00935025|Drug|Placebo|single and multiple oral doses, capsule
75563064|NCT00509535|Drug|vitreoscilla filiformis cream|
75563065|NCT02274584|Genetic|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
76043056|NCT05519839|Drug|SARS-CoV-2 rS Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS, Diluent, and 50 μg Matrix-M1 Adjuvant (SARS-CoV-2 rS Vaccine) on Day 0.
76043057|NCT05519839|Drug|Influenza Vaccine|Intramuscular (deltoid) injections of Comparator influenza on Day 0.
75563066|NCT02274623|Drug|CTAP101 Capsules|escalating doses
75563067|NCT00509613|Drug|Sorafenib|
75563068|NCT00509613|Drug|Sirolimus|
75563069|NCT02953626|Behavioral|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
75563070|NCT00501332|Biological|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
75717851|NCT00802776|Procedure|Femtosecond laser assisted keratoplasty|
75717852|NCT00802776|Procedure|PKP|
75717853|NCT00939861|Procedure|laparoscopy|colorectal resection
75717854|NCT00939861|Procedure|laparotomy|colorectal resection
75717855|NCT00802932|Device|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
75717856|NCT00802932|Device|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
75717857|NCT01057849|Drug|risperidone|3-6 mg per day
75717858|NCT01057849|Drug|olanzapine|5-20 mg per day
75717859|NCT01057849|Drug|Aripiprazole|10-30 mg per day
75717860|NCT00940407|Device|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
75563071|NCT02953353|Device|Active transcranial direct current stimulation (tDCS)|Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
75717861|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (low dose)|
75717862|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (high dose)|
75717863|NCT00794976|Drug|Dexamethasone Passive Patch|
75717864|NCT00794976|Drug|Placebo Patch|
75717865|NCT00939939|Drug|sitagliptin|sitagliptin 100 mg/d for 10 weeks
75717866|NCT00939939|Drug|glimepiride|glimepiride 1 mg/d for 10 weeks
75873715|NCT05191290|Drug|unfractionated heparin|standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis
75873716|NCT05191290|Drug|Sodium Citrate|8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis
75873717|NCT05627544|Procedure|Anesthesia management/Hip replacement surgery|The effect of anesthesia management on blood transfusion practices in hip replacement surgeries
75873718|NCT05627544|Procedure|Demographic data|The effect of demographic data on blood transfusion practices in hip replacement surgeries
76043058|NCT05519839|Drug|CIC Vaccine|Intramuscular (deltoid) injections of co-formulated mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
76043059|NCT03648073|Drug|[68Ga]DOTATATE-PET/MRI|[68Ga]DOTATATE-PET/MRI
75563072|NCT02953353|Other|Hypocaloric diet|During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
75563073|NCT02953353|Other|Sham transcranial direct current stimulation (tDCS)|Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
75563074|NCT00501371|Drug|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
75873719|NCT05627544|Procedure|Chronic diseases|The effect of chronic diseases on blood transfusion practices in hip replacement surgeries
75873720|NCT05627544|Procedure|Postoperative complication|The effect of blood transfusion applications on postoperative complications in hip replacement surgeries
75563075|NCT00501371|Drug|Placebo|soft-gel capsule, Qd, 12 weeks
75563076|NCT00509652|Procedure|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
75563077|NCT00509652|Procedure|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
75563078|NCT00501410|Drug|5-FU|2400 mg/m^2 by vein over 46 Hours On Days 1 & 2.
75563079|NCT00501410|Drug|Cetuximab|Initial Dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8
75873721|NCT05707026|Other|cross fiber fascial manipulation|The group A received three sessions of fascial manipulation in two weeks. FM applied for 5 to 8 minutes at each point.
76043060|NCT03622411|Device|speech app|language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
76043061|NCT03622411|Device|brain games|language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
76043062|NCT03622411|Behavioral|aphasia therapy|language exercises provided by the speech therapist in hospital
76043063|NCT05533879|Other|Tele-yoga|Women with chronic low back pain will be taken to group-based Tele-Yoga sessions of 60 minutes three times a week for 4 weeks, in an internet-based telerehabilitation environment.
76043064|NCT05369845|Other|questionary|the patient will complete validated questionnaires, at three periods (at the time of the initiation of the CPAP, and during the 2 planned follow-up consultations: four months and at 1 year) The validated questionnaires are as follows: Illness Perception Questionnaire (IPQ-R), Beliefs about Medicines Questionnaire (BMQ), Morisky Medication Adherence Scale (MMAS), Hospital Anxiety and Depression Scale (HADS), Rollnick Scale.
76043065|NCT05529745|Other|Neurorehabilitation cerebellar cognitive disorder|Influence of neurorehabilitation treatment lines of physiotherapy and exercise therapy including scheduled occupational therapy to adapt and improve cognitive-affective disorders in cerebellar lesions.
75417789|NCT01404143|Procedure|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
75563080|NCT00501410|Drug|Dasatinib|Starting dose level: 100 mg by mouth daily on days 1-14.
75563081|NCT00501410|Drug|Leucovorin|400 mg/m^2 by vein on day 1.
75563082|NCT00501410|Drug|Oxaliplatin|85 mg/m^2 by vein on day 1.
75441688|NCT01637337|Procedure|percutaneous nephrolithotomy|percutaneous nephrolithotomy
75441689|NCT01637350|Procedure|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
75563083|NCT02953392|Device|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
75563084|NCT02953392|Device|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
75563085|NCT02953392|Device|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
75563086|NCT02953392|Device|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
75563087|NCT00501449|Behavioral|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
75563088|NCT00508833|Biological|287615 containing HBsAg with adjuvants|
75563089|NCT02955953|Drug|LY2963016|Administered SC
75563090|NCT02953275|Drug|vedolizumab|standard of care
75563091|NCT02953275|Drug|Pentoxifylline|added to vedolizumab
75563092|NCT02953275|Drug|placebo|added to vedolizumab
75441690|NCT01637363|Behavioral|Psychoeducation|6 x 2 hours of psychoeducation
75441691|NCT01637376|Drug|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
75563093|NCT00501488|Drug|rosiglitazone|
75563094|NCT02953119|Other|Prehabilitation|
75563095|NCT02955563|Other|CSDM Web-Based Tool Intervention|The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
75717867|NCT00537082|Drug|FTY720|Administered orally once daily for 6 months
75717868|NCT00537082|Drug|Placebo|Administered orally once daily for 6 months
75717869|NCT03828487|Device|Masimo O3 Neonatal Sensors|Regional Oximetry sensor for Neonates
75717870|NCT03828487|Device|510(k) cleared sensor|Cleared Regional Oximetry sensor for Neonates
75717871|NCT00795054|Other|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
75717872|NCT04012983|Diagnostic Test|gingival crevicular fluid level|gingival crevicular fluid collection
75717873|NCT00805662|Drug|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
75717874|NCT03988153|Combination Product|Probiotic Milk Formula|Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
75563096|NCT00508911|Drug|GW876008|GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
75563097|NCT00508911|Drug|COC|COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
75563098|NCT02955719|Drug|Sertraline|
75417790|NCT01404156|Drug|(Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)"
75563099|NCT02955719|Drug|Venlafaxine|
75717875|NCT04014309|Other|Supportive and survivorship care program|Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
75563100|NCT02955719|Other|CBT/Psychological Therapy|
75563101|NCT02955719|Other|Psychiatric Consultation|
75717876|NCT04014309|Other|Usual care|Usual care
75717877|NCT04978012|Drug|Fluzoparib and Camrelizumab|Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
75717878|NCT00803088|Device|The Alair System|Treatment of airways with the Alair System
75563102|NCT02955719|Other|Lifestyle Intervention Resources|
75563103|NCT00509691|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
75563104|NCT00509691|Genetic|polymerase chain reaction|
75563105|NCT00509691|Other|diagnostic laboratory biomarker analysis|
75717879|NCT01061203|Drug|Grazax|Treatment with 75.000 SQ-T once daily
75717880|NCT01061203|Drug|Placebo|Tablet with no active grass component.
75717881|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
75563106|NCT00509691|Other|flow cytometry|
75563107|NCT00509691|Other|immunologic technique|
75563108|NCT00501527|Biological|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
75563109|NCT00501527|Other|Placebo|Placebo 2 drops daily
75563110|NCT00509730|Procedure|Urodynamics|
75563111|NCT02955524|Drug|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
75563112|NCT02955524|Drug|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
75563113|NCT02953041|Drug|Glycopyrronium|long-acting muscarinic antagonist
75563114|NCT02953041|Drug|Indacaterol|ultra long-acting beta agonist
75563115|NCT00501566|Drug|satavaptan (SR121463B)|
75563116|NCT00509808|Device|Electrostimulation|"1st month GN wearing (activated or sham mode)~2nd month wearing (opposite mode)~3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes~6th - 8th month: activated GN wearing for 1, 5 or 10 minutes~9th - 11th month: activated GN wearing for 1, 5 or 10 minutes"
75563117|NCT00501605|Drug|AZD2171|
75563118|NCT00509847|Drug|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
75563119|NCT01248494|Drug|BEZ235|"Dose level 1: 400mg PO BID~Dose level -1: 400mg PO in AM and 200mg PO in PM~Dose level -2: 200mg PO BID"
75563120|NCT01248494|Drug|BKM 120|"Dose Level 1: BKM120, 100 mg PO daily~Dose level -1: BKM120, 80 mg PO daily~Dose Level -2: BKM120, 60 mg PO daily"
75563121|NCT01248494|Drug|Letrozole|All levels: 2.5mg/day PO
75717882|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
75717883|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
75563122|NCT01248494|Drug|BKM120|"Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
75563123|NCT00509886|Drug|Drysol|20% aluminum chloride hexahydrate
75717884|NCT00935181|Behavioral|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
75717885|NCT00324961|Drug|adefovir dipivoxil tablets|adefovir dipivoxil once daily 10 mg orally
75717886|NCT04002232|Device|CPP-ACP-NaF varnish|calcium phosphate containing fluoride releasing varnish to prevent caries
75563124|NCT00509886|Drug|Drioff|1% aluminum acetate
75717887|NCT04013451|Behavioral|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
75873722|NCT05707026|Other|stretching techniques(sleeper stretch and cross body adduction stretch)|Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets.
75417791|NCT01404156|Other|Carboplatin paclitaxel plus concurrent radiotherapy|"5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:~paclitaxel: 50 mg / m2 IV over 1 hour~carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion~Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~1. Dose specifications:~Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.~Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment ."
75563125|NCT00501683|Drug|Radiolabelled GSK189075|
75563126|NCT02952573|Drug|JNJ-42756493|Once daily dosing
75563127|NCT02952573|Drug|Dexamethasone|Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
75563128|NCT03459963|Device|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
75873723|NCT05189028|Drug|gemcitabine and cisplatin|Neoadjuvant chemotherapy:gemcitabine and cisplatin
75873724|NCT05609058|Device|dedicated treatment board with no degree|the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
75563129|NCT01248572|Device|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
75563130|NCT02953080|Other|Call for life mHealth adherence support|Daily/ weekly pill reminder support Health Info-tips Appointment visit reminders Self-reported symptom support
75563131|NCT00501722|Drug|satavaptan (SR121463B)|
75563132|NCT02952768|Behavioral|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
75417792|NCT01404169|Drug|E2020|In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
75563133|NCT01248611|Drug|fentanyl|nasally, dose titrated to effect
75563134|NCT00509964|Drug|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
75563135|NCT00509964|Drug|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
75717888|NCT05357014|Diagnostic Test|echocardiography|evaluation of cardiac function hn children on regular heamodialysis by echocardiography
76043066|NCT05533723|Procedure|Endoscopic epidural neuroplasty|"EEN catheter, iDolphine S2 (Meta Biomed Co., Ltd, Osong, Korea) was placed in the epidural space through sacral hiatus. EEN was done on the target segments.~During EEN, normal saline was infused into epidural space under epiduroscopic vision. Dexamethasone (5 mg), 0.3% mepivacaine 10 mL, and hyaluronidase (3000 IU) were injected through catheter at the target segments. Holmium-Yag laser was used to cut epidural fibrous bands and for coagulation of epidural bleeding."
75417793|NCT01404169|Drug|Placebo|Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
75563136|NCT04696874|Procedure||All testes were fixed to the ipsilateral sub-dartos pouch. All epididymides and vasa deferentia were carefully examined, and any observed anomalies were recorded.
75563137|NCT02952729|Drug|XMT-1522|one intravenous dose administered in-clinic every 21 days
75563138|NCT00501761|Behavioral|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
75563139|NCT00501761|Behavioral|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
75563140|NCT00501761|Behavioral|Suggested Exercise Program|Exercise program performed over 7 days.
75563141|NCT01248650|Drug|nalfurafine hydrochloride|
75563142|NCT00510471|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
75563143|NCT00501839|Drug|clomiphene citrate|
75563144|NCT00510003|Drug|Pimecrolimus|Pimecrolimus cream 1 %
75563145|NCT00501878|Drug|2.5% or 10% phenylephrine|
75563146|NCT00510549|Procedure|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
76043067|NCT05533723|Procedure|Percutaneous epidural neuroplasty (PEN)|PEN catheter, EDEN-CC (JMT, Yangju, Korea) was placed in the epidural space and neural foramen . PEN was done on the target segments. Dexamethasone (5 mg), 0.3% mepivacaine 10 ml, and hyaluronidase (3000 IU) were injected through the PEN catheter.
76043068|NCT05529667|Drug|INCB054828, Paclitaxel|"phase 1>~- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent."
75563147|NCT00501917|Drug|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
76043069|NCT05533645|Other|Questionnaire|These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
75417794|NCT01404182|Biological|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
75417795|NCT01404195|Dietary Supplement|Ensure Plus Advance|Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
75417796|NCT01404247|Other|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
75417797|NCT01404247|Procedure|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
75563148|NCT00510588|Other|training|regular physical exercise training for 6 months
75563149|NCT00510588|Other|training + metformin|regular physical exercise training in combination with metformin for 6 months
75563150|NCT00510588|Other|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
75563151|NCT00501956|Drug|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
75563152|NCT00510627|Device|Radiofrequency Ablation (RFA)|The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
75563153|NCT00510627|Drug|Chemotherapy|Standard of care chemotherapy regimen
75563154|NCT02953236|Procedure|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
75563155|NCT02953236|Procedure|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
76043070|NCT03571633|Drug|Trastuzumab + Paclitaxel|During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)
76043071|NCT03571633|Drug|Pegfilgrastim|During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
76043072|NCT03535597|Device|Quikclot Radial Pad|The QuikClot® Radial® pad will be applied over the radial artery access site covered with either a Coban™ bandage or a Tegaderm™ dressing after TRA.
76043073|NCT03473353|Other|Medical Scribe|Trained Medical Scribes will be present in the exam room to take notes on the the electronic medical record so that clinicians can focus all their attention to the interaction with the patient and parent.
75417798|NCT01404273|Behavioral|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
75417799|NCT01404286|Behavioral|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
75417800|NCT01404299|Dietary Supplement|Nutritional Supplementation|- Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)
75417801|NCT01404299|Other|Control|- No intervention, except monthly home visits
75417802|NCT01404312|Drug|Rifapentine (RPT)|"RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets)."
75417803|NCT01404312|Drug|Isoniazid (INH)|Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
75417804|NCT01404312|Dietary Supplement|Pyridoxine (Vitamin B6)|"Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH."
75417805|NCT01404338|Drug|Halobetasol 0.05% ointment|
75417806|NCT01404338|Drug|Placebo Ointment|
75417807|NCT01404351|Device|PEAK PlasmaBlade|
75417808|NCT01404351|Procedure|Scalpel and Traditional Electrosurgery|
75417809|NCT01404364|Drug|Triamcinolone|0,3mL intravitreal injection of Triamcinolone, single dose
75417810|NCT01404364|Drug|Chlorpromazine|2,5mL Chlorpromazine retrobulbar injection, single dose
75417811|NCT01404377|Procedure|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
75417812|NCT01404390|Drug|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
75417813|NCT01404390|Drug|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
75417814|NCT01404403|Device|Rapid System|
75417815|NCT01404442|Drug|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
75563156|NCT00502034|Drug|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
75563157|NCT00502034|Drug|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
75563158|NCT00510666|Drug|Saline|Saline infusion adjunct to morphine PCA pump
75563159|NCT00510666|Drug|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
75563160|NCT00510666|Drug|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
75563161|NCT00510666|Drug|Saline|Preemptive saline as a control group to tramadol one
75563162|NCT00508092|Procedure|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
75563163|NCT01248845|Other|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
75563164|NCT00510705|Other|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
75417816|NCT01404442|Drug|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
75417817|NCT01404442|Drug|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
75563165|NCT00510705|Other|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
75563166|NCT00510705|Other|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
75717889|NCT04846140|Device|transcranial electrical stimulation (tES)|Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
75717890|NCT00935337|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
75717891|NCT00935337|Behavioral|Sleep Hygiene|treatment as usual
75417818|NCT01404455|Other|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
75417819|NCT01404468|Device|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
75417820|NCT01404468|Other|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
75417821|NCT01404468|Device|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
75563167|NCT00502073|Drug|cyclosporine|
75563168|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
75563169|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
75717892|NCT00809250|Biological|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
75717893|NCT00935415|Drug|Montelukast|Montelukast 5 mg
75717894|NCT00935415|Drug|Placebo|capsules of matching placebo
75563170|NCT01248923|Drug|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
75563171|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
75563172|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
75563173|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
75563174|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
75563175|NCT01249001|Drug|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
75563176|NCT01249001|Drug|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
75563177|NCT01249040|Procedure|Physical therapy|
75563178|NCT01249040|Procedure|steroid intraarticular injection|
75563179|NCT00502112|Drug|lintuzumab|4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
76043074|NCT05365477|Behavioral|Empiric Therapy: Diet|Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to <2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to <100 mg/day
75563180|NCT00502112|Drug|lenalidomide|10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
75563181|NCT04695912|Device|The SENS motion® sensor|"The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity."
75563182|NCT03459495|Device|therapeutic ultrasound|Patients in the ultrasound group will be administered to the posterior neck region for 5 minutes in pulsed mode (pulse rate 1: 1) at 1 MHz, 1.5 W / cm2. The treatment will be done 5 days a week for a total of 10 days
75563183|NCT03459495|Device|placebo ultrasound|When the ultrasonic device is in the closed position, the ultrasonic probe will be applied for 5 minutes in the posterior neck region of the patients. The treatment will be done 5 days a week for a total of 10 days.
75563184|NCT00502190|Device|Silicon ring positioned in the vagina, around the cervix|Silicon ring positioned in the vagina, around the cervix
75563185|NCT01249079|Other|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
75563186|NCT00510822|Drug|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
75563187|NCT00510822|Drug|Placebo|tablet
75563188|NCT00502229|Drug|Clomiphene citrate, metformin, highly purified urinary FSH|
75563189|NCT02953158|Other|Haas Avocado|Hypocaloric weight loss diet
75563190|NCT02953158|Behavioral|Dietary Counseling|Dietary Counseling
75717895|NCT00935571|Drug|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
75717896|NCT00324649|Drug|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
75717897|NCT00324649|Drug|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
75563191|NCT00502268|Drug|Doxercalciferol administration|Doxercalciferol administration
75563192|NCT00502268|Drug|Doxercalciferol administered by 1-84-7-84|Doxercalciferol administered by 1-84-7-84
75563193|NCT02953197|Radiation|FDG-PET guided radiation dose escalation|Selective dose escalation
75563194|NCT00502346|Drug|PM10|
75563195|NCT01249196|Drug|SK-PC-B70M|for dosage
75563196|NCT00510081|Device|Calcium Hydroxylapatite injection|filler injection
75563197|NCT00502385|Drug|AZD2171|
75563198|NCT02952651|Procedure|Pulse oximeter|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
75563199|NCT01249235|Procedure|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
75563200|NCT00510120|Behavioral|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
75717898|NCT03743259|Drug|LuminoMark inj. 0.1mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
75717899|NCT03743259|Drug|LuminoMark inj. 0.2mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
75717900|NCT03743259|Drug|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3~1mL once in this study.
75563201|NCT00510120|Behavioral|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
75563202|NCT00510120|Behavioral|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
75563203|NCT00502424|Device|Splint|
75563204|NCT00510159|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
75717901|NCT04045782|Drug|single arm|switch from originator (Humira) to biosimilar (Imraldi)
75717902|NCT02553720|Other|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
75717903|NCT02553720|Other|aquatic activity plus conventional management|walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
75717904|NCT00935727|Other|Elastographic imaging|ultrasound imaging using a specialized computer that processes the data for tissue hardness
75717905|NCT00803478|Procedure|LASIK|
75717906|NCT03983239|Drug|Fedratinib|Fedratinib
75717907|NCT03983239|Drug|Rifampin|Rifampin
75717908|NCT03983239|Drug|Efavirenz|Efavirenz
75873725|NCT05169606|Other|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
75717909|NCT00935805|Drug|Metformin|850 mg TID
75717910|NCT00935805|Drug|Glybenclamide|10 mg BID
75873726|NCT05169606|Other|Active Isolated Stretch|"AIS is a specific stretching program developed by Aaron Mattes. This technique is based on these four basic principles:~Isolate the muscle to be stretched. Repeat the stretch eight to 10 times. Hold each stretch for no more than two seconds. Exhale on the stretch; inhale on the release."
75873727|NCT05169606|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients
75873728|NCT05599620|Behavioral|AWARE|AWARE addresses alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization.
75417822|NCT01404481|Device|clean intermittent self catheterisation single use vs re use|Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
75417823|NCT01404507|Drug|Gp 2b 3a inhibitor|bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
75417824|NCT01404507|Device|aspiration thrombectomy|Aspiration thrombectomy via aspiration catheter
75417825|NCT01404507|Other|Both use|Both use of intracoronary abciximab and aspiration thrombectomy
75417826|NCT01404520|Other|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
75417827|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg Ferrous sulfate
75563205|NCT00510159|Drug|Praziquantel|
75563206|NCT00502463|Procedure|radio-immunotherapy|
75563207|NCT00502502|Behavioral|Questionnaire|Weekly questionnaires lasting about 30 minutes.
75563208|NCT01249391|Device|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
75563209|NCT02952807|Drug|Misoprostol|vaginal Misoprostol Plus Foley Catheter
75563210|NCT02952807|Device|Foley Catheter|
75717911|NCT00935805|Drug|NPH insulin|Variable SC dose
75717912|NCT00935805|Drug|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
75717913|NCT00935805|Drug|Propranolol|40 mg BID
75717914|NCT00935805|Drug|Captopril|50 mg TID
75717915|NCT00935805|Drug|Amlodipine|10 mg QD
75717916|NCT03986125|Behavioral|Emotional Awareness & Expression Therapy|emotion-focused
75717917|NCT03986125|Behavioral|Mindfulness Meditation Training|meditation training and practice
75563211|NCT02275130|Procedure|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
75563212|NCT02275130|Device|Radiesse Voice (Calcium Hydroxyapatite)|
75563213|NCT03459417|Procedure|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
75563214|NCT03459417|Procedure|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
75563215|NCT03459417|Procedure|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
75563216|NCT00502541|Drug|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
75563217|NCT00502541|Procedure|Standard of Care|Repeat macular grid laser or observation
75563218|NCT03459378|Other|no intervention - retrospective analyses|retrospective data examination, there are no study related interventions
75563219|NCT01249430|Drug|Azacitidine|Given IV
75717918|NCT00935961|Drug|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
75717919|NCT00656370|Drug|recombinant human hyaluronidase|150 Units in 1mL
75717920|NCT01055431|Other|Control bread|Control bread
75717921|NCT01055431|Other|Teff Bread|Teff bread
75717922|NCT00936039|Behavioral|unloading|2 weeks of unloading of a single leg
75717923|NCT00803556|Drug|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
75717924|NCT00803556|Drug|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
75717925|NCT00803556|Drug|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
75717926|NCT00936195|Drug|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
75717927|NCT00936195|Drug|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
75873729|NCT05599620|Behavioral|General Health Promotion|General Health Promotion is an attention and dose matched intervention with no overlapping components with AWARE.
76043075|NCT05365477|Drug|Empiric Therapy: Drug|Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.
75417828|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg ferrous sulfate
75417829|NCT01404533|Dietary Supplement|Ferrous sulfate|6 mg ferrous sulfate
75417830|NCT01404546|Other|cost free pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
75417831|NCT01404546|Other|usual care|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
75417832|NCT01404598|Drug|naproxcinod 750 bid|naproxcinod 750 bid
75417833|NCT01404598|Drug|naproxcinod 3000 mg od|naproxcinod 3000 mg od
75417834|NCT01404598|Drug|naproxen 500 mg bid|naproxen 500 mg bid
75417835|NCT01404637|Drug|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
75417836|NCT01404637|Drug|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
75417837|NCT01404663|Biological|CD133 stem cell injection|Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
75417838|NCT01404676|Drug|Add Vildagliptin|Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
75417839|NCT01404676|Drug|Add Glimepiride|Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
75563220|NCT01249430|Drug|Cytarabine|Given IV
75563221|NCT01249430|Drug|Etoposide Phosphate|Given IV
75563222|NCT01249430|Other|Laboratory Biomarker Analysis|Correlative studies
75563223|NCT01249430|Drug|Mitoxantrone Hydrochloride|Given IV
75563224|NCT01249430|Other|Pharmacological Study|Correlative studies
75563225|NCT02952963|Drug|Chenodeoxycholic Acid|
75563226|NCT02952963|Drug|Colesevelam|
75563227|NCT00510939|Drug|Tipifarnib plus Bortezomib|
75563228|NCT00504062|Drug|budesonide|
75717928|NCT02552550|Procedure|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
75717929|NCT00680186|Drug|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
75717930|NCT00680186|Drug|Dabigatran etexilate|150mg bid
75717931|NCT00936429|Biological|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
75717932|NCT00936429|Biological|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
75717933|NCT00656292|Drug|Simvastatin|40 mg po/nasogastric tube (NG) every day for 6 days
75717934|NCT00656292|Drug|Placebo|1 pill po/NG every day x 6 days
75717935|NCT00936507|Other|Energy Density/Portion Size|
75717936|NCT00352417|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
75417840|NCT01404689|Drug|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
75417841|NCT01404689|Other|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
75417842|NCT01404702|Drug|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
75417843|NCT01404702|Biological|Aldesleukin|"Dose Level 1: 3 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle"
75563229|NCT00504062|Drug|fluticasone|
75563230|NCT03459339|Device|Tethered Capsule Endomicroscopy (TCE)|Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
75563231|NCT00504101|Drug|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
75563232|NCT00504101|Drug|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
75563233|NCT00504101|Drug|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
75717937|NCT00352417|Drug|Placebo|oral dosing, 1 time daily for 12 weeks
75717938|NCT00944541|Drug|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
75717939|NCT00809640|Behavioral|Education (Back Comic-Book)|Through the Back Comic-Book the schoolchildren are taught prevention methods for low back pain.
75717940|NCT01055509|Behavioral|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
75717941|NCT00944619|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
75717942|NCT00944619|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
75717943|NCT00805896|Drug|Songyou|4g/pack
75717944|NCT00805896|Drug|placebo|4g/pack
75717945|NCT00323869|Drug|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
75717946|NCT00323869|Drug|Gemcitabine|Nucleoside analog
75717947|NCT00323869|Drug|Carboplatin|Alkylating agent
75717948|NCT05434832|Behavioral|Virtual Reality|Distraction method
75717949|NCT05434832|Behavioral|Local cold-vibration|Distraction method
75417844|NCT01404715|Drug|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
75417845|NCT01404715|Drug|Imatinib|A single oral dose of 600 mg of imatinib
75417846|NCT01404767|Drug|Esmolol|Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
75563234|NCT00504101|Biological|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
75563235|NCT00510978|Biological|Bifidobacterium infantis 35624|1 sachet/day for one year
75563236|NCT00510978|Biological|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
75563237|NCT00510978|Biological|Placebo|1 sachet per day for 1 year
75717950|NCT01057927|Drug|OC000459|OC000459 capsules 2x100mg BID for 28 days
75717951|NCT01057927|Drug|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
75717952|NCT02559986|Other|telephone interview|telephone interview about their care received during the first year of life and associated events
75563238|NCT02952690|Device|Glidescope® with tip manipulated stylet|The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
75563239|NCT02952690|Device|Glidescope® with standard-curved tip|The style is curved in accordance with the curve of GVL blade
75417847|NCT01404767|Drug|Metoprolol|The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
75563240|NCT00510237|Behavioral|"Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)"|The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
75563241|NCT00504140|Drug|Etoposide|100 mg/m^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
75563242|NCT00504140|Drug|Interferon Alpha|5x10^6 mu/m^2 Subcutaneously Daily for 5 Days
75563243|NCT00510315|Other|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
75563244|NCT02955992|Behavioral|Improving communication during the end-of-life process|
75563245|NCT00511017|Drug|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
75563246|NCT00504179|Procedure|Osteopathic Manipulative Treatment|
75563247|NCT02955875|Behavioral|Pharmaceutical care|Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
75563248|NCT00511212|Drug|intravenous immunoglobulin|
75563249|NCT00510354|Drug|Imatinib mesylate|
75873730|NCT05706792|Device|Nordic Sensi Chair|The Nordic Sensi Chair is an electrically operated rocking chair with built-in MusiCure music composed by Niels Eje. It is equipped with an integrated audio system with music recording based on more than 15 years of research on the calming and mentally stimulating effect of sound. The Nordic Sensi Chair has three different programs: Relax for deep relaxation, Refresh for recovery and Comfort for gentle relaxation. A 5 kg fiber blanket increases the feeling of security and relaxation, while helping users to perceive their own body. In addition to musical programming, the Nordic Sensi Chair provides predefined tactile stimulation and rocking motion, for a relaxing multi-sensory experience. All settings can be easily customized at the touch of a button. For the purposes of this study, the NSC deep relaxation program (Relax Program) was used.
75563250|NCT01241006|Drug|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
75717953|NCT01058083|Drug|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
75873731|NCT05061186|Other|Resistive Expiratory muscle Training Group|"Mild Resistive Expiratory Technique [Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
75417848|NCT01404780|Device|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
75717954|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
75717955|NCT01058083|Drug|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
75717956|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
75717957|NCT01058083|Drug|Placebo|Placebo, Oral, 0 mg, daily, 28 days
75717958|NCT05434676|Device|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 & S4|To assess the safety and effectiveness of IVL treatment used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries
75717959|NCT00323557|Drug|Sargramostim (GM-CSF)|Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
75417849|NCT01404780|Device|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
75417850|NCT01404793|Drug|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
75563251|NCT01241006|Drug|Prednisone|Prednisone 60mg PO q day for 5 days
75717960|NCT00323557|Biological|Pneumococcal Vaccine|Subcutaneously on Day 0
75417851|NCT01404806|Drug|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
75563252|NCT04695951|Dietary Supplement|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
75417852|NCT01404819|Drug|Anesthesia with Xenon|Patients undergo anesthesia with xenon (remifentanil with xenon).
75417853|NCT01404819|Drug|Standard anesthesia|Patients undergo standard anesthesia (remifentanil with propofol)
75417854|NCT01404845|Dietary Supplement|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
75417855|NCT01404845|Dietary Supplement|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
75417856|NCT01404858|Behavioral|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
75563253|NCT04695951|Other|Placebo|A total of 35 patients treated with Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
75563254|NCT01249508|Other|nutrition label|
75563255|NCT00510393|Device|XIENCE V everolimus eluting coronary stent system|
75563256|NCT00510393|Device|MULTILINK VISION coronary stent system|
75717961|NCT02559050|Other|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
75563257|NCT01249547|Drug|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
75873732|NCT05061186|Other|Conventional Breathing Exercise Group|"Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)"
75563258|NCT02952339|Biological|RSV LID ΔM2-2 1030s vaccine|10^5.0 PFU; administered as nose drops
75417857|NCT01404871|Drug|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including > 8 weeks at 250 mg/daily
75417858|NCT01404871|Drug|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including >8 weeks at max dose 50mg daily
75417859|NCT01404871|Drug|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including >8weeks at 120mg daily
75417860|NCT01404884|Procedure|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
75417861|NCT01404897|Other|Dietary Intervention|3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
75417862|NCT01404897|Other|Dietary Intervention|3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
75417863|NCT01404897|Other|Dietary Intervention|3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
75563259|NCT02952339|Biological|Placebo|Administered as nose drops
75563260|NCT00504608|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
75563261|NCT00504647|Device|Biventricular Pacemaker|
75717962|NCT00558363|Drug|Avodart|0.5 mg administered orally once daily
75717963|NCT00558363|Other|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
75717964|NCT00323479|Drug|Anastrozole|1mg/Day oral
75717965|NCT00352105|Drug|cisplatin|20mg/m2/d IV continuous infusion x4 days
75717966|NCT00352105|Drug|fluorouracil|1000mg.m2/d IV continuous x 4 days
75717967|NCT00352105|Drug|Iressa|250mg/PO qd x 2 years
75417864|NCT01404910|Device|Apheresis using Liposorber LA-15 System|The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
75717968|NCT00352105|Radiation|hyperfractionated radiation therapy|120cGy bid
75717969|NCT00944775|Behavioral|Exercise training|10-month exercise training program during hemodialysis sessions
75717970|NCT03988075|Other|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
75717971|NCT03988075|Other|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
75717972|NCT00944853|Dietary Supplement|Liquid zinc syrup|Liquid zinc syrup containing 5 mg zinc as zinc sulfate
75717973|NCT00944853|Dietary Supplement|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
75717974|NCT00944853|Dietary Supplement|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
75417865|NCT01404962|Biological|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
75417866|NCT01404975|Other|Thoracic paravertebral block (PVB)|"We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines."
75417867|NCT01405014|Behavioral|Hold Me Tight|Relationship enhancement group
75417868|NCT01405079|Drug|Gefitinib|Gefitinib 250 mg/day oral daily
75717975|NCT03987997|Device|Early association of electrical muscle stimulation with cyclo-ergometer|Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
75717976|NCT03985891|Drug|Anti-PD-1 Monoclonal Antibody JS001|Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
75417869|NCT01405079|Drug|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
75717977|NCT03985891|Drug|Chemotherapy|Folfox
75717978|NCT00350779|Drug|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
75717979|NCT00350779|Drug|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
75717980|NCT00350779|Drug|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
75717981|NCT00350779|Drug|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
75717982|NCT00350779|Drug|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
75717983|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
75717984|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
75717985|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
75417870|NCT01405092|Device|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
75417871|NCT01405092|Device|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
75417872|NCT01405118|Drug|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
75563262|NCT02952495|Behavioral|Online alcohol educational class|"Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care."
75563263|NCT01249586|Other|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
75563264|NCT00511719|Drug|Technosphere Insulin|48U
75563265|NCT00511719|Drug|Actrapid|24IU
75563266|NCT00504686|Other|manual therapy|manual therapy - thoracic spine thrust manipulation
75717986|NCT00656136|Drug|placebo|Patients receive placebo once daily
75417873|NCT01405131|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
75417874|NCT01405131|Drug|methylprednisolone|tablets 32 mg single dose
75417875|NCT01405144|Drug|5-fluoruracil|5% 5-fluoruracil cream, twice a day, during 3 weeks
75563267|NCT00504686|Other|exercise|therapeutic exercise
75717987|NCT00656136|Drug|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
75717988|NCT00676520|Device|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
75717989|NCT00652938|Biological|HPV Vaccine (GSK580299) Cervarix TM|IM administration
75417876|NCT01405144|Procedure|5-fluoruracil|The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
75417877|NCT01405157|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
75417878|NCT01405157|Drug|methylprednisolone|tablets 16 mg single dose
75717990|NCT00652938|Biological|Engerix B|IM administration
75717991|NCT05434520|Procedure|Preoperative biliary drainage (ERC og PTC-aided)|Placement of biliary stent (plastic, covered SEMS, uncovered SEMS) endoscopic by ERC or placement of plastic catheter by PTC
75873733|NCT05706480|Diagnostic Test|colored periodontal probes (CPP)|The CPP will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
75417879|NCT01405170|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
75417880|NCT01405170|Drug|methylprednisolone|tablets 32 mg single dose
75563268|NCT00511758|Procedure|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
75563269|NCT01245335|Device|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
75563270|NCT01245335|Device|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
75563271|NCT00511290|Other|no generic names|
75563272|NCT00511368|Drug|matching placebo|
75563273|NCT00511368|Drug|Bevirimat|
75563274|NCT01246232|Drug|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
75717992|NCT02559908|Device|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
75717993|NCT00805974|Biological|Biological examinations (blood and urinary).|
75717994|NCT00322621|Drug|Duloxetine|
75417881|NCT01405183|Other|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
75417882|NCT01405235|Drug|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
75417883|NCT01405235|Drug|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
75417884|NCT01405248|Drug|Butylphthalide|20 mg/time per os three times a day. 180days
75417885|NCT01405248|Drug|Placebo|20 mg/time per os three times a day. 180days
75417886|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
75417887|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
75417888|NCT01405261|Drug|I.v. NNC 0113-0987|Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
75417889|NCT01405261|Drug|oral placebo|Subjects will be randomised to receive a single dose of placebo.
75417890|NCT01405274|Other|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
75417891|NCT01405287|Device|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
75417892|NCT01405300|Dietary Supplement|Control|34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver ~1200 kcal.
75417893|NCT01405300|Dietary Supplement|Peanut|34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver ~1200 kcal.
75417894|NCT01405326|Biological|adalimumab|40mg sc. every two weeks for six months
75417895|NCT01405339|Device|Mucosal Atomization Device (MAD)|The use of pulmicort via MAD once a day for a total of 30 days.
75417896|NCT01405339|Device|Budesonide via Nasal Syringe|The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
75417897|NCT01405352|Dietary Supplement|Vitamin A|"25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month"
75417898|NCT01405365|Drug|Metronidazole|Metronidazole 400mg TID for 10 days
75417899|NCT01405365|Drug|Placebo|Placebo pill TID for 10 days
75417900|NCT01405365|Procedure|Scaling and root planning|Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
75417901|NCT01405378|Device|Robot therapy and transcranial direct current stimulation|"Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2)."
75417902|NCT01405391|Drug|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
75417903|NCT01405404|Behavioral|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
75417904|NCT01405404|Other|Parent Training|12-session group on parenting skills and child behavior management
75563275|NCT01246232|Drug|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
75563276|NCT00511407|Device|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
75563277|NCT01248962|Drug|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
75563278|NCT01248962|Drug|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
75563279|NCT02952183|Device|PAMS I|"After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.~Both PAMS I and IOM will be used for monitoring."
75563280|NCT01249742|Behavioral|Internet intervention|Our intervention, Sugarsquare, is a secured treatment environment only accessible by patients of the KDCN and members of the treatment team. Sugarsquare consists of two main sections. The first section is a semi-public setting on which adolescents can exchange experiences with their diabetes (care) through a forum and a real time chat-application. All patients and treatment team members can see all messages posted here. The second section consists of patients' individual pages with treatment overview and an application for private interaction with the treatment team. Patients can only access their own individual page; treatment team members can access pages of all patients. Sugarsquare is a secured webpage, accessible only through computers equipped with the right certificate (access device) and by using the appointed username-password combination.
75563281|NCT00511446|Drug|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
75563282|NCT02956109|Drug|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
75563283|NCT02956109|Drug|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
75563284|NCT02956109|Drug|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
75563285|NCT02952300|Procedure|neolix|single rotation file
75563286|NCT02952300|Procedure|wave one|single reciprocation file
75563287|NCT02955446|Drug|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
75563288|NCT00511524|Drug|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
75717995|NCT02558972|Drug|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
75417905|NCT01405417|Procedure|Endoscopic Peroral Myotomy|Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
75417906|NCT01405430|Biological|Bevacizumab + blood samples|"Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab."
75563289|NCT00511524|Drug|[carbonyl-^11C]GW842166|[carbonyl-^11C]GW842166 will b available as Intravenous solution.
75563290|NCT00511563|Drug|GW876008 and GSK561679|GW876008 and GSK561679
75563291|NCT02955368|Drug|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
75417907|NCT01405482|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle
75563292|NCT02955368|Drug|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
75563293|NCT02955368|Drug|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
75563294|NCT00511602|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
75717996|NCT02558972|Drug|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
75417908|NCT01405482|Other|Normal Saline injection|10 cc of Normal Saline will be injected under EMG guidance into the Anterior and Middle Scalenes and Pectoralis Minor muscle of individual diagnosed with Thoracic Outlet Syndrome.
75417909|NCT01405495|Procedure|MRI-based techniques (sMRI, fMRI, DTI, ASL)|no drugs include
75417910|NCT01405573|Other|Best Supportive Care|Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.
75417911|NCT01405573|Drug|sorafenib|400 mg twice a day
75417912|NCT01405599|Drug|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
75417913|NCT01405612|Drug|Midazolam|Single oral administration on Day 1 or Day 5
75873734|NCT05706480|Diagnostic Test|standard periodontal probes (SPP)|The SPP (William's graduated probe) will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
75417914|NCT01405612|Drug|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
75417915|NCT01405625|Other|Pictogram-based asthma action plan|Asthma action plan using plain language, pictograms, and photographs
75417916|NCT01405625|Other|AAAAI standard of care written action plan|
75417917|NCT01405638|Behavioral|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
75417918|NCT01405638|Behavioral|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
75417919|NCT01405651|Drug|ONO-6950|30 mg, 100 mg, 300 mg at multiple doses
75417920|NCT01405651|Drug|ONO-6950|Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
75563295|NCT00511602|Drug|Technosphere Placebo|Technosphere Inhalation Powder
75563296|NCT00511641|Behavioral|Questionnaire|Questionnaires lasting up to 30 minutes.
75563297|NCT01248455|Drug|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
75563298|NCT00511680|Behavioral|Behavioral Based In-Home Intervention|The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
75563299|NCT00511953|Drug|Gabapentin Extended Release tablets|1800mg
75563300|NCT00511953|Drug|Gabapentin|1800mg
75563301|NCT01249820|Drug|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
75563302|NCT01249820|Drug|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
75563303|NCT02952378|Drug|Albumins|Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
75563304|NCT01247090|Drug|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU * 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
75563305|NCT01247090|Drug|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU * 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
75563306|NCT01247090|Drug|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
75563307|NCT02952417|Other|Excess mortality|Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
75417921|NCT01405664|Other|Weight-Bearing as Tolerated|WBAT immediately after surgery
75417922|NCT01405677|Biological|Epaxal 0.25 mL|12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
75717997|NCT02558972|Drug|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
75563308|NCT00504764|Drug|Arsenic Trioxide|"Induction ATO 0.15 mg/kg/day IV until CR or a maximum of 60 days In isolated molecular relapse ATO will be administered at same dose, 5 days a week, during 6 weeks.~Consolidation ATO 0.15 mg/kg/day IV 5 days week, during 5 weeks"
75563309|NCT00504764|Procedure|Autologous Transplantation|Autologous Transplantation
75717998|NCT02558972|Drug|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
75563310|NCT00504764|Procedure|Allogenic Transplantation|Allogenic Transplantation
75563311|NCT00504764|Drug|ATRA|Consolidation: ATRA 45 mg/m²/day oral during 5 weeks
75417923|NCT01405677|Biological|Epaxal 0.5 mL|24 IU hepatitis A antigen coupled to IRIV
75417924|NCT01405677|Biological|Havrix Junior 0.5 mL|720 EU hepatitis A antigen absorbed onto aluminum hydroxide
75417925|NCT01405703|Other|xrays|xrays from 2 week postop to 5 year postop
75417926|NCT01405716|Behavioral|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
75417927|NCT01405716|Behavioral|Health Education|8-week health education program
75417928|NCT01405755|Behavioral|Appropriate complementary feeding messages|Messages delivered through National Vaccine Program and radio
75417929|NCT01405807|Drug|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
75417930|NCT01405833|Drug|BG00010 (Neublastin)|Multiple doses, weight-based IV administration
75417931|NCT01405833|Drug|Placebo|Single dose IV matched placebo
75417932|NCT01405846|Drug|Gefitinib|250mg od for 6 months
75417933|NCT01405872|Other|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
75417934|NCT01405885|Biological|INO-3605|0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
75417935|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
75417936|NCT01405885|Biological|INO-3401|0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
75417937|NCT01405885|Biological|INO-3609|0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
75417938|NCT01405885|Biological|INO-3605 AND INO-3609|0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
75563312|NCT04519073|Biological|V-306 candidate vaccine|"Each V-306 monomer consists of the following elements:~A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker."
75563313|NCT02952027|Behavioral|Use-recording, patient-reminder alarm for incentive spirometry|
75417939|NCT01405885|Biological|INO-3510|0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
75417940|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
75563314|NCT00504335|Drug|BIO 300 Capsules|
75417941|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
75417942|NCT01405885|Biological|Seasonal Influenza vaccine|0.5ml of vaccine delivered IM
75417943|NCT01405885|Biological|INO-3609|1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
75563315|NCT02951910|Device|Ophylosa tear supplement|Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
75563316|NCT04516577|Other|Assesssing the severity of pulmonary alveolar proteinosis|Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.
75563317|NCT02951754|Drug|Immediate-release Methylphenidate|Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
75563318|NCT00504374|Behavioral|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
76043076|NCT05365477|Behavioral|Selective Therapy: Diet|"Diet:~Volume <2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume~Calcium >250mg male, >200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to<2000mg/d, avoid vitamin D + calcium supplements~Oxalate >40mg Reduce dietary oxalate intake to <100 mg/d; increase fiber intake to 25-35 g/d~Citrate <450mg male, <550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~pH<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Uric acid >800mg male, >750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Sodium >150mmol Reduce sodium intake to <2000mg/d~Sulfate > 80mEq or urine urea nitrogen >14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d"
75417944|NCT01405976|Device|life style modification, noninvasive ventilation, CPAP|life style modification, noninvasive ventilation, CPAP
75417945|NCT01405989|Drug|darexaban|oral
75417946|NCT01405989|Drug|ketoconazole|oral
75417947|NCT01406002|Drug|darexaban|oral
75417948|NCT01406002|Drug|Rifampicin|oral
75417949|NCT01406028|Behavioral|Phone calls|Phone calls to offer emotional support
75417950|NCT01406041|Biological|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
75417951|NCT01406054|Other|neuromuscular exercises|neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
75417952|NCT01406067|Behavioral|Treatment Program for Children with Aggressive Behavior|24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.
75417953|NCT01406067|Behavioral|Play group|12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
75563319|NCT02952066|Procedure|Bronchial biopsy|Bronchial tissue taken during biopsy
75563320|NCT00504413|Drug|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
75417954|NCT01406080|Drug|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
75563321|NCT00504413|Drug|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
75873735|NCT05706480|Diagnostic Test|transgingival sounding with an endodontic file|the gingival thickness using the transgingival sounding. After application of local anesthesia gel an endodontic file (ISO 20) with a rubber stopper will be inserted perpendicularly into the buccal aspect of the gingiva (1 mm below the gingival margin) until it touches the tooth surface. The insertion depth will be ensured through placing the rubber stopper in contact with the gingiva and fixing its position and the distance between the tip and the rubber stopper will be calibrated using a manual calibration device (endodontic ruler).
75563322|NCT00504413|Drug|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
75417955|NCT01406080|Drug|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
75417956|NCT01406106|Dietary Supplement|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
75563323|NCT00513045|Behavioral|IRT|Cognitive behavior intervention
75563324|NCT00513045|Behavioral|Exposure|Exposure intervention
75873736|NCT03383783|Drug|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
75417957|NCT01406119|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
75717999|NCT00809718|Drug|Raltegravir and rifapentine|"Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days"
75718000|NCT05427266|Other|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Standard port site infiltration) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
75417958|NCT01406132|Drug|ASP015K|oral
75417959|NCT01406145|Drug|ASP0777|oral tablet
75417960|NCT01406145|Drug|Placebo|oral tablet
75417961|NCT01406158|Drug|Solifenacin Succinate Formulation A|oral suspension
75417962|NCT01406158|Drug|Solifenacin Succinate Formulation B|oral suspension
75417963|NCT01406158|Drug|Solifenacin Succinate|oral tablet
75417964|NCT01406171|Drug|Isavuconazole|oral
75417965|NCT01406171|Drug|Midazolam|Oral
75417966|NCT01406236|Procedure|Transradial PCI|Transradial PCI
75417967|NCT01406236|Procedure|Transfemoral PCI|Transfemoral PCI
75563325|NCT00513084|Behavioral|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
75563326|NCT02275325|Other|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
75563327|NCT00513123|Procedure|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
75417968|NCT01406249|Drug|SP|"Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle."
75563328|NCT02275403|Procedure|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
75417969|NCT01406249|Drug|XP|"Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
75563329|NCT02275403|Other|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
75563330|NCT04517825|Diagnostic Test|Cepheid Xpert HIV-1 Viral Load Assay|Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
75563331|NCT01249976|Other|blood culture|blood culture
75417970|NCT01406262|Biological|Albiglutide|once weekly subcutaneous injection
75417971|NCT01406262|Drug|Moxifloxacin|oral tablet
75718001|NCT00575042|Drug|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)|160 mg per day for 1 year
75417972|NCT01406275|Drug|Amoxicillin and clavulanate|
75563332|NCT01244438|Drug|FP-1039|FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
75718002|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
75718003|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
75718004|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
75718005|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
75718006|NCT00676208|Behavioral|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
75417973|NCT01406288|Other|HUS standard coverage care (including in ICU)|HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
75417974|NCT01406301|Drug|fondaparinux|fondaparinux
75417975|NCT01406314|Drug|GSK2315698|Intravenous infusion for approximately 48hours followed by subcutaneous injection
75417976|NCT01406327|Drug|Ambrisentan|Ambrisentan
75417977|NCT01406340|Drug|5 mg GSK1278863|5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
75417978|NCT01406353|Procedure|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
75417979|NCT01406366|Behavioral|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
75417980|NCT01406366|Behavioral|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
75417981|NCT01406379|Procedure|Prophylactic clip|Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group
75718007|NCT02533297|Other|Providing clinical skills conditions|
75718008|NCT00656058|Drug|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
75718009|NCT03871764|Diagnostic Test|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
75718010|NCT00537316|Biological|Infliximab (IFX)|IFX intravenous (IV) infusion dosed at 5mg/kg of body weight
75718011|NCT00537316|Drug|Azathioprine (AZA)|AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
75873737|NCT03383783|Drug|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
75417982|NCT01406379|Procedure|Detachable snare|In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
75563333|NCT02951793|Other|AUDIT-C|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C>4 versus AUDIT-C of 4 or below.
75563334|NCT02951793|Other|Smoking history|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
75417983|NCT01406392|Drug|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
75417984|NCT01406392|Drug|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
75563335|NCT02951793|Other|Prior psychotropic medication use|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
75563336|NCT00512187|Other|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
75718012|NCT00537316|Drug|Placebo to Azathioprine|Placebo to AZA tablet orally every day
75417985|NCT01406405|Procedure|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
75417986|NCT01406418|Biological|CR6261 2 mg/kg|Administered as a single 2-hour intravenous infusion
75417987|NCT01406418|Biological|CR6261 5 mg/kg|Administered as a single 2-hour intravenous infusion
75718013|NCT00537316|Drug|Placebo infusion|Placebo to IFX intravenous (IV) infusion
75718014|NCT00803868|Drug|varenicline|up to 1mg po bid for 9 weeks
75718015|NCT00803868|Drug|placebo|placebo matching study drug up to 1mg po bid
75718016|NCT03827395|Biological|HEV 239|Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
75718017|NCT03827395|Other|Placebo|0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 [4.5 - 7.0]).
75718018|NCT04504708|Drug|ZX-101A|Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
75873738|NCT03383783|Drug|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
75873739|NCT03383783|Drug|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
75563337|NCT01241864|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
75718019|NCT00655980|Drug|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
75873740|NCT03627390|Drug|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
75873741|NCT03627390|Drug|BP-C2|BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
75873742|NCT05576376|Procedure|calcaneal osteotomy for intractable plantar fasciitis|plantar displacement calcaneal osteotomy
75417988|NCT01406418|Biological|CR6261 15 mg/kg|Administered as a single 2-hour intravenous infusion
75417989|NCT01406418|Biological|CR6261 30 mg/kg|Administered as a single 2-hour intravenous infusion
75417990|NCT01406418|Biological|CR6261 50 mg/kg|Administered as a single 2-hour intravenous infusion
75417991|NCT01406418|Biological|Placebo|Administered as a single 2-hour intravenous infusion
75417992|NCT01406431|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
75417993|NCT01406431|Drug|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
75417994|NCT01406470|Drug|Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™|IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
75417995|NCT01406483|Other|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
75718020|NCT00655980|Drug|Nitrous oxide and placebo|
75718021|NCT00655980|Other|standard of care|
75873743|NCT05576376|Procedure|plantar fascia open release|open partial release with or without baxter's nerve decompression
75873744|NCT05576376|Procedure|plantar fascia endoscopic release|endoscopic partial plantar fascia release
75873745|NCT03709745|Drug|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
75873746|NCT03709745|Drug|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
75873747|NCT05570526|Dietary Supplement|Melatonin|Puritan's Pride ® Melatonin 5mg tablets orally once daily.
75873748|NCT05570526|Other|Placebo|Placebo tablet once daily.
75417996|NCT01406496|Drug|insulin|Three different timings of insulin delivered by a pump
75417997|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
75563338|NCT01241864|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
75417998|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
75563339|NCT02951715|Drug|zinc gluconate|2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
75417999|NCT01406522|Drug|Oral tacrine|Tacrine, 160 mg per day, four times daily
75418000|NCT01406522|Drug|Oral placebo|Microcrystalline cellulose
75873749|NCT03707639|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
75873750|NCT03707639|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
75418001|NCT01406535|Drug|Vardenafil|5 mg vardenafil per os twice daily
75418002|NCT01406535|Other|Placebo|5 mg placebo per os twice daily
75563340|NCT01243658|Drug|Oxytocin|Oxytocin
75563341|NCT01243658|Other|placebo|placebo
75418003|NCT01406587|Drug|PP4001|50 mg, 1 dose every 12 hours x 4 doses
75418004|NCT01406587|Drug|PP4001|100 mg, 1 dose every 12 hours x 4 doses
75418005|NCT01406587|Drug|PP4001|200 mg, 1 dose every 12 hours x 4 doses
75563342|NCT02951676|Procedure|Extraction|Extraction of impacted third molar teeth
75563343|NCT01249664|Biological|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
75563344|NCT01249664|Procedure|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
75563345|NCT00513162|Drug|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
75563346|NCT00513162|Drug|Etoposide|25 - 50 mg/m^2 By Mouth Daily
75563347|NCT00512226|Other|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2* MRI analysis.
75563348|NCT04513418|Dietary Supplement|Preoperative immunonutrition|Preoperative immunonutrition includes an omega-3 fatty-acid enriched enteral nutritional emulsion given by oral intake, nasogastric feeding tube or jejunostomy 600ml per day, lasting for the whole period of neoadjuvant chemoradiation. Meanwhile, oral intake is encouraged to reach 25-30kcal/kg through regular food.
75563349|NCT00513201|Drug|lyspro|
75563350|NCT00513201|Drug|regular insulin|
75563351|NCT00513279|Drug|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
75563352|NCT00513279|Drug|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
75563353|NCT00512265|Drug|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
75563354|NCT00512265|Drug|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
75418006|NCT01406587|Drug|Placebo|Placebo, 1 dose every 12 hours x 4 doses
75418007|NCT01406600|Drug|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24~48 hours from optimal ovarian stimulation status.
75418008|NCT01406613|Other|Observation|In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
75418009|NCT01406626|Behavioral|Peer Navigator|Peer navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
75563355|NCT00504803|Procedure|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
75718022|NCT00679172|Biological|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
75718023|NCT00679172|Biological|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
75718024|NCT00679172|Biological|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
75718025|NCT00679172|Biological|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
75563356|NCT00513396|Drug|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
75418010|NCT01406639|Drug|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
75563357|NCT00513396|Drug|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
75563358|NCT01249274|Drug|Progesterone|100mgs progesterone twice daily
75563359|NCT01249274|Other|Placebo|Matched placebo pills to be taken twice daily
75718026|NCT00679172|Other|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
75873751|NCT05343689|Procedure|Pneumatic compression|Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
75418011|NCT01406704|Drug|Rosiglitazone|Rosiglitazone (8 mg/day)
75873752|NCT05542914|Behavioral|electronic screening and brief intervention.|e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.
75418012|NCT01406704|Drug|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
75418013|NCT01406704|Drug|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
75418014|NCT01406730|Other|exercise|16 week of periodized progressive running exercise 2-4 times/week
75563360|NCT00512304|Procedure|association chemotherapy and radiochemotherapy|
75563361|NCT04695834|Procedure|Neurolysis peroneal nerve|The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa
75418015|NCT01406743|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
75418016|NCT01406769|Procedure|Bioelectric Impedance Analysis|Undergo preoperative and postoperative lower-extremity lymphedema assessment
75563362|NCT04695834|Other|Maximal physiotherapy|Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
75563363|NCT04695756|Other|COVID-19 pandemic|The exposure of this observational study is the COVID-19 pandemic
75563364|NCT00512382|Device|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
75563365|NCT00512421|Procedure|computer-assisted surgery|
75563366|NCT00504842|Drug|MRX-801|
75718027|NCT01063621|Drug|KW-6500|Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
75718028|NCT02533141|Device|Dynamic Vessel Analyzer (DVA)|Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
75718029|NCT02533141|Device|Laser Doppler Velocimetry (LDV)|Measurement of red blood cell velocity in retinal vessels
75718030|NCT02533141|Drug|Simvastatin|Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
75718031|NCT02533141|Other|Placebo|Placebo, once daily for 4 weeks
75718032|NCT00809796|Drug|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
75718033|NCT05589454|Drug|Atorvastatin Calcium tablets 80mg|Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
75418017|NCT01406769|Procedure|Lymphadenectomy|Undergo lymphadenectomy
75418018|NCT01406769|Procedure|Therapeutic Conventional Surgery|Undergo radical vulvectomy or radical local excision
75563367|NCT00504842|Drug|Placebo|
75563368|NCT00512460|Drug|RTA 744|4.8 mg/m^2 by vein Over 2 Hours On Days 1-3.
75563369|NCT01249157|Device|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
75873753|NCT05542914|Behavioral|Men's Health Project (MHP)|This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.
75873754|NCT03334721|Drug|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
75418019|NCT01406782|Biological|rituximab|
75873755|NCT03334721|Drug|Placebo Oral Capsule|5 day trial of matched placebo
75873756|NCT05144880|Other|electroacupuncture|A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
75873757|NCT03709589|Other|Modified Early Warning Score|Modified Early Warning Score
75873758|NCT03707561|Diagnostic Test|Right Heart Catheterization (RHC)|RHC at the enrollment and every 12 months
75873759|NCT05706246|Diagnostic Test|diagnostics|Serum tryptase levels were evaluated in all suspected children with perioperative hypersensitivity
75873760|NCT05114538|Behavioral|Reciprocal Imitation Training|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and IJA during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal skills. It is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by parents and siblings.
75418020|NCT01406782|Genetic|DNA analysis|
75873761|NCT03627312|Combination Product|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
75873762|NCT03627312|Combination Product|Placebo|Fruit juice drink only
75873763|NCT03627312|Other|Treatment as Usual|Young Offenders Intervention Programme
75873764|NCT03627000|Other|failure after reimplantation|description of cinical and microbiological failure
75873765|NCT03515551|Drug|IMCnyeso|Weekly IV infusions of IMCnyeso
75873766|NCT05558592|Dietary Supplement|Dietary supplementation with fresh oranges|"the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis."
75873767|NCT05558592|Dietary Supplement|Balanced Diet without oranges|the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
75873768|NCT03626844|Procedure|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
75418021|NCT01406782|Genetic|gene expression analysis|
75418022|NCT01406782|Genetic|polymerase chain reaction|
75418023|NCT01406782|Other|laboratory biomarker analysis|
75418024|NCT01406808|Behavioral|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
75418025|NCT01406821|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
75418026|NCT01406821|Procedure|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
75418027|NCT01406834|Behavioral|Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.
75418028|NCT01406847|Other|Spinal Manipulation|High velocity low amplitude joint-biased intervention
75563370|NCT00512499|Behavioral|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
75418029|NCT01406847|Other|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
75418030|NCT01406847|Other|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
75563371|NCT00512499|Behavioral|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
75873769|NCT03626844|Procedure|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
76043077|NCT05365477|Drug|Selective Therapy: Drug|"Drug(s):~For calcium >250mg male, >200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate <450mg male, <550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid >800mg male, >750mg female: allopurinol 300mg.~If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID"
75418031|NCT01406886|Behavioral|Eating rate|
75873770|NCT04694443|Procedure|Multidisciplinary tele-health intervention (physical therapy, neurologist, nurse, psychologist)|Non-pharmacological and pharmacological treatment provided by telemedicine plus in-office visits
75873771|NCT04694443|Other|Standard in-office medical care|Non-pharmacological and pharmacological treatment provided in-office visits
75418032|NCT01406899|Behavioral|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
75418033|NCT01406912|Other|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
75418034|NCT01406912|Other|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
75418035|NCT01406925|Drug|Placebo control|Placebo cream
75418036|NCT01406925|Drug|NRL001 cream|Cream for single-dose intra-anal application
75418037|NCT01406964|Other|CAT test|A CAT test is performed in order to diagnose tubal factor causes
75418038|NCT01406964|Other|Histerosalpingography|A Histerosalpingography is performed.
75873772|NCT05706090|Drug|fentanyl will be added|If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added
75873773|NCT05706090|Procedure|general anesthesia|If adequate anagesia is not provided with the block, general anesthesia will be administered.
76043078|NCT05533489|Other|No intervention|No intervention This study is a retrospective descriptive study.
75718034|NCT05589454|Drug|Atorvastatin Calcium tablets 20mg|Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
75563372|NCT00512499|Behavioral|Intensive Intervention|"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"
75563373|NCT00504452|Drug|KP-1461|Oral dosage, 1600 mg bid for 124 days
75563374|NCT00512538|Device|Bi-layered cell therapy (Apligraf)|
75418039|NCT01407016|Drug|metronidazole IV 500 mg|On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
75563375|NCT00504920|Behavioral|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
75563376|NCT00513513|Drug|TMC114 (darunavir) / ritonavir|
75563377|NCT00504959|Drug|ranibizumab|
75563378|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
75718035|NCT01063699|Procedure|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
75718036|NCT00803946|Drug|Ibuprofen Tablets, 800 mg|
75563379|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
75563380|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
75563381|NCT00504998|Genetic|Rexin-G|Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
75718037|NCT00676130|Drug|trimethoprim-sulfamethoxazole|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"
75718038|NCT00676130|Drug|Cephalexin|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"
75718039|NCT04874818|Diagnostic Test|[89Zr]Df-IAB22M2C PET/CT scan|PET imaging procedure
75418040|NCT01407042|Procedure|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
75418041|NCT01407055|Behavioral|Expectation Manipulation Intervention|The Expectation Manipulation Intervention targets patients' expectations prior to surgery (2 individual sessions, 2 phone calls). Main goal is to enhance positive outcome expectancies, as well as to improve patients' control expectations about possible side effects of the surgery and about their personal management of their coronary heart disease. Further EMI tries to correct dysfunctional beliefs about the coronary heart disease and tries to minimize fears about expected negative consequences.
75718040|NCT02553408|Device|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
75718041|NCT03742882|Drug|CC-90001|CC-90001
75418042|NCT01407055|Behavioral|Supportive Therapy|Supportive therapy employs common factors such as elicitation of affect, reflective listening, feeling understood, but provides no explicit theoretical formulation to the patient. Supportive therapy thus provides a control condition for common factors and therapist attention but lacks the specific intervention part. It will be delivered in the same frequency and at the same time points as the Expectation Manipulation Intervention (2 individual sessions, 2 phone calls).
75418043|NCT01407120|Behavioral|New Beginnings Program|A preventive intervention for divorced families.
75418044|NCT01407133|Device|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|"The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months."
75563382|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
75563383|NCT04695561|Other|Self Myofascial Relaxation|Total of 12 times for 6 weeks
75563384|NCT04695561|Other|Instrument Assisted Soft Tissue Mobilization|Total of 12 times for 6 weeks
75418045|NCT01407133|Device|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
75418046|NCT01407185|Other|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
75418047|NCT01407198|Drug|Nilotinib|Orally, daily 200 - 400 mg BID
75563385|NCT04695561|Other|Only Exercise (Control)|Every day for 6 weeks
75563386|NCT04512794|Device|AcQMap High Resolution Imaging and Mapping System|Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.
75563387|NCT00512616|Drug|Ceftriaxone|
75563388|NCT01249118|Drug|GDC-0973 IV Infusion|IV infusion.
75563389|NCT01249118|Drug|GDC-0973 Oral Capsules|Oral dose.
75563390|NCT00512655|Behavioral|Fall prevention course|Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
75418048|NCT01407198|Radiation|Radiation therapy|External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
75418049|NCT01407211|Dietary Supplement|vitamin A|"25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
75418050|NCT01407224|Behavioral|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
75418051|NCT01407237|Drug|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
75563391|NCT00505037|Drug|ASP1585|Oral
75563392|NCT00505037|Drug|Placebo|Oral
75563393|NCT00505037|Drug|Sevelamer hydrochloride|Oral
75563394|NCT00513552|Drug|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
75563395|NCT02275169|Drug|Urofollitropin|Urofollitropin 75 IU 2 ampoules three times a week for three months
75563396|NCT02275169|Other|Placebo|Placebo ampoules administered three times a week for three months
75563397|NCT02275208|Procedure|SIPS the stomach, intestinal, pylorus, sparing procedure|Bariatric Procedure
75563398|NCT00513630|Drug|Glipizide|
75563399|NCT00513630|Drug|Metformin|
75563400|NCT02275247|Drug|Stellate Ganglion Block|stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
75563401|NCT00513669|Biological|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
75563402|NCT00513669|Biological|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
75563403|NCT04696679|Other|Patient Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France
75563404|NCT04696679|Other|Control group Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)
75563405|NCT04515719|Biological|Belimumab|Belimumab 2mg/kg intravenously
75563406|NCT04515719|Biological|Placebo|Placebo intravenously
75563407|NCT00513786|Drug|Carboplatin|AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
75418052|NCT01407289|Drug|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
75418053|NCT01407302|Other|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
75418054|NCT01407315|Device|GlucoMenDay|"Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once."
75418055|NCT01407315|Device|GlucoMenDay|"Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice."
75418056|NCT01407341|Procedure|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
75418057|NCT01407341|Procedure|bone graft|Receive beta tricalcium-phosphate bone graft
75418058|NCT01407341|Procedure|quality-of-life assessment|Ancillary studies
75418059|NCT01407341|Other|questionnaire administration|Ancillary studies
75418060|NCT01407380|Drug|PWT33597 mesylate|PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
75563408|NCT00513786|Drug|Paclitaxel|175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
75718042|NCT00804024|Device|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
75418061|NCT01407393|Device|Glucosanol|2 tablets 3x daily for 12 weeks
75418062|NCT01407393|Device|Placebo|2 tablets 3x daily for 12 weeks
75418063|NCT01407406|Drug|BIIB023 - low dose IV Dose|
75418064|NCT01407406|Drug|BIIB023 - high dose IV Dose|
75418065|NCT01407419|Other|Treatment Acceleration|"Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.~Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)"
75418066|NCT01407419|Other|Monthly Assessment|Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
75418067|NCT01407432|Drug|Folic acid|Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
75418068|NCT01407432|Drug|placebo of folic acid|Taking of placebo of folic acid by hanging oral route during 3 at 4 months
75418069|NCT01407445|Drug|Placebo|1 tablet/ oral/ 3 times a day for 90 days
75418070|NCT01407445|Drug|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
75418071|NCT01407458|Other|Upper Limb Exercises|Upper limb exercises
75718043|NCT00809874|Dietary Supplement|Casein|
75563409|NCT00513786|Drug|bevacizumab|15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
75718044|NCT00809874|Dietary Supplement|Whey Isolate|
75718045|NCT00809874|Dietary Supplement|Whey Hydrolysate|
75718046|NCT00809874|Dietary Supplement|Alphalact-Albumin|
75718047|NCT00809952|Procedure|recombinant FSH|
76043079|NCT05529433|Procedure|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is highly accepted by the patients as there is no need for local anesthesia. It is a minimal invasive technique which preserves sound tooth structure as caries removal will be done by a sharp spoon excavator. It requires less time during caries removal. There is a chemical bond between the tooth and the glass ionomer adhesive material. So, there is no need for cutting sound tooth structure for retention of the restoration.
75873774|NCT04418791|Behavioral|Modified Intermittent Fasting followed by Regular Diet|Modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours). After 12 weeks of fasting, a period of 12 weeks with a regular diet follows.
75418072|NCT01407458|Other|Normal physical exercises|Exercises usually done by children in physical education classes
75418073|NCT01407471|Drug|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
75563410|NCT00504491|Drug|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
75563411|NCT00512811|Drug|furosemide|
75563412|NCT00513825|Drug|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
75563413|NCT04518254|Biological|Blood collection|A blood sample will be collected before and after treatment administration
75563414|NCT04518254|Drug|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route
75563415|NCT04518254|Drug|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
75563416|NCT04518254|Behavioral|Cognitive tasks|The participants will perform cognitive decision-making tasks: Simon task and masking task after treatment administration
75563417|NCT04518254|Other|Stress exposure|Unpleasant but not painful skin stimulations will be administered to the participants at variable intervals on the left leg during the cognitive tasks
75418074|NCT01407471|Drug|Clobetasol + Placebo|One application 6 days a week during 4 weeks
75418075|NCT01407471|Drug|Placebo + Spironolactone|One application 6 days a week during 7 weeks
75563418|NCT04518254|Behavioral|Anxiety scale|Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks
75563419|NCT04518254|Device|Electromyography (EMG)|Electromyography measurements will be performed during cognitive tasks.
75718048|NCT00676052|Drug|GSK233705 12.5mcg|Once daily via dry powder inhaler
75718049|NCT00676052|Drug|GSK233705 25mcg|once daily via dry powder inhaler
75718050|NCT00676052|Drug|GSK233705 50mcg|Once daily via dry powder inhaler
75873775|NCT04418791|Behavioral|Regular Diet followed by Modified Intermittent Fasting|Regular diet means subject can eat as usual for 12 weeks. Next, a period of 12 weeks fasting follows: modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours).
75873776|NCT03380429|Drug|RELVAR/BREO|RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
75418076|NCT01407471|Drug|Placebo + Placebo|One application 6 days a week during 7 weeks
75418077|NCT01407484|Drug|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
75418078|NCT01407484|Drug|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
75563420|NCT04518254|Device|Electroencephalography (EEG)|Electroencephalography measurements will be performed during cognitive tasks.
75563421|NCT00513864|Drug|Dextromethorphan|one time dose - 0.3mg/kg PO
75563422|NCT00513864|Drug|Codeine|one time dose - 2mg/kg PO
75563423|NCT00513864|Drug|Morphine|one time dose - 0.15mg/kg IV
75563424|NCT01248884|Biological|Infanrix hexa™|3 doses, intramuscular into left thigh
75563425|NCT01248884|Biological|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
75563426|NCT01248884|Biological|GSK217744|3 doses, intramuscular into left thigh
75563427|NCT00512850|Dietary Supplement|Folic acid|Intervention group 1g folic acid per day
75718051|NCT00676052|Drug|GSK233705 100mcg|Once daily via dry powder inhaler
75718052|NCT00676052|Drug|GSK233705 200mcg|Once daily via dry powder inhaler
75718053|NCT00676052|Drug|Placebo|Once daily via dry powder imhaler
75563428|NCT00512850|Other|Placebo|One placebo pill per day
75563429|NCT04695522|Biological|ADR-002K administration|ADR-002K administration
75563430|NCT00512889|Biological|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
75563431|NCT00512889|Genetic|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
75563432|NCT00512889|Drug|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
75563433|NCT00512889|Radiation|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
75563434|NCT01248728|Dietary Supplement|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
75873777|NCT03380429|Drug|Salbutamol|Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
75563435|NCT01248728|Dietary Supplement|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
75563436|NCT00512928|Drug|acenocoumarol|max 5 mg per day during 10 weeks
75563437|NCT00512928|Dietary Supplement|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
75563438|NCT04695405|Genetic|Saliva Genetic Samples|Patients will provide two saliva swabs containing genetic materials.
75563439|NCT02951442|Biological|Biological sample|
75563440|NCT02951442|Procedure|Non invasive Arterial investigations|
75563441|NCT02951442|Procedure|Abdominal tomodensitometry|
75873778|NCT03380429|Device|Smart phone app|Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.
75873779|NCT03380429|Device|HCP Dashboard|The information from sensors will be reviewed by the HCP via an online dashboard.
75563442|NCT02951247|Device|Hearing Aid|Successor of Phonak Virto V90-10 NW O
75563443|NCT00505154|Drug|Rosuvastatin|Rosuvastatin 10 mg tablets od for 6 months
75563444|NCT00505154|Drug|placebo|placebo
75563445|NCT00513903|Behavioral|Minimal intervention|Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
75563446|NCT00513903|Behavioral|Enhanced Intervention|Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
75873780|NCT03380429|Device|Sensors|Clip-on sensors will be fitted to electronically record the actuation data.
75563447|NCT00513942|Other|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
75563448|NCT01246973|Drug|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
75563449|NCT01246973|Drug|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
75563450|NCT00514605|Other|Behavioral counseling|Standard-of-Care counseling at the Point-of-Care.
75563451|NCT00514605|Device|HIV-1 Antibody Test Kit|Assay to detect HIV antibodies
75563452|NCT01246466|Device|Hybrid: AtriCure Bipolar System & EP ablation procedure|AtriCure Bipolar System plus a catheter ablation
75563453|NCT00513981|Drug|leucovorin calcium|
75563454|NCT00513981|Drug|methotrexate|
75563455|NCT00513981|Other|mass spectrometry|
75563456|NCT00513981|Other|pharmacological study|
75718054|NCT05436158|Other|Implant placement in the safe angle position in the anterior maxilla|After assessing the CBCT of patients, the immediate implants will be assessed if they were placed in the safe zone. the safe zone is described as; that there is an angle between the intersection of the incisal long axis perpendicular to the palate or the occlusal plane, and the long axis of the root. When this relation is shifted more palatal, where the incisal plane line will be at the cingulum position or slightly palatal to it, it is named the safe angle position. The more palatal relocation to the cingulum is performed according to the availability of palatal bone, the occlusion with the opposing dentition, the type of the restoration (screw vs cemented).
75718055|NCT05436002|Device|With Cross-linked Hyaluronic Acid|Without Cross-linked Hyaluronic Acid
75718056|NCT02560376|Drug|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
75718057|NCT05435690|Device|Computer-assisted arthroplasty|Computer-assisted arthroplasty
75718058|NCT00535288|Drug|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
75718059|NCT00535288|Drug|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
75718060|NCT00921830|Drug|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
75873781|NCT01313143|Drug|AOP200704|Comparison of AOP200704 with Esmolol
75873782|NCT01313143|Drug|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
75873783|NCT03280615|Dietary Supplement|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
75418079|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
75718061|NCT05435534|Other|ActiveFLS intervention|"A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~Osteoporosis treatments according to national guideline~A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered"
75563457|NCT00505232|Drug|Y-90 Ibritumomab tiuxetan|"Study Design~The present study will be split into two cohorts:~Patients younger than 60 years who will receive 8 chemotherapy cycles~Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) [0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets < 100,000/µl] will be administered 8 to 12 weeks after last chemotherapy."
75563458|NCT00514644|Other|Carotid ultrasound examination|Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.
75563459|NCT00514644|Other|Panorama examination|"Examination with the odontological radiological method Panorama, including a frontal verification image"
75563460|NCT02275442|Other|EPICES scale|
75563461|NCT00514722|Other|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
75563462|NCT01245764|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
75563463|NCT01245764|Biological|Placebo|
75563464|NCT00514059|Drug|Boostrix polio|1 dose (0.5 ml) i.m.
75718062|NCT05435534|Other|Usual care group|Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
75718063|NCT02560220|Biological|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
75873784|NCT03280615|Dietary Supplement|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
75563465|NCT00514761|Drug|AZD6244|oral vial
75563466|NCT00514761|Drug|Capecitabine|oral tablet
75873785|NCT05705934|Other|Exercise|Each session of the exercise program will last 50 minutes and will consist of 4 stages. At these stages, it is aimed to work the social, physical, spiritual and mental parameters of the holistic approach.
75563467|NCT04514315|Procedure|Minimally invasive cardiac valvular surgery|Minimally invasive valve surgery via right mini-thoracotomy.
75873786|NCT05071794|Drug|Propofol|Antiemetic effect of propofol
75873787|NCT05071794|Drug|saline 0.9%|Placebo
75563468|NCT04514315|Procedure|Conventional cardiac valvular surgery|Conventional valve surgery via full median sternotomy
75718064|NCT05356078|Drug|Antidepressant|"Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class"
75873788|NCT03711071|Other|"Workshop ICE training"|The workshop includes training in communication skills in relation to evidence based medicine.
75873789|NCT03710993|Device|oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding transfer standard and reference devices to assess oximeter calibration and accuracy.
75873790|NCT03709433|Behavioral|ACT groups and mobile app|See arm description.
75873791|NCT05705778|Procedure|standard amblyopia treatment|amblyopia treatment following international guidelines and genetic tests.
76043080|NCT05529433|Procedure|Smart Burs|Smart Bur is a polymer bur which removes only soft infected dentin as the cutting edges become dull in contact with the hard affected dentin.Caries removal will be done by Smart Bur mounted on a low speed hand-piece leaving the affected dentin intact. It requires less time for caries removal.
75418080|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
75718065|NCT05435456|Other|Exercise|Strengthening and Relaxation Exercises
75718066|NCT04836832|Drug|Acalabrutinib|Given PO
75718067|NCT04836832|Drug|Duvelisib|Given PO
75718068|NCT02917928|Dietary Supplement|carnosine|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
75718069|NCT02917928|Drug|Placebo|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
75718070|NCT03904420|Other|Clinical Education and Treatment Model|Patients will have self directed equipment education and standardized programming approaches
75718071|NCT03904420|Other|Traditional Model|Standard clinical practice and education
75718072|NCT05358184|Device|High frequency Percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz
75718073|NCT02783300|Drug|GSK3326595|GSK3326595 will be administered with and without food, in tablet and capsule formulation.
75718074|NCT02783300|Drug|Pembrolizumab|Pembrolizumab will be administered.
75873792|NCT03280537|Drug|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
75418081|NCT01407497|Biological|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
75418082|NCT01407497|Biological|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
75418083|NCT01407536|Device|Thermal stimulation system|The subjects meeting our criteria will be randomly assigned to either the experimental group (EXP) or the control group (COT). The EXP and COT received upper extremity thermal stimulation protocol for 30 minutes a day for 20 days. The TS temperature of EXP for noxious stimulation was set at 46-47°C for heat and 7-8°C for cold stimulation; the temperature of COT for innoxious stimulation was set at 40°C for warm and 20°C for cold stimulation.
75418084|NCT01407549|Behavioral|mindfulness group meetings with psychologist|The Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention. Participants will attend weekly group meetings (15-20 individuals per group) in which they will be guided through a progressive experiential exploration of mindfulness. Participants will be asked to develop a daily meditation practice of 30-45 minutes with audio-recordings for guidance, and will report the amount and type of practice in a daily dairy. . A psychologist with rich personal experience in mindfulness who is trained in mindfulness based therapy will be responsible for administering the program.
75418085|NCT01407588|Procedure|Magnetic navigation|Ablation with use of the magnetic navigation system
75563469|NCT03459261|Diagnostic Test|blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)|Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
75418086|NCT01407588|Procedure|Ablation performed with manual navigation|Atrial fibrillation ablation performed with manual navigation
75418087|NCT01407601|Dietary Supplement|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
75418088|NCT01407614|Procedure|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
75418089|NCT01407640|Procedure|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
75418090|NCT01407653|Procedure|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
75418091|NCT01407653|Procedure|Usual care|Classical care
75418092|NCT01407666|Procedure|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
75718075|NCT02781272|Procedure|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
75718076|NCT02781272|Procedure|Blood draw|Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
75718077|NCT02781272|Procedure|Imaging guided biopsy, surgical biopsy or surgical excision|Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
75418093|NCT01407679|Drug|Alitretinoin|1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
75718078|NCT04293484|Device|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
75418094|NCT01407731|Genetic|protein expression analysis|
75563470|NCT01245140|Drug|alitretinoin|to receive verum (20 patients)
75418095|NCT01407731|Genetic|western blotting|
75563471|NCT01245140|Drug|Placebo|to receive placebo (10 patients)
75563472|NCT00514800|Behavioral|Intervention - a validated home BP monitor and support from the specialist nurse|
75418096|NCT01407731|Other|laboratory biomarker analysis|
75418097|NCT01407744|Other|laboratory biomarker analysis|Correlative studies
75418098|NCT01407757|Genetic|DNA analysis|
75418099|NCT01407757|Genetic|gene expression analysis|
75418100|NCT01407757|Other|laboratory biomarker analysis|
75418101|NCT01407757|Other|pharmacogenomic studies|
75418102|NCT01407783|Behavioral|Problem Solving Tools (PST)|The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
75418103|NCT01407796|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|
75418104|NCT01407796|Drug|[18F](+/-)NOS|
75418105|NCT01407809|Device|Venous Sinus Stenting|Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
75418106|NCT01407822|Drug|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
75418107|NCT01407822|Drug|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
75873793|NCT03280537|Drug|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
75873794|NCT04799327|Drug|SHR20004|SHR20004：low dose
75418108|NCT01407835|Biological|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
75418109|NCT01407848|Drug|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
75563473|NCT00514800|Behavioral|Control - usual care (BP monitoring by their practice)|"Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
75563474|NCT02951637|Drug|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
75563475|NCT02951637|Drug|Gefitinib|Gefitinib (250mg daily)
75563476|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
75873795|NCT04799327|Drug|SHR20004|SHR20004: medium dose
75873796|NCT04799327|Drug|SHR20004|SHR20004: high dose
75873797|NCT04799327|Drug|placebo|Placebo
75873798|NCT03842826|Diagnostic Test|Palpation, resistance and stretch tests|Palpation, resistance and stretch tests performed by 2 blinded examiners.
75718079|NCT04293484|Device|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
75718080|NCT05355922|Other|Electrical electrostimulation of the quadriceps muscle|Exercises associated with electrical electrostimulation of the quadriceps muscle of patients with knee osteoarthritis
75418110|NCT01407848|Drug|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
75418111|NCT01407861|Other|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
75418112|NCT01407861|Other|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
75418113|NCT01407887|Drug|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
75418114|NCT01407900|Drug|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
75418115|NCT01407900|Drug|5% Dextrose in Water|four hour infusion IV
75418116|NCT01407913|Procedure|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
75418117|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
75418118|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
75563477|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
75563478|NCT00514839|Behavioral|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
75718081|NCT05355922|Other|Electrical electrostimulation of the quadriceps muscle (placebo)|Exercises associated with electrical electrostimulation (placebo) of the quadriceps muscle of patients with knee osteoarthritis
75718082|NCT00675506|Drug|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
75718083|NCT00675506|Drug|Placebo|2-mg sub-cutaneous injections once daily for 12 months
75873799|NCT05705622|Other|Oral mukositis nurse's education for patients|Education given to patients by nurses on the prevention, treatment and care of oral mucositis
75873800|NCT05029050|Drug|Dexmedetomidine|Continous intravenous infusion
75873801|NCT05029050|Drug|Clonidine|Continous intravenous infusion
75873802|NCT05029050|Drug|Natriumchlorid|Continous intravenous infusion NaCl
75873803|NCT04690231|Drug|Apatinib Mesylate|apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3
75873804|NCT04690231|Drug|ifosfamide and etoposide|ifosfamide and etoposide
75873805|NCT03280381|Other|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
75873806|NCT03280381|Other|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
75418119|NCT01407978|Biological|Vaccination with Fluval P monovalent influenza vaccine|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
75418120|NCT01407978|Biological|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
75418121|NCT01407978|Biological|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
75718084|NCT02558660|Behavioral|Education|Educational intervention about an existing SNAP healthy food incentive program
75718085|NCT02558660|Behavioral|voucher|$10 voucher to spend on produce at farmers markets
75718086|NCT04001920|Other|Training program|12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
75718087|NCT05435378|Drug|Vitamin B3 100 MG Oral Tablet|After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
76043081|NCT05529433|Procedure|Chemo-Mechanical Caries Removal (CMCR)|Selecti-Solve gel is a dental gel which main active ingredient is Papain enzyme which selectively removes the caries without pain and has bacteriostatic, bactericidal and anti-inflammatory properties. The use of CMCR is recommended as an alternative treatment technique in anxious patients. The gel will be applied with a blunt spoon instrument and distributed well into the cavity according to manufacturer's instructions.
75418122|NCT01407991|Other|enteral tube placement accuracy|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
75418123|NCT01407991|Other|NEM method for NG/OG tube placement|measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
75418124|NCT01408004|Drug|Pazopanib|Tablet 800mg qd til progression
75418125|NCT01408004|Drug|Everolimus|tablet 10 mg qd til progression
75418126|NCT01408004|Drug|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
75418127|NCT01408004|Drug|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
75418128|NCT01408004|Drug|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
75418129|NCT01408004|Drug|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
75418130|NCT01408056|Drug|Timolol 0.5% Gel Forming Solution (GFS)|"Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day"
75718088|NCT05435378|Drug|vitamin B9|After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
75718089|NCT05435378|Drug|Placebo|After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
76043082|NCT05533255|Other|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Composite resin at room temperature is used.
76043083|NCT05533255|Other|Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
75418131|NCT01408056|Drug|Mupirocin 2% Ointment|Topical application twice per day for 60 days
75418132|NCT01408069|Drug|MIGRANE|1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
76043084|NCT05529355|Drug|Envafolimab plus Endostar and S-1|Immunotherapy combined with chemotherapy and anti VEGFR therapy
76043085|NCT05529355|Drug|Envafolimab plus Endostar|Immunotherapy combined with anti VEGFR therapy
75418133|NCT01408069|Drug|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
75718090|NCT05435378|Procedure|full mouth non surgical periodontal treatment|full mouth scaling and debridement will be done by the primary investigator using ultrasonic scaler and periodontal curettes. After the non surgical treatment patients will be given oral hygiene instructions where they will be instructed to brush twice daily and shown how to brush using the horizontal scraping technique they will also be instructed to use the dental floss and shown how to use it.
75563479|NCT02951520|Procedure|new technique for lower limb nerve blocks using a single skin puncture (SOFT block)|The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
75563480|NCT01245062|Drug|GSK1120212|MEK inhibitor
75418134|NCT01408095|Drug|LY2608204|Administered orally
75418135|NCT01408095|Drug|Glimepiride|Administered orally
75418136|NCT01408108|Procedure|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique)."
75418137|NCT01408108|Procedure|Laparoscopic primary posterior crural repair|"Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used)."
75718091|NCT04002622|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
75718092|NCT04003324|Behavioral|Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults|Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
76043086|NCT05529355|Drug|Envafolimab plus S-1|Immunotherapy combined with chemotherapy
76043087|NCT05533099|Other|Observational study|Observational study of a device implanted in a previous clinical study
76043088|NCT05533021|Other|Training and Consultancy|In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
75418138|NCT01408121|Other|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
75563481|NCT01245062|Drug|Chemotherapy|Investigator Choice of DTIC or paclitaxel
76043089|NCT03244033|Other|Contextual clinical decision support|Incorporation of contextual data into EHR clinical decision support alerts
76043090|NCT03244033|Behavioral|Contextual survey|Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
75563482|NCT02951286|Device|high pull headgear + OBA|a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.
75563483|NCT02951286|Device|OBA (control group)|A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
75563484|NCT01244984|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
75563485|NCT01244984|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
75563486|NCT04695483|Drug|Corifollitropin alfa|Controlled ovarian stimulation long-acting protocol
75563487|NCT04695483|Drug|Follitropin Beta|Daily controlled ovarian stimulation protocol
75563488|NCT02951403|Procedure|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
75718093|NCT02560454|Behavioral|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance's"
75718094|NCT02560454|Behavioral|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
75718095|NCT03895840|Drug|Zilretta|Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
75718096|NCT00310375|Drug|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
76043091|NCT05528887|Biological|Autologous CAR-T cells|D0: CAR-T cells will be infused intravenously.
76043092|NCT05528887|Drug|Fludarabine|D-5 to D-3: Fludarabine (30 mg/m^2/day) will be administered intravenously for 3 days.
75418139|NCT01408134|Other|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
75418140|NCT01408160|Drug|Cytarabine|Given IV
75418141|NCT01408160|Biological|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
75418142|NCT01408160|Other|Laboratory Biomarker Analysis|Correlative studies
75418143|NCT01408160|Other|Pharmacological Study|Correlative studies
76043093|NCT05528887|Drug|Cyclophosphamide|D-5 to D-3: Cyclophosphamide (500 mg/m^2/day) will be administered intravenously for 3 days.
75418144|NCT01408173|Drug|NPC-11 for intravenous or oral administration.|NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
75418145|NCT01408186|Drug|Rabeprazole|Rabeprazole 20 mg daily
75418146|NCT01408186|Drug|Famotidine|Famotidine 40mg daily
75418147|NCT01408199|Drug|Lenalidomide|5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
75563489|NCT02951403|Other|Conservative treatment|Physiotherapy protocol is introduced to patients.
75563490|NCT01244516|Device|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
75563491|NCT01244516|Device|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
75563492|NCT01244516|Device|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
75563493|NCT02951208|Device|Active tDCS|Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
75563494|NCT02951208|Behavioral|Active VR Motivation Training|Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.
75563495|NCT02951208|Device|Sham tDCS|Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
75563496|NCT02951208|Behavioral|Sham VR Motivation Training|Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
75873807|NCT03270085|Drug|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
75873808|NCT03270085|Other|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
76043094|NCT05532787|Other|Application of acute chest pain risk stratification scores (HEART and EDACS)|Collection of data elements for the HEART Pathway and EDACS-ADP assessments and calculation of scores to risk stratify patients into low risk or high risk
75718097|NCT01061281|Device|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
75418148|NCT01408212|Procedure|Acupuncture treatment|"Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.~Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22~Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)"
75718098|NCT01061281|Device|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
76043095|NCT03009019|Drug|DFN-15 Active|
76043096|NCT03009019|Other|DFN-15 Placebo|
76043097|NCT04425343|Genetic|16s RNA Metagenomics sequencing|The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.
76043098|NCT05340751|Diagnostic Test|Blood drawn|Hemoglobin and Hematocrit Levels
76043099|NCT02575807|Biological|CRS-207|via IV infusion
76043100|NCT02575807|Drug|Epacadostat|PO BID
76043101|NCT02575807|Biological|Pembrolizumab|via IV infusion
76043102|NCT05334589|Device|Prewarming|When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
76043103|NCT05532553|Device|Carotid Doppler U/S|Measurement of carotid intima media thickness by carotid doppler ultrasound
75563497|NCT02951325|Other|Adjuvant RT|"Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~Toxicity:~Weekly RT with toxicity scoring.~RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~QOL will be assessed at baseline f/b 3-6 monthly.~Disease evaluation:~i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated."
75718099|NCT02532985|Other|Negative Control|No added fiber beverage
75718100|NCT02532985|Other|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
75718101|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
75718102|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
75873809|NCT05615454|Device|bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).|The experimental group (receive the BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
75873810|NCT05615454|Device|placebo BEMER|Comparison group (receive placebo BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
75873811|NCT05703204|Drug|QLF32101|The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
76043104|NCT02813785|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
76043105|NCT02813785|Drug|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 21-day cycle.
76043106|NCT04302181|Drug|Ropivacaine injection|6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
76043107|NCT05528341|Biological|NKG2D-CAR-NK92 cells|NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10^6-2×10^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
75718103|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
76043108|NCT05528185|Other|Direct participation of the family member in the daily rounds|When the team arrives at the participating family member's room, the family member will be invited by a member of the healthcare team to come out of the room. The rounding team and structure will be the same as the usual care group with the following exceptions: (1) the family member will be invited to participate in the rounds outside their relative's room; (2) the family member will be provided with an orientation to the medical team members; (3) the family member will be allowed to engage and participate throughout the rounds; (4) at the end of the rounds, the team will summarize the patient's daily care plan; (5) the family member will be prompted to ask questions.
76043109|NCT05532475|Diagnostic Test|measurement of vitreous level of tumor necrosis factor alpha|measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
76043110|NCT05527951|Other|eMBC|The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
76043111|NCT05527951|Other|standard MBC|The control intervention group will implement standard MBC using paper and pencil questionnaires.
75718104|NCT00309907|Biological|etanercept|Given IV and subcutaneously
75718105|NCT00309907|Drug|methylprednisolone|Given IV and orally
75873812|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
76043112|NCT05527795|Other|Frequency and duration of response to adjuvant immunotherapy according to clinical features|"Frequency of relapse to adjuvant immunotherapy according to clinical features~Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features"
76043113|NCT05527795|Other|Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features|Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features
76043114|NCT05527795|Other|Duration of relapse-free survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.
76043115|NCT05527795|Other|Duration of overall survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.
76043116|NCT05527795|Other|Overall response rate|Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.
76043117|NCT05527795|Other|Frequency of adverse events according to clinical features|Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features
75718106|NCT01063777|Other|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
75718107|NCT01063777|Other|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
75718108|NCT00655824|Drug|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
75873813|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
76043118|NCT04128553|Behavioral|Intervention motivational interview group|"Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.~In the present study, an effort was made to help the IG to realize the dilemmas of individuals in the precontemplation stage about exercising, and individuals in the contemplation stage to produce their own solutions. In this direction, techniques such as decision balance, importance, and trust technique were applied, thus enabling them to reveal their feelings, thoughts, and reactions regarding the benefits/harms of doing/not doing exercise. They were supported to raise awareness about the consequences and solutions of the causes."
75718109|NCT03985969|Drug|elafibranor|Elafibranor 120mg is a coated tablet for oral administration
75718110|NCT03985969|Drug|CHRONO-INDOCID|CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
75718111|NCT01061437|Drug|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
75718112|NCT01061437|Drug|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
75718113|NCT01061437|Drug|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
75718114|NCT00575588|Drug|Metformin|open-label metformin
75718115|NCT00575588|Drug|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
75718116|NCT00575588|Drug|Saxagliptin|Saxagliptin 5 mg tablets
75718117|NCT01058317|Drug|Propranolol|Propranolol 2mg/kg divided twice daily
75718118|NCT02553096|Device|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
75718119|NCT00810030|Drug|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
75718120|NCT00810030|Drug|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is >25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height [m] x height [m].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
75718121|NCT00804102|Device|Transcorneal Electrical Stimulation|Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.
75718122|NCT00804102|Device|DTL-electrode attached without energy|DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.
75873814|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
75418149|NCT01408238|Biological|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
75718123|NCT00804180|Behavioral|Self-Injection Anxiety Counseling|This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
75718124|NCT00675428|Drug|BG00002 (natalizumab)|
75418150|NCT01408264|Device|Conventional 0.035 guidewire|0.035 guidewire
75873815|NCT03267511|Drug|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
75873816|NCT05003544|Procedure|Group A|PENG BLOCK
75873817|NCT05003544|Procedure|Group B|Intra-articular
75718125|NCT04049396|Other|Berberine|24 Patient consumed 6,25 g/day Berberine for 6 weeks
75718126|NCT00760916|Drug|UT-15C 1 mg|UT-15C 1 mg
75873818|NCT05003544|Procedure|Group C|Quadratus lumborum block
75418151|NCT01408264|Device|Olympus Visiglide 0.025 guidewire|0.025 guidewire
76043119|NCT05527561|Behavioral|Latin dance: Rumba|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
75418152|NCT01408290|Biological|Vaccination with FAB-3511|One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
75563498|NCT02955680|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
75563499|NCT02955680|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
75718127|NCT00760916|Drug|UT-15C 0.25 mg|UT-15C 0.25 mg
75718128|NCT00760916|Drug|UT-15C 5 mg|UT-15C 5 mg
75718129|NCT00760916|Drug|Placebo|Placebo
75718130|NCT05166200|Other|Experimental Formula|Diabetes-specific study formula
75718131|NCT05166200|Other|Test Meal|Instant oatmeal
75718132|NCT00761228|Drug|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
75418153|NCT01408290|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
75418154|NCT01408290|Biological|Vaccination with FAB-9011|One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
75418155|NCT01408290|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
75718133|NCT00761228|Drug|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
75718134|NCT00921908|Other|2 mBq radioactive technetium diluted in 20 mL saline|
75718135|NCT02558738|Device|ear spray|
75873819|NCT04234945|Drug|Doxycycline Capsule|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
75873820|NCT04234945|Drug|Multivitamins W/Iron Tab|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
75873821|NCT03627156|Behavioral|guided counseling|Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
75418156|NCT01408316|Drug|PX-866|Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
75418157|NCT01408342|Drug|Alemtuzumab and Rituximab|"Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~Cyclosporine 3 mg/kg starting day 21"
75418158|NCT01408355|Drug|PF-06273588|Intravenous, 50 microgram, single dose
75418159|NCT01408355|Drug|PF-06273588|Oral solution, 50 microgram, single dose
76043120|NCT05527561|Behavioral|Latin dance: Cha Cha Cha|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
75418160|NCT01408368|Procedure|Bilateral subtotal thyroidectomy|The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
75418161|NCT01408368|Procedure|Total thyroidectomy|The intervention consisted of total extracapsular thyroidectomy.
75718136|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
75418162|NCT01408381|Other|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
75718137|NCT00758732|Drug|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
75418163|NCT01408394|Drug|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
75418164|NCT01408394|Drug|90 mg controlled release form|This is the 90 mg controlled release form
75418165|NCT01408394|Drug|180 mg controlled release form|This is the 180 mg controlled release capsule
75418166|NCT01408407|Other|Aveeno cream|Apply cream on irradiated area twice a day
75418167|NCT01408407|Other|Alkagin paste|Apply Alkagin paste three times a day.
75418168|NCT01408420|Procedure|MAP > 60 mmHg|During heart surgery a blood pressure with a MAP > 60 mmHg during extracorporeal circulation is used.
75418169|NCT01408433|Other|Single Embryo Transfer|single embryo transfer of a chromosomally normal embryo
75418170|NCT01408433|Other|Double embryo transfer|two (2) embryo transfer of untested embryos
75418171|NCT01408446|Drug|Menthol|Capsule 48mg three times a day after meals 8 weeks
75418172|NCT01408446|Drug|Placebo|Capsule 48mg three times a day after meals 8 weeks
75718138|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
75718139|NCT00758732|Drug|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
75418173|NCT01408472|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
75418174|NCT01408498|Drug|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
75418175|NCT01408524|Drug|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
75418176|NCT01408524|Drug|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
75418177|NCT01408550|Drug|NPB-01|Intravenous immunoglobulin
75718140|NCT00761384|Drug|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
75718141|NCT00758888|Procedure|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
75718142|NCT00758888|Procedure|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
75718143|NCT00758888|Other|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
75718144|NCT02559674|Biological|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
76043121|NCT05527249|Dietary Supplement|Dietary Supplement|20g of protein powder + 650mg of pomegranate extracts
76043122|NCT05527249|Other|Placebo of the dietary supplement|20g of protein powder + 650mg of maltodextrin
75418178|NCT01408550|Drug|Placebo|Physiological saline
75418179|NCT01408589|Drug|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
75418180|NCT01408602|Drug|MRC375|MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
75418181|NCT01408602|Drug|Matching Placebo|Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
75563500|NCT02951169|Other|No intervention|No intervention. Treatment are accordance with clinical practice.
75418182|NCT01408602|Drug|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
75418183|NCT01408654|Behavioral|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
75418184|NCT01408667|Drug|TRC150094|50 mg Tablets once a day
75418185|NCT01408667|Other|Placebo|Tablets once daily
75418186|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
75418187|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
75418188|NCT01408680|Dietary Supplement|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
75418189|NCT01408693|Procedure|Trans-gluteal approach, CLAS|Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
75418190|NCT01408693|Procedure|Anterior minimal invasive approach, AMIS|Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
75418191|NCT01408745|Device|Sternumfix|sternotomy closure with Sternumfix
75418192|NCT01408745|Procedure|steel wire|sternotomy closure with steel wire
75418193|NCT01408758|Other|Virtual Clinician Research Tool (VCRT)|The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
75418194|NCT01408758|Other|No VCRT, only physician counseling at visits|No intervention
75418195|NCT01408797|Procedure|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
75418196|NCT01408797|Drug|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
75418197|NCT01408797|Procedure|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
75418198|NCT01408810|Drug|Infliximab|5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
75418199|NCT01408836|Procedure|Plasma exchange|Plasma exchange
75563501|NCT01244126|Drug|Intranasal fentanyl|2mcg/kg fentanyl IN
75563502|NCT01244126|Drug|morphine IM|0.1 mg/kg morphine IM for postop pain
75563503|NCT01244126|Drug|IV morphine|0.1 mg/kg morphine IV
75718145|NCT02559674|Biological|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
75718146|NCT02559674|Biological|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
75718147|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
75418200|NCT01408836|Drug|Intravenous methyl prednisolone|Intravenous methyl prednisolone
75418201|NCT01408836|Drug|Methyl prednisolone|methyl prednisolone
75418202|NCT01408849|Drug|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
75418203|NCT01408849|Drug|Omeprazole|Standard therapy
75418204|NCT01408875|Device|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
75418205|NCT01408927|Other|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
75418206|NCT01408927|Other|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
75418207|NCT01408927|Other|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
75563504|NCT04695639|Other|Test of Arm Selective Control|It will be used to assess selective voluntary motor control. It is a reliable and valid evaluation tool used to quantify and describe selective voluntary motor control in children with spastic cerebral palsy. The goal of the assessment is to systematically evaluate a person's ability to move the upper extremity with selective voluntary motor control by observing movement control, coordination, fluency, mirroring, and speed at each joint, and then assigning a grade, all in 'real time. Clinically this measure may guide the selection of medical, surgical, or therapy interventions and may improve outcome prognosis after brief training. Raters demonstrated excellent reliability in assessing upper extremity SVMC in a group of children with hemiplegic, diplegic, and quadriplegic CP using the Ttest of arm selective control
75418208|NCT01408953|Biological|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
75418209|NCT01408966|Dietary Supplement|DarkChocolate|Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
75418210|NCT01408966|Dietary Supplement|WhiteChocolate|White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
75418211|NCT01408979|Drug|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
75418212|NCT01408979|Drug|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
75418213|NCT01409005|Drug|Gemcitabine and UFTE chemotherapy|"Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15~UFTE : 200mg/m2 PO q 8 hr, Days 1~21~Interval: every 4 weeks"
75418214|NCT01409018|Drug|Itraconazole|pharmacokinetics
75418215|NCT01409044|Other|Music|"Music listening for the treatment group. Music is from MusicCure selection Dreams. Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively."
75418216|NCT01409083|Device|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
75418217|NCT01409122|Drug|15 mg sodium nitrite inhalation solution|15 mg sodium nitrite inhalation solution Q8H
75418218|NCT01409122|Drug|90 mg sodium nitrite inhalation solution|90 mg sodium nitrite inhalation solution Q8H
75418219|NCT01409122|Drug|45 mg sodium nitrite inhalation solution|45 mg sodium nitrite inhalation solution Q8H
75418220|NCT01409122|Drug|120 mg sodium nitrite inhalation solution|120 mg sodium nitrite inhalation solution or placebo Q8H
75718148|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
75718149|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
75563505|NCT04695639|Other|Hand Held Dynamometer|Hand held dynamometer (Camry Digital Hand Dynamometer Grip Strength, Model EH101-37, China) will be used to assess hand grip strength of the affected upper extremity. It is generally small, portable and relatively cheap reliable measurement instruments to measure muscle strength of the arm and hand in children with spastic cerebral pasly. It is used to measure strength; maximal voluntary isometric contraction; objectively in kilograms, pounds or newtons. Such devices have been proven to have good to excellent reliability in different populations. It represents an easily accessible way to assess muscle weakness in children with cerebral palsy and the overall reliability is considered to be good.
75563506|NCT04695639|Other|Quality of Upper Extremity Skill Test|It will be used to assess function of the affected upper extremity. It is a reliable and valid outcome measure designed to evaluate movement patterns and hand function in children with cerebral palsy. It is designed to be used with children who have neuromotor dysfunction with spasticity and has been validated with children from 18 months to 8 years of age.
75563507|NCT01243892|Device|NuSpin|Device for administration of doses of somatropin.
75563508|NCT01243892|Drug|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
76043123|NCT05532085|Other|Evaluation of pain during voluntary termination of pregnancy with medication following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anes!thesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
75563509|NCT01243775|Drug|Belotaxel|60 mg/m2 3 weekly (day 1)
75563510|NCT01243775|Drug|Belloxa|70 mg/m2 3 weekly (day 2)
75563511|NCT00514293|Drug|bexarotene|
75563512|NCT00514293|Drug|capecitabine|
75563513|NCT00514293|Drug|carboplatin|
75563514|NCT00514293|Drug|cisplatin|
75563515|NCT00514293|Drug|docetaxel|
75563516|NCT00514293|Drug|tretinoin|
75563517|NCT02955641|Drug|Dexamethasone Disodium Phosphate 0.1%|four drops a day for four days after LPI treatment
75563518|NCT02955641|Drug|Nepafenac 0.1%|four drops a day for four days after LPI treatment
75563519|NCT02955641|Drug|Hydroxyethylcellulose 0.19%|four drops a day for four days after LPI treatment
75563520|NCT00514956|Behavioral|Emotional Freedom Techniques (EFT)|
75563521|NCT01243268|Drug|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
75563522|NCT00504530|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
76043124|NCT05532085|Other|Evaluation of pain during a voluntary medical termination of pregnancy following consideration of predictive factors of pain with an established analgesic protocol|"Evaluation of the pain felt by women having a medical abortion following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during a medical abortion will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
75418221|NCT01409122|Drug|25% MTD sodium nitrite inhalation solution|Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
75418222|NCT01409135|Drug|AGS-22M6E|IV Infusion
75418223|NCT01409135|Drug|ASG-22CE|IV Infusion
75563523|NCT00514995|Drug|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
75418224|NCT01409148|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2mCi (1 mg)
75418225|NCT01409174|Drug|Ipilimumab|"Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.~Phase II dose: Maximum tolerated dose (MTD) from Phase I."
75418226|NCT01409174|Drug|Temozolomide|200 mg/m^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
75418227|NCT01409174|Drug|Cisplatin|25 mg/m^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
75418228|NCT01409174|Drug|Interferon Alfa-2b|5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
75563524|NCT01242371|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
75563525|NCT01242371|Dietary Supplement|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
75563526|NCT01242176|Drug|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
75563527|NCT01242176|Drug|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
75563528|NCT00515151|Drug|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
75563529|NCT00515151|Drug|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
75563530|NCT01242020|Drug|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
75563531|NCT00514332|Procedure|stent|stent placement for colorectal cancer obstruction
75563532|NCT01241786|Drug|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and < 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
75563533|NCT01241786|Drug|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
75563534|NCT00514410|Drug|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
75718150|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
75418229|NCT01409174|Drug|Interleukin-2|9 million IU/m^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
75418230|NCT01409187|Drug|Ipilimumab|Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
75418231|NCT01409187|Drug|Interferon|5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
75418232|NCT01409187|Drug|Interleukin-2 (Aldesleukin)|9 million IU/m^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
75418233|NCT01409226|Device|3.0-T MRI|Participants undergo MRI prior to biopsy.
75418234|NCT01409226|Procedure|biopsy|Participants undergo breast biopsy after 3.0-T MRI.
75563535|NCT00514410|Drug|Placebo|Matching placebo taken once a day for three months
75718151|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
75718152|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
76043125|NCT05532085|Other|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
76043126|NCT05532085|Other|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain with established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
75563536|NCT01241318|Drug|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
76043127|NCT02303119|Drug|Rituximab IV|intra-venous, 375 mg/m²
75563537|NCT01241318|Procedure|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
75563538|NCT00514488|Drug|STI571 (400 mg/day; or 800 mg/day)|
75563539|NCT00514527|Drug|oritavancin|Oritavancin as a single, infrequent or daily dose.
76043128|NCT02303119|Drug|Rituximab SC|sub-cutaneous, 1400 mg
75563540|NCT01241279|Device|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
75563541|NCT01241279|Device|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
75563542|NCT00514566|Device|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
75563543|NCT01241240|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
75873822|NCT03802110|Device|commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.|The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
75873823|NCT03316807|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
75873824|NCT03316807|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
75718153|NCT04913636|Device|Treatment Gel|In the evening subjects will perform their regular denture cleaning routine. They will be instructed to sleep without dentures. Subjects will rinse out their mouth with water (if subjects brush their oral mucosa with brush, they will be allowed to continue doing so) and apply the gel to their mucosa where they normally wear upper or lower denture.
75718154|NCT04913636|Other|Sham Control|Subjects will perform their regular denture cleaning routine.
76043129|NCT02006251|Device|Real-time Instrumentation|To prepare the acetabulum and place the implants on the day of surgery, surgeons will receive either parts necessary to create the real-time with a surrogate model of the acetabular surface or standard surgical alignment instruments provided by the manufacturer of the implant. For the experimental group, the surgeon will be provided with 3 parts necessary to create the real-time instrument: (1) a patient-specific surrogate bone model with a built-in guide pin trajectory which was planned in the 3D planning software, (2) a non-specific plastic arm available in different sizes, and (3) bone cement. The real-time instrument is created to position a peripheral guide wire on the acetabular rim to serve as a visual aid for reaming and impacting the acetabular shell using standard reaming tools supplied by the manufacturer. Once the acetabular shell is placed, the procedure is performed in the same manner for both groups, using the standard manufacturer instruments.
75418235|NCT01409278|Procedure|Ropivacaine infiltration and saline infusion.|50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
76043130|NCT02006251|Procedure|Standard Total Hip Arthroplasty|Total hip arthroplasty performed according to standard of care
75718155|NCT00761696|Drug|IPI-926|Oral daily dosing
75718156|NCT00759122|Drug|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
75418236|NCT01409278|Procedure|Ropivacaine infiltration and infusion.|50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
75418237|NCT01409278|Procedure|Normal Saline|50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
75418238|NCT01409304|Device|Deep Transcranial Magnetic Stimulation (DTMS)|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
75873825|NCT04948710|Diagnostic Test|Sonography|Sonographic Venous Doppler Imaging
75873826|NCT04931550|Device|Pacemaker implantation|Different pacing sites will be chosen according to the patients condition.
75873827|NCT03379259|Drug|BGB-A333|Anti-PD-L1 antibody
75873828|NCT03379259|Drug|BGB-A317|Anti-PD-1 antibodies
75873829|NCT05586048|Drug|Yiqi Fumai Lyophilized Injection(YQFM)|No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
75718157|NCT00759122|Drug|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
75718158|NCT00759200|Drug|alb-interferon alfa 2b|900 mcg every 4 weeks
75718159|NCT00759200|Drug|alb-interferon alfa 2b|1200 mcg every 4 weeks
75718160|NCT00759200|Drug|alb-interferon alfa 2b|1500 mcg every 4 weeks
76043131|NCT02575339|Drug|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
76043132|NCT02575339|Drug|MLN0128 (RP2D)|"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
75563544|NCT01241240|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
75563545|NCT02950623|Other|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
75718161|NCT00759200|Drug|alb-interferon alfa 2b|1800 mcg every 4 weeks
75563546|NCT02950623|Other|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
75718162|NCT00759200|Drug|peg-interferon|Peg-interferon alfa 2a: 180 mcg 1x per wk.
75718163|NCT00557505|Drug|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
75718164|NCT02558816|Drug|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199
75718165|NCT00759278|Procedure|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
75718166|NCT01299753|Drug|placebo|identically packed placebo
75718167|NCT01299753|Drug|propranolol|20-40 mg q6-8h
75718168|NCT02559440|Drug|mometasone furoate|50μg, 1 puff in each nostril every evening
75718169|NCT02559440|Drug|Placebo|1 puff in each nostril every evening
75718170|NCT02559440|Drug|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
75718171|NCT02559440|Drug|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
75718172|NCT02559440|Drug|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
76043133|NCT02575339|Drug|Sorafenib|"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"
75718173|NCT02559440|Drug|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
75718174|NCT01190943|Other|Laboratory Biomarker Analysis|Correlative studies
75718175|NCT00944931|Device|DC Brain Polarization|
76043134|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
76043135|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
75563547|NCT00515970|Procedure|Curettage|"Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm."
75563548|NCT00515970|Procedure|Deep excision|12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
76043136|NCT01712659|Drug|Ruxolitinib|Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
75563549|NCT00515970|Procedure|Shave excision|Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
75873830|NCT05405556|Diagnostic Test|eGFR reporting|"To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~only study-related eGFR values >25% below baseline will be reported to patients and providers~all study-related eGFR will be provided to patients and providers"
75873831|NCT04924998|Drug|current treatment of AL-CM|current treatment of AL-CM
75418239|NCT01409317|Device|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
75873832|NCT03328897|Drug|Omalizumab|injection of 150mg or 300 mg
76043137|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
76043138|NCT01640587|Drug|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
76043139|NCT01640587|Drug|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
75873833|NCT03328897|Drug|Placebo|Injection of placebo
75418240|NCT01409317|Device|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
75418241|NCT01409343|Drug|TrasGEX™|Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
75418242|NCT01409356|Behavioral|Diet + exercise|Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
75418243|NCT01409369|Drug|RO4995819|single oral dose
75418244|NCT01409369|Drug|activated charcoal|orally 3 times daily, Days 1-7
75718176|NCT04861220|Behavioral|Physical exercise|"The prescription will be divided into 3 phases:~Warm-up: with the object of removing the body from rest and preparing it to start the activity, it consists of exercises for upper and lower limbs, 1 minute each.~Physical exercise: Object of physical conditioning, it consists or aerobic training with walking and muscle activation through concentric contraction of the rectus abdominis in supine position, sit and get up from a chair and resistance exercises for upper members. The patient must perform 2 sets of 12 repetitions for each exercise with a 1-minute interval between the sessions.~Stretching and relaxing: Streching the arms above the head, stretching the legs and stretching the trunk to the left and right side will be oriented. Each stretching exercise should be done for 20 seconds. The relaxation should be performed in a sitting position, eyes closed, calm and silent place, soft breathing, for 5 minutes."
75418245|NCT01409395|Drug|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
75873834|NCT04918758|Device|Purastat Arm|"Generic name of device and principal intended use(s):~Still PuraStat from a CE mark perspective. PuraStat is an aqueous self-assembling peptide solution of 2.5% concentration RADA16~Indication for use:~PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical:~Bleeding from small blood vessels and oozing from capillaries of the parenchyma of solid organs. Oozing from vascular anastomoses~Bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures~Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon."
75873835|NCT04918758|Drug|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
76043140|NCT05531851|Other|Instrument Assisted Soft Tissue Mobilization|"For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin."
75418246|NCT01409395|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
75718177|NCT00202761|Behavioral|PIH|Intensified training
75718178|NCT04012281|Device|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
75718179|NCT00674570|Drug|Hydrocortisone|25 mg/oral one hour prior to extinction task
75718180|NCT00674570|Drug|D-Cycloserine|50 mg/oral one hour prior to extinction task
75718181|NCT00674570|Drug|Placebo|One hour prior to extinction task
75718182|NCT00940563|Drug|Imatinib|
75718183|NCT00759512|Other|Therapeutic Touch|
75418247|NCT01409408|Drug|Aliskiren|300 mg of aliskiren daily for 8 weeks.
75418248|NCT01409408|Drug|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
75418249|NCT01409421|Behavioral|motivational interviewing|counseling intervention
75718184|NCT00940641|Drug|AZD7325|IV Dose
75718185|NCT00940641|Drug|AZD7325|oral dose
75718186|NCT00761852|Drug|Ruboxistaurin|32 mg daily for 2 weeks
75718187|NCT00761852|Drug|Placebo|1 tab po QD for 2 weeks
75418250|NCT01409421|Behavioral|three phone calls to remind patients to take their eye drops|reminder phone calls
75418251|NCT01409447|Device|Biphasic osteochondral composite|We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
75418252|NCT01409460|Procedure|Oburator Nerve block|Use of selective pain block.
75418253|NCT01409460|Procedure|Sham Injection in pectineus muscle.|Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
75418254|NCT01409473|Radiation|Prostate SBRT with concurrent boost to intraprostatic lesion(s)|40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
75718188|NCT00940719|Dietary Supplement|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
75563550|NCT00515970|Procedure|Curettage|"Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining."
75563551|NCT04695249|Behavioral|Exposure intervention using 360 degree videos|The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
75563552|NCT00516009|Drug|DEXAMETHASONE|
75418255|NCT01409486|Other|Drawing blood spots from Newborns|Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
75418256|NCT01409512|Procedure|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
75418257|NCT01409538|Other|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
75563553|NCT00516009|Other|PLACEBO|
75563554|NCT02950584|Other|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
75418258|NCT01409538|Other|Control condition|"This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control."
75418259|NCT01409551|Procedure|VATS hyperthermic chemoperfusion|VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
75418260|NCT01409551|Procedure|Bedside talc slurry pleurodesis|Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
75563555|NCT02950584|Other|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
75563556|NCT01240811|Drug|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
75563557|NCT01240811|Drug|Levonorgestrel IUD|
75563558|NCT01240811|Drug|Copper T380A IUD|
75563559|NCT03459144|Drug|verteporfin|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.
75563560|NCT03459144|Drug|verteporfin and ranibizumab|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
75718189|NCT00940797|Drug|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
75718190|NCT00940797|Drug|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
75718191|NCT00759590|Procedure|CT scan and Pressure volume curve|CT scan
75718192|NCT04012905|Drug|Corticosteroids for Systemic Use|"Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month"
75418261|NCT01409590|Behavioral|Exercise program|Homogenous exercise program in local fitness centers
75418262|NCT01409590|Behavioral|Diet|Weigh loss diet program prescribed by a professional nutritionist
75418263|NCT01409603|Drug|darexaban|oral
75418264|NCT01409603|Drug|Naproxen|oral
75418265|NCT01409616|Drug|darexaban|oral
75418266|NCT01409616|Drug|darexaban (double dose)|oral
75418267|NCT01409616|Drug|Acetyl Salicylic Acid|oral
75418268|NCT01409616|Drug|clopidogrel|oral
75418269|NCT01409642|Behavioral|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
75418270|NCT01409642|Behavioral|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
75418271|NCT01409642|Behavioral|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
75563561|NCT03459105|Procedure|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
75563562|NCT03459105|Procedure|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
76043141|NCT01610713|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
75563563|NCT03459105|Drug|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
75563564|NCT01240382|Drug|3% DE-089 ophthalmic solution|
75418272|NCT01409655|Behavioral|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
75418273|NCT01409668|Dietary Supplement|L. Amylovorus|L. Amylovorus
75418274|NCT01409668|Dietary Supplement|L. Fermentum|L. Fermentum
75418275|NCT01409694|Drug|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
75418276|NCT01409694|Drug|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
75418277|NCT01409694|Drug|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
75418278|NCT01409720|Other|exercise|tailored isometric physical exercise
75418279|NCT01409733|Device|TACE using Drug Eluting Beads loaded with Doxorubicin|100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
76043142|NCT01606189|Drug|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
75418280|NCT01409759|Procedure|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
75418281|NCT01409499|Procedure|hepatic resection|palliative hepatectomy followed by sorafenib
75418282|NCT01409499|Procedure|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
75418283|NCT01409499|Drug|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
75418284|NCT01409824|Other|CDSS|Clinical Decision Support System
75418285|NCT01409850|Device|Aqualizer|The Aqualizer is a soft splint with water-filled pads.
75418286|NCT01409850|Device|Soft splint|
75563565|NCT01240382|Drug|0.1% sodium hyaluronate ophthalmic solution|
75563566|NCT00516087|Biological|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10^7 cells/m2 Day 14 2x10^7 cells/m2~Group Two Day 0 2x10^7 cells/m2 Day 14 1x10^8 cells/m2~Group Three Day 0 1x10^8 cells/m2 Day 14 2x10^8 cells/m2"
76043143|NCT01606189|Drug|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
76043144|NCT01606189|Drug|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
76043145|NCT05526859|Other|Kinsiotaping for wrist flexor muscles|The flexor muscles of the wrist area will be targeted.
76043146|NCT05526859|Other|Kinesiotaping for wrist extensor muscles|The extensor muscles of the wrist area will be targeted.
76043147|NCT05524987|Behavioral|ANDES INTERVENTION|ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits and a text messaging program for 12 consecutive months
75418287|NCT01409876|Radiation|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
76043148|NCT01663987|Drug|tiotropium bromide|18 mcg once a day (QD)
76043149|NCT01663987|Drug|Placebo|once a day (QD)
75418288|NCT01409889|Behavioral|Diabetes Prevention Program|
75418289|NCT01409889|Behavioral|Healthy Living Program|
75418290|NCT01410019|Other|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
75418291|NCT01410032|Procedure|Plate fixation|Reconstruction plate
76043150|NCT05526781|Device|Clareon monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
75563567|NCT01244828|Drug|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
75563568|NCT00504192|Drug|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
75873836|NCT03266107|Device|Intracept|Radiofrequency ablation of the basivertebral nerve using the Intracept System
76043151|NCT05531773|Other|follow up of COVID-19 Patients|"In each participating center a post COVID-19 outpatient clinic is already working or will be settled up to care COVID-19 patients after the acute phase. At the post COVID-19 clinic patients will undergo routine blood exams and will be visited by Infectious Diseases physicians after recovery from the acute episode of COVID-19 disease. According to the clinical issues of the patients and the procedures of the study, if necessary, the patients will be visited by other practitioners (Pneumologists, Cardiologists, Neurologists, Physiatrist and Psychologists or others).~Patients who have been already visited at the post COVID outpatient clinics from 01/03/2020 and for whom data of the acute phase and the follow up have been collected will be enrolled in the study and retrospectively analyzed."
75418292|NCT01410032|Procedure|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
75418293|NCT01410045|Procedure|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
75418294|NCT01410136|Procedure|Chondrofix Osteochondral Allograft|Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
75418295|NCT01410149|Other|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
75418296|NCT01410149|Other|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
75418297|NCT01410149|Other|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
75563569|NCT01243346|Drug|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
76043152|NCT05305651|Drug|Sotrovimab|Sotrovimab dose and administration per standard of clinical care
75418298|NCT01410162|Drug|Tacrolimus|tacrolimus extended release capsules vs Prograf
75418299|NCT01410175|Device|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
75418300|NCT01410201|Drug|Dexamethasone Intravitreal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
76043153|NCT05526625|Other|Ultrasound-based measurements of IVC & IJV.|Ultrasound-based measurements of IVC & IJV.
76043154|NCT05524831|Other|KINESIOTAPE|kinesiotape will be applied on orbicularis oris muscle
76043155|NCT05524831|Other|oromotor training|selected oromotor training: Perioral sensory stimulation ,Tapping,Tongue pressure,Jaw exercises andIntraoral stimulation
75563570|NCT01249443|Drug|vorinostat|Given PO
75563571|NCT01249443|Other|diagnostic laboratory biomarker analysis|Correlative studies
76043156|NCT05531695|Behavioral|Exercise (either aerobic or flexibility)|
75418301|NCT01410214|Drug|Erlotinib|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
75418302|NCT01410214|Drug|vinorelbine/cisplatin|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
75563572|NCT01249443|Other|pharmacological study|Correlative studies
75563573|NCT01249443|Drug|carboplatin|Given IV
75563574|NCT01249443|Drug|paclitaxel|Given IV
75418303|NCT01410253|Other|Combination of four techniques of physiotherapy|The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
75418304|NCT01410253|Other|Combination of three techniques of physiotherapy|Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
75418305|NCT01410253|Other|Combination of two techniques of physiotherapy|Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
75563575|NCT01243073|Drug|Imetelstat|
75563576|NCT01242488|Biological|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
75563577|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
75563578|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
75563579|NCT01242488|Biological|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
75563580|NCT01242488|Biological|CDP6038|60 mg sc at Weeks 0, 4 and 8
75563581|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 4 and 8
75563582|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 4 and 8
75563583|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
75563584|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
75563585|NCT01242488|Other|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
75563586|NCT00516243|Other|placebo|Given PO
75563587|NCT00516243|Other|quality-of-life assessment|Ancillary studies
75563588|NCT00516243|Procedure|questionnaire administration|Ancillary studies
75873837|NCT03378635|Drug|Dasiglucagon|Glucagon analog
75873838|NCT03378635|Drug|GlucaGen|Native glucagon
75873839|NCT03378635|Drug|Placebo|Placebo for dasiglucagon
75873840|NCT03326869|Device|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
76043157|NCT05531617|Procedure|Intubation|Study groups Intubated with Macintosh or cmac video laryngoscopes
76043158|NCT05524519|Drug|Basic treatment|"Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist."
75563589|NCT00516243|Procedure|laboratory biomarker analysis|Correlative studies
75418306|NCT01410253|Other|standard therapy|Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
75718193|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
75718194|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
75418307|NCT01410266|Other|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
75418308|NCT01410279|Other|Inspiratory muscle training|The load is adjusted weekly in thirty percent of maximal inspiratory pressure of the subject.
75418309|NCT01410292|Other|GI and fiber meals|meals with different fiber content and glycemic index
75418310|NCT01410292|Other|meals|four different meal regarding GI and fiber content
75418311|NCT01410331|Biological|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
75418312|NCT01410331|Biological|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
75418313|NCT01410331|Biological|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
75563590|NCT00516243|Drug|defined green tea catechin extract|Given PO
75563591|NCT01240889|Drug|Fluticasone|nasal spray
75718195|NCT02559518|Device|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
75718196|NCT02559518|Device|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
75873841|NCT05692284|Other|routine care group|Firstly, informed consent was obtained from the patients in the control group, a pre-test was applied with the existing data collection methods, and routine nursing care continued. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
75873842|NCT05692284|Other|Care in accordance with Orem's theory group|Firstly, informed consent was obtained from the Intervention group, for which the pre-test was applied, and then care was given during their stay in the hospital in accordance with Orem's theory. This care was performed when the patient came to each chemotherapy cycle. After discharge, patient follow-up and care continued with the mobile application designed with Orem's theory, which will ensure the continuity of this care given in the clinic. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
75418314|NCT01410331|Biological|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
75418315|NCT01410370|Radiation|6MV-X ray|3Gy/time, 5 times/week, a total of 10 times
75418316|NCT01410370|Drug|Endostar|7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
75418317|NCT01410383|Drug|Placebo|Tablets taken daily
75418318|NCT01410383|Drug|Eprotirome|Tablets taken daily
75418319|NCT01410383|Drug|Eprotirome|Tablets taken daily
75418320|NCT01410435|Drug|Monofer|Infusion according to current HB level
75418321|NCT01410461|Device|quantitive sensory testing|Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
75418322|NCT01410461|Device|Ultrasound testing|Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
75563592|NCT01240889|Drug|Fluticason|2 sprays per day in each nostril
75563593|NCT00516282|Drug|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
75563594|NCT00516282|Drug|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
75563595|NCT02950389|Device|PMMA filter|
75563596|NCT02950389|Device|HFR17 filter|
75563597|NCT02950389|Device|F7 filter|
75563598|NCT04511117|Other|Control group|ProTaper Next rotary system and iRoot SP sealer with composite restorations.
75718197|NCT02559518|Device|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
75418323|NCT01410500|Drug|Carfilzomib|Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
75418324|NCT01410513|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
75718198|NCT02559518|Device|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
76043159|NCT05524519|Procedure|PSA|Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
75418325|NCT01410539|Device|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
76043160|NCT05524519|Procedure|TSA|Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
75418326|NCT01410539|Drug|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
75563599|NCT04511117|Other|Endocrown group|ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
75873843|NCT03710837|Other|Pain neuroscience education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
75873844|NCT03710837|Other|Red flag education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
75418327|NCT01410591|Device|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
75563600|NCT04512092|Behavioral|Compassionate Mind Training for Caregivers|CMT-C is a 12-session group program, each lasting about 2,5 hours, which run on a weekly basis. The program is organized across 3 modules: 1) Our mind according to a compassion-based approach (to provide insight into the evolved and socially shaped mind and the affect regulation systems); 2) Compassionate mind training (understanding and cultivating the attributes and competencies of compassion in its three flows, and addressing its fears); and 3) final session (revising key information and practices and its application to the RCH practices/routines). Its sessions have the following structure: 1) Check-in (grounding exercise, reviewing the previous session, sharing the weekly practice); 2) Exploration of the session theme (psychoeducation and experiential practices followed by group opportunities for share experiences and discussion); 3) Check-out (session summary and application to the self, youths and RCH practices, weekly practice challenge, session evaluation, session take-off).
75563601|NCT01249521|Drug|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
75563602|NCT04513301|Drug|Sintilimab|Sintilimab (200 mg q3w ×2 cycle)
75418328|NCT01410591|Device|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
75418329|NCT01410617|Procedure|hemodialysis|3 sessions hemodialysis before CABG
75418330|NCT01410630|Diagnostic Test|FLT-PET/CT|Standard of Care
75418331|NCT01410630|Diagnostic Test|FDG-PET/CT|Standard of Care
75718199|NCT02559518|Device|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
75563603|NCT04513301|Radiation|Radiotherapy|RT 50-60Gy/25-30f
75873845|NCT01182727|Drug|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
75873846|NCT00624715|Drug|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint"
75873847|NCT00624715|Drug|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
75418332|NCT01410630|Drug|FLT|5 mCi IV
75418333|NCT01410643|Other|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
75418334|NCT01410656|Behavioral|Telephone Implementation Intention|Telephone implementation intention counseling
76043161|NCT05524519|Procedure|CCA|Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
76043162|NCT05524441|Other|Circadian Disruption - Quasi-Experimental|2 conditions: comparing trips with circadian disruption to trips without circadian disruption
75418335|NCT01410656|Behavioral|Self-completed implementation intention|Self-administered implementation intention intervention
75563604|NCT04516421|Dietary Supplement|Protein supplementation|The experimental group contained 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
75563605|NCT04516421|Dietary Supplement|Placebo oat drink|placebo oat drink contained 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
75563606|NCT01249599|Procedure|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
76043163|NCT02380677|Drug|CRLX301|
76043164|NCT02380287|Drug|humanized monoclonal antibody against human IL-17|
76043165|NCT02343003|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
76043166|NCT02343003|Drug|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
76043167|NCT04900701|Other|Energy status|Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
75418336|NCT01410669|Behavioral|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
75563607|NCT04512014|Diagnostic Test|serum lactate|perioperative measurement of lactate levels
75563608|NCT01249677|Drug|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
75418337|NCT01410682|Other|0,12% digluconate chlorhexidine|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
75418338|NCT01410682|Other|toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
75563609|NCT04697043|Procedure|Systemic therapy followed by surgery if the disease is not progressive|Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The systemic therapy followed by surgery if the disease is not progressive.
75563610|NCT04511975|Drug|IBI188|IBI188: 100 mg/mL, intravenous infusion once a week
75563611|NCT04511975|Drug|Azacitidine|Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
75563612|NCT04511663|Combination Product|Assertive community treatment|The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.
75563613|NCT04511663|Combination Product|Basic public health services.|The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
75718200|NCT04012515|Device|Electrode Pads|Participants wear six electrode pads in total; three different types of pad, worn in the same positions on both sides of the face. The pads on the left-hand side of the face are replaced daily, and those on the right-hand side are replaced every other day. The pads do not administer a medical treatment or perform any other active function. The purpose of the intervention is to determine which combination of pad and replacement regime maximises the tolerability of wear over a 30-day period.
75718201|NCT00759746|Behavioral|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
75718202|NCT00759746|Behavioral|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
75563614|NCT04519931|Other|Stress ball|The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
75873851|NCT03334409|Drug|Ascorbic Acid|Given IV
75873852|NCT03334409|Drug|Pazopanib Hydrochloride|Given PO
75873853|NCT04821726|Device|Drug eluting balloon (Vmoky)|Use Vmoky Drug Eluting Balloon to treat patients with symptomatic intracranial atherosclerosis stenosis
75873854|NCT02891915|Drug|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
75563615|NCT02950194|Procedure|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
75873855|NCT02891915|Drug|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
75563616|NCT04511936|Device|i-Lumen AMD|Microcurrent stimulator
76043168|NCT02394561|Biological|Secukinumab|Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
75418339|NCT01410708|Drug|Dasatinib|
75418340|NCT01410721|Behavioral|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
75563617|NCT04511936|Device|i-Lumen AMD Sham|Sham microcurrent stimulator
75563618|NCT01249794|Procedure|non invasive ventilation|continuous positive airways pressure
75563619|NCT04519736|Device|Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage|
75873856|NCT02891915|Drug|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
75873857|NCT02891915|Other|Placebo|Placebo
75418341|NCT01410721|Behavioral|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
75563620|NCT02950116|Device|Perform three multiple breath nitrogen washout tests (N2-MBW-test)|"Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~Patient's breathing pattern is stable for a minimum of 5 breaths~Start of washout by inhaling 100% oxygen (initiated by lab technician)~Continuous stable breathing pattern until end of washout test~End target = 1/40th of start N2 concentration~To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~Three N2-MBW-tests are performed consecutively. Time between each test is [duration of the previous test*1.5] (e.g. test duration = 6 min., time to next test = 6*1.5 = 9 min.)"
75563621|NCT04511897|Drug|An'ningpai|An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
75718203|NCT00759746|Behavioral|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
75718204|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
75718205|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
75718206|NCT00940953|Drug|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
75718207|NCT00759824|Drug|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
75718208|NCT04012593|Behavioral|Diary|
75718209|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
75718210|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
75718211|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
75418342|NCT01410734|Drug|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
75718212|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
75718213|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
75718214|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
75718215|NCT00760058|Device|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
75718216|NCT00760058|Device|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
75718217|NCT00760058|Device|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
75873858|NCT04096092|Other|No intervention|No intervention
75418343|NCT01410747|Drug|Tacrolimus|oral
75418344|NCT01410760|Other|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
75418345|NCT01410786|Procedure|Conventional Instrumentation|Standard Oxford surgical instruments
75873859|NCT02891681|Device|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
75873860|NCT03707483|Combination Product|combination of vitamin C and platelet rich fibrin|combination of vitamin C and platelet rich fibrin
76043169|NCT04904913|Drug|IBI362|IBI362 administered subcutaneously (SC) once a week.
76043170|NCT04904913|Other|placebo|placebo administered subcutaneously (SC) once a week.
75418346|NCT01410786|Procedure|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
75418347|NCT01410838|Other|Broth|200 mL of sodium chloride containing broth, consumed three times per day
75418348|NCT01410838|Other|Broth|200 mL of MSG containing broth consumed three times per day
75563622|NCT04695093|Other|Ultra Low Emission Zone (ULEZ)|"The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area."
75563623|NCT04519463|Drug|Xylocaine Mucosal Product|Xylocaine 10% Nasal Spray
76043171|NCT02342223|Device|Voluma|
75563624|NCT04519463|Drug|Placebo|Sodium Chloride 0.9%
75563625|NCT02950311|Drug|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
75563626|NCT02950311|Other|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
75563627|NCT04519424|Biological|CSL324|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
75563628|NCT04519424|Drug|Placebo|Normal saline (0.9% sodium chloride)
75563629|NCT04696770|Behavioral|Mindfulness|Mindfulness techniques will be taught to the participants
75563630|NCT04511780|Other|questionnaire filling|assessment of post-traumatic stress, anxiety and burn out
75563631|NCT04696848|Drug|CKD-516 plus Durvalumab|"Stage 1 : dose escalation durvalumab (1500 mg Q4W) in combination with CKD-516 at 1 of 3 planned dose levels (9, 11, or 13 mg/m2 twice a week for 3 weeks in each cycle, Q4W).~Stage 2 : durvalumab (1500 mg Q4W) in combination with CKD-516 at recommended phase 2 dose (twice a week for 3 weeks in each cycle, Q4W)."
75563632|NCT04511585|Behavioral|Great Live and Move Challenge|Physical activity program for children
76043172|NCT02393547|Drug|Varenicline|All subjects receive Varenicline
76043173|NCT02393547|Drug|Lorcaserin|All subjects receive Lorcaserin
76043174|NCT02574637|Drug|Brazikumab IV Infusion|Brazikumab IV infusion as per protocol specified dosing schedule.
76043175|NCT02574637|Drug|Brazikumab SC Injection|Brazikumab IV infusion as per protocol specified dosing schedule.
76043176|NCT02574637|Drug|Placebo|Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
76043177|NCT05531539|Device|WELMO sensors vest|Wearing of a vest equipped with lung auscultation and EIT sensors for signal acquisition and transmission
75418349|NCT01410851|Other|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
75418350|NCT01410864|Device|DuraSeal Exact Spine Sealant System|DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
75563633|NCT04519346|Other|intradermal injection|Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
75563634|NCT02950077|Behavioral|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
75563635|NCT04519112|Procedure|Catheter Ablation|Catheter Ablation with RMN and MCN
76043178|NCT05526235|Behavioral|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, has been adapted for use on a smartphone or other device with internet access. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
75418351|NCT01410864|Other|Control|Devices or drugs used to seal the dura (other than DuraSeal)
75418352|NCT01410903|Device|TheraSorb Ig|1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
75418353|NCT01410916|Drug|Eculizumab (Soliris®)|Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
75563636|NCT01249950|Other|feasibility|feasibility
75718218|NCT00762242|Procedure|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
75418354|NCT01410929|Procedure|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
75563637|NCT00505271|Genetic|Rexin-G|"Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity."
75563638|NCT01249989|Behavioral|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
75718219|NCT02558426|Procedure|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
75718220|NCT00561951|Drug|fesoterodine fumarate|8mg tablets OD for 12 weeks
75718221|NCT00561951|Drug|Placebo|Corresponding placebo tablets OD for 12 weeks
75718222|NCT00561951|Drug|fesoterodine fumarate|4mg tablets OD for 12 weeks
75718223|NCT02558348|Drug|AL3818|Administered orally
75418355|NCT01410955|Dietary Supplement|Probiotic formula|Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
75418356|NCT01410955|Dietary Supplement|Placebo|Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
75418357|NCT01410968|Drug|vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells|Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
75418358|NCT01411020|Procedure|endotracheal intubation|to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
75418359|NCT01411046|Diagnostic Test|Synacthen test|250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
75563639|NCT01249989|Behavioral|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
75718224|NCT00762398|Device|Masimo hemoglobin-meter|Placing a probe on the finger
75718225|NCT00762398|Biological|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
75718226|NCT00760136|Procedure|Computed Tomography|CT imaging of bilateral knee
75718227|NCT04552886|Biological|TH-1 Dendritic Cell Immunotherapy|Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
75718228|NCT00762632|Drug|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
75718229|NCT00762632|Drug|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
75718230|NCT00322387|Drug|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
75718231|NCT00561015|Drug|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
75718232|NCT00561015|Drug|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
75718233|NCT00561015|Drug|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
75718234|NCT00945087|Other|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
75418360|NCT01411059|Behavioral|yoga|yoga classes 2 times per week for 32 weeks
75418361|NCT01411072|Drug|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
75418362|NCT01411072|Drug|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
75418363|NCT01411098|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
75418364|NCT01411098|Radiation|intensity-modulated radiation therapy|Undergo IMRT
75873861|NCT03626766|Behavioral|Photo in Verification Alert|Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
75418365|NCT01411098|Drug|cisplatin|Given IV
75418366|NCT01411098|Drug|etoposide|Given IV
75418367|NCT01411111|Drug|Rosuvastatin 10 mg|days 1-14
75418368|NCT01411111|Drug|GSK2190915 30mg|1x30mg tablet, days 8-14
75418369|NCT01411111|Drug|GSK2190915 100mg|1x100mg tablet, days 8-14
75418370|NCT01411124|Drug|gabapentin enacarbil|600 mg investigational compound
75418371|NCT01411124|Drug|diphenhydramine|50 mg active comparator
75418372|NCT01411124|Drug|placebo|placebo
75418373|NCT01411176|Drug|Menthol|20 mL NPO-11 in a prefilled plastic syringe
75418374|NCT01411176|Drug|Placebo|The placebo is included same additives as active comparator.
76043179|NCT05526235|Behavioral|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
76043180|NCT05526235|Behavioral|Psychological First Aid (PFA)|PFA is a brief intervention consisting of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.
76043181|NCT05531383|Drug|Memantine Hydrochloride|study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) & serum NSE levels in patients with moderate to severe TBI as well as their outcome.
75418375|NCT01411189|Drug|Menthol|20 mL NPO-11 in prefilled syringe
75418376|NCT01411202|Drug|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
75418377|NCT01411202|Other|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
75418378|NCT01411254|Drug|Betamethasone Microsphere (DE-102） Low Dose|
75418379|NCT01411254|Drug|Betamethasone Microsphere (DE-102） High Dose|
75418380|NCT01411254|Drug|Sham|
75563640|NCT01249989|Behavioral|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
75563641|NCT04511351|Drug|Chidamide|chidamide administration during radiation and chemotherapy phase in the study group
76043182|NCT05524207|Procedure|carotid artery stenting|Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
76043183|NCT02392611|Drug|Alobresib|Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
76043184|NCT02392611|Drug|Exemestane|Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
75418381|NCT01411280|Drug|methylphenidate|Ritalin 10mg, Ritalin 20mg
75418382|NCT01411293|Other|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
75418383|NCT01411293|Other|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
75418384|NCT01411306|Other|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
75418385|NCT01411306|Procedure|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
75418386|NCT01411358|Biological|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
75418387|NCT01411358|Biological|elderly aged over 60|one dose of 0.5mL AdimFlu-S
75418388|NCT01411371|Procedure|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
75418389|NCT01411371|Drug|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
75563642|NCT04519268|Diagnostic Test|Adult patients scheduled for an elective general surgical operation.|"The anesthesiologist, who is in charge of preoperative assessment at each hospital unit, will assess patients who are scheduled for elective surgery; and will inform senior anesthesiologists (with a minimum 3 years of experience) & consultant anesthesiologists, about the patients' data.~Patients data with all requested preoperative investigations & required preparations, peri-operative course and post-operative outcome will be collected."
75563643|NCT01244256|Drug|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
75563644|NCT01244256|Drug|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
75563645|NCT04511507|Procedure|hemoadsorption|three consecutive sessions of hemoadsorption in patients with liver failure
75873862|NCT03626766|Behavioral|Photo in Banner|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
75563646|NCT01249833|Drug|Oseltamivir|Oseltamivir 75mg BID for 5 days
75563647|NCT04511546|Device|BPET Prototype Scan|Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
75563648|NCT02275143|Radiation|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
75418390|NCT01411384|Procedure|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
75563649|NCT04511390|Device|Transparent, reusable respirator|A novel respirator with dual N95 filter cartridges
75563650|NCT02950233|Drug|NMDA active|NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).
75563651|NCT02950233|Drug|Steroid active|Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
75718235|NCT00560937|Drug|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
75418391|NCT01411384|Device|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
75418392|NCT01411397|Other|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
75718236|NCT00560937|Drug|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
75418393|NCT01411397|Other|mesh repair|mesh repair of strangulated hernia without resection
75418394|NCT01411410|Drug|Paclitaxel|"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."
75563652|NCT02950233|Drug|NMDA placebo|NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID [first week]; 1 capsule BID [following three weeks]).
75563653|NCT02950233|Drug|Steroid placebo|Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
75563654|NCT01249404|Biological|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
75563655|NCT01249404|Drug|Placebo|I.M. injection on day 1 (single treatment cycle)
75563656|NCT04511000|Drug|Lipilou®(generic atorvastatin drug) 20 mg|Patients assigned to experimental group are treated with Lipilou® 20 mg
75563657|NCT04511000|Drug|Lipilou®(generic atorvastatin drug) 10 mg|Patients assigned to comparator group are treated with Lipilou® 10 mg
75563658|NCT04519385|Drug|Tocilizumab|Tocilizumab therapy
76043185|NCT02392611|Drug|Fulvestrant|Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
75563659|NCT04519385|Drug|Dexamethasone|dexamethsone pulse therapy
75563660|NCT01249365|Biological|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
76043186|NCT02378961|Drug|VOX|100 mg tablet(s) administered orally once daily with food
76043187|NCT02378961|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
75563661|NCT00506051|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
75563662|NCT00506051|Drug|pemetrexed|intravenous infusion
75563663|NCT00506051|Drug|ZD6474 (vandetanib) 300mg|
75563664|NCT00504465|Drug|dinoprostone|
75563665|NCT04518800|Drug|Jin Youli(PEG-rhG-CSF)|Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle
75563666|NCT00516360|Device|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
75718237|NCT00945165|Behavioral|Exercise intervention|various exercise characteristics
76043188|NCT02378883|Device|Apollo™ Onyx™ Delivery Micro Catheter|
75563667|NCT04510883|Behavioral|PACO|The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
75418395|NCT01411410|Drug|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
75563668|NCT04510883|Behavioral|Waiting list + PACO|Waiting list + PACO
75563669|NCT01249131|Drug|Cobimetinib|Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
75563670|NCT04510961|Other|Paraffin baths therapy|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks. Prepare the paraffin device and blocks of paraffin wax. Put the paraffin wax blocks inside the tank and set the thermostat 35 to 40◦C. Melting paraffin was taken from 90 to 120 minutes. Adjust the suitable temperature for each patient before immersion of patient's hand. Submerge patient's hand completely for three to four seconds then withdraw it
75563671|NCT04510649|Drug|Part A|in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11
75563672|NCT04510649|Drug|Part B|in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
75418396|NCT01411423|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
75418397|NCT01411436|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable HCC
75418398|NCT01411449|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Patients who will need to undergo contrast enhanced MRI with Primovist
75418399|NCT01411462|Device|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
75563673|NCT01249092|Drug|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
75563674|NCT02275182|Drug|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
75418400|NCT01411475|Other|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
75563675|NCT02275182|Drug|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
75563676|NCT05653947|Procedure|Root canal instrumentation, 2.5% NaOCl irrigation|Root canal instrumentation, 2.5% NaOCl irrigation
75718238|NCT00945165|Behavioral|No exercise|No exercise control period
76043189|NCT05145829|Diagnostic Test|Diagnostic Test: Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
76043190|NCT05531071|Device|Biofeedback electrical stimulation|treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.
76043191|NCT05531071|Procedure|Acupuncture|acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.
76043192|NCT05531071|Combination Product|Acupuncture combined with biofeedback electrical stimulation|treated with acupuncture combined with biofeedback electrical stimulation.
75418401|NCT01411514|Drug|Prednisone|Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
75418402|NCT01411514|Drug|Placebo|Placebo tablets. They will be administered during 25 days
75418403|NCT01411540|Dietary Supplement|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
75418404|NCT01411553|Other|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
75418405|NCT01411566|Behavioral|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
75418406|NCT01411566|Behavioral|regular treatment|regular treatment
75563677|NCT01248936|Drug|RO5185426|
75563678|NCT01248780|Drug|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
75563679|NCT01248780|Drug|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
75563680|NCT01248780|Drug|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
75563681|NCT01248468|Drug|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
75563682|NCT01248468|Drug|Sumatriptan|100 mg Sumatriptan
75563683|NCT01248468|Drug|Placebo|placebo
75563684|NCT02275299|Drug|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
75718239|NCT04012437|Device|Sphincter Control Training (SCT)|The SCT + device consists of 8 different exercises and an educational session into a app using a masturbation electronic aid device
75718240|NCT04012437|Behavioral|Sphincter Control Training (SCT)|The SCT consists of 4 different exercises and an educational session into a app using a masturbation electronic aid device
75418407|NCT01411605|Behavioral|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
75563685|NCT02275299|Drug|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
75563686|NCT02275299|Drug|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
75718241|NCT00945399|Procedure|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
75718242|NCT00945399|Procedure|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
75718243|NCT00941187|Other|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
75718244|NCT04012359|Diagnostic Test|Lung ultrasound|Non-invasive external ultrasonography of the chest wall
75718245|NCT04012359|Diagnostic Test|Chest radiography|Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
75718246|NCT04012359|Diagnostic Test|Pulmonary function tests|Pulmonary function evaluation as part of routine care for emphysematous patients
75718247|NCT04012359|Other|Clinical examination|Standard clinical examination performed by investigating physician
75718248|NCT04012047|Drug|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
75718249|NCT04012047|Drug|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
76043193|NCT05518591|Behavioral|Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)|Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
75718250|NCT00941265|Drug|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
75718251|NCT00941265|Drug|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
75718252|NCT00941343|Drug|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
75718253|NCT00561795|Drug|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
75718254|NCT00561795|Drug|carboplatin|IV over one hour every 3 weeks of 6 cycles
75718255|NCT00561795|Drug|paclitaxel|IV 175 mg/m^2 given over 3 hours on day one of a 21 day cycle for six cycles
75718256|NCT00652626|Drug|azacitidine|
76043194|NCT05518513|Drug|Bupivacain|adductor canal block with 0.25% bupivacaine
75718257|NCT00941421|Device|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
75418408|NCT01411618|Other|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
75418409|NCT01411631|Dietary Supplement|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
75418410|NCT01411657|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
75418411|NCT01411670|Drug|Human protein C concentrate|Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
75563687|NCT02955576|Device|Microneedle HA patch|"The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
75563688|NCT02955576|Device|Patch|"The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale."
75563689|NCT02955576|Other|Control|"All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
75563690|NCT01247922|Drug|Erlotinib|continuous oral Erlotinib 85 mg/m^2 per day
75418412|NCT01411670|Drug|Activated protein C|Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
75718258|NCT00560703|Drug|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
75718259|NCT00560703|Drug|placebo|sugar capsule
75718260|NCT00308737|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
75718261|NCT00308737|Drug|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
75718262|NCT04711902|Drug|Secukinumab (AIN457)|Biological
75418413|NCT01411670|Drug|Placebo comparator|Standard treatment
75418414|NCT01411683|Device|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
75718263|NCT04711902|Other|Secukinumab Placebo|Matching placebo
75418415|NCT01411709|Drug|Vitano|two 200mg tablets per day for 14 days
75418416|NCT01411722|Device|Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)|Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
75418417|NCT01411735|Drug|Enalapril|2.5mg titrated up to 10mg twice daily
75418418|NCT01411735|Drug|placebo|2.5mg titrated up to 10mg twice daily.
75418419|NCT01411748|Dietary Supplement|Reflor|5 million unit/day, orally, beginning on the second day of life, until discharge from hospital
75418420|NCT01411748|Drug|mikostatin|50000 unit/3 times a day, both for orally and by orogastric route
75418421|NCT01411761|Dietary Supplement|Reflor|5 million unit/day, first 15 day of life
75718264|NCT00941499|Drug|HAI Oxaliplatin|140 mg/m^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
75718265|NCT00941499|Drug|5-FU|900-1750 mg/m^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
75718266|NCT00941499|Drug|Bevacizumab|10 mg/Kg by vein on Day 1 of 21 day cycle.
75718267|NCT00941499|Drug|Cetuximab|Loading dose of 250-500mg/m^2 and Maintenance dose of 125-250 mg/m^2 by vein on Day 1 of 21 day cycle.
75718268|NCT00941499|Drug|Leucovorin|200 mg/m^2 by vein on Days 1 and 2 of each 21 day cycle.
75718269|NCT00941499|Drug|5-FU|300-400 mg/m^2 bolus + 600-1000 mg/m^2 infusion over 22 hours on Days 1-2 of each cycle.
75718270|NCT00941499|Drug|Bevacizumab|7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
75718271|NCT04752384|Drug|Buprenorphine|Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.
75718272|NCT04752384|Drug|Tramadol|Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.
75418422|NCT01411761|Other|serum physiologic|1 cc added to one feeding in a day
75418423|NCT01411787|Behavioral|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
75418424|NCT01411800|Drug|250 mg capsule|Two 250 mg capsules will be administered for 500 mg dose
75418425|NCT01411800|Drug|250 mg tablets|Two 250 mg tablets will be administered for a 500 mg dose
75418426|NCT01411826|Behavioral|Information + Narratives + Support Group|Information from CDC website Narratives about CRCS written by others Peer social support among study participants
75418427|NCT01411826|Behavioral|Information Only|Information from CDC website on colon cancer screening.
75418428|NCT01411865|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
75418429|NCT01411865|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
75418430|NCT01411878|Behavioral|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
75563691|NCT04518956|Procedure|inter maxillary fixation with shockwave therapy|Shockwave therapy device which give 1500-4000 pulses per session with or without anesthesia, and the treatment session takes approximately 5-10 minutes at the day after surgery.
75718273|NCT04752384|Device|Oral Mucositis (OM) Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
75418431|NCT01411878|Behavioral|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
75563692|NCT04518956|Procedure|Inter maxillary fixation and exposure to low intensity pulsed|Low-intensity pulsed ultra sound was applied three times weekly for six weeks from the second day after surgery.
75563693|NCT04518956|Procedure|Inter maxillary fixation|Closed reduction will be done. Intermaxillary fixation (IMF) will be secured after proper reduction of the fractured segments to assure proper occlusion using upper and lower arch bars or eyelet wires for six weeks.
75718274|NCT00941577|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
75718275|NCT00941577|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
75718276|NCT00945789|Drug|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
75718277|NCT00945789|Procedure|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
75418432|NCT01411904|Device|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
76043195|NCT05518279|Drug|Tranexamic Acid Pill|Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.
76043196|NCT05518279|Drug|Placebo Oral Tablet|Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
75418433|NCT01411930|Drug|Intramuscular olanzapine, aripiprazole|"1st clamp: single intramuscular 10.0 mg dose of olanzapine~2nd clamp: single intramuscular 9.75 mg dose of aripiprazole"
75563694|NCT01246206|Drug|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
75418434|NCT01411930|Drug|Intramuscular aripiprazole, olanzapine|"1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2nd clamp: single intramuscular 10.0 mg dose of olanzapine"
75418435|NCT01411956|Other|"24-minute video episode of patient education TV sitcom White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
75418436|NCT01411956|Other|Placebo video|The control group watched a 25-minute patient education video on depression.
75418437|NCT01411969|Drug|External Nasal Dilator Strip; 0.05% oxymetazoline chloride|External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
75418438|NCT01412008|Drug|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
75418439|NCT01412073|Drug|oxytocin|group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
75418440|NCT01412073|Drug|Misoprostol|misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby & the placenta
75418441|NCT01412099|Behavioral|peer counseling|Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.
75563695|NCT04510610|Drug|Camrelizumab and Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
75563696|NCT01246011|Drug|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
75563697|NCT04518878|Drug|Eltrombopag|Fixed dose of eltrombopag oral 25mg daily
75563698|NCT04518878|Drug|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
75563699|NCT01244490|Drug|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
75563700|NCT01244490|Drug|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
75563701|NCT01244490|Drug|Placebo Comparator|Placebo
75418442|NCT01412099|Behavioral|Feedback report|Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
75418443|NCT01412125|Other|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
75563702|NCT00506090|Procedure|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
75563703|NCT04510376|Device|Test Article|Omeza Collagen Matrix
75563704|NCT04510376|Other|Positive Control|1.0 mg/mL Histamine Base
75563705|NCT04510376|Other|Negative Control|Aqueous Negative Control
76043197|NCT05523583|Other|questionnaire|A trained interviewer (Clinical Research Associate : CRA) will administer a questionnaire soon after the diagnosis on the phone (within 15 calendar days after diagnosis). The participants are followed up during the first year following the diagnosis through 3 follow-up assessments (at 3, 6, and 12 months after the baseline assessment) and hospital record reviews. At each follow-up, a brief questionnaire will be administered by an interviewer (CRA) via telephone.
76043198|NCT04424953|Device|McGrath videolaryngoscope|A brand of a commonly-used videolaryngoscope which has a camera at the end of the laryngoscope to visualize the vocal cords
76043199|NCT04424953|Device|Direct laryngoscope|Classic direct laryngoscope that depends on visualization of the vocal cords by the operator
75873863|NCT03626766|Behavioral|Photo in Banner and Verification Alert|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
75873864|NCT05683145|Behavioral|Computerized Cognitive Behavioral Therapy for Insomnia|This is a computerized version of cognitive behavioral therapy for insomnia that is augmented by support from a licensed mental health professional. The intervention consists of 6 modules designed to provide education regarding sleep and insomnia, establish behavioral modifications to reduce insomnia symptoms, and monitor progress. Participants will be able to complete these intervention at their own pace, which will take between 6-9 weeks.
75873865|NCT04671342|Device|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing.
76043200|NCT05523193|Other|Formal treatment model|Formal treatment model , no further surgery or minimally invasive treatment was performed
75418444|NCT01412125|Other|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
75418445|NCT01412138|Other|genetic analysis|"To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.~In vitro culture conditions for cell proliferation.~To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.~Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group."
75418446|NCT01412203|Behavioral|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
75563706|NCT01243944|Drug|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
75563707|NCT01243944|Other|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
75873866|NCT04764929|Device|Helmet CPAP|Vyatil nonpowered oxygen tent system
75873867|NCT03627078|Other|motor interference therapy|
75873868|NCT03627078|Other|Relaxation exercises|In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
75418447|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
75418448|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|
75563708|NCT04518488|Other|Exercises|Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.
75563709|NCT04518488|Other|Informational Support Group (Control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
75873869|NCT05560854|Behavioral|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
75873870|NCT03051217|Other|Placebo|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use Q2W"
75873871|NCT03051217|Drug|Certolizumab Pegol|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
75873872|NCT05114785|Diagnostic Test|Multi Parametric Cardiac Magnetic Resonance|Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics
75873873|NCT05080621|Drug|Ripretinib|50 mg tablets
75873874|NCT05080621|Drug|binimetinib|15 mg tablets
76043201|NCT05523037|Drug|Sevoflurane|For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration
76043202|NCT05523037|Drug|Remimazolam|For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
76043203|NCT04625647|Drug|Sotorasib|Given PO
76043204|NCT05122741|Drug|P2Y12 Potent Inhibitor + Aspirin for STEMI patients|Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)
75563710|NCT04510571|Other|Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next|Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
75873875|NCT05035303|Procedure|Nor-Epinephrine injection versus saline during PCNL|The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
76043205|NCT05122741|Drug|Clopidogrel + Aspirin for CCS patients|Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
76043206|NCT05517889|Diagnostic Test|Optical coherence tomography|Optical coherence tomography is a non-invasive scanner which generates real-time in-vivo images of the skin and its adnexal structures. Images are generated by light-interferometry.
76043207|NCT05525767|Drug|Bevacizumab|All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
76043208|NCT05522725|Other|Single-use wipes installed at the bedside|
75418449|NCT01412242|Other|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
75418450|NCT01412294|Drug|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
75418451|NCT01412307|Drug|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
75418452|NCT01412307|Drug|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
75873876|NCT03637621|Other|ORIF|open reduction internal fixation of the distal humerus
76043209|NCT05025085|Drug|AGEN1777|An immunoglobulin gamma (IgG1) antibody
76043210|NCT05025085|Drug|a PD-1 inhibitor|Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
76043211|NCT05522491|Drug|Olaparib|All subjects enrolled will receive olaparib.Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
76043212|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
76043213|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
75418453|NCT01412307|Other|Bio-specimen Retention|Samples with DNA and without DNA
75418454|NCT01412320|Other|Cocoa|dissolved in water twice daily
75418455|NCT01412320|Other|Cocoa|dissolved in water twice daily
75563711|NCT04510571|Other|Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files|Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
75418456|NCT01412346|Other|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
75418457|NCT01412359|Drug|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
75563712|NCT00516399|Drug|povidone-iodine 1.25% ophthalmic solution|
75873877|NCT04179097|Diagnostic Test|Finger photoplethysmography|Bilateral finger photoplethysmogray, bilateral brachial artery Doppler, Aorta artery Doppler
76043214|NCT02340975|Biological|MEDI4736|MEDI4736 will be administered by IV infusion.
75563713|NCT00516399|Drug|natamycin ophthalmic suspension, USP 5%|
75418458|NCT01412385|Biological|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
75418459|NCT01412385|Biological|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
75418460|NCT01412385|Biological|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
75563714|NCT04518527|Device|Tape|The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
75563715|NCT00516438|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
75418461|NCT01412398|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CAPD who have received Fosrenol for hyperphosphatemia
75563716|NCT00516438|Drug|Topotecan|intravenous infusion
76043215|NCT02340975|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion.
76043216|NCT02340975|Biological|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
76043217|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
75418462|NCT01412411|Behavioral|Nutritionl Education|to assess the change in behaviour
75418463|NCT01412411|Dietary Supplement|Oral Iron Supplementation along with Nturition Eductaion|
75563717|NCT02275949|Device|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
75563718|NCT02275949|Device|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
75563719|NCT02275949|Device|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
75563720|NCT02275949|Device|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
75563721|NCT02275949|Device|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
75718278|NCT00945789|Biological|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
75718279|NCT04737096|Drug|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
75873878|NCT03046056|Drug|Filgotinib|Tablet(s) administered orally once daily
76043218|NCT02392377|Drug|Paclitaxel|Given IV or IVPB
76043219|NCT02392377|Drug|Carboplatin|Given IV or IVPB
76043220|NCT02392377|Drug|Oxaliplatin|Given IV
76043221|NCT02392377|Drug|Leucovorin Calcium|Given IV
75418464|NCT01412411|Dietary Supplement|Multiple micronutrient fortification plus Nutrition Education|
75418465|NCT01412437|Dietary Supplement|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
75418466|NCT01412437|Drug|sapropterin dihydrochloride|20 mg/kg for 4 months
75418467|NCT01412437|Drug|sapropterin dihydrochloride|
75718280|NCT04737096|Drug|Placebo|placebo
75718281|NCT04737096|Device|tDCS|tDCS
75718282|NCT00941811|Drug|Imiquimod|Local Imiquimod three times weekly for 16 weeks
75418468|NCT01412450|Device|nitinol stent|implantation of one Protégé EverFlex stent
75563722|NCT00516477|Biological|voretigene neparvovec-rzyl|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
75418469|NCT01412463|Device|stent placement|"pre-dilation of the study lesion is mandatory~stent placement with 1 Protégé Everflex+ stent~only 1 stent is allowed within the study protocol~post-dilation may be performed but is not mandatory"
75418470|NCT01412489|Device|HYALOBARRIER Gel|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
75418471|NCT01412502|Other|IES-R and HDAS scores|The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
75418472|NCT01412515|Drug|everolimus|everolimus per os 10mg per day
75873879|NCT03046056|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
75563723|NCT00516516|Dietary Supplement|L-Carnitine|L-Carnitine, 1g orally, twice daily
75418473|NCT01412528|Other|Allergen extracts|
75418474|NCT01412567|Drug|Vaccine+HBIG|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
75418475|NCT01412567|Drug|Vaccine+Placebo|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
75418476|NCT01412580|Other|observational follow-up|observational follow-up
75418477|NCT01412593|Biological|Stem cell transplant|Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
75418478|NCT01412606|Procedure|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
75418479|NCT01412632|Drug|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
75418480|NCT01412645|Dietary Supplement|Resveratrol|"500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months"
75563724|NCT00516516|Dietary Supplement|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
75873880|NCT02849587|Drug|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
75873881|NCT04647786|Device|Prototype medical device (SEA CtV)|A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
75873882|NCT03347279|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
75873883|NCT03347279|Other|Placebo|Placebo subcutaneous injection
76043222|NCT02392377|Drug|Fluorouracil|Given IV
76043223|NCT02392377|Radiation|Radiation Therapy|Undergo radiation therapy
76043224|NCT02392377|Procedure|Therapeutic Conventional Surgery|Undergo esophagectomy
75418481|NCT01412658|Dietary Supplement|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
75418482|NCT01412658|Dietary Supplement|Glycerol placebo|"Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily."
75418483|NCT01412671|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
75418484|NCT01412684|Procedure|Distal pancreatectomy with partial splenectomy|Distal pancreatectomy with partial splenectomy
75418485|NCT01412697|Behavioral|Fruit and vegetable intake in rural youth|A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
75418486|NCT01412723|Other|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
75418487|NCT01412723|Other|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
75418488|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
76043225|NCT02392377|Other|Laboratory Biomarker Analysis|Correlative studies
75873884|NCT04615104|Procedure|Operative|surgical treatment
75563725|NCT00505349|Behavioral|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
75563726|NCT02275988|Drug|K-877|
75418489|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
75418490|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
75873885|NCT04615104|Procedure|Nonoperative|nonsurgical treatment
75873886|NCT03998683|Drug|Guselkumab 100 mg|Guselkumab 100 mg will be administered as SC injection.
75873887|NCT03998683|Drug|Placebo|Placebo will be administered as SC injection.
75873888|NCT03637465|Behavioral|Hydrate Philly|"Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods)."
76043226|NCT02340819|Drug|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
76043227|NCT04904289|Other|All intervention of real world|We analyzed all data we can obtain from our databases
75418491|NCT01412736|Drug|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
75563727|NCT02275988|Drug|Clarithromycin|
75563728|NCT00516594|Procedure|Diet with polyfructans and viscous fibers or soy protein|
75418492|NCT01412775|Behavioral|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration."
75418493|NCT01412788|Procedure|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
75563729|NCT02950155|Drug|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
75563730|NCT02950155|Drug|Sodium Chloride solution|A single infusion of Placebo/Sham.
75873889|NCT03262441|Drug|Mycophenolate Mofetil 500Mg Tab|500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
75563731|NCT00516633|Behavioral|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
75418494|NCT01412788|Procedure|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
75418495|NCT01412814|Device|AposTherapy Biomechanical System|The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
75563732|NCT00516672|Drug|pazopanib|Pazopanib oral tablet
75418496|NCT01412814|Other|Physical Therapy Program|Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
75563733|NCT00516672|Drug|Lapatinib|Lapatinib oral tablet
75563734|NCT00516711|Drug|Sevoflurane|
75563735|NCT00516750|Drug|cisplatin|
75563736|NCT00516750|Drug|doxorubicin hydrochloride|
75563737|NCT00516750|Drug|methotrexate|
75563738|NCT00516750|Drug|vinblastine|
75563739|NCT00516750|Genetic|gene expression profiling|
75563740|NCT00516750|Procedure|neoadjuvant therapy|
75563741|NCT02276105|Other|Questionnaires|On three time-points (Baseline, Retest, Follow-Up), each participant has to fill out the questionnaires: Michigan Hand Questionnaire, EuroQol EQ-5D-5L and the Short Form SF-12 Health Survey
75873890|NCT05201664|Procedure|Surgical Extrusion|Relocation of the remaining tooth structure to a more coronal position within the same original socket.
75873891|NCT04580394|Drug|AD109|Oral administration before bed
75873892|NCT04580394|Drug|Atomoxetine|Oral administration before bed
75873893|NCT04580394|Drug|R-oxybutynin|Oral administration before bed
76043228|NCT02340663|Device|SOVA Bite Splint|Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
76043229|NCT02340663|Device|Michigan Bite Splint|Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
76043230|NCT02573467|Drug|Bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
76043231|NCT02573467|Drug|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
75418497|NCT01412827|Radiation|1/2 dose of 99mTc OR 201Tl tracers|"Rest: Imaging will occur 30 to 60 minutes after injection of tracer.~Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer."
75563742|NCT04694625|Other|Structured Rehabilitation Program|Early Function Phase (Protective phase) week 1 Progressive Function Phase (Recovery Phase) 2nd and 3rd week Advance Function Phase (Activity Phase) 4th week
75563743|NCT04694625|Other|Conventional Physical Therapy|• Rapid post-operative mobilization • Range of motion exercises started • Passive extension by placing pillow under foot • Flexion-by dangling the leg over the side of bed • Muscle strengthening exercises • Weight bearing is allowed on 1st post-operative
75418498|NCT01412840|Other|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
75418499|NCT01412840|Other|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
75418500|NCT01412853|Other|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
75418501|NCT01412892|Drug|RAD001: Everolimus|10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
75418502|NCT01412996|Procedure|surgery|single ACCESS laparoscopic cholecystectomy
75418503|NCT01412996|Other|SURGERY|CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
75563744|NCT00505427|Dietary Supplement|Alpha Lipoic Acid|
76043232|NCT04903899|Combination Product|177Lu-DOTATATE|A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
75418504|NCT01413022|Drug|Oxaliplatin|
75418505|NCT01413022|Drug|Irinotecan|
75418506|NCT01413022|Drug|Leucovorin|
75418507|NCT01413022|Drug|Fluorouracil|
75418508|NCT01413022|Other|laboratory biomarker analysis|Correlative studies
75418509|NCT01413022|Other|flow cytometry|Correlative studies
75418510|NCT01413022|Other|immunohistochemistry staining method|Correlative studies
75418511|NCT01413022|Other|pharmacological study|Correlative studies
75418512|NCT01413022|Drug|PF-04136309|
75418513|NCT01413035|Biological|MSC|1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
75418514|NCT01413048|Drug|Carvedilol 25mg|Tablet, q.d.
75418515|NCT01413048|Drug|AGSCT101 12.5mg|Tablet, q.d.
75418516|NCT01413061|Procedure|Subtalar Arthrodesis|
75418517|NCT01413074|Other|Peritoneal Dialysis treatment|PD treatment
75563745|NCT00506168|Drug|Irinotecan, Capecitabine|
75563746|NCT02950038|Drug|Ibrutinib|560 mg given by mouth daily in a 28 day cycle.
75563747|NCT02950038|Drug|Nivolumab|3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
75563748|NCT02276144|Other|Liver ultrasound|For evaluate whether fatty liver is exist or not
75563749|NCT02949960|Drug|DMT210 Topical Gel|DMT210 Topical Aqueous Gel 5% applied twice daily
75563750|NCT02949960|Drug|Vehicle Control|Topical Vehicle Gel applied twice daily
75563751|NCT02276183|Dietary Supplement|Nutrition intervention, test formula|
75873894|NCT04580394|Drug|Placebo|Oral administration before bed
75418518|NCT01413074|Other|Hemodialysis treatment|HD treatment
75418519|NCT01413113|Drug|pazopanib hydrochloride|Given PO
75418520|NCT01413113|Radiation|iodine I 131|Given IM
75563752|NCT02276183|Behavioral|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
75563753|NCT02949999|Drug|Voclosporin|
75563754|NCT04510415|Drug|Olmutinib|"600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
75563755|NCT02949882|Dietary Supplement|Yakult|Containing at least 6,5*10^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
75563756|NCT02949882|Dietary Supplement|Dairy Peach Drink (AH Basic)|Commercially available dairy drink with peach flavour.
75563757|NCT04517942|Behavioral|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
75418521|NCT01413126|Dietary Supplement|Whole peanuts without skins, Peanut butter, or no peanuts (control)|In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
75418522|NCT01413139|Device|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
75418523|NCT01413152|Biological|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
75563758|NCT04517942|Other|Video + Expressive Writing|Brief video-based intervention (4 hours across two meetings)
75563759|NCT02949609|Other|Mirror Therapy|Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
75563760|NCT02949609|Other|Control Therapy|Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
75563761|NCT04510220|Drug|Ofatumumab|Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.
75563762|NCT04510220|Drug|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo [F-18]PBR06-PET (microglial activation).
75563763|NCT02949648|Device|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
75873895|NCT04580394|Diagnostic Test|Digit System Substitution Test|a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
75873896|NCT02781727|Drug|Once weekly subcutaneous injection of TransCon hGH|Once weekly subcutaneous injection
75563764|NCT04510337|Drug|standard rocuronium dose|0.6 mg/kg rocuronium during induction of anesthesia
75563765|NCT04510337|Drug|Magnesium sulfate|50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium
75563766|NCT02949687|Procedure|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
75563767|NCT04510259|Procedure|Selective Brachial plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1: 200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
75563768|NCT04694898|Behavioral|Standard programme|The control arm will receive national standard programme for women and children under the age of 2 years. This includes 1) national nutrition and health care including iron & folic acid (IFA) supplementation in pregnancy; 2) early initiation and exclusive breastfeeding until 6 months of age; 3) timely introduction of liquid and semi-solid complementary foods; and 4) diversified complementary foods.
75563769|NCT04694898|Behavioral|SURE intervention|"The SURE package includes: 1) promoting diversified agriculture; 2) promoting infant and young child feeding practices; 3) women empowerment in decision making related to agriculture, food and health; and 4) enhanced food security and Water, Sanitation and Hygiene (WASH) practices."
75563770|NCT00516867|Radiation|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
75563771|NCT00516867|Radiation|UV radiation|UVB 1.4 % and UVA 98.6
75563772|NCT02949765|Drug|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
75563773|NCT02949765|Dietary Supplement|Iron-rich diet|
75563774|NCT04694664|Other|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
75873897|NCT02781727|Drug|Once daily subcutaneous injection of Genotropin|Once daily subcutaneous injection
75873898|NCT03626610|Behavioral|Exercise prehabilitation during chemotherapy before surgery|Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
75418524|NCT01413230|Drug|cholecalciferol|100 000 UI of cholecalciferol per week during 4 then 100 000 UI of cholecalciferol per month for 6 months
75418525|NCT01413243|Drug|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
75418526|NCT01413269|Radiation|radiotherapy|"one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week."
75418527|NCT01413282|Radiation|Cardiac CT|Calcium scan and CT coronary angiography
75418528|NCT01413295|Drug|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
75418529|NCT01413295|Other|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
75563775|NCT04518176|Procedure|bilateral uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally
75718283|NCT04725006|Device|Spinal cord stimulation system|These systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain. Stimulation will be applied to the system using an external stimulator to see if sensations can be evoked in the participant's limb/foot.
76043233|NCT05517733|Biological|Platelet Rich Fibrin|"for the preparation of PRF, A well-trained professional nurse drew 10ml of patient blood from the antecubital vein and transferred it to a test tube without anticoagulant. The blood sample was immediately centrifuged for 10-12 minutes at 3000 rpm. L-PRF was ready to use after centrifugation.~PRF membrane was put over the implant and slightly tucked under the soft tissue periphery, then held in place with a figure-of-8 suture by 0.5 proline suture"
75418530|NCT01413347|Procedure|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
75418531|NCT01413347|Procedure|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
75418532|NCT01413373|Radiation|cone beam computed tomography|A preoperative CBCT is performed for all patients in this study for medical reason
75418533|NCT01413373|Radiation|computer tomography|One cone beam computer tomography examination before surgery
75418534|NCT01413386|Device|biliary stent|palliative treatment for malignant patients
75563776|NCT04518176|Drug|Oxytocin|20 units by slow intravenous drip injection
75563777|NCT04694859|Device|Transcatheter Aortic Valve Implantation|Transfemoral or transapical Transcatheter Aortic Valve Implantation
75563778|NCT04510064|Drug|Camrelizumab plus mFLOT regimen|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.
75563779|NCT04510064|Procedure|R0 surgery|The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
75563780|NCT02275520|Device|NIO Adult device|IO access-1
75418535|NCT01413412|Procedure|Ventral hernia repair using full thickness skin graft|25 patients
75418536|NCT01413412|Procedure|Ventral hernia repair using mesh|25 patients
75418537|NCT01413438|Procedure|Craniotomy|
75563781|NCT02275520|Device|Bone Iniection Gun|IO access-2
75563782|NCT02275520|Device|EZ-IO|IO access-3
75563783|NCT02275520|Device|Jamshidi Intraosseous Needle|IO access-4
75873899|NCT03707327|Other|Game Ready|the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
75718284|NCT02553018|Drug|Methotrexate|
75718285|NCT00950079|Drug|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
75873900|NCT03707327|Other|Ice pack|the participants remained for 20 minutes with cryotherapy with ice pack
75873901|NCT01343082|Drug|DE-111 ophthalmic solution|
75873902|NCT03374189|Device|EZ close|EZ close used.
75718286|NCT00950079|Drug|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
76043234|NCT05517733|Device|Diode laser|"A 980 nm diode laser device (BIOLASE) was applied in a circular motion to the blood formed at the socket orifice at a power of 1W for 1 minute with a continuous wave mode, the application was done without touching the pooling blood and with a non-activated tip of the fiber optic.~The laser application cycle was repeated 3-5 times to yield a stable fixed blood clot covering the dental implant with no oozing blood from its periphery."
76043235|NCT02337387|Biological|Blosozumab|Administered SC
75418538|NCT01413451|Drug|Amatuximab (MORab-009)|
75418539|NCT01413477|Drug|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
75563784|NCT02275520|Device|Cook Intraosseous Needle|IO access-5
75563785|NCT04694703|Drug|Covid-19 group|Routine COVID-19 treatment
75718287|NCT00941967|Drug|gemcitabine hydrochloride|Given IV
75718288|NCT00941967|Drug|oxaliplatin|Given IV
75718289|NCT00941967|Drug|sorafenib tosylate|Given orally.
75718290|NCT00655746|Drug|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
75873903|NCT03374189|Device|Carter Thomason|Carter Thomason used.
76043236|NCT02337387|Other|Placebo|Administered SC
75563786|NCT04694742|Other|data collecting|"Within 24h from ICU admission, the ventilatory efficiency will be assessed by the following Ventilatory Ratio equation:~Ventilatory Ratio = [minute ventilation (ml/min) × PaCO2 (mm Hg)]/(predicted body weight × 100 × 37.5).~Where PaCO2 is the partial pressure of carbon dioxide in mmHg in the arterial blood.~Tha quasi-static compliance will be calculated according to the equation:~C=Tidal Volume/(Paw plateau - PEEP total)~where Paw plateau is the airway pressure measured during 4 seconds of inspiratory pause, PEEP total is the airway pressure measured during 4 seconds of expiratory pause.~In the same time frame, complete blood count, d-dimer, sequential organ failure assessment score, blood gas analysis, haemodynamic and ventilatory parameters will be collected."
75563787|NCT04510181|Dietary Supplement|amino acid-based blend|blended (listed in descending order) L-lysine, L-arginine, oxo-proline, N-acetyl-l-cysteine, L-glutamine, and Schizonepeta tenuifolia
75418540|NCT01413490|Drug|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
75418541|NCT01413555|Other|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
75418542|NCT01413568|Drug|POL6326|
75563788|NCT00516945|Drug|Lamivudine|
75563789|NCT04510103|Drug|Moisturizer A, F#9155-005|OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
75563790|NCT04510103|Other|Moisturizer B, F#E1387-004|Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
75563791|NCT04510103|Procedure|Regression|2 week regression period after 6 weeks of moisturizer use.
75418543|NCT01413568|Procedure|Leukapheresis|
75418544|NCT01413568|Procedure|PBSC Transplant|
75418545|NCT01413581|Drug|rhBSSL (recombinant human bile-salt-stimulated lipase)|rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
75418546|NCT01413581|Drug|Placebo|Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
75418547|NCT01413594|Behavioral|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
75418548|NCT01413607|Device|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
75563792|NCT04510103|Procedure|Non-Regression|Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
75563793|NCT00516984|Procedure|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
75563794|NCT00516984|Procedure|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
76043237|NCT04903665|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
75418549|NCT01413607|Device|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
75418550|NCT01413620|Drug|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
75418551|NCT01413633|Procedure|cholecystectomy|single incision laparoscopic cholecystectomy
75563795|NCT00516984|Procedure|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
75418552|NCT01413646|Dietary Supplement|Walnut Supplementation|Eight weeks of walnut supplementation
75563796|NCT02275598|Drug|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
75418553|NCT01413646|Dietary Supplement|No walnut supplementation|Eight weeks without walnut supplementation
75418554|NCT01413659|Biological|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
75418555|NCT01413672|Device|Use of CASTLE barrier|Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
75418556|NCT01413685|Other|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
75418557|NCT01413711|Drug|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
75563797|NCT02275598|Drug|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
75563798|NCT00517023|Device|Sleuth Implantable Loop Recorder|ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
75563799|NCT00517023|Other|Other|Routine care and tests usually offered for syncope patients.
75563800|NCT04510025|Diagnostic Test|Magnetic Resonance Imaging|We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
75563801|NCT00517062|Drug|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
75563802|NCT00517062|Drug|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
75563803|NCT00517140|Procedure|Repeat Caesaen section|
75563804|NCT00517140|Procedure|vaginal delivery|
75563805|NCT02275676|Other|bioelectrical impedance analysis|
75563806|NCT02275676|Other|indirect calorimetry|
75563807|NCT00517179|Drug|Vardenafil 10mg|
75563808|NCT04517981|Behavioral|Psychological intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
75563809|NCT04517981|Other|Comprehensive intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
75563810|NCT00517218|Drug|Genasense® (, oblimersen sodium G3139)|
75563811|NCT00506207|Drug|S-1, Irinotecan, Oxaliplatin|
75418558|NCT01413763|Drug|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
75418559|NCT01413763|Drug|Placebo cream|placebo cream applied daily for 2 weeks
75418560|NCT01413776|Dietary Supplement|Corn Soya Blend+|A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
75418561|NCT01413789|Drug|Dermatix|1 application of Dermatix
75418562|NCT01413789|Drug|Kelocote|1 application of Kelocote
75418563|NCT01413789|Drug|BAP scar gel|1 application of BAP scar gel
75418564|NCT01413789|Drug|Alhydran|1 application of Alhydran
75418565|NCT01413789|Drug|Bap Scar Care T|1 application of BAP Scar Care T
75563812|NCT00517257|Drug|Atorvastatin|80 mg orally once daily for 24 weeks
75563813|NCT00517257|Drug|Placebo|Placebo tablet orally once daily for 24 weeks
75563814|NCT00506246|Drug|Propofol|"intravenous (total intravenous anaesthesia)~induction and maintenance"
76043238|NCT02574247|Procedure|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
75563815|NCT00517335|Procedure|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
76043239|NCT02391363|Behavioral|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
75418566|NCT01413789|Drug|Bap Scar Care S|1 Application of Bap Scar Care S
75418567|NCT01413789|Drug|Mepiform|1 application of Mepiform
75418568|NCT01413789|Drug|Scar Ban Elastic|1 application of Scar Ban Elastic
75563816|NCT04517708|Other|Nutritional counseling|Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months
75563817|NCT04517240|Other|endoscopy|upper and lower endoscopy and fecal calprotectin test
75563818|NCT01243242|Drug|Metadoxine (MG01CI)|MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
75563819|NCT01242813|Drug|ACZ885|
75563820|NCT00517491|Drug|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
75563821|NCT00517569|Genetic|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
75563822|NCT00517569|Drug|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
75563823|NCT00506363|Procedure|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
75563824|NCT01242111|Drug|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
75718291|NCT00338455|Drug|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
75718292|NCT00338455|Drug|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
75718293|NCT00950157|Other|Presentation of information on approval based on a surrogate outcome and levels of caution|"Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement."
75718294|NCT00806208|Drug|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
75718295|NCT00806208|Drug|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
76043240|NCT02391363|Behavioral|Information and referral|Resource counseling and follow-up for mental health and basic needs
76043241|NCT05522335|Biological|BBV154(Intranasal) & covaxin|Intervention Covaxin
76043242|NCT05512429|Other|measured of body composition with computed tomography|Multislice and single-slice computed tomography images were used for assessment of body composition including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle mass volume (SMMV)
75418569|NCT01413828|Drug|concurrent|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
75418570|NCT01413828|Drug|sequential|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
75418571|NCT01413841|Drug|Nasal oxygen|3 l oxygen
75418572|NCT01413841|Drug|Regular nasal air|3 l nasal air
75418573|NCT01413854|Drug|sugar pill|One tablet two times daily during four weeks
75873904|NCT04385173|Drug|B7-H3 CAR-T|The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide will be stopped during the infusion of B7-H3 CAR-T
76043243|NCT05522257|Diagnostic Test|[18F]-JK-PSMA-7 PET/CT scan|A [18F]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). We expect to make a [18F]-JK-PSMA-7 PET/CT scan in 15 out of 60 patients per cohort.
76043244|NCT04903509|Drug|BI 1820237|BI 1820237
75718296|NCT00806208|Drug|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
75718297|NCT00806208|Drug|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
76043245|NCT04903509|Drug|Placebo|Placebo
76043246|NCT04903509|Drug|Saxenda®|Saxenda®
75718298|NCT00806208|Other|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
76043247|NCT04903509|Drug|Paracetamol-ratiopharm®|Paracetamol-ratiopharm®
75418574|NCT01413854|Drug|Diclofenac|50 mg, two times daily (oral adm.) during four weeks
75718299|NCT00942045|Biological|Biologic - Osteocel Plus|Osteocel Plus
76043248|NCT05517499|Drug|Dexamethasone|Randomized clinical trial
76043249|NCT05450211|Device|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.
75418575|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
75418576|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
75418577|NCT01413893|Drug|linifanib|QD daily
75418578|NCT01413906|Drug|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
75718300|NCT05301309|Behavioral|breastfeeding consultation|Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
75718301|NCT00651924|Behavioral|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
75718302|NCT00804258|Drug|intraperitoneal chemotherapy|
75718303|NCT00804258|Other|educational intervention|
75718304|NCT00804258|Other|medical chart review|
75718305|NCT00804258|Other|questionnaire administration|
75718306|NCT00804258|Procedure|assessment of therapy complications|
75718307|NCT00804258|Procedure|end-of-life treatment/management|
75718308|NCT00804258|Procedure|psychosocial assessment and care|
75718309|NCT00804258|Procedure|quality-of-life assessment|
75563825|NCT04517591|Behavioral|The Take a STAND for health|A 4-month parallel-group randomised controlled trial will be performed, in which patients post-bariatric surgery will be assessed at baseline pre-surgery (PRE-BAR), 3 months after surgery and pre-intervention (PRE-INT) and 4 months after intervention (POST). Moreover, a sub-sample of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 5-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.
75418579|NCT01413984|Behavioral|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
75418580|NCT01414023|Behavioral|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
75418581|NCT01414023|Behavioral|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
75563826|NCT04517630|Diagnostic Test|urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic|Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
75563827|NCT00517608|Device|Laparoscopic colectomy|
75563828|NCT04517201|Drug|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
75563829|NCT04517201|Drug|Physician based insulin regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
75563830|NCT01241604|Device|BiPAP S/T|Mechanical Non-invasive Ventilation
75563831|NCT01241604|Device|BiPAP Auto SV3|Auto Servo Ventilation Device
75563832|NCT00517647|Drug|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
75563833|NCT01241292|Biological|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
75563834|NCT01241292|Biological|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
75563835|NCT00517686|Other|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
76043250|NCT05450211|Device|Patient controlled analgesia|Patient-controlled analgesia will be used for pain control after surgery in both groups.
75418582|NCT01414049|Procedure|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
75418583|NCT01414049|Procedure|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
75563836|NCT00517725|Drug|carvedilol|
75718310|NCT00950313|Other|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
76043251|NCT05512351|Drug|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
76043252|NCT04898985|Diagnostic Test|ImmunoSEQ|experiment assay
75563837|NCT00517725|Drug|bisoprolol|
75563838|NCT00517725|Drug|Nebivolol|
75563839|NCT04512248|Behavioral|Quit and Stay Quit Monday Model|Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
75718311|NCT00950313|Other|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
75563840|NCT04516889|Procedure|Doubled sutured SFIOL|Recruited subjects would undergo implantation of SFIOL with the modified technique under either local or general anesthesia. The surgeon would mark the sclerotomies as per routine sutured SFIOL at 2mm behind the nasal and temporal limbus, followed by passage of 2 pairs of prolene sutures. The intraocular lens with islets would be implanted into the posterior chamber and sutured to the sclera as per single suture SFIOL.
75563841|NCT02276261|Procedure|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
76043253|NCT05517343|Other|Real-time endoscopic optical diagnosis|The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
76043254|NCT05517187|Other|no intervention|Regenerative endodontic treatment induced with blood clot in root canal space as a secondary treatment for failed root canal treated incisors
76043255|NCT05517187|Biological|Platelet rich fibrin|Regenerative endodontic treatment with platelet rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
76043256|NCT05512273|Procedure|Piezosurgery assisted osteotomy|Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol
76043257|NCT05512273|Procedure|Conventional drilling osteotomy|bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
76043258|NCT05521711|Other|Food|Commercially available powders or liquids
76043259|NCT05517109|Other|Hemodynamic goal including lower goal of systolic blood pressure|Different hemodynamic goals in different study arms
76043260|NCT05516875|Drug|JM-010|JM-010
76043261|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
76043262|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
76043263|NCT02569957|Drug|Acetylcysteine|Given IV and PO
76043264|NCT01649427|Drug|Prograf|Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
76043265|NCT01649427|Drug|Tacrolimus Hexal|"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."
76043266|NCT05521633|Drug|Metformin and Pioglitazone|Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
76043267|NCT05512195|Radiation|New delineation approach|New delineation approach
75563842|NCT02276261|Procedure|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
75563843|NCT01240863|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
75718312|NCT00678392|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily [BID] with continuous dosing
75563844|NCT01240863|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
75563845|NCT02275715|Behavioral|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
75563846|NCT04517045|Drug|Dachengqi decoction|Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
75873905|NCT04385173|Drug|Temozolomide|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
75563847|NCT04517045|Drug|probiotic L9|L92 2 tablets/time, tid, oral or nasal feeding
75563848|NCT04517045|Other|Conventional treatment|Conventional treatment
75563849|NCT02955485|Other|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
75563850|NCT01240746|Biological|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
75563851|NCT01240746|Biological|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
75563852|NCT01240746|Biological|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to <9 years), Intramuscular
75563853|NCT04513028|Dietary Supplement|Beta-Glucan|500mg (1 capsule) by mouth twice a day for 21 days.
75563854|NCT04516382|Drug|PTG-300|Active drug
75563855|NCT04517123|Other|Prone Positioning|Prone Positioning
75563856|NCT01240590|Drug|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
75563857|NCT01240590|Drug|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
75563858|NCT04516187|Diagnostic Test|signs and symptoms, blood tests|signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)
75563859|NCT02949804|Behavioral|Comparison between two groups|Comparison will be made between smokers and non smokers regarding vasovagal tendency
75563860|NCT01240200|Drug|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
75563861|NCT01240200|Device|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
75563862|NCT04516460|Device|Interventional arm: endoscopic resection plus PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
75563863|NCT00504543|Drug|AEB071|oral, twice daily
75563864|NCT00504543|Drug|Certican|twice daily
75563865|NCT00504543|Drug|Neoral|twice daily
75718313|NCT00678392|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily [BID] with continuous dosing
75718314|NCT00950391|Drug|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
75873906|NCT03261037|Other|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
76043268|NCT05512117|Device|Midline insertion|Midline catheter insertion
75563866|NCT02949570|Drug|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
75563867|NCT02949843|Drug|Chemotherapy|Receive other treatment
75418584|NCT01414062|Behavioral|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
75418585|NCT01414062|Behavioral|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the NYC-based not-for-profit, God's Love We Deliver
75418586|NCT01414088|Other|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
75418587|NCT01414088|Other|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
75418588|NCT01414088|Other|glucose 5%|infusion, 23 ml/kg, during 50 minutes
75418589|NCT01414101|Drug|ISIS CRP Rx or Placebo|
75418590|NCT01414140|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Women inserted Mirena for intrauterine contraception.
75418591|NCT01414218|Behavioral|Humor as a Way of Life Seminar|One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
75418592|NCT01414231|Drug|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
75418593|NCT01414283|Drug|PSMA ADC|PSMA ADC administered IV
75418594|NCT01414296|Drug|PSMA ADC|PSMA ADC administered IV
75418595|NCT01414335|Dietary Supplement|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
75418596|NCT01414335|Other|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
75418597|NCT01414348|Behavioral|Conventional rehabilitation.|1 hour / 2x / week for up to 15 sessions
75563868|NCT02949843|Biological|Immunotherapy|Receive other treatment
75418598|NCT01414348|Behavioral|Novel rehabilitation approach|1 hr, 2x/week for up to 15 sessions
75418599|NCT01414374|Drug|Herbal medicine|Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
75418600|NCT01414374|Drug|Iron|Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
75418601|NCT01414387|Procedure|Carotid filter|"Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott."
75418602|NCT01414387|Procedure|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
75563869|NCT02949843|Other|Laboratory Biomarker Analysis|Correlative studies
75563870|NCT02949843|Biological|Nivolumab|Given IV
75563871|NCT02949843|Biological|Pembrolizumab|Given IV
75418603|NCT01414400|Other|Blood draw for culture|Blood will be drawn and sent for culture.
75418604|NCT01414439|Behavioral|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
75418605|NCT01414465|Drug|Orlistat|Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
75418606|NCT01414478|Other|Protein Shake|Protein shake contains 30 grams of protein in 11 fluid ounces.
75418607|NCT01414504|Biological|Prevenar + PPV|0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
75418608|NCT01414504|Biological|Infant PCV (Prevenar) + PPV at 9 months|0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
75418609|NCT01414504|Biological|No Prevenar + PPV at 9 months|no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
75418610|NCT01414504|Biological|Control|control, 0.1mL Pneumovax at 3-5yrs
75563872|NCT02949843|Drug|Targeted Molecular Therapy|Receive drug targeting secondary mutation
75563873|NCT02949843|Drug|Tyrosine Kinase Inhibitor|Given PO
75563874|NCT04516343|Device|Robotic Ankle Assist Device (RAAD)|The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP
75718315|NCT00804336|Drug|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
75718316|NCT00804336|Drug|RAD001|Given orally once a day
75718317|NCT00942201|Drug|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
75718318|NCT00942201|Drug|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
75718319|NCT00804414|Drug|SBG|Solution for topical use
75718320|NCT00804414|Drug|Placebo Comparator|Solutin for topical use
75718321|NCT00942435|Drug|YM150|oral
75718322|NCT00942435|Procedure|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
75718323|NCT05301075|Drug|Rhomboid Intercostal and Sub-Serratus block|Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
76043269|NCT02375373|Other|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
75563875|NCT00517764|Drug|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
75418611|NCT01414517|Dietary Supplement|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
75418612|NCT01414517|Dietary Supplement|Maltodextrin|a non-prebiotic carbohydrate
75563876|NCT04516265|Procedure|neurodevelopmental treatment|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
75563877|NCT04516265|Procedure|video-based trunk training|Games developed for the use of children with cerebral palsy will be used for trunk training.
75418613|NCT01414530|Drug|oral contraceptive|ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
75418614|NCT01414530|Drug|NSAID|ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
75873907|NCT03261037|Other|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
75418615|NCT01414543|Other|Information Sheet|Providing the Participant with information regarding the aim of the experiment
75418616|NCT01414543|Other|Consent|Providing a consent form for participants. The participant is aware of his or her rights
75418617|NCT01414543|Other|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
75418618|NCT01414543|Other|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
76043270|NCT05521555|Procedure|Total knee arthroplasty|First intention total knee arthroplasty
76043271|NCT02336607|Drug|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
75418619|NCT01414556|Other|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
75418620|NCT01414556|Other|saline|
75563878|NCT04516265|Procedure|Video-based trunk training will apply with Theratogs|Video-based trunk training will apply with Theratogs
75563879|NCT00517803|Dietary Supplement|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
75563880|NCT00517803|Dietary Supplement|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
75563881|NCT00517803|Dietary Supplement|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
75418621|NCT01414569|Drug|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
75418622|NCT01414582|Device|Anodal tDCS|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
75418623|NCT01414582|Other|Motor Training|All participants will receive a standardised motor training intervention for the upper paretic limb
75418624|NCT01414595|Genetic|DNA analysis|
75418625|NCT01414595|Genetic|DNA methylation analysis|
75418626|NCT01414595|Genetic|RNA analysis|
75418627|NCT01414595|Genetic|gene expression analysis|
75418628|NCT01414595|Genetic|polymorphism analysis|
75418629|NCT01414595|Other|laboratory biomarker analysis|
75418630|NCT01414595|Other|medical chart review|
75418631|NCT01414608|Radiation|Brachytherapy|Undergo brachytherapy
75418632|NCT01414608|Drug|Carboplatin|Given IV
75418633|NCT01414608|Drug|Cisplatin|Given IV
75563882|NCT00517803|Dietary Supplement|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
75718324|NCT00950547|Device|CARDIOPAT|Cell Saver System at bedside for ICU stay
75718325|NCT00950547|Device|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
75718326|NCT00946179|Biological|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
75718327|NCT00946257|Drug|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
75718328|NCT00950625|Drug|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
75418634|NCT01414608|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
75418635|NCT01414608|Drug|Paclitaxel|Given IV
75418636|NCT01414608|Other|Quality-of-Life Assessment|Ancillary studies
75418637|NCT01414621|Other|atrial tissue sample|atrial tissue sample from CABG patient
75418638|NCT01414647|Dietary Supplement|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
75718329|NCT00950625|Drug|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
75418639|NCT01414647|Dietary Supplement|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
75873908|NCT03261037|Other|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
75418640|NCT01414647|Other|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
75418641|NCT01414660|Procedure|transplantation|transplantation of islet, kidney or liver
75418642|NCT01414673|Drug|HCG|5000 IU
75563883|NCT01243125|Drug|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
75418643|NCT01414686|Other|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
75418644|NCT01414699|Behavioral|Variety|These conditions will have snack served with an increase of fruit variety.
75563884|NCT01243125|Drug|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
75563885|NCT04516304|Dietary Supplement|Placebo|4 tablets/d (2 in the morning and 2 in the evening)
75563886|NCT04516304|Dietary Supplement|S-equol|4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
75563887|NCT01242930|Drug|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
75418645|NCT01414699|Behavioral|Non-Variety|These conditions will receive a snack without a variety of fruit.
75718330|NCT04461158|Behavioral|Patient Navigator Services|The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support
75563888|NCT01242930|Drug|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
75418646|NCT01414712|Other|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
75418647|NCT01414725|Other|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al [2009]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
75418648|NCT01414725|Other|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
75563889|NCT01242930|Drug|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
75563890|NCT01241331|Drug|BLI1100|BLI110 topical cream
75563891|NCT01241331|Drug|Vehicle cream|Vehicle topical cream
75563892|NCT04516031|Procedure|Posterior Component Separation with Transversus Abdominis Muscle Release|The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.
75563893|NCT04516031|Procedure|Mesh-only repair|The prosthetic mesh only repair was done as described by Wantz in 1991.
75718331|NCT00942513|Other|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
75718332|NCT00942513|Other|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
75718333|NCT00942513|Other|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
75718334|NCT00942513|Other|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
75718335|NCT00942513|Other|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
75718336|NCT00942513|Other|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
75718337|NCT00942513|Other|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
75563894|NCT04515758|Other|Exercise and Cognitive Training|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class. Cognitive training: focuses on dual-task training (provided by an Android tablet). Each cognitive task requires the participant to choose and execute the response appropriate for the stimuli presented. Participants must prioritize their response and perform tasks as fast as possible while maintaining accuracy. The difficulty of the training is individualized and progressive based on their ongoing performance.
75418649|NCT01414725|Other|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
75718338|NCT04049318|Other|Education+ exercise (delivered digitally)|The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.
75718339|NCT04049630|Drug|LEV 1 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
75718340|NCT04049630|Drug|LEV 1,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
75873909|NCT03710759|Other|Assistive autogenic Drainage|Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
76043272|NCT02336607|Drug|Felodipine tablet (Plendil)+Hydrochlorothiazide|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
75418650|NCT01414751|Behavioral|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
75418651|NCT01414751|Behavioral|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
75718341|NCT04049630|Drug|LEV 2,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
75718342|NCT04049630|Drug|Placebo|5 tablets of placebo will be administrated to the participants.
75718343|NCT00942591|Drug|Interferon beta 1b|
75873910|NCT03372551|Device|somofilcon A 1 day test lens|Contact lens
75873911|NCT03372551|Device|somofilcon A 1 day control lens|Contact lens
75873912|NCT03707249|Drug|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
75873913|NCT03707249|Drug|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
75873914|NCT03326323|Procedure|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
75873915|NCT05682911|Drug|Zingiber officinale L. tablets|Zingiber officinale L. tablets 500mg twice daily
75873916|NCT05682911|Drug|Simvastatin 20mg|Simvastatin 20mg once a day for 2 months
75873917|NCT05480592|Drug|HS-10380|Administered orally as a tablet
75718344|NCT00942591|Drug|Atorvastatin|
75718345|NCT02559362|Behavioral|Survey|
75873918|NCT05480592|Drug|Placebo|Administered orally as a tablet
76043273|NCT02336607|Drug|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
76043274|NCT02336607|Drug|Felodipine tablets (Plendil)+Lisinopril (Zestril)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
76043275|NCT02374671|Device|VisAbility Micro Insert|Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.
76043276|NCT02569801|Drug|Fulvestrant|Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
75418652|NCT01414764|Other|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
76043277|NCT02569801|Drug|GDC-0810|GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
76043278|NCT05521477|Dietary Supplement|SLAB51|One dose of probiotic consists of a bag of probiotic powder to dissolve in a glass of water according to the manufacturer instructions. Each bag contains 100 billion bacteria of the following strains: streptococcus thermophilus DSM 32245, 2 Bifidobacteria lactis DSM 32246 and DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244 and Lactobacillus brevis DSM 27961.
75418653|NCT01414764|Drug|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
75418654|NCT01414790|Procedure|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
75418655|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg/fenofibrate 160 mg per day
75418656|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg per day
75563895|NCT04515758|Other|Exercise Training Only|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class.
75563896|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
75563897|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 4) & matching placebo administered orally once daily
75563898|NCT01241214|Drug|Cetirizine|Ceterizine administered once daily
75873919|NCT04990531|Diagnostic Test|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
75873920|NCT04990531|Diagnostic Test|Blood sample|Blood sample for diagnostic testing
76043279|NCT05516641|Dietary Supplement|Soluble Corn Fiber|once daily additive to diet
76043280|NCT05516641|Dietary Supplement|Maltodextrin|once daily additive to diet
76043281|NCT05521165|Other|therapeutic exercises|strengthening exercises for gluteus medius and APTA guided program for NSCLBP
76043282|NCT05511727|Device|single versus double Foley's catheter in pre-induction cervical ripening|The single balloon catheter (i.e. Foley catheter [FC]) and Cook cervical ripening balloon have been the most commonly used mechanical method
76043283|NCT05516407|Drug|FEN164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
76043284|NCT05511571|Device|Transcutaneous electrical neural stimulation (TENS)|The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.
75418657|NCT01414816|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
75418658|NCT01414829|Procedure|Gastroscopy|The reason for gastroscopy will be not related to the study
75418659|NCT01414842|Device|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
75563899|NCT01241214|Drug|Placebo|Matching placebo administered twice daily.
76043285|NCT05511571|Other|Progressive relaxation exercises (PRE)|The PRE group: The PRE application was implemented in the patient room. A quiet and calm environment was prepared in the room for the intervention. The PRE application was implemented by the women under the researchers' instructions. Each session lasted 30 minutes. A total of five sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held. The PRE application includes exercises based on stretching and then the relaxation of different muscle groups, accompanied by deep breathing. The exercises were carried out in the following way: First doing a deep breathing exercise and then stretching all the muscles from feet to face accompanied by breathing in, keeping the breath, and finally relaxing the muscles by breathing out at the same time.
75418660|NCT01414842|Device|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
75418661|NCT01414868|Drug|leukotriene receptor antagonist (montelukast)|montelukast (10 mg, once per night)
75418662|NCT01414881|Drug|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
75418663|NCT01414881|Drug|Placebo|Placebo administered subcutaneously (SC) once weekly
76043286|NCT05511571|Other|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)|The TENS+PRE group: The PRE and TENS applications were carried out together in this group. The administration of the interventions was the same as in groups where only TENS and only PRE applications were carried out. In this group, first, a 30-minute PRE application was implemented, which was followed by a 30-minute-TENS application.
75418664|NCT01414894|Other|Fluid manipulation|Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
75418665|NCT01414894|Other|Blood Pressure Manipulation|Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
75418666|NCT01414907|Behavioral|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
75418667|NCT01414933|Other|Biopsy|Breast metastases biopsy
75418668|NCT01414946|Other|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
75418669|NCT01414946|Other|Intravenous nutrition with amino acids|Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient's measured resting energy expenditure.
75418670|NCT01414972|Drug|Vitamin A|1 cap vitamin A 25000 IU/day for 3 month
75418671|NCT01414972|Drug|placebo|1 cap placebo/day for 3 month
75718346|NCT00950781|Procedure|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
76043287|NCT02573311|Drug|tamsulosin hydrochloride|
75418672|NCT01414985|Biological|AAVrh.10CUCLN2|There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
75418673|NCT01414998|Behavioral|Stress Ball vs Nicotine-free E-Cigarette|"In a cross over design, participants will be randomly allocated to:~use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
75418674|NCT01414998|Behavioral|Nicotine-free E-Cigarette vs De-nicotinised Cigarette|"In a cross over design, participants will be randomly allocated to:~use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
75418675|NCT01415011|Drug|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
75418676|NCT01415024|Procedure|second LV lead in CRT|second LV lead in CRT
75418677|NCT01415037|Procedure|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
75418678|NCT01415050|Device|Whole body vibration|15 times WBV
75563900|NCT01240512|Drug|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
75563901|NCT04513769|Behavioral|Vegan diet|Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
75563902|NCT00517842|Drug|ViNeuro|
75563903|NCT04515368|Biological|Immunization|Immunisation with one of four licensed vaccines
75563904|NCT01240629|Other|laboratory biomarker analysis|Correlative study
75563905|NCT01240629|Other|questionnaire administration|Correlative study
75563906|NCT01240629|Drug|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
75718347|NCT00946335|Drug|veliparib|Given PO
75718348|NCT00946335|Drug|temozolomide|Given PO
75718349|NCT00946335|Other|pharmacological study|Correlative studies
75563907|NCT04515446|Diagnostic Test|Rapid test for diagnosis orientation|Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
75418679|NCT01415063|Procedure|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
75563908|NCT04515446|Diagnostic Test|quantitative PCR|Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
75718350|NCT00946335|Other|laboratory biomarker analysis|Correlative studies
75873921|NCT05467332|Device|HIGH FLOW NASAL OXYGEN|"BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES."
75873922|NCT04680390|Behavioral|Standard of care engagement practices|The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
75873923|NCT04680390|Behavioral|Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
76043288|NCT05520853|Radiation|SBRT combined with PD-1 inhibitors and thoracic hyperthermia|At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
76043289|NCT05511493|Device|fractional Erbium-YAG laser|Platelet-rich plasma with fractional Erbium-YAG laser in localized stable vitiligo
75718351|NCT00760370|Drug|Zoledronic Acid|4 mg intravenous (iv), one treatment
75718352|NCT00762944|Device|Biomet TMJ Replacement System|Total replacement of the temporomandibular joint with a Biomet TMJ Replacement System
75718353|NCT00763022|Drug|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
75718354|NCT00763022|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
75873924|NCT04663620|Behavioral|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
75873925|NCT04663620|Behavioral|No Saving Babies Lives Programme|No comprehensive neonatal healthcare package
75873926|NCT04625088|Other|Standardized liquid test meal|During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
76043290|NCT05511493|Device|microneedling|Platelet-rich plasma with microneedling in localized stable vitiligo
75418680|NCT01415063|Procedure|TACE-RFA|TACE first, then RFA within 2 weeks
75418681|NCT01415076|Procedure|Insufflation with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
75718355|NCT00763022|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
75718356|NCT00760448|Drug|insulin detemir|
75718357|NCT00760448|Drug|insulin NPH|
75418682|NCT01415089|Behavioral|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
75563909|NCT03459066|Diagnostic Test|Institution-Group|"The study includes three measurement times:~Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
75563910|NCT00506402|Drug|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
75563911|NCT02949531|Drug|oxygen|
75718358|NCT04392284|Behavioral|Diet Counseling|"Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting ~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
75718359|NCT04392284|Behavioral|Exercise Counseling|"Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting ~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
75718360|NCT00760604|Procedure|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
75718361|NCT00763178|Drug|Duloxetine|"Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
75718362|NCT00760682|Procedure|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
75563912|NCT00517959|Radiation|Stereotactic Conformal radiotherapy|SCRT
75563913|NCT00517959|Radiation|Conventional radiotherapy|
76043291|NCT05516251|Device|Transcutaneous Supraorbital Nerve Stimulator|SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
75418683|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 1: 50 ug
75563914|NCT04515992|Behavioral|High Intensity Body-weight Circuit Training (HIBC)|HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
75563915|NCT00518232|Drug|OROS-methylphenidate|
75418684|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
75418685|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
75563916|NCT04515602|Procedure|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
75873927|NCT04625088|Drug|Atropine + Standardized liquid test meal|During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
75873928|NCT03568422|Drug|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 & 16
75873929|NCT03568422|Drug|Paclitaxel|80 mg/m2 IV days 1, 8 & 15 every 28 days
75873930|NCT03484494|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.
75418686|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
75418687|NCT01415102|Drug|Placebo|Inhaled
75418688|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
75418689|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
75563917|NCT04515602|Procedure|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
75873931|NCT03937141|Drug|ADU-S100|intratumoral
75418690|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
75873932|NCT02547493|Biological|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
75418691|NCT01415102|Drug|Placebo|Inhaled
75563918|NCT04515602|Drug|PARPi|For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
75563919|NCT00517998|Drug|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
75563920|NCT00505505|Drug|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
75718363|NCT04351178|Behavioral|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three goals in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and significant others. The significant others will be informed about the participant's goals and the planned strategies for reaching the goals. The participants will practice the activities in their home environment supported by mobile phone calls and text messages. In addition they will be given information about stroke.
75718364|NCT04351178|Behavioral|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
75418692|NCT01415128|Drug|Omeprazole|Once a day dosing of Omeprazole (40 mg) for 8 days
75563921|NCT00505583|Drug|MOA-728|
75718365|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
75718366|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
75718367|NCT00308581|Other|Placebo|placebo administered 4-weekly in Active 1
75718368|NCT00678080|Drug|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
75718369|NCT00678080|Drug|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
75718370|NCT00658320|Drug|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
75718371|NCT00658320|Drug|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
75873933|NCT02547493|Biological|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
75563922|NCT00518271|Drug|Rapamune® (Sirolimus)|
75563923|NCT00518271|Drug|Tacrolimus|
75563924|NCT00518271|Drug|Corticosteroids|Perioperative
75563925|NCT04518605|Dietary Supplement|Low protein breakfast|Low protein yoghurt containing approx. 2 g protein per 100 g. Participants will be asked to consume ~60 g bread, 20 g jam and 250 ml juice for breakfast.
75873934|NCT02547493|Drug|Abatacept|Abatacept started on frst day
75418693|NCT01415128|Drug|Rosiglitazone|Single dose of Rosiglitazone (8 mg) for 1 day
75418694|NCT01415128|Drug|Desipramine|Single dose of Desipramine (50 mg) for 1 day
75418695|NCT01415141|Drug|Peginterferon alfa-2a|180ug subcutaneously, weekly
75418696|NCT01415141|Drug|Ribavirin|"Administered orally twice a day as follows:~weight < 75kg - 1000mg weight ≥ 75kg - 1200mg"
75418697|NCT01415141|Drug|telaprevir|750mg every 8 hours, orally
75418698|NCT01415154|Device|NeuroStar TMS|NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
75418699|NCT01415193|Procedure|Selective Tibial Nerve block|Use of selective pain block.
75418700|NCT01415193|Procedure|Sciatic Nerve Block|Use of Sciatic Nerve Block
75873935|NCT03259789|Drug|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
75873936|NCT03259789|Drug|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
75418701|NCT01415206|Behavioral|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
75418702|NCT01415206|Behavioral|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
75563926|NCT04518605|Dietary Supplement|High protein breakfast|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.
75418703|NCT01415219|Other|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
75418704|NCT01415245|Device|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
75418705|NCT01415271|Other|Internet Communication|bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
75418706|NCT01415284|Drug|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
75418707|NCT01415297|Drug|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
75418708|NCT01415336|Drug|Doxorubicin, Cyclophosphamide|doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
75418709|NCT01415336|Drug|doxorubicin, Capecitabine|doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
75418710|NCT01415362|Device|Transcranial Direct Current Stimulation|"For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit."
75718372|NCT00658320|Drug|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
75718373|NCT00658320|Drug|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
75873937|NCT03259789|Drug|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
75418711|NCT01415375|Behavioral|Prostate Cancer Screening Education|tailored telephone education on prostate cancer testing
75418712|NCT01415375|Behavioral|Fruit and Vegetable Intake Education|tailored telephone education about fruit and vegetable consumption
75418713|NCT01415388|Dietary Supplement|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
75418714|NCT01415414|Drug|Iopromide (Ultravist, BAY86-4877)|CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
75418715|NCT01415466|Drug|Cresto|tablet, 20mg
75418716|NCT01415466|Drug|Olmetec|tablet, 40mg
75418717|NCT01415466|Drug|Cresto, Olmetec|tablet, 20mg and 40mg
75418718|NCT01415479|Behavioral|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
75418719|NCT01415479|Behavioral|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
75563927|NCT04518605|Other|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
75563928|NCT00518310|Drug|Placebo|
75563929|NCT00518310|Drug|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
75563930|NCT00518388|Behavioral|Focus Group|Focus groups each lasting about 2 hours.
75563931|NCT00518388|Behavioral|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
75563932|NCT02955407|Other|no intervention|observational case-control study
75718374|NCT00658320|Drug|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
75718375|NCT02558192|Dietary Supplement|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
75718376|NCT02558192|Dietary Supplement|PLACEBO|1 vials q12 for 15 days
75718377|NCT04137614|Procedure|Drug coated balloon (DCB)|Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.
75418720|NCT01415479|Behavioral|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
75418721|NCT01415492|Behavioral|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
75418722|NCT01415492|Behavioral|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
75418723|NCT01415505|Drug|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
75418724|NCT01415557|Other|Non-Fortified Control Product|Non-Fortified Control Beverage
75418725|NCT01415557|Other|Micronutrient Fortified Test Product|Micronutrient Fortified Test Beverage
75418726|NCT01415596|Drug|salbutamol|
75418727|NCT01415596|Drug|Placebo|
75418728|NCT01415622|Device|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
75418729|NCT01415622|Procedure|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
75418730|NCT01415635|Dietary Supplement|Nutritional intervention using|"The study is af 12 week randomized clinical trail with inclusion of 96 patients at nutritional risk, according to the NRS-2002 system. The intervention group is is given a tailored nutritional care(the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)."
75563933|NCT00518193|Drug|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
75718378|NCT04137614|Procedure|Digital substraction angiography (DSA)|DSA was used to evaluated the stenosis of renal artery
75718379|NCT02553252|Other|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
75718380|NCT02558270|Drug|Dapagliflozin|
75718381|NCT02558270|Drug|Placebo|
75718382|NCT00804492|Behavioral|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
75718383|NCT00763568|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
75418731|NCT01415661|Other|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
75563934|NCT04519814|Procedure|selective laser trabeculoplasty (SLT)|Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.
75563935|NCT00518427|Drug|Insulin Glargine|"Lantus (insulin glargine [rDNA origin] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."
75563936|NCT04515173|Diagnostic Test|Artificial intelligence diagnosis and treatment assistance system|An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
75563937|NCT00518466|Drug|topiramate|25 mg modified-release capsules
75563938|NCT00518466|Drug|phentermine|7.5 mg immediate-release capsules
75563939|NCT00518466|Drug|topiramate|100 and 25 mg immediate-release tablets
75563940|NCT00518466|Drug|phentermine|37.5 and 7.5 mg immediate-release tablets
75718384|NCT00763568|Biological|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
75718385|NCT04049006|Other|complex treatment|The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
75718386|NCT00806754|Drug|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
75718387|NCT00806754|Drug|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
75718388|NCT00760760|Drug|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
75718389|NCT00760760|Drug|control|equivalent amount of fat as butter
75718390|NCT00764816|Other|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
75563941|NCT04518020|Procedure|40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA|40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
75563942|NCT00518505|Other|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
75418732|NCT01415687|Drug|Polyethylene Glycol-Based Lavage|"Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours."
75563943|NCT04518761|Procedure|Elective surgery|Any patient who needs to undergo an elective surgery.
75563944|NCT00519714|Dietary Supplement|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
75563945|NCT00519714|Dietary Supplement|Placebo|Placebo
75718391|NCT00764816|Other|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
75873938|NCT03259555|Drug|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
75563946|NCT00518544|Drug|administration of hydroxyehtyl starch|colloid is administered during operation according to blood loss.
75563947|NCT00506480|Procedure|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
75563948|NCT04694508|Device|Headphones (Disok, Alicante, España)|A pair of non-reusable headphones (Disok, Alicante, Spain)
75563949|NCT04515056|Drug|Papain 10 µg|The area will be exposed to 10 µg of papain.
75563950|NCT04515056|Drug|Papain 50 µg|The area will be exposed to 50 µg of papain.
75563951|NCT04515056|Drug|Papain 100 µg|The area will be exposed to 100 µg of papain.
75563952|NCT04515056|Other|Vehicle|The area will be exposed to vehicle
75563953|NCT04515056|Drug|Papain 1 SPT|Papain will be applied by 1 SPT prick thought the skin
75563954|NCT04515056|Drug|Papain 5 SPT|Papain will be applied by 5 SPT pricks thought the skin
75563955|NCT04515056|Drug|Papain 25 SPT|Papain will be applied by 25 SPT pricks thought the skin
75563956|NCT04515056|Other|Cowhage|The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
75563957|NCT00518583|Drug|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
75718392|NCT00810654|Dietary Supplement|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
75718393|NCT00810654|Dietary Supplement|Placebo|Placebo
75873939|NCT03259555|Drug|Placebo|Administered orally daily for 3 weeks.
75873940|NCT03702751|Procedure|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
75718394|NCT00764894|Device|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
75418733|NCT01415687|Drug|Pico-Salax (Magnesium Citrate) plus Bisacodyl|"If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre."
75418734|NCT01415700|Device|Functional electrical stimulator|The stimulator is surgically implanted
75563958|NCT04514900|Behavioral|Video Chat +Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide detailed weekly feedback on diet and exercise.
75718395|NCT00804726|Device|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
75718396|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
75418735|NCT01415700|Device|feet orthosis|feet orthosis specifically mold
75418736|NCT01415713|Drug|S-1,Leucovorin,Oxaliplatin,Gemcitabine|Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
75418737|NCT01415726|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 ~ 7 hrs.
75718397|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
75418738|NCT01415739|Other|laboratory biomarker analysis|Correlative studies
75418739|NCT01415765|Drug|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
75418740|NCT01415765|Drug|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
75418741|NCT01415765|Drug|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
75563959|NCT04514900|Behavioral|Video Chat + Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
75718398|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
75718399|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
75718400|NCT00322153|Drug|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
75718401|NCT00322153|Drug|Placebo|Matching placebo oral administration once daily.
75418742|NCT01415765|Drug|Vincristine|CIV on days 1-4 of every 21 day cycle
75718402|NCT00806910|Drug|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
75718403|NCT00806910|Other|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
75718404|NCT00807066|Drug|Gefitinib|Gefitinib 250 mg/day
75718405|NCT00807066|Drug|Platinum|Platinum based chemotherapy with cycles every 21 days
75718406|NCT01058551|Device|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
75873941|NCT03702751|Procedure|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
75718407|NCT00804960|Drug|Letrozole|1) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
75718408|NCT00804960|Drug|Std IVF Protocol|2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
75873942|NCT03259087|Drug|MK-3866|Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
75873943|NCT03257995|Drug|Indacaterol maleate|150 μg via Concept1 device
75873944|NCT03257995|Drug|Indacaterol acetate|150 μg via Concept1 device
75418743|NCT01415765|Drug|Cyclophosphamide|IV on day 5 of each 21 day cycle
75418744|NCT01415765|Drug|Doxorubicin|CIV on days 1-4 of each 21 day cycle
75418745|NCT01415765|Drug|Rituximab|IV on day 1 of each 21 day cycle
75418746|NCT01415765|Drug|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
75418747|NCT01415778|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
75718409|NCT00805116|Dietary Supplement|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
75418748|NCT01415778|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
75718410|NCT00805116|Dietary Supplement|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
75718411|NCT03985735|Drug|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
75873945|NCT03257995|Drug|Placebo|Capsule containing no active ingredients delivered via Concept1 device
75873946|NCT03049488|Biological|VRC-RSVRGP084-00-VP|VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.
75873947|NCT03049488|Other|Aluminum Hydroxide Suspension|Aluminum Hydroxide Suspension, alum, is an adjuvant.
75873948|NCT04484922|Drug|Dexmedetomidine|continuous infusion of dexmedetomidine during the surgery
75418749|NCT01415791|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
75418750|NCT01415804|Device|endoprosthesis|Thoracic aortic stentgraft
75418751|NCT01415830|Biological|Anti-scorpion venom serum Birmex|the dose may be required for the patient according to clinical manifestations and evolution
75718412|NCT00807222|Drug|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
75718413|NCT00657618|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
75718414|NCT02553564|Other|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~Determination of the participants's estimated dry weight (EDW).~The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~Write new dialysis orders.~Dialysis Access- review access and determine any changes required in treatment"
75718415|NCT00657540|Drug|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
75718416|NCT00657540|Drug|Saline|50 mL of saline infused over 10 minutes
75718417|NCT00672620|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
75718418|NCT00672620|Drug|Duloxetine|Duloxetine capsules
75718419|NCT00672620|Drug|Placebo|Placebo-matching capsules
75418752|NCT01415830|Biological|Anti-scorpion venom serum Alacramyn|The dose may be required fot the patient according to clinical manifestations and evolution
75418753|NCT01415856|Device|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
75418754|NCT01415856|Device|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
75418755|NCT01415895|Drug|Naltrexone and Clonidine Combination|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
75418756|NCT01415895|Drug|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
75418757|NCT01415947|Device|V Chordal|"V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae off-pump . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords."
75718420|NCT00805272|Other|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
75873949|NCT04484922|Drug|Normal saline|continuous infusion of normal saline during the surgery
75418758|NCT01415973|Dietary Supplement|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
75418759|NCT01415973|Dietary Supplement|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
75418760|NCT01416012|Behavioral|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
75418761|NCT01416012|Behavioral|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
75563960|NCT04514900|Behavioral|Discussion Board for Social Support +Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
76043292|NCT05516251|Drug|Topiramate 25Mg Tab|Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
76043293|NCT05520697|Behavioral|Nutritional intervention|Nutritional treatment with caloric restriction.
75418762|NCT01416012|Behavioral|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
75418763|NCT01416012|Behavioral|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
75418764|NCT01416038|Biological|DPX-Survivac|Vaccine targeting survivin antigen will be administered subcutaneously.
75418765|NCT01416038|Drug|low dose cyclophosphamide (oral)|Low dose cyclophosphamide will be taken by mouth.
75563961|NCT04514900|Behavioral|Discussion Board for Social Support+Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide personalized, detailed weekly feedback on diet and exercise.
75563962|NCT00519753|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
75418766|NCT01416051|Dietary Supplement|Olibra|Fractionated palm oil and fractionated oat oil in the proportion of 95:5
75418767|NCT01416051|Other|Placebo|100% milk fat
75563963|NCT00519792|Drug|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
76043294|NCT05520697|Behavioral|Mental exercise.|Mental exercise.
76043295|NCT05520697|Behavioral|Physical training.|Exercise.
75418768|NCT01416103|Other|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
75418769|NCT01416103|Other|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
75418770|NCT01416116|Drug|QUTENZA|topical
75418771|NCT01416116|Drug|Lidocaine|topical
75418772|NCT01416116|Drug|Tramadol|oral
76043296|NCT04886791|Procedure|Vaginal NOTES hysterectomy|Vaginal assited NOTES hysterectomy
76043297|NCT04886791|Procedure|Vaginal hysterectomy|Vaginal hysterectomy
76043298|NCT05516173|Diagnostic Test|Blood Pressure Monitoring, Ambulatory|To monitor the blood pressure during 24 hours.
76043299|NCT02571049|Drug|DFN-11|Sumatriptan 3 mg versus 6 mg
76043300|NCT04597801|Drug|Alcon|Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
76043301|NCT04885465|Behavioral|web-based psychoeducational support|Caregivers in the experimental group will have access to psycho-educational support through a web-based plattform during 3 months.
76043302|NCT05520385|Diagnostic Test|blood group and Rh|check of blood group , Rh for patient and control
75418773|NCT01416168|Other|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
75418774|NCT01416207|Drug|Avonex|4 weekly injections of Avonex (IM)
75418775|NCT01416220|Drug|Lithium|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l."
75418776|NCT01416220|Drug|Paroxetine|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines."
75418777|NCT01416233|Procedure|autologous fat grafting to the orbit|subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
75418778|NCT01416246|Procedure|Fractionated Stem Cell Infusions|Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is < or = to 50 and/or age > 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
75418779|NCT01416259|Drug|Withdraw treatment|
75563964|NCT00519870|Drug|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
75563965|NCT00519870|Drug|losartan|II: losartan
75563966|NCT00519870|Drug|Nifedipine, losartan|I: nifedipine II: losartan
75563967|NCT00518700|Other|new MPS|
75563968|NCT00518700|Other|RepleniSH|
75563969|NCT00519909|Other|Dairy calcium|Diets with different content of calcium and fat
75563970|NCT04694937|Device|heart rate variabilty measured by pulse oximetry|"Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points."
75718421|NCT00764972|Drug|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
75718422|NCT00765050|Biological|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
76043303|NCT05516095|Device|Transcranial magnet stimulation|Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.
75418780|NCT01416298|Other|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and > 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching >10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after >10% is achieved is acceptable and now will be put into standard clinical practice.
75418781|NCT01416311|Drug|Eltrombopag|
75418782|NCT01416324|Drug|placebo|Vehicle used to dilute the powder for oral administration.
75718423|NCT00673790|Drug|Nebivolol with concomitant losartan or lisinopril|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
75418783|NCT01416324|Drug|0.1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
75563971|NCT02949492|Drug|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
75418784|NCT01416324|Drug|0.3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
75718424|NCT00673790|Drug|HCTZ with concomitant losartan or lisinopril|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
75718425|NCT00673790|Drug|Placebo with concomitant losartan or lisinopril|Placebo with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
75718426|NCT00763646|Drug|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
75418785|NCT01416324|Drug|1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
75563972|NCT04512599|Other|Prebiotic Bar|The prebiotic bar is a proprietary formula created by the study co-investigators, who will not be involved in participant recruitment, selection or outcome measures.The prebiotic bars will be shipped and stored at room temperature prior to consumption.
75718427|NCT00763880|Drug|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
75718428|NCT00763880|Drug|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
75718429|NCT00765440|Dietary Supplement|therapeutic nutritional supplementation|Given orally
76043304|NCT05516095|Device|Sham Transcranial magnet stimulation|Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
76043305|NCT04296955|Other|Motivational interview as a new health communication intervention|Same as intervention name
76043306|NCT04979533|Device|Insufflator oxygen tubing|high flow, low pressure oxygen with pressure relief valve and luer Lock connections delivered at 15 L/min through surgeon's laryngoscope.
76043307|NCT05511259|Other|exercise|Square stepping exercise
76043308|NCT05520151|Dietary Supplement|ORAL IMPACT treatment|the group of patients will be received a 7-days course of ORAL IMPACT
76043309|NCT05520151|Other|control|no intervention
76043310|NCT04297423|Drug|Plenvu|randomization 1:1
75418786|NCT01416324|Drug|3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
75418787|NCT01416324|Drug|10 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
75418788|NCT01416324|Drug|30 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
75718430|NCT00765440|Other|placebo|Given orally
75718431|NCT00657150|Drug|Enoxaparin|40 mg once daily
75718432|NCT00657150|Drug|Dabigatran etexilate|220 mg once daily
75718433|NCT00770354|Drug|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
75718434|NCT00770354|Drug|Letrozole|Daily 2.5 mg oral letrozole tablet
75718435|NCT02553486|Other|quality of life evaluation|
75418789|NCT01416324|Drug|60 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
75418790|NCT01416337|Drug|GSK1120212|2 mg single dose tablet on Day 1 of study
75418791|NCT01416337|Drug|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
75563973|NCT00518739|Drug|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 & beyond).
75718436|NCT00670748|Biological|Anti-NY ESO-1 T-cell receptor PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
75718437|NCT00670748|Drug|aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
75418792|NCT01416350|Drug|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
75418793|NCT01416350|Drug|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
75418794|NCT01416350|Drug|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
75418795|NCT01416363|Drug|Firategrast immediate release tablet|Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.
75418796|NCT01416363|Drug|Firategrast modified release tablet|Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.
75563974|NCT04514861|Device|Wireless Lumee Oxygen Platform|The Lumee Oxygen Platform is designed to monitor oxygen dynamics with a hydrogel placed in subcutaneous tissue
75718438|NCT00670748|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
75718439|NCT00670748|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
75718440|NCT00670748|Biological|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
75718441|NCT00646776|Drug|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
76043311|NCT05515861|Procedure|Endoscopic ultrasound|Using endoscopic ultrasound (EUS) to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect. Endoscopic cyanoacrylate injection is performed again if the diameter of variceal vein is larger than 5 mm and with blood flow signal. After the injection, the blood flow signal is confirmed disappear by endoscopic ultrasound. Patients in the EUS group required endoscopic ultrasound assessment at each stage of the follow-up period.
76043312|NCT04295941|Drug|TraZODone Hydrochloride 300 MG|Oral administration of Trazodone once-a-day.
75418797|NCT01416363|Drug|Firategrast gastro-retentive solution|Firategrast solution is clear colorless solution and subject will administer it via nasogastric route.
75418798|NCT01416376|Drug|SRT2379|SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
75418799|NCT01416376|Drug|Placebo|For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
75418800|NCT01416415|Other|Video education on proper eye drop instillation technique|The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
75418801|NCT01416415|Other|Placebo video education on healthy eating tips|The video is approximately seven minutes long and teaches tips to promote healthy eating.
75418802|NCT01416480|Drug|Theobromine 300mg|Capsule, b.i.d.
75418803|NCT01416480|Drug|Levodropropizine 10mg|Syrup, t.i.d.
75418804|NCT01416493|Drug|s.c. injections of bovine intestinal Alkaline Phosphatase|daily subcutaneous treatment with two injections of 2000IU bIAP for three days
75418805|NCT01416506|Other|No Drug|It's a surveillance
75563975|NCT00519948|Drug|new MPS, opti-free express no rub MPS|
75563976|NCT04514666|Other|Breath analysis|The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified
75563977|NCT02949102|Dietary Supplement|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
75418806|NCT01416519|Procedure|Continuous Positive Airway Pressure (CPAP) facial mask|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
75873950|NCT04481958|Behavioral|I-PROTECT|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
76043313|NCT05510869|Procedure|"Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally"|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch & Lomb
76043314|NCT05510869|Procedure|Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch & Lomb
75418807|NCT01416519|Procedure|Assisted deep inspiration technique|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
75418808|NCT01416545|Behavioral|Educational program in cardiovascular prevention|a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
75418809|NCT01416545|Behavioral|Lifestyle counseling|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
75418810|NCT01416558|Drug|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks~Given until progression, unacceptable toxicity, patient's request or withdrawal from Study"
75563978|NCT02949102|Dietary Supplement|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
75563979|NCT04514822|Diagnostic Test|Dynamic PET|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
75563980|NCT04514588|Dietary Supplement|caffeine consumption|In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
75718442|NCT00646776|Drug|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)"
75718443|NCT00765596|Other|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
75718444|NCT04048928|Behavioral|maximal strength training|The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
75563981|NCT02276300|Drug|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
75718445|NCT02558114|Drug|Ribavirin|
75718446|NCT00770666|Drug|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
76043315|NCT05510869|Procedure|Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.|small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch & Lomb
76043316|NCT05515705|Device|EUS navigation system|Incorporation of the EUS navigation system to the EUS scope
76043317|NCT05515549|Other|Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers|"The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group."
75718447|NCT00770666|Drug|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
75718448|NCT00764036|Drug|artesunate|add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
75718449|NCT00764114|Drug|antibiotic|6 or 12 weeks
75718450|NCT00811200|Drug|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
75718451|NCT00811200|Drug|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
75718452|NCT00811200|Other|sham|at baseline one sham-injection
75718453|NCT00764192|Procedure|blood sample|blood sample before and after a single HD
75718454|NCT00764192|Procedure|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
75873951|NCT04446390|Other|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
75873952|NCT04446390|Other|colgate cavity protection|fluoride toothpaste as a part of a caries preventive regimen
75873953|NCT03257137|Other|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
76043318|NCT02573155|Drug|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
75418811|NCT01416597|Biological|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
75718455|NCT00811356|Drug|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
75718456|NCT00765908|Device|Angioplasty balloon|90 second balloon inflation x 2
75873954|NCT02338921|Drug|Sitagliptin|"100mg qd per oral during 24months~compared with other treatment groups"
75563982|NCT02276300|Drug|Sargramostim|Sargramostim is part of Her2 vaccination
75418812|NCT01416623|Drug|henatinib|Henatinib Maleate Tablets
75418813|NCT01416649|Drug|Exenatide|Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
75873955|NCT02338921|Drug|Dapagliflozin|"10mg qd per oral during 24months~compared with other treatment groups"
75873956|NCT02338921|Drug|Lobeglitazone|"0.5mg qd per oral during 24months~compared with other treatment groups"
75873957|NCT02338921|Drug|Glimepirde|
75873958|NCT02338921|Drug|Metformin|
75873959|NCT01313845|Drug|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
75873960|NCT01313845|Drug|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
75873961|NCT04782661|Drug|JNJ-70075200|JNJ-70075200 solution or solid formulations will be administered orally.
75873962|NCT04782661|Drug|Placebo|Placebo solution will be administered orally.
75563983|NCT02276300|Drug|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
75718457|NCT00765908|Device|Angioplasty balloon|30 seconds or less balloon inflations x 2
75718458|NCT00765986|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
75718459|NCT00765986|Other|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
75418814|NCT01416662|Drug|gemcitabine hydrochloride|
75418815|NCT01416701|Dietary Supplement|Vitamin D (D3, cholecalciferol)|Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
75418816|NCT01416701|Dietary Supplement|Placebo (cellulose)|Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
75418817|NCT01416727|Other|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
75418818|NCT01416727|Other|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
75563984|NCT02276300|Drug|Imiquimod|Imiquimod is part of Her2 vaccination
75563985|NCT02949453|Behavioral|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:~first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
75873963|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'A' ) in fluid responsive position
75873964|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'A') in non-fluid responsive position
75873965|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'B') in fluid responsive position
75873966|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'B') in non-fluid responsive position
76043319|NCT02573155|Drug|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
75418819|NCT01416740|Procedure|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
75418820|NCT01416740|Drug|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
75418821|NCT01416753|Device|UCR|BVM-based regulation of ultrafiltration and conductivity
75418822|NCT01416753|Device|UTR|BVM-based regulation of ultrafiltration; regulation of temperature
75418823|NCT01416766|Other|Self-monitoring-nurse-primary care provider feedback loop|Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
75418824|NCT01416779|Behavioral|Writing Intervention|Finding Balance Writing Intervention
75418825|NCT01416792|Procedure|Centrifugation|
75418826|NCT01416792|Procedure|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
75563986|NCT04514939|Other|Elevation of the legs during bed rest|Patients of Group A will will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
75418827|NCT01416818|Drug|Xiaoyao Pill|herb extracts,were received two times a day for 12 weeks without dose changing.
75563987|NCT02949414|Procedure|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
75563988|NCT02955173|Procedure|Surgery|Laparoscopic or open surgery for resection of gastric or rectal cancer
75563989|NCT00520026|Drug|lithium|
75563990|NCT00520026|Drug|placebo|
75563991|NCT00518856|Other|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
75418828|NCT01416818|Drug|Bupleurum+Ginkgo|herb extracts, were received two times a day for 12 weeks without dose changing.
75718460|NCT00766064|Drug|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily*, Week 6: fixed dose,~*Criteria to increase the dose from 3 mg to 6 mg daily are 1] absence of any side effects, 2] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
75418829|NCT01416818|Drug|placebo|The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
75418830|NCT01416844|Biological|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
75718461|NCT00770744|Drug|Zicronapine|5-7mg/day; orally, encapsulated tablets, once daily
75418831|NCT01416857|Other|RDDT|
75418832|NCT01416870|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
75418833|NCT01416870|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
75418834|NCT01416883|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
75418835|NCT01416896|Procedure|Hemodialysis using the standard venous needle|Hemodialysis using the standard venous dialysis needle
75418836|NCT01416896|Procedure|"Hemodialysis using a new venous needle, the BME needle"|"Hemodialysis using a new venous dialysis needle or the BME needle"
75563992|NCT00518856|Other|Standard of care|continued with current standard of care for birth attendants
75563993|NCT02955251|Drug|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
75563994|NCT02955251|Drug|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
75563995|NCT00518895|Drug|dacarbazine plus Genasense|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
75563996|NCT00518895|Drug|dacarbazine plus placebo|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
75563997|NCT02275754|Behavioral|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
76043320|NCT02573155|Drug|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
76043321|NCT02573155|Drug|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
76043322|NCT02573155|Drug|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
75418837|NCT01416896|Procedure|"Hemodialysis using a new venous needle, the BME needle"|"One hemodialysis using a new venous needle, the BME needle"
75418838|NCT01416896|Procedure|Hemodialysis using the standard venous needle|One hemodialysis using the standard venous needle
76043323|NCT02573155|Drug|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
75418839|NCT01416909|Other|Laxative Treatment|Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
75563998|NCT02275754|Behavioral|PN Only|Participants will be navigated by PN on request
75418840|NCT01416909|Other|Standard of Care|Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
75418841|NCT01416909|Other|Assessment Questionnaires|Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
75418842|NCT01416948|Drug|Methylphenidate Hydrochloride 20 mg|For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.
75418843|NCT01416948|Drug|Placebo Capsule|For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
76043324|NCT02573155|Drug|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
76043325|NCT02573155|Drug|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
75563999|NCT02954978|Drug|Placebo Oral Capsule|"25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up."
75564000|NCT02954978|Drug|Nilotinib 150mg oral capsule [Tasigna]|25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
75564001|NCT02954978|Drug|Nilotinib 300mg oral capsule [Tasigna]|25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
75564002|NCT00520065|Other|enteral nutritional formula|Meal glucose tolerance test
75718462|NCT00770744|Drug|Olanzapine|10-15mg/day; orally, encapsulated tablets, once daily
76043326|NCT02573155|Drug|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
75418844|NCT01416948|Drug|Galantamine 12 mg|For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
75564003|NCT00520065|Other|Diabetes specific enteral product|Meal Glucose tolerance test
75564004|NCT00518934|Other|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
75718463|NCT00770822|Device|HIFU (Sonablate® 500)|High Intensity Focused Ultrasound
75718464|NCT00770822|Device|Brachytherapy|Standard of care
75718465|NCT00764348|Other|no treatment|
75718466|NCT00655668|Drug|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
75418845|NCT01416961|Radiation|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
75564005|NCT00520104|Drug|intranasal ketamine|drug interaction
75564006|NCT00519012|Drug|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
76043327|NCT02573155|Drug|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
75418846|NCT01416961|Drug|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
75418847|NCT01416961|Drug|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
75873967|NCT04492098|Diagnostic Test|MAIT cells|1- Decidual tissues will be washed in phosphate buffer saline (PBS), and then preserved in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin and 5% fetal bovine serum (GIBCO BRL, Thermo Fisher Scientific, USA) until transfer to the laboratory. At the flow cytometry laboratory, the tissue samples will be minced finely and enzymatically digested by adding 3 ml collagenase enzyme type Ia and 2 ml PBS for 40 minutes at 37°C in shaking water path at 100 r.p.m. Cell suspensions obtained will be filtered, then the pellet after centrifugation will be treated with red blood cells lysing solution and washed with PBS.
75418848|NCT01416974|Drug|cyclophosphamide|Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
75418849|NCT01416974|Biological|modified T cells|followed by consolidative therapy with the modified T cells in 3 planned cohorts.
75564007|NCT00519012|Drug|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
75564008|NCT00520143|Biological|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
75873968|NCT04683991|Procedure|Subepithelial connective tissue graft|A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
75873969|NCT04361838|Behavioral|prayer|receive prayers daily while in ICU
75873970|NCT03242863|Other|Food proportionality|Proportions of high and low energy dense foods manipulated
75418850|NCT01417013|Other|Systane Ultra|Lubricant Eye Drops
75418851|NCT01417013|Other|Optive|Lubricant eye drops
75418852|NCT01417052|Drug|50 mg LX3305 QD|50 mg LX3305 once daily in capsule form
75418853|NCT01417052|Drug|100 mg LX3305 QD|100 mg LX3305 once daily in capsule form
75418854|NCT01417052|Drug|150 mg LX3305 QD|150 mg LX3305 once daily in capsule form
75418855|NCT01417052|Drug|200 mg LX3305 QD|200 mg LX3305 once daily in capsule form
75418856|NCT01417052|Drug|250 mg LX3305 QD|250 mg LX3305 once daily in capsule form
75418857|NCT01417052|Drug|300 mg LX3305 QD|300 mg LX3305 once daily in capsule form
75418858|NCT01417052|Drug|400 mg LX3305 QD|400 mg LX3305 once daily in capsule form
75418859|NCT01417052|Drug|250 mg LX3305 BID|250 mg LX3305 twice daily in capsule form
75418860|NCT01417052|Drug|500 mg LX3305 QD|500 mg LX3305 once daily in capsule form
75418861|NCT01417052|Drug|Placebo|Matching placebo dosing in capsule form
75873971|NCT03044106|Device|CLRT|CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
75873972|NCT03196986|Drug|mil60|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
75873973|NCT03196986|Drug|Bevacizumab|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
76043328|NCT02573155|Drug|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
76043329|NCT05045755|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
76043330|NCT05519761|Device|Implantation of veinous access ports|"The surgeon, anaesthetist and interventional radiologist should be thoroughly familiar with the surgical procedure, instruments, and device characteristics prior to performing the implantation.~The nurse has also to be familiar with the implantable port since he/she intervenes in it at the time of the Huber needle puncture and solution injection."
75418862|NCT01417065|Drug|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
75418863|NCT01417143|Drug|TKI258 (Dovitinib):|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
75418864|NCT01417169|Drug|micafungin|Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting <50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
75418865|NCT01417182|Drug|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
75418866|NCT01417221|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
75418867|NCT01417247|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
75564009|NCT03459027|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g) acutely
75564010|NCT03459027|Dietary Supplement|Beetroot powder|Nitrate devoid beetroot powder (10g) acutely
75564011|NCT00520182|Behavioral|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids [MUFA]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
75564012|NCT00520182|Behavioral|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
75564013|NCT00520182|Behavioral|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
75418868|NCT01417273|Dietary Supplement|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
75418869|NCT01417273|Drug|Drug: placebo|1 cap placebo/day for 12 month
75418870|NCT01417299|Dietary Supplement|RPh201|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
75418871|NCT01417299|Dietary Supplement|saline|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
75418872|NCT01417312|Dietary Supplement|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
75418873|NCT01417312|Dietary Supplement|Placebo|Daily intake of placebo capsules for 3 months
76043331|NCT05510791|Dietary Supplement|Nuun Sport Drink|Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.
76043332|NCT05510791|Dietary Supplement|Control|Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
75564014|NCT02954900|Other|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
76043333|NCT05515471|Drug|SHR8058 eye drops|SHR8058 eye drops
76043334|NCT05515471|Drug|saline eye drops.|saline eye drops.
76043335|NCT05515315|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
75418874|NCT01417351|Dietary Supplement|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
76043336|NCT05515315|Drug|Albumin paclitaxel|Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks
75418875|NCT01417351|Dietary Supplement|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
75418876|NCT01417364|Drug|Testosterone enanthate|100 mg. IM weekly throughout study
75418877|NCT01417364|Drug|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
75418878|NCT01417364|Drug|Placebo|Injected IM weekly throughout study
75564015|NCT02954900|Other|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
75718467|NCT00770900|Drug|montelukast sodium|"Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children >15 years took 10mg tablet of montelukast"
76043337|NCT05515315|Drug|Nedaplatin|Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks
76043338|NCT05515315|Radiation|radiotherapy|50-60Gy/25-30f
76043339|NCT05510713|Device|Hemodialysis Catheter|We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous
76043340|NCT05519371|Drug|Remimazolam|"During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped."
76043341|NCT05519371|Drug|Propofol|During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
76043342|NCT04948645|Drug|ABBV-CLS-7262|Oral
75418879|NCT01417390|Drug|Drug: Gemcitabine and cisplatin|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
75418880|NCT01417390|Drug|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
75564016|NCT02949336|Radiation|Observational use of fluoroscopy|Minimal radiation exposure (0.17 mSv) for observational purpose
76043343|NCT04948645|Drug|Placebo|Oral
76043344|NCT05515003|Other|Individualized patient education|Patients in the intervention group will be applied one-session individualized patient education by the researcher. Educational session will last between 30 and 60 minutes. Problem-focused education will be applied related to the issues that the patient had difficulty in coping with. The subjects that the patient lacks knowledge about will be determined and the patient will be trained on these subjects and a discussion session will be arranged in the form of questions and answers. The education topics will include; fatigue, diarrhea/constipation, abdominal pain, mental health, nutrition, exercise and sleep.
76043345|NCT04847947|Drug|Cholecalciferol|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks
76043346|NCT04847947|Drug|Placebo|Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
76043347|NCT05519137|Device|Active lighting intervention|Lighting intervention designed to impact the circadian system
76043348|NCT05519137|Device|Control lighting intervention|Lighting intervention designed to have no impact on the circadian system
75564017|NCT04514237|Drug|BOS172767 enantiomer E1 or E2|Oral tablets
75418881|NCT01417403|Drug|hydroxychloroquine|Given PO
75418882|NCT01417403|Radiation|radiation therapy|Undergo radiotherapy
75418883|NCT01417429|Drug|Galantamine|8mg/a day or placebo
75418884|NCT01417429|Drug|IV Nicotine|1.0 mg/70 kg of nicotine against saline
75418885|NCT01417442|Genetic|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
75418886|NCT01417468|Behavioral|CLSI, MI, CR|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
75564018|NCT04514237|Drug|Placebo|Oral tablets
75564019|NCT00520260|Drug|bromfenac|0.09%, BID, 6 weeks
75564020|NCT00520260|Drug|ketorolac|0.4%, BID, 6 weeks
76043349|NCT05510479|Other|Software as medical device|At home measurements of visual acuity through a mobile app
76043350|NCT05518981|Device|Respiratory Remote Patient Monitor (Spire Health Tag)|"The RPM service, tailored to chronic respiratory disease patients, utilizes a system that includes three components: undergarment-adhered cardiorespiratory sensors, in-home data transmission hub, and web-based clinical dashboard. The sensors are a set of six proprietary, skin-safe devices that include sensors for intermittent photoplethysmography, continuous respiratory force, and tri-axis accelerometers for activity. Clinical liaisons monitor deviations from patient-specific baselines and contact subjects for a risk assessment call, including questions about symptoms. If a subject fails the risk assessment, they are escalated to the site to be seen, and potentially treated, by their pulmonologist."
75418887|NCT01417468|Behavioral|CLSI - Unknown|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
75418888|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)|
75418889|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab|
75418890|NCT01417507|Procedure|cognitive assessment|Undergo neurocognitive assessment
75418891|NCT01417507|Procedure|magnetic resonance imaging|Undergo MRI
75418892|NCT01417507|Other|laboratory biomarker analysis|Correlative studies
75564021|NCT04514354|Behavioral|GEST|On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
75564022|NCT00520338|Drug|celecoxib|"placebo~celecoxib 400 mg oral single dose"
75564023|NCT04694391|Genetic|whole exome sequence|To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
76043351|NCT05514925|Drug|Bevacizumab Injection [Avastin]|Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
75418893|NCT01417507|Other|questionnaire administration|Ancillary studies
75418894|NCT01417507|Procedure|quality-of-life assessment|Ancillary studies
75418895|NCT01417546|Drug|NHS-IL-12|NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
75418896|NCT01417572|Drug|lidocaine|to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
75418897|NCT01417585|Behavioral|Client-centered ADL intervention|Client-centered ADL refers to rehabilitation of activities of daily living specifically guided by the needs as expressed by the client/patient and her/his significant others, a process that specifically aims to support the client by taking the client's goals and views as the guide for the rehabilitation process.
75418898|NCT01417585|Behavioral|Usual ADL intervention|The variation of strategies and ways to conduct usual ADL rehabilitation according to the routines and praxis of the participating rehabilitation units randomized to supply the control condition.
75418899|NCT01417598|Other|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
75564024|NCT00520377|Drug|MD05|recombinant human GDF-5 coated onto beta-tricalcium phosphate
75564025|NCT00520377|Device|Beta-TCP and autologous bone|beta-tricalcium phosphate and autologous bone
75564026|NCT00519051|Other|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
75564027|NCT02948946|Procedure|NETest|5 mL of blood will be drawn from participants for testing.
75418900|NCT01417598|Other|Nordic walking (only osteoporosis group)|To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
75564028|NCT00520416|Procedure|Carbon dioxide angiogram|see description of procedure
75564029|NCT02948673|Dietary Supplement|Glutathione|4 oral GSH tablets/day (1000mg/day) for 4 weeks
75564030|NCT02948673|Other|Placebo|4 oral placebo tablets for 4 weeks
75418901|NCT01417611|Procedure|i-scan CE, SE, TE mode|I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
75564031|NCT02597075|Other|standard therapy + physical activity program|
75564032|NCT02597075|Other|standard therapy|
75564033|NCT04694118|Other|rebound therapy|3 days a week in 12 weeks
75564034|NCT00519129|Device|3D-imager|3D-imager vs fluoroscopy during coloscopy
75564035|NCT00519168|Procedure|Urine sample|Standard of care
75564036|NCT00519168|Device|Electrode sleep recorder|Standard of care
75564037|NCT00519168|Procedure|phlebotomy|Standard of care
75418902|NCT01417624|Other|CMR Guidance in terms of guiding LV lead implantation|"Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.~The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only."
75564038|NCT02275832|Drug|3 % Minoxidil lotion|
75564039|NCT02275832|Drug|Placebo|
75564040|NCT00519207|Drug|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
75564041|NCT00519207|Drug|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
75564042|NCT02590094|Drug|Intravitreal bevacizumab or intravitreal ziv-aflibercept|Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
75564043|NCT00520455|Drug|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
75564044|NCT02275871|Other|MRI|High risk screening MRI will be performed as part of the patient's routine care.
75564045|NCT02275871|Other|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
75873974|NCT04051632|Device|Medtronic 670G insulin pump|"percent of patients who continue to use Medtronic 670G over time~impact of 670G on glycemic control: hemoglobin A1c, time in range"
75564046|NCT02948439|Other|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
75564047|NCT02590757|Device|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
75564048|NCT02590757|Device|N-CPAP|Nasal-continuous positive airway pressure
75873975|NCT03170856|Other|Sub-maximal exercise|Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 20 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
75873976|NCT03139968|Device|(sham) radiation absorbing drape (RADPAD®)|
75564049|NCT02949375|Drug|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
75564050|NCT02949375|Drug|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
75564051|NCT02949375|Drug|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
75564052|NCT04514432|Other|Music|If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
75564053|NCT02949180|Device|Five minutes puls wave recording|iPhone will be positioned on the index finger for five minutes to record a pulse wave
75564054|NCT02598947|Other|Manual therapy|Exercise, behaviour change interventions and manual therapy
75564055|NCT02949258|Drug|oxaliplatin|oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
75564056|NCT02949258|Drug|etoposide|etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
75564057|NCT02949258|Drug|epirubicin|epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
75564058|NCT02949258|Drug|S1|Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
75564059|NCT04514081|Drug|Chidamide; Decitabine; Camrelizumab|"Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.~Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.~Camrelizumab is a humanized anti-PD-1 monoclonal antibody."
75564060|NCT04514081|Drug|Decitabine+Camrelizumab|Decitabine+Camrelizumab
75564061|NCT02948517|Other|Time restricted feeding|Time restricted feeding
75564062|NCT04514120|Other|AJESS scoring process|We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site [left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.
75564063|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
75418903|NCT01417637|Radiation|Low level laser therapy|Ga As diode laser (890 nm) Mustang 2000+, Russia), with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles. Laser therapy will be applied on all painful muscles three times a week for four weeks.
75564064|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
75564065|NCT04514042|Procedure|Peroral endoscopic myotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as peroral endoscopic myotomy. All the procedures will be documented with photographs or videorecordings.
75418904|NCT01417637|Radiation|Placebo group|In this group, the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects. Laser therapy will be applied on all painful muscles three times a week for four weeks.
75418905|NCT01417650|Radiation|Low level laser therapy|In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
75418906|NCT01417650|Radiation|Low level laser therapy|In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
75418907|NCT01417663|Drug|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
75718468|NCT00770900|Drug|Comparator: placebo comparator|Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
75564066|NCT04514042|Procedure|Flexible endoscopic septotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as flexible endoscopy septotomy. All the procedures will be documented with photographs or videorecordings.
75718469|NCT00766220|Drug|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
75718470|NCT00766220|Drug|Cetuximab|"400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."
75718471|NCT00766220|Drug|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
75718472|NCT00807300|Radiation|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
75873977|NCT04377919|Dietary Supplement|Cranberry|The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
75873978|NCT04377919|Dietary Supplement|Placebo|The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
76043352|NCT05514925|Procedure|Peripheral Retinal Cryoapplication|In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
76043353|NCT05514847|Drug|Aspirin 81Mg Ec Tab|81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
76043354|NCT05514847|Drug|Aspirin 162Mg Ec Tab|162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
75418908|NCT01417663|Behavioral|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
75418909|NCT01417676|Radiation|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
75418910|NCT01417689|Other|Encouragement to attempt eye drop instillation with a specific technique|Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
75418911|NCT01417702|Device|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
75564067|NCT00519246|Drug|Saline|Saline 5 ml administrated intravenously
75564068|NCT00519246|Drug|Opioid|Butorphanol tartrate 1 mg i.v.
75564069|NCT00519246|Drug|Opioid|Butorphanol Tartrate 2 mg i.v.
75564070|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 50 mg i.v.
75564071|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 100 mg i.v.
75564072|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 10 mg i.v.
75564073|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 20 mg i.v.
75564074|NCT00519987|Drug|intranasal ketamine|intranasal ketamine
75564075|NCT00519324|Drug|Everolimus|10 mg/day (2 tablets of 5 mg each)
75564076|NCT04514471|Other|Unventilated filter cigarettes|Currently marketed unventilated cigarettes
75718473|NCT00807300|Procedure|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
75718474|NCT00813540|Behavioral|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
76043355|NCT05510401|Other|SECURIDRAP® SELFIA®|Use of SECURIDRAP® SELFIA® for 15 night
76043356|NCT05510323|Drug|Prednisolone|RAS blockade as much as tolerated or allowed
76043357|NCT05510323|Drug|Prednisolone plus Cyclophosphamide|RAS blockade as much as tolerated or allowed
76043358|NCT05514691|Diagnostic Test|iStatis COVID-19 Ag Rapid Test|SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
76043359|NCT05514691|Diagnostic Test|"COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (Labcorp)"|The Labcorp COVID-19 RT-PCR or EURORealTime SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
75718475|NCT00813540|Other|Usual Care|Usual Care
75718476|NCT00770978|Drug|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
75718477|NCT00770978|Drug|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
75718478|NCT02557724|Procedure|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
75718479|NCT02557724|Procedure|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
75564077|NCT04514471|Other|Ventilated filter cigarettes|Currently marketed ventilated cigarettes
76043360|NCT05514613|Other|retrospektif study; The effect of tracheostomy tecnique method on complications|retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques
76043361|NCT05510167|Behavioral|Study arm|Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
76043362|NCT05514379|Behavioral|cognitive training|Cognitive training focused on executive function, attention and working memory delivered either by the therapist in a group setting (experimental group) or by a specialized software for cognitive training (Rehacom) at home.
75418912|NCT01417715|Device|Endomicroscopy|Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
75564078|NCT00520650|Drug|Aripiprazole|
75564079|NCT04513535|Other|Thoracic Manipulation|A supine thoracic manipulation will be utilized. Participants will be lying supine on the plinth with their arms crossed over their chest, making sure the forearms are not crossed. An experienced clinician will place their hand on the inferior segment (T4); the superior segment (T3) will be placed in the midrange of thoracic flexion and extension. The clinician will apply a high velocity, end range, anterior to posterior thrust by using their body weight to deliver the thrust through the participants crossed elbows, thus creating a bilateral gapping of the facet joints. If a cavitation is achieved after the first thrust, the thoracic manipulation intervention is complete. If not, one more attempt will be made to achieve a cavitation. Regardless of if there was a cavitation or not, after the second attempt the intervention is complete.
75718480|NCT00766298|Behavioral|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
75718481|NCT00766298|Behavioral|Weight Loss|The reduction of kcal/day through implementation of low fat diet
76043363|NCT04128397|Device|traditional stimulation site continuous theta burst stimulation (cTBS)|before cTBS treatment, MRI was used to confirm the stimulation site
76043364|NCT04128397|Device|precise stimulation site cTBS|before cTBS treatment, rs-fMRI was used to confirm the stimulation site
76043365|NCT02568475|Behavioral|"Provision of Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
76043366|NCT05507671|Biological|BCG (Bacillus Calmette-Guérin) vaccine|Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
76043367|NCT05507671|Other|Placebo|Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion
76043368|NCT02568397|Drug|Lanabecestat|Administered orally
76043369|NCT02568397|Drug|Dabigatran etexilate|Administered orally
76043370|NCT02566525|Device|CytoSorb|Cytosorb device use during cardiopulmonary bypass
75418913|NCT01417754|Drug|Toremifene|20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
75418914|NCT01417767|Drug|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
75418915|NCT01417767|Drug|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
75418916|NCT01417806|Drug|Topotecan and Pasireotide|Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days
75418917|NCT01417819|Other|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
75564080|NCT04513535|Other|Cervical Manipulation|Participants will be lying supine on the plinth on the table. A high velocity low amplitude manipulation will be performed to the cervical spine by an experienced clinician.The clinician will place the right proximal phalanx of the index finger over the posterolateral aspect of the articular pillar at the right C4/C5 segment to maximally influence the C5 myotomal distribution. The clinician's left hand will be cradling the participants head. The participant will be brought into midrange flexion-extension, ipsilateral side bend, and contralateral rotation of C4/5. Once a firm end feel is felt the manipulation will be administered into left rotation in an arc toward the left eye. If a cavitation is achieved after the first thrust, the intervention is complete. If not, one more attempt will be made to achieve a cavitation;after the second attempt the intervention is complete.
75564081|NCT04513535|Other|glenohumeral posterior glide mobilization|Participants will be instructed to lay supine on the plinth and a plastic orthopedic wedge will be placed under their scapula for stabilization on the side that is receiving the mobilization. The experienced clinician will stand on the same side being mobilized and held the participant's arm proximal to the medial and lateral humeral epicondyles. The clinician will hold the participant's arm in the scapular plane, approximately 55 degrees of abduction and slight ER with a grade one long axis distraction applied and sustained throughout the entire mobilization. A grade three oscillatory mobilization will be applied for three sets of 30 seconds with a 30 second rest in between.
76043371|NCT05514145|Device|Nance/Transpalatal arch space maintainer|A combined design of both Nance and Transpalatal arch space maintainers as a space maintainer for the maxillary arch in mixed dentition
75718482|NCT00766298|Behavioral|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
75718483|NCT00569166|Behavioral|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
75718484|NCT00569166|Behavioral|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
75718485|NCT00569166|Behavioral|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
76043372|NCT05514145|Device|Nance space maintainer|Conventional space maintainer for the maxillary arch used in mixed dentition
76043373|NCT05513989|Device|modified Magill forceps|modified pediatric Magill forceps was used to assist nasotracheal intubation.
76043374|NCT05513989|Device|Magill forceps|Magill forceps was used to assist nasotracheal intubation.
75418918|NCT01417832|Drug|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
75418919|NCT01417832|Drug|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
75418920|NCT01417845|Behavioral|High Intensity Exercise Training|"High intensity resistance and aerobic training~Resistance training is performed 2 days per week for 3 months~Aerobic training is performed on the same days as resistance training and 1 additional day per week."
75718486|NCT00764426|Drug|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
75718487|NCT00764426|Drug|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
75873979|NCT04408092|Drug|Granulocyte Macrophage Colony Stimulation Factor|Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
75873980|NCT03043560|Drug|Ezogabine|daily for 5 weeks
75873981|NCT03043560|Drug|Placebos|placebo pill daily for 5 weeks
75718488|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
76043375|NCT05513911|Other|Acute Intermittent Hypoxia|Acute Intermittent Hypoxia is administered in 30-60 second bouts of 9% O2 concentration, followed by 60-90 seconds of normoxic air concentrations (21% O2, room air). This procedure is repeated 15 times for a 30 minute session
75873982|NCT04051554|Other|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
76043376|NCT05513755|Procedure|cardioneuroablation|Endocardical radiofrequency ablation of vagal ganglia located close to pulmonary veins antra and interatrial septum.
75873983|NCT04051554|Other|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
76043377|NCT05513677|Device|M4D|Coated catheter
76043378|NCT05513677|Device|Standard of Care|Standard of Care
76043379|NCT05507593|Biological|DLL3-CAR-NK cells|Patients of Group A will be received 1x10^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10^9 DLL3-CAR-NK cells infusion treatment.
76043380|NCT05507281|Procedure|Ultrasound-guided Erector Spinae Plane Block|ultrasound-guided ipsilateral Erector Spinae Plane Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
76043381|NCT05507281|Procedure|Retrolaminar Block|ultrasound-guided ipsilateral Retrolaminar Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
75418921|NCT01417845|Behavioral|Moderate Intensity Exercise Training|"Moderate intensity resistance and aerobic training~Resistance training is performed on 2 days per week for 3 months.~Aerobic training is performed on the same days as resistance training and 1 additional day per week."
75564082|NCT04513535|Other|Sleeper stretch|Participants will be positioned in a side lying position with the arm to be stretched on the table. The arm to be tested will then be positioned at a 90-90 shoulder abduction and elbow flexion position. A support will be positioned behind the patient to ensure there is no compensatory trunk movement during the stretch, and an examiner verified the arm is in a 90-90 position. A sleeper stretch will be subsequently completed, in which the participant will internally rotate the arm to stretch the posterior shoulder musculature. Three, thirty second stretches will be completed
75873984|NCT04051476|Other|3-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
75873985|NCT04051476|Other|6-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.
75873986|NCT04051476|Other|12-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.
75873987|NCT04051476|Other|Warm water footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
75873988|NCT02145403|Drug|Carfilzomib|"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."
75873989|NCT02145403|Drug|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
75418922|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
75873990|NCT03255733|Device|Intense Therapeutic Ultrasound Treatment|
75873991|NCT03255655|Device|Intense Therapeutic Ultrasound Treatment - ITU|
75418923|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
75418924|NCT01417897|Drug|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
75418925|NCT01417897|Drug|Insulin aspart|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
75418926|NCT01417897|Drug|Regular human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
75418927|NCT01417923|Drug|vitamin D|P.O.4000 units Vit D per day for 6 weeks
75564083|NCT00519363|Drug|atorvastatin|atorvastatin 40mg, given orally daily for 3 months.
75564084|NCT02595710|Other|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
75564085|NCT02595710|Other|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
75718489|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
75873992|NCT02899988|Drug|Mirikizumab|Administered SC
76043382|NCT05507281|Procedure|Control|General anesthesia
76043383|NCT05507047|Drug|Enamel Matrix Protein|Enamel matrix derivated is used with transcrestal sinus lifting treatment
76043384|NCT04757857|Drug|Rivaroxaban 10 mg|Rivaroxaban pharmaceutical form will be tablets of 10 mg
76043385|NCT04754191|Drug|Enfortumab vedotin|Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
75564086|NCT02595710|Other|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
75418928|NCT01417949|Other|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
75418929|NCT01417975|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
75418930|NCT01417975|Behavioral|Passive Sitting Group|Participants will be required to sit passively on a chair for 10 minutes.
75418931|NCT01417988|Drug|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
75564087|NCT00519402|Other|tonsillar examination and questionnaire completion|
75564088|NCT02591030|Drug|GEMCIS|"At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~Cisplatin 25 mg/m² over 1 hour at D1 and D8~Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8."
75564089|NCT02591030|Drug|mFolfirinox|"At D1 of each cycle, i.e. every 15 days for 6 months:~Oxiplatin: 85 mg/m² (IP/120 minutes)~Irinotecan: 180 mg/m² (IV/90 minutes)~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan~5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1"
75418932|NCT01417988|Drug|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
75564090|NCT00519441|Other|pH study|All patients will have 48 hour pH study
75564091|NCT02955017|Behavioral|traditional follow_up|"Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~Two days of a complete medical check at 9 and 15 months"
75564092|NCT02955017|Behavioral|"distance follow-up new technologies"|"Multidisciplinary support with long distance monitoring Mobile apps.~Two days of a complete medical check at 9 and 15 months"
75564093|NCT00519480|Drug|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
75564094|NCT00519480|Drug|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
75564095|NCT00519480|Drug|Placebo|Placebo will be available as an oral tablets.
75564096|NCT04696211|Other|Music-with-movement exercise|A music-with-movement exercise programme to reduce chronic pain in older adults.
75564097|NCT00520689|Device|Silicone Hydrogel Contact Lens|use of lens over 2 days
75873993|NCT02899988|Drug|Placebo|Administered SC
76043386|NCT04747327|Behavioral|mandate public|mandate by airlines, bars, restaurants
76043387|NCT04747327|Behavioral|employer mandate|your employer requires vaccination
76043388|NCT04747327|Behavioral|incentive reward|$1,000 tax credit
76043389|NCT04747327|Behavioral|penalty|$1000 tax penalty
76043390|NCT04747327|Behavioral|incentive lottery small|100,000 smaller monetary amount
75418933|NCT01418027|Other|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
75418934|NCT01418027|Other|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
75418935|NCT01418053|Drug|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
75564098|NCT02955056|Drug|Forsteo|20 micrograms/80 microlitres solution for injection in pre-filled pen
75718490|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
75718491|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
75718492|NCT00807378|Other|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
76043391|NCT04747327|Behavioral|incentive lottery medium|200,000 mid monetary amount
76043392|NCT04747327|Behavioral|incentive lottery large|1 million dollar lottery
76043393|NCT04747327|Behavioral|cash small|smaller guaranteed cash amount
76043394|NCT04747327|Behavioral|cash medium|mid sized quarenteed cash amount
76043395|NCT04747327|Behavioral|cash large|large quarenteed cash amount
75418936|NCT01418053|Drug|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
75418937|NCT01418066|Drug|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
75564099|NCT00520728|Behavioral|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
75564100|NCT02954939|Drug|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
76043396|NCT04747327|Behavioral|invitation for exercise financial incentive study|financial incentives earned when increasing exercise behaviors
76043397|NCT04747327|Behavioral|invitation for exercise social incentive study|social incentives earned when increasing exercise behaviors
76043398|NCT04747327|Behavioral|invitation for sleep social incentive study|social incentives earned when increasing sleep
75418938|NCT01418066|Drug|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
75418939|NCT01418079|Device|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
75418940|NCT01418105|Procedure|Videofluroscopic swallow study (VFSS)|Barium, radiation
76043399|NCT04747327|Behavioral|invitation for sleep financial incentive|Financial incentives earned when increasing sleep
75418941|NCT01418105|Procedure|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
75418942|NCT01418105|Procedure|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
76043400|NCT05513287|Other|On the period of covid 19|In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
76043401|NCT05513131|Drug|Venetoclax；Azacitidine；Homoharringtonine|A cycle every 28 days Treatment with Venetoclax 100mg d1，200mg d2，400mg d3~d14； Azacitidine 75mg/m2/d，d1~d7 Homoharringtonine 2mg/d d1~d7
75418943|NCT01418118|Drug|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
75564101|NCT02954939|Drug|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
75564102|NCT00519519|Drug|Omeprazole|intravenous 80mg bolus followed by 8mg / hr for 3 days
75564103|NCT00520806|Drug|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
75564104|NCT00520806|Drug|Placebo|Intravenous infusion for 48 h
75564105|NCT00505739|Drug|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
75564106|NCT00519597|Device|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
75564107|NCT00519558|Drug|somatropin|
75564108|NCT05149820|Other|Electronic Point of Care Randomisation tool|Two designs of electronic point of care randomisation tool will be evaluated.
76043402|NCT05509465|Device|Ergonomic chinrest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting.
76043403|NCT05509465|Device|Ergonomic chinrest used with a low Super Kun shoulder rest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
75418944|NCT01418118|Drug|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
75418945|NCT01418118|Drug|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
75418946|NCT01418118|Drug|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
75418947|NCT01418131|Drug|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
75418948|NCT01418131|Drug|Placebo|Placebo
75418949|NCT01418144|Procedure|Transversus abdominis plane (TAP) block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
75418950|NCT01418144|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
75418951|NCT01418157|Drug|Acetazolamide|125 mg twice daily until 4380 meters altitude
75418952|NCT01418157|Drug|Placebo|Twice daily
75564109|NCT05149820|Drug|Magnesium|Liberal Strategy: magnesium supplementation at serum level < 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level < 1.0 mmol/L
76043404|NCT05506657|Other|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
76043405|NCT05506657|Other|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
75564110|NCT02948985|Other|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
75564111|NCT04513457|Other|Liver resection and Neoadjuvant chemotherapy|
75564112|NCT04513457|Other|Liver resection and Adjuvant chemotherapy|
75718493|NCT04048772|Behavioral|CALM IVF|The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.
75418953|NCT01418170|Other|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
76043406|NCT05512975|Dietary Supplement|Dairy protein porridge arm|Regular porridge ingredients with additional delical whey protein fortification
75564113|NCT04513457|Other|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy|
75418954|NCT01418183|Procedure|Trigeminal nerve block|5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
75564114|NCT04513457|Procedure|Liver resection|
75564115|NCT02276339|Other|Exercise|The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
75564116|NCT00521040|Drug|Levocetirizine dihydrochloride|
75718494|NCT04048772|Other|Standard of Care|Patients will receive the standard of care IVF treatment at the University of Iowa.
75718495|NCT00764582|Drug|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery"
75718496|NCT00764582|Drug|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery"
75718497|NCT00766454|Genetic|DNA analysis|
75718498|NCT00766454|Genetic|mutation analysis|
75718499|NCT00766454|Genetic|polymorphism analysis|
75718500|NCT00766454|Other|laboratory biomarker analysis|
75718501|NCT00766454|Other|medical chart review|
75718502|NCT00766454|Other|questionnaire administration|
75718503|NCT00766454|Procedure|evaluation of cancer risk factors|
75718504|NCT00813618|Drug|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
75718505|NCT00813618|Drug|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
75718506|NCT00813618|Drug|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
75718507|NCT00771212|Other|Observational pain control study|Observational pain control study
75564117|NCT04696601|Diagnostic Test|Olfactory test|The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.
75564118|NCT04513730|Other|Rehabilitation|A device originally designed with the function of keeping the user in a comfortable position of pelvic suspension, in dorsal decubitus, with fixation in the popliteal region and ankles was built to promote lumbar traction. The device is designed in autoCAD software with 2d technical representations and 3d electronic model. It consists of a structure of pipes and fittings and padded material at the support points.
75564119|NCT00521118|Other|Laboratory Biomarker Analysis|Correlative studies
75564120|NCT00521118|Procedure|Therapeutic Conventional Surgery|Undergo second curettage
75418955|NCT01418183|Procedure|Trigeminal nerve block|2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
75418956|NCT01418183|Procedure|Trigeminal nerve block|5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
75418957|NCT01418235|Biological|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
76043407|NCT05512975|Dietary Supplement|Plant protein porridge arm|Regular porridge ingredients with the addition of extruded soya protein fortification and soya milk instead of regular dairy milk
75564121|NCT04694235|Dietary Supplement|Egg intervention|Eggs are boiled until the white and yolk are firm (ca. 8 minutes) to maintain quality and safety and ensure the eggs are safe for consumption.
76043408|NCT05512975|Dietary Supplement|Control Porridge arm|Regular porridge ingredients with no additional protein fortification
75564122|NCT04513340|Drug|WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS|CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
75564123|NCT02949063|Behavioral|Comfortable Cafeteria Program|6-week program integrated into the cafeteria lunchtime to build capacity of supervisors and students to create a positive social and emotional atmosphere so that students can enjoy eating their lunch and socializing with peers.
75564124|NCT04513379|Drug|Efavirenz 600mg|EFV 600 mg per day given orally
75564125|NCT04513379|Drug|Efavirenz 400mg|2 tablets of EFV 200 mg per day given orally
75564126|NCT05142839|Procedure|EUS-CD|EUS-guided choledochoduodenostomy
76043409|NCT05512897|Procedure|erector spinea plane block|in assistance of ultrasound for visualization anesthetic injection point. 30-40 mL Ropivacaine 0.375% plus 2 mg Dexamethasone administered on each side will be administered between thoracic transversus process and longitudinal spine muscle
75418958|NCT01418235|Biological|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
75418959|NCT01418235|Biological|DNA-C2 + MVA-C|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
75418960|NCT01418235|Biological|DNA-C2 + MVA-C + gp140/MF59|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
75418961|NCT01418274|Drug|danoprevir|oral doses of danoprevir
75418962|NCT01418274|Drug|escitalopram|oral doses of escitalopram
75418963|NCT01418274|Drug|ritonavir|oral doses of ritonavir
75418964|NCT01418300|Drug|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
75564127|NCT05142839|Procedure|EUS-GEA|EUS-guided gastroenterostomy
75564128|NCT00521157|Drug|Go Medical Naltrexone implants|Naltrexone implants 3.2 g (double of 1,6 g)
75564129|NCT04694352|Other|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
75564130|NCT04694352|Other|Conventional Physical therapy|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour"
75564131|NCT00505817|Drug|Cetrorelix and Leuprolide|
75564132|NCT02948595|Other|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
75564133|NCT02948595|Other|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
75564134|NCT04513262|Procedure|mechanical ventilation during video-assisted surgery|observed variation of ventilatory parameters during video-assisted surgery
75564135|NCT00521391|Other|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
75564136|NCT00521430|Biological|anti-thymocyte globulin|
75564137|NCT00521430|Drug|busulfan|
75564138|NCT00521430|Drug|cyclosporine|
75718508|NCT02557802|Biological|Fluenz Tetra|Intranasal spray, 0.2 ml dose
75718509|NCT02557802|Biological|Fluarix Tetra|Intramuscular injection, 0.5 ml dose
75564139|NCT00521430|Drug|fludarabine phosphate|
75718510|NCT04048226|Drug|Placebos|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
75418965|NCT01418391|Procedure|Transversus Abdominis Plane block|"TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12~18 hours upon to the regional anesthetics choose"
75418966|NCT01418404|Other|Noxious TS|hot, cold alternately, noxious TS in study A
75418967|NCT01418404|Other|Innocuous TS|warm, cool alternately, Innocuious TS in study A
75418968|NCT01418404|Other|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
75718511|NCT04048226|Drug|Dexmedetomidine +Ketamine|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
75718512|NCT00811746|Drug|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
75718513|NCT00811746|Drug|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
75418969|NCT01418404|Other|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
75418970|NCT01418404|Other|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
75564140|NCT00521430|Drug|methotrexate|
75564141|NCT00521430|Drug|methylprednisolone|
75564142|NCT00521430|Procedure|allogeneic hematopoietic stem cell transplantation|
75564143|NCT00521430|Procedure|peripheral blood stem cell transplantation|
75564144|NCT00521196|Device|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
75564145|NCT00521469|Device|Pro Adjuster|
75564146|NCT00505973|Drug|SCA-136|
75564147|NCT00521274|Biological|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
75564148|NCT00521274|Drug|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
75418971|NCT01418404|Other|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
75418972|NCT01418417|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
75418973|NCT01418430|Drug|CHOP-daclizumab|
75564149|NCT05146778|Procedure|Opioid-free anesthesia|OFA group will be sedated using dexmedetomidine and lidocaine.
75418974|NCT01418443|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
75418975|NCT01418456|Drug|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
75564150|NCT05146778|Procedure|Conventional opioid-based anesthesia|Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
75418976|NCT01418469|Dietary Supplement|Caseinate|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
75418977|NCT01418469|Dietary Supplement|Whey protein isolate|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
75564151|NCT04694430|Procedure|Blood sample|2 ml venous blood was collected and separated into serum.
75564152|NCT04694430|Other|Data collection|"Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~Assess COPD using ABCD assessment tool."
75564153|NCT04694430|Procedure|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
75564154|NCT00505700|Drug|velcade|
75564155|NCT00505700|Drug|Idarubicin|
75564156|NCT00505700|Drug|Cytarabine|
75564157|NCT04694274|Device|stabilization splint|The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.
75718514|NCT00811746|Other|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
75718515|NCT00766766|Behavioral|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
75718516|NCT00766766|Behavioral|Telephone Coaching Sessions|Telephone Coaching Sessions
75718517|NCT00766766|Behavioral|Physician Feedback Letter|Physician Feedback Letter
75718518|NCT04048070|Drug|Flurbiprofen Axetil|One kind of NSAIDs, 200mg for 48 hours after surgery.
75718519|NCT04048070|Drug|Sufentanil|One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery
75418978|NCT01418469|Dietary Supplement|Soy|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
75418979|NCT01418469|Dietary Supplement|soy+BCAA|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
75418980|NCT01418495|Other|Cytology Specimen Collection Procedure|Correlative studies
75418981|NCT01418495|Other|Pharmacological Study|Correlative studies
75418982|NCT01418508|Behavioral|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
75418983|NCT01418508|Behavioral|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
75418984|NCT01418521|Drug|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
75418985|NCT01418521|Drug|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
75564158|NCT04694274|Procedure|physical therapy|Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.
75873994|NCT02939131|Behavioral|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
75564159|NCT04694274|Device|placebo splint|The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
75418986|NCT01418534|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
75418987|NCT01418547|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
75418988|NCT01418560|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
75418989|NCT01418573|Other|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
75418990|NCT01418573|Other|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
75418991|NCT01418573|Other|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
75418992|NCT01418586|Drug|Torrent's Alfuzosin Extended Release Tablet|
75564160|NCT02948283|Other|Laboratory Biomarker Analysis|Correlative studies
75564161|NCT02948283|Drug|Metformin Hydrochloride|Given PO
75564162|NCT02948283|Other|Pharmacological Study|Correlative studies
75564163|NCT02948283|Drug|Ritonavir|Given PO
75564164|NCT02948283|Other|Quality-of-Life|Ancillary studies
75564165|NCT02948283|Other|Questionnaire|Ancillary studies
75418993|NCT01418599|Drug|Torrent's Alfuzosin Extended Release Tablet|
75418994|NCT01418612|Drug|Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited|
75418995|NCT01418625|Drug|Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)|
75564166|NCT02275910|Drug|E7090|
75873995|NCT02939131|Behavioral|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
75873996|NCT04052282|Device|Mobile Health App|There is no intervention
75564167|NCT00521508|Procedure|gene transcription and cytometry|samply of 30 ml of blood
75564168|NCT00523146|Drug|Kanion Capsule|
75564169|NCT00506012|Drug|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
75564170|NCT04693728|Behavioral|Resilient Intrinsic Self-Regulation Strategies in Extremes|The manualized intervention covered resilience strategies organized into four modules: (1) engagement, (2) social relatedness, (3) transformation of pain and (4) building a good life. The modules were delivered in 8 weekly sessions of 90 minutes each.
75418996|NCT01418651|Drug|Savella|milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
75418997|NCT01418664|Dietary Supplement|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
75418998|NCT01418677|Drug|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
75564171|NCT04512872|Biological|CT-P41|60 mg/mL single dose, Solution for injection in PFS
75564172|NCT04512872|Biological|EU-approved Prolia|60 mg/mL single dose, Solution for injection in PFS
75564173|NCT00521547|Procedure|Electroacupuncture|
75564174|NCT05144867|Radiation|Stereotactic Radiosurgery|All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
75564175|NCT05144672|Diagnostic Test|Laboratory tests|"Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.~Serum irisin."
75564176|NCT05144672|Other|Anthropometric measurements|Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI
75564177|NCT05144672|Procedure|Electrocardiogram and Fundus examination|Fundus examination by direct ophthalmoscope
75564178|NCT05144672|Other|Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.
75564179|NCT05144672|Other|Brachial index|The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm
75564180|NCT05144672|Diagnostic Test|Laboratory tests|Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).
75564181|NCT05144672|Radiation|Abdominal ultrasound.|It will be performed for patients only.
75564182|NCT02948166|Procedure|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
75564183|NCT02948166|Procedure|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
75564184|NCT04694040|Device|Modjaw® device|Analysis of mandibular kinematics with Modjaw® device
75564185|NCT04694469|Procedure|Closed reduction and percutaneous pinning (CRPP)|Operated for supracondylar humeral fractures
75564186|NCT04693923|Procedure|Fluid challenge|Fluid challenge according to the assigned group
75564187|NCT00523185|Drug|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
75564188|NCT00523185|Drug|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
75564189|NCT04512443|Drug|Daflon|All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
75418999|NCT01418677|Drug|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
75419000|NCT01418677|Drug|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
75564190|NCT04512404|Drug|HMG-CoA Reductase Inhibitor|
75564191|NCT04693962|Diagnostic Test|Plasmatic Fibroblast Growth Factor-23 by means of ELISA|Plasma levels of FGF-23 will be measured by ELISA
75419001|NCT01418716|Other|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
75564192|NCT05149118|Procedure|Polydeoxyribonucleotide (PDRN)|A total 1mL of PDRN was injected along the suture line at distance of 1cm in one day and two days after the surgery.
75419002|NCT01418716|Other|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
75564193|NCT00521664|Biological|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
75564194|NCT00521664|Biological|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
75564195|NCT00521703|Drug|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
75873997|NCT03646526|Drug|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
75564196|NCT00521703|Drug|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
75419003|NCT01418729|Drug|Pravastatin|"Treatment:~Patients will be randomized in two groups, A and B:~Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h."
75419004|NCT01418742|Drug|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
75564197|NCT05144321|Other|Impact of environment upon obstetrical|Impact of environment upon obstetrical
75564198|NCT05144321|Other|neonatal and maternal adverse outcome|neonatal and maternal adverse outcome
75564199|NCT00523224|Procedure|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
75564200|NCT00523224|Biological|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
75718520|NCT04048070|Behavioral|Extended perioperative counseling|The extended perioperative counseling contained additional information, including surgery procedures, importance of medicine treatment and medical help to relieve depression and anxiety about disease during peri-operation period.
75718521|NCT04048070|Behavioral|Shorter fasting food and water time before surgery|The patients in ERAS group were required to fast food for 6 to 8 hours and provided 12.6% maltodextrin carbohydrate supplement beverage for 2 hours before surgery
75718522|NCT04048070|Behavioral|Conventional perioperative counseling|THe conventional perioperative counseling included the risk of surgery and prognosis of disease and other things patients need to know.
75873998|NCT03646526|Drug|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
75873999|NCT03643718|Procedure|Emergency General Surgery|Emergency General Surgery and Trauma operative/non operative management
75874000|NCT03646370|Drug|Tenofovir Alafenamide|Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
75874001|NCT04322448|Device|Mechanomyography (MMG)|MMG, as described in the cohort descriptions, to be used during surgery to see if they are predictive of patient outcomes.
75419005|NCT01418742|Drug|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
75564201|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
75564202|NCT00521742|Drug|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
75564203|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
75564204|NCT00521742|Drug|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
75564205|NCT05144204|Behavioral|Low FODMAP diet|Low FODMAP diet instruction to irritable bowel syndrome patients.
75564206|NCT05144165|Other|Experts consensus|Consensus opinion using Delphi Methodology
75564207|NCT00521781|Drug|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
75564208|NCT00521781|Drug|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
75564209|NCT00521781|Drug|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
75564210|NCT05144126|Other|CT radioraphic assessment|CT radioraphic assessment
75564211|NCT00521820|Drug|Pioglitazone|Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.
75564212|NCT00521820|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
75564213|NCT00523263|Device|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
75564214|NCT00523263|Device|Human umbilical vein femoro-popliteal bypass|
75419006|NCT01418755|Biological|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
75718523|NCT04048070|Behavioral|Regular fasting food and water time before surgery|The stricter control of preoperative fasting requirements, prohibiting solids and liquids from previous midnight to operation time.
75564215|NCT04696328|Biological|Human (allogeneic) iPS cell derived-cardiomyocyte sheet|Transplantation
75564216|NCT00521859|Drug|Cloretazine|800 mg/m^2 by vein daily
75419007|NCT01417793|Behavioral|Smoking Cessation Program|Comparison of smoking cessation rate among different smoking cessation program
75419008|NCT01418768|Other|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
75419009|NCT01418794|Device|High dose rapamycin stent|Concentration of rapamycin is 2.5%
75419010|NCT01418794|Device|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
75564217|NCT00521859|Drug|Fludarabine|25 mg/m^2 by vein daily x 5 Days
75564218|NCT02954861|Other|No intervention|No intervention
75564219|NCT00521898|Procedure|Descemet Membrane Endothelial Keratoplasty (DMEK)|
75564220|NCT02954666|Device|radio-frequency ablation|"Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval < 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval < 600 ms after 5 minute of waiting time; 5 radiofrequency applications > 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
75874002|NCT03643640|Behavioral|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
75564221|NCT00521937|Other|Dermagen®|Weekly topical applications
75564222|NCT02954705|Other|Non interventional study|This is a non interventional study because all levies are performed during visit planned for the care of patients.
75718524|NCT00655356|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
75718525|NCT00655356|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
75718526|NCT00571064|Drug|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
75718527|NCT00811824|Behavioral|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
75718528|NCT04045626|Procedure|corneal cross-linking|Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
75564223|NCT04693611|Behavioral|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 24 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants without any neurocognitive disorder.
75419011|NCT01418807|Procedure|TRANSVAGINAL SPECIMEN EXTRACTION|Transvaginal specimen retrieval following posterior colpotomy
75419012|NCT01418807|Procedure|TRANSUMBILICAL SPECIMEN EXTRACTION|Transumbilical specimen retrieval following enlargement of the umbilical port
75419013|NCT01418820|Device|Verum stimulation|10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
75564224|NCT04693611|Procedure|Functional near-infrared spectroscopy (fNIRS)|The acquisition by fNIRS will be performed in each CS session in four regions of interest (ROIs) in the prefrontal cortex: left dorsolateral prefrontal cortex (LDLPFC); left medial prefrontal cortex (LMPFC); right medial prefrontal cortex (RMPFC); right dorsolateral prefrontal cortex (RDLPFC).
75564225|NCT02954822|Drug|Evogliptin→Evogliptin+Glimepiride→Glimepiride|"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"
75718529|NCT04045392|Behavioral|Mediterranean diet|Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
75718530|NCT00811980|Drug|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
75718531|NCT00766844|Device|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
75718532|NCT03895372|Drug|PF-06826647 or Placebo|Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
75718533|NCT03895372|Drug|PF-06826647|Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
75718534|NCT02551926|Behavioral|mobile text messages|
75718535|NCT02551926|Behavioral|virtual community|
75718536|NCT02551926|Behavioral|brochures|
75564226|NCT02954822|Drug|Glimepiride→Evogliptin→Evogliptin+Glimepiride|After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
75564227|NCT00522015|Drug|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
75718537|NCT02551926|Other|Usual care|
75718538|NCT02551926|Device|mobile phone|
75718539|NCT00775034|Drug|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
75718540|NCT00775034|Procedure|Drainage|Mesh repair for open incisional hernia repair with drainage
75718541|NCT00813696|Drug|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
75718542|NCT00813696|Drug|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
75718543|NCT02557880|Behavioral|Sleep Application Diary|Tool used to document sleep hygiene.
75718544|NCT02557880|Behavioral|Treatment As Usual|Sleep hygiene counseling
75718545|NCT00771290|Procedure|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
75718546|NCT00813774|Biological|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
75718547|NCT00813774|Biological|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
75718548|NCT00813774|Biological|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
75564228|NCT02954744|Procedure|HIFU treatment|High intensity focused ultrasound
75564229|NCT00523380|Drug|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
75564230|NCT00523380|Drug|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
75564231|NCT00506870|Device|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
75564232|NCT00506870|Device|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
75564233|NCT02948322|Device|CMRI|Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
75564234|NCT02948322|Drug|Gadolinium|gadolinium injection will be performed during CMRI in patients and healthy volunteers.
75419014|NCT01418820|Device|Placebo stimulation|10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
75419015|NCT01418872|Other|Didactic Concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
75419016|NCT01418898|Other|Dietary Intervention|Nutrient fortified oat beverage
75564235|NCT02948322|Procedure|OGTT|Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
75419017|NCT01418911|Other|questionnaire|questionnaire only
75564236|NCT05143580|Behavioral|Cognitive therapy|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education.~Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~Use gamification to evaluate: pain relief skills, lung expansion skills."
75564237|NCT05143580|Behavioral|Routine care|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education."
75564238|NCT00522054|Other|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
75564239|NCT00506987|Drug|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
75564240|NCT00506987|Drug|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
75718549|NCT02557490|Drug|oxaliplatin and raltitrexed|"TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)"
75718550|NCT00775112|Device|pillow|use of pillow for lumbar punctures
75718551|NCT00813852|Behavioral|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
75718552|NCT02551848|Drug|Botulinum toxin type A|
75874003|NCT03643640|Other|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
75874004|NCT04166994|Behavioral|Exercise and diet|IMPACT Intervention
75874005|NCT04166994|Other|No Intervention: Usual Care|No exercise or diet specialization.
75874006|NCT03644420|Diagnostic Test|Clinical evaluation|Functional scores for the pathological joint will be determined
75874007|NCT03644420|Diagnostic Test|Radiology|
75419018|NCT01418950|Other|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
75564241|NCT02276820|Biological|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
75564242|NCT00522093|Drug|TJ-100|TJ-100 2.5g three times per day for 6 weeks
75419019|NCT01418963|Drug|RO5285119|single and multiple ascending oral doses
75718553|NCT00807534|Drug|ipratropium bromide|ipratropium bromide nebulization
75874008|NCT03644420|Diagnostic Test|Dynamic contrast-enhanced magnetic resonance imaging|Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.
75419020|NCT01418963|Drug|placebo|single and multiple oral doses
75419021|NCT01418976|Behavioral|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
75564243|NCT00506558|Procedure|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
75874009|NCT03644420|Diagnostic Test|Evaluation of histological status|Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
75874010|NCT03646292|Drug|Pioglitazone|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
75874011|NCT03646292|Drug|Empagliflozin|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
75419022|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] Syringe|Single dose administration with pre-filled syringe
75564244|NCT00506558|Procedure|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
75564245|NCT00523458|Drug|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
75874012|NCT03646292|Drug|Combination of pioglitazone and empagliflozin|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
76043410|NCT05509387|Device|transcranial direct current stimulation and naming training|Participants will receive mild stimulation or no stimulation along with naming training
76043411|NCT05506501|Procedure|unilateral epidural anesthesia|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
75718554|NCT00807534|Drug|placebo|placebo nebulization
75718555|NCT00807534|Behavioral|constant rate step test|nebulization of 500ug
75718556|NCT00807534|Behavioral|constant rate shuttle walk test|nebulization of 500ug
75419023|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] auto-injector|Single dose administration with auto-injector
75419024|NCT01419002|Radiation|neoadjuvant RTx|Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
75419025|NCT01419002|Procedure|Surgery|Surgery and adjuvant chemotherapy according to German S3-guidelines
75419026|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =>90 mL/min)
75718557|NCT00812058|Drug|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
75718558|NCT00812058|Drug|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
75718559|NCT05589142|Behavioral|Time Restricted Eating|Eating calories only during a specific feeding window.
75718560|NCT05589064|Behavioral|Experimental: Dietetic counseling|Patients will receive dietary counselling to increase caloric and nutrient intake, stabilize glycemia, and optimize hydration.
75718561|NCT05589064|Dietary Supplement|Active Comparator: Omega-3, vitamin D3 and creatine monohydrate|Patients will be prescribed dietary supplements which will be taken daily for 8 weeks, as per the supplement protocol.
75718562|NCT05589064|Behavioral|Other : Physiotherapy treatment|Patients will receive weekly physiotherapy treatment.
76043412|NCT05506501|Procedure|Ultrasound guided femoro/ sciatic nerve block|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
75419027|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr <30 mL/min)
75419028|NCT01419093|Other|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on [feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
75564246|NCT00507065|Drug|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
75718563|NCT00807690|Drug|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
75718564|NCT00813930|Behavioral|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
75718565|NCT05355844|Drug|Benzoyl peroxide|Benzoyl peroxide application in the incision area before surgery
75718566|NCT00814008|Drug|Insulin|Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin, Lilly, Fegersheim, France
75874013|NCT03345407|Drug|Placebo ELLIPTA|Placebo will be administered via oral inhalation route once daily in the morning.
75874014|NCT03345407|Drug|Nemiralisib ELLIPTA 50 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
75874015|NCT03345407|Drug|Nemiralisib ELLIPTA 100 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
75874016|NCT03345407|Drug|Nemiralisib ELLIPTA 250 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
76043413|NCT05506267|Device|Trachea Sound Sensor (TSS)|Use the TSS and commercial vital sign monitors to develop a diagnostic algorithm that detects and predicts hypoventilation due to opioids and anesthetic medication
76043414|NCT05512663|Device|Irreversible Electroporation (IRE)|The area of the prostate that was positive for cancer based on the transperineal prostate biopsy will be targeted for ablation via the NanoKnife System. An MRI/TRUS fusion device probe will be placed in the rectum and the prostate will be visualized in both sagittal and axial views. The ultrasound grid which was used during the mapping biopsy will be oriented using anatomical landmarks and used to identify the location of the positive biopsy cores. The NanoKnife Single Electrode Probes will be surgically inserted into the prostate through the perineum using MRI/TRUS fusion guidance and the ultrasound grid for guidance.
76043415|NCT05512507|Behavioral|Physical Therapy Program|Physical Therapy Program
75419029|NCT01419106|Device|Ultrasound (A point of care ultrasound protocol)|Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
75419030|NCT01419119|Drug|Cholecalciferol|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
75419031|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
75419032|NCT01419119|Drug|Cholecalciferol|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
75419033|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
75419034|NCT01419132|Drug|Furosemide|125-250 mg furosemide bid
75419035|NCT01419132|Drug|Furosemide|125-250 mf furosemide bid
75419036|NCT01419145|Other|Multimodal intervention|Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
75419037|NCT01419145|Other|Standard care|Standard cancer care
75419038|NCT01419210|Other|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
75419039|NCT01419210|Other|Educational Presentations|Attend a two-hour presentation each week for four weeks
75564247|NCT00507065|Drug|Placebo|
75564248|NCT00522132|Drug|Artesunate|intravenous application
75564249|NCT00523497|Device|Non invasive mechanical ventilation|
75564250|NCT00522210|Drug|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
75718567|NCT00814008|Drug|Glucose|"Glucose:~Dosage form : intravenous infusion, infusion period 60 minutes per dose level Dosage: at a rate to maintain blood glucose level at 100mg ; 20mg/100ml Glucose"
75419040|NCT01419210|Other|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
75564251|NCT00522210|Other|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
75564252|NCT05143151|Biological|CD276 CAR-T cells|CD276 CAR-T cells infusion
75419041|NCT01419210|Other|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
75419042|NCT01419262|Drug|Vitamin D - Cholecalciferol 400 IU|One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
75419043|NCT01419262|Drug|Vitamin D3 - Cholecalciferol 2000 IU|One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
75419044|NCT01419288|Other|Treadmill Training|The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
75419045|NCT01419301|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is program based on daily meditation practice that guides an individual towards increased awareness and self-regulation of thoughts and actions. MBSR is easier to implement and may be shown to be more effective than cognitive-behavioral stress reduction, and is more applicable to patients with chronic illness.
75419046|NCT01419327|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
75419047|NCT01419340|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
75419048|NCT01419353|Drug|estradiol valerate|2 mg P.O / day for 1-6 days.
75419049|NCT01419366|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
75564253|NCT00523536|Behavioral|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
75564254|NCT00523575|Dietary Supplement|Cubitan|400 ml/d
75564255|NCT05143112|Biological|Allogeneic CD19 CR-T cell|Allogeneic CD19 CR-T cell infusion
75564256|NCT00523653|Other|blood test|looking at DNA
75564257|NCT05142995|Diagnostic Test|sleep study|Assessment of sleep disorders using either sleep study or a set of sleep questionnaires (Epworth sleepiness scale, SF36, Pittsburgh sleep quality index)
75564258|NCT00522249|Drug|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
75564259|NCT00522249|Drug|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
75874017|NCT03345407|Drug|Nemiralisib ELLIPTA 500 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
75419050|NCT01419392|Drug|Sildenafil citrate|25 mg orally, 4 times per day for 21 days
75419051|NCT01419392|Drug|matching placebo|orally, 4 times per day for 21 days
75419052|NCT01419405|Drug|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
75419053|NCT01419405|Drug|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
75419054|NCT01419405|Drug|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
75419055|NCT01419431|Procedure|Laparoscopic resection|Inflammatory response in laparoscopic surgery
75419056|NCT01419444|Behavioral|Airflow Exercises for Voicing|Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
75419057|NCT01419457|Drug|Favipiravir|1200 mg BID for Day 1 + 800 mg BID for Day 2-5
75419058|NCT01419457|Drug|Favipiravir|800 mg BID for Day 1 + 400 mg BID for Day 2-3
75419059|NCT01419457|Drug|Favipiravir|800 mg Single Dose
75419060|NCT01419470|Drug|dapoxetine|"multiple dosing~12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine"
75419061|NCT01419483|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
75419062|NCT01419496|Genetic|protein expression analysis|
75564260|NCT00522249|Drug|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
75718568|NCT00814086|Drug|Paclitaxel|Given IV or intraperitoneally
75718569|NCT00814086|Drug|Cisplatin|Given intraperitoneally
75718570|NCT04114786|Device|3D-printed mask|After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
75419063|NCT01419496|Other|flow cytometry|
75564261|NCT05148767|Drug|Neoadjuvant chemoradiotherapy based on irinotecan|"Patients with locally advanced rectal cancer treated with irinotecan-based chemoradiotherapy were enrolled in this study. The dose of irinotecan is determined by the genotype of UGT1A1.Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）."
76043416|NCT05509153|Drug|NAC|1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
76043417|NCT05509153|Drug|Placebo|Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
75419064|NCT01419496|Other|laboratory biomarker analysis|
75419065|NCT01419509|Genetic|DNA methylation analysis|
75419066|NCT01419509|Genetic|microarray analysis|
76043418|NCT05506189|Other|mobile application program with human coach|6-months mobile application program with human coach for life-style modifiation including diet and exercise
75419067|NCT01419509|Genetic|polymerase chain reaction|
75564262|NCT00522288|Device|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
75564263|NCT00522288|Device|Spectacle|Spectacles for the treatment of myopia
75564264|NCT00522327|Other|remote simultaneous medical interpreting|remote simultaneous medical interpretation
75874018|NCT03345407|Drug|Nemiralisib ELLIPTA 750 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
76043419|NCT05506033|Procedure|rapid GCs taper|After a complete response was achieved, the GCs dose was halved from the original dose.
76043420|NCT04594837|Device|PTR Physical Therapy while wearing Robot group (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
76043421|NCT04594837|Other|Physical Therapy Only (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
75419068|NCT01419509|Other|laboratory biomarker analysis|
75564265|NCT00522327|Other|usual and customary|usual and customary interpreting
75564266|NCT00522327|Other|ENglish speaking|English speakers
76043422|NCT04594837|Device|Cross over group for Physical Therapy n Sub-Acute group. (Phase II)|Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
75419069|NCT01419548|Drug|ABT-888|
75419070|NCT01419548|Drug|Carboplatin|
75419071|NCT01419548|Drug|Paclitaxel|
75419072|NCT01419587|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
75419073|NCT01419600|Drug|AZD8683|Single Dose Inhaled IMP via Turbuhaler
75419074|NCT01419600|Drug|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
75419075|NCT01419613|Behavioral|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
75419076|NCT01419613|Behavioral|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
75419077|NCT01419652|Other|hold hypoglycemic meds|continue versus hold hypoglycemic medications
75564267|NCT05148728|Procedure|Endoscopic fulguration|already included. WE will use Storz monopolar device for fulguration
75564268|NCT00523692|Drug|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
75564269|NCT00523692|Drug|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
75564270|NCT03458949|Other|awareness campaign|awareness campaign for colorectal cancer screening in the workplace
75564271|NCT05148689|Drug|Oxymetazoline hydrochloride Cream, 1%|Cream
75564272|NCT05148689|Drug|Rhofade™ (oxymetazoline) cream, 1%|cream
75564273|NCT05148689|Drug|Placebo|cream
75564274|NCT03458910|Behavioral|HRV training|Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
75564275|NCT05148650|Diagnostic Test|Standard laboratory coagulation tests and rotational thromboelastometry measurements|"Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM."
75874019|NCT03345407|Drug|Albuterol (Salbutamol) MDI or nebules|Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
76043423|NCT04594837|Device|Chronic Stroke Subjects to receive robotic gait training therapy.|Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
75419078|NCT01419678|Other|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
75419079|NCT01419691|Drug|auranofin|6 mg twice a day for a total of 12 mg total daily dose
75419080|NCT01419730|Drug|Vitamin D3|Vitamin D3 50,000 IU
75564276|NCT00523731|Procedure|Angiogenic Cell Precursors (ACPs) or Vescell TM|
75564277|NCT00523770|Procedure|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
75564278|NCT00522405|Procedure|TACE|"Under local anesthesia, the Femoral artery would be punctured~A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~Superselective catheterization of the hepatic artery feeding the tumor would be done~By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~Gelfoam particles would be injected following this for embolization"
76043424|NCT05509075|Dietary Supplement|nutraceuticals|antioxidants
75564279|NCT00522444|Drug|Nebulized Magnesium Sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
75564280|NCT00522444|Other|Nebulized normal saline|standard of care
76043425|NCT05508919|Device|Biofeedback|EMG, RESP, and TEMP Biofeedback Training
76043426|NCT05508919|Other|Writing Sessions|The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week
76043427|NCT04741789|Drug|Capmatinib|Tablet for oral use, dose Up to 400mg, twice daily
75419081|NCT01419730|Behavioral|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
75419082|NCT01419756|Device|VentriPoint Medical System|The Knowledge Based Reconstruction (KBR) method generates a 3D reconstruction of the RV based on the Piecwise smooth subdivision surface method but without requiring manual border tracing. Instead KBR reconstructs a new patient's ventricular surface from the placement of anatomic landmark points on a 2D ultrasound image
75419083|NCT01419782|Other|Whole-body vibration|Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
75419084|NCT01419808|Procedure|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
75419085|NCT01419808|Procedure|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
75419086|NCT01419821|Drug|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
75874020|NCT03345407|Drug|Standard of care therapy|SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
75874021|NCT03621332|Other|Questionnaire|Online/paper questionnaires
75564281|NCT05148143|Drug|Raltitrexed combined with oxaplatin|Raltitrexed combined with oxaplatin as second line treatment of cholangiocarcinoma
75874022|NCT02537418|Drug|durvalumab|
75874023|NCT02537418|Drug|tremelimumab|
75874024|NCT01264549|Device|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
75874025|NCT05692752|Other|No intervention|Expression of miR-133a &208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
75874026|NCT03626298|Drug|Adapalene|third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
75874027|NCT03626298|Drug|Nicotinamide, ABA and Zinc PCA|combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
76043428|NCT04735393|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
75419087|NCT01419821|Other|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
75419088|NCT01419847|Drug|Ciclopirox|
75419089|NCT01419847|Drug|Placebo|
75419090|NCT01419873|Drug|Actrapid Human Insulin|Actrapid Insulin is a drug used in routine neonatal practice to treat hyperglycaemia. The intervention in this study was to base dosing on insulin by a computer based-model approach as opposed to sliding scales, fixed protocols or clinician intuition
75419091|NCT01419899|Behavioral|Brief motivational intervention|A 20-30 minute motivational based discussion
75564282|NCT00523887|Drug|Fentanyl transdermal therapeutic system|
75419092|NCT01419912|Dietary Supplement|soy milk|
75874028|NCT03626298|Drug|Placebos|Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
75874029|NCT03255187|Dietary Supplement|Fish oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA [24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)].
76043429|NCT04735393|Drug|Placebo Comparator|Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
76043430|NCT04735393|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
76043431|NCT04735393|Drug|Placebo Comparator|Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
75564283|NCT02276534|Behavioral|SENSE Theatre|A peer-mediated, theatre-based intervention.
75564284|NCT02276534|Behavioral|Delayed Intervention|
75564285|NCT00506636|Behavioral|Tissue engineering for hair follicle regeneration|
75564286|NCT00522561|Other|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
75564287|NCT05145218|Drug|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
75419093|NCT01419912|Dietary Supplement|cow's milk|
75419094|NCT01419925|Biological|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
75564288|NCT05145218|Drug|Paclitaxel injection|Paclitaxel is a novel anti-microtubule agent.
75564289|NCT05145218|Drug|TQB2450 injection|TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
75564290|NCT00523926|Drug|TMC207|
75419095|NCT01419925|Biological|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
75564291|NCT05146271|Procedure|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome
75564292|NCT00522639|Other|18F-deoxyglucose (FDG)|contrast medium
75564293|NCT00522678|Drug|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
75564294|NCT00522678|Drug|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
75564295|NCT05140850|Biological|neuroimaging examination,neuro-cognitive test,blood pressure,blood sample|neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
75564296|NCT00522717|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
75564297|NCT00522717|Behavioral|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
75564298|NCT05142098|Drug|Dexamethasone|Intramuscular
75564299|NCT05142098|Drug|Etoricoxib 60 mg|Orally
75564300|NCT00523965|Drug|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
75564301|NCT00523965|Drug|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or > 25 kg Miltefosine 50 mg once daily if patient weighs <25 mg
75718571|NCT04114786|Device|Thermoplastic mask|Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
75718572|NCT00669110|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"tablet~subjects randomly assigned to 10-200 mg/day by age group~6 month treatment period(~182 days)"
75564302|NCT00523965|Drug|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
76043432|NCT05508841|Other|tDCS and Cognitive Training|Participants will receive mild stimulation or no stimulation along with cognitive training
75564303|NCT00523965|Drug|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
75564304|NCT05141669|Drug|Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
75564305|NCT00522756|Drug|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
75564306|NCT00522756|Drug|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
75564307|NCT02954783|Behavioral|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
75564308|NCT02954783|Behavioral|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
75718573|NCT04604860|Behavioral|Fitness intervention|Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).
75718574|NCT00654732|Drug|Bleomycin|Given IV
75718575|NCT00654732|Drug|Dacarbazine|Given IV
75718576|NCT00654732|Drug|Doxorubicin Hydrochloride|Given IV
75718577|NCT00654732|Biological|Rituximab|Given IV
75718578|NCT00654732|Drug|Vinblastine|Given IV
75718581|NCT00771368|Drug|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
75718582|NCT00767156|Other|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
75718583|NCT00767156|Other|Base cream|The subjects use the base cream on the face, twice per day
75718584|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
75718585|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
75874030|NCT03255187|Dietary Supplement|Sunflower seed oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
75564309|NCT04693845|Behavioral|Collaborative Assessment and Management of Suicidality|"CAMS is a suicide-focused intervention that stabilizes the suicidal patient and identifies, targets, and treats patient-defined suicidal drivers-the problems (e.g., trauma, financial issues, relationship loss) that compel a patient to consider suicide. CAMS is theoretically agnostic, patient-centered, and can be used across different suicidal populations and clinical settings."
75564310|NCT04693845|Behavioral|Treatment as Usual|Treatment as Usual was based on the staff, policies, and procedures of the community mental health center Next Day Appointment clinic (CMHC) affiliated with our university. Research therapists and the research psychiatrist were hired from the CMHC staff who followed standard CMHC policies and procedures.
75564311|NCT05141240|Drug|Ribiciclib|Participants who initiated CDK4/6i therapy
76043433|NCT05502445|Other|educational intervention|"In this group, the steps below are added:on the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance. On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements."
75419096|NCT01419925|Biological|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
75419097|NCT01419925|Biological|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
75419098|NCT01419938|Device|Light therapy and Cognitive behaviour therapy|Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
75419099|NCT01419938|Device|Light therapy|Light therapy every morning during 30-45 minutes for two weeks.
75419100|NCT01419951|Behavioral|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
75564312|NCT05141240|Drug|Palbociclib|Participants who initiated CDK4/6i therapy
75564313|NCT05141240|Drug|Abemaciclib|Participants who initiated CDK4/6i therapy
75874031|NCT03646136|Procedure|Retained fluid|Retained fluid
75419101|NCT01419951|Other|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
75564314|NCT00522912|Procedure|Trichiasis surgery|Posterior lamella tarsal rotation
75874032|NCT03646136|Procedure|Emptied fluid|Emptied fluid
75874033|NCT05508672|Other|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)|We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.
75874034|NCT05508672|Other|"Traditional smoking is harmful education"|"In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians."
76043434|NCT05505877|Drug|BR790+Tislelizumab|"BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose."
75564315|NCT00522912|Procedure|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
75564316|NCT02954627|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
75874035|NCT03643406|Other|Mental Fatigue|modified stroop task
75419102|NCT01419951|Behavioral|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
75419103|NCT01419964|Drug|Group 01|ACH24
75874036|NCT03643406|Other|Control|documentary
75564317|NCT00524004|Biological|Anti-CsbD Bovine IgG|Three times a day for seven days
75564318|NCT00524004|Other|Placebo|Three times a day for seven days
75419104|NCT01419964|Drug|Group 02|Placebo
75419105|NCT01419990|Drug|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
75564319|NCT00524004|Biological|Anti-CS17 Bovin IgG|Three times a day for seven days
75564320|NCT05145803|Device|Polyvinylalcohol strip [diagnostic]|The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
75564321|NCT04694079|Procedure|Group 1, CMR-guided/aided VT ablation|"Ablation of the anatomical channels of heterogeneous tissue within the scar"
75564322|NCT04694079|Procedure|Group 2, CMR-aided VT ablation|"Ablation of the electrical conduction channels within the scar"
75564323|NCT04694079|Procedure|Group 3, Electroanatomical guided ablation|Ablation guided by an electro-anatomical system without the aid of CMR
75564324|NCT05146076|Other|home-based physical training|home-based physical training minimum 150 min./week with telemonitoring
75564325|NCT05146076|Other|institutional physical training|institutional physical training supervised by physiotherapist 2-3 times 60 min./week
75564326|NCT04696367|Procedure|Emergency laparotomy|Midline laparotomy for acute intra-abdominal pathology
75564327|NCT02948127|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
75564328|NCT02948127|Biological|Placebo|Administered as nose drops
75564329|NCT05146583|Procedure|Autologous bone marrow aspirate injected intradiscal after microdiscectomy|Harvested from SI-joint, 2-5ml BMA is injected in the discectomy defect.
75564330|NCT05146583|Procedure|Discectomy only|Transflaval discectomy with or without the use of a microtube (according to surgeons' preference).
75564331|NCT02948010|Device|Auto CPAP + comfort feature A|Auto CPAP + comfort feature A using Fisher & Paykel Healthcare CPAP Device
75564332|NCT02948010|Device|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
75874037|NCT03643328|Biological|blood samples|Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.
75419106|NCT01419990|Drug|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
75419107|NCT01419990|Drug|Placebo|Placebo oral capsules, qd, 10 days
75419108|NCT01420003|Procedure|Bone Marrow Aspiration|3 per study
75419109|NCT01420003|Procedure|Tonsil Biopsy|Optional upon completion of study
75419110|NCT01420042|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
75564333|NCT02948010|Device|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
75564334|NCT02948010|Device|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
75564335|NCT02948010|Device|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
75564336|NCT02948010|Device|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
75564337|NCT02948010|Device|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
75874038|NCT03643328|Biological|nasal swabs|Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
75419111|NCT01420042|Drug|Placebo|Lemon flavoured cordial and Water for Injection
75419112|NCT01420055|Drug|fingolimod|
75419113|NCT01420094|Drug|Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter [mL]) between 1-4 hours post dental surgery.
75419114|NCT01420094|Drug|Acetaminophen (Tylenol extra strength)|Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
75874039|NCT04097262|Other|Own-Price Elasticity|The price of fruit will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
75419115|NCT01420094|Drug|Placebo|Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
75419116|NCT01420133|Other|Regimen|regimen normal in salt and sugar
75419117|NCT01420133|Other|Standard regimen|with diet low in salt and sugar
75419118|NCT01420159|Drug|Methoxyflurane|Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
75419119|NCT01420172|Other|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
75419120|NCT01420185|Genetic|RNA analysis|
75874040|NCT04097262|Other|Cross-Price Elasticity|The price of fruit will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
75419121|NCT01420185|Genetic|gene expression analysis|
75419122|NCT01420185|Genetic|microarray analysis|
75419123|NCT01420185|Genetic|reverse transcriptase-polymerase chain reaction|
75419124|NCT01420185|Other|laboratory biomarker analysis|
76043435|NCT05508685|Other|HIIT and Cognitive Reassessment|Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.
75419125|NCT01420198|Behavioral|Lifestyle intervention|Increased physical activity and improved food habits
75419126|NCT01420211|Drug|Primovist® 0,25 mmol/ml solution for injection|intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
75419127|NCT01420211|Device|MRI|lmaging of 20 slices (thickness: 3 mm; max. time of imaging 10 s) before and 0.25, 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50, 60, 90 and 120 min after intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist®
75419128|NCT01420224|Other|Commercial airline flight|Normal scheduled passenger flight
75564338|NCT02948010|Device|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
75564339|NCT02948010|Device|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
75564340|NCT05145998|Dietary Supplement|Glucola|50 grams of Glucola sugar beverage
75564341|NCT05145998|Dietary Supplement|Whole pea meal|Whole cooked peas with spaghetti sauce and a slice of bread.
75564342|NCT05145998|Dietary Supplement|Pea flour meal|Pea flour with spaghetti sauce and a slice of bread.
75564343|NCT05145998|Dietary Supplement|Whole lentils|Whole cooked lentils with spaghetti sauce and a slice of bread.
75564344|NCT05145998|Dietary Supplement|Lentil flour|Lentil flour with spaghetti sauce and a slice of bread.
75874041|NCT03644264|Drug|PA21|sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.
76043436|NCT05508685|Other|HIIT group|Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.
76043437|NCT05508685|Other|Emotional regulation strategy group|Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.
76043438|NCT05508685|Other|placebo group|Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
75419129|NCT01420263|Procedure|Re-feeding residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
75419130|NCT01420263|Procedure|Fresh Feeding Breastmilk or Formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
75419131|NCT01420302|Procedure|Nurse directed insulin titration|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
75419132|NCT01420302|Procedure|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
75419133|NCT01420328|Drug|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin
75564345|NCT05145959|Device|Maskin Probe|The eyelids are examined using meibography to evaluate which eyelids are more severe (right or left). A drop of proparacaine 0.5% solution is added and a bandage contact lens is placed. To avoid patient discomfort, anesthetic ointment is instilled using a sterile cotton-tipped applicator. In some cases, 4% lidocaine can be directly applied to the lid margin. The Maskin probe will be passed through the gland orifice perpendicular to the lid margin. After first using a 1-mm probe, a 2- or 4-mm probes may be used in cases of persistent resistance. The BCL is removed and the eyes are rinsed with sterile preservative-free saline. The patient is given preservative-free artificial tears to use every hour. A brief slit lamp exam will performed in order to ensure that there is no unanticipated damage to the lid or cornea. The probing device will be properly disposed of in the sharps containers.
75419134|NCT01420341|Drug|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
75564346|NCT02948205|Procedure|3D group|infertility patient get TU-LESS by 3D Laparoscopy
75419135|NCT01420341|Drug|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
75718586|NCT05358028|Other|Hand Arm Bimanual Intensive Technique including Lower Extremity (HABIT-IL)|"HABIT-ILE along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities.~Functional task as maintaining ADL:~i.Eating with spoon while standing ii. Combing hair while standing. iii. Counting cards while standing and putting them in box. Standing and walking I. standing with support of upper extremity II. walking with the help walkers III. walking on parallel bar playing activities: I. playing with cards while standings II. taking toys out of box and putting them in other box while standing III. grasping a fixed rod by hand and trying to maintain balance on physio stability ball"
75419136|NCT01420367|Drug|metronidazole and cephalzolin|IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
75564347|NCT02948205|Procedure|normal group|infertility patient get normal laparoscopic surgery
75564348|NCT05148377|Drug|Liquaemin|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
75564349|NCT05148377|Drug|Heptar|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
75874042|NCT03644264|Drug|sevelamer carbonate|sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
75874043|NCT04051788|Other|Step Aerobics|Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.
75419137|NCT01420393|Procedure|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
75419138|NCT01420393|Other|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
75419139|NCT01420406|Other|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
75419140|NCT01420406|Other|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
75419141|NCT01420406|Other|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
75419142|NCT01420406|Other|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
75419143|NCT01420419|Other|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
75564350|NCT00524160|Drug|Fentanyl transdermal patch|
75564351|NCT00523029|Behavioral|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
75564352|NCT00524199|Drug|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
75419144|NCT01420419|Other|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
75419145|NCT01420432|Biological|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat repeated after three months
75564353|NCT00524199|Other|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
75564354|NCT00523068|Drug|Tolterodine|
75564355|NCT00523068|Procedure|tension free vaginal tape|
75718587|NCT05358028|Other|Hand Arm bimanual intensive Technique (HABIT)|"HAIBT along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities HAIBT along with the conventional Bobth treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities~Playing activities on table:~I. building towers with Lego blocks, II. Holding book by one hand and turning pages , III. Playing games with cards, IV. Drawing random impressions on paper, V. taking toys out of one box and placing them in other box one by one~Activities of daily living :~I. eating with spoon from bowel II. combing hair while sitting, III. opening of bottle cap for drinking water Age appropriate video games while sitting will be provided according to the ease of children"
75564356|NCT00524238|Drug|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
75564357|NCT02276378|Drug|Telmisartan low|
75564358|NCT02276378|Drug|Telmisartan high|
75564359|NCT02276378|Drug|Hydrochlorothiazide (HCTZ)|
75564360|NCT02276378|Other|Japanese meal|
75718588|NCT00771524|Drug|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
75718589|NCT00649428|Biological|Autologous Human Fibroblast (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
75564361|NCT00525954|Drug|A-002|
75564362|NCT04696250|Drug|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
75564363|NCT05145842|Procedure|floroscopy|After proper antiseptic dressing and draping, sacral hiatus was identified. the position of the needle was confirmed by lateral and anteroposterior fluoroscopic images. The needle was introduced up to S3 level for proper spread of the drug.
75564364|NCT05145842|Procedure|ultrasound+fluoroscopy|After proper antiseptic dressing and draping, the caudal region will be shown in the longitudinal section using sterile probe cover and gel. Under ultrasonographic imaging, the sacrococcygeal ligament will be crossed and the needle will not be advanced any further once the sacral canal is entered. The fluoroscopy phase of the combined imaging will be started and the needle position will be checked by taking an anteroposterior view. The needle tip will be positioned at the sacral 3 level. The needle will be repositioned until the proper position is achieved. The research will be terminated at this point and the time to this stage and the radiation exposure dose will be obtained.
75718590|NCT00649428|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Three injection visits administered 5 ± 1 weeks apart on each side of the face."
75718591|NCT05588050|Device|smart phone application and AutoCAD software|to assess the validity and reliability of smart phone application and AutoCAD software in assessing knee joint position sense in patients with patellofemoral pain syndrome
75419146|NCT01420445|Drug|YHD001 dose level 1|three times daily / 7 days
75419147|NCT01420445|Drug|YHD001 dose level 2|three times daily / 7 days
75718592|NCT00767234|Procedure|Observation|Standard of Care
75718593|NCT00767390|Device|ACL Patch|Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
75718594|NCT02552082|Device|Scorpio NRG posterior stabilized (PS)|
75564365|NCT00524433|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
75419148|NCT01420445|Drug|Pelargonium sidoides extract|6-9mL three times daily / 7 days
75419149|NCT01420445|Drug|placebo|three times daily / 7 days
75419150|NCT01420458|Drug|Experimental|Bioequivalence of two drug formulations
75564366|NCT00524433|Drug|placebo|
75564367|NCT03458832|Diagnostic Test|FSHD-specific functional rating scale|The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
75564368|NCT03458832|Device|Electrical Impedance Myography|EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
75564369|NCT05142878|Device|Ultracore Repose® mattress|Residents will be placed on the Ultracore Repose® mattress during 14 days
75564370|NCT00524550|Dietary Supplement|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
75564371|NCT05145647|Radiation|Add-on Brachytherapy|Brachytherapy protocol starts within 2 weeks after consolidative EBRT, subjects who are enrolled will receive brachytherapy with specified balloon applicator. High-dose-rate (HDR) brachytherapy system will be used in the treatment, 5-Gy per fraction is delivered to the pre-treatment esophageal length of primary tumor(s), second treatment will be finished within 2 weeks after the first one, a total of 10Gy in 2 fractions will be delivered.
75564372|NCT05145647|Device|"BRAXX Esophageal Brachytherapy Applicator"|The device is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.
75564373|NCT05148416|Radiation|High intensity laser treatment|20 patients received high power laser therapy . Zimmer High power laser applied by laser probe perpendicular to and in slight contact with the skin around knee joint , the total energy was delivered to the patient during one session was 1060 j in 3 phases of treatment.
75564374|NCT05148416|Device|sham HILT.|"20 patients received placebo laser  sham laser . The same treatment protocol of HILT was given to the sham group, but the laser instrument was switched off during applications. All laser applications were performed by the same physiotherapist."
75718595|NCT04000438|Drug|DF01|The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
75718596|NCT04000438|Drug|PL1|The subject receives sc injections once daily of placebo solution for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
75419151|NCT01419522|Other|Gait Training Method|Treadmill training at constant velocity
75419152|NCT01420471|Drug|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
75419153|NCT01420471|Other|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
75419154|NCT01420484|Other|different blood pressure intervals|In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
75419155|NCT01420497|Drug|intra-articular infiltration|intra articular infiltration
75419156|NCT01420497|Drug|epidural infiltration|epidural infiltration
75419157|NCT01420510|Drug|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
75419158|NCT01420510|Drug|Placebo vaginal gel|Application of a placebo vaginal gel
75419159|NCT01420523|Drug|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
75419160|NCT01420562|Procedure|blood sampling|During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
75419161|NCT01420575|Behavioral|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
75419162|NCT01420575|Behavioral|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
75419163|NCT01420614|Procedure|Femoral approach|diagnostic and interventional procedures by femoral artery access
75419164|NCT01420614|Procedure|Radial approach|diagnostic and interventional procedures by radial artery access
75419165|NCT01420640|Behavioral|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
75419166|NCT01420640|Behavioral|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
75419167|NCT01420640|Behavioral|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
75419168|NCT01420640|Behavioral|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
75419169|NCT01420640|Behavioral|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
75564375|NCT05148416|Other|knee osteoarthritis conventional exercises program|"knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
75564376|NCT02947932|Drug|Resveratrol|pre-ERCP intervention
75564377|NCT02947932|Drug|Indomethacin|post-ERCP intervention in high risk patients
75564378|NCT02947893|Drug|Placebo Capsule(s) Once a Day by Mouth|1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
75564379|NCT02947893|Drug|Nilotinib Capsule(s) Once a Day by Mouth|1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
75564380|NCT05141747|Drug|MRG002|Administrated intravenously
75718597|NCT00771680|Drug|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
75419170|NCT01420666|Drug|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
76043439|NCT05505799|Other|Intubation Checklist|A preprocedure checklist will be made available to clinicians, and they will be educated on proper use of the checklist
76043440|NCT05505799|Other|Standard Care|Clinicians will intubate as per their usual practice
75419171|NCT01420666|Drug|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
75419172|NCT01420666|Drug|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
75419173|NCT01420666|Drug|Placebo|placebo, three tablets four times a day, orally, with food
75419174|NCT01420692|Drug|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
75419175|NCT01420692|Drug|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
75564381|NCT05146154|Drug|Imipenem/Cilastatin/Relebactam 1.25g|Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
75564382|NCT00524667|Drug|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until >1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
75564383|NCT05145686|Diagnostic Test|Matris metalloproteinase -2, -8, -9 expressions|. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.
75564384|NCT00524706|Drug|S-1, oral Leucovorin, Oxaliplatin|
75564385|NCT05145179|Drug|SSGJ-705|0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
75564386|NCT04692987|Other|Decision-aid video|Decision-aid video will be developed to disseminate knowledge and to raise awareness on colorectal cancer screening
75564387|NCT05147870|Procedure|Peritoneal irrigation|For patients allocated to the irrigation group, peritoneal lavage was performed at the surgeon's discretion based on surgical findings and preference.
75718598|NCT00771680|Drug|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
76043441|NCT02567227|Other|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
76043442|NCT02567227|Other|Active Control|Computer, multimedia and group based health education programs.
75419176|NCT01420718|Drug|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
75419177|NCT01420718|Drug|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
75564388|NCT05147870|Procedure|Suction only|In the suction only group, one surgical gauze each was placed in the splenophrenic space and Morison's pouch to soak up any remaining purulent fluid followed by turning the patient into the Trendelenburg position for inspection of the lower abdominal cavity. Any interloop adhesions were carefully divided and the gauze-wiping maneuver was used to soak up the residual peritoneal fluid, and all bowel loops were investigated to the root of the mesentery.
75564389|NCT05142644|Procedure|ultrasound|An extra ultrasound performed during pregnancy
75564390|NCT02947542|Device|One-catheter concept|Coronary angiography will be performed using the one-catheter concept.
75564391|NCT02947542|Device|Standard catheter|Coronary angiography will be performed using a standard catheter.
75874044|NCT04051788|Other|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
75874045|NCT03641534|Procedure|Lung Ultrasound examination|Use of lung ultrasound to detect pulmonary complications
75419178|NCT01420744|Drug|BT086|"BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.~Infusion rate:~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period."
75419179|NCT01420744|Drug|1% Human Albumin infusion|"1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)"
75419180|NCT01420757|Procedure|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
75718599|NCT00771680|Drug|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
75874046|NCT03641534|Procedure|Compression ultrasonography (CUS)|CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
75874047|NCT03641534|Procedure|Echocardiography|Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
75874048|NCT03641534|Procedure|Inferior Vena Cava ultrasound|Measurement of the inferior vena cava diameter
75419181|NCT01420796|Other|Swallowing exercise|"Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side."
75564392|NCT02946762|Other|Test and treat|All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
75564393|NCT00507143|Drug|irinotecan|
75564394|NCT00507182|Procedure|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
75564395|NCT00525993|Drug|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
75564396|NCT00525993|Drug|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
75564397|NCT00526032|Procedure|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
75564398|NCT05147714|Device|Surgical Pleth Index (SPI)|SPI data were recorded at one-minute intervals during the last five minutes (6 times in total) until the entropy value reached 60
75564399|NCT02947854|Drug|Fimaporfin (Photosensitizer)|
75564400|NCT02947854|Biological|Hiltonol (Poly-ICLC)|
75564401|NCT02947854|Biological|HPV E7 (Human Papilloma Virus E7) peptides|
75564402|NCT02947854|Biological|KLH (Keyhole Limpet Hemocyanin)|
75564403|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
75564404|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
75564405|NCT05147363|Device|Shockwave Intravenous lithotripsy with a Supera stent|Pre-dilation with the option of using a 2-3mm balloon to cross a lesion for lithotripsy with the shockwave device followed by placement of supera stent.
75718600|NCT02552784|Behavioral|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
75718601|NCT04003558|Other|No interventions|As this is a patient registry, there are no interventions.
75874049|NCT03641534|Procedure|Passive leg raising test (PLR)|Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
75874050|NCT03641534|Procedure|Orthogonal polarization spectral imaging (OPS)|Measurement of capillary flow in the rectal microcirculation
75874051|NCT03641534|Procedure|Urine collection (Foley catheter)|For urinalysis, biochemistry, urine microscopy, pH, and culture.
75564406|NCT00526149|Drug|BI 2536|
75564407|NCT00526149|Other|high performance liquid chromatography|
76043443|NCT02336451|Drug|Ceritinib|LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.
76043444|NCT02374593|Drug|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
76043445|NCT02374593|Device|Ultrasound|
76043446|NCT01648101|Drug|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
75564408|NCT00526149|Other|mass spectrometry|
75564409|NCT00526149|Other|pharmacological study|
75564410|NCT05147285|Other|stabilization exercises|Patients will be applied only online supervised stabilization exercises three times a week for 8 weeks.
75564411|NCT05147285|Other|combined exercises|Patients will be applied online supervised aerobic exercise training and stabilization exercises.Aerobic exercises will be performed for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when stabilization exercises are not performed.
75564412|NCT05147285|Other|Physical activity recommendations|The importance of physical activity will be explained to the patients and appropriate physical activity recommendations will be made.
75564413|NCT00507221|Drug|Albendazole|"Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days"
75564414|NCT00507221|Drug|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
75564415|NCT00507221|Drug|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
75564416|NCT04693299|Diagnostic Test|colonoscopy|A colonoscopy scheduled within the normal pathway of care will be performed. No interventions will be performed.
75564417|NCT00507260|Behavioral|Food Record|A record of the amount and kind of food and drink you intake will be completed.
75564418|NCT00507260|Other|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
75564419|NCT03458793|Behavioral|Group walking and group educational workshops|"The experimental group will take part in 12 week intervention consisting of group walking and group educational workshops.~Group walking sessions will run once weekly for up to 45 minutes each in small groups (up to 8-9 people per group) and will be delivered by a trained walk leader once weekly for duration up to 45 minutes per session.~Group educational workshops will be delivered in the form of a group presentation once weekly for up to 45 minutes by the research team (i.e. the PhD student) on a variety of topics focused on the healthy ageing, such as eye hygiene, mental health and well-being, preventing falls, social support, nutritional guides, physical activity recommendations for older adults and other topics"
75564420|NCT00507338|Procedure|PCI|early PCI for NSTEMI; primary PCI for STEMI
75564421|NCT02946723|Procedure|ultrasound|Lead implantation surgery for SNM using ultrasound guided technique
75564422|NCT02946723|Procedure|X-ray|Lead implantation surgery for SNM using X-ray technique
75564423|NCT05140031|Other|PNE4Adults|"It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain."
75564424|NCT02947737|Other|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
75564425|NCT02947737|Other|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
75718602|NCT00767468|Drug|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
75718603|NCT05074914|Procedure|oesophagectomy|removal of oesophagus
75718604|NCT00812136|Behavioral|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
75874052|NCT03641534|Procedure|Venous blood samplings|for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
75874053|NCT03641534|Procedure|Electrocardiogram|all patients will have an ECG performed on enrolment as a non-invasive investigation
75874054|NCT03641534|Procedure|GlycoCheck|GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
75874055|NCT03643250|Other|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
75874056|NCT03643250|Other|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
75564426|NCT05147012|Other|Data collected|"The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients."
76043447|NCT01648101|Drug|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
75718605|NCT00669032|Device|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
75419182|NCT01420796|Other|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
75564427|NCT04693104|Device|PVA Hydrogel|PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.
75718606|NCT00669032|Other|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
75718607|NCT04001998|Drug|BLD-2660|Randomized to active product
75564428|NCT04693104|Device|Synvisk-One®|Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
75564429|NCT05146934|Radiation|high resolution CT|Ground glass，honeycomb，reticulation, consolidation
75564430|NCT05146895|Drug|Imiquimod treatment|As an control arm, for patients with flat warts
75564431|NCT05146895|Device|Local Hyperthermia at 44℃|As an experimental arm, for patients with flat warts
75718608|NCT04045236|Other|Registry|Data collection
75718609|NCT04045314|Other|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
75718610|NCT00775424|Biological|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
75718611|NCT00775424|Biological|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
75718612|NCT00775424|Biological|PLACEBO|PLACEBO
75718613|NCT00775424|Biological|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
75419183|NCT01420796|Other|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
75419184|NCT01420822|Drug|Fluticasone|Collection of safety data
75718614|NCT04652622|Device|Mindful Garden|Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
75419185|NCT01420835|Other|Auriculotherapy (protocol group)|The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
75419186|NCT01420835|Other|without protocol group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
75564432|NCT02947776|Behavioral|PEER|The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
75564433|NCT02947776|Behavioral|USUAL|The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
75564434|NCT05143073|Behavioral|Alcohol use disorder and strategies to reduce risk educational material|Participants will be directed to educational information (~5 minutes) regarding alcohol use disorder and strategies to reduce risk which they will read.
75718615|NCT00814242|Procedure|surgical resection|radical resection performed in patinets with HCC.
75718616|NCT00814242|Procedure|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
75874057|NCT03643250|Other|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
75874058|NCT03643250|Other|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
75419187|NCT01420861|Drug|GTx-758|two GTx 758 tablets per day
75419188|NCT01420887|Procedure|Continuous Passive Motion|Continuous passive motion.
75419189|NCT01420887|Procedure|Physical Therapy|Physical therapy.
75419190|NCT01420900|Device|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
75419191|NCT01420900|Device|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
75564435|NCT05143073|Behavioral|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material|Participants will be directed to educational information (~10 minutes) regarding complex polygenic risk scores, alcohol use disorder and strategies to reduce risk which they will read.
75419192|NCT01420913|Drug|Pregabalin|Pregabalin 300mg a day
75564436|NCT02946372|Procedure|internal limiting membrane transplantation (ILMT)|internal limiting membrane autologous transplantation (ILMT)
75718617|NCT00775502|Drug|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
75874059|NCT03643250|Other|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
75874060|NCT05692674|Radiation|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;
75874061|NCT02298348|Drug|Sorafenib|Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
75874062|NCT02298348|Drug|Cyclophosphamide|250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
75874063|NCT02298348|Drug|Topotecan|0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
75874064|NCT03643094|Dietary Supplement|Golden Black Seed|1 capsule per day for 8 weeks.
75874065|NCT02929329|Drug|Omecamtiv Mecarbil|Omecamtiv mecarbil tablets for oral administration
75419193|NCT01420952|Drug|[11C]LY2428703|
75419194|NCT01420978|Procedure|CSF Diversion|CSF drainage
75419195|NCT01421004|Drug|TKI258|
75419196|NCT01421030|Procedure|Percutaneous pulmonary valve implantation or open heart surgery|Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
75419197|NCT01421043|Drug|triazolam liquid oral drops|0.25 mg single dose oral drops
75419198|NCT01421043|Drug|triazolam tablets|0.25 mg single oral dose
75419199|NCT01421082|Device|Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)|Lung Volume Reduction Coil (LVRC)
75419200|NCT01421108|Behavioral|Framing (Gain-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
75564437|NCT02946567|Other|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
76043448|NCT01648101|Other|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
76043449|NCT02336373|Drug|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
76043450|NCT02372799|Drug|Vilazodone|
76043451|NCT02372799|Drug|Placebo|
76043452|NCT02372799|Drug|Fluoxetine|
76043453|NCT02566993|Drug|Lurbinectedin (PM01183)|
76043454|NCT02566993|Drug|Doxorubicin (DOX)|
75564438|NCT02946567|Other|Generic Game|Participants will play a generic game without any particular information about hearing health care.
75564439|NCT00524784|Biological|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
75419201|NCT01421108|Behavioral|Framing (Loss-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.~The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing."
75419202|NCT01421121|Biological|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
75419203|NCT01421121|Biological|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
75419204|NCT01421121|Biological|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
75419205|NCT01421121|Biological|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
75564440|NCT00524862|Drug|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
75564441|NCT00524862|Device|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
75564442|NCT05146817|Other|Oral care|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
76043455|NCT02566993|Drug|Cyclophosphamide (CTX)|
76043456|NCT02566993|Drug|Vincristine (VCR)|
76043457|NCT02566993|Drug|Topotecan|
75419206|NCT01421121|Biological|Placebo|0.5ml placebo, two doses, 28 days interval
75419207|NCT01421160|Drug|sodium citrate and citric acid|sodium citrate and citric acid equivalent to 1 mEq/ml bicarbonate (usual dose 10-30 mls/day diluted with water)
75419208|NCT01421173|Drug|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
75564443|NCT02946450|Drug|Other: Not applicable-observational study|
75564444|NCT05149703|Other|Mezieres Postural Treatment|Implementation of 12 weeks suitable postures of Mezieres method
75564445|NCT00524901|Drug|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
75564446|NCT00524901|Drug|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
76043458|NCT05508607|Other|CDI-risk Classification Tool|This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
76043459|NCT05508529|Dietary Supplement|Chaga Mushroom|Effect of chaga on immune/mood support
76043460|NCT05508529|Dietary Supplement|Algae Extract|Effect of algae extract on immune/mood support
76043461|NCT05508529|Dietary Supplement|Black Cumin Seed Oil|Effect of black cumin seed oil on immune/mood support
76043462|NCT05508529|Dietary Supplement|Black Cumin Seed Oil + Astaxanthin|Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support
76043463|NCT05508529|Dietary Supplement|Black Cumin Seed Oil + Omega 3|Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support
76043464|NCT05508529|Dietary Supplement|Placebo|Placebo control
76043465|NCT05505487|Other|integrated care model|The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
76043466|NCT05508451|Procedure|Double jaw surgery|A type of orthognathic surgery
76043467|NCT05508373|Biological|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
75419209|NCT01421173|Drug|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
75419210|NCT01421173|Drug|Busulfan|"AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.~Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5."
75419211|NCT01421173|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
75419212|NCT01421173|Procedure|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
75419213|NCT01421173|Drug|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
75419214|NCT01421173|Drug|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
75419215|NCT01421173|Drug|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
75419216|NCT01421173|Drug|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
75419217|NCT01421199|Procedure|Myringotomy|tube placement for children with multiple ear infections
75419218|NCT01421212|Biological|Hepatitis B Immune Globulin (Boca HBVIg)|"Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses).~Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study."
75419219|NCT01421238|Behavioral|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
75419220|NCT01421316|Radiation|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
75419221|NCT01421368|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
75419222|NCT01421368|Drug|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
75419223|NCT01421368|Drug|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
75419224|NCT01421407|Device|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
75419225|NCT01421433|Drug|Tandrilax|Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
75419226|NCT01421433|Drug|Dolamin Flex|Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
75419227|NCT01421485|Behavioral|Integrated treatment program|CBT, psychopharmacological treatment, family treatment, HIV prevention, case management
75419228|NCT01421485|Behavioral|Treatment as Usual|Treatment in community, case management
76043468|NCT02311881|Drug|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
76043469|NCT02311881|Drug|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
76043470|NCT02311881|Drug|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
75419229|NCT01421550|Procedure|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
75419230|NCT01421550|Procedure|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
75419231|NCT01421563|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
75419232|NCT01421576|Dietary Supplement|High fat meal|offer high fat-meal in the morning before drug intake.
75419233|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
75564447|NCT02954588|Dietary Supplement|Pyridoxamine|
75874066|NCT02929329|Drug|Placebo|Matching placebo tablets
75874067|NCT02929329|Drug|Standard of Care|Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
75874068|NCT03240133|Drug|BCX7353|oral liquid formulation
76043471|NCT02565511|Biological|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
76043472|NCT02565511|Other|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
75419234|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
75419235|NCT01421628|Other|Fitness exercise program|Exercise program, daily frequency, duration of 6 weeks.
75419236|NCT01421680|Dietary Supplement|Ensure powder|Ensure powder(500kcal) per day for 7 weeks
75419237|NCT01421693|Drug|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days~14 years and older - 2g once daily for 7 days~Intravenous infusion. Vials of crystalline powder."
75419238|NCT01421693|Drug|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
75419239|NCT01421706|Drug|Sibutramine-clopidogrel|Sibutramine-clopidogrel
75419240|NCT01421706|Drug|sibutramine-Clarithromycin|sibutramine-Clarithromycin
75419241|NCT01421745|Other|Cultural Competence Education module|A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
75419242|NCT01421758|Behavioral|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
75564448|NCT02954588|Dietary Supplement|Placebo|
75564449|NCT04692792|Dietary Supplement|Placebo drink|consume 1 bottle (50 mL) per day for 8 weeks
75564450|NCT04692792|Dietary Supplement|Dai Dai flower drink|consume 1 bottle (50 mL) per day for 8 weeks
75564451|NCT02954549|Dietary Supplement|Vitamin D3|As in Arms
76043473|NCT02565511|Drug|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
75564452|NCT02946411|Procedure|Cardiac surgery|Glucose level will be measured after cardiac surgery.
75564453|NCT05145608|Drug|Lamotrigine ER tablet 50mg|In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
75564454|NCT05143034|Dietary Supplement|TCI66207 Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
75564455|NCT05143034|Dietary Supplement|Placebo Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
75874069|NCT03240133|Drug|Placebo|oral liquid formulation to match BCX7353
75874070|NCT03814356|Drug|Methylphenidate|IV MPH
76043474|NCT02565511|Other|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
76043475|NCT02565511|Other|Alum|Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
76043476|NCT05505331|Radiation|three-Dimensional ultrasonography|transadominal and transvaginal examination
76043477|NCT05505331|Radiation|Magnetic resonance imaging|multiplanar T2-weighted sequences and pre-contrast T1-weighted imaging in either the sagittal or axial plane
75419243|NCT01421758|Behavioral|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
75419244|NCT01421784|Other|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
75419245|NCT01421823|Drug|alpha agonist ointment|2 weeks local treatment with alpha agonist ointment
75419246|NCT01421823|Drug|Placebo|2 weeks local treatment with placebo ointment
75564456|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
75564457|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
75564458|NCT05146349|Other|Minnesota RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
75564459|NCT00525018|Device|contact heat evoked potential stimulator|
75564460|NCT05146232|Other|induction of anesthesia|induction of anesthesia during gastric sleeve surgery
75564461|NCT05146232|Other|maintainance of anesthesia|maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based
75564462|NCT05146232|Other|monitoring|electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.
75564463|NCT05146232|Other|First postoperative analgesia|IV acetaminophen will be administered every 6 h
75564464|NCT05146232|Other|Second postoperative analgesia|50 mg IV dexketoprofen every 8 h for the first 48 h.
75874071|NCT03642860|Drug|Triheptanoin|Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
76043478|NCT05505331|Procedure|myomectomy|myoma excision
76043479|NCT02561455|Drug|Gilteritinib|oral tablet
76043480|NCT02561299|Device|Peripheral Orbital Atherectomy System|Orbital Atherectomy
76043481|NCT02561299|Device|014 Drug Coated Balloon|Drug Coated Balloon
76043482|NCT04549051|Device|Tenex|Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis
76043483|NCT04549051|Drug|Local anesthetic|Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
76043484|NCT04547413|Behavioral|STI/HIV Intervention Behavioral Intervention Program|In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
76043485|NCT05505253|Drug|Alfacalcidol 0.0005 MG|Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
76043486|NCT05505253|Drug|Placebo|Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
76043487|NCT05501977|Procedure|thoracotomy|thoracic surgery for pulmonary diseases
76043488|NCT04784377|Other|high intensity laser in addition to traditional physical therapy exercises|"high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
75419247|NCT01421836|Procedure|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
75419248|NCT01421836|Procedure|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
75564465|NCT00525096|Drug|placebo|2 tablets twice a day per os
75564466|NCT00525096|Drug|Celecoxib|2*200 mg tablets twice a day per os
75419249|NCT01421862|Genetic|DNA methylation analysis|
75419250|NCT01421862|Genetic|RNA analysis|
75419251|NCT01421862|Genetic|gene expression analysis|
75419252|NCT01421862|Genetic|microarray analysis|
75419253|NCT01421862|Genetic|mutation analysis|
75419254|NCT01421862|Genetic|nucleic acid sequencing|
75419255|NCT01421862|Other|laboratory biomarker analysis|
75419256|NCT01421875|Genetic|DNA methylation analysis|
75419257|NCT01421875|Genetic|RNA analysis|
75419258|NCT01421875|Genetic|gene expression analysis|
75419259|NCT01421875|Genetic|microarray analysis|
75419260|NCT01421875|Genetic|nucleic acid sequencing|
75564467|NCT00525096|Drug|Exemestane|Exemestane 25 mg per day per os
75564468|NCT05142176|Other|Erector spinae catheters insertion|Ultrasound-Guided ESPB The ESPB will be performed with the child in a right lateral decubitus position under aseptic precautions by a high frequency (6-13 MHz) linear ultrasound transducer
75718618|NCT05582668|Procedure|Bariatric surgery|Bariatric surgery
76043489|NCT04784377|Other|low level laser in addition to traditional physical therapy exercises|"patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
75564469|NCT05142176|Drug|Postoperative pain management|IV acetaminophen 15 mg/kg every 8 hours as a component of multimodal analgesia.
76043490|NCT04784377|Other|traditional physical therapy exercises|Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
75564470|NCT00525213|Drug|Rob 803|two capsules per day during 12 weeks
75564471|NCT00525213|Drug|Placebo|two capsules per day during 12 weeks
75564472|NCT04693026|Drug|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
76043491|NCT04541095|Other|EX_IMF|Infant formula with large amounts of beta-palmitate (about 60%).
76043492|NCT04541095|Other|ST_IMF|Infant formula with low amounts beta-palmitate (about 10%).
76043493|NCT02566759|Drug|TAK-831 Oral Suspension|TAK-831 oral suspension.
75419261|NCT01421875|Other|laboratory biomarker analysis|
75564473|NCT04693026|Drug|Baricitinib|Baricitinib oral tablet form
75564474|NCT04693026|Drug|Tocilizumab|Tocilizumab IV Infusion
75564475|NCT02276859|Drug|insulin aspart|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
75564476|NCT02276859|Drug|insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
76043494|NCT02566759|Drug|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
76043495|NCT02566759|Drug|TAK-831 Tablet|TAK-831 tablet.
76043496|NCT04782349|Other|mulligan mobilization with low level laser therapy and traditional physical therapy exercises|"for mulligan mobilization: for improving the limited range of motion of shoulder joint, the therapist will apply posterolateral mobilization for the shoulder joint. Three sets of painless glides of 10 repetitions will be applied with a rest interval of 30 s between each set.~For low level laser application: Laser specifications is as follows: 850 nm wave length and pulsed application with 8 W applied for 20 minutes. laser will be applied over painful points of the shoulder.~For traditional physical therapy exercises: the patients will receive the following exercise program: self stretching exercises for shoulder joint, pully exercises, back climbing exercises, finger ladder exercises, circumduction exercises and pendulum exercises"
75564477|NCT02276859|Drug|insulin glulisine|A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
75419262|NCT01421901|Drug|Ertapenem|Ertapenem i.v,m 1g, once a day, 3 days
75419263|NCT01421901|Procedure|appendectomy|
75564478|NCT05143970|Drug|IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB|"Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD)."
75564479|NCT00526266|Behavioral|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
75564480|NCT00526266|Behavioral|Diaphragmatic Breathing (DB)|"Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping."
75564481|NCT05149547|Diagnostic Test|blood culture versus mNGS detection|peripheral 4ml for mNGS detection
75564482|NCT04692753|Other|Training and education|Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
75564483|NCT05146115|Other|Realization of the Athletic Shoulder Test and the Modified Athletic Shoulder Test|The participants will have to perform both tests two times, with a 7-10 days rest period between the two sessions
75564484|NCT02946606|Drug|GX-H9|Human growth hormone
75564485|NCT02946606|Drug|Genotropin|Human growth hormone
75564486|NCT00525252|Drug|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
75564487|NCT00525252|Drug|placebo|Placebo will be orally administered for 12 consecutive weeks
76043497|NCT04782349|Other|low level laser therapy and traditional physical therapy exercises|patients in this group will receive low level laser and traditional physical exercises as described before for group (A)
75718619|NCT00775580|Drug|Atenolol 100mg Tablets|
75419264|NCT01421914|Other|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
75874072|NCT03642860|Drug|Placebo Oil|Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
75419265|NCT01421927|Drug|Lenalidomide|"Start between Day+100 and Day+120 post-transplant~- Initial dose: 5 mg/day every day~In the absence of thrombocytopenia < 75000/mm3 or neutropenia < 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.~- Duration~until persistent stringent complete response for 3 months~or progression defined by IMWG criteria12~or unacceptable toxicity~or one year after transplant"
75419266|NCT01421940|Drug|Placebo drug|After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
75874073|NCT03707171|Drug|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
75419267|NCT01421940|Drug|Udenafil|After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
75419268|NCT01421953|Device|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
75564488|NCT05149391|Biological|CD19/CD20-directed Chimeric Antigen Receptor T Cells|Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously
75564489|NCT02947191|Biological|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
75564490|NCT02947113|Drug|Cisplatin|Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
75564491|NCT02947113|Radiation|hypofractionated radiotherapy|Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
75718620|NCT00767546|Drug|Botulinum toxin|60- 100 units Local injection to the rash area
75718621|NCT00654498|Drug|Pramipexole|
75718622|NCT00654498|Drug|Placebo|
75718623|NCT00771992|Procedure|Bronchoscopy|Bronchoscopy with segmental allergen challenge
75874074|NCT03707171|Drug|placebo|Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
75874075|NCT03795246|Procedure|Consultation|Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
76043498|NCT04782349|Other|physical therapy exercises|The patients will receive traditional physical therapy exercises only as described before for group (A)
75718624|NCT00670046|Drug|valproic acid|given orally
75718625|NCT00670046|Other|standard of care follow-up|participant follow the standard of care for patient with metastatic prostate cancer
75718626|NCT00814398|Procedure|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
75718627|NCT00814398|Procedure|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
75419269|NCT01421966|Biological|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
76043499|NCT05507983|Drug|Tranexamic acid|Tranexamic acid 1500 mg
75419270|NCT01421966|Biological|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
75564492|NCT02947113|Drug|Pemetrexed|Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
75564493|NCT02947113|Drug|Etoposide|etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
75718628|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
75718629|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
75718630|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
75874076|NCT03795246|Biological|Biological Test|"Blood test:~FSH, LH, E2 and AMH~4 tubes of 7 mL"
76043500|NCT05507983|Drug|Placebo|Placebo, sodium chloride 0.9%
76043501|NCT05501509|Procedure|Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Using a 3-hole third plate and high resistance sutures across the acromioclavicular joint to achieve horizontal and vertical stability of the joint
76043502|NCT05501509|Procedure|Coracoclavicular fixation for the management of an unstable acromiclavicular luxation|Isolated coracoclavicular repair using a 3 hole third plate.
76043503|NCT05501431|Device|Verily Study Watch|The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
76043504|NCT05504785|Device|DexCom G6 continuous glucose monitor|Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).
76043505|NCT05504629|Behavioral|Concurrent training order 1|atag
76043506|NCT05504629|Behavioral|RT+ET|aetaer
75419271|NCT01421979|Dietary Supplement|Energy Drink, Taurine, Caffeine|
75419272|NCT01421992|Drug|Methylphenidate|One Tablet of methylphenidate, 20 mg per day during 3 weeks
76043507|NCT05501197|Other|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
75564494|NCT05149274|Drug|DWP14012 Tablet A|DWP14012 10mg
75564495|NCT05149274|Drug|DWP14012 Tablet B|DWP14012 40mg
75564496|NCT02947464|Procedure|Standard clinical practice|Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.
75564497|NCT02947464|Device|Standard clinical practice + Rapid Maxillary Expansion|Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
75718631|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
75718632|NCT00560391|Drug|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
75718633|NCT00767780|Device|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
75419273|NCT01421992|Drug|Placebo|one tablet placebo per day during 3 weeks
75718634|NCT00775736|Drug|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
75718635|NCT00775736|Drug|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
75874077|NCT03795246|Procedure|Pelvic Ultrasound|Antral Follicles Count
75419274|NCT01422005|Other|Simultaneous Bimanual training|"Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy."
75564498|NCT00525291|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
75718636|NCT00775736|Drug|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
75419275|NCT01422005|Other|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
75419276|NCT01422018|Drug|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
75419277|NCT01422096|Drug|Leuprolide|depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if > 37.5 kg im once
75419278|NCT01422109|Drug|YH14659|YH14659 capsule by oral
75419279|NCT01422109|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
75419280|NCT01422122|Drug|Vitamin D3|4000 mg per day, one tablespoon syrup per day
75419281|NCT01422122|Drug|Placebo|one table spoon Syrup per day
75419282|NCT01422174|Procedure|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
75419283|NCT01422252|Device|Vigi'Fall®|Precocious fall detection device
75419284|NCT01422278|Other|Rehabilitation|Three weeks of rehabilitation in Hospital.
75564499|NCT00525291|Device|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
75564500|NCT02276690|Biological|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
75718637|NCT00942669|Device|SleepStrip OTC(TM)|self contained SAS screening device
75718638|NCT01058629|Device|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
75718639|NCT00537238|Drug|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
75718640|NCT00537238|Drug|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
75718641|NCT00772226|Device|music pillow|according to randomisation patients will receive with/without music.
76043508|NCT05501197|Other|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
75718642|NCT00772226|Device|pillow without music|According to randomisation patients will receive a pillow with/without music
75419285|NCT01422291|Drug|paracetamol|1 gr
75419286|NCT01422291|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
75419287|NCT01422291|Drug|Dexketoprofen|50 mg
75419288|NCT01422291|Drug|Paracetamole|1 gr
75419289|NCT01422317|Drug|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
75419290|NCT01422317|Drug|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
75419291|NCT01422330|Drug|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
75419292|NCT01422343|Procedure|percutaneous transluminal angioplasty femoro-popliteal|percutaneous transluminal angioplasty femoro-popliteal
75419293|NCT01422395|Procedure|Freezing|Vitrification
75419294|NCT01422447|Other|regular intervention|the subjects in the control group live in the used model
75419295|NCT01422447|Other|community intervention|in addition to regular intervention, those subjects in the intervention group will be given education intervention.
75874078|NCT03642704|Drug|Reinforced preventive ARV therapy|"If the mother is HIV-1 or HIV 1/2 infected:~zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight < 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."
76043509|NCT05504473|Device|NEURO-BLINK Device|The NEURO-BLINK is a class IIa medical device that intends to restore the blink function in patients with facial palsy through the application of transcutaneous electrical stimulation.
75564501|NCT02276690|Biological|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
75564502|NCT02947269|Drug|Prucalopride|Prucalopride 2mg capsule
75564503|NCT02947269|Drug|Placebo Oral Capsule|Placebo capsule
75564504|NCT00526305|Drug|Vincristine|1,5 mg/m2 i.v., days 1 and 8
75564505|NCT00526305|Drug|Daunorubicin|60 mg/m2, i.v., days 1 and 8
75564506|NCT00526305|Drug|Prednisone|60 mg/m2 day, i.v. or oral, days 1 to 14
75564507|NCT00526305|Drug|L-Asparaginase|10.000 UI/m2, i.v., days 5-7 and 11-13. Total: 6 doses.
75564508|NCT00526305|Drug|Mitoxantrone|12 mg/m2 i.v days 15, 16 and 17
75564509|NCT00526305|Drug|Cytosine Arabinoside|1.500 mg/m2 /12 hours, days 16, 17 and 18 (total: 6 doses) If slow response to treatment: 3.000 mg/m2/12 hours, days 18, 19, 20 and 21 (8 doses)
75874079|NCT03706937|Other|Semi directive interview|Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
75874080|NCT05682833|Procedure|Non surgical periodontal therapy|Subgingival ultrasonic debridement + manual root planning
75874081|NCT02030964|Drug|DFMO|
75419296|NCT01422460|Biological|Platelet Rich Plasma|"Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)"
75419297|NCT01422473|Device|EnSeal Trio Tissue Sealing Device|For surgery in ligating and dividing vascular tissue during abdominal surgery.
75874082|NCT02030964|Drug|Celecoxib|
75874083|NCT02030964|Drug|Cyclophosphamide|
75419298|NCT01422486|Drug|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
75419299|NCT01422499|Drug|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
75564510|NCT00526305|Drug|Hydrocortisone|10 mg ,15 mg or 20 mg depending of age
75564511|NCT00526305|Drug|Mercaptopurine|50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
75874084|NCT02030964|Drug|Topotecan|
76043510|NCT05504317|Drug|AK111|Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.
76043511|NCT05504317|Drug|Placebo|Subjects will receive corresponding dose of placebo injection subcutaneously.
76043512|NCT05504239|Drug|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
75564512|NCT00526305|Drug|Cyclophosphamide|600 mg/m2 day, i.v., days 1 to 15 in consolidation
75564513|NCT00526305|Drug|Dexamethasone|10 mg/m2 day, oral or i.v. days 1-14 5 mg/m2 day, oral. or i.v., days 15-21
75564514|NCT04696016|Procedure|Skin conductance guided antinociception|The value of skin conductance guides the titration of sufentanil
75564515|NCT04696016|Procedure|Standard care antinociception|The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
75564516|NCT02276768|Drug|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
75874085|NCT03372083|Drug|Deferasirox|Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.
75874086|NCT03044886|Dietary Supplement|vitamin D|Subjects took vitamin D or placebo
75874087|NCT02961764|Drug|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
75874088|NCT02961764|Drug|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
76043513|NCT05504239|Drug|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
76043514|NCT04587661|Behavioral|off-the-shelf digital CBT|Cognitive behavioral therapy for depression and anxiety
75564517|NCT02276768|Drug|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
75564518|NCT02276768|Drug|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
75564519|NCT02276768|Drug|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
75419300|NCT01422512|Biological|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
75419301|NCT01422525|Procedure|spectral domain optical coherence tomography|RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
75419302|NCT01422551|Behavioral|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
75419303|NCT01422551|Behavioral|a psycho-educational control|a single-day psycho-educational seminar
75419304|NCT01422564|Device|Metal on Metal Hip System|Total hip arthroplasty with a metal on metal component system
75419305|NCT01422564|Device|Highly Cross Linked Polyethylene cup System|Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
75419306|NCT01422577|Device|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
75419307|NCT01422577|Device|White light Endoscopy|White light Endoscopy
75419308|NCT01422590|Drug|Sitagliptin|Single oral administration of sitagliptin 100 mg
75419309|NCT01422590|Drug|Mitiglinide|Single oral administration of mitiglinide 10 mg
75564520|NCT02276768|Other|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
75564521|NCT02946255|Behavioral|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
75564522|NCT02946255|Behavioral|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
75874089|NCT03371459|Drug|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
75564523|NCT02946255|Behavioral|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
75874090|NCT03371459|Drug|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
75874091|NCT03642548|Drug|bifico|Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.
75874092|NCT03642548|Drug|placebo|Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
75874093|NCT02961920|Device|IE ratio 1:1|Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
76043515|NCT04587661|Behavioral|adapted digital CBT|Cognitive behavioral therapy for depression and anxiety for individuals from a minority group with SCD
75419310|NCT01422590|Drug|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
75419311|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
75419312|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
75419313|NCT01422616|Drug|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus [maximum bolus dose of 9mg] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
75419314|NCT01422616|Drug|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
75419315|NCT01422616|Other|Intensive blood pressure (BP) lowering|"Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
75419316|NCT01422616|Other|BP management policies|"Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
75419317|NCT01422629|Device|Ultrasonic ablation device|High Intensity focused ultrasound treatment
75419318|NCT01422642|Device|legacy posterior stabilized high-flexion (NexGen LPS-Flex)|NexGen legacy posterior stabilized high-flexion (NexGen LPS-Flex) total knee system
75419319|NCT01422642|Device|legacy posterior stabilized standard (NexGen LPS)|NexGen legacy posterior stabilized standard (NexGen LPS) total knee system
75419320|NCT01422668|Other|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
75419321|NCT01422681|Device|minimally invasive extracorporeal carbon dioxide removal|"The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).~Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min)."
75419322|NCT01422707|Drug|Hydrocortisone|10 mg/m2/per day PO at bedtime (X4 weeks)
75419323|NCT01422733|Drug|Hydrocortisone|10mg/m2/per day PO at bedtime (X12 weeks)
75419324|NCT01422733|Drug|dexamethasone|1 mg PO twice
75419325|NCT01422733|Drug|Cosyntropin|250 micrograms IV twice
75419326|NCT01422733|Drug|rhCG|25 mcg IV twice
75419327|NCT01422772|Biological|VM202RY|0.5mg intramuscular injection
75419328|NCT01422772|Biological|VM202RY|1mg intramuscular injection
75564524|NCT05148221|Other|Questionnaires|Once each participant signs an informed consent form upon agreeing to participate in the study, they will be asked to complete a simple demographic questionnaire including year in program, work schedule, self-reported height and weight, age, and sex. They will also be interviewed by a faculty of university of Wisconsin-Eau Claire (UWEC) regarding their current and past exercise habits, exercise preferences, and perceived exercise barriers. Two questionnaires listed above (Occupational Fatigue Exhaustion Recovery (OFER 15) and Maslach Burnout Inventory (MBI)) will also be completed by each participant on Qualtrics online platform.
75564525|NCT05148221|Other|Actigraph and activPAL devices|Actigraph and activPAL devices will be set up based on the demographic information and will be provided to each participant to wear for 7 consecutive days during all waking hours and sleep, except when bathing or swimming. If the first 7-day monitoring period was an overnight inpatient week, the second 7-day monitoring period will be scheduled during a non-overnight week. A day before the first day of the second monitoring period, a new set of Actigraph and activPAL devices will be delivered to each participant. Once the second monitoring period ends, devices will be retrieved from each participant, and data will be downloaded from devices.
75874094|NCT02961920|Device|IE ratio 1:2|Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
75718643|NCT00946413|Behavioral|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
75419329|NCT01422772|Biological|VM202RY|2mg intramuscular injection
75419330|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
76043516|NCT04651699|Device|Active Transcranial Direct Current Stimulation|The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
76043517|NCT04651699|Device|Sham Transcranial Direct Current Stimulation|The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
76043518|NCT02335983|Drug|Carfilzomib|Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
75564526|NCT00526383|Drug|Tricyclic antidepressants|antidepressant version medical dispositive
75564527|NCT05145257|Dietary Supplement|Elix Cycle Balance|Each day in the morning and at night in the week prior to the menstruation, the participants will take 6 full droppers of Elix Cycle Balance
75564528|NCT05147753|Drug|Moxonidine|0.6 mg moxonidine daily
75564529|NCT00525408|Biological|Mycobacterium w.|Immunomodulator
75564530|NCT00525408|Drug|Docetaxel|Chemotherapeutic agent
75564531|NCT00508235|Behavioral|Questionnaire|Questionnaire about the patient's relationship with their best friend.
75419331|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
75419332|NCT01422811|Behavioral|Multicomponent strategy to reduce avoidable length of stay|"The strategy comprises two integrated components:~Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team."
75419333|NCT01422811|Other|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
75564532|NCT00525447|Drug|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
76043519|NCT02335983|Drug|Lenalidomide|Administered orally once daily on days 1-21 of each 28-day cycle.
76043520|NCT02335983|Drug|Dexamethasone|Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
75564533|NCT00525447|Drug|lenalidomide|Up to 25 mg daily of a 21-day cycle.
75564534|NCT00525447|Drug|dexamethasone|40 mg administered weekly.
76043521|NCT04640311|Drug|Daprodustat|Daprodustat will be available as oral tablets.
76043522|NCT05274529|Behavioral|Psychological health and flexibility|A remote coaching programme concentrating on psychological health and flexibility
76043523|NCT05274529|Behavioral|Work ability|A remote coaching programme concentrating on work ability
76043524|NCT05274529|Behavioral|Sleep and recovery|A remote coaching programme concentrating on sleep and recovery
76043525|NCT05274529|Behavioral|Healthy lifestyle|A remote coaching programme concentrating on healthy lifestyle
76043526|NCT05274529|Other|No coaching|Participants also have the option to choose no coaching for the coming 3 month period.
75564535|NCT00525486|Drug|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
75564536|NCT05145101|Biological|Prevnar13|Patients receive one dose of Prevenar13 followed by one dose of Pneumovax23 2 months later
75564537|NCT02946060|Other|Audiobooks|iPods with audiobooks
75564538|NCT02946060|Other|Tempo-pace synchronized playlists|Playlists with or without RAS
75564539|NCT02946060|Other|Usual Care|iPods containing either a silent track or white noise
75564540|NCT00525564|Drug|Placebo|Placebo diskus inhalation powder
75564541|NCT00525564|Drug|Salmeterol diskus inhalation powder|50 micrograms twice a day
76043527|NCT04578691|Device|"Anatase Spine Surgery Navigation System"|using navigation system in pedicle screw placement in spine surgery
76043528|NCT04578691|Device|Medtronic Stealthstation S7 Treatment Guidance System|using navigation system in pedicle screw placement in spine surgery
76043529|NCT02334423|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
76043530|NCT02334423|Other|0.9% sterile, unpreserved saline|Placebo
76043531|NCT02310789|Drug|Ivacaftor|150mg administered orally twice daily.
76043532|NCT02310789|Drug|β-Adrenergic cocktail|Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
75419334|NCT01422863|Behavioral|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
75564542|NCT04693143|Other|A randomized controlled open-label clinical trial.|This was a single-center; open-label randomized controlled trial performed at a Pediatric Intensive Care Unit (PICU) in tertiary care hospital
75564543|NCT03453125|Behavioral|Spanish modified Story Memory Technique (mSMT)|
75564544|NCT04692909|Device|dTMS with mPFC stimulation|dTMS with Brainsway's H7 device, stimulating the mPFC.
75419335|NCT01422902|Other|Plasticity-based Cognitive Training|
75564545|NCT02953964|Other|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
75564546|NCT02953964|Other|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
75419336|NCT01422902|Other|Non-plasticity-based Training|Computer games
75718644|NCT00946413|Behavioral|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
75718645|NCT03982771|Drug|Bortezomib|-Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
75718646|NCT03982771|Drug|Cyclophosphamide|-Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
75874095|NCT05283668|Biological|i-PRF|"Local anesthesia was achieved using field block technique.~A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~Laser irradiation parameters were adjusted as follows: Wavelength [940 ± 10 nm], irradiation mode [contact continuous wave], Power [2 W] and 300 μm fiber tip diameter (Jokar et al., 2019).~The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
76043533|NCT02310789|Drug|Pilocarpine Nitrate 5%|Administered subcutaneously using Macroduct sweat stimulator device.
76043534|NCT02310789|Device|Macroduct sweat stimulator|
76043535|NCT02372253|Drug|Verapamil|
76043536|NCT02372253|Drug|Placebo|
76043537|NCT02559895|Drug|ALD403|
76043538|NCT02559895|Drug|Placebo|
76043539|NCT02371629|Drug|NVA237|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
76043540|NCT02371629|Drug|Placebo|Placebo to NVA237
76043541|NCT02371629|Drug|Salbutamol|All patients received salbutamol (100 μg) as only rescue medication
76043542|NCT02559817|Drug|Linaclotide Dose A|
76043543|NCT02559817|Drug|Linaclotide Dose B|
76043544|NCT02559817|Drug|Linaclotide Dose C|
76043545|NCT02559817|Drug|Linaclotide Approved Adult Dose|
76043546|NCT02559817|Drug|Matching Placebo|
75564547|NCT02953964|Other|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
75564548|NCT02954003|Device|Endo Bypass System|Subject is implanted with the device for up to 3 years.
75419337|NCT01422928|Procedure|Medical Acupuncture|"Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~GV.14~LI.11 (bilateral)~SP.6 (bilateral)~SP.10 (bilateral)~ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported."
75419338|NCT01422941|Device|CAVU Attune Device|The CAVU Attune device is used with LAGB.
75419339|NCT01422954|Drug|Chloroquine prophylaxis|Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
75419340|NCT01422954|Drug|Mefloquine prophylaxis|Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
75419341|NCT01422954|Biological|Immunization|Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
75718647|NCT03982771|Drug|Dexamethason|Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
75419342|NCT01422954|Biological|Controlled Human Malaria Infection|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
75419343|NCT01422954|Drug|Malarone|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
75419344|NCT01422967|Behavioral|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
75419345|NCT01422980|Other|1- Test dairy product containing specific ingredients|
75419346|NCT01422980|Other|2- Control dairy product without specific ingredients|
75419347|NCT01422993|Other|12 Week Exercise Program|Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
75419348|NCT01423006|Procedure|Radio-Frequency Ablation (RFA) ENCAGE™|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
75419349|NCT01423019|Dietary Supplement|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
75419350|NCT01423019|Dietary Supplement|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
75419351|NCT01423019|Other|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
75419352|NCT01423032|Drug|bendamustine|100 mg/m² iv, day 1+2, q4w
75419353|NCT01423032|Drug|Fludarabine|25 mg/m² iv, days 1-5, q4w
75718648|NCT00775814|Drug|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
75419354|NCT01423123|Drug|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
75419355|NCT01423123|Biological|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
75419356|NCT01423123|Drug|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
75419357|NCT01423136|Device|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
75419358|NCT01423175|Drug|Clofarabine, ara-C|
75419359|NCT01423175|Drug|FLAMSA|
75419360|NCT01423188|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
75419361|NCT01423188|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
75419362|NCT01423214|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
75419363|NCT01423214|Procedure|Laparoscopic surgery|Conventional laparoscopic procedures
75564549|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
75718649|NCT00775814|Drug|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
76043547|NCT05504005|Device|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
76043548|NCT02564887|Device|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
75564550|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
75564551|NCT02954042|Device|Pelvital probe|Pelvital probe
75564552|NCT02954042|Device|Placebo Probe|Placebo Probe
75564553|NCT00526422|Procedure|Dental Preventive|
75419364|NCT01423227|Behavioral|Home-based pulmonary rehabilitation|One home visit plus weekly telephone calls for 8 weeks
75419365|NCT01423227|Behavioral|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
76043549|NCT04517929|Other|Group Psychotherapy|9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
75564554|NCT03459365|Device|Euflexxa|Aspirations performed before each injection and at six weeks.
76043550|NCT04577443|Drug|Adenosine|To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
75419366|NCT01423240|Drug|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
75419367|NCT01423240|Drug|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
75419368|NCT01423240|Drug|Placebo|Placebo once daily orally in the evening
75419369|NCT01423266|Procedure|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
76043551|NCT04577443|Drug|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
76043552|NCT02333487|Drug|Lu AF35700|5 mg tablets for oral administration
76043553|NCT05500729|Other|Hamstrings maximal voluntary isometric contraction.|Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
75564555|NCT00525681|Drug|cyclosporine A|Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.
75564556|NCT00525681|Drug|tacrolimus|Dosing of tacrolimus is given twice daily and individualized as per center practice.
75564557|NCT03455387|Diagnostic Test|sampling of the serum marker sFlt1 and PlGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
75564558|NCT03456635|Other|guided antimicrobial prophylaxis|During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
76043554|NCT05500729|Other|Quadriceps maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
76043555|NCT04411537|Drug|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
75718650|NCT03966885|Behavioral|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
76043556|NCT04411537|Drug|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
76043557|NCT04411537|Drug|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1*28 6/6) or 65mg/m2 qw (UGT1A1*28 6/7)
76043558|NCT04411537|Radiation|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
76043559|NCT05500495|Other|no intervention|no intervention
76043560|NCT05503615|Other|Observational|No application will be made to the control group.
76043561|NCT05503615|Other|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
76043562|NCT05503537|Procedure|post-isometric relaxation technique|Post-isometric relaxation technique will be performed by asking the patient to contract his calf muscles using 20% of his strength. Maintain the contraction for 10 second with 15 second of rest time between each contractions. A total of 4 contractions will be performed.
75564559|NCT04692636|Diagnostic Test|Measure: BP measurements, inter-dialysis BP variability, intra-dialysis hypotension|BP will be measured at the beginning and end of each dialysis session in a seated position by a trained dialysis nurse in accordance with the routine unit practice and entered into an electronic database. BP was measured using validated oscillometric BP monitor equipped in hemodialysis machines (Fresenius 4008S or Nikisso DBB-05), which were maintained as per dialysis unit protocols.
75564560|NCT02955095|Device|Quit Smoking Phone Application|The app will be downloaded on participants' phones, and used by the participant for 30 days to make a quit attempt. Participants will be encouraged to use the app every day and to utilize all of its features, including features such as setting a quit date, taking the assessment section, and entering cigarette use and reasons for cravings
75564561|NCT02276898|Drug|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
75564562|NCT02276898|Drug|Isotonic Saline 0.9% (Placebo)|
75874096|NCT05283668|Procedure|Diode Laser|"Local anesthesia was achieved using field block technique.~A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~Laser irradiation parameters were adjusted as follows: Wavelength [940 ± 10 nm], irradiation mode [contact continuous wave], Power [2 W] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
75874097|NCT03371381|Biological|JNJ-64041757|Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
76043563|NCT05503537|Procedure|Static stretching|Static stretching will be performed by asking patient to perform dorsiflexion till the point of discomfort. The patient will hold the stretch for 15 second and 5 repetitions will be performed.
76043564|NCT05503537|Procedure|Basic Cardiac Rehabilitation Protocol|Ankle pumps, leg slides, walking
76043565|NCT05503459|Other|Bicycle learning|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), bicycle learning (40 min), and cool-down (10 min). In the bicycle training activity, participants were asked to ride on a training bicycle with training wheels to gain better control of the bike in a gradual way. Participants then progressed from the training bicycle to a two-wheel bicycle. To keep participants on the learning curve, they were asked to ride through an obstacle course that was progressively more difficult to negotiate. The obstacles were designed by a focus group, which consisted of four physical education teachers from participating schools and one experienced cycling coach with more than five years of coaching experience.
75564563|NCT00508313|Procedure|Thermal Imaging|Thermal imaging sessions, each taking approximately 10 minutes.
75419370|NCT01423292|Procedure|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
75564564|NCT02945982|Drug|Entecavir+Carvedilol|The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
75874098|NCT03371381|Drug|Nivolumab|Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
75874099|NCT03710681|Biological|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
75874100|NCT03044730|Drug|Capecitabine|Given PO
76043566|NCT05503459|Other|Stationary cycling|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), stationary cycling (40 min), and cool-down (10 min). For stationary cycling activity, they were also asked every 10 mins during exercise to indicate their ratings of perceived exertion (target range: 3-5). Participants were positively reinforced verbally with compliments for their efforts in the training program and their daily improvements were visualized through graphs kept in the child's home.
76043567|NCT04510129|Diagnostic Test|OncoPrism™ assay|OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
76043568|NCT05500027|Diagnostic Test|serum test|serum test of sCD58 and TGFbeta1
75419371|NCT01423292|Drug|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
75419372|NCT01423292|Drug|Placebo|placebo
75419373|NCT01423305|Drug|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
75419374|NCT01423305|Drug|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
75419375|NCT01423318|Drug|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
75419376|NCT01423318|Drug|placebo|single dose subcutaneously
76043569|NCT04630171|Device|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
75564565|NCT02945982|Drug|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
75564566|NCT00508352|Procedure|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
75564567|NCT02947230|Other|Tailored Knowledge Translation|Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
75564568|NCT02954393|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
75718651|NCT03966885|Behavioral|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
75874101|NCT03044730|Other|Laboratory Biomarker Analysis|Correlative studies
75874102|NCT03044730|Biological|Pembrolizumab|Given IV
75419377|NCT01423357|Other|Condom distribution and peer education|Condom distribution and condom demonstrations by youth peer educators at least twice a week
75419378|NCT01423370|Drug|YHD1023|5g oral once daily
75419379|NCT01423370|Drug|YHD1023|5g oral twice a day
75419380|NCT01423370|Drug|YHD1023|10g oral once daily
75419381|NCT01423370|Drug|Cialis|5mg oral once daily
75419382|NCT01423370|Drug|Placebo|Oral
75564569|NCT02954393|Drug|Metronidazole active phase|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
75564570|NCT02954393|Drug|Metronidazole healing phase|Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
75718652|NCT04048148|Device|Novel designed myopia control spectacle lenses|A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.
75874103|NCT03737058|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
75419383|NCT01423409|Device|pictorial VAS|Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
75419384|NCT01423409|Device|usual VAS|usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
75419385|NCT01423435|Drug|TRK-100STP|oral
75419386|NCT01423448|Other|bulletin board|An asynchronous online bulletin board for people with experience of depression
75419387|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
75419388|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
75419389|NCT01423487|Drug|Metformin|0.5g bid 26 weeks
75419390|NCT01423487|Other|Starch tablets|0.5g bid 26 weeks
75419391|NCT01423500|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
75419392|NCT01423500|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
75419393|NCT01423500|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
75419394|NCT01423500|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
75419395|NCT01423500|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
75419396|NCT01423500|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
75419397|NCT01423500|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
75419398|NCT01423513|Other|Fibular Taping|Tape with be applied with tension.
75419399|NCT01423513|Other|Sham Taping|Tape will be applied without tension
75419400|NCT01423526|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, single administration
75419401|NCT01423526|Drug|Placebo|Placebo tablets, oral administration, single administrations
75718653|NCT00772460|Device|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
76043570|NCT04630171|Device|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
75419402|NCT01423539|Drug|bendamustine|Intravenous repeating dose\n
75419403|NCT01423539|Drug|navitoclax|Oral repeating dose\n
75419404|NCT01423539|Drug|rituximab|Intravenous repeating dose\n
75419405|NCT01423565|Device|Deep Brain Stimulation (Medtronic, Activa PC)|"Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently crossed over to receive the other type of stimulation"
75564571|NCT02954393|Drug|Amoxicillin active phase|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
75564572|NCT02954393|Drug|Amoxicillin healing phase|Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
75564573|NCT02954393|Drug|Placebos active phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
75564574|NCT02954393|Drug|Placebos healing phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
75874104|NCT05476887|Drug|KP104|KP104 intravenously (IV loading + subcutaneous [SC] maintenance every week [QW] or every 2 weeks [Q2W]) will be administered.
75874105|NCT02961374|Drug|Erlotinib|Given PO
75874106|NCT02961374|Drug|Erlotinib Hydrochloride|Given PO
75874107|NCT05468853|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting medial prefrontal cortex
75874108|NCT05468853|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the inion
75874109|NCT04700787|Drug|Sulopenem|sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
75564575|NCT02947152|Drug|HKT288|Cadherin-6-targeting antibody-drug conjugate for intravenous administration
75419406|NCT01423578|Behavioral|Hatha Yoga (HY)|3 Sessions of yoga instruction
75564576|NCT02954276|Drug|Omexa Sublingual Sumatriptan tablet|75 mg
75718654|NCT03965403|Device|Arm motor function retraining with BURT|Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
75718655|NCT00775892|Device|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
75564577|NCT02954276|Drug|Imitrex Oral Product|100 mg
75718656|NCT00775970|Behavioral|walking activity|
75874110|NCT04783233|Biological|Chitosan succinamide|Chitogel will be tested for suitability as a packing material in tympanoplasty surgery.
75874111|NCT04783233|Biological|Gelfoam|Gelfoam is the current packing material for tympanoplasty surgery.
75874112|NCT05248035|Other|Adult patient hospitalized in ICU|acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
75874113|NCT02714049|Behavioral|sex therapy|60 minutes each time, in person or on the telephone
75874114|NCT02714049|Drug|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
75419407|NCT01423578|Behavioral|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
75419408|NCT01423578|Behavioral|Smoking Cessation Counseling|4 smoking cessation counseling visits.
75419409|NCT01423591|Drug|infliximab|Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
75419410|NCT01423591|Drug|inactive powder|Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
75419411|NCT01423656|Drug|LEO 29102|
75564578|NCT02947074|Behavioral|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
75564579|NCT00507494|Drug|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
75564580|NCT00526500|Behavioral|Tilt Table With Integrated Stepping System|Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.
75564581|NCT00507533|Procedure|Continuous positive airway pressure|
75718657|NCT00942747|Drug|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
75874115|NCT04777539|Other|At-home natalizumab treated MS patient|"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"
75874116|NCT02951429|Drug|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
75874117|NCT02951429|Drug|Placebo|Placebo matched with sildenafil.
75874118|NCT02951429|Drug|Sildenafil|Sildenafil will be given as 20 mg, TID.
76043571|NCT04630171|Other|Group #3: Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
75564582|NCT00526539|Other|Total hip replacement, Spectron and Taperloc|
75718658|NCT03863470|Behavioral|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
75718659|NCT00946491|Drug|Haloperidol 10 mg Tablets (Cord Laboratories)|
76043572|NCT04630171|Device|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
76043573|NCT04630171|Device|Group #5: Ultrasound (US) utilized for identification of site for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
75564583|NCT00507611|Procedure|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
75419412|NCT01423656|Drug|Placebo|Placebo Comparator: LEO 29102 vehicle
75419413|NCT01423695|Drug|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
75419414|NCT01423708|Drug|Everolimus|Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of >5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels <5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
75564584|NCT00507650|Dietary Supplement|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
75564585|NCT00507650|Dietary Supplement|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
75564586|NCT02946957|Behavioral|Cognitive Behavior Therapy for Insomnia|Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
75564587|NCT02946957|Behavioral|Education Only Control|Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
75564588|NCT00507806|Drug|perflutren lipid microsphere|
75564589|NCT00526578|Behavioral|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
75419415|NCT01423721|Drug|Bromihexine hydrochloride syrup|syrup
75564590|NCT00508430|Drug|ASP8825|oral
75564591|NCT00508430|Drug|Placebo|oral
75718660|NCT00946491|Drug|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
75718661|NCT00776126|Device|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
75718662|NCT03336190|Behavioral|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
76043574|NCT04630171|Other|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
75564592|NCT00526617|Drug|ABT-888|Oral capsules
75564593|NCT00526617|Drug|Temozolomide|Oral capsules
75564594|NCT00507845|Drug|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
75564595|NCT04693065|Other|ponseti|Standard of care, treatment by ponseti method
75718663|NCT00776204|Device|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
75718664|NCT00776204|Device|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
75718665|NCT00776204|Device|Taxus Libertè|Taxus Libertè stent placed in coronary artery
75419416|NCT01423721|Drug|Bromihexine hydrochloride granules|granules
75419417|NCT01423747|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
75419418|NCT01423747|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
75419419|NCT01423747|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
75419420|NCT01423747|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
75419421|NCT01423747|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
75419422|NCT01423747|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
75419423|NCT01423747|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
75419424|NCT01423786|Dietary Supplement|Early Oral Nutrition|Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
75419425|NCT01423799|Dietary Supplement|Nutritional supplements containing arginine, n-3 and nucleotides|Nutritional intervention with immuno-nutrients
75419426|NCT01423799|Dietary Supplement|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
75419427|NCT01423825|Biological|Sub C gp140 Vaccine|100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
75419428|NCT01423825|Biological|MF59C.1 Adjuvant|MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
75419429|NCT01423825|Other|Sodium chloride|Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
75419430|NCT01423838|Drug|Solifenacin|5 mg, oral, once in a day
75419431|NCT01423838|Drug|Oxybutynin|5 mg, oral, three times in a day
75419432|NCT01423864|Drug|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
75419433|NCT01423864|Drug|solumedrol|Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 > FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
75718666|NCT04011969|Diagnostic Test|Score assessment|Asia Pacific Colorectal Screening (APCS) is a validated tool to predict the risk of colorectal cancer in asymptomatic Asian population. The scoring system comprises of three categories: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-7). Patients with moderate and high risk will undergo further examinations.
75718667|NCT04011969|Diagnostic Test|Blood sampling|"Blood samples will be taken before colonoscopy procedure to evaluate the level of serum CEA by ELISA method and to evaluate the presence of NF-ҡB by immunohistochemical method.~Carcinoembryonic antigen (CEA) is a well-known marker for colorectal cancer. A pre-treatment serum CEA level of ≥ 5 ng/mL is associated with poor prognosis in colorectal cancer patients.~NF-ҡB is a chronic inflammation marker found in colorectal cancer patients."
75419434|NCT01423890|Genetic|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
75718668|NCT04011969|Diagnostic Test|Fecal sampling|"Fecal samples will be taken before colonoscopy procedure to be tested for FIT and to evaluate the gut microbiome.~Fecal immunochemical test (FIT) is a recommended screening method for colorectal cancer. Detection of hemoglobin over a certain level in fecal samples indicated a positive FIT. Patients with positive FIT will undergo further examinations.~Gut microbiome examination will be conducted with next generation sequencing (NGS) method."
75419435|NCT01423903|Drug|OPB-51602|A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
75419436|NCT01423929|Drug|Oxygen|Fitting of Oxymask TM and treatment with 10 L O2/min
75419437|NCT01423929|Device|Room air|Fitting of Oxymask TM
75419438|NCT01423955|Drug|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
75419439|NCT01423955|Drug|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
75419440|NCT01423968|Biological|Lipopolysaccharide infusion|Lipopolysaccharide 4 nanogram/kg body weight
75419441|NCT01423968|Other|saline|
75419442|NCT01423994|Procedure|pacemaker|"A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.~Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.~Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.~Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on."
75419443|NCT01423994|Procedure|implantable loop recorder|The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate <50 bpm, High Heart Rate >165 bpm, and Pause > 3 seconds.
75419444|NCT01424007|Behavioral|Weight loss|Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
75419445|NCT01424020|Other|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
75718669|NCT05355610|Drug|Gentamicin|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
75419446|NCT01424046|Drug|basal insulin glargine|Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
75419447|NCT01424046|Drug|standard therapy|Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
75419448|NCT01424059|Other|WEDQ-B (questionnaire)|Questionnaires are answered after delivery; within 48 hours and after five weeks
75419449|NCT01424111|Drug|Escitalopram|An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
75419450|NCT01424111|Other|Healthy Control|No Treatment
75419451|NCT01424124|Drug|YHD001 dose level 1|Tablet, three times daily / 8 weeks
75419452|NCT01424124|Drug|YHD001 dose level 2|Tablet, three times daily / 8 weeks
75419453|NCT01424124|Drug|Singulair|Tablet, one times daily / 8 weeks
75419454|NCT01424124|Drug|Placebo|Tablet, one times daily / 7 days
75419455|NCT01424137|Device|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
75419456|NCT01424137|Device|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
75419457|NCT01424137|Device|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
75419458|NCT01424150|Other|Liberal fluid therapy|Liberal protocol group is designed to provide approximately 6.0L per day.
76043575|NCT05503381|Procedure|Laparoscopic radical resection of low rectal cancer with transanal specimens|According to the standard laparoscopic anterior rectum resection, the rectum was separated 2-3cm below the tumor, the rectum was severed 1-2cm from the lower edge of the tumor, the rectal stump was connected with the tumor through the anus, and the sigmoid colon was severed 10cm from the upper edge of the tumor. The stapler head was placed in the sigmoid colon stump, and then the sigmoid colon stump was closed with a linear cutting closure device. Then, the sigmoid colon stump is returned to the abdominal cavity through the anus, the distal rectal stump is closed with a suture purse or a linear cutting closure device, and the stapler body is inserted through the anus, and then the anastomosis is completed.
75419459|NCT01424150|Other|Restrictive fluid therapy|Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
75419460|NCT01424163|Drug|Single dose reduced|Treatment 1 (Part A)
75419461|NCT01424163|Drug|Single dose standard|Treatment 2 (Part A)
75419462|NCT01424163|Drug|Multiple Dose|Treatment 3 (Part A)
75718670|NCT05355610|Drug|Dexamethasone|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
76043576|NCT04696081|Other|occurence of atrial fibrillation|all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
76043577|NCT05503147|Drug|Sativex|Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
75419463|NCT01424163|Drug|Multiple Dose|Part B
75419464|NCT01424176|Drug|Dexpramipexole (dose 1)|
75419465|NCT01424176|Drug|Dexpramipexole (dose 2)|
75419466|NCT01424202|Device|Mechanical Insufflation Exsufflation|"After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse."
75419467|NCT01424241|Drug|Sandostatin LAR|This will be a open label dose escalation study of Sandostatin LAR 10 Mg, 20Mg, 30 Mg up to 40 mg if necessary.
75419468|NCT01424254|Device|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
75419469|NCT01424254|Procedure|Push-Enteroscopy|currently recommended standard
75419470|NCT01424267|Device|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
75419471|NCT01424280|Drug|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
75419472|NCT01424280|Drug|Placebo|Single dose of matching placebo tablets
75419473|NCT01424319|Drug|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
75564596|NCT02946177|Biological|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
75564597|NCT02946177|Other|Sterile Saline|0.5 mL of sterile Saline administered im
75564598|NCT04693455|Drug|ZD03|ZD03 capsule
75564599|NCT04693455|Other|Placebo|placebo capsule
75564600|NCT02946138|Radiation|carbon-ion radiotherapy|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
75564601|NCT00507884|Procedure|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
75564602|NCT00507962|Drug|Cisplatin|100 mg/m^2 Intraarterial On Day 1 Every 4 Weeks
75419474|NCT01424319|Drug|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
75419475|NCT01424319|Drug|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
76043578|NCT04619095|Dietary Supplement|Psyllium|See the information already included in the arm descriptions.
76043579|NCT04619095|Dietary Supplement|Placebo|See the information already included in the arm descriptions.
75419476|NCT01424332|Drug|Darexaban|oral
75564603|NCT00507962|Drug|Liposomal Doxorubicin|Starting dose 20 mg/m^2 IV On Day 1 Every 4 Weeks
75564604|NCT02946099|Procedure|Reciproc files in reciprocating motion|An endodontic file that works through a reciprocating motion
76043580|NCT05499949|Diagnostic Test|NASH screening|Evaluate liver steatosis and elasticity using transient elastography in the FONS group
76043581|NCT05499949|Diagnostic Test|Cardiac dysfunction screening|Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography
76043582|NCT05499949|Diagnostic Test|Liver biopsy|For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure.
76043583|NCT04490005|Other|pupillometry|evaluation of pupillary reflex by using the Neuroptics Pupillometer every 4 hours during ICU stay
76043584|NCT04482595|Drug|BIO 300 Oral Suspension|Suspension of genistein nanoparticles
76043585|NCT04482595|Drug|Placebo|Matched placebo for BIO 300 Oral Suspension
76043586|NCT05499793|Dietary Supplement|Zingiber Officinale powder|Ginger powder
76043587|NCT05499793|Dietary Supplement|Placebo|Starch powder
75564605|NCT02946099|Procedure|ProTaper Next files in continuous rotary motion|An endodontic file that works through a continuous rotary motion
75564606|NCT02954315|Other|Almonds|
75564607|NCT04692948|Other|Chimeric antigen receptor T cells (car-t)|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
75718671|NCT00552669|Drug|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
75718672|NCT00552669|Device|Drug Eluting stent|Any Drug eluting stent
75419477|NCT01424332|Drug|Acetyl Salicylic Acid (ASA)|oral
75419478|NCT01424345|Drug|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
75718673|NCT02557568|Other|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
75718674|NCT00768170|Drug|MK0633|MK0633 (50 mg) Oral, single dose
76043588|NCT05499715|Biological|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
76043589|NCT04557553|Dietary Supplement|Lagenbone|Traditional Chinese medicine herbal formula
76043590|NCT05502991|Drug|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
76043591|NCT02333331|Drug|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
76043592|NCT02333331|Other|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
76043593|NCT02563561|Drug|Apaziquone|One dose of apaziquone administered by intravesical administration
76043594|NCT02563561|Other|Placebo|Matching placebo (containing 12 mg FD&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
75419479|NCT01424345|Drug|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
75419480|NCT01424358|Other|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
75419481|NCT01424384|Drug|Citalopram|Neurophysiological testing.
75564608|NCT00508508|Behavioral|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
75718675|NCT00943059|Drug|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
75419482|NCT01424384|Drug|GSK424887|Neurophysiological testing
75419483|NCT01424384|Drug|Plactebo To Match|Neurophysiological testing
75419484|NCT01424423|Drug|Placebo|Placebo
75419485|NCT01424423|Drug|GSK1223249|I.V. Infusion
75419486|NCT01424436|Biological|GSK933776|1mg/kg dose group
75564609|NCT00508508|Behavioral|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
75564610|NCT02485938|Drug|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
75718676|NCT00943059|Drug|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
75874119|NCT04622709|Drug|Furosemide (loop diuretic) Tablets|Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not >320mg/day for the 2nd & 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not >320mg/day for the 2nd & 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
75419487|NCT01424436|Biological|GSK933776|3mg/kg dose group
75419488|NCT01424436|Biological|GSK933776|6mg/kg dose group
75419489|NCT01424449|Radiation|[11C]PHNO|examine the effects of [11C]PHNO mass carry-over and displaceable binding
75419490|NCT01424449|Drug|Aripiprazole|A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)
75419491|NCT01424462|Drug|A|Single dose treatment IR formulation
75419492|NCT01424462|Drug|B|Low Extended release single dose
75419493|NCT01424462|Drug|C|Medium extended release formulation
75419494|NCT01424462|Drug|D|High extended release rate single dose
75419495|NCT01424475|Genetic|Healthy|Healthy Volunteers
75419496|NCT01424475|Genetic|PKD Patients|PKS Patients
75419497|NCT01424488|Drug|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
75564611|NCT00508586|Drug|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
75564612|NCT02946216|Genetic|ctDNA analysis|
75718677|NCT00943137|Drug|5-Fluorouracil|"Chemotherapy will be one of the following:~de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
75718678|NCT05547568|Procedure|Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy|
75564613|NCT00508040|Drug|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
75564614|NCT00508040|Drug|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
75564615|NCT02946840|Device|FNA with 25 G Beacon needle|
75419498|NCT01424488|Drug|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
75419499|NCT01424540|Drug|GSK2336805 150mg|Single Dose
75564616|NCT00508664|Radiation|Radiation|Radiation start in week 11
75874120|NCT03706859|Procedure|Pneumatic tourniquet inflation pressure|Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
75419500|NCT01424540|Other|Placebo|Single Dose
75419501|NCT01424553|Other|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
75564617|NCT00508664|Drug|Cetuximab|Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
75564618|NCT00508664|Drug|Docetaxel|75 mg/m2 i.v. day 1 3 times
75564619|NCT00508664|Drug|Cisplatin (TP)|75 mg/m2 i.v. day 1 3 times
75564620|NCT00508664|Drug|5-Fluorouracil (TPF) (only until Feb 2009)|Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
75564621|NCT02946684|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
75564622|NCT02946684|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
75419502|NCT01424579|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
75564623|NCT02953379|Drug|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
75564624|NCT02953379|Drug|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
75564625|NCT02946645|Device|Neuromuscular Bite (orthotic/sub-lingual)|Bite is a device which simulates a set of properly positioned teeth
75564626|NCT02946645|Procedure|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises~Place knuckle of index finger between top and bottom teeth.~Remove it, keeping the teeth separated one-knuckle apart.~Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
75564627|NCT02946645|Other|Placebo|No interventions.
75564628|NCT02954120|Other|no intervention provided|
75564629|NCT02946801|Drug|Essential oils|
75564630|NCT02946801|Drug|Essential oils without alcohol|
75564631|NCT02946801|Drug|Sterile water|
75564632|NCT02953808|Drug|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
75564633|NCT02953808|Drug|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
75564634|NCT02953847|Drug|Rimactane|150 mg capsules, Sandoz MCC registration # A/20.2.3/784
75564635|NCT02953847|Drug|Rifafour e-275|Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
75564636|NCT02953847|Drug|Rimactazid 150/75|Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
75419503|NCT01424579|Other|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
75564637|NCT00526695|Drug|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
75564638|NCT02953730|Drug|PEG-rhG-CSF|
75564639|NCT00526929|Drug|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
75419504|NCT01424579|Other|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
75564640|NCT02953691|Drug|Galacto-Oligosaccharide|Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
75564641|NCT02953691|Drug|Maltodextrin (Placebo)|Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
75564642|NCT02953535|Drug|Magicbuvir|1 tablet contains 400 mg sofosbuvir
75564643|NCT02953535|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
75564644|NCT02953535|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
75564645|NCT02953613|Device|NIRS/IVUS|Cardiac catheterization using infraredx
75564646|NCT02953574|Procedure|daily sleep enhancement nursing protocol|
75564647|NCT00526734|Biological|filgrastim|
75419505|NCT01424592|Device|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
75564648|NCT00526734|Biological|pegfilgrastim|
75564649|NCT00526734|Drug|melphalan|
75419506|NCT01424605|Procedure|DLT intubation|Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
75564650|NCT00526734|Procedure|autologous hematopoietic stem cell transplantation|
75419507|NCT01424618|Drug|Leuprolide|leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
75419508|NCT01424618|Drug|Ganirelix|Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
75419509|NCT01424631|Procedure|single incision laparoscopic appendectomy|
75419510|NCT01424631|Procedure|conventional laparoscopic appendectomy|
75419511|NCT01424657|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography
75564651|NCT00508703|Radiation|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
75564652|NCT00508703|Procedure|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
75564653|NCT00526773|Other|telephone management plus a motivational intervention|heart failure intervention
75564654|NCT00526773|Other|telephone management with standard patient education|heart failure intervention
75564655|NCT02953496|Drug|vonapanitase|Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
75564656|NCT00508781|Behavioral|Multiphoton laser image in cutaneous pathology|
75564657|NCT00508859|Drug|Sertraline|maintenance treatment with sertraline
75564658|NCT00508859|Drug|placebo|placebo
75564659|NCT00526851|Other|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
75419512|NCT01424657|Procedure|MRCP|magnetic resonance cholangiopancreatography
75419513|NCT01424709|Drug|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
75419514|NCT01424709|Drug|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
75564660|NCT00508898|Drug|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
75564661|NCT00508898|Drug|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
75564662|NCT02944890|Device|Drug Eluting Balloon Catheters(RESTORE DEB）|
75564663|NCT02944890|Device|Drug Eluting Balloon Catheters(SeQuent® Please）|
75564664|NCT00508937|Other|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
75564665|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
75564666|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
75564667|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
75564668|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
75718679|NCT00772616|Drug|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
75419515|NCT01424735|Drug|Mycobacterium w.(Mw)-freeze dried extract 0.5ml|0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
75419516|NCT01424748|Dietary Supplement|Tahitian Noni Juice|noni fruit juice
75419517|NCT01424748|Dietary Supplement|Placebo|Placebo juice
75564669|NCT04692558|Biological|HYALURONIC ACID|Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.
75419518|NCT01424761|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 300 mg/d (150 mg/bid)
75419519|NCT01424761|Other|Placebo|Placebo :starch
75419520|NCT01424774|Drug|CardioGen-82|CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
75419521|NCT01424800|Device|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
75564670|NCT04692558|Procedure|coronally advanved flap with connective tissue harvesting|Coronally advanced flap surgery with connective tissue harvesting from palate
75564671|NCT02952599|Drug|Edoxaban|Prescribed according to approved label
75718680|NCT00772616|Drug|Sufentanil|dosage according to usual criteria
75718681|NCT00768326|Drug|Zicronapine|"Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks"
75718682|NCT00768326|Drug|Zicronapine|"Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks"
75564672|NCT00526968|Drug|EVT 101|8 mg capsule, single oral dose
75564673|NCT00526968|Drug|EVT 101|15 mg capsule, single oral dose
75874121|NCT05682755|Drug|Chidamide|initial time：platelet count ≥50×10^9/L after allo-HSCT initial dose: 5 mg oral twice weekly initial adjustment: according to the platelet count tested weekly platelet count ≥50×10^9/L-increased by 5 mg 20×10^9/L≤ platelet count <50×10^9/L-remains unchanged platelet count <50×10^9/L- reduced by 5 mg maximum dose: 20 mg oral twice weekly terminal time: 180 days after allo-HSCT
75874122|NCT01312103|Behavioral|Internet-based safety decision aid|"Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan."
75874123|NCT01312103|Behavioral|Usual Care Safety Plan|"Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource."
75874124|NCT03708887|Drug|Low dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 1 g/d by mouth for 1 year
75564674|NCT00526968|Drug|placebo|Placebo capsule, single oral dose
75564675|NCT00510419|Drug|"InvestigationalAuto-injector (sumatriptan succinate)"|
75874125|NCT03708887|Drug|High dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
75874126|NCT03708887|Drug|Control drug|Matching placebo capsules,1 g/d by mouth for 1 year
75874127|NCT05321537|Other|Therapeutic exercises|A somatosensory training and an endurance-strength training protocol
75564676|NCT00527007|Other|External cooling|External cooling
75564677|NCT00510536|Drug|Acetaminophen|dose to be determined by investigator
75564678|NCT00510536|Drug|NSAID|dose to be determined by investigator
75564679|NCT03458715|Drug|SGLT2 inhibitor (Empagliflozin 25 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
75564680|NCT03458715|Drug|DPP4 inhibitor (Linagliptin 5 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
75564681|NCT00510575|Device|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
75718683|NCT00768326|Drug|Zicronapine|"Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks"
75718684|NCT00768326|Drug|Zicronapine|"Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"
75718685|NCT00768326|Drug|Zicronapine|"Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"
75718686|NCT00768326|Drug|Placebo|"Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks"
75718687|NCT00951717|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
75718688|NCT00768404|Drug|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
75874128|NCT04595019|Radiation|SBRT|Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
75874129|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
75564682|NCT02944812|Drug|Chidamide|Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained.
75564683|NCT00510614|Drug|tinidazole|1 gram twice weekly for 12 weeks
75874130|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
75718691|NCT00776282|Drug|loratadine 10 mg orally disintegrating|
75718692|NCT00943293|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
75718693|NCT00943293|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
75718694|NCT00943293|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
75718695|NCT00776360|Drug|oxytocin|80mIE/min as continuous infusion for 70 minutes
75718696|NCT00776360|Drug|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
75874131|NCT05228145|Genetic|NGN-101|Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.
75874132|NCT05214807|Device|KiOmedine® CM-Chitosan|KiOmedine® CM-Chitosan is a fluid implant intended for synovial fluid supplementation for the symptomatic treatment of osteoarthritis (OA). This Investigational Medical Device (IMD) is administered via intra-articular injection and is classified as a Class III Device under Council Directive 93/42/EEC (Annex IX, rule 8). A key component of the IMD is a soluble derivative of highly purified chitosan of non-animal origin, an exclusive natural linear glucosamine polysaccharide extracted from the edible white mushroom, Agaricus bisporus. KiOmedine® CM-Chitosan is sterile, non-pyrogenic, resorbable and composed of 2% (w:w) carboxymethyl chitosan (CM-chitosan).
75564684|NCT00510614|Drug|Placebo|one pill twice weekly for 12 weeks
75564685|NCT00508976|Drug|Injected bupivacaine post-operatively|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
75718697|NCT00946725|Drug|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
75718698|NCT00946725|Drug|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
75718699|NCT03041740|Drug|Perfluorooctyl Bromide|Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
75718700|NCT00772694|Drug|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
75718701|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
75718702|NCT00951873|Drug|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
75718703|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
75718704|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.1 mL, Intradermal
75718705|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.5 mL, Intramuscular
75718706|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, Intradermal
75419522|NCT01424826|Drug|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
75419523|NCT01424826|Drug|Rifampicin|< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days > 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
75419524|NCT01424826|Drug|Raltegravir|800 mg bd for 4 days
75564686|NCT00508976|Drug|Streamed bupivacaine versus streamed normal saline|Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
75564687|NCT00508976|Drug|Aerosolized bupivacaine versus aerosolized saline|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
75564688|NCT00508976|Drug|Injected lidocaine pre-incision vs saline pre-incision|Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
76043595|NCT05499481|Drug|Antibiotic|"The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy."
75874133|NCT05214807|Device|Synvisc-One®|Synvisc-One (Hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing Hylan A and Hylan B polymers produced from chicken combs. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. Hylan A has an average molecular weight of approximately 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in buffered physiological sodium chloride solution (pH 7.2 ± 0.3) and is unique in that the hyaluronan is chemically crosslinked.
75564689|NCT00509015|Drug|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S&25mg P/20 kg, 1 day, single dose
75564690|NCT00509015|Drug|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
76043596|NCT05564533|Behavioral|Heart-Smile Training Intensive Introduction Program (HST-IIP)|"Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation."
75564691|NCT00509015|Drug|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
75564692|NCT00509015|Drug|placebo tablets|3 days of lactose tablets (160mg) albochin
75564693|NCT04692246|Other|Plant-based oral rinse|Oral rinse enriched with plant-based essential oils.
75564694|NCT04692246|Other|Placebo oral rinse|Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
75564695|NCT00509054|Procedure|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
75718707|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
75718708|NCT00943371|Drug|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
75718709|NCT00943371|Drug|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
76043597|NCT04413955|Device|Seraph®-100 Microbind® Affinity Blood Filter|Use of an extracorporeal broad-spectrum sorbent hemoperfusion filter to removed SARS-CoV-2 virus and circulating cytokines from the blood
76043598|NCT05498077|Procedure|Body scan meditation|Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
75564696|NCT00509132|Drug|trodusquemine|
75564697|NCT02945202|Device|Biometry|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
75564698|NCT02945202|Device|Refraction|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
75718710|NCT00552513|Procedure|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (and within 24 hours of randomisation).
75718711|NCT00552513|Procedure|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
76043599|NCT04140955|Procedure|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
75419525|NCT01424839|Radiation|craniospinal irradiation|"Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)~Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)~Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)"
75419526|NCT01424839|Drug|Carboplatin, Etoposide, Ifosfamide|• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
75564699|NCT02945202|Device|Corneal Topography|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
75564700|NCT00509210|Drug|telaprevir (VX-950)|
75419527|NCT01424839|Radiation|ventricular irradiation|"Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
75419528|NCT01424839|Drug|Cisplatin, etoposide, Ifosfamide (standard)|Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
75564701|NCT00528060|Drug|Atazanavir|2pills/day
76043600|NCT05497765|Dietary Supplement|Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza|Take 4 tablets with warm water twice a day
75564702|NCT00528060|Drug|Ritonavir|1 pill/day
75718712|NCT00946803|Behavioral|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
75564703|NCT00528060|Drug|Tenofovir/emtricitabine|1 pill/day
75564704|NCT03459560|Drug|PolyPill|After the baseline enrollment and excluding non-eligible participants, we randomized villages to Polypill and control arms. Follow-ups are scheduled for 1, 3, and 6 months after the initial enrollment in the Polypill arm and every six months thereafter. For the minimal care arm, the follow-ups are arranged every six months.
75564705|NCT00527085|Drug|AMG 073|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
75564706|NCT00527085|Drug|Placebo|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
75564707|NCT00509327|Drug|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
75564708|NCT00509327|Drug|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
75564709|NCT02945007|Drug|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
75718713|NCT00943449|Drug|4SC-201|oral administration
75718714|NCT00943449|Drug|Sorafenib|oral administration
76043601|NCT05497765|Dietary Supplement|Silibinin extract|Take 4 tablets with warm water twice a day
76043602|NCT05497765|Dietary Supplement|Placebo|Take 4 tablets with warm water twice a day
75564710|NCT00509405|Drug|potassium citrate|6 times 10 mEq per day, oral for 24 months
75564711|NCT00528099|Drug|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
75564712|NCT00509444|Behavioral|Educational materials|
75564713|NCT00509444|Behavioral|educational materials, plus patient navigation|
75564714|NCT00528138|Other|Laboratory Test|CRP, white blood cell count, hepatic function tests
75564715|NCT00509483|Radiation|Radioactive iodine|Radioactive iodine preceded by rhTSH
75564716|NCT02945865|Other|Pain assessment|Pain assessment with assessment tools
75564717|NCT00510770|Device|CPAP application|
75718715|NCT00952029|Biological|bevacizumab|
75718716|NCT00952029|Drug|FOLFIRI regimen|
75718717|NCT00952029|Drug|fluorouracil|
75718718|NCT00952029|Drug|irinotecan hydrochloride|
75718719|NCT00952029|Drug|leucovorin calcium|
76043603|NCT05564143|Procedure|EUS-guided gastroenterostomy (EUS-GE)|Treatment
76043604|NCT05564143|Procedure|Laparoscopic gastroenterostomy (LGE)|Treatment
76043605|NCT05564065|Procedure|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
76043606|NCT05564065|Procedure|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
76043607|NCT05497609|Other|no intervention. Care as ususal|No intervention
75419529|NCT01424839|Drug|Cisplatin, Etoposide, Ifosfamide (high dose)|Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
75564718|NCT02945709|Behavioral|Personalized Attention control training (ACT)|In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.
75718720|NCT00560313|Biological|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
75874134|NCT02454855|Drug|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
75874135|NCT02454855|Drug|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
75718721|NCT00560313|Biological|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
76043608|NCT04047511|Device|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
76043609|NCT04047511|Behavioral|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.
76043610|NCT04047511|Behavioral|Group Psychoeducation|A single sesstion will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
76043611|NCT03983707|Device|Purastat®|Use of Purastat®
75718722|NCT00667862|Drug|Panobinostat|
75419530|NCT01424839|Radiation|focal irradiation|• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
75419531|NCT01424852|Dietary Supplement|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
75718723|NCT00952107|Device|FLARE imaging system|Testing of operation of imaging system
75718724|NCT00952185|Other|cytology specimen collection procedure|
75718725|NCT00952185|Other|fluorescent antibody technique|
75718726|NCT00952185|Procedure|assessment of therapy complications|
75718727|NCT00776516|Drug|mirabegron|oral
75718728|NCT00776516|Drug|rifampin|oral
75718729|NCT00946959|Procedure|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
75419532|NCT01424865|Genetic|fluorescence in situ hybridization|
75419533|NCT01424865|Other|immunohistochemistry staining method|
75718730|NCT00768638|Drug|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
75718731|NCT00768638|Drug|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
75718732|NCT00952263|Biological|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
75874136|NCT03343067|Drug|elagolix|Tablets
75874137|NCT03343067|Drug|estradiol/norethindrone acetate (E2/NETA)|Capsules
75874138|NCT05205525|Other|Restrictive antibiotic strategy|Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
75419534|NCT01424865|Other|immunologic technique|
75419535|NCT01424865|Other|laboratory biomarker analysis|
75419536|NCT01424891|Drug|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
75419537|NCT01424891|Drug|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
75419538|NCT01424891|Drug|Placebo|treatment with placebo over 8 weeks
75419539|NCT01424904|Dietary Supplement|DGB-01 Supplementation|"Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.~Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks."
75419540|NCT01424956|Device|Automated Breast Ultrasound (ABUS)|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
75419541|NCT01425008|Drug|MLN2480|Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
75874139|NCT05205525|Other|Aggressive antibiotic strategy|Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
75564719|NCT02945709|Behavioral|Non-personalized Attention control training (ACT)|"In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences."
75419542|NCT01425034|Other|casts for the thumb|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
75419543|NCT01425034|Other|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
75419544|NCT01425060|Behavioral|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.
75564720|NCT02945709|Behavioral|Control training.|In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
75718733|NCT02557958|Drug|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
75718734|NCT02557958|Drug|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
75718735|NCT00776672|Drug|Fosinopril 40mg Tablets|
75874140|NCT05196165|Other|No Intervention|No investigational product (IP) will be administered in this study
75874141|NCT04707183|Drug|Lidocaine IV Infusion|Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
75874142|NCT04707183|Drug|2% Lidocaine via ESPB|10 ml of 2% lidocaine will be infused through ESPB in treatment group
75718736|NCT00535132|Drug|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
75718737|NCT00535132|Drug|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
75718738|NCT00570908|Drug|sunitinib|Sutent
75718739|NCT00570908|Drug|capecitabine|concurrently
75718740|NCT00570908|Radiation|WBRT|Whole Brain Radiotherapy 30 Gy in 10 fractions
75874143|NCT04703205|Drug|Ivermectin 3 MG|Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state)
75874144|NCT04703205|Drug|Placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
75874145|NCT03706781|Drug|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer|Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
76043612|NCT04424875|Drug|3 mg melatonin|patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
75874146|NCT03706781|Drug|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%|Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
76043613|NCT04424875|Drug|Placebo|patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
76043614|NCT05563363|Other|Hospital-like treatment in patients' home|Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.
75564721|NCT00509561|Biological|cetuximab|
75564722|NCT00509561|Drug|capecitabine|
75564723|NCT00509561|Drug|cisplatin|
75419545|NCT01425060|Other|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
75419546|NCT01425073|Other|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
75419547|NCT01425086|Device|Embrace, PCM, warming blanket|"Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment."
75419548|NCT01425099|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
75419549|NCT01425099|Drug|Prednisone|Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
75874147|NCT04681365|Other|Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)|Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)
75874148|NCT03706703|Drug|Endostar|continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
76043615|NCT05563363|Other|standard inpatient treatment|Inpatient treatment on addiction ward
76043616|NCT03961555|Biological|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
75874149|NCT03706703|Drug|Docetaxel|docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
75564724|NCT00509561|Radiation|radiation therapy|
75419550|NCT01425125|Drug|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
75419551|NCT01425151|Device|i-Gel|Oropharyngeal leak pressure Insertion success
75419552|NCT01425151|Device|ProSeal|Oropharyngeal leak pressure Insertion success
75419553|NCT01425164|Drug|Ivabradine|ivabradine tablets, 5 to 7.5 mg bis-in-die.
75419554|NCT01425164|Drug|Carvedilol|carvedilol tablets, 12.5 to 25 mg bis-in-die.
75564725|NCT02945943|Other|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
75564726|NCT02945943|Other|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
75564727|NCT00509639|Drug|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
75874150|NCT03706703|Drug|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
75874151|NCT03706703|Drug|Pemetrexed|pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
76043617|NCT03961555|Biological|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
76043618|NCT03961555|Biological|Rabies vaccine|it should be administered in deltoid muscle
76043619|NCT04277845|Drug|Bortezomib, Lenalidomide, Dexamethasone|Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
76043620|NCT03874117|Other|Twice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
76043621|NCT03874117|Other|Thrice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
75419555|NCT01425177|Procedure|Normal Saline Irrigation|After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
75419556|NCT01425216|Drug|Sorafenib|Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
75419557|NCT01425242|Drug|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
75419558|NCT01425242|Drug|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
75564728|NCT02945904|Procedure|adrenalectomy|Unilateral adrenalectomy for Conn's adenoma
75874152|NCT05279573|Dietary Supplement|Omega-3 and/or botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
75874153|NCT05279573|Other|Control product consumption|Product with identical characteristics to the experimental product. Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
75419559|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
75874154|NCT05182905|Drug|AZD1390|"Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy"
75874155|NCT05682287|Device|448kHz capacitive resistive monopolar radiofrequency|Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
75874156|NCT05682287|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
75874157|NCT05642403|Drug|XW001|Inhaled XW001
75874158|NCT05642403|Drug|Placebo|Matched inhaled placebo
76043622|NCT05497141|Device|Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
75419560|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
75564729|NCT02952716|Biological|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
75564730|NCT02952716|Other|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
75874159|NCT03706547|Biological|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
75874160|NCT03706547|Drug|Fludarabine|30mg/m2/d
75874161|NCT03706547|Drug|Cyclophosphamide|300mg/m2/d
76043623|NCT02559505|Biological|Seasonal IIV 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
76043624|NCT02559505|Other|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
75884250|NCT05579210|Behavioral|Online relapse prevention therapy|Participants in the e-RPT group will receive 10 weekly predesigned online modules. The content of this program will involve interactive therapy modules based on the principles of. On average each module consists of 30 slides and should take approximately 45 minutes to complete. At the end of each module, participants will be assigned homework to be completed and submitted to their respective therapists up to 48 hours before their next weekly session. The therapists will develop personalized feedback by using session-specific therapy feedback templates. These templates ensure that feedback is also more standardized and structured between different patients and therapists. In previous studies, therapists have been able to effectively use these templates to prepare feedback in approximately 15-20 minutes. The contents of each session are outlined on the detailed description section.
76043625|NCT02559505|Biological|Seasonal IIV 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
76043626|NCT04470349|Device|LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
76043627|NCT04470349|Device|Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
75564731|NCT00528177|Drug|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning."
76043628|NCT05563207|Other|traditional Chinese medicine health education standard path|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
75419561|NCT01425320|Drug|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
75419562|NCT01425320|Drug|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
75564732|NCT00509678|Drug|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
75564733|NCT00528216|Drug|Capsaicin Dermal Liquid|
75419563|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
75419564|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
75874162|NCT04640727|Procedure|open reduction|A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.
76043629|NCT05563207|Other|The contents of the health intervention mainly included:Graphic and text education|When the patient was admitted to the hospital, the responsible nurse had a comprehensive understanding of the patient's disease cognition and psychological state, and based on this, an individualized intervention plan was formulated. With the help of publicity boards, brochures and other forms of pictures and texts, to popularize the knowledge and precautions of disease treatment for patients
76043630|NCT05563207|Other|The contents of the health intervention mainly included:Language education|adopt one-to-one method to inform patients of the principles, effects and precautions of chemotherapy, eliminate patients' misunderstandings, and repeat language education for many times during the treatment process to strengthen patients' memory
75564734|NCT00528255|Drug|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
75564735|NCT02953106|Drug|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
75564736|NCT02953106|Drug|Placebos|Placebo nasal spray
75564737|NCT02944773|Procedure|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
75564738|NCT02952833|Drug|Saline|Sodium chloride solution.
75564739|NCT02952833|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
75564740|NCT02952989|Drug|SGN-2FF|SGN-2FF oral daily dosing.
75564741|NCT02952989|Drug|pembrolizumab|200 mg every 3 weeks by IV infusion
75718741|NCT00773084|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
75564742|NCT00509717|Other|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
75564743|NCT00509717|Other|control|educational manual
75564744|NCT02952794|Procedure|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
75564745|NCT00509756|Drug|FXR-450|capsule, single oral doses from 10 mg to 450 mg
75718742|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
75564746|NCT00509756|Drug|Placebo|capsule similar to active drug
75564747|NCT00510926|Drug|Imatinib Mesilate (Glivec)|
75564748|NCT00509834|Drug|hLF1-11|"The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10"
75564749|NCT00509834|Drug|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
75564750|NCT00509834|Drug|Placebo|Placebo
75564751|NCT02952560|Other|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
75564752|NCT03459404|Combination Product|Sufentanil NanoTab PCA System|15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
75564753|NCT00527202|Drug|botulinum toxin A|Botulinum toxin A versus saline in parallel groups
75564754|NCT03459989|Diagnostic Test|Ultrasound|Samsung H60 Ultrasound
76043631|NCT05563207|Other|The contents of the health intervention mainly included:Psychological education|guide patients to express their own emotions, according to the patient's personality, cultural background, etc., after communicating with family members and negotiating, selectively inform the patient's actual condition
75564755|NCT00527241|Behavioral|Raices nuevas|8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
75874163|NCT04640727|Procedure|closed reduction|we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
75874164|NCT05682209|Drug|Octreotide Injection|100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
75874165|NCT05682209|Other|Sterile water|1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
76043632|NCT05563207|Other|The contents of the health intervention mainly included:Dietary education|instruct patients to follow the principles of light, easy to digest and balanced nutrition
76043633|NCT05563207|Other|The contents of the health intervention mainly included:Complication education|Actively inform patients about complications in advance, and guide their prevention methods, such as increasing water intake, avoiding activities of affected limbs after chemotherapy, etc. Patients with vomiting, hair loss and other adverse reactions are prone to negative emotions such as anxiety and depression , timely take corresponding measures and appease the patient, inform them that it is a normal phenomenon, and guide them to maintain a good attitude.
76043634|NCT05497063|Drug|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine|Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
75564756|NCT00527280|Procedure|Feasibility ot face transplantation|Feasibility ot face transplantation
75564757|NCT02952521|Procedure|Blood Draw|CA125 and ctDNA
75564758|NCT02952521|Procedure|Tumor Tissue Biopsy|Only collected at time of surgery if patient undergoes surgical debulking
75564759|NCT00527358|Behavioral|SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)|"community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
75564760|NCT00509951|Behavioral|One-session exposure treatment|Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.
75718743|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to <10.5 g/dL had occurred.
75718744|NCT00781391|Drug|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
75718745|NCT00781391|Drug|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
75874166|NCT05258513|Dietary Supplement|Placebo Supplementation|8 weeks of placebo supplementation
75874167|NCT05258513|Dietary Supplement|GG sourced from Annatto|8-weeks of Geranylgeraniol supplementation
75874168|NCT04637841|Other|Kinesiology Taping Appliying|"Kinesiology tape will be applied to left foot plantar fascia of the participants in diabetes mellitus and control group.~During taping, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position. A Palm Shape taping procedure will be applied to the plantar fascia."
75874169|NCT04637841|Other|Myofascial Release Technique Appliying|"Myofascial release technique will be applied (during 5 minutes) to right foot plantar fascia of the participants in diabetes mellitus and control group~During appliying technique, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position."
75718746|NCT00781391|Drug|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
75718747|NCT00781391|Drug|placebo warfarin|placebo warfarin
75718748|NCT00781391|Drug|placebo edoxaban|placebo edoxaban
75718749|NCT00776750|Biological|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
75874170|NCT05682131|Drug|Realgar Indigo naturalis formula|Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk
75874171|NCT05682131|Combination Product|Conventional chemotherapy|conventional chemotherapy
76043635|NCT05497063|Drug|G-COSPE® tablets|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
76043636|NCT05496985|Diagnostic Test|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
75718750|NCT00534976|Drug|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily"
75874172|NCT03632577|Device|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
75564761|NCT00509951|Behavioral|Augmented one-session exposure treatment|Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
75874173|NCT03632577|Device|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.
75874174|NCT04620993|Other|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position."
75874175|NCT04620993|Other|Evaluation of navıcular drop|The amount of navicular drop of both feet will be measured
75874176|NCT04620993|Other|Evaluation of plantar pressure distrubution|The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
75874177|NCT03708497|Drug|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
75874178|NCT03708497|Drug|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
75419565|NCT01425385|Other|Near infrared spectroscopy monitoring|This is an observational study without interventions
75564762|NCT02945670|Behavioral|Focus Group|We had recruited 64 women and completed 7 focus group sessions
75419566|NCT01425385|Other|Autoregulation monitoring|There are no interventions in this observational study
75419567|NCT01425398|Drug|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
75564763|NCT00510965|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
75419568|NCT01425398|Drug|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
75564764|NCT02945826|Drug|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
75564765|NCT02945826|Device|PET/MRI|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
75564766|NCT00509990|Drug|Pimecrolimus|Pimecrolimus cream 1 %
75564767|NCT02945358|Procedure|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
75564768|NCT02952209|Device|Xenograft|
75874179|NCT03708497|Drug|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
75874180|NCT02961218|Drug|ACZ885|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
75874181|NCT02961218|Drug|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
75874182|NCT02949947|Drug|Ferric Carboxymaltose|15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
75419569|NCT01425411|Drug|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
75419570|NCT01425424|Other|Vitamin D supplementation|Vitamin D
75419571|NCT01425450|Drug|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
75419572|NCT01425450|Drug|HF1020 placebo|Single dose: HF1020 placebo capsule
75564769|NCT02945397|Behavioral|Group-based activity|Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
75564770|NCT02945397|Behavioral|Individual activity|Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
75564771|NCT02952287|Device|4D PC MRI acquisition|Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
75564772|NCT04695782|Radiation|Pencil beam proton radiotherapy|Doseescalated pencil beam proton Therapy
75564773|NCT00527436|Dietary Supplement|fish oil|Fish oil pills will be taken daily for 12 weeks
76043637|NCT04277611|Procedure|Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.|patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.
75419573|NCT01425476|Drug|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
75419574|NCT01425476|Drug|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
75419575|NCT01425476|Drug|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
75419576|NCT01425502|Behavioral|DQIP Intervention|"The DQIP intervention comprises of:~Educational outreach~Information technology application~Financial incentives"
75419577|NCT01425515|Behavioral|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
75419578|NCT01425554|Other|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
75419579|NCT01425554|Other|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
75718751|NCT00534976|Drug|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily"
75718752|NCT00768794|Dietary Supplement|Acidophilus|"Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.~The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region."
75718753|NCT00768794|Dietary Supplement|Acidolphilus|The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
75874183|NCT02949947|Dietary Supplement|Iron Supplements|Participants take iron supplements by mouth every day for up to 3 months.
75874184|NCT02949947|Behavioral|Questionnaire|Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
75874185|NCT03642392|Other|Identification and treatment of early tendinopathy|Participants receive initial guidance about load reduction when tendinopathy
75718754|NCT00773162|Drug|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
75419580|NCT01425554|Other|Air-plethysmography of the neck|Air-plethysmography of the neck
75419581|NCT01425554|Other|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
75419582|NCT01425567|Drug|Intravenous Lipid Emulsion Comprised of Fish Oil|IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
75419583|NCT01425580|Drug|liraglutide|1.8 mg s.c. (QD)
75419584|NCT01425580|Drug|glimepiride|4 mg p.o. (QD)
75419585|NCT01425580|Drug|Metformin|500 mg p.o. (BID)
75419586|NCT01425606|Other|blood test|blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
75419587|NCT01425619|Biological|Cream of Macrogol cetostearyl ethers|The cream will be applied on the volar aspect of both arms for 1 hour
75419588|NCT01425619|Drug|Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %|1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
75564774|NCT00527436|Dietary Supplement|Placebo|Placebo (corn oil) will be taken daily for 12 weeks
75564775|NCT03459911|Drug|Cozaar 100mg Tablet|Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe & Dohme B.V. , Haarlem, the Netherlands)
75564776|NCT03459911|Drug|Losartan potassium 100mg|Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
75564777|NCT02945592|Behavioral|Cueing|
75564778|NCT03459872|Procedure|Acupuncture|Alternative medicine therapeutic intervention
75564779|NCT03459872|Device|RU-Fit|FDA approved medical device for the measurement of fine motor control
75564780|NCT02945514|Other|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
75718755|NCT00773162|Drug|Sugar Pill|Sugar pill to match seroquel
75718756|NCT00768950|Procedure|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
75718757|NCT00768950|Procedure|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
75564781|NCT03459833|Drug|Hyaluronic Acid|Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
75564782|NCT05648487|Drug|HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery|"HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~After the surgery, continue to use standard adjuvant chemotherapy."
76043638|NCT05561413|Behavioral|Mindfulness and exercise|The mindfulness and exercise group aims to gradually increase participants exercise levels so that they begin to achieve the recommended levels along with the strengthening exercises for all major muscle groups. Along side this mindfulness will be introduced and built on to help consolidate exercise uptake and help manage symptoms experienced by the participants.
75564783|NCT04695665|Other|Cervical pain|Exercise program for cervical spine according to McGill's approach.
75564784|NCT04695665|Other|Thoracic pain|Exercise program for thoracic spine according to McGill's approach.
75564785|NCT04695665|Other|Lumbar pain|Exercise program for lumbar spine according to McGill's approach.
76043639|NCT05561413|Behavioral|Mindfulness|The delivery of this practice will be through the app downloaded by participants. The practice based on mindfulness based stress reduction (MBSR). Will build on practice over the 8 weeks.
76043640|NCT05560945|Drug|0.32% Sodium Fluoride Dentifrice Toothpaste|Toothpaste
75419589|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.
75419590|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
75419591|NCT01425645|Other|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
75564786|NCT00527553|Dietary Supplement|not enriched egg|daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
75564787|NCT00527553|Dietary Supplement|lutein|daily lutein enriched egg
75718758|NCT00769028|Drug|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
76043641|NCT05560945|Drug|1.5% Arginine Dentifrice|Toothpaste
75564788|NCT00527553|Dietary Supplement|zeaxanthin|daily zeaxanthin enriched egg
75564789|NCT00527553|Dietary Supplement|egg product from enriched eggs|daily egg product from lutein enriched eggs
75564790|NCT00511082|Drug|OPB-31121|Patients will receive OPB-31121 administered orally, once daily for 4 weeks.
75564791|NCT00527631|Radiation|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
75419592|NCT01425658|Drug|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
75419593|NCT01425658|Drug|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
75419594|NCT01425658|Drug|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
75564792|NCT00511121|Drug|STI571 and PEG INTRON|
75718759|NCT00769028|Drug|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
75718760|NCT00321763|Biological|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
75718761|NCT00321763|Biological|Fluarix TM|Single dose, Intramuscular injection
75718762|NCT02822716|Procedure|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
76043642|NCT05560945|Drug|8.0% Arginine Dentifrice|Toothpaste
75874186|NCT05681975|Diagnostic Test|Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.
75874187|NCT03642314|Diagnostic Test|HIV self test kit|HIVST receptor will be invited to priority access to PrEP sites
75874188|NCT03341507|Device|classical laryngoscopy|the laryngoscopy with the McIntosh laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.
75564793|NCT00527670|Procedure|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
75564794|NCT00527670|Procedure|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
75564795|NCT00511160|Procedure|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
75564796|NCT00511160|Procedure|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
75564797|NCT02953223|Other|Free amino acid infant formula|Patients who will be fed a free amino acid based infant formula
75564798|NCT00528489|Biological|PennVax B|DNA vaccine containing the HIV genes Gag, Pol, and Env
75564799|NCT00528489|Biological|IL-12|Cytokine injection
75564800|NCT00528489|Biological|IL-15|Cytokine injection
75718763|NCT02822716|Device|Ultrasound|
75718764|NCT00776828|Drug|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
75718765|NCT04002466|Other|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
75874189|NCT03341507|Device|rigid tube for laryngoscopy|the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
75564801|NCT00528684|Biological|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
75564802|NCT02953028|Device|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
75564803|NCT02953028|Device|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
75564804|NCT04692051|Drug|Nab-paclitaxel + Cisplatin|Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
75564805|NCT04692051|Drug|Gemcitabine + Cisplatin|Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
75564806|NCT00510029|Drug|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
75564807|NCT00528723|Drug|salbutamol 100 mcg|To be used as needed for symptom relief
75564808|NCT00528723|Drug|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
75564809|NCT00528723|Drug|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
75564810|NCT00510107|Drug|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
75564811|NCT00510107|Drug|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
75718766|NCT00776906|Device|Advance® 18PTX® Balloon Catheter|
75718767|NCT00776906|Device|Advance® 18LP Balloon Catheter|
75718768|NCT00773240|Drug|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
75718769|NCT00773240|Drug|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
75718770|NCT01063933|Drug|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
75419595|NCT01425697|Other|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
75564812|NCT00528762|Behavioral|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
75564813|NCT03459326|Other|IIEF (International Index of Erectile Function questionnaire )|"The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~Erectile function (score 1 to 30)~Orgasmic function (score 0 to 10)~Desire (score 2 to 10)~Sexual satisfaction (score 0 to 15)~Overall satisfaction (score 2 to 10)"
75564814|NCT01580514|Drug|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
75564815|NCT01580514|Drug|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
75718771|NCT02556866|Drug|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
75564816|NCT00528918|Drug|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
75564817|NCT00510185|Other|systematic coronary intervention|Coronary angiography within 72 hrs
75718772|NCT02556866|Drug|Prednisone|
75718773|NCT02556866|Drug|Placebo|
75419596|NCT01425697|Other|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
75718774|NCT01064011|Procedure|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
76043643|NCT05559463|Dietary Supplement|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
76043644|NCT05559385|Device|Robot-Assissted Therapy|Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.
76043645|NCT05559385|Procedure|Conventional Rehabilitation|It is an upper extremity rehabilitation program prepared in line with individual needs.
76043646|NCT04047277|Behavioral|Cognitive Behavioral Therapy|The manualized CBT protocol is five sessions that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
76043647|NCT04224961|Device|Respiratory Muscle Training|Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.
75419597|NCT01425736|Drug|Chemotherapy|Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
75419598|NCT01425736|Drug|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );"
75419599|NCT01425762|Other|Drug Dose|100 versus 200 mcg IT morphine
75419600|NCT01425775|Drug|vitamin D 25(OH)D|2000IU/day for 12 months
75419601|NCT01425775|Other|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
75419602|NCT01425788|Biological|Osiris Phleum pratense|
75419603|NCT01425788|Biological|Osiris Phleum pratense|
75419604|NCT01425788|Biological|Osiris Phleum pratense|
75419605|NCT05386940|Other|PKN1 level|different PKN1 level after on-pump cardiac surgery
75419606|NCT05386862|Behavioral|Reduce THC Use|Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
75419607|NCT05386823|Drug|HF1K16|A range of doses of HF1K16 will be tested based on the assessment of safety, tolerability and pharmacokinetics.
75564818|NCT00510185|Other|coronary intervention only for cases refractory to medical therapy|Initially conservative treatment with coronary angiography only for recurrent ischemia
75419608|NCT05386823|Drug|Placebo|Placebo
75419609|NCT05386667|Drug|Majezik %0.25 oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
75419610|NCT05386667|Other|Aftamed oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
75564819|NCT00515190|Drug|S-1,oxaliplatin|"Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles."
75564820|NCT00511277|Drug|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
75718775|NCT01064011|Procedure|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
75718776|NCT00769106|Biological|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
75718777|NCT01064089|Drug|HSP990|
76043648|NCT04424563|Device|ventilators|all patients in both groups will be ventilated if shocked and no recordable blood pressure
75419611|NCT05386667|Other|Crystalin oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
75419612|NCT05386667|Procedure|Free gingival graft harvesting|Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.
75419613|NCT05386498|Procedure|precured composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
75419614|NCT05386498|Procedure|Contact making instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
75419615|NCT05386498|Procedure|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
76043649|NCT04424563|Drug|aminocaproic acid|4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
75419616|NCT05386446|Drug|Interferon gamma human recombinant (IFN-G)|nasal form
75419617|NCT01425112|Procedure|Phacoemulsification|Surgery for complications of trabeculectomy
75419618|NCT05386433|Drug|Paxlovid|"Paxlovid contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir [PF-07321332] is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.~Ritonavir is co-administered with nirmatrelvir to help slow its metabolism in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus."
75419619|NCT05386433|Drug|standard-of-care|standard-of-care of COVID-19
75419620|NCT05386316|Other|Multilevel intervention for racial disparities in severe maternal morbidity and mortality|"In addition to standard enhance prenatal care (EPC) services, the following will be offered.~Community level. We will make EPC services (i.e., MIHP and Healthy Start) available via telehealth with flexible hours to women who are eligible for Healthy Start (primarily minority women) who decline traditional (i.e., home visiting) services.~Provider/practice level. We will provide actionable maternal health-focused anti-racism training to health system administrators, physicians, residents, midwives, nurses, front desk staff, schedulers, public health officers, EPC staff, doulas, WIC staff, and lactation consultants.~System level. Counties will implement equity focused community care maternal safety bundles. Community care is care provided by outpatient, EPC, community-based organizations, and linkages between hospital care and these settings."
75419621|NCT05386316|Other|Standard Enhanced Prenatal Care (EPC) services|"Pregnant women in comparison counties will receive whatever EPC services (MIHP and/or Healthy Start) they naturalistically choose to receive.~Maternal Infant Health Program (MIHP). All women in Michigan who are Medicaid insured are eligible for MIHP. MIHP offers monthly home visiting and care coordination to supplements regular care during pregnancy and up to 12 months post birth. MIHP offers care coordination; risk assessment; individual care plan; evidence-based interventions; transportation; education; and referrals.~Healthy Start. Health Start is a federally funded program for minority women that offers more intensive EPC services delivered by race/ethnicity matched community health workers. Community health workers offer peer support; resilience and problem solving; risk assessment; facilitating provider-client communication; collaborative care; system navigation, including transition from prenatal care to postnatal primary care; and supportive referrals."
75419622|NCT05386290|Drug|Infliximab|A TNFα inhibitor in UC and CD treatment
75419623|NCT05386290|Drug|Vedolizumab|An integrin receptor antagonist in UC and CD treatment
75419624|NCT05386290|Drug|Ustekinumab|An IL-12/IL-23 inhibitor in CD treatment
76043650|NCT04424563|Drug|Novo Seven|200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (>10 gm%) another 2 doses of aFVII received
76043651|NCT04038151|Device|Hybrid Leg|The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.
76043652|NCT04038151|Device|Prescribed Passive Prosthesis|Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
75718778|NCT00773318|Procedure|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
76043653|NCT05496361|Device|Tianyi Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
75564821|NCT00529074|Device|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
75419625|NCT05386290|Drug|conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)|Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
75419626|NCT05386251|Behavioral|BPT/OST|See Arm description.
75564822|NCT02953184|Drug|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
75564823|NCT02953184|Drug|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
75419627|NCT05386251|Behavioral|Peer Support|See Arm description
75419628|NCT05386212|Device|web app healthcare instructions for relieving back pain|This study designed web-based dynamic pain relief instructions for women with spinal compression fractures.
75419629|NCT05386186|Drug|Glimepiride|Initiate glimepiride 1-4mg once daily as an add-on therapy to metformin and adjust the glimepiride dosage to 1-6 mg once daily in the first 12 weeks according to the diabetes management guideline recommended by the Chinese Diabetes Society.
75419630|NCT05386186|Drug|Sitagliptin|Add sitagliptin 100mg once daily in all patients randomized to this arm.
75419631|NCT05386160|Drug|Ranibizumab Injection [Lucentis]|intravitreal injection of Ranibizumab；
75419632|NCT05386160|Device|Phacoemulsification|Phacoemulsification
75419633|NCT05386121|Procedure|Ultrasound-guided Erector Spinae Plane Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane deep to erector spinae muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the spinous process on a parasagittal plane, to visualize the erector spinae muscle and transverse process, directing the needle craniocaudally using the in-plane technique. The spread of the injectate will be observed to distribute within this plane.
75718779|NCT03946306|Drug|5,25% NaOCl with syringe needle irrigation alone|In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
76043654|NCT05496361|Device|Solitaire FR Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
75564824|NCT02953184|Drug|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
75564825|NCT02953184|Drug|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
75564826|NCT02953184|Drug|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
75564827|NCT02953184|Drug|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
75564828|NCT02953184|Procedure|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
75564829|NCT02953184|Procedure|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
75718780|NCT03946306|Device|EDDY|In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
75718781|NCT05184452|Drug|PGDM1400LS (5mg/kg, IV)|5 mg/kg to be administered via IV infusion
75564830|NCT02953184|Procedure|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
75564831|NCT00515229|Drug|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch"
75564832|NCT00511316|Drug|Montelukast/ Singulair|20 mg daily for six months
75564833|NCT00511316|Drug|Placebo|Placebo 20 mg daily for 6 months
75718782|NCT05184452|Drug|PGDM1400LS (20mg/kg, IV)|20 mg/kg to be administered via IV infusion
75718783|NCT05184452|Drug|PGDM1400LS (20mg/kg, SC)|20 mg/kg to be administered via SC infusion
75718784|NCT05184452|Drug|PGDM1400LS (40mg/kg, IV)|40 mg/kg to be administered via IV infusion
75718785|NCT05184452|Drug|PGDM1400LS (40mg/kg, SC)|40 mg/kg to be administered via SC infusion
76043655|NCT05496127|Other|Sensorimotor Exercises and Yoga|Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
75564834|NCT02944695|Other|audit|Practice adherence to guidelines
75564835|NCT02952950|Other|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
75564836|NCT02951091|Other|biomarker screening|immunohistochemistry and in situ hybridization
75718786|NCT05184452|Drug|PGDM1400LS (1.4g, IV)|1.4gram to be administered via IV infusion
75718787|NCT05184452|Drug|PGDM1400LS (1.4g, SC)|1.4gram to be administered via SC infusion
75718788|NCT05184452|Drug|VRC07-523LS (20mg/kg, IV)|VRC07-523LS 20mg/kg administered via IV infusion
75718789|NCT05184452|Drug|VRC07-523LS (20mg/kg, SC)|VRC07-523LS 20mg/kg administered via SC infusion
75718790|NCT05184452|Drug|VRC07-523LS (1.4g, IV)|VRC07-523LS 1.4g administered via IV infusion
75718791|NCT05184452|Drug|VRC07-523LS (1.4g, SC)|VRC07-523LS 1.4g administered via SC infusion
75718792|NCT05184452|Drug|VRC07-523LS (40mg/kg, IV)|VRC07-523LS 40mg/kg administered via IV infusion
75718793|NCT05184452|Drug|PGT121.414.LS (20mg/kg, IV)|PGT121.414.LS 20mg/kg administered via IV infusion
75718794|NCT05184452|Drug|PGT121.414.LS (20mg/kg, SC)|PGT121.414.LS 20mg/kg administered via SC infusion
75718795|NCT05184452|Drug|PGT121.414.LS (1.4g, IV)|PGT121.414.LS 1.4g administered via IV infusion
75564837|NCT00511394|Drug|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
75564838|NCT00511394|Drug|Normal Saline|Infusion of 100 mL of Normal Saline
75564839|NCT00529230|Behavioral|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
75564840|NCT00529230|Other|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
75564841|NCT02952443|Behavioral|Exercise|Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).
75564842|NCT02952443|Behavioral|Control|The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
75564843|NCT00529269|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
75564844|NCT02952911|Device|Smartphone and Smartwatch|Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
75564845|NCT00515268|Drug|GSK256066|GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
75564846|NCT00515268|Drug|Placebo|Subjects will receive placebo inhaler.
75564847|NCT00515307|Procedure|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
75564848|NCT01356966|Drug|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
75718796|NCT05184452|Drug|PGT121.414.LS (1.4g, SC)|PGT121.414.LS 1.4g administered via SC infusion
75419634|NCT05386121|Procedure|Ultrasound-guided Quadratus Lumborum Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane between the quadratus lumborum and psoas major muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the L2 spinous process on an axial plane, to visualize the transverse process with psoas major muscle anterior, quadratus lumborum muscle lateral and erector spinae muscle posterior to it. The needle is inserted from the medial side of the probe and advanced laterally using the in-plane technique. The spread of the injectate will be observed to distribute within the target plane.
75718797|NCT05184452|Drug|PGT121.414.LS (40mg/kg, IV)|PGT121.414.LS 40mg/kg administered via IV infusion
75718798|NCT05356624|Other|Mulligan Mobilization|It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week
75419635|NCT05386121|Device|Ultrasound Machine|Sonosite S-Nerve (USA) with a linear multi-frequency 6-13 MHz (hockey stick) transducer
75419636|NCT05386121|Device|Echogenic needle|A 22-gauge 80 mm needle the sonoplex needle manufactured by PAJUNK (USA)
75564849|NCT01356966|Drug|Placebo|2 placebo pills PO BID for12 weeks
75564850|NCT01356966|Dietary Supplement|Folate|Folate 1 mg daily for 12 weeks
75564851|NCT02952677|Behavioral|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
75718799|NCT05356624|Other|Soft Tissue Mobilization|in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
75564852|NCT02952677|Behavioral|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
75564853|NCT02952677|Other|Control|Participants received usual care
75564854|NCT02944734|Drug|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
75564855|NCT02944734|Drug|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
75718800|NCT00308113|Drug|Prednisone|Prednisone 0/75 mg/kg/day.
75564856|NCT02944734|Drug|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
75564857|NCT02944734|Drug|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
75564858|NCT00510263|Drug|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
75718801|NCT00308113|Dietary Supplement|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
75718802|NCT03903640|Device|Optune|-Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.
75718803|NCT03903640|Biological|Nivolumab|-Standard of care
75564859|NCT00510263|Drug|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
75564860|NCT00510263|Drug|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
75564861|NCT00510263|Drug|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
75564862|NCT00515346|Device|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
75564863|NCT00511589|Other|chagas disease diagnostic|
75564864|NCT00515385|Drug|MGAWN1|"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"
75564865|NCT00515385|Drug|MGAWN1|Single IV dose
75564866|NCT00515385|Other|Placebo|Single IV dose
75564867|NCT00515424|Drug|RKI983|
75564868|NCT00511628|Drug|Risperidone|As prescribed
75564869|NCT00529347|Device|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
75564870|NCT00510302|Behavioral|Questionnaire|Questionnaire regarding melanoma risk-reduction.
75564871|NCT00510302|Behavioral|Interview|Interview via telephone about topics related to melanoma risk-reduction.
75564872|NCT00529425|Drug|Ropivacaine|
75718804|NCT03903640|Biological|Ipilimumab|-Standard of care
75718805|NCT05157386|Other|Braining|Core components of Braining: Personnel-led training sessions, motivating contact with psychiatric staff, measurement and evaluation before and after the training period; usually 12 weeks. PE is added on to treatment as usual (TAU). The training sessions are moderate to intense aerobic group training, 30-45 minutes. Each training session is preceded by a short (5-10 minutes) individual meeting with staff including assessment of daily form, motivational work, and the opportunity to ask questions. The target frequency for participation is preferably at least three training sessions/week during a 12 week period. The training period for each patient begins with an informative and motivating group or individual lecture or and an individual introductory meeting with staff including psychiatric and somatic examination, self-assessment scales for symptoms and quality of life, and blood samples. The training period ends with a meeting with staff with follow-up on the parameters.
75718806|NCT03982849|Drug|Hydroquinone 4% Cream|Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
75718807|NCT03982849|Drug|silymarin 0.7% cream|Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
75564873|NCT03459755|Behavioral|Physical Activity|"Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise."
75564874|NCT00515580|Procedure|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
75564875|NCT00510341|Behavioral|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
75564876|NCT02950974|Drug|Sterofundin|Fluid loading
75564877|NCT02950974|Drug|NSS|Fluid loading
75564878|NCT03459716|Other|No intervention|No intervention
75564879|NCT00529581|Drug|C105|
75564880|NCT02952755|Drug|Co-administration of DWC20155/DWC20156|
75718808|NCT05154344|Drug|Capmatinib|Available through expanded access
75718809|NCT05357872|Device|deep anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
75564881|NCT02952755|Drug|DWC20162|
75564882|NCT02950935|Drug|Progesterone|subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
75564883|NCT02950935|Drug|Placebo|subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
75564884|NCT02952404|Procedure|Educational workshop|The educational workshop for improved perineal support during vaginal delivery
75564885|NCT00515658|Device|theta-burst rTMS|
75564886|NCT00529620|Drug|sulfalene-pyrimethamine plus amodiaquine|Monthly treatments during the malaria transmission season
75564887|NCT00529620|Drug|dihydroartemisinin plus piperaquine|Monthly treatments during the transmission season
75564888|NCT00529620|Drug|sulfadoxine pyrimethamine plus piperaquine|Monthly treatments during the malaria transmission season
75564889|NCT00529698|Biological|Biologically active recombinant Tat protein|
75564890|NCT02952014|Dietary Supplement|C4 Extreme|Pre-Workout Dietary Supplement
75564891|NCT02952014|Dietary Supplement|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
75419637|NCT05386121|Drug|Fentanyl|Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)
75419638|NCT05386121|Drug|Pethidine|Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
75419639|NCT05386056|Drug|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
75419640|NCT05386056|Drug|Sinoporphyrin Sodium|0.2mg/kg, intravenously on day -2 of cycle 1.
75419641|NCT05386056|Procedure|Photodynamic therapy|PDT to primary site of ESCC will be given on day -1 of the treatment (24 hours after injection of DVDMS).
75419642|NCT05386004|Other|Birth-Specific Stereogram Cards (BSSC)|Focus on Birth-Specific Stereogram Cards (BSSC) during uterine contractions in latent active and transitional phase
75564892|NCT02952014|Dietary Supplement|Placebo|Pre-Workout Dietary Supplement
75564893|NCT00529737|Procedure|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
75564894|NCT00529737|Procedure|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
75718810|NCT05357872|Device|light anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
75718811|NCT03983005|Procedure|EUS-B-FNA|Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
75718812|NCT01061593|Dietary Supplement|Immunoxel|1 lozenge once per day
75718813|NCT01061593|Other|Placebo|1 lozenge once per day
75718814|NCT00769262|Other|Conservative weaning|Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
75718815|NCT00769262|Other|Aggressive Weaning|Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
75718816|NCT03979261|Diagnostic Test|evolution of sex ratio according to age|Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
75718817|NCT00777218|Drug|propranolol|standard pediatric doses, based on body weight
75718818|NCT00777218|Drug|zonisamide|standard pediatric dosages, based on body weight
75718819|NCT00777218|Drug|topiramate|standard pediatric dosages, based on body weight
76043656|NCT05496049|Device|Triburter|Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.
75419643|NCT05385939|Other|Observational|This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.
75419644|NCT05385900|Drug|Penpulimab combination with anlotinib and chemotherapy|Penpulimab: fixed dose of 200 mg, administered on day 1 of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14 of each cycle, orally once a day, about half an hour before breakfast (the time of daily administration should be the same as possible), with warm water, every 3 weeks Repeat 1 time
75564895|NCT00512993|Drug|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
75564896|NCT00529776|Procedure|Continuous lateral rotation therapy|
75564897|NCT00513032|Drug|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
75564898|NCT00529815|Device|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
75564899|NCT00529815|Device|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
75419645|NCT05385861|Drug|nanoliposomal irinotecan plus carboplatin|"Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= [(140-age) x weight x 0.85 (if female)] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria."
75564900|NCT00513110|Genetic|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
75564901|NCT00513110|Drug|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
75564902|NCT00513110|Drug|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
75419646|NCT05385848|Procedure|Autologous Platelet-rich Plasma (PRP) Injection|PRP contains a high concentration of platelets which contains multiple vaso-active peptides and cytokines such as Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) and Sphingosine-1-phosphate. Many of these cytokines have been implicated in important roles in ovarian function, follicular genesis and oocyte maturation. Intraovarian autologous PRP infusion was recently introduced in the context of addressing ovarian insufficiency, with several studies showing an increase in ovarian function and promising ART outcomes. Possible mechanisms include anti-inflammatory and mitogenic potentials in this growth factor rich fraction contributing towards tissues regeneration. Through being involved in the cell regeneration cycle, autologous PRP potentially gives women with premature ovarian insufficiency (POI) or diminished ovarian insufficiency (DOR) hope in achieving a healthy genetically related offspring.
75564903|NCT00529854|Other|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
75564904|NCT00511745|Drug|Rabeprazol|As prescribed
75564905|NCT02951897|Procedure|lobectomy|
75564906|NCT02951897|Procedure|segmentecomy|
75718820|NCT04047758|Drug|Palbociclib + Letrozole|(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment [3 weeks on (days 1-21) and 1 week off (days 22-28)], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
75718821|NCT04047758|Drug|Letrozole|Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
75564907|NCT02951897|Drug|chemotherapy（pemetrexed+CISPLATIN）|
75564908|NCT02951897|Procedure|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
75718822|NCT00922064|Procedure|ECT|ECT series consisting of 6 to 14 ECTs
75564909|NCT02951897|Other|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E&M-) CTCs.
75564910|NCT02945124|Other|K tape|Applying K tape to children to the lower limb muscles during motor activities.
75564911|NCT02944929|Other|Self-rehabilitation program|The self-rehabilitation program will be based on muscle stretching, strengthening and task oriented exercises. For each patient, two exercises will be selected by the therapist for each of these 3 domains (total of 6 exercises) from a list of 50 exercises.
75718823|NCT05355064|Drug|Trehalose|Enrolled subjects will daily take 4 g of trehalose in oral administration for 24 weeks.
75718824|NCT00307801|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
75718825|NCT00307801|Drug|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
75718826|NCT00671060|Drug|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
75564912|NCT00511823|Drug|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
75564913|NCT00511823|Drug|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
75564914|NCT00511823|Drug|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
76043657|NCT05496049|Device|Incentive spirometry|They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.
76043658|NCT05495893|Drug|Cyclophosphamide|The patients will be divided into two groups randomly. Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
76043659|NCT05495893|Drug|Mycophenolate Mofetil|The patients will be divided into two groups randomly. Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
75419647|NCT05385835|Other|Training|A training module was prepared by explaining the theoretical and practical parts of the application of blood pressure measurement from the brachial artery with a slide presentation and an animation video. The knowledge and skills of nurses in blood pressure measurement before education were measured. The training module was delivered to the nurses from the online system. At the end of the two-week training period, the knowledge and skill levels of the nurses will be measured again.
75419648|NCT05385822|Behavioral|Pelvic Floor Muscle Training|"Isolated, quite light tension in the pelvic floor 10 times, where the tension is released immediately~Constant tension for 30 seconds twice, with a 30-second pause~Total relaxation for 1 minute They must perform these exercises once a day during the trial period of 3 months"
75419649|NCT05385744|Biological|BCD-132|anti-CD20 monoclonal antibody
75564915|NCT00511823|Drug|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
75419650|NCT05385744|Drug|Teriflunomide|Teriflunomide 14 mg
75419651|NCT05385731|Other|Nordic Walking (NWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
75419652|NCT05385731|Other|Free Walking (FWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
75564916|NCT00515736|Drug|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
75419653|NCT05385731|Other|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
75419654|NCT05385627|Procedure|Ankle block|Injection of local anaesthetics at the level of the ankle blindly (local infiltration analgesia). The dose, volume, and type of local anaesthetic will be registered.
75419655|NCT05385614|Behavioral|de:)press|Patients will receive de:)press for the duration of six weeks. They will be encourages to use the app at least three times a week, up to once per day.
75419656|NCT05385445|Behavioral|Audit and Feedback|The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit & Feedback interventions to change prescribing and laboratory ordering.
75564917|NCT00515736|Drug|Placebo|vehicle
75564918|NCT02952482|Procedure|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
75564919|NCT00511940|Drug|acamprosate|999 mg/day - 2997 mg/day, oral
75564920|NCT00511940|Other|placebo|oral, placebo
75564921|NCT02950857|Drug|EPEG|(Pegylated erythropoeitin)
75564922|NCT00513149|Drug|Clopidogrel|Clopidogrel 600 mg loading
75564923|NCT00515814|Device|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation & mobility.
76043660|NCT03542461|Drug|Nivolumab 10 MG/ML Intravenous Solution|240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.
75419657|NCT05385419|Diagnostic Test|Bronchoscopic and thoracoscopic frozen section biopsies|Flexible bronchoscopy for patients with lung endobronchial lesion, the bronchoscopic biopsy will be sent for frozen section and permenant paraffin section Medical thoracoscopy for patients with undiagnosed pleural effusion, the thoracoscopic biopsy will be sent for both frozen section and permenant paraffin section
75419658|NCT05385276|Procedure|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above umbilicus after maximum retraction the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm) .
75419659|NCT05385276|Procedure|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
75419660|NCT05385250|Other|Bone sparring radiotherapy|Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
75419661|NCT05385237|Diagnostic Test|4D-MRI|Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.
75419662|NCT05385198|Behavioral|VOICE care|"I phase:build a relationship with parents and where the Values of the parents and NICU staff is shared.~II phase: discuss with the parents the Opportunities the parents can have to be more involved in the care of their baby.~III phase: Integration of the involvement of the parents in the care of their baby. The experiences of parents need to be shared with the NICU staff. Any raising issue about the involvement of care by the parents can be discussed and see if improvement is needed.~IV phase:Control of the knowledge about the care of their baby before going home and if the parents have any issues which need to be arranged before discharge.~V phase:Evaluation. During this conversation the overall experiences of the parents will be discussed and if there are any further questions related to the care of their baby at home will be explored and discussed."
75419663|NCT05385185|Drug|Camrelizumab or envafolimab|combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
75419664|NCT05385172|Other|No any intervation.|This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years.
75419665|NCT05385146|Other|qigong|Chan-Chuang qigong with breathing meditation for 15 weeks
75419666|NCT05385133|Procedure|Computer guided condylar position|post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
75564924|NCT02944344|Behavioral|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
75564925|NCT02952326|Procedure|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
75564926|NCT02952326|Procedure|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
75564927|NCT02944227|Drug|Lucentis|Lucentis fixed-treatment arm
75564928|NCT04695938|Diagnostic Test|MRI|MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
75419667|NCT05385133|Procedure|Manual condylar position|post-osteotomy condylar position was performed using the conventional manual method
75564929|NCT04691778|Procedure|CTO PCI with the first-choice Gladius guidewire|CTO PCI using antegrade wiring strategy with the first-choice Gladius guidewire
75419668|NCT05385120|Procedure|Temporary Portocaval Shunt|In Temorary Portocaval Shunt Group (TPCS group), Hilar dissection( division of Hepatic artery, Bileduct) is followed by temporary portocaval shunt formation during recipient Hepatectomy.
75564930|NCT04691778|Procedure|CTO PCI without the first-choice Gladius guidewire|CTO PCI using standard antegrade wire escalation strategy
75419669|NCT05385107|Diagnostic Test|Serum procalcitonin concentration|
76043661|NCT03542461|Other|Best Supportive Care|Care that aims to optimize the comfort, function and social support of the patients and their family at all stages of the illness. Best Supportive Care (BSC)includes the use of analgesics, antibiotics, blood tranfusions, blood products, radiotherapy, corticosteroids, antiemetics, antidiarrheals, vitamins and any intervention aiming the improvement of patient's discomfort. Any chemotherapy, immunotherapy and targeted therapy are not considered as part of BSC.
75564931|NCT00513188|Biological|denileukin diftitox|
76043662|NCT04201639|Device|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
75419670|NCT05385094|Diagnostic Test|S Creatinine concentration|
75564932|NCT00513188|Drug|cyclophosphamide|
75564933|NCT00513188|Drug|cytarabine|
75564934|NCT00513188|Drug|doxorubicin hydrochloride|
75564935|NCT00513188|Drug|leucovorin calcium|
75564936|NCT00513188|Drug|methotrexate|
75718827|NCT00671060|Drug|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
76043663|NCT04201015|Device|Heart rate optimisation using force frequency data|Programming heart rate rise according to the force frequency relationship
76043664|NCT04191967|Device|Thermocoagulation|Treatment of positive screening results will be performed using the Liger Thermocoagulator device
75718828|NCT00769418|Drug|odanacatib|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days."
75718829|NCT00769418|Drug|Comparator: Placebo|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days."
75874190|NCT05216744|Drug|Ceftriaxone 1000mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
75419671|NCT05385094|Diagnostic Test|Serum Cystatin C concentration|
75718830|NCT05257252|Behavioral|"Persons With Disability Friendly Nursing Education Program"|Persons With Disability Friendly Nursing Education Program developed based on the Story Theory, 2 weeks program
75419672|NCT05385094|Diagnostic Test|Urinary Creatinine Clearance|
75874191|NCT05216744|Drug|Cefixime 800mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
75419673|NCT05385081|Other|genomic profiling|next generation sequencing
75419674|NCT05385068|Drug|Niraparib|"Niraparib 200 or 300mg* QD PO continually;~*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight <77 kg or platelets count <150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL.~For patients who had experienced grade 4 adverse events from previous use of PARPi, niraparib staring dose was 200 mg QD.~Anlotinib 10mg QD PO from Day 1 to 14 of every 21-day cycle"
75564937|NCT00513188|Drug|prednisone|
75564938|NCT00513188|Drug|vincristine sulfate|
75564939|NCT00513188|Genetic|protein expression analysis|
75564940|NCT00513188|Other|flow cytometry|
75564941|NCT00513188|Other|laboratory biomarker analysis|
75564942|NCT02950779|Other|Handgrip Strength Measurement|
75564943|NCT00513266|Biological|bevacizumab|
75564944|NCT00513266|Biological|cetuximab|
75564945|NCT00513266|Drug|fluorouracil|
75564946|NCT00513266|Drug|irinotecan hydrochloride|
75564947|NCT00513266|Drug|leucovorin calcium|
75564948|NCT00513266|Drug|oxaliplatin|
75564949|NCT00513266|Other|laboratory biomarker analysis|
75564950|NCT00513266|Procedure|adjuvant therapy|
75564951|NCT00513266|Procedure|biopsy|
76043665|NCT05491291|Other|Patients with chronic wound of the lower limbs|The rating scale will be passed at three different times, day 1, day 15 and day 75.
76043666|NCT02556307|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
76043667|NCT02556307|Drug|Ribavirin|Ribavirin according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
76043668|NCT02861521|Device|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
76043669|NCT02861521|Device|Sham|Sham shoe modification
76043670|NCT05495347|Other|patients diagnosed with OSA|All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
76043671|NCT05491135|Biological|HMB002|The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.
76043672|NCT02232997|Other|Standard Hydration|Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class>II, or LVEF < 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
75419675|NCT05385029|Drug|Thyroxine|treatment for hypothyroidism or hyperthyroidism
75419676|NCT05385003|Dietary Supplement|anserine|During the study period, subjects are instructed to take one capsule of anserine daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
75564952|NCT00513266|Procedure|conventional surgery|
75718831|NCT00773552|Drug|solifenacin succinate|5mg PO Qday x 90 days
76043673|NCT02232997|Other|Simplified Hydration|Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class>II, or LVEF <35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
76043674|NCT05491057|Drug|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
76043675|NCT05490901|Diagnostic Test|Exercise hemodynamic test|Assessment of pulmonary hemodynamics during exercise by right heart catheterization and cardiac function during exercise by a simultaneous transthoracic echocardiography
75419677|NCT05385003|Dietary Supplement|Sunflower peptide|During the study period, subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
75419678|NCT05385003|Dietary Supplement|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
75564953|NCT00513266|Procedure|neoadjuvant therapy|
75564954|NCT00513383|Drug|Panitumumab|Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
75564955|NCT00513383|Drug|Carboplatin|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
75564956|NCT00513383|Drug|Paclitaxel|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
75564957|NCT00513383|Radiation|Intensity Modulated Radiation Therapy|Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
75718832|NCT00773552|Drug|placebo|1 tab PO Qday x 90 days
75718833|NCT04002700|Drug|Haloperidol|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
75718834|NCT04002700|Drug|Typical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
75419679|NCT05384990|Device|Stochastic Resonance Electric Stimulation|Subjects will be asked to perform postural transitions like sit to stand, gait initiation, sit to walk and Timed up and the Go (TUG) functional test. This will entail a subsensory electrical signal with a white noise frequency distribution. Proprioceptive SR electrical stimulation will be delivered by BIOPAC Systems, Inc. stimulators that are current limited to deliver less than 10 milli ampere of current. Electrical stimulation will be delivered to muscles and joints along the legs and hips. The stimulation intensity will be very low, below the sensory threshold of the participant.
75564958|NCT00513383|Drug|5-Fluorouracil|Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
75564959|NCT00513383|Drug|Docetaxel|Intravenously on day 1 of a 21-day cycle for 3 cycles
75564960|NCT00513383|Drug|Cisplatin|Intravenously on day 1 of a 21-day cycle for 3 cycles
75564961|NCT00513422|Dietary Supplement|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
76043676|NCT05495191|Diagnostic Test|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A [Xa] along the arterial contour line) and at the inner point (Φb; signal intensity at position B [Xb]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
76043677|NCT05495113|Device|YMS-201B (Device: Mind STIM)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
75874192|NCT05681897|Procedure|Platelet-Rich Plasma Injections (PRP) on the Scalp|each subject will be treated with 3x PRP injections on the scalp with 2 weeks interval in addition to daily minoxidil administration.
75874193|NCT03641222|Device|Acupuncture|Traditional Chinese Medicine (TCM) Acupuncture
76043678|NCT05495113|Device|Sham stimulation using YMS-201B|Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
76043679|NCT04364737|Biological|Convalescent Plasma|SARS-CoV-2 convalescent plasma (1-2 units; ~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
76043680|NCT04364737|Other|Saline solution|Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
75419680|NCT05384977|Drug|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
75419681|NCT05384639|Device|Dual-task Group|Participant will cycle and perform cognitive training simultaneously.
75419682|NCT05384639|Device|Cycling Group|Participant will cycle only.
75419683|NCT05384639|Device|Cognitive Group|Participant will perform cognitive training only.
75564962|NCT00513422|Dietary Supplement|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
75564963|NCT00513422|Dietary Supplement|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
75874194|NCT01345058|Drug|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:~Week 1: 50 mg twice a day~Beginning Week 2: 100 mg twice a day."
75874195|NCT01345058|Drug|levetiracetam|Low dose ≤1500 mg/day, High dose >1500 mg/day
75874196|NCT05393739|Device|Theta burst transcranial magnetic stimulation (TBS) procedure|The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
76043681|NCT02559115|Radiation|68Ga-RM2 (RM2)|
76043682|NCT02559115|Device|PET/CT Scan|
75564964|NCT00513422|Dietary Supplement|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
75564965|NCT02944305|Procedure|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
75718835|NCT04002700|Drug|Atypical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
75718836|NCT00769496|Drug|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
75718837|NCT05354908|Other|scientific and academic productivity|Number and quartile of scientific products generated by the group
75718838|NCT04098653|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
75874197|NCT03642236|Drug|Ibrutinib|Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
75718839|NCT04098653|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
75874198|NCT02262117|Other|standard care|No specific medical care
75874199|NCT02262117|Drug|specific treatment|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
75419684|NCT05383755|Behavioral|Digital intervention for pregnant adolescents living with HIV|The newly developed digital intervention will include SMS for reminder purposes and Web-based components such as virtual simulations, gamified elements, and didactic content to educate and build relevant skills (e.g., disclosure self-efficacy) to facilitate social support from caregiving family members. The intervention will (1) raise awareness about the intersecting stigmas of HIV and pregnancy; (2) highlight the effects of these stigmas on disclosure and social support; and (3) increase self-efficacy and communication skills for disclosure and enlistment of family members as social support allies. The goal of the intervention is to improve PMTCT engagement among pregnant unmarried ALHIV. Our theory-informed Web-based intervention will be use 3C Institute's Dynamic e-Learning Platform (DeLP), a customizable software platform that implements the evidence-based cognitive theory of multimedia learning (CTML) to effectively engage users.
75419685|NCT05379413|Drug|Botulinum toxin type A|Botulinum neurotoxin (BoNT) Type A injection with either OnaBoNT-A, AboBoNT-A, IncoBoNT-A
75874200|NCT03642158|Device|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
76043683|NCT05494957|Drug|New regimen(BdqCfzLzd+XY)|The basic regimen consists of bedaquiline, clofazimine, linezolid, and 2-3 drugs such as amikacin and tigecycline are selected according to the drug use history and in vitro culture drug sensitivity results to form the regimen, and the treatment period is usually more than 12 months, and the doses of various drugs are used for the regular drug use.
75874201|NCT05389215|Drug|DWN12088|DWN12088 Xmg Tablet (BID)
75718840|NCT04098653|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
75874202|NCT05389215|Drug|Placebo|Placebo 0mg Tablet (BID)
75718841|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
75718842|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
75718843|NCT04002154|Device|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
75718844|NCT00777374|Drug|Patch|epicutaneous application of allergen patch
75874203|NCT01345292|Device|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
75874204|NCT01345292|Drug|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
75874205|NCT01345292|Drug|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
75874206|NCT03340961|Drug|DFD-29 Extended Release Capsules (40 mg)|Oral Treatment
75874207|NCT03340961|Drug|DFD-29 Extended Release Capsules (20 mg)|Oral Treatment
75874208|NCT03340961|Drug|Oraycea® (doxycycline) Capsules|Oral Treatment
75874209|NCT03340961|Drug|Placebo Capsules|Oral Treatment
75874210|NCT04077879|Drug|ASP1617|Oral
75874211|NCT04077879|Drug|Placebo|Oral
75874212|NCT03340025|Device|PICO Single Use Negative Pressure Wound Therapy System|Class II negative pressure wound therapy powered suction pump
75874213|NCT03340025|Device|xeroform gauze|traditional surgical dressing of xeroform gauze and padding
75874214|NCT05283434|Drug|Arnica|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the experimental group will take the recommended doses of Arnica 1M coated sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
75718845|NCT00777374|Drug|Placebo patch|epicutanoeus application of a placebo patch
75718846|NCT05297123|Drug|All-trans retinoic acid|All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.
75718847|NCT05297123|Drug|Arsenic Trioxide|ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)
75718848|NCT05297123|Drug|Realgar-Indigo naturalis formula|60 mg/kg/d for 8 weeks
75718849|NCT00654420|Drug|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
75874215|NCT05283434|Drug|Placebo|Sugar pill placebo
75874216|NCT03643874|Drug|Halix albuterol 90 mcg|albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg
75874217|NCT03643874|Drug|albuterol HFA MDI 90 mcg|albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
75874218|NCT03641144|Device|Navigation laser|Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
75419686|NCT05379374|Combination Product|bupivacaine and morphine|Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
75419687|NCT05375708|Radiation|Stereotactic body radiation therapy (SBRT)|Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.
75419688|NCT05375708|Drug|Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)|"CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is <70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks."
75419689|NCT05375279|Procedure|Lip Salivary Gland Biopsy|Obtaining few salivary glands from the partipants' lip that will be studied using the Congo Red staining method.
75419690|NCT05373810|Other|Surgery|all interventions are allowed
75564966|NCT04695821|Device|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
75564967|NCT00515892|Drug|Immunotoxin therapy|
75564968|NCT00515892|Drug|CAT-8015 Immunotoxin|
75564969|NCT00515892|Procedure|Biological therapy|
75564970|NCT00515892|Procedure|Antibody Therapy|
75564971|NCT00515892|Procedure|Monoclonal Antibody Therapy|
75564972|NCT00513539|Drug|porfimer sodium|
75564973|NCT00513539|Procedure|biliary stenting|
75564974|NCT00515931|Radiation|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
75564975|NCT04695470|Drug|Fruquintinib and Sintilimab|"fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w"
75564976|NCT04691973|Behavioral|Health and lifestyle tool|Health and lifestyle tool used online
75718850|NCT00654420|Drug|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
75874219|NCT03641144|Device|Traditional laser|Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
75874220|NCT03642002|Other|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
75564977|NCT04691973|Other|Usual care|Usual care at ordinary healthcare provider
75564978|NCT00511979|Drug|Technosphere Insulin|
75564979|NCT00511979|Drug|Technosphere insulin|
75564980|NCT00511979|Drug|Technosphere insulin|
75564981|NCT00511979|Drug|Regular human insulin|
75564982|NCT02950701|Device|Observational data collection.|
75564983|NCT00513578|Biological|PR1 leukemia peptide vaccine|
75564984|NCT00513578|Biological|incomplete Freund's adjuvant|
75564985|NCT00513578|Biological|sargramostim|
75564986|NCT02950662|Other|Overdenture|Active comparator will be metal housing and peek housing
75718851|NCT00773630|Drug|Cilostazol|100 mg Cilostazol
75718852|NCT03683836|Diagnostic Test|No intervention|No intervention
75718853|NCT05356312|Biological|Vaccination|Personalized neoantigen vaccination
75718854|NCT05353114|Other|3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).|The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
75718855|NCT04016922|Other|Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C|"Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\U ratio.~* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US."
76043684|NCT05494879|Behavioral|microkinesitherapy treatment|"The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions."
76043685|NCT05490823|Device|A smartphone app for anemia screening|This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
76043686|NCT04424485|Procedure|Total thyroidectomy (TT)|Standard TT procedure for thyroid carcinoma, for both groups
75718856|NCT03646474|Drug|tranexamic Acid infusion|The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
75419691|NCT05372965|Other|experimental-periodontitis-mirna-223-gingival tissue-saliva samples|Non-surgical periodontal treatment will be applied to individuals with periodontitis, gingival samples will be collected during the treatment, clinical measurements and saliva collection will be repeated 4 weeks after the treatment. MiRNA-223 gene expression analysis will be performed by real-time PCR (Polymerase Chain Reaction) method in saliva and gingival samples of individuals. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
75419692|NCT05372965|Other|control-clinical healthy mirna-223-gingival tissue-saliva samples|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample will be collected from the clinically healthy group. A tissue sample will be collected during the clinical crown lengthening operation.
75419693|NCT05339633|Drug|[14C]-D-0502|Drug: [14C]-D-0502 and D-0502
75718857|NCT03646474|Drug|saline infusion|In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
75718858|NCT00808002|Drug|Raltegravir|Raltegravir 400 mg every 12 hours
75718859|NCT00808002|Drug|Maraviroc|Maraviroc 300 mg every 12 hours
75718860|NCT00808002|Drug|Tenofovir/Emtricitabine|Tenofovir/Emtricitabine 300/200 mg every 24 hours
75718861|NCT00307489|Drug|tenofovir DF|300 mg tablet, once daily (QD)
75718862|NCT00307489|Drug|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
75718863|NCT04001764|Procedure|The radial artery cannulation over 2 cm of the wrist|The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.
75718864|NCT04001764|Procedure|The radial artery cannulation in the distal 3/4 area of the forearm|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
76043687|NCT04424485|Procedure|Central lymph node dissection (CLND)|Standard CLND for thyroid carcinoma, for both groups
75564987|NCT02952053|Device|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
75419694|NCT05335174|Device|Device: HemoSphere monitor and Acumen IQ sensor.|Patients will be placed on this monitor for the duration of study in the PACU. Followed by 30-day phone call to record cardiovascular complications.
75564988|NCT02952053|Device|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
75564989|NCT00513656|Drug|Oxycodone|
75564990|NCT00513656|Drug|Oxycodone/Naloxone|
75564991|NCT00529932|Other|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
75718865|NCT04001764|Procedure|The radial artery cannulation in the distal 1/2 area of the forearm|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
75718866|NCT00812292|Drug|TMC278|
75718867|NCT04003168|Drug|Human BCMA targeted T Cells Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
75718868|NCT00812370|Drug|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
75718869|NCT05284786|Device|nerve ultrasonography|Ultrasonography of different nerves was performed using a high frequency 18 MHz probe (esaote Ultrasound systems). Each nerve was scanned in axial plane, and the cross-sectional area (CSA) was measured at standardized anatomical points, in brief: median nerve in upper arm, elbow, forearm; ulnar nerve in upper arm and forearm; tibial nerve in popliteal and ankle; peroneal nerve in popliteal fossa, sural nerve in the calf and the vagus nerve.
75874221|NCT03642002|Other|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
75874222|NCT03642002|Other|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
75874223|NCT03642002|Behavioral|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
75874224|NCT03642002|Other|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
75874225|NCT03339713|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1*10^11 vp.
75564992|NCT00529932|Other|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
75718870|NCT00645840|Drug|Anakinra|Patients will receive daily anakinra therapy for 28 days
75874226|NCT03339713|Biological|Fluarix|Fluarix will be administered as intramuscular injection.
75874227|NCT03339713|Biological|Placebo|Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
75874228|NCT03641066|Device|Ankle Brace|Each participant will complete the 1 minute walking and 2 minute running under 5 conditions [1] un-braced, [2] Active Ankle 329 Ankle Sleeve, [3] AS1Pro (a lace-up brace), [4] Eclipse 1 (single-upright brace), and [5] Eclipse 2 (double upright brace)
75874229|NCT03641768|Device|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
75419695|NCT05312060|Device|PC Pneumatic compression|Pneumatic compression of the operated limb
75419696|NCT05312060|Other|AE Antithromboembolic exercises|Exercises for the edema
75419697|NCT05299697|Drug|TG103 15 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
75419698|NCT05299697|Drug|TG103 22.5 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.
75419699|NCT05299697|Drug|Placebo|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.
75564993|NCT00513734|Other|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
75564994|NCT00513734|Other|Lacrilube ointment|lubricant put into eye (inferior formix)
75564995|NCT00531102|Other|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
75564996|NCT00531102|Other|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
75564997|NCT02951858|Behavioral|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
75564998|NCT02951858|Behavioral|Control Group|The participants only receive the materials about the harm of substance use.
75564999|NCT00529971|Behavioral|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
75565000|NCT00529971|Other|Control|Treatment as usual, which could include medications or psychotherapy
75565001|NCT02951741|Other|RTHRA group|hematologic variables measurement in patients undergoing revision total hip replacement
75565002|NCT00530127|Drug|placebo|Same dose and frequency as treatment
76043688|NCT04424485|Diagnostic Test|Sentinel lymph node (SLN) bopsy|Intrathyroidal injection of ICG for SL biopsy, for only experimental group
75419700|NCT05296655|Other|Reflux Symptom Index Inventory (diagnostic survey)|Kazakh versions of the Reflux Symptom Index Inventory will be filled patients
75419701|NCT05296655|Other|Reflux finding score|laryngoscopy with a score RFS
75419702|NCT05286918|Procedure|The intervention (CRP-guided) group|"The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to <5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
75419703|NCT05259254|Other|Mobile Application|the mobile application will be consist of 4 modules which are: video observed therapy, health education, reminder system, and feedback.
75419704|NCT05259254|Other|Direct Observed Therapy|it is a specific strategy that require identification, training, and supervision by various parties such as healthcare worker, community volunteer, or family members to directly monitor the ingestion of anti-TB medication. DOT was aimed to improve medication adherence by active monitoring and documenting the consumption of each dose taken. Conducting DOT is not only limited to directly observe the treatment, but also can assess medication side effects as well as to document the visit and information regarding medications (e.g., frequency and timing of taking medication).
75419705|NCT05252624|Drug|placebo|Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
75565003|NCT00530127|Drug|deferiprone|100 mg/mL
75565004|NCT00530127|Drug|deferiprone|100 mg/mL
75565005|NCT00530127|Drug|placebo|Same dosage and frequency as study drug
75565006|NCT00530127|Drug|deferiprone|100 mg/mL
75565007|NCT02951936|Device|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
75565008|NCT02951936|Device|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
75565009|NCT00513851|Drug|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
75565010|NCT00513851|Drug|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
75565011|NCT04691934|Procedure|Anesthesia management|Patients who underwent cesarean section and had positive PCR nasopharyngeal swabs for COVID-19 were included in the study. Patients who tested negative and were clinically suspicious were excluded from the study. PCR test was not performed on all elective and emergency pregnant women to be taken for cesarean section in our hospital. It was only applied to patients with symptoms or patients who were suspected. All patient demographics and information about anesthesia were analyzed retrospectively from the patient files.
75565012|NCT00513890|Device|Infantflow [EME, Brighton, England]|
75565013|NCT02944266|Other|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
75565014|NCT00512018|Device|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
75565015|NCT00512018|Other|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
75718871|NCT00773708|Drug|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
75565016|NCT00530205|Other|physiologic testing|
75565017|NCT00530205|Other|questionnaire administration|
75565018|NCT00530205|Procedure|management of therapy complications|
75565019|NCT00530205|Radiation|radiation therapy|
75565020|NCT00512057|Drug|allopurinol|allopurinol 300mg twice a day
75565021|NCT00512057|Drug|placebo|placebo
75565022|NCT00531141|Other|examination only|OCT performed twice
75718872|NCT00307333|Device|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
75718873|NCT00762359|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
75718874|NCT00762359|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
75565023|NCT00513929|Dietary Supplement|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
75565024|NCT00531180|Procedure|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
75718875|NCT04003090|Drug|Citicoline|After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
75718876|NCT00777530|Drug|Bosutinib (SKI-606)|
75419706|NCT05252624|Drug|Henagliflozin 5Mg Tab|Single oral tablet
75419707|NCT05237622|Device|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data on lung volume changes will be measured using electrical impedance tomography.
75565025|NCT00531180|Procedure|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
75419708|NCT05234411|Other|Evaluation of ketogenic diet impact on ketonemia|Ketonemia and glycemia levels monitoring during different phases of menstrual cycles
75718877|NCT00814476|Other|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
75718878|NCT00814476|Other|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
75718879|NCT04002856|Device|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
75718880|NCT01061749|Biological|Cixutumumab|Given IV
75718881|NCT01061749|Other|Laboratory Biomarker Analysis|Correlative studies
75718882|NCT01061749|Other|Pharmacological Study|Correlative studies
75718883|NCT01061749|Drug|Selumetinib|Given PO
75718884|NCT02551614|Procedure|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
75718885|NCT02551614|Procedure|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
75718886|NCT02551614|Procedure|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
75718887|NCT05350306|Device|Chincup|Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.
75874230|NCT03641768|Device|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
76043689|NCT04424485|Diagnostic Test|Identification of parathyroid glands (PGs)|Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
75419709|NCT05216484|Biological|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
75565026|NCT00512174|Other|BladderScan BVI 3000|
75565027|NCT00531219|Procedure|Transgastric Appendectomy|The appendix will be removed through an incision in the stomach and pulled out through the mouth
75565028|NCT00531219|Procedure|Transgastric Cholecystectomy|The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
75718888|NCT05350306|Other|Control group|The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
75718889|NCT03978949|Drug|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
75419712|NCT05167656|Other|Intraoral manual therapy|Six intraoral manual therapy sessions based on ischemic compression and pain pressure release of the temporomandibular region muscles, applied bilateral.
75419713|NCT05167656|Other|Extraoral manual therapy|Six extraoral manual therapy sessions based on ischemic compression, pain pressure release and pressure sliding of the temporomandibular region muscles, applied bilateral.
75419714|NCT05167656|Other|Exercise and counselling|"Information about etiology, contributing and related factors, natural history and prognostic of the pathology of temporomandibular disorders.~Counselling based on: diet, habits like tabacism, stress and anxiety control, physical activity and awareness of dental clenching.~Exercise daily program based on active and passive mobility of the temporomandibular joint, stretching exercises and self massage."
75419715|NCT05122715|Device|Additional PET/CT Scan|The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.
75565029|NCT00513968|Genetic|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
75718890|NCT03978949|Drug|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
75718891|NCT05356234|Behavioral|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|The Intervention group will be assigned a Case Manager and placed in the next available On My Shoulders (OMS) curriculum that offers strategies to help individuals develop a strong and healthy self in the service of making current and/or future relationships of all forms (parent-child, romantic, family, work) successful and satisfying. This curriculum is intended to equip men (and, where applicable, women) with the skills they need to build and nurture healthy relationships. This curriculum should help participants improve family functioning. Additionally, Transforming Impossible into Possible (TIP) financial literacy curriculum will be utilized to help participants increase job retention for those currently employed, improve wages through additional educational and training opportunities, and learn skills to better manage family finances. This curriculum should help participants increase economic stability and mobility.
75718892|NCT00769964|Drug|VA111913 TS / placebo|
75718893|NCT03327922|Device|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
75419716|NCT05115422|Behavioral|'Coping with Brain Fog' program|The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.
75419717|NCT05113615|Drug|Tiotropium Bromide|respimat inhaler 2.5mcg/puff
75419718|NCT05113615|Drug|Matching placebo|matching placebo Respimat inhaler
75419719|NCT05047432|Other|Non-interventional trial|Non-interventional trial
75565030|NCT00513968|Drug|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
75565031|NCT00530244|Dietary Supplement|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
75565032|NCT00530244|Dietary Supplement|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
75565033|NCT00514007|Drug|OSI-906|OSI-906 administered orally
75565034|NCT00530283|Other|PET-CT|
75565035|NCT00512213|Dietary Supplement|Immunonutrition for 5 days preoperative|Impact vs Meritene
75565036|NCT00512213|Dietary Supplement|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
75565037|NCT02951585|Device|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
75565038|NCT02951585|Device|PLACEBO|Intra-articular injection of physiological serum (saline solution)
75565039|NCT04691349|Drug|CAR-T|The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
75718894|NCT01066117|Other|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
75718895|NCT00770042|Drug|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
75419720|NCT05041504|Behavioral|Peer navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for prostate cancer via the True North Peer Navigation website. Participants will be matched with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Participants will also have access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer.
75419721|NCT05041504|Other|Active wait list control|Participants in the active wait list control group will receive usual care and access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer. After completion of the study, patients in the active wait list control group will be matched with a peer navigator.
75419722|NCT05037630|Behavioral|Self-guided Digital Tool for Problematic Alcohol Use|See arm/group-description
75419723|NCT05030233|Behavioral|Nurse-Administered Touch Intervention|The nurse-administered touch intervention is a bare-handed, comforting touch intervention administered during an episode of essential nursing care. The bedside nurse will cradle the infant's head with one hand, using the other hand to gently support the infant's lower body and legs in a flexed position. The touches will be administered for 1 minute at the start of the essential care episode, 30 seconds after the diaper change, and 1 minute at the conclusion of the care episode.
75718896|NCT00770042|Drug|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
75419724|NCT05013957|Diagnostic Test|Methylation analysis|Methylation analysis
75565040|NCT02951624|Behavioral|Control|Control intervention
75565041|NCT02951624|Behavioral|Breaker|Short breaks of physical activity
75565042|NCT02951624|Behavioral|Prolonger|longer breaks of physical activity
75565043|NCT02951624|Behavioral|Intermediate|Intermediate breaks of physical activity
75565044|NCT00531258|Device|rTMS|Bilateral rTMS
75565045|NCT00531258|Device|Sham rTMS|sham rTMS
75565046|NCT02951468|Procedure|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed [14]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
75565047|NCT03459248|Other|Dual therapy|combination of 10 mg metoclopramide with 4 mg ondansetron
75565048|NCT03459248|Other|Monotherapy|10 mg metoclopramide
75565049|NCT03459248|Other|General anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation.
75565050|NCT00531297|Procedure|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
75718897|NCT00770042|Drug|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
75718898|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 8
75718899|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 6
75718900|NCT00770042|Drug|Avanafil|Avanafil 200mg Days 1 and 6
75718901|NCT03321370|Diagnostic Test|Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention|Continuous electrocorticography via subdural electrode strips for 1 to 3 weeks in the neuro intensive care unit following traumatic brain injury
75565051|NCT00512291|Drug|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
75565052|NCT02944032|Other|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
75565053|NCT02944032|Other|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
75565054|NCT00514163|Drug|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
76043690|NCT05490745|Behavioral|Skills4Parenting+|Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.
76043691|NCT05490745|Other|Waiting-list (nocebo)|Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
76043692|NCT05494645|Drug|Exparel|Liposomal bupivicaine
76043693|NCT05494645|Drug|Peripheral Nerve Block|Peripheral nerve block without Exparel
76043694|NCT05494567|Drug|Tadalafil 5mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1
76043695|NCT05494567|Drug|Tamsulosin Hcl 0.4 mg|patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2
75565055|NCT00514163|Drug|gemcitabine|gemcitabine DIV on day one , 8th and 15th
75565056|NCT04691466|Procedure|Joint replacement|Routinely performed hip- or knee replacement
75565057|NCT04695548|Other|Concentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
75565058|NCT04695548|Other|Isometric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
76043696|NCT05494567|Drug|solifenacin 10 mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
76043697|NCT04331587|Device|BF-P190 4 mm thin bronchoscope|"EVIS EXERA III Bronchofiberviedoscopes~Olympus"
76043698|NCT04331587|Device|BF-MP190F 3 mm ultrathin bronchoscope|"EVIS EXERA III Bronchofiberviedoscopes~Olympus"
76043699|NCT04331587|Device|Radial ultrasound probe (UM S20-17S)|-Olympus
75718902|NCT03982615|Device|Laser-Lok abutment|"Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment."
75718903|NCT03982615|Device|Standard healing abutment|Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
75718904|NCT00777686|Procedure|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
76043700|NCT04331587|Device|PeriView FLEX 21G Single Use Aspiration Needle|"NA-403D-2021~Gyrus ACMI, Inc."
75718905|NCT00654186|Drug|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
75718906|NCT03275818|Drug|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
75718907|NCT03979105|Drug|Ketamine|Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
76043701|NCT00609115|Device|AMES device (test)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
76043702|NCT00609115|Device|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
76043703|NCT00609115|Device|AMES device (crossover)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
75419725|NCT04981977|Behavioral|Care Transitions Intervention|CTI is delivered by a trained Care Transitions Coach (Coach) who works closely with patients to ensure a smooth transition from hospital to home following an acute hospitalization. The patient, caregiver, and Coach work together to maximize the involvement of interdisciplinary experts, ensuring that the appropriate professionals are involved, issues are addressed, goals are understood, and the discharge care plan is executed correctly. There are three aspects to CTI; the first is the initial hospital visit, followed by an in-home visit, concluding with telephone follow-up over a 28-day period. During these visits, the Coach focuses on four conceptual areas, referred to as pillars (i.e., Personal Health Record, Medication Management, Red Flags, and Physician Follow up). The Coach ensures the patient understands and utilizes the Personal Health Record to facilitate communication and ensure continuity of care plan across providers and settings.
75565059|NCT04695548|Other|Eccentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.
75565060|NCT04695548|Other|Analytic passive stretching|The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
75565061|NCT04691388|Drug|Amlotinib+Sindili|All patients will receive Sindelizumab combined with Antinib Hydrochloride capsule every 3 weeks
75718908|NCT00773942|Behavioral|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
75718909|NCT00773942|Behavioral|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
75718910|NCT01061905|Behavioral|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
75718911|NCT01061905|Behavioral|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
75718912|NCT01061905|Behavioral|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
76043704|NCT05494411|Drug|Mitomycin for pyelocalyceal solution|
76043705|NCT05494333|Other|no intervention|NO intervention
76043706|NCT04080895|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
75718913|NCT00814554|Behavioral|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
76043707|NCT04080895|Drug|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
75718914|NCT00814554|Behavioral|Screening strategy|2. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
75718915|NCT00814554|Other|Environmental strategy|3. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
75419726|NCT04981977|Behavioral|Care Transitions Intervention and Peer Support|The PS intervention for this study is based upon the principles of motivational interviewing, which is a person-centered, goal-directed method to enhance intrinsic motivation for change by exploring and resolving ambivalence. A recent meta-analysis found the mean effect size for MI to be significantly larger for racial and ethnic minority samples (0.79 vs. 0.26) as compared to non-Hispanic Whites, highlighting its potential benefit and cultural relevance for minority populations. Patients in this arm of the study will receive the 28-day CTI intervention with a 2-month long Peer Support (PS) intervention provided by trained peer educators (PEs).
75419727|NCT04981977|Other|Usual Care|The researchers will follow a control group of patients who meet study inclusion criteria. These older adults will participate in the traditional discharge case-management offered by the hospital where they were admitted and discharged. UC at our three partner hospitals consists of: (1) routine inpatient nurse intake that includes screening about housing, substance abuse, and functional status; (2) medication reconciliation performed by treating practitioners; (3) discharge patient education provided by inpatient nurses; (4) a list of resources for safety-net clinics and community-based services; and (5) for patients with severe chronic illness (e.g. heart failure) there may be a planned home visit by a nurse practitioner.
75419728|NCT04883944|Other|Intervention group|"Mother will be involved in implementing the non-pharmacological techniques during the performance of the heel stick procedure as follow:~swaddling;~non-nutritive sucking with pacifier in infants with PMA < 32 weeks;~nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~holding;~exposure to maternal voice."
75565062|NCT04695626|Procedure|The combination of bone marrow stimulation and modified suture bridge(Greenhouse tec)|According to the anteroposterior diameter of the injury, single or double high braided thread were used to suture the tendon in a modified Mason Allen way without knotting. Bone marrow stimulation was carried out in the footprint area of rotator cuff. A 2.0 mm diameter cone was created with a depth of 1 cm and a spacing of 5 mm. Six to eight holes were made due to the diameter of the tear of rotator cuff until blood and fat droplets exudate. Then the threads were passed through the locking eyelet of the lateral row anchor. After tightening the threads, the anchor was screwed in at the distal part of the gteater tuberosity. With this new technique, the rotator cuff was repaired by one lateral row anchor without medial row knotting.
75565063|NCT00530322|Procedure|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
75565064|NCT04695743|Other|Online Cognitive Stimulation Therapy|Participants will attend 14 x 1 hour online CST sessions that involve a variety of activities to stimulate the brain and focus on cognitive strengths based on a variety of themes i.e. childhood, using money, etc. This will aim to be multisensory and give choice and empowerment to participants. Benefits of face to face CST are shown to slow cognitive decline and improve quality of life. Adapting it for online use will investigate whether participants can still benefit in this way.
75565065|NCT02943486|Other|dac-MSCs|Cell-free therapy
75565066|NCT02943486|Other|MSCs|Cell-based therapy
75565067|NCT02943486|Drug|Fitostimoline|Triticum vulgare
75565068|NCT00514202|Drug|Placebo|matched placebo
75565069|NCT00514202|Drug|Dextroamphetamine SR|60 mg/day
75565070|NCT00530361|Drug|Nesiritide|
75718916|NCT00761969|Other|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
75718917|NCT00774020|Drug|Zoledronic acid|5mg, i.v. single dose
75718918|NCT04100447|Drug|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
76043708|NCT04080895|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
76043709|NCT04080895|Drug|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2
76043710|NCT04265209|Drug|SPECT|[123I]-FP-CIT SPECT imaging procedure
75565071|NCT00512408|Drug|testosterone|
75565072|NCT00530400|Drug|cefuroxime|preoperative intravenous 1.5g cefuroxime
75565073|NCT00530400|Drug|placebo|preoperative intravenous placebo
75565074|NCT00531336|Drug|intravitreal injection of Bevacizumab (Avastin)|1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
75565075|NCT00531336|Drug|Pegaptanib (Macugen)|0.3 mg intravitreally applied every 6 weeks as long as required
75565076|NCT00530478|Drug|Donepezil|
75565077|NCT00531375|Device|Silicone hydrogel contact lens|
75419729|NCT04883944|Other|Standard care group|"A second nurse will perform the non-pharmacological techniques during the performance of the heel stick procedure without the maternal involvement as follow:~swaddling;~non-nutritive sucking with pacifier in infants with PMA < 32 weeks;~nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~holding."
75419730|NCT04850378|Drug|Dalteparin|Drug: Dalteparin 200 units/kg once a day for 4-7 days.
75419731|NCT04850378|Drug|Apixaban|Drug: Apixaban 5 mg twice a day for 4-7 days.
75565078|NCT00530556|Drug|zolpidem|
75718919|NCT03274804|Biological|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
75419732|NCT04834882|Other|Data collection (|online survey
75419733|NCT04809103|Drug|cis-diamminedichloroplatinum|Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC
75419734|NCT04804371|Drug|F18-FDG|Evaluate FDG uptake
75419735|NCT04797234|Other|Control|There will be no intervention to the control group.
75565079|NCT00512486|Biological|MEDI-563|"BIW-8405/MEDI-563 administered at one of five dose levels:~0.03 mg/kg intravenous injection~0.1 mg/kg intravenous injection~0.3 mg/kg intravenous injection~1.0 mg/kg intravenous injection~3.0 mg/kg intravenous injection~Following the -3.0 mg/kg dose level,~BIW-8405/MEDI-563 administered at one of two lower dose levels:~0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection"
75565080|NCT00530595|Drug|candesartan or valsartan or losartan|
75565081|NCT02951507|Other|O T unilateral attachment|O T unilateral attachment system
75565082|NCT02951507|Other|New design of extracoronal attachment system|O T unilateral attachment
75718920|NCT03274804|Drug|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
75874231|NCT03641768|Device|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
76043711|NCT04265209|Drug|PET|[18F] LBT-999 PET imaging procedure
75419736|NCT04797234|Other|Experiment|The experimental group will be trained for 6 weeks.
75419737|NCT04830527|Behavioral|EMA prompting for patients|"EMA prompting will consist of the delivery of the PHQ-4 and PANAS questionnaires, as well as basic identification, therapy motivations and expectations, location, current activity and social interactions.~These prompts will be presented to patients during a 7 day period, 5 times per day."
75419738|NCT04830527|Behavioral|PDF Reports for therapists|After the patients' EMA data is collected, a previously designed R script will summarize and transform the data into a brief and graphic report for therapists in the experimental arm of the study. These reports are intended to provide detailed information about the patients' mood, anxiety levels, positive and negative affects, as well as crossed data such as mood according to location, anxiety according to activity, etc.
75419739|NCT04776031|Device|R:GEN Laser System|Laser Treatment
75565083|NCT00512525|Drug|Ghrelin and saline (as placebo)|Intravenous infusion
75565084|NCT00531492|Behavioral|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
75565085|NCT00531492|Other|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
75565086|NCT00512564|Other|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
75565087|NCT02943759|Drug|Neem leaf extract|A natural irrigant solution act as anti-inflammatory and anti bacterial
75565088|NCT02943759|Drug|Chlorhexidine gluconate|2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
75565089|NCT00514241|Device|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
75565090|NCT02944110|Drug|Glucagon receptor antagonist LY2409021|single oral dose of 300mg
75718921|NCT05493449|Combination Product|UHT Milk|In this group of participants, UHT milk, 180 mL was provided and results were compared with control and flavored milk group
75718922|NCT05493449|Combination Product|Flavored Milk|In this group of participants, flavored milk, 180 mL was provided and results were compared with control and UHT group
75718923|NCT00774098|Drug|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
75718924|NCT00774098|Drug|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
75565091|NCT02944110|Drug|Placebo|Oral dose of placebo tablets
75565092|NCT03459209|Other|tube feeding|The obtained milk aliquots undergo in vitro administration through three different tube feeding techniques.
75565093|NCT02943837|Procedure|Device: 22G FNA needle|
75565094|NCT02943837|Procedure|Device: 20G FNB needle|
75565095|NCT00530751|Other|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool [GREAT]) are explored.
75565096|NCT02951975|Drug|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
75565097|NCT00514397|Drug|motexafin gadolinium|
75565098|NCT00514397|Drug|temozolomide|
75565099|NCT00514397|Procedure|adjuvant therapy|
75718925|NCT00774098|Dietary Supplement|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
75565100|NCT00514397|Procedure|quality-of-life assessment|
75565101|NCT00514397|Radiation|radiation therapy|
75718926|NCT00774098|Drug|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
75718927|NCT00761891|Other|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
75718928|NCT00777842|Device|GTX™ Drug Eluting Coronary Stent System|Drug eluting stent
75718929|NCT04002076|Behavioral|Robot-assisted hand combined with occupational therapy|Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
75718930|NCT04002076|Behavioral|Traditional occupational therapy|Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
75718931|NCT00774332|Drug|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
75718932|NCT00321685|Biological|Bevacizumab|Given IV
75718933|NCT00321685|Drug|Capecitabine|Given PO
75718934|NCT00321685|Drug|Fluorouracil|Given IV
75718935|NCT00321685|Drug|Leucovorin Calcium|Given IV
75565102|NCT02943603|Drug|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
75565103|NCT00514436|Behavioral|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
75565104|NCT00531687|Drug|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
75565105|NCT00531687|Drug|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
75565106|NCT00531687|Drug|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
75718936|NCT00321685|Drug|Oxaliplatin|Given IV
75718937|NCT00321685|Radiation|Radiation Therapy|Undergo radiotherapy
75718938|NCT00321685|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
75718939|NCT00778076|Device|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
75718940|NCT00778076|Device|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
75718941|NCT05196412|Device|PulseOn Arrhythmia Monitor device|Wearing of the wrist device for a period of two weeks
75718942|NCT00779090|Procedure|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
76043712|NCT04077619|Behavioral|Modern pain neuroscience approach|Modern pain neuroscience approach. The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
76043713|NCT04077619|Behavioral|Usual care physiotherapy|Usual care evidence-based physiotherapy The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
76043714|NCT04251169|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as 30 minutes IV infusion every 3 weeks beginning in Cycle 1
75419740|NCT04771052|Other|COVID Rehabilitation Program for the Elderly (CORE)|In the intervention unit, two teams (core team: physiotherapists and service healthcare workers; specialized team: occupational therapist, registered dietician, social worker) are dedicated to the patients hospitalized in COVID-19 unit. To prevent malnutrition, caused by disease-associated inflammation, the Nutrition as Medicine program (prescribed small doses (30 or 60 mL; 2 kcal/mL) of oral nutrition supplement dispensed with medication pass, 1 to 4 times a day), has been systematically implemented (collective prescription). To improve muscle strength, balance and tissue oxygenation and concomitantly reduce immobilization and risk of falls, each patient has a private pedal exerciser, resistance elastic bands and free weights to perform a progressive, monitored and individualized rehabilitation program thrice a day.
75565107|NCT00514475|Drug|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
75718943|NCT04002778|Diagnostic Test|Fine needle aspiration|
75718944|NCT04002778|Diagnostic Test|Rapid on-site evaluation|
75718945|NCT02557022|Other|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
75718946|NCT01564342|Procedure|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
75718947|NCT00779480|Drug|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
75718948|NCT03902392|Dietary Supplement|NaturOx Group (A)|Comparison between dietary supplement and placebo
76043715|NCT04251169|Drug|Paclitaxel|Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
75419741|NCT04765371|Drug|DEXAMETHASONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
75565108|NCT00530829|Drug|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
75565109|NCT00512681|Drug|Irinotecan, Oxaliplatin, TS-1|"S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1~Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1"
75565110|NCT00530868|Other|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
75565111|NCT00530868|Drug|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
75718949|NCT03902392|Other|Placebo Group (B)|Comparison between dietary supplement and placebo
75718950|NCT00306787|Drug|Famciclovir|Famciclovir 500 mg tablet
75718951|NCT00306787|Drug|Valacyclovir|Valacyclovir 500 mg capsule
75718952|NCT00306787|Drug|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
75718953|NCT00306787|Drug|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
75718954|NCT00778232|Drug|Gabapentin tablets 800 mg|
75718955|NCT01564264|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
75718956|NCT00774488|Other|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
75718957|NCT01066195|Drug|iressa|iressa 250mg per day every day
75718958|NCT01066195|Drug|alimta|alimta 500mg/m2 every 3 weeks
75718959|NCT03147742|Drug|Ruxolitinib|Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
75718960|NCT00774644|Drug|Clarithromycin 500mg|
75718961|NCT03979027|Dietary Supplement|Breakfast: ready-to-eat-cereal and milk|
75565112|NCT00530907|Drug|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
75565113|NCT00530907|Drug|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
75565114|NCT02951663|Dietary Supplement|Protein|
75419742|NCT04765371|Drug|PREDNISOLONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
75565115|NCT00530985|Behavioral|Benefits Counseling|Help deciding whether to work
75718962|NCT00778388|Biological|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
75419743|NCT04744363|Drug|Stelara PFS|Pre filled syringes filled with AVT04 and Stelara
75565116|NCT00530985|Behavioral|VA Orientation|Orientation to services available at VA
75565117|NCT00531024|Drug|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
75565118|NCT00531024|Drug|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
75565119|NCT00512759|Drug|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
75718963|NCT00778388|Drug|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
75718964|NCT05123092|Other|Ultrasound guided lumbar erectae spinae block|One group by using ultrasound for making erectae spinae block
75718965|NCT05123092|Other|Intrathecal Morphine injection|Injecting intrathecal morphine
75718966|NCT05356156|Procedure|Closure of the mesenteric defects|The surgically created mesenteric defects will be closed after radical gastrectomy with D1+/D2 lymph node dissection.
75718967|NCT05356156|Procedure|Non-closure of the mesenteric defects|The surgically created mesenteric defects will not be closed after radical gastrectomy with D1+/D2 lymph node dissection.
75419744|NCT04727541|Drug|Bintrafusp alfa|Neoadjuvant therapy with bintrafusp alfa
75419745|NCT04700735|Device|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
75419746|NCT04673162|Drug|Methylprednisolone, Placebo|iv administration
75419747|NCT04665375|Drug|DOR/3TC/TDF|switch antiretroviral regimen to doravirine/lamivudine/tenofovir disoproxil fumarate once daily for 1 year
75419748|NCT04658082|Device|H.G.R (GWave) non-invasive glucometer|Glucose tolerance test
75565120|NCT00531726|Device|DBS of Cg25|
75419749|NCT04647071|Dietary Supplement|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
75419750|NCT04647071|Dietary Supplement|Control|Microcrystalline cellulose
75419751|NCT04638244|Behavioral|Music|Brief Online Music
75565121|NCT00514670|Other|Alcohol-based hand sanitizer & quaternary ammonium wipes|
75565122|NCT00531063|Drug|Everolimus (RAD001)|
75565123|NCT00512837|Behavioral|Mobile phone technology|
75565124|NCT02943798|Drug|etoposide plus carboplatin|etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
75565125|NCT02943798|Drug|Paclitaxel plus carboplatin|Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
75565126|NCT00512915|Device|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
75565127|NCT02943369|Drug|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
75565128|NCT02943369|Drug|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
75565129|NCT02943330|Other|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
75565130|NCT00514748|Procedure|DIEP|flap survival, operation time, flap complications, donor site morbidity.
75565131|NCT00514748|Procedure|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
76043716|NCT04073329|Other|post operative measure of reduction|measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with > 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as < 1 mm step and < 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
75419752|NCT04638244|Behavioral|Reading messages|Reading psychoeducational messages
75565132|NCT02943876|Other|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
75565133|NCT00515957|Genetic|genetically modified CTLs in combo with CD45 antibodies|"LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level <100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10^7 cells/m2~1x 10^8 cells/m2 3 x 10^8 cells/m2~1 x 10^9 cells/m2"
75565134|NCT00514826|Other|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
75419753|NCT04572568|Other|Multi-disciplinary assessment|"Comprehensive evaluation by multidisciplinary experts;~Preoperative multi-modal imaging examination was applied to determine the angioarchitecture, functional fiber bundle, and hemodynamics."
75718968|NCT04001530|Drug|Half Normal Saline 0.45% Infusion Solution Bag|Randomization to half normal saline
75718969|NCT04001530|Drug|Normal Saline 0.9% Infusion Solution Bag|Randomization to normal saline
76043717|NCT04279951|Other|Resistance exercise|High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
76043718|NCT04279951|Dietary Supplement|Omega-3|1 gram of omega-3 per day for 20 weeks
76043719|NCT04279951|Dietary Supplement|Placebo|1 gram of sunflower oleic oil per day for 20 weeks
76043720|NCT05494099|Procedure|endoscopic maxillary mega-antrostomy|a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.
76043721|NCT05494099|Procedure|Endoscopic Modified Medial Maxillectomy|In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.
76043722|NCT05494099|Procedure|Modified endoscopic pre-lacrimal approach|The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
76043723|NCT04165837|Drug|FB-101|Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
76043724|NCT04165837|Drug|Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
76043725|NCT04163341|Behavioral|Adapted Common Elements Treatment Approach|The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
76043726|NCT04279561|Procedure|Computed Tomography|Undergo 68Ga-PSMA-11 PET/CT
76043727|NCT04279561|Drug|Gallium Ga 68 Gozetotide|Given IV
76043728|NCT04279561|Procedure|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET/CT
75419754|NCT04566081|Other|iTALKbetter: deterministic|A word retrieval therapy application
75419755|NCT04566081|Other|iTALKbetter: reactive|A word retrieval therapy application
75419756|NCT04560556|Diagnostic Test|Point-of-Care (POC) Rapid HIV Test|Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
75565135|NCT02943642|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
75565136|NCT02943642|Drug|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
75565137|NCT02943720|Drug|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
75565138|NCT02943720|Drug|placebo|placebo
76043729|NCT01662895|Drug|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
76043730|NCT01662895|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
76043731|NCT05494021|Other|Whole-process management software|Enrolled participants will managed by a pre-designed software. The software would provide helpful assistance, such as lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.
75419757|NCT04560556|Diagnostic Test|Fourth Generation Antigen/antibody (Ag/Ab) HIV Test|Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
75419758|NCT04531566|Dietary Supplement|Oral Feed|Infant will be seen by occupational therapist (OT) twice a week and assessed for oral cues. If infant shows oral cues then the occupational therapist will proceed with feeding strategies. Oral feeding strategies include pacifier dips, open nipple trials with syringe controlled bolus size (1-4mls) and po trials up to 10mls.
75419759|NCT04531566|Dietary Supplement|Usual care|Infants will not start oral feeds until on HFNC 2 Litres or less. Oral feeds will be started on the discretion of the physician.
75419760|NCT04524221|Drug|PTG-100|PTG-100, 600mg taken twice daily in capsule form for 42 days
75419761|NCT04524221|Drug|Placebo|Placebo taken twice daily in capsule form for 42 days
75565139|NCT04695353|Procedure|Telemedicine: Virtual visits (videoconferences, texts)|Patients will receive clinical care by using telemedicine (virtual visits)
75565140|NCT02944149|Procedure|tubal ligation by minilaparotomy|Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
75718970|NCT05344846|Other|Guided imagery|The individuals in this group will be provided with guided imagery application. Guided imagery will be applied to the participants in the hospital environment 6-10 hours after the cesarean section. Afterwards, guided imagery application will be requested every day for two weeks.
75718971|NCT05282056|Diagnostic Test|CAD analysis|CAD shows the radiologist automatically delineated areas of potential COVID-19 affection, together with an overall lung affection percentage.
75718972|NCT05278936|Other|The cataract surgery and the anterior vitrectomy|Surgical
75718973|NCT00991900|Device|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
75718974|NCT00769067|Drug|Erlotinib|Continuous oral dosing at 150 mg daily.
76043732|NCT05494021|Device|LDCT detection|LDCT were performed in both arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
75419762|NCT04500951|Other|Optimized resting environment|"Alarms from feeding pumps will be relayed to the nurse call system for all intervention periods. Alternatively meals will be timewise reorganized to not interfer with the intervention resting periods. Signs reminding staff not to disturb will be posted for all intervention periods.~For each patient the close team of rehabilitation professionals will agree upon a guideline suggesting the optimal resting environment for the specific patient. The guideline wil be based on knowledge gathered from relatives on pre-injury preferences. Furthermore, the guideline will be developed based on a toolbox of possible intervention representing best practice. The toolbox has been designed according to the categories of the International Classification of Functioning.~The intervention will designed individually for each patient."
75419763|NCT04500951|Other|Standard resting environment|The control condition, standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward. Pressure ulcers and positioning believed to induce pain will be avoided.
75419764|NCT04452175|Other|JUUL E-CIGARETTE|JUUL E-CIGARETTE USAGE FOR 24 WEEKS
75718975|NCT00769067|Drug|PF-00299804|Continuous oral dosing at 45mg daily
75718976|NCT00321373|Biological|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
75718977|NCT00321373|Biological|FluarixTM|Single dose, Intramuscular injection
75718978|NCT02826928|Biological|blood sample withdrawn|
76043733|NCT05493943|Device|Pulsed ElectroMagnetic Field (PEMF) therapy|Application of PEMF using treatment coils in eproximity to the area where treatment is desired.
76043734|NCT05493943|Other|Pulsed ElectroMagnetic (PEMF) therapy|Control arm.
75718979|NCT04001608|Drug|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12
75718980|NCT04001608|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
75718981|NCT00667394|Biological|Bevacizumab|Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
76043735|NCT05493865|Behavioral|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|This study will be a two-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents and their parents by comparing to a no-intervention waitlist control group.
75718982|NCT00667394|Drug|MLN-518 (Tandutinib)|Tandutinib 500 mg by mouth daily dose twice a day.
75718983|NCT00667394|Procedure|Quality-of-life assessment|Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
75718984|NCT04103021|Device|Port-A-Cath|Totally implanted central venous access device
75718985|NCT05357326|Drug|Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
75718986|NCT05357326|Device|Orthokeratology|wear orthokeratology at night while sleeping
75718987|NCT05357326|Drug|Atropine Sulfate 0.04% Eye Drop|use one drop into subconjunctiva
75718988|NCT00778466|Drug|metformin hydrochloride 1000 mg tablets|
75718989|NCT00761735|Biological|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
75565141|NCT04695509|Drug|"moderate propofol sedation (Bispectral index monitoring 70-90; The Richmond Agitation and Sedation scale (RASS) -2 - -3"|Two peripheral venous blood catheters are placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, noninvasive blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol light-moderate sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C*. After 26 patients are recruited, the blood plasma is analyzed by conducting the enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
76043736|NCT04318171|Device|3D Imaging.|"When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:~Plaque volume where detectable.~Max area stenosis.~Volumetric stenosis.~Measured length.~3D GSM. The entire assessment should not take more than 45 minutes."
75419765|NCT04444687|Diagnostic Test|Test for SARS-CoV-2|"As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)~After intubation samples are acquired in the OR~tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)~blood sample (as part of standard operation procedures for CoVID-19 patients)~fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy~Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)~Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR."
76043737|NCT05499091|Procedure|Skin biopsy, blood sample, urine sample|blood samples, urine samples, skin samples.
75419766|NCT04431622|Device|Hearing aid amplification algorithms|The investigators will use stimulus waveforms that have been amplified and recorded for each individual's hearing loss. These waveforms will be created using Desired Sensation Level, Version 5-C hearing aid targets on a continuum of increased signal manipulation. The NIH-funded open hearing aid platform will be used to provide precise control over hearing aid parameters to create waveforms with linear and fast-acting compression amplification. A third set of waveforms will be created using a current clinical hearing aid that uses typical noise reduction and compression parameters. Investigating the effects of hearing aid algorithms in young normal-hearing and older normal-hearing listeners will aid in interpretation of these effects in the older hearing-impaired listeners.
75718990|NCT00761735|Drug|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
75718991|NCT00569946|Drug|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
75419767|NCT04421677|Drug|Phenylbutyrate Oral Tablet|Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.
75718992|NCT00778544|Drug|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
75718993|NCT04001374|Drug|Ticagrelor|90mg tablet bid for 12 months
75718994|NCT04001374|Drug|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
75718995|NCT02602067|Combination Product|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
75718996|NCT02556320|Drug|anti-epileptic drug|Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
76043738|NCT05489809|Procedure|Endotracheal extubation with suctioning|General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.
76043739|NCT05489809|Procedure|Endotracheal extubation with positive pressure|General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
76043740|NCT05493631|Biological|MG1113|MG1113 subcutaneous (SC) injection
75718997|NCT02556320|Biological|Blood sampling|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
75718998|NCT05330494|Other|transcutaneous electrical acupoint stimulation(TEAS)|transcutaneous electrical acupoint stimulation (TEAS), the modern therapies derived from traditional acupuncture, which could activate nerve endings or fibers and generate action potentials.s. TEAS uses self-adhesive electrodes placed on the surface of acupoints, instead of needles for electrical stimulation.The resulting stimulation signals, which are transmitted to the spinal cord and brain, stimulate the central nervous system to generate specific chemical mediators to induce relevant physiological effects.
75718999|NCT03869658|Behavioral|COCO application|All participants will complete a screening survey to determine their eligibility for the study, if eligible and willing to participate, he or she will sign an informed consent form. Once participants are enrolled in the study, a demographics questionnaire will be completed along with 5 days of food tracking on the COCO application. Between days 3 and 7, participants will complete two 24-hr diet recall, one a day, and a patient satisfaction questionnaire.
76043741|NCT05498857|Drug|Intramuscular ephedrine|Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
76043742|NCT05498857|Drug|Placebo|Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
76043743|NCT04424329|Dietary Supplement|Fibers and probiotics|A blend of fibers and seven probiotics
76043744|NCT05498545|Biological|LUCAR-B68 cells product|Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen
75719000|NCT05265910|Drug|olopatadine hydrochloride ophthalmic solution 0.7%|Pataday® Once Daily Relief Extra Strength (eyedrop)
75874232|NCT03641768|Device|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
75419768|NCT04418414|Drug|Gene therapy|CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
75419769|NCT04418414|Other|Biological|G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.
75419770|NCT04413240|Device|Telerehabilitation|"VRRS is a medical device to perform cognitive telerehabilitation and home speech therapy in online or offline mode.~K-Wand is an additional device to VRRS for motor telerehabilitation of the upper limb and trunk. It works with a set of motion sensors through light recognition technology.~Khymu is a set of sensors added to the VRRS used to carry out motor telerehabilitation activities of the lower limb. The use in combination with the K-Wand is able to allow full-body motor telerehabilitation.~Patients will have at their home a special workstation connected to the internet. The same equipment will also be present in the reference structure. Only the online telerehabilitation mode will be used, including an audio and video teleconference. The rehabilitator will be able to remotely control the patient's system. The patient, will see on his screen the exercises to be performed, their realization and the results achieved."
75719001|NCT05265910|Drug|loratadine 10 mg|Claritin® Tablets 24-Hour (tablet)
75719002|NCT05265910|Drug|Tears Naturale|Tears Naturale® II (eyedrop)
75719003|NCT05265910|Drug|Placebo|Placebo tablet (tablet)
75874233|NCT03254485|Drug|IW-1973|Oral Tablet
76043745|NCT05489497|Procedure|Primary closure with or without omental grafting|Primary closure with or without omental grafting
76043746|NCT05489419|Behavioral|Multimodal Prehabilitation|Physical and cardiopulmonary training, personalized nutrition and treatment of anxiety and depression.
75874234|NCT03254485|Drug|Placebo Oral Tablet|Oral Tablet
76043747|NCT05493319|Other|Exercises|Both groups will train three times a week, twice synchronously online and once asynchronously, considering a standardized exercise guideline. In all intervention sessions, conventional exercises will be guided by the standardized exercise guideline previously developed by the study team, for 4 weeks. Hypopresive, strength and resistance exercises group will receive static hypopressive exercise in supine position, with variant of arms in flexion, abduction and extension, consisting of 3 exercises at the end of the intervention with strength and resistance exercises.
75719004|NCT02601521|Behavioral|Internal tobacco coach|"The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program."
76043748|NCT05498467|Drug|Anakinra|100 mg Anakinra injections s.c.
76043749|NCT05498467|Drug|Sodium Chloride 9mg/ml Injection|9 mg Sodium Chloride injections s.c.
75419771|NCT04413240|Other|Conventional rehabilitation|It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated.
75419772|NCT04399200|Device|Treatment according to standard care recommandation|SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
75719005|NCT02601521|Behavioral|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
75719006|NCT00814866|Drug|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
75719007|NCT00991978|Other|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
76043750|NCT05498311|Radiation|Intraoperative Radiotherapy (IORT)|The Intrabeam Photon Radiosurgery System will deliver 20 Gy in the act of breast surgery
76043751|NCT05498311|Procedure|Breast conservative surgery|Breast conservative surgery with the aim of resecting breast tumour and with or without oncoplastic surgery
76043752|NCT05498311|Radiation|External Beam Hypofractionated Radiotherapy (EBRT)|A External Beam Hypofractionated Radiotherapy will be administered after surgery. y. The dose per fraction will be 2.67 Gy per session. EBRT will be performed daily from Monday to Friday for fifteen fractions.
75419773|NCT04347538|Other|Saline Nasal Irrigation|Saline nasal irrigation BID
75565142|NCT04695509|Drug|"deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)"|Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
75719008|NCT00645528|Other|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
75719009|NCT04001140|Behavioral|Enhancement of emotion regulation skills|Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
75719010|NCT00812448|Dietary Supplement|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
75719011|NCT05326672|Drug|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
75719012|NCT05326672|Drug|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
76043753|NCT05489263|Other|No intervention|No intervention
75719013|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
75719014|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
76043754|NCT05486221|Other|Extensive cardiologic work-up|Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
76043755|NCT05489107|Other|Ziverel|Within a first flexible rectoscopy (Day 1) the product will be applied transanally. Then the patients will apply it as enemas twice daily for 7 days. On day 8 (after treatment completion), and on day 31 (after 23 days of no treatment) follow-up flexible rectoscopies will be performed.
76043756|NCT05492929|Other|The deep breathing group|The deep breathing group
76043757|NCT05492929|Other|4-7-8 breathing technique|4-7-8 breathing technique Group
76043758|NCT02557399|Drug|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
76043759|NCT02557399|Drug|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
76043760|NCT02557399|Drug|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
76043761|NCT05485909|Other|Radiofrequency ablation|For multiple intrahepatic lesions, select 1 to 2 lesions for radiofrequency ablation
75565143|NCT02943135|Drug|lidocaine in-situ gel|lidocaine in-situ gel
75419774|NCT04347538|Other|Saline with Baby Shampoo Nasal Irrigation|Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.
75419775|NCT04340206|Behavioral|face-to-face support and Chatbot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to support adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program. In addition, they meet and get support from their human coach (i.e., psychology student) twice in the face-to-face meetings.
75419776|NCT04340206|Behavioral|only chat-robot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program.
75419777|NCT04340206|Behavioral|Control group, no intervention|Behavioral: No intervention
75419778|NCT04334031|Genetic|Biobanking with genetic analysis|Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
75719015|NCT00295633|Drug|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
75419779|NCT04334031|Other|SF-12 questionnaire|Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
75419780|NCT04333953|Other|No intervention|No intervention, observational study
75565144|NCT02943135|Drug|placebo in-situ gel|placebo in-situ gel
75565145|NCT02951234|Other|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
75565146|NCT02951234|Other|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
75565147|NCT00531765|Other|sodium bicarbonate infusion|short infusion of sodium bicarbonate
75565148|NCT00531804|Drug|gantenerumab|Administered iv at escalating doses (7 cohorts)
75565149|NCT02951390|Other|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
75565150|NCT02950610|Device|"Breath analysis - electronic signature Breath-print"|Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
75719016|NCT00295633|Drug|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
75565151|NCT02943252|Drug|Apatinib|apatinib 500 mg in tablet once daily
75565152|NCT02943252|Drug|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
75565153|NCT00514982|Drug|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
75565154|NCT00514982|Drug|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
75565155|NCT00514982|Drug|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
75565156|NCT00514982|Drug|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
75565157|NCT00514982|Drug|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
75565158|NCT00514982|Drug|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
75565159|NCT02950532|Other|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
75719017|NCT00295633|Drug|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
75719018|NCT00295633|Drug|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
75419781|NCT04323501|Other|Experimental treatment|"Exercises may include UPPER LIMB Passive exercises (stretching), each one greater or equal to 10 minutes; greater or equal once a day: pectoralis; back muscles and triceps; subscapular muscle; elbow flexor; both pronator muscles; flexor of the wrist and fingers; flexor, adductor and opponent muscles of the thumb.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: shoulder abduction, flexion, external rotation; elbow extension and supination; wrist extension; finger extension; thumb extension and abduction.~LOWER LIMB Passive exercises, each one greater or equal to 10 minutes; greater or equal once a day: hamstring; adductor of the hip; gluteus muscles.~Greater or equal to 5 minutes; greater or equal to twice a day: soleus and gastrocnemius.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: hip abduction and flexion; knee flexion; dorsiflexion of ankle; seat-standing"
75565160|NCT00531999|Drug|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
75565161|NCT00531999|Drug|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
75565162|NCT00516035|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
75419782|NCT04323501|Other|Control group|Usual care
76043762|NCT05485909|Drug|Regorafenib and Toripalimab Combination|Toripalimab 200 mg, iv drip, d1, d15, q4w, Regorafenib 80mg, po, d1-d21, Q4w.
75419783|NCT04318951|Behavioral|Intensive communicative-pragmatic social interaction.|"ILAT requires individuals with aphasia to engage in social interaction. Groups of three patients and a therapist are seated around a table and provided with picture cards showing different objects (e.g., bottle). Each card has a duplicate that is owned by one of the other players. The goal is to obtain this duplicate from a fellow player by requesting the depicted object (e.g., Give me the […]). If the duplicate is available, the addressee hands over the corresponding card to the person who initiated the request sequence. If the duplicate is not available, the addressee rejects the request. In the event of misunderstandings, the players ask clarifying questions. Throughout the training, participants use formulaic expressions to indicate whether a request is accepted (Here you are, Thank you, You're welcome), rejected (I'm sorry, No problem, Too bad) or unclear (Pardon me?). Treatment duration will be four weeks."
75419784|NCT04318951|Behavioral|Standard care.|Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.
75419785|NCT04311762|Drug|cisplatin|Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)
75565163|NCT05318118|Procedure|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|Arthroscopic reconstruction of damaged Medial Meniscus using Fast-Fix (Smith & Nephew) implant.
75565164|NCT05318118|Procedure|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|Arthroscopic reconstruction of damaged Medial Meniscus using Fiber-Stitch (Arthrex) implant
75565165|NCT05319912|Drug|ALXN1840 Enteric-coated Tablet|ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
75565166|NCT05319912|Drug|ALXN1840 Non-coated Capsule|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
75565167|NCT05319912|Drug|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
75565168|NCT00515138|Drug|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
75565169|NCT04695587|Diagnostic Test|123 MIBG scintigraphy testing|123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.
75719019|NCT00812526|Procedure|Suction cup application|
75565170|NCT04695587|Diagnostic Test|MSNA|MSNA in subacute phase and 12 months after the acute episode
75565171|NCT04695587|Diagnostic Test|ABPM|ABPM in subacute phase and 12 months after the acute episode
75565172|NCT04695587|Diagnostic Test|ECHO|ECHO in subacute phase and 12 months after the acute episode
75565173|NCT04695587|Diagnostic Test|24hour ECG|24hour ECG in subacute phase and 12 months after the acute episode
75565174|NCT04695587|Diagnostic Test|CMR|CMR in 12 months after the acute episode
75565175|NCT00515255|Drug|Minocycline|Capsules
75565176|NCT02943018|Other|anovaginal distance variation|Kappa calculation
75565177|NCT00516113|Drug|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
75719020|NCT00812526|Procedure|Squatting|
75719021|NCT02368444|Behavioral|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
75419786|NCT04293601|Other|interventional nursing care|"The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~NCPAP duration < 48 hours (h)~Gestational Age (GA) > 32 weeks (wks)~Current weight > 1500 g~Interventions:~alternating mask or nasal prongs once per shift~skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~NCPAP duration from 48 to 72 h~GA from 32 to 28 wks~Current weight from 1500 to 1000 g~Interventions:~alternating mask or nasal prongs twice per shift~skin assessment (excoriation, erythema or skin breakdown) twice per shift~repositioning of device once per shift~High:~NCPAP duration > 72 h~GA < 28 wks~Current weight < 1000 g~Interventions:~alternating mask or nasal prongs twice per shift~skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~repositioning of device every 3 h per shift"
75419787|NCT04293601|Other|Standard nursing care|"Use of hydrocolloid as nasal barrier dressing~Appropriate size of headbands, indicated by production company~Appropriate size of mask or binasal prongs, indicated by production company~Frequently assess skin integrity, every 4 hours~Replace hydrocolloid if it's dirty or displaced~Humidity and heat gases"
75565178|NCT02942940|Device|mobile app|The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).
76043763|NCT04139395|Drug|68Ga-Citrate PET/MRI|Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
76043764|NCT04139395|Drug|67Ga-Citrate SPECT|67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan
76043765|NCT04139395|Device|Positron Emission Tomography|Imaging with 68Ga-Citrate PET/MRI
76043766|NCT04139395|Device|Magnetic Resonance Imaging|Imaging with 68Ga-Citrate PET/MRI
76043767|NCT04139395|Device|SPECT|Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
76043768|NCT02555371|Biological|Mepolizumab 100mg|Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.
76043769|NCT02555371|Drug|Placebo|The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
76043770|NCT05489029|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
76043771|NCT04122235|Other|LETSGO follow-up|Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
76043772|NCT02555215|Drug|dimethyl fumarate|administered orally
75565179|NCT02942940|Other|conventional in-person|Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
75719022|NCT05068596|Other|expermintal|progressive resistive functional strength training in the plantigrade foot position plus designed physical therapy program
75719023|NCT05068596|Other|CONTROL|Designed physical therapy program
75719024|NCT00570674|Drug|Abraxane|
76043773|NCT05485597|Device|Myosuit-based gait training|In a period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit. The sessions will be started with a therapist, and if possible and as soon as possible, the patient will train with an assistant. During the therapy sessions, the patient will be asked to perform various task-specific exercises with the Myosuit, such as Sit-to-stand-, Balance- and walking exercises. Depending on the individual skill level of the participant, a higher level of difficulty in task-specific exercises can be performed. The training sessions are set to last 45 minutes. All training sessions will be accompanied by a certified (physio)therapist or trained assistant and a study investigator.
76043774|NCT05492305|Drug|GLP-1 receptor agonist|Treatment with any GLP1 receptor agonist e.g. liraglutide, semaglutide, dulaglutide for either obesity or type 2 diabetes mellitus
76043775|NCT02555683|Drug|QAW039|QAW039 150 mg once daily
76043776|NCT02555683|Drug|QAW039|QAW039 450 mg once daily
76043777|NCT02555683|Drug|Placebo|Placebo once daily
76043778|NCT04424095|Diagnostic Test|In-office vascular visit|The patient will be examined to search for signs or symptoms of chronic venous disease (teleangiectasia, reticular veins, varicose veins, skin changes, pain, itching, heavy legs, ankle edema)
76043779|NCT04424095|Diagnostic Test|Echo Duplex of lower limbs|The venous system of lower limbs will be checked in order to detect any vein dilation and reflux.
76043780|NCT02554981|Drug|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
75419788|NCT04257565|Device|Wheeled Knee Walker|The Wheeled Knee Walker allows total offloading of a healing limb and may diminish excessive force on the contralateral limb.
75419789|NCT04257565|Other|Usual and Customary Care|This group will receive usual and customary care for treatment of their diabetic foot ulcer
75419790|NCT04223362|Other|Community-based physical activity programme|After completing a pulmonary rehabilitation programme, participants will enrol a 6-months personalised community-based physical activity programme, which will include 2 sessions/week, with the aerobic training being the cornerstone. Patients will receive the PICk UP manual and a diary to register their physical activities. During the 1st month the physiotherapist will guide patients through 4 types of outdoors and indoors physical activities. Patients will then be asked to choose and commit to 1 or 2 activities, according to their preferences, which they shall integrate for another 5 months. During this period, the support provided by physiotherapist will decrease over time.
75419791|NCT04223362|Other|Pulmonary Rehabilitation|Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
75565180|NCT04695197|Drug|Artemether-lumefantrine (AL)|Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to < 15 20 + 120 15 to < 25 40 + 240 25 to < 35 60 + 360 >=35 80 + 480; Twice daily for 3 days (total, six doses)
75719025|NCT00570674|Drug|Erbitux|
75419792|NCT04203472|Device|Budesonid or budesonide/fomoterol administered by DPI|Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg
75419793|NCT04203472|Device|Budesonid or budesonide/fomoterol administered by MDI|Budiair 200 mcg or Atimos 12 mcg
75719026|NCT00570674|Drug|Carboplatin|
75565181|NCT04695197|Drug|Pyronaridine-artesunate (PA)|Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to < 8 60 + 20 8 to <15 120 + 40 15 to <20 180 + 60 20 to <24 kg 180 + 60 24 to <45 360 + 120 45 to <65 540 + 180 >=65 720 + 240; Once-daily for 3 days (total, three doses).
75565182|NCT05317962|Diagnostic Test|Transthoracic echocardiogram|Abbreviated transthoracic echocardiogram
75719027|NCT00570674|Radiation|Intensity Modulated Radiation Therapy|
75719028|NCT00808314|Drug|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
75874235|NCT03621176|Other|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
75874236|NCT03641612|Other|one shape|canal fluid sample before and after root canal instrumentation
75565183|NCT00516152|Drug|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis~7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~3 Fludarabine 30 mg/m(2)IV~2 REST Tacrolimus 0.01 mg/kg CIVI~1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~1 Methotrexate 5mg/m(2)IV~3 Methotrexate 5mg/m(2)IV~6 Methotrexate 5mg/m(2)IV~7 G-CSF 5mcg/kg SQ daily~11 Methotrexate 5mg/m(2)IV~90 Evaluate Response"
75565184|NCT00516191|Drug|Liposomal Doxorubicin/Melphalan/Bortezomib|"Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV~The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)"
75565185|NCT05319483|Other|No intervention|No intervention.
75565186|NCT00516308|Device|NightHawk|
76043781|NCT02556775|Biological|A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment|To be determined by the physician
76043782|NCT02556775|Biological|HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
76043783|NCT01662505|Drug|Volasertib|Patient to receive volasertib
75719029|NCT00808314|Drug|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
76043784|NCT05485363|Diagnostic Test|ultrasonographic measurement of the optic nerve sheath diameter|Assessing the optic nerve sheath diameter as an indicator of intracranial pressure during different positions and on specific time intervals in patients undergoing laparoscopic sleeve gastrectomy
75419794|NCT04168814|Other|Observational test|Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site. Covid-19 diagnosis.
75419795|NCT04134871|Behavioral|Group walk and one to one coaching|Participants will be invited to attend a group education session, weekly group walks and fortnightly coaching sessions
75419796|NCT04072146|Drug|Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|Cross over bioavailability study
75419797|NCT04072146|Drug|OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg|Cross over bioavailability study
75719030|NCT00812682|Drug|Symbicort|
75719031|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
75719032|NCT00768989|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
75719033|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
75719034|NCT00768989|Drug|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
75874237|NCT03641612|Other|protaper next|canal fluid sample before and after root canal instrumentation
75565187|NCT00515333|Drug|TRx0014|Hard capsule; 60 milligrams; t.i.d.
75874238|NCT00769327|Drug|imatinib mesylate|
75565188|NCT00515333|Drug|TRx0014|Hard capsule; 30 milligrams; t.i.d.
75565189|NCT00515333|Drug|Placebo|Hard capsule; 0 milligrams; t.i.d.
75565190|NCT00515333|Drug|TRx0014|Hard capsule, 100 milligrams, t.i.d.
75565191|NCT02943174|Behavioral|MIND programme for cancer patients|Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
75874239|NCT00769327|Drug|nilotinib|
75874240|NCT00769327|Genetic|cytogenetic analysis|
75874241|NCT00769327|Genetic|fluorescence in situ hybridization|
75874242|NCT00769327|Genetic|microarray analysis|
75874243|NCT00769327|Genetic|mutation analysis|
75874244|NCT00769327|Genetic|polymerase chain reaction|
75874245|NCT00769327|Genetic|polymorphism analysis|
75874246|NCT00769327|Other|laboratory biomarker analysis|
75565192|NCT02943174|Other|Treatment as Usual (TAU)|Standard personalized treatment of cancer
75874247|NCT01068704|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, ~ 12 months depending on response
75874248|NCT01068704|Drug|Lapatinib|Tablets, Oral, 1500 mg, once daily, ~ 12 months depending on response
75565193|NCT02941887|Behavioral|Behavior Analysis|One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
75565194|NCT00515450|Biological|GB-0998 (Intravenous immunoglobulin)|
75565195|NCT00515450|Procedure|Plasmapheresis|
75565196|NCT00516347|Genetic|comparative genomic hybridization|
76043785|NCT05491993|Diagnostic Test|Sky Medical™ Rapid Antigen Test|Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.
76043786|NCT03986749|Procedure|Doppler ultrasonography after bursa augmentation|Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
75565197|NCT00516347|Genetic|genetic linkage analysis|
75565198|NCT00516347|Other|laboratory biomarker analysis|
75565199|NCT00516347|Other|questionnaire administration|
76043787|NCT04074733|Diagnostic Test|Patient undergoes a ULD scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
76043788|NCT04074733|Diagnostic Test|Patient undergoes a standard X-ray|"The following doses will be applied:~For the pelvis : front view and profile for the hip. For the dorsal spine : front and profile. For the lumbar spine : front and profile For the extremities : front and profile"
76043789|NCT04074733|Diagnostic Test|Patient undergoes a classic-dose scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
75419798|NCT04058847|Other|Your Heart Forecast|1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.
75441692|NCT01637389|Other|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
75565200|NCT00516347|Procedure|study of high risk factors|
75565201|NCT02941848|Drug|HGP0816|
75565202|NCT02941848|Drug|HGP1404|
75565203|NCT02941848|Drug|HCP1306|
75565204|NCT00515489|Drug|Risperidone|as prescribed
75565205|NCT02941653|Device|Potassium nitrate 2% gel|"Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
75719035|NCT00768989|Drug|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
75719036|NCT04991038|Device|DAISe Device|Thrombectomy using the DAISE device
75719037|NCT04991038|Device|Trevo or Solitaire|Thrombectomy using TREVO or Solitaire device
75719038|NCT00779714|Drug|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
75719039|NCT00779714|Drug|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
75719040|NCT00779714|Drug|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
75719041|NCT00812760|Drug|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
76043790|NCT05488717|Other|art-based mandala application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
76043791|NCT05485207|Drug|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
76043792|NCT03897907|Other|Psychologically Informed Education Video|"The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)"
76043793|NCT03897907|Other|Anatomy Education Video|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
76043794|NCT05488639|Other|Registration of football exposure and occurrence of injuries and illnesses only|"Injury & illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days."
75419799|NCT04040153|Behavioral|Guiding Good Choices|Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
75565206|NCT02941653|Device|Potassium oxalate 5% gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
75565207|NCT02941575|Other|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
75565208|NCT02941575|Other|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
75565209|NCT00515606|Drug|helium:oxygen|
75874249|NCT01068704|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, ~ 12 months depending on response
75874250|NCT05179681|Other|Nasal High -Flow Oxygen Therapy|patients receiving transnasal humidified rapid-insufflation ventilatory exchange
75565210|NCT02941731|Drug|HIP1403|Oseltamivir 6mg/mL
75565211|NCT02941731|Drug|HGP0919|Oseltamivir phosphate 6mg/mL
75565212|NCT05319210|Procedure|Venous catheter application|To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.
75565213|NCT02951039|Drug|Edoxaban|Prescribed according to approved label
75874251|NCT03339401|Other|Standard of Care|Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
75419800|NCT04001972|Behavioral|Brief advice (AWARD model)|"Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention."
75419801|NCT04001972|Drug|NRT-S|One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette <30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette >30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
75565214|NCT02951117|Drug|Venetoclax|Tablet
75565215|NCT02951117|Drug|ABBV-838|Intravenous infusion
75565216|NCT02951117|Drug|Dexamethasone|Tablet or intravenous infusion
76043795|NCT05488561|Diagnostic Test|CBC with differential ,ESR ,CRP, Amyloid level , FMF gene|leucocytosis , high ESR and CRP ,amyloid level indicates inflammation positive FMF gene indicates having the disease .
76043796|NCT03879109|Drug|Chemotherapy FOLFIRINOX, 6 cycles|"oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)"
76043797|NCT03879109|Radiation|Radiochemotherapy|Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
75565217|NCT02941809|Behavioral|Open-Label Placebo (OLP)|We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation.
75565218|NCT02951000|Procedure|platysma suture|
75565219|NCT02951000|Procedure|no platysma suture|
75565220|NCT02941770|Behavioral|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
75719042|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
75874252|NCT03339401|Drug|Brincidofovir|Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
75874253|NCT05179525|Drug|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
75874254|NCT05179525|Drug|Risperdal 4mg Tablet|4 mg oral risperidone once daily for 7 days
76043798|NCT03879109|Procedure|Surgery|"Surgery will be performed at:~Arm A: 8 weeks (±1) after the end of treatment~Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~Total mesorectal excision (TME)~Extended-TEM (e-TME)~Pelvic exenteration (PE)"
76043799|NCT05485129|Device|BIORICS|Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
75719043|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
75719044|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
75719045|NCT00814944|Drug|Sirolimus|Subconjunctival injection of placebo in each eye.
75719046|NCT05308498|Diagnostic Test|ESView software with proscan|Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
75719047|NCT05308498|Diagnostic Test|Rapid software with SBI|Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
76043800|NCT04032535|Drug|CHF6523|CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)
76043801|NCT05488327|Drug|Lenalidomide|All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
76043802|NCT05488171|Drug|Methylone|Single oral dose of 200 mg of methylone.
76043803|NCT05488171|Drug|3,4-methylenedioxymethamphetamine|Single oral dose of 100 mg of MDMA.
75565221|NCT02941770|Other|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
75565222|NCT02950181|Device|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
75565223|NCT02941536|Diagnostic Test|Circulating tumor cells evaluation|Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
75874255|NCT05179291|Other|Buzzy Group|The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
76043804|NCT05488171|Drug|Placebo|Single oral dose of placebo.
75565224|NCT02951078|Procedure|Thulium Laser en Bloc Resection of bladder tumor|
75565225|NCT02951078|Procedure|Electrical transurethral resection of bladder tumor|
75565226|NCT05319171|Device|TAVR|TAVR
76043805|NCT05480137|Procedure|NSE scoring balloon and plain balloon angioplasty|Using NSE scoring balloon or plain balloon in BPA surgery.
76043806|NCT05480059|Other|A questionnaire|A Questionnaire-based Assessment of the Psychiatric Co-morbidities and Health-related Quality of life in Patients with Irritable Bowel Syndrome
75565227|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
76043807|NCT05485051|Other|2% chlorhexidine digluconate solution with surface-active agents|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
75419802|NCT04001972|Behavioral|IM Apps and Chatbot|Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
75719048|NCT00779792|Drug|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
75874256|NCT05179291|Other|Virtual Realitiy-VR Group|VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
76043808|NCT05485051|Other|Usual Baths|Bathing will be performed at least daily using soap and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
76043809|NCT05479903|Procedure|acupuncture|Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients
75419803|NCT04001972|Behavioral|Regular SMS message|Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
76043810|NCT05479903|Behavioral|computerized cognitive training system|One-on-one cognitive training by an experienced cognitive therapist, combined with an existing computerized cognitive training system
75419804|NCT03987906|Behavioral|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
75565228|NCT02950376|Other|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
75565229|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
75565230|NCT02942901|Procedure|PET-CT|
75565231|NCT00515645|Other|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
75565232|NCT02950220|Drug|Ibrutinib|Given PO
75565233|NCT02950220|Other|Laboratory Biomarker Analysis|Correlative studies
75719049|NCT00779792|Drug|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
75719050|NCT00779792|Drug|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
75719051|NCT00779792|Drug|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
75719052|NCT00779792|Drug|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
76043811|NCT05479903|Behavioral|aerobic exercise|Patients are trained by experienced physical therapists with the help of elastic bands and physical therapy devices
76043812|NCT05479903|Behavioral|tranditional cognitive training|One-on-one cognitive training with an experienced cognitive therapist, combined with traditional cognitive training methods (e.g., balls, cards, counting, daily conversation, etc.)
76043813|NCT05479903|Other|Conventional treatment|Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
75565234|NCT02950220|Biological|Pembrolizumab|Given IV
76043814|NCT05484817|Diagnostic Test|Assessment of cardiovascular risk factor, endocrine hormones and related biomarker|Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
75719053|NCT00992134|Drug|Rituximab, Bendamustine, Cytarabine|"Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.~Four to six cycles. Recycle every 28 days."
76043815|NCT05479825|Procedure|inflation- deflation line combined with ICG fluorography|Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
76043816|NCT05484583|Drug|Durvalumab + carboplatin/cisplatin + etoposide|Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip
76043817|NCT05484583|Radiation|Consolidation radiotherapy|Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.
76043818|NCT05484583|Drug|Durvalumab|Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion
75565235|NCT00515684|Drug|bevacizumab (Avastin)|
75565236|NCT02941497|Behavioral|Social marketing and health promotion campaign|Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
75565237|NCT02950883|Drug|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline"
75565238|NCT02950883|Drug|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline"
75719054|NCT02551536|Drug|Montelukast|
75719055|NCT02551536|Drug|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
75874257|NCT05692206|Other|evaluation|Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
75874258|NCT03370289|Biological|BLB-750 Vaccine (Qinghai RG strain)|BLB-750 Injection
75874259|NCT01344824|Biological|bevacizumab|15 mg/kg once per 21 day cycle (up to 4 cycles).
76043819|NCT05479747|Drug|post operative analgesics|post-operative pain killer
76043820|NCT05487937|Other|Use of Toleriane Ultra to relieve face allergic skin|The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
75719056|NCT02551536|Drug|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
75874260|NCT01344824|Drug|carboplatin|Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
75874261|NCT01344824|Drug|erlotinib hydrochloride|150mg, daily for 21 day cycle (up to 4 cycles)
76043821|NCT05487781|Combination Product|Tirfostina/L-Carnitina|Estudio clínico fase 1 para describir la seguridad biológica y la farmacocinética de la tirfostina AG-17
76043822|NCT05487469|Drug|Thymosin Alpha1|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead
76043823|NCT05487469|Other|Blank Control|the Control group did not receive Thymosin alpha 1 or any placebo.
75719057|NCT02556164|Procedure|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
75719058|NCT02556164|Other|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
76043824|NCT05479669|Diagnostic Test|Echocardiography|Transthoracic echocardiograms will be performed at inclusion. Echocardiographic parameters that will be evaluated are measures of atrial size (including left atrial volume, right atrial dimensions, left ventricular function and dimensions (including left ventricular dimensions, septal wall thickness, posterior wall thickness, systolic function, Simpson biplane left ventricular ejection fraction), parameters of diastolic dysfunction (including E, A, E/A ratio, deceleration time, E' and E/E' ratio) and valve (dys)function.
76043825|NCT05479669|Diagnostic Test|24 hour Holter monitoring|24-hours Holter monitoring will be used to determine markers of increased risk of ventricular arrhythmias, such as non-sustained ventricular tachycardias, and ventricular premature beats and doublets. Also the presence and pattern of AF and runs of supraventricular tachycardias are determined.
75419805|NCT03963570|Behavioral|Safe Step - digital exercise program|"After receiving the Safe Step application the participants view an instruction movie on how to use the application to create and progress their own individual exercise program. The exercises, presented in video format, are organized into 10 predetermined groups with a main focus to improve balance (3 groups), increase lower-limb strength (4 groups), and improve gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~They can use the app to plan their exercises, set reminders, register their exercise, and view statistics of their progress. A virtual physiotherapist deliver motivational messages and feed-back. At the end of every month, of the 1 year intervention period, the participants will receive an email asking them to report any falls during the past month by answering a short digital survey. This message will provide a new video each month with general falls prevention information besides exercise."
75419806|NCT03963570|Behavioral|Control group|Participants randomized to the control condition will only be given information. They will receive exactly the same email messages as the intervention group with falls prevention information and a request to report any falls. At the end of the 12 month intervention we will, in addition to the other questions, ask if they have started to do any exercises during the intervention period. After the 12 month follow-up assessment the control group will be offered the Safe Step application.
75419807|NCT03945084|Drug|Niraparib|"Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily <77 kg or <150,000 µL: 200 mg (2 X 100 mg capsules) daily*~* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy"
75419808|NCT03945084|Other|Best supportive care|"In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment."
75419809|NCT03920241|Behavioral|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
75419810|NCT03920241|Behavioral|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
75565239|NCT05317767|Biological|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
75565240|NCT05317767|Biological|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
75565241|NCT02950454|Other|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
75565242|NCT02950454|Other|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
75565243|NCT02942862|Drug|Orcein staining|Prognostic value of venous emboli detected by orcein staining
75565244|NCT04695158|Drug|COVID-19 group (Group I)|Routine COVID-19 treatment
75565245|NCT04695158|Drug|Type II Diabetes Mellitus and COVID-19 group (Group II)|Routine Type II Diabetes Mellitus and COVID-19 treatments
75719059|NCT00815022|Drug|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
75565246|NCT05317650|Other|Multi-gravitational suspension-based therapy (M-Gravity)|Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
75719060|NCT00774722|Drug|Metronidazole|10% ointment, three times daily for 14 days
75419811|NCT03920241|Other|Control Group|A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
76043826|NCT05479669|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Multiple short-axis cine images will be acquired throughout the entire LV with a steady-state free precession sequence. Left ventricular volumes, ejection fraction and myocardial mass will be measured on the short-axis stacks at end diastolic and end systolic frames. Ten to 15 minutes after an intravenous bolus injection of a gadolinium-based contrast agent late gadolinium enhancement will be performed with a segmented inversion recovery gradient-echo sequence, using the same image orientation as in the short-axis stacks. The presence, location and morphology of myocardial fibrosis will be described. The extent of myocardial scar will be quantified using computer-assisted planimetry and expressed as a percentage of left ventricular mass. Pre- and post-contrast T1 measurements will be obtained using a single-shot modified Look Locker inversion recovery sequence. Extracellular volume (a measure of diffuse myocardial fibrosis) will be quantified.
76043827|NCT05479669|Diagnostic Test|99mTc-HDP scan|Patients will receive a 99mTc-HDP scan. 3 hours after the technetium 99m-hydroxymethylene diphosphonate bolus injection, imaging will be performed using a gamma-camera equipped with a collimator which guides individual gamma-rays emitted by the radionuclide. For planar imaging, a collimator will be used to transfer only those gamma-rays which pas in a perpendicular course. Sequentially, a SPECT-CT will be performed in the same session to improve sensitivity. SPECT/CT will be performed on a SPECT/CT dual head gamma camera system. SPECT images will be acquired using a 128 x 128 matrix, 180 degrees of rotation, 64 views, 15s per view. Visual image analysis will be performed by two blinded and experienced nuclear medicine physicians. Data will be scored according to a routine scoring system on a scale from 0 (no cardiac uptake of 99m technetium and normal bone uptake) to 3 (high cardiac uptake, higher than bone uptake).
75719061|NCT00808392|Biological|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
76043828|NCT05479669|Diagnostic Test|ECG|A 12-lead electrocardiogram will be performed at the 1-year and 2-year follow-up visit to determine the heart rhythm and heart rate.
75719062|NCT00808392|Biological|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
75719063|NCT04045548|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
75719064|NCT04045548|Drug|Placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
75719065|NCT02262988|Procedure|Total knee replacement|Total knee replacement (TKA)
75719066|NCT02556944|Device|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
75419813|NCT03896191|Procedure|Revision TKR surgery|This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.
75565247|NCT02950142|Other|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
75565248|NCT02950142|Other|CPOE without order sets for lab testing|CPOE only
75565249|NCT04691310|Device|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
75565250|NCT00515762|Device|elasto-gel cap|scalp cooling cap
75565251|NCT02941341|Drug|r-hFSH|As per standard practice
75565252|NCT00515801|Drug|glibenclamide|glibenclamide 15 mg single dose
75719067|NCT00808548|Other|counseling, emotional support|
75719068|NCT00808548|Other|emotional support|emotional support during the interview
75719069|NCT00808548|Other|emotional support|emotional supporting during the interview
75719070|NCT04920136|Procedure|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The flap will be then elevated with a split-thickness flap beyond the mucogingival junction where it is sutured at this apical position using a mattress (5-0, monocryl) suture. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.
75874262|NCT01344824|Drug|pemetrexed disodium|500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
75874263|NCT04320511|Device|CT-V|CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
75874264|NCT04292197|Drug|18-MC Compound|18-MC
75874265|NCT01311947|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a at 180 ug weekly for 24 weeks
75565253|NCT00515801|Drug|placebo|placebo capsules, single dose
75419814|NCT03896191|Other|No intervention.|This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
75565254|NCT03458364|Device|High flow nasal cannula|High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
75419815|NCT03894657|Diagnostic Test|Nasal brushing|Nasal scrapping at visit V0
75419816|NCT03894657|Other|Sputum sample|"Visit V0 : 1 Aliquot for Sputum biobank~Visit V1 : 2 Aliquots~for Sputum biobank~for pharmacokinetic (PK) study~Visit V2 : 2 Aliquots~for Sputum biobank~for pharmacokinetic (PK) study"
75419817|NCT03894657|Other|blood sample|"Visit V0 : Additional 14 mL~5 mL in ethylenediaminetetraacetic acid (EDTA) tube for DNA Analysis~3 mL in Dry tube for Serum biobank~6 mL in acid citrate dextrose (ACD) tube for peripheral blood mononuclear cell (PBMC) biobank~Visit V1 : Additional 9 mL~2x3 mL in dry tube for pharmacokinetic (PK) study~3 mL in Dry tube for Serum biobank~Visit V2 : Additional 6 mL~3 mL in dry tube for pharmacokinetic (PK) study~3 mL in Dry tube for Serum biobank"
75565255|NCT03458364|Device|Noninvasive ventilation|Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
75565256|NCT00515840|Other|Physiotherapist|Physiotherapist administered breathing retraining programme
75419818|NCT03894657|Drug|Orkambi|"Study the predictive value for improvement of the respiratory function after 24 weeks of Orkambi treatment.~Orkambi treatment is part of usual care."
75565257|NCT05317611|Drug|Intraperitoneal instillation of ondansetron and bupivacaine|The aim is to detect the effect of intraperitoneal instillation of ondansetron for prevention of postoperative nausea and vomiting
75565258|NCT05317611|Drug|Intravenous ondansetron and intraperitoneal instillation of bupivacaine|The aim is to detect effect of intravenous ondansetron for prevention of postoperative nausea and vomiting
75565259|NCT05317611|Drug|Intraperitoneal instillation of bupivacaine|The aim is to detect effect of intraperitoneal instillation of bupivacaine
75565260|NCT04695314|Device|Massage|Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes
75565261|NCT04695314|Procedure|Experimental insert|Raised shoe insert, insert used for massage
75565262|NCT04695314|Procedure|Sham insert|Flat shoe insert, insert used for massage
75719071|NCT04920136|Procedure|Free Gingival graft|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area was sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
75719072|NCT00780104|Drug|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
75719073|NCT00780104|Drug|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
75719074|NCT00815100|Drug|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
75719075|NCT00815100|Drug|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
75719076|NCT00992212|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
75719077|NCT04047680|Drug|Sofosbuvir / Velpatasvir Oral Tablet|Sofosbuvir/velpatasvir for 12 weeks
75719078|NCT04047680|Drug|Sofosbuvir and Ledipasvir|Sofosbuvir and ledipasvir for 12 weeks
75719079|NCT04047680|Drug|Sofosbuvir Tablets|Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks
75719080|NCT04047680|Drug|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir for 12 weeks
75719081|NCT04047680|Drug|Elbasvir / Grazoprevir Oral Tablet|Elbasvir/grazoprevir for 12 weeks
75419819|NCT03886467|Other|Community-based nutrition education|Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
75419820|NCT03882463|Device|Continuous glucose monitoring with the stop insulin pump function|"Children with type 1 diabetes using insulin pump and continuous glucose monitoring without the stop insulin pump functionare then using the predictive system for stopping before hypoglycaemia medtronic Minimed with SmartGuard technology."
76043829|NCT05484427|Other|Telemedicine|Replacement of the regullar meeting with diabetologist by remote communication only
76043830|NCT05484271|Procedure|Rotator cuff repair|The patients received the arthroscopic rotator cuff repair.
76043831|NCT05479435|Behavioral|Blue Prescription Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. It will be followed up with the blue prescription program once a week for 12 weeks and will be re-evaluated at the end of the 12th week. Motivation and support will be provided according to the blue prescription philosophy, home exercise program, physical activity selection, obstacles to the activity are discussed, the participant will be asked to determine the appropriate program and keep an activity diary. Throughout the study, the participant will be able to communicate with the physiotherapist by any method (phone, SMS, email).
75419821|NCT03881228|Behavioral|Increasing the completion of IPT|Behavioral intervention with three components to increase the completion of IPT among children
75419822|NCT03861481|Drug|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
75419823|NCT03861481|Other|Placebo|Subjects will receive placebo in a specified sequence during the treatment period.
75565263|NCT05317572|Drug|80 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
75719082|NCT04047680|Drug|Glecaprevir and Pibrentasvir|Glecaprevir/pibrentasvir for 12 weeks
75719083|NCT00815178|Behavioral|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
75419824|NCT03853941|Behavioral|Intervention|Theory-based communication training programme delivered to healthcare professionals
75419825|NCT03821649|Behavioral|SOONER Training and Naloxone Kit Kit|Participants are shown our unique overdose response education video and given the associated kit to take home.
75719084|NCT00815178|Behavioral|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
75719085|NCT00774878|Drug|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
75719086|NCT00774878|Drug|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
75874266|NCT05137496|Drug|Ruxolitinib|0.3mg/kg/d, iv.gtt, for at least 2 weeks
75874267|NCT05137496|Drug|methylprednisolone|2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
75874268|NCT03708185|Dietary Supplement|Beta-alanine|N/A: see arm description
75874269|NCT03708185|Dietary Supplement|Placebo|N/A: see arm description
75874270|NCT03640676|Device|FlowOx|FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
75874271|NCT03640598|Procedure|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate
75419826|NCT03821649|Behavioral|Community or Hospital-Based Training|Referral to standard of care for Naloxone training
75419827|NCT03811262|Procedure|ESP BLOCK|local anesthetic will be injected between transverous process and erector spinae muscle
75419828|NCT03811262|Procedure|PECS BLOCK|local anesthetic will be injected between pectoralis minor and pectoralis major (10 ml) and between pectoralis minor and serratus (20 ml)
75719087|NCT04917172|Diagnostic Test|postoperative acute pancreatitis evaluation|Surgical resection and reconstruction will be carried out according to the Institutional standards. After the surgical procedure, serum pancreatic amylase and lipase activity will be systematically measured two hours after surgery on postoperative day (POD) 0 and every day at 7 a.m. until POD 5 according to our institutional policy. At our institution, the upper limit of normal for serum pancreatic amylase is 52 U/L and for serum lipase is 60 U/L. Postoperative protocols included the routine measurement of inflammatory markers (white blood cell [WBC] count and C-Reactive Protein [CRP]). A urine trypsinogen strip test will be done on POD 1. A trypsinogen-2 concentration of more than 50 µg/l is considered a positive test. As routine clinical practice, a post-operative imaging will be scheduled to check for potential surgical morbidity. Abdominal magnetic resonance imaging (MRI) will be assessed on POD 3.
75874272|NCT03640598|Procedure|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
76043832|NCT05479435|Behavioral|Video Based Home Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
76043833|NCT05479435|Behavioral|Supervised Group Exercise Program|DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Exercises will be done with a physiotherapist for 12 weeks 3 days a week and will be evaluated again at the end of the 12th week.
75874273|NCT03339245|Other|Fructose Solution (75 Grams)|Fructose given in divided doses at breakfast and dinner.
76043834|NCT05479357|Drug|Oxytocin|10 iu will be given intravenously.
76043835|NCT05479357|Drug|Carbetocin|100 micrograms will be given intravenously.
76043836|NCT05487391|Drug|QL1706 injection|QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
75419829|NCT03758833|Diagnostic Test|preimplantation genetic test of embryo by new generation sequencing (NGS)|This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
76043837|NCT05487391|Drug|Vinorelbine Tartrate|Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
76043838|NCT05487391|Drug|Paclitaxel|Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
76043839|NCT05487391|Drug|Cisplatin|Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
76043840|NCT05487391|Drug|Carboplatin|Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
76043841|NCT05487391|Drug|Pemetrexed|Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
76043842|NCT05487391|Drug|Placebo|Placebo
75419830|NCT03758833|Procedure|Single embryo transfer|Transfer of single embryo
76043843|NCT05484193|Drug|GnRH agonist|GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
75419831|NCT03758833|Procedure|Double embryo tranfer|Transfer of two embryos
75419832|NCT03730974|Device|Protac Ball BlanketTM (7kg Flexible)|All patients will wear a MotionLogger Micro Watch from Ambulatory Monitoring Inc. NY in all four weeks during all 24hours of the day.
75419833|NCT03716466|Other|Endotracheal intubation|Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure
75419834|NCT03716466|Other|No airway intervention|Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
75419835|NCT03708198|Drug|Liposomal Bupivacaine|intercostal block
75874274|NCT03339245|Other|Glucose Solution (75 grams)|Glucose given in divided doses at breakfast and dinner.
75874275|NCT03044574|Device|SCD|Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
76043844|NCT05484193|Drug|Progesterone|vaginal progesterone for luteal phase support
76043845|NCT05479279|Other|Neck Stabilization Training Program|3 times a week stretching exercises approximately 10 mins dumb bell exercises - 2 sets of 15 reps with weights varying from 1 to 2 kg cranio-cervical isometrics for 10 sec with 15 sec breaks between holds with 10-15 reps Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
76043846|NCT05479279|Other|Conventional physical therapy|Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
76043847|NCT03796195|Drug|.5% Bupivacaine|Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
76043848|NCT05484037|Other|CANATEXTS|Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.
76043849|NCT05478967|Procedure|IVA injection before vitrectomy|Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
76043850|NCT05483959|Other|BIPAP mode/SIMV PC mode|BIPAP is a mode of ventilation recently used in ARDS
76043851|NCT04268407|Drug|Amoxicillin Clavulanate|compare the duration of antbiotic use: 2 day versus 7 day
75419836|NCT03706729|Device|Spraino|"Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch developed with the purpose of minimizing lateral shoe-surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the study sponsor, Spraino® ApS. The participants will receive four pairs of Spraino® upon their enrollment to the study."
75419837|NCT03695068|Behavioral|RISE Intervention|Described in Arms description.
75419838|NCT03683498|Biological|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
75719088|NCT00815256|Procedure|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
75419839|NCT03654599|Behavioral|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
75719089|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
75719090|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
75719091|NCT00815334|Procedure|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
75719092|NCT00778778|Drug|cefprozil 500mg tablets|
75719093|NCT00815412|Behavioral|Counseling in use of health care|
75719094|NCT00815412|Behavioral|Counseling in diet, exercise|
75719095|NCT00815412|Other|Control|
75719096|NCT00305773|Drug|vorinostat|Given orally once daily
75719097|NCT00305773|Drug|vorinostat|Given orally three times daily
75719098|NCT00778856|Procedure|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
75719099|NCT02552004|Device|pCLE|Histological examination by pCLE technique preceding the frozen section
75719100|NCT02552004|Drug|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
75719101|NCT00780182|Drug|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
75719102|NCT00812994|Drug|Escitalopram|SSRI antidepressant
75719103|NCT00812994|Drug|Placebo|
75719104|NCT00780260|Behavioral|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
75719105|NCT00784394|Drug|diindolylmethane|Given PO
75719106|NCT00784394|Other|placebo|Given PO
75719107|NCT00784394|Other|pharmacological study|Correlative studies
75719108|NCT00784394|Other|laboratory biomarker analysis|Correlative studies
75719109|NCT00784394|Other|quality-of-life assessment|Ancillary studies
75719110|NCT00778934|Other|Intimate Health Gel|Intimate Health Gel
75719111|NCT04047524|Other|Monitoring using a FitBit|Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
75719112|NCT02556398|Behavioral|Sugar Sleuth|"Educational module and use of smart phone app (Sugar Sleuth)"
75719113|NCT00305695|Other|Laboratory Biomarker Analysis|Correlative studies
75719114|NCT00305695|Drug|Zoledronic Acid|Given IV
75719115|NCT00784472|Drug|oxycodone|intravenous according to patients weight, pn.
75719116|NCT00784472|Drug|morphine|intravenous administration according to patients weight, pn.
75719117|NCT00779012|Biological|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
75419840|NCT03654599|Behavioral|Digital Stories Intervention|Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
75419841|NCT03654599|Behavioral|Information Control Intervention|Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.
75419842|NCT03648476|Behavioral|ICAN|A 6-week group therapy sessions once a week for 90-120 minutes.
75419843|NCT03641196|Device|Fixed appliance|Use of a cemented modified palatal Nance appliance presenting a bite-plane
75419844|NCT03641196|Procedure|Composite bite plane|treatment with a composite build up in the palatal aspect of the upper central incisors.
75719118|NCT00784706|Other|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
75874276|NCT03044574|Device|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
75874277|NCT03044574|Drug|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
75565264|NCT05317572|Drug|120 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
75565265|NCT05317572|Drug|160 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
75565266|NCT02950805|Drug|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
75719119|NCT00784706|Other|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
75719120|NCT00784706|Other|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
75719121|NCT00647556|Drug|adapalene gel, 0.3%|applied topically once daily in the evening
75719122|NCT00647556|Drug|tretinoin 0.05% emollient cream|applied topically once daily in the evening
75874278|NCT02959892|Drug|Amphetamine|Amphetamine tablets.
75874279|NCT02959892|Drug|TAK -041|TAK-041 oral suspension.
75874280|NCT02959892|Drug|[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)|[11C]PHNO injection.
76043852|NCT04014751|Other|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
75419845|NCT03608982|Other|Simulated patient|The simulated patient is a professional actor and Belgian Red Cross employee, who combines acting distress and pain with moulage, to mimic the injuries as truthfully as possible. For feasibility reasons, the simulant will only be included in two sections of the course: the respective treatments of burns and stroke. The remainder of the course will be taught without simulated patient by the professional first aid tutors.
75419846|NCT03608982|Other|No simulated patient|Instead of a simulated patients, participants get to watch video clips on first aid techniques.
76043853|NCT05489653|Behavioral|mixed music|Learn about the effects of listening to music and doing activities with it on sleep.
75419847|NCT03578393|Device|Virtual Reality Educational Program|The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
75565267|NCT02950805|Drug|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
75565268|NCT02950727|Device|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
75419848|NCT03562806|Diagnostic Test|PET/MR image acquisition|Acquisition of PET and MR sequences on SIGNA PET/MR device.
75565269|NCT02950727|Device|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
75719123|NCT03978559|Drug|caspofungin|caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days
75419849|NCT03559426|Drug|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
75419850|NCT03559426|Drug|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
75565270|NCT02950571|Behavioral|Digital Picture Frame|The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.
75565271|NCT02950571|Behavioral|Standard Care|High level of support from an interdisciplinary team.
75565272|NCT02942745|Behavioral|Betel Nut Cessation Social Support|The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
75719124|NCT03978559|Drug|TMP/SMZ(trimethoprim/sulfisoxazole)|TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
75719125|NCT03978559|Drug|Methylprednisolone|40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
75719126|NCT03981133|Behavioral|offer a pacifier|offer a pacifier to normal newborn infants the first days of life
75719127|NCT03981133|Behavioral|no pacifier|not to offer a pacifier at 15 days of life
75719128|NCT00813072|Drug|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
75719129|NCT00813072|Drug|irinotecan|300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
75719130|NCT00813072|Drug|docetaxel|"75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
75719131|NCT03980821|Drug|AZD4635|AZD4635 taken orally
75719132|NCT00813228|Drug|Sitagliptin (Januvia)|
75565273|NCT02942745|Behavioral|Betel Nut Cessation Booklet|Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
75565274|NCT00515918|Dietary Supplement|iron|
75565275|NCT02950688|Biological|Seasonal LAIV|10^7.0 fluorescent focus units (FFU); administered by intranasal spray
75565276|NCT02950688|Biological|Placebo|Administered by intranasal spray
75565277|NCT02950688|Biological|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10^6 TCID50; administered intranasally
75565278|NCT00516425|Biological|pegfilgrastim|
75565279|NCT00516425|Drug|cyclophosphamide|
75419851|NCT03557762|Behavioral|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
75419852|NCT03537937|Other|Lower SpO2 Target|SpO2 target 90% (range 88-92%)
75419853|NCT03537937|Other|Intermediate SpO2 Target|SpO2 target 94% (range 92-96%)
75419854|NCT03537937|Other|Higher SpO2 Target|SpO2 target 98% (range 96-100%)
75565280|NCT00516425|Drug|doxorubicin hydrochloride|
75565281|NCT00516425|Drug|epirubicin hydrochloride|
75419855|NCT03491280|Genetic|NGS Diagnostic|Blood take for genetic diagnostic.
75419856|NCT03484000|Behavioral|Online Mindfulness Based Cancer Recovery (MBCR)|MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement
75565282|NCT00516425|Genetic|proteomic profiling|
75419857|NCT03444753|Drug|BMS-986299|Specified dose on specified day
75565283|NCT00516425|Other|diagnostic laboratory biomarker analysis|
75565284|NCT00516425|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
75565285|NCT00516425|Other|pharmacological study|
75565286|NCT00516425|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
75565287|NCT00516425|Procedure|adjuvant therapy|
75565288|NCT02942706|Drug|Cetuximab|anti-EGFR monoclonal antibody
75419858|NCT03444753|Biological|Nivolumab|Specified dose on specified day
75419859|NCT03444753|Biological|Ipilimumab|Specified dose on specified day
75719133|NCT00320593|Device|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
75719134|NCT00320593|Device|Single Vision Lenses (SVLs)|Single vision lenses
76043854|NCT05487001|Procedure|dexamethasone group|"1) Arm l (dexamethasone group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 188 ml + dexamethasone 10 mg (2 ml))~Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
75419860|NCT03413982|Other|Registry|Patient registry
75419861|NCT03360838|Other|CogCheck|Performance of study participants in the application
75419862|NCT03337945|Drug|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
75719135|NCT00813306|Drug|AZD2066|13 mg oral solution, 1 single dose
75719136|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
75719137|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
75719138|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
75719139|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
75719140|NCT00813384|Drug|AMG 208|AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
76043855|NCT05487001|Procedure|sham group|"2) Arm ll (sham group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 190 ml~Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
75419863|NCT03314480|Diagnostic Test|Standardized physical examination|Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
76043856|NCT05483725|Biological|Booster dose of mRNA vaccine|Administration of SARS-CoV-2 mRNA vaccine.
75565289|NCT02942706|Drug|mFOLFOX6|Oxaliplatin+LV5FU2
75565290|NCT02942706|Drug|FOLFIRI|Irinotecan+LV5FU2
76043857|NCT05486845|Other|survey|We are planning a questionnaire survey. We combine our own questions with validated, official questionnaires. Validated forms ask for an assessment of the extent of low back pain and the quality of experienced stress.
75565291|NCT00516464|Drug|Lucentis (ranibizumab)|
75565292|NCT02942628|Other|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
75565293|NCT04694690|Other|Self adhesive resin cement|Self adhesive resin cement
75565294|NCT04694690|Other|Resin cement|Resin Cement system used after surface treatment
75565295|NCT00516542|Drug|letrozole|A daily dose of 2.5 mg will be used throughout the study.
75565296|NCT00516542|Drug|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
75565297|NCT00516542|Other|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
75565298|NCT05305170|Diagnostic Test|Levels of EETs, DHETs and HETEs|The plasmatic concentration of EETs, DHETs, and HETEs.
75719141|NCT01061983|Device|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
76043858|NCT05478889|Procedure|Minimally invasive pancreatoduodenectomy|Whipple's procedure using minimally invasive (laparoscopic/robotic) techniques
76043859|NCT05478811|Device|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio
75419864|NCT03286309|Device|soft robot hand system|subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
75419865|NCT03242070|Other|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
75419866|NCT03203694|Behavioral|Walking|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
75419867|NCT03203694|Behavioral|Lower body heating|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
75419868|NCT03170700|Behavioral|Nutrition program with in-person parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
75419869|NCT03170700|Behavioral|Nutrition program with online parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
76043860|NCT05478811|Device|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method)
76043861|NCT03781141|Procedure|Wound closure|Comparison of two wound closures
76043862|NCT05486767|Diagnostic Test|Transient elastography|Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
75719142|NCT00808626|Drug|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
75719143|NCT04017078|Other|diagnosis of carotid artery calcification on digital panoramic radiograph|Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
76043863|NCT05478655|Other|visual analog scale|VAS was studied: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital and further 1, 3, 6, 12 months after the injury; 5) at the rehabilitation stage. Intervals between analgesia were also studied.
75719144|NCT00808704|Drug|recombinant human erythropoietin|r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
75719145|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
75719146|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
75719147|NCT00320515|Drug|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
75719148|NCT00320515|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
75719149|NCT02551458|Other|Systematic surgery|
75874281|NCT05425277|Behavioral|Reciprocal Intervention Teaching (RIT)|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and initiating joint attention during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal social-communicative skills. RIT is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by caregivers and siblings.
76043864|NCT03753607|Other|No intervention|No intervention
76043865|NCT03981445|Behavioral|ARTAS Adapted Patient Navigation|Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
75719150|NCT02551458|Other|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
75719151|NCT01066273|Device|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
75719152|NCT00808782|Device|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
75719153|NCT00808782|Device|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
75719154|NCT02550834|Other|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
75719155|NCT00662012|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
75719156|NCT00808860|Dietary Supplement|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
75565299|NCT05302947|Drug|Baricitinib Oral Tablet|Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
75565300|NCT05302947|Drug|Tocilizumab Injection|Tocilizumab was administered by a single intravenous dose of 400 mg
76043866|NCT03981445|Behavioral|Adherence Counseling|Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
76043867|NCT05483647|Procedure|Local infiltrative anaesthesia|In prone position, before the skin incision, patients in G1 underwent local infiltrative anaesthesia et the level of incision. The skin, subcutaneous tissue and muscles up to the foramen intervertebral were anesthetized by the surgeon employing forty millilitre solution of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018%.
76043868|NCT05483647|Procedure|Erector spine plane block|The transverse vertebral process of the required level of spine was identified using the mobile C-arm X-ray System. When the tip of the 22G needle reached to the transverse vertebral process 3 cm lateral to the spinous process, a solution of 40 millilitres of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018% was injected under the erector spinae muscle bilaterally.
76043869|NCT05478577|Other|Motor rehabilitation|Treatments for upper limb recovery (e.g. occupational therapy, technology devices, conventional therapy)
75565301|NCT05302947|Drug|Netakimab|Netakimab was administered by a single subcutaneous injection of 120 mg
75565302|NCT05302947|Other|Standard of care therapy|SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
75565303|NCT02941419|Biological|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
75565304|NCT04694768|Behavioral|Rehabilitation|Rehabilitation program
75719157|NCT00808860|Dietary Supplement|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
75419870|NCT03142035|Drug|Dienogest 2 MG|Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
75419871|NCT03142035|Drug|gonapeptyl|gonadotropic releasing hormone agonist
75565305|NCT03458481|Drug|SOF|400 mg tablet administered orally once daily
75719158|NCT04045002|Other|'MyPinkMom' educational intervention|"The intervention will be carried out for 2 weeks. There will be three sessions of 'MyPinkMom' that will be delivered to respondents per week. In each session, a respective 'MyPinkMom' video with audio explanation will be delivered to respondents in intervention group through WhatsApp application. It will be delivered every alternate day per week and each video will take about 3 minutes duration. Each session has its own objective and different content.~Each of the respondent in the intervention group will be given 'MyPinkMom' diary in which they are required to document time of iron tablet intake daily as well as time of reading of 'MyPinkMom' material in each session. At the end of the intervention, a meeting with all the respondents from the intervention group will be held for question and answer session."
75419872|NCT03142035|Procedure|IVF/IVF+ART|In-vitro fertilization +/- assisted reproductive technology
75419873|NCT03076723|Other|Change in shunt opening pressure|An individually determined change in shunt opening pressure is compared to no change in opening pressure.
75419874|NCT03076723|Other|Simulated change in shunt opening pressure|The shunt opening pressure is reset to the same setting.
75565306|NCT03458481|Drug|DAG181|Capsule administered orally once daily
75565307|NCT02950103|Drug|Phosphoethanolamine|Phosphoethanolamine PO daily
75565308|NCT02942394|Device|sinus-Obliquus Stent System|
75719159|NCT00815568|Drug|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7~D-2) Busulfan (3.2mg/kg, iv, D-6~D-3) Total body irradiation (200cGy/day, D-2,-1)
75719160|NCT00815646|Drug|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
76043870|NCT05486299|Procedure|Robotic assisted single-port general surgery|Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
75719161|NCT01066351|Drug|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
75719162|NCT01066351|Drug|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
75565309|NCT00516620|Behavioral|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
75565310|NCT00516620|Behavioral|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
75565311|NCT00516620|Behavioral|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
76043871|NCT05478421|Procedure|Collagen sponge|The bone cavity will be filled with collagen sponge.
75419875|NCT03057652|Device|ReWalk|"ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
75419876|NCT03057652|Device|EKSO|"EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
75419877|NCT03057652|Device|REX|"REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
75419878|NCT03053713|Behavioral|Mediterranean diet pattern|Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
75419879|NCT03053713|Behavioral|Habitual diet (control)|Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
75419880|NCT03008746|Other|water used for oral wash|
75419881|NCT03008746|Other|sputum|
75419882|NCT03008746|Other|oral wash|
75565312|NCT00516620|Behavioral|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
75565313|NCT00516620|Behavioral|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
75565314|NCT00516620|Behavioral|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
75719163|NCT00817752|Dietary Supplement|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
75719164|NCT03980353|Other|Questionnaires|The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
75719165|NCT00808938|Device|MST|Magnetic Seizure Therapy
76043872|NCT05478421|Procedure|GBR|The bone cavity will be applied with guided bone regeneration with deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
75719166|NCT02532361|Device|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
75719167|NCT02532361|Procedure|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
75719168|NCT00809016|Radiation|3-dimensional conformal radiation therapy|
75719169|NCT00809016|Radiation|fludeoxyglucose F 18|
75719170|NCT00809016|Radiation|intensity-modulated radiation therapy|
75419883|NCT02980003|Drug|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.
75565315|NCT00516620|Behavioral|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
75565316|NCT00516620|Behavioral|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
75874282|NCT05425277|Behavioral|Daily Routines|The Routines webinar was adapted from a web-based tutorial developed by PI Stone and colleagues (Ibanez et al., 2018). The webinar covers topics such as why everyday routines are important, especially for children with ASD, specific steps for increasing children's participation in routines, and how to use strategies such as visual supports to clarify expectations, and provides numerous video examples of caregivers using different strategies. Providers are also given access to a video library of caregivers using the Daily Routines strategies with their children, as well as a workbook to use with families during treatment.
75419884|NCT02980003|Drug|i.v. sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.
75419885|NCT02980003|Drug|oral sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
75419886|NCT02884323|Device|geko™ device|The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
75419887|NCT02786875|Other|low Glycemic Index Mediterranean diet|All carbohydrate foods will be low GI choices (GI<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
75419888|NCT02786875|Other|Mediterranean diet|General recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
75419889|NCT02786875|Behavioral|Moderate physical activity|Brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.
75419890|NCT02786875|Behavioral|Basic physical activity|General recommendations for physical activity
75565317|NCT02949752|Drug|Aripiprazole|Aripiprazole 5 mg every morning will be prescribed for 12 weeks
75565318|NCT05299983|Other|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
75565319|NCT05299983|Other|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites:~North American Menopause Society: https://www.menopause.org/for-women~National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
75565320|NCT04694963|Procedure|Blood sample|2 ml venous blood was collected and separated into serum.
75565321|NCT04694963|Procedure|Data collection|"Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;"
75565322|NCT04694963|Procedure|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
75419891|NCT02786875|Drug|high level Vitamin D|Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach normal blood levels of 60-80 ng/ml of 25(OH)D.
75565323|NCT02942550|Drug|Methylnaltrexone bromide (Relistor®).|
75565324|NCT02942550|Drug|Sodium Chloride 9mg/mL|
75719171|NCT03980431|Diagnostic Test|FBY PET Examination|A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
75719172|NCT00817830|Drug|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
75719173|NCT00815724|Behavioral|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
75874283|NCT03252145|Device|PhysioTouch|The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
75565325|NCT02949986|Behavioral|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
75565326|NCT02942589|Other|Meal portion size|
75565327|NCT02949596|Behavioral|Quality of life and quality of sexual life questionnaires|
75565328|NCT02941302|Procedure|Detecting of Biological Borders of Gliomas|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
75565329|NCT00516698|Genetic|polymorphism analysis|
75565330|NCT00516698|Other|high performance liquid chromatography|
75874284|NCT03252145|Other|Manual Lymph Drainage (MLD)|MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
75419892|NCT02786875|Drug|normal level Vitamin D|Vitamin D (cholecalciferol) will be given only if vitamin D insufficiency is detected to bring blood levels up to normal ranges of 30ng/mL.
75419893|NCT02778256|Device|Vestibular stimulation|A specific vestibular stimulation technique is applied to the experimental group
75419894|NCT02778256|Device|Sham vestibular stimulation|Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
75419895|NCT02767882|Drug|Dexamethasone|Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
75419896|NCT02767882|Drug|Saline|Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
75419897|NCT02420184|Device|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
75419898|NCT02420184|Other|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
75419899|NCT02319408|Radiation|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
75565331|NCT00516698|Other|laboratory biomarker analysis|
75565332|NCT00516698|Procedure|radiomammography|
75719174|NCT02552862|Drug|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
75719175|NCT02552862|Drug|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
75719176|NCT00661778|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
75719177|NCT00661778|Drug|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
75719178|NCT00661778|Drug|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
75419900|NCT02264223|Dietary Supplement|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
75419901|NCT02264223|Dietary Supplement|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
75419902|NCT02246257|Other|Simvastatin|LDL > 2.5 is treated with 40 mg
75419903|NCT02246257|Other|Losartan|BT > 140/90 mmHg treated with 50 mg OD
75419904|NCT02246257|Other|Losartan|DM BT > 130/80 mmHg treated with 50 mg OD
75565333|NCT02949557|Procedure|Decortication + bone grafts|
75565334|NCT02942433|Behavioral|Behavior Change Communication|9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement
75565335|NCT02942433|Behavioral|Community Mobilization|Listening and discussions groups, 2 male and 2 female groups per study site meet weekly for 39 weeks and will receive training on gender equity, intimate partner violence (IPV), life skills, community mobilization, non-violent conflict resolution for listening and discussion group (LDG) facilitators to support knowledge and skill set acquisition of LDG members. There will be a joint couple's session every month to foster mutual learning and understanding in addition to community mobilization incentives led by LDGs and encouragement of family members of LGD members to listen to the radio and attend LDG sessions once every 3 months. Participants will also receive awareness raising and street theater to engage families and community members.
75874285|NCT05124002|Drug|Recombinant Human Adenovirus Type 5|H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10^12 vp) if the maximum diameters of lesion is > 10 cm.
75565336|NCT02942433|Behavioral|Advocacy|Training and 6-month follow up of religious/community leaders and religious leaders support community mobilization activity of local listening and discussion group (LGD).
75419905|NCT02246257|Other|Losartan|Microalbuminuria (urinary albumin creatinin ratio > 30 mg) treated with 100 mg OD
75419906|NCT02246257|Other|Metformin|HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks
75419907|NCT02246257|Other|Outpatient rheumatology department|(4 times yearly)
75419908|NCT02246257|Other|Refered to general practice|
75419909|NCT02197221|Drug|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
75565337|NCT02942316|Device|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively~after induction, before opioid administration~after opioid administration, steady state~surgical incision~end of procedure"
75565338|NCT04694612|Drug|Favipiravir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
75874286|NCT05124002|Drug|HAIC of FOLFOX|Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
75874287|NCT01661400|Drug|Metronomic Cyclophosphamide|
75874288|NCT01661400|Drug|Thalidomide|
75874289|NCT02959814|Other|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
75874290|NCT03666624|Behavioral|Personalized care network|The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
75874291|NCT03368807|Device|Continuous Glucose Monitoring|Commercially available
75874292|NCT03368807|Drug|Insulin Lispro|As prescribed.
75419910|NCT02197221|Drug|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
75565339|NCT04694612|Drug|Placebo|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
75719179|NCT04045080|Device|AMADEO|"AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.~Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient.~In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia."
75565340|NCT04694612|Drug|Remdesivir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
75565341|NCT02942238|Procedure|CME|"the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)"
75565342|NCT02942238|Procedure|D3|"the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation"
75419911|NCT02131779|Behavioral|Men's Workshops|Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
76043873|NCT05478421|Procedure|CS/GBR|The bone cavity will be applied with guided bone regeneration with collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
76043874|NCT05483569|Other|Complex Decongestive Physiotherapy|Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.
76043875|NCT05483569|Other|Multidimensional Diaphragmatic Breathing Exercises|Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.
76043876|NCT05483569|Other|Facial Release Technique|Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
75419912|NCT02131779|Behavioral|Co-Educational Workshops|One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
75419913|NCT02076958|Behavioral|Community Health Advisor education|
75419914|NCT02010385|Drug|Octreotide|
75419915|NCT02010385|Drug|Saline|
75419916|NCT01989299|Device|ILR implantation|
75419917|NCT01949714|Procedure|Removal of adrenal tumor|
75419918|NCT01079325|Drug|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
76043877|NCT04273087|Other|Observation|Clinical signs and symptoms
75419919|NCT01079325|Other|Saline|
75565343|NCT02950064|Drug|BTP-114|"Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors."
75565344|NCT02941224|Device|SELUTION DCB (sirolimus coated balloon)|
75565345|NCT02949791|Procedure|Cytoreductive surgery|Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
75719180|NCT04045080|Other|Training|training
75719181|NCT04045080|Other|OT Training|training
76043878|NCT05478343|Biological|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
76043879|NCT05478187|Device|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
75565346|NCT02949791|Other|Low Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
75419920|NCT00704561|Device|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
76043880|NCT05478187|Other|Traditional visual cues - Control group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
75565347|NCT02949791|Other|High Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
75565348|NCT02941107|Drug|Rotarix (RV1)|ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P[8] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.
76043881|NCT05478109|Drug|[14C]XZP-3287|360 mg suspension containing 50µCi of [14C] XZP-3287
76043882|NCT05475535|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy
75419921|NCT00704561|Device|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
75419922|NCT00704561|Device|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
75419923|NCT00704561|Device|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
75419924|NCT00223145|Radiation|Radiotherapy 70 Gy|Radiotherapy to the prostate
75565349|NCT02941107|Drug|Placebo|The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
75565350|NCT02949713|Behavioral|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
75565351|NCT00518219|Drug|TW|TW,120mg/d
75565352|NCT00516854|Drug|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
75565353|NCT04694729|Other|videoconference-based|Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.
75565354|NCT04694729|Other|video-based|The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
75419925|NCT00223145|Radiation|Radiotherapy 76 Gy|Radiotherapy to the prostate
75419926|NCT00223145|Drug|Androgen blockade|Duration : 6 months
75419927|NCT01425827|Drug|duloxetine HCL|60 mg/day duloxetine for 16 weeks
75719182|NCT00789932|Behavioral|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
75719183|NCT00789932|Behavioral|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
75719184|NCT04047212|Diagnostic Test|biopsy for oral cancer|surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions
75419928|NCT01425827|Drug|placebo|similar looking tablets to the active agent for 16 weeks
75419929|NCT01425840|Drug|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
75565355|NCT05318742|Procedure|laser|Endolaser photocoagulation during PPV
75719185|NCT04047212|Diagnostic Test|periodontal examination|Periodontal clinical examination to all by periodontal charting
75719186|NCT00319735|Procedure|Radiation Therapy|External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
75719187|NCT00319735|Procedure|Surgery|Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
76043883|NCT05475535|Behavioral|Self-Compassion|Self-Compassion focused exercises
76043884|NCT05475535|Behavioral|Active Control|Engagement in a mobile application (Cooperation skills)
75419930|NCT01425905|Other|The Blues Program|
75565356|NCT02949869|Other|Spinal Sonography|As described previously
75565357|NCT02940990|Radiation|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
75565358|NCT02940990|Drug|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
75565359|NCT00518297|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
75565360|NCT00518297|Drug|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
75719188|NCT00319735|Procedure|Tissue Sample|For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission
75419931|NCT01425905|Other|Hey Durham|
75565361|NCT00518297|Drug|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
76043885|NCT05475457|Behavioral|R3|Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
76043886|NCT05475379|Biological|Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)|"Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited"
75565362|NCT04691583|Other|Fast diet|"Fast diet of High control ：From May 24, 2018, the method of fast diet was adopted on alternate days. According to the dietary records of normal diet, the normal caloric intake of each subject was calculated. Fast diet was carried out according to 2/3, 1/2, 1/3 and 1/4 of the original normal caloric intake.Each caloric stage last for 4 days, and the total cycle of fast diet was 31 days.~Fast diet of Low control ：After the intervention of fast diet of high control, the subjects were allowed to continue the diet fast diet every other day. It was suggested that the daily caloric intake was 600kal/ day for males and 500kal/ day for females."
75565363|NCT00518414|Other|Marketed infant formula with DHA and ARA|
75719189|NCT02556242|Other|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
76043887|NCT05483257|Device|Multigene panel for next-generation sequencing|HLA-I genotyping based on next-generation sequencing for prognosis evaluation
75565364|NCT00518414|Other|Milk-based infant formula with DHA and ARA|
75565365|NCT00518414|Other|Milk-based formula with DHA, ARA, prebiotics|
75565366|NCT02277015|Device|Miller Laryngoscope|Direct Laryngoscopy
75719190|NCT02556242|Other|Generalised Indoor residual spraying|IRS is carried out as normally practiced
76043888|NCT05475223|Diagnostic Test|End Tidal Carbon Monoxide Value|A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
76043889|NCT03699553|Behavioral|LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain|8 positive emotion skills taught over 5-6 weeks to help individuals cope with chronic pain and stress.
76043890|NCT03699553|Behavioral|Emotion Reporting Control Group|Attention matched control condition, participants will report their daily emotions over 5-6 weeks online.
76043891|NCT05474677|Procedure|closure of the abdominal fascia|The abdomen will be closed in intervention group with continuous PDS 2\0 sutures and size zero in control group.
75719191|NCT01062139|Drug|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
75565367|NCT02277015|Device|The Berci-Kaplan DCI|Videolaryngoscope-1
75565368|NCT02277015|Device|The AirTraq|Videolaryngoscope-2
75565369|NCT02277015|Device|GlideScope GVL|Videolaryngoscope-3
75719192|NCT01062139|Drug|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
75719193|NCT00780650|Drug|Atomoxetine|80 mg oral dose, once per day for 6 weeks
75719194|NCT00780650|Drug|Placebo|80 mg dose once per day for 6 weeks
75565370|NCT02277015|Device|The Pentax AWS|Videolaryngoscope-4
75565371|NCT02942199|Other|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
75565372|NCT00518453|Biological|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
75719195|NCT00653328|Drug|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
75874293|NCT05225129|Other|blood flow restriction exercise|blood flow restricted exercise, resistance training will be applied, corresponding to 30% of 1 maximum repetition for 8 weeks, 2 days in a week
76043892|NCT04424017|Biological|Specific anti-SARS-CoV-2 antibodies|"A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA)."
76043893|NCT05477797|Drug|Ixazomib DX/Lenalidomide DX|After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
76043894|NCT05483179|Diagnostic Test|CPET|Cardiopulmonary exercise test
75719196|NCT00653328|Drug|doxil|50 mg/m2 intravenously every 28 days
75419932|NCT01425918|Behavioral|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
75419933|NCT01425918|Behavioral|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
75565373|NCT05318664|Other|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
75719197|NCT01664182|Biological|Bevacizumab|Given IV
76043895|NCT05477641|Procedure|Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block|Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
75419934|NCT01425931|Procedure|Heart Lung machine|measurement of microcirculation with O2C device
75565374|NCT02942121|Other|LifeScience Technologies application|Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
75565375|NCT02941185|Drug|Devit-3 Oral Drop|
75565376|NCT00518492|Procedure|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
75719198|NCT01664182|Drug|Pazopanib Hydrochloride|Given PO
75719199|NCT01664182|Drug|Sorafenib Tosylate|Given PO
75719200|NCT01664182|Drug|Sunitinib Malate|Given PO
75719201|NCT01664182|Biological|Trebananib|Given IV
75719202|NCT00780728|Drug|Sildenafil|
75719203|NCT00809172|Drug|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
75719204|NCT00809172|Drug|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
75719205|NCT02552940|Drug|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
75719206|NCT00780806|Biological|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
75719207|NCT00780806|Procedure|Blood draw|Blood draw
75719208|NCT02551380|Drug|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
75719209|NCT02551380|Other|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
75719210|NCT00784862|Drug|Anastrozole|1mg, orally, once daily
76043896|NCT05477641|Procedure|Fascia Iliaca Compartment Block|Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
76043897|NCT05472259|Drug|Nanoliposomal irinotecan|In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
75719211|NCT00784862|Drug|Tamoxifen|20mg, orally, once daily
76043898|NCT05472259|Drug|5 FU|In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
76043899|NCT05472259|Drug|Leucovorin|In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
75419935|NCT01425957|Procedure|Lumbar puncture|"All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36)."
75419936|NCT01425983|Dietary Supplement|amino acid composition (asn01)|"Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
75419937|NCT01425983|Other|Placebo|"Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
75419938|NCT01425996|Drug|Lipotecan® (TLC388)|"Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~Cohort Ax: TLC388 MTD x 6 dose + 3DCRT"
75419939|NCT01426022|Other|Nutrition|Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
75419940|NCT01426022|Behavioral|mood manipulation|Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
75419941|NCT01426048|Other|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
75719212|NCT02556476|Procedure|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
76043900|NCT05472259|Drug|Oxaliplatin|Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
76043901|NCT04266145|Drug|intravenous dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline
76043902|NCT04266145|Drug|adductor canal block dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline
76043903|NCT05477329|Device|Lenses|The test lens is manufactured in a standard FreeForm technology (exactly like a standard progressive addition lens which is similar in terms of the graduall power profile induced in both lens). It does not demand any special manufacturing processes.
75419942|NCT01426061|Other|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
75419943|NCT01426061|Other|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
75419944|NCT01426061|Other|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
75419945|NCT01426074|Drug|Bevacizumab 5 mg/kg|Intravenously every two weeks
75719213|NCT02556476|Procedure|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
75719214|NCT02556476|Procedure|renal replacement therapy|the procedures used to treat acute kidney injury
75719215|NCT02556476|Procedure|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
75719216|NCT00642642|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Administration of 3 study treatments administered 14 ± 7 days apart."
75419946|NCT01426087|Drug|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
75419947|NCT01426087|Procedure|endoscopic therapy|gastroscope plus EIS/EVL/HI
75419948|NCT01426100|Drug|CKD-828 40/2.5mg|Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
75419949|NCT01426100|Drug|CKD-828 40/5mg|Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
75419950|NCT01426100|Drug|Telmisartan 80mg|Telmisartan 80mg monotherapy
75419951|NCT01426126|Drug|Genexol PM|Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
75419952|NCT01426139|Device|Percutaneous Coronary Intervention Biotronik Orsiro DES|Stenting
75419953|NCT01426165|Drug|Magnesium Sulfate|8 grams over 4 or 8 hours depending on randomization
75419954|NCT01426178|Device|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|"After written information and consent, patients are randomised in two groups: NAVA first or PSV first.~They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter."
75419955|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
75419956|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
75565377|NCT02942043|Drug|Bevacizumab|"Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard."
75565378|NCT00516971|Drug|Esomeprazole 20mg once daily|
75565379|NCT02942082|Other|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
75565380|NCT02942082|Other|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
75719217|NCT00642642|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Administration of 3 study treatments administered 14 ± 7 days apart."
75719218|NCT00780884|Device|acupuncture|16 sessions of acupuncture treatment, twice a week.
75719219|NCT00818064|Drug|anti-IL-20|Single s.c. injection (per dose cohort)
75719220|NCT00818064|Drug|placebo|Single s.c. injection (per dose cohort)
75419957|NCT01426256|Dietary Supplement|Cholecalciferol|Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
75419958|NCT01426282|Other|no intervention|no intervention
75565381|NCT00517088|Drug|IPAQ|
75565382|NCT02939664|Device|Banded (with polypropylene mesh) gastric bypass|The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.
75565383|NCT02939664|Procedure|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
75565384|NCT00518570|Drug|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
75565385|NCT02939586|Procedure|Haemodiafiltration post-dilution model|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.
75719221|NCT00784940|Drug|Anastrozole|1mg, orally, once daily
75719222|NCT00784940|Drug|Tamoxifen|20mg, orally, once daily
75719223|NCT00790166|Device|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
75719224|NCT00790166|Device|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
75719225|NCT00790166|Device|CPAP + No added humidity|ambient humidity
75719226|NCT02552706|Dietary Supplement|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
75419959|NCT01426282|Other|health education|"15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults "
75419960|NCT01426295|Device|Caphosol|"The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC> 500/mm3), and / or mucositis grade 0."
75419961|NCT01426295|Drug|Bicarbonate de sodium|"Treatment of the early start on the day of conditioning and stop when the ANC> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®."
75419962|NCT01426321|Other|Imaging guided LV lead positioning|"LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images."
75565386|NCT02939586|Procedure|Haemodialysis|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
75565387|NCT00517127|Drug|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
75565388|NCT00517127|Drug|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
75565389|NCT05174130|Device|RESPIRA device.com® Advanced|Ventilation of patients with continuous monitoring of the patient's clinical parameters and the parameters that the investigational medical device shows.
75565390|NCT00518648|Other|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
75419963|NCT01426334|Drug|dasatinib|Given PO
75419964|NCT01426334|Other|diagnostic laboratory biomarker analysis|Correlative studies
75565391|NCT00518648|Other|Usual care|Usual care
75565392|NCT03458208|Drug|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition"
75565393|NCT03458208|Drug|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition"
75565394|NCT03458208|Drug|Metformin|"Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
75565395|NCT03458208|Drug|Glucophage®|"Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
75719227|NCT02552706|Dietary Supplement|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
75419965|NCT01426334|Other|pharmacological study|Correlative studies
75419966|NCT01426334|Drug|cyclosporine|Given PO
75419967|NCT01426399|Drug|LC15-0444|LC15-0444 50mg qd (8 days once daily)
75419968|NCT01426399|Drug|Metformin|Metformin 1000 mg bid (8 days twice daily)
75565396|NCT00517166|Device|CAT (Combat Arms Tourniquet)|device
75565397|NCT02939625|Device|muscle training|
75565398|NCT02939625|Device|Continue Positive Airway Pressure|
75565399|NCT02939625|Device|bilevel positive airway pressure|
75565400|NCT00517205|Procedure|Non-contrast helical computerized tomogram (NCHCT)|
75565401|NCT00517283|Drug|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
75719228|NCT00790244|Drug|doxorubicin , ifosfamide|doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
75719229|NCT00790244|Drug|doxorubicin, ifosfamide|Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
75565402|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
76043904|NCT05477251|Procedure|microwave ablation|MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
75419969|NCT01426399|Drug|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
75565403|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
75565404|NCT02940912|Drug|Apomorphine|cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
75565405|NCT02940912|Drug|Placebo|cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
75419970|NCT01426451|Other|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
75419971|NCT01426451|Other|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
75419972|NCT01426464|Drug|0.005% Latanoprost dosed once.|0.005% Latanoprost dosed once. Placebo lotion dosed once.
75419973|NCT01426490|Dietary Supplement|Vitamin C|Vitamin C, 100 mg/d
75419974|NCT01426490|Dietary Supplement|Vitamin B6|Vitamin B6, 50mg/d
75419975|NCT01426490|Dietary Supplement|Folic acid|Folic acid 400 microgram/d
75565406|NCT00518726|Biological|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
75565407|NCT02941029|Other|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
75565408|NCT03459053|Behavioral|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
75565409|NCT02940795|Other|Coke|Patients were given a 20 ounce bottle of Coke Cola.
75565410|NCT02940795|Other|Diet Rite|Patients were given a 12 ounce can of Diet Rite.
75565411|NCT00517322|Drug|ramipril|ramipril 2.5- 5 mg once daily
75565412|NCT00517322|Drug|irbesartan|irbesartan 150-300 mg once daily
75565413|NCT02939430|Drug|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
75565414|NCT02939430|Drug|Intravenous neostigmine and atropine|
75565415|NCT00517400|Device|Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham|
75719230|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
75419976|NCT01426490|Dietary Supplement|Vitamin B6 plus folic acid|Vitamin B6, 50 mg; folic acid, 400 microgram
75565416|NCT02940717|Other|Vita suprinity|New glass ceramic material
75565417|NCT02940717|Other|Emax CAD|standard etchable glass ceramic used for laminate venneers
75565418|NCT00518765|Drug|Aliskiren|
75565419|NCT00518765|Drug|Aliskiren plus placebo|
75565420|NCT00518765|Drug|Aliskiren|
75565421|NCT00518765|Drug|Aliskiren plus placebo|
75565422|NCT02939469|Other|Physiologic maneuvers|"Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
75565423|NCT00517478|Procedure|Blood Sample|
75565424|NCT02939391|Drug|KW-6356|Oral administration
75565425|NCT02939391|Drug|KW-6356|Oral administration
75565426|NCT02939391|Drug|Placebo|Oral administration
75565427|NCT00518804|Behavioral|Functional Behavioural Skills Group and Parent Training|
75565428|NCT02940873|Behavioral|HARPdoc courses|A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
75565429|NCT02940873|Behavioral|BGAT courses|A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
76043905|NCT05477251|Procedure|lobectomy|lobectomy for GGOs located in hilar regions
75565430|NCT00517517|Biological|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
75419977|NCT01426542|Drug|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
75419978|NCT01426542|Other|No medication, but routine heart surgery|No medication, but routine heart surgery
75419979|NCT01426568|Behavioral|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
75419980|NCT01426607|Device|AMO|
75419981|NCT01426620|Dietary Supplement|Blueberry powder|The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
75419982|NCT01426633|Drug|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
75565431|NCT02939352|Device|Real continuous Theta Burst Stimulation|Continuous Theta Burst stimulation delivered
75565432|NCT02939352|Device|Sham continuous Theta Burst Stimulation|active sham Continuous Theta Burst stimulation delivered
75565433|NCT00517673|Drug|GSK945237|
75565434|NCT00517673|Drug|Sugar Pill|Placebo
75565435|NCT02940756|Drug|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
75565436|NCT02940756|Drug|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
75719231|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
75874294|NCT04013971|Other|Game without VR|During the AGRF biofeedback game without virtual reality (VR) participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game without VR for 4 minutes.
75719232|NCT00818142|Behavioral|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
76043906|NCT02554513|Device|EPG Tx|behavioral intervention that incorporates a device that provides visual biofeedback
75419983|NCT01426646|Drug|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
75419984|NCT01426646|Drug|S-1 plus cisplatin|"S-1 plus cisplatin every 3 weeks, a total of eight cycles~S-1: 40mg/m2 orally twice daily (days 1-14)~Cisplatin: 60mg/m2 IV on day 1"
75419985|NCT01426659|Behavioral|parental stimulation according to protocol|"verbal stimulation every day image of the Protocol Dire et Faire"
75419986|NCT01426672|Other|Monovision Correction (with the help of glasses or contact lenses)|
76043907|NCT02554513|Behavioral|SPT|A treatment hierarchy involving integral stimulation
75419987|NCT01426698|Procedure|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
75565437|NCT02940756|Drug|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
75565438|NCT02949245|Procedure|Interventions|"Procedure/Surgery: Routinely performed surgical correction of spinal deformity~Routinely performed surgical correction of spinal deformity"
75565439|NCT02939547|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
75565440|NCT02949167|Behavioral|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
75565441|NCT02941068|Drug|fluconazole and caspofungin|
75565442|NCT00517712|Drug|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
75565443|NCT00518843|Behavioral|FBT-BN|Mobilizing parents to curtail binge eating and purging
76043908|NCT05477173|Behavioral|The Strengths and Difficulties Questionnaire (SDQ) Parent Version Parent : It consists of 25 questionnaires used to screen for behavioral problems in children aged 4-17 years.|screen by using psychometric scales
75419988|NCT01426724|Drug|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
75565444|NCT00518843|Behavioral|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
75565445|NCT00517907|Drug|Preimplantation factor (PIF-1)|"The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration."
75565446|NCT02939274|Drug|Verteporfin|
75565447|NCT02939274|Device|Continuous Low-Irradiance Photodynamic Therapy (CLIPT)|
75719233|NCT00815958|Procedure|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
75719234|NCT00815958|Procedure|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
75719235|NCT00785018|Drug|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
75719236|NCT00785018|Drug|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
75719237|NCT00821340|Genetic|rAAV2-hRPE65|Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
75719238|NCT00790322|Drug|SBG|Soluble beta-1,3/1,6-glucan is a solution for oral use
75419989|NCT01426737|Drug|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
75565448|NCT00518921|Drug|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
75565449|NCT00518921|Drug|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
75565450|NCT00518921|Drug|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
75565451|NCT00518921|Drug|Placebo|Placebo, double dummy
75565452|NCT02940678|Other|No intervention|
75719239|NCT00790322|Other|Placebo|Solution for oral use
75719240|NCT00534352|Drug|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
75719241|NCT00642174|Drug|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
75719242|NCT00642174|Drug|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
75719243|NCT04001296|Behavioral|21 day Brush Day and Night school programme|Children participating in the 21 day Brush Day and Night school programme are provided with toothpaste and a toothbrush each and enjoy brushing instruction, supervised brushing, and the singing of songs to facilitate learn the importance of brushing day and night, and stickers and calendars to track progress. A celebration is held at the end of the programme with certificates and rewards. The programme is supported by colourful and attractive materials with bespoke cartoon characters. Parents are provided with educational leaflets.
75419990|NCT01426750|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
75565453|NCT04694183|Drug|Paclitaxel + S-1 + anti-PD-1 antibody (Peritoneal metastasis)|"Drug：Paclitaxel~50mg/m², intravenous drip administration, d1, d8, q3w.~Drug：Paclitaxel~20mg/m², intraperitoneal administration, d1, d8, q3w.~Drug:S-1~Oral, d1-14, q3w.~Drug:Camrelizumab~200mg，Intravenous drip administration, d1, q3w."
75565454|NCT04694183|Drug|SOX regimen + anti-PD-1 antibody (Liver metastasis, para-aortic lymph node metastasis )|"Drug:Oxaliplatin~Injection: 130mg/m² intravenous drip administration, d1, q3w.~Drug:S-1~Oral, d1-14, q3w.~Drug:Camrelizumab~200mg，Intravenous drip administration, d1, q3w."
75874295|NCT04013971|Other|Game with VR|During the AGRF biofeedback game with virtual reality (VR) participants will walk on a split-belt treadmill with a head-mounted VR display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game with VR for 4 minutes.
76043909|NCT04570969|Procedure|Erector spinae plane block|Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
75565455|NCT00516659|Biological|Heat-Labile Enterotoxin of Escherichia coli (LT)|Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
75419991|NCT01426776|Procedure|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
75565456|NCT00516659|Biological|Placebo|The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
75565457|NCT00518960|Drug|ProAlgaZyme|
75419992|NCT01426802|Drug|vildagliptin|Drug 50mg vildagliptin bid
75565458|NCT02940600|Device|Normothermic machine perfusion|Patients undergoing liver transplant with the use of grafts preserved with normothermic perfusion machine
75565459|NCT02940600|Procedure|Static cold storage|Patients undergoing liver transplant using statically cold preserved grafts
75565460|NCT02949401|Behavioral|Use of Virtual Reality App|The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
75565461|NCT03458091|Device|THRIVE|Oxygenation during apnea using transversal humidified oxygen
75565462|NCT03458091|Device|Endotracheal intubation|Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
75565463|NCT04694144|Device|telescoping intramedullary nail|All osteogenesis imperfecta patients with lower limb skeletal deformities corrected with multiple corrective osteotomies and insertion of two parts male and female segments of intramedullary telescoping nail
75565464|NCT00517946|Drug|pseudoephedrine hydrochloride|
75565465|NCT00517946|Drug|cetirizine hydrochloride|
75719244|NCT00992290|Biological|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
75719245|NCT00992290|Biological|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
75719246|NCT02550444|Drug|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
75719247|NCT02550444|Drug|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
76043910|NCT05471635|Biological|COVID-19 Vaccine|All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
76043911|NCT03383419|Drug|Epclusa|If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
76043912|NCT05477017|Drug|SGLT2 inhibitor|Selective inhibitors of the sodium and glucose co-transporter 2 (SGLT2) originated as antidiabetic drugs thanks to their hypoglycemic and glycosuric effect.
75719248|NCT02550444|Drug|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
75719249|NCT00665366|Drug|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
75719250|NCT00665366|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
75719251|NCT00665366|Drug|Lithium|Participant's ongoing dose
75719252|NCT00665366|Drug|Valproate|Participant's ongoing dose
76043913|NCT02554903|Drug|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
76043914|NCT02554903|Drug|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
75719253|NCT00992368|Procedure|reduction mammaplasty|patients submitted to reduction mammaplasty
75719254|NCT01141738|Behavioral|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
75719255|NCT01141738|Behavioral|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
75719256|NCT00775684|Drug|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
75719257|NCT00775684|Drug|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
76043915|NCT03329131|Device|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
75719258|NCT00775684|Drug|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
75719259|NCT04001218|Drug|Injection of hypertonic saline|Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
75719260|NCT04001218|Drug|Injection of Isotonic saline|Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
75719261|NCT02556008|Drug|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
75419993|NCT01426815|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
75419994|NCT01426815|Drug|Golimumab|The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
75419995|NCT01426841|Radiation|Adaptive Radiation|Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment
75419996|NCT01426880|Drug|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
75419997|NCT01426880|Drug|background treatment|"background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients)."
75419998|NCT01426906|Drug|Ketoconazole|Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
75419999|NCT01426906|Drug|rifampicin|Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
75420000|NCT01426919|Other|Head CT scan and blood draw within 12 hours of injury|
76043916|NCT03328195|Device|Neuro RX Gamma synchronous|Twenty minute treatment, six days per week for 12 weeks
76043917|NCT03328195|Device|Sham|Twenty minutes, six days per week for 12 weeks with sham device
76043918|NCT03328195|Device|Neuro RX Gamma asynchronous|Twenty minutes, six days per week for 12 weeks with sham device
76043919|NCT05482087|Drug|XZP-3621|ALK inhibitor-treated ALK-positive NSCLC treatment
76043920|NCT02332707|Drug|Grazoprevir|One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
76043921|NCT02332707|Drug|Uprifosbuvir|Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
76043922|NCT02332707|Drug|Elbasvir|One EBR 50 mg tablet (Part A), taken q.d. by mouth.
76043923|NCT02332707|Drug|Ruzasvir|Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
76043924|NCT02332707|Drug|Uprifosbuvir (+) Grazoprevir (+) Ruzasvir|Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
76043925|NCT02332707|Drug|Ribavirin|RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
76043926|NCT02370615|Drug|TAK-272|TAK-272 tablet.
75565466|NCT00517985|Drug|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
75565467|NCT04690920|Drug|Tocilizumab|Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
75565468|NCT00519038|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
75565469|NCT00519038|Other|Usual Care|Usual care is the current practice actually performed in the hospital
75565470|NCT04691895|Other|SARS-CoV2 infection|Confirmed COVID19 cases The definitions of COVID19 state are according to the WHO document released in March 2020. A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
75565471|NCT00518024|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
75420001|NCT01426932|Other|Video recording of Head Impulse Test|Video recording of Head Impulse Test
75420002|NCT01426945|Genetic|protein expression analysis|
75420003|NCT01426945|Other|immunohistochemistry staining method|
75565472|NCT02939508|Other|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
75565473|NCT02939508|Other|Non-colon originated: Neostigmin, Colonoscopy decompression|
75565474|NCT00518102|Drug|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
75719262|NCT00992524|Drug|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
75719263|NCT00992524|Drug|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
75719264|NCT00785096|Other|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
75719265|NCT00998842|Device|Recom Model 100|Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
75719266|NCT00998842|Device|GE 5000 ECG Monitor System|Wired ECG system
75719267|NCT00781040|Other|Severe sepsis vs. non-severe sepsis|To compare these two groups
76043927|NCT02370615|Drug|Digoxin|Digoxin tablet.
76043928|NCT02370615|Drug|Itraconazole|Itraconazole oral solution
76043929|NCT02370615|Drug|Midazolam|Midazolam syrup.
76043930|NCT02307513|Drug|Apremilast|Tablets for oral administration
76043931|NCT02307513|Drug|Placebo|Tablets for oral administration
75420004|NCT01426945|Other|laboratory biomarker analysis|
75420005|NCT01426971|Drug|IBUPROFEN + CAFFEINE|Pharmaceutical form: capsule Route of administration: oral
75420006|NCT01426971|Drug|IBUPROFEN|Pharmaceutical form: capsule Route of administration: oral
75420007|NCT01426035|Drug|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
75420008|NCT01426984|Drug|methylphenidate|a capsule containing 20 mg
75420009|NCT01427010|Radiation|[18F]FDG-PET-voxel intensity-based IMRT|Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography ([18F]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
75420010|NCT01427023|Device|APTIMA Trichomonas vaginalis (ATV) Assay|APTIMA Trichomonas vaginalis (ATV) Assay
76043932|NCT02332239|Behavioral|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~Eight-week longitudinal tailored text-message program"
76043933|NCT02332239|Behavioral|Control (EUC)|"In-ED brief session, discussing home safety & nutrition~Eight-week longitudinal home safety & nutrition text-message program"
75420011|NCT01427036|Procedure|MISS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate."
75420012|NCT01427036|Procedure|PHS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate."
76043934|NCT02370537|Drug|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
76043935|NCT02370537|Drug|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
76043936|NCT02330055|Procedure|Forty-five degrees elevated upper body position|
76043937|NCT02330055|Procedure|non-elevated upper body position|
75874296|NCT04013971|Other|Traditional Biofeedback Interface|"For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes."
75874297|NCT05179213|Drug|Azacitidine|75 mg/m2 subcutaneously on days 1-7
76043938|NCT02330055|Device|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
76043939|NCT02330055|Other|Stop-Bang questionnaire|"The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference."
76043940|NCT02330055|Other|Epworth Sleepiness Scale|"The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition."
76043941|NCT02330055|Other|P-SAP Score|"The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance."
76043942|NCT02330055|Other|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
76043943|NCT02306265|Device|FFDM|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
76043944|NCT02306265|Device|DBT|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
76043945|NCT02329743|Drug|RX-10045|topical therapy
76043946|NCT04896567|Diagnostic Test|Cell isolation|Tissue from kidney biopsy will be used to isolate Cluster Differentiation 34+ cells.
76043947|NCT02329431|Behavioral|activation curriculum|psychosocial activation curriculum
76043948|NCT02329431|Behavioral|support group|parent directed support group
76043949|NCT02328105|Drug|Carboplatin|Dosing: AUC = 6; on Day 1
75565475|NCT00518102|Other|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
75565476|NCT02939235|Drug|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
75565477|NCT02939235|Drug|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
76043950|NCT02328105|Drug|Abraxane|100 mg/m^2; Days 1, 8, 15
76043951|NCT02305797|Drug|Extended-release lorazepam|Extended-release lorazepam capsules
76043952|NCT02305797|Drug|Placebo|Placebo capsules
76043953|NCT01646073|Biological|Adalimumab|adalimumab eow
76043954|NCT01646073|Biological|placebo|placebo
76043955|NCT02328027|Drug|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
75565478|NCT00518141|Drug|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
75565479|NCT02938962|Drug|Tranexamic Acid|
75565480|NCT00519701|Drug|hydroxyurea|
75565481|NCT02939040|Behavioral|Positive Activities|"The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery."
75565482|NCT02939157|Other|Cardiac diagnostic ultrasound|Point-of-care ultrasound for diagnosing heart failure in primary care patients
75565483|NCT00519155|Drug|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
75565484|NCT00519155|Procedure|Open flap debridement|Open flap debridement alone
75565485|NCT02939196|Procedure|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
75565486|NCT02939196|Procedure|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
75565487|NCT00519740|Other|inhalative specific bronchial provocation with grass-pollen|
75565488|NCT04691076|Drug|Propofol|Propofol is administered by target-controlled infusion
75565489|NCT04691076|Drug|Esketamine|Esketamine is intravenously administrated
76043956|NCT02551159|Biological|MEDI4736|Anti-PD-L1 antibody
76043957|NCT02551159|Biological|Tremelimumab|Anti-CTLA-4 Antibody
76043958|NCT02551159|Biological|MEDI4736+Tremelimumab|
76043959|NCT02551159|Biological|Cetuximab|Monoclonal Antibody
76043960|NCT02551159|Drug|5-fluorouracil (5FU)|Chemotherapy Agent
76043961|NCT02551159|Drug|Cisplatin|Chemotherapy agent
76043962|NCT02551159|Drug|Carboplatin|Chemotherapy Agent
76043963|NCT05482009|Other|Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment|The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
76043964|NCT05481853|Procedure|One Anastomosis Gastric Bypass|
76043965|NCT04539379|Drug|Magnesium sulfate|intravenous infusion
76043966|NCT04539379|Drug|Labetolol|intravenous infusion
76043967|NCT04529473|Dietary Supplement|Eubacterium hallii|Eubacterium hallii, ≥ 1x10^9 live bacterial cells (per capsule)
76043968|NCT04529473|Other|Placebo|Placebo capsules are identical to the active treatment
75420013|NCT01427049|Device|renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
75420014|NCT01427062|Other|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
75420015|NCT01427062|Other|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
75420016|NCT01427075|Procedure|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
75420017|NCT01427088|Device|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
75420018|NCT01427114|Drug|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
75565490|NCT04691076|Drug|Fentanyl|Fentanyl is intravenously administrated
75565491|NCT00519935|Behavioral|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
75565492|NCT04690842|Diagnostic Test|PTH measurements post-thyroidectomy (at 5 and 60 min post thyroid removal)|We implement an algorithm employing PTH levels post-thyroidectomy to stratify patients according to their postsurgical risk for hypoparathyroidism, and to distinctively manage them in the immediate postsurgical period. High risk patients are quickly supplemented with Calcium iv and activated 25OH vitamin D. Low risk patients are clinically controlled and calcium level were checked at 24 and 48 hs post thyroidectomy.
75565493|NCT02949323|Other|urinary stone|patients of group one have urinary stones
75719268|NCT00995254|Behavioral|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
75719269|NCT00785174|Device|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
75565494|NCT04690959|Other|neural mobilization|Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
75719270|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
75719271|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
75719272|NCT00992680|Device|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
75719273|NCT00642018|Drug|docetaxel|Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
75420019|NCT01427140|Other|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
75420020|NCT01427140|Other|Saturated fatty acid group|Addition of saturated fatty acids to the diet in the form of pastries
75420021|NCT01427153|Procedure|Orthopaedic manual physical therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
75420022|NCT01427153|Procedure|Corticosteroid Injection|Corticosteroid injection to the tibiofemoral joint
75420023|NCT01427166|Other|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
75565495|NCT04690959|Other|Sham intervention|it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
75565496|NCT02949206|Drug|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
75874298|NCT05179213|Drug|Chidamide|20mg orally per week continuously
75719274|NCT00642018|Drug|LY2181308 sodium|LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
76043969|NCT05470153|Device|Continuous Positive Airway Pressure|For each patient with Obstructive Sleep Apnea, titration of Continuous Positive Airway Pressure (CPAP) pressure will be performed by conventional polysomnography or using auto-CPAP equipment using a validated protocol. The CPAP device should have an hour meter recording system, so that machine-on time hours could be checked at each clinical visit.
75420024|NCT01427192|Drug|acetazolamide|250 mg bid
75420025|NCT01427192|Other|Supplemental oxygen|Oxygen deliverded by nasal cannula
75420026|NCT01427192|Procedure|Non-invasive ventilation|Bi-level non-invasive ventilation via nasal mask
75420027|NCT01427192|Other|Room air|Room air applied via sham oxygen concentrator
75420028|NCT01427192|Drug|Placebo tablet|Placebo tablet (Mannitol) similar to acetazolamide
75420029|NCT01427205|Drug|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
75420030|NCT01427205|Drug|OSI-906|150 mg by mouth twice a day.
75420031|NCT01427205|Other|Placebo|Placebo taken by mouth twice daily.
75420032|NCT01427218|Other|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
75420033|NCT01427218|Behavioral|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
75420034|NCT01427218|Behavioral|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
75420035|NCT01427218|Other|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
75420036|NCT01427231|Dietary Supplement|glucose|The effect of a glucose solution on cognitive performance will be measured.
76043970|NCT05470075|Drug|HR18042 tablets|Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
76043971|NCT05470075|Drug|HR18042 tablets|Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
76043972|NCT05470075|Drug|HR18042 tablets|Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
75719275|NCT00642018|Drug|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
75719276|NCT00532948|Drug|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
75719277|NCT00998920|Drug|S-equol|oral, BID, 14 days
75719278|NCT00998920|Drug|Placebo|oral, BID, 14 days
75420037|NCT01427231|Dietary Supplement|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
75420038|NCT01427231|Dietary Supplement|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
75420039|NCT01427244|Drug|trastuzumab|monoclonal antibody
75420040|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation A
75420041|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
75420042|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
75420043|NCT01427270|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
75420044|NCT01427270|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
75420045|NCT01427270|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
75719279|NCT00998998|Behavioral|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
76043973|NCT05470075|Drug|Tramadol hydrochloride SR Tablets|Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
76043974|NCT05470075|Drug|Placebos|Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
75874299|NCT03338855|Drug|Dapagliflozin|"The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2."
75420046|NCT01427283|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
76043975|NCT05476627|Diagnostic Test|Biomarkers|Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
76043976|NCT05481619|Drug|Vedolizumab|"Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit."
76043977|NCT05476471|Behavioral|multicomponent exercise training program|One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
76043978|NCT05481385|Behavioral|Reference preparation-Reference preparation-Test Preparation|Under fed conditions, subjects randomly divided into RRT group were given one tablet of reference preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of test preparation after cleaning period.
76043979|NCT05481385|Behavioral|Reference preparation-Test Preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
75719280|NCT00998998|Behavioral|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
75719281|NCT00998998|Dietary Supplement|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
76043980|NCT05481385|Behavioral|Test Preparation-Reference preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
76043981|NCT02305563|Drug|BMS-936564|
76043982|NCT02305563|Drug|Cytarabine|
75874300|NCT05499624|Device|MicroTrend System|The hands-free device measures oral mucosal carbon dioxide pressure (POMCO2) and functions outside of the body and does not require a surgical procedure or any significant deviation from standard practice to operate.
75420047|NCT01427283|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
75420048|NCT01427283|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
75420049|NCT01427322|Drug|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
75420050|NCT01427322|Radiation|Radiation therapy|Standard radiation therapy
75874301|NCT03367793|Device|Spectacles - Clinically Derived|Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.
75420051|NCT01427335|Drug|calcium|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
75565497|NCT02949206|Drug|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
76043983|NCT02327325|Behavioral|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
76043984|NCT02327325|Behavioral|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
76043985|NCT02304705|Drug|Sildenafil|20 mg three times daily by mouth for 90 days
76043986|NCT02304705|Drug|Placebo|One capsule three times daily by mouth for 90 days
76043987|NCT02553499|Biological|MK-1248|IV infusion
76043988|NCT02553499|Biological|pembrolizumab|IV infusion
76043989|NCT04507009|Device|Ozone|topical gaseous ozone application
76043990|NCT04507009|Other|CGF|concentrated growth factor (CGF) application
75420052|NCT01427335|Drug|0.9 % saline|0.9 % saline intravenous infusion
75420053|NCT01427348|Procedure|with assistant|head extension by an assistant during direct laryngoscopy
75420054|NCT01427348|Procedure|without assistant|without head extension by an assistant during direct laryngoscopy
75420055|NCT01427387|Drug|ASP0456|oral
75420056|NCT01427387|Drug|Placebo|oral
75420057|NCT01427400|Drug|Botulinum Toxin-A|100 Units diluted in 25cc saline
75420058|NCT01427400|Drug|Saline|Dispensed in a 25cc syringe
75420059|NCT01427426|Dietary Supplement|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
75420060|NCT01427426|Other|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
75420061|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Consult
75420062|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Control - Standard of Care
75420063|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Newsletter
75420064|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Parent Letter
75420065|NCT01427478|Drug|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
75420066|NCT01427478|Drug|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
75420067|NCT01427491|Device|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
75420068|NCT01427491|Device|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
75420069|NCT01427530|Device|Deep Brain Stimulation|Deep Brain Stimulation
75420070|NCT01427543|Behavioral|MILE intervention|Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
75420071|NCT01427569|Drug|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
75420072|NCT01427569|Other|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
75420073|NCT01427582|Drug|Trabectedin|Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
75565498|NCT02949206|Drug|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
75565499|NCT02939001|Device|iris recognition scanner|
76043991|NCT04507009|Other|Traditional treatment|Alvogyl application
76043992|NCT04468789|Other|Six-month ARV dispensing|Patients in the intervention group who meet eligibility criteria will receive a six-month supply of antiretroviral medications, rather than the standard of care supply which is typically 2-3 months.
76043993|NCT05476315|Other|Emergency surgery during covid-19 pandemic|Patients undergoing emergency surgery during the covid period and compared with emergency interventions before the pandemic
76043994|NCT02553421|Device|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
76043995|NCT04270591|Drug|Glumetinib|The investigational product will be orally administrated when fasting at dose level of 300mg QD
76043996|NCT02549287|Behavioral|SafeCare|An evidence-based home visiting program
76043997|NCT02549287|Behavioral|Supportive Case Management|Child welfare services as usual
75719282|NCT00992758|Biological|Iodine-131 Anti-B1 Antibody|"Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached."
76043998|NCT05469451|Procedure|Low level laser therapy|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
76043999|NCT04505527|Behavioral|Lateral stepping|Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.
76044000|NCT04505527|Behavioral|Forward walking|Subjects will have a typical forward walking
76044001|NCT05476159|Drug|Indocyanine green solution|"Adequate perfusion was defined as the direct and clear visualization of the fluorescence along the gastric tube, relative to the excised specimen, after an estimated time of 150-180 s after i.v. administration injection"
75719283|NCT00641706|Drug|vorinostat|Given orally
76044002|NCT05476159|Device|Gastric bypass|Roux and Y Gastric bypass
76044003|NCT02553265|Drug|Carbidopa Low-Dose|300 mg/day
75719284|NCT00641706|Procedure|therapeutic conventional surgery|Patient undergoes surgery
75719285|NCT00641706|Drug|bortezomib|Given IV
75719286|NCT00995332|Drug|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
75719287|NCT00992914|Procedure|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
75719288|NCT00992914|Procedure|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
75420074|NCT01427621|Procedure|remote ischemic pre and postconditioning (RIPC)|RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
75420075|NCT01427634|Behavioral|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
75420076|NCT01427634|Other|Usual Care|Receive usual care as provided by the VAD clinical team.
75420077|NCT01427647|Procedure|Laparoscopic technique and thoracic epidural anesthesia|We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
75719289|NCT00999232|Drug|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
76044004|NCT02553265|Other|Placebo|A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
75719290|NCT00999232|Drug|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
75719291|NCT00993070|Drug|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
75719292|NCT00993070|Drug|placebo|vehicle gel, applied 4 times per day for 8 weeks
76044005|NCT02553265|Drug|Carbidopa High-Dose|600 mg/day
76044006|NCT04269967|Other|Receiving routine rehabilitation care via tele-rehabilitation system|Drain care education, self-massage techniques and exercise (PT and OT)
76044007|NCT05480839|Procedure|M-IBCS|Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant
76044008|NCT05480839|Procedure|ReLA-IBCS Early|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia
76044009|NCT05480839|Procedure|ReLA-ISBCS|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia
75565500|NCT02949440|Procedure|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.
76044010|NCT03514459|Other|Systems Analysis and Improvement Approach|SAIA has five steps. The first step uses an Excel-based tool to quantify drop- offs, or people who did not progress, in each step of a process (Figure 1). This tool also allows the user to see the downstream effect when improving one step in the cascade, and holding the other steps constant. Step 2 involves process flow mapping with clinic staff to identify modifiable bottlenecks in the process. Step 3 develops and implements a workflow modification to address a bottleneck identified in step 2 (continuous quality improvement [CQI] step). Step 4 assesses impact of the modification and recalculates the cascade analysis in step 1 (CQI step). Step 5 repeats the cycle for CQI. SAIA draws from systems engineering in the Toyota Production Systems and from research in LMICs. Studies in quality improvement in LMICs highlight that CQI processes led to more sustainable, effective, and appropriate interventions (42-44).
76044011|NCT03215095|Drug|Durvalumab (Medi4736)|durvalumab 1500 mg IV every 4 weeks
76044012|NCT03215095|Radiation|Radioiodine (RAI)|100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
76044013|NCT02561195|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
75565501|NCT02949440|Procedure|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
76044014|NCT02561195|Biological|Placebo|0.5 mL intramuscular injection
76044015|NCT05389163|Device|Giomer based injectable resin composite|Giomer material has been introduced as the true hybridization of glass ionomer and resin composite, containing surface pre-reacted glass ionomer (S-PRG) filler particles within a resin matrix. Giomer combines caries protection through fluoride release and recharge of glass ionomers and the esthetics, physical and handling properties of resin composite
76044016|NCT05389163|Device|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) have been developed to combine the advantages of both resin composite and glass ionomer; the good mechanical properties, esthetic of resin composite added to anticariogenic activity and chemical bonding to tooth structure of glass Ionomer.
75565502|NCT02938884|Device|HidrateSpark Water Bottle|HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
75565503|NCT05135052|Device|Rhenium-SCT|Rhenium-SCT irradiation device
75565504|NCT02948972|Procedure|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
75565505|NCT02948972|Procedure|In vitro fertilization without surgery|IVF without endometriosis surgery
75565506|NCT05108454|Drug|Multiple micronutrient supplementation|Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
75719293|NCT00993304|Drug|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
75719294|NCT00993304|Drug|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
75719295|NCT05189002|Drug|Dimolegin 40 mg|Dimolegin - DD217 - 40 mg
75719296|NCT05189002|Drug|Dimolegin 60 mg|Dimolegin - DD217 - 60 mg
76044017|NCT01663103|Drug|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
76044018|NCT01663103|Drug|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
76044019|NCT05509673|Other|Lipofilling (sublesional fat grafting)|
75420078|NCT01427660|Behavioral|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
75420079|NCT01427660|Behavioral|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
75420080|NCT01427673|Procedure|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
75420081|NCT01427686|Drug|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
75420082|NCT01427686|Drug|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
75420083|NCT01427699|Drug|T2-18C3 therapeutic antibody|1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
75565507|NCT04694222|Device|Nd:YAG laser|For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
75719297|NCT05189002|Drug|Fragmin|Fragmin 5000 IU in 0.2 ML Prefilled Syringe
75719298|NCT00644358|Drug|vilazodone|titration to 40 milligrams (mg) every day (qd) for 1 year
75719299|NCT01564498|Other|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
75719300|NCT00993538|Procedure|Blood sampling|
76044020|NCT05501951|Other|tDCS stimulation|The transcranial direct current stimulation (tDCS) method has emerged in the recent years as a non-invasive, safe, cheap, convenient and effective means to modulate brain functions and behaviours
76044021|NCT05501951|Other|Sham stimulation|For the sham group, the electrode positioning will be randomly allocated to be identical to either the DLPFC or the OFC group, and active stimulation will be delivered for the first 30 seconds only
76044022|NCT05303753|Other|fermented dairy protein with prebiotic fiber|During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
76044023|NCT04281797|Diagnostic Test|Intestinal microbiome new generation sequencing|Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
76044024|NCT05501639|Drug|tiotropium|tiotropium
76044025|NCT05501639|Drug|long-acting β2-agonists (LABA)|long-acting β2-agonists (LABA)
76044026|NCT05501639|Drug|inhaled corticosteroids (ICS)|inhaled corticosteroids (ICS)
75719301|NCT00993538|Procedure|Bone marrow aspiration|
75719302|NCT00821418|Device|PulseHaler treatment|treatment is for two weeks, 3 times per day
75719303|NCT00821418|Device|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
75719304|NCT00993694|Drug|chemotherapy|
75719305|NCT00993694|Drug|dapsone|
75719306|NCT00993694|Other|medical chart review|
75565508|NCT04690881|Behavioral|Psychodrama group psychotherapy|In order to reduce the fear of cihildbirth, pregnant women are given 90 minutes right after the training in addition to the routine pregnancy training. In the psychodrama-based pregnancy education program, fear of childbirth were assesment by sociometric measurement in order to increase the awareness of pregnant women about birth fear levels in the first week. Afterwards, they were given the opportunity to express themselves about the factors that may cause fear in pregnant women (their previous traumatic experiences, negative prejudices about childbirth, etc). The group members shared about their process in the first session and the session was ended. The session was evaluated with other researchers. In the following sessions, in order to strengthen their coping with the fear of childbirth, besides psychodrama warm-up games, the basic techniques of psychodrama, role switching, matching and mirror were used in protogonist works.
75565509|NCT00519233|Drug|AGS-1C4D4|IV
75565510|NCT02940561|Drug|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
75565511|NCT02940561|Drug|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
75565512|NCT00519974|Other|counseling intervention|
75565513|NCT00519974|Other|study of socioeconomic and demographic variables|
75565514|NCT00519974|Procedure|management of therapy complications|
75420084|NCT01427764|Device|manual and ultrasonic instruments|"The individuals were instructed regarding causes and consequences of periodontal disease as well as prevention techniques, including the sulcular brushing technique and flossing. The retention factors of plaque (caries cavities, excess supragingival restorations and calculus) were removed during the initial visits. Clinical parameters were initially assessed 30 days after initial therapy.~The quadrants were randomly assigned and a total of 28 teeth were examined and treated. One side was treated with Gracey curettes (Hu-Friedy™ - Chicago, IL, USA) - control group and the other side with ultrasonic instruments (Profi II Ceramic™, Dabi Atlante - Ribeirão Preto, São Paulo, Brazil) - the test group, using the tip for subgingival instrumentation Perio Sub (Dabi Atlante ®)."
75420085|NCT01427816|Drug|KCT-0809|
75565515|NCT00519974|Procedure|psychosocial assessment and care|
75719307|NCT00993694|Procedure|assessment of therapy complications|
75420086|NCT01427816|Drug|KCT-0809|
75420087|NCT01427816|Drug|Placebo|
75719308|NCT04000828|Device|Placement of Sensimed Triggerfish|Sensimed Triggerfish is placed on the corneal surface
75420088|NCT01427829|Behavioral|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
75420089|NCT01427842|Drug|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
75420090|NCT01427855|Other|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
75420091|NCT01427855|Other|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
75420092|NCT01427855|Other|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
75420093|NCT01427855|Other|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
75420094|NCT01427855|Other|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
75420095|NCT01427855|Other|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
75420096|NCT01427868|Drug|LB80380 maleate salt|183 mg (150 mg as a free base)
75420097|NCT01427868|Drug|LB80380 free base|150 mg
75565516|NCT02940366|Drug|Pitavastatin 4 mg orally daily|Pitavastatin 4 mg orally daily for 24months
75565517|NCT02940366|Drug|Atorvastatin 20 mg orally daily|Atorvastatin 20 mg orally daily for 24months
75565518|NCT00519272|Behavioral|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
75565519|NCT02940405|Drug|Ketorolac Tromethamine|A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
75565520|NCT02940405|Drug|Placebo|The placebo given as a tablet one hour before staring the root canal treatment
75565521|NCT02940444|Drug|Heparin|
75565522|NCT00520052|Drug|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
75719309|NCT00640926|Drug|Radezolid|300 mg/day, orally for 7-10 days
75719310|NCT00640926|Drug|Radezolid|450 mg/day orally for 7-10 days
75719311|NCT00640926|Drug|Radezolid|900 mg/day orally for 7-10 days
75565523|NCT04690647|Other|Opioid and non opioid postoperative analgesia.|Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
76044027|NCT05501405|Other|Electroencephalogram and eye-tracking recordings|"Participants will perform two tasks: recognize the expression (explicit recognition of the expression) or detect the change in color of the cross (implicit processing of the expression). Each participant will perform two tasks x 6 models x 5 expressions, i.e. 60 stimulations, for a stimulation duration of approximately 30 minutes.~Recognition of the emotional facial expression with a choice among 5 possibilities. Two neutral faces of the same person will be presented side by side. When the participant has looked at the central fixation cross for one second, one of the two faces will produce an expression. The participant will have to indicate as quickly as possible which expression it is, while his or her eye movements are recorded. Each participant will have to recognize 5 expressions x 8 models, i.e. 40 trials for a duration of approximately 5 to 10 minutes"
75420098|NCT01427894|Other|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
75565524|NCT04690647|Other|Fascia iliaca compartment block|Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.
75565525|NCT04690647|Drug|Dexamethasone|Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
75719312|NCT03892564|Drug|MC2-01 Cream, irradiation|One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
75719313|NCT03892564|Drug|MC2-01 Cream, no irradiation|One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
75420099|NCT01427946|Drug|IPI-504|
75719314|NCT03892564|Drug|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
75420100|NCT01427946|Drug|Everolimus|
75719315|NCT03892564|Drug|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
76044028|NCT05509361|Biological|AK101 injection SC|AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.
76044029|NCT04577963|Drug|Fruquintinib|Oral VEGFR inhibitor
76044030|NCT04577963|Drug|Tislelizumab|PD-1 inhibitor
76044031|NCT05076929|Diagnostic Test|ultrasound|Ultrasonographic measurement of Inferior Vena Cava Collapsibility Index
75420101|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|"Atropin 10µg/kg~Mivacurium 200µg/kg immediately followed by~Fentanyl 2µg/kg"
75420102|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|"Atropin 10µg/kg~Fentanyl 2µg/kg, repeat max. two times~Mivacurium 200µg/kg"
75420103|NCT01427998|Dietary Supplement|olive leaf extract|olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
75420104|NCT01427998|Other|placebo|placebo
75420105|NCT01428037|Drug|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
75420106|NCT01428037|Drug|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
75420107|NCT01427127|Drug|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
75420108|NCT01428050|Drug|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
75420109|NCT01428050|Drug|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
75420110|NCT01428154|Drug|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
75420111|NCT01428180|Drug|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
75420112|NCT01428180|Procedure|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
75565526|NCT00519311|Behavioral|Health Intervention Package|CHAP and Ask Diary
75565527|NCT02938845|Behavioral|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
75565528|NCT02938845|Procedure|total laparoscopic hysterectomy(TLH)|
75565529|NCT02938845|Procedure|total abdominal hysterectomy(TAH)|
75565530|NCT00519350|Procedure|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
75565531|NCT00519467|Drug|Chlorproguanil-dapsone-artesunate (CDA)|
75565532|NCT02940483|Drug|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
75565533|NCT04974684|Device|HeartMate 3|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
75420113|NCT01428180|Drug|Ibuprofen|3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
75420114|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
75420115|NCT01428232|Other|implementation of the Baby-Friendly Hospital Initiative|Implementation of BFHI steps 1-9 in maternities
75420116|NCT01428232|Other|BFHI steps 1-9 +well-child clinic|Implementation of BFHI steps 1-9 in maternities and provision of breastfeeding support including culturally appropriate educational messages and metaphors as the ongoing aspect of step 10 in well-child clinic
75420117|NCT01428271|Other|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
75420118|NCT01428284|Drug|Canagliflozin/Probenecid|Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
75420119|NCT01428297|Drug|BPR277 ointment (controlled application)|
75719316|NCT03892564|Drug|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
75420120|NCT01428297|Drug|Placebo (Vehicle)|
75420121|NCT01428297|Drug|BPR277 ointment|
75420122|NCT01428297|Drug|Placebo (Vehicle)|
75420123|NCT01428297|Drug|BPR277|
75420124|NCT01428297|Drug|Placebo (Vehicle)|
75719317|NCT00821496|Drug|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
75719318|NCT00999622|Other|laboratory biomarker analysis|
75719319|NCT00999622|Other|questionnaire administration|
75719320|NCT00818220|Procedure|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
75420125|NCT01428310|Dietary Supplement|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
75719321|NCT00818220|Other|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
75719322|NCT03891862|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
75420126|NCT01428310|Dietary Supplement|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
75719323|NCT03891862|Drug|Placebo oral capsule|non-active dosage form
76044032|NCT05509205|Other|Turkish Validity and Reliability of The PSS Scale|This study is about validation of the Pound Satisfaction Scale to Turkish. The level of satisfaction with the rehabilitation service and treatment of 130 stroke patients undergoing stroke rehabilitation will be evaluated with the Pound satisfaction scale.
75420127|NCT01428323|Device|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
75420128|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
75420129|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
75420130|NCT01428375|Drug|(1) Paracetamol injection|Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
75420131|NCT01428375|Other|Sterile water|Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
75420132|NCT01428388|Drug|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
75420133|NCT01428388|Drug|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
75420134|NCT01428401|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus ( AM) at a rate of 3 g three times per day
75420135|NCT01428401|Other|Placebo|at a rate of 3 g three times per day
75420136|NCT01428414|Drug|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
76044033|NCT04285697|Other|infection prevention bundle|"The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family"
76044034|NCT05501015|Other|Ice chips|Consuming small amounts of ice chips with supervision
75420137|NCT01428414|Drug|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
76044035|NCT04535531|Drug|SB206 10.3% berdazimer|Topically once daily
75420138|NCT01428414|Drug|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
75420139|NCT01428414|Drug|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
75565534|NCT04974684|Drug|Apixaban|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
75420140|NCT01428427|Drug|GSK1120212|Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
75420141|NCT01428427|Drug|Gemcitabine|Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
75565535|NCT00520091|Drug|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
75719324|NCT00640614|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
75719325|NCT02550912|Drug|Vitamin D3|vitamin D drops for paediatrics
75719326|NCT02550912|Other|Placebo|glucose syrup with same taste and color to vitamin D3 drops
75420142|NCT01428440|Radiation|18FML10|apoptosis imaging radio ligand
75420143|NCT01428466|Drug|GSK2585823|CLDM1%/BPO3%
75719327|NCT00999700|Drug|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
75719328|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
75719329|NCT00999700|Drug|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
75719330|NCT00999700|Drug|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
75565536|NCT00520091|Drug|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
75565537|NCT00520091|Drug|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
76044036|NCT04535531|Drug|vehicle gel|Topically once daily
76044037|NCT04532645|Drug|Olaparib|Olaparib
76044038|NCT02560025|Drug|Alisertib|
76044039|NCT02560025|Drug|Cytarabine|
76044040|NCT02560025|Drug|Idarubicin|
76044041|NCT02560025|Drug|Daunorubicin|Can be used in place of idarubicin
75420144|NCT01428466|Drug|Benzoyl peroxide 3%|Benzoyl peroxide 3%
75420145|NCT01428466|Drug|Benzoyl peroxide 5%|Benzoyl peroxide 5%
75565538|NCT00520091|Radiation|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
75565539|NCT00520091|Procedure|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
75565540|NCT05095623|Other|Natural History Observation|This is a natural history study.
75565541|NCT00520169|Drug|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
75565542|NCT00519506|Other|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
75420146|NCT01428466|Other|Vehicle|placebo
75565543|NCT02938533|Behavioral|Intervention|The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
75719331|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
75719332|NCT00818298|Drug|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
75719333|NCT00821574|Drug|Fluvastatin|Fluvastatin: daily 80 mg, oral
76044042|NCT05500937|Drug|UDCA|UDCA vs. placebo together with statin in ASCVD patients
76044043|NCT05500859|Other|Data collection at Baseline, 3 months after baseline (BL), 1-year follow-up, Telephone follow-up and questionnaire 3 years and 5 years after BL|Data collection (Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters)
76044044|NCT04744025|Device|Microfluidics chamber|Unwashed sperm will be placed into the inlet chamber of the microfluidics device. The most motile sperm will swim to the outlet chamber, and these sperms will be used for intracytoplasmic sperm injection (ICSI) into the eggs.
75719334|NCT00821574|Drug|Valsartan|Valsartan: daily 160 mg, oral
75719335|NCT00821574|Drug|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
75719336|NCT00995800|Drug|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
75719337|NCT00818376|Other|Dental prophylaxis|Two randomized quadrants will be cleaned with a prophylaxis to disrupt dental biofilm presence.
75420147|NCT01428479|Drug|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
75420148|NCT01428479|Drug|Placebo|Placebo solution will be administered intravenously.
75719338|NCT00993850|Behavioral|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
75420149|NCT01428492|Drug|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
75719339|NCT00993850|Other|Bipolar education|Psychoeducation
75719340|NCT00816192|Procedure|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
75719341|NCT00999778|Behavioral|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
75719342|NCT00999778|Behavioral|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
76044045|NCT04744025|Other|Density Gradient Centrifugation|Sperm will be washed and centrifuged according to standard protocol, and these washed sperm will be used for ICSI.
76044046|NCT05500781|Behavioral|Coaching HER|The CoachingHER coach education program is a six-module online program aimed at upskilling coaches in [the effectiveness, feasibility, and acceptability of the Coaching HER; the first online program aimed at reducing gender stereotypes for coaches]. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
76044047|NCT04524455|Drug|Blinatumomab|Blinatumomab will be administered as a continuous intravenous infusion (cIV).
75719343|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
76044048|NCT04524455|Drug|AMG 404|AMG 404 will be administered as an intravenous infusion (IV).
75719344|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
75719345|NCT00761657|Drug|Roxadustat|Capsule
75420150|NCT01428492|Drug|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
75420151|NCT01428492|Drug|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
75565544|NCT00520208|Drug|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
75565545|NCT00520247|Drug|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
75565546|NCT00519545|Behavioral|Prayer|Data collection on physiological biomarkers
75565547|NCT02949050|Biological|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
75719346|NCT00761657|Drug|Placebo|Capsule
76044049|NCT04524455|Drug|Dexamethasone Premedication|Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
76044050|NCT05508893|Radiation|CT Angiography|A CTA will be performed on asymptomatic individuals
75420152|NCT01428505|Radiation|[18F]PBR111|radioligand to assess binding to TSPO
75420153|NCT01428518|Drug|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
76044051|NCT05508893|Diagnostic Test|Exercise stress test|A routine exercise stress test will be performed on a bicycle
76044052|NCT05500625|Procedure|Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection|Standard diagnostic endoscopy will be done and Fundal varices will be assessed. EUS procedures will be performed using linear endoscope under general anesthesia. Use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. Puncture the gastric fundal variceal vein at the lower esophagus near the cardia and place the coil into the shunt and immediately inject with sclerosant and cyanoacrylate under the guidance of EUS using a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. Use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
76044053|NCT05500625|Procedure|Ballon-occluded retrograde transvenous obliteration|A balloon occlusion catheter will be inserted into the venous end of the gastro-renal or gastro-caval shunt via the right femoral vein or internal jugular vein. Balloon-occluded retrograde venogram will be done to evaluate degree of retrograde filling of the gastric varices and presence of collateral veins. Any significant large collateral veins seen will be occluded with coils using microcatheter to prevent leakage of the sclerosant into the systemic circulation. Then, sclerosant agent (ethanol-amine oleate, Sodium tetradecyl sulphate, or polidocanol) will be injected into the portosystemic shunt till complete filling of the gastric varices and part of the feeding veins. Finally, the balloon left in place for 2-12 hours then gradually will be deflated when complete occlusion of blood flow of the target shunt is achieved.
75565548|NCT02949050|Biological|SCIT|Treatment group consists of patients who completed > 1 year of SCIT while control group patients did not undergo SCIT
75565549|NCT02940132|Drug|SC10914|SC10914 will be administered orally.
75565550|NCT00519662|Drug|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
76044054|NCT04789889|Radiation|intraoperative radiotherapy|intraoperative radiotherapy
76044055|NCT04789889|Radiation|postoperative radiotherapy|postoperative radiotherapy
76044056|NCT04640519|Other|Usual care|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
76044057|NCT04640519|Other|TASC intervention|TASC patients will receive a BP monitoring kit and electronic tablet with patient tailored BP infographics. They will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
76044058|NCT04411901|Drug|Cholecalciferol (vitaminD3)|Theraputic vitamin D3 for CF and non CF bronchiectasis children
76044059|NCT05500547|Other|"US Public Health Service USPSH criteria for assessment of success of resin composite restorations"|"US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months."
75420154|NCT01428531|Drug|Fondaparinux Sodium|
75420155|NCT01428544|Drug|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
75420156|NCT01428570|Device|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
75420157|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ lower dose (10^8 TU) at weeks 0, 8 and 16.
75420158|NCT01428596|Biological|saline solution|Saline solution 1.0 ml SQ at weeks 0, 8 and 16.
75420159|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ higher dose (10^9 TU) at weeks 0, 8 and 16.
75420160|NCT01428609|Procedure|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
75420161|NCT01428622|Device|Respimat|aqueous and ethanolic solution
75420162|NCT01428622|Device|Respimat|aqueous and ethanolic solution
75420163|NCT01428622|Device|Respimat|aqueous and ethanolic solution
75420164|NCT01428622|Device|Respimat|aqueous and ethanolic solution
75420165|NCT01428622|Device|Respimat|aqueous and ethanolic solution
75420166|NCT01428622|Device|Respimat|aqueous and ethanolic solution
75420167|NCT01428622|Device|Respimat|aqueous and ethanolic solution
75420168|NCT01428622|Drug|Olodaterol|aqueous solution
75874302|NCT03367793|Device|Spectacles - Metric Technique #1 Derived|Prescription spectacle lenses determined by metric-derived objective technique #1. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Visual Strehl ratio in the spatial domain (VSX). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #1 Derived.
75874303|NCT03367793|Device|Spectacles - Metric Technique #2 Derived|Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.
75874304|NCT01209234|Behavioral|Standard-of-Care Education|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
75874305|NCT01209234|Drug|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
75874306|NCT04151953|Diagnostic Test|Blood sample collection|Blood sample collection for markers of myocardial injury
75565551|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
75874307|NCT03626220|Procedure|acupuncture|manually manipulate acupuncture at CV6 and three acupoints on each arms and legs
75719347|NCT00816270|Procedure|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
75719348|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
75719349|NCT00999856|Device|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
75719350|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
75420169|NCT01428622|Drug|Olodaterol|aqueous solution
75420170|NCT01428622|Drug|Olodaterol|aqueous solution
75420171|NCT01428622|Drug|Olodaterol|aqueous solution
75420172|NCT01428622|Drug|Olodaterol|aqueous solution
75719351|NCT00999856|Device|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
75420173|NCT01428622|Drug|Olodaterol|aqueous solution
75420174|NCT01428622|Drug|Olodaterol|aqueous solution
75420175|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
75420176|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
75420177|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
75420178|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
75420179|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
75420180|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
75420181|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
75565552|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
75565553|NCT04925466|Device|CPAP at pressure of 10 cmH2O|Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography
75565554|NCT04925466|Device|CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
75565555|NCT00520364|Other|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
75565556|NCT02949089|Drug|ACH04|The subjects will receive the study medication in each group
75565557|NCT02940210|Device|Mediclore® (adhesion barrier)|
75565558|NCT02948816|Behavioral|Facebook|Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.
75719352|NCT00999856|Device|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
75719353|NCT00319501|Drug|Placebo|Intramuscular autoinjector; administered at onset of an episode
75719354|NCT00319501|Drug|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
75719355|NCT00994006|Dietary Supplement|Magnesium oxide|520 mg of elemental magnesium q.d.
75565559|NCT02948816|Behavioral|Facebook + Food|Participants will spend 30 minutes on a Facebook page that is food related posts.
75565560|NCT02948816|Behavioral|Colouring|Participants will spend 30 minutes colouring quietly.
75565561|NCT04880694|Drug|STC3141|"To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
75565562|NCT04880694|Drug|STC3141|"To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
75565563|NCT00520442|Drug|ibuprofen|
75719356|NCT00994006|Dietary Supplement|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
75719357|NCT00818610|Drug|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
75719358|NCT00818610|Drug|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
75719359|NCT01000012|Device|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
75565564|NCT00520442|Drug|acetamin w codeine|
75565565|NCT02948894|Device|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
75565566|NCT04870320|Behavioral|Endeavor: Computer-Based Cognitive Stimulation Intervention|Endeavor application will be utilized by participant on iPad
75565567|NCT04870320|Behavioral|Words!: Computer-Based Cognitive Stimulation Intervention|Words! application will be utilized by participant on iPad
75565568|NCT04870320|Other|Quality of Life (QOL) Questionnaires|Standardized QOL questionnaire will be administered at each study visit
75565569|NCT03458013|Behavioral|Mindfulness Meditation|Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
75565570|NCT02948738|Behavioral|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
75565571|NCT02948738|Behavioral|Standard Asthma Education|Basic review of asthma action plan and inhaler use
75565572|NCT02938572|Drug|NNC0143-0406|Administered subcutaneously (s.c. under the skin)
75565573|NCT02938572|Drug|Insulin Aspart|Administered subcutaneously (s.c. under the skin)
75565574|NCT02940054|Other|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
75565575|NCT02940093|Other|Stem cell transplantation|Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
75565576|NCT02948699|Dietary Supplement|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
75420182|NCT01428622|Drug|BI54903|ethanolic solution
75420183|NCT01428622|Drug|BI54903|ethanolic solution
75420184|NCT01428622|Drug|BI54903|ethanolic solution
75420185|NCT01428622|Drug|BI54903|ethanolic solution
75420186|NCT01428622|Drug|BI54903|ethanolic solution
75420187|NCT01428622|Drug|BI54903|ethanolic solution
75420188|NCT01428622|Drug|BI54903|ethanolic solution
75420189|NCT01428648|Behavioral|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
75420190|NCT01428141|Drug|E7050|Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
75420191|NCT01428687|Behavioral|Sleep Duration|Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
75420192|NCT01428687|Behavioral|No change in sleep|This group is taught to maintain their current sleep habits.
75420193|NCT01428726|Drug|NT-KO-003|NT-KO-003 is a coated tablet, administered once a day
75565577|NCT00521417|Behavioral|short-term dynamic therapy|
75565578|NCT00521417|Behavioral|long-term dynamic therapy|
75565579|NCT02938728|Other|Biopsies|
75565580|NCT02938650|Drug|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
75565581|NCT04694417|Other|Compression stocking|Please see the description of the intervention in another section
75420194|NCT01428739|Device|MRS|Procedure
75420195|NCT01428804|Device|transcranial Direct Current Stimulation (tDCS)|Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
75420196|NCT01428817|Drug|Carbetocin|20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75420197|NCT01428817|Drug|Carbetocin|40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75420198|NCT01428817|Drug|Carbetocin|60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75420199|NCT01428817|Drug|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75420200|NCT01428817|Drug|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75565582|NCT04694417|Dietary Supplement|Magnesium tablet|Please see the description of the intervention in another section
75565583|NCT04694417|Other|Placebo tablet|Please see the description of the intervention in another section
75420201|NCT01428830|Procedure|7-day catheterization following fistula repair surgery|This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
75420202|NCT01428830|Procedure|14 day catheterization|This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
75420203|NCT01428843|Drug|FERRISAT|A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
75420204|NCT01428843|Drug|PLACEBO|A single infusion of Glucose 5% solution during inclusion visit
75420205|NCT01428908|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
75420206|NCT01428908|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
75420207|NCT01428908|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
75420208|NCT01428908|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
75420209|NCT01428921|Behavioral|Theory based education and brief motivation interview|"Standard education programme as described above,~Plus~Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~Follow-up phone call would be arranged within 1 week after using CPAP.~Video, slides and booklets would be used as education media."
75420210|NCT01428947|Procedure|Arterial approach|Randomization to right radial or femoral approach
75420211|NCT01428960|Dietary Supplement|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
75420212|NCT01428986|Drug|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
75420213|NCT01428999|Dietary Supplement|probiotics|probiotics 1 pack (2g) bid for three weeks
75420214|NCT01429012|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
75565584|NCT00520598|Biological|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
75565585|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
75420215|NCT01429012|Other|Culture medium without MSC.|2 ml of culture medium.
75565586|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
75420216|NCT01429025|Biological|rituximab|IV
75420217|NCT01429025|Drug|bendamustine|IV
75565587|NCT00520598|Biological|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
75565588|NCT00520598|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
75565589|NCT00520598|Biological|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
75565590|NCT02939898|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
75565591|NCT02939898|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
75565592|NCT00520637|Drug|EZN-2208|
75420218|NCT01429025|Drug|lenalidomide|PO
75420219|NCT01429090|Procedure|blood sampling|blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
75420220|NCT01429090|Drug|Vagantin®|administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
75420221|NCT01429090|Drug|methantheline solution|administration 100 ml methantheline solution (100 mg methantheline bromide)
75420222|NCT01429090|Procedure|Measurement of salivation|"Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing"
75420223|NCT01429090|Procedure|Measurement of accommodation|Accommodation was measured with the optometer according to Schober (Velhagen 1972)
75420224|NCT01429090|Procedure|Pupillometry|Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
75420225|NCT01429116|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
75420226|NCT01429129|Drug|Nicotine replacement therapy|Nicotine transdermal patches as per product monograph
75420227|NCT01429142|Behavioral|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
75565593|NCT02938338|Procedure|Bariatric surgery|Bariatric surgery, with an anticipated mean weight loss of 30 kg
75565594|NCT00521495|Device|neodymium permanent magnet|"3/4 diameter by 1/8 thick permanent magnet"
75565595|NCT00521495|Device|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
75565596|NCT00521495|Device|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
75565597|NCT02939703|Other|Diet|Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
75565598|NCT02938221|Device|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
75565599|NCT00520754|Drug|levocetirizine dihydrochloride|
75565600|NCT00520832|Device|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
75565601|NCT00520832|Device|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
75420228|NCT01429142|Behavioral|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
75565602|NCT02939859|Procedure|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
75565603|NCT02939859|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
75565604|NCT02939859|Procedure|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
75565605|NCT00521534|Device|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
75565606|NCT02277132|Drug|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
75565607|NCT02277132|Drug|Placebo|Placebo tablets three times daily orally from randomization until delivery
75420229|NCT01429155|Genetic|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
75565608|NCT00520871|Drug|Blueberry juice|
75565609|NCT00520949|Drug|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
75565610|NCT00520949|Drug|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
75565611|NCT00520949|Drug|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
75565612|NCT00520949|Drug|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
75565613|NCT02938104|Dietary Supplement|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
75565614|NCT02938104|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
75565615|NCT02938104|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
75565616|NCT02948504|Procedure|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
75565617|NCT02938260|Drug|Metoprolol vs Diltiazem|
75565618|NCT00520988|Behavioral|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
75420230|NCT01429181|Drug|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
75420231|NCT01429194|Procedure|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
76044060|NCT05508737|Drug|Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)|Single arm: Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
75420232|NCT01429246|Dietary Supplement|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
75420233|NCT01429246|Dietary Supplement|Salt Substitute|Estimated 30 grams per day per household member
75420234|NCT01429337|Drug|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).
75420235|NCT01429337|Drug|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.
75420236|NCT01429363|Procedure|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
75565619|NCT04781244|Device|EndWarts® FREEZE|EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.
75565620|NCT04781244|Device|Liquid nitrogen|Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
75565621|NCT00521027|Device|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
75565622|NCT00521027|Procedure|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
75565623|NCT02938182|Drug|clopidogrel|clopidogrel troche 75 mg daily for three months
75565624|NCT00521066|Device|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
75565625|NCT02931552|Behavioral|Nuevo Amancer-II Stress Management Program|Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
75420237|NCT01429376|Other|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
76044061|NCT04281329|Procedure|Magnetic resonance imaging|Cardiac magnetic resonnance imaging before catheter ablation.
75420238|NCT01429376|Other|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).~Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.~Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
75874308|NCT05571241|Behavioral|Fast rehabilitation program|1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
75874309|NCT05691894|Drug|18F-FAPI|Patients will receive a tracer dose of 18F (8-10mCi) labelled FAPI
75420239|NCT01429376|Other|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.~All questionnaires were completed on the day of initial pulmonary function tests and three months later."
75565626|NCT00521105|Other|Virtual visit|Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
75420240|NCT01429376|Other|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
75420241|NCT01429402|Drug|Botulinum Toxin Type A|1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
75565627|NCT02938065|Procedure|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
75565628|NCT02938065|Other|2% milk|16 participants will drink 10 ounces of 2% milk
75565629|NCT02938065|Other|apple juice|16 participants will drink 10 ounces of apple juice
75565630|NCT02938065|Other|ensure clear|16 participants will drink 10 ounces of ensure clear
75874310|NCT05691894|Drug|68Ga-FAPI|Patients will receive a tracer dose of 68Ga (2-5mCi) labelled FAPI
76044062|NCT04333511|Device|TPS (NEUROLITH)|6 treatments of TPS over 2 weeks
76044063|NCT04333511|Device|Sham-TPS (NEUROLITH)|6 treatments of Sham-TPS over 2 weeks
76044064|NCT04231799|Procedure|Bathing|Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
75719360|NCT01000012|Device|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
75719361|NCT02551302|Device|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
76044065|NCT05508659|Drug|Duvelisib|Duvelisib PR2D bid po. until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
76044066|NCT05508659|Drug|SG001|240mg, each two weeks,iv,until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
75420242|NCT01429402|Drug|Botulinum Type A|b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
75420243|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
75874311|NCT05178511|Drug|Ensartinib|Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
75874312|NCT05571163|Drug|AMG 510|Tablets
76044067|NCT05508581|Procedure|microwaves ablation of varicose veins|"Microwave ablation is an endovenous treatment. This is a similar treatment approach as laser ablation and radiofrequency ablation. Endovenous means that the treatment device is inside the vein during treatment."
76044068|NCT05500157|Procedure|aspiration sclerotherapy versus laparoscopic fenestration|See arm description
76044069|NCT05499923|Device|Debonding|Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
76044070|NCT05508425|Diagnostic Test|oral glucose tolerance test using water at room temperature|The use of water at room temperature to solve the 75g glucose.
75420244|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
75420245|NCT01429415|Drug|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
75565631|NCT00521183|Drug|Cytochlor|The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
76044071|NCT05508425|Diagnostic Test|oral glucose tolerance test using hot water|The use of hot water to solve the 75g glucose.
76044072|NCT05508425|Diagnostic Test|oral glucose tolerance test using cold water|The use of cold water to solve the 75g glucose.
75420246|NCT01429415|Drug|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
75565632|NCT00521183|Drug|Tetrahydrouridine|A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
75565633|NCT00521183|Radiation|Radiation Therapy|One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
75565634|NCT02938026|Procedure|Bariatric surgery|
75565635|NCT02938026|Behavioral|Telephone Intensive Lifestyle Counselling|
75565636|NCT00521573|Other|Dark chocolate|
75719362|NCT02551302|Device|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic"
76044073|NCT05508425|Diagnostic Test|oral glucose tolerance test using hot water with tea bag|The use of hot water with tea bag to solve the 75g glucose.
76044074|NCT05508425|Diagnostic Test|oral glucose tolerance test using room temperature water with tea bag|The use of room temperature water with tea bag to solve the 75g glucose.
76044075|NCT05508425|Diagnostic Test|oral glucose tolerance test using cold water with tea bag|The use of cold water with tea bag to solve the 75g glucose.
75420247|NCT01429428|Other|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
76044076|NCT05508425|Diagnostic Test|Oral glucose tolerance test using bubble water at room temperature|The use of bubble water at room temperature to solve the 75g glucose.
75420248|NCT01429428|Other|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
75420249|NCT01429467|Device|Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)|Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
75420250|NCT01429480|Procedure|Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block|
75420251|NCT01429480|Procedure|Preoperative Ultrasound Guided Posterior TAP Block|
75420252|NCT01429480|Drug|Patient controlled analgesia|
75420253|NCT01429506|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
75565637|NCT02937714|Other|School Mental Health training|School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents & school based interventions for various psychiatric problems
75565638|NCT00521612|Drug|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
75420254|NCT01429506|Drug|Intensive medical management|Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
75420255|NCT01429519|Drug|RPh201, botanical drug product|topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
75420256|NCT01429545|Drug|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
75420257|NCT01429545|Drug|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
75420258|NCT01429571|Other|No intervention|No intervention
75420259|NCT01429610|Drug|Rituximab+mVPDL|"Induction:~Dauno 90 mg/m2/d by civ (d1-3)~Vinc 2 mg iv (d1, 8)~Pred 60 mg/m2/d po (d1-14)~for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~Rituximab 375mg/m2/d (d8)~Consolidation A (cycle1)~D 45 mg/m2/day by continuous iv (d1, 2)~V 2 mg iv (d1, 8)~P 60 mg/m2/day po (d1-14)~for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~Rituximab 375mg/m2/d (d8)~Consolidation B (cycles2&4)~Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~Eto 150 mg/m2/d iv over 3 hr (d1-4)~Rituximab 375mg/m2/d d8~Consolidation C (cycles 3&5)~Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~Rituximab 375mg/m2/d (d8&22)~Maintenance (for 2 years)~- for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~Consider alloHCT"
75420260|NCT01429636|Behavioral|Modified Relaxation (MR)|The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
75420261|NCT01429636|Behavioral|Applied Relaxation (AR)|Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
75420262|NCT01429649|Procedure|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
76044077|NCT05508425|Diagnostic Test|Oral glucose tolerance test using bubble water|The use of cold bubble water to solve the 75g glucose.
75565639|NCT00521612|Drug|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
75565640|NCT02937909|Other|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
75420263|NCT01429662|Behavioral|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
75420264|NCT01429662|Behavioral|Lifestyle Education (LE)|Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
75565641|NCT00521261|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
75565642|NCT02931591|Drug|Metformin|Metformin is administered as an oral solution
75565643|NCT02931591|Drug|Growth Hormone|Growth Hormone- no specific band
75565644|NCT02931591|Drug|Placebo|
75565645|NCT00521300|Drug|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
75565646|NCT00521300|Procedure|Direct surgery for acromegaly|Direct transsphenoidal surgery
75719363|NCT00995878|Procedure|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
75420265|NCT01429675|Drug|bonviva|150mg Ibandronate once a month
75420266|NCT01429688|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
75420267|NCT01429701|Drug|polymyxin B sulphate + prednisolone + benzocaine + clioquinol|applied 3 times / day at lesion
75420268|NCT01429701|Drug|betamethasone + gentamicin + tolnaftato + cleoquinol|applied 3 times / day at lesion
75565647|NCT02931435|Procedure|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
75565648|NCT02931435|Procedure|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
75565649|NCT02931825|Behavioral|Reminder letter|"The letter will consist in several parts:~Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~Request information if they've done their follow-up or if we have incorrect information~Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer"
75565650|NCT00523133|Drug|naltrexone|50 mg naltrexone daily for 3 months
75565651|NCT00523133|Drug|naltrexone|50 mg of naltrexone daily for 6 months
75565652|NCT00523133|Behavioral|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
75565653|NCT00523133|Behavioral|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
75565654|NCT02937792|Drug|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
75565655|NCT00521729|Procedure|Exposure to Cold Temperature|
75565656|NCT02931474|Drug|Tesamorelin|Growth Hormone-Releasing
75565657|NCT02931474|Other|Placebo|
75565658|NCT02931357|Device|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
75719364|NCT00995878|Procedure|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
75565659|NCT02931357|Drug|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
75565660|NCT00521768|Behavioral|Prolonged exposure|
75565661|NCT02937597|Behavioral|ePBP: eProficiency Based Progression|National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
75565662|NCT02937597|Behavioral|eS: eScenarios|National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
75565663|NCT02937597|Behavioral|HSE|National HSE e-learning programme only
75565664|NCT04694027|Drug|Omega 3 fatty acid|omega 3 1000 mg
75565665|NCT04694027|Drug|VitaE|vitamin e 400 mg
75719365|NCT00761579|Drug|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
75719366|NCT00994084|Behavioral|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
75420269|NCT01429714|Device|Individually tailored duration of elastic compression therapy|Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
75420270|NCT01429714|Device|Elastic compression therapy with a standard duration of 24 months|Elastic compression therapy with a standard duration of 24 months
75420271|NCT01429740|Drug|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
75420272|NCT01429740|Drug|Placebo|Placebo oral solution or capsules
75420273|NCT01429753|Other|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
75420274|NCT01429753|Device|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
75420275|NCT01429766|Other|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed~st visit Within one day of the date of simulation~nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
75420276|NCT01429779|Drug|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
75565666|NCT00521807|Procedure|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
75565667|NCT04577274|Dietary Supplement|smoothie with regular formulas (SM)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
75565668|NCT04577274|Dietary Supplement|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
75565669|NCT04577274|Dietary Supplement|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
75565670|NCT02937675|Drug|Tomivosertib (eFT-508)|eFT508
75565671|NCT00523172|Procedure|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
75565672|NCT00523172|Procedure|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
75565673|NCT00523172|Procedure|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
75565674|NCT02937519|Device|Chrono-chemotherapy pump:Melodie|
75565675|NCT02937519|Device|Routine intravenous drip|
75565676|NCT02937519|Drug|induction Chrono-chemotherapy|
75565677|NCT02937519|Drug|induction Routine-chemotherapy|
75565678|NCT02937519|Drug|cisplatin chrono-chemotherapy|
75420277|NCT01429805|Device|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
75420278|NCT01429818|Drug|Glimepiride/metformin|4/1000 mg tablets once a day foe eight weeks
75420279|NCT01429818|Drug|Metformin|1000 mg tablets once daily for eight weeks
75420280|NCT01429831|Drug|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
75420281|NCT01429844|Drug|Tacrolimus|Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
75420282|NCT01429844|Drug|Cyclosporine|Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
75420283|NCT01429870|Drug|Steroid active treatment|Triamcinolone in unguentum leniens 0.1%
76044078|NCT05508347|Drug|Nituzumab/placebo|"Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy"
76044079|NCT05499845|Diagnostic Test|butanol threshold test and smell identification tests|no additional intervention
76044080|NCT04476953|Drug|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient.
75565679|NCT02937519|Drug|cisplatin routine-chemotherapy|
75420284|NCT01429896|Other|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
75420285|NCT01429909|Device|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2*.
75420286|NCT01429935|Drug|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
75420287|NCT01429935|Drug|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
75420288|NCT01429935|Other|placebo|capsules contain starch
75420289|NCT01429961|Drug|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1~14
75420290|NCT01429974|Other|amniometer model po1|"The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.~The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform."
75420291|NCT01430000|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
75565680|NCT02937519|Radiation|intensity-modulated radiation therapy|
76044081|NCT04476953|Drug|Fisetin|~20 mg/kg/day oral, NG or D tube course for 2 consecutive days
75420292|NCT01430013|Drug|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
75420293|NCT01430039|Procedure|blood sample|Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
75420294|NCT01430039|Procedure|Blood sample - venous blood 10 ml.|venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
75420295|NCT01430052|Drug|Drug: gemcitabine, S-1|Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.
75420296|NCT01430052|Drug|gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
75565681|NCT03457974|Other|saliva|salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
75719367|NCT00994084|Behavioral|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
76044082|NCT05508113|Other|ozone autohemotherapy|After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
75719368|NCT04100525|Behavioral|Neuropsychological testing intervention plus follow up|Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
76044083|NCT05499533|Procedure|implant site preparation|a hole were created in the edentulous ridge area before implant placement
76044084|NCT05508035|Drug|Sacubitril / Valsartan|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
75719369|NCT01000168|Other|Treadmill therapy and conventional walking therapy.|"The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period."
76044085|NCT05508035|Drug|Ramipril|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
76044086|NCT04411355|Dietary Supplement|control by dietitian|
75420297|NCT01430065|Drug|ASP015K|oral
75420298|NCT01430065|Drug|Tacrolimus|oral
75420299|NCT01430078|Drug|ASP015K|oral tablet
75420300|NCT01430078|Drug|ASP015K|solution via oral capsule
75420301|NCT01430117|Biological|Four different concentrations of Poa pratensis allergen extract, positive control and negative control|Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
75420302|NCT01430143|Behavioral|Exercise|Daily exercise for 12 weeks.
75420303|NCT01430156|Drug|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
75420304|NCT01430156|Drug|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
75420305|NCT01430195|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
75420306|NCT01430195|Procedure|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
75420307|NCT01430208|Procedure|resectoscopy|hysteroscopy for myomas G0 and/or polyps
75420308|NCT01430221|Behavioral|Mindfulness-based Personalized Health Planning|
75420309|NCT01430221|Other|Structured & Guided Education|
75420310|NCT01430234|Drug|Panzytrat 25.000 FIP-E units of Lipase|patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
75420311|NCT01430247|Other|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
75565682|NCT00521963|Biological|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
75565683|NCT02937402|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
76044087|NCT04411355|Other|Exercise programs|In line with the address information of the intervention patients, purpose/content of the study was discussed with the gyms of municipalities and patients were made to benefit from these facilities for free. For the patients preferring private gyms, it was ensured that discounts were made for the patients.
75420312|NCT01430260|Drug|Ciclesonide|200 ㎍ once daily
75420313|NCT01430260|Drug|Levocetirizine|5mg once daily
75420314|NCT01430260|Drug|Ciclesonide & Levocetirizine|"Omnaris (ciclesonide) 200 ㎍ once daily~Levocetirizine 5mg once daily"
75565684|NCT02937402|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
75565685|NCT02937363|Dietary Supplement|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
75565686|NCT02937363|Other|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
75565687|NCT04693871|Device|Transesophageal ultrasound|Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
75565688|NCT02948348|Drug|Nivolumab|Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
75565689|NCT02948348|Drug|Ipilimumab|For only Cohort D,1 mg/kg at six-week intervals
75420315|NCT01430286|Behavioral|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
75565690|NCT02937480|Other|Task-specific training|The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
75565691|NCT02937480|Other|Global stretching, memory exercises, health care orientation|The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
75565692|NCT04693910|Other|Multimedia-Based Hormone Therapy Information Program|The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.
75719370|NCT01000246|Biological|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
76044088|NCT04411355|Behavioral|control by psychiatrist|The psychiatrist assessed the suitability of the patients to the study, assessed the patients having adaptation problems with respect to lifestyle changes in monthly controls and also played roles in teaching the coping methods to patients and applying and interpreting the hospital anxiety and depression scale.
76044089|NCT04390139|Drug|XCEL-UMC-BETA|Administration on top of the standard administered treatment
76044090|NCT04390139|Other|Placebo|Administration on top of the standard administered treatment
75420316|NCT01430286|Behavioral|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
75420317|NCT01430312|Drug|azelaic acid pre-foam formulation|
75420318|NCT01430312|Drug|Vehicle pre-foam formulation|
75420319|NCT01430312|Drug|Water|
75420320|NCT01430312|Drug|Sodium lauryl sulfate|
75420321|NCT01430364|Device|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
75420322|NCT01430364|Device|BIOSS Lim|
75420323|NCT01430364|Device|CarloS|
75420324|NCT01430377|Procedure|SB predilatation|Initial SB [predilatation.
75420325|NCT01430377|Procedure|No SB predilatation|Without SB predilatation
75420326|NCT01430416|Drug|AEB071|
75420327|NCT01430429|Drug|NI-0801|
75420328|NCT01430481|Dietary Supplement|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
75420329|NCT01428674|Other|Interpersonal Mindful Compassion with Touch|A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
75719371|NCT00627042|Biological|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
76044091|NCT04381637|Device|NIPE monitor|NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.
76044092|NCT04381637|Procedure|Tetanic stimulations|"Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3."
76044093|NCT02566889|Drug|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
76044094|NCT05564585|Other|Kinesio Taping|Kinesio tape was applied over the calf muscle of either leg.
76044095|NCT05564585|Other|Sham Taping|The sham tape was applied over the calf muscle of either leg.
76044096|NCT05564507|Diagnostic Test|TEE simulation-based training|"All participants of the TEE simulation-based training group received:~a traditional didactic training using e-learning with a national free-access online course;~two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator."
75420330|NCT01428674|Other|Reading while extending loving kindness|The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
75420331|NCT01430507|Drug|Revamilast|Tablet, Low dose, Once daily for 12 weeks
76044097|NCT03713255|Procedure|PVB group|Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
75565693|NCT02937441|Other|Ultrasonic Measurement|"How we measure;~First measurement shall be taken in 4 hours.~Second measurement shall be taken at 12 hours in mild and 12-18 hours measurement shall be taken for severe diabetic ketoacidosis,~Third measurement shall be taken after fluid treatment.~Fourth measurement shall be taken at patients polyclinic control."
75719372|NCT00319111|Drug|bosentan|"Oral bosentan~Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight < 40 kg)"
75719373|NCT00994396|Dietary Supplement|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
75420332|NCT01430507|Drug|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
75420333|NCT01430507|Drug|Revamilast|Tablet, High dose, Once daily for 12 weeks
75420334|NCT01430507|Drug|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
75420335|NCT01430520|Drug|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
75565694|NCT00523211|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
75565695|NCT00523211|Drug|Placebo|One tablet of placebo once daily.
75565696|NCT02931318|Behavioral|Nevsehir|The data of the study were collected with the questionnaire
75719374|NCT00994396|Dietary Supplement|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
75719375|NCT00818688|Procedure|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
75719376|NCT03978013|Other|Pomegranate juice|Pomegranate juice
75719377|NCT03978013|Other|Apple juice|Apple juice
75420336|NCT01430520|Drug|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
75420337|NCT01430533|Drug|azelaic acid pre foam formulation|
75420338|NCT01430533|Drug|Vehicle pre foam formulation|
75420339|NCT01430533|Drug|Water|
75420340|NCT01430598|Procedure|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
75420341|NCT01430598|Other|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
75420342|NCT01430637|Genetic|DNA analysis|
75420343|NCT01430637|Genetic|RNA analysis|
75420344|NCT01430637|Genetic|gene expression analysis|
75420345|NCT01430637|Genetic|mutation analysis|
75420346|NCT01430637|Genetic|nucleic acid sequencing|
75565697|NCT03458897|Diagnostic Test|serial functional magnetic resonance imaging (MRI)|All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
75565698|NCT02937246|Device|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
75719378|NCT00821808|Device|Compression Device|"The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~Immediately following device application~1 hour~4 hours~8 hours"
75719379|NCT00821808|Device|Profore®|"Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~Immediately following device application~1 hour~4 hours~8 hours"
75420347|NCT01430637|Genetic|polymerase chain reaction|
75420348|NCT01430637|Other|laboratory biomarker analysis|
75420349|NCT01430637|Other|pharmacogenomic studies|
75420350|NCT01430650|Drug|Oral strogen|2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
75420351|NCT01430650|Drug|Transdermal strogen|One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
75420352|NCT01430676|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
75420353|NCT01430689|Biological|Inactivated Influenza Vaccine Trivalent Types A and B|"Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~Home visits weekly until the infant is born and reaches 6 months of age~If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
75420354|NCT01430689|Biological|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|"Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~Home visits weekly until the infant is born and reaches 6 months of age~If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
75420355|NCT01430702|Device|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
75420356|NCT01430715|Other|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, > 5th % to < 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
75420357|NCT01430780|Drug|nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
75420358|NCT01430780|Drug|control group|placebo
75565699|NCT02937246|Device|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
75565700|NCT00522158|Drug|simvastatin|
75565701|NCT00522158|Drug|atorvastatin|
75565702|NCT02937324|Device|CloudUPDRS smartphone software assessment|Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
75565703|NCT02937324|Other|Clinical assessment|A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
75565704|NCT00522197|Dietary Supplement|multi-herbal agent ACAPHA|
75719380|NCT04000984|Behavioral|Mindfulness Based Training (MBT) Program|Participants in the MBT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. Mindfulness, defined as caring moment-to-moment awareness, will be cultivated through the teaching and formal practice of sitting and walking meditation, body scan, and mindful movement (e.g. yoga). Participants will also be taught how to practice mindfulness informally when eating, engaging in pleasurable activities and through interactions with others. Participants will be encouraged to practice approximately 30 minutes a day, and will be provided handouts as well as guided audio recordings of formal practices taught in session to aid their practice at home.
75719381|NCT04000984|Behavioral|Cognitive Rehabilitation Training|Participants in the CRT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. The 8 week-program will consist of the following components: (i) identifying and working on at least one personal rehabilitation goal related to everyday life that is associated with cognitive difficulties; (ii) reviewing and building on the use of practical memory strategies, and or introducing and teaching the use of a new strategy or memory aid; (iii) introducing techniques for learning new information and associations, identifying the preferred strategy, and encouraging the application of this strategy in daily life; (iv) providing practice in maintaining attention and concentration; and (v) exploring current ways of coping with stress and anxiety as well as providing relaxation techniques to help aid with coping (Clare, 2007). Participants will be provided with instructional hand-outs as well as logs to record, monitor and evaluate their progress.
76044098|NCT03713255|Procedure|MTP block group|Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
76044099|NCT03713255|Procedure|Control Group|Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
75420359|NCT01430793|Drug|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
75420360|NCT01430793|Drug|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
75420361|NCT01430793|Drug|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
75420362|NCT01430793|Drug|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
75565705|NCT00522197|Dietary Supplement|Sugar Pill|
75565706|NCT00522236|Biological|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."
75565707|NCT02931123|Drug|lattulose and rifaximine|
76044100|NCT05564351|Other|eye mask and ear plug|black eye mask and silicon ear plug
76044101|NCT04283201|Other|Physical activity|Moderate activity 150 min per week
76044102|NCT04283201|Other|Macronutrient modification|Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
75420363|NCT01430806|Drug|Dronedarone arm|PO Dronedarone 400 mg BID
75420364|NCT01430806|Drug|Dronedarone|Dronedarone PO 400 MG BID
76044103|NCT03673553|Other|Multimodal treatment of patients with FM|The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.
75874313|NCT03708107|Device|MEP|MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
75420365|NCT01430858|Device|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
75420366|NCT01430858|Other|Vibration therapy|"Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion & strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion & strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low & high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion & strain gauge readings will be captured."
75420367|NCT01430884|Other|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
75420368|NCT01430910|Drug|CAZ104|IV infusion
75420369|NCT01430910|Drug|Avibactam|IV infusion
75565708|NCT02948114|Other|Control: Cow milk-based infant formula|
75565709|NCT02948114|Other|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
75565710|NCT02948114|Other|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
75565711|NCT02948114|Other|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
75719382|NCT00816426|Drug|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
75874314|NCT03708107|Other|Ischemic compression|Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
75874315|NCT04110457|Procedure|spinal decompression|spinal surgery by decompression or fixation
75565712|NCT02937207|Drug|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
76044104|NCT03673553|Other|Association of people with fibromyalgia|The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
76044105|NCT05507957|Diagnostic Test|direct reporting of time to positivity of blood culture to ICU to know its effect to patients managment|-Disinfection using povidone-iodine, alcohol preparation or chlorhexidine gluconate ethanol (CHG-ALC ), so that each type was used on 40 patients
76044106|NCT02566577|Biological|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
76044107|NCT02566577|Biological|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
76044108|NCT02566577|Device|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
75420370|NCT01430910|Drug|Ceftazidime|IV infusion
75420371|NCT01430923|Drug|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
75420372|NCT01430923|Drug|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
75420373|NCT01430949|Procedure|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
75420374|NCT01430975|Drug|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
75420375|NCT01430975|Drug|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
76044109|NCT05481229|Other|nutritional interventions|Nutritional intervention will be initiated in patients at risk of overweight and obesity. A targeted nutritional intervention will be carried out, which will include consultation on dietary habits and physical activity as determined by diet and physical activity records. Consultations will be aimed at improving lifestyle and maintaining an adequate body weight.
76044110|NCT05507801|Other|High Protein Milkshake|A milkshake with high protein level; including whey protein, fat free strawberry yogurt and whole milk - 337 kcal, 27 g carbohydrate, 57 g protein, 16 g fat.
76044111|NCT05507801|Other|Normal Milkshake|A milkshake with normal protein level; including nesquik (strawberry), fat free strawberry yogurt, whole milk, double cream, whey protein and sweetener - 331 kcal, 64 g carbohydrate, 17 g protein, 19 g fat.
75420376|NCT01431001|Device|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)|The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
75420377|NCT01431040|Other|No bowel prep|Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
75420378|NCT01431040|Other|Clear liquid diet and 2 Fleet's enemas|Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
75420379|NCT01431053|Drug|aspirin|Aspirin 50mg po daily
75420380|NCT01431053|Drug|Exemestane|Exemestane 25mg po daily
75420381|NCT01431066|Device|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
75420382|NCT01431066|Device|ActiPatch PRFE Device|Actipatch PRFE device
75420383|NCT01431092|Drug|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
75420384|NCT01431092|Drug|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
75420385|NCT01431118|Other|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
75420386|NCT01431118|Other|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
75420387|NCT01431183|Behavioral|Mailed influenza vaccination reminder notice|Influenza vaccination reminder sent by postal mail
75420388|NCT01431196|Biological|Autologous dendritic cell vaccination|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
75420389|NCT01431222|Device|percutaneous treatment by implanting a Mitra Clip device|With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
75565713|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
75565714|NCT02937207|Drug|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
75565715|NCT02937207|Drug|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
75565716|NCT02937207|Drug|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
75565717|NCT02937207|Drug|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
75565718|NCT02937207|Drug|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
75565719|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
75565720|NCT02937207|Drug|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
75565721|NCT02937207|Drug|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
75565722|NCT02937207|Drug|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
75565723|NCT02937207|Drug|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
75565724|NCT00522314|Device|NIV and ACBT|
75565725|NCT00522314|Other|Active Cycle of Breathing Techniques|
75565726|NCT04690062|Drug|Brolucizumab-Dbll|intravitreal injection of Brolucizumab (BEOVU)
76044112|NCT03300713|Other|MOCITRAINING program|The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.
76044113|NCT03300713|Other|usual follow-up|usual follow-up
75420390|NCT01431235|Behavioral|cognitive behavioral therapy for treating ADHD symptoms|5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
75420391|NCT01431261|Other|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
75420392|NCT01431261|Behavioral|Pain management|Educational sessions in pain management 4 times
75420393|NCT01431352|Drug|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
75420394|NCT01431352|Drug|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
75420395|NCT01431365|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
75420396|NCT01431365|Behavioral|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
75420397|NCT01431404|Biological|Etanercept (Enbrel)|prefilled syringe, SC
75420398|NCT01431404|Biological|HD203|HD203, prefilled syringe, SC injection
75565727|NCT04694495|Diagnostic Test|16S rRNA gene sequencing of cervical secretions|"16S rRNA gene sequencing of vaginal secretions: using NGS technology to assess the microbiota of the vaginal secretions~Microecology assessment of vaginal secretions: morphology test, functional assessment and Nugent score assessment of the vaginal secretions are included.~Genotyping of HPV and detection of sexually transmitted diseases pathogens based on the cervical exfoliated cells~Thinprep cytologic test of cervical exfoliated cells: to evaluate the grade of cervical intraepithelial neoplasia"
76044114|NCT05563883|Other|event occurence|occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...
75420399|NCT01431430|Drug|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
75565728|NCT02936934|Drug|Morphine|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours"
76044115|NCT04424693|Drug|Tdap Vaccine Administration|Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
75420400|NCT01431430|Drug|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
75420401|NCT01431443|Other|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
75420402|NCT01431443|Other|Placebo Chocolate|Placebo intervention
75420403|NCT01431456|Drug|Dabigatran|Dabigatran
75420404|NCT01431456|Drug|Rivaroxaban|Rivaroxaban
75420405|NCT01431456|Drug|Nadroparin|Nadroparin
75420406|NCT01431469|Dietary Supplement|Cow's milk|Powdered Whole Cow's Milk
75420407|NCT01431469|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
75719383|NCT00816426|Drug|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
76044116|NCT05563571|Drug|Methylprednisolon, Lidocaine|Intra-articular cortisone injection
75420408|NCT01431495|Drug|Pidogrel|Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
75420409|NCT01431495|Drug|Plavix|Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
76044117|NCT05563571|Other|Pulsed radiofrequency, Lidocaine|pulsed radiofrequency of shoulder joint and suprascapular nerve
76044118|NCT02489903|Drug|RRx-001|
76044119|NCT02489903|Drug|Cisplatin|
76044120|NCT02489903|Drug|Etoposide|
76044121|NCT02489903|Drug|Carboplatin|
75420410|NCT01431547|Drug|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m^2, and escalated for successive cohorts of participants until MTD is found
75420411|NCT01431547|Drug|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
75565729|NCT02936934|Drug|Oxycodone|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours."
75565730|NCT02936973|Device|Real catgut implantation at acupoints|"Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week ."
76044122|NCT02489903|Drug|Irinotecan|
76044123|NCT02489903|Drug|Vinorelbine|
76044124|NCT02489903|Drug|Doxil|
76044125|NCT02489903|Drug|Gemcitabine|
76044126|NCT02489903|Drug|Taxane|
76044127|NCT02489903|Drug|Paclitaxel|
76044128|NCT02489903|Drug|Nab-Paclitaxel|
76044129|NCT02489903|Drug|Pemetrexed|
76044130|NCT05563493|Other|Treatment group, Chair-Based Exercise Training|"The weights of the elastic bands to be used in the exercises will be determined by the physiotherapist according to the abilities and development of the participants.~The intensity of the exercise will be adjusted according to the dyspnea or fatigue patients feel according to the Modified Borg Scale.~During the exercises, heart rate and oxygen saturation will be measured with a pulse oximeter, and blood pressure will be measured with a sphygmomanometer.~Chair-based exercise training will be applied to the patients every day they are hospitalized."
76044131|NCT05563493|Other|Control group, Breathing exercise|Breathing exercise will be applied to the patients every day they are hospitalized.
76044132|NCT01815281|Device|Foot Mechanical Stimulation (GONDOLA)|
75565731|NCT02936973|Device|sham catgut implantation at acupoints|"Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group."
75565732|NCT00522353|Dietary Supplement|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
75565733|NCT00522353|Dietary Supplement|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
75565734|NCT04690296|Device|cathetherization approach|real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization
75565735|NCT00522470|Drug|rosiglitazone|
75565736|NCT04689789|Diagnostic Test|optical coherence tomography angiography|optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
75874316|NCT05691582|Device|GRAIL|"The subjects experiment GRAIL virtual reality for three days, during which they deal with 4 different activities.~In the first activity subjects are required to ask over the treadmill in a snow environment.~in the second they are required to stand over the moving platform in a simulation of a boat pitch.~in the third they have to walk over a bridge with a slope. in the fourth the subjects are required to try so interact with virtual reality and to ski between snowman.~if it is possible, on the last day a gait analysis is executed"
76044133|NCT01658111|Device|Robot Group|"The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).~The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well."
75420412|NCT01431547|Drug|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
75420413|NCT01431560|Device|fixation of the ankle fracture (Solco )|fixation with metallic implant
75565737|NCT00522509|Drug|Floxuridine FUDR|
75565738|NCT02937090|Other|Blood Draw|Blood sample will be drawn from participants at study entry.
75565739|NCT02937090|Other|Stool collection|Stool will be collected from participants at study entry.
75565740|NCT00522587|Drug|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
75565741|NCT00522587|Drug|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
75874317|NCT03532555|Dietary Supplement|Zinc Acetate|Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
75874318|NCT03532555|Other|No supplemental zinc|Infants will receive standard of care, which is currently no supplemental zinc
76044134|NCT01658111|Procedure|Traditional physiotherapy|Active or passive exercises.
76044135|NCT01174199|Drug|vorinostat|Given orally
75565742|NCT00522587|Drug|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
75565743|NCT00522587|Drug|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
75565744|NCT00522587|Drug|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
76044136|NCT01174199|Drug|temsirolimus|Given IV
76044137|NCT01174199|Other|laboratory biomarker analysis|Correlative study
76044138|NCT01174199|Procedure|positron emission tomography/computed tomography|PET scan
76044139|NCT04475549|Drug|IW-6463 Tablets|IW-6463 tablets administered orally (daily)
75420414|NCT01431560|Device|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
75420415|NCT01431586|Drug|JDtic|"The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug."
75565745|NCT00522587|Drug|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
75565746|NCT00522587|Drug|Fixed remifentanil dose 1|Dose 1 of remifentanil
75565747|NCT00522587|Drug|Fixed remifentanil dose 2|Dose 2 of remifentanil
75565748|NCT00522587|Drug|Fixed remifentanil dose 3|Dose 3 of remifentanil
75565749|NCT00522587|Drug|Fixed remifentanil dose 4|Dose 4 of remifentanil
75565750|NCT00522587|Drug|Fixed remifentanil dose 5|Dose 5 of remifentanil
75565751|NCT00522587|Drug|Fixed remifentanil dose 6|Dose 6 of remifentanil
75565752|NCT04689633|Procedure|nerve block|bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
75874319|NCT01347307|Radiation|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
75565753|NCT00522665|Drug|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
75565754|NCT00522665|Biological|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
75565755|NCT00522665|Biological|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
75565756|NCT00522704|Other|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
75565757|NCT00522743|Drug|growth hormone and gonadotropin-releasing hormone agonist|GH & GNRHa treatment
75719384|NCT00816426|Drug|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
75719385|NCT00816426|Drug|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
75719386|NCT00816426|Drug|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
75719387|NCT00996190|Drug|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
75719388|NCT03860064|Other|Non intervention|Non
75719389|NCT00996268|Drug|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
75874320|NCT01347307|Radiation|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
75874321|NCT03373110|Behavioral|Online Mindfulness Based Cognitive Therapy|see arm description
75874322|NCT03373110|Behavioral|Online Cognitive Behavioral Therapy|see arm description
75874323|NCT03373110|Behavioral|Fitbit Alone|see arm description
75420416|NCT01431599|Radiation|short-course radiation|33Gy/10 fractions
75420417|NCT01431612|Drug|Esmolol administration|50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
75420418|NCT01431612|Drug|Phenylephrine infusion|0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
75565758|NCT00522743|Drug|growth hormone|GH treatment
75565759|NCT02937012|Drug|Bezafibrate|Bezafibrate 200 mg manufactured in a pill/capsule presentation
75420419|NCT01431612|Drug|Lactated Ringer´s solution|Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
75565760|NCT02937012|Drug|Ursodeoxycholic Acid|The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study
75874324|NCT03993457|Drug|Escitalopram|Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
75874325|NCT03993457|Drug|Bupropion|Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
75420420|NCT01431625|Other|Combined Training (endurance and strength exercises)|"All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:~.- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.~- Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient."
75420421|NCT01431651|Dietary Supplement|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
75420422|NCT01431664|Drug|multikinase inhibitor AT9283|
75420423|NCT01431664|Other|laboratory biomarker analysis|
75565761|NCT02937012|Drug|Placebo (for Bezafibrate)|Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
75420424|NCT01431664|Other|pharmacological study|
75565762|NCT00522782|Drug|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
75565763|NCT00522782|Device|Nitric Oxide Analyzer|Niox NO analyzer
75565764|NCT00522821|Drug|intravenous immunoglobulins|"Adults: 600 mg/kg bodyweight every 3 weeks~Children: 800 mg/kg bodyweight every 3 week"
75565765|NCT00522821|Drug|antibiotics|"Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid."
75565766|NCT02937051|Other|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
75565767|NCT02930928|Other|Accuracy of weight estimation|Computer based comparison
75565768|NCT00522860|Procedure|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
75420425|NCT01431677|Procedure|Muscle Biopsy|
75420426|NCT01431690|Drug|warfarin|A single 25 mg dose of warfarin
75420427|NCT01431690|Drug|omefas|4 x 1 g capsule dose of Epanova®
75420428|NCT01431690|Drug|omega-3-acid ethyl esters|4 x 1 g capsule dose of Lovaza®
75420429|NCT01431729|Other|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
75420430|NCT01431742|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
75565769|NCT00522860|Procedure|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
75565770|NCT02936895|Drug|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
75565771|NCT02936895|Drug|Placebo|Placebo for 2 days
75565772|NCT00522899|Behavioral|Group 1|Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
75565773|NCT00522899|Behavioral|Group 2|Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
75565774|NCT00522899|Behavioral|Group 3|Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
75565775|NCT00522899|Behavioral|Group 4|Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
75565776|NCT02931006|Other|water|
75565777|NCT02931006|Other|bovine milk|
75565778|NCT00522938|Drug|CHR-2797 (tosedostat)|Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
76044140|NCT05497895|Biological|5% thymoquinone (TQ) gel|Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.
75420431|NCT01431768|Device|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
75420432|NCT01431781|Drug|Stilamin+common daily treatment|"dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.~Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory."
75420433|NCT01431781|Other|Common daily practice|Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
75420434|NCT01431833|Drug|TR-701 FA|Oral single dose 200 mg
75420435|NCT01431859|Biological|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
76044141|NCT05497895|Biological|SRP and placebo|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
75420436|NCT01431859|Other|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
75420437|NCT01431885|Procedure|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
75420438|NCT01431885|Procedure|Cervical change|Diagnosis will be made by digital examination of cervical change
75420439|NCT01431898|Drug|GS-9669 tablets|
75420440|NCT01431898|Drug|Placebo to Match GS-9669 tablet|
75420441|NCT01431911|Drug|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
75420442|NCT01431911|Drug|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
75420443|NCT01431924|Drug|Higher-dose inhaled corticosteroids|fluticasone propionate 110 or 220 mcg
75420444|NCT01431924|Drug|Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination|Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
75565779|NCT00522938|Drug|erlotinib|Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
75565780|NCT02936856|Device|Hepatic Arteriography|
75565781|NCT04694105|Drug|Dexmedetomidine injection|perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
75565782|NCT04694105|Drug|Dexamethasone|perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)
75874326|NCT05571085|Other|Core Stability Exercises|Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.
75565783|NCT04694105|Drug|saline|perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline
75565784|NCT02930694|Drug|JNJ-54175446 (capsule)|Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
75565785|NCT02930694|Drug|JNJ-54175446 (suspension)|Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
75719390|NCT00996268|Drug|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
75719391|NCT00816504|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
76044142|NCT05497895|Procedure|Only SRP-one stage prophylaxis|The Group III patients will be subjected to one-stage oral prophylaxis.
76044143|NCT04471337|Drug|BAY1817080|BAY1817080 will be administered orally as tablet.
75420445|NCT01431937|Drug|GSK2018682|Active Drug
75420446|NCT01431937|Drug|Placebo|Placebo
75420447|NCT01432028|Drug|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
75420448|NCT01432028|Drug|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
75420449|NCT01432067|Other|Adapted physical activity|Physical activity advices according to a program adapted to physical status of the patient.
75420450|NCT01432067|Other|Classic physical activities|Daily physical activities based on a standard guide
75420451|NCT01432080|Drug|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
75420452|NCT01432080|Drug|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
75420453|NCT01432080|Drug|Montelukast|Montelukast 10 mg PO qhs for 3 months
75420454|NCT01432080|Drug|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
75420455|NCT01432093|Other|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
75719392|NCT01000402|Drug|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
75719393|NCT00640224|Drug|rosiglitazone|4 mg daily for 6 months
75565786|NCT00523016|Procedure|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
75719394|NCT00640224|Drug|drospirenone/ethinyl estradiol|1 tab (3mg/30mcg) daily for 6 months
75565787|NCT00523016|Procedure|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
75420456|NCT01432093|Other|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
75420457|NCT01432106|Drug|Aliskerin/Valsartan and Rampiril|"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of < 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)"
75420458|NCT01432119|Device|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
75719395|NCT01000558|Other|biologic sample preservation procedure|
75719396|NCT02550990|Behavioral|Cognitive training|
75719397|NCT02550990|Behavioral|Aerobic exercise training|
75719398|NCT02550990|Behavioral|Sequential combination of aerobic exercise and cognitive training|
75874327|NCT05571085|Other|PNF Exercise Program|PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.
75874328|NCT05571007|Other|True acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
75874329|NCT05571007|Other|Sham acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
75874330|NCT03348306|Device|MRI|Brain and cardiac MRI in one time with gadolinium injection.
75874331|NCT03348306|Biological|Blood sample collection|A blood sampling is also collected for hematocrit measure.
75420459|NCT01432119|Drug|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
75420460|NCT01432119|Drug|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
75420461|NCT01432119|Procedure|Break-Through Scan|"Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
75420462|NCT01432132|Behavioral|Interview|Face-to-face audio recorded interview. It should take about 1 hour to complete.
75420463|NCT01432132|Behavioral|Questionnaire|Questionnaire about demographic information such as age and ethnicity.
75420464|NCT01432158|Biological|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
75719399|NCT03742804|Biological|Intratumoral G100|G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
75420465|NCT01432158|Biological|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
75420466|NCT01432184|Procedure|strategies to reverse decrease in rSO2|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
75420467|NCT01432197|Other|ADL intervention|1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
75420468|NCT01432210|Other|Post-prandial Feeding Study|
75420469|NCT01432223|Drug|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
75874332|NCT05570773|Other|peer support program|Peer support: It has been suggested that peer support provides an alternative way for students to learn and makes a positive contribution to both academic and psychosocial aspects of higher education (Hogan, Fox, Barratt-See 2017). Peer academic support involves academic encouragement (support for lowering exam-related stress and motivation for lessons) and solving students' academic problems (answering questions about lessons, sharing study habits, studying together, answering questions about assignments)
75874333|NCT04677439|Drug|Flumatinib|600 mg of Flumatinib orally daily for 24 months
75874334|NCT03309072|Device|tDCS|active tDCS
75874335|NCT03309072|Device|sham tDCS|sham tDCS
75420470|NCT01432249|Drug|Enbrel group|will be decided by treating physicians
75420471|NCT01432301|Drug|uridine triacetate|uridine triacetate granules, 10gms, q6H x 20 doses
75420472|NCT01432314|Other|Radiation therapy|"A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT."
75420473|NCT01432314|Other|Transarterial chemoembolization|"A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop."
75420474|NCT01432340|Biological|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
75420475|NCT01432353|Drug|DFRF4539A|multiple ascending doses
75420476|NCT01432418|Other|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
75420477|NCT01432431|Procedure|spiritual therapy|Undergo palliative spiritual care
75420478|NCT01432431|Other|questionnaire administration|Ancillary studies
75420479|NCT01432431|Other|survey administration|Ancillary studies
75420480|NCT01432431|Other|counseling intervention|Undergo palliative spiritual care
75420481|NCT01432431|Other|psychosocial support for caregiver|Undergo palliative spiritual care
75420482|NCT01432431|Procedure|psychosocial assessment and care|Undergo palliative spiritual care
75420483|NCT01432470|Drug|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
75420484|NCT01432470|Drug|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
75420485|NCT01432483|Drug|Denileukin diftitox (ONTAK)|Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
75420486|NCT01432496|Drug|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity
75420487|NCT01432496|Drug|saline 15 ml|Nebulization of saline 15 ml in the peritoneal cavity
75719400|NCT00822042|Other|Samples and procedures|"Scanner, histomorphometry : at the inclusion and M3 visits~whole blood samples, cytoponction : at the inclusion and M3 visits"
75719401|NCT01000714|Drug|Psirelax|
75565788|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
75420488|NCT01432509|Other|Prediabetes screening and prospective follow-up over 5 years|"The study period per patient is 5 years. The planned schedule of the study is as follows :~Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and < 1,26 g/l) or fasting blood glucose ≥ 1 g/l and < 1,10 g/l with HbA1c ≥ 6,5%.~First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).~Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.~End of study phone call"
75719402|NCT00822198|Device|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
75719403|NCT01000792|Drug|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
75420489|NCT01432522|Drug|Epinephrine|"Intranasal epinephrine 5 mg /spray~Intramuscular epinephrine 0.3 mg~Intranasal saline spray"
75719404|NCT01000792|Drug|Levocetirizine|Levocetirizine
75719405|NCT02550756|Drug|CTNX-4975|
75719406|NCT01000870|Drug|MNI-513-01|Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
75719407|NCT01000948|Drug|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
75719408|NCT01001026|Biological|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
76044144|NCT04356599|Other|Early dynamic 18F-FDG PET/CT assessment of cerebral glucose uptake|The intervention will consist in a dynamic cerebral 18F-FDG PET study performed at D2+/-1. Kinetic modeling will be performed using in-house software at the global, regional, and voxel level. In addition, cerebral perfusion and blood-brain-barrier permeability will be assessed at D4+/- 1 using perfusion MRI and permeability MRI.
76044145|NCT05562869|Drug|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
76044146|NCT04085237|Drug|Ropivacaine injection|30ml of 0.375% ropivacaine with 5mcg/ml of epinephrine will be injected into the fascial plane on the anterior spinae muscle.
75420490|NCT01432548|Procedure|ischemic preconditioning|Surgery with ischemic preconditioning in liver resection
75420491|NCT01432587|Drug|Diflunisal|Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
75565789|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
75719409|NCT01001026|Biological|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
75719410|NCT01001182|Other|non interventional|non interventional
75719411|NCT01001260|Drug|No ASA|Alternative antiplatelet therapy instead of aspirin
75565790|NCT02948153|Other|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
75719412|NCT01001260|Drug|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
75719413|NCT01001260|Drug|325 mg ASA|high dose of aspirin prior to PTCA
75874336|NCT03625908|Device|OCT-guided PCI|Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
75874337|NCT03625908|Device|Angiography-guided PCI|Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
75420492|NCT01432613|Procedure|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
75565791|NCT02930733|Drug|Bupivacaine|30 ml %0,25 bupivacaine bilaterally
75719414|NCT00996424|Drug|Acetylcysteine|Inhalation with N-Acetylcysteine
75719415|NCT00996424|Drug|normal saline|Inhalation with normal saline solution
75719416|NCT00994474|Procedure|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
75719417|NCT00994474|Procedure|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
75719418|NCT05220280|Drug|Imatinib|Oral imatinib 400 mg tablet once a day for 14 days.
75719419|NCT05220280|Drug|Infliximab|Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
75719420|NCT00318643|Drug|Mitomycin C|intravesical administration
75719421|NCT00318643|Drug|Chemophase|intravesical administration
76044147|NCT04085237|Other|Sham|Saline will be used at the same amounts as the ropivacaine arm.
76044148|NCT05497661|Other|448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.|448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.
75420493|NCT01432639|Other|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
75420494|NCT01432665|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
75420495|NCT01432665|Drug|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
75420496|NCT01432665|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
75420497|NCT01432691|Procedure|Hemi (hemialloplastik)|THA vs hemi
75420498|NCT01432704|Drug|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
75420499|NCT01432717|Biological|ACE-536|Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
75420500|NCT01432717|Other|Placebo|Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
75420501|NCT01432743|Procedure|NavX Fusion|Using NavX Fusion to guide catheter ablation
75420502|NCT01432743|Procedure|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
75420503|NCT01432769|Dietary Supplement|dietary supplement high in energy and protein|"patients in the standardized diet will receive extra 500 kcal from the dietary supplement"
75420504|NCT01432782|Drug|Placebo|Saline 4 ml
75420505|NCT01432782|Drug|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
75420506|NCT01432795|Device|Gliding aids for medical compression stockings|"Each subject tests devices:~3 gliding aids for stockings with closed tips~3 gliding aids for stockings with open tips~2 stocking butlers using~3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~2 superimposed compression stockings class 1 (18 - 21 mmHg)"
75565792|NCT02930733|Drug|Saline|2 ml saline subcutaneously bilaterally
75565793|NCT02931162|Other|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
75874338|NCT05570695|Behavioral|attention right training, ARTNF|In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.
75874339|NCT05570695|Behavioral|attention left training, ALTNF|In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.
75565794|NCT02931162|Other|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
75565795|NCT00523055|Drug|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
75420507|NCT01432821|Other|Apomorphine (Experimental product)|"Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~Sequence A during visit 2 followed by sequence B during visit 3~or sequence B during visit 2"
76044149|NCT05497661|Other|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
75565796|NCT02930967|Biological|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
76044150|NCT04080869|Drug|retinyl palmitate|topical retinyl palmitate loaded ethosomes
75420508|NCT01432834|Other|Laser in situ keratomileusis (LASIK)|"During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH & Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol."
75420509|NCT01432834|Other|Photorefractive keratectomy (PRK)|"The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected."
75420510|NCT01432860|Behavioral|In-person counseling|The design is a 3 [in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care] X 7 [baseline, 4, 8, 12, 16, 20, and 24 month follow-up] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
75420511|NCT01432860|Behavioral|Workbook|Participants will read a workbook and perform skills training exercises.
75565797|NCT02947958|Other|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
75420512|NCT01432860|Behavioral|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
75565798|NCT02947958|Other|Hospital (control)|The patient will keep his usual care at the tertiary care.
75565799|NCT04761081|Behavioral|Habitual physical activity assessment|7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
75565800|NCT00523289|Drug|Bupivacaine|Dosage: 150mg at once for anesthesia induction
75719422|NCT00996814|Behavioral|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
75874340|NCT05570695|Behavioral|sham attention right training, ARTsham|During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).
75565801|NCT00523289|Drug|Ropivacaine|Single dose of ropivacaine, 150mg
76044151|NCT04080869|Drug|Tretinoin|topical tretinoin
76044152|NCT05562791|Drug|[68Ga]PSMA|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
75565802|NCT03457857|Other|Cleanser|Cosmetic Baby Cleanser/Shampoo
75565803|NCT03457857|Other|Cleanser and Lotion|Cosmetic Baby Cleanser/Shampoo and Baby Lotion
76044153|NCT05562791|Diagnostic Test|PET/CT imaging|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
76044154|NCT00560495|Drug|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
76044155|NCT00560495|Other|immunoenzyme technique|
75420513|NCT01432873|Drug|Oral selenium|Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
75420514|NCT01432873|Drug|Oral placebo|Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
76044156|NCT00560495|Other|laboratory biomarker analysis|
76044157|NCT00560495|Radiation|Tc 99m sestamibi|
76044158|NCT00560495|Radiation|radiation therapy|once daily, 5 days a week, for 6-7 weeks
75719423|NCT01001650|Biological|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|"Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If > 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose."
76044159|NCT05497505|Device|Pacmed Critical|For patients in the On-period, Pacmed Critical will be available as decision support after initial eligibility screening for ICU discharge by treatment team
76044160|NCT05499299|Behavioral|Google ads|Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
76044161|NCT05499221|Device|Carriere motion appliance|The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.
75420515|NCT01432912|Behavioral|Physician Educational Seminar|Participating Physicians will attend an hour long seminar on smoking cessation counselling.
75420516|NCT01432925|Procedure|surgical intervention on Buruli ulcer|Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
75420517|NCT01432964|Procedure|Orbital revision surgery|Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
75420518|NCT01432977|Drug|paracetamol /droperidol|
75565804|NCT04506216|Other|cohort|"During a regular follow-up visit, the following data will be collected:~questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~bio-electric impedance analysis~insulin pump and sensor data collection"
75565805|NCT00524381|Drug|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
75565806|NCT00524381|Drug|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
75719424|NCT01001728|Radiation|Imaging investigations (with radiation)|
75719425|NCT00318565|Device|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
75719426|NCT00994552|Other|Pressure support ventilation|Pressure support ventilation
75719427|NCT00994552|Other|Pressure control ventilation|Pressure control ventilation
76044162|NCT02559713|Drug|Vedolizumab|Vedolizumab IV infusion
76044163|NCT01358981|Drug|LY2881835|Administered orally
76044164|NCT01358981|Drug|Placebo|Administered orally
76044165|NCT05499065|Procedure|Fluorescence guided detection of tumor positive margins|To test if the fluorescence can guide the location for fresh frozen section sampling intra-operatively
76044166|NCT05499065|Drug|Cetuximab-IRDye800|Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization
76044167|NCT04317599|Other|Non Interventional study|Non Interventional study
76044168|NCT04230161|Other|Standard long-lasting insecticidal net|Yahe LN (Yamei Industry) contains a pyrethroid insecticide.
76044169|NCT04230161|Other|Chlorfenapyr insecticide treated net|Interceptor G2® (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
75565807|NCT03457779|Dietary Supplement|Glucose|"The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of [1,2-13C] glucose as an IV"
75565808|NCT03458858|Other|Mixed Berry Diet|Mixed Berry Treatment
75420519|NCT01432977|Drug|paracetamol / ondansetron|
75420520|NCT01432990|Device|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
75420521|NCT01432990|Other|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
75420522|NCT01433003|Procedure|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
75420523|NCT01433029|Other|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
75420524|NCT01433029|Other|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
75420525|NCT01433068|Device|NBTXR3|One intratumor implantation by injection
75420526|NCT01433094|Behavioral|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
75420527|NCT01433094|Behavioral|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
75565809|NCT03458858|Other|Carbohydrate Control Jello|Carbohydrate Control
76044170|NCT04230161|Other|Indoor residual spraying|Fludora Fusion (Bayer Vector Control) is a spray containing two active ingredients: clothianidin, a neonicotinoid insecticide, and deltamethrin, a pyrethroid insecticide.
76044171|NCT05498909|Other|Multidisciplinary joint diagnosis and treatment mode|Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
76044172|NCT04038437|Drug|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
75420528|NCT01433120|Dietary Supplement|Lactobacillus paracasei ssp paracasei F19|10^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
75420529|NCT01433120|Dietary Supplement|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
75565810|NCT03458858|Other|Fiber Enriched Jello|Fiber Control
75565811|NCT03458858|Other|Low Fiber Mixed Berry Juice|Anthocyanin Control
75565812|NCT03457740|Dietary Supplement|Formula 1|Dietary supplement for strength, testosterone, sexual function, quality of life
75565813|NCT03457740|Dietary Supplement|Formula 2|Dietary supplement for strength, testosterone, sexual function, quality of life
75565814|NCT03457740|Dietary Supplement|Placebo|Placebo comparison
75565815|NCT04502667|Drug|Cholecalciferol|1000U or 2000U every 24 hours orally
75565816|NCT00524498|Drug|OPC-18|OPC-18: 500IU * 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
75565817|NCT00524498|Drug|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
75719428|NCT01001884|Other|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
75719429|NCT03983083|Behavioral|Physical activity|Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
75719430|NCT01325389|Dietary Supplement|Myo-Mel|
75719431|NCT01325389|Dietary Supplement|Placebo|
75719432|NCT00994708|Drug|esomeprazole|
75719433|NCT01064557|Drug|all-trans retinoic acid (ATRA)|
75719434|NCT01001962|Drug|empagliflozin|ACTIVE TREATMENT FOR DIABETES
75719435|NCT01001962|Drug|Metformin|ACTIVE TREATMENT FOR DIABETES
75719436|NCT01002040|Biological|Arepanrix|Group A receives one dose of Arepanrix
75719437|NCT01002040|Biological|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
75719438|NCT03978169|Diagnostic Test|pleuropulmonary ultrasound|three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
76044173|NCT04038437|Drug|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
76044174|NCT05491577|Other|Filling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire|The SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire will all be filled in by the patients.
75420530|NCT01433120|Dietary Supplement|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
75420531|NCT01433133|Biological|implantation|subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
75420532|NCT01433185|Other|Text message|Text messages sent to women before and after delivery
75420533|NCT01433224|Genetic|DNA methylation analysis|
75420534|NCT01433224|Genetic|RNA analysis|
75420535|NCT01433224|Genetic|mutation analysis|
75420536|NCT01433224|Genetic|nucleic acid sequencing|
75565818|NCT04492917|Other|CV4|The osteopath was sitting at the head of the examination table, with the subject lying supine. The osteopath approximated with the hands the lateral angles of the occipital squama, taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
75565819|NCT04492917|Other|ST|The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point
75719439|NCT00304915|Behavioral|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
75565820|NCT04492917|Other|Sham CV4|the sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
75565821|NCT04492917|Other|Sham ST|The sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
75565822|NCT00523406|Procedure|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
75565823|NCT03457662|Combination Product|OMC and pseudo-SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
75719440|NCT05206786|Other|Conventional preventive work out|Female players in the control group will carry out a conventional preventive work that is organised in 3 training days per week. First training session includes preventive strength and proprioception exercises. Junior and senior teams (above 16 years old) will also do plyometrics exercises. In the second training session, players will do preventive strength exercises with an increased load compared to the previous session and proprioception exercises. Junior and senior players will also do anaerobic work. In the third session, players will perform reaction speed exercises.
76044175|NCT04282733|Behavioral|Mindfulness Rounds|"Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice."
75420537|NCT01433224|Genetic|polymerase chain reaction|
75420538|NCT01433224|Genetic|polymorphism analysis|
75420539|NCT01433224|Other|laboratory biomarker analysis|
75420540|NCT01433224|Other|medical chart review|
75420541|NCT01433237|Genetic|RNA analysis|
75420542|NCT01433237|Genetic|gene expression analysis|
75420543|NCT01433237|Other|laboratory biomarker analysis|
75420544|NCT01433276|Drug|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
75420545|NCT01433276|Drug|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
75565824|NCT03457662|Combination Product|OMC and SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
75565825|NCT00524615|Drug|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
75420546|NCT01433302|Procedure|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
75565826|NCT00524654|Procedure|HVLA chiropractic manipulation|
75565827|NCT03458819|Diagnostic Test|Isolation of peritoneal mesothelial cells|HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
75565828|NCT04689750|Diagnostic Test|Next generation sequencing|"Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.~Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing."
75565829|NCT02948192|Other|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
75565830|NCT02936817|Device|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
75420547|NCT01433367|Device|CerPass® Total Disc Replacement|Single level cervical disc disease
75565831|NCT02936817|Radiation|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
75874341|NCT05570695|Behavioral|sham attention left training, ALTsham|During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
75420548|NCT01433380|Drug|PF-05175157|One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
75420549|NCT01433380|Drug|Placebo|One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
75565832|NCT00523445|Drug|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
75565833|NCT00523445|Drug|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
75565834|NCT02936661|Drug|Tranexamic Acid|
75565835|NCT02936661|Drug|Placebo|
75565836|NCT02948075|Drug|Quisinostat|
75565837|NCT02948075|Drug|Paclitaxel|
75565838|NCT02948075|Drug|Carboplatin|
75874342|NCT02986789|Device|In vivo SpHb and PVi Monitoring|Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
75874343|NCT03223428|Drug|Xermelo|This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
75874344|NCT02777424|Drug|Prothrombin Complex Concentrate|Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
75420550|NCT01433393|Drug|TAK-875|
75420551|NCT01433393|Drug|TAK-875|
75420552|NCT01433393|Drug|Placebo|
75420553|NCT01433406|Drug|TAK-875|
75420554|NCT01433406|Drug|TAK-875|
75420555|NCT01433419|Drug|TAK-875|
75420556|NCT01433419|Drug|TAK-875|
75420557|NCT01433432|Drug|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
75420558|NCT01433445|Drug|panobinostat|Given 3 times a week, every other week in 28-day cycles.
75420559|NCT01433445|Drug|ruxolitinib|Given twice daily in 28-day cycles.
75420560|NCT01433458|Drug|RLX030A|RLX030 is administered as a continuous 24 hour infusion
75420561|NCT01433484|Behavioral|Maintenance of Weight Loss--Control|As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
75420562|NCT01433484|Behavioral|Maintenance of Weight Loss--Experimental|
75420563|NCT01433510|Drug|Grazax|1 tablet/day - pre and co-seasonal
75420564|NCT01433523|Drug|ALK HDM AIT Placebo|Oral lyophilisate, Placebo, to be administered sublingually once daily
75420565|NCT01433523|Drug|ALK HDM AIT 6 DU|Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
75420566|NCT01433523|Drug|ALK HDM AIT 12 DU|Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
75565839|NCT04690725|Drug|TQB3525|TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
75565840|NCT02930811|Drug|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
75565841|NCT02930811|Drug|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
75565842|NCT02947919|Behavioral|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
75565843|NCT04690569|Diagnostic Test|MeMed BV|The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
75719441|NCT05206786|Other|Gluteus maximus strengthening specific program|"Female players will carry out a gluteus maximus strengthening work out in addition to the control group programme. Of the following four exercises, the first and the third ones will be done on the first training session and the second and the fourth exercises will be done on the second one. Dosage will be 2 sets of 10 repetitions for each leg.~Clam Shell: Lateral decubitus with the knees and hips bend, the working leg placed on top of the other. Separate this knee while feet stay in contact.~Unilateral gluteal bridge: Supine decubitus with one foot flat on the floor and bent knee. This leg pushes the ground with the foot until the pelvis is lifted while the other leg remains straight.~Quadruped hip extension with knee extension : Quadruped on forearms. Straighten the hip by bringing the whole leg up and back with knee extension.~Quadruped hip extension with bent knee: Performed as the previous one, but during this one, the knee of the working leg is bent at 90º."
75719442|NCT03980197|Other|Active surveillance and preemptive isolation|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
75719443|NCT03980197|Other|Control|No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
75719444|NCT00997048|Procedure|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
75719445|NCT00997048|Procedure|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
75719446|NCT02532829|Other|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
75420567|NCT01433562|Drug|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
75420568|NCT01433562|Drug|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
75420569|NCT01433575|Drug|RO4917838|10 mg single oral dose
75420570|NCT01433575|Drug|RO4917838|20 mg single oral dose
75565844|NCT00523523|Behavioral|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
75420571|NCT01433588|Device|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
75420572|NCT01433588|Other|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
75420573|NCT01433601|Behavioral|Enhanced Treatment Support (ETS)|"An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup."
75420574|NCT01433614|Drug|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
75420575|NCT01433614|Drug|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
75420576|NCT01433614|Drug|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
75565845|NCT00523523|Behavioral|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
75565846|NCT02947880|Drug|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
75719447|NCT01002196|Behavioral|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
75420577|NCT01433627|Other|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
75420578|NCT01433627|Other|trans-radial and long-term bivalirudin infusion|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
75874345|NCT02777424|Biological|Fresh Frozen Plasma|Pooled collection of plasma from donors
75420579|NCT01433627|Other|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
75420580|NCT01433627|Other|Trans-femoral and Short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
75420581|NCT01433627|Other|trans-femoral and long-term bivalirudin infusion|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
75565847|NCT02947880|Drug|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
75565848|NCT04690491|Other|follicular cyclus|Days of cyclus 6-12
75565849|NCT04690491|Other|luteal cyclus|Days of cyclus 20-24
75565850|NCT00523562|Other|diet intervention|controlled hypercaloric high fructose, high fat, or high fat/high protein diet
75565851|NCT02930655|Drug|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
75565852|NCT02930655|Drug|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
75420582|NCT01433627|Other|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
75420583|NCT01433653|Behavioral|Cognitive Behavioral Therapy for Complicated Grief|Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
75565853|NCT04690803|Drug|air cooling|intervention is adding air-cooling to treatment
75565854|NCT00523757|Drug|Spironolactone|
75420584|NCT01433666|Drug|roflumilast (EU: Daxas, USA: Daliresp)|Acute intervention: 1 time each dose on different days. Capsulated
75565855|NCT00523757|Drug|Placebo|
75565856|NCT00524693|Drug|Montelukast|4mg sachets
75565857|NCT00524693|Drug|Placebo granules|
75565858|NCT02931201|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
75420585|NCT01433666|Drug|Placebo|Acute intervention: single administration, capsulated form.
75565859|NCT00524732|Biological|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
76044176|NCT05491343|Drug|MedroxyPROGESTERone Injection [Depo-Provera]|The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
76044177|NCT05491343|Device|Other|Follow up using US
76044178|NCT05498285|Behavioral|UPSCALER app|Usage of mobile app to guide rehabilitation after surgery
75420586|NCT01433666|Drug|roflumilast|Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
75565860|NCT02930772|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z46-100)"
75874346|NCT05360550|Drug|LSP-5415|pregnancy prevention
76044179|NCT05498363|Biological|Bacteriophage therapy|Difficult-to-treat bacterial infections were treated with bacteriophages (selected from a collection of 25 individual bacteriophages and 6 bacteriophage cocktails), which were shown to target the patient's infecting bacterial strain (in vitro)
76044180|NCT05491265|Behavioral|Intermittent Kangaroo mother care|Skin to skin contact between mother and preterm newborn between gestational age 28 weeks to 36+6 weeks for three sessions per day ,each contact session of two hours .
75565861|NCT04693481|Other|nature exposure|Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
75565862|NCT02930382|Other|Baroreflex assessment|
75565863|NCT02947724|Drug|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
75565864|NCT02936583|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-067)"
75565865|NCT02936544|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code:Z09-054)
75565866|NCT02936427|Drug|Dexamethasone|perineural infiltration of dexamethasone
75565867|NCT00523913|Drug|rosiglitazone|
76044181|NCT05497193|Drug|perampanel|China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.
76044182|NCT05486195|Drug|SDI-118|SDI-118 Powder in Capsule
76044183|NCT05486195|Drug|Placebo|Matching Placebo
76044184|NCT05486039|Behavioral|Changing behaviour|Changing the lying position and mattress system
75420587|NCT01433679|Behavioral|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
75565868|NCT02930499|Device|Hyalomatrix extra-cellular matrix|An exta-cellular matrix made from hyaluronic acid
75565869|NCT02930499|Device|Mepilex wound dressing|A siliconized non-adhesive foam wound dressing
75565870|NCT02947763|Drug|mixture of metronidazole, ciprofloxacin, and minocycline|placement of intracanal medication
76044185|NCT05497739|Drug|Intraperitoneal chemotherapy|5-Fu 1 g/m^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
75565871|NCT02947841|Other|Alternating stimulation|Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
75420588|NCT01433692|Behavioral|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
76044186|NCT05497739|Drug|Adjuvant systemic chemotherapy|Oxaliplatin 85 mg/m^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA < 1.25 m^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m^2), 60 mg Bid, Days 1-10 (BSA > 1.50 m^2).
76044187|NCT04276727|Drug|MINT study IMP|Application of gel for 6 weeks.
76044188|NCT05485883|Drug|Tislelizumab Lenvatinib|Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
75420589|NCT01433705|Other|Rb-82 Pet scans|Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
75420590|NCT01433705|Other|F-18 FDG Pet scans|"Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol."
75719448|NCT01002196|Behavioral|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
75420591|NCT01433705|Other|N-13 ammonia Pet scans|Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
75420592|NCT01433705|Drug|Regadenoson|Regadenoson is used as a stressor; but not to study its effects.
75420593|NCT01433718|Procedure|Neuromuscular and Resistance Training|1 hour/session, 3 sessions/week, 6 weeks
75420594|NCT01433744|Procedure|Non-surgical periodontal treatment|Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
75565872|NCT02947841|Other|Placebo|The control cohort will receive Setting A but Setting B will be identical to Setting A.
75565873|NCT02930421|Other|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
75565874|NCT00523952|Drug|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
75565875|NCT02936349|Other|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
75565876|NCT00524069|Biological|bevacizumab|
75565877|NCT00524069|Drug|capecitabine|
75565878|NCT00524069|Drug|gemcitabine hydrochloride|
75565879|NCT00524069|Other|flow cytometry|
75565880|NCT00524069|Other|laboratory biomarker analysis|
75565881|NCT00524069|Procedure|adjuvant therapy|
75565882|NCT00524069|Procedure|computed tomography|
75565883|NCT00524069|Procedure|neoadjuvant therapy|
75565884|NCT02936193|Procedure|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
75565885|NCT02936193|Procedure|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
75565886|NCT00524810|Drug|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
75565887|NCT00524810|Drug|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
76044189|NCT05485727|Other|The Lokomat® Pro Hocoma USA & Conventional physical therapy|Lokomat Consists of robotic gait orthosis and an advanced body weight support system, combined with a Treadmill. (used for gait training) and Conventional Physical Therapy
76044190|NCT05485727|Other|Conventional Physical Therapy|Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
76044191|NCT04273607|Drug|Subcutaneous Heparin|The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
76044192|NCT02548585|Drug|MEDI0382|MEDI0382 administered subcutaneously.
75565888|NCT00524849|Biological|Zoledronic acid|Zometa 1 mg weekly (intravenous)
75719449|NCT01066429|Drug|Dexamethasone and dose-dense immunochemoterapy|Administration every 14 days of the EDOCH-R scheme.
75719450|NCT01002274|Drug|MCS-2|2 soft-gel capsules Qd for 40 weeks
75719451|NCT03978247|Diagnostic Test|NASHMIR|An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
76044193|NCT02548585|Drug|Placebo|Placebo administered subcutaneously.
75565889|NCT00524849|Drug|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
75420595|NCT01433757|Drug|Ampicillin|Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
75420596|NCT01433757|Drug|Sugar pill|The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
75565890|NCT02936154|Drug|PF-06650833|
75565891|NCT02936154|Drug|placebo|
75719452|NCT05200390|Device|Continuous glucose monitor|FreeStyle Libre 2 system
75420597|NCT01433770|Drug|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
75420598|NCT01433835|Drug|MBX-400|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
76044194|NCT05480371|Device|Conventional tracheal suctioning|"Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations."
75420599|NCT01433835|Other|Placebo|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
75420600|NCT01433861|Procedure|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
75565892|NCT00524888|Procedure|suturing laceration|suturing simple lacerations of the hand
75565893|NCT00524888|Procedure|bioadhesive|using bioadhesive on simple lacerations of the hand
75565894|NCT02936115|Other|TruSkin®|
75565895|NCT02936115|Other|Wound Cover|
75565896|NCT00524927|Drug|Methoxyflurane|
75565897|NCT00524927|Drug|Normal Saline|
75565898|NCT02936310|Behavioral|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
75565899|NCT00524966|Procedure|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
75565900|NCT02935920|Behavioral|Individualized, tailored follow-up program|Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
75565901|NCT02276846|Device|Paclitaxel-Eluting Balloon|
75565902|NCT02935725|Drug|Low dose AUT00206 800mg|
75565903|NCT02935725|Drug|High dose AUT00206 2000 mg|
75565904|NCT02935725|Drug|Placebo|
75565905|NCT02935725|Drug|Ketamine|
75565906|NCT02935725|Other|Saline|
75719453|NCT00994786|Drug|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
75874347|NCT05255874|Other|Aromatherapy|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
75874348|NCT03247543|Drug|Placebo|Placebo was administered once daily
76044195|NCT05480371|Device|Mechanical insufflation/exsufflation|Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
76044196|NCT05476081|Drug|Aspirin|Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
75420601|NCT01433874|Procedure|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
76044197|NCT05476081|Drug|Clopidogrel|Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment
75420602|NCT01433874|Procedure|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
75565907|NCT04693442|Other|taking of blood, urine and blood samples and objective scar assessment|blood, urine and skin tissue sampling & scar assessment questionnaires
75565908|NCT02935764|Drug|Irinotecan|180 mg/m2 iv gtt, d1
75565909|NCT02935764|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
75874349|NCT03247543|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
75874350|NCT03247543|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
75874351|NCT05351190|Device|Dexcom G6 CGM|rtCGM to be worn by user continuously for the duration of the 12 month study
75874352|NCT03637153|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
75874353|NCT03637153|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
75874354|NCT05569525|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy according to the full-mouth debridement protocol.
75874355|NCT01347073|Drug|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
76044198|NCT05476081|Drug|Ticagrelor|Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
76044199|NCT05480215|Device|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
76044200|NCT04479553|Drug|Qizhi Tongluo Capsules|Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
76044201|NCT05476003|Procedure|Ultrasound-guided Bilateral superficial cervical plexus block|"This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus."
76044202|NCT05476003|Drug|Midazolam|All patients will be premedicated with Midazolam (0.02mg/Kg).
75420603|NCT01433874|Procedure|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
75420604|NCT01433874|Procedure|Control group|Co2 was removed by passive exsufflation through the port site.
75420605|NCT01433887|Drug|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
75420606|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
75420607|NCT01433887|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
75565910|NCT02935764|Drug|Leucovorin|400mg/m2 iv gtt,d1
75874356|NCT05569447|Procedure|Balloon Tamponade|A tamponade device that was fashioned using an 18F red rubber catheter and Penrose drain that was cut to the approximate length of the tract and ligated proximally and distally with #0 silk.
75874357|NCT02618551|Procedure|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
75420608|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
75874358|NCT05569057|Drug|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
75420609|NCT01433900|Drug|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
75420610|NCT01433900|Drug|Latanoprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
75420611|NCT01433952|Dietary Supplement|Thiamine|Vitamin B1
75420612|NCT01433952|Dietary Supplement|Placebo|Placebo
75420613|NCT01434004|Behavioral|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
75420614|NCT01434017|Drug|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
75565911|NCT02935998|Drug|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
75719454|NCT00994786|Drug|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
75719455|NCT01002430|Biological|VEGF-D gene transfer|Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
75420615|NCT01434017|Drug|Dexamethasone and droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
75420616|NCT01434017|Drug|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
75420617|NCT01434069|Drug|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
75420618|NCT01434069|Drug|FOLFIRI Infusion|Standard therapy of FOLFIRI
75719456|NCT01002508|Biological|Influenza vaccine|One dose of influenza vaccine
75719457|NCT01002586|Other|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
75719458|NCT01002586|Other|Walking exercise program|walking exercise program
75719459|NCT01002664|Drug|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
75719460|NCT01002664|Drug|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
75719461|NCT00997282|Drug|OPC-262 2.5 mg|orally administered once daily for 24 weeks
75719462|NCT00997282|Drug|OPC-262 5 mg|orally administered once daily for 24 weeks
75719463|NCT00997282|Drug|Placebo|orally administered once daily for 24 weeks
75719464|NCT00997360|Drug|PKI-179|
75719465|NCT00994942|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
75719466|NCT00995098|Dietary Supplement|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
75420619|NCT01434082|Behavioral|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
76044203|NCT02547649|Biological|V114-A|Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
76044204|NCT02547649|Biological|V114-B|Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
76044205|NCT02547649|Biological|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
75565912|NCT02930616|Device|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
75565913|NCT02930616|Device|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
75565914|NCT02930304|Other|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
75565915|NCT02930304|Other|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
75565916|NCT02930304|Other|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
75565917|NCT00524147|Procedure|Pigtail drainage|
75565918|NCT02930109|Drug|PTX-200|During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
75420620|NCT01434095|Procedure|half-dose photodynamic therapy|photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
75420621|NCT01434108|Drug|Ornithine-phenylacetate|"Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days."
75420622|NCT01434134|Drug|Metoprolol|Tablet, target dose 100 mg once daily
75420623|NCT01434134|Drug|Placebo|Tablet, target dose 100 mg once daily
75420624|NCT01434134|Drug|Candesartan|Tablet, target dose 32 mg once daily
75565919|NCT02930109|Drug|Cytarabine|Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
75719467|NCT00995098|Dietary Supplement|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
75420625|NCT01434134|Drug|Placebo|Tablet, 32 mg once daily
75565920|NCT00524186|Drug|fluorouracil|Given IV
75565921|NCT00524186|Drug|irinotecan hydrochloride|Given IV
76044206|NCT05460949|Other|HOLD RELAX STRETCHING OF ILIOPSOAS|"10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~• The stretching exercise was performed 2 times a week for 8 weeks. 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
75565922|NCT00524186|Drug|leucovorin calcium|Given IV
76044207|NCT05460949|Other|WILLIAM'S PROTOCOL|Pelvic tilt Single Knee to chest Double knee to chest Partial sit-up Hamstring stretch Hip Flexor stretch Squat Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols.
75420626|NCT01434147|Drug|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine|Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
75420627|NCT01434160|Drug|Skyla (Levonorgestrel, BAY86-5028)|Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.
75719468|NCT01003912|Biological|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
75719469|NCT01002898|Drug|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
75719470|NCT01003054|Drug|Busulfan|130 mg/m^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
76044208|NCT03097081|Other|No orthosis|The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis
76044209|NCT03097081|Device|Orthosis|Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
76044210|NCT03079297|Drug|L-Leucine|L-leucine is an essential amino acid which will be provided as an effervescent powder mixture to participants.
76044211|NCT03079297|Other|Maltodextrin|Maltodextrin is a nonsweet carbohydrate which will be provided as an effervescent powder mixture similar in taste and appearance to the L-leucine containing effervescent powder mixture
75420628|NCT01434173|Drug|Moxifloxacin (Avelox, BAY12-8039)|Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
75565923|NCT00524186|Drug|sunitinib malate|Taken Orally
75565924|NCT00524186|Other|flow cytometry|Correlative Study
75565925|NCT00524186|Other|pharmacological study|Correlative Study
75565926|NCT04442178|Drug|CYT107|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
75565927|NCT04442178|Drug|Placebo|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
75565928|NCT00525005|Drug|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
75565929|NCT00525200|Drug|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"
75565930|NCT00525200|Drug|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
75565931|NCT02929992|Other|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
75565932|NCT02929992|Other|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
75565933|NCT02929992|Other|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
75565934|NCT02929992|Other|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
75565935|NCT03458780|Drug|Yellow Fever Vaccine|Yellow Fever Vaccine .5 ml
75874359|NCT01315236|Drug|Liposomal amikacin for inhalation (LAI)|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~Subjects can continue with 84 additional days of dosing in the open label extension."
75874360|NCT01315236|Drug|placebo|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~Administration procedures, volume and administration time are similar to LAI.~Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
75874361|NCT03730051|Drug|Gadoterate meglumine|Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
75420629|NCT01434173|Drug|Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin|Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
75719471|NCT01003054|Drug|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
75420630|NCT01434199|Procedure|UPD guidance|A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
75565936|NCT02930148|Other|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
75565937|NCT03458741|Other|Glycogen Supercompensation|The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
75565938|NCT02947568|Other|non-interventional study|
75420631|NCT01434212|Drug|Interferon Alfa-2b, Ribavirin|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
75565939|NCT02930265|Drug|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
75565940|NCT02947490|Other|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
75565941|NCT02947490|Other|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
75719472|NCT01003054|Drug|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is >1500/mcl and platelets >50,000 /mcl, may be titrated to maintain ANC >1.0 and platelets >50,000 /mcl.
75719473|NCT01003054|Procedure|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
75874362|NCT03730051|Drug|Gadobutrol|Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
75874363|NCT03232567|Biological|NasoVAX|Single ascending dose study
75719474|NCT01003132|Other|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
75719475|NCT01004068|Other|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
75719476|NCT01004068|Drug|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
76044212|NCT05475847|Biological|Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection|C-TIL052A injection followed by injection of IL-2
76044213|NCT02535715|Drug|ORMD-0801 capsules- 2x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
76044214|NCT02535715|Drug|ORMD-0801 capsules- 3x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
75719477|NCT01004068|Behavioral|Structured exercise program plus hypocaloric diet|SET plus diet
75719478|NCT03687970|Other|Brief Pain Inventory|-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
75719479|NCT03687970|Other|Hospital Anxiety and Depression Scale|"14 item scale with even of the items relating to anxiety and seven relating to depression~Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression"
76044215|NCT02535715|Drug|ORMD-0801 capsules- 1x16mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
75719480|NCT03687970|Other|Neuropathic Pain Symptom Inventory|-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia [pain provoked by light touch]). Each of the parameters includes recall of the past 24 hours
76044216|NCT05460247|Dietary Supplement|Protein|Participants will receive a diet supplemented by the above protein
76044217|NCT02336815|Drug|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
76044218|NCT02336815|Drug|Dexamethasone|20 mg was given with each dose of Selinexor.
76044219|NCT05466643|Drug|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
76044220|NCT05466643|Drug|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
75420632|NCT01434225|Drug|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
75420633|NCT01434238|Other|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
75420634|NCT01434251|Other|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
75420635|NCT01434264|Procedure|Energy healing|"Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair."
75420636|NCT01434277|Other|Eye Drops with Experimental Preservative|Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
75719481|NCT03687970|Procedure|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers"
76044221|NCT02543203|Biological|Reconnect|Topical Essential Oils mixture and aromatic method
75420637|NCT01434303|Drug|Entinostat|Given PO
75565942|NCT02947490|Other|Standard BP management|GP to measure BP and manage BP control
76044222|NCT02543203|Biological|Coconut oil Comparator|Topical Essential Oils mixture and aromatic method
76044223|NCT05434039|Other|diclofenac phonophoresis|the patients will be in comfortable position and apply diclofenac phonophoresis on upper trapezius and suboccipital muscle by ultrasound device. diclofenac gel was applied circularly with a thickness of 2-3 mm. Then ultrasound with was applied with 1 MHz frequency and 1.5 Wt/cm2 power over the trigger points on the trapezius and suboccipital muscle, for 10 min.
76044224|NCT05434039|Other|high power pain threshold ultrasound|the patients will be in comfortable position and The frequency was set to 1 MHz, and the intensity will be increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe was held there for 4 s; then, the intensity was reduced by 50%, and the probe will be moved over and around the trigger point. This process is done several times for three minutes
75565943|NCT02947490|Other|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
75565944|NCT02929953|Other|chart review|data from charts and from registries will be compared
75565945|NCT02947178|Procedure|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
75565946|NCT02947178|Behavioral|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
75420638|NCT01434303|Other|Laboratory Biomarker Analysis|Correlative studies
75420639|NCT01434303|Drug|Lapatinib Ditosylate|Given PO
75719482|NCT03687970|Procedure|Quantitative sensory testing|"Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio"
75565947|NCT02947178|Behavioral|Pill Count|Patient reported as needed (prn) pain medication usage
75719483|NCT03687970|Procedure|Conditioned pain modulation efficiency|-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
75719484|NCT03687970|Other|Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)|"-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain."
75874364|NCT04621045|Behavioral|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
76044225|NCT05434039|Other|conventional therapy|the patient will receive an active range of motion exercise, stretching and strengthening of all cervical muscles
76044226|NCT05466175|Drug|Olverembatinib|Given PO
76044227|NCT05466175|Drug|Prednisone|Given Intravenous
76044228|NCT05466175|Drug|Vincristine|Given Intravenous
76044229|NCT02546323|Drug|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
76044230|NCT02546323|Drug|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
76044231|NCT02545933|Drug|Prasugrel|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
75420640|NCT01434303|Biological|Trastuzumab|Given IV
75420641|NCT01434329|Genetic|DNA methylation analysis|
75420642|NCT01434329|Genetic|gene expression analysis|
75420643|NCT01434329|Genetic|microarray analysis|
75420644|NCT01434329|Other|laboratory biomarker analysis|
75420645|NCT01434329|Other|medical chart review|
75565948|NCT02947178|Drug|Bupivacaine|
75565949|NCT02947178|Drug|Liposomal Bupivacaine|
75420646|NCT01434355|Other|Laboratory Biomarker Analysis|Correlative studies
75420647|NCT01434355|Other|Questionnaire Administration|Ancillary studies
75420648|NCT01434381|Biological|Pfs25-EPA/Alhydrogel|
75565950|NCT02929797|Biological|CD8+NKG2D+ AKT Cell|AKT: CD8+NKG2D+ AKT cell
75565951|NCT02929797|Drug|Gemcitabine|gemcitabine
76044232|NCT02545933|Drug|Vorapaxar|Vorapaxar will be administered at the dose of 2.5mg once daily
76044233|NCT02545933|Drug|Aspirin|Aspirin will be administered at the dose of 81mg once daily
76044234|NCT02545933|Drug|Ticagrelor|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
76044235|NCT01661179|Drug|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
75565952|NCT00525239|Drug|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
75565953|NCT02929758|Behavioral|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
75565954|NCT02947139|Drug|Co-administration of DWC20155/DWC20156|
75565955|NCT02947139|Drug|DWC20161|
75565956|NCT02929836|Procedure|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
75565957|NCT02929836|Procedure|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
75565958|NCT02929836|Procedure|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
75565959|NCT02929836|Procedure|linear ablation|Right atrial CTI ablation was performed during SR.
75565960|NCT02929836|Device|CARTO|3 dimensional mapping system
75565961|NCT04693052|Other|No interventions|This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
75719485|NCT01004224|Drug|BGJ398|
76044236|NCT05457517|Drug|YL-13027，Sintilimab|"YL-13027 combined with Sintilimab will be used as a cycle for 21 days. YLl-13027 is administered orally twice a day. Starting dose of YL-13027 is 240mg/d，with escalation to 360mg/d in phase Ib, and RP2D was administered orally twice a day in phase II.~Sindilizumab is administered intravenously 200mg every three weeks"
76044237|NCT02545543|Biological|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
75420649|NCT01434394|Drug|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
75420650|NCT01434407|Other|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
75565962|NCT02929914|Procedure|Local anesthesia and rubber dam isolation|Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
75565963|NCT02929914|Procedure|Incomplete caries removal and microbiological samples collection|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.
76044238|NCT02545543|Biological|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
76044239|NCT02545075|Drug|Ipilimumab|
75565964|NCT02929914|Procedure|Dentin washed with sodium 0.9% saline|The remaining dentin was dipped in sodium 0.9% saline for 2min.
75565965|NCT02929914|Procedure|Antimicrobial Photodynamic Therapy|The remaining dentin was disinfected with aPDT for 2 min.
75565966|NCT02929914|Procedure|Microbiological samples collection and Indirect pulp treatment|A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
76044240|NCT02545075|Drug|Dacarbazine|
76044241|NCT03007537|Drug|Erythropoietin|10000 IU erythropoietin, subcutaneous injection
76044242|NCT03007537|Drug|0.9% sodium chloride|0.9% sodium chloride 1ml, subcutaneous injection
76044243|NCT03007537|Procedure|cardiac surgery|included valve, coronary artery bypass graft or surgery for congenital heart diseases
76044244|NCT03004183|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
75420651|NCT01434420|Genetic|BRCA1 BRCA2 PTEN PALB2 mutation|detection of BRCA1 BRCA2 PTEN PALB2 mutation
75420652|NCT01434446|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
75420653|NCT01434459|Drug|Gemcitabine with TheraSphere|Gemcitabine dose will be escalated and combined with therasphere.
75420654|NCT01434524|Drug|LIVACT|LIVACT contains 13.0 g of free amino acids
75719486|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
75719487|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
76044245|NCT03004183|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
76044246|NCT03004183|Radiation|SBRT|Low-dose SBRT
76044247|NCT03004183|Drug|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
76044248|NCT02544763|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
76044249|NCT02544763|Drug|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
76044250|NCT05464771|Procedure|Surgery for hip and knee replacement|Elective inpatient surgery for hip and knee replacement
75565967|NCT02947334|Biological|Bococizumab|Bococizumab PFS
75565968|NCT02947334|Drug|Placebo|Placebo
75565969|NCT00525278|Drug|Levocetirizine dihydrochloride|
75565970|NCT00525317|Drug|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
75565971|NCT02929719|Drug|Test.|gel
75565972|NCT02929719|Drug|Aczone Gel 5%|gel
75565973|NCT02929719|Drug|Placebo|gel
75565974|NCT00525980|Behavioral|Computer Program|"Participants will be given a program to learn about breast cancer risk and genetic testing.~Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor)."
75719488|NCT00530920|Drug|tipranavir|
76044251|NCT02556203|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10mg OD (once-daily)
76044252|NCT02556203|Drug|Acetylsalicylic Acid (ASA)|75-100mg OD
76044253|NCT02556203|Drug|Clopidogrel|75mg OD
76044254|NCT02556203|Drug|Rivaroxaban (Xarelto, BAY59-7939)|In case of NOAF, 20/15 mg OD (once-daily)
75719489|NCT00530920|Drug|ritonavir|
75565975|NCT00525980|Behavioral|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
75874365|NCT04621045|Behavioral|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
75874366|NCT01348490|Drug|Ruxolitinib|Ruxolitinib (INCB018424), 5 mg bid
75565976|NCT00525980|Other|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
75565977|NCT00525980|Behavioral|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
75565978|NCT02929875|Behavioral|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
75874367|NCT03040674|Procedure|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
75874368|NCT03232333|Device|Biologic wound graft|Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
75874369|NCT02310204|Behavioral|multidisciplinary education program|both individual and group education sessions over a 6-month period in addition to standard psoriasis care
75420655|NCT01434550|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
76044255|NCT02556203|Drug|Vitamin K antagonist (VKA)|In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
75420656|NCT01434550|Radiation|Tissue, Blood, Research Imaging (TBRI)|"Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess~Necrosis/apoptosis~Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)~1. Aposense-PET imaging"
75565979|NCT00525356|Device|Medtronic Talent Stent-Graft-System|
75874370|NCT02310204|Other|standard psoriasis care alone|
75874371|NCT04080505|Drug|SSKI- Potassium Iodide|1g/mL, 2 drops orally 3 times a day for 7 days before surgery
75420657|NCT01434576|Biological|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
75565980|NCT04689672|Diagnostic Test|Lung ultrasound|Bedside lung ultrasound
75565981|NCT00525395|Genetic|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
75565982|NCT00525395|Procedure|Continuous phototherapy|Group B: 6 months non-stop treatment.
75565983|NCT04693559|Procedure|secondary alveolar bone graft|Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps
75565984|NCT04693559|Procedure|harvesting of the autogenous bone graft|osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger
75719490|NCT01004302|Procedure|ventral capsular/ventral striatal gamma capsulotomy|Comparison of active radiosurgical with sham radiosurgeries
75719491|NCT01003444|Procedure|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
75874372|NCT05572411|Other|GAITRite Electronic Walkway|Participants will be asked to walk across the electronic walkway to record information relating to their gait pattern. Depending on the age and compliance of the participant, they will be asked to complete 3 passes at 3 speeds, preferred, fast and slow.
75565985|NCT04693559|Procedure|Nanocrystalline Hydroxyapatite|Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect
75565986|NCT04323150|Device|Closed suction systems|Closed suction systems are using for prevention of the ventilator-associated pneumoniae
75565987|NCT04323150|Device|Conventional suction system|The using of open (conventional) suctioning
75874373|NCT05610696|Other|Low impact immersion|Consists of a sequence of shoulder, trunk and hip movements. In this modality, the aim will be to understand the physiological effects of immersion in heat water. Resisted movements (either by turbulence or by floats) or interventional maneuvers in the knee joints will not be performed. Considering the period of 5 minutes for acclimatization to the liquid environment, the program will last approximately 47 minutes.
76044256|NCT05485571|Device|derma pen|"Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks"
75420658|NCT01434576|Biological|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
75420659|NCT01434576|Drug|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
75420660|NCT01434589|Behavioral|STICA Intervention|Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
75420661|NCT01434615|Device|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
75420662|NCT01434615|Other|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
75420663|NCT01434628|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
75565988|NCT00525434|Device|Seraffix LTB|wounds closure by using laser and albumin
75565989|NCT02929524|Drug|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
75719492|NCT01004380|Drug|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
75719493|NCT01003522|Other|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
75719494|NCT01003522|Other|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
75719495|NCT01003522|Procedure|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
75565990|NCT02929524|Drug|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
75565991|NCT00525473|Drug|Azathioprine|azathioprine usual dosage 100mg per day
75719496|NCT01003522|Procedure|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
75719497|NCT01003522|Other|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
75565992|NCT04310475|Other|Virtual reality assisted CBT|This study uses virtual reality technology to assist cognitive behavioural therapy for social difficulties in people with first episode psychosis.
75565993|NCT00526136|Drug|Placebo|
75565994|NCT00526136|Drug|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
75565995|NCT02929446|Procedure|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
75565996|NCT02929446|Procedure|Mobilisation and breathing exercises|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
75719498|NCT01003522|Other|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
75719499|NCT01003522|Other|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
75719500|NCT01004458|Behavioral|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
75719501|NCT01004458|Other|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
76044257|NCT05485337|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
75420664|NCT01434706|Other|Nucleic Acid Amplification Testing|The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
75420665|NCT01434732|Procedure|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
75420666|NCT01434732|Procedure|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
75565997|NCT00526175|Drug|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
75565998|NCT00526175|Drug|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
75565999|NCT00526175|Drug|Daunorubicin|30 mg/m2, i.v., days 8 and 15
75566000|NCT00526175|Drug|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
75566001|NCT00526175|Drug|Cyclophosphamide|1000 mg/m2, i.v., day 22.
75566002|NCT00526175|Drug|Methotrexate|Age <1 year 1-2 years 2-3 years > 3 years MTX 5 mg 8 mg 10 mg 12 mg
75566003|NCT00526175|Drug|Cytosine Arabinoside|Edad <1 year 1-2 years 2-3 years > 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
75566004|NCT00526175|Drug|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
75566005|NCT00526175|Drug|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
75566006|NCT02930031|Dietary Supplement|n-acetylcysteine|20 mg//kg/day, orally, daily for eight days following exercise
75566007|NCT02930031|Dietary Supplement|Placebo|500 mL orally, daily for eight days following exercise
75566008|NCT02929563|Drug|Pantoprazole|
75566009|NCT02929563|Drug|Placebo (for pantoprazole)|
75874374|NCT05610696|Other|Conventional aquatic physiotherapy|include warm-up, strengthening and calming down activities. Aquatic steppes will be used to ensure that all participants will maintain the waterline level approximately in the xiphoid appendix. For strengthening activities, the exercises must be performed at an adequate speed, which ensures a comfortable level for the activity. For this purpose, a subjective feedback will be extracted from the participants constantly. The warm-up sequence consists of six different active hip and knee movements performed at maximum range of motion and contributes to neuromuscular activation. For strengthening, each movement should be performed for 1 minute (30 seconds for each lower limb) followed by a period of 30 seconds of rest between each movement.
75566010|NCT00525551|Drug|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
75719502|NCT01003600|Behavioral|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
75719503|NCT01004536|Device|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
75719504|NCT01004536|Other|no treatment|left untreated during the study period
75874375|NCT05610696|Other|High intensity aquatic physiotherapy|In this modality subjects will perform the same sequence of exercises of the Conventional Aquatic Physiotherapy program will be respected. However the work load and speed will be adjusted to the maximum level. For strengthening, each movement should be performed for 2 minutes (1 minute for each lower limb) followed by a period of 30 seconds of rest between each movement. To guarantee the maximum effort of the participants, verbal stimuli will be constantly provided. The program will last approximately 68 minutes.
75566011|NCT00525551|Drug|Placebo (NaCl)|300 mL 0.9% NaCl
75566012|NCT04689399|Diagnostic Test|Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.|Alle Danish citizens tested for infection with SARS-CoV-2 by swabs in the oropharynx, and subsequently analysis of the specimens by RT-PCR test at Testcenter Danmark's test centers will be included in the study. Participants will, in addition to the oropharyngeal swab they are already schedule for, be examined by a rapid antigen test.
75566013|NCT04288323|Drug|Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid|This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
75874376|NCT03364049|Drug|MK-7162|oral tablets
75719505|NCT01003678|Drug|Clofarabine|"Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug."
75719506|NCT01003756|Other|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
75719507|NCT04000204|Device|HYAJOINT Plus|60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
75719508|NCT04000204|Device|Durolane|60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
75719509|NCT01003834|Behavioral|Computerized brief intervention|Intervention based on Motivational Interviewing technique
75874377|NCT03364049|Biological|Pembrolizumab|IV infusion
75719510|NCT01003834|Behavioral|Computerized health screening|Behavioral intervention
75566014|NCT02946359|Drug|Crizotinib, bevacizumab|Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
75566015|NCT02929173|Other|Allceram|Pressed E-max coping veneered with E-max veneering system
75566016|NCT02929173|Other|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
75566017|NCT02946437|Drug|Sevoflurane|Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
75566018|NCT02946437|Drug|Propofol|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
75566019|NCT02946437|Drug|Midazolam|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
75566020|NCT02946437|Device|MIRUS™System|The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
75566021|NCT02946632|Drug|triple combination therapy|Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
75566022|NCT02946632|Drug|Stepwise add-on therapy|metformin -> glimepirde -> sitagliptin
76044258|NCT05496803|Other|routine education plus digital video disk|Parents receiving routine education plus digital video disk before their children receiving congenital heart disease catheterization. The DVD content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
76044259|NCT05496803|Other|routine education|Parents receiving routine education before their children receiving congenital heart disease catheterization
76044260|NCT05496725|Drug|Micafungin|Pharmacokinetic study under fasting conditions
76044261|NCT05490719|Drug|QL1706|QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
76044262|NCT04424459|Drug|opioid withdrawal|The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
76044263|NCT05496569|Drug|TQB3616 capsule|TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
76044264|NCT05496569|Drug|TQB3616 placebo|Placebo
75566023|NCT02929134|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
75566024|NCT02929134|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
75719511|NCT01003834|Behavioral|Computerized assessment|Behavioral intervention
75719512|NCT01003834|Behavioral|Therapist-delivered motivational intervention|Behavioral intervention
75719513|NCT01004692|Device|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
75719514|NCT04000126|Device|Pupil reflex dilation measurement (PRD)|Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
75719515|NCT04000126|Device|PPI (Pupillary Pain Index)|Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
75719516|NCT04000126|Drug|lidocaine|1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
75719517|NCT04000126|Drug|Placebo|100ml 0,9% NaCl iv 10min before intubation
75719518|NCT04000126|Device|Bispectral Index (BIS)|Bispectral Index will be monitored to assess the depth of anaesthesia
75719519|NCT04000126|Device|HR|HR in beats/min will be measured by the electrocardiogram monitor
75719520|NCT04000126|Device|BP|BP will be measured automatically by an occluding upper arm cuff
75874378|NCT03708029|Other|Revita Allograft|Human placental allograft
75874379|NCT05348772|Drug|AmnioPul-02|Mesenchymal stem / stromal cells, MSC
76044265|NCT04179383|Other|Constitution of a biobank|"We are collecting additional blood and CSF samples for patients (during RCVS episode and after resolution of RCVS episode) and for control subjects to constitute a biobank, in order to compare different biologic parameters between RCVS patients and healthy volunteers. A specific agreement will be asked to patients and control subjects before collection of samples.~This is why this study is classified as 'interventional' rather than 'observational'."
75420667|NCT01434836|Other|active tDCS and working memory training|This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.
75420668|NCT01434836|Other|sham tDCS and working memory training|This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
75420669|NCT01434849|Drug|topical 0.5% Timolol maleate|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
75420670|NCT01434849|Drug|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
75420671|NCT01434862|Drug|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
75420672|NCT01434862|Device|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
75719521|NCT01004926|Device|Echelon foot|One Echelon foot for each subject, for a period of a month.
75874380|NCT05681819|Drug|SHR-1707|Multiple-ascending Dose
75874381|NCT05681819|Drug|SHR-1707 placebo|Multiple-ascending Dose
75566025|NCT04693091|Device|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
75874382|NCT05343078|Drug|Dapagliflozin 10Mg Tab|Participants will take a single-dose Dapagliflozin 10mg P.O. prior to the hemodialysis session for the single-dose pharmacokinetics protocol. In the multiple-dose protocol, Dapagliflozin 10mg P.O. will be taken daily in the morning for one week.
76044266|NCT05485259|Dietary Supplement|DL-alpha lipoic acid|Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.
76044267|NCT05485259|Other|placebo (rice starch)|Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
75420673|NCT01434862|Drug|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
75420674|NCT01434888|Drug|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
75420675|NCT01434888|Drug|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
75420676|NCT01434888|Drug|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
75566026|NCT02929212|Other|Solid Meal|Subjects will receive solid meals during meal study
75566027|NCT02929212|Other|Liquid Meal|Subjects will receive liquid meals, during meal study
75566028|NCT02929212|Drug|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
75566029|NCT02929212|Other|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
75420677|NCT01434901|Drug|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
75566030|NCT02929212|Other|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
75719522|NCT01008826|Dietary Supplement|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
75566031|NCT02947373|Drug|Hyperpolarized Pyruvate|Hyperpolarized Pyruvate
75566032|NCT02929251|Drug|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
75566033|NCT02929251|Drug|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
75719523|NCT01005004|Biological|HuCNS-SC cells|intracerebral transplantation
75719524|NCT01005082|Behavioral|Low salt diet|
75719525|NCT01005082|Behavioral|Water therapy alone|
75719526|NCT01008982|Drug|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
75874383|NCT03706235|Other|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
75874384|NCT03238963|Drug|BI 1467335|Once daily
75874385|NCT03238963|Drug|Placebo|Once daily
75874386|NCT05693298|Device|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
75874387|NCT05693298|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
75566034|NCT02929251|Drug|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
75566035|NCT02929368|Device|PICC implantation under fluoroscopy|PICC Catheter implantation
75566036|NCT02929368|Device|PICC Implantation under Sherlock System|PICC Catheter implantation
75566037|NCT02946281|Behavioral|Do CHANGE|The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
75566038|NCT02929290|Drug|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
75566039|NCT02947451|Other|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
75566040|NCT02947451|Other|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
75566041|NCT02929095|Drug|dexmedetomidine|
76044268|NCT04027049|Device|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
76044269|NCT05490407|Drug|Carboplatin|Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
75566042|NCT02929095|Drug|midazolam|
75566043|NCT02929095|Drug|remifentanil|- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
75566044|NCT02946554|Biological|HepaStem|
75719527|NCT03999736|Device|transcranial direct current stimulation using a Soterix mini-CT device|TDCS is used to non-invasively stimulate the brain through the application of electrical currents to a small region of the scalp using a battery-powered stimulator (Soterix Medical 2018) with rubber electrodes and conductive material (saline-soaked sponges). Both electrodes are attached to the scalp with a band. The stimulation points will be located using the 10-20 system of electroencephalogram (EEG) electrode location (localization carried out using a bespoke head strap). The electrode size of the stimulator used in this study is large (25 cm2) and the current strength used is low (2 mA) resulting in very low current density (0.08 mA/cm2). This protocol applies no more than 30 minutes of stimulation in a single session, which is typical for experimental studies (Brunoni et al. 2015; Loo et al. 2017). TDCS is an investigational device and has proceeded with a non-significant risk designation in many past trials and not required an investigational device exemption from the FDA.
76044270|NCT04424849|Diagnostic Test|CT-Scan|Chest CT scan on admission to the intensive care unit
76044271|NCT05490173|Other|Exosomes derived from mesenchymal stromal cells (MSCs)|Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants
76044272|NCT05485025|Behavioral|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
76044273|NCT05485025|Behavioral|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
76044274|NCT05484947|Diagnostic Test|Elisa HIV testing|HIV testing on a voluntary basis
75420678|NCT01434901|Drug|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
75420679|NCT01434901|Drug|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
75420680|NCT01434901|Drug|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
75420681|NCT01434914|Drug|octenisept®|Cutaneous solution
75420682|NCT01434914|Drug|Placebo|Cutaneous use
75420683|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
75420684|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
75420685|NCT01434940|Other|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
75420686|NCT01434953|Behavioral|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
75420687|NCT01434953|Behavioral|Unlabeled prehypertension|"A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed."
75566045|NCT02928861|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
75719528|NCT01005160|Drug|Metformin|CKD-501 0.5mg, metformin 1000mg
75566046|NCT02946476|Other|prognostic impact of non cardiac comorbidities|
75719529|NCT01005160|Drug|CKD-501|CKD-501 0.5mg, metformin 1000mg
75719530|NCT03878758|Device|BD Nano™ PRO|Insulin Pen needle
75420688|NCT01434966|Other|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
75566047|NCT02928900|Behavioral|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
75566048|NCT00525668|Drug|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
75566049|NCT00525668|Drug|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
75566050|NCT02928783|Behavioral|Home-based cardiac rehabilitation|
75566051|NCT02946593|Behavioral|Stroll Safe outdoor fall prevention program|The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 & 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
75566052|NCT02946593|Behavioral|Outdoor fall prevention brochure|The control group participants will be given a written brochure on tips for preventing outdoor falls.
75566053|NCT02928822|Behavioral|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
75566054|NCT02928822|Behavioral|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
75566055|NCT00525707|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
75566056|NCT02929017|Other|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
75719531|NCT03878758|Device|33G Artsana Insupen Extr3me|Insulin Pen Needle
75719532|NCT03878758|Device|34G Artsana Insupen Extr3me|Insulin Pen Needle
75719533|NCT03878758|Device|Simple Diagnostics Comfort EZ™|Insulin Pen Needle
75719534|NCT03878602|Procedure|Delayed umbilical cord clamping|Umbilical cord will be clamped after 1 min after the birth of the newborn
75719535|NCT03878602|Procedure|Immediate umbilical cord clamping|Umbilical cord will be clamped immediately after the birth of the newborn
75719536|NCT01005238|Drug|Lamivudine|
75719537|NCT01005238|Drug|Telbivudine|
75719538|NCT01009216|Drug|ABT-384|Doses will be administered daily for 5 days.
75420689|NCT01434966|Other|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
75420690|NCT01434966|Other|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
75420691|NCT01435005|Other|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
75420692|NCT01435005|Other|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
75420693|NCT01435057|Procedure|exercise training|comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
75566057|NCT02929017|Other|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
75566058|NCT00526214|Drug|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
75566059|NCT02928744|Other|COPD|Plethysmography
75566060|NCT02928744|Other|COPD|Forced oscillations
75566061|NCT02928705|Procedure|physician operated telemedical prehospital analgesia|Ambulances in the EMS of the city of Aachen are equipped with a portable telemedicine system. In emergencies requiring intravenous analgesia paramedics can use this system to contact the tele-EMS physician with an audio-connection. Vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) can be transferred in real-time. The transmission of still pictures - taken with an official smartphone - and video streaming from the inside of the ambulance are also possible. The tele-EMS physician supports the paramedics and can delegate the application of morphine and other analgesics based on two predefined algorithms for trauma and non-trauma cases that are displayed on a context-sensitive telemedical documentation system in the teleconsultation center.
75566062|NCT02928705|Procedure|prehospital analgesia by on-scene EMS physicians|This (control) group represents the conventional treatment in German emergency medical service (EMS). In addition to an ambulance manned with paramedics, a prehospital EMS physician is deployed to conduct analgesic treatment on-scene. Treatment data for this group are selected from the time period before implementing teleconsultation in routine and therefore represent a historical control group.
75566063|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
75566064|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
75566065|NCT00526253|Procedure|Hypothermosol|After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
75566066|NCT02928939|Other|drug-drug or drug-disease interaction|
75566067|NCT03457584|Procedure|air arm|epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
75566068|NCT03457584|Procedure|BSS arm|epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
75566069|NCT02928666|Other|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
75566070|NCT02947256|Procedure|standard laparoscopic cholecystectomy|which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
75719539|NCT01005394|Device|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
75719540|NCT05224414|Behavioral|Cognitive bias modification for interpretation bias|Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
76044275|NCT05484791|Other|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization(LRSM) technique during two sessions per week. The LRSM technique is applied while patients are lying on their side. The uppermost hip and knee are placed in 90 degree flexion, this is to assist rotational stress, and the lower leg is placed in extension. The lower shoulder is strongly pulled; thus, the upper shoulder is positioned toward the posterior and the pelvis moves anteriorly. The clinician stands in front of the patient. They stabilize the upper shoulder with one hand, and place the palm of the other hand behind the hard part of the ilium wing, with forearm horizontal and fingers turned toward the clinician. A rotational force is applied with pressure in the horizontal direction by pulling the hand on the ilium toward the clinician. In this position, 30 slow repeated movements are performed. The same practice is performed on both sides
76044276|NCT05496413|Device|STARSTIM|In order to evaluate the working memory ability of schizophrenic participants, a task was designed that needs to be performed by them. Firstly, a stimulus of six different color circles of same size in a gray background would be given for 500ms. This would be followed by 2000ms delay phase and then a test array would be appeared. The test array would be exactly same to the stimulus array but with or without change in color of only one circle. The test array would appear on the screen till the participants record their response and they would be asked to respond if the test array matches to the stimulus or not.
76044277|NCT05496257|Other|direct pulp capping in primary molars|caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
76044278|NCT05490095|Drug|SVG101 (T)|5mg of SVG101
76044279|NCT05490095|Drug|Afinitor (R)|5mg of Afinitor
75719541|NCT05224414|Behavioral|Psychoeducation|Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
76044280|NCT05484635|Procedure|Diagnostic laparoscopy and inguinal mesh removal|Surgical examination and treatment of groin pain following inguinal hernia surgery by surgical exploration with a laparoscope or removal of mesh laparoscopically
76044281|NCT05484635|Procedure|Diagnostic laparoscopy|Surgical examination through laparoscopy without removal of mesh
76044282|NCT04424381|Drug|Rivaroxaban 20 MG Oral Tablet [Xarelto]|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet [Xarelto].
75566071|NCT02947256|Procedure|RI approach|which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
75566072|NCT02928510|Procedure|Biospecimen Collection|Undergo biospecimen collection
75566073|NCT02928510|Procedure|Colonoscopy|Undergo colonoscopy
75566074|NCT02928510|Procedure|Colposcopic Biopsy|Undergo colposcopic biopsy
75566075|NCT02928510|Drug|Idelalisib|Given PO
76044283|NCT04424381|Drug|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
76044284|NCT05496179|Drug|Prucalopride|Prokinetic
75566076|NCT02928510|Other|Laboratory Biomarker Analysis|Correlative studies
75566077|NCT02928510|Other|Pharmacological Study|Correlative studies
75566078|NCT02928510|Procedure|Physical Examination|Undergo physical examination
75566079|NCT02928510|Procedure|Sigmoidoscopy|Undergo sigmoidoscopy
76044285|NCT05496179|Drug|Metoclopramide|Prokinetic
76044286|NCT04157621|Device|Active taVNS|Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
76044287|NCT04157621|Device|Sham Stimulation|Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
75566080|NCT04692974|Device|Mobile phone application and smart watch|Mobile phone application prompts
75566081|NCT02928393|Drug|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
75566082|NCT02928393|Drug|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
75566083|NCT02947412|Other|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
75566084|NCT02928354|Drug|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
75566085|NCT02928354|Drug|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
75566086|NCT02928354|Drug|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
75566087|NCT02946944|Drug|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \ g + 10 mg apixaban 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
75566088|NCT02946944|Drug|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
75566089|NCT02928471|Dietary Supplement|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
75566090|NCT02946983|Other|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
75566091|NCT02946983|Other|Control|Intragastric administration of distilled water
76044288|NCT05496101|Procedure|Intraoperative CLI + FAR LightPath imaging|"Imaging System: The LightPath Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post marketing study).~Radiopharmaceutical:~18F-FDG is a routinely used Positron Emission Tomography (PET) / Computed Tomography (CT) radiopharmaceutical"
75566092|NCT02928432|Drug|Steroids switch|Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
75566093|NCT02928549|Behavioral|semi-structured interviews|
76044289|NCT05496023|Device|Percutaneous coronary intervention|"Pre-PCI angio-FFR was calculated and virtual pullback was generated~Automated algorithm to calculate delta angio-FFR per unit length and co-registered onto coronary angiogram was developed~PCI was performed using 2nd generation DES"
75566094|NCT02947061|Drug|S1 plus Docetaxel|S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
75719542|NCT01005472|Drug|sunitinib malate|
75566095|NCT02947061|Drug|Capecitabine plus Docetaxel|Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
75566096|NCT02928276|Other|RheumaKit: Prediction of the response to anti-TNFs DMARDs|
75719543|NCT01005472|Drug|temozolomide|
75719544|NCT03742726|Device|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
75719545|NCT01005550|Drug|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
75719546|NCT01005550|Drug|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
75566097|NCT02946320|Device|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
75566098|NCT02946320|Device|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
76044290|NCT05489939|Drug|The compound methyl salicylate liniment|The compound methyl salicylate liniment (Ammeltz) has been developed by Japan Sendai Kobayashi Pharmaceutical Co. and has been listed in Japan for many years. It is composed of various components, such as methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol.
75566099|NCT02946320|Device|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
75420694|NCT01435070|Procedure|Kirschner wire fixation|"The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment."
76044291|NCT05484323|Other|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
76044292|NCT05484323|Other|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
75566100|NCT02928627|Other|Analysis of microRNA expression|sample analysis
75566101|NCT02928315|Drug|Magnesium Sulfate|The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
75719547|NCT01005550|Drug|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
75719548|NCT01005550|Drug|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
75719549|NCT03999580|Drug|vitamin D3|"3000 or 4000 UI/ day:~Weight at inclusion < 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion < 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance"
75719550|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po
75719551|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
75719552|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
75566102|NCT02928315|Other|control|100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
75566103|NCT00525746|Behavioral|Interview|Interview lasting about 50 minutes.
75566104|NCT04692090|Other|Yoga|"Each class started with a check-in period during which any questions or concerns could be raised, after which the patients were given 5 minutes for seated meditation and 10 minutes for Shavasana (lying down in a restorative position).~The following poses were instructed during the course: standing poses with mountain pose (tadasana), chair pose (utkatasana), extended triangle pose (utthita trikonasana), extended side angle pose (utthita parshvakonasana), warrior 1 (virabhadrasana 1), warrior 2 (virabhadrasana 2) and tree pose (vrikshasana). The intervention was applied twice a week for 10 weeks."
75566105|NCT00526409|Drug|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
75719553|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
75719554|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
75566106|NCT00526409|Drug|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
75874388|NCT03701035|Behavioral|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
75874389|NCT03701035|Behavioral|Non-aerobic training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
76044293|NCT05484323|Diagnostic Test|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
75566107|NCT00526409|Drug|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
75874390|NCT03337139|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
75420695|NCT01435070|Procedure|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
75420696|NCT01435083|Drug|Desmopressin|120 µg, oral lyophilisate, sublingual use
75566108|NCT00526409|Drug|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
75566109|NCT00526409|Drug|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
75566110|NCT00526409|Drug|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
75566111|NCT00526409|Drug|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
75420697|NCT01435096|Drug|BN80927|Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
75420698|NCT01435109|Behavioral|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
75420699|NCT01435109|Behavioral|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
75420700|NCT01435109|Behavioral|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
75420701|NCT01435135|Biological|ALVAC-HIV|1 mL per injection containing 10^6 CCID50/dose administered
75420702|NCT01435135|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
75420703|NCT01435135|Biological|ALVAC-HIV Placebo|1 ml per injection
75420704|NCT01435135|Biological|AIDSVAX B/E Placebo|1 ml per injection
75566112|NCT02928237|Device|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
75566113|NCT00526448|Drug|ribavirin|2000 mg/day
75566114|NCT00526448|Drug|ribavirin|1000-1200 mg/day
75566115|NCT00526448|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
75420705|NCT01435148|Procedure|Deep Brain Stimulation, implanted|Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.
75420706|NCT01435161|Drug|Nifedipine,|Nifedipine 30-60mg/day
75420707|NCT01435161|Drug|Telmisartan|Telmisartan 80-160mg/day
75420708|NCT01435200|Drug|Intravenous iron|Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
75420709|NCT01435213|Drug|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
75420710|NCT01435213|Drug|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
75566116|NCT00526448|Drug|epoetin beta|epoetin beta 450 UI/week
75566117|NCT02928159|Device|Mecta spectrum 5000Q device|LAP-ST and Right Unilateral (RUL) electrode placement.
75566118|NCT05647629|Procedure|Total hip arthroplasty|hip prosthesis surgery
75566119|NCT00525863|Drug|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to ~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
75566120|NCT02928198|Device|ABSORB BVS|
75566121|NCT04692545|Dietary Supplement|Immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
75566122|NCT04692506|Other|Probiotic|The study product is probiotic
75566123|NCT00527865|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
75566124|NCT00527865|Drug|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
75566125|NCT00526487|Device|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
75719555|NCT05734222|Procedure|A new method of repair of the abdominal wall of mid-lateral postoperative ventral hernias|"It is planned to study potential sources of bleeding and hematoma formation during SRM plastic surgery. On this basis, recommendations on the technique of the operation will be formulated.~It is supposed to find a way to preserve intercostal neurovascular bundles when performing SRM repair. This should improve the quality of abdominal wall reconstruction by preserving neurovascular bundles of muscles and reducing neuroalgic pain syndrome.~It is proposed to develop a method for combining retromuscular and subaponeurotic spaces in the treatment of mid-lateral hernias~It is planned to substantiate the effectiveness and expediency of the application of the developed surgical techniques based on the analysis of the immediate and long-term results of treatment."
75719556|NCT01005628|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
75566126|NCT00526487|Device|Endovascular Repair|Endovascular Repair
75566127|NCT02928081|Procedure|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
75719557|NCT00530842|Drug|Tiotropium plus Salmeterol|
75719558|NCT00530842|Drug|Fluticasone/Salmeterol|
75719559|NCT01005784|Drug|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
75719560|NCT01005784|Drug|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
75420711|NCT01435213|Drug|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
75420712|NCT01435213|Other|Cold pressor test|30-45 min cold pressor test of the foot
75420713|NCT01435213|Drug|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
75420714|NCT01435213|Drug|Placebo|A single dose of placebo (capsules) administered orally
75420715|NCT01435239|Device|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
75566128|NCT02928081|Procedure|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
75719561|NCT05734144|Procedure|The intraoperative ERCP has been performed immediately before LC|combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
75719562|NCT05734144|Procedure|POES followed by LC|Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
76044294|NCT05484323|Other|Cookie containing 2.5 g spirulina|TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
75719563|NCT01005862|Biological|PF-04360365|10 mg/kg, single dose administered intravenously
76044295|NCT05495867|Procedure|implant placement|implant placement in edentulous area
75719564|NCT01005862|Drug|Placebo|Placebo
75420716|NCT01435239|Device|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
75420717|NCT01435252|Drug|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
75719565|NCT01005940|Device|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
75719566|NCT05733988|Procedure|Bailout edge to edge|Edge to edge repair is the suture of the mitral valve leaflets in the regurgitant spot. It can be used as a bailout procedure when the first attempt of mitral valve repair with other surgical techniques is not satisfactory at intraoperative echo control. In this case, a second run of cardiopulmonary bypass is carried out, the heart is reopened and an edge-to-edge is performed.
75719567|NCT01006096|Drug|erlotinib|100mg tablet, once daily for 16 weeks
76044296|NCT05489861|Behavioral|M-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
75420718|NCT01435278|Device|Glucosanol|2 tablets taken 3 times a day.
75420719|NCT01435291|Drug|Advagraf Capsule|"Other Names:~FK506E~MR4~tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
75566129|NCT00526565|Behavioral|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
75420720|NCT01435291|Drug|Prograf Capsule|"Other Names:~FK506E~MR4~tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
75420721|NCT01435317|Device|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
75566130|NCT00526565|Behavioral|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
75719568|NCT01006096|Other|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
75719569|NCT01006174|Other|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
75719570|NCT01006174|Other|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
75719571|NCT01006174|Other|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
76044297|NCT05489861|Behavioral|F-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
76044298|NCT04423991|Device|COViage|Machine learning intervention
75420722|NCT01435330|Drug|BVS857|
75420723|NCT01435330|Drug|Placebo|
76044299|NCT05483699|Other|Squeezing a ball|The children in the squeezing soft ball group were given the ball before the procedure. They were told to squeeze and loosen the ball with the hand that was not used for the procedure while intravenous cannula was being inserted.
76044300|NCT05483699|Other|Blowing bubbles|The children in the blowing bubble group were shown the bubble blower before intravenous cannulation and they were told how bubbles were formed and how they would blow. During intravenous cannulation, the child blew the blower
76044301|NCT05483699|Other|Kaleidoscope|Children in the Kaleidoscope group were given the kaleidoscope before intravenous cannulation and they were shown how to use it. The children were told to look at the kaleidoscope during the procedure until the procedure ended
75566131|NCT02928003|Procedure|Lung surgery|Genetic analysis and questionnaires
75566132|NCT02946827|Dietary Supplement|Balanced low FODMAPs /gluten free diet|
75566133|NCT02946827|Dietary Supplement|Balanced gluten free diet|
75719572|NCT05733442|Other|Treatment as usual (TAU)|TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.
75719573|NCT05733442|Other|CHaRRM-CN|The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
75719574|NCT01006408|Procedure|Low Level Laser|Low Level Laser twice a week for 8 weeks
76044302|NCT05489315|Device|Positioning with peanut ball|If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.
75566134|NCT02928042|Other|Lactobacillus bacteria|Antimicrobial effects of Lactobacillus bacteria (LAB) and nisin bacteriocin on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
76044303|NCT05489315|Other|Traditional positioning|If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
76044304|NCT05495477|Device|EIT|Evaluation of ventilation distrinution during deep sedation through EIT
75420724|NCT01435343|Drug|fludarabine|30 mg/m2/day intravenously on days 1 to 4
75420725|NCT01435343|Drug|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
76044305|NCT05495399|Procedure|Spondylectomy|Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
76044306|NCT05495399|Radiation|SBRT|Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
76044307|NCT05483543|Drug|Pamiparib|Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
76044308|NCT04139213|Drug|buprenorphine/naloxone oral product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
76044309|NCT04139213|Drug|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
75420726|NCT01435343|Drug|cytarabine|2 g/m2/day intravenously on days 1 to 4
75420727|NCT01435343|Drug|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
75566135|NCT02946671|Biological|Mogamulizumab|Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.
75566136|NCT02946671|Biological|Nivolumab|Nivolumab (3.0 mg/kg) is administered.
75566137|NCT02927886|Procedure|Per-oral endoscopy pyloromyotomy|
76044310|NCT04139213|Other|Pharmacy maintenance addiction care|Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
76044311|NCT04139213|Drug|oral naltrexone|To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
75566138|NCT02927886|Procedure|Intrapyloric injection of Botulinum toxin|
75719575|NCT01006408|Procedure|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
75719576|NCT01006486|Other|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
75420728|NCT01435343|Drug|plerixafor|intravenously from days 1 to 4
75420729|NCT01435395|Drug|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
75420730|NCT01435434|Device|the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.|
75420731|NCT01435447|Drug|FLu-Bu-Cy|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
75420732|NCT01435473|Procedure|Cardiac Surgery|
76044312|NCT05495165|Other|Therapeutic education for patients in nutrition|Stakeholders give preventive therapeutic education recommandations in their specific expertize
76044313|NCT04112849|Diagnostic Test|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
76044314|NCT05495009|Other|Standard of care+virtual reality glasses|At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
75566139|NCT00526604|Behavioral|work related rehabilitation|"The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
76044315|NCT05494931|Procedure|corneal neurotomy|Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
76044316|NCT04071587|Device|Brain Computer Interface training|Training with RecoveriX system.
76044317|NCT04071587|Behavioral|Control|Standard physiotherapy and occupational therapy according to clinical routines.
76044318|NCT05494775|Drug|Anti-vascular endothelial growth factors (Anti-VEGFs)|Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
76044319|NCT03937037|Procedure|Saline irrigation|100ml saline irrigation after CBD stone removal with routine ERCP procedure
76044320|NCT04272203|Drug|ABBV-184|Intravenous (IV) infusion
75420733|NCT01435486|Drug|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
75420734|NCT01435486|Drug|Normal saline|Placebo with an equivalent volume of normal saline.
75420735|NCT01435499|Biological|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
75566140|NCT02946164|Behavioral|Stick To It|The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
75566141|NCT02946710|Biological|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
75566142|NCT02927730|Other|no interventions|no interventions
75566143|NCT04692402|Device|Solitaire™ thrombus retrieval device|After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.
75719577|NCT01006486|Other|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
75719578|NCT01006564|Other|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
75719579|NCT01006564|Other|Other|Insertion of gold seeds into prostate for image registration.
75719580|NCT01006720|Drug|Sugammadex|"Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
75719581|NCT01006720|Drug|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
75719582|NCT01006720|Drug|Saline|Saline 0.9% (Saline)
75719583|NCT04000048|Genetic|sequencing of the complete exome|Once the pathological diagnosis is confirmed (WHO 2016), a tumor fragment will be selected and frozen for each lobe. DNA extraction will be performed for each fragment. The samples (4 different DNAs per GDBG corresponding to the DNA extracted from each of the 3 lobes and the blood DNA) will be sent to the Montpellier Genomix platform for sequencing of the complete exome.
75719584|NCT05733052|Other|Polyester suture|A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
76044321|NCT05482841|Diagnostic Test|Lung ultrasound score|To evaluate the incidence of pulmonary atelectasis in the post-anesthesia care unit (PACU) using lung ultrasound.
76044322|NCT05494463|Device|Miller blade|After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
76044323|NCT05488925|Drug|Vitamin E|Evion, 400 mg
76044324|NCT05488925|Drug|Diclofenac Sodium|Voltral SR100, 100 mg
76044325|NCT05488925|Drug|Piroxicam|Feldene, 20 mg
76044326|NCT05488925|Drug|Tramadol|Tramal, 50 mg
76044327|NCT05482763|Drug|Terbinafine Topical Gel|Topical application of terbinafine
76044328|NCT05482763|Drug|Itraconazole 200 mg|systemic itraconazole pulse therapy
76044329|NCT05482763|Drug|Terbinafine 250 mg|systemic terbinafine
76044330|NCT05482763|Drug|Ciclopirox Topical Gel|Topical application of ciclopirox
75420736|NCT01435499|Drug|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
75420737|NCT01435538|Behavioral|Care pathway.|The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
75566144|NCT02927808|Behavioral|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
75566145|NCT02927652|Other|Questionnaires|"New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed."
75566146|NCT02946086|Behavioral|HABIT-ILE with prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation
75566147|NCT02946086|Behavioral|HABIT-ILE without prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
75566148|NCT00526643|Drug|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
75420738|NCT01435551|Other|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
75420739|NCT01435564|Behavioral|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
75566149|NCT00526643|Drug|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
75566150|NCT02945163|Drug|Tenofovir|Tenofovir Disoproxil Fumarate
75566151|NCT02945163|Drug|Lamivudine|Lamivudine
75566152|NCT02945163|Drug|Efavirenz|Efavirenz
75420740|NCT01435564|Behavioral|pedometer only|Participants in this group will receive only a pedometer.
75566153|NCT00526682|Dietary Supplement|Irvingia/cissus combo|
75566154|NCT02927574|Device|DCB|
75874391|NCT03337139|Behavioral|Standard Remote Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
76044331|NCT05482763|Drug|Amorolfine 50 MG/ML|Topical application of amorolfine
76044332|NCT05482685|Behavioral|Questionnaire|Conduct a 10-minute survey
75420741|NCT01435590|Procedure|Curette v/s endocervical brush|
75420742|NCT01435629|Drug|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
75420743|NCT01435642|Other|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
75566155|NCT02927574|Device|POBA|
75566156|NCT02927418|Behavioral|Strength & Conditioning|
75566157|NCT02927418|Behavioral|Control|
75566158|NCT00526760|Drug|Dexmedetomidine|
75566159|NCT00526838|Drug|XL228|1-hour IV infusion
76044333|NCT05482529|Other|Integrative omics|Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
76044334|NCT05482373|Dietary Supplement|Oleuropein from olive tree|The capsules intake will last for a total of 4 months.
75420744|NCT01435694|Behavioral|Lokomat (Hocoma, Switzerland)|
75566160|NCT02927379|Drug|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
75566161|NCT02927379|Drug|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
75566162|NCT02927379|Drug|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
75566163|NCT00526877|Drug|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
75566164|NCT02927496|Drug|Doxycycline|"Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)"
75874392|NCT03337139|Behavioral|Digital Data Sharing Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
76044335|NCT05482373|Dietary Supplement|Placebo|The capsules intake will last for a total of 4 months.
76044336|NCT05482295|Biological|Hepatitis B vaccine lot 1|3 doses of Hepatitis B vaccine lot 1
75566165|NCT02927496|Drug|Placebo|Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
75420745|NCT01435694|Behavioral|Conventional Therapy|
75566166|NCT00526916|Drug|[C-11]PBR28|
75420746|NCT01435707|Other|epidural steroid injection with Triamcinolone 40mg|epidural steroid injection with Triamcinolone 40mg
75566167|NCT02927535|Drug|TNF blockers monotherapy|
75566168|NCT00527969|Drug|HT1001 extract of Panax quinquefolius L|
75566169|NCT00527033|Drug|YM178|Oral
75566170|NCT00527033|Drug|Placebo|Oral
75420747|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 20 mg|Selective transforaminal epidural block with triamcinolone 20 mg
75566171|NCT02945891|Device|HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens|Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
75420748|NCT01435707|Other|caudal epidural steroid injection with Triamcinolone 20mg|caudal epidural steroid injection with Triamcinolone 20mg
75420749|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 40 mg|Selective transforaminal epidural block with triamcinolone 40 mg
75420750|NCT01435720|Biological|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
75420751|NCT01435720|Biological|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
75420752|NCT01435720|Biological|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
75420753|NCT01435720|Biological|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
75420754|NCT01435811|Biological|Norovirus challenge pool (GII.4, CIN-1)|Norovirus challenge pool (GII.4, CIN-1)
75420755|NCT01435837|Drug|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
75420756|NCT01435837|Drug|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
75420757|NCT01435837|Drug|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
75420758|NCT01435837|Drug|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
75420759|NCT01435850|Procedure|primary total hip arthroplasty|All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
75420760|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
75566172|NCT02945072|Procedure|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
75566173|NCT02945072|Procedure|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
75566174|NCT02924922|Procedure|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
75719585|NCT01006876|Drug|Coumadin|Continuous oral Coumadin therapy through the catheter ablation procedure
75719586|NCT01006876|Drug|Coumadin|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
75719587|NCT01006876|Drug|Coumadin|Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
75719588|NCT05043220|Device|PPG and PROM|description will follow
75719589|NCT01006954|Drug|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
75719590|NCT01006954|Drug|Flare up|Flare up protocol in poor responders for IVF/ICSI
75719591|NCT05732818|Device|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
75719592|NCT01007188|Other|1.5PD almonds|average American diet plus 1.5 oz per day almonds
75420761|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
75420762|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
75420763|NCT01435876|Procedure|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
75420764|NCT01435876|Procedure|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
75420765|NCT01435876|Procedure|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
75420766|NCT01435876|Procedure|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
75719593|NCT01007188|Other|3.0PD almonds|average American diet plus 3.0 oz per day almonds
75719594|NCT01007188|Other|Base (without almonds)|average American diet without almonds
76044337|NCT05482295|Biological|Hepatitis B vaccine lot 2|3 doses of Hepatitis B vaccine lot 2
76044338|NCT05482295|Biological|Hepatitis B vaccine lot 3|3 doses of Hepatitis B vaccine lot 3
76044339|NCT05482295|Biological|Hepatitis B vaccine (registered)|3 doses of Hepatitis B vaccine (registered)
76044340|NCT05482217|Behavioral|Psychoeducation, problem solving and rehearsal (cognitive behavioural intervention)|"The highlights of the intervention.~Session 1: Rapport building and knowledge of HIV~Session 2: Identifying and Dealing with barriers to good adherence~Session 3: Identifying and dealing with problems in relation to depression and adherence:~Session 4: Identifying and dealing with negative cognitions, handling privacy, accessing social Support, and adjusting to HIV and antiretroviral treatment~Session 5: Rehearsal of practical tips on adherence, handling slips, and strategies to improve quality of life.~All sessions involved brief periods of relaxation, homework, and a homework review. The last session was concluded with the assessment of satisfaction with the program. The programs were conducted for 60 minutes weekly for five weeks.~They were delivered by a trained lay counselor and supervised by the principal investigator for five weeks."
76044341|NCT05482139|Procedure|Incisional hernia repair with mesh|open or laparoscopic repairs of incisional hernia with mesh
75420767|NCT01435915|Drug|Ropinirole|"Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period."
76044342|NCT04069091|Behavioral|'Enjoy your Bump' (iloodottaa.fi) online self-help intervention|"The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi)."
75420768|NCT01435941|Drug|Non-steroidal anti-inflammatory drug (NSAID)|Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
75420769|NCT01435941|Drug|Triptan|Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
75420770|NCT01435954|Drug|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
75420771|NCT01435954|Drug|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
75420772|NCT01435967|Other|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
75420773|NCT01435980|Procedure|Gastric Bypass|basal treatment and Gastric Bypass
75420774|NCT01435980|Drug|Exenatide|basal treatment and Exenatide
75420775|NCT01435993|Drug|GSK1223249|Intravenous infusion
75420776|NCT01435993|Other|Saline placebo|placebo intravenous infusion
75420777|NCT01436058|Biological|mesenchymal stem cell|intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
75420778|NCT01436097|Behavioral|Information provision intervention|Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
75420779|NCT01436097|Behavioral|information provision + flat incentive|Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
75420780|NCT01436097|Behavioral|Information provision + tiered incentive|In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.
75420781|NCT01436097|Behavioral|Usual Care|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
75719595|NCT05035576|Drug|OPN-019|400 mg OPN-019, 2 sprays per nostril (one dose)
75719596|NCT03882424|Biological|TRS003|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
75719597|NCT03882424|Biological|China-approved Bevacizumab|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
75719598|NCT03882424|Biological|US-licensed Avastin|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
75719599|NCT05732662|Radiation|SBRT|24-50Gy/8-12.5Gy/3-4f
75719600|NCT05732662|Drug|Cadonilimab|10 mg/kg,q3w
75719601|NCT03879772|Drug|Mometasone furoate nasal spray|intranasal administration
75719602|NCT03879772|Drug|Beclomethasone dipropionate nasal spray|intranasal administration
75719603|NCT03879772|Drug|Placebo nasal spray|intranasal administration
75420782|NCT01436123|Other|Stenting and micro-infusion of NP|Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
75566175|NCT02924922|Procedure|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
75566176|NCT02924922|Device|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
75566177|NCT02924922|Device|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
75566178|NCT02924922|Drug|Mannitol|
75566179|NCT04692896|Drug|lidocaine|different concentrations of lidocaine with same concentration of adrenaline
75566180|NCT02927340|Drug|Lorlatinib|
75566181|NCT00528008|Other|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
75566182|NCT00528008|Other|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
75420783|NCT01436123|Device|Implantation of everolimus-eluting stent|Put stent in ischemia-related coronary artery by indications for PCI
75420784|NCT01436136|Other|Control|GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
75566183|NCT02925039|Other|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
75566184|NCT02925039|Other|Treatment as usual|Treatment as usual
75566185|NCT02946203|Other|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
75566186|NCT02946203|Other|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
75566187|NCT02924961|Device|Triathlon PS total knee system with mobile-bearing|
75566188|NCT02924961|Device|Triathlon PS total knee system with fixed-bearing|
75566189|NCT04692740|Drug|Chlorambucil, Oral, 2 Mg|Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.
75566190|NCT02925000|Drug|TLC178|TLC178
75566191|NCT04692857|Procedure|supra inguinal fascia iliaca block|injection of 30,40 or 50 ml of 0.2 ropivacaine .
75420785|NCT01436136|Other|Intervention Group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
75420786|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours
75420787|NCT01436188|Procedure|Alternate frequency CSR sampling procedure|an alternative frequency of CSF sampling procedure for 36 hours
75420788|NCT01436188|Procedure|Standard frequent CSR sampling procedure with 800 mg ibuprofen|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
75420789|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours.
75420790|NCT01436188|Procedure|Alternative lower frequency CSR sampling procedure|an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
75566192|NCT00528047|Drug|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
75566193|NCT01580462|Other|Observational study|"Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
75566194|NCT02926989|Drug|Plasmalyte Glucos 50 mg/mL|Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
75566195|NCT02926989|Drug|0.45% saline in 5% dextrose|Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
75719604|NCT03879772|Drug|Chlorpheniramine maleate syrup|oral administration
75719605|NCT01007266|Behavioral|Assignment of a Lay Patient Partner|
75874393|NCT05439096|Other|Functional Exercise|Among Functional Exercises, cobra position is most effective in reducing pelvic pain while others are cat and fish position.Kegel exercises along with other strengthening activities for pelvic floor muscles have been accounted for in writing to favorably affect primary dysmenorrheal.
75420791|NCT01436214|Drug|APC-100|Daily oral, dose escalation, 28-day cycle(s)
76044343|NCT05494307|Drug|Terbutaline|Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
76044344|NCT05494307|Drug|Danazol|Orally danazol at a dose of 200 mg twice daily for 16 weeks
76044345|NCT05488379|Other|Group well child care|Beginning with the 1-month well child care visit, mother-infant dyads will participate in well child care together, with subsequent visits occurring at the American Academy of Pediatrics recommended intervals (2, 4, 6, 9, 12, 15, and 18 months of age).
76044346|NCT05494151|Diagnostic Test|Investigation of the metabolic substrate|A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
75420792|NCT01436240|Behavioral|questionnaire administration followed by cognitive interviews|Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
75566196|NCT04692272|Behavioral|Exercise in the XBOX kinect|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
75566197|NCT02924805|Other|Telemedical care|Telemedically guided care based on a standard operating procedure
75566198|NCT02924649|Procedure|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
75566199|NCT00528125|Procedure|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
76044347|NCT05482061|Other|visual analog scale (VAS).|The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
75566200|NCT00528125|Procedure|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
75420793|NCT01436331|Other|Treatment As Usual (TAU)|Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
75566201|NCT02945696|Procedure|laparoscopic guided nerve blocks|It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
75566202|NCT02945696|Drug|Ropivacaine|Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
76044348|NCT05481983|Other|Walk exercise|The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
76044349|NCT05481983|Other|One-on-one clinical exercise training|One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
75566203|NCT02926872|Other|There is no intervention in the study|
75566204|NCT02926794|Behavioral|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
75566205|NCT02926794|Behavioral|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
75566206|NCT02926794|Behavioral|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
75566207|NCT02926794|Behavioral|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
75566208|NCT00528164|Behavioral|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
75566209|NCT02924766|Drug|Niraparib|Participants will start with niraparib 200 mg once daily.
75566210|NCT02924766|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4*60 mg) once daily orally.
75566211|NCT02924766|Drug|Abiraterone Acetate|Participants will receive 1000 mg (4*250mg) once daily.
75566212|NCT02924766|Drug|Prednisone|Participants will receive 10 mg (1*5 mg twice daily).
75719606|NCT05027620|Other|Motor-cognitive exercise therapy in the home|"Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period."
75719607|NCT01007344|Dietary Supplement|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
76044350|NCT05488223|Dietary Supplement|AGPI ω-3 (Triple Strength Fish Oil®)|The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
75420794|NCT01436331|Behavioral|TAU+CBT for pts+Family Intervention+CM.|The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
75420795|NCT01436383|Other|Hypoxic exposure|Hypoxic exposure
75420796|NCT01436409|Other|echography|echography during labor
75566213|NCT02926755|Procedure|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
75566214|NCT00528281|Drug|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
75566215|NCT00528281|Drug|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
75566216|NCT00528320|Device|Ovatio CRT|
75566217|NCT02926599|Behavioral|Personal Optimization Training|
75566218|NCT01580501|Drug|Tadalafil and Sildenafil|PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
75420797|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV003|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
75420798|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV005|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
75420799|NCT01436422|Biological|Placebo|One subcutaneous injection at Day 0 and Day 180 of placebo
75420800|NCT01436448|Drug|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
75566219|NCT02924532|Biological|immediate post operative bioassay of Parathyroid Hormone|
75566220|NCT00528359|Drug|quetiapine or olanzapine or risperidone or aripiprazole|
75719608|NCT01007344|Dietary Supplement|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
75719609|NCT01007422|Behavioral|telephone-based intervention|
75719610|NCT01007422|Other|communication intervention|
75719611|NCT01007422|Other|intervention by caregiver|
75719612|NCT01007422|Other|medical chart review|
75719613|NCT01007422|Other|survey administration|
75719614|NCT01007422|Procedure|end-of-life treatment/management|
75719615|NCT01007422|Procedure|pain therapy|
75719616|NCT01007422|Procedure|psychosocial assessment and care|
75719617|NCT01007500|Drug|Dexamethasone|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
75420801|NCT01435902|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
76044351|NCT05488223|Dietary Supplement|AGPI ω-3 + MUFA (avocado oil)|AGPI ω-3 (0.9g) + MUFA (avocado oil) (0.9g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
75420802|NCT01435902|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
75420803|NCT01436474|Drug|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
75420804|NCT01436474|Drug|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
75420805|NCT01436513|Drug|Premarin reference tablet (fasted)|Premarin reference tablet, single dose, fasted conditions
75566221|NCT02946008|Radiation|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
75566222|NCT02946008|Procedure|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
75566223|NCT02944721|Genetic|Genetical analyses|
75719618|NCT01007500|Drug|Ondansetron|Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
75719619|NCT05725252|Drug|NVP-2203|NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
76044352|NCT05488223|Dietary Supplement|MUFA (avocado oil) (1.8g)|MUFA (avocado oil) (1.8g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
76044353|NCT05493917|Biological|an inactivated SARS-CoV-2 vaccine named BBIBP-CorV|Completed 2 doses of an inactivated SARS-CoV-2 vaccine more than 6 months ago and received a third dose of the vaccine
76044354|NCT05481515|Device|Pulse oximetry|Pulse oximeters will be evaluated against routine arterial blood gas measurements
75420806|NCT01436513|Drug|Premarin new tablet (fasted)|Premarin new tablet, single dose, fasted conditions
75420807|NCT01436513|Drug|Premarin reference tablet (fed)|Premarin reference tablet, single dose, fed conditions
75420808|NCT01436513|Drug|Premarin new tablet (fed)|Premarin new tablet, single dose, fed conditions
75420809|NCT01436539|Drug|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
75420810|NCT01436539|Drug|Adefovir Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
75420811|NCT01436565|Drug|MM-121 (SAR256212)|"Pharmaceutical form:solution~Route of administration: Intravenous"
75420812|NCT01436565|Drug|SAR245408|"Pharmaceutical form:tablet~Route of administration: oral"
75566224|NCT02944721|Other|Chronic pain identification questionnaires|
75566225|NCT02944721|Other|Neurophysiological and psychophysical evaluations|
75566226|NCT02944721|Other|Quality of life questionnaires|
75719620|NCT05725252|Drug|NVP-2203-R|administration of active comparator
75719621|NCT00642954|Drug|Vorinostat|Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
75719622|NCT00642954|Drug|Lenalidomide|Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
75719623|NCT00642954|Drug|Dexamethasone|Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
75719624|NCT01007890|Other|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
75719625|NCT00816660|Biological|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
75719626|NCT00816660|Biological|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
75420813|NCT01436578|Drug|Posaconazole oral suspension 40 mg/mL|Posaconazole oral suspension prescribed according to the current local label
75420814|NCT01436604|Other|Cardiac MRI|"The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~Sequences locating anatomical~T2 black blood (such as ESF)~rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage."
75420815|NCT01436617|Other|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
75420816|NCT01436630|Other|Step Test and Six Minute Walk.|The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
75420817|NCT01436669|Device|Home Telemonitoring System (The Zodiac, Philips Health care)|Full blood count (FBC) home tele-monitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count).
75420818|NCT01436695|Device|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
75420819|NCT01436721|Device|Surgicel® absorbable Haemostat|The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
75420820|NCT01436734|Other|Fasting glycemia|no intervention
75420821|NCT01436734|Other|Hypoglycemia|Insulin induced hypoglycemia
75420822|NCT01436747|Drug|Paricalcitol|2 micrograms daily, peroral, 24 weeks
75566227|NCT02924493|Other|Diet low in fermentable carbohydrates (low FODMAP diet)|The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
75420823|NCT01436747|Drug|Placebo|2 micrograms daily, peroral, 24 weeks
75420824|NCT01436786|Other|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
75420825|NCT01436812|Procedure|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
75420826|NCT01436812|Procedure|positive end expiratory pressure|PEEP 0 cmH2O
75420827|NCT01436825|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
75420828|NCT01436838|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
75420829|NCT01436851|Biological|Storage mite allergen extracts|Nasal provocation with increasing doses of storage mite allergen extracts
75420830|NCT01436877|Device|Insertion of Temporary Implantable Nitinol Device (TIND)|Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
75420831|NCT01436890|Drug|Revamilast|Tablet. Low dose, Once daily for 12 weeks
75420832|NCT01436890|Drug|Revamilast|Medium dose, Once daily for 12 weeks
75420833|NCT01436890|Drug|Revamilast|High dose, Once daily for 12 weeks
75566228|NCT00527150|Drug|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
76044355|NCT05481515|Device|Spectrophotometry|Spectrophotometry will be used to measure skin tone
75566229|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
75566230|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
75719627|NCT00819000|Drug|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
76044356|NCT03906227|Device|ENUMERATION OF CD5+ B Cells|A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
75420834|NCT01436890|Drug|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
75420835|NCT01436903|Device|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
75420836|NCT01436916|Drug|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
75420837|NCT01436916|Drug|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
75420838|NCT01436929|Drug|Silymarin|Silymarin 140mg 1tab bid for 8 weeks
75420839|NCT01436929|Drug|Placebo|Placebo 1tab bid
75420840|NCT01436942|Behavioral|Exercise|"The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes."
75420841|NCT01436955|Drug|Placebo|multiple oral doses
75420842|NCT01436955|Drug|RG1662|Cohorts receiving multiple oral doses
75420843|NCT01436981|Procedure|CABG|Preparation of artery mammaria interna
76044357|NCT05487521|Drug|Methylprednisolone and or prednisolone|we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
75420844|NCT01436994|Procedure|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
75420845|NCT01436994|Procedure|Dose Titration|"The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil."
75420846|NCT01436994|Drug|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
75566231|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
75566232|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
75719628|NCT00640146|Drug|Methylnaltrexone bromide|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
75719629|NCT00640146|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
75566233|NCT00527189|Behavioral|Balance Exercises|Home based balance exercises based on Otago Exercise programme
75719630|NCT00819078|Drug|Bupropion|300 mg/d
75719631|NCT00819078|Drug|Placebo|no dosage
76044358|NCT05481281|Drug|Dexmedetomidine|I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion
76044359|NCT05481281|Drug|Ketamine|0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
76044360|NCT05487443|Drug|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
75719632|NCT01008046|Drug|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
76044361|NCT05481203|Behavioral|The Kaleidescope|During the nasopharyngeal swab collection process, the researcher held a kaleidoscope to each child's eye, leisurely turning it and asking about the colors and shapes seen within it.
75420847|NCT01436994|Drug|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
75420848|NCT01436994|Drug|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
75420849|NCT01437007|Drug|TKM-080301|
75420850|NCT01437020|Drug|SCH708980 Anti-IL-10 monoclonal|Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
75420851|NCT01437020|Drug|AmBisome|Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
75420852|NCT01437046|Drug|Doxazosin|Doxazosin 16mg/day
76044362|NCT05481203|Behavioral|The visual illusion cards|Just before the nasopharyngeal swab participants were allowed to check the cards andwere askedwhat they saw in them.
75566234|NCT00527228|Drug|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
75566235|NCT00527228|Drug|placebo|
75566236|NCT02926482|Behavioral|Prescriber Recruitment Bundle (PRB)|The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
75566237|NCT00527267|Drug|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
75719633|NCT01008046|Drug|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
75719634|NCT00819312|Drug|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
75719635|NCT01008124|Other|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
75719636|NCT01008124|Other|Placebo maneuver|3 cycles placebo maneuver initial session.
75719637|NCT05006560|Other|Pulmonary Rehabilitation (usual care)|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days.
75719638|NCT05006560|Other|Pulmonary Rehabilitation (usual care) + familiarization with components of the aftercare program|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days. Additionally, participants use several functions of the aftercare program's mobile application. This includes using the application during endurance and strength training (as part of usual care) and using a consumer activity monitor to count daily steps.
75719639|NCT05006560|Other|After care: Exercise and physical activity promotion|"Participants will agree with their therapist on an exercise plan (endurance and resistance training) that are made available for participants through the study's mobile app. Frequency and duration of endurance and strength training are prescribed in accordance with exercise guidelines for persons with COPD. However, they can be adjusted according to participants needs.~Next to the exercise, participants receive physical activity counseling. This consists of phone or video calls with a therapist, group video calls with a therapist, a complementary e-learning course as well as complementary functions of the study's mobile app."
75874394|NCT05439096|Other|High Frequency Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation, best treat primary dysmenorrhea. Transcutaneous Electrical Nerve Stimulation is proposed as an incredible spasm decrease, lessening torment, decline of analgesics and improving personal satisfaction in primary dysmenorrhea patients.
76044363|NCT05493527|Device|noninvasive high frequency oscillatory ventilation|"A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~a frequency of 10 Hertz ( range, 8-12 Hz);~an inspiratory time of 50% (1:1)~an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
76044364|NCT05493527|Device|noninvasive positive pressure ventilation|"NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~Peep ranging from 5 to 10 cmH2O,~Peak inspiratory pressure range 15-25 cmH2O~Rate range 40-50 breath/minute~FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
76044365|NCT02558231|Drug|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
75420853|NCT01437046|Drug|Placebo|
76044366|NCT02558231|Drug|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
75719640|NCT05005624|Other|ADL performance|"All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
76044367|NCT02558231|Drug|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
76044368|NCT05487365|Device|Comunicare Solutions Smartphone Application|The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.
75566238|NCT00527267|Drug|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
75719641|NCT00317473|Biological|FMP1/AS02A Malaria vaccine|Subjects vaccinated with FMP1/AS02 vaccine
75420854|NCT01437059|Drug|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
75420855|NCT01437059|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
75420856|NCT01437072|Other|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
75420857|NCT01437137|Device|classic-laryngeal mask airway (c-LMA)|Insertion of c-LMA
75420858|NCT01437137|Device|i-gel™|Insertion of I-gel
75420859|NCT01437150|Device|Anatomical locking plate|This is a new fixation treat for acetabular posterior wall fracture.
75420860|NCT01437150|Procedure|The Reconstructive Plate|Reconstructive plate was used very common in treatment of acetabular fracture.
75566239|NCT02924298|Behavioral|SLIMM|Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
75566240|NCT02924415|Behavioral|Tele-care support|Psychoeducation treatment based on telemedicine
75566241|NCT02924415|Other|Control group|Standard care
75566242|NCT02944994|Other|Unified protocol|This is a transdiagnostic cognitive behavioral therapy
75566243|NCT02944994|Other|Routine Care|This arm will reflect typical care received in routine mental health care
75566244|NCT02924181|Device|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
75566245|NCT00527306|Dietary Supplement|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
75566246|NCT02926287|Other|Ambulatory surgery|All patients who accepting participation to the study and operated for prolapse surgery, Patient eligible for Ambulatory surgery and return home on the same day if delivery criteria are satisfied ( Chung criteria+tsuccessful trial of void) Patient not eligible for Ambulatory surgery are included as control group
75719642|NCT00317473|Biological|Imovax Rabies vaccine|Subjects vaccinated on corresponding FMP1/AS02A vaccination days
75719643|NCT00530218|Drug|Ganciclovir|Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
75719644|NCT00761267|Drug|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days."
76044369|NCT05487365|Other|Completing a quality of life (QOL)-questionnaire|Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
75719645|NCT00761267|Drug|Fluconazole|Subjects may be switched to oral fluconazole [6-12 mg/kg/day (not to exceed 800mg/day] provided they meet specified criteria. Maximum total treatment duration is 49 days.
75719646|NCT03982303|Drug|Hemay102|Hemay102 was administered through i.v. infusion for 4hrs.
76044370|NCT05487287|Device|Kinematic computational analysis of the hand (Leap Motion device)|"Kinematic computational analysis exercises:~Finger extension~Wrist extension~Finger separation~Finger clamp"
76044371|NCT04269785|Device|Cryoballoon ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)
75420861|NCT01437163|Device|TopHat 655 rejuvenation system|TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
75719647|NCT04099979|Other|No Intervention|There is no intervention for this study
75719648|NCT00303667|Biological|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
75719649|NCT00303667|Biological|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10^7 cells/kg.
75420862|NCT01437163|Device|Laser and/or Light Hair Rejuvenation System|A red incandescent light source replaces all lasers and light emitting diodes.
75420864|NCT01437215|Device|Ventana Fenestrated Stent Graft System|Endovascular repair of juxtarenal or pararenal aortic aneurysm
76044372|NCT04269785|Device|Radiofrequency ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
76044373|NCT04275011|Other|Progressive Resistance and Impact Exercise|Full body resistance and impact exercises will be performed twice a week for 30-45 minutes over a 6 month period. There will be at least one day of rest between scheduled exercise sessions. Participants will be individually prescribed variations of push, pull, squat, lift and carry movements targeting major muscle groups that they can safely complete, and accessory exercises to help develop movement patterns. Exercises will challenge both the upper and lower body using functional movement patterns. Each muscle group will be trained twice a week. During the first month, participants will focus on completing exercises with good form at a low intensity. Once form is mastered, exercises will be progressed (by increasing load, or challenge of the movement) to a moderate to high exercise intensity (80-85% 1RM) so that the participant can complete a maximum of 8 (~80% 1RM) or 6 (~85% 1RM) repetitions with 1-2 repetitions in reserve for 3 sets at a rating of perceived exertion (RPE) of 8-9.
75420865|NCT01437228|Drug|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
75420866|NCT01437228|Drug|placebo|NO İNTERVENTİON
75719650|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
75719651|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 40 mg/m^2 on Days -18 through -14
75719652|NCT00303667|Procedure|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
75420867|NCT01437254|Drug|CPERT|Single 340 MBq CPERT scan in first 10 subjects
75420868|NCT01437254|Drug|GPERT|Single 340 MBq GPERT scan in up to 20 case-matched controls
75566247|NCT02924259|Device|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
75566248|NCT02944916|Device|IryPump R Set|
75566249|NCT02924454|Drug|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
75566250|NCT02924454|Drug|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
75566251|NCT02924454|Drug|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
75566252|NCT02924454|Drug|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
75719653|NCT00303667|Radiation|total body irradiation|Administered on Day -13, 200 cGy two times.
76044374|NCT04275011|Other|Static Balance and Postural Exercise|Participants in the attention control group will perform static posture and balance exercises (e.g., low intensity yoga poses) and will be given the same attention as the participants in the intervention group. The small group exercises will be performed twice a week, 30-45 minutes per session, over 6 months, with at least one day of rest between each session. The exercise program will be supervised by a certified personal trainer and yoga instructor who is BoneFit trained.
75566253|NCT04692038|Device|Forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS|During the operation, under the guidance of Augmented Reality Navigation, the bronchoscope will reach the location of the target pulmonary nodules, and the EBUS probe will be inserted through the bronchoscope working channel, and gradually approach the target nodules to obtain EBUS images. After typical EBUS images are observed and the location is confirmed, the EBUS probe will be withdrawn and biopsy forceps and puncture biopsy needle will be used to obtain samples at the target locations respectively.
75566254|NCT02924337|Drug|Placebo|
75719654|NCT00303667|Biological|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
75719655|NCT00303667|Drug|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
76044375|NCT05481047|Device|HPI|based on HPI values, clinicians will administer drugs or fluids in order to avoid arterial hypotension
75566255|NCT02924337|Drug|Imeglimin|
75566256|NCT02924337|Drug|Moxifloxacin|
75566257|NCT00528515|Drug|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
75566258|NCT00528515|Drug|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
75566259|NCT02923986|Drug|BP1001 (varying dose)|BP1001 (varying dose)
75566260|NCT02923986|Drug|BP1001 (fixed dose)|BP1001 (fixed dose)
75719656|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
75719657|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 35 mg/m^2 on Days -18 through -14
75719658|NCT01066741|Drug|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
75566261|NCT02923986|Drug|Dasatinib|Dasatinib
75566262|NCT00528554|Procedure|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
75566263|NCT00528554|Procedure|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
75566264|NCT02926248|Drug|Colchicine|Colchicine is an anti-fibrotic and anti-inflammatory drug
75566265|NCT02926248|Other|Placebo|
75566266|NCT02945735|Behavioral|Attention Modification|Feedback according to participants' viewing patterns, in order to modify their attention.
75566267|NCT02924025|Behavioral|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
75874395|NCT03964363|Behavioral|Unsupervised home-based physical prehabilitation|Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
75420869|NCT01437280|Biological|CGTG-102|"VP=virus particle~Dose Level 1: 3x10^10 VP/injection~Dose Level 2: 1x10^11 VP/injection~Dose Level 3: 3x10^11 VP/injection~Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).~Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.~The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.~Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used."
75420870|NCT01437293|Drug|L-dopa / carbidopa / entacapone (LCE)|For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
75420871|NCT01437306|Drug|Lofexidine HCl|400 mcg (2 x 200 mcg tablets) administered orally as a single dose
75420872|NCT01437358|Other|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
75566268|NCT00528593|Drug|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
75566269|NCT00528632|Other|Specimen biopsy and serum laboratory tests|"Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides"
75566270|NCT02926326|Drug|BCT197|A single dose of BCT197
75719659|NCT01066741|Drug|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
75566271|NCT02926326|Drug|Azithromycin|3 daily doses of Azithromycin
75566272|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
75566273|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
75719660|NCT00761189|Drug|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
75874396|NCT03710447|Other|HIIT + WB-EMS|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling."
75874397|NCT03710447|Other|WB-EMS + HIIT|"12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling."
75566274|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
75566275|NCT02924103|Device|Contamination free bacterial swab|"A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule."
75719661|NCT01064869|Behavioral|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~Motivational interviewing based on stages of change model to encourage change and adherence~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
75719662|NCT01062295|Device|Siesta-System|
75874398|NCT03710447|Other|HIIT + CST|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling."
75566276|NCT00528710|Dietary Supplement|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
75420873|NCT01437371|Drug|- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
75566277|NCT02926443|Other|Upper Extremity Neuromuscular Training Program|Neuromuscular and strengthening shoulder exercises in a group setting.
75566278|NCT02926443|Other|Usual Physiotherapy Care|One-on-one physiotherapy care in a clinical setting.
75420874|NCT01437384|Drug|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
75420875|NCT01437410|Procedure|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
75420876|NCT01437436|Procedure|ventilation tube|ventilation tube insertion
75420877|NCT01437462|Drug|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
75420878|NCT01437462|Drug|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
75566279|NCT00528749|Other|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
75566280|NCT02924142|Device|OT Cap attachment|The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
75566281|NCT02945462|Biological|autologous mesenchymal stem cells|Patients will be injected with autologous mesenchymal stem cells, intracavernously
75566282|NCT00528827|Drug|Cardene® I.V.|"5 mcg/kg/min Cardene I.V.~2.5 mcg/kg/min Cardene I.V.~0.5 mcg/kg/min Cardene I.V."
75566283|NCT02926170|Drug|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
75566284|NCT02926170|Drug|acenocumarol|Doses will be adjusted according to INR
75566285|NCT04691765|Drug|Kineret|escalating doses of drug will be administered to 3 groups of 4 patients for 7 months
75566286|NCT04689204|Drug|CTA30X|CTA30X cell injection by intravenous infusion
75566287|NCT04691687|Drug|Furosemide|IV loop diuretic therapy
75566288|NCT04691687|Drug|IV Solution|IV Placebo comparator
75719663|NCT01062295|Device|Standard headrest|
75719664|NCT00529516|Biological|Fluarix|Single dose, Intramuscular injection
75719665|NCT00529516|Biological|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
75719666|NCT01008358|Biological|CP 675,206|
75566289|NCT02923908|Other|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
75566290|NCT02923908|Other|Voice Recording|A voice recording will be made for the duration of the tasting period.
75566291|NCT02923908|Other|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
75566292|NCT02923908|Other|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
75566293|NCT04110327|Device|MicroStent|Treatment of arterial stenosis or occlusion with the MicroStent Perihperal Vascular Stent System
75719667|NCT01008436|Drug|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
75420879|NCT01437475|Biological|Sci-B-Vac|10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
75420880|NCT01437514|Radiation|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
75420881|NCT01437553|Device|iMAP|IVUS and iMAP analysis for acute coronary syndromes
75420882|NCT01437566|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
75566294|NCT04049175|Drug|Treatment A|Tablet of CHF 6532
75566295|NCT04049175|Drug|Treatment B|Tablet of CHF 6532
75566296|NCT04049175|Drug|Treatment C|Tablet of CHF 6532
75566297|NCT04049175|Drug|Treatment D|Tablet of CHF 6532 placebo
75566298|NCT02926131|Other|Blood sampling|"One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system"
75719668|NCT01008436|Drug|Control|Traditional surgical Hemostasis
75719669|NCT00316693|Biological|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
75420883|NCT01437566|Drug|GDC-0941|Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
75420884|NCT01437566|Drug|GDC-0941 Matching Placebo|Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
75420885|NCT01437566|Drug|GDC-0980|Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
75420886|NCT01437566|Drug|GDC-0980 Matching Placebo|Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
75566299|NCT04692311|Device|an intelligent client-centred task-oriented training|3 x 45min of training with i-ACT system
75719670|NCT00316693|Biological|Aimmugen™|Intramuscular injection, 3 doses
75719671|NCT01008514|Procedure|adjuvant therapy|
75719672|NCT01008514|Radiation|accelerated partial breast irradiation|
75719673|NCT01008514|Radiation|intracavitary balloon brachytherapy|
75719674|NCT05099692|Behavioral|filling out the questionnaire|all participants in our study are invited to choose at least 1 question in 15 questions or provide their own questions regarding their doubt about the CR after filling in their personal information
75566300|NCT04692311|Other|Semi-structured interview|Participants, patients and therapists, were invited to a semi-structured interview after training period.
75420887|NCT01437579|Procedure|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
75420888|NCT01437579|Procedure|cystoscopy|cystoscopy under general anesthesia
75420889|NCT01437592|Drug|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
75420890|NCT01437618|Drug|FOLFOXIRI plus bevacizumab|"BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by~IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by~5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks"
75420891|NCT01437631|Procedure|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
75566301|NCT02923869|Drug|Levobupivacaine|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
75566302|NCT02923869|Drug|Bupivacaine|Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
75566303|NCT00528905|Drug|AZD3480|oral capsule
75566304|NCT02923791|Biological|Filgrastim Hospira|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
75566305|NCT02923791|Biological|US-Approved Neupogen|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
75719675|NCT01008592|Drug|levocetirizine or placebo|oral administration, single tablet, 5 mg.
75566306|NCT02926092|Diagnostic Test|Observation|Observation of progression of disease over time
75719676|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
75719677|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
75874399|NCT03710447|Other|CST + HIIT|"12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling."
75566307|NCT00527462|Procedure|Bronchoscopy|bronchoscopy with segmental allergen challenge
75420892|NCT01437644|Drug|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
75420893|NCT01437670|Drug|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
75420894|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
75420895|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
75420896|NCT01437696|Other|placebo|No liquid cholecalciferol will be added to the food.
75566308|NCT00527462|Other|Exposure to ultrafine carbon black particles|Exposure to ultrafine carbon black particles for 2 hours
75566309|NCT04689243|Procedure|ALA-PDT|Low concentration ALA-PDT, 3 times a week.
75566310|NCT04689243|Procedure|red light|red light, 3 times a week.
75566311|NCT00527540|Drug|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
75566312|NCT02926053|Procedure|Surgical removal of tumor tissue for T cell production|Surgical removal of > 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
75566313|NCT02926053|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
75719678|NCT00316303|Drug|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
75719679|NCT00316303|Behavioral|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
75719680|NCT01062529|Drug|Somatostatin|4 h of 150 microgram infusion
75719681|NCT00760877|Drug|Nilotinib|Supplied in 200 mg capsules
75719682|NCT00760877|Drug|Imatinib|Supplied in 100 mg and 400 mg capsules
75719683|NCT03977545|Diagnostic Test|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
75719684|NCT00302731|Drug|Estradiol , estriol , progesterone|
75719685|NCT00302731|Drug|estradiol, progesterone|
75719686|NCT00302731|Drug|estriol, progesterone|
75420897|NCT01437748|Drug|Indacaterol maleate|Dry powder, 300 mcg, only one inhalation with 24 hours duration
75420898|NCT01437748|Drug|Tiotropium bromide|Dry powder, 18 mcg, only one inhalation with 24 hours duration
75420899|NCT01437761|Device|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
75420900|NCT01437774|Device|thrombectomy (ReStore or Merci)|Each arm will use either ReStore or Merci as the primary thrombectomy device
75420901|NCT01437800|Drug|Glimepiride / Extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
75420902|NCT01437813|Drug|Glimepiride/ Extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
75420903|NCT01437826|Drug|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
75719687|NCT00302731|Drug|equine estrogens m-progesteroneacetate|
75719688|NCT00780143|Drug|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
75719689|NCT01581229|Procedure|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
75420904|NCT01437826|Drug|placebo|placebo had an identical appearance as intervention
75420905|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
75719690|NCT01581229|Procedure|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
75719691|NCT01007968|Drug|LBH589|
75719692|NCT03999034|Diagnostic Test|questionnaire completion|Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
75719693|NCT01065025|Drug|4SC-205|Repeated ascending oral doses of 4SC-205.
75420906|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
75420907|NCT01437865|Drug|Gadofosveset contrast agent enhanced MRI Axilla|A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
75420908|NCT01437904|Procedure|Outpatient Recovery|Patients go home following Percutaneous nephrolithotomy
75566314|NCT02926053|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
75420909|NCT01437904|Procedure|In hospital recovery|Patients are hospitalized following Percutaneous nephrolithotomy
75874400|NCT03710369|Drug|Placebo|The placebo pill was compounded by McDonalds Pharmacy.
75420910|NCT01437917|Other|20% amylose bread|20% amylose bread
75420911|NCT01437917|Dietary Supplement|10% amylose bread|10% amylose bread
75420912|NCT01437917|Dietary Supplement|Carbohydrates|50g of carbohydrates ingested with 400 ml of water
75566315|NCT02926053|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
75566316|NCT02926053|Drug|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
75566317|NCT00527579|Drug|[F-18]FBR|
75566318|NCT00527657|Drug|Lomustine|Starting dose 30 mg/m^2 by mouth daily on Day 1 and 29.
75566319|NCT00527657|Drug|Temozolomide|75 mg/m^2 by mouth daily on Days 1 to 42.
75719694|NCT00779909|Drug|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
75874401|NCT03710369|Drug|Sildenafil|Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
75874402|NCT05681663|Other|Electroshock Wave therapy|Randomized- Controlled trial
75566320|NCT00527657|Drug|Thalidomide|200 mg/m^2 by mouth daily.
75566321|NCT02925897|Behavioral|Behaviour change and motivational interviewing|nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
75566322|NCT00528983|Drug|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
75719695|NCT00779909|Other|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
75719696|NCT05559112|Other|Vitamin D-enriched mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.
75874403|NCT03706157|Drug|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
75566323|NCT00528983|Drug|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
75420913|NCT01437930|Dietary Supplement|n-3 PUFA|"products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~linseed oil (20g/d)(PPM, Magdeburg)~echium oil (20g/d) (HARKE Nutrition)~microalgae powder(12g/d)(HARKE Nutrition)"
75420914|NCT01437527|Behavioral|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
75566324|NCT00528983|Drug|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
75566325|NCT02923752|Device|MRI|Contrast-enhanced MRI
75566326|NCT00529022|Drug|Azacitidine|75 mg/m^2 Subcutaneous Injection or by vein Daily for 5 Days.
75420915|NCT01437527|Behavioral|therapy as usual|Body image therapy as usual
75566327|NCT00529022|Drug|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
75719697|NCT05559112|Other|Study Powder|Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks. Study powder is a commercially available carbohydrate.
75719698|NCT01065103|Procedure|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
75874404|NCT03706157|Drug|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
75420916|NCT01437982|Drug|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
75420917|NCT01437982|Drug|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
75420918|NCT01438021|Other|pharmacological study|Correlative studies
75420919|NCT01438021|Drug|methotrexate|Given intraventricularly
75566328|NCT00529022|Drug|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
75566329|NCT02923596|Procedure|History of prior Surgery|History of prior Surgery will be reviewed
75566330|NCT02923596|Radiation|History of Radiation Therapy|History of prior radiation therapy will be reviewed
75566331|NCT00527696|Procedure|transvaginal obturator tape|
75566332|NCT02923557|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
75566333|NCT02923635|Procedure|Standard wide local excision.|Excision of breast cancer without integration of plastic technique
75566334|NCT02923635|Procedure|oncoplastic breast surgery.|Integration of plastic techniques with oncological surgery for resection of breast cancer.
75566335|NCT00529139|Device|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
75566336|NCT00529139|Device|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. <90 mg/dL (<15 mmol/L)
75420920|NCT01438086|Drug|mecasermin|Intracoronary bolus
75420921|NCT01438086|Drug|mecasermin|Intracoronary bolus
75420922|NCT01438086|Drug|0.9% sodium chloride injection|Intracoronary bolus
75566337|NCT02925975|Drug|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
75566338|NCT02925975|Device|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
75566339|NCT02925975|Procedure|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
75566340|NCT00527813|Procedure|prone position|prone position for at least 16 hours per day
75566341|NCT02925936|Other|Thyroid facing the anode end of xray machine|Thyroid position: facing the anode end of xray machine
75566342|NCT02925936|Other|Thyroid facing the cathode end of xray machine|Thyroid position: facing the cathode end of xray machine
75566343|NCT00527852|Device|Flocked swab|
75566344|NCT04692428|Procedure|Locoregional analgesia|the supra-inguinal fascia iliaca block versus the femoral nerve block
76044376|NCT05480969|Other|Heart failure educational intervention|Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
75420923|NCT01438112|Biological|CG0070 Adenovirus Vector|CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
75566345|NCT04259892|Biological|2019-nCoV PCR|Nasopharyngeal swabs
75566346|NCT02945033|Drug|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
75719699|NCT04273685|Behavioral|Cognitive remediation training, social recovery therapy|10 weeks cognitive remediation training plus social recovery therapy. One hour face to face contact time with intervention therapist per week. At-home cognitive remediation training completion.
75420924|NCT01438112|Other|Control Arm: Quadruple Choice|Quadruple Choice Treatment Options: (same as listed above)
75420925|NCT01438125|Other|MF-4181|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
75420926|NCT01438125|Other|Standard surgical wound closure|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
75420927|NCT01438138|Other|diagnostic laboratory biomarker analysis|Correlative studies
75420928|NCT01438190|Drug|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
75566347|NCT02945033|Drug|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
75566348|NCT02945033|Procedure|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
75566349|NCT02945033|Biological|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
75566350|NCT02945033|Biological|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
75566351|NCT02945111|Behavioral|Real-time view|
75566352|NCT02945111|Behavioral|No visual support|
75566353|NCT04256967|Other|Body and health focused study environment|Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
75420929|NCT01438190|Drug|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
75420930|NCT01438203|Procedure|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
75420931|NCT01438203|Procedure|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
75719700|NCT04273685|Other|treatment as usual|10 weeks Treatment as usual non directive counselling One hour face to face contact time with intervention therapist per week.
75719701|NCT00302107|Drug|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
75719702|NCT00302107|Drug|Placebo|Look-a-like placebo tablets under double-blind conditions
75719703|NCT02602301|Drug|Oxytocin|different oxytocin diluents and effect on fetal bilirubin&sodium levels.
75719704|NCT04097483|Behavioral|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
75566354|NCT02944760|Other|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
75420932|NCT01438242|Device|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
75420933|NCT01438281|Drug|SYL1001|SYL1001 eye drops. topical administration
75420934|NCT01438320|Dietary Supplement|Quercetin|Bioflavonoid
75420935|NCT01438333|Dietary Supplement|lactobacillus brevis tablets|5 tablets a day for 6 weeks
75420936|NCT01438333|Dietary Supplement|PLACEBO|5 tablets a day for 6 weeks
75420937|NCT01438346|Behavioral|Substance Abuse Education|10 weeks of usual care for substance abuse.
75420938|NCT01438346|Behavioral|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
75420939|NCT05607927|Procedure|Parks surgery|Parks surgery
75420940|NCT05607927|Procedure|PE-Bacon surgery|PE-Bacon surgery
75420941|NCT05607433|Device|cook ®Airway Exchanger Catheter|A tube exchanger is a small calibre , flexible tube used to guide endotracheal intubation through a supraglottic device.
75420942|NCT05607277|Procedure|Endovascular Repair of abdominal aortic aneurysms|Femoral artery access
75420943|NCT05607212|Other|Kettlebell Swing|Participants will perform two-handed kettlebell swings using the interval training protocol outlined in the study carried out by Jay et. al. (2011). The protocol calls for 30 seconds of work, followed by 30-60 seconds of rest for a total of 10 intervals. The mechanics of the kettlebell swing will follow those outlined in the study carried out by McGill et. al. (2012). All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability. The weight is higher than previous and similar study by Brandon et al to ensure measurable differences between experimental and comparison groups.
75420944|NCT05607212|Other|Isometric Hold|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals. Participants will mimic initial kettlebell swing position by standing shoulder width apart with their back straight, and hips and knees flexed. Participants will be cued to squeeze their glutes and look straight ahead while they hold the weight for the 30 second interval. All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability.
75420945|NCT05607212|Other|Control|Control group: participants will be educated on the benefit of a kettlebell swing.
75566355|NCT02923518|Other|Questionnaire|Observational study without any intervention described under intervention type
75719705|NCT04925206|Biological|ET-01|Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
75566356|NCT02923479|Device|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
75566357|NCT02923479|Other|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
75719706|NCT04908358|Other|Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Stimulation of vagus nerve in the outer ear
75719707|NCT04908358|Other|Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Sham stimulation of vagus nerve in the outer ear
75719708|NCT00760487|Device|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
75719709|NCT00316225|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2) IV every 21 days for 6 cycles
75719710|NCT04097405|Drug|D-0120|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
75719711|NCT04097405|Drug|Placebo oral tablet|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
75566358|NCT02923479|Other|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
75566359|NCT02923479|Device|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
75566360|NCT02923479|Device|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
75719712|NCT00586703|Device|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
75719713|NCT04988152|Biological|sotrovimab|sotrovimab IV infusion, single dose
75719714|NCT04988152|Other|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
76044377|NCT05480813|Device|Automated KINCISE™ impaction system versus handheld traditional mallet|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
76044378|NCT05480813|Other|Efficiency and ergonomics analysis and physical assessments|Operational efficiency, ergonomic impaction, cognitive/physical/stress level evaluations,
76044379|NCT05480501|Biological|IM19 CAR-T cells|IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
75566361|NCT02944838|Behavioral|Senior Change Makers Advocacy Program|see description
75566362|NCT02944838|Behavioral|Senior Change Makers Physical Activity Program|see description
75719715|NCT04988152|Biological|sotrovimab|Sotrovimab IM injection, single dose
76044380|NCT05486819|Drug|Propofol Injection|adding lignocaine or sodium bicarbonate to propofol to reduce pain during injection
76044381|NCT05480423|Behavioral|Mindfulness-based intervention|1. Psychoeducation video on mindfulness and mindful parenting. 2. Audio files of mindfulness exercises including mindfulness of breath, body scan, mindful stretching, mindfulness of soles of the feet, befriending exercises. 3. Informal mindfulness exercises by applying mindfulness in daily lives
76044382|NCT05480345|Diagnostic Test|Impedance cardiography|Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
75719716|NCT04988152|Other|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
75874405|NCT03707795|Drug|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days|Participants will be given four IM injections throughout the study
75874406|NCT01312025|Procedure|conventional laparoscopic cholecystectomy|
75874407|NCT01312025|Procedure|modified laparoscopic cholecystectomy|
75420946|NCT05606939|Device|intestinal ultrasound|"All patients will be evaluated using intestinal ultrasound with special emphasis on intestinal wall thickness as well as stratification and Visualization of the vascularization of the bowel using color Doppler sonography also visualization of motility.~Findings of intestinal ultrasound will be compared regrading colonoscopic findings"
75874408|NCT05176535|Dietary Supplement|FertyBiotic Balance|Lactobacillus rhamnosus BPL 205, Lactobacillus plantarum BPL207 and Lactobacillus crispatus BPL209
75874409|NCT03042312|Drug|177Lu-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
75420947|NCT05605028|Behavioral|Mental Health lifestyle intervention|The focus is to identify 10 potential groups of causes and working on reversing them. The 10 factors are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
75420948|NCT05605028|Other|Dietitian-led|A group of people that visit the dietitian will be used as comparison against the Mental Health lifestyle intervention
75420949|NCT05596370|Diagnostic Test|cell free DNA in blood and urine, metabolite/microbiome in urine and stool|cell free DNA in blood and urine, metabolite/microbiome in urine and stool
75566363|NCT00529256|Behavioral|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
75719717|NCT04854148|Other|Smartphone Movement Health Assessment|Participants will perform the assessment using an App installed on a smartphone device. Following the smartphone assessment, gold standard clinical assessments will be performed and scored for comparison
75719718|NCT00586625|Drug|Bepreve|One drop, both eyes, twice a day
75874410|NCT05171231|Device|HEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD|"HEMOCOLLAGENE® is an absorbable, sterile and hemostatic sponge, composed of type I undenatured, native and lyophilized bovine collagen (0.027 g per sponge).~HEMOCOLLAGENE® will be inserted into oral sites (mainly the alveoli dental) after post-extraction or post-invasive dental surgical procedure, in case of bleeding not controled by usual hemostatic method. HEMOCOLLAGENE® will be let in place and will undergo a complete and natural absorption after several weeks."
75566364|NCT04231968|Drug|AK0529|AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days according to the weight of patients.
75566365|NCT04231968|Drug|Matching placebo of AK0529|The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
75719719|NCT00586625|Drug|Placebo|One drop, both eyes, twice a day
75874411|NCT03706001|Other|Psychotherapy|Psychotherapy has gained increasing acceptance as a major treatment option for mood disorders.
76044383|NCT02554877|Drug|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
76044384|NCT02554877|Drug|Placebo|oral tablet
76044385|NCT05486741|Other|Optical cehernce tomography|OCT macula and disc
76044386|NCT05493137|Other|No intervention will be provided|No intervention will be provided, this is an observational study
76044387|NCT05480267|Procedure|surgical treatment for lumbar spondylolisthesis|There are two surgical treatments for lumbar spondylolisthesis; one is UBE, and another is MIS-TLIF
75874412|NCT05692986|Diagnostic Test|A vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery is completed.|This is a randomized control trial that will compare chlorhexidine vaginal prep with iodine vaginal prep. Our primary outcome will be assessed using a vaginal swab test to look for aerobic and anaerobic cultures. Positive cultures will be defined as colony forming count of >5000cfu. All patients will receive preoperative antibiotics. Patients will receive a vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery was completed.
75874413|NCT03360071|Drug|Allergen Immunotherapy Extract|Allergen Immunotherapy treatment mixture to be delivered subcutaneously
75874414|NCT03360071|Drug|Allergen Immunotherapy Control|Allergen Immunotherapy Control Solution to be delivered subcutaneously
75874415|NCT05692830|Drug|Alcohol|Alcohol administered orally at multiple doses and consumption speeds to test transdermal device accuracy
75874416|NCT05092776|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
75874417|NCT05092776|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
75420950|NCT05596110|Behavioral|TENS and KT|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
75420951|NCT05596110|Behavioral|TENS and sham taping|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
75566366|NCT00529295|Drug|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
75566367|NCT00529334|Radiation|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
75874418|NCT03710213|Behavioral|Text Message-based Intervention|The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
75874419|NCT04745507|Other|Inpatient Equivalent Home Treatment|At-home psychiatric treatment by means of a multiprofessional clinic team (an equivalent to stationary psychiatric care).
76044388|NCT05480189|Other|Non-intervention|Non-intervention,with real world study
76044389|NCT05493059|Other|Data collection|o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
76044390|NCT05493059|Other|Questionnaires|"o Administration of two standardized questionnaires by telephone in prospective:~Dermatology Life Quality Index (DLQI)~Treatment Satisfaction Questionnaire for Medication (TSQM)"
75566368|NCT04218903|Behavioral|Combined training performed four times per week (CT4)|CT4 will perform four combined training sessions per week throughout 12 weeks. Each session will be composed 10-15 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 3 exercises) followed by 20-25 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
75566369|NCT04218903|Behavioral|Combined training performed two times per week (CT2)|CT2 will perform two combined training sessions per week throughout 12 weeks. Each session will be composed 20-30 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 6 exercises) followed by 40-50 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
75566370|NCT02945306|Procedure|Adenotonsillectomy|
75566371|NCT02945306|Drug|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
75566372|NCT02945618|Device|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
75719720|NCT03999502|Device|Endomina|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
75719721|NCT00636168|Drug|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
75719722|NCT00636168|Drug|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
75719723|NCT04098263|Biological|LMN-101|variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
75719724|NCT04102631|Diagnostic Test|colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
75719725|NCT04102631|Diagnostic Test|colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
75420952|NCT05596110|Behavioral|KT and sham TENS|KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.
75566373|NCT02945618|Other|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
75874420|NCT05681429|Drug|Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib|To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
75874421|NCT05024760|Drug|Chlorhexidine|Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
75566374|NCT02922933|Drug|entinostat|HDAC (histone deacetylase inhibitor)
75874422|NCT05024760|Drug|Hydrogen Peroxide|Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
75874423|NCT05176067|Radiation|Thoracic Three-dimensional Radiotherapy|Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
75874424|NCT03705689|Other|validation of Bitts|No intervention, observation of photographs of stool
75874425|NCT05319522|Behavioral|Acute Exercise|Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
75874426|NCT02949011|Drug|Baloxavir Marboxil|Tablets taken orally
75874427|NCT02949011|Drug|Placebo to Baloxavir Marboxil|Matching tablets taken orally
75874428|NCT02949011|Drug|Oseltamivir|Capsules taken orally
75566375|NCT02922933|Dietary Supplement|Omeprazole|Proton pump inhibitor
75566376|NCT02922933|Dietary Supplement|Famotidine|Histamine-2 blocker
75566377|NCT00529412|Other|Seprafilm|two sheets per body
75566378|NCT00529490|Drug|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
75566379|NCT00529490|Drug|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
75566380|NCT02923089|Other|Muffin: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
75719726|NCT00759941|Drug|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
75719727|NCT00759941|Drug|Placebo eye drops|One drop three times a day in both eyes for 3 months
75874429|NCT02949011|Drug|Placebo to Oseltamivir|Matching placebo capsules taken orally
76044391|NCT05492981|Behavioral|Enhanced (intervention) education|See arm description
75719728|NCT00759941|Drug|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
75719729|NCT00915863|Procedure|Billroth-II-type reconstruction|surgical procedure
75719730|NCT00915863|Procedure|Isolated Roux-en-Y type reconstruction|surgical procedure
75874430|NCT05595954|Other|Preoperative data collection|Preoperatively, patients will be assessed with Montreal Cognitive Assessment (MoCA), Geriatric Depression Scale (GDS), Clinical Frailty Scale, 3-minute Diagnostic interview for Confusion Assessment Method-defined delirium (3D-CAM, incl. severity score), modified National Institutes of Health Stroke Scale (mNIHSS), and hand grip strength measurement (using a hand dynamometer) to establish a baseline measurement of the physical, cognitive and mental status.
75874431|NCT05595954|Diagnostic Test|Intraoperative NIRS|Intraoperatively, NIRS data will be collected and recorded in real-time.
75874432|NCT05595954|Diagnostic Test|Intraoperative TCD|Intraoperatively, TCD data will be collected and recorded in real-time.
75420953|NCT05596110|Behavioral|Sham TENS and sham taping|Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
75420954|NCT05578859|Drug|AMG 510|Single oral dose of AMG510.
75420955|NCT05563688|Other|Hypoxia exposure|"Each participant will be exposed to the hypoxic environment on 2 occasions (one after a normal sleep night and one after sleep deprivation).~Each exposure will be for 5 hours at a FiO2 of 13.2% (3500 m simulated altitude).~This exposure will be carried out in a normobaric hypoxic tent (Sporting Edge®)."
75420956|NCT05563688|Other|Sleep deprivation|"Each participant will be exposed to sleep deprivation on 2 occasions (one before normoxia exposure and one before hypoxia exposure).~Each sleep deprivation involves a time spent in bed of 3 hours (03h00 - 06h00). Sleep deprivation will be carried out in a sleep apartment. Sleep duration and quality will be assessed using a sleep headband (Dreem®), actigraphs Actiwatch® and E4 Empatica®) and a sleep diary."
75719731|NCT00528424|Biological|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
75719732|NCT00315445|Drug|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
75719733|NCT00315445|Drug|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
75719734|NCT00315445|Drug|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
75719735|NCT00315445|Drug|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
75719736|NCT03687736|Biological|AbobotulinumtoxinA|AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6
75874433|NCT05595954|Diagnostic Test|Intraoperative invasive MAP|Intraoperatively, invasive arterial blood pressure data will be collected and recorded in real-time.
75874434|NCT05595954|Diagnostic Test|Postoperative NIRS|Postoperatively, NIRS monitoring will be continued in the ICU after the surgery until (i) endotracheal extubation, or (ii) for the first 24 hours or (iii) until emergency re-operation, whichever occurs first.
75420957|NCT05563688|Behavioral|Cognitive tasks|"Participants will perform several cognitive tasks in the following conditions:~in normoxia (FiO2 = 21%) after a night of usual sleep (> 6 hours) ;~in normoxia (FiO2 = 21%) after a night of reduced sleep (3 hours);~in normobaric hypoxia (FiO2 = 13.2%) after a night of normal sleep (> 6 hours);~in normobaric hypoxia (FiO2 = 13.2%) after a night of reduced sleep (3 hours)."
75566381|NCT02923089|Other|Muffin: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
75566382|NCT02923089|Other|Wheat muffin|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
75566383|NCT02923089|Other|Soup: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
75566384|NCT02923089|Other|Soup: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
75719737|NCT04861324|Behavioral|Dietary Intervention|Increasing fruit and vegetable by two servings a day and at least 30 min a day of postprandial physical activity
75719738|NCT04857580|Device|CTS Device|Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
75719739|NCT00779675|Biological|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
75874435|NCT05595954|Other|Postoperative data collection|Postoperatively patients will be evaluated for POD with 3D-CAM or CAM-ICU and for clinical stroke with mNIHSS. Postoperative neurocognitive disorders will be assessed using MoCA.
75420958|NCT05548946|Other|PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)|"All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy)."
75874436|NCT05595954|Diagnostic Test|Collection of serum biomarker panel|The serum biomarker panel will consist of four markers of neurological injury glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), t-tau and ubiquitin-C-terminal-hydrolase-L1 (UCH-L1). Blood samples will be obtained preoperatively, after ICU admission, on postoperative day 1, 2, 6 (or hospital discharge, whichever occurs first) and between 6 and 12 weeks after surgery.
75874437|NCT05595954|Diagnostic Test|Collection of blood sample for genetic study|A blood sample for the genetic study will be obtained preoperatively.
75874438|NCT03787368|Drug|BAY1213790|Single intravenous infusion of BAY1213790 (Two different doses)
75566385|NCT02923089|Other|Potato soup|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
75566386|NCT02923089|Other|Chili: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
75566387|NCT02923089|Other|Chili: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
75566388|NCT02923089|Other|Rice chili|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
75566389|NCT00527891|Procedure|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
75566390|NCT02923050|Behavioral|Simple Suppers|Theory-based 10-week family meals program
75566391|NCT02945267|Drug|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
75566392|NCT02945267|Drug|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
75874439|NCT03787368|Drug|0.9% sodium chloride solution|Single intravenous infusion of Placebo (0.9% sodium chloride solution)
75874440|NCT03705611|Diagnostic Test|HIV self-testing only|Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
75874441|NCT03705611|Behavioral|HIV self-testing secondary accuracy|A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
75874442|NCT05145725|Behavioral|Quality of life questionnaires|Different questionnaires to fill : SRS-22r, SF-36 score, TAPS, KIDSCREEN10
75874443|NCT03705533|Drug|Telmisartan|Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
75874444|NCT03705533|Drug|Micardis|Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
75874445|NCT05177627|Other|Theoretical and classroom learning interventions|"aim of intervention: introduce students to the conceptual framework of fundamental of care, focus on three dimensions necessary for the delivery of high-quality fundamental care (the nurse-patient relationship; addressing different fundamental needs; and a context that supports these goals)~components and activities:~educational interventions to understand how the communication and the relationship of trust between nurse and patient are the prerequisites for high quality nursing care;~drawing attention to five essential relational elements for establishing the nurse-patient relationship (Trust; Focus; Anticipate; Know; Evaluate)~mode of delivery:~classroom lessons on philosophies and theories on communication and trust~small-group learning on realistic cases focused on fundamental needs to develop reflexivity, analytical skills, investigation~duration of the intervention: 12 hours of theoretical and classroom learning"
76044392|NCT04235465|Other|Dynamic Gait Index|The Dynamic Gait Index (DGI) measures functionality and dynamic balance in walking and stair climbing. The DGI consists of 8 items including normal gait on flat ground, gait with speed changes, gait with horizontal head movements, gait with vertical head movements, gait and pivot turn, gait and step over an obstacle, gait around obstacles and steps up and downstairs. The performance on each item is rated on a 4-point scale ranging from 0 (severe disorder) to 3 (independent walking). The total score is 24.
75566393|NCT02926014|Device|Videolaryngoscopy|A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
75719740|NCT03980119|Other|HITSystem 3.0|The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
75719741|NCT04097093|Other|No intervention|No intervention
75566394|NCT02926014|Other|Reflux Symptom Index Questionnaire|A validated clinical tool for suspecting laryngopharyngeal reflux (LPR). The questionnaire was proposed by Belafsky et al. (2002) and consists of 9 most common gastroesophageal reflux disease (GERD) and LPR symptoms: hoarseness or a problem with your voice; clearing your throat; excess throat mucus or postnasal drip; difficulty swallowing food, liquids, or pills; coughing after you ate or after lying down; breathing difficulties or choking episodes; troublesome or annoying cough; sensation of something sticking in your throat or a lump in your throat; heartburn, chest pain, indigestion, or stomach acid coming up. Each symptom is evaluated on a scale from 0 to 5 (0 - no complaint, 5 - severe symptom). The sum of all symptom evaluations ranges from 0 to 45.
75719742|NCT04097171|Other|Diet|Participants will consume each diet for 14 days in a crossover design.
75719743|NCT00759863|Behavioral|Lifezig|Personalized Reminiscence Video
75719744|NCT03998722|Device|Vagivital|Vagivital once Daily for 12 weeks
75566395|NCT02926014|Other|Dysphagia Screening Questionnaire|"A validated questionnaire, proposed by Ohkuma et al. (2002). Lithuanian version of the questionnaire consists of 16 questions: choking during swallowing meals / liquids; difficulty eating solid foods; difficult swallowing; feeling of food getting stuck in the throat; longer than before eating time; feeling of food remaining in the mouth; feeling that food or liquid is going up into the throat from the stomach; feeling of food being stuck in the esophagus; weight loss; food getting stuck in the throat; food falling from the mouth; difficulty coughing during or after meals; occurrence of pneumonia; hoarseness; coughing during the night. Interpretation of dysphagia screening questionnaire:~Advanced symptom - 2 points; Moderate intensity symptom - 1 point; No symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points."
75566396|NCT00529607|Drug|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
75566397|NCT00529607|Procedure|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
75566398|NCT00529607|Procedure|cardiac MRI|before discharge and after 6 months
75719745|NCT04102943|Drug|tacrolimus tablet|"Orally, twice a day in the morning and night~After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment."
76044393|NCT05486429|Combination Product|Abdominal ultrasound and lipid profile|"All patients will be subjected to: -~Complete history taking with stress on:~Age, sex, comorbid conditions (diabetes, hypertension, ischemic heart disease)~History of intake of lipid lowering drugs.~Thorough clinical examination:~General examination, vital sign, height, weight, body mass index. Abdominal examination (hepatomegaly, splenomegaly, ascites)~Laboratory Investigation:~1.Lipid profile (total cholesterol, triglyceride, HDL, LDL, VLDL (~.2Liver function tests (ALT, AST, Albumin, Bilirubin, PT, PC, INR) 3.Complete blood picture. 4.Serology for HBV, HCV. 5.Serum creatinine. 6.Fasting and postprandial blood sugar.~Radiological Investigation:~1.Abdominal ultrasound.~FIB - 4 it combines platelets count, ALI, AST and age.~AST/Platelets ratio index is calculated as (AST/upper limit of normal range) /Platelets count (10^9/L) ×100."
75719746|NCT04102943|Drug|tacrolimus capsules|"Orally, twice a day in the morning and night~After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment."
75566399|NCT00529607|Procedure|blood sampling|"routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3"
75566400|NCT02922972|Device|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
75719747|NCT00759785|Drug|dalotuzumab (MK0646)|Single intravenous infusion
75719748|NCT00300781|Drug|neratinib|
75719749|NCT00315055|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
76044394|NCT05492903|Behavioral|COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)|A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.
76044395|NCT05486351|Other|Observation|Patients are observed for stroke or systemic embolism and haemorrhagic transformation
75566401|NCT00529646|Drug|APD791|
75566402|NCT02922855|Behavioral|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
75566403|NCT02922855|Behavioral|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
75719750|NCT00315055|Biological|DTaP-IPV//PRP~T combined|0.5 mL, IM
75719751|NCT00315055|Biological|Hepatitis B vaccine|0.5 mL, IM
75719752|NCT00528970|Drug|MOA-728|MOA-728 will be administered per the dose and schedule specified in the arm.
75719753|NCT00528970|Drug|Placebo|Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
75719754|NCT00759395|Drug|AZD2327|Tablet, Oral, Daily
75719755|NCT00759395|Drug|Placebo|Tablet, Oral, Daily
75719756|NCT00293293|Other|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
76044396|NCT05475587|Other|Routine care|Both two groups received the same routine care.
75566404|NCT02922855|Behavioral|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
75566405|NCT04689321|Other|No intervention|This is not an interventional study.
75566406|NCT00527930|Drug|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"
75566407|NCT00529841|Drug|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
75719757|NCT00293293|Other|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
76044397|NCT05480033|Behavioral|Imagery Technique|The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
75566408|NCT00529880|Drug|Fludarabine , cytarabine|
75566409|NCT02922504|Behavioral|Music intervention group|
75566410|NCT02922504|Behavioral|Controlled group|
75566411|NCT02944643|Other|Mindfulness and Support Groups|
75566412|NCT02925702|Drug|Radium 223 55mBq/Kg every 4 weeks intravenously|Radium-223 55kBq/kg infusion IV every 4 weeks
75566413|NCT00531089|Drug|Rituximab|Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
75566414|NCT02922699|Drug|OMEZ 40|Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
76044398|NCT05479955|Other|5 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. The women in this group received 5 minutes of skin-to-skin contact as a clinic routine.
75566415|NCT02922699|Drug|OMEZ 80|Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
75566416|NCT02944604|Drug|PEG-rhG-CSF|
75566417|NCT02922660|Drug|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
75566418|NCT02922660|Procedure|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
75719758|NCT00293293|Other|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
75566419|NCT02922660|Procedure|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
75566420|NCT02922660|Drug|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
75566421|NCT02922660|Drug|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
75566422|NCT02276924|Device|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
75566423|NCT02922465|Drug|K-877|
75566424|NCT02922465|Drug|Clopidogrel|
75566425|NCT02944292|Procedure|Deepening of sedation|Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
75566426|NCT02944292|Drug|Propofol|"Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered)."
75566427|NCT02922426|Drug|ALKS 3831|Daily dosing for 21 consecutive days
75566428|NCT02922426|Drug|Olanzapine|Daily dosing for 21 consecutive days
75566429|NCT02922426|Drug|Placebo|Daily dosing for 21 consecutive days
75566430|NCT04691921|Behavioral|Current clinical practices of participating physicians|Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19
75566431|NCT00529919|Dietary Supplement|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
75566432|NCT02922114|Other|Ultrasonography|B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
75566433|NCT02925663|Behavioral|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
75566434|NCT02943629|Device|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
75566435|NCT02943629|Device|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
75566436|NCT02943629|Device|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
75566437|NCT02925624|Procedure|Pulmonary vein isolation|
75566438|NCT00531128|Behavioral|High/Low Sitosterol|
75566439|NCT02925351|Procedure|Computed Tomography|Undergo PET/CT scan
75566440|NCT02925351|Radiation|Fluorine F 18 Clofarabine|Given IV
75566441|NCT02925351|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75884251|NCT05579210|Behavioral|Face to face relapse prevention therapy|Participants in the face-to-face intervention will meet with their therapist weekly through Microsoft Teams (video conference). During these 1-hour sessions, therapists will follow the same 10-week structure and content as e-RPT. Though compared to e-RPT, in face-to-face sessions, the homework will be reviewed with the participant, during the session, providing the appropriate feedback. Then the therapists will prepare a weekly patient report of each session for the principal investigator. At the end of each session, participants will receive the same homework as the e-RPT condition which they will receive feedback on during the following face-to-face session. Following the 10-week face-to-face intervention, participants will have the opportunity to join the e-RPT program.
75566442|NCT02944409|Device|total knee prothesis VEGA System|total knee replacement
75566443|NCT00531167|Drug|combination of lamivudine+adefovir vs entecavir|Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
75566444|NCT02944214|Drug|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
75566445|NCT02944214|Drug|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
75566446|NCT02925546|Drug|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
75566447|NCT02925546|Drug|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
75566448|NCT02925546|Drug|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
75566449|NCT02944331|Procedure|Endovenous steam ablation|
75719759|NCT00293293|Drug|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
75719760|NCT05774613|Dietary Supplement|Effect of a Hibiscus sabdariffa beverage|Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion
75719761|NCT05774574|Dietary Supplement|Cannabidiol (CBD) supplementation|Daily supplementation with 1 ml hemp oil containing 60 mg CBD, applied orally
75719762|NCT05774574|Dietary Supplement|Placebo supplementation|Daily supplementation with 1 ml hemp oil containing 0 mg CBD, applied orally
75874446|NCT05177627|Other|Simulation interventions|"aim of intervention:~To develop active listening and use of non-verbal and verbal communication skills to establish a therapeutic relationship based on compassion, trust and respect; to apply the FoC conceptual framework, reflexivity and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities: - Implementation of communication simulation activities to develop interaction skills with patients; Implementation of simulation activities to apply the FoC conceptual framework and reflection to meet patient fundamental needs in realistic scenarios.~mode of delivery:~- simulation activities on communication and trust Use ad hoc validated scenarios to apply the FoC conceptual framework to develop reflection and meet patient fundamental needs.~duration of the intervention: 25 hours"
75420959|NCT05548946|Other|Secondary Questionnaires (self-report and informant questionnaires)|"The patients fill in a standard test battery during the first weeks of their admission in the institutions, including questionnaires and interviews. The research team will analyze the results retrospectively.~This includes:~YSQ- SF16 (Young & Brown, 1994; Pauwels et al., 2018) GPS (van Alphen et al., 2006) HoNOS 65+ (Burns et al., 1999) HAP 2.0 (Barendse & Thissen, 2006) SCL-90-R (Derogatis, 1983; Dutch version: Arrindell, & Ettema, 1975, 1986, 2005) ADP-IV (Schotte & De Doncker, 1998) CERQ (Garnefski et al., 2007) UCL (Scheurs et al., 1994; 1988) BIS/BAS Scales (Carver & White, 1994) EC Scale of the ATQ (Rothbart et al., 2000) BSI (Derogatis, 1975; Dutch version: Beurs, 2008) SIPP-SF (derived from the SIPP-118; Verheul et al., 2008) SMI (Young et al., 2008) WHO-5 (Dutch version: WHO, 1998) SQ3-SF (Young & Brown, 2005) SCID-5-P (First et al., 2017; Dutch translation: Arntz et al., 2017)"
75420960|NCT05548946|Diagnostic Test|Clinical Ratings of the dimensional model|"Clinical ratings of criteria A and B will also be collected. Only a small part of the patients will be selected for this, in order to make the research more feasible. The rater (a clinician or researcher) assesses the patient (in terms of level of personality functioning and personality traits) by means of (structured) clinical interviews. Given clinical ratings of the dimensional criteria are not part of the standard care in either institution, the ratings can be conducted by the doctorandus and Master Thesis students, trained by the doctorandus (in order not to overburden the clinicians).~The clinical interviews that will be used for the ratings are:~The Semigestructureerd Interview voor Persoonlijkheidsfunctioneren DSM-5 (STIP) (Hutsebaut et al., 2014).~The Structured Clinical Interview for the DSM-5 (SCID-5-AMPD) (First et al., 2018), only if a Dutch translation is available by the time of this intervention."
75719763|NCT05774561|Diagnostic Test|Arm A - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.
75719764|NCT05774561|Diagnostic Test|Arm B - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.
75874447|NCT05177627|Other|Internship interventions|"Aim of intervention: to apply active listening and non-verbal communication skills; to use the FoC conceptual framework, reflexivity, and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities:~- to establish effective and trusting communication with patients to demonstrate compassion and respect and to enable patients to remain calm, involved and dignified; to apply the FoC conceptual framework to meet patient fundamental needs.~mode of delivery:~attendance of clinical internship~analysis and reflections guided by the clinical preceptor on real cases using elements of FoC conceptual framework.~duration of the intervention: 150 hours of internship."
75874448|NCT05143541|Device|AEON Endostapler|Surgery with AEON Endostapler
75874449|NCT03710057|Drug|Ivabradine|A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
75874450|NCT03357731|Drug|HNO Donor|Infusion
75566450|NCT02922075|Biological|Connective tissue graft|A 1.5 mm thick soft tissue graft removed from the palate with determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
75566451|NCT02922075|Biological|Collagen matrix graft|A 15x20 mm collagen matrix trimmed according to determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
75566452|NCT02922075|Device|Immediate implant|A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque > 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
76044399|NCT05479955|Other|60 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
75874451|NCT03357731|Drug|Nitroglycerin (NTG)|Infusion
75420961|NCT05548946|Other|PID-5-BF+M and LPFS-BF 2.0 (Informant questionnaires)|In the clinical population, participants will be asked to include an informant (family member, partner, friend, acquaintance), to fill in an informant version of the PID-5-BF+M and LPFS-BF 2.0 questionnaires. It is also possible for the patient to participate in the study without giving permission to include an informant. The informant will be asked to fill in the informant versions of the questionnaires, which contain the exact same items as the self-report versions, adjusted to the third person.
75420962|NCT05539209|Behavioral|OKquit|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys plus OKquit Smartphone App including tailored messages and on-demand content designed to assist participants in their cessation attempt.
75420963|NCT05539209|Behavioral|Standard Helpline Care|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys.
75420964|NCT05525013|Drug|Simvastatin Powder|Simvastatin gel placed as an intracanal medication
75420965|NCT05525013|Drug|Calcium Hydroxide|Calcium hydroxide intracanal medication
75420966|NCT05515328|Drug|[¹⁴C] BI 685509 formulation 1|[¹⁴C] BI 685509 formulation 1
75420967|NCT05515328|Drug|[¹⁴C] BI 685509 formulation 2|[¹⁴C] BI 685509 formulation 2
75420968|NCT05515328|Drug|BI 685509 formulation 3|BI 685509 formulation 3
75420969|NCT05502601|Procedure|Non-surgical periodontal treatment|"SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
75420970|NCT05497830|Other|RISK-INDEX|Presentation of RISKINDEX to the physician after approximately 2 hours. The ML RISKINDEX is a prediction model based on laboratory data from the ED. It is based on date of birth, sex and at least four laboratory data which are sampled within the first two hours of the ED visit. Laboratory data that are used as input include samples that are commonly drawn in patients that require treatment from an internal medicine physician, such as urea, albumin, C-reactive protein (CRP), lactate and bilirubin.
75420971|NCT05496855|Other|Conventional follow-up|Patients in the conventional/usual care arm will be treated according to current conventional follow-up regimen with PROs, blood tests, and face-to-face visits with an experienced nurse or a rheumatologist every 6 months. They can contact the hospital if they are experience worsening of their disease.
75420972|NCT05496855|Other|Remote monitoring|"The patients in the remote monitoring arm will use a web-app (Youwell) for self-reporting patient reported outcomes (PROs) and CRP/ESR, displaying results for PROs over time, and for synchronous (video) or asynchronous (chat) communication with healthcare providers. The patients will receive a SMS reminder for tasks (e.g., self-reporting PROs or registering results from blood tests) every month.~A study coordinator/nurse will monitor the PROs and blood test (CRP/ESR) results, and respond to chat messages. Based on the algorithm, a triaging functionality in the Youwell platform will aid healthcare providers in highlighting which patients needs attention."
75420973|NCT05485688|Other|sleep apnea|This prospective observational study will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese [BMI>=27] & 30 non-obese [BMI<27]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate).
75566453|NCT02922075|Procedure|Tooth extraction|Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
75874452|NCT03357731|Other|Placebo|Infusion
75874453|NCT04563702|Biological|VXA-CoV2-1|non replicating Ad5 adjuvanted oral tableted vaccine
75874454|NCT03709979|Device|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
75874455|NCT03357341|Device|Mobile spirometer|Mobile spirometer will be used to measure FEV1 values weekly.
75874456|NCT03357341|Device|Device sensor|Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
75566454|NCT02922075|Device|Immediate restoration|A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
75719765|NCT05774535|Other|Experimental|"Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.~The following assessments will be performed within 10 days before the thyroidectomy procedure:~informed consent;~personal data and medical records;~registration of medical therapy and post-procedural pharmacological protocol~surgical check;~supra-aortic trunks EchocolorDoppler;~pre-procedural blood sampling.~The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:~surgical checks;~registration of drug therapy;~recording of all adverse events that occurred during hospitalization~supra-aortic trunks EchocolorDoppler and cIMT measurement;~blood sampling."
75874457|NCT03357341|Drug|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
75874458|NCT03357341|Device|Activity monitor|Subjects will be required to wear activity monitors daily to record their physical activity.
75874459|NCT03357341|Other|electronic diary card|Electronic diary card will be completed daily by subjects in COPD cohort.
75420974|NCT05484830|Procedure|Individualized HDR-approach|"Heparin concentration necessary to achieve target ACT > 480 sec. calculated based on individual HDR-curve.~If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required."
76044400|NCT05479877|Drug|sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India|Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
75420975|NCT05484830|Procedure|Conventional ACT-approach|"Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA).~Additional heparin until ACT > 480 sec. If ACT < 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT > 480 sec. during normothermic CPB, and target ACT > 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT > 40 seconds, additional protamine (25-50 mg i.v.)."
75420976|NCT05473884|Device|lesion preparation devices|successful recanalization of femoropopliteal artery occlusion and then followed by lesion preparation devices and plain old balloon angioplasty
75420977|NCT05473884|Device|conventional balloon|Lumen gain is achieved by plain old balloon angioplasty under working inflation pressure.
75420978|NCT05463757|Drug|Vismodegib|Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)
75420979|NCT05463757|Drug|Sonidegib|Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)
75874460|NCT03357341|Other|CAT|Subjects will be required to complete CAT monthly.
75874461|NCT03357341|Other|ACT|Subjects will be required to complete ACT monthly.
75874462|NCT05177549|Other|Bilateral knee examination with Lachmeter®|Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee
75874463|NCT04900818|Drug|TJ033721|Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)
75874464|NCT05177237|Drug|Endostar|Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
75874465|NCT05177081|Device|Preemptive management using home BIA monitoring system|Patients check their body composition and fluid using Home BIA system. Investigators analyze patients' body congestion status and send patient's edema status and direction of extra-diuretics usage to enrolled patients every one week.
75874466|NCT05671289|Diagnostic Test|analysis of urine volatile organic compounds|gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
75420980|NCT05451446|Dietary Supplement|proprietary water|They are randomized to consume a proprietary water product for five-free living days and to drink on the heat stress chamber day.
75420981|NCT05451446|Other|Active comparator|They are randomized to consume a carbohydrate drink for five-free living days and to drink on the heat stress chamber day.
75566455|NCT02922075|Biological|Bone regeneration|All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
75566456|NCT02922075|Drug|Post operative medication|Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
75719766|NCT05774522|Other|Measurement of pharyngeal critical airway closing pressure|The Pcrit will be measured on an automatic controlled device specially designed by the engineers of the inserm neophen team capable of varying the pressures from +4 to -20 centimeters of water, by a nasal mask whose pressures are connected to a pneumotachograph. The measurements will be performed in supine position.
76044401|NCT05479877|Drug|Biodentine (Septodont, Saint-Maur-des-Fossés, France)|Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
75719767|NCT05774522|Other|Acoustic pharyngometry|Acoustic pharyngometry is an non-invasive technique consisting of the propagation of an acoustic wave from the lips to the larynx providing information on the lengths, cross-sectional areas and volumes of the air spaces.
76044402|NCT05492747|Other|Kangaroo Care an Effect|Researchers evaluated vital signs and oxygen saturation of preterm infants in the kangaroo care group 15 minutes before kangaroo care. After the baby's mother was admitted to the NICU, she was assisted by the researcher for hand hygiene and they went to the incubator together. The mother was seated in a comfortable chair next to the incubator. After the researcher covered the head and back of the preterm baby with a baby blanket, she took it from the incubator and placed it between the mother's breasts, with the head up and upright. The baby was supported not only by the neck and shoulders, but also by the whole body. Skin contact between mother and baby was ensured at the highest level. The baby was positioned so that its lips were touching the mother's nipple. The researcher waited until the baby opened its mouth.
75719768|NCT05774522|Other|Upper airway ultrasound|Airway ultrasound is a non-invasive imaging allowing visualization and measurements of the tongue base and retrovascular fatty infiltration. Its main interest remains the evaluation of the tongue base which is clinically difficult.
75719769|NCT05774457|Behavioral|Voice training|Traditional vs. virtual reality
75719770|NCT05774418|Biological|BNT162b2 COVID-19 Vaccine|BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
75420982|NCT05451446|Other|Placebo|They are randomized to consume water for five-free living days and to drink on the heat stress chamber day.
75420983|NCT05435924|Other|Turkish validity and reliability|"Explanation of the Turkish version of the scale.~Translating the Turkish version of the scale into English to ensure consistency with the original scale.~First application of scales to participants by two examiners separately.~Second application of the scales to the participants by one examiner.~Statistical analysis and scaling"
75420984|NCT05426447|Other|Dietary intervention of reduced protein intake|6-wk dietary intervention of reduced protein intake
75719771|NCT05774379|Device|virtual reality and fatigue education|virtual reality distraction for 3 days and fatigue education for children
75719772|NCT05774379|Behavioral|fatigue education|fatigue education for children
75719773|NCT05774314|Behavioral|Community Health Worker Intervention|Communities that are randomized into the Treatment arm will receive the Flourish program. Communities with a Flourish program will select and train a Community Health Worker from the Transform program participants. At the end of the Transform program, a Savings Group will be formed from the Transform program participants. The Savings Group will nominate households to participate in the Flourish program and research study. The Community Health Worker will approach the nominees and attempt to enroll them into the Flourish program and research study. If the nominees agree to be enrolled in the Flourish program, the Community Health worker will provide screening, referral, counseling, and treatment services to the household for the duration of the study.
75874467|NCT04747067|Device|BIOPURE 260HF dialyzer|Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)
75566457|NCT02922075|Device|Definitive prosthesis|Definitive implant-supported restorations were performed 6 months after dental implant placement.
75719774|NCT05774275|Drug|Pegylated Liposomal Doxorubicin|In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
75719775|NCT05774275|Drug|Doxorubicin|75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
75719776|NCT05774275|Drug|Anti-PD-1 monoclonal antibody|200 mg, d1, q3w
75874468|NCT05646953|Other|Facial Beauty Oil|"Mode of Usage Step 1- Wash face, pat dry Step 2 - Gently massage 2-3 drops of Vasu Facial Beauty Oil over the face and neck till it gets absorbed and keep it overnight.~Step 3 - Use it for 60 days Frequency - Daily before going to bed. Route of Administration - Topical"
75420985|NCT05426447|Other|Dietary intervention of normal protein intake|6-wk dietary intervention of normal protein intake
75420986|NCT05418088|Biological|Anti-CD19/CD20/CD22 CAR T-Cells|Given IV
75719777|NCT05774275|Radiation|Radiotherapy|BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
75719778|NCT05774262|Procedure|Pacemaker implantation|Elective pacemaker implantation (DDDR) for functional AVB according to the 2021 ESC Guidelines for Cardiac Pacing
75874469|NCT03039738|Device|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) & Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
75874470|NCT03039738|Device|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
75420987|NCT05418088|Drug|Cyclophosphamide|Given IV
75420988|NCT05418088|Drug|Fludarabine Phosphate|Given IV
75420989|NCT05399966|Dietary Supplement|Monarda Didyma extract|Monarda Didyma extract; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
75420990|NCT05399966|Dietary Supplement|Placebo|Maltodextrin; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
75566458|NCT02922075|Other|No soft tissue graft|No soft tissue graft was used
75566459|NCT02944487|Drug|Lucerastat|Hard gelatin capsule for oral administration containing lucerastat
75566460|NCT02944487|Drug|Placebo|Matching placebo capsules
75566461|NCT00531245|Drug|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
75566462|NCT00529997|Device|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
75884252|NCT01363505|Device|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
75884253|NCT02134964|Drug|OLT1177 Capsules|OLT1177 Capsules are an experimental drug.
75884254|NCT02134964|Drug|Placebo Capsules|Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
75719779|NCT05774262|Procedure|Cardioneuroablation (CNA)|"Experimental method; elective implantable loop recorder (ILR) and biatrial, binodal, atomically and electroanatomically guided CNA with extracardiac vagal nerve stimulation (ECVS) prior and after procedure monitoring (disappearance of ECVS-induced AVB with the goal of achieving post-procedure and maintaining a target heart rate > 50 beats per minute). CNA procedure is performed with radio-frequency generators and irrigated catheters and with support of 3D-electroanatomic mapping system.~CNA group will receive external ECG recorders. The major reason for external ECG recorders is to provide documentation of clinical AVB, as well as monitoring of patients before and after CNA (or PM implantation, if accepted). In case of severe AVB symptoms always the emergency system will be called."
75719780|NCT05774171|Other|no intervention|no intervention
75719781|NCT05774158|Other|Physiotherapy assessment|Of the individuals included in the study; Information about age, height, body weight, type of congenital heart disease, surgical history, drug use, comorbid chronic disease, education level and occupation will be obtained. Functional Capacity, Peripheral Muscular Strength, Hand Grip Strength, Fatigue, Physical Activity Level, Quality of Life, Social Participation, Depression Anxiety Stress Level and Physical Activity Barriers will be evaluated
75719782|NCT05774119|Other|breakfast with coffee|breakfast with coffee with 6 mg/caffeine/kg body weight
75719783|NCT05774119|Other|breakfast with water|breakfast with 250 mL of water
75719784|NCT05774106|Behavioral|Participatory action research|First, a participatory intervention with nurses through the recording of four focus groups with the aim of understand, plan, change and maintain the practices surrounding the relationship therapy with their patients. Second, this intervention will be measured by administering scales to patients linked to the mental health case management program that provides service to different areas of the Barcelona Metropolitan Area. The variables to measure will be the quality of the therapeutic relationship, the recovery of the person and the overall functionality. These variables will be measured before and after finishing the participatory intervention.
75719785|NCT05774028|Drug|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen|P-GEMD regimen (Every 3 weeks as a cycle, a total of 6 cycles) : Pegaspargase 3750 IU, d2; Gemcitabine 1000mg/m2, d1; Etoposide 65mg/m2, d2-d4; Mitoxantrone hydrochloride liposome 12mg/m2, d1; Dexamethasone 40mg/d, d1- d4.
75874473|NCT05681117|Other|multi-component nutrition education|"Classroom-based nutrition education 40 minutes once a week for 4 weeks~SMS Reminders SMS reminders containing healthy nutrition tips 2 times a week, 1 weekday, 1 weekend, starting with nutrition education and throughout the education (4 weeks)~Brochure Distribution Brochures prepared in accordance with the content of classroom-based nutrition education were distributed immediately after the nutrition education.~Controversial Supermarket Tour Nutrition label reading activity aimed at gaining the ability to evaluate product contents, in line with the information explained in module 4, in the supermarket tour planned to be organized once with an appropriate number of student groups (maximum 7 people) after the nutrition education"
75874474|NCT05007899|Drug|Ferrous sulfate|Alternate day dosing of ferrous sulfate
75874475|NCT05147142|Device|Low Intensity Focused Ultrasound|Brainsonix BX Pulsar 1002
75874476|NCT05636345|Other|pain science education|A full day of pain science education
75420991|NCT05390034|Behavioral|ART|Session 1: Description of the group & Psychoeducation Session 2: Breathing and muscle relaxation Session 3: Importance of practice/motivation Session 4: Nonjudgemental awareness Session 5: Acceptance and tolerance Session 6: Self-support Session 7: Analysis of emotions Session 8: Modification of emotions Session 9: Practice and contextual applications + end of group
75420992|NCT05390034|Behavioral|Relaxation|Session 1: Description of the groupe & Psychoeducation Session 2: Breathing control 1 Session 3: Breathing control 2 Session 4: Muscle relaxation Session 5: Visualisation Session 6: Stretching Session 7: Schultz relaxation Session 8: Schultz relaxation Session 9: Summary and end of group
75420993|NCT05387525|Drug|Tirbanibulin (Klisyri®) 10 mg/g ointment|Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm^2 of the face or scalp with Actinic Keratosis (AK).
75874477|NCT04507373|Drug|Simvastatin 40mg|40mg oral daily for 10 weeks
75874478|NCT01312337|Drug|salvage iressa|Iressa 250mg per day until progression
75884255|NCT01363583|Drug|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
75719786|NCT05773937|Drug|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
75719787|NCT05773924|Device|triLift system|To evaluate the efficacy of the triLift™ treatment
75874479|NCT05174897|Behavioral|emotional liberation technique|experimental group; The child, to whom an intravenous catheter will be applied, is placed on a stretcher. pain ve score fear will be evaluated before the procedure. Then, the emotional liberation technique (EFT) will be applied for 10 minutes and an intravenous catheter will be applied to evaluate the pain and fear scores during and after the procedure.
75874480|NCT05232149|Drug|Orelabrutinib( lower dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia
75719788|NCT05773911|Device|4% chitosan gel (pH 3.48).|Reciprocal Chitosan brush with 4% chitosan gel (pH 3.48).
75874481|NCT05232149|Drug|Orelabrutinib( higher dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia
75874482|NCT05552495|Drug|CKD-386(4) F1|1 Tablet
75719789|NCT05773911|Device|Reciprocal Chitosan brush|Reciprocal Chitosan brush
75719790|NCT05773898|Other|other|The interviewers will collect data from relatives using questionnaires and evaluation grids based on an identification form, a Life Trajectory questionnaire, an anthropological evaluation grid, a retrospective psychiatric diagnosis questionnaire (SCID), a socio-demographic questionnaire, a questionnaire on suicide risks and a questionnaire on emotional state.
75874483|NCT05552495|Drug|CKD-386(4) F2|1 Tablet
75874484|NCT05552495|Drug|D013, D326, D337|D013 1 Tablet, D326 1Tablet, D337 1 Tablet
75874485|NCT05076227|Drug|IM injection of vaccination (mRNA vaccination)|mRNA vaccination
75874486|NCT05076227|Drug|IM injection of vaccination (vector based vaccination)|vector based vaccination
75874487|NCT04420403|Other|Manual Therapy|Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.
75874488|NCT04420403|Other|Cervical Stabilazation Exercise (CSE)|The CSE program aims to maintain a neutral spine position and activate deep cervical muscles during exercises. It is performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program will start with postural training and then the cervical bracing technique with the activation of deep neck flexors for CSE was performed. The patients will be asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises will be increased weekly. It will be carried out 2 days a week for 6 weeks (12 sessions) by the supervisor physiotherapist.
75874489|NCT05551949|Drug|Vaginal estradiol tablets|Vaginal estradiol tablets (10mcg).
75874490|NCT05283954|Drug|Combination regimen: Fluoxetine, Prednisolone, Ivermectin|"Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days."
75884256|NCT01363583|Drug|normal saline|0.5-1.5 ml/hour during 4 days
75884257|NCT02135120|Drug|Combined spinal epidural anesthesia technique with intrathecal morphine|
75420994|NCT05387525|Drug|Diclofenac Sodium 3% Gel|Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
75420995|NCT05384041|Device|Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)|The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.
75420996|NCT05384041|Device|Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)|The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
75420997|NCT05373316|Radiation|Ultrahypofractionated MR-guided radiotherapy boost|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
75420998|NCT05371275|Drug|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
75420999|NCT05370794|Drug|rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono|recombinant hCG
75421000|NCT05370794|Drug|rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono|recombinant FSH
75421001|NCT05343507|Drug|Ketalar 50 MG/ML Injectable Solution|Intravenous solution (other info already provided)
75421002|NCT05343507|Drug|Placebo|Saline Solution
75566463|NCT03458585|Other|Self-administered questionnaire|Self-administered questionnaire
75566464|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
75566465|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
75566466|NCT02922348|Drug|Hormone Replacement Therapy|Hormone replacement therapy as indicated in Arm 1
75719791|NCT05773885|Device|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|"The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
75719792|NCT05773885|Other|Conventional rehabilitation|"The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
75719793|NCT05773859|Biological|XP-DC vaccinations|Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
75566467|NCT02922348|Drug|Combined Oral Contraceptives|Combined oral contraceptives as indicated in Arm 2
75874491|NCT05283954|Drug|Combination regimen: Albendazole, Vitamin C|"Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days."
75874492|NCT01312415|Drug|Levobupivacaine|Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
75874493|NCT01312415|Drug|Intrathecal morphine|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
75566468|NCT02922270|Other|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
75566469|NCT00527501|Drug|Travoprost/brinzolamide|
75566470|NCT02943512|Other|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
75566471|NCT02925468|Device|Bite turbo|In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
75874494|NCT05143775|Procedure|Awake craniotomy|Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
75874495|NCT03036852|Drug|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
75421003|NCT05340712|Dietary Supplement|new infant formula|New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.
75421004|NCT05340712|Dietary Supplement|Standard formula|Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
75874496|NCT04979117|Device|Superb Microvascular Imaging (SMI) (Toshiba)|to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.
75566472|NCT02922387|Drug|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
75719794|NCT05773833|Behavioral|"Go Healthy program"|Weekly food boxes of fresh fruits and vegetables for 16 weeks; healthy eating and traditional foods curriculum available inside the box; monthly in-person healthy eating and traditional Indigenous foods cooking workshop; Indigenous cooking demonstration video website links to accompany recipes; and a kitchen starter kit with kitchen cooking supplies
75421005|NCT05321914|Behavioral|Exercise training|Exercise will consist of 1 set x 9 exercises x 3 sessions per week x 6 weeks. The load to be used during training will be calculated as 80% of one-repetition maximum (1RM) with each set performed to failure. 1RM will be re-tested on week 3, and the load adjusted accordingly, and upon completion of the study. During the training period, all sessions of training will be supervised by the researcher. The following exercises will be performed: Bench press, biceps curl, lat pull down, overhead press, lateral raise, leg extension, leg curl and calf raise.
75421006|NCT05309941|Other|Internal Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on intuitive eating principles.
75421007|NCT05309941|Other|External Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on traditional nutrition education principles such as label reading.
75421008|NCT05303298|Device|Anti-reflux oesophageal stent|Fully covered self-expanding metal stent with anti-reflux mechanism
75421009|NCT05303298|Device|Conventional oesophageal stent|Fully covered self-expanding metal stent without an anti-reflux mechanism
75421010|NCT05290883|Dietary Supplement|Novel yoghurt drink containing Polar Lipids|Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption
75421011|NCT05273281|Procedure|Transabdominal plane block|Peripheral nerve block
75566473|NCT02922387|Behavioral|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
75719795|NCT05773807|Other|Bispectral index|In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
75719796|NCT05773807|Other|Observer's assessment alert Sedation|In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
75719797|NCT05773807|Procedure|Gastroscopy|Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
75421012|NCT05273281|Procedure|Quadratus lumborum block|Peripheral nerve block
75421013|NCT05243394|Other|Gamified virtual reality treadmill gait training with tDCS|Progressive treadmill gait training in a gamified virtual reality environment with tDCS
75421014|NCT05243394|Other|Gamified virtual reality treadmill gait training|Progressive treadmill gait training in a gamified virtual reality environment
75421015|NCT05243394|Other|Treadmill gait training|Progressive treadmill gait training
75421016|NCT05228847|Dietary Supplement|Human milk-derived HMF|Fortification with human milk-derived product
75421017|NCT05228847|Dietary Supplement|bovine milk-derived HMF|bovine milk-derived HMF
75421018|NCT05226962|Dietary Supplement|Ketone monoester|A commercial liquid supplement ingested in a dose intended to provide ~0.35 g of ketone monoester per kg body mass of the participant
75421019|NCT05226962|Other|Placebo|A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
75421020|NCT05215210|Other|Bitter-gourd|12-week intervention of 3.6 grams of dried bitter-gourd supplements
75421021|NCT05215210|Other|Cucumber|12-week intervention of 3.6 grams of cucumber supplements
75566474|NCT00530153|Behavioral|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
75719798|NCT05773807|Drug|Propofol|Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
75719799|NCT05773794|Dietary Supplement|Soymilk, green tea, or blueberry|One dose of soymilk, green tea, or blueberry blends (460mL) with breakfast.
75719800|NCT05773794|Dietary Supplement|Control group|Breakfast with milk or water, without soymilk, green tea, or blueberry blends.
75719801|NCT05773781|Other|PuraBond|Application of PuraBond to surgical field
75719802|NCT05773729|Genetic|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
75719803|NCT05773716|Behavioral|Pelvic floor muscle training|Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2~6-second and a 2~6-second relaxation following each one.
75884258|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
75566475|NCT00530153|Dietary Supplement|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
75566476|NCT02922309|Behavioral|Vocal Training Via Telepractice|Vocal Training Via Telepractice, delivered by integrated communication service
75566477|NCT02922309|Behavioral|Vocal Training Via face-to face practice|Vocal Training Via face-to face practice at medical facilities
75566478|NCT00530192|Other|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
75566479|NCT02922231|Biological|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
75719804|NCT05773716|Other|Electroacupuncture|Participants will also receive electroacupuncture at bilateral Zhongliao (BL33), Huiyang (BL35), Zhongji (CV3), Guanyuan (CV4) and Dahe (KI12). During each therapy session, the electroacupuncture stimulation of acupoints in the abdomen and sacral regions will last for 30 minutes in total (15 minutes for each region) with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
75719805|NCT05773716|Other|Sham electroacupuncture|Sham electroacupuncture will be carried out with pragmatic placebo needles on the same acupoints in the experimental group. Procedures, electrode placements, and other treatment settings will also stay the same but with no electrical stimulation output.
75719806|NCT05773690|Other|Movement quality|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing mobility, stability and motor control exercises.
75874497|NCT01312493|Drug|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
75421022|NCT05213832|Drug|Isoflurane Inhal Soln|Administration of isofluorane in patients with severe SAH
75421023|NCT05186064|Diagnostic Test|whole genome sequencing|whole genome sequencing will be performed on tumor material after re-resection per standard of care
75421024|NCT05175651|Behavioral|Genetic risk assessment|A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.
75421025|NCT05164159|Drug|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 ~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
75566480|NCT02921724|Device|TreC-Onco|"TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:~Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.~Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher."
75566481|NCT04691882|Behavioral|Diaphragmatic contraction|Sequential periods (30 s) of voluntary diaphragmatic contraction after meal ingestion
75566482|NCT04691882|Behavioral|Diaphagmatic relaxation|Sequential periods (30 s) of voluntary diaphragmatic relaxation after meal ingestion
75566483|NCT02925507|Other|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
75874498|NCT01312493|Radiation|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
76044403|NCT05492669|Drug|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
76044404|NCT05492669|Drug|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
75421026|NCT05164159|Drug|remimazolam group|In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
75421027|NCT05164146|Drug|propofol|during the induction, remimazolam dose was controlled according to sedline (Psi target 40)
75566484|NCT00531323|Drug|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
75719807|NCT05773690|Other|Conventional Resistance Training|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing traditional strength training exercises
75719808|NCT05773625|Device|Just-In-Time Adaptive Intervention|Participants will be exposed to a new innovative app to test.
75719809|NCT05773612|Other|Rock Steady Boxing Class|Rock Steady Boxing is a non-contact fitness program designed specifically for people with Parkinson's Disease.
75874499|NCT05309837|Dietary Supplement|Polydextrose|Polydextrose-enriched food products
75874500|NCT05309837|Dietary Supplement|placebo-controlled|Control food products
75874501|NCT04313244|Biological|9vHPV vaccine|9vHPV intramuscular injection
75874502|NCT04313244|Biological|Dengue Tetravalent Vaccine (TDV)|TDV subcutaneous injection
75884259|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
75884260|NCT02135198|Drug|2 mg AZD7325|A single 2 mg oral dose of AZD7325
76044405|NCT02554721|Drug|Cilostazol|
76044406|NCT02554721|Drug|Acetylsalicylic acid|
76044407|NCT02554721|Drug|Clopidogrel|
76044408|NCT03810911|Drug|Darbepoetin|Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
75884261|NCT02135198|Drug|10 mg AZD7325|A single 10 mg oral dose of AZD7325
75884262|NCT02135198|Drug|Placebo|A single oral dose
75884263|NCT03131999|Drug|Imatinib Mesylate 400Mg Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
75884264|NCT03131999|Drug|Placebo - Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
75884265|NCT01319357|Drug|Saxagliptin|orally 5 mg/d for 6 weeks
75421028|NCT05164146|Drug|remimazolam|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
75566485|NCT00531323|Drug|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
75566486|NCT02921880|Other|Cardiac Rehabilitation|
75566487|NCT02921958|Behavioral|occupational therapy|Family-centered occupational therapy services
75566488|NCT04689126|Procedure|surgical or nonsurgical endodontic treatment|Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
75566489|NCT00531362|Drug|Plain aspirin|Plain aspirin 75 mg or 150 mg
75566490|NCT02925585|Other|Pre/post imaging|
75421029|NCT05156333|Dietary Supplement|Respecta|"Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed."
75566491|NCT00531401|Drug|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
75566492|NCT02925273|Other|palmar grasp without dorsal stimulation|"The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~Flexion at the distal interphalangeal joint of the hand~Flexion at the proximal interphalangeal joint of the hand~Flexion at the metacarpal-phalangeal joint of the hand"
75566493|NCT02925273|Other|standard palmar grasp test with dorsal stimulation|The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
75566494|NCT00531440|Drug|Everolimus (RAD001)|
75566495|NCT04015011|Combination Product|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
75719810|NCT05773560|Device|virtual reality rehabilitation|All patients will receive VR-assisted rehabilitation. The VR-assisted rehabilitation is proceed with SyncVR® (Padualaan, Netherlands ) equipment, which is composed of a head set (PICO NEO 3) and one dashboard (TABLET), enabling the patients to receive stepwise rehabilitation program with 360° videos activities (SyncVR Medical Platform). The VR-assisted rehabilitation will be performed two times per day, 30 minutes per training. The first training will start on the second post-operative day.
75719811|NCT05773547|Device|MSOT measurements|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
75421030|NCT05132517|Diagnostic Test|Kölner Neuropsychologische Screening für Schlaganfall-Patienten|The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.
75566496|NCT02944526|Drug|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
75566497|NCT02944526|Drug|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
75566498|NCT04013763|Other|wheat containing skin care products|stop or continue using wheat containing skin care products
75566499|NCT00530309|Drug|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
75566500|NCT00530309|Drug|Placebo|Subjects will also receive placebo.
75566501|NCT02917785|Device|Karman curettage|
75566502|NCT04000854|Drug|Calcium hydroxide (Calacept)|Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
75884266|NCT01319357|Drug|Placebo|orally for 6 weeks
75884267|NCT02135354|Drug|Azithromycin|"From day 1 up to and including day 3: 500 mg azithromycin PO once a day~From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
75884268|NCT02135354|Drug|Placebo|"From day 1 up to and including day 3: 500 mg placebo PO once a day~From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
75884269|NCT01319435|Procedure|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
75884270|NCT05416099|Procedure|laser|grid vs micropulse laser
75884271|NCT02140034|Procedure|Extensive Peritoneal Lavage|
75884272|NCT02055053|Drug|0.5% Bupivicaine|Local anesthetic
76044409|NCT03801005|Biological|Blood and Marrow sample|"Twenty patients will be included in a prospective way over a period of nine months. No additional medullary or serum samples will be carried out in addition to those required for the clinical routine. Only an additional blood sample taken during a routine blood test will be recovered as part of the research. Just as some leftover bone marrow, taken as part of a usual unused follow-up will be recovered as part of this trial.~The persons concerned will be recruited on the occasion of their hospitalisation in one of the hematology services participating in the research, or during their consultation with one of the hematologists of the corresponding service (or services). On this occasion, detailed information on their pathology and research will be given, as well as the information document on the proposed research protocol."
76044410|NCT03799523|Other|Temporary skin markings|To use temporary markings in lieu of localization tattoos.
75421031|NCT05114447|Other|Routine medical care|"Eligible subjects will be contacted from physicians, by telephone or directly when they attend the clinical centre for control visits. Once the patients have provided their signed informed consent, they will have to fill in the clinical form and to perform routine functional/clinical tests.~Subjects will be investigated at baseline (T0), at 6-month follow-up (T6) and at 12-month follow-up (T12).~All the possible variations that could occur in the patients' disease status and disease management, according to the routine medical care, will be registered and taken into account in the RISER study.~RISER study is not a clinical trial, but it is an observational study without any specific drug administration by the investigators. Participants will receive interventions, which can include medical products, such as drugs or devices, or procedures, as part of their routine medical care but they will not be assigned to specific interventions by the investigator as in a clinical trial."
75566503|NCT03994614|Other|TEAS|Patients in the experimental group will be given TEAS treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26).
75566504|NCT00530387|Drug|19 organic sunscreen filters and 5 topical NSAIDs|
75566505|NCT04689165|Biological|Experimental Group A meningococcal polysaccharide vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
75566506|NCT04689165|Biological|Control Group A meningococcal polysaccharide vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
76044411|NCT03799523|Other|Surface imaging|To use light-based surface imaging for patient positioning during radiation treatment.
76044412|NCT02552225|Drug|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
75719812|NCT05773534|Diagnostic Test|MSOT|Similar as the conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via laser light, leading to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same transducer head that releases the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
76044413|NCT02552225|Other|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
76044414|NCT05474261|Procedure|Valsalva maneuver|Valsalva maneuver: increase intrabdominal pressure
75719813|NCT05773508|Device|Video regulation and emergency kit|Video regulation and emergency kit
75719814|NCT05773469|Other|Exercise|Ski traverse of Greenland polar Icecap
75719815|NCT05773469|Other|Nutrition|Maximising energy intake by consuming over the theoretical 2.4 x RMR
75421032|NCT05114447|Other|Telephone interview|"Eligible subjects will be contacted by telephone from trained personnel of the Research Unit. Once the signed informed consent is obtained by each enrolled subject, they will be invited to answer the phone questionnaire.~Subjects will be investigated at baseline (T0) and at 12-month follow-up (T12). Subjects fitting the epidemiological definition of severe/uncontrolled asthma will be invited at the Pisa clinical centre to have routine clinical/functional tests.~Each subject performing baseline clinical/functional tests at the Pisa clinical centre will be clinically and functionally re-assessed"
75421033|NCT05111431|Drug|Dexmedetomidine Hydrochloride Nasal Spray|"In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray."
75421034|NCT05111431|Drug|Dexmedetomidine hydrochloride nasal spray blank preparation|"In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
75421035|NCT05095792|Other|Observational - no intervention|This is an observational study with no intervention.
75421036|NCT05093426|Other|Stage 2 Digital sleep diary app|Participants in Stage 2 will be asked to download a digital sleep diary app and complete a sleep log every day for 21 days.
75566507|NCT04689087|Combination Product|TTFields|For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
75566508|NCT00530543|Procedure|Robot-assisted gait training|
75566509|NCT00530582|Drug|progesterone|300mg progesterone /placebo each for 21 days
75566510|NCT00530660|Biological|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
75566511|NCT02917863|Drug|L-Thyroxine (tablet, per os)|
75421037|NCT05056090|Procedure|Patients will receive MV in PP|Putting the patient in a prone position
75566512|NCT02917863|Drug|L-Thyroxine (oral drops, solution)|
75566513|NCT00530699|Drug|AZD1152|intravenous
75719816|NCT05773443|Device|Digital biomarkers|Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
76044415|NCT05473949|Drug|Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
76044416|NCT05473949|Drug|Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
76044417|NCT04424069|Procedure|Refractive surgery|Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures
76044418|NCT05492279|Dietary Supplement|sheep ghee|natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
75874503|NCT04977947|Behavioral|Healthy Eating for My Infant|The intervention targets problem solving to overcome barriers, behavioral rehearsal and practice of healthy behaviors, promoting readiness to change, goal setting, self-monitoring, and behavioral tracking. Two standard treatment modules will be provided to each family by a study interventionist focusing on infant nutritional requirements, responsive feeding, and mealtime behaviors. Two additional treatment modules will be selected to address the unique needs articulated by each family (e.g., food insecurity, eating healthy on a limited income, emotional eating, engaging other caregivers, maternal mental health). Modules will consider the influence of maternal trauma history and mental health on feeding and eating behavior. The intervention also includes two peer counselor-led sessions during which families can discuss implementation of recommendations and barriers to change with a member of their community who can problem solve and support change.
75421038|NCT05044325|Drug|GSK3884464|GSK3884464 will be administered
75421039|NCT05044325|Drug|Placebo|Placebo to match GSK3884464 will be administered.
75874504|NCT04294290|Biological|hCT-MSC infusion|This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
75566514|NCT02917824|Device|High-intensity IMT|30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
75421040|NCT05035199|Behavioral|Spiritual Distress and Resources Questionnaire (SDRQ)|The SDRQ is a validated self-rating instrument to assess spiritual distress and resources. It focuses on beliefs, attitudes, experiences and practices of various kinds (every day and extraordinary), as well as on (dis-)connectedness. It consists of 22 items covering three subscales: spiritual resources, spiritual distress, and spiritual coping (Peng-Keller et. al., 2020, submitted). We constructed five additional questions to find out more why patients want to include spiritual aspects in their treatment.
75566515|NCT02917824|Device|Low-intensity IMT|30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
75566516|NCT00530738|Drug|Lipoplus|i.v. fat emulsion for parenteral nutrition
75719817|NCT05773430|Behavioral|Targeted Neurocognitive Training|Only two cognitive domains will be targeted for training (10 hrs of training in each, for a total of 20 hours). Two or more cognitive exercises may be employed within a cognitive domain. These exercises provide both immediate and intermittent feedback and are customized to the participants' individual ability; the difficulty and/or complexity of each game are systematically decreased/increased based on participants' performance to always be challenging, but not overly frustrating. Typically, in an hour session, one exercise (e.g., Mental Map) will be engaged at a time (20-30 minutes) before switching to another exercise (e.g., Hawkeye) in another domain for 20-30 minutes. This helps the participant remain engaged but avoid fatigue.
75719818|NCT05773235|Diagnostic Test|Combined 3- and 7 Tesla-MRI|7 Tesla-MRI including the following sequences: susceptibility weighted imaging (SWI), T1, T2, FLAIR, quantitative mapping sequences (T1mapping, qSM)
75566517|NCT00530738|Drug|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
75874505|NCT05108909|Device|MRI, CT, and serum biomarkers|magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
75874506|NCT05309694|Combination Product|Paragard® T380A Intrauterine Copper Contraceptive with New Inserter|"Paragard® IUS with Investigational Inserter combines the current insertion tube and white rod to form a new pre-assembled inserter device that supports a single hand operation.~The device is used to pass the IUS through the cervical canal and into the uterine cavity and facilitates insertion of the T shaped Paragard® IUS implant into the uterus."
75874507|NCT05131529|Other|Taste-focused labels|"We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger)."
76044419|NCT05492279|Dietary Supplement|sunflower oil|natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
76044420|NCT02552147|Drug|Transdermal nicotine|
76044421|NCT02552147|Other|Transdermal placebo|
76044422|NCT05479487|Drug|Fluzoparib+Apatinib|Fluzoparib 100mg bid+ Apatinib 375mg qd
76044423|NCT05479487|Drug|Fluzoparib Monotherapy|Fluzoparib 150mg bid
75566518|NCT02921685|Drug|Monalizumab|Four dose levels will be tested.
75566519|NCT02944175|Drug|Sugammadex|At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
75566520|NCT02944175|Drug|Neostigmine|At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
75566521|NCT02917746|Drug|Imiquimod|Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
75566522|NCT02917746|Procedure|Large Loop Excision of the Transformation Zone|Patients in this group are treated with LLETZ.
75566523|NCT04688892|Device|Cupping|dynamic cupping
75566524|NCT02944370|Behavioral|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
75566525|NCT00531557|Drug|Darunavir ritonavir|
75874508|NCT05131529|Other|Carbon impact labels|We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.
75874509|NCT05131529|Other|Changing default menu options|We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
75874510|NCT04784598|Other|Insoles adapted in flip-flop sandals|participants of both groups individually received a pair of customized flip-flop sandals, with or without foot pieces, covered with smooth synthetic leather
76044424|NCT05479409|Radiation|Neoadjuvant radiotherapy|radiation therapy combined with chemotherapy prior to surgery
76044425|NCT05479253|Diagnostic Test|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture images, prompt abnormal lesions and the parts covered by the examination (the stomach is divided into 26 parts).
75421041|NCT05029713|Diagnostic Test|Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)|The use of handgrip dynamometer and BIA will be used to screen all liver transplanted patients for sarcopenic obesity, using a muscle strength cut-off <27 Kg in men and <16 Kg in women and a standardized muscle mass cut-off <0.789 ASMM/BMI for men and 0.512 ASMM/BMI for women.
75566526|NCT02921568|Device|P200TE|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
75566527|NCT02921568|Device|Spectral OCT/SLO|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
75566528|NCT02944097|Dietary Supplement|Vineatrol 30 native powder|
75566529|NCT02944097|Dietary Supplement|Vineatrol 30 micelles|
75566530|NCT02917902|Other|Food boxes|Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
75566531|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
76044426|NCT05479175|Drug|Ibuprofen|Ibuprofen
76044427|NCT05479175|Device|Diode laser|Diode laser
76044428|NCT05479175|Device|Nonactive Diode laser|Nonactive Diode laser
76044429|NCT05472857|Biological|Claudin 18.2 CAR-T|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
76044430|NCT05491889|Biological|trans arterial chemoembolization|trans arterial chemoembolization in patient with partial portal vein thrombosis
76044431|NCT02534935|Biological|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
75421042|NCT05016232|Behavioral|PrEP N' Shine: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
76044432|NCT02534935|Biological|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
75421043|NCT05016232|Behavioral|PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)|"Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
75566532|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
75566533|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
75566534|NCT02921646|Other|Measure of resting energetic expenditure|measure of resting energetic expenditure
75566535|NCT02943707|Procedure|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
75566536|NCT02943707|Drug|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
75566537|NCT00531635|Drug|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
75566538|NCT02917551|Other|7 days of adequate antibiotic treatment|
75566539|NCT02917551|Other|14 days of adequate antibiotic treatment|
75874511|NCT05097677|Other|Not applicable (observational study)|Not applicable (observational study)
75566540|NCT00531674|Dietary Supplement|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
75566541|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
75566542|NCT00531674|Dietary Supplement|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
75421044|NCT05015543|Other|Personal Training Program|One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.
75566543|NCT00531674|Dietary Supplement|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
75421045|NCT04975568|Other|App and face-to-face physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites. During the app used they will have 6 face-to-face sessions in 6 people groups with a physical Therapist in a 3 months period
75421046|NCT04975568|Other|App physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites.
75421047|NCT04956939|Drug|Low dose levodopa|Low frequency is defined as ≤ 3 LD doses a day
75566544|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
75566545|NCT00531674|Dietary Supplement|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
75566546|NCT02921529|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
75719819|NCT05773183|Drug|Testosterone|In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
75874512|NCT05268822|Other|Home exercise|Movement control exercise with or without specific breathing techniques
75874513|NCT05268510|Drug|Pembrolizumab|400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
75874514|NCT05268510|Drug|Olaparib|300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
75566547|NCT02921529|Other|false stimulation|Electrodes were attached to specific acupoints without electric current
75566548|NCT02943824|Other|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
75566549|NCT02943824|Other|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
75566550|NCT02921607|Other|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
75566551|NCT00530933|Procedure|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
75566552|NCT00530933|Procedure|Transcutaneous tibial nerve stimulation|30 minutes once weekly
75719820|NCT05773183|Drug|GnRH|20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
75874515|NCT05268510|Drug|mFOLFOX-6|Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles
75874516|NCT05268510|Drug|CapOX|Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
75566553|NCT00530933|Procedure|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
75566554|NCT02917668|Other|FreeO2|Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
75566555|NCT02917668|Other|Usual care|Oxygen delivery manually titrated by the nursing staff for a SpO2 target of > or = 95 %
75719821|NCT05773157|Behavioral|Online Modules|Participants receive modules to improve responsive feeding practices of caregivers
75719822|NCT05773144|Behavioral|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
75719823|NCT05773144|Behavioral|Progressive stretching|Static stretching of eight major muscle groups
75719824|NCT05773131|Device|VR collaborative visualization system|Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
75874517|NCT05042453|Device|Splentis® POP Tissue Anchoring System|Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis
75874518|NCT05309681|Other|Epworth's sleepiness scale; unstimulated saliva sample|Unstimulated saliva sample; Epworth's sleepiness scale
76044433|NCT05430295|Procedure|phacoemulsification|cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients
75421048|NCT04956939|Drug|High dose levodopa|High frequency dosage is defined as ≥ 5 LD doses per day
75421049|NCT04955470|Drug|Ketamine Injectable Solution|A 10 mg/mL solution of ketamine will be infused over a 40 minute period at a dose of 0.05mg/kg.
75421050|NCT04955470|Drug|Midazolam Injectable Solution|A 5 mg/mL solution of midazolam will be infused over a 40 minute period at a dose of 0.02 mg/kg.
75874522|NCT05033717|Other|Tissue Flossing Technique|"Subjects will receive tissue-flossing intervention on bicep muscle for 30 sec to 2 min with an occlusion pressure of 100 mmHg.~After removal of flossing, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 rep, 4 sets for a single day and 3 days per week for 2 weeks in total."
75874523|NCT05033717|Other|Static Stretching Technique|"Subjects will perform passive static stretching exercises of bicep muscle. Each stretch will last for 30 sec at 100% of stretch intensity with 4 reps for each, 1 set per day and 3 days per week for total duration of two weeks.~After the application of static stretch, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 reps, 4 sets for a single day and 3 days per week for 2 weeks in total."
75566556|NCT00531713|Drug|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
75719825|NCT05773027|Behavioral|SAFE|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
75874524|NCT05026931|Other|Foam rolling|Group A will be treated with foam rolling effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
75874525|NCT05026931|Other|Stretching exercises|Group B will be treated with stretching exercises effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
75874526|NCT05477693|Biological|Experimental 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
75874527|NCT05477693|Biological|Control 23-valent PPV|The control vaccine was manufactured by Merck Sharp & Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
75874528|NCT03638843|Procedure|Gastric mucosal devitalization|Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
75421051|NCT04955470|Drug|Normal Saline 0.9% Injectable Solution|A 0.9% normal saline solution will be infused over a 40 minute period.
75874529|NCT04927325|Other|Set of Photos|A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
75421052|NCT04944121|Drug|RSLV-132|10 mg/kg RSLV-132 administered by intravenous infusion
75566557|NCT02921334|Procedure|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
75566558|NCT00530972|Drug|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg <75 kg, 1200 mg >75 kg)
75566559|NCT02943863|Device|HFNC followed by conventional nasal cannula|
75566560|NCT02943863|Device|Conventional nasal cannula followed by HFNC|
75566561|NCT02943278|Behavioral|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
75719826|NCT05773027|Behavioral|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
75874530|NCT05309447|Other|data collection|The study entails the collection of clinical, functional, radiological, and biomechanical data.
75874531|NCT05309213|Biological|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level:5 x 10^4 CAR+ T cells/kg,1x 10^5 CAR+ T cells/kg,3 x 10^5 CAR+ T cells/kg,1 x 10^6 CAR+ T cells/kg
75874532|NCT05309057|Dietary Supplement|Intermittent Fasting|Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
75566562|NCT02943278|Behavioral|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
75566563|NCT02943434|Other|Processed food|This is examining the effects of processed foods on diet-induced thermogenesis.
75566564|NCT02917707|Other|normal colorectal tissues|The investigators will extract total protein, DNA and RNA from these groups.
75566565|NCT02921451|Device|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
75421053|NCT04944121|Drug|Sodium Chloride 0.9%|0.9% sodium chloride administered by intravenous infusion
75566566|NCT02943317|Drug|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
75421054|NCT04925401|Behavioral|The Information brochure will be created on the basis of information given by the French pediatric network Courlygone and the French National Authority for Health.|An information brochure on fever in children and how to deal with a paediatric febrile episode and usual medical management.
75566567|NCT02943317|Drug|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
75421055|NCT04922645|Drug|Ferric Citrate 1 gram Oral Tablet|Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).
75566568|NCT02917590|Other|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
75566569|NCT02917590|Other|Single-task obstacle crossing training|Obstacle crossing training
75566570|NCT02943356|Drug|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
75719827|NCT05772975|Biological|H-PRF (Horizontal-platelet rich fibrin)|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. it serves as a biological healing matrix by supporting cell migration and cytokine release. H-PRF is obtained by horizontal centrifugation using (Bio-PRF) centrifuge on 700 g force for 8 minutes. This way the cells separate much more efficiently throughout the entire membrane/clot.
75874533|NCT05438303|Drug|AZD9833|AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
76044434|NCT05430295|Procedure|monofocal intraocular lens implantation|implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
75421056|NCT04922645|Drug|Standard of care phosphate-lowering therapy|Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.
75421057|NCT04922567|Drug|Lenalidomide|25mg po on day 1-10
75566571|NCT02921373|Biological|19F Cell Sense-labeled PBMC|"Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging."
75566572|NCT02921373|Device|MRI|Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
75421058|NCT04922567|Drug|Cyclophosphamide|750mg/m² iv on day1
75566573|NCT02943239|Drug|REGN1033|REGN1033
75421059|NCT04922567|Drug|Doxorubicin|50mg/m² iv on day 1
75421060|NCT04922567|Drug|Vincristine|1.4mg/m² iv on day 1
75421061|NCT04922567|Drug|Prednisone|100mg po on day1-5
75566574|NCT02943239|Drug|REGN2477|REGN2477
75566575|NCT02943239|Other|Placebo|Placebo
75566576|NCT02917512|Drug|HU00701|Cyclosporine 0.01% + 3% trehalose
75566577|NCT02917512|Drug|HU007|Cyclosporine 0.02% + 3% trehalose
75566578|NCT02917512|Drug|Restasis|Cyclosporine 0.05%
75566579|NCT02917512|Drug|Placebo|Vehicle
75566580|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks & 9 months
75566581|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks & 9 months
75566582|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6&14 weeks & 9 months
75421062|NCT04899882|Other|KinHémo|Evaluation and cardiovascular training, combination of resistance and flexibility training
75566583|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks & 9 months
75421063|NCT04873232|Biological|Engensis|Injections with Engensis in study VMDN-003-2
75566584|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks & 9 months
75719828|NCT05772975|Biological|E-PRF|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. In order to extend its resorption period heating method is used. After centrifugation of blood using (Bio-PRF) centrifuge on 700 g force for 8 minutes top layer is heated for 10 minutes at 75°C in BIO-Heat device. When cooled it is mixed with cell rich buffy coat. This way PRF with extended life is obtained.
75719829|NCT05772936|Behavioral|Balance training|perturbation induce step training to improve reactive stepping with paretic leg.
75421064|NCT04873232|Other|Placebo|Injections with Placebo in study VMDN-003-2
75421065|NCT04851704|Behavioral|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
75421066|NCT04835077|Other|aerobic exercise|Structured aerobic exercises (Each session will consist of 50 minutes and will be divided into three parts: 5 minutes of warm-up exercises, 40 minutes of aerobic exercises, 5 minutes of cool down exercises) will be taught in the first session.
75421067|NCT04835077|Other|postural stabilization exercises|Structured postural stabilization exercises (strengthening exercises, balance-coordination exercises, flexibility exercises) will be taught in the first session.
75421068|NCT04801745|Other|Healthy vegan diet|Participants will attend group lessons and individual nutrition counseling to help them adopt a healthy vegan diet.
75421069|NCT04801745|Other|My Plate - Low Purine|Participants will attend group lessons and individual nutrition counseling to help them adopt a balanced diet in accordance with my plate, and emphasis on choosing low purine options from the protein food groups.
75566585|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6&14 weeks & 9 months
75566586|NCT00531908|Drug|furosemide|furosemide
75421070|NCT04801745|Other|Amla fruits|Participants will be provided with powdered amla fruits, and will be instructed to take 3g per day.
75421071|NCT04788368|Procedure|Surgical resection|Surgical resection with either of the above mentioned techniques
75719830|NCT05772923|Radiation|Contact x-ray brachytherapy|With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.
75719831|NCT05772923|Procedure|Local excision|Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
75421072|NCT04780217|Biological|T3011|T3011 will be administered through IV drip or pumping.
75421073|NCT04765774|Other|Ekspressive touch|Patients will be divided into three groups. The expressive touch group will touch the patient's hand.
75421074|NCT04765774|Other|Music|The music chosen by the patient will be played in the music group.
75874534|NCT05438303|Drug|Midazolam|Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole
75421075|NCT04715061|Other|Resting state (Control)|Participants were asking to sit on a sofa for 50 minutes.
75566587|NCT03403569|Drug|Triptolide Wilfordii|In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.
75566588|NCT03403569|Drug|Placebo Oral Tablet|In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
75874535|NCT05438303|Drug|Omeprazole|An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam
75874536|NCT05438303|Drug|Dabigatran Etexilate|A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2
75421076|NCT04715061|Other|Moderate Intensity Continuous Exercise (MICE)|MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)
75421077|NCT04715061|Other|High Intensity Interval Exercise (HIIE)|HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels > 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
75566589|NCT00531791|Drug|prednisone group|Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
75719832|NCT05772884|Other|Supervised Exercise Intervention|Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.
75566590|NCT00531791|Drug|Advair group|Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
75566591|NCT02943551|Other|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
75566592|NCT02943551|Other|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
75719833|NCT05771571|Other|Functional olive oil, enhanced with orange peel extract|The functional olive oil was enriched with 10% w/w orange peel extract
75719834|NCT05771571|Other|Control|Refined olive oil
75719835|NCT05771519|Behavioral|HIV disclosure intervention|This will be a biobehavioral intervention focused on helping men with HIV to disclose their HIV status to a personal confidant inclusive with specific focus on sexual partners.
75874537|NCT05438303|Drug|Celecoxib|A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
75874538|NCT05432141|Biological|sIPV vaccine /DTaP vaccine|All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
75874539|NCT05432141|Biological|sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine|All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
75719836|NCT05771467|Other|Optical Coherence Tomography Angiography (OCTA) • Biometry • Auto refractometry • Non contact tonometry|Ophthalmologic Examination Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)
75874540|NCT04868279|Behavioral|Web-Based Interactive Nurse Support Program Based on Health Promotion Model|Nursing education will be given on healthy behaviors such as nutrition, exercise, health responsibility and stress management according to the health promotion model. The researcher will make phone calls with the intervention group for 6 months (12 times in total), twice a month. During telephone interviews, individuals will be talking about the use of the website, the points that are not understood or need to be emphasized, their application of health promotion behaviors, the obstacles they experience during the application and the suggestions for this.
75874541|NCT04859231|Other|Control|Cow's milk-based formula
75719837|NCT05769894|Other|No intervention given|No intervention is planned. Blood samples will be taken at different stages.
75719838|NCT05769296|Device|Headpulse measurements|Placement of headset on subject
75719839|NCT05768893|Device|Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm|Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.
75719840|NCT05768893|Device|Er:YAG Laser 2940nm|Warts with this intervention treated only with the Er:YAG laser.
75719841|NCT05767866|Drug|YK-029A|Daily dose of YK-029A
75719842|NCT05766995|Device|Waterpik Water Flosser|A pulsating water flosser and jet tip designed to clean between the teeth and below the gingival margin.
75719843|NCT05766995|Device|Oral-B Water Flosser|A water flosser and specialized tip that delivers water with microbubbles of air
75719844|NCT05766995|Device|Waxed Dental Floss|Nylon string used to clean between the teeth manually
75719845|NCT05761119|Other|Physical activity|The focus of the intervention is on exercises that can improve venous return, and consists of progressive walking training at moderate and high intensity as well as guidance on physical activity. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to hit 30 min. times/day at moderate intensity. After 14 days, the patient receives physiotherapeutic guidance in physical activity and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achieve 2 x 20 min./week of high-intensity physical activity. After one month of training, the patient will be guided on maintaining and possibly progressing physical activity.
75719846|NCT05761106|Other|Oculomotor Therapy|It will consist exercise of a convergence technique and an accommodative technique.
75719847|NCT05761106|Other|Therapy for Temporomandibular Disorder|It will consist exercise of a ATM and cervical spine.
75874542|NCT04859231|Other|Investigational|Cow's milk-based formula with added source of enriched whey protein
75874543|NCT05308823|Procedure|Stent|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
75874544|NCT04804319|Other|9-days habitual diet|9-days study with habitual diet including one standardized breakfast on a single day
76044435|NCT05429359|Other|CPET: CardioPulmonary Exercise Test for CSII users|"Baseline~VO2peak measurement~Breakfast~100% bolus insulin~CSII users: 100% basal"
75566593|NCT02943551|Other|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
75566594|NCT02943551|Other|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
75566595|NCT02943551|Other|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
76044436|NCT05429359|Other|AEX1: Aerobic Exercise Test 1 for CSII users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~CSII users: -2h target 150 mg/dL"
75421078|NCT04700774|Behavioral|Behavioral activation|Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko & Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.
75719848|NCT05746130|Behavioral|Plastic-free nutrition program|"Applying the plastic-free diet as four meals (three main meals, one snack) in pension kitchen. Promoting of glass water bottle giving and daily use.~Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample."
76044437|NCT05429359|Other|AEX2: Aerobic Exercise Test 2 for CSII users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~CSII users: -1h target 150 mg/dL"
76044438|NCT05429359|Other|CPET: CardioPulmonary Exercise Test for MDI users|"Baseline~VO2peak measurement~Breakfast~100% bolus insulin~MDI users: 100% basal"
75421079|NCT04654104|Other|check immune check points|we will evaluate the expression of immune check points
75421080|NCT04651465|Behavioral|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
75421081|NCT04636632|Drug|fosaprepitant|fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
75566596|NCT02921178|Other|Omalizumab|comparision of using Omalizumab and non-Omalizumab treatment
75566597|NCT03279276|Procedure|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
75719849|NCT05746130|Behavioral|Interactive education|"Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample"
75719850|NCT05746130|Behavioral|BPA exposure feedback|Feedback about BPA levels in theirs urinary sample
75719851|NCT05743335|Biological|JCXH-221|Participants will be randomized to either placebo or JCXH-221 for Phase 1. For Phase 2, participants will either be randomized to JCXH-221 or a FDA approved Active comparator.
76044439|NCT05429359|Other|AEX1: Aerobic Exercise Test 1 for MDI users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~MDI users: 50% basal"
76044440|NCT05429359|Other|AEX2: Aerobic Exercise Test 2 for MDI users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~MDI users: 80% basal"
76044441|NCT02723773|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
76044442|NCT02544451|Drug|LUM/IVA|"Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older)."
76044443|NCT02544451|Drug|LUM/IVA|LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).
76044444|NCT05455333|Other|Questionnaires|Sends and returns questionnaires to families.
76044445|NCT02544373|Device|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
76044446|NCT02551991|Drug|nal-IRI|
76044447|NCT02551991|Drug|5 fluorouracil|
76044448|NCT02551991|Drug|Leucovorin|
76044449|NCT02551991|Drug|Oxaliplatin|
76044450|NCT04268615|Other|Covert Saccades and Virtual Reality|During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
76044451|NCT04268615|Other|Actives versus passives Head Impulses|Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
76044452|NCT04268615|Other|Visually guided saccades|Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
75719852|NCT05743335|Biological|Active Comparator|Participants will be randomized in Phase 2 to either JCXH-221 or a FDA approved Active Comparator,
75566598|NCT02943044|Device|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
75566599|NCT02921217|Dietary Supplement|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
75566600|NCT02921217|Dietary Supplement|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
75566601|NCT02921217|Dietary Supplement|Control|Placebo: 300 mg maltodextrin.
75566602|NCT02943122|Device|Ambulatory blood pressure monitor|
75566603|NCT00531986|Drug|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
75566604|NCT00531986|Drug|HAART|Patients will continued their current HAART
75566605|NCT00531869|Behavioral|biases towards products|
75719853|NCT05743335|Other|Placebo|Participants will be randomized in Phase 1 to either JCXH-221 or placebo
75719854|NCT05739513|Diagnostic Test|miRNA analysis in plasma|blood sample
75719855|NCT05737147|Device|Zero Heat Flux Thermometer|Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
75719856|NCT05736796|Other|Lumber strengthening exercises|Complex Training program to Achieve the normal postural. Lumber Extension Excersie will be done to prevent the lumber straighten.
75719857|NCT05736796|Other|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
75874545|NCT05308745|Dietary Supplement|Yakult®|Fermented milk drink containing over 6.5×10^9 CFUs of L. casei Shirota/65 ml
76044453|NCT05472389|Other|Video-electroencephalography|All patients will be monitored 24 hours. Whenever possible, duration of the long-term monitoring will be extended to 48 hours, including a second full night polysomnography. These recordings will also allow us to assess sleep architecture and to capture seizures in some patients video , EEEG, EKG, respiration and other polysomnography data will be centralized at Hospices Civils de Lyon. A copy of the EEG-EKG data required to address the objectives related to cardiac features will then be electronically transferred to Partner 2 (Bonn) Evaluation will be performed blind to other data by the Partner 1 (Lyon) for the respiratory data and by the Partner 2 (Bonn) for the EKG data All primary outcomes and secondary outcomes will be assessed with respect to duration of epilepsy and frequency of convulsive seizures during the baseline period.
75566606|NCT02917434|Dietary Supplement|Very Low Energy Diet (VLED)|Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
75421082|NCT04633603|Device|FeverFriend mobile application|Registration, documentation of patients profile, documentation of fever events, following advice regarding the patient and the care-giver, documentation of follow up notifications.
75421083|NCT04632225|Biological|Engensis|Lyophilized biologic to be reconstituted containing Engensis
75421084|NCT04632225|Other|Placebo|Injectable liquid
75421085|NCT04631562|Drug|ALXN1820 SC|ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
76044454|NCT05472389|Other|Blood Samples|Blood samples will be collected at V2 in all patients. A total of seven blood samples of 4 ml each will be collected, including five EDTA and two dry. Samples EDTA plasma and serum will then be prepared after centrifugation. In children < 10 kg, only 5 samples of 4 ml each (22 ml in total), including four EDTA and one dry.
75421086|NCT04631562|Drug|ALXN1820 IV|ALXN1820 IV (450 mg) will be administered as an IV infusion.
75421087|NCT04631562|Drug|Placebo SC|Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
75421088|NCT04631562|Drug|Placebo IV|Placebo IV will be administered as an IV infusion.
76044455|NCT05491811|Drug|Ensartinib|Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
75566607|NCT02920827|Combination Product|Dapivirine Vaginal Ring|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
75566608|NCT02920827|Combination Product|Placebo vaginal ring|Placebo vaginal ring containing no dapivirine
75566609|NCT05319743|Other|Medicaid Expansion|Expansion of Medicaid, 01/01/2014
75874546|NCT05308745|Dietary Supplement|Placebo|Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
75874547|NCT04803227|Drug|Emricasan|Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.
75874548|NCT04803227|Other|Placebo|Placebo BID *days 1-14). Oral (capsule) administration.
75421089|NCT04629131|Biological|TNM002 Dosage 1 (10 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 10 μg/kg, Intramuscular injection, given once.
75421090|NCT04629131|Biological|Placebo|placebo to match TNM002 Dosage 1, given once
75421091|NCT04629131|Biological|TNM002 Dosage 2 (35 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 35 μg/kg, Intramuscular injection, given once
75421092|NCT04629131|Biological|Placebo|placebo to match TNM002 Dosage 2, given once
75421093|NCT04629131|Biological|TNM002 Dosage 3 (100 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 100 μg/kg, Intramuscular injection, given once
75421094|NCT04629131|Biological|Placebo|placebo to match TNM002 Dosage 3, given once
75421095|NCT04629131|Biological|TNM002 Dosage 4 (250 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 250 μg/kg, Intramuscular injection, given once
75421096|NCT04629131|Biological|Placebo|placebo to match TNM002 Dosage 4, given once
75421097|NCT04583358|Drug|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
75421098|NCT04583358|Other|Placebo (oral)|Orally administered placebo comparator taken once daily
75566610|NCT02921100|Procedure|cytology|The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.
75566611|NCT02921100|Procedure|DNA ploidy|DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy
76044456|NCT05491811|Drug|Bevacizumab|Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
76044457|NCT05472233|Procedure|Suture removal after Coronally Positioned Flap|Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
76044458|NCT05491733|Drug|APX001|Low-load oral tablet
76044459|NCT05491733|Drug|APX001A|High-load oral tablet
76044460|NCT05478785|Drug|Cisplatin micelle injection (HA132)|HA132 will be administered intravenously (IV), once per 3 weeks.
75566612|NCT02921100|Procedure|EUS-FNA|All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.
75566613|NCT02921100|Device|EUS-guided fine needle|
76044461|NCT05471297|Other|There is no intervention|There is no any intervention
75566614|NCT02943005|Procedure|Rotator cuff repair|
75566615|NCT02943161|Dietary Supplement|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
75719858|NCT05736471|Diagnostic Test|Computational dissociation of the causes of cognitive rigidity in depression|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
76044462|NCT05478395|Other|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
76044463|NCT05478317|Procedure|ECL- mPZ|"Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin."
76044464|NCT05478317|Procedure|ECL-OF|"Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured."
76044465|NCT01661933|Biological|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
76044466|NCT01661933|Biological|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
76044467|NCT02865551|Device|Foley catheter|Extended bladder catheterization after epidural anesthesia.
76044468|NCT02865551|Device|Short term catheter|Intermittent catheterization every 4 hours after epidural anesthesia.
75719859|NCT05732298|Device|intermittend theta burst stimulation (iTBS)|600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday
75719860|NCT05732051|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy
75719861|NCT05732051|Dietary Supplement|Placebo|Matching placebo b.i.d as long as the patient is receiving anthracycline therapy
75566616|NCT02921139|Radiation|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
75566617|NCT02921139|Procedure|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
75566618|NCT05319704|Other|Test of effort on cycle on concentric or excentric mode|participants may receive 4 interventions sequentially during the protocol
75719862|NCT05731479|Other|Diathermy + exercise group|The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.
75719863|NCT05731479|Other|Diathermy placebo + exercise group|The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
76044469|NCT02865551|Drug|Epidural anesthesia|Performance of epidural anesthesia by a certified anesthesiologist.
75719864|NCT05717088|Other|24% Sucrose solution|"Infants will either receive oral sucrose (24%) 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight < 1500g, 1500-2500g, and > 2500g respectively."
75719865|NCT05715099|Drug|Saffron|Dietary Supplement: saffron supplement for IBD
75719866|NCT05715099|Drug|Placebo|Dietary Supplement: placebo for IBD
75421099|NCT04576650|Device|Summit System|Surgical implantation of the Summit system (consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities) for Safety and efficacy testing of the Medtronic Summit System.
75421100|NCT04545060|Biological|VIR-7831 (sotrovimab)|VIR-7831 (sotrovimab) given by intravenous infusion (single dose)
75421101|NCT04545060|Drug|Placebo|Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
75421102|NCT04527913|Behavioral|Interdental Oral Hygiene Instruction (Int-OHI)|"Int-OHI will be given focusing on the interdental device of the allocated group for each patient and will be given only once at timepoint T-7. No further formal Int-OH instructions will be given, unless specifically asked by the patient.~Int-OHI will be delivered by trained dental hygienist/periodontist."
75421103|NCT04527913|Procedure|One session of professional supragingival scaling and polishing|A session of professional supragingival scaling and polishing: instrumentation will be performed by a trained dental hygienist/periodontist with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed.
75421104|NCT04527913|Procedure|Oral Hygiene Instruction (OHI)|"OHI will be given focusing on manual toothbrushing and will be given only once at timepoint T-7. No further formal OH instructions will be given, unless specifically asked by the patient.~OHI will be delivered by trained dental hygienist/periodontist."
75421105|NCT04481321|Biological|Biological/Vaccine|
75566619|NCT05319704|Other|Kinetics on concentric or excentric mode during test of effort|participants may receive 4 interventions sequentially during the protocol
75421106|NCT04469270|Biological|Engensis|Intramuscular injections
75421107|NCT04469270|Other|Placebo|Intramuscular injections
75566620|NCT05318456|Dietary Supplement|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.
75566621|NCT05318456|Dietary Supplement|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.
75566622|NCT05318456|Other|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.
75719867|NCT05713357|Procedure|Catheter ablation|Endocardial catheter ablation
75719868|NCT05708716|Behavioral|Modified ketogenic diet using an exogenous ketogenic formula|Participants will follow a modified ketogenic diet consuming a daily exogenous ketogenic meal replacement formula while limiting their carbohydrate intake for 12 weeks.
75719869|NCT05708716|Behavioral|Online cognitive training|Participants will complete a daily session of 5 online cognitive training tasks for 12 weeks.
75719870|NCT05707195|Other|Questionnaire|"A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit"
75719871|NCT05687396|Device|virtual reality|virtual reality designed as cycling in the forest
75719872|NCT05687396|Other|conventional pulmonary rehabilitation|pulmonary rehabilitation
75719873|NCT05685771|Device|Phase-targeted auditory stimulation|Bursts of pink noise (50 ms) played during deep non-REM sleep at specific phases of sleep slow waves.
76044470|NCT02797769|Drug|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
76044471|NCT02797769|Drug|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
76044472|NCT05471219|Other|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces|Informed consent was obtained from the mothers to take pictures of newborns who were delivered in the delivery room, routinely cared for, dressed and breastfed by the researcher. A 10-minute visual track was created to be turned into a slide from approximately 70 photos. Vaginal examination was performed between the 4th and 6th minutes while focusing on this visual trace.
76044473|NCT05478083|Drug|Leuprorelin|Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.
76044474|NCT02750657|Genetic|Molecular Profiling|Whole Genome Sequencing
76044475|NCT02544217|Drug|KH176|
76044476|NCT02544217|Drug|placebo|
76044477|NCT05427565|Other|caffeine|The investigators will ask participant to only intake 200 mg of caffeine one hour before the experiment (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the experiment
75421108|NCT04455152|Behavioral|self-control|avoiding eating sweets as a way of building self-control strength
75421109|NCT04395053|Drug|SHR1459|"TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h."
76044478|NCT05427565|Other|Experimental time|The investigators will ask participant to attend the experiment in the morning or afternoon
75421110|NCT04382391|Device|gammaCore® Sapphire (non-invasive vagus nerve stimulator)|"Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.~For acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment."
75719874|NCT05681637|Other|Breathing mixtures of O2 and N2 and monitoring SpO2 on each finger|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
76044479|NCT02533999|Device|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
76044480|NCT02533999|Device|Electrosurgery|Surgical method for tonsillectomy and adenoidectomy.
76044481|NCT02306551|Other|Biological and psycho-social risk and resilience factors|Naturalistic study, no active intervention or exposure is administered
75719875|NCT05671848|Other|Recordings of thalamic activity|Recordings of thalamic activity will be performed at home, in ecological conditions. They will be realized during 4 distinct conditions each week between M3 and M6 post implantation: at rest and during tremor-induced movements. For these recordings, stimulation will be either turned Off or On. Three successive recordings of 30 seconds separated by 1 minute will be made for each condition.
75719876|NCT05667922|Drug|Tacrolimus|0.05-0.10mg/kg/d, twice orally, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it is effective.
76044482|NCT05455177|Other|Digital first-line intervention for osteoarthritis including exercise and education|The digital OA management programme was delivered by a smartphone application, including education and exercises based on a face-to-face osteoarthritis self-management programme provided nationwide in Sweden and designed according to national and international guidelines. Over 12 weeks, which is the recommended minimum duration of a self-management intervention for OA, a total of 163 exercise sessions and 31 educational sessions are provided.
76044483|NCT02533531|Device|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
76044484|NCT05426707|Device|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
76044485|NCT05426707|Device|Sham-RIC|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
76044486|NCT02533453|Biological|Bydureon|exenatide once weekly
76044487|NCT05424835|Drug|SHR-A1811|SHR-A1811
75874549|NCT04735913|Drug|Abiraterone acetate tablets|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
75874550|NCT04910867|Behavioral|Components of Genetic Counseling|"The APOL1 testing program is designed to help living donor candidates to reduce their decisional conflict and enhance their informed consent regarding living donation. This intervention component entails: (1) an artificial intelligence-based conversational agent chatbot providing foundational information about the relationship between APOL1 and kidney disease and living donor outcomes, and APOL1 testing. The chatbot helps to relieve the workload on clinicians and scale up information giving. (2) The transplant nephrologist counseling component includes discussion about the APOL1 test results and shared decision making about donation, in a culturally competent manner, so as to enhance donor candidates' informed consent for living donation."
75566623|NCT02920905|Drug|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
75874551|NCT04910867|Diagnostic Test|APOL1 genetic testing|APOL1 genetic testing will be performed while live kidney donor candidates are undergoing donor evaluation to identify whether they are at elevated risk of kidney disease post-donation. This risk information is expected to better enable donor candidates to make meaningful informed decisions about donating.
75874552|NCT04910867|Other|EHR integration|APOL1 genetic test results will be integrated into the electronic health record to provide clinical decision support to transplant nephrologists in evaluating donor candidates.
75874553|NCT04906889|Drug|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
75719877|NCT05667909|Drug|Rituximab|375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
75719878|NCT05667896|Drug|glucocorticoid + tacrolimus|Prednisone 0.4-0.5mg/kg/d; Tacrolimus 0.05-0.10mg/kg/d, oral administration in two times, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it becomes effective.
75719879|NCT05667883|Drug|glucocorticoid + cytoxan|The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
75874554|NCT04906889|Drug|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
75874555|NCT04906889|Drug|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
75874556|NCT02945657|Drug|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
75421111|NCT04382391|Other|Standard of care therapies|Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms
75421112|NCT04375202|Drug|Colchicine 1 MG Oral Tablet|Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.
75421113|NCT04365205|Procedure|Endobronchial biopsy|Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.
75719880|NCT05667805|Drug|Platelet Concentrate|Liberal use (standard treatment)
75719881|NCT05667805|Drug|Prothrombin Complex Concentrate|Liberal use (standard treatment)
75421114|NCT04364373|Procedure|Left colon resection|"This procedure is performed for tumours in splenic flexure and proximal and descending colon.~Left colic artery is divided at its origin. Sigmoid arteries and superior rectal arteries are preserved. Inferior mesenteric vein is divided at the lower border of the pancreas. The colon is divided about 10 cm proximal and distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment a handsewn or stapler end-to-end or side-to-side colonic anastomosis is performed."
75421115|NCT04364373|Procedure|Sigmoid colon resection|"This procedure is performed for tumours in sigmoid colon. Corresponding sigmoid arteries are divided at their origin. Left colic artery and superior rectal artery are preserved. Inferior mesenteric vein is divide close to the left colic artery. Proximal and distal margin compose 10 cm from the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph nodes dissection. After removal of the resected colonic segment a handsewn end-to-end or side-to-side or stapler colonic anastomosis is performed."
75719882|NCT05667805|Other|Restricitve Use|Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
75719883|NCT05660460|Diagnostic Test|Spirometry|The method of examination, Spirometry, is noninvasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
75719884|NCT05657288|Other|Breathing mixtures of O2 and N2 and monitoring SpO2 on finger and left wrist|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
75719885|NCT05651542|Behavioral|Comprehensive Self-Management Intervention|In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
75719886|NCT05651542|Other|Control|The control group will receive standard care.
75719887|NCT05644496|Drug|Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release|Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
75874557|NCT05358743|Other|Probiotic group|Participants will use the probiotic product once daily (1 tablet/day) for 8 weeks
75719888|NCT05639634|Dietary Supplement|Chlorella supplementation|Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.
75719889|NCT05639634|Other|12 week cardiovascular training programme|Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (~ 5 min), a main physical conditioning phase (~ 40 min), and a cool-down phase (~ 5 min).
75719890|NCT05639634|Dietary Supplement|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.
75719891|NCT05619003|Device|Biatain Silicone Sacral Bandage|Biatain Silicone sacral will be applied on the sacral area as prevention of Pressure Ulcers
75719892|NCT05616780|Other|Physiological test|Lung volume measurements will be obtained using nitrogen washout and body plethysmography
75719893|NCT05607498|Drug|EMB07|EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
75719894|NCT05603416|Dietary Supplement|Perilla frutescens extract|oral dissolvable powder - dosage 300mg
75874558|NCT05358743|Other|Placebo group|Patients will chew placebo products (blueberry tablets) once daily (1 tablet/day) for 8 weeks.
75421116|NCT04364373|Procedure|Distal sigmoid colon resection or anterior resection|"This procedure is performed for tumours in distal sigmoid colon or rectosigmoid junction. Superior rectal artery is divided below the origin of left colic artery. Left colic artery is preserved. Inferior mesenteric vein is divide close to the left colic artery. The colon is divided about 10 cm proximal and 5 cm distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment handsewn or stapler colo-rectal anastomosis is performed."
75719895|NCT05603416|Dietary Supplement|Placebo|oral dissolvable powder - dosage 300mg no active ingredient
75421117|NCT04345744|Procedure|Periodontal surgery|Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.
75421118|NCT04345744|Device|Hyaluronic and 0.2% chlorhexidine mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
75566624|NCT02920905|Drug|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
75874559|NCT05308589|Device|CPPF|Continuous Postoperative Pericardial Flush
75874560|NCT04716959|Procedure|Prepectoral Prosthetic Breast Reconstruction|The prepectoral approach involves placing the tissue expander on top of the pectoralis muscle.
75421119|NCT04345744|Device|Chlorhexidine 0.2% mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
75874561|NCT04716959|Procedure|Subpectoral Prosthetic Breast Reconstruction|The subpectoral approach involves placing the tissue expander under the pectoralis muscle with or without acellular dermal matrix (ADM).
75566625|NCT02920905|Drug|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
75566626|NCT02920944|Device|EUS-FNB with 20 gauge ProCore needle|EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
75566627|NCT02920944|Device|EUS-FNB with 22 gauge ProCore needle|EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
75566628|NCT02917395|Device|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
75566629|NCT05319392|Diagnostic Test|Observational study|Exploration of transcriptomic signatures related to tumor microenvironment having a significant role in prognosis of gastric adenocarcinoma patients
75566630|NCT02917200|Drug|Moxifloxacin|Oral route
75566631|NCT02917200|Device|DAV132|Oral route
75566632|NCT02917200|Other|Negative control|Oral route
75566633|NCT05318144|Other||
75566634|NCT05319275|Drug|Acetyllevocarnitine Hydrochloride Tablets|500 mg (2×250 mg/tablet) after meal, 3 times per day
75566635|NCT05319275|Drug|Placebo|500 mg (2×250 mg/tablet) after meal, 3 times per day
75421120|NCT04329572|Drug|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) for 5 days.
75421121|NCT04329572|Drug|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
75874562|NCT02948777|Drug|Evolocumab|
75874563|NCT04868747|Drug|Lidocaine|The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
75874564|NCT04868747|Drug|normal saline|The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
75421122|NCT04323137|Behavioral|Risk reduction|Mailed letter, SMS, and/or patient portal message
75421123|NCT04323137|Behavioral|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
75566636|NCT02920515|Drug|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
75566637|NCT02920515|Drug|Zhibo dihuang pills|Traditional Chinese Medicine
75874565|NCT04693325|Procedure|Prolonged normothermic machine perfusion|First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted [NMP1]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) [PNMP3] and consequently 6 hours (n=6) [PNMP6].
75874566|NCT04684823|Device|Patch Cap|A prescription container cap to track the dispensing of an oral dose of medication with an associated app which tracks the adherence to medication regimen.
75874567|NCT04684823|Device|Patch App|A mobile app that is used with Patch Cap to track adherence to medication regimen
75874568|NCT05357651|Drug|LB1410|anti-PD-1 and anti-TIM-3 bispecific antibody
75719897|NCT05594654|Other|Smart Phone Application|"Breathe is an app that can be used by people with asthma to promote collaborative self-management. It is a platform that empowers patients to self-manage their condition. Breathe helps patients detect when they might be exacerbating or adequately controlled based on symptoms entered by the user into the application. The application then feeds these symptoms through a rules-based algorithm that identifies the early onset of an exacerbation, based on the user's zone of control or action plan. It also stores the patient's self-management action plan and gives them relevant instructions when it sees that their symptoms are getting better or worse. These instructions are delivered through a chatbot that provides information, support, and education to the patient through a friendly, human-like text message conversation."
75421124|NCT04323137|Behavioral|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
75421125|NCT04322552|Drug|Apatinib Mesylate|Apatinib at a dosage of will be administered daily from on D5 through D16
75421126|NCT04322552|Drug|Digoxin tablet|Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
75421127|NCT04321148|Procedure|standard of care PCI|optimal medical care PCI
75421128|NCT04321148|Procedure|Impella-protected PCI|Impella-protected PCI
76044488|NCT05424835|Drug|Pyrotinib in combination with Capecitabine.|Pyrotinib in combination with Capecitabine.
76044489|NCT05424601|Behavioral|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
76044490|NCT05424601|Behavioral|PsyPills|PsyPills is a mobile app designed to provide personalized psychological pills
76044491|NCT02533375|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
76044492|NCT05410873|Drug|MitoQ Compound|Mitoquinol mesylate
75421129|NCT04316104|Behavioral|CuidaTXT|Culturally tailored text messages including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
75566638|NCT02920515|Drug|Dabu ying pills|Traditional Chinese Medicine
75566639|NCT02942069|Behavioral|Blood glucose measured using CGM during standardized physical activity|Standardized exercise on bicycle at 70% of the participants work capacity for ½ hour.
75566640|NCT02917356|Other|Spiritual laying on of hands (SP)|"The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
75566641|NCT02917356|Other|Non-spiritual Laying on of Hands|"The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
76044493|NCT05410873|Drug|Placebo|Placebo
76044494|NCT05410795|Diagnostic Test|Magnetic resonance imaging|Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
76044495|NCT02551055|Drug|MLN1117|MLN1117 Tablets
75421130|NCT04285814|Diagnostic Test|Whole Fetal Cell (WFC) Testing|Performing WFC testing on blood specimens.
75421131|NCT04240717|Behavioral|Patient Decision Aid|The Patient Decision Aid is an interactive, web-based tool that provides information on advanced melanoma and its treatment options with a strong focus on immunotherapies (i.e. response to therapy, risk of side effects).
75421132|NCT04234061|Combination Product|ibrutinib and Tisagenlecleucel|Single-arm study investigating combination of ibrutinib and Tisagenlecleucel treatment
75421133|NCT04189848|Drug|Semaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
75421134|NCT04189848|Drug|Dulaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
75421135|NCT04179695|Other|Consulting with PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
75421136|NCT04179695|Other|Consulting without PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
75874569|NCT03638609|Device|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
75874570|NCT05330273|Drug|Ganaplacide|Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
75874571|NCT05330273|Combination Product|Lumefantrine|Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration
75874572|NCT05330273|Drug|Efavirenz|Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
75874573|NCT01312259|Other|"Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis"|Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
75874574|NCT05329259|Biological|13-valent pneumococcal conjugate vaccine|One dose of 13vPnC (0.5mL) will be administered intramuscularly.
75874575|NCT03638531|Device|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
75421137|NCT04156334|Procedure|Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia|QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
75566642|NCT02917356|Other|Control group|"The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
75566643|NCT02920554|Procedure|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
75566644|NCT02920554|Procedure|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
75874576|NCT03638531|Device|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
75421138|NCT04092764|Device|Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks. The acupoints will be stimulated by the electroacupuncture machine with alternating frequencies in order to induce endorphins at different points in the nervous system. Frequencies between 2 Hz and 100 Hz will be utilized. Sterile single-use needles will be placed at Ba Feng, four points on the dorsum of each foot between the digits. KI2 (Rang Gu), a point located at the soles of the feet and SP-4 (Gongsun) will also be needled per recommendation of our acupuncturist. A total of 12 needles will be used per participant.
75421139|NCT04092764|Device|NeuroMetrix|The NeuroMetrix is a point-of-care conduction device that will be used to measure peripheral neuropathy
75421140|NCT04092764|Device|Rydel-Seiffer tuning fork|The level of periphal neuropathy will be measured by vibration detection using a Rydel-Seiffer graduated tuning fork placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated weights at the ends, and as the amplitude decreases, the intersection of the triangles moves upward on the weight. This test will be performed three times and a mean of the scores calculated. Vibration sensation is lost sooner in CIPN, which means that lower scores are associated with increased CIPN
75566645|NCT02942849|Drug|r-hFSH|As per standard clinical practice
75566646|NCT02917005|Drug|Palbociclib|CDK 4/6 inhibitor
75566647|NCT02917005|Drug|Exemestane|Aromatase inhibitor
76044496|NCT02551055|Drug|TAK-659|TAK-659 Tablets
76044497|NCT02551055|Drug|Alisertib|Alisertib Tablets
76044498|NCT02551055|Drug|Paclitaxel|Paclitaxel intravenous infusion
76044499|NCT02551055|Drug|Docetaxel|Docetaxel intravenous infusion
75566648|NCT02917005|Drug|Goserelin|LHRH agonist
75566649|NCT02920632|Behavioral|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
75566650|NCT02920632|Behavioral|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
75566651|NCT02942810|Drug|WCK 5222|IV infusion over a period of 60 minutes
75874577|NCT03638765|Biological|DCVax-Direct|activated, autologous dendritic cells
75421141|NCT04078906|Other|n3-LCPUFA enriched Intravenous Lipid Emulsion|To start from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
75421142|NCT04036968|Drug|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
75566652|NCT02920710|Drug|Repository Corticotropin Injection|"Initial treatment with 80 units daily for ten days (induction phase)~Maintenance treatment with 80 units twice weekly (maintenance phase)"
75566653|NCT02941913|Drug|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
75719898|NCT05573243|Other|bonding strategies|The universal adhesive can be bonded using 3 different bonding strategies. Therefore, three bonding strategies will be assigned for 3 arms: etch-and-rinse, selective enamel etching, self-etch
75719899|NCT05554978|Drug|Landiolol|patient receives landiolol in addition to standard-of-care
75719900|NCT05554978|Drug|Sodium Chloride (NaCl) 0.9%|Placebo
75421143|NCT03980171|Drug|Obinutuzumab|A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.
75566654|NCT05319002|Behavioral|Group EMDR|The eight phases of the adapted group EMDR protocol was administered during each session: 1. Meeting: Explaining the nature of trauma, group rules, name tags, filling in the scales. 2. Preparation: Exploring children's support system, explaining EMDR, safe place, resource exercise, and installation with bilateral stimulation (BLS, butterfly hug or knee tapping). 3. Assessment: Drawing the worst image on a small separate sheet of paper, SUD level, (negative cognition, emotions, body sensations - if possible). 4. Desensitization: It is done with drawing on 4 separate papers with BLS (butterfly hug or knee tapping). 5. Installation: With the healing story written according to the adaptive information processing (AIP) model, the installation is accompanied BLS. 6. Body scan: A positive body state is installed with the relaxation technique. 7. Closure & future template: Strong closure with artwork. 8. Re-evaluation: if possible.
75874578|NCT05254847|Drug|Capecitabine combined with lenvatinib and tislelizumab|Capecitabine combined with lenvatinib and tislelizumab
75566655|NCT02917161|Device|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
75874579|NCT05249699|Drug|Isoniazid|prevent the development of tuberculosis
75874580|NCT05249699|Other|without any additional anti-tuberculosis treatment|reduce the number of Participants With Treatment-Related Adverse Events
75874581|NCT04751669|Dietary Supplement|Vitamin and trace elements|Dietary supplement oral route, once a day, during 14 days
75874582|NCT04751669|Dietary Supplement|Placebo|Dietary supplement (placebo) oral route, once a day, during 14 days
75874583|NCT04640909|Other|Peripheral blood samples withdrawal|Peripheral blood samples evaluation
75719901|NCT05538273|Other|Early removal of urinary catheter postoperatively|removal of urinary catheter less than 24 hours after surgery
75719902|NCT05538273|Other|Late removal of urinary catheter postoperatively|removal of urinary catheter greater than 24 hours after surgery
75719903|NCT05516212|Dietary Supplement|CAFMONO supplementation|"CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND"
75421144|NCT03980171|Drug|Venetoclax|During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.
75421145|NCT03980171|Drug|Lenalidomide|During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.
75719904|NCT05516212|Dietary Supplement|CAFMIPS_1 supplementation|"CAFMIPS_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND"
75719905|NCT05516212|Dietary Supplement|CAFMIPS_2 supplementation|"CAFMIPS_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY."
75874584|NCT04738019|Diagnostic Test|Medical examination or treatment.|Medical examination or treatment when delayed on-set nodule or other side effects occur due to Y-Solution filler injection.
75874585|NCT04731233|Biological|Plasma Rich in Growth Factor (PRGF) Supplementation|After rinsing the joint, the TMJ will be injected with blood plasma rich in growth factors (PRGF). PRGF supplementation which is an autologous platelet-enriched plasma obtained from patient's own blood, which after activation with calcium chloride allows the release of a pool of biologically active proteins that influence and promote a range of biological processes.
75874586|NCT04731233|Drug|Triamcinolone Acetonide|After rinsing the joint, the TMJ will be injected with 40 mg of triamcinolone acetonide with 5 mg bupivacaine.
75874587|NCT05292053|Drug|TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation|TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
75874588|NCT04584203|Diagnostic Test|Bedside Echocardiography|"All the intensivists performing the TTE in the involved centers fulfill the criteria of the American Society of Echocardiography and of the European Society of Intensive Care.~Medicine to be considered as experts in critical care echocardiography. Each center performs the TTE evaluation by means of the ultrasound device available in the unit equipped with the tissue Doppler imaging program and a phased array transducer of 2.5 MHz and doppler signals is recorded along with the electrocardiogram.~For the purpose of this study, the following TTE parameters are recorded from the apical 4-chamber view during each set of measurements:"
75566656|NCT02941952|Device|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
75566657|NCT02917044|Procedure|Atrial Fibrillation Ablation|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
75566658|NCT02917044|Device|Catheters used to isolate pulmonary veins|Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
75566659|NCT02917044|Procedure|Atrial Fibrillation Ablation with HD mapping to isolate PVs|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
76044500|NCT05470673|Procedure|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
75421146|NCT03926013|Drug|JNJ-63898081|JNJ-63898081 will be administered.
75421147|NCT03880032|Behavioral|Cognitive Behavioral Therapy Intervention for Anxiety|Happy Mother Healthy Baby (HMHB) is a CBT-based psychosocial intervention for expectant women experiencing anxiety during their pregnancy. Strategies such as empathetic listening, thought challenging, behavior activation, problem management, take-home exercises, and family involvement are employed by HMHB.
75421148|NCT03860077|Drug|Very Low Nicotine Content Cigarettes|Very Low Nicotine Content Cigarettes
75421149|NCT03860077|Drug|Normal Nicotine Content Cigarettes|Normal Nicotine Content Cigarettes
75421150|NCT03848793|Drug|HS-20004|treatment
76044501|NCT05470673|Procedure|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
75566660|NCT02917044|Device|Rhythmia HD mapping|Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
75566661|NCT02942693|Drug|Apatinib|Apatinib will be used as induction therapy in experimental arm.
75566662|NCT02942693|Radiation|Particle Therapy|Same total dose and fractionation will be used in both arms.
75719906|NCT05516212|Dietary Supplement|Placebo treatment|Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
76044502|NCT05470361|Procedure|stellate ganglion block (SGB)|The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
76044503|NCT05459285|Biological|14028 injection|14028 injection, single dose, s.c. injection
75719907|NCT05509959|Behavioral|Women SHINE|Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.
76044504|NCT05459285|Biological|dulaglutide injection|dulaglutide injection(TRULICITY®), single dose, s.c. injection
75719908|NCT05509959|Behavioral|Control|Single group session and access to website
76044505|NCT02542943|Device|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
76044506|NCT02542943|Device|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
75421151|NCT03848351|Behavioral|Oral Hygiene Instruction (OHI)|OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
75566663|NCT02916888|Other|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
75719909|NCT05508243|Other|Hyaluronic Nasal Spray|Health care product - nasal application
75719910|NCT05505019|Other|Music listening|This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.
75719911|NCT05505019|Other|Podcast listening|This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.
75719912|NCT05494346|Device|Measurement of peak nasal flow.|Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
75719913|NCT05481931|Drug|prabotulinumtoxinA|Botulinum toxin Type A powder for solution for injection
76044507|NCT02542943|Other|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
76044508|NCT02542943|Drug|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
76044509|NCT03284957|Drug|Amcenestrant|"Pharmaceutical form: capsule~Route of administration: oral"
76044510|NCT03284957|Drug|Palbociclib|"Pharmaceutical form: capsule~Route of administration: oral"
76044511|NCT03284957|Drug|Alpelisib|"Pharmaceutical form: tablet~Route of administration: oral"
76044512|NCT03284957|Drug|Everolimus|Pharmaceutical form: tablet
76044513|NCT03284957|Drug|Abemaciclib|Pharmaceutical form: tablet
76044514|NCT02542865|Dietary Supplement|Fortified malt based food|Fortified malt based food
76044515|NCT05477771|Procedure|Arthroscopic rotator cuff repair|The rotator cuff tears were repaired under arthroscopy. A subacromial decompression was performed in all patients. Then the long head of the biceps with severe lesions were treated by tenotomy while the others were reserved according to the surgeon's judgment during the surgery.
75566664|NCT02916888|Other|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
75566665|NCT02941874|Other|Blood sample collection during an OGTT to assess IRAP blood concentration|Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
75566666|NCT02941835|Radiation|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
75566667|NCT02920593|Drug|Vitamin D3|Vitamin D prophylaxis
75566668|NCT02942732|Dietary Supplement|cholecalciferol (Euro-Pharm International, Canada)|All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
75566669|NCT02942459|Other|Music therapy|25 Weekly Hours of Music Therapy by an Educated Music Therapist
75566670|NCT02942459|Other|Music Listening|25 weekly Hours of Being Together with an unknown Care Staff Member
75719914|NCT05476289|Other|No intervention|No intervention
76044516|NCT03644927|Behavioral|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
75566671|NCT02920437|Behavioral|Four-week weekly intervention to reduce salt intake|The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.
75719915|NCT05466630|Diagnostic Test|Serological field test for HAT|Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
75719916|NCT05466630|Diagnostic Test|malaria rapid test|RDT detecting HRP2 plasmodium antigen.
76044517|NCT03644927|Behavioral|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
75421152|NCT03848351|Procedure|Professional supragingival scaling and polishing|Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
75719917|NCT05466630|Diagnostic Test|Immunologic laboratory tests|Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
75874589|NCT04584203|Procedure|Spontaneuos breathing trial|The Spontaneous Breathing Trial will be performed accordingly to the clinical practice of the involved centers (a total support - including positive end-expiratory pressure plus pressure support equal or lower to 8 cmH20)
75874590|NCT04584203|Diagnostic Test|Bedside Echocardiography_1|Echocardiography performed within 24h from patient's admission - not optional
75874591|NCT04584203|Diagnostic Test|Bedside Echocardiography_2|Echocardiography performed within 12h from patient's spontaneous breathing trial - not optional
75874592|NCT04584203|Diagnostic Test|Bedside Echocardiography_3|Echocardiography performed at 60 +/- 12h from patient's admission - optional
75874593|NCT04584203|Diagnostic Test|Bedside Echocardiography_4|Echocardiography performed 24h after patient's estubation - optional
76044518|NCT03611153|Drug|AZD4831 Oral Myeloperoxidase Inhibitor|A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
76044519|NCT03611153|Drug|Placebo oral capsule|A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
76044520|NCT02542631|Device|Bolus Insulin Patch (Calibra Finesse)|
75421153|NCT03847493|Other|Endothelial Glycocalyx|Non-invasive assessment of endothelial glycocalyx dimensions.
75421154|NCT03763448|Procedure|Infrapatellar Fat Pad preservation|In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
76044521|NCT02542631|Device|Insulin Pen (Novo-Nordisk FlexPen®)|
75421155|NCT03763448|Procedure|Infrapatellar Fat Pad resection|In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
75421156|NCT03729206|Diagnostic Test|intravital microscopy|intravital microscopy with sidestream dark-field imaging
75566672|NCT02920437|Other|Usual government pamphlets|The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
75421157|NCT03687411|Procedure|Neuraxial ultrasonography|Ultrasound gel is applied to lower back lumbar spine of patient and placed with an ultrasound probe around the sacral region. The graphical interface of the software integrated with ultrasound machine will help identify the sacrum. The probe is moved in until the L3/4 interspinous space is identified for skin surface marking. Once the longitudinal scan is completed, the investigator will turn the probe 90° clockwise for transverse scan to identify ligamentum flavum.
75421158|NCT03674307|Other|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
75566673|NCT02942420|Drug|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
75566674|NCT02920359|Drug|LEUPRORELIN ACETATE|
75566675|NCT02916849|Other|Safe Step|Strength and balance exercise-digital version
75566676|NCT02916849|Other|OEP|Strength and balance exercise -paper version
75566677|NCT02941796|Drug|HCP1105|
75566678|NCT02941796|Drug|HCP0918|
75719918|NCT05466630|Diagnostic Test|Molecular laboratory tests|Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
75566679|NCT02941796|Drug|HCP0816|
75566680|NCT02916654|Dietary Supplement|sucrosomial iron|administration of sucrosomial iron
75566681|NCT02916654|Drug|Sulphate iron|administration of sulphate iron
75874594|NCT05288621|Device|electroacupuncture|"For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment."
75874595|NCT05306639|Other|Rehabilitation|rehabilitation sessions using spinal magnetic stimulation or neuromodulation
75566682|NCT02916576|Device|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
75719919|NCT05462132|Drug|SYNB1353|SYNB1353 IMP is formulated as a nonsterile solution intended for oral administration. SYNB1353 is subsequently lyophilized to form the bulk drug product. The lyophilized product is sieved into powder form and filled into high-density polyethylene (HDPE) bottles. Placebo will be manufactured using an inactive powder that is color matched to the SYNB1353 drug product. L-Methionine will be supplied as dry powder and will be suspended in a diluent prior to use.
75874596|NCT05207111|Drug|Revefenacin Inhalation Solution|Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.
75874597|NCT03256097|Device|XDP sound processing strategy - Period 0|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
75874598|NCT03256097|Device|XDP sound processing strategy - Period 1|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
75874599|NCT03256097|Device|VG sound processing strategy - Period 1|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
75421159|NCT03674307|Other|Regular Screening|Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
75421160|NCT03658044|Other|Participation in the internet forum|Active participation in the forum with encouragement to participate on a weekly basis
75566683|NCT02941562|Radiation|Short-course radiotherapy|Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
75566684|NCT02941562|Drug|FOLFOX4 chemotherapy,preoperative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
75874600|NCT03256097|Device|XDP sound processing strategy - Period 2|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
75874601|NCT03256097|Device|VG sound processing strategy - Period 2|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
75874602|NCT03256097|Device|XDP sound processing strategy - Period 3|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
75874603|NCT03256097|Device|VG sound processing strategy - Period 3|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
75421161|NCT03658044|Other|Placebo|No intervention performed. Patients are offered to read the open pages on the website
75421162|NCT03654950|Other|No intervention|Interviews and questionnaires
75421163|NCT03643016|Other|Surgical strategy based on a software|Surgical strategy décision based on a software
75421164|NCT03637413|Dietary Supplement|Hindmilk|Mother will be taught to separate her milk and infant will receive only hindmilk for feeds
75874604|NCT03256097|Device|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
75874605|NCT05195567|Diagnostic Test|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
75874606|NCT05195567|Diagnostic Test|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
75874607|NCT04697381|Biological|somatropin - GH naïve pediatric cohort|somatropin 0.245 mg/kg/week
75566685|NCT02941562|Radiation|Radiotherapy of neo-adjuvant therapy|Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
75421165|NCT03576495|Other|PACTS curriculum|"The cultural dexterity curriculum, known as PACTS (Provider Awareness Cultural Dexterity Toolkit for Surgeons) focuses on developing cognitive skills to adapt to individual patients' needs to ensure personal, patient-centered surgical care.~The curriculum is comprised of four educational modules on establishing trust in the physician-patient relationship, communicating effectively with patients with limited English proficiency, discussing informed consent, and issues surrounding pain management. Each module consists of an independent learning activity, an interactive role-play, and a post-lesson assessment."
75566686|NCT02941562|Drug|Concurrent chemotherapy of neo-adjuvant therapy|Capecitabine 825mg/m2 twice daily 5 days/week
75874608|NCT04697381|Biological|somatropin - GH treated cohort|somatropin 0.084 mg/kg/week
75421166|NCT03571347|Behavioral|Self Help Plus|5-session psychosocial intervention
75421167|NCT03571347|Other|Enhanced Treatment As Usual|Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
75566687|NCT02941562|Procedure|Radical rectal cancer resection|Radical rectal cancer resection
75566688|NCT02941562|Drug|FOLFOX4 chemotherapy,post-operative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
75566689|NCT02942888|Dietary Supplement|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
75566690|NCT02942888|Dietary Supplement|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
75566691|NCT02916420|Drug|Pomalidomide|4mg/day, d1-d21, 28 days per cycle
75566692|NCT02916420|Drug|Dexamethasone|≤70 years,40mg/day; >70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
75874609|NCT04697381|Biological|somatropin - adult cohort|somatropin 0.084 mg/kg/week
75874610|NCT01312571|Behavioral|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
75874611|NCT01312571|Behavioral|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
75874612|NCT04732793|Device|Hyruan ONE®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
75421168|NCT03558724|Drug|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure
75421169|NCT03558724|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.
75421170|NCT03547037|Drug|JNJ-63723283|JNJ-63723283 will be administered intravenously.
75421171|NCT03547037|Drug|Erdafitinib|Erdafitinib will be administered orally.
75421172|NCT03533660|Behavioral|Feedback|Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources
75566693|NCT05318924|Drug|Ghrelin|Participants will receive an infusion that is intended to raise ghrelin level up to a steady plateau.
75566694|NCT05318924|Other|Placebo|Participants will receive a saline infusion as the placebo control condition.
75874613|NCT04732793|Device|Durolane®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
75874614|NCT04695977|Drug|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
75874615|NCT04695977|Drug|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
75421173|NCT03533660|Behavioral|Enhanced Usual Care|Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources
76044522|NCT05459051|Diagnostic Test|Rest-angina physiological assessment|The degree of stenosis required to cause angina at rest will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and iFR.
75421174|NCT03512496|Dietary Supplement|Acute energy drink - Placebo|Colored water
75421175|NCT03512496|Dietary Supplement|Acute energy drink - Caffein|Sugar free energy drink at 5mg/kg caffeine
75421176|NCT03512496|Dietary Supplement|Acute energy drink - Decaf|Sugar free decaf energy drink (vitamins only)
75566695|NCT02920398|Drug|turoctocog alfa pegol|Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
75566696|NCT05318885|Other|A Randomized Controlled Study|For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
75719920|NCT05458622|Biological|Blood sample|"- Total volume of blood (on each sampling occasion): 54,5mL.~Whole blood will be collected in EDTA, 1 tube of 10 mL for DNA (genotyping, methylation arrays; at baseline for genotyping and at EOS visit for methylation arrays). From this, an aliquot of 0.5 mL for baseline cell numbers (cell proportions, CyTOF/flow cytometry) at all time points; capture of leukocytes for blood single cell RNA seq. at all time points and 5 mL for cell stimulations for cell metabolome (C13 to be added), and 1 tube of 10 mL for cell stimulations (CyTOF) at baseline.Tempus tube: 1 tube of 3 mL for RNA, 1 tube of 3mL for whole blood RNA seq.; to be taken at all time points. Plasma will be obtained and aliquoted from these tubes; to be obtained at all time points.~Serum: 2 tubes of 10 mL without anticoagulant for measurements of anti-drug antibodies, hydroxychloroquine levels, cytokines and analytes, proteome, and autoantibodies; to be taken at all time points."
76044523|NCT05459051|Diagnostic Test|Exercise-angina physiological assessment|The degree of stenosis required to cause angina during exercise will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and iFR.
76044524|NCT02542397|Genetic|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
76044525|NCT05457491|Biological|Human platelet extract (cosmetic product)|A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
76044526|NCT05457491|Other|Vanicream Gentle Facial Cleanser|A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
75421177|NCT03416127|Drug|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
75421178|NCT03416127|Drug|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
75421179|NCT03416127|Drug|Placebo|Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
75421180|NCT03399149|Other|Systematic evaluation by an intensivist|implementation of a standardized procedure for patient care in ICU
75421181|NCT03293069|Drug|Deferiprone|One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
75421182|NCT03293069|Drug|Placebo Oral Tablet|the placebo twice daily morning and evening.
75421183|NCT03266315|Biological|FloraBaby|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
75421184|NCT03266315|Other|Placebo|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
75421185|NCT03232346|Drug|Vivitrol|Oral naltrexone induction procedure followed by Vivitrol
75421186|NCT03232346|Drug|Buprenorphine|5-week buprenorphine taper
75566697|NCT02916342|Procedure|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
75566698|NCT02916342|Procedure|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
75566699|NCT05318846|Drug|HRS4800 tablets|Dosing frequency: single dose; Route of administration: oral
75566700|NCT05318846|Drug|Placebo tablets|Dosing frequency: single dose; Route of administration: oral
75719921|NCT05458622|Biological|Urine sample|- Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted;
75566701|NCT02920203|Genetic|Heart and spleen tissue|genetic sequencing
76044527|NCT05457491|Other|EltaMD UV Daily Broad-Spectrum SPF 40|A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
75566702|NCT02942381|Drug|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
76044528|NCT05457491|Other|EltaMD PM Therapy Facial Moisturizer|A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
76044529|NCT05457491|Other|Vanicream Lite Lotion|Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
76044530|NCT05477615|Drug|Lazertinib|- Lazertinib 240mg (3 tablets, 80mg/1tablet) once a day, oral, before disease progression
75874616|NCT04908761|Procedure|Transmuscular quadratus lumborum block|Patients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
76044531|NCT05477615|Drug|Pemetrexed|- Pemetrexed 500mg/m2 is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
75421187|NCT03227731|Drug|Truvada|Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
75566703|NCT02942381|Drug|Placebo|
75566704|NCT02920281|Other|Polysomnography|
76044532|NCT05477615|Drug|Carboplatin|- Carboplatin AUC x 5 mg/mL.min is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
75566705|NCT02941718|Behavioral|Sleep Advancement Counseling|Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
75566706|NCT02941718|Behavioral|General Health Information|Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
75566707|NCT02920320|Other|Internet-based self-help program|
75719922|NCT05458622|Biological|Saliva sample|- Saliva: will be collect in special container for saliva microbiome and methylation;
75874617|NCT04908761|Procedure|Placebo|For patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block.
75421188|NCT03209349|Procedure|Water Exchange Sigmoidoscopy|See arm description.
75421189|NCT03209349|Procedure|Air Insufflation Sigmoidoscopy|See arm description.
75421190|NCT03203512|Dietary Supplement|Fish oil capsules|Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
75421191|NCT03203512|Dietary Supplement|High-oleic safflower oil capsules|High-oleic safflower oil capsules for 12 weeks
75421192|NCT03200015|Drug|Metformin|Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
75421193|NCT03149640|Drug|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
75421194|NCT03149640|Drug|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
75421195|NCT03141736|Other|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
75566708|NCT03458468|Drug|Tranexamic Acid|1g Tranexamic acid prior to skin incision
75566709|NCT03458468|Drug|Saline|Equivalent volume of saline prior to skin incision
75566710|NCT02919891|Other|Questionnaire|Questionnaires
75566711|NCT02941679|Drug|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
75566712|NCT02941679|Drug|HGP1011|Boehringer Ingelheim
75566713|NCT02941679|Drug|HCP0910|GlaxoSmithKline
75566714|NCT02919930|Device|Switch from oronasal to nasal mask during ASV treatment|One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.
75566715|NCT02919930|Device|Switch from nasal to oronasal mask during ASV treatment|One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
75566716|NCT02942537|Device|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
75566717|NCT02942537|Procedure|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
75566718|NCT02916537|Drug|CTT1057|Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
75566719|NCT02916537|Procedure|Prostatectomy|Radical prostatectomy with lymph node dissection
75566720|NCT02916615|Other|High nitrate vegetables|vegetables naturally high in nitrate
75566721|NCT02916615|Dietary Supplement|Low nitrate vegetables + nitrate|pill containing KNO3
75566722|NCT02916615|Other|Low nitrate vegetables|vegetables naturally low in nitrate
75719923|NCT05458622|Biological|Stood sample|- Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C
75874618|NCT03324581|Drug|OPC-64005|OPC-64005 film coated tablets
75874619|NCT03324581|Drug|Atomoxetine|Atomoxetine gelatin capsules
75874620|NCT03324581|Drug|Placebo|OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
75874621|NCT02943473|Drug|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
75421196|NCT03141736|Other|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]
75421197|NCT03141736|Other|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
75421198|NCT03141736|Other|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]
75421199|NCT03098355|Biological|4SCAR19/22 T cells|CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
75421200|NCT03098355|Drug|Interleukin-2|Interleukin-2 of 250,000iu/m^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
75421201|NCT03090841|Biological|Bio-specimen collected|
75421202|NCT03036423|Behavioral|Online video education|
75421203|NCT03036423|Behavioral|Computerized mental exercises|
75421204|NCT02986334|Drug|Naproxen|Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
75421205|NCT02986334|Drug|Omeprazole|Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.
75421206|NCT02986334|Drug|Placebo|Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
75421207|NCT02966483|Procedure|TaTME|Transanal Total Mesorectal Excision
75874622|NCT03629873|Drug|Chidamide|Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m^2 IVD d-6; Etoposide 150mg/m^2/d qd IVD d-5~-2; Cytarabine 150mg/m^2 q12h IVD d-5~-2; Cyclophosphamide 1.0g/m^2/d qd IVD d-5~-2
76044533|NCT05477537|Other|Adapted physical activity program|subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
75566723|NCT02942342|Procedure|Computed Tomography (CT) Scan|CT Scans will be used as a diagnostic tool for asymptomatic CAD.
75566724|NCT02916459|Device|21G EBUS-TBNA needle|
76044534|NCT05477537|Other|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
75421208|NCT02966483|Procedure|LpTME|Conventional Laparoscopic Total Mesorectal Excision
75421209|NCT02933073|Biological|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
75421210|NCT02863718|Drug|Ibrutinib|Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
75421211|NCT02863718|Drug|Placebo|Placebo 420mg daily
75421212|NCT02836106|Other|Butter|Butter with jam and three slices of bread
75421213|NCT02836106|Other|Cheese|Cheese with jam and three slices of bread
75421214|NCT02836106|Other|Whipped cream|Whipped cream with jam and three slices of bread
75421215|NCT02836106|Other|Sour cream|Sour cream with jam and three slices of bread
75421216|NCT02813850|Device|oxygen therapy|Oxygen therapy early in the night (2L/min) during 4hours per days
75566725|NCT02916459|Device|Flexible 19G EBUS-TBNA needle|
75566726|NCT02942303|Drug|Dysport|
75566727|NCT02942303|Procedure|lateral orbicularis injection|
75566728|NCT02942303|Procedure|Lateral orbicularis + corrugator injection|
75566729|NCT02920086|Behavioral|Nutrition Education Program|"The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~Nutritional education will be provided to ICU patents' families by a dietitian~Tracking of nutritional information by family~Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)"
75566730|NCT02920086|Other|Decision Support Program|"Families will be provided with a web-based decision support tool (My ICU Guide)~Families will meet with the ICU medical team early in ICU stay to review goals of care"
75566731|NCT02942147|Device|TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
75566732|NCT02942147|Procedure|Conventional or Pulse Radiofrequency|In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
75719924|NCT05458622|Procedure|Tissue sample|"- Tissue samples for organ-specific manifestations:~Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
75566733|NCT02916381|Procedure|PEC block + General anaesthesia|Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
75566734|NCT02916381|Procedure|General anaesthesia|
75566735|NCT02920047|Drug|Fimasartan/Amlodipine|Treatment B
75566736|NCT02920047|Drug|Fimasartan + Amlodipine|Treatment A
75566737|NCT02920125|Drug|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
75719925|NCT05450224|Behavioral|VVC-delivered Massed Imaginal Exposure|Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
75719926|NCT05446051|Device|the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV)|Phase I Interventions：eRAPID-MV(TRAEs survey)
75719927|NCT05446051|Device|the telephone triage decision support system (TTDSS)|Phase I Interventions：TTDSS
75719928|NCT05441267|Drug|Semaglutide Oral Tablet|Oral semaglutide 14mg daily (option to reduce to 7mg daily)
75719929|NCT05441267|Drug|Placebo oral tablet|Placebo oral semaglutide
75719930|NCT05438888|Drug|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
75719931|NCT05438888|Drug|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
75719932|NCT05430074|Device|HM Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of HM casts.
75719933|NCT05430074|Device|Fibreglass Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of Fibreglass casts.
75719934|NCT05424406|Behavioral|Active phototherapy|Timed bright light exposure delivered in a controlled laboratory setting (10,000 photopic lux) designed to delay the DLMO to 4 am or later.
75719935|NCT05424406|Behavioral|Control phototherapy|Timed less intense light exposure delivered in a controlled laboratory setting (100 photopic lux) that still has a perceptible alerting effect but is not designed to shift circadian phase.
75719936|NCT05424406|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
75566738|NCT02920125|Combination Product|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
75421217|NCT02770066|Device|Percutaneous transluminal renal angioplasty|"Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia)~Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician~Antiplatelet therapy (usually standard)~Cholesterol-lowering drugs (usually standard)~Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated)~Smoking cessation, diet and physical activity (usually standard)"
75566739|NCT02920125|Other|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
75566740|NCT02942030|Other|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
75719937|NCT05424406|Behavioral|Sleep education control|Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
75719938|NCT05423327|Procedure|No Intervention|Single blood draw
75719939|NCT05411731|Other|Conventional physical therapy treatment|"The control group (group A) will receive the exercise program which focused on improving the arm function as well as shoulder abduction and external rotation for 10 week.~stretching Aeroplan positioning"
75719940|NCT05411731|Other|Constraint induced movement therapy|The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
75719941|NCT05407480|Other|Observational|Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome
76044535|NCT02549339|Drug|LEO 43204 gel|
75421218|NCT02679495|Behavioral|Active measures of lifestyle modification|
75566741|NCT02916264|Procedure|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
75566742|NCT02941991|Biological|hESC-RPE|sub-retinal injection
75566743|NCT02915952|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
76044536|NCT02549339|Drug|Vehicle gel|
75421219|NCT02668289|Other|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
75421220|NCT02668289|Other|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
75421221|NCT02668289|Other|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
75421222|NCT02668289|Other|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
75421223|NCT02668289|Other|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
75719942|NCT05392504|Other|Core stability exercise|The core stability training consist of three phases
76044537|NCT05469503|Dietary Supplement|TOTUM-854|12 weeks of TOTUM-854 supplementation
76044538|NCT05469503|Dietary Supplement|Placebo|12 weeks of placebo supplementation
76044539|NCT02549027|Drug|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
76044540|NCT02549027|Drug|MK-6096|Oral MK-6096 tablets (5 mg strength)
76044541|NCT02549027|Drug|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
75421224|NCT02668289|Other|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
75421225|NCT02668289|Other|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
75421226|NCT02668289|Procedure|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
75566744|NCT02915952|Other|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
75566745|NCT05318495|Device|Standard Colonoscopy|The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).
75719943|NCT05392504|Other|Scroth's Program|The Schroth program include exercises for rotational breathing, spinal elongation, deflexion, stretching, de-rotation, and strengthening
75719944|NCT05385484|Behavioral|Receives mobile banking account with incentives to save|Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
75874623|NCT04294043|Drug|Gallium nitrate|Study subjects will receive an infusion of gallium nitrate.
75874624|NCT05019833|Device|Signals collection|A non-CE marked embedded software will be temporarily uploaded in the implanted device, in order to enable the collection of sensors signals.
76044542|NCT05477303|Other|taking a picture of a painful facial expression|Immediately after surgery, the patient's facial expression and the NRS score and ANI score reported by the patient are checked together.
76044543|NCT05478629|Other|Survey|Questioning through google forms
75719945|NCT05377541|Procedure|Surgical treatment of femur fracture|Definitive surgical treatment of femur fracture.
75421227|NCT02668289|Other|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
75421228|NCT02655315|Drug|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
75874625|NCT05019677|Drug|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
75874626|NCT02899793|Drug|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
75421229|NCT02655315|Drug|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
75421230|NCT02436733|Procedure|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
75421231|NCT02436733|Drug|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
75421232|NCT02426502|Drug|Conversion to Advagraf|Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
75421233|NCT02426502|Drug|conversion of non-immunosuppressant drugs to once daily|"Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative."
75566746|NCT05318495|Device|CAD-EYE|CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.
75566747|NCT05318495|Device|G-EYE|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
75566748|NCT02920164|Device|Auricular acupuncture|Auricular acupuncture with indwelling permanent needles
75566749|NCT02920164|Device|Placebo acupuncture|Placebo acupuncture with placebo needles
75719946|NCT05377112|Drug|SYNB8802v1|"SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites."
75874627|NCT04981145|Drug|Iguratimod Tablets|Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
75874628|NCT04981145|Drug|Hydroxychloroquine Sulfate Tablets|Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
75874629|NCT04258631|Drug|Hydromorphone|Given IT
75874630|NCT04258631|Procedure|Laparotomy|Undergo laparotomy
76044544|NCT02709395|Device|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
76044545|NCT02529553|Drug|LY3076226|Administered IV
76044546|NCT02547935|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
76044547|NCT02547935|Drug|Saxagliptin 2.5 mg|Tablets administered orally once daily for 24 weeks.
76044548|NCT02547935|Drug|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
75719947|NCT05377112|Other|Placebo|placebo powder will be aliquoted into high density polyethylene (HDPE) bottles and diluted in the same formulation buffer as SYNB8802v1 lyophilized powder. The placebo consists of corn starch and dyes to color match the placebo to the SYNB8802v1 powder for oral suspension
75719948|NCT05354362|Combination Product|ATG-010 and ATG-008|Patients enrolled will receive consecutive daily treatment at assigned dose level. The starting dose of ATG-010 at the dose escalation phase will be 60 mg QW, which could be escalated to 80 mg QW, 100 mg QW, 60 mg BIW. In case 60 mg QW of ATG-010 with any dose of ATG-008 is NOT tolerable, 40 mg QW ATG-010 could be explored. The starting dose of ATG-008 will be 15 mg QD, which could be escalated to 20 mg QD, with maximum of 30 mg QD. SRC will be consulted before each dose escalation starts.
75874631|NCT04258631|Drug|Liposomal Bupivacaine|Drug
75421234|NCT02426502|Drug|Conversion to once daily MPA|"Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~Patients taking azathioprine will be maintained on the same dose.~Patients will be maintained on the same prednisone dose."
75421235|NCT02360891|Other|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
75874632|NCT04258631|Other|Questionnaire Administration|Ancillary studies
75566750|NCT02940938|Other|Applying pulse oximeter sensor|During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
75566751|NCT02941055|Other|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
75566752|NCT02941055|Other|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
75566753|NCT02919852|Procedure|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
75566754|NCT02941094|Device|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
75719949|NCT05351736|Drug|Lurasidone|Treatment with lurasidone
75719950|NCT05343065|Device|BlueStar 10|An app that coaches individuals with diabetes and supports insulin-dosing based on continuous glucose monitor data
75719951|NCT05337098|Other|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
75719952|NCT05335928|Drug|Abatacept plus|"Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC"
75874633|NCT04877015|Device|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
75874634|NCT04877015|Device|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
75874635|NCT03638063|Diagnostic Test|Adenosine Triphosphate|Adenosine Triphosphate aerosol
75421236|NCT02360683|Other|patients with Parkinson's disease|
75421237|NCT02275156|Biological|Evolocumab|Administered by subcutaneous injection
75566755|NCT02941094|Device|Ultrasound|Xario, Toshiba Tokyo Japan
75566756|NCT02941133|Other|Neural Mobilization|Neural mobilization techniques aimed at the lumbar root that is affected
75566757|NCT02941133|Other|Standard Care|Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
75719953|NCT05335928|Drug|Placebo|Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
75719954|NCT05319561|Other|Antibiotic Use Report|"The Antibiotic Use Report uses both text and graphics to communicate successes and improvement opportunities specific to the VAMC for which it is prepared. The graphs summarize overall antibiotic use over the previous year, with additional information regarding use of broad- and narrow-spectrum agents. Further, each Antibiotic Use Report compares or benchmarks the individual VAMC for which it is prepared to other VAMCs in the same Medical Complexity Group. This approach adapts and expands peer comparison, which has proven effective at reducing inappropriate antibiotic use in outpatient settings."
75874636|NCT03638063|Diagnostic Test|capsaicin|capsaicin aerosol
75874637|NCT04869371|Drug|Docetaxel injection|75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
75874638|NCT04869371|Drug|Triptorelin Pamoate for Injectable Suspension|15mg every 12 weeks
75566758|NCT02916069|Device|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
75566759|NCT02916069|Device|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
75566760|NCT02916069|Device|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
75566761|NCT02941016|Drug|Evolocumab or Alirocumab|All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
75566762|NCT02941172|Other|Cold exposure|Controlled cold exposure is performed before and during PET scan
75566763|NCT02941172|Other|[18F]FMPEP-d2|PET radiotracer used in imaging
75566764|NCT02941172|Other|[18F]FDG|PET radiotracer used in imaging
75719955|NCT05310097|Behavioral|CPT|CPT will be delivered over the course of 12 one-hour weekly sessions (maximum of 18 weeks to complete treatment). Participants will have the option of receiving CPT in-person or via videoconferencing.
75874639|NCT04869371|Drug|Prednisone Acetate Tablets|5 mg oral low dose prednisone, once daily
75874640|NCT03320369|Other|Elemental Diet Therapy|Elemental diet is a formula composed of amino-acids, carbohydrates, and lipids that is 100% nutritionally complete
75566765|NCT02916225|Behavioral|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
75566766|NCT02916225|Behavioral|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
75874641|NCT02650895|Biological|Efprezimod alfa|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
75566767|NCT02916186|Biological|Acellular Dermal Matrix|Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
75874642|NCT02650895|Drug|Saline|0.9% sodium chloride
75566768|NCT02916186|Procedure|Tunnel technique with the subepithelial connective tissue graft|Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
75874643|NCT04742231|Device|Hand-held dynamometer|Maximum Grip Strength will be measured using a hand-held dynamometer (K-FORCE Grip dynamometer®. Kinvent Biomequanique S.A.S, Montpellier, France) during the preoperative, intraoperative (Awake craniotomy) and postoperative period.
75566769|NCT03200379|Other|directly acting antivirals (DAAs)|Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
75719956|NCT05310097|Behavioral|MS|The MS protocol consists of eight strategies: categorization, evaluation, application, cue-based reminders, practice remembering, attention recruitment, praising recall, and repetitions.
75874644|NCT03320057|Drug|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
75874645|NCT03320057|Other|Training on mifepristone dispensing|Pharmacists were offered a training on medication abortion and mifepristone dispensing
76044549|NCT04258111|Biological|IBI310 (anti-CTLA-4 antibody)|Specified dose on specified days
76044550|NCT04258111|Biological|Sintilimab(anti-PD-1 antibody)|Specified dose on specified days
76044551|NCT02554019|Biological|BT063|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
76044552|NCT02554019|Biological|Placebo|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
75566770|NCT02941484|Procedure|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
75566771|NCT02941484|Procedure|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
75566772|NCT02915913|Behavioral|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
75566773|NCT02915913|Behavioral|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
75719957|NCT05286957|Drug|adjuvant tislelizumab and chemotherapy for MRD+ patients|"MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)"
75719958|NCT05286957|Drug|adjuvant tislelizumab and chemotherapy for MRD+ patients|patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
75874646|NCT04741139|Drug|Acetaminophen and Diphenhydramine Only Product|Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
75874647|NCT03316547|Other|SENSE Program|Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises [passive range of motion (PROM), gentle stretching]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
75874648|NCT02740205|Other|Algorithm for enteral nutrition support|Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
75874649|NCT02738255|Device|Varnum mouthpiece|An adhesive mouthpiece with a central opening applied during sleep
76044553|NCT05468411|Other|Oral application of miracle fruit pill|Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.
76044554|NCT05468411|Other|Oral application of sugar candy|To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.
75421238|NCT02185235|Device|Electrical Stimulation|"The Chartered Society of Physiotherapy recommends the following standard for electrical devices.~Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.~Treatment time: 5 minutes initially, gradually increasing to 20 minutes."
75421239|NCT02185235|Device|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
75421240|NCT02185235|Other|Pelvic Floor Training|"First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.~Repeat this exercise to 20 minutes each session."
75421241|NCT02124902|Drug|Docetaxel|
75566774|NCT02915913|Behavioral|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
75421242|NCT02124902|Drug|Carboplatin|
75421243|NCT02124902|Procedure|FDG-PET/MR|"Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~This is not optional for final 30 participants enrolled on the study"
75566775|NCT02915913|Other|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
75566776|NCT02277002|Device|Cabin Air Filtration|
75566777|NCT02277002|Other|Placebo|No Cabin Air Filtration
75719959|NCT05286957|Drug|adjuvant chemotherapy for MRD- patients|MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
75566778|NCT04688619|Behavioral|"Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
75566779|NCT04688619|Behavioral|"Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
75719960|NCT05282108|Drug|Carcemia|Generic Imatinib
75719961|NCT05282108|Drug|Glivec|Imatinib
75719962|NCT05275751|Drug|TRPA1-inhibitor|Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
75719963|NCT05275751|Drug|TRPV1-inhibitor|Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid
75719964|NCT05275751|Drug|TRPM3-inhibitor|Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid
75719965|NCT05275751|Drug|Placebo|No pharmacological intervention
75719966|NCT05275751|Drug|Chloride-channel inhibitor|Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid
75566780|NCT02919735|Drug|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
75719967|NCT05268133|Dietary Supplement|Aronia|As described in experimental arm
75719968|NCT05268133|Dietary Supplement|Control|As described in placebo comparator arm
76044555|NCT05476835|Combination Product|respiratory exercises - incentive spirometer - walking|respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
76044556|NCT02327169|Drug|MLN2480|MLN2480 tablets.
76044557|NCT02327169|Drug|MLN0128|MLN0128 capsules.
76044558|NCT02327169|Drug|Alisertib|Alisertib tablets.
75566781|NCT02919735|Drug|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
75566782|NCT02941250|Device|ISSD emulator|induced tachy-arrhythmia to be terminated by ISSD emulator
75566783|NCT02919774|Drug|POMA|"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"
75566784|NCT02919774|Drug|placebo|matching placebo tablets
75566785|NCT02941445|Drug|sitagliptin and metformin|
75566786|NCT02941445|Drug|Metformin|
76044559|NCT02327169|Drug|Paclitaxel|Paclitaxel IV infusion.
76044560|NCT02327169|Drug|Cetuximab|Cetuximab IV infusion.
76044561|NCT02327169|Drug|Irinotecan|Irinotecan IV infusion.
75566787|NCT02941757|Behavioral|Mediterranean diet Intervention|"Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~Peer-education and support~Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~Email or text message encouragement and reminders during the intervention."
75566788|NCT02919501|Drug|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
76044562|NCT02327013|Drug|vortioxetine 10 mg tablet|Oral tablets, once daily
76044563|NCT02327013|Drug|vortioxetine 20 mg tablet|Oral tablets, once daily
76044564|NCT02327013|Other|Placebo tablet|Oral tablets, once daily
76044565|NCT02301975|Drug|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
76044566|NCT02301975|Drug|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
76044567|NCT02301975|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
76044568|NCT02301975|Drug|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
75421244|NCT02067182|Drug|Dabigatran|"Antral pulmonary vein ablation for patients with AF~left atrial fibrosis/electrical scar assessment by electroanatomical mapping~followed by 6 months OAC (3 months blanking period + 3 months observation period)~in case of AF-recurrence in month 4-6: re- pulmonary vein ablation~followed again by 6 months OAC (3 months blanking period + 3 months observation period)~AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:~Experimental arm (group A): OAC with dabigatran for 12 months~Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later"
75566789|NCT02919501|Other|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
75874650|NCT04824989|Behavioral|Sleep Health in Preschoolers (SHIP)|SHIP is an 8 session home visiting intervention to reduce child sleep problems using a framework that draws from motivational interviewing and social cognitive theory, and effectively improves sleep timing, duration, and quality. Following ecological assessment of child sleep and sleep routines, feedback is provided on family strengths and challenges in the child sleep domain, with motivational interviewing to increase parent knowledge of sleep, correct misperceptions, and raise outcomes expectations. The remaining sessions are targeted modules that give tailored feedback and education, and coach the parent in setting manageable goals, identifying action steps, anticipating barriers, and supporting positive behaviors. Targets: bedtime scheduling, consistency, and routines; media use, independent sleep onset, nightmares and fears, night wakings, and early waking; sleep location, nap issues, engaging other caregivers.
75421245|NCT02003612|Other|Not applicable - observational study|No intervention exists as this is a retrospective observational study
75719969|NCT05262725|Behavioral|Values-based Behavioral Activation|Initially, patients complete a values assessment in which they identify personal values in various life domains. With the assistance of a clinician, patients set incremental behavior goals to move their daily actions to better align with their self-reported values. Goal completion allows the patient to achieve outcomes consistent with recovery, and they potentially experience enjoyment, self-efficacy, and confidence as they progress through the treatment.
75719970|NCT05255276|Drug|Sitravatinib 50 mg|50 mg Sitravatinib on Day 1 (Group 1A)
75719971|NCT05255276|Drug|Sitravatinib 100 mg|100 mg Sitravatinib on Day 1 (Group 2A)
75719972|NCT05255276|Drug|Itraconazole|Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)
75719973|NCT05255276|Drug|Rifampin|Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)
75421246|NCT01940341|Drug|TAF|25 mg tablet administered orally once daily
75421247|NCT01940341|Drug|TDF|300 mg tablet administered orally once daily
75421248|NCT01940341|Drug|TAF Placebo|Tablet administered orally once daily
75719974|NCT05252858|Device|nCAP Signal Relief Patch|nCAP Signal Relief Patch post-operatively applied to the subject's surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU)
75874651|NCT04824989|Behavioral|Family Check-Up (FCU)|FCU is an 8 session home visiting intervention to reduce behavior problems for children through improved parenting. Over 30 years of research establishes its efficacy in reducing behavioral and emotional problems, including in low income toddlers. Following ecological assessment of behavior management and child behavior, family receives feedback on family strengths and challenges within the behavioral domain via a motivational interviewing approach. The remaining sessions are targeted modules drawn from the Everyday Parenting curriculum, individualized based on parent goals and identified challenge areas. Each session begins by establishing a collaborative skill set, involves teaching the rationale for a skill, teaching and modeling effective use of the skill, and then role play and experiential practice to coach the parent to success. Targets can include Positive Behavior Support, Limit Setting and Monitoring, Family Routines, Communication, and Problem Solving.
75421249|NCT01940341|Drug|TDF Placebo|Tablet administered orally once daily
75421250|NCT01877837|Drug|Alemtuzumab|"Adjusted Ideal Body Weight Formula: AIBW = IBW + [(0.4) x (ABW - IBW)]~b) Medications~i.) Alemtuzumab I. Hb S% must be < or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued >48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below"
75566790|NCT02919501|Drug|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
75421251|NCT01877837|Drug|Fludarabine|I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
75421252|NCT01877837|Drug|Melphalan|"I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. *Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.~II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion."
75421253|NCT01877837|Procedure|Stem Cells|Infusion of Hematopoietic Stem Cells
75566791|NCT02940782|Procedure|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
75566792|NCT02940782|Procedure|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
75566793|NCT02940782|Device|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
75874652|NCT04824989|Behavioral|Oral Health, Child Safety, and Environmental Health Intervention (Active Control)|This intervention serves as an active control condition to ensure that observed effects are due to the intervention content, rather than to study processes, staff attention, or general support and problem solving. The intervention is designed to be comparable to SHIP and FCU in intensity, personal contact, session structure and approach, but focused on Oral Health, Child Safety, and Environmental Health, domains which should not immediately affect study outcomes.
75874653|NCT04762433|Device|Kegel Exercise Pregnancy Training - app|"KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT."
75874654|NCT04752761|Behavioral|Extrambulatory digital PROMs detection|An alternative PROMs evaluation method will be used in which the questionnaire will be administered to the patient digitally (Google Forms) in an outpatient environment
75874655|NCT04108091|Drug|Treatment for TTR amyloidosis|The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
75874656|NCT04108091|Drug|Treatment for TTR amyloidosis|The usual adult dose is 61 mg of tafamidis orally once daily.
75421254|NCT01624142|Biological|Evolocumab|Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
75566794|NCT02919579|Drug|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
75566795|NCT02919579|Drug|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
75874657|NCT04853147|Drug|palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,
75874658|NCT04853147|Drug|palonosetron, dexamethasone, and 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
75874659|NCT03315689|Drug|Vehicle|Vehicle Topical Solution
75874660|NCT03315689|Drug|ATI-50002|ATI-50002 Topical Solution
75874661|NCT03436901|Diagnostic Test|MRI with DWI vs CT|MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
75421255|NCT01539746|Procedure|TAVI without BAV|Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
75421256|NCT01539746|Procedure|TAVI standard procedure|TAVI standard procedure including BAV before valve deployment
75421257|NCT01535807|Device|CorMatrix extra cellular matrix (ECM)|"Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.~No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
75421258|NCT01375764|Biological|Evolocumab|Administered by subcutaneous injection
75421259|NCT01375764|Drug|Ezetimibe|Administered orally once a day
75874662|NCT03314519|Diagnostic Test|Lung ultrasonography by experienced anaesthesiologist|Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
75874663|NCT03314519|Diagnostic Test|Fiberoptic bronchoscopy for double lumen tube's position|Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
75874664|NCT04699799|Other|Present odors to participants while recording brain activity|Present odors to participants while recording brain activity
75874665|NCT01856855|Radiation|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
75421260|NCT01375764|Other|Placebo to Evolocumab|Administered by subcutaneous injection
75421261|NCT01286038|Drug|Eltrombopag|In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
75566796|NCT02919579|Other|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
75566797|NCT02919579|Drug|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
75566798|NCT04688697|Procedure|prepectoral implant-based reconstruction|In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.
75421262|NCT01253707|Drug|AMG 337|AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
75566799|NCT04688697|Procedure|subpectoral implant-based reconstruction|In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.
75566800|NCT02940821|Other|Toothbrushing|Mechanical plaque removal
75566801|NCT02940821|Other|Fluoridated Dentifrice (.15% sodium monofluorophosphate)|Fluoridated dentifrice application
75421263|NCT00722046|Biological|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
75421264|NCT00722046|Biological|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
75421265|NCT00722046|Biological|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
75421266|NCT00722046|Drug|Placebo|Placebo every 60 days (10 doses total)
75421267|NCT00722046|Biological|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
75566802|NCT02940821|Other|Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)|Application of Tooth Whitening Agent in Dentifrice
75566803|NCT02940821|Other|Whitening (4.5% hydrogen peroxide)|Application of Whitening Agent
75566804|NCT02940821|Other|Other Fluoridated Dentifrice (.454% stannous fluoride)|Fluoridated dentifrice application
75566805|NCT02941601|Drug|Necitumumab|Administered IV
75566806|NCT02941601|Drug|Gemcitabine|Administered IV
75421268|NCT00722046|Biological|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
75421269|NCT00614523|Drug|Placebo|Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
75421270|NCT00614523|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
75421271|NCT00523341|Biological|Denosumab|Administered by subcutaneous injection once every 6 months.
75421272|NCT00364013|Drug|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
75421273|NCT00364013|Drug|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m^2 IV bolus followed by 600 mg/m^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
75421274|NCT00345839|Drug|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
75421275|NCT00345839|Drug|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
75421276|NCT00330759|Biological|Denosumab|120 milligrams by subcutaneous injection every 4 weeks
75566807|NCT02941601|Drug|Carboplatin|Administered IV
75566808|NCT02940899|Other|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
75566809|NCT03631719|Biological|Wolbachia-carrying Ae.aegypti mosquitoes|Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).
75566810|NCT04691453|Procedure|QM-C Hysterectomy|This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.
75566811|NCT04691453|Procedure|QM-B Hysterectomy|Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
75874666|NCT04689347|Drug|Bevacizumab|Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
75719975|NCT05252858|Other|Standard of Care|Subjects will undergo surgery using the approved ERAS anesthetic and post-operative pain management protocols. At Shadyside Hospital, the ERAS Protocol for these subjects involves preoperative meloxicam 15mg PO, gabapentin 300mg PO, acetaminophen 1g PO. Intra-operative, patients receive a spinal block (bupivacaine) and propofol IV sedation. Postoperative pain medication is titrated to the individual patient's level of pain (0-10). 0.2 mg IV hydromorphone can be given for breakthrough pain, oxycodone 5mg PO for moderate pain (4-6) and oxycodone 10 mg PO for severe pain (7-10). Ketorolac 15 mg IV is given Q6H during the hospital stay. Discharge medication may be Norco 5-325mg as prescribed by the surgeon.
75874667|NCT04689347|Drug|Irinotecan|irinotecan 165 mg/sqm intravenous infusion every 2 weeks
75874668|NCT04689347|Drug|Leucovorin|leucovorin 200 mg/sqm intravenous infusion every 2 weeks
75719976|NCT05243199|Drug|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
75874669|NCT04689347|Drug|5Fluorouracil|48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
75874670|NCT04689347|Drug|Temozolomide|Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
75874671|NCT03313037|Biological|Multivalent|Pneumococcal conjugate vaccine
75421277|NCT00330759|Drug|Zoledronic Acid|4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
75874672|NCT03313037|Biological|Prevnar 13|Pneumococcal conjugate vaccine
75874673|NCT03313037|Biological|PPSV23|Pneumococcal polysaccharide vaccine
75421278|NCT00113763|Other|Best supportive care|Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
75874674|NCT03313037|Other|Saline|Placebo
75874675|NCT04685759|Other|In-Person Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.
75874676|NCT04685759|Other|Virtual Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
75874677|NCT02420795|Drug|Akt/ERK Inhibitor ONC201|Given PO
75421279|NCT00113763|Drug|Panitumumab|Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
75874678|NCT02420795|Other|Laboratory Biomarker Analysis|Correlative studies
75874679|NCT02420795|Other|Pharmacological Study|Correlative studies
75874680|NCT04674995|Procedure|Stent placement|All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
75421280|NCT00102323|Drug|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
75421281|NCT00102323|Biological|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
75874681|NCT02384759|Drug|aflibercept|
75874682|NCT02384759|Drug|LV5FU2|
75874683|NCT03638219|Other|Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020.|Data collection, follow up and bioscore calculation at the end of study
75874684|NCT05276843|Combination Product|Qigong exercise program|Qigong is a low-impact, weight-bearing exercise characterized by gentle movements designed to dissipate force throughout the body while the subject changes poses, with well-coordinated sequences of both isometric and isotonic segmental movements in the trunk and 4 extremities.
76044569|NCT02301975|Drug|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
75874685|NCT05276765|Procedure|cad/cam socket sealing abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
75874686|NCT05276765|Procedure|standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
75421282|NCT01438359|Drug|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
75874687|NCT03334175|Drug|Walnuts|1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
75874688|NCT05276687|Drug|Betadine|Wound irrigation
75421283|NCT01438359|Drug|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
75421284|NCT01438359|Drug|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
75421285|NCT01438372|Drug|Intravenous iron sucrose|Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
75421286|NCT01438372|Drug|Oral ferrous sulfate|Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
75421287|NCT01438385|Procedure|Interventional Endoscopy|Advanced imaging endoscopic or therapeutic endoscopy
75566812|NCT02940743|Behavioral|Education (Edu)|This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
75719977|NCT05243199|Drug|Irbesartan|The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
75719978|NCT05229211|Device|Cardiac monitoring|Continuous ECG monitoring via VitalConnect patch worn on the chest.
75719979|NCT05227716|Drug|Perioperative magnesium sulfate|Administration of magnesium sulfate as an adjunct in anesthesia
75719980|NCT05218343|Behavioral|"EHR-based nudge interventions"|Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
75719981|NCT05217433|Other|Olive leaf extract|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
75719982|NCT05217433|Other|Placebo|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
75874689|NCT05276687|Drug|Vancomycin|instillation in the wound
75874690|NCT04616339|Drug|PF-06882961 100 mg|"PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)"
75874691|NCT02942771|Drug|0.075mg/kg TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
75719983|NCT05195996|Drug|Propranolol|intravenous propranolol for case patients
75874692|NCT02942771|Drug|0.15mg/kg TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
75874693|NCT02942771|Drug|0.25mg/kg TT301/MW189|0.25 mg/kg IV twice daily on Days 1 through 5
75421288|NCT01438398|Procedure|Submucosal endoscopic myotomy with mucosal flap technique|Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.
75421289|NCT01438398|Procedure|Submucosal Endoscopic Mucosal Flap (SEMF) technique|
75421290|NCT01438437|Procedure|PAI|Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
75421291|NCT01438437|Procedure|RFA|Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
75421292|NCT01438450|Drug|Oral|"Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week"
75421293|NCT01438450|Other|Supportive|No specific therapy will be given
75719984|NCT05195996|Drug|Saline|intravenous saline for placebo
75874694|NCT02942771|Drug|0.30mg/kg TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
75874695|NCT02942771|Drug|Placebo|0.9% sodium chloride
75874696|NCT05276375|Drug|Bronchipret|Bronchipret syrup (3x 5,4 ml daily) until day 14
75421294|NCT01438463|Biological|Placebo|Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
75421295|NCT01438463|Biological|PURETHAL Mites 6,667 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
75874697|NCT04697771|Other|Fine Motor Skills Training|Fine Motor Skills Training The sessions will be held by considering the fine motor skills training and the criteria of fidelity of the fine motor interventions suggested by Pfeiffer et al. Each goal was enriched with activities and games that improve fine motor skills and handwriting performance.
75421296|NCT01438463|Biological|PURETHAL Mites 20,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
75421297|NCT01438463|Biological|PURETHAL Mites 50,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
75421298|NCT01438463|Biological|PURETHAL Mites 100,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
75566813|NCT02940743|Behavioral|SM intervention|During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
75566814|NCT02940743|Behavioral|Social Cognitive Therapy (SCT)|This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
75874698|NCT05275985|Diagnostic Test|68Ga-FAPI Positron Emission Tomography-Computed Tomography|The patients with suspected pancreatic lesions were included. They underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The treatment methods were decided according to the results of 68Ga-FAPI PET/CT.
75874699|NCT05275829|Other|Tele simulation|Interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform).
75421299|NCT01438502|Drug|HyperHAES® (hypertonic saline/HES)|After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
75421300|NCT01438515|Drug|Rifampin|600mg po once daily x 7 days
75421301|NCT01438515|Drug|Doxycycline|100mg po twice daily x 7 days
75566815|NCT03458390|Device|HyGIeaCare colon irrigation|PillCam COLON for visualization of bowel lining
75421302|NCT01438515|Other|2% mupirocin ointment|~ 1cm applied to the anterior nares twice daily for 7 days
75421303|NCT01438515|Other|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
75421304|NCT01438528|Device|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
75421305|NCT01438554|Drug|Pazopanib|
75421306|NCT01438554|Drug|GSK1120212|
75421307|NCT01438567|Drug|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
75421308|NCT01438567|Drug|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
75421309|NCT01438580|Drug|Warfarin|Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
75421310|NCT01438580|Drug|aspirin|100mg aspirin was administrated every day
75421311|NCT01438593|Procedure|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
75421312|NCT01438606|Biological|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
75421313|NCT01438606|Biological|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
75421314|NCT01438632|Device|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
75421315|NCT01438645|Device|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
75421316|NCT01438671|Procedure|Nintendo Wii Fit|The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
75421317|NCT01438671|Procedure|Traditional balance training|This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
75421318|NCT01438684|Drug|RPh201|400 microliter s.c. twice a week for 3 months
75421319|NCT01438684|Drug|Saline|400 microliter Saline solution s.c. twice a week for 3 months
75421320|NCT01438697|Behavioral|Internet Intervention|Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
75421321|NCT01438697|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
75421322|NCT01438723|Drug|Metformin|prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
75421323|NCT01438723|Drug|Placebo|prior to CABG surgery 3 day treatment with placebo capsules three times a day
75421324|NCT01438736|Drug|Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)|Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
75421325|NCT01438736|Drug|Etonogestrel 68 mg subdermal implant|Etonogestrel 68 mg subdermal implant for 6 months
75421326|NCT01438749|Drug|Placebo|Single dose
75421327|NCT01438749|Drug|RO4917838|Single doses (3 dose levels)
75421328|NCT01438749|Drug|diazepam|Single dose
75421329|NCT01438762|Behavioral|Patient information and education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
75421330|NCT01438762|Other|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class."
75874700|NCT03036150|Drug|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
75566816|NCT03160638|Drug|Azithromycin 250 mg|Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
76044570|NCT02301897|Drug|Telapristone Acetate|Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
75719985|NCT05195359|Behavioral|Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore|The Dein Schlaf. Dein Tag. application powered by SleepScore is a validated sleep measurement application using sonar technology that also provides evidenced-based sleep advice and sleep education content based on a user's objectively measured nightly sleep data. As participants engage with the app, the Dein Schlaf. Dein Tag. application provides personalized and dynamic sleep content and sleep and circadian rhythm improvement advice based in the principles of sleep hygiene, sleep-circadian science, and cognitive behavioral psychology. Participants will also receive personalized sleep challenges tailored to improve their sleep and circadian rhythms. Each challenge lasts for 7 tracked nights, ranging from optimizing sleep habits to limiting caffeine intake, and more. Additional sleep improvement features embedded within the app include sleep sanctuary bedroom checks, sleep sounds, smart alarms, bedtime reminders, and sleep education blogs and science content.
76044571|NCT02301897|Drug|Placebo|Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
75421331|NCT01438788|Other|Low protein diet|Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
75421332|NCT01438801|Drug|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS <0).
75566817|NCT02940704|Procedure|Reciproc|"Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~Reciproc file selection: R40 (40/0.06) is to be used."
75566818|NCT02940704|Procedure|One Shape|"Coronal preflaring will be performed using Gates Glidden drill.~Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
75566819|NCT02940587|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
75566820|NCT02919540|Other|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
75566821|NCT02919462|Drug|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
75566822|NCT02919462|Drug|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
75566823|NCT02919462|Drug|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
75566824|NCT02919462|Drug|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
76044572|NCT02301429|Device|Model 20105|implant and follow-up of study device
75566825|NCT02919462|Drug|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
75566826|NCT02919462|Drug|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
75566827|NCT02941367|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
76044573|NCT04883385|Other|medical data collection|collection of medical data from patients' medical records
75566828|NCT02941367|Drug|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
75566829|NCT02941367|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
75421333|NCT01438827|Drug|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
75566830|NCT02941367|Drug|basal insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75566831|NCT03153150|Drug|Apixaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
75719986|NCT05192876|Radiation|Radiotherapy|Outcomes and adverse events using radiation therapy
76044574|NCT04883229|Device|Halo Neuroscience Neurostimulator|"Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks."
76044575|NCT04882839|Combination Product|psychotherapy assisted psilocybin|psychotherapy for patients while under the influence of psilocybin
75421334|NCT01438827|Drug|Placebo|Suspension for Injection, Every 6 weeks for one year
75421335|NCT01438853|Biological|TNX-832|Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
76044576|NCT02300259|Drug|LY2623091|Administered orally
75421336|NCT01438853|Drug|Placebo|Single intravenous dose of saline control
75421337|NCT01438866|Other|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
75421338|NCT01438866|Other|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
75421339|NCT01438892|Drug|tDMARDs|Traditional DMARDs for RA
75421340|NCT01438892|Drug|biodmards|Biologic DMARDs
75421341|NCT01438905|Other|Small amplitude (Grade IV) mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
75874701|NCT03036150|Drug|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
76044577|NCT02300259|Drug|Itraconazole|Administered orally
76044578|NCT02300259|Drug|Simvastatin|Administered orally
75421342|NCT01438905|Other|High velocity, low amplitude (Grade V) mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
75421343|NCT01438918|Drug|SD-6010|200 mg tablets once a day for 2 years
75421344|NCT01438918|Drug|SD-6010|50 mg tablets once a day for 2 years
75421345|NCT01438918|Drug|Placebo|Placebo tablets once a day for 2 years
75421346|NCT01438931|Drug|DA-9501|Dexmedetomidine hydrochloride variable dose
76044579|NCT02300259|Drug|Tadalafil|Administered orally
76044580|NCT02300259|Drug|Diltiazem|Administered orally
76044581|NCT02367885|Drug|TAK-850 0.5 mL injection|TAK-850 injection
75421347|NCT01438931|Drug|placebo|
76044582|NCT02367885|Drug|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
76044583|NCT02367729|Device|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
75421348|NCT01438944|Drug|Nicabate 21mg transdermal NRT|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
75421349|NCT01438970|Device|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
75421350|NCT01439022|Behavioral|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
75421351|NCT01439022|Behavioral|Hand Writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
75421352|NCT01439061|Device|Device: easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
75421353|NCT01439100|Drug|Oxycodone/Naloxone Prolonged Release tablets|
75421354|NCT01439100|Drug|Placebo|Dummy tablet
75421355|NCT01439152|Drug|BAY94-9343|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
75719987|NCT05190939|Diagnostic Test|water as bladder distending media|water will be used for bladder dissension during cystoscopy
75719988|NCT05190939|Diagnostic Test|intravenous dye|intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
75719989|NCT05190939|Diagnostic Test|No intervention|Saline only, no dye
75719990|NCT05187858|Drug|LNP3794|LNP3794 capsules administered orally once daily
75874702|NCT03332771|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
75874703|NCT03332771|Drug|Glimepiride|"Pharmaceutical form: capsule~Route of administration: oral"
75874704|NCT03332771|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
75874705|NCT03332771|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
75874706|NCT03332771|Drug|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
75874707|NCT03625830|Device|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
75719991|NCT05172752|Other|Citizen Scientist Training Program|Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.
75719992|NCT05172752|Other|Stakeholder Consultation Core Program|Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
75874708|NCT03625830|Device|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
75874709|NCT04123704|Drug|Sitravatinib|sitravatinib capsule
75874710|NCT04108104|Drug|Cyproheptadine|3-month treatment
75421356|NCT01439152|Drug|BAY94-9343 (Expansion)|BAY94-9343 was administered intravenously in this study. The dose for this expansion cohort was 5.5mg/kg administered as a 1 hour infusion every 21 days.
75421357|NCT01439152|Drug|BAY94-9343 (1.8 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
75874711|NCT04108104|Drug|Alpress LP|3-month treatment
75421358|NCT01439152|Drug|BAY94-9343 (2.2 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
75566832|NCT03153150|Drug|Rivaroxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
75874712|NCT05304468|Radiation|IMRT|Patients in experimental group received reduced dose IMRT
75874713|NCT05304468|Drug|induction chemotherapy|cisplatin-based induction chemotherapy for two cycles
75874714|NCT05304468|Drug|cisplatin concurrent chemotherapy|cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
75421359|NCT01439178|Drug|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
75421360|NCT01439191|Drug|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
75566833|NCT03153150|Drug|Edoxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
75566834|NCT03153150|Drug|Dabigatran|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
75566835|NCT03153150|Drug|Acenocoumarol|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
75874715|NCT03310775|Behavioral|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
75566836|NCT03153150|Drug|Phenindione|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
75874716|NCT03619434|Procedure|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
75874717|NCT03619434|Procedure|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
76044584|NCT02367729|Device|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
75421361|NCT01439191|Drug|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
75421362|NCT01439230|Drug|Donepezil|10 mg Tablet
75421363|NCT01439230|Drug|Aricept®|10 mg Tablet
75421364|NCT01439243|Drug|Donepezil|10 mg Tablet
75421365|NCT01439243|Drug|Aricept®|10 mg Tablet
75421366|NCT01439256|Behavioral|Computer Controlled Telephone Counseling|The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
75421367|NCT01439256|Other|Physician information and management recommendations|Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
75421368|NCT01439308|Drug|Placebo|SB-705498 placebo
75566837|NCT03153150|Drug|Warfarin|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
75719993|NCT05120089|Other|muscle energy technique and myofacial release (physiotherapy techniques)|Each technique will be applied for three month (3 session/week)
75719994|NCT05113966|Drug|Trilaciclib|Single-use, sterile powder to be reconstituted and further diluted with 250 mL of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
75719995|NCT05113966|Drug|Sacituzumab Govitecan-hziy|10 mg/kg reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
75874718|NCT05250102|Device|Pulse oximeter sensors|Pulse oximeter reading will be compared to CO-oximeter reading.
75874719|NCT05275595|Other|Medical records review|"Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January."
75874720|NCT05275595|Other|Medical records review|Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
75874721|NCT04582799|Device|ECCO2R|Extracorporeal CO2 Removal
75874722|NCT04582799|Device|NIV|Non-invasive ventilation
75421369|NCT01439308|Drug|SB-705498|12mg intranasal SB-705498
75719996|NCT05110326|Other|ERGON Technique|"Hot pack for 15 minutes.~Patient position: Prone with knee flexion approximately 45◦.~Position of therapist: Standing at the affected side of patient.~Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~Strengthening exercises for quadriceps and hamstring will then be performed.~Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~Wall sits: For 10 seconds, 5 sets."
75874723|NCT05248308|Device|Embozene Microspheres|"Embozene Microspheres are manufactured by Varian Medical Systems (Palo Alto, CA). These microspheres are non-resorbable hydrogel microspheres coated with polyzene-F. Embozene microspheres are approved for use in treating arteriovenous malformations, hypervascular tumors such as uterine fibroids and hepatomas, and prostatic arteries in patients with benign prostatic hyperplasia.~One of the causes of chronic pain in the setting of a knee arthroplasty may be increased blood flow to the specific area(s) of pain. The purpose of this procedure is to reduce blood flow (embolize) to specific parts of the knee which are contributing to your pain.~This procedure is performed by infusing the Embozene particles into specific knee arteries (genicular arteries) in the region of knee pain."
75874724|NCT04236245|Device|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
75874725|NCT03330119|Drug|Alternate Management|With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.
76044585|NCT02366637|Drug|Placebo|Orally inhaled placebo twice a day (BID) for 4 weeks
76044586|NCT02366637|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
76044587|NCT02300103|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
76044588|NCT02300103|Drug|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76044589|NCT02326467|Drug|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
76044590|NCT02299635|Drug|PF-03084014|Tablet, 10 mg, twice a day.
75421370|NCT01439321|Biological|Eltrombopag|Switched to Eltrombopag
75421371|NCT01439321|Biological|Romiplostim|Switched to Romiplostim
75421372|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
75421373|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
75421374|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
75421375|NCT01439386|Procedure|Catheter ablation|PVAI with or without CTI ablation
75421376|NCT01439386|Procedure|Catheter ablation|CTI ablation only
75421377|NCT01439399|Drug|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
75421378|NCT01439399|Drug|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
75874726|NCT03330119|Drug|Control|The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
75874727|NCT05123274|Behavioral|Social Support Mobilization|Five main sessions and two booster sessions focused on providing accurate information about HIV medical care, increasing participants' feelings of resilience and self-worth, and mobilizing or creating social supports.
75421379|NCT01439399|Drug|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
75421380|NCT01439399|Drug|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
75421381|NCT01439412|Procedure|Acupuncture and standard treatment|"This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.~In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.~The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes."
75421382|NCT01439412|Other|Standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
75421383|NCT01439425|Behavioral|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
75566838|NCT02940431|Other|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
75566839|NCT02940431|Other|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
75719997|NCT05110326|Other|Proprioceptive Neuromuscular Facilitation (PNF) stretching|"The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~The procedure will be repeated 3 times in every session.~Strengthening Exercises:~Same as ERGON Group"
75874728|NCT05123274|Behavioral|Individual Care Counseling|Twenty-minute individual counseling session focused on HIV medical care
76044591|NCT02299635|Drug|PF-03084014|Tablet, 50 mg, twice a day
76044592|NCT02299635|Drug|PF-03084014|Tablet, 100 mg, twice a day
76044593|NCT02366091|Drug|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
76044594|NCT02366091|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
76044595|NCT02366091|Drug|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
75421384|NCT01439438|Drug|Topiramate coated tablet|Test formulation
75421385|NCT01439438|Drug|Topamax® coated tablet|Reference formulation
75566840|NCT05317598|Other|Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)|It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
75566841|NCT02916147|Drug|Sevoflurane|
75566842|NCT02916147|Drug|Propofol|
75566843|NCT04688970|Other|no intervention|no intervention
75566844|NCT05317559|Behavioral|room light|The room light condition (n=10) included one night of sleep in dim light (< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.
75566845|NCT02915562|Other|exercise|
75874729|NCT03040986|Other|Laboratory Biomarker Analysis|Correlative studies
75874730|NCT03040986|Drug|Selumetinib Sulfate|Given by mouth (PO)
75421386|NCT01439451|Procedure|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
75719998|NCT05109884|Diagnostic Test|PSMA PET Scan|[68Ga]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan
75719999|NCT05109884|Diagnostic Test|FDHT PET Scan|[18F]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan
75874731|NCT05261022|Behavioral|Love Together, Parent Together (L2P2)|Love Together Parent Together (L2P2) is a brief, low-intensity relationship intervention intended to improve the interparental relationship for parents of young children.
75874732|NCT03983382|Diagnostic Test|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
75421387|NCT01439464|Device|4 CIS one-touch titanium cage|4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)
75566846|NCT02915718|Procedure|protein A immunoadsorption|protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
75874733|NCT03936660|Other|Intense Education Intervention|Intervention will involve guideline-based care education.
75874734|NCT03039192|Drug|Esketamine|Intranasal esketamine solution 84 milligram (mg)
75874735|NCT03039192|Other|Placebo|Intranasal Placebo solution
75421388|NCT01439464|Device|Bonglass-SS SSLPB|Bonglass-SS SSLPB(BioAlpha Inc.)
75421389|NCT01439490|Other|FES-PET|Patients undergo FES-PET prior to obtaining histology
75421390|NCT01439503|Behavioral|Intervention|"The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms."
75421391|NCT01439516|Behavioral|Information|Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
75421392|NCT01439529|Other|Device programming: nominal|CRT device is programmed to nominal values
75720000|NCT05101564|Drug|Alpelisib|Alpelisib 300 mg
75874736|NCT03039192|Other|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
75874737|NCT05370612|Device|Dexcom G6 CGM|"Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data.~Experimental Group will wear CGM for the duration of their pregnancy.~Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy."
75874738|NCT05370612|Other|Participant Finger Stick Glucose Monitoring|Standard of care for individual participant
75874739|NCT02428842|Procedure|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
75874740|NCT02428842|Procedure|Blood sampling|Blood sampling will be performed before and after treatment.
75874741|NCT02367690|Drug|Selinexor|Topical gel
75874742|NCT02367690|Other|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
75874743|NCT02367690|Other|Vehicle Gel|Topical vehicle gel with no active ingredients.
75421393|NCT01439529|Other|Programming optimization by QRS|CRT device is programmed by QRS optimization
75421394|NCT01439542|Radiation|Stereotactic Body Radiation|"Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week~Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week"
75421395|NCT01439542|Drug|Luteinizing Hormone Releasing Hormone (LHRH) Agonist|12 months (2x6 month depot) of androgen suppression with LHRH agonist
75421396|NCT01439607|Other|Bone marrow and blood sampling|Bone marrow and blood sampling
75421397|NCT01439646|Other|it is a retrospective study, hence no active intervention|since it is an observational restrospective study hence no active intervention is planned
75421398|NCT01439698|Device|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
75421399|NCT01439750|Drug|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
75720001|NCT05101564|Drug|Tamoxifen|Tamoxifen 20 mg
75720002|NCT05101564|Drug|Zotatifin|Zotatifin 0.10mg/kg (by weight)
75720003|NCT05101564|Drug|Fulvestrant|Fulvestrant 500 mg
75720004|NCT05061316|Dietary Supplement|Nestlé Impact Advanced Recovery|Immunonutrition drink that helps support the immune system: reduces risk of prolonged hospital stay and complications after surgery.
75566847|NCT03458351|Device|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
75566848|NCT03458351|Device|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
75566849|NCT02915757|Device|EDOR test|"The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.~The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.~Blood sample and clinical assessment"
75874744|NCT03698279|Biological|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
75874745|NCT03698279|Biological|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
75874746|NCT03698279|Biological|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
75874747|NCT03698279|Biological|Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
75874748|NCT03698279|Biological|FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
75720005|NCT05058963|Behavioral|Mantram repetition program|"Week 1: Define and describe the characteristics of a mantram as taught by Eknath Easwaran and how it relates to posttraumatic stress (PTSD) Week 2: Identify ways to choose and use mantram repetition for training attention and targeting craving.~Introduction to substance craving and identify triggers for use. Week 3: Describe the relationship between the PTSD/stress response, mantram repetition and the relaxation response Week 4: Describe at least two benefits of slowing down versus automatic pilot for stress reduction Week 5: Describe at least two benefits of one-pointed attention versus multitasking for stress reduction Week 6: Demonstrate how one-pointed attention and slowing down complement each other for making healthy choices Week 7: List at least five strategies for making mantram repetition a part of your life Week 8: Discuss applications of mantram repetition, one-pointed attention and slowing down for overall health and substance use"
75720006|NCT05036993|Behavioral|Coaching|Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
75720007|NCT05022290|Procedure|Single-syringe diluted with normal saline technique|Adenosine is mixed with normal saline up to 20 ml in a single syringe before administering to the patient by the IV bolus method.
75874749|NCT03628950|Procedure|ICSSB group|At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
75421400|NCT01439750|Drug|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
75720008|NCT05010525|Drug|ATG-016|48 patients enrolled, orally, each 3 week (21-day) a cycle
75720009|NCT05005741|Drug|Beinaglutide|Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
75720010|NCT05005741|Drug|Dulaglutide|Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.
75720011|NCT05002829|Other|Restricted Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
75720012|NCT05002829|Other|Liberal Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
76044596|NCT02299167|Drug|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
75421401|NCT01439750|Drug|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
75421402|NCT01439789|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
75421403|NCT01439789|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
75421404|NCT01439828|Drug|N-acetylcystein|Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
75421405|NCT01439841|Dietary Supplement|Multi-strain probiotic|The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
75720013|NCT04974216|Drug|Tafasitamab|Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
75720014|NCT04974216|Drug|Lenalidomide|Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
75720015|NCT04974216|Drug|Rituximab|Administration: IV at 375mg/m2 C1 to C6: D1
75720016|NCT04972552|Dietary Supplement|coenzyme Q10|Participants will take 800-1200 mg of coenzyme Q10 capsule per day
75421406|NCT01439841|Dietary Supplement|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk
75421407|NCT01439893|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
75720017|NCT04972552|Other|Watermelon diet|Participants will be asked to eat watermelon at a minimum of one meal per day 3-5 days a week
75720018|NCT04972552|Other|Usual Diet|Participants will be asked to eat a usual diet but not eat any watermelon as part of their usual diet
75720019|NCT04972552|Other|Placebo|Participants will be asked to take 800-1200 mg of a placebo capsule per day
75720020|NCT04955925|Diagnostic Test|Ultrasound examination of the optic nerve sheath diameter|The optic nerve sheath diameter is examined using ultrasonography.
75720021|NCT04947865|Other|Peripheral nerve stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
75720022|NCT04947865|Device|Commercial knee brace|Knee brace used to limit knee mobility in healthy individuals to imitate stroke survivors and measure resulting gait kinematics and surface muscle activity.
75720023|NCT04934332|Procedure|Ultrasound|Ultrasound examination at 1 week and 5 weeks after admission.
75874750|NCT03628950|Procedure|ISB group|The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
75874751|NCT05275283|Other|PEEP|6 cmH2O of PEEP
75874752|NCT01529034|Drug|USL261|
75874753|NCT05275049|Combination Product|PT plus translingual stimulation device|PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
75874754|NCT05275049|Combination Product|PT plus translingual stimulation control device|Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
75421408|NCT01439893|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
75874755|NCT03036072|Other|Strict normothermia|
75874756|NCT03036072|Device|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
75874757|NCT03619512|Genetic|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
75874758|NCT03619512|Genetic|RNA sequencing|Characterization of tumor transcriptomic profile.
75874759|NCT03619512|Other|Mass spectrometry|Characterization of tumor proteomic profiles.
75874760|NCT03038880|Drug|Faricimab|Faricimab was administered via IVT injections as specified during the treatment period.
75421409|NCT01439906|Procedure|Surgical correction of the deformity|"Three different surgical techniques are used:~lumbar fusion vs thoraco-lumbar fusion~iliac fixation vs fixation to the sacrum~posterior + interbody fusion vs posterior interbody fusion"
75421410|NCT01439932|Device|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people [Andrew 1987]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). [Linda et al 2007]"
75421411|NCT01439958|Drug|Inhalation|Twice daily inhalation for a maximum of three years.
75874761|NCT03038880|Drug|Ranibizumab|Ranibizumab was administered via IVT injections as specified during the treatment period.
75874762|NCT03038880|Drug|Sham Procedure|The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
75874763|NCT01192464|Drug|autologous CAR.CD30 EBV specific-CTLs|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
75874764|NCT05038644|Drug|XmAb18968 - Dose level -1|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
75874765|NCT05038644|Drug|XmAb18968 - Dose level 0 (starting dose)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
75874766|NCT05038644|Drug|XmAb18968 - Dose level 1|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
75566850|NCT02919384|Other|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
75566851|NCT05296616|Behavioral|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
75874767|NCT05038644|Drug|XmAb18968 - Dose level 2|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
75874768|NCT05038644|Drug|XmAb18968 - Dose level 3|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
75874769|NCT03035916|Other|Transversus abdominis plane block|Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
75874770|NCT03035916|Other|Epidural anesthesia|Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
75874771|NCT03035916|Other|control|The Control group receives standard IV-inhaled general anesthesia.
75421412|NCT01439984|Drug|Clomipramine|Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
75874772|NCT01702571|Drug|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
75874773|NCT03675516|Other|No specific intervention|Usual care
76044597|NCT01647711|Drug|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
75566852|NCT02915640|Other|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
75720024|NCT04934332|Procedure|CT scan|CT scan at 5 weeks after admission. CT scan reader will be blinded to clinical data.
75421413|NCT01440023|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
75421414|NCT01440023|Behavioral|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
75720025|NCT04934332|Procedure|Clinical examination|Weekly clinical examination from week-2 to week-5.
75421415|NCT01440023|Behavioral|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
75421416|NCT01440036|Procedure|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
75566853|NCT06026189|Diagnostic Test|urine-first strategy|Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
75566854|NCT06026163|Drug|Caffeine citrate|Caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base)
75566855|NCT06026163|Other|Placebo|Equivalent volume of saline
75720026|NCT04924699|Drug|MRG002|Administrated intravenously
75720027|NCT04924699|Drug|Trastuzumab Emtansine for Injection|Administrated intravenously
75720028|NCT04909229|Device|PEAR-003b PDT Intervention|The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.
75720029|NCT04909229|Device|Fitbit|Patients will receive a Fitbit and receive standard of care
75720030|NCT04909229|Behavioral|Sleep education materials|Patients will receive sleep hygiene and healthy sleep tips.
75720031|NCT04907539|Drug|RXC004|"RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules."
75720032|NCT04907539|Biological|Nivolumab|Nivolumab will be administered via IV infusion, 480 mg q4w.
75874774|NCT01637688|Dietary Supplement|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
75874775|NCT05655000|Procedure|Neonatal thymus transplantation|The donor's neonatal thymus vessels will be dissected right after the routinary partial thymectomy. These vessels will be anastomosed into the recipient's penetrating vessels within the radial forearm by using a supermicrosurgical technique. The graft will be explanted at day 14-21 after the procedure.
76044598|NCT03171545|Behavioral|Patient Activation|Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
76044599|NCT03171545|Behavioral|Provider Education|Staff in clinics assigned to this group will receive team training and a checklist.
76044600|NCT05476757|Biological|rDEN2Δ30-7169|rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
76044601|NCT02547233|Drug|LEO 43204 gel|
75421417|NCT01440062|Drug|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
75421418|NCT01440062|Drug|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
75566856|NCT06026150|Other|Ultrasound scanning of inguinal area for femoral nerve and artery|ultrasound scanning of inguinal region is done in femoral fracture patient to identify femoral artery and nerve
75566857|NCT06026137|Procedure|eFisioTrack Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity using the efisioTrack system without supervision by the physiotherapist.
75566858|NCT06026137|Procedure|Excercises Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity supervised by the physical physiotherapist in a hospital room.
75720033|NCT04907539|Biological|Denosumab|"Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic"
75720034|NCT04907097|Dietary Supplement|Monomeric and oligomeric flavanols|Monomeric and oligomeric flavanols will be derived from Vitis vinifera seeds extract.
75720035|NCT04907097|Other|Placebo|Placebo capsuled will be used as a comparator.
75720036|NCT04894682|Biological|Vaccine inoculation against SARS-CoV-2|Inoculation with any type of approved vaccines according to the standard or recommended dose
76044602|NCT02547233|Drug|Vehicle gel|
76044603|NCT05476679|Drug|RZL-012|50mg/ml drug formulation
75874776|NCT01632930|Other|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
75566859|NCT06026124|Behavioral|Retrieval-based word learning|"Learning sessions: Children will practice novel nouns in the context of a story book on Day 1. They will learn 4 words in each of the two conditions. Study only condition: they will simply hear the information (word & meaning) as part of the story. Spaced retrieval condition: they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. In the study only practice condition, children will simply continue to hear the information. This practice schedule is repeated the next day (Day 2) using the same story book.~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word and meaning twice. One week after Day 1, this recall test is completed again. The child will also complete a recognition test: the child will hear a novel noun and point to its referent in an array of 3."
75566860|NCT06026111|Behavioral|High-Intensity Interval Training|Home-based, virtually supervised, aerobic exercise intervention with trained exercise specialist. Exercise is high intensity in an interval fashion. Participants will be provided with home stationary bike, heart-rate monitor/watch, and automatic blood pressure cuff.
75874777|NCT03231943|Drug|GSK3640254|GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
76044604|NCT05476679|Drug|RZL-012+Lidacaine injection prior treatment|5ml lidocaine will be injected 10 minutes before RZL-012 treatment
76044605|NCT05476679|Drug|RZL-012+Medrol|oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
76044606|NCT05476679|Drug|RZL-012+Celecoxib+Zyrtec|200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
75720037|NCT04885205|Behavioral|cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I program is a 6-week, 1x/week, one-on-one program. The delivery of CBT-I will be done remotely over a secure teleconference service (Zoom) or phone. Participants will maintain a sleep diary during the course of the program to aid in tailoring the intervention. Each session lasts about 45-60min:
76044607|NCT05476679|Drug|RZL-012+facial and neck wrap|Universal Facial Band
76044608|NCT02546765|Drug|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
75421419|NCT01440075|Other|Cardiac evaluation|"complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
76044609|NCT02546765|Drug|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
75421420|NCT01440088|Drug|TH-302 in Combination with Doxorubicin|"300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302."
75421421|NCT01440088|Drug|Doxorubicin|"Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle."
75720038|NCT04884087|Behavioral|Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day|Participants receive 3 EMA survey prompts daily for the duration of the study.
75720039|NCT04884087|Behavioral|Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day|Participants receive 6 EMA survey prompts daily for the duration of the study.
75720040|NCT04884087|Behavioral|Incentive Structure - fixed|"Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week."
75874778|NCT03231943|Drug|Placebo|Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
75874779|NCT01578239|Drug|Octreotide LAR|"In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died."
76044610|NCT02546765|Drug|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
76044611|NCT02546765|Drug|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
76044612|NCT02553629|Drug|Rocuronium|
76044613|NCT05453981|Behavioral|Transdiagnostic Sleep and Circadian Intervention|Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy. It targets common sleep disturbances in disorders and has improved disorder-focused symptoms and sleep and circadian functioning in patients with Severe mental illness (SMI).
76044614|NCT03073031|Device|Tablet: Samsung Galaxy Tab A|
76044615|NCT05476445|Procedure|Control|Root canal treatment
75566861|NCT06026111|Behavioral|Moderate-Intensity Continuous Training|Home-based, virtually supervised, aerobic exercise intervention with trained exercise specialist. Exercise is moderate intensity in a continuous fashion. Participants will be provided with home stationary bike, heart-rate monitor/watch, and automatic blood pressure cuff.
75874780|NCT01578239|Drug|177Lu-DOTA0-Tyr3-Octreotate|Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
75874781|NCT05274893|Drug|SYHX2011 and Abraxane®|IV infusion, 260 mg/m^2
75720041|NCT04884087|Behavioral|Incentive Structure - prize based|"Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90)."
75720042|NCT04864639|Other|Transition of Care Model|Participants with diabetes, Hispanic/Latinos, adults will receive newly developed discharge instructions.
75874782|NCT01220531|Biological|Cultured Thymus Tissue|Potential recipients of cultured thymus tissue are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted under general anesthesia in the operating room. Cultured thymus tissue is placed into the subject's quadriceps. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one-year post-implantation. At approximately year 2 post-implantation, subjects are contacted for data collection.
75874783|NCT01220531|Procedure|Blood Draw|
75874784|NCT01220531|Drug|Rabbit anti-thymocyte globulin|Three IV doses of 2 mg/kg RATGAM are given prior to implantation of cultured thymus tissue for immune suppression groups 2, 3, and 4. Each dose is given over 12 hours. RATGAM is usually given on days -5, -4, and -3 prior to implantation of cultured thymus tissue.
75720043|NCT04830397|Drug|QLS-101|Ophthalmic solution 1x daily
75720044|NCT04830397|Drug|Timolol Maleate|Ophthalmic solution 1x daily
75720045|NCT04821960|Behavioral|Tailored Mindfulness Program for Fear of Memory Loss|The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.
75720046|NCT04821960|Behavioral|Conventional Mindfulness Program|Routine non-tailored mindfulness lessons and activities.
75874785|NCT01220531|Drug|Cyclosporine|Csa may be given every 8 or every 12 hours orally or IV before and after implantation of cultured thymus tissue for immune suppression groups 3 and 4. The Csa dose is dependent on T cell numbers and the target CSA trough levels. Csa is weaned as per protocol.
75874786|NCT01220531|Drug|Tacrolimus|If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 or every 12 hours orally or IV before and after implantation of cultured thymus tissue. FK506 dose is dependent on T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.
75421422|NCT01440114|Drug|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
75421423|NCT01440114|Drug|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
75874787|NCT01220531|Drug|Methylprednisolone or Prednisolone|Steroids IV or orally may be given before and/or after implantation of cultured thymus tissue. Steroid administration and dosage depends on T cell numbers. Steroids are weaned as per protocol.
75874788|NCT01220531|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) may be given if the T cell count remains elevated 5 days after implantation of cultured thymus tissue. If MMF is given, the dose is 15 mg/kg/dose every 8 hours IV or orally. MMF may be stopped at 35 days or continued for up to six months after implantation of cultured thymus tissue.
75874789|NCT05572099|Diagnostic Test|ExoDx Prostate|Observational only.
75874790|NCT05255471|Drug|Olaparib|Olaparib 300 mg, film-coated tablets, twice daily PO, d1- 28 continuously
75874791|NCT05255471|Drug|Chemotherapy drug|"Platinum-based chemotherapy at the Investigator's choice among the following regimens:~Carboplatin (AUC5) plus Pegylated Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 every 28 days for a maximum of 8 cycles;~Carboplatin (AUC4) plus Gemcitabine 1000mg/m2 on day 1, 8 every 21 days for a maximum of 8 cycles;~Carboplatin (AUC5) plus Paclitaxel (175mg/m2) every 21days for a maximum of 8 cycles"
75421424|NCT01440127|Drug|Metformin|Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
75421425|NCT01440140|Other|Closed-loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
75421426|NCT01440140|Other|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
75566863|NCT06026085|Other|Skinceuticals skin care product(CE)|Skinceuticals skin care product(CE FERULIC)+routine sun protection
75566864|NCT06026085|Other|fraxel laser therapy|Fraxel DUAL 1550/1927 Laser System
75566865|NCT06026085|Other|0.9% normal saline|0.9% normal saline+routine sun protection
75566866|NCT06026072|Other|CLAD-V SCORE|the CLAD-V score is measured by the doctor during the emergency take care. After 7 days the patient will be call back to compare the prediction of CLAD-V score and the reality of surgical intervention or no.
75566867|NCT06026020|Other|Biological samples collection|Samples of blood, faeces, saliva are collected for analysis.
75566868|NCT06026007|Other|advices|each pregnant woman was advices how to elevate her legs and daily positions to elevate edema
75566869|NCT06026007|Other|Traditional physical therapy|each pregnant woman was advised about daily routine in addition to circulatory exercise
75566870|NCT06026007|Other|Acupressure|each pregnant woman was advised about daily routine in addition to acupressure therapy
75566871|NCT06025981|Other|Preliminary Phase|In the preliminary phase, the characterization of the functionality of the SWalker robotic system, as well as the functionality of the Virtual Reality system, will be carried out. All descriptive usability questionnaires completed by the participants and electro-biomechanical parameters will be collected using the robot's measurement systems to analyze the functionality.
75566872|NCT06025981|Other|Phase I - Early gait rehabilitation|In the first phase, the participants will carry out the rehabilitation program for hip fracture in acute phase that will last 6 weeks. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the usual rehabilitation guidelines that integrate exercises aimed at improving strength, gait, functional mobility and balance. In the case of the experimental group, a robotic walker will be used to practice walking.
75566873|NCT06025981|Other|Phase II - Maintenance gait function ( with VR)|In the second phase, participants will carry out a 6-week program to consolidate walking function. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the use of the robotic system for gait exercise. In the case of the experimental group, the use of virtual reality will also be integrated.
75566874|NCT06025968|Behavioral|i-CBT|The content is based on manual by Perlis et al (2015) and has slightly reworked by the research team by shortening treatment from seven to six sessions and allowing for day-time naps that may be necessary for patient with MS (Siengsukon et al. 2020). Due to the high prevalence of fatigue in people with MS, naps during the day may be a necessity to cope with everyday tasks. In cases where patients could not refrain from naps, they were advised to limit them to maximum 20 minutes and to take them as early in the day as possible. Other components are sleep restriction, sleep hygiene, stimulus control and cognitive techniques..
75720047|NCT04804891|Biological|Cell Therapy|Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
75720048|NCT04802590|Drug|Ibrutinib 560 mg|560mg/d continuously from C1D2 to end C24
75421427|NCT01440153|Other|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
75566875|NCT06025968|Behavioral|Applied relaxation|Treatment consits of 6 modules. The main components in the training program will be progressive muscle relaxation, short relaxation with release only and without tension, and finally the participants will be taught rapid relaxation.
76044616|NCT05476445|Procedure|Laser|Root canal treatment+Laser application
75566876|NCT06025955|Procedure|minimally invasive non- surgical therapy|hand and ultrasonic instrumentation will be done
75720049|NCT04802590|Drug|Venetoclax 10 MG Oral Tablet [Venclexta]|20mg/d from C2D1 to C2D7
75566877|NCT06025955|Procedure|open flap debridement|flap surgery will be done
76044617|NCT05476445|Procedure|Cryotherapy|Root canal treatment + Cryotherapy application
75720050|NCT04802590|Drug|Venetoclax 50 MG Oral Tablet [Venclexta]|50mg/d from C2D8 to C2D14
75720051|NCT04802590|Drug|Venetoclax 100 MG Oral Tablet [Venclexta]|100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
76044618|NCT05466461|Procedure|Beautifil Flow Plus X.|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel.Single Bond TM Universal will be applied to cavity walls and margins with agitation for 20 seconds.The adhesive will be light-cured for 20 seconds. Then Beautifil Flow Plus X composite will be placed
75720052|NCT04797260|Genetic|Gene therapy|Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
75720053|NCT04780477|Dietary Supplement|Experimental: High Fiber Diet (HFD)|Experimental: High Fiber Diet (HFD) pre-portioned entrées for two meals/d in mos. 1-3, and one meal/d in mos. 4-6. Participants continue on their respective diets in mos. 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250g of legumes per day (~1 ½ cups cooked) in months 1-3 provided in two pre-portioned single serving entrées (i.e. ~125g each). A study nutritionist will provide in-person and written guidance for including sides that are nutritionally balanced with energy intake to lose 1-2 lbs. /wk.
75874792|NCT03241927|Biological|Pembrolizumab|Day 1 of each 3 week cycle
75566878|NCT02916030|Dietary Supplement|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
75720054|NCT04780477|Dietary Supplement|Healthy American Diet|Healthy American Diet pre-portioned meal replacement entrées with legumes replaced by lean chicken/meat. A study nutritionist will provide in-person and written guidance for including sides that are nutritionally balanced with energy intake to lose 1-2 lbs. /wk.
75421428|NCT01440153|Other|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
75421429|NCT01440166|Drug|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
75874793|NCT03936751|Device|CPAP|This is the standard treatment for OSA.
75421430|NCT01440166|Other|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
75874794|NCT03936751|Device|Nasal Strips|Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
76044619|NCT05466461|Procedure|Activa bioactive restorative|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel. Bonding agent will be applied on the entire cavity and light-cured for 20 seconds then Activa bioactive restorative composite will be applied and cured for 20 seconds.
75421431|NCT01440192|Biological|PDA001 (cenplacel-L)|1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 & 8
75874795|NCT05571865|Dietary Supplement|Probiotic|Oral administration of a probiotic
75421432|NCT01440205|Behavioral|Easy list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy."
75421433|NCT01440205|Behavioral|Challenging list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult."
75720055|NCT04776993|Drug|Methimazole|Methimazole for 72 weeks
75421434|NCT01440205|Behavioral|Control|No check box element
75421435|NCT01440231|Drug|Placebo|Matching placebo administered by subcutaneous injection, once weekly
75421436|NCT01440231|Drug|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
75566879|NCT06025916|Drug|Tranexamic acid|20 ml of oral solution TA (100mg/ml)
75566880|NCT06025890|Other|Functional Training.|"Based on the modularization of core ability improvement, specific ability improvement and ability strategy acquisition, learning problems and interpersonal relationships, social adaptation; and other programs, sometimes combined with computer-aided cognitive training, parenting behavior management training and/or mindfulness training, aerobic exercise and other intervention forms, can achieve personalized functional training intervention for children. Use brain near-infrared imaging technology to capture multimodal neuroimaging features of young children; use high-precision repetitive transcranial direct current stimulation technology to conduct positive neural enhancement and adjustment training on the target brain area. Based on physical therapy stimulation, neuromodulation improves core symptoms in children."
75720056|NCT04776993|Procedure|Radioiodine or thyroidectomy|Treatment with radioiodine or with thyroidectomy
75720057|NCT04771663|Other|Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger|The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.
75720058|NCT04766138|Device|Fecobionics|Fecobionics is a new device to be inserted through the anal canal into rectum for studying defecation
75421437|NCT01440231|Drug|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
75421438|NCT01440231|Drug|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
75421439|NCT01440231|Drug|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
75874796|NCT03329885|Drug|BMS-986251|Escalating oral dose
75874797|NCT03329885|Other|Placebo|Escalating oral dose
75874798|NCT05255315|Behavioral|Comparative analysis comparing the morbidity of the antebrachial free flap to that of the temporal flap flap during exenteration as well as the rate of fitting patients with epithesis.|"A retrospective analysis will be performed by comparing the computerized data of patients reconstructed with a free antebrachial flap to that of patients reconstructed with a temporal muscle flap.~Another analysis, this time prospective, will be carried out by comparing the answers to the reconstruction specific questionnaires as well as the POSAS scores of patients reconstructed with either a free antebrachial flap or a temporalis muscle flap."
76044620|NCT02546609|Drug|Leu-Met-Sil 0.5|NS-0200 low dose
76044621|NCT02546609|Drug|Leu-Met-Sil 1.0|NS-200 high dose
76044622|NCT02546609|Drug|Placebo|Placebo
75566881|NCT06025890|Other|Observe.|Children with language disorders and ADHD were recruited at an early age when symptoms first appeared. Professional assessments were conducted to evaluate clinically relevant developmental and cranial nerve function indicators using near-infrared brain imaging technology. Follow-up was conducted for two years, and the outcome indicators were language disorder and attention deficit hyperactivity disorder.
75566882|NCT06025864|Other|Breastfeeding|"Over the 6 months of the intervention, 1 video per month was sent, a total of 6 videos, via the mobile application, with guidance on breastfeeding: the importance of maternal hydration; myths and truths about the mother's diet; practical guidance on breastfeeding; baby's gastric capacity; picking up and positioning the baby during breastfeeding and storing milk for the return to work. There were also 1 call per month, with an average duration of 15 minutes, with a breastfeeding consultant nutritionist, aiming to solve doubts and difficulties that month. In order to provide complete assistance, virtual groups were created via the WhatsApp application, with a nutritionist and a health academic to solve doubts, provide emotional support and exchange information when necessary.~According to the region or municipality of origin of the mother-baby dyad, when necessary, this study provided the loan of a breast pump during the follow-up period or 6 months."
75566883|NCT06025851|Drug|Anti-human CCL24 monoclonal antibody (CM-101)|Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)
75874799|NCT04663841|Other|transcranial magnetic stimulation|transcranial magnetic stimulation is delivered as part of routine care and is not managed by this observational study
75874800|NCT00490763|Behavioral|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
75874801|NCT02941523|Drug|NOX66|NOX66 administration
75566884|NCT06025851|Drug|Placebo|Placebo Comparator
75566885|NCT06025825|Drug|Articaine Hydrochloride + Epinephrine|"Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction."
75566886|NCT06025825|Drug|Lidocaine Hydrochloride + Epinephrine|Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group
75566887|NCT06025812|Biological|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
75566888|NCT06025812|Biological|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).
75566889|NCT06025786|Combination Product|Benazir Nashonuma Program (BNP)|"Benazir Nashonuma Program (BNP)~Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy.~Conditional Cash Transfer (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
75566890|NCT06025773|Drug|Lansoprazole 15 mg|AD-2121 (Lansoprazole 15 mg), Oral, Capsule
75720059|NCT04753658|Drug|lorlatinib|Oral
75720060|NCT04752891|Other|AOM diagnosis with app|the diagnosis made by a senior physician using a traditional otoscope. the diagnosis made by the junior physician using an otoendoscope fixed on a connected smartphone
75720061|NCT04752891|Other|AOM diagnosis without app|the diagnosis made by a senior physician and by the junior physician, using a traditional otoscope
75566891|NCT06025773|Drug|Lansoprazole 15mg/Calcium carbonate 600mg|AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
75566892|NCT06025630|Drug|TUDCA|Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
75566893|NCT06025630|Drug|Placebo|Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
75874802|NCT02941523|Drug|Carboplatin|Carboplatin administration
75874803|NCT03666143|Drug|Sitravatinib|120 mg orally once daily in combination with tislelizumab
75874804|NCT03666143|Drug|Tislelizumab|200 mg IV once every 3 weeks
75874805|NCT03609203|Other|10 Weeks of Strength Trailing|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
75566894|NCT06025617|Other|Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders|The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.
75566895|NCT06025617|Other|Diagnostic as usual|"Diagnostic as usual consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP."
75566896|NCT06025552|Drug|TU7710|In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1~4 PK, PD, safety, and exploratory efficacy data.
75566897|NCT06025552|Drug|Normal saline|Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
75566898|NCT06025539|Behavioral|Animal-assisted resilience training|Participants take part in 12 sessions (120 minutes each), each session focuses on a topic that is related to resilience. The intervention takes part outdoors on a farm, and includes interactions with several different animals. The training takes place in small groups, and includes exercises, observations, and discussions.
75566899|NCT06025487|Biological|Bexsero|two doses of Bexsero are applied intramuscularly with a one-month interval between doses
75566900|NCT06025474|Drug|Vortioxetine 20Mg Tab|Encapsulated vortioxetine immediate release tablets, once daily
75874806|NCT03609203|Other|Group Nutrition Discussion: week 1, week 5 and week 10|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
75874807|NCT00360425|Drug|ferumoxytol|
75874808|NCT00360425|Drug|moxifloxacin|
75566901|NCT06025474|Drug|Paroxetine 20 Mg Oral Tablet|Encapsulated paroxetine tablets, once daily
75874809|NCT00360425|Drug|placebo|
75874810|NCT02938585|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
75874811|NCT02938585|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
75874812|NCT00233597|Drug|ferumoxytol or oral iron|
75874813|NCT04661267|Dietary Supplement|Stem Cell Support Formula|This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.
75874814|NCT04661267|Dietary Supplement|Placebo|The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.
75874815|NCT05571631|Other|exercise|Arm ergometer will aplied as an aerobic exercise. Combination of balance training and arm ergometer exerise program will applied.
75874816|NCT04282811|Drug|Venetoclax|Patients treated with venetoclax-based regimens outside clinical trials in Italy
75874817|NCT05220059|Dietary Supplement|Polyphenol extract|Single dose
75566902|NCT06025474|Drug|Sertraline 50 MG|Encapsulated sertraline tablets, once daily
75566903|NCT06025474|Drug|Citalopram 20mg|Encapsulated citalopram tablets, once daily
75566904|NCT06025474|Drug|Escitalopram 10mg|Encapsulated escitalopram tablets, once daily
75566905|NCT06025474|Drug|Duloxetine 60 MG|Encapsulated duloxetine tablets, once daily
75566906|NCT06025474|Drug|Pregabalin 75mg|Encapsulated pregabalin tablets, once daily
75566907|NCT06025461|Other|no intervention|no intervention
75566908|NCT06025409|Drug|Leuprolide Acetate 11.25 MG/ML|Subcutaneous injection
75566909|NCT06025383|Dietary Supplement|L-Citrulline|2 weeks of L-Citrulline supplementation (6 grams/day)
75566910|NCT06025383|Dietary Supplement|Placebo|2 weeks of microcrystalline cellulose supplementation (8 capsules/day)
75566911|NCT06025357|Dietary Supplement|L-Citrulline supplementation|4 weeks of L-Citrulline supplementation (10 grams/day).
75566912|NCT06025357|Dietary Supplement|Placebo|4 weeks of microcrystalline Cellulose supplementation.
75566913|NCT06025279|Other|Ultrasound Scan|Clinical professionals will conduct non-invasive ultrasound scans from the specified body views and subsequently save the acquired data.
75566914|NCT06025266|Device|Evaluation of Viscoelastic and mechanical properties with MyotonPRO|MyotonPro™, a handheld, non-invasive and painless device, is used for non-invasive measurement of the biomechanical and viscoelastic properties of soft biological tissues such as superficial skeletal muscles, fascia, tendons and ligaments. The properties of the structures can be measured from different regions during complete rest or contraction.
75874818|NCT05220059|Dietary Supplement|Placebo|Maltodextrin
75874819|NCT03229759|Drug|Octenidine Dihydrocloride in aqueous solution|application of investigational product
75874820|NCT03229759|Other|Vehicle Control|application of vehicle control
75421440|NCT01440270|Drug|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy"
75720062|NCT04741932|Other|Dementia Care Management (DCM)|"A computerized Information and Care Management System (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care)."
75720063|NCT04693520|Drug|ALZ-801|ALZ-801 265 mg twice daily (BID)
75421441|NCT01440309|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
75421442|NCT01440309|Drug|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
75421443|NCT01440335|Drug|Oral R,R'-Fenoterol|
75421444|NCT01440335|Drug|Oral Racemic Fenoterol|
75421445|NCT01440348|Procedure|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
75421446|NCT01440361|Drug|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
75421447|NCT01440361|Drug|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
75421448|NCT01440400|Procedure|Ultrasound guided spinal anesthesia|Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
75421449|NCT01440413|Biological|Blood and tumor sample|"Blood samples will be collected on the first day of the first cycle of chemotherapy (before injection of chemotherapy), on the first day of the third cycle (before injection of chemotherapy), on day of surgery and 6 months after surgery and in case of relapse.~Tumor samples will be collected on diagnosis, on surgery and on the first day of the third chemotherapy course (optional)."
75720064|NCT04679961|Device|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
75720065|NCT04671875|Drug|Recombinant Humanized Monoclonal Antibody MIL93|"PART I :The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg,respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.~PART II:One recommended dose will be conducted from 6 dose groups based on results of PART I."
75874821|NCT03229759|Other|Saline Control|application of placebo
75874822|NCT03558191|Drug|SHR-1210|A humanized monoclonal immunoglobulin PD-1 antibody
76044623|NCT02534909|Biological|LFG316|"LFG316 will be administered to all patients enrolled in the study~LFG316: Treatment periods 1-3 and first 4 weeks of period 4. LNP023: Treatment Period 4"
76044624|NCT02534909|Drug|LNP023|LNP023 will be administered in period 4 to patients who participate in period 3 of this study and are willing to join long term extension study with LNP023.
75421450|NCT01440426|Procedure|Autologous connective tissue graft with rotated papilla flap|Subepithelial connective tissue graft harvested from hard palate
75421451|NCT01440426|Device|Collagen matrix construct (Mucograft)|Mucograft Collagen Matrix combined with rotated papilla flap
75421452|NCT01440439|Drug|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
75421453|NCT01440439|Drug|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
75421454|NCT01440478|Drug|LY2140023|Administered orally
75421455|NCT01440478|Drug|Ammonium chloride|Administered orally
76044625|NCT03030755|Other|Optical coherence tomography|
75566915|NCT06025240|Diagnostic Test|cf-DNA|In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is >20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.
75566916|NCT06025240|Diagnostic Test|Immunological Events following renal transplant in older age|Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the <60 and >60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
75566917|NCT06025240|Other|Determining Predictive Models for Post-transplant HLA-specific Antibody Formation|A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
76044626|NCT02553317|Biological|Caplacizumab|"First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
75874823|NCT03476681|Drug|NEO-201 in combination with pembrolizumab|NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
75566918|NCT06025214|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
75720066|NCT04669249|Behavioral|PROCare|PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
75874824|NCT03620825|Other|Dehydration by sauna exposure|Participants repeatedly undergo sauna exposures until they loose 3% of their body weight.
76044627|NCT02553317|Biological|Placebo|"First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
75720067|NCT04667702|Behavioral|Interviews|We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.
75720068|NCT04660162|Device|Iontophoresis|By using the PeriIont (Perimed, Jarfalla, Sweden) device, 0.5 mL of a 10 mg/ml Sodium nitroprusside solution was used transdermally and ionised with a current strength of 200 µA for 1 minute.
75720069|NCT04660162|Other|Stepwise occlusion|The upper arm was occluded for 30 seconds with a pneumatic cuff up to 50 mmHg, 80 mmHg, 110 mmHg, 140 mmHg, and 170 mmHg. The volunteer had rest for 5 minutes between each occlusion procedure.
75421456|NCT01440478|Drug|Sodium bicarbonate|Administered orally
75421457|NCT01440491|Other|Physiotherapy exercise|once a day, during 15 minutes, for 12 weeks
75421458|NCT01440504|Other|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
75421459|NCT01440530|Behavioral|Educational Intervention|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
75720070|NCT04570553|Procedure|surgical staging|Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
75874825|NCT03620825|Drug|Indomethacin|Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
75874826|NCT01312649|Behavioral|Experimental psychology methods (computer tests)|
75874827|NCT01312727|Other|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
75421460|NCT01440530|Other|Usual Care|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
75566919|NCT06025214|Drug|ADVAIR DISKUS® 500/50|2 inhalations in one study period
75874828|NCT03228433|Drug|TAK-418|TAK-418 Capsule.
75874829|NCT03228433|Drug|TAK-418 Placebo|TAK-418 placebo-matching capsules.
75874830|NCT04463797|Other|Square-stepping exercise|The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.
75874831|NCT04463797|Other|Stretching and strengthening|whole-body stretching and upper extremity strengthening
76044628|NCT03029351|Drug|Exenatide Extended Release for Inj Susp 2 MG|Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
75566920|NCT06025201|Behavioral|Resting State EEG|During this intervention, participants will be asked to not think about anything in particular while EEG is recorded. Resting state will be conducted with either the participants having their eyes open, or eyes closed.
75566921|NCT06025201|Behavioral|Picture Viewing EEG|During this intervention, participants will view emotionally charged pictures for a short period of time. Afterwards, participants will be asked to rate their emotional reactions to the pictures. EEG will be recorded during this intervention.
75566922|NCT06025201|Behavioral|Stop Signal EEG|During this intervention, participants will be asked to respond quickly to a visual stimulus with a button press. At times, participants will be asked to inhibit their responses. EEG will be recorded during this intervention.
75566923|NCT06025188|Other|training set|LASSO regression analysis, Logistic regression analysis, Nomogram
75720071|NCT04546516|Device|HYAcorp Lips and HYAcorp Face|Dermal filler injection to different facial areas
76044629|NCT03029351|Drug|Placebo|placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
76044630|NCT02325219|Drug|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
76044631|NCT02325219|Drug|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
75566924|NCT06025175|Radiation|Low level Lazer therapy|30 patients will receive low level lazer therapy 3 times a week for 12 weeks.
75566925|NCT06025175|Other|Routine exercises|30 patients will receive only routine exercises 3 times a week for 12 weeks.
75566926|NCT06025162|Drug|enoxaparin|dose of enoxaparin at 48 hours post-VTE prophylaxis initiation
75720072|NCT04546152|Device|HYAPROF® SOFT and HYAPROF® BALANCE|Dermal filler injection to different facial areas
76044632|NCT02325219|Drug|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
75720073|NCT04545944|Drug|Vonoprazan|20 mg tablets administered orally
75421461|NCT01440582|Drug|Panobinostat|"Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.~Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.~Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.~Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle."
75566927|NCT06025097|Drug|Combination Solution|Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
76044633|NCT02325219|Drug|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
75566928|NCT06025084|Drug|Egg Shell nanoparticles|Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
75720074|NCT04545944|Drug|Midazolam|2 mg syrup administered orally
75874832|NCT03930121|Other|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)|Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
75874833|NCT01496118|Drug|panobinostat|Specified dose on specified days
75874834|NCT01496118|Drug|carfilzomib|Specified dose on specified days
75874835|NCT02936869|Behavioral|Performance-based monetary incentives|
75720075|NCT04529928|Device|Carillon Mitral Contour System|Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
75720076|NCT04522804|Drug|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
75720077|NCT04520763|Other|5min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-80% MVV 15-30min after ingestion of 75g of glucose
75874836|NCT05083884|Other|No Intervention|This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
75874837|NCT03606096|Biological|Boostrix IPV infant acellular Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis
75874838|NCT03606096|Biological|Boostrix IPV infant whole Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis
75874839|NCT03606096|Biological|TT infant acellular Pertussis|mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis
75874840|NCT03606096|Biological|TT infant whole Pertussis|mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
75874841|NCT03309605|Drug|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
75874842|NCT03309605|Drug|Placebo|Placebo
75421462|NCT01440582|Drug|Bortezomib|"Induction Therapy (Part A, 21-day cycles): 1.3 mg/m^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 1.3 mg/m^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8."
75874843|NCT02936635|Drug|tirasemtiv|Oral
75874844|NCT03227029|Biological|RSV ΔNS2/Δ1313/I1314L|10^6 plaque-forming units (PFU); administered as nose drops
75874845|NCT03227029|Biological|RSV 276|10^5 PFU; administered as nose drops
75874846|NCT03227029|Biological|Placebo|Isotonic diluent, administered as nose drops
75566929|NCT06025071|Drug|colchicine|Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.
76044634|NCT02297841|Device|Experimental: Novel lubricant Miami Fragrance|
75874847|NCT05571475|Other|Simulated competition|During a competition, athletes will typically compete for a reward, against opponents and in the presence of others. This will be replicated in the laboratory.
75566930|NCT06025058|Device|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
75566931|NCT06025019|Behavioral|parent-based Electronic Health intervention|"The eHealth intervention comprises 12 modules on three interaction modules related to physical activity, dietary behavior, and sleep. The intervention groups will be invited to a WeChat group. A 3-minute video (made on the TikTok APP) will be sent to each WeChat group. Based upon the social media studies recommendation, five to nine members in a group will produce the desirable group interactive effect. Therefore, the present study allocates eight parents to one WeChat group. In total, there will be 26 groups (206 parents) according to the sample size calculation. Consistent with Social Cognitive THeory, the content of each module will follow the four steps: 1. Attention (Read educational material and watch TikTok/Douyin video (less than 3 minutes). 2.Retention (parental interaction). 3.Reproduction (Set goals and conduct behaviors). 4.Motivation (feedback and making changes)."
75566932|NCT06025006|Other|alternative to incarceration|place of respite with housing plus intensive follow-up
75720078|NCT04520763|Other|15min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-70% MVV 15-30min after ingestion of 75g of glucose
75720079|NCT04503395|Device|ESAR treatment: Endograft + Heli-FX Endoanchor|ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
75720080|NCT04503395|Device|FEVAR treatment : Fenestrated endograft|Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
75720081|NCT04477356|Procedure|SU|Aliquot 1.2 ml Ferticult Flushing media (Fertipro, Belgium) into 14 ml tube and then gently add 1 ml semen sample to the bottom of the tube (in case of larger semen volume, use multiple 14 ml tubes). The tubes then will be hold at an angle of 45 degrees for 45-60 minutes at 37C. Collect 1 ml of supernatant and then wash with 2 ml Ferticult Flushing media by centrifugation at 1200 RPM for 10 minutes. Keeping 0.3 ml washed semen for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
75720082|NCT04477356|Procedure|DG|Add 1.5 ml Sil-select 90% first and then 1.5 ml Sil-select 45% (Fertipro, Belgium) into centrifuge tube, then gently add 1 - 1.5 ml semen on the top of Sil-select layer and centrifuge at 1200 RPM for 15 minutes. Discard upper layer, collect 0.5 ml lower layer into new tube and then wash with 2 ml Ferticult Flushing media at 1200 RPM for 10 minutes. Discard upper layer then collect 0.3 ml lower layer for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
76044635|NCT02297841|Device|Experimental: Novel lubricant Miami no Fragrance|
75421463|NCT01440582|Drug|Lenalidomide|"Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.~Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle."
75421464|NCT01440582|Drug|Dexamethasone|"Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle."
75421465|NCT01440582|Behavioral|Symptom Questionnaire|Completed on day 1 of each cycle.
75421466|NCT01440608|Drug|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
75421467|NCT01440608|Drug|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
76044636|NCT02297841|Device|KY Liquid lubricant|
76044637|NCT02297841|Device|Astroglide Gel lubricant|
76044638|NCT02324361|Other|Physical Activity|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
76044639|NCT02324361|Behavioral|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
75421468|NCT01440608|Dietary Supplement|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
75421469|NCT01440621|Drug|Modafinil|Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
75566933|NCT06024993|Device|Flow-controlled ventilation (FCV)|30 minutes of FCV, delivered with the CE-marked Evone ventilator (Ventinova medical, the Netherlands)
75566934|NCT06024993|Device|Conventional volume-controlled ventilation (VCV)|30 minutes of conventional VCV, delivered with the CE-marked Aisys CS3 (GE Healthcare, USA) or Flow-i (Getinge, Sweden) ventilators.
75566935|NCT06024967|Drug|PEG-somatropin|PEG-somatropin
75566936|NCT06024954|Other|aromatherapy|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
75720083|NCT04472351|Behavioral|ASCEND-I|"The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties."
75720084|NCT04455724|Device|Negative pressure incisional wound therapy|A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues.
75720085|NCT04455724|Device|Standard sterile dressing|A standard, sterile island dressing
75566937|NCT06024954|Other|music therapy|"The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes."
75720086|NCT04425434|Other|OBSERVATIONAL|We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
75720087|NCT04425421|Other|OBSERVATIONAL|OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
75720088|NCT04409925|Drug|rhDNase I|Inhaled nebulisations
75720089|NCT04405700|Other|Pharmacovigilance surveillance program|The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
75720090|NCT04394325|Behavioral|Digital information tool|The patients randomized to group A will receive verbal and written information regarding the digital information tool and how to use it, as well as verbal and written information about the study. They will also receive information about the different instruments and surveys they will be asked to answer at different occasions during the RT treatment period. The applied instruments for data collection will be administrated in person or by post at the baseline collection and by post (including pre-paid return envelope) on consecutive collections. Approximately 30 patients (in group A) will be asked to make regular notes in a notebook during the waiting period prior start of RT as well as during RT treatment period. Following completion of the RT treatment period individual in-depth and telephone interviews will take place with 10-12 patients that accept participation.
75720091|NCT04393285|Drug|Abemaciclib|Abemaciclib 150mg orally twice a day
75720092|NCT04393285|Drug|Letrozole|Letrozole 2.5mg orally once a day
75720093|NCT04391283|Drug|Osimertinib|The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity according to the prescription information and clinical practice. It can be taken with or without food at the same time each day.
75720094|NCT04374799|Drug|Heparin|two doses of heparin
75720095|NCT04374799|Drug|Placebos|placebo
75720096|NCT04373382|Behavioral|Peer Resilience Champion|PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.
75720097|NCT04373382|Behavioral|Enriched Survey Feedback|This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.
75874848|NCT03487614|Behavioral|Behavior-based parental intervention|Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
75874849|NCT05015634|Other|Active Arm|Patient develops possible cardiac symptoms, takes an ECG, BP and oxygen saturation as per their training. Patient will receive a phone call by the trial cardiologist who will have access to a high-quality ECG trace, as well as blood pressure and oxygen saturations, and coupled with the clinical history, can decide on the most appropriate course of further management. With remote follow up over the phone at 3, 6 and 9 months.
75421470|NCT01440621|Drug|Pyridoxine|Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
75421471|NCT01440673|Drug|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
75566938|NCT06024954|Other|aromatherapy and music therapy|Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
75874850|NCT05015634|Other|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
75874851|NCT03329573|Drug|Paroxetine IR tablets A|Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
75874852|NCT03329573|Drug|Paroxetine IR tablets B|Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
75874853|NCT00604201|Biological|Umbilical Cord Blood|unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
75720098|NCT04367857|Other|COVID-19 Serology|Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19
75874854|NCT00492349|Drug|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
75874855|NCT00492349|Drug|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
75874856|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.25 mL, Intramuscular
75874857|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.5 mL, Intramuscular
75874858|NCT03308825|Biological|Fluzone High-Dose vaccine|0.5 mL, Intramuscular
75874859|NCT04235855|Device|Endoscopic USG guided Liver biopsy|Diagnostic yield with EUS guided liver biopsy - Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed.
75421472|NCT01440686|Drug|Somatropin|A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
75566939|NCT06024915|Drug|TQ05105 tablets|TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
75566940|NCT06024915|Drug|Itraconazole capsule|Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
75421473|NCT01440686|Drug|Placebo|Tablets, oral administrations
75421474|NCT01440712|Drug|Gastrografin|Administration of 100 ml of gastrografin by the nasogastric tube, only once.
75421475|NCT01440712|Drug|physiological serum|Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
75421476|NCT01440725|Biological|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
75421477|NCT01440725|Procedure|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
75421478|NCT01440738|Behavioral|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
75421479|NCT01440751|Device|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
75566941|NCT06024915|Drug|Rifampicin Capsule|Rifampicin is a strong inducer of CYP3A.
75720099|NCT04367857|Behavioral|Health Care Worker Survey|The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
75720100|NCT04343586|Device|Blue light phototherapy|Phototherapy- Wavelength: 417±15 nm
75566942|NCT06024850|Other|Datas collected|"Datas collected by medical record: medical data (weight, height, smoking status, history) and socio-demographic data (age, occupation, type of injury) information, assessment of knee function before surgery, at 6 months and 1 year after surgery, magnetic resonance imaging (MRI) and radiological imaging at 1 year after surgery, results of the Iso-kinetic Muscle Assessment Test at 1 year after surgery to objectively determine the recovery of muscle function~The data collected will be used to perform a statistical analysis to evaluate the factors predicting a good long-term post-surgical evolution"
75566943|NCT06024837|Other|CT Images|Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
75720101|NCT04333238|Other|New progress note template|Residents assigned to document with new progress note template
75720102|NCT04333238|Other|Standard progress note template|Residents assigned to document with standard progress note template
75874860|NCT04235855|Device|Percutaneous Liver Biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
75874861|NCT05196503|Biological|Treatment|"Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF."
75874862|NCT03328325|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
75874863|NCT03328325|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
75874864|NCT03476603|Drug|Irbesartan|Patients are tested for their normal prescription irbesartan medication
75874865|NCT03476525|Drug|Fluoxetine|Patients are tested for their normal prescription fluoxetine medication
76044640|NCT02365233|Drug|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
76044641|NCT02365233|Drug|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
75566944|NCT06024824|Radiation|Dose-Painted Intensity Modulated Radiotherapy|"Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT.~Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.~Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions."
75566945|NCT06024811|Behavioral|supporting nursing care|Supportive nursing care was applied during the intrapartum period. Latent Active Transition phase,birt, postpartum period
75566946|NCT06024798|Diagnostic Test|Photon-Counting-Computed-Tomography|Initial and follow up (after 4 weeks) PCCT acquisition of the affected area of the lower extremity. Image acquisition will be performed on the PCCT
75566947|NCT06024772|Procedure|ultiparametric Magnetic Resonance Imaging|Undergo mp-MRI
75566948|NCT06024772|Drug|Perflutren lipid microsphere|Given IV
75566949|NCT06024772|Procedure|Transrectal Ultrasound|Undergo transrectal mp-US
75720103|NCT04298723|Device|Percutaneous closure of the LAA (Watchman / Watchman FLX)|LAA closure procedure will be done by experienced operators according to the local SOP. LAA closure will be performed under fluoroscopic and TEE guidance within conscious sedation or general anesthesia. Antibiotic single-shot prophylaxis should be administered peri-procedurally (i.e., cefazolin 2 g). The specific anatomy of the LAA is evaluated and an appropriately sized CE-marked device (WatchmanTM or Watchman FLXTM) is deployed. LAA angiography and TEE imaging is performed to identify optimal positioning of the device and to exclude a relevant leak. Following device deployment, patients will receive a therapy according to the manufacturers IFU, currently Aspirin and clopidogrel for 3 months followed by single Aspirin up to 12 months. Alternatively, 3 months of NOAC followed by Aspirin monotherapy up to 12 months are possible.
75720104|NCT04288947|Other|Disrespect and Abuse in Maternity Care|Changing the culture of disrespect and abuse in maternity care
75720105|NCT04288570|Procedure|suture anchor socket creation with punch|suture anchor socket creation with punch
75720106|NCT04288570|Procedure|suture anchor socket creation with drill|suture anchor socket creation with drill
76044642|NCT02365233|Drug|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
76044643|NCT02324205|Device|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
76044644|NCT02324049|Drug|SBC-103|
76044645|NCT02364999|Drug|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
76044646|NCT02364999|Drug|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
76044647|NCT02364999|Drug|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
75566950|NCT06024772|Procedure|Biopsy of Prostate|Undergo prostate biopsies
76044648|NCT02364999|Drug|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
76044649|NCT02322879|Drug|First Treatment Period|(duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
75566951|NCT06024746|Drug|Finerenone|Oral finerenone.
75566952|NCT06024746|Drug|Empagliflozin|Oral empagliflozin.
75566953|NCT06024681|Other|Faecal microbiota transplant|Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics
75874866|NCT04112693|Procedure|Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020.~The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse."
75874867|NCT03366467|Other|SADE|The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.
75421480|NCT01440751|Drug|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
75874868|NCT03366467|Other|RDE|The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
75874869|NCT05039489|Drug|Antipsychotic drugs|Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
75874870|NCT05039489|Device|cTBS（the left temporoparietal cortex as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
75421481|NCT01440790|Dietary Supplement|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
75421482|NCT01440790|Dietary Supplement|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
75421483|NCT01440790|Dietary Supplement|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
75421484|NCT01440790|Dietary Supplement|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
75421485|NCT01440829|Drug|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
75421486|NCT01440842|Other|Closed-loop insulin delivery|Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
75421487|NCT01440842|Other|Standard IV insulin infusion sliding scale|Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
75421488|NCT01440855|Other|CIS (Cancer Information Service) Information Sheet|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
75720107|NCT04266275|Drug|Curcumin C3 Complex|"Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
76044650|NCT02322879|Other|Washout|(duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
76044651|NCT02322879|Drug|Second Treatment Period|(duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
75874871|NCT05039489|Device|cTBS （the left cerebellum Crus II as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
75566954|NCT06024629|Device|cOCT and LC-OCT|"cOCT: conventional optical coherence tomography (cOCT) is an established imaging modality within dermatology that enables visualization of the architecture of the skin with a penetration depth of 1.0 - 1.5mm.~LC-OCT: Line-field confocal optical coherence tomography (LC-OCT) is a new emerging diagnostic modality within the field of dermatology. LC-OCT enables tridimensional imaging of the skin with a cellular resolution and BCC features on LC-OCT have been described. However, the penetration depth of LC-OCT (500µm), is limited compared to the penetration depth of cOCT (1.0-1.5mm)"
75874872|NCT05008289|Device|Magnetic transcutaneous spinal cord stimulation|In the active group, non-invasive spinal cord stimulation will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (thoracic level T2-T3). The intensity of stimulation will represent 100% of the motor threshold, which is determined by abdominal muscle contractions, found from single pulses, gradually applied every 10 seconds until the onset of contractions. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hertz repeated at 5 Hertz. In total 1200 pulses will be applied for 3 minutes and 58 seconds.
75874873|NCT05008289|Device|Transcutaneous electrical nerve stimulation|"To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS). The surface electrodes of TENS (model Neurodyn®️, Ibramed®️) will be placed in parallel at the height of the thoracic level T2-T3, with the following parameters: 80Hertz, 150ms, approximately at 60 miliampère.~In the placebo group, a coil will be allocated in the thoracic region T2-T3, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, away from its field of view, to provide the idea from the sound stimulus that it is being stimulated."
75720108|NCT04266275|Drug|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
75874874|NCT04967105|Device|Near-infrared spectroscopy|Before the induction of anesthesia, NIRS sensors were placed on both sides of the flank area that overlies the kidney to monitor renal SO2, whose alteration trends over time during operation will be recorded and evaluated in later analysis.
76044652|NCT02322411|Device|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
76044653|NCT02322411|Behavioral|Compensatory approaches|
76044654|NCT02322021|Drug|E2609|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
76044655|NCT02322021|Drug|Placebo|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
76044656|NCT02363439|Drug|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly|IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
76044657|NCT02363283|Drug|Glembatumumab Vedotin|Given IV
75421489|NCT01440855|Other|Facing Forward booklet|NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
75720109|NCT04245449|Behavioral|TEAACH|"TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required ~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities."
75421490|NCT01440868|Procedure|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher & Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm ).
75566955|NCT06024616|Behavioral|TARANG|"TARANG is structured to be interactive to empower young women to navigate newly formed relationships, improve women's awareness on sexual reproductive health and challenge inequitable gender norms with an aim to reduce unintended pregnancies. TARANG will also provide women with life skills education to improve mobility and agency. Each TARANG intervention women's group will have ~6-7 members and may meet up to twice a month for 8 months.~Vikalp's moderators will also conduct light touch sessions for mothers-in-law and husbands of newly married women. In conjunction with Vikalp, the research team from NEERMAN will recruit mothers-in-law of soon-to-be-married women to participate in 4 group sessions provided weekly for 1 month before the start of the intervention for newly married women. Husbands will be provided 4 group sessions spaced roughly 2 months apart throughout the course of the 8 months the newly married women are engaged in the intervention."
75720110|NCT04210700|Procedure|Fascia iliaca compartment block|"A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle."
75874875|NCT04098497|Behavioral|Mobile intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
75566956|NCT06024577|Behavioral|Walking|Prescribed 150 minutes per week of moderate to vigorous walking.
75566957|NCT06024577|Behavioral|Variety|Prescribed 150 minutes per week of moderate to vigorous variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training.
75566958|NCT06024577|Behavioral|Progressive|Prescribed 150 minutes per week of moderate to vigorous progressive variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training. Participants can choose which exercise they want to do, and can do as much or little as they want.
75566959|NCT06024564|Device|Sonu Acoustic Resonance Therapy|Participants will receive Sonu treatment twice a day for 90 days
75874876|NCT04045223|Other|Blood samples|Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
75874877|NCT04003961|Other|STOP- BANG Questionnaire and Epworth sleepiness scale|STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
75874878|NCT03986957|Other|No interventions|No interventions - observational study
75874879|NCT03665545|Drug|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
75874880|NCT03665545|Drug|IMA950/Poly-ICLC and pembrolizumab|IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
75874881|NCT03305081|Device|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
75874882|NCT04079881|Drug|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
75874883|NCT03891329|Device|Acticor/Rivacor ICDs/CRT-Ds|pre-defined device programming, measurements and follow-up schedule
75874884|NCT03891329|Device|Plexa S DX|Implantation, measurements and follow-up schedule
75874885|NCT03325673|Device|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
76044658|NCT02363283|Other|Laboratory Biomarker Analysis|Correlative studies
75566960|NCT06024525|Device|Paclitaxel-Coated Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
75874886|NCT03325673|Device|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
75874887|NCT03223909|Drug|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
75566961|NCT06024525|Device|Paclitaxel-Releasing Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
75566962|NCT06024499|Drug|HY209GEL Active|Selected two among three doses (HY209GEL 0.5% or 1% or 2%) in PART1
75720111|NCT04210700|Procedure|Pericapsular nerve group block|A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
75720112|NCT04207086|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
75720113|NCT04207086|Drug|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).
75874888|NCT03223909|Drug|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
75566963|NCT06024499|Other|Placebo|Placebo
75566964|NCT06024473|Device|rTMS|Transcranial Magnetic Stimulation
75566965|NCT06024473|Device|rTMS+iVCT|Transcranial Magnetic Stimulation and immersive virtual reality
75566966|NCT06024460|Procedure|non-pharmacological treatment strategy|Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
75874889|NCT03223909|Drug|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
75566967|NCT06024460|Procedure|pharmacological treatment strategy|"Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.~This group is treated using the above treatment strategies, and no drug is specified."
75566968|NCT06024447|Procedure|Subgingival Instrumentation|Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
75874890|NCT03733925|Drug|Golimumab|Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
76044659|NCT02363283|Other|Pharmacological Study|Correlative studies
76044660|NCT02321319|Drug|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
75566969|NCT06024421|Drug|favipiravir|Light yellow, film-coated tablet, each containing 200 mg of favipiravir
75720114|NCT04194359|Drug|Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine|Humanized PD-1 antibody (Sintilimab, IBI308)+bevacizumab+oxaliplatin+capecitabine
75720115|NCT04168008|Behavioral|WISH Adherence|The educational sessions will consist of an adherence-centered curriculum.
75874891|NCT03649711|Drug|Ticagrelor 90mg|Ticagrelor Pill
75566970|NCT06024421|Drug|Placebo|Light yellow, film-coated tablet
75566971|NCT06024395|Behavioral|Dental FearLess|Dental FearLess is a self-administered CBT-based mobile app that takes approximately 1 hour to complete.
76044661|NCT02294175|Device|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
75566972|NCT06024382|Other|twin block|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
75874892|NCT03649711|Drug|Clopidogrel 75mg|Clopidogrel Pill and a matching placebo to conceal frequency
75874893|NCT03649711|Drug|Aspirin 81 mg|Aspirin Pill
75874894|NCT05181631|Other|Biobanking|"Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL. "
75874895|NCT03303521|Drug|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
75421491|NCT01440894|Device|Comparison test|"Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.~DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D."
75720116|NCT04168008|Behavioral|WISH Parenting|The educational sessions will focus on parenting and baby care.
75874896|NCT03303521|Drug|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
75874897|NCT03214081|Drug|Vonoprazan|Vonoprazan tablets
75874898|NCT05181397|Drug|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
75874899|NCT02888171|Drug|ferric citrate|Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
75874900|NCT02888171|Drug|ferrous sulfate|Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
75874901|NCT02932891|Drug|DSXS topical|topical treatment
75874902|NCT04517903|Other|eye rubbing questionnaire|eye rubbing questionnaire
76044662|NCT02294175|Procedure|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
76044663|NCT02088541|Drug|Selinexor|Selinexor oral tablet.
76044664|NCT02088541|Drug|Hydroxyurea|
75421492|NCT01440907|Other|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
75720117|NCT04066907|Other|Integrated Disease Management|Multidisciplinary intervention comprising of patient education, self management strategies and medication optimization
76044665|NCT02088541|Drug|Ara-C|Ara-C Subcutaneous Injection.
76044666|NCT02294019|Drug|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
75421493|NCT01440933|Drug|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
75566973|NCT06024382|Other|twin block combined with low level laser|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
75566974|NCT06024356|Drug|Thymalfasin|Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.
75566975|NCT06024343|Procedure|MPD Repair or Reconstruction|During laparoscopic or robotic pancreatic tumor enucleation, if the main pancreatic duct (MPD) is damaged due to its proximity or encasement by the tumor, MPD repair or reconstruction is performed.
75566976|NCT06024317|Behavioral|Chanjo Kwa Wakati - Knowledge Intervention|Counseling scripts assessing and addressing vaccination-related knowledge gaps
75720118|NCT04053491|Procedure|Hand surgery under regional anesthesia|In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
76044667|NCT02320149|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day,
76044668|NCT02320149|Drug|Placebo|Placebo-matching sarecycline tablets taken orally at the same time each day.
75566977|NCT06024317|Behavioral|Chanjo Kwa Wakati - Reminders|Reminders of upcoming vaccination due dates, sent to the mother's mobile phone
75421494|NCT01440933|Drug|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
75874903|NCT05181319|Other|occurrence of bronchopulmonary dysplasia|We observe the incidence of bronchopulmonary dysplasia
75566978|NCT06024317|Behavioral|Chanjo Kwa Wakati - Incentives|Conditional incentives for timely vaccination, tailored to each child's vaccination schedule
75566979|NCT06024317|Behavioral|Chanjo Kwa Wakati - Service notifications|Service notifications (e.g., related to stockouts or service non-availability), sent to the mother's mobile phone
75720119|NCT04041232|Drug|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
75421495|NCT01440985|Drug|Nicotine|Nicotine Gum 2 mg, Lot number GD922A
75421496|NCT01440985|Drug|Nicotine|Nicotine gum 4 mg, Lot number GC962A
75421497|NCT01440985|Drug|Nicotine|Nicotine Microtab 2 mg, Lot number GB196G
75566980|NCT06024304|Device|Synthes TFNA|Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.
75566981|NCT06024304|Device|Trigen InterTAN|Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
75874904|NCT03302975|Device|Real-time visual biofeedback during treadmill running|Real-time biofeedback of braking forces during running
75720120|NCT04038541|Dietary Supplement|Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|"Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)"
75874905|NCT03212521|Drug|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
75566982|NCT06024278|Behavioral|Caregiver educational videos|The intervention will be culturally tailored education videos for caregivers receiving hospice services.
75566983|NCT06024265|Drug|ER2001 injection|The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
75566984|NCT06024252|Drug|TACE|TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.
75421498|NCT01440998|Drug|Carboplatin|Given IV
75421499|NCT01440998|Drug|Dasatinib|Given PO
75421500|NCT01440998|Other|Laboratory Biomarker Analysis|Correlative studies
75421501|NCT01440998|Drug|Paclitaxel|Given IV
75421502|NCT01441011|Behavioral|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
75421503|NCT01441011|Behavioral|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
75421504|NCT01441024|Drug|DAS181|20 mg per day of DAS181-FO3 for 5 days
75566985|NCT06024213|Procedure|Sentinel lymph node identification|Intervention description: Intraoperative identification of sentinel lymph node
75874906|NCT05181241|Drug|Dimolegin|"Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia"
75874907|NCT05181163|Diagnostic Test|swab|Swabs from site of infection will be taken
75874908|NCT03212365|Drug|Fixed dose|Participants will receive 40 mg enoxaparin twice daily
75566986|NCT06024213|Drug|indocyanine green|Intervention description: indocyanine green (5 to 10 mg [ie, 2 to 4 mL of a 2.5 mg/mL solution]) administered by periareolar or peritumoural route
75566987|NCT06024213|Drug|methylene blue|1%), 2-5 mL administered by periareolar or peritumoural route
75566988|NCT06024213|Drug|Technetium (99mTc)|(99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route
75566989|NCT06024200|Other|transcutaneous electrical acupoint stimulation|Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.
75566990|NCT06024200|Other|transcutaneous electrical acupoint stimulation sham stimulation|Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.
75720121|NCT04038541|Dietary Supplement|Probiotics (Visbiome®)|"Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)"
75720122|NCT04037501|Other|Care Management|A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
75720123|NCT04030000|Drug|Paclitaxel/Carboplatin|IV paclitaxel in combination with IP carboplatin
75720124|NCT04030000|Radiation|Pelvic radiation therapy|EBRT and vaginal brachytherapy
75720125|NCT04009174|Other|Imaging Panel|"Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~[18F]-FCH PET + Dynamic CT~MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~3D-Transrectal ultrasound~Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~[18-F]-DCFPyL PET+Dynamic CT~PET/MRI with endorectal coil~3D-Transrectal Ultrasound~Optional Sodium (23Na) MRI"
75720126|NCT03983161|Drug|Fedratinib|Fedratinib
75720127|NCT03965676|Other|Dual-Energy Computed Tomography examination|Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia < 360μmol/L (baseline DECT is in the domain of usual care).
75720128|NCT03957590|Drug|Tislelizumab|Administrated at dose of 200 mg intravenously (IV)
75720129|NCT03957590|Drug|Placebo|Placebo to match tislelizumab
75720130|NCT03957590|Drug|Paclitaxel|Administered as 135 mg/m² IV injection
75720131|NCT03957590|Drug|Cisplatin|Administered as 25 mg/m² IV injection
75720132|NCT03957590|Radiation|Radiotherapy|Administered at a total dose of 50.4 Gy in 28 fractions
75720133|NCT03921866|Drug|Palbociclib|Palbociclib
75720134|NCT03888027|Behavioral|WalkMORE group|Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
75720135|NCT03887221|Drug|Safinamide 50 mg|Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
75874909|NCT03212365|Drug|Variable dose|Participants will receive 0.5mg/kg enoxaparin twice daily
76044669|NCT05407909|Drug|SYHX2001|SYHX2001 tablets, oral
75874910|NCT03487627|Behavioral|Electronic and Care Support Manager Contact|This intervention will consist of electronic and Care Support Manager (CSM) contacts with parents from the first week following their adolescent's discharge from hospitalization through the first 3 months after discharge. The electronic application content will be accessible and delivered to parents weekly. Parents will also be able to enter a keyword on their electronic device to access content and material in real time. The CSM contacts will supplement the informational content delivered electronically by providing opportunities to ask questions about the electronic application material, and by checking on progress toward treatment follow through for their youth, identifying and problem solving any difficulties and concerns, and addressing health needs of each parent.
75566991|NCT06024187|Procedure|Cold dissection|The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.
75720136|NCT03887221|Drug|Safinamide 100mg|Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
75874911|NCT03487627|Behavioral|Enhanced Treatment-as-usual (TAU)|TAU typically involves a discharge planning session by unit staff with the adolescent and their parent(s) to discuss safety monitoring and referrals for mental health services following discharge from psychiatric hospitalization. Investigators will augment this usual care by providing written materials to families outlining some of the key considerations for caring for their adolescent. These written materials will include brochures with information for parents following adolescent suicidal behavior, a listing of resources including instructions for when to call 911 or go to the emergency room, and information regarding the National Suicide Prevention Lifeline. Written materials will be provided to both the enhanced TAU participants as well as participants receiving the electronic and CSM intervention.
75874912|NCT05328505|Radiation|Image-guided Radiotherapy|de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.
75874913|NCT03273257|Drug|Riociguat|"Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
75874914|NCT03273257|Drug|Placebo|Placebo will be given analogue to riociguat with matching tablets.
75874915|NCT03273257|Procedure|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
75874916|NCT04316741|Behavioral|Snapcoach|A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
76044670|NCT05423509|Other|Dynamic myofascial manipulation|Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
75421505|NCT01441024|Other|Placebo|20 mg per day of Lactose for 5 days
75421506|NCT01441128|Drug|PF-02341066/PF-00299804|Combined PF-02341066 and PF-00299804
75421507|NCT01441128|Drug|PF-02341066/PF-00299804|Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
75421508|NCT01441167|Biological|PfSPZ|
75421509|NCT01441193|Biological|HIV-1 Tat/delta-V2 Env combined vaccine|
75421510|NCT01441193|Biological|HIV-1 delta-V2 Env vaccine|
75421511|NCT01441193|Biological|HIV-1 Tat vaccine 7.5 microg|
75421512|NCT01441193|Biological|HIV-1 Tat vaccine 30 microg|
75874917|NCT02700035|Other|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
75566992|NCT06024187|Procedure|Electrocautery Dissection|The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.
76044671|NCT05423509|Other|Standard AIS treatment with observation or bracing|Observation with radiographs and bracing of curves greater than 20 degrees
75566993|NCT06024161|Other|Weight gain|≥5% weight gain
75566994|NCT06024161|Other|Weight loss|≥5% weight loss after arthroplasty
75566995|NCT06024161|Other|Weight unchanged|<5% weight change after arthroplasty
76044672|NCT05422417|Device|Prolonged intermittent theta burst stimulation (piTBS)|Participants in the prolonged dosage (1800 pulse) of intermittent TBS (iTBS) active stimulation group will receive 2-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
75566996|NCT06024148|Other|phone survey|patients complete a 10-minute telephone questionnaire on their osteoporosis management
75566997|NCT06024135|Device|NeoKidney|Progressive exposition to NeoKidney device starting with only one NeoKidney therapy on a mid-week day and 5 SDHD sessions with the usual device in week one, followed by 2 NeoKidney therapies and 4 SDHD sessions with the usual device in week 2, and only progressing to a full week on NeoKidney after a safety review.
76044673|NCT05422417|Device|20Hz rTMS|Participants in the 20 Hz rTMS (2000 pulse) active stimulation group will receive 2-week 2s- and-10s off, total 50 cycles at each hemisphere/session, at an intensity of 100% resting motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
75566998|NCT06024122|Other|IRM exam|A non-sedated MRI scan will be performed to assess the structure and function of the children's brains
75566999|NCT06024109|Device|Closure of the Vaginal Cuff after Total Hysterectomy|Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
75567001|NCT06023511|Device|Electrical muscle stimulation|While study subjects are connected to standard ICU monitors, electrical muscle stimulation will be applied at the level of the quadriceps muscle to induce palpable or visible muscle contraction. (No control group or sham procedure in this study).
75567002|NCT06023498|Other|Manual Therapy and Exercise|"The 20-minute manual therapy procedures will include:~Distraction-manipulation: manually assisted segmental lumbar traction manipulation using a specialized treatment table~Neural mobilization: rhythmic stretches of the sciatic and femoral nerves75~Hip, sacroiliac and lumbar facet mobilizations to improve joint mobility~Soft tissue mobilization of lumbopelvic and lower extremity muscles using manual pressure over taut bands/myofascial trigger points and post-isometric (contract-relax) stretching techniques."
75567003|NCT06023498|Other|Intramuscular Electroacupuncture|As described previously
75567004|NCT06023459|Drug|Injectable extended-release buprenorphine|Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial ~2-week period of induction/stabilization.
75567005|NCT06023459|Drug|Sublingual buprenorphine-naloxone|Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial ~2-week period of induction/stabilization.
75567006|NCT06023394|Device|Laryngeal Mask Airway|Laryngeal mask airway will be used as an airway device for Cohort A in the standard fashion.
75567007|NCT06023394|Device|Endotracheal Tube Device|Endotracheal tube airway will be used as an airway device for Cohort B in the standard fashion.
75567008|NCT06023277|Biological|ConvitVax|ConvitVax is a personalized vaccine designed to treat women with breast cancer. The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.
75567009|NCT06023251|Other|Clinical Nutrition|"Nutritional care plan implementation, including~A step-up and step-down nutritional protocol guided by caloric and protein ratio~Monitoring plan including daily nutritional intake assessment by a dietician and (para)medical supervision by a nutrition support pharmacist and nurse concerning dysphagia, refeeding syndrome, electrolytes abnormalities and access issues~Indirect calorimetry measurements to assess metabolic needs and body impedance analysis to assess body composition on regular time points~Dedicated and specialized dietician and nurse involvement~Adaptive communication policy (translating to native language) and culturally appropriate food regimens and artificial nutrition."
75874918|NCT02522507|Behavioral|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
75874919|NCT03637751|Behavioral|Behavioral|Trier Social Stress Test
75421513|NCT01441206|Drug|rifampin|"Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth < 32 weeks - PNA < 14 days: 10 mg/kg QD GA at birth < 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA < 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD"
75421514|NCT01441219|Device|Colon 2|Ingest one colon 2 capsule
75421515|NCT01441232|Drug|LX4211|400 mg of LX4211 administered as two 200 mg tablets
75567010|NCT06023238|Procedure|Treatment of Chronic TKA PJI|Patients will all undergo standard of care treatment for a chronic total knee arthroplasty prosthetic joint infection.
75567011|NCT06023225|Behavioral|Pain|Postoperative pain levels
75567012|NCT06023225|Behavioral|Opioid use|Postoperative opioid use
76044674|NCT05422417|Device|sham control|Half of the patients in the sham group received 2-week the same prolonged iTBS parameter stimulation (sham- prolonged iTBS), and the other half received the same 20 Hz rTMS parameter stimulation using a sham coil (sham-20 Hz rTMS), which also improved the blinding process
75421516|NCT01441232|Drug|Januvia®|100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
75421517|NCT01441258|Behavioral|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
75421518|NCT01441258|Behavioral|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
75421519|NCT01441258|Behavioral|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
75421520|NCT01441271|Procedure|Ileal diversion and lavage|The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution [GoLytely®; Braintree Laboratories] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes [500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days] via a Malecot catheter [24 French] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole [500mg q8 hours] for 10 days.
75720137|NCT03863808|Behavioral|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
75720138|NCT03863808|Other|Strengthening exercises|Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
75720139|NCT03859648|Device|BONEBRIDGE|Bone Conduction Implant
75567013|NCT06023186|Drug|mavacamten|Study participants will receive mavacamten under the standard of care
75567014|NCT06023134|Diagnostic Test|Echocardiography|Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
75567015|NCT06023134|Diagnostic Test|Right heart catheterization|"Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload."
75567016|NCT06023121|Diagnostic Test|Measurement of levels of an exosome-based liquid biopsy signature|Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
75874920|NCT03637751|Behavioral|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
75874921|NCT04495673|Device|Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (2 5-visit blocks of 46 minutes) of active tDCS to DLPFC (dorsolateral prefrontal cortex)
75874922|NCT04495673|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (1 5-visit block of 46 minutes of active tDCS and 1 5-visit block of sham tDCS)
75874923|NCT04495673|Behavioral|Cognitive Training|Executive functioning tasks
75874924|NCT04270877|Drug|Naltrexone Pill|Treatment with LDN for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
75874925|NCT04270877|Drug|Placebo oral tablet|Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
76044675|NCT05450653|Device|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the delivery Microcatheter (BALTACCI-BDPE100)|A Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus with severe congenital diaphragmatic hernia (o/e LHR <25% with liver up) during the FETO procedure between gestational age 27 weeks 0 days and 29 weeks and 6 days. The fetal tracheal balloon will be removed at between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
75421521|NCT01441271|Procedure|total abdominal colectomy|The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
75421522|NCT01441284|Drug|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
75421523|NCT01441284|Drug|placebo|placebo
75421524|NCT01441297|Drug|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
75421525|NCT01441310|Procedure|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
75567017|NCT06023082|Dietary Supplement|Colon Broom Premium supplement|"The product contains the following ingredients:~Psyllium Seed Husk Powder L-Carnitine Tartrate Capsimax® Cayenne Fruit Extract Chromium (as Chromium Picolinate) Vitamin B6 (as Pyridoxine HCl) Vitamin B12 (as Cyanocobalamin) Iron"
75720140|NCT03852875|Other|Education|Same
75720141|NCT03852875|Other|Control|Same
75720142|NCT03786666|Procedure|Carotid artery recanalization CEA or carotid artery stenting|Carotid artery recanalization CEA or carotid artery stenting
75720143|NCT03760588|Drug|Sacubitril/valsartan|Target dose 97/103 mg b.i.d .
76044676|NCT05405725|Biological|ENZ215|Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)
75421526|NCT01441323|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
75421527|NCT01441323|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
75421528|NCT01441336|Procedure|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
75567018|NCT06023043|Drug|Dexamethasone|Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
75567019|NCT06023017|Behavioral|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
75421529|NCT01441362|Procedure|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
75421530|NCT01441362|Procedure|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
75567020|NCT06023017|Behavioral|standard perioperative care without any prone position training|Patients in the control group (C group) received standard perioperative care without any prone position training.
75567021|NCT06022978|Procedure|Submucosal Saline Injection|Inject 3-5 mL of saline into the submucosa within 10 minutes using a single-use 22G mucosal needle. The puncture point is located 0.5 cm from the edgeof the lesion, and the saline injection is stopped when the esophageal mucosa is elevated by approximately 1 cm.
75720144|NCT03729778|Biological|Prevnar-13|One time administration of prevnar-13 vaccine
75720145|NCT03718260|Diagnostic Test|[18F]-DCFPyL PET/ CT scan (PSMA PET)|Participants will undergo re-staging with [18F]-DCFPyL PET/CT Scan (PSMA PET).
75720146|NCT03649048|Drug|High-Dose Cisplatin|Intravenous administration of High-Dose Cisplatin
75567022|NCT06022978|Procedure|Blue laser Imaging and Magnifying Endoscopy|It is a new system for image-enhanced endoscopy using laser light. By clicking a button on the endoscope only , endoscopists can electronically stain and magnify the digestive tract lesions. This system can help endoscopists observe leisons more clearly and improve diagnosic accuracy.
75567023|NCT06022965|Other|Best Practice|Receive SOC
75567024|NCT06022965|Other|Comprehensive Geriatric Assessment|Complete CARG-GA
75567025|NCT06022965|Other|Electronic Health Record Review|Ancillary studies
75567026|NCT06022965|Other|Questionnaire Administration|Ancillary studies
75567027|NCT06022965|Other|Supportive Care|Receive GA-based interventions
75874926|NCT03271307|Behavioral|Optimized PITC|Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
75874927|NCT03271307|Diagnostic Test|Facility HIVST|HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
75567028|NCT06022965|Other|Telemedicine|Receive GA-based interventions via telemedicine
75567029|NCT06022952|Other|Stone MD stent radar|Mobile app
75567030|NCT06022939|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Given IV
75567031|NCT06022939|Procedure|Biopsy|Undergo fat pad biopsy
75567032|NCT06022939|Procedure|Biospecimen Collection|Undergo blood and urine specimen collection
75567033|NCT06022939|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
75567034|NCT06022939|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75567035|NCT06022939|Drug|Bortezomib|Given SC
75567036|NCT06022939|Procedure|Computed Tomography|Undergo CT scan
75567037|NCT06022939|Drug|Cyclophosphamide|Given PO or IV
75567038|NCT06022939|Drug|Daratumumab and Hyaluronidase-fihj|Given SC
75567039|NCT06022939|Drug|Dexamethasone|Given PO or IV
75567040|NCT06022939|Procedure|Echocardiography|Undergo echocardiography
75567041|NCT06022939|Procedure|Magnetic Resonance Imaging|Undergo MRI
75567042|NCT06022939|Drug|Melphalan|Given IV
75720147|NCT03649048|Drug|Low-Dose Cisplatin|Intravenous administration of Low-Dose Cisplatin
75567043|NCT06022939|Procedure|Positron Emission Tomography|Undergo PET-CT
75720148|NCT03649048|Radiation|Radiotherapy|Participating centres are to follow their local radiation treatment planning and delivery techniques.
75720149|NCT03642626|Drug|KYMRIAH|FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
75720150|NCT03642626|Drug|YESCARTA|CD19-directed genetically modified autologous T cell immunotherapy
75874928|NCT03271307|Diagnostic Test|Index HIVST|HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
75874929|NCT03271151|Drug|Cymbalta|"Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain"
75874930|NCT03271151|Other|Placebo|Placebo to compare outcomes against Duloxetine
75874931|NCT03245723|Procedure|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethysmography
75567044|NCT06022939|Procedure|Stem Cell Isolation|Undergo stem cell collection
75720151|NCT03642626|Drug|Fludarabine 30mg/m2 4 doses|30 mg/m2 IV daily for 4 doses
75720152|NCT03642626|Drug|Cyclophosphamide 500 mg/m2; 2 doses|500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
75720153|NCT03642626|Drug|Fludarabine 30mg/m2 3 doses|30 mg/m2 IV daily for 3 doses
75567045|NCT06022939|Other|Survey Administration|Ancillary study
75720154|NCT03642626|Drug|Cyclophosphamide 500 mg/m2; 3 doses|500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
75720155|NCT03642626|Drug|Fludarabine 25mg/m2 3 days|25 mg/m2 i.v. daily for 3 days
75567046|NCT06022900|Behavioral|Online training group|online health education with video call
75567047|NCT06022900|Behavioral|Face-to-face training group|Face-to-face health education with home visit
75567048|NCT06022874|Other|Phoilex Releaf Gel|"Patients will be given the Releaf Gel to apply to the affected areas daily. They will be examined at the following time points: Immediately after application, 1 week, 2 weeks, and 4 weeks.~The instructions given to the patient shall be to apply one pump per every affected area, wash hands before applying to affected area, apply twice a day (morning, and evening), apply on clean skin, and application after showering is advised.~The number of pumps of Phoilex Releaf gel will be documented within a chart provided to the patient. It is suggested that not more than 25 lesions compassing an area greater than 50 cm² in total be treated during the course of this study.~The maximum dose would be 240 mL of Phoilex Releaf gel in 30 days. The minimum dose would be 0.5 mL (one pump) of the Phoilex Releaf gel in 30 days. The maximum daily dose of CBD per day 46 mg per application, equivalent to 92 mg per day."
75567049|NCT06022861|Drug|LY01015|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period
75567050|NCT06022861|Drug|Fluorouracil|Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
75720156|NCT03642626|Drug|Cyclophosphamide 250 mg/m2; 3 days|250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
75720157|NCT03642626|Drug|Tecartus|TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
75720158|NCT03642626|Drug|Abecma, Intravenous Suspension|Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
75720159|NCT03642626|Drug|Cyclophosphamide 900 mg/m2; 1 day|Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
75720160|NCT03642626|Drug|Breyanzi Injectable Product|Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
75720161|NCT03621982|Drug|ADCT-301|intravenous infusion
75720162|NCT03621982|Biological|Pembrolizumab|intravenous infusion
75421531|NCT01441388|Drug|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
75421532|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
75421533|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
75874932|NCT03245723|Procedure|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
75567051|NCT06022861|Drug|Cisplatin|Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period
75567052|NCT06022861|Drug|Opdivo®|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
75720163|NCT03612648|Radiation|Three Fraction Accelerated Partial Breast Irradiation|"TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System"
75720164|NCT03612648|Procedure|Partial mastectomy|-Standard of Care
75720165|NCT03608163|Drug|Naloxone|Naloxone Nasal Spray
75874933|NCT03245723|Procedure|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
75720166|NCT03608163|Drug|Diazoxide|Diazoxide (oral)
75720167|NCT03608163|Drug|Placebo (for Naloxone)|Sterile water nasal spray
75720168|NCT03608163|Drug|Placebo (for Diazoxide)|Taste matched oral placebo for diazoxide
75720169|NCT03604445|Drug|BI 905677|Solution for infusion
75720170|NCT03573700|Drug|Cyclophosphamide|Given IV
75720171|NCT03573700|Drug|Fludarabine|Given IV
75720172|NCT03573700|Drug|Mesna|Given IV
75874934|NCT03245723|Procedure|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
75874935|NCT02349971|Device|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
75874936|NCT05003921|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
76044677|NCT05405725|Biological|Prolia|Enrolled women with postmenopausal osteoporosis will receive Prolia
75720173|NCT03573700|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
75720174|NCT03573700|Biological|CD19- specific CAR engineered autologous T-cells (SJCAR19 product)|Given IV
75720175|NCT03567837|Other|Fructose + Glucose Beverage|The intervention is an oral sugar challenge with blood sampling over three hours.
75720176|NCT03539848|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
75874937|NCT03301649|Drug|Generic Ivermectin Lotion 0.5%|Topical lotion, generic formulation of the brand product.
75874938|NCT03301649|Drug|Sklice® (Ivermectin) Lotion 0.5%|Topical lotion, brand product.
75421534|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
75421535|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
75567053|NCT06022848|Procedure|occipital nerve stimulator|Quantitative sensory testing
75567054|NCT06022835|Other|Chlorhexidine Gluconate-gel (CHG) Dressing|Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
75874939|NCT03301649|Drug|Vehicle Lotion|Topical lotion, placebo. Has no active ingredient.
75874940|NCT03637439|Other|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
75874941|NCT03637439|Other|Ultrasound-guided Percutaneous Needle|Same protocol without electricity
75874942|NCT04647617|Behavioral|Quantitative weight -bearing and report exercise sign data every weekly|keep their normal live style
75421536|NCT01441388|Drug|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
75421537|NCT01441388|Drug|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
75421538|NCT01441427|Drug|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
75421539|NCT01441427|Drug|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
75421540|NCT01441427|Drug|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
75421541|NCT01441427|Drug|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
75567055|NCT06022796|Other|Healthy Ketogenic Ready-to-Eat Meals|Participants will be provided nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet. In addition, HK-RTE meals will be provided to participants as a form of meal replacement for lunch and dinner over 1 month. Participants will be expected to follow a healthy ketogenic diet thereafter.
75720177|NCT03530371|Drug|Dexmedetomidine Hydrochloride|intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
75421542|NCT01441427|Drug|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
75720178|NCT03521830|Drug|Nivolumab|480mg IV every 4 weeks
75720179|NCT03521830|Drug|Ipilimumab|1mg/kg IV every 4 weeks for 4 doses
75421543|NCT01441453|Procedure|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
75421544|NCT01441479|Device|In Vitro Diagnostic Device aid in diagnosing|
75421545|NCT01441505|Drug|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
75720180|NCT03521830|Drug|Relatlimab|480 mg IV q4wks
75720181|NCT03496610|Drug|Liposomal Bupivicaine|Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
75720182|NCT03496610|Procedure|QL Block|Patient will receive ultrasound guided QL Block
75720183|NCT03489122|Behavioral|yoga|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
75720184|NCT03489122|Behavioral|walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
75720185|NCT03456934|Other|Modified infant formula|Test formula with lower protein content than standard formula
75720186|NCT03456934|Other|Standard infant formula|Standard infant formula
75720187|NCT03449485|Drug|Chlorprothixene|Patients are tested for their normal prescription chlorprothixene medication
75720188|NCT03448783|Drug|Apixaban|Patients are tested for their normal prescription apixaban medication
75720189|NCT03433417|Device|Cutera truSculpt|One truSculpt treatment delivered 0 to 90 days before scheduled Abdominoplasty to one side of the tissue to be removed during abdominoplasty
75874943|NCT03222973|Drug|BIIB033 (opicinumab)|Administered as specified in the treatment arm
75874944|NCT03222973|Drug|Placebo|Administered as specified in the treatment arm
75874945|NCT01144416|Biological|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
76044678|NCT02540083|Device|DBT and FFDM|Subjects underwent FFDM breast imaging followed by DBT breast imaging
75421546|NCT01441505|Drug|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
75567056|NCT06022796|Other|Healthy Ketogenic Diet|Participants will receive nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet, without the provision of HK-RTE meals.
75567057|NCT06022783|Other|Virtual reality intervention|Watching a relaxing video with using VR-G for 20 minutes
75720190|NCT03424421|Procedure|subscapular sling|semitendinosus subscapular sling procedure
75720191|NCT03418649|Drug|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
75720192|NCT03418649|Drug|Placebo Oral Tablet|PO once daily for 10 days
75720193|NCT03346343|Device|Non-invasive forced airway oscillometry|This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.
75720194|NCT03327441|Other|Almonds|Almonds will be provided as 15% energy
75720195|NCT03327441|Other|Omelette|Omelettes will be provided as 15% energy
75567058|NCT06022770|Dietary Supplement|Nutritional counseling，Enteral Nutrition|patients with esophageal cancer and gastric cancer undergoing chemotherapy were selected as the study objects for nutritional risk screening, malnutrition assessment and quality of life assessment. Randomly enter the nutrition consultation group (NC) and nutrition support treatment group (NST)
75874946|NCT01144416|Biological|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
75874947|NCT01144416|Drug|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
75874948|NCT01144416|Drug|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
75567059|NCT06022744|Drug|LX109|LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
75874949|NCT00335777|Drug|Migranal nasal spray at 1 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
75874950|NCT00335777|Drug|Migranal nasal spray at 4 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
76044679|NCT02293863|Drug|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
76044680|NCT02293863|Drug|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
76044681|NCT02293863|Drug|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
76044682|NCT02293395|Drug|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
76044683|NCT02293395|Drug|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
76044684|NCT02293395|Drug|Clopidogrel|Clopidogrel 75 mg once daily orally.
76044685|NCT02293395|Drug|Ticagrelor|Ticagrelor 90 mg twice daily orally.
76044686|NCT02025985|Drug|Selinexor|"Route of administration and dosage form: Oral tablet; Doses: 35 mg/m^2 BIW, 35 mg/m^2 QW, 50 mg/m^2 BIW, 50 mg/m^2 QW, 60 mg/m^2 BIW, 60 mg/m^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles."
76044687|NCT05450341|Device|rTMS over right frontal target|Low frequency (1 Hz) rTMS over right inferior frontal gyrus
76044688|NCT05450341|Device|rTMS over right temporal target|Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
76044689|NCT04423081|Other|EXIT scale|completion of EXIT scale translated in french
75567060|NCT06022731|Diagnostic Test|Panoramic Radiography|this retrospective study includes analysis of radiographs previously taken from patients for various purposes
75567061|NCT06022718|Other|Taping|Kinesio taping and Rigid taping was applied.
75567062|NCT06022692|Device|Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
75567063|NCT06022692|Drug|tislelizumab (BeiGene, China) combined with PD-1 inhibitor|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
75720196|NCT03326141|Behavioral|Otago Exercise Program|The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
75720197|NCT03326141|Device|Physical activity monitors (e.g., Fitbit)|We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
75720198|NCT03326141|Behavioral|Interpersonal Behavior Change Strategies|The interpersonal content will include facilitated discussed about including PA into social routines, identifying and problem-solving social and environmental barriers to PA, social support for exercise, and friendly social comparisons about practicing PA outside the small group setting and interpreting/ sharing data.
75720199|NCT03326141|Behavioral|Intrapersonal Behavior Change Strategies|The intrapersonal content will include encouragement and guidance to identify baseline PA patterns, develop and refine personally meaningful goals and plans, identify and problem solve personal barriers to staying physically active, integrate PA into personal routines, and monitor goal outcomes
75874951|NCT04424004|Other|COVID-19 PCR and serology testing|"PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months."
75874952|NCT03764137|Drug|[89Zr]Panitumumab PET-MRI|All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.
75874953|NCT03625518|Drug|prostaglandins E2|insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction
75874954|NCT03625518|Device|intracervical balloon catheter combined with pitocin|insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
75874955|NCT03469297|Device|Brown Glaucoma Implant|The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
75874956|NCT00972738|Drug|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
75720200|NCT03326141|Other|Information about Health and Wellness|Information about health and wellness varies in dose, according to time spent in each condition that addresses behavior change. Topics in condition 1 include sleep, vaccinations, supplements, fall risk factors, memory, hearing and pain guided by information for older adults available on the NIA and CDC websites. Topics in conditions 2 and 3 include fall risk factors and sleep. Topics in condition 4 include fall risk factors.
75874957|NCT00972738|Drug|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
75567064|NCT06022679|Other|CBCT|CBCT examination in supine position A computerized 3D-analysis using Dolphin Imaging 11.95 software was performed in each CBCT.
75567065|NCT06022666|Other|Geriatric assessment|Geriatric assessment through PATH clinic which includes an evaluation of comorbidities, health trajectory and baseline frailty as well as conducting an in-depth discussion with the patient on how frailty stage impacts decision-making about surgery in order to co-develop a care plan.
75567066|NCT06022653|Other|Treatment|EVAR,TEVAR,PTA
75567067|NCT06022640|Behavioral|Educational and supportive care|The trial had a total of 75 participants assigned to the intervention group, whereby they were provided with an educative and supporting program specifically developed by a clinical pharmacist. The intervention group was provided with assistance via a series of five visits, which included an initial visit upon admission, subsequent visits for monitoring medication, ovulation, and negative effects, as well as visits dedicated to giving emotional support. Additionally, a follow-up visit was conducted after the egg collecting process and embryo transfer.
75874958|NCT00972738|Drug|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
75874959|NCT03452839|Drug|Meropenem|Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
75567068|NCT06022627|Behavioral|Pranayama Yoga|Doing practice of paranayam yoga which including breathing exercises yoga-life energy
75874960|NCT04701281|Combination Product|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
75421547|NCT01441518|Other|Home care|"Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia ."
75421548|NCT01441518|Other|Hospital care|"Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists."
75567069|NCT06022614|Drug|Use Bupivacaine 0.25% Injectable Solution|Group A Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml normal saline.
75567070|NCT06022614|Drug|Bupivacaine 0.25% Injectable Solution plus Dexmedetomidine|Group B Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml dexmedetomidine
75720201|NCT03315832|Drug|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
75720202|NCT03315832|Drug|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
75720203|NCT03292601|Device|Cinch Smart Strap|"The study device is a small (with dimensions of 1.5 x 2 x 3/8 and weighing approximately 0.9-oz) Bluetooth-enabled and battery-powered monitor with Velcro strap that attaches to orthopaedic braces for scoliosis in place of the traditional strap and buckle. When the Velcro strap is tightened, the device measures tension in Newtons with the vector of force parallel to and away from the device, reflecting the pulling force required to keep the brace fitted on the patient."
75720204|NCT03292601|Other|Cinch Mobile App|The Cinch App allows patients and parents to track and edit treatment information, sync data from the Cinch Smart Strap, and view compliance data. The app connects via Bluetooth to the Cinch Smart Strap and allows patients and parents save and sync data from the device.
75720205|NCT03124355|Drug|placebo sugar pill|placebo single oral dose
75874961|NCT05012670|Drug|[14C]-Paxalisib Capsule|Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
75874962|NCT04313478|Behavioral|Low Birth Weight and Normal Weight infants|This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
75874963|NCT05180929|Device|Dual M1-tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
76044690|NCT02528305|Other|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&6, 8 sprints in sessions 7&8, 9 sprints in sessions 9&10 and 10 sprints in sessions 11&12.
75421549|NCT01441531|Drug|gabapentin 600 mg po|Given one hour before surgery
75421550|NCT01441531|Drug|Placebo pill given one hour before surgery|Placebo pill given
75567071|NCT06022601|Device|DNA Nudge|DNA Nudge wearable, DNA-based dietary advice
75567072|NCT06022588|Drug|Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA|a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate. Participants received 0.80 gram 13C-butyrate (7.3 mMol butyrate / 29 mMol 13C) dissolved in 50 mL water at baseline
75720206|NCT03124355|Drug|Pyridostigmine Pill|pyridostigmine bromide 30 mg single oral dose
75720207|NCT03124355|Drug|Galantamine Pill|Galantamine hydrobromide 8mg single oral dose
76044691|NCT05450263|Behavioral|Interoceptive exposure|A pilot study addressing the efficacy and feasibility of an interoceptive exposure technique.
76044692|NCT05403775|Other|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
75874964|NCT05180929|Device|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
75874965|NCT05180929|Device|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
75874966|NCT04249830|Biological|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
75874967|NCT04249830|Device|CliniMACS TCR α/β Reagent Kit and CliniMACS CD19|The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).
75874968|NCT03243305|Drug|AMPHORA|non-hormonal contraceptive vaginal gel
75874969|NCT04168632|Other|OPTIMAT|The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
75874970|NCT03882918|Drug|OV101|Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
75874971|NCT03222583|Drug|Placebo|Matching placebo tablet for oral administration
76044693|NCT05403775|Other|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
75874972|NCT03222583|Drug|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
75874973|NCT05282329|Device|Transcranial alternating Current Stimulation (tACS)-active|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
75874974|NCT05282329|Device|Transcranial Alternating Current Stimulation (tACS)-sham|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
75874975|NCT01314391|Genetic|mutation analysis|
75874976|NCT01314391|Genetic|polymerase chain reaction|
76044694|NCT05420701|Procedure|TEE|Patients in the surgical arm (LAAC) will be arranged to do TEE, which is not considered standard of care.
76044695|NCT05420311|Other|MedDiet Arm|A balanced hypocaloric diet in macronutrients (MedDiet)
75567073|NCT06022588|Drug|U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA|a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline
75720208|NCT03124355|Device|Vagal stimulation|Vagal stimulation will be given at 50 Hz during the tilt table tests
75720209|NCT03124355|Device|Sham vagal stimulation|Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
76044696|NCT05420311|Other|KetoDiet Arm|A very low carbohydrate diet (KetoDiet).
75567074|NCT06022588|Diagnostic Test|Breath test|Breath tests were performed at the following time points baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours after ingestion of 13C-butyrate and 13C-glucose. Breath samples were obtained by blowing a single breath of air through a straw into a test tube. Two breath samples were collected at all mentioned time points. Measurement of 13CO2 is performed using mass spectrometry (IDMicro Breath, Compact Science Systems, Newcastle-Under-Lyme, United Kingdom) using procedures described earlier for galactose and methacetin breath tests, and expressed as an absolute increase in the 13CO2-to-12CO2 ratio in delta permil (δ‰).
75720210|NCT03122652|Drug|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
75720211|NCT03122652|Drug|Placebo Oral Tablet|1 tablet once a day
75720212|NCT03028779|Procedure|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
75720213|NCT03011268|Other|Discontinuation of anti-TNF treatment|Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences
75720214|NCT03011268|Other|Continuation of anti-TNF treatment|Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
75720215|NCT02956031|Other|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
75567075|NCT06022588|Diagnostic Test|Exercise + breath test|The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion
75421551|NCT01441544|Behavioral|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
75567076|NCT06022575|Procedure|Telehealth integrated care|Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
75874977|NCT01314391|Other|laboratory biomarker analysis|
75874978|NCT04180397|Drug|Furosemide|Furosemide 10 mg/ml for injection/infusion
75421552|NCT01441557|Drug|3,4-diaminopyridine|test dose 10 mg then 20 mg, then depending on tolerance and efficacy full-dose administration(from 10mg /8h to 20 mg /8h)
75567077|NCT06022575|Procedure|Conventional health care|Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
75421553|NCT01441583|Device|RAAT|For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
76044697|NCT05420311|Other|IF Arm|An intermittent fasting (IF) approach
75874979|NCT04180397|Drug|Isotonic saline|Isotonic saline used as placebo (injection/infusion)
75874980|NCT04540445|Other|Pupillary Assessment|Pupillary assessment with handheld pupillometer
76044698|NCT05402761|Behavioral|Nurse-guided BBTi group|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi. In the end of week 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
75421554|NCT01441583|Device|RYTHMIQ|For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
75421555|NCT01441622|Device|AL539 (SRETT)|recording data with AL539 (SRETT)
75874981|NCT04629911|Device|THRIVE|Patients will receive HFNO therapy during laryngomicrosurgery. Patients will undergo a gastric ultrasound examination after HFNO therapy.
75874982|NCT03625674|Behavioral|explanation when prescribing psychoactive medicine|explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
75874983|NCT03295721|Drug|HTX-011|HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
75874984|NCT03295721|Drug|Saline Placebo|Saline placebo by instillation
76044699|NCT05402761|Behavioral|Mobile-delivered BBTi group|They will use the app in conjunction with the standard BBTi procedures provided by the app, such as stimulus control, sleep restriction and audio-guided relaxation techniques (suggest to use before bedtime).
75421556|NCT01441648|Other|contact lens wear|tinted contact lens wear
75567078|NCT06022536|Drug|SSS40|Subjects injected with SSS40
75567079|NCT06022536|Drug|Placebo|Subjects injected with Placebo
75567080|NCT06022523|Diagnostic Test|Data acquisition using DT-400 pulse oximetry system|Acquisition of photopleth data during profound hypoxia using a Consolidated Research DT-400 pulse oximetry system.
75567081|NCT06022484|Other|The present study does not contain any intervention|The present study does not contain any intervention
75567082|NCT06022471|Procedure|Stapes surgery|Stapedectomy operation
75567083|NCT06022224|Biological|hAd5-S-Fusion+N-ETSD|Clear and colorless liquid. Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10^11 viral particles/mL.
75567084|NCT06022224|Biological|Placebo (0.9% (w/v) saline)|Clear and colorless liquid.
75874985|NCT03295721|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg by injection
75874986|NCT03295721|Device|Luer-lock applicator|Applicator for instillation
75874987|NCT03295721|Device|Vial access device|Device for withdrawal of drug product
75567085|NCT06021561|Diagnostic Test|Diagnosis of pain|Pain will be investigated - type, origin, level
75567086|NCT06020755|Drug|Toripalimab|200mg q2w intravenous
75567087|NCT06020755|Drug|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
75720216|NCT02956031|Other|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
75720217|NCT02956031|Procedure|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
75720218|NCT02945774|Radiation|(18F)-FEPPA|PET ligand that binds to activated microglia, a marker of neuroinflammation
75874988|NCT00803790|Drug|alendronate sodium+vitamin D combination|A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
75874989|NCT00803790|Drug|Comparator: alendronate|A single dose tablet of 70mg alendronate in one treatment period of each sequence.
75874990|NCT00803790|Dietary Supplement|Comparator: Vitamin D|Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
76044700|NCT05447065|Dietary Supplement|Vitamin D supplement|Only the experimental group (D) received the vitamin D supplement.
75720219|NCT02944578|Drug|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
76044701|NCT05402605|Procedure|ICSI with AOA|"Step 1: All post-ICSI oocytes will be added in the medium drop in AOA dish, these oocytes will be placed in the incubator at 37oC, 6% CO2, and 5% O2 for 20 minutes.~Step 2: After 20 minutes, calcium ionophore stock (Sigma-Aldrich - USA) will be diluted into 10µM drops in AOA dish.~Step 3: After 10 minutes of incubation, all post-ICSI oocytes will be moved to the AOA drop, then this dish will be put back in the incubator for 10 minutes.~Step 4: After 10 minutes, all the oocytes in drop AOA will be moved to another drop for rinsing and then put back in the incubator for 20 minutes.~Step 5: After 20 minutes, the oocytes will be moved into drop AOA and then put back in the incubator for 10 minutes.~Step 6: After 10 minutes, all post-ICSI oocytes will be added in the medium drop, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2"
76044702|NCT05402605|Procedure|ICSI without AOA|Conventional ICSI procedure will be performed without the application of AOA.
76044703|NCT05401357|Drug|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
75874991|NCT03637985|Device|resistive exercise|resistive exercise by elastic band for 12 weeks
76044704|NCT05401357|Drug|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
76044705|NCT05401279|Drug|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.
75567088|NCT06020521|Other|Three spectrometry differents technics|"Collection of expired air as follows:~For online mass spectrometry techniques (PTR-MS and SICRIT)~For offline mass spectrometry (GCxGC-MS)~Performing volatolome analyses:~By PTR-TOF-MS (Ionicon) and SICRIT-HRMS (SICRIT module (Plasmion) coupled to a Q-exactive instrument (Thermofisher)) for online analyzes~By two-dimensional gas chromatography coupled with mass spectrometry (Pegasus BT-4D, Leco) for the desorption tubes."
75567089|NCT06020430|Radiation|CTV omitted or delineated|Patients who responded to the induction therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radical radiotherapy group or CTV-delineated radiotherapy group.
75567090|NCT06020248|Other|Wear clothing that has been exposed to cigarette smoke for 3 hours.|Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.
75567091|NCT06020027|Behavioral|Water is K'é|Four-month multi-level, family-based intervention that is grounded in Navajo culture and promotes individual knowledge, motivation and skills; social norms; and environmental changes (access to drinking water). At minimum, the enrolled child and primary caregiver will attend monthly sessions, with an open invitation to other family members. Families will also receive social media posts and develop a family access plan by selecting strategies (if needed) to boost their confidence in their water sources at home. ECE sites will also develop a tailored access plan, selecting strategies to increase confidence in water offered at the ECE site, and implement their access plan with study team support.
75567092|NCT06019962|Device|digital pelvic inclinometer|It is a reliable and valid instrument for measuring pelvic tilt angle
75874992|NCT03637985|Device|aerobic exercise in form of treadmill walking|aerobic exercise in form of treadmill walking for 12 weeks
75567093|NCT06019754|Procedure|combined Lumbar and sacral plexus block|performing an ultrasound-guided combined Lumbar and sacral plexus block using one-point puncture
75567094|NCT06019741|Drug|Rivaroxaban and aspirin 80|rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery
75720220|NCT02944578|Drug|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
75874993|NCT03568188|Procedure|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
75720221|NCT02943291|Behavioral|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
75567095|NCT06019741|Drug|Aspirin 80|aspirin 80 mg orally post coronary bypass surgery
75720222|NCT02943291|Behavioral|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
75720223|NCT02893943|Dietary Supplement|Probiotics|
75720224|NCT02893943|Dietary Supplement|Placebo|
75720225|NCT02889523|Drug|Tazemetostat|Tablets 200 mg, to be administrated per os
75720226|NCT02889523|Drug|Rituximab|375 mg/m²/dose, D1
75720227|NCT02889523|Drug|Cyclophosphamide|750 mg/m²/dose, D1
75720228|NCT02889523|Drug|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
75720229|NCT02889523|Drug|Doxorubicin|50 mg/m²/dose, D1
75720230|NCT02889523|Drug|Prednisolone|40 mg/m2 in the morning D1 to D5
75874994|NCT03568188|Biological|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
75567096|NCT06019468|Other|Envolizumab combined with radiotherapy|Application of Envolizumab combined with radiotherapy for neoadjuvant treatment of locally advanced thymic cancer. Firstly, 20-40Gy radiation therapy was administered 10-20 times. Within one week after the start of radiation therapy, Envolizumab (300 mg, D1, Q3W, subcutaneous injection) was administered. Immunotherapy was maintained for 2-4 cycles, and surgery was performed after evaluation by the attending physician.
75720231|NCT02782741|Drug|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
76044706|NCT05401279|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four to six 21-day cycles.
75567097|NCT06018701|Device|"A dental device made of zirconia. This is a new invention and does not exist generically. The given generic name of the invention (dental device) is Dantya Nikhan."|Dental device is surgically placed and cemented with PMMA bone cement on edentulous region.
75720232|NCT02782741|Drug|Alglucosidase alfa (GZ419829)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
75720233|NCT02771626|Drug|CB-839|Glutaminase inhibitor
75874995|NCT03568188|Device|MRI|MRI exam will be regularly performed during patient follow up.
76044707|NCT05401279|Drug|Cisplatin|Cisplatin 70mg^m2 will be administered on Day 1 for four to six 21-day cycles.
76044708|NCT05420077|Biological|RVM-V001 10 µg|Low Dose
76044709|NCT05420077|Biological|RVM-V001 30 µg|Mid Dose
75421557|NCT01441674|Behavioral|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
75567098|NCT06018389|Behavioral|Structural only|"A shared list of school policies for or related to, school-based social events at school premises. The policy initiatives include (but are not limited to): increasing the number of social events without alcohol; promoting non-alcoholic beverages at parties; working with student associations regarding their roles and responsibilities; encouraging parental involvement at school events and disseminating the schools' alcohol policy among students and parents. The school principal and management will be responsible for the implementation and enforcement of the policies.~The Information-based interactive parent meetings will be 45 minutes and will take place at the schools. Parents will be offered concrete, research-informed advice about how they can reduce risk of hazardous substance use and promote well-being among their adolescents. Following a 15-minute presentation, the group leader facilitates a discussion and exchange of experience between parents."
75567099|NCT06018389|Behavioral|Structural+Group MI|"Within school classes, students are divided into groups of 5-8 students and each group will be assigned a group leader from the research team. The group-based Motivational Interviewing (group MI) is manualized and consists of two one-hour group sessions administered over two consecutive weeks. The first session is focused on Tell your story, Gains from not drinking, and Social norms. In the second session, the focus is on Personal values, Linking values with behavior and Planning/choices regarding alcohol. Both group MI sessions will take place at the schools during the school day."
75421558|NCT01441700|Procedure|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
75567100|NCT06018298|Other|Treatment as usual (TAU)|the components of treatment as usual (TAU) are summarised and assessed by the items of the DUNDRUM-3: physical health, mental health, substance misuse, problem behaviours, self care and activities of daily living, education occupation and creativity, family and intimacy.
75567101|NCT06018038|Diagnostic Test|Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)|Cardiopulmonary Exercise Testing (CPET)
75567102|NCT06017843|Other|Camps site selection for active case finding for TB using MATCH-AI|The primary intervention in this study is the roll-out of MATCH-AI, an artificial intelligence software that models sub-district TB prevalence, to guide site selection of ACF camps. The MATCH-AI tool uses a Bayesian modelling approach to predict TB prevalence to a resolution of 10,000 population that are mapped as polygons. The model integrates data from a range of sources including historical TB facility notification data, previous ACF data as well as contextual factors such as demographics, income, population density, health indicators such as vaccination coverage and climate related variables to predict localized TB prevalence. In the intervention arm, camps will be conducted primarily in locations guided by MATCH-AI.
75567103|NCT06017804|Other|Muscle energy technique|Participants were required to adopt a supine position. MET's post-isometric relaxation method was chosen. The therapist gently flexed the patient's hip until the limitation bar-rier was detected. At this stage, isometric contractions against resistance were applied. After that, the patients were told to resist the movement with only 25% of their strength. Before the leg was released, the contraction was maintained for 7-10 seconds. On exhale, the knee joint was straightened (extended) towards its new barrier, and a stretch was applied and maintained through that barrier for 30 seconds. This procedure was carried out six times.
75720234|NCT02771626|Drug|Nivolumab|PD-1 inhibitor
75421559|NCT01441752|Drug|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
75421560|NCT01441752|Drug|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
75421561|NCT01441778|Drug|NSS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
75567104|NCT06017804|Other|Self-myofascial release technique|A foam roller was rolled from the ischial tuberosity to the back of the knee on the side being tested while the participant remained seated in a long sitting position. Individuals were instructed to keep all of their body weight on the leg being evaluated. They spent 30-40 seconds rolling one hamstring at a time in each set (10 times back and forth).
75567105|NCT06017544|Procedure|PCI|The T2DM affected by AMI will be referred for receiving PCI.
75567106|NCT06017362|Drug|Insulin|Topical insulin 1UI/ml 4 times a day
75567107|NCT06017362|Drug|Artificial tear|Artificial tears 4 times a day
75720235|NCT02616302|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
75720236|NCT02515370|Other|Friends for Life Circles (FLCs).|"The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs"
75720237|NCT02469753|Drug|NSAIDs|continuous daily
75720238|NCT02469753|Drug|NSAIDs|on demand
75720239|NCT02469753|Drug|anti-TNF|
75567108|NCT06016218|Drug|Simvastatin|Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
75421562|NCT01441778|Drug|BHS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
75421563|NCT01441791|Procedure|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
76044710|NCT05420077|Biological|RVM-V001 60 µg|High Dose
76044711|NCT02532517|Device|CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System|
75720240|NCT02374242|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.
75720241|NCT02374242|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activation. Ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T-cell mediated anti-tumour immune responses.
75720242|NCT02366598|Other|Hemp shake|Hemp protein shake
75720243|NCT02366598|Other|Soybean shake|Soybean protein shake
75720244|NCT02366598|Other|Control|Non-protein shake
76044712|NCT05418595|Other||
76044713|NCT02545049|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
75421564|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
75567109|NCT06013618|Drug|Naxitamab monotherapy|Naxitamab is administered on days 1, 3, and 5
75567110|NCT06013618|Drug|GM-CSF|Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.
75720245|NCT02314988|Drug|Tranexamic Acid|"3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL."
75720246|NCT02314988|Drug|Placebo|"Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline."
75874996|NCT03568188|Other|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
76044714|NCT02545049|Drug|Placebo|Matching placebo to be taken orally, once daily.
76044715|NCT05451095|Drug|BI 474121|BI 474121
76044716|NCT05451095|Drug|Placebo|Placebo
76044717|NCT05451095|Drug|Ketamine hydrochloride|Ketamine hydrochloride
76044718|NCT05476133|Other|Executive functions training-elementary and Promoting executive function in in the classroom|evidence based practice that target executive function skills in early elementary years.
76044719|NCT05476055|Genetic|NGS|In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
76044720|NCT04423835|Procedure|Paley's Principle osteotomy|. The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs. An isosceles triangle template was used for osteotomy, and the medial cortex was left intact. K-wires were used to fix the osteotomy laterally.
75421565|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
75421566|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
75421567|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
75421568|NCT01441817|Procedure|Internal fixation|Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
75421569|NCT01441830|Device|Radial extracorporeal shock wave therapy|The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
75421570|NCT01441856|Procedure|Open or Laparoscopic left hemihepatectomy|Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
75421571|NCT01441856|Procedure|Open or Laparoscopic right hemihepatectomy|Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
75421572|NCT01441869|Drug|Onglyza (saxagliptin)|Oral tablets, 5 mg , single dose
75421573|NCT01441869|Drug|Diabex|Extended release oral tablets, 1000 mg, single dose
75421574|NCT01441869|Drug|5-mg saxagliptin/1000 mg metformin|Extended release fixed dose combination tablet, single dose
75421575|NCT01441869|Drug|Diabex|Extended release oral tablets, 500 mg, single dose
75567111|NCT06013618|Drug|Irinotecan|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
75567112|NCT06013618|Drug|Temozolomide|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
75567113|NCT06013618|Drug|Naxitamab in combination therapy|Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.
76044721|NCT05450705|Biological|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
75421576|NCT01441869|Drug|5-mg saxagliptin/500 mg metformin|Extended release fixed dose combination tablet, single dose
76044722|NCT02954081|Drug|Phase I: Fumaric acid esters. Phase II: Apremilast|Apremilast
75567114|NCT06013618|Drug|GM-CSF with combination regimen|GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.
75567115|NCT06013618|Drug|Sintilimab|Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.
75874997|NCT03568188|Procedure|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
75567116|NCT06012734|Drug|LB-100|IV on day 1 and day 3
75720247|NCT02256904|Procedure|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
75720248|NCT02256904|Procedure|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
75874998|NCT03568188|Biological|blood test|if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
75874999|NCT03568188|Biological|urine test|if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
76044723|NCT02517125|Device|Transoral robotic-assisted surgery with Da Vinci Xi|
75421577|NCT01441908|Drug|Pravastatin|40mg or 80mg dose 28 days for 6 month period
75421578|NCT01441921|Dietary Supplement|Pistachios|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
75567117|NCT06012734|Drug|Atezolizumab|IV on day 1
75875000|NCT00442338|Drug|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
75875001|NCT00442338|Drug|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
75875002|NCT00442338|Drug|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
75875003|NCT03506412|Drug|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
75421579|NCT01441921|Other|control diet|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
75421580|NCT01441934|Drug|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
75421581|NCT01441934|Drug|Sugar pills|placebo t.i.d.
75567118|NCT06012539|Other|Qualitative (interviews)|Interviews were held with participants at three different time points, approximately six months apart. Interviews were taped and analyzed for common themes.
75567119|NCT06012461|Other|Closed-loop DBS stimulation for 24 hours|Continuous closed-loop modulation for 24 hours
75567120|NCT06012461|Other|Open-loop DBS stimulation for 24 hours|Continuous open-loop modulation for 24 hours
75567121|NCT06012461|Other|Closed-loop DBS stimulation for 72 hours|Continuous closed-loop modulation for 72 hours
75875004|NCT03420768|Drug|BMS-986263|Administered by intravenous (IV) infusion
75875005|NCT03420768|Other|Placebo|Administered by intravenous (IV) infusion
75875006|NCT03625440|Diagnostic Test|The Digit span test and PASAT with waterpipe smoking|Cognitive tests at baseline and 30minutes after waterpipe smoking
75875007|NCT03625440|Diagnostic Test|The Digit span test and PASAT without waterpipe smoking|The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
75875008|NCT02316834|Other|Laboratory Biomarker Analysis|Correlative studies
76044724|NCT02532283|Drug|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
75567122|NCT06012461|Other|Open-loop DBS stimulation for 72 hours|Continuous open-loop modulation for 72 hours
76044725|NCT02532283|Drug|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
76044726|NCT02532283|Drug|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
76044727|NCT01807897|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
75875009|NCT02316834|Drug|BMN 673|"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."
75875010|NCT02879136|Drug|Methylphenidate|Patient will be randomized to Methylphenidate
75875011|NCT02879136|Other|Physical Therapy|All Patients will have standard of care PT used for PD patients
75875012|NCT02879136|Drug|Atomoxetine|Patient will be randomized to Atomoxetine
75875013|NCT00250458|Drug|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
75421582|NCT01441986|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
75421583|NCT01441986|Drug|Amantadine|Amantadine hydrochloride 100 mg; tablets; single, oral dose.
75421584|NCT01441986|Drug|Pacebo 1 (placebo for Amantadine)|Talets for oral use; single dose.
75421585|NCT01441986|Drug|Placebo 2 (fo Dextromethorphan)|Capsles for oral administration; single dose.
75421586|NCT01441999|Device|Less rigid rod|Titanium rod with semi rigid end
75421587|NCT01441999|Device|Rigid Rod|Rigid Titanium rods
75421588|NCT01442012|Other|Ear seeds|The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
76044728|NCT01807897|Device|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
76044729|NCT01807897|Behavioral|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
75421589|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
75567123|NCT06011551|Device|The ReGelTec HYDRAFIL™ System|The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.
75875014|NCT00250458|Drug|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
75720249|NCT02190500|Other|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
75720250|NCT02174055|Behavioral|Patient Interviews|participate in a brief interview
75720251|NCT02174055|Behavioral|newly developed questionnaire|10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
75720252|NCT02174055|Behavioral|Pilot Testing the Draft Measure|The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
75720253|NCT02091583|Dietary Supplement|Butter, sunflower and safflower oil|
75720254|NCT02091583|Dietary Supplement|High Oleic Canola Oil and DHA (HOCO-DHA)|
75720255|NCT02091583|Dietary Supplement|Barley beta-glucan|
75421590|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
75720256|NCT02091583|Dietary Supplement|HOCO-DHA and Barley beta-glucan|
75720257|NCT02032953|Dietary Supplement|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
75720258|NCT02032953|Drug|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg*min. Ten minuts after starting the insulin, and when the the blood glucose is<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
75875015|NCT01965132|Drug|Biologic or targeted synthetic DMARD|
75421591|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
75567124|NCT06011551|Other|Conservative Care Management|Conservative care management (including physical therapy and/or pain medication)
75567125|NCT06011369|Procedure|Fluorescence in thyroid surgery|Fluorescence in thyroid surgery
75720259|NCT02029833|Other|Regular Canola Oil|
75720260|NCT02029833|Other|High Oleic Canola Oil|
75720261|NCT02029833|Other|Western Type Diet - Common Dietary Oils|
75720262|NCT01850355|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
75875016|NCT01667133|Drug|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
75875017|NCT01667133|Drug|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
75720263|NCT01582776|Drug|Lenalidomide and GA101|1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
75567126|NCT06011278|Other|Community Supported Videos|"Volunteers will be asked to create a maximum of three minutes of content that will psychosocially strengthen and motivate pediatric oncology patients. In the videos, information will be given about not using words such as cancer/oncology/tumor and not including private and personal information. Videos will be created in such a way that they can be edited, merged or deleted accordingly. The applications of volunteer individuals will be made through social media (Instagram), the collection of these videos will be followed in accordance with the voluntary consent forms, and the volunteers will be informed in detail about the use of visual and verbal data.~Children will be sent videos featuring different volunteers each week. The content of the videos will be controlled by the child clinical psychologist and researchers. Inappropriate videos will not be included in the research."
75567127|NCT06010797|Device|Showing Pre-treatment photographs of the patient|Extra-oral and intra-oral dental photographs of patients were taken before starting Orthodontic treatment. Experimental group were shown their photographs while control group were not shown their photographs.
75720264|NCT01464164|Drug|Sotatercept|"Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks"
76044730|NCT05446831|Drug|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily. The decision to initiate rescue therapy was made after assessment of the extent of bleeding, patient preferences, lifestyle and activity, the complications of specific therapies, comorbidities that predisposed patients to bleeding and the tolerance of side effects. If a platelet count over 300,000/μL was observed for two consecutive tests at least 2 weeks apart, baricitinib treatment was interrupted.
75421592|NCT01442051|Procedure|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB < 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB <7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
75567128|NCT06010576|Procedure|EUS-guided rendezvous|A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
75720265|NCT01464164|Drug|Sotatercept with prednisone boost|"Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg)."
75720266|NCT00602459|Drug|Cyclophosphamide|Given IV
75720267|NCT00602459|Drug|Fludarabine Phosphate|Given IV or PO
76044731|NCT02431351|Drug|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
75567129|NCT06010576|Procedure|Early precut papillotomy group|The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
75567130|NCT06009991|Drug|Remimazolam besylate|"Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need)."
75720268|NCT00602459|Other|Laboratory Biomarker Analysis|Correlative studies
75720269|NCT00602459|Drug|Lenalidomide|Given PO
75720270|NCT00602459|Biological|Rituximab|Given IV
75720271|NCT00591175|Behavioral|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
75421593|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
75421594|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
75421595|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
75421596|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
75421597|NCT01442116|Procedure|stress echocardiography|safety and efficacy of stress echocardiography
75421598|NCT01442142|Behavioral|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
75421599|NCT01442142|Behavioral|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
75421600|NCT01442142|Behavioral|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
75421601|NCT01442168|Drug|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
75421602|NCT01442168|Drug|atovaquone/proquanil|malanil according to label
75720272|NCT00591175|Behavioral|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
75720273|NCT00591175|Behavioral|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
75720274|NCT00199069|Drug|Asparaginase|
75720275|NCT00199069|Drug|Vincristine|
75421603|NCT01442207|Procedure|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
75421604|NCT01442207|Procedure|Standard Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~Standard management for placenta previa.~Hospital admission for vaginal bleeding/hemorrhage~Antenatal corticosteroids > 24w0d of gestation~Tocolytic therapy per physician's discretion~Magnesium sulfate for neuroprotection~Fetal Heart Rate Monitoring~Avoidance of digital examinations of the cervix~Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM > 34 wks, worsening maternal or fetal condition )~Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
75421605|NCT01442233|Procedure|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
75720276|NCT00199069|Drug|Daunorubicin, Adriamycin|
75875018|NCT03947775|Drug|9-valent HPV vaccination|Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) [38]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
75421606|NCT01442233|Procedure|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
75421607|NCT01442259|Drug|AFQ056|
75421608|NCT01442272|Drug|Hidroferol®|Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
75421609|NCT01442272|Drug|Paricalcitol: Zemplar®|Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
75421610|NCT01442272|Drug|Habitual medication|Habitual medication
75567131|NCT06009991|Drug|Propofol|"Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance"
75720277|NCT00199069|Drug|Cyclophosphamide|
75567132|NCT06009120|Other|Education|The education program emphasized the characteristics of the oral stage, positive traits that can be acquired when the baby's needs are met during this stage, negative traits that may develop in the baby when their needs are not met, and the relationship between the oral stage and breastfeeding.
75567133|NCT06008639|Device|treatment group-Device: NirsCure - Active NirsCure - Active settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
75567134|NCT06008639|Device|placebo group-Device: NirsCure - Sham NirsCure - Sham settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
75567135|NCT06008405|Drug|TQB2928 Injection + Azacitidine for injection|"TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47.~Azacitidine for injection is a nucleoside metabolism inhibitor that inhibits DeoxyriboNucleic Acid (DNA) methyltransferase, reduces DNA methylation and alters gene expression."
75875019|NCT01498770|Drug|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
75875020|NCT01498770|Drug|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
75720278|NCT00199069|Drug|Ifosfamide|
75720279|NCT00199069|Drug|Cytarabine|
75720280|NCT00199069|Drug|Mitoxantrone|
75720281|NCT00199069|Drug|Methotrexate|
75720282|NCT00199069|Drug|6-Mercaptopurine|
75720283|NCT00199069|Drug|6-Thioguanine|
75720284|NCT00199069|Drug|VM26|
76044732|NCT05464277|Other|Oxygen|Oxygen to achieve assigned SpO2 (or FiO2) targets will be administered to study subjects. The treating clinician can alter oxygenation targets at any time if deemed necessary. The oxygenation goal will be based on SpO2 rather than arterial oxygen saturation (SaO2) or arterial pressure oxygen (PaO2) from arterial blood gases. However, PaO2 can be used instead in situations where the treating clinician considers that peripheral perfusion is poor or SpO2 readings are unreliable. Assigned SpO2 targets will apply to the study subjects for a total duration of 6 hours from intubation or until death or until transfer to the operating theater (whatever comes first).
76044733|NCT01295125|Device|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
76044734|NCT01295125|Procedure|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
76044735|NCT05398705|Drug|Cepharanthine|Low-dose: Day 1~5: 20mg, Q8H X 5 days (60mg/day)+SMT
76044736|NCT05398705|Drug|Placebo|"Day 1~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc."
76044737|NCT05398705|Drug|Cepharanthine|"High-dose: Day 1~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc."
76044738|NCT02540291|Drug|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
75875021|NCT01498770|Drug|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
75875022|NCT01498770|Drug|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
75875023|NCT01498770|Drug|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
75875024|NCT01498770|Drug|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
75567136|NCT06008184|Other|24 hours sampling of 4 biological fluids (blood, ISF, sweat and saliva)|"24 hours sampling of 4 biological fluids:~blood: sampling every 20 minutes (through a venous catheter)~ISF: automated sampling every 20 minutes (microdialysis technique connected to U-Rhythm device)~Sweat : collection of 1 to 3 samples at 4 differents timepoints~Saliva : sampling every hour (except during the night)"
75875025|NCT01498770|Drug|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
75875026|NCT01498770|Drug|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
76044739|NCT05397769|Drug|Envafolimab Plus Chemoradiotherapy|Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
76044740|NCT05475977|Diagnostic Test|MSCT chest|Multi slice Computed Tomography of the chest
76044741|NCT05464043|Diagnostic Test|evaluation of second line glucose homeostasis|blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
76044742|NCT05475899|Device|Instrument assisted soft tissue mobilization|Application of IASTM on the plantar fascia with 10-15 strokes followed by stretching
76044743|NCT05416255|Diagnostic Test|Measuring synovial fluid components|Using speialized techniques to measure S.F. components
76044744|NCT02540213|Device|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
76044745|NCT05444413|Biological|ultrasound-guided platelet rich plasma nerve block|selected persons are treated by ultrasound-guided platelet rich plasma nerve block and the regular medicine
75567137|NCT06008184|Other|24 hours sampling of ISF or sweat (after validating the correlation with blood)|24 hours sampling in an ambulatory setting
75567138|NCT06006975|Radiation|Computed Tomography (CT) and Computed Tomography Angiography (CTA)|CT and CTA examinations are performed as a routine procedure to evaluate SAH severity and to diagnose cerebral vasospams and delayed cerebral ischemia.
75567139|NCT06006975|Diagnostic Test|Multimodal physiological monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) measured in middle cerebral artery and heart rate.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
75875027|NCT01498770|Drug|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
75720285|NCT00199069|Drug|Dexamethasone / Prednisolone|
75720286|NCT00199069|Procedure|CNS Irradiation|
75720287|NCT00199069|Procedure|Mediastinal Irradiation|
76044746|NCT05415865|Combination Product|Alkalinized Lidocaine|20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be installed in the bladder with a catheter.
76044747|NCT05415865|Drug|Placebo Sodium Chloride 0.9% Inj|20 ml of Sodium Chloride 9 g/L and 10 ml of Sodium Chloride 9 g/L will be pulled up and mixed in a syringe on site, and 30 ml solution in total will afterwards be installed in the bladder with a catheter.
76044748|NCT05463887|Behavioral|Individualized preventive care recommendations (decision tool)|Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making
76044749|NCT05463575|Drug|Ketohexokinase inhibition|participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
75720288|NCT00199069|Procedure|Stem Cell Transplantation|
75567140|NCT05998382|Behavioral|Online group-based parent-mediated intervention program|The program is an online group-based parent-mediated intervention program implemented in 2 sessions of 2 hours once a week for 6 weeks. In the first part of the weekly sessions, the topic of that week is explained to the parents. In the second part, videos recorded by the parents are watched and feedback is given to the parents. At the end of the session, written materials about that week's practices and homework are sent to the parents
75567141|NCT05993390|Drug|Sugammadex|Intravenous administration of sugammadex 2mg/kg.
75567142|NCT05993390|Drug|Neostigmine|Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg
75567143|NCT05990790|Drug|Desflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
75720289|NCT00199043|Drug|Allopurinol|
75720290|NCT00199043|Drug|Rasburicase|
75720291|NCT02601989|Drug|Tadalafil|
75720292|NCT02601989|Drug|Placebo|Per oral intake of placebo for six weeks
75720293|NCT01067053|Drug|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
75720294|NCT04097015|Device|Alpha-Stim M|Alpha-Stim M with and Ocular Interface and a Spinal Interface
75720295|NCT01067131|Biological|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
75720296|NCT01067131|Biological|PEV7C9|capsule intravaginal application contains excipient only
75720297|NCT01067131|Biological|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
75720298|NCT01067131|Biological|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
75720299|NCT02601287|Biological|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
75421611|NCT01442285|Behavioral|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
75421612|NCT01442298|Procedure|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
75421613|NCT01442298|Procedure|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
75421614|NCT01442311|Other|enhanced DOT (both pegylated interferon alfa-2a and ribavirin)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
75421615|NCT01442311|Other|standard DOT (PEG-DOT control arm)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
75421616|NCT01442324|Procedure|Irreversible electroporation (IRE)|Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
75421617|NCT01442415|Behavioral|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
75421618|NCT01442428|Drug|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
75421619|NCT01442428|Drug|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
75421620|NCT01442428|Drug|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
75567144|NCT05990790|Drug|Sevoflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
75567145|NCT05990790|Drug|Propofol|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
75720300|NCT01067365|Drug|Androxal|12.5 mg once daily
75875028|NCT01498770|Drug|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
75875029|NCT01498770|Drug|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
75875030|NCT01498770|Drug|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
75875031|NCT01498770|Drug|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
75421621|NCT01442428|Drug|Placebo|Atorvastatin placebo
75421622|NCT01442454|Other|chronic pancreatitis|No intervention, subjects followed through surgery
75720301|NCT01067365|Drug|Androxal|25 mg once daily
75720302|NCT00568776|Drug|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
75720303|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
75720304|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
75720305|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
75720306|NCT04021511|Other|OAR application by a nurse|As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
75875032|NCT00140946|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
75875033|NCT00140946|Drug|Comparator: placebo / Duration of Treatment: 16 weeks|
75875034|NCT00095004|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
75875035|NCT00095004|Drug|Comparator: placebo / Duration of Treatment: 1 day|
75875036|NCT00967746|Drug|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
75875037|NCT00967746|Drug|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
75421623|NCT01442480|Dietary Supplement|Fish oil|Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
75421624|NCT01442480|Dietary Supplement|Olive oil|Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
75720307|NCT01067443|Drug|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
75720308|NCT01067443|Drug|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
75720309|NCT01067443|Drug|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
75875038|NCT00967746|Drug|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
75875039|NCT00967746|Device|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
75720310|NCT01065259|Drug|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
75875040|NCT00092118|Drug|Montelukast|one 10 mg tablet, taken once daily at bed time for 6 weeks
75875041|NCT00092118|Drug|Comparator: Placebo|one placebo tablet, taken once daily at bed time for 6 weeks
75720311|NCT01065259|Drug|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
75875042|NCT00920634|Drug|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
75720312|NCT00822666|Drug|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
75875043|NCT05167578|Behavioral|Medication reconciliation|A pharmacist will go through all medicines physicians have prescribed, over-the-counter medicines (OTC) and food supplements one by one to assess the actual medicine used by the patient. If a pharmacist identifies medication discrepancies between physician's prescriptions and patient's self-reported use of medicine during the medication reconciliation, she/he will find out the patients' reasons for adjusting the medication.
75875044|NCT00092040|Drug|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
75875045|NCT00092040|Drug|Comparator: risedronate / Duration of Intervention: 12 mo|
75875046|NCT04925154|Behavioral|The only intervention will be the information brochure that will be given after the first questionnaire.|The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
75875047|NCT05582928|Device|Neurofeedback|Neurofeedback training during which participant will be asked to change the size of a bar using different strategies to vary the parameters of its current brain's states (neurofeedback training) computed on the realtime EEG signals.
75875048|NCT04914780|Behavioral|Education|Education intervention with mobile application for 4 weeks
75875049|NCT05225142|Procedure|Modified minimally invasive surgery|Surgical intervention alone
75875050|NCT05225142|Procedure|Modified minimally invasive surgery with enamel matrix derivative|Surgical intervention with local application of regenerative biomaterial
75875051|NCT05225142|Procedure|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Surgical intervention with local application of regenerative biomaterial and bone replacement graft
75875052|NCT03261947|Drug|TAK-931|TAK-931 hard gelatin capsules
75875053|NCT05654844|Radiation|LC images|Angular and Linear Measurements were compared in mandibular symphysis region using the LC images
75421625|NCT01442506|Other|biopsies|taking biopsies
75720313|NCT00816816|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
75720314|NCT00816894|Drug|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
75875054|NCT05654844|Radiation|CBCT images|Angular and Linear Measurements were compared in mandibular symphysis region using the CBCT images
75875055|NCT05224284|Other|BPA levels|BPA (Bisfenol A) in blood and ejaculate samples
75875056|NCT05224128|Drug|Imatinib 200mg|Imatinib have to be taken 200mg/day orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
75567146|NCT05990504|Device|ultrasound real-time guidance combined with Dural Puncture Epidural Labor Anagesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
75875057|NCT05224128|Drug|Placebo|Capsules (similar appearance with imatinib) without active substance have to be taken orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
75421626|NCT01442506|Other|biopsy|biopsy
75421627|NCT01442519|Biological|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
75421628|NCT01442519|Drug|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
75421629|NCT01442532|Drug|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
75567147|NCT05990504|Device|ultrasound real-time guidance combined with Epidural Labor Anagesia|Epidural is a traditional labor analgesia technique.
75567148|NCT05990244|Diagnostic Test|Magnetic Resonance Elastography|Undergo MRE and routine MRI
75720315|NCT00816894|Drug|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
75720316|NCT00922350|Other|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
75720317|NCT00922350|Other|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
75421630|NCT01442532|Drug|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
75567149|NCT05990244|Procedure|Assessment and Recording|Undergo recording of tumor stiffness during surgery and molecular pathological classification through genetic analysis
75720318|NCT00922350|Other|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
75720319|NCT00922350|Other|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
75720320|NCT00635154|Biological|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
75720321|NCT00635154|Drug|Dexamethasone acetate|"Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"
75875058|NCT04976946|Other|Comprehensive questionnaire|Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
75875059|NCT04949880|Device|Neurovascular Drug-Eluting Balloon Dilatation Catheter|The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
75875060|NCT04050852|Drug|Nusinersen Treatments|Antisense oligonucleotide, which targets the SMN2 pre-mRNA, particularly exon 7.
75875061|NCT05065242|Behavioral|Cognitive Behavioural Therapy|Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts.
75875062|NCT04051086|Biological|Physical examination and Urine and blood samples|"Only one visit for each participant : A large majority of visits will be part of patients' usual care~Medical examination : birth, weight, gender, blood pressure, medical history~Urine and blood samples"
75875063|NCT04051086|Biological|Urine and blood samples|"Only one visit for each participant~Medical history~Urine and blood samples"
75421631|NCT01442532|Drug|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
75567150|NCT05986136|Drug|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
75567151|NCT05986136|Drug|Dapagliflozin 10mg Tab|Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
75875064|NCT05223660|Drug|Low dose KT07|A single dose of 4 capsules, followed by multiple doses on Days 8-12
75421632|NCT01442532|Drug|Placebo|Form=tablet, route=oral use, for 14 days
75421633|NCT01442532|Drug|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
75720322|NCT00778895|Biological|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
75875065|NCT05223660|Drug|High dose KT07|A single dose of 6 capsules, followed by multiple doses on Days 8-12
75875066|NCT05223660|Drug|Low dose Placebo|A single dose of 4 capsules, followed by multiple doses on Days 8-12
75875067|NCT05223660|Drug|High dose Placebo|A single dose of 6 capsules, followed by multiple doses on Days 8-12
75875068|NCT03590730|Device|ICD implantation|ICD will be implanted according to current guidelines recommendations.
75875069|NCT03625206|Behavioral|Cognitive bias modification training|These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
75421634|NCT01442545|Drug|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
75421635|NCT01442558|Drug|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
75421636|NCT01442571|Device|Hyaluronic Acid Injection|
75421637|NCT01442571|Drug|Saline Injection|
75567152|NCT05983016|Device|Philips EPIQ-7, Philips Healthcare, Bothell, WA, USA|"All patients had their abdominal aortic aneurysm maximum anterior-posterior diameter estimated with two-dimensional ultrasound using a 5 MHz curved array transducer (Philips® C5-1 transducer, Philips Healthcare, Bothell, WA, USA).~After the acquisition, a three-dimensional ultrasound acquisition was performed with a 3D-matrix transducer (Philips® X6-1 transducers, Philips Healthcare, Bothell, WA, USA)."
75875070|NCT03625206|Behavioral|Control training|These exercises are matched to the task demands of the modules of cognitive bias modification training
75875071|NCT05223426|Other|Cognitive training|A cognitive training program will be individually developed for each participant based on baseline neuropsychological tests. It will include: Computerized cognitive training: this training include: the Dual-Task, the Stroop and the N-Back task. The tasks are accompanied by feedback based on the participant's responses (e.g., progress graph, feedback, etc.). In order to promote participants' learning, the level of difficulty of the tasks increased as training sessions progressed. Two sets of stimuli will be used to maximize the generalization of learning. Memory training: This training is adapted from the MEMO+ training program (Belleville et al., 2018). These sessions, also home-based, will be done through online video and are covering a variety of topics: memory (normal aging, mnemonic strategies), attention, aging, etc. Each week, participants will be asked to complete the equivalent of 6 training sessions of 15 minutes each, for a total of 1h30 per week.
75875072|NCT05223426|Other|Usual Care|Participants will be asked to continue the care and follow-up as usually planned with the attending cardiologist. Apart from weekly follow-ups with the research team member, no changes will be made to the participant's medical care.
75421638|NCT01442584|Procedure|ovarian transplantation|ovarian transplantation
75421639|NCT01442597|Behavioral|Standard Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.
75567153|NCT05982392|Drug|Tramadol|Tramadol 100mg will be given 60 minutes before start of procedure.
75567154|NCT05982392|Drug|Naproxen Sodium|Naproxen sodium 550mg will be given 60 minutes before start of procedure.
75720323|NCT00778895|Biological|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
76044750|NCT05463575|Other|Placebo|participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
75720324|NCT02550678|Biological|ASN-002|ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
75720325|NCT02550678|Drug|5-FU|5-FU is chemotherapeutic agent used to treat various cancers.
75421640|NCT01442597|Behavioral|Individual clinician-provided CBT|Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.
75421641|NCT01442597|Behavioral|CBT4CBT|Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
75421642|NCT01442610|Drug|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
75421643|NCT01442610|Drug|Placebo|Placebo 1tablet once daily for 8 weeks
75567155|NCT05982392|Drug|Placebo|Placebo will be given 60 minutes before start of procedure.
75720326|NCT00293215|Drug|111-Indium-CMD-193|111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
75720327|NCT00293215|Drug|CMD-193|CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
75720328|NCT00822744|Drug|SSR411298|"Form: capsule~Route: oral administration with food"
75720329|NCT00822744|Drug|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food"
75875073|NCT04897776|Device|Central Thalamic Stimulation|Stimulation of the bilateral thalamic CL is a promising approach in human patients to improve conscious arousal. To restore conscious arousal by stimulation of the thalamic intralaminar CL it is necessary to provide bilateral stimulation, placing one lead in each thalamus. Bilateral thalamic CL stimulation was shown previously to improve human conscious arousal and is based on existing research in patients with disorders of consciousness.
75875074|NCT04897776|Device|Hippocampal Stimulation|The hippocampus has been a target for brain stimulation for seizure reduction in epilepsy. While the efficacy of HC stimulation varies considerably among different studies, the surgical procedure and therapeutic electrical stimulation are well tolerated by patients, with few peri-operative complications being reported, and histopathologic analysis not revealing a difference between stimulated and non-stimulated hippocampal tissue (Han et al. 2014)
75875075|NCT04852848|Behavioral|Connect2Test Intervention|Brief assessment based feedback and motivational interviewing intervention
75421644|NCT01442623|Other|Vestibular Rehabilitation|"The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program."
75421645|NCT01442636|Device|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
75421646|NCT01442662|Drug|pazopanib + gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
75421647|NCT01442701|Other|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
75421648|NCT01442727|Drug|sodium selenite|200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
75421649|NCT01442727|Drug|placebo|dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
75421650|NCT01442740|Procedure|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
75720330|NCT00822744|Drug|Placebo (for SSR411298)|"Form: capsule~Route: oral administration with food"
75720331|NCT04102787|Other|cardiac educational program|"Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management."
75875076|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
75875077|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
75875078|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
75875079|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
75421651|NCT01442753|Behavioral|Family-Skills Training|Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
75720332|NCT01065337|Biological|tissue repair cells (TRC)|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
75720333|NCT01065337|Biological|bone marrow stem cells (BMC)|bone marrow stem cells
75720334|NCT00819468|Drug|Teduglutide|Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
75720335|NCT04102553|Drug|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
75720336|NCT04102553|Drug|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
75720337|NCT01067599|Other|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
75720338|NCT01067599|Other|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
75720339|NCT01067599|Other|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
75720340|NCT00822822|Behavioral|First Questionnaire|Complete questionnaire before completing health history
75720341|NCT00822822|Behavioral|Health History|Complete electronic health history
75720342|NCT00822822|Behavioral|Second Questionnaire|Complete questionnaire after completing electronic health history
75720343|NCT02601131|Biological|Platelet transfusion|
75720344|NCT00778817|Biological|IMC-A12|Given IV
75875080|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
75875081|NCT03098979|Drug|Placebo|Orally once daily for 20 weeks
75875082|NCT03625362|Dietary Supplement|Hydrogen|Hydrogen-rich water
75875083|NCT03625362|Dietary Supplement|Placebo|Tap water
75421652|NCT01442766|Drug|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
75421653|NCT01442766|Drug|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
75720345|NCT00778817|Drug|mitotane|Given orally
75720346|NCT00293059|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
75720347|NCT00293059|Drug|Placebo|Matching placebo to be taken orally daily.
75720348|NCT00756275|Drug|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
75720349|NCT00756275|Drug|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
75720350|NCT00756275|Behavioral|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
75720351|NCT02601053|Other|Dull movie|A dull movie (duration approximately 90 minutes)
75720352|NCT02601053|Other|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
75720353|NCT02601053|Other|Heart rate measurement|Heart rate measurement using a actiheart device
75720354|NCT01065493|Other|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
75875084|NCT03625596|Dietary Supplement|L-Arginine|Acute intervention (3 hours)
75875085|NCT03625596|Dietary Supplement|Nitrate / Nitrite|Acute intervention (3 hours)
75875086|NCT03625596|Dietary Supplement|Placebo|Acute intervention (3 hours)
75875087|NCT04802304|Other|Beyond Bias Treatment|The intervention has three components: 1) a summit that includes impactful stories told to and by family planning providers that highlight the consequences of provider bias, 2) a forum for continued communication between providers, and 3) a rewards program where clinics in which providers exhibit less biased client interactions or who have improved the most towards this end will be rewarded with social recognition and a ceremony.
75875088|NCT05416827|Procedure|slow-release dexamethasone implant|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
75421654|NCT01442805|Behavioral|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
75421655|NCT01442805|Behavioral|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
75421656|NCT01442818|Drug|Dilaudid PCA|PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
75421657|NCT01442818|Drug|Dilaudid IV Scheduled|Nurse administered IV Dilaudid 0.5mg every 2 hours.
75421658|NCT01442831|Drug|Human ADME|Oral single dose
75421659|NCT01442857|Radiation|MRI|High resolution MRI of the brachial plexus
75421660|NCT01442870|Drug|Metformin|Metformin
75421661|NCT01442883|Device|Simplicity Catheter|percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
75421662|NCT01442909|Drug|Docetaxel and pemetrexed|docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
75421663|NCT01442922|Other|completion of the (VAS) for level of back pain|Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
75567156|NCT05975619|Device|HyperSight imaging|Subjects are scheduled for 1 to 5 HyperSight imaging sessions, which will occur on the same days as their standard clinical visits during planning and treatment delivery. A total of 5 to 10 HyperSight CBCT images will be acquired over all imaging sessions.
75567157|NCT05973162|Other|Virtual Realty Training|"They would be receiving treatment as follow:~Virtual Reality is a technology that aims to completely immerse the user inside the computer generated world, giving the impression to the user that they have stepped inside the synthetic world. RA mobile phone , head mounted display (HMD) will be used and videos of patient's interest will be played on phone which will create a 3D world around the patient.~And while watching conventional physical therapy will be performed side by side.~Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
75567158|NCT05973162|Other|Transverse friction massage (TFM)|"They would be receiving treatment as follow:~Transverse friction massage (Soft tissue mobilization technique) on the surrounding burn region for 5-10min in intervals. Frequency: 3 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 10 mins Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
75567159|NCT05972031|Behavioral|Person-centred integrated care intervention|See arm description.
75567160|NCT05971966|Other|Virtual Reality technique|"They would be receiving treatment as follow:~Specific exercises by using virtual reality with conventional treatment. The VR game included holopoint,hot squat and portal stories that will target the hamstring, quadriceps and gluteas muscles.Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: virtual reality gaming exercises Conventional PT including patellar mobilization+ ultrasound on anterior knee in supine lying + stretching of ITB . Frequency: 10 reps with 5 sec hold for 3 times/week for 4 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
75567161|NCT05971966|Other|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of quadriceps and hamstring muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Muscle energy technique to improve range of motion.~Conventional PT including patellar mobilization + ultrasound on anterior knee in supine lying + stretching of ITB. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
75567162|NCT05971953|Other|Muscle Energy Technique|"They would be receiving treatment as follow:~The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance( 75% of his and her available strength). After the relaxation, the muscle is lengthened more aggressively beyond the barrier and held for up to 15 seconds. Frequency: 10 reps for 4 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 20 mins"
75567163|NCT05971953|Other|Conventional PT|"They would be receiving conventional treatment as follow:~including hot pack for 10 mins ischemic compression for 60 seconds .Frequency: 5 reps with 60 sec hold for 4 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
75720355|NCT01065493|Behavioral|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
75720356|NCT00758459|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
75720357|NCT00758459|Drug|Placebo|Dosing to match AZD1236
75720358|NCT03977389|Procedure|Total wrist denervation|Study of the files
75720359|NCT05460143|Other|Near-infrared Spectroscopy scan|Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
75720360|NCT05460143|Other|Magnetic Resonance Imaging scan|Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
75720361|NCT04096547|Drug|Rivaroxaban|rivaroxaban for stroke prevention of atrial fibrillation
75720362|NCT02600975|Biological|R21 with ASO1B|R21 with ASO1B
75720363|NCT00298831|Drug|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
75720364|NCT00298831|Drug|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
75720365|NCT02532595|Procedure|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
75720366|NCT02532595|Procedure|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
75720367|NCT00758069|Drug|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
75720368|NCT00758069|Drug|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
75720369|NCT00758069|Drug|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
75720370|NCT01067677|Drug|Metaclopramide|0.5 mg/kg for rescue after PONV
75720371|NCT01067677|Drug|Ondansetron|0.1 mg/kg (max 4 mg0
75720372|NCT01067677|Drug|diphenhydramine|0.25 mg/kg (max 25 mg)
75720373|NCT01067677|Drug|Saline|equal volume (5 ml)as experimental rescue medications
75720374|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day"
75720375|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day"
75720376|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day"
75720377|NCT02600741|Other|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
75720378|NCT02600741|Other|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
75875089|NCT05416671|Behavioral|guided narrative technique-writing|The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
75720379|NCT02600741|Drug|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
75720380|NCT02600741|Drug|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720381|NCT02600741|Drug|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720382|NCT02600741|Drug|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720383|NCT02600741|Drug|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720384|NCT02600741|Drug|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720385|NCT02600741|Drug|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75875090|NCT04958421|Device|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
75875091|NCT04980690|Biological|IBC0966|IBC0966 is an investigational product.
75567164|NCT05971810|Dietary Supplement|immunonutrition supplement of ORAL IMPACT™|For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.
75567165|NCT05971810|Other|oral chlorhexidine decontamination|For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.
75875092|NCT05076513|Drug|Niraparib|"In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~For patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily."
75567166|NCT05970146|Drug|Ultrasound guided Stellate ganglion block|Under visualization with ultrasound, a 22-gauge, 5-cm needle inserted perpendicular to the skin to rest anteriorly to the precervical fascia. 6 mL lidocaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL is used. After injection of a 0.5-mL test dose to exclude intravascular positioning, the remainder of the appropriate dose was administered. The patient will be encouraged to lie flat for 3 minutes after the injection and then to sit up.
75567167|NCT05970146|Drug|unilateral cervical epidural|Aseptic betadine skin preparation will be performed and sterile drapes will be applied. Local anesthetic infiltration of the skin at C7-T1 interspace will be done using 2-3 mL of lidocaine 2% with guidance of the C-arm an 18-gauge. Tuohy needle will be inserted at C7-T1 interspace and directed towards either right or left epidural recess according to the site of the operation. Identification of entering the epidural space will be confirmed by hanging drop technique. The position of the needle is the confirmed by injection of 1 mL of non-ionized diluted dye (omnipause 300) to confirm unilateral spread of the dye. After that, a test dose was administrated, consisting of 2 mL of 2% lidocaine with 1:200,000 epinephrine.
75720386|NCT02600741|Drug|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720387|NCT02600741|Drug|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720388|NCT02600741|Drug|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720389|NCT02600741|Drug|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75875093|NCT05076513|Radiation|Radiation therapy|Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.
75720390|NCT02600741|Drug|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75875094|NCT05450094|Behavioral|Screening Only|The Screening Only intervention integrates enhancements to school-based mental health (SBMH). Each school's typical SBMH service delivery system will be enhanced with biweekly meetings of voluntary school teams (comprised of administrators, school counselors, general and special education teachers, and other school-employed mental health professionals) to 1) follow standardized evidence-based intervention decision making process to identify students with mental health risk, plan and/or refer for an evidence-based intervention, monitor intervention progress, and adjust intervention plans as needed; 2) administer teacher-rated and student self-report universal screening twice annually; 3) review screening and related school records data to identify students with mental health risk; and 4) review screening, referral, and receipt data to monitor progress of entire SBMH service delivery system.
75720391|NCT02600741|Drug|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720392|NCT02600741|Drug|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75875095|NCT05450094|Behavioral|Enhanced Screening|The Enhanced Screening intervention involves the enhancements to school-based mental health (SBMH) of the Screening Only intervention with the addition of 3 empirically supported enhancements: 1) Voluntary school teams will review screening and service receipt data disaggregated by racial/ethnic subgroups to identify and problem solve inequities. 2) Unintentional bias training for voluntary school teams, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 3) Mental Health Literacy training for voluntary school teams in awareness and understanding of students' mental health well-being and need for intervention.
75875096|NCT01119183|Behavioral|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
75875097|NCT01119183|Behavioral|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
75421664|NCT01442922|Other|completion of the (OLBPQ) for assessment of function|Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
75875098|NCT05066919|Procedure|Open plantar fasciotomy|In the surgical treated group, the plantar fascia is defined percutaneously (medial and lateral margin). An incision is then made just distal to the heel pad medially over the plantar fascia. A resection is performed 1 cm in length with a width corresponding to 50% of the medial band. The skin is sutured with nylon/nonresorbable suture. Postoperatively, the operated foot is elevated for the first 24 hours. Then free mobilization in postoperative shoe (ProCare shoe) is allowed. The dressing is left untouched for 3-5 days, after which it can be changed to a patch. After 14 days the sutures are removed and the patient allowed using regular shoes.
76044751|NCT05415553|Procedure|IOBT|Surgery of inferior oblique muscle belly transposition for treatment of primary position hypertropia with inferior oblique overaction
76044752|NCT05415553|Procedure|IO-Rec|Surgery of inferior oblique muscle recession for treatment of primary position hypertropia with inferior oblique overaction
75421665|NCT01442935|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
75421666|NCT01442935|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
75421667|NCT01442935|Drug|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
75720393|NCT02600741|Drug|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720394|NCT02600741|Drug|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720395|NCT02600741|Drug|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720396|NCT02600741|Drug|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720397|NCT02600741|Drug|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720398|NCT02600741|Drug|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720399|NCT02600741|Drug|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
75720400|NCT03979573|Diagnostic Test|Multiparametric MRI|Multiparametric prostate MRI (mp-MRI)
75421668|NCT01442935|Drug|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
75421669|NCT01442935|Drug|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
75421670|NCT01442935|Drug|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
75421671|NCT01442935|Drug|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
75421672|NCT01442961|Procedure|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
75421673|NCT01442961|Procedure|vaginal : vaginal hysterectomy|Vaginal hysterectomy
75875099|NCT05066919|Other|Conservative treatment|In the conservative treatment group, patients are instructed in performing stretching exercises with plantar fascia specific stretching exercises 10 x 10 seconds, 3 times daily and high load strength training are every other day for 3 months. Each high load strength exercise consists of 3 seconds of concentric phase (lifting up with the heel) and 3 seconds of eccentric phase (lowering the heel) with 2 seconds of isometric pause (pause at maximum lifted heel). 12 repetitions max (RM) are performed, defined as the maximum (over) weight the patient can lift 12 times with full range of motion while performing the exercise correctly. 3 x 12 exercises are performed per workout. After 2 weeks, the load is while the number of repetitions is reduced to 10 RM with an increase to 4 repetitions per workout. After 4 weeks the intensity is increased to 8RM with 5 set. Patients are instructed to increase the load throughout the training period.
75875100|NCT05422482|Biological|GC1123|ICV-administered Hunterase, Idursulfase-ß
75875101|NCT05418465|Drug|Huangqi Guizhi Wuwu decoction|Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
75875102|NCT05418465|Drug|Dapagliflozin|Dapagliflozin, 10mg at a time, once a day. Oral administration.
75421674|NCT01442974|Drug|Gemcitabine plus nab-paclitaxel|Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
75421675|NCT01442987|Drug|Irbesartan/Atorvastatin A|once daily, P.O. 8week
75421676|NCT01442987|Drug|Irbesartan|once daily, P.O. 8week
75567168|NCT05969912|Other|Graston Technique (Instrumented assisted soft tissue mobilization)|"They would received Graston technique (Instrumented assisted soft tissue mobilization) as follow:~Using lubricant (Vaseline) on the skin then a stainless steel instrument to relax the fascia and muscles. Frequency: 60 reps per min for 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Graston technique (Instrument assisted soft tissue mobilization)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
75567169|NCT05969912|Other|Bowen's Technique(Soft tissue technique)|"They would received Bowen's technique (Soft tissue technique) as follow:~Bowen moves (15 - 20 times) with 2 mins gap between each set. Frequency: 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Bowen's technique (Soft tissue technique)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
75421677|NCT01442987|Drug|Atorvastatin A|once daily, P.O. 8week
75421678|NCT01442987|Drug|Placebo|once daily, P.O. 8week
75421679|NCT01442987|Drug|Irbesartan/Atorvastatin B|once daily, P.O. 8week
75421680|NCT01442987|Drug|Atorvastatin B|once daily, P.O. 8week
75421681|NCT01443013|Other|Renal Transplant|urinary sample at month 3, 6 and 12
75567170|NCT05964881|Procedure|sacrospinous hysteropexy|sacrospinous hysteropexy
75567171|NCT05961540|Other|Conventional care|"Instruct parents to follow up with the baby at the doctor's appointment.~Provide telephone follow-up visits at 1 month, 3 months, and 6 months of age to assess the baby's feeding and physical development (height and weight)."
75421682|NCT01443039|Drug|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
75421683|NCT01443052|Other|Gait analysis|walking on an electronic walkway GAITRite® at self-selected speed
75421684|NCT01443065|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
75567172|NCT05961540|Behavioral|Breastfeeding behavioural intervention for mothers of infants with CHD|"Based on the Behavioural Change Wheel theory,the intervention program is developed and implemented to promote the change in breastfeeding behavior of mothers with CHD infants,so as to improve the exclusive breastfeeding rate of this population.Specific programs include:~Evaluate signs of hunger and satiety in infants.~Family visits, face-to-face guidance on breastfeeding skills, breast milk storage and management.~Training methods for promoting breast milk secretion.~To explain common feeding difficulties manifestations and treatment methods in infants with CHD.~Establish a breastfeeding promotion alliance.~Teach mothers to weigh their babies before and after breastfeeding to determine breast milk intake.~Assess and guide the growth and development of infants with CHD."
75567173|NCT05961462|Behavioral|Exercise training|Patients randomized to the exercise group will be offered aerobic exercise plan containing 12 sessions over 4 weeks (3 times per week).
75567174|NCT05960695|Other|Stretching|"Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds. The exercises will be done online by the physiotherapist.~The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises."
75567175|NCT05960695|Other|Relaxation|Diaphragmatic breathing will be taught as a relaxation exercise. The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.
75720401|NCT03979573|Diagnostic Test|Radiomics|Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.
75720402|NCT03979573|Diagnostic Test|MR-guided Biopsy|MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.
75720403|NCT03979573|Diagnostic Test|Molecular Markers|Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
75875103|NCT03261167|Drug|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
75875104|NCT03261167|Drug|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
75875105|NCT05416359|Drug|TQB3915 tablets|TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
75421685|NCT01443065|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
75421686|NCT01443065|Drug|5-fluoro-uracil|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
75421687|NCT01443065|Drug|panitumumab|6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
75421688|NCT01443065|Drug|AMG102|10mg/kg over 60 mn every 2 weeks up to progression or toxicity
75875106|NCT05418309|Drug|Tislelizumab Nab paclitaxel|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
75875107|NCT05137548|Drug|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
75875108|NCT05137548|Drug|Tenofovir 300Mg Oral Tablet|Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth
76044753|NCT05394649|Device|Intravascular Lithotripsy|"A new device has been designed by Shockwave Medical Inc. for the treatment of calcified vascular lesions to support stent delivery: the C2 Shockwave Medical® (IVL), Inc. coronary lithotripsy system. The system is based on lithotripsy to induce microfractures in the calcified plaque before low-pressure balloon dilation. The C2 Shockwave Medical® coronary lithotripsy (IVL) system consists of an IVL Catheter with two lithotripsy emitters enclosed within an integrated balloon, an IVL Generator, and an IVL Connector Cable."
75875109|NCT04534842|Drug|SYNB1618|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
75875110|NCT04534842|Drug|SYNB1934|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
75875111|NCT04526093|Other|TruTrace™ verified Medical Cannabis products|With the introduction of TruTrace™ verification, cannabis products can be clearly identified. Key information, including cannabinoid and terpene compositions can be collated into a Master Strain Certificate.
75875112|NCT05091294|Other|Local anesthetic injection rate in spinal anesthesia|Administering intrathecal local anesthetics for all patients according to height and weight.
75875113|NCT02725853|Device|tDCS|Application of 1.5 mA tDCS for 30 minutes
75875114|NCT02725853|Device|sham tDCS|Application of sham tDCS for 30 minutes
75875115|NCT02725853|Behavioral|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
76044754|NCT05394649|Device|Rotational Atherectomy|Rotational Atherectomy is a technique of calcic coronary plaque preparation based on the debulking of superficial calcium by a high-speed burr in order to improve vessel compliance and immediate vessel lumen gain before stenting.
75875116|NCT02725853|Behavioral|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
75875117|NCT04505891|Behavioral|Education|Kidney health education will be delivered prior to discharge by trained nurse educators.
75567176|NCT05956184|Device|Intrauterine Device Insertion|All womens will be placed in a gynecological position and underwent a bimanual examination to better determine whether the uterus was in the anteverted or retroverted position. Subsequently, a speculum will be inserted, and the cervix will be disinfected with betadine. In the conventional method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and after entering the uterine cavity with a hysterometry the IUD is inserted. In the direct method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and without using hysterometry the IUD is directly inserted. The strings will be cut approximately 2-3 cm after the cervix, and the Pozzi forceps and speculum will be removed. The accuracy of the IUD placement will be confirmed using pelvic ultrasound. The process will take about five minutes.
75875118|NCT04505891|Behavioral|Education and follow-up|In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
75875119|NCT05340894|Procedure|MCKENZIE exercises|McKenzie method is popular amongst physiotherapists as a management approach for spinal pain and McKenzie exercises for LBP are beneficial treatment for increasing flexibility of spine and improving the pain with better results in pain relief
75875120|NCT05340894|Procedure|WILLIAM'S exercises|William flexion exercise is to reduce pain or soreness and provide lower trunk stability by actively developing the abdominal muscles,gluteus maximus and hamstring, passively stretching the hip flexors and lower back muscles(sacro spinalis) and to restore or improve the work balance between the postural flexor and extensor muscle groups
75875121|NCT03294941|Combination Product|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
75875122|NCT03632499|Other|rehabilitation|rehabilitation
75875123|NCT03098433|Drug|Liothyronine|Single dose
76044755|NCT02552303|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
76044756|NCT02552303|Drug|Armodafinil|Active medication
76044757|NCT02552303|Drug|Placebo|Placebo for Nuvigil (armodafinil)
76044758|NCT01660711|Drug|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
76044759|NCT01660711|Drug|Leucovorin|400 mg/m2 by IV infusion over 2 hours
76044760|NCT01660711|Drug|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
76044761|NCT01660711|Drug|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
76044762|NCT02544113|Drug|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
76044763|NCT02544113|Drug|Placebo|Normal transplant immunosuppression
75567177|NCT05952544|Drug|essential amino acids and keto-analogues supplementation|very low protein diet plus essential amino acids and keto-analogues supplementation
75567178|NCT05952544|Other|low protein diet|patients were on low protein diet only
75875124|NCT03098433|Drug|Levothyroxine|Active comparator
75875125|NCT03098433|Drug|Placebos|Placebo
75875126|NCT05044650|Dietary Supplement|KOVIR capsule combined with background treatment|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
75875127|NCT03294317|Device|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
75875128|NCT05320926|Drug|Clopidogrel monotherapy|Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
75875129|NCT05320926|Drug|Aspirin monotherapy|Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
75875130|NCT05320926|Device|zotarolimus-eluting stent (Resolute Onyx ®)|zotarolimus-eluting stent (Resolute Onyx ®)
75567179|NCT05949749|Diagnostic Test|Epitope exploration|Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.
75567180|NCT05949073|Procedure|Non-impregnated retraction cords/ less than 10 minutes|lower first molar will be prepared for full coverage restoration, plain retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
75567181|NCT05949073|Procedure|Non-impregnated retraction cords/ more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then a plain retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
75875131|NCT05415891|Behavioral|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.
75875132|NCT05415891|Device|You℞ Decision prescribing platform|The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
75720404|NCT01325545|Other|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
75567182|NCT05949073|Drug|impregnated gingival retraction cord - less than 10 minutes|lower first molar will be prepared for full coverage restoration, Aluminum chloride-impregnated retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
75567183|NCT05949073|Drug|impregnated gingival retraction cord - more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then an Aluminum chloride-impregnated retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
75720405|NCT01067755|Device|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
75720406|NCT01065649|Drug|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
75875133|NCT05418075|Other|Psychotherapy|If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
75720407|NCT01065649|Drug|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
75875134|NCT04928118|Other|Evaluate the blood flow and pressure into kidneys|"Renal artery pressure and flow measures will be obtained using dedicated equipment positioned into the renal artery under fluoroscopic guidance.~A pulmonary artery catheter will be used to measure the pressure inside participant's renal vein and to collect small blood samples to measure oxygen content."
75875135|NCT04375553|Other|Aerobic exercise|Intradialytic aerobic exercise
75875136|NCT05417997|Dietary Supplement|Kunamin®|Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)
75720408|NCT01062685|Diagnostic Test|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
75720409|NCT01065727|Other|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
75720410|NCT01065727|Other|natalizumab|monthly natalizumab during 3 years
75720411|NCT01067833|Drug|K201 Tablet|oral tablet, x28 days
75720412|NCT01067833|Drug|Placebo Tablet|oral tablet, x28 days
75720413|NCT01065805|Biological|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
75720414|NCT01067911|Dietary Supplement|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
75875137|NCT05417997|Drug|Favipiravir|Antiviral medication used to treat influenza
75875138|NCT05417997|Drug|Enoxaparin|Anticoagulant medication
75567184|NCT05944913|Device|Prevena|PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
75567185|NCT05942820|Drug|BWC0977|SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
75567186|NCT05942820|Drug|Placebo|"SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.~Other Names:~• Compounded solution minus BWC0977"
75421689|NCT01443091|Other|application of mother's own colostrum|application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
75421690|NCT01443091|Other|application of sterile water|application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
75567187|NCT05942313|Drug|Buprenorphine/ Methadone exposure|Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
75567188|NCT05934981|Procedure|Laparoscopic surgery under low pressure and warm and humidified CO2 Insufflation|low pressure pneumoperitoneum (5-7mmHg) and use warm (35°C), humidified (95% relative humidity) CO2 insufflation.
75567189|NCT05934981|Procedure|Laparoscopic surgery under low pressure and conventional Insufflation|low pressure pneumoperitoneum (5-7mmHg), and use standard room temperature with dry insufflation.
75720415|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
75720416|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
75720417|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
75720418|NCT00311623|Drug|Rapamycin 3mg|Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
75875139|NCT05417997|Drug|Lansoprazole|Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
75875140|NCT05417997|Drug|Paracetamol|Analgesic to treat minor aches and pains, and fever reducer.
75875141|NCT05417997|Drug|Ceftriaxone/ Clarithromycin|Inhibits the production of pneumolysin
75875142|NCT05417997|Drug|Methylprednisolone|Treat inflammation, severe allergies, flares of chronic illnesses
75875143|NCT04292574|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
75875144|NCT03292913|Behavioral|Positive Health Check|Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
75875145|NCT03292913|Behavioral|Standard of Care|Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
75875146|NCT04167995|Drug|Probiotic Formula lacteal forte|Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
75875147|NCT03704844|Other|non applicable|non applicable
75421691|NCT01443104|Device|Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)|Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
75421692|NCT01443104|Device|Everolimus-eluting stent with a durable polymer|Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
75421693|NCT01443117|Biological|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
75421694|NCT01443117|Biological|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
75421695|NCT01443117|Biological|Placebo Vaccine|Administered as a 0.5 mL IM dose
75421696|NCT01443143|Other|Portion-controlled diet|During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.
75421697|NCT01443143|Dietary Supplement|Usual Diet|"During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to Eat how you would normally eat if you were not in this study."
75421698|NCT01443169|Drug|Sequence 1 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421699|NCT01443169|Drug|Sequence 1 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421700|NCT01443169|Drug|Sequence 1 - Treatment C:Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421701|NCT01443169|Drug|Sequence 1 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
75421702|NCT01443169|Drug|Sequence 1 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
75421703|NCT01443169|Drug|Sequence 2 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421704|NCT01443169|Drug|Sequence 2 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
75567190|NCT05933954|Radiation|5GFR2 non ionizing EMW exposure|"A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not. The exposure time is 20 minutes.~After the exposure, the participants will wait one hour and a 7.5-mm biopsy by punch (two pieces: one 5-mm punch + half a 5-mm punch) will be performed under local anesthesia on each arm. The wound will be closed by a simple suture. A second set of samples will be taken 24h after the exposure, using the same procedure.~For each participant, 1 full biopsy per arm and per time-point will be used for single-cell-RNA-sequencing analysis. The selected method uses generic probed sequencing and does not generate patient-specific genomic information."
75567191|NCT05933044|Drug|Durvalumab|Chemoradiotherapy plus durvalumab
75421705|NCT01443169|Drug|Sequence 2 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421706|NCT01443169|Drug|Sequence 2 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75567192|NCT05930119|Drug|HMPL-453|300 mg HMPL-453
75567193|NCT05930119|Drug|Rabeprazole|20 mg of rabeprazole will be administered by mouth once daily.
75567194|NCT05929131|Other|discharge instructions with pamphlet|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
75720419|NCT00311623|Drug|Rapamycin 6mg|Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
75421707|NCT01443169|Drug|Sequence 2 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
75720420|NCT00311623|Procedure|Radical prostatectomy|Radical prostatectomy performed on Day 15
75720421|NCT01067989|Drug|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~Capecitabine Tab. 500mg, 1+2/day, continuously.~Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~Celecoxib Tab. 200mg, 1x2/day, continuously.~Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
75720422|NCT00528112|Drug|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
75720423|NCT00528112|Drug|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
75875148|NCT04005144|Drug|Binimetinib|Given PO
75421708|NCT01443169|Drug|Sequence 3 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421709|NCT01443169|Drug|Sequence 3 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421710|NCT01443169|Drug|Sequence 3 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
75421711|NCT01443169|Drug|Sequence 3 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421712|NCT01443169|Drug|Sequence 3 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
75421713|NCT01443169|Drug|Sequence 4 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
75421714|NCT01443169|Drug|Sequence 4 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421715|NCT01443169|Drug|Sequence 4 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421716|NCT01443169|Drug|Sequence 4 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
75421717|NCT01443169|Drug|Sequence 4 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
75421718|NCT01443182|Behavioral|STAIR|Skills Training in Affective and Interpersonal Regulation
75421719|NCT01443182|Behavioral|MPE|Modified prolonged exposure (MPE)
75720424|NCT00633594|Drug|Rituximab|"DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1."
75720425|NCT00633594|Drug|Bortezomib|"DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1."
75720426|NCT00633594|Drug|Lenalidomide|"DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest"
75720427|NCT03742648|Other|Physiotherapy|Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
75421720|NCT01443182|Behavioral|EMDR|Eye movement desensitization and reprocessing
75720428|NCT00817128|Procedure|PEPT|Pain Exposure Physical Therapy
75720429|NCT00817128|Procedure|CBO standard|Standard therapy as defined in CBO guideline 2006
75720430|NCT04840888|Drug|LY3484356|Administered orally.
75720431|NCT04840888|Drug|Omeprazole|Administered orally.
75720432|NCT04840888|Drug|Itraconazole|Administered orally.
75720433|NCT04840888|Drug|Carbamazepine|Administered orally.
75421721|NCT01443195|Drug|Iron preparation|"Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~Before starting iron supplementation (maximum one week before).~At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation)."
75421722|NCT01443208|Drug|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
75421723|NCT01443208|Drug|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
75421724|NCT01443208|Drug|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
75421725|NCT01443221|Drug|mitiglinide and metformin|Free combination of Mitiglinide 10mg and Metformin 500mg
75567195|NCT05929131|Other|discharge instructions with video|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
75720434|NCT04944160|Other|Medical records analysis|To review of medical records to describe diagnosis and severity of the disease.
75720435|NCT04944160|Other|Comparison of cohorts|To compare pre and post Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
75720436|NCT04707976|Device|Navina Smart|CE-marked NavinaTM Smart including Navina Smart App.
75875149|NCT04005144|Drug|Brigatinib|Given PO
75875150|NCT05418933|Other|Family workshop|Family workshops for 5 courses, with 6-7 families in one course. The workshops were 2 hours per session, one time per week, for a total of 6 weeks.
75720437|NCT04707976|Other|Standard Bowel Care|Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
75720438|NCT00755807|Drug|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
75720439|NCT00755807|Drug|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams [mg] QD for 12 weeks).
75720440|NCT03998644|Other||
75720441|NCT05372224|Drug|Cholecalciferol|4000 IU were administrated once a day for 3 months.
75421726|NCT01443221|Drug|mitiglinide and metformin|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
75421727|NCT01443234|Other|OxIGen|Internet-based intervention with 12 sessions over 4 weeks
75720442|NCT04638322|Other|HIFT Group|An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
75421728|NCT01443234|Other|OxIGen: control version|A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
75421729|NCT01443247|Drug|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
75720443|NCT04819594|Other|Elequil aromatabs ®|100% pure essential oils in a unique controlled delivery system for relaxation, comfort, and sleep. Scented tabs on a self-adhesive label will be placed on the nurses's uniform for 4 hours to provide aromatherapy for the clinical setting.
75720444|NCT00916019|Other|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
75720445|NCT00631410|Drug|sunitinib + mFOLFOX6|37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
75720446|NCT00631410|Drug|sunitinib + mFOLFOX6|50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
75720447|NCT04097951|Drug|Combinations|Montelukast and Bepotastine Combination
75421730|NCT01443260|Biological|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
75421731|NCT01443273|Other|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
75567196|NCT05929131|Other|verbal discharge instructions only|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
75567197|NCT05926427|Drug|Orelabrutinib|150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up
75567198|NCT05926427|Drug|Rituximab|375 mg/m^2 ivgtt, D0 of each 28-day cycle
75421732|NCT01443312|Genetic|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
75421733|NCT01443325|Drug|lidocaine patch|1 patch for 12 hours within each 24 hours period
75421734|NCT01443338|Drug|Triptergium Wilfordii|Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
75567199|NCT05926427|Drug|Chemotherapy|Not specified, recommended regimen according to histopathologic type
75567200|NCT05925777|Device|THEAL (Mectronic, Bergamo)|laser therapy high intensity
75567201|NCT05925270|Behavioral|mhGAP-Remote|One in-person session followed by standardized SMSs to reinforce the concepts learned in the first session. The intervention follows principles of the World Health Organization's Mental Health Gap Action Programme (mhGAP). Study interventionists can provide telephonic support to participants to implement the skills.
75567202|NCT05925270|Behavioral|mhGAP-Standard|Four in-person sessions with up to two booster sessions following the principles of World Health Organization's Mental Health Gap Action Programme (mhGAP).
75567203|NCT05924386|Procedure|patients reciveing all on 4 fixed mandibular prosthesis usimg conventionally screw retained multiunit abutments|Multiunit abutments is considered a gold standard screw retained abutments. Multi-unit abutments are used to correct for varying heights among the implants, to establish a level restorative platform for the prosthesis, as well as to situate the implant connection even with or just below the gingival surface. Also they are used to correct the angulation of implants, helping to keep the screw access holes away from the facial surfaces of the restoration, and facilitate the path of insertion of prosthesis.
75567204|NCT05924386|Procedure|all on 4 fixed mandibular prosthesis using OTbridge attachment system|"The OT bridge attachment system introduced by (Rhein 83) is a global, well-established system used in the removable prosthetic protocols, the presence of seeger acetal ring placed between the sub-equatorial area of the OT Equator and the cylindrical Extragrade abutment compensates the space between the extragrade abutment and the OT equator attachment correcting the minor misalignments that produced during the prosthetic procedure and resulting in more passive fit."
75567205|NCT05924321|Drug|Carbetocin|Single infusion of Carbetocin
75567206|NCT05924321|Drug|Placebo|Single IV infusion of matching placebo
76044764|NCT05442697|Device|PEMF treatment|Patient will receive a PEMF treatment. The involved leg will be exposed to PEMF for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of PEMF exposure in total.
75421735|NCT01443338|Drug|Acitretin|Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
75421736|NCT01443377|Biological|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
75421737|NCT01443416|Biological|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
75421738|NCT01443416|Biological|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
75567207|NCT05924321|Drug|Placebo and Moxifloxacin|Single IV infusion of matching placebo in combination with Single Oral dose of Moxifloxacin
75567208|NCT05922332|Dietary Supplement|Rich medium chain fatty acid milk powder group|In intervention group,there are 32 infants.They will be fed with rich medium chain fatty acid milk powder, formula with MCT content of 39%, total energy of 68kcal/100ml, and feeding frequency at a 3-hour interval
75567209|NCT05922332|Dietary Supplement|Regular milk powder group|In control group,there are 32 infants.They will be fed regular milk powder,formula with MCT content of less than 30%, total energy of 67kcal/100ml, and feeding frequency at a 3 hours interval
75567210|NCT05922280|Other|subtalar and talo-crural mobilization|"Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines."
75421739|NCT01443429|Drug|beraprost sodium(BPS)|
75421740|NCT01443455|Behavioral|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
75567211|NCT05922280|Other|International Working Group of the Diabetic Foot care guidelines|"Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension"
75567212|NCT05919628|Other|ResPsyPark group|Evaluation of the parkinson's disease patient's score over different psychological questionnaires and a therapeutical observance questionnaire
75567213|NCT05917275|Drug|Amlodipine|4 weeks of Amlodipine
75720448|NCT04096469|Behavioral|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
75720449|NCT04096469|Behavioral|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
76044765|NCT05442697|Device|Placebo treatment|Patient will receive a placebo treatment. The involved leg will be exposed to placebo treatment for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of placebo exposure in total.
76044766|NCT02538965|Drug|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
75567214|NCT05917275|Drug|Olmesartan|4 weeks of Olmesartan
75567215|NCT05917275|Drug|Hydrochlorothiazide|4 weeks of Hydrochlorothiazide
75567216|NCT05917275|Drug|Amlodipine/Olmesartan|4 weeks of Amlodipine/Olmesartan
75720450|NCT00822978|Drug|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
75720451|NCT02599883|Radiation|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
75720452|NCT03686176|Other|Virtual Reality|A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
76044767|NCT02543801|Drug|Liposomal Bupivacaine|Periarticular injection
76044768|NCT02543801|Drug|Ropivacaine|Periarticular injection
76044769|NCT02543801|Drug|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
75421741|NCT01443455|Behavioral|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
75421742|NCT01443455|Behavioral|delayed entry control|"Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~--------------------------------------------------------------------------------"
75421743|NCT01443481|Drug|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
75421744|NCT01443507|Other|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
75421745|NCT01443520|Drug|Placebo|The subjects will be given orally placebo twice a day for 8 days prior to the study.
75421746|NCT01443520|Drug|Duloxetine|The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
75421747|NCT01443520|Drug|Venlafaxine|The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
75421748|NCT01443533|Behavioral|LARC Script|The LARC Script is a one-minute educational script that describes long-acting reversible contraceptive methods.
75567217|NCT05914870|Other|Multi-component training|"The multicomponent training group will perform 60 minutes of training per session:~10 minutes of joint mobility exercises and dynamic stretching.~20 minutes of strength work with 2 exercises; the first, bench press, at an intensity of 50% of your 1RM. The number of repetitions will be individualised for each subject by testing the loss of speed in the series with respect to the first repetition (15% loss); the second, the squat, at an intensity of 60% of your 1RM. The number of repetitions shall be individualised for each subject by means of the loss of speed test in the series with respect to the first repetition (10% loss). The rest between sets will be 3 minutes.~20 minutes of continuous cardiovascular work. The intensity will be increased every 4 weeks, from week 1 to 4 between 55%-65%FCR or VO2peak, from week 5 to 8 between 65%-%75%FCR or VO2peak and from week 9 to 12 between 75%-%85%FCR or VO2peak.~10 minutes of cool down and static stretching."
75720453|NCT00817284|Drug|bevacizumab and Irinotecan and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15.~Irinotecan:~Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
75875151|NCT03291587|Other|Personnel Training and Coaching Calls|"Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation."
75875152|NCT03856788|Drug|Saline|40 mL sterile normal saline
75875153|NCT03856788|Drug|Bupivacaine|40 mL 0.25% bupivacaine
75875154|NCT03625284|Dietary Supplement|Placebo|Edible oil
76044770|NCT02543801|Drug|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
76044771|NCT02543801|Drug|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
76044772|NCT02543801|Drug|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
76044773|NCT02481635|Drug|Gemcitabine|
76044774|NCT02481635|Drug|Nab-paclitaxel|
76044775|NCT02481635|Radiation|Radiation Therapy|
76044776|NCT02481635|Procedure|Surgical Resection|
76044777|NCT02535065|Device|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
76044778|NCT05461313|Other|Constrained Liner|Subjects in this arm will receive a constrained liner (Freedom or G7 Freedom Constrained Acetabular Liner, Zimmer Biomet)
75567218|NCT05914870|Other|Continuous Cardiovascular Training|"The Continuous Cardiovascular Training group will perform 60 minutes of training per session distributed as follows:~Preparatory Phase: 10 minutes of standardised warm-up with joint mobility exercises and dynamic stretching.~Main Training Phase:~In this phase we will work 40 minutes of continuous aerobic exercise, maintaining the same intensity range throughout the session. We will increase the intensity every 4 weeks, from 1 to 4 you will work between 55%-65%FCR or VO2peak, from 5 to 8 between 65%-%75%FCR or VO2peak and from 9 to 12 between 75%-%85%FCR or VO2peak.~Post-training phase: 10' cool down and static stretching."
75567219|NCT05911321|Drug|Isatuximab|Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.
75720454|NCT00817284|Drug|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
75720455|NCT04096235|Other|RAM Nasal Cannula|The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
75720456|NCT00823056|Dietary Supplement|probiotics|placebo
75421749|NCT01443559|Genetic|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
75720457|NCT00823056|Dietary Supplement|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
75421750|NCT01443559|Genetic|homogenic cornea|homogenic corneas were sterilised by radiation
75421751|NCT01443572|Drug|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
75567220|NCT05911321|Drug|Pomalidomide|Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.
75567221|NCT05911321|Drug|Dexamethasone|Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
75567222|NCT05910996|Procedure|Conversion from vv-ECMO to va-ECMO|Conversion from vv-ECMO to va-ECMO
75567223|NCT05910658|Behavioral|Competence in Romance and Understanding Sexual Health (CRUSH)|Manualized curriculum targeting sexual health and behavior in intimate relationships designed to meet the specific needs of autistic adults
75567224|NCT05907668|Drug|IMVT-1401 (batoclimab)|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
75720458|NCT04096157|Drug|Isavuconazonium sulfate IV|Intravenous (IV) via nasogastric (NG) tube
75720459|NCT04096157|Drug|Isavuconazonium sulfate capsules|Oral
75720460|NCT00819624|Other|Interactive Voice Response System (IVRS)|Telephone based system
75720461|NCT00819624|Other|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
75720462|NCT00823290|Drug|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
75720463|NCT00823368|Drug|STX209|
75720464|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
75421752|NCT01443572|Drug|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
75421753|NCT01443585|Device|Progressive Addition Lens (Shamir PrimeIITM) Spectacles|A pair of progressive addition lenses manufactured according to the subject's personal prescription.
75421754|NCT01443624|Drug|critical care patients venofer|100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
75421755|NCT01443650|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
75421756|NCT01443663|Biological|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
75421757|NCT01443676|Drug|Bevacizumab|Bevacizumab will be added to radiotherapy
75720465|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
75421758|NCT01443676|Radiation|Radiation therapy|Radiation therapy
75720466|NCT00755417|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
75875155|NCT03625284|Dietary Supplement|FucoVital|Microalgae oil extract
75567225|NCT05903417|Drug|Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg|The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium chloride solution. t-PA and DNase are not mixed together in one syringe. In brief , both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.
75567226|NCT05903417|Other|Saline irrigation with 250 mls normal saline (over 1 hour)|subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
75567227|NCT05901311|Drug|LY3537982|Administered orally.
75567228|NCT05901311|Drug|[¹⁴C]-LY3537982|Administered orally.
75567229|NCT05901311|Drug|[¹⁴C]-LY3537982|Administered IV.
76044779|NCT05461313|Other|Dual Mobility|Subjects in this arm will receive a dual mobility cup (Avantage Dual Mobility Liner, Zimmer Biomet)
75421759|NCT01443689|Biological|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
75421760|NCT01443689|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
75567230|NCT05898555|Device|Skiin garment and pods|"Participants will be asked to wear a Skiin smart garment over their own clothes.~Small motion capture markers will be placed on their body and pressure-sensitive insoles placed into their shoes to measure the pressure underneath their feet during the study tasks.~Once the sensors are ready for collection, participants will be asked to complete 5 tasks associated with their daily activities: 1. Locomotion; 2. Lower limb strength - repeated sit-to-stand-to-sit transitions; 3. Lower limb strength and locomotion - Timed Up and Go; 4. Free walking during a 2min walk; 5. Standing balance, postural control."
75567231|NCT05896007|Drug|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
75875156|NCT03210961|Drug|PF-06826647 tablet|PF-06826647 tablet for oral administration
75875157|NCT03210961|Drug|PF-06826647 oral suspension|PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
75421761|NCT01443689|Drug|Conventional therapy|Participants will be given conventional therapy only.
75421762|NCT01443702|Drug|Lapis Judaicus|2 g capsule per day.
75421763|NCT01443702|Drug|Placebo|2 g capsule per day.
75421764|NCT01443715|Behavioral|Stepped Care IPT-A (SCIPT-A)|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
75421765|NCT01443715|Behavioral|Treatment as Usual|Standard treatment in the community
75421766|NCT01443741|Other|Therapeutic education|Specific program for FIT Therapy and specific program for traditional way
75567232|NCT05896007|Drug|Rituximab|375 mg/m^2 ivgtt, D0 of each 28-day cycle
75567233|NCT05896007|Drug|Methotrexate|3.5 g/m^2 ivgtt, D1 of each 28-day cycle
75567234|NCT05896007|Drug|Temozolomide|150 mg/m^2 ivgtt, D1-D5 of each 28-day cycle
75567235|NCT05893433|Device|Bedside cycling|"participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment."
75567236|NCT05893433|Other|control|the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
75567237|NCT05891132|Drug|10 ml of lidocaine 2%|10 ml of lidocaine 2% for perineal infiltration at the time of crowning
75875158|NCT03210961|Other|Placebo oral solution/suspension|placebo oral solution for the single ascending dose, first cohort only
75875159|NCT03210961|Other|Placebo tablet|Matching placebo tablet
75875160|NCT04797078|Procedure|Transperineal biopsy|Transperineal free hand MRI-US fusion prostate biopsy
75875161|NCT04797078|Procedure|Transrectal biopsy|Transrectal MRI-US fusion prostate biopsy
76044780|NCT05411159|Procedure|Opioid-Free Anesthesia (OFA)|"Opioid-free general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
75567238|NCT05891132|Drug|lidocaine prilocaine cream 15gm|Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
75567239|NCT05890924|Other|WAST questionnaire|"WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence.~(ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)"
75875162|NCT03638921|Drug|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
75421767|NCT01443754|Procedure|LIMA-LAD surgical revascularization|"Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:~use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;~minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another."
75720467|NCT03685708|Biological|HEPLISAV-B|HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
75421768|NCT01443754|Procedure|PCI|"State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.~Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites."
75421769|NCT01443780|Dietary Supplement|Selenium and ubiquinon (Q10) combined|A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo
75421770|NCT01443806|Drug|Oseltamivir|75 mg, one time
75421771|NCT01443832|Dietary Supplement|Fe57 and Fe58-FeSO4 stable isotopes|[57Fe] and [58Fe]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
75421772|NCT01443871|Other|Aromatherapy|Subject will assigned inhale aromatherapy
75421773|NCT01443871|Other|Pure water|Subject will assigned inhale Pure water
75421774|NCT01443884|Dietary Supplement|Grape powder, followed by placebo powder|For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
75567240|NCT05890638|Drug|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
75567241|NCT05890638|Drug|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
75720468|NCT00819702|Other|Model Care|The Model Care provided training to pediatric health care providers to assess parental psychosocial risk factors to child maltreatment.
75720469|NCT03684928|Device|Comfilcon A (test)|Daily wear contact lenses
75720470|NCT03684928|Device|Senofilcon C (control)|Daily wear contact lenses
75720471|NCT00817440|Other|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
75720472|NCT00817440|Other|Fasting|3 days of fasting and then the same as arm 1
75720473|NCT00777803|Drug|NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))|NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
75720474|NCT00777803|Drug|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
75720475|NCT00819858|Dietary Supplement|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
75567242|NCT05887440|Behavioral|isokinetic strength training of knee extensor and flexor muscles|"Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks.~Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)"
75567243|NCT05885867|Behavioral|Seniors with mild cognitive impairment over 65 years of age|"A total of 30 subjects will perform four tasks per person for a single task (motor task) and a double task (motor task + cognitive task), and the test order will be randomly assigned. The subject's prefrontal cortex activity will be measured using fNIRS (NIRSIT, OBELAB).~The single task will be to perform a 10-meter walk test and an 8-way walk test as exercise tasks. as not affected by acceleration and deceleration. The dual task will be carried out together with the exercise task and the cognitive task. The cognitive task will be a simple calculation problem so that it can be performed without much difficulty when walking.Subjects will perform a total of three iterations and have a break of 20 seconds before each task begins."
75567244|NCT05885503|Biological|RC-28E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
75567245|NCT05885503|Biological|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
75567246|NCT05884788|Other|free interview, and questionnaires in a second time|"After inclusion in the study, patients will be met for a free interview. The interview will be conducted using an open-ended interview method with the patients to allow free expression of their life history, using open and broad questions to avoid the influence of the interviewer as much as possible.~Each interview will be conducted by the same person to allow for better interpersonal reproducibility.~After the interview, the patients will be seen again to complete two questionnaires:~An attachment questionnaire: Relationship Scales Questionnaire~A questionnaire on symptoms: Distress thermometer"
75567247|NCT05884190|Other|Remote Medical Model (RMM)|Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive
75720476|NCT00819936|Procedure|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
75720477|NCT00819936|Procedure|backward walking|physiotherapy with use a backward walking type of physiotherapy
75421775|NCT01443884|Dietary Supplement|Placebo powder followed by grape powder|For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
75567248|NCT05884190|Other|Community Health Model (CHM)|Utilization of community health workers trained in a strength-based trauma informed dyadic evidence-based approach.
75567249|NCT05884190|Other|SoC|SoC for Postpartum Hypertension
75567250|NCT05882929|Other|Watching Cartoons|The cartoon will be watched after the child comes to the service after the operation and the postoperative period is prepared (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.).
75720478|NCT03993587|Other|Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography
75421776|NCT01443897|Dietary Supplement|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
75421777|NCT01443897|Dietary Supplement|placebo capsule|0 IU vitamin D2
75421778|NCT01443897|Other|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
75720479|NCT00527488|Drug|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
75720480|NCT00527488|Drug|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
75720481|NCT00527488|Drug|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
75720482|NCT00527488|Drug|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
75421779|NCT01443897|Other|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
75421780|NCT01443897|Other|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
75421781|NCT01443936|Biological|Ad4-H5-VTN vaccination-tonsillar route|
75421782|NCT01443936|Biological|Ad4-H5-vaccination-oral route|
75421783|NCT01443962|Other|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
75567251|NCT05882929|Other|ball spin|ball squeezing will be applied after the child comes to the service after the operation and after the postoperative period preparation is made (taking the vital signs, dressing the clothes, controlling the bleeding, telling the feeding time, etc.).
75567252|NCT05881915|Drug|Phenylephrine|phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
75567253|NCT05881915|Drug|Epinephrine|epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
75567254|NCT05880238|Behavioral|Intervention group|The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.
75720483|NCT00820014|Drug|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
75720484|NCT00825864|Drug|diclofenac drops|one drop 4 times a day for 3 months
75720485|NCT00825864|Drug|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
75720486|NCT00916799|Device|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
75567255|NCT05880238|Other|Control group|The control group will continue their education according to the preschool education curriculum.
75567256|NCT05876949|Biological|Denosumab|AVT03 (denosumab) or Xgeva (denosumab) will be given as 1 time subcutaneous injection)
75567257|NCT05869812|Drug|CaHMB (Dietary supplement, not Drug)|The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
75567258|NCT05869812|Dietary Supplement|CaLa|Comparative placebo
75567259|NCT05869019|Other|education|Premature baby care training will be provided.
75720487|NCT00825942|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
75567260|NCT05868824|Other|Blood sample|A blood sample for assessing cytokines will be performed at baseline and at follow-up visit 3 months after initiation of treatment. The blood sample will be performed as part of blood tests done for standard AD follow up.
75720488|NCT00823446|Device|Revera Wound Care|Revalesio Part Number MDW0060
75421784|NCT01443962|Other|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
75421785|NCT01443975|Procedure|x-pander|Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
75421786|NCT01443988|Device|iStent|Implantation of two iStent devices
75421787|NCT01443988|Drug|Travoprost|Travoprost drops
75421788|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
75421789|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
75720489|NCT00823446|Device|Normal Saline|Sodium Chloride for Irrigation
75720490|NCT00527332|Drug|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
75720491|NCT00527332|Drug|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
75720492|NCT00527332|Drug|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
75720493|NCT00527332|Drug|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
75720494|NCT00527332|Drug|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
75421790|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
75421791|NCT01444014|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
75421792|NCT01444053|Device|No Intervention|No Intervention
75421793|NCT01444066|Procedure|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
75421794|NCT01444118|Biological|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
75567261|NCT05862636|Behavioral|Mindfulness Training|"All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers."
75567262|NCT05860231|Device|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
75567263|NCT05860231|Device|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
75567264|NCT05858736|Drug|AI-061|A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
75567265|NCT05856708|Other|DISEASE|
75567266|NCT05856669|Device|Virtual reality gaming|This study aims to combine the motivational delivery of therapy which is an immersive virtual reality with the foundational concepts of mirror therapy. By utilizing a recalibration software, the participant will be able to achieve magnified movements on their screen as compared to the limited movement that is occurring in reality. The recalibration software takes each plane of movement of the gaming controller and magnifies the participant's range of motion in order to promote greater participation and success in the game that they are playing (Walkin VR). By using the fundamental concepts of mirror therapy in an immersive virtual reality setting, the investigators aim to mimic the results of mirror therapy while increasing motivation and adherence to the therapeutic program to increase overall upper extremity function.
75567267|NCT05851430|Device|PEF ablation|Pulsed Electric Field (PEF) Ablation per institutional standard of care
75567268|NCT05847829|Device|T-REEX algorithm|Phase locked transcranial stimulation.
75567269|NCT05843877|Biological|Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy|Islet cells are isolated from patients healthy pancreatic tissue. Following total pancreatectomy, these autologous cells are injected into the portal vein, to implant in the liver and produce insulin.
76044781|NCT05411159|Procedure|Standard general anesthesia (OA)|"Standard general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
76044782|NCT05431907|Drug|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
76044783|NCT05448911|Procedure|Intraoperative navigation combined with Catheter screw technique|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
76044784|NCT05448911|Procedure|Open reduction and internal fixation with steel plate|Open reduction and plate internal fixation is the most commonly used method to treat pelvic fracture, which can achieve anatomical reduction and rigid fixation. However, this method requires extensive dissection of the surrounding soft-tissue fracture and is invasive
75421795|NCT01444131|Drug|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
76044785|NCT02530619|Drug|Alisertib|Given PO
76044786|NCT02530619|Other|Laboratory Biomarker Analysis|Correlative studies
76044787|NCT02530619|Other|Pharmacological Study|Correlative studies
75421796|NCT01444131|Drug|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
75421797|NCT01444144|Other|Fracture union|Retrospective records review post-operatively until fracture resolved.
75421798|NCT01444157|Other|Palliative homecare nursing|The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
75567270|NCT05843877|Procedure|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)|As a standard procedure, the tumor-affected region of the pancreatic head with surrounding tissue and lymph nodes is removed during surgery. Reconstruction is performed by pancreaticojejunostomy.
76044788|NCT02530385|Other|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
75875163|NCT05417919|Other|Solution-oriented Nursing in Violence Against Women (SONVAW)|The Personal Information Form was filled in by the students themselves before the program. İSKEBE was filled before, after the program and at the follow-up 3 months later. 3 days were determined for the program for the students in the experimental group, and the program was applied for 60 minutes a day for 6 weeks, allowing the students to participate in the program on a suitable day
76044789|NCT02530385|Biological|FMT Capsules|Capsules will be generated as per FDA-approved procedures
76044790|NCT02362425|Drug|N-acetylcysteine|
75421799|NCT01444170|Dietary Supplement|dicreatinol sulfate|nutritional supplement
76044791|NCT02362425|Drug|Placebo|
75421800|NCT01444170|Drug|placebo sugar pill|
75567271|NCT05839899|Drug|Mifepristone plus one dose Misoprostol|Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
75567272|NCT05839899|Drug|Mifepristone plus two doses Misoprostol|Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
75567273|NCT05839860|Other|Salt 3 g|Placebo group taking a breakfast meal and 3g salt on tomatoes before fasting for 7 hours
75567274|NCT05839860|Other|Salt 6 g|Intervention group taking a breakfast meal and 6g salt on tomatoes plus 1 L water before fasting for 7 hours
75720495|NCT00527332|Drug|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
75720496|NCT00527332|Drug|Morphine|5 mg is given IV (intravenously) before end of surgery
75720497|NCT00820092|Drug|Xerecept 1.0|24 hour infusion
75875164|NCT04853667|Other|Interview|Semi-structured interview, lasting a maximum of one hour
75567275|NCT05839860|Other|Salt 9 g|Intervention group taking a breakfast meal and 9g salt on tomatoes plus 1 L water before fasting for 7 hours
75567276|NCT05838560|Drug|Dasatinib + quercetin|dasatinib 100mg / quercetin 1250mg The intervention will involve the participant taking both dasatinib and quercetin combined.
75567277|NCT05837754|Other|C8-C12|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
75567278|NCT05837754|Other|Placebo|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
75875165|NCT03242759|Drug|nintedanib|Drug
76044792|NCT02362269|Dietary Supplement|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
76044793|NCT02529995|Drug|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
75720498|NCT00820092|Drug|Xerecept 2.0|24 hour infusion
75720499|NCT00820092|Drug|Xerecept 3.0|24 hour infusion
75720500|NCT00823524|Biological|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
75720501|NCT05269810|Drug|SA001 Low dose|3 tablets b.i.d for 8 weeks
75720502|NCT05269810|Drug|SA001 Mid dose|3 tablets b.i.d for 8 weeks
75875166|NCT03242759|Drug|pirfenidone|Drug
75875167|NCT04050930|Other|Mastication|Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness
76044794|NCT02529995|Drug|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
75720503|NCT05269810|Drug|SA001 High dose|3 tablets b.i.d for 8 weeks
75720504|NCT05269810|Drug|Placebo|3 tablets b.i.d for 8 weeks
75421801|NCT01444183|Behavioral|Progressive muscle relaxation|"Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
75421802|NCT01444183|Behavioral|Sham exercise|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
75421803|NCT01444196|Drug|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
75421804|NCT01444235|Drug|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
75421805|NCT01444235|Drug|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
75421806|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg once daily
75567279|NCT05836883|Biological|ExoFlo|Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles
75421807|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg bid
75421808|NCT01444261|Dietary Supplement|Fer-in-Sol|Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
75421809|NCT01444261|Other|control|No dietary supplements
75421810|NCT01444274|Device|Obalon Gastric Balloon(s)|One or two balloons administered per patient
75421811|NCT01444313|Device|narafilcon A contact lens|Soft contact lenses with UV protection
75421812|NCT01444313|Device|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
75421813|NCT01444326|Other|Dairy|"During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew)."
75421814|NCT01444339|Biological|Pneumococcal Vaccine Formulation 1|0.5 mL, intramuscular (1 middle dose)
75421815|NCT01444339|Biological|Pneumococcal Vaccine Formulation 2|0.5 mL, intramuscular (2 low doses)
75421816|NCT01444339|Biological|Pneumococcal Vaccine Formulation 3|0.5 mL, intramuscular (2 middle doses)
75567280|NCT05836883|Other|Local injection of normal saline|Placebo
75567281|NCT05835882|Biological|Red Blood Cell concentrates from organ donor|"Intervention is a 3-step procedure consisting of 1) recovering blood from the donor during organ procurement; 2) processing donor blood to RBC units; 3) transfusing donor blood to recipients, if necessary during surgery.~Donor blood recovery. A: Donor evaluation. During the donor workup, the donor coordinator team gathers additional information from the donor relatives. If no contraindication to blood collection exists, the donor-recipient ABO-crossmatch is performed, and if negative the donor is considered eligible. B: Donor blood collection. It is carried out by a trained investigator, through the continuous autotransfusion system CATSmart (Fresenius Kabi) in the surgery room.~Donor blood processing, carried out using the continuous flow CATSmart device. About 4 RBC units are collected.~Donor RBC unit transfusion to recipients according to procedures usually adopted at our hospital (final hb level 8-9 g/dL)."
75421817|NCT01444339|Biological|Pneumococcal Vaccine Formulation 4|0.5 mL, intramuscular (2 middle doses)
75421818|NCT01444339|Biological|Pneumococcal Vaccine Formulation 5|0.5 mL, intramuscular (2 high doses)
75421819|NCT01444339|Biological|Placebo|0.5 mL, intramuscular
75421820|NCT01444352|Biological|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
75421821|NCT01444352|Biological|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
75421822|NCT01444352|Biological|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
75421823|NCT01444352|Biological|Placebo|0.5 mL, Intramuscular
75421824|NCT01444404|Drug|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
76044795|NCT05431517|Procedure|Analysis of ERCP records|Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.
76044796|NCT04260425|Other|Serving of oatmeal made from low avenanthramides oats and water|One serving size (40 grams dry weight) of low avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
76044797|NCT04260425|Other|Serving of oatmeal made from high avenanthramides oats and water|One serving size (40 grams dry weight) of high avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
75421825|NCT01444443|Device|Closed-loop control|Blood glucose controlled by algorithm
75421826|NCT01444443|Other|Open-loop control|Blood glucose controlled by patient
75421827|NCT01444482|Biological|Matrix M|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
75421828|NCT01444482|Biological|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
75421829|NCT01444508|Drug|"Ringer-lactate SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
75421830|NCT01444508|Drug|HES 130/04|"Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD."
75421831|NCT01444521|Drug|irinotecan and cisplatin|"irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
75421832|NCT01444534|Device|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
75421833|NCT01444534|Device|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
75720505|NCT04017156|Procedure|implant installation|All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
75720506|NCT00823602|Drug|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
75720507|NCT00823602|Drug|suprefact|GnRH agonist, standard protocol
75720508|NCT00820326|Drug|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
75720509|NCT00820326|Drug|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
75720510|NCT04602286|Other|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
75720511|NCT00752609|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
76044798|NCT05408897|Diagnostic Test|liquid biopsy|A test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy.
75720512|NCT03684304|Device|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
75720513|NCT04023539|Dietary Supplement|Cinnamomum zeylanicum|Capsules of 2 g cinnamomum zeylanicum orally
75720514|NCT04023539|Other|Placebo|Placebo capsules
75720515|NCT05255068|Behavioral|OPTIMAL|A person-centered mealtime care intervention
75720516|NCT04093583|Procedure|Exodontia|Atraumatic exodontia followed by simple suture
75720517|NCT04093583|Drug|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
75875168|NCT05180617|Behavioral|Music Therapy|Music therapy participants will interact both musically and verbally with the therapist and will be given a range of both electronic and acoustic instruments from which they can choose to play. Music therapy sessions will be based upon music improvisation, and as such participants are not required to have any previous instrument or other music experience and be invited to improvise freely using the instruments. The music therapist will accompany participants in the improvisation. This provides participants with an opportunity to connect with emotions and feelings connected to hidden psychic material. Following improvisations, the therapist and client will identify these moments of interest which can be further explored either verbally or through further improvisation. The music created within sessions will be recorded and participants can take a copy of the recordings home and it will be used in the therapeutic monitoring and analysis of sessions.
75875169|NCT05415579|Other|Traditional Chinese medicine (TCM)|TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
75875170|NCT03416010|Behavioral|COPE-P|"Session 1 ABCs (A=Antecedent or Activator event, B=Belief that follows the event, C=Consequence: how you feel and how you behave).~Session 2 self-esteem and positive self-talk, including ways to build self-esteem and the group provides examples of how to change unhealthy habits into healthy ones.~Session 3 stress/coping during pregnancy. Physical and emotional responses to stress are discussed along with healthy snacking and healthy ways to cope with typical stresses.~Session 4 planning, goal setting and the 4-step problem solving process. Session 5 dealing with emotions in healthy ways through positive thinking and effective communication.~Session 6 coping with stressful situations encountered during pregnancy while continuing to reinforce the thinking-feeling-behaving triangle."
75875171|NCT03656029|Drug|Cannabis|Participants will smoke as much of the cigarette as they wish
75875172|NCT03656029|Drug|Placebo|Participants will smoke a placebo cigarette
75875175|NCT03097029|Drug|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
75421834|NCT01444547|Drug|paclitaxel and cisplatin|"Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
75567282|NCT05835011|Drug|Decitabine/Cedazuridine|Oral FDC tablets administration
75567283|NCT05835011|Drug|Magrolimab|IV administration
75720518|NCT04093583|Device|Preparation of PRGF using Endoret technology|Preparation of PRGF using Endoret technology following manufacturer instructions
75720519|NCT00916097|Drug|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
75720520|NCT00629772|Drug|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
75875176|NCT02545517|Biological|Rabipur|Subjects in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm
75421835|NCT01444573|Device|implantable continuous monitor|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
75421836|NCT01444586|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
75421837|NCT01444612|Drug|dalteparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
75421838|NCT01444612|Drug|enoxaparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
75567284|NCT05834569|Drug|Acetaminophen and Ibuprofen|Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.
75567285|NCT05834569|Drug|Normal saline|Patients in the control group will be administered equal amounts of normal saline at the same time points.
75567286|NCT05832164|Other|Multifactorial intervention|"Adherence to a Mediterranean diet.~Progressive aerobic and anaerobic exercise program.~Review of polypharmacy~Group socialization activities"
75421839|NCT01444612|Drug|fondaparinux|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
75567287|NCT05831683|Other|Introduction of Standard Operating Procedure regarding lung protective ventilation during general anaesthesia.|The Standard Operating Procedure document will be introduced. The SOP document will cover the theoretical background, definition, and recommendations/criteria of LPV. The SOP document will reflect the most recent LPV guidelines.
75875177|NCT02545517|Procedure|Blood sampling|Blood samples were drawn from all subjects at day 1 and then at subsequent year intervals from extension study day 1 onwards.
75875178|NCT03636841|Device|medical device with CE marking (Ultravision ©)|Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
76044799|NCT05447819|Procedure|Reverse shoulder arthroplsaty|Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty
75421840|NCT01444612|Drug|unfractionated heparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
75720521|NCT00629772|Drug|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
75875179|NCT04206995|Other|Solid Phase Microextraction (SPME)|A SPME fibre is held directly above skin cancer, or healthy skin for a period of less than 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
75875180|NCT04206995|Other|Absorptive patch|An adsorptive patch, covering skin cancer and healthy skin sites will be applied for a period of maximum 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
75567288|NCT05825040|Behavioral|Online guided transdiagnostic cognitive behavioural therapy|The contents of guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. Customized guidance will be provided by coaches once a week based on participants' performance
75720522|NCT00526630|Drug|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
75720523|NCT00526630|Drug|Placebo|Participants will be given placebo instead of active MPD.
75720524|NCT00755183|Drug|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
75875181|NCT03625128|Drug|F-18|This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
76044800|NCT05447585|Device|Coronary atherectomy system of Shanghai MicroPort Rhythm|Coronary Atherectomy System utilizes a diamond-coated eccentric crown to expand the lumen diameter via centrifugal forces while rotating over an atherectomy guide wire.
76044801|NCT05447585|Device|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
76044802|NCT05447117|Procedure|Micropulse laser|532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).
76044803|NCT05429021|Drug|IMM-BCP-01|Single dose of IMM-BCP-01
75421841|NCT01444625|Other|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
75421842|NCT01444625|Other|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
75421843|NCT01444638|Device|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
75421844|NCT01444664|Procedure|Surgical Clipping of Aneurysm|Surgical clipping of intracranial aneurysm
75421845|NCT01444677|Drug|MB12066|MB12066 300mg
75421846|NCT01444677|Drug|MB12066|MB12066 400mg
75720525|NCT00755183|Drug|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
75875182|NCT03625050|Procedure|Chuna + Usual care(Celecoxib and esomeprazole)|"Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~CT and UC group will receive the same UC regimen."
76044804|NCT05429021|Drug|Placebo|Placebo matching single dose of IMM-BCP-01
76044805|NCT02319759|Drug|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
75421847|NCT01444677|Drug|MB12066|MB12066 100mg
75875183|NCT03625050|Drug|Usual care(Celecoxib and esomeprazole)|"Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp)."
75875184|NCT03257813|Drug|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
75875185|NCT03257813|Drug|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
75421848|NCT01444677|Drug|MB12066|MB12066 200mg
75720526|NCT00826254|Drug|Vitamin K|180 micrograms vitamin K daily
75720527|NCT00826254|Drug|Vitamin K|"2 capsules daily 180 micrograms vitamin K daily or placebo~1 year"
75720528|NCT00823758|Behavioral|Focus Groups|6 to 8 participants per group.
75720529|NCT00823758|Behavioral|Personal Interviews|Conducted by phone and audiotaped.
75720530|NCT00826332|Procedure|transabdominal ultrasound|transabdominal ultrasound
75720531|NCT00826332|Procedure|transvaginal ultrasound|transvaginal ultrasound
75720532|NCT00526162|Device|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
75720533|NCT02600195|Behavioral|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
75720534|NCT02550600|Procedure|iLA activve treatment|"iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P_peak - PEEP) ≤15 cm H2O and P_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow)."
75875186|NCT03210259|Drug|Humira®|Duration - 58 weeks
75875187|NCT03210259|Drug|BI 695501|Duration - 58 weeks
76044806|NCT02319759|Drug|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
76044807|NCT02319759|Drug|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
76044808|NCT02293005|Drug|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
76044809|NCT02319525|Other|Computerized patient decision-aid|The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
75421849|NCT01444677|Drug|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
75421850|NCT01444690|Drug|Dimiracetam|Capsules for oral administration twice daily
75421851|NCT01444690|Drug|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
75421852|NCT01444703|Other|licorice solution|licorice (0.5 g)
75421853|NCT01444703|Other|sugar solution|sugar (5 g).
75421854|NCT01444729|Drug|Xiapex|Xiapex administration will follow SMPC
75421855|NCT01444729|Procedure|surgery|Non-pharmacological treatment
75421856|NCT01444768|Other|Computerized Physician Order Entry|Computer ordering system allowing emergency department physicians to order medications, laboratory tests, radiology studies, and nursing interventions
76044810|NCT02319525|Other|Usual care (lupus pamphlet)|Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology [ACR]) regarding lupus and its treatments, that explained risks and benefits of various treatments
76044811|NCT02292927|Behavioral|Post-intervention arm = Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
75421857|NCT01444807|Drug|sorafenib|sorafenib 400 mg bid
75421858|NCT01444820|Radiation|hypofractionation|Centres using IMRT will use the dose painting technique to treat the prostate + proximal 1-cm SV to 6800 cGy in 25 fractions while the pelvic lymph nodes will receive 4500 cGy in 25 fractions. For patients with T3b, the whole SV is to be treated to 6800 cGy. Institutions using 3D-CRT will deliver the required dose to the pelvic volume (including pelvic lymph nodes and boost volume) - 4500 cGy - and a concomitant boost to the prostate and proximal 1-cm (or the whole SV if involved) SV to 6800 cGy.
75421859|NCT01444820|Radiation|conventional|"The first phase: whole pelvis including the prostate and regional lymph nodes treated with 4400 cGy in 22 fractions.~The second phase: prostate + proximal 1-cm SV treated with 3200 cGy in 16 fractions.~For patients with T3b, the whole SV is to be treated to 7600 cGy."
75421860|NCT01444833|Drug|Candesartan|32 mg per day duration 6 months
75421861|NCT01444846|Drug|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
75421862|NCT01444846|Drug|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
75421863|NCT01444846|Drug|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
75875188|NCT04773678|Drug|CBP-201|CBP-201 subcutaneous (SC) injection.
75875189|NCT04773678|Drug|Placebo|Placebo subcutaneous (SC) injection.
76044812|NCT02292849|Behavioral|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
76044813|NCT02292849|Other|Standard Mental Health Referral|Standard mental health referral to a community agency
76044814|NCT02318667|Biological|Golimumab|Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
76044815|NCT02292771|Drug|Retosiban|Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
75421864|NCT01444846|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
75421865|NCT01444859|Dietary Supplement|Trenev Trio®/Healthy Trinity®|Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
75421866|NCT01444859|Dietary Supplement|Placebo|Daily placebo for 10 weeks
76044816|NCT02292771|Drug|Atosiban|Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
75421867|NCT01444872|Drug|TRV120027|IV infusion
75421868|NCT01444872|Drug|Normal Saline|IV infusion
75421869|NCT01444885|Drug|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
75421870|NCT01444976|Drug|local anesthesia|patients will receive only topical anesthesia with 1% lidocaine
75421871|NCT01444976|Behavioral|hypnosis|Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
75421872|NCT01444976|Drug|Midazolam|Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
75567289|NCT05825040|Behavioral|Online self-guided transdiagnostic cognitive behavioural therapy|The contents of self-guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. No customized guidance will be provided to participants in the self-guided group.
75875190|NCT03257657|Behavioral|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
75875191|NCT03257657|Behavioral|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
75875192|NCT04319757|Drug|ACE1702|ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously
75875193|NCT04319757|Drug|Cyclophosphamide|Lympho-conditioning agent
75875194|NCT04319757|Drug|Fludarabine|Lympho-conditioning agent
75875195|NCT04576806|Other|Body temperature|Warming of administered fluid bolus
75875196|NCT04576806|Drug|Fluid bolus|Administration of fluid bolus of crystalloid of 500ml over 15 minutes
75421873|NCT01444989|Other|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
76044817|NCT02292771|Drug|Placebo matching retosiban|A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
75421874|NCT01444989|Other|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
75421875|NCT01445002|Biological|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
75421876|NCT01445002|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
75421877|NCT01445002|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
75421878|NCT01445002|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
75421879|NCT01445015|Behavioral|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
76044818|NCT02292771|Drug|Placebo matching atosiban|A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
76044819|NCT04880187|Drug|AXA1125|AXA1125 administered BID with or without food
76044820|NCT04880187|Drug|Placebo|Matching Placebo administered BID with or without food
76044821|NCT02291913|Drug|Everolimus|
75421880|NCT01445015|Other|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
75875197|NCT04576806|Other|Room temperature|Cooling of administered fluid bolus
76044822|NCT02291913|Drug|Exemestane|Anti-estrogen therapy
75421881|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.
75875198|NCT05180461|Drug|emodepside|emodepside tablet
75875199|NCT05180461|Drug|matching placebo of emodepside|emodepside matching placebo tablet
75875200|NCT05180461|Drug|ivermectin|ivermectin tablet (overencapsulated for blinding)
75875201|NCT05180461|Drug|matching placebo of ivermectin|matching placebo of overencapsulated ivermectin tablet
76044823|NCT02291913|Drug|Tamoxifen|Anti-estrogen therapy
76044824|NCT02291913|Drug|Fulvestrant|Anti-estrogen therapy
76044825|NCT02291913|Drug|Anastrozole|Anti-estrogen therapy
76044826|NCT02291913|Drug|Letrozole|Anti-estrogen therapy
76044827|NCT02291913|Drug|Toremifine|Anti-estrogen therapy
76044828|NCT02291679|Drug|Linaclotide|
75421882|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
75421883|NCT01445054|Drug|111Indium CHX-A|111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
75421884|NCT01445106|Drug|Nelfinavir|
75421885|NCT01445106|Drug|Nelfinavir Mesylate|
75421886|NCT01445119|Drug|Enzastaurin (LY317615)|
75421887|NCT01445119|Drug|Carboplatin|
75421888|NCT01445132|Drug|Allogeneic Cell Therapy w/ Tumor-derived Lypho|
75421889|NCT01445197|Biological|Biostate|200 IU/kg administered daily
75875202|NCT05229861|Behavioral|HIIT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.
76044829|NCT02291679|Drug|Matching Placebo|
76044830|NCT02291601|Drug|Chlorhexidine Gluconate|comparison with other CHG products
76044831|NCT02291601|Other|Vehicle|Excipients of CHG product only.
76044832|NCT02291601|Drug|DynaHex-2|2% CHG solution
76044833|NCT02360475|Biological|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
76044834|NCT02360475|Biological|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
76044835|NCT02360475|Biological|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
76044836|NCT02360475|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
76044837|NCT02360397|Drug|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
76044838|NCT02317809|Drug|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
76044839|NCT02317809|Drug|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
75567290|NCT05825040|Behavioral|Online self-guided mindfulness-based intervention|The contents of online self-guided mindfulness-based intervention are developed by clinical psychologists and psychological well-being officers. The intervention consists of 6 modules. Contents include mindfulness and auto-pilot, react and respond, aversion, craving, equanimity, and 'suffering', thoughts and letting go, starting with loving kindness, and mindfulness in life.
75720535|NCT02550600|Procedure|Control group|"The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group."
75720536|NCT03875482|Drug|Risankizumab|Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously
75875203|NCT05229861|Behavioral|MCT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
75875204|NCT05180305|Diagnostic Test|Mitomic Prostate Test|Mitomic Prostate Test
75875205|NCT05415345|Biological|Cecolin|Bivalent HPV Vaccine
75875206|NCT05415345|Biological|Hecolin|Hepatitis E vaccine
75875207|NCT05205889|Behavioral|Mobile intervention on values and goals in patients with chronic pain.|The protocol consists of 10 daily sessions, 10-20 Minutes each. After each session participants will complete daily measures. Participants will learn about values and a values based life. Further they will identify their own values and are encouraged to set a goal to pursue those values. Based on this, barriers to achieving goals are explained and a corresponding commitment will be made.
75875208|NCT03704454|Dietary Supplement|50 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
75875209|NCT03704454|Dietary Supplement|100 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
75875210|NCT03704454|Dietary Supplement|Placebo and then 50 mg PYC|4 weeks on placebo, then 4 weeks on PYC
75875211|NCT03704454|Dietary Supplement|Placebo and then 100 mg PYC|4 weeks on placebo, then 4 weeks of PYC
75875212|NCT05417529|Other|music therapy intervention|"Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation"
75421890|NCT01445210|Procedure|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
75567291|NCT05820347|Device|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|Estimation of inspiratory muscle pressure by an artificial intelligence algorithm integrated in the mechanical ventilator (FlexiMag, Magnamed, Brazil).
75567292|NCT05819710|Drug|TS-142|Single dose of 5 mg of TS-142
75875213|NCT05417529|Drug|Standard Preparation|Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
75875214|NCT02496611|Drug|Weight loss with pharmacotherapy|Participants randomized to the drug intervention group will receive Exenatide extended-release.
75875215|NCT02496611|Drug|Weight loss without pharmacotherapy|Participants randomized to the placebo group will receive a placebo.
75875216|NCT03105570|Procedure|Areola Sparing Mastectomy|A small circular incision would be made to separate nipple from breast and an additional incision directly extended from nipple or located at other part of breast such as infra-mammary fold and subaxillary area would be made to remove the total mammary parenchyma. Routine implant based or flap base reconstruction would be performed subsequentially. Nipple reconstruction is optional.
75875217|NCT04767048|Procedure|bilateral mucosectomy + tonsillectomy|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
75875218|NCT04767048|Procedure|tonsillectomy|tonsillectomy (unilateral or bilateral at the choice of the investigator)
75875219|NCT03237481|Drug|HTX-011|HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
75875220|NCT03237481|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg by injection
76044840|NCT02359851|Biological|Pembrolizumab|Given IV
75875221|NCT03237481|Drug|Saline placebo|Saline placebo by instillation
76044841|NCT02359851|Other|Laboratory Biomarker Analysis|Correlative studies
75421891|NCT01445210|Procedure|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
75567293|NCT05819710|Drug|TS-142|Single-dose of 10 mg of TS-142
75567294|NCT05819710|Drug|Zopiclone|Single-dose of 7.5 mg of zopiclone
75421892|NCT01445223|Drug|Lopinavir ritonavir|400mg BD 100mg BD
75421893|NCT01445223|Drug|Atazanavir ritonavir|300mg QD 100mg QD
75421894|NCT01445223|Drug|Efavirenz|600mg QD
75421895|NCT01445236|Other|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
75421896|NCT01445249|Procedure|Landmark guided ankle block.|25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
75567295|NCT05819710|Drug|Placebo|Single-dose of placebo
75567296|NCT05816551|Other|Controlled hyperthermia|Individuals will be exposed to a control trial (no hyperthermia) and a controlled hyperthermia trial.
75567297|NCT05815875|Combination Product|STEADI Program|The investigators will conduct STEADI Algorithm for Falls Prevention educational sessions for healthcare providers in the neurosurgery unit, including doctors, nurses, physical therapists, and pharmacists. All healthcare providers in the neurosurgery unit will be invited to attend the educational sessions. Their participation will be voluntary and no obligations will be made, though. Healthcare providers will be invited to attend one 2-hour educational session. In each session, The investigators will have between 8-10 healthcare providers. The educational sessions will be delivered in the classroom available in the neurosurgery unit to facilitate the healthcare providers' access. PowerPoint presentations, videos, quizzes, case studies, and in-class discussions will be used to deliver learning content during the educational sessions. Healthcare providers will then be asked to apply the STEADI interventions on a group of patients.
75720537|NCT03875482|Drug|Placebo solution for risankizumab|Placebo solution in prefilled syringes, self-administered subcutaneously
75720538|NCT04095767|Device|Neurothrombectomy|Intra-arterial recanalization therapy or mechanical thrombectomy (MT) is a therapeutic option for patients who are not candidates for t-PA or in whom t-PA has failed. MT is performed by means of various devices (Merci Revive, Penumbra, etc.). There are currently two major approaches to MT: the so-called stent retrievers (used with or without a balloon catheter), and catheters used for direct aspiration (manual with syringe or by aspiration pump via distal access catheters [DACs]). Moreover, both techniques can be combined. MT may be performed following IV t-PA, as a stand alone therapy, or in conjunction with IA thrombolysis.
75720539|NCT00820404|Drug|BLI-489|
75720540|NCT00820404|Drug|Placebo|
75875222|NCT03237481|Device|Luer-lock applicator|Applicator for instillation
75875223|NCT03237481|Device|Vial access device|Device for withdrawal of drug product
75567298|NCT05815875|Other|Routine care|The control group participants will receive routine care. Routine care involves only assessing for falls using Morse Falls Scale (MFS). MFS assesses a patient's fall risk upon admission, following a change in status, and at discharge or transfer to a new setting.
75720541|NCT00820482|Drug|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
75720542|NCT00820482|Drug|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
75421897|NCT01445249|Procedure|PNS guided block.|This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
75720543|NCT00754793|Drug|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
75720544|NCT00754793|Drug|placebo|inactive comparator; titrated as per protocol over 12 weeks
75720545|NCT00826410|Device|Redon drain|subcutaneous suction drain after laparotomy for two days
75720546|NCT00826488|Device|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
75720547|NCT04102397|Procedure|Vojta therapy after standard therapy|Vojta Therapy ~20 minutes/session: Application of the Reflex Creeping complex, activating several stimulus points on the facial and the nuchal sides (Figure 3a), and then the activation of the Reflex Rolling complex in both the supine position and with the patient lying on his or her side, alternating between nuchal and facial stimulation and guiding from the head.
75421898|NCT01445262|Drug|Levocetirizine|
75720548|NCT04102397|Procedure|Standard therapy|"~50 minutes/session:~TENS Current (20 minutes, phase duration=0.10 microseconds, frequency=50 Hz). The intensity applied depended on the patient's tolerance for the treatment (Figure 2a).~Pulsating ultrasound (5 minutes around the shoulder, frequency=1MHz, intensity=1 W/cm2) (Figure 2b).~Kinesiotherapy. In stages: at first assisted (with isometric exercises), then free, and finally, with resistance, usually with elastic bands (Figure 2c).~Cryotherapy (5 minutes)."
75875224|NCT03704220|Drug|Warfarin|Removal of anticoagulation with warfarin
75875225|NCT03222349|Drug|Diazepam Buccal Film|Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
75875226|NCT02927925|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
75875227|NCT03208933|Drug|Pirfenidone|Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
75875228|NCT05168917|Diagnostic Test|LIAISON Calprotectin|Immunoassay for fecal calprotectin measurement
75421899|NCT01445275|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
75421900|NCT01445275|Other|Medical Chart Review|Ancillary study
75421901|NCT01445275|Other|Study of Socioeconomic and Demographic Variables|Ancillary studies
75421902|NCT01445340|Drug|Romidepsin (FR901228)|
75875229|NCT05163951|Procedure|Trabeculectomy|trabeculectomy
75875230|NCT05163951|Procedure|SPI+GSL+GT|Peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT)
75875231|NCT03207763|Device|Microneedle Formulation 1|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
75421903|NCT01445379|Drug|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
75421904|NCT01445392|Biological|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 &amp; 5 of a 21 day cycle for 2 cycles
75421905|NCT01445392|Drug|Pemetrexed|500 mg/m^2 on day 1 of each 21 day cycle until disease progression
75567299|NCT05811403|Other|Epigallocatechin gallate (EGCG)|Epigallocatechin gallate (EGCG) is a white powder that can be obtained from tea leaves. It accounts for 50-60 % of catechin content of tea polyphenols with a wide range of biological activities including antioxidant, antimicrobial, anti-inflammatory, immune regulatory, anti-tumour effects.
75567300|NCT05811403|Other|Sodium hypochlorite (NaOCl)|Sodium hypochlorite (NaOCl) is an excellent non-specific proteolytic and antimicrobial agent that provides disinfection of the dentin-pulp interface.
75567301|NCT05811403|Other|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate (MTA) is the material of choice for pulp capping in vital pulp therapy.
75720549|NCT00826566|Dietary Supplement|Caffeine|2 times 250 mg caffeine per day
75421906|NCT01445392|Drug|Cisplatin|75 mg/m^2 on day 1 of each 21 day cycle until disease progression
75720550|NCT00826566|Dietary Supplement|placebo|2 times 250 mg per day
75421907|NCT01445392|Biological|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
75421908|NCT01445405|Drug|Bortezomib (Velcade, PS-341)|
75421909|NCT01445405|Drug|Cetuximab|
75421910|NCT01445405|Drug|Cisplatin|
75421911|NCT01445405|Procedure|Radiation Therapy|
75421912|NCT01445418|Drug|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
75421913|NCT01445431|Other|Virgin Coconut Oil|Virgin coconut oil applied to the test site twice daily for four weeks
75421914|NCT01445431|Other|Mineral Oil|Mineral oil applied to the test site twice daily for four weeks
75421915|NCT01445444|Behavioral|Habit Reversal Training|"8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).~The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.~components:~Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.~Session 2. implement habit reversal, including awareness training, competing response training, and social support.~Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy."
75567302|NCT05811403|Other|Premixed bioceramic putty|Bioceramic putty is a premixed, ready-to-use calcium silicate-based material which can be used as a pulp capping material.
75567303|NCT05805735|Other|Face care product (Eye cream)|The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
75567304|NCT05804318|Device|Daily adaptive SBRT with urethral sparing|The radiation plan for each daily fraction is adapted from the initial plan based on cone beam CT imaging acquired while the participant is laying on the treatment machine.
75720551|NCT03999190|Drug|NPA radiotracer|"[11C]NPA radiotracer, 2 injection per subject~Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
75875232|NCT03207763|Device|Microneedle Formulation 2|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
75875233|NCT02423772|Behavioral|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
75875234|NCT03220711|Device|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
75875235|NCT03220711|Drug|Fluorescein|Fluorescent dye used for imaging contrast only.
75567305|NCT05799287|Biological|Telitacicept|Telitacicept 240 mg SC
75567306|NCT05799287|Drug|Placebo|Placebo to Telitacicept
75720552|NCT03999190|Drug|Raclopride radiotracer|"[11C]raclopride radiotracer, 2 injections per subject~Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
75421916|NCT01445522|Drug|ABT-888|
75421917|NCT01445522|Drug|Cyclophosphamide|
75421918|NCT01445561|Drug|Interleukin-2 (100,00 IU/m(2) SQ)|100,000 International Units/m2 SQ daily for 5 days
75567307|NCT05789134|Other|self-sampling kits for STI testing in the laboratory|Participants will receive the self-sampling kits and their submitted samples would be sent to laboratory for testing
75567308|NCT05789043|Drug|camrelizumab+apatinib+TMZ|camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
75567309|NCT05789043|Drug|camrelizumab+apatinib|camrelizumab 200mg，q2w+apatinib 250mg qd
75567310|NCT05789043|Drug|camrelizumab|camrelizumab 200mg，q2w
75720553|NCT03999190|Drug|Dextroamphetamine|Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
76044842|NCT01607905|Drug|Selinexor|Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
76044843|NCT01607905|Drug|Acetaminophen|Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
75421919|NCT01445587|Drug|Part 1; Cohort 1|On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
75875236|NCT04767165|Diagnostic Test|MRI|Dynamics of Bone marrow fat fraction by mDixon-quant (%)
75875237|NCT02417688|Device|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
75421920|NCT01445587|Drug|Part 1; Cohort 2|For Cohort 2, on Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 150mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 150mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the MTD will be determined unless the PK and Pharmacodynamic data indicates another dose level should be evaluated. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
75421921|NCT01445587|Drug|Part 2; Stage 1|Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
75875238|NCT05136729|Behavioral|Self-Natural Posture Exercise training|SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
75875239|NCT04766034|Behavioral|Simulated Grocery Shopping Exercise|Participants will click a link and simulate a shopping experience by selecting a week's worth of Supplemental Nutrition Assistance Program (SNAP)-eligible groceries for their household in a web-based supermarket platform
75421922|NCT01445587|Drug|Part 2, Stage 2|Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
75421923|NCT01445600|Drug|ALTARGO(retapamulin)|Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
75421924|NCT01445639|Drug|Dexmedetomidine|Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
76044844|NCT02389543|Drug|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
76044845|NCT02389543|Drug|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
75421925|NCT01445639|Drug|Normal saline|as placebo
75720554|NCT04093817|Device|cardio pulmonary bypass machine|cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
75720555|NCT02549976|Procedure|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
75720556|NCT02549976|Procedure|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
75720557|NCT02549976|Procedure|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
75421926|NCT01445691|Drug|5-ALA (Gliolan)|20 mg/kg administered once 3-5 hours prior to surgery
75720558|NCT02549976|Procedure|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
75720559|NCT00586469|Biological|Fluviral|One dose, Intramuscular injection
75720560|NCT00820560|Drug|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
75720561|NCT05244694|Drug|Insulin|Priming dose then a constant infusion at 40 mU•m-2•min-1
75720562|NCT00820638|Device|myomo e100|use of the myomo e100 in home
75720563|NCT04023383|Drug|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
75875240|NCT03237013|Behavioral|Facial Morphing Intervention|Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
75720564|NCT04023383|Drug|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
75421927|NCT01445704|Dietary Supplement|Probiotics|"The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05."
76044846|NCT02389543|Drug|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
75421928|NCT01445704|Dietary Supplement|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
75421929|NCT01445743|Biological|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
75421930|NCT01445756|Drug|Lidocaine|During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
75567311|NCT05784051|Drug|Experimental group|medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain >10% after 2 lines of AAD treatment).
75567312|NCT05784051|Drug|Control group|patients of this group have no therapeutic or no treatment modification such as drug therapy
75567313|NCT05783791|Diagnostic Test|Newborn Screening Assay|"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~Is noninvasive~Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~Does not by design or intention introduce energy into a subject, and~Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."
75567314|NCT05781334|Other|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
75720565|NCT00626028|Drug|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
75720566|NCT00626028|Drug|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
75720567|NCT00626028|Drug|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
75720568|NCT00777257|Biological|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
75720569|NCT00777257|Biological|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
76044847|NCT02536963|Device|Pediatric Vision Scanning device|The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
76044848|NCT02536963|Other|Reference examination|Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
75720570|NCT00777257|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
76044849|NCT05441605|Other|Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections|Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
76044850|NCT00843037|Drug|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
75421931|NCT01445756|Drug|Placebo|Placebo; no topical lidocaine administered
75421932|NCT01445782|Drug|AZD2115|Multiple dose, oral inhalation (nebuliser solution)
75567315|NCT05775926|Other|Education|Nursing Care and Challenges Training for Nurses Caring for Dying Cancer Patients and Their Families was given in 4 modules and 2 days.
75567316|NCT05764720|Radiation|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
75567317|NCT05763771|Behavioral|Smart Phone App|Collection of data
75567318|NCT05763771|Other|NIcotine Patches|Place on the skin
75567319|NCT05760937|Drug|BMS-986447|Specified dose on specified days
75567320|NCT05760937|Drug|Placebo|Specified dose on specified days
75720571|NCT00820716|Other|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
75720572|NCT00826644|Drug|Belotecan|Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks
75720573|NCT00826644|Drug|Etoposide|Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks
75720574|NCT00826644|Drug|Cisplatin|Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks
75567321|NCT05758805|Device|mini-invasive esophagoscopy|mini-invasive esophagoscopy assessment of esophageal thermal injury (ETI) after an AF ablation session in an HP-SD setting, and with a tip CF sensing ablation catheter
75421933|NCT01445782|Drug|Placebo|Multiple dose, oral inhalation (nebuliser solution)
75421934|NCT01445808|Behavioral|Psychodynamic Motivation and Training Program (PMT)|The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
75421935|NCT01445808|Behavioral|Advice in Exercise Training (+Ex)|Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
75421936|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor, cardiologist
75421937|NCT01445860|Drug|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
75720575|NCT04095533|Other|Tibialis anterior muscle cross-sectional area assessment by ultrasound|"Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg."
75720576|NCT04095533|Other|Muscle strength assessment|Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
75720577|NCT04018560|Behavioral|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
75720578|NCT00916877|Radiation|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
75720579|NCT00824148|Device|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
75720580|NCT00824148|Other|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
75720581|NCT04925050|Drug|VB0004|Each study part (A,B and C) will be completed sequentially or with partial overlapping. Safety and PK data through at least day 8 from a subsequent cohort will be reviewed by the SMC prior to dosing the fed period of FE cohort. Safety data will be assessed by SMC after completing each cohorts in MAD healthy volunteers and MAD mild Hypertension patients.
75720582|NCT04925050|Other|Matching Placebo for VB0004|Matching Placebo
75720583|NCT00826722|Drug|Levetiracetam|1000 mg tablet
75720584|NCT04922944|Drug|COVID-19 vaccine|Two-dose COVID-19 vaccine
75875241|NCT03237013|Behavioral|Mindfulness Intervention|Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
75875242|NCT02415036|Device|Delcath Hepatic Delivery System|
75875243|NCT02415036|Drug|Melphalan|
75875244|NCT04752267|Procedure|Computed Tomography|Undergo PET/CT
75875245|NCT04752267|Drug|18F-FMAU|Given IV
75875246|NCT04752267|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
75875247|NCT04752267|Procedure|Positron Emission Tomography|Undergo PET/CT
75875248|NCT02117700|Dietary Supplement|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
75875249|NCT02117700|Dietary Supplement|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
75875250|NCT02117700|Other|Placebo twice/day|Placebo capsules twice/day for 16 weeks
75421938|NCT01445925|Procedure|Pulmonary vein isolation (PVI)|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
75567322|NCT05758805|Device|HP-SD AF ablation by a CF sensing catheter|AF ablation session in an HP-SD setting and with a tip CF sensing ablation catheter
75567323|NCT05758766|Dietary Supplement|Plant-based omega-3-FA|Plant-based omega 3 Fatty Acids
75567324|NCT05757973|Drug|Talquetamab|Talquetamab will be administered subcutaneously.
75567325|NCT05755308|Procedure|Autologous FMT|Autologous faecal microbiota transplantation by colonoscopy.
75567326|NCT05755308|Procedure|Placebo FMT|Placebo FMT will consist of 250 mL water. Placebo infusions will be delivered by colonoscopy.
75567327|NCT05743010|Drug|APL-1401|APL-1401 capsules orally once daily
75567328|NCT05743010|Drug|Placebo|Placebo capsules orally once daily
76044851|NCT05392543|Other|Brunnstrom movement therapy.|"Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery."
76044852|NCT05392543|Other|Mirror Therapy|"Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session."
76044853|NCT05414773|Other|measurement of axial length and keratometry by sonographers with a topographic module|measurement of axial length and keratometry by sonographers with a topographic module
75720585|NCT02549586|Drug|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
76044854|NCT05441527|Device|MI Paste, then, Biotene Dry Mouth Gel|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
76044855|NCT05441527|Device|Biotene Dry Mouth Gel, then, MI Paste|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
76044856|NCT05391919|Other|Multimodal technology (MT)|"Patients will receive a course of rehabilitation with multimodal correction using BOS-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, in moderate paresis of the upper limb, the neurointerface Exokist-3 with EEG registration will be used. The program for IS patients includes 15 sessions with the MT: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
75720586|NCT00820794|Drug|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
75720587|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
75720588|NCT00820794|Drug|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
75720589|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
75720590|NCT04516876|Other|Camp-based bimanual intensive training(BIT)|The day-camp BIT model will be delivered in a group-based design. In day-camp model, each child is assigned to a trained therapist to maintain at least a 1:1 to 1:2 ratios of therapy and child. The therapist will monitor and modify the activities to fit each individual's ability and need to make sure the intervention quality is equivalence to the individualized treatment method. The chosen tasks of each intervention session have to be considering the child's preference, age-appropriated, and at the right level of difficulty. Target movements are embedded in the functional activities, whereby the environment is manipulated to vary task requirement and the difficulty is graded to match the child's capacity.
75720591|NCT04044378|Drug|Famitinib|famitinib with RP2D orally daily
76044857|NCT05391919|Other|Conventional rehabilitation (CR)|The patients will recieve Conventional rehabilitation technology (physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients includes 15 sessions with the CR: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
75720592|NCT04044378|Drug|Ifosfamide|ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion
75720593|NCT04044378|Drug|Camrelizumab|camrelizumab 200mg infusion once Q2W
75720594|NCT04512586|Procedure|Conduction System pacing and AV node ablation|See study arm description.
76044858|NCT05440435|Diagnostic Test|digital radiography (DR)|Patients with bone injury received routine and mobile DR sequential examination.
75720595|NCT04512586|Procedure|Atrial fibrillation ablation by pulmonary vein isolation|See study arm description
75720596|NCT04914052|Other|Filming facial expressions|Study participants' facial expressions will be videoed by a camera placed in front of the patient's bed during their stay in the post anesthesia care unit.
75720597|NCT00628758|Drug|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
75875251|NCT04864080|Behavioral|Computer game/task|N-back, COGED, PacMan game, Bandit task, Websurf task.
75567329|NCT05742633|Other|Active release technique|"Active Release Technique was applied to patient in prone lying, knee flexed at 90. The therapist placed his elbow tip on taut band of piriformis and direct pressure applied, patient wias then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This was repeated 5-7 times.~A total of 18 sessions was given over a period of 6 weeks (3 sessions per week)"
75567330|NCT05742633|Other|Self-myofascial release|"Patient position in prone lying Therapist was standing beside the patient at the waistline, working on the contralateral side.~Piriformis muscle was located by an imaginary line drawn between the midpoint of the lateral aspect of the sacrum and the greater trochanter. A contact was established in the gluteal area about 3 cm from the sacrum. Patent was guided to use a foam roller followed by a massage ball.~A total of 18 sessions were given over a period of 6 weeks (3 sessions per week)"
75720598|NCT00628758|Drug|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
75567331|NCT05741138|Other|Core strengthening|"Plank 1-3 sets of 10-15 reps per side at a slow tempo Side plank Draw in and lift, holding for 5 seconds with purposeful engagement of the core and leg musculature. Keep the head, shoulders, hips, knees and feet in a straight line.~Bridges - Lie supine with your knees bent and the feet flat on the floor. Lift your pelvis off the ground while supporting on your feet and shoulders. The bridge can be progressed by lifting one foot off the ground end extending the knee Leg rises - Lie on your back with your legs straight and your arms by your sides. Then lift one leg 4 inches of the ground. Your back has to stay flat on the floor. Don't allow it to arch. Alternate. The exercise can be progressed by lifting both legs at the same time."
75421939|NCT01445925|Procedure|Pulmonary vein isolation + linear lesions|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
75421940|NCT01445925|Drug|Pharmacological Substrate modification|at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
75421941|NCT01445938|Drug|SAR97276A|"Pharmaceutical form:solution for injection~Route of administration: intramuscular"
75421942|NCT01445938|Drug|arthemeter + lumefantrine (ACTs)|"Pharmaceutical form:tablet~Route of administration: oral"
75567332|NCT05741138|Other|Conventional treatment|Hot pack and TENS for 10 minutes (lumbar region and calf muscles) Ultrasound for 10 mins (lumbar region and calf muscles) Gentle passive stretching (calf muscles) Isometric exercises (lumbar region)
75567333|NCT05739201|Procedure|interscalene nerve block|Patients will receive interscalene nerve block, in which the patient will be in supine position with the head turned to the contralateral side using an ultrasound scan to identify the C5 and C6 nerve roots between the scalene muscles.15 ml of 0.25% Bupivacaine will be deposited between the C5 and C6 nerve roots, within the interscalene groove using a 22 gauge-regional block needle.
75567334|NCT05739201|Procedure|anterior suprascapular nerve block|Patients will receive anterior suprascapular nerve block, in which the patient will be in supine position with the head turned to the contralateral side, using an ultrasound the nerve will be traced as it diverges from the brachial plexus to lie under the omohyoid muscle in the supraclavicular fossa. 15 ml of 0.25% Bupivacaine will be deposited lateral to the suprascapular nerve, underneath the omohyoid muscle using a 22 gauge-regional block needle.
75720599|NCT04491604|Biological|Topical Beremagene Geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
75720600|NCT04491604|Other|Placebo|Matching masked inactive topical gel
75720601|NCT00824226|Dietary Supplement|magnesium|magnesium 350 mg tablets once a day for 3 weeks
75875252|NCT04864080|Behavioral|Health surveys online|Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
75421943|NCT01445964|Drug|Atenolol|Atenolol oral administration
76044859|NCT05440045|Drug|6MW3211|6MW3211 injection, 30mg/kg, Q2W
75720602|NCT03999112|Other|Metacognitive Reflection and Insight Therapy (MERIT)|A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
75421944|NCT01445964|Drug|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
75421945|NCT01445964|Drug|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
75421946|NCT01445990|Device|Lactate-meter: LactatePro (ARKRAY Inc)|Capillary glucose and lactate measurement. Every hours for the first 24 hours, and every 4 hours for the next 4 days.
75421947|NCT01446029|Device|Video Telemonitoring Device with Clinical Care Modules|Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
75421948|NCT01446055|Device|ResQ processed bone marrow sample|Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
75421949|NCT01446055|Device|Ficoll conventional cell processing method|Comparison of different cell processing methods
75421950|NCT01446068|Dietary Supplement|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
75421951|NCT01446081|Behavioral|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
75421952|NCT01446094|Drug|regadenoson|Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
75421953|NCT01446107|Other|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
75421954|NCT01446107|Other|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
75421955|NCT01446107|Other|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
75720603|NCT00821028|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3
75720604|NCT00821106|Procedure|Right radial|diagnostic or interventional procedures performed through right transradial approach
75875253|NCT03236779|Other|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
75875254|NCT03096483|Device|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
75875255|NCT05100277|Genetic|Oncotype DX® Assay|After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
75875256|NCT05100277|Other|Cost|Changes in treatment costs were estimated from Pérola Byington Hospital.
75875257|NCT04763538|Other|Standard of care|Patients are treated according to the standard of care for each individual disease.
76044860|NCT02531035|Drug|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
76044861|NCT02531035|Drug|Placebo|Placebo, once daily, before the first meal of the day
75421956|NCT01446107|Other|placebo control|application of water onto tooth surface every year
75421957|NCT01446120|Drug|NPH-Insulin Injection|
75421958|NCT01446120|Drug|Insulin loaded Orally Dissolved Films (insulin-ODF|
75421959|NCT01446146|Behavioral|Informed decision making|40 minute session with a clinician. Participants will learn about the available PTSD treatment options and will be given a decision aid with more information.
75421960|NCT01446146|Behavioral|Placebo session|Participant will complete clinician-administered measures in a 40-minute session.
75421961|NCT01446185|Device|Oncotype DX breast cancer test|The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.
75421962|NCT01446211|Drug|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
75567335|NCT05739201|Procedure|Peri-capsular nerve group block|Patients will receive PENG block, in which the patient will be in supine position and the patient's arm will be placed in external rotation and abducted at 45 degrees, using an ultrasound the humeral head, the tendon of the subscapularis muscle and the deltoid muscle over it will be defined, 15 ml of 0.25% Bupivacaine will be placed between the deltoid muscle and subscapularis tendon using a 22 gauge-regional block needle.
75875258|NCT05417373|Other|calculated radscore|The development cohort is case_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
75875259|NCT04543812|Drug|Ferric citrate|Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
75875260|NCT04543812|Drug|Placebo|Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
75875261|NCT02932579|Other|Pharmacogenomic Testing|Saliva collection (5mL)
75421963|NCT01446211|Drug|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|"Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
75421964|NCT01446224|Drug|Pazopanib|Patients treated with pazopanib
75421965|NCT01446224|Drug|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
75567336|NCT05735327|Drug|No intervention|As this is an observational study, no intervention will be administered.
75421966|NCT01446263|Procedure|Radial access versus femoral access for coronary angiography and intervention|Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
75421967|NCT01446276|Dietary Supplement|Resveratrol|500 mg 3 times daily for six month
75421968|NCT01446276|Other|Placebo|1 placebo tablet 3 times daily for six month
75421969|NCT01446302|Dietary Supplement|Double meal|A standardized meal is served 1 h after start of HD and 1 h after end of HD.
75567337|NCT05731063|Procedure|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts|fabrication of surgical guide to aid in chin bone harvesting and another guide to help for accurate placement and simultaneous placement in anterior maxillary defective area.
75875262|NCT02932579|Drug|Ibuprofen|400 mg
75875263|NCT02932579|Drug|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
75875264|NCT02932579|Drug|acetominophen|650 mg
75875265|NCT02932579|Drug|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
75875266|NCT03701412|Radiation|MRI|MRI brain
75421970|NCT01446315|Behavioral|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
75421971|NCT01446315|Behavioral|Asthma APGAR tools|Usual care
75421972|NCT01446328|Drug|Amisulpride|Tablets, dose range 50-1200 mg/ day
75421973|NCT01446328|Drug|Aripiprazole|Tablets, dose range 5-30 mg/ day
75421974|NCT01446328|Drug|Olanzapine|Tablets, dose range 2.5-20 mg/ day
75421975|NCT01446341|Procedure|Below knee plaster casting|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
75421976|NCT01446341|Procedure|Functional rehabilitation|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
75421977|NCT01446406|Device|MONARCA|Monitoring affective symptoms entered by the patient every day.
75421978|NCT01446406|Device|NON-MONARCA|A mobile phone for communication purposes only. No application has been installed.
75421979|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
75720605|NCT00821106|Procedure|left radial|diagnostic or interventional procedures performed through left transradial approach
75720606|NCT00826878|Drug|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
75421980|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
75720607|NCT00826956|Procedure|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
75720608|NCT00827034|Drug|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
75720609|NCT00827034|Drug|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
75720610|NCT00827034|Drug|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
75720611|NCT00754559|Drug|Tocilizumab|8mg/kg iv every 4 weeks
75421981|NCT01446458|Drug|Modified FOLFIRINOX|Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
75421982|NCT01446458|Radiation|Stereotactic Body Radiotherapy (SBRT)|Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
75421983|NCT01446484|Biological|CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
75720612|NCT02600585|Biological|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
75720613|NCT02600585|Biological|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
75720614|NCT00525148|Drug|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
75875267|NCT05417295|Procedure|Inflating air into the bronchial cuff before changing position|Inflating air into the bronchial cuff before or after changing position
75875268|NCT05417295|Procedure|Inflating air into the bronchial cuff after changing position|Inflating air into the bronchial cuff after changing position
75875269|NCT03624894|Other|impression|common polyvinylsiloxane oral impression
75875270|NCT04748757|Drug|recombinant human annexin A5|recombinant human annexin A5, manufactured as SY-005
75875271|NCT04748757|Drug|Placebo|Normal saline 50 ml
75875272|NCT03207451|Drug|Vorapaxar|Vorapaxar is the principle study drug and will be given to all subjects.
76044862|NCT05389111|Other|Internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, will be led by a professional of the training field, specialist of the trail activity and trained in the use of mental strategies
75421984|NCT01446484|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
75421985|NCT01446484|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
75421986|NCT01446484|Drug|Sirolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
75421987|NCT01446484|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
75567338|NCT05730946|Diagnostic Test|Interview- based questionnaire|Interview-based questionnaire by the use of an interview guide to explore and understand the Challenges faced in the past and the concerns for the future experienced by parents of CLP patients.
75567339|NCT05726786|Drug|Immunonutrition|"Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.~IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag"
75567340|NCT05720416|Dietary Supplement|protein supplementation|protein supplementation for 16 weeks
75875273|NCT03207451|Drug|Vorapaxar and Aspirin|Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
75567341|NCT05720416|Behavioral|muscle strength training|muscle strength training for 16 weeks
75567342|NCT05720416|Other|usual care|no intervention
75720615|NCT00754325|Drug|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
75875274|NCT03207451|Drug|Vorapaxar and Clopidogrel|Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
75875275|NCT03207451|Drug|Vorapaxar, Aspirin, and Clopidogrel|Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
76044863|NCT05389111|Other|Non internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, and will be conducted by a professional of the training field, specialist of the trail activity and coach of mountain guide
76044864|NCT05387395|Other|NO intervention|no intervention
75567343|NCT05718648|Drug|BI 1015550|BI 1015550
75720616|NCT00754325|Drug|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
75720617|NCT00524680|Dietary Supplement|cholecalciferol|Given orally
75720618|NCT04794322|Diagnostic Test|Uterine lavage, or a wash of the womb|Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.
75720619|NCT04794322|Diagnostic Test|Blood sample|Participants undergo two blood draws (one required, one optional) up to 31 days before surgery
76044865|NCT05004805|Drug|Methylene Blue|MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.
75720620|NCT04794322|Diagnostic Test|Pap smear|Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.
75720621|NCT00628212|Drug|Teneligliptin 10mg|
76044866|NCT05004805|Drug|Saline nasal spray|Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
75567344|NCT05712239|Other|Advices|The advices will include patient's reassurance and description of possible causes of neck pain such as poor working ergonomics, common bad postures especially while using electronic devices for long periods and not adjustable sleeping pillows. Also, patient will be educated how to modify these different causes and asked to apply gentle neck range of motion exercises
75567345|NCT05712239|Other|Cervical and Scapular Stabilization Exercises|"Deep neck flexor training will be performed in neurodevelopment stages (supine at first week using pressure biofeedback unit , prone at second week, quadrupedal at third week, bipedal at fourth week).~Scapular stabilization exercises will include modified prone cobra, trapezius muscle exercise progression (3 stages), wall press and extension of the thoracic spine using foam roller. The modified prone cobra and the first stage of trapezius muscle exercise progression will be applied during the first two weeks. The second and third stages of trapezius muscle exercise will be applied during the last two weeks of our rehabilitation program. All exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets with 20 sec rest between each set. While wall press and thoracic extension exercises will be applied throughout the 4 weeks for 3 sets of 10 repetitions with 20 sec rest between each set."
75720622|NCT00628212|Drug|Teneligliptin 20 mg|
75720623|NCT00628212|Drug|Teneligliptin 40 mg|
75720624|NCT00628212|Drug|Placebo|
75720625|NCT05160610|Behavioral|Multilevel intervention|Multilevel intervention based on AACTT theory
75720626|NCT00298363|Drug|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
76044867|NCT05412745|Device|Kaloidon Plus|topical application; twice daily
76044868|NCT05412745|Device|silicone gel|topical application; twice daily
76044869|NCT04261387|Drug|LUT014 Gel|Topical application qd for 28 days
75720627|NCT00298363|Drug|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
75720628|NCT00298363|Drug|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
75720629|NCT00298363|Drug|TDF placebo|Placebo to match TDF QD
75720630|NCT00298363|Drug|FTC/TDF placebo|Placebo to match FTC/TDF QD
75720631|NCT00298363|Drug|ETV placebo|Placebo to match ETV QD
75720632|NCT00821262|Drug|sevoflurane|
75720633|NCT00821262|Drug|propofol|
75720634|NCT00824694|Other|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
75720635|NCT00824694|Other|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
75720636|NCT00824694|Other|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
75720637|NCT00830622|Other|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
75720638|NCT01065883|Behavioral|community health worker|community health workers will provide education in the home
75720639|NCT01065883|Behavioral|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
76044870|NCT04261387|Drug|Placebo for LUT014 Gel|Matching placebo for qd topical application for 28 days
76044871|NCT05412199|Device|Percussion Massage Therapy|Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.
76044872|NCT05412199|Device|Graston|Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.
75567346|NCT05712239|Other|Lumber Core Stability Program|"The program will be performed in three stages: activation, dynamic stabilization, and advanced core strengthening stages. Each stage will be applied for 4 sessions.~The activation stage will be based on the learning to activate transversus abdominis muscle from crock lying position using pressure biofeedback unit. In the dynamic stabilization stage, the patient will be instructed to slowly raise both arms in the scapular plan then return to the sides while maintaining the transversus abdominis muscle activation. Also, the patient will apply bridging exercise in this stage. The advanced core strengthening stage will include prone plank and side plank (right and left sides). All the exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets. The rest of 20 sec will be taken between each set."
75567347|NCT05711927|Device|SNOO Smart Sleeper|"Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The preemie mode will be enabled, which caps motion at level 2 out of 5."
75720640|NCT00830700|Other|CATMH intervention|This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
75720641|NCT00830778|Procedure|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
75720642|NCT00830778|Procedure|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
75875276|NCT03704142|Device|Sound World Solutions CS50+|Participants will be tested using the Sound World Solutions CS 50+ hearing devices.
75875277|NCT03704142|Device|Tweak Focus|Participants will be tested using the Tweak Focus hearing devices.
75875278|NCT03704142|Device|IQ Earbuds|Participants will be tested using the IQ Earbuds hearing devices.
75875279|NCT03704142|Device|Bose Hearphones|Participants will be tested using the Bose Hearphones hearing devices.
75875280|NCT05040451|Device|Carillon Mitral Contour System|"The Carillon Mitral Contour System (XE2) consists of the following components:~An implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~A delivery system which consists of a custom 9F delivery catheter and a handle assembly."
75875281|NCT05089123|Biological|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
75567348|NCT05711927|Device|Traditional bassinet|Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.
75875282|NCT05089123|Biological|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
75875283|NCT04540770|Drug|HuL001|Anti-ENO1 monoclonal antibody
75421988|NCT01446484|Drug|Cyclosporine|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
75875284|NCT03671421|Procedure|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
75875285|NCT03703908|Drug|CCX140-B|Orally administered tablet
75875286|NCT02361125|Drug|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
75875287|NCT02361125|Behavioral|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
75875288|NCT03350503|Device|AcrySof IQ Toric A-code IOL|Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
75875289|NCT03350503|Procedure|Cataract surgery|Removal of cataractous lens and implantation of IOL
75421989|NCT01446484|Drug|Everolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
75421990|NCT01446484|Procedure|Kidney transplantation|Living related kidney transplantation
75421991|NCT01446497|Drug|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
75421992|NCT01446497|Drug|Timolol|Twice per day, 1 drop at each time
75875290|NCT03701256|Procedure|Bilateral ultrasound guided TAP bloc|In the TAP group: Bilateral ultrasound guided TAP bloc for laparoscopic gynecologic surgery
75875291|NCT03701256|Drug|Neuromuscular blockade agent: Atracurium 01mg/kg per bolus|In the TRAC group: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus for maintaining muscular relaxation and immobilization during laparoscopic gynecologic surgery
75875292|NCT04780581|Drug|Dexamethasone|6 mg/24h - 10 days
75875293|NCT04780581|Drug|Methylprednisolone|250 mg/ 24h - 3 days
75875294|NCT01526135|Drug|mFolfirinox|"mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
75567349|NCT05708352|Behavioral|Keto Diet|The experimental intervention includes a strict and controlled diet that manages daily macronutrient breakdown and increases the ratio of dietary fat relative to protein and carbohydrate consumption.
75875295|NCT01526135|Drug|Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
75720643|NCT03981913|Behavioral|Simon Task with high-density EEG recording|"The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected."
75720644|NCT02548572|Device|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
75875296|NCT03703830|Device|Cerebellar transcranial direct current stimulation|Cerebellar transcranial direct current stimulation (ctDCS) will be applied during 25 minutes at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle.
75875297|NCT03703830|Other|Treadmill locomotor training|The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
75875298|NCT03703830|Device|Sham Cerebellar transcranial direct current stimulation|Sham Cerebellar transcranial direct current stimulation (ctDCS sham) will be applied during 30 seconds at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle. However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
75875299|NCT04697589|Dietary Supplement|Memophenol 300 mg|300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
75875300|NCT04697589|Dietary Supplement|Memophenol 600 mg|600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
75567350|NCT05708352|Behavioral|Standard Anti-Cancer Diet|Dietitian sessions will utilize the American Institute for Cancer Research Food resources and will reference foods low in fats such as fruits, vegetables and whole grains, providing key micronutrients and phytonutrients. Sessions will also focus on dietary support to help decrease any treatment related symptoms.
75421993|NCT01446510|Other|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
75421994|NCT01446523|Drug|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
75421995|NCT01446523|Drug|Lactulose|Syrup 30 ml BD for 12 weeks
75421996|NCT01446536|Other|Checklist cohort|CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
75421997|NCT01446549|Other|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
75567351|NCT05708040|Device|InPen Medtronic|Patients with DM1 ≥ 18 years of age who initiate Inpen system.
75567352|NCT05708040|Device|Minimed 780G system|Patients with DM1 ≥ 18 years of age who initiate Minimed 780G system.
75875301|NCT04697589|Dietary Supplement|Placebo|Colored maltodextrin
75875302|NCT03701178|Other|BioHPP PEEK|milled BioHPP PEEK in a new material can be used as a dental restoration
75421998|NCT01446549|Procedure|Deep Brain Stimulation|Deep Brain Stimulation implantation
75421999|NCT01446562|Biological|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
75422000|NCT01446588|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
75422001|NCT01446601|Device|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
75422002|NCT01446614|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
75422003|NCT01446627|Other|There is no intervention for this study|None, no intervention made.
75567353|NCT05703334|Other|Kinesio tap|Applied on pulmonary muscles :diaphragm muscle and abdominal muscle and sternocleinomastoid muscle 3 time per weak for 2 mounth
75567354|NCT05702255|Other|Active acupressure|Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions
75567355|NCT05702255|Other|Sham acuptressure|The same protocol as the active acupressure group.
75567356|NCT05701657|Other|Diet A|This diet has high amounts of fruits/vegetables, whole grains, and beans, moderate amounts of dairy, meat/poultry/eggs, fish, nuts/seeds, and vegetable oils, and very low amounts of sugar sweetened drinks and desserts. Menus are developed for 1600kcal, 2100kcal, 2600kcal and 3200 kcal.
75567357|NCT05701657|Other|Diet B|This diet has high amounts of refined grains, meat/poultry/egg, sugar sweetened drinks, sweets, snacks, desserts, and processed foods. It has a moderate amount of dairy and low amounts of fruits/vegetables, whole grains, and fish. Menus are developed for 1600kcal, 2100kcal, 2600kcal and 3200 kcal.
75567358|NCT05701657|Other|Diet C|This diet has moderate-high amounts of vegetables, meat/poultry/egg, fish, nuts/seeds, and fats/oils, low amounts of fruits and dairy, and very low amounts of grains and sugars. Menus are developed for 1600kcal, 2100kcal, 2600kcal and 3200 kcal.
75567359|NCT05701657|Other|Liquid Mixed Meal Tolerance Test|A liquid mixed meal tolerance test will occur in Module 1 and Module 3. For this test, participants will drink two servings of Ensure® Original, vanilla flavor. The meal will also contain acetaminophen (Tylenol) which will show how the smoothie moves through the participant's gut.
75567360|NCT05701657|Other|Diet-Specific Mixed Meal Tolerance Test|The diet-specific mixed meal tolerance test is administered at the end of each dietary intervention period in Modules 2 and 3. The meal test is a breakfast meal similar to the one eaten on the 14-day diets. Thus, three test meals will be used, one for each of the three test diets (Diet A, Diet B, Diet C). The energy (kcal) level of the breakfast meal will be based on each participant's diet prescription. The nutritional composition diet-specific MMTT will be the same test meal for all participants.
75567361|NCT05701215|Drug|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months
75567362|NCT05700422|Drug|Varenicline Nasal Spray|OC-01 (varenicline solution) 0.03 mg nasal spray
75567363|NCT05694247|Device|CorNeat KPro|The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.
75720645|NCT00524368|Drug|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
75720646|NCT00524368|Drug|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
75720647|NCT00777101|Drug|Neratinib|Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
75720648|NCT00777101|Drug|Lapatinib|Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
75720649|NCT00777101|Drug|Capecitabine|Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
75875303|NCT05417139|Other|Immunotherapy+induction chemotherapy+radiotherapy|All enrolled patients received Sintilimab (200mg, d1, q3w) + GP (gemcitabine 1000mg / m2, d1, d8 + cisplatin 80mg / m2, d1, q3w) for 4-6 cycles followed by radiotherapy of primary site and cervical metastasis, and Sintilimab (200mg, q3w) treatment was continued during and after radiotherapy until disease progression or toxicity or up to 2 years.
75720650|NCT00830856|Drug|Fluconazole|Fluconazole 800mg po qday
75720651|NCT00830856|Drug|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
75875304|NCT03703752|Diagnostic Test|Multi-detector CT scan|This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
75875305|NCT03288779|Device|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
75422004|NCT01446640|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10^6 MSCs per kg; intrathecal administration of up to 1x10^6 MSCs per kg.
75422005|NCT01446653|Behavioral|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
75422006|NCT01446653|Behavioral|Video|Video arm will provide information via documentary video
75422007|NCT01446653|Behavioral|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
75422008|NCT01446679|Drug|atrovastatin|oral
75875306|NCT03206749|Drug|VX-150|Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
75720652|NCT00830856|Drug|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
75720653|NCT01068067|Other|drug (tacrolimus and SchE) and genetics|Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.
75875307|NCT03206749|Drug|HB/APAP|Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.
75875308|NCT03206749|Drug|Placebo|Participants received placebo matched to VX-150 and HB/APAP for 2 days.
75720654|NCT01068067|Drug|tacrolimus|After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
75875309|NCT04635969|Behavioral|Sexual Health and Development Education for Children With Intellectual Disability|Sexual Health and Development Education for Children With Intellectual Disability: It is aimed to eliminate the problems related to personal care and cleaning of children with mental retardation, to learn the symptoms of adolescence and to learn the methods of protection from abuse.
75720655|NCT00827190|Drug|ILS-920|
75720656|NCT00297427|Procedure|Acupuncture|Acupuncture twice weekly for 6 weeks.
75875310|NCT04754646|Device|Split-face injection of RHA® 4 with a cannula into a single NLF.|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).~The brand of cannula used for injection is up to the discretion of the Treating Investigator (TI), providing the cannula is registered for use by the US FDA."
75875311|NCT04754646|Device|"Split-face injection of RHA® 4 with a needle (TSK 27G x ½) into the contralateral NLF."|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF)."
75875312|NCT03705923|Procedure|Bariatric surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
75875313|NCT03255941|Drug|DMPA|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.
75875314|NCT03255941|Drug|Sayana Press|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
75422009|NCT01446718|Biological|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
75567364|NCT05687526|Biological|Telitacicept 2.5 mg/kg|Subjects will be given Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.
75567365|NCT05687318|Device|DeFrame|DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
75875315|NCT03703674|Drug|GCSF|Granulocyte-colony stimulating factors (G-CSF)
75567366|NCT05681377|Drug|Flumazenil|After cessation of remimazolam infusion, flumazenil 0.2 mg is administered intravenously over 15 seconds. If consciousness is not adequately restored within 3-5 minutes, a second dose of 0.1 mg intravenously over 15 seconds is administered. If necessary, 0.1 mg may be administered repeatedly at 3-5 minute intervals, and the maximum dose of 1 mg should not be exceeded.
75567367|NCT05681026|Behavioral|Yoga Sessions|Participants will have up to 12 sessions, 3 sessions per week, over the first 30 days of your hospitalization.
75567368|NCT05681026|Behavioral|Questionnaries|Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.
75567369|NCT05681026|Behavioral|Interviews|Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).
75422010|NCT01446731|Biological|mRNA transfected dendritic cell|"Autologues monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."
75422011|NCT01446731|Drug|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
75567370|NCT05680818|Drug|Encaleret|Administered as film-coated tablet for oral use
75567371|NCT05680818|Dietary Supplement|Standard of Care|Calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
75567372|NCT05677984|Procedure|Awaken prone positioning ventilation|patients were mandated to keep a prone position for at least 12 hours.
75567373|NCT05674942|Other|Patients with urinary tract infection and chronic kidney disease|The data that will be collected from the electronic patient records at the clinics through a google form will include sociodemographic (age, sex, weight and occupation), comorbidities (e.g., HTN, DM), medications used, renal functions (serum creatinine, and CKD stage calculated by 2021 CKD-EPI creatinine equation), and in case of positive urine culture (type of microorganism and antibiogram).
75875316|NCT03705390|Drug|ILB|Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks
75720657|NCT00297427|Other|Sham acupuncture|Twice a week for 6 weeks
75875317|NCT04805424|Procedure|Lipo-abdominoplasty|Abdominoplasty plus liposuction
75875318|NCT04805424|Procedure|Abdominoplasty|Abdominoplasty
75720658|NCT00830934|Procedure|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
75875319|NCT03705312|Device|Transcatheter mitral valve repair|Transcatheter mitral valve repair performed using the MitraClip device
75720659|NCT00830934|Procedure|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
75720660|NCT00524134|Drug|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
75875320|NCT03705312|Other|Guideline-directed medical therapy|Standard medical therapy for heart failure as recommended by HF guidelines
75422012|NCT01446757|Procedure|The intervention group|Medical assessment (co-morbid condition, physical and neurological examination, medication review, nutrition, and blood-tests to identify anaemia, diabetes, metabolism and liver- and kidney function); assessment of functioning (ADL/IADL, fall risk), psychological assessment (cognitive decline and depression) and assessment of social and environmental conditions. The care plan is based on the CGA and will be individualised and carried out in discussion with the patient and his/her caregivers. The care will be carried out by an inter-professional Geriatric Team with employees from both the county council and the municipality. The team consists of a core team (including geriatrician and nurse) and a support team (including a social worker, occupational therapist, dietician, pharmacist, physiotherapist, and dental hygienist). The care will involve treatment for unstable medical conditions and support of patients and their caregivers. The team will have regular team conferences.
75720661|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
75720662|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
75720663|NCT00777023|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
75720664|NCT05062330|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days
75422013|NCT01446757|Procedure|control group|No intervention
75720665|NCT05062330|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days
75720666|NCT00297037|Drug|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
75875321|NCT03701100|Device|tDCS|tDCS
75875322|NCT03701022|Drug|SHR1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
75875323|NCT04221165|Drug|Opioids|Opioids will be prescribed as per institutional standards.
75422014|NCT01446770|Device|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
75875324|NCT04221165|Drug|PAiN - multimodal analgesia|PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
75875325|NCT03255629|Drug|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
75875326|NCT03255629|Device|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
75875327|NCT03031938|Drug|Investigational medical product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
75875328|NCT03587571|Procedure|Surgical intervention|Open reduction and plate osteosynthesis.
75875329|NCT01143779|Drug|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
75875330|NCT03558737|Other|Nasal high-frequency jet ventilation (nHFJV)|Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway
75720667|NCT03978065|Diagnostic Test|Confocal microscopy|"For this purpose live stains will be combined with a confocal imaging setup equipped with 6 laser lines. A major advantage of this technique is that tissue specimens do not need to be fixed prior to analysis. Such an approach does not only allow tissue viability and integrity assessment in an unprecedented speed and accuracy, but also promises to shed new light into quality assessment and prognosis in kidney transplantation. The investigators herein wish to establish the predictive values of this technology in kidney transplantation.~The methodology used in this trial is referred to as BIOPSYCHRONOLOGY - as a reference to dendrochronology, or tree ring dating. Leaving the biopsy sample intact facilitates its analysis, just as drills are used for tree-ring counting."
75720668|NCT04093193|Procedure|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
75720669|NCT00292981|Drug|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
75720670|NCT02598869|Drug|Triamcinolone Acetonide|injection of triamcinolone acetonide
75720671|NCT04095455|Procedure|pectoral nerves block group|ultrasound guided block of nerve supply of surgical site
75720672|NCT04095455|Drug|Ketamine plus magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
75720673|NCT04095455|Drug|Control group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
75720674|NCT04095299|Radiation|50.4 Gy to the tumor and elective volume|Standard radiotherapy
75720675|NCT04095299|Radiation|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume|Experimental radiotherapy
75720676|NCT04095299|Drug|Capecitabine 825 mg/m2 twice daily on weekdays|Standard chemotherapy
75720677|NCT00296725|Drug|Fluoxetine|Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day *All increases only if tolerated.
75567375|NCT05669430|Drug|GV20-0251|Increasing doses of GV20-0251 given intravenously as monotherapy.
75567376|NCT05669430|Drug|GV20-0251|GV20-0251 RP2D given intravenously as monotherapy.
75720678|NCT00296725|Drug|Imipramine|Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. *All increases only if tolerated.
75422015|NCT01446783|Drug|mecasermin|0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.
75567377|NCT05668559|Procedure|repetitive transcranial magnetic stimulation|"The rTMS mode consists of a cluster stimulus delivered every 0.2 seconds (5 Hz), with each cluster stimulus consisting of three burst stimuli with a 50 Hz body frequency. The duration of a single stimulus was approximately 40 seconds, for a total of 600 pulses. Stimulation takes place bilaterally in the dorsolateral prefrontal cortex (DLPFC).~All enrolled patient in the rTMS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes on postoperative day 1 to 5 after the surgery."
75567378|NCT05668559|Procedure|Sham Stimulation|Shaman stimulation uses the same protocol (600 pulses per session, 3 sessions per set, ISI≥30 min, 3 sets) with the coil set at 90 against the skull on postoperative day 1 to 5 after the surgery.
75567379|NCT05668416|Other|education|The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital. Education brochure (Day surgery training brochure); An educational brochure was prepared by the researchers in line with the literature and practices in the institution. The brochure was composed of 3 sections: pre-operative, on the day of the operation and after the operation.
75567380|NCT05661279|Procedure|general anesthesia|general anesthesia
75567381|NCT05661279|Procedure|general anesthesia plus Rhomboid intercostal block|the patients will be positioned in lateral decubitus with moving the scapula laterally by abducting the ipsilateral arm across the chest. under complete aseptic situations A high-frequency (6-12 MHz) linear US probe will be put medial to the medial border of the scapula in an oblique sagittal plane with the orientation marker directed cranially.at the T6-7 level, the tissue plain between the rhomboid major and intercostal muscles is identified, and a single injection of 25mL of bupivacaine (0.25%) will be administered via 18-gauge Tuohy advanced in plane from a superomedial to an inferolateral direction, followed by general anesthesia
75567382|NCT05661279|Procedure|Serratus anterior plane block|The patient will be positioned supine with his arm abducts at 90°. the US high frequency (6-12 MHz) linear probe of sonosite M turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be put in sagittal plane at the midaxillary line. identification of the fascial plane between the serratus anterior muscle and external intercostal muscles will be performed between the fourth and fifth ribs in the midaxillary area . At this point the18-gauge Tuohy needle will be advanced in plane with injection of 25mL of 0.25 %, bupivacaine. followed by general anesthesia
75567383|NCT05660681|Drug|glycerin 0.7%/PEG 400 0.3%|Eye drop with active agents from the OTC Monograph.
75567384|NCT05660681|Drug|polyethylene glycol 400 0.4%/propylene glycol 0.3%|Eye drop with active agents from the OTC Monograph.
75422016|NCT01446783|Drug|Saline|0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
75422017|NCT01446822|Device|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
75567385|NCT05660239|Other|Community Intervention|To evaluate the impact of a community intervention in reducing epilepsy stigma in adolescents.
75720679|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
75720680|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
75720681|NCT00523978|Device|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
75875331|NCT03558737|Other|Nasal intermittent positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
75422018|NCT01446822|Device|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
75422019|NCT01446835|Device|nelfilcon A contact lens with print|Investigational spherical contact lens
75422020|NCT01446835|Device|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
75422021|NCT01446848|Dietary Supplement|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
75422022|NCT01446887|Other|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
75567386|NCT05655351|Biological|anti-SARS-Cov-2 vaccination|For the purposes of the study, 10 mL of venous blood will be collected from each patient.
75720682|NCT00523978|Drug|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
75720683|NCT02599727|Other|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
75720684|NCT02599727|Other|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
75720685|NCT00296647|Drug|nicotine patch|Decreasing dosages from 21 to 7 mg over 12 week period
75720686|NCT00296647|Drug|nicotine patch|Decreasing dosage from 21 to 7 mg over 12 weeks
75875332|NCT03703596|Drug|Anlotinib Hydrochloride|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
75875333|NCT03703596|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
75875334|NCT01137773|Drug|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
75567387|NCT05648292|Behavioral|Neuropsychological tests and psychological questionnaires|"The clinical group will complete:~the BCcogSEP: a comprehensive neuropsychological examination~the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression~The control group will complete:~the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression"
75567388|NCT05647005|Other|Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
75567389|NCT05647005|Other|Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
75567390|NCT05644067|Biological|SumayaVac-1(SUM-101)|One immunization every 4 weeks for 3 months (total 3 immunizations)
75567391|NCT05644067|Biological|Verorab|One immunization every 4 weeks for 3 months (total 3 immunizations)
75567392|NCT05644067|Biological|CHMI|Controlled Human Malaria Infection (CHMI)- challenge with Plasmodium falciparum sporozoites in a sub-group of participants who received SumayaVac-1(SUM-101) or Verorab
75567393|NCT05643144|Device|Continuous Glucose Monitoring|CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
75567394|NCT05642923|Drug|Synthetic Vitamin B1|Synthetic Vitamin B1 400 mg per day
75567395|NCT05641363|Drug|Ketorolac Tromethamine|ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.
75720687|NCT00296647|Drug|nicotine lozenge|4 mg nicotine lozenge: dosage according to package directions for 16 weeks
75720688|NCT00296647|Drug|bupropion|dosage according to prescription directions: 12 weeks
75720689|NCT00296647|Drug|patch + lozenge|dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
75720690|NCT00296647|Drug|bupropion + lozenge|dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
75720691|NCT00754013|Drug|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally."
75720692|NCT00754013|Drug|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally."
75720693|NCT04094987|Device|inter-fascial pressure|The pressure between the fascia and the pressure line added to the catheter tip will be measured.
75720694|NCT01062919|Procedure|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
75720695|NCT01062919|Procedure|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
75720696|NCT00523744|Drug|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
75720697|NCT00523744|Drug|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
75720698|NCT00523744|Drug|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
75720699|NCT00523744|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
75720700|NCT03979625|Other|Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies|Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.
75875335|NCT01137773|Drug|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
75875336|NCT03700944|Other|Yoga training|Complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week.
75422023|NCT01446900|Drug|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
75422024|NCT01446900|Drug|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
75422025|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
75422026|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
75422027|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
75422028|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
75422029|NCT01446926|Biological|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
75422030|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
75422031|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
75422032|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
75422033|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
75422034|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
75422035|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
75422036|NCT01446952|Drug|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
75422037|NCT01446978|Biological|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
75422038|NCT01446978|Biological|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
75567396|NCT05638139|Biological|SygeLIX-F + SygeLIX-G|SygeLIX-F (plug) is inserted through the internal orifice while cryptoglandular space is filled by SygeLIX-G (gel).
75875337|NCT03632031|Device|Oasis Extracellular Matrix|Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
75875338|NCT01568385|Drug|TAK-438|
75567397|NCT05636241|Other|conventional physiotherapy program|The conventional physiotherapy program consists of stretching exercises for lower extremities, strength exercises for core, upper, and lower extremity muscles, sit to stand exercises, and balance exercises.
75567398|NCT05636241|Other|whole body vibration training program|The whole body vibration training program sessions consisted of three 3-min bouts of vibration of 20 Hz and a peak-to-peak amplitude of 2mm with a 3-min rest in between, in addition to conventional physiotherapy exercises for children with cerebral palsy.
75567399|NCT05636228|Drug|INV-102|INV-102 Ophthalmic Solution
75567400|NCT05636228|Drug|Vehicle|Vehicle Ophthalmic Solution
75567401|NCT05634889|Radiation|De-escalation|No regional radiotherapy. Radiotherapy towards the remaining breast after breast conserving surgery, but no radiotherapy at all after mastectomy.
75567402|NCT05624710|Drug|INCB054707|INCB054707 75 mg will be administered orally on Day 1.
75875339|NCT03700866|Procedure|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
75875340|NCT04525092|Device|Online Pre-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of >44L/session reinjected in pre-dilution mode. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
75875341|NCT04525092|Device|Conventional Hemodialysis|Using the following parameters: maximum Blood flow rate allowed by vascular access, dialysate rate of 500 mL/min, no convection. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
75875342|NCT04525092|Device|Online Post-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of >22L/session reinjected in pre-dilution mode. The dialysate composition and net ultrafiltration rate will be prescribed according to participant's characteristics. Usage of intra-dialysis anticoagulation is mandatory.
75875343|NCT03703518|Other|Mixed reality|"This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
75875344|NCT03703518|Other|Conventional exercise group|This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
76044873|NCT05412199|Other|Dynamic Stretching|Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
76044874|NCT05411965|Drug|BR3003(T)|"Test drug (T):BR3003 Boryung Pharmaceutical Co., Ltd."
76044875|NCT05411965|Drug|BR3003B(R1)|"Reference drug 1 (R1): BR3003B of Celltrion Pharm, Inc."
76044876|NCT05411965|Drug|BR3003C(R2)|"Reference drug 2 (R2): BR3003C of AstraZeneca Korea"
75422039|NCT01446991|Drug|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
75422040|NCT01446991|Drug|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
75422041|NCT01447043|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
75422042|NCT01447056|Biological|LMP specific T cells|"Three dose levels will be evaluated:~Dose Level 1: 2×10^7 cells/m2; Dose Level 2: 1×10^8 cells/m2; Dose Level 3: 2×10^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."
75422043|NCT01447069|Drug|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains <100 bpm
75422044|NCT01447095|Drug|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
75422045|NCT01447095|Drug|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
75422046|NCT01447095|Drug|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
75422047|NCT01447108|Device|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (PainShield™)|"All subjects will be treated four weeks with a placebo PainShield™ while continuing with their current pharmaco- analgesic regimen. Aferterwards all subjects will be crossed over to active Painshield™ therapy for the next four weeks.~The Painshield™ device is a patch, which will be applied to their forehead for six-eight hours during night while sleeping."
75567403|NCT05623072|Device|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in vmPFC
75720701|NCT04094831|Other|Health education|The intervention group will receive health education through CKD campaign and mHealth technology. During the half day CKD campaign, health education materials (leaflet and short textbook and recording notebook) will be provided to the study participants. A nephrologist will facilitate the campaign and contents (Annex-3) of the text book and leaflet (Annex-4) will be discussed. Important message from the text book (such as stage, risk factor, preventive measures) will be used to develop the leaflet. In addition,Basic health education information about CKD is included in the contents to help patients gain knowledge, awareness, and improve their behaviors. Discussion on basic kidney diseases, risk factors, and preventive measures of CKD is performing by CHWs over a mobile phone call to the study patients. The patients have the liberty to discuss their health-related issues with the CHWs over a period of 10 minutes
75720702|NCT00831012|Biological|rDEN3delta30/31-7164|A live attenuated, recombinant DEN3 candidate vaccine virus
75422048|NCT01447160|Drug|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
75422049|NCT01447173|Drug|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
75875345|NCT03700710|Behavioral|Self-Guided Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform."
75875346|NCT03700710|Behavioral|Dietitian-led Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.~Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis."
75422050|NCT01447186|Behavioral|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
75422051|NCT01447186|Behavioral|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
75422052|NCT01447186|Behavioral|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
75567404|NCT05623072|Device|Sham tDCS|20 min, vmPFC Sham tDCS
75567405|NCT05618691|Drug|GFH312|Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.
75567406|NCT05618691|Other|Placebo|Placebo will be administered to subjects in the placebo group
75567407|NCT05616546|Biological|Influenza Vaccine|The vaccine used in this study will be a licensed seasonal inactivated influenza vaccine for intramuscular injection that is approved by the FDA. Enrolled subjects will receive licensed seasonal inactivated influenza vaccine (administered as a part of the study).
75567408|NCT05614557|Device|Stratacel|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
75720703|NCT01068145|Drug|SCH 527123|Very low dose SCH 527123, once daily for 7 days
75720704|NCT01068145|Drug|SCH 527123|Low dose SCH 527123, once daily for 7 days
75720705|NCT01068145|Drug|SCH 527123|Medium dose SCH 527123, once daily for 7 days
75422053|NCT01447199|Behavioral|Health and Diet Questionnaire|Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
75422054|NCT01447212|Drug|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
75422055|NCT01447212|Drug|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
75422056|NCT01447212|Drug|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
75720706|NCT01068145|Drug|SCH 527123|High dose SCH 527123, once daily for 7 days
75720707|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
76044877|NCT04261075|Biological|IPH5201|Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
75422057|NCT01447212|Drug|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
75567409|NCT05614557|Device|Stratamed|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
75567410|NCT05609435|Other|REASSURE|REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
75567411|NCT05607511|Other|Probiotics baby immunity formula (SIM03)|Daily oral intake of a probiotics sachet
75422058|NCT01447238|Device|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|"Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.~The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual."
75422059|NCT01447251|Behavioral|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS <4.5, moderate risk as PreDx DRS ≥4.5 and <8.0, and high risk as PreDx DRS ≥8.0.
75567412|NCT05606874|Other|Pre-heating of flowable resin composite used as a pit and fissure sealant.|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
75720708|NCT01068145|Drug|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
75875347|NCT03700632|Other|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
75422060|NCT01447264|Procedure|Land exercises|3 times a week. 50 minutes in every session. Performed by educational professor
75422061|NCT01447264|Procedure|Water exercises|3 times a week. 50 minutes in every session. Performed by educational professor
75422062|NCT01447277|Procedure|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
75422063|NCT01447277|Procedure|Femoral Block only|Performing a preoperative sciatic nerve block only
75422064|NCT01447303|Other|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
75422065|NCT01447316|Other|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
75720709|NCT01068145|Drug|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
75720710|NCT01068145|Drug|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
75720711|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
75720712|NCT05428475|Diagnostic Test|[18F]FDG-PET Scan|185 MBq of [18F]FDG will be administered IV 30 minutes prior to PET scan. Images will be acquired for 30 minutes. Resulting images will be evaluated for patterns of FDG-uptake to support the diagnosis of the participant symptoms of cognitive impairment.
75720713|NCT00824928|Procedure|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
75720714|NCT01063231|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
75720715|NCT02599103|Other|Fat-free milkshake|participants drinks a fat-free milk shakes
75720716|NCT02599103|Other|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
75720717|NCT02599103|Other|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
75875348|NCT03698604|Procedure|Hysterectomy|Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
75875349|NCT03698526|Device|Samsung Gear VR, Galaxy S8, Applied VR App|Virtual Reality Experience
76044878|NCT04261075|Biological|durvalumab|Durvalumab Q3W for a maximum of 2 years
76044879|NCT04261075|Biological|oleclumab|Oleclumab Q3W for a maximum of 2 years
75720718|NCT02599103|Other|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
75875350|NCT03624426|Device|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
75720719|NCT02599103|Other|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
75720720|NCT02599103|Other|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
75875351|NCT03703362|Other|Resistance training|30 supervised training-sessions over 12 weeks
75422066|NCT01447342|Device|Cryo-Touch II|Percutaneous treatment with the device
75875352|NCT01568151|Behavioral|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
75875353|NCT01568151|Behavioral|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
75875354|NCT03698292|Drug|Itopride|Prokinetic Drug
75875355|NCT03698292|Drug|Metoclopramide 10mg|Prokinetic Drug
75422067|NCT01447355|Drug|cholecalciferol|Given PO
75422068|NCT01447368|Drug|Cinacalcet|oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
75422069|NCT01447368|Procedure|Surgical total parathyroidectomy with forearm autografting|Surgical total parathyroidectomy with forearm autografting will be performed
75567413|NCT05606874|Other|Conventional resin fissure sealant|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
75720721|NCT02599103|Other|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
75422070|NCT01447394|Biological|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
75720722|NCT02599103|Other|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
75422071|NCT01447394|Biological|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
75720723|NCT02599103|Other|Tallow|participants drinks the milk shakes prepared from 60g of tallow
75720724|NCT02599103|Other|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
75720725|NCT04352140|Device|Tetragraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
75720726|NCT04352140|Device|ToFscan|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
75720727|NCT00831168|Behavioral|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
75875356|NCT04615455|Drug|ASCs|ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.
75875357|NCT04615455|Drug|Cryostor CS10|CryoStor® CS10 freeze medium
75875358|NCT03703284|Other|Treatments to reduce intracranial pressure|Drugs such as mannitol, glycerin fructose, etc and/or surgery
75875359|NCT01567917|Procedure|CRC surgery|"Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE"
75875360|NCT03698214|Other|reversed shock index < 1|Among patients with isolated TBI, those with an RSI < 1 had higher mortality
75422072|NCT01447394|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
75422073|NCT01447459|Behavioral|Reinforced Asthma Education|"Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.~At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study."
75422074|NCT01447472|Drug|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
75422075|NCT01447485|Drug|Valsartan (VAL489)|
75875361|NCT03698214|Other|reversed shock index ≥ 1|Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
76044880|NCT04452019|Device|Use of standard standing frame|Two training sessions in a standard standing frame, max 30 min. pr. session
75720728|NCT02548494|Drug|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
75875362|NCT03698136|Other|Stimulation of denervated muscles|The study investigates the effect of electrical stimulation on denervated muscles in the forearm and hand regarding muscle structure and thickness. The study will be performed on tetraplegics who have either paralysed the wrist extensor, the short thumb spreader or the muscle between the thumb and index finger.The study lasts 12 weeks and consists of an ultrasound examination at the beginning and end of the study and an intermediate stimulation phase.The stimulation takes place either during an inpatient stay or at home for 12 weeks, 5 times a week 33 minutes.
75720729|NCT02548494|Drug|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
75720730|NCT02548494|Other|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
75875363|NCT03698058|Dietary Supplement|Toddler milk|Commercially available toddler milk
75875364|NCT04613271|Drug|Favipiravir|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
75720731|NCT02548494|Other|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~Administer 1-3 L during the first hour.~Administer 1 L during the second hour.~Administer 1 L during the following 2 hours~Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
75875365|NCT04613271|Drug|Azithromycin|Azithromycin 500 mg once a day for 5 days.
75875366|NCT05415189|Other|Not relevant|This is a non-intervention cohort study
75875367|NCT03094611|Biological|Inotuzumab Ozogamicin|Given IV
75875368|NCT03631953|Drug|Trametinib|Trametinib administered at a fixed dose (1.5 mg daily)
75875369|NCT03631953|Drug|Alpelisib|A panel of 3 doses of ALPELISIB could be tested
75875370|NCT03631953|Biological|Blood sample|Therapeutic biomarkers
75875371|NCT03631953|Device|MRI|A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
75422076|NCT01447498|Other|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~screening and risk assessment~control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: < 60: 0; 60-69: 1; 70-79: 2; >=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___"
75422077|NCT01447524|Behavioral|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
75422078|NCT01447537|Other|Exercise + relaxation|Exercise + relaxation
75422079|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
75422080|NCT01447550|Drug|Bosentan|Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
75875372|NCT01030575|Drug|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
75875373|NCT01030575|Drug|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
75875374|NCT01030575|Drug|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
75875375|NCT01030575|Drug|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
75720732|NCT05049148|Other|Platelet count in excised tumors|Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
75720733|NCT02548416|Procedure|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
75875376|NCT04314687|Biological|Umbilical Cord Mesenchymal Stem Cells|The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
75875377|NCT04314687|Biological|Conditioned Medium|Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.
75875378|NCT04314687|Other|Standard Therapy|Standard therapy for cerebral palsy such as physiotherapy
75720734|NCT02548416|Procedure|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
75875379|NCT04215471|Drug|PD-L1 Antibody SHR-1316|Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
75875380|NCT04561011|Behavioral|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend ~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
76044881|NCT04452019|Device|Use of a new device; Innowalk Pro|Two training sessions in Innowalk Pro, max 30 min pr. session
75875382|NCT04105725|Behavioral|Brief Motivational Intervention+Substance-Free Activity Session|A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.
75875383|NCT04105725|Other|Alcohol + Nutrition Education Session|Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
75720735|NCT00752219|Drug|ceftazidime/NXL104 + metronidazole|IV TID
75720736|NCT00752219|Drug|meropenem|IV TID
75422081|NCT01447563|Drug|Clopidogrel bisulfate|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
75720737|NCT00827268|Behavioral|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
75720738|NCT00825006|Device|Triple site pacing mode|"The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months."
75875384|NCT04066023|Drug|C213 Microneedle System|The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm^2 array) is attached to a 5 cm^2 adhesive patch.
75875385|NCT04066023|Drug|Placebo|The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
75875386|NCT03106987|Drug|Active Comparator: Olaparib tablets|"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
75422082|NCT01447563|Drug|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
76044882|NCT04451473|Procedure|Enhanced Recovery After Surgery (ERAS )|the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
75422083|NCT01447589|Drug|nelfinavir|Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.
75422084|NCT01447589|Radiation|Radical Radiotherapy|Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
75720739|NCT02599805|Device|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
75720740|NCT04774354|Diagnostic Test|POSSUM|These scales will be calculated and compared to the outcomes obtained in our center.
75720741|NCT02598791|Other|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
75720742|NCT02598791|Other|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
75720743|NCT02598791|Other|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
75720744|NCT02598791|Other|OGTT|50 g oral glucose tolerance test
75720745|NCT02598791|Other|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
75422085|NCT01447602|Behavioral|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
75720746|NCT00827346|Drug|Clopidogrel|600 mg now
75875387|NCT03106987|Drug|Placebo|"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
75875388|NCT02932267|Drug|Adapalene 0.3% / BPO 2.5% gel|Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
75875389|NCT04930705|Device|Treatment with TempSure Applicator|Subjects will receive up to 5 treatments on the abdomen.
75875390|NCT03217591|Drug|IW-1973|Oral Tablet
75875391|NCT03217591|Drug|IW-1973|Oral Tablet
75875392|NCT03217591|Drug|Placebo|Oral Tablet
76044883|NCT04451473|Procedure|Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )|the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
76044884|NCT05438017|Device|Dreem 3 System vs PSG|Dreem 3 System to be worn by each participant while undergoing in-lab sleep study with PSG.
75422086|NCT01447615|Behavioral|Bridges|Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.
75567414|NCT05602389|Other|VL-G-A57|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
76044885|NCT05436769|Drug|Klaribact 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
75567415|NCT05602389|Other|VL-G-E12|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
75567416|NCT05602389|Other|Placebo|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
75567417|NCT05601596|Diagnostic Test|Analysis of menstrual blood to predict endometriosis|Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.
75567418|NCT05600244|Procedure|PENG block Technique|A linear probe will be used. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, 30 ml of bupivacaine 0.25% will be injected in the plane beneath the iliopsoas muscle
75720747|NCT00827346|Drug|Clopidogrel|600 mg now and 600 mg in 3 hours
75720748|NCT00827346|Drug|Clopidogrel|900 mg now
75720749|NCT00827346|Drug|Clopidogrel|600 mg now and 300 mg in 3 hours
76044886|NCT05436769|Drug|Klaricid 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
75720750|NCT02549274|Other|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
75720751|NCT02549274|Other|physiotherapy|14 physiotherapy sessions (2 by week)
75875393|NCT04927195|Drug|EDP1867|EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
75567419|NCT05600244|Procedure|Lumbar ESPB Technique|Using the out-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthetic solution, 30 ml bupivacaine 0.25% will be administered leading to hydrodissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurs when administering local anesthetic . All local anesthetic will be administered to this location between the transverse process and the erector spinae muscle
75567420|NCT05600244|Procedure|Transmuscular QLB-t block Technique|A convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest. The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscle, transverse abdominis muscle, internal and externa oblique muscles, and the quadratus lumborum muscle will be identified. A 15 cm 22G insulated needle will be inserted on the posterior corner of the transducer. 30 ml bupivacaine 0.25% will be administered between the quadratus lumborum and psoas muscles into the fascial plane.
75567421|NCT05596916|Other|High frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 5 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
75567422|NCT05596916|Other|Low frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 3 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
75720752|NCT00997750|Drug|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
75720753|NCT03998956|Procedure|CPVI|Circumferential PV isolation only
75720754|NCT03998956|Procedure|CPVI+BOX|Circumferential PV and BOX isolation
75720755|NCT03998956|Procedure|CPVI+BOX+SUB|Atrial substrate ablation apart from circumferential PV and BOX isolation
75720756|NCT00622908|Drug|ISV-403|0.6% TID, 5 days
75720757|NCT00622908|Drug|Vehicle|Vehicle of ISV-403 TID, 5 days
75720758|NCT00997828|Device|everolimus-eluting stent|Xience V stent
75720759|NCT00997828|Procedure|coronary artery bypass graft surgery|coronary artery bypass graft surgery
75720760|NCT02548338|Procedure|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
75720761|NCT00827424|Behavioral|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
75875394|NCT04927195|Drug|Placebo|Placebo oral capsule
75875395|NCT03636763|Drug|data report|"the information gliptin exposure will be reported"
75875396|NCT03031782|Drug|secukinumab|secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
76044887|NCT03937999|Drug|Bezlotoxumab|Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
76044888|NCT05436067|Device|Vestibular rehabilitation app|Delivery of vestibular rehabilitation through an app on a tablet or other portable device. The app takes patients through their rehabilitation session that has been prescribed by a clinician. Exercises are presented in the forms of games that are controlled by head or torso motion via a motion sensor that is placed on that body part. Data on the motion of the patient are calculated from sensor data and sent over the cloud for the clinician to access remotely.
76044889|NCT05377567|Behavioral|TAU + FIBRO-On|Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
76044890|NCT05377567|Behavioral|TAU + FIBRO-Out|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
76044891|NCT05377567|Other|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
75875397|NCT03031782|Other|placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
75567423|NCT05595083|Drug|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
75720762|NCT04095065|Behavioral|itMatters|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing & treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse & sexual risk taking.
75422087|NCT01447615|Behavioral|Bridges PLUS|Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.
75875398|NCT03697902|Diagnostic Test|Ultrasonographic Measurement on Fetal cisterna magna length|"The length measurement on the fetal cisterna magna (CM) with an angle of 0° between the transducer and the axial cerebellar plane of the fetal head (midline structures will be perpendicular to the ultrasound beam). After that, CM will be measured again after moving the transducer approximately 30° towards the fetal occiput.~Measurements will be performed on the axial cerebellar plane using internal landmarks including the cavum septi pellucidi, thalamus, third ventricle, cerebral peduncles and cerebellar hemispheres.The anteroposterior measurement will be made between the posterior border of the cerebellar vermis and the internal face of the occipital bone.~All the ultrasonography examinations were performed abdominally, using 3-5 megahertz (MHz) transducers."
75875399|NCT03697824|Drug|GSK3377794|GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
75567424|NCT05595083|Drug|intravouns dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
75567425|NCT05594043|Drug|MK-6598|Oral tablet
75567426|NCT05594043|Biological|Pembrolizumab|Intravenous (IV) infusion
75875400|NCT03697824|Drug|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.
75875401|NCT03697824|Drug|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
75875402|NCT03697824|Drug|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
75875403|NCT03700398|Device|first OE|optical enhancement(OE)，a kind of electron straining endoscopy
75567427|NCT05591703|Behavioral|Clinical Outcomes and Questionnaires|Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
75875404|NCT03700398|Device|first WLI|the routine in the clinical practice
75875405|NCT03702894|Drug|Clavamox|Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus
75875406|NCT03702894|Drug|Augmentin®|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
75567428|NCT05588427|Dietary Supplement|Ketone ester|A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
75567429|NCT05588427|Dietary Supplement|Placebo|Water, 5% sucralose (w/w), octaacetate (1 mM)
75567430|NCT05585710|Other|Pulsed Lavage Washout|Use of pressurized, pulsed triple antibiotic solution to irrigate mastectomy pocket
75720763|NCT04095065|Behavioral|itMatters and itMatters Sexual Violence Prevention|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing & treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse & sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
76044892|NCT01659853|Drug|CD07805/47 gel 0.5%/CD07805/47 Vehicle|"To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily"
75567431|NCT05585710|Procedure|Implant-based breast reconstruction|Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket
75567432|NCT05585710|Procedure|Bilateral or unilateral mastectomy|Standard of care
75567433|NCT05585710|Device|Tissue expander|Standard of care
75567434|NCT05585710|Other|Acellular dermal matrix|Standard of care
75422088|NCT01447615|Other|Usual Care|Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
75422089|NCT01447641|Other|Polysomnography|Overnight physiological recording of sleep
75422090|NCT01447641|Other|Actigraphy|Wristwatch activity to measure basic rest activity cycle and sleep efficiency
75567435|NCT05581173|Device|Purastat SAP gel application|Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter. Purastat is FDA approved and commercially available. Purastat is a peptide solution that self assembles at physiological potential Hydrogen(pH) and forms a gel comprising a network of nanofibers. Its benefits in hemostasis and tissue healing and its biocompatibility have been previously demonstrated in animal models and also in human cases. When the gel comes into contact with blood or tissue fluids, the change in potential hydrogen (pH) and salt concentration causes fiber formation and gelation that block the blood vessels in the hemorrhagic area to generate hemostatic effects and also prevention of scar tissue formation.
75567436|NCT05579691|Biological|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
76044893|NCT01659853|Drug|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
75422091|NCT01447654|Drug|Losartan|100 mg for 12 months.
75567437|NCT05579691|Other|Placebo|Placebo Comparator
75567438|NCT05570630|Behavioral|VAX-MOM COVID-19 Intervention|The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
75567439|NCT05570630|Other|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
75567440|NCT05566262|Drug|Bodewell Calming Cream|Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
75567441|NCT05565443|Device|Blood Brain Barrier Disruption - Functional|Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
75567442|NCT05563155|Drug|Dexamethasone 24 mg|Dexamethasone 24 mg on day 1 after surgery.
75720764|NCT04095065|Behavioral|itMatters Well-being and itMatters Sexual Violence Prevention|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
75720765|NCT04095065|Behavioral|itMatters Well-being|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
75422092|NCT01447654|Drug|Placebo|100 mg for 12 months.
75422093|NCT01447693|Procedure|application of ointment (olive-omega 3 ointment)|
75422094|NCT01447732|Drug|CEP-37250/KHK2804|"Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1."
75422095|NCT01447758|Drug|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
75422096|NCT01447758|Drug|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
75567443|NCT05563155|Drug|Placebo|Placebo tablet given on day 1 after surgery.
75567444|NCT05556655|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive method for stimulating neurons (axons not cell bodies) in the brain.
75567445|NCT05552859|Drug|Insulin glargine 300 U/mL|Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
75720766|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
76044894|NCT05376631|Procedure|Fresh gas flow of 5 L/min|A fresh gas flow of 5 L/min is used during emergence from general anesthesia.
75422097|NCT01447771|Behavioral|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
75422098|NCT01447784|Biological|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
75422099|NCT01447784|Biological|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
76044895|NCT05376631|Procedure|Fresh gas flow of 10 L/min|A fresh gas flow of 10 L/min is used during emergence from general anesthesia.
75422100|NCT01447797|Drug|HCP0912 / Irbesartan and Atorvastatin|Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
75422101|NCT01447810|Other|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
75422102|NCT01447862|Drug|Brinavess (Vernakalant)|3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
75422103|NCT01447862|Drug|Corvert (Ibutilide)|Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
75422104|NCT01447875|Other|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before sedation
75422105|NCT01447875|Drug|propofol or mexmedetomidine|
75567446|NCT05552859|Drug|Insulin degludec 100 U/mL|Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
75567447|NCT05546918|Other|survey, interviews and focus groups|"The 2 groups of participants will be invited to:~complete an anonymous online survey~participate in individual semi-structured interviews and 2 focus groups"
75567448|NCT05544240|Drug|SV-101|SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
75567449|NCT05544227|Drug|SV-102|SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
76044896|NCT05610553|Other|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries to help to reduce intra-operative radiation, puncture time, etc..
75720767|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
75720768|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
75720769|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
76044897|NCT05610553|Other|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
75720770|NCT02598635|Drug|Cholecalciferol|Patients on peritoneal dialysis and 25-(OH) levels <20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
76044898|NCT05593393|Device|Endoscopic ultrasound|The EUS follow-up will be conducted at baseline and every 12 months thereafter. For patients with new WF or HRS in the evaluation, the follow-up physician and the patient can jointly decide whether to perform EUS evaluation in the 6 or 3 month intensive follow-up.
76044899|NCT05376163|Other|Survey Study|Headache Disabilty Index (HDI) will be applied.
75720771|NCT02598635|Drug|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
75720772|NCT00831246|Other|chewing gum - Extra Winterfresh|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
75720773|NCT00831246|Other|Standard Post-Op Care|Patients are given standard post-op care with clear liquid diet as tolerated.
75422106|NCT01447940|Device|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
75422107|NCT01447953|Other|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
76044900|NCT05374369|Diagnostic Test|SDC2 Gene Methylation Test and Q-FIT Test|Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test
76044901|NCT05374369|Procedure|Colonoscopy and/or pathological examination|Subjects underwent colonoscopy and/or pathological examination.
75422108|NCT01447953|Other|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
75422109|NCT01447966|Behavioral|Cognitive Behavioral Therapy|Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
75422110|NCT01447979|Device|portable artificial pancreas system with Control-To-Range algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
75422111|NCT01448005|Device|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
75422112|NCT01448018|Drug|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
75422113|NCT01448018|Procedure|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
75567450|NCT05754710|Drug|Xeljanz|Juvenile Idiopathic Arthritis (JIA) patients with Xeljanz
75567451|NCT05540353|Device|Transvaginal photobiomodulation|Low light laser therapy applied transvaginally using a small vaginal wand with sterile disposable wand covers. The intervention last 3-5 minutes based on a surface area calculation performed at the beginning of the intervention, and involves a gentle in and out motion of the wand to deliver light energy to the muscles of the pelvic floor.
75567452|NCT05540353|Device|Sham therapy|Use of the same vaginal wand as active arm, but without activation of the machine. The intervention last 3-5 minutes, and involves a gentle in and out motion of the wand to massage the muscles of the pelvic floor, without delivery of light therapy.
75567453|NCT05535153|Other|functional movement screen|The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
75567454|NCT05534152|Other|sumac|1% iranian brown sumac
75422114|NCT01448031|Drug|Capsule ASA 81mg/esomeprazole 20mg|Multiple doses administered on Day 1 to 5
75422115|NCT01448031|Drug|Acetylsalicylzuur Apotex Cardio|Multiple doses administered on Day 1 to 5
75422116|NCT01448070|Drug|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
75422117|NCT01448083|Other|Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.|Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
75422118|NCT01448096|Drug|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
75422119|NCT01448096|Procedure|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
75422120|NCT01448109|Drug|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
75422121|NCT01448109|Drug|Sterile air filled vial|"the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days"
75422122|NCT01448122|Other|Avene Compact Honey SPF 50|Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
75422123|NCT01448135|Other|VITAL AF|Semi-elemental, high protein, and high omega-3 fish oil enteral formula
76044902|NCT05610475|Diagnostic Test|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
76044903|NCT05382637|Drug|Somatropin|Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating
76044904|NCT05576389|Drug|Camrelizumab+Fluzoparib|Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
75720774|NCT04093271|Dietary Supplement|Rest-ZZZ|A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm
76044905|NCT04252807|Behavioral|Intervention arm|In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
75422124|NCT01448135|Other|Osmolite 1.2|High protein enteral formula
76044906|NCT04252807|Other|Treatment as Usual|The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
76044907|NCT05372653|Drug|OPA-15406|0.3% or 1% ointment, topical, twice daily, for 52 weeks
76044908|NCT05568511|Other|App-based exercise program|Remotely-controlled, app-guided exercise program
75422125|NCT01448148|Other|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
75422126|NCT01448148|Other|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
75422127|NCT01448174|Drug|Atorvastatin|"Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:~atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or~placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks."
75422128|NCT01448200|Drug|PPI-668|capsules
75422129|NCT01448200|Drug|Placebo|capsules
75422130|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
75422131|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
75567455|NCT05532397|Drug|QPOP category 1|combination regimens with published data in the setting of gliomas
75567456|NCT05532397|Drug|QPOP category 2|combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
75567457|NCT05529459|Procedure|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
75567458|NCT05527769|Procedure|mastectomy + immediate breast reconstruction|pre- or retro pectoral prosthesis
76044909|NCT05568511|Other|Standard of Care|These participants will follow the usual post-sepsis care after returning to home. The participants will be asked to log their daily activities in the app's health diary. The app will be activated for the baseline and follow-up physical function assessments, which will be supervised be a blinded coordinator via a video call.
76044910|NCT05372341|Other|descriptive|posotcovid patients will be elective surgery postoperative outcomes
75422132|NCT01448252|Biological|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
75422133|NCT01448252|Biological|T cell vaccination|Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
75422134|NCT01448265|Procedure|Cryoballoon ablation.|Cryoballoon ablation using a novel circular mapping catheter.
75422135|NCT01448278|Procedure|"All-inside"|"The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation."
75422136|NCT01448278|Procedure|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
75422137|NCT01448291|Drug|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
75422138|NCT01448304|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
75422139|NCT01448317|Drug|Alirocumab (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75422140|NCT01448317|Drug|Alirocumab (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
75422141|NCT01448317|Drug|Placebo (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75422142|NCT01448317|Drug|Placebo (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous"
75720775|NCT04093271|Drug|Active Comparator - Diphenhydramine HCl|DIN 02229960 encapsulated for blinding purposes
75422143|NCT01448330|Drug|HCP0911 / clopidogrel, aspirin|combination tablet vs coadministration
75422144|NCT01448343|Device|Fluid management system 2000 (FMS)|The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
75422145|NCT01448369|Device|Blephasteam|10 minute treatment twice daily
75720776|NCT04093271|Other|Placebo|No active ingredients
76044911|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
76044912|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
75422146|NCT01448369|Device|EyeGiene|10 minute treatment, twice daily
75422147|NCT01448369|Device|Hot compresses|10 minute treatment, twice daily
75422148|NCT01448382|Device|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
75422149|NCT01448395|Drug|[14C]NXL104|500mg/100mL intravenous solution
75422150|NCT01448434|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
75422151|NCT01448434|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
75720777|NCT00831402|Dietary Supplement|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
75875407|NCT03697746|Drug|paracetamol|paracetamol 1000 mg vial
76044913|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
76044914|NCT01660243|Drug|Placebo|Placebo (2capsules) once daily for 8 weeks
76044915|NCT05604703|Diagnostic Test|Periodontal classification|300 patients will be classified according to 1999 armitage and 2018 new periodontal classification and compared.
76044916|NCT05341687|Other|No applicable|No applicable
76044917|NCT05567263|Procedure|Bulk-fill resin composite, (3M, ESPE)|Teeth will be restored with Bulk-fill resin composite, (3M, ESPE)
76044918|NCT05567263|Procedure|Surefil one™ Self-Adhesive Composite Hybrid|teeth will be restored with Surefil one™ Self-Adhesive Composite Hybrid
76044919|NCT05341609|Drug|JT001|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
76044920|NCT05341609|Drug|Paxlovid|Day 1~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
75422152|NCT01448473|Other|4-views series|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
75422153|NCT01448473|Other|2-views serie|The 2-film series will include the following views: anterior-posterior and one lateral.
75422154|NCT01448499|Drug|Clozapine|escalating dose of clozapine up to 900 mg/day
75422155|NCT01448499|Drug|Amisulpride|escalating dose of amisulpride up to 800 mg/day
75422156|NCT01448499|Drug|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
75422157|NCT01448512|Behavioral|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
75422158|NCT01448512|Other|Usual Care|4 time matched sessions focused on health education
75422159|NCT01448538|Drug|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
75567459|NCT05526586|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
75567460|NCT05526586|Other|Zero Alcohol Gum Prototype|Participants will use 20 mL of Zero Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
75422160|NCT01448551|Behavioral|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
75567461|NCT05526586|Other|Alcohol Gum Prototype|Participants will use 20 mL of Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
75567462|NCT05526586|Other|Listerine Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
75720778|NCT00831402|Dietary Supplement|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
75422161|NCT01448564|Other|Laser therapy|The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
75875408|NCT03697746|Drug|Dexketoprofen Trometamol|dexketoprofen trometamol 50 mg bulb
75422162|NCT01448564|Other|Placebo laser therapy|The application of laser therapy will be a low intensity laser.
75422163|NCT01448603|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
75422164|NCT01448603|Biological|ToleroMune Ragweed|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
75422165|NCT01448629|Device|Standard Care|"Participants are using their own product and this procedure is called Standard Care.~Standard Care are the participants own products and may consist of several manufacturer and brand names."
75567463|NCT05526586|Other|5% Hydroalcohol|Participants will use 20 mL of 5% Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
75567464|NCT05525741|Other|Non segmental vitiligo|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~Inform the subject of the goals, constraints and risks of the study and obtain written consent.~Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
75875409|NCT03697746|Drug|Ibuprofen|ıbuprofen 400 mg vial
75875410|NCT03216265|Other|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
75875411|NCT03216265|Other|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
75875412|NCT03216265|Other|No treatment|No treatment.
75875413|NCT03697668|Drug|Imatinib|triple combination for the treatment of malaria
75422166|NCT01448629|Device|River|River is a new developed product with Coloplast as manufacturer
75422167|NCT01448642|Drug|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
75422168|NCT01448642|Drug|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
75422169|NCT01448681|Other|No Interventions|
75422170|NCT01448694|Other|No treatment|No treatment, only collecting observational data.
75720779|NCT00825240|Behavioral|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
75720780|NCT04090307|Behavioral|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for ~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
75720781|NCT04093115|Drug|CX1106|administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
75720782|NCT02548026|Behavioral|High Eating Frequency (High EF)|Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
75875414|NCT03697668|Drug|Dihydroartemisinin-piperaquine|standard malaria treatment
75875415|NCT04387812|Device|Xtrodes home PSG system|Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
75875416|NCT03700164|Other|Temperature|Water-perfused suit.
75875417|NCT03700086|Device|Disposable negative wound pressure device (PICO)|Application of a disposable negative wound pressure device for surgical site infection prevention.
75875418|NCT03700086|Device|OPsite post-op visible standard sterile dressing|Application of a standard sterile wound dressing.
75720783|NCT02548026|Behavioral|Low Eating Frequency (Low EF)|Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
75422171|NCT01448720|Drug|Paliperidone palmitate|Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
75422172|NCT01448733|Drug|Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening|Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
75567465|NCT05525741|Other|Health Volunteers|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~Inform the subject of the goals, constraints and risks of the study and obtain written consent.~Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
75875419|NCT04050384|Device|Baby GentleStick|The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
75875420|NCT03700008|Diagnostic Test|Speech analysis tool|Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
75875421|NCT03700008|Diagnostic Test|Conventional psychological measurements|Using well known and validated psychological measurements to identify the mental state of the participants.
75875422|NCT03697434|Behavioral|Palliative Care referral|Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
75875423|NCT03702738|Drug|N-acetyl cysteine|NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
75567466|NCT05524545|Drug|Evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
75875424|NCT03702660|Other|GIP(3-30)NH2|Peptide derived from the naturally occuring gut hormone GIP
75875425|NCT03702660|Other|Peripheral venous cannulation|Intravenous access for infusions
75875426|NCT03702660|Other|GLP-1|Peptide infusion
75875427|NCT04486950|Drug|TAK-951|TAK-951 intravenous infusion.
75875428|NCT04486950|Drug|TAK-951 Placebo|TAK-951 placebo-matching intravenous infusion.
75875429|NCT03699852|Radiation|Membracel and LED photobiomodulation|Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.
75875430|NCT03699852|Other|Membracel|This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
75875431|NCT03697200|Other|APA|Light touch using vaccaria seeds on specific points of the ear
75875432|NCT03697200|Other|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
75567467|NCT05524545|Drug|Enfortumab Vedotin|Nectin-4 directed antibody and microtubule inhibitor conjugate
75567468|NCT05524454|Device|Novel CBCT Imaging|One or two CBCT images are acquired on the novel CBCT imaging system.
75567469|NCT05516888|Procedure|radiofrequency of gasserian ganglion|radiofrequency ablation of the gasserian ganglion
75720784|NCT04092959|Behavioral|Walking|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
75567470|NCT05516888|Procedure|radiofrequency of the peripheral trigeminal branches|radiofrequency of the peripheral trigeminal branches ( maxillary, mandibular, supraorbital)
75567471|NCT05513742|Drug|CTX-009|IV infusion administered on day 1 and 15 of every 28-day cycle
75875433|NCT03697200|Other|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
75875434|NCT03697044|Procedure|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
75875435|NCT04693416|Other|Intrapersonal Stigma Reduction|Brief intervention for stigma reduction
75422173|NCT01448746|Drug|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
75567472|NCT05509608|Device|RM Electrode|The RM Electrode is a corneal ERG electrode. The distinguishing features of the RM electrode are that it is a soft contact lens with a recessed electrode (i.e. no metal electrode makes direct contact with the eye). The RM Electrode also has an integral speculum to hold the wearer's eye lids open. The electrode is designed for superior positional stability on the eye during testing. These features work together to improve ERG signal quality.
75567473|NCT05509608|Device|ERG Jet Electrode|The ERG Jet electrode is an FDA approved, commercially available corneal ERG electrode.
75567474|NCT05497843|Drug|Chiauranib|50mg, orally once daily
75567475|NCT05496673|Diagnostic Test|Pastorex Latex Agglutination Test|Rapid diagnosis of bacterial meningitis
75567476|NCT05496673|Diagnostic Test|Biofire PCR for meningitis|Rapid diagnosis of multiple forms of meningitis
75567477|NCT05496673|Diagnostic Test|Immy CrAg Lateral Flow Assay|Rapid diagnosis of cryptococcal meningitis
75567478|NCT05488626|Device|Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily online adaptation.
75567479|NCT05488626|Device|Non-Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily image guidance.
75567480|NCT05488626|Drug|Chemotherapy|Concomitant chemotherapy per NCCN or other national guidelines.
75720785|NCT04092959|Behavioral|Chinese square dancing group|Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
75875436|NCT04693416|Other|Interpersonal Stigma Reduction|Brief intervention for support persons of intrapersonal intervention participants.
75567481|NCT05488626|Drug|Immunotherapy|Adjuvant immunotherapy per national or institutional guidelines.
75567482|NCT05486338|Device|Hybrid Argon Plasma Coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
75567483|NCT05485415|Behavioral|Multimodal intervention|Participants in the intervention group will receive personalised advice on sleep, light exposure, meal times and physical activity.
75567484|NCT05485415|Behavioral|Control|General sleep advice
75567485|NCT05484258|Behavioral|Shared Medical Visit|Group visit wherein physician and Social Worker, would be discussing topics relevant to the population.
75567486|NCT05482919|Behavioral|Baseline Survey|The baseline survey, initial PHQ-9 and GAD-7, could be collected prior to surgery after consent, or on the day of surgery, for participants who are undergoing elective surgery or urgent procedures and did not attend pre-operative clinic. Demographic information such as race and ethnicity, pain medications and pain history and baseline self-reported health information will be collected. It will take about 15 minutes to complete.
75720786|NCT04092959|Behavioral|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
75720787|NCT00827580|Drug|Eniluracil|
75875437|NCT03699774|Drug|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
75875438|NCT03699774|Drug|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
75875439|NCT03699696|Drug|Propofol|Induction of anesthesia prior to surgery with propofol
75875440|NCT03699618|Drug|Anti-VEGF|Standard of care treatment with anti-VEGF only
75875441|NCT03699618|Other|Hemorrhage displacement + Anti-VEGF|Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections
75720788|NCT00827658|Procedure|Volar Wrist Block|"Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
75720789|NCT00827658|Procedure|Hypothenar Palm block|"Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
75875442|NCT03696966|Dietary Supplement|Portion-Controlled Meals|Increase dietary structure using portion-controlled meals (PCM)
75875443|NCT03696966|Behavioral|Low-Calorie Diet|Restrict calorie intake daily
75875444|NCT03696966|Behavioral|Intermittent Very-Low Calorie Diet|Severely restrict calorie intake intermittently
76044921|NCT05604391|Procedure|Free gingival graft placed apically|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.
75875445|NCT03702426|Drug|GMCSF|GMCSF 1.5mcg/Kg
75875446|NCT03702426|Drug|Norfloxacin|Tablet Norfloxacin 400 mg
75720790|NCT04094909|Drug|Rh-endostatin|"Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +[nab]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period."
76044922|NCT05604391|Procedure|Free gingival graft placed coronally|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
75720791|NCT05424731|Combination Product|DBV712 250 mcg|Daily epicutaneous delivery.
75720792|NCT02599571|Other|Very low nicotine content cigarettes|Cigarettes containing a reduced amount of nicotine
75720793|NCT02599571|Other|Conventional nicotine content cigarettes|Cigarettes containing a normal amount of nicotine
75720794|NCT00296491|Drug|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
75720795|NCT00296491|Drug|montelukast (MON)|montelukast capsule
75720796|NCT00296491|Drug|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
75720797|NCT00296491|Drug|placebo nasal|vehicle placebo nasal spray
75720798|NCT00296491|Drug|ADVAIR DISKUS|ADVAIR DISKUS
75720799|NCT00296491|Drug|placebo capsule|placebo capsule
75720800|NCT00296491|Drug|placebo DISKUS|placebo DISKUS
75720801|NCT00747617|Drug|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
75720802|NCT02599493|Drug|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
75875447|NCT00265941|Drug|cetuximab|Cetuximab 400 mg/m^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m^2 IV weekly for 7 weeks
75875448|NCT00265941|Drug|cisplatin|Cisplatin 100 mg/m^2 IV on days 1 and 22
75875449|NCT00265941|Radiation|Accelerated Fractionation by Concomitant Boost|3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks
75875450|NCT00265941|Radiation|Intensity-modulated radiation therapy|70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
75875451|NCT03696732|Other|Anxiety questionnaire|Spielberger. State-Trait Inventory questionnaire
75875452|NCT03696732|Other|VAS questionnaire|verbal numerical scale (VNS) anxiety score
75875453|NCT01568541|Drug|Regular toothpastes|One tooth brushing
75875454|NCT01568541|Drug|Children's toothpastes|One tooth brushing
75875455|NCT03699462|Drug|Plasma solution-A injection|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
75875456|NCT03699462|Drug|5% Albumin|The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
75875457|NCT03699384|Drug|Azacitidine|AZA 75 mg/m^2 SC or IV D 1-7 28 day cycle x 1
75875458|NCT03699384|Drug|Avelumab|Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
75875459|NCT03702348|Other|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
75875460|NCT03702192|Device|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
75720803|NCT02599415|Device|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
75720804|NCT04092725|Drug|DAB|Single oral 150-mg dose of DAB on Day 1 AM.
76044923|NCT05565079|Biological|Regenerative tissue matrix and enamel matrix derivative|Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).
76044924|NCT05565079|Biological|Regenerative tissue matrix|Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
75567487|NCT05482919|Behavioral|Post Operative Surveys|Post operative surveys will be collected at one week, two weeks, one month, then monthly up to 6 months after surgery with total of 7 post-op surveys. Refer to Table 1 for visit windows. The study survey could be collected by phone, REDCap texting or email per the subject's preference. Survey content will also include: daily average and maximum self-reported pain scores on a 0-10 Numeric Rating Scale (NRS) pain scale, average hours of sleep, anxiety and depression screens using the PHQ-9 and GAD-7 questionnaires (Months 1, 3, and 5), pain location and quality, percentage of day spent in pain, satisfaction with recovery using a five-point Likert scale, and type, quantity and timing of any medications used for pain (including opioid alternatives).
75720805|NCT04092725|Drug|SCY-078 plus DAB|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
75720806|NCT00296335|Drug|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
75720807|NCT00296335|Drug|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
75875461|NCT03699306|Procedure|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
75875462|NCT03624738|Procedure|Procedure|"Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used"
75875463|NCT04014231|Procedure|Diagnostic Imaging|Undergo placement of single wave application
75875464|NCT04014231|Other|Laboratory Biomarker Analysis|Correlative studies
75875465|NCT05378763|Drug|Poziotinib|Poziotinib tablets
75875466|NCT05378763|Drug|Docetaxel|Docetaxel IV infusion
75875467|NCT03697590|Drug|No curettage|Standard PDT without curettage
75720808|NCT04094597|Drug|Lactoferrin|lactoferrin is given orally in comparsion to placebp
76044925|NCT05341453|Procedure|Individual physiotherapy (SMA-SOC)|Therapeutic procedures according to the recommended standard (SMA-SOC) will be used in the therapy. Elements of breathing gymnastics, vibration techniques, stretching, eccentric and concentric exercise procedures will be combined. Individual physiotherapy will be conducted on the basis of set goals from the kinesiological examination, it will be adapted to the individuality of the child - his cooperation, fatigue and sleep time.
76044926|NCT05341453|Procedure|Hippotherapy|"HT by CP is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators anticipate it´s effect for children with SMA.~Based on a special type of examination, this method precisely determines the type / breed of the horse according to the biomechanics of the movement of its back in the step, the position of the child and the neurophysiological function of the back - differentiation or sensorimotor skills. Furthermore, according to the course of therapy, the physiotherapist determines the pace of the horse's step, its length, selects special manual contacts according to the current situation and adjusts the duration of therapy to the client's fatigue.~Therapy will be performed by therapists with professional competence to perform hippotherapy by children with CP."
76044927|NCT05341453|Procedure|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA. The purpose of this activity is to clean the horse, its possible guide, stroking and contact with the horse, work from the ground.
75720809|NCT04094597|Drug|Placebos|placebp is given in 2 ml saline
75422174|NCT01448759|Other|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
75422175|NCT01448772|Drug|Dronabinol Capsules, 5 mg|Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods
75422176|NCT01448772|Drug|Dronabinol Oral Solution|Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
75422177|NCT01448785|Device|abiliti system implant|Subjects will receive implanted abiliti System.
75720810|NCT04093037|Diagnostic Test|Time #1: Non Invasive Break-Up Time (NIBUT)|"A LacryDiag examination without dye will be realized. All measurements are made without contact. It's calculates the Non Invasive Break-Up Time (NIBUT), Tear Meniscus (TM) height (in millimeters) and number of Meibomian Gland.~These are different pictures taken with LacryDiag and analyzed."
75875468|NCT03697590|Drug|Curettage|Standard PDT
75567488|NCT05482919|Behavioral|Qualitative Interviews|Using sampling to identify adolescents who exhibit higher pain scores or prolonged opioid use compared to peers after completion of the first three surveys (pre-operative, Week 1, Week 2), the study will also select a representative sample of adolescents who are recovering as anticipated. Examples of delayed recovery include a higher proportion of moderate to severe pain scores, dissatisfaction with recovery and prolonged opioid use compared to peers. As a balancing measure, the upper limit of adolescents who are perceived to exhibit delayed recovery that are approached for interviews will be capped at a 3:1 ratio compared to those who are recovering as anticipated, and Investigators will prioritize an equal demographic distribution among the two groups. Interviews will take place over the phone or through a CHOP approved vendor at 1 and 3 months after surgery; audio will be recorded with participant consent.
76044928|NCT05538013|Other|Survey evaluation|Obesity awareness, physical activity, and sedentary time questionnaires will be applied to these cases.
75422178|NCT01448785|Device|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
75422179|NCT01448798|Procedure|Application of a hemostatic gelatin-thrombin matrix|Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
75422180|NCT01448798|Procedure|Use of mono- and bipolar electrocautery and surgical clips|Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
75422181|NCT01448811|Device|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI>40, titrate up propofol dosage, AAI<25, titrated down propofol dosage.
75422182|NCT01448811|Procedure|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
75422183|NCT01448837|Drug|Bimatoprost/Timolol, 24-hour intraocular pressure monitoring|Administered once in the evening
75422184|NCT01448837|Drug|Latanoprost, 24-hour intraocular pressure monitoring|assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
75422185|NCT01448863|Other|Culture medium metabolomic analysis|"During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile."
75422186|NCT01448889|Drug|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
75567489|NCT05477888|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,the Penn State Electronic Cigarette Dependence Index (PS-ECDI ).
75720811|NCT04093037|Diagnostic Test|Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score|"The MicroInstillation of fluorescein Break-Up Time (MIBUT) will be calculated by manual MIBUT and LacryDiag MIBUT.~The Oxford score will be calculated. It's used to clinically determine the severity of dry eyes with minimum score at 0 (none) and maximum score at 5 (very severity)."
75720812|NCT04093037|Diagnostic Test|Time #3: Standard Break-Up Time (SBUT)|The Standard Break-Up Time (SBUT) with fluorescein macroinstillation will be calculated by manual SBUT and LacryDiag SBUT.
75720813|NCT04093037|Diagnostic Test|Time #4: Schirmer test|The Schirmer test will be performed. It consists of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
76044929|NCT05371015|Procedure|quadratus lumborum nerve block (ropivacaine )|Echo guided quadratus lumborum nerve block with ropivacaine
75422187|NCT01448889|Drug|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
75422188|NCT01448902|Drug|OC000459|OC000459 200mg bid for 8 days
75422189|NCT01448902|Drug|Placebo|Placebo bid for 8 days
75422190|NCT01448928|Drug|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
75720814|NCT04093037|Diagnostic Test|Satisfaction questionnaire to the patient|A satisfaction questionnaire to the patient will be completed at the end of the participation at the study.
76044930|NCT05371015|Procedure|quadratus lumborum nerve block (normal saline)|Echo guided quadratus lumborum nerve block with normal saline
76044931|NCT05598463|Device|OASIS Pro|This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
75422191|NCT01448941|Procedure|Temporary extraarticular plate fixation|Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1
75422192|NCT01448941|Procedure|Primary arthrodesis|Primary arthrodesis
75720815|NCT01065961|Drug|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
75720816|NCT01065961|Drug|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
75422193|NCT01448941|Procedure|Primary arthrodesis TMT 2 and 3|Primary arthrodesis TMT 2 and 3 when instability is present
75422194|NCT01448980|Procedure|Thai Traditional Massage (TTM)|Thai Traditional Massage will receive massage 2 time per week for 6 weeks
75422195|NCT01448980|Procedure|Physical therapy program|Physical therapy program 2 times per week for 6 weeks.
75422196|NCT01448993|Drug|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
75422197|NCT01448993|Drug|Placebo|
75422198|NCT01449019|Drug|exendin(9-39)amide|intravenous infusion of exendin(9-39)
75422199|NCT01449019|Drug|saline|intravenous infusion of saline
75422200|NCT01449019|Other|duodenal meal|duodenal perfusion of a meal
75422201|NCT01449019|Other|duodenal saline|duodenal perfusion of saline
75422202|NCT01449032|Biological|MSC|No of cells after culture expansion
75422203|NCT01449032|Biological|Saline|3 cc saline
75422204|NCT01449045|Drug|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
76044932|NCT05340907|Device|Virtual Reality Device|A virtual reality headset is a heads-up display (HUD) that allows users to interact with simulated environments and experience a first-person view (FPV). VR headsets replace the user's natural environment with virtual reality content, such as a movie, a game or a pre-recorded 360-degree VR environment that allows the user to turn and look around, just as in the physical world. Patient undergoing bronchoscopy will be given the device before and during the procedure.
75422205|NCT01449045|Drug|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
76044933|NCT05309161|Dietary Supplement|Crassocephalum rabens extract|dosage: a capsule (180 mg)/day; duration: 1 month
75422206|NCT01449058|Drug|BYL719|taken orally
75422207|NCT01449058|Drug|MEK162|taken orally
75422208|NCT01449084|Procedure|immediate stent removal|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE"
75422209|NCT01449084|Other|Leaving the stent in place|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE"
75422210|NCT01449097|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
75422211|NCT01449097|Procedure|The femoral nerve block|US-guided femoral nerve block with ropivacaine
75422212|NCT01449097|Procedure|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
75422213|NCT01449110|Dietary Supplement|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:~capsule/day of placebo (350 mg maltodextrin) for 6 months~capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
75422214|NCT01449110|Dietary Supplement|Placebo in secondary prevention|"12 months follow-up:~capsule/day (350 mg maltodextrin) for 6 months~capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
75422215|NCT01449110|Dietary Supplement|Grape extract in primary prevention (PP)|"12 months follow-up:~capsule/day (350 mg grape extract) for 6 months~capsules/day (350 mg + 350 mg grape extract) for 6 months"
75422216|NCT01449110|Dietary Supplement|Grape extract in SP|"12 months follow-up:~capsule/day (350 mg grape extract) for 6 months~capsules/day (350 mg + 350 mg grape extract) for 6 months"
75422217|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
75422218|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
75422219|NCT01449123|Drug|Mannitol challenge test & reversibility test|"Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness"
75422220|NCT01449136|Other|Antibacterial cement|Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
75422221|NCT01449188|Drug|ondansetron|FDA approved drug used to treat nausea and vomiting
75422222|NCT01449188|Drug|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
75720817|NCT04092881|Device|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
75720818|NCT04092881|Device|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
75720819|NCT01068223|Drug|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
75720820|NCT01068223|Drug|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
75720821|NCT01068223|Drug|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
76044934|NCT05339659|Device|mHealth Intervention|Mobile health (mHealth) app to motivate and support quitting smoking.
75422223|NCT01449188|Other|saline|USP saline IV solution used as placebo for ondansetron IV.
75422224|NCT01449201|Drug|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
75422225|NCT01449214|Procedure|Ultrasound|Ultrasound-guided technique
75422226|NCT01449214|Procedure|Landmarking|Landmark-guided technique
75422227|NCT01449253|Drug|Sildenafil|20 mg initially and then increased to 20 mg TDS if there is no fall in BP
75422228|NCT01449253|Drug|Bosentan|Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
75720822|NCT03976609|Procedure|Maxillary Expansion|The patients with maxillary transverse deficiency were treated with Haas expander is a tooth and tissue-borne appliance with a jackscrew located at the anterior region of the arch with its arms bent posteriorly and soldered to the first permanent molar bands. Once activated, the appliances opens the palatal suture and increase the transverse dimension of the maxilla.
75422229|NCT01449292|Device|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
75720823|NCT02600273|Other|Usual brand cigarettes|Usual brand cigarettes
75422230|NCT01449292|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
75567490|NCT05477381|Diagnostic Test|Measurement of cervical stiffness by Pregnolia Device|"The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB.~The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix.~The Pregnolia® System will be applied within its intended use."
75720824|NCT02600273|Other|Lower nicotine content cigarettes|SPECTRUM research cigarettes
75875469|NCT05375799|Other|Clinical Observation|"This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects )."
75875470|NCT03636997|Procedure|Draining seton|Number 1 silk suture was passed through the fistula track and tied as loose seton
75875471|NCT03636997|Procedure|Rerouting of track|The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
75720825|NCT02600273|Other|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
75875472|NCT05420883|Other|Acupressure|One minute after the Nonstress test recording starts, sequential pressure will be applied to the Zhi yin (BL67) acupuncture points simultaneously for 2 minutes. The process will be repeated a second time, with a three-minute rest period. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
76044935|NCT02531113|Drug|RPC1063|
76044936|NCT05308069|Device|Single vision contact lens|Subjects will wear a single vision soft contact lens only during the study visit
75567491|NCT05474846|Drug|Melatonin|Given by PO
75567492|NCT05474846|Other|Placebo for Melatonin|Given by PO
75567493|NCT05474846|Drug|Melatonin|Given by PO
75567494|NCT05474846|Drug|Methylphenidate|Given by PO
75567495|NCT05474586|Other|Collavant n2 40 mg/day|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
75567496|NCT05474586|Other|Glucosamine hydrochloride & Chondroitin sulfate|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
75567497|NCT05474586|Other|Microcrystalline cellulose|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
75567498|NCT05473039|Dietary Supplement|Seidivid Ferty4|The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
75567499|NCT05473039|Other|Placebo|The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
75567500|NCT05472090|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
75720826|NCT02600273|Other|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
75567501|NCT05472090|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
75720827|NCT01069393|Other|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
75875473|NCT05420883|Other|Halojen ışık|One minute after the start of the Nonstress test recording, halogen light stimulation will be given from the mother's abdomen over the fetal head for 10 seconds and the procedure will be repeated after 10 minutes. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
75875474|NCT05420883|Other|Control|No application will be made to the control group. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
75422231|NCT01449318|Device|Thermal Sensory Analyzer (Senselab)|"Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.~To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.~To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C)."
75422232|NCT01449344|Drug|Rituximab|Rituximab 375mg/m² IV , day 1
75567502|NCT05470504|Drug|Pegvisomant|30 mg subcutaneously every day for 4 weeks.
75422233|NCT01449344|Drug|High dose Ara-C|Ara-C 2000 mg/m² (patients >65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
75422234|NCT01449344|Drug|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
75422235|NCT01449344|Drug|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
75422236|NCT01449357|Drug|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
75422237|NCT01449383|Dietary Supplement|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
75422238|NCT01449383|Dietary Supplement|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
75422239|NCT01449396|Other|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
75422240|NCT01449396|Procedure|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
75422241|NCT01449396|Procedure|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
75422242|NCT01449422|Device|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
75422243|NCT01449422|Device|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
75422244|NCT01449435|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
75875475|NCT04665973|Behavioral|Therapeutic patient education : oral semi-structured interview|The physiotherapist discusses and goes through each page of the booklet and involves the patient as much as possible. He demonstrates the exercises proposed in the booklet and then ask the patient to perform them in front of him. The physiotherapist tries to identify the patient's needs and suggests different ways to ensure that the patient has different opportunities to maintain the best possible level of PA
75422245|NCT01449448|Drug|Ketorolac|Subacromial injection
75422246|NCT01449448|Drug|Triamcinolone|Subacromial Injection
75567503|NCT05470413|Drug|SHR0302|SHR0302 4 mg
75567504|NCT05470413|Drug|SHR0302|SHR0302 8 mg
75422247|NCT01447992|Device|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
75422248|NCT01449474|Device|Patient matched instruments|The patients undergo TKA with using patient matched instruments
75422249|NCT01449474|Device|Jig based instruments|The patients undergo TKA with using jig based instruments
75567505|NCT05470413|Drug|Placebo|Placebo
75567506|NCT05467488|Procedure|photofunctionalization|UVA and UVC photofunctionalization of dental implants
75567507|NCT05461352|Drug|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
75567508|NCT05461352|Drug|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
75567509|NCT05458141|Behavioral|FYA-003|FYA-003: It is a gamified health education module for children aimed at promoting healthy nutrition, physical activity, health hygiene, and infectious diseases risk reduction within the clinically proven app fooya!
75720828|NCT00747461|Device|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
75720829|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
75720830|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
75422250|NCT01449487|Drug|PPC-5650|Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
75422251|NCT01449487|Drug|Placebo|Solution for administration in the rectum Identical tp active solution but without active drug
75422252|NCT01449500|Dietary Supplement|L. reuteri|Chewable tablet, one tablet/day for 28 days
75422253|NCT01449500|Dietary Supplement|Placebo|Chewable tablet, one tablet per day for 28 days
75422254|NCT01448954|Drug|ADC3680B oral|Once daily for 28 days
75422255|NCT01448954|Drug|Placebo oral|Once daily for 28 days
75422256|NCT01449552|Drug|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
75422257|NCT01449552|Procedure|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
75422258|NCT01449552|Other|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
75422259|NCT01449552|Other|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
75422260|NCT01449565|Drug|Naltrexone|3 monthly intramuscular injections of naltrexone 380 mg (extended release)
75720831|NCT01068301|Drug|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
75720832|NCT04999228|Drug|Infliximab|Infliximab will be administered intravenously at a dose of 5 mg/kg for 0, 2, and 6 weeks, then every 8 weeks for 1 year.
75720833|NCT04999228|Drug|Corticosteroids|Corticosteroid will be given at a dose of 1-2mg/kg/day (maximum 60 mg/kg/day),oral or intravenously for 12 to 14 weeks.
75720834|NCT04092491|Other|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~2 PAXgene RNA tubes of 2 ml each~1 dry tube for creatinine and IgA assay~1 tube of NFs (5ml)"
75720835|NCT01068379|Procedure|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
75720836|NCT01068379|Procedure|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
75720837|NCT04866550|Other|Data collection|Daily record of temperature, weight, heart rate, systolic blood pressure and oxygen saturation
75720838|NCT04092569|Behavioral|Pre-medical consultation structured diabetes self-care education programme|"The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki."
75720839|NCT01063465|Device|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
75720840|NCT03873766|Drug|Intrapleural Medications|The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
75875476|NCT04665973|Behavioral|Therapeutic patient education : booklet (passive)|The booklet (11 pages): explains why it is important to maintain a good level of PA as part of cancer treatment and reviews the most common side effects of cancer therapy and the relative importance of PA in combating these effects (pages 2-3) ; defines PA, its modalities and possible security precautions (pages 4-5), suggests exercises to be performed oneself and a target intensity to be reached (pages 6-8), provides a roadmap to be completed oneself (pages 9-10), and outlines procedures for joining an exercise medicine group (page 11).
75875477|NCT03696654|Procedure|adenotonsillar surgery|when indicated, adenotonsillar surgery for SDB treatment
75422261|NCT01449565|Drug|Placebo|3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
75422262|NCT01449578|Drug|Dexpramipexole|Oral Tablet at varying doses
75422263|NCT01449578|Drug|Dexpramipexole Placebo|Oral tablet at varying doses
75422264|NCT01449604|Radiation|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
75422265|NCT01449604|Radiation|stereotactic radiosurgery|Radio surgery 12 Gy
75422266|NCT01449617|Drug|Aspirin plus clopidogrel|"Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day."
75422267|NCT01449643|Device|Threshold|
75422268|NCT01449643|Device|Sham Threshold|
75422269|NCT01449656|Device|LMA Proseal: control device|LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization
75422270|NCT01449656|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children weighing 10-20kg based on a computer generated randomization
75422271|NCT01449695|Behavioral|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
75422272|NCT01449695|Behavioral|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
75422273|NCT01449695|Behavioral|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
75875478|NCT05420571|Procedure|digital impression|3D printed models after digital impressions
75422274|NCT01449760|Other|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
75422275|NCT01449760|Other|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
75422276|NCT01449773|Dietary Supplement|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
75422277|NCT01449773|Dietary Supplement|Placebo|5 capsules/day containing corn and soybean oil
75422278|NCT01449786|Drug|rMal d 1|25 µg daily as sublingually administered drops, 16 weeks
75422279|NCT01449786|Drug|rBet v 1|25 µg daily administered sublingually as drops over 16 weeks
75422280|NCT01449786|Other|placebo drops|25 µg of placebo Drops daily administered sublingually over 16 weeks
75422281|NCT01449799|Drug|GSK961081 800 microgram dose|To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
75422282|NCT01449799|Drug|Fluticasone Propionate 500 microgram dose|To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
75422283|NCT01449799|Drug|GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately|To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation
75422284|NCT01449799|Drug|GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend|To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
75422285|NCT01449825|Drug|Pazopanib use|Treatment with pazopanib
75422286|NCT01449825|Drug|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
75422287|NCT01449838|Drug|Colistimethate sodium|active
75720841|NCT03873766|Procedure|Surgery|The surgical arm will have either open surgery or a Video assisted Thoracoscopic Surgery (VATS) approach at the discretion of the surgeon
75720842|NCT03873766|Procedure|Pleural Sampling|Pleural fluid may be sampled by the responsible clinical service in the course of clinical care for patients with suspected pulmonary infection or by consulting service after identification of patient. Some patients will have a thoracentesis or tube drainage, and others will have no intervention at the time of referral for study eligibility review. Enrollment reflects real world clinical care and patients will be considered for enrollment regardless of sampling techniques or timing prior to evaluation
75875479|NCT05420571|Procedure|alginate impression|Alginate impressions after plaster model infusion to make models
75422288|NCT01449838|Drug|Saline|placebo
75567510|NCT05457985|Behavioral|Prolonged Exposure for Primary Care (PE-PC)|Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.
75567511|NCT05457985|Behavioral|Full Prolonged Exposure|Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.
75567512|NCT05457985|Behavioral|Clinician Supported PTSD Coach App|This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.
75567513|NCT05450133|Other|Systemic inflammatory index|neutrophil count x platelet count/lymphocyte count
75567514|NCT05450133|Other|BASDAI|Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.
75567515|NCT05450133|Other|ASDAS-ESR|The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
75567516|NCT05450133|Other|ASDAS-CRP|The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).
75422289|NCT01449877|Drug|Trimethoprim-Sulfamethoxazole|Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
75422290|NCT01449890|Behavioral|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
75422291|NCT01449916|Other|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
75422292|NCT01449942|Biological|DNAzyme targeting EBV-LMP1 (DZ1)|"DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
75567517|NCT05450133|Other|MASES|It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
75567518|NCT05447221|Diagnostic Test|The diagnosis of Artificial Intelligence and pathologists|Pathologists and AI will assess the severity of intestinal metaplasia and judge the tumor area of whole slide images of gastric biopsy specimens independently. In addition, the pathologists can not see the diagnosis of AI.
75567519|NCT05444361|Device|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
75875480|NCT03696420|Other|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
75875481|NCT00188695|Procedure|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
75875482|NCT05420415|Other|CSTME|Tumor microenvironment collagen signature
75875483|NCT03882957|Behavioral|Sustained attention|participants will complete a sustained attention task
75875484|NCT03882957|Behavioral|media multi-task|participants will complete multiple media tasks at the same time
76044937|NCT05308069|Device|Multifocal contact lens|Subjects will wear a multifocal soft contact lens only during the study visit
75567520|NCT05444361|Device|Sham Comparator|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
75422293|NCT01449942|Other|Saline|"0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
75422294|NCT01449968|Other|home visit|home visit of UMG
75720843|NCT03873766|Procedure|Pleural fluid drainage|All patients in the study must have tube thoracostomy for drainage of the pleural space. This may have been done by the clinically responsible team or by the study team. Physicians may select chest tubes of any type, but the minimum size is 14 French. For patency, chest tubes 14-20 French should be kept at negative 20 suction and flushed daily. Large bore chest tubes (>20French) may be kept at negative 20 suction at the discretion of the physician managing the chest tube and do not require daily flushing. Supportive care will follow Institutional Guidelines.
76044938|NCT05368519|Device|Brijjit®|Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
75422295|NCT01449968|Other|telephone management|telephone management of the situation reported by the patient's GP
75422296|NCT01449981|Behavioral|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
75422297|NCT01449981|Behavioral|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
75422298|NCT01449994|Device|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
75422299|NCT01450072|Device|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
75422300|NCT01450072|Other|Control arm|Venography and sham angioplasty
75567521|NCT05437679|Other|Blood collection|Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.
75567522|NCT05434117|Behavioral|High-intensity interval Nordic walking|Participants will complete supervised exercise sessions twice weekly for 10 weeks. Exercise specialists will educate participants in proper use of walking poles and basic Nordic walking techniques and supervise the exercise training sessions. HIIT-NoW will be 45 min in duration using Nordic poles and consists of (i) a 10-min warm-up at 30-59% heart rate reserve (HRR, light-to-moderate intensity); (ii) 4 × 4 min of high-intensity work periods at 60-89% HRR (vigorous intensity) interspersed with 3 min of low-intensity work periods at 30-59% HRR (light-to-moderate intensity); and, (iii) a 10-min cooldown at 30-39% HRR (light intensity). To allow participants to acclimatize to the HIIT-NoW protocol, the training intensity will target 60-69% HRR for the first week, 70-79% HRR in the second week, and 80-89% HRR from the third week onward. If participants do not tolerate 89% HRR well, they will exercise as close to 89% HRR as possible.
75567523|NCT05434117|Behavioral|Standard cardiovascular rehabilitation|Individuals assigned to standard CR will attend onsite exercise-based CR comprised of one onsite exercise session per week for 8-10 weeks. The onsite CR offers exercise sessions tailored to the fitness of patients and strengthening exercise.
75567524|NCT05419284|Other|GAPP+Care|"standard physiotherapy 45 minutes per day, 5 day a week (GAPP)~+ 3 extra exercise sessions led by a caregiver (+Care)"
76044939|NCT04255693|Behavioral|diet adherence|"This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes."
75422301|NCT01450163|Drug|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
75875485|NCT03882957|Other|Video|participants will watch a video of media tasks being completed
75875486|NCT04333290|Drug|[11C]MeDAS|PET radiotracer
75875487|NCT03201211|Biological|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
75422302|NCT01450163|Drug|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
75567525|NCT05419284|Other|+Care|"3 extra exercise moments led by a caregiver: one physiotherapist-caregiver-patient exercise session: the physiotherapist will educate and train the caregiver on the exercises and hands-on skills.~Two caregiver-patient exercise sessions"
75567526|NCT05419284|Other|Observation of GAPP+Care|Healthcare workers in the geriatric rehabilitation ward will be interviewed on their opinions on GAPP+Care
75567527|NCT05411718|Drug|Naproxen|Given by PO
75567528|NCT05411718|Drug|Aspirin|Given by PO
75720844|NCT03873766|Radiation|Protocol Image #1|"Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage. The choice of image, either Chest X-ray or CT Chest, is up to the discretion of the treating physician. Based on the imaging, patients will be separated into 2 groups:~A: Complete drainage/re-expansion of the lung: If there is complete drainage of the pleural fluid collection and lung re-expansion based on image #1, patients will follow usual clinical care without randomization and be observed until discharge. Patients will remain in the study and their data will be collected.~B: Incomplete drainage/incomplete lung re-expansion: For those patients that have incomplete drainage of the pleural fluid collection on image #1 and/or the lung does not re-expand."
75875488|NCT03201211|Biological|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
75567529|NCT05409976|Device|GORE® VIAFORT Vascular Stent|Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.
75422303|NCT01450267|Drug|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
75422304|NCT01450267|Drug|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
75567530|NCT05408572|Biological|SON-1010 (IL12-FHAB)|SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.
75567531|NCT05404230|Dietary Supplement|Fish oil|Fish oil containing poly unsaturated fatty acids.
75567532|NCT05404230|Dietary Supplement|Corn oil|Corn oil
75567533|NCT05402813|Other|Pure Tone Audiometry Assessment|Collection of Pure Tone Audiometry data performed in routine practice during study period
75567534|NCT05402813|Other|Quality of Life Questionnaires|Collection of Quality of Life questionnaire's answers during study period
75720845|NCT03873766|Other|Surgical Consultation|A thoracic surgery consultation will be obtained on all patients with incomplete drainage and/or the lung does not re-expand, to determine surgical candidacy. Those patients that the surgical team deem unsafe for surgery will receive clinically appropriate guideline centered, non-surgical, care. These patients will not be randomized but they will remain in the study and their data will be collected. Criteria deeming patients unfit for surgery include, but are not limited to: inability to tolerate single lung ventilation, severe chronic obstructive pulmonary disease (COPD), and risk of surgery prohibitive. Patients not excluded from surgery will be randomized.
76044940|NCT04255693|Behavioral|No diet adherence|"A-posteriori established intervention based on the examinations at the end-point"
76044941|NCT04255693|Behavioral|Change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
75422305|NCT01450436|Other|Peapod assessment|"EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old)."
75422306|NCT01450449|Radiation|Radiotherapy|25 Gy in 5 daily fractions over 1 week
75422307|NCT01450449|Radiation|Radiotherapy|40 Gy in 15 daily fractions over 3 weeks
75422308|NCT01450995|Drug|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
75422309|NCT01450995|Drug|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
75422310|NCT01451320|Drug|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
75422311|NCT01451320|Drug|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
75422312|NCT01451320|Drug|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
75567535|NCT05399433|Other|Biopsy and venous blood|"A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis"
75567536|NCT05397457|Device|low-level light therapy|"Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks."
75567537|NCT05396703|Procedure|TOETVA|Completed procedure.
75567538|NCT05395312|Other|Online blended stepped-care mental well-being platform|"Participants in experimental group will be stratified according to their level of anxiety and/or depressive symptoms.~Level 2 (normal range)~Topic-based personal growth articles, exercises, and chatbots~Webinars and talks on varied mental health related topics~Virtual support community~Level 3 (mild to moderate)~Online self-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~Offline/online skills-based workshops, questions-and-answers sessions, retreats~Level 4 (severe)~Online coach-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~Offline/online group therapy, 4-week group cognitive behavioural therapy or 8-week group mindfulness-based cognitive therapy"
75567539|NCT05395039|Other|VCHIPS|Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
75720846|NCT03873766|Radiation|Protocol Image #2: Chest X-ray PA/Lateral|The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained (protocol image #2). Based on Image #2 the patient will be categorized into one of three groups: satisfactory improvement of pleural fluid collection, unsatisfactory improvement in pleural fluid collection on imaging, or treatment failures.
75875489|NCT03201211|Biological|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
76044942|NCT04255693|Behavioral|No change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
75720847|NCT03873766|Behavioral|Quality of Life|Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires
75720848|NCT02598479|Other|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
75422313|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
75720849|NCT01069471|Biological|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
75720850|NCT04094129|Dietary Supplement|Wismemo|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
75720851|NCT04094129|Dietary Supplement|Placebo|placebo
75422314|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
75422315|NCT01451489|Drug|FK506|FK506:0.05-0.1mg/kg/d
75720852|NCT03683758|Other|FIFA11+|"The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential."
75875490|NCT03201211|Drug|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
75875491|NCT03727191|Other|Control Group (education, guidelines, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
75875492|NCT03727191|Other|Experimental Group (education, guidelines, 2 pckts diet, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
75875493|NCT04633837|Device|Extracellular Matrix Graft Injectable Implant|The extracellular matrix injectable implant will serve as the intervention in this study.
75875494|NCT03622437|Behavioral|Patient-led follow-up|"Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~- access to stoma care by specialist nurses"
75875495|NCT03622437|Other|Standard follow-up|"Patients with sphincter-preserving resection:~- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~outpatient visits at 3, 12 and 36 months~access to stoma care by specialist nurses~All patients:~CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
75875496|NCT05598879|Other|anonymized data collection during programmed surveillance clinical follow up|anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
75875497|NCT03540069|Behavioral|Care Group Cervical Cancer Screening Education Curriculum|a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
75875498|NCT04490343|Diagnostic Test|Abdominopelvic low dose CT|Patients with urinary stones will undergo multiple computed tomography (CT) examinations
75875499|NCT03696264|Dietary Supplement|Amino acid intake|Amino acid intake will range between 0.2-3.0g/kg/d
75875500|NCT04472949|Drug|Durvalumab|Durvalumab: 1500 mg iv
75875501|NCT04472949|Drug|carboplatin|Carboplatin: AUC 5 mg/mL/min iv
75875502|NCT04472949|Drug|etoposide|Etoposide: 100 mg/m2 iv
75875503|NCT04472949|Radiation|Thoracic radiotherapy|Thoracic radiotherapy: 39 Gy in 13 fractions, starting 3-8 weeks after day 1 of last cycle of induction treatment, over 2.5 weeks Prophylactic cranial irradiation (PCI) is allowed but optional: according to local practice, starting 3-8 weeks after day 1 of last cycle of induction treatment Follow up phase Patients will be followed up for 24 months, every 8 weeks.
75875504|NCT03696186|Drug|Luminal type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
75875505|NCT03696186|Drug|Luminal type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
75875506|NCT03696186|Drug|Neuroendocrine type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
75720853|NCT03683758|Other|'Usual' Soccer Warm-up|"This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement."
75720854|NCT03976921|Diagnostic Test|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
75875507|NCT03696186|Drug|Neuroendocrine type-2|Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
75875508|NCT03696186|Drug|Atypical type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
75720855|NCT03976921|Diagnostic Test|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
75720856|NCT04092023|Other|nursing education|Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
75720857|NCT04767958|Diagnostic Test|Spartan COVID-19 Platform|Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
75720858|NCT02599259|Device|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
75720859|NCT02600039|Other|ELTGOL|Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
75875509|NCT03696186|Drug|Atypical type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
75875510|NCT03699072|Device|DermaRep™ Wound Contact Device|Treatment of venous leg ulcers once weekly for 8 weeks along with standard of care dressings
75875511|NCT03964311|Other|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
75875512|NCT03698916|Drug|Celecoxib cream 8%|transdermal delivery of 8% Celecoxib
75875513|NCT03698838|Device|McDESPOT|MRI sequence, mcDESPOT (multicomponent driven equilibrium potential of T1 and T2) that utilizes a computer model that takes T1 and T2 sequences and derives a quantitative value for the myelin content in the myelin sheath
76044943|NCT04255693|Behavioral|Use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes."
75422316|NCT01451489|Drug|Cyclophosphamide|CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
75422317|NCT01451697|Behavioral|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
76044944|NCT04255693|Behavioral|No use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data."
76044945|NCT04248595|Drug|Homoharringtonine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
76044946|NCT04248595|Drug|Azacitidine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
75422318|NCT01451697|Behavioral|Control (Placebo)|The control condition will involve relaxation training.
75422319|NCT01451853|Drug|SPI-1005 Low Dose|"Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen"
75422320|NCT01451853|Drug|SPI-1005 Middle Dose|Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
75875514|NCT03695952|Drug|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
75422321|NCT01451853|Drug|SPI-1005 High Dose|Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
75422322|NCT01451853|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
75720860|NCT02600039|Device|Acapella|Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
75422323|NCT01452243|Drug|Vitamin D and calcium suplementation|The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
75422324|NCT01452256|Drug|Desflurane|4-6 Vol %
75422325|NCT01452256|Drug|Propofol|TIVA to achieve BIS value of 40-60
75720861|NCT01564810|Drug|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
75720862|NCT01564810|Drug|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
75720863|NCT04091945|Drug|LT3001 Drug Product|Active comparator
75422326|NCT01452373|Drug|Placebo|Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
75422327|NCT01452373|Drug|DHEA and Acolbifene|DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
75422328|NCT01452607|Drug|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
75422329|NCT01452607|Drug|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
76044947|NCT04247425|Other|Exercise Counseling|Receive instructional guidance
75422330|NCT01452672|Radiation|Radiotherapy|RT 40 Gy in 15 fractions
75422331|NCT01452672|Radiation|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
75422332|NCT01452958|Biological|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
75422333|NCT01452958|Biological|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
75422334|NCT01453062|Drug|Arzerra|Treatment with Arzerra
75422335|NCT01453283|Drug|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
75720864|NCT04091945|Drug|Placebo|Placebo comparator
75422336|NCT01453608|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
75422337|NCT01453608|Drug|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
75422338|NCT01454128|Behavioral|exercise|36 session supervised exercise intervention
75422339|NCT01454232|Other|stools sampling|stools sampling at baseline, 1, 3 and 12 months
75422340|NCT01454232|Other|adipose tissue biopsy|surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
75720865|NCT04091789|Drug|Pure Femme Tablets|A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
75720866|NCT04091711|Device|ReX-C system|Oral oncolytic medications are dispensed to patients via ReX-C system
75720867|NCT00916955|Other|Observation|Observe development of syndrome over time
75875515|NCT03695874|Other|Phase 1 : fill out 1 scale|"Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
76044948|NCT04247425|Other|Quality-of-Life Assessment|Ancillary studies
76044949|NCT04247425|Other|Questionnaire Administration|Ancillary studies
76044950|NCT04247425|Other|Resistance Training|Complete progressive resistance training
75422341|NCT01454375|Behavioral|Referral to QuitNow Services|QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
75422342|NCT01454700|Device|Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Randomization to 12 months with CSII plus CGM
75422343|NCT01454700|Other|Multiple daily insulin injections (MDI)|Randomization12 months therapy with MDI
75422344|NCT01454752|Drug|Intermittent parasite clearance|Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
75875516|NCT03695874|Other|Phase 2 : fill out 1 scale and 4 questionnaires|"Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
75875517|NCT04458597|Radiation|Image-guided adjuvant pelvic radiotherapy|Image-guided adjuvant pelvic radiotherapy delivered at an SBRT prescription dose of 30 Gy in 5 fractions if feasible, well-tolerated and effective for the adjuvant treatment of high-risk endometrial cancer.
75422345|NCT01454752|Other|Placebo|Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
75422346|NCT01454869|Drug|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
75567540|NCT05394987|Device|Spectacles|"Prescription of refractive error correction in spectacles.~Refractive error will be determined as part of a standard optometric eye exam (performed by a registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group [PEDIG] amblyopia clinical trial protocols): Hypermetropia - not under-corrected by more than +1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia - full correction of the anisometropic difference. Astigmatism - full cylinder power prescribed.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., more than 50% of waking hours) for the duration of the study."
75720868|NCT04094051|Drug|Ibrutinib|In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.
75720869|NCT04093895|Drug|PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) administration
75875518|NCT03695796|Diagnostic Test|biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank|To evaluate and improve the non-invasive diagnosis of liver fibrosis in NAFLD and to develop the non-invasive diagnosis of NASH
75875519|NCT03695640|Drug|Magnesium Sulfate|Addition of magnesium sulfate as an adjuvant to levobupivacaine
76044951|NCT05337709|Other|Education intervention and medication review|Education on osteoarthritis and pain management will be provided to the patients by face-to-face communication at the first meeting, aided with a leaflet, then patients will get the follow-up calls and a video will be shown to enforce the intervention. Medication review includes the assessment of patients' knowledge on the indication, identification of any drug-related problem, and counseling on the proper use of medication.
76044952|NCT05337397|Procedure|Laser ablation|Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.
76044953|NCT05337241|Device|Saline Enhanced Radiofrequency (SERF) Ablation|The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
76044954|NCT05336617|Procedure|colonoscopy|A colonoscopy is an exam used to examine the colon and rectum. During a colonoscopy, a long, flexible tube is inserted into the rectum. A tiny video camera at the tip of the tube allows the doctor to view the inside of the entire colon.
75720870|NCT00522418|Device|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
76044955|NCT05366335|Drug|Live Combined Bifidobacterium and Lactobacillus|The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
75422347|NCT01454869|Drug|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
75720871|NCT00522418|Drug|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
75720872|NCT00624780|Drug|Pregabalin|Pregabalin 150-300 mg given twice a day
75720873|NCT00624780|Drug|Lorazepam|Lorazepam 3-4 mg given twice a day
75720874|NCT00624780|Drug|Pregabalin|Pregabalin 450-600 mg given twice a day
75720875|NCT00624780|Drug|Placebo|Placebo
75720876|NCT00750893|Biological|Rotarix or Rotarix liquid formulation|GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine (oral suspension or prefilled syringe).
75720877|NCT01564888|Procedure|Ulnar artery compression|Compression of ulnar artery for 2 hours with radial artery hemostasis
75720878|NCT00753623|Drug|Ramelteon|ramelteon (8 mg)
75720879|NCT00753623|Drug|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
76044956|NCT05366335|Drug|Normal saline|The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
75422348|NCT01455116|Procedure|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
75720880|NCT02599337|Drug|Nexavar|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
76044957|NCT05366335|Drug|Basic treatment|The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
75422349|NCT01455259|Biological|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
75422350|NCT01455272|Procedure|prophylactic GPBPCI|A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
75422351|NCT05964387|Device|SDF|38% SDF will be applied to the hypoplastic area of the enrolled first permanent molar.
75422352|NCT05964387|Device|Placebo|An inert liquid will be applied to the hypoplastic area of the enrolled first permanent molar.
75422353|NCT05964374|Device|Goal-directed therapy|Goal-directed therapy using HemoSphere® monitor, Acumen® transducer, and Hypotension Prediction Index® algorithm (Edwards Lifesciences, Irvine, USA),
75422354|NCT05964348|Procedure|CT-Scan|semi-automated analyse by anatomical landmarks with a dedicated fully automated software
75720881|NCT02599337|Drug|Sorafenib|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
75720882|NCT00831636|Drug|CP-4055|D1-5 and D8(+2)-12(+2) q4w
75720883|NCT00831636|Drug|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
75720884|NCT00750737|Drug|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
75720885|NCT00750737|Drug|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
75720886|NCT04044612|Other|Medial Unloader Brace|medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
75720887|NCT04119934|Behavioral|Smoking Cessation Intervention Tool|A personalized smoking cessation infographic is provided to the physician/NP alongside the patient's regular spirometry report.
75720888|NCT04093505|Drug|Gemtuzumab Ozogamicin 147|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
75422355|NCT05964309|Other|supine group|after pre-oxygenation in supine position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
75422356|NCT05964309|Other|sitting group|after pre-oxygenation in sitting position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
75720889|NCT04093505|Drug|Gemtuzumab Ozogamicin 1|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
75720890|NCT04093505|Drug|Glasdegib|Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27
75720891|NCT04093505|Drug|Placebo Oral Tablet|Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27
75720892|NCT00622440|Drug|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
75720893|NCT00622440|Drug|Placebo|Placebo twice daily for 48 weeks.
75720894|NCT04759690|Behavioral|Action observation|Action observation group: The participants will first watch the conventional balance exercises with the action observation method on video for 15 minutes.After watching of conventional balance exercise for 45 minutes in 5-10 repetitions.
75720895|NCT04759690|Behavioral|Exercise group|Exercise group is the control group.TheParticipants will only do the conventional balance exercise without action observation for 45 minutes in 5-10 repetitions.
75720896|NCT02597777|Other|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
75720897|NCT02597777|Other|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
75720898|NCT00831714|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
75720899|NCT00831714|Drug|Standard care treatment for VTE prophylaxis|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
75720900|NCT02597699|Drug|Remifentanil + Lidocaïne|
75720901|NCT02597699|Drug|Sufentanil + Lidocaïne|
76044958|NCT05530915|Other|Gel capsule|Single capsule per dose
76044959|NCT05365399|Device|smartphone-based screening tool for neonatal jaundice|In this study we aim to collect data of newborns with wider range of bilirubin levels and high melanin content, and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors. .
76044960|NCT05334277|Drug|Furmonertinib|Furmonertinib 80mg QD
75875520|NCT03695640|Procedure|continuous femoral nerve block|continuous nerve block with levobupivacaine for treatment postoperative pain
75875521|NCT03702114|Device|auricular point detection|This device is only for auricular detection. No additional intervention will be delivered.
75875522|NCT03698760|Diagnostic Test|Olfactory test|"Olfactory test:~All fragrances tested are kept in an airtight case protected from cold and heat.~The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way."
75875523|NCT03702036|Drug|molibresib|molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
75875524|NCT03698682|Drug|Levofloxacin 500mg|One tablet per day for 7 days.
75422357|NCT05964270|Device|e-coach multipel myeloma (MM)|In this study we developed a multimodal patient-centered MM e-coach between September 2019 and June 2020. The content of the intervention consist of eight modules and was tested in a pilot study between June 2020 and August 2020 (F-ITUMM) 22. The e-coach is digitally managed, following three phases of the tiers of VBHC as presented in Figure 1. The tiers are classified in health status, process of recovery and sustainability of health 30. Furthermore, all medication information plus current dose and frequency per unit time are integrated in the e-coach. Reminders are sent if a session or a medication unit time is exceeded. Feasibility was tested for patients as well as healthcare professionals. The F-ITUMM trial concluded that the MM e-coach has the potential to support both recently diagnosed MM patients and healthcare professionals during MM treatment, and is a promising application to improve adherence .
75567541|NCT05391516|Diagnostic Test|Evaluation of shoulder problems|The developed items and Shoulder Pain and Disability Index-SPADI will be directed to the participants.
75567542|NCT05388890|Drug|MLD|Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
75567543|NCT05388890|Drug|WFC|Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
75567544|NCT05385432|Drug|Rabbit Anti thymocyte globulin (rATG)|The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
75720902|NCT00827736|Procedure|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
75875525|NCT03695562|Procedure|sequential drilling technique|Patient with vitamin D deficiency using sequential drilling technique
76044961|NCT05334277|Drug|Furmonertinib|Furmonertinib 80mg QD
76044962|NCT05334277|Drug|Furmonertinib/Pemetrexed/Carboplatin|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
76044963|NCT05334277|Drug|Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
75567545|NCT05385432|Drug|Basiliximab|Simulect® IV 40mg D0 and D4
75720903|NCT00827736|Drug|ISDN ointment|application of ISDN 1% ointment 6 times a day
75720904|NCT00827736|Drug|Placebo|"Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)"
75720905|NCT00744653|Procedure|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
75720906|NCT00998218|Drug|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
75720907|NCT00998218|Drug|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
75875526|NCT03695328|Behavioral|physical activity level|
75875527|NCT03695328|Behavioral|Dietary Intake|
75720908|NCT00825396|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
75720909|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
75875528|NCT04648098|Other|Discharge training and telephone counseling|"The discharge training was given by using different teaching methods in the form of verbal expression, demonstration, and question and answer. The care guide prepared by the researchers in line with the literature was used as a training material for stroke patients and their caregivers.The training varied according to the learning level of individuals but took an average of 40-60 minutes.~Consultation service was given to the caregivers one week after discharge and once a month for three months by telephone call."
75875529|NCT03029832|Drug|MOXR0916|MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
75875530|NCT03029832|Drug|Atezolizumab|Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
75875531|NCT04412187|Diagnostic Test|[18F]-GE-180 PET|serial [18F]-GE-180 PET imaging to assess microglia activation
75720910|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
75720911|NCT04044300|Procedure|Single screw fixation|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.
75875532|NCT04412187|Diagnostic Test|3T MRI|serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness
75875533|NCT04412187|Diagnostic Test|immune cell profiling in blood|Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.
75875534|NCT03695016|Behavioral|ActiveGOALs|13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
75875535|NCT04391595|Drug|Abemaciclib|100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
75875536|NCT04391595|Drug|LY3214996|400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
75875537|NCT04252638|Behavioral|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).
75875538|NCT04252638|Behavioral|Cognitive Behavioral Therapy including Sleep Restriction|CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
75875539|NCT05598567|Other|target controlled infusion - total intravenous general anesthesia|Both interventions are subtypes of general anesthesia.
75720912|NCT04044300|Other|Conservative|Continued pain management and physical therapy.
75720913|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
75875540|NCT05598567|Other|sevoflurane based balanced general anesthesia|Both interventions are subtypes of general anesthesia.
75875541|NCT03701880|Drug|Ivabradine|Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
75875542|NCT03701880|Drug|Bisoprolol|Bisoprolol is beta-blocker
75875543|NCT03692754|Drug|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 month
75875544|NCT03692754|Drug|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 month
76044964|NCT05363371|Behavioral|Minds and Mentors|Participants will be randomized into Minds and Mentors to attend weekly group therapy sessions for 12 week. The mindfulness-based relapse prevention therapy intervention will be led by a licensed counselor for eights weeks followed up by four additional sessions led by a certified recovery support specialist (peer mentor).
76044965|NCT05363371|Behavioral|Twelve Step Intervention Group|Participants will be randomized to the Twelve Step Intervention Group to attend weekly group therapy sessions for 12 week. The twelve step intervention group will be led by a licensed counselor.
76044966|NCT05363137|Other|Chatbot Assistant|The physiotherpy treatment will be supervised via chatbot
76044967|NCT05363137|Other|Standard care|The physiotherpy treatment will be standard care
75422358|NCT05964257|Drug|Botulinum toxin type A|Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
75875545|NCT03692754|Drug|Dexamethasone|Dexamethasone will be given in 40mg po qd for 4 days
75875546|NCT03692598|Device|MIA, Minimally Invasive Annuloplasty Device - Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach
75875547|NCT03692598|Device|MIA, Minimally Invasive Annuloplasty Device - Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach
75875548|NCT03694860|Other|questionnaire|Members of European society of anaesthesiology care will obtain an electronic survey considering their clinical practice in RSI
75875549|NCT03694782|Behavioral|Food diary supply|Each participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops from the garden. Away-from-home food consumption was not recorded. For each food purchase, participants provided details of date, place of purchase, foods purchased (name, quantity and expense incurred), and trip made (origin/where the trip started, destination/where the trip ended, and mode of transportation). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary. To facilitate data entry, all family members were encouraged to help filling out the diary.
75875550|NCT03694782|Behavioral|Actigraph|Participants were instructed to wear a triaxial accelerometer (wGT3X-BT or wActiSleep-BT, Actigraph, Pensacola, FL, USA) fitted with an elastic strap on right side of the hip for 9 consecutive days, except for bathing and performing activities in the water. The Actigraph was accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
75875551|NCT03694782|Behavioral|Questionnaire|Participants received by email a link to complete an online questionnaire about mental and social health, sensibility to food waste, and connection with nature
75875552|NCT03688308|Procedure|Arthroscopic rotator cuff repair with bone marrow aspirate concentrate|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique. Subjects will also be injected with bone marrow aspirate concentrate harvested from the pelvis and centrifuged prior to injection in the shoulder (produced using the Harvest/Terumo BCT system)
75875553|NCT03688308|Procedure|Arthroscopic rotator cuff repair|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique.
75875554|NCT03692520|Biological|SCT200|Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
75875555|NCT04224558|Drug|Mesna|"Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol."
75567546|NCT05385211|Other|Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency|Blood samplings; Glucose monitoring; CFTR variants
75875556|NCT04224558|Drug|Cyclophosphamide|"Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)"
75567547|NCT05379907|Other|SIGNATERA™ ctDNA testing|Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.
75720914|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
75875557|NCT04224558|Drug|Filgrastim|"Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of >1000/μL"
76044968|NCT05332717|Dietary Supplement|Melatonin 5 mg|Participants will be taking one 5 mg tablet of Melatonin 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
76044969|NCT05332717|Dietary Supplement|Placebo (Vitamin C)|Participants will be taking one placebo tablet 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
75567548|NCT05379270|Other|Diet soda|Participants will be asked to drink 24 ounces of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
75875558|NCT04224558|Procedure|Apheresis catheter placement|Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.
75422359|NCT05964257|Drug|normal Saline|Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
75422360|NCT05964244|Device|Vela Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
75422361|NCT05964244|Device|Nivairo Standard Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
75422362|NCT05964192|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|The theta burst stimulation (TBS) technique consists in administering bursts of transcranial magnetic stimulation (TMS) at very high frequency (50Hz) for 5 minutes (3 pulses of stimulation given at 50 hz; 10 bursts/1 s train; inter-train interval : 8 s; number of trains : 30; 100% resting motor threshold; number pulses/session : 900). Total number of sessions : 20 sessions (single daily session).
75567549|NCT05376579|Other|siponimod|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.
75567550|NCT05367037|Device|PhysioVP|The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.
75875559|NCT04224558|Procedure|Leukapheresis|Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10^6 CD34+ cells/kg body weight.
75720915|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
75422363|NCT05964166|Device|TetraGraph NMT Monitor|TetraGraph is a unique, EMG=based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
75422364|NCT05964140|Drug|Different post-operative antibiotic regimens following surgical treatment of mandible fractures|"The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control)."
75422365|NCT05964127|Device|Air flow device|An air/powder device for surface decontamination
75720916|NCT00311311|Drug|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
75720917|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
75875560|NCT04224558|Drug|Fludarabine|Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.
75875561|NCT04224558|Drug|Methylprednisolone|Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines
75875562|NCT04224558|Drug|Diphenhydramine|Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines
75875563|NCT04224558|Drug|Acetaminophen|Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
75422366|NCT05964127|Other|Hand instruments|Periodontal hand instruments
75422367|NCT05964127|Procedure|Access flap surgery|To improve the surgical access for implant decontamination
75567551|NCT05367037|Device|DDD-VPA|In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
75720918|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
75720919|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
75720920|NCT03854604|Other|postoperative pain assessment|evaluation of the efficacy of PI as an objective measure for postoperative pain assessment in pediatric population undergoing adenotonsillectomy.
75720921|NCT02599181|Other|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland.
75720922|NCT04089605|Drug|dexamethasone implant|intravitreal dexamethasone implant injections in vitrectomized patients with DME
75720923|NCT04089605|Drug|Ranibizumab|intravitreal ranibizumab injections in vitrectomized patients with DME
75875564|NCT04224558|Drug|anti-thymocyte globulin (rabbit)|Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.
75875565|NCT04224558|Drug|lymphocyte immune globulin|Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia & Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
75875566|NCT04224558|Biological|Peripheral Blood Stem Cell Infusion|PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.
75422368|NCT05964114|Drug|Vancomycin|Initial dosing based on (a combinations of) pharmacokinetic models tailored to the individual patient. Dose adjustment starting dose (within registered dosing range).
75422369|NCT05964101|Drug|Nivolumab Injection [Opdivo]|Neoadjuvant treatment stage: Nivolumab +Carboplatin AUC+ paclitaxel
75422370|NCT05964062|Device|active rTMS treatment|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
75422371|NCT05964062|Device|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
75422372|NCT05964049|Device|active rTMS treatment|Participants will receive 5 sessions per day of 1800 pulses per session, lasting for 15 days. Individualized targets will be generated using the pBFS method.
75567552|NCT05364905|Drug|Chemotherapy|Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
75720924|NCT02597621|Other|no intervention|no intervention
75720925|NCT02599025|Device|Innowalk cycling system|Innowalk is a unique, motorized medical device
75720926|NCT02599025|Device|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
75720927|NCT00521404|Drug|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
75720928|NCT00521404|Drug|gemcitabine|Gemcitabine - 1000mg/meter sq
75422373|NCT05964049|Device|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
75567553|NCT05360212|Procedure|Anatomy-based fitting (ABF)|MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
75567554|NCT05360212|Procedure|Standard Fitting|These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
75567555|NCT05360212|Procedure|Standard fitting+ ABF|Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
75567556|NCT05355428|Other|offering of breast milk feed 3 hours prior to p lanned surgery start|parents will be asked to offer a breast milk feed (from breast or expressed in bottle) at a given time 3 hours prior to planned induction time
75567557|NCT05354024|Biological|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)
75720929|NCT00311155|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
75720930|NCT03977077|Drug|Albumin binding taxol|125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
75422374|NCT05964036|Device|active TMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized target in the DMPFC will be generated using the pBFS method
75422375|NCT05964036|Device|sham TMS|The parameters in the sham arm are the same as in the active stimulation group. Stimulation was delivered by the same device as the active group fitted with a sham coil
75422376|NCT05964010|Behavioral|Standard Screening|All consented youth age 12-17 years complete a patient-facing, well-validated digital screening tool, the CRAFFT (Knight et al., 2003), which assesses number of days during the past year, and then the past 3 months, during which various formulations of AOD were used. If youth report 0 days of AOD use, the tool asks whether they have ridden in a car whose driver was intoxicated; if this response is negative, they are categorized Low Risk. If youth report > 0 days of AOD use, the tool asks five additional questions assessing use risk and consequences; also, youth who report nicotine use in the past 30 days complete a nicotine dependence checklist (DiFranza et al., 2002). Screen data are then combined to sort youth into three risk categories: Riding Risk Only (no reported AOD use but indicated rode in car driven by intoxicated person), Distant Use (reported AOD use in past year but not past 3 months), or Recent Use (reported AOD use in past 3 months).
75567558|NCT05354024|Biological|BNT162b2 30μg|Vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), 1 dose (booster)
75567559|NCT05352750|Biological|SON-1010|SON-1010 multiple ascending dose
75567560|NCT05349422|Behavioral|Electronic Health Record (EHR) Enabled Teamlets|The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
75720931|NCT03981679|Other|Biological collection|The biological collection will also include samples of blood samples collected before colonoscopy
75720932|NCT03981601|Drug|Lovastatin 40 MG|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
75720933|NCT03981601|Procedure|without drug with Bone graft|after tooth extraction, put teh bone graft wifin tooth socket
75720934|NCT00274651|Drug|belinostat|
75875567|NCT04224558|Drug|Cytoxan|Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
75875568|NCT03089697|Biological|N-Rephasin® SAL200|A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
76044970|NCT05506813|Other|cognitive training and conventional training|cognitive training along with conventional therapy
75567561|NCT05339490|Drug|Progenitor Biological Bandages|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
75567562|NCT05339490|Device|Jelonet|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, Jelonet, as standard bandages, will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
75720935|NCT01068691|Procedure|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|"Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)~Blood pressure~Obstructive sleep apnea syndrome (OSAS)~Carotid-to-femoral pulse wave velocity (PWV)~Biological parameters"
75720936|NCT00274261|Drug|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
75875569|NCT03089697|Other|Placebo|A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
75422377|NCT05964010|Behavioral|Standard Psychoeducation|In the wait area, youth receive a tablet-delivered brief digital AOD education tutorial that includes advice to abstain from or reduce AOD use. The tutorial focuses on adolescent AOD prevalence rates and related behavioral symptoms; AOD use neurobiology and its relation to adolescent health; and common AOD impacts on developmental milestones (see Meredith et al., 2021). Psychoeducation for AOD has shown positive effects as both a universal and selective prevention strategy (Bröning et al., 2021; Das et al., 2016).
75422378|NCT05964010|Behavioral|Standard Brief Negotiated Interview (BNI)|In primary care (PC) office, youth and providers together complete a tablet-supported brief negotiated interview (BNI; see Beaton et al., 2016). The BNI is informed by AOD use data gathered during youth screening (O'Grady et al., 2015). The BNI focuses on (a) education about AOD disorders, including youth and family factors that impact AOD use; (b) user-tailored feedback comparing the given youth's AOD use and related problems to national norms, along with information on neurobiological effects and developmental impacts of frequent use (Harris et al., 2012); (c) motivational tools (e.g., reduction readiness rulers) and decisional balance exercises (weighing positive versus negative personal impacts of AOD use) tailored to the youth's use levels (Slavet et al., 2006; King et al., 2009); and (d) AOD reduction goal-setting interventions tailored to the youth's readiness to change AOD use (Walton et al., 2013).
75720937|NCT00274261|Drug|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
75720938|NCT00624468|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
75720939|NCT00624468|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
75720940|NCT03976687|Drug|EYP001a|Oral tablets
75875570|NCT05598411|Drug|Oral Glucocorticoids|methylprednisolone 24mg qd, 2-week duration
75875571|NCT05598411|Drug|Oral placebo|oral placebo 24mg qd, 2-week duration
75875572|NCT03688230|Drug|abituzumab|1000 mg IV
75875573|NCT03688230|Combination Product|Placebo + Cetuximab + FOLFIRI|400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
75875574|NCT03694314|Dietary Supplement|Omega-3 fatty acids|200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).
75875575|NCT03694314|Dietary Supplement|Placebo|200 mL placebo fruit juice with no effect on the hypothesized outcome.
76044971|NCT05506813|Other|motor dual task training along with conventional therapy|motor dual task training along with conventional therapy
76044972|NCT05300269|Drug|SHR-1701；Capecitabine；Oxaliplatin|"Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m^2, day1, iv, q3w"
75567563|NCT05338528|Behavioral|BE-FIT exercise program|BE-FIT is an evidence-based exercise program that focuses on early mobilization and recovery by minimizing bed rest, promoting functional tasks, and encouraging self-management. The intervention ist based on the Mobilization of Vulnerable Elders (MOVE) program and consists of a bedside exercise plan, done independently by the patient without the need for additional rehabilitation or healthcare staff.
75567564|NCT05338060|Other|prospective collection of surgical exudates (SEs)|prospective collection of surgical exudates (SEs) from patients who are hospitalized for post-operative recovery from esophagectomy or gastrectomy for gastroesophageal cancer
75567565|NCT05330975|Biological|Placebo|0.9% sodium chloride (normal saline) injection
76044973|NCT05358301|Dietary Supplement|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).
76044974|NCT05358301|Dietary Supplement|Placebo|N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
75422379|NCT05964010|Behavioral|Standard Referral to Treatment (RT)|In primary care (PC) offices providers and youth discuss the value of attending counseling services to address AOD-related problems (Cucciare et al., 2015); counseling referral links that the PC site curates with local services; and the value of youth talking directly with caregivers about their AOD involvement as a first step toward support-seeking and behavior change (Gayes & Steele, 2014). Providers directly recommend AOD counseling and facilitate a first appointment for youth who agree.
76044975|NCT05329285|Procedure|Percutaneous Coronary Intervention (PCI)|Alternative treatment
76044976|NCT05356507|Other|Patient population|Questionnaires, standard of care
76044977|NCT05356273|Procedure|Baby massage|Starting from the baby's face first, then the abdomen and chest, back, upper extremities and finally the lower extremities were massaged with semi-circular movements, respectively.
75567566|NCT05330975|Biological|mRNA-1345|Sterile liquid for injection
76044978|NCT05299177|Device|InControl|Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
76044979|NCT05327569|Other|Myofascial Chain Release Techniques|Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.
75567567|NCT05330975|Biological|Afluria® Quadrivalent|single-dose, pre-filled syringe for injection
75567568|NCT05330975|Biological|mRNA-1273.214|Sterile liquid for injection
75567569|NCT05324982|Drug|Oral Placebo|Placebo will be orally self-administered by study participants.
75567570|NCT05324982|Drug|Oral CBG Cannabis|CBG cannabis oil will be orally self-administered by study participants.
75567571|NCT05324345|Behavioral|Prehabilitation group|All patients will be guided to use the network learning platform which including details in text, pictures and videos of their individualized prehabilitation strategy after a complete assessment. Multimodal prehabilitation strategy includes conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence), physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training), nutritional suggestion and optimization (whey protein supplement), and psychological therapy. All movements can be practiced with the reference to the standard videos in the network learning platform. Patients will check the prehabilitation content daily and form their own training tasks in the network learning platform. Standardized short message interviews will be sent to patients twice a week to optimize adherence and promote timely feedback.
75720941|NCT03976297|Other|Control Tower|A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
75720942|NCT00827814|Drug|Dutasteride|Dutasteride 0.5 mg od.
75720943|NCT01069783|Drug|A3309|A3309 in two different dosage levels
75720944|NCT01069783|Drug|A3309|A3309 in two different dosage levels for the duration of the study
75567572|NCT05320731|Procedure|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
75567573|NCT05320731|Procedure|Atomization with lidocaine|A simple atomization device as a modification of the McKenzie technique will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
75567574|NCT05319678|Other|evaluation with Meludia music software|"Measurement instruments:~- MuMu Questionnaire~MuRQoL Questionnaire~Questionnaire for subjects aged 6-17 years~Music tool Meludia (www.meludia.com)~Acoustic analysis of the voice: the Praat programme~Audiological tests"
75567575|NCT05319158|Other|MIT-PB, movement imitation therapy for preterm.|The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement
75567576|NCT05318638|Device|Soft robotic glove|The soft-robotic glove used in the study is the Carbonhand system (Bioservo Technologies, Sweden). It is a CE-marked medical device and it consists of a glove that supports finger flexion via sewn-in tendons and a control unit housing the actuators that pull on the tendons and the batteries. The grip support is activated by applying very light pressure on sensors in the fingertips of the glove, and de-activated by releasing the pressure on the sensors.
75567577|NCT05315674|Diagnostic Test|Frequent assessment of biomarker panel|During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
75567578|NCT05313724|Other|Mind-Body Online Therapy|There are 8 different modules (e.g. relaxation, mindfulness, stress management, disease management, nutrition and exercise behavior) with a mind-body focus available for the patients to independently (time, location) work on.
75567579|NCT05313464|Other|parent-pushed enteral feeding|skin-to-skin enteral nutrition pushed by the parent
75567580|NCT05313464|Other|syringe-push enteral feeding|skin to skin nutrition with syringe pump
75567581|NCT05311761|Other|CogMe Personal Assistant (PA)|Twice a day, in the morning and evening, the electronic tablet with the CogMe PA will be given to the patient by the research assistant. Patients will be asked to respond to a short question and answer (Q&A) session of approximately 5-10 minutes duration. This intervention will continue throughout the hospitalization period, estimated at approximately 5 days.
75567582|NCT05311215|Drug|SL-1002|SL-1002 injectable solution
75720945|NCT01069783|Drug|Placebo|Placebo comparator once daily for the duration of the trial
75720946|NCT00825474|Other|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
75720947|NCT03976765|Other|Rehabilitation program|The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
75422380|NCT05964010|Behavioral|Family Screening|Screening procedures incorporate procedures for youth described for Standard Screening. They also incorporate two sources of caregiver-report data. First is an estimate of youth AOD use based on the Screening 2 Brief Intervention tool (Levy et al., 2016). Second is a 9-item checklist of youth mental health (MH) problems (Achenbach & Rescorla, 2001). If both youth and caregiver report no AOD use or clinical-level MH problem, the family is categorized Low Risk. Otherwise, screen data are combined to sort families into three risk categories: Hidden SU Risk (youth reports AOD use in past year; caregiver reports no youth AOD use in past year), Named MH Risk (caregiver reports no youth AOD use in past year; caregiver reports clinical-level score for at least one youth MH domain), Named SU Risk (caregiver reports youth AOD use in past year).
75567583|NCT05311215|Drug|Placebo|Matching placebo injectable solution
75567584|NCT05310227|Device|Nerivio|The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
75567585|NCT05310175|Device|Electroacupuncture|Filiform needles (0.30×50mm, Hanyi brand, Beijing Medical Appliance, China) and the SDZ-V electric acupuncture (Suzhou Medical Appliance) apparatus will be used. After acupuncture at the acupoints group, the needle handle will be connected with the electrode of the electric acupuncture apparatus.
75720948|NCT01068847|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
75720949|NCT00827892|Drug|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
75720950|NCT00827892|Drug|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
75875576|NCT03694236|Drug|durvalumab|"Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated."
75567586|NCT05310175|Device|Sham acupuncture|Shallow needle insertion of 2-3 mm at sham acupoints without manipulation.
75720951|NCT00831948|Genetic|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
75875577|NCT04043364|Behavioral|LIVE|Learning, Innovation, Volunteers and Empowerment
76044980|NCT04254367|Behavioral|Learn-to-Cope|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
75720952|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
75422381|NCT05964010|Behavioral|Family Psychoeducation|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In the wait area, caregivers receive a tablet-delivered parenting tutorial that covers two AOD risk domains: education about adolescent AOD including prevalence rates, related behavior problems, neurobiological and health effects, and impacts on developmental milestones; and education and video modeling about parenting strategies that reduce or moderate AOD risk, including positive communication, fair and consistent discipline, and non-judgmental conversations about AOD use (Bo et al., 2018). Positive parenting education has been shown effective as a universal and selective prevention strategy in parent-focused AOD prevention trials (Kuntsche & Kuntshce, 2016; Ladis et al., 2019; Van Ryzin et al., 2017). Tutorials are tailored for each risk category.
75720953|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
75720954|NCT04043676|Drug|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
75720955|NCT01325935|Drug|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
75720956|NCT02549742|Procedure|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
76044981|NCT05326945|Other|Presence or Absence of a Blood Pressure Cuff Sheath|Monitoring of microorganism transfer from the sphygmomanometer to the patient, from the patient to the sphygmomanometer in case the sheath designed in the research is put on or not before the blood pressure measurement process
75720957|NCT02549742|Device|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
75720958|NCT02549742|Drug|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
75720959|NCT00521014|Biological|filgrastim|
75720960|NCT00521014|Biological|rituximab|
75720961|NCT00521014|Biological|sargramostim|
75720962|NCT00521014|Drug|carmustine|
75720963|NCT00521014|Drug|cytarabine|
75720964|NCT00521014|Drug|etoposide|
75720965|NCT00521014|Drug|melphalan|
75720966|NCT00521014|Procedure|autologous hematopoietic stem cell transplantation|
75720967|NCT00825552|Drug|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
75720968|NCT00560235|Drug|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
75720969|NCT00827970|Behavioral|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
75875578|NCT03692364|Device|Ceramic-on-ceramic uncemented hip arthroplasty|
75875579|NCT03692364|Device|Metal-on-polyethylene uncemented total hip arthroplasty|
75875580|NCT03688152|Drug|INCB053914|"Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
75875581|NCT03688152|Drug|INCB050465|"Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
75875582|NCT03692286|Combination Product|Silver nanoparticle/Calcium hydroxide|Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide
75720970|NCT00825708|Device|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
75720971|NCT00825708|Device|shamTMS|sham TMS session
75875583|NCT03692286|Drug|Silver Nanoparticles in gel form|Intracanal medication composed of silver nanoparticles in gel form
75875584|NCT03692286|Drug|Calcium Hydroxide Intracanal medication|Calcium hydroxide intracanal medication
75567587|NCT05309772|Diagnostic Test|Basophil activation test (BAT)|"Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT:~• BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c.~MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils."
75567588|NCT05309772|Diagnostic Test|Oral food challenge (OFC)|Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.
75567589|NCT05307289|Other|Biposy|Biopsy at inclusion visit and at disease progression if applicable
75567590|NCT05305443|Behavioral|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
75567591|NCT05305443|Behavioral|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
75567592|NCT05305443|Behavioral|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
75567593|NCT05305443|Behavioral|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.
75567594|NCT05304351|Biological|CRV-101 Vaccine Antigen High Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
75567595|NCT05304351|Biological|CRV-101 Vaccine Antigen Low Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
75567596|NCT05304351|Biological|Shingrix|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
75720972|NCT00291577|Drug|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
75720973|NCT00291577|Drug|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
75875585|NCT05654766|Diagnostic Test|Flow cytometry|Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.
75720974|NCT00520936|Drug|pemetrexed|1910 milligrams per meter squared (mg/m^2) (or 60 milligrams per kilogram [mg/kg] if patient <12 months old), intravenous (IV), for 21 days x 17 cycles
75720975|NCT02549430|Drug|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
75720976|NCT02549430|Drug|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
75720977|NCT02549430|Drug|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
75720978|NCT02549430|Drug|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
75720979|NCT02549430|Drug|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
75720980|NCT00828126|Procedure|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
75720981|NCT00947037|Drug|AP-CD/LD|
75875586|NCT05654766|Diagnostic Test|Platelet aggregation and plasma coagulation|Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
75875587|NCT03694080|Combination Product|Calcium electroporation|Patients with potentially curable colorectal rectal cancer will be treated preoperatively
75875588|NCT03624348|Behavioral|meditation|10 minute per day, 8 week digital meditation
75875590|NCT04059900|Drug|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
75422382|NCT05964010|Behavioral|Family Brief Negotiated Interview (BNI)|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In primary care (PC) offices, caregivers and providers together complete a tablet-supported parenting BNI informed by data from the caregiver screen only that parallels the youth BNI (e.g., AOD education, developmental risks) and also includes motivation, modeling, and goal-setting on positive parenting (e.g., non-judgmental conversations; see above) and effective parent-youth communication about AOD use (Carver et al., 2017).
75567597|NCT05304351|Biological|CRV-101 Vaccine Adjuvant High Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
75567598|NCT05304351|Biological|CRV-101 Vaccine Adjuvant Middle Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
75720982|NCT03867760|Behavioral|Recorded Hypnosis Intervention|The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
75720983|NCT03867760|Behavioral|Recorded Relaxation Intervention|The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
75720984|NCT00943839|Drug|sunitinib malate|
75720985|NCT00943839|Other|laboratory biomarker analysis|
75720986|NCT00943839|Other|pharmacological study|
75720987|NCT00832182|Drug|insulin aspart|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
75720988|NCT00832182|Drug|insulin NPH|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
75720989|NCT05280171|Other|Teach back|"Discharge information was explained by the principal investigator. On the day of discharge, pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.~Teach back is a approach which is used in cognitive psychology experiments describing repeating short sequences of information helps to improve repeat back of information. This teach back technique is recommended as a universal precaution by the agency for healthcare research and quality and the national quality forum."
75720990|NCT05280171|Other|Standard of care|Standard of care
75875591|NCT04059900|Drug|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
75875592|NCT04295148|Procedure|ACL Reconstruction with Semitendinosus graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft
75875593|NCT04295148|Procedure|ACL Reconstruction with Quadriceps tendon-bone graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
75567599|NCT05304351|Biological|CRV-101 Vaccine Adjuvant Low Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
75567600|NCT05304273|Drug|Mifepristone|Participants with 1st trimester miscarriage will receive for medical termination
75567601|NCT05304273|Drug|Letrozole|Participants with 1st trimester miscarriage will receive for medical termination
75567602|NCT05303805|Drug|Sevoflurane|Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
75567603|NCT05303805|Combination Product|Cyteal|Rinsing and cleaning of ulcer.
75875594|NCT03692130|Behavioral|Mindfulness, Acceptance and Commitment-Therapy|Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
75875595|NCT03692130|Behavioral|Jacobson|Relaxation treatment in technique of Jacobson
75567604|NCT05302921|Procedure|Cryoablation Therapy|"Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only."
75875596|NCT04203498|Drug|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
75567605|NCT05302921|Drug|Nivolumab|"Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
75567606|NCT05302921|Drug|Ipilimumab|"Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation [CD]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
75567607|NCT05302609|Biological|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in reinforcement of scleral thinning.
75567608|NCT05300503|Behavioral|Telehome Monitoring|Participants are enrolled into the Telehome Monitoring program
75567609|NCT05299112|Dietary Supplement|Arginine|The intervention parenteral nutrition contains additional arginine (18% arginine content) as compared to standard parenteral nutrition (6.3% arginine content).
75567610|NCT05297591|Other|assessment of UL function and prognostic factors|clinical assessments and questionnaires
75720991|NCT00952497|Drug|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
75875597|NCT04203498|Drug|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
75875598|NCT03687918|Other|Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions|"Principal Objective:~To assess the performances of QCAD/Lyon (AUC and its 95% confidence interval) in characterizing Gleason ≥7 cancers among the lesions delineated on mpMRI from the Dijon University Hospital.~Secondary Objectives:~To compare the diagnostic performance (AUC) of QCAD/Lyon and of the Likert score~To compare the diagnostic performance (AUC) of QCAD/Lyon and of the PIRADS v2 score~To define the best combination of quantitative parameters in the Dijon cohort (if different from that defined in Lyon)"
75720992|NCT04018716|Device|MTA|Indirect capping with MTA
75567611|NCT05296772|Biological|JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody|Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years
75567612|NCT05296772|Biological|Pembrolizumab - anti-PD-1 antibody|200 mg, once every three weeks until disease progression, withdrawal or up to two years
75720993|NCT04018716|Device|Dycal|Indirect capping with Dycal
75875599|NCT03691896|Dietary Supplement|Cholecalciferol 400|dose 400 UNT/day for 12 months
75567613|NCT05289271|Biological|Vaxelis™|Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
75567614|NCT05288374|Drug|Celecoxib 100 mg|Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
75720994|NCT00943995|Drug|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
75720995|NCT00828282|Drug|Simvastatin|Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
75567615|NCT05288374|Drug|Placebo|Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
75567616|NCT05287620|Device|Emerald device|The Emerald device is a wireless sensor that can track the motion, breathing, and sleep of participants without touching or requiring any interaction with the participants, allowing them to go about their normal lives. The Emerald device operates by transmitting and receiving low power radio signals that reflect off of the participant and return back to the device. The power of these signals is 1,000 times lower than what a typical Wi-Fi device transmits. The ability of the device to monitor gait, breathing, sleep, and other metrics has been validated and documented. Studies of the Emerald device in individuals with Parkinson's disease, Alzheimer's disease, and rare diseases have demonstrated the feasibility of monitoring at home and the ability to characterize gait, breathing, and sleep in these populations specifically. In this study, the Emerald device will be used to characterize the mobility, breathing and sleep of the participant.
75720996|NCT00952575|Drug|polyclonal anti-D immunoglobulin|single injection of 300 µg
75720997|NCT00952575|Drug|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
75720998|NCT04012125|Device|flexible thoracolumbar brace|Subjects would wear the flexible thoracolumbar brace over 18 hours a day
75720999|NCT03865732|Drug|Ganaxolone|active drug
76044982|NCT05354167|Other|muscle energy technique|the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session; this technique was applied in 2 sessions for a week for 4 weeks.
76044983|NCT05354167|Other|oscillating manual energy therapy|It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow.
76044984|NCT05353933|Other|Thread embedding acupuncture|Thread embedding acupuncture (TEA) that use chromic catgut thread with 3/0 size with 1 centimeter long for each acupoint (TRUSTIGUT® (C), CPT Sutures Co., Ltd, Ho Chi Minh, Vietnam). Every 2 weeks in 4 weeks (twice), 13 acupoints will be embedded including Xiawan (CV-10), Zhongwan (CV-12), Shangwan (CV-13) and Zusanli (ST-36), Neiguan (PC-6), Geshu (BL-17), Ganshu (BL-18), Pishu (BL-20) in both sides of the body.
76044985|NCT05353933|Drug|Pantoprazole 40mg|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP, Stellapharm J.V. Co., Ltd, Binh Duong, Vietnam) thirty minutes to one hour before the first meal once daily for 4 weeks.
76044986|NCT05325463|Procedure|conventional lung recruitment|The recruitment maneuver will be performed by pressure controlled mode maintaining a steady airway pressure of 15 cmH2O, with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 sec. The peak airway pressure will be maintained for 10 sec or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings.
75721000|NCT03865732|Drug|Placebo|inactive
75721001|NCT00944151|Procedure|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
75721002|NCT00998452|Behavioral|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
75721003|NCT00944307|Drug|raltegravir|raltegravir 400mg orally once
75721004|NCT00944307|Drug|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
75721005|NCT00520546|Other|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq [18F]Fluoroethylcholine chloride (FEC; Eckert & Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
75875600|NCT03691896|Dietary Supplement|Cholecalciferol 800|dose 800 UNT/day for 12 months
75875601|NCT03691896|Drug|Cholecalciferol 1200|dose 1200 UNT/day for 12 months
75875602|NCT03691818|Drug|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
75567617|NCT05284903|Other|Beamformer Benefit: Speech intelligibility and Listening effort|Confirm the improvement in terms of speech intelligibility (measured by OLSA, Oldenburg Sentence Test) and the reduction in terms of listening effort (measured by ACALES) of the I-BF (investigational Beamformer) compared to the R-BF (reference Beamformer), when speech is not coming from the front.
75567618|NCT05284903|Other|Speech Enhancer benefit: Speech intelligibility, Listening effort and Subjective Speech intelligibility|"Confirm the improvement in terms of speech intelligibility (measured by Oldenburg Sentence test) and the reduction in terms of listening effort (measured by ACALES) when the Speech Enhancer is on (SE ON) compared to Speech Enhancer is off (SE OFF) for distant speech or speech from adjacent room.~Confirm the improvement in terms of subjective level to follow a conversation in quiet when SE ON compared to SE OFF for distant speech or speech from adjacent room. Measured by a subjective assessment."
75567619|NCT05284903|Other|Hearing aid benefit: Speech intelligibility in noise (unaided vs aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) in noise with the investigational device (aided condition) compared to the unaided condition.
75721006|NCT00520546|Other|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
75721007|NCT00952887|Biological|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
75875603|NCT03691818|Drug|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
75875604|NCT03691818|Drug|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
75875605|NCT03691818|Drug|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
75721008|NCT00952887|Biological|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
75875606|NCT03687840|Diagnostic Test|gait analysis|Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
75567620|NCT05284903|Other|Hearing aid benefit: Speech intelligibility in noise (aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) with the Reference binaural beamformer compared to the fixed directional.
75567621|NCT05278104|Drug|Zentiva®|Zentiva®
75567622|NCT05278104|Drug|Placebo|Placebo
75875607|NCT03693924|Radiation|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
75875608|NCT03687606|Drug|Human Chorionic Gonadotropin|White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
75875609|NCT03687606|Drug|human menopausal gonadotropin|White freeze-dried cake or powder with specification of 75IU.
75875610|NCT03691740|Device|Ocular light|A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
75875611|NCT04059978|Drug|CBD|1600mg cannabidiol, single oral dose (8 ml oily solution)
75875612|NCT04059978|Drug|Placebo|Placebo p.o, single oral dose (8 ml oily solution)
75875613|NCT04059978|Drug|Remifentanil|Remifentanil 0.1 µg/kg/min i.v. for 30 min
75875614|NCT03199963|Drug|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
75875615|NCT03199963|Drug|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
75567623|NCT05266963|Drug|CREON|The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
75567624|NCT05266963|Drug|Placebo|Placebo
75567625|NCT05260658|Drug|CFTX-1554|CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).
75567626|NCT05260658|Drug|Placebo|CFTX-1554 matching placebo
75721009|NCT00555009|Drug|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
75721010|NCT00555009|Drug|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
75721011|NCT04000516|Behavioral|Time restricted feeding|Restricting the eating window to about 8 hours a day, during waking hours.
75721012|NCT00944385|Drug|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
75721013|NCT01529775|Device|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
75721014|NCT01529775|Device|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
75721015|NCT00953277|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
75875616|NCT04547257|Device|Seraph 100|Bloodfiltration with Seraph 100
76044987|NCT05325463|Procedure|ultrasound- guided lung recruitment|The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area was visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit was 40 cmH2O.
76044988|NCT05353855|Other|No intervention|No intervention
75567627|NCT05255289|Procedure|Urodynamic investigations before and after a trans-obturator tape protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)
75567628|NCT05255289|Procedure|Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O)|Urodynamic investigations (stated above.)
75567629|NCT05255289|Procedure|Urodynamic investigations before and after a mini Arc protocol.|Urodynamic investigations (stated above)
75567630|NCT05255289|Procedure|Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.|Urodynamic investigations (stated above)
75567631|NCT05254587|Device|IOLMASTER 700 TK|4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.
75567632|NCT05250024|Device|UHMWP Cranioplasty|patient specific cranial implant
75567633|NCT05250024|Device|PEEK Cranioplasty|patient specific cranial implant
75567634|NCT05248399|Behavioral|COVID-19 Group Problem Solving|The COVID-19 Group Problem Solving component incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a ~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe & Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.
75567635|NCT05248399|Behavioral|Standard of Care|The standard of care consists of the distribution of brochures containing COVID-19 prevention information.
75567636|NCT05245916|Drug|IBI397|IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
75875617|NCT03636685|Drug|Anlotinib combined with pemetrexed and carboplatin, phase I|"Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
75875618|NCT03636685|Drug|Anlotinib combined with paclitaxel and carboplatin, phase I|"Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
75875619|NCT03636685|Drug|Anlotinib combined with pemetrexed and carboplatin, phase II|Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
75567637|NCT05245916|Drug|IBI397+Sintilimab|IBI397 in combination with sintilimab： Subjects will receive IBI397 combination therapy with sintilimab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
75567638|NCT05245916|Drug|IBI397+Rituximab|IBI397 in combination with rituximab： Subjects will receive IBI397 combination therapy with rituximab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
75721016|NCT00953355|Drug|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
75721017|NCT00953355|Drug|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
75875620|NCT03636685|Drug|Anlotinib combined with paclitaxel and carboplatin, phase II|"Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent"
75875621|NCT03788941|Procedure|left atrial appendage closure and catheter ablation|"Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation."
75721018|NCT00944463|Drug|Gemcitabine+simvastatin|Gemcitabine and simvastatin
75721019|NCT00944463|Drug|Gemcitabine+Placebo|Gemcitabine plus Placebo
75721020|NCT00947583|Biological|Osteocel Plus|biologic
75721021|NCT00956397|Drug|Rifaximin|rifaximin 550 mg TID PO x 10 days
75721022|NCT00956397|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
75721023|NCT00956397|Drug|Placebo|placebo TID x 10 days
75721024|NCT00953433|Device|Endoflex tube|Size decided upon gender.
75721025|NCT00953433|Device|Polyvinyl chloride endotracheal tube with a stylet|Size decided upon gender.
75567639|NCT05240846|Procedure|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
75567640|NCT05240846|Procedure|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on ultrasound assistance paramedian spinal. Spinal anesthesia with a paramedian approach was performed based on the optimum puncture point, suggested puncture angles, and puncture depth. The suggested puncture angles included the cephalad angle measured by the built-in angle program of the ultrasound and the medial angle measured by a 180° protractor (Deli). The puncture depth, the distance from the skin to the posterior complex, was measured utilizing the ultrasound clipper tool.
75875622|NCT03883581|Drug|dextromethorphan HBr and quinidine sulfate|All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
75875623|NCT03824535|Procedure|Computed Tomography|Undergo PET/CT
76044989|NCT05352685|Drug|Propofol Injection|1% propofol is used for target-controlled infusion, and gradually increase the effect concentration at 0.2ug/ml. Make the subject's sedation depth reach light sedation and deep sedation respectively. EEG data were collected during wakefulness, light sedation, deep sedation, and recovery.
76044990|NCT05351281|Device|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient with a life expectancy of less than 3 months.
75567641|NCT05237947|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
75567642|NCT05237947|Other|Questionnaire Administration|Ancillary studies
75567643|NCT05237947|Biological|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
75567644|NCT05237947|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
75567645|NCT05233488|Device|Pulsed Ultrasound Therapy|Ultrasound therapy is applied in the pulsed mode.
75567646|NCT05230368|Drug|Decitabine cycle 1|Decitabine administration (5mg/m²) at days 1, 2, 3
75567647|NCT05230368|Drug|Romidepsin cycle 1|Romidepsin administration (5mg/m²) at days 4, 11, 18
75721026|NCT00953511|Genetic|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
75721027|NCT05300373|Diagnostic Test|ADENOSINE DEAMINASE TEST|ADENOSINE DEAMINASE DEFICIENCY TEST
75721028|NCT00956475|Behavioral|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
75567648|NCT05230368|Drug|Decitabine cycle 2|Decitabine administration (5mg/m²) at days 35, 36, 37
75567649|NCT05230368|Drug|Romidepsin cycle 2|Romidepsin administration (5mg/m²) at days 38, 45, 52
75567650|NCT05230368|Drug|Decitabine cycle 3|Decitabine administration (5mg/m²) at days 70, 71, 72
75567651|NCT05230368|Drug|Romidepsin cycle 3|Romidepsin administration (5mg/m²) at days 73, 80, 87
75721029|NCT00956475|Other|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
75721030|NCT00956475|Procedure|assessment of therapy complications|questionnaire via telephone
75721031|NCT00956475|Procedure|fatigue assessment and management|questionnaire via telephone
75721032|NCT00956475|Procedure|psychosocial assessment and care|questionnaire via telephone
75721033|NCT00956475|Procedure|quality-of-life assessment|questionnaire via telephone
75721034|NCT00956553|Biological|Cervarix|Three doses of Cervarix at month 0, 1 and 6.
75567652|NCT05230368|Drug|Decitabine cycle 4|Decitabine administration (5mg/m²) at days 105, 106, 107
75567653|NCT05230368|Drug|Romidepsin cycle 4|Romidepsin administration (5mg/m²) at days 108, 115, 122
75567654|NCT05223478|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
75567655|NCT05223478|Drug|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
75567656|NCT05219565|Device|Attractive Targeted Sugar Bait (ATSB)|An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
75567657|NCT05216068|Diagnostic Test|NGS|Based on the next generation sequencing (NGS), WES can identify single nucleotide variants (SNVs) and small variants.
75567658|NCT05212298|Dietary Supplement|The gel contains a mixture of glucose and maltodextrin|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
75567659|NCT05212298|Dietary Supplement|Herbal compound low-dose|The total amount of herbal compound capsules is 557 mg.
75567660|NCT05212298|Dietary Supplement|Herbal compound high-dose|The total amount of herbal compound capsules is 1114 mg.
75567661|NCT05206084|Device|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)|Subjects in this arm will be treated with IBS
75567662|NCT05206084|Device|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|Subjects in this arm will be treated with XIENCE
75567663|NCT05205499|Device|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System|Subjects in this arm will be treated with IBS
75721035|NCT00956553|Biological|Gardasil|Three doses of Gardasil at month 0, 1 and 6.
75875624|NCT03824535|Drug|Fludeoxyglucose F-18|Given IV
75875625|NCT03824535|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
75875626|NCT03824535|Procedure|Positron Emission Tomography|Undergo PET/CT
76044991|NCT05321875|Drug|Candesartan|3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
75422383|NCT05964010|Behavioral|Family Facilitated Conversation (FC) & Referral to Treatment (RT)|In PC offices, providers meet separately with youth and caregivers to discuss the value of talking directly with the other family member about AOD risk while practicing positive communication strategies. Whenever both youth and caregiver agree to talk together, providers convene a brief facilitated conversation about AOD risk. In this conversation providers (a) emphasize that a positive youth-caregiver relationship is the strongest protective factor for youth development and (b) follow guidelines for brief triadic risk-reduction interventions focused on positive family communication about AOD risk (Guilamo-Ramos et al., 2020). When indicated, providers directly recommend AOD counseling and facilitate a first appointment for families who agree.
75422384|NCT05963971|Behavioral|PEDALL|twenty-six hour nutrition education intervention delivered virtually over a six month period
76044992|NCT05346367|Radiation|SRT|SRT
75422385|NCT05963971|Other|Standard of care|Nutrition education per institutional standard of care
75422386|NCT05963958|Combination Product|Active HD-tDCS|Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
75422387|NCT05963958|Combination Product|Sham HD-tDCS|Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
75567664|NCT05205161|Drug|AZD0466|All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
75567665|NCT05193526|Other|No intervention|No intervention
75567666|NCT05192421|Behavioral|Wellness Education|Receive wellness education through a weekly email and web portal content.
75567667|NCT05192421|Behavioral|Exercise Videos|Receive pre-recorded exercise videos through a weekly email and web portal content.
75567668|NCT05192421|Behavioral|Livestream Classes|Receive 3 videoconference group exercise classes per week for 8 weeks.
75567669|NCT05188222|Drug|Maltodextrin solution|The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water
75721036|NCT00953589|Drug|ribavirin|Ribavirin - oral administration Subjects with body weight < 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight > 105 kg: 1400 mg/day
75721037|NCT04011501|Procedure|Continuous Erector spinae block|Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
75721038|NCT00947739|Drug|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
75875627|NCT03113643|Drug|Azacitidine|Chemotherapy
75567670|NCT05188222|Drug|Placebo solution|Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
75567671|NCT05182242|Other|Collection of clinical data|family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.
75567672|NCT05182242|Biological|Collection of samples|"Collected during fetal and blood sampling performed as part of care for ACPA:~4 Streck tubes maximum for the pregnant woman for NIPD-Exome, collected prior to invasive fetal sampling~1 additional vial of fetal sample (amniotic fluid or fetal blood) and 1 EDTA tube for each of the two parents"
75567673|NCT05182242|Other|Questionnaires|within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties
75567674|NCT05182242|Other|Parent interviews|as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy
75567675|NCT05182242|Other|Professional interview and focus groups|Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician
75567676|NCT05181137|Drug|SHR0302|Oral tablets taken once daily (QD)
75567677|NCT05181137|Drug|Placebo|Oral tablets taken once daily (QD)
75567678|NCT05177510|Drug|Mifepristone|Progestin Antagonist
75567679|NCT05177510|Drug|Placebo|Placebo
76044993|NCT05346367|Radiation|fSRT|fSRT
76044994|NCT02522767|Drug|Mesalamine|
76044995|NCT02522767|Drug|Placebo|
76044996|NCT05319847|Dietary Supplement|Daily Skin Supplement - Fountain of Youth|Skincare supplement
76044997|NCT02522377|Drug|Ketamine|inter venous injections
75721039|NCT00956787|Drug|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
75721040|NCT00947817|Other|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
75721041|NCT00947895|Drug|Methylprednisolone|IV 1000 mg daily for 3 days
75721042|NCT00947895|Drug|ACTH|IM ACTH 80 mg/day for 5 days.
76044998|NCT02522377|Drug|Midazolam|inter venous injections
76044999|NCT05319613|Other|Virtual clinical visits with home lab kits and mailed HIV PrEP|Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
76045000|NCT05319067|Other|Stool sampling|Stool sample taken at home 24 hours before hospital visit
75567680|NCT05176860|Device|CBCT Imaging|Two research CBCT images will be acquired per subject.
75567681|NCT05174338|Other|Registry|Observational, data collection
75422388|NCT05963945|Device|Carebot AI CXR|The proposed DLAD (Carebot AI CXR) is a deep learning-based medical device designed to assist radiologists in interpreting chest X-ray images acquired in anteroposterior (AP) or posteroanterior (PA) projection. By employing advanced deep learning algorithms, this solution enables automatic detection of abnormal findings by analyzing visual patterns associated with specific conditions. The targeted abnormalities include atelectasis (ATE), consolidation (CON), pleural effusion (EFF), pulmonary lesion (LES), subcutaneous emphysema (SCE), cardiomegaly (CMG), and pneumothorax (PNO). The DLAD functions as a prediction algorithm complemented by various application peripherals, such as web-based communication tools, DICOM file conversion capabilities, and storage and reporting libraries supporting both DICOM Structured Report and DICOM Presentation State formats.
75422389|NCT05963919|Other|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
75567682|NCT05174286|Behavioral|SBIRT|"SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~The investigators will utilize the Culturally-adapted Alive! Program - a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
75567683|NCT05174286|Behavioral|Referral as Usual (RAU)|Referral as Usual will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
76045001|NCT05553457|Device|Testing of MyHand-SCI Device|Subjects will attend 1-20 sessions (approximately 90 minutes) to trial the MyHand-SCI device, including a variety of controls and components.
75875628|NCT03113643|Drug|SL-401|SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
75875629|NCT03113643|Drug|Venetoclax|Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
75721043|NCT00947895|Other|IV placebo|IV placebo (saline) daily for 3 days.
75721044|NCT00947895|Other|IM placebo|IM placebo (saline) daily for 5 days.
75721045|NCT00623766|Drug|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
75721046|NCT00623766|Drug|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
75721047|NCT00623766|Drug|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
75875630|NCT03091491|Drug|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
75875631|NCT03091491|Drug|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
76045002|NCT05318599|Device|Lung auscultation|Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
76045003|NCT05318599|Device|Lung ultrasound|Lung ultrasonography
75422390|NCT05963919|Other|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) by ATS/ERS criteria. Forced expiratory volume in 1 second (FEV1) and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
75422391|NCT05963919|Other|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
75721048|NCT00623766|Drug|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
75721049|NCT00623766|Drug|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
75721050|NCT00623766|Drug|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
75721051|NCT00623766|Drug|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
75721052|NCT00623766|Drug|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
75721053|NCT00623766|Drug|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
76045004|NCT05318599|Other|Quality of Life's questionnaires|Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
76045005|NCT05318599|Diagnostic Test|Pulmonary functional tests|Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
75567684|NCT05170165|Other|Using a clinical decision software to provide specific recommendation of a medication at a certain dosage|During routine follow-up, clinicians, cardiologists, and NPs who have a scheduled visit with an enrolled patient will be offered a medication recommendation. The medication recommendation will be generated by the clinical decision support tool. The software will advise the cardiologist whether an HF medication should be initiated, discontinued, or the dosage titrated and if the patient requires labs. In addition, the software, or decision engine (DE), will be run once weekly and every time the patient has new basic metabolic panel results. If the patient is admitted to the hospital, skilled nursing facility, or inpatient rehabilitation unit, the use of DE will be placed on hold until the patient is discharged and at home.
75721054|NCT00623766|Drug|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
75567685|NCT05168475|Biological|Rituximab|Hospital stock of rituximab used as intervention; biosimilars are allowed
75721055|NCT00953901|Drug|Fresh Frozen Plasma Transfusion|
75721056|NCT00832494|Drug|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
75721057|NCT00953979|Drug|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
75721058|NCT00832728|Other|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
75875632|NCT05293353|Other|NeoKare Breast Milk Fortifier|Powdered product made from human breast milk used to increase nutritional content of mother's own breast milk
75875633|NCT04733235|Drug|Progesterone|ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.
75875634|NCT05598177|Drug|dexmedetomidine|The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
75875635|NCT05598177|Drug|Placebo|The participant will pump saline without dexmedetomidine at the same speed as group D.
75875636|NCT05292105|Device|NC Xperience|Coronary dilatation balloon catheter (non compliant)
76045006|NCT04422691|Diagnostic Test|Lung ultrasound|After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
75567686|NCT05168475|Biological|Infliximab|Hospital stock of infliximab is used in the trial; biosimilars are allowed
75567687|NCT05168475|Biological|Tocilizumab|Hospital-supplied stock.
75567688|NCT05164861|Dietary Supplement|kombucha-based beverage|"kombucha-based beverage: drinking water, black tea, kombucha, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%*), vitamin B1 - 0.4 mg (29%*), B2 - 0.21 mg (13%*), B6 - 0.48 mg (24%*), niacin - 2.74 mg (15%*), folic acid - 24.0 mcg (12%*). Energy value/Caloric content - 54 kilojoules/13 kcal (* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011). Flavours, identical by nutrient's content and nutrients density: black currant berries & juniper berries, or strawberries & lime leaves, or passion fruit & mango.~Portion's volume - 220 ml. Daily intake: 1 portion"
75567689|NCT05164523|Diagnostic Test|24-hour rhythm Holter|Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.
75721059|NCT00832728|Device|ELAD®|ELAD therapy
76045007|NCT05268757|Behavioral|Oral hygiene discontinuation|Oral hygiene discontinuation for 14 days followed by 14 days of regular oral care
75721060|NCT00956865|Other|Voucher|Vouchers given to reimburse transportation
75721061|NCT00956865|Other|Telephone Call|Telephone reminder calls
75721062|NCT00956865|Other|Contact|Contact at senior center to encourage follow up
75721063|NCT00837564|Other|CBASP psychotherapy|specific psychotherapy for chronic depression
75721064|NCT00837564|Drug|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
75721065|NCT00954135|Drug|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
75721066|NCT00954135|Drug|letrozolo+sorafenib+cyclophosphamide|"Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months"
75721067|NCT00832806|Behavioral|Extended IVR (integrated voice response technology)|See detailed description
75875637|NCT03740529|Drug|Pirtobrutinib|Oral
75875638|NCT03740529|Drug|Venetoclax|Oral
75875639|NCT03740529|Drug|Rituximab|IV
75721068|NCT00832806|Drug|Varenicline (Champix)|See detailed description
75721069|NCT00832806|Behavioral|IVR treatment|See detailed description
75721070|NCT00954213|Behavioral|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
75875640|NCT03029208|Drug|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
75875641|NCT03029208|Drug|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
75875642|NCT03029208|Drug|Iron therapy|Iron therapy will be administered if ferritin is <=100 ng/mL and/or TSAT is <=20%.
75875643|NCT03693534|Diagnostic Test|Clinical Pregnancy Rate|The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
75567690|NCT05164523|Diagnostic Test|36 item Short Form Survey (SF-36)|Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.
75875644|NCT03687294|Device|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
75875645|NCT03198715|Drug|DS1040b|DS-1040b in solution for intravenous infusion
75875646|NCT03198715|Drug|Placebo|Saline solution for intravenous infusion
75721071|NCT00832884|Drug|Lacosamide|"0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes"
75721072|NCT00832962|Genetic|Genotyping|Whole blood sample
75721073|NCT00832962|Other|Usual prophylaxis|Prophylactic anti-RhD
75721074|NCT00947973|Behavioral|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
75875647|NCT03693456|Other|Conjunctival Allergen Challenge|Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
75875648|NCT04191330|Device|BiovitalsHF|BiovitalsHFTM is a cloud-based platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.
75422392|NCT05963919|Other|Lower extremity muscle strength test|The 30-Second Chair Test is administered using a folding chair without arms, with a seat height of 17 inches (43.2 cm). The chair, with rubber tips on the legs, is placed against a wall to prevent it from moving. The participant is seated in the middle of the chair, back straight; feet approximately a shoulder width apart, and placed on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance. Arms are crossed at the wrists and held against the chest. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.
75422393|NCT05963893|Behavioral|Uni4Move to sit less and move more|Co-create and implement an action plan to move more and sit less in the university context
75567691|NCT05159453|Biological|Human Insulin|International Unit for International Unit exchange of transdermally delivered Human Insulin for injected Human Insulin or combinations of basal and fast-acting insulins.
75567692|NCT05159453|Device|Finger-actuated, Metered Pump Sprayer|Stock, pharmaceutical grade High Density Polyethylene (HDPE) bottle and HDPE nylon and stainless steel finger-actuated pump sprayer delivering 0.2 mL per pump.
75721075|NCT00947973|Behavioral|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
75721076|NCT02549118|Drug|Tenoxicam|
75721077|NCT02549118|Drug|Pethidine|
75721078|NCT00957177|Drug|Pregabalin|300mg pregabalin orally 1 hour before operation
75721079|NCT00957177|Drug|Placebo|Placebo
75721080|NCT00837642|Diagnostic Test|Transthoracic echocardiography|Full transthoracic echocardiography will be performed.
75721081|NCT00948051|Dietary Supplement|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
75721082|NCT00948051|Dietary Supplement|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
75721083|NCT04044066|Biological|Plasma biomarker|New emerging plasma biomarkers carrying prognositic information
75721084|NCT00954369|Drug|[F-18]W372|"The individual doses of [F-18]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
75721085|NCT00828438|Drug|Lorcaserin 10mg|
75721086|NCT00957255|Device|OrthoADAPT|soft tissue augmentation device
75721087|NCT00957255|Procedure|Standard of care|Standard of care rotator cuff repair
75721088|NCT00828594|Drug|RAD001|
75721089|NCT00828594|Drug|RAD001, sorafenib|
75721090|NCT00833118|Procedure|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
75875649|NCT03691506|Other|Classic CIMT group|Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.
75875650|NCT03691506|Other|Modified CIMT group|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
75721091|NCT00550407|Drug|lamotrigine|lamotrigine 100mg/day or 200mg/day
75422394|NCT05963880|Device|Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)|All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.
75422395|NCT05963841|Device|treatment program|the study aims to set up an artificial intelligence diagnostic assistance program
75422396|NCT05963789|Other|Cervical proprioceptive training|Cervical proprioceptive training: The laser pointer will fixed on the highest point of the subject head with a band, patients sit upright on a chair and kept their head at the neutral position, while setting the laser light at the point on the wall in front of them. From this position, patients will be asked to flex, extend and rotate their head and then return to the neutral position. This training commenced with open eyes and then progress with closed eyes, tracing a pattern and standing position.
75422397|NCT05963789|Other|Traditional exercises|Stretching posterior shoulder capsule Strengthening scapular muscles Shoulder stabilization PNF
75422398|NCT05963776|Device|spirometry|pulmonary function tests using spirometry
75422399|NCT05963750|Other|virtual reality|virtual reality
75422400|NCT05963724|Device|Real-Time Computer Aided Detection|This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)
75422401|NCT05963724|Procedure|Stanford Colonoscopy|This involves white-light colonoscopy
75422402|NCT05963711|Other|chlorhexidine gluconate 4%|"In case BV associated bacteria will be identified (using molecular sequencing) in male samples, decolonization attempt will be conducted, using a daily wash for 5 days with chlorhexidine gluconate 4%. Following decolonization attempt, male participants will undergo re- sampling, to assess for microbiome changes.~In case there is no change in microbial composition, partners will be instructed to repeat decolonization protocol, and apply a 2 cm diameter volume of 2% clindamycin cream topically to the head of the penis and upper shaft (under the foreskin if uncircumcised) twice daily for seven days following repeated decolonization. Re-sampling will follow."
75422403|NCT05963685|Other|standardized MT alarming system|Standardized alarming system via telephone loop in the primary thrombectomy centre triggered immediately after decision to mechanical thrombectomy in stroke patients admitted in primary stroke centers
75422404|NCT05963646|Diagnostic Test|Natural history study|Patients were monitored with a panel of visual function tests and imaging modalities. Functional tests included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), and contrast sensitivity function evaluation (qCSF method). Imaging assessments included fundus autofluorescence, optical coherence tomography and optical coherence tomography angiography.
75422405|NCT05963620|Other|percutaneous coronary intervention vs bypass graft surgery|retrieve long term follow up data on clinical outcome of study population, no intervention
75422406|NCT05963607|Other|Weighted blanket|A blanket sewn with extra weight in it.
75422407|NCT05963594|Dietary Supplement|Oligomalt|The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
75422408|NCT05963594|Dietary Supplement|maltodextrin|The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
75422409|NCT05963581|Behavioral|Salsa Dancing|Participants will complete salsa dancing classes in central Oxford with instructor(s) from the Oxford University Salsa Society
75721092|NCT00550407|Drug|Placebo|placebo once daily
75721093|NCT00837798|Device|CRM Device|Pacemaker, ICD, or CRT device
75721094|NCT02548884|Procedure|Biliary cannulation|
75721095|NCT02547558|Procedure|Arterial blood gases|Measured through radial arterial catheter
75875651|NCT03687216|Procedure|HVPG-guided therapy|"The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails."
75875652|NCT03687216|Procedure|Routing Therapy|Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
75422410|NCT05963490|Drug|Regorafenib|Regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle.
75422411|NCT05963490|Drug|Toripalimab|240 mg intravenously every 3 weeks
75422412|NCT05963490|Radiation|High/low-dose radiotherapy|4-8 fractions of 8-12Gy via SABR and up to 1-10Gy at 0.5-2Gy/fraction via LDRT.
75422413|NCT05963490|Drug|Regorafenib|Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.
75721096|NCT02547558|Procedure|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
75721097|NCT02547558|Procedure|Vital signs|As measured in clinical practice
75721098|NCT02547558|Procedure|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
75422414|NCT05963477|Procedure|laparatomy|all abdominal procedures which are approached by different incisions
75721099|NCT02547558|Procedure|Spirometry|In a daily calibrated spirometer.
75721100|NCT02547558|Drug|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
75721101|NCT00948207|Behavioral|My Living Story|"Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
76045008|NCT05267743|Drug|Tegoprazan 50mg QD|Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
75422415|NCT05963464|Device|SCOUT® Radar occult breast lesion Localization|The SCOUT® Radar occult breast lesion Localization (SRL) uses non-radioactive micro-impulses to guide surgical excision in real time.
75422416|NCT05963412|Other|Meaning Centered Coping Program|"Meaning Centered Coping Program is a psychological intervention program developed for women diagnosed with breast cancer, based on the Meaning Making Model (Park, 2010; Park and Folkman, 1997) and Wong's (2010) principles of Meaning Therapy. Each weekly session had specific topics. These are:~Session 1: Guiding patients to tell the story of their breast cancer and psycho-education; Session 2: Encouraging patients to talk about the effects of breast cancer on their lives and learning to accept their difficult emotions; Session 3: Focusing on cognition through the meaning attributed to breast cancer; Session 4: Learning to take alternative perspectives and defusing their negative thoughts; Session 5: Exploring personal strengths; Session 6: İdentifying important life values and moving toward value-based actions; Session 7: Finding meaning in breast cancer and life; Session 8: Focusing on Future plans and hopes"
75567693|NCT05158270|Procedure|Ultrasound Guided Erector spinae plane block|Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
75567694|NCT05158270|Procedure|Ultrasound Guided Anterior Quadratus Lumborum Block|"Patient will be placed in lateral decubitus position. Under complete aseptic precautions, curved US probe will be placed in midaxillary line immediately above the iliac crest to identify anterior abdominal wall muscles. Probe will be then moved dorsally until visualization of transversus abdominis muscle becoming aponeurotic, then visualization of shamrock sign with psoas major muscle anteriorly, erector spinae muscle posteriorly and quadratus lumborum (QL) muscle adherent to the apex of L4 transverse process. After LA infiltration, a 20 gauge spinal needle will be inserted in-plane from posterior to anterior, and needle tip will be advanced through QL muscle, penetrating the ventral proper fascia of QL muscle. Target site for injection will be fascial plane between QL and psoas major muscles. 1 mL saline will be injected to confirm correct needle-tip position, followed by injection of 20 - 30 mL of 0.25% bupivacaine. Procedure will be performed bilaterally."
75567695|NCT05158270|Other|Intravenous Multimodal Analgesia|Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Morphine, as 3 mg IV bolus at each dose, will be given when VAS equals or above 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
75567696|NCT05149287|Drug|Ceftriaxone|single intravenous dose of 1 g of ceftriaxone
75567697|NCT05149287|Other|Placebo|1% lidocaine and saline
75567698|NCT05144854|Drug|ONO-4538|Specified dose on specified days
75567699|NCT05144854|Drug|Ipilimumab|Specified dose on specified days
75567700|NCT05144854|Drug|Oxaliplatin|Specified dose on specified days
75567701|NCT05144854|Drug|Capecitabine|Specified dose on specified days
75567702|NCT05144854|Drug|S-1|Specified dose on specified days
75567703|NCT05142410|Diagnostic Test|Analysis of post-translational histone modifications via mass spectrometry|"During the GrossHist study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company [Bouvier and Fortier et al. 2021]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4)."
75567704|NCT05142293|Other|Ambulatory procedure|In the same-day hospitalization group, some patients will be hospitalized on an ambulatory process
75567705|NCT05138809|Behavioral|Exercise|Use online exercise platform
75567706|NCT05136456|Drug|SHR1459 Low Dose|SHR1459 oral tablets taken once daily (QD) for 24weeks
75567707|NCT05136456|Drug|SHR1459 High Dose|SHR1459 oral tablets taken once daily (QD) for 24 weeks
75567708|NCT05136456|Drug|Placebo|Placebo oral tablets taken once daily (QD) for 24 weeks
75567709|NCT05136443|Drug|loteprednol etabonate 0.25% ophthalmic suspension|tapering dose
75567710|NCT05133297|Drug|TLL-018|Oral tablets administered at dose1 BID daily for 24 weeks.
75567711|NCT05133297|Drug|TLL-018|Oral tablets administered at dose2 BID daily for 24 weeks.
75567712|NCT05133297|Drug|TLL-018|Oral tablets administered at dose3 BID daily for 24 weeks.
75567713|NCT05133297|Drug|Tofacitinib|Oral tablets administered at 5 mg BID daily for 24 weeks.
75567714|NCT05132088|Drug|semaglutide 50 mg|"Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg."
75567715|NCT05132088|Drug|placebo (semaglutide)|Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
75567716|NCT05131685|Procedure|Reduction|closed reduction under conscious sedation followed by casting
75567717|NCT05131685|Procedure|Immobilization|immobilization in cast without reduction
75422417|NCT05963386|Drug|177Lu-DOTA-EB-FAPI radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 100 mCi (3.7 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
75567718|NCT05131659|Behavioral|Executive function group therapy|This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
75567719|NCT05127291|Other|Dual-task|In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
75567720|NCT05122676|Behavioral|More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)|"This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains."
75567721|NCT05117398|Drug|Dalbavancin administration|"A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance < 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg."
75567722|NCT05117398|Drug|Standard antibiotic therapy|Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
75721102|NCT00948207|Behavioral|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
75721103|NCT00957411|Biological|cetuximab|Given IV
75721104|NCT00957411|Drug|cisplatin|Given IV
75721105|NCT00837954|Device|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
75721106|NCT00837954|Device|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
75721107|NCT00837954|Procedure|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
75422418|NCT05963373|Diagnostic Test|Urine analysis|Diagnostic test
75422419|NCT05963334|Drug|Carboplatin/paclitaxel|Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
75422420|NCT05963321|Device|TDCS|Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region. The equipment will apply a current of 2 mA for 20 minutes.
75875653|NCT05212623|Biological|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
76045009|NCT05267743|Drug|Lansoprazole 30mg QD|Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
75567723|NCT05115461|Device|Biodex Balance System™ SD|Postural stability index values (anteroposterior, mediolateral and overall) will be measured for static and dynamic conditions.
75567724|NCT05115461|Other|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
75567725|NCT05110781|Biological|Atezolizumab|Given IV
75567726|NCT05110781|Radiation|Radiation Therapy|Undergo radiation therapy
75567727|NCT05110781|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75567728|NCT05110508|Behavioral|Text Based Behavioral Intervention for Physical Activity|Text intervention messaging will be sent through an automated text messaging service programmed by the CM Informatics team, which has been approved by the institution. Participants will be asked to wear Garmin physical activity monitor to provide physical activity information throughout the intervention. The Garmin is worn like a wristwatch. The device is small and non-intrusive. The Garmin device is a consumer wearable that will automatically detect and track activity such as walking, running, and cycling. The text messages incorporate information from the Garmin monitor to support physical activity.
75422421|NCT05963308|Behavioral|Healthy Minds|"The group intervention (approximately 5 participants per group, 8 groups) is facilitated by two clinicians and consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective:~Week1: Coping with work stress at work W2 and W3: Recognizing and modifying my dysfunctional beliefs linked to work W4: Overcoming obstacles linked to work functioning and maintaining work W5: To put in place needed work accommodations with the support of the immediate supervisor W6: My strengths and competencies related to work W7: Accepting criticism and asserting myself appropriately W7: My strengths and related skills W8: My best coping strategies for work Both intervention and control participants receive their standard individualized care from their clinician. However, for the experimental participants, the Healthy Minds intervention is an added component to their regular care."
75422422|NCT05963295|Diagnostic Test|toxoplasma igG|Dignosis of toxoplasma
75422423|NCT05963256|Device|Twitch Electrode Array|Monitor train-of-four (TOF) count and percentage
75567729|NCT05110196|Drug|Capmatinib 150 mg|Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
75567730|NCT05110196|Drug|Capmatinib 200 mg|Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
75567731|NCT05100355|Procedure|Physiological serum injection|In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray
75721108|NCT00948285|Procedure|MRI|magnetic resonance imaging (MRI)
75721109|NCT00954525|Drug|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
76045010|NCT05291845|Biological|Candida antigen vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
75721110|NCT00954525|Dietary Supplement|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
75721111|NCT00833274|Behavioral|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
75567732|NCT05100355|Procedure|Contrast agent injection|In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
75567733|NCT05100134|Drug|ceritinib|Patients receive ceritinib
75721112|NCT00833352|Device|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
75721113|NCT00838032|Drug|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
75721114|NCT00838032|Drug|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
75721115|NCT00954603|Drug|quetiapine|25-100 mg
75721116|NCT00954603|Drug|haloperidol|0.5-2 mg
75721117|NCT00531934|Drug|Doxycline|100mg po daily
75721118|NCT00531934|Drug|erlotinib [Tarceva]|150mg po daily
76045011|NCT05291845|Biological|Bivalent HPV vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
76045012|NCT05317195|Other|NP-1|NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
76045013|NCT05317195|Other|NP-2|NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
76045014|NCT05317195|Other|NP-3|NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
76045015|NCT05317195|Other|NP-4|NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
76045016|NCT05317195|Other|Velo-NP|Velo-NP; 10 mg nicotine;
76045017|NCT05317195|Other|Zyn-NP|Zyn-NP; 3 mg nicotine;
75567735|NCT05085860|Behavioral|Moderate-intensity continuous training (MICT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
75721119|NCT02548806|Drug|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
75875654|NCT05212623|Biological|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
76045018|NCT05317117|Diagnostic Test|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|"The NxTek (TM) Malaria Pf Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Pf malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~The NxTek (TM) Malaria Pf/Pv Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum (Pf) on one test line and of pLDH of Plasmodium vivax (Pv) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
75875655|NCT05212623|Biological|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
76045019|NCT05314621|Drug|olopatadine hydrochloride ophthalmic solution 0.7%)|Pataday® Once Daily Relief Extra Strength (eyedrop)
76045020|NCT05314621|Drug|Fluticasone Propionate|Flonase® Allergy Relief (nasal spray)
76045021|NCT05314621|Drug|Tears Naturale|Tears Naturale® II (eye drop)
75567736|NCT05085860|Behavioral|High-intensity interval training (HIIT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
75567737|NCT05084222|Drug|Buventol® Easyhaler® 200 µg/inhalation dmDPI|Two doses will be administered
75567738|NCT05084222|Drug|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|Two doses will be administered
75567739|NCT05084222|Drug|Ventoline® Evohaler® 100 µg/inhalation pMDI|Four doses will be administered via Volumatic spacer
75721120|NCT02548806|Drug|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
75875656|NCT05212623|Biological|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
76045022|NCT05314621|Drug|Saline nasal spray|Saline nasal spray (nasal spray)
75721121|NCT02548806|Drug|Catapres 100μg|Catapres tablet 100μg, single dose
75721122|NCT00828828|Biological|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
75875657|NCT03960138|Device|Intermittent Theta-burst stimulation (iTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
75721123|NCT00833508|Other|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
75721124|NCT00549939|Drug|Alfuzosin|"Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
75721125|NCT00549939|Drug|Placebo|"Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
76045023|NCT05290597|Biological|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
76045024|NCT05314465|Other|Median nerve mobilization|Median nerve mobilization was given 20 oscillations per minute for 3 times & repeated 3 times with a pause of 1 minute between each sets for 5times/week for 4weeks.
76045025|NCT05314075|Procedure|Upper Body Forced Air Warming device|Patients will have the Bair Hugger placed over the body
75422424|NCT05963217|Biological|TBI-2001|"Phase-I portion:~cohort 1: 3×10^5 cells/kg, cohort 2: 1×10^6 cells/kg, cohort 3: 3×10^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion."
75567740|NCT05082129|Device|TransiCap|The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.
75567741|NCT05080660|Drug|LY3526318|Administered orally.
75567742|NCT05080660|Drug|Placebo|Administered orally.
75567743|NCT05080322|Drug|Fluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal Spray|on-demand INS (Fluticasone) combined with nasal spray AH1(Azelastine)
75567744|NCT05080322|Drug|Fluticasone Nasal 50 Mcg/Inh Nasal Spray|on-demand or maintenance
75567745|NCT05079269|Other|Crystalloid Solutions|As above
76045026|NCT05314075|Procedure|Under Body Forced Air Warming device|Patients will have the Bair Hugger placed under the body
76045027|NCT05263609|Drug|Axitinib|If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
75721126|NCT02154412|Other|Respiratory Training|Assembled together using a T-shaped connector, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. During inhalation, the subjects will initiate each breath from residual volume (RV) and to sustain the effort until their lungs feel full. During exhalation, the subjects will breathe from total lung capacity and sustain their effort until their lungs feel empty. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
75567746|NCT05066308|Drug|CBD|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring. The drug is formulated from extracts prepared from Cannabis sativa L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (>95%) CBD that typically contains less than 0.5% (w/w) THC. Cannabidiol is the active ingredient in Epidiolex; inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. Of note, CBD has no psychoactive properties.
75721127|NCT00838188|Other|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
75721128|NCT00833742|Behavioral|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
75721129|NCT00833820|Procedure|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
75875658|NCT03960138|Device|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
75875659|NCT03691272|Device|rTMS - Real Air Film Coil|70% resting motor threshold amplitude; Frequency 10 Hz; 10 trains of 60 pulses/train (total of 600 pulses); Inter-train interval 45s.
75875660|NCT03691272|Device|rTMS - Sham Coil|A sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation.
75875661|NCT03693222|Drug|Tramadol Hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
75567747|NCT05066308|Other|Placebo|Placebo CBD will be identical to the active CBD, a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring, but with no CBD.
75567748|NCT05065190|Drug|nintedanib|nintedanib
75567749|NCT05065190|Drug|Placebo|Placebo
75567750|NCT05057975|Device|Sunrise|Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
75567751|NCT05057975|Device|polysomnography|Reference protocol to diagnose OSA (in-lab or outpatient PSG)
75567752|NCT05056220|Drug|Human albumin|20%
75567753|NCT05056220|Drug|sodium chloride|0.9%
75422425|NCT05963217|Drug|Cyclophosphamide|IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
75422426|NCT05963217|Drug|Fludarabine|IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
75422427|NCT05963204|Combination Product|Sculptra and Alastin Restorative Skin Complex|Biostimulator and cosmetics
75422428|NCT05963204|Combination Product|Sculptra and CeraVe Daily Moisturizing Lotion|Biostimulator and cosmetics
75567754|NCT05054920|Other|concentric exercises|concentric exercises for rotator cuff. internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
75567755|NCT05054920|Other|eccentric exercises|Eccentric exercises exercises for rotator cuff internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
75721130|NCT00833820|Procedure|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
76045028|NCT05263609|Drug|Pembrolizumab|If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
75721131|NCT00272779|Drug|ATV|300mg Oral capsules for 96 weeks
75721132|NCT00272779|Drug|RTV|100mg Oral Capsules for 96 weeks
75721133|NCT00272779|Drug|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
76045029|NCT05263375|Device|Innovalve TMVR system|Innovalve TMVR system
75422429|NCT05963191|Device|Colorectal cancer screening with CAD EYE colonoscopy|"The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa.~In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis."
75422430|NCT05963178|Behavioral|Pre-operative counselling|"A preoperative speech therapy counseling will be carried out the day before the Total Thyroidectomy with the aim of informing patients about the possible conditions of the immediate post-operative period. Therefore, indications of vocal hygiene and hydration standards will be simultaneously administered, to be implemented from the first post-operative day.~Patients will undergo phoniatric follow-up in the immediate post-operative period, at 7 days, 1 month and 3 months post-operatively.~Patients who, at follow-up checks, should present the symptoms of functional post-thyroidectomy syndrome will undergo a cycle of post-operative speech therapy of 8 sessions."
75422431|NCT05963165|Behavioral|Non-phonatory exercises|Muscle exercises that favor glottic adduction without vocal emissions
75422432|NCT05963126|Other|No intervention.|No intervention.
75422433|NCT05963100|Biological|TCR-like CAR-T|intravenous drip of TCR-like CAR-T with indicated doses
75567756|NCT05054920|Other|Stretching|stretching exercise for posterior capsule and pectoralis minor each stretch will be done for 30 seconds and repeated 3 times
75567757|NCT05054153|Other|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 2, Day 5 and Day 6. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
75567758|NCT05054153|Other|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 3, Day 4 and Day 7. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
75721134|NCT00272779|Drug|LPV|400 mg (3 133mg capsules) BID for 96 weeks
75422434|NCT05963087|Drug|Cetuximab Dabrafenib Tislelizumab|Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
75875662|NCT03693222|Drug|Morphine Sulfate|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
76045030|NCT05313997|Drug|Diclofenac Sodium|"at first diclofenac sodium was prescribed to patients with chronic upper back pain.~If the patient's pain persisted, she/he was included in the physical therapy (hotpack 20 minutes, ultrason 5 minutes, Transcutaneous electrical nerve stimulation 20 minutes) program."
76045031|NCT05259241|Diagnostic Test|activated partial thrombin time|This study aims to find which the point-of-care test (ACT or APTT) has the best correlation with the coagulation status during transcatheter cardiac interventions (either TAVR or PCI)
75567759|NCT05054153|Other|intermittent fasting|The period during Day 8 to Day 13 is intermittent fasting period. Participants will experience the moderate fasting on Day 9 and Day 12, which means their daily energy intake is expected to be controlled within 500-600 kcal limit. In these two days, participants will be provided with all three meals. Percentages of macronutrients of provided meals will follow the Recommended Dietary Health guidelines for Chinese residents. The oral glucose tolerance test (OGTT) will be conducted in the morning on Day 8 and Day 13, to test short-term impact of IF intervention on individuals' glucose tolerance. The breakfasts on Day 10 and Day 11 will be the same as that in fasting days. Other meals will be wash-out meals.
75721135|NCT04036006|Behavioral|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
75567760|NCT05050643|Other|EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
75567761|NCT05050643|Other|EBQI-LC|A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
75567762|NCT05039866|Biological|ST-920|No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
75567763|NCT05039203|Device|Indwelling urinary catheter|Removal of indwelling urinary catheter
75567764|NCT05038098|Procedure|Gastrectomy|Undergo surgery
75721136|NCT04036006|Behavioral|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
76045032|NCT05219227|Other|laser acupuncture and abdominal exercises|"laser acupuncture on certain point on the abdomen The following abdominal acupuncture points were irradiated: Cv 8 (Shenque), St 25 (Tianshu, bilateral), and Sp 15 (Daheng~, bilateral). The laser irradiations were applied directly to the skin of the points with a perpendicular beam. 478 J/cm2~Abdominal exercises:~Types of abdominal exercises:~Static abdominal exercises:~Dynamic abdominal exercises:~Hip shrugging exercise from crook lying position:~Lateral flexion of the trunk from crook lying position:~Antero-posterior flexion of the trunk from crook lying position:"
75875663|NCT04059744|Device|Fun-Knee|"Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
75721137|NCT04011423|Other|Unstable shoes plus Whole-body vibration|Wearing unstable shoes during the whole-body vibration training
75721138|NCT04011423|Other|Stable shoes plus Whole-body vibration|Wearing stable shoes during the whole-body vibration training
75721139|NCT00828906|Drug|DuoTrav|DuoTrav Eye Drops
75721140|NCT00948363|Other|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
75721141|NCT00948363|Other|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
75875664|NCT03693066|Other|Ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
75875665|NCT03693066|Other|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
75875666|NCT03693066|Other|Control|
75875667|NCT03631641|Biological|Nivolumab|Given IV
76045033|NCT01657903|Drug|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
76045034|NCT01657903|Drug|Potassium nitrate|All study treatments contain 5% w/w KNO3.
76045035|NCT05256823|Drug|Celecoxib|Patients will be treated with Celecoxib twice daily for 48 weeks.
75422435|NCT05963035|Drug|18F-PFPN|For patients clinically suspected or confirmed clear cell sarcoma of soft tissue, integrated PET/MR or PET/CT imaging will be performed using targeted melanin-specific imaging agent 18F-PFPN. Meanwhile, multiple parameters will be compared with the general imaging agent 18F-FDG.
75422436|NCT05962983|Behavioral|Small Steps for Big Changes Program|Participants will be asked to attend six one on one sessions providing diet and exercise counselling each lasting 20-30 minutes over the course of six weeks. The nutrition counselling will introduce participants to a healthy dietary changes for reducing added sugar intake and refined/processed carbohydrate intake as well as increasing vegetable consumption. After counselling sessions, participants will complete their chosen form of aerobic exercise: 1) traditional continuous exercise that involves exercising at a constant pace for 20-30 minutes (moderate-intensity continuous training, MICT); or 2) interval exercise that involves alternating between 30 seconds and 1-minute of brisk exercise and 1-minute of easy exercise for ~15 min (high-intensity interval training, HIIT). Both exercise forms could be completed on treadmill, elliptical or stationary bike. In total, each session will last approximately one hour.
75422437|NCT05962944|Device|Olympus Cellsens software|Olympus cellsens software will be used to visualise the cells and MS teams screen share will be used to send the live images in real time.
75567765|NCT05038098|Drug|Indocyanine Green|Given peritumorally
75567766|NCT05038098|Other|Iron Conjugated Polymers in Saline Suspension|Given peritumorally
75567767|NCT05031832|Diagnostic Test|HIV test|HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status
75875668|NCT03631875|Drug|Ketamine|use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
75875669|NCT05598099|Behavioral|Concentrated cognitive behavioral therapy|A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life
75875670|NCT03631563|Drug|Immunosuppressive Agent|ATG-Fresenius versus ATG
75875671|NCT03019653|Drug|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
76045036|NCT05256823|Drug|nucleos(t)ide analogue|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
76045037|NCT05218681|Other|"Unit-based Person First Anti-stigma Awareness Rounds"|Educational rounds on stigma
76045038|NCT05218681|Other|Individual Text-based Messaging|Weekly evidence based messages to reduce SUD stigma
75875672|NCT03019653|Drug|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
75875673|NCT02653755|Device|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
75721142|NCT00829062|Device|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
75875674|NCT05077293|Other|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
75875675|NCT05077293|Other|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
75567768|NCT05027048|Drug|Calcium chloride|See arm description above
75567769|NCT05027048|Drug|Saline placebo|see arm description above
75567770|NCT05025059|Procedure|Discussion|Participate in coaching sessions
75567771|NCT05025059|Other|Exercise Intervention|Perform walking exercise
75567772|NCT05025059|Other|Exercise Intervention|Perform strength exercises
75567773|NCT05025059|Other|Informational Intervention|Receive WWE workbook and Growing Stronger Strength Training Program instruction manual
75567774|NCT05025059|Other|Informational Intervention|Maintain exercise log
75567775|NCT05025059|Other|Medical Device Usage and Evaluation|Wear fitness tracker
75721143|NCT03850704|Drug|Selinexor|
75721144|NCT00957879|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
75721145|NCT00957879|Dietary Supplement|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
75721146|NCT00838266|Drug|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
76045039|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis."
75721147|NCT00838266|Other|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
75721148|NCT00834054|Procedure|Double-lung transplantation|Double-lung transplanted patients
75721149|NCT00838344|Other|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
75721150|NCT04011033|Biological|iNKT cells|5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
75721151|NCT04011033|Drug|Cyclophosphamide|CTX will be administered intravenously at a dose of 750mg/m2 2 days before the first iNKT cells infusion.
75721152|NCT04011033|Drug|Human recombinated Interleukin-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
75422438|NCT05962931|Biological|Bioengineered Artificial Mesenchimal Sheet (BAMS)|Each patient assigned to the experimental treatment group will receive 4 BAMS (1 BAMS/week) at a concentration of about 360,000 cells/cm2.
75422439|NCT05962931|Procedure|Standard treatment (Control)|Each patient assigned to the control group will undergo a standard treatment procedure for uncomplicated venous ulcers.
75567776|NCT05025059|Other|Quality-of-Life Assessment|Complete questionnaires
75567777|NCT05025059|Other|Questionnaire Administration|Complete questionnaires
75567778|NCT05025020|Other|interactive 3D tool|The study tool displays 3-dimensional step-by-step animations of autologous and implant-based breast reconstruction procedures.
75721153|NCT04011033|Procedure|TACE|TACE will be conducted to all patients at 0th week and 4th week.
75721154|NCT00829140|Drug|Placebo|
75721155|NCT00829140|Drug|Lorcaserin 10mg BID|
75721156|NCT00998608|Drug|risperidone|risperidone 4mg/d
75721157|NCT02547324|Radiation|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
75721158|NCT02547324|Radiation|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
75721159|NCT04011813|Other|Hypotaurine : antioxidant and osmoregulator|"Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing"
75721160|NCT00998686|Drug|dutogliptin|400 mg
75721161|NCT00998686|Drug|sitagliptin|100 mg
75567779|NCT05025020|Other|BREAST-Q Reconstruction Module|The BREAST-Q Reconstruction Module1-3 has 6 domains that cover various aspects of patient satisfaction and quality of life. BREAST-Q is part of our standard of care for patients treated for breast cancer and referred for reconstruction.
75721162|NCT00829218|Other|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
75721163|NCT00829218|Other|Placebo diet|Juice with nothing added.
75721164|NCT00948519|Device|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
75721165|NCT00948519|Device|Laser only|same only without ICG
75721166|NCT00958269|Drug|dutogliptin|100 mg QD
75875676|NCT05069181|Other|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
75875677|NCT05069181|Other|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
75875678|NCT05069181|Other|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
75422440|NCT05962918|Other|Perinal massage|"Perineal massage was administered to all pregnant women in the experimental group during both the labor and resting phases between contractions. The participants received an average of 5-10 minutes of perineal massage two, four and four to six times at the latent (0-3-cm cervical dilation), active (4-7-cm cervical dilation) and transition (8-10-cm cervical dilation) phases of labor, respectively. These women continued to receive perineal massage at every push throughout the second stage of labor. The researcher midwife gently widened the perineal muscles by making stretching movements with her fingers. Perineal massage was applied using all three of the from one edge to the other, U shape and pressure massage techniques. The researcher gently applied a rhythmic U pressure with both fingers, moving them on the vagina downwards about 3 to 9 o'clock. Each pressure movement was maintained laterally for 1-2 minutes towards the rectum."
75422442|NCT05962879|Behavioral|Resilience Training for Teens|A brief 6-session group-based behavioral intervention for high school aged teenagers at risk of a mental illness.
75422443|NCT05962853|Other|Experimental group (Transcutaneous Electrical Nerve Stimulation)|The application will be applied at 8 hour intervals in the first 24 hours after the surgery.
75422444|NCT05962840|Drug|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
75422445|NCT05962840|Other|Placebo of Telitacicept|Patient will be treated with placebo of Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
75567780|NCT05025020|Other|DQI|The DQI has 3 domains that cover decision-specific questions about what it is like for a patient to make decisions about reconstruction after breast cancer treatment.
75567781|NCT05025020|Other|Ottawa Decision Regret Scale|The validated Decision Regret Scale measures distress or remorse after a health care decision by the use of 5 items to indicate the extent to which the respondent agrees or disagrees with the statements in the regret scale.
75875679|NCT01383603|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
75875680|NCT05065203|Procedure|planned or unplanned Cesarean, operative, or non operative delivery|All types of delivery
75875681|NCT01568775|Drug|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
75567782|NCT05021133|Behavioral|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS to access a patient portal and a video-call system.
75567783|NCT05020678|Biological|NKX019|NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10^8 NK cells (6 × 10^6/kg for patients < 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.
75567784|NCT05018130|Procedure|Calcaneus Osteotomy (Metallic)|Calcaneus Displacement Osteotomy using two metallic screws
75567785|NCT05018130|Procedure|Calcaneus Osteotomy (Bio-integrative)|Calcaneus Displacement Osteotomy using two bio-integrative screws
75567786|NCT05017727|Device|Closed-loop automated oxygen control with Oxygenie Auto-O2 software (SLE6000)|The 'Oxygenie' is a closed loop automated oxygen control system that has been incorporated into a software module for the SLE6000 infant ventilators. This software control system allows targeting SpO2 values by controlling FiO2.
75567787|NCT05014776|Drug|Tadalafil|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.
75721167|NCT00958269|Drug|dutogliptin|200 mg QD
75721168|NCT00958269|Drug|placebo|
75721169|NCT00958269|Drug|sitagliptin|25 mg QD
75875682|NCT01015989|Other|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
75721170|NCT00958269|Drug|sitagliptin|50 mg QD
76045040|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed.~The HUMELOCK II reversible system is used when the rotator cuff is injured."
75875683|NCT01015989|Other|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
75875684|NCT04722549|Dietary Supplement|Placebo|Cellulose
75422446|NCT05962814|Device|EarGenie MVP test|The EarGenie test consists of placing the EarGenie headgear on the infant and running the fNIRS tests via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation. Automatic analyses are run to determine whether the infant heard the sounds or discriminated between them. The infant will be in a natural sleep when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
75422448|NCT05962775|Procedure|Ethanol Sclerotherapy for Endometrioma|2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
75567788|NCT05014776|Drug|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
75567789|NCT05014776|Drug|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
75567790|NCT05014776|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 [1 × 109 colony forming units (CFU) in 100ml NS] will be administered IV on Day 2 of Cycles 1-6.
75567791|NCT05013216|Drug|KRAS peptide vaccine|"KRAS peptide vaccine will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13.~Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
75721171|NCT02547402|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
75721172|NCT02547402|Drug|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
75721173|NCT02547402|Drug|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
75721174|NCT01068925|Drug|GSK1349572|"GSK1349572 QD x 5 days~TPV/RTV 500/200mg BID x 7 days~GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"
75721175|NCT00511810|Drug|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
75721176|NCT00511810|Drug|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
75721177|NCT00834600|Drug|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP >140 mmHg
75721178|NCT00834600|Drug|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure >140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
75721179|NCT00958425|Device|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
75721180|NCT00958425|Device|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
75721181|NCT02547480|Device|TACE with irinotecan loaded LifePearl|Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
75721182|NCT00291499|Drug|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
76045041|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System|Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)
76045042|NCT05284357|Device|Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System|"EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability"
75721183|NCT00291499|Other|Placebo|800 mg placebo/day for 6 months
75567793|NCT05011162|Device|Digital ACT|Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT).
75721184|NCT00838500|Drug|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
75721185|NCT00838500|Drug|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
75721186|NCT00838656|Drug|carboplatin|Given IV in one of two schedules
75721187|NCT00838656|Drug|gemcitabine hydrochloride|Given IV in one of two schedules
75721188|NCT00838656|Drug|paclitaxel|Given IV in one of two schedules
75875685|NCT04722549|Dietary Supplement|Butyrate|Sodium butyrate
75875686|NCT05003427|Drug|68Ga-FAPI-04|68Ga-FAPI-04 were injected into the patients before the PET/CT scans
75875687|NCT04941261|Biological|middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
75422449|NCT05962749|Other|Assessment|3 meter backward walk test (3MBWT), 10 meter walk test (10MWT), Selective Control Assessment of the Lower Extremities (SCALE), Trunk Control Measurement Scale (TCMS), Pediatric Balance Scale (PBS), Functional Independence Measure for Children (WeeFIM), Modified Ashworth Scale (MAS)
75567794|NCT05007275|Biological|1x10^9 vp AZD1222|A single dose of 1x 10^9 vp AZD1222
75567795|NCT05007275|Biological|5x10^9 vp AZD1222|A single dose of 5x 10^9 vp AZD1222
75567796|NCT05007275|Biological|1x10^10 vp AZD1222|A single dose of 1x10^10 vp AZD1222
75721189|NCT03964636|Diagnostic Test|OCT-A (optical coherence tomography)|Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
75721190|NCT03998098|Diagnostic Test|Oxygen Saturation (Oximetry)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
75875688|NCT04941261|Biological|high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
75875689|NCT04941261|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
75875690|NCT00335049|Device|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
75422450|NCT05962723|Procedure|EUS|EUS examination and cystic fluid will be aspirated for analysis, including cystic fluid Glucose, CEA, amylase. Morey's biopsy will be done in the cases feasible for biopsy.
75422451|NCT05962710|Device|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
75422452|NCT05962697|Other|SA controller|Novel controller to be tested
75422453|NCT05962697|Other|TA controller|original controller to be tested
75422454|NCT05962697|Other|SA controller early testing|Novel controller to be tested early testing
75567797|NCT05005312|Drug|PF-07321332|Tablet
75567798|NCT05005312|Drug|Ritonavir|PK Boosting agent
75567799|NCT05004220|Procedure|Plasmapheresis|Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.
75567800|NCT05001984|Drug|Alirocumab|Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.
75875691|NCT00335049|Device|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
75875692|NCT01383525|Device|Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
75875693|NCT05597787|Behavioral|Stigma Reduction Tools|behavioral design, contact, and social norms
75875694|NCT05597787|Behavioral|Education|education and clinical skills
75875695|NCT05597709|Procedure|Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination|Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination
75567801|NCT04999046|Device|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.
75567802|NCT04998201|Drug|ARO-APOC3|ARO-APOC3 Injection
75567803|NCT04998201|Drug|Placebo|Sterile Normal Saline (0.9% NaCl)
75567804|NCT04995328|Other|Radiation Care Gel|The investigational medical product of this study is a hydrogel, Radiation Care® gel which increases moisturizing and it can be applied to the target areas including skin folds and creases.
75721191|NCT03998098|Diagnostic Test|Heart Rate (Pulse)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
75721192|NCT03998098|Diagnostic Test|Respiratory Rate|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
76045043|NCT05284357|Device|Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)|"EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation"
76045044|NCT05284357|Device|Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)|"EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation."
75422455|NCT05962684|Other|ERAS|Implementation of ERAS protocol in elective craniotomy patients
75567805|NCT04994483|Drug|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
75567806|NCT04994483|Drug|Placebo|Matching placebo given b.i.d. for 52 weeks.
75567807|NCT04988945|Procedure|TACE|Procedure of TACE will be standardized.
75567808|NCT04988945|Radiation|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
75567809|NCT04988945|Drug|Durvalumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)
75422456|NCT05962671|Drug|Opioid-sparing based anesthesia|Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
75422457|NCT05962671|Drug|Sevoflurane-based anesthesia|Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
75422458|NCT05962658|Other|qEEG|qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
75422459|NCT05962645|Drug|Vapendavir|This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
75567810|NCT04988945|Drug|Tremelimumab|300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
75567811|NCT04988750|Device|NaviFUS System|Using the neuronavigator to precisely guide the ultrasound energy to brain tissues in real-time and intraoperatively.
75567812|NCT04985565|Other|Dietary Intervention|Participate in Mediterranean diet
75567813|NCT04985565|Procedure|Radical Prostatectomy|Undergo standard of care radical prostatectomy
75567814|NCT04982731|Other|Positive Assurance|"Positive assurance is a low-cost, non-pharmacological strategy commonly used by specialty clinics to manage anxiety in individuals with mTBI. Positive assurance is comprised of words of affirmation given to individuals with a medical condition by a healthcare provider that are centered on hope and positive recovery expectations (i.e., You will recover, This can be treated)."
76045045|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.
75422460|NCT05962632|Drug|Fluoride based varnish (Dentkist Charm Fill Varnish )|topical Fluoride varnish administrated professionally every 3 months in the clinic
75567815|NCT04982614|Biological|Gardasil ® 9|"GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months"
75567816|NCT04979455|Other|Core temperature monitoring|Core temperature will be monitored on the day of exercise
75567817|NCT04979455|Behavioral|Questionnaires|Questionnaires will be completed at baseline and on the day of exercise
75567818|NCT04979455|Other|Heart rate monitoring|Heart rate will be monitored on the day of exercise
75721193|NCT03998098|Diagnostic Test|Blood Pressure|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings."
75721194|NCT00829608|Biological|Human Papillomavirus Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
75721195|NCT00838812|Drug|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
75721196|NCT00553605|Drug|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
75721197|NCT00553605|Drug|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
75721198|NCT02547246|Device|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
75721199|NCT02547246|Device|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
75422461|NCT05962632|Drug|pro care gel remineralizing agent|topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company
75422462|NCT05962632|Device|Mobile application|examine the impact of Mobile application on caries prevention
75567819|NCT04979455|Other|Urine collection|Urine samples will be collected at baseline and on the day of exercise
75567820|NCT04979455|Other|Sleep monitoring|Sleep will be monitored at baseline and on the day of exercise
75422463|NCT05962632|Combination Product|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning,fluoride rinse OTC|interdental cleaning(dental floss),fluoride rinse OTC (B-FRESH MOUTH WASH )
75567821|NCT04979455|Other|Blood collection|Blood samples will be completed at baseline
75567822|NCT04979455|Other|Saliva collection|Saliva samples will be collected at baseline and on the day of exercise
75567823|NCT04979455|Other|Throat swab collection|Throat swab samples will be collected at baseline and on the day of exercise
75721200|NCT00838968|Drug|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
75721201|NCT00829842|Other|oral hygiene|oral hygiene with 0.12% chlorexidine
75721202|NCT00829842|Other|placebo|oral hygiene placebo
75721203|NCT00954759|Procedure|Chiropractic treatment|
75721204|NCT00954759|Procedure|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
75721205|NCT02548182|Device|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults [REF]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
75875696|NCT04908969|Behavioral|Internet-delivered Cognitive Behavior Therapy for Chronic Tic Dosorder/Tourette Disorder|The treatment will be provided through a secure internet platform designed for internet-administered treatments (BASS-4). In the treatment, the patient works through modules of self-help material, each ending in a short quiz with questions about the material. The treatment is supported by a therapist through text-based communication via the platform as well as occasional phone calls when needed. The central component in the treatment is exposure and response prevention (ERP). In ERP, the patient exposes her/himself to situations that trigger premonitory urges (a type of bodily sensation that precede the tic) while practicing to resist the tic. By doing this systematically and repeatedly, the patient gradually learns how to tolerate the premonitory urges and increase the ability to control and resist doing tics. Beyond ERP the treatment consists of other components such as applied relaxation, counter-movements and interventions to decrease stressors in the patient's everyday life.
75875697|NCT05420181|Other|Short 10hr fast|Participants will fast from 11pm the night before the study day
75875698|NCT05420181|Other|Long 16h fast|Participants will fast from 5pm the night before the study day
75422464|NCT05962619|Procedure|arthrocentesis alone|The procedure is done under general anesthesia. The patient is seated inclined at a 45 degree angle with the head turned to contralateral side. The points of needle insertion on the skin, are as follow: a line is drawn from the middle of the tragus to the outer canthus of the eye. The posterior entrance point is located along the canthotragal line, 10 mm from the middle of the tragus line and 2 mm below, the anterior entrance point is placed 10 mm further forward along the line and 10 mm below it . A needle connected to a 10 ml syringe with the Ringer's lactate solution is then inserted into the superior compartment (posterior point), and solution is injected . Another needle is then inserted into the area of articular eminence to enable the free flow of solution through the superior compartment. During the lavage, the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions
75422465|NCT05962619|Procedure|arthrocentesis with hyaluronic acid injection|in this group Once arthrocentesis is completed, an ampule of sodium HA (Hyalgan 1 ml) is connected to the needle in situ And 0.5 ml injected into the superior joint space. Pressure dressing is placed in site of injection. so We use arthrocentesis hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction
75567824|NCT04979455|Other|Stool collection|Stool samples will be collected at baseline and on the day of exercise
75721206|NCT02548182|Other|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
75721207|NCT05352477|Other|Balneotherapy with thermal water|Bath with Acquabios thermal water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
75721208|NCT05352477|Other|Balneotherapy with tap water|Bath with tap water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
75721209|NCT00835302|Procedure|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
75721210|NCT04010955|Drug|Edoxaban Monotherapy|when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
75721211|NCT03851328|Other|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
75422466|NCT05962606|Drug|AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
75567825|NCT04968990|Device|Proton Beam Radiation (PBRT)|The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.
75567826|NCT04968990|Drug|DD-4A Chemotherapy Regimen|Patients will receive standard of care chemotherapy based on diagnosis and stage.
75567827|NCT04968990|Procedure|Complete Surgical Resection|Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy
75567828|NCT04968990|Procedure|Surgical Resection|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
75567829|NCT04968990|Procedure|Partial Nephrectomy|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy.
75567830|NCT04968184|Drug|Placebo|Participants will orally receive placebo matching to KBP-5074 tablets QD.
75422467|NCT05962606|Drug|Placebo|Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
75567831|NCT04968184|Drug|KBP-5074|Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
75567832|NCT04965727|Procedure|Device implantation|The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
75567833|NCT04965688|Drug|Drug determined by treating oncologist based on recommendation from systems biology analysis.|All patients will have a biopsy at the beginning of the trial. The biopsy will be sent for DNA sequencing through FoundationOne(clinical test) and RNA profiling at Fulgent(research test) for determination of activation of various oncogenic pathways and phenotypes. The results will be analyzed and a treatment recommendation will be made to the treating physician based on an algorithm.
75567834|NCT04964895|Other|Questionnaires|"Patients will fill in multiple questionnaires for this study :~EORTC quality of life questionnaire (QLQ) QLQ-C30, EORTC Shq22, Male Sexual Health Questionnaire (MSHQ) only for Men, FSFI (only for women)"
75567835|NCT04959279|Other|ED-TREAT|Patients will be assessed and treated based on a clinical decision support system.
75567836|NCT04957173|Other|Lifestyle intervention|"The intervention includes a total of 17 virtual meetings and aims to achieve a weight loss of 0.8 to 1% of the initial weight per week.~This will include 3 successive phases:~A significant calorie restriction (A minimum deficit of 800 kcal / day of their daily energy expenditure) for a period of 4 weeks;~A moderate calorie restriction (minimum deficit of 500 kcal / day of their daily energy expenditure) for a period of 4 weeks;~A maintenance phase of weight loss for 16 weeks.~An optional phase of monthly follow-ups for a period of 3 months (no intervention)"
75567837|NCT04956770|Procedure|Implantation surgery|"The intervention involves the implantation of:~a neurostimulator: the Activa® RC from Medtronic~a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic"
75567838|NCT04956692|Biological|Pembrolizumab SC|SC injection
75721212|NCT04016688|Procedure|ESPB and TAP block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
75721213|NCT00948831|Biological|Osteocel Plus|biologic
75721214|NCT05300061|Behavioral|Personal Values Intervention|A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.
75721215|NCT05300061|Behavioral|Prosocial Values Intervention|A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
76045046|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible
76045047|NCT05284201|Device|LIFT System|The LIFT System delivers the Functional task practice and ARC Therapy to improve upper extremity function in individuals with tetraplegia.
76045048|NCT05492149|Other|Performance follow-up|Diary performance during rehabilitation will be collected and a CAT questionnaire will be completed by the patient.
76045049|NCT05255263|Other|PIEB|Programmed Intermittent Epidural Bolus with Patient-Controlled Epidural Analgesia
76045050|NCT05255263|Other|CEI|Continuous Epidural Infusion with Patient-Controlled Epidural Analgesia
75422468|NCT05962593|Other|Telephone call|The patients will be randomized for a postoperative telephone call
75567839|NCT04956692|Biological|Pembrolizumab IV|IV injection
75567840|NCT04956692|Drug|Paclitaxel|IV injection
75567841|NCT04956692|Drug|Nab-Paclitaxel|IV infusion
75567842|NCT04956692|Drug|Carboplatin|IV infusion
75422469|NCT05962580|Procedure|Isolated anterior cruciate ligament reconstruction with lateral extra articular tenodesis|Anatomical single bundle ACLR with modified Lemiere technique
75422470|NCT05962580|Procedure|Isolated anterior cruciate ligament reconstruction only|arthroscopic anatomical single bundle ACL Reconstruction
75567843|NCT04956692|Drug|Cisplatin|IV infusion
75567844|NCT04956692|Drug|Pemetrexed|IV infusion
75567845|NCT04955444|Other|Quality improvement bundle|The quality improvement bundle consists of (1) patient education, (2) provider education, and (3) EHR enhancements including order sets and best practice alerts.
75567846|NCT04950439|Other|Collect blood sample|A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
75422471|NCT05962567|Other|Non surgical periodontal therapy|scaling and subgingival debridement
75567847|NCT04947449|Device|fractional CO2 laser|Standard of care laser treatment of burn-related injuries will be performed. This protocol assesses the effects of those treatments on skin blood flow and sweating responses.
75567848|NCT04946305|Other|Lutathera|Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.
76045051|NCT05254717|Other|counselling|intervention groups will receive counselling on improving quality of complementary feeding by soaking complementary foods flours and basic methods of soaking complementary flours.
75422472|NCT05962554|Behavioral|iJobs|iJobs is a 2-week intervention consisting of 5 modules focusing on discovering job skills, job search strategies, preparing effective resumes, exercising different types of interviews, and overcoming setbacks in the job search process. This is an adaptation of the JOBS program.
75422473|NCT05962541|Drug|PDD-TURBT with hexaminolevulinate (Hexvix®)|In order to undergo PDD-TURBT, all eligible patients in the experimental arm will be administered the photosensitizer hexaminolevulinate (85 mg in 50 ml of phosphate buffered saline, Hexvix®) on an inpatient setting through a urethral catheterization of the participant's bladder. During the PDD-TURBT surgery, the bladder will be illuminated with blue light (wavelength 380-450 nm). The operating rooms of the participant institutions will therefore need to have the specialized equipment consisting in the blue-light source (POWER LED SAPHIRA [TM]).
75567849|NCT04943588|Diagnostic Test|HCV RNA (PCR)|We will test HCV positive patients after treatment to observe if they achieve SVR
75721216|NCT05352087|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is minimally invasive surgery to remove the gallbladder.
76045052|NCT05253937|Drug|Epinephrin|The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
76045053|NCT05253703|Other|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
76045054|NCT05218603|Drug|Bortezomib|Maintenance: Administration as per routine clinical practice.
75422474|NCT05962541|Device|Power Led Saphira (TM) from KARL STORZ|This is a light source based on LED technology. It can be used for both White Light (WL) and fluorescence applications in blue light (i.e., Photodynamic diagnosis PDD) for visualizing tumor lesions during trans-urethral resection of bladder tumors (PPD- TURBT).
75422475|NCT05962528|Device|Soft lens|Patients were randomly fitted with five different designs of soft lenses
75567850|NCT04943588|Diagnostic Test|HCV Antibody test (Point of care)|HCV antibody test used to establish if patients have had or are actively infected with HCV
75567851|NCT04943588|Diagnostic Test|AST/ALT and platelets measurement|AST/ALT and platelets to determine APRI score
75567852|NCT04935710|Behavioral|COPE2Thrive|Cognitive Behavioral Therapy-based program to help teens deal with anxiety, stress and depression by showing them how to develop skills needed to stop negative thoughts and start thinking and behaving in more positive ways.
76045055|NCT05218603|Drug|Daratumumab|Maintenance: Administration as per routine clinical practice.
75721217|NCT00948987|Drug|Aspirin|325 mg enteric coated single dose p.o.
75721218|NCT00954837|Procedure|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
75721219|NCT05351931|Dietary Supplement|Salovum and SPC-flakes or corresponding placebo|Salovum and SPC-flakes are foods approved for specific medical purposes.
75721220|NCT05351697|Drug|BR105 injection|0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
75567853|NCT04935710|Genetic|Usual care|Children at risk who are not randomized to COPE2Thrive at any point of time serve as the control group.
75567854|NCT04922281|Device|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
75567855|NCT04917107|Behavioral|Qigong|"The Five Element Qigong Healing Movements practice includes five gentle horizontal and vertical arm and leg movements performed with guided breathing."
75567856|NCT04912466|Drug|Biological: IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
75567857|NCT04910022|Drug|NMS-03305293|Route of administration: Oral
75721221|NCT00744497|Drug|Placebo|
75567858|NCT04910022|Drug|Temozolomide|"Route of administration: Oral~Commercially available temozolomide"
75567859|NCT04902248|Device|The OTSC® System Set|The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion
75567860|NCT04902248|Procedure|angiographic embolization|Transcatheter selective embolization to bleeding arteries
75567861|NCT04894773|Other|Imaginary Resistance Exercises|In imaginary resistance exercises, resistive force is assumed to get applied by the patient after demonstrating some resistive objects and the kind of force exerted by them.
75721222|NCT00744497|Drug|Dasatinib|
75875699|NCT03087513|Drug|Sugammadex Injection [Bridion]|The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.
75875700|NCT03087513|Drug|Placebo|The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
75875701|NCT05420103|Other|Accelerated Stroke Ambulation Program|Stroke Rehabilitation Program
75875702|NCT04868643|Device|The DIMI Renal Replacement Therapy (RRT) System|To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.
75875703|NCT03631485|Other|Exposure_having children with cancer|No intervention. The exposure is having children with cancer.
75721223|NCT00744497|Drug|Docetaxel|
75721224|NCT00744497|Drug|Prednisone|
75721225|NCT00949065|Biological|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
75875704|NCT02917629|Other|Laboratory Biomarker Analysis|Correlative studies
75875705|NCT02917629|Drug|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
75875706|NCT02917629|Other|Pharmacological Study|Correlative studies
75875707|NCT02917629|Other|Placebo|Given PO
75875708|NCT05418543|Procedure|Endoscopic ultrasound with fine needle biopsy|Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
75875709|NCT03692988|Behavioral|Dignity Therapy|Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
75567862|NCT04894773|Other|Physical Resisted Exercises|In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects.
75567863|NCT04891692|Device|StimaWell 120MTRS system|Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
75567864|NCT04889066|Radiation|Stereotactic Radiation Therapy|"24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm."
75721226|NCT05351619|Procedure|oral care bundle implementation|oral care bundle encompasses oral assessment, tooth brushing, oral / lip moisturization, and suctioning oropharyngeal secretions above the cuff.
75721227|NCT05351463|Procedure|papila suture technique|simple interupted vs internal horoizontal matress suture
75721228|NCT00949143|Other|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
75721229|NCT00949143|Other|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
75721230|NCT00955071|Other|Exercise: LVLI|low volume, low intensity
75721231|NCT00955071|Other|Exercise: HVLI|high volume, low intensity
75721232|NCT00955071|Other|Exercise: LVHI|low volume, high intensity
75721233|NCT00955149|Drug|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
75875710|NCT05417841|Drug|Insulin Degludec and Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp BID in T2DM
75875711|NCT05417841|Drug|Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM
75875712|NCT03691194|Dietary Supplement|fresh orange juice|The fresh oranges will be bought from Sysco. They will be squeezed at the kitchen of School of Allied Health Professional with a juicer. They will either be squeezed the night before or on the same day. The juice will not be treated with additional preservatives or sugar. The brand of the juicer is Kitchen Aid. Eight ounces of fresh orange juice needs approximately two and half oranges. They will be put into 32 oz water bottles that were bought from Sysco, and then store them in the refrigerator. They will be given to the subjects every three or four days.
75875713|NCT03691194|Dietary Supplement|concentrated orange juice|The concentrated orange juice will be bought from Sysco then reconstituted. One part of concentrated orange juice needs four parts of water to reconstitute. Then, it will be measured and the reconstituted orange juice will be put into 32 oz water bottles that we bought from Sysco. They will be stored in the refrigerator. The subjects will need to get the reconstituted orange juice every three or four days.
75875714|NCT03691116|Behavioral|Digital Health Profile|Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)
75875715|NCT03691116|Behavioral|Treatment as usual|Ordinary psychological assessment and counseling.
75875716|NCT03691038|Drug|Pregabalin 75mg bid|Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
75875717|NCT03691038|Drug|Pregabalin 25mg, 50mg|Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
75875718|NCT03686982|Other|Active Nitrate Bar|Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione
75875719|NCT03686982|Other|Placebo Bar|No active ingredients
75875720|NCT05597319|Procedure|Liver resection|Liver resection, different kind of according to pathology
75875721|NCT03690960|Procedure|electrospun TAP nanofibers|electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
75567865|NCT04889066|Drug|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
75567866|NCT04883528|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
75567867|NCT04883528|Drug|Placebo|sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
75567868|NCT04870645|Procedure|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
75567869|NCT04870645|Procedure|Conventional Magnetic Resonance Imaging|Undergo conventional MRI
75567870|NCT04870645|Drug|Gadolinium-Chelate|Contrast agent
75567871|NCT04870645|Drug|Iopamidol|Contrast agent
75721234|NCT00747227|Device|modified light transmission intraocular lens|violet visible light blocking acrylic intraocular lens
75721235|NCT00747227|Device|monofocal acrylic intraocular lens|conventional hydrophobic acrylic intraocular lens
75721236|NCT04090541|Other|Rigid Tape|Non-Elastic Tape
75875722|NCT03690960|Procedure|modified TAP paste|modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
75567872|NCT04868149|Procedure|Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS)|Surgery procedure
75567873|NCT04867902|Behavioral|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
75567874|NCT04864392|Drug|LNA043 Dosing Regimen A|Injection to the knee
75567875|NCT04864392|Drug|LNA043 Dosing Regimen B|Injection to the knee
75567876|NCT04864392|Drug|LNA043 Dosing Regimen C|Injection to the knee
75721237|NCT04090541|Other|Kinesiology Tape|Tape can be elongate only one direction
75721238|NCT04090541|Other|Biomechanical Tape|Tape can be elongate only two direction
75721239|NCT04011657|Other|Compulsory CDSS|Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
75721240|NCT04019951|Dietary Supplement|Ca-propionate 1 g|1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
75721241|NCT04019951|Dietary Supplement|Ca-propionate 3 g|3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
75721242|NCT04019951|Dietary Supplement|Placebo|2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
75721243|NCT05351073|Drug|NBO|Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
75567877|NCT04864392|Drug|LNA043 Dosing Regimen D|Injection to the knee
75567878|NCT04864392|Drug|Placebo|Injection to the knee
75567879|NCT04863443|Device|Ultrasound|ultrasound scanner to collect sonographic imaging data from the breast
75721244|NCT04091399|Drug|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
75721245|NCT00955227|Dietary Supplement|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
75721246|NCT00955227|Drug|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
75721247|NCT00949299|Drug|buprenorphine|intradermal injection
75721248|NCT00747149|Drug|Rosuvastatin|Oral
75721249|NCT00271609|Drug|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
75721250|NCT00548847|Biological|GM-CSF|Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
75721251|NCT00548847|Biological|Interferon-α-2b|Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
75567880|NCT04854980|Other|Blood Sample|Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.
75875723|NCT03683160|Other|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
75721252|NCT00949377|Drug|Methylnaltrexone Bromide (MNTX)|The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
75875724|NCT03683082|Drug|Oxygen supplementation|40% FiO2 via Venturi mask
76045056|NCT05217121|Other|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles, the needle will be punctured and 5 ml of saline will be injected into the postero-lateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
75721253|NCT00949377|Drug|Placebo|Normal saline
75721254|NCT00290407|Drug|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
75721255|NCT00290407|Dietary Supplement|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
75422476|NCT05962515|Procedure|ultrasound guided dry needling|Dry needling was applied in the intervention room with sterile conditions the patient in the prone position.The low frequency (2-5 MHz) transducer is placed in the gluteal region in a slightly oblique position and sonographic scanning is started. First, the large mountain shadow of the iliac crest and gluteus maximus muscle is sonographically visualized in the midline. Then the transducer is shifted inferiorly until the sciatic notch is visualized. When the sciatic notch, sciatic nerve and the pear-shaped piriformis muscle above it are visualized, the patient's knee is flexed and the leg is rotated internally and externally, and the typical sliding motion of the piriformis muscle is observed. After the target point is determined, a 22 G spinal needle is applied from lateral to medial or from medial to lateral with in plane technique. The needle is inserted and withdrawn several times until the switch response in the piriformis muscle is observed and extinguished
75422477|NCT05962489|Device|DBS|deep brain stimulation
75567881|NCT04843059|Other|The resident memory T-cell infiltrate in perilesional vitiligo skin|"The 3 groups will receive a combination of narrowband UVB (Nb-UVB) 3 times a week and oral mini pulses of systemic steroids (5 mg of d medrol 16mg twice a week) for 24 weeks.~Three visits will be done (inclusion, Week 12 and 24) A skin biopsy will be done on lesional and peri-lesional area at baseline. Another skin biopsy will be taken after 24 weeks but only in perilesional area. A blood sample for assessing the circulating memory T cells and for checking the tolerance will be performed at baseline, then at W12 and W24."
75721256|NCT05350683|Procedure|Remote ischemic preconditioning|In the 12 hours prior to surgery, the principal investigator performed the remote ischemic preconditioning (RIPC) following the protocol: 4 cycles of inflation/deflation of a pneumatic arterial tourniquet on the non-dominant upper extremity. Considering inflated a pressure of 50mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of deflation. Patients included in the preconditioning group were randomized at a rate of 1:1 consecutively.
75721257|NCT01070017|Other|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
75721258|NCT00955383|Drug|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
75721259|NCT00955383|Drug|Placebo|Matching placebo
75721260|NCT02597387|Drug|Mitoxantrone HCL Liposome Injection|
75721261|NCT01069081|Drug|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
75721262|NCT01069081|Drug|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
75875725|NCT03683082|Drug|Sham O2 (medical air)|Medical air supplementation via Venturi mask
75567882|NCT04839952|Behavioral|Healthy Lifestyles|12 telehealth sessions. The first 5 visits include psycho/medical education plus a motivational interviewing component. The second 7 sessions include psycho/medical education plus a problem solving training component.
75567883|NCT04839952|Behavioral|Education-Only Control|This control condition includes meeting with a clinician for one telehealth visit to review nutrition and physical activity recommendations.
75721263|NCT01069081|Drug|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
75875726|NCT03686826|Procedure|Acquisition of MEP und SSEP|Acquisition of MEP und SSEP at two different time points within 1 to 30 days
75875727|NCT03682926|Other|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
75721264|NCT05350605|Behavioral|Breastfeeding position education with lactation simulation model|pregnant women will receive training with a lactation simulation model once in the last trimester.The pregnant woman will wear the lactation simulation model during the education period and show what she has learned practically on the model.Mothers who have given birth will be supported to practice the breastfeeding position in the postpartum service.
75875728|NCT03690882|Other|systematic review of medical imaging|
75875729|NCT03686748|Behavioral|Two-point discrimination training|Patients will undergo multiple sessions of two-point discrimination training.
75875730|NCT03686748|Behavioral|One-point discrimination training|Patients will undergo multiple sessions of one-point discrimination training.
75721265|NCT04019795|Device|REVIAN 101|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light."
75875731|NCT02927847|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
75875732|NCT02927847|Drug|SPECTRUM Nicotine Research Cigarettes (.03 mg)|For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
76045057|NCT05217121|Other|Modified-thoracolumbar interfascial plane block|US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 15 mL will be injected in each side (30 ml totally).
76045058|NCT05252377|Other|Breathing Exercise|"The patient will be asked to close their eyes~He will be asked to relax his head and neck in a semi-sitting position in bed~The patient will be asked to breathe through the nose for 3 seconds by counting~Then he will be told to hold his breath for 3 seconds~As the last step, he will be asked to breathe out again in 3 seconds."
75567884|NCT04837937|Behavioral|Caregiver vs. Patient [Beginner]|Participants will be assigned a 'Caregiver vs. Patient' [Beginner] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.
75875733|NCT02927847|Behavioral|Behavioral Activation|Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
75875734|NCT02927847|Behavioral|Supportive Counseling|Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
76045059|NCT04900831|Diagnostic Test|Omnipolar Eletroanatomical mapping|Analyse intracardiac EGMs collected with the HD Grid catheter (Abbott, Chicago, IL) during routine Atrial Flutter ablation using the Omnipolar algorithm.
75422478|NCT05962437|Device|Self-guided digital Acceptance and Commitment Therapy|Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks without the involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.
75422479|NCT05962437|Device|FM symptom tracking app (FM-ST)|Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.
76045060|NCT05251519|Other|Kinesio Taping|Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
76045061|NCT05251519|Other|Conventional Rehabilitation|Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
76045062|NCT05214001|Drug|Almotriptan 12.5 Mg Oral Tablet|Treatment for an acute, moderate to severe migraine attack
76045063|NCT05214001|Drug|Ubrogepant 50Mg Tab|Treatment for an acute, moderate to severe migraine attack
75567885|NCT04837937|Behavioral|Caregiver vs. Caregiver|Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.
75567886|NCT04837937|Behavioral|Caregiver vs. Physician|Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.
75567887|NCT04837937|Behavioral|Caregiver vs. Patient [Advanced]|"Participants will be assigned a 'Caregiver vs. Patient [Difficult]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict."
75567888|NCT04835597|Behavioral|Behavioral Assessment|Complete movement assessment
75567889|NCT04835597|Other|Electronic Health Record Review|SAE data is collected
75567890|NCT04825886|Device|Zotarolimus-Eluting Stent|Percutaneous coronary intervention using zotarolimus-eluting stent
76045064|NCT05249881|Drug|Semaglutide Pen Injector|All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
76045065|NCT05279989|Other|Seated Tai Chi Qigong|Participants will receive seated Tai Chi Qigong videos.
76045066|NCT05279989|Other|Health Information Videos|Participants will receive videos of health information.
76045067|NCT05279677|Drug|Fecal microbiota transplantation plus Sintilimab and Fruquintinib|"Microbiota capsules containing 1g gut microbiota, po d1-3 before anti-tumor treatment, total for 8 cycles.~Sintilimab 200mg iv, q3w. Fruquintinib 5mg po d1-14, q3w."
76045068|NCT05278117|Procedure|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
76045069|NCT05277337|Biological|Alluzience|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
76045070|NCT05277337|Biological|powder BoNT-A (BOTOX/Vistabel)|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
76045071|NCT05248945|Drug|Evobrutinib|Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
76045072|NCT05248945|Drug|Carbamazepine|Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
76045073|NCT05248711|Behavioral|Calm Daily Move|The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
76045074|NCT04239313|Biological|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose vaccine.
76045075|NCT04239313|Biological|Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose adjuvant.
76045076|NCT04239313|Biological|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.
76045077|NCT05276167|Device|hyperthermic intravesical perfusion|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
75567891|NCT04825587|Procedure|Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.|By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
75721266|NCT04019795|Device|REVIAN 102|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light."
75721267|NCT04019795|Device|REVIAN 103|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light."
75721268|NCT04019795|Device|REVIAN 100|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy"
75875735|NCT03690804|Device|Evaluation of Autonomic nervous system indices|The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
75721269|NCT01581463|Drug|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
75721270|NCT00955461|Procedure|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
75875736|NCT03682692|Drug|ACEI/CCB|benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
75875737|NCT03682692|Drug|ACEI/DIU|benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
75875738|NCT02886585|Drug|Pembrolizumab|
75875739|NCT02886585|Radiation|MRI|
75875740|NCT02886585|Radiation|PET/CT|
75875741|NCT02886585|Procedure|Stereotactic Radiosurgery|
75875742|NCT01568853|Drug|Norepinephrine|Intravenously, 10 ug/min, 24 hours
75875743|NCT01568853|Procedure|Open abdomen|IAH >=20 mmHg, and ACS emerged, such as low urine and decreased FiO2 quickly.
75422480|NCT05962437|Behavioral|Treatment as Usual (TAU)|Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)
75422481|NCT05962411|Other|Dress in Professional Attire|"Adolescents pretend to be adult e-cigarette buyers by dressing in professional attire."
75422482|NCT05962359|Behavioral|Parent-Implemented Communication Treatment|The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
75422483|NCT05962333|Biological|Intra-arterial delivery of autologous MABs|three times intra-arterial administration of autologous mesoangioblasts in biceps brachii of the left arm at 4-6 week interval
75422484|NCT05962320|Other|Education and counselling|Education and counselling of patients and their parents
75567892|NCT04824911|Drug|Clopidogrel|300mg loading and 75mg/day from day 2
75567893|NCT04824911|Drug|Aspirin|Aspirin(100-300mg/day)
75567894|NCT04824911|Drug|Atorvastatin|Atorvastatin 40-80mg/day
75567895|NCT04824911|Drug|Rosuvastatin|Rosuvastatin 20 mg/day.
75721271|NCT00955461|Procedure|Fractionated Laser treatment|
75875744|NCT01568853|Other|enteral nutrition|500-1500 kcal/day; Nasogastric tube feeding;
75875745|NCT01568853|Other|parenteral nutrition|3000 mL parenteral nutrition fluid, intravenously.
75422485|NCT05962320|Other|Avoiding the use of nasogastric catheters, drains and urinary catheters|Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible
75422486|NCT05962320|Other|Stimulation of intestinal motility in the postoperative period|Stimulation of intestinal motility in the postoperative period
75721272|NCT00917033|Device|GlideScope|Orotracheal intubation
75721273|NCT00917033|Device|Macintosh direct laryngoscope|Orotracheal intubation
75721274|NCT00949455|Drug|lapatinib ditosylate|Given orally
75721275|NCT00949455|Other|Placebo|Given orally
75875746|NCT02960438|Drug|E6011|subcutaneous administration
75875747|NCT02960438|Drug|Placebo|subcutaneous administration
75875748|NCT03690726|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training
76045078|NCT05211973|Device|Wrist Actigraphy Device|a watch like wearable sensor
76045079|NCT05211973|Device|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
76045080|NCT05211973|Device|Chair Scale|a wheel-chair compatible scale to measure body weight
76045081|NCT05211973|Device|Handheld Body Fat Percentage Device|a handheld device that measures body fat percentage
76045082|NCT05211973|Device|Bioelectric Impedance Analysis Scale|a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
76045083|NCT05273983|Behavioral|Behavioural Activation|The intervention will span 6 weeks, including two intervention sessions with the primary care psychologist, and 6-weeks use of a mobile activity scheduling app (Strides). In the first intervention session, the psychologist would provide psychoeducation about depression, therapeutic rationale of behavioural activation, aid the patient in identifying their values and corresponding activities that may correspond with their values, introduce the mobile app, and help the patient schedule initial activities/goals. The second intervention session, which would be flexibly scheduled according to patient need, would focus on troubleshooting/clarification of previously discussed topics.
75567896|NCT04821544|Behavioral|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion
75567897|NCT04820985|Other|Vaginal swab|Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing
75721276|NCT04010799|Drug|CHF 6333|CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
75721277|NCT04010799|Drug|Placebo|Placebo - Part I - SAD Placebo Part II - MAD
75721278|NCT04011579|Other|MSFIT|MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
75422487|NCT05962320|Other|Initiation of oral intake in the early postoperative period|Initiation of oral intake in the early postoperative period
75422488|NCT05962320|Other|Early removal of the patient by reducing postoperative IV fluid infusion|Early removal of the patient by reducing postoperative IV fluid infusion
75422489|NCT05962320|Other|Initiation of early mobilization of the patient in the postoperative period|Initiation of early mobilization of the patient in the postoperative period
75567898|NCT04820985|Other|Blood test|Blood sample to measure plasma dose of progesterone
75875749|NCT03690726|Other|Sham stimulation|Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
75567899|NCT04818489|Drug|Colchicine 0.5 MG|colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the standard protocol
75567900|NCT04818489|Other|the standard protocol only|the local standard protocol for COVID19
76045084|NCT05273515|Other|Virtual Reality and 3D Reconstruction|Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
75721279|NCT00749411|Drug|Placebo|matching placebo
76045085|NCT05273437|Behavioral|System identification experiment for physical activity|The system identification experiment in Just Walk JITAI study has two key components that are the focus of the system identification experiment: daily adaptive step goal recommendations and within-day suggestions to either plan a bout of walking or to inspire reflection and, by extension, an increased urge to go for a walk.
76045086|NCT05481073|Device|UV sensor|Use of UV sensor to be informed about the sun exposure daily through a mobile application
76055849|NCT05885984|Behavioral|Acceptance and Commitment Therapy (ACT) plus health education|Session 1: Reviewing experiences on struggles with CRF, realising consequence of controlling, introducing acceptance as an alternative, adopting virtual mindfulness. Education (patient): epidemiologic features of advanced lung cancer. Session 2: Separate thoughts/feelings related to CRF. Education (patient): treatments and symptoms of advanced lung cancer. Session 3: Reviewing caregiver's experiences of struggling with caregiving burden,introducing acceptance as an alternative. Education (caregiver): epidemiologic features of advanced lung cancer. Session 4: Separate caregivers' thoughts/feelings related to caregiving burden. Education (caregiver): treatments and symptoms of advanced lung cancer. Session 5:Understand the importance of values and clarifying personal values for dyads. Education (dyads): eating suggestions. Session 6: Emphasise ongoing value-based goals and commitment to actions for a meaningful cancer life for dyads. Education (dyads): exercising suggestions.
75721280|NCT00749411|Drug|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
75721281|NCT05342805|Procedure|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler
75721282|NCT00955539|Device|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
75721283|NCT00955539|Device|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
75875750|NCT02853591|Procedure|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
75875751|NCT03686592|Other|Measurement of body awareness|Questionnaires+ interviews
75875752|NCT03808506|Diagnostic Test|Fecal calprotectin|Stool test to look at baseline burden of inflammation
75875753|NCT03686436|Device|ocular coherence tomography|imaging by ocular coherence tomography
75875754|NCT03686358|Procedure|Renal artery angioplasty|"Patients meeting the inclusion criteria were selected from the medical records of renal angioplasty performed at the Rennes University Hospital between 01/01/2010 and 12/31/2013. Each selected patient will receive a notice by mail of information. In the absence of opposition from them within a two weeks, the processing of their data will begin :~Evaluation of the results at 3 years of renal angioplasty on atherosclerotic stenosis performed at Rennes University Hospital~Evaluation of indications of renal angioplasty on stenosis atherosclerosis performed after 2009 at Rennes University Hospital~Identification of prognostic factors"
75875755|NCT03686280|Other|Clinical evaluation|A clinical evaluation of the balance and the walk: is carried out by one of the coordinating physiotherapists of the center where the patient realizes his rehabilitation. The latter performs, according to the functional level of the patient, the following tests: Berg balance scale, FAC, PASS, TUG, 10MWT, 6MWT, paretic lower limb traction index , LBA, SSA and SSV, measurement of spasticity and sensitivity(D0, D30 and D90)
75875756|NCT03686280|Other|Intervention - with Robot|16 sessions of 45 minutes of reeducation with robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
75875757|NCT03686280|Other|Intervention - without Robot|16 sessions of 45 minutes of reeducation without robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
75422490|NCT05962320|Other|Reducing opioid use and ensuring pain management|Reducing opioid use and ensuring pain management
75567901|NCT04810806|Procedure|Immediate coronary angiography within 2 hours after randomization|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
75567902|NCT04810806|Procedure|Delayed coronary angiography after stabilization of heart failure|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
75567903|NCT04803474|Diagnostic Test|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
75422491|NCT05962320|Other|Implement nausea and vomiting prophylaxis|Implement nausea and vomiting prophylaxis
75721284|NCT05296161|Drug|Ocrelizumab|Personalized B cell tailored ocrelizumab treatment
75721285|NCT00949611|Behavioral|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
75721286|NCT00949611|Behavioral|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
75721287|NCT03958149|Device|spinal collar|cervical collar to immobilise the cervical spine
75721288|NCT00949689|Behavioral|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
75721289|NCT00955695|Drug|erlotinib hydrochloride|
75721290|NCT00955695|Drug|gefitinib|
75721291|NCT00955695|Other|questionnaire administration|
75721292|NCT00955695|Procedure|quality-of-life assessment|
75721293|NCT00955695|Radiation|whole-brain radiation therapy|
75721294|NCT00955773|Drug|GSK1120212 plus everolimus|Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
75721295|NCT00549549|Drug|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
75875758|NCT03686280|Other|quality of life assessment|A quality of life assessment: SIS questionnaire completed by the patient, the results of which will be reported in the observation book by the coordinating physiotherapist who carried out the evaluations described above. (D0, D30 and D90)
75422492|NCT05962320|Other|Management of thirsty|Management of thirsty
75422493|NCT05962320|Other|Management of fear and stress|Use of recommended non-pharmacological interventions in the management of fear and stress
75422494|NCT05962307|Drug|Bulevirtide|dose of 2 mg/day subcutaneously
75422495|NCT05962281|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS), a form of non-invasive brain stimulation which involves the use of low intensity currents propagated via the scalp, is widely implemented as both a fundamental and clinical neuroscientific tool. Over the last decades, tDCS showed significant therapeutic promise, as numerous studies revealed that it can result in improved attention and executive functions in patients with neurological disorders, through modification of neuronal excitability.
75721296|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
75721297|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
75875759|NCT03686280|Other|An assessment of patient acceptance of robotic rehabilitation|An assessment of patient acceptance of robotic rehabilitation (for patients in the robot group): self-questionnaire to be filled in by the patient (before carrying out the gait tests in order to avoid influence the results) (D30 ans D90)
75875760|NCT03686280|Other|cognitive assessment|An evaluation of cognitive functions (between D0 and D30): research dysexual cognitive-behavioural syndrome, hemineglect visio-spatial, memory disorders. Done by a doctor evaluator.
75875761|NCT03686280|Other|An evaluation of how to use the robot|An evaluation of the robot's modalities of use (for patients in the robot group): time of use, distance travelled, walking speed, exercise duration, percentage of regulated suspension, number of breaks, average length of breaks, total length of breaks. (D30)
75875762|NCT02957942|Device|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
75422496|NCT05962268|Other|Video based education|The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.
75567904|NCT04781504|Behavioral|Exercise|intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
75875763|NCT04059354|Behavioral|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan (DS-DxTx) focusing on vowels that combines efficacious treatment approaches to use with individuals with Down syndrome. The phonological speech intervention, Phonological Cycles approach, is designed for use with children with highly unintelligible speech and the speech motor learning intervention, Script training is a functional treatment to promote phrase level productions. Both approaches are documented to be efficacious with other speech disorders. The proposed approach takes into account the multiple deficits commonly present in individuals with DS, and based on the acoustic and perceptual finding on vowels from our VTLab. Acoustic and perceptual measures will be used to assess treatment efficacy.
75875764|NCT03640910|Device|OT Equators® (Rhein83)|Attachment systems to retain an implant overdenture
75875765|NCT03640910|Device|Locator® (Zest)|Attachment systems to retain an implant overdenture
75875766|NCT03686046|Other|Exploratory use|Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
75567905|NCT04780659|Biological|Comirnaty (COVID-19, mRNA vaccine)|Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.
75567906|NCT04768023|Drug|Juvit D3|Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
75567907|NCT04768023|Drug|Placebo|Matching amount of vegetable oil to the vitamin D3.
75567908|NCT04763915|Other|Correlative Studies (Survey)|Administer surveys
75567909|NCT04763915|Other|Correlative Studies (Interview)|In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention
75721298|NCT00549549|Drug|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
75721299|NCT00270205|Biological|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
75721300|NCT00270205|Biological|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
75422497|NCT05962268|Other|Face to face education|The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
75721301|NCT00270205|Biological|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
75721302|NCT00955851|Other|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
75721303|NCT00949767|Drug|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
75721304|NCT00949767|Drug|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
76045087|NCT05209711|Procedure|Femoral nerve block under ultrasound control with a electrostimulator peripheral nerves 7.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (7.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
76055850|NCT05885984|Other|Health education|Session 1: health education on the epidemiologic features of advanced lung cancer will be taught to patients. Session 2: health education on treatments and related symptoms of advanced lung cancer will be taught to patients. Session 3: health education on the epidemiologic features of advanced lung cancer will be taught to caregivers. Session 4: health education on treatments and related symptoms of advanced lung cancer will be taught to caregivers. Session 5: health education on eating suggestions for advanced lung cancer patients and caregivers will be taught. Session 6: health education on exercising suggestions for advanced lung cancer patients and caregivers will be taught.
75567910|NCT04763915|Behavioral|GeneSHARE|Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.
75567911|NCT04763915|Behavioral|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
75567912|NCT04763915|Behavioral|Standard-of-care & Adaptive Intervention|Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.
75567913|NCT04758403|Radiation|Navigation Bronchoscopy|Navigation Bronchoscopy procedure will be performed per product instructions and the institution's standard practice.
75567914|NCT04758403|Radiation|Cone beam computed tomography (CBCT)|Per Protocol
75875767|NCT03682380|Drug|Seltorexant High Dose|In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
75567915|NCT04753879|Drug|Nab-paclitaxel|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: Abraxane"
75567916|NCT04753879|Drug|Gemcitabine|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: Gemzar"
75721305|NCT00949767|Drug|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
75721306|NCT00949767|Drug|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
75721307|NCT00949767|Drug|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
75422498|NCT05962255|Drug|Furosemide intravenous infusion|"At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics."
75422499|NCT05962255|Drug|Continous intravenous infusion of 0.9% Sodium Chloride solution|Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
75422500|NCT05962255|Drug|Continous intravenous infusion of 5% Glucose solution|Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
75422501|NCT05962216|Drug|Brexpiprazole|Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders
75422502|NCT05962203|Diagnostic Test|Multi-factorial geriatric assessment, monitoring & management systems|Multi-factorial geriatric assessment, monitoring & management systems, e.g. community-based and home-based exercise programs, polypharmacy
75422503|NCT05962190|Behavioral|Diet|High fat (~60% of total energy intake) diet enriched with either SFA or UFA
75721308|NCT00949767|Drug|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
75721309|NCT00949767|Drug|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
75721310|NCT00949767|Drug|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
75875768|NCT03682380|Drug|Seltorexant Low Dose|In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
75875769|NCT03640442|Other|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
75422504|NCT05962138|Behavioral|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online. In addition participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
75422505|NCT05962112|Other|Metabolic investigations after night-shifts|Metabolic investigations after night-shifts
75422506|NCT05962099|Behavioral|Lifestyle and weight loss advice|Commercially available lifestyle and weight loss intervention
75422507|NCT05962073|Device|HFNC|High-flow oxygen therapy before intubation for preoxygenation
75567917|NCT04753879|Drug|Cisplatin|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: N/A"
76045088|NCT05209711|Procedure|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (7.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
75721311|NCT05299827|Other|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
75721312|NCT00949845|Drug|Endotoxin|
75721313|NCT05206929|Other|Self Managed Care|Self Managed Care
75721314|NCT00622284|Drug|Placebo identical to BI 1356 5mg|Placebo tablet once daily
75721315|NCT00622284|Drug|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
75721316|NCT00622284|Drug|BI 1356|5mg, once daily in the morning for 104 weeks
75721317|NCT00622284|Drug|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
75721318|NCT00269113|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
75721319|NCT00269113|Drug|Standard chemotherapy|As prescribed
75721320|NCT04010487|Genetic|whole exome sequencing and RNA-sequencing|The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
75721321|NCT00949923|Dietary Supplement|tea capsule|3 tea capsules daily for 3 weeks
75721322|NCT01069159|Drug|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
76045089|NCT05272969|Diagnostic Test|Beck depression inventory fast screen (Questionnaire)|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
75422508|NCT05962060|Other|Proprioceptive neuromuscular facilition|PNF Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training. PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility.
75422509|NCT05962060|Other|Electrical muscle stimulator|Electrical Muscle Stimulation (EMS), also known as neuromuscular electrical stimulation (NMES) or electromyo stimulation, is a protocol that elicits a muscle contraction using electrical impulses that directly stimulate your motor neurons.
75422510|NCT05962047|Other|Games of WonderTree Augmented Reality|Participants of group 1 (experimental group) will augmented reality based interventions comprising of games of Wonder Tree
75422511|NCT05962047|Other|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
75422512|NCT05962021|Drug|Toripalimab plus Chemotherapy|Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
75567918|NCT04753879|Drug|Irinotecan|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: N/A"
75567919|NCT04753879|Drug|Capecitabine|"Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~Other Name: Xeloda"
75567920|NCT04753879|Drug|Pembrolizumab|"Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~Other Name: MK-3475; Keytruda"
75721323|NCT01069159|Drug|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
75721324|NCT03975205|Drug|Doxorubicin|To measure bioavailabity of Doxil versus Doxorubicin
75721325|NCT01325779|Drug|heparin|subcutaneous heparin 5000 units every 8 hours
75721326|NCT01325779|Drug|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
75721327|NCT05170659|Drug|Relatlimab|
75721328|NCT05352165|Drug|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
75875770|NCT03640442|Other|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
75875771|NCT03690492|Other|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
75875772|NCT03690414|Drug|Experimental BHVI2|Experimental BHVI2 eye drops
75875773|NCT03690414|Drug|Atropine sulfate 0.02% eye drops|Atropine eye drops
75567921|NCT04753879|Drug|Olaparib|"Patients will receive treatment on Days 1-21 during the maintenance phase.~Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~Other Name: Lynparza"
75567922|NCT04751812|Procedure|High-pain extra|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron po. Betamethasone 4 mg iv.~Anesthesia:~As standard + bolus esketamine 0.25 mg/kg iv + Clonidine 1 µg/kg i.v.~Postoperative pain treatment:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
75875774|NCT03690414|Combination Product|Combination eye drops|Combination eye drops with experimental BHVI2 plus 0.02% atropine
75567923|NCT04751812|Procedure|Low-pain opioid free|"Paracetamol, Etoricoxib, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Infusion Dexmedetomidin 0.2 mikrogram/kg/h iv started 5 min before induction Induction: Esketamin 0.1mg/kg + Propofol 1.5-2 mg/kg iv + rocuronium 0.5 mg/kg iv Start of surgery: Esketamin 0.1 mg/kg iv. Maintenance of anesthesia: Sevoflurane Dexmedetomidin inf 0.2 mikrogram/kg/h Esketamin inf 0.1-0.3mg/kg/h and 0.1 mg/kg adjusted after BP and HR 30 min before end of surgery Lidocaine 1 mg/kg iv~Postoperative pain treatment:~• Dexmedetomidin (inf 01-0.2 µg/kg/h) 4 hours postoperative~If pain NRS ≧3 Esketamin 0.1mg/kg iv + Lidocain 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS ≧3 within 30 min after treatment above is given with Esketamin + Lidocain, 2.5 mg Oxycodone iv. is given and may be repeated."
75875775|NCT02959970|Drug|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
75875776|NCT03690258|Device|Variable load exercise|This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
75875777|NCT03921996|Procedure|Radical prostatectomy (RP) followed by ePLND|ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
75875778|NCT03921996|Procedure|Radical prostatectomy (RP) only|Radical prostatectomy
75567924|NCT04751812|Procedure|Standard|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Target controlled infusion (TCI) with doses of propofol and remifentanil based on age, weight and height. Oxycodone 0.1 mg/kg 30 minutes before cessation of remifentanil.~Postoperative care:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
75567925|NCT04750226|Drug|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
75567926|NCT04742634|Drug|DEC-C|"DEC-C will be provided by Taiho Pharmaceuticals.~Cycle 1 Day 1 may take place between Day 42 & Day 100 post-transplant."
75721329|NCT05352165|Drug|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
75721330|NCT05352165|Drug|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
75721331|NCT05352165|Drug|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
75875779|NCT03690180|Diagnostic Test|serum magnesium|assessment of serum magnesium in all patients
75567927|NCT04742634|Device|MyeloSeq-HD|-Laboratory test developed at Washington University School of Medicine
75721332|NCT05352165|Drug|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
75721333|NCT05352165|Drug|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
75721334|NCT02548260|Device|Syndactyly without compression|three week relative immobilization by syndactyly
75721335|NCT02548260|Device|Syndactyly with compression|three week relative immobilization by syndactyly and compression
75721336|NCT02548260|Device|Rigid splint without compression|three week rigid immobilization by splint
75875780|NCT03623880|Behavioral|Unified Protocol|The unified protocol is a form of cognitive behavior therapy focused on helping the person reduce emotional distress through cognitive changes and behavioral skills. Exercises included confronting emotional-driven behaviors and mindfulness activities.
76045090|NCT05272969|Diagnostic Test|Brief Pain Inventory (BPI) (Questionnaire)|Validated questionnaire for pain.
76045091|NCT05272969|Diagnostic Test|German Pain Inventory (Questionnaire)|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
75721337|NCT02548260|Device|Rigid splint with compression|three week rigid immobilization by splint and compression
75721338|NCT00291187|Drug|20 mg VEC-162|20 mg VEC-162
75721339|NCT00291187|Drug|50 mg VEC-162|50 mg VEC-162
75721340|NCT00291187|Drug|100 mg VEC-162|100 mg VEC-162
75721341|NCT00291187|Drug|Placebo|Placebo
75721342|NCT00956163|Procedure|magnetic resonance imaging|Undergo whole-body MRI
75721343|NCT00956163|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
75721344|NCT00956163|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
76045092|NCT05272969|Diagnostic Test|Fatigue Severity and Disability Scale (FSS) (Questionnaire)|Validated questionnaire for perceived fatigue
76045093|NCT05272969|Diagnostic Test|Rotterdam Handicap Scale (RHS) (Questionnaire)|validated questionnaire to assess a patient's functional ability and level of handicap
76045094|NCT05272969|Diagnostic Test|R-PAct (Questionnaire)|The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
75567928|NCT04742309|Drug|Pecs-2 block (single injection)|For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
75567929|NCT04742309|Drug|Paravertebral block (single injection)|For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
75567930|NCT04736966|Drug|Guselkumab 30mg|30mg of Guselkumab administered by subcutaneous injection
75567931|NCT04736966|Drug|Guselkumab 70mg|70mg of Guselkumab administered by subcutaneous injection
75567932|NCT04736966|Drug|Guselkumab 100mg|100mg of Guselkumab administered by subcutaneous injection
75567933|NCT04734626|Diagnostic Test|Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence|CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise
75875781|NCT03623880|Behavioral|Supportive Therapy|Supportive therapy seeks to improve self-esteem, aid the patient with problem solving, and provide structured support using empathetic listening.
75875782|NCT03681990|Drug|3M CHG/IPA Prep|Apply topically to intact skin
76045095|NCT05272969|Diagnostic Test|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
75422513|NCT05961995|Behavioral|Heartfulness meditation|Heartfulness meditation is a secular, specific, guided meditation technique that includes progressive relaxation with a concentrated focus on the heart.
75567934|NCT04729751|Drug|Maralixibat|"Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base"
75567935|NCT04727593|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|Experimental group: MBCT is program developed by Zindel Segal, Mark Williams, and John Teasdale , based on Jon Kabat-Zinn's Mindfulness-based Stress Reduction (MBSR) program. Participants learn to acknowledge their unhelpful thoughts and feelings, allowing the mind to move from an automatic and spiraling thought pattern to a more conscious emotional processing. Mindfulness practices include breath awareness, sitting and walking meditations, and mindful yoga. In this study, the following MBCT structure will be followed: group setting of 12 participants (maximum); 8 online weekly meetings of 2 hours via a videoconference platform (e.g., Cisco Webex), each one mediated by a trained mindfulness instructor(s); daily home practice of the learned skills; 2 hours of retreat after the fifth week; 6 months of home practice; 4 monthly consolidation sessions of 90 minutes each.
75567936|NCT04727593|Other|Treatment as Usual|In this case, participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral, and intervention for people with significant distress difficulties. Regarding pharmacological intervention, medication intake will be monitored during the study and changes will be registered. The engagement in non-pharmacological interventions such as psychological and psychosocial interventions will also be monitored.
75567937|NCT04726501|Other|Combined chemotherapy with or without involved-field radiotherapy|Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.
75567938|NCT04720534|Drug|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
75567939|NCT04720534|Drug|Placebo|calculated volume to match active treatment by sc injection
75567940|NCT04720274|Device|Electromyopathy (EMG) Shorts|Participants will be asked to complete physical activities while wearing EMG shorts
75875783|NCT03681834|Other|Data collection|Data on the effectiveness and safety of the Cor-Knot® knotting device
75875784|NCT04690413|Device|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
75875785|NCT02740335|Drug|Octaplex|OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
75875786|NCT02740335|Drug|Beriplex P/N (Kcentra)|Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
75422514|NCT05961982|Procedure|Chemical Ablation|Undergo EUS-guided chemoablation
75422515|NCT05961982|Procedure|Computed Tomography|Undergo CT
75422516|NCT05961982|Other|Electronic Health Record Review|Ancillary studies
75422517|NCT05961982|Procedure|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Undergo EUS-FNA
75422518|NCT05961982|Procedure|Endoscopic Ultrasound-Guided Radiofrequency Ablation|Undergo EUS-RFA
75422519|NCT05961982|Procedure|Magnetic Resonance Cholangiopancreatography|Undergo MRI/MRCP
75422520|NCT05961982|Procedure|Magnetic Resonance Imaging|Undergo MRI/MRCP
75875787|NCT03690102|Other|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
75422521|NCT05961969|Procedure|Robotic surgery|"Patients with rectal cancer.~Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis"
75567941|NCT04717310|Drug|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
75721345|NCT00956163|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
75875788|NCT03690102|Other|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
75875789|NCT03685812|Diagnostic Test|Autocad software|The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
75875790|NCT05390151|Procedure|Laser treatment of anal fistula|using a radial laserprobe to treat transsphincteric fistula
75875791|NCT05390151|Procedure|RAF|current golden standard in transsphincteric fistula surgery
75875792|NCT03689790|Procedure|sleeve gastrectomy|sleeve gastrectomy
75875793|NCT03689790|Procedure|gastric bypass|gastric bypass
75567942|NCT04717310|Drug|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
75422522|NCT05961943|Behavioral|RESPONSE-2-PAD|The RESPONSE-2-PAD program will undergo evaluation through a pilot study includes 50 patients living with peripheral arterial disease. Participants will take part in an initial assessment which will measure their sedentary time/physical activity using activPAL and their six-minute walking distance. They will then take part in a 12-week tailored, coaching-based intervention delivered remotely. The intervention involves the use of an activity tracker (sedentary reminder) and an online structured education program coupled with coaching calls that review sedentary time and activity goals weekly. At 12-weeks all participants will be invited to a follow up assessment. Participants will also be invited to take part in a semi-structured interview to explore their views and opinions of the program and its acceptability. At six months all patients will be invited for a final follow-up measurements.
75422523|NCT05961930|Behavioral|Questionnaire|Surgeons will be asked to fill in a short questionnaire after surgery on risk of postoperative infection
75567943|NCT04717310|Drug|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
75567944|NCT04717310|Drug|Vehicle|Twice a day (BID)
75567945|NCT04707469|Drug|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
75567946|NCT04700540|Device|Smartwatch Reminder (SR) system|The Smartwatch Reminder (SR) system will automatically transmit pictures and relevant information, such as name or relationship, to a smartwatch worn by the PWMC when family or friends visit.
75567947|NCT04699149|Other|Transcranial magnetic stimulation|Non-invasive brain stimulation
75567948|NCT04699149|Other|Sham transcranial magnetic stimulation|Non-invasive brain stimulation
75567949|NCT04693598|Biological|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
75567950|NCT04677179|Drug|LY3471851|administered SC
75567951|NCT04677179|Drug|Placebo|administered SC
75567952|NCT04675827|Drug|Pertuzumab and tratuzumab fixed dose combination|Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles
75567953|NCT04675827|Drug|Trastuzumab emtansine|Treatment administration: adjuvant T-DM1 for 14 cycles.
75875794|NCT03681756|Behavioral|WALK|Walking program
75875795|NCT05567757|Biological|Arteriovenous conduit implant|Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity
75875796|NCT03752814|Device|SYNOSTE Nitinail System|Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
75875797|NCT05370027|Device|Transcutaneous Auricular Vagus Nerve Stimulation|Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.
75875798|NCT03689556|Diagnostic Test|FLT PET/CT|Patients will receive 3'-deoxy-3'-[18F]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
75875799|NCT05351151|Procedure|bilateral ultra-sound guided maxillary and mandibular nerve blocks|Interventional group will receive bilateral ultra-sound guided maxillary and mandibular nerve block with ROPIVACAINE 4,75 mg/ml.
75567954|NCT04675034|Biological|MEDI7352|Dose A: MEDI7352 Q2W
75721346|NCT00956163|Radiation|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
75721347|NCT00956163|Other|laboratory biomarker analysis|Correlative studies
75567955|NCT04675034|Biological|MEDI7352|Dose B: MEDI7352 Q2W
75567956|NCT04675034|Biological|MEDI7352|Dose C: MEDI7352 Q2W
75567957|NCT04675034|Biological|MEDI7352|Dose D: MEDI7352 Q2W
75567958|NCT04675034|Biological|Placebo|Placebo to match MEDI7352 Q2W
75875800|NCT05351151|Procedure|Infiltration of Lidocaine 1%|Intervention requiring the infiltration of LIDOCAINE 1% at incision sites by surgeon after general anesthesia induction during maxillo-mandibular osteotomy
75875801|NCT03685656|Other|Slimming gel|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
76045096|NCT05272969|Diagnostic Test|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
75567959|NCT04671095|Device|ERCP procedure with single use duodenoscope|ERCP is an endoscopic procedure done to relieve bile duct obstruction. It is done either under conscious sedation or deep sedation. The endoscope is inserted thorough the mouth and is taken to the second part of duodenum (small bowel). The ampulla is identified and the bile duct is cannulated. Biliary obstruction is relieved either by placing a stent or removing the stone/s
75422524|NCT05961917|Other|5 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 5 cmH2O
75422525|NCT05961917|Other|10 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 10 cmH2O
75422526|NCT05961904|Other|Breastmilk|Study group with receive orally 2 ml breast milk before the heel prick.
75567960|NCT04662151|Biological|AT-100|reconstituted AT-100 for intratracheal administration
75567961|NCT04662151|Procedure|Air-sham|room air for intratracheal administration
75567962|NCT04658641|Device|Boston Scientific: Study tool computer|Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
75567963|NCT04655365|Drug|Enzalutamide capsule|160 mg po id
75567964|NCT04651816|Behavioral|Financial Incentives|Participants will be entered into a lottery to receive a gift card for class attendance.
75567965|NCT04651816|Behavioral|Motivational Message|Participants will be sent motivational messages through out their participation in the PSH DPP program.
75567966|NCT04651816|Behavioral|DPP Program|All Participants will be enrolled in the DPP program.
75567967|NCT04644471|Diagnostic Test|CT scanner|1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition
75567968|NCT04644471|Diagnostic Test|Lung MRI|3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence
75567969|NCT04639141|Combination Product|Synbiotic|Prebiotic + Probiotic
75567970|NCT04639141|Behavioral|Gut-directed Hypnotherapy|Psychotherapy sessions
75721348|NCT04016766|Behavioral|Mobile app prepartying intervention|The intervention is comprised of a theoretically-informed and empirically-supported, brief, accessible, and personalized intervention to address prepartying drinking. the prepartying intervention app will be tailored toward an individual's personal goals, beliefs (perceptions, expectancies, self-efficacy), and behavior (protective strategies), and focus on the core components of brief interventions that have been cited as constructs that mediate the effects of multiple component intervention programs (e.g., correcting perceived norms, use of protective behavioral strategies, increased self-efficacy, challenging expectancies, feedback on blood alcohol level).
75721349|NCT00839046|Behavioral|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
75721350|NCT00839046|Other|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
75721351|NCT00839046|Other|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
75721352|NCT00956241|Procedure|j-pouch coloanal anastomosis|
75875802|NCT03685656|Other|Slimming gel placebo|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
76045097|NCT05272969|Diagnostic Test|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
75422527|NCT05961891|Procedure|The Use of Composite Bone and Nail Bed Graft Combined With Cutaneous Flaps for Reconstruction of Finger Tip Amputations|"The amputated finger tip is cleaned and a composite graft including the nail bed and bone of distal phalanx is taken from the amputated part.~The bone of the amputated part is fixed to the remaining stump of the distal phalanx with an axial 21gauge needle or by a K-wire (0.8 mm).~The nail bed graft is sutured with 6-0 vicryl to the remaining nail bed.~A local or regional cutaneous flap is used to cover the volar aspect and tip of the distal phalanx bone e.g. V-Y advancement flap, thenar flap or cross finger flap .The flap should protrude beyond the tip, providing extra skin which is recontoured to a rounded tip.~The nail plate is inserted in the nail fold to prevent the formation of synechiae between the nail fold and the injured nail bed.~The finger is immobilized for two weeks in a below elbow dorsal slab.~Patients are followed up for 3 months. Postoperative complications and their management will be recorded."
75567971|NCT04636814|Drug|CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily
75721353|NCT00956241|Procedure|side-to-end coloanal anastomosis|
75567972|NCT04636814|Drug|CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily
75567973|NCT04636814|Drug|Placebo|CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily
75567974|NCT04636814|Drug|Roflumilast|- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid
75721354|NCT00835458|Procedure|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
75721355|NCT00956319|Drug|Zolpidem MR|oral
75721356|NCT00956319|Drug|Estazolam|oral
75875803|NCT05339919|Diagnostic Test|gait speed; ct scan;grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
75875804|NCT04059432|Diagnostic Test|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
75875805|NCT01749709|Behavioral|Music listening|
75721357|NCT02547948|Biological|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
75422528|NCT05961878|Dietary Supplement|mediterranean diet with adequate protein intake|balanced mediterranean diet with 1.1 g/kg die protein intake
75422529|NCT05961852|Device|Angioplasty|Angioplasty with cutting and drug-coated balloon
75422530|NCT05961813|Behavioral|Intensive intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation and will complete 6 visits (2 before surgical intervention, 4 visits within the following 12 months), as well as follow up phone calls for progressi monitorization.
75721358|NCT00961779|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
75721359|NCT00961779|Drug|Placebo|Normal saline infusion
75875806|NCT01749709|Behavioral|Audiobook listening|
75875807|NCT01568931|Drug|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
75875808|NCT01568931|Drug|Saline|intracoronary, saline, bolus 1 cc
75422531|NCT05961813|Behavioral|Brief intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation 4 weeks before surgery, as well as follow up phone calls for progressi monitorization.
75875809|NCT05300763|Device|senofilcon A prototype|Test
75875810|NCT05300763|Device|Dailies Total 1|Control
75875811|NCT04800367|Drug|Romosozumab Prefilled Syringe [Evenity]|2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit
75875812|NCT04800367|Drug|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|1 subcutaneous injection of 60 mg/mL every six months from study 12 month visit through the 24 month visit. Injections occur at the 12 and 18 month visits.
75422532|NCT05961800|Behavioral|Cutaneous Probe|A computer-controlled probe delivers temperatures to the skin to measure pain, offset analgesia and onset hyperalgesia.
75422533|NCT05961800|Behavioral|Quantitative Sensory Testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
75422534|NCT05961800|Behavioral|Computer Tasks|Quantitative Sensory Testing (QST) and computer tasks are used to measure changes in pain intensity.
75422535|NCT05961787|Device|SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)|"Investigation on DCB vs DES on Symptomatic or silent ischemic coronary artery disease with indications for PCI~Lesions ≤35 mm in length (visual), diameter 3-4 mm.~A maximum of 2 target lesions on 2 major epicardial coronary target vessels can be treated during baseline procedure. (e.g., one target lesion on one target vessel, or two target lesions on the same target vessel but separated ≥ 15 mm; Or 1 target lesion on each of the target vessels)"
75721360|NCT00835848|Drug|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
75721361|NCT00835848|Drug|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
75721362|NCT00961857|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
75721363|NCT00961857|Drug|Comparator: metformin 500 mg|A single dose of metformin 500 mg tablets
75721364|NCT00961857|Drug|Comparator: sitagliptin|A single 50 mg tablet of sitagliptin
75721365|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
75721366|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
75875813|NCT05279859|Drug|ERAS-007|Administered orally
75875814|NCT05279859|Drug|ERAS-601|Administered orally
75422536|NCT05961774|Device|Transcranial magnetic stimulation|The stimulation point is the lumbar multifidus hotspot. The parameters will be set at frequency 10 Hz, 50 number of pulses, 40 train of stimulation (5 seconds stimulation and 25 seconds inter-stimulation interval). The position of coil will be placed tangentially at 45 degrees on the LM hotspot. The stimulation will be 20 minutes.
75422537|NCT05961774|Device|Neuromuscular electrical stimulation|The neuromuscular electrical stimulation will be set as interferential current 6000 Hz, amplitude 20-50 Hz with scanning mode, duration 20 minutes, intensity to elicit the LM contraction.
75422538|NCT05961761|Drug|Propranolol|propranolol 40 mg x2 daily
75422539|NCT05961761|Drug|Pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks
75567975|NCT04634279|Behavioral|Collaborative care Plus|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In this model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care. In the Collaborative Care Plus condition, the care coordinator involves family in care, teaches family about naloxone use, and provides Caring Contacts, a suicide prevention method, to patients.
75721367|NCT00961857|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablets
75721368|NCT02547792|Biological|VXA-BYW.10 (Low Dose) Oral Vaccine|Enteric coated tablet for oral delivery
75875815|NCT05279859|Drug|Gilteritinib|Administered orally
75875816|NCT05233995|Procedure|Damage Control Surgery|Delayed anastomosis
75875817|NCT03713658|Drug|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
75875818|NCT03713658|Drug|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
75875819|NCT03713658|Drug|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
75422540|NCT05961735|Other|PECS II Block|The Pecs II block is applied to the patients after induction of anesthesia .
75422541|NCT05961735|Other|Combined Serratus Anterior Plane Block|Combined Serratus Anterior Plane Block is applied to the patients after induction of anesthesia .
75422542|NCT05961722|Other|preoperative IV 0.9% saline 200 ml|Group 1 will be infused with IV 0.9% saline 400 mL/h for half an hour (200 mL) starting two hours before anesthesia.
75422543|NCT05961722|Other|preoperative dextrose 5% 200 ml|Group 2 will be infused with dextrose 5% 400 mL/h for half an hour (200 mL) starting two hours before anesthesia .
75422544|NCT05961722|Other|preoperative and intraoperative dextrose 5% 200 ml|Group 3 will be infused with dextrose 5% 400 mL/h for half an hour (200 mL) starting two hours before anesthesia and with dextrose 5% 400 mL/h for half an hour (200 mL) during surgery .
75422545|NCT05961709|Drug|Cemiplimab|Given by IV (vein)
75422546|NCT05961683|Device|NIV plus software|interventions received by infants studied after placing them on ventilator using NIV plus software
75422547|NCT05961670|Device|Neer Infrared Spectroscopy|Premature infants will be studied with brain and lung NIRS before and after surfactant administration
75567976|NCT04623944|Biological|NKX101 - CAR NK cell therapy|NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
75567977|NCT04598919|Drug|Saracatinab|125 mg once daily by mouth for 24 weeks
75567978|NCT04598919|Drug|Placebo|once daily by mouth for 24 weeks
75721369|NCT02547792|Biological|VXA-BYW.10 (High Dose) Oral Vaccine|Enteric coated tablet for oral delivery
75721370|NCT02547792|Other|Placebo Tablets|Enteric coated tablet for oral delivery
75721371|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
75721372|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
75721373|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
75721374|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
75875820|NCT03713658|Drug|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
75875821|NCT03713658|Drug|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
75875822|NCT03713658|Drug|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
75875823|NCT03713658|Drug|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
75875824|NCT03713658|Drug|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
75567979|NCT04590937|Drug|BI 730357|Film-coated tablet
75422548|NCT05961657|Diagnostic Test|Hemodynamic measurements by USCOM|We will measure cardiac output, cardiac index, and systemic vascular resistance index on 3, 7, and 14 postnatal days using the UltraSonic Cardiac Output Monitor.
75422549|NCT05961553|Behavioral|Physical Activity Counseling session|The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.
75422550|NCT05961553|Other|Pulmonary Reabilitation|The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.
75567980|NCT04590937|Drug|CRESTOR®|Film-coated tablet
75567981|NCT04590937|Drug|Lenoxin®|Tablet
75567982|NCT04590937|Drug|MetfoLiquid GeriaSan®|Oral solution
75567983|NCT04590937|Drug|Lasix®|Oral solution
75567984|NCT04576897|Diagnostic Test|Velacur|Ultrasound elasticity imaging
75422551|NCT05961501|Drug|An aqueous solution containing CBD and CBN|An aqueous solution containing CBD and CBN, to drink at home in the dose determined by the attending physician
75422552|NCT05961501|Other|The aqueous solution of placebo|An aqueous solution of placebo, to drink at home in the dose determined by the attending physician
75422553|NCT05961488|Other|Coronary Calcium Score and Coronary CT angiogram|Introduction of early Coronary CT angiogram and Coronary Calcium Score in the first days after a resuscitated out-of-hospital cardiac arrest.
75422554|NCT05961475|Dietary Supplement|Fruit snack 1|Fruit snacks with original level of sugar
75422555|NCT05961475|Dietary Supplement|Fruit Snack 2|Fruit snacks with original level of sugar and mulberry leaf extract
75567985|NCT04571749|Behavioral|Customized handoff|A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
75567986|NCT04565691|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal treatment that is accepted to cause bacteremia in about 50% of the cases.
75567987|NCT04563923|Drug|Avdoralimab (IPH5401)|Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
75567988|NCT04563923|Other|Control|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~Patients of less than 45kg of body weight: 2 tubes of 10g/d~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion"
75567989|NCT04562558|Drug|Methotrexate|50mg intramuscularly on Days 1, 3, 5, 7 . Repeat every 14 days
75567990|NCT04562558|Drug|Leucovorin|15mg intramuscularly on Days 2, 4, 6, 8. Repeat every 14 days
75567991|NCT04562558|Drug|Dactinomycin|1.25mg/m2 (2mg max dose)intravenous every 14 days.
75567992|NCT04560673|Drug|Duloxetine|Given PO
75567993|NCT04560673|Behavioral|Neurofeedback|Receive neurofeedback training
75567994|NCT04560673|Other|Quality-of-Life Assessment|Ancillary studies
75567995|NCT04560673|Other|Questionnaire Administration|Ancillary studies
75567996|NCT04545723|Device|FibriCheck|FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
75567997|NCT04542356|Drug|PEG-rhG-CSF|During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
75567998|NCT04542356|Drug|rhG-CSF|Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
75567999|NCT04530409|Drug|Early-Corticosteroids|early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers
75568000|NCT04528329|Drug|Early-Dexamethasone|early use of dexamethasone as early as laboratory evidence of high inflammatory markers
75875825|NCT03713658|Drug|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
75721375|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
75721376|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
75721377|NCT04009941|Drug|PEG-rhG-CSF|4.5mg per cycle, 24 hours after chemotherapy
75721378|NCT00830466|Drug|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
75422556|NCT05961475|Dietary Supplement|Fruit Snack 3|Fruit snacks with reduced level of sugar
75422557|NCT05961475|Dietary Supplement|Fruit Snack 4|Fruit snacks with zero added sugar
75721379|NCT04412265|Other|Relation between frailty and clinical outcomes in elderly patients with COVID-19.|"To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration."
75721380|NCT00830544|Drug|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
75721381|NCT00830544|Drug|Chemotherapy|Neoadjuvant chemotherapy
75721382|NCT00830544|Drug|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
75721383|NCT04407897|Radiation|Stereotactic radiotherapy|Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
75721384|NCT04382235|Device|Non-invasive ventilatory support|All non-invasive ventilatory support wll be recorded. All collected data is taken and monitored during normal clinical practice without adding any other tests.
75721385|NCT00843570|Drug|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
75422558|NCT05961475|Dietary Supplement|White Bread|White bread with matched carbohydrate as control
75422559|NCT05961449|Behavioral|Cycling exercise|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
75422560|NCT05961449|Behavioral|Cycling control|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase >25% from baseline.
75721386|NCT04010877|Biological|CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells|Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
75721387|NCT05169723|Behavioral|Exertional respiratory activities|participants will perform a series of exertional respiratory activities
75721388|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
75721389|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
75422561|NCT05961436|Procedure|PENG block|Using ultrasound-guided technique, a total of 20ml of 0.25 % bupivacaine will be injected after negative aspiration.
75422562|NCT05961436|Procedure|FN block|Using ultrasound-guided technique, after negative aspiration, 20 mL of 0.25 % bupivacaine will be administered.
75875826|NCT03681522|Procedure|Pelvic plexus block|Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
75875827|NCT03681522|Procedure|Periprostatic nerve block|Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
75568001|NCT04528329|Drug|Late dexamethazone|Use of dexamethasone on deterioration of the cases with increased severity
75422563|NCT05961423|Procedure|Robotic surgery|The patient group undergoing robotic surgery for the treatment of locally advanced colorectal cancer
75568002|NCT04527406|Procedure|posterior hemivertebra resection|The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
75568003|NCT04527406|Procedure|conservative treatment+ delayed posterior hemivertebra resection|In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
75568004|NCT04526288|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
75422564|NCT05961358|Procedure|snapshots or videos of monitor|The mobile device（a phone）was used to obtain the screen image of the monitor, and the arterial blood pressure waveform is extracted by image processing technology.
75422565|NCT05961358|Procedure|Pressure transducer|Arterial catheter were connected to conventional pressure transducers and Flotrac-Vigileo transducers.
75568005|NCT04526288|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
75568006|NCT04524572|Behavioral|Motion sensor|To explore the role of a motion sensor with accompanying web application on step counts, energy balance, and metabolic markers in nurses
75721390|NCT05156463|Combination Product|PAI Tool and Exercise Coaching|Use of PAI tool and self-monitoring tools to increase physical activity and reduce sedentary behaviors. Participants will receive a personalized physical assessment and counseling from healthcare provider, exercise logs and a Garmin activity tracker to use between visits and 9 exercise coaching calls between clinical visits.
75875828|NCT03681444|Other|Regular diet|Patients will be provided with any type of food preferred at any time in any quantity
75875829|NCT03681444|Other|Clear fluid diet|"Patients will be provided with~Plain water~Fruit juices without pulp, such as grape juice, filtered apple juice, and cranberry juice~Soup broth (bouillon or consommé)~Clear sodas, such as ginger ale and Sprite~Gelatin (Jell-O)~Tea or coffee with no cream or milk added~Sports drinks that don't have color"
75875830|NCT03681444|Other|Low residue diet|"The Low Residue Diet is the same as the soft diet with the added limitation of milk to one pint. It provides foods that are easily digestible. It is often used as a transition diet from liquids to the general diet. Indigestible fiber is reduced by using tender cooked vegetables and ripe, canned or cooked fruits from which the tough skins and seeds have been removed. Tender meat or meat made tender in the cooking process is used, thus reducing the amount of connective tissue.~Adequacy: By following the recommended guidelines, the diet will be adequate according to the Recommended Daily Allowance.~Note: For patients with dentures this diet can be modified by the substitution of ground meat for whole meat and excluding all raw vegetables. Personal tolerances determine food choices; avoid foods that cause GI (gastrointestinal) distress prior to the admission even though that food may be on the foods included list."
75721391|NCT05029869|Diagnostic Test|ctDNA|The blood samples for ctDNA and other tumor markers will be first collected within 14 days before surgery, and then be tested after gastrectomy in scheduled interval
75422566|NCT05961345|Other|experimental group|Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.
75422567|NCT05961319|Device|Smart-Home Monitoring|"During the study, various sensors will be employed to capture participant interactions with appliances and furniture. These sensors may include:~Interaction Sensors: These sensors are designed to recognize users' interactions with appliances and furniture within the smart environment.~Smart Biomechanics Devices: Devices such as a Fitbit device an internet of Things grip Dynamometer will be utilized to assess physical balance and strength.~Positioning System using Ultra-Wide Band (UWB) Technology: This positioning system leverages UWB technology, enabling furniture-level accuracies in interpreting self-care activities.~As participants engage with different elements of the smart environment, these sensors will collect data. Additionally, participants will be recorded via video to further enhance the observational data captured during the study."
75721392|NCT02547870|Drug|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
75721393|NCT02547870|Drug|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
75422568|NCT05961280|Procedure|Mastectomy with sentinel lymph node biopsy|
76045098|NCT05272969|Diagnostic Test|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
75721394|NCT02547870|Drug|Aged RPV-LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
75721395|NCT04251897|Device|Novel support surface|This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
75721396|NCT00836238|Behavioral|Interview|Physical Function and Symptom Assessment Interviews
76055851|NCT05885919|Drug|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
75568007|NCT04505371|Behavioral|Wellness Intervention for Smokers with HIV|"WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.~Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study."
75568008|NCT04505163|Procedure|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Arctic Front Advance cryoballoon ablation system to ablate the pulmonary veins to achieve PVI alone
75721397|NCT00836238|Other|Physical Function Tests|3 physical function tests.
75721398|NCT02547168|Device|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
75721399|NCT04016610|Device|Soliton's Acoustic Scar Reduction (SAR)|Treatment of keloid scars for the temporary improvement in appearance.
75721400|NCT00836316|Drug|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
75721401|NCT00962169|Other|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
75721402|NCT00962169|Other|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
76055852|NCT05885919|Drug|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
76055853|NCT05885906|Drug|Aloevera|Mouthwash
75568009|NCT04505163|Device|Cryoballoon PVI + Posterior Wall Isolation|Arctic Front Advance Cardiac Cryoballoon Ablation System to ablate the pulmonary veins and the left atrial posterior wall to achieve PVI + posterior wall isolation within the region of the pulmonary venous component
75568010|NCT04505020|Other|3D Print + Conventional imaging|This group will have a 3D reconstruction of their hip printed using a 3D printer so that the PI can use it in their pre and intra-operative planning along with traditional imaging.
75568011|NCT04505020|Other|Conventional imaging|This group will have CT, MRI and X-Ray imaging completed so that the PI can use it in their pre and intra-operative planning.
75721403|NCT00836394|Device|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
75721404|NCT00843960|Behavioral|behavioral adaptation and symptom management|behavioral adaptation and symptom management
76055854|NCT05885906|Drug|Thyme honey|Mouthwash
76055855|NCT05885906|Drug|Saline|Mouthwash
75422569|NCT05961267|Behavioral|Questionnaire|A gynecological follow-up questionnaire will be proposed to patients with one of the above mentioned pathologies. This is a standardized questionnaire specifically designed for this study.
75422570|NCT05961254|Device|assesment of difficult endotracheal intubation by airway ultrasound|preoperative assesment of airway by ultrasound to predict difficult endotracheal intubation in patients undergoing general anesthsia
75568012|NCT04495608|Drug|Fluconazole|"Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :~From W0 to W2 : 1 caps/ day~From W2 to W4 : 1 or 2 caps/day~From W4 to W6 : 1, 2 or 3 caps/day~From W6 to W18 : 1, 2, 3 or 4 caps/day~The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6).~During the titration period, if 24-hours calciuria is > 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable.~After W6 and until the end of the study, the treatment dose will remain stable (stable period)."
75568013|NCT04495608|Drug|Placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
75568014|NCT04493892|Behavioral|Educational Intervention|Deliver an educational intervention on harmful chemical exposures, such as phthalates, found in hair care products, developed by the research team using empirical evidence with key informant feedback. The intervention will cover phthalates 1) Exposure through HCPs 2) Potential adverse health outcomes for the mother and child 3) Ways to reduce exposure
75568015|NCT04478838|Drug|Risperidone|0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg Tablets
75568016|NCT04478838|Drug|Olanzapine|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg Tablets
75568017|NCT04463316|Diagnostic Test|Retrospective file studies|No intevention, retrospective file study: medical history, laboratory values, additional tests, physical and psychological complaints.
75568018|NCT04460638|Biological|Saliva collection|Saliva samples are regularly collected over a period of up to 30 consecutive days.
75721405|NCT00962325|Behavioral|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
75721406|NCT00839202|Other|FVIII immuno-assay|There is no intervention. This is a study of the differences in assays.
75721407|NCT00962403|Behavioral|Yoga treatment|The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
75568019|NCT04460638|Other|Clinical assessment|The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
75875831|NCT03681444|Diagnostic Test|Colonoscopy|Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
75875832|NCT05475717|Drug|Alprostadil liposome injection|Alprostadil liposome injection, iv drip, QD×4 days (1 to 3 hours before surgery and 3 days after surgery)
76045099|NCT05272969|Diagnostic Test|Muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
76045100|NCT05272969|Diagnostic Test|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
76045101|NCT05272969|Diagnostic Test|Borg Scale|The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
76045102|NCT05272969|Diagnostic Test|Laboratory assessment: Creatine kinase|CK-Level assessment in peripheral blood (peripheral venous blood draw)
75422571|NCT05961241|Other|runnin training program|gradual training program
75422572|NCT05961228|Other|exercise|"Three different posture with and without correction according to the Schroth method"
75422573|NCT05961202|Drug|Hydroxychloroquine|Hydroxychloroquine 200mg bid
75422574|NCT05961202|Drug|Prednisolone|Prednisolone 15mg qd
75875833|NCT03689322|Other|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
75875834|NCT03689322|Other|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
75875835|NCT03689322|Other|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
75875836|NCT04171375|Device|trans-spinal Electrical Stimulation (tsES)|The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
75875837|NCT03685266|Other|Observation|There are no specific interventions in this study; it is observational only. One could argue that the act of observing the participants may change their behavior (the Hawthorne effect).
75721408|NCT05010837|Other|Kinesio taping with abdominal exercises|"Experimental group was given kinesio taping along with abdominal exercises. Kinesio taping was applied in I-band technique. the first band is applied on rectus abdominis from origin to insertion starting from pubic symphysis till the xiphoid process. the second band is applied bilaterally on the left and right side external oblique muscles.~Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed along with kinesio taping."
75568020|NCT04450628|Procedure|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
75875838|NCT05133687|Drug|Bupivacaine Hydrochloride|Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
75875839|NCT03689088|Device|Goldfish|Goldfish will be placed in the eye for 24h monitoring
75721409|NCT05010837|Other|Abdominal exercises|"Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed."
75875840|NCT03689088|Device|Tonometry|Fellow eye will be measured by tonometry
75875841|NCT01383135|Drug|F18-FPPRGD2|Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
75875842|NCT03685032|Drug|Dexamethasone|The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
75875843|NCT03685032|Drug|Ondansetron|The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
75875844|NCT03685032|Drug|0.9% Sodium Chloride Injection|The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
75875845|NCT04109274|Behavioral|Exercise|Exercise component: Aerobic exercise, using recumbent bikes, delivered within the cancer institution. Participants will take part in up to 30-minutes of moderate intensity (50-70% HRmax or 4-6/10 on Rate of Perceived Exertion scale)6 exercise for eight sessions during chemotherapy. An exercise specialist with experience in cancer rehabilitation will supervise the exercise component.
75875846|NCT04109274|Behavioral|Self-Management|Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines
75875847|NCT04109274|Behavioral|Booster Sessions|Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.
75875848|NCT02451111|Drug|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
75721410|NCT04043754|Procedure|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
75721411|NCT04043754|Procedure|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
75721412|NCT00836550|Behavioral|Video|The participants saw a 6 minute video
75721413|NCT00836550|Behavioral|in-person HIV pre-test counseling|
75721414|NCT02546778|Device|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
75568021|NCT04450628|Device|EndoFLIP 1.0 System EF-100|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
75875849|NCT02451111|Drug|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
75875850|NCT03689010|Drug|Azelaic acid foam 15%|Azelaic acid foam 15%
75568022|NCT04447313|Other|Survey Administration|Ancillary studies
75721415|NCT00546819|Biological|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
76045103|NCT05272969|Diagnostic Test|Laboratory assessment: Vitamin D Level|Vitamin D Level in peripheral blood (peripheral venous blood draw)
75721416|NCT00546819|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
75721417|NCT04010643|Behavioral|online cognitive behavioural therapy|oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey & O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
75875851|NCT03689010|Drug|Finacea® (Azelaic acid Foam) 15%|Azelaic acid foam 15%
75875852|NCT03689010|Drug|Vehicle of the test product|Vehicle of the test product
75875853|NCT03681288|Behavioral|Mindful Self-Compassion|Mindful Self-Compassion Intervention
75875854|NCT05451771|Drug|Venetoclax Oral Tablet, 200 mg|200 mg oral tablet daily
75875855|NCT05451771|Device|FISH assay|Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.
75875856|NCT05451771|Drug|Venetoclax Oral Tablet, 400 mg|400 mg oral tablet daily
75875857|NCT05451771|Drug|Dexamethasone Oral, 10 mg|10 mg oral tablet weekly
75875858|NCT05451771|Drug|Dexamethasone Oral, 20 mg|20 mg oral tablet weekly
76045104|NCT05272969|Diagnostic Test|Laboratory assessment: calcium|calcium level in peripheral blood (peripheral venous blood draw)
76045105|NCT05272969|Diagnostic Test|Laboratory assessment: magnesium|magnesium level in peripheral blood (peripheral venous blood draw)
75568023|NCT04447313|Behavioral|Telephone-Based Intervention|Receive ACT telephone coaching
75568024|NCT04447313|Behavioral|Telephone-Based Intervention|Receive SBT telephone coaching
75568025|NCT04446416|Device|NaviFUS System|Open the BBB using focused ultrasound and contrast agent SonoVue®
75568026|NCT04446416|Drug|Bevacizumab|An anti-angiogenic agent to block tumor growth
75568027|NCT04440930|Other|White tea|Mouthwash with white tea five to six times a day for nine weeks
75568028|NCT04440930|Other|Salt water with soda|Mouthwash with salt water and soda eight to ten times a day for nine weeks
75568029|NCT04435496|Device|GYN-CS|placement of the GYN-CS device
75875859|NCT05451771|Drug|Daratumumab Injection|Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.
75875860|NCT05451771|Drug|Bendamustine|Bendamustine will be given at an initial dose of 100 mg/m^2 intravenously on days 1 and 2 in each 28-day cycle.
75422575|NCT05961137|Other|Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol|Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
75721418|NCT04010643|Behavioral|online neurocognitive remediation therapy|NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
75721419|NCT00962481|Drug|Bimosiamose|
75721420|NCT00962481|Drug|Placebo|
75422576|NCT05961137|Other|Conventional Prehospital Suspected Sepsis Protocol|Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
75422577|NCT05961111|Drug|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
75568030|NCT04421378|Drug|Selinexor|Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
75568031|NCT04421378|Drug|Temozolomide (TMZ)|Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
75568032|NCT04421378|Drug|Lomustine (CCNU)|Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
75721421|NCT05299437|Drug|Radioiodine optimized therapy|"124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal.~Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status."
75721422|NCT00621504|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
75721423|NCT00621504|Drug|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
75875861|NCT05451771|Drug|Pomalidomide|Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
75875862|NCT05451771|Drug|Ixazomib|Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
75568033|NCT04421378|Radiation|Standard Fractionated Radiation therapy (RT)|Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
75568034|NCT04421378|Drug|Bevacizumab|Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
75568035|NCT04421378|Device|TTField|Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
75568036|NCT04421378|Drug|Carmustine|Dose and Formulation: 150 or 200 mg/m^2; Route of Administration: Intravenous
75568037|NCT04420702|Device|MRI with DBSI analysis|-The procedure will take approximately 1 hour of the participant's time
75875863|NCT05451771|Drug|Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
75875864|NCT02414139|Drug|INC280 (capmatinib)|
75875865|NCT03680976|Drug|CXA-10|Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
75875866|NCT03680976|Drug|Placebo|Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
75568038|NCT04419077|Behavioral|Virtual reality exposure|"Patients will be exposed to a 10-20 min virtual reality session just before an oncological procedure (invasive act or chemotherapy).~Patients will be able to choose between 4 virtual universes (beach, underwater, forest, space) and seven musical content."
75568039|NCT04409600|Behavioral|Supervised Gait Retraining|The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.
75568040|NCT04409600|Behavioral|Home Based Gait Retraining|The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.
75875867|NCT01383057|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
75721424|NCT00621504|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
75875868|NCT03684954|Other|Prf|Take 10 cc blood from patient and gain prf
75875869|NCT03680898|Device|Rectal swab collection|Patient will provide a rectal swab by following hospital-provided instructions.
75875870|NCT03688932|Other|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
75875871|NCT03688932|Other|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
75875872|NCT03688932|Other|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
75875873|NCT05084313|Other|Manual Therapy|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include forty healthy individuals.
75568041|NCT04409600|Drug|Saline Injection|The participant will receive a saline injection to their painful lower leg compartment(s).
75568042|NCT04409600|Drug|Botulinum Toxin Injection|The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
75568043|NCT04396522|Device|noninvasively Bio-electrical Impedance Analysis (BIA)|By means of noninvasively Bio-electrical Impedance Analysis (BIA) to measure body composition, which divides body weight into different components such as lean body mass and fat mass.
75568044|NCT04384198|Procedure|Sonolysis|Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy
75568045|NCT04381832|Drug|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
75568046|NCT04381832|Drug|Zimberelimab|Zimberelimab is an anti-PD-1 antibody
75568047|NCT04381832|Drug|Quemliclustat|Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.
75568048|NCT04381832|Drug|Enzalutamide|Enzalutamide is an androgen receptor inhibitor
75568049|NCT04381832|Drug|Docetaxel|Docetaxel is type of chemotherapy
75568050|NCT04381832|Drug|SG|Sacituzumab govitecan is an antibody-drug conjugate
75568051|NCT04373512|Drug|Culturelle 10 Billion CFU Capsule (2 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
75568052|NCT04373512|Drug|Culturelle 10 Billion CFU Capsule (4 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
75721425|NCT00621504|Drug|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
75721426|NCT00548145|Drug|Pitavastatin|2 mg by orally/day Duration: 12 months
75721427|NCT00548145|Drug|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
75875874|NCT05084313|Other|Deep-slow breathing|Patients in this group will do slow paced breathing to increase heart rate variability as it can be partially modulated by respiratory effects. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
75875875|NCT05084313|Other|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
76045106|NCT05272969|Diagnostic Test|Laboratory assessment: phosphate|phosphate level in peripheral blood (peripheral venous blood draw)
75568053|NCT04324892|Drug|Treat to target|All patient will received protocolized treatment with an aim to achieve SDAI remission
75568054|NCT04322305|Drug|Pregabalin|Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
75568055|NCT04322305|Other|Placebo|Placebo capsules will be provided twice daily over 8 weeks and one week taper..
75721428|NCT00547911|Drug|Droxidopa|
75721429|NCT00547911|Drug|Carbidopa|
75721430|NCT00547911|Drug|Entacapone|
75875876|NCT03688854|Dietary Supplement|SCFA mixture|Intracolonic administration
75875877|NCT01382979|Behavioral|AlcoholEdu for College|Online course for college freshmen.
75422578|NCT05961072|Device|Vibrotactile sensory feedback device|"The company Saphenus Medical Technology GmbH will provide all of the devices for this study. The non-invasive vibrotactile sensory feedback device consists of 4 vibration -motors, which are placed in a cuff or pant on the patient's residual limb (RL). Furthermore, the system consists of a foot sole with integrated sensors and transmitters. The patient will put the sole of their foot into the shoe of the amputated side.~There are 4 sensors matching the vibration motors - 3 under the forefoot and 1 on the heel - in the foot sole. Depending on whether the patient loads their forefoot or their heel while walking, the assigned vibration motor vibrates on the skin of their RL. The patient will learn which vibration motor is assigned to their forefoot and which to their heel. This gives the patient sensory feedback without having to check with their eyes which part of the prosthetic foot is currently touching the ground."
75875878|NCT05042193|Other|SARS-CoV-2|Observational
75568056|NCT04307992|Device|Prophylactic sac filling with AneuFix|ANEUFIX is administered by injection into the AAA via transferal access at the time of EVAR placement using imaging techniques to guide the place of injection.
75568057|NCT04305158|Drug|Nitrous Oxide|Patient receiving nitrous oxide are evaluated for success of the procedure
75568058|NCT04301778|Drug|Durvalumab|"Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks).~Drug - 1500mg IV"
75568059|NCT04301778|Drug|SNDX-6352|"SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1).~Drug - 3mg/kg IV"
75568060|NCT04291209|Drug|N-Acetyl Cysteine|One ear will be randomly chosen for the experimental treatment of intratympanic NAC. The other ear will serve as the control ear which will not receive any injection.
75568061|NCT04285827|Biological|CSL889|Administered as an IV infusion
75422579|NCT05961007|Biological|Intravitreal injection of IBI302(dose 1)|IBI302(dose 1) intravitreal injection given as protocol
75422580|NCT05961007|Biological|Intravitreal injection of IBI302(dose 2)|IBI302(dose 2) intravitreal injection given as protocol
75568062|NCT04270266|Other|Educational Intervention|Attend educational sessions
75568063|NCT04270266|Other|Meditation Therapy|Attend meditation sessions
75568064|NCT04270266|Other|Questionnaire Administration|Ancillary studies
75875879|NCT03688776|Other|1805AA|A moist snuff product
75568065|NCT04267796|Other|Aerobic Exercise|Complete aerobic training
75568066|NCT04267796|Other|Dietary Intervention|Receive diet recommendations from health coach or registered dietitian
75568067|NCT04267796|Other|Quality-of-Life Assessment|Ancillary studies
75875880|NCT03688776|Other|1805AB|A moist snuff product
75568068|NCT04267796|Other|Questionnaire Administration|Ancillary studies
75875881|NCT03684798|Other|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
75875882|NCT03684798|Other|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
76045107|NCT05272969|Genetic|Genetic test: ACE polymorphism|peripheral venous blood draw for genetic analysis of ACE polymorphism
76045108|NCT05272969|Genetic|Genetic test: ACTN3 polymorphism|peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
75422581|NCT05961007|Biological|Intravitreal injection of IBI302(dose 3)|IBI302(dose 3) intravitreal injection given as protocol
75568069|NCT04267796|Other|Resistance Training|Complete high-resistance circuit training sessions
75568070|NCT04266912|Drug|Avelumab|Given IV
75422582|NCT05961007|Drug|Intravitreal injection of Aflibercept|Aflibercept intravitreal injection given as protocol
75568071|NCT04266912|Drug|Berzosertib|Given IV
75568072|NCT04256824|Drug|coated vicryl plus|Coated Polyglactin 910 with Triclosan (coated vicryl plus)
75568073|NCT04256824|Drug|Vicryl|Coated Polyglactin 910 without Triclosan (vicryl)
75568074|NCT04256213|Drug|Nivolumab and Ipilimumab|"Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)"
75568075|NCT04254237|Procedure|Infraumbilical Hasson trocar incision|Infraumbilical Hasson trocar incision
75568076|NCT04254237|Procedure|Supraumbilical Hasson trocar incision|Supraumbilical Hasson trocar incision
75568077|NCT04248829|Drug|Lazertinib 240 mg/160 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
75568078|NCT04248829|Drug|Gefitinib 250 mg|The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
75568079|NCT04248829|Drug|Lazertinib-matching placebo 240 mg/160 mg|The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
75568080|NCT04248829|Drug|Gefitinib-matching placebo 250 mg|The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
75568081|NCT04248751|Device|Regeneten|A new scaffold material made of highly purified, type I collagen from bovine tendons has shown great promise as a bioinductive implant that helps induce the formation of new tendon-like tissue over the surface of partial- or full-thickness rotator cuff tears. This new graft material has the benefit of decreasing surgery time, as it takes a few minutes to put in place, while increasing healing and tendon thickness.
75875883|NCT05407857|Behavioral|multi-modal non-pharmacological intervention|multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs
75875884|NCT03688698|Radiation|PET/MRI|PET/MRI scans
75568082|NCT04248751|Procedure|Debridement|The bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin
75568083|NCT04248322|Behavioral|Semi-structured interview|Using iterative, semi-structured interviews or focus groups to explore the lived experience with CC and usual customary care (UCC) of catheter users with NLUTD and their caretakers to generate user-defined themes regarding bladder function and catheter-related barriers and the daily impacts on one's life.
75568084|NCT04247763|Other|Saturated Fat Meal|
75568085|NCT04247763|Other|Oleic Sunflower Oil Meal|
75568086|NCT04247074|Biological|botulinum toxin neuromodulator|QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL
75568087|NCT04247074|Biological|Placebo|Placebo will be injected into either the LCL, GL, or both the LCL and GL
75568088|NCT04231448|Drug|R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)|R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV [maximum total 2 mg], and prednisone [or equivalent] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
75568089|NCT04231448|Drug|Tucidinostat|Tucidinostat ：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of Tucidinostat on day 1, day 4, day 8, day 11 in a 21-day cycle.
75721431|NCT00839280|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
75721432|NCT00839280|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
75721433|NCT00836628|Drug|Busulfan|
75721434|NCT00962637|Drug|Androxal|12.5 mg once daily
75721435|NCT00962637|Drug|Androxal|25 mg once daily
75721436|NCT00962637|Drug|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
75721437|NCT00962637|Drug|Placebo|1 capsule daily
75721438|NCT00839358|Drug|albumin|albumine 40 g every 15 days
75721439|NCT00839358|Drug|Midodrine|Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
75721440|NCT00839358|Drug|Placebo|saline solution
75721441|NCT00962715|Biological|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
75721442|NCT00962715|Drug|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
75721443|NCT00962715|Drug|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
75721444|NCT00836784|Other|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
75721445|NCT00836784|Other|New tooth brush|"The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes."
75721446|NCT04886271|Drug|HX009|Eligible participants will receive HX009 treatment at 5mg/Kg via IV infusion over 60-120 minutes, and the scheduled dosing cycle is once every 2 weeks.
75721447|NCT00844116|Device|spirometry|Conventional and telematic spirometry
75721448|NCT00963027|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
75721449|NCT00963027|Drug|Esomeprazole|Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
75721450|NCT00836940|Drug|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
75721451|NCT00837018|Other|physical exercise program|45 min, 3times a week
75422583|NCT05960981|Behavioral|Online-delivered Group-based Parent Mediated Intervention for Young Children with ASD|The program consists of eight weekly 2-hour group sessions, with each group consisting of 8 to 10 families. During the sessions, supervisors present the strategies to the parents and explain how to integrate them into their interactions with their children. Sample videos are shown to illustrate the strategies, and group discussions allow parents to discuss their application. In the second half of each session, the parents' recorded videos are watched, and supervisors provide feedback on whether the strategies were accurately implemented. At the end of each session, supervisors address any questions the parents may have.
75721452|NCT00839592|Other|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
75568090|NCT04231448|Drug|Placebo|Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
75721453|NCT04796649|Device|B-Cure laser pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
75721454|NCT04796649|Device|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
75721455|NCT00837174|Drug|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
75721456|NCT00963183|Drug|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
75568091|NCT04224051|Drug|Metformin|Metformin target dose 2 g daily
75568092|NCT04224051|Other|Standard care|Abdominal aortic aneurysm surveillance
75568093|NCT04216823|Device|perfusion index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
75568094|NCT04216641|Dietary Supplement|Adapted food intervention|Adapted food intervention
75875885|NCT05387343|Diagnostic Test|Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test|Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.
75875886|NCT04220775|Drug|Bintrafusp Alfa|Given IV
75875887|NCT04220775|Other|Quality-of-Life Assessment|Ancillary studies
75568095|NCT04209686|Drug|Paclitaxel|"Patients will receive treatment on Day 1 and 8 starting with cycle 2.~Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~Drug - Paclitaxel - 80mg IV"
75875888|NCT04220775|Other|Questionnaire Administration|Ancillary studies
75568096|NCT04209686|Drug|Olaparib|"Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~Drug - 100 mg or 300mg"
75568097|NCT04209686|Drug|Pembrolizumab|"Patients will receive treatment every 21 days.~Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~Drug - 200mg IV"
75568098|NCT04209114|Biological|Nivolumab|Specified dose on specified days
75568099|NCT04209114|Procedure|Radical cystectomy (RC)|Surgical removal of the bladder
75568100|NCT04209114|Biological|Bempegaldesleukin|Specified dose on specified days
75568101|NCT04203797|Drug|dupilumab|Pre-filled syringe administered by subcutaneous (SC) injections
75568102|NCT04203797|Drug|Matching placebo|Pre-filled syringe administered by subcutaneous (SC)
75568103|NCT04197479|Drug|Placebo|Matching tablets
75568104|NCT04197479|Drug|Resmetirom|Tablet
75568105|NCT04191590|Procedure|nasal brushing and bacteriological sample|A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
75721457|NCT00963183|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
75875889|NCT04220775|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75568106|NCT04190212|Behavioral|High-intensity interval training + standard care|HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
75568107|NCT04188912|Procedure|Biospecimen Collection|Undergo collection of blood, tears, saliva, buccal mucosa, feces, and tissue samples
75568108|NCT04188912|Procedure|Optical Coherence Tomography|Undergo optical coherence tomography
75568109|NCT04188912|Procedure|Spirometry|Undergo portable spirometry
75568110|NCT04188912|Other|Survey Administration|Complete survey
75721458|NCT04042974|Drug|vaginal dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
75721459|NCT04042974|Drug|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
75721460|NCT00844272|Behavioral|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education."
75721461|NCT04783545|Drug|VLX-1005|VLX-1005 infusion
75721462|NCT04783545|Drug|Placebo|Placebo infusion
75721463|NCT00844350|Drug|letrozole , oxytocin,hCG,clomiphene citrate|
75721464|NCT00963261|Behavioral|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
75721465|NCT02547636|Other|Observational study|No intervention will be used in this study.
75875890|NCT02925312|Other|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication facilitated by near, real-time blood glucose monitoring
75875891|NCT04108299|Behavioral|Wait-list control group|For patient participants, they will continue to receive the standard of usual care for their T2D at the CBWCHC during the course of our study. For family/friend participants, they will continue to receive their routine care with their own doctors during the study. At the end of the study, the wait-list control group (both patient and family/friend participants) will be provided the opportunity to receive the counseling videos delivered to them via SMS links.
75875892|NCT04108299|Behavioral|SMS intervention|2-3 SMS-based diabetes videos will be sent to patients each week for 12 weeks (each video within 10 minutes in duration) to both patients and their family members. Patients and their family members will receive the same intervention videos, including basic information about T2D, importance of diabetes self-management at home, behavioral techniques, and family-oriented sessions. BrainShark will be used to determine whether participants view these,videos. For participants who miss 3 consecutive videos, the study team will follow-up with a phone call to identify barriers to watching the video and remind them to review the video.
75422585|NCT05960916|Procedure|Densah® burs|Osseodensification is a non-excavating implant site preparation technique, it creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects.
75568111|NCT04188912|Other|Digital Photography|Undergo digital photography
75568112|NCT04188912|Other|Quality-of-Life Assessment|Ancillary studies
75568113|NCT04188912|Other|Medical Chart Review|Review of medical charts
75568114|NCT04176978|Drug|Rosuvastatin|Patient in this group will receive Rosuvastatin 20mg daily.
75875893|NCT01382823|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
75875894|NCT01980381|Other|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
75422586|NCT05960916|Procedure|Conventional Burs|Conventional burs is the gold standard that used to prepare the osteotomy site by drilling of the bone and creating a bed for implant placement, it is used according to the manufacturer instructions.
75422587|NCT05960838|Device|Ultrasling® Quadrant|Immobilization with the Ultrasling® Quadrant (DJO Global Switzerland Sàrl, Ecublens, Switzerland) shoulder brace after surgical treatment
75422588|NCT05960838|Device|Bledsoe ARC®|Immobilization with the Bledsoe ARC® (Breg Inc., Carlsbad, CA USA) brace after surgical treatment
75568115|NCT04176978|Other|Treat-to-target strategy|Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
75721466|NCT00839670|Other|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
75721467|NCT00839670|Other|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
75721468|NCT04704609|Other|Standard of Care Imaging|We are collecting imaging that is standard of care for uveitis patients
75721469|NCT00963339|Device|Foresee Home|Home Monitoring
75875895|NCT01381965|Procedure|Vitreous surgery for macular hole|Vitreous surgery for macular hole
75875896|NCT01381887|Drug|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
75422589|NCT05960825|Combination Product|injectable platelet rich fibrin versus microosteoperforation|injectable platelet rich fibrin which is second product of blood versus microosteoperforation which is surgical procedure
75422590|NCT05960799|Device|CON - Contiplex C™ (CC)|This is a catheter used for peripherical nerve block that is inserted at the same time that the needle is being introduced. When the target is achieved, the needle is retired.
75422591|NCT05960799|Device|CTN - Contiplex|This is the traditional catheter used in this centre for peripheric nerve block. In this catheter the needle is introduced first. When the target is achieved the catheter is then introduced throw the needle and after that the needle is retired.
75568116|NCT04176965|Device|FINEVISION HP IOL|Cataractous lens will be removed in the study eyes and the FINEVISION HP IOL will be implanted in the capsular bag.
75568117|NCT04176965|Device|Alcon AcrySof SN60AT|Cataractous lens will be removed in the study eyes and the Alcon AcrySof SN60AT IOL will be implanted in the capsular bag.
75568118|NCT04175639|Behavioral|Mobile Health Pain Coping Skills Training (mPCST)|Participating in Mobile Health Pain Coping Skills Training will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic. The therapist delivering the intervention will be at Duke University Medical Center, and patients will be at their community clinic.
75568119|NCT04173728|Other|Standard mixed macronutrients tolerance test|Consumption a standard mixture containing 75g glucose, 60g fat and 20 protein.
75568120|NCT04166435|Drug|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
75568121|NCT04156945|Behavioral|Behavioural intervention|An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.
75875897|NCT01381887|Drug|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
75422592|NCT05960786|Device|Otoband Experimental|Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
75721470|NCT01563393|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
75721471|NCT01563393|Other|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
75721472|NCT00844506|Drug|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
75721473|NCT00844506|Drug|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
75721474|NCT04009707|Other|MoCA (Montreal Cognitive Assessment) test|the MoCA questionnaire is used to assess cognitive disorders
75721475|NCT04009707|Other|BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test|This questionnaire is used to assess cognitive disorders
75721476|NCT00844584|Procedure|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
75422593|NCT05960786|Device|Otoband Sham|Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.
75422594|NCT05960721|Drug|Rivaroxaban 15mg|QD
75422595|NCT05960721|Drug|Aspirin 100mg|QD
75422596|NCT05960721|Drug|Clopidogrel 75mg|QD
75422597|NCT05960721|Drug|Rivaroxaban 10mg|QD
75422598|NCT05960721|Drug|Rivaroxaban 2.5mg|B.I.D
75568122|NCT04156945|Diagnostic Test|HCV RNA home-based test|An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
75568123|NCT04152941|Drug|Olaparib|Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
75875898|NCT01381887|Drug|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
75875899|NCT01381887|Drug|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
75875900|NCT03680664|Device|Active tDCS|Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
75875901|NCT03680664|Other|sham tDCS|The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
76045109|NCT05272969|Genetic|Blood draw for optional genetic exome sequencing|"Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms myalgia, muscle pain, chronic pain, musculoskeletal pain, pain, and nociceptive pain."
76045110|NCT05272033|Device|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
76045111|NCT05243173|Other|Sequencing|Laboratory analysis of samples
76055856|NCT05885854|Drug|XTR003|"Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes."
76055857|NCT05885841|Drug|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
76055858|NCT05885802|Other|No specific intervention other than routine anesthesia protocol|No specific intervention other than routine anesthesia protocol
75568124|NCT04150900|Drug|Bavituximab|Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
75568125|NCT04150900|Drug|Pembrolizumab|Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
75568126|NCT04131036|Other|assessment of joint health and bone density|We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
75422599|NCT05960669|Procedure|3D model guided secondary resection|A prostate model was 3D printed from preoperative pelvic MRI data and used during robot-assisted radical prostatectomy to mark a positive surgical margin and guide secondary resection.
75422600|NCT05960643|Other|Training and application in breast modeling|BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.
75568127|NCT04126798|Other|Behavioural|Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
75568128|NCT04124965|Drug|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
75568129|NCT04121754|Device|MR-001|Participants will walk using the investigational device (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 3 times a week for 5 weeks.
75422601|NCT05960643|Other|Control|No intervention will be made against people in this group.
75568130|NCT04121754|Other|Active Walking|Participants will walk for thirty (30) minutes at a time, 3 times a week for 5 weeks. No mobile devices, music players or headphones will be allowed. They will wear foot sensors during their active walking sessions to measure gait biomechanics.
75721477|NCT00963417|Other|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
75721478|NCT00963417|Procedure|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
75721479|NCT00839826|Drug|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
75721480|NCT00839826|Drug|Enoxaparin|40 mg bid
75721481|NCT00963495|Drug|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
75721482|NCT04042896|Behavioral|exergame|Exergame is 'exercise + game'.
75721483|NCT04042896|Behavioral|treadmill exercise|traditional aerobic exercise
76045112|NCT05207917|Procedure|Gastric bypass|In Roux-en-Y gastric bypass (RYGB), the left crus will be dissected free, any hiatal hernia left in place. The minor curvature is opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler (full length of the stapler), creating an antecolic, antegastric alimentary limb. The opening will be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. The small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.
76045113|NCT05207917|Procedure|Sleeve gastrectomy|In sleeve gastrectomy (SG) a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 4-5 cm from the pylorus up to the angle of Hiss. The left crus is then visualized and inspected for hiatal hernia. Small sliding hernias and wide hiatus are left in situ. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always green or purple, while blue or tan loads are used for the rest of the ventricle. The last stapler is placed 5 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis, no oversewing or buttressing material is routinely used.
76045114|NCT05207917|Procedure|Single anastomosis sleeve ileal (SASI) bypass|The SASI bypass will performed with a similar entry of the abdominal cavity. A 6-port set up and a liver retractor is utilized. The small bowel is measured 300cm from the ileocecal valve, in sequences of 10cm, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 2.5 cm of the 45 mm stapler device is used for firing the anastomosis, which is completed with a 2-0 PDS running suture. The fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
76055859|NCT05885776|Drug|Pyrrolidine、trastuzumab、AI|Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pirotinib+trastuzumab+AI, and their postoperative pathological remission was evaluated.
75721484|NCT00844662|Drug|Fermagate|Film coated tablet 500mg
76055860|NCT05885750|Behavioral|Unprocessed|Participants will consume unprocessed or minimally processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
75422602|NCT05960617|Drug|Empagliflozin|"Oral administration of Empagliflozin:~The starting dose was 0.3 mg/kg/day in 2 divided doses for 3 months. If the subject had an absolute neutrophil count > 1.0 × 10^9/L and clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained.~If the subject had an absolute neutrophil count < 1.0 × 10^9/L but clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained and reassessed 1 month later.~If the subject had an absolute neutrophil count < 1.0 × 10^9/L and no clinical improvement (no change in number of infections and/or no change in IBD activity within 3 months), the dose was increased by 0.1 mg/kg/day and reassessed 3 months later.~Assessments were then performed every 3 months with the same dose modification criteria as above."
75422603|NCT05960591|Device|ADEPTH|ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
75568131|NCT04117087|Drug|KRAS peptide vaccine|"KRAS peptide vaccine will be administered on days 1, 8, and 15. Five boost vaccinations with will be administered at 8 week intervals (on weeks 13, 21, 29, 37, and 45). There is an extended booster phase for Pancreatic Cancer patients with no evidence of disease. These patients have the option of receiving KRAS peptide vaccine every 90 days (± 30 days) for up to 4 additional doses.~Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
75568132|NCT04117087|Drug|Nivolumab|"Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10min/+15min) every 3 weeks for four doses. In the boost phase 480 mg flat dose will be administered every 4 weeks beginning C5D1.~Drug: 3mg/kg IV, 480 mg IV"
75568133|NCT04117087|Drug|Ipilimumab|"Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) every 6 weeks for two doses.~Drug: 1mg/kg IV"
75568134|NCT04116073|Drug|INCMGA00012 (PD-1 antibody)|"Treatment of INCMGA00012 will be administered every 4 weeks (28 days) while patient is on study. Intravenous administration of INCMGA00012 (500 mg) will occur on Day 1 of each 28 day cycle.~Drug: 500 mg is to be administered as a 30 minute IV infusion (-5/+15 min)"
75568135|NCT04098133|Other|data collection for demographic data|data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
75721485|NCT00844662|Drug|Sevelamer hydrochloride|Tablet 800mg
75721486|NCT04678089|Drug|Bortezomib|Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
75721487|NCT00963573|Drug|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
75721488|NCT00963573|Drug|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
75422604|NCT05960136|Procedure|Sinus lift in patients with positive COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with positive COVID-19 history
76045115|NCT05269147|Procedure|Sphenopalatine Ganglion Block (SPGB)|"The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop."
75422605|NCT05960136|Procedure|Sinus lift with negative COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with negative COVID-19 history
75568136|NCT04098133|Other|data collection for clinical data|data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
75422606|NCT05959928|Device|Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely|The HaH team will place Viture Device on the patient's armpit and train the patient and/or caregiver. They will ask to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the Home data collection notebook (HDCN)
75568137|NCT04098133|Other|data collection for treatment data|data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
75568138|NCT04098133|Other|data collection for microbiological data|data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)
75568139|NCT04098068|Drug|MK-3475|MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
75568140|NCT04090723|Behavioral|CBI-CC with peer navigation|Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
75568141|NCT04081493|Other|Low-load blood flow restricted exercise|"Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises"
75568142|NCT04078152|Drug|Durvalumab|IV infusion q4w with 1500mg durvalumab until progressive disease
75568143|NCT04067596|Procedure|epiphysiodesis|"The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase."
75721489|NCT05299593|Drug|tafluprost/timolol|"One ml active drug contains: 15 micrograms of tafluprost and 5 mg of timolol (as maleate).~A single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost and 1.5 mg of timolol. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost and 0.15 mg of timolol. Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day."
75721490|NCT00839904|Behavioral|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
76045116|NCT05241691|Device|Guided Growth Plate System Plus|The implant is thought as one of the surgical options to perform epiphysiodesis and hemiepiphysiodesis minimally invasive, that is without recourse to a corrective osteotomy.
75422607|NCT05959902|Other|Forward Walking|During the 8-week treatment, the participants will undertake 10 minutes of forward walking, as well as a 5-minute warm-up and cool-down, three times a week on an even surface at their normal speed as a home exercise plan. During the warmup and cool down periods, the participants were advised to execute ankle toe motions, heel lift exercises, and hamstring and gastrocnemius-soleus stretches.
75422608|NCT05959902|Other|Physiotherapy Exercises|"Isometric quadriceps exercise. Straight leg raising (SLR) exercise. Isometric hip adduction exercise.~Terminal knee extension exercise:~Semi-wall squat exercise. Quadriceps drill exercise."
76045117|NCT05206747|Device|Blue-blocking glasses|It will transmit 45% of visible light with the following light transmission profile.
75875902|NCT03680664|Behavioral|MBSR|After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
75875903|NCT04878471|Drug|Pudexacianinium chloride|Intravenous
75875904|NCT04878471|Drug|Placebo|Intravenous
75875905|NCT03684720|Other|Discover followed by direct instruction [DD]|The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.
75875906|NCT04877379|Drug|VNRX-7145|β-lactamase inhibitor
75875907|NCT04877379|Drug|VNRX-5024 (ceftibuten)|β-lactam antibiotic
75875908|NCT04877379|Drug|Placebo|Placebo
75875909|NCT01382745|Drug|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
75875910|NCT01382745|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
75875911|NCT03684330|Dietary Supplement|Vitamin D|a dose once a week
75875912|NCT03684330|Other|whole body vibration (WBV)|03 months of WBV training three times per week
75875913|NCT03680430|Radiation|Adaptive radiation therapy|Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
75875914|NCT03688386|Behavioral|Reading intervention|Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
75875915|NCT03688386|Behavioral|Infant bonding|Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
75875916|NCT03688386|Behavioral|LENA recording|The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
75875917|NCT03688386|Behavioral|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
75875918|NCT03688386|Behavioral|LENA summary|All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
75875919|NCT03684252|Behavioral|CBT-based intervention|Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
75875920|NCT03684252|Other|Treatment as Usual|Participants' will receive treatment as usual.
76045118|NCT05206747|Device|Lightly-tinted glasses|It will also filter short wavelength light but at a lower threshold with near identical transmission above this threshold. It will transmit 91% of visible light with the following light transmission profile.
76045119|NCT05205811|Drug|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
76045120|NCT05205811|Drug|Zonisamide|Zonisamide (100 mg/daily) for 7 weeks.
76045121|NCT05205811|Drug|Placebo bupropion|Placebo bupropion for 7 weeks.
75422609|NCT05959837|Other|Adaptive Rowing Exercise|Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity.
75568144|NCT04059640|Device|LiquiBand FIX8 Open Hernia Mesh Fixation Device|"Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.~Subjects will be evaluated intra-operatively, post-operatively, at discharge, and at 12 months post-operatively. The Liquiband surgical study device is considered a permanent implant."
75875921|NCT03684174|Device|Intraocular pressure measurement|Pressure tip or air puff is applied on eye
75875922|NCT03623802|Other|Local Movement Therapy|Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
75422610|NCT05959811|Other|yoga|60 minutes yoga practice ,twice a week for 8 weeks
75875923|NCT03623802|Other|Integral Movement Therapy|Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
75875924|NCT03680118|Device|autogenous rings with GBR and autogenous graft with ti-mesh|"Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures."
75875925|NCT01783041|Drug|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
75875926|NCT01783041|Drug|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
75875927|NCT01569321|Device|MRI|
75875928|NCT01569321|Device|PET-CT scan|
75875929|NCT01569321|Device|PEM scan with ClearPemSonic|
75875930|NCT01381809|Drug|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
75875931|NCT01381809|Drug|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
75875932|NCT03679806|Other|Halliwick|The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
75422611|NCT05959642|Device|dentapen|"Experimental: Controlled Flow Delivery Dentapen according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted upper D teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle"
75875933|NCT03679806|Other|Aquatic Plyometric Exercises|The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
75875934|NCT03679728|Behavioral|First trimester|Analysis of sensorimotor outcomes
75875935|NCT03679728|Behavioral|Second trimester|Analysis of sensorimotor outcomes
75875936|NCT03679572|Procedure|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
75875937|NCT03679572|Procedure|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
75875938|NCT03677466|Drug|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
75568145|NCT04058639|Procedure|"custom felt relief"|Felt is adjusted to the wound by cutting it in different ways and layers once every week
75875939|NCT03677466|Procedure|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
75568146|NCT04058639|Procedure|standard relief treatment|Felt in the shape of a letter U is put around the wound once every week.
75568147|NCT04049981|Device|Superpower Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.
75568148|NCT04030169|Drug|MDMA|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
75568149|NCT04025879|Biological|Nivolumab|Specified dose on specified days
75568150|NCT04025879|Drug|Carboplatin|Specified dose on specified days
75568151|NCT04025879|Drug|Cisplatin|Specified dose on specified days
75568152|NCT04025879|Drug|Paclitaxel|Specified dose on specified days
75568153|NCT04025879|Drug|Pemetrexed|Specified dose on specified days
75568154|NCT04025879|Drug|Placebo|Specified dose on specified days
75568155|NCT04025879|Drug|Docetaxel|Specified dose on specified days
75568156|NCT04022967|Drug|dolutegravir|One daily tablet (50mg) during 96 weeks
75875940|NCT03196297|Drug|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
75721491|NCT04667403|Other|Telemedicine|"In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~If necessary within 24 hours of the connection if it is a weekly connection,~Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention."
75875941|NCT03196297|Drug|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
75875942|NCT03677310|Drug|3% Sodium Chloride|3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
75875943|NCT03677310|Drug|Normal Saline|Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
75875944|NCT03447132|Drug|Fulvestrant 500mg|All patients in all arms will receive Fulvestrant 500mg
75875945|NCT03447132|Drug|Palbociclib 125mg|Dose reduction to 100 mg and 75 mg
75875946|NCT03447132|Drug|Goserelin 3.6 MG|Only for pre or peri menopausal patient
75875947|NCT03447132|Drug|Placebos|Placebo
75875948|NCT04133623|Drug|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
75875949|NCT04133623|Drug|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
75875950|NCT03623724|Behavioral|blended Cognitive-behavioral Therapy|The protocol includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on Moodbuster self-help treatment, delivered over a period of 16 weeks. The Moodbuster includes 7 modules (introduction, psychoeducation, behavioral activation, cognitive restructuring, problem solving, exercise and relapse prevention), a calendar and the possibility of sending and receiving messages to and from therapist, respectively. The mobile phone application will be used to support the therapeutic sessions and register the ecological momentary assessments concerning mood, sleep quality, anxiety and other emotional states that will be collected in a daily basis before, during and after the treatment.
75875951|NCT03623724|Other|Treatment-As-Usual|The protocol consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial).
75875952|NCT03192475|Behavioral|GLB plus phone contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.
75422612|NCT05959642|Device|Traditional metal Syringes|"Active Comparator: Conventional Injection of infiltration upper d a standard technique for the Injection of infiltration upper d will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed to primary molars"
75568157|NCT04022967|Drug|atazanavir boosted with ritonavir|One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
75568158|NCT04022967|Drug|tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir|One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
75875953|NCT03192475|Behavioral|GLB plus newsletter contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.
75568159|NCT04022967|Drug|Lamivudine|One daily tablet (300mg) during 96 weeks
75568160|NCT04021862|Drug|Bermekimab Monoclonal Antibody|Bermekimab 400 mg or 800 mg will be administered subcutaneously.
75568161|NCT04021862|Drug|Placebo|Placebo will be administered subcutaneously.
75568162|NCT04010435|Device|repetitive transcranial magnetic stimulation|high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
75568163|NCT04010435|Device|Galvanic stimulation|galvanic stimulation of the vestibular apparatus
75568164|NCT04003155|Drug|fezolinetant|Oral Tablet
75568165|NCT04003155|Drug|placebo|Oral Tablet
75568166|NCT04003142|Drug|Fezolinetant|Oral tablet
75875954|NCT03683862|Other|orthodontic appliance|Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
75568167|NCT04003142|Drug|placebo|Oral Tablet
75568168|NCT03998813|Drug|Ropivacaine|Locoregional analgesia by femoral triangle catheterization
75568169|NCT03998813|Drug|Ropivacaine|Tissue infiltration
75568170|NCT03997786|Drug|Tildrakizumab|Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
75568171|NCT03997786|Drug|Placebo|(Weeks 0 to 16)
75568172|NCT03997786|Drug|Tildrakizumab|(Weeks 16 to 52)
75568173|NCT03997786|Drug|Tildrakizumab|at every 12 weeks in open label fashion till 5 years (240 weeks).
75568174|NCT03997786|Drug|Tildrakizumab|(Weeks 0 to 16)
75568175|NCT03997786|Drug|Etanercept|(Weeks 0 to 16)
75568176|NCT03997786|Drug|Placebo|(Weeks 16 to 52)
75568177|NCT03991221|Other|Dental Exam|Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert
76045122|NCT05205811|Drug|Placebo zonisamide|Placebo zonisamide for 7 weeks.
75721492|NCT00844740|Drug|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
75875955|NCT03189745|Biological|MenACWY-TT|Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY
75875956|NCT03188263|Other|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
75875957|NCT03188263|Other|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
75875958|NCT03188185|Drug|ALKS 5461|Samidorphan + buprenorphine, administered sublingually
76045123|NCT05205811|Other|E-cigarette|e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
75568178|NCT03991221|Other|Orthodontics consult|Consultation with an orthodontics specialist if a malocclusion requiring early intervention is detected
75568179|NCT03991221|Other|Call back at 6 month|Telephone call back at six months of inclusion in the study if a malocclusion requiring early intervention is detected
75422613|NCT05959538|Behavioral|Building Regulation in Dual Generations (BRIDGE)|The BRIDGE intervention includes 16 weeks of 20-30 minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use). The clinical team will consist of two Master's or PhD level clinical psychology trainees and a parent peer coach. Mood tracking will be completed using a brief weekly survey, including questions on depression, parenting stress, positive mood, and recent stressful experiences.
75568180|NCT03991091|Drug|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.
75568181|NCT03991091|Drug|continuation of oxytocin administration|continuation of oxytocin administration
75568182|NCT03971422|Drug|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
75568183|NCT03971422|Other|Placebo|Subjects will receive placebo at pre-specified time points.
75721493|NCT00840138|Procedure|Surgical reconstruction|"Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube"
75568184|NCT03952754|Behavioral|Hip Hop Nutrition-Math Curriculum|This program teaches children skills needed to understand restaurant-menu boards, how to make healthy food choices, while reinforcing the common core math concepts they are learning in school. The program consists of: 2 lessons a week, of about 1 hour each lesson, for a total of 20 lessons.
75568185|NCT03952754|Behavioral|Food Explorers Program|"After-school program Food Explorers will represent Usual Care. This program comprises food and exploration activities, familiarizing children with diverse foods, nutrition concepts, tasty recipes and physical activity."
75721494|NCT01563159|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
75721495|NCT00844818|Behavioral|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
75721496|NCT00963651|Device|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
76045124|NCT05166967|Drug|Individual Antithymocyte globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
76045125|NCT05166967|Drug|Antithymocyte globulin|A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
76045126|NCT05166343|Drug|Epinephrine Injection|Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s)
75721497|NCT02546700|Drug|Lebrikizumab|Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
75721498|NCT02546700|Drug|Placebo|Matching placebo will be administered subcutaneously once in every 4 weeks.
75721499|NCT00963729|Drug|cyclophosphamide|Given IV
75721500|NCT00963729|Drug|docetaxel|Given IV
75721501|NCT00963729|Drug|epirubicin hydrochloride|Given IV
75721502|NCT00963729|Drug|fluorouracil|Given IV
75721503|NCT00963729|Drug|letrozole|Given orally
75721504|NCT00851214|Device|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
75721505|NCT00851292|Device|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
75875959|NCT03188185|Drug|ALKS 5461 Placebo|Placebo tablet, administered sublingually
75875960|NCT03679182|Drug|Olanzapine|Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
75875961|NCT03679104|Procedure|Closure of mucosotomy using endoscopic clips|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
76045127|NCT05238337|Drug|[14C]-PBI-200|[14C]-radio-labeled-PBI-200
75875962|NCT03679104|Procedure|Closure of mucosotomy using OverStitch™ suturing device|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
75568186|NCT03945656|Drug|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks
75875963|NCT03623568|Drug|glecaprevir/pibrentasvir tablets|12 weeks of treatment with Mavyret
75875964|NCT03186781|Biological|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.
75568187|NCT03945656|Drug|Insulin glargine|Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
75422614|NCT05959538|Behavioral|Dialectical Behavioural Therapy Skill Training|Participants in the DBT arm will participate in 16 weeks of DBT skills training only led by two Master's or PhD level clinical psychology trainees. Participants in the DBT Skills condition will participate in a skills group which follows the DBT Skills Training Manual 2nd Edition (Linehan, 2015) through weekly, synchronous 1.5-hour virtual group therapy sessions. Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness skill domains will be covered. Participants will be asked to complete worksheets between sessions to practice using skills, and will be asked to complete a Diary Card to track DBT skills use each week (Linehan, 2015). Mood tracking will be completed using a brief weekly survey including questions on depression, parenting stress, positive mood, and recent stressful experiences.
75568188|NCT03927079|Biological|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
75721506|NCT00963963|Behavioral|Healthy Futures parent education|Multi-year audio CD parent education
75721507|NCT00844974|Other|Prevalence|Mood and cognitive assessments
75721508|NCT00964041|Drug|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
75721509|NCT00964041|Drug|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
75875965|NCT03186781|Biological|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
75875966|NCT03683706|Behavioral|LTP in My Own Way Plus|LTP in My Own Way Plus is a 12-session integrated intervention-Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
75568189|NCT03927079|Procedure|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
75568190|NCT03927079|Biological|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
75568191|NCT03903211|Drug|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
75568192|NCT03874416|Other|Specific rehabilitation|"Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions."
75568193|NCT03874416|Other|Non-specific rehabilitation|Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
75568194|NCT03866499|Drug|BPI-7711|180 mg, oral, QD
75568195|NCT03866499|Drug|Gefitinib|250 mg, oral, QD
75568196|NCT03866499|Drug|Placebo Tablet|250 mg gefitinib placebo tablet, QD
75568197|NCT03866499|Drug|Placebo capsule|180 mg BPI-7711 placebo capsule, QD
75568198|NCT03861208|Other|diet|foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial
75721510|NCT00840372|Procedure|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
75721511|NCT04009317|Drug|TQ-B3139|a multi-target protein kinase inhibitor.
75721512|NCT04009317|Drug|Crizotinib|a multi-target protein kinase inhibitor.
75721513|NCT03641547|Drug|M6620|M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre-clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
75875967|NCT03623412|Diagnostic Test|75g oral glucose tolerance test|Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM
75875968|NCT03623412|Diagnostic Test|75g GTT|post-partum GTT
75875969|NCT02830165|Other|Laboratory Biomarker Analysis|Correlative studies
75875970|NCT02830165|Other|Quality-of-Life Assessment|Ancillary studies
75875971|NCT02830165|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75568199|NCT03861208|Other|usual diet|foods representing the usually provided foods at childcare are offered
75568200|NCT03848728|Other|SEARCH Youth combination intervention|"Administration of life-stage assessment tool~Structured choice clinic access~Rapid feedback of VL results~Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information"
75721514|NCT03641547|Drug|Cisplatin|Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 & B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
75721515|NCT03641547|Drug|Capecitabine|Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 & B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
75875972|NCT03184987|Drug|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
75568201|NCT03848364|Behavioral|Hip Hop Stroke 2.0|HHS2.0 is an innovative, multimedia program, a brief 3-hour (1hr/day for 3 days), school-based intervention designed to educate at-risk populations concerning stroke symptoms and calling 911 immediately in the event they occur (stroke literacy). HHS2.0 is accessed and delivered via a web link online as self-administered, interactive modules that target 4th and 5th grade children in the school system (ages 9-11) using narrative cartoons and multimedia games.
75875973|NCT03184987|Drug|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
75875974|NCT03184987|Drug|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
75875975|NCT03184987|Other|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
75875976|NCT03184519|Diagnostic Test|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
75568202|NCT03843775|Drug|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
75875977|NCT03184441|Device|Premie Pouch|The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
75875978|NCT05241145|Drug|IVMED-80|Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
75875979|NCT05241145|Other|Placebo|This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
75875980|NCT05240443|Procedure|Bariatric Surgery + Medical Management of CKD.|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
76045128|NCT05205421|Biological|Oncolytic Virus Injection(RT-01)|Intravenous injection a single dose of RT-01
76045129|NCT05166109|Drug|Vamorolone|Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
75568203|NCT03843775|Drug|Encorafenib|encorafenib 450 mg oral QD
75721516|NCT03641547|Radiation|Radiotherapy|Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
75568204|NCT03831477|Device|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
75568205|NCT03822962|Drug|Ibuprofen 600Mg Tablet|ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
75568206|NCT03822962|Other|"Standard Regimen | Tylenol"|Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
75568207|NCT03806387|Drug|Alemtuzumab|Alemtuzumab will be given two times, separated by 1 year.
75568208|NCT03770260|Drug|Ixazomib Citrate|Given PO
75568209|NCT03770260|Drug|Pevonedistat|Given IV
75568210|NCT03767582|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
75568211|NCT03767582|Drug|Nivolumab|Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
75568212|NCT03767582|Drug|CCR2/CCR5 dual antagonist|CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
75721517|NCT00851370|Drug|Omalizumab (Xolair)|Bi-weekly
75721518|NCT00851370|Drug|Placebo|Bi-Weekly
75568213|NCT03767582|Drug|GVAX|Vaccine (5x10^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
75422615|NCT05959395|Device|VectRx Thermal Therapy|Subjects will receive VectRx thermal treatment added to 2 cycles of chemotherapy regimen. The VectRx device will be used under continuous investigator monitoring of internal tissue temperatures via real-time temperature probe data, as well as clinical signs and symptoms reflecting the objectives described above. Up to 5 study subjects will be treated. They will complete VectRx treatment during day 1 prior to 5-FU based (e.g., mFOLFIRINOX) or Gemcitabine based (e.g., Gemcitabine/Nab Paclitaxel) chemotherapy infusion. Thermal treatment will be carefully ramped-up to achieve staged goals of average tumor temperatures between 38°C and 43°C for total treatment times up to 30-70 minutes. The target temperature will be 41.5°C.
75422616|NCT05957900|Behavioral|Multisensory stimulation module|"Tactile Stimulation; Gentle stroking massage with moderate pressure, with warm palms for 3 min in a sequence of chest, upper limbs, and lower limbs in supine position.~Visual Stimulation; Black and white visual stimulation card hung at 8-10 in. from the neonate for 3 min.~Vestibular Stimulation; neonates placed in a hammock for 3 min.~Kinesthetic stimulation: It consist of passive exercises (flexion and extension) of upper and lower limbs; one of the hands support the stimulated limb, whereas the other hand will perform the movements for 3 min. in supine position.~Oral stimulation: the perioral structures will stroke by gently tapping the cheeks, lips and jaw by the index and middle finger for 2 min and stroking the intraoral structures by rubbing the gum and applying downward pressure of the tongue for 2 min. Non-nutritive sucking for 8 minutes.~Olfactory Stimulation for 3 min. using mother's milk.~Auditory Stimulation listening to mother's heart beats for 3 min."
75422617|NCT05957679|Diagnostic Test|Magnetic Resonance Elastography|Undergo MRE and routine MRI
75422618|NCT05957679|Procedure|Assessment and Recording|Undergo grading and recording of tumor stiffness and adhesion during surgery
75721519|NCT00967629|Drug|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
75721520|NCT00967629|Drug|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
75875981|NCT05240443|Other|Medical Management for CKD|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
76045130|NCT05166109|Drug|Placebo|Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
76045131|NCT05204407|Dietary Supplement|Luteolin|The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form
75568214|NCT03762850|Drug|sparsentan|Target dose of 400 mg daily
75568215|NCT03762850|Drug|irbesartan|Target dose of 300 mg daily
76045132|NCT05204407|Dietary Supplement|Placebo|The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form
76045133|NCT01656733|Drug|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
75568216|NCT03762850|Drug|Dapagliflozin|Target dose of 10 mg daily
75875982|NCT03026166|Drug|Ipilimumab|Administered by intravenous infusion
76045134|NCT01656733|Drug|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
76045135|NCT05236543|Drug|AZD4831|Subjects will receive single oral dose only on Day 1 and Day 11.
76045136|NCT05236543|Drug|Itraconazole|Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
76055861|NCT05885750|Behavioral|Mildly processed|Participants will consume mildly processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
76055862|NCT05885750|Behavioral|Heavily refined|Participants will consume heavily refined processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
75422619|NCT05955859|Procedure|Samplings from patient's affected paranasal sinus|Samplings from patient's affected paranasal sinus during endoscopic surgery.
75568217|NCT03759093|Drug|Bortezomib|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
75568218|NCT03759093|Drug|Cyclophosphamide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
75568219|NCT03759093|Drug|Dexamethasone|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
75568220|NCT03759093|Other|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen
75568221|NCT03759093|Drug|Thalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
75568222|NCT03759093|Drug|Bortezomib|Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
75568223|NCT03759093|Drug|Cyclophosphamide|Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
75568224|NCT03759093|Drug|Thalidomide|Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
75568225|NCT03759093|Drug|Dexamethasone|40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
75568226|NCT03759093|Drug|Lenalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
75568227|NCT03759093|Drug|Lenalidomide|Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
75568228|NCT03756961|Drug|Dexmedetomidine|The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
75568229|NCT03756961|Behavioral|Person-centred care (PCC)|The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2
75568230|NCT03756961|Drug|Esketamine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
75568231|NCT03756961|Drug|Lidocaine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.
75422620|NCT05955430|Other|Therapeutic exercise|It consists of strengthening exercises and gradual walking. The lower limb strengthening exercises are individualized and progressive for each patient for twelve weeks. There will be eight face-to-face sessions over four weeks. And then the patient will continue with those exercises for eight more weeks. In addition, they must perform twelve weeks of progressive walking until they are walking at least 30 minutes, 5 days a week at a moderate intensity (defined as moderate shortness of breath while walking).
75875983|NCT03026166|Drug|Nivolumab|Administered by intravenous infusion
75422621|NCT05955430|Other|Pain education|A therapeutic pain education program for patients will be implemented. There will be four 30-minute face-to-face sessions (one session per week). The objective is to change the participants' conceptualization of pain. From seeing pain as a marker of tissue damage to a marker of the body's perceived need for protection. Contents include basic structure of the nervous system, distinction between nociception and pain, peripheral and central sensitization, neuroplasticity and benefits of exercise.
76055863|NCT05885711|Other|self-management|self-managing a pessary: removing, cleaning and inserting
75568232|NCT03756961|Device|Transcutaneous Nerve Stimulation (TENS)|The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.
75568233|NCT03756961|Drug|Remifentanil|The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
75568234|NCT03756961|Drug|Desflurane|The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
75568235|NCT03756961|Drug|Propofol|The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
75568236|NCT03756961|Drug|Oxycodone|The control group receives Oxycodone as the routine pain management drug post-operative.
75568237|NCT03749148|Drug|Dupilumab|anti-IL4-Receptor alpha
75568238|NCT03749148|Drug|Placebo|Placebo
75568239|NCT03737110|Drug|Rilonacept|Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and <18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and <18 years old) injections once weekly
75568240|NCT03737110|Drug|Placebo|Placebo SC injections once weekly
75568241|NCT03735901|Drug|IMP Levodopa 100mg/Carbidopa 25mg|"Study treatment will comprise 3 phases:~Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~full study treatment phase: from day 7 to day 34, 3 times per day (tid).~Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning."
75568242|NCT03735901|Drug|Matching placebo|"Study treatment will comprise 3 phases:~Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning."
75568243|NCT03723590|Device|Esterified Hyaluronic Acid Matrix|A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
75568244|NCT03710122|Drug|Vancomycin|Firvanq by Azurity Pharmaceuticals, Inc.
75568245|NCT03710122|Other|Placebo|Placebo for Vancomycin
75568246|NCT03705741|Behavioral|Resistance exercise|Resistance exercise twice a week during pregnancy week 23-34.
75875984|NCT03026166|Drug|Rovalpituzumab tesirine|Administered by intravenous infusion
75721521|NCT00851448|Dietary Supplement|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
75721522|NCT00289783|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
75721523|NCT00289783|Biological|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
75721524|NCT00289783|Biological|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
75721525|NCT00289783|Biological|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
75568247|NCT03698669|Behavioral|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS involves an initial face-to-face meeting followed by regular phone meetings. In preliminary research, patients found this format to be convenient. The initial meeting includes the patient, the BHS and the PCP; the PCP then regularly receives treatment notes from the BHS. Also, the PCP, who has a longitudinal relationship with the patient, is encouraged to further reinforce TOPPS goals. After each TOPPS session, the BHS also mails a copy of the clinical note to the patient. Additionally, each participant is provided with a workbook that reviews the key elements of each treatment session and provides exercises for at-home practice of skills.
75721526|NCT00289783|Biological|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
75721527|NCT00289783|Biological|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
75875985|NCT03573648|Drug|Avelumab|Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.
75568248|NCT03698669|Behavioral|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity. This control condition was accepted by our participants in preliminary studies; it does not directly target functional impairment, and participants do not set tailored goals relating to their own values. The BHS will communicate with the PCP only if a participant shows signs of clinical deterioration.
75568249|NCT03697304|Drug|BI 754091|Solution for infusion
75568250|NCT03697304|Drug|BI 754111|Solution for infusion
75568251|NCT03697304|Drug|BI 836880|Solution for infusion
75568252|NCT03691077|Drug|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
75568253|NCT03682887|Procedure|Cryoballoon PV isolation group|"Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~Target number of subjects: 278 (138 per group)~Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
75568254|NCT03682887|Procedure|Cryoballoon PV isolation with Additional RA linear ablation group|"Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~Target number of subjects: 278 (138 per group)~Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
75568255|NCT03669926|Radiation|Digital Breast Tomosynthesis+synthetic mammography|Two-view tomosynthesis performed with GE Senographe Pristina.
75721528|NCT00289783|Biological|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
75721529|NCT00840528|Other|ozone|0.4 ppm ozone for 2 hours
75875986|NCT03573648|Drug|Endocrine therapy|"The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)"
75875987|NCT03573648|Drug|Palbociclib|Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
75568256|NCT03662776|Behavioral|BASC-3 survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
75721530|NCT02546466|Procedure|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
75721531|NCT02546466|Procedure|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
76045137|NCT05163769|Device|NeeuroCycle Physical and Cognitive Training System|The NeeuroCycle Physical and Cognitive Training System is a novel multimodal electroencephalogram (EEG)-based physical and cognitive training device. The system mainly comprises of a recumbent bicycle device and a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
76045138|NCT05163769|Device|NeeuroCycle Cognitive Training System|The NeeuroCycle Cognitive Training System is a novel electroencephalogram (EEG)-based cognitive training device. The system mainly comprises of a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
76055864|NCT05885659|Other|Control group (waiting list)|T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet. Participants assigned to this control group will participate in the scheduled assessments (pre- and post-treatment, 1-month, 6-months and 12-months follow-ups) but without receiving any of the intensive treatments previously described (CBT vs. CBT+DiME-SALUD2 protocol).
75568257|NCT03662776|Behavioral|PROMIS survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
75568258|NCT03642067|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
75568259|NCT03642067|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
75721532|NCT02546466|Behavioral|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
75721533|NCT00840606|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fasting
75568260|NCT03642067|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
75568261|NCT03642067|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
75721534|NCT00840606|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fasting
75721535|NCT00845286|Behavioral|Munich Marathon|42,195 km marathon run
75721536|NCT03850002|Other|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
75721537|NCT03975127|Other|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
75875988|NCT03558828|Behavioral|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
75568262|NCT03625648|Drug|Pentoxifylline|The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
75568263|NCT03625648|Drug|Placebo|placebo
75568264|NCT03624933|Behavioral|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
75721538|NCT00840684|Drug|amsacrine|
75721539|NCT00840684|Drug|busulfan|
75721540|NCT00840684|Drug|cytarabine|
75721541|NCT00840684|Drug|daunorubicin hydrochloride|
75721542|NCT00840684|Drug|laromustine|
75721543|NCT00840684|Drug|melphalan|
76045139|NCT05161663|Behavioral|Peer-driven intervention|"This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic."
76045140|NCT05161117|Behavioral|Virtual reality simulation app for caregiver education|"Using a virtual reality headset/goggles, caregivers will engage with an interactive app experience to identify and mediate fall risk hazards in the inpatient care environment. The app will present a hospital bedroom and bathroom laden with fall risks. As the caregiver progresses through the experience, the caregiver will ambulate (virtually) through the environment with the goal of identifying fall risks inherent within that inpatient setting. Fall risks will be targeted and identified using the app sighting function and after focusing on the fall risk for the allotted marking time, will self-resolve."
75875989|NCT03558828|Behavioral|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
75875990|NCT03558828|Behavioral|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
75875991|NCT03558828|Behavioral|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
75875992|NCT03558828|Behavioral|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
75721544|NCT00840684|Drug|mitoxantrone hydrochloride|
75422622|NCT05955430|Other|Percutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four needles located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
75721545|NCT00840684|Procedure|allogeneic hematopoietic stem cell transplantation|
75875993|NCT03558828|Behavioral|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
75875994|NCT03558828|Behavioral|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
75568265|NCT03624933|Behavioral|Contingency Management|If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
75568266|NCT03623867|Drug|Secukinumab|Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48
75568267|NCT03623867|Drug|Placebo|Subject will take placebo once weekly in week 0-4, and once monthly till week 48
75568268|NCT03616535|Other|Cognitive training|The investigators will provide participants with tablets to play brain games.
75568269|NCT03616535|Other|Exercise training|The investigators will provide participants with foot peddlers.
75721546|NCT00840684|Procedure|autologous hematopoietic stem cell transplantation|
75721547|NCT00574080|Drug|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
75721548|NCT00574080|Drug|Induction/Consolidation Dexamethasone|40 mg Days 1-4
75721549|NCT00574080|Drug|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
75721550|NCT00574080|Drug|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
75721551|NCT00574080|Drug|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
75721552|NCT00574080|Drug|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
76045141|NCT05161117|Behavioral|online fall prevention education module|Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.
76045142|NCT05202535|Other|Aerobic exercise training|"Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment.~3x/week on alternate days for 8 weeks at 40-70% of HR Max"
75568270|NCT03616535|Other|Combined cognitive and exercise training|The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.
75568271|NCT03602157|Biological|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10^7, 5x10^7, 1x10^8
75568272|NCT03602157|Biological|ALTCAR.CD30 cells|Fixed dose level of 1x10^8
75568273|NCT03602157|Drug|Bendamustine|70 mg/m^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
75568274|NCT03602157|Drug|Fludarabine|30 mg/m^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
75568275|NCT03601442|Biological|CTL019|CTL019
75568276|NCT03595098|Behavioral|Family Based Cognitive Behavioural Therapy|Family Based Cognitive Behavioural Therapy (FCBT) focuses on the interrelation between thought, emotion, and behaviour, Exposure and Response Prevention, family involvement, homework assignments, and formulating of specific goals for the child. The important, active components is Exposure and Response Prevention. It involves exposing the child to a feared object, situation or thought, and preventing the child from carrying out compulsions to show the child that distress/anxiety can decrease or disappear without performing rituals.
75568277|NCT03595098|Behavioral|Family Based Psychoeducation/Relaxation Training|Family-based Psychoeducation/Relaxation Training (FPRT) as an active control matches the experimental intervention as closely as possible, many elements of the control intervention are similar to FCBT. The main and intended difference between the two approaches is the absence of the Exposure and Response Prevention component, which is deemed the most effective treatment for OCD.
75568278|NCT03594630|Drug|Chemotherapy|Receive chemotherapy
75568279|NCT03594630|Other|Patient Observation|Receive active surveillance
75568280|NCT03594630|Other|Questionnaire Administration|Ancillary studies
75568281|NCT03594630|Procedure|Resection of Rectum|Undergo surgical resection
75568282|NCT03592771|Behavioral|THRIVE App|Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
75568283|NCT03592771|Behavioral|Tailored Feedback Messages|Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
75721553|NCT00574080|Drug|Induction Pegfilgrastim|6 mg Days 6 and 13
75721554|NCT00574080|Drug|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
75721555|NCT00574080|Drug|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
75721556|NCT00574080|Drug|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
75721557|NCT00574080|Drug|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
75721558|NCT00574080|Drug|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
75721559|NCT00574080|Drug|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
75721560|NCT00574080|Drug|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
75721561|NCT00574080|Procedure|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
75721562|NCT00574080|Drug|Transplant 2 Carmustine|300 mg/m2 Day -5
76045143|NCT05202535|Other|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
75568284|NCT03587740|Drug|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
75721563|NCT00574080|Drug|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
75721564|NCT00574080|Drug|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
75875995|NCT03683472|Behavioral|Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety"
75721565|NCT00574080|Drug|Transplant 2 Melphalan|140 mg/m2 Day -1
75721566|NCT00574080|Drug|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
75721567|NCT00574080|Drug|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
75721568|NCT00574080|Drug|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
75721569|NCT00840762|Other|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
75721570|NCT00840762|Other|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
75721571|NCT00845364|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
75875996|NCT03676920|Behavioral|Discussions of Cost App (DISCO App)|The DISCO App is an app-based and patient-focused intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions. The DISCO App allows patients to provide basic demographic information (e.g., employment status, insurance status, etc), and uses that information to provide patients with an individually-tailored list of treatment cost questions they can ask their provider.
75875997|NCT03026088|Drug|Bisoprolol|Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
75875998|NCT03676842|Combination Product|FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB|Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
76045144|NCT05201911|Drug|124I-AT03|IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
75568285|NCT03586999|Drug|Nivolumab|Nivolumab injection is to be administered as an IV infusion.
75568286|NCT03586999|Drug|Etoposide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
75568287|NCT03586999|Drug|Prednisolone|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
75568288|NCT03586999|Drug|Oncovin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
75568289|NCT03586999|Drug|Cyclophosphamide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
75568290|NCT03586999|Drug|Hydroxydaunorubicin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
75568291|NCT03575390|Dietary Supplement|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
75568292|NCT03575390|Dietary Supplement|Pomegranate|Pomegranate extract 500mg
75721572|NCT00845364|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
75721573|NCT04043052|Other|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
75721574|NCT04043052|Other|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
75422623|NCT05955430|Other|Transcutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four patches located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
75422624|NCT05955430|Other|Placebo stimulation|To perform the dry needling placebo, modified needles will be used according to the validation performed by Mitchell et al. 2018, since they generate more puncture sensation than normal needles, which has been shown to generate more analgesia and to be more effective as a placebo. To perform placebo TENS, the protocol established by Rakel et al. 2010 will be used, which consists of applying a TENS of 100 Hz and 100 ms for 30 seconds and then lowering the intensity during the following 15 seconds. Eight sessions will be held during a month (two per week).
75422625|NCT05953818|Diagnostic Test|Chinese version of the Montreal Cognitive Assessment Scale (MoCA) and brain magnetic resonance high resolution structural imaging|Chinese version of Montreal cognitive assessment scale and brain magnetic resonance high resolution structural imaging
75568293|NCT03564522|Procedure|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
75568294|NCT03564522|Radiation|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
75568295|NCT03537495|Drug|Linezolid|"Overall, there is an urgent need for improvement of TBM treatment. LInezolid is known to be well-penetrated to blood brain barrier. A combination of high-dose rifampicin and linezolid as an intensified add-on therapy in the management of TB meningitis has never been studied.~The goal is to assess the most appropriate dose of linezolid for larger follow-up studies and to evaluate the feasibility of a linezolid-containing TBM regimen."
75721575|NCT04043052|Biological|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
75875999|NCT03678948|Device|Radiofrequency-Based Debridement|In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
76045145|NCT05201755|Device|CPAP|Application of PEEP (positive end-expiratory pressure) through a CPAP Helmet with a set PEEP of 10 cmH2O. It is a very well tolerated and noninvasive device commonly used for ventilatory support.
76045146|NCT04232371|Procedure|New Ablation Technique|Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
76045147|NCT04232371|Procedure|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
75422626|NCT05953480|Biological|Redasemtide|Lyophilized white powder reconstituted in 0.9% saline for injection
75422627|NCT05953480|Drug|Placebo|Lyophilized white powder reconstituted in 0.9% saline for injection
76045148|NCT05230381|Drug|Continous infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by 5mg/kg/h tranexamic acid infusion.
76045149|NCT05230381|Drug|Single infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by same volume of 0.9% saline.
76045150|NCT05230381|Drug|Placebo|The 0.9% saline is administered with the same volume at the same speed as the other group.
75876000|NCT03678948|Device|Mechanical Debridement|Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
75876001|NCT03678792|Drug|Buprenorphine/naloxone|Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
76045151|NCT05227417|Behavioral|SMS|Weekly text messages that will be sent automatically by a web-based system to participants' cell-phones. Participants will be able to respond and messages will reach the system. The health providers will be in charge to respond (from the web system) to participants who reply asking for support or any other request.
76045152|NCT05157841|Drug|Bupivacaine liposome injectable suspension 266 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
76045153|NCT05157841|Drug|Bupivacaine HCl|Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
75721576|NCT04043052|Other|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
75876002|NCT03678792|Drug|Morphine|Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
76045154|NCT05157841|Drug|Bupivacaine liposome injectable suspension 133 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
76045155|NCT04241965|Drug|OPC-214870|Tablet(s)
76045156|NCT04241965|Other|Placebo|Tablet(s)
76045157|NCT05193643|Device|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues.
76045158|NCT05225155|Drug|Enoxaparin|Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
75422628|NCT05951140|Other|Usage of the PROTEIN-Application|Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
75422629|NCT05947747|Drug|EXO-CD24|Twice a day for 5 days, dose 10^10
75876003|NCT03678792|Drug|Tramadol|Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
75876004|NCT03683238|Dietary Supplement|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
76045159|NCT05192239|Drug|THC 5|5 milligrams of THC in gummy form
76045160|NCT05192239|Drug|Placebo|Commercially available non-THC fruit snack
76045161|NCT05190445|Drug|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|HER2/4-1BB
76045162|NCT05190445|Drug|Cinrebafusp alfa (PRS-343) in combination with tucatinib|HER2/4-1BB
76045163|NCT05149417|Other|SMS reminding|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
76045164|NCT05149417|Other|telemonitoring|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
75422630|NCT05947747|Other|Placebo|Twice a day for 5 days
75568296|NCT03534518|Other|BWS overground training|BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. The walking tasks will be roughly divided into different domains like skilled walking, balance, dual tasking, walking speed, walking endurance.
75568297|NCT03534518|Other|BWS treadmill training|Training will be conducted on a standard treadmill with an overhead BWS system that can provide active BWS. Participants are allowed to hold the rails but weight bearing is not allowed. BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. Main walking tasks will be endurance (walking long distances at preferred speed) and speed (walking at maximal possible speed).
76045165|NCT05148949|Biological|Standard dosage inactivated vaccine|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
76045166|NCT05148949|Biological|Double dosage inactivated vaccine|This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
76045167|NCT04422067|Other|Fetal cephalometry|Fetal cephalometry
76045168|NCT05219851|Radiation|Cancer patients underwent thoracic intensity-modulated radiotherapy|Cancer patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs
76045169|NCT04422301|Other|Blood flow restriction|an alternative method to produce strength and muscle hypertrophy with lower intensities
76045170|NCT05107999|Drug|Zhizhu Kuanzhong capsules (ZZKZ)|FD patients were treated with ZZKZ and omeprazole for 4 weeks.
75422631|NCT05944159|Behavioral|Study Group|Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
75568298|NCT03525288|Radiation|PSMA -PET/CT simulation|"PET/CT simulation.~If no additional lesions detected: RT as planned per standard care.~If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~If PSMA-PET/CT imaging consistent with widely metastatic disease (>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged."
75721577|NCT00267865|Drug|Methotrexate|6000 mg/m^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
75721578|NCT00267865|Drug|Rituximab|375 mg/m^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate
75876005|NCT03678714|Behavioral|Exercise Intervention|2 sessions of supervised exercise training each week for 8 consecutive weeks and 3 sessions of supervised exercise training each week for the final 4 consecutive weeks, at 57-74% heart-rate max. Each session will last approximately 60 minutes.
75876006|NCT03678714|Behavioral|Lifestyle Physical Activity|Advice and information on how to increase physical activity will be provided. Participants will be asked to monitor and track their daily physical activity using a smart-phone fitness application. The research team will gain permission to access their recorded activity.
75876007|NCT03676686|Device|Nåva Foot Cream|Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
75876008|NCT03305094|Procedure|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
75876009|NCT03676608|Biological|Bee Wax Mammary Areolae|The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams.
75876010|NCT03676608|Other|Usual educational care|The WHO protocol for maternal lactation.
75876011|NCT03678558|Other|Cytochalasin B supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Cytochalasin B
75876012|NCT03672786|Dietary Supplement|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
75876013|NCT03678480|Drug|HTD1801|HTD1801 capsules, 250mg
75876014|NCT03678480|Drug|Ursodeoxycholic Acid|UDCA capsules, 125mg
75876015|NCT03181789|Biological|p24CE1/2 pDNA Vaccine|Administered bilaterally using the Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
75422632|NCT05944159|Other|Control Group|Routin medication therapy was applied to the control group. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
75422633|NCT05942599|Biological|Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months
75422634|NCT05939687|Procedure|mesh|We'll use mesh repair for prevention of stoma-site hernias in the study group.
75568299|NCT03525288|Radiation|Standard-care simulation|No PSMA-PET/CT as part of RT treatment planning.
75568300|NCT03522168|Drug|Risperidone|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
75568301|NCT03522168|Drug|Aripiprazole|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
75568302|NCT03519269|Device|Navio™ Robotics-assisted Surgical System|Intervention will evaluate the utility of robotic-assistance in patients undergoing total knee arthroplasty
75721579|NCT00267865|Drug|Leucovorin|Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
75721580|NCT00851760|Procedure|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
75721581|NCT00851760|Procedure|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
75721582|NCT00851838|Drug|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
75721583|NCT01069237|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
75721584|NCT01069237|Device|Clear Care|Lens Care Solution for contact lenses
75876016|NCT03181789|Biological|p55^gag pDNA Vaccine|Administered bilaterally using the TDS-IM EP device
75876017|NCT03181789|Biological|IL-12 pDNA Adjuvant|Administered bilaterally using the TDS-IM EP device
75876018|NCT03181789|Biological|Placebo|Administered bilaterally using the TDS-IM EP device
75422635|NCT05939687|Procedure|non-mesh|We'll use the layered ligature suturing of the abdominal wall without mesh implantation in the control group.
75568303|NCT03518606|Drug|Durvalumab + Tremelimumab + metronomic Vinorelbine|Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
75568304|NCT03506971|Other|Psychologist's evaluation|The research coordinator psychologist will evaluate: the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.
75568305|NCT03506971|Other|Pediatric Nurse's interventions|"Pediatrics nurses perform preventive home visits that are based on : joint observation with the parents of the baby, play with the baby and his parents, interview with the parents on their parenthood~Rhythm of home visits:~1 every month from birth to 1 year~1 every 2 months from 1 year to 2 years~1 every 3 months from 2 years to 4 years"
75568306|NCT03506971|Other|Joint home visits|"Coordinating psychologist and the referent pediatric nurse will perform home visits. During this time, the psychologist evaluate : the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.~Rhythm of joint home visits:~1 at 4 months~1 at 24 months"
75876019|NCT03181789|Device|Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device|The TDS-IM EP device will be used to administer study product(s).
75876020|NCT03676530|Device|Pro-Tec Shin Splint Compression Wrap|EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
75568307|NCT03497299|Device|Active rTMS (20Hz)|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
75568308|NCT03497299|Device|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
75876021|NCT03117985|Other|no drug|Stopping antiretroviral therapy
75568309|NCT03495154|Device|Parietene DS Composite Mesh|All subjects enrolled will receive the Parietene DS Composite Mesh
75876022|NCT03678246|Procedure|Ramped position|LSFOI glottis view
75876023|NCT03678246|Procedure|Supine position|LSFOI glottis view
75876024|NCT03672708|Diagnostic Test|Cresyl violet|cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
75876025|NCT03672552|Other|FFWP and Improved Oral Care|The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
75422636|NCT05932680|Other|Off Drug Surveillance|After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.
75422637|NCT05931666|Other|Gong Mobilization|"Patients are treated with Gong mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
75876026|NCT03678168|Other|Throat Pack|Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
76045171|NCT05107999|Drug|Doxepin Hydrochloride (Doxepin)|FD patients were treated with doxepin and omeprazole for 4 weeks.
75422638|NCT05931666|Other|Kaltenborn Mobilization|"Patients are treated with Kaltenborn mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
75422639|NCT05930145|Device|Double stentriever|Double stentriever technique
75876027|NCT03678168|Other|Pharyngeal Tampons|Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
75876028|NCT03678090|Drug|tPA standard dosage|Tissue plasminogen activator 25mg dosage
75876029|NCT03678090|Drug|tPA low dosage|Tissue plasminogen activator 2.5mg
75876030|NCT03678012|Drug|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
75876031|NCT03678012|Drug|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
75876032|NCT03678012|Drug|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
76045172|NCT05146921|Dietary Supplement|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:~Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173~10 billion colony-forming units (CFU) per 70 ml cup"
76045173|NCT05146921|Other|Placebo|placebo similar in appearance and taste to the active intervention but with no active bacteria
76045174|NCT05186545|Drug|surufatinib + fulvestrant + chidamide|surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
75721585|NCT00840918|Drug|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
75422640|NCT05930145|Device|Single stentriever|Single stentriever technique
75422641|NCT05928611|Procedure|Inferior alveolar nerve block with dexamethasone|Using articaine for inferior alveolar block with intraligmentary dexamethasone
75721586|NCT00840918|Other|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
75721587|NCT00546117|Drug|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing >30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
75721588|NCT00546117|Drug|placebo|Placebo Solutab in 15 and 30 mg dosages.
75721589|NCT01582165|Drug|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
75568310|NCT03486340|Procedure|Cardiologic assessment|Aggressive ischemic risk factor management
75568311|NCT03480672|Drug|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|intravenous application, 12 months, in 3-week cycle (q3w) 200 mg
75568312|NCT03480672|Other|adjuvant radiochemotherapy|adjuvant radiochemotherapy with cisplatin
75568313|NCT03479255|Behavioral|Smartphone-enabled structured exercise therapy (SE-SET)|The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight, and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call in order to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patient from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent issues related to their care.
75568314|NCT03479255|Behavioral|Standard exercise therapy|The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
75568315|NCT03475186|Drug|Ramipril|2.5 - 5 mg oral, 1x daily for 22 weeks
75568316|NCT03466918|Device|SAPIEN 3 THV with the Commander delivery system|Edwards SAPIEN 3 Transcatheter Heart Valve is implanted using the Commander delivery system
75568317|NCT03454295|Behavioral|Focus Group|Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.
75568318|NCT03454295|Behavioral|Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving
75422642|NCT05928611|Procedure|Buccal infiltratation with dexamethasone|Using articaine for buccal infiltratation with intraligmentary dexamethasone
75721590|NCT01582165|Drug|Placebo.|Placebo once daily vs rosuvastatin for 6 months
75721591|NCT00851916|Radiation|CyberKnife Radiosurgery|CyberKnife Radiosurgery
75721592|NCT03975049|Radiation|Chemoradiation|Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.
75422643|NCT05928611|Procedure|Inferior alveolar nerve block|Using articaine for injection
75422644|NCT05917912|Drug|Amitriptyline Hydrochloride|hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
75422645|NCT05917912|Drug|Placebo|hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
75422646|NCT05913518|Device|Neurofeedback active|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).
75422647|NCT05913518|Device|Neurofeedback placebo|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
75422648|NCT05912452|Other|Percussion Massage Therapy|Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.
75422649|NCT05912452|Other|Kinesiotaping|the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
75876033|NCT03676452|Behavioral|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
75876034|NCT03676296|Drug|Puerarin|Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
75876035|NCT03676296|Drug|Placebo|Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
75422650|NCT05912452|Other|Dynamic stretching|Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
75568319|NCT03454295|Behavioral|Enhanced Usual Care / EUC|"The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. [79]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) [63]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed."
75568320|NCT03421691|Device|excel V Laser|excel V Laser Genesis procedure utilizing 1064 nm laser
75568321|NCT03412058|Procedure|Biopsy|To be performed prior to anti-PD1/PD-L1 treatment initiation
75568322|NCT03412058|Procedure|Biopsy|To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
75876036|NCT03672474|Device|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
75422651|NCT05905601|Behavioral|NORTH|NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
75568323|NCT03412058|Procedure|Biopsy|To be performed at disease progression if medically feasible
75568324|NCT03406572|Device|HFHO Group|"Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~Brand name: Airvo 2"
75876037|NCT03672474|Device|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
75876038|NCT03672240|Drug|APL-1202|To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
75876039|NCT03676140|Drug|Albendazole on Day 1|Albendazole 400 mg oral tablet Single Dose Treatment on D1
75876040|NCT03676140|Drug|Ivermectin on Day 1|Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
75876041|NCT03676140|Drug|Diethylcarbamazine on day 1|Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
75721593|NCT03975049|Drug|FOLFOXIRI Protocol|Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
75721594|NCT03975049|Drug|Folfox Protocol|Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
75876042|NCT03676140|Drug|Azithromycin on Day 1|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
75721595|NCT00841074|Drug|chlorhexidine|0.12% chlorhexidine mouthwash spray, ~1.3 ml, twice a day.
75721596|NCT00841074|Drug|Placebo mouthwash|Placebo mouthwash spray application of ~1.3 ml twice a day.
75876043|NCT03676140|Drug|Azithromycin on Day 8|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
75568325|NCT03406572|Device|Standard O2|Standard oxygen therapy
75876044|NCT03676062|Other|exercise|All exercises programs applied three sessions per week, totally six week.
75422652|NCT05905601|Behavioral|"NORTH Lite"|"NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources."
75876045|NCT03675984|Behavioral|asymmetrical stabilization exercise|Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
75568326|NCT03397602|Behavioral|standard care + moderate-intensity continuous exercise training|Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
75568327|NCT03397602|Behavioral|standard care + high-intensity interval training|Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
75422653|NCT05905120|Drug|Toludivenlafaxine hydrochloride sustained-release tablets|80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
75422654|NCT05904262|Other|Foot Sole Sensation Evaluation|Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
75422655|NCT05903794|Biological|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injecting into one eye of each participant.
75422656|NCT05895357|Other|Musictherapy|The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
75422657|NCT05892523|Procedure|THA|positioning the acetabular cup regarding abduction and anteversion angles with or without concern to spinal deformity
75568328|NCT03390296|Biological|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Given IV
75721597|NCT00964197|Device|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
75721598|NCT00967707|Drug|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
75876046|NCT03677856|Procedure|Paravertebral blockade|Type of anaesthesia
75876047|NCT03677856|Procedure|Thoracic epidural block|Type of anaesthesia
76045175|NCT05107765|Drug|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.
75568329|NCT03390296|Drug|Avelumab|Given IV
75568330|NCT03390296|Drug|Azacitidine|Given IV or SC
75568331|NCT03390296|Drug|Gemtuzumab Ozogamicin|Given IV
75568332|NCT03390296|Drug|Glasdegib|Given PO
75568333|NCT03390296|Drug|Glasdegib Maleate|Given PO
75568334|NCT03390296|Drug|Venetoclax|Given PO
75568335|NCT03390296|Drug|Azacitidine|Given IV or SC
75568336|NCT03386240|Drug|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)|The intervention consists of using Plus group (Triclosan-coated Sutures)
75568337|NCT03386240|Other|Vicryl, monocryl, PDS (not coated with triclosan)|Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
76045176|NCT05107765|Drug|Placebo|Pill capsules will look same as that of active drug.
76045177|NCT05146141|Other|Bent-arm throw exercises|The participants will have to perform bent-arm throw exercises 5 minutes before each training session
76045178|NCT05144971|Diagnostic Test|Glucose, Creatinine|Compare diagnostic tests to reference methods
75422658|NCT05891301|Other|Questionnaires set|The contents of the questionnaire included gender, age, BMI, previous operation history, previous medication history, smoking history,patient mobility in the hospital, etc.Questionnaire was completed on the first postoperative day.From the third day to the end of the seventh day, patients were evaluated daily for gastrointestinal dysfunction.Postoperative mobility was assessed daily.
75568338|NCT03384537|Combination Product|Listerine total care zero|reducing intra-oral cariogenic microorganism.
75568339|NCT03384537|Combination Product|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
75568340|NCT03362801|Diagnostic Test|sarcopenia and mobility measurement|"walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment"
75568341|NCT03338387|Drug|Acipimox|Acipimox
75568342|NCT03338387|Drug|Placebo|Placebo Other Names: Placebo (for Olbetam)
75568343|NCT03334253|Drug|Atropine|Daily 0.01% atropine eyedrops
75568344|NCT03334253|Other|Placebo Eyedrops|Daily placebo eyedrops
75568345|NCT03327467|Biological|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling or autologous)
75568346|NCT03314857|Device|SAPIEN XT THV with the NovaFlex+ delivery system|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
75568347|NCT03306264|Drug|ASTX727|ASTX727 is a tablet for oral administration, containing the fixed-dose combination of 100 mg cedazuridine (a cytidine deaminase inhibitor) and 35 mg decitabine, given by mouth Dailyx5 in 28-day cycles (in Cycle 1 or Cycle 2, then in Cycle 3 and beyond).
75568348|NCT03306264|Drug|Dacogen|Decitabine 20 mg/m^2 one-hour IV infusion Dailyx5 (in one 28-day cycle: either Cycle 1 or Cycle 2).
75568349|NCT03304080|Drug|Anastrozole|1 mg orally daily, day 1 to day 28
75568350|NCT03304080|Drug|Palbociclib|Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
75568351|NCT03304080|Drug|Trastuzumab|8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
75568352|NCT03304080|Drug|Pertuzumab|840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
75876048|NCT03504774|Drug|Cashew or Shrimp Oral Immunotherapy|All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
75876049|NCT03677700|Other|Laser Flare Meter|Measurement of the inflammation of the operated eye and the fellow eye before the surgery and at each post-surgery visit: D7, M1, M2, M3, M6, M12
75876050|NCT03677622|Drug|Voluven to near maximal stroke volume of the heart|Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
75568353|NCT03302156|Drug|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
76045179|NCT05106985|Device|ApplTree reminder app|The reminder app will be introduced to participants to support adherence to chosen goal-related tasks. Reminder app will be introduced following a baseline phase of 10, 16 or 22 days. The duration of the baseline phase will be randomly assigned using an online random number generator.
76045180|NCT04421833|Behavioral|TOVERTAFEL|"The TOVERTAFEL is a small box that can be attached to the ceiling. Inside the box is a high-quality projector, infrared sensors, a speaker, and a processor that work together to project games onto the table. Because the colored objects respond to the movements of the hands and arms, the residents can play with the light itself.~The planned activities provide cognitive, social and physical stimulation through light projections and can all be used individually or in groups with the presence of a caregiver or facilitator. Sixteen play activities are offered."
75568354|NCT03275506|Drug|Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
75568355|NCT03275506|Drug|Chemotherapy - Bevacizumab|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
75568356|NCT03267680|Drug|Cyclophosphamide|Given IV
75568357|NCT03267680|Drug|Indomethacin|Given PO
75568358|NCT03267680|Biological|IRX-2|Given via submucosal injection or SC
75568359|NCT03267680|Other|Laboratory Biomarker Analysis|Correlative studies
75568360|NCT03267680|Dietary Supplement|Multivitamin|Given zinc-containing multivitamin PO
75568361|NCT03267680|Drug|Omeprazole|Given PO
75876051|NCT03672162|Procedure|Total abdominal hysterectomy|Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
76045181|NCT04421833|Behavioral|USUAL activities|"patients can participate in cooking workshops, cinema activities (screening of old films or documentaries on a large screen, in a cozy atmosphere), walks in the garden and the visit of a dog trained in assisted therapy by the animal."
76045182|NCT05106283|Procedure|Deep block and Combined Block|Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
75721599|NCT00967707|Drug|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
75876052|NCT04059120|Other|Experimental group whit specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining
76045183|NCT05184205|Device|Nasal Photodisinfection|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
76045184|NCT05184205|Device|Sham Comparator: Control|Patients who are SARS-CoV-2 positive whose PCR levels are followed but no active intervention will be done. Saline will be used in their nose and the light device will be inserted but not turned on. Patient will be wearing light protecting glasses.
76045185|NCT05183581|Device|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
76045186|NCT05183347|Drug|BI 1291583|BI 1291583
76045187|NCT05183347|Drug|Placebo|Placebo
75568362|NCT03267680|Other|Placebo|Given via submucosal injections or SC
75568363|NCT03267680|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
76045188|NCT05182411|Other|assessment|Turkish version of Leg Activity Measure Rivearmead Mobility Index Nottingham Health Profile Functional Independence Measures
75568364|NCT03256656|Other|electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials|
75568365|NCT03249870|Drug|Inotuzumab ozogamicin (INO)|"INO schedule of administration is as follows:~First induction course: 0.8 mg/m² on day 1, 0.5 mg/m² on day 8, and 0.5 mg/m² on day 15~Second induction course: 0.5 mg/m² on day 1, and 0.5 mg/m² on day 8"
75568366|NCT03244722|Dietary Supplement|Very-low energy Diet (VLED)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
75876053|NCT04059120|Other|Control group whit out specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
75876054|NCT04059198|Drug|Inarigivir soproxil|Inarigivir soproxil 400 mg tablets
75876055|NCT04059198|Drug|Tenofovir alafenamide fumarate (TAF)|Tenofovir alafenamide fumarate 25 mg tablet
75568367|NCT03244722|Other|Standard of care (SOC)|Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women
75568368|NCT03240731|Biological|bone marrow transplant|haploidentical bone marrow transplant
75568369|NCT03235739|Drug|Naloxegol 25 MG|Oral Naloxegol 25 MG
75568370|NCT03235739|Drug|Placebo|matching oral placebo
75568371|NCT03224312|Other|no intervention|no intervention
75568372|NCT03210688|Drug|Prednisolone|Tablet prednisolone
75568373|NCT03210688|Drug|Alfacalcidol|Capsule alfacalcidol 0,5 microgram/day
75568374|NCT03189810|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods [Cardenas-Morales et al. 2013] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
75721600|NCT00964275|Procedure|diagnostic procedure|Standard diagnostic procedures followed
75721601|NCT00964275|Radiation|fludeoxyglucose F 18|PET with flueoxyglucose F 18
75721602|NCT00845598|Drug|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
75721603|NCT00845598|Drug|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
75721604|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
75721605|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
76045189|NCT05102851|Diagnostic Test|Troponin, Lipid profile, HBA1C, Fasting blood glucose level, Creatinine, Body Mass Index|Full history: age, sex, smoking, known diabetes, positive family history high serum creatinine, history of prior percutaneous coronary intervention (PCI) or coronary arteries bypass grafting (CABG), or acute coronary syndrome (ACS). hypertension, diet.
75422659|NCT05888389|Procedure|Nerve Block Anesthesia Combined With Sedative Anesthesia|Patients will firstly receive cranial nerve blocks (ipsilateral auriculotemporal, greater occipital nerve, and lesser occipital nerve block) with 1.5ml~2.0ml 0.5% ropivacaine and 1% lidocaine at each site under standard monitoring. At the same time, intravenous dexmedetomidine infusion will be initiated for sedation at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5 to 1ug/kg/h until the end of the operation. The responsible anesthesiologist could adjust the rate of infusion according to the patient's physical condition. The bispectral index value will be maintained around 60 to 70 via adjusting the infusion of dexmedetomidine.
75422660|NCT05888389|Procedure|General Anesthesia|General anesthesia patients are preoxygenated for 6 min, and standardized anesthesia induction is initiated with propofol 1-2mg/kg or etomidate 0.15mg/kg-0.4mg/ kg, sufentanil 0.2-0.3ug/kg, rocuronium 0.6mg/kg or cisatracuronium 0.2mg/kg for induction. Anesthesia is maintained by total intravenous anesthesia, and intraoperative bispectral index monitoring is maintained between 40 and 60. H3 receptor blocker is given before the end of surgery to prevent nausea and vomiting.
75568375|NCT03189810|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods [Cardenas-Morales et al. 2013] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
75568376|NCT03189810|Behavioral|Weekly Counselling Session|In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
75568377|NCT03176771|Drug|MT-5199|MT-5199 40 mg capsules
75568378|NCT03176771|Drug|Placebo|MT-5199 placebo capsules
76045190|NCT01656967|Device|AMBU Aura-I/aScope 2|Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
76045191|NCT01656967|Device|LMA Fastrach Single Use|The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
76045192|NCT05180539|Behavioral|SPLASH Intervention Condition|Two-session in person group discussions focusing on behaviors in drinking contexts
76045193|NCT05180539|Behavioral|Control Condition|Two-session in person group discussions focusing on college health behaviors
76045194|NCT05100589|Dietary Supplement|PeakATP|Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
76045195|NCT05100589|Dietary Supplement|Placebo|Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
76045196|NCT05142397|Procedure|Focused Ultrasound|Focused ultrasound generates heat effects, mechanical effects and cavitation effects that denature the diseased tissues, facilitate necrosis and allow them to be replaced by surrounding normal healthy tissues.
76045197|NCT05142007|Behavioral|Hypnosis|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
75721606|NCT00251719|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
75422661|NCT05888389|Procedure|Burr hole craniostomy|A single 1.5 cm burr hole is drilled over the maximum width of the hematoma cavity. After coagulating with bipolar diathermy, dura mater is opened with a cruciate incision. A soft catheter is placed carefully in all directions of the hematoma cavity for irrigating subdural collections with 1,000 mL warm Ringer's lactate saline until clarification. The drainage catheter is inserted ½ length of the maximum diameter of the hematoma cavity toward the frontal region. After the skin is closed, the catheter is connected to a soft collection bag that is placed under the head for passive drainage. During the drainage period, participants stay in bed until the drain is removed.
75721607|NCT00968097|Drug|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
75422662|NCT05887726|Drug|Zanubrutinib|Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)
75422663|NCT05887726|Drug|Rituximab|Rituximab 375 mg/m2 i.v d0(21-day cycles)
75422664|NCT05887726|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)
75422665|NCT05887726|Drug|Epirubicin|Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)
75422666|NCT05887726|Drug|Vincristine|Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)
75422667|NCT05887726|Drug|Prednisone|Prednisone 100 mg p.o d1-d5 (21-day cycles)
75422668|NCT05886985|Drug|MatriPlax|MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
75422669|NCT05868005|Other|Clinical decision support system for screening of migrants using the ISMiHealth software tool.|"The implementation of the screening programme will be facilitated using a simple and user-friendly software tool (ISMiHealth).~When an individual attends the PCC for any reason, the tool will generate an alert for health professionals in the EPR system, with recommendations on the conditions that should be considered for screening, based on this patient's characteristics (country of birth, age and sex). Health professionals will decide what diseases/conditions should be screened for, supported by the recommendations of the digital software (intervention centres) or based on their knowledge on the epidemiological background of the diseases (control centres). In any case, health professionals will be responsible for requesting serology tests, chest radiographies and/or referrals to specialists."
75422670|NCT05867550|Drug|Rifaximin 550 MG|Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
75422671|NCT05867550|Drug|Mebeverine 135 MG|Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
75568383|NCT03140748|Other|To evaluate the initial levels and kinetics of serum β-D-glucan|To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
75721608|NCT02547090|Procedure|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
75422672|NCT05867550|Drug|Psyllium Husk|Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
75422673|NCT05867550|Drug|Amitriptyline Hydrochloride 25 MG|Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
75422674|NCT05866809|Drug|HK-660S|Administered orally
75422675|NCT05866809|Drug|Placebo|Administered orally
75422676|NCT05863806|Other|Mulligan Mobilzation|"Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
75422677|NCT05863806|Other|Trasverse Friction Massage|"Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration."
75422678|NCT05861583|Other|fat tissue|fat tissue sample collected while cosmetical liposuction
75422679|NCT05861583|Other|lipoedema tissue (stage 1)|lipoedema tissue sample (stage 1) collected while medical liposuction
75422680|NCT05861583|Other|lipoedema tissue (stage 2)|lipoedema tissue sample (stage 2) collected while medical liposuction
75422681|NCT05861583|Other|lipoedema tissue (stage 3)|lipoedema tissue sample (stage 3) collected while medical liposuction
75568384|NCT03115788|Other|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
75721609|NCT00964587|Behavioral|Education + Problem-Solving Training Self-Study|"Education + Problem-Solving Training Self-Study~One session of Literacy-Adapted Diabetes and CVD Risk Education~Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant."
75721610|NCT00964587|Behavioral|Education + Group Problem-Solving Training|"Education + Group Problem-Solving Training~One session of the Literacy-Adapted Diabetes and CVD Risk Education~Group problem-solving training eight, 90-minute sessions"
75721611|NCT00964587|Behavioral|Education + Individual Problem-Solving Training|"Education + Individual Problem-Solving Training~One session of the Literacy-Adapted Diabetes and CVD Risk Education~Individual problem-solving training (eight, 60-minute sessions)"
75422682|NCT05859308|Other|Virtual Reality Pixel Plucker|A virtual reality task where participants wear the Virtual Reality headset and respond to targets.
75876056|NCT04058964|Biological|Pegylated Recombinant Human Hyaluronidase PH20|Given SC
75422683|NCT05859308|Other|Rock Steady Boxing|An in-person boxing class designed for individuals with Parkinson's disease.
75422684|NCT05856591|Behavioral|Food Resources & Kitchen Skills (FoRKS)|Food Resources & Kitchen Skills (FoRKS) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes with embedded lessons in kitchen organization, tool use, nutrition, budgeting, and shopping.
75422685|NCT05856591|Behavioral|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
75422686|NCT05854251|Drug|Anakinra|Subjects receive an s.c. injection of 100 mg Anakinra on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
75568385|NCT03115788|Other|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
75422687|NCT05854251|Drug|Placebo|0.67 ml of s.c. injection of saline will be taken on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
75568386|NCT03115788|Device|iPad|
75568387|NCT03109795|Drug|Clonidine Pill|sympathetic nerve activity blockade
75568388|NCT03109795|Drug|Hydrochlorothiazide|Blood pressure-lowering control condition
75568389|NCT03012399|Behavioral|Hypnosedation|Undergo hypnosedation
75568390|NCT03012399|Other|Questionnaire Administration|Ancillary studies
75568391|NCT03012399|Behavioral|Verbal Support|Speak with min-body specialist
75568392|NCT03004144|Other|FLOAT|
75568393|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil|
75568394|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan|
76045198|NCT05142007|Behavioral|Mindfulness-based stress reduction|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
75422688|NCT05849753|Device|Advanced artificial pancreas closed-loop technology|Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
75568395|NCT02971956|Drug|Pembrolizumab|Immune checkpoint inhibitor
75568396|NCT02968823|Other|Licorice|ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
75876057|NCT04058964|Biological|Pembrolizumab|Given IV
76045199|NCT05141695|Device|therapeutic repetitive peripheral magnetic stimulation|Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
75422689|NCT05848947|Drug|99mTc-Macro Albumin Aggregate|Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
75422690|NCT05847426|Other|Provision of standard audiological + fNIRS test results|Infants with hearing loss will be tested using functional near-infrared spectroscopy (fNIRS) and a patented analysis algorithm to measure sound detection and discrimination. Their standard audiological test results will also be collected from their audiology service provider/s. Both sets of test results will be given to the participating audiologists in the experimental arm.
75422691|NCT05847426|Other|Provision of standard audiological test results only|The provision of test results to the audiologist will be the same as in the experimental arm, but without the fNIRS test results included.
75422692|NCT05846932|Behavioral|OTEE HORS|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided while participants are riding horses
75568397|NCT02968823|Other|Sugar water|Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
75568398|NCT02967289|Drug|Irinotecan|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes to begin 30 min after folinic acid infusion is started
75568399|NCT02967289|Drug|Folfox Protocol|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
75568400|NCT02956473|Device|Supine MRI|
75568401|NCT02956473|Other|Neoadjuvant Therapy (NAT)|
75568402|NCT02956473|Device|Ultrasound|
75568403|NCT02956473|Device|Mammography|
75568404|NCT02956473|Procedure|Standard of Care|
75568405|NCT02956473|Device|Standard MRI|
75568406|NCT02953301|Drug|resminostat|
75568407|NCT02953301|Drug|Placebo|
75568408|NCT02941705|Biological|Allogeneic Derived Cells|patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
75422693|NCT05846932|Behavioral|OT Clinic|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided in a traditional clinic
76045200|NCT05141695|Device|sham repetitive peripheral magnetic stimulation|rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
75422694|NCT05842733|Drug|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
76045201|NCT05141071|Drug|Ivabradine 5mg Tab|Ivabradine will be administrated enterally
76045202|NCT05141071|Drug|Placebo|50 ml of saline will be administrated enterally
75876058|NCT03024606|Behavioral|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
75422695|NCT05842733|Drug|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
75422696|NCT05842733|Drug|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
75422697|NCT05842239|Device|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
75422698|NCT05841420|Drug|Gemcitabine|Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
75721612|NCT00964587|Behavioral|Usual Care|"Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~Scripted set of instructions will be given along with a verbal description of the materials and the content provided."
75422699|NCT05841420|Drug|Nab paclitaxel|Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
75568409|NCT02941705|Biological|Placebo/Control Arm|patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
75568410|NCT02939742|Drug|Betamethasone|Betamethasone 12mg IM given every 24 hours for two doses
75568411|NCT02939742|Drug|Placebo|Sterile 0.9% normal saline solution given IM every 24 hours for two doses
75876059|NCT03671928|Other|additional blood tube|sampling of an additional tube at the usual blood test to determine the glicentin level
75876060|NCT03671928|Other|additional blood sample|for le group control, another blood sample is taken outside the usual care.
75568412|NCT02916966|Other|Patient Registry|Patient Registry
75568413|NCT02902484|Drug|Nintedanib|Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
75568414|NCT02891811|Drug|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
75568415|NCT02891811|Drug|Thalidomide|100mg orally on days 1-28 in patients <75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
75568416|NCT02891811|Drug|Lenalidomide|25mg p.o. on days 1-21 of each cycle
75721613|NCT00845754|Drug|ketorolac|15mg IV every6 hours for 4doses
75721614|NCT00845754|Drug|saline|15mg IV every 6hrs for 4 doses
75721615|NCT00964665|Drug|albinterferon alfa-2b|
75721616|NCT00964665|Drug|albinterferon alfa-2b|
75876061|NCT03675906|Other|hypoalbuminemia|hypoalbuminemia and acute kidney injury
75876062|NCT03675828|Behavioral|Virtual Visit|The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
75876063|NCT02864160|Behavioral|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
76045203|NCT01656889|Biological|HP-802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
75721617|NCT00964665|Drug|albinterferon alfa-2b|
75721618|NCT00964665|Drug|albinterferon alfa-2b|
76045204|NCT01656889|Biological|Vehicle|(fibrinogen solution & thrombin solution without cells)
75721619|NCT00964665|Drug|Pegasys®|
75721620|NCT00841152|Device|Bioactive glass|Surgical implantation
75721621|NCT00841152|Device|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
75721622|NCT00841152|Procedure|Autograft|Surgical transplantation from iliac crest
75422700|NCT05838053|Procedure|Lobectomy with systemic lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
75568417|NCT02891811|Drug|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients <75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
75568418|NCT02866149|Biological|Blood sampling|Up to 5 blood samplings can be performed at different time points
75568419|NCT02866149|Procedure|Tumor sampling|One tumor sampling can be performed, if applicable
75568420|NCT02866149|Other|Stool sampling|Up to 5 blood samplings can be performed at different time points
75568421|NCT02845882|Drug|Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
75568422|NCT02845882|Drug|6-mercaptopurine,Methotrexate|6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
75568423|NCT02845882|Drug|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
75568424|NCT02845882|Drug|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
75568425|NCT02845882|Drug|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
75568426|NCT02845882|Drug|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
75568427|NCT02845882|Drug|Methotrexate, 6-mercaptopurine|6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
75568428|NCT02829918|Drug|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
75568429|NCT02798042|Other|Urine Sample|We plan to collect a urine sample during the pre-surgical visit.
75721623|NCT00841152|Procedure|Allograft (frozen femoral head)|Surgical transplantation
75721624|NCT02545686|Behavioral|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
75721625|NCT02545686|Behavioral|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
75721626|NCT02545686|Procedure|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
75721627|NCT02545686|Procedure|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
76045205|NCT05097001|Other|DBS programming|DBS readjustment based on COMPUTER or CLINICAL program
75721628|NCT00841230|Drug|Deanxit|Deanxit 1x/day
75721629|NCT00841230|Drug|Lactose placebo|Lactose used as placebo
76045206|NCT05139745|Device|BTL-899|BTL-899 treatment
75568430|NCT02789020|Drug|Rasagiline|Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
75568431|NCT02789020|Other|Placebo|A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
75721630|NCT00841308|Other|Decision to start and titrate drug treatment based only on home blood pressure monitoring|"Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm)."
76045207|NCT04229329|Combination Product|Intensive Finger Individuation Therapy|Interactive robot-mediated treatment aimed at increased individuation done repeatedly for at least1 hour per day for 2 weeks (5 training days a week).
76045208|NCT04229329|Combination Product|Intensive non-directed finger movement therapy|Interactive robot-mediated treatment not aimed specifically at increased individuation done repeatedly for at least 1 hour per day for 2 weeks (5 training days per week)
76045209|NCT05094427|Procedure|Preoperative fluoroscopically-guided dorsal ramus block placed by the operative neurosurgeon|Patients received bupivicaine injections delivered via 22-gauge spinal needle to the junction of the facet and transverse process or ala at multiple spinal levels (2.5-5 cc per injection of 0.25% or 0.5% bupivacaine).
76045210|NCT05092711|Behavioral|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
76045211|NCT05092711|Drug|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
75422701|NCT05838053|Procedure|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
75568432|NCT02789020|Device|Magnetic Resonance Imaging|This test will be performed at baseline and one year.
76045212|NCT05176405|Behavioral|You-Tube Video: Elissa's EE song|Watch You-Tube video utilizing Entertainment-Education communication strategy.
76045213|NCT05176405|Behavioral|Active Comparator: Standard of Care|Reading materials containing information about early breast cancer screening in the form of infographics. Information is adopted from the Saudi Ministry of Health (MOH).
76045214|NCT05175781|Drug|Dexmedetomidine Hydrochloride|is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.
75422702|NCT05837156|Drug|Heptaflurane combined Cyclophenol|Heptaflurane combined Cyclophenol
76045215|NCT05175781|Drug|Ketamine Hydrochloride|Ketamine is an NMDA receptor antagoni
75568433|NCT02789020|Device|functional Magnetic Resonance Imaging|This test will be performed at baseline and one year.
75568434|NCT02789020|Other|Physical Function Performance Test|This test will be performed at baseline and one year.
75568435|NCT02785848|Other|Interviews and Surveys|The investigators will perform semi-structured interviews and surveys on this cohort
75568436|NCT02756273|Device|bridge device|
75568437|NCT02756273|Device|no bridge device|
75568438|NCT02719314|Drug|Glucocorticoid treatment|Glucocorticoid treatment
75568439|NCT02602769|Diagnostic Test|Transcriptome profiling|The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
75568440|NCT02598362|Drug|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
75568441|NCT02585388|Drug|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
75568442|NCT02585388|Drug|Letrozole|Lestrozole at 2,5 mg every day , per oral
75568443|NCT02585388|Drug|Anastrozole|Anastrozole at 1 mg every day, per oral
75568444|NCT02584465|Drug|Tamoxifen|Tamoxifen: 40 mg/day
75568445|NCT02584465|Drug|Regorafenib|Stivarga; 120mg/day
75568446|NCT02579278|Other|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
75568447|NCT02579278|Other|Blood sample (mrEMVI negative patient)|
75568448|NCT02579161|Drug|cephalosporins|Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed
75422703|NCT05837156|Drug|Heptaflurane|Heptaflurane only
75422704|NCT05837156|Drug|Cyclophenol|Cyclophenol only
75422705|NCT05835427|Other|Cervical Extensor Stretch|Fibromyalgia individual: Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
75422706|NCT05835427|Other|Cervical Extensor Stretch|Healthy volunteers : Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
75568449|NCT02579161|Drug|Fluoroquinolones|If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance
75568450|NCT02579161|Drug|Clindamycin|If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.
75721631|NCT00852072|Procedure|Single-operator cholangioscopy-guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
75721632|NCT00852072|Procedure|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
75422707|NCT05834608|Behavioral|Mechanical ventilator-assisted ventilation|After the intravenous anesthesia induction, mechanical ventilator-assisted ventilation with AutoFlow mode of the anesthesia machine (Draeger-Perseus) will be applied before intubation.
75721633|NCT02545920|Other|no intervention|observational study
75568451|NCT02579161|Drug|Ampicillin/Gentamicin|5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
76045216|NCT05175781|Drug|Placebo|Normal saline
76045217|NCT04421911|Drug|Ketoprofen topical|Ketoprofen topical for 21days
76045218|NCT04421911|Drug|Diclofenac Topical|Diclofenac topical for 21days
76045219|NCT05174611|Dietary Supplement|Vitamin D3|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
75422708|NCT05832723|Device|650 nm low-level red-light|Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
75422709|NCT05832060|Device|Active tDCS|Active tDCS will be delivered over TPC for a stimulation session. The anodal electrode will be placed on the left TPC, T7/TP7 position according to the 10-20 International EEG 10-20 System for electrode placement. The cathodal electrode will be placed on the right TPC, T8/TP8 position. Intensity will be set at 1 mA, the duration of stimulation will be 20 min.
75422710|NCT05832060|Device|Active tRNS|Active tRNS will be delivered to bilateral TPC for a stimulation session. The electrodes will be placed on the left and right TPC, respectively T7/TP7 and T8/TP8 position, at 0.75 mA (100-500 Hz) for 20 min.
75422711|NCT05832060|Device|Sham tRNS or tDCS|Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.
75568452|NCT02568124|Drug|Tranexamic Acid|
75568453|NCT02568124|Drug|Placebo|
75568454|NCT02536170|Drug|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
75568455|NCT02536170|Drug|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
75568456|NCT02536170|Other|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
75568457|NCT02535533|Drug|Selenomethionine (SLM)|SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
75568458|NCT02535533|Drug|Axitinib|Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
75876064|NCT02864160|Behavioral|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
76045220|NCT05174611|Other|Placebo|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
76045221|NCT05173753|Other|Novel self-adhesive hybrid composite(Surefil one)|Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.
76045222|NCT04226209|Other|PSSE|Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
76045223|NCT05173207|Diagnostic Test|Videofluoroscopic swallow exam with concurrent monitoring of respiratory-swallow coordination|Participants will undergo simultaneous videofluoroscopy, nasal airflow and respiratory inductance plethysmography testing.
76045224|NCT05173129|Diagnostic Test|Posture Analysis|Posture analysis and assessment of mechanical properties of posture muscles
75568459|NCT02535533|Drug|Selenomethionine (SLM)|Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
75568460|NCT02535533|Drug|Axitinib|Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
75568461|NCT02535533|Drug|Selenomethionine (SLM)|Pilot Phase - Dosing will begin at dose level 3 (4000, 5000 or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days
76045225|NCT05172349|Biological|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
76045226|NCT05133973|Device|FiberSense CGM|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
75568462|NCT02530983|Other|Mayo Clinic Upper Digestive Disease Survey on Paper|Mayo Clinic patients will be asked to complete the Mayo Clinic Upper Digestive Disease Survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
75568463|NCT02530983|Other|Upper Digestive Disease (UDD Monitor) App|"Mayo Clinic and non Mayo Clinic patients can participate by loading the app through the app store. Patient consent will be completed in the app. Patients will be asked to complete questionnaires at their 1.5 month surgical or diagnosis follow up and then every three months for 1 year after their surgery or diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime or as long as they want to participate.~for iOS: https://apps.apple.com/us/app/upper-digestive-disease/id6448756724 for Android: https://play.google.com/store/apps/details?id=com.mayoclinic.uddmobile&pli=1"
75876065|NCT03671616|Biological|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
75568464|NCT02524483|Behavioral|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
75568465|NCT02524483|Behavioral|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
75721634|NCT00841386|Drug|Riboflavin-5-phosphate|Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
75721635|NCT00841386|Drug|Sham cross-linking|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
75422712|NCT05826561|Other|Childhood Asthma Passive Digital Marker|"A childhood asthma Passive Digital Marker (PDM) is an ML algorithm that is able to retrieve and synthesize pre-existing passively collected mother/child dyad prognostic data in digital electronic health record (EHR) to provide an objective and quantifiable marker of a child's risk (probability) and associated pathophysiological phenotype to inform clinician decision-making at point-of-care."
75422713|NCT05823077|Other|Bergamot|The affected knee will be massaged with Bergamot oil for 4 weeks, 2 sessions per week.
75422714|NCT05823077|Other|Placebo|The affected knee will be massaged with sweet almond oil for 4 weeks, 2 sessions per week.
75422715|NCT05818852|Drug|VX-548|Tablets for oral administration.
75422716|NCT05818852|Drug|Moxifloxacin|Capsules for oral administration.
75876066|NCT03675594|Device|CAD/CAM titanium denture base|metallic denture base made of titanium
75876067|NCT03675594|Device|CAD/CAM cobalt/chromium denture bases|metallic denture bases made of cobalt/chromium
75568466|NCT02523443|Other|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
75721636|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
75876068|NCT03675438|Other|Sub-epitheilal TCA Inlay|A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
75876069|NCT03180619|Drug|TAF|Tablet administered orally once daily
75422717|NCT05818852|Drug|Moxifloxacin Placebo|Capsules for oral administration.
75422718|NCT05818852|Drug|VX-548 Placebo|Tablets for oral administration.
75422719|NCT05814146|Drug|Dialysate bicarbonate concentration|"Assess how a lower dialysate bicarbonate affects:~QTc duration during and between hemodialysis sessions~PVC burden during and between hemodialysis sessions~Clinically significant arrhythmia during and between hemodialysis sessions~Intradialytic hypotension~Adverse symptoms during hemodialysis sessions"
75422720|NCT05814146|Device|Dialysate bicarbonate concentration - telemetry monitoring|Patients will be monitored with telemetry on both arms of the trial.
75876070|NCT03669744|Other|telephone survey|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
75876071|NCT03671538|Drug|Anlotinib|Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
75876072|NCT03671538|Drug|pemetrexed|pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;
75876073|NCT03671538|Drug|Cisplatin|Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;
75876074|NCT05426941|Behavioral|Music Imagery|Up to 30 participants will be randomized to receive 8 weekly Music Imagery sessions over 8-12 weeks.
75876075|NCT05426941|Behavioral|Music Listening|Up to 15 participants will be randomized to independent music listening.
76045227|NCT05133817|Drug|Normal saline|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
76045228|NCT05133817|Drug|Norepinephrine (0.025 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
76045229|NCT05133817|Drug|Norepinephrine (0.05 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
75422721|NCT05813392|Behavioral|Digital Cognitive Behavioral Therapy for Insomnia|a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
75422722|NCT05813041|Device|BioCaptis|The BioCaptis is a medical device intended to capture cell-free DNA from peripheral blood for use in liquid biopsy. When used as a cartridge filter during an apheresis procedure in which plasma is passed through the device, the BioCaptis binds cfDNA which can be eluted, concentrated, and used as an input for cancer diagnostic tests.
75422723|NCT05812261|Other|Creating an electro-anatomical map|After the routine pulsed-field ablation procedure, the operator will create an electro-anatomical map using the ablation catheter and a 3D mapping system.
75422724|NCT05803733|Other|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb.
75422725|NCT05803733|Other|Routine strength training|range of motion exercises and strength training
75568467|NCT02523443|Other|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
75568468|NCT02498912|Procedure|Production of Genetically-modified T cells|
75721637|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
75422726|NCT05801341|Device|Lollipop|An oral lollipop swab will be obtained by placing a flocked swab into the mouth and sucking on the swab for 20 seconds as one would suck on a lollipop
75422727|NCT05801315|Device|Glycine powder air polishing|Peri-implant mucositis sites treated with a glycine powder air polishing device (Air-Flow Master Piezon®).
75422728|NCT05801315|Device|Full mouth ultrasonic debridement|Peri-implant mucositis sites are treated with thin ultrasonic tips.
75422729|NCT05800444|Drug|BAY3283142|Oral administration as tablet.
75422730|NCT05800444|Other|Placebo|Oral administration as tablet.
75422731|NCT05798403|Device|electroacupuncture|"All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all needles will be lifting, twirling, and thrusting to reach de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.~An electrical stimulator is applied to ipsilateral BL32 and BL35 (KI12 and ST28) with continuous waves of 30 Hz and currents of 1 to 5.0 mA. During the study, oral Solifenacin Succinate placebo will be used."
75568469|NCT02498912|Drug|Cyclophosphamide|
75568470|NCT02498912|Device|IP Catheter Insertion|
75721638|NCT03952143|Drug|LY900014|Administered SC
75721639|NCT03952143|Drug|Insulin Lispro|Administered SC
75721640|NCT03952143|Drug|Insulin Glargine|Administered SC
75721641|NCT03952143|Drug|Insulin Degludec|Administered SC
75568471|NCT02498912|Genetic|Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells|Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.
75568472|NCT02498912|Drug|Fludarabine|fludarabine dose 25-30 mg/m2 x 3 days
75721642|NCT00968175|Procedure|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
75721643|NCT03071757|Drug|ABBV-368|Intravenous infusion
75721644|NCT03071757|Drug|ABBV-181|Intravenous infusion
75721645|NCT00968331|Drug|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
75721646|NCT00852228|Drug|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
76045230|NCT05133817|Drug|Norepinephrine (0.075 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
76045231|NCT05133817|Drug|Norepinephrine (0.1 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
76045232|NCT05172193|Biological|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
75876076|NCT05420467|Drug|Docetaxel|75 mg/m2, d1, q3w,6 cycles
75422732|NCT05798403|Drug|Solifenacin Succinate Tablets|"During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needlesbeing pulled out."
75422733|NCT05783596|Drug|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.
75422734|NCT05783596|Drug|Glofitamab|T-cell bispecific humanized monoclonal antibody, via IV infusion.
75422735|NCT05783141|Dietary Supplement|New prebiotic follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
75422736|NCT05783141|Dietary Supplement|Standard follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
75876077|NCT05420467|Drug|Carboplatin|AUC 6, d1, q3w,6 cycles
75876078|NCT05420467|Drug|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
75876079|NCT05420467|Drug|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
75876080|NCT05420467|Drug|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
75876081|NCT05420467|Drug|Epirubicin|90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
75876082|NCT05420467|Drug|Cyclophosphamide|600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
75876083|NCT05420467|Drug|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
75876084|NCT05420467|Drug|Epirubicin|90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
75568473|NCT02431897|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
75568474|NCT02431897|Drug|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
75721647|NCT00852228|Drug|HAI chronomodulated chemotherapy|"Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks."
75721648|NCT00852228|Drug|HAI conventional chemotherapy|"Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks."
75568475|NCT02427841|Drug|Fluorouracil|Given IV
75876085|NCT05420467|Drug|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
75568476|NCT02427841|Drug|Gemcitabine|Given IV
75422737|NCT05780853|Diagnostic Test|Tablet Game-based Assessment - YARN assessment service|Tablet game-based assessment to assess neurodevelopmental profile.
75422738|NCT05780853|Diagnostic Test|Adaptive Behavior Assessment System, Third Edition (ABAS-3)|A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.
75422739|NCT05780853|Other|Demographic questionnaire|Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
75568477|NCT02427841|Radiation|Image Guided Radiation Therapy|Undergo IG-IMRT
75568478|NCT02427841|Radiation|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
75568479|NCT02427841|Other|Laboratory Biomarker Analysis|Correlative studies
75568480|NCT02427841|Drug|Nab-paclitaxel|Given IV
75568481|NCT02427841|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75876086|NCT05420467|Drug|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
75876087|NCT05420467|Drug|Cyclophosphamide|600 mg/m2, d1, q3w × 6 cycles
75876088|NCT03671460|Biological|CD19 CAR-T cells|T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
75876089|NCT03675204|Other|No intervention|No intervention
75721649|NCT00267007|Drug|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
75876090|NCT03671382|Behavioral|Communication Training Program and Patient Prompt Sheet|The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
75876091|NCT02915874|Behavioral|Acceptance and Commitment Therapy|
75876092|NCT02818218|Procedure|Liver Transplant|liver transplant recipient surgery
75721650|NCT00267007|Drug|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
75568482|NCT02425566|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
75721651|NCT00841620|Procedure|Haemorrhoidectomy a.m. Milligan|Surgery
75721652|NCT00841620|Procedure|Stapled anopexy|Surgery
76045233|NCT05171335|Drug|Lenvatinib|"Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of <60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time."
76045234|NCT05171335|Procedure|Transcatheter Arterial Chemoembolization|Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
75721653|NCT00964821|Biological|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
75721654|NCT00964821|Other|Immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
75876093|NCT03675048|Dietary Supplement|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
75422740|NCT05776667|Radiation|Hypofractionated Radiation Therapy|"Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by standard of care wide local excision 2-6 weeks later."
75422741|NCT05772845|Behavioral|Acute (24-hour) abstinence|Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
75422742|NCT05772845|Behavioral|Ad libitum smoking/vaping|Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
75568483|NCT02425566|Drug|Nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
75876094|NCT03675048|Dietary Supplement|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
75876095|NCT03022578|Procedure|Laser Interstitial Thermal Therapy|Undergo LITT
75876096|NCT03022578|Drug|Lomustine|Given PO
75876097|NCT03022422|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
75876098|NCT03022422|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
75876099|NCT03023826|Drug|LY3202626 (R-Fasting)|Administered orally
75422743|NCT05772429|Drug|Epidiolex|Administered as an oral solution
75422744|NCT05772221|Other|Screening|Screening assessments to measure social determinants of health in relation to cardiovascular disease.
75422745|NCT05764122|Drug|BIIB131|Administered as specified in the treatment arm.
75721655|NCT00964821|Other|Laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
75876100|NCT03023826|Drug|LY3202626 (T1-Fasting)|Administered orally
75876101|NCT03023826|Drug|LY3202626 (T1-Fed)|Administered orally
75422746|NCT05764122|Drug|Placebo|Administered as specified in the treatment arm.
75568484|NCT02413788|Other|aerobic exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
75568485|NCT02413788|Other|combined exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
75568486|NCT02413788|Device|treadmill|
75721656|NCT00852306|Procedure|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
75568487|NCT02386735|Drug|Placebo|Three days prednisone 40mg, two days placebo
75568488|NCT02386735|Drug|Prednisone|Five days prednisone 40mg.
75568489|NCT02383251|Drug|Pazopanib|Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
75876102|NCT03671070|Drug|Epinephrine|IV Low dose Boluses
75876103|NCT03671070|Drug|Traditional management of shock|"Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency."
75876104|NCT03670992|Procedure|duodenal-pancreatectomy|surgical removal of metastatic repetitions in pancreas and/or other distal sites
75876105|NCT03670758|Diagnostic Test|Protein S activity|Intravenous blood sample
76045235|NCT02522299|Drug|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
75422747|NCT05763797|Behavioral|Individual Interview|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
75568490|NCT02383251|Drug|Paclitaxel|Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
75568491|NCT02348216|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg.
75568492|NCT02348216|Drug|Fludarabine|Administered according to package insert
76045236|NCT02522299|Drug|Placebo|Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
75568493|NCT02348216|Drug|Cyclophosphamide|Administered according to package insert
75568494|NCT02337647|Other|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
75568495|NCT02307331|Device|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
75721657|NCT01071031|Biological|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection"
75721658|NCT01071031|Biological|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection"
75876106|NCT03674658|Drug|Propafenone|oral, TID
75568496|NCT02307331|Device|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
75568497|NCT02307331|Device|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
75422748|NCT05763797|Behavioral|Meditation Exercise|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
75568498|NCT02307331|Device|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
75568499|NCT02307331|Device|Sirius stem|A polished tapered stem
75721659|NCT01071031|Biological|HIV-v (Control)|"Adjuvant only or Water for injection only~Administration: A single subcutaneous injection"
75568500|NCT02292641|Procedure|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
75568501|NCT02272309|Procedure|EEG and EP measurement|
75568502|NCT02204683|Drug|Aflibercept|Intravitreal aflibercept
75422749|NCT05761873|Other|Provision of audit and feedback via email and paper|Provision of A&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
75568503|NCT02157532|Procedure|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
75721660|NCT00968409|Radiation|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
75568504|NCT02157532|Drug|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
75568505|NCT02134301|Drug|Oritavancin|
75568506|NCT02037529|Drug|Eribulin Mesylate|Given IV
75568507|NCT02037529|Other|Laboratory Biomarker Analysis|Correlative studies
75568508|NCT02037529|Drug|Paclitaxel|Given IV
75568509|NCT02037529|Other|Quality-of-Life Assessment|Ancillary studies
75568510|NCT02030028|Drug|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
75568511|NCT01956123|Drug|Follitropin Delta (FE 999049)|
75721661|NCT00968409|Other|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
75721662|NCT00968409|Other|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
75721663|NCT00968409|Drug|F18-FFNP|injection of F18-FFNP
75568512|NCT01956123|Drug|Follitropin Alfa (GONAL-F)|
75876107|NCT03674580|Behavioral|Follow-up of the suicidal patients|No intervention. Follow-up of the suicidal patients
75876108|NCT03674502|Drug|ADU-1604|anti-CTLA-4 monoclonal antibody
75568513|NCT01906814|Drug|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
75876109|NCT03623256|Drug|Spinal fentanyl|25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
75568514|NCT01906814|Drug|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
75568515|NCT01894308|Drug|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
75568516|NCT01894308|Device|Pump Sprayer|A dose of product solution is delivered by means of a metered pump spray.
75876110|NCT03623256|Drug|Spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
76045237|NCT02522299|Device|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
75721664|NCT04010019|Behavioral|Enhanced Facebook Condition|The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
75721665|NCT04010019|Behavioral|Control Facebook Condition|The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
75422750|NCT05761873|Other|Provision of audit and feedback via paper only|Provision of A&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
75422751|NCT05759182|Device|pediatric/adolescent exoskeleton walking system|A pediatric/adolescent exoskeleton will be differentially applied according to each patient's gait level, 30 minutes a day, 3 times a week, 24 times in total for 8 weeks. When applying the intervention, the use of an appropriate stabilizing device (crutches, cane, harness, etc.) will be used according to the gait level of the study subject.
75721666|NCT00841854|Drug|pantoprazole|pantoprazole 40mg bid
75721667|NCT00841854|Drug|bismuth|bismuth 300mg qid
75422752|NCT05748821|Device|Delfi Personal Tourniquet Systems|Measure within & between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
75721668|NCT00841854|Drug|metronidazole|metronidazole 500mg tid
75422753|NCT05734625|Drug|Bupivacaine HCl 0.5% Injectable Solution|Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
75422754|NCT05734625|Drug|Methylprednisolone 40 MG Injection|Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
75568517|NCT01764399|Behavioral|Care4U|
75568518|NCT01762176|Procedure|Protocolized intensive treatment|Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
75568519|NCT01762176|Procedure|Usual care|Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
75568520|NCT01705158|Drug|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
75568521|NCT01700543|Procedure|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
75721669|NCT00841854|Drug|tetracycline|tetracycline 500mg qid
75721670|NCT05299281|Device|Micropulse transscleral cyclophotocoagulation (MP-TSCPC)|"patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively."
75721671|NCT04043130|Behavioral|Pulse|The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
75568522|NCT01673100|Behavioral|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
75568523|NCT01583322|Drug|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
75721672|NCT00968487|Biological|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
75721673|NCT00968487|Other|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 °C (-0.4 °F) (or colder) within 6 hours of collection.
75422755|NCT05726461|Device|AndroidAPS-rt-CGM;|Insulin therapy (aspart, lispro or glulisine) with AndroidAPS-rt-CGM.AndroidAPS-rt-CGM consists of three components:1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone.
75422756|NCT05726461|Device|sensor augmented pump(SAP);|Insulin therapy (aspart, lispro or glulisine) with sensor augmented pump(SAP).SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
75422757|NCT05725291|Drug|AMT-116|Administered intravenously
75422758|NCT05717530|Procedure|wound site local anesthesic infiltration|: at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.
75422759|NCT05717530|Procedure|Erector spina plane block|Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.
75422760|NCT05712096|Drug|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
75422761|NCT05698745|Procedure|bioespecimen samples|Blood, serum, plasma, urine, stools, small/large bowel tissue.
75422764|NCT05688241|Drug|Donor-derived ex-vivo expanded EBV Tscm CTL|Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.
75568524|NCT01583322|Drug|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."
75568525|NCT01571037|Drug|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
75422765|NCT05687825|Procedure|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
75422766|NCT05686031|Other|No interventions were done between groups|No interventions were done between groups
75568526|NCT01571037|Drug|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
75568527|NCT01558427|Procedure|Surveillance|Active clinical surveillance
75422767|NCT05684042|Other|Data analysis: Accuracy measurement of the classifications of the distal radius fracture in the fracture database.|An expert panel (3 in-house experienced specialists) carries out a new fracture classification based on the anonymous radiological images in the interface of the REDCap fracture database. The degree of discrepancy between the expert panel and the database in fracture classifications is analyzed. By evaluating the extracted data, it is analyzed how valid the quality of the collected fracture classifications are, which the medical staff carry out in everyday clinical practice.
75422768|NCT05676853|Drug|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
75422769|NCT05676099|Procedure|Phlebotomy|Participants may elect to submit a blood sample to the Biosample Repository.
75422770|NCT05676099|Procedure|Buccal (cheek) swab|Participants may elect to submit a buccal swab sample to the Biosample Repository.
75568528|NCT01558427|Procedure|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
75568529|NCT01535248|Other|Transthoracic Echocardiography|Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
75568530|NCT01487538|Behavioral|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
75568531|NCT01487538|Behavioral|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
75568532|NCT01487538|Behavioral|Discussion Boards|forum to exchange information and experiences
75422771|NCT05676099|Genetic|Genetic Testing|Biosamples may be processed and analyzed for genetic variants using whole genome sequencing (WGS) or other sequencing methods. Participants whose samples are processed in this manner may be contacted and provided the option to receive TSC1 or TSC2 genetic variant results by opting in using Consent to Return of Genetic Results Form. Participants will be offered a one-time genetic counseling session to review their results, free of charge. CLIA-certified, TSC1 or TSC2 genetic variant results will be returned to participants who opt in to receive such results. Additionally, negative results and results not able to be clinically certified will also be offered to participants with a one-time genetic counseling session to review their results, free of charge using the Return of Genetic Research Results Template Letter. CSS will be responsible for informing clinic participants that their samples have been sequenced and offer to connect participant to the TSC Alliance for further information.
75422772|NCT05676099|Other|Tissue donation after routine clinical procedure|Participants may elect to submit a tissue sample to the Biosample Repository following a medical procedure.
75422773|NCT05675306|Behavioral|Dynamic Temporal and Tactile Cueing Treatment|"DTTC is a dynamic, motor-based treatment approach designed for children with severe CAS. This approach is based on Integral Stimulation (Edeal & Gildersleeve-Neumann, 2011; Maas & Farinella, 2012; Maas et al., 2019; Strand & Debertine, 2000; Strand & Skinder, 1999), in which the clinician instructs the child to listen to me, watch me, and do what I do and systematically taxes and supports the speech motor system to facilitate system-wide change in speech output (Strand, 2020)."
75422774|NCT05673512|Combination Product|Injection of IAH0968 + CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
75422775|NCT05673512|Combination Product|PLACEBO+CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
75422776|NCT05672316|Biological|Balstilimab|Given IV
75422777|NCT05672316|Procedure|Biospecimen Collection|Undergo collection of blood
75422778|NCT05672316|Biological|Botensilimab|Given IV
75422779|NCT05672316|Procedure|Computed Tomography|Undergo CT
75422780|NCT05672316|Drug|Regorafenib|Given PO
75568533|NCT01487538|Behavioral|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
75568534|NCT01469650|Dietary Supplement|cholecalciferal|400 IU/day
75568535|NCT01469650|Dietary Supplement|cholecalciferol|800 IU/day D3
75422781|NCT05671172|Drug|Hyaluronidase|hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS
75422782|NCT05671172|Drug|Bupivacaine Injection|20ml bupivacaine will be injected without additives in the transversus abdominis plane block on each side for postoperative analgesic after CS
75422783|NCT05664893|Drug|Ribociclib Oral Tablet|"600mg per day during registration phase (3 cycles); de-escalation phase (600 to 200mg per day associated to radiotherapy) during 3 other cycles; maintenance phase until 24 months of treatment in total (600mg per day).~All over th etimme, hormonotherapy is received in concomitance"
75422784|NCT05664646|Device|DS8R|transcutaneous stimulation of the spinal cord.
75422785|NCT05664646|Other|Arm Ergometry|Study 1 will use the arm ergometry as a form of exercise.
75422786|NCT05664646|Other|Cool Environment|Study 2 will be completed in a cool environment setting.
75422787|NCT05659719|Other|Recifercept|Patients received recifercept intervention in the phase 2 clinical trial
75422788|NCT05652413|Behavioral|Adapted-Engage-PA|Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
75721674|NCT00848562|Drug|Nicorandil|Oral administration of nicorandil (15 mg/day)
75721675|NCT02546154|Drug|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
75422791|NCT05651555|Behavioral|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution
75721676|NCT03943095|Other|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
75721677|NCT03943095|Other|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
75721678|NCT00852384|Procedure|NIPPV and IRM|"non invasive positive pressure support ventilation (NIPPV group)~alveolar recruitment maneuver (IRM group)"
75721679|NCT00841932|Procedure|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
75422792|NCT05651438|Other|Assessment|Assessment of pain, fatigue, sleep quality, and e-sports-specific features
75422793|NCT05650645|Drug|incobotulinum toxin A|The study intervention is a syringe of 50 units of incobotulinum toxin A total, with 25 units per side, a total of 6 injection sites incobotulinum toxin A diluted into 1 ml of normal saline, injected in equal amounts into the anterior, superior, and posterior auricular muscles using anatomical landmarks. This will be approximately 0.16 mL (8-9 units) of the combined solution per injection site.
75422794|NCT05650645|Drug|Placebo-Saline|Placebo injections will be preservative free normal saline. Injections will be administered similar to the drug injections.
75721680|NCT00852462|Behavioral|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
75721681|NCT02850939|Behavioral|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
75721682|NCT00848640|Drug|Sorafenib|400 mg twice daily
75721683|NCT00968565|Drug|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
75568536|NCT01452269|Behavioral|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
75422795|NCT05650359|Device|OrthoPulse|"The OrthoPulse device is intended to accelerate orthodontic movement of teeth and reduce the overall treatment time for the patient. The device is intended to be used in conjunction with traditional orthodontic treatment with brackets and wires or aligners.~OrthoPulse is an intra-oral (iO), Light Emitting Diode (LED) based, phototherapy device for the stimulation of metabolic activity of the alveolar bone, and the acceleration of orthodontic tooth movement during orthodontic treatment. The device uses safe, high-power LED arrays to produce photons at therapeutic wavelengths in the near infrared (nIR) portion of the light spectrum.~OrthoPulse is an established device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement which may reduce treatment time for braces or clear aligners."
75568537|NCT01431326|Drug|The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:|
75721684|NCT04042818|Diagnostic Test|Rehabilitative Ultrasound|Ultrasound imagining
75721685|NCT04010331|Dietary Supplement|Nokyong Mixture Extract(CME-PI)|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
75876111|NCT03623256|Drug|Spinal Fentanyl and Bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
75422796|NCT05650359|Other|No intervention|No intervention
75422797|NCT05647317|Other|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application that is integrated with a remote blood pressure cuff, heart rate monitor, and scale.
75422798|NCT05645978|Device|Pacemaker insertion|Patients who underwent pacemaker insertion between January 2015 and December 2020
75422799|NCT05645965|Device|ICD insertion|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
75422800|NCT05645939|Other|Diasgnosis of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
75721686|NCT04010331|Dietary Supplement|Placebo|Placebo for 8 week
75721687|NCT00965133|Other|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
75422801|NCT05645926|Procedure|Percutaneous coronary intervention (PCI)|Patients who underwent percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA), and coronary stent insertion
75422802|NCT05645926|Procedure|Coronary artery bypass grafting (CABG)|Patients who underwent coronary artery bypass grafting (CABG)
75422803|NCT05645913|Drug|Oral anticoagulant|Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)
75568538|NCT01397877|Drug|BKM120|per os, 60mg/j, until progression or unacceptable toxicity
75721688|NCT00848796|Drug|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
75721689|NCT00968643|Radiation|radiation therapy|Given in multiple fractions or as a single fraction
75721690|NCT02545764|Other|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
75721691|NCT05251155|Diagnostic Test|Distant best corrected visual acuity assessment|Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.
75721692|NCT00848874|Behavioral|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
75721693|NCT00965211|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 1 Hz to the supplementary motor cortex and then a 2 minute recess.each subject would undergo 5 sessions a week for 4 weeks.
75721694|NCT00842166|Other|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
75721695|NCT00848952|Other|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
75721696|NCT00965289|Drug|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
75876112|NCT03623256|Drug|Epidural fentanyl /spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
75876113|NCT03674268|Diagnostic Test|Management of the Contraversive Pushing Scale|Scale of evaluation of trunk control and pushing behavior in patients with stroke.
76045238|NCT02522299|Device|ELLIPTA|It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
75422804|NCT05636540|Drug|[18F]FluorThanatrace ([18F]FTT)|A pre-treatment 18F-FluorThanatrace ([18F]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
75568539|NCT01307644|Behavioral|Experimental: Web-based only (WO) weight intervention|The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
75568540|NCT01307644|Behavioral|Experimental: WO plus peer-led discussion board (WD)|Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
75568541|NCT01307644|Behavioral|Experimental: WO & professional email counseling (WE)|Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
75568542|NCT01303679|Drug|Paclitaxel|IV, 80mg/m² at d1, d8, d15
75568543|NCT01303679|Drug|Bevacizumab|IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
75568544|NCT01303679|Drug|Exemestane|daily 25 mg (1 pill) oral intake
75568545|NCT01298713|Drug|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
75568546|NCT01298713|Drug|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
75568547|NCT01191697|Drug|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
75568548|NCT01191697|Drug|trastuzumab|Given intravenously on day 1 of each treatment cycle
75568549|NCT01191697|Drug|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
75568550|NCT01191697|Drug|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
75568551|NCT01189643|Drug|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
75568552|NCT01186042|Other|Observational|No intervention
75721697|NCT04042506|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV every 4 weeks
75721698|NCT04042506|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
75876114|NCT02661672|Device|Apollo Device|The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
75876115|NCT02661672|Device|Artemis Device|The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
75876116|NCT03669510|Other|computer guided IAN lateralization surgical technique|Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique
75876117|NCT03674190|Procedure|Anterior Lumbar Interbody Fusion|Anterior Lumbar Fusion(ALIF)
75422805|NCT05630326|Other|comparing, prevalence|Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
75422806|NCT05630326|Other|assessment|comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
75422807|NCT05630326|Other|association|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
75422808|NCT05630326|Other|evaluation|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
75568553|NCT01182506|Behavioral|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
75568554|NCT01092884|Dietary Supplement|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
75568555|NCT01092884|Other|Placebo|This placebo capsule will be taken orally three times daily
75568556|NCT01044745|Drug|rituximab|Given IV
75721699|NCT00251641|Drug|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
75876118|NCT03674190|Procedure|Total Disc Replacement|Total Disc Replacement
75568557|NCT01044745|Drug|mycophenolate mofetil|Given IV or PO
75721700|NCT00251641|Drug|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a <25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
75422809|NCT05620901|Drug|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
75422810|NCT05620901|Drug|Pred Forte|To treat perioperative ocular inflammation and pain;
75422811|NCT05618314|Drug|AT-527|single dose AT-527
75876119|NCT03674034|Other|CTscan and MRI images|CTscan and MRI images segmented according to procedures previously developed by GRAMFC
75422812|NCT05618314|Drug|AT-527|Single dose of AT-527 pre- and post-dialysis
75422813|NCT05618314|Drug|AT-527 and Probenecid|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
75422814|NCT05610995|Device|SENSIUM Patch|The SENSIUM device is a tool to monitor vital signs by applying a connected skin patch whose objective is to detect complications early. The health data is transmitted to the practitioner and in case of disturbance of the parameters, an alert is sent. The patient can be called for consultation or hospitalization if necessary. This device has been tested under real clinical conditions in surgical units. The continuous monitoring of vital signs resulted in earlier detection of sepsis, earlier administration of antibiotics, shorter average length of stay and lower 30-day readmission rates.
75422815|NCT05603104|Drug|Clozapine|See arm description
75422816|NCT05603104|Drug|Esketamine Nasal Product|See arm description
75422817|NCT05603104|Drug|Escitalopram|See arm description
75422818|NCT05603104|Drug|Sertraline|See arm description
75422819|NCT05603104|Drug|Duloxetine|See arm description
75422820|NCT05603104|Drug|Venlafaxine|See arm description
75721701|NCT00842322|Behavioral|high fluid intake|fluid intake of 4 litres per day
75721702|NCT00842322|Behavioral|normal fluid intake|Fluid intake of 2 litres per day
75876120|NCT03670290|Procedure|Fascia iliaca compartment catheter|Patient will evaluate and if VAS score >3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
75876121|NCT03670290|Procedure|epidural catheter|Patient will evaluate and if VAS score >3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
75568558|NCT01044745|Drug|tacrolimus|Given IV
75876122|NCT03670290|Procedure|patient controlled analgesia|Patient will evaluate and if VAS score >3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
75876123|NCT03113760|Drug|Tadekinig alfa|Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
75876124|NCT03113760|Other|0.9% sodium chloride|To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
76045239|NCT05170945|Other|Early bowel preparation for colonoscopy|Early (<24 hours) bowel cleansing prior to colonoscopy.
75422821|NCT05603104|Drug|Lithium|See arm description
75876125|NCT03166735|Drug|BI 1467335|once daily
75876126|NCT03166735|Drug|Placebo|once daily
75568559|NCT01044745|Drug|anti-thymocyte globulin|Given IV
75876127|NCT03082014|Drug|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
76045240|NCT05130307|Behavioral|virtual reality game|participants interact with a computer generated world
75876128|NCT03082014|Drug|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
75876129|NCT03082014|Drug|Atenolol|blood pressure lowering agent - beta-blocker
76045241|NCT05168605|Other|Home visit|Patients receiving home Visits
76045242|NCT01365091|Drug|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
75422822|NCT05603104|Drug|Lamotrigine|See arm description
75568560|NCT01044745|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
76045243|NCT01365091|Drug|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
76045244|NCT01365091|Drug|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
76045245|NCT01365091|Drug|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
76045246|NCT01365091|Drug|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
76045247|NCT05082571|Drug|vadadustat|Vadadustat tablet orally once a day for 52 weeks
75422823|NCT05603104|Drug|Valproate acid|See arm description
75422824|NCT05603104|Drug|Quetiapine|See arm description
75422825|NCT05603104|Drug|Second-line Antidepressants|See arm description
75422826|NCT05603104|Drug|Second-line Antipsychotics|See arm description
75422827|NCT05603104|Drug|Ketamine Hydrochloride|See arm description
75422828|NCT05603104|Drug|Esketamine hydrochloride|See arm description
75422829|NCT05602493|Drug|Soludronate®|In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
75422830|NCT05602493|Drug|sterile saline|sterile saline
75568561|NCT01044745|Other|laboratory biomarker analysis|Correlative studies
75568562|NCT01044745|Biological|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
75568563|NCT01044745|Drug|cyclophosphamide|Given PO or IV
75568564|NCT01044745|Drug|fludarabine phosphate|Given IV
75568565|NCT01044745|Drug|busulfan|Given IV
75568566|NCT01044745|Radiation|total-body irradiation|Undergo TBI
75568567|NCT01044745|Biological|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
75568568|NCT01044745|Biological|immunosuppressive therapy|Undergo immunosuppressive therapy
75568569|NCT00990275|Other|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
75876130|NCT02750605|Device|DEB|Intervention with drug eluting balloon.
75876131|NCT02750605|Device|POBA|Intervention with old technology as comparison
75876132|NCT03673566|Device|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
75876133|NCT05320159|Drug|Secukinumab|Included all the patients treated with secukinumab
75876134|NCT03670212|Drug|Yohimbine Hydrochloride|54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.
75876135|NCT03670212|Drug|Hydrocortisone|10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
75876136|NCT03670212|Drug|Lactose Monohydrate Powder|Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
76045248|NCT04422145|Behavioral|Structured nurse led intervention programme|A diabetes research nurse, over a period of 12 months, provided a structured education programme to participants focussing on the avoidance of hypoglycaemia and the treatment of this if/when it occurred.
76045249|NCT04422145|Other|Standard care|Participants continue on their current diabetes care plan and are looked after by their usual diabetes care provider
76045250|NCT05081869|Other|Exercise Program|An online yoga-based exercise program will be applied for 16 sessions in individuals' own environments. The exercise program will consist of stretching, mobilization, stabilization, strengthening and relaxation exercises.
76045251|NCT05081869|Other|Education Program|There will be video training on the subject for both groups.
75721703|NCT00250705|Drug|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: < 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; > 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
75721704|NCT00849030|Drug|Anastozole (Arimidex)|1mg, orally, once daily
75876137|NCT03673488|Device|TephaFlex™ mid-urethral sling|The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
76045252|NCT05053711|Device|rTMS+rPMS_iTBS_M|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
75568570|NCT00661882|Other|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
75721705|NCT00849030|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
76045253|NCT05053711|Device|rTMS+rPMS_cTBS_M|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
76045254|NCT05053711|Device|rTMS+sham rPMS_M|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
76045255|NCT05053711|Device|rTMS+rPMS_iTBS_U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
76045256|NCT05053711|Device|rTMS+rPMS_cTBS_U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
75721706|NCT00849030|Drug|Anastozole (Arimidex) placebo|1mg, orally, once daily
75721707|NCT00849030|Drug|Tamoxifen (Nolvadex) placebo|20mg, orally, once daily
75721708|NCT00842400|Drug|Metformin, VI-0521, Sitagliptan, Probenecid|"This trial is an open-label, non-randomized, one-sequence crossover study.~metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34~sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39~VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)~2 g (four 500 mg) probenecid tablets on Day 29."
75721709|NCT00842478|Procedure|Toothbrushing|
75721710|NCT02545296|Other|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
75721711|NCT02545374|Other|Telemedicine|
75721712|NCT02545374|Other|Control|
75876138|NCT03165955|Drug|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
75568571|NCT00661882|Other|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
75568572|NCT00661882|Other|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
75568573|NCT00661882|Procedure|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
75876139|NCT03669978|Procedure|Creation of a bone and arterial panorama using EndoNaut® software.|"The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software."
75568574|NCT00580385|Other|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
75568575|NCT00570791|Device|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
75568576|NCT00566826|Behavioral|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
75568577|NCT00566826|Behavioral|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
75876140|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir under fasted conditions
75876141|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions
75568578|NCT00264511|Other|Hyperbaric Oxygen Treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
75568579|NCT05291078|Device|A transcutaneous trigeminal nerve stimulator: High Frequency|30min/day, at least 5 to 7 times a week
75876142|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions
75876143|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
75422831|NCT05602467|Device|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
75422832|NCT05602467|Other|Treatment as usual (TAU)|Treatment-as-usual (TAU) in the Hong Kong outpatient clinic without TPS intervention was given. They would receive the standard care for mild NCD including counselling, lifestyle modification, cognitive training and antidementia medications occasionally depending on the case doctor's judgement.
75422833|NCT05601973|Drug|Amivantamab|Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is <80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
75422834|NCT05601973|Drug|Lazertinib|Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
75568580|NCT05291078|Device|A transcutaneous trigeminal nerve stimulator: Low Frequency|30min/day, at least 5 to 7 times a week
75568581|NCT05291078|Device|A transcutaneous trigeminal nerve stimulator: Sham|30min/day, at least 5 to 7 times a week
75568582|NCT05291078|Device|Sound Therapy|Notch Therapy at least 30min/day, at least 5 to 7 times a week
75568583|NCT02941328|Drug|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
75568584|NCT02941328|Drug|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
75721713|NCT00266695|Drug|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
75721714|NCT00849264|Drug|chemotherapy with endostar|15mg/d×14d
75721715|NCT00849264|Drug|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
75721716|NCT00849264|Drug|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
75721717|NCT00849342|Drug|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
75721718|NCT00842556|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
75721719|NCT00842556|Drug|Glimepiride|Tablets, Oral, 4 mg, Single Dose
75721720|NCT00842556|Drug|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
75721721|NCT00842634|Biological|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
75721722|NCT00842634|Other|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
75721723|NCT00620022|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
75721724|NCT00620022|Drug|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
75721725|NCT00852852|Behavioral|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
75422835|NCT05601973|Drug|Zirabev|Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
76045257|NCT05053711|Device|rTMS+sham rPMS_U|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
76045258|NCT04421287|Drug|Zhenyuan capsule|0.25g/ tablets, 2 tablets / TID, for 12 weeks
76045259|NCT03824275|Drug|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
76045260|NCT05126329|Drug|amcenestrant|tablet for oral use
76045261|NCT05053165|Drug|LB-P6|Healthy subjects will be randomized to receive LB-P6 once daily orally
76045262|NCT05053165|Drug|LB-P8|Healthy subjects will be randomized to receive LB-P8 once daily orally
75422836|NCT05589831|Device|Non-invasive Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist (NAVA) is a new non-invasive ventilation mode that uses the electrical activity of the diaphragm (EAdi) to offer ventilatory assistance in synchrony with patient effort, thus potentially reducing stress and discomfort. It uses electrodes placed on a modified nasogastric feeding tube to detect the electrical activity of the diaphragm (EAdi), such that both the initiation and termination of a breath during each respiratory cycle is in synchrony with the infant's effort
76045263|NCT05053165|Drug|Placebo|Healthy subjects will be randomized to receive placebo once daily orally
75422837|NCT05587010|Device|AFO|ankle foot orthosis
75422838|NCT05587010|Device|lycra sock|custom fitted lycra sock
75422839|NCT05587010|Device|OrthPed splint|novel compression splint
75422840|NCT05586789|Drug|Ranquilon|Two 1 mg tablets 3 times per day for 28 days
75422841|NCT05586789|Drug|Placebo|Two tablets 3 times per day for 28 days
75422842|NCT05574127|Behavioral|Behavioral Activation|"Sessions for both arms (BP & SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
75876144|NCT05192473|Device|Pulse Intravascular Lithotripsy System|Treatment with Pulse Intravascular Lithotripsy System
75876145|NCT05184673|Other|Behavioral and environmental|These are all active comparator yoga sequences
76045264|NCT05079763|Other|Bacterial cellulose-monolaurin hydrogel|Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
76045265|NCT05079763|Other|Placebo cream|Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
76045266|NCT04421521|Procedure|Acupuncture|Acupuncture with disposable needles will be implemented
76045267|NCT05050981|Drug|Hormone replacement therapy|Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
76045268|NCT05050981|Drug|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
75568585|NCT02915796|Biological|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
75568586|NCT02915796|Biological|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
75876146|NCT03055494|Biological|Secukinumab|Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
75422843|NCT05574127|Behavioral|Supportive Psychotherapy|"Sessions for both arms (BP & SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
75422844|NCT05568550|Biological|Pembrolizumab|Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
75422845|NCT05568550|Drug|Olaparib|200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
75422846|NCT05568550|Drug|Androgen Deprivation Therapy|Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
75422847|NCT05568550|Radiation|Radiation Therapy|Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
75422848|NCT05565534|Behavioral|Nurse-practitioner led intervention|"Face-to-face or virtual consultation with NP during chemotherapy infusion with individualized recommendations/medications AND patient education through the Patient Activated Learning System (PALS).~Weekly follow-ups from NP via phone, Zoom, or in-person (patient directed) for 12 weeks/course of chemotherapy."
75422849|NCT05558956|Drug|illuccix 68Ga-PSMA-11 Total Body PET-CT|Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) 68Ga-PSMA-11
75568587|NCT02915796|Procedure|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
75568588|NCT02915796|Biological|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
76045269|NCT05078983|Diagnostic Test|CGA-FI (COMPREHENSIVE GERIATRIC ASSESMENT - FRAILITY INDEX)|GERIATRIC ASSESMENT TEST
75568589|NCT02941289|Procedure|visual search performance of everyday objects in realistic scenes|
75876147|NCT03055494|Biological|Placebo|Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
76045270|NCT05050903|Other|Rhinovirus infection|Inoculation with rhinovirus-16
76045271|NCT05049889|Other|Terrestrial exercise|"At visit 1 (Day 0), an exercise test will be performed (maximal incremental test), followed by a 30-minute submaximal exercise at constant load.~During this exercise, continuous data collection will be performed:~Continuous 12-lead electrocardiogram~Continuous monitoring of blood pressure and ventilation."
76045272|NCT05049889|Other|Swimming exercise|"At visit 2 (Day 7), the subjects will perform a swimming exercise in the experimental pool equipped with a turbine to create a counter-current. The water speed will be constant (4 min per 100 m, i.e. 1.5 km/h). The duration of the exercise will be 30 minutes. Each diver will breathe with the help of a snorkel.~During this exercise, continuous data collection will be performed:~Continuous 12-lead electrocardiogram~Continuous monitoring of blood pressure and ventilation."
76045273|NCT05049889|Device|Transthoracic cardiac ultrasound|The participants will have a transthoracic cardiac ultrasound to measure the dilatations of the cardiac cavities at visit 1 and 2.
75422850|NCT05542849|Drug|Acarbose Tablets 50mg|"Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals."
75422851|NCT05542056|Other|Data and biosample collection|Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation)
75422852|NCT05531552|Drug|clinical pharmacy application|assessment clinical pharmacist in management of CAD and ICU patients.
75568590|NCT02919228|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
75568591|NCT02941211|Device|Aqueduct -100|
75568592|NCT02915484|Device|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
75568593|NCT02940977|Other|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
75876148|NCT03673410|Procedure|Robotic bariatric surgery - revisional|Using robotic techniques during any revesional bariatric surgery
75876149|NCT03673410|Procedure|Laparoscopic bariatric surgery - revisional|Using laparoscopic techniques during any revesional bariatric surgery
75876150|NCT02445768|Other|Cognitive multisensory rehabilitation|
76045274|NCT05049889|Device|Transthoracic pulmonary ultrasound|The participants will have a transthoracic pulmonary ultrasound to quantify the presence of signs of pulmonary vascular overload (comet tails) at visit 1 and 2.
75568594|NCT02915211|Dietary Supplement|Keyo|Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
75876151|NCT03673332|Drug|immune-checkpoint inhibitors therapies|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
75876152|NCT02914548|Drug|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
76045275|NCT05049889|Biological|Blood collection|Several blood samples will be collected at visit 1 and 2.
76045276|NCT04421599|Other|The Necessity of Aspiration|"The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same Intramuscular Injection Application Protocol was applied while all the injections were administered."
76045277|NCT05074459|Drug|Eptinezumab Mammalian Cell Line|Concentrate for solution for IV infusion
76045278|NCT05074459|Drug|Eptinezumab Yeast Cell Line|Concentrate for solution for IV infusion
76045279|NCT05120557|Device|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
76045280|NCT05120011|Dietary Supplement|L-carnitine|L-carnitine-L-tartrate
75568595|NCT02915328|Device|Filterwire EZ™|
75568596|NCT02915328|Device|MO.MA Ultra|
75721726|NCT00849654|Drug|PCI-32765|"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
75721727|NCT00849732|Biological|V520|Intentionally Blank
75721728|NCT00849732|Biological|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^9 vp/d given at Day 1, Week 4, and Week 26
75422853|NCT05525299|Behavioral|Reminiscence-Based Life Review|"The reminiscence chatting activities covering 6 themes include:~Week 1: Instruction of the 'Life Story Narrative Journal' and My 'Childhood' memories Week 2: My 'Adolesces' memories and Memorable moments spent with my family Week 3: My 'Adulthood' memories and My very first full time job Week 4: My thoughts when I received my cancer diagnosis Week 5: My favourite activities before and after receiving a cancer diagnosis Week 6: When COVID-19 hits, _____ changes and The story goes on! The future pages are more to come!~A 'Life Story Narrative Journal' with six themes to recall subjects' memory through the life review reminiscence activities will be given. The Life Story Narrative Journal is a diary booklet that enables the participant to write down and express their thoughts in a narrative."
75422854|NCT05525143|Procedure|Pregnant women who have given birth vaginally or by cesarean section|Full-term pregnant women who have given birth vaginally or by cesarean section with PPH. Descriptive statistics and possible causal factors
75422855|NCT05523934|Drug|Capsaïcine patch|Patients with complex regional pain syndrome under maximal conventional treatment having a supplementary treatment by a capsaïcin patch.
75422856|NCT05518422|Drug|Hyperinsulinemic, euglycemic infusion|60 minute infusion
75422857|NCT05515263|Dietary Supplement|Intervention snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
75422858|NCT05515263|Dietary Supplement|Control snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
75422859|NCT05515250|Device|Use of neurostimulation device|In humans, abdominal pain is modulated by the vagus nerve. Stimulation of the vagus nerve has been suggested to reduce visceral sensitivity and abdominal pain. IB-stim is the Percutaneous Electrical Nerve Field Stimulation (PENS) device. It is a non-invasive, outpatient therapy. PENFS has been shown to be efficacious in pediatric patients with abdominal pain.
75422860|NCT05510154|Behavioral|Brief advice|A single, brief advice session on switching to electronic cigarettes.
75422861|NCT05510154|Behavioral|Single Training|A single, in-depth training session on switching to electronic cigarettes.
75422862|NCT05510154|Behavioral|Training to Competency|Multiple, in-depth training sessions on switching to electronic cigarettes.
75721729|NCT00849732|Biological|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^10 vp/d given at Day 1, Week 4, and Week 26
75422863|NCT05508100|Biological|IO-108|IO-108, intravenously, on Day 1 of each 21-day cycle.
75422864|NCT05508100|Biological|IO-108 + pembrolizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.
75721730|NCT00849732|Biological|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
75721731|NCT00849966|Drug|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
75721732|NCT00849966|Drug|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
75422865|NCT05508100|Biological|IO-108 + tislelizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
75422866|NCT05505448|Drug|REGN14284|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
75422867|NCT05505448|Drug|Matching Placebo|Single ascending IV or SC administration per the protocol
75568597|NCT02915328|Device|Stent Roadsaver®|
75568598|NCT02915328|Device|Carotid Wallstent|
75568599|NCT05238545|Other|gluten-free diet|Diet excluding foods containing gluten.
75568600|NCT02915133|Procedure|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
75422868|NCT05501327|Drug|SLI-F06|Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
75721733|NCT00853008|Drug|Vincristine|Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)
76045281|NCT05120011|Dietary Supplement|L-leucine|L-leucine
75422869|NCT05498233|Drug|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
75422870|NCT05485285|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
75422871|NCT05484297|Behavioral|Crisis Caring Contacts post cards|A series of post cards with Crisis Caring Contacts content sent over 10 months
75422872|NCT05484297|Behavioral|Control post cards|"A series of post cards intended to control for attention received but not including elements thought to be active ingredients in the intervention"
75422873|NCT05476588|Other|Screening|Screening and validation of assessment tool translated into Spanish
75422874|NCT05476510|Drug|Postoperative management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
75422875|NCT05476393|Other|Postoperative management|1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.
75568601|NCT04691336|Behavioral|Educational and Training with counselling|The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
75568602|NCT02915250|Drug|BioChaperone® Combo|Injection of BioChaperone® Combo
75568603|NCT02915250|Drug|Humalog® Mix25|Injection of Humalog® Mix25
75422876|NCT05473026|Behavioral|Gratitude Intervention|Gratitude journaling and goal setting for exercise readiness over eight weeks.
75568604|NCT02915250|Drug|Humalog®|Injection of Humalog®
75568605|NCT02915250|Drug|Lantus®|Injection of Lantus®
75568606|NCT02915250|Drug|Placebo|Injection of 0.9% NaCl
75568607|NCT02277041|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
75568608|NCT02277041|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
75721734|NCT00853008|Drug|Daunorubicin|Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22
75422877|NCT05472142|Other|UP FOR IT - practice facilitation|"Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The practice facilitation collaborative trains and supports clinical teams to use the Model for Improvement to make breakthrough improvements in diabetes care and DSMES utilization by recognizing barriers and changing clinical systems and care practices."
75422878|NCT05472142|Other|UP FOR IT - health information technology|Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
75568609|NCT02915289|Procedure|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
75568610|NCT02915289|Procedure|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
75568611|NCT02939378|Dietary Supplement|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
75568612|NCT02939378|Dietary Supplement|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
75721735|NCT00853008|Drug|Prednisone|Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28
75721736|NCT00853008|Drug|Mitoxantrone|Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation
75721737|NCT00853008|Drug|Cytosine Arabinoside|ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
75876153|NCT02914548|Drug|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
75568613|NCT02915406|Device|CliniMACs|
75876154|NCT03048084|Drug|Levetiracetam|Antiepileptic drug levetiracetam
75568614|NCT02939339|Device|continuous theta burst stimulation (real)|a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
75721738|NCT00853008|Drug|Dexamethasone|Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
75721739|NCT00853008|Drug|Methotrexate (MTX)|Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
75721740|NCT00853008|Drug|Cytarabine|Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
75721741|NCT00853008|Drug|ASP|ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
75721742|NCT00853008|Drug|Mercaptopurine|Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
75721743|NCT00853008|Drug|Teniposide|Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
75721744|NCT00853008|Drug|Hydrocortisone|Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
75721745|NCT00853086|Drug|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
75721746|NCT00853164|Behavioral|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
75721747|NCT00853164|Behavioral|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
75721748|NCT00853164|Behavioral|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
75876155|NCT03048084|Drug|Valproic Acid|Antiepileptic drug valproic acid
76045282|NCT05043259|Biological|inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
75568615|NCT02939339|Device|continuous theta burst stimulation (sham)|a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
75568616|NCT02918916|Other|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
75568617|NCT02918916|Other|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
75568618|NCT02939417|Other|Grape seed extract|Grape seed extract - collagen cross-linking agent
76045283|NCT05043259|Biological|Low dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
75568619|NCT02919033|Other|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
75876156|NCT03165721|Drug|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
75876157|NCT02224872|Procedure|Bone marrow transplant|Day 0
75876158|NCT02224872|Drug|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
75876159|NCT02224872|Drug|Fludarabine|30 mg/M2 IV on days -6 to -2
75876160|NCT02224872|Drug|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
75876161|NCT02224872|Radiation|TBI|200 cGy on day -1
75422879|NCT05472077|Diagnostic Test|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop."
75422880|NCT05471336|Procedure|Enteral Feeding|Feeds of expressed breast milk or donor breast milk will be given. Formula feeds will not be permitted. If the parents do not wish to provide donor milk, whatever volume of expressed mother's milk is available will be given up until the required volume. Feeds will be administered via orogastric or nasogastric tube and administered over 30 minutes.
75876162|NCT02224872|Drug|Mesna|40 mg/kg IV on days 3, 4
75876163|NCT02224872|Drug|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
76045284|NCT05043259|Biological|High dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
75568620|NCT02919033|Device|Self-management|"Usual care~Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~All patients receive proficiency training in using the BP tele-monitor, and mobile App."
75422881|NCT05467735|Other|Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
75568621|NCT02919033|Other|PCTM intervention|"Usual care~Self-management~PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~PCPs and cardiologists receive training of the CareLinker website."
75721749|NCT00923988|Other|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
76045285|NCT05071495|Device|Smartphone application|"Smartphone application named Signal, which connects patients and health providers"
75721750|NCT02545530|Drug|transdermal clonidine|2.5mg/patch per week
75422882|NCT05467345|Device|Contour Next and Contour Plus Elite BGMS testing of neonatal blood|The purpose of this study is to extend the intended use of two BGMSs to include testing of neonatal blood by Health Care Professionals in a clinical setting for the quantitative measurement of glucose levels in neonates.
76045286|NCT05069311|Drug|Multimodal analgesia|"Multimodal analgesia includes the combination of:~morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery"
75721751|NCT00853320|Drug|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
75876164|NCT02224872|Drug|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
76045287|NCT05069311|Drug|Conventional intravenous analgesia|Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
76045288|NCT05036863|Behavioral|Weekly questionnaires|Patients will complete weekly symptom monitoring PROMs. If a symptom exceeds the thresholds for clinical importance, a registered nurse will contact the patient, confirm the symptoms and coordinate the further clinical procedure in line with standard practice.
76045289|NCT05065645|Drug|Angiotensin Converting Enzyme 2|SAD: single dose; MAD: dosage 2x daily for 7 days
76045290|NCT05065645|Drug|Sodium chloride|SAD: single dose; MAD: dosage 2x daily for 7 days
75422883|NCT05467215|Drug|Pure oxygen (99%) from Praxair, Edmonton, DIN# 02014408|Participants will receive oxygen (99%) or room air (placebo) delivered through a face mask at a flow rate of 10 litres/min for 2 minutes. The participants will be exposed twice to both conditions over 4 experiments at a minimum of 2 week intervals between each testing session.
75422884|NCT05464251|Other|Prospective chart review of subjects diagnosed with spinal epidural abscess|Collection and assessment of available clinical, pathological, radiological, and socioeconomic data on subjects presenting with spinal epidural abscess. Standard of care treatment and outcomes for each group will be analyzed.
75721752|NCT00853320|Drug|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
75721753|NCT00853398|Procedure|surgical technique|
76045291|NCT05063383|Other|This study does not involve any interventions|This study does not involve any interventions
76045292|NCT01364467|Drug|Placebo|Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
75721754|NCT00547521|Drug|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
76045293|NCT01364467|Drug|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
76045294|NCT05470387|Drug|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
76045295|NCT05470387|Drug|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
76045296|NCT05468125|Procedure|guidance|either follow the care bundle or the best evidence practice
76045297|NCT05033899|Other|ERAS protocol|to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
76045298|NCT05110417|Drug|Pyridostigmine Bromide 60 Milligrams (mg)|One tablet will be provided to patients during the second visit.
76045299|NCT02520661|Behavioral|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
75876165|NCT02187198|Drug|Buprenorphine|
76045300|NCT05109871|Other|KForce Link|Traction (pull-type) dynamometer
76045301|NCT05061199|Procedure|approach of anastomosis|The approach of anastomosis
76045302|NCT05031481|Drug|Venus 20 + 0,064|Venus vaginal cream 20 + 0,064, single-dose.
75422885|NCT05457881|Dietary Supplement|Scandi-Shake|Scandi-Shake [any of 4 flavors - vanilla, strawberry, banana cream, and caramel] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
75568622|NCT02939456|Other|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
75568623|NCT02918799|Behavioral|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
75568624|NCT02939261|Behavioral|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
75568625|NCT02939261|Behavioral|Control|monthly emails with general health information
75721755|NCT00547521|Drug|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
75721756|NCT02546310|Drug|HTL0009936|
75721757|NCT02546310|Drug|HTL0009936 matching placebo|
75721758|NCT00850044|Drug|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
76045303|NCT05031481|Drug|Venus 20 + 1|Venus vaginal cream 20 + 1, single-dose.
76045304|NCT05031481|Drug|Venus 20 + 4|Venus vaginal cream 20 + 4, single-dose.
75721759|NCT00850044|Drug|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
75568626|NCT02918682|Other|Exercise - FIRST PHASE|the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
75721760|NCT00850044|Drug|placebo for ABT-450|capsules, QD, one dose
75422886|NCT05449795|Device|Device: Contour Next and Contour Plus Elite BGMS testing of arterial blood|The purpose of the study is to extend the intended use of two BGMSs to include testing of arterial blood by Health Care Professionals (HCP) in a clinical setting.
75422887|NCT05445518|Behavioral|Jump Start Plus COVID Support|The Jump Start Plus COVID Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
75422888|NCT05445518|Behavioral|Healthy Caregivers-Healthy Children (HC2)|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom.
75422889|NCT05434000|Drug|Hydroxyurea|Children at risk of developing stroke (TCD values>200cm/s) will be given 20mg/kg of Hydroxyurea
75422890|NCT05433571|Device|Test Lens|Multifocal Toric Contact Lenses manufactured in Senofilcon A (C3) material with UV/HEV filter
75422891|NCT05433480|Drug|BPI-16350|BPI-16350 400 mg, orally once daily
75422892|NCT05433480|Drug|placebo|Placebo 400 mg, orally once daily
76045305|NCT05031481|Drug|Butoconazole nitrate|Butoconazole nitrate vaginal cream, 100 mg single-dose.
75422893|NCT05433480|Drug|Fulvestrant|Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
75422894|NCT05432674|Combination Product|Digital Fall Prevention|Exercises delivered through a tablet and remote motivational calls
75422895|NCT05428735|Procedure|Embolization|Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
75422896|NCT05428215|Drug|17beta Estradiol|Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
75422897|NCT05419960|Diagnostic Test|Vestibular Assessment|"During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~Video Head Impulse Test (vHIT)~Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)"
75721761|NCT00850044|Drug|Placebo for ritonavir|capsules, QD, one dose
76045306|NCT05061121|Other|combined effect|Compare the short- and mid-term effects of Mulligan's SNAGs, Myofascial release, and their combination on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
76045307|NCT05109559|Biological|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
75422898|NCT05419960|Diagnostic Test|Petrous bone Computed Tomography (CT)|"For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear."
75422899|NCT05419960|Diagnostic Test|Magnetic Resonance Imaging (MRI)|"Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings."
75422900|NCT05417646|Other|Hyperglycaemic clamp|Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)
75422901|NCT05417646|Drug|Placebo|Placebo comparator to empagliflozin
75422902|NCT05417646|Drug|Empagliflozin|Single-dose, 25 mg, two hours before clamp
75422903|NCT05415943|Device|Diagnostic microprobe (inPROBE) medical device|Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.
75721762|NCT00266227|Drug|placebo|Intravenous repeating dose
75721763|NCT00266227|Drug|rituximab|Intravenous repeating dose
75721764|NCT00266227|Drug|methotrexate|Oral or parenteral repeating dose
75721765|NCT00266227|Drug|folate|Intravenous repeating dose
75721766|NCT00968877|Drug|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
75721767|NCT02729727|Device|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
75721768|NCT00965367|Device|Acustimulation|Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
76045308|NCT05109559|Biological|Half dose of Ad26.COV2. 2.5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
75721769|NCT00287365|Drug|ozone|2 hour exposure to 0.4 ppm ozone
75721770|NCT00850122|Drug|cefazolin|"Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8"
75721771|NCT00968955|Drug|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
76045309|NCT05109559|Biological|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
76045310|NCT05031247|Other|Wellbeing Program|The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
75721772|NCT00843258|Device|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
75721773|NCT01072279|Other|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
75721774|NCT01072279|Other|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
75876166|NCT03672942|Behavioral|Communication Skills Training|Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.
75876167|NCT03672942|Behavioral|Mindfulness|Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.
76045311|NCT05059093|Diagnostic Test|Classification and segmentation deep learning models|Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
76045312|NCT04218097|Other|Study questionnaire|Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.
75876168|NCT03672942|Behavioral|Placebo|Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
75876169|NCT02642029|Device|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
75876170|NCT02642029|Device|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
75721775|NCT00850278|Other|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
75422904|NCT05414903|Behavioral|Dynamic Visual Acuity|"First, participants will report the direction of the open portion of a Landolt C (right, left, up, or down) with the head still. Ten targets at 5 acuity levels (LogMAR -0.3, 0, 0.3, 0.7, 1.0, corresponding to Snellen visual acuity of 20/10, 20/20, 20/40, 20/100, 20/200) will be identified. Next, a rate sensor will be placed on the subject's head in the plane of the horizontal canals and htDVA will be measured. The Landolt C will be presented automatically when the examiner has moved the subject's head > 150˚/sec. htDVA scores will be the LogMAR at which the subject fails to correctly identify 50% of the visual targets or reaches a LogMAR of -0.3. The overall htDVA score is calculated by subtracting the head still LogMAR from the htDVA LogMAR. htDVA scores will be calculated for right and left head movements separately."
75568627|NCT02918682|Other|Exercise - SECOND PHASE|the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
75721776|NCT05279625|Device|exercise training|using either elastic band, dumbbells, treadmill, cycling, machines for 6 months
75876171|NCT02642029|Device|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
75721777|NCT00853554|Drug|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
75721778|NCT00853554|Drug|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
75876172|NCT04058574|Device|Proprioception measurement on isokinetic dynamometer|Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
75876173|NCT04058730|Procedure|Laparoscopic Roux en Y Gastric by pass surgery|
75876174|NCT04058730|Procedure|Laparoscopic Sleeve Surgery|
75876175|NCT04058730|Other|Standard Medical Management|
75876176|NCT02639923|Procedure|Drawing of 7ml peripheral blood|puncture peripheral vein
75876177|NCT05239975|Biological|SCTV01C|intramuscular injection
75876178|NCT05239975|Biological|Comirnaty|intramuscular injection
75876179|NCT05239897|Device|Continuous theta burst stimulation (cTBS)|Patients assessed for postoperative delirium will be treated by consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions.
75568628|NCT02918682|Other|Exercise - FOURTH PHASE|at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
75568629|NCT02918682|Other|Exercise - THIRD PHASE|participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
75568630|NCT05034536|Drug|Pembrolizumab|Intravenous infusion
75568631|NCT05034536|Drug|Infliximab|Intravenous infusion
75721779|NCT02586597|Device|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
75721780|NCT00843336|Behavioral|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
75721781|NCT00843336|Behavioral|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
75721782|NCT01071109|Procedure|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
75721783|NCT00853710|Other|PSA assay|rapid prostate specific antigen assay.
75721784|NCT00969033|Drug|CS-1008|CS-1008
75422905|NCT05414903|Behavioral|Reading Outcomes|"The TOSWRF will be used to assess reading fluency. Children get 3 minutes to identify as many words as possible by drawing boundaries between successive unrelated words.~The TOSCRF will be used to assess reading fluency. Children are allowed 3 minutes to identify as many contextually related words as possible by drawing boundaries between successive words.~The TILLS will be used to assess reading comprehension. Each subject will read a short passage and answer 3 yes/no questions assessing reading comprehension.~A computer based MNREAD Test will be used to assess reading acuity, critical print size and Reading Accessibility Index.~During the TILLS and MNRead test, eye tracking (Eye Link 1000+ eye tracker) will be used to record fixation duration, saccade length, regression frequency, and total time spent."
75568632|NCT05034536|Drug|Placebo|Intravenous infusion
75568633|NCT05018351|Behavioral|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
75568634|NCT05018351|Behavioral|Peer Navigation|Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on health-related goals, attending health care appointments. and facilitating follow-up activities related to healthcare appointments).
75568635|NCT02915094|Drug|Anakinra|
75568636|NCT02918643|Other|Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients|
75721785|NCT00969033|Drug|irinotecan|irinotecan
76045313|NCT05057767|Drug|Midazolam injection|No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
75422906|NCT05414903|Behavioral|Static Visual Acuity|"The subject's head will be in a headrest. Static visual acuity will be assessed in 9 domains (3 levels of visual target complexity x 3 levels of presentation complexity). The 3 levels of visual target complexity are identifying: 1) colors, 2) the direction of the open prongs of the Landolt C (right, left, up, or down), which does not require alphabet knowledge, and 3) single letters (C, D, H, K, O, N, S, R, V, and Z; NIH Toolbox, Li 2014)). The 3 levels of presentation complexity are identifying: 1) 1-visual optotype, 2) a successive row of 5 visual optotypes flashed for 3 seconds (Hillman 1999), and 3) successive rows of optotypes in paragraph form as quickly as possible (i.e., rapid automatized naming). Outcome parameters will be %-correct at each acuity level and reaction time. Fixation duration, saccade length, saccade frequency, regression frequency, and total time spent will be collected via an eye tracker (Eye Link 1000+ eye tracker [SR Research, EyeLink, Ontario, Canada])."
75422907|NCT05412173|Drug|Molnupiravir|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
75568637|NCT05012891|Other|OneStep Smartphone Application|"OneStep technology is a smartphone application (app) utilizing smartphone sensors to provide ongoing gait diagnostics. The eligible study participants will be asked to download and install the app on their own smartphones and carry the smartphone in their front pants pocket at all times.~The app will collect the required gait parameters but, will not present them (or any summary thereof) to the study participants or their physiotherapists, in order not to influence the rehabilitation plan."
75568638|NCT02939027|Device|Electronic Brachytherapy (6,1 Gy)|A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
75568639|NCT02939027|Device|Electronic Brachytherapy (7 Gy)|A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
75568640|NCT02915172|Drug|Lenvatinib|"Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1."
75568641|NCT02915172|Drug|Capecitabine|Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
75721786|NCT00965601|Behavioral|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
75568642|NCT02938988|Procedure|Antimicrobial photodynamic therapy|Described in arm/group
75568643|NCT02938988|Procedure|Scaling and root planning|Described in arm/group
75721787|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
75721788|NCT00573768|Drug|Placebo|Vehicle 2 times daily
75721789|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
75721790|NCT04042428|Drug|Somatropin injection|Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
75721791|NCT02546076|Device|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
75422908|NCT05407337|Behavioral|Psychotherapy using Narrative Exposure Therapy (NET)|"There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her Life Line and start his/her life story with the peer mediator.~The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish.~The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient.~To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it."
75568644|NCT02938988|Device|red laser|658nm; 0.1W; 2229J/cm², 10s per point
75568645|NCT02938988|Drug|methylene blue dye|
75568646|NCT02918994|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
75721792|NCT02546076|Device|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
75721793|NCT02415387|Biological|typhoid vaccine|Given IM
75721794|NCT02415387|Other|Placebo|Given IM
75721795|NCT00969267|Other|ear-acupuncture A|with needle stimulation
75876180|NCT05239819|Behavioral|Inspiratory muscle training|The initial training intensity of the preoperative threshold IMT trainer (DofinTM, Breathing Strength Builder, Taiwan) was moderate to high intensity (≥50% of MIP), which was according to the patient's baseline level and increased by 5-10% per week. The frequency is 25-30 minutes each time, twice a day and five days per week for at least two weeks. The participants would receive at least 10 times training sessions before surgery
75568647|NCT02939144|Dietary Supplement|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
75876181|NCT05239819|Behavioral|Regulated care and education|Regulated care and education will be applied
75568648|NCT02915055|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
75721796|NCT00969267|Other|stimulation B|with bread stimulation on ear acupuncture point
75721797|NCT00969267|Other|stimulation C|without needle stimulation
75721798|NCT00850434|Device|Modified AutoSet Algorithm|"The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm"
75721799|NCT00850434|Device|Standard AutoSet Algorithm|The standard AutoSet used for treatment of OSA
75721800|NCT00969345|Other|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
75721801|NCT00969345|Other|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
75568649|NCT02915055|Drug|standard oxycodone/acetaminophen|
75568650|NCT02939222|Device|Implant placement|Routine implant placement in the ideal three dimensional implant position
75568651|NCT02938910|Other|non interventional study|Non invasive imaging study without interventional procedures
75568652|NCT04690790|Procedure|Thoracoscopy|Patients who are indicated for thoracoscopic nodulectomy.
75721802|NCT00850512|Drug|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
75721803|NCT00850512|Drug|Zevalin|12-week safety period for Zevalin
75721804|NCT00969423|Device|5mm videoscope|use of 5mm videoscope
75721805|NCT00969423|Device|10mm videoscope|use of 10mm videoscope
75721806|NCT00850590|Drug|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
75721807|NCT00965913|Drug|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
75721808|NCT00965913|Drug|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
75422909|NCT05403268|Device|DeltaScan|Twice daily DeltaScan observations
75568653|NCT01295827|Biological|Pembrolizumab|IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.
75568654|NCT02918838|Behavioral|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
75568655|NCT02918838|Behavioral|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
75568656|NCT02918838|Behavioral|Control Group|
75568657|NCT02918760|Drug|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
75568658|NCT02918760|Other|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
76045314|NCT04997317|Drug|177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)|177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
75422910|NCT05396859|Drug|Decitabine and Cedazuridine|Given PO
75568659|NCT02914743|Behavioral|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
75721809|NCT00965913|Drug|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
75721810|NCT00853866|Drug|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
75721811|NCT00853866|Drug|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
75876182|NCT04969705|Drug|Dexmedetomidine|"60 Patients will be randomly divided into three equal groups:~Group A (n=20) : spinal anesthesia with Dexmedetomidine (5µg ) added to local anesthetic (bupivacaine Hcl ) (10 mg) given intrathecally .~Group B (n=20) : spinal anesthesia using local anesthetic( bupivacaine Hcl) (20 mg) combined with TAP block using Dexmedetomidine (20µg ) after the cesarean section~Group C (n=20) (controlled group ) : Spinal anesthesia using only local anesthetic (bupivacaine Hcl ) (10 mg) ."
75422911|NCT05396859|Drug|Entrectinib|Given PO
75568660|NCT02914743|Procedure|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
75876183|NCT03676374|Drug|Prucalopride|Prucalopride 2mg taken once a day as add-on to PPI (2x/d)
75876184|NCT03676374|Drug|Placebo Oral Tablet|Placebo tablet taken once a day as add-on to PPI (2x/d)
75568661|NCT04983368|Drug|Xanamem® 5 mg|"Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily."
75568662|NCT04983368|Drug|Placebo|Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
75568663|NCT04983368|Drug|Xanamem® 10 mg|"Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily."
75721812|NCT00853866|Device|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
75721813|NCT00853866|Device|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
75876185|NCT03178669|Drug|cobitolimod|Rectal administration
75568664|NCT02918604|Device|infrared technology: Veinsite|peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
75422912|NCT05396859|Other|Laboratory Biomarker Analysis|Correlative studies
75422913|NCT05393830|Behavioral|Sleep Restriction|Three nights of sleep restricted to 4 hours per night.
75422914|NCT05390892|Drug|SGLT2 inhibitor|Empagliflozin, dapagliflozin, or canagliflozin
75422915|NCT05390892|Drug|GLP-1 receptor agonist|Dulaglutide, liraglutide, semaglutide
75422916|NCT05390892|Drug|Combination drug|SGLT2 inhibitor and GLP-1 receptor agonist
75422917|NCT05388045|Other|Patient Reported Outcome Measure|A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.
75568665|NCT01295671|Behavioral|Provision of beverages|Home delivery of specified beverage type
75568666|NCT02918526|Device|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
75721814|NCT00855660|Drug|Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
75568667|NCT02938871|Dietary Supplement|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
75568668|NCT02938871|Dietary Supplement|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
75568669|NCT01295320|Procedure|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
75721815|NCT00855660|Drug|Placebo|Placebo administered as a single tablet, thrice daily, over 14 days.
75721816|NCT00853944|Drug|sitagliptin|Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
75422918|NCT05384067|Behavioral|Mindfulness-based intervention|Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
75721817|NCT02545452|Drug|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
75422919|NCT05382845|Diagnostic Test|Manual pain provocation tests|Validated and empirical pain provocation tests of the pelvic joints will be performed, both to exclude ongoing symptoms, and to diagnose one or several dysfunctions. The participants will be asked questions regarding previous symptoms, traumas, type of profession etc.
75422920|NCT05380089|Other|Increasing water intake|Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
75422921|NCT05376709|Dietary Supplement|Short-Term Calorie Reduction|Align with the R-CHOP regimen, patients in the experimental group will first perform water fast 24 hours before (day 0) and during the first day of R-CHOP (day 1) when they receive Rituximab, Vincristine, Doxorubicin, cyclophosphamide, and prednisolone. On day 2, they will resume normal calorie intake until the day before the next cycle of chemotherapy. While each cycle of R-CHOP takes 21 days, most patients will receive a total of 6-8 cycles over four to six months.
75721818|NCT02545452|Drug|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
75721819|NCT02545452|Drug|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
75876186|NCT03178669|Drug|Placebo|Solution manufactured to mimic cobitolimod
75568670|NCT02918448|Other|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
75568671|NCT04690517|Procedure|tracheal ultrasound|When checking tracheal ultrasound, several signs are used in judgements. Direct signs include reverberation artifact and double ring sign. Indirect sign means checking the bilateral lung sliding.
75721820|NCT02545452|Drug|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
75568672|NCT01295281|Device|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
75568673|NCT01295281|Device|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
75721821|NCT02545452|Other|Tampon|
75721822|NCT00547365|Biological|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
75721823|NCT00854178|Drug|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
75721824|NCT00850668|Biological|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
75721825|NCT04009473|Combination Product|SEGOVA procedure|SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
75422922|NCT05376397|Behavioral|iTHRIVE 365|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) of interventions with mHealth features, THRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. THRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. THRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of BSMM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
75422923|NCT05366218|Biological|Tafasitamab|Antibody vaccination
75721826|NCT00850746|Drug|YM443|Oral
75721827|NCT00850746|Drug|Placebo|Oral
75721828|NCT00850746|Drug|Moxifloxacin|Oral
75721829|NCT00969735|Device|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
75876187|NCT03178201|Drug|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
75422924|NCT05351476|Behavioral|Resistance Exercise|300 Kcal worth of weight lifting, 3 times/week for 12 weeks
75422925|NCT05351476|Behavioral|Endurance Exercise|300 Kcal worth of treadmill walking, 3 times/week for 12 weeks
75876188|NCT04833127|Behavioral|Gender-Enhanced -- Masibambane|"The intervention has components that provide PrEP information, provide information about HIV prevention and contraceptive options, prompt women to think about why they may be at risk for HIV, discuss women's sexual rights, and discuss how women can talk to their male partners about PrEP. The components are conducted by participants on their own time as well as during a real-time live interactive session with trained facilitators."
75721830|NCT00969735|Device|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter > 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
75721831|NCT00850824|Behavioral|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
76045315|NCT04997317|Drug|177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4|177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= [Tyr]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
76045316|NCT04997317|Drug|177Lu-DOTA-JR11 (Phase I/II)|In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
75422926|NCT05348421|Procedure|FTPB|A 22-gauge needle will be advanced from anterior using an in-plane technique and passed through the posterior 'tail' of the transversus muscle. the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg will be injected to separate the transversalis fascia from the transversus muscle.
75721832|NCT00966069|Other|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
75721833|NCT00966069|Other|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
75422927|NCT05348421|Procedure|PENG Block|A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly where the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg
75422928|NCT05345301|Diagnostic Test|Event related desynchronization measurement|Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
75721834|NCT00850902|Other|High Humidity (HH)|High Humidity Level
75721835|NCT00850902|Other|Moderate Humidity|Moderate Humidity Level
75721836|NCT04041882|Drug|68Ga-DOTATATE|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
75721837|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
75721838|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
75876189|NCT04833127|Behavioral|Individually accessed|The intervention includes an individually-accessed online PrEP video and South African government websites on PrEP and on contraception options
75876190|NCT01829958|Drug|rituximab|
75876191|NCT01829958|Drug|prednisone|
75422929|NCT05336630|Device|Forceps|The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. Please note that for the explicit purpose of the study the forceps will be used to grab tissue and not take biopsies. The forceps may still be used to take biopsies if the physician believes it is indicated.
75422930|NCT05334758|Device|Bio-Self COVID-19 Antigen Home Test|At home COVID-19 antigen test kit
75422931|NCT05334758|Device|Standard of Care COVID-19 Test|Standard of care
75876192|NCT01829958|Behavioral|Geriatric Assessment|
75721839|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
75721840|NCT00854256|Procedure|Canaloplasty|Canaloplasty surgery
75721841|NCT00854256|Procedure|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
75721842|NCT00966147|Other|Increasing oxygen delivery .|The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
75721843|NCT04042662|Other|no intervention|no intervention
75721844|NCT00969891|Other|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
75721845|NCT00855972|Drug|Low Dose Naltrexone|
76045317|NCT04997239|Biological|Two doses of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
75721846|NCT00966225|Dietary Supplement|LIP-01|comparison of different dosages of natural health product
75721847|NCT00966303|Other|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
75721848|NCT00854412|Other|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
75422932|NCT05334758|Diagnostic Test|RT-PCR Test|High Sensitivity RT-PCR COVID-19 Test
75721849|NCT00619866|Drug|Elagolix|Elagolix tablets administered orally
75721850|NCT00619866|Drug|placebo|Placebo tablet administered orally
76045318|NCT04997239|Biological|One dose of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
76045319|NCT04216693|Drug|Digoxin tablet|The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.
76045320|NCT04216693|Other|Placebo|The control group will receive the digoxin-like placebo treatment.
76045321|NCT05057611|Other|CRT-targeted strategy associated with a clinical hemodynamic phenotyping to personalize initial resuscitation in septic shock patients|A combination of combine a CRT-targeted strategy with a clinical hemodynamic phenotyping that may aid to personalize initial resuscitation with potential additional fluid-sparing effects.
76045322|NCT05057611|Other|Usual care (UC)|- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, heart rate (HR) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
76045323|NCT01364389|Drug|AIN457|3 mg/kg
75721851|NCT00851058|Behavioral|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
76045324|NCT01364389|Drug|ACZ885|3 mg/kg
75721852|NCT00851058|Behavioral|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
75422933|NCT05333276|Drug|TQB3602 Capsule + AK105 Injection|TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
75721853|NCT00851058|Behavioral|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
76045325|NCT01364389|Drug|Prednisone|20 mg
76045326|NCT01364389|Drug|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
76045327|NCT04996381|Diagnostic Test|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
76045328|NCT05027737|Procedure|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
76045329|NCT05054881|Other|sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
75721854|NCT00851058|Behavioral|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
75721855|NCT02544906|Drug|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
75721856|NCT02544906|Drug|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
75721857|NCT00861276|Drug|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
75721858|NCT00861276|Drug|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
75721859|NCT00861354|Device|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
75721860|NCT02544828|Drug|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
75721861|NCT02544828|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
75876193|NCT03021642|Drug|Tepotinib test (Treatment Period 1)|Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 1 (Day 1)
75422934|NCT05316324|Procedure|Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction with (ADM)
75422935|NCT05316324|Procedure|Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction without ADM
75721862|NCT00861432|Other|additive homeopathic treatment|These patients receive additive homeopathic treatment
75721863|NCT00861510|Drug|ON01910 Na|
75721864|NCT01095003|Drug|Vinflunine plus Capecitabine|"Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
75721865|NCT01095003|Drug|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
75422936|NCT05314374|Dietary Supplement|Ileocolonic-release conjugated bile acid|1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days
75422937|NCT05314374|Drug|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient. 1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days.
75721866|NCT00854568|Drug|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
75721867|NCT00854568|Drug|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
75876194|NCT03021642|Drug|Tepotinib reference (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 2 (Day 22)
75876195|NCT03021642|Drug|Tepotinib reference (Treatment Period 1)|Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 1 (Day 1)
75721868|NCT00854646|Drug|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
75721869|NCT00856362|Drug|Moxidectin|
75721870|NCT00856362|Drug|Midazolam|
75721871|NCT00854802|Drug|Debio 025|Debio 025 supplied in soft gel capsules
75721872|NCT00854802|Drug|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
75568674|NCT02914821|Behavioral|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
75721873|NCT00854802|Drug|Ribavirin|Ribavirin supplied in tablets
75721874|NCT00854802|Drug|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
75721875|NCT00969969|Device|Arthrodesis|arthrodesis using screws and/or a plate
75721876|NCT00969969|Device|Cartiva|Cartiva Synthetic Cartilage Implant
75721877|NCT00854880|Drug|PDC339|
75721878|NCT00854880|Drug|Placebo|
75721879|NCT00966459|Procedure|Computed Tomography|1 low-dose CT is taken
75721880|NCT00958503|Drug|Thiamphenicol|750 and 1500 mg/day;tablets
75721881|NCT00958503|Drug|Placebo|Matched tablets without active ingredient
75721882|NCT00861588|Drug|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
75721883|NCT00861588|Drug|placebo|starch placebo
75721884|NCT00970125|Behavioral|video|outline of the goals of care
75721885|NCT00966615|Other|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
75721886|NCT00966615|Other|glucose-based dialysis solution|2-L exchange; three times a day
75721887|NCT00861666|Behavioral|Forgiveness-Based Writing|"Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task."
75876196|NCT03021642|Drug|Tepotinib test (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 2 (Day 22)
75876197|NCT00354120|Drug|Alentuzumab|Alentuzumab
75876198|NCT00354120|Drug|Globulina antilinfocitaria|Globulina antilinfocitaria
75721888|NCT00861822|Other|Advanced red blood cell transfusion|"Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate"
75721889|NCT00970437|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
75876199|NCT04058808|Other|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
75876200|NCT04058808|Other|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
75876201|NCT04058808|Other|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
75876202|NCT04058808|Other|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
75876203|NCT04058808|Other|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
75876204|NCT04058808|Other|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
75422938|NCT05307250|Behavioral|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE|"In addition to the BSOC, ALHIV and their caregivers will participate in a family strengthening intervention plus a family economic empowerment intervention.~MFG is an evidence-based family-centered, group-delivered, evidence-informed, strength-based 10-session (weekly) intervention for children whose families struggle with poverty. Six additional sessions covering HIV stigma stigma-related issues will be added.~ALHIV will receive a YDA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate."
75568675|NCT04690712|Behavioral|Health Education|"All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy."
75568676|NCT01294696|Drug|Standard of care for treatment of osteoarthritis (OA) of knee(s)|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
75568677|NCT02914704|Device|MRI-HIFU|Treatment of uterine fibroids with MRI-HIFU
75568678|NCT04324255|Procedure|LT|Liver transplantation
75568679|NCT04690751|Drug|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
75568680|NCT04326361|Procedure|Neonatal surgeries|Current practices of neonatal surgeries in India
75422939|NCT05307250|Behavioral|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR).|In addition to BSOC and MFG-HIVSR+FEE, ALHIV in this arm will receive the school-level HIV stigma reduction intervention targeting teachers, school nurses, matrons, and administrators (headteachers, director of studies) in their schools. GED-HIVSR seeks to impart educators in the intervention schools with HIV related knowledge, provide a safe space for educators to explore their personal values and bias that may promote or hinder their role of supportive individuals and systems for ALHIV, and empower them with knowledge and skills to act as change agents within their schools.
75568681|NCT02918487|Drug|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
75568682|NCT02918487|Drug|Placebo|Inactive compound that is similar looking as the intervention
75568683|NCT04207606|Behavioral|Post Epidural Steroid Injection Follow-up|All enrolled patients will undergo epidural steroid injection with fluoroscopy per the Spine Intervention Society guidelines as part of their normal care. Patients will then be contacted for survey responses every 3 days for a maximum of 23 days, to assess pain intensity and change.
75568684|NCT03458078|Drug|Saline Solution|Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.
75568685|NCT03458078|Drug|Magnesium Sulfate|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).
75721890|NCT00970437|Behavioral|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
75721891|NCT02545218|Procedure|Perineorraphy|Surgery for improperly healed perineal tear
75876205|NCT00169806|Other|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
75876206|NCT03021564|Other|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
75568686|NCT03458078|Drug|Midazolam 5 MG/ML Injection|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
75568687|NCT02914860|Device|Cardiac CT|"Cardiac CT - contract enhanced cardiac CT according to standard protocol~D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~Merge CT and D-SPECT image data to generate SUMO map."
75721892|NCT02545218|Other|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
75721893|NCT00966771|Drug|Copper T380 IUD|copper T 380 IUD
75721894|NCT00966771|Drug|Oral levonorgestrel|1.5 mg
75721895|NCT00856440|Drug|Fleets Oral Sodium Phosphate Solution (OSPS)|Osmotic preparation for colonoscopy
75721896|NCT00856440|Drug|Colyte|Lavage preparation for colonoscopy
75721897|NCT00856440|Drug|Dual (OSPS & Colyte)|Combined, two-day preparation utilizing both preparations
75721898|NCT00958659|Other|laboratory biomarker analysis|Correlative studies
75721899|NCT00856596|Drug|Sertaconazole nitrate cream 2%|Once a day topical cream
75721900|NCT00970515|Procedure|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
75721901|NCT00970515|Procedure|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
75721902|NCT04042350|Other|Non-interventional|Exploring clinical risk factors associated with the risk for cardiovascular events and mortality, rather than to evaluate specific drugs.
76045330|NCT05054881|Other|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
76045331|NCT04950283|Diagnostic Test|magnetic resonance examination, anthropometric and metabolic characterization|Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
75721903|NCT00855114|Drug|everolimus|5 mg/day x 7 days by mouth
75721904|NCT00855114|Procedure|therapeutic conventional surgery|Definitive excision of breast cancer tissue
75568688|NCT02914860|Procedure|Ablation Procedure|"CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~Control HFS~At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~Exit and entrance block confirmation~Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
75721905|NCT00856674|Biological|OPL-CCL2-LPM|"CCL2-LPM~intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg~2 doses one week apart"
75721906|NCT00855192|Behavioral|mindful meditation|interpersonal and psycho-educational
75721907|NCT00855192|Behavioral|interpersonal therapy|psycho-educational
75721908|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
75721909|NCT00856752|Drug|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
76045332|NCT05024383|Other|Chemical sensitivity|Chemical sensitivity will be evaluated with paper taste strips embedded with varying concentrations of capsaicin solutions (activates TRPV1) and allyl isothiocyanate solutions (activates TRPA1) applied to the tongues of healthy subjects and site of cancer in oral cancer patients.
76045333|NCT05024383|Other|Mechanical sensitivity|Mechanical sensitivity will be evaluated via von Frey filaments applied to the tongues of healthy subjects and and site of cancer in oral cancer patients.
76045334|NCT04949425|Drug|Adavosertib|Patients will receive Adavosertib orally.
75568689|NCT02914860|Device|D-SPECT|
75568690|NCT04690556|Drug|Lucentis (ranibizumab)|Lucentis® 0.5 mg via intravitreal injection once monthly
75721910|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
75876207|NCT03669900|Procedure|a minimally invasive surgery (SERI)|The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
75876208|NCT03023046|Drug|Cyclophosphamide|Given IV
75876209|NCT03023046|Drug|Dasatinib|Given PO
75876210|NCT03023046|Drug|Doxorubicin|Given IV
75876211|NCT03023046|Drug|Etoposide|Given IV
75568691|NCT04690556|Drug|LUBT010 (proposed ranibizumab biosimilar)|LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
75422940|NCT05307250|Other|Bolstered Standard of Care (BSOC)|All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
75568692|NCT01294579|Biological|Ofatumumab|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years"
75568693|NCT01294579|Drug|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
75568694|NCT03554655|Device|Momentum app|The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
75721911|NCT04042272|Diagnostic Test|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
75721912|NCT04041960|Other|Transcranial magnetic stimulation (TMS)|The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
75721913|NCT00855270|Drug|Placebo|IV saline will be used as placebo for control
75721914|NCT00855270|Drug|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
75721915|NCT03937479|Drug|Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
75876212|NCT03023046|Drug|Imatinib Mesylate|Given PO
75876213|NCT03023046|Other|Laboratory Biomarker Analysis|Correlative studies
75876214|NCT03023046|Drug|Prednisone|Given PO
75876215|NCT03023046|Biological|Rituximab|Given IV
75876216|NCT03023046|Drug|Vincristine Sulfate|Given IV
75876217|NCT03668262|Drug|Cis-atracurium|Different concentration of cis-atracurium
75876218|NCT03669198|Diagnostic Test|NT-Pro BNP|. AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
76045335|NCT05023603|Diagnostic Test|self-report questionnaire|Individual subject factors included and self-report questionnaires will be collected through an interview process.
76045336|NCT05023525|Drug|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
75568695|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
75568696|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
75568697|NCT04972331|Procedure|Arthroscopic Partial Meniscectomy|"Arthroscopic partial meniscectomy was performed by three senior surgeons using two standard portals, no outflow cannula, a 5.5-mm 30° arthroscope, and a pressure-controlled irrigation system.~A standard surgical protocol was used to document possible findings in the cartilage, ligaments, synovium, and medial and lateral meniscus. In each case, surgery was limited to resection with limited debridement of the articular surface lesion, preserving as much of the meniscus as possible. Patients who underwent additional procedures, such as removal of loose bodies or subchondral drilling for any articular lesions, were excluded from this study (Figure 1). No patients underwent total meniscectomy or meniscal repair."
75721916|NCT03937479|Drug|Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
75721917|NCT03937479|Drug|Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
75721918|NCT03937479|Drug|Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
75721919|NCT03937479|Drug|Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
75721920|NCT00855348|Other|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
76045337|NCT05023525|Drug|Placebo, tablet|Matching placebo
75876219|NCT03019458|Dietary Supplement|MINGO|6 20oz sachets will be taken daily by intervention group
75876220|NCT04058340|Dietary Supplement|lactizole nebulization|Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)
76045338|NCT05022589|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, ~30 minutes per session.
76045339|NCT04421209|Drug|Propranolol Hcl 40mg Tab|40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.
76045340|NCT04421209|Drug|Placebo oral tablet|Placebo tablets administered with the same schedule of Propranolol tablets
76045341|NCT05020249|Drug|bimekizumab|Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
76045342|NCT05020249|Other|Placebo|Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
75422950|NCT05304221|Other|Shamir Resistance Calculator|"An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition."
75568698|NCT04972331|Procedure|Platet- Rich-Plasma|Peripheral venous blood was collected from all patients, which was then centrifuged to isolate red blood cells from the upper plasma layer. We used the Arthrex® kit APC®. The upper plasma layer was carefully collected with a serological pipette and placed in a new centrifuge tube or set aside for injection. The 5 mL remaining upper plasma layer was centrifuged again to separate platelet-poor plasma from PRP for 7 min. We activated the PRP sample by adding calcium chloride through ultraviolet irradiation, and then a 4- to 8-mL sample was used for two injections. One injection was performed intra-articularly with a supero-lateral approach. One ultrasound-guided injection was performed at the meniscal wall. Our protocol allowed us to have < 1% blood cells and <1% white cells in the injection.
75721921|NCT00970671|Other|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
75721922|NCT00970671|Other|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
75721923|NCT00970671|Other|No treatment|No laser treatment
75422951|NCT05301348|Device|Photoacoustic Flow Cytometry|Detection of circulating blood clots
75422952|NCT05300698|Device|MRI|compare between MRI and ultrasound for indirect assessment of ocular layers
75876221|NCT04058340|Other|Placebo|0.9% NaCl solution in nebulization
75876222|NCT03669120|Other|Informational Intervention|Receive advice to quit smoking and materials to promote smoking cessation
75422953|NCT05295121|Drug|XC221 100 mg tablets|XC221, 3 discrete doses separated by 7-day wash-out periods
75422954|NCT05294250|Drug|XC8|XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods
75422955|NCT05293769|Other|questionnaire|questionnaire will be filled in by all participants
75422956|NCT05292911|Drug|ALT-801|Injected subcutaneously (SC)
75422957|NCT05292911|Other|Placebo|Injected subcutaneously (SC)
75422958|NCT05291533|Other|Virtual Reality (VR) Mindfulness Program|The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
75422959|NCT05289323|Drug|Neostigmine Methylsulfate|0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
75422960|NCT05289323|Drug|Dextrose 5%/Nacl 0.9% Inj|one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
75422961|NCT05288556|Device|Placement of stoma site enteral feeding tube accessory|The study stoma site accessory will be attached at the stoma site during an enteral tube replacement procedure the patient is scheduled to have as a standard of care procedure. The study stoma site accessory is compatible with commercially available enteral nutrition feeding tubes ranging from size 16 to 20 French tubing that are adjustable to variable length.
75422962|NCT05283512|Other|Preventive treatment with IV-hydration|IV hydration with isotonic 0.9% NaCl
75422963|NCT05283512|Other|Preventive treatment with oral hydration|Oral hydration with regular bottled water
75422964|NCT05281380|Dietary Supplement|GIKAVI|Two tailormade supplements for patients; one for that underwent esophagectomy and one for (sub-)total gastrectomy.
75876223|NCT03669120|Behavioral|Telephone-Based Intervention|Receive individualized text based messages
75422965|NCT05275738|Dietary Supplement|Nicotinamide|Study tablets for nicotinamide are produced by Blackmores Ltd.
75422966|NCT05275738|Other|Placebo|Study tablets for placebo are produced by Blackmores Ltd.
75422967|NCT05273619|Drug|XC8, film-coated tablets, 10 mg|80 mg/day: 4 tablets (40 mg) twice a day
75422968|NCT05273619|Drug|Placebo|4 tablets twice a day
75422969|NCT05272943|Other|Oxgen saturation measurement with validated pulse oximetry|Oxgen saturation will be measured with validated pulse oximetry
75422970|NCT05272943|Other|Oxgen saturation measurement with smart electronics|Oxgen saturation will be measured with smart electronics
75422971|NCT05269849|Drug|Sirolimus|Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
75422972|NCT05264389|Device|Poly-Tape|Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction
75422973|NCT05264168|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
75422974|NCT05264168|Drug|Apixaban|Any apixaban dispensing claim is used as the exposure group
75721924|NCT00967083|Behavioral|Questionnaires/Interviews|Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
75721925|NCT00967161|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
75721926|NCT00967161|Procedure|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
75721927|NCT00967239|Genetic|DNA analysis|
75568699|NCT04972331|Other|Post-intervention|All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.
75721928|NCT00967239|Genetic|polymorphism analysis|
75721929|NCT00967239|Other|laboratory biomarker analysis|
75721930|NCT00967239|Other|pharmacogenomic studies|
75721931|NCT00967317|Drug|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
75721932|NCT00967317|Drug|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
75721933|NCT00959127|Drug|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
75721934|NCT00959205|Device|CARTO 3D|CARTO (3D Electroanatomic imaging)
75876224|NCT04058106|Procedure|A patient who need the cerebral artery aneurysm clipping surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
76045343|NCT04986397|Device|Cold Therapy|A Breg Polar Care Cube with WrapOn Polar Pad, Back will be filled with ice chips and water per manufacturer instructions and applied to the abdomen.
75422975|NCT05262504|Device|İntraocular lens implantation|Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.
75422976|NCT05258903|Procedure|Ulnar artery cannulation|Ulnar artery will be cannulated under USG guidance
75422977|NCT05258903|Procedure|Radial artery cannulation|Radial artery will be cannulated under USG guidance
75422978|NCT05257967|Diagnostic Test|Lumbar puncture and Phlebotomy|Sampling of cerebral spinal fluid and plasma.
75422979|NCT05257174|Dietary Supplement|Jing Si Herbal Tea LIQUID PACKETS|intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months
75422980|NCT05257174|Dietary Supplement|Placebo|intake Placebo twice daily for three months
75422981|NCT05256797|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
75568700|NCT02914665|Drug|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
75568701|NCT02914665|Drug|Placebo|Placebo administered intravenously once daily for 7 consecutive days
75568702|NCT04927169|Drug|Interleukin-7|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
75721935|NCT00959205|Device|Angiography|Conventional fluoroscopically guided activation mapping
75721936|NCT00967395|Other|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
75721937|NCT00967395|Other|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
75721938|NCT00970827|Procedure|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
75721939|NCT00970905|Drug|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
75721940|NCT00970905|Drug|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
75721941|NCT00619476|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
75721942|NCT00619476|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
75876225|NCT04058262|Other|Meditation presential|Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
75422982|NCT05256797|Drug|Apixaban|Any apixaban dispensing claim is used as the exposure group
75422983|NCT05227404|Diagnostic Test|LumiraDX|Point-of-care test for SARS-CoV-2
75422984|NCT05227404|Diagnostic Test|RightSign|Point-of-care test for SARS-CoV-2
75721943|NCT00619476|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
75721944|NCT00619476|Drug|Placebo|placebo
75721945|NCT00970983|Procedure|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
75721946|NCT00970983|Procedure|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
75721947|NCT04009083|Device|Standard of Care MRI|Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
75422985|NCT05227404|Diagnostic Test|Case Control|Genscript assay performed on the plasma sample
75422986|NCT05226468|Drug|NEI-01|"Part1:~Single dose period: Intravenous single dose of NEI-01 with 4 ascending dose levels.~Multiple dose period: Intravenous weekly dose of NEI-01 for 9 weeks with 4 ascending dose levels.~Part2:~Intravenous weekly dose of NEI-01 at the recommended dose obtained from Part 1"
75422987|NCT05226195|Other|Sterile Kinesio Taping|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
75721948|NCT04009083|Other|Fluciclovine PET scan added to MRI|18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
75721949|NCT00971061|Device|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
75876226|NCT04058262|Other|Reiki|Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
76045344|NCT04986397|Other|Standard of Care|Standard post-operative analgesia without the use of cryotherapy.
75568703|NCT04927169|Drug|PLACEBO|IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
76045345|NCT04944199|Other|Physical Activity|Intervention group participants will be enrolled in a standardized step-based program to gradually increase their physical activity. Daily steps will be measured via a pedometer application on a smartphone or wearable device, with a gradual increase in the goal on a weekly basis, with a target intervention of around 4-6 weeks in total. The first week's step count will be used to calculate a baseline step count for the week. At the start of each week, the participants will be asked to increase their daily step counts by 1,000.
75568704|NCT02914626|Drug|Intravitreal ranibizumab|Intravitreal ranibizumab injection
76045346|NCT01364233|Device|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
76045347|NCT04985539|Device|Verily Study Watch|Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
76045348|NCT05014945|Procedure|(atelocollagen group)|Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
75568705|NCT02918331|Drug|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
75568706|NCT02918331|Drug|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
75568707|NCT02918331|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
75721950|NCT00971061|Device|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
75721951|NCT00973635|Other|Web-based education|"Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs."
75568708|NCT02918058|Other|MedSafer|MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
75568709|NCT03457961|Drug|Perampanel|This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
75721952|NCT00861978|Drug|St. John's Wort extract|Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
75721953|NCT00861978|Drug|Placebo|Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
75721954|NCT00971139|Behavioral|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
75568710|NCT02914587|Device|ARTAS System|
75568711|NCT02914587|Other|Manual Implantation|
75568712|NCT02938715|Other|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
75721955|NCT00862056|Procedure|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
75721956|NCT00959361|Behavioral|pharmaceutical care|consultation with the pharmacists and usual care
75721957|NCT04040712|Other|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
75721958|NCT04040712|Other|Sham FMT|Sham fecal microbiota transplantation
75721959|NCT00973713|Drug|RAD001|10mg/d
75721960|NCT00857142|Drug|oxymorphone hydrochloride|
75721961|NCT00857142|Drug|Opana|
75721962|NCT00971217|Other|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
75721963|NCT00971217|Behavioral|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
75721964|NCT00865176|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
75721965|NCT00865176|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
75721966|NCT00973791|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
75422988|NCT05220787|Biological|Cold stored platelets in 100% plasma stored for 10-14 days|Subjects will receive cold stored platelets from the start of surgery until 24 hours after the end of surgery
75422989|NCT05220787|Biological|Room temperature stored platelets in 100% plasma stored for up to 7 days|Subjects will receive room temperature stored platelets from the start of surgery until 24 hours after the end of surgery
75422990|NCT05219994|Other|Hyperoxia Exposure|2 hours of hyperoxia exposure during OGTT
75422991|NCT05219994|Other|Normoxia Exposure|2 hours of normoxia exposure during OGTT
75721967|NCT00973791|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
75568713|NCT02914431|Device|3D Printing Personalized Titanium Plate|The cutting guides were placed onto the planned position. The cutting guides also worked as the drilling guide. Several screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The screw holes on the bones prepared by the cutting guides were used as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding screw holes on the plate to the bone. Afterwards, the position of the osteotomized Le Fort I segment was adjusted till all the remaining corresponding screw holes on bone and plate were aligned.
75568714|NCT02918136|Biological|Adipose derived regenerative cells|
75721968|NCT00865254|Behavioral|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
75721969|NCT00865254|Behavioral|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
75876227|NCT04058262|Other|Meditation (app)|Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
75568715|NCT02918136|Drug|Cortisone Injectable|
75876228|NCT04058262|Other|round of conversation|The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
75568716|NCT01294462|Drug|Ticagrelor|90 mg, oral dose twice daily
75876229|NCT05654688|Other|graston and muscle energy technique|"Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles."
75876230|NCT03668964|Dietary Supplement|Vitamin B2|One capsule of 75 mg Vitamin B2 once a day for 4 weeks
75568717|NCT01294462|Drug|Clopidogrel|75 mg, oral dose once daily
75568718|NCT01294462|Drug|Acetylsalicylic acid ASA|Low Dose ASA
75876231|NCT03668964|Dietary Supplement|Vitamin C|One capsule of 500 mg Vitamin C once a day for 4 weeks
75876232|NCT03668964|Dietary Supplement|Vitamin B2 + C|One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
75568719|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
75568720|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
75568721|NCT01294423|Drug|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
75568722|NCT02918175|Behavioral|mHealth|Personalized step count feedback and medication teaching tool.
75568723|NCT02914353|Drug|EP=7041|Factor X!a Inhibitor
75568724|NCT02914353|Drug|Placebo|Normal Saline
75876233|NCT03668964|Dietary Supplement|Vitamin A|One capsule of 250 µg Vitamin A once a day for 4 weeks
76045349|NCT04983355|Dietary Supplement|Fish Hydrolysate|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
75568725|NCT02938598|Behavioral|Maternal Depression Education and Care-Seeking Motivation|Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
75721970|NCT00865254|Behavioral|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
75721971|NCT00973869|Dietary Supplement|curcumin|
75721972|NCT00973869|Other|high performance liquid chromatography|
75721973|NCT00973869|Other|laboratory biomarker analysis|
75721974|NCT00973869|Other|pharmacological study|
75721975|NCT00973869|Procedure|diagnostic endoscopic procedure|
76045350|NCT04983355|Dietary Supplement|Placebo|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
75568726|NCT02914197|Other|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
75568727|NCT02938832|Behavioral|Advice on what food to choose and eat|Dietary advice
75568728|NCT02910570|Drug|Liraglutide 3 mg (Saxenda)|Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
75568729|NCT02910570|Drug|Liraglutide 3 mg placebo|Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
75568730|NCT02910453|Procedure|Pulmonary lobectomy|
75568731|NCT02938754|Behavioral|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
75721976|NCT00973869|Procedure|therapeutic conventional surgery|
75721977|NCT02544672|Device|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
75721978|NCT00959439|Drug|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
75721979|NCT00959439|Drug|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
75721980|NCT04041492|Dietary Supplement|Supplementation with Vitamin D3 y K2|Supplementation at a dose of 1 capsule every 24 hours x 3 months
75721981|NCT00971373|Other|Vestagen scrubs|antimicrobial impregnated textile
75721982|NCT00862212|Behavioral|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
75721983|NCT00973947|Other|questionnaire administration|
75721984|NCT00973947|Radiation|3-dimensional conformal radiation therapy|
75721985|NCT00973947|Radiation|radiation therapy treatment planning/simulation|
75721986|NCT00857298|Behavioral|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be ~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
75721987|NCT00971451|Other|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
75721988|NCT00971451|Other|TENS|continuous use of TENS during the exercise session
75876234|NCT03668964|Dietary Supplement|Vitamin D3|One capsule of 60 µg Vitamin D3 once a day for 4 weeks
75876235|NCT03668964|Dietary Supplement|Vitamin E|One capsule of 100 mg Vitamin E once a day for 4 weeks
75422992|NCT05218720|Diagnostic Test|EuroSCORE II|"Euro score II: Predicts risk of in-hospital mortality after major cardiac surgery. Risk category will be defined as very low risk <1, low risk 1-2.99, moderate risk 3-4.99, high risk >5.~CAM- ICU: The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) is a tool used to assess delirium among patients in the intensive care unit. It is an adaptation of the CAM which was originally developed to allow non-psychiatrists to assess delirium at the bedside. It ranges from 0 to 7, score greater to or equal to 3 will be considered positive for delirium, further categorized as 0-2 no delirium, 3-5 mild delirium 6-7 severe delirium with 7 being most severe."
75721989|NCT00857376|Dietary Supplement|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
75721990|NCT00974025|Dietary Supplement|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
75721991|NCT00974025|Dietary Supplement|Placebo|Placebo will be administered twice daily for four weeks
75568732|NCT02938754|Behavioral|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
75568733|NCT02938364|Other|Earplugs|Plastic earplugs on both ears
75568734|NCT02938364|Other|Acupressure|Sea Bands put on the wrists of the participant to apply pressure on P6 points
75568735|NCT02938364|Other|Placebo|Non pressure bands put on the wrists of the participant
75568736|NCT01294150|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
75568737|NCT01294150|Other|Cystoscopy|The Control Group will undergo cystoscopy.
75568738|NCT01294150|Device|Crossover|Subjects crossed over and received the UroLift System from the Control Group.
75568739|NCT04324216|Other|3D virtual reality and hands-on aromatherapy|Participants will receive 8-session 3DVR aroma therapy activities. Each session was delivered over 2 hours once a week, and at each session, the participant received hands-on guidance for preparing an aromatherapy product that they could use for the next seven days.
75568740|NCT02938208|Device|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
75568741|NCT04832516|Other|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
75568742|NCT04832516|Other|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
75568743|NCT02910141|Device|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
75568744|NCT04817072|Other|Blood sample|Blood sample (20mL) for pro-inflammatory cytokines assay
75568745|NCT02910336|Other|Quantitative Sensory Testing|sensory testing profile
75721992|NCT00618072|Drug|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
75876236|NCT03668964|Dietary Supplement|Placebo|One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
75568746|NCT04817033|Procedure|Spinal anesthesia with intraoperative dexmedetomidine sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
75721993|NCT00959517|Drug|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
75721994|NCT00959517|Drug|sulphadoxine-pyrimethamine (SP)|
75721995|NCT00959517|Drug|Chloroquine (CQ)|
75721996|NCT00959517|Drug|primaquine (PQ)|
75721997|NCT04008771|Device|SeeQ CdSe 655 ALT|SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
75876237|NCT03668886|Other|multimodal exercise program|warm-up, strengthening exercise, aerobic exercise, cool-down
75876238|NCT02923830|Other|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
75721998|NCT00959595|Drug|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
75876239|NCT02923830|Drug|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
76045351|NCT04983121|Drug|Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)|The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
75721999|NCT00959595|Drug|EMLA cream|50g applied according to description of intervention
76045352|NCT04420897|Procedure|Arterial blood gas samples|Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
75722000|NCT00666926|Drug|PF00562271|125 mg twice daily [BID] with food, tablet
75722001|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
75722002|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
75722003|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
75876240|NCT03668730|Radiation|Intensity-modulated radiation therapy|Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy
75722004|NCT00974103|Other|exercise advise|Exercises
75876241|NCT03668730|Drug|Paclitaxel liposome|Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.
75876242|NCT03668730|Drug|Cisplatin|Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.
75876243|NCT03668730|Drug|5-Fluorouracil|Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
75876244|NCT03623178|Other|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
75876245|NCT03623178|Other|Treatment As Usual|The treatment as usual is the intervention given in our outpatient addictology unit. It consists of an individual treatment program at our outpatient unit with regular appointments with psychiatrists and nurses. The patient can also take part in therapeutic groups and receive help from a psychologist for a targeted program or psychotherapy. The multidisciplinary team also comprises a social worker and an occupational therapist.
75441693|NCT01637389|Other|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
75722005|NCT00974103|Other|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
75722006|NCT00865410|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fasting conditions
75722007|NCT00865410|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
75722008|NCT00974181|Device|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
75722009|NCT00974181|Device|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
75722010|NCT00971607|Drug|Oxygen + Sevoflurane|Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
75568747|NCT04817033|Procedure|Spinal anesthesia with intraoperative midazolam sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
75722011|NCT00971607|Drug|Oxygen (placebo)|Control will receive oxygen only.
75722012|NCT00865488|Biological|ADHEXIL|Adhesions prevention
75722013|NCT00862368|Behavioral|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
75722014|NCT00862368|Behavioral|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
75876246|NCT03668652|Device|Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO"
75568748|NCT04817033|Drug|Dexmedetomidine|Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
75568749|NCT04817033|Drug|Midazolam|Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
75876247|NCT03668652|Procedure|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
75441694|NCT01637428|Device|ActiveCare+S.F.T 3rd generation|Intermittent Pneumatic Compression Device
75441695|NCT01637441|Procedure|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
75441696|NCT01637441|Procedure|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
75568750|NCT01292473|Drug|Placebo|Placebo was supplied lyophilized in vials.
75722015|NCT00862368|Behavioral|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
75722016|NCT00971685|Drug|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
75722017|NCT03861052|Drug|Tirzepatide|Administered SC
75876248|NCT03668574|Other|Aerobic exercise|Aerobic exercise that is defined as a form of exercise lasting 15 to 60 minutes continuous and intensity of 60% to 90% of maximal heart rate.
76045353|NCT04208971|Other|AI-enabled ECG-based Screening Tool for AF|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool to improve atrial fibrillation diagnosis and stroke prevention.
76045354|NCT02291289|Drug|Cetuximab|500 mg/m^2 via IV infusion on Day 1 of every 2-week cycle
76045355|NCT02291289|Drug|FOLFOX induction regimen|Administered per the Investigator's discretion in accordance with locally approved prescribing information.
75441697|NCT01637454|Drug|Noradrenaline|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
75441698|NCT01637454|Drug|Terlipressin|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
75441699|NCT01637467|Other|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
75568751|NCT01292473|Drug|Omalizumab|Omalizumab was supplied lyophilized in vials.
75568752|NCT03026049|Device|deep venous stenting|Deep venous stent
75568753|NCT03457883|Device|herniamesh|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
75568754|NCT03457883|Device|biological graft|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
75568755|NCT02938247|Dietary Supplement|High caloric, high protein ONS|
75568756|NCT02914002|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
75568757|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
75568758|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
75722018|NCT03861052|Drug|Dulaglutide|Administered SC
75722019|NCT00971763|Biological|rituximab|
75722020|NCT00971763|Drug|cyclophosphamide|
75722021|NCT00971763|Drug|gemcitabine hydrochloride|
75722022|NCT00971763|Drug|prednisolone|
75722023|NCT00971763|Drug|vincristine sulfate|
75722024|NCT04018170|Drug|Study drug|oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
75568759|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
75568760|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
75722025|NCT04018170|Drug|Placebo|oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
75722026|NCT00785252|Device|Powered Intraosseous device (EZIO)|EZIO
76045356|NCT02291289|Drug|Fluoropyrimidine (5-FU/LV or capecitabine)|Per Investigator's discretion: 1600-2400 mg/m^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
75722027|NCT00785252|Device|standard central line|placement of a central line
75722028|NCT00857688|Drug|Bismu-Jet|Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
75876249|NCT03668574|Other|Placebo Group|Will be treated with pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes. The devices will be used with disconnected internal cables to obtain the placebo effect
76045357|NCT02291289|Drug|Atezolizumab|800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
75876250|NCT03021018|Drug|Brivaracetam|"Pharmaceutical Form: Solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
75876251|NCT03021018|Drug|Lorazepam|"Pharmaceutical Form: Solution for injection~Route of Administration: intravenous"
76045358|NCT02291289|Drug|Vemurafenib|960 mg vermurafenib BID by mouth
75876252|NCT03669042|Device|PhotoFix|PhotoFix Patch Implantation
75876253|NCT02509507|Drug|Talimogene Laherparepvec|Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 & 2, up to 8mL in Cohorts 3 & 4 of the Group A & Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10^6 PFU/mL to the 2nd dose at 10^7 or 10^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 & 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 [dated 26 October 2021], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.
76045359|NCT02291289|Drug|Bevacizumab|5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
76045360|NCT02291289|Drug|Trastuzumab|Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
76045361|NCT02291289|Drug|Pertuzumab|Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
76045362|NCT02291289|Drug|Cobimetinib|60 mg orally once daily for 3 weeks followed by a 1-week treatment break
75568761|NCT02938286|Device|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
75568762|NCT02938286|Drug|AHES|Topical application at test region I-IV under occlusion for 15 minutes
75568763|NCT02913963|Device|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
75722029|NCT00857688|Other|Placebo|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
76045363|NCT02291289|Drug|5-FU/LV|1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first.
76045364|NCT02317575|Biological|LY900014|Administered SC
76045365|NCT02317575|Biological|Insulin Lispro|Administered SC
76045366|NCT02316717|Biological|IMM-124E|IMM-124E
76045367|NCT02316717|Other|Placebo|Matched placebo
76045368|NCT02290821|Drug|placebo|
76045369|NCT02290821|Drug|Placebos|
75722030|NCT00959829|Other|Music and message|Experimental group: music and message Control group: silence
75722031|NCT00781196|Drug|folic acid|capsule 0.5 mg once a day
75722032|NCT00781196|Drug|placebo|capsule, once a day
75722033|NCT00865644|Drug|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
75722034|NCT00971919|Other|questionnaire administration|
75722035|NCT00971919|Procedure|assessment of therapy complications|
75722036|NCT00971919|Procedure|psychosocial assessment and care|
75722037|NCT00971919|Procedure|quality-of-life assessment|
75722038|NCT00785330|Drug|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
75722039|NCT00785330|Drug|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
75722040|NCT00974649|Behavioral|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
75722041|NCT02555150|Drug|PRC-063|Oral extended-release capsule
75722042|NCT02555150|Drug|lisdexamfetamine dimesylate|Oral capsule
75722043|NCT02555150|Drug|Placebo|Oral placebo capsule
75568764|NCT02913963|Device|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
75568765|NCT01292239|Drug|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
75568766|NCT01292239|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
75568767|NCT01292239|Drug|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
75568768|NCT01292239|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
75568769|NCT02938091|Other|High-fat diet|Typical Western diet
75722044|NCT05279469|Other|no intervention, just observational for D-Dimer level in blood|observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients
75722045|NCT00790946|Drug|Valsartan|Valsartan 80 to 160 mg
75722046|NCT05263102|Device|Vaginal Moisturizing Gel|All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
76045370|NCT02289963|Drug|Placebo (for Alirocumab)|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
76045371|NCT02289963|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
75568770|NCT02938091|Other|Low-fat diet|Traditional Caribbean Hispanic diet
75722047|NCT05179239|Drug|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
75722048|NCT05179239|Drug|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
75722049|NCT05179239|Drug|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|Placebo + paclitaxel + cisplatin/carboplatin ± BP102
75722050|NCT04046666|Device|Functional near infrared spectroscopy|Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
76045372|NCT02289963|Drug|Lipid-Modifying Therapy (LMT)|Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
76045373|NCT02358369|Drug|Bimatoprost|Bimatoprost sustained release Ocular Insert
76045374|NCT02358369|Drug|Timolol 0.5%|BID drops OU, 0.5% ophthalmic solution
76045375|NCT02358369|Device|Placebo Ocular Insert|Placebo ocular insert OU.
75722051|NCT04046666|Procedure|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm."
75422993|NCT05218083|Behavioral|REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)|"REmotely Monitored, Mobile health-supported, High Intensity Interval Training consists of remotely monitored tailored, structured, progressive multidomain physical rehabilitation & personalized instruction & coaching.~Patients complete 3 structured exercise sessions/week consisting of HIIT, strength, balance, and mobility exercises. Following warmup, patients increase workload at a heart rate corresponding to 95% VO2peak for 1-minute before returning to warm-up speed for 1-minute at a heart rate corresponding to 60% VO2peak.~Strength includes functional strengthening exercises for lower extremities & general resistance exercises for major muscle groups.~Balance incorporates static & dynamic exercises, including progressively narrowing base of support with eyes open or closed, reaching forward & backward starting within base of support & progressing to outside base of support.~Mobility rehabilitation includes dynamic start/stop while walking and changing direction while walking."
75422994|NCT05213650|Other|non-abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Non-abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
75876254|NCT02509507|Drug|Pembrolizumab|Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
75876255|NCT04807777|Drug|Ruxolitinib|Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
75876256|NCT03176407|Diagnostic Test|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
76045376|NCT02358369|Drug|Placebo Eye Drops|Placebo eye drops BID OU.
75568771|NCT01291225|Other|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
76045377|NCT02316171|Biological|CVA21|CAVATAK is a purified preparation of CVA21
75568772|NCT01291225|Behavioral|Educational campaign|Educational materials will be developed and distributed in Ross County.
75568773|NCT02909985|Other|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
76045378|NCT02316171|Drug|Mitomycin C|Chemotherapy
75568774|NCT02909985|Other|ERG|Participants will undergo electroretinography using both normal settings and infrared as the stimuli.
75441700|NCT01637467|Other|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
75441701|NCT01637480|Other|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
75568775|NCT02909985|Other|VEP|Participants will undergo visual evoke potential tests using both normal settings and infrared as the stimuli.
75568776|NCT02937974|Drug|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
75568777|NCT02937974|Drug|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
75568778|NCT05600179|Drug|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant
76045379|NCT02315625|Drug|Sunitinib|37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
75568779|NCT01290796|Device|Ajust Adjustable Single-Incision Sling|The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
75568780|NCT02937662|Drug|Idarubicin|Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
75568781|NCT02937662|Drug|Cytarabine|Cytarabine at a dose of 100mg/㎡/d on days 1-7.
75568782|NCT02937662|Drug|Cyclophosphamide|Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
75568783|NCT02937662|Drug|Physician-Directed Regimens without Cyclophosphamide|Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
75568784|NCT02909946|Behavioral|Multi-modal Infection Control Program|"Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~Hand hygiene education to residents and families (resident-level intervention).~Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
75568785|NCT01290757|Drug|Dabigatran etexilate|150 mg Capsugel (T)
75568786|NCT01290757|Drug|Dabigatran etexilate|150 mg Qualicaps (R)
75568787|NCT02937857|Drug|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
75568788|NCT02937857|Drug|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
75568789|NCT04324060|Drug|Danazol + rhTPO (recombinant human thrombopoietin injection)|subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased >50×10e9/L, total course is 6 months
75876257|NCT03175549|Drug|Apremilast|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
76045380|NCT02315625|Drug|Everolimus|10 mg daily will continue until progression or unacceptable treatment-related toxicity
76045381|NCT02357979|Device|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
75876258|NCT03175549|Drug|Placebo|Identical placebo pills taken orally for 14 days
75876259|NCT03174925|Device|Siemens Acuson S3000 ultrasound system|Shear Wave Elastography
75876260|NCT01314937|Drug|Mebendazole|Single-dose 500 mg mebendazole tablet
75568790|NCT04324060|Drug|Danazol + sodium chloride|Danazol 0.2g tid po+ control (sodium chloride)
75876261|NCT01314937|Other|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
75568791|NCT01290718|Drug|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
75876262|NCT04718155|Drug|Atorvastatin|will receive 40 mg atrorvastatin 2 days
75876263|NCT04718155|Other|placebo|will receive 40 mg placebo 2 days
75876264|NCT04668859|Drug|Midodrine|Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.
75568792|NCT01290718|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
75568793|NCT02937935|Biological|Protocol Guided Renal Replacement Therapy|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
75568794|NCT02937935|Biological|On Demand Renal Replacement Therapy|Patients to be randomized to the intervention as per standard of care
76045382|NCT02357979|Other|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
76045383|NCT04886973|Other|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.|Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
75422995|NCT05213650|Other|abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
75422996|NCT05213650|Other|Efferdent|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water.The Efferdent tablet will be used once a week as an intervention to aligner cleaning during invisalign treatment.
75876265|NCT04668859|Drug|Methylcellulose|Placebo will consist of inert methylcellulose
75422997|NCT05213650|Other|Cleaning Crystals|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Invisalign Cleaning Crystals will be used once a week as an intervention to aligner cleaning during invisalign treatment.
75876266|NCT02320201|Device|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
75422998|NCT05205746|Biological|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
75422999|NCT05205746|Biological|Placebo|Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S[recombinant]) Intramuscular
75876267|NCT02261389|Other|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
76045384|NCT02357901|Drug|SUBOXONE|SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
75423000|NCT05196750|Other|Behavioural questionnaires and assessments on mother and child|Questionnaires include, but not limited to, State Trait Anxiety Inventory, Beck Depression Inventory, LYNDON Maternal Health and Well Being, Facial Imitation Task, Deferred Imitation, Habituation, Relational Binding, Behavioural Observation, Mirror Self Recognition, Standardized Assessment and Experimental Task, Snack and Sticker Delay, Implicit Attitude Test
75423001|NCT05195905|Device|PMEG|All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.
75423002|NCT05190575|Drug|TST001|TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
76045385|NCT02357901|Drug|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
75876268|NCT02924688|Drug|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily [QD] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
75423003|NCT05179512|Drug|Tiotropium|Tiotropium dispensing claim is used as the reference group.
75423004|NCT05179512|Drug|salmeterol-fluticasone|Salmeterol/Fluticasone dispensing claim is used as the exposure group.
75423005|NCT05166902|Device|Lens A (comfilcon A lens)|1 month
75568795|NCT04688424|Device|FES|FES will be applied via surface electrodes placed over bilateral quadriceps muscles. FES-stimulation will be ramped from sensory level (the level at which the individual feels a cutaneous sensation from the stimulation) to the maximum-tolerated level using a closed loop system controlled by computer software Subjects will exercise at home, three times per week, with FES on for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
75876269|NCT02924688|Drug|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
75423006|NCT05166902|Device|Lens B (lehfilcon A lens)|1 month
75423007|NCT05164926|Other|perineal massage with St. John's Wort oil|perineal massage with St. John's Wort oil during labor
75423008|NCT05164081|Combination Product|antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).|Hospitals are cluster-randomized to either arm for 2 years and then cross-over to the other arm for another 2 years.
75876270|NCT02924688|Drug|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
75423009|NCT05164081|Combination Product|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
75876271|NCT02924688|Drug|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
75876272|NCT02924688|Drug|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
75876273|NCT02924688|Drug|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
75423010|NCT05162183|Drug|Glimepiride|Glimepiride dispensing claim is used as the reference group.
75568796|NCT04688424|Other|Cycling|Subjects will exercise at home, three times per week, without FES for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
75876274|NCT02924688|Drug|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
75876275|NCT02924688|Drug|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
75876276|NCT02924688|Device|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
76045386|NCT02357901|Drug|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
75568797|NCT02937896|Drug|Desmopressin|40 micrograms Nasal Desmopressin.
75423011|NCT05162183|Drug|Liraglutide|Liraglutide dispensing claim is used as the exposure group.
75423012|NCT05153395|Other|Carbon dioxide breathing|Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
75423013|NCT05153395|Other|Neurovascular Coupling|Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
75423014|NCT05153395|Drug|Human insulin|Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
75423015|NCT05143749|Other|video tutorial|get video tutorial
75722052|NCT04527874|Behavioral|VITAL model|"The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening."
75722053|NCT00972075|Drug|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
75722054|NCT00972075|Drug|placebo|one tablet per day 2 hours before going to bed
75722055|NCT00974727|Other|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
75722056|NCT00785408|Drug|AC2307|subcutaneous, twice daily, low dose
75722057|NCT00785408|Drug|placebo|subcutaneous, twice daily, low dose
75722058|NCT00785408|Drug|AC2307|subcutaneous, twice daily, middle dose
76045387|NCT01601847|Dietary Supplement|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
75423016|NCT05142566|Device|MANTA Vascular Closure Device|Evaluate the safety of ultrasound guided deployment of MANTA VCD.
75568798|NCT02937896|Drug|Ketorolac|30mg intravenous Ketorolac.
75568799|NCT02937896|Drug|Normal Saline|1cc intravenous Normal Saline.
75568800|NCT02937896|Drug|Normal Saline|4 puffs nasal Normal Saline.
75568801|NCT02937779|Drug|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
75568802|NCT02937779|Device|Rapid tests HBe Ag|For all HBs Ag positive women
75568803|NCT04688229|Device|Hummingbird hand training device plus standard of care rehabilitation|The Hummingbird is a comprehensive hardware and software platform that isolates the hand, wrist, and forearm in a neutral and comfortable position, allowing linear force and angular torque to be measured at the finger-tips between 0-10 Newtons at milli-newton resolution at 100 Hz per digit, in 5 degrees of freedom simultaneously, in real-time, for all 5 digits. The platform allows isolating and characterizing fine resolution forces with sufficient sensitivity and resolution to record data in severe paralysis. The platform also comprises therapeutic software to train exploratory, individuated, and inter-digit complex finger movements by coupling force and torque output to NeuroAnimation physics-based virtual interface in engaging therapeutic experiences.
75876277|NCT02924688|Device|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
75423017|NCT05134636|Other|Text triage|The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
75423018|NCT05120167|Diagnostic Test|Endocervical liquid-base cytology|Endocervical sample collected by brushing and preserved in a liquid-base.
75423019|NCT05120167|Diagnostic Test|Endocervical cell block|"Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology."
75423020|NCT05120167|Diagnostic Test|Endocervical curettage|Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
75568804|NCT04688229|Other|Comparison (sham) intervention|During each hour of sham therapy the therapist will select cognitive tasks (e.g. puzzles and games) targeted to a level of difficulty based on the subjects ability. No grasping or object manipulation using the target upper limb will be included in this intervention. Rather, the participant will use either the unaffected limb (or non-targeted limb for SCI subjects) as needed for any particular puzzle or game.
75568805|NCT04688073|Behavioral|Exercise|Running
75722059|NCT00785408|Drug|placebo|subcutaneous, twice daily, middle dose
75568806|NCT04688073|Behavioral|Rest|sit and rest
76045388|NCT01601847|Drug|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
75568807|NCT02937428|Behavioral|Look away from the needle|Participant looks away from the needle during vaccination
75568808|NCT02937428|Behavioral|Look at the needle|Participant looks at the needle during vaccination
75568809|NCT02909790|Device|Curve Low Level Laser Therapy|"Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.)."
75568810|NCT01290679|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
75568811|NCT01290679|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
75722060|NCT00785408|Drug|AC2307|subcutaneous, twice daily, high dose
75722061|NCT00785408|Drug|placebo|subcutaneous, twice daily, high dose
75722062|NCT00974805|Drug|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
75423021|NCT05107466|Diagnostic Test|P300 Visually evoked potential|Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.
75722063|NCT00781352|Drug|nitrous oxide|65% nitrous oxide administered during surgery
75722064|NCT00781352|Drug|nitrogen|Nitrogen administration during surgery
75722065|NCT00960219|Drug|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
75722066|NCT00960219|Drug|placebo|1# BID, oral, for 6 weeks
75722067|NCT02555774|Behavioral|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
75876278|NCT02924688|Device|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
75876279|NCT03668496|Drug|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
75876280|NCT03668496|Drug|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
76045389|NCT04886739|Drug|CGB-400|Topical gel
76045390|NCT04886739|Drug|Vehicle Gel|Topical gel
75423022|NCT05106361|Behavioral|MOSAIC Plus|"Those in the experimental arm will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
75722068|NCT02555774|Behavioral|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
75568812|NCT01290679|Drug|Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
75568813|NCT01290679|Drug|Ribavirin (RBV)|200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
75876281|NCT03668418|Drug|Fluorouracil|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
75876282|NCT03668418|Drug|Lederfolin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
75876283|NCT03668418|Drug|Oxaliplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
75423023|NCT05106361|Behavioral|MOSAIC|Those in the active comparator will receive a mentor mother intervention named Mother AdvocateS In the Community (MOSAIC). This does not include the IPT component.
75423024|NCT05099198|Drug|Sitagliptin|Sitagliptin dispensing claim is used as the reference
75423025|NCT05099198|Drug|Glimepiride|Glimepiride dispensing claim is used as the reference
75568814|NCT03457389|Drug|Cabergoline|Cabergoline tablet
75568815|NCT02937467|Device|SWE|a novel ultrasound-based elastographic method, a new real-time, quantitative, operator-independent, and reproducible technique
75722069|NCT00972231|Other|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
75722070|NCT00791024|Drug|CRC-Pharma 001|50 mg
75876284|NCT03668418|Drug|Irinotecan|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
75876285|NCT03668418|Drug|Docetaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
75568816|NCT02937311|Other|NMES|Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles
75722071|NCT00791024|Drug|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
75722072|NCT03897244|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
75722073|NCT03897244|Drug|Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)|Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
75722074|NCT03897244|Drug|Amoxicillin-Metronidazole Bismuth quadruple therapy|Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
75722075|NCT00974883|Procedure|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
75722076|NCT00974883|Procedure|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
75722077|NCT00664742|Drug|Fluvastatin XL®|Fluvastatin extended release 80 mg
75722078|NCT04046354|Device|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
75722079|NCT04046354|Device|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
75722080|NCT00781430|Drug|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
75876286|NCT03668418|Drug|Cisplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
75876287|NCT03668418|Drug|Epirubicin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
75876288|NCT03668418|Drug|Gemcitabine|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
75876289|NCT03668418|Drug|Nab paclitaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
75876290|NCT03666702|Other|Upper limb physiotherapy programme|Web-based physio programme
75722081|NCT00511342|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
75876291|NCT03666702|Other|Usual care|Usual physiotherapy care
75722082|NCT00511342|Drug|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
75722083|NCT03931785|Drug|MD-7246|Oral tablet
75722084|NCT03931785|Drug|Placebo|Matching oral tablet
75722085|NCT00666536|Drug|valsartan and amlodipine|
75722086|NCT00666536|Drug|valsartan and amlodipine|
75722087|NCT00519532|Drug|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
76045391|NCT02515669|Drug|RO7239361|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
75722088|NCT00666458|Drug|saxagliptin|tablet, per oral, once daily
75876292|NCT03011892|Drug|Ruxolitinib 0.15% Cream QD|Ruxolitinib 0.15% cream QD
75722089|NCT00666458|Drug|sitagliptin|capsule, per oral, once daily
75722090|NCT00974961|Drug|bupivacaine, levobupivacaine|intrathecal injection 15~20mg(for Levobupivacaine) or 10~15mg(for Bupivacaine) once
75722091|NCT00975039|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
75722092|NCT00511108|Drug|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
75722093|NCT00511108|Drug|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
75722094|NCT00511108|Drug|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
75722095|NCT00511108|Drug|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
75423026|NCT05089071|Device|Assist by artificial intelligence system for colon polyp detection|Assist by artificial intelligence system for colon polyp detection
75423027|NCT05088798|Drug|18F-Fluoro Dopa PET/MRI Imaging|The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-[18F]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
75722096|NCT00785642|Drug|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
75876293|NCT03011892|Drug|Ruxolitinib 0.5% Cream QD|Ruxolitinib 0.5% cream QD
75876294|NCT03011892|Drug|Ruxolitinib 1.5% Cream QD|Ruxolitinib 1.5% cream QD
75876295|NCT03011892|Drug|Ruxolitinib 1.5% Cream BID|Ruxolitinib 1.5% cream BID
75876296|NCT03011892|Drug|Triamcinolone 0.1% Cream BID|Triamcinolone 0.1% cream BID
75876297|NCT03011892|Drug|Vehicle Cream BID|Vehicle cream BID
75876298|NCT03017742|Device|Pulse Oximeter|
75876299|NCT02125513|Drug|carboplatin and paclitaxel followed by surgery|
75876300|NCT03667950|Procedure|Hyperspectral Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
76045392|NCT02515669|Drug|Placebo|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
76045393|NCT02515279|Drug|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
76045394|NCT02515279|Drug|Ribavirin|1000-1600 mg day orally for 48 weeks.
75722097|NCT00781586|Dietary Supplement|One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|One A Day Weight Smart Advanced 1 tablet at 1st visit
75876301|NCT03667872|Procedure|Bilateral implantation of DBS system to Habeluna|Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
75876302|NCT03667794|Diagnostic Test|body plethysmography|measurement of conventional lung function parameters
75423028|NCT05086172|Behavioral|Ultrabrief Behavioral Activation|The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
75722098|NCT00781586|Drug|Caffeine|Caffeine 100 mg 1 tablet at 1st visit
75722099|NCT00781586|Drug|Placebo|Placebo 1 tablet at 1st visit
75722100|NCT00785720|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
75722101|NCT00781664|Other|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
75722102|NCT00781664|Drug|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
75722103|NCT00781664|Drug|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
75722104|NCT00781664|Other|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
75722105|NCT00781664|Drug|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
75722106|NCT00781664|Drug|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
75722107|NCT00781664|Drug|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
75722108|NCT00781664|Drug|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
75722109|NCT00781664|Other|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
75876303|NCT03667794|Diagnostic Test|impulse oscillometry|measurement of central and peripheral airway resistance
75876304|NCT03667794|Diagnostic Test|multiple breath washout|measurement of ventilation heterogeneity
75876305|NCT03667638|Combination Product|Platelet-Rich Plasma|Adding PRP to wound bed during surgical debridement
75876306|NCT03666546|Drug|Lactulose crystals 20 g|White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
75722110|NCT00785876|Other|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
75722111|NCT02554916|Behavioral|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
75722112|NCT02554916|Behavioral|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
75722113|NCT02554916|Other|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
75876307|NCT03666546|Drug|Lactulose crystals 30 g|White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
75876308|NCT03666546|Drug|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
76045395|NCT02515045|Drug|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
76045396|NCT02515045|Drug|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
75423029|NCT05086081|Drug|Ticagrelor 90mg|Any ticagrelor dispensing claim is used as the exposure group
75423030|NCT05086081|Drug|Prasugrel 10mg|Any prasugrel dispensing claim is used as the reference group
75423031|NCT05083949|Drug|FDC 12.5mg empagliflozin/850mg metformin|empagliflozin/metformin
75722114|NCT02554916|Device|Dual-Belt Treadmill|
75722115|NCT00791570|Biological|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
75722116|NCT00510952|Drug|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
75722117|NCT00510952|Drug|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
75876309|NCT03666546|Drug|Lactulose liquid 30 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
76045397|NCT02515045|Drug|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
75722118|NCT00617604|Drug|Alefacept|IV and subcutaneous injection
76045398|NCT02515045|Drug|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
76045399|NCT02514577|Drug|IDP-122 Lotion|Topical lotion
75722119|NCT00617604|Drug|placebo|IV and subcutaneous injection
76045400|NCT02514577|Drug|IDP-122 Vehicle Lotion|Topical lotion. No active ingredient.
76045401|NCT04943887|Behavioral|eSupport Health Weekly Group Sessions for PwMS|A formal semi-structured program of psychoeducational support delivered in an online weekly small group format by health coaches (licensed therapists) who specialize in MS.
75423032|NCT05083949|Drug|Empagliflozin|empagliflozin 10mg (R1)
75423033|NCT05083949|Drug|Glifage®|Glifage® 850mg (R2)
75722120|NCT00617604|Drug|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
75876310|NCT03666546|Drug|Glucose|White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
76045402|NCT05463055|Radiation|Proton Therapy System (ProBeam)|All of subjects (tumor patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors) will be treated with Proton radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months ( for this trial). Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.
75568817|NCT02937311|Other|Kinesiotape|The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.
75722121|NCT00617604|Drug|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
75722122|NCT00617604|Drug|Steroids|"Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally"
75876311|NCT03666546|Drug|Still water|250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
75876312|NCT03012828|Drug|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
75876313|NCT03012828|Other|Placebo|
75722123|NCT00865722|Procedure|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
75876314|NCT03667560|Procedure|Dermacell ADM without basement membrane|Patient will be implanted with Dermacell ADM.
75876315|NCT03667560|Procedure|FlexHD|Patient will be implanted with FlexHD.
76045403|NCT02513485|Drug|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
75722124|NCT01012570|Drug|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
75876316|NCT03666936|Other|Social-health care intervention|Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
75876317|NCT04598724|Other|Surveys|Survey will be administered involving questions regarding knowledge and perception of palliative care.
75876318|NCT03010254|Device|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
75876319|NCT03010254|Device|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
75876320|NCT03010254|Procedure|Cataract surgery|IOL bilateral implantation
75876321|NCT04050150|Behavioral|Arm training in standing|Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
75876322|NCT03666468|Other|PlayMed|A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
75876323|NCT03666468|Other|Online Package|Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
75876324|NCT03666468|Other|Paper Guidelines|Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
75423034|NCT05083455|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
75876325|NCT03666390|Drug|Ketamine|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
75876326|NCT03666390|Drug|Midazolam|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
75876327|NCT03008460|Drug|Eziclen®/Izinova®|Oral solution taken the evening before the colonoscopy
75568818|NCT02937311|Other|Standardized Physiotherapy|All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
76045404|NCT02513485|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
75423035|NCT05083455|Drug|Enoxaparin|Any enoxaparin dispensing claim is used as the reference group
75568819|NCT02890186|Device|Narcotrend|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
75568820|NCT02890186|Other|experience|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
75722125|NCT01012648|Drug|Fluid resuscitation|Volume resuscitation
75722126|NCT01012648|Drug|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
75722127|NCT02544594|Device|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
75722128|NCT00858000|Other|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
75876328|NCT03008460|Drug|Klean-Prep®|Oral solution taken the evening before the colonoscopy
75876329|NCT02914236|Device|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
75876330|NCT03623022|Drug|Clinical Center Reference Endotoxin (CCRE)|subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
76045405|NCT02289417|Drug|Apremilast|
76045406|NCT02289417|Drug|Placebo|
76045407|NCT02512861|Drug|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients > 50 kgs"
75423036|NCT05083429|Drug|Salmeterol|Salmeterol inhaler dispensing claim is used as the reference
75423037|NCT05083429|Drug|Tiotropium|Tiotropium dispensing claim is used as the reference
75423038|NCT05078879|Drug|Empagliflozin|This is an open-label pilot study to evaluate the efficacy, safety, and tolerability of empagliflozin as a treatment for severe congenital neutropenia (SCN) in patients with glucose-6-phosphatase 3 (G6PC3) deficiency. Participants will be on a 12-month daily regimen of empagliflozin at a starting dose of 10 mg (phase A), which may be increased after 2 months to 25 mg (phase B). Evaluate the safety and efficacy of the biomarker response (the change in absolute neutrophil count [ANC] after one year of empagliflozin treatment relative to baseline ANC prior to drug treatment) in patients with G6PC3 deficiency.
75722129|NCT02544438|Drug|Astarabine (BST-236)|"Cohort # Astarabine Dose Number of Patients~0.5 gr/m2 (0.3 age>50) 3~1.5 gr/m2(0.8age>50) 3~3.0 gr/m2(1.5 age>50) 3~4.5 gr/m2(2.3 age>50) 6~4.5 gr/m2 (no age limit) 3 up to 6~6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24"
75423039|NCT05078307|Procedure|OHR VS OHV|"Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid."
75423040|NCT05075980|Drug|Cisplatin|Given IV
75423041|NCT05075980|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
75423042|NCT05075980|Other|Quality-of-Life Assessment|Ancillary studies
75722130|NCT03843216|Other|observation|patients not treated
75423043|NCT05075980|Other|Questionnaire Administration|Ancillary studies
75722131|NCT03843216|Other|Physiotherapic scoliosis specific exercise|Specific exercise according to the SEAS (Scientific Exercises Approach to Scoliosis) protocol
75722132|NCT03843216|Device|brace|different kind of braces being elastic, rigid or very rigid. All devices are custom made. The hours of application per day varied from 18 to 24h.
75568821|NCT02909673|Behavioral|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
75722133|NCT00865878|Drug|Aminolevulinic Acid|20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
75722134|NCT00865878|Other|Vehicle|Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
75722135|NCT00661622|Drug|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
75876331|NCT03623022|Drug|Normal saline|subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
75876332|NCT03666078|Procedure|cesarean delivery|women delivered by cesarean section
75876333|NCT03665376|Dietary Supplement|Carbohydrate drink load|Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
75876334|NCT03665376|Combination Product|Enhanced Recovery After Surgery (ERAS)|The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
75876335|NCT03003390|Drug|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given <24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
75423044|NCT05070429|Other|Clinic-based audiological rehabilitative service delivery|Participants will have scheduled clinic-based visits at 6 and 12 months post-randomization to reinforce self-management strategies and perform hearing aid checks.
75876336|NCT03003000|Drug|ibuprofen|
75876337|NCT03003000|Drug|caffeine|
75423045|NCT05070429|Other|Telehealth audiological rehabilitative service delivery|Participants' scheduled clinic-based visits will be complemented with asynchronous and synchronous telehealth that will allow for routine troubleshooting of communication challenges, hearing aid technical issues, and reinforcement of self-management support strategies. At an initial session, participants will be instructed in the use of a study-provided, internet-enabled tablet device for telehealth sessions, re-introduced to the hearing loss toolkit for self-management and C2Hear Reusable Learning Objects within the context of the telehealth platform, re-evaluated on the Client Oriented Scale of Improvement (COSI) goals. Two remote follow-up sessions will be scheduled 3 and 6 weeks later to confirm participants' comfort with the telehealth platform and then completed every 6 months, in addition to scheduled 6-month clinic-based visits.
75441702|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
75441703|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
75876338|NCT03003000|Drug|placebo|
75876339|NCT03665298|Behavioral|Smartphone Application|App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
75568822|NCT02937233|Biological|Zika Virus Purified Inactivated Vaccine|
75568823|NCT02937233|Other|Placebo|
75568824|NCT02909751|Drug|Epirubicin 90 mg/m2 iv|Max. 3 months
75568825|NCT02909751|Drug|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
75568826|NCT02909751|Drug|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
75876340|NCT03665220|Other|Ergonomic adjustments|The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form .
75876341|NCT03665220|Other|Kinesiotherapy plus ergonomic adjustments|This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
75876342|NCT03665220|Other|Healthcare education|This group received health education information, based on an illustrated manual with advice for patients with chronic stroke.
75876343|NCT03666156|Other|No intervention|No Intervention
76045408|NCT02512861|Drug|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients > 50 kgs"
76045409|NCT04980001|Behavioral|Families OverComing Under Stress Trauma Informed Care in Childhood Obesity among Minorities (FOCUS TIC-COM)|FOCUS TIC-COM is a program that helps doctors coach families to recognize how emotions or feelings about various life stressors may affect a child's dietary choices and physical activity. FOCUS TIC-COM is for families of children who have been identified by their doctor as overweight or obese. The goal of the program is to help children and their families understand how their mental health may impact their physical health and develop strategies to address their mental health needs.
76045410|NCT04979299|Other|Wheelchair|Patient will be asked to sit in a wheelchair, and a 5-minute video recording of spontaneous speech capturing the semi-structured iCGI interview is made.
76045411|NCT05012761|Drug|SR419 capsules|Ascending single and multiple doses of SR419 orally
75423046|NCT05067816|Behavioral|Med-South Lifestyle Program|The Med-South Lifestyle Program (MSLP) is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a southeastern US population and includes support for increased physical activity. To promote healthy dietary intake and increased physical activity, the intervention incorporates theory-based behavioral approaches targeting self-efficacy, self-regulation, and internal motivation. The MSLP is delivered in 4 monthly counseling sessions with 3 interim phone follow-up contacts. A maintenance phase lasting 6 months follows the 4-month MSLP and includes 2 phone contacts about 2 months apart. Participants are counseled individually, with 2 in-person counseling visits (at the 1st and 4th counseling visit) and 5 total phone contacts. Each participant is provided with program materials in a participant manual, a cookbook, and a local resource manual identifying community resources to support making targeted behavior changes.
75722136|NCT00661622|Procedure|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
75876344|NCT03514680|Behavioral|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
75876345|NCT04055454|Biological|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
75876346|NCT04055454|Other|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
75876347|NCT03665844|Device|SmartSleep Boost On|"SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS)."
75423047|NCT05064202|Device|Impella 5.5|temporary Mechanical Circulatory Support (tMCS)
75568827|NCT02909751|Drug|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
75722137|NCT00781820|Drug|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
75722138|NCT00781820|Drug|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
75876348|NCT03665844|Device|SmartSleep Boost Off|SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
75423048|NCT05064202|Drug|Inotropes|Enoximone, Dobutamine, Dopamine, Milrinone
75441704|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
75722139|NCT00786110|Drug|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
75568828|NCT02909751|Drug|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
75568829|NCT02909751|Dietary Supplement|Tocotrienol 300 mg x 3 daily|Max. 6 months
75568830|NCT02909829|Device|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm.
75722140|NCT00786110|Drug|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
75722141|NCT00781976|Drug|AZD7295|700mg per day maximum
75722142|NCT00781976|Drug|Placebo|matched placebo
75722143|NCT00782054|Other|Provase|NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
75722144|NCT00782054|Other|Control moisturizer|Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
75722145|NCT00791804|Drug|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~for nebulized administration as required by the patient.~Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
75722146|NCT00791882|Behavioral|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
75722147|NCT02544516|Other|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
76045412|NCT05012761|Drug|Placebo|Ascending single and multiple doses of placebo orally
75722148|NCT02544516|Other|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
75722149|NCT00791960|Drug|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
75722150|NCT00791960|Other|Placebo|single dose, 10 mL normal saline, IV
75876349|NCT04056390|Procedure|Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy|Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.
75441705|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
75722151|NCT00792194|Other|Exercise training|"Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day."
75722152|NCT00792350|Drug|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
75722153|NCT04046198|Other|Educational program|The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
75722154|NCT00792584|Drug|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
75722155|NCT00792584|Drug|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
75722156|NCT00782366|Genetic|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
75876350|NCT03665766|Drug|Cycloserine,Tacrolimus|
75876351|NCT03002610|Other|Pls|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
75876352|NCT03002610|Other|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
75876353|NCT03002610|Other|Scientific abstract|Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
76045413|NCT04979065|Dietary Supplement|Probiotics, Vitamin D|Combination of two supplement that given separately
75876354|NCT03665142|Other|Kinesio taping|Upper trapezius muscle stretching exercise with Kinesio taping (KT) was applied to the study group. KT was applied 8 times in total for 4 weeks with 2 sessions per week. Stretching exercise was done in the morning, afternoon and evening 3 times (repeated 10 times per set) every day for 4 weeks and 5 days of the week.
75876355|NCT03665142|Other|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
75876356|NCT03005106|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
76045414|NCT04979065|Other|Placebo|Placebo with inactive ingredient
75441706|NCT01637532|Drug|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
75441707|NCT01637532|Drug|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
75722157|NCT02556086|Drug|Daclatasvir|
75722158|NCT02556086|Drug|Sofosbuvir|
75722159|NCT00782522|Procedure|Eccentric training program|Eccentric training program
75722160|NCT00782522|Procedure|Traditional training program|Traditional training program
76045415|NCT02288559|Other|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
76045416|NCT02288559|Drug|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
76045417|NCT02288325|Drug|Levomilnacipran ER|Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.
75441708|NCT01637545|Drug|Ramosetron|"G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room~G3 - No medication but regular antiemetics injection if the patient want"
75722161|NCT00782600|Drug|suspension IR|50 mg IR suspension once daily for one day
76045418|NCT02288325|Drug|Placebo|Dose-matched placebo taken orally once daily.
76045419|NCT02509117|Drug|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
76045420|NCT02509117|Drug|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
76045421|NCT02509117|Drug|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
76045422|NCT02509117|Drug|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
76045423|NCT02509117|Drug|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
76045424|NCT02509117|Drug|PF-06751979 multiple dose|Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
75722162|NCT00782600|Drug|CR 1|50 mg shorter release CR once daily for one day
75876357|NCT03005106|Procedure|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
76045425|NCT01654549|Drug|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
75722163|NCT00782600|Drug|CR 2|50 mg medium release CR once daily for one day
75722164|NCT00782600|Drug|CR 3|longer release SR formulation once daily for one day
75722165|NCT00786266|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
75722166|NCT00786266|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
75722167|NCT04093752|Drug|Tirzepatide|Administered SC
75722168|NCT04093752|Drug|Insulin Glargine|Administered SC
75423049|NCT05063201|Drug|Cariprazine 1.5 MG|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
75876358|NCT01004861|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
75441709|NCT01637558|Drug|8 hourly LPV/r during TB treatment|8 hourly LPV/r during TB treatment
75722169|NCT00865956|Behavioral|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
75722170|NCT00865956|Other|Case management|Nurse case manager assigned to participant
75722171|NCT02545062|Other|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
75722172|NCT00866112|Other|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
75722173|NCT00866112|Other|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
75722174|NCT00862602|Behavioral|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet & nutrition and prevention.
75722175|NCT00858156|Drug|BG9928|Oral 75 mg single dose
75722176|NCT00858312|Other|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
75722177|NCT00858312|Other|Low Dairy|less than 1 serving of dairy foods per day.
75722178|NCT00862680|Procedure|4-Dimensional Computed Tomography|Undergo 4D PET/CT
76045426|NCT04978051|Drug|Firazyr|Icatibant 10 MG/ML Prefilled Syringe
76045427|NCT04978051|Other|SoC|The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
76045428|NCT04214353|Diagnostic Test|68Ga-PSMA-PET/CT|All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
76045429|NCT04214353|Diagnostic Test|18FDG-PET/CT|All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
76045430|NCT04977817|Dietary Supplement|Similac Probiotic Tri-Blend|Probiotic dietary supplement, Similac Probiotic Tri-Blend
76045431|NCT04977739|Diagnostic Test|No intervention|No intervention
76045432|NCT04976803|Other|Determination of ATM alteration status.|ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
75441710|NCT01637558|Drug|Nevirapine|
75441711|NCT01637558|Drug|Lopinavir/Ritonavir|
75441712|NCT01637571|Drug|Dexilant|60mg of Dexilant QD for 12 weeks
75441713|NCT01637571|Drug|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
75441714|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 12
75441715|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 6
75722179|NCT00862680|Procedure|4D PET Scan|Undergo 4D PET/CT scan
75722180|NCT02544282|Drug|Levobupivacaine|Pecs II Block
76045433|NCT02508649|Drug|selepressin|
76045434|NCT02508649|Drug|placebo|
76045435|NCT05010421|Drug|Clobetasol 0.05% Emollient Top Cream|Topical corticosteroid treatment of affected vulvar skin areas.
76045436|NCT05010421|Device|Non-ablative CO2 Laser|Superficial non-ablative laser treatment of affected vulvar skin areas.
76045437|NCT02504827|Drug|Ceftazidime/avibactam|Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
76045438|NCT02504671|Drug|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
76045439|NCT02504671|Drug|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
76045440|NCT02504671|Drug|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
75722181|NCT02544282|Drug|NaCl 0.9%|Placebo Pecs II block
75722182|NCT02544282|Drug|Sevoflurane|General Anesthesia
75722183|NCT02544282|Drug|Propofol|General Anesthesia
76045441|NCT02504671|Drug|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
75722184|NCT02544282|Drug|Sufentanil|General Anesthesia
76045442|NCT02314143|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
76045443|NCT02314143|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
76045444|NCT02288091|Drug|Inosine|Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
75568831|NCT02909829|Device|Closed Loop Delivery with Meal Detection Module|Closed Loop Delivery with Meal Detection Module Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm
76045445|NCT04420065|Device|Preferential left ventricular pacing|Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients
75568832|NCT02909829|Device|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate
76045446|NCT04420065|Device|Biventricular pacing|Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
76045447|NCT04973527|Drug|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
75722185|NCT02544282|Drug|Atracurium|General Anesthesia
75423050|NCT05063201|Drug|Placebo|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
75423051|NCT05062304|Drug|Fluticasone Furoate-Vilanterol Trifenatate|Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.
75423052|NCT05062304|Drug|Furoate-umeclidinium-vilanterol|Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.
75423053|NCT05058638|Drug|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
75423054|NCT05057091|Other|Lomber roll techniques group (n=23)|Direct manipulation will be applied to the lumbar region with the lumbar Roll technique. Painful segment will be determined.
75441716|NCT01637636|Drug|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
75722186|NCT02544282|Drug|Paracetamol|Pain Relief
75568833|NCT02909712|Drug|sulfadoxine-pyrimethamine (SP)|"Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:~3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing."
76045448|NCT05009329|Drug|JAB-21822|JAB-21822 will be administered orally
76045449|NCT05009329|Drug|JAB-21822|JAB-21822 will be administered orally
76045450|NCT04972279|Behavioral|Digital message (text + image)|"Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
76045451|NCT02503501|Drug|Insulin glulisine|
75722187|NCT02544282|Drug|Tramadol|Pain Relief
75722188|NCT02544282|Drug|Piritramide|Pain Relief
75722189|NCT00866190|Drug|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
75722190|NCT00866190|Drug|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
75722191|NCT05227482|Radiation|Personalized dosimetry approach|The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
75722192|NCT05227482|Radiation|Standard dosimetry approach|The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
75722193|NCT04041804|Procedure|semirapid maxillary expansion (SRME)|A Banded Hyrax is going to be used in order to provide an increase in the maxillary transverse dimension
75876359|NCT03637361|Drug|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
75722194|NCT00858546|Device|Repetitive transcranial stimulation|Repetitive transcranial stimulation
75722195|NCT04041648|Drug|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
75423055|NCT05057091|Other|Posterior- anterior central vertebral manipulation techniques (n=23)|After initial assessments were made, both groups had high velocity and low amplitude (HVLA) or V. Level manipulation will be applied in the form of 2 different direct manipulation techniques
75423056|NCT05047068|Device|OCS Heart System|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
75423057|NCT05045534|Drug|Comparison of TB-840 treatment with Placebo|Single dose or Multiple Dose of TB-840 treatment
75423058|NCT05030324|Drug|XC221 100 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
75441717|NCT01637636|Drug|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
75722196|NCT04041648|Device|L606 Inhalation System|Single ascending dose
75722197|NCT04041648|Other|Placebo Solution|Single ascending dose
75722198|NCT02544360|Behavioral|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
75722199|NCT00862758|Drug|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
75722200|NCT03928821|Biological|PGT121|20 mg/kg administered intravenously
75722201|NCT03928821|Biological|PGDM1400|20 mg/kg administered intravenously
75722202|NCT03928821|Biological|10-1074|20 mg/kg administered intravenously
75876360|NCT03637361|Drug|Placebo|
75722203|NCT03928821|Biological|VRC07-523LS|20 mg/kg administered intravenously
75722204|NCT00666224|Drug|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
75722205|NCT00666224|Drug|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
75722206|NCT00666224|Drug|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
75876361|NCT03637673|Other|No intervention|No intervention
75876362|NCT00038675|Drug|Imatinib Mesylate (Gleevec)|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
75876363|NCT02974907|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
75876364|NCT02974907|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
75876365|NCT03254459|Drug|Buprenorphine Sublingual Spray|0.5 mg Sublingual Spray
75876366|NCT03254459|Drug|Morphine|4 mg Intravenous Injection
75568834|NCT02909712|Drug|dihydroartemisinin-piperaquine (DHA-PQP)|Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
75876367|NCT03254459|Drug|Oxycodone Hydrochloride|10 mg tablet
75876368|NCT03254459|Drug|Zofran|4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
75568835|NCT02913885|Drug|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
75876369|NCT03620591|Drug|Lidocaine|Intraoperative administration of lidocaine
75876370|NCT03620591|Drug|Placebo|Intraoperative administration of normal saline
75876371|NCT03637283|Procedure|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
75423059|NCT05030324|Drug|XC221 200 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
75423060|NCT05030324|Drug|Placebo|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
75423061|NCT05029466|Drug|Psilocybin|Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.
75441718|NCT01637662|Drug|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
75568836|NCT02913885|Drug|fluoride varnish|fluoride inhibit the progression of white spot lesion
75568837|NCT01290601|Drug|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
75876372|NCT03637283|Procedure|fan-shaped photocoagulation|vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
75876373|NCT04363463|Other|prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
75876374|NCT05178953|Drug|Zinc Sulfate 220 mg Capsules|Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
76045452|NCT02503501|Drug|Placebo|Bacteriostatic 0.9% Sodium Chloride
75876375|NCT05178953|Drug|Pentoxifylline|Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
75876376|NCT02736617|Drug|Ibrutinib|Given PO
75722207|NCT00866268|Device|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
75876377|NCT02736617|Biological|Obinutuzumab|Given IV
75876378|NCT05178719|Device|PMA-zeolite|given for a total period of 4 years
75876379|NCT03637907|Other|Not applicable - no intervention.|No intervention is performed, just a CT with a new detector and comparison with the same patients older image.
75876380|NCT05572619|Device|1st Reading|The medical team visually checks the non-contrast CT without cELVO and diagnose the large vessel occlusion.
75568838|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
75568839|NCT01290601|Drug|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
75876381|NCT05572619|Device|2nd Reading|The medical team visually checks the non-contrast CT with assistance from the cELVO and diagnose the large vessel occlusion.
75568840|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
75423062|NCT05018481|Drug|Sodium Hyaluronate|Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
75423063|NCT05018481|Drug|Placebo|A placebo will be given in capsule form to study participants
75423064|NCT05017649|Biological|Blood sample|Blood sampling.
75722208|NCT00866268|Device|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
75722209|NCT00866346|Biological|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
75876382|NCT04670393|Dietary Supplement|FertyBiotic Woman Plus|4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum
75876383|NCT04670393|Other|Placebo|400 mcg folic acid
75876384|NCT05178251|Procedure|appendectomy|appendectomy for acute appendicitis
75876385|NCT03251963|Drug|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
75876386|NCT03251963|Drug|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
75876387|NCT03287219|Drug|Methylene Blue MMX 25 mg modified release tablets|Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
75876388|NCT03286751|Drug|LY900014|Administered SC
75876389|NCT03286751|Drug|Insulin Lispro|Administered SC
75876390|NCT03249935|Drug|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
75876391|NCT05572151|Procedure|lymph node number|Lymph nodes were harvested during surgical resection of rectal cancer
75423065|NCT05007795|Diagnostic Test|Targeted sequencing using the GenoScreen Deeplex assay|Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.
75568841|NCT02978391|Device|UI-EWD Hemostatic system|Adhesive endoscopic hemostats, powder type
75876392|NCT03622073|Other|Misoprostol treatment by Midwife|Medical management of incomplete abortion
76045453|NCT04971889|Behavioral|Diabetes MNT|Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake
76045454|NCT04971889|Behavioral|Motivational Interviewing|Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise
75568842|NCT02978391|Drug|epinephrine endoscopic injection (conventional therapy)|endoscopic submucosal injection of epinephrine (1: 10,000)
76045455|NCT05007613|Drug|Cabozantinib 40 MG|Cabozantinib (Cabometyx) 40 MG PO QD
76045456|NCT05007613|Drug|Atezolizumab Injection|atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
75568843|NCT01290523|Device|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
76045457|NCT04971265|Behavioral|Low SES/High Supports|Participant will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
75568844|NCT02936882|Procedure|Preoperative gastric ultrasonography|Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
75568845|NCT01290094|Drug|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
76045458|NCT04971265|Behavioral|Low SES/ Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
76045459|NCT04971265|Behavioral|High SES/High Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
75568846|NCT04324957|Other|Neonatal cardio-pulmonary outcome measure used to assess cardio-pulmonary status|Neonatal cardio-pulmonary outcome measure will be used to assess overall status of pulmonaryand cardio-vascular system
75876393|NCT03622073|Other|Misoprostol treatment by Doctor|Medical management of incomplete abortion
75876394|NCT03285113|Device|GiMer Medical MN 1000 External Stimulator|Trial stimulator to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
75876395|NCT03000348|Drug|Cysteamine|Oral Cysteamine Capsule
75876396|NCT03000348|Drug|Placebo Oral Capsule|Placebo Oral Capsule
75876397|NCT03283709|Device|Full-contour monolithic zirconia abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from monolithic multi-layered zirconia
75876398|NCT03283709|Device|Conventional abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from noble or high noble metals, veneered with feldspathic porcelain
75568847|NCT04688346|Drug|HemeRX epinephrine pellets|Racemic Epinephrine Pellet
75568848|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
75568849|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / Squale.|Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
75568850|NCT04324333|Behavioral|Digital wearable system|Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
75568851|NCT04688268|Drug|deep neuromuscular blockade|Train of Four=0/4, Post tetanic count 1-2
75568852|NCT02936726|Behavioral|Exercise, Health Coaching and Meditation|Comparing Exercise, Health Coaching and Meditation In Combination
75568853|NCT02936726|Behavioral|Exercise and Health Coaching|Comparing Exercise and Health Coaching Alone
75568854|NCT02913846|Other|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
75568855|NCT02913846|Other|Muscular assessment|An assessment of muscular force will be performed once a week.
75568856|NCT02913846|Other|Pre-albumine dosage|Dosage performed once a month.
75568857|NCT04762589|Drug|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
75423066|NCT05006885|Drug|ALT-801|Injected subcutaneously (SC)
75423067|NCT05006885|Other|Placebo|Injected subcutaneously (SC)
75423068|NCT05002088|Device|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement
75423069|NCT05001750|Drug|long term prophylactic antibiotics (Nafcillin or Doxycycline)|VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
75423070|NCT04994665|Procedure|sleeve gastrectomy|The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed
75423071|NCT04994665|Procedure|sleeve gastrectomy with omentopexy|After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
75423072|NCT04984473|Device|Inspiratory muscle training|Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
75722210|NCT00866424|Procedure|Hyperbaric oxygen, Mock hyperbaric chamber|"Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.~Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.~Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars."
75722211|NCT00663962|Drug|Pregabalin|"PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op."
75568858|NCT04762589|Drug|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
75423073|NCT04982575|Drug|Semaglutide 2.4 mg|Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
75423074|NCT04982575|Drug|Cagrilintide 2.4 mg|Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
75568859|NCT01289821|Drug|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
75568860|NCT01289821|Drug|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m^2 oxaliplatin as a 2 hour i.v. infusion.
76045460|NCT04971265|Behavioral|High SES/Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
76045461|NCT04970407|Biological|Botulinum toxin type A|Intramuscular Injection, concentration 300 units (U)
76045462|NCT04970407|Biological|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
76045463|NCT04970407|Biological|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
76045464|NCT02502097|Drug|Gefapixant|Gefapixant 50 mg tablet, administered by mouth
76045465|NCT02502097|Other|Placebo|Matching placebo to gefapixant, tablet administered by mouth
76045466|NCT02501629|Drug|Reslizumab|Reslizumab 110 mg was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
75423075|NCT04982575|Drug|Placebo (semaglutide)|"Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
75423076|NCT04982575|Drug|Placebo (cagrilintide)|"Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
75423077|NCT04979884|Drug|cyclosporine|Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
75423078|NCT04971304|Drug|Receipt of granulocyte-colony stimulating factor|Receipt of originator or biosimilar
75423079|NCT04968366|Biological|Autologous dendritic cells pulsed with multiple neoantigen peptides.|Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides. DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation. After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections. For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response. According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness
75423080|NCT04968366|Drug|Temozolomide adjuvant chemotherapy|Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
75423081|NCT04962061|Other|Cognitive Training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
75441719|NCT01637675|Drug|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
75568861|NCT01289821|Drug|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2 hour i.v. infusion.
75568862|NCT01289821|Drug|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m^2 5 FU 46 hour i.v. infusion.
75568863|NCT02913768|Drug|Ondansetron|
75568864|NCT02913768|Drug|Normal saline|
75722212|NCT00663962|Drug|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
76045467|NCT02501629|Drug|Placebo|Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
76045468|NCT02501629|Drug|Non-Oral Corticosteroid (non-OCS) Asthma Medication|Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
76045469|NCT02501629|Drug|Oral Corticosteroid (OCS)|After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
76045470|NCT04969549|Other|Theta burst stimulation|It consists of 20 sessions of iTBS over the dlPFC.
75568865|NCT03457844|Drug|Anlotinib|Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
75568866|NCT03457805|Device|Prostatic Artery Embolization|PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
75722213|NCT00866502|Drug|sNN0031|Continuous ICV infusion for two weeks
75722214|NCT00866502|Drug|Placebo|Continous ICV infusion
76045471|NCT02501473|Drug|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
76045472|NCT02501473|Drug|Pembrolizumab|PD-1 Inhibitor
76045473|NCT02501473|Drug|Rituximab|Rituximab (anti-CD20 antibody)
76045474|NCT02501161|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
76045475|NCT02501161|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
76045476|NCT02500537|Device|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
76045477|NCT05003635|Device|EVEBRA device|Wear 2 weeks pre-operatively for a total duration of 200 hours. Wear 2 weeks post-operatively for 10 hours a day.
75722215|NCT00975117|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) twice a day, for 12 weeks.
75722216|NCT00975117|Dietary Supplement|Spermotrend|One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
75876399|NCT03664986|Drug|Liposomal Bupivacaine|The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
75876400|NCT03492918|Drug|Pembrolizumab|"Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.~All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min)."
75876401|NCT03247673|Drug|CT-P16|CT-P16 is a biosimilar product for Avastin
75876402|NCT03247673|Drug|EU-approved Avastin|EU-approved Avastin
75568867|NCT04690283|Drug|Mimetic granules of Yiqi-Wenjing prescriptions|The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.
75568868|NCT04690283|Drug|Huangqi-Guizhi-Wuwu granules|The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.
75568869|NCT04690283|Drug|Danggui-Sini granules|The intervention relates to a traditional Chinese prescription granules, which contains angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root.
75568870|NCT02913534|Radiation|whole brain radiotherapy|
75568871|NCT02936804|Device|Low Dose Computed Tomography|LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
75722217|NCT00786344|Behavioral|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
75876403|NCT03247673|Drug|US-licensed Avastin|US-licensed Avastin
75876404|NCT03665610|Drug|ozanimod|ozanimod
75876405|NCT03665532|Behavioral|Youth Engagement in Services|Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
75876406|NCT03664908|Other|Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).|biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.
75876407|NCT03622944|Procedure|Muscle Energy Technic|post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
75876408|NCT03622944|Procedure|Deep Friction Massage|deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
75876409|NCT03622944|Procedure|Exercise|spinal stabilization exercise were applied three sessions in a week totally six weeks.
75876410|NCT03247517|Drug|Placebo|Placebo was administered once daily
75876411|NCT03247517|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
75876412|NCT03247517|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
75876413|NCT03665454|Drug|PF-06412562|PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
75876414|NCT03665454|Drug|Standard of Care Placebo|25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
75876415|NCT03664440|Drug|Nevirapine|Patients were randomized 1:1 to continuation arm (NVP-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
75876416|NCT03664440|Drug|Rilpivirine|Patients were randomized 1:1 to switch arm (NVP-based regimens were switched to RPV-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
75876417|NCT03663738|Behavioral|mobile app NOVAME|The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
75876418|NCT03283553|Other|Checklist, MyChart, OpenNotes|1) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.
76045478|NCT04966819|Other|Survivorship Care Initiative|"The survivorship initiative will consist of:~(A) Regular meetings with the rectal cancer oncology pivot nurse (IPO). These meetings present an opportunity for patients to discuss any treatment-related distress or late and long-term side-effect.~(B) Identification of a primary care physician. If the patient is not known to a Primary care physician (PCP), the IPO will add the patient to an accelerated waitlist.~(C) Development of an individualized survivorship plan. During meetings with the oncology pivot nurse, a survivorship care plan will be populated, included information on patient risk factors, treatments completed, pathology findings, and future surveillance planned. This document will be reviewed by the treating colorectal surgeon, and will be subsequently shared with the oncology team, the PCP and the patient (if the patient desires).~(D) Educational resources for patients. Patients will be offered educational materials to help address their specific needs."
75876419|NCT03283553|Other|Usual Care|Routine medical oncology care
75876420|NCT03664596|Dietary Supplement|Sublimated mare's milk|Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
75876421|NCT03664596|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid in the form of 250 mg capsule.
75876422|NCT03283319|Biological|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
75876423|NCT03283319|Biological|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
75876424|NCT03283319|Biological|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
75876425|NCT03283319|Biological|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
75876426|NCT03283319|Biological|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
75876427|NCT03549533|Other|samples of sperm|As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
75876428|NCT03637829|Other|Control|Water
75876429|NCT03637829|Other|White chocolate|Experimental snack treatment
75876430|NCT03637829|Other|Dark chocolate 1|Experimental snack treatment
75876431|NCT03637829|Other|Dark chocolate 2|Experimental snack treatment
75876432|NCT03282227|Drug|M207 Microneedle System|M207 Microneedle System 3.8 mg
75876433|NCT04696835|Diagnostic Test|speech audiometry|65dB, 55dB or 75dB SPL speech audiometry
75876434|NCT05158127|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
76045479|NCT02498821|Device|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
75722218|NCT00858624|Drug|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
75876435|NCT05157035|Behavioral|Mindfulness/Acceptance-Based Smartphone App (MABSA)|This is a mindfulness- and acceptance-based smartphone app. The mindfulness and acceptance exercises embedded in the app are based on the principles of Acceptance and Commitment Therapy. Participants in the intervention group will be using the app for 6 weeks. They are expected to access the meditations and mindfulness exercises within the app on a daily basis.
75876436|NCT05571605|Behavioral|Exercise|Participants randomized to this arm will exercise on a stationary bicycle.
76045480|NCT02498821|Device|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
75568872|NCT02913807|Procedure|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
75722219|NCT04008459|Other|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
75722220|NCT00782990|Procedure|Surgical treatment: TVT|
75722221|NCT00782990|Procedure|Surgical treatment: colposuspension|
75722222|NCT00960453|Drug|Sitagliptin|"Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods"
75722223|NCT00265759|Drug|anastrozole|Given PO
75722224|NCT00265759|Drug|exemestane|Given PO
76045481|NCT02498821|Procedure|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
75568873|NCT02913807|Procedure|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
75568874|NCT02936570|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-067)"
75568875|NCT01289782|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
75568876|NCT01289782|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
75722225|NCT00265759|Drug|letrozole|Given PO
75722226|NCT00265759|Procedure|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
75722227|NCT00786500|Dietary Supplement|Gynostemma pentaphyllum tea|3 grams twice daily, orally
75722228|NCT00786500|Dietary Supplement|Placebo tea|3 grams twice daily, orally
75722229|NCT00972387|Dietary Supplement|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
75722230|NCT00972387|Dietary Supplement|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
75722231|NCT00972387|Dietary Supplement|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
75568877|NCT01289782|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
75568878|NCT01289782|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
75568879|NCT02913417|Device|SIR-Spheres® Yttrium 90|Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
75568880|NCT02913417|Drug|ipilimumab|ipilimumab 1mg/kg every 3 weeks x 4
75568881|NCT02913417|Drug|nivolumab|nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
75568882|NCT02936492|Drug|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
75568883|NCT02936492|Drug|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
75568884|NCT02936492|Drug|BAY1003803 0.01% ointment|Topical administration for 22 h per day
75568885|NCT02936492|Drug|BAY1003803 0.1% ointment|Topical administration for 22 h per day
75568886|NCT02936492|Drug|Lipophilic cream vehicle|Topical administration for 22 h per day
75568887|NCT02936492|Drug|Ointment vehicle|Topical administration for 22 h per day
75876437|NCT05571605|Behavioral|Stretching|Participants randomized to this arm will perform stretching and balance exercise.
75568888|NCT02936492|Drug|Clobetasol propionate|Topical administration for 22 h per day
75568889|NCT02913573|Device|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
76045482|NCT04205539|Drug|Dexmedetomidine|This medication will be administered sublingually using an LMA Intranasal Mucosal Atomization Device, which allows the medication to be administered in the form of a spray. Patients will be instructed to keep the medication in their mouth for about 2 minutes, or until fully absorbed. Pulse oximetry and blood pressure will be monitored throughout the duration of treatment. After the subject is asleep, the second DTI scan will be done.
76045483|NCT02313909|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
75876438|NCT03240575|Drug|Tiotropium|Fixed Dose Combination
76045484|NCT02313909|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|100 mg, once daily, orally, tablet
76045485|NCT02313909|Other|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
76045486|NCT02313909|Other|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
76045487|NCT02287467|Biological|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
75568890|NCT02913573|Drug|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
75568891|NCT01289353|Drug|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
75876439|NCT03240575|Drug|Olodaterol|Fixed Dose Combination
75876440|NCT03240575|Drug|Fluticasone propionate|Fixed Dose Combination
75568892|NCT01289353|Radiation|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
75568893|NCT02913651|Device|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
75568894|NCT02936414|Drug|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
75568895|NCT02936414|Drug|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
75568896|NCT02913300|Drug|Lignocaine 1% concentration solution|
75568897|NCT02913300|Drug|Lignocaine 2% concentration solution|
75568898|NCT02936375|Drug|Iguratimod|25mg twice a day, orally administrated
75568899|NCT02936375|Drug|Cyclophosphamide|1g/m², every 4 weeks, intravenous
75876441|NCT03240575|Drug|Salmeterol|Fixed Dose Combination
76045488|NCT02287467|Biological|Placebo for IVIG|Administered IV as 500 mL of normal saline
76045489|NCT02287233|Drug|Venetoclax|Venetoclax will be taken orally once daily.
76045490|NCT02287233|Drug|Cytarabine|Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
76045491|NCT01646385|Drug|etanercept|use as per routine clinical practice
76045492|NCT01646385|Drug|non-biologic anti-rheumatic drugs|use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
76045493|NCT02286843|Radiation|89Zr-trastuzumab|
75441720|NCT01637675|Drug|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
75568900|NCT02936375|Drug|Azathioprine|2mg/kg·d, once a day, orally administrated
76045494|NCT02286843|Device|PET/CT scan|
75568901|NCT02936375|Drug|Steroids|Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
76045495|NCT02286843|Radiation|89Zr-pertuzumab|
75568902|NCT02913690|Dietary Supplement|Placebo|2 x 150mg capsules daily
75568903|NCT02913690|Dietary Supplement|TRF|2 x 150mg capsules daily
75722232|NCT00972387|Dietary Supplement|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
75568904|NCT01289119|Drug|Alogliptin|Alogliptin tablets
75722233|NCT00866580|Biological|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
75722234|NCT00866580|Biological|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
75722235|NCT00866580|Biological|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
75722236|NCT00744263|Biological|VACCINE: placebo|0.5 mL, single intra-muscular injection
75722237|NCT00744263|Biological|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
75722238|NCT00975273|Behavioral|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
76045496|NCT02282163|Drug|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
76045497|NCT02281773|Drug|BI 409306 100 mg QD|
75568905|NCT01289119|Drug|Placebo to alogliptin|Alogliptin placebo-matching tablets.
75568906|NCT01289119|Drug|Metformin|Stable metformin dose
75722239|NCT00975273|Behavioral|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
75722240|NCT00783068|Drug|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
75876442|NCT05571371|Other|Measuring inflammatory serum biomarkers|Measuring inflammatory serum biomarkers
76045498|NCT02281773|Drug|BI 498306 50 mg QD|
76045499|NCT02281773|Drug|Placebo|
76045500|NCT02281773|Drug|BI 498306 25 mg QD|
76045501|NCT02281773|Drug|BI 409306 10 mg QD|
76045502|NCT02285361|Drug|GIOTRIF 20mg|NSCLC with GIOTRIF 20mg
76045503|NCT02285361|Drug|GIOTRIF 40mg|NSCLC with GIOTRIF 40mg
76045504|NCT02285361|Drug|GIOTRIF 30mg|NSCLC with GIOTRIF 30mg
76045505|NCT02354235|Drug|Teneligliptin|
75441721|NCT01637701|Procedure|PkEP|Plasmakinetic enucleation of the prostate
75441722|NCT01637701|Procedure|B-TURP|Bipolar transurethral resection of the prostate
75441723|NCT01637714|Drug|Multi-strain probiotics|"B. longum BORI: 1 x 109~B. bifidum BGN4: 1 x 109~B. lactis AD011: 1 x 109~B. infantis IBS007: 1 x 109~Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water"
75568907|NCT01289119|Drug|Pioglitazone|Stable pioglitazone dose
75568908|NCT02936336|Other|exercise|circuit exercise, aerobic dance and Tai Chi exercise
76045506|NCT02354235|Drug|Canagliflozin|
76045507|NCT02354235|Drug|Placebo|
76045508|NCT02280291|Drug|Ankle SSB|general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
76045509|NCT02280291|Drug|Ankle OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
76045510|NCT02280291|Drug|DR SSB|general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
75876443|NCT03385265|Behavioral|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
75876444|NCT03385265|Other|Standard of Care|Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
75568909|NCT02913378|Procedure|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
75876445|NCT05571449|Procedure|Open reduction and internal fixation|Internal fixation of the fracture
75876446|NCT05571449|Procedure|Standard osteosynthesis planning|Plain radiograph and CT images are used
75876447|NCT05571449|Procedure|3-D model osteosynthesis planning|A 3D plastic model made from CT images is used
75876448|NCT03280121|Device|EsophyX ZR transoral device|TIF
75876449|NCT03233009|Other|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
76045511|NCT02280291|Drug|DR OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
75568910|NCT02913378|Procedure|Sling|Conservative treatment with sling and rehabilitation
75568911|NCT02936141|Behavioral|Group psychotherapy|Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
76045512|NCT02284893|Drug|Saxagliptin|administered orally once daily
76045513|NCT02284893|Drug|Dapagliflozin|administered orally once daily
76045514|NCT02284893|Drug|Sitagliptin|administered orally once daily
76045515|NCT02284893|Drug|Placebo matching with Saxagliptin|administered orally once daily
76045516|NCT02284893|Drug|Placebo matching with Dapagliflozin|administered orally once daily
76045517|NCT02284893|Drug|Placebo matching with Sitagliptin|administered orally once daily
76045518|NCT02284347|Device|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
75441724|NCT01637714|Drug|Placebo powder|"same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water"
75441725|NCT01637753|Drug|Carmustine(BCNU)|Carmustine Sustained Release Implant
75568912|NCT02913339|Other|mHealth Risk Assessment|Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
75568913|NCT02936180|Biological|HD-TIV|
75568914|NCT02936180|Biological|SD-QIV|
75568915|NCT01289041|Drug|BKM120|
75876450|NCT03233009|Other|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
75876451|NCT03233009|Other|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
75876452|NCT03233009|Other|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
76045519|NCT02279043|Behavioral|Interaction with users of IUC and non-IUC users|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users."
75568916|NCT02913183|Drug|young Fresh Frozen Plasma|Blood plasma from healthy male donors aged 18-30 years old.
75441726|NCT01637753|Procedure|Surgery|Routine tumor resection surgery
75568917|NCT02913183|Drug|old Fresh Frozen Plasma|Blood plasma from healthy male donors aged 40-55 years old.
75568918|NCT01288729|Device|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
75568919|NCT01288729|Device|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
75568920|NCT02936258|Procedure|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
75568921|NCT02936258|Procedure|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
75876453|NCT03233009|Other|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
75876454|NCT04034225|Drug|SNS-301|Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
75876455|NCT04034225|Drug|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
75876456|NCT05571215|Device|Transcranial Direct Current Stimulation|Five sessions of tDCS will be performed following completions of baseline data collection. This will include 3 sessions during week one and 2 sessions in week 2. A tDCS unit (neuroConn Ilmenau, Germany) will be applied to the left DLPFC with participants in the sitting position for a 20 minutes of tDCS. An anodal 2.0 mA current will be applied to each participant, including a 30-second ramp up at the beginning of stimulation and a 30 second ramp down period and the end of stimulation. The left DLPFC (F3 from EEG 10/20 system) will be located using the Beam F3 measurement system. These parameters are consistent with those used in current literature on tDCS for pain. tDCS procedures will be performed by the PI (CA).
75876457|NCT05571215|Behavioral|Pain Neuroscience Education|Immediately following completion of each tDCS intervention, participants will be given a one-on-one PNE session provided also by the PT (CA), who is a licensed healthcare provider with expertise in delivery of the content. This educational session will last about 30 minutes. Initial sessions will involve discussion and questioning of participants about their own understanding of their pain and this information will be used to subsequently individualize the forthcoming educational sessions. The educational sessions will follow the content of Explain Pain, a patient booklet, and will include information on the neurophysiology of pain, pain as typical process, the transition from acute to chronic pain, neuroplasticity, central sensitization, factors that promote pain chronicity. Information will be presented verbally along with visuals on paper.
75876458|NCT03690947|Drug|Intravitreal Ranibizumab|All subjections received 3 initial Ranibizumab injections
75876459|NCT03690947|Procedure|Micropulse Laser|After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
75876460|NCT03690947|Drug|Intravitreal Ranibizumab as needed|After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
75568922|NCT02936258|Procedure|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
75568923|NCT01288612|Device|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
75568924|NCT01288612|Device|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
75568925|NCT02913027|Other|External Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam."
75568926|NCT02913027|Other|Bimanual Exam|
75441727|NCT01637766|Drug|Melphalan (intra-arterial infusion)|"Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.~The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.~The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.~We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts."
75441728|NCT01637779|Behavioral|Fact sheet|fact sheet about pain management during immunization
75441729|NCT01637792|Other|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
75722241|NCT00783068|Drug|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
75722242|NCT00783068|Drug|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
75876461|NCT01313741|Device|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
75876462|NCT02999178|Drug|Nintedanib|
75876463|NCT02999178|Drug|Placebo|
75876464|NCT02959190|Drug|Galcanezumab|Administered SC
75876465|NCT02031614|Procedure|Phlebotomy|Withdrawal of 500 mL of whole blood.
75876466|NCT01344356|Radiation|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
75876467|NCT01344356|Radiation|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
75568927|NCT02913027|Other|Speculum Exam|
76045520|NCT02279043|Behavioral|Interaction with non-IUC users only|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions."
75722243|NCT00866736|Drug|dasatinib|100mg QD
75423082|NCT04962061|Other|Aerobic and resistance exercises|Participants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
75423083|NCT04962061|Other|Stretching and Toning|Participants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
75423084|NCT04951115|Drug|Carboplatin|AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles
75722244|NCT02532049|Biological|ChAd63 Pfs25-IMX313|
75423085|NCT04951115|Drug|Cisplatin|75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles
75722245|NCT02532049|Biological|MVA Pfs25-IMX313|
75423086|NCT04951115|Drug|Etoposide|80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles
75423087|NCT04951115|Drug|Durvalumab|1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression
75568928|NCT04323982|Procedure|new surgical procedure|（ACCC + I / A + PCCC + TA+ A-vit) or （ACCC + I / A + PCCC + IOL + TA + A-vit）
75722246|NCT04008849|Other|Safety and efficacy assessments|Long term safety and clinical outcomes
75722247|NCT00792818|Drug|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
75722248|NCT00792818|Drug|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
75722249|NCT00972465|Drug|Nimotuzumab and chemotherapy|"Experimental: Nimotuzumab and Irinotecan~the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)~the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)"
75722250|NCT00975351|Dietary Supplement|13C5-labelled 5-methyltetrahydrofolic acid|"one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention."
75568929|NCT04323982|Procedure|traditional surgical procedure|（ACCC + I / A + PCCC + A-vit) or （ACCC + I / A + PCCC + IOL + A-vit）
75568930|NCT02936297|Dietary Supplement|High dose Gluten|
75568931|NCT02936297|Dietary Supplement|Low dose Gluten|
75568932|NCT02936297|Dietary Supplement|Lactose free placebo|
76045521|NCT02283411|Device|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
75722251|NCT01071187|Drug|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
75722252|NCT01071187|Drug|Placebo|Placebo
75722253|NCT00618774|Drug|telmisartan40/amlodipine5|
75722254|NCT00618774|Drug|telmisartan80/amlodipine5|
75722255|NCT04008693|Dietary Supplement|Aged Garlic Extract|2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)
75722256|NCT04008693|Other|Placebo|800 mg of maltodextrin (four capsules)
76045522|NCT02351817|Device|Test A|Ostomy appliance
76045523|NCT02351817|Device|Test B|Ostomy appliance
76045524|NCT02351817|Device|Baseline|Ostomy appliance
75568933|NCT01287832|Drug|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
75568934|NCT01287832|Drug|Daptomycin|
75722257|NCT00792896|Behavioral|family conference|family conference
75722258|NCT01071265|Procedure|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
75722259|NCT01071265|Procedure|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
75876468|NCT03640130|Behavioral|Gaze-contingent text enhancement|"In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight."
75423088|NCT04951115|Radiation|Stereotactic Body Radiotherapy|6 Gy of radiotherapy targeting multiple sites of intrathoracic disease on Days 1-5 of cycle 1.
75423089|NCT04949503|Drug|nimotuzumab|Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
75423090|NCT04944043|Drug|TQ05105 Tablet|TQ05105 tablet is a Janus Kinase (JAK) inhibitor, which can inhibit the abnormal activation of JAK 2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK / STAT pathway.
75722260|NCT00792974|Behavioral|A brief psycho-educational intervention|"A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.~This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment."
75876469|NCT03618992|Other|Cholesterol-containing moisturizers|Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
76045525|NCT02351349|Other|multidisciplinary intervention|multidisciplinary intervention
75722261|NCT00858936|Drug|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
75722262|NCT00858936|Drug|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
75722263|NCT03974893|Other|Vegetarian Diet|Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
75722264|NCT00917345|Drug|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
75423091|NCT04940507|Procedure|Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition|Partial ablation of tumor using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel) and blood and CSF draws for liquid biopsy
75423092|NCT04940507|Procedure|Magnetic Resonance Guided Focused Ultrasound Thalamotomy|Ablation of VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel) and blood draws.
75722265|NCT00793052|Drug|Etodalac, Etoricoxib and Dexamethasone|"Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.~Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.~Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction."
75722266|NCT00859092|Dietary Supplement|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
75722267|NCT01071343|Device|Transcutaneous electrical muscle stimulation|After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
75722268|NCT02555852|Drug|esomeprazole|Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
75722269|NCT02555852|Drug|omeprazole|Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
75722270|NCT02555852|Drug|pantoprazole|Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
75423093|NCT04940182|Drug|XC221|Participants will receive XC221 100 mg 2 times a day during 14 full days
76045526|NCT02484547|Drug|Aducanumab (BIIB037)|Low dose
75423094|NCT04940182|Drug|Placebo|Participants will receive Placebo 2 times a day during 14 full days
75423095|NCT04938466|Drug|Long-Acting Growth Hormone (LAGH)|Long-acting growth hormone (LAGH) treatment
75441730|NCT01637792|Other|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
75441731|NCT01637805|Biological|Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene|AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle
76045527|NCT02484547|Drug|Aducanumab (BIIB037)|High dose
76045528|NCT02484547|Drug|Placebo|Placebo
76045529|NCT02517541|Device|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
76045530|NCT02496091|Device|ATLANTIS Abutment|
76045531|NCT02483611|Drug|Magnesium Sulfate|
76045532|NCT02483611|Drug|Lidocaine|
76045533|NCT02483611|Drug|Isotonic Solution|
76045534|NCT02483611|Drug|Cisatracurium|
75423096|NCT04937283|Procedure|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
75568935|NCT02913066|Other|S-1 concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~33 planning target volume times, 60~66 Gray/28~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1~ 14 days, 21 days for a cycle.
75722271|NCT02555852|Drug|lansoprazole|Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
75722272|NCT02555852|Drug|rabeprazole|Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
75722273|NCT02555852|Drug|cimetidine|Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
75722274|NCT02555852|Drug|ranitidine|Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
75722275|NCT02555852|Drug|famotidine|Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
75722276|NCT02555852|Drug|nizatidine|Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
75568936|NCT02913066|Other|S-1 plus Cisplatin concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~30 planning target volume times, Gross tumor volume of primary tumor60~66 Gray/28~33), synchronous chemotherapy S-1 70 mg/m2 1~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1~ 14 days, plus cisplatin 25mg/m2 1~ 4 days, 21 days for a cycle.
75568937|NCT00623701|Biological|Allerslit forte|sublingual placebo preparation, daily
76045535|NCT04963933|Device|Nautilus endovascular device|Patients will be treated with the Nautilus Endovascular device followed by treatment follow up for up to 6 months
76045536|NCT02483533|Drug|LIPO-202|
75568938|NCT00623701|Biological|Allerslit forte|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
75722277|NCT02555852|Drug|niperotidine|Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
75441732|NCT01637818|Procedure|Lichtenstein's operation|
75722278|NCT02555852|Drug|roxatidine|Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
76045537|NCT02483533|Drug|Placebo|
75441733|NCT01637818|Procedure|Mesh Plug Repair|
75568939|NCT02936063|Procedure|Surgical staples|Closure of surgical wound at skin level with surgical staples
76045538|NCT02482129|Drug|LME636 60 mg/mL ophthalmic solution|
76045539|NCT02482129|Drug|Dexamethasone 0.1% ophthalmic solution|
76045540|NCT02482129|Drug|LME636 Vehicle|Inactive ingredients used for masking purposes
76045541|NCT04962529|Procedure|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
75441734|NCT01637818|Drug|Opiate|Postoperative pain therapy
75441735|NCT01637818|Drug|Paracetamol|Postoperative pain therapy
75423097|NCT04937283|Procedure|Lobectomy with hilar and mediastinal lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
75423098|NCT04934514|Biological|IAH0968|IAH0968 is an investigational product.
75423099|NCT04934514|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 intravenous infusion
75423100|NCT04934514|Drug|Cisplatin|Cisplatin 75 mg/m^2 intravenous infusion
75423101|NCT04932980|Drug|Aflibercept|administration of anti-VEGF Aflibercept (Eylea)
75423102|NCT04932980|Drug|Brolucizumab|administration of anti-VEGF Brolucizumab (Beovu)
75423103|NCT04932980|Procedure|early treat and extend (T&E)|extension of treatment intervals (T&E) from the beginning of treatment
75423104|NCT04927390|Drug|Mycophenolate Mofetil 500mg|Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
75423105|NCT04912336|Diagnostic Test|Standard coagulation profile|prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount
75568940|NCT02936063|Procedure|Subcuticular sutures|Closure of surgical wound at skin level with subcuticular sutures
75568941|NCT01287754|Drug|erlotinib [Tarceva]|150 mg daily orally
75568942|NCT02912832|Device|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
75722279|NCT02555852|Drug|ranitidine bismuth citrate|Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
75722280|NCT02555852|Drug|lafutidine|Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
75722281|NCT02555852|Drug|cimetidine combinations|Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
75722282|NCT02555852|Drug|famotidine combinations|Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
75722283|NCT04091009|Drug|Buprenorphine|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
75722284|NCT04091009|Drug|Buprenorphine/naloxone|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
75722285|NCT00866892|Procedure|Irrigation|irrigation
75722286|NCT00866892|Procedure|No irrigation|no irrigation
75722287|NCT00859170|Device|Accordion device|an antiretropulsion device
75722288|NCT02597231|Dietary Supplement|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
75722289|NCT02597231|Other|Placebo|Patients in this group will receive a matching placebo pill.
75423106|NCT04912336|Diagnostic Test|Specific coagulation tests|AT III, anti Xa, ACT, ROTEM
75423107|NCT04912336|Other|Bleeding Scores|Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
75423108|NCT04910711|Drug|Dolutegravir|Dolutegravir-based antiretroviral therapy
75423109|NCT04910711|Drug|Levonorgestrel implant|Women initiating the levonorgestrel implant
75423110|NCT04910711|Drug|Depo medroxyprogesterone acetate injection|Women initiating the depo medroxyprogesterone acetate injection
75423111|NCT04909333|Drug|Exenatide|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously."
75423112|NCT04909333|Drug|0.9% saline solution|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously."
75423113|NCT04907487|Device|MRI|"MRI of routine care includes at least the following sequences:~3D T1 TFE (2 minutes)~T2 TSE (2 minutes)~3D FLAIR (3 minutes)~The sequences added by the research lasting 25 minutes are:~SWI QSM 1.0iso 8 echoes (10 minutes)~SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)~SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)~SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)"
75441736|NCT01637818|Drug|non-steroidal anti-inflammatory drug|Postoperative pain therapy
75568943|NCT02912793|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
75722290|NCT00866970|Biological|ALD518|ALD518 80 mg on Day 1, Week 8 and Week 16
75568944|NCT02935751|Other|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
75876470|NCT03722810|Other|Intervention|"The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher."
76045542|NCT02495857|Device|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
76045543|NCT02495857|Device|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
76045544|NCT02495857|Device|Placebo|0.9% sodium chloride, sterile
75423114|NCT04903249|Behavioral|Core Exercise Promotion Intervention|"Participants are instructed to increase weekly time spent exercising to >90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period."
75423115|NCT04902014|Behavioral|Motivational Interviewing|The individuals will be scheduled for and participate in six biweekly in person SDT based MI sessions. These sessions will take place in the HPCRL at CSU. The MI sessions will be conducted by a PhD student who has been trained by a MI practitioner. Participants will be provided a log book and will be asked to log their PA, with the goal of completing at least 150 minutes of PA per week. They will set biweekly PA goals, which will be discussed in the MI sessions. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
75568945|NCT02912871|Other|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
75568946|NCT02935790|Drug|ACY-241|tablet
75568947|NCT02935790|Drug|nivolumab|infusion
75568948|NCT02935790|Drug|ipilimumab|infusion
75568949|NCT02912637|Other|Hyperpolarized Xenon MRI|MRI & MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
75568950|NCT02912910|Other|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
75722291|NCT00866970|Biological|ALD518|ALD518 160 mg IV on Day 1, Week 8 and Week 16
75568951|NCT02912910|Other|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
75568952|NCT02935829|Other|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75722292|NCT00866970|Biological|ALD518|ALD518 360 mg IV on Day 1, Week 8, and Week 16
75722293|NCT00866970|Biological|Infusion of 0.9% Saline without ALD518|Infusion of 0.9% Saline without addition of ALD518
75722294|NCT00545571|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
75722295|NCT00783380|Biological|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
75722296|NCT00783380|Biological|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
75722297|NCT00793130|Dietary Supplement|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
75722298|NCT04008225|Procedure|Bronchoalveolar lavage|
75722299|NCT00748709|Drug|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
75722300|NCT00793208|Biological|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
75722301|NCT04041024|Other|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
75722302|NCT04041024|Other|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
75722303|NCT00793286|Procedure|Mesh fixation by staples|Mesh fixation by staples
75568953|NCT02935829|Other|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75568954|NCT02935829|Other|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75722304|NCT00793286|Procedure|Mesh fixation by glue|Mesh fixation by glue
75722305|NCT00859404|Drug|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
75722306|NCT02597309|Drug|Canagliflozin|
75722307|NCT04008381|Biological|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2*10^6, 4*10^6, 8*10^6 of cells per kg of body weight).
75722308|NCT00863148|Drug|Clofarabine in combination with IV busulfan and ATG|A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
75722309|NCT00786734|Drug|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
75568955|NCT02935829|Other|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75722310|NCT00786734|Drug|Pitavastatin|4mg daily for 28 days after PCI
75722311|NCT03974581|Other|Primary percutaneous coronary intervention|Patient receives primary percutaneous coronary intervention as part of his treatment; decision to allocate by treating physician.
75722312|NCT03974581|Other|Pharmacoinvasive strategy|Patient receives primary fibrinolysis and subsequent coronary angiography (pharmacoinvasive strategy) as part of his treatment; cases with failed fibrinolysis are scheduled for immediate rescue PCI. Decision to allocate by treating physician.
75722313|NCT04089995|Other|data collection|No intervention
75722314|NCT00960609|Procedure|Ultrasound guided liver resection|
75722315|NCT02544204|Biological|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
75722316|NCT02544204|Biological|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
75722317|NCT00263887|Drug|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
75722318|NCT00263887|Drug|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
75722319|NCT00972699|Behavioral|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
75722320|NCT00867126|Drug|pioglitazone hydrochloride|
75722321|NCT00867126|Other|laboratory biomarker analysis|
75722322|NCT00867126|Other|questionnaire administration|
75722323|NCT00867126|Procedure|quality-of-life assessment|
75568956|NCT02935829|Other|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
75568957|NCT02935829|Other|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
75568958|NCT02912598|Device|Mallinckrodt™ Endobronchial Tube|
75568959|NCT02912598|Device|Fuji Uniblocker™|
75568960|NCT02912598|Device|ETView VivaSight™-SL+EB|
75568961|NCT02912598|Device|COOK© Arndt Endobronchial Blocker|
75568962|NCT02935712|Drug|AZD8601+Placebo (SAD)|"Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.~Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg."
75568963|NCT02935712|Drug|AZD8601+Placebo|Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
75568964|NCT02935712|Drug|Placebo+Placebo|Subjects are randomized to receive 2 placebo treatments.
75568965|NCT02912754|Drug|ruxolitinib|ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
75568966|NCT02912754|Drug|ibrutinib|patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
75722324|NCT00748553|Drug|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
75722325|NCT00748553|Drug|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
75568967|NCT02912676|Drug|Thioguanine (oral)|Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Oral 6-thioguanine is added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
75568968|NCT02912481|Procedure|posterior tibial artery|
75568969|NCT02912481|Procedure|radial artery|
75722326|NCT03974815|Device|ACTIVE|"We will use 28.26cm^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
75722327|NCT03974815|Device|SHAM|"We will use 28.26cm^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
75722328|NCT00661388|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
75568970|NCT02912481|Procedure|dorsalis pedis artery|
75568971|NCT02935985|Other|Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)|"Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
75568972|NCT02935439|Other|Cell Phone|Participants responded to questions about their heart failure symptoms using a cell phone.
75568973|NCT02912169|Procedure|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
75568974|NCT02912169|Biological|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
75568975|NCT02912520|Drug|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
75722329|NCT00867204|Procedure|ERCP|Patients with clinical indication for ERCP were invited to participate in the Study
75876471|NCT03722810|Other|Sham comparator|In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
75423116|NCT04902014|Behavioral|Education|These participants will receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting. These participants will not do any other study related activities. At the conclusion of the study, these participants will be offered the chance to participate in one MI session.
75876472|NCT02236676|Behavioral|Nap after rehearsal trials|Behavioral
75423117|NCT04902014|Behavioral|Wearable Fitness Trackers|Individuals assigned to this experimental condition will be given a wrist-worn WFT and will be instructed to wear it for the duration of the study. They will also download the corresponding mobile application on their smartphones. They will be trained by a member of our team on how to utilize the WFT and mobile application. The intended WFT tracks daily steps, miles traveled, kcals expended, and daily activity time. This device provides these data to the wearer via a small screen. Participants will be instructed to aim to complete at least 150 minutes of PA per week. Researchers will have the capability to track participant daily PA via the WFT and associated API. These individuals will be asked to set biweekly PA goals. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
75441737|NCT01637831|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
75568976|NCT02935166|Other|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
75568977|NCT02935959|Drug|nebulized ketamine|Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
75568978|NCT02935959|Drug|nebulized Dexmedetomidine|
75568979|NCT02935959|Drug|nebulized midazolam|
75568980|NCT02935127|Procedure|Absorbable suture|Vascular anastomoses will be performed with absorbable materials
75568981|NCT02935127|Procedure|Non-Absorbable suture|Vascular anastomoses will be performed with non-absorbable materials
75568982|NCT02912286|Device|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
75568983|NCT02912286|Device|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
75722330|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
75876473|NCT03618368|Device|THERANOVA-500 dialyzer|THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.
75876474|NCT03618368|Device|REVACLEAR-400 dialyzer|REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).
75876475|NCT03618914|Biological|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
75876476|NCT02956460|Device|fanfilcon A|contact lens
75876477|NCT02956460|Device|senofilcon A|contact lens
75876478|NCT03618290|Diagnostic Test|Analyze plasma free fatty acid in blood|"This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression."
75876479|NCT02999100|Drug|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
75876480|NCT02999100|Drug|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
75568984|NCT02912286|Device|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
75568985|NCT02912325|Dietary Supplement|Daily administration: 2 tablets FaseMETS a day|Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
75568986|NCT02935322|Drug|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
75568987|NCT02935322|Drug|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
75568988|NCT02935322|Drug|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
75722331|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
75722332|NCT04040478|Device|Transcutaneous monitoring|"Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery."
75722333|NCT02597465|Drug|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
75568989|NCT02935322|Other|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
75722334|NCT02597465|Drug|Reference1507|Investigators choice including chemotherapy or supportive therapy
75722335|NCT00972855|Drug|Bicalutamide|50 mg Tablet
75568990|NCT02912130|Dietary Supplement|Protein Supplementation|1.2-1.5g/kg/body weight per day
75722336|NCT00972855|Drug|Casodex®|50 mg Tablet
75722337|NCT04090931|Procedure|Orthodontic treatment|leveling and aligning stage in orthodontics
75722338|NCT00786812|Drug|Nilotinib|
75722339|NCT00859716|Biological|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
75722340|NCT00859716|Biological|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
76045545|NCT02495389|Drug|Mirabegron|Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.
75722341|NCT00743483|Drug|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
75568991|NCT02912130|Other|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
75722342|NCT00972933|Drug|ipilimumab|Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
75722343|NCT00867282|Drug|Treatment A|PF-00241939 750ug using inhaler A
75722344|NCT00867282|Drug|Treatment B|PF-00241939 750ug using inhaler B
75722345|NCT00263575|Drug|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
75722346|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
75722347|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
75722348|NCT00748241|Device|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
75722349|NCT00863226|Device|Resonator Device|Application of Magnetic Fields Using the Resonator Device
75722350|NCT00570128|Drug|Donepezil HCl|Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day [mL/day]) orally for participants with body weight (BW) 20 and less than (<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to <50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (>=) 50 kg liquid formulation (1 milligram per 1 milliliter [1 mg/1 mL]) (titrated to 0.1 to 0.2 milligram per kilogram per day [mg/kg/day] based on BW).
75876481|NCT02999100|Drug|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
75876482|NCT02999100|Device|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
76045546|NCT02495233|Drug|Gilteritinib|oral
76045547|NCT02495233|Drug|Erlotinib|oral
76045548|NCT02495077|Biological|Infliximab|A single dose, of 3mg/kg infusion
76045549|NCT02495077|Drug|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
76045550|NCT02495077|Drug|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
76045551|NCT02495077|Drug|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
75568992|NCT02912130|Other|Resistance Exercise|60 minutes per week of progressive resistance training
75722351|NCT00570128|Drug|Placebo|Liquid formulation matched to active treatment for oral administration.
75722352|NCT04042194|Procedure|Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF|A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
75722353|NCT04042194|Procedure|Placement of Implants and Thickening Peri-Implant Mucosa with CTG|The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
75722354|NCT00960921|Drug|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
75722355|NCT00960921|Drug|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
75722356|NCT00863382|Device|Standard Event Monitor|Standard Event Monitor
75722357|NCT00863382|Device|Sleuth Monitor|Implantable Sleuth Recorder
75876483|NCT02749370|Drug|Etanercept|Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
75568993|NCT02935049|Procedure|Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD
75568994|NCT02934893|Other|Medication Management Clinic|referral to medication management clinic from primary care
75568995|NCT02934893|Other|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
75568996|NCT02935647|Drug|Diprivan|
75568997|NCT02934815|Other|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
75568998|NCT02912247|Drug|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
75722358|NCT00743249|Device|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
75876484|NCT03622866|Device|Ultra-high pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
75876485|NCT03622866|Device|Traditional pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
75568999|NCT02912247|Drug|adalimumab|adalimumab, 40mg,subcutaneous injection,once
75876486|NCT03619070|Other|Resistance training, LL|In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)
75876487|NCT03619070|Other|Resistance training, HL|In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)
75569000|NCT02935491|Device|Transcatheter Aortic Valve Implantation (TAVI)|"TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used"
75569001|NCT02935010|Drug|Esomeprazole|proton pump inhibitor
75722359|NCT00743249|Device|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
75722360|NCT00973089|Other|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
75722361|NCT00863460|Radiation|cranial radiotherapy|40 Gy
75722362|NCT00863460|Drug|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
75876488|NCT03619070|Other|Resistance training, HVHL|In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)
75876489|NCT03619070|Other|Control group, CG|The CG groups do not will performed the exercise.
75876490|NCT03618836|Other|Microbiological and biological patterns on vaginal samples|To compare the microbiological and biological patterns between groups
75876491|NCT03435536|Other|Blood samples|Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
75876492|NCT03618602|Drug|Bisthianostat|Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
75876493|NCT03723200|Other|Fibrinogen and blood products|Fibrinogen and blood products
75876494|NCT03618212|Diagnostic Test|MRI|Skeletal MRI and pelvic and spinal MRI
75876495|NCT05001386|Biological|Blood collection for the evaluation of the anti-drugs sensitivity|The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.
75876496|NCT02031848|Other|Diet Intervention|
75423118|NCT04902014|Behavioral|Wearable Fitness Tracker+|These individuals will be given the wrist-worn WFT, be instructed to wear it for the duration of the study AND be scheduled for six SDT based MI sessions. These participants will also be trained by a member of our team on how to utilize the WFT and associated application. They will be instructed to aim to complete 150 minutes of PA per week. These participants will be asked to set biweekly PA goals which will be discussed in MI sessions. Researchers will have the capability to track participant daily PA via the WFT and associated API. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
75722363|NCT00863460|Drug|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58&59 and days79&80
75876497|NCT02031848|Other|Assessments and Diet Intake|
75876498|NCT03617978|Procedure|Hemodynamics parameters|real-time evaluation of cardiac output parameters using the ICON device
75569002|NCT02935010|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
75569003|NCT02935010|Drug|Amoxicillin|antibiotic for H. pylori eradication
75722364|NCT00262951|Biological|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
75876499|NCT03617900|Drug|Ginger|Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
75876500|NCT03617900|Drug|Placebo oral capsule|Lactose monohydrate 400 mg/capsules
75423119|NCT04900168|Device|Intracranial pressure monitoring|An invasive method to monitor the intracranial pressure of patient
75569004|NCT02935010|Drug|Clarithromycin|antibiotic for H. pylori eradication
75569005|NCT02935010|Drug|Metronidazole|antibiotic for H. pylori eradication
75722365|NCT00262951|Drug|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
75876501|NCT03617900|Drug|Paracetamol|500 mg paracetamol. use in need
75876502|NCT05384366|Drug|Neoadjuvant chemotherapy|doublet of taxane and carboplatin
75876503|NCT05572385|Behavioral|CIAT + Conventional neurorehabilitative therapy|CIAT = Constrained induced aphasia therapy
75876504|NCT03616808|Other|Thromboelastometry-guided haemostatic treatment|Administration of blood products and/or procoagulants is based on thromboelastometric assays.
75876505|NCT03616652|Drug|Placebo|Placebo pill
75876506|NCT03616652|Other|Film sequence|The experimental group watches a film about the power of placebo effects.
75876507|NCT03616652|Other|Film sequence|The control group watches a film about sleep.
75876508|NCT03618524|Other|Lower limb hot water immersion|Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
75423120|NCT04897958|Drug|Degarelix|Degarelix dispensing claim is used as the reference group.
75423121|NCT04897958|Drug|Leuprolide|Leuprolide dispensing claim is used as the exposure group.
75423122|NCT04895384|Device|Edwards ClearSight and Masimo SET|Placement of Edwards ClearSight and Masimo SET on the patient intraoperatively.
75423123|NCT04894877|Procedure|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
75423124|NCT04894877|Procedure|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
75569006|NCT02935010|Drug|Levofloxacin|antibiotic for H. pylori eradication
75569007|NCT02912013|Device|Me Mini|Home use hair removal device
75569008|NCT02934776|Device|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
75569009|NCT02911974|Device|Acquire EUS Biopsy Device|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
75722366|NCT00262951|Drug|fluorouracil|administered at a dose of 175 mg/m^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
75722367|NCT00262951|Radiation|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
75876509|NCT02031926|Device|Positive expiratory pressure|
75876510|NCT03607994|Device|HIRREM-SOP|HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
76045552|NCT02495077|Biological|Thymoglobulin®|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
76045553|NCT02495077|Drug|Acetaminophen|"30 to 60 minutes prior to the start of the infusion~Tylenol, 600 to 1000mg by mouth or~Suppository form"
76045554|NCT02495077|Drug|Loratadine|"30 to 60 minutes prior to the start of the infusion~Claritin (Loratadine) 10mg by mouth or~Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
76045555|NCT02495077|Biological|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
76045556|NCT02495077|Drug|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
76045557|NCT02495077|Drug|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion~Claritin (Loratadine) 10mg by mouth or~Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
75423125|NCT04894877|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
75423126|NCT04894877|Behavioral|Lifestyle|diet, physical activity, smoking cessation
75423127|NCT04894877|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
75423128|NCT04892758|Drug|Formoterol fumarate 10 mcg|Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
75423129|NCT04892758|Drug|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
75423130|NCT04892732|Drug|Budesonide|Budesonide dispensing claim is used as the reference group.
75423131|NCT04892732|Drug|Budesonide-Formoterol|Budesonide-Formoterol dispensing claim is used as the exposure group.
75569010|NCT02911974|Device|Expect EUS Aspiration Needle|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
75569011|NCT04690244|Other|Tai Chi Chuan trainings|10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
75569012|NCT02935569|Device|Compression HeadBand|"commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery."
75569013|NCT04690166|Other|The speech records related to the reading document|"The document consists bit, bet, but words and Diyet passage. Volunteers will read the document in front of the microphone and also the speech will recorded by a computer."
75569014|NCT02935530|Drug|s-LMWH|2125KU, subcutaneous injection of 5-10 days
75876511|NCT03607994|Device|NCC|Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
75876512|NCT03617510|Drug|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
76045558|NCT02278341|Drug|Roxadustat|Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
76045559|NCT02278341|Drug|Epoetin alfa|Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.
75876513|NCT03617510|Drug|Placebos|Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
76045560|NCT02278341|Drug|Darbepoetin alfa|Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.
76045561|NCT02278341|Drug|Iron|Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was < 100 ng/mL (< 220 pmol/L) or TSAT < 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
76045562|NCT02282631|Behavioral|Incentive scheme|Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
75876514|NCT03617432|Drug|Chidamide|Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
76045563|NCT02278263|Drug|Tranexamic Acid|Given intravenously or topically
75569015|NCT02935530|Drug|LMWH|4250KU, subcutaneous injection of 5-10 days
75569016|NCT02935530|Drug|Argatroban|20mg, injection for 5-10 days
75569017|NCT02934737|Other|Progression of diabetes|
75569018|NCT02935608|Drug|BIIB074|Administered as specified in the treatment arm
75569019|NCT02935608|Drug|Placebo|Matched placebo
75569020|NCT02935803|Procedure|Trans-vaginal Mesh operation|Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
75569021|NCT02934386|Device|WinMedical WinPack device|
75569022|NCT02912052|Drug|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
75569023|NCT02912052|Drug|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
75722368|NCT00262951|Procedure|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
76045564|NCT02278263|Drug|Normal saline (0.9% NaCl)|Administered in all 3 groups
76045565|NCT02349711|Dietary Supplement|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
75569024|NCT02934620|Device|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
76045566|NCT02349711|Dietary Supplement|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
76045567|NCT02494921|Drug|Docetaxel-PNP|Given IV
76045568|NCT02494921|Drug|Ribociclib|Given Orally
76045569|NCT02494921|Drug|Prednisone|Given Orally
76045570|NCT02494921|Drug|Filgrastim|Given IV
76045571|NCT01653847|Drug|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
76045572|NCT01653847|Drug|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is < 3 ng/mL, or reduced if the trough level is > 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
76045573|NCT02493751|Drug|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
75569025|NCT02934620|Device|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
75569026|NCT02934620|Behavioral|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
75569027|NCT02935881|Device|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
75569028|NCT02935881|Procedure|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
75569029|NCT02934464|Drug|RAMUCIRUMAB|
75569030|NCT02934464|Drug|Paclitaxel|Paclitaxel
76045574|NCT02493751|Drug|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
76045575|NCT02493517|Drug|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
76045576|NCT02493517|Drug|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).
76045577|NCT02493361|Drug|Pembrolizumab|
75569031|NCT02934464|Drug|FOLFOX 4|
75569032|NCT02934464|Drug|mFOLFOX 6|
76045578|NCT02493361|Drug|pIL-12|
76045579|NCT04959799|Drug|Dalbavancin|Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.
76045580|NCT02493127|Other|Standard PCS|Subject completes the standard version of the PCS Questionnaire
76045581|NCT02493127|Other|Grip Strength|Research Assistant takes Grip Strength Measurements
76045582|NCT02493127|Other|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
75569033|NCT02934464|Drug|XELOX|
75569034|NCT02934542|Device|AutoLap system|
75569035|NCT02935413|Device|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
75569036|NCT02935413|Behavioral|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
75569037|NCT02934425|Other|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
75569038|NCT02934425|Other|High pork protein breakfast|High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
75722369|NCT00793364|Dietary Supplement|Stanol ester spread|Stanol ester spread 20 g every day
75423132|NCT04882176|Drug|LM-061|The subjects in each dose level will be administered single oral dose of LM-061 tablet on C0D1, and washout for 5 days. After that, the subjects will be administered multiple oral doses once daily (QD) in continuous 28 days (4 weeks) per treatment cycle, until meet the treatment termination criteria, including disease progression or unaccepted toxicity, etc. After obtaining MTD/RP2D, the Safety Review Committee (SRC) may combine the data of safety, PK, and preliminary efficacy to explore other dosing schedules (such as 3 weeks on and 1 week off).
75423133|NCT04879420|Drug|Teriparatide|Teriparatide dispensing claim is used as the reference group.
75722370|NCT00793364|Dietary Supplement|Placebo spread|Placebo spread 20 g every day
75722371|NCT00793364|Dietary Supplement|Mediterranean Diet|Mediterranean Diet every day
75722372|NCT02597153|Drug|Mitoxantrone HCL Liposome Injection|
75423134|NCT04879420|Drug|Risedronate|Risedronate dispensing claim is used as the exposure group.
75722373|NCT00867438|Procedure|Sigmoidoscopy|
75876515|NCT03617432|Drug|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
75423135|NCT04875520|Other|Screening testing strategy|The intervention we are evaluating is the use of weekly screening testing among students and staff.
75423136|NCT04875520|Other|No screening testing strategy|a group of schools will not receive screening testing.
75423137|NCT04870840|Radiation|Proton Beam Radiation Therapy|Undergo radiation therapy
75423138|NCT04870840|Other|Quality-of-Life Assessment|Ancillary studies
75423139|NCT04870840|Other|Questionnaire Administration|Ancillary studies
75423140|NCT04868539|Other|Artificial Light At Night|90 lux lighting for 19hr/day
75423141|NCT04868539|Behavioral|Sleep Restriction|5-hr of sleep/night
75423142|NCT04858035|Behavioral|Perceptual training|"Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program.~Stimuli are organized into three separate tasks:~Tasks 1 and 3 will train category goodness judgment: Participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels.~Task 2: Participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline."
75423143|NCT04858035|Behavioral|Production training|"Instruction: Discuss tongue shapes for /r/. Pre-practice: relatively unstructured, highly interactive elicitation; provide models and placement cue and KP on every trial.~Structured syllable practice: Practice will occur in blocks of 10 consecutive trials on the same syllable (e.g., 10 /ra/), after which a new syllable will be addressed (e.g., 10 /re/--but note that in the fully blocked condition, the same syllable should occur in two consecutive blocks of 10)."
75722374|NCT00975741|Device|OXIMAX|
75722375|NCT00975741|Device|ASMANEX TWISTHALER|
75722376|NCT00786890|Other|observational, no intervention needed|observational, no intervention needed
75722377|NCT00262873|Drug|bortezomib|
75722378|NCT00867516|Biological|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
75876516|NCT03617432|Drug|Doxorubicin|Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
75423144|NCT04856150|Drug|Q-1802|Q-1802 will be administered intravenously.
75876517|NCT03617432|Drug|Vincristine|Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
75423145|NCT04849910|Biological|VOR33|Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein
75722379|NCT00867516|Biological|Infusion without ALD518'|250 cc Normal saline IV over one hour Weeks 1 and 8.
75722380|NCT00786968|Drug|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
75722381|NCT00975819|Drug|sirolimus|liquid dosing based on trough levels
75722382|NCT02598323|Device|ultrasound|
75722383|NCT00793442|Diagnostic Test|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
75722384|NCT03974737|Device|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
75722385|NCT00973167|Device|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
75722386|NCT00859872|Drug|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
75722387|NCT00859872|Drug|haloperidol|haloperidol IM injection (5-20mg/d)
75876518|NCT03617432|Drug|Etoposide|Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
75876519|NCT03617432|Drug|Prednisone|Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
75876520|NCT03464916|Biological|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
76045583|NCT02478463|Drug|Cabotegravir tablet 30 mg once daily for 28 days.|GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
75722388|NCT02555696|Drug|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
75722389|NCT00961077|Drug|S-1 (TS-1) and Oxaliplatin (Oxalitin)|"S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours~every 3 weeks"
75423146|NCT04849910|Drug|Mylotarg|Infusion of Mylotarg
75423147|NCT04848519|Drug|Pembrolizumab|Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy
75569039|NCT02935218|Behavioral|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
75569040|NCT02934308|Device|Skin Conductance Monitor|
75569041|NCT02934269|Drug|Placebo|
75569042|NCT02934269|Drug|CC-90006|
75569043|NCT02788461|Radiation|Chemoradiotherapy|Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
75722390|NCT00867594|Drug|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
75722391|NCT03974659|Combination Product|Transcranial magnetic stimulation|1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
75722392|NCT02598245|Device|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
75722393|NCT02598245|Device|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
75722394|NCT00787280|Behavioral|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
75722395|NCT00787280|Behavioral|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
75876521|NCT05058716|Diagnostic Test|blood sample|weekly blood sample - coenzym q10 levels
75423148|NCT04848519|Drug|Propranolol Hydrochloride|Given PO for patients on the ICI plus propranolol arm
75423149|NCT04848519|Drug|Nivolumab|Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection
75569044|NCT02788461|Radiation|Chemoradiotherapy with Integrated Boost Dose|Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
75569045|NCT02934035|Drug|Antidepressant|
75876522|NCT04057950|Other|cosmetic product|Disulfure de sélénium versus placebo formula
75876523|NCT03616340|Drug|Shoulder injection|intra articular or subacromial shoulder injection
75876524|NCT03616340|Drug|knee injection|intra-articular knee injection
75423150|NCT04848519|Drug|Avelumab|Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy
75569046|NCT02911740|Other|Urine LAM Ag test|TB diagnostic assay
75569047|NCT02934152|Drug|H pylori eradication|H pylori eradication
75569048|NCT02934152|Other|H pylori eradication timing|Early or late eradication
75876525|NCT03663660|Other|Organizational infrastructure pediatric plan (OIPP)|Restructuration of the hospital sectors with a stratification of health care into 4 levels.
75569049|NCT02935296|Behavioral|Integrated Intervention|systems navigation, psychosocial counseling
75569050|NCT02934074|Other|No intervention|
75569051|NCT02911779|Procedure|change of medilateral angle line during crowning of the head|change of medilateral angle line during crowning of the head
75876526|NCT05035004|Device|Post exercise hot water immersion|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max), followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
75876527|NCT05035004|Device|Exercise|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max).
75876528|NCT05035004|Device|Hot water immersion|Participants will complete 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C), followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
75876529|NCT02996682|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
75876530|NCT02996682|Drug|RBV|Capsules administered orally in a divided daily dose
75876531|NCT03664284|Procedure|subcutaneous disinfection|The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
75876532|NCT02873702|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
75876533|NCT02873702|Drug|Lansoprazole|Lansoprazole capsules.
75569052|NCT02934113|Behavioral|iOTA|The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
75569053|NCT02934113|Behavioral|HWPP|Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
75569054|NCT02935335|Drug|Menotrophin|
75569055|NCT02933996|Device|TEAS+GA group|The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
75569056|NCT02933996|Device|Sham TEAS+GA group|No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
75876534|NCT02873702|Drug|Placebo|Dexlansoprazole placebo-matching capsules.
75569057|NCT02934230|Behavioral|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
75569058|NCT02933840|Device|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
76045584|NCT02478463|Drug|Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL [600 mg] total) IM given once on Day 1 of injection phase
76045585|NCT02491411|Drug|Dexamethasone|Given PO
75569059|NCT02911662|Drug|Cephalexin|Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
75569060|NCT02911662|Drug|Nitrofurantoin|Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
76045586|NCT02491411|Drug|Enzalutamide|Given PO
76045587|NCT02491411|Other|Laboratory Biomarker Analysis|Correlative studies
76045588|NCT02491411|Other|Quality-of-Life Assessment|Ancillary studies
76045589|NCT02517463|Drug|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
76045590|NCT02516605|Drug|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
75569061|NCT02933723|Procedure|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
75722396|NCT05147493|Drug|Isatuximab|Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
75423151|NCT04841798|Other|[11C]SL25.1188 PET radiotracer|Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using [11C]SL25.1188 PET
76045591|NCT02516605|Drug|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
76045592|NCT02516605|Drug|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
76045593|NCT02516605|Drug|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
75876535|NCT03617120|Device|Ergonomic Brace vs hard brace|"Visit 1:~Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~Pressure measurement of participant wearing their hard brace~Visit 2:~Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~3D body scanning (before wearing the Ergonomic Brace)~Fitting of the Ergonomic Brace~Pressure measurement of participant wearing the Ergonomic Brace (instant)~Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~3D body scanning (after wearing the Ergonomic Brace for 2 hours)~Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~Standing in-brace radiograph of the Ergonomic Brace~Doctor consultation"
76045594|NCT02516605|Drug|Part 2: LJN452 Dose level 2|LJN452
76045595|NCT02490475|Drug|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
75423152|NCT04839614|Other|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral|See arm description
75423153|NCT04829188|Behavioral|Structured Telephone Support (STS)|Structured telephone support (STS) consists of post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care within seven days post-discharge.
75569062|NCT02911623|Device|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
75423154|NCT04829188|Behavioral|Low-intensity Remote Patient Monitoring (RPM-Low)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
75423155|NCT04829188|Behavioral|High-intensity Remote Patient Monitoring (RPM-High)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
75423156|NCT04829188|Behavioral|Standard Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' PCP or specialist to coordinate care and ensure timely follow-up.
75569063|NCT02935101|Drug|Prednisolone|formulated for oral administration. encapsulated.
75569064|NCT02935101|Drug|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
75722397|NCT05147493|Drug|Bortezomib|Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
75722398|NCT05147493|Drug|Cyclophosphamide|Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
75722399|NCT05147493|Drug|Dexamethasone|Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
76045596|NCT02490475|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
76045597|NCT02477839|Drug|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
76045598|NCT02477839|Other|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
75722400|NCT05147493|Drug|Lenalidomide|Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
76045599|NCT04939987|Drug|Tramadol|Opioid Control Cohort (One treatment selected)
75876536|NCT03616262|Drug|Botox + Lidocaine|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
75876537|NCT03616262|Drug|Lidocaine alone|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
76045600|NCT04939987|Drug|Gabapentin|Experimental Cohort (Multimodal Approach)
76045601|NCT04939987|Drug|Hydrocodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
75423157|NCT04829188|Behavioral|Enhanced Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives.
75423158|NCT04809506|Biological|additional blood samples|2 additional blood samples (2 x 7ml) at every visit
75423159|NCT04808323|Drug|Capecitabine|825 mg/m^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
75722401|NCT00573534|Drug|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
75722402|NCT03974191|Other|Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.|13-year prospective longitudinal cohort study
76045602|NCT04939987|Drug|Oxycodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
76045603|NCT04939987|Drug|Ketorolac|Experimental Cohort (Multimodal Approach)
76045604|NCT04939987|Drug|Acetaminophen|Experimental Cohort (Multimodal Approach)
76045605|NCT04939987|Drug|Ketorolac tromethamine|Experimental Cohort (Multimodal Approach)
76045606|NCT04939987|Drug|Ketamine|Experimental Cohort (Multimodal Approach)
76045607|NCT04953559|Device|Active cTBS|Active continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
76045608|NCT04953559|Device|Sham cTBS|Sham continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
76045609|NCT02488915|Device|EmboTrap® Revascularization Device|
76045610|NCT02488681|Device|Micra Pacemaker Implant|
76045611|NCT02477605|Device|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
76045612|NCT02477605|Device|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
76045613|NCT02477605|Procedure|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
76045614|NCT02477527|Drug|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
76045615|NCT02477215|Drug|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
76045616|NCT02477215|Drug|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
75569065|NCT04689971|Drug|Standard therapy|Gabapentin, pregabalin, or amitriptyline
75423160|NCT04808323|Device|Initial Dose of Radiation before Dose Escalation|50 Gy over 25 frac.
75423161|NCT04808323|Device|Cohort A: Dose Escalation Radiation|Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.
75423162|NCT04808323|Device|Cohort B: Dose Escalation Radiation|Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.
75423163|NCT04808323|Device|Cohort C: Dose Escalation Radiation|Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.
75423164|NCT04808323|Drug|FOLFOX|After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
75423165|NCT04796285|Device|Lab Clasp|Finger-based interstitial fluid assessment device
75423166|NCT04793529|Drug|Cholecalciferol|Cholecalciferol injection
75423167|NCT06040684|Diagnostic Test|Level of antibodies|The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
75423168|NCT06040671|Other|Vectra M3 imaging|Study subjects from both arms will undergo Vectra M3 imaging to evaluate the result of the surgery.
75423169|NCT06040658|Diagnostic Test|Frailty assessment|Rockwood Clinical Frailty Scale
75423170|NCT06040658|Diagnostic Test|Frailty assessment|Frail NonDisabled Questionnaire (FiND)
75569066|NCT04689971|Drug|Vitamin B combination|Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
75569067|NCT02934945|Drug|budesonide 160μg/formoterol 4.5μg|SMART regimen
76045617|NCT02477215|Drug|Bendamustine (multiple dose levels)|70 mg/m^2, 80 mg/m^2, or 90 mg/m^2 on days 1 and 2
76045618|NCT02477215|Drug|Bendamustine (MTD)|80 mg/m^2 on days 1 and 2
76045619|NCT02487199|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
76045620|NCT02487199|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
76045621|NCT02475733|Drug|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
76045622|NCT02475733|Drug|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
76045623|NCT02475733|Drug|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
75569068|NCT02933762|Drug|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
75876538|NCT02236754|Drug|18F-FP-DTBZ|The drug, no carrier added [18F]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce [18F]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 mCi of [18F]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
76045624|NCT04925947|Drug|KN046|KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
76045625|NCT04942639|Device|JOE|Audiovisual support by the robot when taking maintenance treatments at home.
75423171|NCT06040658|Diagnostic Test|Frailty assessment|Clinician's subjective 'end-of-bed' test
75423172|NCT06040658|Diagnostic Test|Frailty assessment|Healthcare Improvement Scotland FRAIL Scale
75423173|NCT06040658|Diagnostic Test|Frailty assessment|11-item modified Frailty Index (mFI-11)
75423174|NCT06040606|Procedure|In-Hospital COVID-19 Omicron Infection after surgery|Thoracic Surgery Patients with In-Hospital COVID-19 Omicron Infection after surgery
75423175|NCT06040554|Other|Elastic Band Resistance Exercises|8 Warm-Up Exercises followed by 10 Elastic Band Exercises followed by 8 Post-Workout Exercises.
75423176|NCT06040515|Drug|Probiotic Formula|Capsule with 25 billion live strains of Escherichia coli Nissle 1917
75569069|NCT02933762|Drug|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
75569070|NCT02933645|Drug|Actrapid|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
75876539|NCT02236754|Radiation|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
75876540|NCT03615950|Diagnostic Test|Bone Mineral Density (DEXA) scan|Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
75876541|NCT03615950|Diagnostic Test|Vitamin D Measurement|Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
75569071|NCT02933645|Drug|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
75569072|NCT02933645|Radiation|[18F]-FDG PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq [18F]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
75423177|NCT06040489|Drug|Miltefosine 50mg|Oral Miltefosine 50mg bid
76045626|NCT02486653|Drug|Tamsulosin|"Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~Day 1-7: tamsulosin 0.4mg in the evening~Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
75423178|NCT06040489|Drug|Pentoxifylline 400mg|Oral Pentoxifylline 400mg tid
75569073|NCT02933645|Drug|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
75876542|NCT03615950|Diagnostic Test|Height measurement|Height will be measured at baseline and 12 months.
75876543|NCT03615950|Other|Assessment of medication compliance|Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
75423179|NCT06040489|Drug|Liposomal Amphotericin B|Intravenous 25 to 40mg/kg
75423180|NCT06040476|Biological|hUCB|hUCB
75423181|NCT06040437|Behavioral|Be-Prox|Be-Prox is an intervention developed to prevent, uncover and handle negative behavior in kindergartens.
75876544|NCT02911116|Drug|Ustekinumab|Subcutaneous Injection
75876545|NCT02911116|Drug|Ustekinumab|Intravenous Infusion
75423182|NCT06040411|Other|Acupressure|Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points). During the application, the most appropriate position in which the individual would be comfortable was preferred, taking into account the privacy of the individual. First of all, the supine position was preferred, and alternatively, the sitting position was preferred. At the end of the application, it was ensured that the person was in a position that he/she was comfortable.
75569074|NCT02933567|Other|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
75569075|NCT02933684|Drug|Seromycin|Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
75722403|NCT04090385|Device|Transcranial Direct Current Stimulation|Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
75876546|NCT03615872|Device|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
75423183|NCT06040398|Behavioral|JUMPSTART exercise program|The intervention is an early mobilization protocol (JUMPSTART). Four interactive exercise videos, at different intensity levels, include a variety of stretches and exercises designed to improve the full body mobilization of post-TAVR patients. Videos have been developed in consultation with a physiotherapist and cardiac rehabilitation specialist and have been piloted for initial acceptability by patients at the Hamilton General Hospital. The videos will be freely accessible to all eligible patients and their caregivers (regardless of participation in the research study) online (www.hhscebi.ca/projects/jumpstart). A written version of the exercise program, with photographs and detailed instructions, will also be made available. Additional exercise videos will be developed based on patients' needs and feedback received.
75569076|NCT02933684|Behavioral|Virtual Reality Exposure Therapy|Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
75722404|NCT03974425|Drug|Aflibercept Injection [Eylea]|intravitreal injection of Aflibercept in resistant DME.
75722405|NCT00975897|Biological|bevacizumab|
75722406|NCT00975897|Biological|cetuximab|
75722407|NCT00975897|Drug|fluorouracil|
75722408|NCT00975897|Drug|irinotecan hydrochloride|
75722409|NCT00975897|Drug|leucovorin calcium|
75876547|NCT03664206|Diagnostic Test|MRS, conventional TMS and treshold tracking TMS|"Using~two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination"
75423184|NCT06040385|Device|Implant supported hybrid prosthesis|For each patient, implant supported mandibular hybrid prosthesis will be fabricated digitally. Frameworks will be tried in patient's mouth, scanned intraorally by intraoral scanner (IOS).
75423185|NCT06040372|Drug|LB64640|The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.
75423186|NCT06040372|Drug|Placebo|Placebo is provided as a matching placebo
75722410|NCT00975897|Drug|oxaliplatin|
75722411|NCT00975897|Genetic|RNA analysis|
75423187|NCT06040359|Other|The Thriving Mamas programme|Enhanced antenatal course plus usual perinatal care
75722412|NCT00975897|Genetic|cytogenetic analysis|
75722413|NCT00975897|Genetic|fluorescence in situ hybridization|
75876548|NCT03664050|Drug|group A 2.5 mg letrozole oral tablets|2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
75423188|NCT06040359|Other|Usual care|Usual perinatal care
75423189|NCT06040346|Drug|Meplazumab for Injection|Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
75423190|NCT06040333|Other|Exercise|Dynamic Neuromuscular Stabilisation Exercise
75423191|NCT06040333|Other|Standard therapy|Patient education, massage, diaphragmatic breathing, kegel exercise
75423192|NCT06040255|Drug|methylprednisolone, prednisolone, prednisone|Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
75423193|NCT06040216|Other|optical coherence tomography|We observed the postoperative improvement in EIFL severity with optical coherence tomography
75423194|NCT06040190|Drug|topical placebo tablet|Individuals will be instructed to dissolve half a tablet of placebo medication and hold the saliva near the painful oral sites without swallowing, for 3 minutes and then spit. Tablets will contain magnesium silicate, with the same color and flavor as the test medications. Researchers will provide a total of 32 tablets for each participant.
75569077|NCT02933684|Drug|Placebo|Administered in pill form.
75722414|NCT00975897|Genetic|gene expression analysis|
75876549|NCT03664050|Procedure|laparoscopic ovarian drilling|Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
75876550|NCT02998554|Drug|SHP640|Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
75569078|NCT02934867|Other|Protocol phone advice|Protocol phone advice
75569079|NCT02934867|Other|Usual phone advice|Usual phone advice
75569080|NCT02933333|Biological|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
75569081|NCT02933333|Biological|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
75722415|NCT00975897|Genetic|mutation analysis|
75722416|NCT00975897|Genetic|protein expression analysis|
75722417|NCT00975897|Other|diagnostic laboratory biomarker analysis|
75876551|NCT02998554|Drug|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
75876552|NCT02996448|Drug|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
75722418|NCT00975897|Other|immunohistochemistry staining method|
75722419|NCT00975897|Other|questionnaire administration|
75722420|NCT00975897|Procedure|cognitive assessment|
75722421|NCT00867672|Drug|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
75722422|NCT00867672|Drug|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
75722423|NCT00867672|Drug|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
76045627|NCT02486653|Drug|Placebo|"Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~Day 1-7: placebo in the evening~Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
75722424|NCT01071421|Device|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
76045628|NCT02475655|Drug|Ruxolitinib|10 mg orally twice daily for 5 weeks
75423195|NCT06040190|Drug|topical clonazepam tablet|Individuals will be instructed to dissolve half a tablet of clonazepam and hold the saliva near the painful oral sites without swallowing for 3 minutes and then spit. Researchers will provide a total of 32 tablets for each participant.
75423196|NCT06040190|Dietary Supplement|oral alpha-lipoic acid capsule|Participants in this group will be instructed to take oral capsules containing alpha-lipoic acid.
75423197|NCT06040190|Other|topical phytotherapic capsaicin gel|Participants in this group will to apply the gel containing tocapsaicin on painful oral sites.
75423198|NCT06040190|Radiation|local photobiomodulation|Photobiomodulation will be applied during 10 seconds per point at 56 points (three on the vestibular mucosa of the 4 quadrants, four on each labial mucosa, six on each of the two buccal mucosae, six on the hard palate, four on each lateral edge of the tongue, six on the dorsum of the tongue, and four sublingual points) with an intermediate distance of 2 mm. A dose of 12 J/cm² per session will be applied in continuous mode for 10 sessions. The 10 sessions will be applied twice a week for 5 consecutive weeks. The LASER will be applied perpendicularly in contact with the mucosa. All patients and the clinician will wear protective glasses.
75423199|NCT06040177|Drug|Cadonilimab|Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
75423200|NCT06040177|Radiation|Stereotactic radiotherapy|Radiation therapy: Stereotactic radiotherapy (5-8Gy*5F) for portal vein thrombus within 21 days after entry
75569082|NCT02933333|Biological|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
75569083|NCT02911584|Procedure|Laparoscopic procedure|
75722425|NCT00917657|Procedure|Photorefractive keratectomy|
75722426|NCT05145231|Other|GÖZLEMSEL|The scales will be filled by asking the family.
75722427|NCT00783926|Biological|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
76045629|NCT02475265|Drug|estradiol 0.045 mg/levonorgestrel 0.015mg|
75423201|NCT06040177|Drug|Renvatinib|Renvatinib: 8mg (weight <60kg) or 12mg (weight 60kg) once a day until disease progression, intolerable toxicity
75722428|NCT01071499|Drug|Morphine|One dose of morphine (0.1 mg/kg)
76045630|NCT02485717|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
76045631|NCT02485717|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
75423202|NCT06040164|Other|Observational study|No intervention will be performed
75569084|NCT02933294|Procedure|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
75569085|NCT02933294|Procedure|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
75569086|NCT02934828|Drug|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
75569087|NCT02934828|Drug|postoperative chemotherapy|postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
75722429|NCT01071499|Drug|Morphine|One dose of morphine (0.2 mg/kg)
75722430|NCT01071499|Drug|Morphine|One dose of morphine (0.3 mg/kg)
75722431|NCT04040868|Device|the TiRobot system|The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
76045632|NCT05460559|Procedure|Group A (p-PCNL) procedure|In lithotomy position, ureteric catheter will be inserted allowing injection of contrast to obtain a pyelogram. Shifting the patients in prone position will be done. Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
76045633|NCT05460559|Procedure|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
75722432|NCT04040868|Device|Freehand|conventional fluoroscopy-assisted
76045634|NCT02451007|Drug|lurbinectedin (PM01183)|
75423203|NCT06040151|Device|Digizorg mobile app (quality evaluation study)|Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care. Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions. The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.
75423204|NCT06040138|Diagnostic Test|End expiratory occlusion maneuver|An end expiratory occlusion maneuver will be performed during pressure support ventilation in patients with prolonged weaning.
75569088|NCT02670252|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
76045635|NCT02473471|Device|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
75423205|NCT06040112|Device|Tendoregen (Atelocollagen)|Tendoregen (Atelocollagen) injection
75569089|NCT02670252|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
75569090|NCT02670252|Radiation|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
75722433|NCT05142813|Diagnostic Test|Diagnostic Test: Blood specimen collection|Diagnostic Test: Blood specimen collection Study samples must be collected within before treatment with antibiotics or antivirals.
75876553|NCT03663972|Behavioral|articulation therapy|children receive instruction in producing new sounds at the isolation, syllable and word level.
75423206|NCT06040047|Other|Proprioceptive neuromuscular facilitation|Contract relax technique for each neck motion for three repetitions.
75423207|NCT06040047|Other|Passive mobilization|To restore normal joint play, postero-anterior passive joint mobilization of cervical spine segments and cervicothoracic junction in limited motion will be applied.
75876554|NCT03663972|Behavioral|phonologic treatment|children receive instruction in producing new sounds at the word level
75876555|NCT02995980|Device|Dual-Energy Contrast-Enhanced (DECE) mammography|Contrast mammography
75423208|NCT06040021|Other|standardized treatment|Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
75569091|NCT02933177|Behavioral|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~Boards of known photographs to recall autobiographical memories~Newspapers to read, talk, associate memories around an article~Massage Oil, refreshing wipes, cream to reconnect with the body~Clay, cookie pieces, washable felt and paper to create shapes, draw.~Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~Listening to music~Relaxation-Breathing~Cushion, foam balls to vent his energy on secure hardware.~Plush doll or to invest a vector object of affection and empathy~Sensory flash balls that the patient can squeeze, throw, roll.~Games with which the patient can play according to its possibilities."
75722434|NCT03974269|Procedure|TAVI : Transcatether Aortic Valve Implantation|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
75722435|NCT00917189|Behavioral|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
76045636|NCT02450539|Drug|Abemaciclib|Administered orally
75722436|NCT00961155|Drug|cyklezonid|160 mcg once daily
75722437|NCT00961155|Drug|montelukast sodium|5 or 10 mg according to age once daily
75722438|NCT00961155|Drug|placebo|fluticasone placebo twice daily, montelukast placebo once daily
75876556|NCT02995980|Device|digital mammography|routine digital mammography
75423209|NCT06040008|Genetic|blood collection|"3 blood collections over a period of 6 weeks~V0 - Inclusion~V1 - 3 weeks ± 14 days~V2 - 3 weeks ± 14 days~1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~Clinical information obtained at each visit"
75423210|NCT06039969|Other||This is an obvertional study and there is no intervention
75722439|NCT00961155|Drug|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
75722440|NCT00793676|Other|spirometry|
75722441|NCT00793676|Other|blood test|
75722442|NCT00863538|Drug|KPS-0373|
75722443|NCT00260533|Drug|atomoxetine|Flexible dose, up to 50 mg per day
76045637|NCT02450539|Drug|Docetaxel|Administered IV
76045638|NCT02449915|Drug|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
75722444|NCT00260533|Drug|placebo|placebo (matching to atomoxetine)
75722445|NCT02596919|Other|photography|photography of meibomian glands
75722446|NCT00863616|Device|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
75722447|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
75876557|NCT04058496|Other|Blood sampling|Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission
75876558|NCT04055688|Device|Orbeye surgical videomicroscope|The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
76045639|NCT02449915|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
76045640|NCT02420119|Other|non interventional|
76045641|NCT02473393|Drug|OPS-2071 tablet|
75423211|NCT06039956|Procedure|Sentinel lymph Node Biopsy|The SLNB will be performed with 5 ml of undiluted methylene blue injected in equal aliquots, peri-tumoral, followed by a 5-minute massage prior to skin incision. Sentinel nodes will be defined as those that have uptake / visible blue staining or suspicious palpable nodes at the discretion of the operating surgeon. Sentinel nodes will be placed in formalin and sent separately. This will be followed by an immediate completion ALND, which will be similarly placed in formalin and sent separately from the SLNB specimen. Specimen radiographs will be performed on all specimens to confirm location of clip within SLNB vs. ALND specimens.
76045642|NCT02419573|Device|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
75423212|NCT06039943|Device|Wheeze measurement|Acoustic breath sounds will be measured during tidal breathing prior to spirometry and during a spirometry attempt.
75423213|NCT06039917|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
75722448|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
75722449|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
75722450|NCT00973245|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
75722451|NCT00793754|Drug|Aspirin|100 mg / day for 8 weeks
75722452|NCT00793754|Drug|Atorvastatin|40 mg / day for 8 weeks
76045643|NCT02419573|Device|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
76045644|NCT02472847|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
75722453|NCT00793754|Drug|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
75722454|NCT02596763|Drug|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
75722455|NCT03976141|Diagnostic Test|mri|knee mri
75722456|NCT00793832|Behavioral|supervised exercise|supervised exercise
75722457|NCT00793832|Behavioral|Diet advice|Diet Advice
75722458|NCT00860106|Other|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
75722459|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
75722460|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
75722461|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
75722462|NCT00973323|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
75423214|NCT06039917|Other|Manually remind the patients|Medical staff remind patients to review manually.
75423215|NCT06039904|Device|Natural rubber knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either natural rubber and inserted at the front of the support body (to cover the patellar).
75423216|NCT06039904|Device|Sponge knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either sponge and inserted at the front of the support body (to cover the patellar).
75423217|NCT06039891|Drug|Nimotuzumab、Tislelizumab|Subjects will receive Nimotuzumab 400 mg/time, intravenous injection, qw; Tislelizumab 200 mg/time, q3w until disease progression, intolerable toxicity, or 24 months of medication
75423218|NCT06039865|Behavioral|Immediate Intervention|Participants will receive customized weekly reports from the pulse oximetry data collected by the consumer wearable.
75569092|NCT02933177|Behavioral|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~Boards of known photographs to recall autobiographical memories~Newspapers to read, talk, associate memories around an article~Massage Oil, refreshing wipes, cream to reconnect with the body~Clay, cookie pieces, washable felt and paper to create shapes, draw.~Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~Listening to music~Relaxation-Breathing~Cushion, foam balls to vent his energy on secure hardware.~Plush doll or to invest a vector object of affection and empathy~Sensory flash balls that the patient can squeeze, throw, roll.~Games with which the patient can play according to its possibilities."
75722463|NCT00793988|Procedure|Vibration-assisted anaesthesia|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site."
76045645|NCT02472847|Drug|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
76045646|NCT02472145|Drug|Decitabine 20 mg/m^2|Decitabine 20 milligram per square meter (mg/[m^2]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.
75423219|NCT06039865|Behavioral|Waitlist control|Participants only receive usual care from the sleep center.
75423220|NCT06039839|Procedure|Closure of the donor area after CTG harvesting without the use of collagen matrix|"Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~Suturing of the wound in the donor site."
75423221|NCT06039839|Procedure|Closure of the donor area after CTG harvesting with collagen matrix|"Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~Adaptation of sterile collagen matrix to the donor site~Suturing of the wound in the donor site"
75423222|NCT06039800|Other|No intervention|No intervention
75423223|NCT06039748|Other|AngioQFA|FFR measured by pressure wire, AngioQFA computed by coronary angiographic images
75423224|NCT06039722|Device|Pulse ablation catheter|Pulse ablation catheter is used to ablate the junction of left atrium and pulmonary vein, removing pulmonary vein potential
75423225|NCT06039670|Procedure|biliary biopsy|biliary biopsy through a percutaneous approach during a percutaneous biliary drainage
75569093|NCT02911467|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
76045647|NCT02472145|Drug|Talacotuzumab 9 mg/kg|Talacotuzumab 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
75569094|NCT02911467|Device|MRI|MRI scan following the Pyruvate injection
75569095|NCT02934789|Procedure|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
75569096|NCT02934789|Drug|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
75423226|NCT06039657|Other|SEAS training|Patients who opted to participate in the SEAS group underwent SEAS therapy. The SEAS therapy program initially comrised patient education and active self-correction. Subsequently, stabilization of active self correction was tried to be performed through various functional activities. These activities were selected from everyday life examples, with increasing levels of difficulty over time. With SEAS exercises, the activation of self-correction was aimed to be increased through various activities in sitting, standing and walking conditions, with the goal of correcting scoliosis in this way
75569097|NCT02933099|Drug|Aprepitant+palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
75569098|NCT02933099|Drug|palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
75569099|NCT02935023|Radiation|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
75569100|NCT02911506|Other|Polysomnography|
75722464|NCT00793988|Procedure|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
76045648|NCT02448043|Drug|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
76045649|NCT02448043|Other|Placebo: saline|Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days
76045650|NCT02447887|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
76045651|NCT02447887|Drug|Pegylated IFN-alpha 2b|Weekly injection
75569101|NCT02934906|Procedure|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
75569102|NCT02911350|Drug|Hormone Suppressors|
75569103|NCT02911350|Drug|Paclitaxel|
75569104|NCT02911350|Radiation|Radiation Therapy|
75569105|NCT04623983|Device|bonding tray|Orthodontic bonding tray
75569106|NCT02911428|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
75569107|NCT02911389|Other|Home PT via web-based platform|
75569108|NCT02911389|Other|Home PT via paper manual|
75569109|NCT02911389|Other|outpatient PT|
75569110|NCT02933021|Other|Blood sample taken|
75722465|NCT00973401|Other|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
75722466|NCT04040322|Drug|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
76045652|NCT02471755|Device|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
76045653|NCT02471755|Device|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
75423227|NCT06039657|Other|Standard Care|Patients who declined or were unable to participate in outpatient exercise programs received standard care. Standard care included exercises for postural re-education, traditional strengthening and stretching exercises for one session, followed by observation for one year.
76045654|NCT02470429|Device|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
76045655|NCT02470429|Device|Hyabak 0.15% eye drops|Preservative-free
75423228|NCT06039631|Procedure|Surgery|In the surgical group, patients will undergo curative surgery for laryngeal/hypopharyngeal cancer along with cervical lymph node dissection. Organ preservation surgery is recommended.
75722467|NCT04040322|Drug|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
75569111|NCT02933021|Other|Answering a lifestyle questionnaire|
75569112|NCT02933021|Other|Follow-up phone call from researcher (two years after first visit)|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
75569113|NCT02934750|Behavioral|Pursed lip breathing|"Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:~Breathe in through your nose (as if you are smelling something) for about 2 seconds.~Pucker your lips like you're getting ready to blow out candles on a birthday cake.~Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.~Repeat."
75569114|NCT02932709|Behavioral|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
75569115|NCT02911233|Biological|Thromboelastograpgy|
75569116|NCT02932748|Dietary Supplement|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
75722468|NCT00787358|Drug|ZT-031|80 ul subcutaneous injection per day
75569117|NCT02932748|Behavioral|Group Phone (GP)|Weight management program delivered via group conference call.
75569118|NCT02932748|Dietary Supplement|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
75569119|NCT02932748|Behavioral|Individual Phone (IP)|Weight management program delivered via individual phone call.
75722469|NCT00787358|Other|placebo|80 ul daily subcutaneous injection of vehicle only
75569120|NCT02932748|Behavioral|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
75722470|NCT00794066|Procedure|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
75722471|NCT00784004|Other|Breathing Patterns|"All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~Breathing in through the nose only and out through the mouth only~Breathing in through the mouth only and out through the nose only~Breathing in and out through the nose only~Breathing in and out through the mouth only"
76045656|NCT02470429|Drug|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
75569121|NCT02932514|Device|Eversense (Senseonics) Continuous Glucose Monitoring System|"Evaluate accuracy of Eversense CGM System to SMBG Meter.~Compare performance between abdomen and arm insertion sites.~Determine the usability of the Eversense System in a home-use setting for 180 days."
76045657|NCT02447497|Drug|3M CHG/IPA Surgical Skin Preparation - Abdominal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
76045658|NCT02447497|Other|Normal Saline - Abdominal Region|0.9% sodium chloride applied with foam applicator
75423229|NCT06039631|Radiation|Radiation|"In the surgical group, depending on postoperative pathology results, adjuvant radiotherapy or concurrent radiochemotherapy may be administered as deemed necessary. If postoperative pathology indicates extracapsular invasion of lymph nodes or positive surgical margins, concurrent radiochemotherapy based on cisplatin is recommended.~In the concurrent radiochemotherapy group, patients will undergo target delineation based on the scope before induction chemotherapy. Radiotherapy will be administered at a total dose of 70 Gy over 35 fractions, and concurrent chemotherapy will involve weekly administration of cisplatin at a dosage of 30 mg/m²."
75423230|NCT06039631|Drug|Toripalimab|In the both groups, starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
76045659|NCT02447497|Drug|3M CHG/IPA Surgical Skin Preparation - Inguinal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
76045660|NCT02447497|Other|Normal Saline - Inguinal Region|0.9% sodium chloride applied with foam applicator
76045661|NCT02417935|Drug|Duloxetine|Administered orally
75569122|NCT02911311|Drug|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
75569123|NCT02911311|Device|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
75569124|NCT02932631|Other|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
75569125|NCT04690101|Other|none, this is an observational study|none, this is an observational study
75569126|NCT02932358|Other|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
75569127|NCT02932358|Other|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
75569128|NCT04689906|Other|surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis
75569129|NCT04690257|Other|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
75569130|NCT02932397|Drug|Intravenous dose of 0.5 mg/kg of propofol|
75569131|NCT02932397|Drug|Intravenous dose of 0.05 mL/kg of saline solution|
75569132|NCT02932319|Device|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
75722472|NCT00867750|Device|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
75722473|NCT00867750|Drug|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
75722474|NCT00787436|Drug|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
75569133|NCT02932319|Other|expectative|expectative until the next day befor starting the induction
75569134|NCT02911272|Device|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
75569135|NCT02911272|Drug|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
76045662|NCT02417935|Drug|Pregabalin|Administered orally
75569136|NCT02911272|Procedure|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
75569137|NCT02911272|Device|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
75569138|NCT02932241|Behavioral|Computerized Dialectical Behavior Therapy Skills Training|8, 50 minute skill training sessions made available to participants each week
75569139|NCT02911194|Dietary Supplement|a2 milk|replace all milk with a2 milk
76045663|NCT02417935|Drug|Placebo|Administered orally
76045664|NCT02417233|Behavioral|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
76045665|NCT02417233|Behavioral|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
76045666|NCT02447029|Drug|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
76045667|NCT02447029|Drug|standard lidocaine paracervical block|1% lidocaine paracervical injection
75569140|NCT02911194|Dietary Supplement|a1 containing milk|use a1 containing milk
75569141|NCT02932436|Drug|Empagliflozin|10 mg per os daily for 12 weeks
75722475|NCT03945981|Drug|Dolutegravir + Lamivudine FDC|Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
76045668|NCT04938661|Other|Center-Based Cardiac Rehab|36 center-Based Cardiac Rehab Sessions
75423231|NCT06039592|Drug|Captopril Tablets|0.3mg/kg, tid
75423232|NCT06039592|Drug|Metoprolol Oral Tablet|0.2mg/kg, bid
75569142|NCT02932436|Drug|Placebo|amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
75569143|NCT02932670|Other|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
75569144|NCT02910960|Device|Acquire EUS Biopsy Device|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
75569145|NCT02910960|Device|SharkCore Biopsy System|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
75569146|NCT02932124|Device|mechanical chest compression device|
75569147|NCT02932007|Drug|Chloroquine Phosphate|Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
75569148|NCT02932085|Device|Neurostar TMS Therapy System, NeuroStar XPLOR System|Repetitive transcranial magnetic stimulation
75569149|NCT02910882|Drug|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|"PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy."
75569150|NCT02910882|Drug|Gemcitabine|"Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen."
75569151|NCT02910882|Radiation|Radiation|Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
75569152|NCT02931968|Device|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
75569153|NCT02934438|Dietary Supplement|Neo40|
75423233|NCT06039592|Drug|Spironolactone Tablets|2-4mg/kg, bid
75423234|NCT06039592|Drug|Torsemide Tablets|0.2-0.5mg/mg, bid
75423235|NCT06039592|Drug|Potassium citrate powder|0.06g/kg, tid
75569154|NCT02934438|Dietary Supplement|Placebo|
75722476|NCT00784082|Drug|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
76045669|NCT04938661|Other|mHealth|Mobile Health Platform
76045670|NCT04938661|Other|Home-Based Cardiac Rehab|Encouraged to exercise 3 times per week at home
76045671|NCT02416453|Biological|MVA-BN-Filo|One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.
76045672|NCT02416453|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
76045673|NCT02416453|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
75423236|NCT06039553|Procedure|pulmonary artery banding|Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.
75423237|NCT06039540|Drug|Captopril Tablets|0.3mg/kg, tid
75423238|NCT06039540|Drug|Metoprolol Oral Tablet|0.2mg/kg, bid
75423239|NCT06039540|Drug|Spironolactone Tablets|2-4mg/kg, bid
75423240|NCT06039540|Drug|Torsemide Tablets|0.2-0.5mg/mg, bid
75423241|NCT06039540|Drug|Potassium citrate powder|0.06g/kg, tid
75569155|NCT02932046|Dietary Supplement|Standardized noon meal|"The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa."
75722477|NCT03926598|Behavioral|Patient and/or Family Member Intervention|On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.
75722478|NCT03926598|Behavioral|Certified Diabetes Educator Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
75876559|NCT04055688|Drug|5-Aminolevulinic Acid|5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
75876560|NCT02872142|Biological|Albutein 5%|Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
75876561|NCT02872142|Procedure|Plasma Exchange|Plasma Exchange will be performed using albutein 5% as the replacement solution.
75876562|NCT02994654|Device|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
75876563|NCT04882280|Behavioral|Light|10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
75876564|NCT04055610|Device|Gait training using H-MEX exoskeleton|Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
75423242|NCT06039514|Device|GGTCA-AD mobile app|The intervention will be done through an adaptation of the GGTCA app for teenagers: GGTCA-AD. This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in cognitive behavior therapy (CBT) in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
75569156|NCT02934516|Procedure|Cesarean section|"Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally"
75569157|NCT02932202|Other|Longitudinal Nutritional Counseling|
75876565|NCT03615716|Behavioral|Multi-level Violence Prevention Intervention - Boys|Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.
75876566|NCT03615716|Behavioral|Multi-level Violence Prevention Intervention - Caregivers|This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
76045674|NCT02469961|Drug|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
76045675|NCT02469961|Drug|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
76045676|NCT02469961|Other|Interscalene block|Interscalene block is used for the main anesthetic for the case
75569158|NCT02932202|Other|Standard Care|
75876567|NCT04054284|Dietary Supplement|Antidiabetic Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
76045677|NCT02415595|Drug|BMS-955176|HIV Maturation Inhibitor
76045678|NCT02415595|Drug|EFV|EFV
76045679|NCT02415595|Drug|TDF/FTC|TDF/FTC
75569159|NCT02934594|Other|Palliative Decompression|palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
76045680|NCT02446717|Drug|ABT-493, ABT-530|ABT-493 (tablet) dosed with ABT-530 (tablet)
76045681|NCT02446717|Drug|ribavirin (RBV)|Tablet
76045682|NCT02446717|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
75569160|NCT02931929|Drug|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
75569161|NCT02910804|Drug|68Ga-BBN-IRDye800CW|
75569162|NCT02910804|Device|PET/NIRF|
75569163|NCT02910804|Procedure|PET/NIR fluorescent imaging-guided surgery|
75569164|NCT02931734|Drug|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
75569165|NCT02931734|Drug|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
75569166|NCT02931734|Procedure|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
75569167|NCT02934672|Other|Survey|Internet panelists, who self-reported that they or another adult in their household has osteoarthritis, were sent an email invitation to the survey site.
75569168|NCT02931656|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
75569169|NCT02910765|Drug|methylene blue|
75722479|NCT03926598|Behavioral|Physician Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.
75722480|NCT03926598|Behavioral|Front Desk Staff Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
75722481|NCT03926598|Behavioral|Nurse Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
75569170|NCT02910765|Drug|ozone|
75569171|NCT02910765|Other|saline infusion|
75569172|NCT02910765|Other|oxygen|
75569173|NCT02931773|Device|Task Force® Monitor|A head up tilt test carried out with a Task Force monitoring system
75569174|NCT02934633|Behavioral|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
75569175|NCT02934633|Behavioral|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
75569176|NCT02931617|Other|Chest Physiotherapy|
75569177|NCT02931617|Device|Post-therapy lung volume measurements|In both intervention groups.
75569178|NCT02925026|Dietary Supplement|Lactoferrin|
75569179|NCT02925026|Dietary Supplement|Lysozyme|
75569180|NCT02925026|Dietary Supplement|Placebo|
75722482|NCT00784160|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
75722483|NCT00976053|Procedure|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
75569181|NCT02925065|Other|Non-traditional group guitar instruction|A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
75569182|NCT02925182|Device|Er,Cr:YSGG Laser|
75722484|NCT03906747|Other|Interviews, questionnaire and focused group discussions|"To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged."
75876568|NCT04054284|Dietary Supplement|Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
75423243|NCT06039514|Device|GGNeutra mobile app|"the control group will complete another module belonging to the GGTUDE digital platform. Specifically, this app is called GGNEUTRA, and the statements that compose it are totally independent of the target of the study. The operation is similar, sentences appear in the center of the screen, but in this case, the person must accept those sentences that are true, for example: Madrid is the capital of Spain, by dragging it to the top of the screen; and reject those that are false, for example: Tokyo is the capital of Spain, by dragging it to the bottom of the screen."
75423244|NCT06039488|Behavioral|Exercise|"A combination of resistance exercise and cardiovascular exercise (performed 2 days per week for 8-weeks) is tailored to each individual in accordance with their medical/cancer-related history, baseline assessments of physical function, and overall goals.~Resistance exercise includes 6-8 exercises targeting major muscle groups. The first week of the program is used to familiarize participants to the exercises of the program, provide coaching on safe and appropriate technique, and identifying initial load for 2 sets of 12 repetitions (equivalent to ~65% 1 repetition maximum), with a goal of working towards 4 sets of 8 reps. Additionally, participants are asked to perform 20-30 minutes of moderate-to-vigorous aerobic activity (approximately 60-85% age-predicted heart rate maximum) via walking, jogging, or cycling each session."
75569183|NCT02924987|Drug|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
75876569|NCT04494438|Drug|Rituximab|
75569184|NCT04687995|Procedure|Endoscopic myringoplasty|Endoscopic myringoplasty by using two different grafts one each time
75569185|NCT02925104|Drug|INC280|
75569186|NCT02910687|Other|This is an observational study|
75569187|NCT02924909|Drug|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
75569188|NCT02934360|Device|TR(ACE) Assay Testing|Serial plasma testing with TR(ACE) Assay
75569189|NCT02924948|Procedure|Balloon inflation|EUS balloon inflation will be done before insertion through the subjects throat
75569190|NCT02934321|Dietary Supplement|Erythritol|Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.
75569191|NCT02934321|Dietary Supplement|Aspartame|Aspartame is a well tolerated, commonly used artificial sweetener.
75569192|NCT02924831|Other|Acupuncture|Stimulating acupoints by using stainless steel needles with manual manipulation.
75722485|NCT03906747|Other|Review of medical records|"Electronic medical records will be reviewed to collect the following data:~Proportion of patients who fits criteria of EOL who died within 48 hours;~Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration"
75722486|NCT00794300|Device|second magnetic resonance imaging scan|
75722487|NCT00979563|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
75722488|NCT00745901|Drug|Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol|
75876570|NCT03662490|Device|High resolution oesophageal manometry|High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
75876571|NCT04057482|Drug|D|treatment of BV with dequalinium chloride vaginal tablets
75569193|NCT02924831|Other|moxibustion|Stimulating acupoints by using burned moxa
75569194|NCT02924831|Other|placebo|Stimulating acupoints by using stainless steel needles without manual manipulation.
75569195|NCT02934126|Other|breast cancer patients|semi structured face to face interviews
75569196|NCT02924753|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
75569197|NCT02924753|Drug|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
75569198|NCT02924753|Biological|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
75722489|NCT00787670|Other|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
76045683|NCT02469415|Drug|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
76045684|NCT02469415|Drug|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
75722490|NCT00787670|Procedure|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
75423245|NCT06039462|Behavioral|Application of a virtual reality headset|Use of a headset to experience a different reality
75569199|NCT04673136|Device|GI-GENIUS Medtronic|Colonoscopy assisted by GI-GENIUS device
75569200|NCT04673136|Other|Colonoscopy|Standard colonoscopy
75569201|NCT02924792|Device|Reinfusion - Sternal IO needle|
75722491|NCT00787670|Other|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
75569202|NCT02924792|Device|Reinfusion - Intravenous needle|
76045685|NCT02469415|Drug|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
76045686|NCT02446171|Drug|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
76045687|NCT02446171|Drug|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
76045688|NCT02446171|Drug|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
76045689|NCT02446171|Drug|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
76045690|NCT02446015|Drug|SYSTANE® ULTRA Lubricant Eye Drops|
75423246|NCT06039423|Procedure|The M-TAPA block|A high frequency (6-12 MHz) US linear probe was placed in the sagittal plane on the 10 th costal margin in the midline. The probe was then angulated deeply to visualize the lower surface of the costal cartilage. Via in plane technique, a 21 gauge Tuohy needle was inserted cranially between the lower fascia of the costal cartilage and upper fascia of the transversus abdominis muscle by moving the needle tip towards the posterior aspect of the 10 th costal cartilage and 20 mL bupivacaine (0.25 %) was injected.
75569203|NCT02910375|Other|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
75722492|NCT00863850|Drug|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled [14C] bendamustine will be given on day 1 of cycle 1 only.
75722493|NCT00794456|Drug|Passiflora ; Crataegus and Salix|1 tablet PO twice a day
75722494|NCT00794456|Drug|Valeriana|1 tablet PO twice a day
75722495|NCT00860340|Drug|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
75569204|NCT02910375|Other|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
75569205|NCT02924675|Drug|Pregabalin|150mg daily in three doses during three weeks
75722496|NCT00867828|Dietary Supplement|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
75722497|NCT00867828|Dietary Supplement|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
75722498|NCT00867828|Dietary Supplement|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
75722499|NCT00784316|Drug|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
75722500|NCT04040556|Other|Simulation class|Pediatric anesthesia simulation class for anesthesia residences
75722501|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
75722502|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
75423247|NCT06039423|Drug|Ketorolac|conventional general anaesthesia receiving multimodal analgesia
75423248|NCT06039410|Device|ISO-101|ISO-101 is an experimental wearable class 1 medical device which when used is able to raise the blood pressure upon standing via controlled isometric muscular contractions
75569206|NCT02924675|Drug|Placebo|Three doses daily with lactose
75423249|NCT06039332|Procedure|Fitting of the audioprocessor with the auditory implant BCI602|to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures
75423250|NCT06039319|Other|Physical activity|30 minute bout of moderate intensity physical activity performed on a treadmill
75722503|NCT00286429|Drug|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
75722504|NCT00665444|Drug|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
75722505|NCT00860418|Behavioral|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
75722506|NCT00860418|Behavioral|Standard asthma education|Standard asthma education during 2 home visits.
75722507|NCT00867906|Biological|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
75722508|NCT00867906|Biological|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
75722509|NCT00864006|Drug|Divalproex Sodium|
75722510|NCT00864006|Drug|Depakote DR Tablets|
75722511|NCT02554448|Other|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
75423251|NCT06039306|Dietary Supplement|Immunonutrition oral nutrition supplementation|Participant will prescribed with 2 servings of immunonutrition supplement 5 days before surgery and 7 days after surgery
75423252|NCT06039280|Drug|N Acetylcysteine|NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
75876572|NCT04056936|Procedure|Frenotomy|To map the severity determining any possible consequences a tongue-tie may have for breastfeeding and infant nutrition we will follow-up a cohort of tongue-tied infants to register if the feeding, growth, thriving and speech of the infant/child is affected by a tongue-tie.
75423253|NCT06039280|Drug|Dexamethasone|Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure.
75423254|NCT06039280|Other|Placebo|The placebo will be administered in the same way as the drug in the experimental group.
75423255|NCT06039267|Other|Gut Microbiome Testing|Stool microbiome testing using shotgun metagenomic sequencing
75423256|NCT06039254|Drug|HRS-1780|Single dose in each arm
75423257|NCT06039215|Other|Ventilatory adjustments by nurses|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
75423258|NCT06039202|Drug|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim)
75423259|NCT06039202|Drug|TAS-102|TAS-102 is a cytotoxic combination treatment of 2 drugs: trifluridine, a thymidine-based nucleoside analogue, and tipiracil an inhibitor of thymidine phosphorylase.
75423260|NCT06039202|Biological|Bevacizumab|Bevacizumab recombinant humanized monoclonal antibody that binds and neutralizes circulating vascular endothelial growth factor (VEGF)-A.
75423261|NCT06039176|Device|HeartMate 3 (R) left ventricular assist device|No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
75423262|NCT06039163|Drug|HH-120|Participants randomized to active treatment in escalation phase will receive HH-120 administered via inhalation for 5 consecutive days (Day 1 to Day 5). Planned dose levels to be used for the escalation phase of the study are 50 (BID), 50 (TID), and 100 (BID) mg. The expansion phase will begin once the recommended dose for expansion phase determined, based on safety and preliminary efficacy data from the escalation phase.
75423263|NCT06039163|Drug|placebo|Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
75423264|NCT06039150|Procedure|M-TAPA Block|M-TAPA Block; The block will be done by the same experienced anesthesiologist by using ultrasound(USG) after the surgical intervention is completed.The external oblique, internal oblique, and transversus abdominis muscles were shown on the costochondral angle in the sagittal plane at the 10th costal margin by using a high-frequency linear probe. Bilaterally in the midclavicular line at the level of the 10th rib (arcus costarum),0,5 ml/kg 0.25% Bupivacaine (maximum dose 2mg/kg) was administered to between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue.
75423265|NCT06039150|Procedure|Local anesthetic infltration to port sites|Local anesthetic infiltration to port sites; The surgeon infiltrated 0.5 ml/kg of 0.25% Bupivacaine (maximum dose of 2mg/kg) in the skin, subcutaneous tissue, and muscle fascia at each of the three laparoscopic port areas at the end of the surgery.
75423266|NCT06039137|Drug|Cetirizine|Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine
75876573|NCT03663426|Procedure|study group|"High dose corticoids pre-operative and 24h postoperative~Opioid free general anesthesia~Avoid opioids post-operative by continue clonidine, ketamine and lidocaine, only exceptional opioids after NSAID and paracetamol."
75423267|NCT06039124|Other|bevacizumab treatment|Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)
75423268|NCT06039111|Procedure|ICG alone|SLNs will be detected with ICG alone, labelled as such, and subsequent to that tested with Gamma probe for accuracy
75423269|NCT06039098|Device|DCS|DCS monitoring of brain
75423270|NCT06038994|Other|No intervention|This is an obvertional study, and there is no intervention.
75423271|NCT06038968|Drug|Methotrexate 25 MG/ML|Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
75423272|NCT06038968|Procedure|parsplana vitrectomy|Pars plana vitrectomy (PPV) is a technique in vitreoretinal surgery that enables access to the posterior segment for treating tractional retinal detachment in advanced proliferative diabetic retinopathy, in a controlled, closed system.
75876574|NCT03663426|Procedure|control|"No corticoids pre-operative.~Opioid anesthesia~Opioids post-operative after NSAID and paracetamol."
75569207|NCT02910609|Device|Echocardiography|Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
75569208|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic RFA assisted TE|
75569209|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic partial nephrectomy|
75569210|NCT02924558|Other|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
76045691|NCT02415127|Drug|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
76045692|NCT02415127|Drug|Placebo|The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
75876575|NCT03662412|Drug|Sirolimus|Oral solution of sirolimus, 2mg, once a day.
76045693|NCT02468557|Drug|Idelalisib|Tablets administered orally twice daily
75876576|NCT03663270|Device|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
76045694|NCT02468557|Drug|Nab-paclitaxel|125 mg/m^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
76045695|NCT02468557|Drug|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m^2) or racemic leucovorin 400 mg/m^2, oxaliplatin 85 mg/m^2, bolus 5-fluorouracil 400 mg/m^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m^2.
76045696|NCT02413489|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
75569211|NCT02924558|Other|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
75569212|NCT03847545|Drug|Fampridine|sustained-release tablet 10 mg morning and evening.
75876577|NCT02870972|Drug|BCX7353|Plasma kallikrein inhibitor
76045697|NCT02413333|Device|Clear Care Plus contact lens solution|3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
75423273|NCT06038942|Behavioral|Formal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The formal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught formal mindfulness practices (e.g., sitting meditation, body scan, thought meditation, loving-kindness meditation) during the group sessions and will be asked to commit to practicing the strategies independently throughout the project period."
75569213|NCT02924285|Procedure|Procedure (Radiofrequency catheter ablation)|Radiofrequency catheter ablation
75569214|NCT02924285|Drug|Amiodarone|"Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:~Antiarrhythmic Drug Amiodarone"
75569215|NCT02924363|Diagnostic Test|Cardiac MRI with or without contrast dye|MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
75876578|NCT02870972|Drug|Placebo|
75876579|NCT03663192|Device|strain echocardiography|strain echocardiography during septic shock
76045698|NCT02413333|Device|PeroxiClear contact lens solution|3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
76045699|NCT02413333|Device|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per participant's habitual brand
76045700|NCT02413255|Drug|TAK-020|TAK-020 oral solution
76045701|NCT02413255|Drug|TAK-020 Placebo|TAK-020 placebo-matching oral solution
76045702|NCT02444533|Drug|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
76045703|NCT05458219|Drug|IBI343|IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
75876580|NCT03214367|Drug|LY900014|Administered SC
75876581|NCT03214367|Drug|Insulin Lispro|Administered SC
75569216|NCT02924363|Diagnostic Test|Blood sample|Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
76045704|NCT01651039|Drug|Panobinostat|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
75876582|NCT03214367|Drug|Insulin Glargine|Administered SC
76045705|NCT01651039|Drug|Lenalidomide|Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
76045706|NCT01651039|Drug|Dexamethasone|Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
76045707|NCT02349633|Drug|PF-06747775|
76045708|NCT02349633|Drug|Palbociclib|
76045709|NCT02349633|Drug|Avelumab|
76045710|NCT05650125|Other|Biosampling|Biosampling of blood/tumour/adjacent normal tissue
75423274|NCT06038942|Behavioral|Informal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The informal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught how to integrate informal mindfulness into their daily routine and will be guided through a series of demonstrations within the group sessions. Participants will be asked to commit to practicing informal mindfulness independently throughout the project period."
75423275|NCT06038890|Procedure|Holmium laser enucleation of the prostate using the veil-sparing technique|Holmium laser enucleation of the prostate using the veil-sparing technique
75876583|NCT03214367|Drug|Insulin Degludec|Administered SC
75876584|NCT02994108|Behavioral|txt2protect|Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
75876585|NCT02994108|Behavioral|Sexual Health Control|Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
75876586|NCT03663036|Diagnostic Test|Magnetic Resonance Imaging of the shoulder|Clinical and radiological assessments of the shoulders and the donor sites
76045711|NCT02275611|Drug|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
76045712|NCT02275611|Drug|Intranasal Placebo Spray|Intranasal Placebo Spray
76045713|NCT05649891|Other|Emergency Manual|Collection of crisis checklists and fact sheets
76045714|NCT05649735|Device|Logusgyn ovules|"LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
75423276|NCT06038877|Other|Interviews|Individual semi-structured interviews
75423277|NCT06038877|Other|Qualitative analysis|Thematic analysis of the content of responses
75423278|NCT06038864|Diagnostic Test|2 clinical evaluations with 1 month in between|Patients will be evaluated twice with all evaluation methods selected by the international expert group (cfr. aim 1) showing sufficient reliability and feasibility in the patient group with LLL from aim 1
76045715|NCT05649735|Device|Logusgyn Lavander|"LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
76045716|NCT05649735|Other|Placebo|Sterile saline solution
75876587|NCT03614000|Other|Screening Questionnaires|"Measurement tools:~Social Responsiveness Scale (SRS-2) is a validated 65-item scale for the screening of ASD that requires parents to rate the child's behaviors in the previous 6 months. The questionnaire assesses interpersonal behavior, communication and repetitive/stereotypic behavior characteristics of ASD.~The Aseba Questionnaires are validated diagnostic tools that can be filled in by the parents, teachers or children to evaluate various behavioral and emotional problems. The CBCL assesses internalizing (i.e., anxious, depressive and over-controlled) and externalizing (i.e., aggressive, hyperactive, noncompliant and under-controlled) behaviors.~The VG&O The VG&O is a questionnaire developed in Dutch that gives a subscale of parental stress (OBVL), family functioning (VGFO), education habits (VSOG) and life events (VMG). The OBVL will be used"
75423279|NCT06038838|Device|Tioga TMVR System|A bioprosthetic mitral valve, as part of the Tioga TMVR System, is implanted percutaneously in a patient with MR via transfemoral-transseptal access.
75423280|NCT06038786|Behavioral|Resilience Training|A 4 session group-based behavioral intervention which delivers the following skills: mindfulness, metallization, and self-compassion.
75423281|NCT06038773|Diagnostic Test|Diagnosis|"Baseline data were presented with descriptive statistics. Sociodemographic information, pregnancy status, surgical history, exercise habits, gynecologic, obstetric, urologic and gastrointestinal history of the patients were evaluated with the Patient Information Form.Pain intensity was evaluated with the McGill pain questionnaire short form. At the same time, the patients drew the areas where they felt the most pain with the pain maps scale. Pain intensity during sexual intercourse was evaluated with the Visual Analog Scale (VAS).Sexual Abuse Items on the Questionnaire (Modified from Badgley)."
75569217|NCT02934048|Other|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
75569218|NCT02934048|Other|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
75569219|NCT02934048|Other|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
75876588|NCT02032160|Biological|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
75876589|NCT02032160|Biological|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
75423282|NCT06038747|Other|Self-Monitoring|The post-session battery consists of two self-report scales measuring both positive and negative affective reactions of the participants toward their therapist during the therapy session. The general feedback is a brief text that encourages participants to share and discuss their feelings and reflections with their therapist.
75423283|NCT06038747|Other|Individual Psychotherapy|Individual psychotherapy sessions
75876590|NCT03662958|Drug|Lutrate|a novel leuprolide acetate 3.75mg depot
75876591|NCT03662958|Drug|Enantone|market reference leuprolide acetate 3.75 mg depot
75876592|NCT02032082|Other|Carbone monoxide|
75876593|NCT04057170|Other|accelerated protocol and mulligan method|manual therapy technic
75876594|NCT03615638|Other|Fall prevention program|12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
75876595|NCT03636737|Other|pathology associated|list of pathology associated to Pyoderma gangrenosum
75876596|NCT03662256|Other|Current Primary Care Referral Process|Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
75876597|NCT03662256|Other|Telemedicine Referral Process|In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
75876598|NCT03518216|Behavioral|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
75876599|NCT03231371|Drug|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
75876600|NCT03662880|Radiation|Cardiac Magnetic Resonance|Imaging modality used to detection thrombus in left atrium
75876601|NCT03662880|Radiation|Trans-esophageal echo|a procedure in which the ultrasound probe is inserted into the esophagus and ultrasonographic images are obtained of the heart using echo and color Doppler images.
75876602|NCT03613766|Other|Physical activity program|
75876603|NCT04057092|Dietary Supplement|Dietary Supplement INergy-FLD|INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
75423284|NCT06038695|Device|Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB|"Fibro-Gide is the Volume-Stable Collagen Matrix.~Recombinant human platelet-derived growth factor-BB will be found within the device of GEM21S."
75722512|NCT02544126|Device|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
75722513|NCT02544126|Behavioral|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
75876604|NCT03613922|Other|Early Manual Therapy|Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
75876605|NCT03613922|Other|Routine Physiotherapy|Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
75876606|NCT03663114|Drug|Lenvatinib|Lenvatinib capsule
75876607|NCT03526679|Drug|Eribulin|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
75876608|NCT03526679|Drug|Lenvatinib|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
75876609|NCT03615092|Procedure|Root coverage with extended flap technique and acelular dermal matrix|At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
75876610|NCT04056780|Other|Sample collection study|Sample collection and collection of laboratory values
75876611|NCT04844684|Other|Blood and urine collection|Blood sampling urine collections before RYGP and 1 month and 1 year after.
75876612|NCT04057404|Device|Alivecor Heart Monitor|
75876613|NCT03613688|Dietary Supplement|Deepure|Pu'erh Tea extract
75876614|NCT04057326|Drug|Oryz-Aspergillus Enzyme and Pancreatin Tablet|2 tablets/time, 3 times daily,Oral Administration.
75876615|NCT04057326|Drug|Placebo|2 tablets/time, 3 times daily,Oral Administration.
75876616|NCT04573829|Procedure|Home visit|Psychologist come once a week for the carer and three times a week for the patient
75876617|NCT04839146|Biological|ABNCoV2 Vaccine|SARS-CoV-2 vaccine
75876618|NCT02870348|Biological|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
75876619|NCT03615014|Other|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
75876620|NCT03614936|Other|Geriatric Screening Test G8|Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).
75876621|NCT03614936|Other|Geriatric fragility test GERICO|"GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~the socio-cultural evaluation scale,~the ADL autonomy questionnaire,~assessment of locomotor disorders,~nutritional assessment,~the MMSE Cognitive Function Evaluation Questionnaire,~the GDS-4 mood rating scale,~the comorbidity assessment test (Charlson Index)"
75876622|NCT03281720|Procedure|TAD|the same intervention as listed in the arm description
75876623|NCT03613610|Radiation|Radio-frequency ablation of genicular nerves|Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
75876624|NCT03239873|Biological|VARIVAX® PE34 Process|Varicella virus vaccine live manufactured with a new passage extension process (PE34)
75876625|NCT03239873|Biological|VARIVAX® 2016 Commercial Process|Varicella virus vaccine live manufactured with the 2016 commercial process
75876626|NCT03239873|Biological|M-M-R II®|Measles, Mumps, and Rubella virus vaccine live
75876627|NCT05384210|Drug|Milnacipran|Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.
75876628|NCT05384210|Drug|Gabapentin|Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months
75722514|NCT00794612|Drug|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
75722515|NCT00794690|Drug|Cimicifuga racemosa extract for the group|40 mg of Cimicifuga racemosa extract daily dor 12 months
75876629|NCT05384210|Drug|Combined gabapentin/milnacipran|Patients will receive combined gabapentin as group B and MLN as group A
75876630|NCT03613376|Other|Class II compression stockings|Patients in this group will use class II compression stocking continuously until next evening and then next 4 days during daytime
75722516|NCT00860496|Drug|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
75722517|NCT00860496|Drug|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
75722518|NCT00864162|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
75876631|NCT03194672|Behavioral|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
75876632|NCT03614780|Behavioral|30 minutes outdoors|Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
75876633|NCT04804592|Device|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
75876634|NCT04804592|Device|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
75876635|NCT04804592|Device|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
75876636|NCT03213509|Other|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
75876637|NCT04802798|Dietary Supplement|Fibre 1|Food derived fibre presented as a white powder
75876638|NCT04802798|Dietary Supplement|Fibre 2|Food derived fibre presented as a white powder
75876639|NCT04802798|Dietary Supplement|Placebo|Simple sugar, presented as a white powder
75722519|NCT00864162|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
75722520|NCT00787826|Biological|Live Francisella Tularensis Vaccine|"Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20."
76045717|NCT05649657|Other|Cyclic aerobic and resistance training|Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2~3 sessions per week and about 70 sessions in total.
75423286|NCT06038552|Drug|imatinib (IM)|Patients with GIST liver metastases were administered an initial IM dose of 400 mg daily, while those with KIT exon 9 mutations received 600-800 mg daily. All patients continued IM indefinitely unless progression or intolerable adverse reactions.
75722521|NCT00795314|Drug|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
75722522|NCT00795314|Drug|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
75722523|NCT03926169|Drug|Risankizumab|Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
75722524|NCT03926169|Drug|Placebo for risankizumab|Placebo for risankizumab is administered as a SC injection in PFS
75722525|NCT00860808|Drug|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
75876640|NCT02032394|Drug|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
75876641|NCT02032394|Drug|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
75876642|NCT02032394|Drug|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
76045718|NCT02275065|Drug|Bictegravir|Bictegravir tablet(s) administered orally once daily
75569220|NCT02924207|Other|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
75569221|NCT02934087|Procedure|Endovascular Aneurysm Repair|Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
75569222|NCT01287520|Drug|LY2090314|Administered intravenously
75569223|NCT01287520|Drug|pemetrexed|Administered intravenously
75569224|NCT01287520|Drug|Carboplatin|Administered intravenously
75722526|NCT00787982|Device|MRI-Guided Laser Induced Thermal Therapy|LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor
75722527|NCT00285649|Other|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
75722528|NCT00285649|Other|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
75876643|NCT03239483|Drug|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
75722529|NCT00285649|Other|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
75722530|NCT00864240|Drug|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
75876644|NCT03239483|Drug|Placebo gel|Universal HEC placebo gel; administered rectally
75876645|NCT02868554|Device|AcceleDent Aura|Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
76045719|NCT02275065|Drug|Placebo|Placebo to match bictegravir administered orally once daily
75423287|NCT06038552|Procedure|hepatic resection (HR)|HR The determination of the surgical modality was established subsequent to comprehensive consultations tailored to each patient within the Department of Liver Surgery. The surgical strategy was established in consideration of factors such as the residual liver volume, tumour positioning, and the surgeon's personal preference. Employing an intraoperative ultrasonographic to enhance the precision of operative assessment.
75423288|NCT06038552|Procedure|radiofrequency ablation (RFA)|RFA RFA was executed utilizing the commercially accessible Cool-tip™ RFA system or the RF 2000 system. The electrode was percutaneously inserted through a guide needle under real-time ultrasound guidance.The primary objective of the RFA procedures encompassed the complete elimination of the tumour entity, with a prescribed ablative margin of 0.5 cm meticulously factored in.
75876646|NCT02868554|Device|Accelerated Invisalign therapy|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
75876647|NCT01068912|Drug|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
75569225|NCT01287520|Other|ranitidine|Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.
75569226|NCT02924246|Biological|cholera vaccination|Oral cholera vaccination on day 0 and day 14
75569227|NCT02924246|Other|raw milk|raw milk
75722531|NCT00795392|Other|ASA scale|ASA scale evaluation before operation
75722532|NCT00795392|Other|Full-scale psychological assessment|Full-scale psychological evaluation before operation
75722533|NCT02554370|Behavioral|Psychoeducational programme|4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
75876648|NCT01068912|Drug|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
76045720|NCT04875585|Drug|neoadjuvant therapy with Pembrolizumab/Lenvatinib|Neoadjuvant therapy for 6 weeks
76045721|NCT04875585|Procedure|Surgery|surgical resection of primary tumor and lymph-node-dissection.
76045722|NCT04875585|Drug|Adjuvant Treatment Phase|Adjuvant treatment with 15 cycles of Pembrolizumab
76045723|NCT02273973|Drug|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
75569228|NCT02924246|Other|pasteurized milk|pasteurized milk
75569229|NCT02924246|Other|UHT milk|UHT milk
75722534|NCT04018404|Other|FRI CLINICAL PROGRAM|University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
75876649|NCT01068912|Drug|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
75569230|NCT04323865|Diagnostic Test|fetal heart rate variability|No direct intervention, as the study is observational.
75569231|NCT00623740|Drug|hydrocortisone|Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
75569232|NCT00623740|Drug|placebo|intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
75569233|NCT01287403|Other|Refined wheat flour|A treated cereal flour mixed with milk.
75569234|NCT01287403|Other|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
75569235|NCT01287403|Other|Wholegrain wheat flour|A treated cereal flour mixed with milk.
75569236|NCT01287403|Other|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
75569237|NCT01287403|Other|Wholegrain barley flour|A treated cereal flour mixed with milk.
75569238|NCT01287403|Other|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
75569239|NCT02924168|Device|Active Radial Shockwave|Four weekly sessions of active radial shockwave treatment.
75569240|NCT02924168|Device|Sham Radial Shockwave|Four weekly sessions of sham radial shockwave treatment.
75569241|NCT02889913|Other|No intervention only description|No intervention only description
75569242|NCT01287364|Drug|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
75569243|NCT01287364|Drug|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
75876650|NCT03614624|Device|Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips|Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
75876651|NCT03614546|Radiation|SBRT|Stereotactic Body Radiation Therapy (SBRT)
75876652|NCT03614546|Radiation|IMRT|Intensity-modulated Radiation Therapy (IMRT)
75722535|NCT04936880|Device|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
75569244|NCT02924012|Other|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
75569245|NCT02924012|Other|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
75569246|NCT02924012|Other|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
75722536|NCT04936880|Drug|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
75876653|NCT03614546|Procedure|Hepatectomy|Hepatectomy
75722537|NCT00979641|Drug|Docetaxel|
75722538|NCT00864318|Drug|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
75876654|NCT03614546|Procedure|TACE|transarterial chemoembolization (TACE)
75876655|NCT03229109|Device|Spectrophon dehydration body monitor|Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
75569247|NCT02889757|Drug|Acteylcysteine|randomized into three arms
75722539|NCT00864318|Drug|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
75722540|NCT00864318|Drug|Carboplatine|"From cycle 3 to cycle 5 :~Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient"
75423289|NCT06038552|Procedure|transarterial chemoembolization (TACE)|TACE Under a comprehensive assessment of the hepatic arterial blood supply, a selective catheter was introduced into the segmental or subsegmental arteries that supplied the tumour. The regimen of hepatic arterial infusion chemotherapy included infusion of carboplatin 300 mg, a mixture of 50 mg of epirubicin and 8 mg of mitomycin C, intimately blended with 5 mL of lipiodol. Embolization was finally performed with either absorbable gelatin sponge particles or polyvinyl alcohol particles .
75423290|NCT06038253|Device|Fibroscan|Fibroscan is device to detect degree of liver fibrosis in NAFLD patients Dexa scan device detect degree of osteoporosis in NAFLD patients
75423291|NCT06038071|Other|nutrition, IYCF, WASH education|nutrition, IYCF, WASH education
75423292|NCT06038071|Other|scheduled anthropometric screening|anthropometric screening by health care workers at 1, 3, and 6 months
75423293|NCT06038071|Other|family MUAC|family MUAC training for the primary caregiver present at the time of recovery
75722541|NCT00864318|Drug|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
75722542|NCT00864318|Procedure|cytapheresis + transfusion of autologous peripheral blood stem cells|"Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.~At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end"
75722543|NCT00788060|Drug|Everolimus (RAD001)|5mg per day, continuously
75722544|NCT00788060|Drug|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
75722545|NCT00788138|Dietary Supplement|Vitamin D3|250,000 IU of vitamin D3
75722546|NCT00788138|Dietary Supplement|Placebo|Matching Placebo
75722547|NCT00864396|Drug|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
75876656|NCT03614468|Other|Formula A|Formula A is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
75876657|NCT03614468|Other|Formula B|Formula B is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
76045724|NCT02273973|Other|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
76045725|NCT02273973|Drug|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
75569248|NCT02889952|Device|Near infrared camera (NIR)|"Surgical field was examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device)."
75569249|NCT02889835|Device|Supreme Universal Restorative|
75569250|NCT02889835|Device|Supreme Flowable Restorative|
75722548|NCT00745823|Drug|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
75722549|NCT00745823|Drug|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
75722550|NCT00745823|Drug|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
75722551|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 50 mg/day.
75876658|NCT01314131|Behavioral|Stimulation group|"Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~an interest questionnaire for patients. It contains 40 questions about activities.~the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement ."
75569251|NCT02889835|Device|Bulk Fill Flowable Restorative|
75569252|NCT02923973|Other|Transvaginal ultrasound cervical length screening|Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
75569253|NCT01287013|Device|Cone-beam computed tomography (CT)|Imaging
76045726|NCT02273739|Drug|Enasidenib|Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
76045727|NCT05649111|Drug|Difluprednate Eye Drops|post-operative cataract surgery medication regimen. but different dosages between the 2 groups.
75569254|NCT01287013|Device|Conventional Computed Tomography (CT)|Imaging
75569255|NCT02934243|Device|laryngeal mask insertion|airway management with laryngeal mask
75569256|NCT02924090|Drug|Etomidate|Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg
75569257|NCT02924090|Drug|Ketamine|Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.
75569258|NCT02924090|Procedure|Hyperventilation|Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.
75722552|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 100 mg/day.
76045728|NCT02273037|Device|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
75722553|NCT00979797|Other|Community-based interventions to promote maternal and child health|Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
76045729|NCT02273037|Procedure|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
76045730|NCT02465515|Biological|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
76045731|NCT02465515|Biological|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
76045732|NCT02465515|Biological|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
76045733|NCT05561361|Procedure|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
76045734|NCT05561361|Drug|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
76045735|NCT02412631|Drug|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
76045736|NCT02412631|Drug|Varenicline|Chantix is an FDA approved medication for smoking cessation
76045737|NCT02412631|Drug|Placebo|Placebo for lorcaserin
76045738|NCT02272803|Drug|Lenalidomide|
76045739|NCT02272803|Drug|Dexamethasone|
76045740|NCT02272803|Biological|Elotuzumab (BMS-901608)|
75423294|NCT06037811|Drug|Adalimumab|Participants will be randomized 1:1 (non-blinded) to receive either adalimumab (40 mg subcutaneous every 2 weeks for 12 weeks) and prednisone vs prednisone alone. Addition of methotrexate (MTX) and/or hydroxychloroquine (HCQ) is permitted, as needed, at the discretion of the treating rheumatologist. No additional conventional synthetic, targeted synthetic or biologic DMARDs are permitted during the trial.
75423295|NCT06037811|Drug|Prednisone|Prednisone as per standard of care.
75423296|NCT06037616|Other|powerpoint and tutor|Powerpoint on indication of skin suture and tutor for the skill to perform skin suture
75423297|NCT06037616|Other|video skill|Video showing skill to perform a skin suture
75423298|NCT06037616|Other|video errors|Video showing errors of skin suture
76045741|NCT02272725|Drug|Ibuprofen|Ibuprofen
75569259|NCT02924090|Procedure|Electroconvulsive therapy (ECT)|Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
76045742|NCT02272725|Drug|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
76045743|NCT01650805|Drug|ponatinib|45 mg tablet, taken orally once daily
75569260|NCT01286779|Biological|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
75569261|NCT02934165|Behavioral|Family Safety 123|Theoretically-based injury prevention videos for families
75569262|NCT02934165|Behavioral|AAP TIPP sheets|American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
76045744|NCT01650805|Drug|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
76045745|NCT02442349|Drug|AZD9291|Once daily tablet 80 mg
76045746|NCT02411539|Biological|VRC01|40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
75722554|NCT04090073|Procedure|Electroacupuncture|As above
75722555|NCT04090073|Other|Fast-track Perioperative program|As above
75569263|NCT04137770|Other|Ice pack and ketorolac|Scheduled IV ketorolac will be administered and ice packs will be applied to the surgical site
75569264|NCT05594797|Drug|Human BCMA Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
75569265|NCT01286740|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
75569266|NCT02934009|Device|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
75569267|NCT01286311|Behavioral|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
75569268|NCT02923856|Device|The results of clarithromycin susceptibility test of H. pylori isolates|According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
75569269|NCT02923856|Device|Computer generated random number, randomly assigned into groups|The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
75722556|NCT00980031|Drug|Eplerenone|25mg PO daily (QD)for 6 months
75722557|NCT00980031|Drug|Lactose Tablet|Lactose tablet
75722558|NCT02595671|Other|Digital Super Coach|Receive Digital Super Coach during 12 weeks
75722559|NCT02595671|Other|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
75722560|NCT02595671|Other|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
75722561|NCT02595671|Other|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
75876660|NCT03614390|Behavioral|mindfulness based cognitive therapy (MBCT)|a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
75876661|NCT04056234|Procedure|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
75876662|NCT05181215|Drug|Monomethyl Fumarate 190 Mg|2 x oral 95 mg capsules, delayed-release
76045747|NCT02411539|Biological|Placebo|Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
76045748|NCT02465437|Drug|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
76045749|NCT02465437|Drug|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
76045750|NCT02465437|Drug|Part B Open-Label Extension|JBT-101 20mg bid on Days 1-364
76045751|NCT02442271|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
76045752|NCT02442271|Drug|ribavirin|Tablet
76045753|NCT02465203|Drug|Previous treatment in DEB025 study|Follow-up after DEB025 active study
76045754|NCT02463409|Drug|Theophylline|24 hour infusion of IV theophylline
76045755|NCT02528357|Drug|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to <=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
76045756|NCT02528357|Drug|Pembrolizumab|Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
76045757|NCT04910503|Drug|Dexamethasone intravitreal implant|Implant every 4 months if necessary
76045758|NCT04910503|Drug|Fluocinolone Acetonide Intravitreal Implant|Implantation
75569270|NCT02923856|Device|The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups|The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
75722562|NCT02598401|Other|observation|Observational study with no intervention
75423299|NCT06037447|Procedure|3-steps standardized repair-oriented strategy|3-steps standardized repair-oriented strategy, including subvalvular apparatus rehabilitation (leaflet plication if chordae absent on leaflet margin, mal-connected chordae resection if chordae mal-connected to leaflet body, papillary muscle splitting if short chordae or dysplastic or fused papillary muscle etc.), leaflets repair (leaflets plication if functional leaflet prolapse, leaflet cleft closure and patch augmentation for anatomical leaflet defect, etc.) and annuloplasty (posterior annuloplasty for annular dilatation and shallow leaflet coaptation, etc.)
75423300|NCT06037434|Drug|Captopril Tablets|0.3mg/kg, tid
75423301|NCT06037434|Drug|Metoprolol Oral Tablet|0.2mg/kg, bid
75423302|NCT06037434|Drug|Spironolactone Tablets|2-4mg/kg, bid
75569271|NCT02934204|Drug|methotrexate|
75569272|NCT02934204|Drug|temozolomide|
75569273|NCT01286077|Drug|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
75722563|NCT00976287|Procedure|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
75722564|NCT00976287|Procedure|Conserved Therapy|Conserved Therapy
75722565|NCT00976365|Dietary Supplement|THL-P|20ml/bottle, TID, 24weeks
75722566|NCT02596529|Device|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
75722567|NCT02596529|Other|NO Fixation|NO Fixation of the posterior malleolus.
75876663|NCT05181215|Drug|Diroximel Fumarate 462 mg|2 x 231 mg capsules, delayed-release
75722568|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
75876664|NCT02032316|Device|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
75876665|NCT04566575|Other|trans vaginal ultrasound (TVUS)|In the TVUS, the residual myometrium is determined after surgery and the appearance of new cysts in the area of the caesarian section scar is assessed.
75876666|NCT04566575|Other|patient questionnaire|exploratory patient questionnaire regarding satisfaction after correction of isthmocele
76045759|NCT04910425|Drug|Fluorine F 18 DCFPyL|Given IV
76045760|NCT04910425|Drug|Gadobenate Dimeglumine|Given IV
76045761|NCT04910425|Drug|Gadobutrol|Given IV
76045762|NCT04910425|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
75423303|NCT06037434|Drug|Torsemide Tablets|0.2-0.5mg/mg, bid
75423304|NCT06037434|Drug|Potassium citrate powder|0.06g/kg, tid
75423305|NCT06036433|Device|Infrared laser photobiomodulation device|904 super pulsed Infrared laser PBM therapy for the treatment of the signs and symptoms associated with Parkinson's, such as improved motor, non-motor and Quality of Life.
75423306|NCT06036433|Device|Infrared & Red LED photobiomodulation device|Infrared & red LED therapy for the treatment of the signs and symptoms associated with Parkinson's, such as motor, non-motor and Quality of Life.
75423307|NCT06035523|Device|Endoform™ Antibacterial|Application of Endoform™ Antibacterial
75423308|NCT06035523|Device|Endoform™ Natural|Application of Endoform™ Natural
75423309|NCT06035523|Device|Symphony™|Application of Symphony™
75423310|NCT06035237|Other|Cold Spray|Cold Spray: Cold sprays, composed of liquefied gases under high pressure, rapidly evaporate from the applied area, causing a sudden drop in skin temperature. This condition leads to the temporary desensitization of pain receptors or the activation of ion channels, resulting in the brief alleviation of pain sensation. Various medical, non-medical, and surgical methods are employed to manage pain. Cold sprays are among non-medical methods, including massage, cold application, and distraction techniques. Therefore, cold sprays cannot be prescribed like medication. They are used for local anesthesia in cases of acute trauma, injections, blood collection, vein puncture, and similar situations.
75423311|NCT06031740|Procedure|Sclerotherapy with 1.5% polidocanol|"2mL (3%) polidocanol = 60mg; maximal dose: 1mL/column and 4mL/session.~- Group 2: Foam sclerotherapy."
75423312|NCT06031740|Procedure|Foam sclerotherapy.|Tessari's technique; 4mL 3% poilidocanol +16mL air; maximal dose: 2mL/column and 20mL/session.
75423313|NCT06029725|Device|radiofrequency microneedling combined with 1927 nm thulium laser|"session: radiofrequency microneedling + 1927 nm thulium laser~session: 1927 nm thulium laser monotherapy~session: 1927 nm thulium laser monotherapy"
75423314|NCT06029725|Device|radiofrequency microneedling monotherapy|1 session: radiofrequency microneedling monotherapy
75423315|NCT06029218|Radiation|Proteus ONE one daily beam|A single daily beam is used, doubling the dose delivered for this treatment incidence.
75569274|NCT04689152|Biological|Cellgram-LC|Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
75569275|NCT03749655|Behavioral|Physical Activity Promotion|The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
75569276|NCT05590936|Drug|Dimenhydrinate Tablets|2 hours preoperative per os administration of 50 mg dimenhydrinate
75569277|NCT05590936|Drug|Ondansetron iv|Intraoperative intravenous administration of 4 mg ondansetron
76045763|NCT04910425|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
76045764|NCT04910425|Procedure|Positron Emission Tomography|Undergo PET/MRI
75423316|NCT06029218|Radiation|Proteus ONE two daily beam|two daily beams are used, in accordance with the initial treatment plan and the patient's standard of care
75569278|NCT01285960|Device|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
75569279|NCT02933814|Drug|Liposomal Bupivicaine|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
76045765|NCT04910425|Procedure|Transrectal Ultrasonography Guided Biopsy|Undergo TRUS-guided biopsy
75423317|NCT06013943|Drug|Envafolimab+Gemox|"All of drugs were used for 6-8 cycles at the combined treatment stage, then Envafolimab and Gemcitabine continued at maintenance treatment stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 1 years.~Combined treatment stage: Envafolimab(150mg, iH, Q1W, Day1)+Gemcitabine(1000mg/m2, iv, Q3W, Day1 and Day8)+Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8);~Caintenance treatment stage: Envafolimab(400mg, iH, Day1, Q3W)+Gemcitabine(1000mg/m2, po, Day1-14, Q3W)."
75569280|NCT04323826|Other|olive oil-water mixture|50% olive oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
75569281|NCT04323826|Other|olive oil-water emulsion|50% olive oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
75569282|NCT04323826|Other|coconut oil-water mixture|50% coconut oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
75722569|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
75722570|NCT00663260|Drug|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
75722571|NCT00980109|Drug|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
75722572|NCT00980109|Drug|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
76045766|NCT02463331|Drug|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
76045767|NCT02463331|Drug|prednisone|Prednisone 5-15 mg/day until the end of the study
75569283|NCT04323826|Other|coconut oil-water emulsion|50% coconut oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
75569284|NCT04690140|Procedure|Epithelialized free gingival graft|The Epithelialized free gingival graft placed on the prepared bed.
75569285|NCT04690140|Procedure|Modified coronally advanced tunnel technique|Connective tissue graft placed under the prepared tunnel
75722573|NCT00980109|Drug|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
75569286|NCT05578183|Device|theta burst stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
75569287|NCT05578183|Device|sham stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
75569288|NCT05575609|Other|children with Diabetes Mellitus, Type 1|assessment of Relation between anthropometric measurements and balance in children with type 1 diabetes
75569289|NCT02923817|Biological|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
76045768|NCT02463331|Drug|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
76045769|NCT02410837|Procedure|Electromagnetic Navigation Bronchoscopy|
76045770|NCT02314247|Drug|Selinexor|"20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment."
76045771|NCT02463097|Device|Insulin Pump|Closed Loop Algorithm
75569290|NCT02933775|Genetic|CAR-CD19 T cells|Initial dose: A total of 1 - 10×10^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
75569291|NCT02933775|Drug|Fludarabine|30 mg/m^2/day×4 days
75569292|NCT02933775|Drug|Cyclophosphamide|500 mg/m^2/day×2 days
75569293|NCT02923700|Biological|Leukocyte-rich PRP intra-articular injections|
75569294|NCT02923700|Biological|Leukocyte-poor PRP intra-articular injections|
75569295|NCT02923622|Other|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
75569296|NCT02923622|Other|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
75569297|NCT02923622|Other|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
75569298|NCT02923583|Biological|M834|
75569299|NCT02923583|Biological|US-Sourced Orencia®|
75569300|NCT02923583|Biological|EU-Sourced Orencia®|
75722574|NCT00980109|Drug|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
75722575|NCT00740597|Genetic|gene expression analysis|
75722576|NCT00740597|Genetic|polymerase chain reaction|
75722577|NCT00740597|Genetic|western blotting|
75722578|NCT00740597|Procedure|neoadjuvant therapy|
75722579|NCT00740597|Procedure|therapeutic conventional surgery|
75722580|NCT00740597|Radiation|intensity-modulated radiation therapy|
75722581|NCT00976443|Drug|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
75722582|NCT00976443|Drug|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
75569301|NCT02933580|Drug|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
75569302|NCT02933580|Other|Placebo|Participants will receive matching placebo tablets on Day 1.
75569303|NCT02923388|Drug|Injection Mecobalamin,|Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
75569304|NCT02923388|Drug|Tablet Pyridoxine hydrochloride|Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
75569305|NCT02923388|Drug|Intravenous normal saline 1 ml|Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
75569306|NCT02923388|Drug|Placebo pill|Placebo pill orally thrice daily for 5 weeks
75569307|NCT02933658|Drug|Telmisartan|
75569308|NCT02933658|Drug|Amlodipine|
75569309|NCT02933658|Drug|Rosuvastatin|
75569310|NCT02923661|Device|CM LOC|
75569311|NCT02923661|Device|ball attachment|
75569312|NCT02933853|Drug|Faster-acting insulin aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
75569313|NCT02933853|Drug|Insulin Aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
75569314|NCT02923505|Procedure|polygraphy or polysomnography|
75569315|NCT02923310|Biological|Platelets Rich Plasma|
75569316|NCT02923310|Biological|Leucocyte - Platelets Rich Plasma|
75569317|NCT02923310|Drug|Hialuronic Acid|
75569318|NCT00532194|Drug|cediranib|Once-daily oral tablet starting dose 20mg
75569319|NCT02933268|Dietary Supplement|High water intake|High water intake aimed at achieving an urine osmolality < 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
75569320|NCT02933268|Other|Ad libitum water intake|Water intake guided by thirst
75569321|NCT02923154|Drug|MT-3995|
75569322|NCT02923154|Drug|Placebo|
75569323|NCT02665143|Drug|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
75569324|NCT00532272|Drug|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
76045772|NCT05427149|Drug|25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)|It will be evaluated whether there is postpinal shivering in the cases.
75569325|NCT02922920|Other|Tart cherry juice|16 fl. oz of tart cherry juice
75569326|NCT02922920|Other|Placebo|16 fl. oz of placebo
75569327|NCT03292419|Procedure|Topography-guided LASIK|LASIK surgery
75569328|NCT02933385|Behavioral|Health Risks assessement|Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
75569329|NCT02933385|Behavioral|Web-based health discussions|Create interactions between the employees.
75569330|NCT02933385|Behavioral|SOScuisine website|Site that is personalized to the employee. It provides menus, grocery shopping list and other.
75569331|NCT02933385|Behavioral|Health screening|Screen for diabetes, cholesterol, blood pressure and body weight.
75569332|NCT02933385|Behavioral|Closing events|these aim to motivate the employees to continue into the program.
75569333|NCT02933385|Behavioral|Coaching|The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.
75569334|NCT02933385|Behavioral|Social Health platform|
75569335|NCT02933385|Behavioral|Accelerometer provided|Social Health Platform: employees can challenge themselves or each other.
75569336|NCT02922842|Device|Transcutaneous Electrical Nerve Stimulation|
75569337|NCT02933190|Procedure|transvaginal surgery；UAE and D&C|For cesarean scar pregnancy treatment
75569338|NCT02923076|Other|CCR5 delta32/delta32 cord blood transplantation|
75569339|NCT02923037|Procedure|Yoga|Complete guided and home yoga sessions
75569340|NCT02923037|Other|tape measurement of arm|Ancillary studies
75569341|NCT02923037|Other|Quality-of-Life Assessment|Ancillary studies
75569342|NCT02923037|Other|ldex measurement of arms|
75569343|NCT02933229|Device|biopsy|patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.
75569344|NCT02933229|Drug|H. pylori eradication|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
75569345|NCT02922803|Drug|1 combination tablet of Vitamin D3/calcium per day|Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
75722583|NCT00800618|Drug|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
75423318|NCT06011239|Behavioral|Team-building processes|"All staff in one of the four role groups (medical assistants (MAs); clerical/administrative staff; nursing staff; and physicians/nurse practitioners/physician assistants) will be sent an anonymous survey. The survey will ask staff to consider what help participants wish to ask for and what help participants can offer to staff in the other three roles at times when people are busy or overwhelmed. These ideas will be combined into a typed idea list for each role and then staff in clinics will discuss. Once these are finalized the clinics will implement these.~At several points during the year, the study team will send out brief surveys. These surveys will collect the clinic and job role and ask participant to rate how much effort has been made in different ways, and if there are open-ended comments about what is or is not working. This information will be used to improve the intervention at each clinic."
75569346|NCT02922803|Drug|2 combination tablets of Vitamin D3/calcium per day|Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
75569347|NCT02933424|Dietary Supplement|Protein Powder|
75569348|NCT03194568|Device|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
75569349|NCT02922569|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
76045773|NCT02441179|Other|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
75423319|NCT06010927|Drug|ketamine/midazolam|premedication
75423320|NCT06010927|Drug|Ketofol|Pre-extubation
75423321|NCT06008444|Other|Physical Evaluations of post-COVID-19 individuals|In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
75569350|NCT02922569|Other|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
75569351|NCT02922569|Other|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
75569352|NCT02922569|Other|Traumatic Brain Injury Information Session|Ten minutes of viewing traumatic brain injury related news, information, and programs.
75569353|NCT02834559|Drug|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
75569354|NCT02834559|Drug|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
75569355|NCT02922608|Other|simulation practice|simulation session
75569356|NCT02933307|Device|HealthPatch|The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
75569357|NCT02933307|Device|ViSi Mobile|ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
75569358|NCT02922686|Drug|Flucloxacillin|One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
75423322|NCT06008444|Other|Physical Evaluations of non-post-COVID-19 individuals|In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
75423323|NCT06006897|Other|Physical Evaluations of post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis with post-COVID-19 individuals. The data to be obtained from all these evaluations will be collected from the individuals at one time and over a period of approximately 1 hour at the most. Step count tracking with pedometer will be done for each individual for 3 days.
75569359|NCT02922686|Drug|Phenoxymethylpenicillin|One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
75569360|NCT02922686|Drug|Placebo (for phenoxymethylpenicillin)|Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
75569361|NCT02922530|Other|Computerized Plasticity-based Adaptive Cognitive Training|
75569362|NCT02922530|Other|Commercially available computerized training|
75569363|NCT02922452|Drug|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
75569364|NCT02922452|Drug|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
75569365|NCT02922374|Drug|corticosteroids|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
75569366|NCT02933151|Dietary Supplement|Nutritional Supplement|Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
75569367|NCT02922491|Dietary Supplement|vitamin E|daily intake of vitamin E
75569368|NCT02922491|Dietary Supplement|starch|daily intake of starch (control)
75569369|NCT04687722|Other|High Intensity Aerobic Training.|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of high intensity aerobic training at 80-90% of heart rate maximum increased gradually on treadmill and elliptical trainer and then 2-5 minutes of low to moderate intensity cool down exercises.
75569370|NCT04687722|Other|Low intensity Aerobic Training|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of low intensity aerobic training at 40-60% of heart rate maximum increased gradually on elliptical trainer and jogging and then 2-5 minutes of low to moderate intensity cool down exercises.
75569371|NCT03457454|Other|Primary Care Provider/Staff Participants Interview|-Approximately a 30 minute interview
75722584|NCT00800618|Drug|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
75722585|NCT00800618|Drug|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
75722586|NCT00800618|Drug|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
75722587|NCT00800618|Drug|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
75569372|NCT03457454|Other|Patient Participant Interview|-Approximately 45-60 minute interview
75569373|NCT03457454|Other|Patient Participant Anonymous Survey|-Survey completion will take approximately 15 minutes
75423324|NCT06006897|Other|Physical evaluations of non-post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis without post-COVID-19 individuals.
75722588|NCT00800696|Procedure|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
75722589|NCT00980187|Drug|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
75722590|NCT00980187|Drug|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
75722591|NCT00795470|Drug|Antimicrobial|Appropriate antimicrobial based on urine culture results
75722592|NCT00795470|Device|Catheter change|Change urine catheter
75722593|NCT00980421|Dietary Supplement|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
75722594|NCT00284089|Drug|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
75423325|NCT05992519|Diagnostic Test|¸FeNO|FeNO measured with a NIOX VERO device after the methacholine challenge
75423326|NCT05987046|Behavioral|Contrast training|Three sets of three repetitions of parallel squats at 90% of 1RM
75423327|NCT05982717|Other|No intervention|As this is an observational study, no intervention will be administered.
75569374|NCT03457454|Other|Colonoscopy Provider/Staff Participants Interviews|-Approximately a 30 minute interview
75569375|NCT02933112|Device|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
75569376|NCT02922140|Behavioral|pharmaceutical care service|
75569377|NCT02932917|Device|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
75423328|NCT05982405|Other|Training group: Inspiratory muscle training|The individuals in the training group will be performed inspiratory muscle training at 30-50% of the maximal inspiratory pressure. Inspiratory muscle training will be done using an inspiratory muscle training device (PowerBreathe®) that works with the threshold loading principle. Inspiratory muscle training will be done for 15 minutes per a session, 2 times per a day or, if tolerated, 30 minutes per a day and 1 time per a day, 5-7 days/week (one session under the supervision and the others at home), for a total of 6 weeks. Applications made at home will be followed with a diary.
75441738|NCT01637844|Drug|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
75569378|NCT02922179|Drug|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
75441739|NCT01637857|Dietary Supplement|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
75569379|NCT05467644|Procedure|Treatment of Fracture Related Infection|Observational Retrospective Study. Only one group. Patients diagnosed with fracture-related infection and submitted to surgical treatment
75569380|NCT02922062|Other|Canola Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
75569381|NCT02922062|Other|Palm Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
75569382|NCT02922062|Other|Butter|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
75569383|NCT02922101|Behavioral|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
75722595|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
76045774|NCT02441179|Other|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
76045775|NCT02441179|Other|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
75722596|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
75722597|NCT00984633|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
75722598|NCT00984633|Drug|Propofol|4-10 mg/kg/hr maintenance anesthesia
75722599|NCT03975751|Diagnostic Test|The Glasgow Coma Scale (GCS)|Use the common GCS, RASS and self-reported pain assessment for evaluating consciousness, agitation/sedation and analgesia.
75722600|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg [3.7 MBq/kg] (minimum dose 1mCi [37MBq] but not to exceed 5 mCi [185 MBq]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
76045776|NCT05406167|Device|Registry - Observational|Observation Registry for Medical Device
76045777|NCT02462473|Drug|Aripiprazole|Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
75441740|NCT01637857|Dietary Supplement|oligoantigenic diet|oligoantigenic diet associated to life style counseling
75722601|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed > 23 Gy to the kidneys, > 30 Gy to the liver, or > 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
76045778|NCT02462473|Drug|Olanzapine|Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
75441741|NCT01637883|Drug|benzydamine HCl|3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
75441742|NCT01637896|Device|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
75441743|NCT01637896|Device|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
75876667|NCT03613298|Device|HIFU (Focal One®)|Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
76045779|NCT02462473|Drug|Paliperidone|Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
75569384|NCT02922101|Behavioral|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
75569385|NCT02932839|Device|NeuroPort micro-electrode array|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
75569386|NCT02932800|Procedure|"Fixation with ballerina technique and flip"|
75569387|NCT02932800|Procedure|Habitual Fixation|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture
75569388|NCT02932800|Other|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture|
75569389|NCT02921984|Drug|Docetaxel|Docetaxel only: 80 mg/m2 on day one, every 21 days if
75569390|NCT02921984|Radiation|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
75722602|NCT00976755|Drug|everolimus|"Everolimus:~10mg daily"
75722603|NCT00864474|Drug|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
75876668|NCT03661710|Other|Investigating Adherence to Standard of Care Medication and Cardiac Rehabilitation|Information from health care insurance providers on how many patients adhered to prescribed medication and how many underwent cardiac rehabilitation and how adherence influenced cardiovascular outcome will be retrieved
75876669|NCT03212261|Behavioral|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
75876670|NCT04056702|Drug|Elexacaftor-tezacaftor-ivacaftor exposure|Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
75569391|NCT02921984|Drug|Pemetrexed|Pemetrexed only: 500 mg/m2 on day one, every 21 days
76045780|NCT02462473|Drug|Quetiapine|Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
76045781|NCT02462473|Drug|Risperidone|Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
76045782|NCT04465799|Behavioral|ENTREN|ENTREN intervention for children (cognitive-behavioral perspective + motivational interview)
76045783|NCT04465799|Behavioral|ENTREN-F|ENTREN intervention for children + family intervention.
75569392|NCT02921984|Drug|Cisplatin|Cisplatin only: 70 mg/m2 on day one to day three, every 21 days
75569393|NCT02921867|Other|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
75876671|NCT03613142|Procedure|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
75722604|NCT00283387|Drug|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
75722605|NCT00283387|Drug|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
75876672|NCT03613142|Procedure|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
75423329|NCT05982405|Other|Control group: Thoracic expansion exercise|"Individuals in the control group will be performed thoracic expansion exercises. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of deep breathing + holding the deep breath for 3 seconds + slowly emptying all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
75722606|NCT00788216|Other|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
75423330|NCT05958147|Biological|C-PRF|thorough scaling and root planing is performed followed by withdraw of 5ml of blood from antecubital vein of patient with consent . Following C-PRF protocol of 3000rpm for 8 min centrifugation is performed. 1ml of plasma is drawn from the test tube just above the red blood cell layer and allowed to clot and the formed clot is placed in the periodontal pocket after scaling and root planing
75423331|NCT05952648|Procedure|Lower tract respiratory samples|Within 1 hour from HAP or VAP suspicion, quantitative tracheal aspirate or bronchoalveolar lavage will be performed to confirm the diagnosis. Clinicians will be encouraged to perform BAL whenever possible
75423332|NCT05952648|Diagnostic Test|Multiplex PCR assay (Film-array Pneumonia Panel Plus)|The lower tract respiratory samples will be analyzed with Multiplex PCR assay (Film-array Pneumonia Plus).
75423333|NCT05952648|Diagnostic Test|Lower respiratory tract standard culture|The lower tract respiratory samples will be analyzed using convention microbiological methods (including conventional Gram stain and semiquantitative culture on both selective/differential and screening agar media)
75423334|NCT05952648|Diagnostic Test|Blood sample standard culture|When HAP or VAP are suspected, blood samples from peripheral vein will be collected and analyzed with conventional microbiological methods
75423335|NCT05950399|Procedure|Echocardiography|Undergo resting echocardiography
75722607|NCT00976833|Other|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
76045784|NCT04465799|Behavioral|Control group|Behavioral modification of habits
75722608|NCT00976833|Other|Usual Care|Usual Physical Therapy care
76045785|NCT01462097|Behavioral|Aerobic exercise training|12 months of aerobic exercise
76045786|NCT01462097|Behavioral|Health Education|12 months of health education sessions
75423336|NCT05950399|Other|Electronic Health Record Review|Ancillary studies
75423337|NCT05950399|Other|Questionnaire Administration|Ancillary studies
75569394|NCT05467566|Device|Transcranial direct current stimulation|Exercise protocol + application of active direct current stimulation for 30 minutes.
75569395|NCT05467566|Device|Sham Transcranial direct current stimulation|Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
75722609|NCT00788294|Biological|tanezumab|Drug solution given intravenously only once at dose of 10 mg
75722610|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
75722611|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
75722612|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
75423338|NCT05950399|Procedure|Stress Echocardiography|Undergo stress echocardiography
75423339|NCT05939336|Dietary Supplement|Mannooligosaccharides yeast extract|15 g per day of mannooligosaccharide yeast extract.
75423340|NCT05916196|Drug|18F-Fluoroestradiol|18F-FES PET/CT
75423341|NCT05912946|Drug|Interferon|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.
75423342|NCT05912946|Drug|Sodium Hyaluronate|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.
75423343|NCT05912946|Drug|Sodium Chloride Injection|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
75423344|NCT05905224|Device|Invisalign 7-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 7-day wear protocol
75569396|NCT02921945|Biological|SCT800|recombinant human coagulation factor VIII
75569397|NCT04689230|Procedure|upper eyelid blepharoplasty|upper eyelid blepharoplasty
75876673|NCT03662802|Other|Neural Network Classifier|The convolutional neural network is configured to receive an electrocardiogram segment as an input and to generate an output indicative of whether the received electrocardiogram segment represents a cardiac arrhythmia. No specific features of the electrocardiogram are identified to the convolutional neural network, and the received electrocardiogram segment is not filtered, transformed, or processed prior to reception by the algorithm. The algorithm is trained in a similar manner - the electrocardiogram segments are the sole input to the convolutional neural network.
76045787|NCT02440789|Drug|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
75423345|NCT05905224|Device|Invisalign 3-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 3-day wear protocol
75569398|NCT04647825|Other|Collection of data from non-invasive epilepsy monitoring|Creation of a large long-term EEG database for seizure detection/prediction
76045788|NCT02462083|Drug|IDP-118 Lotion|IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
76045789|NCT02538341|Biological|Herpes Zoster (HZ) Vaccine|
76045790|NCT02538341|Drug|Placebo|
75423346|NCT05879523|Drug|HRS-1893|subcutaneous, single dose, multiple doses
75423347|NCT05879523|Drug|Placebo|subcutaneous, single dose, multiple doses
75423348|NCT05877898|Behavioral|CHW Education|Participants will be invited to meet with the CHW to learn about eating healthier to reduce blood pressure and enhance quantity and quality of life.
75569399|NCT04689269|Other|"The simulated easy airway"|A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create an easy airway situation by adjusting the manikin until it becomes in a neutral position
75569400|NCT04689269|Other|"The simulated difficult airway"|"A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create a difficult airway scenario will be established by placing the occiput on an Oasis Elite™ Prone Head Rest, Adult (140 mm in height) (Covidien, Mansfield, MA, USA), and inhibiting head and neck movement by securing the head with an adhesive tape, simulating the effect produced by a cervical-collar."
75569401|NCT04689269|Device|King Vision Laryngoscope|Using a King Vision Laryngoscope for placement of the DLT
75569402|NCT04689269|Device|MacGrath Laryngoscope|Using a MacGrath Laryngoscope for placement of the DLT
75569403|NCT01285609|Drug|Ipilimumab|
75569404|NCT01285609|Drug|Placebo|
75569405|NCT01285609|Drug|Paclitaxel|
75569406|NCT01285609|Drug|Carboplatin|
76045791|NCT05446181|Behavioral|Postoperative delirium|Postoperative delirium
75722613|NCT00795548|Drug|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
76045792|NCT05446181|Procedure|Hip surgery|Orthopedic hip joint surgery under spinal anesthesia
75722614|NCT00980577|Device|NUUS|Sonosite Micro Maxx
76045793|NCT02538107|Drug|Methoxy-polyethyleneglycol epoetin beta|
76045794|NCT02538029|Behavioral|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
76045795|NCT02538029|Behavioral|Single Task Group|Performing motor or cognitive tasks alone.
76045796|NCT05445401|Behavioral|Pre-rehabilitation|Triple pre-rehabilitation interventions of exercise, nutrition and psychology
76045797|NCT05445401|Behavioral|Standard medical care|Traditional care
76045798|NCT05401331|Device|Treadmilll|Hemodynamic changes before and after treadmill use
76045799|NCT05401331|Other|mask|mask
76045800|NCT02272413|Drug|BI 695502|
76045801|NCT02272413|Drug|Avastin|
76045802|NCT02396381|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
76045803|NCT02396381|Other|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
76045804|NCT05426291|Other|BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?|In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
75423349|NCT05877898|Behavioral|CHW Education and Navigation|Participants will be invited to complete all the CHW education arm material and be offered a menu of optional services for personalization including: (1) transportation to the grocery store (weekly for 4 weeks), (2) culturally adapted hypertension-tailored cooking recipes, (3) a virtual cooking class with food delivered to their door led by community partner, (4) access to UF IFAS's online library of healthy food cooking videos, and (5) in-store education on food labels, grocery shopping, and food resource management skills through the Cooking Matters at the Store curricula.
75423350|NCT05856760|Drug|Sparsentan|Target dose of 400 mg daily
75423351|NCT05851963|Device|Sonicare Diamond Clean 9000|Brush teeth with the electric toothbrush 1 daily during the orthodontic treatment
75569407|NCT02921672|Other|Mediterranean Diet|Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
76045805|NCT05648877|Device|Ureteroscope|Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
76045806|NCT05424809|Behavioral|Shared decision-making model|"The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation"
76045807|NCT05648799|Drug|GP30341 capsules 200 mg|orall take of capsules twice a day
75423352|NCT05851963|Device|HydroSonic Pro|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
75423353|NCT05851963|Device|Oral-B 123|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
75569408|NCT04689984|Drug|Standard therapy|Gabapentin, pregabalin, or amitriptyline
75569409|NCT04689984|Drug|Astaxanthin|Astaxanthin 6 mg tablet once daily
76045808|NCT05648799|Drug|Standard therapy|Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
76045809|NCT02120807|Drug|Certolizumab|
76045810|NCT02120807|Drug|cisplatin|
75569410|NCT02921711|Device|LVIS®|Low-profile Visualized Intraluminal Support device
75569411|NCT05467254|Biological|CLL1+CD33 CAR-T|CLL1+CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
75569412|NCT03981341|Drug|Duavive (0.45 estrogens mg and 20 mg bazedoxifene)|Drug given for 3 months in each participant
76045811|NCT02120807|Drug|pemetrexed|
75569413|NCT04620057|Dietary Supplement|butyrate|sodium butyrate (20 mg/kg body weight/day)
76045812|NCT04457531|Drug|LiuWeiLuoBi Granule|LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
75423354|NCT05851963|Device|Curaprox CS 5460|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
75423355|NCT05851859|Other|Cardiac coherence|Use of Cardiac coherence (complementary respiratory training) during 6 month
75423356|NCT05831475|Behavioral|Intergenerational Virtual Paired Exercise|Participants will be paired with someone older/ younger and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
75423357|NCT05831475|Behavioral|Peer Virtual Paired Exercise|Participants will be paired with someone of the same age group and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
75569414|NCT04620057|Other|placebo|cornstarch
75569415|NCT03924440|Diagnostic Test|Proov (Ovulation Double Check) Test|Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check
75569416|NCT01285492|Drug|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
76045813|NCT04457531|Other|Standard medical treatment|Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
76045814|NCT02532647|Drug|Remimazolam|
76045815|NCT02532647|Drug|Midazolam|
76045816|NCT02532647|Drug|Placebo|
76045817|NCT02537015|Drug|Bimatoprost|Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
76045818|NCT05397119|Biological|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
75569417|NCT01285492|Drug|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
75722615|NCT00282919|Drug|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
76045819|NCT05397119|Biological|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
75569418|NCT02889991|Other|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
75569419|NCT02889991|Other|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
75569420|NCT02889991|Other|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
75423358|NCT05828979|Device|UroMems artificial urinary sphincter|Implantation of the device
75423359|NCT05814523|Drug|Ganaxolone|Ganaxolone will be administered as IV solution.
75423360|NCT05814523|Drug|Placebo|Placebo will be administered as IV solution.
75423361|NCT05814523|Drug|Standard of care|A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
75569421|NCT02889991|Other|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:~To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~Monitor longitudinally taut band, with index and middle fingers.~Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~Remove the bridles and perform hemostasis with cotton.~We will give end to the technique placebo of dry needling."
75569422|NCT04615143|Drug|Tislelizumab|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w). After 2 cycles of Tislelizumab and evaluation of resectability, patients will receive surgery in 6 weeks after enrollment. Patients will receive Tislelizumab for 1 year (200mg, iv, q3w, 17 cycles) in 4-6 weeks after surgery.
75722616|NCT00800774|Procedure|LASIK|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
76045820|NCT05397119|Biological|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
75722617|NCT00984789|Drug|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
75722618|NCT00984789|Drug|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
75722619|NCT00864552|Drug|Kogenate (BAY14-2222)|Patients with severe haemophilia A (<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
75722620|NCT03975673|Procedure|hip replacement|Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
75722621|NCT04046822|Drug|Liraglutide 6 MG/ML [Saxenda]|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
75722622|NCT04046822|Drug|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
75423362|NCT05813587|Biological|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
75423363|NCT05813587|Other|Normal saline|Normal saline
75423364|NCT05812040|Diagnostic Test|Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)|all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively
75423365|NCT05810649|Drug|Freshly manufactured 35 kDa hyaluronan fragment|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
75722623|NCT04007835|Drug|Anlotinib Hydrochloride|anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
75722624|NCT05226936|Diagnostic Test|Cell free DNA analysis|samples will be analysed using molecular techniques including sequencing for measuring dd-cfDNA or analysis of the presence of HLA-antibodies using commercial bead-technologies (Luminex or Immucor)
75722625|NCT00795626|Behavioral|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
75722626|NCT00867984|Other|Torsion optimized|Torsion optimized VV timing plus AV optimization (VTI)
75722627|NCT00867984|Other|Usual Care|AV optimization (VTI) only
76045821|NCT05397119|Biological|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
76045822|NCT05397119|Biological|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
76045823|NCT05397119|Biological|H5N1 IIV - IM|90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization
75722628|NCT00800930|Biological|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
76045824|NCT02271945|Drug|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
76045825|NCT02271945|Drug|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
75423366|NCT05806931|Drug|TAS-102, oxaliplatin, irinotecan with bevacizumab|Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
75423367|NCT05804487|Device|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
75441744|NCT01637909|Drug|Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.|All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
75569423|NCT04615143|Drug|Tislelizumab combined with Levatinib|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w); Lenvatinib from Day1 to Day 28 (8/12mg qd). After neoadjuvant treatment and evaluation of resectability, patients will receive surgery in 6weeks after enrollment. Patients will receive Tislelizumab combined with Lenvatinib for 1 year in 4-6 weeks after surgery.
75569424|NCT02921594|Device|Total knee arthroplasty with Vanguard XP|
75569425|NCT02921594|Device|Total knee arthroplasty with Vanguard CR|
75569426|NCT05467137|Device|MSOT|MSOT imaging (after ICG injection)
75569427|NCT02933463|Other|Embrace Wetbond|not require an additional bonding agent hydrophilic, fluoride releasing
75569428|NCT02933463|Other|Clinpro sealant|
75569429|NCT02921633|Other|Intervention letter|
75569430|NCT01284634|Drug|GWP42003 200 mg/day Dose|GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
75722629|NCT00800930|Biological|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
75722630|NCT00868062|Other|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
75722631|NCT00282295|Biological|Boostrix®|GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
76045826|NCT02271945|Drug|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
76045827|NCT05555199|Radiation|99mTc-nanocolloid|Injection of 99mTc-nanocolloid when lung cancer is diagnosed during a navigation bronchoscopy, followed by one or two SPECT/CT-scans.
75569431|NCT01284634|Drug|GWP42003 400 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
76045828|NCT05555199|Drug|ICG|If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
76045829|NCT01660763|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
75423368|NCT05799430|Behavioral|Multidisciplinary medication review|"FP communicate to the PCP patients recently discharged. The medication review process consists in 5 steps:~PCP perform a structured drug review based on information from health record and e-prescribing application. The drug review comprise the appraisal of potentially inappropriate medication based on lists of explicit criteria.~PCP communicates and discuss the results of medication review with GP and PCN, in a brief meeting face-to-face, with possible adaptation of the recommendations.~FP, PCN and PCP agree on a personalized therapeutic plan for the patient that includes actions to optimize the therapy.~FP and PCN share plan with the patient and/or carer with possible adaptation of the recommendations and agree about actions to be implemented.~FP and PCN communicate to PCP final agreement with patient and/or carer~FP and/or PCN follow-up implantation of agreed recommendations using standard health care procedures"
75569432|NCT01284634|Drug|GWP42003 800 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
75569433|NCT01284634|Drug|Placebo|Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
75569434|NCT02932722|Other|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
75569435|NCT02932722|Drug|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
75569436|NCT02932722|Drug|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
75569437|NCT02921516|Behavioral|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
75569438|NCT02921516|Behavioral|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
75569439|NCT02921516|Behavioral|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
75569440|NCT01284361|Device|30 cm Intermittent Catheter|Randomized cross-over
75423369|NCT05799430|Behavioral|Control group|Usual care by FP an PCN
75423370|NCT05799326|Drug|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.
75423371|NCT05799326|Drug|Levofloxacin simulant|Levofloxacin simulant is placebo.
75569441|NCT01284361|Device|40 cm Intermittent Catheter|randomized cross-over
75569442|NCT02921438|Device|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
75569443|NCT02932761|Drug|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
75722632|NCT00282295|Biological|Menactra™|Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
75722633|NCT00742781|Dietary Supplement|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
75722634|NCT00663026|Drug|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
75722635|NCT00663026|Drug|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
75722636|NCT00663026|Drug|placebo|Placebo subcutaneous injection once per week for 6 months
75722637|NCT00280735|Drug|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
75722638|NCT00280735|Drug|docetaxel|75 mg/m² intravenously, once, every 3 weeks
75722639|NCT02555462|Device|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
75423372|NCT05796544|Behavioral|Remote self-care education|The intervention group will receive a total of four remote educational sessions over 2 months.
75423373|NCT05796544|Behavioral|In-person self-care education|The active comparator group will receive a total of four in-person educational sessions over 2 months.
75569444|NCT02932761|Procedure|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
75569445|NCT01283971|Drug|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
75722640|NCT00979719|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
75722641|NCT00979719|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
75722642|NCT01070251|Behavioral|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
75423374|NCT05782010|Device|PexyEazy|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
75423375|NCT05776901|Device|C-STRESS|Participants were asked to use the C-STRESS app daily for 6 weeks to participate in Cognitively Based Compassion Training (CBCT) lessons, watch guided meditation videos, complete short reflective exercises, and engage with other content provided in C-STRESS (i.e., attending drop-in sessions, journaling, completing mood and wellbeing check-ins, and reading educational articles on depression, anxiety, and stress)
75423376|NCT05775731|Diagnostic Test|Tests for markers of inflammation and activated hemostasis|Volunteers who do not have exclusion criteria, are invited to complete the three questionnaires and to choose a date for blood drawing based on whether they are shift workers or not. Blood is immediately processed for platelet markers, and stored for inflammation and coagulation markers
75423377|NCT05775068|Radiation|Radiotherapy|Radiotherapy
75423378|NCT05769595|Biological|MK-2060|Lyophilized powder diluted in normal saline for IV infusion
75423379|NCT05769595|Drug|Placebo|IV infusion
75569446|NCT01283971|Drug|adalimumab|Adalimumab 40 mg SC every 2 weeks.
75569447|NCT01283971|Drug|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
75423380|NCT05732753|Other|Mindfulness + Education in Neurophysiology of pain|An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
75722643|NCT01070251|Behavioral|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
75876674|NCT03613064|Other|Socially Enhanced Transitional Care Intervention|Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
75876675|NCT03612986|Dietary Supplement|SYALOX® 300 Plus|Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
75876676|NCT03612986|Dietary Supplement|Placebo|Placebo comparator. No chemical effect expected
75876677|NCT03612440|Drug|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
76045830|NCT01660763|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
75423381|NCT05731024|Device|close-loop synchronization controller with SPONT mode|One-hour period where the pressure support of spontaneous breath will be automatically titrated based on pressure and flow waveform analysis obtained from the patient.
75423382|NCT05731024|Device|Conventional synchronization settings with SPONT mode|One-hour period where the pressure support of spontaneous breath will be manually set.
75423383|NCT05722821|Other|Hypopressive intervention|"Hypopressive abdominal gymnastics is based on a basic level hypopressive exercise program that will be:~A duration of 12 weeks with a frequency of 2 sessions a week and lasting 45 minutes each. Hypopressive abdominal exercises will be performed individually adapted to the capacity of the participant.~There will be an initial anatomical training of the muscles involved in carrying out the exercise and practice in the respiratory technique for a duration of 15 minutes. Afterwards, hypopressive exercises will begin for 20-30 minutes, changing positions if possible."
75423384|NCT05721560|Device|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
75423385|NCT05720468|Other|Exercise|Combined endurance and resistance exercise training
75569448|NCT01283971|Drug|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
75569449|NCT01283971|Drug|methotrexate|Methotrexate 10-25 mg weekly.
75569450|NCT01283971|Drug|folate|Folate at least 5 mg weekly.
75722644|NCT00801008|Behavioral|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
75722645|NCT03975283|Drug|Exparel 266 MG Per 20 ML Injection|266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
75876678|NCT03612440|Other|normal saline|receive matching placebo (equal volum of normal saline)
76045831|NCT04875273|Device|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine
76045832|NCT04875273|Device|Kinesiology Tape application|Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine
76045833|NCT04859049|Procedure|infromedial single injection|"Group 1: We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin."
75722646|NCT03975283|Drug|Bupivacaine Hcl 0.25% Inj|0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
75722647|NCT00795782|Procedure|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
75423386|NCT05720468|Other|No Exercise|Continue usual level of physical activity; option to participate in exercise training program after 26-week intervention period
75423387|NCT05711602|Other|Pilates|raining based on a basic level Pilates exercise program will be as follows: A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty.
75423388|NCT05710783|Biological|AVX-COVID/12|Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
76045834|NCT04859049|Procedure|medial canthus injection|": We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid classical medial canthal injection"
75423389|NCT05710783|Biological|ChAdOx-1-S[recombinant]|Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine
75569451|NCT05466981|Behavioral|Cognitive Behavioral Counseling|The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
75569452|NCT02921282|Genetic|Genotype dopamine|Laboratory investigations of nicotine reinforcement
75569453|NCT02921282|Genetic|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
75569454|NCT02921360|Drug|acetylsalicylic acid|
75569455|NCT02932605|Drug|Placebo|Placebo
75569456|NCT02932605|Drug|Cannabidiol|Cannabidiol
75569457|NCT02921204|Other|Vitamin D status|There is no intervention in this study
75569458|NCT01283581|Drug|Delafloxacin|300mg IV every 12 hours for 5-14 days
75569459|NCT01283581|Drug|Linezolid|600mg IV every 12 hours for 5-14 days
75569460|NCT01283581|Drug|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
75569461|NCT05466903|Dietary Supplement|Early diet opening|Effects of early dietary recovery after colon polypectomy and colonoscopic mucosal resection on postoperative hemorrhage in patients
75569462|NCT01283542|Drug|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
75569463|NCT05466864|Device|Belun Sleep platform|BSP(Belun Technology Company Limited) is a novel wearable system using a neural network algorithm that consists of a patented wearable device (Belun Ring), a charging cradle, and cloud-based software. The Belun Ring, an FDA-cleared pulse oximeter, acquires signals from the radialis indicis artery of the proximal index finger. The Belun Ring total sleep time can be derived from features extracted from accelerometer, SpO2, and PPG signals, whereas Belun Ring AHI can be derived from Ring-TST and features extracted from HRV and SpO2 changes. The BSP proprietary OSA detection algorithm was using neural network. BSP performance can be improved by training the algorithm through continual data collection. To our knowledge, BSP is the only validated sleep platform using a medical-grade wearable pulse oximeter, actigraphy, and artificial intelligence algorithm that has the capability to identify sleep stages, detect OSA events, and monitor autonomic nervous system activity changes during sleep.
75722648|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
75722649|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
75722650|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
75722651|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
75569464|NCT02921048|Dietary Supplement|omega-3 fatty acids|
75569465|NCT02932488|Drug|Sumatriptan|Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
75569466|NCT02921165|Drug|analgesic mouth rinses (dissolved Aspirin)|Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
75569467|NCT02921165|Drug|Normal saline rinses.|Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
75423390|NCT05709067|Dietary Supplement|Probiotic|6 Billion CFU per day
75722652|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
75722653|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
75722654|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 8.
75722655|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 8.
75722656|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10^10vp at week 8.
75722657|NCT00801086|Drug|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
75722658|NCT00801086|Drug|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
75876679|NCT03662724|Drug|Venetoclax|Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
75423391|NCT05709067|Dietary Supplement|Placebo|0 CFU per day
75423392|NCT05696847|Drug|Tirzepatide|Administered SC
75569468|NCT01283386|Drug|Chlorambucil|10 mg/m^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
75569469|NCT01283386|Drug|Cyclophosphamide|150 mg/m^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
75569470|NCT01283386|Drug|Fludarabine|20 mg/m^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
75569471|NCT01283386|Drug|Rituximab|375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
75569472|NCT05466786|Other|Standard Management|Standard Management
75876680|NCT03662568|Drug|GLS4|Administered GLS4 120 mg orally three times daily in fed state
75423393|NCT05696847|Drug|Placebo|Administered SC
75423394|NCT05695469|Device|Smart resuscitation glove (ResuGlove)|Participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). Participants in the ResuGlove group will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes.
75423395|NCT05695469|Other|Traditional CPR|Participants in the traditional CPR group will perform hand-only CPR without the ResuGlove and feedback guidance for 2 minutes.
75569473|NCT02920931|Drug|Tenofovir disoproxil|
75569474|NCT01283152|Drug|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
75569475|NCT01283152|Drug|Lactulose|If randomized to this arm, subjects will receive 10-30 grams per standard of care
75569476|NCT02932527|Behavioral|Questionnaire about cannabis consumption|Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.
75569477|NCT02932527|Procedure|blood intake|blood intake is done for infertile male exposed and infertile male not exposed.
75569478|NCT02932527|Procedure|Semen samples collection|Semen samples are collected for infertile male exposed and infertile male not exposed.
75569479|NCT01283035|Drug|Akt Inhibitor MK2206|Given PO
75569480|NCT01283035|Other|Laboratory Biomarker Analysis|Correlative studies
75722659|NCT00788606|Drug|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
75569481|NCT02920853|Behavioral|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
75722660|NCT00801164|Drug|Frio Mouth Rinse Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
75423396|NCT05682027|Diagnostic Test|ultrasound of the diaphragm|"Parameters measured during ultrasound:~Thickening fraction; End-expiratory thickness, and; Diaphragm excursion."
75569482|NCT02920853|Behavioral|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
75569483|NCT02932371|Device|ECOM™.|
75569484|NCT02932371|Device|Trans-esophageal echography|
75569485|NCT01283464|Drug|Retinol|1.0% cream
75569486|NCT01283464|Drug|Tretinoin|0.02% cream
75722661|NCT00801164|Drug|Frio Mouth Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
75722662|NCT00801320|Procedure|Tumor collection|Tumor collected at the time of planned surgery
75569487|NCT01282801|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
75569488|NCT01282801|Drug|Effexor® XR|150 mg Extended-Release Capsule
75722663|NCT00795860|Behavioral|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
75722664|NCT00795860|Behavioral|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
75722665|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
75722666|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
75722667|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
75569489|NCT02920814|Other|Cognitive Behavioural Therapy|Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
75569490|NCT00532350|Drug|QAT370|
75569491|NCT00532350|Drug|Placebo|
75569492|NCT00532350|Drug|Tiotropium|
75569493|NCT02920775|Other|Non-interventional study - retrospective database review|
75569494|NCT02932566|Drug|Pirfenidone|Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
75569495|NCT02932566|Drug|Placebo|Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
75569496|NCT00532389|Drug|LBH589|
75569497|NCT02920580|Procedure|Extubation|This is an extubation by removal of endotracheal tube which must be done on the day of randomization or the following day. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.
75722668|NCT00260065|Drug|Decitabine|20mg/m^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
75722669|NCT00796094|Other|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
75722670|NCT01072435|Device|Patient-controlled sedation|Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
76045835|NCT05420675|Other|Single Leg Squat|After initial data collection (Demographic data, Inclusion criteria), surface electromyography EMG assessments will be obtained from 1 muscle ( Vastus Medialis). EMG evaluation will be done in different arm positions during the single leg squat. These records will be taken in 4 different situations: 1) Arms free, 2) Arms flexed to 90 degrees, 3) Hands on hips, 4) Arms across the chest.
75423397|NCT05679492|Biological|Meplazumab foe injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
75423398|NCT05679492|Other|Normal saline|Normal saline
75722671|NCT01072435|Device|Target-controlled infusion|Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
75722672|NCT01072513|Other|Semen analysis|Semen analysis before and after proton radiation therapy.
75722673|NCT00796172|Behavioral|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
75722674|NCT00796172|Behavioral|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
75722675|NCT01071655|Drug|BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|"BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly"
75722676|NCT01071655|Drug|BVZ+XELOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
75876681|NCT03662568|Drug|RTV|Administered RTV 100 mg orally three times daily in fed state
75876682|NCT03662568|Drug|ETV|Administered orally ETV 0.5 mg once daily in fasted state
75876683|NCT03662568|Drug|TDF|Administered TDF 300 mg orally once daily in fasted state
76045836|NCT01937117|Procedure|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
76045837|NCT01937117|Drug|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
76045838|NCT01937117|Drug|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
76045839|NCT02268045|Biological|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
76045840|NCT02268045|Biological|Mabthera|Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
76045841|NCT02536781|Drug|Anthocyanin|Anti-inflammation gel
75423399|NCT05664087|Drug|Periowave®|The tooth extraction sockets were filled with photosensitizer methylene blue. The guide head of the laser periodontal therapy instrument (Piperway Laser periodontal therapy instrument) was placed in the tooth extraction sockets to probe and move around the tooth extraction sockets for 1 minute. At the end of irradiation, a cotton ball dipped in saline was used to wipe the guide head and rinse the photosensitizer out of the socket
75423400|NCT05637177|Behavioral|Anging Wisely|The program includes 11 meetings of two hours in a group of up to eight people. The sessions are held weekly. Each lesson is given a homework assignment. A total of 10 groups will take place.
75423401|NCT05637177|Behavioral|Music therapy|Music therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 12. A total of 10 groups will be implemented.
75423402|NCT05637177|Behavioral|Reminiscence therapy|Reminiscence therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 10. A total of 5 groups will be implemented.
75423403|NCT05637177|Behavioral|Cognitive training|"Intervention cognitive training will take place once a week for 45 minutes for 20 weeks. Seniors can choose from two options: 1. group training full-time or home training (online) using the comprehensive training program MENTEM."
75423404|NCT05637177|Behavioral|Educational activities|Interventions in educational activities will run for one academic year. In total, seniors will attend 16 lectures in each educational module. The lectures will run 1 x 14 days for 90 minutes.
76045842|NCT02536781|Drug|Placebo|Blank gel
75423406|NCT05607784|Behavioral|Formative Research- Content Translation|"This formative research includes brainstorming translation of content and reviewing wireframe prototypes generated from this process. It also includes attending to cultural, developmental, and gender considerations.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
75569498|NCT02920580|Procedure|Usual Care|Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow prompt extubation to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.
75722677|NCT00801476|Procedure|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
76045843|NCT05440253|Device|dry needling|Dry needling of the trigger point of the gluteus medius in patients diagnosed with non-specific low back pain.
75423407|NCT05607784|Behavioral|Formative Research- Content Feedback and Acceptability|"This formative research includes providing feedback on the proposed content and ensure contextual acceptability in schools.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
75423408|NCT05606432|Other|Instructor-led, one-on-one exercise group|Participants will participate in 3 exercise sessions per week for 24 weeks. Each session will last 15 - 40 minutes. Increasing by 5 - 10 minutes each week. The program focuses on improving heart and lung fitness using movement with music. The program will be fit to individuals' abilities. The exercise is prescribed at a moderate intensity level, which is monitored through a wearable heart rate monitor and custom designed online platform (Telerehab). A tablet will be given by the study. Data collected include exercise minutes and heart rate. Live sessions that participants attended with the instructor will be video-recorded and later uploaded to the telehealth platform. Upon completion of the 24-week program, participants will be able to access exercise routines online for an additional 12 weeks. In addition, participants will receive access to live exercise classes offered by the National Center on Health, Physical Activity and Disability.
75423409|NCT05606432|Other|Self-guided control with virtual fitness membership|Participants will receive a tablet and 36-week virtual fitness membership that is offered via Lakeshore Foundation. The membership will give participants full access to live and recorded adapted classes, such as Seated Yoga, ABC's of Balance, and Total Body Conditioning. Participants will be given further details during the orientation (after the physical tests of the baseline assessment).
75569499|NCT02932644|Other|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
75722678|NCT02531581|Drug|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output <500cc
75722679|NCT02531581|Drug|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
75722680|NCT04046510|Drug|Ocytocin|Administration of lower doses of Ocytocin in bolus and continuous infusion
76045844|NCT05440253|Procedure|ischemic compression|Ischaemic trigger point compression of the gluteus medius in patients diagnosed with non-specific low back pain.
75722681|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose|A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
75722682|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses|Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
76045845|NCT05544747|Other|Action Observation Therapy|"following phases will be included in action observation therapy group:~upper limb active range of motion (AROM) exercises.~reaching movement or object manipulation.~upper limb functional tasks."
75722683|NCT00788840|Drug|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
75722684|NCT00788840|Drug|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
75722685|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
75569500|NCT02932644|Other|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
75569501|NCT02920697|Drug|S 55746|S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
75722686|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
75722687|NCT00742625|Drug|daunorubicin hydrochloride|Given IV
75722688|NCT00742625|Drug|cytarabine|Given IV
76045846|NCT05544747|Other|Mirror Therapy|"following phases will be included in mirror therapy group:~AROM exercises),~reaching movement or object manipulation, and~functional task practice"
76045847|NCT05439863|Device|transcatheter heart valve|patients with severe aortic valve disease underwent transcatheter heart valve
76045848|NCT05392283|Device|AERO vacuum cupping device|The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
75722689|NCT00742625|Drug|bortezomib|Given IV
75722690|NCT00801710|Device|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
75722691|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
75722692|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
75722693|NCT01070485|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
75722694|NCT00618618|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
75722695|NCT00618618|Drug|Placebo|
75722696|NCT00796250|Biological|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
75876684|NCT03612362|Device|"Improved Injera Baking Biomass Stove"|"Replacing of the Ethiopian traditional Injera baking biomass stove with improved baking biomass stove, the well-known commercially distributed type of baking stove in Ethiopia, will be the intervention for this study. Control HHs will continue to use the traditional baking biomass stove. Concerning intervention duration, since the life span of the Ethiopian improved baking stove is about 5 years, the length of the intervention period will be one year to account for seasonal factors that have major effect on both ARI incidence & HAP level in Ethiopia as well as to maintain a balance between achieving a sufficiently long follow-up period for outcome measurements & suitably short follow-up period to decrease attrition."
75876685|NCT03661554|Biological|BCMA CAR-T Cells|The Chinese name of CAR-T cells is chimeric antigen receptor T cells. It is through gene transfection technology, so that patients with T lymphocytes can carry B cell-specific antigens, so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.
75423410|NCT05590962|Other|EHR Nudge|Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥3 for Stage IV cancer patients and ≥5 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.
75569502|NCT05466708|Drug|Esketamine combined with dexmedetomidine|"Asic ketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature.~Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature."
75569503|NCT05466708|Drug|Dexmedetomidine|Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
75569504|NCT02920541|Drug|S 055746|S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
75569505|NCT01282294|Device|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
75722697|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
75722698|NCT00796250|Drug|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
75876686|NCT02993250|Drug|AL-335|Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
76045849|NCT05647941|Diagnostic Test|Detection of levels of circulating EV-derived lncRNA-GC1|For patients with gastric cancer receiving neo-adjuvant chemotherapy, the dynamic changes of EV-derived lncRNA-GC1 was detected to identify whether is can serve as a monitoring biomarker for treatment response.
76045850|NCT05647785|Device|Long-term follow-up of cerena™|Long term follow-up for eligible participants from the RESTORE study
75423411|NCT05587348|Behavioral|Best Practice Advisory|Provider will get Best Practice Advisory or Message from DCE in intervention practices
75423412|NCT05587348|Behavioral|Peer Support|Patients referred to DSMES classes will be randomized to get a peer supporter
75569506|NCT02932293|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
75876687|NCT02993250|Drug|Odalasvir (ODV)|Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
75876688|NCT02993250|Drug|Simeprevir (SMV)|Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
75876689|NCT03612284|Device|contact lens insertion solution|"This contact lens solution is being tested for safety and comfort and is not an intervention. Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire."
75569507|NCT02920502|Dietary Supplement|Arm 2: cholecalciferol 50,000 IU|One time dose of cholecalciferol 50,000 IU
75569508|NCT02920502|Dietary Supplement|Arm 3: cholecalciferol 100,000 IU|One time dose of cholecalciferol 100,000 IU
76045851|NCT05647785|Device|Long-term follow-up of attune™|Long term follow-up for eligible participants from the RESTORE study
75423413|NCT05572437|Device|Music Therapy|Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-anesthesia room, during surgery and in the PACU.
75423414|NCT05568381|Device|digital CBT-I|Sleepio is a digital cognitive behavioral therapy (CBT) program designed to treat insomnia. The program is fully automated, and its underlying algorithms drive the delivery of information, support, and advice.
76045852|NCT02267187|Procedure|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
75423415|NCT05568381|Other|Online Sleep Health Education package|Wait-listed control participants will have full access to three online modules for the duration of the study. The information in these modules will provide non-tailored basic sleep information and content will contain text and basic images but will not be personalised to the individual participant.
75569509|NCT02920502|Dietary Supplement|Arm 4: cholecalciferol 200,000 IU|One time dose of cholecalciferol 200,000 IU
75569510|NCT02920502|Other|Arm 1: Placebo|One time dose of Placebo
75569511|NCT01282216|Biological|Havrix|1440 ELISA units, or 1 mL, IM
75569512|NCT01282216|Biological|PCV13|0.5 mL IM
75569513|NCT04323709|Other|Data collection|Clinical data are collected from the medical record of the institution. At admission, date were collected on age, gender, body mass index, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment, hypertension, diabetes, hypercholesterolemia, smoking, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, Left Ventricular Ejection Fraction(LVEF), Tricuspid Annular Plane Systolic Excursion, mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump and biochemical parameters. During hospitalization data were collected on reason for initiation of VA-ECMO and its characteristics (duration, type, flow L/min, RPM, FiO2), length of stay in ICU, catecholamines and inotropes maximal dose and length of administration, patients with heart transplantation or LVAD. In patients with levosimendan treatment, timing of administration regarding ECMO canulation was collected
75569514|NCT04323709|Other|Data analysis|Continuous variables were presented as mean ± standard deviation and compared using Student's t-test or Mann-Whitney U-test depending on their normality. Categorical variables were presented as counts and percentages and compared using Pearson's chi-squared test or Fisher's exact test, as appropriate. Survival at day 28 was estimated using the Kaplan-Meier method and compared using the log rank test. Investigators conducted a multivariable logistic regression with propensity score matching, which was defined as the probability of exposure to levosimendan. Results were reported as odd ratios (ORs) together its 95%CI assuming a 5% level of statistical significance. All analyses were carried out using STATA 15.0 (Stata Corp, College Station, Texas 77845 USA).
75569515|NCT01281865|Other|diagnostic laboratory biomarker analysis|Correlative studies
75722699|NCT00796250|Drug|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
75722700|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
75722701|NCT00796250|Biological|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
76045853|NCT02267187|Drug|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
75569516|NCT01281865|Drug|everolimus|Given PO
75722702|NCT01070563|Other|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
76045854|NCT02267187|Device|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
75569517|NCT01281865|Drug|imatinib mesylate|Given PO
75569518|NCT02932683|Device|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
75722703|NCT01012726|Procedure|Colonoscopy|During the colonoscopy, we instill Acetylcystein and Doxycyline into the fistula.
75722704|NCT00788918|Drug|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
75569519|NCT02920658|Drug|NAVS Naphthalan|
75569520|NCT02920658|Drug|0.05% Betamethasone dipropionate|
75722705|NCT02596373|Drug|Mitoxantrone Hydrochloride Liposome Injection|
75722706|NCT00246805|Device|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
76045855|NCT02267187|Other|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
75423416|NCT05549362|Other|Dial Health Research Study|To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.
75423417|NCT05548985|Drug|Midodrine Oral Tablet|oral midodrine tablet (5 mg) 90 min before performing spinal block
75423418|NCT05548985|Drug|Metoclopramide|oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
75423419|NCT05546827|Procedure|Surgical resection|Surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
75423420|NCT05540106|Behavioral|Nature Coloring Packet|Coloring packet containing nature scenes
75423421|NCT05540106|Behavioral|Geometric Shape Coloring Packet|Coloring packet containing geometric shapes
75423422|NCT05540106|Behavioral|Activity Book|Pages containing word searches, connect the dots, etc.
75423423|NCT05540106|Behavioral|Blank Paper and Pencil|Blank sheets of paper and a pencil.
75569521|NCT02889679|Procedure|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
75722707|NCT00801866|Drug|Bevacizumab|Intravitreal administration
75722708|NCT00801866|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation
75722709|NCT04088747|Diagnostic Test|Ultrasound Imaging|B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
75722710|NCT03973879|Biological|PVSRIPO|Oncolytic polio/rhinovirus recombinant
75722711|NCT03973879|Drug|Atezolizumab|Antibody
75722712|NCT00519376|Drug|GW642444M|drug
75722713|NCT00519376|Drug|GW642444H|drug
75722714|NCT00519376|Drug|placebo|
75722715|NCT00860964|Drug|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
75722716|NCT00860964|Drug|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
75722717|NCT00745121|Device|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
76045856|NCT02532179|Biological|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
75423424|NCT05535270|Diagnostic Test|Oxford Depression Questionnaire (ODQ)|"The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of emotional blunting: not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections ."
75423425|NCT05528315|Drug|ABX-002|ABX-002
75722718|NCT00864630|Behavioral|Computer-based problem solving therapy|Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
76045857|NCT04422977|Diagnostic Test|Sars-Cov-2 serology|Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
75722720|NCT04088903|Drug|Daratumumab|>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
75722721|NCT02545140|Other|No intervention|
75722722|NCT05395871|Behavioral|Behavioural Message|Messaging involving increased salience, increasing positive emotions and information on health consequences
75722723|NCT05395871|Behavioral|Behavioural Message + Video|Messaging as above. The video also includes information on emotional consequences, problem solving, anticipated regret, reducing negative emotions and credible source techniques.
75722724|NCT05395871|Other|Usual Care Message|Standard usual care message involving link to non-behavioural science informed video
75722725|NCT01009372|Behavioral|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
75722726|NCT00861120|Drug|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
75722727|NCT00861120|Drug|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
75722728|NCT00864786|Drug|PF03635659|Inhaled doses of 200 mcgQD
75722729|NCT00864786|Drug|PF03635659|Inhaled doses of 600 mcg QD
75423426|NCT05528315|Drug|Placebo|Placebo
75423427|NCT05525091|Other|Feeding Evaluation|Feeding Evaluation with Device
75423429|NCT05499962|Behavioral|Social Networking Strategies|Assess whether PrEP-using Black SMM can serve as an Interventionist to get their social and sexual network members to uptake and adhere to PrEP
75423430|NCT05496959|Drug|Lutetium Lu-177 PNT2002|Given IV
75722730|NCT00864786|Drug|PF03635659|Inhaled doses of 1000 mcg QD
75722731|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
75722732|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
75722733|NCT03841656|Procedure|PARORISKIMPLANT|Patients attending periodontal and implant treatment at the Department of Periodontology of the Dental Faculty at Strasbourg, France, between 2000-2015.
76045858|NCT05389241|Other|Method A|The subjects will perform tasks on the liver phantom (identification of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method A means that the trainings set up is performed first with Method A an after that with Method B.
75423431|NCT05496959|Other|Quality-of-Life Assessment|Ancillary studies
75423432|NCT05496959|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75722734|NCT00740051|Drug|Linagliptin|5mg once daily
75722735|NCT00740051|Drug|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
75423433|NCT05495646|Procedure|Central catheter insertion|The data will be obtained through the review of the medical records and the clinical follow-up of each patient to evaluate the technique of inserting the device, the possible risk factors of catheter-related infection, its clinical manifestations and the data microbiological.
75423434|NCT05484622|Drug|Vorasidenib|Administered orally as tablets.
75423435|NCT05484622|Drug|Pembrolizumab|Administered as IV infusion.
75423436|NCT05473741|Drug|Second Generation Long-Acting Injectable Antipsychotic Medications|Patients who have been stabilized on long-acting injectable formulations of paliperidone palmitate, risperidone and aripiprazole will be followed for 48 weeks to determine the rate of relapse when adherence is established. Blood samples to measure plasma antipsychotic levels and prolactin levels, and urine samples for drug screen will be collected at baseline and at the 24-week and 48-week time points.
75423437|NCT05456620|Other|Exercise therapy|"The intervention treatment consists of a progressive 4-stage, criteria-based exercise protocol, in which the amount of tendon compression is limited. This includes:~Education: Specific information on the importance of limiting tendon compression during rehabilitation, as well as general information on load management, the importance of active exercise therapy and setting expectations.~Orthotic treatment: heel inserts to reduce ankle dorsiflexion during daily activities and sports~Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) restricting the amount of tendon compression by limiting dorsiflexion of the ankle and prohibiting stretching"
75423438|NCT05456620|Other|Exercise therapy (usual care)|"The control treatment consists of a progressive 4-phase, criteria-based exercise protocol, in which the amount of tendon compression is not limited. This includes:~Education: general information on load management, the importance of active exercise therapy and setting expectations.~No orthotic treatment.~Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) without any restriction around tendon compression and encouraging stretching"
75423439|NCT05435300|Other|PET Scan|Participants will undergo two PET scans throughout the study.
75423440|NCT05435053|Drug|Nivolumab|"Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
75423441|NCT05435053|Device|Irreversible electroporation (IRE)|"Percutaneous ablation of a primary in-situ (or locally-recurrent) or metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is FDA-approved for medical use."
75423442|NCT05433116|Drug|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy
75423443|NCT05433116|Drug|Lenvatinib|20mg once daily orally, start concomitant to cycle 2 of pembrolizumab
75423444|NCT05418998|Behavioral|Executive function (EF) training|EF training will involve at-home computer- or tablet based training to improve several EF processes, including divided attention, response inhibition, switching, and working memory updating. Training session duration = 30 min x 3 session/week.
75423445|NCT05401214|Drug|Niraparib plus Abiraterone Acetate (Nira/AA) combination|Nira 100 milligrams (mg)/AA 500 mg combination will be administered orally as immediate-release film coated tablets.
75423446|NCT05401214|Drug|Prednisone/Prednisolone|Prednisone/Prednisolone 10 mg will be administered orally.
75423447|NCT05379010|Procedure|Endodontic Microsurgery|Surgical removal of 3 millimeters of the root-end, removal of the apical pathology, Root-end preparation and retrograde filling. The entire procedure is done under magnification.
75423448|NCT05377151|Other|Mobile application|"Nutrition intervention using either mHealth interventions or conventional methods will be carried out among pregnant women).~Subjects will be allocated into three groups, namely, two interventions group which are:~Group 1: mHealth intervention group (98 subjects)~Group 2: mHealth intervention group + dietitian consultation (98 subjects)~Group 3: control group (98 subjects)"
75423449|NCT05373212|Drug|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
75722736|NCT00740051|Drug|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
75722737|NCT00864864|Drug|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
75722738|NCT00868686|Device|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
75722739|NCT00868686|Device|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
75569522|NCT02889679|Procedure|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
75569523|NCT02889679|Procedure|Standard polypectomy|Standard polypectomy will be performed for diminutive (<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
75569524|NCT02890030|Behavioral|Questionnaire|"Neurotoxicity~Medications of interest~General health~Family history"
75569525|NCT02920619|Device|Ultrasound|Imaging of the rectus femoris, lower-trapezius, brachioradialis, tibialis anterior, middle deltoid, and pectoralis major will be conducted in Veteran participants during a single visit to the Washington D.C. Veterans Affairs Medical Center. Imaging will be conducted by investigators experienced with quantitative ultrasound using diagnostic musculoskeletal B-mode ultrasound with a 10 Mhz linear transducer.
75423450|NCT05373212|Drug|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
75569526|NCT01281202|Drug|Vigabatrin|Tablets
75569527|NCT01281202|Drug|Matching Placebo|Tablets
75722740|NCT00868686|Device|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
75423451|NCT05373199|Drug|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
75423452|NCT05373199|Drug|Euglycemic clamp with Lantus®|Administration of a single dose of Lantus® during an euglycemic clamp procedure.
75569528|NCT02889718|Device|CONCERT-CL® station|"During cancer surgery (surgery > 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~Port B = open loop: Analgesic~Port A = closed loop: Hypnotic~Port C = closed loop: Curare"
75423453|NCT05373199|Drug|Euglycemic clamp with Humalog®|Administration of a single dose of Humalog® during an euglycemic clamp procedure.
75423454|NCT05366907|Other|No intervention is done|It is a descriptive cross-sectional study so no groups like case/controls are present. All the cases are included in the study.
75569529|NCT02889718|Other|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
75569530|NCT02932215|Drug|lorcaserin|Open label
75569531|NCT02932215|Other|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
75423455|NCT05359692|Biological|INCAGN01876|INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.
75423456|NCT05359692|Biological|retifanlimab|retifanlimab will be administered via IV Q4W
75423457|NCT05353361|Drug|SHR-A1811：Pyrotinib|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
75423458|NCT05353361|Drug|SHR-A1811；Pertuzumab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
75569532|NCT01281124|Drug|Azacitidine|Given subcutaneously
75722741|NCT00868764|Drug|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
75722742|NCT00518986|Drug|armodafinil|200 mg/day
75722743|NCT00518986|Drug|placebo|placebo
75722744|NCT00870324|Device|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
75569533|NCT01281124|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
75569534|NCT01281124|Other|Pharmacological Study|Correlative studies
75423459|NCT05353361|Drug|SHR-A1811；Adebrelimab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip
75423460|NCT05353361|Drug|SHR-A1811；Albumin paclitaxel|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
75569535|NCT00623857|Dietary Supplement|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
75722745|NCT00870324|Device|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
75876690|NCT03661476|Behavioral|Oculo-Motor Exercises (OME)|"Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
75423461|NCT05352919|Drug|Litifilimab|Administered as specified in the treatment arm.
75423462|NCT05352919|Drug|Litifilimab-matching placebo|Administered as specified in the treatment arm.
75423463|NCT05344560|Device|soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore|TEST Lens
75423464|NCT05344560|Device|ACUVUE OASYS 1-Day for Astigmatism|CONTROL Lens
75423465|NCT05313607|Other|Designed physical therapy|Attention is given to improve motor function, conducted for 30 minutes
75423466|NCT05313607|Other|Occupational therapy|included exercises facilitating hand skills, conducted for 30 minutes
75423467|NCT05313607|Other|Conventional Therapy|aimed to improve the affected upper extremity function, conducted for 30 minutes
75423468|NCT05313607|Other|Plyometric training|basically focuses on upper extremity strength training conducted for 30 minutes
75423469|NCT05296681|Drug|NBT-NM108|Patients receive irinotecan-based chemotherapy per standard of care.
75423470|NCT05287763|Procedure|Palatal soft tissue graft harvesting|After local anaesthesia, a horizontal incision 2 mm apically from the gingival margin will be carried out using a #15C blade. The standardized rectangular graft with a thickness of 1.5 mm will be harvested from distal aspect of canine till first molar. The graft will be lifted and separated using tissue forceps and a blade till it is free from all sides.
75423471|NCT05284214|Biological|Sargramostim|Sargramostim for injection
75423472|NCT05284214|Biological|Ipilimumab-containing therapy|Treatment for cancer containing ipilimumab at either 1 mg/kg or 3 mg/kg, intravenously..
75423473|NCT05273476|Procedure|apically repositioned flap+ xenogeneic collagen matrix +free gingival graft|Harvest a strip free gingival graft from the palate, then place it above apically repositioned flap and fix xenogeneic collagen matrix to the recipient bed
75569536|NCT00623857|Dietary Supplement|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
75569537|NCT00623857|Dietary Supplement|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
75569538|NCT00623857|Dietary Supplement|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
75569539|NCT05466435|Other|Heavy Slow Resistance|Heavy slow resistance exercise will be given twice a week for 12 weeks along with traditional physical therapy program
75569540|NCT05466435|Other|Control group|Traditional physical therapy program only will be given twice a week for 12 weeks
75569541|NCT02920424|Drug|JNJ-56022473|Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
75569542|NCT02920424|Drug|Placebo|Subjects will receive matching placebo.
75569543|NCT01280968|Biological|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
75569544|NCT01280968|Biological|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
75569545|NCT02889445|Drug|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
75569546|NCT02920385|Drug|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
75569547|NCT02920385|Drug|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
75569548|NCT02920385|Drug|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
75569549|NCT02920385|Drug|Placebo|Oral administration once daily together with semaglutide
75722746|NCT04089683|Other|Swab stick|Swab sticks collected from Web Spaces, Scrub, Anterior Nares
75722747|NCT00864942|Drug|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
75569550|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
75569551|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
75569552|NCT01280812|Behavioral|Control (pedometer only)|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
75569553|NCT02932020|Drug|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
75722748|NCT00864942|Drug|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
75569554|NCT02932020|Drug|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
75569555|NCT02932020|Device|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
75569556|NCT02932020|Drug|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
75569557|NCT02932098|Behavioral|Discharge instructions reminders|"Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.~Participants will receive a reminder of discharge instructions everyday for the first week post-discharge."
75569558|NCT02932098|Behavioral|Prompts to report symptoms via the web-enabled app|Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)
75569559|NCT02932098|Behavioral|Clinical Alerts|Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
75722749|NCT00864942|Drug|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
75876691|NCT03612830|Procedure|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
75876692|NCT03612830|Procedure|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
75569560|NCT05466396|Behavioral|smoking|Smoking history and spirometry are used to define groups
75569561|NCT02920307|Procedure|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
75569562|NCT02920307|Procedure|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
75569563|NCT02920307|Procedure|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
75569564|NCT02920307|Procedure|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
75569565|NCT01280656|Drug|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
75569566|NCT01280656|Drug|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
76045859|NCT05389241|Other|Method B|The subjects will perform tasks on the liver phantom (identifikation of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method B means that the trainings set up is performed first with Method B an after that with Method A.
76045860|NCT05438615|Other|Corneal Refractive Therapy-spherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
76045861|NCT05438615|Other|Corneal Refractive Therapy-aspherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
75423474|NCT05263063|Other|Comparison of Face-to-face, Synchronous and Asynchronous Use of Methods Used for Balance Assessment in Individuals With Chronic Stroke|On the first day, information about the patient and the disease, filling in the patient data form and face-to-face evaluation will be made face to face with the patients. The next day, one of the synchronous and asynchronous tele-evaluation methods will be applied. Face-to-face interview and face-to-face evaluation will be made by the first physiotherapist in a clinical setting. The synchronous tele-assessment will be evaluated online in real time by the second physiotherapist. For asynchronous tele-assessment, a reference evaluation video will be sent to the patients. Relatives of the patients will be asked to watch this video, make the evaluation and take a video recording at the same time. Then, these video recordings will be evaluated separately by the first and second physiotherapists and the results will be compared. Each assessment will take approximately 30 minutes.
75569567|NCT01280656|Drug|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
75722750|NCT00864942|Drug|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
75722751|NCT00870402|Drug|Spironolactone|25 mg per day for 9 months
75423475|NCT05247489|Drug|Ruxolitinib 1.5% cream|Ruxolitinib cream 1.5% applied twice a day (BID).
75569568|NCT01280656|Drug|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
75722752|NCT00870402|Drug|Placebo|Placebo 1 tablet per day for nine months
75722753|NCT00742391|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
75722754|NCT00742391|Drug|Vehicle gel|two day treatment
75722755|NCT05227560|Other|Complementary Therapies|The emotional freedom technique was applied to the experimental group.
75722756|NCT02596139|Other|No Interventions|
75722757|NCT03841266|Diagnostic Test|recurrence risk evaluation|Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.
75722758|NCT00742235|Drug|ergocalciferol|Ergocalciferol 50,000 IU given every other day for 5 total doses
75722759|NCT00868920|Other|patient control of pump|Patient controls sedation pump during colonoscopy.
75722760|NCT00868920|Other|anesthesiologist controlled sedation|Anesthesiologist will control the sedation pump during colonoscopy.
75876693|NCT03661788|Drug|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
75876694|NCT03661788|Drug|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
76045862|NCT04422665|Other|Resistance exercise|Single-legged resistance exercise
75569569|NCT05466162|Other|Soft tissue mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
75423476|NCT05247489|Device|NB-UVB phototherapy|NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit
75423477|NCT05229588|Drug|Lurbinectedin 4 MG Injection [Zepzelca]|"Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate."
75423478|NCT05223673|Biological|Futuximab/modotuximab|Concentrate for solution for infusion, futuximab/modotuximab will be administered via IV route, once weekly of each cycle at 9 mg/kg/dose at Cycle 1 Day 1 and then at 6 mg/kg/dose. Each cycle is up to 28 days.
75423479|NCT05223673|Drug|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
75423480|NCT05223673|Drug|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
75423481|NCT05221944|Other|Patients had a history of antithrombotic therapy|Patients with antithrombotic drugs were identified and grouped and their medical records were reviewed.
75569570|NCT05466162|Other|Joint and nerve mobilization|"Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
75423482|NCT05221944|Other|Patients had no history of antithrombotic therapy|Patients had no history of antithrombotic therapy
75722761|NCT00742079|Drug|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
75423483|NCT05221580|Drug|Ryzodeg®|Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
75423484|NCT05215197|Drug|intracochlear platelet rich fibrin administration|intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
75423485|NCT05209191|Behavioral|Student Athlete Wellness Portal|A web-based design that illustrates various opioid misuse and diversion resistance strategies.
75722762|NCT00742079|Behavioral|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
75423486|NCT05203198|Behavioral|Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training|Self-directed, technology-based, depression prevention program for adolescents and parents.
75423487|NCT05194267|Device|transcranial direct current stimulation (tDCS)|tDCS alters brain excitability using a weak electric field induced through two electrodes and could potentially improve symptoms of depression
75423488|NCT05192889|Drug|Venetoclax|Given oral (PO).
75423489|NCT05192889|Drug|Navitoclax|Given oral (PO).
75423490|NCT05192889|Drug|Dexamethasone|Given orally (PO) or intravenously (IV).
75423491|NCT05192889|Drug|Vincristine|Given intravenously (IV).
75423492|NCT05192889|Drug|Calaspargase Pegol|Given intravenously (IV).
75423493|NCT05192889|Drug|Dasatinib|Given oral (PO).
75423494|NCT05192889|Drug|Cytarabine|Given intravenously (IV) or Intrathecal (IT).
75423495|NCT05192889|Biological|Blinatumomab|Given intravenously (IV).
75423496|NCT05192889|Drug|Methotrexate|Given intravenously (IV), oral (PO), or Intrathecal (IT).
75423497|NCT05192889|Drug|Mercaptopurine|Given oral (PO).
75423498|NCT05192889|Drug|Cyclophosphamide|Given intravenously (IV).
75423499|NCT05192889|Drug|Etoposide|Given intravenously (IV).
75423500|NCT05192889|Drug|Leucovorin|Given oral (PO) or intravenously (IV).
75423501|NCT05192889|Drug|Intrathecal Triples|Given Intrathecal (IT).
75423502|NCT05192889|Drug|Pegaspargase|May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
75423503|NCT05192889|Drug|Erwinia asparaginase|To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
75423504|NCT05192889|Radiation|Radiation|See detailed description section.
75722763|NCT04730362|Device|guedel airway|"Anesthesia will be conducted by induction with 1-2~• Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%. The goal is to maintain the patient spontaneous ventilation throughout the procedure. Monitoring of the patients is done by MRI compatible pulse oximetry for heart rate and oxygen saturation which is connected to MRI control room."
75722764|NCT04730362|Device|supraglottic airway|supraglottic airway
75423505|NCT05188196|Procedure|alveolar ridge preservation|Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
75423506|NCT05168163|Biological|Atezolizumab|Given IV
75423507|NCT05168163|Drug|Cabozantinib|Given PO
75423508|NCT05168163|Drug|Lenvatinib|Given PO
75423511|NCT05122182|Drug|Candesartan Cilexetil|Angiotensin Receptor Blocker (ARB)
75423512|NCT05122182|Drug|Repagermanium|C-C chemokine receptor type 2 (CCR2) antagonist
75423513|NCT05122182|Drug|Candesartan Placebo|Angiotensin Receptor Blocker (ARB) placebo
75423514|NCT05122182|Drug|Repagermanium Placebo|C-C chemokine receptor type 2 (CCR2) antagonist placebo
75423515|NCT05113784|Drug|Meplazumab for Injection|humanized antibody target CD147
75423516|NCT05113784|Drug|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
75423517|NCT05113186|Drug|Lenvatinib Pill|"The design of study is summarized as follows:~Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)"
75423518|NCT05112731|Diagnostic Test|BAFF and MGO|measurement of BAFF and MGO levels before reperfusion and after 3 months
75722765|NCT04730362|Drug|propofol bolus and then anesthesia sevoflurane|Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%
75423519|NCT05086627|Drug|Tislelizumab|Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
75569571|NCT03741530|Drug|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
75423520|NCT05086627|Radiation|Short-course radiotherapy|Patients were treated with short-course neoadjuvant radiotherapy
75569572|NCT03741530|Other|Standard management for ICH|Usual care and drug in hospital
75569573|NCT01280617|Drug|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
75569574|NCT01280617|Drug|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
75569575|NCT02920268|Other|Dance and yoga intervention|
75722766|NCT00876096|Other|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
75722767|NCT00662792|Drug|Tiotropium (Tio18GEL)|18 µg Tiotropium (Tio18GEL) inhalation powder
75722768|NCT00662792|Drug|Salmeterol MDPI (Salm50DPI)|50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)
75722769|NCT00662792|Drug|Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)|18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S_DPI) twice daily (BID)
75722770|NCT00662792|Drug|Tiotropium/Salmeterol (T+S_PE)|Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) inhalation powder
75569576|NCT02932137|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2）
75569577|NCT02889484|Procedure|Lumbar disc hernia surgery|
75569578|NCT02889328|Drug|Regorafenib|Regorafenib 100mg continuous dosing arm
75569579|NCT02932059|Behavioral|Metamemory|Metamemory evaluation using a sentence construction strategy
75722771|NCT01009450|Procedure|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
75569580|NCT01280266|Drug|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
75569581|NCT01279447|Drug|0.25% Bupivacaine|10cc, single dose, US guided injection
75569582|NCT01279447|Drug|Normal Saline|10cc, single dose, US guided injection
75569583|NCT05466045|Other|Olive oil application in hemodialysis patients with pruritus|Experimental group: In addition to routine care, a brown glass bottle containing extra virgin olive oil was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
75569584|NCT05466045|Other|Normal saline application in hemodialysis patients with pruritus|Control group: In addition to routine care, a brown glass bottle containing normal saline was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
75569585|NCT02920034|Device|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
75569586|NCT02920034|Device|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
75569587|NCT02920034|Device|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
75569588|NCT02931981|Procedure|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
75569589|NCT02920151|Other|balance exercises circuit|Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
75722772|NCT01009450|Procedure|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
75569590|NCT02932254|Drug|Magnesium Sulfate|After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
75569591|NCT02932254|Drug|Saline|After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
75569592|NCT02920112|Behavioral|Telephone based Cognitive Behavioral Therapy|6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
75569593|NCT02920190|Drug|Liraglutide|1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months
75569594|NCT05465850|Diagnostic Test|Modified USPHS criteria|It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
75569595|NCT02919878|Drug|Gemcitabine|Nucleoside analog- Chemotherapy
75423521|NCT05086627|Drug|Capecitabine+Oxaliplatin|Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
75423522|NCT05074420|Drug|Baricitinib|Given Orally
75423523|NCT05069597|Drug|CREON|Capsule; Oral
75423524|NCT05058391|Biological|Elaprase|Participants will receive a single dose of Elaprase 0.5 mg/kg intravenous infusion every week on Day 1.
75569596|NCT02919878|Radiation|XRT|pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
75569597|NCT02919878|Drug|capecitabine|Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
75569598|NCT02931786|Drug|propofol|propofol, midazolam and atropine administration via intravenous cannula.
75569599|NCT02931786|Drug|Ketamine propofol mixture|Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
75569600|NCT02931747|Dietary Supplement|Placebo|Subjects are received Placebo once daily for 16 weeks.
75569601|NCT02931747|Dietary Supplement|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
75569602|NCT02931747|Dietary Supplement|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
75569603|NCT02919605|Drug|Single dose of Pentamidine|The patients will come to the hospital to take a single dose of the Pentamidine.
75569604|NCT02919605|Drug|Two doses of Pentamidine|The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
75569605|NCT02919605|Drug|Three doses of Pentamidine|The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
75569606|NCT02931708|Other|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
75569607|NCT02919800|Biological|MOD-5014|MOD-5014, a long-acting modified recombinant Factor VIIa
75722773|NCT00870480|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
75569608|NCT02919800|Other|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
75722774|NCT00870480|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
75722775|NCT01009528|Device|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
75722776|NCT00742001|Biological|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
75722777|NCT00870558|Drug|ethiodized oil|Given as an intra-arterial infusion
75722778|NCT00870558|Radiation|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
75569609|NCT04687605|Procedure|Temporary hypercapnia|Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
75722779|NCT00869076|Other|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
75722780|NCT00869076|Other|Usual care|Patient was managed by their primary care physician as usual
75569610|NCT02931630|Other|Whey protein powder|60 g of whey protein powder
75569611|NCT02931630|Other|Maltodextrin powder|60 g of Maltodextrin powder
75569612|NCT02931630|Other|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
75569613|NCT02931630|Other|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
75569614|NCT02931669|Other|Qualitative Descriptive Study|
75569615|NCT02919722|Behavioral|Music Therapy|The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
75569616|NCT02931864|Other|Online mindfulness training|5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
75569617|NCT02931864|Other|Online symptom management|5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
75569618|NCT00532428|Drug|Raloxifene|60 mg QD
75569619|NCT00532428|Drug|Raloxifene|120 mg QD
75569620|NCT00532428|Drug|Placebo|Placebo
75569621|NCT02919839|Other|non-Interventional|
75569622|NCT00532467|Drug|SRX251|
75722781|NCT01565278|Drug|Soybean oil (Standard treatment)|1. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
75722782|NCT01565278|Drug|Soybean oil + Fish oil|Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
75569623|NCT02919527|Other|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
76045863|NCT05388539|Procedure|Theta Burst Stimulation|3 TBS sessions per day, with an offer of 1200 pulses per session and a 30-minute interval between sessions. This protocol will be applied to patients for 15 days, totaling 45 stimulation sessions. The stimulations will be directed to the left dorsolateral prefrontal cortex (F3 obtained by the Beam method) and will be performed in a Magventure MagPro R30 device.The stimulation will be delivered at 100% of the motor threshold and will last for 6 minutes.
75423525|NCT05052983|Drug|Nemolizumab|Participants will receive either 1 [30 milligram (mg)] or 2 (2×30 mg) subcutaneous injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants will receive the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
75722783|NCT00616902|Drug|paricalcitol injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
75423526|NCT05052983|Drug|Placebo|Participants will receive either 1 (30 mg) or 2 (2x30 mg) subcutaneous injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants will receive the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
75423527|NCT05048173|Procedure|Sentinel lymph node mapping and biopsy|Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive
75423528|NCT05048173|Procedure|Lymphadenectomy|Conventional lymphadenectomy
75569624|NCT02919527|Other|Stretching|Static Stretching performed at the anterior thigh
75569625|NCT00532506|Drug|SK-0403|
75569626|NCT02919644|Biological|autologous dendritic cells loaded with autologous tumour homogenate|Each vaccine dose consists of 10_7 autologous dendritic cells loaded with autologous tumor homogenate
75569627|NCT02919644|Drug|IL2|Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
75569628|NCT05465733|Drug|Envafolimab;Pemetrexed|single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
75569629|NCT02919488|Other|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
76045864|NCT05388539|Procedure|Sham Stimulation|The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS. It will also occur three times a day, with a duration of 6 minutes. The interval time between procedures will be of 30 minutes. It will take place for the same 15 weekdays, totalizing 45 sham stimulations.
75423529|NCT05036252|Diagnostic Test|Cardiopulmonary Exercise Test|All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.
75423530|NCT05036252|Diagnostic Test|Echocardiogram|Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.
75423531|NCT05036252|Diagnostic Test|Echocardiography|As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.
75569630|NCT02919488|Other|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
75569631|NCT00533286|Drug|benzodiacepine|diazepam (2 x 5 mg/ die)
75569632|NCT03680456|Drug|Ferric carboxymaltose|maximum of 750mg in U.S. is given, maximum of 1000mg in EU
75722784|NCT00616902|Drug|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
75722785|NCT00869154|Behavioral|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
75722786|NCT00869154|Behavioral|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
75722787|NCT00801944|Drug|Solifenacin succinate|oral
75722788|NCT00801944|Drug|Placebo|oral
76045865|NCT05416853|Procedure|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin or the radial, and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open.
75569633|NCT03680456|Drug|Crystalloid|an equivalent volume dose of Natriumchlorid is administered
75569634|NCT03673787|Drug|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
75569635|NCT03673787|Drug|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
75722789|NCT00741611|Device|HD Mesh Ablation System|Ablation using the HD Mesh Ablation System
76045866|NCT05416775|Drug|SHR-8068；Adebrelimab|SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion
75722790|NCT00741611|Drug|Anti-arrhythmic drugs|5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
75722791|NCT00876252|Biological|IC43|
75722792|NCT00876252|Drug|Placebo|NaCl
75722793|NCT00870714|Drug|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
75722794|NCT00870714|Drug|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
75722795|NCT00796484|Drug|XL888|Administered orally
75722796|NCT02596217|Drug|ABBV-066|SC injection
75722797|NCT02596217|Drug|ABBV-066|IV infusion
75722798|NCT02596217|Drug|Placebo|SC injection (stage 1)
75722799|NCT02596217|Drug|Placebo|IV infusion (stage 2)
75569636|NCT05465694|Procedure|2-minute-time interval of per oral 24% sucrose|Experiment began with a five-minute observation period of all outcome measures while infant was resting in an incubator. Later, attendant nurse gave 1 ml of 24% sucrose solution on neonate's tongue. In the 2-two minute-time interval prior to heel lance intervention, following two minutes of waiting period, heel lance procedure was applied to infant's foot. In no time interval of sucrose given immediately prior to heel lance intervention, attendant nurse performed heel lance procedure immediately after giving 1 ml of 24% sucrose solution sucrose on tongue. Infant's facial actions and heart rate, and oxygen saturation were recorded by using two video cameras. Recording was carried out by a nurse during whole procedure. After collecting data, researcher watched videos separately and scored them by using PIPP-R. Measurement of study outcome relied on data collection strategies: Neonatal close-up video recording of infant facial actions, pulse oximeter, observation for adverse events.
75722800|NCT00876330|Other|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
75423532|NCT05034913|Other|Digital photography measurements|"The participant will be instructed to take off any thick outer layers and leave on shirt and pants. Tops will be gathered to make cloth tight to body. The participant will stand next to an 8 ½ x 11 piece of paper taped to a wall, to use as a reference for linear regression calculations."
75423533|NCT05034822|Drug|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
75722801|NCT00876330|Other|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
75722802|NCT00876330|Other|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
75722803|NCT00876330|Other|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
75722804|NCT02598011|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
75722805|NCT02598011|Drug|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
75722806|NCT00869310|Drug|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
75722807|NCT00869310|Drug|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
75722808|NCT00662558|Drug|celecoxib|200 mg capsules BID for 6 weeks
75722809|NCT00662558|Drug|tramadol HCL|50 mg capsules QID for 6 weeks
75722810|NCT00869388|Biological|rBBX-01|
75722811|NCT00870792|Behavioral|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
75722812|NCT00869466|Behavioral|behavioral dietary intervention|
75722813|NCT00869466|Behavioral|exercise intervention|
75423536|NCT05024058|Drug|Ligelizumab|Ligelizumab treated groups and arms
75423537|NCT05024058|Other|Placebo|Placebo treated groups and arms
75423538|NCT05013008|Drug|Finerenone (Kerendia, BAY94-8862)|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
75423539|NCT05013008|Drug|Placebo|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
75423540|NCT05011188|Biological|FOR46|Given intravenously (IV)
75423541|NCT05011188|Biological|Enzalutamide|Given orally (PO)
75423542|NCT05011188|Drug|Pegfilgrastim|6mg given subcutaneously (subQ)
75423543|NCT05002387|Device|NanoScope™ Operative Arthroscopy (Arthrex, Inc)|Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
75423544|NCT05001269|Drug|nedosiran|Monthly subcutaneous dosing throughout study period
75423545|NCT04992299|Behavioral|Mindfulness-Based Intervention|6-week mindfulness-based intervention of 6 weekly 1 hour group sessions
75423546|NCT04992299|Behavioral|Cognitive-Behavioral Therapy|6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions
75722814|NCT00869466|Other|counseling intervention|
75722815|NCT00869466|Other|educational intervention|
75722816|NCT00869466|Other|laboratory biomarker analysis|
75722817|NCT00869466|Other|questionnaire administration|
75722818|NCT00869466|Procedure|quality-of-life assessment|
76045867|NCT05416775|Drug|SHR-8068；adebrelimab and platinum-based chemotherapy|SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
76045868|NCT05416775|Drug|Adebrelimab；platinum-based chemotherapy|Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
76045869|NCT05388227|Other|Pole Walking|Group training sessions will be offered at the participating independent living/retirement communities. Training sessions will be held either indoors or outdoors, 2-3 times a week, for 20-60 min/session, over 12 weeks.
76045870|NCT02409667|Biological|Secukinumab|Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
76045871|NCT01641939|Drug|Taxane|Standard taxane (docetaxel 75 mg/m^2 IV every 3 weeks or paclitaxel 80 mg/m^2) IV once a week according to investigator choice.
75423547|NCT04992299|Behavioral|Health Education|6-week health education didactic program of 6 weekly 1 hour group sessions
75423548|NCT04945486|Other|Peer-mentor intervention|Peer-mentor support for up to 6 months
75569637|NCT05465694|Procedure|no time interval of per oral 24% sucrose|no time interval of per oral 24% sucrose
75569638|NCT03615248|Device|BreatheSuite|"BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~the dose was given,~the metered dose inhaler was properly shaken,~the metered dose inhaler is properly aligned,~the flow of medication is appropriate and~there is no accidental exhalation into the inhaler."
75569639|NCT04805112|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing. Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
76045872|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg IV every 3 weeks
76045873|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 2.4 mg/kg IV once a week
76045874|NCT04934839|Diagnostic Test|Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.|"Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts."
76045875|NCT01641861|Device|Papacarie®|Papacarie® is chemo-mechanical method for caries removal
75423549|NCT04936022|Other|Isometric Exercise|Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
75423550|NCT04936022|Behavioral|Standard care lifestyle advice|Healthy lifestyle advice for hypertension, given by a healthcare professional.
75423551|NCT04935671|Dietary Supplement|chamomile tea n saffron|20 mg of chamomile and 1 mg saffron in a teabag given twice daily for a month in combination with allopathic treatment for depression.
75423552|NCT04917861|Biological|mRNA-1893|Solution for injection
75423553|NCT04917861|Biological|Placebo|0.9% sodium chloride solution for injection
75569640|NCT03571802|Drug|Simvastatin|"The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
75722819|NCT00869466|Procedure|support group therapy|
76045876|NCT01641861|Procedure|Conventional method|caries removal by using rotary instrument.
76045877|NCT05511285|Behavioral|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online, in addition to usual care.
76045878|NCT02409355|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
76045879|NCT02409355|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
76045880|NCT02409355|Drug|Cisplatin|Cisplatin will be administered at 75 milligrams per square meter (mg/m^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
76045881|NCT02409355|Drug|Gemcitabine|Gemcitabine will be administered at 1000 mg/m^2 (when coadministered with carboplatin) or 1250 mg/m^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
76045882|NCT04874259|Procedure|Living donor liver transplantation|Living donor liver transplantation
76045883|NCT05647707|Dietary Supplement|L-Carnitine|The 36 patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose of 50 mg/kg IV every 8 h.
76045884|NCT02408887|Procedure|Total Thyroidectomy (TT)|Total removal of thyroid
76045885|NCT02408887|Procedure|Prophylactic central neck lymph node dissection (pCND)|Lymph node dissection
76045886|NCT02266875|Drug|hypertonic saline|
76045887|NCT02266875|Drug|standard saline|
76045888|NCT04135443|Behavioral|3T Tune in! Turn on! Turn up!|A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-17. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.
76045889|NCT04135443|Behavioral|General Health App|The control group will download a mobile app that addresses general health behaviors, specifically drinking more water.
76045890|NCT05647395|Behavioral|Tracheal tube cuffs differ in deflation|When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
76045891|NCT02438371|Drug|Nifedipine|
76045892|NCT02438371|Drug|Indomethacin|
76045893|NCT04419987|Genetic|draw blood|search for new genetic variations (when the diagnostic exploration will have been non informative) by sequencing exons.
76045894|NCT05647239|Device|Shotblocker|Shotblocker is a small plastic tool that can be used in all age groups in reducing pain due to injection, is non-medicinal, non-invasive, easy to use, and inexpensive and does not require material preparation
76045895|NCT02438137|Drug|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
76045896|NCT02438137|Drug|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
76045897|NCT04920565|Device|hemoperfusion with polymyxin B|polymyxin B is covalently immobilized on polystyrene strands, selectively removes endotoxin and at the same time there is no leaching of the ligand, immobilization is carried out by electrostatic interaction and Vanderwals force
75569641|NCT04799652|Other|Survey|Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.
76045898|NCT02437903|Device|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
76045899|NCT02437513|Device|NewBreez|Intralaryngeal prosthesis to protect the airways
76045900|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
76045901|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
76045902|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)|Single dose administered intranasally on Day 1
76045903|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
75569642|NCT02919332|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
75569643|NCT02919332|Radiation|Fludeoxyglucose F-18|Given IV
76045904|NCT04909021|Other|Placebo (single-dose)|Single dose administered intranasally on Day 1
76045905|NCT04909021|Other|Placebo (two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
76045906|NCT02460991|Device|DEB-TACE|
75569644|NCT02919332|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT
75569645|NCT05465577|Other|CC Links|The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.
76045907|NCT02460991|Drug|Sorafenib|
76045908|NCT02460679|Drug|EPI-589|An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
75569646|NCT02919254|Dietary Supplement|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
75569647|NCT02919254|Other|Placebo|Fruit juice cordial containing negligible nitrate
75569648|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
75569649|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
75569650|NCT05463315|Device|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
75569651|NCT02919371|Drug|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
75569652|NCT02919371|Drug|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
75569653|NCT05460819|Other|Acupuncture treatment|"Acupoint selection: Hegu-Yinxi acupoint group (clearing heat and relieving sweat), Sanyinjiao-Fuliu acupoint group (nourishing yin and tonifying kidney), Tianshu-uteri acupoint group (special effect points) (12 acupoints on both sides).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
75722820|NCT05226546|Drug|Platelet rich plasma (PRP)|PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
76045909|NCT02459899|Drug|Placebo|Placebo, once daily, before the first meal of the day
76045910|NCT02459899|Drug|Sotagliflozin|Sotagliflozin,once daily, before the first meal of the day
76045911|NCT02436889|Drug|Mirabegron|
76045912|NCT02436889|Drug|Tolterodine Tartrate|
76045913|NCT02436811|Behavioral|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
76045914|NCT02436811|Behavioral|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
76045915|NCT02436811|Behavioral|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
75569654|NCT05460819|Other|Sham Acupuncture treatment|"Selecting acupoints: Select the side opening positions of the 6 acupuncture points in the real acupuncture group, and select non-meridian and non-points (points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
75423554|NCT04905849|Behavioral|Adaptive Cognitive Control Trainer (ACCT)|"Module 1: Attention=> This module demands an active scan of the screen in search for a target, much like traditional visual search tasks. Participants quickly identify the direction that a probe target is facing (up, down, left, right), and are aided by the presence of directional cue indicating where the location of the target will appear.~Module 2: Goal Management=> Requires participants to rapidly switch their focus based on distinct rules. Participants are presented with exemplar objects along with a target, and are asked to indicate which exemplar presented is most like the target.~Module 3: Working Memory=> Engages spatial working memory resources similar to the Corsi block task. Participants memorize the location of objects on screen followed by a 5-7 second delay period, with a correct response leading to a greater number of potential targets to be memorized on the next trial (and vice versa)."
75423555|NCT04905849|Behavioral|Active Control App|The app used here is undergoing expectancy-matching at the present time, will be updated with the final app characteristics when completed out of a list of several possibilities
75569655|NCT02919410|Device|iodophor-impregnated adhesive drapes|
75569656|NCT02919410|Other|No adhesive drapes|
75569657|NCT02919215|Behavioral|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
75569658|NCT04748016|Other|3D printed (3DP) bone models + CT imaging|In addition to CT-MPR and CT-3DR, 3DP models will be used for surgical planning and intraoperative visualization.
75722821|NCT05226546|Other|olfactory training|"The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training."
76045916|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
76045917|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
76045918|NCT02436577|Drug|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
76045919|NCT02265705|Drug|Baricitinib|Administered orally
76045920|NCT02265705|Drug|Placebo|Administered orally
75569659|NCT04748016|Other|CT imaging|CT-MPR and CT-3DR used for surgical planning and intraoperative visualization.
75722822|NCT00802022|Device|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
75722823|NCT00869700|Drug|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
75722824|NCT00788996|Behavioral|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
75722825|NCT00869856|Drug|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
75722826|NCT00802256|Procedure|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
75722827|NCT00876486|Drug|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
75722828|NCT00876486|Drug|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
75722829|NCT00802334|Drug|generic lopinavir/ritonavir|"Screening visit~• Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~Baseline visit~• (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~Week 4~Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
75722830|NCT00876564|Other|Trauma patients|
75569660|NCT04736901|Drug|Enoxaparin|0.5 mg/kg every 12 hours
75569661|NCT04736901|Drug|Enoxaparin|40 mg/day
75569662|NCT04736901|Drug|Rivaroxaban|10 mg once daily
75569663|NCT04736901|Drug|Rivaroxaban|20 mg once daily
75569664|NCT04736901|Drug|Apixaban|2.5 mg twice daily
75569665|NCT04736901|Drug|Apixaban|5 mg twice daily
75569666|NCT02919176|Drug|Mirabegron|Mirabegron 50 mg/day
75569667|NCT02919176|Drug|Pioglitazone|Pioglitazone 30 mg/day
75569668|NCT02919176|Drug|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
75569669|NCT04734678|Drug|Tocilizumab|400 mg IV only once
75569670|NCT04734678|Drug|Infliximab|5 mg/kg/day IV for 2 doses 12-24 hours
75722831|NCT00796640|Drug|ER Paliperidone|
75722832|NCT00876642|Drug|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
76045921|NCT02459665|Biological|Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
75569671|NCT02919059|Drug|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
75722833|NCT00796796|Drug|Temsirolimus|
75722834|NCT00796796|Radiation|Radiation therapy|
75722835|NCT03794076|Drug|Cromoglycate|Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray
75722836|NCT03794076|Drug|Placebo|Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
75722837|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
75722838|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
75722839|NCT00870948|Drug|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
75722840|NCT00739973|Drug|Placebo|
75722841|NCT00739973|Drug|Aliskiren 150 mg tablet|
75423556|NCT04895956|Procedure|Intra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
75423557|NCT04895956|Procedure|Extra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
75423558|NCT04895956|Device|Ultrasound|To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
75722842|NCT00739973|Drug|Aliskiren 300 mg tablet|
75722843|NCT00739973|Drug|Amlodipine 5 mg capsule|
75722844|NCT00739973|Drug|Amlodipine 10 mg capsule|
75722845|NCT00739973|Drug|Aliskiren/amlodipine 150/5 mg tablet|
75722846|NCT00739973|Drug|Aliskiren/amlodipine 150/10 mg tablet|
75722847|NCT00739973|Drug|Aliskiren/amlodipine 300/5 mg tablet|
75722848|NCT00739973|Drug|Aliskiren/amlodipine 300/10 mg tablet|
75722849|NCT00876720|Device|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
76045922|NCT02459665|Drug|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
76045923|NCT02459665|Biological|Vaginal Lcr35-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
76045924|NCT02265237|Drug|ombitasvir/paritaprevir/ritonavir|tablets
76045925|NCT02265237|Drug|ribavirin|tablets
76045926|NCT04874025|Drug|Ibrance|Observational study of Ibrance 75 mg, 100 mg and 125 mg.
75722850|NCT00876720|Device|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
75722851|NCT00789230|Procedure|primary suture closure|primary suture closure of hernia
75722852|NCT00789230|Device|mesh enforced closure|mesh enforced closure of hernia
75722853|NCT00869934|Other|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
75722854|NCT00869934|Other|Behavior Therapy|Sleep restriction and stimulus control
75722855|NCT00869934|Other|Cognitive Therapy|Cognitive restructuring therapy
75722856|NCT00802568|Biological|anti-thymocyte globulin|
75722857|NCT00802568|Drug|busulfan|
75423559|NCT04888767|Other|Interval Training Hight Intensity Program|"Rehabilitation stay in hospitalization with 18 days of training sessions~Training on an ergometer~Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible"
75722858|NCT00802568|Drug|fludarabine phosphate|
75423560|NCT04883827|Other|Blood collection|20-40 mL of blood to extract cell free DNA
75423561|NCT04883827|Other|Urine collection|up to 15 mL of urine to extract cell free DNA
75423562|NCT04869085|Behavioral|e-PainSupport|Patients and caregivers assigned to the e-PainSupport condition will download the app on their own device, or they will be given a project tablet with wireless capability if they do not have their own device. All receive specific training for the intervention. They will also receive a hardcopy of the e-PainSupport manual and a trouble-shooting guide. Contact information will be provided in the app and on paper for technical problems. Caregivers complete Education Module, and patients may complete it. Caregiver or patient will fill out Pain Report daily. Pain Summary for Nurses is an automatically generated graphic summary of patients' Pain Reports over time. Nurses have access to this information during the time the patients and caregivers use e-PainSupport.
75423563|NCT04827901|Drug|XEN1101|two 10 mg capsules
75423564|NCT04827901|Drug|Placebo|matching placebo
75569672|NCT02919059|Drug|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
75722859|NCT00802568|Procedure|allogeneic bone marrow transplantation|
75722860|NCT00802568|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75722861|NCT00870012|Drug|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
75876695|NCT03661398|Device|Transcatheter Mitral Valve Replacement|All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
75876696|NCT03612128|Other|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
75722862|NCT00870012|Other|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
75722863|NCT00510874|Biological|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
75722864|NCT00510874|Biological|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
75876697|NCT03612128|Other|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
75876698|NCT03612752|Dietary Supplement|CMI-168|Dietary supplement
75876699|NCT03612752|Other|Placebo|Placebo
75876700|NCT03611660|Behavioral|Traditional Healthy Lifestyle Program|Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
76045927|NCT05484219|Device|Functional navigation|Surgeon removes brain tumor or vascular malformation and assesses location of motor areas with functional navigation and intraoperative neuromonitoring
75876701|NCT03611660|Behavioral|Mindfulness Meditation Instruction|Participants receive six mindfulness sessions.
75876702|NCT03612674|Procedure|Standard colonoscopy|Current standard of care colonoscopy.
75876703|NCT03612674|Device|ARC Endocuff Vision|Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
75876704|NCT02989194|Drug|VIS410 low dose|Single intravenous fixed low dose of VIS410
75876705|NCT02989194|Drug|VIS410 high dose|Single intravenous fixed high dose of VIS410
75876706|NCT02989194|Drug|Placebo|Single intravenous infusion of placebo
75569673|NCT05421507|Radiation|Radioactive Iodine-125 Seeds Implantation|Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.
75569674|NCT00533364|Drug|SBG (Soluble beta-glucan)|Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.
75876707|NCT03612518|Behavioral|Text and Voice Messages|Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
75876708|NCT03612518|Behavioral|Interactive Phone Call|Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
75569675|NCT02918786|Device|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
76045928|NCT02263365|Drug|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
75423565|NCT04826900|Procedure|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 200 units to 500 units. The dose range of each target muscle is as below: 20 and 75 units for flexor carpi ulnaris and flexor carpi radials; 12.5-35 units per fascicle in the flexor digitorum sublimis and flexor digitorum profundus (maximum dose: 120 units for each of these muscles); 10-35 units in the flexor pollicis longus; 25-100 units in the brachioradial ; 50-200 units in the biceps brachii; and 25-75 units in the pronator teres
75569676|NCT02918786|Device|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
75569677|NCT04731753|Device|mechanical debridement|The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
75569678|NCT02918981|Behavioral|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
75569679|NCT02918981|Dietary Supplement|14 g Whey protein|
75569680|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine|
75423566|NCT04826900|Other|Robotic therapy (RT)|A wearable robotic hand system will be used in this study. The robotic hand system consisted with a wearable exoskeletal hand, sensor glove, and a control box. On the exoskeletal hand, there are five actuators on each of finger structure that can provide external power to bring individual finger moving. The sensor glove has five sensors that can detect the finger's posture during movement and then manipulates exoskeletal hand via the control box. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeleton hand, and the unaffected hand does the certain transitive and intransitive tasks as the mirror group, and then makes the affected hand do the same movements driven by the exoskeleton robotic hand.
75569681|NCT02918981|Dietary Supplement|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
75569682|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
75569683|NCT02918981|Other|Water control|
75569684|NCT04727775|Drug|Favipiravir|Antiviral drugs
75569685|NCT04727775|Drug|Remdesivir|Antiviral drugs
75722865|NCT00802724|Behavioral|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
76045929|NCT05647083|Other|Massage therapy|Classical massage will be applied to the hands and feet, which is expected to take an average of 30 minutes.
75569686|NCT02918825|Drug|Olanzapine|Olanzapine
75569687|NCT02918825|Drug|Paliperidone|Paliperidone
75569688|NCT05420376|Procedure|Split Mesh|TEP repair of inguinal hernias using either split or whole mesh
75569689|NCT02919020|Other|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
75569690|NCT02919020|Other|Resistance exercise|resistance exercise to strengthen lower limbs
75569691|NCT04724070|Genetic|NGS, PDO/PDX establishment|Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
75569692|NCT02918903|Procedure|Minimal caries removal|the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
75569693|NCT02918903|Procedure|Complete caries removal|the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
75876709|NCT03661242|Behavioral|Physical activity|Patients in shared care arm has regular combined visits with Oncologist and Clincal Exercise Physiologist (CEP). Individual physical activity plan developed by CEP for patients in shared care arm.
76045930|NCT02261493|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
75569694|NCT05407935|Behavioral|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
75569695|NCT05407935|Behavioral|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
75569696|NCT02918747|Drug|pegaspargase|"P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four."
75569697|NCT02918747|Drug|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
75569698|NCT02918747|Drug|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
76045931|NCT02261493|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
75569699|NCT02918747|Drug|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
75569700|NCT02918747|Drug|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
75569701|NCT02918747|Drug|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
75423567|NCT04826900|Other|Robotic mirror therapy (RMT)|Wearable robotic hand system and mirror system will be used in this group.. The patients in the group will wear the robotic hand to do the mirror therapy. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeletal hand, a mirror box with a mirror will be placed in the patient 's midsagittal plane beside the unaffected hand to block his or her view of the affected hand. The patient's unaffected hand does the certain transitive and intransitive tasks and the patient will be instructed to look at the reflection of the unaffected hand in the mirror as if it is the affected hand (the visual input). At the same time the affected hand will be passively moved by the exoskeleton robotic hand which is under the .control of the unaffected hand.
75569702|NCT02918747|Drug|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
75569703|NCT02918747|Drug|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
75569704|NCT02918747|Radiation|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
75569705|NCT02918708|Biological|Synflorix|10-valent pneumococcal conjugate vaccine
75876710|NCT05383820|Drug|Ketorolac|The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
75569706|NCT02918708|Biological|Prevenar13|13-valent pneumococcal conjugate vaccine
76045932|NCT05646849|Other|Connected application|Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
75569707|NCT02918591|Drug|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
75569708|NCT02918513|Behavioral|Wellness Element 1 - Exercise|1. Daily wellness element focusing on Exercise; adherence documented online daily
75569709|NCT02918513|Behavioral|Wellness Element 2 - Mindfulness|2. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
75569710|NCT02918513|Behavioral|Wellness Element 3 - Sleep Hygiene|3. Daily wellness element focusing on sleep hygiene; adherence documented online daily
75569711|NCT02918513|Behavioral|Wellness Element 4 - Social Connectedness|4. Daily wellness element focusing on Social Connectedness; adherence documented online daily
75569712|NCT02918513|Behavioral|Wellness Element 5 - Nutrition|5. Daily wellness element focusing on Nutrition; adherence documented online daily
75569713|NCT02918513|Behavioral|Wellness Element 6 - Wellness Exercises|6. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
75569714|NCT02918513|Behavioral|Wellness Element 7 - Motivational Messages|7. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
75569715|NCT02918240|Procedure|Appointment intervals|
75569716|NCT02918240|Device|fixed orthodontic braces|
75569717|NCT04680039|Device|Continuous monitoring|Identifying intradialytic hypotension using a PPG-based wearable monitor
75569718|NCT02918045|Device|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
75569719|NCT02918045|Device|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
75569720|NCT02918123|Biological|FURESTEM-CD Inj.|Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
75876711|NCT04055766|Device|DeepDoc AI-based Decision Support System|Patients are diagnosed by the DeepDoc within 24 hours of admission.
75569721|NCT05400096|Other|Psychological therapy|The protocol for the group will be developed collaboratively between the chief researcher and the supervisor based in the weight management service. The protocol will contain Compassion Focused Therapy (CFT) based therapeutic approaches, but the group will integrate some Acceptance and Commitment Therapy (ACT) concepts.
75569722|NCT02917850|Procedure|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
75569723|NCT02917850|Procedure|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
75722866|NCT00802724|Behavioral|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
75569724|NCT03825575|Device|Low level laser therapy (LLLT)|A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
75569725|NCT00532545|Drug|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
75722867|NCT00871026|Procedure|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
75722868|NCT00871026|Procedure|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
75876712|NCT04660214|Device|septotomy|endoscopic diverticulotomy
75569726|NCT03819062|Device|Low Level Laser Therapy|A 3 week treatment period with 8 treatment sessions in total.
75569727|NCT04674111|Device|Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)|The Vortex System is indicated to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
75423568|NCT04826900|Other|Functional task training|After either 45 minutes of RT or RMT, all participants receive 15 minutes of training in functional tasks. The functional tasks included taking up and holding bowl or using eating utensils , bringing a cup for drinking, drying sucks by clips, open ing or closing door , turning on or off the light, cleaning the table or window and so on . The functional tasks training will be bases on the needs and ability of patients.
75423569|NCT04819906|Drug|Estetrol 20 mg|One estetrol monohydrate (E4) 20 mg tablet plus four matching placebo tablets orally once
75423570|NCT04819906|Drug|Estetrol 100 mg|Five estetrol monohydrate (E4) 20 mg tablets orally once
75569728|NCT03792737|Device|Spiral PDS Plus|The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
75569729|NCT03792737|Device|Spiral MONOCRYL Plus|The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
75722869|NCT00802802|Drug|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
75722870|NCT00802802|Drug|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
76045933|NCT04855773|Other|PrEPmate|"PrEPmate is a multi-component mHealth intervention grounded in the information, motivation, behavioral skills (IMB) theory of behavior change and developed through user-centered design. PrEPmate promotes personalized communication between patients and providers through interactive weekly check-in messages asking participants how PrEP is going, allowing navigators to identify patients needing more help in taking PrEP, and customized daily pill-taking reminder messages. Trained PrEP navigators reach out to participants who indicate they need assistance via text or phone call and provide tailored support. Additionally, the platform supports 2-way communication between patients and PrEP navigators, including reminders for upcoming clinic visits. Participants are provided links to key information about PrEP (PrEP Basics), and video testimonials of peers taking PrEP. Messages are available in English and Spanish. PrEPmate is aimed at both patients and PrEP navigators."
75722871|NCT00870168|Drug|chemotherapy|
75876713|NCT03612050|Behavioral|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
75423571|NCT04819906|Drug|Placebo|Five placebo tablets orally once
75423572|NCT04819906|Drug|Moxifloxacin 400 mg|One moxifloxacin 400 mg tablet orally once (open-label)
75423573|NCT04809766|Biological|Autologous Mesothelin-specific TCR-T Cells|Receive FH-TCR Tᴍsʟɴ IV
75423574|NCT04809766|Drug|Cyclophosphamide|Given IV
75569730|NCT03792737|Device|PDS Plus|PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
75722872|NCT00870168|Genetic|gene expression analysis|
75722873|NCT00870168|Other|laboratory biomarker analysis|
75722874|NCT00870168|Procedure|breast biopsy|
75722875|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
75722876|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
76045934|NCT04855773|Device|Dot Diary|Dot Diary is a mobile phone app that integrates an electronic pill-taking and sex diary and delivers real-time feedback on PrEP protection. Using the self-management model to increase self-efficacy and patient empowerment, participants log daily PrEP pill-taking and sexual behaviors in the app, which then provides real-time feedback on the level of protection achieved from PrEP (high, medium, low), and customized instructions on doses of PrEP needed to achieve or maintain high protection. Participants can also view a weekly and monthly calendar, including visualizations of the proportion of sex acts covered by PrEP. Finally, the Dot Diary app incorporates gamification components, including an ability to earn sex-positive badges, to increase engagement. Dot Diary is aimed only at patients.
76045935|NCT02260791|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
76045936|NCT02260791|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
76045937|NCT02260635|Drug|Evacetrapib|Administered orally
76045938|NCT02260635|Drug|Placebo|Administered orally
76045939|NCT04872855|Device|patient with knee arthroplasty|patient with HLS KneeTec cementless and hybrid fixation prosthesis
76045940|NCT05466201|Drug|Eltrombopag 25 MG Oral Tablet|Since thrombopoietin receptor agonists (TPO-RAs) have never been regularly used for promotion of cell engraftment post hematopoietic stem cell transplantation HSCT), we design this eltrombopag intervention to evaluate the safety and efficacy of TPO-RAs post HSCT.
75569731|NCT03792737|Device|MONOCRYL Plus|MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
75569732|NCT03792737|Device|VICRYL Plus|VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
75569733|NCT04686942|Diagnostic Test|After sonazoid|0.015ml/mg sonazoid enhanced US to detection of liver metastases.
76045941|NCT05466201|Drug|Supportive care|Patients receive transfusion of blood products, including platelets and red blood cells.
76045942|NCT02259231|Drug|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
76045943|NCT02259231|Drug|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
76045944|NCT02259231|Drug|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
76045945|NCT02259231|Drug|Omaveloxolone Capsules (10 mg/capsule)|Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
76045946|NCT02259231|Drug|Omaveloxolone Capsules (50 mg/capsule)|Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
75423575|NCT04809766|Drug|Fludarabine|Given IV
75423576|NCT04809766|Drug|Bendamustine|Given IV
75569734|NCT03782519|Other|Dialysis frequency reduction|At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)
75722877|NCT00876876|Drug|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
75722878|NCT01012804|Genetic|western blotting|
75722879|NCT01012804|Other|immunohistochemistry staining method|
75722880|NCT01012804|Other|laboratory biomarker analysis|
75722881|NCT00796874|Other|active surveillance|Correlative Study
75722882|NCT00796874|Other|imaging biomarker analysis|Correlative Study
75722883|NCT00796874|Procedure|biopsy|Tissue Removal
75722884|NCT00796874|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
75722885|NCT00796874|Procedure|magnetic resonance imaging|Radiolical Medical Imaging
76045947|NCT02258529|Drug|Idelalisib|150 tablets administered orally twice daily
76045948|NCT02258529|Biological|Rituximab|375 mg/m^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
76045949|NCT05646225|Other|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
75569735|NCT03782519|Other|Frailty diagnosis|Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
75569736|NCT00533403|Drug|MK0686|
75722886|NCT00796874|Procedure|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
75722887|NCT00876954|Procedure|Normothermia|Warming without increase in core temperature
75722888|NCT00876954|Procedure|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
75722889|NCT01565434|Other|CR1 impact|
75423579|NCT04785287|Biological|Anti-CTLA4 Monoclonal Antibody BMS-986218|Given IV
75423580|NCT04785287|Biological|Nivolumab|Given IV
75722890|NCT04898036|Device|Blue Light Therapy|This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
75722891|NCT04898036|Device|Sham Light Therapy|To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
75423581|NCT04785287|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75722892|NCT01565512|Drug|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
75722893|NCT01565512|Drug|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
75423582|NCT04780269|Device|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group, with the aid of a vaginal speculum after cervical cleaning with an aseptic solution. The balloon will be inflated with 60 mL of sterile 0.9%% sodium chloride (NaCl) after insertion past the internal os. The external end of the catheter is taped to the inner thigh without applying any traction or tension.
75423583|NCT04780269|Drug|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
75423584|NCT04769323|Device|Virtual Reality|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
75423585|NCT04769323|Other|Traditional home exercises|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
75423586|NCT04742907|Drug|TU-100|Treatment with investigational product
75423587|NCT04742907|Drug|Placebo|Treatment with placebo product
75423588|NCT04735926|Drug|Calcifediol 75mcg|Soft gelatin capsule. Oral administration once per week
75423589|NCT04735926|Drug|Calcifediol 100mcg|Soft gelatin capsule. Oral administration once per week
75423590|NCT04735926|Drug|Calcifediol 125mcg|Soft gelatin capsule. Oral administration once per week.
75423591|NCT04735926|Other|Placebo|Soft gelatin capsule. Oral administration once per week.
75423592|NCT04735926|Other|Placebo|Soft gelatin capsule. Oral administration once per week.
75423593|NCT04721158|Device|Continuous glucose monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
75423594|NCT04693338|Other|Quality-of-Life Assessment|Ancillary studies
75423595|NCT04693338|Other|Questionnaire Administration|Ancillary studies
75423596|NCT04693338|Other|Supportive Care|Receive ICP tasks
75722894|NCT00739661|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
75423597|NCT04626947|Biological|Bezlotoxumab|Bezlotoxumab infusion
75423598|NCT04625270|Drug|avutometinib (VS-6766)|avutometinib (VS-6766) monotherapy
75423599|NCT04625270|Drug|avutometinib (VS-6766) and defactinib|avutometinib (VS-6766) and defactinib combination
75423600|NCT04620811|Drug|lirentelimab|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
75423601|NCT04619043|Device|Ankle Orthotic|
75423602|NCT04595825|Biological|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
75423603|NCT04595825|Other|Placebo|Placebo - intravenous infusion
75722895|NCT00739661|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
76045950|NCT05646225|Other|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes
75569737|NCT05381883|Other|Questionnaire|"Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes"
75569738|NCT00533481|Drug|MK0557|
76045951|NCT05449275|Other|Faradic current|The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
76045952|NCT05449275|Other|Ankle foot orthosis|AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
76045953|NCT02256969|Drug|Blephamide|
76045954|NCT02256969|Drug|GenTeal PM Night-Time|
76045955|NCT02256969|Procedure|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
75569739|NCT03756155|Procedure|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
75569740|NCT00533520|Drug|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
76045956|NCT02256969|Procedure|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
76045957|NCT05438121|Device|SeQuent Please Neo|DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
76045958|NCT05645991|Dietary Supplement|Coconut Sap Powder (CSP)|CSP was given once daily (1.5 g/day) for 8 weeks.
75569741|NCT00533559|Drug|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
75569742|NCT00533559|Drug|Placebo|Placebo comparator
75569743|NCT03685253|Drug|Niagen|Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
75569744|NCT03685253|Drug|Placebo|Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
75569745|NCT04673604|Diagnostic Test|Assessment of ocular surface staining (Oxford score 0-15 scale)|Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
75569746|NCT04673604|Drug|mean diurnal intraocular pressure-lowering|At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
75569747|NCT03663608|Procedure|WALANT Technique|pure local anaesthesia and without use of a tourniquet (WALANT Technique) for trigger finger release surger
75569748|NCT04602819|Device|PicoSure 755nm picosecond alexandrite laser with diffractive lens|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.
75722896|NCT04895930|Drug|Furmonertinib|80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).
76045959|NCT05645991|Dietary Supplement|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
76045960|NCT02256891|Device|PRFM|
76045961|NCT02256891|Procedure|Double Row|
76045962|NCT02256267|Drug|LY2835219|Administered orally
76045963|NCT02256267|Drug|Rifampin|Administered orally
76045964|NCT01641471|Device|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current.
76045965|NCT01641471|Device|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
76045966|NCT05429463|Biological|Sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
75423604|NCT04595097|Device|inspiratory muscle traiing|The patients are encouraged to inhale against a load to increase the inspiratory muscle strength and endurance
75423605|NCT04594772|Drug|Folfirinox|Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2). Treatment will continue for 2 cycles (4 doses), and then re-evaluation will be performed. If a decision to continue with FOLFIRINOX is made, it will be administered for another 4 cycles (8 doses).
75423606|NCT04594772|Drug|Gemcitabine|At the first planned analysis, if a switch is indicated based on prespecified criteria , gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) - another standard regimen in this setting - will be used. It will be administered for 4 cycles (12 doses).
75423607|NCT04594772|Radiation|radiation therapy|Radiation therapy may be used prior to surgery, based on findings on the final pre-operative scan per standard of care. Radiation therapy will be delivered in patients with artery and venous involvement meeting the Intergroup definition for borderline resectable disease. Radiotherapy will be delivered via a hypofractionated approach over 10 fractions and will include target volumes to the primary tumor and elective coverage of vascular structures at risk. Radiation will be delivered with concurrent chemotherapy.
75423608|NCT04594772|Procedure|Pancreatectomy|Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy. Staging laparoscopy may be performed at the time of planned laparotomy but is not required. Either standard or pylorus-preserving pancreaticoduodenectomy, distal subtotal pancreatectomy, or total pancreatectomy may be performed. Surgical drains and enteral tubes (e.g. gastrostomy and/or jejunostomy tubes) may be placed at the discretion of the operating surgeon.
75423609|NCT04561206|Drug|Brentuximab Vedotin|Given IV
75423610|NCT04561206|Biological|Nivolumab|Given IV
75569749|NCT04602819|Device|ApolloVue® S100 Image System|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.
75569750|NCT04602819|Device|Cutometer® dual MPA 580|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.
76045967|NCT05429463|Drug|Carboplatin|AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
76045968|NCT05429463|Drug|Albumin-Bound Paclitaxel|260 mg/m^2 by IV infusion Q3W, given on cycle day 1.
76045969|NCT02255565|Drug|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
76045970|NCT02255565|Drug|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
75423611|NCT04536363|Drug|Analogs, Prostaglandin E1|"Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days"
75569751|NCT04602819|Device|VISIA®|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
75569752|NCT05348109|Other|Well finished cases|To decide whether extraction or non-extraction decision will be made for each case
75569753|NCT00532181|Behavioral|Savings Behavior and Consumer's Approach to Risk|
76045971|NCT02255565|Drug|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
75569754|NCT00532220|Drug|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
75569755|NCT00532220|Drug|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
75569756|NCT00532584|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
75569757|NCT03457259|Device|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
75569758|NCT03457259|Device|Midline|Pt. will receive midline
76045972|NCT01640301|Biological|Aldesleukin|Given SC
76045973|NCT01640301|Drug|Cyclophosphamide|Given IV
76045974|NCT01640301|Drug|Fludarabine Phosphate|Given IV
76045975|NCT01640301|Other|Laboratory Biomarker Analysis|Correlative studies
75423612|NCT04536363|Drug|Standard therapeutic protocol|"Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours"
75423613|NCT04520971|Device|780G|780G closed-loop insulin delivery system (Medtronic)
75423614|NCT04520971|Device|standard of care|continue with standard of care treatment (pump without closed-loop or MDI)
75423615|NCT04515524|Other|Non-Interventional|No study treatment will be administered in this study
75423616|NCT04504526|Drug|68Ga-Pentixafor|Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET/CT.
75423617|NCT04500912|Device|Supraflex Cruz 60 Micron|percutaneous coronary intervention
75569759|NCT04687332|Other|Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)|One group was treated with IA and the single use tryptophan adsorber, the other group was treated with PE and the Plasmaflow (see above). In total, all patients receive 5 treatments.
75569760|NCT05467709|Drug|Midazolam|2 mg Day 1 and Day 16
75569761|NCT05467709|Drug|CTP-543|12 mg q12 hour for 14 consecutive days starting on Day 3
75569762|NCT00532623|Drug|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
75569763|NCT00532623|Drug|Sequential|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
75569764|NCT04687488|Other|Fluorescein|For droplet visualization, we will use fluorescein, which has been used for many years in medicine for diagnostic purposes and is safe upon topical administration, as a tracer. There are no local or systemic side effects of topical sodium fluorescein (5). Fluorescein is routinely used in the mouth to stain dental plaque (6). Through the lacrimal duct, the nasal cavity is exposed to fluorescein when it is used for ophthalmological purposes (7). Allergic reactions have been described to intravenous injection, which is not part of our trial. In the setting of head-and-neck and otolaryngological surgeries, coating the mouth with fluorescein has been used to quantify droplet spread, to assess for risk of transmission of COVID-19 (8). Hence, fluorescein can be safely applied to nasal and oropharyngeal cavities. We will use a similar approach, coating the nasal cavity, to study droplet spread from the nose during naso-gastric intubation for motility or reflux testing.
76045976|NCT01640301|Biological|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
76045977|NCT01642407|Drug|Sildenafil|Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
76045978|NCT02255097|Biological|pembrolizumab|
76045979|NCT02254551|Drug|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
76045980|NCT02254551|Drug|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
75423618|NCT04500912|Device|Ultimaster Tansei 80 Micron|percutaneous coronary intervention
75423619|NCT04498650|Drug|PQ912|PQ912 50 mg tablets and 150 mg tablets
75423620|NCT04498650|Drug|Placebo|Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
76045981|NCT05651139|Device|Electrical Vibration Device|An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
75722897|NCT04895930|Drug|Anlotinib|10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).
76045982|NCT05642793|Drug|proactive Anti-VEGF (conbercept) use|preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
75423621|NCT04494334|Procedure|Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis|Blood samples and Nasosorption sampling
75423622|NCT04488419|Drug|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
75423623|NCT04488419|Drug|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
75423624|NCT04481919|Drug|Protocolized diuretic therapy|The urine sodium, urine creatinine and serum creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance.
75423625|NCT04446585|Device|Automated External Defibrillator (AED)|Deployment of AEDs
75423626|NCT04446585|Other|Training in cardiopulmonary resuscitation and AED use|Residents will undergo 30-minute courses at study start and if needed during the trial period. During the course they will also be recruited as citizen responders
75423627|NCT04446585|Other|Activation of citizen responders|Citizen responders will be activated in case of suspected cardiac arrest through the heart runner app.
75423628|NCT04427306|Drug|T-Vec|(talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
75423629|NCT04421222|Drug|EPI-7386 (QD)|Once daily oral dose of EPI-7386
75722898|NCT00615030|Drug|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
75423630|NCT04421222|Drug|EPI-7386 (BID)|Twice daily oral dose of EPI-7386
75423631|NCT04421222|Drug|Abiraterone acetate|Once daily dose of abiraterone acetate
75423632|NCT04421222|Drug|Apalutamide|Once daily dose of apalutamide
75423633|NCT04421079|Dietary Supplement|Trans-resveratrol|150mg, 300mg, 450mg
75722899|NCT00615030|Drug|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
75722900|NCT00615030|Drug|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
76045983|NCT05642793|Drug|passive Anti-VEGF (conbercept) use|No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
76045984|NCT05642013|Procedure|Early prosthesis reimplantation|Early prosthesis reimplantation, within 16 to 30 days after implants removal
76045985|NCT05642013|Other|Retrospective analysis of medical records|Analysis of 50 records of operated patients managed with classical two-stage implant exchange
76045986|NCT05650983|Behavioral|Aerobic exercise; Resistance exercise|To investigate affect/effect of dissimilar modes of exercise, Aerobic exercise versus Resistance exercise, on execution function and psychological symptoms in heroin addicts, 1 hour of characteristic exercise protocols aiming to (a) maximize the strain on the cardiovascular system with Aerobic exercise(60-70% of heart rate recovery) and (b) promote the greatest hypertrophy response with Resistance exercise(65% of 1 repetition maximum & repeated up to 15 time) were used. Both exercise programs were designed to match the male heroin addicts, with medium-intensity Strength-Trained for Resistance exercise and playing balloon volleyball for Aerobic exercise. Two exercise groups performed at 65% of their pre-determine peak oxygen uptake.
76045987|NCT05405985|Drug|Nemolizumab|Nemolizumab with Auto-Injector (AI).
76045988|NCT05405985|Drug|Nemolizumab|Nemolizumab with Dual-Chamber Syringe (DCS).
76045989|NCT05640375|Drug|Methylprednisolone|Single dose, 1 mg/kg
76045990|NCT05650671|Device|instrumented wheelchair|Measurements of pressure, temperature and humidity at the subject/cushion interface
76045991|NCT01641237|Drug|sodium fluoride|fluoride as sodium fluoride
76045992|NCT01641237|Drug|no added fluoride in a silica base|no added fluoride
75423634|NCT04421079|Dietary Supplement|Concord grape juice|8 oz, 16 oz, 24 oz
76045993|NCT04861779|Drug|HSK29116|Oral HSK29116
76045994|NCT05378997|Drug|TCP-25 gel 0.86 mg/ml or placebo gel|TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
76045995|NCT05378997|Drug|TCP-25 gel 2.9 mg/ml or placebo gel|TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
76045996|NCT05378997|Drug|TCP-25 gel 8.6 mg/ml or placebo gel|TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
76045997|NCT05623605|Drug|Moringa mouthwash|using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days
75423635|NCT04421079|Dietary Supplement|Grape seed polyphenol extract|450mg, 900mg, 1200mg
76045998|NCT05623605|Drug|star anise mouthwash|using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
76045999|NCT05623605|Drug|Indian costus mouth wash|using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
76046000|NCT05617209|Other|thrombin generation measurement|Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)
76046001|NCT01639833|Device|Veriset Hemostatic Patch|Topical hemostat
75569765|NCT04687488|Other|Particle measurement|Quantification of aerosol will be done using a medical particle counter, as used for hospital safety measurements.
75569766|NCT00533598|Drug|MK0557|
75569767|NCT05467592|Other|Standard Physical Therapy care|All therapy will be given as it would have routinely been administered in the clinic. Standard care for all patients includes physical therapy and chiropractic treatment at each visit. There is a nurse practitioner on site. If necessary, patients can receive trigger point injections to the musculature around the back and neck, platelet rich plasma, or headache injections by the nurse practitioner. These interventions vary on a case by case basis. Involvement in the study will not impact the patients plan of care. We will collect this information as confounders and factor into statistical analysis.
75569768|NCT00532662|Drug|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
75569769|NCT00532337|Drug|ONO-5334|Placebo - 24/mos.
75569770|NCT00532337|Drug|ONO-5334|100mg QD /24 months
75569771|NCT00532337|Drug|ONO-5334|50mg BID /24 mos.
75569772|NCT00532337|Drug|ONO-5334|300mg QD /24 mos.
75569773|NCT00532337|Drug|ONO-5334|Alendronate 70mg once weekly / 24 mos
75569774|NCT05467436|Drug|Local anesthetics, IV sedation drugs and analgesics.|Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
75569775|NCT00533676|Drug|MK0524A, /Duration of Treatment : 8 Weeks|
76046002|NCT01639833|Device|TachoSil®|Topical Hemostat
76046003|NCT01639131|Drug|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
76046004|NCT01639131|Drug|Docetaxel|intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
76046005|NCT01639131|Drug|Filgrastim or Pegfilgrastim|filgrastim (granulocyte colony-stimulating factor [G-CSF]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
76046006|NCT01641159|Drug|Buspirone|Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
75423636|NCT04421079|Drug|Placebo|Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
75423637|NCT04416152|Procedure|Pelvic reconstruction surgery|Pelvic reconstruction surgeries, such as anterior/posterior colporrhaphy, sacrospinous ligament fixation, transvaginal mesh repair and sacrocolpopexy.
75423638|NCT04414683|Procedure|staging surgery|laparoscopic or laparotomic staging surgery
75423639|NCT04412928|Procedure|mid-urethral sling procedure|mid-urethral sling procedure
75423640|NCT04396145|Diagnostic Test|Subjective Visual Vertical|All subjects will have Virtual SVV before and after the operation
75423641|NCT04395261|Diagnostic Test|Wideband Tympanometry|
75423642|NCT04390724|Other|Y90 radioembolization|Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
75876714|NCT03660774|Other|No treatment given|The participants will undergo a brief physical examination focused on neurologic function (muscle function, sensation, coordination, walking). Parents will be asked by the study team or the psychologist about their children and will complete several commonly used standard surveys about brain development, thinking, behavior, and decision making. The participants will also engage with the psychologist to evaluate development or thinking (IQ), and depending on their age they may be asked to complete one or more commonly used standard surveys about behavior and decision making.
75876715|NCT03611894|Other|radiological comparison|comparison between clinical and radiological characteristics
76046007|NCT01641159|Drug|Placebo|Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
75569776|NCT00533676|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
75423643|NCT04328714|Drug|Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells|"To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume."
75423644|NCT04298892|Other|clinical data and sample collection|Patients with hematologic malignancies and disorders will be asked to donate part of the samples collected as per clinical practice for the management of their disease for the aims of this study. In addition, patients will be asked to donate one oral swab sample, and urine samples. Collection of these additional samples is a non-invasive procedure with no associated risks for patients. Clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures) will be collected.
75423645|NCT04296110|Behavioral|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.
75569777|NCT05467319|Drug|Ferric Derisomaltose Injection|1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
75569778|NCT05467319|Drug|Normal saline|100 mL of 0.9% normal saline (w/v) by intravenous infusion
75569779|NCT04590300|Other|QUESTIONNAIRES|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
75876716|NCT03622554|Other|Adapted Physical Activity (APA)|12 APA sessions of 60 minutes
75876717|NCT03622554|Other|Therapeutic Patient Education (ETP)|Personalized ETP with 3 group sessions (1h30) and one at the end of the course (1h) and educational follow-up by phone at 3, 6 and 12 months
75876718|NCT02032472|Other|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
75876719|NCT03611504|Device|Hemospray®|Hemospray® application
75876720|NCT03622710|Other|Rehabilitation therapy|Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
76046008|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
75722901|NCT00615030|Drug|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
75722902|NCT02596061|Behavioral|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
75876721|NCT02954510|Drug|ferumoxytol|ferumoxytol will assess patency of coronary arteries
75722903|NCT02596061|Other|Incentives|Patients receive incentives for completing smoking cessation activities.
75876722|NCT03060330|Procedure|Modified Laparoscopic Ventral Mesh Rectopexy|This group will undergo modified laparoscopic ventral mesh rectopexy alone
75876723|NCT03060330|Procedure|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
76046009|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
75423646|NCT04296110|Other|Music Relaxation Therapy|We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
75423647|NCT04294771|Drug|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
75423648|NCT04294264|Drug|Oxaliplatin|Given IV
75423649|NCT04294264|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
75722904|NCT00789308|Drug|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
75722905|NCT00789308|Drug|Heparin|Anticoagulation
75722906|NCT00789308|Drug|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
75722907|NCT00789308|Drug|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
75722908|NCT00789308|Drug|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
75722909|NCT00789308|Drug|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
75876724|NCT02032784|Drug|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
75876725|NCT02032784|Other|No Octreotide|No drug
75876726|NCT03611426|Drug|rhThrombin ( Topical )|Active Substance
75876727|NCT03611426|Drug|placebo|saline solution
75876728|NCT03658824|Other|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
76046010|NCT01641081|Drug|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
75423650|NCT04263766|Other|Transcranial magnetic stimulation|TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
75423651|NCT04250415|Procedure|Surgery|
75423652|NCT04237649|Drug|KAZ954|KAZ954 will be administered in every arm.
75423653|NCT04237649|Drug|PDR001|KAZ954 + PDR001
75423654|NCT04237649|Drug|NIR178|KAZ954 + NIR178
75423655|NCT04237649|Drug|NZV930|KAZ954 + NZV930
75423656|NCT04225988|Drug|Extended-release tacrolimus|Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.
75722910|NCT00789308|Drug|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
75722911|NCT00789308|Drug|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
75722912|NCT00789308|Drug|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
76046011|NCT01641081|Drug|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
76046012|NCT01641081|Drug|Placebo|Placebo in the Pressair for 14 days
75722913|NCT00518284|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m^2.
75722914|NCT02595359|Drug|Moxifloxacin|Moxifloxacin intracameral
75722915|NCT00871104|Drug|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
75722916|NCT00871104|Drug|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
75722917|NCT02554292|Device|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
75722918|NCT02595515|Other|Chiropractic treatment|Procedure: chiropractic treatment.
75722919|NCT02595515|Other|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
76046013|NCT01640925|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
76046014|NCT01640925|Other|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
76046015|NCT05369481|Drug|Sildenafil 2%|Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
75423657|NCT04225988|Drug|Immediate-release tacrolimus|Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.
75423658|NCT04211155|Other|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
75423659|NCT04211155|Other|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
75423660|NCT04203199|Device|Real rTMS to the mPFC using H7 Coil|This will be delivered with the Brainsway H7 coil system; 1200 pulses with the H7 coil helmet. Blinded using active/sham operator cards.
75423661|NCT04203199|Device|Real rTMS to the dlPFC using H1 Coil|This will be delivered with the Brainsway H1 coil system; 3000 pulses with the H1 coil helmet. Blinded using active/sham operator cards.
76046016|NCT05369481|Drug|Minoxidil 5 %|Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
75423662|NCT04199351|Drug|AMG 171|2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.
75423663|NCT04199351|Drug|Placebo|AMG 171 placebo
75423664|NCT04191733|Device|KINCISE(TM) Surgical Automated System|Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
75423665|NCT04170634|Other|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
75423666|NCT04170335|Procedure|Bariatric surgery|Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
75722920|NCT03868566|Drug|SNP-612 dose1|Subjects will take dose1 once a day orally for 12 weeks
76046017|NCT04853979|Other|PRONE POSITION|Any combination of prone or side position for 3 hours, 3 times a day for 3 days
76046018|NCT04853589|Device|Hyaluronic acid gel|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.
76046019|NCT04853589|Device|Hyaluronic acid gel + carrier|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
76046020|NCT01638429|Drug|Neomycin|Neomycin: 500mg po bid for 10 days
76046021|NCT01638429|Drug|Rifaximin|Rifaximin: 550mg po tid for 10 days
76046022|NCT04847973|Other|Medically-Tailored Meals (MTMs)|12 weeks of home-delivered MTMs, delivered weekly, containing food for 3 meals per day on 5 days of the week
76046023|NCT04847973|Dietary Supplement|Protein supplementation shakes|12 weeks of 1 bottle of Ensure Max Protein shake every day, in addition to partcipants' standard diet
76046024|NCT05058807|Other|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
75423667|NCT04163640|Other|intra-ovarian platelet rich plasma injection|patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
75423668|NCT04149249|Other|Computer-Assisted Intervention Video Doctor|Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.
75722921|NCT03868566|Drug|SNP-612 dose2|Subjects will take dose2 once a day orally for 12 weeks
75722922|NCT00796952|Behavioral|focused attention sessions|"Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period."
75423669|NCT04149249|Other|Computer-Assisted Intervention no Video Doctor|Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
75423670|NCT04129138|Other|Survey Administration|Complete survey
75423671|NCT04068038|Other|Ventilation protocol|An evidence based ventilation protocol will be implemented at participating sites. This will include limits on peak inspiratory pressure (28cmH2O), driving pressure (16cmH2O), tidal volume (mild 8ml/kg, mod/severe 6ml/kg), positive end expiratory pressure to fraction of inspired oxygen table, permissive hypercarbia (mild allow pH 7.30, mod/severe allow pH 7.20) and permissive hypoxia (mild SpO2 92-97%, mod/severe SpO2 88-92%).
75876729|NCT03658746|Drug|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
75876730|NCT03658746|Drug|one proton pump inhibitor, colloidal bismuth pectin|All patients need these two drugs.
75876731|NCT03658746|Drug|two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)|Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
75876732|NCT02032862|Drug|Sage extract, 3400 mg , DER 1:17|
75876733|NCT03611192|Other|Multicomponent exercise|Aerobic exercise: 15~20 mins Resistance exercise: 15 mins Balance exercise: 15~20 mins Flexibility exercise: 10 mins
75876734|NCT03611192|Other|Home-program exercise|60 mins exercise
75423672|NCT04049097|Drug|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
75423673|NCT04033679|Other|Active TDCS|Participants will receive active TDCS stimulation.
75423674|NCT04033679|Other|Sham TDCS|Participants will receive sham TDCS stimulation.
75423675|NCT04023253|Drug|Mirabegron|Mirabegron 25 mg
75423676|NCT04023253|Drug|Solifenacin|Solifenacin 5 mg
75423677|NCT04017793|Behavioral|Mindfulness Based Stress Reduction|Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.
75569780|NCT05467241|Behavioral|Self-induced therapeutic tremor (SITT) combined with mindfulness|"SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. The muscles will gently shake, and release built up stress. This shaking of the muscles lets the participant's body physically let go of tension and stress.~Mindfulness is the ability to be fully present in a moment. This allows focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them.~Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed by what's going on around the participant."
75876735|NCT02990910|Drug|Individualized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
75876736|NCT02990910|Device|conventional opioid analgesia|(b) all received 25μg/kg morphine
75876737|NCT04056000|Dietary Supplement|Caffeine|200 mg of caffeine, 60 minutes before exercise
75876738|NCT04056000|Dietary Supplement|High-carbohdyrate breakfast|Ingestion of a high-carbohydrate breakfast 60 minutes before exercise
75876739|NCT04056000|Behavioral|60-minutes of steady state exercise|See intervention name
75423678|NCT04017793|Behavioral|Relaxation Group|8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
75423679|NCT04007029|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV
75423680|NCT04007029|Drug|Cyclophosphamide|Given IV
75423681|NCT04007029|Drug|Fludarabine Phosphate|Given IV
75423682|NCT04007029|Biological|Tocilizumab|Given IV
75423683|NCT04003051|Other|Internet-Based Intervention|Use Project Prepare website
75423684|NCT04003051|Other|Quality-of-Life Assessment|Ancillary studies
75423685|NCT04003051|Other|Questionnaire Administration|Ancillary studies
75423686|NCT04002310|Drug|BI 754132|One single injection
75423687|NCT03982511|Behavioral|PCIT-Health|PCIT-Health (also known as Parents Active in Their Children's Health; PATCH) is an adaptation of Parent-Child Interaction Therapy. PCIT-Health targets (1) the parent-child relationship and (2) parenting efficacy both in general contexts (child play time and clean up time) and specifically in the context of obesity risk-related behaviors (child feeding, family mealtime, and child screen time).
75569781|NCT05467202|Drug|CLL1 CAR-T|A single infusion of autologous CLL1 CAR-T cells administered intravenously
75423688|NCT03959631|Behavioral|Virtual Communities of practice|based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
75423689|NCT03931265|Diagnostic Test|ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer
75423690|NCT03911141|Behavioral|Gamification|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
75423691|NCT03911141|Behavioral|Financial|"Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
75423692|NCT03905525|Drug|CFZ533|Biological
75423693|NCT03905525|Other|Placebo|liquid placebo for injections
75569782|NCT05338788|Other|neck pain and dual task|"The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB)."
75569783|NCT05466968|Drug|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
75569784|NCT05466968|Drug|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
75569785|NCT05466812|Drug|Sr-89|"strontium-89 chloride treatment~periodical evaluation and follow-up"
75569786|NCT00533754|Procedure|drawing blood|
75569787|NCT05466773|Behavioral|Hemodialysis eating index (HDEI) base education intervention|The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.
75569788|NCT00533793|Procedure|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
75569789|NCT00533832|Device|vagus nerve stimulation (VNS)|"intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase."
75876740|NCT03611348|Drug|Latanoprost|"Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded."
75876741|NCT03611348|Device|Microneedling|A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
75876742|NCT04055532|Other|Neuraceq|Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
75423694|NCT03887650|Drug|Liposomal Bupivicaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
75876743|NCT04055064|Dietary Supplement|glucose control nutritional shake, nutrition education|Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
76046025|NCT05058807|Other|Tai Chi group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions. 1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left; 9.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
75423695|NCT03887650|Drug|Bupivacaine 0.5%|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
76046026|NCT04853511|Device|OCT-FLIM (optical coherence tomography-fluorescence life time)|comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
75569790|NCT05466617|Behavioral|Mobile Health for Physical Activity Behavior Change|All participants received visualized step-by-step instructions (eg, search and download on Google Play or App Store, user registration, goal setting, and PA behavior tracking) on the assigned PA app (PuzzleWalk or Google Fit) and used it from the beginning of the intervention start (fourth week) until the end of the intervention (eighth week). Both the PuzzleWalk and Google Fit groups received reminders regarding the use of the PA app during the first week of the intervention period and autonomously continued to use the app until the intervention ended.
75569791|NCT04484610|Drug|Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain|Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
75423696|NCT03877341|Procedure|posterolateral fusion|Instrumented posterolateral fusion is a spinal surgery that combines bone graft fusion with the use of hardware like screws and rods to stabilize the spine, correct alignment, and promote successful fusion. It's used for various spinal conditions.
75569792|NCT04687670|Diagnostic Test|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the ERA test will be provided to participants and their gynecologists for the personalized embryo transfer.
75569793|NCT04687670|Diagnostic Test|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
76046027|NCT04853355|Drug|Spironolactone 50 mg|Add Spironolactone 50 mg to previous regimen
75569794|NCT05466266|Device|ICE|All patients received ICE examination.
75569795|NCT05466266|Device|TEE|All patients received TEE examination.
75876744|NCT02033018|Drug|Aflibercept Injection|Aflibercept intravitreal injection
76046028|NCT04419285|Behavioral|Locomotion task|The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.
75876745|NCT02033096|Drug|Stannsoporfin|No intervention was administered during this observational study
75876746|NCT02033096|Drug|Placebo Control|No intervention was administered during this observational study
75876747|NCT02033096|Other|Phototherapy (as needed)|No intervention was administered during this observational study
75876748|NCT03661164|Procedure|corneal cross linking|Iontophoretic corneal cross linking
75876749|NCT03658590|Drug|Dexamethasone|a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
75876750|NCT03658590|Drug|Distilled Water|a prefilled syringe with two milliliters of distilled water intravenously.
75876751|NCT03622476|Drug|concentrated FVIII|Intervention if the assessment considers that the treatment is inadequate
76046029|NCT04419285|Behavioral|Posturology task SOT (Sensory Organization Test)|The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.
75423697|NCT03877341|Procedure|posterior lumbar interbody fusion|Posterior lumbar interbody fusion (PLIF) is a spinal surgery that involves removing problematic discs, inserting bone graft material, and sometimes a spacer, to promote fusion and stabilize the spine.
75423698|NCT03854500|Drug|Tenecteplase|0.4 mg/kg single bolus intravenously
75423699|NCT03854500|Drug|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
75423700|NCT03810924|Behavioral|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
75423701|NCT03810924|Behavioral|Ergometer|Riding ergometer
75423702|NCT03810924|Behavioral|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
75423703|NCT03810924|Behavioral|Reading Newspaper|Participants read newspaper
75569796|NCT05307354|Other|Tibial Nerve Mobilization|The person performing tibial nerve mobilization will start mobilization by keeping the lower extremity in a horizontal position, with the patient's hip and knee in 45° flexion and ankle in neutral position. Then, in order to mobilize the tibial nerve better, the patient will bring the patient's toes to the extension position, the ankle to the dorsiflexion and eversion position, and the knee joint to the extension to provide appropriate stabilization. Finally, while the patient is in this position, mobilization will be completed by plantar flexion of the distal ankle and flexion of the toes to allow the nerve to slide further distally. This mobilization technique will be performed by an experienced physician/physiotherapist twice a week for 4 weeks, and the patients will be given 5 sets of 10 cycles with a 1-minute rest period in each set.
75722923|NCT00796952|Behavioral|Valchuff|"Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment."
75722924|NCT00796952|Behavioral|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
75423704|NCT03783949|Drug|Ganetespib|Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
75569797|NCT05307354|Other|Foot-ankle range of motion exercises|In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
75722925|NCT02595827|Other|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
75876752|NCT03658434|Radiation|Palliative radiotherapy|Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
75876753|NCT03227861|Drug|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
75569798|NCT05466227|Other|Implementation of Modified Valsalva maneuvre|"Modified Valsalva maneuvre:~Patient is attached to 12-lead ECG monitoring~The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~Patient's legs are elevated (45°) for 15 seconds~Afterwards, the patient is placed back in an upright position~If not efficient, this maneuver can be repeated up to two times"
75569799|NCT04472793|Diagnostic Test|SARS-CoV-2|"Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~Testing monthly serum samples to document post-viral infection."
75876754|NCT03451955|Other|Gluten-free diet|Participants in the intervention group abstain from gluten for 6 months.
76046030|NCT04419285|Behavioral|The quality of life questionnaire|Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
76046031|NCT01639755|Device|new texture shaped breast implants|breast implant surgery
76046032|NCT04844853|Device|electroencephalography|128-channel electroencephalography
76046033|NCT04844853|Device|Tactile stimulation|Vibrotactile sequence on the forearm
76046034|NCT04844853|Behavioral|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
76046035|NCT04844853|Behavioral|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
76046036|NCT04844853|Behavioral|Laby 5-12|Test of motor planning using labyrinths
76046037|NCT04844853|Behavioral|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
75876755|NCT03428945|Drug|Hydroxychloroquine|Hydroxychloroquine for oral administration, dosed by weight
75876756|NCT03428945|Drug|Placebo|Placebo tablet identical to active drug
76046038|NCT04844853|Behavioral|Stroop animals|Stroop test for preK children using animals instead of words
76046039|NCT05310981|Behavioral|iCanChange|iCC is a psychological app based intervention that will be delivered in form of up to 24 brief (10-15 minutes) interactive modules developed based on the principles of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). During the intervention, participants will be offered MI and CBT-based activities (i.e., modules and strategies) aiming at facilitating change in cannabis use. At any point during the intervention, participants can reference modules that had been completed. Due to the frequency of behavioral stage changes in this population (e.g., regression in behavioral stage of change), stage of change will be monitored regularly throughout the intervention. During the follow-up period (i.e., Week 12-24), participants will have continuous access to the smart phone application and all built-in add-ons as described above. During this period, they will have access to 3 booster session.
76046040|NCT05369091|Drug|Simvastatin 10mg|Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
75569800|NCT05466149|Drug|Furmonertinib|240mg QD on a continuous dosing schedule.
75722926|NCT00871416|Device|NovoFine® needle 6 mm|
75722927|NCT00871416|Device|NovoFine® needle 12 mm|
75722928|NCT00614874|Drug|rosiglitazone|2mg, 4mg, 8mg
75722929|NCT02553980|Behavioral|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
75722930|NCT02553980|Other|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
76046041|NCT04652037|Device|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|Implantation during bilateral cataract surgery of a new non-diffractive extended vision presbyopia and astigmatism correcting intraocular lens (Acrysof IQ Vivity Toric Extended Vision Intraocular Lens)
76046042|NCT01601535|Drug|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
76046043|NCT01601535|Drug|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
75569801|NCT00532701|Drug|Peg-IFN + WB RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 5-16"
75722931|NCT00727415|Drug|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
75722932|NCT00727415|Drug|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
76046044|NCT01601535|Drug|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
76046045|NCT05422365|Drug|Intravenous immunoglobulin (IVIG), 10% solution for infusion|The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
76046046|NCT04641273|Drug|BAY1817080|Tablet, intake orally.
76046047|NCT04641273|Drug|Placebo for BAY1817080|Tablet, intake orally.
76046048|NCT04641273|Drug|Placebo for Pregabalin|Capsule, intake orally.
76046049|NCT04641273|Drug|Pregabalin|Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
76046050|NCT04832763|Procedure|Biospecimen Collection|Undergo collection of blood sample
75722933|NCT00727415|Drug|Lenalidomide|"All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).~In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose."
75722934|NCT00803192|Drug|Famotidine Tablets, 40 mg|
76046051|NCT04832763|Other|Medical Chart Review|Review of medical charts
76046052|NCT04832763|Other|Physical Performance Testing|Undergo physical function testing
76046053|NCT04832763|Other|Quality-of-Life Assessment|Ancillary studies
76046054|NCT04832763|Other|Questionnaire Administration|Complete questionnaire
76046055|NCT04852731|Procedure|Cardiac MRI|Injected cardiac MRI
76046056|NCT04852731|Other|Blood collection|Blood collection (including genetics at the inclusion visit)
76046057|NCT04852731|Procedure|Prolongation of the MRI examination|Prolongation of the MRI examination (4D flow sequence ; about 10 min)
76046058|NCT05000853|Drug|Iron Carboxymaltose|Iron supplementation when is needed according to usual care
75423705|NCT03783949|Drug|Niraparib|Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
75423706|NCT03783949|Drug|Carboplatin|In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
75423707|NCT03783949|Drug|Paclitaxel|Paclitaxel dose will be 175mg/m² (q3w)
75423708|NCT03783949|Drug|Gemcitabine|Gemcitabine dose will be 1000mg/m² (q3w, d1 & d8)
75423709|NCT03777722|Device|Tailored Lighting Intervention|Lighting Intervention - active or placebo
75423710|NCT03777657|Drug|Tislelizumab|200 mg IV on Day 1 during each 21-day cycle
75423711|NCT03777657|Drug|Placebo|Placebo to match tislelizumab on Day 1 during each 21-day cycle
76046059|NCT04832529|Procedure|No packing of perianal abscess cavity|introducing new method to no packing of abscess cavity.
76046060|NCT04998591|Behavioral|Fasting|fasting for 7 days (caloric intake <500 kcal in liquid form)
76046061|NCT04419129|Device|Oxford UKA|knee arthroplasty
76046062|NCT04419129|Device|Vanguard TKA|knee arthroplasty
76046063|NCT04586985|Drug|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
76046064|NCT04586985|Drug|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
75423712|NCT03777657|Drug|Cisplatin|80 mg/m² IV on Day 1 during each 21-day cycle
75423713|NCT03777657|Drug|Oxaliplatin|130 mg/m² IV on Day 1 during each 21-day cycle
75423714|NCT03777657|Drug|Capecitabine|1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) during each 21-day cycle
75423715|NCT03777657|Drug|5-FU|800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle
75423716|NCT03764891|Procedure|Uphold|Uphold system in treating women with cystocele
75423717|NCT03764891|Procedure|Perigee|Perigee system in treating women with cystocele
75423718|NCT03755297|Other|Blood sample analysis of patients treated as standard care|Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
75423719|NCT03722719|Other|the Knack|The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.
75423720|NCT03722719|Other|PFMT|The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.
75423721|NCT03722719|Other|The Knack + PFMT|These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
76046065|NCT04586985|Drug|FTX-6058 - Two Dosing Periods|Subjects will receive FTX-6058
75423722|NCT03699254|Drug|Valganciclovir|"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
75423723|NCT03699254|Drug|Ganciclovir|"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
75423724|NCT03693690|Procedure|Vaginal laser thermotherapy|Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence.
76046066|NCT04586985|Drug|FTX-6058 / Midazolam Syrup|Subjects will receive FTX-6058 and midazolam syrup
76046067|NCT04586985|Drug|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
75569802|NCT00532701|Drug|Peg-IFN + LD RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-6~Rapid virologic response (RVR) at week 4 of therapy: achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
75569803|NCT00532701|Drug|Peg-IFN + WB RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: not achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
75722935|NCT00544557|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
76046068|NCT05260749|Procedure|real-time fMRI neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
76046069|NCT05260749|Procedure|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI sham neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
76046070|NCT04852419|Drug|ZN-c5|ZN-c5
75722936|NCT02554214|Device|Glafkos drainage device|
75876757|NCT05181059|Diagnostic Test|Dual-layer spectral computerized tomography (DLSCT)|Contrast enhanced DLSCT scan using a 128-slice dual-layer detector (IQon Spectral CT, Philips Health Systems) will be performed. Patients will be placed in prone position during the DLSCT scan in order to improve the visualisation of breast tissue and comparability with MRI images. During the examination we will administer a nonionic low-osmolar iodinated contrast agent (Optiray©) in order to visualise tumor angiogenesis.
76046071|NCT05249673|Other|global postural reeducation|"GPR interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
76046072|NCT05249673|Other|neck stabilization training|"Each exercise session will be comprised 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.~performed. The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient."
75569804|NCT00532701|Drug|Peg-IFN + WB RBV for 48 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: not achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
75876758|NCT03409289|Device|RUSH Exam|Within two hours of return of spontaneous circulation, the following elements of the RUSH exam will be performed: focused evaluation of the heart, inferior vena cava, abdomen and aorta with the addition of evaluation for DVT and ocular ultrasound.
75876759|NCT05180747|Other|Frequency of physical therapy sessions|Physical therapy sessions consisted of standard of care practice at our center of excellence i two different frequencies. All patients in both groups received 12 physical therapy sessions. Patients in the burst group received 2 physical therapy sessions per week in 6 weeks, while patients in the spaced group received 1 session every 2 weeks for 6 months.
76046073|NCT05245539|Drug|CVL-231|CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.
76046074|NCT04840875|Biological|chimeric antigen receptor T cell treatment|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
75569805|NCT00532701|Drug|Peg-IFN + LD RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
75569806|NCT01276639|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
75423725|NCT03680755|Behavioral|Internet-based intervention for dental anxiety|Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
75423726|NCT03634930|Behavioral|observation|Observation of growth, infant bodycomposition, 24h-drinkingvolume
75423727|NCT03559621|Behavioral|mobile-based lifestyle intervention|one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
75569807|NCT01276639|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
75876760|NCT01336712|Procedure|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
75876761|NCT03208127|Drug|Treatment with Direct Acting Antiviral tablet|HCV Treatment for 12 Weeks
75876762|NCT02865122|Drug|NTRA-9620|Oral daily dose
75876763|NCT02865122|Drug|Placebo|Oral daily dose
75876764|NCT05383430|Diagnostic Test|: Conners rating scale-Stanford-Binet Intelligence Scales- stuttering severity index third edition (SSI-3) .|Questionaire tests for ADHD -IQ-Stuttering severity assessment
76046075|NCT05408403|Other|Regional anesthesia TFPB|Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
75423728|NCT03550131|Behavioral|Innovations in Dementia Empowerment and Action (IDEA)|The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
75423729|NCT03550131|Behavioral|Reducing Disabilities in Alzheimer's Disease (RDAD)|The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
75423730|NCT03522246|Drug|Rucaparib|Oral rucaparib will be administered twice daily
75423731|NCT03522246|Drug|Nivolumab|IV nivolumab will be administered once every 4 weeks
75423732|NCT03522246|Drug|Placebo Oral Tablet|Placebo tablets will be administered twice daily
75569808|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
75569809|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
75569810|NCT05465915|Device|Electroconvulsive therapy|Patients are treated with ECT.
75569811|NCT05465837|Procedure|Tracheostomy|Early and Late Tracheostomy (</= 10 days: Early and >10 days: Late)
75569812|NCT05465759|Other|disease|Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.
75876765|NCT03611114|Dietary Supplement|Blood orange juice|
75876766|NCT03611114|Dietary Supplement|Control drink|
75876767|NCT02033330|Dietary Supplement|phenolics form orange peel|
76046076|NCT05408403|Other|Regional anesthesia QLB|Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
76046077|NCT05620797|Other|Immediate loading of the implants|Patients of this group will be rehabilitated by implant-retained mandibular overdenture with immediate loading of the implants as opposed to conventional maxillary complete dentures.
76046078|NCT05620797|Other|Delayed loading of the implant|Patients of this group will be rehabilitated by implant retained mandibular overdenture with delayed loading of the implants (after 3 months) opposed by conventional maxillary complete dentures
75423733|NCT03522246|Drug|Placebo IV Infusion|IV placebo will be administered once every 4 weeks
75569813|NCT00532415|Drug|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
75569814|NCT00532454|Drug|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
75569815|NCT01275625|Drug|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
75569816|NCT05465720|Behavioral|falls-prevention programs|Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.
75423734|NCT03513328|Drug|Thiotepa--single daily dose|Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
75423735|NCT03513328|Drug|Thiotepa--escalated dose|Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
75423736|NCT03502967|Drug|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
75423737|NCT03502967|Drug|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
75569817|NCT05463458|Other|nutrition|Standard of nutrition Care plus adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) anti-oxidants.
75423738|NCT03498716|Drug|Atezolizumab|"Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year"
75423739|NCT03498716|Drug|Paclitaxel|Paclitaxel will be administered by IV, 80 mg/m^2 every week for 12 weeks.
75423740|NCT03498716|Drug|Dose-dense Doxorubicin or dose-dense Epirubicin|"Dose-dense doxorubicin will be administered by IV, 60 mg/m^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m^2) every 2 weeks for a total of 4 doses"
75423741|NCT03498716|Drug|Cyclophosphamide|Cyclophosphamide will be administered by IV, 600 mg/m^2 every 2 weeks for 4 doses
75569818|NCT05459792|Procedure|median nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
75569819|NCT05459792|Procedure|radial nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
75569820|NCT05459792|Procedure|local infiltration|intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle
75569821|NCT04686825|Drug|DA-8010 2.5mg (Fasting)|Test drug l : DA-8010 2.5mg (Fasting)
75569822|NCT04686825|Drug|DA-8010 2.5mg (Fed)|Test drug ll : DA-8010 2.5mg (Fed)
75569823|NCT04686825|Drug|DA-8010 5mg (Fasting)|Test drug llI : DA-8010 5mg (Fasting)
75569824|NCT04686825|Drug|DA-8010 5mg (Fed)|Test drug lV : DA-8010 5mg (Fed)
75569825|NCT05455892|Other|Clinical data collection during hospitalization in short geriatric units.|Retrospective clinical data collection, at time of infection and 10 days later. Correlation between mortality and gravity. Identification of predictive mortality factors such as frailty, preexisting comorbidities, complications and treatments. Description of medical prescription evolutions.
75569826|NCT05454800|Other|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Scoliosis specific corrective exercises and physical activity counseling
75569827|NCT05454800|Other|Scoliosis Specific Corrective Exercises|Only scoliosis specific corrective exercises
75569828|NCT04686552|Dietary Supplement|cinnamon|6 g of ground cinnamon
75722937|NCT00877110|Drug|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
75423742|NCT03447119|Behavioral|Living Well with a Disability|Implementation of an adapted health promotion program.
75423743|NCT03441295|Procedure|Dynamic Intraligamentary Stabilization|DIS, Ligamys
75569829|NCT00533988|Device|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
75569830|NCT05285748|Behavioral|Self-Paced Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in self-selected intensity PA.
75569831|NCT05285748|Behavioral|Prescribed Moderate Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in moderate intensity PA consistent with national guidelines.
75569832|NCT05424887|Drug|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
75423744|NCT03441295|Procedure|Internal Brace Ligament Augmentation|IBLA
75569833|NCT05424887|Drug|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
75569834|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
76046079|NCT04916223|Other|Therapeutic massage|"The massage therapists were scheduled on a rotating schedule with two alternates scheduled for each day to ensure adherence to assigned study arm and to avoid therapist effect as much as possible. For each enrolled subject, the therapist assessed the subject and created a treatment plan depending on his/her individual needs and preferences. For example, if a subject reported bothersome lower extremity pain, the therapist might focus the massage on that lower extremity or might avoid massaging that lower extremity, depending solely on the preference of the subject. Massage duration was determined by the assigned study arm."
75423745|NCT03441295|Procedure|ACL Reconstruction|Conventional
75569835|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
75569836|NCT00533637|Drug|Placebo|Citrate buffer with preservatives
75423746|NCT03430310|Other|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
75423747|NCT03430310|Other|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
75876768|NCT03941093|Drug|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX|"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
76046080|NCT04830735|Drug|Dasatinib Anhydrous|Given PO
76046081|NCT04830735|Drug|Placebo Administration|Given PO
76046082|NCT04489095|Diagnostic Test|Electrophysiology Study|After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
75423748|NCT03424161|Device|Secret RF|Subjects will receive treatment with the Secret RF device
76046083|NCT04840173|Behavioral|Music|During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
75569837|NCT05466695|Drug|Tadalafil 5mg/sildenafil 25 mg|patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
75569838|NCT05284500|Procedure|Pediatric cardiac surgery with cardiopulmonary bypass|All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
75569839|NCT05423639|Device|palodent|innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.
75569840|NCT05423639|Device|optracontact|The instrument is used to achieve large and tight proximal contacts in posterior teeth.
75569841|NCT05281185|Drug|Extended half-life FVIII concentrates with PK-guided dosing|Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis
75569842|NCT05281185|Drug|standard half-life FVIII concentrates with weight-based dosing|standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
75569843|NCT00532532|Drug|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
75569844|NCT00532532|Drug|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
75722938|NCT00727259|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
76046084|NCT05335317|Device|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50% overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm (total handpiece length of 10 centimeter (cm), 20 treatment points along vagina), from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 100 milliseconds (ms), pause between packets of 50 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
76046085|NCT05335317|Drug|Topical hormone estriol|Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.
76046086|NCT05335317|Diagnostic Test|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis (to include the participant in the study).
76046087|NCT05335317|Diagnostic Test|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
76046088|NCT05335317|Diagnostic Test|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), immunocytochemical examination and cytology (to evaluate procedure efficiency).
75722939|NCT00727259|Drug|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
75722940|NCT00789386|Drug|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
75722941|NCT00789386|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
75722942|NCT05157282|Device|TESS|Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
75722943|NCT05157282|Other|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
75569845|NCT00532532|Drug|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
75876769|NCT03941093|Drug|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX|"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
76046089|NCT05335317|Diagnostic Test|Cervical oncocytology test.|Cervical smear for oncocytology test (to include the participant in the study).
76046090|NCT05335317|Diagnostic Test|Extended colposcopy|Extended colposcopy is performed under a microscope using a Lugol to determine external changes in the epithelium in order to determine atrophy and pathologies of the cervix and vaginal vault (dysplasia, erosion, cancer, etc.) (to include the participant in the study).
76046091|NCT05335317|Diagnostic Test|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
76046092|NCT05335317|Other|King's Health Questionnaire|The King's Health Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
75423749|NCT03413189|Other|Review of medical records|Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)
75423750|NCT03413189|Other|Assessment of physical and cognitive function|This will be performed in person through the Function Independence Measure (FIM), grip strength, functional reach, 6-minute walk test (6MWT) and Montreal Cognitive Assessment (MoCA-Blind).
75423751|NCT03413189|Other|Interview of patients, carers and/or family members|Questions will be asked to participants regarding their recovery from Intensive Care to establish themes
75423752|NCT03409159|Device|LAAC|Left atrial appendage closure
75423753|NCT03404180|Procedure|Peripheral nerve block|All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
75423754|NCT03404180|Drug|Intravenous Sedatives|Intravenous sedation using propofol or dexmedetomidine will be administered.
75569846|NCT04393935|Behavioral|Pharmacy delivered PrEP Intervention|Men who are eligible and agree to the clinical screener will be provided with a pre-packaged kit of self-administered tests for HIV, rectal chlamydia, syphilis and gonorrhea and creatinine and directed back to the private area of the pharmacy to perform their screenings. Participants will be asked to return the screening tests to the pharmacy technician. The pharmacy technician will process/ interpret the results of the rapid HIV test first in case a treatment referral needs to be set up. Then s/he will process/interpret the results of a rapid rectal chlamydia, syphilis, gonorrhea and rapid finger prick creatinine test. HIV negative customers will be provided with their results and be given a 7-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Participants will be contacted after 3 months to determine whether they continued PrEP use.
75569847|NCT05405036|Other|simulated patient|In the last month of the Measurement and Evaluation course in Physiotherapy, a simulated patient session will be held four times (with disease in the cervical-lumbar-shoulder and knee region). Students will be evaluated by the methods they learned about patients. 10 days before and after the simulated patient sessions, the questionnaire will be applied in Turkish for validity and reliability, and then the questionnaire will be repeated after the simulated patient sessions are over, and the effect of the smile patient sessions on the perceived communication skills of the patient will be examined.
75569848|NCT05354297|Device|Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Expert guidance via coaching
76046093|NCT05335317|Diagnostic Test|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. pH (potential of hydrogen) will be investigated by test-lines paper (to evaluate procedure efficiency).
76046094|NCT05335317|Diagnostic Test|Ultrasound investigation|Ultrasound investigation with General Electric Voluson E8 Expert for assessing blood vessels (Doppler sonography) and vaginal wall thickness measurement (to evaluate procedure efficiency).
76046095|NCT05335317|Diagnostic Test|Perineometry|Pressure force of vaginal walls measurement with IEASE device (to evaluate procedure efficiency).
75569849|NCT05354297|Device|Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Fitness and wellness guidance
76046096|NCT05335317|Diagnostic Test|Optical coherence tomography|Optical non-invasive method of investigation vaginal mucus morphological and functional condition.
75423755|NCT03404180|Procedure|Lateral femoral cutaneous nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
75569850|NCT05354297|Device|Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Behavioral weight loss program
75722944|NCT05157282|Other|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
75722945|NCT05157282|Device|sham-TESS|Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
75423756|NCT03404180|Procedure|Obturator nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
76046097|NCT05335317|Diagnostic Test|Biopsy|Biopsy of the vaginal wall to assess the condition of the vaginal wall and compare the obtained data with the data of optical coherence tomography.
76046098|NCT05335317|Diagnostic Test|Femoflor screen|Femoflor screen for the study of vaginal microbiocenosis, specifically for the detection of the pathogens, opportunistic flora and normal flora and their qualitative and quantitative evaluation (to include the participant in the study).
76046099|NCT04829721|Other|Educational Intervention with video|Women randomized to an educational video workshop group.
76046100|NCT04419441|Drug|Immune checkpoint inhibitor|concomitant administration of radiotherapy and immune checkpoint inhibitor
75569851|NCT05354297|Device|Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app|Multi condition support
75423757|NCT03403465|Other|FDG PET scan|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
75423758|NCT03390686|Drug|Bevacizumab|15 mg/kg IV every 3 weeks on Day 1
75569852|NCT05276544|Behavioral|Dietary intervention|Dietary intervention: Preparation and follow-up of diet program.
75569853|NCT00532571|Drug|CoQ10|
75569854|NCT05346614|Behavioral|Lifestyle intervention|Lifestyle coaching will be given on a digital app-based platform. Individuals will receive real-time feedback via a smart scale, activity monitor, and continuous glucose monitor (first 4 weeks, longer if required). Coaching will be focused on gradual behavior change, assisted by digital nudges, one-on-one, and small group coaching sessions. Coaching will include education regarding lifestyle to improve health literacy with respect to diet and diabetes management. Additionally, coaches will guide participants in the implementation of individualized diet and exercise program with varying levels of carbohydrate restriction and caloric deficit.
75569855|NCT00532610|Drug|GSK189075|
75569856|NCT04322565|Drug|Colchicine|Cochicine 1mg/day
75569857|NCT04687826|Other|Goal directed fluid therapy|Patients in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique.
75569858|NCT04687826|Other|Liberal fluid therapy|Patients in 2017 got liberal intraoperative fluid therapy influenced by their anaesthesiologist.
75569859|NCT05267691|Procedure|Excision|Surgical excision of the lesion and histopathology evaluation using Hematoxylin and Eosin stains
75569860|NCT05342285|Diagnostic Test|Flow mediated dilation|flow mediated dilation in brachial artery
75569861|NCT05259189|Drug|NBL-012 Injection|a single subcutaneous injection
75722946|NCT00789464|Dietary Supplement|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
75569862|NCT05259189|Drug|Placebo|a single subcutaneous injection
75722947|NCT00789464|Drug|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
76046101|NCT05329779|Drug|brexanolone|Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.
75423759|NCT03390686|Drug|HD204|15 mg/kg IV every 3 weeks on Day 1
75423760|NCT03390686|Drug|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
75423761|NCT03390686|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
75423762|NCT03373552|Diagnostic Test|Platelet function assay|Platelet function assay
75423763|NCT03373201|Drug|Tasimelteon|Oral capsule
75569863|NCT05333354|Other|education strategy|The educational course of the experimental group will last for 6 weeks, including classroom teaching and simulated situational teaching. The classroom teaching will be divided into 3 times, a course of about 2 hours at a time; after the class, simulated situational teaching is also arranged for 4 hours at a time/ Caring for many patients with delirium, and performing related research. The simulated scenario lesson plan plans to design 3 major themes (delirium assessment, delirium risk factors, delirium prevention, each major theme will have 2 scenarios, each The simulation teaching exercise starts with pre-briefing, and after the end, debriefing reflection and discussion with the students.
75423764|NCT03373201|Drug|Placebo|Oral capsule
75722948|NCT03967067|Procedure|liver resection|Open or laparoscopic, major or minor hepatectomy performed using the clamp-crush technique and intermittent clamping of hepatic pedicle
75722949|NCT00977067|Drug|GDC-0152|Intravenous escalating dose
75722950|NCT00797030|Drug|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
75722951|NCT00797030|Drug|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
75423765|NCT03357926|Diagnostic Test|24 hour Holter ECG Monitoring|24 hour Holter ECG Monitoring
75423766|NCT03345342|Drug|PP6M|Participants will receive intramuscular injection of PP6M.
75423767|NCT03345342|Drug|PP3M 350 mg eq.|Participants will receive intramuscular injection of PP3M 350 mg eq.
75722952|NCT00877188|Other|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
75722953|NCT02593955|Behavioral|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
75722954|NCT02593955|Behavioral|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
75876770|NCT03611036|Other|Strength training|Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
75423768|NCT03345342|Drug|PP3M 525 mg eq.|Participants will receive intramuscular injection of PP3M 525 mg eq.
75423769|NCT03345342|Drug|PP1M|Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
75423770|NCT03345342|Other|Placebo|Participants will receive matching placebo.
75423771|NCT03290547|Device|Cutera enLighten laser|Subjects will receive laser treatments.
75423772|NCT03270969|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive daily TDF/FTC for 14 days
75423773|NCT03264131|Drug|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
75423774|NCT03264131|Drug|CHEP|"Cyclophosphamide- 750 mg/m^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."
75423775|NCT03233347|Drug|Brentuximab Vedotin|Given IV
75423776|NCT03233347|Drug|Dacarbazine|Given IV
75423777|NCT03233347|Drug|Doxorubicin|Given IV
75423778|NCT03233347|Other|Laboratory Biomarker Analysis|Correlative studies
75423779|NCT03233347|Biological|Nivolumab|Given IV
75423780|NCT03233347|Drug|Vinblastine|Given IV
75423781|NCT03192176|Drug|Fezolinetant|Oral Capsule
75423782|NCT03192176|Drug|Placebo|Oral Capsule
75876771|NCT03611036|Other|Endurance training|Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
75722955|NCT00977145|Biological|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|"Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.~Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions."
76046102|NCT05329779|Drug|placebo|The placebo is a 0.45% sodium chloride infusion.
75423783|NCT03151564|Diagnostic Test|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
75423784|NCT03151564|Diagnostic Test|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
75423785|NCT03151564|Diagnostic Test|Deep Learning Image Reconstruction (DLIR)|Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
75423786|NCT03114462|Radiation|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
75722956|NCT05226000|Drug|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
75423787|NCT03114462|Behavioral|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
75423788|NCT03076606|Diagnostic Test|ophthalmologist examination|ophthalmologist examination after geriatric consultation
75423789|NCT03061123|Other|Questionnaire|
75423790|NCT03048370|Procedure|Left body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
75423791|NCT03048370|Procedure|Right body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
75423792|NCT03048370|Procedure|Left warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
75722957|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
75722958|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
75569864|NCT00532688|Drug|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
75722959|NCT00803348|Drug|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
75423793|NCT03048370|Procedure|Right warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
75569865|NCT00534144|Drug|iron sucrose injection, USP|iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks
75722960|NCT00918047|Drug|SPN-804O|Open Label study
75722961|NCT00980733|Dietary Supplement|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
75722962|NCT00980733|Dietary Supplement|Yoghurt|Plain yoghurt same as in intervention group without fortification
75722963|NCT00877266|Procedure|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
75722964|NCT02553824|Drug|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
75722965|NCT02553824|Drug|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
75722966|NCT00980889|Device|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
75722967|NCT00980889|Device|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
75722968|NCT04039854|Drug|Isoflurane, Sevoflurane or Desflurane|"The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU."
75722969|NCT04039854|Drug|Propofol|Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
75876772|NCT03610958|Device|Epitomee Device|A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
75569866|NCT00534144|Drug|sodium ferric gluconate complex in sucrose injection|sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
75569867|NCT00534183|Drug|Olanzapine|Olanzapine in dose range of 10-20mg
75569868|NCT00534183|Drug|Risperidone|Risperidone 1-6mg
75569869|NCT00534183|Drug|Haloperidol|Haloperidol 10-20mg
75722970|NCT04045730|Drug|Gemcitabine|All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
75722971|NCT00977223|Drug|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
75423794|NCT03048370|Procedure|Left cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
75722972|NCT00803426|Procedure|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
75722973|NCT00977301|Drug|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
75722974|NCT00977301|Drug|olanzapine|15 mg olanzapine single dose
75722975|NCT00977301|Drug|olanzapine|10 mg olanzapine single dose
75722976|NCT00803504|Procedure|ocular blood flow measurement|
75722977|NCT00735371|Drug|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
75876773|NCT04603157|Behavioral|Hybrid Exercise Training|Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
76046103|NCT04419753|Behavioral|attention focus walking training|Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.
75423795|NCT03048370|Procedure|Right cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
75423796|NCT03024333|Other||Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
76046104|NCT04850937|Drug|Esketamine|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
75722978|NCT00735371|Drug|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
75722979|NCT00735371|Drug|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
75722980|NCT00735371|Drug|Placebo|Placebo will be identical to test product.
76046105|NCT04850937|Drug|normal saline|The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
76046106|NCT04851717|Drug|Remimazolam|Remimazolam for intravenous sedation
76046107|NCT04464057|Dietary Supplement|early oral feeding or early enteral nurtrion|The patients in the experimental group were fed orally within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
76046108|NCT01638819|Biological|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
76046109|NCT01638819|Biological|Placebo|Saline
75569870|NCT05303714|Combination Product|FOLFOX and PIPAC|"A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system."
75569871|NCT05298605|Behavioral|Faith in Action! Church-based Navigation Model|Cancer screening education and navigation by identified trained navigators in faith based settings + American Cancer Society Screening Guidelines pamphlet
75569872|NCT05298605|Other|Control|Presentation on healthy behaviors (physical activity, nutrition) + American Cancer Society Screening Guidelines pamphlet
75569873|NCT05296928|Procedure|laparoscopic incision|laparoscopic umbilical trocar entry pathways
76046110|NCT04849143|Other|Stingless bee honey ( Kelulut honey)|"The honey will be acquired from Brainey Sdn Bhd, a company that provides stingless bee honey certified with Good Manufacturing Practice (GMP), ISO 22000, and Halal.~As the honey used is not medical-grade honey, sterilization with 25kGy gamma-ray irradiation will be done for safety purposes to eradicate any potential life-threatening infection such as spores from Clostridium botulinum."
76046111|NCT04849143|Other|Gel dressing|Smith-Nephew's Intrasite gel
76046112|NCT01363713|Drug|DE-114 ophthalmic solution|
76046113|NCT04414917|Drug|Twin block|Dental local anesthetic administered to target the jaw 'closer' muscles, temporalis and masseter
75569874|NCT05223387|Device|Axiom TL REG|"Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
75722981|NCT00518206|Biological|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
75722982|NCT00518206|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
75569875|NCT05223387|Device|Axiom BL REG|"Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
75569876|NCT00532727|Drug|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
75722983|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 5 µg|0.5 mL, IM, 2 injections 21 days apart
75722984|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 10 µg|0.5 mL, IM, 2 injections 21 days apart
75722985|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 20 µg|0.5 mL, IM, two injections 21 days apart
75569877|NCT00532727|Drug|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
75569878|NCT04261218|Drug|tomivosertib|Tomivoserib is supplied as a 100 mg capsule, to be taken orally.
75569879|NCT04261218|Drug|paclitaxel|Taken weekly according to the current market label in combination with experimental tomivosertib.
75569880|NCT05274620|Behavioral|IntelliCare|A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
75722986|NCT00984945|Biological|Placebo|0.5 mL, IM, two injections 21 days apart
75722987|NCT00871650|Other|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
75722988|NCT00871650|Other|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
75722989|NCT00871650|Other|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
75423797|NCT03016013|Biological|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.Study investigator evaluate the patients of curative effect.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
75423798|NCT03016013|Biological|RC18 160 mg plus MTX|The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
75722990|NCT04046588|Diagnostic Test|Infrared thermography|A thermal imager (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) will be used to record thermal images. The temperature of corresponding sites on the Heart and Lung meridians will be analyzed.
75722991|NCT04046588|Procedure|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian, respectivey. During moxibustion, the temperature change of relevant sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~Intervention in the Heart meridian: moxibustion will be performed above the acupoint HT3 of the Heart meridian~Intervention in the Lung meridian: moxibustion will be performed above the acupoint LU5 of the Lung meridian."
75423799|NCT02990130|Other|Observational|
75423800|NCT02988297|Drug|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
75423801|NCT02988297|Drug|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
75423802|NCT02988271|Other|Interview|Participate in interview
75423803|NCT02988271|Procedure|Meditation Therapy|Complete meditation therapy
75423804|NCT02988271|Procedure|Quality-of-Life Assessment|Complete questionnaires
75423805|NCT02988271|Procedure|Supportive Care|Receive supportive care
75423806|NCT02940496|Drug|Elbasvir/Grazoprevir|Given PO
75423807|NCT02940496|Other|Laboratory Biomarker Analysis|Correlative studies
75423808|NCT02940496|Biological|Pembrolizumab|Given IV
75423809|NCT02940496|Drug|Ribavirin|Given PO
75423810|NCT02910492|Device|enLighten Laser|Dual-pulse duration laser for the treatment of skin rejuvenation
75423811|NCT02897908|Procedure|vibration controlled transient elastography (VCTE)|Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.
75423812|NCT02848885|Other|Active TDCS|Participants will receive active tDCS stimulation.
75722992|NCT04981431|Drug|Elinzanetant (BAY3427080)|Oral administration
75423813|NCT02848885|Other|Sham TDCS|Participants will receive sham tDCS stimulation
75423814|NCT02828761|Device|Coronary Calcium Scoring|Scan with 64-detector row or better CT scanners with quantification by the Agatston method.
75423815|NCT02828761|Procedure|Standard Care|Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
75423816|NCT02823171|Drug|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
75423817|NCT02823171|Drug|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
75423818|NCT02808455|Drug|(Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
75423819|NCT02808455|Drug|(Treatment B)|A single 80-mg oral solution dose of pacritinib
75423820|NCT02807207|Drug|A: pacritinib|Treatment A
75423821|NCT02807207|Other|B: Placebo|Treatment B
75423822|NCT02807207|Drug|C: moxifloxacin|Treatment C
75423823|NCT02807116|Drug|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
75423824|NCT02807116|Drug|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
75722993|NCT04981431|Drug|Placebo|Oral administration
75423825|NCT02807116|Drug|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
75423826|NCT02704377|Other|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
75423827|NCT02704377|Procedure|Dual X-ray Absorptiometry|Undergo iDXA
75423828|NCT02704377|Other|Laboratory Biomarker Analysis|Correlative studies
75423829|NCT02704377|Other|Quality-of-Life Assessment|Ancillary studies
75423830|NCT02704377|Other|Questionnaire Administration|Ancillary studies
75423831|NCT02680743|Other|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
75423832|NCT02677961|Other|Observation|
75423833|NCT02603835|Device|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
75423834|NCT02531594|Behavioral|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
75423835|NCT02531594|Behavioral|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
75423836|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
75569881|NCT05262998|Procedure|Plate fixation|"Procedure: plate fixation~Plate fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. A standard surgical protocol was used, the approach was moved inferiorly, the fracture was reduced, sometimes with osteosutur and fixed with an antero-superior anatomical plate. 3.5mm Locked and cortical screws were used on both sides of the fracture. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
75722994|NCT00879918|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
75722995|NCT00803582|Procedure|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
75722996|NCT00803582|Procedure|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
75722997|NCT01565590|Drug|Dexmedetomidine|0.2-1.5 mcg/kg/hr
75569882|NCT05262998|Procedure|Intramedullary Screw|"Procedure: Intramedullary screw fixation~Intramedullary screw fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. Intramedullary screw fixation was performed by using a 1.6 or 2.8 mm-diameter threaded guide pin and a 85-100 mm long, 4.5 or 6.5 mm-diameter cannulated screw tapped in along the guide pin. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin.~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
76046114|NCT04414917|Device|iPill dispenser|An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).
75423837|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
75569883|NCT04687410|Device|ProControl, MediGlobe|standard 22G FNA needle
76046115|NCT04411329|Drug|Bupivacaine|local anesthetics, steriod, alpha 2 blockers
75423838|NCT02495311|Procedure|myomectomy or adenomyomectomy|
75423839|NCT02465541|Procedure|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
76046116|NCT04411329|Drug|Dexamethasone|dexamethazone
76046117|NCT04411329|Drug|Dexmedetomidine|dexmedetomidine
76046118|NCT04411329|Drug|Hyalouridinase|hyalouridinase
75423840|NCT02465541|Other|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
75423841|NCT02465541|Other|educational intervention|Undergo enhanced usual care
75423842|NCT02465541|Other|quality-of-life assessment|Ancillary studies
75423843|NCT02465541|Other|questionnaire administration|Ancillary studies
75423844|NCT02456857|Biological|Bevacizumab|Given IV
75423845|NCT02456857|Drug|Everolimus|Given PO
75423846|NCT02456857|Other|Laboratory Biomarker Analysis|Correlative studies
75423847|NCT02456857|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75423848|NCT02370875|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
75569884|NCT04687410|Device|TopGain, Medi-Globe|novel 22G crown-cut FNB needle
75569885|NCT00532766|Drug|Jusline|
75569886|NCT04687449|Dietary Supplement|Curcumin therapy|Clear capsules (made of vegetable cellulose) with turmeric extract (500 mg, 95% curcuminoids), Bioperine (5 mg, improves absorption), and inactive ingredients (microcrystalline cellulose, vegetable magnesium stearate, silicon dioxide).
76046119|NCT05171673|Drug|Licart™ (diclofenac epolamine) topical system|The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
75423849|NCT02370875|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
75423850|NCT02365467|Device|Valiant Mona LSA Thoracic Stent Graft System|
75423851|NCT02350205|Biological|Self assembled skin substitute (SASS)|All patients in Phase B will receive Self assembled skin substitute (SASS)
75569887|NCT04687449|Other|Placebo|Clear capsules (made of vegetable cellulose) with inactive ingredients (lactose monohydrate and food color); the capsules will be matched in size and color of the content to the preparation used in the Curcumin capsule.
75569888|NCT04687449|Other|Standard care|The standard of care for COPD.
75569889|NCT05258786|Behavioral|Pre-labor ultrasound as a visual biofeedback device for maternal pushing education and pelvic floor training|"Ultrasound examination with the screen turned to the provider will assess the bladder movements at rest and during contraction of the pelvic floor and fetal head descent at rest and during pushing.~The provider will turn the screen to the patient and explain the anatomical landmarks: bladder, fetal head, birth canal direction.~A repeat of the first stage (1) with the screen turned to the patient: the biofeedback process. Bladder displacement will serve as a marker of pelvic floor contraction, and the delta in the progression angle will serve as a marker for effective pushing.~Finally, the provider will turn the screen again from the patient and repeat the first stage."
75569890|NCT04221009|Behavioral|MI and CBT 4-session manualized intervention|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
75423852|NCT02284074|Other|Nasal LPS spray|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
75423853|NCT02284074|Other|Experimental: Nasal LPS spray 1µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
75569891|NCT04203693|Drug|Tildrakizumab|The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
75569892|NCT04200924|Other|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
75722998|NCT01565590|Drug|propofol|5-80 mcg/kg/min
75423854|NCT02284074|Other|Experimental: Nasal LPS spray 10 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
75423855|NCT02284074|Other|Experimental: Nasal LPS spray 30 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
75423856|NCT02284074|Other|Experimental: Nasal LPS spray 100 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
75722999|NCT00877422|Dietary Supplement|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
75423857|NCT02265770|Drug|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
75423858|NCT02265770|Drug|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
75423859|NCT02265770|Drug|Chemotherapy + Valproate|"Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.~Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses."
75876774|NCT05453747|Other|Exercise|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
76046120|NCT04811937|Diagnostic Test|Computer-aided polypectomy decision support by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedbackwill be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp and the information to help the polypectomy.
75423860|NCT02265770|Radiation|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
75423861|NCT02265770|Drug|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
75569893|NCT04200924|Other|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
75723000|NCT00980967|Other|Study of predictive factors|Identification of predictive factors for lung chronic rejection outcome in lung transplant recipients
75723001|NCT04088201|Device|Glucose measurements|We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
75723002|NCT04007133|Other|Girerd test|This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
75723003|NCT00797186|Other|Intensive risk factor management|Aggressive medical and lifestyle therapy.
76046121|NCT05147415|Other|Placebo|Inactive comparator
76046122|NCT05147415|Drug|Tesomet|Fixed-dose combination
76046123|NCT04827069|Drug|Clifutinib Besylate|receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
75423862|NCT02265770|Drug|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
76046124|NCT04786743|Other|endoscopic intervention|performing endoscopy
76046125|NCT04390581|Device|Juvéderm® VOLIFT with Lidocaine|Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.
75423863|NCT02265770|Radiation|conformal radiotherapy +/- boost|"Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions"
75423864|NCT02140242|Drug|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5
75569894|NCT05230979|Other|Common bean baked snack|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
75569895|NCT05230979|Other|Cooked beans|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
75569896|NCT05230979|Other|White bread|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
75723004|NCT00586313|Device|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
76046126|NCT01637961|Drug|Alisertib|Given PO
76046127|NCT01637961|Other|Laboratory Biomarker Analysis|Correlative studies
76046128|NCT05114577|Behavioral|Recovery Sleepers program.|Attend two, 90-minute remote discussion groups (~10 other participants and 2 study team members) via Zoom. During these groups, participants will receive educational materials about how to improve sleep. They will also discuss sleep and sleep-related behaviors, including how active substance use and recovery may have changed sleep, with a small group of other participants.
76046129|NCT05114577|Behavioral|Email recommendations|Receive recommendations (via email) to help improve sleep
75423865|NCT02140242|Procedure|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
75423866|NCT02050906|Behavioral|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
75423867|NCT02050906|Behavioral|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
75423868|NCT02050906|Other|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
75423869|NCT02050906|Behavioral|telephone based counseling|Undergo behavioral activity and nutritional counseling
75423870|NCT02050906|Procedure|quality-of-life assessment|Ancillary studies
75423871|NCT02050906|Other|questionnaire administration|Ancillary studies
75423872|NCT02043158|Behavioral|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
76046130|NCT05114265|Drug|KUR-101|Single oral dose of KUR-101
76046131|NCT05114265|Drug|OxyNorm|Single oral dose of OxyNorm
75423873|NCT02043158|Behavioral|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
75723005|NCT00586313|Procedure|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
76046132|NCT05114265|Drug|Placebo|Single oral dose of placebo
76046133|NCT04419051|Other|Owlet Band|The Owlet Band is a wearable fabric band pregnancy tracker made up of small sensors that are able to detect natural low-level electrical signals normally produced by the mother's heart and baby's (fetal) heart.
76046134|NCT04277715|Behavioral|Parent training|Parents will learn evidence-based techniques for increasing support and decreasing accommodation of children's chronic symptoms.
75423874|NCT01990196|Drug|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
75423875|NCT01990196|Drug|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
75569897|NCT05230979|Other|Anhydrous glucose (first session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume a reference glucose solution containing 25 g of anhydrous glucose per 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to drink the reference glucose solution. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
75723006|NCT00871806|Drug|Commercial tablet with water|40 mg tablet, given once to each subject
75723007|NCT00871806|Drug|ODT #1 without water|40 mg tablet given once to each subject
75723008|NCT00871806|Drug|ODT #2 without water|40 mg tablet given once to each subject
76046135|NCT04183335|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
76046136|NCT04183335|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
76046137|NCT04183335|Drug|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
76046138|NCT04183335|Drug|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
76046139|NCT04183335|Drug|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
76046140|NCT04419363|Drug|Burosumab Injection|Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
75723009|NCT00871806|Drug|ODT #1 with water|40 mg tablet given once to each subject
75723010|NCT00871806|Drug|ODT #2 with water|40 mg tablet given once to each subject
75723011|NCT02553668|Drug|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
75723012|NCT02553668|Device|Facemask|
75723013|NCT00877578|Dietary Supplement|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
75723014|NCT00877578|Dietary Supplement|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
75723015|NCT03967145|Behavioral|Determining quality of life|Quality of Life
75723016|NCT04007913|Behavioral|teleCBIT|Eight sessions of individual behavior therapy
75723017|NCT04046432|Dietary Supplement|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)
75723018|NCT04046432|Dietary Supplement|Placebo|Maltodextrin was used as a placebo.
75723019|NCT02593799|Procedure|Endoscopy|Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
76046141|NCT04825431|Drug|TAS-205, [14C]TAS-205|single oral administration under fasted conditions on day 1
76046142|NCT04241679|Device|Auditory Nerve Test System|"The Auditory Nerve Test System provides an electrically-evoked signal from within the cochlea to facilitate intraoperative auditory nerve monitoring. The auditory nerve can be measured both at the root entry zone of the brainstem (eCNAP) and with scalp electrodes (eABR). Data on the health of the auditory nerve will be collected immediately prior to tumor dissection, during tumor dissection, and immediately after tumor dissection. The main purpose of this study is to determine feasibility of this novel intraoperative monitoring protocol.~Secondarily, if the auditory nerve is visually confirmed to be intact following tumor resection then the patients will receive a cochlear implant during the same surgery."
76046143|NCT04225767|Combination Product|Calcium electroporation|Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
75423876|NCT01990196|Drug|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
75423877|NCT01990196|Drug|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
75423878|NCT01968109|Biological|Relatlimab|
75423879|NCT01968109|Biological|Nivolumab|
75569898|NCT05230979|Other|Anhydrous glucose (second session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
75569899|NCT05230979|Other|Common bean baked snack (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
75423880|NCT01968109|Biological|BMS-986213|Relatlimab + Nivolumab
76046144|NCT04212273|Diagnostic Test|Diagnostic Sonazoid-CEUS and EOB-MRI|Undergo Sonazoid-CEUS and EOB-MRI
76046145|NCT04824183|Other|Music intervention|Three WhatsApp sessions will be delivered before the surgery. In the first session, participants will describe their experience with the diagnosis of breast cancer and acceptance. In the second session, participants will be educated on anxiety before their surgery, how anxiety is being managed in the hospital and self-care strategies for anxiety like MI, how to report preoperative anxiety. The third session will include postoperative pain education. The pain education will include information about the type of pain to expect after surgery, medications, pain reporting and MI for pain management. Telephone session; on the day of surgery and at 24 and 48 hours after surgery, a reminder will be sent to the participants by WhatsApp group chat. Face-to-face; MI delivery will involve the delivery of the MP3 to participants and monitoring of their use for 30 minutes both on the day of surgery and 24 and 48 hours after surgery.
76046146|NCT04199793|Device|Lavare On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
76046147|NCT04199793|Device|Lavare Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
76046148|NCT04823871|Procedure|Speiser-catheter for uterine and tubal lavage|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
75423881|NCT01780727|Procedure|EGHEM|Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
75423882|NCT01612351|Drug|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
75569900|NCT00532818|Drug|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
75569901|NCT00532818|Drug|Placebo|Cisplatin + Topotecan plus placebo
75569902|NCT04687397|Behavioral|Rehabilitation|Multidisciplinary rehabilitation
75723020|NCT04039698|Other|Telemedicine|Telemedicine monitoring and teleconsultation by video calls
75423883|NCT01612351|Drug|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
75876775|NCT05453747|Other|Exercise 2|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
76046149|NCT04820829|Other|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
75423884|NCT01612351|Drug|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
75423885|NCT01612351|Drug|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
75423886|NCT01612351|Drug|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
75569903|NCT05209035|Drug|Trazodone|Trazodone 50mg daily
75723021|NCT04039698|Drug|Velpatasvir/Sofosbuvir|Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
75723022|NCT04006821|Drug|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
75723023|NCT04006821|Drug|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
75423887|NCT01612351|Radiation|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
75723024|NCT00871884|Behavioral|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
75723025|NCT00871884|Behavioral|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
75723026|NCT00871884|Behavioral|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
75423888|NCT01612351|Radiation|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
75423889|NCT01612351|Procedure|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
75423890|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
75569904|NCT05209035|Other|Placebo|Starch 50mg
75569905|NCT04687202|Other|follow up and record|None additional intervention was applied to the subjects.
75569906|NCT00534261|Drug|Interferon beta-1a|IM injection
75569907|NCT04687319|Biological|bronchial mucus collection|mucus resulting from respiratory physiotherapy sessions for patients with cystic fibrosis or COPD, bronchial aspirations resulting from the bronchial fibroscopy programme
75569908|NCT04687280|Other|non interventional|non interventional, study on data
75569909|NCT04686708|Other|Emergency general surgical admissions|All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).
75876776|NCT05432687|Diagnostic Test|evaluation of deep abdominal wall before surgery|: cough test (L guillarme) + ulstrasonography of transversus abdominis
75876777|NCT03913481|Procedure|Acute normovolemic hemodilution|In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.
75876778|NCT03913481|Procedure|Standard care|Best available treatment without ANH
76046150|NCT04820829|Other|Moderate RM, Moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
76046151|NCT04820829|Other|Low RM, High NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
76046152|NCT04820673|Drug|Sarecycline|Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
76046153|NCT04114539|Drug|Ecopipam|Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
76046154|NCT05298579|Other|Yoga exercises|Yoga-based exercise training includes a warm-up and cool-down period for beginners
76046155|NCT03280719|Device|Prone Radiotherapy|Prone positioning for regional nodal irradiation using the crawl breast couch.
76046156|NCT03280719|Radiation|Acceleration|Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
76046157|NCT03280719|Device|Supine Radiotherapy|Supine positioning for regional nodal irradiation using breastboard.
75876779|NCT03661944|Diagnostic Test|functional performance test|Functional performance test is to test the ability of the athletes in functional movements
76046158|NCT03280719|Radiation|Hypofractionation|Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
76046159|NCT04699929|Drug|YH001|YH001 will be administered intravenously over 60minutes every three weeks (Q3W) for up to 1 years .
75423891|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
75423892|NCT01376505|Biological|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
76046160|NCT03256149|Drug|Dexamethasone|
76046161|NCT03256149|Drug|Placebo|Normal saline (IV placebo)
76046162|NCT04105257|Diagnostic Test|All patients|Comparison of the results of the CTP with MRI
75569910|NCT00534300|Drug|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
75876780|NCT02864498|Drug|DS107|
75876781|NCT02864498|Drug|Placebo|
75876782|NCT03238781|Drug|Placebo|Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
75876783|NCT03238781|Drug|AMG 301|AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.
76046163|NCT04097769|Drug|HX009|During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
75423893|NCT01376505|Biological|Extension HER-2 vaccine trial at OBD|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
76046164|NCT04089033|Procedure|Pneumatic Retinopexy|The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.
75876784|NCT02033408|Drug|AB (antibiotics)|"PO Vancomycin 250mgX4/d for 3 weeks~PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
76046165|NCT04089033|Procedure|Pars Plana Vitrectomy|For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
76046166|NCT04819893|Biological|Maternal blood sampling|5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
76046167|NCT04819893|Biological|Umbilical cord blood sampling|0.5mL sample from the umbilical cord after childbirth standard protocols
76046168|NCT04819893|Biological|Placenta sampling|Sampling of 3 cotyledons by cutting across the thickness of the placenta
75423894|NCT01336920|Drug|carfilzomib|Given IV
76046169|NCT04819893|Other|Data collection|Newborn, Maternal and Premature Retinopathy Screening Data Collection
76046170|NCT03253263|Drug|OHB-607|Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
76046171|NCT04797117|Diagnostic Test|blood sample|"The blood samples for the study for each patient will be collected in the form of additional tubes.~either 1 tube of blood of 4 ml and 2 tubes of blood of 10 ml once a day for 1 or 2 days maximum (or 48 ml maximum) during his hospitalization~either 2 tubes of 10 ml or 20 ml maximum once during his hospitalization."
75569911|NCT00534300|Drug|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
75569912|NCT05202405|Drug|AD-221|AD-221 Oral Tablet
75423895|NCT01256593|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
75423896|NCT01215201|Procedure|Scaling and Root Planing|Use periodontal hand instruments (curettes) to remove plaque, bacteria, and deposits on the root's surfaces.
75569913|NCT05202405|Drug|AD-221A and AD-221B|AD-221A Oral Tablet + AD-221B Oral Tablet
75569914|NCT00532857|Drug|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
75569915|NCT05200377|Diagnostic Test|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
75569916|NCT05190458|Other|High Velocity Nasal Insufflation|High velocity nasal insufflation (HVNI), a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than HFNC which uses large bore cannula, has the ability to accomplish complete purge of extra thoracic dead space at flow rates of 35 litres/min and may be able to provide ventilatory support in patients with respiratory failure in addition to oxygenation support in patients with overlap syndrome.
75569917|NCT05190458|Other|Non-invasive mechanical ventilation|Noninvasive ventilation (NIV) refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube).
75569918|NCT04169334|Behavioral|Prolonged planned program for the stay at the obstetric department|A five day planned and designed program delivered to the family while at the obstetric department.
75423897|NCT01215201|Procedure|Diode Laser + Scaling and Root Planing|First: Periodontal hand instruments (curettes) were used to remove plaque, bacteria, and deposits on the root's surfaces (within a periodontal pocket) Then: Biolase 940 nm Ezlase diode laser was used to sterilize a periodontal pocket. Power: 0.80 Watts Wavelength: 940 nm Energy level: 0.80 Joules/second Mode of beam delivery: continuous
75423898|NCT01179009|Drug|Ketamine|Controlled IV ketamine infusion (0.00225mg/kg-min. [18% (0.0125 mg/kg-min.).
75423899|NCT01179009|Drug|Clonidine|Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
75723027|NCT02554994|Other|Multifactorial intervention|"There are six components of intervention in this study.~For all participants:~Group exercise~Nutritional supplement(commercial liquid formula will be provided every day).~For selected participants:~Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
75723028|NCT02554994|Other|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
76046172|NCT03180411|Behavioral|Interview|"Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes."
76046173|NCT03180411|Behavioral|Questionnaire|Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
76046174|NCT03107247|Drug|Imaging Time|Participants will be asked to be imaged at an additional time point.
76046175|NCT05652777|Device|NeoSpot|Pregnant women will undergo screening of their vital signs using the NeoSpot device.
76046176|NCT05652621|Dietary Supplement|probiotics|Resistant dextrin (water-soluble dietary fiber), Lactobacillus reuteri PLBK1, Luo Lactobacillus delbrueckii, Lactobacillus griffii PLBK3, Lactobacillus acidophilus PLBK4, Bifidobacterium lactis PLBK5）
76046177|NCT01636947|Drug|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
76046178|NCT01636947|Drug|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
76046179|NCT01636947|Drug|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
76046180|NCT01636947|Drug|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
75423900|NCT01179009|Drug|placebo|IV saline (i.e. placebo ketamine)
75423901|NCT01000038|Other|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
76046181|NCT01636947|Drug|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
76046182|NCT01636947|Drug|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
75423902|NCT01000038|Other|Walking|Half hour daily, five days a week for 8 weeks
75423903|NCT00918775|Other|Follow-Up Care|Undergo follow-up
75423904|NCT00918775|Other|Laboratory Biomarker Analysis|Correlative studies
75423905|NCT00798551|Behavioral|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
75423906|NCT00716066|Biological|Anti-Thymocyte Globulin|Given IV
75423907|NCT00716066|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
76046183|NCT05652387|Behavioral|Father Inclusive Prenatal Care|Pregnant and parenting couples participate in co-parenting and parenting education, and job skills and education readiness
76046184|NCT05214027|Other|Treadmill-Based Exercise (60% VO2 Max for 60 minutes)|"Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max."
76046185|NCT05214027|Other|Rest (60 minutes)|Each participant will undergo a 60-minute rest period in a randomised order.
76046186|NCT01635933|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
76046187|NCT01635933|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
76046188|NCT01635855|Device|Belotero®|Hyaluronic acid dermal filler
75423908|NCT00716066|Drug|Carmustine|Given IV
75723029|NCT04007679|Other|Pain neuroscience education|Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
75723030|NCT02592785|Drug|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
75723031|NCT00871962|Other|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
76046189|NCT04808115|Drug|KDS-1001|"Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle"
76046190|NCT05652309|Procedure|spinal block and obturator nerve block|spinal block and obturator nerve block
76046191|NCT03052725|Drug|reslizumab|Reslizumab was provided in a pre-filled syringe.
76046192|NCT04818801|Biological|Recombinant two-component COVID-19 vaccine (CHO cell)|The spike (S) protein is the main surface antigen of SARS-CoV-2, mediates entry of SARS CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The RBD interacts with ACE2 and can generate potent neutralizing anti-RBD antibodies.
76046193|NCT04818801|Other|Placebo|Normal saline (0.9% sodium chloride solution),
76046194|NCT04793919|Drug|Mylotarg|See the protocol
76046195|NCT04793919|Drug|Arsenic Trioxide|See the protocol
75723032|NCT00803816|Drug|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
76046196|NCT04793919|Drug|All-trans retinoic acid|See the protocol
75423909|NCT00716066|Drug|Cytarabine|Given IV
75423910|NCT00716066|Drug|Etoposide|Given IV
76046197|NCT05356767|Procedure|Pharmacomechanical thrombolysis|Pharmacomechanical thrombolysis
76046198|NCT05651763|Other|Stimulation and exercise group|Exercise protocol + application of active direct current stimulation for 30 minutes.
76046199|NCT05651763|Other|Exercise and sham stimulation group|Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
76046200|NCT02837445|Device|PHC ON|Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
76046201|NCT02837445|Device|PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
76046202|NCT02817633|Drug|TSR-022|TSR-022 will be administered.
76046203|NCT02817633|Drug|Nivolumab|Nivolumab will be administered.
76046204|NCT02817633|Drug|TSR-042|TSR-042 will be administered.
76046205|NCT02817633|Drug|TSR-033|TSR-033 will be administered.
75423911|NCT00716066|Other|Laboratory Biomarker Analysis|Correlative studies
75423912|NCT00716066|Drug|Melphalan|Given IV
75423913|NCT00716066|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
75423914|NCT00716066|Drug|Prednisone|Given PO
75423915|NCT00716066|Procedure|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
76046206|NCT02817633|Drug|Docetaxel|Docetaxel will be administered.
76046207|NCT02817633|Drug|Pemetrexed|Pemetrexed will be administered.
75569919|NCT05180903|Other|X-tra base & GrandioSO reinforced by Ribbond|The missing peripheral tooth structure will be built up via 2-mm wedge-shaped a universal hybrid resin composite, GrandioSO . Then the polyethylene fibers will be wetted with an unfilled resin first . After removing the excess resin, fibers will be covered with a very thin layer of flowable composite X-tra base . After that, fibers will be bonded immediately against the peripheral missing walls and cured for 20 seconds. Then a bulk-fill flowable resin composite lining X-tra base will be applied in approximately 4 mm thick in bulk increments as needed to fill the cavity 2 mm short of the occlusal cavosurface and each increment will be light cured for 20 s. The remaining occlusal part of the cavity will be restored with a universal hybrid resin composite, GrandioSO . The shade of the composite will be selected according to the teeth to be restored. All cavities will be restored with open-sandwich technique (Deliperi, et al. 2017).
75423916|NCT00562640|Biological|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
75423917|NCT00562640|Biological|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
75423918|NCT00562640|Drug|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
75423919|NCT00562640|Other|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
75723033|NCT00872040|Other|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
75423920|NCT04791917|Behavioral|Eccentric Biceps Flexion|Muscle lengthening biceps exercise
75423921|NCT04791917|Behavioral|Concentric Biceps Flexion|Muscle shortening biceps exercise
75423922|NCT04791384|Drug|Abemaciclib|taken orally
75423923|NCT04791384|Drug|Elacestrant|taken orally
75423924|NCT04787302|Drug|CVL-231|Cohort 1: 30mg dose of CVL-231
75723034|NCT04087499|Device|Acupuncture|acupuncture treatment on selected acupoint
75723035|NCT00797264|Drug|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
75723036|NCT00797264|Drug|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
75876785|NCT02033408|Drug|CS (corticosteroids) Only|"methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
76046208|NCT02817633|Drug|Cisplatin|Cisplatin will be administered.
75423925|NCT04787302|Drug|CVL-231|Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded
76046209|NCT02817633|Drug|Carboplatin|Carboplatin will be administered.
76046210|NCT02817399|Device|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
76046211|NCT02817399|Device|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
75423926|NCT04787302|Drug|CVL-231|Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2
75423927|NCT04787289|Drug|Bevacizumab|Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
75423928|NCT04785417|Other|touch screen tablet|traditional occupational therapy in addition to games on tablet
75423929|NCT04784221|Radiation|Radiation by protontherapy associated to nanoparticles injection|"Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles.~Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26.~The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy"
75423930|NCT04781361|Drug|Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose|Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
75569920|NCT05191251|Diagnostic Test|HEMSTOP questionnaire|A HEMSTOP questionnaire is obtained during the anesthesia consultation.
76046212|NCT02817399|Procedure|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
76046213|NCT05651529|Dietary Supplement|exogenous ketone salt supplement|Dietary Supplement: Fasting water and with exogenous ketone salt supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
76046214|NCT05651529|Dietary Supplement|exogenous carbohydrate supplement|Dietary Supplement: Fasting water and with exogenous carbohydrate supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
76046215|NCT05651451|Device|Laser acupuncture|24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point
76046216|NCT05651451|Dietary Supplement|energy-restricted diet|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
75423931|NCT04781361|Drug|Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L|"Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride < 130 mmol/L"
75423932|NCT04773587|Drug|ARQ-151 Active|ARQ-151 Cream 0.15% - Active
75423933|NCT04773587|Drug|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
75423934|NCT04767555|Procedure|ILM (inner limiting membrane) peeling|The standard technique for the removal of the inner limiting membrane is a dye-assisted ILM peeling established since 20 years as the standard of care to treat vision loss due to epiretinal membranes or macular holes in eyes with an otherwise stable retina, but not during retinal detachment surgery. Other dyes may show a stronger staining effect but since there is evidence of a potential toxicity of ICG the investigators use the well-tolerated and for this purpose approved trypan blue dye Membrane Blue ® (Dorc). This intervention will be performed in addition to standard vitreoretinal re-attachment surgery.
75876786|NCT02033252|Device|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
75423935|NCT04751760|Biological|collection of blood and urine|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
75569921|NCT04686513|Other|Observation|observational study
75569922|NCT05152004|Drug|Pariet|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
75876787|NCT03610880|Drug|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
75876788|NCT03610880|Drug|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
76046217|NCT04791969|Drug|Naltrexone Hydrochloride|Intermittent Oral Naltrexone, 50 mg
75569923|NCT05152004|Drug|Amolin|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
75569924|NCT05152004|Drug|Klaricid|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
75569925|NCT05152004|Drug|Flagyl|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
75569926|NCT00534339|Device|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
75569927|NCT05132153|Drug|Milrinone|will be given by nebulization
75569928|NCT05132153|Drug|Normal saline|will be given by nebuliztion
75569929|NCT00534378|Drug|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
75569930|NCT05131997|Drug|AD-221|PO, Once daily(QD), 8 weeks
75569931|NCT05131997|Drug|AD-221A|PO, Once daily(QD), 8 weeks
76046218|NCT04791969|Drug|Placebo|Intermittent Oral Placebo
76046219|NCT04791969|Behavioral|Ecological Momentary Intervention|"Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use."
76046220|NCT05651373|Drug|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
76046221|NCT05651373|Drug|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
75569932|NCT05131997|Drug|AD-221B|PO, Once daily(QD), 8 weeks
75423936|NCT04749641|Biological|Histone H3.3-K27M Neoantigen Vaccine Therapy|"The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC."
75423937|NCT04745299|Biological|Lenzumestrocel|Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months
75423938|NCT04745299|Drug|Riluzole|concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts
75423939|NCT04745299|Drug|Placebo Comparator|"Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months"
75569933|NCT05131997|Drug|AD-221C|PO, Once daily(QD), 8 weeks
76046222|NCT05651373|Drug|CertolizumabPegol injection|200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
75569934|NCT00534456|Drug|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
75569935|NCT00534456|Drug|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
75569936|NCT05167773|Device|tonometer|A subject undergoes intraocular pressure measurement with tonometer
75569937|NCT05163990|Other|transcutaneous acupoint electrical stimulation|The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
75569938|NCT05077631|Drug|ACD856|Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
75569939|NCT05077631|Drug|Placebo|Placebo oral solution
76046223|NCT05198583|Other|E-Fit|The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
76046224|NCT05605119|Drug|AUR105|Once daily
76046225|NCT02607033|Other|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
75723037|NCT00797264|Drug|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
76046226|NCT02607033|Other|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
75423940|NCT04742777|Drug|rapamycin|Taken orally 1mg daily for 8 weeks
76046227|NCT03905889|Drug|Abemaciclib|Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
76046228|NCT03905889|Drug|Sunitinib|Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
75423941|NCT04741750|Other|Simplified HCV care within a mobile medical unit|Delivers guideline-based care for HCV in a stream-lined manner on a mobile medical unit
75423942|NCT04737616|Device|CO2 laser|Fractional CO2 vaginal laser for genitourinary syndrome of menopause
75423943|NCT04737616|Device|OCT|Optical coherence tomography endoscope
75569940|NCT05077631|Drug|ACD856 (fed cohort)|Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
76046229|NCT05582187|Drug|Fosmanogepix|a single dose of fosmanogepix administered by mouth under fasted conditions
76046230|NCT04804059|Drug|[14C]-APX001 Oral Solution|Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
76046231|NCT04804059|Drug|[14C]-APX001 Solution for Infusion|Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
76046232|NCT03846765|Drug|Phenylephrine|"Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period."
76046233|NCT03846765|Drug|Dobutamine|"Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period."
76046234|NCT05163405|Drug|Bortezomib|Self-administration of subcutaneously Velcade.
76046235|NCT05474469|Other|Diaphragmatic breathing exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
76046236|NCT05474469|Other|Abdominal muscle strengthening exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
76046237|NCT02426307|Procedure|TAVR|TAVR: Transcatheter Aortic Valve Replacement
75723038|NCT00981201|Drug|Celecoxib|"Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
76046238|NCT02426307|Procedure|SAVR|SAVR: surgical Aortic Valve Replacement
76046239|NCT02325531|Other|Low support|"EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and~BASIC WEBINAR, Annual, 1-hour, topics such as:~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows"
75423944|NCT04725201|Drug|Intravenous unfractionated heparin|See experimental arm description for intervention description.
75423945|NCT04725201|Drug|Sham|See sham comparator arm description for intervention description.
75423946|NCT04724239|Drug|Sintilimab|200mg IV on Day 1 Q3W
75723039|NCT00981201|Drug|Celecoxib|"Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
75723040|NCT00981201|Drug|Placebo|"Months 1-3:~By mouth twice daily."
75723041|NCT00981201|Drug|Placebo|"Months 4-6:~By mouth twice daily."
75876789|NCT02097121|Biological|BOTOX®|Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.
75423947|NCT04724239|Drug|Chidamide|30mg PO BIW each 3-week cycle
75423948|NCT04724239|Drug|IBI305|7.5mg/kg IV on Day 1 Q3W
75423949|NCT04715750|Drug|[18F]-PI2620|[18F]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of [18F]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
75876790|NCT02033486|Device|TOBI + DBT|
75876791|NCT05298215|Biological|UB-221|UB-221 is a recombinant humanized IgG1 monoclonal antibody with neutralizing capability against soluble human IgE and CD23-bound IgE for the treatment of allergic diseases. The activity of UB-221 is directly through the high-affinity binding with soluble and membrane bound IgE. The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking and down-regulation of FcεRI (high affinity IgE receptor) expression on those cells. The binding to CD23-bound IgE may inhibit IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes.
75876792|NCT05298215|Other|sterile saline solution|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
75876793|NCT02747420|Device|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
76046240|NCT02325531|Other|Medium support|"Same as provided to the low support arm, PLUS~STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group~ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 & 3."
76046241|NCT02325531|Other|High support|"Same as provided to the low and medium support arms, PLUS~- PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion."
76046242|NCT02325531|Other|Comparison|No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR.
76046243|NCT05366985|Procedure|Socket shield technique with computer guided sectioning of the root|"A computer guide was used to section the root, leaving the coronal 2/3 of its labial part attached to the socket. An implant was then placed.~Preoperative and Postoperative (5 months later) intraoral scans were superimposed with a digital software to assess the dimensional changes of the labial alveolar ridge. Linear changes at 1,3 and 5 mm from the gingival margin and mean linear changes in a specified Area Of Interest (AOI) were measured"
75423950|NCT04705870|Device|cerebral MRI|"MRI of routine care in the context of MS includes at least the following sequences:~3D T1 TFE (2 minutes)~T2 TSE (2 minutes)~3D FLAIR (3 minutes)~SWI EPI 0.6 iso (7 minutes)~The sequences added by the search are:~SWI non EPI QSM 6 echo (10 minutes)~SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)~SWI EPI to TR equivalent to SWI non EPI (6 minutes)"
75423951|NCT04705727|Drug|Budesonide Formoterol Drug Combination|This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).
75423952|NCT04705727|Drug|nebulisation of terbutaline|Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
75423953|NCT04677777|Biological|PP-007|PP-007 is pegylated carboxyhemoglobin
75423954|NCT04677777|Other|Standard of care|Patients randomized to this treatment will not receive the experimental treatment, but will receive the standard of care at the institution.
75569941|NCT00532961|Drug|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
75723042|NCT04842708|Diagnostic Test|vaccination against COVID19|subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.
75723043|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
75723044|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
75723045|NCT00797342|Drug|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
75723046|NCT00872118|Behavioral|Brief Intervention for Socially Anxious Drinkers (BISAD)|integrated alcohol and social anxiety individual intervention
75723047|NCT00872118|Behavioral|Enhanced Alcohol Skills Building and Education Program|alcohol-focused group intervention
76046244|NCT02204787|Device|transcranial direct current stimulation|
75423955|NCT04674683|Drug|HBI-8000 in combination with nivolumab|Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight < 40 kg, nivolumab will be dosed at specific doses on specific days.
75423956|NCT04674683|Drug|Placebo in combination with nivolumab|Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
75423957|NCT04672161|Other|Vaccine Education|A baseline educational intervention on vaccination and its role in the health maintenance of patients with IBD will be provided to all participants. Those on immunosuppressive therapies and/or those age 65 or older will also be offered the pneumonia vaccine educational intervention. Finally, patients aged 18-26 and those 27-45 who have never been vaccinated for HPV or those with high risk for HPV will additionally receive the HPV educational intervention.
75423958|NCT04666740|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.
75423959|NCT04666740|Drug|Olaparib|Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
75423960|NCT04662944|Drug|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
75423961|NCT04662944|Drug|ranibizumab|There is no treatment allocation. Patients administered Ranibizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
75423962|NCT04662944|Drug|aflibercept|There is no treatment allocation. Patients administered Aflibercept by prescription that have started before inclusion of the patient into the study will be enrolled.
75423963|NCT04657822|Drug|Crizanlizumab|Concentrate for solution for infusion for Intravenous use
75423964|NCT04648410|Other|questionnaire|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
75723048|NCT05279391|Drug|Dexamethasone|Dexamethasone 6-8 mg once daily
75723049|NCT05279391|Drug|Low molecular weight heparin|Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
75723050|NCT05279391|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
75723051|NCT05279391|Drug|Tocilizumab|IV administration of Tocilizumab as a single dose of 8mg/kg
76046245|NCT05393895|Drug|CSF-1|One drop bilaterally twice daily for approximately 6 weeks
76046246|NCT05393895|Drug|Vehicle|One drop bilaterally twice daily for approximately 6 weeks
75423965|NCT04646499|Device|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.
75723052|NCT05279391|Drug|Baricitinib|4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to <60 ml/min/1.73 m2)
75723053|NCT05279391|Drug|Dornase Alfa Inhalant Product|Inh. 2,500 U/twice daily, for up to 14 days.
76046247|NCT05365737|Other|Oral rinse|Participants use mouthwasher for a given time.
76046248|NCT05365737|Other|Saliva harvest|Non-stimulated saliva harvesting
76046249|NCT05355831|Device|Active Transcranial Direct Current Stimulation|See arm/group description
76046250|NCT05355831|Device|Sham stimulation|See arm/group description
76046251|NCT04787367|Procedure|TAP block|"An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine."
75723054|NCT00789542|Device|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
75723055|NCT00789542|Other|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
75876794|NCT02747420|Device|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
75876795|NCT03238001|Device|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
75876796|NCT02747108|Behavioral|Blood Test Group Intervention|Patients randomly assigned to the Blood Test Group will complete an HbA1c blood test around the time of their next primary care appointment. Following the HbA1c test, their VA primary care provider will be notified of the test result and will be provided with a detailed interpretation of the result. Trained study staff will then provide brief counseling by phone and written information by mail about their test result. The brief counseling and written information will be based on the American Diabetes Association and National Diabetes Prevention Program guidelines and will emphasize the risk of progression to type 2 diabetes mellitus and the rationale for preventive strategies, encourage aerobic exercise and a calorie-restricted diet to promote and maintain weight loss, and set a goal of achieving and sustaining a weight loss of at least 5% of body weight.
75876797|NCT02747108|Behavioral|Brochure Group Intervention|Participants will be asked to review a handout from the National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations on or around the same date as their next primary care appointment.
75876798|NCT05256095|Behavioral|Thinking in Speech|Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.
75876799|NCT02075671|Drug|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
75423967|NCT04635826|Drug|Adderall 10Mg Tablet|Participants will be administered Adderall
75876800|NCT02075671|Device|Blu-U Light Therapy|Intervention used in experimental and sham arms
75876801|NCT02075671|Other|Placebo vehicle only|Intervention only includes the placebo vehicle solution
75423968|NCT04635826|Drug|Placebo|Participants will be administered placebo
75423969|NCT04629781|Drug|Docetaxel micellar|There will be three dose levels, 1-3, with each level consisting initially of a cohort containing 3 patients. One additional dose level, dose level -1, shall be allowed in the event that dose level 1 is considered too toxic
75569942|NCT00532961|Drug|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
75876802|NCT02560298|Drug|Capecitabine|
75876803|NCT02560298|Drug|Carboplatin|Given IV
75876804|NCT02560298|Drug|Cisplatin|Given IV
75876805|NCT02560298|Drug|Fluorouracil|Given IV
75569943|NCT04138524|Other|SAFIR©|Early Supportive intervention for families of patients with acquired brain injuries.
75569944|NCT05121792|Behavioral|Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy|The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.
75569945|NCT00534534|Behavioral|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
75423970|NCT04624945|Diagnostic Test|APTT CWA (Activated partial thromboplastin time clot waveform analysis), Procalcitonin and Serological/Inflammatory markers (KL-6, SPA, MIG, Presepsin)|"Primary Aim: To validate the use of APTT CWA (Activated partial thromboplastin time clot waveform analysis) and ICIS (Intensive Care Infection Score), as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.~Secondary Aim: To examine the evolution of CWA, immuno-parameters (KL-6, SP-A, MIG, presepsin) and various WBC (white blood cell count) activation markers over the time in relation to diagnosis of sepsis, development of positive blood cultures and mortality or recovery. Blood parameter measurements using a 3-part and 5-part differential analyser will be performed. KL-6, SP-A, MIG, presepsin are serum biomarkers - MIG (Monokine induced by gamma interferon), SP-A (Surfactant protein A), KL-6 (Krebs von den Lungen 6)."
75423971|NCT04614922|Behavioral|Acceptance and Commitment Therapy|ACT-based rehabilitation is an interdisciplinary group rehabilitation which includes 7 sessions of group-based ACT therapy. Each session lasts 2½ hours and is offered twice a week. The ACT sessions will be based on a detailed intervention manual, developed specifically for group treatment. Each group will include a maximum of eight patients. The patients are asked to do homework between each ACT-group session.
75423972|NCT04613349|Other|MRI|"All patients included will benefit from the two methods of evaluating the anatomical relationships between the facial nerve and the parotid tumor:~New medical imaging technique evaluated: high-resolution 3 Tesla parotid MRI with specific sequences and gadolinium injection;~Gold standard: Intraoperative examination."
75569946|NCT05062070|Drug|TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
75423973|NCT04608474|Drug|Evolocumab|Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.
75423974|NCT04608474|Drug|Statins (Cardiovascular Agents)|Previously prescribed statin therapy.
75569947|NCT05062070|Drug|Vehicle Topical Gel|TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
75569948|NCT00534573|Drug|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
75569949|NCT04686890|Procedure|erector spinea plane block administered preoperative open nephrectomy|erector spinae plane block applied in this group before open nephrectomy
75569950|NCT04686890|Procedure|intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg|intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
75723056|NCT04087733|Drug|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
75723057|NCT00880152|Behavioral|Mindfulness-based stress reduction|An 8-week course in mindfulness training
75723058|NCT00922220|Other|stationary bike|Participants rode a stationary bike for five minutes
76046252|NCT02061891|Procedure|Invasive coronary evaluation (Deferred)|Invasive coronary angiography and revascularization (PCI/CABG)
75876806|NCT02560298|Other|Laboratory Biomarker Analysis|Correlative studies
75569951|NCT00533000|Procedure|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
75569952|NCT00534612|Procedure|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
75876807|NCT02560298|Drug|Paclitaxel|Given IV
76046253|NCT02061891|Procedure|Invasive coronary evaluation (Acute)|Invasive coronary angiography and revascularization (PCI/CABG)
76046254|NCT03797157|Dietary Supplement|H2MF|H2MF is a human milk-based breastmilk fortifier for preterm infants
76046255|NCT03797157|Dietary Supplement|Bovine milk-based fortifier|Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
76046256|NCT02039739|Device|Orsiro™ Drug Eluting Stent group|
75876808|NCT02560298|Other|Quality-of-Life Assessment|Ancillary studies
76046257|NCT05210049|Diagnostic Test|Esocheck/Esoguard|All enrolled patients will complete the Esocheck screening test. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus. The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM. These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men. Diagnostic yield of this test among Veterans is unknown.
75569953|NCT00533039|Drug|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
75569954|NCT00533039|Drug|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
75569955|NCT05103306|Drug|Empagliflozin 25 MG|Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor
75569956|NCT05103306|Drug|INS|Basal insulin add on the background OADs
75723059|NCT00922220|Other|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
75723060|NCT00922220|Other|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
75723061|NCT00977847|Other|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
75723062|NCT02595203|Drug|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
75723063|NCT02595203|Drug|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
75723064|NCT04828746|Procedure|Ultrasound Guided Skin Marking|Using ultrasound for skin marking pre-procedure
75876809|NCT02033642|Behavioral|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
75876810|NCT02033642|Behavioral|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
76046258|NCT03766113|Other|Neurofeedback coupling electroencephalogram and functional MRI in time actual|One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
75569957|NCT05042999|Device|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments. Non pharmacological technique to reduce pain and anxiety during a procedure.
75569958|NCT05102097|Behavioral|Warm-up|Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
75569959|NCT05102097|Behavioral|Main exercise|Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
75569960|NCT05102097|Behavioral|Cool down|Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
75569961|NCT05102097|Behavioral|Standard of care|Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
75569962|NCT05007002|Device|Robot-based therapy|Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
75569963|NCT04106037|Other|Data extraction from medical files|Data extraction from medical files
75723065|NCT00789620|Drug|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
75723066|NCT00789620|Drug|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
75423975|NCT04600414|Other|Collaborative Care for Mental Health Disorders|CoCM is based on six key principles: 1) evidence-based, 2) measurement-based, 3) team-based, 4) population-based, 5) patient-centered, and 6) accountable. CoCM supports the delivery of evidence-based pharmacological and psychosocial treatments. CoCM is measurement-based with screening and monitoring of patient-reported outcomes over time to assess treatment response and facilitate treatment adjustments. CoCM is team-based led by a primary care provider with support from a care manager in consultation with a psychiatrist who provides treatment recommendations for patients who are not responding. CoCM is population-based whereby a registry is used to monitor treatment engagement and facilitate the identification of patients falling through the cracks. CoCM is patient-centered with proactive outreach to engage and activate patients. Collaborative care is accountable with continuous quality improvement to meet clinic performance benchmarks.
75423976|NCT04600414|Other|Collaborative Care for Opioid Use Disorder|"Pharmacologic treatment of OUD will rely mainly on transmucosal buprenorphine/naloxone prescribed by primary care providers with DATA 2000 waivers. Measurement-based care and treat to target are fundamental principles of CoCM and will be incorporated into the intervention. Care managers will ask four yes/no questions about: 1) opioid withdrawal symptoms, 2) illicit opioid craving, 3) illicit opioid use, 4) medication side effects. If necessary, consulting psychiatrists will then recommend a change to the treatment plan to the primary care provider. In the case of buprenorphine/naloxone, options for changing the treatment plan include: 1) increasing the dosage (max dose 32mg), 2) augmenting with clonidine, 3) switching to injectable buprenorphine, and/or 4) intensifying psychosocial interventions. If the patient is experiencing medication side effects, but not opioid withdrawal symptoms or illicit opioid craving, consideration will be given to lowering the medication dosage."
75423977|NCT04593043|Drug|Warfarin|Warfarin dispensing claim is used as the reference
75423978|NCT04593043|Drug|Dabigatran|Dabigatran dispensing claim is used as the exposure
75569964|NCT04980443|Diagnostic Test|CELTiC test|The CELTiC test is a blood-based test consisting of four mRNA markers and the risk factor age.
75723067|NCT03970265|Diagnostic Test|extraction of ELF and ILF from explanted lung tissue; meropenem concentration in ELF and ILF; ELF on postoperative day 1-5 when bronchoscopy is performed within clinical routine.|Interventions will only be performed on explanted lung tissue ex vivo and on supernatant of bronchoscopy and are therefore non-invasive
75723068|NCT00803894|Drug|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
75723069|NCT00803894|Drug|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
75723070|NCT00803894|Drug|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
75569965|NCT00534651|Drug|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
75723071|NCT05371925|Drug|Sulodexide|one 250LRU sulodexide capsule twice a day for 8 weeks
75569966|NCT04971980|Drug|hUC-MSC infusion (BC-U001)|The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10^6 cells/kg body weight, 1.0x10^6 cells/kg body weight, 1.5x10^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
75569967|NCT04965779|Device|Abdominal Binder|Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
75723072|NCT00985023|Procedure|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
75723073|NCT00985023|Procedure|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
75723074|NCT00797420|Drug|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
75723075|NCT00797420|Drug|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
75723076|NCT00981513|Biological|Trivalent live attenuated seasonal influenza vaccine|One dose
75723077|NCT00981513|Biological|Monovalent live attenuated pandemic influenza vaccine|One dose
75723078|NCT00981513|Biological|Saline|One dose
75723079|NCT00872274|Drug|sumatriptan 100mg|
75723080|NCT00734747|Device|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
75723081|NCT00805688|Behavioral|Questionnaires|Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)
75423979|NCT04593030|Drug|Warfarin|Warfarin dispensing claim is used as the reference
75423980|NCT04593030|Drug|Apixaban|Apixaban dispensing claim is used as the exposure
75569968|NCT04965779|Other|Postpartum nursing care|Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
75423981|NCT04566302|Device|SECM Skin Imaging|Consented Participants will be asked to allow their forearm to be imaged by the dermatoscope on the same skin/lesions as a control comparison. We will be trying to image pigmented skin/lesions present on the forearm. This will be followed by imaging using the SECM Skin imaging device
75423982|NCT04565509|Behavioral|General Communication Message|A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.
75423983|NCT04565509|Behavioral|Focused/Targeted Message|A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.
75423984|NCT04565509|Behavioral|Best Message Alone|The best message will be either the general or focused/targeted message described above.
75569969|NCT04960241|Procedure|Homebased telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
75723082|NCT00805688|Procedure|Blood Draws|Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.
75423985|NCT04565509|Behavioral|Best Message + Augmented Message or Implementation Strategy|The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
75569970|NCT04960241|Procedure|Homebased rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
75569971|NCT04960241|Procedure|No physical rehabilitation|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
75569972|NCT05080959|Drug|CPL-01|Subjects will receive a single dose
75569973|NCT05080959|Drug|Naropin 150 MG Per 20 ML Injection|Subjects will receive a single dose
75723083|NCT00805688|Device|Pedometer|Worn daily to measure physical activity.
75423986|NCT04563741|Behavioral|MOVE!+UP|behavioral weight management intervention developed for Veterans with PTSD
75423987|NCT04563741|Behavioral|MOVE!|standard VA weight management intervention
75723084|NCT00880308|Drug|LDE225|
75723085|NCT00797498|Other|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
75723086|NCT04006899|Device|Bioelectrical Impedance Monitor|Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
75723087|NCT02595047|Procedure|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
75723088|NCT00872352|Procedure|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
75723089|NCT00985179|Behavioral|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
75723090|NCT00872586|Drug|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
75423988|NCT04556240|Device|VitalConnect Platform|The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological and irregular heart rhythm data in home and healthcare settings. This includes heart rate, electrocardiogram (ECG), heart rate variability (R-R interval), breathing rate, arrhythmia detection, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data is transmitted wirelessly to a central location where it is stored for analysis. The VitalConnect Platform can be configured by authorized persons to notify healthcare professionals when physiological data falls outside selected parameters
75423989|NCT04554394|Device|CellFX Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
75423990|NCT04536870|Diagnostic Test|Echocardiography|Ultrasound of heart
75423991|NCT04536870|Diagnostic Test|ECG screening|Single lead ECG screening twice daily for two weeks
75423992|NCT04536870|Diagnostic Test|ECG Screening|12-lead ECG screening
75423993|NCT04535128|Other|No intervention|No intervention
75423994|NCT04532229|Drug|Nimotuzumab+CRT(concurrent IMRT and TMZ)|"Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.~Other Names: h-R3~Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.~Other Names: TMZ"
75423995|NCT04519879|Other|Clinical Observation|Undergo clinical observation
75423996|NCT04519879|Other|Patient Observation|Undergo active surveillance
75423997|NCT04519879|Other|Questionnaire Administration|Ancillary studies
75569974|NCT05080959|Drug|Placebo|Subjects will receive a single dose
75876811|NCT03226769|Device|TrueTear™|Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.
75876812|NCT03226769|Device|Thermalon Dry Eye Compress|Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.
75569975|NCT00533078|Dietary Supplement|omegaven|Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
75423998|NCT04519879|Drug|White Button Mushroom Extract|Given PO
75423999|NCT04519177|Behavioral|Sleep Health Education Program (SHEP)|Sleep Health Education Program (SHEP) including screening for common sleep disorders
75424000|NCT04518410|Biological|bamlanivimab 7000mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
75424001|NCT04518410|Biological|BRII-196+BRII-198|1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
75424002|NCT04518410|Biological|AZD7442 (IV)|300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
75569976|NCT05064267|Diagnostic Test|phlebotomy|phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.
75569977|NCT04942730|Drug|Fludarabine|30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT
75424003|NCT04518410|Biological|AZD7442 (IM)|Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
75876813|NCT01330615|Drug|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
75424004|NCT04518410|Drug|SNG001|1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
75424005|NCT04518410|Drug|Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
75424006|NCT04518410|Biological|BMS-986414 + BMS-986413|Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
75569978|NCT04942730|Drug|Bendamustine Hydrochloride|130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT
75569979|NCT04942730|Drug|Busulfan|1 mg/kg po qid x 3 days, Days -5 through -3
75569980|NCT04942730|Drug|Cyclophosphamide|50 mg/kg iv x 2 days, Days +3 through +4
75569981|NCT04942730|Drug|Mycophenolate Mofetil|45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35
75569982|NCT04942730|Drug|Tacrolimus 5Mg Cap|0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.
75569983|NCT04068402|Device|Vivio System|The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
75569984|NCT04909190|Procedure|Increased saline flush volume|Additional flushing of the stentgraft delivery system.
75723091|NCT00872586|Drug|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
75424007|NCT04518410|Biological|SAB-185 (3,840 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
75569985|NCT04034901|Device|Monitoring of cardiorespiratory parameters with BORA Band|"The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~Activity~Step count~Heart rate~Respiratory rate~Skin temperature~SpO2"
75569986|NCT05062590|Other|Recommendations|Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP
75569987|NCT04903964|Other|family-centered nutrition education|There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.
75569988|NCT00534690|Procedure|One-Lung ventilation|Low Vt, High PEP
75723092|NCT00726557|Biological|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
75723093|NCT00726557|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
75723094|NCT00977925|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
75876814|NCT01330615|Drug|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
75723095|NCT00977925|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
75723096|NCT00803972|Drug|rHuPH20|recombinant human hyaluronidase PH20
75723097|NCT00803972|Drug|Insulin Human Injection|injection
75723098|NCT00803972|Drug|Insulin Lispro Injection|injection
75569989|NCT00534690|Procedure|One-Llung ventilation|High Vt, low PEP
75569990|NCT04901936|Drug|Pegcetacoplan|Complement (C3) inhibitor
75569991|NCT01272193|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
75723099|NCT00880386|Drug|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
75569992|NCT01272193|Drug|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
75569993|NCT04899206|Drug|With an Antidepressant Drug|Current users of an antidepressant drug.
75723100|NCT00978081|Drug|aminolevulinic acid hydrochloride|Patients undergo continuous or fractionated photodynamic therapy.
75723101|NCT00804050|Drug|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
75723102|NCT00804050|Drug|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
75723103|NCT00877734|Drug|baclofen|10 mg Baclofen administered tid for 11 weeks
75723104|NCT00877734|Drug|placebo|Placebo administered tid for 11 weeks
75723105|NCT00877734|Behavioral|BRENDA counseling|
75424008|NCT04518410|Biological|SAB-185 (10,240 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
75424009|NCT04518410|Drug|CASIRIVIMAB + IMDEVIMAB|600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
75723106|NCT00981591|Drug|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
75723107|NCT00981591|Drug|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
75876815|NCT03636529|Dietary Supplement|Tart cherry juice|Participants randomized to consume for 4-weeks either placebo beverage or single-strength tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage for 4 weeks to account for timing and order effects.
75876816|NCT03636529|Other|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
75424010|NCT04518410|Drug|Placebo for Bamlanivimab 7000mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
75569994|NCT04899206|Drug|Without an Antidepressant Drug|Non-current users of an antidepressant drug.
75569995|NCT04019613|Diagnostic Test|Lung ultrasound|Lung ultrasound will be performed at baseline (resting), prior to exercise with passive leg elevation, after 1.5 minutes of 20 Watts exercise, during each subsequent stage, at peak workload and at 1 minute recovery. Pulmonary thermodilution will be performed at rest, peak stress and at 1 minute recovery.
75569996|NCT04687163|Drug|HAIC of 130 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
75569997|NCT04687163|Drug|HAIC of 85 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
75569998|NCT04687163|Drug|TKI|sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight <60 kg)
75569999|NCT04017117|Procedure|under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh|comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
75570000|NCT00533156|Device|Vascular access site closure (7F Ensure)|
75570001|NCT04686812|Behavioral|Worksite health promotion program|Physical activity, nutrition, and stress management programs
75570002|NCT01270828|Drug|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
75570003|NCT01270828|Drug|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
75570004|NCT03995862|Other|Questionnaire|A questionnaire should be completed by the patient the day of inclusion. Health data will be collected in patients medical file from inclusion to the date of the end of study (i.e. no follow-up for the last patient included and a maximum of three years of follow-up for the first patient included).
75424011|NCT04518410|Drug|Placebo for Bamlanivimab 700mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
75424012|NCT04518410|Drug|Placebo for BRII-196+BRII-198|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
75424013|NCT04518410|Drug|Placebo for SNG001|Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
75570005|NCT00533195|Drug|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
75723108|NCT04545216|Other|Long-distance mountain running|Impact of a mountain race on the knee cartilage
75424014|NCT04518410|Drug|Placebo for Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
75570006|NCT00533195|Device|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients."
75570007|NCT03987165|Other|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
75570008|NCT03982407|Drug|68Ga-PSMA-11 PET/MRI|The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
75570009|NCT00533234|Device|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
75723109|NCT00978159|Drug|esomeprazole|esomeprazole 20 mg po for 4 weeks
75723110|NCT00978159|Drug|Famotidine|Famotidine 40 mg po for 4 weeks
75723111|NCT00804206|Drug|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
75723112|NCT00804206|Drug|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
75424015|NCT04518410|Drug|Placebo for SAB-185 (low dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
75723113|NCT00877812|Dietary Supplement|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
75424016|NCT04518410|Drug|Placebo for BMS-986414 + BMS-986413|Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
75570010|NCT04687124|Dietary Supplement|Fish oil|Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
75570011|NCT04687124|Other|standard care|No specified intervention
75876817|NCT05034029|Drug|Metformin hydrochloride sustained release tablets|Oral
75876818|NCT05034029|Drug|Placebo|Placebo
75723114|NCT00877812|Dietary Supplement|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
75723115|NCT00981903|Drug|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
75723116|NCT00738881|Drug|Erlotinib Hydrochloride|Given PO
75723117|NCT00738881|Drug|Pemetrexed Disodium|Given IV
76046259|NCT03766113|Other|Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference."
76046260|NCT03766113|Other|Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program"
76046261|NCT04785339|Behavioral|intervention in adult Latinx immigrants|Participants will complete self-report outcome measures at pre (baseline) and post, and they will receive the intervention in-between these assessments. Thus, the time frame for data collection is 10 weeks.
76046262|NCT03757377|Device|BackBeat Moderato System|Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
76046263|NCT03757377|Device|BackBeat Moderato Sytsem|Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
76046264|NCT04418505|Device|Vielight RX Plus|The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
75424017|NCT04518410|Drug|Placebo for AZD7442 (IV)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
76046265|NCT03746847|Drug|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
75424018|NCT04518410|Drug|Placebo for AZD7442 (IM)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
75424019|NCT04518410|Drug|Placebo for SAB-185 (high dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
75424020|NCT04518410|Biological|bamlanivimab 700mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
76046266|NCT01635153|Dietary Supplement|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
75424021|NCT04517864|Drug|PF-06651600|50 mg tablet, dosed as 200 mg QD or 50 mg QD 50 mg capsule, dosed as 50 mg QD
75570012|NCT01269385|Biological|alemtuzumab|Given subcutaneously
75424022|NCT04517864|Drug|Placebo|tablet, dosed as 4 tablets QD or 1 tablet QD
75424023|NCT04507204|Drug|Adhansia XR|Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
75424024|NCT04507204|Drug|Concerta|An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
75424025|NCT04500457|Behavioral|Exposure-based Treatment for Perfectionism (ETP)|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
75424026|NCT04498052|Other|EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening|"The intervention will consist of the following core items:~An EHR-integrated shared decision making (SDM) tool for providing information on the risks and benefits of lung cancer screening through low-dose computed tomography (LDCT) testing. This intervention is referred to as Decision Precision+.~Suggestions in the EHR to offer SDM for LDCT for patients eligible for lung cancer screening according to USPSTF guidelines. These suggestions include those provided by the EHR's Health Maintenance module as well as an EHR-integrated Disease Manager system for disease management and health maintenance.~Improvements may also be introduced based on user feedback. All major enhancements will be introduced with the support and approval of the appropriate governance group.~Following roll-out, clinic leaders may also receive periodic feedback on use of the intervention and LDCT screening rates, as well as advice on how to improve intervention adoption."
75570013|NCT01269385|Biological|rituximab|Given IV
75723118|NCT00797654|Behavioral|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
75723119|NCT00797654|Behavioral|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
76046267|NCT01635153|Dietary Supplement|Micronutrient|Dar-vite Multivitamin
75570014|NCT01269385|Drug|PGG beta-glucan|Given IV
75570015|NCT01269385|Other|flow cytometry|Correlative studies
75723120|NCT00877968|Dietary Supplement|Whole wheat banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g"
75723121|NCT00877968|Dietary Supplement|Whole pea flour banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g"
75723122|NCT00877968|Dietary Supplement|Whole wheat biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g"
75723123|NCT00877968|Dietary Supplement|Whole pea flour biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g"
75723124|NCT00877968|Dietary Supplement|Whole wheat pasta|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g"
76046268|NCT04446039|Drug|Escitalopram|Treatment for depression
76046269|NCT04446039|Drug|Paroxetine|Treatment for depression
76046270|NCT04446039|Drug|Fluoxetine|Treatment for depression
76046271|NCT04446039|Drug|Mirtazapine|Treatment for depression
75570016|NCT01269385|Other|laboratory biomarker analysis|Correlative studies
75570017|NCT01269385|Genetic|DNA analysis|Correlative studies
75570018|NCT01269385|Genetic|fluorescence in situ hybridization|Correlative studies
75570019|NCT01269385|Genetic|polymerase chain reaction|Correlative studies
75570020|NCT01269385|Genetic|polymorphism analysis|Correlative studies
75570021|NCT01269385|Genetic|mutation analysis|Correlative studies
75570022|NCT02715635|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
76046272|NCT04446039|Drug|Duloxetine|Treatment for depression
76046273|NCT04446039|Drug|Sertraline|Treatment for depression
75570023|NCT02715635|Dietary Supplement|Concentrate beetroot Juice|140 ml containing ~8 mmol of inorganic nitrate
75570024|NCT02715635|Dietary Supplement|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
75570025|NCT04685954|Device|Filtek Bulk-Fill Posterior|Bulk-fill restorative composite
75570026|NCT04685954|Device|Filtek Ultimate Universal|Incremental restorative composite
75570027|NCT00532974|Biological|EP1090|Low dose
75876819|NCT03637127|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
76046274|NCT04446039|Drug|Venlafaxine|Treatment for depression
76046275|NCT04446039|Drug|Tianeptine|Treatment for depression
76046276|NCT04446039|Drug|Vortioxetine|Treatment for depression
75570028|NCT00532974|Biological|EP1090|High dose
75570029|NCT00533013|Other|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
75570030|NCT00533013|Other|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
75570031|NCT02071862|Drug|CB-839|CB-839 monotherapy
75570032|NCT02071862|Drug|Pac-CB|CB-839 in combination with standard dose paclitaxel
75570033|NCT02071862|Drug|CBE|CB-839 in combination with standard dose everolimus
75570034|NCT02071862|Drug|CB-Erl|CB-839 in combination with standard dose erlotnib
75570035|NCT02071862|Drug|CBD|CB-839 in combination with standard dose docetaxel
75570036|NCT02071862|Drug|CB-Cabo|CB-839 in combination with standard dose cabozantinib
76046277|NCT04446039|Drug|Desvenlafaxine|Treatment for depression
76046278|NCT04446039|Drug|Bupropion|Treatment for depression
76046279|NCT05087979|Device|Stable airway management (SAM) device|SAM is positioning device that will maintain patient's head, neck, and therefore their airway in the correct position during their procedure.
76046280|NCT05036967|Drug|HF medication|Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
76046281|NCT03647007|Other|FIFA 11 for health|The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
76046282|NCT02014311|Procedure|CTA+CTP guided treatment strategy|CTA+CTP guided treatment strategy
75424027|NCT04494048|Other|Endoscopic Bariatric Therapies|Participation in this study will allow for data collection through medical chart review for at least 6 standard of care visits up to 1 year after consenting to participate in this registry study. The exposure of interest is total body weight loss, safety and efficacy
75876820|NCT03637127|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
75424028|NCT04487574|Drug|XC221|Participants will receive XC221 100 mg 2 times a day during 14 days
75570037|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
75570038|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
75570039|NCT05051085|Behavioral|"Internet-delivered treatment: SpilleFri."|The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
75570040|NCT01268683|Drug|Glyburide for Injection|Administered as specified in the treatment arm.
75570041|NCT05037201|Behavioral|Text message|The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
75570042|NCT02021474|Drug|AGX-201|Subcutaneous injection
75424029|NCT04487574|Drug|Placebo|Participants will receive Placebo 2 times a day during 14 days
75424030|NCT04486391|Drug|Tislelizumab|200 mg administered via intravenous (IV) infusion once every 3 weeks
75424031|NCT04486391|Drug|Salvage Chemotherapy|Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
75876821|NCT02864342|Device|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
75424032|NCT04482855|Device|Low-level laser|Low-level laser therapy
75424033|NCT04481893|Behavioral|Use of a virtual reality headset|"The intervention will consist of 2 sessions of 30 minutes each, based on the use of a virtual reality headset with the AQUA® application.~The 1st session will take place on the day of the surgical intervention, upon arrival in hospital, after reception in the room.~The 2nd session will take place the same day, post-operatively, once the awakening is satisfactory (within 3 to 6 hours after the intervention)"
75424034|NCT04481139|Drug|SHR0302|SHR0302, oral, once daily
75424035|NCT04481139|Drug|SHR0302 placebo|SHR0302 placebo, oral, once daily
75570043|NCT02021474|Drug|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|Subcutaneous injection
75570044|NCT01268566|Drug|MEDI-575|MEDI-575 as an IV infusion.
75570045|NCT05010291|Behavioral|Standard of Care (SOC) text message reminder to attend clinic appointment|SOC one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
75570046|NCT05010291|Behavioral|Loss aversion framed text message reminder to attend clinic appointment|Loss aversion framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
75570047|NCT05010291|Behavioral|Social norms framed text message reminder to attend clinic appointment|Social norms framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
75570048|NCT05010291|Behavioral|Altruism framed text message reminder to attend clinic appointment|Altruism framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
76046283|NCT02014311|Procedure|CTA guided treatment strategy|CTA guided treatment strategy
75570049|NCT01268488|Device|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
75876822|NCT02864342|Device|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
76046284|NCT05034861|Device|cCTG|Self-applied home computerized CTG device used twice weekly instead of standard Doppler assessment once weekly.
75570050|NCT04686071|Other|PNF method|Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
75570051|NCT04686071|Other|Standard rehabilitation|In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
75570052|NCT01268098|Drug|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
75570053|NCT00533052|Behavioral|Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
75570054|NCT01674803|Device|Orsiro|biodegradable polymer sirolimus eluting stent
75570055|NCT01674803|Device|Synergy|biodegradable polymer everolimus eluting stent
75570056|NCT01674803|Device|Resolute Integrity|durable polymer zotarolimus-eluting stent
76046285|NCT05034861|Diagnostic Test|Doppler|Standard Doppler assessment provided once weekly in case of late FGR with positive end diastolic flow in the umbilical artery.
75424036|NCT04472026|Behavioral|Counseling using the electronic conversation aid|This conversation aid will help you and your doctor discuss ways to care for your thyroid nodule. We will evaluate the acceptability of the conversation aid and barriers to implementation in clinical practice. Post visit semi structured interviews and recordings of the clinical visits will be qualitatively analyzed. We hypothesize that the conversation aid will be accepted and facilitate the decision making process.
75424037|NCT04463667|Other|exercise|Collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.
75876823|NCT03237065|Drug|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
75570057|NCT04959825|Drug|Melatonin 5 mg|study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
75723125|NCT00877968|Dietary Supplement|Whole pea pasta|"Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g"
75723126|NCT00877968|Dietary Supplement|White bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g"
75723127|NCT00877968|Dietary Supplement|Boiled yellow peas|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --> 250 g cooked Available CHO: 52.8 g"
76046286|NCT05032677|Procedure|Conventional Epidural Technique|Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
75570058|NCT04959825|Drug|Sugar Coated Tablets|the control group patients will receive placebo tablets one hour before induction of anesthesia
75570059|NCT04955184|Device|non-invasive monitoring|non-invasive measurements of cardiac output
75723128|NCT00878046|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
76046287|NCT05032677|Procedure|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
75570060|NCT05471453|Dietary Supplement|DHEA|75 mg DHEA supplementation per day for 3 months before IVF
75570061|NCT05471453|Dietary Supplement|DHEA+CoQ10+Tocotrienol|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
75723129|NCT00657020|Drug|Nicotine|Nicotine lozenge containing 4 mg of nicotine
75723130|NCT00657020|Drug|Placebo|Placebo lozenge
75723131|NCT04773288|Other|Live feedback during handwashing|Live feedback provided during handwashing on display
76046288|NCT05002959|Device|Anatomic TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.
75570062|NCT04949607|Dietary Supplement|Inulin fructooligosaccharide|Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.
75570063|NCT03457233|Drug|Gonadotropins|1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
75570064|NCT03457233|Drug|GNRH antagonist|cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
75723132|NCT03921723|Drug|Dolutegravir dispersible tablet|DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
75723133|NCT03921723|Drug|Dolutegravir oral suspension|DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
75723134|NCT03921723|Drug|Dolutegravir oral solution|DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
75723135|NCT00872664|Dietary Supplement|carotenoids|beta-carotene, lycopene, lutein
75723136|NCT00872742|Behavioral|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
75723137|NCT00872742|Behavioral|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
75876824|NCT03237065|Drug|Ferric carboxymaltose|Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. The dose of ferric carboxymaltose for the individual subject was 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
76046289|NCT05002959|Device|Reverse TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.
75876825|NCT02620826|Procedure|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
75424038|NCT04462497|Other|Prototype device|Patients will receive the prototype head and neck support device to be used intraoperatively.
76046290|NCT01871727|Drug|E7777 9 mcg/kg|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
75424039|NCT04458532|Other|Aerobic Training|300 min/wk for 16 weeks
75424040|NCT04458532|Other|Aerobic Training|150 min/wk for 32 weeks
75424041|NCT04458532|Other|Aerobic Training|300 min/wk for 32 weeks
76046291|NCT05266989|Other|Transcranial Direct Current Stimulation|Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
76046292|NCT01636713|Drug|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
75424042|NCT04458532|Other|Aerobic Training|150 min/wk for 16 weeks
75876826|NCT02620826|Procedure|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
75424043|NCT04448938|Other|MRI|"The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.~A consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation.~The subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO."
75424044|NCT04448938|Other|visual acuity|Patients with NO will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. During this consultation, an OCT, a visual field and the measurement of visual acuity will be performed. This visit and the examinations carried out correspond to the usual care of patients suffering from NO and followed at the Adolphe de Rothschild Foundation Hospital
75424045|NCT04444622|Biological|AlloStim|Living bioengineered, non-genetically manipulated, activated Th1-like immune cells differentiated and expanded from precursor cells purified from blood of healthy unrelated donors
75424046|NCT04442971|Behavioral|Music Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to their preferred music.
75424047|NCT04442971|Behavioral|Alternative Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to an audio book.
75424048|NCT04442971|Behavioral|No Auditory Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and hear silence.
75424049|NCT04442061|Device|Transcranial magnetic stimulation|"Before the stimulation, identification of a motor hotspot and active motor threshold (AMT) will be performed. The TMS will be applied on the intermittent theta-burst modality (iTBS), i. e., 2 s of TBS trains (30 pulses) repeated every 10 s for 190 s, with a total number of 600 pulses (Huang et al, 2005). The whole TMS session, including preparation, will last up to 1h.~The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue"
75424050|NCT04442061|Device|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist.
75876827|NCT05121077|Other|Training|2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
75876828|NCT03171415|Drug|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
75876829|NCT03171415|Drug|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
75876830|NCT03829241|Drug|Troriluzole|100 mg capsule
76046293|NCT01636713|Drug|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
76046294|NCT01636713|Drug|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
76046295|NCT04801095|Drug|WM-S1-030|WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.
75876831|NCT03829241|Drug|Placebo|Placebo matched to troriluzole
76046296|NCT04800237|Drug|VQW-765|oral capsule
76046297|NCT04800237|Drug|Placebo|oral capsule
76046298|NCT03591861|Procedure|Ketogenic diet|"Children under 2 years will immediately start on a full calorie classical 3:1 ketogenic diet. The 3:1 ratio indicates that the diet contains 3 g of fat for every 1 g of protein + carbohydrate, which results in about 87% of calories coming from fat.~Children 2 years or older will skip breakfast and lunch on the day of admission but start a full calorie 3:1 ketogenic diet at dinner."
76046299|NCT03591861|Drug|BCNU|-Standard of care
75570065|NCT03457233|Drug|Human chorionic gonadotropin Chorimon|10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
75570066|NCT03457233|Drug|Natural progesterone|400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
75876832|NCT05210959|Other|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
75723138|NCT05056155|Other|Systane Complete|Propylene glycol 0.6% eye drops for replenishing deficiencies in both the lipid and aqueous layers of the tear film
76046300|NCT04832919|Behavioral|Nurse-Community-Family Partnership Intervention|Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
76046301|NCT05264961|Behavioral|voice therapy|sessions of voice therapy
76046302|NCT01600053|Drug|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
75723139|NCT00878124|Dietary Supplement|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
76046303|NCT04821297|Other|Health Promotion and Education|Receive messages
76046304|NCT04821297|Other|Survey Administration|Complete survey
76046305|NCT04821297|Other|Interview|Participate in an interview
75723140|NCT00878124|Other|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
75723141|NCT00978237|Drug|EFV|one pill QD VO.
76046306|NCT03569241|Radiation|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
75723142|NCT00978237|Drug|LPV/r|2 pills QD VO
75570067|NCT00535808|Drug|nitroprusside|Administration of nitroprusside
75570068|NCT00535808|Drug|nitroglycerine|Administration of nitroglycerine
75570069|NCT00535808|Drug|sevoflurane|Administration of Sevoflurane
75723143|NCT00872820|Behavioral|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
76046307|NCT03569241|Radiation|metastasis-directed treatment|stereotactic body radiotherapy
76046308|NCT03569241|Procedure|salvage Lymph Node Dissection|metastasis-directed treatment
75570070|NCT04920903|Drug|COR588|Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
75570071|NCT04920903|Drug|Placebo|Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
75570072|NCT05471063|Drug|Amphotericin B Colloidal Dispersion|Amphotericin B Colloidal Dispersion 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) . The course of induction therapy is at least four weeks.
76046309|NCT03569241|Drug|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
75876833|NCT05090423|Other|balance training alone|"The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
75876834|NCT05090423|Other|balance training and neurodynamic intervention for the common peroneal nerve|"The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
75876835|NCT01984879|Other|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
75876836|NCT03620461|Drug|Gemcitabine - nabpaclitaxel|efficacy and safety
76046310|NCT04716387|Other|Standard LLIN|Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.
76046311|NCT04716387|Other|Piperonyl butoxide ITN|Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.
76046312|NCT04716387|Other|Pyriproxyfen ITN|Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
76046313|NCT04716387|Other|Chlorfenapyr ITN|Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
76046314|NCT01068249|Drug|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
76046315|NCT01068249|Drug|RAD001 (Everolimus)|10 mg by mouth daily
75570073|NCT05471063|Drug|flucytosine|Flucytosine 100 mg/kg/d for induction therapy and consolidation therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks, and consolidation therapy for at least 6 weeks.
75570074|NCT05471063|Drug|fluconazole|Fluconazole (400-600 mg/d) for consolidation therapy for at least 6 weeks.
75570075|NCT04920396|Device|E>Eye IRPL|Regulated intense pulsed light therapy
75723144|NCT00872820|Behavioral|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
75723145|NCT00978315|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
75570076|NCT04920396|Device|Warm compress|Fabric mask with anti-bacterial coating filled with BodyBeads® heated in a microwave for 30 seconds before application over the eyes for 5 minutes
75723146|NCT00978315|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
75570077|NCT05471024|Procedure|Digitized Mounted Articulator Scan|Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.
75570078|NCT05471024|Procedure|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
76046316|NCT01035099|Drug|Letrozole|"Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level <150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level >350 pg/ml - 7.5 mg;"
75570079|NCT05471024|Procedure|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
75723147|NCT00878202|Device|SCAD information system|Clinical follow-up and continuation of therapeutic education by telemedicine during 3 months
75723148|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
75723149|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
75723150|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
75723151|NCT00978393|Drug|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
75723152|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
75723153|NCT00978393|Drug|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
75723154|NCT04740996|Drug|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
75570080|NCT04912206|Diagnostic Test|Point-of-Care Ultrasound|Abdominal clinician-performed Ultrasound
75570081|NCT05470946|Device|Double balloon enteroscopy|Double balloon enteroscopy (EN-580T, Fujifilm, Japan)
75570082|NCT04910100|Drug|Nebivolol Ophthalmic Suspension 1 Percent|1 drop instilled into each eye twice daily
75570083|NCT04910100|Drug|Nebivolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
75723155|NCT04040010|Dietary Supplement|Colostrum supplementation for bone loss|Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.
75723156|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
75723157|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"
75424051|NCT04442061|Device|Neuronavigation|The neuronavigation system will allow to guide the stimulation using the individual anatomical MRI acquired with MRI, and to record the position and orientation of the coil during successive stimulations
75723158|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
75723159|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"
75723160|NCT00544167|Drug|Doxorubicin|
75723161|NCT00544167|Drug|Cyclophosphamide|
75424052|NCT04442061|Device|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
75723162|NCT00544167|Drug|Paclitaxel|
75723163|NCT00544167|Drug|Sorafenib|
75723164|NCT00659438|Drug|ZD6474 (Vandetanib)|300mg orally, once daily
75723165|NCT00659438|Drug|Bicalutamide|150mg orally, once daily
75424053|NCT04442061|Genetic|Salivary samples|The DNA will be extracted from the salivary sample to genotyping analyses on the BDNF (Val66Met) and COMT (Val158Met) polymorphism
75723166|NCT00659438|Drug|Placebo|orally, once daily
75723167|NCT00878358|Other|Hydrotherapy|
75723168|NCT00878358|Other|Physiotherapy|
75424054|NCT04442061|Other|Clinical scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
75424055|NCT04417127|Other|Integrated Community-Based (ICB) Care|The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.
75723169|NCT02553200|Device|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
75723170|NCT02553200|Device|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
75723171|NCT02553200|Device|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
75723172|NCT05225844|Drug|Camrelizumab|Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle
75723173|NCT05225844|Drug|Apatinib Mesylate|Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle
75723174|NCT00878514|Drug|Alprazolam|Alprazolam 1 mg tablet
75723175|NCT00878514|Drug|Xanax|Xanax 1 mg tablet
75723176|NCT00804284|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
75723177|NCT00804284|Biological|Other DTap Vaccines|0.5 mL, Intramuscular
76046317|NCT01035099|Drug|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
75723178|NCT00804440|Drug|Ibuprofen Tablets, 800 mg|
75723179|NCT00880854|Drug|BCG and CP-675,206|"Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15"
75723180|NCT00804518|Other|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at ~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
75723181|NCT00880932|Behavioral|Electronic Alert|
75723182|NCT00543855|Drug|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
75876837|NCT05056493|Other|Caremap app|The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).
75876838|NCT01314781|Drug|solifenacin|solifenacin 5mg tablet once daily
75876839|NCT01314781|Procedure|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
75876840|NCT01330693|Drug|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
75876841|NCT01330693|Drug|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
75876842|NCT01913977|Device|Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min|Abylcap settings
75424056|NCT04417127|Other|Microfinance|"Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning."
75424057|NCT04414397|Device|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC injectable gel
75570084|NCT04910100|Drug|Timolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
75570085|NCT04910100|Drug|Timolol Ophthalmic Solution 0.5 Percent|1 drop instilled into each eye twice daily
75570086|NCT01268059|Drug|Carboplatin|Carboplatin (carboplatin area under the plasma concentration-time curve [AUC] of 6 milligram per milliliter into minute [mg/mL*min] administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
75876843|NCT01913977|Device|Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min|Abylcap settings
75876844|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min|Abylcap settings
75876845|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min|Abylcap settings
75876846|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min|Abylcap settings
75876847|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min|Abylcap settings
75876848|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min|Abylcap settings
75876849|NCT01330771|Drug|hMG-HP/r-FSH|
75723183|NCT00543855|Drug|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
76046318|NCT00990483|Device|3D mammograpgy system|In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition).
76046319|NCT05362383|Device|transcutaneous electrical nerve stimulation (TENS):Enraf Nonius® S82 model|Will be used TENS device with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 milliampere. TENS electrodes (diameter 35-52 mm) will be placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the anterior temporal muscle. The device will be applied in an identical manner to all patients in both groups and kept in position for the same time period (30 min) and for the control group the the device will be not switched on
76046320|NCT00973011|Drug|FCFD4514S|Intravitreal escalating dose
75424058|NCT04414397|Other|No-treatment control|Participants received no treatment for 3 months and then received an optional delayed treatment with JUVÉDERM VOLUMA® XC and an optional touch-up treatment 30 days later.
75424059|NCT04404036|Device|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
75424060|NCT04385108|Biological|Blood collection on admission and longitudinally|33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
76046321|NCT03560349|Drug|Lidocaine HCl Gel 2%|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
76046322|NCT03560349|Drug|placebo gel|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
76046323|NCT04812639|Other|Buccal infiltration technique|a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth
76046324|NCT04812639|Other|Inferior alveolar nerve block technique|a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
76046325|NCT04418583|Diagnostic Test|Three-dimensional imaging|Three-dimensional surface images, acquired by the Artec Leo
76046326|NCT05157399|Device|Otoband|Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
76046327|NCT05157399|Device|Placebo Device|Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
76046328|NCT04418973|Other|VOCs analysis in exhaled air|using an electronic nose and a mass spectrometry
76046329|NCT00434343|Other|Global Therapeutic Massage (GTM)|
76046330|NCT00434343|Other|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
75723184|NCT00543855|Drug|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
75723185|NCT00543855|Drug|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
75723186|NCT00797810|Drug|Rituximab|
75723187|NCT03831048|Device|OCS Heart System|Preserving and assessing donor after circulatory death hearts for transplant
75723188|NCT03831048|Other|Cold Storage|Active comparator intervention
75723189|NCT00881010|Behavioral|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
76046331|NCT04435431|Drug|Mesdopetam|Oral use
76046332|NCT04435431|Drug|Placebo|Oral use
76046333|NCT02246673|Drug|RDEA3170 15 mg|
76046334|NCT02246673|Drug|RDEA3170 10 mg|
76046335|NCT02246673|Drug|RDEA3170 2.5|
76046336|NCT02246673|Drug|RDEA3170 5 mg|
76046337|NCT02246673|Drug|Febuxostat 40 mg|
76046338|NCT02246673|Drug|Febuxostat 80 mg|
76046339|NCT03532425|Drug|B/F/TAF|B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily
76046340|NCT03532425|Drug|Atripla|Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily
75424061|NCT04385108|Biological|Blood collection on their first consultation and 10 to 14 days later|33 mL of blood collected on their first consultation and 10 to 14 days later
75424062|NCT04373005|Diagnostic Test|Nasopharyngeal (NP) swab|A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
75424063|NCT04337944|Procedure|Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
75424064|NCT04332744|Drug|Enzalutamide|Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
75424065|NCT04332744|Drug|Talazoparib|Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
75424066|NCT04331002|Drug|Zilretta|ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.
75424067|NCT04331002|Other|Placebo|5 mL normal saline
76046341|NCT03532425|Drug|B/F/TAF Placebo|Tablet taken orally once daily
75424068|NCT04327973|Biological|ATB200|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
76046342|NCT03532425|Drug|Atripla Placebo|Tablet taken orally once daily
76046343|NCT03503877|Device|EmbryoScope Plus|All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data
75424069|NCT04327973|Drug|AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
75424070|NCT04320394|Diagnostic Test|QuantiFERON Monitor®|The test will be realised to evaluate sepsis induced immunosuppression on patient with septic shock
75424071|NCT04291820|Procedure|Intravenous induction and desflurane anaesthesia maintenance|Anaesthesia will be inducted with intravenous propofol + opioid and maintained with desflurane according to the BIS levels
75424072|NCT04291820|Procedure|Inhalation induction with sevoflurane and anaesthesia maintenance with sevoflurane|Anaesthesia will be inducted with sevoflurane and maintained with sevoflurane according to the BIS levels
75424073|NCT04279054|Drug|Morphine Sulfate 150 mcg|Use of 150mcg of morphine sulfate for neuraxial block (dosing difference)
75424074|NCT04279054|Drug|Morphine Sulfate 50mcg|Use of 50mcg of morphine sulfate for neuraxial block (dosing difference)
76046344|NCT03503877|Other|GLOBAL MEDIA|Embryos will be cultured in GLOBAL media
76046345|NCT03503877|Other|SAGE MEDIA|Embryos will be cultured in SAGE media
76046346|NCT04811469|Drug|CBP-174|CBP-174 oral solution, given once
76046347|NCT04811469|Drug|Placebo|Placebo oral solution, given once
76046348|NCT02246439|Drug|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
76046349|NCT02246439|Drug|Placebo Oral Tablet|Placebo
76046350|NCT02245737|Drug|Lanabecestat|Administered orally
76046351|NCT02245737|Drug|Placebo|Administered orally
76046352|NCT04191447|Drug|Flamboyant 200/12|Flamboyant 200/12 capsule
76046353|NCT04191447|Drug|Budesonide / Formoterol 400/12|Budesonide / Formoterol 400/12 capsule
76046354|NCT04191447|Other|Flamboyant 200/12 Placebo|Flamboyant 200/12 Placebo capsule
76046355|NCT04191447|Other|Budesonide / Formoterol 400/12 Placebo|Budesonide / Formoterol 400/12 Placebo capsule
76046356|NCT02244957|Device|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations <88% while on stable bi-level settings.
76046357|NCT02244957|Drug|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
76046358|NCT02243865|Device|Chordate System S200 + CT100 (active treatment)|Chordate S200 + CT100 (active treatment) gives Kinetic Oscillation Stimulation for 15 minutes to each nostril and by that giving an effect on the autonomic nervous system (ANS).
76046359|NCT02243865|Device|Chordate System S200 + CT100 (placebo treatment)|Chordate S200 + CT100 (placebo) is used in the same way as Active treatment, but no Kinetic Oscillation Stimulation is given. Catheter is not inflated and no vibration is given.
76046360|NCT03443739|Other|Intermittent Fasting|Intermittent Fasting with abstinence from food and drink daily from sunrise to sunset for nineteen consecutive days in March 2018
76046361|NCT02243631|Drug|Probenecid|Treatment
76046362|NCT04183413|Other|DSD|This intervention consist of three Differentiated Service Delivery Models in which stable clients can be enrolled. The fast-track model gives preferential treatment to enrolled clients. Clients arrive at clinics, usually early in the morning, and can see the nurse as well as collect their medication without queuing. This model mainly targets the working population. The facility-based treatment clubs consist of bimonthly meetings where clients meet in groups of approximately 20 members. They receive health counselling, risk factor screening and medication prescription. This model mainly targets clients living close to the facility. The community advisory groups consist of groups of up to six clients. Groups are equipped with a point of care blood pressure and blood glucose measurement devices. They take turns in collecting the medication for the entire group and meet on a monthly basis. This model targets clients in hard-to-reach areas.
75570087|NCT01268059|Drug|Paclitaxel|Paclitaxel 200 milligram per square meter (mg/m^2) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
75570088|NCT01268059|Drug|MEDI-575|MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
75424075|NCT04273867|Other|Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument|This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.
75723190|NCT00881010|Behavioral|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
75424076|NCT04263051|Drug|UCPVax + Nivolumab|"UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care."
75424077|NCT04263051|Drug|standard chemotherapy|Second line chemotherapy at the choice of the investigator
75570089|NCT04901598|Other|Running anaerobic sprint test and aerobic test|subjects walk a mile with maximum steps and their heart rate will not exceed 180 beats per minute during the test and the execution time will not be less than 9 minutes (RAST test)
75570090|NCT00535886|Dietary Supplement|Man-made Trans FA|EA as 6% of total energy
75723191|NCT04921605|Device|DragonFly transcatheter mitral valve clamping system|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
75723192|NCT00656474|Drug|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
75723193|NCT00656474|Drug|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
75723194|NCT00873210|Drug|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
75723195|NCT00978471|Drug|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
75723196|NCT04017416|Behavioral|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
75723197|NCT00804674|Drug|bupivacain|
75723198|NCT00804674|Drug|placebo|
75723199|NCT00881088|Drug|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
75723200|NCT00881088|Drug|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
75723201|NCT00981981|Dietary Supplement|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
75723202|NCT00981981|Dietary Supplement|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
75723203|NCT00981981|Dietary Supplement|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
75424078|NCT04243148|Combination Product|Home exercise program for 12 months.|Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.
75570091|NCT00535886|Dietary Supplement|Natural Trans FA|VA as 6% of total energy
75570092|NCT00535886|Dietary Supplement|Oleic Acid|OA as 6% of total energy
75424079|NCT04243148|Combination Product|Multispecies probiotic: Vivomixx®|"Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435*, Bifidobacterium infantis DSM 24737® / NCIMB 30436*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440**~* Re-classified as B. lactis ** Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study."
75570093|NCT01267825|Drug|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
75570094|NCT01267825|Drug|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
75570095|NCT02889406|Behavioral|Motivational intervention|motivational interviewing schema
76046363|NCT04183413|Other|CDP|Community Distribution Points are set up on a monthly basis in communities linked to the clinic. Healthcare staff sets up a temporary point of contact where clients can obtain screening for diabetes and hypertension, health counselling, referral to primary or tertiary facilities, and medication.
76046364|NCT03986229|Other|"Evaluate the variation in the travel speed of the center of pressure with and without compression garments."|"Each evaluation will be done according to the following protocol:~Evaluation of the pain~Berg test~One test per condition starting with open eyes~Standardized instructions:~Break about 15 minutes (wash-out) between each test.~Both conditions will be tested on the same day.~Evaluation in an environment free from visual and audible interference."
76046365|NCT03396783|Biological|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
76046366|NCT03396783|Other|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
75570096|NCT00593242|Biological|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
75570097|NCT00593242|Other|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
75723204|NCT00981981|Dietary Supplement|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
76046367|NCT05233449|Device|NoL monitor|NoL monitor : non invasive, adhesive digital device
76046368|NCT05233449|Procedure|Stimulation|Stimulation : 100 Hertz, 5 seconds, 10-30-60 milliamps, inner forearm
76046369|NCT02242305|Drug|Hyoscine Butylbromide - Tablet|
76046370|NCT02242305|Drug|Hyoscine Butylbromide - Capsule|
76046371|NCT02242305|Drug|Placebo|
76046372|NCT02240121|Drug|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
76046373|NCT02240121|Drug|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
76046374|NCT04780425|Behavioral|DESMOND|as previously described
76046375|NCT04780425|Other|usual care|usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
76046376|NCT02239263|Device|Nucleus 6 Sound Processor|
76046377|NCT02238483|Drug|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
76046378|NCT02238483|Drug|Placebo|Inhaled placebo solution
76046379|NCT01632891|Drug|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
76046380|NCT01632891|Drug|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
76046381|NCT01632891|Drug|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
75570098|NCT05470829|Drug|ZM-H1505R|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28"
75570099|NCT05470829|Other|ZM-H1505R Placebo|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28"
76046382|NCT01632891|Drug|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
76046383|NCT01632891|Drug|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
76046384|NCT02208999|Device|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
76046385|NCT02208843|Drug|Afatinib|Afatinib tablet once daily until progression
76046386|NCT02208063|Drug|Telavancin|
75424080|NCT04243148|Combination Product|Branched-chain amino acids (BCAA)|Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.
75424081|NCT04243148|Combination Product|No specific intervention.|Follow up as a clinical practice
75424082|NCT04237935|Drug|Ticagrelor 90mg|Ticagrelor 90 mg dispensing claim is used as the exposure group
75424083|NCT04237935|Drug|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
75424084|NCT04237922|Drug|Prasugrel 10mg|Prasugrel 10mg dispensing claim is used as the exposure group
75424085|NCT04237922|Drug|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
75424086|NCT04233021|Drug|Osimertinib|Osimertinib 80 mg/d
75424087|NCT04228289|Drug|Oxytocin|40 IU intranasal spray
75424088|NCT04228289|Other|Placebo|matching intranasal spray
76046387|NCT02208063|Drug|Vancomycin|
76046388|NCT02208063|Drug|Daptomycin|
76046389|NCT02208063|Drug|Synthetic penicillin|
76046390|NCT02208063|Drug|Cefazolin|
76046391|NCT02207907|Drug|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
76046392|NCT02207907|Drug|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
76046393|NCT02207829|Drug|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
75424089|NCT04227821|Other|Vasopressor and/inotrope therapy|In pediatric patients admitted to the pediatric intensive care, with the persistent hemodynamic instability after fluid resuscitation, the vasopressor and/or inotrope therapy will be initiated
75723205|NCT00981981|Dietary Supplement|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
75723206|NCT00878592|Behavioral|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
75723207|NCT00978549|Drug|docetaxel|
75723208|NCT00978549|Drug|steroid therapy|
75723209|NCT00978549|Other|questionnaire administration|
76046394|NCT02207829|Drug|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
75424090|NCT04215536|Drug|Empagliflozin|Empagliflozin dispensing claim is exposure
76046395|NCT02207829|Drug|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
76046396|NCT02207829|Drug|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
76046397|NCT02237157|Drug|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
75570100|NCT00593281|Drug|Hylenex|Add Hylenex to SC injection of Morphine
75723210|NCT00978549|Procedure|nausea and vomiting therapy|
75723211|NCT00978549|Procedure|pain therapy|
75424091|NCT04215536|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
75723212|NCT00978549|Procedure|quality-of-life assessment|
75424092|NCT04215523|Drug|Dapagliflozin|Dapagliflozin dispensing claim for any dose is exposure
75424093|NCT04215523|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim for any dose is reference
75424094|NCT04215081|Device|Gait training using ExoAtlet exoskeleton|Subjects will learn to use the ExoAtlet II exoskeleton, with the assistance of a trained medical professional, to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
75723213|NCT00978549|Procedure|standard follow-up care|
75723214|NCT00978549|Radiation|radiation therapy|
75723215|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
75424095|NCT04210726|Drug|25% Hypertonic Saline Bath|25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).
75723216|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
75723217|NCT00656084|Drug|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar-->Novantrone-->Rituxan.
75723218|NCT00656084|Drug|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan."
75723219|NCT00656084|Drug|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan."
75723220|NCT00985335|Other|Neem Based External Application Cream|Apply externally 3-4 times per day
75723221|NCT00982059|Other|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
75723222|NCT00873600|Drug|chemotherapy|
75723223|NCT00873600|Other|medical chart review|
75723224|NCT00873600|Other|questionnaire administration|
75723225|NCT00873600|Procedure|adjuvant therapy|
75723226|NCT00873600|Procedure|assessment of therapy complications|
75723227|NCT00873600|Procedure|cognitive assessment|
75723228|NCT00873600|Procedure|psychosocial assessment and care|
75723229|NCT00873600|Procedure|quality-of-life assessment|
76046398|NCT02237001|Device|Suture-based meniscal repair|Suture-based meniscal repair
76046399|NCT02236611|Drug|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
76046400|NCT02236611|Drug|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
76046401|NCT02234583|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
76046402|NCT03705663|Behavioral|PrEP initiation|Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
76046403|NCT03686397|Drug|SVT-15652|1 vial twice daily
76046404|NCT03686397|Drug|Placebo|1 vial twice daily
75424096|NCT04210726|Other|0.9% Isotonic Saline Bath|0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
75570101|NCT04327102|Behavioral|Health education tools combined with health literacy intervention|On the basis of the control group, the intervention measures to improve the health literacy of patients were implemented and self-made health education tools were used. During hospitalization, health knowledge lectures shall be organized for patients. Before the activity, the theme of the activity shall be clarified. Each participant shall be organized by the educator to sit on the tool chart in a U-shape. According to the theme of the tool map, patients interact with educators. And learn the knowledge content related to hypertension health literacy. Before the end of the activity, the educator will review all the contents discussed in the activity quickly, answer the questions in the activity, and help the participants to sort out and consolidate the knowledge acquired in the education. Follow up intervention for patients after leave hospital.
75723230|NCT04016948|Device|Probe-based confocal laser endomicroscopy optical biopsy|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
75723231|NCT04016948|Device|Intra-operative frozen section|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
75723232|NCT04007211|Device|ABT13107|Dose: 3mL, maximum 10mL
75723233|NCT04007211|Device|Hyalobarrier|Dose: 10mL
76046405|NCT02233803|Drug|NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler|Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
75424097|NCT04202731|Behavioral|PBS Study|Sleep extension intervention
75424098|NCT04194346|Procedure|Lung ultrasound|Healthy volunteers will have lung ultrasonography at 15 predetermined sites for a common volume continuum between 5 and 15 cc/kg. For each volume, 3 respiratory cycles will be recorded.
75424099|NCT04186676|Other|MINOCA registry|Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes
75424100|NCT04186676|Diagnostic Test|CCTA Phenotypes|"Complete normal coronary arteries~Diffuse non-obstructive coronary artery disease~Non-obstructive high-risk plaques~Myocardial bridges"
75424101|NCT04169347|Drug|Oxaliplatin|2 week cycles
75570102|NCT00536003|Drug|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
75570103|NCT00536003|Drug|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
75570104|NCT00593476|Other|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
75570105|NCT00593476|Other|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
75723234|NCT00881166|Drug|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
75723235|NCT00881166|Drug|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
75723236|NCT00881166|Drug|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
75723237|NCT00881166|Drug|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
75570106|NCT00593515|Behavioral|Family cognitive behavioral therapy|12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
75570107|NCT00593515|Behavioral|Child-focused cognitive behavioral therapy|12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
75876850|NCT03164551|Device|GERI+ incubator|The embryo culture of consented participants were carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos were reviewed firstly by GERI Assess software, using bright-field imaging. Finally the embryo(s) with the highest EEVA grade are transferred were followed up until the achievement of implantation and confirmation of pregnancy.
75723238|NCT00881166|Drug|MP-470 + carboplatin/etoposide|Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
76046406|NCT02233803|Drug|SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler|Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
76046407|NCT02233803|Drug|NEUMOTEX 400 (Budesonide 400 mcg)|Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
75424102|NCT04165408|Device|Contino|The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
75424103|NCT04135937|Drug|Bupropion|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
75570108|NCT00533091|Biological|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
75570109|NCT00533091|Other|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
75570110|NCT00536042|Drug|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
75570111|NCT01606384|Drug|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
75570112|NCT01606384|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
75424104|NCT04135937|Drug|Varenicline|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
75570113|NCT01606423|Drug|Placebo|Administered orally, single dose
75570114|NCT01606423|Drug|LY2409021|Administered orally, single dose
75570115|NCT01606462|Drug|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
75570116|NCT00533130|Procedure|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
75570117|NCT00533130|Procedure|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
75570118|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition."
75723239|NCT00804752|Drug|Adding vitamin D|Adding 1000IU/Vitamin D daily
75723240|NCT00804752|Drug|Vitamin D|Addition of 1000IU/day Vitamin D
75723241|NCT05225766|Other|bupivacaine|used for peripheral block
75723242|NCT00804830|Drug|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
75723243|NCT00982215|Drug|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
75723244|NCT00982215|Drug|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
75424105|NCT04135937|Behavioral|Cognitive Behavioral Therapy|Behavioral intervention; modules include identifying reasons for quitting, setting a quit date, breathing relaxation technique, identifying smoking triggers, identifying social support, and education about relapse prevention
75424106|NCT04135937|Drug|Nicotine Replacement Therapy|Participants may be prescribed single-formulation NRT (i.e., nicotine patch) or dual NRT (patch + rescue method such as nicotine gum, inhaler, or lozenges).
75424107|NCT04135937|Behavioral|Relapse Prevention Text Messaging|Participants will be invited to utilize SmokefreeVET, a mobile text messaging service for military Veterans trying to quit smoking. The 6- to 8-week program provides 24/7 encouragement, advice, and tips to help smokers quit smoking and stay quit.
75424108|NCT04135703|Behavioral|Risk Prevention Services + Housing|opioid and related prevention services in addition to 6 months of rental assistance
75424109|NCT04135703|Behavioral|Risk Prevention Services Only|opioid and related prevention services for 6 months
75424110|NCT04134754|Other|6% Carbon dioxide/50% oxygen/balance nitrogen mixture|In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
75424111|NCT04126070|Drug|Androgen Deprivation Therapy|Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
75570119|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery."
75570120|NCT01606579|Drug|PRI-724|PRI-724
75570121|NCT01606579|Drug|PRI-724|PRI-724 in combination with dasatinib
75570122|NCT01606579|Drug|PRI-724|PRI-724 in combination with low dose ara-C therapy
75570123|NCT00533169|Drug|ZD6474|Part A = Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m^2 by mouth daily on days 2-28.
75570124|NCT00533169|Drug|Retinoic Acid|Part B, C = 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
75570125|NCT01606696|Behavioral|HIIT|Higher intensity interval training.
75570126|NCT01606696|Behavioral|Standard intensity non-interval training|Standard intensity non-interval training.
75570127|NCT00593632|Dietary Supplement|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
75570128|NCT00533208|Drug|MK0524|
75570129|NCT00593671|Procedure|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
75723245|NCT00873678|Biological|Whole blood sample|Whole blood sample (10 ml)
75723246|NCT00798044|Behavioral|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
75424112|NCT04126070|Drug|Nivolumab|Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
75424113|NCT04126070|Drug|Docetaxel|Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
75723247|NCT00798044|Behavioral|Patient Feedback|Weekly feedback reports provided to counselors
75723248|NCT00978705|Drug|Autologous cultured keratinocyte cell|3x10^7 cell/ vial
75723249|NCT00805922|Other|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
75424114|NCT04120987|Drug|Lifitegrast 5% Ophthalmic Solution|BID OU
75424115|NCT04118530|Other|HSCT Patients|Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
75570130|NCT02892721|Other|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
75723250|NCT00978783|Device|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
75570131|NCT00593710|Drug|Losartan|Losartan (25mg OD)
75570132|NCT00593710|Drug|Atenolol|Atenolol (25-50mg OD)
75570133|NCT04885686|Device|Endomethasone N RCS|Root canal sealer
75723251|NCT00978783|Device|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
75723252|NCT00982293|Device|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
75723253|NCT00982293|Device|Resonator device - sham|"Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on"
75723254|NCT02553278|Device|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
75723255|NCT02553278|Device|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
75723256|NCT00613938|Drug|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
75723257|NCT00613938|Drug|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
75723258|NCT00613938|Drug|oxycodone|10mg capsule q4-6 hrs for 3 days
75723259|NCT00613938|Drug|placebo|1 capsule q4-6 hrs for 3 days
75723260|NCT00978861|Drug|Hydrogen Peroxide|Whitening product syringe type
75723261|NCT00805064|Drug|triamcinolone and bevacizumab|
75424116|NCT04106102|Device|Transcramial Direct current stimulation|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
75424117|NCT04106102|Device|Placebo|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
75424118|NCT04101110|Other|Renal biopsy|Kidney biopsy will be done to understand the nature and degree of structural kidney damage
75570134|NCT04885686|Device|Endomethasone SP RCS|Root canal sealer
75570135|NCT00593749|Behavioral|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
75876851|NCT03164551|Device|Conventional incubator|The embryo culture of consented participants were carried out in conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade were transferred and were followed up until the achievement of implantation and confirmation of pregnancy.
75876852|NCT02863328|Drug|semaglutide|Oral administration once-daily.
75876853|NCT02863328|Drug|empagliflozin|Oral administration once-daily.
76046408|NCT02233803|Drug|Salbutamol 100 mcg pMDI|Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
76046409|NCT02233647|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
76046410|NCT02233647|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
76046411|NCT02233413|Device|Active LLLT helmet application|LED helmet applied with light activated
76046412|NCT02233413|Device|Non-active LLLT helmet application|LED helmet applied without light activated
76046413|NCT04778631|Device|Heat therapy|Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
76046414|NCT04778631|Device|Cryotherapy|Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
76046415|NCT01632579|Drug|LY3023703|Administered orally
76046416|NCT01632579|Drug|Placebo|Administered orally
76046417|NCT01632579|Drug|Celecoxib|Administered orally
75570136|NCT00593749|Behavioral|Control|control group in study
75570137|NCT00536081|Drug|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
75570138|NCT02892643|Procedure|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
75570139|NCT02892643|Procedure|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
75876854|NCT03040141|Drug|Low dose of VIS410|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
76046418|NCT01632345|Drug|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
76046419|NCT01632345|Drug|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
76046420|NCT01632345|Drug|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
76046421|NCT01632345|Drug|Placebo for Doravirine|Placebo tablets matching doravirine
76046422|NCT01632345|Drug|Placebo for Efavirenz|Placebo tablets matching efavirenz
76046423|NCT02232243|Drug|Hydroxychloroquine, 200mg twice dailiy|Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.
76046424|NCT02232243|Drug|Hydroxychloroquine, 400mg twice daily|Hydroxychloroquine, 400mg twice daily (800mg/day total) was given to subjects for up to 14 days prior to surgery.
75570140|NCT00593944|Biological|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
75876855|NCT03040141|Drug|High dose of VIS410|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
75876856|NCT03040141|Drug|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
75876857|NCT02033564|Device|Macintosh/Miller Laryngoscope|
75876858|NCT02033564|Device|Glidescope Laryngoscope|
75876859|NCT02937701|Biological|ABP 710|Administered by intravenous infusion
75876860|NCT02937701|Biological|Infliximab|Administered by intravenous infusion
75876861|NCT05186623|Drug|Vedolizumab, Ustekinumab, or Tofacitinib|Drug administration and prospective follow-up for evaluating response
76046425|NCT04776837|Behavioral|Observational Cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
76046426|NCT02205333|Biological|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
76046427|NCT02205333|Biological|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
76046428|NCT02205333|Biological|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
76046429|NCT02205333|Biological|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
76046430|NCT04776369|Drug|Lidocaine IV|single-bolus of lidocaine IV 4 mg/kg
76046431|NCT04776369|Drug|Magnesium Sulfate Injection|single-bolus of magnesium sulfate IV 30 mg / kg
76046432|NCT04776369|Drug|IV saline|Saline IV 50 ml
76046433|NCT02230683|Drug|IDN-6556|25 mg BID
76046434|NCT02230527|Drug|Ticagrelor|90mg twice a day by mouth
76046435|NCT02230527|Drug|Clopidogrel|75mg once a day by mouth
76046436|NCT02204319|Device|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
76046437|NCT02204007|Device|3D imaging & surrogate bone model|3D imaging & surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
75723262|NCT04007445|Behavioral|Formally Directed Group (Exercise Group)|This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
75723263|NCT04007445|Other|Self-Directed Group (Control Group)|This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
75570141|NCT00536159|Other|Medicaid Maternal and Infant Support Services|Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
75723264|NCT00881244|Drug|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
75723265|NCT00655928|Drug|N-acetylcysteine|N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
75723266|NCT00655928|Drug|0.9% saline|0.9% saline 1 litre intravenous over 12 hours pre-operatively
75570142|NCT00536159|Other|Nurse-CHW team|A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
75570143|NCT00594139|Biological|Autologous neobladder construct|provision of an autologous neo-bladder construct
75570144|NCT04882449|Device|Bodyport Scale|The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
75723267|NCT04038762|Procedure|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
76046438|NCT02203851|Drug|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
75424119|NCT04089059|Device|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor~Cordella Delivery System~myCordella Patient Reader~Reader Dock~Cordella Calibration Equipment (CalEQ)~myCordella Hub~Cordella Data Analysis Platform (CDAP)"
75424120|NCT04060147|Drug|Cilofexor|Tablets administered orally once daily
75570145|NCT00594217|Drug|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
75570146|NCT00594217|Other|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
75570147|NCT01606774|Other|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
75570148|NCT00536237|Drug|Comparator: niacin / Duration of Treatment: 17 Weeks|
75424121|NCT04038567|Behavioral|Mobile mindfulness-based training|The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 8 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
75424122|NCT04031014|Device|BTL EMSELLA Active treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 100% for active treatment
75424123|NCT04031014|Device|BTL EMSELLA Sham Treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 5% for sham treatment
75570149|NCT00536237|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
75723268|NCT00805220|Other|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
75570150|NCT00536237|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
75723269|NCT00798200|Other|Exercise program|All exercise programs will include endurance and strength exercises.
75570151|NCT01606813|Other|Usual Care|Standard care
75570152|NCT01606813|Behavioral|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
75723270|NCT00873756|Drug|FOLFOX regimen|Intravenous repeating dose
75723271|NCT00873756|Drug|bevacizumab|Intravenous repeating dose
75723272|NCT00873756|Drug|dulanermin|Intravenous repeating dose
75876862|NCT01330849|Behavioral|ADHD Toolkit|For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.
75876863|NCT01330849|Other|Waiting List Control group|Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
75876864|NCT04602845|Drug|Fentanyl|50ug Fentanyl intravenously
76046439|NCT02228967|Behavioral|SBIRT|"SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk."
75570153|NCT01606813|Behavioral|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
75570154|NCT01606813|Behavioral|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
75876865|NCT04602845|Drug|Flurbiprofen|50mg Fentanyl intravenously
75876866|NCT04602845|Drug|Midazolam|2.5mg midazolam in 2ml normal saline intravenously
75876867|NCT04602845|Drug|Remimazolam|3mg Remimazolam in 2ml normal saline intravenously
75876868|NCT01330927|Drug|VA106483|"Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above"
75570155|NCT04874376|Device|IOL implantation experimental (Isopure 1.2.3.)|Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection
75570156|NCT00533247|Drug|Celecoxib|
75570157|NCT01260181|Drug|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
75570158|NCT00536276|Dietary Supplement|Vitamin D2|Daily enteral dose of 100IU/kg
75570159|NCT00536276|Dietary Supplement|Vitamin D3|Daily enteral dose of 100IU/kg
75876869|NCT04966325|Drug|LC350189 200mg|Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
75570160|NCT02892565|Other|Blood sample|
75876870|NCT04966325|Drug|Placebo|Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
75876871|NCT04966325|Drug|Moxifloxacin 400mg|Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
75876872|NCT04966325|Drug|LC350189 600mg|Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
75876873|NCT05096377|Other|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
76046440|NCT03155061|Drug|ONO-4578|ONO-4578 specified dose on specified days
76046441|NCT03155061|Drug|ONO-4538|ONO-4538 specified dose on specified days
75876874|NCT03169153|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
76046442|NCT02985411|Behavioral|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
76046443|NCT02985411|Other|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
76046444|NCT02227875|Drug|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
76046445|NCT02227875|Drug|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
76046446|NCT02203149|Drug|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
75424124|NCT04023591|Procedure|Surgery/Occupational Therapy|Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
75424125|NCT04019093|Drug|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
75424126|NCT04019093|Other|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
75424127|NCT04019041|Drug|bermekimab|bermekimab 2 mL (200 mg/mL) pre-filled syringe
75424128|NCT04019041|Drug|placebo|placebo 2 mL pre-filled syringe
75424129|NCT04018092|Device|Active NIR-PBM|See Experimental arm for description.
75876875|NCT03169153|Device|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
76046447|NCT02203149|Drug|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
76046448|NCT02203149|Drug|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
76046449|NCT02203149|Drug|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
75424130|NCT04018092|Device|Sham NIR-PBM|See Sham Comparator arm for description.
75424131|NCT04013399|Device|Continuous Positive Airway Pressure|The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.
75424132|NCT04011891|Procedure|Robotic Partial Nephrectomy|Robotic partial nephrectomy using da Vinci robot.
76046450|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
75424133|NCT04011891|Procedure|Open Partial Nephrectomy|Standard open partial nephrectomy
75424134|NCT03988439|Drug|IDP-118 Lotion|Topical
75570161|NCT02690064|Dietary Supplement|Acute Antioxidant|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
75570162|NCT02690064|Dietary Supplement|Chronic Antioxidant|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
75570163|NCT02690064|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
75876876|NCT03168919|Radiation|Fractionated Radiation|Standard of care fractionated radiation therapy will be given to the tumor.
75424135|NCT03975946|Procedure|Rheopheresis procedure|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
75424136|NCT03975946|Biological|Blood Sample|Biological analysis
75570164|NCT00594373|Drug|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
75876877|NCT03168919|Drug|Temozolomide|Standard of care temozolomide will be given along with radiation therapy
76046451|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
76046452|NCT02202759|Drug|MLN0264|MLN0264 IV infusion
76046453|NCT02226549|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
76046454|NCT02226549|Drug|VDV|VDV 80 mg tablet administered orally once daily
76046455|NCT02226549|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76046456|NCT02226003|Drug|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
76046457|NCT02226003|Drug|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
75723273|NCT00798278|Drug|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
75876878|NCT03168919|Device|MRI|Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
75876879|NCT05089669|Other|Interactive e-book|The nasogastric tube feeding interactive e-book has a lot of elements such as text content, videos, pictures, links, and other interactive content with which the students can interact. The participants can use the interactive e-book to learn nasogastric tube feeding.
75424137|NCT03975946|Procedure|Shamapheresis procedure|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
75876880|NCT05089669|Other|paper textbook|The paper textbook has text content and pictures. The participants can use the paper textbook to learn nasogastric tube feeding.
75876881|NCT05080387|Other|Blood sample|Blood samples will obtained for measurement of neopterin level through ELIZA
75876882|NCT04108819|Dietary Supplement|Ketogenic Diet|Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
75424138|NCT03974958|Genetic|Tissue-library|circulating biomarkers (miRNA panel) analysis of blood samples
75424139|NCT03956745|Behavioral|sleep-wake timing|Study participants will have one inverted day when they are scheduled to sleep ~12h opposite their usual sleep time.
75723274|NCT00798278|Procedure|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
75723275|NCT00873834|Drug|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
75424140|NCT03956745|Behavioral|constant routine|Study participants will spend ~28-50 hours awake, inactive, sitting in bed, in constant lighting and temperature.
75723276|NCT00873834|Drug|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
75723277|NCT00873990|Other|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
75723278|NCT00873990|Other|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
75723279|NCT00655850|Drug|Paclitaxel|"Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~Dexamethasone 20mg, intravenously (IV)~Diphenhydramine 50 mg IV~Ranitidine 50 mg IV~Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~Dose Level 1 ________80 mg/m2/weekly~Dose Level -1 ________70 mg/m2/weekly"
75876883|NCT03205163|Biological|Advate (Low Dose)|Participants received a single IV low dose of Advate 25 IU/kg.
75876884|NCT03205163|Biological|Advate (High Dose)|Participants received a single IV high dose of Advate 65 IU/kg.
75876885|NCT03205163|Biological|BIVV001 (Low Dose)|Participants received single IV low dose of BIVV001 25 IU/kg.
75876886|NCT03205163|Biological|BIVV001 (High Dose)|Participants received single IV high dose of BIVV001 65 IU/kg.
75424141|NCT03954002|Diagnostic Test|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
75723280|NCT00655850|Drug|Gemcitabine|"Premedication~Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~Prior to receiving paclitaxel chemotherapy~Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~Dose Level 2 ________300 mg/m2/weekly~Dose Level 1 ________200 mg/m2/weekly~Dose Level -1 ________150 mg/m2/weekly"
75723281|NCT00655850|Biological|Avastin|"The dose of Avastin is 10 mg/kg IV every 2 weeks~It will be administered following the administration of chemotherapy~The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~It should not be administered or mixed with dextrose solutions."
75570165|NCT00594373|Drug|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
75723282|NCT00881322|Dietary Supplement|BC-130 (Gas Defense)|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish."
75723283|NCT00881322|Dietary Supplement|Placebo|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD&C yellow #5 Lake, FD&C blue #1 Lake, FD&C red #46 Lake and vegetable capsule"
76046458|NCT02226003|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
75424142|NCT03938532|Device|Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
75424143|NCT03938532|Device|Tidal Volume Measurement using the Philips Respironics NM3 monitor|Tidal Volume Measurement using the Philips Respironics NM3 monitor
75723284|NCT02553434|Device|Pigtail catheter|Insertion of pigtail catheter
75570166|NCT00594412|Procedure|Diagnostic Radiology: 1H-MRS of the liver|
75570167|NCT02892799|Other|NICOM-Guided Diuresis|NICOM-based assessment of PLR-induced change in cardiac index
75723285|NCT04038918|Other|progressive muscle relaxation exercise|In addition to standard postoperative rehabilitation, intervention group will receive PMR exercises focusing on reduce overall body tension, anxiety. The intervention group will perform the PMR exercise in accompanying with a qualified physiotherapist for postoperative 3 days (2 times/day; along 30 minutes for one session).
76046459|NCT02226003|Drug|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
76046460|NCT02226003|Drug|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
75424144|NCT03936465|Drug|BMS-986158|BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
75424145|NCT03936465|Drug|BMS-986378|BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
75424146|NCT03936062|Drug|Sitagliptin|Sitagliptin dispensing claim is used as the exposure
75424147|NCT03936062|Drug|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
75424148|NCT03936049|Drug|Liraglutide|Liraglutide dispensing claim is used as the exposure group
75424149|NCT03936049|Drug|DPP-4 inhibitor|DPP-4 inhibitor dispensing claim is used as the reference group
75570168|NCT02892799|Other|Standard of Care|
75570169|NCT05470166|Drug|Lidocaine IV|lidocaine infusion as bolus 1.5mg/kg then 2mg/kg/hr
75570170|NCT05470166|Other|saline IV|saline infusion same volume as lidocaine
75570171|NCT00594529|Procedure|Surgery|Liver resection for metastatic liver lesions
75570172|NCT05470127|Device|Prostate biopsy needle|Prostate tissue biopsy with a biopsy needle
75570173|NCT05470049|Drug|SHR8554 Injection and SHR0410 Injection|Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose
75570174|NCT05470049|Drug|SHR8554 Injection and SHR0410 Injection|Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose
75570175|NCT05470049|Drug|SHR8554 Injection and Placebo for SHR0410 Injection|Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection
75570176|NCT02412579|Other|None - Standard of Care|
76046461|NCT02225223|Device|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
76046462|NCT02225223|Device|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
75424150|NCT03936036|Drug|Linagliptin|Linagliptin dispensing claim is used as the exposure
75424151|NCT03936036|Drug|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
75424152|NCT03936010|Drug|Canagliflozin|Canagliflozin dispensing claim is exposure
75424153|NCT03936010|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
76046463|NCT02469519|Drug|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
76046464|NCT02469519|Other|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
76046465|NCT01634139|Drug|Tiotropium low dose QD|2 actuations once daily in the evening
75424154|NCT03930849|Behavioral|AIMS|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
75424155|NCT03930849|Behavioral|AIMS plus|Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
75424156|NCT03930381|Other|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
75424157|NCT03921541|Drug|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
75424158|NCT03921541|Drug|Placebo|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
75876887|NCT01781143|Device|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
76046466|NCT01634139|Drug|Tiotropium high dose QD|2 actuations once daily in the evening
76046467|NCT01634139|Drug|Placebo|2 actuations once daily in the evening
76046468|NCT02224755|Device|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
76046469|NCT02224755|Device|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
76046470|NCT02404441|Biological|PDR001|anti-PD1 antibody
76046471|NCT02101281|Drug|rhNGF 20 µg/mL|1 drop for each eye, twice daily for 28 day
76046472|NCT02101281|Drug|rhNGF 4 µg/mL|1 drop each eye, twice daily for 28 day
76046473|NCT02224599|Biological|TAPA-pulsed DC vaccine|Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
76046474|NCT02224599|Drug|Cyclophosphamide Pill|Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
76046475|NCT02224599|Drug|Imiquimod Topical Cream|Topical Imiquimod Cream will be applied after vaccination.
76046476|NCT02201901|Drug|SOF/VEL|400/100 mg tablets administered orally once daily
75424159|NCT03919448|Biological|Bevacizumab|Single-dose infusion
75570177|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
75570178|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
75570179|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
75570180|NCT01259869|Drug|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
75876888|NCT03681145|Behavioral|Counselor delivered telehealth intervention|This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
75570181|NCT05469932|Device|Rexon device|Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
75570182|NCT00594607|Device|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
75570183|NCT00594607|Device|Fx8 (Fresenius)|Polysulphone dialysis membrane
75570184|NCT02116335|Drug|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
75570185|NCT02116335|Drug|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
75570186|NCT05469776|Procedure|bicruciate-retaining total knee arthroplasty|
75570187|NCT05469776|Procedure|posterior-stabilized total knee arthroplasty|
75723286|NCT04038918|Other|standard postoperative physiotherapy program|After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.
75723287|NCT02553122|Drug|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
75723288|NCT02553122|Device|tourniquet|A tourniquet is applied to the thigh to stop/ decrease blood flow
75723289|NCT00874068|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
75723290|NCT00874068|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
75723291|NCT00805298|Drug|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
75723292|NCT00805298|Drug|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
76046477|NCT02201901|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76046478|NCT04775043|Diagnostic Test|HFRDIS questionnaire completion|HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
76046479|NCT02201277|Device|Filter Placed|
76046480|NCT02224053|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
75424160|NCT03904615|Dietary Supplement|Whey Protein|30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
75424161|NCT03904615|Dietary Supplement|Collagen Protein|30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
76046481|NCT02224053|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
75424162|NCT03904615|Dietary Supplement|Placebo|30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge
75424163|NCT03900637|Drug|Leuprorelin acetate|In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
75424164|NCT03900637|Drug|Letrozole|2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
75424165|NCT03900637|Genetic|MammaPrint|In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
75570188|NCT05469659|Drug|Tofogliflozin|Tofogliflozin 20 mg is orally administered once daily for 104 weeks before or after breakfast.
75570189|NCT05469659|Drug|Metformin|Metformin is started at 500 mg daily and orally administered in 2 to 3 divided doses immediately before or after meals. The dose during the maintenance period is determined by observing the effect, but is usually 750 to 1,500 mg daily. Metformin is orally administered for 104 weeks throughout post-start period. The dose may be adjusted according to the patient's condition, but the maximum daily dose should be 2,250 mg.
75570190|NCT04686006|Drug|Potassium Iodide|
75570191|NCT05469620|Dietary Supplement|Meal|Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.
75723293|NCT00805298|Drug|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
75723294|NCT00805298|Drug|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
75723295|NCT00726323|Drug|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
75723296|NCT00881400|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
75723297|NCT00881400|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
76046482|NCT02224053|Drug|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
76046483|NCT02224053|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
76046484|NCT04774731|Other|Whole Body Vibration|Receiving WBV training three times a week before initiation of dialysis sessions for 12 weeks. Subjects stand on a platform of WBV for 3 minutes in every training session.
76046485|NCT04774107|Drug|P1101 + Ribavirin|P1101 400 µg SC
76046486|NCT02457793|Drug|Cobimetinib|Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
75570192|NCT05469620|Other|Education|Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.
75570193|NCT00535704|Behavioral|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
76046487|NCT02457793|Drug|GDC-0994|GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
75723298|NCT00805376|Drug|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
75424166|NCT03893045|Drug|ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
75723299|NCT00805376|Procedure|Tumor Removal|Surgical Tumor Resection
75723300|NCT00246571|Drug|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
75424167|NCT03893045|Drug|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
75876889|NCT01759537|Device|Ankylos dental endosseous implants-Sub-crestal|Implants placed subcrestally
75876890|NCT01759537|Device|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
75876891|NCT04859075|Other|Bifidobacterium longum 35624|1 capsule daily
75876892|NCT03204539|Drug|Wilate|Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
75876893|NCT01331317|Drug|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
76046488|NCT01650259|Drug|OAD|OAD except Trazenta tablets
76046489|NCT01650259|Drug|Trazenta|Linagliptin
76046490|NCT04908085|Behavioral|Occupational Performance Coaching|Six sessions of OPC delivered by telephone over 10 weeks.
75424168|NCT03878407|Other|Monitoring of ARCH variants|Blood samples will be tested for mutations, before patients are given Standard of Care chemotherapy/radiation or after given Standard of Care chemotherapy/radiation. Another testing is done after 3 months and after 1 year if positive for ARCH.
75424169|NCT03877354|Other|Data from anaesthesia records for ventilation setting screening|Data from anaesthesia records will be retrospectively screened for the ventilation settings
75570194|NCT00535704|Behavioral|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
75570195|NCT05469542|Device|Everbeat Ring|The primary objective of this study is to assess the concordance of specific ECG parameters obtained in the everbeat nine-lead ECG waveform with those obtained in the comparable leads from a standard 12-lead ECG recorder.
75570196|NCT01808820|Biological|Dendritic Cell Vaccine|Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.
75876894|NCT03638947|Device|Swab and decolonization using povidone-iodine cleansing|Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
75876895|NCT01722019|Device|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
75424170|NCT03877354|Other|Data from intensive care records for ventilation setting screening|Data from paediatric intensive care charts will be retrospectively screened for the ventilation settings
75876896|NCT01722019|Device|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
75876897|NCT01666873|Procedure|patients that undergo a total knee prosthesis|
75424171|NCT03867344|Other|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.
75876898|NCT03502681|Drug|Eribulin Mesylate|"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m^2;~Dose level 0: 1.1 mg/m^2;~Dose level +1: 1.4 mg/m^2"
75876899|NCT03502681|Drug|Avelumab|Days 1, 15 Avelumab (10mg/kg)
75876900|NCT02860130|Drug|Prismocitrate 18|Modality of CVVHDF
75876901|NCT02860130|Other|No Anticoagulation|Modality of CVVHDF
75424172|NCT03867344|Other|Normoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
75424173|NCT03865836|Biological|ATB200|
75570197|NCT01808820|Biological|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
75424174|NCT03865836|Drug|AT2221|
75570198|NCT01808820|Drug|Imiquimod|5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
75570199|NCT01808820|Procedure|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
75723301|NCT00246571|Drug|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~Docetaxel - 75-100 mg/m2 every 3 weeks~Paclitaxel - 175-200 mg/m2 every 3 weeks~Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
75723302|NCT00805454|Drug|OPC-34712|Single oral dose, 0.5 to 25 mg
75876902|NCT05051605|Biological|COVID-19 Vaccine|Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.
75570200|NCT05469386|Drug|Methylphenidate Hydrochloride ER|Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)
75570201|NCT05469386|Behavioral|Behavioral classroom|Enhanced positive behavior supports implemented in classroom
75424175|NCT03832985|Genetic|Receive an adult-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
75424176|NCT03832985|Genetic|Receive a pediatric-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
75424177|NCT03832985|Genetic|Control - No Result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have not received an adult-onset genomic result.
75424178|NCT03821272|Biological|PepCan|50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
75424179|NCT03821272|Biological|Placebo|0.9% Saline solution per dose administered intradermally in the extremities
75424180|NCT03818737|Biological|Bone Marrow Derived MSCs|Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis. The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
75570202|NCT05469386|Drug|Placebo|Placebo capsule
75570203|NCT05469386|Behavioral|General Classroom|General education classroom procedures
75570204|NCT05469386|Behavioral|Academic Accommodations|Accommodations are introduced to support the child's independent seat work completion and quiz scores
75570205|NCT01462890|Biological|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
75570206|NCT01462890|Drug|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
75570207|NCT01462890|Drug|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
75570208|NCT01462890|Other|specialized pathology review (Germany only)|before randomization
75723303|NCT02553356|Drug|PT2385|
75723304|NCT00805610|Biological|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
75876903|NCT04938817|Biological|coformulation pembrolizumab/quavonlimab|Intravenous (IV) infusion
75876904|NCT04938817|Drug|lenvatinib|Oral administration
75876905|NCT04938817|Biological|MK-4830|IV infusion
75876906|NCT04938817|Biological|coformulation favezelimab/pembrolizumab|IV infusion
76046491|NCT02434939|Drug|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
76046492|NCT02434939|Drug|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
75723305|NCT00798356|Other|Yoga training|Yoga training for 12 weeks
75723306|NCT00734591|Drug|Exubera|Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
75723307|NCT00734591|Other|Randomized diabetes therapy|"Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.~Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice)."
75723308|NCT02554058|Device|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
75723309|NCT00798512|Device|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
75723310|NCT00798668|Dietary Supplement|Liquid Supplements|Liquid supplement that provides 12.5% of the subjects total energy requirement.
75723311|NCT00798668|Dietary Supplement|Solid Supplement|Solid supplement that provides 12.5% of the subjects total energy requirement.
75723312|NCT02553044|Dietary Supplement|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
75723313|NCT00569270|Drug|Placebo|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
75723314|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
75723315|NCT00545103|Drug|SPD476, MMX™ mesalazine, 2.4g extended release tablet|SPD476 2.4g administered Once Daily (QD)
75723316|NCT00545103|Drug|SPD476, MMX™ mesalazine, 4.8g extended release tablet|SPD476 4.8g administered Once Daily (QD)
75723317|NCT00545103|Drug|Placebo|Placebo administered Once Daily (QD)
75723318|NCT00586157|Drug|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
75723319|NCT00586157|Drug|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
75723320|NCT00809432|Device|Face mask (Dust Respirator)|Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
75723321|NCT00809432|Other|No Face mask|Subjects will not wear a face mask to reduce their personal exposure to air pollution
75723322|NCT02595125|Device|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
75723323|NCT02552654|Behavioral|Stress Film|Film scene with severe physical and sexual violence.
75723324|NCT02552654|Drug|Hydrocortisone|10mg
75723325|NCT02552654|Drug|Placebo|
75723326|NCT04045574|Procedure|The 1T1T concept versus conventional implant loading protocol|Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
75723327|NCT00809666|Device|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
75723328|NCT00978939|Other|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
75570209|NCT05469152|Diagnostic Test|ds-MCE and EGD|"Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
75570210|NCT05469113|Drug|Repaglinide|Administered orally.
75570211|NCT05469113|Drug|Selpercatinib|Administered orally.
75570212|NCT01259713|Drug|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
75723329|NCT00978939|Other|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
75723330|NCT00809744|Drug|cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration
76046493|NCT02434471|Device|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~Respiratory-triggered T1w DISCO LAVA precontrast~Respiratory-triggered T1w DISCO LAVA in the portal venous phase~Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
76046494|NCT02457637|Other|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
76046495|NCT02457325|Drug|Surgery with 2%Articaine first, then Surgery with 4% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
76046496|NCT02457325|Drug|Surgery with 4%Articaine first, then Surgery with 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
75570213|NCT01259713|Drug|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
75570214|NCT00594724|Procedure|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
76046497|NCT02434081|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
75723331|NCT00809822|Drug|NPB-01|Intravenous immunoglobulin
75723332|NCT00809822|Drug|Placebo|Physiological saline
75723333|NCT04006587|Device|incentive spirometer|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
75723334|NCT00246337|Drug|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
75570215|NCT00622882|Other|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
75570216|NCT01052727|Procedure|Laparoscopic Cholecystectomy|
75570217|NCT00622921|Behavioral|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
75723335|NCT00246337|Drug|MK0974|MK0974 25 mg; one orally-administered dose
75723336|NCT00246337|Drug|MK0974|MK0974 50 mg; one orally-administered dose
75723337|NCT00246337|Drug|MK0974|MK0974 100 mg; one orally-administered dose
76046498|NCT02222493|Biological|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
75723338|NCT00246337|Drug|MK0974|MK0974 200 mg; one orally-administered dose
75723339|NCT00246337|Drug|MK0974|MK0974 300 mg; one orally-administered dose
75723340|NCT00246337|Drug|MK0974|MK0974 400 mg; one orally-administered dose
75570218|NCT05469035|Other|Mobile-based video|Nurses in the experimental group participated in mobile-based video learning.
75723341|NCT00246337|Drug|MK0974|MK0974 600 mg; one orally-administered dose
75723342|NCT00246337|Drug|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
75570219|NCT05469035|Other|Face-to-face|Nurses in the experimental group participated in face-to-face learning.
75570220|NCT02892526|Other|Abdominoplasty with exeresis of cutaneous tissue|
75723343|NCT02552576|Biological|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
75570221|NCT02892526|Other|Collection of cutaneous tissue|
75723344|NCT00809900|Dietary Supplement|Experimental|Administration of of 480 mL cranberry juice
75723345|NCT01581853|Drug|Lopinavir/ritonavir 800 mg / 200mg|Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
76046499|NCT02222493|Biological|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
75723346|NCT02594969|Other|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
75723347|NCT00798746|Behavioral|Telephone Questionnaire|Ten questions regarding symptoms of reflux
75723348|NCT01070641|Drug|Carvedilol|Carvedilol 12.5mg QD
76046500|NCT02433379|Device|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
75876907|NCT04114994|Diagnostic Test|Boston Cognitive Assessment (BoCA)|"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.~BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.~After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts."
75570222|NCT01259401|Behavioral|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
75723349|NCT01070641|Procedure|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
75876908|NCT01366729|Device|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
75876909|NCT01366729|Device|Cane walking|All walking activities must take place with cane from waking until sleeping
75876910|NCT04485325|Drug|Tofacitinib|5 mg twice daily, p.o.
75876911|NCT04485325|Biological|Etanercept|50 mg once per week, s.c.
75876912|NCT03610178|Other|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.1 mmol/L fasting and <7.0 mmol/L postprandial) are not achieved insulin therapy is started
75424181|NCT03818737|Biological|Adipose-derived MSCs|Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
75424182|NCT03818737|Biological|Umbilical Cord Tissue (UCT) MSCs|Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
75570223|NCT01259401|Behavioral|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
75723350|NCT00982449|Other|FIAU-PET-CT-2|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
75723351|NCT00982449|Other|FIAU-PET-CT-4|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
75723352|NCT02593721|Procedure|Median Nerve Neural Mobilization|Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
75723353|NCT02593721|Drug|Ibuprofen|The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
75723354|NCT00798824|Procedure|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
75723355|NCT00798824|Procedure|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
75876913|NCT03610178|Other|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.3 mmol/L fasting and <7.8 mmol/L postprandial) are not achieved insulin therapy is started
75876914|NCT02033798|Drug|Tamsulosin|Once Daily 0.2mg per oral for 6 months
75876915|NCT03609632|Other|Dietary Supplement: Glucose|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
75570224|NCT05471466|Procedure|Surgical incision|Surgical incisions to the neck as part of the management of the head and neck condition.
75570225|NCT00594841|Procedure|Open Reduction Internal Fixation of AC joint dislocation|"Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~Anatomic reduction of the AC joint~Definitive fixation with a hook plate and screws"
75424183|NCT03818737|Drug|Corticosteroid injection|The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
75723356|NCT00798824|Device|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
75723357|NCT00798824|Device|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
75723358|NCT00798902|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
75723359|NCT00798902|Other|Iliac crest autograft|autograft
75723360|NCT00979173|Drug|AC480|Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
75723361|NCT00985647|Drug|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
75723362|NCT00806468|Drug|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
75723363|NCT00982527|Drug|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
75723364|NCT00982527|Drug|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
75424184|NCT03801785|Other|Pacifier|The pacifiers used in this clinical trial have the same shape and material. They are produced by Artsana S.P.A. for soothing children. As such, the FDA has no jurisdictions over pacifiers (US FDA regulations May 15, 2012 https://www.fdaimports.com/blog/pacifiers-fda-change-abi-system/) because they are not medical devices intended for teething.
75424185|NCT03795922|Drug|MT10109L|MT10109L will be injected into the GL.
75424186|NCT03795922|Drug|Placebo|Placebo will be injected into the GL.
75723365|NCT00798980|Drug|Mirena (BAY86-5028)|Nulliparous Women
75723366|NCT00243919|Behavioral|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
75876916|NCT04491110|Other|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.
75570226|NCT00594841|Other|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
75570227|NCT05468879|Drug|Glimepiride|Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
75570228|NCT05468879|Drug|Amaryl®|Amaryl®
75723367|NCT00243919|Behavioral|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
75723368|NCT00243919|Behavioral|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
75723369|NCT00725621|Biological|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
75570229|NCT05471427|Drug|Taxane chemotherapy|Patients underwent taxane chemotherapy according to clinical practice for metastatic prostate cancer
75723370|NCT00613626|Drug|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
75876917|NCT04491110|Other|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
75723371|NCT00613626|Drug|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
75876918|NCT02986854|Biological|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
75876919|NCT02887183|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
75570230|NCT04130074|Device|duplex doppler ultra sound and CT|graded compression US done in different positions then take MSCT with contrast on abdomen to compare with
75570231|NCT00536354|Other|Postural Orientation|
75570232|NCT04320433|Diagnostic Test|Oral glucose tolerance test|Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
75570233|NCT05471388|Diagnostic Test|serum asprosin|assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
75723372|NCT00613626|Drug|Placebo|Matched placebo oral daily
75876920|NCT03167359|Radiation|Hypofractionated Simultaneous Integrated Boost Radiotherapy|Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.
75876921|NCT03658356|Other|Video instructions|Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
75876922|NCT03660462|Dietary Supplement|FeSO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
75876923|NCT03660462|Dietary Supplement|FePO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
75424187|NCT03794089|Behavioral|Brief anxiety intervention|Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills
75570234|NCT05558449|Device|Hypnosedation|"Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
75570235|NCT05558449|Drug|Midazolam injection|Midazolam intravenous injection 1 mg until RASS -3
75570236|NCT05558449|Device|Virtual reality|"Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
75424188|NCT03794089|Behavioral|Usual PC-MHI care|Anxiety treatment with mental health provider in local primary care clinic
75424189|NCT03789149|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
75570237|NCT04326907|Procedure|Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy|Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
75570238|NCT05468801|Other|Individualized Homeopathic Remedy|An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.
75570239|NCT05468801|Other|Placebo|Placebo plus Standard Pharmacologic Treatment
75570240|NCT04326946|Device|Alfapump|alfapump implementation
75570241|NCT04326985|Biological|Autologous Mesenchymal Stem Cells Treatment (MSCs)|The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.
75570242|NCT04326985|Drug|Hyaluronic acid (HA)|The HA group patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.)
75570243|NCT00536393|Drug|Doxorubicin|
75876924|NCT03660462|Dietary Supplement|HiFePO4 1 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
75424190|NCT03777982|Drug|Prednisone|Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
75424191|NCT03777982|Drug|Apalutamide|Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.
75570244|NCT00536393|Drug|Doxorubicin pegylated|
75570245|NCT00595387|Other|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
75876925|NCT03660462|Dietary Supplement|HiFePO4 2 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
75876926|NCT01331395|Other|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
75424192|NCT03777982|Drug|Abiraterone Acetate|Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself
75876927|NCT03660306|Procedure|opioid anesthesia|opioid anesthesia means using sufentanil during surgery
75876928|NCT03660306|Procedure|opioid free anesthesia|opioid free anesthesia means giving no opioids during surgery
76046501|NCT01439997|Drug|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
76046502|NCT02199795|Device|Contralaterally Controlled Neuromuscular Electrical Stimulation|
75424193|NCT03777982|Drug|LHRH Agonist or Antagonist|Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
75424194|NCT03769025|Behavioral|Suboxone Remote Observed Dosing|The remote observed dosing group will use the provided smartphone to video record themselves taking their Suboxone dose each day
75424195|NCT03769025|Other|Suboxone Attention Control|Attention control group will send a text message daily confirming that they have taken their Suboxone dose
75424196|NCT03762473|Drug|Study Group|Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
75424197|NCT03762473|Drug|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of < 1 at month 1, and BK data available and month 2,3, 6,9,12.
75570246|NCT00595387|Other|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
75570247|NCT00595543|Drug|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
75424198|NCT03760237|Other|observation only|No intervention, observational study only
75424199|NCT03745989|Drug|MK-8353|Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
75570248|NCT00595543|Drug|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
75570249|NCT00595543|Drug|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
75570250|NCT05519098|Device|COLO-SW-1|Patient will undergo a CADe-assisted colonoscopy procedure with use of the COLO-SW-1 software.
75570251|NCT00595660|Procedure|FNA - fine needle aspiration|Fine Needle aspiration
75570252|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
76046503|NCT02199795|Device|Cyclic Neuromuscular Electrical Stimulation|
76046504|NCT02403817|Behavioral|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
76046505|NCT02403817|Behavioral|Eye Motor Training|Game play will be controlled by the player's eye movements (via an eye tracking device)
76046506|NCT02403817|Behavioral|Hand Motor Training|Game play will be controlled by the player's hand movements (via a joystick).
75424200|NCT03745989|Drug|Selumetinib|Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
75424201|NCT03737695|Procedure|Biospecimen Collection|Undergo biospecimen collection
75424202|NCT03737695|Other|Medical Chart Review|Undergo clinical information collection
75570253|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
75570254|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
75570255|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
75570256|NCT05504746|Drug|SHEN26 capsule|"Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used."
75570257|NCT05504746|Drug|SHEN26 capsule|Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
75570258|NCT05504746|Drug|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose."
75723373|NCT00613626|Drug|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
75723374|NCT00985803|Other|Physical Activity: Cardio training (CT)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
75723375|NCT00985803|Other|Physical Activity: Endurance exercise training (ET)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
75723376|NCT00810056|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
75723377|NCT00810056|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
75570259|NCT05504746|Drug|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days."
75570260|NCT02892370|Drug|SHR0302|SHR0302 tablets (10 mg)
75723378|NCT00979329|Other|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
75723379|NCT00810134|Procedure|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
75723380|NCT00810134|Procedure|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
75723381|NCT04008303|Procedure|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
75723382|NCT00806780|Procedure|on table cholangiography|x-ray imaging of common bile duct
75723383|NCT02592239|Device|Functional brain MRI|Functional brain MRI before and after test meal ingestion
75723384|NCT02592239|Dietary Supplement|A warm ham and cheese sandwich and a 200 ml fruit juice|
75570261|NCT04326868|Drug|Benzimidazole Anthelmintic|The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
75570262|NCT05468762|Procedure|Transfemoral tranScatheter aortic valvE implantation|Transcatheter aortic valve implantation (TAVI) is an established treatment modality in patients ≥ 75 years old with severe symptomatic aortic stenosis after Heart Team evaluation
75723385|NCT00874146|Genetic|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
75723386|NCT00982605|Procedure|EBUS_TBNA|EBUS during bronchoscopy
75723387|NCT00874224|Procedure|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
75723388|NCT00874224|Procedure|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
75723389|NCT00725543|Biological|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
75723390|NCT00881478|Other|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
75723391|NCT00881478|Other|Nutrition counseling|Nutrition counseling with registered dietician
75723392|NCT00985881|Device|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
75723393|NCT00985881|Device|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
75723394|NCT00917813|Drug|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
75570263|NCT00595738|Other|Standard of care therapy for severe decompensated heart failure|Standard of care therapy for severe decompensated heart failure
75723395|NCT00917813|Drug|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
75723396|NCT00239005|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
75723397|NCT00239005|Drug|Mycophenolate Mofetil (MMF)|
75876929|NCT03658200|Other|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
75876930|NCT03658200|Other|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
76046507|NCT04773249|Device|Lateral Epicondylitis Bandage|The lateral epicondylitis bandage was first used by Ilfeld in 1965, and it is a non-elastic band that prevents the expansion of the muscles in the proximal forearm. A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
75424203|NCT03729739|Diagnostic Test|QFR-based diagnostic strategy|Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
75424204|NCT03729739|Diagnostic Test|FFR-based diagnostic strategy|Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
75876931|NCT03660150|Other|Evaluation of health-related quality of life|Short Form-36 Medical Outcomes Survey (SF-36), and Brief Version of Burn Speciﬁc Health Scale (BSHS-B) are used for the present evaluation.
75876932|NCT03659994|Dietary Supplement|Multivitamin|Vitabeard
75876933|NCT03659994|Dietary Supplement|Placebo|Placebo
75424205|NCT03724552|Device|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
75424206|NCT03724552|Device|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
75570264|NCT00595777|Behavioral|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
75723398|NCT02594891|Device|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
75723399|NCT02594891|Device|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
75723400|NCT00616434|Drug|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
75723401|NCT00616434|Drug|Placebo|Placebo IM injection, self-administered per protocol.
75723402|NCT01581697|Dietary Supplement|Oat bran|
75424207|NCT03721783|Procedure|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
75424208|NCT03674983|Behavioral|Conditional Economic Incentive (CEI)|"If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes."
75723403|NCT00652340|Drug|apricoxib/erlotinib|"apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert"
76046508|NCT04773249|Device|Wrist Extension Splint|Wrist extension splint is an upper extremity orthosis that keeps the wrist at 15-20 degrees of extension with the polyethylene bar it contains. A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
75723404|NCT00652340|Drug|erlotinib/placebo|"erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day"
75723405|NCT00257725|Drug|B-MPH|Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
75723406|NCT00544869|Drug|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
75723407|NCT00725075|Drug|MK-8435 (Org 25935) 4-8 mg|Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
75723408|NCT00725075|Drug|Placebo|Matching placebo for MK-8435 (Org 25935) administered orally BID
76046509|NCT04189653|Other|Continuous Monitoring|Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
76046510|NCT02403271|Drug|Ibrutinib|BTK Inhibitor
76046511|NCT02403271|Drug|Durvalumab|Anti PDL-1
76046512|NCT02219685|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
76046513|NCT02219685|Drug|Placebo|Tablet administered orally once daily
75424209|NCT03665688|Device|Outpatient Dilapan-S|After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L&D unit for standard protocol of labor induction.
75424210|NCT03665688|Device|Inpatient Dilapan-S|"After Dilapan-S placement, subjects will be admitted to L&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
75424211|NCT03659045|Other|scale of pain|The measurement is simple, reproducible, performed using a scale of pain rated from 0 to 10 (0 absence of pain, 10 maximum of pain felt)
75424212|NCT03648021|Drug|Paracetamol|">50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
75570265|NCT00595816|Other|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
75723409|NCT00725075|Drug|MK-8435 (Org 25935) 12-16 mg|Administered orally BID for a final concentration of 24-32 mg/day
75723410|NCT00874302|Drug|Proellex|One 25mg capsule taken orally once every day.
75723411|NCT00874302|Drug|Proellex|Two 25mg capsules Proellex (50mg) taken orally once every day
75723412|NCT02593643|Drug|Ketamine|
75723413|NCT02593643|Drug|Midazolam|
75723414|NCT02593643|Other|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
75723415|NCT05261087|Other|No intervention|Individuals will not receive any interventions
75723416|NCT00881556|Drug|Palifermin|60 mcg/kg/day for 6 days
75723417|NCT00881556|Drug|Fludarabine|30 mg/m2 IV x 1 for 6 days
75876934|NCT01068600|Drug|Indacaterol|Once daily via single-dose dry powder inhaler (SDDPI)
75876935|NCT01068600|Drug|Placebo to indacaterol|Once daily via SDDPI
75876936|NCT01067976|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
76046514|NCT02457247|Drug|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
76046515|NCT02457247|Drug|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
76046516|NCT02457247|Drug|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
76046517|NCT04929535|Drug|Hydrogen Peroxide 30 % Topical Solution|Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
76046518|NCT02402647|Behavioral|CREST|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
76046519|NCT02402647|Behavioral|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
75424213|NCT03648021|Drug|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
75424214|NCT03646656|Behavioral|reciprocal peer support and non reciprocal coach support|Peers and peer coaches provide mutual or one-way support to initiate and sustain behavioral improvements for cardiovascular health, with additional education from study staff.
75424215|NCT03640845|Other|tele-expertise|"Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.~Tele-expertise is realized in three stages, that are~the transmission, the collection and the organization of the data,~the analysis of the data and their confrontation with the referential and recommendations~the writing of a Personalized Pharmaceutical Plan"
75424216|NCT03613792|Drug|Remifentanil|Opioid analgesic
76046520|NCT00752583|Procedure|Peritoneal dialysis|Blood, urine and dialysate sampling
75424217|NCT03613792|Drug|Fentanyl|Opioid analgesic
75424218|NCT03613792|Drug|Midazolam|Benzodiazepine
75424219|NCT03613792|Drug|Ketamine|Analgesic
75424220|NCT03611881|Behavioral|Counseling|4 or 8 weeks of behavioral counseling support to promote smoking cessation.
75723418|NCT00881556|Drug|Busulfan|4 mg/kg/day IV divided BID for 4 days
76046521|NCT00752583|Procedure|Haemodialysis|Blood, urine and dialysate sampling
76046522|NCT02198235|Drug|Dexamethasone|
76046523|NCT02198235|Drug|Buprenorphine|
76046524|NCT04917133|Behavioral|Adapted Physical Activity program|classic 4-week rehabilitation program (standard care) + 6 APA workshops per week with collective care
76046525|NCT04917133|Other|Control|classic 4-week rehabilitation program (standard care)
76046526|NCT04916431|Drug|mRNA-6231|Sterile frozen liquid dispersion for injection
76046527|NCT00346125|Biological|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
75424221|NCT03611881|Drug|Nicotine patch|2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
75424222|NCT03611881|Behavioral|Community Resource|Counselor-facilitated referral to a community-based program to address social needs.
75424223|NCT03594734|Behavioral|Group Lifestyle Balance™|The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
75424224|NCT03594734|Other|Attention Control Group|"The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication."
75723419|NCT00881556|Drug|Lorazepam|0.02-0.05 mg/kg for 5 days
75723420|NCT00881556|Drug|Alemtuzumab|20 mg/m2 IV for 5 days
75723421|NCT00881556|Drug|Tacrolimus|0.03mg/kg/24 hours as continuous infusion for 4 days
75723422|NCT03969797|Device|RADIAQBIO Heart Guardian HR-501|Arm one offers ECG data and electric shocks recorded during AED operation.
76046528|NCT00346125|Drug|doxorubicin hydrochloride|65 mg/m^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
76046529|NCT00346125|Drug|ifosfamide|9 g/m^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m^2 by continuous IV infusion over 7 days beginning on day 1
76046530|NCT00346125|Drug|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
76046531|NCT00346125|Procedure|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
75723423|NCT00874380|Other|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
76046532|NCT00346125|Radiation|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
76046533|NCT04418349|Procedure|"posterior component separation modified TAR technique Transversus Abdominids Release"|"Evaluation of posterior component separation modified TAR technique Transversus Abdominids Release in the treatment of parastomal hernia"
76046534|NCT02253147|Device|TEOSYAL® RHA Ultra Deep|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles."
75424225|NCT03575598|Drug|Sitravatinib|Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
75723424|NCT00881634|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
76046535|NCT02217501|Drug|Clopidogrel|Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
76046536|NCT02217501|Drug|Acetylsalicylic acid (ASA)|Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
76046537|NCT01649869|Other|Placebo|Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
75723425|NCT00881634|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
75723426|NCT00874458|Procedure|magnetic resonance imaging|
75723427|NCT00874458|Procedure|radiomammography|
76046538|NCT01649869|Drug|Valganciclovir|Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
76046539|NCT02197377|Device|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
75424226|NCT03575598|Biological|Nivolumab|Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
75424227|NCT03572166|Diagnostic Test|Arginine infusion|Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
75723428|NCT00874458|Procedure|ultrasound imaging|
75723429|NCT00878670|Drug|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
75723430|NCT00874536|Dietary Supplement|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
75723431|NCT00874536|Dietary Supplement|Placebo|
75723432|NCT00733499|Device|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
75723433|NCT00733499|Device|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
75723434|NCT00878748|Drug|Effexor XR|
75723435|NCT00878748|Other|Effexor XR discontinue|
76046540|NCT02197377|Device|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
76046541|NCT02400307|Drug|Bictegravir|75 mg tablet administered orally
75723436|NCT04088045|Device|Autologous platelet rich plasma and 5% dextrose solution injections.|"One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves."
76046542|NCT02196675|Device|Endocutter|The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
75723437|NCT00652028|Drug|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
76046543|NCT04772703|Diagnostic Test|COMET ASSAY|The description in the detailed description of the study
76046544|NCT02399449|Drug|Brand sodium ferric gluconate|brand product
76046545|NCT02399449|Drug|Generic sodium ferric gluconate|generic product
76046546|NCT02217345|Drug|Growth hormone|growth hormone, Genotropin (Pfizer)
76046547|NCT02217345|Drug|Placebo|placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
75570266|NCT05468723|Device|Carecube Negative Pressure Isolation Chamber|Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses [which may include physicians, physician assistants, Registered Nurses, Licensed Practical Nurses, medical technicians and emergency medical technicians (EMTs)] . Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded on an hourly basis. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.
75570267|NCT00595855|Procedure|trabeculectomy|Cairns-like trabeculectomy, limbus based, with 5_FU supplementation and argon laser suturelysis
75723438|NCT02592473|Device|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
76046548|NCT04906447|Behavioral|Guided Relaxation|Guided relaxation uses the mind to reduce pain, promote well-being, and improve physical function. Guided relaxation is a state of concentration and focused attention that gives people more control over their pain experience and its impact and an increased sense of well-being.
75424228|NCT03572166|Diagnostic Test|Hypertonic saline infusion|Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
75424229|NCT03570450|Drug|Adipose derived Stem Cell|4 doses
75424230|NCT03570450|Other|placebo|placebo
75570268|NCT00595855|Procedure|deep sclerectomy|deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
75570269|NCT00595972|Drug|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
75570270|NCT00596050|Drug|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
75570271|NCT00596050|Drug|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
75876937|NCT02858492|Drug|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
75876938|NCT02858492|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
75424231|NCT03563417|Procedure|Percuteneous Coronary Intervention|PCI of Chronic Total Occlusions
75424232|NCT03563417|Other|Optimal Medical Therapy|Initiation and titration of optimal medical therapy in the control arm.
75424233|NCT03555435|Other|Moving Forward On Your Own|Participants in this group will use the online program on their own for 6 weeks.
75424234|NCT03555435|Behavioral|Moving Forward with Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
75424235|NCT03555435|Behavioral|Wait|Participants in this group will wait 6 weeks.
75570272|NCT05468684|Other|no intervention|there are no interventions planned, we observe the patients in a cohort study which is named inception cohort study because we test participants before the condition develops.
75570273|NCT02888899|Behavioral|Biofeedback|
75570274|NCT02888899|Drug|Loperamide|
75570275|NCT02888899|Drug|Stool bulking agent (sterculia or ispaghula husk)|
76046549|NCT04906447|Other|Acupuncture|Acupuncture is a body-based therapy that includes the insertion of thin needles at strategic points on the body that has been proven effective for reducing pain.
75424236|NCT03551392|Device|Medx Console System|This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
75424237|NCT03551392|Device|Sham Medx Console System|This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
75424238|NCT03551392|Device|Vielight 810 intranasal stand alone unit|Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
75424239|NCT03551392|Device|Sham Vielight 810 intranasal stand alone unit|"Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week."
75424240|NCT03540732|Other|Indirect Calorimetry directed feeding.|Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)
75570276|NCT02888899|Other|PTNS|
75570277|NCT05470959|Other|ACTIVA bioactive|bioactive ionic resin composite
75570278|NCT05470959|Other|Riva LC|resin-modified glass ionomer
75570279|NCT00624091|Procedure|Cardiac surgery|Cardiac surgery within 48 hours of randomization
75570280|NCT00624091|Procedure|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
75570281|NCT05468645|Drug|[14C]Hemay005|Name: [14C]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
75570282|NCT00596128|Behavioral|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
75570283|NCT00596206|Drug|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
75876939|NCT01067508|Other|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
75876940|NCT03609554|Other|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
75570284|NCT00596245|Drug|MT400|MT 400, naproxen sodium 550mg
75570285|NCT00596284|Behavioral|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
75570286|NCT00596284|Behavioral|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
75876941|NCT01067352|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
76046550|NCT01652287|Drug|BB-12 supplemented strawberry yogurt|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
76046551|NCT01652287|Other|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
75570288|NCT05468528|Procedure|catheter radiofrequency ablation(individualized stepwise linear without pulmonary vein isolation)|individualized stepwise linear ablation without pulmonary vein isolation
75570289|NCT05468528|Procedure|catheter radiofrequency ablation(PVI)|pulmonary vein isolation
75570290|NCT05427448|Diagnostic Test|Measurement of amyloid and pTau blood biomarkers|Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
76046552|NCT02251743|Device|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~Average voltage of theta waves~Average voltage of beta~Average ratio of theta to beta power (TBR)"
76046553|NCT04189575|Other|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
75570291|NCT00624130|Drug|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
75570292|NCT00624130|Drug|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
75570293|NCT05468450|Drug|Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant|Direct injection Foam sclerotherapy
75570294|NCT05468450|Device|Endovenous Laser Ablation (EVLA)|EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
75570295|NCT04686123|Other|Active Stretching or Self-stretching exercises|Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
75570296|NCT04686123|Other|Active strengthening Or Self-Strengthening exercises|Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
75570297|NCT04320355|Other|Soft tissue manual therapy|The intervention is a type of massage.
75723439|NCT00738101|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
75723440|NCT00810212|Procedure|PLF with autograft|6 subjects
75723441|NCT00810212|Biological|PLF with NeoFuse|6 subjects low dose
76046554|NCT02428855|Drug|Dasatinib|
76046555|NCT02428699|Other|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
76046556|NCT02428699|Other|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
76046557|NCT02428231|Drug|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
76046558|NCT02397889|Drug|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
76046559|NCT02397889|Drug|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
76046560|NCT02396953|Drug|Lanreotide PRF|
76046561|NCT04905589|Dietary Supplement|BetaQuik™|MCT (Medium chain triglycerides)
75424241|NCT03540732|Procedure|Cycle Ergometry|Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.
75424242|NCT03521518|Diagnostic Test|Conner's Continuous Performance Test-3|CPT-3 allows quantitative assessment of visuospatial, attention and reaction time in patients being evaluated for Normal Pressure Hydrocephalus undergoing a CSF tap test.
75424243|NCT03521115|Behavioral|Smart Choices 4 Teens|This is a web-based prevention program designed to convey information about alcohol and relationships and the types of choices that they are making regarding these topics. General communications was another core element of the program that provided parents and teens with some key elements of talking to each other.
75424244|NCT03520413|Other|PRACTICE-DM|Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
75424245|NCT03520413|Other|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
75424246|NCT03447509|Device|iTMS|Small magnetic pulse will be given to the brain in a non invasive manner.
76046562|NCT04905589|Dietary Supplement|WheyBasics|Whey Protein Isolate
76046563|NCT04905589|Other|Iso-voluminous water|Iso-voluminous Water as comparitor to Betaquik or WheyBasics
76046564|NCT02387983|Drug|Posaconazole|Posaconazole 300 mg solid oral tablet
75424247|NCT03447509|Other|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
76046565|NCT02395627|Drug|Tamoxifen|
75424248|NCT03447509|Device|Sham iTMS|Sham or fake stimulation will be given to the brain in a non invasive manner.
75570298|NCT00535860|Drug|Teriparatide|Daily for 96 days
75570299|NCT05388721|Other|Clinical data and specimen collection|"Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible."
75723442|NCT00810212|Biological|PLF with NeoFuse|6 subjects medium dose
75723443|NCT00810212|Biological|PLF with NeoFuse|6 subjects high dose
76046566|NCT02395627|Drug|Vorinostat|
76046567|NCT02395627|Drug|Pembrolizumab|
76046568|NCT02395471|Device|Cytosponge™ Cell Collection Device|Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
76046569|NCT02395081|Dietary Supplement|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
76046570|NCT02395081|Dietary Supplement|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
76046571|NCT02395081|Dietary Supplement|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
76046572|NCT02394925|Device|Multifocal Test Contact lens|Used in a daily wear modality
76046573|NCT02427607|Drug|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
76046574|NCT02425111|Drug|Vedolizumab|Vedolizumab intravenous injection
75876942|NCT02986074|Device|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
75876943|NCT02986074|Device|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
76046575|NCT04916119|Drug|IBI323|In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
75876944|NCT03658122|Behavioral|Parent-Child Care|Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
75876945|NCT02920242|Drug|Rifaximin (Sandoz GmbH) tablet|200 mg tablet administered orally.
76046576|NCT02424565|Drug|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
76046577|NCT02424565|Other|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
76046578|NCT02424253|Drug|ZPL-3893787|ZPL-3893787
76046579|NCT02424253|Drug|Placebo|Matched Placebo
76046580|NCT02393755|Drug|Capecitabine|Given PO
76046581|NCT02393755|Other|Laboratory Biomarker Analysis|Correlative studies
76046582|NCT02393755|Drug|Nintedanib|Given PO
76046583|NCT02393755|Other|Pharmacological Study|Correlative studies
76046584|NCT05454319|Device|Biofeedback|Home-based biofeedback with medical device
76046585|NCT02393209|Drug|Docetaxel|Docetaxel intravenous infusion
76046586|NCT02393209|Drug|TAK-117|TAK-117 Tablets
75424249|NCT03447509|Other|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
75424250|NCT03440567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
76046587|NCT02424097|Drug|CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste|"MI Paste & MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray"
76046588|NCT02424097|Drug|1,100pm F-toothpaste and 0.5%NaF rinse|"Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)"
76046589|NCT02392507|Drug|Necitumumab|Administered IV
75424251|NCT03440567|Drug|Avelumab|Given IV
75424252|NCT03440567|Drug|Carboplatin|Given IV
75424253|NCT03440567|Drug|Etoposide Phosphate|Given IV
75723444|NCT00799136|Drug|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
75723445|NCT02592395|Drug|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
75723446|NCT02592395|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
75723447|NCT00810290|Behavioral|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
76046590|NCT02392507|Drug|Nab-Paclitaxel|Administered IV
76046591|NCT02392507|Drug|Carboplatin|Administered IV
76046592|NCT04904341|Drug|Cerebrolysin|neuroprotection treatment
76046593|NCT01651117|Behavioral|Peer Mentoring|Patients will receive peer mentoring.
76046594|NCT02386189|Behavioral|Patient Care Coordination Training|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
76046595|NCT02385799|Drug|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
75570300|NCT02892331|Behavioral|Moderate intensity exercise training (MOD-INT)|Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
75876946|NCT02920242|Drug|Rifaximin (Xifaxan)|200 mg tablet administered orally
75424254|NCT03440567|Drug|Ibrutinib|Given PO
75876947|NCT02920242|Drug|Placebo|Matching Placebo tablet administered orally
75876948|NCT02985996|Drug|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
76046596|NCT02385799|Drug|Sertraline|Active medication
75424255|NCT03440567|Drug|Ifosfamide|Given IV
75424256|NCT03440567|Other|Laboratory Biomarker Analysis|Correlative studies
76046597|NCT02422303|Drug|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
75424257|NCT03440567|Biological|Rituximab|Given IV
75570301|NCT02892331|Behavioral|High Intensity exercise training (HI-INT)|Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
75570302|NCT00536549|Device|Guardian RT|
75570303|NCT00536549|Behavioral|Education about the self monitoring blood glucose|
75570304|NCT04208074|Other|Exercise Intervention|Participants will exercise under the supervision of expert personal trainers and follow an optimized exercise program tailored to the strength and fitness level of each participant. Participants will exercise for 16 weeks; 2 days a week at the gym for an hour and 2 days of the week at home for 45 minutes.
75570305|NCT00596479|Drug|Filgrastim (rG-CSF)|
76046598|NCT02392195|Other|Non-interventional|Observational
76046599|NCT02391961|Drug|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
75424258|NCT03440567|Biological|Utomilumab|Given IV
75424259|NCT03423667|Drug|N-acetylcysteine|N-acetylcysteine (1200 mg) administered twice a day during 5 days
75570306|NCT05387668|Drug|BGB-23339|Administered orally as a tablet.
75424260|NCT03423667|Drug|Lactose powder|Placebo comparator.
75424261|NCT03419897|Drug|Tislelizumab|Administered intravenously
75424262|NCT03418129|Device|Mindfulness|Neuromodulatory intervention for pain management
75424263|NCT03418129|Device|Neurofeedback|Neuromodulatory intervention for pain management
75424264|NCT03418129|Device|Relaxation|Neuromodulatory intervention for pain management
75424265|NCT03411239|Device|Adult esophageal balloon catheter (obc)|Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
75424266|NCT03378531|Drug|AEB1102|modified human arginase I
75424267|NCT03377049|Drug|Acetazolamide|1 g acetazolamide through a peripheral IV line
75424268|NCT03355976|Drug|Nivolumab|240mg flat dose every 2 weeks
75424269|NCT03355976|Drug|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks
75570307|NCT05387668|Drug|Placebo|Administered orally as a tablet.
75570308|NCT04207957|Drug|Olorofim|150 mg
75570309|NCT05383339|Other|Blood collection|- 56mL blood collected additionally to routine care
75570310|NCT00535977|Dietary Supplement|Broccoli|400g ITC-enriched broccoli per week for 12 months
75570311|NCT00535977|Dietary Supplement|Peas|400g frozen garden peas per week for 12 months
75570312|NCT05342077|Behavioral|Virtual Reality-Reward Training (VR-RT)|Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
75570313|NCT05342077|Behavioral|Virtual Reality-Memory Training (VR-MT)|Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral autobiographical memories.
75570314|NCT00596518|Drug|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
75570315|NCT00536016|Drug|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
75570316|NCT00596557|Drug|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
75723448|NCT00799214|Drug|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
75723449|NCT00799214|Drug|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
75723450|NCT00799214|Drug|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
75723451|NCT00733421|Drug|etoricoxib|90 mg once daily
75723452|NCT00733421|Drug|tramadol|100 mg twice daily
75723453|NCT00613080|Drug|capecitabine|1650 mg/m^2/day orally 5 days/week during radiotherapy.
75723454|NCT00613080|Drug|oxaliplatin|
75424270|NCT03345563|Behavioral|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
75424271|NCT03345563|Behavioral|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
75723455|NCT00613080|Procedure|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
75424272|NCT03345563|Behavioral|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
75424273|NCT03344796|Behavioral|Goal attainment|After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.
75570317|NCT04326556|Other|Prospective cohort for etiological and prognostic purposes|Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
75723456|NCT00613080|Radiation|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
75723457|NCT00613080|Drug|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m^2, IV continuous infusion over 46 hours, day 1."
75723458|NCT00806858|Device|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
75723459|NCT00917891|Drug|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
75424274|NCT03335488|Drug|RAVICTI|RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
75424275|NCT03335488|Drug|NaPBA|"NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose~NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose"
75570318|NCT00596596|Drug|prucalopride|0,5 mg once daily
75570319|NCT00596596|Drug|prucalopride|1 mg once daily
75723460|NCT00917891|Drug|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
75570320|NCT00596596|Drug|2 mg prucalopride|2 mg once daily
75570321|NCT00596596|Drug|4 mg prucalopride|4 mg once daily
75570322|NCT00596596|Other|Placebo|placebo once daily
75723461|NCT03871166|Other|Blood transfusion|"Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit.~Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU.~[Time Frame: 01/2007 - 12/2018]"
76046600|NCT02391961|Drug|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
76046601|NCT02384941|Drug|Placebo|Placebo once daily, before first meal of the day.
76046602|NCT02384941|Drug|Sotagliflozin|Sotagliflozin once daily, before first meal of the day.
75424276|NCT03324802|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75570323|NCT05468294|Drug|F16IL2|F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.
75570324|NCT05468294|Drug|Nivolumab, fixed dose|Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
75570325|NCT00596674|Behavioral|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
75723462|NCT02554136|Drug|HGP0918|
76046603|NCT02384551|Other|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
75424277|NCT03324802|Other|Quality-of-Life Assessment|Ancillary studies
75424278|NCT03324802|Radiation|Radiation Therapy|hypofractionated radiation therapy
75424279|NCT03323437|Drug|Risperidone|Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
75424280|NCT03306355|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
75424281|NCT03306355|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
75723463|NCT02554136|Drug|HGP0816|
76046604|NCT02384395|Drug|Dolutegravir 50 mg|Initial therapy for AHI
75424282|NCT03300141|Other|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
75424283|NCT03300141|Other|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
76046605|NCT02384395|Drug|Lamivudine 300 mg|Initial therapy for AHI
76046606|NCT02384395|Drug|Abacavir 600 mg|Initial therapy for AHI
75424284|NCT03300141|Other|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
75424285|NCT03298633|Other|ICSI|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
75570326|NCT00596674|Other|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
75570327|NCT02892175|Procedure|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
75570328|NCT00536588|Genetic|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10^9 to 3 x 10^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
75570329|NCT00596791|Drug|tafluprost|prostaglandine analoque
75570330|NCT05312866|Procedure|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
75570331|NCT05312866|Procedure|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
75723464|NCT02554136|Drug|HGP0918 + HGP0816|
75723465|NCT00732875|Biological|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
75723466|NCT00799370|Procedure|Early weight bearing|Weight bearing performed immediately after surgery
75723467|NCT00799370|Procedure|Delayed weight bearing|Weight bearing performed 2 months after surgery
75723468|NCT00874692|Other|BMS and sterilisation programme|BMS with reduced hot water temperature and sterilisation programme
75723469|NCT00881790|Other|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
75723470|NCT05097456|Device|carbon dioxide laser|carbon dioxide laser
75723471|NCT05097456|Device|sham laser|sham laser
75723472|NCT00810446|Drug|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.."
75723473|NCT00810524|Drug|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
75570332|NCT05470803|Biological|AstraZeneca/Fiocruz|4th dose of SARS-CoV-2 vaccine
75570333|NCT05470803|Biological|Pfizer/Wyeth|4th dose of SARS-CoV-2 vaccine
75723474|NCT00810524|Drug|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
75723475|NCT00810524|Drug|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
75876949|NCT02985996|Drug|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
75723476|NCT00810524|Drug|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
75876950|NCT03225833|Drug|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
75424286|NCT03298633|Other|Conventional IVF|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
75424287|NCT03273972|Other|Written Informed Consent|To be completed prior to conducting any study related procedures
75424288|NCT03273972|Other|Inclusion/Exclusion check|Eligibility check
75424289|NCT03273972|Other|Full Clinical Chemistry and Haematology Bloods|Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
75424290|NCT03273972|Other|Serum sample for systemic markers and lipid sub-fractions|Serum samples may be stored for later analysis.
75424291|NCT03273972|Other|Pregnancy Test|If applicable for women of child bearing potential
75424292|NCT03273972|Other|12 Lead ECG|participant resting supine
75424293|NCT03273972|Other|Blood Pressure and Heart Rate|Measured in the seated position after 5 minutes rest
75570334|NCT05470803|Biological|Clover SCB-2019|4th dose of SARS-CoV-2 vaccine
75570335|NCT00622960|Other|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
75570336|NCT00622960|Other|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
75570337|NCT05468255|Other|removal of exercise|Subjects will stop doing their normal exercise routines for 3 or 5 days and then subjects will resume doing their normal exercise routines for 3 days.
75570338|NCT04326790|Drug|Colchicine|Low-dose colchicine treatment, 0.5 mg bid
75570339|NCT04326790|Drug|Standard treatment|Standard treatment
75723477|NCT00810680|Drug|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
75723478|NCT00799448|Drug|repaglinide|
75723479|NCT00799448|Drug|biphasic human insulin 30|
75723480|NCT00799448|Drug|insulin NPH|
75723481|NCT00806936|Drug|human insulin|Any kind of human insulin administered at the discretion of the physician
75723482|NCT00806936|Drug|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
75876951|NCT03225833|Drug|Placebo|0.9% Sodium Chloride
75876952|NCT03659760|Other|Group Isolated|Eyes closed with patch and ears plugged between 24:00-06:00
75876953|NCT03659682|Drug|Semaglutide|subcutaneous, 1.0 mg, weekly, 48 months
75876954|NCT03203447|Drug|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
75876955|NCT03203447|Drug|suprachoroidal sham|sham suprachoroidal procedure
75876956|NCT03203447|Drug|Lucentis or Avastin|IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
75876957|NCT03659526|Diagnostic Test|Deformation imaging|Deformation parameters derived using myocardial velocity imaging or speckle tracking
75876958|NCT02858726|Drug|CR845 0.5 mcg/kg|IV medication delivered three times/week
75723483|NCT00807170|Drug|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
75876959|NCT02858726|Drug|CR845 1 mcg/kg|IV medication delivered three times/week
75876960|NCT02858726|Drug|CR845 1.5mcg/kg|IV medication delivered three times/week
75570340|NCT05468177|Combination Product|neoadjuvant chemotherapy|"Cetuximab: 500mg/m2,day1, every 2 weeks. mFOLFOX: oxaliplatin 85mg/m2, day 1;LV 400mg/m2, day 1;5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h) (every 2 weeks).~Anti-PD-1(Sintilimab Injection):200mg every 3 weeks. Surgery will be performed after 4 cycles for locally advanced or initially resectable metastatic right colon cancer.If the initial unresectable metastatic right colon cancer were converted into resectable metastases, and surgery will be performed. Patients who failed to convert after 6 cycles of treatment will be withdrawn from the study.Cetuximab +mFOLFOX was treat for 8 cycles, and Anti-PD-1 was treated for one year in the perioperation period unless disease progression, toxicity intolerance, initiation of new anti-tumor therapy."
75570341|NCT00596986|Drug|Duloxetine|Duloxetine 30mg up to 120mg per day.
75424294|NCT03273972|Other|Arterial Stiffness|Measure of functional and structural changes which accompanies cardiovascular disease
75424295|NCT03273972|Other|Central Haemodynamics|Measure of functional and structural changes which accompanies cardiovascular disease
75424296|NCT03273972|Other|Carotid Intima Media Thickness|Measurements will be repeated three times, and the average of the median values will be recorded
75723484|NCT00807170|Radiation|Whole Brain Radiotherapy (WBRT)|
75723485|NCT00807170|Drug|ZD6474|200 mg as a once daily oral dose, 21 days
75723486|NCT00807170|Drug|ZD6474|300 mg as a once daily oral dose, 21 days
75723487|NCT00799526|Procedure|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
75424297|NCT03273972|Other|Forearm blood flow studies|Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
75424298|NCT03273972|Other|Concomitant medication check|Review of medication taken by the participant
75424299|NCT03273972|Other|Medication compliance check (Pill count)|Ensure prescribed statin has been taken
75876961|NCT02858726|Drug|Placebo|IV medication delivered three times/week
75876962|NCT03203291|Device|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
75876963|NCT03609476|Procedure|Room temperature saline instillation|Saline is used as room temperature
75424300|NCT03273972|Other|Physical examination|Check overall health
75424301|NCT03273972|Other|Medical history|Review of volunteers medial history
75424302|NCT03273972|Other|AE/SAE review & reporting|Monitor safety from the point of consent
75723488|NCT00799526|Procedure|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
75723489|NCT02553902|Device|Sleep position trainer|
75723490|NCT02553902|Device|Mandibular advancement device|
75723491|NCT02553902|Device|Continuous positive airway pressure|
75723492|NCT00615264|Drug|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
75723493|NCT00615264|Drug|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
75876964|NCT03609476|Procedure|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
75876965|NCT03609476|Procedure|No saline instillation|No saline is used prior to catheter removal
75876966|NCT04549610|Dietary Supplement|HMB supplementation|Group taking oral HMB supplementation in a blinded capsule form.
75876967|NCT04549610|Dietary Supplement|Placebo treatment|Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.
75876968|NCT01068678|Drug|insulin degludec|Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
75876969|NCT01068678|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
75876970|NCT03202511|Drug|Probenecid Oral Tablet|Included in arm/group descriptions.
75876971|NCT03202511|Drug|Tenofovir disoproxil fumarate/Emtricitabine|Included in arm/group descriptions.
75876972|NCT03609710|Device|Transanal tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
75876973|NCT03609710|Procedure|Left colic artery preservation|Left colic artery preservation during operation for lower rectal cancer
75876974|NCT03609710|Procedure|Anastomotic reinforcing sutures|Anastomotic reinforcing sutures during operation for lower rectal cancer
75876975|NCT03609710|Device|Robotic surgery|Robotic low anterior resection for rectal cancer
75876976|NCT03637049|Drug|PBI-4050 and midazolam|A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
75876977|NCT03636971|Drug|hyaluronic acid with mannitol|single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)
75570342|NCT00596986|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
75723494|NCT00799682|Drug|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
75723495|NCT00799682|Drug|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
75723496|NCT00810758|Drug|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
75570343|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
75570344|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
75570345|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
75723497|NCT00810758|Drug|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
75723498|NCT00810758|Drug|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
75723499|NCT00732641|Drug|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
75723500|NCT03829020|Drug|Bortezomib|Given SC
75723501|NCT03829020|Drug|Metformin Hydrochloride|Given PO
75723502|NCT03829020|Drug|Nelfinavir Mesylate|Given PO
75723503|NCT00810836|Drug|BG00012|oral
75723504|NCT00810836|Drug|BG00012|Oral
75723505|NCT00810836|Drug|placebo|oral placebo
75723506|NCT00874926|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
75723507|NCT00810914|Drug|bupivicaine epidural|bupivicaine continuous epidural infusion
75876978|NCT03636971|Drug|hyaluronic acid with sorbitol|single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
75876979|NCT03636971|Drug|Placebos|single shot injection of saline, same volume
75876980|NCT03610100|Drug|Acelarin|825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
75876981|NCT03610100|Drug|Gemcitabine|1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
75876982|NCT03657966|Biological|DCVAC/OvCa|activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
75876983|NCT03657966|Drug|Standard of Care Chemotherapy|either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
75876984|NCT03659370|Other|Fumigation|use Fumigation to increase the improvement of osteoarthritis of knee
75723508|NCT00810914|Drug|bupivicaine epidural infusion patient epidural|bupivicaine
75876985|NCT03659370|Other|Acupuncture|Acupuncture
75570346|NCT04326517|Procedure|Nephrectomy|Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.
75723509|NCT00810914|Drug|bupivicaine|patient controlled anesthesia only
75723510|NCT00878904|Drug|epirubicin hydrochloride|
75876986|NCT03659292|Other|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
75876987|NCT03659292|Other|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.
76046607|NCT02420353|Drug|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
76046608|NCT02420353|Drug|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
75723511|NCT00878904|Drug|panobinostat|
75570347|NCT00597064|Drug|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
75570348|NCT00536627|Biological|DNA vaccine pCMVS2.S|Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
75876988|NCT03659292|Other|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
75570349|NCT00597103|Other|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
75570350|NCT00597103|Other|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
75723512|NCT00878904|Genetic|gene expression analysis|
75723513|NCT00878904|Genetic|protein expression analysis|
75723514|NCT00878904|Genetic|western blotting|
75723515|NCT00878904|Other|immunologic technique|
75723516|NCT00878904|Other|laboratory biomarker analysis|
75723517|NCT00878904|Other|pharmacological study|
75723518|NCT00810992|Behavioral|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
75876989|NCT03659292|Other|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
75876990|NCT03659058|Drug|silymarin|silymarin 140 three times daily
75876991|NCT03659058|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
76046609|NCT02391337|Drug|Bisoprolol|Drug intervention
75876992|NCT03659058|Drug|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
75876993|NCT03659058|Drug|Colchicine|Colchicine 0.6
76046610|NCT02391337|Drug|Digoxin|Drug intervention
76046611|NCT02382991|Device|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
76046612|NCT02382991|Device|NMPK-3C60|1 month with NMPK - 3 months with 3C60
75570351|NCT00597103|Other|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
75570352|NCT00597142|Device|Express™ Renal Premounted Stent System|"This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:~Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery~Lesion length ≤15mm~Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen~RVD 4.0-7.0mm"
75570353|NCT02909595|Device|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter [Extractor Pro RX [M00547000, M00547010, or M00547020]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
75570354|NCT02909595|Device|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V [FG-V435P or FG-V425PR]; Olympus Corp., Shang hai,China).
75570355|NCT04326712|Other|conventional manufactured socket|Presssure disturubition will be measured in conventional manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
76046613|NCT02390557|Other|Survey|PDQS survey reports only
75424303|NCT03273972|Drug|Dosing|To be performed at the end of the visit following completion all other study visits
75424304|NCT03268200|Other|segmental reexamination|segmental reexamination during colonoscopy
75424305|NCT03261700|Behavioral|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran's self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV and red flags, 3) improving coping and self- care, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
75424306|NCT03261700|Other|Information and referral condition|Participants randomized to this arm will receive a brochure-based intervention, consisting of education, support and problem solving, safety planning as well as resources and referrals to address an array of health and social issues associated with IPV (including in VA and the community).
75424307|NCT03244072|Drug|Moxifloxacin|Intracameral injection
75424308|NCT03244072|Drug|Placebo|intracameral injection
75424309|NCT03238417|Other|Evidence-Based Quality Improvement|Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
75424310|NCT03226197|Dietary Supplement|Ketone ester drink|Ketone ester drink
75424311|NCT03219047|Other|Best Practice|Receive standard of care
75424312|NCT03219047|Drug|Ibrutinib|Given at standard dose and schedule
75424313|NCT03219047|Other|Patient Derived Xenograft|Xenograft developed
75424314|NCT03219047|Other|Personalized Medicine|Receive treatment based on the results of the PDX models
75424315|NCT03215277|Drug|Bimekizumab|One bimekizumab dose will be administered.
75424316|NCT03215277|Drug|Certolizumab pegol|Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
75424317|NCT03215277|Other|Placebo|Placebo will be provided to maintain the blinding.
75570356|NCT04326712|Other|3D manufactured socket|Presssure disturubition will be measured in 3D manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
75570357|NCT04326595|Procedure|surgical and medical evacuation|surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics
75570358|NCT00597181|Procedure|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
75570359|NCT00597181|Procedure|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
75570360|NCT00597220|Dietary Supplement|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
75570361|NCT00597220|Drug|Placebo|Placebo
75876994|NCT03659058|Other|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
75876995|NCT01331473|Procedure|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
75876996|NCT01331473|Procedure|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
75876997|NCT03658980|Behavioral|Health Education Intervention|Face-to-face health education intervention on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminder at Day 7, 30 and 90.
75876998|NCT03635905|Drug|Gabapentin|Gabapentin (Neurontin®) is FDA-approved for the treatment of post-herpetic neuralgia and seizure disorder. Off-label uses include chronic refractory cough, neuropathy, hot flashes, restless leg syndrome, social anxiety disorder, and post-operative pain
75876999|NCT03635905|Drug|Placebo|Methylcellulose placebo capsule
75877000|NCT02960113|Drug|scopolamine patch|Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
75424318|NCT03214510|Drug|Bupivacaine|Given via thoracic epidural catheter or TAP block
75424319|NCT03214510|Drug|Fentanyl|Given via thoracic epidural catheter
75424320|NCT03214510|Drug|Hydromorphone Hydrochloride|Given via thoracic epidural catheter
76046614|NCT02390557|Other|YESHealth|Arm 3: YESHealth and PDQS survey reports to providers
75570362|NCT02892097|Device|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
75570363|NCT02892097|Device|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
75424321|NCT03214510|Device|Implanted Medical Device|Undergo placement of thoracic epidural catheter
75424322|NCT03214510|Device|Implanted Medical Device|Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block
75570364|NCT02892097|Behavioral|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
75424323|NCT03214510|Drug|Liposomal Bupivacaine|Given via TAP block
75424324|NCT03214510|Behavioral|Questionnaire|Ancillary studies
75424325|NCT03200340|Drug|EC-18|Oral administration of EC-18 twice daily
75570365|NCT00597259|Drug|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
75570366|NCT00597259|Drug|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
75570367|NCT05468060|Drug|PA1010|Placebo as control
75570368|NCT02892253|Device|Near Infrared Camera (NIR)|Surgical field is examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
75723519|NCT00810992|Behavioral|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
76046615|NCT01649791|Drug|lenalidomide|Given orally
76046616|NCT01649791|Other|laboratory biomarker analysis|Correlative study
76046617|NCT01649791|Procedure|lymph node biopsy|Correlative study
76046618|NCT01649791|Procedure|bone marrow aspiration|Correlative study
76046619|NCT01649791|Other|pharmacological study|Correlative study
75424326|NCT03200340|Drug|Placebo|Placebo to match EC-18 capsule administration
75424327|NCT03185013|Biological|VGX-3100|1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
75424328|NCT03185013|Biological|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
75723520|NCT00737711|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
75723521|NCT00881946|Drug|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
75723522|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
76046620|NCT01649791|Other|flow cytometry|Correlative study
75424329|NCT03185013|Device|Electroporation (EP)|Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
75424330|NCT03182907|Biological|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
75570369|NCT05470764|Drug|PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
75570370|NCT05470764|Drug|TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
75570371|NCT00597298|Device|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
75570372|NCT00597298|Device|sham threshold|non-training physical activity
75570373|NCT04320550|Diagnostic Test|abdominal ultra sound|non invasive tests to exclude pathological causes
75570374|NCT05271019|Device|Threshold load device|"Inspiratory Muscle Training (IMT) for 3 months:~Though a threshold loading device (5 sets of 6 repetitions, 1session/day, 5 days/week). the inspiratory load will start at 30% of MIP, or up to the maximum patient-tolerable load (max 60% of MIP), no more than 3-5/10 on the modified Borg scale."
76046621|NCT01649557|Drug|OPC-34712|oral administered once daily
75424331|NCT03182907|Drug|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
75424332|NCT03182907|Drug|Antibacterial drug treatment (ABD)|ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
75424333|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
75424334|NCT03170960|Drug|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
75570375|NCT04326634|Other|controlled exercises|controlled exercises
75570376|NCT04326634|Other|non controlled exercises group|non controlled exercises
76046622|NCT02390245|Other|Free Eye Screenings|This group will receive free eye screening and follow-up comprehensive ophthalmic exam if recommended.
75424335|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
75424336|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
75424337|NCT03159676|Radiation|Proton beam|Proton beam
75424338|NCT03143673|Device|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
75570377|NCT00597337|Behavioral|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
75570378|NCT00597415|Drug|celecoxib|celecoxib 200mg
75570379|NCT00597415|Drug|placebo|placebo
76046623|NCT02390245|Other|Enhanced Intervention|This group will receive ophthalmic referral and a navigator for assistance in scheduling appointments; confirming appointments via phone, mail, email and/or text message; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and trained medical interpreters as needed.
75723523|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
76046624|NCT02390245|Other|Usual Care|This group will receive ophthalmic referral.
76046625|NCT02390167|Device|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
76046626|NCT02347657|Drug|VX-661 Plus Ivacaftor Combination|FDC tablet, oral use
75424339|NCT03091725|Procedure|Roux-en-Y gastric bypass surgery|A bariatric surgery procedure which will help individuals achieve 16-18% weight loss
75424340|NCT03091725|Behavioral|Very low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose 16-18% of their body weight.
75570380|NCT00597454|Other|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
75424341|NCT03036813|Drug|voxelotor|
75570381|NCT04686110|Other|angiographic optical coherence tomography|angiographic optical coherence tomography
75570382|NCT00597532|Dietary Supplement|Soy|soy (soy protein supplementation 50 grams/day)
75570383|NCT00597532|Dietary Supplement|Milk|placebo (milk protein supplementation 50 grams/day)
75723524|NCT00807326|Drug|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
75570384|NCT00597610|Other|Transrectal ultrasound 3-D (TRUS)|Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
75570385|NCT00597649|Drug|Bicifadine|SR dosage form of 400 mg bid or tid for one year
75570386|NCT04686032|Other|Advanced early Rehabilitation Program|Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS* for incisional pain (30min)
75570387|NCT04686032|Other|Early ambulation|Patient education & Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
75570388|NCT00597688|Drug|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
75570389|NCT00597688|Drug|Placebo gel|Oral mucosal application of placebo gel
75723525|NCT00875082|Drug|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
75723526|NCT00875082|Drug|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
75723527|NCT02552342|Drug|methylprednisolone|
75723528|NCT02552342|Drug|Normal saline|
75723529|NCT00811226|Drug|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
76046627|NCT02347657|Drug|Ivacaftor|Tablet, oral use
76046628|NCT02347657|Drug|VX-661 Plus Ivacaftor Combination Placebo|FDC tablet, oral use
76046629|NCT02347657|Drug|Ivacaftor placebo|Tablet, oral use
75424342|NCT03036813|Other|Placebo|
75424343|NCT03027141|Behavioral|Face recognition task|Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
75723530|NCT00238303|Drug|vorinostat|Given orally
75877001|NCT02960113|Device|acupressure point P6|Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
75877002|NCT04850365|Procedure|Hysteropexy|"Abdominal Sacral cervicopexy:~The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.~Vaginal Sacrospinous cervicopexy:~This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion."
75877003|NCT02919696|Drug|Abemaciclib|Administered orally
75877004|NCT02740452|Device|ligamys technique|Ligamys technique (device) or standard technique
75723531|NCT00238303|Procedure|conventional surgery|Patients undergo surgery to remove tumor
75877005|NCT02740452|Other|standard technique (anatomic reconstruction)|Ligamys technique (device) or standard technique
75877006|NCT02935673|Drug|lumicitabine|Oral administration of lumicitabine as tablet.
75877007|NCT02935673|Drug|Placebo|Oral administration of matching placebo.
75723532|NCT00737633|Drug|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
75877008|NCT03622398|Procedure|Total knee arthroplasty with HXLPE liner|Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.
75570390|NCT00597844|Other|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
75723533|NCT00811460|Drug|Placebo|sc for 4 days
75723534|NCT00811460|Drug|taspoglutide|300micrograms/day sc for 2 days
75877009|NCT03622398|Procedure|Total knee arthroplasty with conventional polyethylene liner|Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
75877010|NCT03201809|Device|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
75877011|NCT03201809|Drug|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
75877012|NCT04458324|Drug|Buspirone Hydrochloride|Subjects take 30 mg buspirone HCl twice a day for 6 months.
75877013|NCT04458324|Drug|Buspirone placebo|Subjects take a placebo tablet twice a day for 6 months.
75570391|NCT00597844|Other|undergo voice evaluation and fMRI prior|in approximately one month and six months
75723535|NCT00811460|Drug|taspoglutide|800 micrograms/day sc for 2 days
75877014|NCT04458324|Device|Noninvasive Ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
75877015|NCT04458324|Device|Sham Non-invasive ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
75877016|NCT04458324|Other|Functional Electrical Stimulation Row Training (FESRT)|Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
75877017|NCT02858154|Other|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
76046630|NCT02347189|Device|Melody Transcatheter Pulmonary Valve PB1016|
75570392|NCT05467982|Behavioral|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.
75570393|NCT05467982|Behavioral|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
75570394|NCT05470530|Drug|Dexamethasone|Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
75723536|NCT00875238|Biological|trastuzumab|
75723537|NCT00875238|Drug|doxorubicin hydrochloride|
75723538|NCT00875238|Genetic|polymorphism analysis|
75723539|NCT00875238|Other|laboratory biomarker analysis|
75723540|NCT00875238|Other|questionnaire administration|
75723541|NCT00875238|Procedure|assessment of therapy complications|
75723542|NCT00875238|Procedure|magnetic resonance imaging|
75723543|NCT02552498|Procedure|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
75877018|NCT02858154|Other|Low flow oxygen by nasal cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
75877019|NCT03657420|Drug|ABI-009|ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.
75877020|NCT03657420|Drug|Pomalidomide|Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.
75877021|NCT03657420|Drug|Dexamethasone|Dexamethasone is a steroid which is believed to kill cancer cells
75570395|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
75877022|NCT02684214|Behavioral|Prevention Plus +|Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
75723544|NCT00732251|Drug|Allopurinol|Allopurinol: 300-600 mg/day over a 24 month period
75723545|NCT00811538|Procedure|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
75723546|NCT00811538|Procedure|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
75723547|NCT00811616|Device|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
75723548|NCT00882024|Drug|Tranilast|150 mg tranilast tablets, bid, 12 weeks
75877023|NCT02684214|Behavioral|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
75877024|NCT03657498|Procedure|Combined orthodontic-orthognathic treatment|combined treatment including orthodontics and orthognathic surgery
75877025|NCT03657498|Procedure|Standard orthodontic treatment|treatment with standard orthodontic procedures
75570396|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
75877026|NCT03657186|Dietary Supplement|ProbioSatys™|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
75877027|NCT03657186|Other|Placebo|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
75877028|NCT02985450|Biological|Engerix-B|Hepatitis B Vaccine
75877029|NCT03657030|Drug|CVN424|SAD / MAD
75877030|NCT03657030|Drug|Placebo|Placebo
75877031|NCT02908464|Device|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
75877032|NCT02907216|Biological|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
75570397|NCT02909517|Other|cSLO imaging|
75570398|NCT02891902|Other|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
75570399|NCT00598117|Behavioral|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~Initial QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS"
75723549|NCT00882024|Drug|Tranilast|75 mg tablets, bid, 12 weeks
75723550|NCT00882024|Drug|Placebo|Placebo tablets, bid, 12 weeks
75723551|NCT00799760|Drug|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
75723552|NCT00799760|Drug|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
75723553|NCT00799760|Drug|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
75723554|NCT00875316|Drug|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
75877033|NCT02907216|Biological|Rotarix|Two doses administered orally
75877034|NCT02984982|Drug|Alirocumab SAR236553|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
75877035|NCT02984982|Drug|Atorvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
75877036|NCT02984982|Drug|Rosuvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
76046631|NCT02382133|Device|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
76046632|NCT02346877|Behavioral|Personalized Patient Counselling|In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
76046633|NCT02346721|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
76046634|NCT02389621|Drug|Lusutrombopag|Tablets for oral administration
76046635|NCT02389621|Drug|Placebo|Tablets for oral administration
76046636|NCT02388997|Drug|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
76046637|NCT02388997|Biological|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
75570400|NCT02891980|Biological|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
75570401|NCT02891980|Biological|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
75570402|NCT00536666|Drug|Iron oligosaccharide|
75723555|NCT00799838|Drug|Ketoprofen|"Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
75723556|NCT00799838|Drug|Placebo (for Ketoprofen)|"Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
75723557|NCT00799838|Drug|Amoxicillin|"Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d"
75723558|NCT00799916|Drug|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
75723559|NCT00799916|Drug|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
76046638|NCT02388763|Device|Stenfilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
76046639|NCT02388763|Device|Narafilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
75723560|NCT00737477|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
75723561|NCT00256867|Drug|GSK523338|
75877037|NCT02984982|Drug|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
75877038|NCT02984982|Drug|Bezafibrate|"Pharmaceutical form: tablet~Route of administration: oral"
76046640|NCT02388295|Drug|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
76046641|NCT02388295|Drug|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
76046642|NCT02345161|Drug|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
76046643|NCT02345161|Drug|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
75723562|NCT00800072|Device|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
75723563|NCT00882180|Drug|ALN-VSP02|IV infusion administered every two weeks
75723564|NCT00800150|Drug|fludarabine phosphate|
75723565|NCT00800150|Drug|melphalan|
75877039|NCT02984982|Drug|Ezetimibe|"Pharmaceutical form: tablet~Route of administration: oral"
75877040|NCT02984982|Drug|Antiplatelets|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
76046644|NCT02345161|Drug|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
76046645|NCT02345161|Drug|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
76046646|NCT02345161|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
75570403|NCT04207762|Diagnostic Test|18F-AmBF3-TATE PET/CT|Blood pressure, heart rate, and oxygen saturation levels and EKG monitoring (vital signs) will be recorded prior to the injection and at three other stages of the scan visit. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
76046647|NCT02251275|Drug|Tolvaptan|Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
76046648|NCT02379637|Drug|N-acetylcysteine|
76046649|NCT02379637|Drug|Placebo|
76046650|NCT02195583|Drug|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
76046651|NCT02195583|Drug|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
76046652|NCT02195583|Drug|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
76046653|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
75424346|NCT03007953|Behavioral|Palliative Care|Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
76046654|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
76046655|NCT02195583|Drug|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
76046656|NCT02379091|Drug|Namilumab|Namilumab subcutaneous injection
76046657|NCT02379091|Drug|Placebo|Namilumab placebo-matching subcutaneous injection
76046658|NCT02379091|Drug|Methotrexate|Methotrexate tablets
76046659|NCT02379091|Drug|Folic/folinic acid|Folic/folinic acid tablets
76046660|NCT02378935|Drug|VOX|100 mg tablet(s) administered orally once daily with food
76046661|NCT02378935|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
76046662|NCT02378935|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75424347|NCT02984163|Behavioral|Exercise|Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.
75424348|NCT02981940|Drug|Abemaciclib|Abemaciclib capsule
75424349|NCT02981940|Procedure|Surgery|Surgery
75424350|NCT02930668|Dietary Supplement|Glucosanol 350mg|
75424351|NCT02930668|Dietary Supplement|Glucosanol 500mg|
75424352|NCT02930668|Dietary Supplement|Placebo|
76046663|NCT02250651|Drug|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
76046664|NCT02250651|Other|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
76046665|NCT02250651|Drug|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
75424353|NCT02922192|Drug|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
75570404|NCT04207762|Diagnostic Test|Routine blood draw|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after [18F]AmBF3-TATE administration.
75424354|NCT02921191|Drug|filgrastim, TBO-filgrastim or pegfilgrastim|First cycle
75570405|NCT04128943|Other|symptom questionnaire|"A weekly filled in symptom questionnaire for reported symptoms of AA and/or PNH (yes/no, grade, date). Grading according to current grading systems (Common Terminology Criteria for Adverse Events,CTCAE).~Data collection and processing via the ePRO application by Kaiku Health Ltd"
75424355|NCT02920021|Drug|Etokimab|Humanized monoclonal antibody, administered by intravenous infusion
75424356|NCT02920021|Drug|Placebo|Administered by intravenous infusion
75723566|NCT00800150|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75570406|NCT04128943|Other|recording of vital signs|Record function for vital parameters (blood pressure, temperature and pulse); Data collection and processing via the ePRO application by Kaiku Health Ltd
75570407|NCT04128943|Other|European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire|The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
75570408|NCT04128943|Other|interview|Interview with the patients and responsible medical team by phone or during hospital visit about functional problems regarding the application (duration: 15-30 min) to avoid incorrect use of the application, at week 3 and month 3 and month 6
75570409|NCT05467826|Drug|Sofosbuvir/Velpatasvir + Ribavirin|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
75424357|NCT02919618|Radiation|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
75570410|NCT05467826|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
75723567|NCT00800150|Radiation|intensity-modulated radiation therapy|
75723568|NCT00800150|Radiation|tomotherapy|
75723569|NCT00800150|Radiation|total marrow irradiation|
75723570|NCT00800150|Radiation|total nodal irradiation|
75723571|NCT04019717|Drug|AT-527|Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase
75723572|NCT04019717|Drug|Daclatasvir|Inhibitor of HCV nonstructural protein 5A (NS5A)
75424358|NCT02911701|Drug|Acetaminophen|
75424359|NCT02911701|Drug|Ibuprofen|
75424360|NCT02905370|Behavioral|Progressive Multi-Component (PMC)|"Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program."
75424361|NCT02905370|Behavioral|Enhanced Usual Care (EUC)|"Participants in the Enhanced Usual Care group will receive standardized physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education.~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group."
75723573|NCT00879216|Drug|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
75723574|NCT00879216|Drug|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
75723575|NCT00807404|Procedure|histopathologic examination|
75723576|NCT00807404|Procedure|optical coherence tomography|
75424362|NCT02896257|Other|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
75723577|NCT02592161|Drug|Experimental|"Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks"
75723578|NCT00800306|Drug|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
75723579|NCT00800306|Drug|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
75723580|NCT01581775|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
75424363|NCT02881203|Device|Breathe Well|Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
75424364|NCT02881203|Device|RPM|Varian Real-time Position Management (RPM) system
75424365|NCT02874742|Drug|Lenalidomide|Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
75424366|NCT02874742|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
75424367|NCT02874742|Drug|Dexamethasone|Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
75424368|NCT02874742|Drug|Daratumumab|Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
75424369|NCT02840019|Device|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
75424370|NCT02840019|Procedure|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
75723581|NCT04039152|Other|Clinical pharmacists recommendations to optimize antibiotics use|Optimal dosing, drug bug mismatch
75723582|NCT04046276|Behavioral|High Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
75877041|NCT02984982|Drug|Anticoagulants|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
75877042|NCT04357158|Device|AeonoseTM|All participants will be asked to breathe into an electronic nose (eNose, the AeonoseTM, The eNose Company, Zutphen, the Netherlands) for 5 minutes during the pre-colonoscopy intake and just prior to the procedure to assess reproducibility (with >2 weeks in between).
76046666|NCT02250651|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
76046667|NCT02377921|Drug|aceneuramic acid extended-release (Ace-ER)|tablets for oral use
75424371|NCT02818842|Other|Primary Health Insurance Fund data|"Data collected are:~First and last name of mother~Age~Mother's date of birth~Theorical date of beginning of pregnancy~Childbirth date"
75570411|NCT04127734|Procedure|The efficacy of various interventions for anastomotic leakage after rectal cancer resection are investigated|Investigated interventions comprise conservative, radiological, endoscopic and surgical (including stoma formation) interventions
75570412|NCT00598156|Drug|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
75570413|NCT00598156|Drug|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
75877043|NCT03622242|Device|Pain threshold index|In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
75570414|NCT00598195|Drug|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
75570415|NCT00598234|Drug|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
75877044|NCT03622242|Device|Wavelet index|In wavelet index monitor, monitor patients' wavelet index based on electroencephalography as an indicator of depth of anesthesia and adjust infusion rate of propofol according to wavelet index
75424372|NCT02818842|Other|Prenatal Diagnostic Center of Toulouse University Hospital data|"Data collected are :~First and last name of the mother~Mother's birth date~Mother Obstetric history~Course of pregnancy~Drug exposure (name, decision period)~Medical termination of pregnancy (date, cause ...)~Malformations (description, test results, gender of the child,~Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology)."
75424373|NCT02818842|Other|Mother and child protection data collection|"Date collected are :~Name and surname of Mother~Date of birth of the mother~Obstetric history of the mother (the first certificate to 8 days)~Course of pregnancy (1st certificate to 8 days)~Birth data (1 certificate to 8 days)~Child gender,~Age of the child at the time of the review,~Weight, height and head circumference of the child~American Pediatric Gross Assessment Record (1 certificate to 8 days)~Neonatal diseases (1 certificate to 8 days)~Birth defects (1 certificate to 8 days)~Death (age at death)~History (certificates at 9 and 24 months)~Current diseases (certificates at 9 and 24 months)~Psychomotor development (certificates at 9 and 24 months).~Date of drugs issue~Amount of drug issued~Type of feeding (1 certificate to 8 days)"
75424374|NCT02818842|Other|Medicalisation Program of Information Systems data|"Data collected are :~First and last name of the mother~Mother's birth date~History of abortions (date and cause)"
75424375|NCT02806843|Device|Rehab InterCap system and 3D Kinect|The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
75877045|NCT03656796|Other|Treadmill training with auditory cues|Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min
75877046|NCT03656796|Other|Treadmill training without auditory cues|Participants should walk in comfortable speed on the treadmill for 30 min.
75570416|NCT00598390|Drug|[11C]MePPEP|
76046668|NCT02377921|Drug|Placebo|tablets for oral use
76046669|NCT02311153|Device|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
75424376|NCT02805023|Biological|BGC101 (autologous EnEPC preparation)|Intramuscular injections - single treatment session
75424377|NCT02805023|Biological|Control medium|Intramuscular injections - single treatment session
75424378|NCT02793999|Device|Near-Infrared Spectroscopy (NIRS)|
75424379|NCT02791880|Procedure|Transcatheter Aortic Valve Replacement|The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
75424380|NCT02749292|Drug|Rituximab|re-dosing dependent on interventional arm parameter.
75424381|NCT02734017|Other|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
75424382|NCT02715609|Drug|Disulfiram|
75877047|NCT02258490|Biological|G-CSF mobilized CD34+ selected cells for transplantation|After screening and enrollment, donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using standard National Marrow Donor Program guidelines. CD34+ cell selection will be performed according to procedures given in CliniMACS Operating Manual and institutional Standard Operating Procedures. If storage after CD34+ selection is necessary, product will be kept in a monitored refrigerator. During storage, leukocyte concentration should not exceed 2 x 108 cells/ml using platelet poor plasma to adjust cell concentration. If donor's plasma is not available, CliniMACS buffer will be used. Cell processing will be performed by personnel trained by Miltenyi on CliniMACS system prior to initiation of clinical product selection. After tests are performed and product passes release criteria, patient will receive final product. No conditioning regimen will be administered prior to cell infusion.
75877048|NCT03656484|Drug|Tetracycline-Metronidazole (TM) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
75570417|NCT04326205|Device|transcranial direct current stimulation, tDCS|"The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice."
75877049|NCT03656484|Drug|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
75877050|NCT04309578|Drug|Trastuzumab, Capecitabine and Cisplatin|"Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1"
75877051|NCT03656952|Drug|PF-06700841|a single oral dose of 200 mg PF-06700841
75723583|NCT04046276|Other|Conventional Physical Therapy|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
75877052|NCT03656952|Drug|Placebo|Placebo matching PF-06700841
75877053|NCT03656952|Drug|moxifloxacin|a single oral dose of 400 mg moxifloxacin
75877054|NCT03656406|Behavioral|Lateral decubitus positioning|After the DLT intubation, the patient is placed in lateral decubitus position
75877055|NCT03656406|Device|Cuff-manometer|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning.
75424383|NCT02715609|Drug|Copper Gluconate|
75424384|NCT02715609|Procedure|Surgery|
75424385|NCT02715609|Radiation|Radiation|
75424386|NCT02715609|Drug|Temozolomide|
75424387|NCT02714881|Drug|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
75877056|NCT02237976|Behavioral|Self-hypnosis|
75877057|NCT02237976|Behavioral|Routine practice|
75424388|NCT02714881|Radiation|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
75424389|NCT02707744|Other|no intervention|
75424390|NCT02689076|Other|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
75424391|NCT02689076|Other|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
75424392|NCT02619136|Procedure|Transfusion|Red Blood Cell Transfusion
75424393|NCT02576990|Biological|Pembrolizumab|IV infusion
75723584|NCT04046276|Behavioral|Medium Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
75723585|NCT00731939|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
75723586|NCT01072591|Drug|MEDI-578|intravenous infusion, once
75424394|NCT02550561|Device|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
76046670|NCT02311153|Device|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
76046671|NCT02195427|Device|TEOSYAL® RHA Global Action|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles."
75424395|NCT02524171|Behavioral|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
75424396|NCT02513225|Behavioral|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
75424397|NCT02513225|Other|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
75424398|NCT02511106|Drug|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
75424399|NCT02511106|Drug|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
75424400|NCT02511106|Drug|Open-label AZD9291 80 mg/40 mg|Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
75424401|NCT02500589|Behavioral|Behavioral mood management|The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
75570418|NCT04326205|Device|functional electrical stimulation, FES|"The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice."
75570419|NCT04326205|Other|no stimulation|Both tDCS and FES will not be used in this section.
75570420|NCT00598429|Drug|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
75570421|NCT05470452|Other|The reading process is assisted by ENDOANGEL|Diagnosis of benign and malignant lesions with the help of ENDOANGEL
75570422|NCT05470452|Other|No ENDOANGEL assistance during the reading process|Diagnosis of benign and malignant lesions without the help of ENDOANGEL
75570423|NCT00598546|Behavioral|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
75877058|NCT03656250|Diagnostic Test|PET/CT scans|(approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
75877059|NCT02981472|Drug|Apixaban|Specified dose on specified days
76046672|NCT02195427|Device|TEOSYAL® RHA Deep Lines|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles."
76046673|NCT02214225|Biological|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
75424402|NCT02500589|Other|Health education|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information."
75424403|NCT02494882|Drug|Ruxolitinib|
75424404|NCT02494882|Drug|Dasatinib|
75424405|NCT02494882|Drug|Dexamethasone|
75424406|NCT02481830|Drug|Nivolumab|
75570424|NCT00598624|Drug|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
75570425|NCT02891785|Behavioral|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
75723587|NCT01072591|Drug|Placebo for MEDI-578|Intravenous infusion, once
75723588|NCT00882258|Drug|12.5 mg Proellex|12.5 mg Proellex administered orally daily
75723589|NCT00882258|Drug|25 mg Proellex|25 mg Proellex administered orally daily
75723590|NCT00882258|Drug|Placebo|Administered orally daily
75424407|NCT02481830|Drug|Topotecan|
75424408|NCT02481830|Drug|Amrubicin|
75723591|NCT00811694|Other|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
75723592|NCT04038606|Other|Determination of acceptance and / or rejection of mastectomy|Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
75723593|NCT03741595|Behavioral|Item spacing|Spatial proximity of items to one another
76046674|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
75424409|NCT02478138|Procedure|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
75424410|NCT02478138|Drug|Indocyanine Green (ICG)|
75424411|NCT02478138|Device|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
75424412|NCT02477111|Device|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
75424413|NCT02467738|Radiation|Brachytherapy|Undergo brachytherapy with Cesium-131
75424414|NCT02467738|Drug|Cesium-131|Undergo brachytherapy with Cesium-131
75424415|NCT02467738|Procedure|Conventional surgery|Undergo surgical resection
75723594|NCT00879294|Device|Motion sickness wristband|No drugs are involved.
75723595|NCT00879294|Dietary Supplement|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
75723596|NCT01072747|Biological|bovine heparin|5.000UI/mL bottle with 5mL
75723597|NCT01072747|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
75723598|NCT02594657|Procedure|pedal rate on 50 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
75723599|NCT02594657|Procedure|pedal rate on 80 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
75877060|NCT02981472|Drug|Vitamin K Antagonist (VKA)|Specified dose on specified days
76046675|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
75424416|NCT02426814|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
76046676|NCT02250183|Device|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
76046677|NCT02250183|Device|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
75877061|NCT02981472|Drug|Low Molecular Weight Heparin (LMWH)|Specified dose on specified days
76046678|NCT02249949|Drug|efatutazone|Given PO
76046679|NCT02249091|Drug|Selinexor|Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m^2 or 6 doses of 60 mg per induction cycle).
75424417|NCT02426814|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
75424418|NCT02425943|Device|injectable poly-L-lactic acid Sculptra Aesthetic|
75424419|NCT02416674|Procedure|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
75424420|NCT02416674|Drug|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
75424421|NCT02383173|Other|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
75877062|NCT03656172|Biological|Haemoglobin measure|Haemoglobin measure before and one month after standard iron treatment
75877063|NCT03656094|Drug|Pembrolizumab plus chemotherapy|Pembrolizumab plus chemotherapy
76046680|NCT02249091|Drug|Idarubicin|Infusion, iv, 10 mg/m^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
76046681|NCT02249091|Drug|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m^2, iv,
76046682|NCT02248857|Other|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
76046683|NCT02248857|Other|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
75424422|NCT02383173|Other|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
75424423|NCT02380690|Behavioral|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
75877064|NCT03656094|Drug|Placebo plus chemotherapy|Placebo plus chemotherapy
75877065|NCT04298034|Drug|Labetalol, Nifedipine|Antihypertensive treatment that is safe and well studied in peripartum women.
75877066|NCT02982720|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously.
75877067|NCT02982720|Drug|Sylatron|Sylatron will be administered subcutaneously.
76046684|NCT02213055|Drug|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
75570426|NCT00536094|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
75570427|NCT00536094|Behavioral|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
75424424|NCT02368132|Behavioral|Group Delivered TEP|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
76046685|NCT02213055|Drug|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
76046686|NCT02310763|Biological|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
76046687|NCT02310763|Drug|Placebo|
75424425|NCT02368132|Behavioral|Individual Delivered TEP|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
75424426|NCT02362997|Drug|Pembrolizumab|Anti-PD-1 monoclonal antibody
75424427|NCT02341118|Genetic|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
75424428|NCT02311673|Drug|Setmelanotide|subcutaneous injection
75424429|NCT02311673|Drug|Placebo|Subcutaneous injection
75424430|NCT02300870|Drug|Optison|Echocardiogram with IV contrast
75723600|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
75723601|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
75723602|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
75723603|NCT00879372|Drug|tianeptine|tianeptine 12,5mg TID
75723604|NCT00879372|Drug|Placebo|Placebo 12.5 mg TID
75723605|NCT00731783|Drug|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
75723606|NCT00731783|Drug|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
75723607|NCT00731783|Behavioral|Hygiene protocol|"Follow key hygiene tips indefinitely. Tips are:~Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~Use liquid(pour or pump) soaps instead of bar soaps.~Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~Do not share personal care items such as razors and brushes.~Wash all sheets and towels in hot water. Wash sheets every week.~Use towels and wash cloths only once before washing and do not share."
75723608|NCT00879450|Other|Booklet|booklet given to parents for home exercises
75723609|NCT02592083|Drug|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
75723610|NCT02592083|Drug|Palbociclib|
75723611|NCT04589676|Behavioral|Naloxone training|The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
75424431|NCT02285725|Procedure|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
75424432|NCT02285725|Procedure|Injections of BMAC + PRP + HA|All patients will receive up to 12 intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA
75424433|NCT02269150|Biological|fecal microbiota transplantation (FMT)|
75723612|NCT00724451|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
75723613|NCT00724451|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
75723614|NCT00724451|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
75723615|NCT00724373|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
75723616|NCT00724373|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
75723617|NCT02594579|Drug|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
75723618|NCT02594579|Drug|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
75723619|NCT02593409|Drug|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
75570428|NCT05466344|Device|Herbst Group|"Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~When reactivation of the telescopic piston is needed, extension rings are used."
75570429|NCT05466344|Device|TFBC Group|"The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~Finally follow finishing steps for each patient."
75570430|NCT02891746|Other|non invasive sampling|
75723620|NCT00724061|Biological|Pegylated interferon α-2b|PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
75723621|NCT00724061|Other|Psoralens with ultraviolet light A|Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
75723622|NCT00724061|Other|Narrowband-ultraviolet light B|The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
76046688|NCT02342743|Device|CEFALY|
76046689|NCT04891315|Diagnostic Test|Blood test for soluble VAP-1 (sVAP-1).|~5ml blood will be taken and sVAP-1 will be measure by Enzyme linked Immunosorbent Assay
76046690|NCT02377063|Dietary Supplement|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
76046691|NCT02309515|Other|Laboratory Biomarker Analysis|Correlative studies
76046692|NCT02309515|Drug|Lenalidomide|Given PO
76046693|NCT02309515|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
75424434|NCT02269150|Other|No fecal microbiota transplantation (FMT), routine management|
75723623|NCT04936386|Behavioral|Survey|The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
76046694|NCT02309359|Biological|ALX-0061|
75723624|NCT05195424|Diagnostic Test|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care
76046695|NCT02309359|Other|Placebo|
76046696|NCT02309359|Drug|Methotrexate|Stable background dose of commercially available methotrexate (not provided by the Sponsor).
76046697|NCT02247531|Drug|Lampalizumab|10 mg dose of lampalizumab administered intravitreally.
75424435|NCT02233738|Behavioral|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
75570431|NCT00598741|Other|DCE-MRI|"Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.~MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner."
75723625|NCT02594423|Device|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
75570432|NCT00598858|Drug|Docetaxel|Given IV
75570433|NCT00598858|Drug|Prednisone|Given PO
75570434|NCT02909166|Drug|aliskiren|
75570435|NCT05466305|Device|Gold plated chrome cobalt alloy|Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
75570436|NCT04207684|Drug|Testosterone injection|250 mg of testosterone cypionate (equivalent to 174,8 mg of testosterone) administered via intramuscular injection in a single dose (2 mL)
75570437|NCT02909400|Drug|KH176|
75570438|NCT02909400|Drug|placebo|
75570439|NCT05604950|Diagnostic Test|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
75570440|NCT03135067|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
75570441|NCT00536133|Drug|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
75570442|NCT00536133|Other|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
75570443|NCT05603858|Procedure|Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
75570444|NCT02909478|Drug|Aprepitant+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)"
75723626|NCT02594423|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
75723627|NCT04087187|Drug|Treatment A|Subject will be given AZD5718 Dose A tablet once daily
75723628|NCT04087187|Drug|Treatment B|Subjects will be given AZD5718 Dose B tablet once daily
75723629|NCT04087187|Drug|Treatment C|Subjects will be given AZD5718 Dose C tablet once daily
75723630|NCT04924764|Other|Conventional physical therapy.|Conventionally used intervention for subacute and chronic neck pain.
75723631|NCT02592005|Other|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
76046698|NCT02247531|Other|Sham Comparator|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
76046699|NCT02375971|Drug|Ranibizumab|Administered as an intravitreal injection
76046700|NCT02375971|Procedure|Laser therapy|Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
76046701|NCT02308735|Other|N/A - No intervention|
76046702|NCT02212197|Drug|leuprolide acetate FluidCrystal® injection depot|
76046703|NCT02212197|Drug|leuprolide acetate|
76046704|NCT02193165|Drug|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
76046705|NCT02193165|Drug|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
75424436|NCT02233738|Behavioral|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
75424437|NCT02220426|Drug|Xenon|Inhalation of hyperpolarized xenon gas
75424438|NCT02123121|Drug|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
75570445|NCT02909478|Drug|Dexamethasone+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)"
75570446|NCT03005626|Other|Therapeutic education|
75570447|NCT03005626|Other|Standard follow-up|
75570448|NCT00536211|Behavioral|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at ~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
75570449|NCT00536211|Drug|Metformin|oral tablet, 1000 mg daily for 17 days
75570450|NCT02914873|Procedure|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
75570451|NCT00536705|Drug|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
75570452|NCT00624208|Drug|droperidol and saline|droperidol 20 mcg.kg-1 and saline
75570453|NCT00624208|Drug|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
75570454|NCT00624208|Drug|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
75570455|NCT00624208|Drug|saline and saline|saline and saline
75570456|NCT00624247|Other|routine HIV testing|Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
75570457|NCT00536783|Drug|Quetiapine|
75570458|NCT00536289|Device|Blunt needle|Blunt tipped suture needle
75570459|NCT05601791|Procedure|Epidural Steroid Injection|Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat
75570460|NCT05601791|Procedure|Percutaneous Laser Disc Decompression|Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine
75570461|NCT05470062|Device|arch support insoles (FootDisc)|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
75570462|NCT04685642|Drug|Aspirin|Aspirin (100mg/day)
75570463|NCT04685642|Drug|Atorvastatin|Atorvastatin (20mg/day)
75570464|NCT02909244|Biological|Biological sampling|Biological sampling
75570465|NCT04685564|Drug|RBD1016|"Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission."
75570466|NCT04685564|Drug|Placebo|the same as RBD1016
75570467|NCT02909283|Procedure|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
75570468|NCT02908932|Dietary Supplement|Phospholipid-bound omega-3 supplement|The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.
75570469|NCT02908932|Dietary Supplement|Placebo supplement|Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.
75570470|NCT05595785|Behavioral|Physical-Based Yoga Practice|Physical-based yoga classes emphasized Bishnu Ghosh lineage hatha yoga. The 50 minute yoga classes were twice per week for four weeks. The yoga instructor had certifications in both Bikram and Amrit yoga practices and training in Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis
75570471|NCT05595785|Behavioral|Mindfulness-Based Yoga Practice|The mindfulness-based yoga classes included all elements of the physical-based yoga classes with the addition of mindfulness cues. The mindfulness cues included body scan, mindful movement, and yoga nidra. Certification of the instructor included the Integrative Amrit Method of Yoga Nidra that was inclusive of the use of mindfulness cues that coincided with the physical postures of yoga.
75570472|NCT02909205|Other|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
75570473|NCT02909205|Other|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
75570474|NCT05579795|Procedure|Detethering of the spinal cord|Release of the tethered spinal cord
75723632|NCT00882414|Drug|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
75723633|NCT00882414|Drug|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
75424439|NCT02123121|Drug|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
75424440|NCT02123121|Other|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
75424441|NCT02123121|Other|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
75424442|NCT02009579|Drug|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
75424443|NCT02009579|Drug|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
75723634|NCT02593487|Drug|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
75424444|NCT01959698|Drug|Carboplatin|Given IV
75424445|NCT01959698|Drug|Carfilzomib|Given IV
75424446|NCT01959698|Drug|Etoposide|Given IV
75424447|NCT01959698|Drug|Ifosfamide|Given IV
75424448|NCT01959698|Other|Laboratory Biomarker Analysis|Correlative studies
75424449|NCT01959698|Other|Pharmacological Study|Correlative studies
75424450|NCT01959698|Biological|Rituximab|Given IV
75424451|NCT01910402|Drug|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
75424452|NCT01910402|Drug|Atazanavir|Atazanavir capsule 300 mg
75424453|NCT01910402|Drug|Ritonavir|Ritonavir tablet 100 mg
75424454|NCT01910402|Drug|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
75570475|NCT05312346|Diagnostic Test|seum zinic,vit B12, parathyriod function|seum zinic,vit B12, parathyriod function
75570476|NCT05568563|Drug|Ethyl chloride|Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
75570477|NCT05568563|Other|Honey|Honey is a natural dietary product
75723635|NCT02593487|Drug|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
75570478|NCT00536861|Drug|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
75877068|NCT03655938|Procedure|Piezocision combined minimally invasive alveolar bone regeneration|The piezocision surgery was performed two weeks after orthodontic appliance placement. The patients received local anesthesia in mandibular arch and vertical interproximal incisions were made below the interdental papillae in the midline, from the mesial aspect of each canine and in between each of the posterior lower teeth. The periostium was then released in order to create two subperiotal envelopes connecting the vertical incisions together. Thereafter, corticotomies were performed in the region of the incisions with a piezotome (Acteon, Merignac, France) and the envelopes were filled with a beta tricalcium phosphate, a resorbable biomaterial in order to thicken the buccal bone plate. Resorbable 5-0 sutures were used to close the flaps. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
76046706|NCT02193165|Drug|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
75570479|NCT05469984|Drug|Ampicillin Only Product|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
75723636|NCT00875784|Drug|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
75723637|NCT00875784|Drug|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
75424455|NCT01790373|Behavioral|Suubi+Adherence|"Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~Financial education and workshops on asset-building, future planning, and protection from risks~Mentorship from a young adult/near-peer~Family-based microenterprise development training~Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
75723638|NCT00875784|Drug|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
76046707|NCT01617460|Drug|Aripiprazole|Flexibly dose administered orally once daily
76046708|NCT01890148|Drug|AZD5069|oral BD administration of 45 mg AZD5069
75424456|NCT01790373|Behavioral|Bolstered Standard of Care|"-Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
75424457|NCT01772420|Drug|Eltrombopag Olamine|Given PO
75570480|NCT05469984|Drug|ampicillin plus gentamicin|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
75723639|NCT00875784|Drug|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
75723640|NCT00875862|Procedure|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
76046709|NCT01889602|Drug|Lorazepam|Lorazepam: 2mg, po, 1x
76046710|NCT01889602|Other|Placebo|Non-active placebo, po, 1x
76046711|NCT01889602|Drug|Topiramate 100mg|Topiramate: 100 mg, po, 1x
76046712|NCT01889602|Drug|Topiramate 150mg|Topiramate: 150 mg, po, 1x
76046713|NCT01889602|Drug|Topiramate 200mg|Topiramate: 200 mg, po, 1x
75570481|NCT00536900|Behavioral|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
75570482|NCT00536900|Behavioral|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
75570483|NCT05312190|Drug|ZhenQi BuXue KouFuYe|Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
75723641|NCT00882492|Biological|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
75723642|NCT00882492|Biological|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
75424458|NCT01772420|Other|Laboratory Biomarker Analysis|Correlative studies
75424459|NCT01772420|Drug|Lenalidomide|Given PO
75424460|NCT01728363|Drug|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
75424461|NCT01614197|Drug|Temsirolimus|Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
75723643|NCT04038450|Other|No intervention|No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
75723644|NCT00879528|Other|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET:~PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
75877069|NCT03656640|Drug|Gammanorm|Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
75877070|NCT00849667|Drug|Farletuzumab|Farletuzumab IV infusion.
76046714|NCT01935700|Drug|Colchicine|"Adjustment the dosage of colchicine during study:~The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day."
75424462|NCT01614197|Drug|Etoposide|100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
75570484|NCT05312190|Drug|Progesterone Capsules|The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
75570485|NCT00537173|Procedure|Core Biopsy|biopsy
75570486|NCT00537173|Procedure|Blood Collection|Blood/serum sample
75570487|NCT00537173|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
75570488|NCT00537173|Drug|Avastin|Avastin 10 mg/kg IV, day 1 and 15
75570489|NCT00537212|Other|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
75570490|NCT00537212|Other|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
75877071|NCT00849667|Drug|Carboplatin|Carboplatin IV infusion.
75877072|NCT00849667|Drug|Taxane|Taxane (Paclitaxel or Docetaxel) IV infusion.
75877073|NCT00849667|Drug|Farletuzumab-matched placebo|Farletuzumab-matched placebo IV infusion.
75877074|NCT03201419|Drug|FE 201836|Oral solution for daily intake
76046715|NCT01618162|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
76046716|NCT01618162|Drug|placebo|Injected subcutaneously (under the skin) once daily.
75877075|NCT03201419|Drug|Desmopressin|Desmopressin Orally Disintegrating Tablet (ODT)
75877076|NCT03201419|Drug|Placebo oral solution|Manufactured to mimic experimental drug
75877077|NCT03201419|Drug|Placebo ODT|Manufactured to mimic experimental drug
75877078|NCT01331629|Other|ART-THERAPIE|8 sessions of art therapy during radiotherapy
75424463|NCT01614197|Drug|Cyclophosphamide|440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
75570491|NCT00537212|Other|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
75570492|NCT02503839|Drug|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
75570493|NCT02503839|Biological|H56:IC31|Therapeutic and prophylactic TB vaccine
75570494|NCT05469750|Drug|Dalpiciclib+ letrozole +capecitabine|Continue medication to disease progression
75570495|NCT05530109|Other|Neuropsychological screening and high resolution EEG recording|Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized
75877079|NCT01764633|Biological|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
75723645|NCT00879528|Other|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET~PET positive, the consolidation therapy consists of 2 phases:~phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells~phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.~If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
75877080|NCT01764633|Drug|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
75424464|NCT01614197|Drug|Methotrexate|"PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.~Age 1 - 1.99 give 8 mg of methotrexate~Age 2 - 2.99 give10 mg of methotrexate~Age 3 - 8.99 give 12 mg of methotrexate~Age ≥ 9 give 15 mg of methotrexate~PATIENTS WITH CNS 2 or 3 DISEASE~-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
75570496|NCT05469516|Device|Ulthera System [Ulthera, Inc.]|"The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~- Non-invasive treatment of Axillary Hyperhidrosis"
75570497|NCT05469516|Device|Merz Radiesse Injectable Implant|Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
75570498|NCT03457181|Other|music|effect of music on anxiety scores
75570499|NCT03457181|Other|operating room noise|effect of operating room noise on anxiety scores
75570500|NCT00537251|Drug|Insulin glargine|
75570501|NCT05311410|Other|Non-bloody dental procedures (control group)|Control group composed of 30 positive patients for SARS-CoV-2, from the same ICU, submitted to non-bloody procedures.
75570502|NCT05311410|Procedure|Bloody dental procedures (study group)|Study group consisting of 30 patients who require open dental treatment and with a positive PCR test for SARS-CoV-2 prior and admitted to the Intensive Care Unit.
75877081|NCT02924389|Drug|dolutegravir|Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.
75877082|NCT02924389|Drug|Triumeq|Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
75877083|NCT02924389|Drug|Truvada|Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
75877084|NCT05440981|Device|iTind device|Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.
75877085|NCT01315093|Drug|Heparin, Low-Molecular-Weight|Heparin from start till hcg test
76046717|NCT02193087|Drug|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
76046718|NCT02193087|Drug|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
76046719|NCT02193087|Drug|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
75723646|NCT00731549|Drug|Aripiprazole IM Depot|300mg or 400mg
75723647|NCT00875940|Other|Diagnostic imaging procedures.|
75877086|NCT01315093|Drug|no heparin|
76046720|NCT02193087|Drug|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
76046721|NCT01617070|Drug|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
76046722|NCT01617070|Dietary Supplement|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
76046723|NCT04771767|Drug|Ketamine|Patients will receive 6 sub-anesthetic IV ketamine infusions over 8 weeks, each one lasting 40 minutes.
76046724|NCT04771767|Behavioral|Online Trauma-Focused Cognitive Behavioural Therapy|Participants will enrol in a 12-week online CBT program mirroring in-person trauma-focused CBT.
75570503|NCT03457194|Biological|Quadrivalent Influenza Vaccine|Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.
75570504|NCT03457194|Biological|DTP Vaccine (Multiple Actives)|Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.
75570505|NCT05469399|Other|Experimental Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). After these applications, the students will be given a theoretical course on the admission of the patient to the clinic after the operation. After the theoretical lesson, a link for the virtual reality game application consisting of three different cases will be sent to the students for them to play on the phone and computer. Students will play this game application for a week. After the game application process, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
75570506|NCT05469399|Other|Control Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). No application will be made to the students for one week. One week later, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
75424465|NCT01614197|Drug|Hydrocortisone|"Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.~COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
75877087|NCT03235349|Drug|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
75877088|NCT01331707|Device|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
76046725|NCT02341417|Drug|Cinacalcet|Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
75570507|NCT05454137|Behavioral|Shared medical appointment|Shared medical appointment
76046726|NCT01888900|Drug|DUAL|Asunaprevir and Daclatsvir
76046727|NCT01888900|Drug|QUAD|Asunaprevir, daclatsvir, peginterferon and ribavirin
75723648|NCT00882570|Drug|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
75570508|NCT03457064|Behavioral|PA+Social Adherence Intervention(PASAI)|While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
75570509|NCT05433740|Device|Proseal Laryngeal mask fixation|fixation with Proseal Laryngeal mask adjustable ligament
75570510|NCT05294133|Behavioral|physical activity|physical activity
75570511|NCT00537368|Drug|CNTO 888|
75723649|NCT00882570|Drug|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
75723650|NCT00885456|Behavioral|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
75723651|NCT00885456|Behavioral|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
75723652|NCT00882726|Drug|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
75877089|NCT01331707|Device|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
75877090|NCT03235115|Device|Methafilcon A IV|Contact Lens
75877091|NCT03235115|Device|Ocufilcon B|Contact Lens
75877092|NCT03235115|Device|Omafilcon A|Contact Lens
75877093|NCT03953807|Drug|Dexamethasone Intravitreal Implant|Implant 700 μg
75877094|NCT03662711|Drug|Bronchodilator Agents|Fluticasone furoate/vilanterol
75877095|NCT03662711|Drug|Bronchodilator Agents|Tiotropium
75877096|NCT03662711|Drug|Bronchodilator Agents|Indacaterol
75877097|NCT03662711|Drug|Bronchodilator Agents|Umeclidinium/vilanterol
75877098|NCT03662711|Drug|Bronchodilator Agents|Fluticasone propionate/salmeterol
76046728|NCT02340949|Drug|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
76046729|NCT02340949|Drug|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
76046730|NCT02340949|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
76046731|NCT02340949|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
76046732|NCT01646203|Biological|IMC-TR1|Administered intravenously
75570512|NCT05399342|Other|No Intervention|Patients in the LAAOS III trial either had or did not have their left atrial appendage occluded at the time of surgery in that trial. No further intervention is required in this cohort, it is observational follow-up only.
75570513|NCT05285709|Diagnostic Test|Biomarker|blood and urine sampling before and after surgery (1-admission to operating ward, 2-leaving operation ward, 1st day postop, 2nd day postop, 5th day postop, or the day patient leaves hospital, whichever is first)
75570514|NCT05285709|Diagnostic Test|RRI measurement|patients able to cooperate will have renal resistive index measured before and after surgery (admission to operating ward, leaving operating ward)
75570515|NCT05282238|Diagnostic Test|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose). The measurement of DeltaPnose will be obtained considering the average of 3 values registered during 3 breath after at least 3 minutes of stable and constant respiratory pattern. Pnose values will be measured before extubation (T0) and 30 minutes (T1), 2 hours (T2), 4 hours (T3), 12 hours (T4) , 24 hours (T5) and 48 hours (T6) after extubation.
75570516|NCT00536367|Other|No intervention - observational study only|
75570517|NCT05468775|Behavioral|Naked eye 3D vision training|20 minutes of naked eye 3D vision training every day
75723653|NCT00882726|Drug|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
76046733|NCT02375347|Other|Chickpea Enhanced Diet (Short term)|"Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.~Stool Samples collected at Day 1, Day 9, and Day 14."
76046734|NCT02374957|Drug|Cilostazol|100 mg twice daily for 90 days
75570518|NCT05384717|Other|Fidget Device|Fidget spinner, stress ball, pop-it, or fidget cube
75570519|NCT05384717|Other|Control group|No intervention
75723654|NCT00882726|Drug|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
75723655|NCT00882726|Drug|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
75723656|NCT00882804|Drug|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in ~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
75723657|NCT00882804|Drug|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
75570520|NCT02399839|Drug|lomitapide|As prescribed by Physician.
75570521|NCT04321486|Other|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.
75723658|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
75723659|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
76046735|NCT02374255|Behavioral|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
76046736|NCT02308033|Drug|Metronidazole|
76046737|NCT02308033|Drug|Gel vehicle|
76046738|NCT02339155|Biological|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
76046739|NCT02339155|Biological|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
76046740|NCT02339155|Drug|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
76046741|NCT02211261|Biological|PF-06293620|subcutaneous, single dose 0.3 mg/kg
75570522|NCT05468658|Other|Designing the birthing unit according to the philosophy of Feng Shui|"The cabinets will be painted using salmon and pastel green.~It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~Live nature videos and sounds will be projected onto the wall.~Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~Natural plants will be placed.~Lighting will be used.~Bed linen will be designed according to the Feng Shui.~Wooden bell will be used.~Turtle, elephant and Wu Lou objects will be placed.~The Bagua mirror will be placed.~Crystals will be placed.~Natural stones will be placed.~The fountain will be placed in the east compass direction of the unit.~Straw bamboo separator will be used."
76046742|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
75424466|NCT01614197|Drug|Cytarabine|"For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~Age 1 - 1.99 give 30 mg of Cytarabine~Age 2 - 2.99 give 50mg of Cytarabine~Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~16 mg for patients age 1-1.99~20 mg for patients age 2-2.99~24 mg for patients 3-8.99 years of age~30 mg for patients >9 years of age"
75424467|NCT01584063|Behavioral|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
75424468|NCT01520701|Device|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
75570523|NCT04319926|Drug|lidocaine topical system 1.8%|One topical system is applied to the subject's back for 12 hours.
75570524|NCT04319926|Drug|lidocaine patch 5%|One generic lidocaine patch is applied to the subject's back for 12 hours.
75570525|NCT04320043|Procedure|Anterior cervical decompression|Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
75570526|NCT05382416|Behavioral|SHARE! Peer Toolkit Training|The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
75570527|NCT05194579|Combination Product|PF-06881894 by on-body injector|PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection
75570528|NCT05194579|Combination Product|PF-06881894 by prefilled syringe|PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection
75570529|NCT04320472|Other|Follow up|Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
75723660|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
76046743|NCT02211261|Biological|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
76046744|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
76046745|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 3 mg/kg
76046746|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
75570530|NCT05378594|Diagnostic Test|Nasal allergen challenge|graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
75723661|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
75723662|NCT00882960|Drug|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
75877099|NCT03662711|Drug|Bronchodilator Agents|Beclometasone dipropionate/formoterol
76046747|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 6 mg/kg
76046748|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
76046749|NCT02211261|Biological|PF-06293620|Intravenous infusion single dose 1 mg/kg
76046750|NCT02211261|Biological|Placebo|Intravenous infusion normal saline single dose
75570531|NCT05468580|Procedure|Endoscopic Coeliac Artery Release (eCAR)|Endoscopic Coeliac Artery Release (eCAR); The Median Arcuate Ligament will be cleaved via an endoscopic retroperitoneal approach using a 4 trocar technique described in detail by van Petersen (12). To rule out learning curves and procedural variation all the procedures will be performed by two experienced eCAR surgeons in the MST-Dutch Expert Centre of Gastrointestinal Ischemia. All procedures will be videotaped. Both eCAR surgeons will not be involved in the follow up procedures.
75424469|NCT01520701|Drug|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
76046751|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
76046752|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
76046753|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
76046754|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
75424470|NCT01422148|Drug|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
75424471|NCT01422148|Drug|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
75424472|NCT01341964|Drug|Clopidogrel|600mg (2 pills)
75424473|NCT01341964|Drug|Aspirin|325mg (1 pill)
75424474|NCT01341964|Drug|Aspirin|81mg (1 pill)
75424475|NCT01293214|Procedure|Limb transplantation|
75570532|NCT05468580|Procedure|Sham Operation|The sham operation consists of making 4 incisions up to the fascia similar to endoscopic AC release (eCAR). After 60 to 75 minutes of general anesthesia, in accordance with the average operating time of eCAR, the sham operation is ended. This study design allows for patient and observer blinding and for the sham group the eCAR approach is still feasible if the CARoSO outcome support this without applying additional scar tissue.
75723663|NCT00882960|Drug|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
75723664|NCT00883038|Other|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
75877100|NCT03662711|Drug|Bronchodilator Agents|Budesonide formoterol
75877101|NCT03662711|Drug|Bronchodilator Agents|Glycopyrronium
75877102|NCT03662711|Drug|Bronchodilator Agents|Aclidinium
76046755|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
76046756|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
76046757|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
76046758|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
75424476|NCT01267812|Drug|bortezomib|Given SC or IV
75424477|NCT01267812|Biological|rituximab|Given IV
75424478|NCT01267812|Other|laboratory biomarker analysis|Correlative studies
75424479|NCT01267812|Other|immunohistochemistry staining method|Correlative studies
75424480|NCT01267812|Genetic|RNA analysis|Correlative studies
75424481|NCT01267812|Genetic|gene expression analysis|Correlative studies
75570533|NCT04206943|Biological|Car-T Cell Therapy|"Lymphodepletion Protocol:~-6. Day: Cyclophosphamide 300 mg / m^2 i.v.~-5. -4. and -3. Days: Fludarabine 30 mg / m^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements."
75877103|NCT03662711|Drug|Bronchodilator Agents|Umeclidinium
75570534|NCT01313923|Drug|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
75570535|NCT01313884|Drug|Irinotecan|50 mg/m2/day x 5 days
75570536|NCT01313884|Drug|Vincristine|2 mg/m2 to a maximum of 2 mg
76046759|NCT02170077|Drug|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
75424482|NCT01267812|Genetic|DNA analysis|Correlative studies
75424483|NCT01267812|Other|pharmacological study|Correlative studies
75570537|NCT01313884|Drug|Temozolomide|100 mg/m2/day x 5 days followed by 2 weeks treatment-free
75570538|NCT01313884|Drug|Doxorubicin|Starting dose 75 mg/m2 to a maximum of 450mg/m2
75424484|NCT01267812|Other|pharmacogenomic studies|Correlative studies
75424485|NCT01267812|Other|Questionnaire Administration|
75424486|NCT01247974|Device|CorMatrix ECM for Pericardial Closure|Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
75424487|NCT01236521|Drug|Pharmacological (MED)|"During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment."
75424488|NCT01236521|Behavioral|Behavioral treatment (CBT)|There will be 8 sessions of pain self-management and coping skills.
75424489|NCT01226797|Drug|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
75424490|NCT01226797|Drug|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
75424491|NCT01142908|Behavioral|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
75570539|NCT01313884|Drug|Cytoxan|1200 mg/m2
75570540|NCT01313884|Drug|Pegfilgrastim|6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
75570541|NCT05352659|Behavioral|Face-to-face and online LGBTQ+ training|The intervention consists of Organization-level technical assistance in regard to LGBTQ climate of the organization AND Clinician-level face-to-face virtual workshop LGBTQ competency training, virtual clinical consultations, and links to publicly available LGBTQ training.
75877104|NCT03662711|Drug|Bronchodilator Agents|Formoterol
75877105|NCT03662711|Drug|Bronchodilator Agents|Indacaterol glycopyrronium
75877106|NCT03662711|Drug|Bronchodilator Agents|Salmeterol
75877107|NCT03662711|Drug|Bronchodilator Agents|Tiotropium olodaterol
76046760|NCT02170077|Drug|Placebo|Placebo tablets administered orally
76046761|NCT02210091|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
76046762|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
76046763|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
76046764|NCT02338999|Radiation|PET/CT|The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.
76046765|NCT02338999|Drug|Pioglitazone|Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.
76046766|NCT02338999|Drug|Placebo|
75570542|NCT05352659|Behavioral|On-line training|This study arm receives only links to publicly available on-line LGBTQ training.
75570543|NCT01158664|Device|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
75570544|NCT01158664|Device|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
75424492|NCT01051895|Other|high risk HPV DNA testing|Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
75424493|NCT01051895|Other|Active comparator: Routine colposcopy|Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
75424494|NCT01042379|Drug|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
75570545|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
75424495|NCT01042379|Drug|AMG 386 with or without Trastuzumab|Arm is closed.
75424496|NCT01042379|Drug|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
75570546|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
75570547|NCT05193240|Diagnostic Test|preliminary swallowing test|"Patients will be included before the surgery. During this inclusion visit, we will perform a preoperative swallowing test.~Immediately after surgery (H2-H24 after extubation), we will perform a preliminary swallowing test, an ultrasound examination of the vocal cords and a nasofibroscopy to determine the mobility of the vocal cords. A physiotherapist will carry out the first two assessments. An ENT physician will perform the nasofibroscopy. The ENT physician performing the nasofibroscopy will not know the conclusions of the tests carried out by the physiotherapist immediately after the operation.~At last, on day 4 after extubation, we will repeat the preliminary swallowing test and the ultrasound examination to measure the evolution of cord mobility.~30 days after the surgery, we will realize a follow-up on medical file and mark the end of the research."
75570548|NCT00537563|Drug|Telithromycin|
75570549|NCT00536406|Behavioral|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
75570550|NCT00536406|Behavioral|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
75570551|NCT01135459|Drug|CEP-33457|CEP-33457 will be administered per dose and schedule specified in the arm description.
75424497|NCT01042379|Drug|MK-2206 with or without Trastuzumab|Arm is closed.
75424498|NCT01042379|Drug|AMG 386 and Trastuzumab|Arm is closed.
76046767|NCT02169219|Drug|Glucocorticoids|"Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~60mg for 2 weeks~40mg for 2 weeks~30mg for 1 week~20mg for 1 week~10mg for 1 week~5mg for 1 week"
76046768|NCT02169219|Drug|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
75424499|NCT01042379|Drug|T-DM1 and Pertuzumab|Arm is closed.
75424500|NCT01042379|Drug|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
75424501|NCT01042379|Drug|Ganetespib|Arm is closed.
75424502|NCT01042379|Drug|ABT-888|Arm is closed.
75570552|NCT01135459|Drug|Placebo|Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
75570553|NCT00537602|Drug|miglustat|
75570554|NCT00537602|Drug|placebo|
75570555|NCT05178667|Dietary Supplement|High dose|Food supplements are consumed during 3 months by healthy volunteers.
75570556|NCT05178667|Dietary Supplement|Low dose|Food supplements are consumed during 3 months by healthy volunteers.
75570557|NCT05178667|Dietary Supplement|Maltodextrin|Food supplements are consumed during 3 months by healthy volunteers.
75877108|NCT03662711|Drug|Bronchodilator Agents|Aclidinium/formoterol
75424503|NCT01042379|Drug|Neratinib|Arm is closed.
75877109|NCT03662711|Drug|Bronchodilator Agents|Olodaterol
75570558|NCT00221572|Procedure|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
75723665|NCT00883038|Other|low-fat vegetarian diet|The low-fat vegetarian diet (~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
75877110|NCT03662711|Drug|Bronchodilator Agents|Formoterol/glycopyrronium bromide/beclometasone dipropionate
75877111|NCT03662711|Drug|Bronchodilator Agents|Fluticasone furoate/umeclidinium bromide/vilanterol
76046769|NCT02191605|Behavioral|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
76046770|NCT02191605|Behavioral|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
76046771|NCT02191137|Drug|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
76046772|NCT02168439|Drug|Dexmedetomidine|
76046773|NCT02168439|Drug|Midazolam|
76046774|NCT02190591|Device|Peanut Labor Ball|Peanut Labor Ball
75424504|NCT01042379|Drug|PLX3397|Arm is closed.
75424505|NCT01042379|Drug|Pembrolizumab - 4 cycle|Arm is closed.
75424506|NCT01042379|Drug|Talazoparib plus Irinotecan|Arm is closed.
75424507|NCT01042379|Drug|Patritumab and Trastuzumab|Arm is closed.
75424508|NCT01042379|Drug|Pembrolizumab - 8 cycle|Arm is closed.
75723666|NCT00883194|Drug|PRF-108|Ropivacaine
75877112|NCT02923531|Drug|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
76046775|NCT02190435|Device|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
76046776|NCT02190435|Device|Conventional technique|Conventional Technique
75424509|NCT01042379|Drug|SGN-LIV1A|Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
75424510|NCT01042379|Drug|Durvalumab plus Olaparib|Arm is closed.
75424511|NCT01042379|Drug|SD-101 + Pembrolizumab|Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for >T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
75424512|NCT01042379|Drug|Tucatinib plus trastuzumab and pertuzumab|Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
75424513|NCT01042379|Drug|Cemiplimab|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
75570559|NCT00536445|Device|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
75570560|NCT01259284|Drug|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
75570561|NCT01259284|Dietary Supplement|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
75723667|NCT00883194|Drug|Placebo|PRF-108 Placebo
75723668|NCT00883194|Drug|Ropivacaine|Solution
75723669|NCT00883194|Drug|PRF-110|
75877113|NCT02923531|Drug|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
75877114|NCT02934503|Biological|Pembrolizumab|200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.
75877115|NCT02934503|Drug|Cisplatin|75 mg/m2
75877116|NCT02934503|Drug|Carboplatin|AUC 6
75877117|NCT02934503|Drug|Etoposide|IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
75877118|NCT02934503|Radiation|Radiation therapy|Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
75877119|NCT03636217|Other|LGI-Milk Breakfast|This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
75877120|NCT03636217|Other|LGI-Kefir Breakfast|In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.
75877121|NCT03636217|Other|HGI-Kefir Breakfast|In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
76046777|NCT02338843|Drug|LJPC-501|Treatment arm
76046778|NCT02338843|Drug|Placebo|PBO
76046779|NCT02190279|Drug|18F DCFBC|Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
76046780|NCT02190279|Drug|Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)|
76046781|NCT02135445|Drug|TAK-385|TAK-385 tablet
76046782|NCT02135445|Drug|Degarelix|Degarelix injection
76046783|NCT02374099|Drug|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
76046784|NCT02374099|Drug|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
75424514|NCT01042379|Drug|Cemiplimab plus REGN3767|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
75570562|NCT01259284|Other|Placebo|"Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge."
75570563|NCT03457025|Drug|Oral Corticosteroids|Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
76046785|NCT02134977|Drug|Leuprorelin Acetate|Leuprorelin Acetate SR 11.25 mg Injection Kit
75570564|NCT03457025|Drug|Oral antivirals|acyclovir 400mg: one pill 4 times daily for 7 days
75570565|NCT03457025|Device|Hyperbaric Oxygen Therapy|2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
75570566|NCT01259245|Other|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
75877122|NCT04563247|Diagnostic Test|IgG SARS CoV 2 antibodies|The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
75877123|NCT02937545|Other|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
76046786|NCT02374021|Drug|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
75424515|NCT01042379|Drug|Trilaciclib with or without trastuzumab + pertuzumab|"Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles~For HER2+:~Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization"
75424516|NCT01042379|Drug|SYD985 ([vic-]trastuzumab duocarmazine)|SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
75424517|NCT01042379|Drug|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
75570567|NCT01259245|Other|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
75570568|NCT00537719|Drug|GSK716155|albiglutide subcutaneous injection
75570569|NCT00537719|Drug|Placebo|placebo injection
75570570|NCT04685603|Biological|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
75877124|NCT02937545|Other|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
75877125|NCT03636139|Device|transcranial DC stimulation : anodal|anodal stimulation of the right dlPFC (i.e. F4) for 20 minutes
75877126|NCT03636139|Device|transcranial DC stimulation : sham|sham stimulation of the right dlPFC (i.e. F4) for 20 minutes
76046787|NCT02374021|Drug|Sulfasalazine|1 gm bid
76046788|NCT02374021|Drug|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
76046789|NCT02374021|Drug|Etanercept|50 mg SC weekly
76046790|NCT02374021|Drug|Adalimumab|40 mg SQ every other week
76046791|NCT02372383|Drug|Ethambutol|Anti-mycobacterial oral drug
76046792|NCT02372383|Drug|Rifampin|Anti-mycobacterial oral drug
76046793|NCT02372383|Drug|Azithromycin|Anti-mycobacterial oral drug
76046794|NCT02372383|Drug|Pancrelipase|Pancreatic enzyme replacement therapy
75877127|NCT05435131|Diagnostic Test|GCF obtaining|GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
75570571|NCT04685837|Other|therapeutic exercise|"As soon as the study investigators have obtained a significant sample of patients with non-specific sub-acute low back pain, the intervention will begin.~The principal investigator will perform an individual assessment of the patients. At the end of the assessment, he will randomly distribute them into two groups. Tele-rehabilitation group and face-to-face group.~On the one hand, the main researcher will explain the application works to the tele-rehabilitation group. For 8 weeks, they have to perform 2 therapy exercise training sessions following the instructions on the application.~On the other hand, the researcher will explain the protocol to be followed by the group face to face. In addition, he will provide a schedule to follow a correct development of the protocol. Like the tele-rehabilitation group, they will carry out 16 sessions over 8 weeks.~At the end of the protocol, the principal investigator will perform an individualized assessment of each of the study participants."
75877128|NCT05435131|Diagnostic Test|Saliva Obtaining|Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
75424518|NCT01042379|Drug|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
75877129|NCT05435131|Diagnostic Test|Serum obtaining|Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
75424519|NCT01042379|Drug|Amcenestrant|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks
76046795|NCT01648699|Drug|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
76046796|NCT02134353|Drug|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
76046797|NCT02134353|Drug|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
76046798|NCT01646125|Drug|AUY922|AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
75877130|NCT01314209|Drug|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
75877131|NCT05434429|Other|mobile application|Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
76046799|NCT01646125|Drug|Docetaxel|Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
76046800|NCT01646125|Drug|Pemetrexed|Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
75877132|NCT05431075|Drug|Amoxicillin|Included in quadruple eradication medication.
76046801|NCT01362790|Drug|Pentostatin|Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle
75877133|NCT05431075|Drug|Tetracycline tid|Included in quadruple eradication medication.
76046802|NCT01362790|Drug|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
76046803|NCT01362790|Biological|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
76046804|NCT01362790|Biological|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles"
76046805|NCT02167893|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
76046806|NCT04759989|Procedure|Actual Body Weight Dosing|30cc/kg initial bolus calculated using Actual Body Weight
76046807|NCT04759989|Procedure|Adjusted Body Weight Dosing|30cc/kg initial bolus calculated using Adjusted Body Weight
76046808|NCT04759989|Procedure|Ideal Body Weight Dosing|30cc/kg initial bolus calculated using Ideal Body Weight
75570572|NCT00536562|Behavioral|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition & psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
75570573|NCT04685174|Device|Invos Model 5100C Cerebral/Somatic Oximeter|To measure the correlation between post arterial and venous anastomoses (reperfusion) NIRS values of transplanted kidney and post-transplant graft failure as manifested in initiation of renal replacement therapy post transplant
75723670|NCT04038528|Behavioral|telemonitoring of T2DM|"Baseline record of:~Weight~Height~BMI~Abdominal circumference~Winsor Index~ECG~Retinography~Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups.~Telemedicine group (intervention):~Blood sugar (two measurements per week).~Body weight (weekly)~Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed~Control group (control):~Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications.~Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter"
75723671|NCT04037436|Other|Strength and Balance Training & Nutrition Education|Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
75877134|NCT05431075|Drug|Tetracycline qid|Included in quadruple eradication medication.
75424520|NCT01042379|Drug|Amcenestrant + Abemaciclib|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
75570574|NCT00537758|Behavioral|Cognitive Behavior Therapy|
75877135|NCT05431075|Drug|Bismuth Potassium Citrate|Included in quadruple eradication medication.
75424521|NCT01042379|Drug|Amcenestrant + Letrozole|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
75424522|NCT01042379|Drug|ARX788|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
75424523|NCT01042379|Drug|ARX788 + Cemiplimab|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
75877136|NCT05431075|Drug|Colloidal Bismuth Pectin|Included in quadruple eradication medication.
75877137|NCT05431075|Drug|Esomeprazole 20mg|Included in quadruple eradication medication.
75877138|NCT04709393|Other|FRAX+SARC-F questionnaire pre-screening|Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
76046809|NCT02167035|Drug|Combigan Two Times Daily (BID)|
76046810|NCT02167035|Drug|Simbrinza Three Times Daily (TID)|
76046811|NCT01615198|Drug|Olmesartan|10 mg, 20 mg, 40 mg capsules
76046812|NCT01615198|Drug|Placebo|Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
75424524|NCT01042379|Drug|VV1 + Cemiplimab|VV1, 3x10^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
75424525|NCT01042379|Drug|Datopotamab deruxtecan|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
75570575|NCT00537758|Behavioral|CBT and BWL|
75570576|NCT00537758|Behavioral|Behavioral Weight Loss Treatment|
76046813|NCT01615198|Drug|LCZ696|100 mg, 200 mg tablets
75570577|NCT04685096|Other|Test product creme|twice daily application of creme containing 2% NMN
75570578|NCT04685096|Other|Reference creme|twice daily application of reference creme
75570579|NCT05121090|Behavioral|Educational program|"The educational program is based on dietary, physical activity, psychology, and sophrology approaches dispensed by health care professionals. Evaluations will consist of anthropometric measurements (height, weight, body mass index), behavioural questionnaires, and basic physical tests (handgrip, squats, balance, …).~Optionally, a saliva collection will be proposed to obtain the DNA required for genetic analyses."
75570580|NCT00537797|Other|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
75570581|NCT00537836|Drug|BAY 86-5310 (ZK 283197)|3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
75570582|NCT00537836|Drug|Placebo|Placebo, once daily p.o. over 8 weeks
75570583|NCT00537836|Drug|17ß-estradiol|1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
75570584|NCT05468268|Device|20 Hz rTMS|rTMS stimulation
75723672|NCT04037436|Other|Usual Care|During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
75723673|NCT00888732|Drug|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
75723674|NCT00730925|Drug|BIBW2992|tablet BIBW high dose
75723675|NCT00730925|Drug|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
75723676|NCT00236899|Drug|Gemcitabine|"Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).~Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
75424526|NCT01042379|Drug|Datopotamab deruxtecan + Durvalumab|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
75424527|NCT01042379|Drug|Zanidatamab|Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
75424528|NCT01042379|Drug|Lasofoxifene|Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
75424529|NCT01042379|Drug|Z-endoxifen|Z-endoxifen: 10 mg QD, p.o., for 24 weeks
75424530|NCT01042379|Drug|ARV-471|ARV-471: 200 mg QD, p.o, for 24 weeks
75570585|NCT05468268|Device|Sham rTMS|Sham stimulation
75424531|NCT01042379|Drug|ARV-471 + Letrozole|ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
75570586|NCT02277171|Device|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
75570587|NCT00537875|Dietary Supplement|Ginger|Capsule, 1000 mg, BID, 3 days
75570588|NCT00537875|Dietary Supplement|Placebo|Capsule, 1000 mg, BID, 3 days
75570589|NCT00551564|Drug|rosiglitazone maleate|Rosiglitazone tablets 4 mg dose will be administered orally by subjects
75570590|NCT05105061|Drug|Ketamine (Ketalar)|0.5 mg/kg of body weight
75570591|NCT05105061|Drug|Placebo|IM injection of matching placebo
75723677|NCT00236899|Drug|Docetaxel|"Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
75723678|NCT00236899|Drug|Paclitaxel|"Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
75723679|NCT00611130|Drug|vigabatrin|Tablets twice a day for 9 weeks
75570592|NCT04870463|Procedure|Maxillary and mandibular Cone Beam Computed Tomography record|A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
75570593|NCT00551603|Drug|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
75570594|NCT00551603|Drug|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
75723680|NCT00611130|Drug|placebo|tablets twice daily for 9 weeks
75723681|NCT00885690|Drug|Sertindole|Sertindole 16-24 mg once daily
75723682|NCT00885690|Drug|Olanzapine|Olanzapine 10-20 mg
75723683|NCT00888810|Drug|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
75723684|NCT00888810|Drug|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
75723685|NCT02542176|Other|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
75723686|NCT02542176|Other|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
75723687|NCT00256243|Drug|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
75723688|NCT00256243|Drug|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
76046814|NCT02337907|Drug|Placebo|for blinding purposes
75570595|NCT05093712|Other|Educational Intervention|Watch educational video
75570596|NCT05093712|Other|Survey Administration|Complete surveys
75570597|NCT04864262|Other|Photovoice|Photovoice is a method that uses photographs and dialogue to share experiences, understand an issue and promote positive change. Group meetings will be held four times throughout the photovoice intervention. The goals of the group meetings are to share knowledge about falls and fall prevention, identify commonalities in the issues raised by the participants, and discuss ways in which these issues could be addressed, both at individual and societal levels. For two photo assignments, participants will be asked to take 4-6 pictures for an assigned question. The question for photo assignment #1 will be 'What decreases your likelihood of falling?' The question for photo assignment #2 will be 'How do you reduce the risk of falling so that you can participate in meaningful activities?' Following each photo assignment, participants will complete an individual semi-structured interview with the peer mentor and the research trainee, who will have a background in physical or occupational therapy.
75570598|NCT04853264|Device|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
75570599|NCT04853264|Device|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by a registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture instituted in the hospital where the study will be conducted.
75570600|NCT05075811|Drug|Ossium vBM-MSC|Vertebral bone marrow derived mesenchymal stem cells
75570601|NCT05075811|Other|Placebo|Normal Saline
75570602|NCT04806191|Other|Evidence based treatment strategy|Evidence-based clinical examination and treatment plan
75570603|NCT04806191|Other|Targeted patient information package|GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).
75570604|NCT04806191|Other|Treatment as usual (TAU)|Usual care as provided by the GP
75570605|NCT05067426|Other|Exercise|high-intensity interval training sessions
75570606|NCT00551681|Device|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
75570607|NCT00551681|Device|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
75570608|NCT04686045|Other|observational study|observational study
75570609|NCT00551720|Behavioral|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
75570610|NCT00551720|Behavioral|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
75570611|NCT04686201|Device|Diabetes Mobile Application|incorporating mobile application usage in managing diabetes mellitus patient in health clinics
75723689|NCT00256243|Drug|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
75723690|NCT00256243|Drug|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
75723691|NCT00256243|Drug|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
75424532|NCT01033188|Procedure|Single bundle|"Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
75424533|NCT01033188|Procedure|Double bundle|"Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith & Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
75424534|NCT00544115|Drug|busulfan|
75424535|NCT00544115|Drug|cyclophosphamide|
75424536|NCT00544115|Drug|cyclosporine|
75424537|NCT00544115|Drug|etoposide|
75424538|NCT00544115|Drug|fludarabine phosphate|
75424539|NCT00544115|Drug|melphalan|
75424540|NCT00544115|Drug|methotrexate|
75424541|NCT00544115|Drug|mycophenolate mofetil|
75424542|NCT00544115|Drug|sirolimus|
75424543|NCT00544115|Drug|tacrolimus|
75570612|NCT00551798|Procedure|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
75570613|NCT05056584|Biological|Glucagon infusion|One hour glucagon-clamp followed by one hour of blood sampling
75570614|NCT05056584|Biological|Primed tracer infusion|Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,
75570615|NCT05467995|Biological|AK111|AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
75570616|NCT05467995|Biological|Placebo|Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
75877139|NCT03758417|Biological|LCAR-B38M CAR-T Cell|Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
75877140|NCT01329835|Behavioral|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
75570617|NCT00551915|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
75877141|NCT01329835|Other|brochure|brochure given after randomization
75877142|NCT03636659|Drug|Amphotericin B Liposome|Manufactured for: Auromedics Pharma LLC, USA
75877143|NCT03636659|Drug|AmBisome (Amphotericin B) Liposome|Marketed by: Astellas Pharma US, Inc. USA
75877144|NCT04892173|Drug|NBTXR3|Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.
76046815|NCT02337907|Drug|Placebo|
76046816|NCT02337907|Drug|BI 409306|
76046817|NCT02337907|Drug|Donepezil|
75570618|NCT00551915|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
75877145|NCT04892173|Drug|Cetuximab|Solution for infusion
75877146|NCT04892173|Radiation|Radiation Therapy|Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
75877147|NCT03199391|Device|BioWick SureLock Implant|The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
75877148|NCT01329913|Drug|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
75877149|NCT01329913|Drug|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
75877150|NCT01329913|Drug|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
75877151|NCT01329913|Drug|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
75877152|NCT01329913|Drug|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
75877153|NCT01329913|Drug|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
75877154|NCT01329991|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
75877155|NCT01329991|Drug|Placebo|Matching placebo for PLX5622
75570619|NCT00551915|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
75570620|NCT00551915|Biological|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
75877156|NCT03198767|Drug|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
76046818|NCT01913470|Drug|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
76046819|NCT02372071|Device|BiliCare|Two measurements with the BiliCare device
75570621|NCT00551915|Biological|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
75570622|NCT00551954|Drug|acarbose|100 mg (tablets) t.i.d.
75570623|NCT00551954|Drug|placebo|one tablet t.i.d.
75570624|NCT05467956|Other|Covid-19|Covid-19 disease
75570625|NCT04981236|Procedure|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.3% will be injected.
75570626|NCT04981236|Procedure|Periarticular block|The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
75877157|NCT03198767|Dietary Supplement|Carbohydrate 50%|50% carbohydrate in breakfast meal
75877158|NCT03198767|Dietary Supplement|Carbohydrate 25%|25% carbohydrate in breakfast meal
76046820|NCT02337751|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
76046821|NCT02166333|Dietary Supplement|200 IU/d cholecalciferol|
76046822|NCT02166333|Dietary Supplement|1000 IU/d cholecalciferol|
76046823|NCT02166333|Dietary Supplement|2000 IU/d cholecalciferol|
76046824|NCT02166333|Dietary Supplement|4000 IU/d cholecalciferol|
75570627|NCT00551993|Procedure|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
75723692|NCT00256243|Drug|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
75877159|NCT03198767|Dietary Supplement|Carbohydrate 8%|8% carbohydrate in breakfast meal
75877160|NCT03198767|Dietary Supplement|Carbohydrate 0%|0% carbohydrate in breakfast meal
75877161|NCT03198767|Dietary Supplement|Psyllium|Powder 6 grams
75723693|NCT04037202|Other|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
75877162|NCT03198767|Dietary Supplement|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
76046825|NCT02132949|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m^2 IV on Day 1 of each cycle q3w.
76046826|NCT02132949|Drug|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m^2) intravenous (IV) given on Day 1 of each cycle q2w.
75570628|NCT00551993|Procedure|Laparoscopic Sacral Colpopexy|Standard laparoscopy
75570629|NCT00552149|Drug|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
75570630|NCT05467878|Other|The anesthesia and analgesia technique preferred by the anesthetist will be recorded.|In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.
76046827|NCT02132949|Drug|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m^2 IV for the first cycle and the dose may be escalated to 100 mg/m^2 for subsequent cycles q3w.
76046828|NCT02132949|Drug|Doxorubicin|Participants will receive doxorubicin 60 mg/m^2 IV on Day 1 of each cycle q2w.
76046829|NCT02132949|Drug|Epirubicin|Participants will receive epirubicin 100 mg/m^2 IV on Day 1 of each cycle q3w.
76046830|NCT02132949|Drug|Paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV given weekly.
76046831|NCT02132949|Drug|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
75424544|NCT00544115|Procedure|allogeneic hematopoietic stem cell transplantation|
75424545|NCT00544115|Procedure|peripheral blood stem cell transplantation|
75424546|NCT00544115|Radiation|total-body irradiation|
75424547|NCT00150488|Device|Uracyst|2% weekly for 6 weeks, monthly for 4 months
75424548|NCT01455285|Device|transcutaneous electrical nerve stimulation|
75424549|NCT01455350|Procedure|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
75424550|NCT01455350|Drug|lidocaine|10 weeks of daily topical 5% lidocaine application
75570631|NCT03455699|Device|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
75570632|NCT03455699|Device|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
75723694|NCT01325857|Procedure|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
75723695|NCT01325857|Procedure|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
75723696|NCT01325857|Procedure|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
75877163|NCT03162055|Drug|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
76046832|NCT02132949|Drug|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
75877164|NCT03162055|Drug|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
75877165|NCT02927145|Biological|RH5.1/ ASO1|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."
75877166|NCT03980535|Procedure|Magnetic Resonance Imaging|Undergo MRI
75424551|NCT01455636|Other|Hand Sanitizer|The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
75877167|NCT03980535|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
76046833|NCT02165397|Drug|Ibrutinib|Participants will receive 420 mg of Ibrutinib orally.
76046834|NCT02165397|Drug|Placebo|Participants will receive placebo capsules orally.
76046835|NCT02165397|Drug|Rituximab|Participants will receive rituximab 375 mg/m^2 IV.
75877168|NCT03688919|Behavioral|Self-Regulation Intervention|The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
75877169|NCT01331785|Drug|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
75570633|NCT03455699|Device|Roll-In (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
76046836|NCT02132637|Drug|Insulin Peglispro|Administered SQ
76046837|NCT02132637|Drug|Insulin Glargine|Administered SQ
76046838|NCT02164929|Procedure|TAP block|
76046839|NCT02164929|Procedure|Epidural|
76046840|NCT02164929|Procedure|Paravertebral block|
76046841|NCT02164929|Drug|Acetaminophen 1g IV|
76046842|NCT02164929|Drug|Dexamethasone 4mg|
76046843|NCT02164929|Drug|Midazolam up to 2mg|
76046844|NCT02164929|Drug|Propofol 1-2.5 mg/kg|
75424552|NCT01455636|Dietary Supplement|Improved Micronutrient Powder|A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
75424553|NCT01455636|Other|No hand sanitizer|"All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.~No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed"
75570634|NCT00536640|Drug|Erlotinib|150 mg per os, given daily until tumor progression
75570635|NCT00536640|Drug|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
75570636|NCT00536640|Drug|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
75570637|NCT00536640|Drug|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
75570638|NCT00552227|Drug|ruboxistaurin|oral 32 mg daily
75570639|NCT00552227|Other|placebo|placebo
75570640|NCT00536679|Drug|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
75570641|NCT00536679|Drug|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
75570642|NCT00536679|Drug|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
75570643|NCT04793477|Device|instrumentation technique in pulpectomies|comparison of three file systems for pulpectomies in primary molars
75570644|NCT04974801|Device|Provox Life|Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)
75570645|NCT04974801|Device|Usual Care|Continued Usual Care routines.
75723697|NCT00888888|Procedure|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
75723698|NCT00236197|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
76046845|NCT02164929|Drug|Sevoflurane to keep a bispectral index of between 40-60|
76046846|NCT02164929|Drug|Local infiltration with 10 mL of plain ropivacaine 0.25%|
76046847|NCT02164929|Drug|Lidocaine|1.5% lidocaine
76046848|NCT02164929|Drug|Epinephrine|1:200,000 epinephrine
76046849|NCT02164929|Drug|Hydromorphone|400-800 mcg Hydromorphone will be given preoperatively
76046850|NCT04749615|Drug|Periarticular Injection (PAI)|PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.
76046851|NCT04749615|Drug|Saline Control Periarticular Injection (PAI)|equal volume of saline will be used in place of analgesics used in PAI injections
75570646|NCT04967430|Drug|Peginterferon Lambda-1A|"Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose."
75570647|NCT04967430|Other|Placebo|The placebo will be 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
75570648|NCT04783103|Device|a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil|3 weeks home use
75570649|NCT01259089|Drug|erlotinib hydrochloride|Given orally
75570650|NCT01259089|Drug|Hsp90 inhibitor AUY922|Given IV
75877170|NCT01382589|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
75877171|NCT01382589|Device|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
75877172|NCT01381653|Other|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
75877173|NCT03671759|Behavioral|Start: On Caffeine|In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
75877174|NCT03671759|Behavioral|Start: Off Caffeine|In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
75877175|NCT01384227|Drug|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
75570651|NCT01259089|Other|laboratory biomarker analysis|Correlative studies
75877176|NCT01315171|Dietary Supplement|Medium chain triglycerides|4 tablespoons/day for 2 weeks
75877177|NCT04631835|Drug|HS-10352|Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
75877178|NCT04646369|Behavioral|"screening as usual"|Participants in this group will receive usual care at their pediatric primary care practice following information, psychoeducation, and referral to a mental health treatment provider
75424554|NCT01455636|Dietary Supplement|No Micronutrient Powder|I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
75424555|NCT01456026|Dietary Supplement|Glycated beta-lactoglobulins.|oral, 20 g, single administration
75424556|NCT01456026|Dietary Supplement|Non-glycated beta-lactoglobulins|20 g, oral, single administration,
75424557|NCT01456078|Drug|177Lu-DOTA-TATE|"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."
75570652|NCT01259089|Procedure|needle biopsy|Undergo image-guided needle biopsy (correlative studies)
75570653|NCT01259089|Genetic|mutation analysis|Correlative studies
75570654|NCT01259089|Other|pharmacological study|Correlative studies
75570655|NCT05467839|Device|derma pen|Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
75570656|NCT05142436|Other|Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
75570657|NCT05142436|Other|Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B|42001399, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
75723699|NCT00236197|Drug|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
75723700|NCT02541708|Drug|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
75877179|NCT04646369|Behavioral|Screening Wizard 2.0|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
75424558|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
75424559|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
75570658|NCT05142436|Other|Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B|42001401, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
75570659|NCT05142436|Other|Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B|40007386, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
75570660|NCT05142436|Other|Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode A
75424560|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
75424561|NCT01456520|Drug|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
75424562|NCT01456520|Drug|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
75570661|NCT04960176|Procedure|Acupuncture|Acupuncture will be applied by using 0,25x25mm needles.
75570662|NCT04960176|Procedure|Non-invasive Sham Acupuncture|Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
75570663|NCT05466513|Other|Facial tactile stimulation|Tactile stimulation was given around the face with soft tissue paper for two minutes.
75570664|NCT00552266|Drug|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
75570665|NCT04943757|Drug|Bendamustine Hydrochloride|50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
75570666|NCT04943757|Drug|Cyclophosphamid|25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
75570667|NCT00552383|Procedure|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff [this includes 3 of the investigators], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
75570668|NCT04942704|Other|Non interventional Imaging - MRI|MRI Scanning using short protocols
75570669|NCT00552500|Drug|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
75723701|NCT02541708|Drug|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
75723702|NCT00278629|Biological|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
75877180|NCT04646369|Behavioral|Screening Wizard 2.0 + SOVA|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment. SOVA is a peer-support website that social workers and doctors moderate on a 24 hour a day basis.
75877181|NCT01382511|Drug|Simvastatine|80 mg
75877182|NCT02888119|Device|PRISMA 3T MRI scanner (Siemens Medical Solutions)|A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
76046852|NCT01888432|Drug|Everolimus + reduced tacrolimus|Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
75570670|NCT05465265|Behavioral|Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)|Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
75570671|NCT00552539|Other|'educational video'|'educational video'
75723703|NCT00883350|Behavioral|RIDE e-health application|The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
75723704|NCT03973567|Drug|selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants|On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
75723705|NCT03973567|Other|conventional therapy|Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
75424563|NCT01456559|Other|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.~Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
75424564|NCT01456572|Dietary Supplement|ensure plus|17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
75424565|NCT01456572|Dietary Supplement|standardized test meal|scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
75424566|NCT01456585|Other|Gemcitabine|
75424567|NCT01456585|Drug|CP-870,893|
75570672|NCT04917783|Behavioral|Passport Card|"After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report."
75570673|NCT04917783|Behavioral|No Passport card|After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
75723706|NCT00883428|Other|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
75723707|NCT03975361|Other|Bliss-Believe|The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
75723708|NCT00885924|Drug|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
75723709|NCT00885924|Drug|Placebo|NaCl 0.9%
75877183|NCT03631329|Diagnostic Test|Doppler sonographic measurement|First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
76046853|NCT01888432|Drug|Standard tacrolimus|Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
75723710|NCT01071811|Behavioral|Pedometer-based intervention|The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
75877184|NCT03684447|Drug|Propofol|Series of 6 treatments with propofol.
75877185|NCT03684447|Drug|Propofol|Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
76046854|NCT02188719|Biological|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is <50/mm^3 or when the maximal dose of 4.5/mg/kg has been given.
76046855|NCT02188719|Biological|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
75570674|NCT02277314|Procedure|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
75723711|NCT01071889|Drug|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
75723712|NCT01071889|Drug|Placebo|Placebo - only excipients with no API
75723713|NCT00612690|Behavioral|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
76046856|NCT02188719|Drug|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
76046857|NCT02188719|Drug|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
76046858|NCT02188719|Drug|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
76046859|NCT02188719|Drug|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
75424568|NCT01456650|Drug|Glyburide|"Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:~Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening."
75424569|NCT01456806|Other|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
75424570|NCT01457040|Drug|TBI+CY+VP-16|CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
75424571|NCT01457040|Drug|FA+TBI+CY+VP-16|NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10~-6d; AraC: 1g/m2/d, -10d~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
75424572|NCT01457209|Other|Acupuncture|"Needle placement in abdominal muscles, in m. vastus lateralis, lower leg and hands.~Stimulation: Manual rotation of the needles and electrical stimulation of the needles in the abdominal muscles and m. vastus lateralis will be stimulated electrically with low burst frequency Duration: 30 min Treatment: 3 times/wk during 5 weeks."
75570675|NCT04756388|Other|Strategy Development|Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.
75570676|NCT04756388|Other|Computerized Cognitive Training|Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.
75570677|NCT01258738|Biological|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
75570678|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
75723714|NCT00612690|Behavioral|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
75877186|NCT04505059|Procedure|Precision cardiac anesthesia|Aperi-operative anesthetic management through target-controlled infusion to accurately control the patient blood concentration, with combination of bispectral index and neuromuscular monitoring to adjust the dosage of general anesthetics.
75424573|NCT01457248|Device|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
75424574|NCT01457248|Device|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
75424575|NCT01457508|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
75424576|NCT01457508|Biological|DTPa-HBV-IPV (Infanrix penta™)|Three doses administered intramuscularly
75424577|NCT01457508|Biological|Hib (Hiberix™)|Three doses administered intramuscularly
75424578|NCT01457586|Biological|Blood transfusion|Blood transfusion in perioperative period.
75424579|NCT01457586|Biological|No blood transfusion|No transfusion in the perioperative period.
75877187|NCT04505059|Procedure|Conventional cardiac anesthesia|The anesthesia strategy is mainly depending on the anesthesiologist's clinical experience
75424580|NCT01457794|Other|School meals based on the principles of the New Nordic Diet|The study participants are provided with three daily school meals for 3 month
75424581|NCT01458093|Other|colonoscopy|evaluation of surveillance timing adequacy as compared to the guidelines
75570679|NCT01258738|Other|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
75570680|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
75723715|NCT03973411|Drug|Prophylactic ondansetron|Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
75723716|NCT03973411|Drug|Placebo|Pacients will receibe standard spinal anesthesia
75877188|NCT01382433|Procedure|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
75877189|NCT01382433|Behavioral|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
75424582|NCT01458145|Behavioral|Minding the Baby Home Visiting Program|Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
75570681|NCT04900077|Device|Carriere® Motion™ Appliance|class II malocclusion corrector
75570682|NCT00552656|Device|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
75570683|NCT05604456|Procedure|secondary ear reconstruction based on Nagata method|Secondary auricular reconstructions based on Nagata method were conducted on patients who sought for secondary revision.
75723717|NCT00883506|Drug|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
75723718|NCT00883506|Drug|Lisinopril 40 mg Tablet under fasting conditions.|
75723719|NCT00883506|Drug|Lisinopril 40 mg Tablet under fed conditions.|
75723720|NCT04268784|Drug|DNL343|Single and repeating oral dose(s)
75570684|NCT01824537|Biological|HPV vaccine, Gardasil 9|Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).
75570685|NCT01824537|Biological|Hepatitis A vaccine|Provided by Sanofi Pasteur.
75570686|NCT04863339|Drug|Tranexamic acid|Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
75570687|NCT04863339|Drug|Placebo|Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
75877190|NCT01382433|Behavioral|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
75877191|NCT03549299|Biological|LSC2|Topical application of IMP on target eye
75424583|NCT01458184|Behavioral|PhoneCare system|"The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through virtual visits and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation)."
75877192|NCT01315327|Drug|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
75877193|NCT01315327|Drug|Olive oil|Placebo
75723721|NCT04268784|Drug|Placebo|Single and repeating oral dose(s)
75723722|NCT00278473|Behavioral|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
75723723|NCT00278473|Behavioral|Supportive Therapy|Social Support Problem-Solving Group Treatment
75877194|NCT01314599|Drug|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."
75877195|NCT04243863|Drug|VNRX-7145|Part 1: one dose Part 2: 28 doses (once every 8 hour [q8h] dosing for 9 days with a single morning dose on Day 10)
75877196|NCT04243863|Drug|Placebo|Part 1: one dose Part 2: 28 doses (once every 8 hour [q8h] dosing for 9 days with a single morning dose on Day 10)
75877197|NCT02635633|Device|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7*(DEF-DM1) [DEF = distance over EF; DM1 = distance over M1]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
75424584|NCT01458314|Other|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
75424585|NCT01458314|Other|Rehabilitation without NIV|Training in patients without NIV adoption
75424586|NCT01458353|Procedure|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
75424587|NCT01458353|Procedure|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
75424588|NCT01458431|Drug|Levobupivacaine|continuous levobupivacaine subfascial infusion
75570688|NCT04684277|Drug|antidepressant treatment|depression recieve antidepressant treatment
75570689|NCT04684277|Other|antidepressant treatment combined with Internet-based interventions|depression recieve antidepressant treatment combined with Internet-based interventions
75570690|NCT05604183|Procedure|non-invasive hyperspectral retinoscopy|The Principal Investigator or a trained medical nurse (under the supervision of the principal investigator) will take an image of the retina of the patient with the Mantis Photonics hyperspectral retinoscopy camera.
75570691|NCT05604183|Procedure|blood sample|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will draw a small blood sample according to the standard medical procedures for drawing blood samples.
75570692|NCT05604183|Diagnostic Test|Test of cognitive ability on tablet computer with CoGNIT software|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
75570693|NCT05603871|Procedure|ligamentoplasty of ligamentum teres|"An addition to the steps of the open reduction, the following were done:~Identification of ligamentum teres~Ligamentoplasty of ligamentum teres"
75723724|NCT04037280|Other|Exercise|Four type of exercises will be delivered to patients. These exercises differ for posology and typology.
75723725|NCT00278395|Drug|Vorinostat|Given orally
75723726|NCT00889044|Drug|clopidogrel by chewing|600 mg clopidogrel by chewing
75723727|NCT00889044|Drug|Placebo|Placebo p.o
75723728|NCT00889122|Behavioral|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
75877198|NCT03197129|Other|sensory adapted waiting room|The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. A lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
76046860|NCT02188719|Drug|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
76046861|NCT02188719|Drug|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
76046862|NCT02188719|Drug|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
75424589|NCT01458431|Drug|NaCl|continuous NaCl subfascial infusion
75424590|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
75424591|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
75424592|NCT01458782|Procedure|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
75424593|NCT01458808|Other|Dietary sodium restriction|Restriction of 2 grams on daily sodium diet intake.
75424594|NCT01458808|Other|Dialysate sodium concentration reduction|Reduction of dialysate sodium concentration from 138 to 135 mEq/L
75424595|NCT01459328|Radiation|Radiotherapy|"Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day~Injected Leucovorin 20 mg/m2/day for 5 days"
75424596|NCT01459328|Radiation|Radiotherapy|"Conventional long course chemo-radiation:~Radiation 50Gy in 25 daily fractions over 5 weeks~Bolus 5 Fluorouracil 350mg/m2/d for 5 days~Injected Leucovorin 20mg in both the first and last (5th) week of radiation~Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks."
76046863|NCT02188719|Procedure|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level >/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level </=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
75424597|NCT01459393|Drug|5-ALA Photodynamic Therapy|
75424598|NCT01459393|Drug|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
75424599|NCT01459445|Drug|Metformin, Ethinylestradiol 30µg-Drospirenone|Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
75424600|NCT01459458|Behavioral|Family Planning-based Partner Violence Intervention|"The intervention includes three major components:~Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.~Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.~Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed."
75424601|NCT01459523|Procedure|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
75723729|NCT00886002|Drug|Fentanyl; Buprenorphine; Naloxone|
75723730|NCT00883584|Drug|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
75723731|NCT00883584|Drug|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
75723732|NCT00883662|Drug|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
75723733|NCT03669822|Other|Standard of care|Care decisions driven by local physicians; this is an observational cohort.
75723734|NCT00883818|Drug|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
75570694|NCT04651985|Other|Eccentric strengthening exercises of the Achilles tendon|This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
75570695|NCT04853940|Other|Data collection and clinical testing of subjects|6-months follow-up with clinical testing at 3 and 6 months
76046864|NCT02188719|Procedure|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
76046865|NCT02188719|Procedure|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
75424602|NCT01459523|Procedure|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
76046866|NCT02188719|Procedure|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
76046867|NCT01934140|Biological|Meningococcal vaccine GSK134612|1 dose administered intramuscularly in the non-dominant deltoid region.
76046868|NCT04416100|Diagnostic Test|Pulmonary function tests|Spirometry or plethysmography, measurement of diffusion capacity
76046869|NCT04416100|Diagnostic Test|Imaging|HRCT and echocardiography as scheduled within routine clinical examinations
75424603|NCT01459523|Procedure|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
75424604|NCT01459523|Procedure|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
75424605|NCT01459744|Behavioral|Communication training for cardiologists.|"Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills."
75424606|NCT01459744|Other|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
75424607|NCT01459757|Other|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
75424608|NCT01459874|Behavioral|Organizational model for remote monitoring|An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
75570696|NCT04647968|Procedure|Primary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.
75570697|NCT04647968|Procedure|Secondary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
75723735|NCT00889356|Drug|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
76046870|NCT04416100|Biological|Blood sampling|Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping
76046871|NCT01933672|Drug|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
76046872|NCT01933672|Drug|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
76046873|NCT01933672|Drug|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
75723736|NCT00889356|Drug|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
75723737|NCT00886080|Procedure|Pulmonary vein isolation using microwave energy|The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
75570698|NCT04630184|Behavioral|Exposure intervention in virtual reality|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) with cognitive restructuring and VR exposure supervised by psychologists
75570699|NCT04630184|Behavioral|Exercise|Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).
75723738|NCT00889434|Dietary Supplement|ECGC|1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
75723739|NCT00889434|Dietary Supplement|Tocotrienol|One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
75877199|NCT04217135|Drug|evidence-based medications vs. high-dose hydralazine + evidence-based medications|randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
75877200|NCT01337401|Drug|Cediranib|30mg once daily, oral until disease progression
75877201|NCT01337401|Drug|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
76046874|NCT02164539|Drug|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
76046875|NCT02164539|Drug|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
76046876|NCT02164539|Drug|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
75424609|NCT01459965|Procedure|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
75424610|NCT01459965|Procedure|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
75424611|NCT01460004|Device|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
75424612|NCT01460017|Procedure|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
75424613|NCT01460017|Procedure|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
75424614|NCT01460030|Drug|Cinacalcet HCl|Oral administration
75424615|NCT01460043|Drug|Homeopathy|Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
75424616|NCT01460043|Drug|placebo|corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
75570700|NCT04630184|Behavioral|Placebo|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) Discussion around social physical anxiety, stress management (relaxation and breathing) supervised by psychologists
75570701|NCT00552734|Device|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
75570702|NCT00552773|Drug|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
75570703|NCT00536718|Genetic|gene expression analysis|
75570704|NCT00536718|Genetic|molecular diagnostic method|
75570705|NCT00536718|Genetic|polymorphism analysis|
75570706|NCT00536718|Genetic|protein expression analysis|
75570707|NCT00536718|Other|medical chart review|
75723740|NCT00889434|Dietary Supplement|EGCG + Tocotrienol|combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
75723741|NCT00612534|Drug|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
75723742|NCT00612534|Drug|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
75723743|NCT00612534|Drug|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
75723744|NCT00612534|Drug|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
75877202|NCT01331863|Procedure|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
75723745|NCT02542254|Drug|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
75723746|NCT02542254|Drug|Ipratropium|40 micrograms ipratropium administered using a pMDI
75877203|NCT04178603|Other|Exercise, insulin infusion|Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
75424617|NCT01460069|Drug|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
75424618|NCT01460069|Drug|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
75424619|NCT01460095|Other|HbA1c measurement and education|three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
75424620|NCT01460108|Device|AeriSeal System|20 mL
75424621|NCT01460121|Device|SpotOn's corrective elements for dizziness|Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
75877204|NCT01333891|Drug|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
75877205|NCT01333891|Drug|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
75877206|NCT01333891|Device|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
75424622|NCT01460121|Device|Placebo|
75424623|NCT01460134|Drug|CDX-1127|"Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127."
75424624|NCT01460134|Drug|CDX-1127|"Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
75570708|NCT00536718|Other|questionnaire administration|
75570709|NCT04831164|Other|NA (not an interventional study)|(not an interventional study)
76046877|NCT02188485|Behavioral|ENGAGE|Up to 10 sessions delivered in the home.
75570710|NCT04816617|Behavioral|Aerobic exercise intervention|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
75723747|NCT02542254|Drug|RPL554|6 mg RPL554 administered using a nebuliser
75723748|NCT02542254|Drug|Salbutamol matched placebo|Placebo pMDI
75723749|NCT02542254|Drug|Ipratropium matched placebo|Placebo pMDI
75723750|NCT02542254|Drug|RPL554 matched placebo|Nebulised placebo
75877207|NCT01333891|Device|Goldmann applanation tonometer|intraocular pressure measurements
75877208|NCT01333891|Device|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
75877209|NCT04853875|Drug|Tetracycline, Metronidazole, Bismuth subcitrate|52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
75877210|NCT04853875|Drug|Amoxicillin, Metronidazole, Clarithromycin|52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
76046878|NCT02132247|Drug|Diclofenac hydroxyethylpyrrolidine|
76046879|NCT01629381|Drug|Rivaroxaban|10 mg os once daily for 1 week
76046880|NCT01629381|Drug|placebo|10 mg os once daily for 1 week
76046881|NCT02131311|Device|disposable, single-use pessary|
75877211|NCT03196973|Drug|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
76046882|NCT05269017|Drug|Vitamin D3|Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks
75424625|NCT01460134|Drug|CDX-1127|"Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
76046883|NCT05269017|Drug|Budesonide nasal spray|64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
76046884|NCT01628913|Drug|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
75570711|NCT04816617|Behavioral|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
75424626|NCT01460147|Other|DXA scan + MRI|This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).
75723751|NCT00883974|Behavioral|Sensitivity Training|"The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping."
75877212|NCT03196973|Drug|DF289|1 vial into the affected ear twice daily for 7 days
75877213|NCT03196973|Drug|DF277|1 vial into the affected ear twice daily for 7 days
75424627|NCT01460173|Other|Divided Attention Steering Simulator (DASS)|Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
75424628|NCT01460186|Other|Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)|Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
75424629|NCT01460199|Drug|CTP-499|"3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)"
75424630|NCT01460199|Drug|placebo|tablets
75424631|NCT01460212|Drug|SSRI antidepressants|SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
75570712|NCT04543682|Drug|0.125 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours
75570713|NCT04543682|Drug|0.25 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours
75723752|NCT00889590|Drug|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
75877214|NCT01333969|Procedure|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
75877215|NCT03196505|Drug|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
76046885|NCT01628913|Drug|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
76046886|NCT02164383|Drug|Nicotine patch|4-week starter kit of nicotine patch
76046887|NCT02164383|Behavioral|Cessation Counseling|5 brief counseling sessions
76046888|NCT02164383|Device|Mobile Games|
76046889|NCT02131233|Drug|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
76046890|NCT02131233|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily
76046891|NCT02131233|Drug|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
75424632|NCT01460212|Behavioral|Cognitive-Behavior Therapy|The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
75424633|NCT01460251|Drug|DiaPep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
75424634|NCT01460277|Procedure|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
75424635|NCT01460277|Procedure|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
75424636|NCT01460316|Biological|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
75424637|NCT01460329|Device|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
75424638|NCT01460355|Drug|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
75424639|NCT01460355|Drug|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
75424640|NCT01460420|Drug|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
75424641|NCT01460420|Drug|Len (lenalidomide)|"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified."
75424642|NCT01460433|Procedure|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
75424643|NCT01460459|Behavioral|a specific frequency of SMBG|"Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly"
75424644|NCT01460472|Biological|Racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
75424645|NCT01460472|Other|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
75424646|NCT01460498|Drug|Azacitidine (AZA)|Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.
75424647|NCT01460498|Drug|Tyrosine kinase inhibitor (TKI)|Continuation of dose already receiving during previous 6 months.
75424648|NCT01460498|Drug|Azacitidine|75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
75424649|NCT01460537|Drug|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
75424650|NCT01460537|Drug|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
75570714|NCT04543682|Procedure|open reduction and internal fixation with an angular stable plate (PHILOS)|open reduction and internal fixation with an angular stable plate (PHILOS)
75424651|NCT01460537|Drug|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
75877216|NCT03196505|Drug|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
75424652|NCT01460537|Drug|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
75424653|NCT01460537|Drug|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
75424654|NCT01460550|Procedure|Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
75877217|NCT01334047|Biological|DC-006 vaccine|Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
75877218|NCT01337557|Drug|Bepotastine|1.5% bid
75877219|NCT03636815|Other|physical therapy|Cardiopulmonary rehabilitation for patients who receive left ventricle assist device
76046892|NCT02131233|Drug|Placebo to Reformulated Raltegravir|Placebo to reformulated raltegravir 2 tablets orally once daily
75424655|NCT01460550|Procedure|Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
75424656|NCT01460563|Drug|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
75424657|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
75424658|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
75424659|NCT01460602|Drug|MTD of Velcade, Nipent and Rituxan established in Part 1|"One of the following dose levels will be chosen and used in Part 2:~(VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~(VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~(VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~(VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1"
75424660|NCT01460615|Drug|Hydrocortisone|
75424661|NCT01460667|Drug|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
75424662|NCT01460667|Drug|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
75424663|NCT01460693|Drug|Imatinib|Oral Imatinib 100mg daily
75424664|NCT01460693|Drug|Dasatinib|Oral Dasatinib 100mg daily
75424665|NCT01460706|Drug|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
75424666|NCT01460758|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
75424667|NCT01460758|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
75570715|NCT05603676|Other|Intermittent hypoxia-hyperoxia conditioning|The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
75723753|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
75424668|NCT01460758|Device|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
75424669|NCT01460771|Device|TDCS (Transcranial Direct-current Stimulation)|active TDCS
75424670|NCT01460771|Device|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
75424671|NCT01460797|Other|Glycemic Index Diets and Metformin hydrochloride|1g of Metformin hydrochloride a day in High Glycemic Index Diet
75424672|NCT01460823|Procedure|Percutaneous Cochlear Implantation using image guided surgical techniques|Percutaneous Cochlear Implantation using image guided surgical techniques.
75424673|NCT01460836|Drug|Tobramycin solution for inhalation|
75424674|NCT01460836|Drug|Aztreonam lysine for inhalation|
75424675|NCT01460888|Drug|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
75424676|NCT01460888|Radiation|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
75424677|NCT01460953|Behavioral|health literacy training video|participants will watch a training video
76046893|NCT02131233|Drug|Placebo to Raltegravir|Placebo to raltegravir 1 tablet orally twice daily
76046894|NCT02131155|Drug|Placebo|Once daily
76046895|NCT02131155|Drug|Afatinib|Once daily
76046896|NCT01933594|Drug|Romidepsin|RMD administered over 4 hours via an intravenous (IV) catheter.
76046897|NCT01933594|Drug|Placebo for Romidepsin|Placebo for RMD administered over 4 hours via an IV catheter.
75424678|NCT01460966|Procedure|Filtrap™ + Thrombus aspiration catheter|Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
75424679|NCT01460966|Procedure|Thrombus aspiration catheter|Thrombus aspiration catheter only
75424680|NCT01460979|Drug|Temsirolimus|25mg weekly intravenous until progression
75424681|NCT01460992|Procedure|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
75424682|NCT01461018|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
75424683|NCT01461031|Drug|nefopam|nefopam infusion for postoperative 24 hours
75424684|NCT01461031|Drug|normal saline (control)|normal saline infusion for postoperative 24 hours
75424685|NCT01461083|Drug|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of [18F]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not >10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
75424686|NCT01461109|Drug|[18F] CFPyPB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
75424687|NCT01461148|Biological|FSP peptides|100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
75424688|NCT01461174|Drug|Modafinil|200 mg tablet, single dose
75424689|NCT01461174|Drug|Donepezil|Donepezil or placebo, 5 mg tablet one per day, 15 days
75424690|NCT01461174|Drug|Memantine|Memantine or placebo, 10 mg tablet one per day, 15 days
75424691|NCT01461187|Other|exercise during pregnancy|supervised aerobic physical exercises twice a week.
75424692|NCT01461200|Other|Swab of vestibule and middle meatus of nose|Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
75424693|NCT01461213|Drug|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
75424694|NCT01461239|Procedure|fiber post and resin core - self-adhesive cement|pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
75424695|NCT01461239|Procedure|cast post and core|Ni-Cr alloy cast post and core luted with self-adhesive resin cement
75424696|NCT01461239|Procedure|fiber post luted with conventional resin cement|fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
75424697|NCT01461252|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
75424698|NCT01461252|Procedure|Radiation|Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
75424699|NCT01461265|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
75424700|NCT01461330|Other|DASH diet plus exercise|"DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat~Exercises: the recommended physical activity will consist of using a pedometer during the experimental period."
75424701|NCT01461330|Other|ADA diet|Adoption of ADA diet.
75424702|NCT01461343|Other|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
75424703|NCT01461356|Procedure|Minimally invasive total knee replacement|A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.
75424704|NCT01461356|Procedure|Standard approach total knee replacement|A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
75877220|NCT01337713|Other|Swedish Massage|Swedish massage, 45 minutes, 2 x per week for 6 weeks
76046898|NCT04623190|Behavioral|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
75877221|NCT01337713|Other|Light Touch|Light touch, 45 minutes, 2 x week for 6 weeks
75877222|NCT03196349|Drug|Warfarin|Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
75424705|NCT01461382|Other|Treadmill Desks|Treadmill Desk were installed in subjects personal workspace.
75424706|NCT01461382|Other|Treadmill Desks|Treadmill desks were installed in subjects personal workspace six months after phase I started.
75570716|NCT05603676|Other|Placebo intervention|Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
75570717|NCT04802616|Drug|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).
75570718|NCT04802616|Drug|Placebo|Matched tablets without any active substance.
75570719|NCT04473092|Device|TMVR|Patients who undergo TMVR for MR at the PI´s site
75570720|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
75723754|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
75570721|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
75723755|NCT00736853|Drug|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
75877223|NCT03196349|Drug|Apixaban 2.5 MG|Will be randomized to receive open label apixaban of 2.5 mg twice daily
75877224|NCT03196349|Drug|Rivaroxaban 10 MG|Will be randomized to receive open label rivaroxaban of 10mg daily
75877225|NCT01331941|Drug|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
75877226|NCT01331941|Drug|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
75877227|NCT02886715|Drug|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
75570722|NCT04772274|Drug|Ustekinumab|45 mg, single-dose
75723756|NCT04037514|Drug|Paracetamol|Intravenous paracetamol 15 mg/kg/6h
75723757|NCT04037514|Drug|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
75723758|NCT00889668|Device|GlucoTrack|comparison of different glucose monitoring devices
75723759|NCT00884130|Procedure|laparoscopic colorectal resection|
75723760|NCT00884130|Procedure|open colorectal resection|
75877228|NCT02886715|Drug|Tazorac®|Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
75877229|NCT02886715|Drug|Placebo|Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
75877230|NCT04403737|Device|Rothman Index|The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
75877231|NCT04360837|Procedure|alveolar recruitment|incremental and decremental positive end-expiratory pressure alveolar recruitment
75877232|NCT01337791|Drug|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
75570723|NCT04398797|Other|PATINA algorithm|Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
75723761|NCT00730847|Biological|Cervarix|Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
75723762|NCT00573066|Drug|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
75723763|NCT00889980|Other|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
75877233|NCT01334203|Drug|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
75877234|NCT03085797|Drug|Mepolizumab|Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
75877235|NCT03085797|Drug|Placebo|Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
75877236|NCT03085797|Drug|Mometasone furoate|All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations [50 g/actuation] in each nostril once daily).
75877237|NCT04262791|Device|Wrist Actigraphy Device|Wrist Actigraphy Device
76046899|NCT04623190|Behavioral|PREVENT tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
76046900|NCT01932970|Drug|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
76046901|NCT01912768|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
76046902|NCT01912768|Device|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
75570724|NCT03457311|Drug|G.S.P. Oral Solution 400 mg/ml|Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
75570725|NCT04370327|Other|Pain Free Exercise (PF)|Patients will exercise until the onset on claudication (1 on the rating scale)
75877238|NCT04262791|Device|Sleep Headband|Sleep Headband
75877239|NCT02560597|Procedure|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most."
75877240|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
75877241|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
75570726|NCT04370327|Other|Moderate Claudication Pain Exercise (MOD-P)|Patients will exercise until they experience moderate claudication pain (2 on the rating scale)
75723764|NCT02541552|Drug|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
75723765|NCT00886314|Drug|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
75723766|NCT00886314|Other|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
75723767|NCT00890214|Drug|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
76046903|NCT01912768|Device|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
76046904|NCT02305849|Drug|Peficitinib|oral tablet
76046905|NCT02305849|Drug|Placebo|oral tablet
76046906|NCT02305849|Drug|Methotrexate|Oral tablet/capsule
76046907|NCT02371759|Drug|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
75424707|NCT01461408|Behavioral|Health Education Session|"The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect-their hairdressers-will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.~The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26."
75424708|NCT01461421|Behavioral|Nutrition Education|Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.
75424709|NCT01461421|Behavioral|Behavioral Weight Loss Strategies|Participants are taught self-monitoring and goal setting techniques.
75424710|NCT01461421|Behavioral|Standard Cognitive Techniques|Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.
75424711|NCT01461421|Behavioral|Acceptance Based Techniques|Participants are taught how to accept and change their perception of their thoughts and emotions.
75723768|NCT00890214|Drug|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
75723769|NCT00890292|Drug|JNJ-31001074|
75723770|NCT02543736|Device|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
75877242|NCT01334359|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
75877243|NCT01569165|Procedure|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
76046908|NCT02371759|Drug|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
76046909|NCT02371759|Drug|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
76046910|NCT02371759|Drug|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
76046911|NCT02531633|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
76046912|NCT02531633|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
76046913|NCT02531633|Drug|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
76046914|NCT02531633|Drug|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
76046915|NCT05415605|Device|Lung Strain|The main objective of this study is to describe the physiological values of lung strain in healthy volunteers as well as its variations induced by non-invasive positive pressure ventilation and their correlation with tidal volume.
76046916|NCT02536313|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
76046917|NCT02536313|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
76046918|NCT05435651|Behavioral|Multitask game-based digital therapy|To practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week.
76046919|NCT05435651|Behavioral|Schulte Grid digital game|To practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week.
76046920|NCT05415059|Device|Covatech Stoma bag material|Strips of Covatech Stoma bag used to asses adhesion of 3M material to be used in LEAFix device
75570727|NCT04370327|Other|Maximal Claudication Pain Exercise (MAX-P)|Patients will exercise until they experience maximal claudication pain (4 on the rating scale)
75570728|NCT00536835|Drug|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
75424712|NCT01461434|Device|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
75570729|NCT04362527|Drug|Milrinone 1 Mg/mL Solution for Injection|Blinding procedure will be set up for the administration of the treatment
75424713|NCT01461447|Biological|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
75424714|NCT01461460|Drug|TR-701 FA 1200 mg|6 tablet of T-701 FA
75424715|NCT01461460|Drug|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
75570730|NCT04362527|Drug|Saline solution for injection|Blinding procedure will be set up for the administration of the treatment
75570731|NCT05579145|Other|5-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 5 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
75723771|NCT00923520|Drug|DMS 612|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
75570732|NCT05579145|Other|10-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 10 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
75570733|NCT04755114|Other|Turkish Music|Turkish Music;In choosing the music, patients will be asked about their favorite vocalist and music pieces before the procedure. The researcher will then download these music pieces from YouTube and create a 30-minute list and listen to patients.
75723772|NCT02543424|Behavioral|Motor, cognitive and neuropsychological assessment|Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
75877244|NCT01569243|Other|Text messages|"Participants will receive diabetic medical care as usual.~Participants will be given an ActiHealth pedometer to measure daily activity.~In addition, they will be enrolled to receive the study text messages."
75424716|NCT01461460|Drug|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
75723773|NCT00612456|Drug|Pazopanib|Pazopanib eye drops formulation
75723774|NCT00730691|Drug|Placebo|Placebo-matching capsules
75723775|NCT00730691|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
75723776|NCT00730691|Drug|Duloxetine|Overencapsulated duloxetine capsules
75723777|NCT02543502|Procedure|periodontal treatment|treatment of periodontal cleaning
75723778|NCT00890370|Procedure|Airway clearance technique|
75424717|NCT01461460|Drug|Placebo|6 placebo tablets
75723779|NCT00890448|Other|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
75723780|NCT00235495|Biological|Albumin|human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset
75723781|NCT00235495|Drug|Saline|equivalent volume of isotonic saline control
75877245|NCT01569243|Other|Usual care|"Participants will receive diabetic medical care as usual.~In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
75877246|NCT03157531|Device|B-Laser™ Atherectomy System|The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
75877247|NCT02535091|Drug|YKP3089|see above
75877248|NCT01382277|Drug|Rosuvastatin|Rosuvastatin 20 mg per day for 76 weeks
75877249|NCT03630939|Drug|ESR-114|ESR-114 Topical Gel
75424718|NCT01461486|Device|Continuous Positive Airway Pressure (CPAP)|The device is a flow generator used to open the airway during sleep.
75424719|NCT01461486|Device|Oral Appliance (BRD)|The device increases the volume of the airway by mandibular traction.
75570734|NCT04755114|Other|comedy movie|Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. In the selection of comedy films, the opinions of two experts from Mimar Sinan University, Faculty of Fine Arts, Department of Cinema and Television and İnönü University will be preferred, and the films Kemal Sunal and Şener Şen, one of the actors that Turkish people know closely, laugh most and have settled into their culture, will be preferred.
75570735|NCT04748952|Device|Densah burs|Osseodensification is a non-excavating implant site preparation technique. It creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects. The autografting occurs along the entire length of the osteotomy through a hydrodynamic process with the use of irrigation. The result is a consistently cylindrical and densified osteotomy.
75877250|NCT03630939|Other|Placebo|Placebo Topical Gel
75877251|NCT02507791|Other|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
75877252|NCT01382199|Drug|Lactoferrin|
75877253|NCT01337869|Procedure|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
75877254|NCT01337869|Procedure|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
75424720|NCT01461512|Drug|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
75424721|NCT01461512|Drug|Placebo administration|NaCl isotonic
75424722|NCT01461525|Procedure|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
75424723|NCT01461525|Procedure|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
75424724|NCT01461564|Procedure|Colonoscopy|Screening colonoscopy
75877255|NCT01381497|Drug|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
75570736|NCT00552851|Drug|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
75877256|NCT01381497|Drug|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
75570737|NCT01614171|Biological|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
75570738|NCT05567367|Combination Product|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
75424725|NCT01461577|Drug|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
75570739|NCT05567367|Drug|Vardenafil Oral Tablet|20 mg oral vardenafil tablet.
75570740|NCT05562024|Biological|T cell injection targeting B7-H3 chimeric antigen receptor|The subjects will be administered once.
75570741|NCT00536952|Drug|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
75570742|NCT00536952|Drug|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
75570743|NCT00536952|Radiation|Radiation Therapy|5 days per week for 4 weeks
75570744|NCT04684004|Other|To report number of HF events and deaths|In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
75424726|NCT01461590|Other|Whole blood|30mls/kg transfused over fours hours
75424727|NCT01461590|Other|Whole blood|20mls/kg transfused over four hours
75424728|NCT01461603|Dietary Supplement|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
75424729|NCT01461603|Dietary Supplement|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
75570745|NCT04286438|Drug|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.~In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion.~In patients presenting with intracranial hemorrhage (ICH), brain imaging within 2 hours of initiation of study drug and at least one follow-up brain imaging performed 12-24 hours post completion of PB2452."
75570746|NCT04675632|Procedure|Endovascular Therapy|the most commonly used surgical options include: ordinary balloon dilatation， drug-coated balloon (DCB) dilatation and bare stent implantation.
75877257|NCT01384149|Device|external slt|Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
75877258|NCT01384149|Device|standard slt|Nd:YAG LASER SLT gonioscopic laser treatment
75877259|NCT04451317|Other|Questionnaire, phone call|phone call and 3 questionnaires on a digital platform
75877260|NCT01381419|Drug|GSK1144814|Single dose.
75424730|NCT01461616|Drug|NPH|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
75424731|NCT01461616|Drug|Detemir|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
75424732|NCT01461616|Drug|Glargine|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
75424733|NCT01461642|Other|Self management asthma plan indorsment.|Subjects adherence to asthma self management plan will be monitored through web-based support.
75570747|NCT04282616|Other|Home-based unstructured physical activity program|Counselling on physical activity according to American College of Sports Medicine guidelines
75570748|NCT04282616|Other|Home-based structured low-intensity physical activity program|Structured home-based low-intensity intermittent walking program
75570749|NCT04282616|Other|In-hospital structured supervised physical activity program|Supervised exercise training program
75877261|NCT01381419|Drug|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
75877262|NCT01381419|Drug|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
75877263|NCT03635827|Combination Product|NBTX-001 Xenon Inhaler|The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
75877264|NCT03635827|Combination Product|Placebo|The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
75424734|NCT01461681|Procedure|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
75424735|NCT01461694|Device|Intense Pulsed Light (IPL)|Half Face Treated with IPL
75424736|NCT01461694|Device|Alexandrite Laser|Half face treated with Alexandrite Laser
75877265|NCT04530201|Device|Colli-Pee Small Volumes (10 mL) device|Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.
75424737|NCT01461720|Other|Standard medical care|Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
75424738|NCT01461720|Biological|Autologous bone marrow-derived mesenchymal stem cells|Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
75424739|NCT01461746|Drug|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
75424740|NCT01461746|Drug|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
75424741|NCT01461746|Radiation|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
75424742|NCT01461759|Drug|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
75570750|NCT00537147|Biological|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
75723782|NCT02541474|Other|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
75570751|NCT00537147|Biological|Placebo|Placebo for WN/DEN4delta30 vaccine
75570752|NCT04656951|Drug|Daratumumab|Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
75570753|NCT00537186|Drug|Iron oligosaccharide|
75570754|NCT04251260|Other|Positioning in flexion|"The intervention group will be positioned in flexion (i.e. lower limbs in flexion, hand in midline) with an aid, the Snuggle up (Philips, USA). With positioning, the neonates bottom is tucked down in the snuggle up pocket, legs are aligned and gently flexed and hands towards midline and near the face.~Positioning will be demonstrated to the nursing staff of the Neonatal Intensive Care Unit (NICU). The intervention group will receive positioning during day and night throughout the intervention period."
75424743|NCT01461759|Drug|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
75570755|NCT04244786|Device|Transcranial direct current stimulation|tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
75570756|NCT04642014|Biological|COVID-19 convalescent plasma treatment|"The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.~Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity."
75570757|NCT04234334|Other|Consume 2 eggs with spinach per day|Participants will be randomly allocated to consume either 2 eggs or 2 egg substitutes with spinach daily for 4 weeks and after a 3-week wash out, they will be allocated to the alternate treatment
75723783|NCT03017105|Other|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
75424744|NCT01461772|Radiation|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
75424745|NCT01461772|Drug|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
75424746|NCT01461772|Drug|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
75723784|NCT03017105|Other|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
75723785|NCT02541630|Behavioral|Big Mind|mindfulness based intervention
75570758|NCT04234334|Other|Egg Subsitute with spinach per day|Egg Subsitute with spinach per day
75723786|NCT03968471|Behavioral|Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma|"The aim of the present study is to evaluate which is the best scoring tool to determine the histological response to chemotherapy in localized Ewing sarcoma of bone.~The study will exam all the different systems to evaluate the histological necrosis after neo-adjuvant chemotherapy in all patients with localized Ewing sarcomas of bone surgically treated between 1982 and 2012."
75723787|NCT00884364|Other|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
75424747|NCT01461785|Biological|Addition of PRP ( platelet rich plasma) to the lipograft|"27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP"
75424748|NCT01461785|Procedure|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
75424749|NCT01461798|Dietary Supplement|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
75424750|NCT01461798|Dietary Supplement|Placebo Yogurt|Yogurt without the active principle
75424751|NCT01461798|Dietary Supplement|yogurt|yogurt without plant stanols
75424752|NCT01461850|Drug|Neoadjuvant chemotherapy + Interval Debulking Surgery|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
75570759|NCT00552890|Other|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
75570760|NCT00552890|Other|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
75570761|NCT04200755|Drug|Dupilumab 300Mg Solution for Injection|First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
75570762|NCT04200755|Other|Placebo|First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
75570763|NCT04173533|Drug|Oral azacitidine|Oral azacitidine (CC-486) 200 mg tablet
75570764|NCT04173533|Drug|Matched placebo|Oral azacitidine (CC-486) matched placebo tablet
75570765|NCT05544591|Drug|611 Q2W|subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)
75723788|NCT00884364|Behavioral|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
75877266|NCT01382121|Behavioral|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
75570766|NCT05544591|Drug|611 Q4W|subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)
75570767|NCT05544591|Drug|Matching placebo|subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
75723789|NCT04088279|Diagnostic Test|MRI|Oxygen enhanced and fourier decomposition MRI
75570768|NCT01534065|Device|Barricaid|Implanted intra-operatively during discectomy
75723790|NCT00886860|Drug|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
75723791|NCT00886860|Drug|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
75723792|NCT00884442|Drug|Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)|60 mg nifedipine
75723793|NCT00884442|Drug|Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)|60 mg nifedipine
75723794|NCT04087265|Diagnostic Test|Transabdominal ultrasound|Transabdominal ultrasound will be performed 30 minutes before colonoscopy
75424753|NCT01461850|Procedure|Primary Debulking Surgery + Adjuvant Chemotherapy|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
75723795|NCT02543580|Other|transcutaneous electric acupoint stimulation|electrodes are attached o the skin and electric stimulation is given
75877267|NCT01382121|Behavioral|Control|watching a video unrelated to the fitness test and self-efficacy
75877268|NCT04095403|Other|Tarp Assisted Cooling|Body cooling utilizing a tarp and water
75877269|NCT04095403|Other|passive cooling|Supine rest.
75877270|NCT01332175|Device|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
75877271|NCT01332175|Device|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
75570769|NCT05539794|Behavioral|lifestyle and physical exercise|"the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions."
75570770|NCT01258348|Drug|Drug: LY573636-sodium|"Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression."
75570771|NCT01258348|Drug|Sunitinib|"37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression."
75570772|NCT01258075|Drug|High-dose colesevelam|3.75 grams colesevelam hydrochloride in oral suspension
75570773|NCT01258075|Drug|Low-dose colesevelam|0.625 grams colesevelam hydrochloride in oral suspension
75570774|NCT01257568|Device|Rejuvenate Modular Hip|Rejuvenate Modular Hip
75570775|NCT04687878|Drug|Insulin|20 IU twice a day, intranasally, every day for 12 weeks
75570776|NCT04687878|Drug|Normal saline|twice a day, intranasally, every day for 12 weeks
75723796|NCT02543580|Other|electrode attached but no stimulation|electrodes are attached o the skin but no stimulation is given
75877272|NCT01332175|Procedure|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
75424754|NCT01461876|Drug|antiretroviral therapy|Standard of care antiretroviral therapy
75570777|NCT05116774|Drug|BCX9930|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
75570778|NCT05116774|Drug|Eculizumab|Administered by intravenous infusion per current dose regimen
75570779|NCT05116774|Drug|Ravulizumab|Administered as intravenous infusion per current dose regimen
75570780|NCT04687839|Procedure|Induction of suction blister|For each subject, 2 superficial wounds will be made on the inner aspect of each forearm using the suction blister model.
75723797|NCT02543034|Device|Betafoam Wound Dressing|Foam dressing including Betadine iodine
75723798|NCT02543034|Device|Petrolatum Gauze|Gauze dressing
75723799|NCT02543034|Device|Allevyn Wound Dressing|Foam dressing
75877273|NCT03159091|Drug|Rengalin|Oral administration.
75877274|NCT03159091|Drug|Placebo|Oral administration.
75723800|NCT02594345|Other|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
75877275|NCT03196193|Procedure|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
75877276|NCT03196193|Device|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
75877277|NCT03196193|Device|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
75877278|NCT01337947|Drug|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
75877279|NCT03540563|Other|Blood draw|Blood will be drawn to assess ctDNA
75723801|NCT00278161|Biological|Pegfilgrastim|6 mg SQ 24-48 hours after last dose of cyclophosphamide.
75877280|NCT01338103|Drug|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
75570781|NCT04687839|Other|Transepidermal water loss (TEWL)|"At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~For subsequent visits, before product application"
75570782|NCT04687839|Other|Macrophotography|"At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~For subsequent visits, before product application"
75723802|NCT00278161|Biological|Rituximab|375 mg/m^2/day on Days 1, 4, 8, 11, 45, and 52.
75723803|NCT00278161|Drug|Cyclophosphamide|50 mg/kg/day on Days 15, 16, 17, and 18.
75723804|NCT04038216|Procedure|Single-stage surgery|the bone-anchored hearing implant will be inserted in one surgery
75570783|NCT04687839|Device|Wound healing medical device|Twice daily application on superficial wounds
75723805|NCT04038216|Other|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
75723806|NCT02541396|Drug|Wafermine|35 or 70 mg ketamine in a sublingual wafer
75723807|NCT02541396|Drug|Oxycodone|5 mg oxycodone capsule
75723808|NCT02541396|Drug|Placebo|Placebo capsule or placebo wafer
75424755|NCT01461889|Other|Transfuse plasma to High INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first
75424756|NCT01461889|Other|Transfuse plasma to Low INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
75424757|NCT01461941|Drug|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
75424758|NCT01461941|Drug|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
75424759|NCT01461967|Drug|Placebo|Single ascending doses
75424760|NCT01461967|Drug|RO5508887|Single ascending doses
75424761|NCT01461967|Drug|RO5508887|Single doses
75424762|NCT01462006|Drug|sirolimus|randomized to drug or placebo, followed by washout, followed by crossover
75424763|NCT01462006|Other|Placebo|randomized to drug or placebo, followed by washout, followed by crossover
75424764|NCT01462019|Device|Photobiomodulation|"the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.~The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions."
75424765|NCT01462032|Behavioral|Training Executive, Attention and Motor Skills (TEAMS)|Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home
75424766|NCT01462032|Behavioral|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
75424767|NCT01462058|Dietary Supplement|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
75570784|NCT01256788|Device|Euflexxa|4 injections of 2ml of Euflexxa
75570785|NCT01256788|Other|Saline|4 injections of 3 ml of sterile saline
75570786|NCT01256671|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
75570787|NCT04687566|Drug|Dextromethorphan|The participants will take dextromethorphan 60 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
75570788|NCT04687566|Drug|Memantine|The participants will take memantine 5 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
75570789|NCT04687566|Drug|Dextromethorphan and memantine|The participants will take dextromethorphan (60 mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
75723809|NCT00890526|Other|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from ~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
75723810|NCT00890526|Other|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
75570790|NCT04687566|Drug|Placebo|The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
75877281|NCT01315405|Behavioral|Emotional facial expression recognition tests|"20 patients with an Idiopathic Parkinson's disease~+ 20 paired healthy volunteers (on sex, age, and education)~After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)~Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)"
75877282|NCT03529877|Biological|allo-APZ2-EB|intravenous infusion of allo-APZ2-EB
75424768|NCT01462058|Drug|Placebo|Placebo, daily, 12 weeks
75424769|NCT01462123|Other|endoscopic assessment of colonic polyps|
75424770|NCT01462136|Drug|ACHN-490 Injection|7.5 mg/kg single dose administered intravenously over 30 minutes
75424771|NCT01462149|Drug|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
75424772|NCT01462149|Drug|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
75424773|NCT01462175|Drug|RO5503781|
75570791|NCT04683809|Other|Telerehabilitation|Patients will attend rehabilitation sessions through online programmes for rehabilitation
75570792|NCT01256476|Drug|pitavastatin|pitavastatin 4 mg once daily (QD)
75570793|NCT01256476|Drug|pravastatin|Pravastatin 40 mg once daily (QD)
75570794|NCT05507892|Drug|canagliflozin|Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is a used to treat type 2 diabetes. Canagliflozin lowers blood sugars by causing the kidneys to excrete more glucose in the urine.
75570795|NCT05507892|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure renal plasma flow (RPF) PAH (Basic Pharma, Geleen, Netherlands) has been used to measure RPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
75570796|NCT04128371|Biological|Nucala (mepolizumab)|Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials will be reconstituted with 1.2 ml sterile water for injection (according to the product labeling) and secondarily diluted in 100-250 ml of 0.9% normal saline (NaCl) for infusion (to a final concentration of 0.3-7.5 mg/ml).
75570797|NCT04684043|Device|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
75570798|NCT04684082|Device|Colonic irrigation with the Colon Hydromat|"A designated health professional will administer to the patient the colonic irrigation procedure - using the Colon Hydromat device, a CE certified device for colonic irrigation and cleansing before endoscopic procedures."
75424774|NCT01462188|Procedure|Immediate stenting|Primary coronary stenting
75424775|NCT01462188|Procedure|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
75424776|NCT01462201|Device|Non Invasive Ultrasound|Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
75424777|NCT01462214|Drug|Everolimus|Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
75424778|NCT01462240|Device|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
75424779|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
75424780|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
75424781|NCT01462331|Other|Sucrose|12g/dose, three times a day
75424782|NCT01462396|Device|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
75424783|NCT01462409|Device|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
75877283|NCT03621761|Behavioral|Telephone-based Cognitive Behavioral Therapy|"Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue."
75877284|NCT03621761|Drug|Modafinil|Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
75424784|NCT01462409|Device|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
75424785|NCT01462409|Device|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
75424786|NCT01462422|Drug|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
75424787|NCT01462422|Drug|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
75424788|NCT01462448|Procedure|Blood Draw|Single blood draw of 30 ml
75424789|NCT01462474|Drug|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
75424790|NCT01462474|Drug|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
75424791|NCT01462474|Radiation|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
75424792|NCT01462487|Drug|Treatment with zanamivir|Subjects treated with zanamivir
75424793|NCT01462500|Drug|Miltefosine|Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
75424794|NCT01462513|Biological|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
75424795|NCT01462513|Biological|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
75424796|NCT01462552|Drug|Lapatanib|Prescription of lapatinib (Tykerb)
75424797|NCT01462591|Dietary Supplement|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
75424798|NCT01462604|Other|non-drug intervention educational programme|educational programme
75424799|NCT01462617|Drug|GSK2269557|Study Drug
75424800|NCT01462617|Drug|GSK2269557 matching placebo|Study Drug
75723811|NCT00890526|Other|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
75723812|NCT00890526|Other|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
75424801|NCT01462643|Drug|LAS41004|once daily, topical ointment, 100 microgram per day
75424802|NCT01462656|Drug|Non-EZG containing AED polytherapy|AED polytherapy without EZG
75877285|NCT03221387|Device|Humidified nasal high flow with oxygen|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
75877286|NCT04527575|Biological|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.
75424803|NCT01462656|Drug|EZG containing AED polytherapy|AED polytherapy including EZG
75424804|NCT01462656|Drug|Non-EZG AED monotherapy|AED monotherapy without EZG
75424805|NCT01462656|Drug|EZG AED monotherapy|Any off-label use of EZG as monotherapy
75424806|NCT01462669|Drug|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
75424807|NCT01462669|Drug|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
75424808|NCT01462669|Drug|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
75424809|NCT01462669|Drug|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
75570799|NCT04683887|Device|Tape application|Application of the tape with lymphatic technique to the fingers, both dorsally and volarly, of wrist fractured patients treated with a forearm cast
75877287|NCT04527575|Other|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)
75877288|NCT03318861|Genetic|KITE-585|A single infusion of KITE-585 autologous anti-BCMA CAR T cells
75424810|NCT01462708|Drug|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not >10% of 10 mCi limit)of [18F]MK-9470, followed by PET imaging.
75424811|NCT01462721|Device|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
75424812|NCT01462734|Procedure|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
75424813|NCT01462747|Device|KULIST|Twice daily dosing for 8 weeks
75424814|NCT01462786|Drug|ATX-101|2 mg/cm2 ATX-101
75877289|NCT03318861|Drug|Cyclophosphamide|Administered intravenously
75877290|NCT03318861|Drug|Fludarabine|Administered intravenously
75424815|NCT01462799|Behavioral|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
76046921|NCT05610761|Behavioral|Core stabilization exercises with Kegel exercises|Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.
75424816|NCT01462799|Behavioral|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
75424817|NCT01462825|Dietary Supplement|tomato ketchup meal|A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
75424818|NCT01462825|Dietary Supplement|Placebo meal|Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
75424819|NCT01462838|Biological|P16_37-63|100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
75570800|NCT05506956|Drug|Flotetuzumab|Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
75570801|NCT05506722|Device|Testes shocker|It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
75570802|NCT05504616|Other|Health technology-based intervention strategy|Patient-centered, technology-based intervention strategy aimed at increasing physical activity in patients with axSpA
75570803|NCT04108364|Behavioral|Voice adaptive training for aphasia|Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
75570804|NCT05502276|Procedure|Endoscopic Full-Thickness Resection (EFTR)|Full Thickness Endoscopic Resection using the FTRD Ovesco Device
75570805|NCT05502276|Procedure|Endoscopic Submucosal Dissection (ESD)|Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
75424820|NCT01462851|Drug|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
75424821|NCT01462851|Drug|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
75424822|NCT01462851|Drug|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
75424823|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
75424824|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
75424825|NCT01462864|Behavioral|Structured Lifestyle Education|A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
75424826|NCT01462903|Biological|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
75570806|NCT04106999|Drug|Dexmedetomidine|Drug infusion will be delivered intra-operatively
75570807|NCT04106999|Drug|Placebos|Normal Saline will be infused as a control drug
75570808|NCT04105049|Other|Observation of psychological aspects|Motivational, socioeconomic, family, stress, and other aspects are tested.
75570809|NCT05003089|Drug|BAY1834845|Tablet, oral.
75570810|NCT05003089|Drug|BAY1830839|Tablet, oral.
75570811|NCT05003089|Drug|Prednisolone|Tablet, oral.
75570812|NCT05003089|Drug|Placebo|Tablet, oral.
75877291|NCT01381341|Drug|linifanib|QD on Day 1 of Periods 1 and 2
75877292|NCT01384071|Device|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
75877293|NCT01384071|Device|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
75424827|NCT01462916|Dietary Supplement|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control [I/C] and control to intervention [C/I] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
75723813|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
75424828|NCT01462968|Device|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
75424829|NCT01462994|Other|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
75424830|NCT01463020|Behavioral|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
75723814|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
75723815|NCT00255151|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
75723816|NCT00890760|Biological|AdCh63 ME-TRAP|5 x 10*10 vp IM
75877294|NCT01379391|Drug|Recombinant Human Thrombopoietin (rHTPO)|"Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT."
75877295|NCT03631251|Drug|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
75877296|NCT04152213|Behavioral|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
75877297|NCT03084315|Device|E-Cig Zero Nicotine|E-Cig Zero Nicotine
75877298|NCT03084315|Device|E-Cig 24mg Nicotine|E-Cig 24mg Nicotine
75877299|NCT03187301|Drug|APL-130277|APL-130277 single dose
75424831|NCT01463020|Other|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
75877300|NCT03187301|Drug|Placebo|Placebo single dose
75877301|NCT03187301|Drug|Moxifloxacin|moxifloxacin 400mg single dose
75877302|NCT01379313|Procedure|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
75877303|NCT01379313|Procedure|1:1 ratio|I:E ratio of 1:1 is applied.
75877304|NCT01379313|Procedure|2:1 group|Inverse I:E ratio of 2:1 is applied.
75877305|NCT01379313|Procedure|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
75424832|NCT01463046|Drug|Panobinostat|"Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8"
75723817|NCT00890760|Biological|MVA ME-TRAP|2 x 10*8 pfu ID
75723818|NCT00890760|Other|Sporozoite challenge|Infected mosquito bite
75723819|NCT00890760|Biological|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10*10 vp MVA ME-TRAP 2 x 10*8 pfu
75723820|NCT00890838|Dietary Supplement|Omegaven-IV FO|will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
75723821|NCT04037670|Procedure|SASI bypass|Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
75723822|NCT03973957|Device|Indwelling pleural catheter placement|Indwelling pleural catheter placement by interventional pulmonologist
75723823|NCT03973957|Drug|Fentanyl Citrate|Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
75570813|NCT01256008|Behavioral|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
75570814|NCT01256008|Behavioral|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
75570815|NCT04066127|Device|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
75570816|NCT04066127|Device|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
75723824|NCT03973957|Drug|Talc Slurry|Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
75877306|NCT01381263|Behavioral|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
75877307|NCT01381263|Other|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
75424833|NCT01463046|Drug|Cytarabine|"Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9."
75424834|NCT01463046|Drug|Daunorubicin|"Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5."
75424835|NCT01463085|Other|Low-fat dairy|Dietary Intervention of 3 servings per day of low-fat dairy
75424836|NCT01463124|Behavioral|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
75424837|NCT01463124|Behavioral|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
75424838|NCT01463137|Behavioral|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
75723825|NCT03973957|Device|Drainage collection bag|Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
75424839|NCT01463150|Drug|Clopidogrel|Clopidogrel 150mg per day for 15 days
75424840|NCT01463150|Drug|Prasugrel|Prasugrel 5mg per day for 15 days
75877308|NCT02963285|Other|Nasopharyngeal temperature probe|Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
75424841|NCT01463163|Drug|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
75877309|NCT01381185|Drug|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
75877310|NCT01383837|Behavioral|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
75424842|NCT01463163|Drug|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
75723826|NCT00658658|Biological|Panitumumab|Panitumumab administered by intravenous infusion
75723827|NCT00723203|Drug|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
75723828|NCT00723203|Genetic|gene expression analysis|Day 1 and day 28 samples
75723829|NCT00723203|Genetic|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
75877311|NCT01383837|Behavioral|Health Promotion|Health Promotion Intervention
75570817|NCT04976101|Device|Sinosuidal Galvanic Vestibular Stimulation|stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency (VLF) bipolar, ± 2 mA, 0.025 Hz oscillating current sGVS between the mastoids
76046922|NCT05610761|Behavioral|Kegel exercises|"Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds)."
75570818|NCT04976101|Device|Placebo|When assigned to placebo arm of the study, the patients will undergo same procedure as the treatment, only current will not be passed. (the device will still be placed on the mastoid process)
75570819|NCT04206826|Device|PREDELFI|It's a natural film which contains a concentrated alpha-GOS (alpha-galacto-oligosaccharide) soy extract, a milk protein concentrate containing caseins and whey proteins and vegetable glycerin
75570820|NCT04206826|Device|CONTROL|It's a natural film which is devoided of active ingredient. It contains sodium alginate; vegetable glycerin, caramel, beta carotene and water.
75570821|NCT04207021|Dietary Supplement|Experimental: Curcumin derivate|two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
75877312|NCT02946047|Drug|Ixazomib 1 MG|1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
75877313|NCT02946047|Drug|Ixazomib 2 MG|2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
75877314|NCT02946047|Drug|Ixazomib 3 MG|3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
75877315|NCT02946047|Drug|Ixazomib 4 MG|4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
75877316|NCT05422287|Other|Virtual Reality Glasses|Group 1
75877317|NCT05422287|Other|Thermomechanical Stimulation Device|Group 2
75877318|NCT05421897|Drug|Dinutuximab with Chemotherapy|Rapid infusion of dinutuximab in 4 hours or less
75877319|NCT03077919|Drug|Ropivacaine|0.5% ropivacaine
75877320|NCT03077919|Drug|Sham treatment|preservative-free normal saline
76046923|NCT05414825|Other|focus group interview|Group interview gathering words, views, symptoms and its repercussions, and main issues of the subjects regarding severe dysmenorrhea
76046924|NCT04423133|Behavioral|Online Family Literacy Program|Parent-child dyads will participate in 8 weekly online health-themed workshops that introduce language and literacy skills. Participants will also receive 2-3 text messages per week for the duration of the program and children's books.
76046925|NCT04423289|Other|Farmalarm|Monitoring after COVID-19 discharge from hospital via Farmalarm app
76046926|NCT05413499|Other|Biomarkers research|For a part of the included population, the children with a mTBI and without indication of CT scan, a non-routine blood sample will be planned
75570822|NCT04207021|Dietary Supplement|Placebo|two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
75723830|NCT00723203|Other|laboratory biomarker analysis|Day 1 and day 28 samples
75723831|NCT00891072|Drug|R-(-)-gossypol acetic acid|Given orally
75723832|NCT00891072|Drug|paclitaxel|Given IV
75723833|NCT00891072|Drug|carboplatin|Given IV
75723834|NCT00891072|Other|pharmacological study|Correlative studies
75723835|NCT02591927|Drug|Glucose-Insulin-Potassium|Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
75723836|NCT02591927|Drug|Glucose 5%|Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
75723837|NCT04037046|Behavioral|Screening HCV attached onto CCR screening|Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
75723838|NCT04037046|Behavioral|Screening HCV attached onto CCR screening by self-testing|Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
75723839|NCT04037046|Behavioral|Screening HCV at primary care center|DBS for HCV screening at primary care center
75723840|NCT00807716|Other|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
75723841|NCT00807716|Other|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
75723842|NCT00891150|Drug|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
76046927|NCT04423445|Other|Laser acupuncture combined with acupressure|Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
76046928|NCT02187861|Drug|Venetoclax|Venetoclax will be administered as per the schedule specified under arm description.
76046929|NCT02187861|Drug|Bendamustine|Bendamustine will be administered as per the schedule specified under arm description.
76046930|NCT02187861|Drug|Rituximab|Rituximab will be administered as per the schedule specified under arm description.
75424843|NCT01463176|Behavioral|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
75424844|NCT01463189|Behavioral|painACTION: Arthritis|"Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute booster sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs."
75723843|NCT00800462|Drug|Oxybutynin Cl|15 mg qd for 3 months
75723844|NCT00800462|Drug|Trospium Cl|20mg bid for 3 months
75723845|NCT00800462|Drug|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
75424845|NCT01463215|Drug|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
75723846|NCT00233389|Drug|Rebamipide|
75723847|NCT00884520|Drug|[F-18] VM4-037|"The individual doses of [F-18]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
75723848|NCT02551952|Device|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
75877321|NCT01377675|Other|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
75877322|NCT01380951|Drug|telbivudine|telbivudine 600mg/d 96 weeks
75877323|NCT01377597|Drug|ranibizumab|
75877324|NCT03220217|Drug|Satoreotide trizoxetan 5-20μg|Positron emission tomography (PET) imaging agent
75570823|NCT03457272|Other|New risk assessment|"Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles."
75424846|NCT01463228|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
75424847|NCT01463228|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
75424848|NCT01463241|Behavioral|Behavioral and Affective Skills in Coping (BASIC)|The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills [Belief Repair, Action, Solving Problems, Incentives, and Calming]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
75424849|NCT01463280|Drug|tumescent lidocaine infiltration|Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
75424850|NCT01463319|Other|air insufflation|air insufflation during insertion phase colonoscopy
75570824|NCT05467683|Behavioral|Exposure-Based Therapy|"Treatment will consist of 12 one-hour sessions, delivered over the course of 12 weeks. EBT will be delivered by trained and experienced license-eligible clinicians. The study clinician will develop a personalized assessment and treatment plan for each patient. Consistent with contemporary models of EBT, exposure practice aims to help patients reestablish a sense of safety around feared cues. Hence, exposure exercises are planned to ensure violation of threat expectancies. That is, exposure practice is deemed appropriate and effective if it allows the patient to learn that what they feared would happen does not happen. Practice will occur across relevant contexts both within and outside the session (i.e., homework) and clinicians will guide patients in processing practice to facilitate the consolidation of safety learning. To achieve these ends, study clinicians will use the manual Personalized Exposure Therapy: A Person-Centered Transdiagnostic Approach."
75723849|NCT01326091|Other|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
75723850|NCT02543190|Behavioral|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
75723851|NCT03973801|Other|Auricular acupuncture|National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
75723852|NCT00887094|Behavioral|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
75723853|NCT00887094|Behavioral|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
75723854|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
75723855|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
75723856|NCT02542878|Device|Foam roller|A bout of 60 seconds of myofascial release with foam roller
75723857|NCT00884598|Drug|cilengitide|
75723858|NCT00884598|Other|pharmacological study|
75723859|NCT00884598|Radiation|radiation therapy|
75424851|NCT01463319|Other|warm water irrigation|warm water irrigation during insertion phase colonoscopy
75723860|NCT02552264|Behavioral|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
75723861|NCT00891306|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
75723862|NCT00891306|Drug|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
75723863|NCT00891306|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
75877325|NCT03220217|Drug|Satoreotide trizoxetan 30-45μg|Positron emission tomography (PET) imaging agent
75877326|NCT03204695|Device|Percutaneous LAA Closure|LAA Closure with the WaveCrest LAA Occlusion System (study device)
75570825|NCT01255423|Drug|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
75723864|NCT00891306|Drug|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
75877327|NCT03204695|Drug|Anticoagulation or Clopidogrel|Subjects either continue on anticoagulation or receive clopidogrel
75877328|NCT03979391|Diagnostic Test|Tear collection and lumbar punction|Tear collection and lumbar punction will be performed in order to detect supernumerary oligoclonal bands
75877329|NCT03192137|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
76046931|NCT03958487|Behavioral|Video feedback, Feedback online|The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
75877330|NCT03192137|Other|Vehicle|Vehicle twice daily for 16 days
75877331|NCT03618095|Device|LOTUS Edge Valve System|TAVR with the LOTUS Edge Valve System
75877332|NCT04542785|Other|Rate control|Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
76046932|NCT05435261|Procedure|BKA|"Below Knee Amputation:~Under spinal anesthesia~BKA~closure in layers (terminal closure) with suction drain."
75424852|NCT01463332|Drug|I.V injection of 10 ml normal saline|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
75424853|NCT01463332|Drug|I.V injection with 0.25mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
75424854|NCT01463332|Drug|I.V injection of 0.50mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
75424855|NCT01463345|Other|Blood transfusion|Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 7.5 g/dl. Blood products should be given to maintain Hgb levels >7.5 g/dl.
75424856|NCT01463345|Other|Blood transfusion|Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 9.0 g/dl. Blood products should be given to maintain Hgb levels > 9.0 g/dl.
75424857|NCT01463436|Dietary Supplement|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
75424858|NCT01463436|Dietary Supplement|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
75424859|NCT01463449|Procedure|gastric bypass|Low grade inflammation in adipose tissue before and after gastric bypass
75570826|NCT01255423|Drug|Placebo|Placebo, 4 times daily
75877333|NCT03287375|Drug|PIPAC|
75877334|NCT03881059|Other|BMS-986165 Placebo|Participants will receive BMS-986165 matching placebo QD
75570827|NCT01255306|Other|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~On 7th postoperative day~On 30th postoperative day~On 90th postoperative day~On 180th postoperative day"
75723865|NCT02552108|Behavioral|Behavioural experiments for intolerance of uncertainty (BE-IU)|
75723866|NCT00807794|Drug|MEDI-507|0.012 mg/kg dose given twice between 60 to 72 hours apart
75723867|NCT00807794|Drug|MEDI-507|0.06 mg/kg dose given twice between 60 to 72 hours apart
75723868|NCT00807794|Drug|MEDI-507|0.12 mg/kg dose given twice between 60 to 72 hours apart
75723869|NCT00807794|Drug|MEDI-507|0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
75723870|NCT00807794|Drug|MEDI-507|0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
75877335|NCT03881059|Drug|BMS-986165 Dose A|Participants will receive BMS-986165 Dose A QD.
75877336|NCT03881059|Drug|BMS-986165 Dose B|Participants will receive BMS-986165 dose B QD.
75877337|NCT03881059|Drug|Ustekinumab|Participants will receive ustekinumab SQ injection QD.
75877338|NCT03881059|Other|Ustekinumab Placebo|Participants will receive ustekinumab SQ matching placebo QD
75877339|NCT01338337|Drug|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
76046933|NCT05435261|Procedure|Debridement with Ex_Fix (salvage)|"Debridement and External Fixation (salvage):~Under spinal anesthesia~wound debridement and wash.~external fixation."
76046934|NCT05434091|Drug|PF-07291177|PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
75424860|NCT01463475|Procedure|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
75424861|NCT01463488|Drug|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
75424862|NCT01463488|Drug|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
75424863|NCT01463501|Other|Neoadjuvant chemoradiotherapy|Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
75570828|NCT01255306|Drug|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
75570829|NCT04006964|Device|Resmon PRO FULL v2|Measurement of lung impedance by the Forced Oscillation Technique
75424864|NCT01463501|Other|Adjuvant chemoradiotherapy|Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
75570830|NCT01254721|Drug|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
75570831|NCT01254721|Drug|lithium|300mg tablet, oral
75570832|NCT04519671|Drug|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)
75570833|NCT04519671|Other|Placebo|Normal saline
75570834|NCT04207099|Device|MolecuLight i:X Imaging Device|The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
75877340|NCT02861534|Drug|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
75424865|NCT01463514|Procedure|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
75877341|NCT02861534|Drug|Placebo for vericiguat|2.5, 5.0, or 10.0 mg orally once daily
75424866|NCT01463514|Procedure|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
75570835|NCT05575258|Other|44-Day Diet Conventionally Sourced - YELLOW Diet|Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.
75570836|NCT05575258|Other|44-Day Diet Agro-Ecologically Sourced - GREEN Diet|Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
75570837|NCT04862533|Drug|Beta-Alanine|Participants will receive 1150mg of beta-alanine three times a day
75570838|NCT04862533|Drug|Placebo|Participants will receive matching placebo three times a day
75877342|NCT02034032|Procedure|Regenexx SD|stem cell treatment
75877343|NCT02034032|Behavioral|Exercise Therapy|exercise therapy control
75877344|NCT02034188|Biological|Umbilical cord mesenchymal stem cells|
75424867|NCT01463540|Device|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
75877345|NCT03167255|Drug|NS-065/NCNP-01|Received during weekly intravenous infusions
75877346|NCT03140969|Drug|QR-110|RNA antisense oligonucleotide for intravitreal injection
76046935|NCT05434091|Drug|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
76046936|NCT05379179|Drug|Ketamine|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
76046937|NCT05379179|Drug|Fentanyl|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
76046938|NCT05610605|Other|Health intervention programme: FRAGSALUD|The FRAGSALUD Program consists in two parts, a first part of health education that will be taught in a group in four sessions, and a second part of individual treatment and follow-up, individual consultations will have a bimonthly periodicity until reaching one year, at which time that the program ends and a final evaluation will be carried out to assess whether the changes are maintained 15 months after the start.
76046939|NCT05378477|Device|X92001752|The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
76046940|NCT05378477|Device|RID Super Max Solution|RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
76046941|NCT05378477|Drug|Nix Crème|Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.
76046942|NCT05378477|Device|Pouxit Végétal|Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.
76046943|NCT05377385|Behavioral|Questionnaire|Questionnaire about usability of the Omnipod DASH insulin administration system
76046944|NCT02163993|Drug|Galcanezumab|Administered SQ
75570839|NCT04862533|Procedure|Pelvic floor muscle training (PFMT)|Participants in both groups will undergo PFMT training program
75570840|NCT05570656|Device|XSENS-Awinda|"The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day."
75723871|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.
76046945|NCT02163993|Drug|Placebo|Administered SQ
76046946|NCT05383001|Drug|combination regimen tremelimumab /durvalumab|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Durvalumab 1500 mg fixed dose plus tremelimumab 300 mg fixed bolus dose~Maintenance Therapy:~Durvalumab 1500 mg fixed dose Q4W up to 12 cycles within the study"
76046947|NCT05383001|Drug|platinum-based chemotherapy (SoC)|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Continuation of second-line chemotherapy with 2-4 further cycles (Q3W) platinum-based combination therapy.~Maintenance Therapy:~Optional continued maintenance therapy with pemetrexed according to marketing authorization will be allowed for a maximum of 13 cycles."
76046948|NCT02527421|Drug|DFD01 Spray|DFD-01 (betamethasone dipropionate) Spray, 0.05%
76046949|NCT02163915|Drug|TAK-137|TAK-137 tablets
76046950|NCT02163915|Drug|TAK-137 Placebo|TAK-137 placebo-matching tablets
76046951|NCT05610371|Drug|Lidocaine|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml. This dose of lidocaine was calculated to allow maximal benefits with minimal potential complications. The maximal dose of lidocaine is 5mg\kg in adults which translates to 200mg in a 40kg patient. We have set 200 mg as the maximal dose of lidocaine in our study, assuring the dosage is safe. The rest of the procedure following the first 1000ml of saline was completed using saline alone as needed.
75723872|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
76046952|NCT05610371|Drug|Saline|The control group underwent hysteroscopy using a saline distension medium.
75570841|NCT04853095|Procedure|Peritoneal fixation (PerFix)|PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
75570842|NCT04853095|Procedure|Standard of care|ePLND without peritoneal flap fixation
76046953|NCT02163759|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
75424868|NCT01463540|Device|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
75424869|NCT01463553|Procedure|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
76046954|NCT02163759|Other|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
76046955|NCT02163759|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
76046956|NCT02163759|Other|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
75877347|NCT03083847|Drug|Chloroquine Phosphate|Chloroquine has been widely used for treatment and prophylaxis of malaria since 1946 (Most, London et al. 1984). It was the treatment of choice for uncomplicated malaria for decades because it was safe, well tolerated, affordable and highly effective for the treatment of malaria. However, increasing spread of chloroquine- resistant Pf over the last two decades has severely limited its use (Wellems 2002). Chloroquine phosphate is U.S Food and Drug Administration (FDA) approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf.
75877348|NCT03083847|Drug|Pyrimethamine|Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January2014)
75723873|NCT04045418|Device|Laser doppler|"A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively."
75424870|NCT01463566|Device|Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System|Gender Solutions Natural Knee Flex System in total knee arthroplasty
75723874|NCT00807872|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
75723875|NCT00813722|Behavioral|phone call|patients received or not phone calls to give orientation abou treatment
75877349|NCT03083847|Biological|Sanaria PfSPZ Challenge|Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
75723876|NCT00813722|Drug|amlodipine (calcium chanel blocker) and losartan (at1 antagonist)|2,5 mg tid and 25 mg tid
75877350|NCT01377519|Procedure|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
75877351|NCT01377519|Procedure|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
75877352|NCT03082677|Drug|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
75877353|NCT03136055|Drug|Pembrolizumab|Given Intravenously (IV)
76046957|NCT02371369|Drug|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
76046958|NCT02371369|Drug|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
76046959|NCT02187783|Drug|LEE011|Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
76046960|NCT02337361|Behavioral|Electronic SBI|"Bilingual (English and Spanish) e-SBI with four key components:~1) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies."
76046961|NCT02336737|Device|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
75424871|NCT01463579|Other|Exercise Programme|"Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home."
75723877|NCT00813722|Drug|atenolol (beta blocker) and hydrochlorothiazide (diuretic)|25 mg tid and 12,5 mg tid
75723878|NCT00812318|Drug|GSK1265744 10 mg oral solution|GSK1265744
75723879|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
75723880|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
75723881|NCT00812396|Drug|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
75723882|NCT00812396|Drug|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
75723883|NCT00812396|Drug|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
75723884|NCT00807950|Drug|Simvastatin|
75723885|NCT02552030|Device|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
76046962|NCT02336737|Drug|Technetium Tc99m Sulfur Colloid|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
76046963|NCT02336737|Drug|Isosulfan blue dye|Injection of a single dose of isosulfan blue dye
76046964|NCT02130765|Device|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
75723886|NCT02552030|Device|iPhone 4s|
75723887|NCT00649220|Drug|Memantine|memantine tablets, twice a day (bid), for 20 weeks
75723888|NCT00812630|Drug|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
75723889|NCT00813878|Genetic|protein analysis|protein analysis
76046965|NCT02305381|Drug|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
76046966|NCT02305381|Drug|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
76046967|NCT02336425|Drug|QGE031|QGE031 120 mg per 1 mL liquid in vial
76046968|NCT02336425|Drug|Placebo|Placebo to QGE031 0 mg per 1 mL liquid in vial
76046969|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
76046970|NCT02163447|Drug|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
76046971|NCT02163447|Drug|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
76046972|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for infants|
76046973|NCT02163447|Drug|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
76046974|NCT02370667|Other|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
76046975|NCT02370667|Other|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
75723890|NCT00813878|Genetic|protein expression analysis|protein expression analysis
75877354|NCT03136055|Drug|Irinotecan|Given IV
75877355|NCT03136055|Drug|Paclitaxel|Given IV
75877356|NCT01380873|Drug|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
75877357|NCT01380873|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
75877358|NCT01380873|Drug|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
75877359|NCT03789045|Diagnostic Test|Metabolic thresholds and fat oxidation points relationship|Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
75723891|NCT00813878|Genetic|proteomic profiling|proteomic profiling
75723892|NCT00813878|Other|diagnostic laboratory biomarker analysis|Performed one time on study
75723893|NCT00813878|Other|immunohistochemistry staining method|Performed one time on study
75723894|NCT00813878|Other|liquid chromatography|Performed on samples collected one time on study
75723895|NCT00813878|Other|mass spectrometry|Performed on samples collected one time on study
75723896|NCT00813878|Procedure|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
75723897|NCT00813878|Procedure|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
75723898|NCT00813878|Procedure|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
75877360|NCT03221309|Other|Evaluate model of care for HCV-infected adults with on-going opioid misuse|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
75877361|NCT01379235|Other|Pilatis exercise|12 weeks of pilatis exercise 3 times a week.
76046976|NCT02370667|Other|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
76046977|NCT02130297|Device|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
75424872|NCT01463579|Other|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
76046978|NCT01931956|Device|MitraClip® implant|Percutaneous mitral valve repair using MitraClip implant
75723899|NCT02551640|Other|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group."
75723900|NCT00654368|Biological|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
76046979|NCT01887418|Drug|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
75424873|NCT01463592|Biological|RENESSANS , INTERFERON ALPHA 2b, Ribavirin|ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
75424874|NCT01463592|Drug|Interferon Alfa-2b AND RIBAVIRIN|INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
75723901|NCT00654368|Drug|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
76046980|NCT01887418|Drug|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
76046981|NCT01887418|Drug|Delatestryl 200 mg IM Treatment C|Standard of care
76046982|NCT01886716|Behavioral|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
76046983|NCT01886716|Behavioral|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
75424875|NCT01463592|Biological|RENESSANS|ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
75723902|NCT04017026|Device|Implantation|Implantation of 6 mm short implants
76046984|NCT01886716|Behavioral|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
76046985|NCT01912612|Drug|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
76046986|NCT02370511|Device|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
76046987|NCT02303041|Drug|Buparlisib|Administered orally at starting dose of 80 mg/day
76046988|NCT02303041|Drug|Sonidegib|Administered orally at starting dose of 200 mg/day
75424876|NCT01463605|Drug|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
75424877|NCT01463644|Drug|Mepolizumab|This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.
75424878|NCT01463644|Drug|placebo|The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
75424879|NCT01463709|Device|PulseCure pulse generator and Derm-pulse electrode|"PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure"
75424880|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
75723903|NCT00812864|Drug|Capecitabine|"Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day"
76046989|NCT02302807|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
76046990|NCT02302807|Drug|Docetaxel|Docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
76046991|NCT02302807|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
75723904|NCT00808184|Drug|CPT-11, Raltegravir (Isentress®), Midazolam|
75723905|NCT02551562|Other|NuDerm® System|The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
75723906|NCT02551562|Other|Placebo|Basic skin care regimen
75723907|NCT00814190|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
75723908|NCT00812942|Procedure|colonoscopy|colonoscopy screening
75723909|NCT00812942|Procedure|faecal test|faecal occult blood test for screening
76046992|NCT02302807|Drug|Vinflunine|Vinflunine 320 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
76046993|NCT02335489|Device|Implantation with the commercially available Axium neurostimulator|
76046994|NCT02527343|Drug|volanesorsen|300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).
76046995|NCT02527343|Drug|Placebo|Volanesorsen-matching placebo administered SC injection.
76046996|NCT05582057|Behavioral|Strengths to Grow: Preteen|An online, strength based parenting program for parents of preteens (aged 9-14).
76046997|NCT05373875|Diagnostic Test|Doppler ultrasound|Doppler to listen and classify the arterial signal in the ankle and arm (Ankle brachial pressure index (ABPI))
75424881|NCT01463735|Dietary Supplement|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
75570843|NCT04785469|Other|Low-load eccentric training|"Aerobic exercise training on a downhill walking treadmill with the following settings: 10% negative incline and constant speed corresponding to 75% of the average speed recorded during the initial 6-Minute walk test.~Resistance training: 5 minutes of warm-up on the manual ergometer, then 3 sets for 10 repetitions of the leg extension (performed unilaterally in eccentric phase) with a load of 75% of 1 repetition maximum (concentric) for the first two weeks. The following two weeks, 3 sets for 10 repetitions will be performed on the leg press (performed unilaterally in the eccentric phase) with 75% load of 1 repetition maximum (concentric). In addition, patients will perform 3 upper extremity strengthening exercises (free weights or elastic bands), including 2 sets of 10 repetitions for each exercise."
75723910|NCT00647426|Drug|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
75424882|NCT01463748|Other|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
75424883|NCT01463748|Other|Placebo|starch
75424884|NCT01463761|Device|ANS activity|This ANS activity is measured by nocturnal heart rates records with Holter ECG.
75424885|NCT01463774|Drug|Treatment A: Canagliflozin tablet|Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
75424886|NCT01463774|Drug|Treatment A: Metformin IR tablets|Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
75723911|NCT00647348|Drug|Simvastatin|80mg simvastatin oral once daily for 24 months
75723912|NCT00647348|Drug|Placebo|Oral placebo tablet once daily for 24 months
75723913|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
75424887|NCT01463774|Drug|Treatment B: Canagliflozin/metformin fixed dose combination tablets|Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
75424888|NCT01463787|Procedure|microsurgical varicocelectomy in inguinal approach|In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.
75424889|NCT01463787|Procedure|microsurgical varicocelectomy in subinguinal approach|In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
75723914|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
75723915|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
75723916|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
75723917|NCT00647270|Drug|Placebo|Pre-filled syringe. See arm for more detail
76046998|NCT05538065|Other|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
75723918|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
75723919|NCT00813254|Behavioral|Questionnaire|Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
75723920|NCT00645944|Drug|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
75723921|NCT00645944|Drug|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
75723922|NCT03869840|Device|Sensor to spot check blood levels|Sensor to check blood levels, not used as intervention
75723923|NCT00813332|Drug|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
75723924|NCT00813332|Drug|Placebo plus Docetaxel|Placebo plus Docetaxel
75877362|NCT05421117|Procedure|Laparoscopic adnexal mass extraction|Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
75424890|NCT01463800|Behavioral|Structured exercise training|12 weeks low level ambulatory structured exercise training
75424891|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
75424892|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
75424893|NCT01463813|Dietary Supplement|Placebo|Inactive placebo
75424894|NCT01463852|Drug|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
75424895|NCT01463865|Drug|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
75424896|NCT01463865|Drug|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
75424897|NCT01462760|Device|Assessment with inclinometer|joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer
75424898|NCT01462760|Device|Assessment with actigraph|joint assessment with actigraph The actigraph used in this trial is the Motion Pod. It's an analysis and reeducation systems by biofeedback. The manufacturer is Movea.
75424899|NCT01463904|Procedure|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
75424900|NCT01463917|Drug|Hypertonic solution|Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
75424901|NCT01463917|Drug|Isotonic|Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
75570844|NCT04785469|Other|Usual care|"Aerobic exercise training using the cycle ergometer at an intensity calculated as follows: 2 minutes with load equal to 20% of maximum load, then 25 minutes with initial load at 50% of maximum load calculated as 103.217 + (30.500xGender) + (-1.613xAge) + [0.002x6-Minute walk work (6MWW)]. [Sex: female = 0; male:1] [6MWW = 6-Minute walk distance x weight in kg].~Resistance training: 5 minutes of warm-up on the manual ergometer, then 5 exercises for upper and lower limbs performed with free weights or elastic bands. For the first 2 weeks will be performed 2 sets X 20 repetitions with 1 minute break between sets and a load that allows to perform no more than 20 repetitions. For the following 2 weeks, 3 sets of 10 repetitions x 10 repetitions with 2 min break between sets and a load that allows for no more than 10 repetitions."
75723925|NCT04708496|Drug|Artemether-lumefantrine|"A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria."
75723926|NCT00646958|Drug|Radezolid|450mg PO QD
75723927|NCT00646958|Drug|Radezolid|450mg PO BID
75723928|NCT00646958|Drug|Linezolid|600mg PO BID
75723929|NCT00813410|Procedure|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
75570845|NCT03989102|Biological|PfSPZ Vaccine|PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.
75570846|NCT03989102|Other|Normal Saline|Sterile isotonic (0.9%) normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe; and will be used as a placebo, rather than a comparator vaccine
75570847|NCT01254643|Biological|V503|V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
75570848|NCT04491825|Diagnostic Test|Skin suction blistering and skin biopsies|Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.
75570849|NCT01254604|Drug|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
75570850|NCT01254604|Drug|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
75570851|NCT03980093|Behavioral|Education|Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
75570852|NCT03980093|Behavioral|Values|An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
75570853|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
75570854|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
75424902|NCT01463930|Behavioral|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
75424903|NCT01463930|Behavioral|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
75424904|NCT01463943|Other|Probiotic|
75424905|NCT01463943|Other|Probiotic|
75424906|NCT01463943|Other|Probiotic|
75424907|NCT01463956|Drug|Boceprevir|Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
75424908|NCT01463956|Biological|Peg-Interferon α-2b or Peg-Interferon α-2a|Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
75570855|NCT03945734|Behavioral|Expressive Helping|Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
75877363|NCT05421039|Behavioral|Exposure to unintended injuries|"After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers"
75877364|NCT03609398|Biological|RVF Vaccine|1.0 mL dose given SQ in upper arm
75877365|NCT04378400|Procedure|Sacrocolpopexy|Sacrocolpopexy is offered to patients with symptomatic prolapse (≥stage II) of the vaginal apex (vault or cervix). The procedure involves dissection of the promontory and the vaginal vault, suturing of two meshes to the anterior and posterior aspect of the vagina using minimally three rows of sutures on each side, and one row at the apex. Thereafter the mesh is fixed with staples to the promontory and the peritoneum closed, with staples and a running suture.
75723930|NCT04045808|Other|radiographic evaluations were done|For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
75723931|NCT00817544|Drug|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
75877366|NCT03426657|Combination Product|Durvalumab + Tremelimumab + RT|Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
75877367|NCT02858180|Drug|Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)|1 pill once daily of SOF/LDV FDC
75877368|NCT03082599|Device|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
75424909|NCT01463956|Drug|Ribavirin|Ribavirin: capsules 200 mg (weight-based daily dose: <65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; >105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
75424910|NCT01464008|Drug|Pegylated interferon alfa-2a and ribavirin|all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
75424911|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
75424912|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
75424913|NCT01464073|Behavioral|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
75723932|NCT00642746|Drug|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
75723933|NCT00642746|Drug|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
75723934|NCT00642746|Drug|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
75723935|NCT00642746|Drug|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
75723936|NCT00642746|Drug|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
75723937|NCT00814268|Drug|Clopidogrel|75mg tablet, oral administration once daily
75723938|NCT00814268|Drug|Clopidogrel placebo|Matching tablet, oral administration once daily
75723939|NCT00814268|Drug|Aspirin|100mg tablet, oral administration once daily
75877369|NCT04232384|Procedure|Standard Paracentesis|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).
75723940|NCT00808262|Biological|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
75723941|NCT00817622|Dietary Supplement|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
76046999|NCT05538065|Other|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
76047000|NCT05538065|Other|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory [BPA]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
75424914|NCT01464073|Behavioral|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
75424915|NCT01464073|Behavioral|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
75424916|NCT01464073|Dietary Supplement|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
75424917|NCT01464086|Other|whole body MRI|whole body MRI at inclusion, one and two years
75424918|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
75424919|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
75723942|NCT00808418|Drug|Elesclomol Sodium|Chemotherapy agent
75723943|NCT00808418|Drug|Docetaxel|Chemotherapy agent
75723944|NCT00817700|Other|Sleep restriction|Sleep restriction.
75723945|NCT04572152|Biological|AK119|Subjects will receive AK119 by intravenous administration.
75723946|NCT04572152|Biological|AK104|On the same day subjects will receive AK104 by intravenous administration.
75570856|NCT03939065|Device|Sensor Augmented Pump Therapy|Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
75723947|NCT00642668|Drug|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
75723948|NCT00817934|Drug|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
75877370|NCT04232384|Procedure|Roll Over Paracentesis|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
75877371|NCT03609086|Other|Melatonin analysis|Measurement of 6-hydroxymelatonin
75723949|NCT00814424|Device|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
75723950|NCT00814424|Device|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
75424920|NCT01464112|Drug|JNJ-2641585 / VELCADE / Dexamethasone|JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
75424921|NCT01464125|Drug|Fosmidomycin|Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
75424922|NCT01464125|Drug|Azithromycin|Azithromycin capsules 250 mg x 3 twelve-hourly for three days
75424923|NCT01464138|Drug|Fosmidomycin and Clindamycin co-administration|Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
75570857|NCT03939065|Device|Standard of Care with CGM|Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
75570858|NCT01254565|Drug|Etelcalcetide|Administered intravenously (IV) at the end of hemodialysis
75570859|NCT01254565|Drug|Placebo|Administered intravenously at the end of hemodialysis
75570860|NCT04772053|Procedure|Tumor biopsy|Archived or fresh tumor biopsy samples will be collected.
75723951|NCT00729833|Drug|CP-751,871|CP-751,871 IV, every 3 weeks
75723952|NCT00729833|Drug|Sunitinib|Sunitinib - daily dosing
75570861|NCT02889055|Device|patient requiring the MIRUS (mechanical ventilation)|
75570862|NCT01254409|Biological|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
75570863|NCT01254409|Other|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
75570864|NCT04324177|Other|Demographic data, morbidity data|To detect association between the demographic data of pediatric patients including age ,sex,hospital stay and clinical data including the diagnosis and co morbidity with the outcome of pediatric patients admitted to ICU of Assiut University children hospital
75570865|NCT04684160|Device|Fixed-bearing TKA|
75723953|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
75723954|NCT00645788|Drug|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
75723955|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
75723956|NCT00645788|Drug|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
75723957|NCT00808496|Other|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
75877372|NCT02034344|Procedure|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
75877373|NCT02034344|Procedure|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
75877374|NCT02034344|Procedure|Urine collection|Urine will be collected from all participants.
75424924|NCT01464203|Other|CT coronary angiography|"CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries."
75424925|NCT01464203|Other|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
75424926|NCT01464242|Drug|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
75424927|NCT01464242|Drug|Placebo|Placebo 400mg orally 3 times a day for 20 days
75570866|NCT04684160|Device|Mobile-bearing TKA|
75570867|NCT04390698|Procedure|paravertebral block|Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.
75570868|NCT04390698|Drug|opioid free anesthesia|propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
75570869|NCT04390698|Procedure|sham block|Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.
75570870|NCT04390698|Procedure|opioid general anesthesia|propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
75570871|NCT01254331|Drug|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
75570872|NCT04673578|Drug|Celecoxib|Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
75570873|NCT04673578|Other|Placebo|Microcrystalline cellulose
75570874|NCT05414058|Drug|Apo-Methylphenidate ER|The study medication will be administered by a clinical registered nurse (RN), alongside their other medications. Patients will continue their regular medications as per standard of care.
75570875|NCT03757403|Drug|RDD1609|RDD1609 to be applied on the perianal area BID
75570876|NCT03757403|Drug|Mebendazole 100 MG|Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
75877375|NCT02745587|Radiation|radiotherapy|high dose external beam radiotherapy limited to the prostate(bed)
75877376|NCT02691845|Behavioral|BA (brief advice)|
75877377|NCT02691845|Behavioral|SHE (supervised and home-based exercise)|
75877378|NCT02691845|Behavioral|HE (health education)|
75570877|NCT04381923|Device|Helmet Continuous Positive Airway Pressure (CPAP)|Helmet CPAP will be initiated at a pressure of 5 cmH20 and fraction of inspired oxygen (Fi02) of < 60%. If oxygen saturation (Sp02) remains < 92%, pressure will be increased to 10 cmH20. FiO2 will then be tapered to target a SpO2 ≥ 92%. Breaks with intervening HFNO use will be provided as needed for meals and during hours of sleep.
75570878|NCT04381923|Device|High Flow Nasal Oxygen (HFNO)|HFNO will be initiated at a flow rate of 40 LPM and a fraction of inspired oxygen (Fi02) of < 60%. If oxygen saturation (SpO2) remains < 92%, the flow rate will be increased to 60 LPM. FiO2 will then be adjusted to target a SpO2 ≥ 92%. Patients with discomfort due to HFNO may have their flow rate decreased until the discomfort resolves.
75570879|NCT00537342|Biological|Immunotherapy with modified extract of O. europaea pollen|Sublingual (2 drops daily during 2 months)
75570880|NCT04338516|Device|Ossix™ Bone|a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
75570881|NCT04338516|Device|Bio-Oss® Collagen|90% bovine derived xenograft granules and 10% porcine collagen
75570882|NCT00537420|Drug|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
75570883|NCT00537420|Drug|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
75570884|NCT00537420|Drug|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
75877379|NCT02691845|Behavioral|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
75570885|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
75570886|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
75570887|NCT00537420|Drug|Sibutramine|Sibutramine will be taken once daily with or without food
75723958|NCT00808496|Other|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
75723959|NCT00808496|Other|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
75424928|NCT01464242|Drug|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
75723960|NCT00814736|Drug|UK369,003|oral tablet, once a day
75424929|NCT01464281|Drug|Peginterferon alfa 2a|Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
75424930|NCT01464294|Device|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
75723961|NCT00814736|Drug|sildenafil|single oral dose on day 14 or day 17
75424931|NCT01464294|Device|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
75424932|NCT01464320|Drug|ABT-614|Active
75424933|NCT01464320|Drug|Placebo Comparator|Placebo
75424934|NCT01464372|Device|Electrical Field Stimulation Device|Treatment with Electrical Field Stimulation Device
75424935|NCT01464372|Device|Sham Nerve Stimulation Device|Use of the sham device
75424936|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
75424937|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237 mL
75424938|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
75424939|NCT01464398|Behavioral|Stress reduction|8 weekly sessions
75424940|NCT01464398|Behavioral|Stress reduction with Health education|8 weekly sessions
75424941|NCT01464450|Drug|Rivaroxaban|Single 20 mg-dose
75723962|NCT00814736|Drug|sildenafil matching placebo|single oral dose on day 14 or day 17
75723963|NCT00818090|Drug|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
75570888|NCT04295889|Diagnostic Test|Approach A (PeeSpot urine collection device).|The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
75570889|NCT04295889|Diagnostic Test|"Approach B (ACR | EU Test kit)."|"The participant will receive the ACR | EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app."
75723964|NCT03869606|Device|NICOM by Cheetah Medical|Observational measurement, Cardiac Output, Pre- and Post Anesthesia
75723965|NCT00642356|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
75723966|NCT00642356|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
76047001|NCT05308277|Device|Leo device monitoring|After consent and enrollment, the child's respiratory impedance will be continuously recorded using the Leo device throughout the day and night during the entire hospital stay or ED visit. The device may be taken off for up to 1 hour per day (i.e., break during bath / shower time). The device will be applied to the skin overlying the mid-sternum area on the chest wall after cleaning of the skin with an alcohol swab after consent has been obtained. The device will be changed every 72 hours or earlier, by the participant's guardian, depending on signs of defect in the signal quality or battery exhaustion, based on daily check of the signal by the research team. Remote monitoring of the child's chest impedance will continue using the Leo device after discharge from hospital/ED for 7 days.
75570890|NCT03534284|Behavioral|Cognitive Behavioral Therapy for Insomnia|Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.
75570891|NCT03534284|Drug|Trazodone|trazodone tablet
75570892|NCT03534284|Drug|Placebo|Inactive pill manufactured to mimic trazodone tablets.
75570893|NCT00537459|Drug|16448|
76047002|NCT05307887|Device|Sync VR Medical PICO G2 4K Virtual Reality Technology|Virtual reality headset and software
76047003|NCT01931566|Drug|Pioglitazone|Pioglitazone SR tablets
76047004|NCT01931566|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets
76047005|NCT05511077|Other|Diet|Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.
75570894|NCT03504215|Other|Exercise Intervention|Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
76047006|NCT04248725|Behavioral|E-TIPS|Chronic pain self-management strategies for employed individuals with physical disabilities
76047007|NCT05372939|Drug|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
76047008|NCT05372939|Other|Placebo (oral)|Orally administered placebo comparator taken once daily
75570895|NCT03457038|Biological|Blood Test|"Addition to the current care but during the normal follow-up visit :~At the entrance to the service: search for bacterial 16S RNA in the blood~Additional blood tests (4) at T6-12-18 and 36h~At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.~1 time per day: Assay of CRP and PCT from samples taken in common practice~J30: Assessment of the vital status of the patient"
75570896|NCT04218279|Other|Sleep Health Education|Intervention materials include 10 brief education modules that the target population will review/view on a secure study-specific website.
75570897|NCT04183374|Other|Life style|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
75570898|NCT01254292|Drug|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
75570899|NCT01254292|Drug|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
75723967|NCT00642278|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
75723968|NCT00642278|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
76047009|NCT05372939|Combination Product|Humira (adalimumab)|Humira comparator is administered subcutaneously, on Humira frequency schedule.
76047010|NCT05372705|Behavioral|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
76047011|NCT04247477|Other|Ventilation strategy|Patients are ventilated in randomized order with three different ventilation strategies (A,B and C)
76047012|NCT01912456|Biological|Low-volume C1-esterase inhibitor|
76047013|NCT01912456|Biological|Higher-volume C1-esterase inhibitor|
76047014|NCT01912456|Biological|Low-volume placebo|
76047015|NCT01912456|Biological|Higher-volume placebo|
75570900|NCT04178538|Procedure|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique
75424942|NCT01464463|Behavioral|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
75570901|NCT04178538|Procedure|Standard ACL reconstruction with all inside technique|Standard ACL reconstruction with all inside technique
75570902|NCT04092777|Behavioral|Strong Minds|The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.
75570903|NCT04092777|Other|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
75570904|NCT00553007|Procedure|Periodontal therapy|Normal periodontal therapy is performed.
75570905|NCT04075383|Procedure|immediate dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
75570906|NCT04075383|Procedure|immediate-delayed dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
75570907|NCT00537498|Drug|Urokinase|"Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is > 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is < 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is < 1,6g/l treatment must be stopped and continued after rising up to >2g/l"
75570908|NCT01254019|Drug|GSK2402968 6mg/kg/week|subcutaneous
75570909|NCT04687644|Behavioral|Online education|Education group
75723969|NCT00642278|Drug|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
75723970|NCT00808574|Behavioral|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
75723971|NCT00543543|Biological|Comparator: GARDASIL|GARDASIL (quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
75723972|NCT00543543|Biological|Experimental: V503|V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
76047016|NCT05307653|Procedure|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
75424943|NCT01464463|Behavioral|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
75424944|NCT01464463|Behavioral|CBASP|"Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship."
75424945|NCT01464476|Drug|Azimilide Dihydrochloride|Azimilide 75 mg. Once daily, oral administration
75424946|NCT01464476|Drug|Placebo|Dose-matched placebo. Once daily, oral administration
75723973|NCT00812786|Drug|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
75723974|NCT00645164|Other|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
75723975|NCT00645164|Drug|Xenaderm|20 mg under Finn chambers
75723976|NCT00815048|Drug|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
75570910|NCT03055871|Behavioral|Habit formation intervention|In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
75570911|NCT03055871|Behavioral|Physical activity planning intervention|This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
75570912|NCT04683458|Device|Drug-coated device|The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
75570913|NCT04319497|Device|Subjective refraction|Subjective refraction measurements will be performed by two testers for all the patients included
75570914|NCT04319497|Device|Autorefraction|Five autorefraction measurements will be performed for all the patients included
76047017|NCT05307653|Procedure|Erector spinea plain block|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
75570915|NCT04319497|Device|Wavefront aberrometry|Five wavefront measurements will be performed for all the patients included
75570916|NCT01253317|Drug|rhIGF-1|1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
75570917|NCT00537537|Drug|Telbivudine|
75570918|NCT02863874|Device|VicrylPlus®|Suture
75570919|NCT02863874|Device|Vicryl®|Suture
75570920|NCT04319770|Device|enamel matrix derivative (EMD)|periodontal regenerative surgery with enamel matrix derivative (EMD) (control)
76047018|NCT05307653|Procedure|Caudal block|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
76047019|NCT05340491|Drug|Toripalimab|240mg, D1, every 3 weeks per cycle, three cycles with chemotherapy and eight cycles after IMRT
75877380|NCT05336357|Device|Goal-Directed Therapy|"Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 70 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell."
76047020|NCT05340491|Drug|Chemotherapy|Gemcitabine: 1.0g/m2, D1 and D8, Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
76047021|NCT05340491|Radiation|Intensity modulated radiotherapy|total 60-66Gy, 1.8-2.0Gy/f/day
75424947|NCT01464489|Drug|Atropine|"Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition"
75424948|NCT01464489|Drug|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
75570921|NCT04319770|Device|hyaluronic acid (HA)|periodontal regenerative surgery with hyaluronic acid (HA) (test)
75570922|NCT04073472|Drug|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
75570923|NCT01253200|Device|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
75570924|NCT01253200|Device|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
75570925|NCT00553046|Other|survey administration|application of a family survey on last 3 months of life for their relatives under HMV
76047022|NCT05306093|Dietary Supplement|Nutraceutical|Food supplements are consumed during 8 weeks by healthy volunteers
75424949|NCT01466608|Drug|Rosuvastatin|Oral administration of rosuvastatin 20 mg once daily for 21 days.
75424950|NCT01463657|Device|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
75570926|NCT04515901|Drug|2% lidocaine|Viscous lidocaine
76047023|NCT05306093|Dietary Supplement|Maltodextrin|Food supplements are consumed during 8 weeks by healthy volunteers
75570927|NCT04515901|Other|Placebo|Methylcellulose and cherry flavouring
75570928|NCT01253044|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
75570929|NCT01253044|Behavioral|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
75723977|NCT00815048|Drug|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
75723978|NCT02551796|Procedure|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
75424951|NCT01463657|Device|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
75723979|NCT02551796|Procedure|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
75723980|NCT02551796|Procedure|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
76047024|NCT04251065|Drug|Daratumumab|"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP).~Induction phase:~4-6 courses (according to response after cycle 4 and to patient compliance) of D-GDP every 21 days pursuant to the following schedule: Daratumumab cycle 1: 8 mg/kg i.v. on day 2 and on day 9; cycle 2-6: 16 mg/kg i.v. on day 2 and day 9) Gemcitabine 1000 mg/sm i.v. day 1 and day 8 (gemcitabine on day 8 to be skipped in case of grade 3-4 toxicity) Cisplatin 75 mg/sm i.v. day 1 Dexamethasone 40 mg i.v. or po days 1-2-3-4-9 G-CSF from day 3 to 6, and from day 10 to 13 (to be prolonged if necessary)~Maintenance:~starting 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade > 1, after toxicity is resolved) and up to 24 cycles from start of D-GDP according to the following schedule: Daratumumab 16 mg/kg single administration every 28 days."
76047025|NCT01885936|Drug|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
76047026|NCT01885936|Drug|Placebo|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
76047027|NCT05509127|Drug|Modified universal adhesive|Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
75424952|NCT01466634|Procedure|percutaneous coronary intervention with stent|patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
75424953|NCT01466647|Drug|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
75877381|NCT03160885|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
75877382|NCT03160885|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
75877383|NCT00730717|Drug|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
75877384|NCT00730717|Drug|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
75877385|NCT01332409|Drug|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
75877386|NCT03181451|Drug|Ferric Maltol|To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
75877387|NCT03495973|Drug|Ustekinumab|Participants that are initiated on treatment with ustekinumab and are registered in Swibreg will be recruited into the cohort. All aspects of treatment and clinical management of participants will be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.
75877388|NCT00480805|Drug|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
75877389|NCT00480805|Drug|Comparator : ramipril /Duration of Treatment : 8 Weeks|
75570930|NCT02646527|Behavioral|Dignity Therapy|Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
75877390|NCT00406783|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
75570931|NCT04685889|Procedure|Resin infiltration|"A sufficient amount of HCl was applied to the lesion using the icon etch syringe included in the set and was allowed to sit for 2 minutes. After washing with water for 30 seconds, the tooth was dried using an air spray. Once the enamel surface appeared chalky, Icon® dry application was initiated.~Ethanol was applied to the lesion using the Icon® dry syringe included in the set, and after 30 seconds it was dried using an air spray. Sufficient amount of resin infiltrant was applied to the lesion using the Icon® infiltrant syringe. The resin infiltrant was applied to the lesion surface by massaging with the tip of the syringe in circular movements for 3 minutes such that it penetrates the surface thoroughly. The resin infiltrant was polymerized for 40 seconds with a light device."
75877391|NCT00406783|Drug|Placebo|Placebo tablet, once daily for 15 days
75877392|NCT03179891|Drug|Diazepam Buccal Film 12.5 mg|All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
75877393|NCT01334671|Drug|Atorvastatin|Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
75877394|NCT01332565|Drug|GSK1349572|50mg tablet
76047028|NCT05509127|Drug|Conventional universal adhesive|Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
75424954|NCT01466712|Drug|Tiotropium + formoterol/beclometasone|Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
75424955|NCT01466712|Drug|tiotropium + placebo|Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
75424956|NCT01466738|Biological|HRV-16 (100 TCID50)|Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
75424957|NCT01466738|Biological|HRV-16 (1000 TCID50)|Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
75424958|NCT01466777|Procedure|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
75424959|NCT01466777|Procedure|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
76047029|NCT05338229|Device|the engineer-built system, video-game based Kinect sensor|The engineer-built system, video-game based Kinect sensor was developed by the researcher team.
75424960|NCT01466803|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
75424961|NCT01466803|Drug|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
75424962|NCT01466816|Dietary Supplement|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
75424963|NCT01466829|Drug|Parathyroid hormone|100 microgram daily. S.c
75424964|NCT01466829|Drug|Placebo|Placebo; saline injection.
75570932|NCT04206514|Behavioral|Person Centered Care - Post Abortion Support|Post abortion phone based support
75570933|NCT05504902|Device|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with Advanced stage Parkinson's disease
75424965|NCT01466842|Procedure|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
75424966|NCT01466855|Drug|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
75424967|NCT01466868|Drug|MK2206|"Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms."
75424968|NCT01466894|Biological|IMM 124-E|Tablets orally twice a day for 24 weeks
76047030|NCT05336591|Other|Covid-19 pandemic|All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.
75424969|NCT01466894|Biological|Placebo|Tablets orally twice daily for 24 weeks
76047031|NCT05531513|Behavioral|Virtual Reality (VR) Meditation|"The VR-Meditation intervention comprises an evidence-based 360-degree high-definition video VR application incorporating elements of nature, mindfulness and compassion. The VR-Meditation intervention is 4 weeks long and includes includes 4 different themes during the course of the program. Each week will focus on a distinct theme and will consist of two 20-minute VR sessions starting with a 10-minute guided meditation related to the weekly theme (one new meditation per week), followed by 10 minutes of open exploration of the virtual environment, for a total of 8 distinct sessions. The weekly themes are as follows:~Week 1 - Mindfulness of the Environment~Week 2 - Embodied Mindfulness~Week 3 - Embodied and Embedded Compassion~Week 4 - Mindfulness, Compassion, and the External Environment~In addition to baseline measures, participants in the VR Meditation condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
76047032|NCT05531513|Behavioral|Psychoeducational Pamphlet|"The Psychoeducational Pamphlet intervention is 4 weeks long. Participants receive 1 pamphlet per week for a total of 4 different pamphlets. Handouts will provide information about managing stress and enhancing well-being, without referencing nature, mindfulness or compassion (e.g., eating habits, sleep hygiene, relaxation training, art exercises). The handouts will be based on empirical findings and will be written in accessible language with visual charts and specific practices to facilitate their implementation by participants. At the end of the study (i.e., after follow-up), Psychoeducation Pamphlet participants will receive access to the VR-Meditation program.~In addition to baseline measures, participants in the Psycho-educational Pamphlet condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
75424970|NCT01466907|Other|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
75424971|NCT01466907|Other|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
75424972|NCT01466933|Behavioral|Responsive parenting|On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
75570934|NCT04001556|Diagnostic Test|Minor Salivary gland Biopsy|Minor salivary gland biopsy with injection of lidocain
75570935|NCT04001556|Diagnostic Test|ARFI|Acoustic Radiation Force Impulse on Major Salivary Glands
75570936|NCT04001556|Diagnostic Test|MSG US|Ultrasonography of Major Salivary Glands
75570937|NCT04320589|Drug|Dexmedetomidine|which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
75570938|NCT04320589|Drug|General anesthetic|1) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, ACI & ACRB e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]
75570939|NCT04319458|Behavioral|Fotonovela|Secret Feelings/Sentimientos Secretos
75570940|NCT04319458|Behavioral|Control|NIH Brochure: Depression: What You Need to Know
75570941|NCT01252966|Behavioral|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
76047033|NCT05301491|Other|Dance Therapy Group|"Dance therapy group patients are going to be treated 3 days a week for 8 weeks. Patients who started treatment are going to be randomly divided into groups that includes four individuals, due to COVID-19 pandemic preventions.~Dance therapy is going to be applied with individualized choreographies specially prepared for the patients, taking the expert opinion of the dance therapist. Choreographies of different dance genres (step/aerobic dance, zumba, salsa, bachata, oriental etc.) are going to be used in the program. Sessions are going to be with the practitioner in a bright, clean, empty and noiseless room in front of a full-length wall mirror. The practitioner is going to participate to dance therapy throughout the sessions, allowing patients to imitate movements. Session duration is going to be 40 minutes. Patients will be given a one-minute rest period during music transitions."
75570942|NCT01252966|Behavioral|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
75570943|NCT00537615|Drug|PD 0332334|
75570944|NCT02582957|Other|Sigh breaths|Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
76047034|NCT05301491|Other|Exercise Group|"The patients in the control group is going to perform conventional low back exercises. The program of the patients will start with stretching and warming exercises, and will continue with strengthening exercises.~Exercises planed for control group;~Unilateral hip-knee flexion (self-assisted exercise)~Bilateral hip-knee flexion (self-assisted exercise)~Straight leg lifting with the aid of a sheet/rigid band~Posterior pelvic tilt~Bridge building exercise~Cat-camel exercise~Half shuttle in sagittal plane~Right and left rotational shuttle~Trunk hyperextension in prone position~Rotational exercise with hip-knee flexed in supine position Patients are going to do exercises with ten repetitions. As the sessions progressed, the number of repetitions will be increased."
76047035|NCT05301491|Other|Pyhsiotherapy Modalities|20 minutes hotpack, 3-5 minutes ultrasound and 20 minutes conventional type Transcutaneous Electrical Nerve Stimulation (TENS) are going to be applied to lumbar region of all patients in prone position.
75877395|NCT02973815|Behavioral|NU-HOME Intervention|The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
75570945|NCT03990909|Dietary Supplement|Branched Chain Amino Acids|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
75570946|NCT03990909|Dietary Supplement|Rice Protein|60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
75877396|NCT01338727|Behavioral|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
75570947|NCT03990909|Dietary Supplement|Microcrystalline Cellulose|60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
75570948|NCT01252810|Drug|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
75570949|NCT04206709|Procedure|aerobic effort|Active upper limbs pedaling while maintaining a pulse calculated to be approximately 60% of the predicted maximum heart rate of each patient for 20 minutes.
75877397|NCT01332643|Genetic|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
75877398|NCT05185765|Other|Bread|Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
75877399|NCT03160573|Drug|ClōSYS® Unflavored Rinse|
75877400|NCT03160573|Drug|ClōSYS® Flavored Rinse|
76047036|NCT05368415|Drug|Norepinephrine|mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
75424973|NCT01466933|Behavioral|Child Development|On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
76047037|NCT05529173|Drug|Povidone-Iodine 10%|Nasal swab stick application of Povidone-Iodine 10% prior to surgery
75424974|NCT01466946|Behavioral|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin & Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
75424975|NCT01466959|Other|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
75424976|NCT01466959|Other|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
75424977|NCT01466998|Other|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
75424978|NCT01466998|Other|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
75424979|NCT01467011|Drug|Enteric-coated Mycophenolate Sodium|1440mg/day for 6 months posttransplant
75424980|NCT01467024|Other|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
75570950|NCT04206709|Other|passive pedaling|20 minutes passive pedaling by upper limbs.
75570951|NCT00537654|Drug|Treatment sequence A|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
75570952|NCT00537654|Drug|Treatment sequence B|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
75570953|NCT00537654|Drug|Treatment sequence C|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
75570954|NCT00537654|Drug|Treatment sequence D|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
75570955|NCT04397692|Device|Nitric Oxide delivered via LungFit™ system|Patients will receive inhalations of 80 ppm for 40 min 4 times a day
75570956|NCT01252186|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
75877401|NCT03160573|Other|Placebo-Flavored Oral Rinse|Flavor-matched placebo rinse
75570957|NCT01252186|Drug|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
75570958|NCT01252186|Drug|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
75570959|NCT03988335|Drug|RIST4721|RIST4721 oral solution
75570960|NCT03988335|Drug|Placebo|Placebo oral solution
75877402|NCT03160573|Other|Placebo-Unflavored Oral Rinse|Unflavored-matched placebo rinse
75877403|NCT01314677|Procedure|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
76047038|NCT05529173|Drug|0.9% NaCl Solution|Nasal swab stick application of 0.9% NaCl Solution prior to surgery
76047039|NCT05335109|Drug|Xenon|"Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days."
75570961|NCT00537693|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
75570962|NCT04320316|Drug|Crysvita (burosumab-twza) Treatment|KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
75570963|NCT01731782|Drug|bupivacaine|
75570964|NCT01731782|Drug|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
75570965|NCT02889211|Behavioral|Gambling Task|
75424981|NCT01467050|Other|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
75570966|NCT01251952|Drug|Denileukin Diftitox (Ontak)|"After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360."
75570967|NCT04356430|Drug|Abiraterone Acetate|1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
75570968|NCT04356430|Drug|Prednisone|5 mg oral low dose prednisone, once daily
75570969|NCT04356430|Drug|Goserelin 10.8 mg|10.8 mg goserelin hypodermic once per 12 weeks
75570970|NCT01352195|Behavioral|Forever Free Booklets|Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
75877404|NCT01314677|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
75877405|NCT05185687|Behavioral|First Come, First Served|"Respondents will view the following description of the plan: Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'"
75877406|NCT05185687|Behavioral|Random|"Respondents will view the following description of the plan: People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
75570971|NCT04321135|Behavioral|Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly.They will also receive a participant informational binder (wellness guide) with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
75570972|NCT04321135|Behavioral|Self-Guided Lifestyle Program (Control Arm)|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging
75570973|NCT04320238|Drug|recombinant human interferon Alpha-1b|recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
75570974|NCT04320238|Drug|thymosin alpha 1|thymosin alpha 1 subcutaneous injection 1 time per week.
75723981|NCT00808652|Other|Measurement of flow mediated dilation of brachial artery.|"Flow-mediated brachial artery reactivity will be measured and flow-mediated vasodilatation will be assessed with the subject's arm using a 15 MHz linear array ultrasound.~Study Phases:~Flow-mediated (endothelial-dependent) vasodilatation (FMD): Following a 2-minute baseline period, a longitudinal image of the artery will be obtained. A tourniquet placed around the forearm proximal to the target artery will be inflated to a pressure 50 mmHg higher than the subject's systolic blood pressure and held for 5 minutes. Cuff will be then deflated. A continuous scan will be performed at deflation, 60 and 90 seconds after cuff deflation, with frozen and Doppler measurements recorded at similar intervals to the baseline phase.~NTG-induced (non-endothelial-dependent) vasodilatation (NTG): After vessel recovery, sublingual 375 mg of isosorbide dinitrate spray will be administered, and scanning will be performed continuously for 5 minutes thereafter."
75723982|NCT02551484|Device|Measurements using NIRS|
76047040|NCT05335109|Drug|Oxygen 30 %|"Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days"
76047041|NCT05300399|Device|mHealth app|The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
76047042|NCT04137575|Behavioral|ConquerFear-Group|The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.
76047043|NCT04137575|Behavioral|Relaxation Training|The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
76047044|NCT05299229|Diagnostic Test|Echocardiogrpahy and non-invasive monitoring|Study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff.
75570975|NCT04320121|Dietary Supplement|Nelutri™|Nelutri™ 2,000 mg/day for 12 weeks
75723983|NCT02551484|Device|TCPO2 measurements|
76047045|NCT05333237|Dietary Supplement|Intervention #1: ProvideXtra Drink|Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
76047046|NCT05333237|Dietary Supplement|Intervention #2: Fresubin Energy Drink|Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
75570976|NCT04320121|Dietary Supplement|Placebo group|Placebo 2,000 mg/day for 12 weeks
75570977|NCT04320004|Behavioral|Education|Subject receives education
75570978|NCT04320004|Behavioral|Education with Reminder|Subject receives education with reminder
75877407|NCT05185687|Behavioral|Disadvantaged Priority & Random|"Respondents will view the following description of the plan: Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them."
75877408|NCT04470661|Diagnostic Test|Ultrasonography|"Point-of-care ultrasound:~Kidney length and echogenity,~Bladder scanning~VCI measures~Lung B lines and effusion~Cardiac measurements; EF, TAPSE, TR Vmax, Diameters, LV filling pressures"
76047047|NCT05333237|Dietary Supplement|Intervention #3: Generic Glucose Solution|Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
76047048|NCT01912222|Drug|IXAZOMIB|
75424982|NCT01467050|Other|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
75424983|NCT01467089|Other|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
75424984|NCT01467115|Radiation|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
75424985|NCT01467115|Drug|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
75570979|NCT04320004|Behavioral|Education + Disposal Bag|Subject receives education and disposal bag
75723984|NCT02551484|Other|2-minute walk test|
75723985|NCT00723125|Drug|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
75723986|NCT00723125|Drug|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
76047049|NCT05367791|Other|POSTUR|Training sessions without any stimulation
76047050|NCT05367791|Other|Localised Vibration|Training sessions with localized vibration
75570980|NCT04320004|Behavioral|Education + Disposal Bag with Reminder|Subject receives education + disposal bag with reminder
75570981|NCT01229072|Biological|Heparin sodic|Heparin sodic 150UI/kg
75723987|NCT00723125|Drug|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
75723988|NCT00815126|Procedure|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
75723989|NCT02594189|Other|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
76047051|NCT05367791|Other|Somatosensory Electrical Stimulation|Training sessions with somatosensory electrical stimulation
76047052|NCT05366855|Biological|Imsidolimab|Solution for infusion Solution for injection
76047053|NCT05366855|Other|Placebo|Solution for injection
76047054|NCT05332301|Other|High-fat test meal|Ingestion of a mixed macronutrient breakfast meal providing 846 kcal, of which 58% is fat, 29% is carbohydrate and 13% is protein.
76047055|NCT04250207|Drug|K-321 Solution|K-321 solution drops
76047056|NCT04250207|Drug|Placebo Solution|Placebo solution drops for K-321
76047057|NCT05500703|Drug|Dexmedetomidine Injectable Solution|continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
76047058|NCT05500703|Drug|Sodium Chloride 0.9% Inj|the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
75570982|NCT01229072|Biological|heparin liquemine|Heparin sodic 150UI/kg
76047059|NCT05331833|Radiation|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.|
76047060|NCT05366231|Drug|Kesuting syrup|"Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
75570983|NCT04685733|Device|Non-invasive hemodynamic measurements|Non-invasive hemodynamic measurements
75424986|NCT01467115|Biological|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
75424987|NCT01467115|Drug|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
75424988|NCT01467115|Drug|Erythropoetin|Subcutaneous or intravenous
75424989|NCT01467115|Drug|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
75570984|NCT01228643|Biological|Pancreatic enzimes|- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
75570985|NCT01228643|Device|Creon ®|- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
75570986|NCT04685460|Other|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images were used in this study.
75570987|NCT01199978|Radiation|Fractionated proton radiation|Given daily for approximately 5.5 weeks
76047061|NCT05366231|Drug|LianHuaQingWen Granules|"Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
75570988|NCT01199978|Drug|Losartan|25mg or 50mg daily, oral administration, for approximately 6 months.
76047062|NCT05365295|Other|DRM (Deese, Roediger et McDermott task)|"Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes."
75570989|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
75570990|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
75570991|NCT04283513|Drug|Virazole|Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
75570992|NCT01251367|Biological|Botulinum toxin type A|I.M. (intramuscular) injection on day 1 of each treatment cycle.
75570993|NCT03910998|Drug|Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
75570994|NCT03910998|Drug|Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2|Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
75570995|NCT04685148|Drug|Transdermal patch estradiol|Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
75570996|NCT04685148|Drug|Transdermal patch placebo|Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
75877409|NCT02736227|Drug|Tacrolimus Withdrawal and Everolimus Monotherapy|During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
75877410|NCT01334905|Drug|YM178|oral
75877411|NCT02623985|Device|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
75570997|NCT04258358|Other|CASCADE ways of working|Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
75570998|NCT02888548|Procedure|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
75570999|NCT02888548|Procedure|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
76047063|NCT05330585|Device|Hearing aids|Participants will listen to stimuli in the environment while wearing hearing aids which should make the stimuli more audible. Speech in noise performance is expected to improve and PFC oxygenation is expected to be reduced in this condition.
75571000|NCT03888222|Drug|Placebo Oral Tablet|"Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) ."
75571001|NCT03888222|Drug|Bosutinib Oral Tablet|Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
75571002|NCT01250509|Behavioral|Craving and Lifestyle Management through Mindfulness|A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
75723990|NCT04044638|Other|Resistance trainining|Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G * Tech-branded automatic digital device (MASTER model).
75877412|NCT02623985|Device|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
76047064|NCT05330585|Other|Unaided|Participants will listen to stimuli in the environment with their hearing loss. Speech in noise performance is expected to decline and PFC oxygenation is expected to be increased in this condition.
75571003|NCT04239638|Diagnostic Test|Cervical Spinal MRI|Cervical Spinal MRI images of 500 patients will be entered into the system for modeling
75571004|NCT03883893|Drug|Intravenous acetaminophen|Intravenous acetaminophen will be given in the OR.
75571005|NCT03883893|Other|Normal saline|Normal saline will given if randomized to this group.
75571006|NCT04319575|Drug|root canal treatment and intracanal medicament|"after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks."
75571007|NCT00537732|Drug|omeprazole|20 mg daily
75571008|NCT00537732|Drug|omeprazole|20 vs. 60 mg daily, genotype dependent
75571009|NCT04180436|Drug|rivaroxaban 20 mg once daily 8 days|Blood samples for the measurement of rivaroxaban PK parameters
75571010|NCT00537927|Procedure|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
75571011|NCT01250119|Drug|erlotinib [Tarceva]|150 mg daily, orally
76047065|NCT05295407|Genetic|Genetic Assessment|The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
76047066|NCT05295251|Other|medical ,oncological and surgical treatment of cases of acute abdomen|medical treatment and surgical intervention during covid-19 pandemic
76047067|NCT02525861|Biological|GLASSIA|Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
76047068|NCT05293613|Device|extracorporeal shock wave lithotripsy|shock wave transmited from the device through patient body towards the stone to disintegrate it
76047069|NCT02524847|Drug|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
75571012|NCT04682444|Drug|Enisamium Iodide|Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).
75571013|NCT04682444|Drug|Placebo|Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
75571014|NCT04320277|Drug|Baricitinib|Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
75723991|NCT00808730|Procedure|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
76047070|NCT02524847|Procedure|Extracorporeal Photopheresis (ECP)|
76047071|NCT05328401|Device|Verum laser acupuncture|Applied verum laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
75571015|NCT05300529|Other|Vestibular Rehabilitation Exercises|The Vestibular Rehabilitation program focuses on stabilizing the gaze and gaining the Vestibular Ocular Reflex (VOR). The general mechanisms of recovery from vestibular injuries are vestibular adaptation and replacement exercises, which are designed to improve gaze stability and the interaction between sight and the vestibular system during head movements. The exercises will be carried out progressively according to the tolerance of the patient, varying the stimulus in intensity and frequency.
75571016|NCT05300529|Other|Conventional Rehabilitation exercises|The conventional rehabilitation program in which exercises are performed to improve joint range, flexibility, and gait. It will always be done with the eyes open, on a firm surface and will not include training in sensory strategies
76047072|NCT05328401|Device|Sham laser acupuncture|Applied sham laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
76047073|NCT05526365|Other|Reduced Idea Density|Question idea density reduced (ratio of propositions to total words used).
76047074|NCT04422275|Drug|Budesonide|The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.
76047075|NCT04422275|Behavioral|High-Concentration Essential Oil|High-concentration essential oil will include 1 ml of essential oil per jar.
76047076|NCT04422275|Drug|Placebo|The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
76047077|NCT04422275|Behavioral|Low-Concentration Essential Oil|Low-concentration essential oil will include 0.1 ml of essential oil per jar.
76047078|NCT02525627|Device|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
76047079|NCT02525627|Device|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
76047080|NCT02525627|Device|Symax stem|Orthopaedic implant
75571017|NCT04163549|Behavioral|Safe at Home|Discussion-based intervention
75571018|NCT01250002|Drug|Placebo|Placebo will receive the same volume of saline infusion.
75571019|NCT01250002|Drug|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
75571020|NCT05491876|Other|Chest physiotherapy with breathing exercises and ACBT|Group A got chest physiotherapy with breathing exercises and ACBT
75571021|NCT05491876|Other|Chest physiotherapy with breathing exercises|Group B got chest physiotherapy with breathing exercises.
75571022|NCT04171141|Drug|PF-07062119|PF-07062119
75571023|NCT04171141|Drug|Anti-PD1|Anti-PD1 PF-06801591
75571024|NCT04171141|Drug|Anti-VEGF|Anti-VEGF IV (bevacizumab)
75571025|NCT04157153|Device|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
75877413|NCT02623985|Device|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
75877414|NCT01332877|Behavioral|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
75877415|NCT01332877|Behavioral|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
75877416|NCT05095337|Drug|[14C]SHR1459|Patients will receive single dose of orally [14C]SHR1459 on Day 1.
76047081|NCT02525627|Device|Accolade TMZF stem|Orthopaedic implant
76047082|NCT04422587|Other|RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
76047083|NCT05361941|Device|EP Granules with Tobramycin|EP Granules with Tobramycin is a Ca-salt resorbable intended for orthopedic applications as a bone void filler for bone gaps or voids and in cases where risk of post-operative infection is high, such as the first stage of a two-stage revision of an infected total joint.
76047084|NCT05361941|Device|empty voids|Voids are left empty
76047085|NCT05291507|Device|Muse MRgFUS System|The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.
75571026|NCT04119596|Diagnostic Test|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
75571027|NCT04119596|Genetic|DNA-microarray genotyping|Taking a saliva sample for genotyping
75571028|NCT04107389|Behavioral|Art Psychotherapy, Art Therapy|Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
75571029|NCT04107389|Behavioral|Wait List|Wait list control group. Participants randomised to Wait List group or Intervention group.
75571030|NCT05329116|Drug|Lidocaine 2% Injectable Solution|"Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection"
75571031|NCT05329116|Biological|Platelet-rich plasma|8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
75571032|NCT04107116|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
75571033|NCT04107116|Other|Usual Care|Usual care as provided by local oncologists
75877417|NCT01335139|Biological|Sublingual immunotherapy (SLIT)|Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
75877418|NCT01335139|Biological|Subcutaneous immunotherapy (SCIT)|Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
75877419|NCT01335139|Other|Placebo|Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
75877420|NCT05030129|Dietary Supplement|5-Hydroxytryptophan / Vitamin B6|5-hydroxytryptophan, also known as 5-HTP has a nutraceutical status and has never been approved as a drug for any indication, but as a dietary supplement has been used extensively for several disorders for many years such as in the therapy of depression, fibromyalgia, obesity, insomnia and chronic headache
75877421|NCT05030129|Drug|Ergoloid Mesylate|Ergoloid Mesylates, trade name Hydergine, is a mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids, dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine. Ergot alkaloids are dopamine agonists which activate dopamine receptors (in the basal ganglia and other parts of the brain involved in motor function) and a prolactin inhibitor. Ergot is a strong vasoconstrictor and thus helps to reduce bleeding by narrowing of the blood vessels.
75877422|NCT05030129|Other|Placebo|Placebo capsules
75877423|NCT01335217|Procedure|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
76047086|NCT02129205|Drug|PF-06650808|Dose Escalation Phase [Part 1] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
75571034|NCT04105595|Device|Septal defect closure|Device closure of atrial septal defect
75571035|NCT04069637|Combination Product|Growth-sparing instrumentation and titanium levels|Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
75571036|NCT00537849|Device|Sonablate 500(SB-500)|
75723992|NCT00722423|Behavioral|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
75723993|NCT00722423|Behavioral|Usual Care Model|
75723994|NCT02593331|Drug|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
76047087|NCT02129205|Drug|PF-06650808|Dose Expansion Phase [Part 2] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
75571037|NCT03995771|Other|Questionnaire delivery|A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
75571038|NCT00537888|Drug|fluconazole|Intravenous or oral 400 md/d
75571039|NCT05307510|Device|Prefabricated splint|Subjects will be provided either a prefabricated splint
75571040|NCT05307510|Device|Custom Orthosis|Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
75571041|NCT05264142|Drug|Voriconazole 200mg|Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
75571042|NCT05264142|Drug|FluvoxaMINE 50 Mg Oral Tablet|Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
75723995|NCT02593331|Other|Placebo|Participants will receive a single dose of placebo on Day 1.
75571043|NCT05264142|Drug|Omeprazole 10 MG Oral Tablet|Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
75571044|NCT01246960|Biological|Ramucirumab|Administered intravenously
75723996|NCT00640562|Drug|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
75723997|NCT00640562|Drug|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
75877424|NCT05239559|Device|Bubble CPAP oxygen delivery device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~A nasal interface connecting the child's airway with the circuit:~An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines."
76047088|NCT05289479|Procedure|Pre-heating of resin composite before application|the effect of preheating of resin composite before application in class II cavities
76047089|NCT05289479|Procedure|no pre-heating of resin composite before application|The control group
76047090|NCT05360693|Procedure|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done & patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
75424990|NCT01467115|Drug|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
75723998|NCT00585923|Device|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
75571045|NCT01246960|Drug|Placebo|Administered intravenously
75571046|NCT01246960|Drug|Oxaliplatin|Administered intravenously
75571047|NCT01246960|Drug|Leucovorin|Administered intravenously
75571048|NCT01246960|Drug|5-Fluorouracil|Administered intravenously
75571049|NCT03870269|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
75571050|NCT00544986|Drug|Anastrozole|
75571051|NCT01244620|Drug|sitaxentan|sitaxsentan 100 mg QD for 6 days
75571052|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
75571053|NCT01244620|Drug|sitaxsentan|sitaxsentan 100 mg QD for 6 days
75571054|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
75571055|NCT01244620|Drug|sitaxsentan|sitaxentan 100 mg QD for 6 days
75571056|NCT01244620|Drug|sildenafil|sildenafil 20 mg TID for 6 days
75723999|NCT00585923|Device|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
75877425|NCT01338961|Procedure|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
76047091|NCT05360693|Procedure|immediate implant placement with socket bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
76047092|NCT04245605|Procedure|Coronary angiography|Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
75424991|NCT01467115|Drug|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
75571057|NCT04682717|Device|perfusion index monitoring for postinduction hypotension|Hemodynamic parameters will be recorded at 1-min intervals till 10 min after intubation. Hypotension will be defined as a drop in SBP to <30% of baseline or absolute MAP <60 mmHg. MAP <55 mmHg (severe hypotension) will be treated immediately by rapid intravenous fluid administration (10 ml/kg) and ephedrine sulphate 6 mg IV boluses. Bradycardia will be defined as HR <50 bpm or decrease by more than 30% below baseline value, whichever will be lower and will be treated with atropine 0.6 mg IV boluses. The incidence of hypotension will be calculated in 2 sets - 5 min after induction of anesthesia (effect of induction agent) and first 15 min after induction (effect of induction process and endotracheal intubation).
75571058|NCT04319692|Dietary Supplement|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks
75571059|NCT04319692|Dietary Supplement|Placebo group|This group takes placebo for 8 weeks.
75571060|NCT05238480|Device|XC mouthguard|Use of a Xtreme Conventional custom-made mouthguard while playing rugby
75571061|NCT05238480|Device|XP mouthguard|Use of a Xtreme Pro custom-made mouthguard while playing rugby
75571062|NCT04682327|Other|Response to anti-PD-1/PD-L1|Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
75571063|NCT04682327|Other|Non-response to anti-PD-1/PD-L1|Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
75571064|NCT02889640|Other|SAGA Innovations|An intensive math tutoring program
75571065|NCT02889640|Other|Scale-up tutors|Tutors who have been selected for hire via the one in three-and-a-half randomization process
75571066|NCT02889640|Other|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
75571067|NCT00545142|Drug|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
75571068|NCT00545142|Drug|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
75571069|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
75724000|NCT04019639|Device|application of CG Paste+EasyFoam|Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
75877426|NCT01339039|Drug|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
75877427|NCT01339039|Drug|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
75877428|NCT01339039|Drug|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
76047093|NCT05324969|Behavioral|MM-based MI|9 remote mindful-based MI sessions will be delivered to promote participating parents' mindful eating, mindful movements, and mindful family interactions. Parents will be encouraged to act as changing agents for their families.
76047094|NCT05324969|Other|healthy education|9 health education emails will be sent to participating parents in the control group
75877429|NCT01339039|Drug|Plerixafor|Daily administration for 5-9 days prior to surgery
75571070|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
75571071|NCT01267201|Drug|methylprednisolone|tablet 32 mg single dose
75571072|NCT04323514|Dietary Supplement|Vitamin C|10 gr of vitamin C intravenously in addition to conventional therapy.
75571073|NCT00545220|Behavioral|problem-solving training|
75571074|NCT00545220|Behavioral|sham intervention|
75571075|NCT03755492|Other|Absorbent pad for urinary incontinence|6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
75724001|NCT04019639|Device|application of EasyFoam|Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
75424992|NCT01467128|Other|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
75571076|NCT05175573|Device|SuperNO2VA Et Nasal Positive Pressure Mask|Nasal mask with capnography providing continuous positive airway pressure at 10LPM
75571077|NCT05175573|Device|Supplemental Oxygen Face Mask|Face mask with capnography providing oxygenation at 10 LPM
75571078|NCT03736616|Drug|Carboplatin|Chemotherapy
75571079|NCT03736616|Drug|Ifosfamide|Chemotherapy
75571080|NCT03736616|Drug|Etoposide|Chemotherapy
75571081|NCT03736616|Biological|Rituximab|Anti-CD20 mAb
75724002|NCT00818558|Biological|ISET Methode|Sampling of blood - ISET Methode
75724003|NCT03955679|Genetic|AVXS-101|AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). AVXS-101 will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
75724004|NCT00815204|Procedure|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
75724005|NCT00815204|Procedure|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
75724006|NCT00721955|Drug|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
75724007|NCT00721955|Drug|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
75724008|NCT00721955|Drug|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
75724009|NCT00585689|Drug|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
75724010|NCT00585689|Drug|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
75724011|NCT00585689|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
75724012|NCT00585689|Procedure|Radical Cystectomy|
75724013|NCT00721799|Drug|18F-Fluorothymidine PET scan|18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
75724014|NCT00815282|Other|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
75424993|NCT01467128|Other|No Intervention|Normal hospital pharmaceutical care
75424994|NCT01467141|Drug|insulin aspart|Injected s.c. (under the skin) three times a day
75424995|NCT01467141|Drug|human insulin|Injected s.c. (under the skin) 30 minutes before the meals
75424996|NCT01467141|Drug|isophane human insulin|May be administered s.c. (under the skin) in both treatment groups thrice daily
75571082|NCT03736616|Drug|Carmustine|Chemotherapy
75571083|NCT03736616|Drug|Cytarabine|Chemotherapy
75571084|NCT03736616|Drug|Melphalan|Chemotherapy
75571085|NCT03736616|Other|Autologous HSCT|Cellular Therapy
75571086|NCT03736616|Drug|Acalabrutinib|Bruton's Tyrosine Kinase Inhibitor
75571087|NCT04684680|Dietary Supplement|zamzam water|will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
75571088|NCT04684680|Dietary Supplement|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
75724015|NCT02591693|Behavioral|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
76047095|NCT02128269|Biological|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
75571089|NCT03718403|Drug|Theophylline|Theophylline will be given to maintain a peak level between 10-15 mcg/mL
75424997|NCT01467180|Device|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
75571090|NCT00545259|Drug|AEB071|
75571091|NCT00537966|Drug|Dolutegravir|In this arm patients with primary HIV-1 infection are treated with standard antiretroviral combination therapy (only drugs that have been approved by Swiss Medic)
75571092|NCT00537966|Drug|Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate|standard dosage
75571093|NCT00537966|Drug|Raltegravir|standard dosage
75571094|NCT00537966|Drug|Darunavir|standard dosage
75571095|NCT00537966|Drug|Ritonavir|used only as booster for the protease inhibitors that are prescribed in this study according to standard boosting
75571096|NCT00537966|Drug|Rilpivirine|standard dosage
75724016|NCT00818636|Behavioral|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
75724017|NCT02593019|Drug|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
75724018|NCT00818714|Radiation|SBRT|"SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD"
75724019|NCT00818792|Device|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
75877430|NCT01339039|Procedure|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 & 15).
75571097|NCT00537966|Drug|Lamivudine|standard dosage
76047096|NCT05324735|Drug|Pentoxifylline|All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.
76047097|NCT05324735|Drug|Placebo|All participants will receive placebo (orally ingested) twice a day for 12 weeks.
76047098|NCT05360459|Radiation|Exposure to radiotherapy|Characterization and quantification of intestinal and vaginal microbiota in patients affected by cervical or endometrial cancer who have received pelvic radiotherapy more than 24 months ago.
75424998|NCT01467180|Device|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
75424999|NCT01467193|Dietary Supplement|Fat diet|Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.
75571098|NCT00537966|Drug|tenofovir|standard dosage
75425000|NCT01467193|Other|2h standardized aerobic exercise|Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours
75425001|NCT01467206|Behavioral|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
75425002|NCT01467206|Behavioral|Standard care|Standard care as it is given to all stoke patients after stroke
75571099|NCT00537966|Drug|Emtricitabine|standard dosage
75571100|NCT00537966|Drug|Abacavir|standard dosage
75571101|NCT03456492|Diagnostic Test|serum sodium|Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.
75724020|NCT00729365|Drug|Ramipril|"ACE inhibitor known as Ramipril~Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo."
75724021|NCT00729365|Drug|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
75724022|NCT00729365|Drug|Placebo|"Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo."
75724023|NCT00818870|Drug|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
75724024|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
75724025|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
75571102|NCT01266967|Drug|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
75571103|NCT03456414|Other|Virtual reality exercise during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
75571104|NCT00538005|Biological|bevacizumab|
75571105|NCT00538005|Drug|oxaliplatin|
75571106|NCT00538005|Drug|sorafenib tosylate|
75724026|NCT00922376|Device|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
75877431|NCT03176459|Drug|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
76047099|NCT01626885|Drug|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
76047100|NCT05360225|Diagnostic Test|therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.
75425003|NCT01467219|Procedure|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
75425004|NCT01467219|Procedure|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
75425005|NCT01467219|Procedure|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
76047101|NCT05359055|Drug|SPH3127 tablet|100mg once daily on Day 1 and Day 8
75571107|NCT03610412|Other|Cinnamomum Cassia|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
75571108|NCT03610412|Other|Placebo (calcined magnesia)|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
75571109|NCT00538044|Drug|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
75425006|NCT01467219|Radiation|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
75571110|NCT00538083|Other|Chocolate|74 grams of single dose solid dark chocolate versus placebo
75571111|NCT00538083|Other|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
75571112|NCT00538083|Other|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, & placebo given for six weeks
75571113|NCT00545337|Drug|Insuline glulisine|
75571114|NCT01266850|Biological|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
75425007|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
75425008|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
75425009|NCT01467258|Drug|Amantadine|Single dose
75425010|NCT01467284|Behavioral|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
75724027|NCT02594267|Drug|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, & Prednisone"
75724028|NCT02594501|Device|COBRA PzF|
75724029|NCT02594501|Device|Drug Eluting Stent|
75724030|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
75724031|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
75724032|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
75724033|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
76047102|NCT05359055|Drug|Itraconazole|200mg once daily from Day 3 to Day10.
76047103|NCT05359055|Drug|SPH3127 tablet|200mg once daily on Day 1 and Day 12.
76047104|NCT05359055|Drug|Rifampin|600mg once daily from Day 3 to Day13.
76047105|NCT02524379|Drug|Glyburide|3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
76047106|NCT02524145|Other|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
75425011|NCT01467284|Behavioral|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
76047107|NCT02524145|Drug|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
76047108|NCT02524145|Drug|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
75425012|NCT01467297|Drug|ceftidoren|ceftidoren 200 mg bid for 5 days
75724034|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
75425013|NCT01467297|Drug|levofloxacin|levofloxacin 500 mg once daily for 7 days
75425014|NCT01467310|Drug|GSK1120212|1.5 to 2.0 mg taken orally every day for seven days.
75724035|NCT00254293|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
75724036|NCT00585221|Drug|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
76047109|NCT02524145|Drug|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
76047110|NCT05357417|Drug|utidelone|30mg/m2 (±10%), day 1-5 every 3-week cycle
75425015|NCT01467323|Drug|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
75724037|NCT00585221|Drug|Imatinib|Continue imatinib until progression.
76047111|NCT05357417|Drug|Bevacizumab|15mg/kg, day 1
76047112|NCT01658813|Drug|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
76047113|NCT02187471|Drug|DS-5565|DS-5565 15 mg QD or BID; tablet for oral use
76047114|NCT02187471|Drug|Pregabalin|Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
75425016|NCT01467323|Drug|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
75425017|NCT01467336|Procedure|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
75425018|NCT01467362|Drug|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
75425019|NCT01467362|Drug|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
75425020|NCT01467362|Drug|desonide 0.1% cream|cream, once a day (in the evening) during flares
75425021|NCT01467362|Other|Foaming gel|for the washing and cleaning
75425022|NCT01467375|Drug|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
75425023|NCT01467388|Procedure|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
75425024|NCT01467401|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
75425025|NCT01467401|Drug|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
75425026|NCT01467414|Drug|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
75724038|NCT02594033|Drug|insulin aspart|All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
75724039|NCT00253747|Drug|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
75724040|NCT00253747|Drug|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
76047115|NCT02187471|Drug|Placebo tablet|Placebo tablet for oral use, matching DS-5565 tablet
75425027|NCT01467440|Device|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
75425028|NCT01467453|Device|Triggerfish|The Triggerfish is a contact lens with an embedded sensor to track changes in intraocular pressure during a period of 24 hours.
75425029|NCT01467518|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
75425030|NCT01467518|Drug|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
75425031|NCT01467531|Drug|Dolutegravir|50mg q 24h
75571115|NCT01266850|Biological|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
75724041|NCT00252733|Drug|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
75724042|NCT03974035|Drug|Second infiltration pre-extubation with ropivacaine|The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
75425032|NCT01467531|Drug|Rlipivirine|25mg q24h
76047116|NCT02187471|Drug|Placebo capsule|Placebo capsule for oral use, matching pregabalin capsule
75425033|NCT01467531|Drug|GSK1265744|30mg q24h
75425034|NCT01467544|Other|Tai Chi class|The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
75425035|NCT01467596|Device|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
75425036|NCT01467622|Procedure|Chest tube removal|Chest tube removal on the basis of local recommendations for postoperative chest tube management
75425037|NCT01467635|Device|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
75425038|NCT01467648|Drug|Doripenem|"(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
75425039|NCT01467648|Drug|Doripenem|"(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
75425040|NCT01467687|Drug|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
75425041|NCT01467726|Drug|Velusetrag|Capsules
75425042|NCT01467726|Drug|Velusetrag|Capsules
75425043|NCT01467726|Drug|Placebo|Capsules
75425044|NCT01467739|Device|Ambu ® aScope®|
75425045|NCT01467739|Device|a conventional reusable fiberscope|
75425046|NCT01467752|Procedure|MCP joint|reconstruction of metacarpophalangeal (MCP) joint using a bone graft
75571116|NCT00538122|Device|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
76047117|NCT02525471|Drug|RNS60|"RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase."
76047118|NCT05285423|Procedure|Novel technique of Vocal cord Laterlization with Prolene suture.|The procedure will be performed under General anesthesia, preferably with a tracheostomy so that the extent of vocal cord lateralization could be ascertained intraoperatively.
75425047|NCT01467765|Other|Elental|200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
75425048|NCT01467778|Device|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
76047119|NCT05284409|Drug|Pethidine|36 patients will receive 0.5 mg/kg Pethidine IVI
76047120|NCT05284409|Drug|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI
76047121|NCT05284409|Drug|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI
76047122|NCT01658735|Device|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
76047123|NCT01658735|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
76047124|NCT01658735|Device|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
76047125|NCT02523599|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
76047126|NCT02523599|Other|Placebo|Plain collagen implant (vehicle)
75425049|NCT01467778|Device|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
75425050|NCT01467791|Other|Observation|Observe patients
75571117|NCT03431480|Biological|Autologous Human Placental Cord Blood Mononuclear Cells|Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
76047127|NCT05492357|Other|Liquid platelet-rich fibrin|Liquid platelet-rich fibrin is prepared from the patient's blood and injected into the extraction socket every two weeks (up to 3 months = Just 4 times of application)
76047128|NCT05492357|Other|Advanced Platelet-rich fibrin plus|A-PRF+ is placed into the extraction socket immediately after tooth extraction
75425051|NCT01467804|Drug|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
75425052|NCT01467804|Drug|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
75425053|NCT01467817|Behavioral|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
75425054|NCT01467817|Behavioral|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
76047129|NCT05490797|Other|app based training with conventional therapy|The experimental group will receive an additional mobile application therapy including , dexterity fine motor skills, bowling game, scribble game and peglight game in addition to the conventional therapy for hand function.
75571118|NCT00545376|Procedure|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
75571119|NCT00545376|Procedure|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
75724043|NCT01071967|Other|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
76047130|NCT05490797|Other|conventional therapy|conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
75425055|NCT01467830|Procedure|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
76047131|NCT05321303|Other|Serious Game|"Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability."
76047132|NCT05321303|Other|Standard Patients|Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
76047133|NCT04422353|Other|Video Dance classes|The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
75425056|NCT01467843|Behavioral|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
75425057|NCT01467843|Behavioral|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
75425058|NCT01467856|Procedure|PAP Device Procedure|"Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP > 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic."
75571120|NCT00545376|Other|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
75571121|NCT00538161|Other|Ventilation strategy|
75724044|NCT00275821|Drug|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
75425059|NCT01467908|Device|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
75425060|NCT01467921|Drug|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
75571122|NCT00545415|Dietary Supplement|Order 1|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
75724045|NCT00275821|Drug|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
76047134|NCT04422353|Other|Unsupervised physical activities|The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
75425061|NCT01467986|Drug|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
75425062|NCT01467986|Drug|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
75425063|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
75425064|NCT01467986|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
75425065|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
75425066|NCT01467986|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
75425067|NCT01468025|Drug|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
75425068|NCT01468025|Other|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
75877432|NCT03176459|Drug|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
75877433|NCT01339117|Other|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
75425069|NCT01468025|Drug|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
75425070|NCT01468038|Drug|Trazodone|active trazodone and sentra pm-like placebo
75877434|NCT01339117|Other|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
75877435|NCT01335295|Drug|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
75877436|NCT05239481|Device|colonoscopy position identification sheet|According to the body position requirements of the left lying position during colonoscopy, the research group used ink to add the body position prompt sign on the disposable bed sheet .Through the position identification, patients can intuitively understand the position that should be used in the operation and the position that should be placed in each part of the body.
75877437|NCT05239481|Device|Traditional disposable cleaning sheet|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient.
75877438|NCT01332955|Drug|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
75724046|NCT00275821|Drug|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
75724047|NCT01070797|Biological|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10^6 rCTLs/m2~Level Two: 1 x 10^7 rCTLs/m2~Level Three: 2 x 10^7 rCTLs/m2~Level Four: 5 x 10^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
75877439|NCT01332955|Biological|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
75877440|NCT01332955|Drug|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
75877441|NCT05224895|Procedure|General Anesthesia in Trendelenburg position for robotic prostatectomy|in this arm, changes in preoperative and postoperative airway measurements and correlation with postoperative critical airway events will be monitored.
75877442|NCT01335373|Drug|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
75877443|NCT05221463|Behavioral|Video-assisted breastfeeding training|Breastfeeding training was given to the experimental group for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and routinely used by nurses in breast milk training in neonatal units. During the training, mothers were allowed to watch breast milk and breastfeeding training videos. On the third day after the training, feedback was received from the applications in the video regarding the knowledge and skills of the mother, and the mother's questions were answered.
75877444|NCT05221463|Behavioral|The hospital's routine general breastfeeding training|The control group was given the hospital's general breastfeeding training for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and used routinely by nurses in breast milk training in neonatal units, and the questions of the mother were answered. The mothers in this group performed the routine breastfeeding process and no other interventions were made.
75877445|NCT03204721|Other|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
75877446|NCT05218811|Device|Cryoablation Assisted Partial Nephrectomy|Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
75877447|NCT05185219|Drug|Valerian|A natural plant
75571123|NCT00545415|Dietary Supplement|Order 2|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
75425071|NCT01468038|Other|Sentra PM|Active Sentra PM and trazodone-like placebo
75571124|NCT00545415|Dietary Supplement|Order 3|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
75571125|NCT00545415|Dietary Supplement|Order 4|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
75571126|NCT00545415|Dietary Supplement|Order 5|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
75571127|NCT00545415|Dietary Supplement|Order 6|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
75877448|NCT01315483|Other|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap >+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
75877449|NCT01333267|Drug|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
75877450|NCT01333267|Drug|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
75425072|NCT01468038|Drug|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
75425073|NCT01468038|Drug|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
75425074|NCT01468051|Biological|four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine
75571128|NCT00545493|Drug|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
75571129|NCT00545493|Drug|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
75571130|NCT01266460|Biological|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
75571131|NCT01266460|Other|Laboratory Biomarker Analysis|Correlative studies
75571132|NCT05119257|Biological|Bispecific antibodies (bsAB)|BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.
76047135|NCT05354999|Dietary Supplement|Sodium bicarbonate and caffeine|On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
75425075|NCT01468051|Biological|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
75425076|NCT01468064|Genetic|Autologous BMSCs transplantation|"The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
75425077|NCT01468064|Genetic|Autologous EPCs transplantation|"The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
75425078|NCT01468064|Genetic|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
75425079|NCT01468103|Procedure|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
75425080|NCT01468103|Procedure|Laser Iridotomy|alternative choice to surgical iridectomy
75425081|NCT01468129|Other|Cell Saver|
75425082|NCT01468155|Drug|dabigatran|30 days pre ablation and 90 days post ablation
75425083|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
75571133|NCT01266265|Drug|inhaled prostacyclin|Tyvaso
76047136|NCT05354531|Procedure|anterior subcutaneous internal fixator ( INFIX)|INFIX was invented based upon the same biomechanical principle as the traditional external fixator, but it is placed subcutaneously. It proved to be stiffer than the traditional external fixator, and at the same time eliminates the open pin tracts, which increased the infection rate and nursing care
76047137|NCT02187159|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
75571134|NCT01266265|Drug|inhaled prostacyclin|As prescribed by the physician
76047138|NCT02187159|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
76047139|NCT02187159|Drug|Placebo tablet|Placebo tablet (matching DS5565) for oral administration
75425084|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
75571135|NCT01266265|Drug|prostacyclin|As prescribed by the physician
75571136|NCT01266265|Drug|subcutaneous and intravenous prostacyclin|As prescribed by physician
75571137|NCT01266265|Drug|oral ERA|As prescribed by physician
75571138|NCT01266265|Drug|oral PDE5 inhibitors|As prescribed by physician
75724048|NCT03973099|Dietary Supplement|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
76047140|NCT02187159|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
75425085|NCT01468168|Drug|DE-101 Ophthalmic Suspension Vehicle|Ophthalmic suspension vehicle; QID
75571139|NCT00538200|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
75571140|NCT00538200|Other|Dietary Advice|Standard dietary advice
75571141|NCT00545649|Behavioral|Exercise and education|
75724049|NCT00275509|Drug|Thymoglobulin|
75724050|NCT00275509|Drug|Daclizumab|
75724051|NCT00275509|Other|Plasmapheresis|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
75724052|NCT00275509|Drug|Mycophenolate mofetil|2 gm/day. Standard of care
75724053|NCT00275509|Drug|Tacrolimus|To achieve serum level of 8-10 ng/ml.
75724054|NCT00275509|Drug|Dexamethasone|100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
75724055|NCT00275509|Drug|Prednisone|Taper over three months to 5 mg daily
76047141|NCT02335411|Biological|pembrolizumab|IV infusion
76047142|NCT02335411|Drug|cisplatin|IV infusion
76047143|NCT02335411|Drug|5-FU|IV infusion
76047144|NCT02335411|Drug|capecitabine|oral tablets
75425086|NCT01468194|Other|Breathing procedure 1|inhalation during one step, exhalation during the next step
75425087|NCT01468194|Other|Breathing procedure 2|inhalation and exhalation during one step
75425088|NCT01468220|Other|Endurance training|Endurance training three times per week over six weeks
75425089|NCT01468259|Drug|Droxidopa|The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
75425090|NCT01468272|Drug|free comb. beclomethasone DPI and formoterol DPI|free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
75571142|NCT00545649|Behavioral|Education|
75571143|NCT03268382|Drug|APR-246|Intravenous infusion
75571144|NCT03268382|Drug|Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion
75571145|NCT01266148|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
75571146|NCT01266148|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
75571147|NCT01266148|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
75571148|NCT01266148|Drug|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
76047145|NCT02186301|Drug|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
76047146|NCT02186301|Drug|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
76047147|NCT02186223|Device|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
76047148|NCT02163057|Biological|INO-3112|1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.
76047149|NCT02163057|Device|CELLECTRA™-5P|CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.
76047150|NCT02185521|Other|patient assessment|Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
76047151|NCT01599585|Behavioral|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
76047152|NCT02185053|Drug|CPC-201|
75571149|NCT01266148|Drug|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
75571150|NCT00538239|Drug|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
75571151|NCT00538239|Drug|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
75571152|NCT03263897|Device|insufflation|mobile interface driven insufflation of the ear canal
75724056|NCT00275509|Drug|Cytogam|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
76047153|NCT02161731|Drug|Evacetrapib|Oral administration
76047154|NCT02161731|Drug|Warfarin|Oral administration
76047155|NCT02124759|Drug|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
75571153|NCT03263897|Device|placebo insufflation|mobile interface driven placebo insufflation of the ear canal
76047156|NCT02124759|Drug|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
75571154|NCT00545727|Behavioral|Diet|Whole-foods, low glycemic index diet
75571155|NCT00545727|Other|Standard diet|Standard diet meeting American Diabetes Association guidelines
75571156|NCT01266070|Drug|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
75571157|NCT05270148|Other|HIIT|12 weeks training High-Intensity Interval Training consists of 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes).Depending on the number of training session, the loadand the series will increase up to 40% more than the maximum load.
75571158|NCT05270148|Other|Fat Max|12 weeks training Fatmax consist in 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. MICTprogram will consist of sessions of approximately ˜45min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
75571159|NCT00538278|Other|Database|database
75724057|NCT01072045|Drug|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
75724058|NCT01072045|Drug|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
76047157|NCT02124759|Drug|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
75425091|NCT01468272|Drug|CHF 1535 50/6 NEXT DPI|four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
75425092|NCT01468285|Drug|betahistine dihydrochloride|betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
75425093|NCT01468285|Other|placebo|placebo tablets b.i.d., six weeks treatment
75571160|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
75425094|NCT01468298|Other|Isostretching|All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
75425095|NCT01468298|Other|Global Posture Reeducation|All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
75425096|NCT01468324|Drug|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
75425097|NCT01468363|Device|Dry weight adjustment|Dry weight adjustment according to BCM results
75425098|NCT01468376|Dietary Supplement|GLU-01|14 day dosing
75425099|NCT01468376|Dietary Supplement|GLU-02|14 day dosing
75425100|NCT01468376|Dietary Supplement|GLU-03|14 day dosing
75425101|NCT01468376|Dietary Supplement|GLU-04|14 day dosing
75425102|NCT01468376|Dietary Supplement|GLU-05|14 day dosing
75425103|NCT01468376|Dietary Supplement|GLU-06|14 day dosing
75425104|NCT01468389|Drug|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
75425105|NCT01468389|Drug|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
75571161|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
75571162|NCT03228563|Other|Probioics|CKD Patients were supplemented with two capsules of probiotics containing 2.5*10^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
75571163|NCT01265953|Drug|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
75571164|NCT01265953|Dietary Supplement|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
75571165|NCT01265875|Drug|Human Secretin|Dose Escalation
75571166|NCT00545805|Procedure|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
75571167|NCT00545805|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
75425106|NCT01468402|Procedure|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
75425107|NCT01468415|Drug|phenol|1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
75425108|NCT01468441|Drug|Triptorelin|Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
75425109|NCT01468441|Drug|Cetrorelix|When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
75425110|NCT01468467|Drug|AC220|Oral Liquid
75425111|NCT01468480|Drug|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
75425112|NCT01468480|Drug|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
75425113|NCT01468480|Drug|MultiCal|application of Multical in forth group as a pulp dressing agent
75425114|NCT01468480|Drug|Dycal|application of Dycal in first group as a pulp dressing agent
75425115|NCT01468519|Drug|Insulin|Insulin via continuous subcutaneous insulin infusion
75571168|NCT01265797|Device|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
75877451|NCT01333267|Drug|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
75877452|NCT03155269|Dietary Supplement|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
75877453|NCT03155269|Dietary Supplement|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
75877454|NCT02906670|Drug|Sym013|Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
75425116|NCT01468519|Drug|Insulin|insulin via multiple daily injections
75724059|NCT01072123|Other|Quest for the Code|interactive asthma-based computer program
75877455|NCT01339195|Behavioral|French adaptation of NINDS-Canadian Stroke Network battery|"clinical: post-stroke neurological follow-up assessment~neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~MRI"
75877456|NCT01339351|Behavioral|Therapeutic Group by Teleconference|10 sessions
75877457|NCT01335451|Drug|AZD5213|Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
75877458|NCT01335451|Drug|Placebo|Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
76047158|NCT02124759|Other|High Fat diet|The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
76047159|NCT02124759|Other|Low Fat diet|The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
76047160|NCT02302339|Drug|glembatumumab vedotin|
75425117|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
75571169|NCT01265797|Device|Sham Device|participant wears sham device for 20 minutes daily for 28 days
75724060|NCT01073059|Drug|Valproic acid and Ertapenem|
75724061|NCT00252577|Drug|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
75724062|NCT00252499|Drug|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
75724063|NCT00252499|Drug|fenofibrate|PPAR-alpha agonist, reduces triglycerides
75724064|NCT00252499|Drug|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
75724065|NCT00252499|Drug|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
75724066|NCT00252187|Drug|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
75571170|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
75571171|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
75877459|NCT01335529|Drug|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"Screen period from Week-8~Standard treatment from day 0 to week 4 (W4)~Three-drug-regimen (Boceprevir introduction) from W4 to W8~HCV RNA determination at W8 determines treatment group and participation duration:~If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
75877460|NCT01335607|Drug|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
75425118|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
75425119|NCT01468571|Drug|Spironolactone|50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
75425120|NCT01468571|Drug|Placebo|"Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks."
75425121|NCT01468610|Drug|desvenlafaxine|50-100 mg daily for 8 weeks
75425122|NCT01468623|Other|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
75571172|NCT01265719|Other|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
75571173|NCT01265719|Other|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
75724067|NCT00252187|Other|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
75877461|NCT01335607|Drug|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
75877462|NCT02906358|Behavioral|Community-based pain self-management|
75877463|NCT02906358|Behavioral|Clinic-based pain self-management|
75877464|NCT00308347|Drug|MK0954, losartan / Duration of Treatment: mean 3.4 years|
76047161|NCT02302339|Drug|glembatumumab vedotin and varlilumab|
75571174|NCT03148496|Device|Biologic Mesh|Biologic mesh placed during surgery
75571175|NCT03148496|Procedure|Small Bites|0.5 cm x 0.5 cm sutures used
75571176|NCT03148496|Procedure|Large Bites|1.0 x 1.0 sutures used
75571177|NCT00538395|Drug|Adriamycin, Taxol and Cytoxan|Chemotherapy
75877465|NCT00308347|Drug|Placebo / Duration of Treatment: mean 3.4 years|
75877466|NCT02186834|Drug|Selinexor|Selinexor orally as outlined in the study treatment arm.
75425123|NCT01468623|Other|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
75425124|NCT01468636|Drug|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
75425125|NCT01468636|Drug|Placebo|200mg BID x 8 weeks
75425126|NCT01468649|Device|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
75425127|NCT01468688|Drug|STI571|
75425128|NCT01468688|Drug|BKM120|BKM120 combination therapy
75724068|NCT00572910|Biological|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
75724069|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
75724070|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
75724071|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
76047162|NCT02302339|Drug|glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|
76047163|NCT02302339|Drug|glembatumumab vedotin and CDX-301|
76047164|NCT04895917|Drug|daratumumab and pomalidomide|Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
75571178|NCT01265563|Drug|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
75571179|NCT01265563|Drug|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
75571180|NCT01265563|Drug|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
75571181|NCT01265563|Drug|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
76047165|NCT02161575|Drug|Ranibizumab|Intraveal injections of 0.5mg ranibizumab
75571182|NCT01265563|Drug|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
75571183|NCT03025139|Other|Educational Intervention|Attend survivorship education
75571184|NCT03025139|Other|Laboratory Biomarker Analysis|Correlative studies
75571185|NCT03025139|Procedure|Meditation Therapy|Attend mindfulness meditation
75571186|NCT03025139|Other|Questionnaire Administration|Ancillary studies
75425129|NCT01468714|Drug|PF-04937319 / ketoconazole|Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
75571187|NCT00545922|Behavioral|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
75571188|NCT00545922|Behavioral|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
75571189|NCT01265056|Drug|Gabapentin|"On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg* daily.~Study day 8-11: 800mg TID 2400mg* daily [Optional increase to 2400 if pain scores are still 4 on NRS]~Study day 11: 1200mg TID 3600mg* daily [Optional increase to 3600 if pain scores are still >4 on NRS]~* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation."
75571190|NCT01265056|Drug|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
75571191|NCT05656651|Behavioral|High intensity interval exercise training|Endurance training adapted to age, resting heart rate
75571192|NCT02942498|Drug|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
75571193|NCT02942498|Drug|Placebo|Placebo
76047166|NCT02370121|Drug|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
76047167|NCT02370121|Drug|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
75425130|NCT01468727|Dietary Supplement|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
75571194|NCT00545961|Drug|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
75571195|NCT00545961|Drug|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
75571196|NCT02935517|Biological|AGTC-402|AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
75571197|NCT00538551|Other|Database|Database
75425131|NCT01468727|Dietary Supplement|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
75571198|NCT01264939|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
75571199|NCT01264939|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
75724072|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
76047168|NCT02161185|Drug|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
75877467|NCT02186834|Drug|Liposomal doxorubicin|Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
75425132|NCT01468740|Drug|Doxorubicin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
75571200|NCT01264939|Drug|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
75877468|NCT02186834|Drug|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
76047169|NCT02159469|Combination Product|Testosterone enanthate auto-injector|Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
76047170|NCT02123511|Drug|acetylcysteine|Oral rinse
76047171|NCT02123511|Other|placebo|Oral rinse
75425133|NCT01468740|Drug|Bleomycin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
75425134|NCT01468740|Drug|Vinblastine|"The four-drug ABVD chemotherapy regimen contains vinblastine~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
75425135|NCT01468740|Drug|Dacarbazine|"The four-drug ABVD chemotherapy regimen contains dacarbazine~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
75425136|NCT01468740|Drug|Etoposide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
75571201|NCT01264939|Drug|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
75571202|NCT00538668|Drug|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
75571203|NCT02889367|Drug|Odalasvir 100 mg|Participants will receive odalasvir 2*50 mg tablet, orally once on Day 1.
75571204|NCT02889367|Drug|Placebo|Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
75571205|NCT02889367|Drug|Odalasvir 500 mg|Participants will receive odalasvir 10*50 mg tablet, orally once on Day 1.
75877469|NCT03144687|Drug|Itacitinib|Itacitinib self-administered orally once daily .
76047172|NCT02123511|Other|quality-of-life assessment|Ancillary studies
76047173|NCT02123511|Other|questionnaire administration|Ancillary studies
75877470|NCT03144687|Drug|Ruxolitinib|Ruxolitinib self-administered orally at the stable dose of < 20 mg daily established before entering the study.
75877471|NCT04335890|Biological|Vaccination with IKKb matured Dendritic Cells|IKKb matured autologous monocyte derived dendritic cells loaded with RNAs; intravenous Infusion with a dose escalation starting with 7.5 mio Dendritic Cells for the first vaccination up to 30 mio cells per vaccination
76047174|NCT04746339|Drug|Apixaban 2.5 MG|Apixaban 2.5mg twice daily for 30 days
76047175|NCT04746339|Drug|Placebo|placebo twice daily for 30 days
75425137|NCT01468740|Drug|Cyclophosphamide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
75425138|NCT01468740|Drug|Vincristine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
75425139|NCT01468740|Drug|Procarbazine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
75425140|NCT01468740|Drug|Prednisone|"The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
75425141|NCT01468753|Procedure|Vaginal Insemination|Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
75425142|NCT01468766|Other|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
75425143|NCT01468766|Other|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
75425144|NCT01468779|Dietary Supplement|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
75571206|NCT02889367|Drug|Odalasvir (Up to maximum 1000 mg)|Participants will receive odalasvir to be decided up to maximum of 20*50 mg tablet, orally once on Day 1.
75571207|NCT02922647|Device|suprapubic catheterization|Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
75425145|NCT01468779|Dietary Supplement|Sugar pill|
75425146|NCT01468948|Drug|Octanoic Acid|
75425147|NCT01468961|Behavioral|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
75425148|NCT01468805|Procedure|Cockroach mitigation/extermination|
75425149|NCT01469026|Radiation|PET/CT or Conventional diagnostics including CT|"Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml)."
75425150|NCT01469078|Drug|Monofer®|Single Bolus Injections
75425151|NCT01469091|Behavioral|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
75425152|NCT01469104|Other|3 day fast|Subjects will fast for 72 hours
75571208|NCT02922647|Device|transurethral catheterization|Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
75571209|NCT05543356|Biological|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
75571210|NCT05543356|Biological|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
75571211|NCT05543356|Biological|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
75571212|NCT05543356|Biological|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
75877472|NCT01624532|Biological|GC1109 or Placebo of GC1109|"Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks."
75425153|NCT01469104|Other|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
75877473|NCT03608930|Device|Disposable Polypectomy Snare,JHY-SD-23-230-30-A1|The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
75877474|NCT03080961|Device|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
75877475|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
75877476|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
75877477|NCT01538966|Drug|Pegvisomant|
75877478|NCT01538966|Drug|Octreotide LAR|
75877479|NCT01538966|Drug|Lanreotide|
75877480|NCT01377285|Drug|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
75877481|NCT01377285|Drug|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
75877482|NCT01377285|Drug|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
75877483|NCT03609242|Behavioral|STOP-HPV bundle intervention|This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
75425154|NCT01469117|Other|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
75425155|NCT01469130|Drug|MEK162|MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
75425156|NCT01469143|Drug|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
75425157|NCT01469143|Drug|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
75571213|NCT05543356|Biological|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
75571214|NCT05543356|Biological|Bivalent Moderna|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg)will be administered on day 0 of the study.
75571215|NCT05543356|Biological|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg) will be administered on day 0 of the study.
75571216|NCT05543356|Biological|Bivalent Moderna|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
75724073|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
75571217|NCT00546039|Drug|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
75571218|NCT00546039|Drug|Placebo|Capsule
75571219|NCT02916719|Device|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
75571220|NCT01264081|Drug|Lapatinib|500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
75571221|NCT00538707|Behavioral|2-minute Bondet test|2-minute Bondet test
75724074|NCT00163657|Drug|Daclizumub|anti-rejection drug
75724075|NCT00163657|Drug|Tacrolimus|anti rejection drug
75724076|NCT00163657|Drug|Cyclosporine|anti rejection drug
75724077|NCT00163657|Drug|MMF|anti rejection drug
75877484|NCT03609164|Procedure|Suture-bridge augmentation of single-row repair|
75877485|NCT03630783|Behavioral|Combined Cognitive Bias Modification|
75877486|NCT03630627|Drug|SB26|SB26 administered intravenously
75571222|NCT00538746|Device|BIPAP|
75425158|NCT01469169|Drug|Iloprost (Ventavis inhaled, BAYQ6256)|2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
75571223|NCT00538746|Device|PSV|
75571224|NCT00538746|Device|PSV + CPAP|
75571225|NCT05042778|Other|Auriculotherapy|A licensed acupuncturist (holder of civil liability insurance) with more than nine years of experience with this technique will apply auriculotherapy. Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used at the actives auricular points around the vagus nerve area.
75571226|NCT02711969|Drug|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
75571227|NCT00538941|Dietary Supplement|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
75571228|NCT00538941|Dietary Supplement|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
75571229|NCT01263925|Drug|Alprostadil (Prostaglandin E1)|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
75571230|NCT01263925|Drug|Pentoxifylline|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
75571231|NCT01263925|Drug|Placebo to Pentoxifylline oral|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
75425159|NCT01469260|Other|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
75425160|NCT01469273|Drug|Mutaflor® Suspension|Application of Mutaflor-Suspension on 10 consecutive days.
75425161|NCT06078462|Other|job related activities|Different types of effort offered by female physiotherapist and female dentist during clinical practicing with patients in internship year
75425162|NCT06078449|Device|Therapeutic Ultrasonic|Ultrasound is a therapeutic modality that has been used by physical therapists to achieve therapeutic benefits. It is alternating compression and rarefaction of sound waves with a frequency of >20,000 cycles/second. Therapeutic ultrasound frequency will be used by 0.7 to 3.3 MHz. Maximum energy absorption in soft tissue will be 2 to 5 cm. Intensity decreases as the waves penetrate deeper. It is applied using a round headed wand or probe that is put in direct contact with the patient's skin. Ultrasound gel must be used on all surfaces of the head as a conducting medium in order to assist in the transmission of the ultrasonic waves & to reduce friction.
75425163|NCT06078449|Drug|Hyaluronan intra-articular injection|The type of Hyaluronan injection that will be used in this study consists of High Molecular Weight Hyaluronic acid (High MW HA 3000 kDa), will be given by the orthopedic surgeon.
75425164|NCT06078423|Biological|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
75571232|NCT01263925|Drug|Placebo to Alprostadil (Prostaglandin E1) intravenous|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
75571233|NCT04323631|Drug|Hydroxychloroquine|Oral
75571234|NCT04323631|Other|The control group will not receive hydroxychloroquine|The control group will not receive hydroxychloroquine
75571235|NCT00546234|Drug|tiotropium|18 mcg daily via Handihaler
75571236|NCT00546234|Drug|long acting beta agonist|Turbohaler, 6 & 12 mcg
75571237|NCT03455348|Other|catheter insertion|catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
75571238|NCT00539019|Other|calories measured 5x following wound healing|measure REE at various time points postburn
75571239|NCT00539097|Dietary Supplement|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
75724078|NCT03971149|Behavioral|EMPOWER|EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
75877487|NCT03630627|Drug|Placebo|Placebo administered intravenously
75877488|NCT02905266|Biological|Nivolumab|-Specified dose on specified days
75877489|NCT02905266|Biological|Ipilimumab|-Specified dose on specified days
75877490|NCT03889899|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
75571240|NCT02664506|Behavioral|Word repetition after a time delay.|This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
75571241|NCT05042037|Dietary Supplement|(Microbial cell preparation) probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
75571242|NCT05042037|Other|Placebo|Placebo sachet with no microbial cell preparation
75724079|NCT01073683|Procedure|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
75724080|NCT01073683|Drug|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
75877491|NCT01380795|Biological|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
75571243|NCT02664038|Behavioral|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
75425165|NCT06078423|Biological|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
75571244|NCT02623439|Drug|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
76047176|NCT02122887|Behavioral|Peace-Building Intervention Process|"The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders."
76047177|NCT02182947|Device|Capsule endoscopy|Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
76047178|NCT04755075|Drug|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
76047179|NCT04755075|Drug|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
76047180|NCT02370043|Drug|KQ-791|Capsules administered orally while fasting, in up to 3 periods
75425166|NCT06078423|Biological|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
76047181|NCT02370043|Drug|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
75571245|NCT00546312|Device|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
75571246|NCT02599922|Biological|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
75571247|NCT00539175|Device|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
76047182|NCT02370043|Drug|Placebo|Capsules, administered orally, in 1 period
76047183|NCT02301403|Drug|Nicotine patch|8 weeks of nicotine patch
76047184|NCT02301403|Behavioral|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
76047185|NCT02301403|Drug|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
75425167|NCT06078423|Biological|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
75425168|NCT06078410|Procedure|Cardiac surgery|The TA-BSM group will undergo transapical beating-heart septal myectomy and the group of cardiac surgery involving left heart operation will udergo patients received cardiac surgery involving left heart operation, such as valvuloplasty, valve replacement, repair of auricular septal defect, repair of auricular/ventricular septal defect.
75571248|NCT00539175|Device|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
75571249|NCT02277353|Other|Fluid loading to evaluate fluid responsiveness|loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
75571250|NCT00539292|Procedure|Primary placement of a spring-loaded silo|
75571251|NCT00539292|Procedure|Primary Closure|primary closure of abdomen
75571252|NCT00539331|Drug|AZD2171|oral tablet
75571253|NCT00539331|Drug|Paclitaxel|intravenous infusion
76047186|NCT02301403|Drug|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
76047187|NCT02301403|Behavioral|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
75571254|NCT00539331|Drug|Carboplatin|intravenous injection
75571255|NCT00546468|Procedure|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
75571256|NCT00546468|Procedure|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
75571257|NCT02236013|Drug|Gilteritinib|Oral
75571258|NCT02236013|Drug|Idarubicin|lyophilized powder administered intravenously
76047188|NCT02301403|Behavioral|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
76047189|NCT02301403|Behavioral|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
75425169|NCT06078397|Device|remote programming|Remote programming (RP) is a new type of patient management method after DBS surgery, which allows physicians to understand the patient's movement symptoms and adjust parameters through video conferencing. At the same time, the RP system also includes device checks, medication adjustments, psychological counseling, and other contents. Compared to standard programming that requires going to the hospital, the application of RP can save the burden on patients and their caregivers.
75425170|NCT06078397|Device|standard programming|Programming refers to a series of methods that set the parameters of the IPG after the implantation of DBS, and adjust the device parameters based on the patient's symptoms during subsequent follow-up to maintain the efficacy of electrical stimulation.
75425171|NCT06078371|Other|Opioid-free pain treatment|Pain treatment includes any medications up to the medical team's discretion aside from opioids.
75425172|NCT06078254|Device|ULTRASOUND|Ultrasound and CT chest for all patients
75425173|NCT06078202|Drug|ABBV-903|Tablet; oral
75571259|NCT02236013|Drug|Cytarabine|solution administered intravenously
75571260|NCT02236013|Drug|Daunorubicin|solution administered intravenously
75571261|NCT03456999|Biological|MAU868|MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.
75571262|NCT03456999|Biological|Placebo|Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
76047190|NCT02301169|Behavioral|Heat pain stimuli A|
76047191|NCT02301169|Behavioral|Video A|
76047192|NCT02301169|Drug|Administration of T4P1001 capsules|This treatment is given as add on therapy to patients' regular analgesic
76047193|NCT02301169|Behavioral|Heat pain stimuli B|
76047194|NCT02301169|Behavioral|Video B|
76047195|NCT02301169|Drug|Administration of placebo capsules|This treatment is given as add on therapy to patients' regular analgesic
76047196|NCT02333383|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
75571263|NCT00539409|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
76047197|NCT02332915|Behavioral|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
76047198|NCT02369341|Biological|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
76047199|NCT02121795|Drug|FTC/TDF|200/300 mg FDC tablets administered orally once daily
76047200|NCT02121795|Drug|F/TAF|Tablets administered orally once daily
76047201|NCT02121795|Drug|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
76047202|NCT02121795|Drug|FTC/TDF Placebo|Tablets administered orally once daily
76047203|NCT02121795|Drug|F/TAF Placebo|Tablets administered orally once daily
76047204|NCT02158533|Drug|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
76047205|NCT02158533|Drug|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
76047206|NCT02158533|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
76047207|NCT02120781|Biological|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
76047208|NCT02120781|Drug|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
75425174|NCT06078163|Other|supplementation|daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions
75425175|NCT06078163|Other|rehabilitation|rehabilitation protocol lasting 20 sessions.
75425176|NCT06078137|Other|Usual PROMs and new PROMs strategy|Patients randomized to intervention receive both usual PROMs and new PROMs strategy
75425177|NCT06078124|Behavioral|Sibling Support for Adolescent Girls in Emergencies|"The Sibling Support for Adolescent Girls in Emergencies (SSAGE) intervention is a gender-transformative, 12-week program utilizing a whole family approach wherein an adolescent girl, her male sibling, and a male and female caregiver participate in sessions that are age- and gender-specific and combined with family-wide discussions of session learnings. The sessions are interactive, engaging, and promote self-reflection and discussion on topics such as power, gender, interpersonal communication, and healthy relationships. Given the whole-family approach, SSAGE addresses intersections between spousal relationships, caregiver-child relationships, and relationships between siblings, as they pertain to supporting the mental health and psychosocial well-being of adolescent girls."
75425178|NCT06078111|Behavioral|Prism 10 + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with 10 degrees of visual field deviation
75425179|NCT06078111|Behavioral|Neutral Prism + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with no visual field deviation
75425180|NCT06078098|Other|Clinical Information|We will recruit AIH patients and collect important clinical information and laboratory investigation, together with biological samples.
75425181|NCT06078085|Other|Postoperative rehabilitation program|The rehabilitation program is created by a physical therapist
75425182|NCT06078059|Biological|Knee aspiration + UCB-MSCs|Knee aspiration and the application of cultered allogeneic umbilical cord blood-derived mesenchymal stromal stem cells (UCB-MSCs).
75425183|NCT06078059|Other|Knee aspiration|Knee aspiration
75425184|NCT06078046|Behavioral|Mind-body interventions|Parallel randomized controlled trial
75571264|NCT01263691|Biological|BioThrax|BioThrax
75571265|NCT01263691|Biological|AV7909 Formulation 1|AV7909 Formulation 1
75571266|NCT01263691|Biological|AV7909 Formulation 2|AV7909 Formulation 2
75571267|NCT01263691|Biological|AV7909 Formulation 3|AV7909 Formulation 3
75571268|NCT01263691|Biological|AV7909 Formulation 4|AV7909 Formulation 4
75571269|NCT01263691|Drug|Control|Saline control
75571270|NCT02178410|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
75425185|NCT06078020|Other|Interview|Semi-structured interview to assess understanding and acceptability at 3+/-2 and 14+/-7 days after consent
75425186|NCT06078007|Behavioral|MyMoodCoach|The MyMoodCoach prevention intervention is an evidence-based online intervention based on cognitive-behavioral therapy principles such as behavioral activation, problem solving and challenging negative thoughts.
75425187|NCT06077890|Other|Digital Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be able to access home-based rehabilitation strategies through dynamic content provided by SIMPLI.REHAB digital tool.
75425188|NCT06077890|Other|Conventional Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be given home-based strategies in a printed paper brochure.
75425189|NCT06077851|Device|Continuously monitoring|Included patients are monitored with WARD equipment the first days after discharge. Monitoring will last for a maximum of three days.
75425190|NCT06077825|Other|postoperative rehabilitation|30 patients took postoperative rehabilitation after total hip arthroplasty surgery, 3 times a week, for 6 weeks. They took conventional rehabilitation (hip range of motion exercises, progressive strengthening exercises for hip and knee muscles, balance and proprioceptive exercises and gait training).
75425191|NCT06077812|Behavioral|RELAXaHEAD Smartphone App|Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.
75425192|NCT06077812|Behavioral|In-Person Training|Participants will receive in-person training in migraine self-management techniques.
75425193|NCT06077812|Behavioral|Virtual Training|Participants will receive virtual training in migraine self-management techniques.
75425194|NCT06077747|Procedure|Coil Embolization of the Lumbar Vein|Catheter based venography will first confirm Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus congestion. The lumbar vein will then be coil embolized.
75425195|NCT06077734|Other|In vitro analyse|In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies
75425196|NCT06077708|Dietary Supplement|Vitamin D3K2|Non-surgical periodontal treatment was applied to all individuals included in the study. 2 drops of the preparation containing 25 µg D3 [1000 IU] and 11.25 µg K2 in each drop were given per day to participants in the test group.
76047209|NCT02120625|Device|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
75425197|NCT06077708|Other|Saline Solution|Non-surgical periodontal treatment was applied to all individuals included in the study and saline solution (0.9% NaCl) was given as placebo, 2 drops per day to particiapants in the control group.
75425198|NCT06077682|Drug|Cyclopentolate|Well-known eye drop used for cycloplegic refraction among children.
75425199|NCT06077682|Drug|Tropicamide|Well-known eye drop used for cycloplegic refraction among children.
75425200|NCT06077604|Other|Assessment of exposure to air pollution|For each patient, exposure to air pollution will be assessed over a period immediately prior to any flare-up and over four periods at a distance from the flare-up.
75425201|NCT06077552|Other|pyramidal training by treadmill|pyramidal training by treadmill for 40 minutes per session three sessions per week for eight weeks in addition to the diet health advises
75425202|NCT06077539|Drug|Dexmedetomidine|a selective a-2 adrenoceptor agonist, has sedative, analgesic, and anxiolytic effects.
75425203|NCT06077539|Drug|Ketamine|NMDA (N-methyl-D-aspartate) receptor antagonist
75425204|NCT06077539|Drug|Magnesium|NMDA (N-methyl-D-aspartate) receptor antagonist
75425205|NCT06077539|Other|normal saline 0.9% NaCL|saline will be given as bolus over 10 min then will be infused as maintenance by the same rate of the other groups
75425206|NCT06077474|Other|Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)|Administer the DSM-5 PTSD-RI-5 scale in 155 patients with exposed to traumatic events.
75425207|NCT06077448|Device|MRI|imaging modality
75425208|NCT06077435|Device|AI|AI system
75425209|NCT06077409|Other|Skin To Skin|"Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure."
75425210|NCT06077409|Behavioral|Gentle Human Touch|Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
75425211|NCT06077383|Dietary Supplement|Weizmania Coagulans BC99|Probiotics group subjects take probiotics every day for 8 weeks.
75425212|NCT06077370|Device|deep TMS|Deep Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
75425213|NCT06077370|Device|Sham TMS|Sham Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
75425214|NCT06077357|Other|MMSE Test|Mini Mental State Examination (MMSE), is a brief mental test used to assess individuals' cognitive functions. This test evaluates basic cognitive abilities such as memory, attention, calculation, language, orientation, and problem-solving. MMSE is commonly used for monitoring and assessing mild cognitive impairments, dementia, and other neurological conditions. This test is typically scored out of 30, with higher scores indicating better cognitive function.
75571271|NCT02178410|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
75571272|NCT02178410|Dietary Supplement|Fish oil placebo|Fish oil placebo
75571273|NCT02178410|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
75425215|NCT06077357|Other|PASE Test|"The PASE test stands for Physical Activity Scale for the Elderly. This scale is used to assess the physical activities undertaken by elderly individuals in their daily lives. The PASE test allows for the evaluation of both daily activities such as walking, climbing stairs, and household chores, as well as exercise routines. It is used to determine the level of physical activity in elderly individuals and support the process of healthy aging."
75425216|NCT06077357|Other|The PRISMA-7 Frailty Scale|The PRISMA-7 Frailty Scale is a tool used to assess the level of frailty in elderly individuals. This scale evaluates signs of frailty such as physical activity, fatigue, weight loss, and difficulties with vision and hearing. PRISMA-7 is employed in determining the risk of frailty in the elderly and aids in identifying appropriate treatment and support methods.
75571274|NCT00539448|Drug|insulin glargine|in combination with insulin Glulisine as bolus regimen
75571275|NCT00539448|Drug|insulin glulisine|in combination with insulin Glargine as bolus regimen
75571276|NCT02100254|Behavioral|behavioral intervention|View personal narrative informational video
75571277|NCT02100254|Behavioral|behavioral intervention|View fact-based informational video
75571278|NCT04323358|Diagnostic Test|Biometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
75571279|NCT04323358|Diagnostic Test|Keratometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
76047210|NCT02120469|Drug|everolimus|Given PO
76047211|NCT02120469|Drug|eribulin mesylate|Given IV
76047212|NCT02120469|Other|pharmacological study|Correlative studies
76047213|NCT02120469|Other|laboratory biomarker analysis|Optional correlative studies
76047214|NCT02157519|Other|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
76047215|NCT02180061|Biological|Pembrolizumab|IV infusion
76047216|NCT02179515|Biological|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
76047217|NCT02120157|Drug|Cyclophosphamide|Chemotherapy administration
75571280|NCT05539846|Procedure|modified blood collection method|The bevel of the needle head of the blood collection needle was downward, and the needle was inserted into the skin with the bevel of the needle parallel to the skin.
75571281|NCT01808456|Biological|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
75571282|NCT01808456|Biological|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
75571283|NCT01781741|Combination Product|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
75571284|NCT01781741|Other|quality-of-life assessment|Ancillary studies
75571285|NCT01715714|Drug|Statin Recapture Therapy|Given 12h and 2h before CABG
75571286|NCT01715714|Drug|Placebo|Given 12h and 2h before CABG.
75571287|NCT01540253|Drug|PI3K inhibitor BKM120|Given PO
75571288|NCT01540253|Drug|docetaxel|Given IV
76047218|NCT02120157|Radiation|TBI|Radiation Therapy
76047219|NCT02120157|Drug|Busulfan|Chemotherapy Administered
76047220|NCT02120157|Other|Unmanipulated Bone Marrow|Bone Marrow Transplant
76047221|NCT02120157|Drug|Tacrolimus|Immunosuppressive Drug Administered
76047222|NCT02120157|Drug|Mycophenolate mofetil|Immunosuppressive Drug Administered
76047223|NCT02119299|Device|SMART device|Sensor Monitored Alimentary Restriction Therapy (SMART) device
76047224|NCT04753827|Other|Drug eluting stent|Put a Drug eluting stent in the blood vessel
76047225|NCT04753827|Other|Durg coated balloon|Put a Durg coated balloon in the blood vessel
76047226|NCT02156271|Drug|ramelteon|
76047227|NCT02156271|Drug|placebo|
76047228|NCT01365455|Drug|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
75571289|NCT01540253|Other|pharmacological study|Correlative studies
75571290|NCT01540253|Other|questionnaire administration|Ancillary studies
75571291|NCT01540253|Other|laboratory biomarker analysis|Correlative studies
75571292|NCT01497392|Drug|dovitinib lactate|Given PO
76047229|NCT01365455|Drug|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
76047230|NCT02155881|Drug|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
75571293|NCT01497392|Drug|gemcitabine hydrochloride|Given IV
75571294|NCT01497392|Drug|capecitabine|Given PO
75571295|NCT01497392|Other|laboratory biomarker analysis|Correlative studies
75724081|NCT00887172|Drug|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
75724082|NCT00887172|Drug|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
75724083|NCT00887172|Drug|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
76047231|NCT02155881|Drug|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
76047232|NCT05279807|Drug|Zofenopril|Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
76047233|NCT05279807|Drug|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
76047234|NCT05319431|Biological|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
75571296|NCT01497392|Other|enzyme-linked immunosorbent assay|Correlative studies
75571297|NCT01497392|Other|pharmacological study|Correlative studies
75571298|NCT01310192|Device|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
76047235|NCT05319431|Drug|Lenvatinib|Subjects will receive lenvatinib until disease progression or for a maximum of 24 months
76047236|NCT05319431|Procedure|TACE|On demand TACE
76047237|NCT05276531|Drug|subcutaneous progesterone|clinical pregnancy rates
75571299|NCT05106855|Radiation|Low Laser Radiation|One group will receive laser application to check if there is acceleration of healing.
75571300|NCT05106855|Other|Changing the implant surface|Changing the treatment surface of the dental implant to see if osseointegration occurs more quickly.
75571301|NCT05106855|Radiation|Low Laser Radiation off|This group will receive laser application off.
75571302|NCT05106855|Procedure|Implant placement immediately after tooth extraction|When the last alternative is tooth extraction, this will be done, and in the same surgical intervention the dental implant will be placed.
75571303|NCT05106855|Procedure|Installing the dental crown with early loading|The installation of the dental crowns will be performed in a period of 6 to 8 weeks, after the dental implant has been installed.
75571304|NCT00539565|Drug|prednisolone|"2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30"
75571305|NCT00539565|Drug|placebo|
75571306|NCT00539604|Procedure|MDCT and Coronary Angiography|
76047238|NCT05276531|Drug|vaginal progesterone|clinical pregnancy rates
76047239|NCT05352581|Diagnostic Test|BD Veritor At-Home|BD Veritor At-Home rapid self testing
76047240|NCT05352581|Diagnostic Test|BD Veritor Professional|BD Veritor Professional rapid test
76047241|NCT05318651|Device|Kwit SAS - smoking cessation app|Kwit is a mobile app for smoking cessation. Different CBT techniques are used by the app already been proved as effective : Case analysis craving tool, Achievements badges,Diary, Goal (outcome) setting, A 9-steps preparation program, psychological education, Emotional monitoring, Access to groups on social networks, different strategies ( NRT/water/meditation), Motivational cards.
76047242|NCT01658579|Drug|HOE901-U300 (new formulation of insulin glargine)|
76047243|NCT01658579|Drug|Lantus (insulin glargine)|
75425217|NCT06077357|Other|TAMPA Test|"The TAMPA test, abbreviated from Tampa Scale for Kinesiophobia, is a scale used to assess fears related to pain. This scale is employed to evaluate the fear of pain and avoidance behaviors associated with it. By measuring individuals' attitudes and fears towards pain, the TAMPA test helps identify their emotional and behavioral responses in this area."
75571307|NCT00539760|Drug|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
75571308|NCT00539760|Drug|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
75425218|NCT06077357|Other|(JAMAR) Muscle Test|The JAMAR Muscle Test is a widely used clinical assessment tool for evaluating hand grip strength. It involves using a device called a dynamometer to measure the force exerted by a person's hand when squeezing the instrument. This test provides valuable information about an individual's upper body strength, which can be important in various medical and rehabilitative contexts. The JAMAR Muscle Test is often utilized in physical therapy, sports medicine, and other healthcare fields.
75571309|NCT00539799|Drug|prednisolone|5 - 7.5 mg/day
75571310|NCT00539799|Drug|Placebo|Matched placebo to prednisolone
75571311|NCT00945152|Drug|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
75724084|NCT00609492|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
75571312|NCT00945152|Drug|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
75724085|NCT00609492|Biological|Infanrix™-IPV/Hib|Single dose, intramuscular injection
75724086|NCT00230971|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
75877492|NCT04339998|Diagnostic Test|Point-of-Care Ultrasonography (POCUS)|"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~B lines: absent (< 3 lines), present (> 3 lines), fused~Consolidation: yes or no~a. Bilateral: yes or no~Pleural Effusion: yes or no~Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~Parasternal long axis~Parasternal short axis~Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~EPSS (E-point septal separation): normal (<10 mm), abnormal (>10 mm)~Left ventricular (LV) mass approximation by septal thickness~Left Ventricular Chamber Size by internal diameter at diastole"
75877493|NCT01380717|Drug|Beta-blocker, ACE-inhibitor|Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
75724087|NCT00230971|Drug|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
75571313|NCT00546507|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
75571314|NCT00546507|Drug|celecoxib|
75571315|NCT00546507|Other|placebo|
75571316|NCT00546546|Drug|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
75877494|NCT01380717|Drug|Calcium Channel Blockers, ACE-Inhibitor|Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
75877495|NCT04292652|Procedure|AAA surgery|EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
75877496|NCT01569399|Other|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
75877497|NCT02982018|Device|senofilcon A with new UV blocker|Investigational Contact Lens
75877498|NCT02982018|Device|senofilcon A|J&J Marketed Contact Lens
75877499|NCT03080493|Drug|Gabapentin 600mg|Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
75571317|NCT00659711|Drug|Januvia (Sitagliptin) 100 mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
75571318|NCT00659711|Drug|Placebo|will be placed on a placebo for 12 weeks.
75571319|NCT00546624|Drug|MK0777|
75571320|NCT00580346|Device|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
75571321|NCT00546663|Drug|inhaled 7% hypertonic saline (HS)|"7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"
75571322|NCT00300599|Device|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
75571323|NCT00300599|Other|Placebo|Placebo
75425219|NCT06077357|Other|Fatigue Severity Scale|The Fatigue Severity Scale (FSS) is a self-report questionnaire used to assess the severity of fatigue in individuals. It consists of nine items that measure the impact of fatigue on various aspects of daily life, such as physical functioning, motivation, and mental clarity. The FSS is commonly used in clinical settings and research studies to quantify the level of fatigue experienced by individuals with various medical conditions, including chronic illnesses, neurological disorders, and mental health conditions. It provides valuable information for healthcare professionals in understanding and managing fatigue-related symptoms.
75425220|NCT06077318|Other|Keyhole repair|The keyhole technique involves placing a mesh with a slit in the central hole around the intestinal ring, allowing facilitating the passage of the intestine through the central slit.
75425221|NCT06077318|Other|Sugarbaker repair|The modified Sugarbaker technique uses a mesh to place a patch on the lateralized intestine, effectively preventing herniation of abdominal contents through the stoma.
75877500|NCT03080493|Drug|Placebo oral capsule|Packaged identical to gabapentin dosing
76047244|NCT05561309|Drug|HR18034;Ropivacaine Hydrochloride Injection|"Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution"
75425222|NCT06077292|Behavioral|15% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 15% less potent than baseline
75571324|NCT00546702|Drug|Insuline Glulisine|
75877501|NCT03080493|Drug|acetaminophen/codeine and ibuprofen|Over the counter analgesic medications
75877502|NCT03655626|Other|Sepsis Watch|The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
76047245|NCT05352503|Device|Watching videos with nature images accompanied by nature sounds with virtual reality glasses|The video with nature images accompanied by the sounds of nature with virtual reality glasses will be watched 3 times a day for at least 5 minutes for 2 days.
75425223|NCT06077292|Behavioral|35% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 35% less potent than baseline
75425224|NCT06077279|Behavioral|Horticultural Therapy Program|Horticultural Therapy Program Is selected plant therapy
75425225|NCT06077162|Other|Diabetes Nutrition Education Classes|Diabetes nutrition education offered by registered dietitian in group-based classes.
75425226|NCT06077162|Other|Healthy Food Security Resource|Participants offered security resource which is a $30.00 Aldi (grocery store) gift card provided weekly for 12 weeks.
75571325|NCT02581007|Drug|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
75571326|NCT02581007|Drug|Melphalan|
75571327|NCT02581007|Drug|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
75571328|NCT02581007|Procedure|peripheral blood stem cell transplant|
75571329|NCT00546741|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
75571330|NCT00546741|Drug|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
75571331|NCT00546741|Drug|Dapagliflozin + Metformin|"Tablets, Oral, once daily, single dose~Dapagliflozin: 20 mg~Metformin: 1000 mg"
75571332|NCT02540330|Drug|Fulvestrant|
75571333|NCT00546858|Other|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
75571334|NCT00546936|Drug|ranibizumab|0.5mg ranibizumab
75571335|NCT00546936|Drug|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
75571336|NCT02438891|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
75571337|NCT00546975|Dietary Supplement|Resource Support®|
75571338|NCT00546975|Dietary Supplement|Resource Protein®|
76047246|NCT05270525|Drug|Ensifentrine|Ensifentrine twice daily administered with jet nebulizer for 8 weeks
75571339|NCT00546975|Dietary Supplement|Placebo|
75724088|NCT02541318|Behavioral|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
75877503|NCT01339910|Drug|Fludarabine and Busulfan|"(Flu/Bu)~Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)~Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4"
75877504|NCT01339910|Drug|Fludarabine and Melphalan|"(Flu/Mel)~Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)~Melphalan: 140 mg/m^2 on Day -2"
76047247|NCT05270525|Drug|Placebo|Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
76047248|NCT05317013|Drug|CBD|CBD
76047249|NCT05317013|Other|Placebo|Placebo
76047250|NCT04949555|Other|Primary congenital glaucoma evaluation|long term evaluation of primary congenital glaucoma management
76047251|NCT04422509|Biological|lanadelumab|single dose, or two doses administered iv
76047252|NCT04422509|Other|regular care|no lanadelumab administration, treated according to regular care
75571340|NCT05006313|Device|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
75571341|NCT01263496|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
75571342|NCT01263496|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
75571343|NCT01263496|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
75571344|NCT01263496|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
75877505|NCT01339910|Drug|Busulfan and Fludarabine|"(Bu/Flu)~Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2~Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)"
75877506|NCT01339910|Drug|Busulfan and Cyclophosphamide|"(Bu/Cy)~Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4~Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
76047253|NCT05313893|Biological|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
76047254|NCT05349773|Procedure|Pneumatic tourniquet, endoscopic left radial artery harvesting|"Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes."
76047255|NCT05268497|Drug|Esketamine|Esketamine will be self-administered as nasal spray.
76047256|NCT05268497|Behavioral|Cognitive Behavioral Therapy (CBT)|Clinician-directed CBT supplemented by the Mindset app will be administered.
76047257|NCT05268497|Drug|Antidepressant|Antidepressant will be administered orally.
75571345|NCT01263496|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
75724089|NCT02542722|Behavioral|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
75724090|NCT02542722|Behavioral|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
76047258|NCT05311943|Drug|olverembatinib|olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
75425227|NCT06077136|Other|whole body vibration|"3 sessions per week consisted of different types of exercises, all of which were performed while the child will be is under WBV using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~WBV session duration: 10 minutes (rest periods can be incorporated (1-2 minutes maximum 3 times during the session)~frequency: 12 Hz~Amplitude: 2 (fixed)~duration of each exercise: 2-3 minutes~starting positions differ according to each exercise; upper limb weight-bearing and weight shift (from prone, prone on elbows, sitting, standing).~upper limb active exercises using toys/ balls / wand. Involving throwing, catching, transfer between both hands (according to the abilities of each child).~coordination exercises by asking the child to approximate the index finger of both hands together, perform finger-to-nose (eyes open and closed), and finger-to-therapist finger exercises."
75425228|NCT06077110|Other|P-OMICs-flow services|The Service Intervention is the P-OMICs-flow clinic being delivered at The Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.
75425229|NCT06077097|Genetic|Biological samples|This project also includes an auxiliary exploratory biological study of subcellular mechanisms, using high-throughput sequencing (Next Generation Sequencing, NGS) to identify gene expression variations in order to determine the resilience/vulnerability of the variables studied with respect to the DC experience (cytogenetics and transcriptome).
76047259|NCT05557175|Device|Repetitive transcranial magnetic stimulation|The active rTMS group will receive a 1 Hz inhibitory low-frequency rTMS protocol hotspot of the contra-lessional primary motor cortex (M1), will deliver a continuous pulse of 1 pulse per second totalling 1200 pulses of 80% active motor threshold stimulation. The duration of the stimulation will last for 20 minutes thrice a week for four weeks (12 sessions). The motor threshold will be the minimum single-pulse TMS intensity necessary to elicit a motor-evoked potential greater than 50μV in more than 5 out of 10 consecutive trials. The standard 70 mm figure-of-eight air-cooled coil handle (MagPro) will be held at right angle to the skull for effective M1 stimulation. The participants in the active rTMS groups will receive a subthreshold stimulation intensity for muscle contraction with no painful peripheral sensation
76047260|NCT05557175|Device|Sham rTMS|The sham rTMS will be applied using the same parameters as the active rTMS but the coil will be rotated 90° away from the scalp so that minimal or no flow of current will be induced
76047261|NCT05266859|Other|Calcium hydroxide|Calcium hydroxide in the power/liquid form will be used and placed on the exposed pulp
75571346|NCT00547014|Drug|Placebo Comparator: Cohort 1 Placebo|Drug: placebo for cohort 1 as single dose
75724091|NCT00211081|Drug|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
76047262|NCT05266859|Other|MTA|Mineral trioxide aggregate will be used as a powder / liquid form and placed over the exposed pulp
75571347|NCT00547014|Drug|52364 3 mg|3 mg capsule single dose administered orally as a single dose
75571348|NCT00547014|Drug|Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo|Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
75724092|NCT05278806|Other|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~Population health coordinators (PHCs) will lead equity huddles with providers to review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will formulate a follow up plan for each patient that the PHCs will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc.~In addition, patients may be referred to the community health worker (CHW) hypertension management program. Patients will work with the CHW for 3-6 months. During this time the CHW will focus their efforts on patient education/coaching, remote blood pressure monitoring, addressing psychosocial and socioeconomic barriers to care and care coordination."
75877507|NCT01339910|Drug|Cyclophosphamide and Total Body Irradiation|"(Cy/TBI)~TBI: 1200-1420 cGy on Days -7 to -4~Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
76047263|NCT05266859|Other|PRF|PRF will be placed directly over the exposed pulp
76047264|NCT05310851|Other|PIOMI and non-nutritive sucking|"PIOMI group; The first three minutes of the five minutes include massages aimed at strengthening the cheeks, lips, gums and tongue; the last two minutes consist of non-feeding suction application.~Infants in the Non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes."
76047265|NCT02154087|Biological|HP802-247|260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
75571349|NCT00547014|Drug|52364 10 mg|Drug: 52364 30 mg capsule as a single dose
75571350|NCT00547014|Drug|52364 30 mg|Drug: 52364 30 mg capsule administered as a single dose
75571351|NCT00547014|Drug|52364 100 mg|Drug 52364 100 mg capsule administered as a single dose
75571352|NCT00547014|Drug|52364 1 mg|1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
75571353|NCT04681937|Combination Product|Subacromial Injection (hyaluronic acid) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
75571354|NCT04681937|Combination Product|Subacromial Injection (Platelet-Rich-Plasma) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
76047266|NCT05219201|Device|partial-body cryotherapy chamber session|"The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~at -30°C for sham cryotherapy session~at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions)."
75571355|NCT04681937|Combination Product|Subacromial Injection (methylprednisolone acetate) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
75571356|NCT04681937|Combination Product|Subacromial Injection (Serum Saline) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
75571357|NCT00547053|Drug|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
76047267|NCT05346731|Drug|Ondansetron|Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
75571358|NCT02131649|Device|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
75571359|NCT00547092|Drug|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
75724093|NCT05278806|Other|Equity Dashboard and Population Health Coordinator Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~In addition, population health coordinators (PHCs) will lead disparities focused huddles with providers. During the huddle, they will review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will then formulate a follow up plan for each patient that the Population Health Coordinators will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc."
75724094|NCT03971227|Device|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
75724095|NCT03971227|Device|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
75724096|NCT00884676|Drug|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~Schedule B: Day 1 of each 3-week cycle."
75724097|NCT00884676|Drug|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
75724098|NCT02542800|Behavioral|Episodic memory task|
75724099|NCT02542800|Device|fMRI|
76047268|NCT05346731|Drug|Dexamethasone|Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
75571360|NCT00547092|Drug|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
75571361|NCT00547131|Drug|temozolomide|
75571362|NCT00547131|Other|laboratory biomarker analysis|
75571363|NCT00547131|Other|liquid chromatography|
75571364|NCT00547131|Other|mass spectrometry|
75571365|NCT00547131|Other|pharmacological study|
75571366|NCT00547131|Procedure|conventional surgery|
75571367|NCT00547131|Radiation|stereotactic radiosurgery|
75571368|NCT01964495|Drug|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
75571369|NCT01964495|Drug|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
75724100|NCT04036812|Procedure|Superficial cervical plexus block|superficial cervical plexus nerve block will be performed under the guidance of ultrasound
75724101|NCT04036812|Other|Control group|ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
75724102|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
75877508|NCT03622164|Radiation|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)|CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.
75877509|NCT03622164|Radiation|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)|CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
75571370|NCT01964495|Drug|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
75571371|NCT00547170|Drug|Doxycycline pre-operatively|"Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
75425230|NCT06077084|Other|Physiotherapy|"4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum"
75571372|NCT00547170|Drug|Doxycycline post-operatively|"Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
75571373|NCT00900809|Biological|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
75571374|NCT01263223|Drug|LY2216684|Administered orally
75571375|NCT01263223|Drug|Placebo|Administered orally
75571376|NCT00547209|Drug|air|60% air combined with 40% oxygen for ventilation
75425231|NCT06077058|Other|Nicotine Replace Therapy (NRT) sampling|The intervention involves a Zoom/WhatsApp meeting or face-to-face session with a trained counselor who introduces NRT use, possible side effects, and patch dosage based on a previous RCT guide. An online intervention pack with a pamphlet and 1-week free NRT sample (14mg or 21mg patch) is mailed to participants. After 1 week, the counselor follows up. If participants need more patches, an additional pack is mailed, and they are advised to obtain further patches from smoking cessation services or pharmacies. NRT patch users may experience skin reactions, insomnia, or vivid dreams; if severe side effects occur, they are asked to stop using NRT.
75571377|NCT00547209|Drug|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
75571378|NCT00547287|Drug|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
76047269|NCT05346731|Drug|Aprepitant|"Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight > 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally"
75571379|NCT00547287|Drug|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
75571380|NCT02908958|Biological|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
76047270|NCT05346731|Drug|Olanzapine|Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
75571381|NCT02908958|Biological|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
75571382|NCT01263106|Drug|LY2216684|18-mg LY2216684 oral dose
75571383|NCT01263106|Drug|Theophylline|200-mg theophylline oral dose
75571384|NCT00547326|Procedure|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
75571385|NCT00547326|Procedure|Treatment with placebo|Treatment with placebo
75571386|NCT01263028|Drug|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
75571387|NCT00547404|Drug|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
75571388|NCT02908919|Procedure|Colonoscopy|The quality of bowel preparation, which is checked during colonoscopy
75571389|NCT04323319|Device|ESWT, Graston Technique|"The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week."
75571390|NCT01262989|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
75571391|NCT01262989|Drug|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
75571392|NCT00547443|Drug|carboplatin|Given IV
75571393|NCT00547443|Drug|paclitaxel|Given IV
76047271|NCT02118597|Drug|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
75877510|NCT01377207|Procedure|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
75877511|NCT02237066|Device|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
75877512|NCT02237066|Device|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
76047272|NCT02118597|Drug|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
76047273|NCT02118597|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
75425232|NCT06077058|Behavioral|Simple exercise education (SEE)|All participants will be given a handgrip at study enrolment. The SEE includes a Zoom/WhatsApp meeting or face-to-face session including 1) watching a 5-minute video (www.youtube.com/watch?v=mZex2Wwy3fU) showing a chair professor of public health demonstrating the 10s-E, including the simple exercises with and without handgrip. The video also encourages participants to 1) follow the exercise instructions during the video demonstration; 2) perform the exercises whenever they experience craving or an urge to smoke during the quitting process; and 3) increase their exercise frequency and intensity as much as possible, which may also increase their grip strength. Participants will also receive a leaflet with exercise instructions and motivational messages.
75425233|NCT06077058|Other|Chat-based instant messaging|Participants will receive individualized chat-based encouragement and support messages about motivation and preparation for quit attempts using WhatsApp for 8 weeks. A trained smoking cessation counsellor will have real-time (synchronous), one-to-one interaction with the participants and provide personalized motivational, behavioural support according to the participants' needs. The conversation intensity will be flexible and depends on the participant. The conversation will also be integrated with brief advice using the Behaviour Change Techniques (BCTs) (18) and the AWARD (Ask, Warn, Advise, Refer, Do-it-again) intervention model (11). The intervention protocol will be similar as that in our previous RCT on CBIM (19). For participants who receive the SEE and NRTS, the trained counsellor shall follow-up on their compliance and provide adequate advice in adhering to these interventions.
75571394|NCT00547443|Drug|sorafenib tosylate|Given orally
75571395|NCT00547443|Radiation|radiation therapy|Given 5 days a week for 7.5 weeks
75571396|NCT02908997|Other|MindMate|A dementia-specific mobile reminding application
75571397|NCT00547482|Device|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
75571398|NCT02909075|Device|PET/CT scans|
75571399|NCT02909075|Device|MRI|
75877513|NCT03655392|Behavioral|Individualized educational program|IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
75877514|NCT03655392|Diagnostic Test|Induced sputum collection|All participants performed induced sputum collection
76047274|NCT02118597|Drug|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
76047275|NCT01659125|Behavioral|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
76047276|NCT05218889|Drug|surufatinib + camrelizumab + nab-paclitaxel + S-1|"phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40-60mg bid, according to BSA, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1"
75571400|NCT03456258|Diagnostic Test|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
75571401|NCT02909114|Radiation|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
75571402|NCT02277210|Other|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
75724103|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
75724104|NCT00887328|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
75425234|NCT06077058|Other|Chatbot for smoking cessation|The information and access to the chatbot will be introduced to participants. Through the chatbot service, participants shall access to practical information on smoking cessation 24 hours at any time, such as details on cessation services and skills for tackling cravings. By using the second-generation chatbot, participants could receive personalized risk information and recommendations for smoking cessation, as well as reach to a counsellor through WhatsApp live chat for urgently needed advice.
75425235|NCT06077019|Drug|Vilanterol and Fluticasone Furoate|Participants inhale 25 µg vilanterol + fluticasone furoate daily
75425236|NCT06077019|Drug|Indacaterol and Mometasone Furoate|Participants inhale 125 µg indacaterol + mometasone furoate daily
75425237|NCT06077019|Drug|Placebo|Participants inhale placebo daily
75425238|NCT06077006|Other|questionnaires Only|questionnaires Only
75724105|NCT00887328|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
76047277|NCT05218889|Drug|nab-paclitaxel + gemcitabine|nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
75425239|NCT06076993|Behavioral|BodyKind programme|"BodyKind is a four-session, teacher-led, school-based programme for adolescents aged 15-17 years. This programme was developed by a team of international experts in body image and incorporates empirically supported principles of cognitive dissonance (which involves publicly criticising body ideals) and self-compassion (which involves reappraising self-critical evaluations). BodyKind also contains a social activism component that aims to tackle appearance biases, discrimination and racism and promote greater inclusivity and compassion for others.~Programme Outline Lesson 1. Appearance Bias Lesson 2. Self-compassion & social media Lesson 3. Compassion for others Lesson 4. Becoming agents of change Learning Objectives~To cultivate skills in awareness, mindfulness, non-judgement, reflection, conscientiousness, compassion~To decrease levels of body dissatisfaction and self-criticism~To improve levels of self-compassion, positive body image, psychological wellbeing"
75425240|NCT06076967|Behavioral|Mindfulness Awareness Practices for ADHD (adapted)|The Mindful Awareness Practices (MAPs) for ADHD program is an 8-week, group-based mindfulness program for adults with ADHD.
75425241|NCT06076967|Behavioral|Services-As-Usual|Services-As-Usual includes the standard academic support services provided by university disability/accessibility offices.
75571403|NCT04682171|Other|Low level laser therapy|"Gallium aluminium arsenide laser device will be used with wavelength of 850nm, power 100 mW, spot size of 1.0 mm and energy of 6J/point for 60seconds. Total 8 points will be irradiated. It will take 20 minutes.~Patient will receive treatment in supine position with the affected knee(s) slightly flexed supported by the pillow or rolled towel.~On the affected knee the laser probe will placed with full contact with skin at 8 points. Three points at medial side of the knee, three points at lateral side and two points at the medial edge of the bicep femoris muscle tendon and semitendinosus muscle tendon in the popliteal fossa"
75724106|NCT00609336|Drug|gemcitabine hydrochloride|Given IV
75724107|NCT00609336|Drug|docetaxel|Given IV
75724108|NCT00609336|Drug|capecitabine|Given PO
75724109|NCT00609336|Radiation|intensity-modulated radiation therapy|Undergo IMRT
75724110|NCT00609336|Drug|oxaliplatin|Given IV
75724111|NCT00609336|Procedure|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
75724112|NCT00609336|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
75724113|NCT00609336|Other|laboratory biomarker analysis|Correlative studies
75724114|NCT02542566|Procedure|Physiotherapy rehabilitation|Physiotherapy rehabilitation
75724115|NCT00612066|Drug|rosiglitazone maleate|
75571404|NCT04682171|Other|Conventional Exercise Therapy|"Quadriceps isometric strengthening exercises.~Range of motion and active stretching exercises applied to hamstring and quadriceps muscle.~Hamstring muscle isometric exercises~Active ankle pump.~Short arc terminal extension exercises for the knee joint.~Static and dynamic strengthening exercises for the hip abductors, adductors and extensor group of muscles.~Non-weight bearing progressive resistance exercises with weighted cuffs, with progression to closed chain exercises as patient's pain allows.~Isometric exercises were applied with 6 second contractions and rest period of 2 seconds. Isotonic exercises were started as 10 repetitions with half of weight of 10 RM, 10 repetitions with three fourth of this weight and 10 repetitions with whole 10 RM"
75571405|NCT02277288|Other|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
75425242|NCT06076954|Behavioral|CoolMinds|CoolMinds consists of 11 adolescent sessions and 9 parent sessions to be completed simultaneously during a 14-week treatment period. The main components comprise psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The parent program also comprises information on how to handle school absenteeism for parents and teachers or pedagogues. The intervention is mainly transdiagnostic within the anxiety disorders but also includes diagnosis specific modules and content allowing for more personalized treatment. The treatment is delivered via a telephone app but can also be accessed via computer.
75571406|NCT00547560|Drug|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
75571407|NCT02908607|Device|Thermal imaging|Examination of the cervix by thermal imaging camera
75724116|NCT02541084|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
75724117|NCT02542488|Other|STOPBANG Questionnaire|"8 question screening tool comprised of the following questions:~S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI >35 kg/m2? A: Are you >50 years old? N: Is your neck circumference >40cm? G: Is your gender male?"
75877515|NCT03655392|Diagnostic Test|Spirometry|All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
75571408|NCT00547599|Drug|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
75571409|NCT02908451|Biological|AbGn-107|Antibody Drug Conjugate
75571410|NCT00547677|Radiation|stereotactic radiosurgery|
75571411|NCT02908763|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
75571412|NCT00547716|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
75571413|NCT00547716|Drug|Placebo comparator|
75571414|NCT02908802|Dietary Supplement|Probiotic|Probiotic
75724118|NCT02542488|Diagnostic Test|Overnight pulse oximetry|All participants will be given a Masimo Rad8 pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
75724119|NCT02542488|Other|Epworth Sleepiness Scale|A questionnaire that rates how tired they are doing everyday tasks
75724120|NCT00887406|Drug|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
75724121|NCT00887406|Drug|GSK961081 3mcg SD|single dose delivered via nebulsier
75571415|NCT02908802|Dietary Supplement|Placebo|Probiotics capsules without the active ingredient
75571416|NCT02908646|Procedure|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
75571417|NCT02908646|Procedure|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
75571418|NCT02908568|Device|Spring device|Brisk dilatation of fhe mouth.
75571419|NCT02908568|Device|Mandible stimulator|Stimulation of fhe mouth.
75724122|NCT00887406|Drug|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
75724123|NCT00887406|Drug|Placebo SD|single dose via nebuliser
76047278|NCT05262569|Other|ileus|retrospectively allocation according to a postoperative outcome-ileus
76047279|NCT01657253|Drug|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
75724124|NCT00887406|Drug|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
75724125|NCT00887406|Drug|GSK961081 200mcg SD|single dose via nebuliser
75724126|NCT00887406|Drug|GSK961081 300mcg SD|single dose via nebuliser
75724127|NCT00887406|Drug|GSK961081 100mcg RD|repeat dose via nebuliser
75724128|NCT00887406|Drug|GSK961081 300mcg RD|repeat dose vai nebuliser
75425243|NCT06076941|Other|Education|"Before the training was given to the pregnant women in the experimental group who agreed to participate in the study, the Introductory Information Form, the Form for Assessing Pregnant Women's Behaviors Towards Oral and Dental Health, and the Form for Assessing Pregnant Women's Knowledge Levels Towards Oral and Dental Health were applied by face-to-face interview method. The application of the forms took 20-30 minutes. Then, a training time was planned on a suitable date for the pregnant women.~In order to ensure the effectiveness of the training, to answer the questions of the pregnant women effectively and to be able to direct them to the dentist in line with their needs, the training was applied in groups of maximum five people. Lecture, question and answer and demonstration methods were used in the training.~One month after the training, the necessary forms were applied to the pregnant women and the study was terminated."
75425244|NCT06076928|Device|Brain Computer Interface integrated HandyRehab platform (BCI-HR)|To test the usability, safety and efficacy of an experimental prototype of a wearable hand robotic glove integrated with brain computer interface system being developed and researched.
75571420|NCT02908412|Drug|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
75571421|NCT04686474|Drug|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
76047280|NCT01657253|Drug|Systane|Instill 1 drop in each eye four times a day, for 60 days
76047281|NCT02117427|Biological|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
76047282|NCT02117349|Drug|Raplixa|Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
76047283|NCT02117349|Device|Gelfoam|Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
76047284|NCT02117349|Drug|Rescue treatment|Thrombin-containing hemostats included in standard care at the site
76047285|NCT05213663|Other|assessment|To examine the awareness of parents of Cerebral Palsy children about the disease, physiotherapy and rehabilitation.
75425245|NCT06076928|Device|HandyRehab (HR)|A wearable hand robotic glove approved by Health Sciences Authority, class I commercial device
75571422|NCT04686630|Other|Video based observational gait analysis and SCALE Test|Twenty-four spastic diparesis and eighteen spastic hemiparesis cases were included in the study. Data was collected from 84 lower extremities. There were 22 female and 20 male patients aged between 4-18 years. Personal and disease-related information of 42 individuals with diplegic or hemiparetic CP were recorded by using the data collection form. Information collection form; The patient's name-surname, age, gender, height, weight, history, gestational age, birth weight, SCALE Test, GMFCS, Modified Ashworth Scale (MAS), Range of Motion (ROM), EVGS, affected side and previous surgical histories were recorded and their functional levels were determined and recorded.
75571423|NCT02908256|Drug|Geloplasma (PVI)|In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
75877516|NCT03655392|Diagnostic Test|Nitric oxide measure|All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
76047286|NCT05167253|Biological|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
75571424|NCT02908256|Drug|Geloplasma (delta PP)|In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
75571425|NCT00547872|Procedure|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
75571426|NCT02908295|Drug|Rectal Misoprostol|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
75571427|NCT02908295|Drug|Placebo|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
75877517|NCT03655392|Other|Questionnaires ACT, ACQ, AQLQ, BDI|All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
76047287|NCT01626495|Biological|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
76047288|NCT02177175|Drug|Carvedilol|
76047289|NCT02177175|Other|placebo|
76047290|NCT02153073|Drug|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
76047291|NCT01657877|Drug|Calcium sodium phosphosilicate|CSP high percentage weight by weight
75877518|NCT03655392|Other|Symptoms Diary|All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
75571428|NCT03809442|Drug|Ropivacaine + Ketamine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
75877519|NCT03655392|Diagnostic Test|Peak flow measure|All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
75877520|NCT03655392|Diagnostic Test|Exhaled breath condensate air measurement|Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
75425246|NCT06076928|Other|Standard Treatment of Care|Standard Conventional Occupational Therapy
75425247|NCT06076915|Behavioral|Exergame training|"During the exergame intervention period, the participants in the respective group will be asked to train at least two times per week for 10 minutes per session. The proposed 10 to 15 min-sessions can also be split up into multiple short training slots during the day, to thus reach the targeted 10 minutes. Moreover, the participants are allowed to train even more during their exergame-intervention period of six weeks. However, during the control period of six weeks, they are prohibited from training on the device.~The training program will start with four pre-defined programs of the Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification) program. This training program will be adapted weekly by the investigator to generate new stimuli through varying games and thereby also further support the motivation."
75571429|NCT03809442|Drug|Ropivacaine + Tramadol|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
75571430|NCT03809442|Drug|Ropivacaine + Midazolam|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
75571431|NCT03809442|Drug|Ropivacaine + Dexmedetomidine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
75571432|NCT03809442|Drug|Ropivacaine + Dexamethasone|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
75571433|NCT03809442|Drug|Ropivacaine|Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
75571434|NCT02908217|Drug|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
75571435|NCT02908217|Drug|Placebo|6 Intravenous infusions of placebo every 4 weeks.
75571436|NCT00547950|Drug|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid*1year.
75877521|NCT03655314|Other|NEWT|The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
75877522|NCT03655314|Other|Usual care|The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
75877523|NCT03608618|Biological|MCY-M11|Intraperitoneal administration
76047292|NCT01657877|Drug|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
75877524|NCT03608618|Drug|Cyclophosphamide|Intravenous administration for preconditioning
75425248|NCT06076902|Device|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch (Pitch-Patch Tissue Reinforcement Device))|The Pitch-Patch is a single-use device intended to reinforce the rotator cuff following or during repair by sutures or suture anchors where weakness exists in the soft tissue.
75571437|NCT02908373|Other|Implementation of the coaching model|20 hours methodological help for each nursing home and an implementation kit
75571438|NCT00534729|Drug|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
75571439|NCT02908139|Device|BR-102 plus PWA|Monitoring of Arterial Stiffness and Central Aortic Pressure
75877525|NCT03655158|Device|ozone device ( Ozonytron XL )|The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
75877526|NCT03654924|Device|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
75877527|NCT03654846|Device|EmergencyEye|EmergencyEye Smartphone App
75877528|NCT04184648|Other|no interventions|no intervention
76047293|NCT01657877|Drug|Placebo|No CSP and no fluoride
76047294|NCT05254925|Drug|Sunscreen oil with 6% Bemotrizinol|Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
75425249|NCT06076902|Device|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented without a synthetic polyester patch|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch.
75425250|NCT06076889|Behavioral|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the portal for 2 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference.
75425251|NCT06076850|Device|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Active|"Treatment protocol:~EFD 0.096 mJ/mm2~2 sessions / week; 5000 shocks / session~6 weeks treatment~total: 12 sessions~Li-ESWT to start after removal of indwelling catheter"
75425252|NCT06076850|Device|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Sham|"Treatment protocol:~EFD 0 mJ/mm2~2 sessions / week; 5000 shocks / session~6 weeks treatment~total: 12 sessions~Li-ESWT to start after removal of indwelling catheter"
75425253|NCT06076837|Drug|Botensilimab|an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody
75425254|NCT06076837|Drug|Balstilimab|a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2
75425255|NCT06076837|Drug|Chloroquine Phosphate|an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy
75571440|NCT02908139|Device|Tanita MC780 MA S|The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
75571441|NCT00534768|Procedure|active debridement|debridement on 1st, 3-5th and 7th postoperative days
75571442|NCT00534768|Procedure|control group|Postoperative debridement on 7th postoperative day
75571443|NCT00547989|Drug|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
75571444|NCT00547989|Drug|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
75877529|NCT04203290|Drug|Bupivacaine|%0.25 bupivacaine solution
75877530|NCT04203290|Drug|Sevoflurane|End tidal sevoflurane concentration
75877531|NCT02237144|Other|Cash transfer|1500 taka ($18.75) per household distributed monthly
75571445|NCT00547989|Drug|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
75571446|NCT00534807|Drug|Vinflunine|
75571447|NCT00534807|Drug|Rifampin|
75571448|NCT02908022|Device|Electroacupuncture Analgesia|"For the MRI sessions, acupuncture needles will be inserted next to the cuff placed on the left leg and will be connected to electrodes. Low-amplitude electrical current will be activated when a button is pressed via a handheld device, controlled by the acupuncturist, in order to reduce pain, acting as an analgesic.~Additionally, electroacupuncture-induced analgesia will be used for the treatments. During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. Low-amplitude electrical current will be activated by the acupuncturist using the same electroacupuncture device as in the MRI machine."
75571449|NCT02908022|Device|Hokanson Rapid Cuff Inflator|The Hokanson Rapid Cuff Inflator will be placed on the lower right leg of the subject and utilized for pain testing purposes according to the protocol. Ascending pressures will be administered using the cuff to elicit different pain intensities.
75877532|NCT02237144|Other|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
75877533|NCT02237144|Other|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
75877534|NCT02237144|Behavioral|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
76047295|NCT05254925|Other|Sunscreen oil vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
75877535|NCT02981082|Drug|Dimethyl Fumarate (DMF)|Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.
75877536|NCT02981082|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
76047296|NCT05254925|Drug|Dispersion of 6% BEMT in petrolatum|Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
75425256|NCT06076837|Drug|Celecoxib|a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)
75425257|NCT06076824|Drug|Methylprednisolone|The intervention group will recieve 7 mg/kg/day (or a maximum of 500 mg/day) of intravenous Methylprednisolone an hour before TAVR followed by 15 mg / 12h of Prednisone during 5 days after the intervention (starting 24h after the administration of Methylprednisolone).
75425258|NCT06076824|Other|Placebo|Saline solution
75425259|NCT06076772|Drug|Palbociclib|The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors
75425260|NCT06076759|Drug|Intrathecal morphine or dexmedetomidine|Intrathecal injection
75425261|NCT06076746|Behavioral|NIC Psychotherapeutic Intervention(s) for İneffective Coping|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
75425262|NCT06076746|Behavioral|psychotherapeutic intervention|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
75425263|NCT06076720|Device|New head-mounted visual aids|New head-mounted visual aids such as Beyes, HOLA, Acesight and OXSIGHT are the latest wearable electronic visual aids
75425264|NCT06076642|Biological|TAK-881|Participants will receive SC infusion of TAK-881.
75425265|NCT06076629|Other|Low temperature (16#) group|The exposure group will be exposed to low temperature (16#) in a chamber for about 2 hours, resting during the whole periods.
75571450|NCT00534846|Drug|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
75571451|NCT00534846|Drug|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
75571452|NCT00548067|Drug|Valsartan/hydrochlorothiazide (HCTZ)|
75571453|NCT00548067|Drug|Valsartan/amlodipine|
75724129|NCT00887406|Drug|Placebo RD|repeat dose via nebuliser
76047297|NCT05254925|Other|Petrolatum vehicle|Petrolatum vehicle
76047298|NCT05205941|Drug|MMV688533|Not exceeding 200mg
75425266|NCT06076629|Other|Moderate temperature (22#) group|The exposure group will be exposed to thermoneutral temperature (22#) in a chamber for about 2 hours, resting during the whole periods.
75425267|NCT06076616|Behavioral|Prehabilitation and rehabilitation|A personalized lifestyle counseling programme.
75877537|NCT02237222|Other|Gait rehabilitation|
75425268|NCT06076603|Drug|nebulized polymyxin B|The experimental group received intravenous combined nebulization of polymyxin B
75425269|NCT06076590|Drug|maintenance fluid|Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.
75425270|NCT06076577|Behavioral|Prehabilitation Exercise Group|A set of core stabilization exercises and scoliosis specific exercises will be given to patients.
75425271|NCT06074380|Drug|MIST surfactant|Surfactant will be given via MIST while neonate is on CPAP
75425272|NCT06074367|Drug|Vitamin C 500 MG Oral Capsule(High dose 2g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins & vitamin C 500 mg (2 g-daily in 4 divided doses) started one day before operation till the end of hospital stay or development of post operative atrial fibrillation
75571454|NCT00548067|Drug|Amlodipine/hydrochlorothiazide(HCTZ)|
75571455|NCT00548067|Drug|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
75591966|NCT06078826|Other|foot massage|Massage will be applied by the researcher in the research. Towel, sponge, etc. under the foot to be worked on. The foot will be held at a 45 degree angle While applying, 1-2 drops of liquid Vaseline will be used to moisten the hand. A total of 30 minutes of foot massage will be made for each individual, 15 minutes per foot. Foot massage will start 30 minutes before the start of aspiration and massage will continue throughout the aspiration period. Since the speed of the massage movements and the number of repetitions should be at the normal frequency, the massage will be done at a speed that does not disturb the individual, has a non-stimulating and calming effect and does not tire the practitioner. In the massage, efflorescence (stroking), petrissage and friction (circular rubbing) movements that support circulation and relax the tissues will be used. Evaluations will be made before the foot massage, at the end of the foot massage and 30 minutes after the foot massage.
75877538|NCT02034266|Dietary Supplement|Omega-3 supplementation|5 mL twice daily, administered under the tongue
75571456|NCT02907827|Other|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
75571457|NCT00534885|Biological|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
75724130|NCT04397406|Drug|levobupivacaine|The patients will receive 15 ml of 0.125% levobupivacaine.
75724131|NCT04397406|Drug|Dexmedetomidine|The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.
75571458|NCT00534885|Biological|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
75724132|NCT04397406|Drug|Fentanyl|The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
75571459|NCT00534885|Biological|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
75571460|NCT00534885|Biological|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
75724133|NCT02542332|Other|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
75877539|NCT03654612|Drug|Apatinib|Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
75571461|NCT02907671|Procedure|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
75571462|NCT00548106|Dietary Supplement|partially hydrolyzed whey|Total infant feeding by study formula.
75724134|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.5%
75724135|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.2%
75724136|NCT00891540|Drug|placebo|Isotonic NaCl
75425273|NCT06074367|Drug|Vitamin C 500 MG Oral Capsule(Low-dose 1g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins, vitamin C 500 mg (1 g-daily in 2 divided doses) and also received 2 capsules containing starch to be completely equivalent in frequency to the other groups. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
75724137|NCT00887718|Biological|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
75571463|NCT00548106|Dietary Supplement|Nan HA|Total infant diet by study formula.
75571464|NCT02907749|Drug|Spironolactone and carvedilol|Patients are treated with carvedilol in combination with spironolactone.
76047299|NCT05205473|Procedure|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
76047300|NCT05205473|Procedure|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
75571465|NCT02907749|Drug|Carvedilol|Patients are treated with carvedilol only.
75571466|NCT00534924|Drug|Vit C|
75571467|NCT00534924|Procedure|Postconditioning|
75571468|NCT00534924|Other|no intervention|
75724138|NCT00573144|Drug|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
75724139|NCT00573144|Drug|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator)
75724140|NCT00891696|Drug|Rapamycin|Single 16-mg oral dose
75877540|NCT03654534|Dietary Supplement|NutrenOpimum|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
75425274|NCT06074367|Drug|placebo capsules|A sixty CABG Patients commenced on maximum tolerated dose of b-blocker, statins and placebo capsules containing starch mimic vitamin C capsules was taken every 6 hrs. The placebo capsules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
75571469|NCT00548223|Drug|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid*1year
75571470|NCT00548223|Drug|placebo|Capsule, 0.18g, 2#, Bid*1year
75571471|NCT02907593|Drug|Budesonide in Calfactant|Budesonide in Calfactant
75571472|NCT00548301|Drug|cyclosporine|
75571473|NCT02907710|Drug|Endostar|intravenous infusion
75571474|NCT02907710|Drug|DDP|
75724141|NCT00891696|Other|Amino acid supplementation|Nutritional drink containing essential amino acids
75724142|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
75724143|NCT00891696|Drug|Sodium nitroprusside|Variable rate for 3 hours
75724144|NCT00891696|Device|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
75724145|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
75724146|NCT00640328|Drug|Ofatumumab 100|100mg
75724147|NCT00640328|Drug|Ofatumumab 300|300mg
75724148|NCT00640328|Drug|Ofatumumab 700|700mg
75724149|NCT00640328|Drug|Placebo|matching placebo
75724150|NCT00163189|Drug|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
75877541|NCT01066104|Drug|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
75571475|NCT03781362|Drug|CPI-100|CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
75425275|NCT06074354|Behavioral|Attention-control group|Participants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm. They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites. Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
75425276|NCT06074354|Behavioral|MY-RIDE group|MY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
75877542|NCT01066104|Drug|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
75877543|NCT02736968|Drug|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules
75425277|NCT06074341|Behavioral|Mindfulness-based relapse prevention|"Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness."
75425278|NCT06074341|Behavioral|Online Mutual Support Groups|Mutual support groups are free, peer-led organizations that are designed to help individuals with substance use disorders and other addiction-related problems. Mutual support groups often focus on communication and exchange of addiction and recovery experience and skills. Individuals participate in activities that engage, educate, and support patients recovering from substance use disorder from others facing similar challenges. Mutual help organizations that will be offered as referrals include: Alcoholics Anonymous (AA), In The Rooms, and SMART Recovery.
75425279|NCT06074328|Device|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset as a form of neurorehabilitation in patients who suffer a traumatic brain injury.
75425280|NCT06074276|Other|Food: whole almonds|60 grams or (~2 oz) will be consumed 5 times per week.
75425281|NCT06074276|Other|Food: non-nut snack|Protein and calorie matched non-nut-based food will be consumed 5 times per week by mouth
75425282|NCT06074250|Dietary Supplement|Fish oil|1500mg EPA +1000mg DHA daily
75425283|NCT06074250|Dietary Supplement|Probiotics|Combination strain of lactobacillus and bifidobacteria
75877544|NCT02736968|Other|Placebo|Placebo
75425284|NCT06074250|Behavioral|Prebiotics|Dietary consult with follow-up to ensure target fiber intake is met.
75571476|NCT03781362|Drug|Capecitabine|Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period
75571477|NCT02907515|Device|cm-loc attachment|cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
75571478|NCT02907515|Device|ball attachment|ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
75571479|NCT03767907|Behavioral|Computer-based Training for Cognitive Behavioural Therapy|Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
75571480|NCT03767907|Behavioral|Treatment As Usual|Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
75571481|NCT04682249|Drug|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
75571482|NCT04682249|Drug|Sintilimab|Sintilimab
75877545|NCT02980224|Drug|OmegaD|OmegaD Softgels
75877546|NCT02980224|Drug|Placebo|Placebo Softgels
75877547|NCT03653910|Device|Airtraq|Airtraq is a kind of videolaryngoscope for intubation
75877548|NCT03653910|Device|Macintosh|Macintosh is a traditional laryngoscope for intubation
75877549|NCT03608306|Other|Resin-modified glass ionomer|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
75571483|NCT04682249|Drug|Apatinib|Apatinib
75571484|NCT00548379|Drug|vitamin D|vitamin D 100,000 units once in 3 months
75571485|NCT00548379|Drug|placebo|olive oil 1ml
75425285|NCT06074250|Behavioral|Diet Quality|one time dietary consult at enrollment to discuss strategies to improve overall diet.
75425286|NCT06074224|Other|Sleep assessment score|The patients in the intervention group will include those for whom their clinician was given their sleep questionnaire result before the visit.
75425287|NCT06074224|Other|No Score|The patients in the control group will include those for whom their clinician was not given their sleep questionnaire result before the visit.
75425288|NCT06074185|Drug|Ipratropium Bromide|The study intervention involves implementing a treatment bundle that includes inhaled ipratropium bromide and dexamethasone.
75425289|NCT06074172|Drug|Cannabidiol in Oral Dose Form|Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado). CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO. Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.
75425290|NCT06074172|Drug|Placebo in Oral Dose Form|Placebo press pills provided by Steve Goods CBD (Longmont, Colorado). Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO. Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
75425291|NCT06074159|Behavioral|In-clinic report-back|Investigators measure whether report-back from a clinician improves environmental health literacy, including leading to greater shifts in exposure-reducing health behaviors
75425292|NCT06074107|Drug|BEBT-908 for injection|The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
75425293|NCT06074094|Drug|Control Test|Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
75425294|NCT06074081|Other|motor relearning program|MRP is a therapy to regain particular motor function and neglecting accessory movements by engaging cognitive behavior .
75425295|NCT06074081|Other|mirror therapy|Mirror therapy enhance functional activities in patient with hemiplegic stroke. For betterment of result high quality methodological studies and larger sample size is required.
75425296|NCT06074042|Other|previous pulmonary tuberculosis|Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.
75425297|NCT06074029|Drug|Immune Checkpoint Inhibitors|Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab
75571486|NCT04682054|Procedure|ocular surgery|surgery to remove the pathological eye tissue
75571487|NCT04972617|Diagnostic Test|albumin function analysis (ABIC)|After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.
75571488|NCT04682210|Drug|Sintilimab|Sintilimab 200mg IV Q3W
75571489|NCT04682210|Drug|Bevacizumab|Bevacizumab 7.5mg/kg IV Q3W
75571490|NCT04682015|Other|WeChat platform group|Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment and side effects of antihypertensive drugs. Participants will be reminded to take their blood pressure regularly and enter the blood pressure readings into the WeChat platform. If participants enter extremely high or low readings, they will be asked to seek medical help from doctors. Participants can also consult doctors online via WeChat platform by text and voice messages, or voice calls.
75724151|NCT04036890|Drug|2% minocycline hydrochloride controlled-delivery system (MHS)|The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
75724152|NCT04036890|Drug|Placebos|It is the same gel as MHS but without active ingredient minocycline hydrochloride.
75724153|NCT00887874|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
75425298|NCT06073990|Behavioral|Brief Behavioral Treatment for Insomnia (BBTi)|The intervention consists of four weeks of BBTi. During the first week, participants will receive face-to-face sleep assessments and sleep hygiene education. In the second week, a phone interview will be conducted to assess the patient's progress and provide appropriate relaxation techniques. Unsatisfactory responses to sleep restriction therapy or stimulation control methods will be addressed through face-to-face interviews in the third week. The fourth week will involve an overall review and evaluation conducted via a telephone interview.
75425299|NCT06073964|Behavioral|Trauma Resilience & Understanding Self-help Therapy|A self-help psychosocial therapeutic intervention requiring one to undergo a basic training in its community-based utilization.
75425300|NCT06073925|Drug|VIT D|50000 IU per week of VIT D
75425301|NCT06073912|Procedure|Open sinus lifting|Sinus lateral window to graft the floor of the sinus using sinus red diamond stone
75425302|NCT06073912|Procedure|Collecting blood sample|Blood sample is collected to harvest PRP and PRF
75571491|NCT03664089|Behavioral|Ankle weights (2.5 pounds [1.1 kg]/ankle)|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
75571492|NCT03664089|Behavioral|Control|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
75571493|NCT04682132|Diagnostic Test|COVID-19 antigen and antibody tests, and influenza rapid test|Study volunteers will be offered free COVID-19 and influenza testing and the opportunity to complete an electronic survey about any symptoms.
75571494|NCT00548496|Drug|SB-751689|SB-751689
75571495|NCT00548496|Other|Placebo|Placebo to match
75571496|NCT03661905|Other|Cognitive therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
75571497|NCT03661905|Behavioral|Exposure and Response Prevention|Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
75571498|NCT02907476|Behavioral|Iyengar Yoga|
75571499|NCT02907476|Behavioral|Walking|
75571500|NCT04971876|Device|HLR-1|Initial injection of HLR-1 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL.
75571501|NCT04971876|Device|HLR-2|Initial injection of HLR-2 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL per NLF.
75425303|NCT06073912|Procedure|Bone graft harvesting|Bone graft harvesting from the chin area
75425304|NCT06073912|Procedure|Autogenous corticocancellous block graft|Simultaneous implant placement with sinus lifting and grafting using autogenous corticocancellous block, stabilized inside the sinus using clamp or screws that will be removed before closure
75425305|NCT06073912|Procedure|Mineralized plasmatic matrix graft|Simultaneous implant placement with sinus lifting and grafting using mineralized plasmatic matrix that is formed using PRP of the patient mixed with particulate autogenous graft from the chin area
75425306|NCT06073912|Device|Centrifuge|Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups
75425307|NCT06073912|Device|ACM bur|Auto Chip Maker will be used to collect the autogenous particulate bone graft for the sticky bone graft
75425308|NCT06073873|Drug|Ozanimod|According to local product label
75425309|NCT06073860|Drug|Luspatercept|According to the approved label
75571502|NCT04971876|Device|HLR-3|Initial injection of HLR-3 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 4mL per cheek.
75571503|NCT02907554|Drug|cyclosporine A|the intervention group receives 2.5 mg/kg of cyclosporine
75571504|NCT02907554|Drug|Placebo|control group receives a placebo
75571505|NCT03657303|Device|Magnetic resonance imaging (MRI)|Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
75571506|NCT02907632|Drug|Metoclopramide|"Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.~Duration: Until the child completes 40 weeks of post menstrual age."
75571507|NCT02907632|Drug|Placebo|Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
75571508|NCT02907437|Drug|Minocycline|Minocycline as an add-on drug (200 mg/day)
75571509|NCT02907437|Drug|Placebo|(200 mg/day)
75877550|NCT03608306|Other|Bulk-fill glass hybrid restorative|It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
75877551|NCT03654144|Drug|Dienogest|oral tablets
75425310|NCT06073847|Drug|Fedratinib|According to the approved label
75425311|NCT06073808|Device|AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft|Dehydrated human amnion/chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management of chronic wounds. These commercially available allografts contain concentrated cytokines and growth factors known to promote wound healing. Preclinical studies suggest that dHACM allografts provide a complex, biologically-driven mechanism to promote soft tissue repair and regeneration, including stimulation of mesenchymal stem cell migration and dermal fibroblast proliferation, establishment of a supportive inflammatory environment, and restoration of extracellular matrix integrity with positive tissue architecture remodeling. Clinically, dHACM allografts have been shown to improve healing time and wound closure rates in chronic wound patients. However, no study to date has evaluated the impact of dHACM allografts on nipple necrosis following NSM.
75425312|NCT06073808|Device|Control Device|Control device will be applied to non-experimental breast. Each patient will serve as their own control.
75425313|NCT06073795|Procedure|sympathetic block|LSGBs will be performed at the lower third of the L2 or the upper third of the L3 vertebra without any premedication. The targeted lumbar vertebra will be identified with an anteroposterior (AP) fluoroscopic imaging in the FL group or with an US longitudinal tracing approach from the caudad to cephalad direction in the US group. The skin entry point will be infiltrated with 1% lidocaine. Then, a curved 21 G, 15-cm Chiba needle will be advanced toward the target using the posterolateral approach in both groups. Each patient will undergo LSGBs according to the allocated group.
75571510|NCT02907437|Other|Probiotics|(450 mg/day)
75571511|NCT00548535|Procedure|Reliability of complication assessment|
75877552|NCT03654144|Drug|Combined Oral Contraceptive|oral tablets
75877553|NCT03654456|Biological|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
75877554|NCT02591615|Drug|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
75877555|NCT02591615|Drug|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
75425316|NCT06073769|Drug|Oral azacitidine|Maintenance therapy according to the approved label
75571512|NCT02907047|Other|tourniquet inflated|
75571513|NCT02907047|Other|tourniquet not inflated|
75877556|NCT02591615|Drug|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
75877557|NCT02591615|Drug|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
75877558|NCT03077607|Drug|Talazoparib|Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
75877559|NCT03077607|Drug|Itraconazole|100 mg oral dose
75877560|NCT03077607|Drug|Rifampin|600 mg oral dose
75877561|NCT03608462|Device|repetitive transcranial magnetic stimulation(DLPFC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
75877562|NCT03608462|Device|repetitive transcranial magnetic stimulation(LPC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
75877563|NCT04215588|Device|Hemostasis Management System Plus|Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.
75425317|NCT06073756|Radiation|Echocardiogram|Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
75425318|NCT06073730|Procedure|Experimental: Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time >2h) Sorafenib 600mg/d, d8-14 (FLT3/ITD mutation positive patients)
75571514|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
75877564|NCT04215588|Device|Activated Coagulation Timer System Plus|The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.
76047301|NCT05160935|Behavioral|Education|"Each patient will be informed about the study, and written consent will be obtained from patients who agree to participate in the study, explaining the purpose and duration of the study. A Patient Identification Form will be filled, the patient's vital signs will be evaluated, and the State-Trait Anxiety Inventory will be administered to the patient.~Before the coronary angiography procedure, the patients in the experimental group will be trained by the researchers using the training booklet. Trait Anxiety Inventory will be re-administered to the patients after the procedure. Vital signs of patients will be monitored.~In the control group; In line with the information in the patient consent form before the coronary angiography procedure, verbal information will be given about the coronary angiography procedure within the scope of the routine procedure in the clinic. After the procedure, the State-Trait Anxiety Inventory will be applied again. Vital signs will be taken."
76047302|NCT04422197|Biological|Botox|effect of botox injection in abdominal wall muscle post major abdominal surgery in terms of postoperative pain, incidence of incisional hernia.
76047303|NCT04422197|Procedure|surgery without botox injection|surgery without botox injection
76047304|NCT05204303|Diagnostic Test|24-hour pH-impedance monitoring|Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.
76047305|NCT05204303|Other|Symptom questionnaires|Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)
75425319|NCT06073730|Procedure|Active Comparator: Standard dose of Venetoclax + Azacitidine|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-28 Azacitidine (AZA) 75mg/m2/d, d3-9
75571515|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
75571516|NCT01262872|Biological|Synflorix™|Intramuscular injection
76047306|NCT05204303|Other|ROME IV Diagnostic Questionnaire|A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)
76047307|NCT05203367|Drug|BAR502|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."
76047308|NCT05203367|Drug|Placebo|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
76047309|NCT05203289|Drug|BI 695501 - higher concentration|BI 695501 - higher concentration
75571517|NCT01262872|Biological|Prevnar13™|Intramuscular injection
75571518|NCT01262872|Biological|Tritanrix™-HepB/Hib|Intramuscular injection
75571519|NCT01262872|Biological|Polio Sabin™|Orally
75571520|NCT01262872|Biological|M-Vac™|Intramuscular injection
75571521|NCT01262872|Biological|Stamaril™|Intramuscular injection
75571522|NCT03622320|Other|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
75571523|NCT00534963|Procedure|cervical vs. uterine placement of balloon catheter|
75877565|NCT03608228|Other|Measuring electrical signals from the brain|If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
76047310|NCT05203289|Drug|BI 695501 - lower concentration|BI 695501 - lower concentration
76047311|NCT05370755|Drug|ICP-189|Administered orally
76047312|NCT02175771|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
75571524|NCT02907125|Behavioral|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
75571525|NCT02907125|Behavioral|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
75425320|NCT06073717|Behavioral|Exercise|Participants will complete a 5-month exercise program structured in 4 blocks of 5 weeks. Three supervised and combined aerobic/strength exercise sessions each week will be performed together with an aerobic weekly challenge. Aerobic exercise will be performed for 20-30 minutes using a treadmill, bicycle, or circuit training at light to moderate intensities (40-75% of heart rate reserve) during the first two blocks; gradually achieving high intensity (>75% of HHR) in the last two blocks. Heart rate and the subjective perception of the exertion scale (6-20 Borg scale) will be monitored. Strength exercises will be started at light to moderate intensities (2 sets of 15-20 repetitions at 40-50% of repetition maximum), performed muscle actions at high intensities in the last two blocks (2 sets of 8-15 repetitions at 50-75% RM); using elastic bands, free weights, and weights gym exercises.
75571526|NCT02907125|Behavioral|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
76047313|NCT02175771|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
76047314|NCT02175771|Drug|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
75724154|NCT00887952|Procedure|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
76047315|NCT02175771|Drug|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
75425321|NCT06073717|Behavioral|Dual-Task Training|Participants will complete the same four-block exercise program in terms of type, frequency, intensity, and volume of physical/motor training. Simultaneous with the progression of physical/motor training, the complexity of cognitive stimulation will be increased according to the performance of the participants. General dual-task training will be performed, which describes the use of a physical/motor intervention with different cognitive stimulations (memory, language, intelligence, attention, processing speed, calculation, inhibitory control) that are not specific to the methods to be used for their assessment.
75571527|NCT02907320|Drug|CYCLO 3 ® FORT|
75571528|NCT02907320|Drug|MPFF|
75571529|NCT02907320|Drug|placebo CYCLO 3 ® FORT|
75571530|NCT02907320|Drug|placebo MPFF|
75571531|NCT02907164|Behavioral|Email invitation|Receive emails encouraging them to sign up
75571532|NCT02907164|Behavioral|Social norm|Receive information about how many people have signed up
75571533|NCT02907164|Behavioral|Intrinsic, health motive|Receive information about how the challenge helps people to stay fit in a fun way
75571534|NCT02907164|Behavioral|Extrinsic, reward motive|Receive information about how the challenge helps people to stay active and earn rewards
75877566|NCT03622086|Other|Foundations of Fitness Program|The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight & Wellness Center research core.
75877567|NCT02977572|Device|Non-Invasive Ventilation|In arm description
75877568|NCT02977572|Device|Continuous Positive AirwayPressure CPAP|In arm description
76047316|NCT02175771|Drug|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
75571535|NCT04323085|Behavioral|Speech-in-Noise Treatment Program|Speech therapy program for hypophonia.
75571536|NCT04323085|Behavioral|Speech-to-Noise Feedback Device Program|Speech Feedback device program for hypophonia.
75724155|NCT00887952|Procedure|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
75724156|NCT02550860|Drug|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
75724157|NCT02550860|Drug|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
75724158|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
75724159|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
75425322|NCT06073717|Behavioral|Health and Wellness|Participants randomly assigned to the health and wellness group will be advised and re-educated to support and improve health aspects. Participants in this group will aim to achieve the physical activity recommendations, and in addition, they will receive bi-weekly emails and phone call coaching with tools to empower patients with knowledge about physical exercise, nutrition, and brain health guidelines. Following completion of the 5-month exercise program, this group will receive an exercise program for 12 weeks.
75724160|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
75877569|NCT02746874|Procedure|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
76047317|NCT01657799|Drug|Veliparib|Veliparib capsules for oral administration
75425323|NCT06073691|Behavioral|Exercise intervention|Practice systematic and regular aerobic physical exercise (walking and running).
75425324|NCT06073691|Other|Placebo|Placebo
75425325|NCT06073678|Other|Photobiomodulation|Irradiation with red laser on palate wound each 48h for 4 sessions.
75425326|NCT06073678|Other|Protection with surgical dressing|Protection of the palatal wound with surgical dressing for 7 days
75425327|NCT06073652|Other|Control 1st age starter infant formula|A standard bovine milk-based term infant formula.
75425328|NCT06073652|Other|Experimental1st age starter infant formula|Same content as Control formula plus supplemented 7 HMOs, MOS and B. infantis.
75425329|NCT06073639|Procedure|Autogenous dentin graft|Dentin graft is made from the participant extracted tooth by using Kometa Smart Dentin Grinder
76047318|NCT01657799|Drug|Placebo|Placebo to veliparib capsules for oral administration
75425330|NCT06073613|Diagnostic Test|oral health status|"CSDs medical records: Information related to epidemiological characteristics and chronic inflammatory skin conditions (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,…) were recorded from medical records:~Pemphigus~Mixed connective tissue disease~Atopic dermatitis~Psoriasis~Erythroderma~oral health status: oral clinical parameters were evaluated:~Full mouth bleeding on probing scores~Pocket probing depth~Clinical attachment level~debris index~calculus index~the number of oral lesions"
75425331|NCT06073587|Diagnostic Test|Scintigraphy scan|Scans will be performed as specified in the arm description.
75571537|NCT05519488|Behavioral|Rubato Life Music|Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
76047319|NCT01657799|Radiation|Whole brain radiation therapy|30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays
75425332|NCT06073574|Diagnostic Test|Cardiac MRI|MRI Scans as specified in the corresponding arm group.
76047320|NCT05249777|Drug|TD0069 hard capsule|TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
75425333|NCT06073548|Other|Questionnaires and interviews|Patients wiill be asked to fulfill questionnaires at inclusion and 6 months after. An interview will be offered to a sub-sample of patients (approximately 20 patients).
76047321|NCT05249777|Drug|TD0069 Placebo|TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
76047322|NCT02116803|Drug|dovitinib|Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
76047323|NCT02116803|Drug|fulvestrant|Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
76047324|NCT05201027|Device|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
75425335|NCT06073483|Device|Toumai Endoscopic surgery System|5G remote gastrectomy on subjects using the Toumai endoscopic surgery system
75425336|NCT06073392|Other|Educational video|Educational video in animation mode
75425337|NCT06073353|Behavioral|THRIVE-M|"THRIVE-M is a self-administered psychosocial mobile application for patients living with multiple myeloma that includes the following five modules:~Health module - teaching patients about physical symptoms and strategies to cope with physical symptoms~Relationships module - helping patients articulate different support needs and communication styles in navigating relationships~emotions module - helping patients identify connections between thoughts, feelings, and behaviors, as well as helpful states of mind and gratitude~Lifestyle module - helping patients practice skills for saving up energy and using self-care strategies~Reflection module - teaching patients to reflect on their lives, meaningful relationships, and sense of purpose.~Each module takes about 15-20 minutes to complete and participants will be instructed to complete all modules within an eight-week period."
75425338|NCT06073327|Dietary Supplement|dark chocolate|30g of dark or white chocolate was provided by the nutritionist for 30 days
75425339|NCT06073327|Dietary Supplement|White chocolate|30g of white chocolate was provided by the nutritionist for 30 days
75425340|NCT06073288|Other|Surgical specimens of CD and no-IBD patients|Specimens of CD patients and patients without IBD-related disease (ex. diverticulitis) will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
75724161|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
75724162|NCT02550782|Drug|Bupivacaine|patient- controlled infraclavicular perineural marcaine infusion
75724163|NCT02550782|Drug|Dexmedetomidine|patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
75877570|NCT02746874|Procedure|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
76047325|NCT05156411|Other|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied
76047326|NCT02115321|Drug|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
76047327|NCT02115321|Drug|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
76047328|NCT02115321|Drug|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
76047329|NCT05248841|Drug|HEC-Glargine|Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
75425341|NCT06073236|Behavioral|The healthy day-project|The content of the intervention will be based on what comes out of the cocreation sessions, which means that it is not yet possible to know what the intervention will exactly consist of. The idea is to compile two co-creation groups, both consisting of preschool teachers and preschoolers' parents. Within both co-creation groups, feasible and easy-to-use strategies to implement both at preschool and at home embedded within preschoolers' play-based learning will be the goal. Both co-creation groups will investigate and develop ways to incorporate play-based learning within health promotion throughout the day at home and at preschool.
75425342|NCT06073197|Procedure|erector spinae plane block|Erector spinae plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block. Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
75571538|NCT05519488|Behavioral|Music of their desire|patients will be asked to listen to a minimum of 45 minutes per day of music (or a total of 12 hours), of their desire, which the participant considers as stress relief music for a period of a 2 weeks (or a total of 12 hours)
75571539|NCT02907281|Other|Observational|Observational
75571540|NCT04323241|Other|Controlled cord traction|In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
75571541|NCT02899637|Device|Active high-frequency Transcranial Magnetic Stimulation|Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week
76047330|NCT05248841|Drug|US-Lantus|Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
75571542|NCT02899637|Device|Sham high-frequency Transcranial Magnetic Stimulation|Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
76047331|NCT05248139|Drug|Intraoperative delivery of medication, Kenalog (Triamcinolone)|Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
75571543|NCT03574623|Device|Electrical Stimulator|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).
75571544|NCT03574623|Behavioral|Occupational Therapy|Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
75571545|NCT02899676|Other|neuropsychological testing|
75571546|NCT02899676|Other|functional magnetic resonance imaging|
75571547|NCT02899676|Other|simple arithmetic operations|
75877571|NCT01377129|Procedure|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
75877572|NCT01377129|Procedure|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
75877573|NCT02558075|Behavioral|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
76047332|NCT05248139|Drug|Topical post-operative eyedrops, Prednisolone acetate|Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
76047333|NCT04230239|Drug|CPX-351|"CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine"
75425343|NCT06073197|Procedure|combined deep and superficial serratus anterior plane block|Combined deep and superficial serratus anterior plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
75425344|NCT06073171|Biological|Blood sample|7.5 mL will be sampled on EDTA tube for each patient
75425345|NCT06073171|Biological|Cutaneous biopsy|4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients
75425346|NCT06073171|Genetic|High troughput sequencing of human's exome|Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
75425347|NCT06073145|Device|conventional transcranial Doppler probe and wearable ultrasound patch.|Comparison of the measurements from conventional transcranial Doppler probe and wearable ultrasound patch.
75571548|NCT00548574|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
75571549|NCT00548574|Drug|Mesalazine|
75571550|NCT02899559|Behavioral|Message|Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
75571551|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
75571552|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
75571553|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
75877574|NCT01377051|Drug|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
75877575|NCT01377051|Drug|Placebo|Dry powered, same to study drug, only one inhalation
76047334|NCT05199389|Device|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
75571554|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
75571555|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
75724164|NCT04037982|Procedure|laparoscopic pancreaticoduodenectomy|During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
75425348|NCT06073132|Drug|AC-203|The investigational product is formulated as 1% topical ointment
75425349|NCT06073132|Drug|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
75425350|NCT06073080|Other|Protein Nutrition During Recovery|Dietary Protein Nutrition Distribution
75724165|NCT04037982|Procedure|Open pancreaticoduodenectomy|During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
75724166|NCT00888030|Other|there are no interventions currently listed for this study|
75425351|NCT06073028|Other|20-minute gait training|All subjects undergo two 20-minute gait trainings using two different kinds of auditory cueing (temporal or spatial), one week apart (D1 and D8).
75425352|NCT06073015|Drug|Esketamine|Group S received a subanesthetic dose of esketamine 0.2mg/kg (2ml/50 mg) 5 minutes before the procedure began.
75425353|NCT06072989|Biological|B4T2-001 autologous CAR-T|Each subject will receive multiple intravenous infusions of B4T2-001 autologous CAR-T without preparative chemotherapy (lymphodepletion)
75425354|NCT06072976|Dietary Supplement|Standard of Care|Standard of care arm: Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age.
75425355|NCT06072976|Dietary Supplement|Exclusive Human Milk|Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
75425356|NCT06072963|Drug|Semaglutide|The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
75571556|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
75571557|NCT01262677|Drug|placebo|matched to the active drug
75591967|NCT06078800|Drug|YL-17231|After a screening period of approximately 14 days, eligible patients will receive oral YL-17231 once or twice daily until documented disease progression, unacceptable AEs, intercurrent illness preventing further administrations of study treatment, investigator's decision to withdrawal, the patient's consent of withdrawal, pregnancy, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient's consent of withdrawal, lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
75571558|NCT02899442|Other|collective prevention in workplace|From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
76047335|NCT05247125|Combination Product|Blue light exposure + Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
76047336|NCT05247125|Drug|Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed.
76047337|NCT05247125|Device|Blue light exposure|Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
75425357|NCT06072963|Drug|Intranasal insulin|The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
75425358|NCT06072963|Other|Semaglutide placebo|Rybelsus semaglutide - this medicine will simulate taking the pill Rybelsus /semaglutide once a day. A pill identical to the medicine pill will be given.
75425359|NCT06072963|Other|Intranasal insulin placebo|The placebo used in this study is saline. The investigators will administer saline, with exactly the same methods as the INI insulin (twice per day, 20 seconds each sniff, in each nostril.
75425360|NCT06072950|Other|Usual care|Patients received usual care
75571559|NCT00535041|Drug|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
75571560|NCT02899364|Drug|Sodium thiosulfate|see description under experimental arm
75877576|NCT03217175|Device|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
76047338|NCT05247125|Combination Product|Placebo|Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening
75425361|NCT06072937|Device|IntelliStent|Staged implantation of IntelliStent. The system comprises a nitinol self-expanding stent with a hollow element delivered over-the-wire into the main pulmonary artery or its left and right branches, using an 18 Fr transfemoral introducer sheath. The stent consists of two sections, one with a larger diameter and one with a smaller diameter, available in 6 sizes suitable for vessel sizes ranging from 20mm to 30 mm. Additional smaller sizes are currently under development.
75571561|NCT02899364|Drug|Sodium chloride 0.9%|see description under placebo comparator arm
75571562|NCT02899364|Procedure|primary percutaneous coronary intervention|Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
75591968|NCT06078787|Drug|Olaparib 150 MG|Olaparib should be dosed 2 x 150 mg tablets (300 BID)
75591969|NCT06078761|Behavioral|Healthy Eating Active Lifestyle (HEAL) Program|Evidence-based lifestyle medicine program for cancer survivors
75591970|NCT06078735|Device|Vascular closure with LockeT device|For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.
75877577|NCT03217175|Device|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
75877578|NCT03217175|Drug|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
75591971|NCT06078696|Drug|Siplizumab|Premedication with diphenhydramine 50 mg PO is to be given 1 hour prior to siplizumab infusion. Premedication with hydrocortisone succinate 100 mg IV infused over 30 minutes and acetaminophen 650 mg PO are to be given at least 30 minutes prior to siplizumab infusion. Siplizumab 4.8 mg/kg total is given on Day -14 and 0.6mg/kg is given on days -6, -1, 0, and +1. It will be given as an IV infusion over 1 hour.
76047339|NCT05154851|Biological|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
76047340|NCT05154383|Biological|Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)|Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.
76047341|NCT05154383|Biological|Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine|Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.
76047342|NCT05245877|Drug|enoxaparin/tinzaparin/dalteparin|Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
76047343|NCT05194475|Other|Thermogenic Ready-to-drink Beverage|Thermogenic ready-to-drink beverage, which will be ingested by the participant.
76047344|NCT05194475|Other|Placebo Ready-to-drink Beverage|Placebo ready-to-drink beverage, which will be ingested by the participant.
76047345|NCT05245175|Other|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
75571563|NCT02899364|Other|cardiac magnetic resonance imaging|CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
75571564|NCT00548613|Biological|MESENDO|Intracoronary transplantation of autologous stem cells via balloon catheter
76047346|NCT05245175|Other|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
76047347|NCT05245175|Other|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
75425362|NCT06072924|Behavioral|Isotonic Endurance Exercise|Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day
75571565|NCT00548613|Biological|MESENDO|Intracardiac transplantation of autologous stem cells via direct injection
75571566|NCT04206865|Drug|Sacubitril-Valsartan|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion
75571567|NCT04206865|Drug|Standard Oral Vasodilators|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
75877579|NCT03217175|Drug|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
75877580|NCT01379079|Drug|Acetylsalicylic acid|aspirin intake at bedtime
75877581|NCT01379079|Drug|Acetylsalicylic acid lysinate|aspirin intake on awakening
75877582|NCT02034968|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
75877583|NCT03652506|Device|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
75877584|NCT03652506|Procedure|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
75877585|NCT03652506|Procedure|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
75877586|NCT03607760|Device|ECMO|the patients with severe respiratory failure were supported by ECMO
75425363|NCT06072924|Behavioral|Sham Exercise|Pressing tongue against pressure sensor at a low threshold (1-5kPa) 30x/day
75425364|NCT06072898|Drug|Psilocybin|Psilocybin ([3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate), 25mg PO.
75425365|NCT06072898|Drug|Niacin|Niacin (Vitamin B3; nicotinic acid), 100mg PO.
75425366|NCT06072872|Device|Use of portable CPAP|Patients use portable CPAP during exercise
75425367|NCT06072859|Other|Humidified Forest Oils|60mls Limonene in 200mls water humidified with a diffuser.
75571568|NCT02899247|Procedure|Surface sealant|"Device:~Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA)."
75571569|NCT02899247|Procedure|No surface sealant|"Device:~Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA)."
75571570|NCT00535080|Drug|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
75571571|NCT02899403|Other|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
76047348|NCT05245175|Other|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
75877587|NCT03607760|Device|conventional mechanical ventilation|the patients with severe respiratory failure were supported by conventional mechanical ventilation
75425368|NCT06072859|Other|Virtual Reality using Surface Pro and headphones|Surface Pro has a looped visual that can be manipulated by the participant to simulate walking on a forest path or through a forest visual. This is paired with headphones to experience ambient forest sounds.
75425369|NCT06072846|Behavioral|Reiki Energy Therapy|Reiki Therapy will be applied to the intervention group
75425370|NCT06072820|Device|Salivary Sampling|"Inclusion visit: After signature of the informed consent, all subjects will perform 3 consecutive Endotest® Diagnostic during the visit and 1 at-home.~Circadian circle visit: 6 included subjects will be asked to come back for a full day. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit.~Repeatability-intermediate fidelity-stability-interferences visit: a maximum of 16 included subjects will be asked to come back for this visit. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit."
75425371|NCT06072729|Other|comparison of magnesium sulphate versus cold compression|This study will involve a total of 70 participants who will be divided into two groups. One group will receive magnesium sulphate, while the other group will receive cold compression. The severity of phlebitis will be assessed in both groups using a visual phlebitis (VIP) rating scale.
75425372|NCT06072716|Drug|Chitosan|chitosan loaded with miconazole nanoparticles gel
75571572|NCT01262638|Drug|ETC-1002|ETC-1002 daily for 12 weeks
75877588|NCT01380561|Drug|asimadoline|10mg [14]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
75877589|NCT03608150|Device|Luminopia One|Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.
75877590|NCT03608150|Device|Refractive Correction|Standard of care refractive correction (ex. spectacles)
75877591|NCT05182983|Other|Tongue images，coating on the tongue and clinical data|Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.
75877592|NCT02522429|Device|Low Intensity Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
76047349|NCT05245175|Other|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
76047350|NCT05152277|Drug|HRS9531|Administered SC once
76047351|NCT05152277|Other|placebo|Administered SC once
76047352|NCT05152277|Drug|HRS9531|Administered SC for multiple dose
75571573|NCT01262638|Drug|Placebo|Placebo daily for 12 weeks
75571574|NCT02899520|Other|Reference method|Electrostimulation associated to perineal training
75571575|NCT02899520|Other|CMP ® method|Method based on Knowledge and Control of Perineum
75571576|NCT00535119|Drug|Carboplatin|Given IV
75571577|NCT00535119|Other|Laboratory Biomarker Analysis|Correlative studies
75571578|NCT00535119|Drug|Paclitaxel|Given IV
75571579|NCT00535119|Other|Pharmacological Study|Correlative studies
75571580|NCT00535119|Drug|Veliparib|Given PO
75571581|NCT00535158|Drug|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
75571582|NCT00535197|Biological|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
75571583|NCT04684407|Procedure|ROOT CANAL TREATMENT|TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
76047353|NCT05152277|Other|placebo|Administered SC for multiple dose
76047354|NCT05243381|Biological|20 ml blood test|20 ml blood test
75571584|NCT04942080|Biological|CALR allele burden quantification|"DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~at diagnosis and follow-up (inclusion period: 3 years)~max 1 sample/year~secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"
75571585|NCT03436992|Dietary Supplement|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
75571586|NCT03436992|Dietary Supplement|Resveratrol|1500 mg trans-resveratrol
75425373|NCT06072677|Behavioral|Healthy Minds Program|The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
75425374|NCT06072625|Dietary Supplement|Extra virgin organic olive oil (ULTRA PREMIUM)|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
75425375|NCT06072573|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
75571587|NCT03436992|Other|Placebo|placebo
75571588|NCT00548769|Drug|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
75571589|NCT00548769|Drug|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
75877593|NCT02974140|Device|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
75877594|NCT02974140|Procedure|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
75877595|NCT02311725|Behavioral|aTAU + sTVi|Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
75425376|NCT06072573|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
75425377|NCT06072560|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
76047355|NCT05150171|Other|e-self-management intervention|The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
75425378|NCT06072560|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
75425379|NCT06072547|Other|Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original)|Access to all varieties of on! 4mg nicotine pouch products (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), throughout the trial.
75425380|NCT06072547|Other|Access to Original on! 4mg nicotine pouches|Access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
75425381|NCT06072547|Other|Non-Flavored then complete flavor on! nicotine pouches|Access to non-flavored (i.e., Original) on! 4mg nicotine pouch products during the first 3 weeks and then access to all varieties (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) of on! 4mg nicotine pouch products during the rest of the trial
75425383|NCT06072508|Biological|Blood sampling|Blood sampling (at day 0 and day 3) for Vasn, Angiotensin 2 and clotting markers.
75425384|NCT06072495|Other|real time MRI|ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects
75425385|NCT06072443|Behavioral|Digital Health Companion (mobile App)|Participants will complete education modules, health literacy evaluations, and PRO assessments in the Digital Health Companion.
75425386|NCT06072417|Other|Assessment without intervention at High altitude|Assessments at High altitude corresponding to Baseline measures
75877596|NCT02311725|Behavioral|aTAU + Attention Control Videos|Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
75877597|NCT03653754|Diagnostic Test|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
75877598|NCT02237300|Behavioral|VR based cue-exposure therapy|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
75425387|NCT06072417|Other|Relocation to sea level for 2 days|Participants will be relocated to sea level and intervention and have assessements there.
75425388|NCT06072404|Biological|OxigenOzone_Insufflation|intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.
75425389|NCT06072365|Other|nutritional intake questionnaire|patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after
75425390|NCT06072352|Other|Perineal cleansing using chlorhexidine acetate solution|Perineal cleansing using chlorhexidine acetate solution
75425391|NCT06072352|Other|Normal saline|Perineal cleansing using normal saline
75425392|NCT06072248|Drug|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
75425393|NCT06072248|Procedure|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
75425394|NCT06072248|Device|ventilator|ventilator
75425395|NCT06072235|Behavioral|Verbal communication|Verbal communication; by talking and listening
75571590|NCT00548769|Drug|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
75571591|NCT00548769|Drug|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
75571592|NCT01262560|Drug|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
75571593|NCT01262560|Drug|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
75571594|NCT01262560|Drug|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
75571595|NCT03429894|Device|Percutaneous Coronary Intervention|Drug eluting stent implant
75571596|NCT04686669|Drug|FOR-6219 capsule formulation|FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
75877599|NCT02237300|Behavioral|Additional Cognitive-behavioral treatment|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
75877600|NCT04932005|Drug|DZD2269|Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
75425396|NCT06072222|Drug|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
75877601|NCT04932005|Drug|placebo|Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
75425397|NCT06072222|Procedure|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
75425398|NCT06072222|Device|ventilator|ventilator
75425399|NCT06072157|Drug|AK006|Intravenous Infusion
75425400|NCT06072157|Drug|Placebo|Intravenous Infusion
75425401|NCT06072118|Drug|Adrenomedullin|Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.
75425402|NCT06072105|Other|Telemedicine visits|Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
75877602|NCT02974842|Device|MAKO 7|Hysteroscopic cell sampling
76047356|NCT05149157|Other|Symptomatic malaria|This observational study will be recruiting patients who have symptomatic malaria (confirmed by presence of asexual stage parasitaemia of any Plasmodium species on blood film)
75425403|NCT06072105|Other|Multidisciplinary, personalized symptomatic treatment|Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
75425404|NCT06072092|Device|BIS Monitor|No interventions will be administered, but in addition to the standard of care according to the Guidelines of the European Resuscitation Council 2021, a frontal EEG-monitoring (BIS), a CPRMeter and a FlowMeter will be installed. The study will be observational only; the readings of the BIS monitor will be blinded to the treating PRU team.
75425405|NCT06072066|Dietary Supplement|Skin Barrier Oral Supplement|Supplment powder
75571597|NCT04686669|Drug|FOR-6219 tablet formulation|FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
75571598|NCT04207450|Other|Placebo gel|Placebo gel application followed by placebo solution application (distilled water)
75571599|NCT04207450|Other|Placebo Gel + 5% Glutaraldehyde Aqueous Solution|Placebo gel followed by 5% aqueous glutaraldehyde solution
75425406|NCT06072027|Diagnostic Test|cytology|Conventional cytology will be performed in parallel with VISIOCYT cytology in order to compare the two results.
75425407|NCT06072014|Other|Virtual reality|A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
75571600|NCT04207450|Other|Phosphoric Acid 37% + Solução aquosa de glutaraldeído a 5%|37% phosphoric acid application followed by 5% aqueous glutaraldehyde solution
75571601|NCT04686396|Device|Demineralized bone matrix|Demineralized bone matrix
75571602|NCT04322773|Drug|RoActemra iv|single dose treatment with tocilizumab 400 mg intravenously
75571603|NCT04322773|Drug|RoActemra sc|single dose treatment with tocilizumab 2 x 162 mg subcutaneously
75571604|NCT04322773|Drug|Kevzara sc|single dose treatment with sarilumab 1 x 200 mg subcutaneously
75571605|NCT04322773|Other|Standard medical care|management as usual
75877603|NCT05083611|Other|GraMI|The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
75425408|NCT06072001|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
75425409|NCT06072001|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
75571606|NCT04322812|Device|Active PBMT|The Active PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA) will be used. The ACTIV PRO emits 30mW of 905nm, 300mW of 850nm, 200mW of 660nm and 0mW of 455nm light via an electric diode energy source. PBMT will be applied using the direct contact method with light pressure on the skin. The PBMT application time will be 120 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according widespread pain index [WPI] ), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 60 Joules (J) per region. The total dose might vary between patients and each session.
75571607|NCT04322812|Device|Placebo PBMT|The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator. PBMT will be applied using the direct contact method with light pressure on the skin. The placebo PBMT application time will be 115 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according WPI), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 0 Joules (J) per region. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
75571608|NCT04070443|Drug|Ponatinib|30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.
75571609|NCT04070443|Drug|Imatinib|400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.
75571610|NCT02888782|Other|Pharmacist Consultation|
75571611|NCT04686591|Drug|AZD9977 capsule 50 mg|100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
75571612|NCT04686591|Drug|[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|One 100 µg dose of [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
75571613|NCT04686591|Drug|[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)|One 100 mg dose of [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
75571614|NCT04043494|Drug|Cyclophosphamide|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
75571615|NCT04043494|Drug|Cytarabine|"No involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2).~Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)"
75571616|NCT04043494|Drug|Dexamethasone|Part of the experimental therapy in Randomization R1 (Protocol Ia-Dexamethasone) and in Randomization R2 (Intensified Protocol M)
75571617|NCT04043494|Drug|Daunorubicin|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
76047357|NCT05148845|Biological|Booster vaccine|"To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen) COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonke participants~In addition we will continue to evaluate VE of the Sisonke Boost compared to:~i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa."
76047358|NCT05192837|Behavioral|Intensive preoperative smoking cessation counselling|"The study intervention consists of an interview by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery with individual counselling and offered nicotine substitution. The intervention meeting is based on the Chronic Care Model (CCM) to improve quality of ambulatory care.~In brief, the intervention includes:~Informative content about advantages of smoking cessation~Scheduling service for a motivational interview by a TSS in office to implement a treatment plan~For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2-3 weeks before surgery~Patients will be encouraged by a TSS to use nicotine replacement. Bupropion or Vareniclin will be provided on an individual basis~TSS will schedule repeated follow-up meetings to support smoking abstinence or nicotine reduction before and after surgery for all patients"
76047359|NCT05192525|Device|mChemotherapy|"The intervention is composed of one core intervention mChemotherapy, one pre-chemotherapy consultation, and two app follow-up visits. mChemotherapy will be specifically utilized to facilitate symptom self-management for intervention group covering chemotherapy for six weeks. The mChemotherapy includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. Intervention group participants will be given an individual username and password to log in to the mChemotherapy platform. The intervention nurses will deliver the intervention and contact patients through this platform."
75425410|NCT06071988|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
75425411|NCT06071988|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
75425412|NCT06071975|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
75425413|NCT06071975|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
75425414|NCT06071962|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
75425415|NCT06071962|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
75425416|NCT06071949|Drug|Adezunap|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
75425417|NCT06071949|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
75425418|NCT06071936|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
75425419|NCT06071936|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
75425420|NCT06071910|Device|ER-REBOA catheter|To achieve rapid aortic occlusion
75425421|NCT06071897|Drug|monoclonal antibodies GD2|"Main target of this trial is to estimate tolerability and toxicity of combination of standard chemotherapy (N5 and N6) with anti-GD2 MAB~N5Q. N5 (see above) Dinutuximab beta 10 mg/m2 i.v., days 5-9*~N6Q. N6 (see above) Dinutuximab beta 10 mg/m2 i.v., days 6-10*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy"
75877604|NCT03653676|Other|Exercise Test (CIIT)|The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
75425422|NCT06071871|Drug|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8. Patients need to stay in hospital for 24 hours.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15. (Patients may need to stay in hospital for 24 hours.) Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-12 (as relevant)."
75877605|NCT03536247|Procedure|Initial therapy with papillary balloon dilation|patients will first undergo papillary dilation
75425423|NCT06071871|Drug|Polatuzumab vedotin|Polatuzumab is given intravenously at a dose of 1.8mg/kg on Cycle 1 Day 2, and then Day 1 of Cycle 2-Cycle 6.
75425424|NCT06071871|Drug|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
75877606|NCT03536247|Procedure|Initial therapy with intraductal lithotripsy|patients will first undergo intraductal laser or electrohydraulic lithrotripsy
75877607|NCT03172481|Drug|PRC-063 oral capsules|Daily dose
75877608|NCT03172481|Drug|Placebo oral capsules|Daily dose
75877609|NCT01163487|Drug|Dichloroacetate|25-50mg/kg per day; oral
75877610|NCT01163487|Device|EF5|21 mg/kg; IV
75425425|NCT06071832|Other|Instructions for family Zoom session|Within both play and reading conditions, we will manipulate the method of enacting the structured activities with the goal of facilitating different types of grandparent-initiated joint attention.
75425426|NCT06071819|Diagnostic Test|Structured Clinical Interview for DSM-5|A structured interview will be administered to confirm the diagnosis reported in clinical charts
75571618|NCT04043494|Drug|Doxorubicin|Part of standard chemotherapy
75571619|NCT04043494|Drug|Ifosfamide|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
75877611|NCT02855450|Drug|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
75571620|NCT04043494|Drug|6-Mercaptopurine|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
75571621|NCT04043494|Drug|Methotrexate|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
75571622|NCT04043494|Drug|PEG asparaginase|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Protocol Ib* (Randomization R2)
75571623|NCT04043494|Drug|Prednisone|Part of standard chemotherapy
75571624|NCT04043494|Drug|Prednisolone|No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
75877612|NCT02855450|Drug|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
75425427|NCT06071806|Other|Topical Application of 5-Fluorouracil|The entire cyst lining radically enucleated in conjunction with any overlying mucosa, followed by extensive cavity thorough curettage, peripheral ostectomy was carried out for all bony walls to remove the microscopic satellite cyst, with identification, isolation, retraction, and preservation of the lingual and inferior alveolar bundle,a sterile radiopaque quarter-inch ribbon gauze coated with 5-FU cream was packed into the surgical wound. Closure of the wound was then done in the usual manner using 3/0 vicryl leaving approximately1 cm of a small distal end of the gauze exposed to allow for easy removal after 24 hours postoperatively
75425428|NCT06071689|Device|screw retained prosthesis|all-on-4 screw-retained prosthesis.
75425429|NCT06071533|Drug|Dandshen|Dandshen injection 20ml /day
75425430|NCT06071364|Diagnostic Test|Ultrasonography imaging and Hand-held dynamometer (HHD)|"Ultrasound imaging system will be used to evaluate the thickness, cross -sectional area and fat infiltration of lumbar extensors lumbar multifidus , erector spinae and quadratus lumborum muscles.~The hand-held dynamometer assessing isometric lumbar muscles strength"
75571625|NCT04043494|Drug|Thioguanine|Part of standard chemotherapy
75571626|NCT04043494|Drug|Vincristine|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
75571627|NCT04043494|Drug|Vindesine|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
75571628|NCT04686357|Diagnostic Test|EMMA/ALICE|"Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the EMMA/ALICE test will be provided to participants and their gynecologists. Depending on the test results, there are 3 different possibilities:~Normal result~Ultralow or Dysbiotic result~Abnormal result (pathogens) All probiotics and antibiotics that will be used in the study are already authorized by the local health authorities and will be prescribed under their technical data sheet/brochure conditions following the medical indications."
75571629|NCT04686357|Diagnostic Test|EMMA/ALICE|Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
76047360|NCT05475197|Device|Kinesio taping|We planned to perform two different taping applications to evaluate the acute effect of kinesio taping application on the carpal tunnels of individuals with carpal tunnel syndrome.
75425431|NCT06071312|Biological|single FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through a single infusion of FMT
75591972|NCT06078696|Procedure|Exchange Transfusion|Patient will undergo a red blood cell exchange transfusion to achieve a Hemoglobin S (HgbS) level < 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
75724167|NCT03862820|Diagnostic Test|dynamic ultrasound|move abdomen with ultrasound probe to predict intraabdominal adhesions
75724168|NCT00884988|Drug|Lymphomyosot|20 drops X3/day, until discharge
75425432|NCT06071312|Biological|sequential FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through multiple infusions of FMT (sequential approach)
75425433|NCT06071273|Other|Group A: online real-time home based exercise using the online platform|"Patients that will be randomly assigned to this group will be exercising at home by providing data of their vital signs during exercise and at rest. To succeed this, they will be provided with the appropriate equipment (e.g., a smart watch able to assess the electrical signs of the heart (i.e., ECG) and heart rate, an automated blood pressure monitor, and an electrical body scale) which will be directly linked to the online platform.~The online real-time supervised home-based exercise program is identical to Group B, the only difference is that it is performed at home. Each session has a duration of 60 minutes consisting of 40 mins of aerobic exercise and 20mins of resistance training. The overall intensity is kept to moderate based on ratings of perceived exertion (i.e., 13-14 in Borg's scale 6-20). The program will last for 6 months with exercise sessions taking place thrice per week."
75425434|NCT06071273|Other|Group B: supervised community based exercise intervention|Identical exercise program to Group A, the only difference is that Group performs the supervised exercise in community based health clubs/gyms.
75877613|NCT03477045|Dietary Supplement|Single dose fish oil|Fish oil consumed within a single high fat test meal
75877614|NCT03477045|Dietary Supplement|Repeated dose fish oil|Fish oil consumed daily for 8 weeks
75571630|NCT02899481|Other|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
75724169|NCT00884988|Drug|Placebo remedy|20 drops X3/day, until discharge
75877615|NCT03477045|Dietary Supplement|single dose Camelina seed oil|camelina seed oil consumed within a single high fat test meal
75425435|NCT06071208|Drug|Gliflozin|to study whether the use of gliflozin prevented diabetic complications
75425436|NCT06070415|Device|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
75425437|NCT06070415|Other|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
75425438|NCT06070415|Other|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
75571631|NCT02899286|Biological|PEG-BCT-100|PEGylated recombinant human arginase
75571632|NCT00535275|Drug|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
75571633|NCT00535275|Drug|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
75571634|NCT04322344|Drug|Escin|treatment with escin or escinate sodium
75877616|NCT03477045|Dietary Supplement|repeated dose camelina seed oil|camelina seed oil consumed daily for 8 weeks
75877617|NCT01379001|Drug|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
75425439|NCT06070207|Procedure|TEP group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
75425440|NCT06070207|Procedure|eTEP group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
75425441|NCT06070181|Device|Enamel matrix derivate|'Applying Enamel matrix derivate in the periodontal pockets after completing the non-surgical periodontal treatment
75425442|NCT06070181|Procedure|Non-surgical periodontal treatment|No additional/adjunctive treatment with Emdogain
75571635|NCT04322344|Drug|standard therapy|antiviral drugs
75571636|NCT04322422|Drug|Inhaled corticosteriod/long-acting beta-agonist plus Montelukast|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
75571637|NCT04322422|Drug|Inhaled corticosteriod/long-acting beta-agonist only|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
75571638|NCT02899169|Drug|Realgar-Indigo naturalis formula|
75724170|NCT00818948|Drug|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
75877618|NCT01379001|Drug|Placebo|IM or PO placebo
75425443|NCT06070142|Procedure|TEP Group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
75425444|NCT06070142|Procedure|eTEP Group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
75425446|NCT06069687|Biological|MELPIDA|A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg
75425447|NCT06069557|Other|Respiratory exercise|This group will undergo intervention. The participants will be assessed in terms of abdominal distension and shoulder pain in preoperative period. Respiratory exercise training will be given in the preoperative period. At the 1st, 2nd, 3rd, 4th, 5th, 4th, 5th, and 6th hours postoperatively, 10 deep breathing exercises will be performed in semi fowlers 45º position. During this 6-hour period, the patient will be asked to give 10 deep breaths into the incentive spirometer every 2 hours. Patients will be evaluated for abdominal distension and shoulder pain at the 1st, 2nd, 3rd, 4th, 5th, and 6th hours postoperatively and mobilization times will be measured in the first 6 hours.
75877619|NCT01379001|Drug|Donepezil|donepezil 5mg PO x 1
75877620|NCT02035124|Drug|BKM 120|
75877621|NCT02035124|Drug|Cabazitaxel|
76047361|NCT02367781|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
75425448|NCT06069492|Other|Wheat-containing food|One daily serving of 38 grams wheat-containing pasta contains either 5000 mg wheat protein (standard-dose group) or 650 mg wheat protein and 4350 gluten-free flour (low-dose group)
75425449|NCT06068478|Drug|Qingzhu Granules|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
75425450|NCT06068478|Drug|Qingzhu Granules Placebo|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
75425451|NCT06068387|Procedure|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
75425452|NCT06067932|Radiation|Foot X rays|Radiographs of ankle and foot anteroposterior/dorsoplantar were taken in standing position with a centralized beam on the ankle joint.
75571639|NCT02899169|Drug|all-trans retinoic acid|
75571640|NCT02899169|Drug|Arsenic trioxide|
75425453|NCT06067932|Diagnostic Test|Clinical examination + scores|The American Orthopedic Foot and Ankle Society Score (AOFAS- midfoot section and 1st Forefoot ray, Forefoot ray 2-5) and the foot function index (FFI) were assessed
75425454|NCT06067698|Drug|"Mesalamine and alpha-lipoic acid"|Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
75425455|NCT06067698|Drug|"Mesalamine and Placebo"|Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
75425456|NCT06067295|Other|Non-Interventional Study|Non-interventional study
75425457|NCT06067282|Other|Microteaching|"This program selects five kinds of core teaching skills for training, and the training program is extracted in Microteaching ."
75425458|NCT06067191|Drug|RV299|Oral Suspension
75425459|NCT06067191|Drug|Placebo|matching placebo
75425460|NCT06067100|Drug|Indacaterol and Mometasonefluroate (low dose)|Participants are administered 125 µg indacaterol + mometasonefluroate
75425461|NCT06067100|Drug|Placebo|Participants are administered placebo
75425462|NCT06067100|Drug|Indacaterol and Mometasonefluroate (high dose)|Participants are administered 500 µg indacaterol + mometasonefluroate
75425463|NCT06066853|Drug|MDMA|MDMA-assisted psychotherapy
75425464|NCT06066827|Drug|Minoxidil Topical|20 subjects received minoxidil only for the treatment of AGA
75425465|NCT06066827|Other|Secretome from adipose-derived stem cells|20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA
75425466|NCT06066827|Combination Product|Combination of minoxidil and secretome from adipose-derived stem cells|20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA
75571641|NCT02899169|Drug|Hydroxyurea|
75571642|NCT05517031|Other|ASDAS score , VAS score, BASFI score , Katz ADL index|Scores that done on patient to fullfill criteria of diagnosis , and measure affection of disease on patients and their daily living activity
75571643|NCT04322188|Other||this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice
75571644|NCT02899130|Drug|Polyherbal|Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
75571645|NCT02899130|Drug|Placebo|Inactive compound that is similar looking as the intervention
75571646|NCT00548964|Drug|Lithium|600-900mg of Li carbonate
75571647|NCT00548964|Drug|Ketamine|0.5mg/kg of ketamine
75571648|NCT04322227|Drug|Foliglurax 10 mg (treatment A)|Foliglurax 10 mg, (BID) capsules, orally
75877622|NCT03172325|Drug|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
75724171|NCT04036734|Diagnostic Test|Longitudinal|Longitudinal orientation of ultrasound to long axis of vein to guide access needle
75724172|NCT04036734|Diagnostic Test|Transverse|Transverse orientation of ultrasound to long axis of vein to guide access needle
76047362|NCT02367781|Drug|Carboplatin|Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
76047363|NCT02367781|Drug|Nab-Paclitaxel|Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 of each 21-day cycle.
76047364|NCT02367781|Drug|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
75571649|NCT04322227|Drug|Foliglurax 30 mg (treatment B)|Foliglurax 30 mg, BID capsules, orally
76047365|NCT02152761|Drug|bimagrumab|Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
76047366|NCT02152761|Other|placebo|Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
75571650|NCT04322227|Drug|Placebo (treatment C)|Placebo, BID capsules, orally
75571651|NCT02889601|Other|Psycho-behavioural assessment|DAPHNE Scale
75571652|NCT02898896|Biological|blood test|Additional 21 ml of blood will be collected
75571653|NCT02899013|Other|No intervention|Observational study to describe Perianal Lesions in a Cohort of Crohn's Disease Patients.
75571654|NCT02899091|Biological|CB-AC-02|"Stage1:~① Group1: CB-AC-02, 2.0 x 10^8 cells on day 0~② Group2: CB-AC-02, 2.0 x 10^8 cells, on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20~26 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10~19 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)"
76047367|NCT05191277|Drug|Treatment 'discontinuation of antidepressant medication'|Pharmacological intervention: Participants will discontinue their antidepressant medication.
75571655|NCT02899091|Biological|Placebo|"Stage2:~Placebo on day 0 and on week 4 (repeated injection)"
75571656|NCT04323007|Diagnostic Test|Nephrotic patients|Laboratory measures will include Blood sugar Urine analysis with 24hrs protein in urine Complete blood count Liver function tests Kidney functions test Plasma lipid levels Thyroid functions test Abdominal ultrasound Antithyrperoxidase Renal biopsy
75571657|NCT04684290|Procedure|Alcohol Septal Ablation|Participants will be treated with alcohol septal ablation.
76047368|NCT05191277|Drug|Treatment 'continuation of antidepressant medication'|Pharmacological intervention: Participants will remain on their antidepressant medication.
76047369|NCT05191277|Behavioral|Expectation 'high'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).
75571658|NCT04684290|Procedure|Surgical Septal Myectomy|Participants will be treated with surgical septal myectomy.
75571659|NCT00549003|Device|Rapid Diagnostic Test for P. falciparum malaria|
75571660|NCT02898857|Other|biopsies|The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
75571661|NCT00549081|Dietary Supplement|DHEA|oral DHEA tablets 75 mg daily
75571662|NCT02898779|Drug|Primaquine, R-Primaquine, S-Primaquine, SR Primaquine|"Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ."
76047370|NCT05191277|Behavioral|Expectation 'moderate'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
75571663|NCT00535431|Drug|AER 001|60 mg (in nebuliser), twice daily for 28 days
75571664|NCT00535431|Drug|placebo|Sterile saline nebulised, twice daily for 28 days
75571665|NCT02898701|Behavioral|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
75571666|NCT00549120|Drug|Propranolol|40 mg tablets
75571667|NCT00549120|Drug|Salbutamol|Metered dose inhaler (600 μg)
75571668|NCT00549120|Drug|Ipratropium|Metered dose inhaler (40 μg)
75571669|NCT00549120|Drug|Placebo|Placebo for propranolol tablets
75571670|NCT04680884|Drug|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
75877623|NCT03172325|Drug|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
75877624|NCT03172325|Drug|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
75877625|NCT03172325|Drug|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
76047371|NCT04242173|Drug|Cemiplimab-Rwlc|Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
76047372|NCT02152605|Drug|UMEC/VI|Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
75425467|NCT06065774|Procedure|The Laterally Closed Tunnel Technique with SCTG|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments [devmed] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
75571671|NCT04680884|Drug|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
75571672|NCT04680884|Drug|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
75877626|NCT03653520|Drug|Diazepam|5 or 10mg
75877627|NCT03653520|Drug|Tramadol|50mg or 100mg
75571673|NCT04680884|Other|Standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
75724173|NCT01073215|Behavioral|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
75877628|NCT03653520|Drug|Ondansetron|1 or two tabs
75877629|NCT03653520|Drug|MKO melt|1 or 2 MKO melts
75877630|NCT01378923|Behavioral|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
75877631|NCT01378923|Behavioral|TAU|have access to standard jail programs and services
75571674|NCT03318588|Procedure|Vitrectomy|Pars plana vitrectomy
75571675|NCT02898428|Device|Continuous glucose monitoring (CGM)|
75724174|NCT01073215|Behavioral|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
75724175|NCT05278728|Drug|Nimotuzumab|200,400,600 or 800mg weekly until progression or AEs
75724176|NCT05278728|Drug|Irinotecan|180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
75724177|NCT01073761|Drug|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
75724178|NCT03862664|Procedure|Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation
75877632|NCT02034734|Drug|ASP3652|oral
75877633|NCT03608072|Drug|BI 690517|3 sequential dose groups
75877634|NCT03608072|Drug|Placebo|3 sequential dose groups
75877635|NCT03630471|Behavioral|PRIDE 'Step 1' problem-solving intervention|"The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home."
76047373|NCT02152605|Drug|Placebo|Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
76047374|NCT02152371|Drug|Dulaglutide|Administered SQ
75425468|NCT06065774|Drug|The Laterally Closed Tunnel Technique with collagen matrix mucograft|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments [devmed] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
75571676|NCT00549159|Device|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
75571677|NCT00549159|Device|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
75571678|NCT02898311|Device|immediate loading of posterior implants with chairside CAD-CAM composite crown|
75571679|NCT00549237|Dietary Supplement|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
75571680|NCT00549237|Other|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
75571681|NCT02898545|Device|SEEQ monitor|An external cardiac rhythm monitor
75571682|NCT00535470|Drug|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
75571683|NCT02898467|Other|diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
75571684|NCT02898467|Other|non-diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
75724179|NCT00819104|Drug|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
75571685|NCT03284112|Behavioral|Old SCHOOL Hip-Hop|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
75571686|NCT03284112|Behavioral|My Plate|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
75571687|NCT02898584|Other|BP Track|
75571688|NCT03455309|Biological|NDV-3A|Single dose administered by intramuscular injection
75571689|NCT03455309|Biological|Placebo|Single dose administered by intramuscular injection
75571690|NCT00549315|Device|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
75571691|NCT00535509|Radiation|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
75571692|NCT00535509|Other|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
75571693|NCT00535509|Drug|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
75571694|NCT02898350|Device|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
75571695|NCT02898350|Device|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
75877636|NCT03630471|Behavioral|Enhanced usual care|There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
76047375|NCT02152371|Drug|Placebo|Administered SQ
75724180|NCT00819104|Drug|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
75724181|NCT00819104|Drug|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
75724182|NCT00819104|Drug|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
75724183|NCT00819104|Drug|Amlodipine 5mg|tablet,oral,OD,8 weeks
75724184|NCT02542098|Drug|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
75724185|NCT03617094|Device|Early percutaneous vertebroplasty (EPV)|Treatment consists of percutaneous acrylic bone cement injection using a trocar under scope control and general anesthesia.
75571696|NCT02898350|Device|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
75571697|NCT02898350|Device|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
75877637|NCT04054986|Diagnostic Test|F-Var3 PET/CT|Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.
75571698|NCT00549354|Device|Endoluminal Graft|
75724186|NCT03617094|Device|Standard Conservative treatment (CT)|Treatment consists of using a made-to-measure 3 point thoracolumbar corset,that is worn for 3 months: night and day during the first 6 week period of the treatment, and then only the day for the next 6 week period.
75877638|NCT04054986|Other|Blood draw|Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.
75724187|NCT02541162|Behavioral|Oral information and interviews|interviews about sexuality and self experience during the disease
75724188|NCT04036656|Drug|SYHA136 0.5 mg|oral tablet
75877639|NCT03653286|Other|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
75877640|NCT03653286|Other|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
75877641|NCT01208090|Drug|ACT-128800|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
75877642|NCT01208090|Drug|Placebo|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
75425469|NCT06065774|Procedure|Modified Coronally Advanced Tunnel Technique with SCTG.|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
75425470|NCT06065774|Drug|Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
75571699|NCT02898038|Dietary Supplement|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
75571700|NCT00535548|Biological|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
75571701|NCT02897999|Biological|QBKPN|QBKPN Site Specific Immunomodulators
75571702|NCT02897999|Other|Placebo|Placebo
75724189|NCT04036656|Drug|SYHA136 1 mg|oral tablet
75724190|NCT04036656|Drug|SYHA136 2.5 mg|oral tablet
75724191|NCT04036656|Drug|SYHA136 5 mg|oral tablet
75724192|NCT04036656|Drug|SYHA136 10 mg|oral tablet
75724193|NCT04036656|Drug|SYHA136 20 mg|oral tablet
75724194|NCT04036656|Drug|SYHA136 35 mg|oral tablet
75724195|NCT04036656|Drug|SYHA136 50 mg|oral tablet
75724196|NCT04036656|Drug|Placebo matching SYHA136 0.5 mg|oral tablet
75724197|NCT04036656|Drug|Placebo matching SYHA136 1 mg|oral tablet
75724198|NCT04036656|Drug|Placebo matching SYHA136 2.5 mg|oral tablet
75724199|NCT04036656|Drug|Placebo matching SYHA136 5 mg|oral tablet
75724200|NCT04036656|Drug|Placebo matching SYHA136 10 mg|oral tablet
75724201|NCT04036656|Drug|Placebo matching SYHA136 20 mg|oral tablet
75724202|NCT04036656|Drug|Placebo matching SYHA136 35 mg|oral tablet
75724203|NCT04036656|Drug|Placebo matching SYHA136 50 mg|oral tablet
75724204|NCT02541240|Other|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
75724205|NCT04036422|Device|Rejoyce (Rehabilitation Joystick for Computerized Exercise)|Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.
75724206|NCT04036422|Other|Conventional physical therapy|A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.
75724207|NCT04036422|Other|Occupational therapy|Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
75724208|NCT00892164|Device|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
75724209|NCT00892164|Device|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
76047376|NCT02152371|Drug|Insulin Glargine|Administered SQ
75425471|NCT06064955|Behavioral|Peer Support|Former caregivers will be paired with a current caregiver based on a similar personal attribute (e.g., relationship to care recipient). Each pair will complete at least five virtual face-to-face (video) interactions and at least 10 other interactions either via phone call, email, or text messaging over the 6-month time period.
75425472|NCT06064864|Drug|Infliximab-Dyyb|Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
75571703|NCT01262365|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
75571704|NCT01262365|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
75571705|NCT01262365|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
75571706|NCT03244176|Drug|Avelumab|"All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
75571707|NCT02898155|Other|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
75571708|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
75571709|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
75571710|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
75571711|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
75571712|NCT03971110|Drug|Zoladex and Casodex|The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
75724210|NCT00640016|Other|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
75724211|NCT00640016|Biological|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
75724212|NCT00640016|Biological|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
75724213|NCT00640016|Other|CAT-354 10 mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
75724214|NCT04036578|Device|A 12-week PFMT bio-assisted surface electromyographic program|
76047377|NCT02152371|Drug|Metformin|Administered orally
76047378|NCT02332291|Drug|Escitalopram|Escitalopram 10-20mg daily
76047379|NCT02332291|Drug|Bupropion XL|Bupropion XL 150-450mg daily
76047380|NCT01656395|Drug|MK-1029|MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
76047381|NCT01656395|Drug|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
76047382|NCT01656395|Drug|Placebo|Parts I-II: Participants will receive Placebo tablets QD
75571713|NCT00549432|Device|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
75571714|NCT02897882|Other|Lung transplant|Pain evaluation
75571715|NCT03932812|Behavioral|Options Counselor Health Educator (OC-HE) Intervention|The OC-HE will meet in person with the participant one time and five times via telephone to provide options counseling based on modules developed by the research team
75571716|NCT03456024|Other|Questinnaire|
75877643|NCT03085017|Device|BoneSeal|BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
75571717|NCT04322266|Drug|HCP1701|Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
75877644|NCT03085017|Device|Ostene|OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
75877645|NCT04210050|Device|Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.|"In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time.~For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring."
75877646|NCT04210050|Diagnostic Test|Arterial blood gas (ABG) and serum bicarbonate level|Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
75571718|NCT04322266|Drug|HCP1306|Ezetimibe /Rosuvastatin
75571719|NCT04322266|Drug|HGP0904|Amlodipine
75877647|NCT04210050|Diagnostic Test|Overnight home oximetry and transcutaneous CO2 monitoring|will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
75425473|NCT06064422|Behavioral|BeatIt-MV|BeatIt-MV, designed to be implemented with minimally verbal autistic individuals, is an adaptation of BeatIt-2. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
75425474|NCT06062095|Procedure|AI-powered computer-aided diagnosis (CADx)|Real time AI will be used to diagnosis polyps found during colonoscopy.
75425475|NCT06060704|Drug|Envafolimab|150mg Qw, delivered as a single 1.5ml subcutaneous injection in under 30s , every 4 weeks for one cycle(Q4w).
75571720|NCT04322266|Drug|HGP0608|Losartan potassium
75724215|NCT00892242|Drug|Zoledronic acid|
75724216|NCT00885066|Drug|capecitabine|
75425476|NCT06060704|Drug|Trifluridine/Tipiracil|35 mg/m2 (maximum single dose of 80 mg), po, on days 1-5 and 8-12 of each treatment cycle, twice daily for 28 days, within 1 hour after breakfast or dinner take medicine.
75425477|NCT06060704|Drug|Bevacizumab|ivgtt, 5mg/kg, d1, d15, every 4 weeks for one cycle (Q4w). The subjects will receive Trifluridine/Tipiracil plus Bevacizumab and Envafolimab until disease progression, intolerable toxicity, initiation of other anti-tumor therapy, death, withdrawal of informed consent, or loss of follow-up.
75425478|NCT06060275|Diagnostic Test|serum sample and nerve conduction study and cerebrospinal fluid study|serum sample and cerebrospinal fluid study to detect Neurofilament light chain Nerve conduction study
75571721|NCT02897726|Drug|NVP-1402|Oral
75571722|NCT02897726|Drug|NVP-1402R|Oral
75571723|NCT03208959|Drug|HTI-1090|IDO/TDO inhibitor
75571724|NCT04322110|Other|PronoKal Method|Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support
75571725|NCT04322110|Other|Low calorie diet|Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
75724217|NCT00885066|Drug|erlotinib hydrochloride|
75724218|NCT00885066|Drug|gemcitabine hydrochloride|
75724219|NCT00885144|Dietary Supplement|Nutributter|"Test dose of standard supplementary lipid based nutrient supplement (LNS). 15 grams of Nutributter will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation."
75571726|NCT02897804|Behavioral|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing & treatment services.
75571727|NCT02897804|Behavioral|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75724220|NCT00885144|Dietary Supplement|LNS-20gM|Test dose of modified LNS-20gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
75571728|NCT02897804|Behavioral|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75571729|NCT02897804|Behavioral|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75571730|NCT02897804|Behavioral|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
75571731|NCT02897804|Behavioral|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75877648|NCT03653130|Behavioral|Crossroads Orchestra Participatory Music Program|The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
75877649|NCT03215771|Device|MyoPro Motion-G|The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
75877650|NCT03215771|Other|Motor Learning-Based Therapy|Motor learning-based (MLB) therapy included movement practice as close to normal as possible, high repetition, progression of challenge, part versus whole task practice, and knowledge of results. Treatment was customized to abilities of each subject and consisted of both MyoPro training and MLB therapy without device. Training with device was progressed using a hierarchy of challenge to increase complexity of movement. MLB therapy without device followed the same hierarchy, incorporating training of movements that could not be accomplished with the device and those that were trained with device. Movement quality was monitored and training practice was incrementally progressed as subject demonstrated improved ability to perform a given task/movement component. Subjects performed a custom home exercise program (HEP) on non-clinic days, increasing repetition as tolerated. At conclusion of in-clinic phase, individuals transitioned to a home phase where they continued to use the HEP.
75877651|NCT04266990|Other|Planned Sweat collection|Four times a day at fixed time points (9:30, 11:30, 13:30, 15:30), a researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher.
75877652|NCT04266990|Other|Spontaneous Sweat collection|As the patient will be under continuous monitoring, sweat and saliva samples will be also collected during and/or right after a seizure occurs if the volunteer is not holding a gauze at that time. The sweat samples will be collected by the researcher by applying a sterile gauze to the patients hands, either during or immediately following a seizure during 10 minutes.
76047383|NCT02114931|Biological|ABP 501|Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
76047384|NCT05185739|Drug|Pembrolizumab|Pre-operative Pembrolizumab (200mg IV every 3 weeks) for 2 cycles
75425479|NCT06058884|Drug|Alteplase|Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
75425480|NCT06058520|Drug|Fecal Microbiota - lyophilized|Patients receive 2 capsules daily for one week followed by one capsule daily for 2 weeks. MTT capsules are derived from a single donor per patient.
75425481|NCT06058520|Drug|Placebo drug|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product.
75425482|NCT06058403|Dietary Supplement|20g whey protein drink ingestion|Ingestion of a 300 mL drink containing 20g whey protein
75425483|NCT06058403|Dietary Supplement|20g native canola protein drink ingestion|Ingestion of a 300 mL drink containing 20g native canola protein
75425484|NCT06058403|Dietary Supplement|20g processed canola protein #1 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #1
75425485|NCT06058403|Dietary Supplement|20g processed canola protein #2 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #2
75425486|NCT06057727|Behavioral|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.
75571732|NCT02897804|Behavioral|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75571733|NCT02897804|Behavioral|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
76047385|NCT05185739|Drug|Lenvatinib|Pre-operative Lenvatinib (8 or 12mg PO once daily according to bodyweight <60gk≥) for 6 weeks
75425487|NCT06057727|Behavioral|Default pended order|A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
75425488|NCT06057727|Behavioral|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.
75425489|NCT06057727|Behavioral|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
75425490|NCT06057246|Other|Test meal with postprandial samples|The mixed-nutrient test meal consists of a sandwich made with bread, spread cheese, air-cured beef, and one apple. Nutritional composition of the meal will be: total energy (TE) content 532 kcal, carbohydrates 68,4 g (49.3% TE), total fat 17.1 g (29.5% TE), protein 27.8 g (21.4% TE), and fibre 6 g. Before and over 4 hours after the meal, venous blood samples will be taken for biochemical evaluations at the time points -15'; 0'; 15'; 30'; 60'; 120'; 180'; 240'.
75425491|NCT06056739|Device|Alio platform|Remote monitoring platform
75425492|NCT06054295|Other|Biospecimen collection|Collection of both blood and saliva samples from participants at the time of study enrollment
75425493|NCT06054295|Other|Questionnaire Administration|The brief questionnaire will assess health history, demographics, environmental exposures, family history of cancer, and birth characteristics.
75425494|NCT06052410|Other|Early Intervention|Based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children at risk of developmental delay between 24-36 months, activity-based training is aimed at the development of sensory and cognitive skills in addition to the training of motor skills, which are intensively discussed in the content of the approach. Individualized early occupational therapy intervention including strategies was implemented.
75425495|NCT06052410|Other|Home Programme|For the control group, evaluation tests were first applied to the babies selected by simple random sampling method. An individualized home program was given according to the evaluation results. Home programs include activities for every skill area and were prepared together with the parents, taking into account the criteria suggested for the success of the home program. Based on these criteria, it was checked whether the family had received another home program, and while preparing the program, care was taken not to overload the parents, importance was given to the family's willingness to receive the home program, activities and goals were decided in cooperation with the parent, thus facilitating the applicability of the activities in daily life, ensuring that the number of activities was 6. Care was taken to ensure that the activity was not too much, the parent was given the necessary time to implement the program, and a phone call was made to the parent every 3 weeks.
75571734|NCT02897804|Behavioral|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
75571735|NCT02897804|Behavioral|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75571736|NCT02897804|Behavioral|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75571737|NCT02897804|Behavioral|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75571738|NCT02897804|Behavioral|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
75571739|NCT02897804|Behavioral|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75571740|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75724221|NCT00885144|Dietary Supplement|LNS-20gNoM|Test dose of modified LNS-20gNoM (milk free) supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gNoM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
75425496|NCT06050915|Drug|DISC-3405|DISC-3405 is administered as a single dose IV infusion or subcutaneous injection
75724222|NCT00885144|Dietary Supplement|LNS-10gM|Test dose of modified LNS-10gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-10gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
75425497|NCT06050915|Drug|DISC-3405|DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection
75425498|NCT06050915|Drug|Placebo|Placebo is administered as a single dose IV infusion or subcutaneous injection
75571741|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
76047386|NCT05185739|Drug|Pembrolizumab and Lenvatinib|Pre-operative combination of pembrolizumab and lenvatinib at the standard doses and duration as per cohort 1 and 2
75571742|NCT02897804|Behavioral|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
75571743|NCT02897804|Behavioral|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
76047387|NCT05184881|Other|Retrolaminar block|2- Cervical retrolaminar block: will be performed on prone-positioned patients. Under fluoroscopic visualization, after identification of the lamina at the desired level, a 25-gauge, 3.5-inch spinal needle was introduced and when the needle tip will be confirmed at the posterior aspect of the cervical lamina corresponding to cervical facet arthropathy level. 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) will be injected.
75571744|NCT02897804|Behavioral|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
76047388|NCT05184881|Other|Medial Branch Block|1- Cervical medial branch block: will be performed on prone-positioned patients using a posterior approach. Under fluoroscopic visualization, after identification of the waists of the articular pillars at the desired levels, each medial branch block was administered with a 25-gauge, 3.5-inch spinal needle. When the place of the needle tip will be confirmed at the mid-point of the waists of articular pillars, 1 ml of the mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml) will be injected at each level.
75571745|NCT02897804|Behavioral|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75724223|NCT00885222|Device|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
76047389|NCT05144711|Procedure|Selective caries excavation|Selective caries excavation leaving stained but leathery dentine towards the pulp
76047390|NCT05144711|Procedure|Non selective caries excavation|Complete excavation of caries regardless of the risk of pulp exposure
76047391|NCT05238935|Other|prescribed physiotherapy course|provide full assessment and treatment program as postoperative rehabilitation management
75425499|NCT06050915|Drug|Placebo|Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
75425500|NCT06050109|Drug|OFS continues to use group after 5 years use|Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
75425501|NCT06050109|Diagnostic Test|Immunohistochemical detection of HR status|Enrolled patients must be HR-positive premenopausal breast cancer patients
75425502|NCT06049134|Biological|PCV20|Given by Injection into the muscle
75571746|NCT02897804|Behavioral|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
75571747|NCT02897804|Behavioral|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75571748|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75571749|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75571750|NCT02897804|Behavioral|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
75571751|NCT02897804|Behavioral|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75571752|NCT02897804|Behavioral|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
76047392|NCT05184725|Device|SaMD CARINAE|SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.
75591973|NCT06078696|Procedure|Total Body Irradiation|Radiation dose is 2Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
75724224|NCT00888108|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
76047393|NCT05238623|Diagnostic Test|additional EIT Measurement|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement. The lunghealthy Patients in the control group only receive a EIT.
75425503|NCT06049056|Other|Invitation|During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
75425504|NCT06048588|Drug|YN001|In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg for 2 weeks. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg for 4 weeks.
75425505|NCT06048588|Drug|Placebo for YN001|The injection solution to mimic the YN001
75425506|NCT06048588|Drug|rosuvastatin calcium tablets|In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily for 4 weeks.
75571753|NCT02897804|Behavioral|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75724225|NCT00888108|Drug|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
75724226|NCT00885300|Drug|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
75724227|NCT00885300|Drug|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
75724228|NCT00888186|Drug|levodopa/carbidopa|intestinal gel, for continuous daytime infusion
75724229|NCT00892320|Drug|ER OROS paliperidone|
75724230|NCT00892398|Drug|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
75724231|NCT00892398|Procedure|standard care|standard post-operative care after trabeculectomy with mitomycin C
75724232|NCT00892476|Dietary Supplement|Calcium Supplementation|"Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight < 1000 g Actual Weight < 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp"
75877653|NCT04266990|Other|Healthy volunteers sweat collection|A researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher. The healthy samples will be collected on the same floor of Ghent University Hospital and as close as possible to where patients reside
75425507|NCT06047678|Behavioral|Cardiovascular fitness|A randomized single-blind controlled trial tested the hypothesis that different variants of resistance training (antagonistic lower and upper body training, agonistic lower and upper body training, and aerobic training) have different effects on blood pressure (systolic and diastolic), aortic pulse wave velocity (PWVao), and augmentation index (Aix) values and compared subjects with normotension and hypertension during and after exercise session.
75877654|NCT03636425|Other|Questionnaire administration to gather information|In the questionnaire there are questions about the training (number of kilometers traveled by runners on average, total height difference, number of training sessions per week, training ground) questions on other activities carried out (gym, bicycle, etc.) number of competitions that runners participated in the month, used footwear, musculoskeletal disorders in the last 12 months, which health professional the runner has addressed, which physiotherapy therapies did.
75877655|NCT01380483|Drug|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
75425508|NCT06040450|Other|Questionnaire survey|On outdoor sports practice activity, barriers to practice, impacts on well-being.
75724233|NCT00892476|Other|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
75724234|NCT00892554|Dietary Supplement|Docosahexaenoic Acid|Capsules providing 10 mg DHA/kg body weight/day taken once daily
75724235|NCT00892554|Dietary Supplement|Corn/soy oil|Capsules taken once daily
75724236|NCT02541786|Drug|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
75724237|NCT02541786|Drug|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
75724238|NCT00888342|Drug|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 < 90%. If SpO2 < 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
75724239|NCT00888342|Drug|zopiclone|5 mg sedative given approximately 1 hour before sleep
75724240|NCT00888342|Other|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
75724241|NCT00892632|Procedure|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
75724242|NCT00608868|Drug|Gefitinib|Gefitinib tablet 250mg once daily orally
75877656|NCT01380483|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
75724243|NCT00888420|Other|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
75724244|NCT00895518|Behavioral|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
75724245|NCT00888498|Other|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
76047394|NCT05184413|Other|Multimodal treatment|A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
76047395|NCT05184413|Other|Unimodal treatment|An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
75425509|NCT06035458|Diagnostic Test|Diagnostic radiology|Clinical procedures include bone mineral measurement (bone densitometry, dxa) performed according to clinical practice; venipunctures for laboratory assessments (haematology and blood chemistry; bone turnover biomarkers P1NP and CTX).
75425510|NCT06032598|Dietary Supplement|Berry extract 1|The study foresees the intake of 1 capsule per day during 84 days
75425511|NCT06032598|Dietary Supplement|Berry extract 2|The study foresees the intake of 1 capsule per day during 84 days
75425512|NCT06032598|Dietary Supplement|Placebo|The study foresees the intake of 1 capsule per day during 84 days
75425513|NCT06032169|Other|Patients of a surgical intensive care unit having an arterial catheter|Patients of a surgical intensive care unit having an arterial catheter undergoing noninvasive measurements of AP in the two studied positions (semi-recumbent or horizontal).
75571754|NCT02897804|Behavioral|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
75571755|NCT02897804|Behavioral|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75724246|NCT00888498|Other|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
75724247|NCT00888498|Other|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
75724248|NCT00892788|Behavioral|contingency management|Prize-based contingency management for weight loss
75724249|NCT00892788|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
76047396|NCT05183789|Diagnostic Test|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits).
76047397|NCT01657019|Drug|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
76047398|NCT02329327|Biological|Andexanet|There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
75425514|NCT06030947|Procedure|Coronally Advanced Flap combined with a Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with a connective tissue graft harvested from the palate.
75425515|NCT06030947|Procedure|Coronally Advanced Flap combined with a Meshed Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with a meshed connective tissue graft harvested from the palate.
75425516|NCT06030947|Device|Meshing of Connective Tissue Graft|The harvested connective tissue graft is meshed with a scalpel blade before being unfolded and placed on the recipient site.
75425517|NCT06028295|Dietary Supplement|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
75425518|NCT06028295|Dietary Supplement|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
75425519|NCT06028295|Dietary Supplement|Placebo|The study foresees the intake of 2 capsules per day during 84 days
75425520|NCT06025994|Other|MULTI-DOMAIN LIFESTILE INTERVENTION|All participants in the multi-domain lifestyle group will receive five different kinds of intervention: i) strict management of CV and metabolic risk factors, ii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iii) exercise training iv) dietary counselling, v) psychological intervention.
76047399|NCT05235269|Drug|I124-AT01 only|Intravenous injection of I124-AT01 on Day 1 and again at Week 6 followed by a full body Positron Emission Tomography/Computed Tomography (PET/CT) scan.
76047400|NCT02328937|Device|etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
75425521|NCT06021938|Device|Immersive virtual reality (IVR) & Music therapy|The patient will be offered a digital therapy session based on immersive virtual reality (IVR) and a music therapy session, 60 minutes apart. The IVR session will be based on medical hypnosis (GAMIDA®) and the music therapy session will be based on the choice of music the patient wishes. Each session will last 15 minutes. Patients will start either with the medical hypnosis session by IVR or with the music session depending on the randomization carried out before the start of the study. The random order will be provided by software (CleanWeb).
75425522|NCT06021600|Drug|Cladribine|Given by PO and Given by IV (vein)
75425523|NCT06020781|Drug|bupivacaine and dexmedetomidine.|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
75877657|NCT02745392|Drug|ZP-Zolmitriptan|ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
76047401|NCT02328937|Device|lotrafilcon B|
76047402|NCT02328937|Device|comfilcon A|
76047403|NCT05181605|Drug|Folfirinox and Stereotactic Body Radiotherapy|Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
76047404|NCT02328547|Drug|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
76047405|NCT02328547|Drug|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
75877658|NCT02745392|Drug|Placebo|Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
76047406|NCT02300311|Drug|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
76047407|NCT02300311|Drug|placebo matching nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
76047408|NCT05141903|Dietary Supplement|Dietary supplement, probiotic, antibiotic conditioning -all groups|Dietary supplement, probiotic, antibiotic conditioning -all groups
75425524|NCT06020781|Drug|bupivacaine only|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
75571756|NCT02897804|Behavioral|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75724250|NCT00900978|Biological|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
75724251|NCT04036500|Drug|Estradiol Tablets|Patients will be given estradiol: 1 mg oral or 1 mg sublingual.
75724252|NCT00895596|Drug|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
75724253|NCT00901056|Device|Extracorporeal Shockwave Therapy|Energy Density - 0.02 - 0.15 mJ/mm2
76047409|NCT05140499|Drug|Liposomal bupivacaine|Popliteal nerve block
75425525|NCT06020781|Drug|bupivacaine|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
75425526|NCT06017791|Other|tunnel technique with a 3D printed PEEK shell to fill the skeletal subnasal depression|"The area will be anesthetized using infiltration technique with 1.5ml of anesthetic solution containing Articaine Hydrochloride 68 mg/1.7 ml with Adrenaline 0.017 mg/1.7 ml~Two bilateral full thickness vertical incisions will be created using a #15 blade above the maxillary canines in the alveolar mucosa~A subperiosteal tunnel connecting the two vertical incisions will be created using a periosteal elevator/tunneling knife until the complete communication between the two ends is established~The custom made PEEK framework will be inserted from the incision on one side and eased through until it sits in the subnasal concavity.~Once fitted in place the shell will be fixed in place using two mini screws bilaterally, one on each side.~The two vertical incisions will be closed by interrupted sutures 6-0 Polyglycolic acid suture material"
75425527|NCT06017583|Drug|Tislelizumab|Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed.
75724254|NCT00895674|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
75724255|NCT00892944|Drug|AZD2516|Fractionated single oral dose
75724256|NCT04035330|Combination Product|etidronate in sodium hypochlorite|using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
75425528|NCT06017583|Drug|Capecitabine|Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
75425529|NCT06017583|Drug|Oxaliplatin|Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
75724257|NCT04035330|Combination Product|sodium hypochlorite|irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
76047410|NCT05140499|Drug|Bupivacaine Hydrochloride 0.5 % Injectable Solution|Continuous nerve catheter
76047411|NCT05233631|Procedure|Therapeutic Endoscopic ultrasound|A minimally invasive procedure to assess digestive (gastrointestinal) and lung diseases. Procedure allows detailed imaging of the regional anatomy by approximating the frequency transducer to the region of interest.
76047412|NCT04229381|Procedure|Physical Therapy|Undergo physical therapy
75724258|NCT02540694|Device|Endosonography|
75877659|NCT03622008|Drug|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
75877660|NCT03622008|Other|Placebo|Placebo IV
75877661|NCT04063202|Other|Observation|The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
75877662|NCT01378845|Drug|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
75877663|NCT01378845|Drug|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
76047413|NCT04229381|Other|Quality-of-Life Assessment|Ancillary studies
76047414|NCT04229381|Other|Questionnaire Administration|Ancillary studies
75877664|NCT03606122|Drug|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
76047415|NCT04229381|Procedure|Relaxation Therapy|Undergo progressive muscle relaxation
75425530|NCT06017583|Radiation|SIB-IMRT|The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy.
75425531|NCT06017583|Radiation|IMRT|The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy.
75425532|NCT06008353|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
75425533|NCT06007365|Device|Z5m Dental Implants|This is an observational study, collecting data on the use of Z5m Dental Implants.
75425534|NCT06002906|Drug|Indocyanine green|Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.
75425535|NCT06002906|Device|Stryker 1688 AIM system|The Stryker 1688 AIM system used during laparoscopic surgery which is sensitive in the visible and infrared spectrum. ICG (SPY AGENT™ GREEN) is used with the SPY mode in the Stryker 1688 AIM fluorescence imaging system to perform intraoperative fluorescence angiography.
75425536|NCT06002399|Device|cataract surgery|cataract surgery
75425537|NCT05999955|Drug|Neomycin|The active-control in the phase II study was a commercial form of nasal spray containing Neomycin. Neomycin sulfate is an antibiotic belonging to the group of aminoglycosides that have a bactericidal mechanism due to inhibition of bacterial protein biosynthesis.
75425538|NCT05999955|Combination Product|Bacillus subtilis DSM32444|DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device.
75425539|NCT05998317|Drug|At-night Dexamethasone|Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
75425540|NCT05998317|Drug|At-induction Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
75425541|NCT05996458|Other|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
75425542|NCT05996458|Other|Risk factor investigation;|Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.
75571757|NCT02897804|Behavioral|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75571758|NCT02889250|Device|Medtronic Activa SC DBS, Lead Model 3387|Deep Brain Stimulation
75571759|NCT02889094|Other|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
75571760|NCT02897687|Behavioral|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
75571761|NCT02897687|Behavioral|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
76047416|NCT05178485|Drug|Bupivacain|FDA approved drug
75571762|NCT01262287|Drug|Dutasteride|dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
75571763|NCT01262287|Drug|Placebo|placebo capsules in same number as active drug, daily for 8-week treatment period
76047417|NCT05178485|Other|Normal Saline|FDA approved
75724259|NCT04035096|Drug|Ascorbic Acid|"Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~The final dose will be kept for 12 weeks.~Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
75877665|NCT03606044|Device|3D-models|"The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly"
75724260|NCT04035096|Other|Control group|"Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~Usual care"
75724261|NCT00608322|Drug|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
75724262|NCT00608322|Other|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
75425543|NCT05996458|Other|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
75425544|NCT05996380|Drug|SHR-3167|SHR-3167, Single administration
75425545|NCT05996380|Drug|SHR-3167 Placebo|SHR-3167 Placebo Single administration
75425546|NCT05996354|Device|Concave Supra-arch Branched stent-graft system|To evaluate the efficacy and safety of the Concave Supra-arch Branched stent-graft system for endovascular treatment of aortic arch diseases.
75425547|NCT05988827|Device|NGenuity|Cataract surgery performed under microscope using NGenuity
75724263|NCT04035018|Procedure|pharmacopuncture therapy|The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.
75724264|NCT04035018|Procedure|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
75724265|NCT00608244|Drug|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
75877666|NCT03605888|Behavioral|Koa Family|"Koa Family is a 6-month program consisting of a whole-person lifestyle program (WPLP) combined with text messaging and social media support and a neighborhood tree planting campaign. The WPLP will bring groups of 8 to 10 mothers living in the same community together for 22 weekly 90-minute support sessions. Each session will cover a topic on whole-person living, including healthy eating, physical activity, stress reduction, coping, and well-being. Participants will receive brief text messages on their cell phones to encourage healthy lifestyle choices. Participants also will be invited to join a secret Facebook group where they can support one another in healthy lifestyle change. Finally, participants will have an opportunity to take part in a neighborhood tree planting campaign."
75877667|NCT03076515|Device|Nerivio Migra neurostimulation|transcutaneous electrical stimulation
76047418|NCT05229185|Device|DeXtreme training (error-enhancement)|15-20 min DeXtreme - 15 min conventional therapy - 15-20 min DeXtreme
75425548|NCT05984433|Device|Auricular acupuncture|Electro auricular acupuncture
75425549|NCT05984004|Drug|0.9% NaCl isotonic saline solution|The placebo-control in the phase I study was a 0.9% NaCl isotonic saline solution. This nasal spray solution has no pharmacological effect, but is considered to have a cleansing effect on the nose, supporting the treatment of nasal symptoms in nasal pathology. The solution is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19). The solution is bottled in the same fully-sealed nasal spray device containing Bacillus subtilis DSM 32444 postbiotic, used for Sperovid.
76047419|NCT05175365|Behavioral|Dance|Each session consists of a 60-minute dance class taught by a professional dancer. Dance classes begin with a seated warm-up with various coordination, rhythm, range of motion, memorization and coordination exercises. The level of difficulty of the exercises increases as the sessions progress. Balance is also an important part of training as well as the feeling of being part of a group, of interacting with each other. The hour ends with stretching in a sitting position.
75571764|NCT01262092|Drug|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
75571765|NCT04322071|Other|Interview|Qualitative interviews only
75571766|NCT03455946|Behavioral|DASH cloud with Alexa|"Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system."
75425550|NCT05984004|Combination Product|Bacillus subtilis DSM32444, inactivated|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/PCBA-LA
75571767|NCT03165279|Procedure|Zenith Alpha Abdominal stentgraft|
75571768|NCT04680962|Biological|MabionCD20 (candidate biosimilar to rituximab)|Intravenous infusion, 10 mg/ml concentrate, 500 ml
76047420|NCT05228951|Drug|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
76047421|NCT05174039|Drug|Miglustat 100Mg Oral Capsule|Subjects will initiate miglustat at Week 1 and dosing will be escalated until 600mg/d. If a subject has not reached the maximum dose (600 mg/d) by Week 8, the Week 8 dose will be subject's MTD.
75571769|NCT04680962|Biological|MabThera®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
75571770|NCT04680962|Biological|Rituxan®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
75877668|NCT03076515|Device|Sham Nerivio Migra|electrical stimulation- shame mode
76047422|NCT04422119|Procedure|Multi-Foam dressing|Application of a multi-layer foam dressing with Safetac in surgical wound
75877669|NCT03605810|Other|No Intervention|This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
76047423|NCT04422119|Procedure|Usual care|Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
76047424|NCT02300233|Drug|Volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
76047425|NCT02300233|Drug|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
75571771|NCT01261975|Procedure|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
75571772|NCT01261975|Procedure|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
75571773|NCT02897531|Procedure|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
75571774|NCT02897531|Procedure|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
75571775|NCT00549471|Other|physiotherapy|CG children will undergo a program of intensive physiotherapy
75571776|NCT00549471|Other|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
75571777|NCT01261780|Device|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
75571778|NCT01261780|Drug|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
75571779|NCT02897843|Device|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
75571780|NCT02897843|Device|sham tDCS|sham tDCS
75571781|NCT03088410|Drug|Zidovudine|neonatal 4 weeks prophylactic
75571782|NCT03088410|Drug|Nevirapine|neonatal 4 weeks prophylactic
75571783|NCT02897765|Biological|NEO-PV-01|Personal cancer vaccine
75571784|NCT02897765|Biological|Nivolumab|monoclonal antibody against PD1
75571785|NCT02897765|Other|Adjuvant|immune adjuvant
75571786|NCT02897570|Dietary Supplement|Glucose|50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
76047426|NCT05137379|Behavioral|A joint functional score based on the affected joint|A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )
75571787|NCT02897570|Dietary Supplement|Milk & Cereals|A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
75571788|NCT02897570|Dietary Supplement|Milk, apple & snack|A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
75571789|NCT02897570|Dietary Supplement|Milk, apple & bread w/ cream|A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
75571790|NCT02897570|Device|EEG_pre|Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
75571791|NCT02897570|Device|EEG_post|Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
76047427|NCT02175225|Drug|Deferoxamine Mesylate|
76047428|NCT02175225|Drug|Placebo (for Deferoxamine Mesylate)|
76047429|NCT05170841|Drug|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 MG|Administered as one single tablet to be taken every 8 hours
76047430|NCT05170841|Drug|Tramadol Hydrochloride 100 MG|Administered as two capsules with 50 mg each to be taken every 8 hours
75425551|NCT05982860|Behavioral|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been established by Morris et al. (2015) to improve brain health, and reduce the risk or slow progression of neurodegenerative diseases. In this diet model, which is similar to the Mediterranean diet, the diet score changes according to the frequency of consumption of some foods. The more consumption of foods such as green leafy vegetables, other vegetables, berries, nuts, whole grains, fish (not fried), beans, poultry (not fried), and the limited consumption of butter/margarine, cheese, red meat and products, fast fried foods, and pastries & sweets ensure more score. Also, regular consumption of wine (1 glass/d) and using olive oil as primary oil in meals increases the score. Berries, fish, and hardaliye (instead of wine) will be supplied to players as well as recommendations for consumption frequencies of food components in MIND diet to increase total score.
75425552|NCT05982548|Other|VR intervention|"VR intervention of no more than 7 minutes~Participants viewed the home as a first person character and experience psychotic phenomena including auditory hallucinations."
75425553|NCT05982548|Other|VR control intervention|"VR intervention of no more than 7 minutes~Participants viewed the same home as a first person character without psychotic phenomena"
75425554|NCT05982262|Other|Naturopathic-pharmacological consultation|The naturopathic-pharmacological consultation includes a naturopath and a clinical pharmacist and will consist of at least two meetings.
75425555|NCT05978713|Drug|Tirzepatide|Administered SC
75425556|NCT05975385|Device|Acupuncture|Acupuncture at points points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang
75425557|NCT05974852|Other|Ocrelizumab|Non-interventional
75425558|NCT05974839|Other|Ocrelizumab|Non-interventional
76047431|NCT05170841|Drug|Placebo|Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 MG or two capsules if matching Tramadol Hydrochloride 100 MG
75425559|NCT05974254|Device|Acupuncture|Electroacupuncture
75724266|NCT00608244|Drug|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
75724267|NCT00893100|Drug|Diltiazem|2%,3 times daily
75724268|NCT00895908|Behavioral|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
75724269|NCT00895908|Behavioral|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
75724270|NCT00895986|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
75724271|NCT00895986|Behavioral|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
75724272|NCT02539914|Other|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
75724273|NCT02539914|Other|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
75724274|NCT00901212|Device|Device programming|6-month period
76047432|NCT05169671|Drug|ATH-1020|ATH-1020 in oral capsule form
76047433|NCT05169671|Drug|Placebo|Placebo in oral capsule form
75425560|NCT05973383|Behavioral|LongLife Active- Basic|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars."
75571792|NCT04686162|Other|bae application|"Patients will be assisted by a research team member to install and configure the application bae on their smartphone; then, they will be trained to use it.~Bae proposes 4 types of assessments :~5 times a day during 3 days, every month (5 minutes) : patients can assess their emotions, their thoughts, their behavior and their occurrence context.~Weekly (7 minutes) : consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends), and their quality of life.~Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.~Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help.~They can contact a relative or call the psychiatric emergency service directly by clicking on a button.~Patients can try to identify their own warning signs, to prevent suicidal behavior."
75425561|NCT05973383|Behavioral|LongLife Active- Standard|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Standard are also offered a community with social support."
75571793|NCT02897492|Other|Blood testing in a newly described method|"To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations."
75571794|NCT02897180|Biological|Nyaditum resae(R)|Capsules containing Nyaditum resae(R)
75571795|NCT02897180|Biological|Placebo|Capsules containin Placebo
75571796|NCT00549588|Other|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
76047434|NCT05109221|Device|ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients
76047435|NCT05107583|Behavioral|Low-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
76047436|NCT05107583|Behavioral|High-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
75571797|NCT00549588|Other|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
75571798|NCT00549588|Other|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
75571799|NCT00549588|Other|Intervention: none (only UV)|
75877670|NCT03605732|Behavioral|self help sleep hygiene intervention application|This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.
75571800|NCT02897102|Behavioral|Training|Training program based on abacus and other activities
75571801|NCT02897102|Other|Different group activities|ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
75571802|NCT01261624|Drug|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
75877671|NCT03605732|Other|patients education|Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
76047437|NCT05107583|Behavioral|Fasted Exercise|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
76047438|NCT05106491|Device|Synchronized Cardiac Support with the icor kit|Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
75571803|NCT02888938|Other|pelvic radiography|
75571804|NCT02888938|Other|pelvic MRI|
75571805|NCT02888938|Other|pelvic CT-scan|
75571806|NCT04322032|Drug|Reference drug|D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.
75571807|NCT04322032|Drug|Test drug|CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
75724275|NCT00896376|Biological|trastuzumab|
75724276|NCT00896376|Other|laboratory biomarker analysis|
75724277|NCT00896376|Other|pharmacological study|
75724278|NCT00901290|Drug|monophasic oral contraceptive|mg, oral dose
75724279|NCT00901290|Drug|AZD7325|mg, oral dose
75724280|NCT04018014|Other|CT angiography|CT angiography in detection of pulmonary embolism
76047439|NCT05135273|Biological|Pfs230D1-EPA/Matrix-M Vaccine|Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.
75571808|NCT03711331|Other|FilmArray® Pneumonia panel plus|Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
75571809|NCT03711331|Other|Standard care|Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results
75425562|NCT05973383|Behavioral|LongLife Active- Premium|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Premium are also offered a community with social support plus private on-line health consultations. The number of private health consultations is 3 for a 3 months subscription, 4 for a 6 months subscription, and 6 for a 12 months subscription."
75571810|NCT02887053|Device|MRI|
75724281|NCT00893256|Drug|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
75571811|NCT04321798|Behavioral|Physical Activity|Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
75724282|NCT00893256|Drug|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
75724283|NCT00893256|Drug|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
75724284|NCT00893256|Drug|Placebo|Placebo: once daily
75877672|NCT04951635|Drug|Almonertinib|"The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
75571812|NCT05532982|Other|Interviews and Surveys|Qualitative interviews and surveys
75724285|NCT00605280|Drug|Standard of Care|Clinicians decision to use optional laser therapy.
75877673|NCT04951635|Drug|Placebo Almonertinib|"The initial dose of Placebo Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
76047440|NCT05135273|Biological|Verorab Rabies Vaccine|Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.
75724286|NCT00605280|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
76047441|NCT05133713|Device|Catheter directed therapy|Thrombectomy
75571813|NCT02897336|Procedure|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
75571814|NCT02897336|Procedure|interlaminar|interlaminar epidural corticosteroid injection
75571815|NCT04321642|Drug|Entonox|Entonox gas with mouth piece
75571816|NCT04321642|Drug|Not receive Entonox|Not receive any gas
75571817|NCT04321681|Other|no intervention|no intervention
75571818|NCT02897219|Drug|ipragliflozin|Oral administration once daily
75571819|NCT02897219|Drug|Placebo|Oral administration once daily
75571820|NCT02897219|Other|Insulin Therapy|Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
75724287|NCT00901368|Drug|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
75724288|NCT00901368|Drug|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
75724289|NCT00607386|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
75724290|NCT04034940|Other|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
76047442|NCT05133713|Drug|Systemic anticoagulation|Conservative therapy
75724291|NCT00901446|Device|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
75571821|NCT04321603|Behavioral|Walking|Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
75425563|NCT05970484|Behavioral|DrinksRation|DrinksRation (www.drinksration.app; formerly called InDEx) app was developed following the Medical Research Council Complex Intervention Guidelines and using a co-design methodology. It was developed by the King's Centre for Military Health Research (King's College London) and Lancaster University, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app was designed to support veterans drinking at a hazardous or harmful level by providing bespoke advice and support.
75425564|NCT05970484|Behavioral|BeAlcoholSmart|BeAlcoholSmart is a progressive web app (PWA). The app can take advantage of smartphone features such as push notifications and haptics without requiring the participant to download via an app store. The app will contain a 7-day alcohol unit calculator and generic public health guidance on safe drinking. Participants will also receive reminders via email prompting them to consult the guidance as part of the BeAlcoholSmart. Control participant participants will be invited to complete all questionnaires via Qualtrics, with an email reminder being sent when they are due.
75571822|NCT02882685|Procedure|Roux-en-y gastric bypass|
75571823|NCT02882685|Procedure|Single anastomosis gastric bypass|
75877674|NCT03984968|Biological|CD19 CAR-T cells infusion combined with feeding T cells (FTCs)|"Phase1 study Optimal biological doses of feeding T cells identification CAR-T cells infusion combined with FTCs will be given in Philadelphia chromosome positive B-ALL patients with remission. FTCs will be administered at the dose of 5×106/kg, 3.25×106/kg or 2×106/kg two hours after ssCART-19 infusion on day 1 and once again administered at the same dose on day 8.~Phase 2 Expansion Study CAR-T cells infusion combined with FTCs at optimal biological dosage determined in Phase 1 study will be given in expanded Philadelphia chromosome positive B-ALL patients with remission. Bayesian optimal design is applied in this Phase 2 study to monitor the toxicity and efficacy at the specified interim analyses. The total expected sample sizes are 40."
75425565|NCT05965895|Procedure|Ultrasound-guided continuous serratus anterior plane block|Patients will receive US-guided SAP block with a bolus of 2 mg/kg levobupivacaine made up to a volume of 40 ml followed by an infusion of 0.125% levobupivacaine will be commenced at rate of 8 ml/hr for 48 hr.
75425566|NCT05965895|Drug|intravenous dexmedetomidine infusion|Patients will receive initial loading dose of dexmedetomidine of 1 µg/kg over 30 min followed by a continuous infusion at a rate of 0.5 µg/kg/hr for 48 hr.
75425567|NCT05964400|Behavioral|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
75425568|NCT05963425|Other|Physical activity|This physical activity program will be based only on the work of basic physical traininig, in which specifically and mainly the strength and resistance will be worked, but also flexibility
75425569|NCT05963425|Other|usual clinical practice|usual clinical practice
75571824|NCT04321720|Other|3-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.
75571825|NCT04321720|Other|6-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.
75571826|NCT04321720|Other|12-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.
75571827|NCT04321720|Other|Warm water only|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
75571828|NCT04321837|Dietary Supplement|Coral Complex 3|Coral-derived calcium supplement fortified with vitamin D3
75571829|NCT04321837|Drug|Ibandronate|Bisphosphonate
75571830|NCT04321837|Dietary Supplement|Vitamin D3|Oral vitamin D3
75571831|NCT02897414|Other|Surveillance of state medical examiner databases|
75724292|NCT00901524|Drug|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
75724293|NCT00893412|Drug|Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)|1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
75724294|NCT00893412|Procedure|Hysterosalpingography (HSG)|One HSG using a metal canula or balloon catheter, 30 minutes after tablet
75724295|NCT00893412|Drug|Placebo|
75724296|NCT00896688|Procedure|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
75724297|NCT00896766|Genetic|loss of heterozygosity analysis|
75724298|NCT00896766|Genetic|microarray analysis|
76047443|NCT05133089|Device|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
76047444|NCT05224427|Behavioral|Near-Peer Coaching|Targeted coaching by near-peer medical students
76047445|NCT05129423|Drug|MTPS9579A|MTPS9579A will be administered.
76047446|NCT05129423|Drug|Placebo|Placebo matched with MTPS9579A will be administered.
76047447|NCT05129189|Drug|ASC22 group|The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
75425570|NCT05959746|Other|AI-STROKE application|Complete neurological exam of stroke patients will be filmed by healthcare workers and themselves using the AI-STROKE application
76047448|NCT02299375|Drug|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
75425572|NCT05958225|Behavioral|SEE Change Business and Personal Agency Training|"A three day residential training based on SEE Change's Empowered Entrepreneur Training curriculum. This training will be led by a certified SEE Change trained facilitator. The workshop will include individual and group exercises that allow participants to increase their self-awareness, build mental tools for resiliency and adaptability in their life, create life visions and key tools to create behavior change. Additional exercises will include specific business related content including record keeping, financial planning and marketing strategies based on the Business Model Canvas tool.~After the 3 day training, the participants will receive a supportive message through an interactive voice recording, once a week for 6 weeks. In addition, they will be contacted once a month, for three months (either by phone or in person) by the trainer to see how they are doing on their goals."
76047449|NCT02299375|Drug|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
76047450|NCT02299375|Drug|Salbutamol MDI|Salbutamol MDI will be provided as a rescue medication.
75425573|NCT05957822|Drug|TXA|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
75425574|NCT05957822|Diagnostic Test|TEG6|performing thromboelastography (TEG6)
75425575|NCT05956171|Other|Intra-articular corticosteroid injection|5 ml blind intra-articular corticosteroid injection
75425576|NCT05956171|Other|Ultrasound Guided Hydrodilatation with corticosteroid injection|15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance
75571832|NCT02858934|Radiation|Tomotherapy|"Dose prescription:~Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).~Target volumes:~Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.~Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.~CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.~Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface."
75724299|NCT00896766|Genetic|polymorphism analysis|
76047451|NCT04421651|Behavioral|Dance Movement Therapy group|DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks.
76047452|NCT05223959|Behavioral|Culturally adapted Psychoeducation|This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).
76047453|NCT02151903|Drug|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
76047454|NCT05221307|Other|exercises|Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
75724300|NCT00896766|Genetic|tumor replication error analysis|
76047455|NCT05102201|Device|Paro (social robot) intervention|Participants in the Paro group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks
75571833|NCT02897453|Device|The Spinal Tethering System|An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
75724301|NCT00896844|Behavioral|emotional disclosure|writing about emotional events from the past
75724302|NCT00896844|Behavioral|placebo writing|writing about how they spent their time the previous day
75724303|NCT04036344|Behavioral|Peer Mentorship Program|Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
75724304|NCT00893490|Device|Ahmed Glaucoma Valve (AGV)|AGV implantation
76047456|NCT02151591|Drug|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
76047457|NCT05101421|Dietary Supplement|Rice ceramide supplementation|At the dosage of 40mg daily for 3 months
76047458|NCT02174523|Drug|40mg lurasidone|
76047459|NCT02174523|Drug|placebo|
76047460|NCT05099783|Diagnostic Test|late gadolinium enhanced magnetic resonance imaging|Candidate inpatients or outpatients will be identified if pharmacological or electrical cardioversion has be performed and MRI were performed after cardioversion at least twice.
75425577|NCT05954182|Behavioral|Cognitive Intervention|This is a virtual, group cognitive intervention. 12 live, weekly sessions will occur during the first 3 months of the study. Groups will be made up of 5-10 participants and will be led by a neuropsychologist. These sessions will include education on the brain and cognitive function as it relates to epilepsy, as well as compensatory strategies for use in daily life. After the 12 sessions, participants will be asked to continue to practice what they learned for the next nine months until their participation ends.
75724305|NCT00893490|Drug|Mitomycin C (MMC)|3 minute MMC application
76047461|NCT05128877|Other|relaxation techniques|Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
75724306|NCT00893490|Procedure|amniotic membrane coverage|single layer coverage of amniotic membrane
75571834|NCT00549627|Device|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
75571835|NCT02896829|Behavioral|Interruption of the treatment by Imatinib|
75571836|NCT02854566|Device|osteosynthesis|Fracture reduction and fixation with screws/plates/cables (standard of care)
75571837|NCT00549666|Drug|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
75571838|NCT00549666|Drug|Placebo 40 mg|Placebo 40 mg once daily during treatment period
75724307|NCT00901758|Drug|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
75571839|NCT00549666|Drug|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
76047462|NCT02297815|Drug|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
76047463|NCT02297815|Drug|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
75571840|NCT04680806|Device|Er,Cr:YSGG laser 2780 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
75724308|NCT00901758|Drug|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
75724309|NCT00893568|Other|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
75571841|NCT04680806|Device|Diode laser 940 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
75571842|NCT04680767|Drug|LY3502970|Administered orally.
75571843|NCT04680767|Drug|[¹⁴C]-LY3502970|Administered orally.
75724310|NCT00896922|Genetic|microarray analysis|
75724311|NCT00896922|Other|immunohistochemistry staining method|
75724312|NCT00896922|Other|laboratory biomarker analysis|
75724313|NCT02539680|Procedure|endoscopy|duodenal biopsies
75877675|NCT04884399|Drug|CMAB818|vascular endothelial growth factor (VEGF) inhibitor
75877676|NCT04884399|Drug|Lucentis®|vascular endothelial growth factor (VEGF) inhibitor
76047464|NCT02114385|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
76047465|NCT02114385|Biological|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
75877677|NCT03605576|Procedure|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
76047466|NCT05220605|Drug|BromAc|Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.
76047467|NCT05098457|Device|GP0112|Injectable gel
76047468|NCT05098457|Device|Restylane Lyft Lidocaine|Injectable gel
75724314|NCT00901836|Radiation|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
75425580|NCT05945602|Other|Neurophysiologic Biomarker Assessments|Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.
75571844|NCT00551538|Drug|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
75571845|NCT00551538|Drug|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
75425581|NCT05943626|Behavioral|Circadian Intervention|The circadian intervention group will receive counseling and instruction to reduce evening and nighttime light exposure, increase morning room light and sunlight exposure, and to finish all food consumption at least 4 hours before bedtime.
75425582|NCT05942495|Behavioral|short-term schema focused group therapy|There are two intervention phases. The first concerns the pre-treatment phase, which consists of five online sessions and three face-to-face sessions. The second intervention phase is the short-term SFGT. The SFGT consists of 17 weekly group sessions.
75425583|NCT05939674|Drug|Flumazenil|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.3mg of flumazenil according to allocated groups.
75425584|NCT05939674|Drug|normal saline|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.9% normal saline according to allocated groups.
75425585|NCT05939427|Other|NGAGE tool|Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
75571846|NCT04680494|Other|moderate intensity physical exercise|
75571847|NCT04680494|Other|high intensity physical exercise|
75571848|NCT04680494|Other|rest|
75571849|NCT03694522|Biological|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
75571850|NCT03694522|Drug|Placebo|Administered by intravenous infusion over approximately 30 minutes
75571851|NCT03694522|Drug|Modified FOLFOX6|"mFOLFOX6 regimen consists of the following:~Oxaliplatin 85 mg/m² IV infusion over 120 minutes~Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours"
75571852|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
75571853|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
75571854|NCT04931901|Device|EMG TOF device|Use of Stimpod NMX450X as an electromyographic neuromuscular monitor
75571855|NCT04207645|Diagnostic Test|Modified RIPASA score|Clinical Prediction Rules consist of clinical and laboratory parameters to aid diagnosis of acute appendicitis
75571856|NCT05512585|Other|awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)|in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
75571857|NCT02896790|Other|Interviews with 2 oncologists and 10 patients|
75571858|NCT02896790|Other|Interviews with 15 patients|
76047469|NCT02114151|Drug|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
76047470|NCT02114151|Drug|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
75724315|NCT00901836|Procedure|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
75724316|NCT04017780|Device|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
75724317|NCT04017780|Device|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
75724318|NCT04017780|Device|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
75724319|NCT00897078|Other|laboratory biomarker analysis|
75724320|NCT00897078|Other|medical chart review|
75724321|NCT00897078|Other|metabolic assessment|
75724322|NCT00897078|Other|questionnaire administration|will be obtained at a single clinic visit
75724323|NCT00897078|Procedure|assessment of therapy complications|
75425586|NCT05937308|Device|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
75571859|NCT04207528|Behavioral|Writing|After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
75724324|NCT00638690|Drug|Placebo|Four tablets once daily until disease progression
75571860|NCT04319848|Other|TE-EK treatment group|Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
75571861|NCT02897024|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
75877678|NCT03605576|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
75877679|NCT01378767|Dietary Supplement|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
75877680|NCT03607604|Genetic|Next generation sequencing (NGS)|Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
75877681|NCT04868721|Procedure|micro-osteoperforations|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
75877682|NCT03605420|Other|Family visit prior to hospital admission|Family receiving one visit prior to hospital admission for surgery
75724325|NCT00638690|Drug|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
75724326|NCT00638690|Drug|Prednisone/prednisolone|5 mg twice daily until disease progression
75724327|NCT02540928|Drug|AMG 319 hydrate|
75724328|NCT02540928|Drug|Placebo|
75724329|NCT00893646|Behavioral|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
75724330|NCT00893724|Drug|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
75877683|NCT03170609|Biological|Multivalent group B streptococcus vaccine|Various formulations at three dose levels
75877684|NCT03170609|Biological|Placebo|Saline Control
75877685|NCT03605186|Other|Chamomile oral cryotherapy|The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
75571862|NCT04207489|Procedure|endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer|Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
75571863|NCT04320160|Procedure|Platelet rich plasma|"Eight milliliters of blood sample will be aspirated from the patient's peripheral vein, and the sample will be centrifuged at 1,500 rpm for 5 minutes.~A 30-G needle will be used for superficial intradermal (ID) microinjections (0.1 mL per injection and space about 1 cm apart)"
75571864|NCT04320160|Procedure|Fractional CO2 laser|"Fifteen lesions will be treated by Fr: CO2 laser (10,600 nm; KES Corporation, Beijing, China).~Scanner spot size will be adjusted based on the lesion size. Density selected will be 0.6 in the static mode.~Two passes with minimal overlap will be delivered. The laser will be applied to the vitiligo lesion and over a thin rim of healthy skin"
75571865|NCT03678493|Biological|Fecal Microbiota Transplant (FMT)|Oral Capsule
75571866|NCT03678493|Other|Placebo|Oral Capsule
75571867|NCT02896946|Radiation|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
75571868|NCT04321447|Other|Clinical practice guideline for prevention and management of extravasation injury|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
75571869|NCT00624169|Procedure|An optimized perioperative course|A number of interventions before, during and after surgery
75571870|NCT03627130|Drug|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
75571871|NCT03627130|Drug|Potassium Chloride|Potassium Chloride capsules for 5 days
75571872|NCT02896868|Drug|LY3041658|Administered IV.
75571873|NCT02896868|Drug|Placebo|Administered IV.
75571874|NCT04321096|Drug|Camostat Mesilate|Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
75571875|NCT04321096|Drug|Placebo oral tablet|Placebo
75571876|NCT00549861|Procedure|Cardiac Magnetic Resonance study|Cardiac MRI study
75571877|NCT04321018|Dietary Supplement|Mixed meal with medium chain triglycerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.
75571878|NCT04321018|Dietary Supplement|Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
75571879|NCT04320784|Other|Time restricted eating|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
75571880|NCT04320784|Other|Control|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
75724331|NCT00893724|Dietary Supplement|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine [SR] - 1[500mg] tablet bid Tocopherols [200IU], Tocotrienol [10mg], CoQ10 [50mg] - combination capsule bid Sustained Release Niacinamide - 1 [750mg] tablet bid Vitamin C - 1 [1000mg] sustained release tablet bid N-acetyl Cysteine - 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
75877686|NCT03605186|Other|Oral cryotherapy|The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
75571881|NCT03556696|Device|ANI-REMI-loop|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
75571882|NCT03556696|Device|remifentanil pK/pD target administration device|standard practice, remifentanil administration using Minto's pK/pD model
75571883|NCT03556696|Drug|Remifentanil|Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the [50-70] range.
75571884|NCT03556696|Drug|Propofol|propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in [40-60] range
75571885|NCT03556696|Device|ANI monitor|"ANI (Analgesia Nociception Index) value is used in the std_practice arm for guidance of the remifentanil Ce target"
75571886|NCT04320706|Drug|Oral Oxytocin|Administration of oxytocin (24 international units) orally
75571887|NCT04320706|Drug|Oral Placebo|Administration of placebo orally
75571888|NCT03523819|Drug|CS1002|Dose levels will be escalated following a modified 3+3 dose escalation scheme
75571889|NCT03523819|Drug|CS1003|Fixed dose at 200mg in combination with CS1002 on a specified dose level
75571890|NCT04207567|Behavioral|Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays|Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
75571891|NCT02896673|Procedure|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A"
75724332|NCT00893724|Drug|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine [SR] - 1 [500mg] tablet bid Tocopherol [200IU], Tocotrienol [10mg], CoQ10 [50mg] combination capsule bid Sustained Release Niacinamide 1 [750mg] tablet bid Vitamin C 1 [1000mg] sustained release tablet bid N-acetyl Cysteine 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 [50mg] tablet qd
75724333|NCT00893802|Other|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
75724334|NCT00819338|Dietary Supplement|Efamax|5g daily as capsules for 3 months
76047471|NCT05098379|Behavioral|Tele-Rehabilitation Home Exercise Program|"Participants will engage in 150 minutes of exercise per week (30 min/day for 5 days/week) for 8 weeks and will have weekly virtual Exercise Coaching sessions with a trained project team member. Customized home exercise programs will be reviewed weekly during the coaching sessions and will be modified as needed to ensure participants can complete their exercises safely and effectively. Exercise coaches will send weekly messages to 'check-in' with participants in order to motivate and remind participants to adhere to their tailored home exercise programs.~During weekly exercise coaching sessions, exercises will be reviewed for form, safety, and progression. Exercises will be revised as needed to ensure that they are in line with participants' goals, needs, and preferences."
76047472|NCT05220293|Drug|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.
75571892|NCT02888704|Drug|ADSTEM Inj. (Adult human mesenchymal stem cells)|Comparison of different dosages of the drug in the aspect of safety and efficacy.
75571893|NCT03512158|Other|Non-invasive respiratory support mode|A mode of providing respiratory support via nasal masks or prongs
75571894|NCT02896439|Device|Neurophysiological MONITORING|"The neurophysiology team perform:~Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~Establishment of a spacer or forceps in the greater or lesser sciatic notch~Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~At the end of the incision~On the establishment of a spacer or forceps in the greater or lesser sciatic notch~When towing layout~At the end of the intervention"
75724335|NCT00893880|Drug|1% gaseous Nitric Oxide blended in Oxygen|1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
75724336|NCT00815438|Procedure|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
75571895|NCT02896478|Other|No intervention. Only observational study|
75571896|NCT02896322|Radiation|Partial breast irradiation with cyberknife|
75724337|NCT00815594|Drug|bevacizumab|0.05ml, 1.25mg
75724338|NCT00897234|Other|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
75571897|NCT02896166|Other|microwave ablation|eligible patients will be treated with microwave ablation in the primary tumor sites
75571898|NCT00553709|Drug|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
75571899|NCT02896244|Other|no intervention|
75571900|NCT00551694|Drug|GSK256073A tablets|
75571901|NCT00551733|Drug|carboplatin|Given IV
75571902|NCT00551733|Drug|paclitaxel|Given IV
75571903|NCT00551733|Drug|paclitaxel poliglumex|Given IV
75571904|NCT02896283|Radiation|Low-level laser therapy|Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
75571905|NCT02896283|Radiation|Turned-off laser|Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
75571906|NCT00551772|Drug|SB-742457|
75571907|NCT02896205|Drug|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
75571908|NCT02896205|Drug|Placebo|Subjects will be given matching placebo for 6 months
75724339|NCT00815672|Behavioral|Exercise|Progressive walking and resistance exercise treatment
75571909|NCT04922424|Drug|Atorvastatin|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.
75571910|NCT04922424|Other|placebo|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential
75571911|NCT00550056|Behavioral|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
75571912|NCT00550056|Behavioral|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
75724340|NCT00897312|Biological|infliximab|
76047473|NCT05220293|Device|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
75571913|NCT02896634|Biological|clinical biology analyzes spectrometry mass|clinical biology analyzes spectrometry mass
75571914|NCT00551811|Drug|SB-656933-AAA|SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
75571915|NCT00551811|Drug|Placebo|Placebo tablets will be intended to be administered orally.
75571916|NCT00553748|Drug|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
75571917|NCT00551850|Drug|AV-412|oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
75571918|NCT02896049|Device|Hyperthermia|treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
75571919|NCT00550095|Drug|valsartan|
75571920|NCT02895893|Behavioral|PrEP Smart|Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
75571921|NCT00551889|Drug|celecoxib|
75571922|NCT00551889|Drug|cyclophosphamide|
75571923|NCT00551889|Other|laboratory biomarker analysis|
75571924|NCT00550212|Drug|neratinib|HKI-272, Single-dose capsule and solution
75571925|NCT02895932|Radiation|PET imaging|Serotonin, Dopamine and Amyloid PET imaging
75571926|NCT00551967|Procedure|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
75571927|NCT02896010|Other|Sweetch App + DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
75571928|NCT02896010|Other|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
75571929|NCT00552006|Behavioral|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
75724341|NCT00897312|Biological|pegylated interferon alfa|
75724342|NCT00897312|Biological|ticilimumab|
75724343|NCT00897312|Drug|ribavirin|
75724344|NCT00897312|Other|high performance liquid chromatography|
75724345|NCT00897312|Other|laboratory biomarker analysis|
75724346|NCT02540460|Drug|LCB01-0371 800mg|LCB01-0371 800mg
75724347|NCT02540460|Drug|LCB01-0371 800mg BID|LCB01-0371 800mg BID
75724348|NCT02540460|Drug|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
75724349|NCT02540460|Drug|Placebo|Placebo
75724350|NCT00543387|Drug|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
76047474|NCT04752189|Behavioral|Enhanced Replicating Effective Programs (Enhanced REP)|Deploy Enhanced REP to optimize the delivery of a drug use prevention intervention in community schools and test its feasibility, acceptability, and appropriateness; Enhanced REP includes tailoring the curriculum, training, and providing ongoing provider consultation, or facilitation, to support implementation.
76047475|NCT04752189|Behavioral|Standard implementation|Standard implementation of the Michigan Model for Health is akin to Standard REP and includes the curriculum materials, standard training and as-needed technical assistance.
75425587|NCT05936047|Biological|Vertebral bone marrow clot|vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot will be applied on each side of the vertebra according to the number of segments to be fused.
75425588|NCT05935306|Drug|Ibuprofen|All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.
75425589|NCT05935306|Other|Photobiomodulation simulation|The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off.
75425590|NCT05935306|Device|Photobiomodulation|. Patients will receive FBM and will be treated identically to the G2 group. The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away.
75425591|NCT05935306|Other|Ibuprofen simulation|Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)
75425592|NCT05934838|Drug|Tazemetostat Pill|Participants will take 800 mg of tazemetostat twice a day starting 7 days before apheresis and continue to take tazemetostat until lymphodepletion, which is chemotherapy given prior to receiving the CAR T cells. Participants will stop taking tazemetostat after lymphodepletion until after CAR T cell infusion. Once lymphocyte counts increase, tazemetostat will be resumed and tazemetostat will be taken for 6 - 12 months, depending on participant response.
75425593|NCT05930678|Procedure|No ventilation with face mask|During the period of apnea (in general anesthesia), the patient did not help with face mask
75425594|NCT05930678|Procedure|Ventilation with face mask|During the pperiod of apnea (in general anesthesia), the patient did help with face mask
75425595|NCT05926219|Behavioral|Fatiguing Exercise|Volunteers will perform knee extension exercise of the dominant limb while seated in a chair designed for exercise of the knee extensor muscle group. The chair will be equipped with a lever arm, aligned with the axis of rotation of the knee and fixed to the distal shank, 2 centimeters proximal to the ankle joint. The lever arm will be instrumented to provide resistance and measure velocity. The volunteers will perform 3-5 maximum voluntary contractions (MVC) to determine peak torque. Once established, volunteers will rest for 5 minutes before initiating the fatigue protocol, whereby they will perform repeated MVC of the dominant limb against resistance equal to or less than 50% of MVC until range of motion cannot be maintained. Because the goal of this exercise is to uniformly fatigue the quadriceps muscle group, this exercise will be performed continuously. It is expected to take between 1 and 3 minutes to achieve the desired level of fatigue.
75571930|NCT00552006|Behavioral|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
75571931|NCT02895854|Radiation|Hypofractionated RT 5 x 7,25 Gy|
75571932|NCT02895854|Radiation|LDR-brachytherapy with I125 seeds|
75571933|NCT00550251|Device|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
75724351|NCT00543387|Drug|docetaxel|Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m^2 Q12H during the first 2 days of each 21-day cycle.
76047476|NCT02297503|Drug|Azzalure|Glabellar lines
76047477|NCT02297503|Device|Restylane/Emervel filler|Facial tissue augmentation
76047478|NCT02297503|Device|Restylane Skinbooster|Facial skin rejuvenation
76047479|NCT04421885|Drug|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
76047480|NCT04421885|Drug|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
76047481|NCT02113449|Drug|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
76047482|NCT02366923|Device|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
76047483|NCT02366923|Device|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
76047484|NCT02326597|Other|Decision Aid Tool|The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
75877687|NCT01314755|Dietary Supplement|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
75877688|NCT01314755|Dietary Supplement|An iso-caloric, iso-nitrogenous control feed|
76047485|NCT02326597|Other|Standard Practice|Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
75571934|NCT00550251|Device|Placebo wristbands|Elasticated wrist bands without active bead.
75571935|NCT01261390|Behavioral|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
75877689|NCT03605108|Dietary Supplement|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs~HU36 - 30 mg~HU58 - 20 mg~Bacillus clausii -25 mg~Bacillus coagulans 10B - 35 mg~Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
75877690|NCT03605108|Other|Placebo|Rice flour only
75425596|NCT05921487|Behavioral|Time Restricted Eating|Time Restricted Eating Protocol: Subjects will be instructed to limit caloric consumption to a 12-hour TRE window for the first two weeks of the study, and then transition to a 10-hour TRE window. The window start-time will be self-selected (individualized). During the eating window, subjects will not be restricted on types or quantities of food consumed, and will be advised to continue their usual diets. Subjects will not be required to monitor their caloric intake. During the fasting period, subjects will be encouraged to stay hydrated and drink ample water. Outside the designated eating window, subjects are only permitted to consume medication, water, or zero-calorie herbal drinks such as unsweetened tea or black coffee.
75425597|NCT05910736|Behavioral|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
75425598|NCT05910216|Other|Dance & Music (Online)|This is a social telerehabilitation with dance and music. It will include artistic form, imageries using scenic arts, imageries using aspects of theater and storytelling, movement improvisation, choreography and sequence of movements, complex dance movements, fluidity of movement or connection between one movement and another, rhythmicity and/or movement built with music. It will include instructions for motor learning, music, and socialization
75425599|NCT05910216|Other|Multimodal Therapeutic Exercise & Music (Online)|This is a social telerehabilitation with multimodal therapeutic Exercise and Music. It is restricted to the execution of movements within series and standardized and fixed repetitions, with a background music. It will not include dance. It will include instructions for motor learning, music, and socialization.
75571936|NCT01261390|Device|Sham PAP (Sham)|In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
75877691|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
75877692|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
75425600|NCT05900466|Drug|Metformin|500 mg Metformin ER tablets once daily in the morning for 8 weeks
75425601|NCT05900466|Drug|Placebo|Matching tablets once daily in the morning for 8 weeks
75877693|NCT04904549|Biological|Placebo|Pharmaceutical form: liquid. Route of administration: intramuscular administration.
76047486|NCT02366767|Device|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
75425602|NCT05895929|Drug|Mepolizumab|In vitro exposure of human nasal epithelial cells to mepolizumab
75877694|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
76047487|NCT02366767|Device|Control|Threshold suspend
76047488|NCT02150343|Drug|HDM-SPIRE|1 dose every 4 weeks
76047489|NCT02150343|Drug|Placebo|1 dose every 4 weeks
76047490|NCT02149875|Drug|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
76047491|NCT02149875|Drug|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
76047492|NCT02149875|Drug|Placebo|100 ml saline intravenous infusion once daily for 10 days.
76047493|NCT05096507|Procedure|Hip fracture Surgery (Primary)|Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
75877695|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
75724352|NCT02551250|Device|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
75724353|NCT02551250|Device|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
75877696|NCT03605030|Device|Novel Lead Based Armboard|Novel Lead Based Armboard
75877697|NCT03605030|Device|Standard Armboard|Standard Armboard (without lead)
76047494|NCT05125367|Procedure|coronary stent implantation|coronary stent implantation using everolimus-eluting balloon expandable stents
75724354|NCT03455556|Biological|Anetumab Ravtansine|Given IV
75877698|NCT03604952|Diagnostic Test|COPD patients|Tests performed one week before Ramadan (C), and during the second (R-2) and the fourth weeks of Ramadan (R-4)
76047495|NCT05125367|Procedure|bypass grafting|coronary artery bypass graft
75425603|NCT05891626|Behavioral|Group intervention|"An enhanced electronic reminder mechanism specialized on vaccines and actively highlight vaccine standing orders in the system.~Set up a data benchmarks, so clinic managers or providers are able to aggregate immunization data, red flag missed opportunities, and facilitate modifying vaccine promotion plans.~Other components:~missed opportunities and doubts/hesitancy about immunization as a whole;~specific questions with regard to specific vaccines;~health conditions and socioeconomic/demographic vulnerabilities (insufficient resources in health literacy, linguistic or cultural considerations); and~challenges in patient-clinician interactions. These components will be addressed through team training/meetings, pamphlets, physician-led speech in online videos, and group messages via MyChart on the clinic level."
75425604|NCT05891483|Drug|SHR-1905 Injection|SHR-1905 Injection
75425605|NCT05891483|Drug|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
75724355|NCT03455556|Biological|Atezolizumab|Given IV
75724356|NCT03455556|Other|Laboratory Biomarker Analysis|Correlative studies
75724357|NCT04045106|Other|Proprioceptive Neuromuscular Facilitation Patterns|The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.
75425606|NCT05890833|Diagnostic Test|The risk of falls|Heel-Rise-Test, Chair-Rise Test, Semi-tandem stand, Trunk Rise Test, and Foot-tapping speed. Test battery two includes Timed Up and Go test, 10 Meter Walk Test, Six Minute Walk test, The Falls Efficacy Scale International FES-I, The Morse Fall Scale.
75425607|NCT05888519|Other|FID123300 ocular lubricant|Investigational ocular lubricant
75425608|NCT05888519|Other|FID123301 ocular lubricant|Investigational ocular lubricant
75425609|NCT05888519|Other|FID122505 ocular lubricant|Comparator ocular lubricant
75425610|NCT05880004|Behavioral|Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications|The primary intervention is a mobile application (app) which supports food pantries to recruit, train and schedule volunteers; provide a safe, remote form of client choice; and provides a means of sharing real-time status information with clients, pantries, food banks, and emergency operation centers. Following formative work, user centered design, and usability testing, the SAFPAS app will be implemented in three stages, where each stage introduces new features. Pantry clients will be encouraged to download the app and learn its key features at the end of baseline data collection. During the first weeks of each stage, training of participating food pantry directors/staff and Maryland Food Bank (MFB) staff will take place - focusing on use of any new features. Initial training will be follow up by proficiency testing.
75425611|NCT05879159|Behavioral|Questionnaires|Survey
75425612|NCT05877612|Device|Implantable spinal cord stimulator|Spinal cord stimulation is possible thanks to implantable spinal cord neurostimulators. These are medical devices, which include a stimulation electrode and an implantable box, designed to deliver electrical stimulation for pain relief. The electrode is implanted in the epidural space in order to stimulate the posterior cords of the spinal cord through the dura mater, at the dorsal or cervical level.
75425613|NCT05876533|Device|Cordio HearO|"Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or app) that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients"
75425614|NCT05875961|Biological|Low dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
75425615|NCT05875961|Biological|Intermediate dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
75425616|NCT05875961|Biological|High dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
75425617|NCT05875961|Biological|High dose A/H2N3c non-adjuvanted|Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine
75425618|NCT05875961|Biological|Lowest dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
75425619|NCT05875961|Biological|Low dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
75425620|NCT05868408|Other|Control Formula|Infant formula made with intact protein - minimum 1.8g protein/100kcal
75724358|NCT04045106|Other|Proprioceptive Neuromuscular Facilitation stretching|was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group
75425621|NCT05868408|Other|Experimental Formula 1|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
75425622|NCT05868408|Other|Experimental Formula 2|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
75425623|NCT05860881|Drug|Sirolimus Topical Cream|The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
75425624|NCT05860881|Other|Placebo|Cream containing only the base, or vehicle.
75425625|NCT05858502|Biological|Blood sample collection|Blood sample collection between inclusion and 3 months max 55 ml at each visit
75571937|NCT01261390|Device|Active PAP with RT Support (Active-Beh)|In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
75724359|NCT04045106|Other|Passive range of motion|ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
75724360|NCT04017624|Other|Fresh Truck with stipend|"Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location."
76047496|NCT05124899|Drug|CAP UnScented|Sunscreen lip balm.
76047497|NCT05124899|Drug|CAP Herbal Mint Flavour|Sunscreen lip balm.
76047498|NCT05124899|Drug|CAP Mountain Berry Flavour|Sunscreen lip balm.
76047499|NCT05124899|Drug|SPF Standard Sunscreen|SPF Standard (7 percent [%] Padimate-O and 3% Oxybenzone)
75425626|NCT05858502|Other|Saliva sample collection|Saliva sample collection between inclusion and 3 months
75425627|NCT05858502|Other|Nasopharyngeal and nasal sample collection|Nasopharyngeal and nasal sample collection between inclusion and 3 months
75425628|NCT05858502|Other|Exhaled Breath Condensate (EBC)|Exhaled Breath Condensate (EBC) between inclusion and 3 months
75425629|NCT05847244|Drug|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner)
75425630|NCT05835154|Behavioral|Assessment|Complete checklist
75425631|NCT05835154|Other|Questionnaire Administration|Complete questionnaires
75425632|NCT05835154|Other|Interview|Undergo semi-structured feedback interview
75425633|NCT05835154|Other|Electronic Health Record Review|Review of medical records
75425634|NCT05830929|Procedure|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
75425635|NCT05829005|Device|Transcranial magnetic stimulation (TMS)|TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
75425636|NCT05825222|Dietary Supplement|E-PR-01 (Low dose)|One Capsule to be consumed twice a day
75571938|NCT01261390|Device|Active PAP with Behavioral Modification (Active+Beh)|In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
75877699|NCT02237378|Radiation|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
75425637|NCT05825222|Dietary Supplement|E-PR-01 (High Dose)|One Capsule to be consumed twice a day
75425638|NCT05825222|Dietary Supplement|Placebo|One Capsule to be consumed twice a day
75425639|NCT05824182|Device|FACE self-help App|The FACE self-help app was developed based on well-established non-invasive psychological principles that have been used in other web-based self-help interventions. The app consists of two component, emotion regulation and social information processing/social skills with four modules each. Each module includes readings describing scientific knowledge about ACEs and ACEs related topics, as well as exercises to encourage participants to actively reflect on what was learned in the readings and to apply their knowledge and practice skills. Each module is divided in several submodules that include readings and exercises.
75571939|NCT02895815|Combination Product|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit [SRAK-02 kit] and third arm accessory).
75571940|NCT02895815|Combination Product|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
75425640|NCT05820698|Other|The Mediterranean style diet|"Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week.~Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study."
75425641|NCT05820698|Other|The UK diet|"Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week.~Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study."
75425642|NCT05820698|Other|Time-restricted eating|Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees
75425643|NCT05818475|Other|Angiography-guided PCI|Non-culprit lesion treatment will be based on visual estimation by angiography. The evaluation of PCI result will be also based only on angiography.
75571941|NCT02895503|Behavioral|Yoga|Participate in yoga
75571942|NCT02895503|Behavioral|Support Group Therapy|Participate in emotional support group therapy
75571943|NCT02895503|Other|FACT-L|This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, & Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
75571944|NCT02895503|Other|Pulmonary function test|The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
75571945|NCT03455764|Drug|MCS110|MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
75571946|NCT03455764|Drug|Dabrafenib|Dabrafenib attack different proteins that promote the growth of cancerous cells
75571947|NCT03455764|Drug|Trametinib|Trametinib attack different proteins that promote the growth of cancerous cells
75571948|NCT04902495|Other|MTA Pro Root|pulp therapy
75877700|NCT03607916|Drug|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
75877701|NCT03607916|Drug|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
76047500|NCT05124665|Behavioral|Social Support|"The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description."
76047501|NCT05122013|Behavioral|A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy|A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.
76047502|NCT05122013|Behavioral|Control group|Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
76047503|NCT02112045|Drug|Granix|
76047504|NCT02112045|Drug|High dose melphalan (HDR)|
75877702|NCT03607916|Drug|Morphine|100µg morphine
76047505|NCT02112045|Procedure|Autologous Stem Cell Transplant (ASCT)|
76047506|NCT01629693|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
76047507|NCT01629693|Device|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
75877703|NCT04709627|Device|enFlow IV Fluid and Blood Warming System|The enFlow IV fluid/blood warming system's intended use is for warming blood, blood products and intravenous solutions prior to administration.
75877704|NCT01141712|Procedure|Autologous transplant|Participants will receive the BEAM conditioning regimen followed by autologous HCT.
75877705|NCT01141712|Drug|BCNU|Participants will receive BCNU 300 mg/m^2 Day -6
75877706|NCT01141712|Drug|Etoposide|Participants will receive Etoposide 100 mg/m^2 BID Days -5 to -2
75877707|NCT01141712|Drug|Cytarabine|Participants will receive Cytarabine 100 mg/m^2 BID Days -5 to -2
75877708|NCT01141712|Drug|Melphalan|Participants will receive Melphalan 140 mg/m^2 Day -1
75877709|NCT00145145|Biological|MAGE-3.A1 peptide and CpG 7909|
75877710|NCT05190263|Other|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
75877711|NCT03607448|Device|Freestyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
75877712|NCT02034890|Drug|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
76047508|NCT02147691|Drug|Azelaic acid 15%|Applied to the face each AM and PM
75425644|NCT05818475|Other|Angiography-derived FFR PCI indication and planning|Non-culprit lesion treatment will be based on angiography-derived FFR result. In case of positive assessment, PCI will be planned according to the virtual PCI plan based on the physiology pullback curve.
75425645|NCT05817318|Device|Renal Denervation|Arrhythmia burden pre-to-post renal denervation as assessed by an implantable cardiac monitor
75425646|NCT05816382|Drug|TAK-861|TAK-861 tablets
75425647|NCT05816148|Other|Questionnaire survey|On leisure physical activity, barriers to physical activity and quality of life.
75425648|NCT05801913|Biological|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
75425649|NCT05801913|Procedure|Biospecimen Collection|Undergo blood sample collection
75571949|NCT04902495|Other|MTA HP Repair|pulp therapy
75724361|NCT04017624|Other|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
75724362|NCT00815828|Other|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
76047509|NCT02147691|Drug|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
75425650|NCT05801913|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75425651|NCT05801913|Procedure|Computed Tomography|Undergo CT
75425652|NCT05801913|Procedure|Leukapheresis|Undergo leukapheresis per SOC
75425653|NCT05801913|Procedure|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy per SOC
75425654|NCT05801913|Procedure|Magnetic Resonance Imaging|Undergo MRI
75425655|NCT05801913|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
75425656|NCT05801913|Procedure|Positron Emission Tomography|Undergo PET
75425657|NCT05801913|Procedure|X-Ray Imaging|Undergo x-ray
75425658|NCT05798481|Drug|Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.|Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
75571950|NCT04902495|Other|Biodentine|pulp therapy
75571951|NCT00552162|Procedure|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
75571952|NCT00552162|Procedure|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
75571953|NCT02895659|Procedure|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
76047510|NCT02111811|Other|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
75425659|NCT05791435|Device|PneuRIP|Measuring respiratory indices through Respiratory Inductance Plethysmography
75425660|NCT05791435|Other|biofeedback to assist with breathing|Measuring respiratory indices through Respiratory Inductance Plethysmography and providing visual biofeedback on a tablet screen
75425661|NCT05791279|Other|Heart age|information about their ECG-based Heart-Age and the Heart Age gap, i.e. the difference between chronological and ECG-based Heart Age.
75425662|NCT05789303|Drug|Belantamab mafodotin|Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)
75425663|NCT05789303|Drug|Carfilzomib|"Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15~Cycles 2-8: 56 mg/m2 on Days 1/8/15~Cycles 9+: 56 mg/m2 on Days 1/15"
75425664|NCT05789303|Drug|Pomalidomide|3 mg Day 1-21 of 28-day Cycle
75425665|NCT05789303|Drug|Dexamethasone|"Cycles 1-4: 40 mg Days 1/8/15/22~Cycles 5+: 20 mg Days 1/8/15/22"
75571954|NCT00552201|Drug|Tacrolimus|Administration Twice a day after adjustment to blood level
76047511|NCT01655693|Drug|Doxorubicin 20 mg/m2|
76047512|NCT01655693|Drug|Doxorubicin 30 mg/m2|
76047513|NCT01655693|Drug|Best Standard of Care|
75425666|NCT05788484|Drug|CDX-585|CDX-585 is administered by infusion every 2 weeks
75877713|NCT02015351|Drug|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
75425667|NCT05788328|Drug|Dabigatran etexilate (DE)|Dabigatran etexilate (DE) as oral capsule
75425668|NCT05788328|Drug|Rosuvastatin|Rosuvastatin as oral tablet
75425669|NCT05788328|Drug|PF-07081532|PF-07081532 as oral tablets
75425670|NCT05787249|Behavioral|Patient nudge|Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
75425671|NCT05787249|Behavioral|Provider nudge|Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
75571955|NCT02895464|Other|Exercise|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
75571956|NCT03391882|Drug|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
75724363|NCT04006197|Other|laryngostroboscopy and histoh-pathology|videolaryngoscopy and laryngostroboscoby will be performed .the latter will be pathological in case of highly reduced or abolished amplitudes of vocal fold vibration and if there is reduction of mucosal wave propagation.also direct microlaryngoscopy under general anathesia will be done and excesional biobsy will be taken followed by histopatholpgical examination .the histological finding will be catagorized into the following categories according to (WHO): squamous cell hyperplasia with non dysplasia,mild dysplasia,moderate dysplasia,sever dysplasia,carcinoma in situ and squamous cell carcinoma.
75877714|NCT03604796|Drug|Rectal Solution|Rectal acetaminophen at 15 mg/kg x 4/day for three days
75425672|NCT05784311|Drug|Cefuroxime|1500mg IV cefuroxime thrice daily during five days.
75425673|NCT05784311|Drug|Metronidazole|500mg IV metronidazole thrice daily during five days.
75877715|NCT03604796|Drug|Intravenous Infusion|Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
75877716|NCT03607292|Procedure|Anterior sciatic nerve block|A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
75877717|NCT03607292|Procedure|Posterior sciatic nerve block|Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
75425674|NCT05782673|Device|wearable MAIJU for motor assessment|The novel multisensor wearable MAIJU will be used to measure infants' motor performance at home. The recordings are repeated at 2 months intervals betveen 6 and 18 months of age.
75425675|NCT05779852|Other|self-hypnosis and dressing|self-hypnosis during dressing
75425676|NCT05779852|Other|dressing|dressing without self-hypnosis
75425677|NCT05779228|Behavioral|Mode Switching Training|Wear of colored lenses for 1 hr, 5 times per day, for 5 days
75425678|NCT05778851|Device|EsoGuard result|Education slide-set EsoGuard and patient cases including EsoGuard result
75425679|NCT05777824|Combination Product|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
75425680|NCT05777824|Radiation|postoperative radiaotherapy|postoperative radiotherapy (60Gy or 50Gy)
75425681|NCT05775159|Drug|MEDI5752|CTLA-4/Anti-PD-1 Bispecific Antibody
75425682|NCT05775159|Drug|Bevacizumab|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
75425683|NCT05775159|Drug|Lenvatinib|Daily use per oral (8 mg capsules/day for participants < 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
75425684|NCT05775159|Drug|AZD2936|anti- PD-1 and TIGIT bispecific antibody
75425685|NCT05775159|Drug|Gemcitabine|1000 mg/m2, IV infusion
75425686|NCT05775159|Drug|Cisplatin|25 mg/m2, IV infusion
75425687|NCT05767086|Drug|Gonadotropin releasing hormone antagonist (Cetrotide)|clinical pregnancy rates
75425688|NCT05767086|Drug|Medroxyprogesterone Acetate (Tarlusal)|clinical pregnancy rates
75425689|NCT05767086|Drug|Dydrogesterone|clinical pregnancy rates
75425690|NCT05766748|Drug|Azeliragon|Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
75425691|NCT05765890|Other|No treatment given|No treatment given
75425692|NCT05762250|Other|Auricular Acupuncture|Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
75425693|NCT05759286|Behavioral|Aromatherapy|Aroma therapy will apply before 5 minutes and during IANB injection in children, aromatherapy will apply through a nasal mask similar to one that uses when applying nitrous oxide after putting a 3d printed perforated box on the mask's circular halo on its surface, in this box cotton bolls impregnated with 3 drops of a 15% lavender-neroli oils blend are placed and then the child will smell the scent of aromatic oil blend from the box's perforated bottom surface which faces child's nose
75425694|NCT05759286|Behavioral|Music|Music will be played from a speaker in the treatment environment and will start 5 minutes before anesthesia and will be played through the whole anesthesia process, the music used will be chosen by the child from his favourite cartoon
75425695|NCT05759286|Behavioral|Control|using a tell-show-do approach and children will put on a nasal mask without the box that contains an aromatic oil blend for the placebo effect
75425696|NCT05756985|Procedure|Specimen Collection|Collect and preserve glioblastoma tissue for exploratory analyses to generate hypotheses for future studies.
75425697|NCT05750745|Drug|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity & Gum toothpaste is containing 0.454% w/w SnF2.
75425698|NCT05750745|Drug|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million (ppm) fluoride as Sodium fluoride (NaF).
75571957|NCT03391882|Drug|subcutaneous apomorphine|subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
75571958|NCT00550329|Drug|Glipizide GITS|
75877718|NCT05134259|Device|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
75877719|NCT03604484|Procedure|Tricuspid annuloplasty|Tricuspid annuloplasty
75877720|NCT02311049|Radiation|Hypofractionation|
75877721|NCT02237456|Procedure|Comparison of OCT scans|
75877722|NCT02237456|Procedure|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
75877723|NCT02237534|Drug|Lanthanum carbonate|
75877724|NCT02237534|Drug|Calcium Carbonate|
75425699|NCT05750745|Drug|Sensodyne Repair and Protect|Sensodyne Repair and Protect toothpaste is containing 5.0% w/w calcium sodium phosphosilicate (CSPS).
75425700|NCT05749887|Procedure|salvage surgery|"Open/minimally invasive salvage surgery performed when cervical biopsy and/or PET/CT scan ( SUVmax ≥2.5 ) indicate patients with residual tumor intrapelvic 4-12 weeks after standard CCRT.~Surgery type:~No parametrial involvement, extrafascial hysterectomy;~There is parametrial involvement, extensive hysterectomy(Q-MC);~Only bladder invasion, anterior pelvic exenteration;~Only rectal invasion, posterior pelvic exenteration or total pelvic exenteration;~Invasion of bladder and rectum, total exenteration.~The pelvic lymph nodes are removed at the same time when 18F -FDG PET /CT indicates that the SUVmax is ≥ 2.5."
75425701|NCT05746546|Drug|Transdermal Nicotine patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
75425702|NCT05746273|Drug|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
75425703|NCT05746273|Drug|Transdermal Placebo Patch|Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
75571959|NCT02895620|Biological|Xpert bladder Test|Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
75571960|NCT00550485|Drug|escitalopram|escitalopram 4 mg
75571961|NCT01261000|Drug|Pegvisomant|Pegvisomant used as indicated
75877725|NCT03607214|Other|Placebo|"Placebo nasal spray~Film Sequence"
75425704|NCT05744700|Dietary Supplement|Inulinase|Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
75425705|NCT05744700|Dietary Supplement|Maltodextrin placebo|Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
75425706|NCT05742295|Drug|Vitamin K|Coadministration of vitamin K with the first dose of cefoperazone/sulbactam
75425707|NCT05741216|Other|OTF Ocular Lubricant|Ocular lubricant in 1 of 3 test formulations
75425708|NCT05741216|Other|Ocular Lubricant|Commercially available ocular lubricant
76047514|NCT05090657|Combination Product|methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation|After topical application photosensitive solution bilateral nasal light diffusers will be inserted into each nostril and two 2-minute non-thermal light applications of 670 nm light will be used to activate the photosensitizer to achieve an oxidative burst to destroy pathogens.
76047515|NCT05120765|Behavioral|The CONNECT Program|The CONNECT Program is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT). The group sessions take place once a week and they last 90 minutes each.
75425709|NCT05740956|Drug|HS-10502|HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.
75571962|NCT00550524|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
75425710|NCT05738486|Drug|Donanemab|Administered IV
75425711|NCT05738486|Drug|Placebo|Administered IV
75425712|NCT05736939|Other|Out-patient Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both <4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
75425713|NCT05733364|Dietary Supplement|Capsules with B vitamins & taurine|Administered orally in a span of 28 days between mealtimes
75425714|NCT05733364|Other|Microcrystalline cellulose placebo|Administered orally in a span of 28 days between mealtimes
75425715|NCT05731765|Diagnostic Test|Machine Learning Model|Automated machine learning system for the detection of spontaneous venous pulsations and quantification of intracranial pressure
75425716|NCT05728372|Drug|Copper Cu 64-DOTA-pembrolizumab|Given IV
75425717|NCT05728372|Procedure|Positron Emission Tomography|Undergo PET scan
75425718|NCT05728372|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75425719|NCT05727007|Diagnostic Test|MRI in colon cancer|The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
75425720|NCT05727007|Diagnostic Test|CT in colon cancer|The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
75571963|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra|
75571964|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems|
75571965|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic|
75571966|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems|
75571967|NCT02895425|Other|Registry (No intervention)|
75571968|NCT00550563|Dietary Supplement|cholecalciferol|Oral
76047516|NCT05089019|Drug|Selpercatinib|Administered orally
75425721|NCT05717907|Device|suction catheter|a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
75425722|NCT05717179|Diagnostic Test|Ultrasound|At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint.
75425723|NCT05714020|Other|Real rTMS|Repetitive transcranial magnetic stimulation (rTMS) is applied to the primary motor cortex. The protocol consists of 15 minutes of 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses.
75425724|NCT05714020|Other|Sham rTMS|A sham coil is also used to mimic the clicking sound of the transcranial magnetic coil and skin stimulation.
75425725|NCT05706532|Diagnostic Test|active standing|Data are acquired with patients resting in supine position for 10 minutes and for 10 minutes during active standing
75425726|NCT05702684|Other|electronic Holistic Needs Assessment (eHNA)|eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.
75425727|NCT05700045|Drug|Dexmedetomidine|each side dexmedetomidine 0.5ug/kg TAP block
75425728|NCT05699941|Device|Ectoin® Inhalation Solution|Ectoin Inhalation Solution (Class-IIa Medical Device Directive (MDD) legacy medical device) is an isotonic, aqueous solution containing Ectoin 1.3 % and sea salt 0.6%. It is used for moistening the lung epithelium by the Ectoin hydro complex and supports the barrier function of the lung epithelium. The inhalation solution can be administered with jet, mesh, and ultrasound nebulizers.
75425729|NCT05696834|Procedure|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
75425730|NCT05695261|Biological|Microbial Transplantation Therapy|Subjects randomized to the MTT/antibiotic arm will be administered oral MTT capsules over the course of 28 days.
75571969|NCT00550563|Genetic|polymerase chain reaction|companion study
75571970|NCT00550563|Genetic|polymorphism analysis|companion study
75571971|NCT00550563|Genetic|protein expression analysis|companion study
75571972|NCT00550563|Genetic|reverse transcriptase-polymerase chain reaction|companion study
75571973|NCT00550563|Genetic|western blotting|companion study
75877726|NCT03602456|Other|Kentucky HEALTH|KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
76047517|NCT04226339|Procedure|total knee arthroplasty with a kinetic alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery"
76047518|NCT04226339|Procedure|total knee arthroplasty with a mechanical alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment"
76047519|NCT05048849|Biological|MVC-COV1901(S protein with adjuvant)|Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
76047520|NCT01655381|Drug|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
75571974|NCT00550563|Other|high performance liquid chromatography|companion study
75571975|NCT00550563|Other|laboratory biomarker analysis|companion study
75571976|NCT00550563|Other|pharmacological study|companion study
76047521|NCT05117333|Other|Reminder (information letter)|Reminders
76047522|NCT05048537|Radiation|18F-FACBC PET/CT|10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins
76047523|NCT01656161|Drug|Triptorelin embonate 22.5 mg|
76047524|NCT05048381|Diagnostic Test|Next Generation Sequencing|Next Generation Sequencing of sweat and whole blood samples for non-coding miRNAs to define biomarkers that enable to differentiate between patients with active tuberculosis, a differential diagnostic disease and healthy individuals.
75571977|NCT00550563|Procedure|adjuvant therapy|Additional therapy
75571978|NCT00550563|Procedure|immunoscintigraphy|additional testing
75877727|NCT03607136|Other|exercise training|Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
75877728|NCT03604328|Drug|PA5108|single ocular implant, administered on day 1
76047525|NCT05081141|Diagnostic Test|Diagnostic test for HHV8 exposure|Venipuncture for blood sampling
75571979|NCT02895698|Device|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
76047526|NCT05114993|Device|wearing a disposable surgical mask|Physiologic vital signs will be monitored every minute for 5 minutes without a mask, followed by every minute for 15 minutes with a surgical mask.
75571980|NCT02895698|Other|Stretching exercises|"The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~Standing self-stretching of the calf muscles.~Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~All stretches were done six times and the duration of each stretch is 30 seconds."
75571981|NCT02895191|Drug|ulinastatin|Patients will receive the study drugs for 7 to 14 days
75425731|NCT05695261|Drug|Antibiotic|Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.
75425732|NCT05695261|Other|Placebo (in place of MTT)|Subjects randomized to the placebo arm will be administered oral placebo capsules in place of MTT over the course of 28 days.
75571982|NCT02895191|Drug|placebo|Patients will receive the placebo for 7 to 14 days
75571983|NCT02895269|Behavioral|Collaborative shared care|Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
75571984|NCT04765020|Behavioral|Experimental: moderate to high-intensity exercise|"Four parts:~Initial consultation with recommendations for general physical activity, brochure with exercise recommendations~Once per week multi-modal group-based exercise (endurance, strength, mobility, coordination)~Once per week supervised multi-modal individual training session (endurance, strength, mobility, coordination). Intensity: 60-80% of max. HR~Activity trackers with individual movement goals that will be adjusted every two weeks"
75571985|NCT00550641|Other|physical therapy|physical therapy in warm pool performing stretching
75571986|NCT00550641|Other|physical therapy|physical therapy in warm pool performing Ai Chi
75724364|NCT02540304|Behavioral|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
75724365|NCT00808964|Drug|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
75724366|NCT00982839|Procedure|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
75724367|NCT00982839|Procedure|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
76047527|NCT05080283|Device|CP1110 Sound Processor System|Sound Processor
76047528|NCT05080283|Device|Nucleus 7 Sound Processor (model: CP1000) system|Sound Processor
76047529|NCT05046275|Other|Data analysis|No intervention, data analysis only
76047530|NCT04422041|Other|Time to discharge less than 24 hours|Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
75425733|NCT05695261|Other|Placebo (in place of antibiotics)|Subjects randomized to the placebo arm will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
75425734|NCT05695183|Device|IV SafeLock|Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
75425735|NCT05684692|Drug|Siltuximab|A chimeric immunoglobulin G mAb, via intravenous infusion.
75425736|NCT05684692|Drug|Erenumab-Aooe|Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
75571987|NCT04680650|Drug|Anesthesia was maintained with sevoflurane|After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.
75724368|NCT00897468|Other|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
75877729|NCT03606902|Procedure|Group f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
75877730|NCT03606902|Drug|Group F: Continous epidural infusion of bupivacaine plus fentanyl|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg /Kg Fentanyl initial bolus, then from the 1st hour continuous epidural infusion of 0.0625% bupivacaine with µ/Kg/h Fentanyl fixed for the next 5 hour during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
75571988|NCT04680650|Drug|Anesthesia was maintained with propofol|After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
75724369|NCT00897468|Other|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
75724370|NCT02551406|Device|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
75571989|NCT00550758|Drug|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
75571990|NCT00550758|Device|spirometry|spirometry
75571991|NCT04680572|Procedure|arthroplasty|arthroplasty for fracture neck of femur
75571992|NCT00552435|Device|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
75724371|NCT00988299|Other|exercise|exercise sessions at 45% and 60% of maximum effort
75724372|NCT00809042|Drug|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
76047531|NCT04422041|Other|Discharge time between 24 and 48 hours|Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
75425737|NCT05684692|Drug|Siltuximab Matching Placebo|Dextrose 5% in water, via intravenous infusion.
75425738|NCT05684692|Drug|Erenumab-Aooe Matching Placebo|0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
75425739|NCT05678257|Drug|Fosifloxuridine Nafalbenamide|Intravenous infusion
75425740|NCT05678257|Drug|Leucovorin|Intravenous infusion
75425741|NCT05678257|Drug|Irinotecan|Intravenous infusion
75425742|NCT05678257|Biological|Bevacizumab|Intravenous infusion
75425743|NCT05678257|Drug|5-FU|Intravenous infusion
75571993|NCT02895308|Behavioral|Online psychoeducation|The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
75571994|NCT02895308|Behavioral|Face-to-face psychoeducation|The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
75724373|NCT00809042|Drug|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
76047532|NCT05045027|Procedure|Biospecimen Collection|Undergo collection of tissue samples
76047533|NCT05045027|Procedure|Diagnostic Imaging|Undergo multinuclear metabolic imaging
75425744|NCT05671146|Device|anti-gravity treadmill|participants will perform exercises with partial weight-bearing by using an anti-gravity treadmill
75425745|NCT05671146|Other|Weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a weight-bearing position
75425746|NCT05671146|Other|Non weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a non-weight-bearing position
76047534|NCT05045027|Procedure|Magnetic Resonance Imaging|Undergo MRI
75425747|NCT05669027|Device|Neurofeedback|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.
75425748|NCT05669027|Device|Sham (Placebo Control)|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).
75425749|NCT05658146|Drug|Mavacamten Capsule 1|Specified dose on specified days
75425750|NCT05658146|Drug|Mavacamten Capsule 2|Specified dose on specified days
75425751|NCT05658146|Drug|Mavacamten Capsule 3|Specified dose on specified days
75425752|NCT05656248|Drug|CPX-351|Given Intraveneously (IV)
75425753|NCT05656248|Drug|MHA|Given Intrathecal (IT)
75425754|NCT05656248|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
75425755|NCT05654948|Other|computerised cognitive performance test : MindPulse|In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
75571995|NCT00550797|Biological|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
75571996|NCT00550797|Biological|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
75571997|NCT02895113|Drug|Aspirin|Patients suffering from type 2 diabetes will be randomized to receive 100 mg/day or placebo for one year
75571998|NCT02895113|Other|Placebo|Patients in this arm will be treated with placebo
75425756|NCT05646602|Drug|Collagenase Clostridium Histolyticum|Intralesional injection
75425757|NCT05646602|Device|Duolith SD1 T-TOP|Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
75425758|NCT05646199|Drug|Metformin|Participants will receive metformin
75571999|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
75572000|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
75572001|NCT02895386|Device|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
75572002|NCT02895386|Other|Sham procedure|Sham procedure + continuing current antihypertensive medications.
75572003|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
75572004|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
75425759|NCT05646199|Drug|Semaglutide Injectable Product|Participants in this group will receive injectable Semaglutide
75425760|NCT05643690|Diagnostic Test|UriFind Bladder Cancer Assay|The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
75425761|NCT05641649|Drug|Sodium valproate and valproic acid extended release tablet|Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
75425762|NCT05640115|Procedure|Ureteral Stent|A ureteral stent is a soft, hollow tube that is placed temporarily into the ureter. The stent allows the urine to drain. The stent has a coil on each end that keeps it from moving. The top end coils in the kidney and the lower end coils inside the bladder.
75425763|NCT05640115|Procedure|Percutaneous Nephrostomy Tube Placement|A percutaneous nephrostomy is the placement of a small, flexible rubber tube (catheter) through your skin into your kidney to drain your urine. It is inserted through your back or flank.
75425764|NCT05639972|Drug|Conditioning, E7 TCR-T cells, and aldesleukin|Participants will receive induction E7 TCR-T cell therapy.
75425765|NCT05638776|Drug|REGEND001 Autologous Therapy Product|Transplantation of Autologous Therapy Product by
75425766|NCT05638776|Drug|Placebo|Transplantation of Placebo
75425767|NCT05632523|Other|Blood sample|Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion
75425768|NCT05632523|Other|urinary sample|Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion
75572005|NCT00550875|Biological|placebo|Sublingual. 2 drops/daily 2 years
75572006|NCT02894996|Drug|fluid challenge|fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
75572007|NCT00552630|Device|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
75572008|NCT00552630|Drug|placebo|placebo with same characteristics as drug
75572009|NCT02894957|Drug|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
76047535|NCT05043857|Radiation|Stereotactic Body Radiotherapy (SBRT)|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after tumor resection targeting 2 volumes~CTV1 (clips+isotropic 5mm expansion, edited on anatomic barriers): receiving 40 Gy in 5 fractions of 8 Gy~CTV2 (CTV1+ anisotropic 10-15 mm expansion including corresponding vessels, retroperitoneum posterior to the SMV/SMA or celiac axis, edited on anatomic barriers): receiving 30 Gy in 5 fractions of 6 Gy."
75425769|NCT05632211|Biological|AVT05|Pre filled syringes filled with AVT05
75425770|NCT05632211|Biological|Simponi|Pre filled syringes filled with Simponi
75425771|NCT05629091|Device|FibDex|Nanofibrillar cellulose wound dressing
75425772|NCT05629091|Device|Epicite hydro|Wound dressing
75425773|NCT05629091|Device|Epiprotect|Wound dressing
75425774|NCT05625906|Other|Multi-media experiential training programme|"Webpage and mobile applications of training material on ACP, to be offered four weeks before the workshop~A three-hour multimedia workshop (8-10 nurses per group) including enhanced lectures and a role play encounter with standardised patients. Immediate feedback on their quality of decision support skills will be given. The workshops will be delivered by an experienced advance practice nurse with a palliative care specialty.~Writing a reflective journal after the role play with standardised patients"
75425775|NCT05625438|Device|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
75425776|NCT05623449|Other|Clinical examination|Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
75425777|NCT05623449|Other|Anxiety and Depression Scale (HAD)|To screen for anxious and depressive symptoms
75425778|NCT05623449|Procedure|pain scale|Measurement of pain intensity
75425779|NCT05623449|Procedure|hypnosis consultation|5 hypnosis consultation
75425780|NCT05623449|Procedure|Maintenance|Qualitative assessment
75425781|NCT05623449|Other|Data collection|Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
75572010|NCT02894879|Device|BreatheMAX®|"Modify chest physical therapy~oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~Coughing with splinting 3 times/set~Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
75572011|NCT02894879|Other|Routine treatment|"Routine chest physical therapy~Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~Coughing with splinting 3 times/set~Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
75572012|NCT00550992|Biological|anti-thymocyte globulin|
75724374|NCT00809042|Drug|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
75572013|NCT00550992|Drug|asparaginase|
75425783|NCT05609825|Drug|LY3875383|Administered SC.
75572014|NCT00550992|Drug|busulfan|
75572015|NCT00550992|Drug|cyclophosphamide|
75572016|NCT00550992|Drug|cyclosporine|
75572017|NCT00550992|Drug|cytarabine|
75572018|NCT00550992|Drug|daunorubicin hydrochloride|
75572019|NCT00550992|Drug|etoposide|
75724375|NCT00809042|Drug|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
75724376|NCT02539602|Behavioral|The Need to Know students received the N2K curriculum as described previously|
75724377|NCT00988377|Other|dietary intervention|whey protein 10-40 g
75425784|NCT05609825|Drug|Placebo|Administered SC.
75572020|NCT00550992|Drug|leucovorin calcium|
75572021|NCT00550992|Drug|melphalan|
75724378|NCT00988377|Other|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
75724379|NCT02551328|Drug|sevofluorane|Continuous infusion of sevofluorane
75425785|NCT05606757|Drug|BOTOX Dose A|Injection; intramuscular
75425786|NCT05606757|Drug|Placebo for BOTOX|Placebo
75425787|NCT05606757|Drug|BOTOX Dose B|Injection; intramuscular
75425788|NCT05606757|Drug|BOTOX Dose C|Injection; intramuscular
75425789|NCT05605470|Biological|ChulaCov19 BNA159 vaccine (50 mcg)|Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
75425790|NCT05605470|Biological|Pfizer/BNT vaccine (30 mcg)|Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
75425791|NCT05605470|Biological|COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)|Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
75425792|NCT05589038|Other|Baby Wash/Shampoo|Parent participant will bathe the baby participant with the baby wash/shampoo at least 3 times per week, but no more than once daily.
75572022|NCT00550992|Drug|mercaptopurine|
75572023|NCT00550992|Drug|methotrexate|
75572024|NCT00550992|Drug|mitoxantrone hydrochloride|
75572025|NCT00550992|Drug|pegaspargase|
75572026|NCT00550992|Drug|prednisolone|
75572027|NCT00550992|Drug|prednisone|
75572028|NCT00550992|Drug|therapeutic hydrocortisone|
75572029|NCT00550992|Drug|thioguanine|
75572030|NCT00550992|Drug|vincristine sulfate|
75572031|NCT00550992|Procedure|allogeneic bone marrow transplantation|
75572032|NCT00550992|Procedure|allogeneic hematopoietic stem cell transplantation|
75572033|NCT00550992|Procedure|umbilical cord blood transplantation|
75724380|NCT00897546|Other|laboratory biomarker analysis|
75724381|NCT00982917|Behavioral|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
75724382|NCT00982917|Behavioral|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
75724383|NCT00901914|Biological|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
75724384|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
75724385|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
75724386|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
75724387|NCT00815906|Drug|SBI-087|IV, Single dose
75724388|NCT00815906|Drug|SBI-087|IV, Single dose
75724389|NCT00815906|Drug|SBI-087|SC, Single dose
75724390|NCT00815906|Drug|SBI-087|SC, Single dose
75724391|NCT00988455|Radiation|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
75724392|NCT00897624|Genetic|gene expression analysis|
75724393|NCT00897624|Genetic|reverse transcriptase-polymerase chain reaction|
75724394|NCT00897624|Other|laboratory biomarker analysis|
75724395|NCT00815984|Procedure|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
75572034|NCT02895074|Procedure|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
75572035|NCT02895074|Procedure|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
75572036|NCT02895074|Drug|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
75572037|NCT02895074|Drug|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
75572038|NCT02894918|Drug|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
75572039|NCT00551109|Drug|placebo|placebo, oral administration, once daily for 8 weeks
75425793|NCT05589038|Other|Baby Lotion|Parent participant will use the baby lotion on baby participants at least once daily.
75425794|NCT05588245|Behavioral|Standard of Care|Participants will undergo the same SDoH screener (AHC-Health Related Social Needs Tool) as full intervention participants, which will serve as the basis for a one-time brief session with the clinical research coordinator that will involve review of a 'Resource Guide' that provides a listing of available community resources to meet common social needs. Participants in this arm will also complete other prenatal and postpartum data collection items over the course of the study (with the exception of qualitative interviews).
75425795|NCT05588245|Behavioral|Community-based prenatal/perinatal/postpartum patient navigator|Uses Freeman's principles of navigation to enhance patient access to care (e.g., help patients manage appointments), promote patient self-efficacy (e.g., connect patients to community housing, food, transportation resources), and sustain engagement with the healthcare system (e.g., bridge perinatal and primary care).
75425796|NCT05586308|Behavioral|Text-massaging suport|Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
75724396|NCT00986037|Drug|ABT-308|Single IV doses
75425797|NCT05586308|Behavioral|Financial incentive|"Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample"
75425798|NCT05586308|Behavioral|Media literacy|Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
75425799|NCT05585411|Procedure|Left bundle branch area pacing|"LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~RBBB configuration observed during unipolar tip pacing~One of the following should be met:~Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 [LV activation time]) of >10ms during increasing output~Short and constant stim-LVAT and the shortest stim-LVAT <75ms in non-LBBB and <85ms in LBBB~Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~LBB potential (LBB-V interval of 15 to 35ms)~Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP)."
75425800|NCT05585411|Procedure|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
75572040|NCT00551109|Drug|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
75572041|NCT00551109|Drug|SA4503 High|High dose, oral administration, once daily for 8 weeks
75572042|NCT02894723|Dietary Supplement|L-arginine|30 ml arginoline contains 5 gr l-arginine
75572043|NCT02894723|Dietary Supplement|syrup|The same bottle of the experimental group, but without l-arginine
75724397|NCT00986037|Drug|ABT-308|Multiple SC doses x 3
75724398|NCT00986037|Drug|Placebo|Single IV dose
75724399|NCT00986037|Drug|Placebo|Multiple SC doses x 3
75724400|NCT00901992|Behavioral|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
75572044|NCT00551187|Biological|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
75572045|NCT00551187|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
75572046|NCT00551187|Biological|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
75572047|NCT02894528|Drug|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
75572048|NCT02894528|Drug|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
75572049|NCT02894450|Other|blood test|bioassay xaban
75572050|NCT00551265|Drug|Cyclophosphamide|Given IV
75572051|NCT00551265|Procedure|Laboratory Biomarker Analysis|Correlative studies
75572052|NCT00551265|Biological|Oregovomab|Given IV
75572053|NCT02894489|Device|corneal lenses|wear corneal lenses on daily basis
75572054|NCT02894489|Device|large diameter lenses|
75724401|NCT00901992|Behavioral|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
75724402|NCT00983151|Drug|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
75724403|NCT00897780|Behavioral|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
75425801|NCT05580289|Other|half-shower and hot pack|The patients in the experimental group will be given hot application and half shower applications and the pain levels of the patients and the development of bladder retention will be followed.
75572055|NCT00551304|Device|Ardian Catheter|
75425802|NCT05575531|Other|MEWSS and Nursing Guide Application|MEWSS and Nursing Guide application will be used for the patients in the experimental group. According to the Nursing Guide application, patients with MEWS above 4 will be monitored every 5 minutes, while those with a score below 4 will be monitored for 10 minutes. will be followed intermittently. Nursing interventions will be made in accordance with the problems experienced by patients with a score above 4.
75425803|NCT05570422|Drug|KRC-01|KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.
75425804|NCT05570422|Radiation|External Beam Radiation Therapy|"Target definition for EBRT will be based on 3D imaging by computed tomography, positron emission tomography with computed tomography, or MRI.~Intensity-modulated radiotherapy (IMRT) must be used.~IMRT should be given once daily Monday-Friday, 5 fractions per week."
75425805|NCT05570422|Drug|cisplatin|"Weekly concomitant cisplatin (40 mg/m2) during EBRT~Neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/m2) are not allowed.~Adjuvant chemotherapy (after completion of EBRT+BT) is not allowed."
75425806|NCT05570422|Radiation|brachytherapy|"BT treatment planning will be based on 3D-image-guided BT by MRI.~Low-dose-rate, pulsed-dose-rate, or high-dose-rate BT"
75425807|NCT05569148|Combination Product|Faricimab PFS Configuration|Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.
75425808|NCT05565092|Drug|ALXN1820|ALXN1820 will be administered subcutaneously.
75425809|NCT05560802|Other|WHOs Labour care guide|Guidelines for monitoring labor progress, the WHOs LCG
75425810|NCT05558124|Drug|Vyxeos|Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
75572056|NCT02894606|Drug|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
75572057|NCT02894606|Drug|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
75724404|NCT00635570|Drug|Ortho Tri-cyclen Lo|Low dose oral contraceptive
75724405|NCT00635570|Device|NuvaRing|Contraceptive vaginal ring
75572058|NCT02894567|Device|Intraoperative test during a deep brain stimulation surgery|The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
75572059|NCT00551343|Drug|Exenatide|10ug Exenatide single s.c. injection
75572060|NCT00551382|Drug|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
75572061|NCT00551382|Drug|Placebo|Look alike tablets or granules 1 per day for 12 weeks
75572062|NCT02894684|Drug|Aztreonam|14 days of AZLI: 75mg TDS PLUS IV Colistin
75572063|NCT02894684|Drug|Standard Care|14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
75572064|NCT02894645|Drug|Prednisolone|Oral
75572065|NCT02894645|Drug|Dexamethasone|Oral
75572066|NCT02894645|Drug|L-Asparaginase|Intramuscular injection
75724406|NCT00893958|Drug|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
76047536|NCT04421807|Other|Scapulatoracic stabilization exercises|Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually
75724407|NCT00986115|Drug|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
75724408|NCT00986115|Drug|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
75724409|NCT00983229|Procedure|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
75425811|NCT05558124|Drug|Gemtuzumab Ozogamicin|"Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7"
75425812|NCT05557513|Device|STANDARD Q COVID-19 Ag Test|"Device Name: STANDARD Q COVID-19 Ag Test Manufactured by SD Biosensor, Inc., Korea~Purpose: To detect COVID-19 (Its manufacture specification sensitivity was at 84.97% and specificity 98.4%)"
75425813|NCT05549765|Procedure|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
75425814|NCT05549765|Procedure|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
75425815|NCT05548647|Behavioral|Behavioral Treatment|All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh < 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.
75572067|NCT02894645|Drug|Vincristine|Intravenous
75572068|NCT02894645|Drug|Methotrexate|Intrathecal/ Intravenous/ Oral
75572069|NCT02894645|Drug|Daunorubicin|Intravenous
75572070|NCT02894645|Drug|Doxorubicin|Intravenous
75572071|NCT02894645|Drug|Cyclophosphamide|Intravenous
75572072|NCT02894645|Drug|Cytarabine|Intravenous/ Subcutaneous injection
75425816|NCT05548647|Drug|Placebo|An inactive saline solution administered via subcutaneous injection
75425817|NCT05548647|Drug|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|Semaglutide 2.4 mg is a once weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist that has been FDA approved for weight loss
75425818|NCT05548114|Procedure|EUS-guided gastrojejunostomy|AXIOS lumen-apposing metal stent will be used to create a gastrojejunostomy under EUS guidance.
75425819|NCT05548114|Procedure|Surgical gastrojejunostomy|A surgical gastrojejunostomy will be created via laparoscopic (preferred) or open technique, as clinically appropriate.
75425820|NCT05547698|Procedure|Off-pump lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, pneumonectomy starting by the less perfused lung in the scan, stump preparation, lung implantation, reperfusion, gradual release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, chest closure.
75572073|NCT02894645|Drug|6-Mercaptopurine|Oral
75572074|NCT02894645|Drug|Thioguanine|Oral
75572075|NCT02894645|Drug|Fludarabine|Intravenous
75572076|NCT02894645|Drug|Imatinib|Oral (For BCR-ABL ALL only)
75572077|NCT02894372|Device|Oral spray 1|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
75572078|NCT02894372|Device|Oral spray 2|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
75572079|NCT00552747|Drug|fenofibrate|fenofibrate 160 mg capsules qd
75572080|NCT00552747|Drug|placebo|capsules placebo
75572081|NCT00004553|Procedure|Electromyography|
75572082|NCT00551499|Device|CRT + AOP|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
75572083|NCT02277327|Behavioral|Plans of Action and Care Transitions|"Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)"
75572084|NCT02277327|Behavioral|Routine Care|"Subjects randomized to the control group will continue to receive routine care within the medical home program"
75572085|NCT05428124|Other|In vitro fertilisation|In vitro fertilisation
75724410|NCT00809120|Device|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
75572086|NCT05427851|Procedure|pulpotomy|coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
75572087|NCT05427851|Device|Diode laser - fonalaser|diode laser beam application
75572088|NCT04584333|Behavioral|Brief intervention|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established. Prochaska and DiClemente (1983) proposed a transtheoretical model of change in which different stages of change are identified that have been found to be predictive of adherence to treatment and its efficacy (Prochaska, Norcross and DiClemente, 1994). The RCQ includes three of the stages of change: Precontemplation, Contemplation and Action. In the Precontemplation stage, the person does not consider that he has a problem and has no intention of changing, in the Contemplation stage, he begins to contemplate that he has a problem and the possibility of change is raised and in the action stage, he has already started actively make a change in your behavior.
75724411|NCT04035876|Drug|Camrelizumab plus apatinib|Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
75724412|NCT00902070|Drug|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
75724413|NCT00635492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
75877731|NCT03606902|Drug|Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
75877732|NCT03606902|Procedure|Group L f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
75724414|NCT00635492|Drug|any human insulin or analog insulin(s) given in any regimen by subcutaneous injection|
75724415|NCT00543309|Drug|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
75724416|NCT00543309|Drug|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
75724417|NCT00543309|Drug|placebo|Placebo bolus on CPB, then placebo infusion
75724418|NCT00902148|Device|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
75724419|NCT00894114|Biological|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
75724420|NCT00894114|Biological|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
75724421|NCT00986193|Procedure|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
75724422|NCT00986193|Procedure|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
75425821|NCT05547698|Procedure|Venoarterial ECMO lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, heparin, peripheral or central venoarterial ECMO cannulation, first pneumonectomy, stump preparation, lung implantation, reperfusion, release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, ECMO decannulation, chest closure.
75425822|NCT05540418|Other|lavender oil inhalation|Two drops of lavender (2%) essential oil were dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses. They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation. Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed.
75425823|NCT05536492|Procedure|A-PRF|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
75425824|NCT05536492|Procedure|ALLOGRAFT|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
75425825|NCT05535049|Procedure|Non-surgical periodontal treatment|Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.
75425826|NCT05534412|Other|Academic Detailing|"Provider Assessment. Physicians and advance practice providers will complete questionnaires before the intervention that assess their knowledge about the treatment for UI in women.~Mealtime Lecture. A group meeting will take place for the physicians in the intervention groups. All aspects of incontinence care will be addressed-including elements of the history and physical examination, initiation of conservative treatment, as well as when to refer for second-line therapies performed by specialists-utilizing the the principles of Academic Detailing.~Monthly individual feedback. Physicians and their clinical champion specialist will meet for individual coaching one month after the mealtime lecture to discuss and review the physician's previous performance as measured by the baseline chart abstraction. Physicians will have monthly check-ins with their clinical champion via a combination of quarterly synchronous Zooms and monthly asynchronous emails."
75425827|NCT05534412|Other|Electronic Clinical Decision Support|Intervention physicians will have access to electronic clinical decision support consisting of note templates, order sets, interruptive alerts, and a notification of patients who screen positive for UI.
75425828|NCT05534412|Other|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
75425829|NCT05534412|Other|Electronic Referral|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
75572089|NCT03455790|Diagnostic Test|Aerobic Capacity|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
76047537|NCT04421807|Other|Complex decongestive therapy (CDT)|In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
75425830|NCT05530343|Diagnostic Test|Seattle protocol|Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.
75572090|NCT05427617|Drug|Control group|Physician chosen treatment
75572091|NCT05427617|Drug|Case group|Druggable ctDNA alterations-guided therapy
75572092|NCT04581018|Other|Health supplements|28 days of health supplements (synbiotic), 4g daily
75572093|NCT05427500|Drug|5 mL of 0.5% preservative-free bupivacaine|IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.
75572094|NCT04564482|Radiation|CRT|50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO
75572095|NCT04564482|Radiation|SCPRT|25 Gy in 5 Gy fractions over 5 working days
75572096|NCT04564482|Radiation|CROSS Protocol|41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W
75572097|NCT04564482|Diagnostic Test|PD-L1 PET|10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.
75572098|NCT04564404|Other|Survey|Questionnaire to ask about the willingness-to-buy applications in neuromuscular monitoring.
75572099|NCT03455751|Genetic|PGx-guided post-operative pain management|Post-operative pain management as indicated by pharmacogenomic testing results.
75572100|NCT03455712|Behavioral|Gestational Weight Gain Card|The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
75572101|NCT05427305|Drug|TAB008|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
75572102|NCT05427305|Drug|Bevacizumab|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
75572103|NCT05427188|Behavioral|Stress paradigm|HV will receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator
75572104|NCT05427188|Behavioral|Sham paradigm|HV will receive mental arithmetic challenges where threat components from the program and/or the investigator are absent
75572105|NCT01099449|Drug|calcium gluconate|Given IV
75572106|NCT01099449|Drug|magnesium sulfate|Given IV
75572107|NCT01099449|Other|placebo|Given IV
75572108|NCT01099449|Drug|oxaliplatin|
76047538|NCT02111577|Biological|DCVAC/PCa|DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
75425831|NCT05530343|Diagnostic Test|WATS3D brushings|Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.
76047539|NCT02111577|Biological|Placebo|Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
75425833|NCT05511805|Other|Visual Analogue Scale (VAS),|The pain levels of the individuals participating in the study will be evaluated with the Visual Analog Scale. According to VAS, in the severity of pain; '0' means no pain, '10' means worst pain imaginable. During the study, the participants will be asked to rate their pain experienced in daily life and pain during evaluation between 0-10 points. Individuals with pain intensity of 3 and above according to VAS will be included in the study.
75572109|NCT05427071|Device|Magnetic seed localization|Magnetic seed guided localization
75572110|NCT04471740|Procedure|CSF shunt diversion|Clinical response to a CSF shunt insertion
75572111|NCT04680143|Drug|Systemic erythropoietin injection|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
75572112|NCT05426798|Drug|TQB2618 injection azacitidine, AZA decitabine, DAC|"Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation."
75572113|NCT01234402|Biological|Ramucirumab DP|"10 mg/kg I.V.~Day 1 of every-21-day cycle"
75572114|NCT01234402|Biological|IMC-18F1|"12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle"
75572115|NCT01234402|Drug|Capecitabine|"1000 mg/m^2 orally~Twice a day for 14 days"
75572116|NCT05464017|Device|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|"An improvement to the mHealth triage tool using a machine learning approach, optimizing the efficiency of call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the Cameroon Trauma Registry, as well as post-discharge phone contact attempts and survey information. The backbone of the estimators is the ensemble machine learning algorithm the Superlearner, which has been applied to medical contexts, including injury and trauma. It is a theory-driven method based on cross-validation, which combines potentially many different learners (e.g., standard regression, tree regression, random forest, neural nets) such that the model chosen (a weighted average of the learners) is asymptotically equivalent to the so called Oracle - the learner that fits optimally for the data-generating distribution. Note, double-robust CV-TMLE versions of this estimator are available as the tmle3mopttx function in tlverse."
75572117|NCT05426720|Other|no intervention|no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.
75425834|NCT05511805|Other|Oswestry Low Back Pain and Disability Questionnaire|The Oswestry scale will be used to determine the level of functional disability due to low back pain. In this questionnaire, 10 questions are asked about pain intensity, social life, weight lifting, walking, personal care, sitting, sleeping, sexual life, standing and travel. Each question has 6 options and the patient is asked to choose the statement that best describes his or her condition.
75572118|NCT01260922|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
75572119|NCT01260922|Drug|Aricept®|10 mg Orally Disintegrating Tablet
76047540|NCT05111795|Device|Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres|SIRT work-up procedure and SIRT procedure
76047541|NCT05216445|Behavioral|Mindfulness Training|The Mindfulness Training will be an 8-week course, with group-based online weekly sessions. The mindfulness training, translated and adapted in Urdu, includes 8 guided audio meditations and one introductory audio recording which gives the participants an overview and introduction of the forthcoming 8-week training (e.g what mindfulness is, some common terms used repeatedly). It also includes 8 chapters, corresponding to each week and a workbook to record home practice. The training will start with an online group session after which the participants will be emailed the 1st week's reading material (chapter 1), audio recordings (for that week), home practice (for that week). At the start of every week, the participants will be emailed the required material for that week. Online sessions will be conducted weekly. The participants will also be sent poems and/or quotations relating to the week's theme and based on the session proceedings.
76047542|NCT04751877|Drug|Isatuximab|Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
76047543|NCT04751877|Drug|Lenalidomide|Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
76047544|NCT04751877|Drug|Bortezomib|Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
76047545|NCT04751877|Drug|Dexamethasone|Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
76047546|NCT02170779|Behavioral|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
76047547|NCT02170779|Other|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
75572120|NCT05426642|Other|E-health Video KaSEH|The e-health video KaSEH is produce based on Protection Motivation Theory to enhance women's motivation towards cervical cancer screening.
75572121|NCT05426642|Other|Brochure|The brochure contain the information regarding cervical cancer and its screening
75572122|NCT01233817|Other|Progressive strength training|the systematic increase in resistance weights
75572123|NCT04206748|Device|iGlucose Smart Meter System|Subjects will have routine care enhanced by use of theThe iGlucose Smart meter system. This is an example of integration of a SMBG system with internet-based technology; including cell phone notifications for reminders, feedback, and communication with clinicians
75724423|NCT02540382|Device|covered stent|A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
75877733|NCT03604250|Dietary Supplement|Lifestyle plus prebiotic supplement|Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
75877734|NCT03604094|Procedure|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
75877735|NCT03602378|Diagnostic Test|salivary cortisol|5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).
76047548|NCT04751799|Device|Virtual reality headset before colposcopy|Patients wear a virtual headset presenting 360° 3D views of relaxing environments
75425835|NCT05511805|Other|Functional Low Back Pain Scale|The Functional Low Back Pain Scale will be used to evaluate how much the low back pain experienced by the people who will be included in the study affects their daily living activities. Evaluated functions; work and school activities, home activities, wearing shoes or socks, leaning forward, lifting an object from the ground, habits, sleeping, walking, sitting, climbing stairs, standing and driving. The questionnaire consists of 12 questions, and each item scores in the range of 0-5 points.
75425836|NCT05511805|Device|Prokin TecnoBody isokinetic balance 2 device|For the one-leg balance test, the subject is positioned on one leg at the origin of the platform. The participant is asked to look at any stationary point or object in front of him. Participants are allowed to experiment on the platform of the meter for approximately 2-3 minutes. The stem sensor apparatus is then attached to coincide with the xiphoid projection. After the torso sensor is attached, the patient is placed in the dominant side position on one foot and the static balance test measurement is started. 30 seconds from the patient in this position. asked to stop.
75425837|NCT05511805|Device|EMG|In our study, electromyography (EMG) device will be used to evaluate muscle strength. Electromyography is a method by which electrical activity analysis of muscles can be performed. In the study, the erector spina and multifidus muscles will be measured. Measurements are made with electrodes placed on the skin surface.
75425838|NCT05511805|Device|Algometer|The pressure perception and pain threshold of pain sensitivity are determined and recorded with an algometer. The details of the application will be explained to the participant and it will be emphasized that the feeling of pressure he feels causes pain and that he should give a 'stop' command. The pressure force is increased until the patient receives the 'stop' command in the area to be applied. It is stopped by the command from the patient and the response on the algometer screen is recorded. These measurements are repeated 3 times. The average of these three recorded measurements is determined.
75572124|NCT04206748|Device|Routine Care-RX meter|Subjects will receive routine care with the insurance prescribed glucose meter. They will self manage with traditional diabetes diary.
75572125|NCT05426603|Procedure|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode
75572126|NCT05426603|Procedure|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
75572127|NCT01233232|Drug|Placebo|Oral dose bid
75877736|NCT03602378|Device|Holter Medilog AR12 Plus|Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV
76047549|NCT04751799|Device|Virtual reality headset during colposcopy|Patients wear a virtual headset presenting 360° 3D views of distracting environments
76047550|NCT02147067|Drug|Ranolazine|Ranolazine 1,000 mg twice daily
76047551|NCT02147067|Drug|Placebo|Placebo
76047552|NCT02170389|Other|Laboratory Biomarker Analysis|Correlative studies
76047553|NCT02170389|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
76047554|NCT02170389|Biological|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
76047555|NCT02146599|Other|Administration of patient self-assessment|
75572128|NCT01233232|Drug|AZD5069 50mg|Oral dose bid
75572129|NCT01233232|Drug|AZD5069 80mg|Oral dose bid
75572130|NCT01233076|Device|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
76047556|NCT02146131|Device|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
75425839|NCT05511805|Device|Goniometer|Using the universal goniometer's measure of knee joint range of motion, sense of proprioception will be evaluated. For measurement, subjects are asked to lie on a stretcher in the prone position. The pivot point of the goniometer is placed in the center of the lateral knee joint condyle. The fixed arm of the goniometer is fixed in parallel at the level of the thoracantary major, and the movable arm is positioned at the level of the head of the fibula and the lateral malleolus. First of all, starting from the 0° extension position to the knee joint, the angle desired by the physiotherapist is made and the value in the goniometer is recorded. Then, the patient is asked to bring the knee joint, which is still in 0° extension, to the angle brought by the physiotherapist. Then the angle brought by the patient to the knee joint is recorded.
75425840|NCT05510843|Drug|THB001|100 mg capsules for oral administration
75425841|NCT05509660|Behavioral|PUMA+|Transdiagnostic CBT
75425842|NCT05509660|Behavioral|PUMA|Transdiagnostic CBT
75572131|NCT01233076|Device|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
75572132|NCT04389879|Other|Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer|Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
75572133|NCT05426018|Drug|SY-009 capsules|3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
75572134|NCT01212094|Drug|Rituximab|
75572135|NCT01212094|Other|normal saline|normal saline
75572136|NCT05425706|Other|application of SNAGs technique|in experiment group, the SNAGs technique was applied to 16 participants in addition to conventional therapy.
75572137|NCT05425628|Device|"NeoChord Transcatheter Mitral Repair System (or NeoChord System)"|"The NeoChord Transcatheter Mitral Repair System is a system of delivery devices and implantable Neochordae and Anchor. The system is designed to percutaneously deliver and deploy the implantable ePTFE sutures, Neochordae as artificial chordae at the mitral valve and connect them to the implantable ventricular anchor, Anchor, using a catheter based system placed into the left side of the heart through the interatrial septum."
75572138|NCT05457426|Procedure|robotic right hemicolectomy with CME|The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
75572139|NCT05425589|Procedure|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
75572140|NCT05425394|Behavioral|Delay first bath|Newborns delay first bath to 8 hours after birth
75877737|NCT03602378|Device|Polar V800|Polar V800 with sensor - during 5 minutes for measuring HRV
75877738|NCT03602378|Device|AGE reader|for measuring Advanced Glycation End products (AGEs)
76047557|NCT02146131|Device|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
76047558|NCT02107131|Drug|Intravitreal ranibizumab 0.3mg|
76047559|NCT02106975|Drug|Ascorbic Acid|Intervention
76047560|NCT02106975|Drug|Placebo: 5% Dextrose in water|Placebo
75425843|NCT05508022|Behavioral|Breathing exercise|Before the enema is applied, breathing exercises will be applied to the participants in the intervention group.
75572141|NCT05425316|Behavioral|Home Recordings|If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.
75572142|NCT05425316|Behavioral|In-patient Recordings|If patients are admitted to UM hospital for suspected or confirmed OHE, with patient assent, physician study staff will assist the patient in recording a paragraph reading task, a picture description task, and an animal naming task.
75877739|NCT03602300|Drug|Ravidasvir test formulation produced by Doppel|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
75877740|NCT03602300|Drug|Ravidasvir reference formulation produced by EEPI|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
75572143|NCT05425316|Behavioral|Same-Day Study Visit - Regular Appointment|Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.
75877741|NCT03606824|Drug|Pitavastatin and placebo|The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.
76047561|NCT02145429|Behavioral|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
75724424|NCT02540382|Device|bare stent|"A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.~The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.~The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.~It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions."
75877742|NCT03606824|Drug|Pitavastatin and levothyroxine|The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
75877743|NCT03602222|Behavioral|Mobile web training LGBT mental health|Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
76047562|NCT05133765|Device|Insulin pump|Alterations in insulin pump therapy or carbohydrate consumption
76047563|NCT02144337|Behavioral|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
76047564|NCT04417881|Other|MEESSI score|MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
75572144|NCT05425316|Behavioral|Same-Day Study Visit - Procedure|Staff will call patients in anticipation of in-person procedure visits to set up a same-day study visit, prior to procedure if sedation is planned. Patients will record the three speech tasks at this time.
75572145|NCT05425316|Behavioral|Phone Call Follow-up Visits|Non-physician study staff will call the patients every 3 months and, using a phone script, will ask them survey questions about their hepatic health.
75572146|NCT05419401|Drug|Capivasertib film-coated tablet, 200 mg|400mg dose, oral, fasted
75724425|NCT00986271|Procedure|EVLI was determinated by PiCCO plus system.|
75724426|NCT00988611|Other|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
75724427|NCT00897936|Genetic|DNA methylation analysis|
76047565|NCT02520011|Drug|Alvocidib|
75877744|NCT03602222|Behavioral|In-person training LGBT mental health|In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
75425844|NCT05495425|Drug|NPC-12Y gel|NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
76047566|NCT02520011|Drug|Cytarabine|
76047567|NCT02520011|Drug|Mitoxantrone|
75425845|NCT05495425|Drug|NPC-12Y placebo gel|NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
75425846|NCT05493722|Other|PS and OS stimulation order 1|PS, OS, OS
75572147|NCT05419401|Drug|[14C]AZD5363 (Capivasertib)|"Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted"
75572148|NCT04436393|Diagnostic Test|Guardant360 test|tumor cfDNA testing
75572149|NCT04330560|Device|Exercise telemonitoring connects to healthcare platform|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) link to the healthcare practitioner
75572150|NCT04330560|Device|Exercise self-monitoring|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) for exercise self-monitoring.
75724428|NCT00897936|Genetic|comparative genomic hybridization|
76047568|NCT05110625|Behavioral|preDIABE-TEXT|Participants will receive text messages (three per week) in their mobile phones during six months.
76047569|NCT05110625|Other|Online Education|Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
76047570|NCT04224233|Other|Home-based physical activity programme|iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
76047571|NCT04224233|Other|Usual care|Participants will receive a leaflet with exercises and PA recommendations.
75572151|NCT04330560|Device|Exercise teleconsultation|Conducted through smartphone video call app.
75572152|NCT04330560|Procedure|Other CR components|Including dietary, psychology, education conducted at the center.
75572153|NCT04330560|Procedure|Standard care|Undergoing standard care by cardiac rehabilitation at the center
75877745|NCT03604016|Drug|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
75877746|NCT03604016|Drug|L-carnitine|Besifovir dipivoxil 150 mg
75877747|NCT03604016|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
75877748|NCT03219333|Drug|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
75425847|NCT05493722|Other|PS and OS stimulation order 2|OS, PS, OS
75425848|NCT05493722|Other|PS and OS stimulation order 3|OS, OS, PS
75425849|NCT05493007|Procedure|Sandbag motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
75425850|NCT05493007|Procedure|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine.
75572154|NCT05409885|Other|General anesthesia|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
75572155|NCT05409885|Other|Spinal anesthesia|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
75572156|NCT04327479|Diagnostic Test|Assessment of cardiovascular diseases and cardiovascular risk factors|At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
75724429|NCT00897936|Genetic|fluorescence in situ hybridization|
75724430|NCT00897936|Genetic|microarray analysis|
75724431|NCT00897936|Genetic|polymerase chain reaction|
75724432|NCT00897936|Other|diagnostic laboratory biomarker analysis|
75724433|NCT00897936|Other|immunologic technique|
75724434|NCT00988689|Other|Dietary Intervention|soup with or without starch
75724435|NCT04006977|Dietary Supplement|a multistrain probiotic product (DSF)|In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.
75724436|NCT04006977|Dietary Supplement|Placebo|In Arm 1, participants will receive standard medical therapy plus the placebo.
75572157|NCT01232569|Drug|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
75724437|NCT04332432|Drug|belapectin|intravenous
75425851|NCT05491681|Biological|intravenous delivery of allogeneic bone marrow-derived MSCs|MSCs
75425852|NCT05487378|Dietary Supplement|PKU GOLIKE|AA protein Substitute for the dietary management of PKU, PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
75425853|NCT05487196|Drug|Clonidine|Clonidine belongs to the drug classification of antihypertensives
75425854|NCT05487196|Drug|Dexmedetomidine|Dexmedetomidine belongs to the drug classification of sedatives
75425855|NCT05487196|Drug|Fentanyl|Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care
75425856|NCT05487196|Drug|Ropivacaine|Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
75425857|NCT05483907|Drug|BBT-877|BBT-877 24 weeks + Follow-up 4 weeks
75425858|NCT05483907|Drug|Placebo|Placebo 24 weeks + Follow-up 4 weeks
75425859|NCT05482828|Drug|JGT (Jaeumgeonbi-Tang) tablet|JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
75425860|NCT05482828|Drug|Placebo tablet|Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
75425861|NCT05480579|Biological|placebo|Dose4 placebo of single IV injection
75425862|NCT05480579|Biological|IBI311|Dose2 IBI311 of single IV injection
75425863|NCT05480579|Biological|IBI311|Dose4 IBI311 of single IV injection
75425864|NCT05480579|Biological|placebo|Dose3 placebo of single IV injection
75572158|NCT01232569|Drug|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
75572159|NCT00552864|Drug|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
75724438|NCT00988767|Biological|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
75425865|NCT05480579|Biological|placebo|Dose1 placebo of single IV injection
75425866|NCT05480579|Biological|IBI311|Dose1 IBI311 of single IV injection
75425867|NCT05480579|Biological|IBI311|Dose 3 IBI311 of single IV injection
75425868|NCT05480579|Biological|placebo|Dose2 placebo of single IV injection
75425869|NCT05479968|Device|Spectrocor device|This feasibility study is intended to document the feasibility, safety, and usability of the Investigational device.
75425870|NCT05471700|Drug|Azacitidine|Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.
75425871|NCT05471700|Drug|Venetoclax|Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.
75425872|NCT05469178|Drug|Bemcentinib|Bemcentinib capsules will be administered orally.
75425873|NCT05469178|Drug|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as part of CIT every 3 weeks.
75425874|NCT05469178|Drug|Pemetrexed|Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
75724439|NCT00898014|Genetic|fluorescence in situ hybridization|
75724440|NCT00898014|Other|immunologic technique|
75724441|NCT00898014|Other|laboratory biomarker analysis|
75724442|NCT00569582|Drug|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
75724443|NCT00894192|Device|Izon Wavefront-guided lenses|Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
75724444|NCT00894192|Device|Conventional lenses|We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
75572160|NCT00552864|Drug|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
75572161|NCT04419584|Drug|Modified Qing-Ying Decoction|Herbal granules
75572162|NCT04419584|Drug|Identical looking placebo|Placebo granules
75572163|NCT04416542|Diagnostic Test|Home Sleep Testing|"Two-night Home Sleep Tests (HSTs) will be conducted using commercially available Home Sleep Test equipment. The HST will be ordered by the clinical center through a HIPAA compliant HST service that has been selected by the study sponsor.~The HSTs will be scored and interpreted according to AASM Guidelines by board certified sleep physicians affiliated with the HST service. The HST will be scored using the 4% oxygen desaturation rule."
75572164|NCT01211665|Drug|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
75572165|NCT01211665|Drug|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
75572166|NCT04401176|Drug|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
75572167|NCT04401176|Drug|Onabotulinum Toxin A|Intradetrusor onabotulinumtoxinA injection (0.5mL x 20 sites)
75572168|NCT02887612|Other|ctDNA test|
75572169|NCT04393922|Behavioral|Acoustic stimuli (Startle)|A startle stimulus (120 dB, 500 Hz, 50 ms) will be delivered through headphones
75572170|NCT04389905|Behavioral|Dental education - Motivational Interviewing|Motivational Interviewing - Focusing on oral/dental health
75572171|NCT01232491|Drug|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
75572172|NCT01232491|Dietary Supplement|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
75572173|NCT05388591|Other|Musicotherapy|Music listening with the application Music Care (style of music chosen by the patient) during wound suturing
75572174|NCT04355234|Diagnostic Test|identify SARS-CoV-2 infection by serology|Blood samples at delivery to identify SARS-CoV-2 infection by serology
75572175|NCT04355234|Biological|collection of biological samples|Creation of a specific collection of biological samples for new investigations thanks to the collection of several biological samples at the time of maternal SARS-CoV-2 infection, at delivery and in the postpartum period in the parturient and her newborn.
75572176|NCT04335305|Drug|Tocilizumab|IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
75572177|NCT04335305|Biological|Pembrolizumab (MK-3475)|IV infusion over 30 minutes, 200 mg; single dose
75572178|NCT04253951|Diagnostic Test|Lung Ultrasound (LUS)-monitored feeding trial|LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
75572179|NCT04248530|Device|Renal denervation|DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
75572180|NCT04255212|Other|Soft tissue treatment|Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
75572181|NCT04255212|Other|Mechaninsms explanation|Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
75572182|NCT04255212|Other|Control Group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
75724445|NCT00988845|Dietary Supplement|Indole-3-carbinol|200 mg bid po X 8 weeks
75724446|NCT00894270|Procedure|Sterile air injection|Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.
75724447|NCT00894270|Procedure|Placebo injection|Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.
75572183|NCT04255212|Other|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
75724448|NCT00894270|Device|Novofine needle|Novofine 5mm needle
75877749|NCT03168867|Behavioral|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
76047572|NCT04222829|Procedure|Megadose Shinbaro Pharmacopuncture|"Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases."
76047573|NCT05037539|Drug|Fentanyl Citrate 50Mcg/Ml Inj_#1|Injectable Fentanyl in Sublingual Route 50 mcg
76047574|NCT05037539|Drug|Morphine|Oral Morphine Syrup 2.5 ml ( 5 mg)
76047575|NCT02519231|Drug|Naproxen|Naproxen 440mg 1x pid
76047576|NCT02519231|Drug|Placebo|Placebo tablet 440mg 1x pid
76047577|NCT02106351|Biological|Botulinum toxin type A|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
76047578|NCT04998539|Other|Wheelchair forward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
76047579|NCT04998539|Other|Wheelchair backward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
76047580|NCT04998539|Other|Upright technique|Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
76047581|NCT04998539|Other|Wheelie technique|Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
76047582|NCT04998539|Other|Wheelchair occupant upright body position|The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
76047583|NCT05036603|Other|chest physiotherapy|diffferent chest physiotherapy methods
76047584|NCT05071235|Device|LG1 (LLLT group 1)|Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².
75425875|NCT05469178|Drug|Carboplatin|Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks.
75425876|NCT05461378|Drug|Evusheld|Participants who have received or plan to receive Evusheld.
75572184|NCT04207268|Behavioral|Gardening and Nutrition Advice|Participate in gardening activities, gardening instructions and nutrition advice
75572185|NCT04207268|Behavioral|Nutrition Advice|Participate in only nutrition advice
75572186|NCT05353803|Other|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
75572187|NCT00552903|Behavioral|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
75724449|NCT00819416|Drug|5% albumin|5% albumin for the first 7 days of care in the ICU
75724450|NCT00819416|Drug|Normal Saline|Normal Saline for the first 7 days of care in the ICU
75724451|NCT04005807|Drug|BPN-14967|BPN-14967 oral capsules
75724452|NCT04005807|Drug|Placebo|Oral capsules
75724453|NCT00898092|Genetic|microarray analysis|
75877750|NCT01064622|Drug|vismodegib|Given PO
75877751|NCT01064622|Drug|gemcitabine hydrochloride|Given IV
75877752|NCT01064622|Other|hydrocortisone/placebo|Given PO
76047585|NCT05071235|Device|LG2 (LLLT group 2)|Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².
76047586|NCT05071235|Device|LG3 (LLLT group 3)|Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².
76047587|NCT05071235|Device|CG (control group)|Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.
76047588|NCT05071235|Procedure|Dressing|Application of Helianthus annuus oil dressing.
76047589|NCT02143947|Device|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
75572188|NCT04176029|Device|lung ultrasound|Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.
75572189|NCT04152980|Drug|Pentoxifylline|The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
75572190|NCT01232452|Drug|Pemetrexed|Administered intravenously (IV)
75572191|NCT01232452|Drug|Cisplatin|Administered IV
75572192|NCT01232452|Drug|Cixutumumab|Administered IV
75572193|NCT01211197|Drug|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
75572194|NCT01211197|Drug|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
75572195|NCT01211197|Drug|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
75572196|NCT04208802|Other|Use of fluoridated toothpaste|Use of fluoridated toothpaste
75572197|NCT04208802|Other|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
75572198|NCT04208802|Other|Wearing of an intraoral device with resin samples|Wearing of an intraoral device with resin samples
75572199|NCT04679519|Other|Drop Jumps|Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
75572200|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-1|Section 1: Deep breathing exercises: A deep breath is taken as far as possible by raising the arms up to the sky. Breathing is held for 4-5 seconds after deep inspiration. Breathing is performed rhythmically and slowly, while the arms are placed in a normal position. After deep inspiration, one can exhale either by forming the lips in the whistling position or by laughing. In each deep breathing exercise technique, the expiration time of the exhalation process should be longer than the inspiration time.
75572201|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-2|Section 2: Warm-up exercises (10 minutes): Hands are clapped by holding parallel to each other. The fingertips and the palms touch each other, stimulating the acupuncture points on both hands, and the individual's energy level rises. In order to further raise the energy level and synchronize the movements of the group, a rhythm is added in the form of 1-2, 1-2-3. After several rhythmic hand-clapping movements, one more movement is added. Hands are clapped by swinging left and right. Then, an audible rhythm in the form of ho, ho, ha-ha-ha is also added to the hand-clapping movement. People in the group look at each other, and smile.
75572202|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-3|"Section 3: Childish games (10 minutes): Childish games are used that will help to laugh for no reason, just like a child. Imagining these games and plays, the arms are raised upwards in the form of a Y with palms facing the sky, motivating the group by saying very good (clap), very good (clap), yes. The leader of laughter yoga speaks out very good (clap), very good (clap), hey (arms to the right and left) to keep the group's energy high and generate enthusiasm in the deep breathing exercises and laughter exercises sections. According to the energy and desire of the group, this section is completed after about 10 minutes."
75724454|NCT00898092|Genetic|molecular genetic technique|
75724455|NCT00898092|Genetic|mutation analysis|
76047590|NCT02143947|Device|Full Contact Orthosis|"The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene."
76047591|NCT02075073|Biological|SB3|
75724456|NCT00898092|Genetic|polymerase chain reaction|
75724457|NCT00898092|Genetic|reverse transcriptase-polymerase chain reaction|
75724458|NCT00898092|Other|diagnostic laboratory biomarker analysis|
75724459|NCT00983697|Procedure|therapeutic conventional surgery|
75724460|NCT00983697|Radiation|fludeoxyglucose F 18|
76047592|NCT02075073|Biological|EU sourced Herceptin®|
76047593|NCT02075073|Biological|US sourced Herceptin®|
76047594|NCT02074059|Drug|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
76047595|NCT02074059|Device|nCPAP alone|nCPAP therapy
76047596|NCT02143713|Drug|Elagolix|Elagolix tablets administered orally
75572203|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-4|"Section 4: Laughter exercises (15 minutes): This section contains a variety of laughter exercises that will laugh, such as greetings, laughter cream, exploding balloon laughter, preparing and drinking strawberry milk, bonuses, hot soup, lion, aloha, bird, appreciation, elevator, and cream pie. A laugh is raised by doing only laughter exercises for no reason at all. At the end of this section, relaxation is achieved for about three minutes using deep breathing exercises. The group is given verbal guidance Put your hand on your heart, feel your heartbeat, let's exhale with a smile, make a wish or pray, smile as if we had achieved our wish, and the laughter yoga session is terminated."
75572204|NCT04679792|Diagnostic Test|Dynamic posturography|Balance evaluation
75572205|NCT04679363|Other|Active release technique|ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.
76047597|NCT04738149|Drug|Bimatoprost|Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks
75572206|NCT04679363|Other|Post isometric relaxation|PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
75572207|NCT00553137|Drug|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
75572208|NCT00553137|Drug|fluconazole|150 mg fluconazole tablets once daily for 14 days
75572209|NCT04679246|Behavioral|Participatory intervention|Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments
75572210|NCT04090775|Drug|Opdivo Injectable Product|"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."
75572211|NCT04090775|Drug|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."
75572212|NCT04090775|Drug|Cytoxan|"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."
75572213|NCT04090775|Procedure|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
75572214|NCT00553176|Other|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
75572215|NCT04166136|Other|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
75572216|NCT04166136|Other|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
75724461|NCT00902460|Drug|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
75724462|NCT00902460|Drug|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
75724463|NCT00988923|Other|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
75724464|NCT00988923|Other|No intervention|the intervention tool was switched in off, only bolus was activated
75724465|NCT02539446|Behavioral|stable condition|
75724466|NCT02539446|Behavioral|unstable condition|
75724467|NCT02539446|Behavioral|attentional focus|
76047598|NCT04738149|Device|Excimer laser|Participants will be receiving excimer laser 2x a week for 12 weeks
75724468|NCT00989079|Drug|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
75724469|NCT00989079|Drug|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
75724470|NCT00809198|Other|Sodium Hyaluronate|
75724471|NCT00809198|Other|Carboxymethylcellulose sodium|
75724472|NCT00898170|Procedure|myoma removal|surgical removal of myoma by hysterectomy
76047599|NCT04738149|Device|Microneedling with a dermaroller|Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
76047600|NCT02519855|Biological|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
76047601|NCT02519855|Biological|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
76047602|NCT02519855|Biological|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
76047603|NCT02142387|Other|BLS CPR program with dispatcher assisted CPR simulation|the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
75572217|NCT04166136|Other|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
75724473|NCT04006743|Behavioral|The swaddling group|The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
75572218|NCT04089839|Other|Non-Interventional|Non-Interventional
75572219|NCT04045145|Drug|NBI-74788|NBI-74788 administered orally for 14 consecutive days.
75572220|NCT01232296|Drug|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
75572221|NCT01232296|Drug|sorafenib|400 mg p.o. b.i.d.
75572222|NCT04041011|Drug|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
76047604|NCT05070455|Biological|Asceniv™|Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
75572223|NCT04041011|Drug|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
75572224|NCT04041011|Drug|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
75572225|NCT02888236|Drug|LEO 32731|
75572226|NCT02888236|Drug|LEO 32731 Placebo|
75572227|NCT04136379|Diagnostic Test|INR monitoring using a CoaguChek POC device|INR monitoring using a CoaguChek POC device
75572228|NCT01231984|Device|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
76047605|NCT05034575|Other|Eye Tracking Technology Sensor|Eye tracking will be performed using Tobii Pro eye tracking technology sensor (Tobii Pro Fusion, Stockholm, Sweden), providing binocular eye tracking up to 250 Hz. The sensor, positioned on the inferior aspect of the computer monitor, reflects infrared (IR) light beams off of each cornea and are subsequently captured.
76047606|NCT05069987|Other|Virtual Reality Immersion|An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax & Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
76047607|NCT05069207|Other|POWER breathe K5|Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
76047608|NCT05068817|Other|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
76047609|NCT05068817|Other|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
76047610|NCT05068817|Other|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
76047611|NCT04421183|Diagnostic Test|draw blood|draw blood from the all of patients
75724474|NCT04006743|Behavioral|The expressed breast milk group|In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
75724475|NCT04006743|Behavioral|The facilitated tucking group|Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.
75572229|NCT01231984|Device|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
75572230|NCT01231984|Device|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
75724476|NCT04006743|Behavioral|The swaddling and expressed breast milk group|Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
76047612|NCT04219319|Drug|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
75572231|NCT04684095|Behavioral|electronic patient report outcome|ePRO was conducted every two weeks in addition to routine follow-up
75724477|NCT04006743|Behavioral|The facilitated tucking and expressed breast milk group|Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
76047613|NCT04996121|Drug|XZP-5955 tablets|"Phase I dose escalation:~For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase I dose expansion:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase II:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle"
76047614|NCT02518919|Other|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
76047615|NCT02518919|Other|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
76047616|NCT04995887|Device|Jada® System|The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
75572232|NCT01210807|Device|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
75572233|NCT01210807|Device|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
75572234|NCT00552942|Procedure|laparoscopic gastric bypass plus omentectomy|
75572235|NCT03969095|Behavioral|Tongue Pressure Resistance Training|2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.
75572236|NCT05302479|Other|COMPASS 31 questionnaire|A 31 question questionnaire that measures autonomic symptoms.
75572237|NCT00554138|Drug|placebo|1 dd for 7-10 days
75572238|NCT00554138|Drug|rosuvastatin|1 dd 20 mg for 7-10 days
75572239|NCT03455595|Procedure|Endoscopic exams|Coloscopy
75572240|NCT03923387|Device|MynxGrip|Vascular Closure
75572241|NCT03923387|Other|Manual compression|Manual compression is a commonly used method to achieve hemostasis of femoral artery
75724478|NCT00986505|Drug|Lidocaine|Intravenous lidocaine once a week
75724479|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
75724480|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
75572242|NCT01231555|Drug|GSK2248761 100 mg once daily|1x100 mg capsule plus matching placebo
75572243|NCT01231555|Drug|GSK2248761 200 mg once daily|2x100 mg capsules
75572244|NCT01231555|Drug|Efavirenz 600 mg once daily|1x600mg tablet
75572245|NCT05288907|Drug|Lidocaine Ointment|Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
75572246|NCT04683861|Procedure|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565; Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
75877753|NCT01376895|Behavioral|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
75425877|NCT05460988|Procedure|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
75425878|NCT05460988|Procedure|Non surgical re-instrumentation|The sites showing remaining pockets (PD>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
75425879|NCT05452642|Behavioral|DASH diet|Participants in this arm will be taught a DASH diet plus psychological skills to support dietary adherence.
75425880|NCT05452642|Behavioral|Very low-carbohydrate diet|Participants in this arm will be taught a very low-carbohydrate diet plus psychological skills to support dietary adherence.
75425881|NCT05447286|Drug|NYX-783|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
75572247|NCT01210651|Behavioral|Hatha Yoga Practice Group|The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
75724481|NCT04017858|Behavioral|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).|"Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis"
75724482|NCT04017858|Behavioral|Patients will be submitted to total knee replacement.|"Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively"
75724483|NCT03687333|Drug|ALGLUCOSIDASE ALFA (MYOZYME)|"Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion"
75724484|NCT00902616|Dietary Supplement|L-arginine|3gm TDS for three months
75572248|NCT01210651|Behavioral|Attention Control Education Group|The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
75572249|NCT03911336|Drug|Group A - test:Tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
75572250|NCT03911336|Drug|Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
75572251|NCT03911336|Drug|Group C - Control 2: tooth extraction and intake of a Non-Nsaid|Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
75572252|NCT04683822|Other|Telerehabilitation|Patients will attend telerehabilitation sessions
75572253|NCT03850535|Drug|Idasanutlin|Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
75724485|NCT00902616|Dietary Supplement|Placebo Lactose powder|3gm TDS for 3 months
75724486|NCT00984087|Device|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
75425882|NCT05447286|Drug|Placebo|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
75724487|NCT00898326|Other|biopsy|Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
75724488|NCT00989313|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
75425883|NCT05447286|Drug|Oxycodone|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
75724489|NCT04035954|Other|exercise|The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
75724490|NCT02539524|Other|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
75724491|NCT02539524|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
75425884|NCT05446766|Behavioral|Self-guided Exposure-based Digital Intervention for Health Anxiety|"An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days."
75425885|NCT05442112|Behavioral|Wellness Patient Message|The intervention is a detailed patient message containing information on strategies for exercise in MS, how to maintain proper sleep, and dietary improvements to maximize health. These strategies are derived from information provided by the National MS Society in their website and covers these topics in greater detail than would normally be addressed in a normal clinic visit. The message also directs patients to the National MS Society website if they would like more information.
75572254|NCT03850535|Drug|Cytarabine|Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
75425886|NCT05439226|Other|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
75425887|NCT05433220|Other|Best Practice Advisory using Electronic Health Record|Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
75572255|NCT03850535|Drug|Daunorubicin|Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m^2 QD as IV infusion.
75572256|NCT03850535|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)|After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
75572257|NCT05285436|Device|CloudCath System|The CloudCath System enables drainage and measures turbidity, reported as a numeric score, in peritoneal dialysate effluent.
75425888|NCT05431595|Drug|Haloperidol|Given by Vein (IV)
75572258|NCT05263089|Other|PALFIQUE® Universal Flow; Tokuyama, Tokyo, Japan (super low flowability)|"Supplied in L-syringe with nozzle and dispensing Tips. Super Low has low flowability, non-slumping, non-running, and precision stacking properties. The layer dispensed will be 2 mm. in thickness and cured for 40 s."
75572259|NCT05263089|Other|ESTELITE® Alpha; Tokuyama, Tokyo, Japan|The composite was inserted using the incremental technique. Each increment of 2 mm was cured for 40 s.
75724492|NCT00984243|Procedure|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm^2 Excimer-dye laser: 100-200 Joules/cm^2"
75724493|NCT00815750|Other|Information Gathering|An information gathering phase leading to development of a new decision aid.
75724494|NCT00815750|Other|Decision Aid|To test the newly developed decision aid.
75877754|NCT01376895|Behavioral|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
75877755|NCT01380405|Behavioral|education intervention|"Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
75877756|NCT04850391|Other|Mobile app|To compare changes induced by the movile app intervention among the three study groups
75877757|NCT04163718|Drug|Umbralisib|800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
75877758|NCT04171635|Radiation|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
75877759|NCT04171635|Radiation|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
75877760|NCT01378689|Other|Storytelling online video|patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
75877761|NCT03630549|Other|Standard of Care|Clinic-based HIV care
75877762|NCT03630549|Other|Village-based ART refill|Option to get ART refill and care by the village health worker
75425889|NCT05431595|Drug|Chlorpromazine|Given by Vein (IV)
75425890|NCT05431595|Drug|Valproate|Given by Vein (IV)
75425891|NCT05431595|Drug|Placebo|Given by Vein (IV)
75425892|NCT05427006|Device|Z5-BL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
75425893|NCT05427006|Device|Z5-TL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
75572260|NCT03850301|Drug|XBD173|7 days treatment
75572261|NCT03850301|Drug|Etifoxine|7 days treatment
75572262|NCT04114929|Other|Threshold-based Training|Specific ventilatory markers determined from a cardiopulmonary test and the correlating heart rate will be used to determine exercise intensity
75877763|NCT04153539|Behavioral|Walking along a busy road|The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
75572263|NCT04114929|Other|Standard Care|Using the standard care cardiac rehabilitation guidelines exercise will be based on estimated heart rate maximum followed by the karvonan method to calculate 40-70% heart rate reserve
75572264|NCT03792932|Procedure|Laparoscopic distal pancreatectomy|Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
75572265|NCT03792932|Procedure|Open distal pancreatectomy|Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
75572266|NCT05255367|Combination Product|(poly)phenols rich foods|"Prior to start the intervention (initial time of the study) the volunteers will follow their habitual diet during 30 days as a control period, and then they will start with the intervention period (baseline) following their habitual diet supplemented with (poly)phenol rich products during 60 days (after intervention).~At the beginning of the study (initial time), at the beginning of the intervention (baseline) and at the end of the intervention (after the intervention) with rich (poly)phenols foods, biological samples (blood, urine and feces) and anthropometric measurements will be taken. In addition, the participants will record the food intake weekly with a 24 h dietary-recall form."
75425894|NCT05415514|Other|Instrumented assessment of muscle function|During the instrumented evaluations, we will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
75425895|NCT05412914|Drug|Remimazolam infusion|Remimazolam infusion for anesthesia induction
75425896|NCT05412914|Drug|Propofol infusion|Propofol infusion for anesthesia induction
75425897|NCT05408195|Device|CHATBOT use|Patients benefiting from chemotherapy with outpatient follow-up (conventional follow-up by telephone calls) have the possibility to receive a weekly remote questionnaire (by email or SMS) via a CHATBOT on any terminal. This automated questionnaire collects data (completed by the patient and/or their caregivers) on tolerance and compliance to the care plan.
75425898|NCT05407389|Drug|KT-301 (formerly US-APR2020)|KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).
75425899|NCT05407038|Other|Exercise Counseling|Receive call from health coach
75877764|NCT04153539|Behavioral|Walking in a traffic-free park|The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
75425900|NCT05407038|Other|Exercise Intervention|Undergo routine exercise
75877765|NCT01063764|Drug|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
75877766|NCT04117815|Device|Paxman Scalp Cooling System|"All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~Minimum 30 minutes pre-infusion cooling~Cooling for the duration of chemotherapy infusion~Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session."
75425901|NCT05407038|Other|Internet-Based Intervention|Receive Android tablet
75425902|NCT05407038|Other|Interview|Complete a qualitative interview
75425903|NCT05407038|Other|Medical Device Usage and Evaluation|Wear Garmin Vivofit and Nonin 3150 WristOx2 pulse oximeter
75425904|NCT05407038|Other|Questionnaire Administration|Ancillary studies
75425905|NCT05406856|Radiation|External beam radiation therapy: IMRT/VMAT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
75425906|NCT05406856|Radiation|External beam radiation therapy: IMPT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
75425907|NCT05406856|Drug|Cisplatin|The standard chemotherapy regimen is weekly cisplatin (40 mg/m2) for 5 weeks.
75425908|NCT05406856|Radiation|Brachytherapy|Brachytherapy is performed using a high-dose rate (HDR) after loading system to deliver a boost to any residual tumor and the cervix. Brachytherapy dose is (21-) 28 Gy in fractions of 7 Gy specified at 100% isodose around the high-risk CTV, according to the EMBRACE-II prescription protocol. The aim is to reach an equivalent dose in 2 Gy fractions including EBRT (EQD2_D90) of the high-risk CTV between 90-95 Gy, using MRI-guided adaptive brachytherapy.
75425909|NCT05377177|Device|Accelerated Theta Burst Stimulation|B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
75425910|NCT05356572|Device|Investigational Skin Preparation Device|Removal of hyperkeratotic skin with Investigational Skin Preparation Device
75425911|NCT05356572|Device|GMDN 47102 / Electrode Skin Abrasive Pad|Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation
75425912|NCT05356572|Device|UMDNS 13-230 / Biopsy punch (Dermal Curette)|Removal of hyperkeratotic skin with Disposable Dermal Curette
75425913|NCT05354726|Other|Assessments parameters|Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
75425914|NCT05352971|Other|Biomarker quantification|Patient blood samples will be tested on 2 different platforms
75425915|NCT05351294|Other|Questionnaires|"All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique."
75572267|NCT03753620|Device|simultaneous fMRI and EEG + peripheral measures|Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.
75724495|NCT00894582|Procedure|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
75724496|NCT05712681|Drug|JP-1366 20mg tablet|T : JP-1366 20mg tablet after the meal
75877767|NCT04117815|Other|Alopecia Assessments|"Patients (study group and reference group) will be assessed at the following time Points:~Baseline~at the half-way Point of the cyles~at the last CT cycle~3 months after completion of Treatment~6-9 months after treatment completion~The assesments include the following~Photographs of the head, which are evaluated using the CTCAEv4.0~Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire"
75877768|NCT03073629|Diagnostic Test|Clinical Pathway|Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
75572268|NCT03753620|Device|EEG and peripheral measures|cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
75877769|NCT03652350|Procedure|CT-guided microwave ablation|Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
75425916|NCT05351294|Combination Product|Early Radiation Oncology Involvement Alongside Standard Oncologic Care|Early Radiation Oncology Involvement Alongside Standard Oncologic Care
75425917|NCT05350163|Biological|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
75425918|NCT05330195|Other|Bicycle Ergometer Training|Bicycle ergometer training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group.
75425919|NCT05330195|Other|Home-based exercise group|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
75572269|NCT04095156|Diagnostic Test|In vitro assays.|Biochemical and flow-cytometry analysis of specimen collected.
75572270|NCT03750266|Other|No intervention data collected through routine scans|No intervention, we wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH.
75572271|NCT04679129|Drug|ASC42|Oral tablets
75572272|NCT04679129|Drug|Placebo|Oral tablets
75724497|NCT05712681|Drug|JP-1366 20mg tablet|R : JP-1366 20mg tablet under fasting condition
75724498|NCT00898404|Other|laboratory biomarker analysis|Correlative studies
75724499|NCT05712603|Diagnostic Test|FIB4-score|A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
75724500|NCT05712603|Diagnostic Test|Vibration controlled transient elastography|VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
75724501|NCT05712603|Diagnostic Test|Enhanced Liver Fibrosis test|The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
75877770|NCT02880189|Device|Orbera Intragastric Balloon|The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
75425920|NCT05325307|Other|Acupressure|The experimental group will start with HT7 points and continue LI4 and EX-NH3 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
75425921|NCT05325307|Other|Placebo acupressure|In the placebo acupressure group , the points 1.5 cm away from the HT7, LI4, and EX-NH3 points will be applied for an average of 15 minutes. Less pressure will be applied.
75425922|NCT05307692|Drug|Seltorexant|Seltorexant 20 mg will be administered orally as a tablet.
75425923|NCT05307692|Drug|Placebo|Matching placebo will be administered orally as a tablet.
75425924|NCT05307198|Drug|Oxaliplatin|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.~The dose of oxaliplatin used for rectal artery infusion was uncertain because there were no previous study. We design this study with Oxaliplatin 85mg/㎡for rectal artery infusion chemotherapy in Day 1 every 3 weeks and repeat for 2 cycles, based on intravenous chemotherapy regimens recommended by NCCN（mFolfox6）.If there were severe side effects caused by oxaliplatin observed within first 5 patients, we would decreasing the dose of oxaliplatin depending on the multidisciplinary discussion of researchers.~We acknowledged that our study did not determine the most appropriate dosage of oxaliplatin used for artery infusion, but rather performed a novel therapeutic method for microsatellite stable locally advanced rectal cancer."
75425925|NCT05307198|Procedure|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
75425926|NCT05307198|Drug|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 4 cycles.
75425927|NCT05307198|Drug|Anti-PD-1 monoclonal antibody|Anti-PD1 antibody 200mg/m2 in Day 2 after Rectal Artery Infusion Chemotherapy. Repeat every 3 weeks for 2 cycles.
75724502|NCT00898482|Other|This is a non-intervention study for all groups.|This is a non-intervention study.
75724503|NCT00898482|Other|study of socioeconomic and demographic variables|Non-intervention study.
75724504|NCT03667443|Dietary Supplement|Myo-inositol + folic a. + α-lactalbumin|3 months of treatment
75724505|NCT03667443|Dietary Supplement|Myo-inositol + folic a.|3 months of treatment
75724506|NCT00902694|Behavioral|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
75724507|NCT00902694|Other|Control|group health classes quarterly with topics not related to weight
75724508|NCT03646071|Drug|RX108|RX108
75724509|NCT00902772|Drug|Lorazepam|mg, oral dose
75724510|NCT00902772|Drug|AZD7325|mg, oral dose
75724511|NCT00902772|Drug|Placebo|
75877771|NCT02880189|Procedure|Endoscopic Ultrasound Guided Core Liver Biopsy|
75877772|NCT04053972|Drug|Lenvatinib|oral lenvatinib after hepatectomy
75425928|NCT05304104|Behavioral|Cognitive Behavioral Therapy (CBT)|The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
75425929|NCT05302167|Behavioral|Molehill Mountain app|"The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study."
75425930|NCT05302167|Device|Molehill Mountain app|As above.
75877773|NCT01380249|Drug|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
75877774|NCT04054518|Drug|Durvalumab|Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
75877775|NCT01378611|Device|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
75877776|NCT03652896|Procedure|anatomical liver resection|Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
75877777|NCT04565847|Drug|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
75877778|NCT04565847|Drug|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
75877779|NCT03075891|Drug|Ivermectin 1% cream|Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
75877780|NCT03075891|Drug|Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|1 Capsule once-daily for 12 weeks
75877781|NCT03075891|Other|Oral placebo capsules|1 Capsule once-daily for 12 weeks
75877782|NCT02013167|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
76047617|NCT04995731|Behavioral|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH)|Bleeding type, age, race, parity, early menarche or late menopause, body mass index, body composition, hypertension, type II diabetes, anovulation, polycystic ovary syndrome and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
75877783|NCT02013167|Drug|Standard of Care Chemotherapy|"FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 & 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients > 60 years: Idarubicin 5 mg/m² day 1 & 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
76047618|NCT04995731|Procedure|transvaginal ultrasound examination|All patients will undergo a standard transvaginal ultrasound examination followed by power Doppler endometrial vascularity assessment. After ultrasound examination, all patients will undergo endometrial sampling either through hysteroscopy or dilatation and curettage operation (D, C) or will have histopathological evaluation of biopsy specimens obtained by hysterectomy. Histopathological evaluation will serve as a gold standard for the ﬁnal diagnosis.
75425931|NCT05301270|Diagnostic Test|EMG Evaluation|Muscle activations in the lower extremity and trunk muscles during compensatory postural responses will be evaluated. The Delsys Trigno IM (Delsys Inc. Natick, Massachusetts, USA) wireless surface electromyography (EMG) system will be used to evaluate muscle activation. In the lower extremity; Muscle activations of tibialis anterior, gastrocnemius, quadriceps and hamstring muscle groups and erector spinae in the trunk will be evaluated. While the muscle groups above the stump on the amputated side of the individuals in the amputation group will be evaluated, all muscle groups specified on the healthy side will be evaluated. In the control group, all muscle groups on the dominant side, but on the non-dominant side, all other muscles except the tibialis anterior and gastrocnemius muscles will be evaluated in order to be compatible with the amputation group.
75425932|NCT05293938|Drug|Obeticholic Acid 5 MG|once daily, oral administration
75724512|NCT03637647|Diagnostic Test|Cardiopulmonary exercise testing|The CPET involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
75877784|NCT03805737|Other|Amulez and sunlight|Amulez and sun exposure for 2 hours
75877785|NCT03805737|Other|Amulez and red light treatment|Amulez and red light treatment for 10 minutes
75877786|NCT01378533|Drug|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d*8cycles
75425933|NCT05293938|Drug|Obeticholic Acid 10 MG|once daily, oral administration
75425934|NCT05293938|Drug|Standard of Care: UDCA|No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
75425935|NCT05290493|Drug|NB-001|NB-001 is a non-stimulant activator of multiple metabotropic glutamate receptors (mGluRs).
75425936|NCT05290493|Other|Placebo|Matching, inactive placebo
75425937|NCT05287100|Drug|Midodrine Oral Tablet|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
75425938|NCT05287100|Other|Standard Medical Treatment|"Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is < 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to < 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3"
75724513|NCT00894660|Drug|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
75724514|NCT00894660|Drug|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
75724515|NCT05712525|Diagnostic Test|G-Tech Wireless Patch System (WPS)|Noninvasive monitoring of myoelectrical signals
76047619|NCT05066321|Behavioral|Mindfulness Oriented Recovery Enhancement Sessions|The MORE intervention will involve 8 weekly sessions (approximately 1 hour each), during which participants will be taught how to use mindfulness skills to regulate addiction severity, pain, and stress.
76047620|NCT05063279|Other|Progressive resistance training|Progressive resistance training, performed with a target number of repetitions of 10 per set. Sets are performed to exhaustion, and external load will be adjusted to meet the target number of repetitions.
75877787|NCT02630199|Drug|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
75724516|NCT02539212|Device|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
76047621|NCT05060627|Drug|Belantamab mafodotin|"In phase 1:~Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination"
76047622|NCT05060627|Drug|Carfilzomib|"In phase 1:~Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination"
75425939|NCT05285670|Behavioral|Digital counseling plus interactive two-way SMS dialogue|We will utilize a digital counseling tool on a tablet to provide initial reproductive life planning counseling while waiting for an HIV care provider. We will then use Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women following enrollment and for up to 2 years. Women will receive automated theoretically grounded SMS messages targeting the appropriate reproductive health needs and will have the capability to respond and spontaneously message a nurse based at the clinic. . Automated SMS will be delivered at times and in languages based on patient preferences, weekly the first 3 months, every other week in months 4-12, and monthly during the last year of the trial. If there is a change in the reproductive health needs, more frequent messaging will be re-initiated at the same frequency as enrollment.
75425940|NCT05279014|Other|Meal timing|A high-carbohydrate (1 g/kg body mass) meal to be consumed either 1.5-3 hours before or immediately after exercise. Those consuming the meal after exercise will have fasted for at least 8 hours before exercise.
75425941|NCT05275426|Drug|LY2880070|Patients will receive treatment in 21-day cycles with LY2880070 50 mg twice daily orally on days 2-6, 9-13, and 16-20
75425942|NCT05275426|Drug|Gemcitabine|Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15
75425943|NCT05271903|Behavioral|MAMA Intervention|"The MAMA intervention will be based on PRONTO International's simulation training program to improve obstetric care delivery. The PRONTO curriculum is based on simulation and debrief of clinical scenarios, case-based learning, skills stations, and interactive teamwork and communication activities. Through the training, providers review and learn clinical skills related to obstetric care and emergencies, while reflecting on and practicing principles of respectful maternity care. The simulation exercises give providers and opportunity to act as the patient and develop empathy for the patient experience, and debriefing after simulation includes a reflection and discussion about RMC principles. The training will be two full days, followed by a refresher training in the clinical setting after one month."
75425944|NCT05265728|Drug|Natalizumab|Administered as specified in the treatment arm
75572273|NCT05236452|Other|Training for traditional and modern care providers|The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
75572274|NCT04678934|Procedure|TAVR|Transcatheter aortic valve replacement
75572275|NCT04679090|Other|Exercise Program|Participants will exercise twice a week for twelve weeks total.
75572276|NCT05228535|Dietary Supplement|Human milk fortifier|Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
75724517|NCT02539212|Device|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
75724518|NCT00721409|Drug|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
75724519|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
75724520|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
75877788|NCT02630199|Drug|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
76047623|NCT05060627|Drug|Dexamethasone|Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients > 75 years old., Q4W
76047624|NCT04421105|Drug|Lysergic acid diethylamide (LSD) 5µg|
76047625|NCT04421105|Drug|Lysergic acid diethylamide (LSD) 10µg|
76047626|NCT04421105|Drug|Lysergic acid diethylamide (LSD)20 µg|
76047627|NCT04421105|Drug|Placebo|
76047628|NCT02518685|Device|TransPyloric Shuttle|
76047629|NCT02518685|Device|Sham procedure|
76047630|NCT02518685|Behavioral|Lifestyle Counseling|The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
75425945|NCT05262907|Device|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
75425946|NCT05262907|Device|Ventripoint Echocardiogram|Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.
75425947|NCT05259917|Drug|Placebo|Placebo to KVD900 Tablet
75425948|NCT05259917|Drug|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
75425949|NCT05259917|Drug|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
75572277|NCT03689660|Other|Virtual Reality Training|Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.
75572278|NCT03689660|Other|Biofeedback Training|biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.
75572279|NCT03689660|Other|Conventional rehabilitation|Participants will receive a 12-week conventional rehabilitation program.
75572280|NCT05209893|Other|Telerehabilitation|Application based video home exercise for the knee osteoarthritis
75425950|NCT05251324|Other|Hot Flush Induction|A temperature-controlled, water-circulating heating pad at a constant temperature of 107˚F will be placed on the participant's torso, a microwaved heating neck pad will be placed on the participant's neck, and two warm balloons will be placed in the participant's hands for 30 min. Subjective (verbal start and end point to be marked on LabChart software) and objective (skin conductance and skin temperature) measures of hot flushes will be recorded.
75572281|NCT05209893|Other|Paper Based Rehabilitation|Paper instruction based home exercise for the knee osteoarthritis
75572282|NCT03688100|Behavioral|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
75425951|NCT05242731|Device|MSmonitor, a self-management/education program with e-health interventions|A self-management/education program with e-health interventions
75425952|NCT05242731|Device|"Video calling program Better-close"|Video calling program.
75425953|NCT05242731|Device|Researchmanager program|Case Report Form, Datamanagement program
75425954|NCT05242276|Device|USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY|The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. . It is inserted vaginally through the cervical canal into the endometrial cavity. The uterine manipulator facilitates the uterus mobilization during the surgery, generating tension on the main supporting elements of the uterus to improve surgical field exposure and provide a landmark for the colpotomy.
75572283|NCT03688100|Drug|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
75572284|NCT04000503|Behavioral|Self-collected HPV testing for cervical cancer screening|Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.
75572285|NCT03653117|Device|Transperineal laser ablation|Minimal invasive coagulation of prostatic tissue by laser
75724521|NCT05712369|Other|Blood sampling|"Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction."
75425955|NCT05224141|Biological|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
75572286|NCT03653000|Procedure|Ultrasound guided brachial plexus blockade|Ultrasound probe disposed on the shoulder, on the deltoid muscle. in plane puncture toward the brachial artery and injection of local anaesthetics around the brachial artery
75572287|NCT03653000|Drug|local anaesthetic injection|Local anesthetic injection (ropivacaine) at this new site
75572288|NCT03963687|Other|Standard Nursing Education Intervention|Genetics Education Program for Nurses (GEPN) which is available free online for more than 20 years
75572289|NCT03963687|Other|New Nursing Education Intervention|Web-based Genomics/ Genetics Nursing Education is a free online course that will be designed by the research team.
75425956|NCT05224141|Drug|Saline placebo|Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
75572290|NCT03639389|Drug|Bupivacaine|Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
75572291|NCT03639389|Drug|Analgesics|Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
75724522|NCT02539290|Behavioral|Detection of ovulation|Detecting the luteinizing hormone surge using test sticks in a urine sample
75724523|NCT02539290|Procedure|Uterine flushing|Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
75724524|NCT02539290|Procedure|Vaginal flushing|Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
75724525|NCT02539290|Behavioral|Sexual intercourse|Sexual intercourse within 12 hours after intervention
75724526|NCT00898716|Drug|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
76047631|NCT05024747|Drug|NicoDerm CQ patch (GSK Dungarvan)|A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm^2) surface area will be placed topically.
75425957|NCT05224141|Drug|Etoposide|Etoposide 100 mg/m^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
75425958|NCT05224141|Drug|Cisplatin|Cisplatin 75 mg/m^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
75425959|NCT05224141|Biological|Atezolizumab|Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
75425960|NCT05224141|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
75425961|NCT05222178|Drug|HMI-103|HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
75425962|NCT05215977|Drug|MW031|"The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
75572292|NCT05174091|Other|Functional Movement Screen, Spinal Mouse, Core Endurance, Funcitonal Capacity|Due to the difficulties in the diagnosis and treatment of NSLBP, it has been causing many problems such as limitation of activation, socioeconomic burden, and biopsychosocial factors for years. It is thought that the effectiveness of treatment will increase if the needs and problems of individuals with NSLBP are clearly revealed beforehand. Although there are studies on core endurance and physical capacities in individuals with NSLBP in the literature, the number of studies examining functional movement analysis and spinal mobility in individuals with NSLBP is very few. Therefore, aim of this research is to compare functional movement analysis, physical capacity, core endurance, and spinal mobility in individuals with and without NSLBP. With the results we will reveal, we aim to contribute to the evaluation and treatment of patients with NSLBP. Thus, the negative effects of this pathology, which causes serious labor and financial losses, can be minimized.
75572293|NCT03603665|Biological|NTM-1633|NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.
75572294|NCT03603665|Other|Placebo|0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
75572295|NCT03943641|Other|This is not an intervention study|This study is based on retrospective analysis of linked routinely-collected healthcare data
75572296|NCT03579173|Diagnostic Test|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
75724527|NCT05277948|Other|active thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
75877789|NCT01378455|Other|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
75877790|NCT01378455|Other|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
75877791|NCT03759951|Behavioral|DoIT-1|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.
76047632|NCT05024747|Drug|NicoDerm CQ (Alza)|A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm^2 surface area will be placed topically.
75425963|NCT05215977|Drug|Placebo|"subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
75425964|NCT05212766|Biological|COVID infection|Infections with COVID 19
75425965|NCT05212766|Biological|COVID vaccination|Vaccination against COVID 19
75572297|NCT03579173|Diagnostic Test|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
75572298|NCT03579173|Diagnostic Test|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
75724528|NCT05277948|Other|sham thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
75724529|NCT00894816|Dietary Supplement|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
75724530|NCT00894816|Dietary Supplement|Placebo|Infant cereals without any addition
75724531|NCT00542997|Biological|Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)|IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
75425966|NCT05212766|Diagnostic Test|Oral examination|Assessment of oral and periodontal health status
75572299|NCT05172531|Drug|Cisatracurium Besylate|Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。
75572300|NCT05172531|Drug|saline 0.12ml/kg/hr|saline 0.12ml/kg/hr
75724532|NCT04035720|Other|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
75425967|NCT05211570|Drug|AB8939|Intravenous injection (from an initial dose of 0.9 mg/m²)
75425968|NCT05211570|Drug|Azacitidine|Subcutaneous injection (75 mg/m²)
75425969|NCT05206435|Drug|Electronic Cigarette|Electronic Cigarettes are provided to replace tobacco cigarettes
75425970|NCT05206435|Drug|Nicotine Lozenge|Nicotine Lozenges are provided to replace tobacco cigarettes
75572301|NCT03570983|Drug|Allopurinol|Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
75572302|NCT03570983|Drug|Carmustine|Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
75572303|NCT03570983|Drug|Etoposide|Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
75572304|NCT03570983|Drug|Cytarabine|Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.
75572305|NCT03570983|Drug|Melphalan|Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
75572306|NCT05170815|Procedure|Spine surgery|Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.
75724533|NCT00903084|Drug|Tenofovir Disoproxil Fumarate|300-mg tablet
75724534|NCT00984477|Drug|AZD5122|A single dose of oral suspension
75724535|NCT00984477|Drug|Placebo|A single dose of oral suspension
75724536|NCT00984477|Drug|AZD5122|A single intravenous infusion
75724537|NCT02541006|Drug|Tiotropium 18 mcg|tiotropium 18 mcg once a day
75572307|NCT03540758|Drug|Diazoxide|"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
75425971|NCT05204472|Device|Burst DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
75572308|NCT03540758|Drug|Nicotinic acid|T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
75572309|NCT03540758|Drug|Placebo|"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study."
75572310|NCT05154045|Other|Experimental Formula|Diabetes-specific study formula
75572311|NCT05154045|Other|Test Meal|Instant oatmeal
75572312|NCT05135481|Procedure|phrenectomy|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
75572313|NCT05135481|Other|Increased lactation support|Management in group 2 will include increased lactation care both during hospital stay and post discharge.
75572314|NCT04678778|Behavioral|Physical and Cognitive Activity|There are three sessions a week for the course of 12 weeks. Each session consists of 5 trials.
75572315|NCT03787797|Diagnostic Test|Echocardiography|Assessment of epicardial adipose tissue thickness
75724538|NCT02591771|Drug|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
75724539|NCT00986817|Drug|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
75572316|NCT03187379|Drug|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
75572317|NCT03187379|Drug|Bupivacaine|60cc Bupivacaine
75572318|NCT03182231|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
75572319|NCT05124288|Other|Observations on Relapsed AML Allogeneic Transplanted patients|This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.
75572320|NCT03077360|Behavioral|Lifestyle|Lifestyle changes to lose weight or become more fit
75724540|NCT00986817|Drug|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
75572321|NCT03722511|Dietary Supplement|Amino Acid Based Medical Food/Drink|Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
75724541|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
75724542|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
75572322|NCT02964884|Drug|Lovastatin|Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
75572323|NCT02964884|Behavioral|reading tutoring intervention|After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)
75572324|NCT02964884|Drug|Placebo Oral Tablet|Those in the placebo group will receive a tablet daily
75572325|NCT02964884|Behavioral|"Other Academic sham tutoring"|No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
75572326|NCT04683705|Diagnostic Test|Ultrasound|"High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI)."
75572327|NCT02837042|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
75572328|NCT04683744|Other|Semi-structured interviews-Patients|The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.
75572329|NCT04683744|Other|Semi-structured interviews-Health system|The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
75425972|NCT05204472|Device|Tonic DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
75425973|NCT05203614|Behavioral|Household Contribution|Questionnaires
75572330|NCT05098470|Drug|Metformin|1500-2000 mg per day for 8 weeks
75425974|NCT05203614|Behavioral|Outside Contribution|Questionnaires
75425975|NCT05203614|Behavioral|Control|Questionnaires
75572331|NCT05098470|Drug|Insulin Glargine|Long-acting insulin for 8 weeks
75724543|NCT02591849|Dietary Supplement|Glucagon-like peptide-1 (GLP-1)|
75724544|NCT02591849|Other|Isotonic saline|
75425976|NCT05198570|Other|Pharmacokinetic analysis|Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring
75572332|NCT05098470|Drug|Dorzagliatin|Oral Glucokinase Activator 75 mg twice daily for 8 weeks
75572333|NCT02710643|Drug|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
75572334|NCT05093205|Drug|PF-06882961|Tablets
75572335|NCT05093205|Drug|Atorvastatin|Tablets
75572336|NCT05093205|Drug|Midazolam|Syrup
75572337|NCT05093205|Drug|Levonorgestrel & Ethinyl Estradiol|Tablet
75572338|NCT00552981|Procedure|inhalation of warm air in a Finnish sauna|three times on three following days, each 2-3 minutes
75572339|NCT00552981|Procedure|inhalation of ambient air in a Finnish sauna|three times on three following days, each 2-3 minutes
75572340|NCT02623751|Drug|KHK2375|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
75724545|NCT02591849|Other|Hyperglycemic clamp|
75724546|NCT00898794|Biological|bevacizumab|
75724547|NCT00898794|Other|coagulation study|
75724548|NCT00898794|Other|laboratory biomarker analysis|
75724549|NCT00898794|Other|platelet aggregation test|
75572341|NCT02623751|Drug|Exemestane|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
75572342|NCT00553215|Procedure|quality-of-life assessment|
75572343|NCT00553215|Procedure|questionnaire administration|
75572344|NCT02469155|Drug|ITI-007|
75572345|NCT02469155|Drug|Risperidone|
75425977|NCT05198479|Radiation|77 Lu-DOTA0-Tyr3-Octreotate|Treatment will consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0 -Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
75572346|NCT02469155|Drug|Placebo|
75572347|NCT02465606|Drug|Lebrikizumab|Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
75572348|NCT02465606|Drug|Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)|Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
75572349|NCT05080530|Drug|Cholecalciferol|Effect of Vitamin D on diabetic neuropathy symptoms
75572350|NCT00554177|Drug|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
75572351|NCT00554177|Drug|Placebo|2 doses of 1200mg, administered 2-3 days apart
75572352|NCT03487692|Other|Diabetes MESSAGES Program|Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
75572353|NCT03487692|Other|Diabetes MESSAGES Program (second trial)|During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
75572354|NCT02456675|Drug|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
75572355|NCT02456675|Drug|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
75572356|NCT02456675|Drug|itacitinib|The dose of itacitinib will be given orally once daily (QD).
75572357|NCT02456480|Drug|CLS001|topical gel
75572358|NCT02456480|Drug|Vehicle|topical gel
75572359|NCT03425565|Drug|Pembrolizumab|3 weekly cycles of Pembrolizumab administered by IV
75425978|NCT05196308|Drug|Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)|"Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator."
75425979|NCT05196308|Drug|Placebo administration|"For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator."
75425980|NCT05192330|Device|Virtual Reality Glasses|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale (pain) were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, virtual reality glasses were given by the nurse researcher to intervention group for 30 minutes.
75572360|NCT04678700|Other|Chest physiotherapy post-covid19|"The sessions are divided into the following modules;~Directed abdominal-diaphragmatic ventilation (10 times).~Costal expansion exercises with the help of flexion and abduction of the upper limbs. (10 times)(1).~Self-passive stretching of the ribcage and neck muscles, accessory to inspiration. The purpose of the stretching will be to increase the flexibility of the muscles to improve the vital capacity as has already been evidenced in other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (25)(26).~Relaxation time;Jacobson's progressive relaxation; we scan the body's condition.~Post-session evaluation by taking the respiratory frequency/ min and the Borg's dyspnea index, and level oxigen after the exercises."
75572361|NCT05073627|Drug|Dicloxacillin|Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
75572362|NCT04678739|Drug|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
75572363|NCT04678739|Drug|Tocilizumab|Actemra IV Infusion
75724550|NCT00986895|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
75724551|NCT00898872|Other|cryopreservation|
75572364|NCT00554255|Drug|SB751689|
75572365|NCT00554333|Biological|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
75572366|NCT00554333|Biological|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
75572367|NCT03418701|Behavioral|Health Smart for Weight Loss|We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
75572368|NCT03368196|Drug|DS-8201a|An antibody drug conjugate
75572369|NCT02436824|Drug|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
75572370|NCT02436824|Other|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
75572371|NCT02433158|Drug|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.
75572372|NCT05029479|Other|Bonding in NCCLs|bonding agent which can resist moisture and has shorter decalcifying and curing time
75572373|NCT02428088|Drug|Dasotraline|Dasotraline 2 mg once daily
75572374|NCT02428088|Drug|Dasotraline|Dasotraline 4 mg once daily
75724552|NCT02593877|Device|VHA algorithm|Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
75425981|NCT05192330|Behavioral|Therapeutic Touch|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS (pain) scoring scale were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, therapeutictouch were given by the nurse researcher to intervention group for 30 minutes.
75425982|NCT05187377|Drug|Growth Hormone|Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.
75425983|NCT05187377|Drug|Saline|Placebo (saline) will be administered subcutaneously once daily.
75572375|NCT02428088|Drug|Placebo Comparator|Placebo once daily
75572376|NCT03261609|Other|preterm birth|The study compares young adult subjects born premature (< 29 weeks) versus term (-> 37 weeks)
75724553|NCT05712135|Other|supine position|The patient group whose cuff pressure was measured in the supine position
75572377|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2|
75572378|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2|
75572379|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2|
75572380|NCT02422979|Combination Product|PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
75572381|NCT02422979|Combination Product|PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
75572382|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
75724554|NCT05712135|Other|prone position|The patient group whose cuff pressure was measured in the prone position
75724555|NCT05712135|Other|semi-fowler position|The patient group whose cuff pressure was measured in the semi-fowler position
75724556|NCT03948113|Other|Dialysis|
75724557|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
75425984|NCT05186688|Behavioral|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
75425985|NCT05186636|Other|KPI reports|Quarterly
75425986|NCT05186636|Other|Prescriber reports|Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices
75572383|NCT03230565|Drug|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
75572384|NCT03230565|Drug|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
75572385|NCT02416076|Device|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
75572386|NCT02416076|Device|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
75572387|NCT02389985|Drug|CRLX101|
75572388|NCT02389985|Drug|Paclitaxel|
75572389|NCT02377895|Drug|Nasapaque Nasal Solution|
75572390|NCT02377895|Drug|Placebo Saline Nasal Solution|
75572391|NCT05018832|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75572392|NCT03455075|Drug|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
75572393|NCT03455075|Drug|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
75572394|NCT03455075|Drug|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
75572395|NCT05007132|Biological|Panitumumab 20 milligram/ML|Participants receive Panitumumab at 6mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
75572396|NCT05007132|Biological|Bevacizumab|Participants receive bevacizumab at 5 mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
75572397|NCT05007132|Drug|Trifluridine/Tipiracil Hydrochloride|Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
75572398|NCT04684017|Drug|Anlotinib hydrochloride|anlotinib 10 mg/day orally (from days 1 to 14 in a 21-day cycle)
75572399|NCT04684017|Drug|Etoposide|100mg/m2 iv on days 1-3 every 21 days for 4 cycles
75572400|NCT04684017|Drug|Carboplatin|AUC 5 iv on day 1 every 21 days for 4 cycles
75572401|NCT00554450|Drug|Dapagliflozin|Tablets, Oral, once daily
75572402|NCT04683666|Procedure|Bariatric surgery|Laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), as primary bariatric procedures, were performed. ^Postoperative complications were assessed.
75572403|NCT00554489|Behavioral|exercise intervention|participation in physical activity intervention program weeks 2 through 5
75572404|NCT00553020|Drug|Insulin glargine|"Lantus (commercial formulation, Reference):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)~NPH-insulin (Protaphan) (Test):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"
75572405|NCT00554528|Device|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization"
76047633|NCT05058833|Diagnostic Test|Echocardiography|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
75425987|NCT05184478|Drug|Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.|"Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing <50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing <50kg) or 2mL (participants ≥50kg) is reached."
75425988|NCT05184478|Drug|Placebo|"The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase."
75425989|NCT05182749|Biological|bacteriophage|A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution
75572406|NCT00554528|Procedure|arthrodesis - cervical disk surgery|discectomy and arthrodesis
75425990|NCT05182749|Other|Placebo|Placebo orally administered with sodium bicarbonate solution
75425991|NCT05178030|Other|vena punction|Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis. Blood for analysis of mutation in ctDNA will be collected at the same moment a CT-scan is performed
75572407|NCT04683198|Drug|camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
75724558|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
75724559|NCT04086719|Drug|BMS-986165|Oral administration of tablet BMS- 986165
75724560|NCT04086719|Drug|Pyrimethamine|Oral administration of Pyrimethamine in combination with BMS-986185
75724561|NCT00898950|Drug|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
75724562|NCT00898950|Drug|Aspirin|300mgs/day orally for 2 weeks
75724563|NCT00898950|Drug|Aspirin|aspirin 900mgs QID orally for 2 weeks
76047634|NCT05058833|Diagnostic Test|Coronary flow reserve and index of microcirculatory dysfunction|Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
75425992|NCT05169970|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients with a low or intermediate risk Decipher score will receive radiation targeting the seminal prostate and seminal vesicles to a dose of 40 Gy in 5 fractions delivered every other day.
75572408|NCT04683198|Drug|Apatinib Mesylate|Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.
75572409|NCT04683198|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).
75572410|NCT04683198|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
75724564|NCT00898950|Other|placebo tablet|placebo tablet with lactose and excipients.
75724565|NCT04034784|Device|Discrete(TM)|A designated volume of Discrete(TM) (according to cohort) is applied intraperitoneally
75724566|NCT04034784|Other|Control Lactated Ringer's Solution (Control LRS)|A designated volume of LRS (according to cohort and equivalent to volume of Discrete(TM)) is applied intraperitoneally
76047635|NCT02520089|Procedure|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
75572411|NCT00554567|Behavioral|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
75724567|NCT03622515|Combination Product|Anesthesia level and cerebral perfusion pressure|Anesthetic dose and blood pressure
75425993|NCT05169970|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients with high risk Decipher scores will receive radiation targeting the prostate and seminal vesicles to a dose of 40 Gy in 5 fractions with a simultaneous integrated boost to 45 Gy of any dominant intraprostatic lesion as well as radiation to the pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered every other day.
75425994|NCT05169359|Behavioral|Speak Up! Video|Once a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones.
75572412|NCT02346422|Genetic|MYDICAR Phase 1|Single dose of MYDICAR
75724568|NCT00899028|Genetic|comparative genomic hybridization|
75425995|NCT05168618|Biological|Atezolizumab|Given IV
75425996|NCT05168618|Drug|Cabozantinib S-malate|Given PO
75425997|NCT05166512|Behavioral|DPP Cooks|6 'food agency' based cooking skills classes during the first 4 months of the DPP
75724569|NCT00899028|Genetic|fluorescence in situ hybridization|
75724570|NCT00899028|Genetic|gene expression analysis|
75724571|NCT00899028|Genetic|microarray analysis|
75425998|NCT05166512|Behavioral|DPP|Standard DPP
75724572|NCT00899028|Genetic|protein expression analysis|
75425999|NCT05143255|Behavioral|KNOW|KNow the Optimal Way (KNOW) is a manualized ADRD patient-care partner intervention designed to increase engagement in advance care planning (ACP) and completion of advance directives among early stage ADRD patients and their care partners using theoretically grounded distress tolerance techniques (inhibitory learning theory) and communication skills (cognitive-social processing theory) consistent with recommended guidelines for discussions about ACP in ADRD care.
75572413|NCT02346422|Genetic|MYDICAR Phase 2|Single dose of MYDICAR
75572414|NCT02346422|Genetic|Placebo Phase 2 only|Single dose of placebo
75572415|NCT03048552|Behavioral|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
75572416|NCT02342249|Drug|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
75572417|NCT02342249|Drug|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2*300 mg tablets) will be administered over 5-6 days.
75572418|NCT02342249|Drug|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
75572419|NCT02342249|Drug|Placebo|Subjects will receive matching placebo of Oseltamivir
75572420|NCT04683276|Procedure|pars plana vitrectomy with ILM inverted flap|Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and >2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
75572421|NCT02933970|Other|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
75572422|NCT02339129|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
75724573|NCT00899028|Other|immunohistochemistry staining method|
75724574|NCT00899028|Other|laboratory biomarker analysis|
75724575|NCT00899028|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
75724576|NCT00899028|Other|medical chart review|
75724577|NCT00899028|Procedure|diagnostic bronchoscopy|
75724578|NCT05279235|Drug|JT001|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
75724579|NCT05279235|Drug|JT001 placebo|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
75724580|NCT05279235|Drug|Favipiravir|Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days
75724581|NCT05279235|Drug|Favipiravir placebo|Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days
75724582|NCT00903318|Behavioral|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
76047636|NCT02520089|Procedure|Platelet Rich Plasma plus bone autograft|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
75877792|NCT03759951|Behavioral|DoIT-2|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.
76047637|NCT05056883|Drug|K-237 0.3-0.4mg/kg (once daily)|Ivermectin 3mg tablet
76047638|NCT05056883|Drug|Placebo 0.3-0.4mg/kg (once daily)|Placebo 3mg tablet
75426000|NCT05138380|Device|Foot orthoses|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist > 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
75426001|NCT05138380|Device|Flat shoe insert|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist > 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
75426002|NCT05133596|Other|Clinical examination|The investigator will conduct a clinical examination to rule out other causes of olfactory impairment independent of COVID-19. The investigator will also collect the following information: socio-demographic data (age, sex, blood type, weight, height, etc.), history of olfaction disorder symptoms, past or current treatments received and tobacco/alcohol consumption.
75572423|NCT02339129|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
75426003|NCT05133596|Other|Blood collection|12ml-blood sample
75572424|NCT04678622|Device|Bioferula3D|Custom splint with 3D technology classified as a custom medical device
75572425|NCT04971798|Biological|Cell-free Stem Cell-derived Extract Formulation (CCM)|Intraarticular injection
75572426|NCT04678388|Drug|Reference drug|1 Cap., single oral administration under fasting condition
76047639|NCT04991597|Other|Cold Compress Pack|Palmar aspect of forearm will have a cold compress pack placed on it.
76047640|NCT04991597|Other|Room Temperature Compress Pack|Palmar aspect of forearm will have a room temperature compress pack placed on it.
75572427|NCT04678388|Drug|Test drug 1|1 Tab., single oral administration under fasting condition
75572428|NCT04678388|Drug|Test drug 2|1 Tab., single oral administration under fasting condition
75572429|NCT02884206|Drug|LCZ696|LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
76047641|NCT04991597|Drug|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
76047642|NCT04991597|Drug|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
76047643|NCT02105961|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
76047644|NCT02105961|Drug|Placebo|Sterile 0.9percent sodium chloride solution
76047645|NCT04950101|Other|anal sampling|anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not
76047646|NCT04949867|Drug|Glucagon|Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.
76047647|NCT04949867|Device|Closed-loop System|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
75572430|NCT02884206|Drug|Valsartan|Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
75572431|NCT02884206|Drug|Placebo of LCZ696|Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
75426004|NCT05133596|Other|Olfactory evoked potentials|Olfactory evoked potentials will be recorded during olfactory tests.
75572432|NCT02884206|Drug|Placebo of Valsartan|Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
75572433|NCT04678973|Behavioral|Self-compassion mindfulness practice|"Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey."
75572434|NCT04961541|Biological|ICC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
75572435|NCT04961541|Biological|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
75572436|NCT04961541|Biological|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
75572437|NCT02326454|Drug|talaporfin sodium|1 mg/kg
75572438|NCT02326454|Drug|Saline|
75724583|NCT04035252|Diagnostic Test|Carotid artery reactivity test (CAR-test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
75724584|NCT03917823|Device|Cryoneurolysis|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.
75724585|NCT03917823|Device|Sham comparator|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
75724586|NCT00229723|Drug|gefitinib (Iressa)|250 mg oral tablet
75724587|NCT00229723|Drug|cisplatin|intravenous infusion
75724588|NCT00229723|Radiation|radiotherapy|radiation therapy
75724589|NCT00229723|Drug|Gefitinib (Iressa)|500 mg oral tablet
75724590|NCT04035798|Drug|Memantine or placebo|BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
75724591|NCT00894894|Drug|MP-470|escalating daily doses of amuvatinib
75724592|NCT00894894|Drug|amuvatinib (MP-470)|escalating doses of daily amuvatinib
75572439|NCT02326454|Device|Drug Activator 100 J/cm|Light Dose: 100 J/cm
75724593|NCT00903474|Other|questionnaire administration|
75724594|NCT00903474|Other|study of socioeconomic and demographic variables|
75724595|NCT00903474|Procedure|CAM exercise therapy|
75724596|NCT00903474|Procedure|psychosocial assessment and care|
75724597|NCT00903474|Procedure|quality-of-life assessment|
75724598|NCT00903474|Procedure|stress management therapy|
75724599|NCT01075477|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
76047648|NCT05018897|Behavioral|To Share or Not to Share|Strategic disclosure intervention to help participants evaluate the pros and cons of disclosing suicidality and provide guidance on best way to disclose to get needs met. Six one-hour virtual sessions conducted weekly.
75426005|NCT05133596|Other|Brushing of olfactory slits|collection of olfactory slits cells.
75426006|NCT05133596|Other|Neurological examination and neuropsychological assessment|"MOCA, BREF~CVLT~WAIS IV, MEM III~Right-side and left-side empan, Trail Making Test A and B (TMT), verbal fluency tests, PASAT, Attention Assessment Test~Benton's Line Judgement, VOSP~Assessment of psychological status, fatigue and screening for psychiatric comorbidities: depression & anxiety scales (HAD scale, mADRS depression scale, STAI anxiety scale), Fatigue Severity Scale."
75426007|NCT05133596|Other|Nasal endoscopy|Nasal endoscopy
75426008|NCT05133596|Other|Assessment of olfactory and taste functions|"scales: VAS and TSS~Sniffin Stick test"
75426009|NCT05133128|Other|blood samples|blood samples
75426010|NCT05131113|Other|Physical exercise|Physical exercise
75426011|NCT05120375|Drug|BAT6021|Ⅳ infusions
75426012|NCT05115695|Other|traditional physiotherapy approach|Traditional upper extremity strengthening and tonus regulation (weight shifting, weight bearing, active reaching in sitting exercises) exercises consisting of Neurodevelopmental Therapy (NDT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
75426013|NCT05115695|Other|muscle strengthening exercise/Proprioceptive Neuromuscular Facilitation (PNF)|Muscle strengthening with scapular and upper extremity patterns of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
75426014|NCT05114746|Radiation|177Lu-PSMA-617|administered intravenously at a dose of 7.4 GBq (+/- 10%). A 7.4 GBq dose is equivalent to 200 mCi or 7400 MBq.
75426015|NCT05114746|Radiation|68Ga-PSMA-11|68Ga-PSMA-11 is manufactured by radiolabeling of PSMA-11 precursor with 68Ga directly at clinical trial sites immediately prior to administration into participants. The 68Ga used for radiolabeling will be eluted from the 68Ge/68Ga generator. 68Ga-PSMA-11 will be prepared as a sterile solution and administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi).
75572440|NCT02326454|Device|Drug Activator 200 J/cm|Light Dose: 200 J/cm
75572441|NCT02324309|Drug|BIOD-531|
75572442|NCT02324309|Drug|Humalog Mix 75/25|
75426016|NCT05114746|Other|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator (Post taxane population only)
75724600|NCT04006275|Drug|Sonovue and Sonazoid|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
75724601|NCT04006275|Drug|Sonazoid and Sonovue|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
75724602|NCT00987051|Procedure|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
75724603|NCT01075555|Drug|pravastatin sodium|
75724604|NCT01075555|Drug|sorafenib tosylate|
75724605|NCT03972787|Device|Proactive social robot|ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
75724606|NCT00606684|Drug|GW642444 6.25|GW642444 6.25
76047649|NCT05018897|Behavioral|Peer Support|Peer-led support group for mood disorders. Six one-hour virtual sessions conducted weekly.
75426017|NCT05104866|Drug|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
75426018|NCT05104866|Drug|Capecitabine|Tablet. Oral route of administration. Active comparator
75572443|NCT02324309|Drug|Humulin R U-500|
75426019|NCT05104866|Drug|Gemcitabine|IV Infusion. Active comparator
75426020|NCT05104866|Drug|Eribulin|IV Infusion. Active comparator
75426021|NCT05104866|Drug|Vinorelbine|IV Infusion. Active comparator
75572444|NCT02324309|Drug|BIOD-531|
75572445|NCT04941456|Other|Open Tracheostomy|Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.
75572446|NCT04941456|Device|PMV in place|Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.
75572447|NCT02307851|Biological|Quadrivalent VLP Vaccine|
75572448|NCT02307851|Biological|Comparator TIV|
75572449|NCT02826213|Device|LifePort® perfusion device|Renal Perfusion with LifePort® perfusion device
75572450|NCT02826213|Device|Waves perfusion device|Renal Perfusion with Waves perfusion device
75572451|NCT02306291|Drug|GMI-1271|E-selectin antagonist
75572452|NCT02306291|Drug|Mitoxantrone|induction chemotherapy
75426022|NCT05090371|Drug|Ofatumumab|3 loading doses followed by administration every 4 weeks as per label
75426023|NCT05090371|Drug|Disease modifying treatment (DMT)|Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening
75572453|NCT02306291|Drug|Etoposide|induction chemotherapy
75572454|NCT02306291|Drug|Cytarabine|induction chemotherapy
75572455|NCT02306291|Drug|Idarubicin|induction chemotherapy
75724607|NCT00606684|Drug|GW642444 3mcg|once daily
75877793|NCT03759951|Behavioral|DoIT-3|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.
75877794|NCT03759951|Behavioral|Control|No training will be performed during a 1-year period. Participation only in measurements.
75426024|NCT05089409|Drug|ATB1651, 2 mg/mL|The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
75426025|NCT05089409|Drug|ATB1651, 5 mg/mL|The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
75426026|NCT05089409|Drug|ATB1651, 10 mg/mL|The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
75426027|NCT05089409|Drug|ATB1651, 20 mg/mL|The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
75426028|NCT05089409|Drug|ATB1651, 30 mg/mL|The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
75426029|NCT05089409|Other|Placebo|The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days
75572456|NCT02302079|Drug|ASP8232|oral capsule
75572457|NCT02302079|Drug|ranibizumab|intravitreal (IVT) injection
75572458|NCT02302079|Drug|Placebo|oral capsule
75572459|NCT02302079|Other|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
75572460|NCT01210495|Drug|Axitinib (AG-013736)|Axitinib [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
75572461|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
75572462|NCT01210495|Drug|Placebo|Placebo [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
75572463|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
75572464|NCT02289716|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
75572465|NCT02289716|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
75572466|NCT02289716|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
75572467|NCT04922697|Other|Educational Intervention|Watch educational videos and use wearable air pollution sensor
75572468|NCT04922697|Other|Questionnaire Administration|Complete questionnaires
75724608|NCT00606684|Drug|GW642444 12.5mcg|GW642444 12.5mcg
75724609|NCT00606684|Drug|GW642444 25mcg|GW642444 25mcg
75724610|NCT00606684|Drug|GW642444 50mcg|GW642444 50mcg
75724611|NCT00606684|Other|placebo|placebo
75724612|NCT01075633|Procedure|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
75724613|NCT01075633|Procedure|Colonoscopy with sedation|Colonoscopy with sedation
75724614|NCT00627926|Biological|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
75724615|NCT00627926|Drug|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
75724616|NCT00627926|Drug|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg
75724617|NCT00627926|Other|Placebo|Telaprevir matching placebo
75724618|NCT03973021|Biological|Very small embryonic-like stem cell(VSEL)|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
75724619|NCT05711589|Procedure|CBA was performed under intracardiac echocardiography guidance without fluoroscopy|Zero-X group: Patients undergoing ICE-guided CBA
75724620|NCT05711589|Procedure|cryoablation (CBA) was performed under fluoroscopic guidance|cryoablation (CBA) was performed under fluoroscopic guidance
75724621|NCT05711511|Procedure|conventional obturation technique|cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
75724622|NCT05711511|Device|Obtura II|"is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle"
76047650|NCT05018117|Drug|Nicotine gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
75724623|NCT02539056|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
75724624|NCT05711433|Procedure|pancreatic surgery|pancreaticoduodenectomy and distal pancreatectomy
76047651|NCT05018117|Other|Placebo gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
75724625|NCT05278182|Drug|Naoxintong Capsule|Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months
75724626|NCT05278182|Drug|Placebo|Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months
76047652|NCT04203329|Device|Femoral Venous Vascular Closure|Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
76047653|NCT05016869|Drug|fruquintinib plus capecitabine|"Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W"
75426030|NCT05086796|Behavioral|Substance Use Treatment and Recovery Team (START)|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~Triage~Engage, Assess, and Plan~Treat~Communicate and Coordinate~Follow up~Monitor"
75426031|NCT05085574|Drug|Famotidine|80 mg tablet, QID for 14 days
75426032|NCT05085574|Drug|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
75426033|NCT05085574|Drug|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
75724627|NCT00228553|Drug|Armodafinil 100 to 250 mg/day|Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
75724628|NCT00922506|Drug|doxazosin plus tolterodine SR|doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
75724629|NCT00816140|Drug|Cravit based triple therapy|"Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days"
76047654|NCT02141997|Biological|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
76047655|NCT02141997|Biological|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
76047656|NCT04411433|Drug|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
75426034|NCT05084729|Device|Imagio OA/US|Imagio optoacoustic
75572469|NCT02289092|Behavioral|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
75426035|NCT05084248|Drug|Ergocalciferol Capsules|Capsules of ergocalciferol at 400 IU and 4000 IU
75572470|NCT04918095|Device|CareCOPD Platform|The subjects will be provided with CareCOPD devices for home monitoring of airway impedance, medication use, and symptoms data.
75572471|NCT02267642|Biological|AbGn-168H|monoclonal antibody
75572472|NCT04917822|Behavioral|Emotion regulation|Emotion regulation arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics include raising awareness of emotions (e.g., learning emotions theories), developing skills to manage emotions (e.g., attention deployment, cognitive changes, response modification), and facilitating parent-child relationship (e.g., gratitude). For children, the main topics are similar to that in parents' intervention. In this arm, we give more specific examples and simple explanations to the children.
75572473|NCT04917822|Behavioral|Information provision|Information provision arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics in these four sessions include learning the general information about Hong Kong such as education and medical care, housing condition, employment and training. For children, the main topics include learning the general information about Hong Kong, such as education, community facility, and learning method.
75572474|NCT02267525|Drug|Velusetrag|
75572475|NCT02267525|Drug|Placebo|
75572476|NCT04678076|Drug|Ketoprofen Lysine|A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
75572477|NCT04678076|Drug|Ketoprofen Oral Product|A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
75426036|NCT05081687|Drug|Folfirinox|5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
75572478|NCT00554645|Behavioral|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
75724630|NCT00816140|Drug|Klaricid based triple therapy|"Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days"
75426037|NCT05081674|Drug|Alectinib|600mg 1OD
75426038|NCT05081674|Drug|Pembrolizumab|200mg every 21 days
75572479|NCT00554645|Other|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
75426039|NCT05081674|Drug|Nivolumab|6mg/kg every 4 weeks
75426040|NCT05081674|Drug|Erlotinib|150mg
75572480|NCT02257619|Drug|Itacitinib|Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.
75572481|NCT02257619|Drug|docetaxel|Administered as an intravenous infusion in the clinic at 75 mg/m^2 Q3W for Part 1 of the study.
75724631|NCT00903708|Drug|LY2275796|100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
75724632|NCT00899184|Genetic|polymorphism analysis|
75724633|NCT00899184|Other|laboratory biomarker analysis|
75724634|NCT00899262|Other|immunohistochemistry staining method|
75724635|NCT00899262|Other|laboratory biomarker analysis|
75724636|NCT00899262|Other|sputum cytology|
75724637|NCT00899262|Procedure|Fourier transform infrared spectroscopy|
75724638|NCT00899262|Procedure|diagnostic bronchoscopy|
75724639|NCT00899340|Genetic|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
75724640|NCT00899340|Genetic|microarray analysis|microarray analysis
75724641|NCT00899340|Genetic|protein expression analysis|protein expression analysis
75426041|NCT05077332|Drug|Famotidine|80 mg tablet, QID for 14 days
75426042|NCT05077332|Drug|Celecoxib|400 mg (initial dose) then 200 mg capsule, BID for 5 days
75426043|NCT05077332|Other|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
75426044|NCT05076708|Other|IQOS|All participants switch from cigarette smoking to IQOS use for a 14-day phase.
75426045|NCT05076006|Drug|PF-06700841|Active study drug
75426046|NCT05076006|Drug|Placebo|placebo comparator
75426047|NCT05073484|Drug|BAT6021|Ⅳ infusions
75426048|NCT05073484|Drug|BAT1308|Ⅳ infusions
75426049|NCT05073224|Diagnostic Test|Active Straight Leg Raise Test|The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.
75426050|NCT05073224|Other|Active Straight Leg Raise Fatigue Task|The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
75426051|NCT05073224|Other|Lower Extremity Strength Testing|"A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task."
75572482|NCT04683471|Device|Stimulator|Neuromodulation
75572483|NCT04683471|Device|Sham|Sham
75572484|NCT02235272|Drug|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
75572485|NCT02235272|Drug|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
75572486|NCT04891302|Drug|Clevudine|Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
75572487|NCT04891302|Drug|Placebo|Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
75572488|NCT02229929|Drug|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
75572489|NCT02229929|Drug|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
75572490|NCT02229929|Drug|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
75572491|NCT02229929|Drug|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
75572492|NCT02229929|Drug|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
75572493|NCT02229929|Drug|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
75572494|NCT02224235|Drug|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
75877795|NCT04563065|Other|Exercise program|All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation and final talk (comments and sharing) will be performed (12-15 minutes).
75724642|NCT00899340|Other|immunohistochemistry staining method|immunohistochemistry staining method
75724643|NCT00899340|Other|laboratory biomarker analysis|laboratory biomarker analysis
75877796|NCT04563065|Other|Healthy lifestyle advise|This intervention consists of providing infographics and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations and fundamental exercises to perform during pregnancy.
75877797|NCT02588781|Drug|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
75877798|NCT01063062|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
75877799|NCT01063062|Drug|Methotrexate|methotrexate as per standard of care in clinical practice.
75426052|NCT05073224|Diagnostic Test|Ultrasound imaging of abdominal wall|Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
75426053|NCT05067998|Dietary Supplement|IV Vitamin Infused Therapy Treatment|Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
75572495|NCT02224235|Device|Resolute Integrity DES|Resolute Integrity DES
75572496|NCT02224235|Device|COBRA PzF|
75572497|NCT02224235|Drug|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
75572498|NCT02529852|Drug|Lenalidomide|"Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I."
75572499|NCT02529852|Drug|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
75724644|NCT00899418|Genetic|gene expression analysis|
75724645|NCT00899418|Genetic|polymerase chain reaction|
75724646|NCT00899418|Genetic|polymorphism analysis|
75724647|NCT00899418|Other|immunohistochemistry staining method|
75724648|NCT00899496|Other|immunological diagnostic method|
75724649|NCT00899496|Other|physiologic testing|
75572500|NCT02529852|Drug|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
75724650|NCT00894972|Other|Rehabilitation following lumbar disc surgery (discectomy)|Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
76047657|NCT04411433|Drug|Favipiravir (3600 mg + 1600 mg)|"Drug: Favipiravir (3600 mg + 1600 mg) Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
75426054|NCT05067998|Drug|Herbal medicine|Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
75426055|NCT05062317|Drug|Leucovorin|Given by PO
75426056|NCT05062317|Drug|5-FLUOROURACIL|Given by IV
75426057|NCT05062317|Drug|Oxaliplatin|Given by PO
75426058|NCT05062317|Drug|Irinotecan|Given by IV
75572501|NCT02529852|Drug|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
75877800|NCT04418739|Drug|Human albumin|Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
75426059|NCT05062317|Drug|Capecitabine|Given by IV
75426060|NCT05062317|Drug|Bevacizumab|Given by IV
75426061|NCT05055258|Drug|KVD824|KVD824 300 mg Modified-Release Tablets
75426062|NCT05055258|Drug|Placebo to KVD824|Placebo to KVD824 300 mg Modified-Release Tablets
75572502|NCT02529852|Drug|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
75572503|NCT02529852|Drug|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
75426063|NCT05049577|Device|Analgesia/Nociception Index (ANI)|V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.
75426064|NCT05048979|Other|Exercise|Telehealth-facilitated supervised exercise program. Veterans with PAD will be enrolled in a 12-week, 3 day a week, aerobic training program in a self-selected location.
75426065|NCT05045768|Drug|(Gelsectan, Devintec Sagl)|Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.
75572504|NCT02223182|Biological|Viaskin Milk 150 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
75572505|NCT02223182|Biological|Viaskin Milk 300 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
75572506|NCT02223182|Biological|Viaskin Milk 500 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
75572507|NCT02223182|Biological|Viaskin Placebo|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
75724651|NCT04035642|Radiation|IGRT 24 Gy Single dose|Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.
75724652|NCT04035642|Procedure|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
75724653|NCT04035642|Device|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
75426069|NCT05036109|Drug|Aspirin|by mouth every day for up to 90 days
75426070|NCT05036109|Drug|Vitamin D|by mouth every day for up to 90 days
75426071|NCT05036109|Dietary Supplement|Diet|Patients will receive counseling promoting a plant-based diet and avoidance of Western dietary patterns in a one on one session with a licensed dietitian prior to day 1.
75426072|NCT05036109|Other|Physical Activity|The exercise goal is to increase recreational physical activity from baseline by at least 10 MET hours per week, which is equivalent to 150 minutes of moderate activity weekly
75426073|NCT05036109|Behavioral|Behavioral Support Counseling Sessions|Patients will undergo a one-on-one counseling session prior to day 1
75426074|NCT05033821|Behavioral|Adapted FOY+ImPACT|The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
75724654|NCT04035642|Device|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
75877801|NCT01314989|Drug|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
75877802|NCT01314989|Drug|Sugar pill|liquid placebo
75426075|NCT05030675|Drug|Fostamatinib|Given PO
75426076|NCT05027490|Other|CANUT support|CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
75426077|NCT05027490|Other|Anthropometric measures|These measures include weight, waist size, hip size and brachial circumference
75426078|NCT05027490|Other|Prehension strength measurement|Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
75426079|NCT05027490|Behavioral|QVA Questionnaire|Food quality of life questionnaire
75572508|NCT02222948|Drug|Vatelizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75572509|NCT02222948|Drug|Placebo (for Vatelizumab)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75572510|NCT02221232|Drug|Chloraprep|Apply topically.
75572511|NCT02221232|Drug|ZuraPrep|Apply topically.
75572512|NCT02221232|Drug|ZuraPrep Vehicle|Apply topically.
75572513|NCT02206100|Drug|PER977|reversal of edoxaban-induced anticoagulation
75572514|NCT02206100|Drug|Placebo|Reversal of edoxaban-induced anticoagulation
75572515|NCT02206100|Drug|enoxaparin|
75724655|NCT00895050|Other|Review of clinical records|
75877803|NCT04483115|Drug|TPN171H|Tablets; Oral; Single dose
75877804|NCT04483115|Drug|Placebo|Tablets; Oral; Single dose
75877805|NCT04483115|Drug|Tadalafil|Tablets; Oral; Single dose
75572516|NCT02421159|Behavioral|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
75572517|NCT02421159|Behavioral|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
75426080|NCT05027490|Behavioral|QLQ C30 Questionnaire|Quality of Life questionnaire Core 30
75572518|NCT02409303|Behavioral|Screen-Refer-Treat Intervention|This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
75572519|NCT00554723|Drug|NeuroAid|4 capsules 3 times daily, for three months
75724656|NCT00895128|Drug|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
75877806|NCT03569865|Device|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
75572520|NCT00554723|Drug|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
75572521|NCT00554762|Drug|GW842166X|Administer
75426081|NCT05027490|Behavioral|Scratch & Snif Test|The Scratch & Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
75426082|NCT05027490|Behavioral|Taste Strip Test|The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
75426083|NCT05027490|Behavioral|24 H feed back questionnaire|This questionnaire describes patient's food and drink intakes during the last 24 ours
75572522|NCT01231516|Drug|GSK1349572|50mg once daily
75572523|NCT01231516|Drug|Raltegravir|400mg twice daily
75572524|NCT01231516|Drug|GSK1349572 Placebo|Inactive placebo tablet once daily
75572525|NCT01231516|Drug|Raltegravir Placebo|Inactive placebo tablet twice daily
75572526|NCT04668911|Other|Swab|PCR test for SARS-CoV2, oral and nasal swab
75724657|NCT00895128|Drug|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
75724658|NCT00895206|Drug|individual adapted immunosuppression|individual adapted immunosuppression
75724659|NCT00895206|Drug|golden standard therapy|golden standard therapy
75724660|NCT00899652|Genetic|Southern blotting|
75724661|NCT00899652|Genetic|chromosomal translocation analysis|
75724662|NCT00899652|Genetic|cytogenetic analysis|
75724663|NCT00899652|Genetic|gene rearrangement analysis|
75724664|NCT00899652|Genetic|mutation analysis|
75724665|NCT00903942|Radiation|radiation therapy|1) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
75877807|NCT04054362|Drug|Paclitaxel protein bound|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
75877808|NCT04054362|Drug|Cisplatin|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
75877809|NCT04054362|Drug|Gemcitabine|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
75572527|NCT04669106|Other|laboratory clinical trial study|The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
75572528|NCT04668755|Device|Charcot Restraint Orthotic Walker 3d printed sole|"The Charcot Restraint Orthotic Walker (CROW) consists of anterior and posterior shells creating a total contact environment based on a rocker sole. the sole is manufactured by 3d printed Metamaterial .~Manufacture of the 3d printed sole of the CROW paths through two stages ;Computer aided designing (CAD) and computer aided manufacturing (CAM) ."
75572529|NCT04668755|Device|Generic Charcot Restraint orthotic walker|It is a clamshell (two piece) design that provides complete/total contact over the shin, calf and foot. The CROW reduces all motion in the ankle and foot to reduce potential for further injury. It is fully padded on the inside, and the bottom is covered with a material similar to shoe soling. It is not worn with a shoe.
75572530|NCT01231321|Drug|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
75572531|NCT04668677|Other|On-line questionnaire|On-line questionnaire about working life, medical care, functional recovery, quality of life and psychological state.
75572532|NCT04668482|Device|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
75572533|NCT04668482|Device|SCS is switched on|Spinal cord stimulator is functioning
75572534|NCT04668560|Behavioral|Five ways to wellbeing course|A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
75572535|NCT01627548|Behavioral|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
75572536|NCT04668404|Diagnostic Test|Sonoclot|Sonoclot machine
75572537|NCT01210222|Biological|Trebananib|Given IV
75572538|NCT04668287|Behavioral|Increasing self-esteem|During 5 weeks, participants will be part of one of the working groups in which they'll be taught by a counselor about how a low self-esteem develops and what have to be done for improving self-esteem, based on the Melanie Fennel' model.
75724666|NCT00903942|Drug|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
75724667|NCT05278026|Other|guideline recommended routine treatment|
75724668|NCT00899964|Behavioral|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
75724669|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
75724670|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
75426084|NCT05027490|Behavioral|Condiment questionnaire|This questionnaire used to assess condiments consumption
75426085|NCT05027490|Behavioral|Tobacco questionnaire|This questionnaire used to assess tobacco consumption
75426086|NCT05027490|Other|Nutrition interview|This interview will be conducted by a dietician
75426087|NCT05017688|Procedure|Blood and stool sample collection|Collection of blood samples (55 mL) Collection of fecal samples (10g)
75724671|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
75724672|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
75724673|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
75572539|NCT01210144|Drug|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
75724674|NCT00643916|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to <6 years of age)
75724675|NCT00900042|Genetic|DNA ploidy analysis|
75724676|NCT00900042|Genetic|DNA stability analysis|
75724677|NCT00900042|Genetic|chromosomal translocation analysis|
75724678|NCT00900042|Genetic|cytogenetic analysis|
75426088|NCT05011890|Device|Moovcare® use|Moovcare® performs symptom monitoring by automatically delivering ePRO surveys on common symptoms experienced by lung cancer patients. Results are stored in a secure web-based portal for provider review. Providers will manage ePRO responses through a combination of reports graphically displaying responses over time and e-mail alerts about concerning levels or combinations of symptoms.
75572540|NCT01210144|Drug|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (>) 16 millimeter (mm), and with estradiol (E2) > 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
75572541|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
75572542|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
75572543|NCT05423470|Behavioral|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
75724679|NCT00900042|Other|flow cytometry|
75426089|NCT05005819|Drug|[18F] APN-1607|Subjects will undergo PET imaging using [18F]APN-1607.
75426090|NCT04988282|Drug|Methylprednisolone Tablet|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
75426091|NCT04985513|Procedure|Ventilation during cardiopulmonary bypass|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
75572544|NCT05423470|Behavioral|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
75724680|NCT00900042|Other|laboratory biomarker analysis|
75724681|NCT00895362|Drug|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
75724682|NCT00895362|Drug|Cetuximab|Loading dose of 200 mg/m^2 (maintenance 125 mg/m^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
75724683|NCT02538978|Biological|Autologous Bone Marrow Concentrate (aBMC)|"Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System"
75724684|NCT02538978|Biological|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
75572545|NCT04668053|Other|Traditional training protocol|Mobility and core strengthening and the steps and lunges As per athletes requirement Body weight squat with 12 reps, Body weight split squat with 8 each side, Bilateral hip raise with 12 reps, Push-up with15 reps and Cricket related skills as per coach advised
75572546|NCT04668053|Other|Hip flexor resistance protocol|"Warm up prior to training The loop bands (Resistance-band©) that were used are in several colors-Red, black, yellow, blue and green extended from strongest type to weakest.~Athletes executed 3 training sessions of 3 sets per week for 6 weeks.~The relative load was:~Week 1----15 RM Week 2-4----10 RM Week 5-6----8 RM The Therapist has ensured a concentric contraction of 3-s, an isometric contraction of 2-s, eccentric contraction of 3-s, rest for 2-s prior to the next repetition and rest for 2-min prior the next set.~It took 10 min to complete each session, with rest between sets."
75572547|NCT01209949|Drug|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|Apply adapalene BPO gel once daily in the evening for 12 weeks
75572548|NCT04667936|Other|Treatment group|None, solely treatment documentation
75572549|NCT04667975|Drug|CKD-702|In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.
75572550|NCT04831593|Other|Group El|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
75572551|NCT04831593|Other|Group Em|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
75572552|NCT04667858|Device|Home Ovulation Test|Visual read home ovulation test
75572553|NCT04825509|Device|Ultrasound|"Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line."
75572554|NCT04667897|Drug|601 1.25mg|Solution for injection (intravitreal use)
75572555|NCT04667897|Drug|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
75724685|NCT00904098|Drug|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
75724686|NCT00904098|Drug|Usual Care|Current treatment used to treat all migraine headaches
75724687|NCT00904176|Drug|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
75724688|NCT00904176|Drug|Warfarin|Tablets, Oral, 25 mg, Single Dose
75724689|NCT00904176|Drug|Digoxin|Tablets, Oral, 0.25, Single Dose
75572556|NCT04683081|Device|mechanical cervical ripening|mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
75572557|NCT01209832|Drug|Tasisulam|Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
75572558|NCT01209832|Drug|Midazolam|1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
75572559|NCT04667819|Drug|Sodium Hyaluronate|We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
75572560|NCT04683159|Drug|Brimonidine Tartrate 0.15% Oph Soln|1 drop of brimonidine 0.15% (~0.05mL) 15 minutes prior to surgery
75572561|NCT04683159|Drug|Brimonidine Tartrate 0.025% Oph Soln|1 drop of brimonidine 0.025% (~0.05mL) 15 minutes prior to surgery
75572562|NCT01230892|Drug|Nebivolol|10 mg PO qday
75572563|NCT01230892|Drug|Atenolol|100 mg PO qday
75572564|NCT04667624|Drug|Twynsta|Manufactured by Boehringer Ingelheim
75572565|NCT04667624|Drug|LodineT|•Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea
75572566|NCT03455400|Device|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
75572567|NCT04667351|Drug|2400 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
75724690|NCT00900276|Other|immunologic technique|
75572568|NCT04667351|Drug|1200 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
75572569|NCT01230814|Drug|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
75572570|NCT01230814|Drug|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
75724691|NCT00900276|Other|laboratory biomarker analysis|
75724692|NCT00900276|Other|mass spectrometry|
75724693|NCT02540070|Procedure|Periarticular|
75572571|NCT01230307|Drug|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
75572572|NCT01230307|Drug|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
75572573|NCT04810377|Procedure|EUS-guided gastroenterostomy|First after an upper endoscopy is performed, a catheters passed throughout the endoscope channel and with x-ray verification, a guide wire is passed up to the third portion of duodenal loop. then small intestinal is filled with saline solution up to 1500cc and contrast solution. Then an endoscopic ultrasound examination will be carried out where a loop of the small intestine that is located less than 2 cm apart from the gastric wall will be looked for. Once the intestinal loop is identified a direct antegrade puncture will be performed with a luminal apposition prosthesis release system . Finally, correct position is verified with x-ray and we will look for any misplacement or leakage during this process or the presence of bleeding. Endoscopic treatment will be performed if necessary. Subsequently, the participants will go to monthly follow-up with clinical evaluation, laboratory and radiological test will be carried out until the participants dies.
75724694|NCT02540070|Procedure|Motor free|
75572574|NCT00556595|Procedure|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
75572575|NCT00556595|Procedure|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
75724695|NCT02540070|Procedure|Motor free with dex|
75724696|NCT02540070|Drug|Ropivacaine|
75724697|NCT02540070|Drug|epinephrine|
75724698|NCT02540070|Drug|morphine|
75724699|NCT02540070|Drug|Ketorolac|
75724700|NCT02540070|Drug|Dexmedetomidine|
75724701|NCT02540070|Drug|saline|
75724702|NCT00900354|Genetic|molecular genetic technique|
75724703|NCT00900354|Other|mass spectrometry|
75724704|NCT00900354|Other|pharmacological study|
75724705|NCT00904254|Radiation|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
75724706|NCT00905814|Drug|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
75724707|NCT00905814|Drug|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
75724708|NCT00905892|Dietary Supplement|Hyperlipidic overfeeding|100g per day of cheese + 40g per day of almonds + 20g per day of butter
75724709|NCT00900432|Other|immunoenzyme technique|
75724710|NCT00900432|Other|laboratory biomarker analysis|
75724711|NCT00900510|Procedure|Incision and drainage|
75724712|NCT00900510|Drug|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
75724713|NCT00900510|Drug|Placebo|
75724714|NCT00904410|Other|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
75724715|NCT00160693|Biological|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
75724716|NCT00900588|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
75724717|NCT00906048|Drug|Levofloxacin (HR355) and Rifampicin Therapy|"Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight < 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight > 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin"
75572576|NCT01209598|Drug|Palbociclib 200mg|Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
75572577|NCT01209598|Drug|Palbociclib 125mg|"Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food."
75572578|NCT04809090|Behavioral|SMT|Standard 8 SMT (Stress Management Training) psychological interviews.
75572579|NCT04809090|Device|App CA|An APP together a CA (Conversational Agent).
75572580|NCT00556634|Drug|Efavirenz|"Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)"
75572581|NCT01209520|Drug|Cisplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
75572582|NCT01209520|Drug|Carboplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
75724718|NCT00906126|Drug|Misoprostol|Oral misoprostol
75426092|NCT04983654|Diagnostic Test|patients with limb ulcers|"For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:~Microvascular analysis (laser doppler, TcPO2),~Neurological analysis ( sensitivity testing with thermal and mechanical test),~Analysis of physical characteristics of red blood cells and inflammatory marks,~Analysis of cytokine and metalloproteases in the wound fluid,~Assessment of healing according usual treatment"
75572583|NCT01209520|Drug|Paclitaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
75572584|NCT01209520|Drug|Vidaza|Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
75572585|NCT01209520|Procedure|Tumor Specimen for Methylation Analysis|Obtained from tissue of resected NSCLC tumor.
75572586|NCT01209520|Procedure|Blood Sample for Methylation Analysis|Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
75572587|NCT01209520|Drug|Vinorelbine|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
75572588|NCT01209520|Drug|Docetaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
75572589|NCT01209520|Drug|Pemetrexed|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
75572590|NCT01209325|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
75724719|NCT04034472|Other|Interdisciplinary intervention in obesity|Interdisciplinary weight loss intervention associate to the use of digital technology to treat obesity and related disorders
75724720|NCT05277870|Device|Nanodropper adaptor|Patients will use their standard prescription for open-angle glaucoma or ocular hypertension with a Nanodropper attachment on the medication bottle.
75724721|NCT05277870|Device|control|Patients will use their prescribed IOP-lowering medication using standard eyedropper on the medication bottle.
75724722|NCT00900744|Drug|Tamoxifen|20 mg daily
75724723|NCT02539758|Other|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
75724724|NCT02539758|Device|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
75426093|NCT04983654|Diagnostic Test|For patients without limb ulcers|"For patients without limb ulcers : at inclusion visit only~Microvascular analysis (laser doppler, TcPO2),~Neurological analysis (sensitivity testing with thermal and mechanical test),~Analysis of physical characteristics of red blood cells and inflammatory marks"
75724725|NCT02539758|Device|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
75426094|NCT04978727|Biological|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
75724726|NCT00643760|Drug|Placebo|placebo
75724727|NCT00643760|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
76047658|NCT04411433|Drug|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
75426095|NCT04978727|Biological|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
75426096|NCT04978727|Biological|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
75426097|NCT04962932|Behavioral|Internet-deliviered exposure-based CBT|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
75426098|NCT04962932|Behavioral|Internet-delivered stress management treatment|The intervention last for 10 weeks and include: Internet-SMT include life-style advice (e.g., exercise, sleep advice), relaxation and problem-solving skills to reduce stress. Patients are offered regular online contact with a psychologist with the same frequency and intensity as in the CBT arm.
75426099|NCT04962230|Drug|PF-07321332/ritonavir|PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
75426100|NCT04962230|Drug|Carbamazepine|In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
75426101|NCT04962230|Drug|PF 07321332/ritonavir|In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
75426102|NCT04947150|Behavioral|Location-triggered notification|"If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF."
75426103|NCT04947150|Behavioral|Reflections on benefits of change|Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.
75426104|NCT04947150|Behavioral|Coach monitoring|Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.
76047659|NCT04411433|Drug|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
76047660|NCT04411433|Drug|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
75426105|NCT04947150|Behavioral|Household support|If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
75426106|NCT04943445|Drug|carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
75572591|NCT01209325|Other|laboratory biomarker analysis|
75572592|NCT04805541|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
75572593|NCT04805541|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
76047661|NCT04411433|Drug|Hydroxychloroquine combined with Azithromycin|"Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
75572594|NCT04805541|Device|Diabetic retinopathy screening|"Screening for existence of More than mild or Vision-threatening Diabetic Retinopathy, and/or Diabetic Macular Edema."
75572595|NCT04667273|Procedure|Neuromuscular Electrical Stimulation (NMES)|"In Neuromuscular Electrical Stimulation (NMES) application, 4 surface electrodes will be placed in the swollen part of the lower trapezius and serratus anterior muscles of each patient.~NMES will be applied for 20 minutes in rehabilitation mode with a 4-channel device.~Frequency: 80 Hz Amplitude: 0-100 mA (0-0.01 V) Current time-Pulse: 200 μsec Wave form: Biphasic Cycle time: 8 seconds of tetanic muscle stimulation for all patients, with a 2 second rise and fall time and stimulation It will be set as 3 seconds between. It is important to visually observe the contraction to determine the intensity of stimulation."
75426107|NCT04943445|Radiation|Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
75426108|NCT04943445|Drug|Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.|Consolidation immunotherapy
75426109|NCT04939883|Drug|Carvedilol|Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications
75426110|NCT04939883|Drug|Placebo|Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
75426111|NCT04935528|Biological|serology and ELISPOT test|27 mL blood sample to study the humoral and the cellular immune response
75426112|NCT04935528|Biological|serology|7 mL blood sample to study the humoral response
75572596|NCT04667273|Procedure|Exercise Training (ET)|"Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband."
75572597|NCT04798677|Dietary Supplement|ABBC1 Immunoessential|Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor
76047662|NCT04987463|Drug|Vigabatrin|Vigabatrin in capsules administered orally, initially (between V1 and V2) once daily in the evening,and starting from V2 administered two times daily.
76047663|NCT04987463|Drug|Rapamycin|Rapamycin in liquid administered orally, in the morning, every other day or daily depending on the patient's body weight. The starting dose of rapamycin will be calculated according to the body weight of the patient measured at V1.
76047664|NCT04987463|Drug|Placebo|Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.
75426113|NCT04933695|Drug|Sotorasib|Oral tablet
75426114|NCT04931732|Biological|ctDNA analysis|ctDNA analysis of patients with suspected primary glioma tumors and in patients with suspected recurrence.
75572598|NCT04798677|Dietary Supplement|Placebo|Powder for dissolution in water, excipents. Lemon flavor
75572599|NCT04667429|Other|Food|HEC83518 40mg will be taken orally fasted or with food
75572600|NCT04667429|Drug|HEC83518|HEC83518 will be taken orally before sleep for 15 days
75572601|NCT04667429|Drug|placebo|The placebo will be administered before sleep for 15 days.
75426115|NCT04926818|Drug|Fingolimod|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
75426116|NCT04926818|Drug|Ofatumumab|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
75426117|NCT04926818|Drug|Siponimod|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
75426118|NCT04926818|Other|Fingolimod placebo|Fingolimod matching placebo capsule
76047665|NCT04987463|Drug|Placebo|Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
76047666|NCT01628367|Procedure|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
76047667|NCT01628367|Device|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
76047668|NCT01628367|Biological|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
75426119|NCT04926818|Other|Siponimod placebo|Siponimod matching placebo tablet
75426120|NCT04926818|Other|Ofatumumab placebo|Ofatumumab matching placebo autoinjector
75572602|NCT04667546|Other|Survey|Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
75724728|NCT00643760|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
75724729|NCT00643760|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
75426121|NCT04923126|Drug|Mirdametinib|By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
75572603|NCT04784754|Drug|Melatonin|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
75724730|NCT00643760|Drug|Pregabalin|pregabalin 300mg/day
75724731|NCT00904644|Drug|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
76047669|NCT01628367|Biological|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
76047670|NCT01628367|Biological|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
76047671|NCT01628367|Drug|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
76047672|NCT01627899|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
76047673|NCT05012735|Drug|Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
76047674|NCT05012735|Device|Prototype Ultrathin Hydrocolloid Bandage|Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
76047675|NCT04946903|Drug|RLD2007|Take it once per period.
76047676|NCT04946903|Drug|RLD2008|Take it once per period.
75426122|NCT04920422|Other|No intervention|Retrospective analysis using database without any intervention assigned in the study.
75426123|NCT04919317|Drug|Dexamethasone 4mg|The experimental group received 4mg dexamethasone added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
75426124|NCT04919317|Drug|Saline|The control group received 1mL of 0.9% saline added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
75572604|NCT04784754|Drug|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
75572605|NCT04666883|Other|Review of records and follow up|Follow up to identify patients who developed splenic hilar nodal metastases
75572606|NCT04666805|Drug|Tamoxifen|20 mg/d, oral administration
75572607|NCT04666805|Drug|Toremifene|60 mg/d, oral administration
75572608|NCT04666805|Drug|Anastrozole|1 tablet (1 mg) per day, oral administration
75724732|NCT02539836|Dietary Supplement|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
75724733|NCT02539836|Diagnostic Test|MRI in quantifying liver fat with MRS|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
75724734|NCT04034628|Device|Peritoneal Catheter Insertion - Laparoscopic|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
75724735|NCT04034628|Device|Peritoneal Catheter Insertion - Percutaneous|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
75724736|NCT00906360|Drug|sunitinib malate|Given orally or by percutaneous gastrostomy tube
75724737|NCT00906360|Other|pharmacological study|Correlative studies
76047677|NCT04946903|Drug|HCP1902|Take it once per period.
76047678|NCT04985825|Drug|Imgatuzumab|Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
75572609|NCT04666805|Drug|Letrozole|Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.
75572610|NCT04666805|Drug|Exemestane|The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
75724738|NCT00906360|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
76047679|NCT02519777|Drug|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
76047680|NCT02519777|Drug|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
76047681|NCT02519777|Drug|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
75426125|NCT04915248|Drug|Daratumumab|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
75724739|NCT00906360|Biological|cetuximab|Given IV
75724740|NCT00643682|Other|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
75724741|NCT00904800|Drug|AZD0837|tablet, oral, once daily, 1+5 days
75724742|NCT00904800|Drug|Placebo|Placebo
75724743|NCT00906438|Dietary Supplement|2006-RD-05|300 mg daily, once a day for 28 consecutive days
75724744|NCT00906438|Dietary Supplement|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
75724745|NCT00819494|Procedure|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
75724746|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
75724747|NCT00603798|Drug|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
75877810|NCT04054362|Drug|Paricalcitol|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
75877811|NCT04467281|Drug|89Zr-DFO-daratumumab|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
75877812|NCT04467281|Diagnostic Test|PET/CT|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
75877813|NCT04350879|Other|Data record|Data record
76047682|NCT02519777|Drug|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
76047683|NCT05008913|Drug|[14C]Adavosertib|Patients will receive a single administration of [14C]Adavosertib as an oral solution on Day 1.
76047684|NCT04982705|Drug|[Part 1.1] IDG-16177|[Part 1.1] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
76047685|NCT04982705|Drug|[Part 1.1] Placebo of IDG-16177|[Part 1.1] subjects will receive a single oral dose of IMP.
76047686|NCT04982705|Drug|[Part 2] Sitagliptin|Administration of Sitagliptin 100mg once daily for 4 weeks.
76047687|NCT04982705|Drug|[Part1.2] IDG-16177|[Part 1.2] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
76047688|NCT04982705|Drug|[Part 2] IDG-16177|[Part 2] Administration once daily for 4 weeks.
76047689|NCT04982705|Drug|[Part 1.2] Placebo of IDG-16177|[Part 1.2] Administration once daily for 14 days.
76047690|NCT04982705|Drug|[Part 2] Placebo of IDG-16177|[Part 2] Administration once daily for 4 weeks.
76047691|NCT04202783|Other|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
75426126|NCT04915248|Drug|Bortezomib|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
76047692|NCT04944095|Other|Change in SARS-CoV-2 Antibody Levels|Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
75426127|NCT04915248|Drug|Dexamethasone|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
75426128|NCT04910841|Device|CGM GUARDIAN 2|continuous blood glucose monitoring system
75426129|NCT04902326|Behavioral|Automated educational text messages|"During the first two weeks, participants receive a series of educational messages delivered via text message. These messages welcome participants to the study, set expectations for the next 12 months, and establish a general level of knowledge among all participants on prediabetes, the Diabetes Prevention Program (DPP), and metformin.~For the next 11.5 months, participants receive three automated text messages per week that provide evidence-based educational content about prediabetes and tips on prevention. Additionally, participants receive monthly messages reminding them about their health insurance plan's coverage of the DPP at no cost and coverage of metformin as a low co-pay medication, and monthly messages providing feedback on their participation in the DPP and use of metformin in the previous calendar month. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months."
75426130|NCT04902326|Behavioral|Autonomy-supportive automated educational text messages|Participants receive the same text messages as in the automated educational text message intervention, but the thrice weekly messages have been modified, where applicable, to support the participant's autonomy, in accordance with principles of Self-Determination Theory. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months.
75572611|NCT04666376|Other|evaluation of the effectiveness of vitrification technique on ovarian tissue quality|there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
75572612|NCT04666337|Procedure|ultrasound-guided supraclavicular brachial plexus blockade|Ultrasound-guided supraclavicular brachial plexus block was done using an ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe. The brachial plexus and its relation to the surrounding structures were viewed while the patient was supine and the head turned 45° to the contralateral side. In the supraclavicular fossa, the probe was placed in the coronal plane to visualize the subclavian artery and the brachial plexus in a transverse sectional view. After skin sterilization and local anesthetic administration, an insulated needle was then introduced lateral to the ultrasound probe and parallel to the long axis of the probe. Once the needle penetrated the brachial plexus cluster, the local anesthetic mixture was injected incrementally after negative aspiration for blood or air just next to the artery, then the needle was repositioned to inject on the upper pole of the artery.
75572613|NCT04739319|Other|N/A Observational study|N/A Observational study
75572614|NCT00556790|Procedure|Standard Care|standard fluid regime, delayed feeding
75572615|NCT00556790|Procedure|Fast Track care|restrictive fluid regime, early oral feeding, enforced mobilisation
75724748|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
76047693|NCT02515331|Drug|LHW090|Capsule - oral dose
76047694|NCT02515331|Drug|Placebo|Capsule - oral dose
76047695|NCT02515097|Drug|IDP-122 Lotion|Medicated topical lotion
76047696|NCT02515097|Drug|IDP-122 Vehicle Lotion|Vehicle topical lotion with no active ingredient
75724749|NCT00819572|Biological|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
75724750|NCT00819572|Drug|Placebo|
76047697|NCT02141295|Drug|5-FU|5-FU will be administered according to dose and schedule described in respective arm.
76047698|NCT02141295|Drug|Bevacizumab|Bevacizumab will be administered according to dose and schedule described in respective arm.
76047699|NCT02141295|Drug|Folinic acid|Folinic acid will be administered according to dose and schedule described in respective arm.
76047700|NCT02141295|Drug|Oxaliplatin|Oxaliplatin will be administered according to dose and schedule described in respective arm.
76047701|NCT02141295|Drug|Vanucizumab|Vanucizumab will be administered according to dose and schedule described in respective arm.
76047702|NCT02514551|Drug|Ramucirumab|Administered IV
76047703|NCT02514551|Drug|Paclitaxel|Administered IV
76047704|NCT02141217|Drug|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
76047705|NCT02141217|Drug|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
76047706|NCT02138253|Drug|IDN-6556|
76047707|NCT02138253|Drug|Placebo|Placebo control
76047708|NCT02514473|Drug|VX-809|
76047709|NCT02514473|Drug|Placebo|
76047710|NCT02514473|Drug|VX-770|
76047711|NCT02513771|Drug|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
75877814|NCT03652194|Other|in vitro evaluation of epithelial immune response during C. glabrata infection|"study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~study of protein expression by the Western-Blot method"
76047712|NCT02513771|Drug|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
75877815|NCT03652194|Other|study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates|"in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~in vivo evaluation measured by a survival study on a CD-1 mouse model."
75724751|NCT00908622|Procedure|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
75877816|NCT04322019|Other|Data record|Data record
75877817|NCT04315467|Drug|SGM-101|A one-time infusion of SGM-101
76047713|NCT02104947|Drug|idarucizumab|idarucizumab
76047714|NCT02513459|Drug|Risankizumab 600 mg IV|Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
75877818|NCT04315467|Device|Near infrared camera imaging system|Near infrared camera imaging system
75426131|NCT04902326|Behavioral|Financial incentives|Participants in this arm have the opportunity to earn a financial incentive ranging from $50 to $250 per month for taking an evidence-based action to prevent T2DM (i.e., engagement in a DPP or fill of a metformin prescription) in the previous month.
75426132|NCT04902326|Behavioral|Tailored text messages|Participants receive twice-weekly tailored text messages that link evidence-based actions to prevent T2DM to the participant's self-identified top values, roles, and strengths. Text messages are also tailored, when possible, to participants' self-reported importance of taking action to try to prevent T2DM (i.e., participating in the DPP or taking metformin), confidence in being able to take such preventive action, and past preventive actions taken.
75572616|NCT04738461|Other|Telerehabilitation|The Posterior Glenohumeral Capsule Stretching Exercise, Pectoral Stretching Exercise, Push-up Against Wall Exercise, Scapular Plan Exercise, 90 Degree Shoulder Flexion Exercise, Isometric External Rotation Exercise and Isometric Internal Rotation Exercise will be applied according to the severity of the disease and the size of the disability.
75877819|NCT01785342|Other|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
75877820|NCT01378143|Drug|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
75877821|NCT05073107|Other|"Mobile Dental Application, Dental Monitoring (DM)"|"o The Test group will be required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~Day 0 (To be taken at the clinic)~Day 7 (To be taken in the evening after brushing teeth)~Day 14 (To be taken in the evening after brushing teeth)~Day 21(To be taken in the evening after brushing teeth)~Day 28 (To be taken before study Visit 2) There is a window period of +1 day for the intra-oral videos."
75877822|NCT02973048|Drug|Hyperbaric bupivacaine|The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
75877823|NCT02973048|Drug|Hyperbaric prilocaine|The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
75877824|NCT05028413|Behavioral|Participants Shown their Breath Alcohol Content Measurement|Each time a Breath Alcohol Content (BrAC) Measurement is taken by the research team, the participant is shown the measurement before completing the paper visual analog scale scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
75572617|NCT04738461|Other|Standard Physiotherapy|Active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
75724752|NCT00908622|Procedure|Cardiac revascularization|Cardiac revascularization
75724753|NCT02538588|Device|Nebulizer 1|
75724754|NCT02538588|Device|Nebulizer 2|
75724755|NCT03323502|Behavioral|ACP Specialist Program|New structured role with responsibility for ACP
75724756|NCT00630812|Drug|inhaled mannitol|400 mg BD for 26 + 26 weeks
75724757|NCT00630812|Drug|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
76047715|NCT02513459|Drug|Risankizumab 180 mg SC|Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
76047716|NCT02104557|Other|Non intervention|Non intervention
76047717|NCT02104557|Other|Non intervention|Non intervention
75426133|NCT04901494|Drug|SSRI|Selective serotonin reuptake inhibitor
75426134|NCT04892199|Drug|Semaglutide, 1.34 mg/mL|Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.
75426135|NCT04892199|Drug|Semaglutide-placebo|"The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study."
75426136|NCT04888702|Device|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
75426137|NCT04888689|Device|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
75426138|NCT04888689|Device|IMU|"IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes."
75426139|NCT04887129|Diagnostic Test|COVID-19 RT-PCR test|"Participating individuals (students and employees) will be tested for COVID-19 (RT-PCR) using a specimen collected using a mid-turbinate swab.~This asymptomatic testing regime starts on or after (if scheduling testing requires this to begin on a different day) enrollment and is repeated every 5-14 days for up to 16 months . Anyone testing positive is followed up as described below for symptomatic individuals.~Those presenting with symptoms will be also tested for COVID-19 (RT-PCR). Those with negative test results will return to the asymptomatic testing protocol.~Students who test positive are retested then 3 days until two negative tests. Employees who test positive also be tested every 3 days until two negative tests."
75426140|NCT04887129|Other|COVID-19 Vaccine Education Campaign|Utilizing information from focus groups, the investigators will develop and deploy an educational campaign aimed at improving vaccine hesitancy and student health
75426141|NCT04882891|Device|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
75572618|NCT04738461|Other|Home Exercise Group|The same exercise program applied to telerehabilitation group.
75572619|NCT00556868|Other|Breakfast/no breakfast|"A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention"
76047718|NCT04209023|Device|Transcranial Magnetic Stimulation|Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
76047719|NCT04982081|Biological|hiPSC-CM therapy|20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.
75426142|NCT04877522|Drug|Asciminib single agent|Taken orally, twice daily (BID) or once daily (QD), in fasting state
75572620|NCT00556907|Radiation|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
75572621|NCT00556907|Device|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
75572622|NCT04721457|Drug|Distilled Water|Control group
75426143|NCT04877522|Drug|Asciminib|Taken orally, once daily, in the morning with low-fat meal or twice daily in fasting state
75426144|NCT04877522|Drug|Imatinib|Taken orally, once daily, in the morning with low-fat meal
75426145|NCT04877522|Drug|Nilotinib|Taken orally, twice daily, on an empty stomach
75426146|NCT04877522|Drug|Bosutinib|Taken orally, once daily, with food
75426147|NCT04877522|Drug|Dasatinib|Taken orally, once daily in a fasted state, 1 or 2 hours before a meal
75426148|NCT04876456|Drug|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
75426149|NCT04871594|Drug|Nivolumab|On day 1, 22, and 43 240mg
75426150|NCT04866147|Procedure|Cardiothoracic surgery|Cardiac & large intrathoracic vessels, respiratory, thoracic, mediastinal & diaphragmatic procedures
75426151|NCT04866147|Procedure|Breast surgery|Breast resections & mastectomies
75426152|NCT04866147|Procedure|Gastrointestinal surgery|Digestive & spleen
75426153|NCT04866147|Procedure|Genitourinary surgery|Urinary tract, genital & retroperitoneal tissue
75426154|NCT04866147|Procedure|Orthopaedic surgery|Back & neck, shoulder & upper arm, hip & thigh, knees & lower leg
75426155|NCT04858867|Radiation|rhTSH-stimulated I-124 dosimetry|"Preparation:~Low iodine diet 7 days prior to I-124 ingestion until 24 hours post-ingestion~Thyrogen injections 24 and 48h prior to I-124 ingestion~Procedures following Jentzen et al:~Ingestion of capsule with 37±10% MBq I-124~I-124 PET/CT at 24 and 96h post-ingestion~Blood draws at 2, 24 and 96h post-ingestion~Whole body counting at 2, 24 and 96h post-ingestion"
75426156|NCT04858867|Radiation|Intra-therapeutic I-131 dosimetry|"Procedures following EANM guidelines:~I-131 SPECT/CT at 2, 6, 24, 96 and 144h post-ingestion~Blood draws at 2, 6, 24, 96 and 144h post-ingestion~Whole body counting at 2, 6, 24, 96 and 144h post-ingestion"
75426157|NCT04852471|Behavioral|Standard Post-Operative Counseling + FACT-G|Counseling at discharge + FACT-G at enrollment, at 15-18 and at 30-32 days post-operative.
75426158|NCT04852471|Behavioral|PROM symptom tracker|A 12-item symptom tracker adopted from the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE), delivered via text, on days 4, 6, 8, 12, 18, 24, and 30 post surgery.
75572623|NCT04721457|Drug|1% Povidone Iodine (PVP-I)|Over-the-counter antiseptic mouth rinse
75572624|NCT04721457|Drug|1.5% Hydrogen Peroxide (H2O2)|Over-the-counter antiseptic mouth rinse
75877825|NCT04110405|Behavioral|Stepped Care|This stepped care model involves three steps. Step 1 is a peer and nurse co-led 8-session group based upon BRIDGES. Step 2 is peer or nurse led 6-session individual meetings based upon Interpersonal Psychotherapy. Step 3 is primary care physician led medication treatment with Amitriptyline.
75426159|NCT04848857|Drug|Colchicine|colchicine is a potent anti-inflammatory drug which is currently recommended for the treatment of pericarditis and acute gout attacks, but also familial Mediterranean fever and Behçet disease. This drug acts on inflammation through inhibition of microtubule polymerization by binding free tubule dimers. Colchicine blunts monocyte and neutrophil invasion at the site of inflammation and reduces intracellular trafficking and thus the release of cytokine and production of reactive oxygen species and a variety of proteolytic enzymes.
75426160|NCT04848857|Drug|Placebo|the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
75426161|NCT04846556|Other|data collection|data collection : gender, weight, biological data (platelets, hemoglobin, creatinine, liver function tests), performance status, type of Venous Thromboembolic Event (VTE) and cancer, anticancer and anticoagulant therapy, adverse events (bleeding, recurrence of Venous Thromboembolic Event (VTE), death) up to 6 months after their Venous Thromboembolic Event (VTE).
75426162|NCT04826562|Drug|Dolutegravir/Lamivudine|single tablet antiretroviral
76047720|NCT05006105|Device|seven-day ECG Holter|Participants receive a seven-day ECG Holter after hospital discharge.
76047721|NCT05006105|Device|24-hour blood pressure monitor|Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.
76047722|NCT05006105|Other|Questionnaire: vision of mHealth|Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.
75572625|NCT04721457|Drug|0.075% Cetylpyridinium Chloride (CPC)|Over-the-counter antiseptic mouth rinse
75572626|NCT04721457|Drug|0.1% Sodium Hypochlorite|Over-the-counter antiseptic mouth rinse
75572627|NCT04721457|Other|No rinse group|second control group
75572628|NCT04666415|Other|Osteopathic treatment|Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
75572629|NCT00557024|Procedure|RFA|radiofrequency ablation
75572630|NCT00557024|Procedure|radiotherapy after RFA|radiotherapy after RFA
75572631|NCT04666493|Other|Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum|The Facing Your Fears program (FYF; Reaven et al. 2011) is a CBT-based group treatment program that has been adapted for the needs of children with high-functioning ASD. The current project will adapt the FYF program for virtual delivery and examine its effectiveness.
75572632|NCT04711785|Behavioral|Multicomponent exercise program|"The exposed group will carry out the following program of specific muscle strength and cardio physical activity aimed at reducing frailty.~For 2.5 hours per week."
75572633|NCT04666220|Other|VETC evaluation|We will evaluate VETC presence on tissue specimens
75572634|NCT04684758|Other|Self-completion of a questionnaire|The questionnaire will be translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service, if necessary.
75572635|NCT04666142|Other|Comparison of the personal characteristics of the experimental and control groups|General characteristics of the individuals in the experimental and control groups were compared.
75426163|NCT04823689|Procedure|reductions|"Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula."
75426164|NCT04817540|Drug|Herzuma|8mg/kg IVF loading dose at first cycle -> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
75426165|NCT04806165|Behavioral|Repeated Administration|A discussion with the chatbot, including follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
75572636|NCT04666142|Other|Light applied experimental group, control group treated with standard intensive care lighting|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"
75572637|NCT04650126|Biological|ATM001|monovalent anti-TNF-receptor 1 antibody format
75572638|NCT04650126|Biological|ATM001 Placebo|ATM001 Placebo
75877826|NCT04110405|Behavioral|Standard of Care plus Healthy Lifestyle|Standard outpatient care supplemented with literature on healthy lifestyles will serve as an enhanced control condition. In each clinic, non-specialty mental health care is available in the form of counseling from doctors or nurses along with psychiatric medication management. Given the difficulties faced by women in Tajikistan, ethical responsibility compels us to enhance the control condition by having nurses distribute written materials on healthy eating, physical fitness, and personal hygiene, at a reading level which will be widely accessible.
75426166|NCT04806165|Behavioral|Personalized Recommendation|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder.
76047723|NCT05006105|Other|Questionnaire: user experience & feeling of safety|Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.
76047724|NCT05006105|Device|Insertable loop recorder|Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
75426167|NCT04806165|Behavioral|Motivational Interviewing|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
75426168|NCT04806165|Behavioral|Core Modules Only|A discussion with the chatbot, including only the core modules.
75572639|NCT04665908|Other|Assessment by PT/Orth surgeon|Assessment by orthopaedic surgeon or a PT
75572640|NCT04644744|Device|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
75724758|NCT00906516|Drug|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
75724759|NCT03299478|Other|Will look for immune infiltration|
75724760|NCT00908700|Procedure|Surgical occlusion of the left atrial appendage|Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.
75724761|NCT00908700|Procedure|Best medical practice|Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
75724762|NCT03291522|Procedure|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
75877827|NCT02932943|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
75877828|NCT02932943|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
76047725|NCT02069379|Drug|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
76047726|NCT02069379|Drug|Placebo|Placebo capsules prepared identically to Metformin capsules
75572641|NCT04644744|Device|Normothermic machine perfusion (NMP)|End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
75426169|NCT04806165|Behavioral|Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
75426170|NCT04806165|Behavioral|Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
75572642|NCT04665986|Drug|Navelbine|Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
75572643|NCT04665986|Drug|Docetaxel|Docetaxel 90mg/m2 on day 1, every 3 weeks
75724763|NCT00629798|Drug|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients > or = to 4 years of age or 1.0 mg/kg IV for patients < 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
76047727|NCT02511431|Drug|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
76047728|NCT02511431|Drug|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
75426171|NCT04806165|Behavioral|Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and identifying a personalized recommendation for accessing help for their eating disorder.
75572644|NCT04638309|Drug|APR-548 + Azacitidine|APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
75572645|NCT04666103|Procedure|Intraoperative thermal ablation|"After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
75572646|NCT04633473|Behavioral|SIB-Time Web-Application Tool|Parent-child dyads will use the SIBTime app in a 4-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
75572647|NCT04666064|Diagnostic Test|Covid19 RT-PCR|patients admitted to ER for suspicion of COVID-19 infection will have a SARS-CoV-2 RT-PCR test
75724764|NCT00160615|Drug|Levetiracetam|"Pharmaceutical form: Film-coating tablets~Concentration: 250 mg/ 500 mg~Route of administration: oral use"
75724765|NCT03158454|Procedure|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
75724766|NCT03158454|Procedure|Non-Capsula Closure|No capsular closure procedure is performed.
75724767|NCT00819650|Drug|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na[131I],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
75724768|NCT00906594|Drug|latanoprost|
75724769|NCT03970759|Drug|Stannous Fluoride Dentifrice|Experimental stannous fluoride (0.454%) dentifrice
75724770|NCT03970759|Drug|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
76047729|NCT02511431|Other|Placebo|Placebo
75724771|NCT03970759|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
75724772|NCT00905112|Other|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
75724773|NCT00905112|Other|Standard OB Care|Receive standard obstetrical care
75724774|NCT00643448|Drug|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
75724775|NCT00643448|Drug|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
76047730|NCT05005247|Biological|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
76047731|NCT02137785|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
75572648|NCT04666064|Other|lung ultrasound|patients admitted to ER for suspicion of COVID-19 infection who has a SARS-CoV-2 RT-PCR test and for whom the emergency doctor decide to perform a lung ultrasound
75572649|NCT04665830|Drug|Evolocumab|treated patients with evolocumab for high cholesterol
75572650|NCT04631133|Device|Lumbar Implant for Stiffness Augmentation (LISA)|The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
75572651|NCT04665791|Biological|Intranasal inoculation with Neisseria lactamica|Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.
75426172|NCT04806165|Behavioral|Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
75572652|NCT04665674|Other|Standard of care|Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
75572653|NCT04683237|Drug|Liraglutide Injection|Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.
75572654|NCT04683237|Drug|Megestrol Acetate 160 MG|160mg po qd
75572655|NCT04665518|Other|Acupressure|Acupressure will be applied to the patients in the acupressure group for 10 min before the venipuncture procedure. Venipuncuture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
75572656|NCT04568694|Procedure|Delayed Lung Transplantation|Transplants with a planned recipient anesthesia start time between 10:00 pm and 6:00 am will be allowed to move to a start time between 6:00 am and 8:00 am at the earliest. Donor lung(s) cross clamp time must occur between 5:00 pm and 4:00 am. Lungs that meet criteria will be transported in the usual fashion in a cooler of ice at 4oC. Upon arrival to NYULH, the lungs will be transferred to cold static preservation at 10oC within a specific incubator located in a NYULH OR (MYTEMP™65HC, Benchmark Scientific).
75572657|NCT04568694|Procedure|Conventional Lung Transplantation|Reference Therapy
75572658|NCT04549701|Other|CAVAL US-guided Therapy|Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.
75724776|NCT00643448|Drug|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
75724777|NCT03972631|Behavioral|Lifestyle education|Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.
75724778|NCT03972631|Behavioral|Intensive lifestyle intervention|One to one intensive lifestyle intervention according to the diet and activity plan
75724779|NCT03972631|Behavioral|Hypocaloric low-carbohydrate diet plan|A diet plan with restricted calorie and carbohydrate intake
75426173|NCT04806165|Behavioral|Psychoeducation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders.
75426174|NCT04806165|Behavioral|Psychoeducation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
75572659|NCT04549701|Other|Standard of care|Standard of care will be provided.
75572660|NCT04665362|Drug|Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib|"Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib"
75724780|NCT00908778|Drug|Vitreosolve|intravitreal injection
75724781|NCT00908778|Drug|Vitreosolve|intravitreal injection
75724782|NCT00905190|Drug|Ondansetron|24 mg one time
75724783|NCT00908856|Biological|autologous bone marrow mononuclear cell transfusion|a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
75724784|NCT00908856|Biological|marrow stromal cells|a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)
75877829|NCT04054206|Drug|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
75426175|NCT04806165|Behavioral|Psychoeducation, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and identifying a personalized recommendation for accessing help for their eating disorder.
75426176|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
75426177|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and identifying a personalized recommendation for accessing help for their eating disorder.
75426178|NCT04806165|Behavioral|Psychoeducation, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
76047732|NCT02137785|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
75426179|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
75572661|NCT04683120|Diagnostic Test|Zenith FLIM Diagnostics|In-vitro
75572662|NCT04665401|Behavioral|Tailored MERIT|see arm description
75572663|NCT04665401|Behavioral|Standard MERIT|see arm description
75572664|NCT04503291|Procedure|Metal stent placement|Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
75572665|NCT04498182|Drug|AR15512|Administered via topical ocular instillation, one drop per eye, twice daily for 84 days. Both eyes will be treated.
75572666|NCT04498182|Drug|Vehicle|Administered via topical ocular instillation, one drop per eye, twice daily for 84 days. Both eyes will be treated.
75572667|NCT04494555|Device|Static socket|For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.
75572668|NCT04494555|Device|User adjusted socket|Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.
75724785|NCT00908856|Drug|placebo|a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
75724786|NCT00905502|Drug|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
76047733|NCT02137785|Device|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
75572669|NCT04494555|Device|Microprocessor-adjusting sockets|"A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation."
75724787|NCT00905502|Drug|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
75724788|NCT00908934|Drug|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
75724789|NCT00908934|Drug|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
75724790|NCT00908934|Drug|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
75724791|NCT00908934|Drug|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
75724792|NCT00604500|Drug|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
75877830|NCT03603938|Drug|potassium losartan|treated with bedtime or awakening doses of potassium losartan
75877831|NCT03652116|Drug|Wound infiltration by Bupivacaine|Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
75877832|NCT03652116|Drug|Wound infiltration by Pethidine|Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
75572670|NCT04665167|Behavioral|Body image exposure|Exposure therapy is a key element of evidence-based cognitive behaviour therapy for eating disorders . Body image exposure intervention involves deliberate, planned, and systematic exposure to the body image. Participants will be asked to stand so that they can see their whole body - far enough back. Participants will be asked to look at their bodies on screen. Participants will be continually encouraged by the facilitator for looking at and talking about the body parts.
75572671|NCT04665167|Behavioral|Self-compassion|The self-compassion intervention condition consists of Neff's self-compassion exercises. These exercises are part of the self-compassion intervention condition. Meditation text used in this study is obtained from the following link https://self-compassion.org/category/exercises/.
75572672|NCT04459884|Procedure|mechanical ventilation|mechanical ventilation > 48h
75572673|NCT04665011|Device|Indicor|A simple, non-invasive tool to report pulse response to a Valsalva maneuver
75572674|NCT04665011|Device|Caretaker|non-invasive blood pressure monitor
75572675|NCT04665284|Drug|Empagliflozin|Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
75572676|NCT04665284|Drug|Usual care group|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
75572677|NCT04432974|Device|Automatic closed-loop anesthesia|Total intravenous anesthesia performed with the ACTIVA automatic control system
75877833|NCT03603860|Device|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line
75877834|NCT03602144|Other|Carbohydrate|Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
75572678|NCT04664894|Drug|Sofosbuvir|the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population
75572679|NCT04424394|Device|DualStim Therapy|6 DualStim Therapies over a period of 7 weeks.
75572680|NCT04424394|Biological|Umbilical cord-derived Wharton's Jelly|2 intracavernosal injections over a period of 7 weeks.
75572681|NCT04424394|Other|Saline|2 intracavernosal injections over a period of 7 weeks.
75877835|NCT03602144|Other|Protein|Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
76047734|NCT01655069|Drug|Solifenacin succinate suspension|Oral suspension
76047735|NCT02068599|Drug|TV-45070|TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
76047736|NCT02068599|Drug|Placebo|Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
75572682|NCT04664660|Other|Retrospective analysis of obstetrics outcomes|Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
75572683|NCT04664699|Device|Plethymographic Variability Index|"All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. In the PVI group, a pulse oximetry probe was connected to the fourth finger of the hand that did not have an arterial cannulation. The pulse oximeter was connected to a monitor The Massimo ® pulse oximeter (Massimo Corp., Irvine, CA, USA), which has a module for PVI measurements.~PVI ≥13% indicates volume responsiveness, and PVI < 13% indicates adequate volume"
75572684|NCT04664699|Device|Standard Monitoring|All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. Patients were resuscitated according to mean arterial pressure/ heart rate and urine output.
75572685|NCT04664504|Combination Product|Concurrent Chemoradiotherapy Radiotherapy|50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.
75572686|NCT04664504|Radiation|Short-course Radiotherapy|25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
75572687|NCT04664504|Radiation|Local dose increase of Short-course Radiotherapy|25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
75572688|NCT04664504|Drug|Consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses*3 weeks per course.
75877836|NCT03603782|Dietary Supplement|2.5% protein|2.5%
75572689|NCT04664504|Drug|Adjuvant chemotherapy|2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses*3 weeks per course
75572690|NCT04664504|Procedure|TME|Total mesorectal excision
75426180|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
75572691|NCT04415073|Drug|SNDX-6352|SNDX-6352
75724793|NCT00905658|Dietary Supplement|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
76047737|NCT04708509|Device|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. Patients will be followed for 72 hours after extubation, when the clinical outcome case report form will be completed.
75572692|NCT04415073|Drug|Placebo|Placebo comparator
75572693|NCT00557102|Biological|cetuximab|
75724794|NCT00905658|Procedure|standard follow-up care|Patients undergo standard monitoring
75724795|NCT00906672|Device|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
75572694|NCT00557102|Biological|filgrastim|
76047738|NCT01654601|Drug|DWCZP|Multiple dose
75724796|NCT00906672|Procedure|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
75724797|NCT00627458|Biological|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
75724798|NCT00909168|Drug|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|"FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6"
75724799|NCT00905736|Procedure|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
75724800|NCT00905736|Procedure|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
75426181|NCT04800783|Diagnostic Test|Swallowing ultrasound|Ultrasound assessment of the tongue movement and thickening, the geniohyoid and suprahyoid muscles echogenicity, thickness and thickening, the hyoid bone elevation, and the number of swallowing trial.
75426182|NCT04799899|Behavioral|Adapted MBCT|The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
75426183|NCT04799899|Behavioral|Cardiac Health Enhancement|The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
75724801|NCT00906750|Biological|FluMist|FluMist is a live attenuated intranasal influenza vaccine
75724802|NCT00906750|Biological|Inactivated influenza vaccine|Inactivated influenza vaccine
75724803|NCT00816218|Drug|Pioglitazone|pioglitazone, 45 mg daily
75572695|NCT00557102|Drug|fluorouracil|
75572696|NCT00557102|Drug|irinotecan hydrochloride|
75572697|NCT00557102|Drug|leucovorin calcium|
75572698|NCT04682808|Drug|FCN-338|FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.
75572699|NCT04664543|Other|Free diet|To follow the regular dietary habits with no restriction nor modification.
75572700|NCT04664543|Other|Three days low residue diet|To follow the three days before colonoscopy a diet with low content in fiber or residues.
75572701|NCT04682613|Behavioral|"Experimental: Prevention Program young In Favor of Myself, active teachers"|"Prevention program: young In Favor of Myself, with teacher participation"
75572702|NCT04682613|Behavioral|"Experimental: Prevention Program young In Favor of Myself, no teacher involvement"|"Prevention program: young In Favor of Myself, without teacher participation"
75572703|NCT04664816|Drug|n-3PUFAs Treatment|Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
75572704|NCT04664816|Drug|Placebo Treatment|Placebo orally, twice a day for at least 12 months.
75877837|NCT03603782|Dietary Supplement|protein 5%|5%
75877838|NCT03603782|Dietary Supplement|protein 10%|10%
75877839|NCT03603782|Dietary Supplement|protein 15%|15%
76047739|NCT01654601|Drug|Clozaril|multiple-dose
76047740|NCT01654523|Device|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
76047741|NCT05001113|Procedure|the subxiphoid approach thoracoscopic thymectomy|A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.
76047742|NCT05001113|Procedure|the lateral intercostal approach thoracoscopic thymectomy|"Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces."
76047743|NCT04978649|Drug|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
75572705|NCT04682691|Drug|Erythromycin (400mg)|parturients will receive oral Erythromycin (400mg)
75724804|NCT01562964|Behavioral|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
75572706|NCT04682691|Drug|metoclopramide (10mg)|will be receive oral metoclopramide (10mg)
75724805|NCT01562964|Behavioral|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
75572707|NCT04682691|Dietary Supplement|naturally flavored water|will be receive naturally flavored water
75426184|NCT04795232|Other|COD45|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 27.6 meters and will include two changes of direction of 45 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
75572708|NCT04664348|Other|Posteroanterior mobilization (neutral)|"Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment."
75572709|NCT04664348|Other|Posteroanterior mobilization (extension)|"Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain."
76047744|NCT04978649|Drug|Amlodipine|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
75572710|NCT04682886|Diagnostic Test|diagnosis|there is no intervention diagnosis or treatment for patients
75724806|NCT00819728|Drug|Docetaxel|35mg/m2 IV each week for 4 weeks
75724807|NCT00819728|Drug|Irinotecan|50mg/m2 IV each week for 4 weeks
75426185|NCT04795232|Other|COD90|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 21.2 meters and will include two changes of direction of 90 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
75426186|NCT04789577|Biological|FLU-Q-PAN H7N9 Formulation 1|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
75724808|NCT00906828|Drug|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
75724809|NCT00906828|Drug|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
75724810|NCT00906828|Drug|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
75724811|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
75724812|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
75877840|NCT03603782|Dietary Supplement|A2: Peptamen 1.5 Vanilla without Breakfast|Peptamen withoug breakfast
75877841|NCT03603782|Dietary Supplement|B2: only breakfast (no product)|only breakfast
75877842|NCT03603782|Dietary Supplement|C2: 5% protein with breakfast|C2: 5% protein consumed with breakfast
75572711|NCT04664114|Behavioral|Virtual Reality|Ultrasound images of the fetus in the 28th week of pregnancy of the women in the intervention group were recorded. These images were shown to the woman through virtual reality glasses during the labor. Routine practices in the hospital were made to the women in the control group. VAS (Visual Analog Scale) was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale (POBS) and Perinatal Anxiety Screening Scale (PASS) were administered.
75724813|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
76047745|NCT04978415|Procedure|peribulbar block versus subtenon's block|"Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery."
76047746|NCT02508935|Drug|XARTEMIS XR|XARTEMIS XR [7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)] Extended-Release Tablets
75426187|NCT04789577|Biological|FLU-Q-PAN H7N9 Formulation 2|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.
76047747|NCT02508701|Behavioral|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
76047748|NCT05000333|Other|Self-questionnaire|The study will be proposed to caregivers who work at Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, who agree to answer the questionnaire anonymously
76047749|NCT02507375|Drug|Erlotinib|Erlotinib will be administered as oral tablets.
75426188|NCT04789577|Biological|FLU-Q-PAN H7N9 Formulation 3|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.
75426189|NCT04789577|Biological|AS03B|Participants received two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
75426190|NCT04789577|Biological|AS03A|Participants received two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
75426191|NCT04789577|Drug|Placebo|Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.
75572712|NCT04682418|Device|xvision Spine sytem|pedicle screw placement will be performed using the XVS navigation system
75572713|NCT04664036|Diagnostic Test|ultrasound|ultrasound to check for NAFLD according to Saverymuttu criteria
75572714|NCT04664036|Diagnostic Test|elastography|elastography to compare liver stiffness indices
75572715|NCT04664036|Diagnostic Test|controlled attenuation parameter (CAP)|CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis
75877843|NCT03603782|Dietary Supplement|D2: 5% protein 30 min before breakfast|D2: 5% protein consumed 30 min before breakfast
75426192|NCT04772456|Drug|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) [ 13C]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize [13C]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and [13C]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as [1- 13C]pyruvate, [2- 13C]pyruvate and [1,2- 13C]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body [Koletzko et al., 1997]."
75572716|NCT04664036|Diagnostic Test|FLI|the FLI is a score panel designed to screen for NAFLD
75572717|NCT04664036|Diagnostic Test|FIB-4|the FIB-4 is a score panel designed to screen for significant fibrosis
75572718|NCT04664036|Diagnostic Test|NFS|the NFS is a score panel designed to screen for significant fibrosis
75572719|NCT01209286|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
75572720|NCT05423080|Drug|Bolus injection of remimazolam|Participants in this group are administered 0.2 mg/kg remimazolam via the bolus injection method for 20 seconds during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will administer additional doses of 0.05 mg/kg repeatedly until LOC occurs.
75877844|NCT01946867|Device|NBTXR3 activated by IMRT|
75572721|NCT05423080|Drug|Infusion of remimazolam|Participants in this group are administered remimazolam at a rate of 6 mg/kg/hr via the continuous infusion method during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will escalate infusion dose to 12 mg/kg/hr until LOC occurs.
75724814|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
75877845|NCT01550315|Procedure|Pulsitile Arterial Tonometry (PAT) Protocol|"A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~Continuous recording of pulsatile blood volume responses from both hands will be initiated.~After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
75877846|NCT01550315|Device|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
75877847|NCT01550315|Device|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
75426193|NCT04756609|Procedure|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice|"I- A SARS-CoV2 self-administered questionnaire about SARS-CoV2 symptoms, possibilities of close contacts, risk exposure situations and socio-demographic characteristics will be offered to patients included who are capable of filling it out.~The patient will fill out the questionnaire and hand it in to the nurse caring for him/her.~The nurse, regardless of the answers to the questionnaire, will offer the SARS-CoV2 screening.~A nasopharyngeal swab for SARS-CoV2 will be carried out.~A patient will be considered as symptomatic if he/she presents one or more symptoms listed in the questionnaire.~For symptomatic patients, a SARS-CoV2 for multiplex PCR will be carried out. This analysis takes 75 minutes.~For asymptomatic patients, a RT-LAMP test will be carried out. This analysis takes 5 to 15 minutes."
75572722|NCT04663763|Drug|PD-1 antibody|Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.
75572723|NCT04663763|Drug|Capecitabine|Usage: 1000mg/m2 d1-14 q3w
75572724|NCT04663763|Drug|Oxaliplatin|Usage: 130mg/m2 d1 q3w
75572725|NCT04663880|Other|Exposure to placebo in EEC|Patients are exposed to placebo (saline solution) in the EEC for 4h maximum
75572726|NCT04663880|Other|Exposure to three concentrations of HDM allergen in EEC|Patients are exposed to different concentrations of airborne HDM allergen (Der p1) in the EEC for 4h maximum
75572727|NCT04663880|Other|Exposure to a single concentration of HDM allergen in EEC|Patients are exposed to a single concentration of airborne HDM allergen (Der p1) in the EEC for 4h maximum
75877848|NCT02972658|Drug|Lanabecestat|Administered orally
76047750|NCT02507375|Drug|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
75572728|NCT04663919|Procedure|Bariatric surgery-RYGB|"After the creation of a 15-25-cc gastric pouch from the upper stomach, transection of proximal jejunum 70 cm from Treitz ligament also called alimentary tract and anastomosis of the distal end of jejunum to the gastric pouch, and thereafter, anastomosis of the proximal end of transected jejunum to the distal part of the jejunum at 150 cm below the site of transection (jejunoileal anastomosis)."
75724815|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
75572729|NCT04663919|Behavioral|Dietary intervention|High-calorie medical nutrition program to ensure weight gain
75724816|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
75877849|NCT02853032|Device|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
76047751|NCT05000177|Other|30-minute computer typing task|The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.
75572730|NCT04353102|Drug|YH002|YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
75572731|NCT04663958|Diagnostic Test|Detection / Screening|The patients were followed up in the postoperative care unit. The presence of postoperative pulmonary complications was evaluated, and the time of discharge was recorded. On the 30th day after discharge, patients were called and checked their status in terms of mortality.
75877850|NCT02853032|Device|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
76047752|NCT05000177|Other|30-minute rest|Rest for 30 minutes
75572732|NCT04351737|Drug|Intracanalicular Dexamethasone, (0.4 mg) Insert|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.
75572733|NCT04351737|Drug|Prednisolone Acetate|To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
75572734|NCT04347915|Drug|Clevudine|Clevudine 120mg once a day for 14 days (up to 21 days)
75572735|NCT04347915|Drug|Placebo|Matching Placebo once a day for 14 days (up to 21 days)
75572736|NCT03455361|Procedure|Stark Implant with low primary stability|
75572737|NCT04663685|Other|Exercise program|Participants will start with receiving two 1-on-1 exercise sessions per week. Each session is anticipated to last 30 minutes. As progress is made, participants will be encouraged to exercise independently outside the structured sessions while continuing to receive a 1-on-1 session each week. The individualized exercises are aligned with functional movements to promote personal relevance: balance, pull, squat, push, hinge, lift & carry and calf raise.
75572738|NCT04663685|Other|Nutrition education|Participants will receive a nutrition education booklet and have access to 5 online videos that correspond to key topics in the booklet, including: reading nutrition labels, types of protein, foods containing protein, incorporating protein into meals, spreading protein in meals throughout the day. Participants will attend three 60-minute nutrition seminars led by a dietitian, where the group will review content from the booklet and videos, and discuss personalized strategies for protein intake.
75572739|NCT04663451|Radiation|radioacive iodine therapy|Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
75572740|NCT04185051|Drug|JNJ-67953964|Participants will receive JNJ-67953964 as oral capsules.
75724817|NCT00909402|Drug|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
75724818|NCT00909402|Drug|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
75724819|NCT00909402|Drug|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
75724820|NCT00821366|Behavioral|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
75572741|NCT04185051|Drug|Placebo|Participants will receive matching placebo oral capsules.
75572742|NCT04663412|Other|Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)|Patients diagnosed with vulvar squamous cell carcinoma (FIGO IB stage) underwent bilateral radical vulvectomy, SLN search and removal, and bilateral inguinal lymphadenectomy at the Cannizzaro Hospital Operative Unit of Obstetrics and Gynecology Department (Catania, Italy). 3 ml of indocyanine green (ICG) 0.5 mg/mL was administered in 3 peritumoral injections under general anesthesia to screen the SLN. The images were acquired using an intraoperative infrared camera system, which allowed intraoperative visualization of the SLN. An SLN was identified for each patient. The lymph nodes examined by the pathologist were negative for metastatic localization of the disease. However, patients underwent bilateral inguinofemoral lymphadenectomy, as this procedure is not currently codified as a gold standard for the detection of SLN in vulvar cancer.
75572743|NCT04175028|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
75572744|NCT04663490|Diagnostic Test|Neutrophil to Lymphocyte Ratio|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
75724821|NCT00821366|Dietary Supplement|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
75724822|NCT00821366|Drug|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
75724823|NCT02538120|Other|Microvascular assessment|Microvascular assessment
75877851|NCT02853032|Device|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
75877852|NCT02232087|Drug|Salmeterol|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
75877853|NCT02232087|Drug|fluticasone propionate|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
75572745|NCT04662983|Device|VR-training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different pace and intensity of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
75572746|NCT04119765|Biological|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
75572747|NCT04119765|Biological|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
75572748|NCT04119765|Procedure|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
75426194|NCT04756609|Other|Usual emergency department practice with physician-directed diagnostic testing|The physician offers a SARS-CoV2 test according to current recommendations. The tests are prescribed as a means of diagnosis for patients presenting symptoms suggestive of Covid-19 or as a means of diagnosis for patients requiring hospitalisation for another cause, before their transfer to hospital. Patients will be cared for according to usual procedures of each hospital. Patients tested positive will be asked to fill out the DEPIST-COVID questionnaire. Patients who had not completed it will be contacted by phone to answer the questions over the phone.
75426195|NCT04752826|Drug|BI-1808|BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose [Phase I, Part A] and at Recommended Dose for Part B [Phase I, Part B and Phase IIa] by intravenous (IV) infusions every 3 weeks.
75724824|NCT03862118|Other|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
75724825|NCT02537964|Other|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
75724826|NCT00819884|Drug|AZD1656|Oral suspension
75877854|NCT03168425|Other|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
75724827|NCT00821444|Drug|ziprasidone|40 mg capsule, single dose x 3
75724828|NCT00821444|Drug|B16 Fasted|40 mg tablet, single dose X 3
76047753|NCT02507219|Drug|Ibuprofen|On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
76047754|NCT02483975|Drug|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
76047755|NCT02483975|Drug|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
76047756|NCT02483975|Drug|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
75426196|NCT04752826|Drug|Pembrolizumab 25 Mg/mL Solution for Injection|Pembrolizumab a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
75572749|NCT04119765|Procedure|central pressure measurement|central pressure will be measured thank to the Complior® device
75572750|NCT04663139|Drug|Xla1|Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)
75572751|NCT04663139|Drug|Placebo|Matching placebo
75572752|NCT04095780|Other|Advanced oral hygiene care programme|"Brush teeth with standardized power tooth brush twice a day.~Rinse mouth with chlorhexidine twice a day.~Oral hygiene education"
75572753|NCT04095780|Other|Oral hygiene instruction|Oral hygiene education
75572754|NCT04662788|Drug|NK cells/Combined Monoclonal Antibodies|Each subject receive NK cells/Combined Monoclonal Antibodies
75572755|NCT04088994|Other|AOT Pathological Model Experimental Group|The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.
75724829|NCT00821444|Drug|B16 Fed|40 mg tablet, single dose X 3
75877855|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
75877856|NCT00004445|Procedure|Surgery|
75572756|NCT04088994|Other|AOT Healthy Model Control Group|The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
75572757|NCT04065516|Procedure|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
75877857|NCT00004445|Device|IRS-8|
76047757|NCT02483975|Drug|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
75877858|NCT01380015|Other|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
75572758|NCT04037007|Procedure|Fistulotomy - High experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
75572759|NCT04037007|Procedure|Fistulotomy - Low experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
75572760|NCT04037007|Procedure|Conventional (guidewire) cannulation- High experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
75572761|NCT04037007|Procedure|Conventional (guidewire) cannulation - Low experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
75426197|NCT04749368|Drug|BRII-835 (VIR-2218)|BRII-835 (VIR-2218) will be given by subcutaneous injection
75572762|NCT04010253|Device|SIMEOX|Instrumental airway clearance by the medical device SIMEOX
75572763|NCT04010253|Other|Autogenic drainage|Manual aiway clearance by autogenic drainage
75877859|NCT01380015|Other|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
75877860|NCT03603704|Drug|LY3209590|Administered SC
75426198|NCT04749368|Biological|BRII-179 (VBI-2601) with IFN-α|BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
75877861|NCT03603704|Drug|Placebo|Administered SC
75877862|NCT03652584|Other|High Protein Diet|
75426199|NCT04749368|Biological|BRII-179 (VBI-2601)|BRII-179 (VBI-2601) will be administered by intramuscular injection
75426200|NCT04737382|Diagnostic Test|biopsy|The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard
75426201|NCT04737382|Diagnostic Test|ctDAN analysis|ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.
75426202|NCT04733183|Drug|Dacarbazine|Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
75426203|NCT04733183|Drug|onfekafusp alfa|L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
75426204|NCT04732884|Device|Smartsens, Gelenic AG; with biofeedback|The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
75426205|NCT04732884|Device|Smartsens, Gelenic AG; without biofeedback|Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
75426206|NCT04732624|Drug|Oral Rehydration Solution|Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
75426207|NCT04732624|Drug|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
75426208|NCT04722133|Drug|HERZUMA+mFOLFOX|Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
75877863|NCT03652584|Other|Control Diet|
75877864|NCT03330561|Drug|PRS-343|PRS-343
75877865|NCT03603626|Drug|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
75572764|NCT04662866|Drug|Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg|Comparison of 4 different antihyperglycemic drugs
75426209|NCT04701437|Behavioral|Peer mentor|Peer mentors will contact participants within 72 hours of enrollment to discuss the early release period, gauge their readiness for HCV treatment, and identify ancillary needs. They will also accompany the participant to their first medical appointment with an HCV provider and any future appointments if requested by the participant. Peer mentors will offer participants social support throughout the 6 months they are enrolled in the study.
75426210|NCT04701437|Behavioral|Standard of care|Passive referral to a HCV provider
75426211|NCT04700046|Drug|Mexiletine 167 mg|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg) immediate release, oral capsules.
75724830|NCT00909558|Biological|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|"The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.~The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks."
75426212|NCT04700046|Drug|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
75426213|NCT04687956|Procedure|LYMPHA|Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
75426214|NCT04687956|Procedure|control|In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
75426215|NCT04664829|Drug|Bexarotene|Administered orally once a day. Starting dosage: 200mg/m^2
75426216|NCT04664829|Drug|Capecitabine|Administered orally twice a day. Dosage: 1000mg/m^2
75724831|NCT00819962|Drug|Bupivacaine|Local anesthetic
75877866|NCT03603626|Drug|Placebo oral capsule|Placebo administered 1 hour before surgery
75877867|NCT03652038|Drug|TD-8236|Study drug to be administered via inhaler device
75572765|NCT04662476|Dietary Supplement|Vitamin D3|Vitamin D3 supplement
75877868|NCT03652038|Drug|Placebo|Placebo to be administered via inhaler device
75572766|NCT04008927|Diagnostic Test|HCV screening|All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
75426217|NCT04651400|Drug|Antithrombin III|Antithrombin III
75724832|NCT00819962|Other|TAP|
75724833|NCT00927342|Other|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
75724834|NCT00927342|Other|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
75724835|NCT00542919|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
75724836|NCT03861962|Other|"DNA sequencing called new generation (or NGS)"|"Redo HLA-typings with a method exploring all the genes (add DQA1, DRB3 / 4/5, DPB1 and DPA1), i.e. DNA sequencing called new generation, when this has not been done after the graft as part of the standard care"
75724837|NCT00820118|Drug|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~atazanavir : 300 mg/d~ritonavir : 100 mg/d~abacavir 600 mg and lamivudine 300 mg : once a day~tenofovir 245 mg and emtricitabine 200 mg : once a day"
75724838|NCT00927498|Drug|conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
75877869|NCT03651960|Other|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
75877870|NCT01377909|Drug|statin|daily statin orally for 48 weeks
75426218|NCT04651374|Device|geko T3|The device stimulates the peroneal nerve.It will be applied for the entire duration of ICU stay and replaced once every 24 hours.
75426219|NCT04650984|Drug|Onfekafusp alfa|Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
75426220|NCT04650984|Drug|Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
75426221|NCT04649502|Combination Product|Metformin|Metformin in combination with doxycycline
75426222|NCT04637087|Other|Atrial fibrillation risk electronic health record alert|Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
75877871|NCT04053660|Procedure|Non-surgical periodontal treatment|Mechanical non-surgical treatment were performed
75877872|NCT01731522|Behavioral|EF condition|
75572767|NCT04008927|Diagnostic Test|Diagnosis of hepatitis C|HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL). In addition a measure of the liver stiffness will be performed.
75426223|NCT04632576|Other|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will given.
75426224|NCT04629651|Drug|Captopril|Oral, to be administered per the dose escalation scheme.
75426225|NCT04614103|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.
75426226|NCT04614103|Biological|LN-145|A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.
75572768|NCT04008927|Drug|HCV treatment|Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
75572769|NCT04662437|Diagnostic Test|Venous blood was collected for biochemistry testing|From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
75572770|NCT03986424|Drug|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
75572771|NCT03986424|Drug|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg to be taken orally, twice daily
75572772|NCT04662593|Behavioral|Whole Health Program|A mind-body-spirit intervention to improve health and well-being including weight loss.
75572773|NCT03974451|Device|IOL implantation experimental|Implantation of of PhysIOL trifocal FineVision® POD F IOL
75877873|NCT05463159|Other|Transcutaneous electrical nerve stimulation|All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
75572774|NCT03974451|Device|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
75572775|NCT04661969|Procedure|Surgery|(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
75572776|NCT03943368|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
75572777|NCT03899181|Device|Translumbosacral Neuromodulation Therapy (TNT)|A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.
76047758|NCT02047227|Drug|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
75426227|NCT04614025|Biological|PLX-PAD|PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells
75426228|NCT04604444|Behavioral|Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech|Intensive Comprehensive Aphasia (ICAP) and Apraxia of Speech Program
75724839|NCT00927498|Drug|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
75724840|NCT00820196|Drug|Nexagon®|
75426229|NCT04601857|Drug|futibatinib and pembrolizumab|Patients will receive futibatinib at an oral dose of 20 mg daily and pembrolizumab at an intravenous dose of 200 mg every 3 weeks
75572778|NCT03899181|Other|Sham TNT Therapy|This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.
75724841|NCT00820196|Drug|Nexagon® vehicle|
75877874|NCT02972502|Drug|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
75877875|NCT02972502|Drug|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
75426230|NCT04601415|Diagnostic Test|ECG from handheld device|Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
75426231|NCT04594993|Device|INFINITY™ with ADAPTIS™ Technology Total Ankle System|Total Ankle Replacement
75426232|NCT04591951|Behavioral|I2-ART|Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
75426233|NCT04591951|Other|Usual care|Care as usual
75426234|NCT04591405|Biological|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 360 children (5-11 years old) on 0 day
75426235|NCT04591405|Biological|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
75426236|NCT04591405|Biological|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 5640 children (5-11 years old) on 0 day
75426237|NCT04591405|Biological|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
75426238|NCT04585243|Device|Evalyn Brush|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
75426239|NCT04583878|Diagnostic Test|Blood draw (Visit 1)|Labs will be drawn at Visit 1, also referred to as screening (within 60 days of diagnosis) with the standard of care labs drawn.
75572779|NCT03883230|Diagnostic Test|GLYWD|As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
75572780|NCT00557180|Drug|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
75572781|NCT00557180|Drug|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
75572782|NCT00557180|Drug|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
75572783|NCT03818724|Device|CoolLoop® cryoablation system|Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System
75724842|NCT00909636|Drug|ABT-333|See arm description for more information
75724843|NCT00909636|Drug|Placebo|See arm description for more information
75724844|NCT05711355|Procedure|Use of Platelet-Rich Plasma after meningomyelocele sac repair|Wound healing with the use of Platelet-Rich Plasma after surgical meningomyelocele pouch repair
75724845|NCT05711355|Procedure|meningomyelocele sac repair|meningomyelocele sac repair without Platelet-Rich Plasma
75724846|NCT00816296|Other|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
75724847|NCT00816296|Other|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
75877876|NCT02972502|Other|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
75877877|NCT02972502|Drug|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
75877878|NCT05462067|Device|AT LARA IOL|EDOF IOL for treatment of cataract
75877879|NCT05462067|Device|AT LISA Tri IOL|Trifocal IOL for treatment of cataract
75572784|NCT00557219|Drug|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
75572785|NCT00557219|Drug|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
75572786|NCT00557219|Drug|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
75572787|NCT00539877|Drug|irinotecan|"Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment."
75572788|NCT03798405|Behavioral|Proactive Analgesic Inpatient Narcotic-Sparing|Medications suggested to the physician with enhanced ease of ordering.
75572789|NCT03796338|Device|Sleep Profiler|Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
75572790|NCT00557336|Drug|somatropin|
75724848|NCT00816296|Other|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
75724849|NCT00816296|Other|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
75877880|NCT05461911|Dietary Supplement|Nutrison Advanced Cubison|(20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support
75426240|NCT04583878|Diagnostic Test|Blood draw (Visits 2 and 3)|Labs will be drawn at Visit 2 (12 weeks post-diagnosis with a range of 10-16 weeks) and Visit 3 (12 months ± 30 days) for research purposes only and will be collected at Children's Medical Center and processed at UT Southwestern Medical Center.
75426241|NCT04578327|Device|Prosthetic hand|Different types of conventional prosthetic limbs will be used by subjects.
75426242|NCT04578327|Procedure|Peripheral Nerve Interface|Different types of peripheral nerve stimulation will take place
75724850|NCT00909714|Device|DC-Stimulator to apply tDCS|Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
75724851|NCT00909714|Device|DC-Stimulator to apply Sham tDCS|Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
75724852|NCT00816374|Other|Reading materials and discussions|"We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:~The American Cancer Society~The American Academy of Dermatology~The Skin Cancer Foundation~The pamphlets contain information about ways to reduce risk for skin cancer including:~Sun protection practices~Risk factors for melanoma~Information about what melanoma looks like~How to do skin self-examinations~There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets."
75724853|NCT00816374|Other|Reading materials and discussions|"We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:~Melanoma and skin cancer protection guidelines~The benefits of skin screening practices~Ways to protect yourself from the sun~In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets."
75572791|NCT00539916|Behavioral|Regular orange juice consumption|600 mL /day.
75572792|NCT04661618|Device|Gym Tonic programme and Gym equipment|12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
75572793|NCT00539955|Behavioral|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
75572794|NCT00539955|Behavioral|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
75572795|NCT04661696|Drug|Paclitaxel (albumin-bound)|The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
75572796|NCT03775980|Device|Emprint Microwave Ablation System|Microwave Ablation of colorectal liver metastases
75572797|NCT04661462|Other|online survey|We invite volunteers after COVID-19 to participate in an online survey.
75572798|NCT03766191|Behavioral|Food Ads|Exposure to foods ads embedded in an age-appropriate TV program
75724854|NCT00816374|Other|Questionnaires|"Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~knowledge of melanoma~current and past skin cancer screening practices~current and past sun protection practices~attitudes about skin cancer and sun protection~feelings about relative's melanoma diagnosis and treatment"
75724855|NCT00906906|Device|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
75724856|NCT00159913|Drug|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
75724857|NCT00159913|Drug|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
75724858|NCT00159913|Drug|Placebo|oral; 3 times a day(TID)
75572799|NCT03766191|Other|Non-food Ads|Exposure to non-food ads embedded in an age-appropriate TV program
75572800|NCT04661228|Diagnostic Test|Composite International Diagnostic Interview 5th version (CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders in the general population
75572801|NCT06087536|Drug|OMN6|"Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days"
75572802|NCT06087536|Drug|Placebo|3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
75724859|NCT00159913|Drug|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
75724860|NCT05498259|Drug|Orelabrutinib|Orelabrutinib 150mg qd PO
75724861|NCT05498259|Biological|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle
76047759|NCT02047227|Drug|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
75572803|NCT06087523|Other|Multidisciplinary discussion|"Multidisciplinary discussion: Participants will be diagnosed and categorized in regards of pulmonary disease on basis of medical record, PFT, HRCT, and questionnaires.~PFT: Participants will undergo body plethysmography (with diffusion) and six-minute walk test.~Analysis of circulating biomarkers: We will store glasses with serum and glasses with plasma and analyse them for circulating biomarker.~Questionnaires: Participants will complete Danish versions of three questionnaires.~Saint George's Respiratory Questionnaire Interstitial Pulmonary Fibrosis~Systemic Lupus Activity Questionnaire~Lupus Impact Tracker~Review of medical record and clinical investigation with focus on SLE and pulmonary disease.~Thoracic and diaphragmatic ultrasound: The participants will undergo a 14 zone protocol, and be evaluated for b-lines and pleural thickening/irregularities. Diaphragm function will be evaluated according to the M-mode method, area method, and for thickening."
75724862|NCT05498259|Drug|CHOP-like Regimen|cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
75724863|NCT00820274|Procedure|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
75877881|NCT01569477|Behavioral|Incentives for abstinence and treatment engagement|Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
75877882|NCT01569477|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
75877883|NCT03601988|Radiation|Concurrent chemo-radiotherapy|Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy
75877884|NCT03601988|Drug|Chemotherapy|Chemotherapy group receive 8 cycles of XELOX.
75877885|NCT03606590|Device|NovoTTF-100L(P) device|Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
76047760|NCT02047227|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
75572804|NCT06087471|Dietary Supplement|Intervention snack|The intervention snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
75572805|NCT06087471|Dietary Supplement|Control Snack|The control snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
75724864|NCT00821600|Drug|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
75724865|NCT00987207|Drug|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
75724866|NCT00987207|Other|No injection|No cyclosporine A is administered before aortic cross-declamping.
75877886|NCT03606590|Drug|Sorafenib|Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
75877887|NCT02971800|Drug|sodium fluorescein injection 10%|
75877888|NCT03601910|Drug|D308 10mg Tab.|D308 10mg Tab.1T single oral administration under fasting condition
76047761|NCT02483585|Drug|Erenumab|Administered once a month by subcutaneous injection
76047762|NCT02483585|Drug|Placebo|Administered once a month by subcutaneous injection
75877889|NCT03601910|Drug|CKD-380 10mg Tab.|CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
75877890|NCT03163667|Drug|Placebo|oral tablets
76047763|NCT02046993|Behavioral|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
75572806|NCT06087289|Drug|KAND567|"KAND567 is a drug in capsule and is intended to be orally administered approximately every 12 hours (±1 hour) with an initial loading dose on Day 2 of two times the dose specified for that dose group (e.g., 2 x 250, 2 x 375, 2 x 500, or 2 x 625 mg KAND567, depending on the dose group; in Part 2, this is the RPIID), followed by a KAND567 dose (Day 2, evening dose) that corresponds to the given dose level. On Days 3 to 7, the subjects will be orally administered the specified KAND567 dose (e.g., 250, 375, 500, or 625 mg BID, depending on the dose group; in Part 2, this is the RPIID).~During the second week of dosing (Days 8 to 14) in Part 1 and Part 2, the subjects will be orally administered KAND567 at a dose of 250 mg BID. One treatment cycle is defined as a 21-day period, and each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression)."
75572807|NCT06087289|Drug|Carboplatin|Carboplatin will be administered i.v. according to standard of care at a dose of AUC 5. One cycle is defined as a 21-day period with chemotherapy given on Day 1. Each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression). The carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC 5 × (GFR + 25). GFR should be calculated using the Cockcroft-Gault formula. The maximum carboplatin dose is based on a calculated GFR that is capped at 125 mL/min for subjects with normal renal function.
75572808|NCT06087263|Drug|Regorafenib|Given by PO
75572809|NCT06087224|Other|Teleneonatology|Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
75572810|NCT06087211|Drug|Duloxetine and magnesium sulphate|this group will receive Duloxetine 30 mg orally and an intravenous (IV) infusion of magnesium sulphate 50mg/kg mixed with 200ml normal saline (NS) 1 hour before surgery
75572811|NCT06087211|Drug|Duloxetine|this group will receive Duloxetine 30 mg orally and 200ml NS infusion 1 hour before surgery
75572812|NCT06087211|Drug|placebo|will receive placebo capsule and an IV infusion of 200ml NS 1 hour before surgery
75572813|NCT06087185|Behavioral|Mindful Eating|Mindful Eating practices will be taught during a weekly meeting lasting 150 minutes and individuals will be encouraged to integrate the practices learned into their daily lives, for at least 15 minutes a day, being progressively integrated into the other practices that will be taught in subsequent weeks. There will be a WhatsApp group with reminders during the week and audio for guided practice.
75572814|NCT06087185|Behavioral|Video Group|"Composed of 5 videos sent weekly produced by trained professionals. The topics discussed will be relevant to the management of anxiety in general and lifestyle changes.~Video 1: Psychoeducation of anxiety. Video 2: Healthy eating. Video 3: Sleep hygiene. Video 4: Physical activity. Video 5: Substance use. This protocol used as a control was effective as a Psychoeducation Group in improving anxiety symptoms in patients with generalized anxiety disorder."
75724867|NCT04044326|Procedure|The Solero Microwave Ablation|The Solero Microwave Ablation system (Angiodynamics Ltd, USA) with a single microwave applicator operating at a 2.45 GHz will be used to perform MWA
76047764|NCT02046993|Behavioral|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
76047765|NCT02101983|Drug|Cytosine Arabinoside|
76047766|NCT04974593|Other|low fat diet|A trained dietitian will provide instruction of the LFD according to standard practice.
75724868|NCT00604188|Drug|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
75724869|NCT00604188|Drug|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
75724870|NCT03913377|Device|Spectacles|Subjects' own habitual spectacles
75724871|NCT03913377|Device|ACUVUE OASYS®1-Day with HydraLuxe™ Technology|Test 1
75724872|NCT00820352|Drug|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
75877891|NCT03163667|Drug|CB-839|oral tablets
75877892|NCT03163667|Drug|everolimus|oral tablets
76047767|NCT04974281|Combination Product|PD-1 and Lenvatinib Plus TACE|PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE )： Patients were recommended to receive TACE once every 6 weeks. Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.
75877893|NCT03651570|Device|PTSD Coach|PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.
76047768|NCT02482805|Behavioral|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
76047769|NCT02503865|Drug|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
75724873|NCT00820352|Drug|placebo|placebo twice a day for 12 weeks
75724874|NCT00927654|Drug|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
75724875|NCT00927654|Drug|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
75426243|NCT04571502|Other|CareHeroes|CareHeroes (CH) is IT that addresses lack of caregiver support and education about ADRD care that often result in depression, burden, and low caregiving self-efficacy. The CH intervention provides caregivers with electronic and video-based educational materials, links to services, and self-assessments for depression and burden that offer feedback. It also allows the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the provider. The clinical trial evaluates the impact of the addition of an AAC interface (e-communication board) to CareHereos that relies on touchscreen technology, pictures, and text to support PWD with communication deficits so that the PWD can engage and communicate about preferences and experiences with the caregiver and provider about their daily and clinical care. The minimal intervention group will only have access to a paper version of the AAC.
75724876|NCT05709327|Other|Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)|Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
75877894|NCT03651570|Behavioral|Game application|This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
75877895|NCT03603548|Drug|Envarsus|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
75426244|NCT04558931|Drug|CellProtect|In vitro expanded and activated autologous NK cells
75877896|NCT03603548|Drug|Advagraf|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
75426245|NCT04558931|Drug|Isatuximab|Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
75426246|NCT04557085|Drug|Cenobamate|Cenobamate tablets
75426247|NCT04557085|Drug|Placebo|Matching placebo tablets
75572815|NCT06087172|Diagnostic Test|Six Minutes Stepper Test (6MST)|Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
75572816|NCT06087159|Behavioral|mHealth Toolkit for Wellness & Empowering Lives of School Community (mWEL)|mWEL-App is a preventive intervention tool for teachers and parents as a self-help support. It integrates three key mental health presentive service functions: i) comprehensive screen to assess mental health (anxiety, depression), stress, and related contextual risks; ii) a tailored strength and weakness profile/report with recommendations to promote self-awareness and mental health knowledge; and iii) tailored evidence-based strategies and additional support and clinical resources to improve skills in stress management, emotion regulation, and maintain mental wellness. mWEL will be designed as a self-administered tool. Participating parents and teachers can access to mWEL app after they sign up for an account. Intervention participants will have access to the App anytime within a 3-5 month study period.
75572817|NCT06087094|Drug|HRS-7450 ；Placebo|HRS-7450 or Placebo
75724877|NCT02550704|Procedure|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
75426248|NCT04555694|Drug|Cyclosporine|Used to increase tear production in patients who have dry eye caused by inflammation
75426249|NCT04555694|Drug|Loteprednol Etabonate|Used to treat inflammation of the eye
75877897|NCT03651492|Behavioral|questionnaire administration|All the patients will be administered the Pittsburgh Questionnaire after completion of ABPM.
75877898|NCT03954782|Drug|Nintedanib 150 mg and 100 mg soft capsules|Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.
75877899|NCT03954782|Drug|Oral treatment of placebo soft capsule|Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
75877900|NCT01330199|Other|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
75426250|NCT04555694|Drug|Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert|Used to treat inflammation of the eye
75426251|NCT04541667|Other|Air|Air will be used for luminal inflation.
75426252|NCT04541667|Other|Carbon Dioxide|Carbon dioxide will be used for luminal inflation.
75426253|NCT04537871|Procedure|Bioelectric Impedance Analysis|Undergo bioelectric impedance analysis
75426254|NCT04537871|Procedure|Biospecimen Collection|Undergo collection of blood samples
75426255|NCT04537871|Procedure|Cardiopulmonary Exercise Testing|Undergo cardiopulmonary exercise test
75426256|NCT04537871|Procedure|Echocardiography|Undergo echocardiogram
75426257|NCT04537871|Procedure|Physical Performance Testing|Undergo physical function tests
75426258|NCT04537871|Procedure|Pulmonary Function Test|Undergo pulmonary function test
75572818|NCT06087068|Drug|Thyroxine|The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
75572819|NCT06087055|Drug|GST-HG171/Ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
75572820|NCT06087055|Drug|Itraconazole|Administered orally once daily for 9 days from Days 8 through 16
75724878|NCT00927732|Drug|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
75572821|NCT06087055|Drug|GST-HG171/Ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 12 through Day 14
75572822|NCT06087042|Diagnostic Test|serum and unstimulated salivary samples|"Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC"
75572823|NCT06087016|Other|Urine vibrational analysis|Urine vibrational analysis
75572824|NCT06087003|Drug|Basiliximab Injection|As an induction treatment for kidney transplantation
75572825|NCT06087003|Drug|rabbit ATG|As an induction treatment for kidney transplantation
75572826|NCT06086990|Device|Contigo Application|Contigo, a smartphone app, focuses on two main goals: monitoring cancer patients for early signs of drug toxicity and offering educational content to empower them in managing clinical challenges linked to their diagnosis and treatment. Monitoring involves patients inputting experiences via oncology-related questionnaires, with weekly checks for chemotherapy toxicity using a validated questionnaire (PRO-CTCAE). Severe cases trigger alerts, while milder ones receive educational guidance. Data collected is shared with healthcare providers. Educational content, backed by scientific evidence and expert collaboration, covers cancer-specific topics and healthcare processes to enhance patients' self-awareness and self-care practices.
75572827|NCT06086925|Drug|Black Raspberry|Each BRB contains 1 gram of black raspberry powder equal to roughly 6 black raspberries.
75426259|NCT04537871|Other|Questionnaire Administration|Ancillary studies
75572828|NCT06086886|Drug|BMS-986454|Specified dose on specified days
75572829|NCT06086886|Other|Placebo|Specified dose on specified days
75572830|NCT06086860|Other|Mulligan mobilization with dry needling.|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
75426260|NCT04537871|Procedure|Ultrasound|Undergo musculoskeletal ultrasound
75426261|NCT04527003|Drug|Cannabidiol (CBD) Extract|Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.
75877901|NCT03651726|Drug|THX-110 (dronabinol plus PEA)|2.5 mg dronabinol capsules and 400 mg PEA tablets
76047770|NCT02503865|Dietary Supplement|"Analimentary detoxication"|Vegetable and salt diet
75426262|NCT04527003|Drug|Norethindrone Acetate|Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
75426263|NCT04527003|Other|Placebo|a substance or treatment which is designed to have no therapeutic value
75426264|NCT04515797|Drug|Glecaprevir and Pibrentasvir|4 weeks of treatment starting within 24 hrs of kidney transplant
75426265|NCT04511026|Drug|Lymphoseek|Radioactive diagnostic agent
75426266|NCT04511026|Device|Single Photon Emission Computed Tomography (SPECT)|Imaging test
75426267|NCT04511026|Drug|Indocyanine Green (ICG)|Cyanine dye used in medical diagnostics manufactured by Akorn Inc.
75572831|NCT06086847|Other|progressive resistant exercises|"Group A (Experimental Group):~• Warm up Exercise + stretching Exercise (upper and lower extremity) + progressive resistance exercises Warm up Exercise (for 5 min) Stretching (upper and lower extremity)~3. Progressive Resistance exercises:~Leg press :( dual leg press): Leg press target the~Quadriceps or quads .but they also work your Hamstrings.~Leg curls (dual leg curls):~Leg curls Target the hamstrings and Calf muscles Leg Extension~The Muscles worked:~Rectus femoris~Vastus lateralis~Vastus medialis~Vastus intermedius~4. Arm lat pull (dual arm lat pull):~Back extension (lumber extension):"
75426268|NCT04511026|Device|Neoprobe Gamma Detection System NPB11L(Model1102)|Neoprobe Gamma Detection System NPB11L(Model1102) made by Devicor Medical Products, Inc.
75426269|NCT04510051|Drug|Cyclophosphamide|Given IV
75426270|NCT04510051|Drug|Fludarabine|Given IV
75426271|NCT04510051|Biological|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given intraventricularly
76047771|NCT01623531|Drug|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
76047772|NCT02503787|Device|Spinal Cord Stimulation (SCS)|SCS programming options
75426274|NCT04501185|Device|total hip arthroplasty|The indication for total hip arthroplasty is mainly osteoarthritis.
75426275|NCT04498208|Behavioral|Physical Prehabilitation|First, an evaluation of patient's aerobic capacity, functional mobility, functional strength, ambulation, fall risk, and overall mobility will be done by a trained member of the research team. Based on their functional level and preexisting conditions, therapeutic exercises will be recommended to optimize their strength, endurance, flexibility, and functional mobility in preparation for surgery. Decisions about the interventions are based on the assessment, individual patient characteristics, environmental factors, surgical type, and monitoring of the client's response and progress. Weekly sessions are 30-45 minutes long to monitor the client's response and progress their program. Based on their response to exercise (evaluated also by 2 apps: Timed Walk App and Smart Metronome & Tuner App), re-evaluation via the assessments described above, change their plan of care (alter frequency, resistance, exercises) or discontinuation of treatment could be decided.
75426276|NCT04498208|Behavioral|Stress Reduction Prehabilitation|Participants will have the opportunity to learn techniques for mindfulness that have been established to reduce stress and assist with pain management with a member of the research team. Patients will be offered to listen to audio recording of relaxation sessions. Each session contains a relaxation technique that the patient practices while listening to the recording. Then the technique is used the next as a baseline to introduce a new technique more advanced. For some patients who struggle with the techniques the program will be adapted. Patients will choose 2 or 3 techniques and work on them.
75724879|NCT00927732|Drug|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
75724880|NCT04423575|Other|Outpatient health care pathway|A surgical procedure performed as an outpatient procedure means that the patient leaves the hospital before 8pm the same day. The surgery is identical but the standard care pathway is reinforced to insure a safe return to home.
75724881|NCT00227539|Drug|cisplatin|
75724882|NCT00227539|Drug|pemetrexed disodium|
75724883|NCT00227539|Procedure|adjuvant therapy|
76047773|NCT04943471|Other|Big Five Questionnaire, Patient health questionnaire-9 and generalised anxiety disorder -7 questionnaire|Questionnaire
75572834|NCT06086808|Other|Resistance Training|A resistance training program will be used as a progressive, high-intensity protocol. The training stimulus will be provided using free weights. The exercises will consist of bench presses, biceps curls, triceps extensions, Latissimus Dorsi pull-down exercises, hamstring curls, and calf raises. The intensity of the training stimulus will be at a working range of 6 to 8 repetitions (2 sets). The training stimulus will subsequently be increased using the 7-RM (repetition maximum) method when 2 sets of 6 to 8 repetitions are completed with proper form and without discomfort. Other key strength exercises will include mini-squats, mini-lunges, and lunge walks. The number of sets completed and the load lifted for each exercise will be recorded for each participant in every class.
75724884|NCT00227539|Procedure|therapeutic conventional surgery|
75877902|NCT03651726|Drug|Placebo|Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
76047774|NCT02482571|Device|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from ~21% (room air) to ~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
76047775|NCT02481947|Drug|BLI400 Laxative|21 gm BLI400 powder
75426277|NCT04498208|Behavioral|Cognitive Prehabilitation|Cognitive prehabilitation will consist on the daily use of Lumosity training program, an already existing free app built to increase memory skills. The program proposed by Lumosity is tailored to each patient. The use of Lumosity will be monitored at each in-person session. Patients will be expected to complete at least three 5-minute sessions of Lumosity training per day.
75426278|NCT04498208|Behavioral|Nutrition Prehabilitation|Nutrition prehabilitation will involve transitioning the patient to the Mediterranean diet with targets regarding hydration and the proportion of fruits, vegetables, whole grains, and healthy fats the patient will consume in a given day. This nutritional program is flexible, and it allows for specific physician and nutritionist-recommended dietary needs to be incorporated. The patient is also given tools to encourage success in healthier eating, including recipes, sample menus, healthy restaurant options, meal kit options, and local CSA box options
75426279|NCT04494347|Procedure|MitraClip TMVR and Watchman LAAO|The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
75426280|NCT04480463|Drug|SCD411|IVT (intravitreal) injection
75426281|NCT04480463|Drug|Aflibercept|IVT injection
75724885|NCT00227539|Radiation|fludeoxyglucose F 18|
75724886|NCT00816530|Device|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density > 50% is confirmed by routine digital screening mammography, ABUS will be performed.
75724887|NCT00927966|Drug|RAD001|Taken orally once a day.
75724888|NCT00927966|Drug|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
75724889|NCT00227305|Drug|quetiapine fumarate|Oral dosing, flexible dosing
75724890|NCT00720941|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
75724891|NCT00720941|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
76047776|NCT02481947|Drug|Lubiprostone|24 mcg capsule bid
76047777|NCT02503085|Drug|Nurofen for Children®|
76047778|NCT02503085|Drug|Algifor Dolo Junior®|
76047779|NCT02481869|Biological|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
76047780|NCT02481869|Drug|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
76047781|NCT02502149|Biological|rFVIIIFc|As per arm description
76047782|NCT02480621|Drug|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
76047783|NCT02046603|Drug|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
75426282|NCT04470609|Biological|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
76047784|NCT02046603|Drug|DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
76047785|NCT02046603|Drug|Oral Corticosteroids|Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
75572835|NCT06086808|Other|General Fitness and Toning|The general fitness and toning program will consist of stretching exercises, range-of-motion exercises, basic core-strengthening exercises, balance exercises, and relaxation techniques. Key balance exercises will include tandem stand, tandem walking, and single leg stance (eyes opened and closed). No additional loading (e.g., hand weights or resistance bands) will be applied to any of the exercises. This group will serve to control for confounding variables such as physical training received by traveling to the training centers, social interaction, and changes in life style secondary to study participation.
75572836|NCT06086782|Other|autogenic inhibition|Group 1 will receive AI-MET with conventional treatment. AI include stretching of the affected muscle and performing isometric contraction with 50% of the total patient's effort in the same muscle that will being stretched and position hold for 10 seconds, with 5 seconds of rest after every repetition. This procedure will repeat 5 times.
75572837|NCT06086782|Other|reciprocal inhibition|Group 2 receive RI-MET with conventional treatment. The RI also include stretching of the affected muscle but contrary to AI, isometric contraction of the antagonist muscles with the 50% of total patient's effort will follow. This position holds for 10 seconds, while agonist's muscle will still in the stretched position, with 5 seconds of rest after every repetition. This procedure will repeat 5 times too.
75572838|NCT06086769|Device|High flow nasal canula|Measurement of diaphragm thickening fraction, respiratory rate and esophageal pressure swing with calculation of diaphragmatic pressure-time product without the use of HFNC and with the use of HFNC at 20 and 40 Liters per minute
75572839|NCT06086743|Other|Experimental Group|This group will perform 10 minutes of same warm up exercises. After warm up participants will perform 4 resistance exercises with induced EMS. The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises. the intensity of EMS would be 100A and it would remain same throughout training session. The current administered would be galvanic current. Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
75572840|NCT06086743|Other|Control Group|Group B (Control group)will perform 10 minutes of same warm up exercises (Arm swings, jogging on the spot, Walks on treadmill). Group B will perform same 4 resistance exercises without EMS. These 4 exercises include Bicep curls, Triceps dips, Quadriceps chair and squats.The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises and the participants will be instructed, not to perform any kind of exercise during this period.Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
75572841|NCT06086678|Other|Conventional physical therapy|"Deep breathing exercise.~Diaphragmatic breathing exercise.~Pursed lip breathing exercise."
75724892|NCT05704335|Other|Questionnaire administration|A trained physician will administer a structured questionnaire
75724893|NCT00821756|Behavioral|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
76047786|NCT02046603|Drug|Methotrexate|Methotrexate per investigator's discretion.
75724894|NCT00924222|Drug|Sevoflurane|Sedation with sevoflurane
75724895|NCT00924222|Drug|Propofol|Sedation on intensive care unit with propofol
75724896|NCT03866642|Device|Cadence Total Ankle Replacment|Cadence Total Ankle prosthesis
75724897|NCT00987285|Behavioral|CASM +|Computer Assisted Self Management plus Social Support
75724898|NCT00987285|Behavioral|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
75724899|NCT03972319|Dietary Supplement|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
76047787|NCT01885078|Drug|Baricitinib|Administered orally
76047788|NCT01885078|Drug|Placebo|Administered orally
76047789|NCT02046369|Drug|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
76047790|NCT02046369|Drug|Placebo|Placebo Comparator once daily
76047791|NCT02101359|Drug|T2380|200 microlitres of T2380 will be administrated intracamerally
76047792|NCT02101359|Drug|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
75572842|NCT06086678|Other|Hydrotherapy|"Water walking exercise.~Forward lunges exercise.~Single leg balance exercise.~Side stepping exercise.~Push ups exercise.~Standing knee lifts exercise."
75572843|NCT06086678|Other|Aerobic exercise|Aerobic exercise in form of treadmill training when each child was standing on the treadmill, should be ensure that this standing in an upright position, and according to each child, the therapist corrected the height of the handrails. Ask the child to keep looking forwards along the walking on the treadmill aiming to encourage the setting of walking free. The treadmill training would be completed for each child when the child completes three stages in 1-min training cycles. First stage: the child grasped on to the rails with both hands in first 15 s of every 1-min. Second stage: the child grasped on to the railings with one hand in the second 15 s. And final stage: the child didn't grasp on to the railings in last 30 s. Every child performed this procedure twenty times
75724900|NCT00928122|Device|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
75724901|NCT00928122|Device|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
75426283|NCT04470609|Biological|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
75426284|NCT04470609|Biological|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
75426285|NCT04470609|Biological|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
75426286|NCT04464759|Drug|Nivolumab|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
75426287|NCT04464759|Drug|Hydroxychloroquine|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
75426288|NCT04464759|Drug|Ipilimumab|Combination of nivolumab, hydroxychloroquine and ipilimumab
75426289|NCT04462601|Other|Biomarker detection|Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
75426290|NCT04443010|Drug|Onfekafusp alfa|"This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone."
75572844|NCT06086665|Drug|Niraparib|Niraparib
75426291|NCT04443010|Drug|Temozolomide|Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
75426292|NCT04423237|Drug|Deferasirox|DEFERASIROX administered as per clinical practice and according to technical note
75426293|NCT04416750|Drug|Imatinib Mesylate|Treatment with Imatinib
75426294|NCT04412538|Biological|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
75426295|NCT04412538|Biological|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
75426296|NCT04412538|Biological|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
75426297|NCT04412538|Biological|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
75426298|NCT04412538|Biological|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
75426299|NCT04412538|Biological|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
75426300|NCT04412538|Biological|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
75426301|NCT04412538|Biological|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0,14
75572845|NCT06086652|Diagnostic Test|PET/CT|detection of possible primary tumor
75572846|NCT06086639|Other|Online Occupational Therapy Group Training|In this study, a 4-week online occupational therapy group training was conducted by an occupational therapist specialized in the field of nutrition. The content of the training, which takes place one hour a week, is given below; Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs
75724902|NCT00928122|Device|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
76047793|NCT02101359|Drug|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
75426302|NCT04411732|Device|MyotonPro|Measurement of relaxation time, stiffness and elasticity of the following muscles, using the MyotonPro® device: on both sides thenar and hypothenar, m. biceps brachii, m. triceps brachii, m. deltoideus, m. quadriceps femoris, m. tibialis anterior and gastrocnemius muscles.
75572847|NCT06086613|Drug|AGA2115|"In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.~In Part C, participants will receive AGA2115 in multiple doses administered as a SC injection."
75572848|NCT06086613|Drug|Placebo|"In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection.~In Part C, up to 2 cohorts will receive multiple doses of placebo administered as a SC injection."
75572849|NCT06086600|Other|Instrument Assisted Soft Tissue Mobilization|"give gentle strokes from proximal to distal to check for trigger point or taut band. After knowing the exact location, give gentle strokes with minimal pressure in all directions by keeping the instrument in 30 to 60 degree angle. Application time will be between 40- 120 seconds.~Conventional treatment will include~Hot pack for 10-15 min (calf muscles)~Stretching exercises of gastro-soleus (10reps x 2Sets).~Post session : Cold pack for 5 minutes (calf muscles)"
75572850|NCT06086600|Other|Dynamic oscillatory stretch technique|"Passively dorsiflexe the ankle to a point of the first stretch sensation. The next component to DOS, 2- second, passive stretch with slow oscillations at end range was applied. This procedure is repeated 10 times in each set with total of 3 sets .Therefore,10reps x2 second hold oscillation x 3 sets are given.Conventional treatment will include~Hot pack for 10-15 min (calf muscles)~Stretching exercises of gastro-soleus (10reps x 2Sets).~Post session : Cold pack for 5 minutes (calf muscles"
75572851|NCT06086548|Other|metabolomic on plasma sample|metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling
75724903|NCT00928122|Device|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
75724904|NCT00928122|Device|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
75724905|NCT05702931|Drug|Semaglutide 14 MG [Rybelsus]|At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.
75724906|NCT05702931|Drug|Placebo|Saline
75724907|NCT01075711|Drug|Prednisone|According to SPC
75572852|NCT06086509|Other|Music|Children were played music during computerized tomography.
75877903|NCT01781039|Device|Hearing Aid fitting|Subjects with hfPTAs ranging from 0-55 dB HL will be recruitedwith 100 persons self-reporting difficulty HIN (> 50% of the time), and 100 persons reporting little difficulty HIN (< 50% of the time) will be randomly assigned to one of five groups (n = 200) based on enabled HA features using an online random assignment tool. Unaided HIQ and HIN assessments will be conducted in the sound field, and baseline DPOAE and CAP assessments will be measured. Subjects will be fit with binaural premium level receiver-in-the canal HAs (Phonak B90 or equivalent model at the start of the study) with 56 dB SPL gain receivers, using closed domes, and programmed to NAL-NL2 target gain, and randomly assigned to the groups.
75877904|NCT03603470|Other|EOS imagery|Whole body EOS imaging in seated and standing position
75877905|NCT00107250|Drug|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
75877906|NCT00107250|Drug|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
75877907|NCT00107250|Drug|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
75877908|NCT00107250|Drug|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
76047794|NCT02100969|Drug|HIZENTRA ®|Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
76047795|NCT01885000|Drug|Brimonidine tartrate was applied cutaneously once daily for 8 days.|
76047796|NCT01885000|Drug|Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.|
75877909|NCT03606434|Other|Hypoxic exposure|30 minutes of intermittent hypoxia
75877910|NCT03603392|Other|Physical activity program|
75877911|NCT03651258|Behavioral|Implementation of ALIJEU|"The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay."
75877912|NCT03167411|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
76047797|NCT04735341|Device|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
76047798|NCT04171960|Other|Blood Draw Within 12 Hours of Injury|- Specimens collected for i-STAT testing and, if applicable, for optional collection of DNA for possible future genetic testing.
75572853|NCT06086496|Device|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
75724908|NCT00820508|Drug|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
75724909|NCT00907062|Dietary Supplement|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
75724910|NCT01073371|Drug|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
75724911|NCT00820586|Procedure|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
75724912|NCT00928278|Drug|Treatment A|Inhaled, 300/150, single dose
75572854|NCT06086483|Drug|Ropivacaine 0.2% Injectable Solution|"20 mL 0.5% ropivacaine was injected into the PENG block~20 mL 0.5% ropivacaine was injected into the Adductor Canal block"
75426303|NCT04411732|Diagnostic Test|Six-minute walk test|The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. The 6MWT has been used with a variety of other conditions than the chronic obstructive pulmonary disease (COPD) such as heart failure and stroke and is widely used in neuromuscular diseases. The six-minute-walk-test will be conducted as recommended by the American Thoracic Society. In this study, the six-minute-walk test will be performed once on visit 1 to detect the impact of muscle weakness, muscle stiffness and myotonia on muscular endurance.
75426304|NCT04411732|Diagnostic Test|Semiquantitative muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular dystrophies are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. Spinal muscular atrophies and neuropathies also showed an increase in muscle echo along with atrophy of the muscle and increase in depth of subcutaneous tissue, but a persisting bone echo. In several other myopathies, similar changes are seen. In semi-quantitative muscle ultrasound, muscle intensity will be documented using the 4-point Heckmatt score. In addition to that, cutis, subcutaneus fat and muscle will be measured in mm.
75572855|NCT06086483|Drug|0.9%sodium chloride|"20 mL 0.9% sodium chloride was injected into the PENG block~20 mL 0.5% sodium chloride was injected into the Adductor Canal block"
75724913|NCT00928278|Drug|Treatment B|Inhaled, 300/150, single dose
75877913|NCT03167411|Drug|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
75572856|NCT06086457|Radiation|Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 50Gy in 25 fractions to planning gross tumor volume (PGTV) with involved site included.
75724914|NCT00928278|Drug|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
75724915|NCT00928278|Drug|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
75724916|NCT03970369|Behavioral|Usual care|Personalized goals and an activity prescription.
75724917|NCT03970369|Behavioral|Monitor|Participants wear a step counter to track activity goals.
75724918|NCT04034394|Other|Electromoxibustion|Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
75724919|NCT04034394|Other|Knee health education|Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
75724920|NCT04005573|Dietary Supplement|VD3|VD3 50000 IU/ week for 8 weeks
75724921|NCT04005573|Dietary Supplement|omega 3- FA|Omega 3 FA group 300 mg once daily for 8 weeks
75877914|NCT02035436|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
75724922|NCT04005573|Dietary Supplement|VD3 and omega- 3FA|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
75724923|NCT04005573|Other|no intervention|no intervention is given
75724924|NCT03970213|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|IV TXA given during surgery
75724925|NCT03970213|Drug|Normal Saline 0.9% Infusion Solution Bag|IV saline given during surgery
75877915|NCT02035436|Other|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
75724926|NCT00821834|Drug|clopidogrel (SR25990)|"Form: tablets~Route: oral"
75724927|NCT00821834|Drug|ticlopidine|"Form: tablets~Route: oral"
75724928|NCT00821834|Drug|Placebo|"Form: tablets~Route: oral"
75724929|NCT00924534|Drug|Placebo|Placebo
76047799|NCT04171960|Other|3T MRI|- 3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury.
76047800|NCT04171960|Other|In-Person Outcome Assessment at Baseline|-3 Outcome Assessments administered at Baseline.
75572857|NCT06086457|Drug|TP or PF regimen depended on investigator's choice.|A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.
75572858|NCT06086457|Biological|PD-1 inhibitor|Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).
75572859|NCT06086405|Device|Patients underwent cardiorespiratory support|Patients underwent cardiorespiratory support using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator
75572860|NCT06086366|Other|[11C]DTBZ PET scan|One [11C]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
75572861|NCT06086366|Other|[18F]SDM8 PET scan|One [18F]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
75572862|NCT06086366|Other|MRI scan|One MRI scan
75572863|NCT06086353|Drug|Tafamidis|Patients on tafamidis will be observed
75877916|NCT03601754|Diagnostic Test|Treadmill/Bicycle exercise testing|"Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W"
75572864|NCT06086327|Drug|68Ga-Pentixafor|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
75572865|NCT06086314|Other|reactive exercise training in addition to a neurorehabilitation program|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the red light sensor is on, and withdrawing his/her hand as soon as the sensor goes out.
75572866|NCT06086314|Other|reactive exercise training with co-contraction in addition to a neurorehabilitation program|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the green light sensor is on, and holding his/her hand on the sensor for 5 seconds and then withdrawing it.
75724930|NCT00924534|Drug|SLV337|SLV337 400 mg/day
75724931|NCT00924534|Drug|SLV337|SLV337 800 mg/day
75877917|NCT03606356|Drug|Onabotulinum toxin A|Cranial Subcutaneous Injections
75572867|NCT06086314|Other|neurorehabilitation program with functional reaching training|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Doing functional stretching to the anterior, right and left while standing.
75572868|NCT06086288|Drug|Pembrolizumab, Etoposide, Cisplatin or Carboplatin|Induction Phase (4 cycles, 1Cycle=3W): Pembrolizumab 200 mg + Etoposide + Cisplatin or Carboplatin; Maintenance Phase (16 Cycles, 1Cycle=6W): Pembrolizumab 400 mg
75572869|NCT06086262|Device|Hydraulic hand dynamometer (Jamar, Product model J00105, U.S.A)|"The hydraulic hand dynamometer is a reliable and valid an evaluation tool that's used to measure isometric grip force (hand grip strength) .~The hydraulic pinch gauge is a reliable and valid an evaluation tool that's used to measure isometric pinch force."
75572870|NCT06086236|Device|Transcutaneous Auricular Vagus Nerve Stimulation|Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.
75572871|NCT06086223|Procedure|ankle arthroscopy with ORIF|we will go for fixation of the fracture with association of scope intervention pre and post fixation
75572872|NCT06086223|Procedure|fracture ankle fixation without ankle arthroscopy|we will go for fixation of the fracture alone with no scope intervention
75724932|NCT00924534|Drug|SLV337|SLV337 1400 mg/day
75877918|NCT02237768|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
75724933|NCT04005417|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
75724934|NCT04005417|Drug|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
75572873|NCT06086210|Other|Low-level laser therapy|Low-level laser therapy was applied to each area for 1 minute, with a wavelength of 808 nm and a dose of 2j/cm2 for a total of 5 minutes,10j/cm2 in continuous mode. A total of 15 sessions were applied 5 days a week for 3 weeks.
75572874|NCT06086210|Other|Sham|Sham therapy was applied to each area for 1 minute, with a wavelength of 0 nm and a dose of 0j/cm2 for a total of 5 minutes, 0j/cm2. A total of 15 sessions were applied 5 days a week for 3 weeks.
75572875|NCT06086158|Procedure|Nordic Reverse Protocol|The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
75572876|NCT06086119|Diagnostic Test|to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.|Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis
75724935|NCT04005417|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
76047801|NCT04171960|Other|In-Person Outcome Assessment at Follow-Up|- Full set of Outcome Assessment at 2 weeks, 6 weeks, and 6 months following injury.
76047802|NCT04171960|Other|Phone Outcome Assessment|- 6 Outcome Assessments administered at 3 months following injury by Phone.
76047803|NCT04171960|Other|Blood Draw After 12 Hours of Injury|- Specimens collected at 12-24 hours, 2 weeks, and 6 month following injury then processed for storage for future use.
76047804|NCT01884688|Drug|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
76047805|NCT01883362|Drug|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
76047806|NCT01883362|Other|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
76047807|NCT02100813|Drug|LEO 43204|
76047808|NCT02100813|Drug|Placebo|
76047809|NCT04724967|Drug|CeraVe Hydrating Cleanser|topical cleanser applied twice a day for 28 days
75426305|NCT04411732|Diagnostic Test|Hand-held Dynamometry of muscle strength|Muscle strength will be assessed by handheld dynamometry using the MicroFET2 myometer, produced by Hoggan Health Industries. This test is widely used in patients with neuromuscular diseases. To perform a test, the examiner holds the dynamometer stationary while the patient exerts a maximal force against the dynamometer. The patient makes a gradual increase in force and then completes an isometric hold for 4-5 seconds. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, knee extension, knee flexion, foot extension, foot flexion.
76047810|NCT04724967|Drug|CeraVe Moisturizing Cream|topical cream applied twice a day for 28 days
76047811|NCT01930162|Drug|HSC835|HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
76047812|NCT04630912|Other|Acceptance and Commitment Therapy|There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
76047813|NCT02045979|Drug|BI 695501|BI 695501 single s.c. injection
76047814|NCT02045979|Drug|adalimumab-EU source|adalimumab-EU source single s.c. injection
75572877|NCT06086106|Procedure|caudal block|The caudal block involves the injection of a local anesthetic Bupivacaine dose of 0.75 to 1 ml/kg the maximum volume was 10 mL with 0.25% concentration into the caudal epidural space, targeting the sacral nerve roots. to provide a high effect and duration of analgesia
75572878|NCT06086106|Procedure|Dorsal Penile Nerve Block DPNB|DPNB is A type of pain control post-operative, often performed as a circumferential infiltration of the root of the penis (ring block). Two skin wheals are raised at the dorsal base of the penis, one on each side just below and medial to the pubic spine. A 25-gauge, 37.5-mm needle is introduced on each side, and the bupivacaine (1 to 1.5 mL) maximum dose 2 ml concentration 0.25% for infants is injected superficially and deep along the lower border of the pubic ramus to anesthetize the dorsal nerve. For a complete ring of infiltration,
75572879|NCT06086106|Drug|Systemic opioids|Systemic opioids belong to a class of analgesics, they act by attaching to opioid receptors in the brain and spinal cord. For relief of pain, they are frequently utilized in a variety of surgical procedures and can be given intravenously, and in intramuscular injections. Although opioids are considered highly effective in pain control, they can lead to several adverse effects, such as nausea, vertigo, and respiratory depression, some of which can be dangerous.
75572880|NCT06086041|Procedure|cochlear implant|cochlear implant
75572881|NCT06086002|Device|Microwave ablation|Microwave ablation will be performed by using single antenna (Emprint, Medtronic) with overlapping ablation or two antennas (Starwave, STARmed) with simultaneous ablation.
75572882|NCT06085989|Behavioral|Infant directed singing|In every known human culture and historical period, infant-directed singing exists as a natural feature of parental care for newborn infants. Infant-directed singing is effective in regulating infant affect and in capturing an infant's attention for a longer period than infant-directed speech. Parental stress significantly decreases when parents are encouraged to use their own voices to soothe their infants with a song or a lullaby of their choice.
75572883|NCT06085989|Behavioral|Standard care|Standard breastfeeding support to mothers with breastfeeding difficulties provided by health care professionals.
75572884|NCT06085976|Drug|Octreotide|"A loading dose of 100 mcgr of octreotide will be administered in the intervention group, diluted in 100 ml of SSF to be passed in 30 minutes.~Subsequently, it will be administered in continuous perfusion at 25 mcgr/h in the intervention group.~The drug can be administered through a peripheral or central venous line at the choice of the anesthesiologist, since the drug has a density that allows its administration by both routes."
75572885|NCT06085976|Other|Placebo|In the case of the control group, 100 ml of SSF will be administered to be passed in half an hour and then an perfusion of SSF.
75877919|NCT02237768|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
76047815|NCT02045979|Drug|adalimumab-US source|adalimumab-US source single s.c. injection.
76047816|NCT01929226|Biological|ETI-204|Monoclonal Antibody
76047817|NCT01929226|Other|Placebo|Placebo for ETI-204
76047818|NCT04703751|Device|Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter|Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
76047819|NCT05122702|Drug|modified Shenling Baizhu San|modified Shenling Baizhu San granules, twice daily for 12 weeks.
75572886|NCT06085950|Device|Transcranial Ultrasonic Stimulation prototype|Transcranial Ultrasonic Stimulation prototype delivers personalized low-intensity ultrasound stimulation
75426306|NCT04411199|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
75426307|NCT04411199|Other|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
75426308|NCT04407247|Biological|Infliximab|Given IV
75426309|NCT04407247|Biological|Vedolizumab|Given IV
75426310|NCT04402216|Behavioral|Child Life-led preparation|Support from a certified child life specialist in preparation for MRI
75426311|NCT04402216|Behavioral|MRI preparation video|A descriptive video about what to expect when undergoing MRI
75426312|NCT04402216|Behavioral|KindVR Virtual Reality MRI Preparation Experience|A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
75572887|NCT06085937|Drug|Ketamine|Patients will receive 0.2mg/kg of IV ketamine
75572888|NCT06085898|Drug|Stryphnodendron Adstringens 3% - once daily post bath|Intimate Soap
75572889|NCT06085846|Device|Vivally® System Wearable, Non-Invasive Neuromodulation System, and Mobile Application|Vivally® System Wearable, Non-Invasive Neuromodulation System and Mobile Application to treat patients with the conditions of urinary incontinence and urinary urgency.
76047820|NCT05122702|Other|Placebo|Placebo granules, twice daily for 12 weeks.
75426313|NCT04398680|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered
75426314|NCT04392154|Biological|Lebrikizumab|Subcutaneous injection
75426315|NCT04389450|Biological|PLX-PAD|PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells
75426316|NCT04389450|Biological|Placebo|Placebo solution for injection
75426317|NCT04364230|Drug|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
75426318|NCT04364230|Drug|NeoAg-mBRAF|BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
75426319|NCT04364230|Drug|PolyICLC|polyICLC, local adjuvant
76047821|NCT04734405|Drug|Prof-001|Prof-001 cream
75426320|NCT04364230|Drug|CDX-1140|CDX-1140, local adjuvant
76047822|NCT04734405|Drug|Fluconazole 150 mg|Fluconazole capsule
75426321|NCT04362722|Drug|L19IL2 +L19TNF|Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (~1.08 mg) and 200 µg L19TNF.
75426322|NCT04350866|Other|Expert Recommendations for Implementing Change (ERIC) bundle of strategies|"Develop a formal implementation blueprint/checklist~Conduct educational meetings; Develop & distribute educational materials~Organize implementation meetings~Audit and provide feedback~Facilitation~Increase demand with marketing to patients~Promote adaptability~Involve patients and family; Use their feedback; Prepare them to be active participants"
75572890|NCT06085820|Behavioral|Experimental (birth ball)|"It is a large and firm ball made of soft, thick plastic, inflated with air. It can be easily inflated and deflated, washable, available in different sizes (55-65-75 cm in diameter) and strong enough to carry weight up to 136 kg.~When the literature was examined, it was seen that birth balls between 55-75cm were generally used in accordance with the intended use. Appropriate ball size will be determined by the participant's height. In order for the pregnant woman to continue balance exercises, she should be allowed to sit on the round birthing ball with her knees and hips at an angle of approximately 90°, with an upright spine.~birth ball; It is performed in sitting (pelvic rocking movement, forward-backward and right-left rocking, forward-supported sitting, springing movement), kneeling and squatting (hugging the ball and pelvic rocking movement) positions."
75572891|NCT06085820|Behavioral|Experimental (birth dance)|"Thanks to the birth dance, the expectant mother perceives less pain. In fact, it is known that a change in position is effective in the perception of pain. On the other hand, if the woman focuses on a point other than the pain during the act, it makes it easier for her to perceive the pain less. The low cost of this application increases its usability.~The most appropriate time for the birth dance is from the active phase of the first phase of labor until the end of this phase . The expectant mother dances with rhythmic movements accompanied by soothing and soothing music with the help of a birth supporter (midwife, relative, spouse or partner). Optionally, sacral massage can be added to the birth dance. In fact, in addition to reducing the pain experienced through freedom of movement, upright position and massage, it is also aimed to provide emotional support to the woman."
75572892|NCT06085794|Procedure|Endoscopic combined intrarenal surgery|Combined complex stone clearance with mini-nephroscope and flexible URS
75572893|NCT06085794|Procedure|Percutaneous nephrolithotomy|Clearance of renal stone with nephroscope in prone position
75572894|NCT06085781|Other|fMRI|Functional Magnetic Resonance Imaging
75572895|NCT06085781|Other|Oral Pimonidazole|200 mg and 300 mg tablets
76047823|NCT04734405|Drug|Placebo cream|ointment base to mimic Prof-001
76047824|NCT04734405|Drug|Placebo capsule|encapsulated lactose powder to mimic 150 mg fluconazole capsule
76047825|NCT02045433|Radiation|SABR Boost Therapy|"Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment."
75572896|NCT06085768|Behavioral|VRE intervention|Virtual reality exposure therapy is a new treatment technology developed in recent years. This technology combines virtual reality technology with traditional exposure therapy, and uses virtual reality technology to present the exposure scenes required for exposure therapy. Therefore, it can break through the limitations of time and space and more intuitively display some things that are difficult to simulate in the treatment room. Scenes do not require the client to undergo treatment through imaginary exposure, thereby increasing the immersion and reality of the treatment. Over the past two decades, numerous studies have explored and proven the effectiveness of virtual exposure therapy.
75572897|NCT06085716|Behavioral|Psychoeducational Intervention|Participants in the PI group will complete the educational sessions only.
75572898|NCT06085716|Drug|Open Label Placebo|This group will only take placebo capsules every day.
75572899|NCT06085716|Behavioral|Psychoeducational Intervention+Placebo|This group will take the placebo capsules every day, as well as completing the educational sessions.
75572900|NCT06085703|Drug|Henagliflozin|Henagliflozin will be initiated and maintained at 5mg/day every morning. If necessary, the dose can be increased to 10mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
75572901|NCT06085703|Drug|Gliclazide|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
75572902|NCT06085690|Behavioral|evidence-based intervention Plan for the Prevention of CRBSI in ICU patients|"On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention."
75572903|NCT06085625|Behavioral|Pre-Surgery Survey|Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery). You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.
75724936|NCT01073839|Drug|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
76047826|NCT01911442|Drug|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
76047827|NCT01911442|Drug|Lurasidone|Lurasidone 60 mg once daily
75426323|NCT04344626|Device|Intra-operative brain tonometry|Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
75426324|NCT04333147|Biological|Otilimab (GSK3196165)|GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.
75426325|NCT04333147|Drug|csDMARD(s)|Stable dose of csDMARD(s) as standard of care (SoC).
75426326|NCT04332341|Drug|Nicotinamide riboside (NR)|Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
75426327|NCT04325659|Device|Bridge Device|An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal
75426328|NCT04325659|Drug|Lofexidine|FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
75426329|NCT04325659|Drug|Placebo|Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
75426330|NCT04325659|Device|Sham Bridge Device|Inactive Bridge Device which is applied and looks identical to the active Bridge Device
75426331|NCT04314375|Drug|Low Dose Budesonide|3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
75572904|NCT06085625|Behavioral|Post-Surgery Surveys|"After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey.~Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing."
75724937|NCT00820742|Drug|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
75724938|NCT00928356|Procedure|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
75724939|NCT00928356|Procedure|Off Pump CABG|Standard of Care Off Pump CABG
75426332|NCT04314375|Drug|High Dose Budesonide|6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
76047828|NCT01911442|Drug|Placebo|Placebo
75426333|NCT04314375|Drug|Placebo|Matching placebo once daily.
75426334|NCT04310397|Drug|Dabrafenib|Given PO
75426335|NCT04310397|Biological|Spartalizumab|Given IV
75426336|NCT04310397|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75426337|NCT04310397|Drug|Trametinib|Given PO
75724940|NCT03743454|Other|No intervention|No intervention will be applied.
76047829|NCT01928758|Drug|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
76047830|NCT01928758|Drug|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
75877920|NCT03606278|Other|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
75572905|NCT06085586|Other|Early Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
75572906|NCT06085586|Other|Normal Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
75572907|NCT06085560|Behavioral|Usual Care Message|Usual care is provided by the FQHC for the screening option chosen.
75572908|NCT06085560|Behavioral|Implementation Intention Intervention: Standard Message|Implementation Intention Intervention module includes standard messaging in addition to the usual care provided by the FQHC for the screening option chosen.
75572909|NCT06085560|Behavioral|Implementation Intention Intervention: Culturally-Targeted Message|Implementation Intention Intervention module includes culturally-targeted framing of health information messages in addition to the usual care provided by the FQHC for the screening option chosen.
76024523|NCT03561441|Drug|Tailored standard hydration|"Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~At 8 hours, if pain (<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
75572910|NCT06085547|Behavioral|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include rural-targeted information
75572911|NCT06085547|Behavioral|Rural-Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a two and a half minute video based messaging adjunct meant to enact a rural-targeted framing of health information presented to White rural individuals.
75724941|NCT05698251|Behavioral|Uncertainty distress model|Psychological therapy intervention based on elements of traditional Cognitive Behaviour Therapy (CBT) for anxiety, illness uncertainty and intolerance of uncertainty.
75724942|NCT00585533|Drug|Erlotinib (Tarceva)|Erlotinib
75724943|NCT00924690|Other|Behavioral Messages|Participants will read 10 behavioral messages about colon cancer screening and physical activity.
75724944|NCT00924690|Other|Generic Messages|Individuals will read 10 generic messages about colon cancer screening and physical activity.
75724945|NCT04719741|Other|Parallel Assignment|Prospective, Triple blinded, randomized, controlled trial
75724946|NCT04085861|Behavioral|Mental health literacy in dancers|Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
76047831|NCT01910116|Drug|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
76047832|NCT01910116|Drug|Placebo|The study medication and placebo were identical in appearance.
76047833|NCT01614886|Drug|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
76047834|NCT01614886|Drug|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
76047835|NCT04622254|Drug|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
76047836|NCT04622254|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
76047837|NCT01880554|Device|Contrast-enhanced intraoperative ultrasound|"Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:~Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages"
75426338|NCT04308278|Drug|2LEBV® / 2LXFS®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
76047838|NCT04171726|Drug|Edoxaban|A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.
76047839|NCT02100657|Drug|Plitidepsin|
76047840|NCT02100657|Drug|Bortezomib|
76047841|NCT02100657|Drug|Dexamethasone|
75426339|NCT04308278|Drug|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
75426340|NCT04304963|Other|NO intervention - observational study|NO intervention - observational study
75426341|NCT04303403|Drug|Trametinib|Taken orally once daily
75426342|NCT04303403|Drug|Ruxolitinib|Taken orally twice daily
75572912|NCT06085469|Behavioral|Temporal Adaptation Approach|the temporal adaptation: It includes giving importance to the use of time, choosing meaningful activities, adjusting the time used during these activities and improving it. Such adaptation serves to improve an individual's quality of life, health, and occupational participation.
75572913|NCT06085456|Diagnostic Test|Hematologic features|Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
75572914|NCT06085443|Device|Ear Hygiene|2 sprays in each ear, every 3 days at home
76047842|NCT02067663|Device|Paragard|The IUD will be placed as part of standard clinical care.
76047843|NCT02067663|Drug|Mirena|The IUD will be placed as part of standard clinical care.
76047844|NCT01909804|Drug|SOF|400 mg tablet administered orally once daily
76047845|NCT01909804|Drug|VEL|Tablet administered orally once daily
76047846|NCT01909804|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76047847|NCT01880086|Drug|Clomiphene citrate|
76047848|NCT01880086|Drug|Placebo|Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
75426343|NCT04302103|Biological|RC18 160mg|subcutaneous injection
75426344|NCT04302103|Biological|RC18 240 mg|subcutaneous injection
75426345|NCT04289571|Diagnostic Test|VR Motility Tool|Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
76047849|NCT01879852|Behavioral|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
75426346|NCT04286178|Dietary Supplement|creatine monohydrate|Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.
75572915|NCT06085430|Device|Kubota Glass|Kubota Glass employs white light producing micro-LEDs covered by masks which create a patterned target. The patterned images are defocused by micro-lenslets and projected to the retinal periphery by a central mirror. Parameters of interest to evaluate in this investigation include but are not limited to dioptric amount of defocus, brightness (cd/m2), spectrum of illumination, and shape of the target mask. In each scenario, right eyes will be exposed to the stimulus, whereas left eyes serve as controls. The order of exposures to the various stimuli will be randomized to participant and investigator.
75877921|NCT03606278|Other|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
76047850|NCT01879852|Behavioral|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
76047851|NCT01879618|Drug|Fragmin|variable dosing regimen
75426347|NCT04286178|Dietary Supplement|ubiquinol|Coenzyme Q10 (CoQ10, ubiquinol) will be taken at a dose of 10mg/kg/day divided into 2 daily doses with a daily maximum of 500mg. CoQ10 will be administered orally in 50mg softgels containing 50mg of ubiquinol (Active Q®), provided by Tishcon Corporation.
75426348|NCT04286178|Dietary Supplement|glucose tablet|Creatine placebo will be in the form of a glucose tablet with identical appearance and taste to the active supplement. The number of tablets/day will be determined based on the dose of creatine required for each patient.
75426349|NCT04286178|Dietary Supplement|gel capsule|Ubiquinol placebo will be in the form of a gel capsule with identical appearance to the active supplement. The number of capsules/day will be determined based on the dose of ubiquinol required for each patient.
75426350|NCT04286178|Behavioral|Exercise|"Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)"
75572916|NCT06085417|Drug|Bupivacaine + dexamethasone|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
75724947|NCT04085861|Behavioral|Mental health literacy in dance teachers|Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
75724948|NCT00628862|Drug|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
75724949|NCT00628862|Drug|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
75724950|NCT00628862|Drug|Turbuhaler® placebo|placebo inhaled twice daily
75724951|NCT00907140|Procedure|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
75724952|NCT05420727|Drug|Ga-68-PSMA-11 PET/CT|Ga-68-PSMA-11 PET/CT imaging
75426351|NCT04285853|Drug|Oxycodone|5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
75426352|NCT04285853|Drug|Placebo oral tablet|"Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets."
75426353|NCT04271007|Drug|Mometasone Furoate|mometasone furoate
75572917|NCT06085417|Drug|Bupivacaine + magnesium sulphate|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
75572918|NCT06085417|Drug|bupivacaine|bupivacaine
75572919|NCT06085404|Procedure|Blood sample|Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
75572920|NCT06084520|Diagnostic Test|Current Opioid Misuse Measure (COMM)-SWE|Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.
75572921|NCT06084520|Diagnostic Test|Oral fluid drug test|Oral fluid sampling to detect drugs. Analysis with LC-HRMS
75426354|NCT04252547|Other|Kangaroo Care|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.
75572922|NCT06084520|Diagnostic Test|PETh|Alcohol use detection
75572923|NCT06084520|Diagnostic Test|ASI-SR|Cross-validation form
75572924|NCT06084520|Diagnostic Test|AUDIT|Cross-validation form
75426355|NCT04252547|Other|Control|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before feeding when they are included in the study and then they will be breastfed by their mothers. The chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. Also, the infant's heart rate and oxygen saturation will continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weighed without a diaper change and his/her weight will be recorded. When the care process is over, it will be taken back in the incubator to sleep.
76047852|NCT01926886|Drug|Trastuzumab|Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
76047853|NCT01909336|Drug|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
75572925|NCT06084520|Diagnostic Test|DUDIT|Cross-validation form
75572926|NCT06084520|Diagnostic Test|Brief Pain Inventory - BPI|Cross-validation form
75572927|NCT06084520|Diagnostic Test|Patient Global Impression of Change PGIC|Cross-validation form
75572928|NCT06084520|Diagnostic Test|GAD-7|Cross-validation form
75572929|NCT06084520|Diagnostic Test|Patient Health questionnaire (PHQ9)|Cross-validation form
75572930|NCT06084520|Diagnostic Test|DBS - cannabis test|cross-validation form
75572931|NCT06084520|Other|Sample of Blood for later DNA and immunological analysis in future studies|sample collection for future studies
75572932|NCT06084416|Drug|Sovilnesib|Sovilnesib tablets will be given orally.
75572933|NCT06084000|Device|Drug-coated balloon (Bingo© [Paclitaxel-coated Balloon], Yinyi Ltd., China)|"Patients treated with DCB will receive dual antiplatelet therapy (DAPT, aspirin plus P2Y12 inhibitor) for 1-3 months, followed by long-term single antiplatelet therapy (SAPT, aspirin or P2Y12 inhibitor).~Patients with bailout stenting will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration in Drug-eluting stent Arm), and then followed by long-term SAPT."
75724953|NCT05420727|Drug|Lu-177-ITG-PSMA-1|Lu-177-ITG-PSMA-1 treatment
75724954|NCT04085783|Procedure|PRP|Platelet Rich Plasma
76047854|NCT01909336|Drug|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
76047855|NCT01909336|Drug|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
76047856|NCT01926028|Biological|NDV-3A|0.5mL injection IM
76047857|NCT01926028|Biological|NDV-3|0.5mL injection IM
76047858|NCT01926028|Biological|Placebo|aluminum hydroxide and buffered saline
76047859|NCT01925950|Drug|orBec|
75572934|NCT06084000|Device|Drug-eluting stent|"Patients treated with DES will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration below), and then followed by long-term SAPT.~Special consideration:~Patients will take additional assessment (both DAPT score and PRECISE-DAPT score) to determine their personalized duration of DAPT.~The duration of DAPT is extended to 12 months for patients diagnosed as acute coronary syndrome within 12 months.~If anticoagulation is indicated, patient will receive a short-term triple antithrombotic therapy (generally 1 to 4 weeks), followed by a variable length of dual antithrombotic therapy (oral anticoagulation (OAC) plus a single antiplatelet agent, preferably clopidogrel) and subsequent long-term OAC mono-therapy. The duration of dual antithrombotic therapy is determined by bleeding risks (HAS-BLED score) according to current guidelines."
75572935|NCT06083831|Other|feeding type|In our department, the ICU patients received continuous feeding or sequential feeding. Patients received continuous feeding with a constant velocity by an enteral feeding pump over one day. In sequential feeding type, after achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d), the patients received intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.
75572936|NCT06083467|Diagnostic Test|Amyloid PET scan|Positron Emission Tomography (PET) scan using either Florbetaben F18 or 11C-PiB radiotracer
75572937|NCT06083467|Diagnostic Test|Brain MRI Scan|MRI scan of the brain
75572938|NCT06083467|Behavioral|Neurologic exam|Neurologic exam and assessments, including video interview
75572939|NCT06083376|Other|Spinal Stabilization Exercise|Spinal stability exercises are commonly used isometric and isotonic exercises. A spinal stabilization exercise training program will be applied to the exercise group participants using the telerehabilitation method (simultaneous connection) 3 days a week for 8 weeks and a total of 24 sessions.
76047860|NCT01925950|Drug|Placebo|
76047861|NCT04415320|Drug|X-396(Ensartinib)|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
75572940|NCT06083376|Other|physical activity counseling|Control group participants will first be given initial evaluations and verbal physical activity recommendations will be given. Patients will be contacted by phone at the 2nd, 4th and 6th weeks and reminded about the importance of physical activity.
75572941|NCT06083233|Diagnostic Test|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and cerebrospinal fluid sampling (sample 1 in measurement)
75572942|NCT06083233|Diagnostic Test|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
75572943|NCT06083233|Procedure|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
75572944|NCT06083233|Procedure|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of cerebrospinal fluid (5 days, 1 month a 2 months after surgery)
75572945|NCT06083233|Procedure|Blood sampling #1|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery
75572946|NCT06083233|Procedure|Blood sampling #2|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours after surgery
75572947|NCT06083233|Procedure|Blood sampling #3|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 5 days after surgery
75572948|NCT06083233|Procedure|Blood sampling #4 and #5|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
75572949|NCT06083038|Drug|Alpelisib|Patients will receive standard of care alpelisib
75572950|NCT06083038|Device|FreeStyle Libre 2 Continuous Glucose Monitor|All patients will wear Abbott FreeStyle Libre 2 system to obtain CGM data (glucoses measured every minute for 14 days). CGM monitors will be placed at least 10 days prior to starting alpelisib and continue CGM for at least 3 months while taking alpelisib.
75572951|NCT06082895|Behavioral|Birth self-efficacy enhancement training based on motivational interviewing method|Birth self-efficacy enhancement training based on motivational interviewing method
75572952|NCT06081452|Behavioral|Survey|Members of the public will be asked to complete a survey that collects information on individuals perception of health and disease and their views on breath testing.
75724955|NCT00987363|Other|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
75724956|NCT04086563|Other|Action observation|look at a clip of a hand doing neurodynamic exercises.
76024524|NCT03555149|Drug|Regorafenib|Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
76024525|NCT03555149|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
76024526|NCT03555149|Drug|Imprime PGG|Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
76024527|NCT03555149|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
76047862|NCT01878292|Drug|Placebo|Dose matched placebo tablets, once per day, oral administration.
76047863|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 15 mg per day, oral administration
75572953|NCT06081088|Other|Graded Motor Imagery (GMI) training|"GMI consists of three basic components:~Left / Right Discrimination training (Lateralization training): For lateralization training, patients will be trained by asking them to distinguish between right and left with images taken at various angles and positions in the RecogniseTM (NOI-Australia) applications (shoulder and hand sections) (In weeks 1 and 2).~Motor Imagery (Explicit Motor Imagery): At this stage, the participant will be asked to imagine doing various functional activities (brushing teeth, combing hair, etc.) in the position they feel most comfortable in and in a quiet environment (In weeks 2 and 3).~Mirror Therapy (providing visual feedback through a mirror): In this phase, active ROM exercises and progressive resistance exercises with simultaneous movement of the affected and unaffected extremities will be applied using a standard size posture mirror (In weeks 3-6).~This program will be applied for 6 weeks (3 sessions per week)."
75877922|NCT01952847|Other|Placebo|mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
75877923|NCT01952847|Drug|Glutamine|mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
75426356|NCT04239911|Behavioral|mHealth app|The mHealth app will provide heart failure-specific education to home health aides and allow them to report clinical observations and ask nurses questions in real-time.
75426357|NCT04239911|Behavioral|Virtual training course|Virtual training course on heart failure for home health aides.
75724957|NCT04086563|Other|Mirror therapy|With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
76047864|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 30 mg once per day, oral administration
75724958|NCT04086563|Other|Neurodynamic exercises|active movement of the dominant hand. Do neurodynamic exercises.
75724959|NCT04086563|Other|Strength|Execute a short strength training for the dominant hand
76047865|NCT01908634|Dietary Supplement|Milk-based Strawberry Beverage without meal|
75724960|NCT00820820|Biological|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
75724961|NCT00820820|Biological|placebo|Vehicle (water for injection), 0.5 ml, once
75724962|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
75724963|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
75724964|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
75877924|NCT01952847|Behavioral|Questionnaires|Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
76024528|NCT03555149|Drug|Isatuximab|Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
76024529|NCT03555149|Drug|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
76024530|NCT03555149|Drug|Idasanutlin|Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
76024531|NCT03555149|Drug|AB928|AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
76024532|NCT03555149|Genetic|LOAd703|LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
76047866|NCT01908634|Dietary Supplement|Water-Based Strawberry Beverage without meal|
76047867|NCT01908634|Dietary Supplement|Milk-based strawberry Beverage with meal|
76047868|NCT01908634|Dietary Supplement|Water-Based strawberry Beverage with meal|
76047869|NCT01878214|Behavioral|Targeted messaging|6 targeted mailed messages and 6 booster text messages
76047870|NCT01878214|Behavioral|Standard messaging|1 informational letter
76047871|NCT01907854|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
76047872|NCT01907854|Drug|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
76047873|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
75426363|NCT04235322|Drug|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
75426364|NCT04235322|Drug|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
76047874|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
76047875|NCT02480153|Biological|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
75572954|NCT06081088|Other|Conventional Physiotherapy|Conventional physiotherapy program includes passive, active-assistive (wand exercises) and active ROM exercises for shoulder joint, passive / active posterior and anterior capsule stretching exercises, superior-inferior, mediolateral and distraction techniques for scapular mobilization exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, static and dynamic stabilization exercises for proprioception exercises. To reduce the pain that may occur after exercises, cold application and Transcutaneous Electrical Nerve Stimulation (TENS) will be applied to benefit from their analgesic effects. Cold application will be applied around the shoulder using a coldpack (gel pack) cold therapy for 15 minutes. Conventional TENS application around shoulder will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes for 15 minutes.This program will be applied for 6 weeks (3 sessions per week).
75572955|NCT06081088|Other|Home Exercise Program|The home exercises program includes shoulder jonit active ROM exercises, active posterior and anterior shoulder capsule stretching exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, shoulder proprioception exercises, and cold therapy. This program will be applied for 6 weeks (3 sessions per week).
75572956|NCT06080347|Other|Anti-inflammatory Diet|Dietary intervention
75572957|NCT06080347|Other|Healthy Diet|Dietary intervention
75572958|NCT06080126|Other|Control: per usual practice|160 patients were included as per usual practice.
75572959|NCT06080126|Other|Intervention MAF|160 patients were included with MAF intervention.
75572960|NCT06079801|Device|Transcranial direct current stimulation (tDCS)|TDCS was delivered by a DC-Stimulator (Newronika, Italy) over both DLPC. The electrodes (35 cm2) were soaked in 0.9% NaCl. The anode was positioned on the left dorsolateral prefrontal cortex and the cathode on the right dorsolateral prefrontal cortex.
75572961|NCT06079801|Drug|anti-CGRP-mAbs|CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies
75572962|NCT06079541|Drug|JMKX003142 will be administered orally|oral once
75572963|NCT06079541|Drug|JMKX003142 will be administered orally|oral once
75572964|NCT06079541|Drug|JMKX003142 will be administered orally|oral once
75572965|NCT06079541|Drug|Placebo in Cohorts 1 to 7|oral once
75572966|NCT06079541|Drug|Placebo in 3 Cohorts|oral once
75877925|NCT03597932|Device|standardized handover checklist|Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
76047876|NCT02480153|Biological|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
76047877|NCT04972253|Drug|Infigratinib|Oral, dosage per protocol
75572967|NCT06078969|Drug|Prednisone|For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)
75877926|NCT02237846|Biological|Human umbilical cord tissue-derived mesenchymal stem cells|
75877927|NCT03601676|Other|Integration of electronic clinical decision support|Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
76047878|NCT02500979|Drug|Pramlintide acetate|Pramlintide acetate administered by a separate pump
76047879|NCT02500979|Drug|Placebo|Placebo administered by separate pump
76047880|NCT02500979|Drug|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
76047881|NCT02500979|Drug|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
75572968|NCT06078306|Drug|Azacitidine Injection|Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection
75572969|NCT06078306|Drug|Venetoclax|Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral
75572970|NCT06078306|Drug|CD19CD22 CAR-T|After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion
75572971|NCT06078228|Drug|Propfol - Fentanyl- Atracurium|investigate the reliability of preanesthetic ultrasound measurements of the carotid artery FTc and the internal jugular vein collapsibility index in predicting hypotension during the induction of general anesthesia.
75572972|NCT06077981|Procedure|Submucous Endoscopic Dissection with hydroxyethylamide|The resection will be performed in three stages using hydroxyethylamide : delimitation, incision and dissection. Initially we will inject the hydroxyethylamide and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
76047882|NCT02500901|Drug|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
75426365|NCT04230395|Behavioral|CAP|4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.
75426366|NCT04230395|Other|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
75426367|NCT04224519|Biological|sIPV batch 1|Type I 30 DU, Type II 32 DU, Type III 45 DU
75426368|NCT04224519|Biological|sIPV batch 2|Type I 30 DU, Type II 32 DU, Type III 45 DU
75426369|NCT04224519|Biological|sIPV batch 3|Type I 30 DU, Type II 32 DU, Type III 45 DU
75426370|NCT04220515|Biological|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Type I D antigen 30DU;Type II D antigen 32DU;Type III D antigen 45 DU
75426371|NCT04219332|Drug|Subserosa injection of indocyanine green|After preoperative exploration, the indocyanine green powder (Dandong Yichuang Pharmaceutical Co) is dissolved in 0.5 mg/ml of sterile water and the prepared solution (1.5 ml for each point) is injected along the subserosal of the stomach at 6 specific points along the lesser and greater curvature of the stomach.
75572973|NCT06077981|Procedure|Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye)|The resection will be performed in three stages using Hyaluronic acid (TS-905 Blue Eye) : delimitation, incision and dissection. Initially we will inject the Blue-Eyed and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
75572974|NCT06077955|Procedure|Mini-gastric bypass with stapled anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler."
75724965|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
75724966|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
75426372|NCT04219332|Drug|submucosal injection of indocyanine green|One day before surgery, 1.25 mg/ml indocyanine green (Dandong Yichuang Pharmaceutical Co) was prepared in sterile water and 0.5 ml of the solution was injected into the submucosal layer at 4 quadrants around the primary tumor, amounting to 2.5 mg of indocyanine green.
75426373|NCT04211649|Drug|3 days of antibiotherapy|Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
76047883|NCT02500901|Drug|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
75426374|NCT04210687|Procedure|trapeziometacarpal limited excision|Narrow pseudarthrosis CMC1
75426375|NCT04210687|Procedure|Trapeziectomy|Simple trapeziectomy
75426376|NCT04204616|Drug|Nemolizumab|Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
75426377|NCT04202094|Diagnostic Test|Physical examination|A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
75426378|NCT04202094|Diagnostic Test|Scrotum ultrasound|A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.
76047884|NCT02479139|Biological|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
76047885|NCT02479139|Biological|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
75572975|NCT06077955|Procedure|Mini-gastric bypass with hand-sewn anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture."
75572976|NCT06077396|Procedure|radial artery cannulation|radial artery cannulation
75572977|NCT06076668|Drug|Dexmedetomidine|Patients will receive an intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.
75572978|NCT06076668|Drug|Melatonin 3 MG|Patients will receive oral melatonin tablet 3 mg 9:00 p.m.
75572979|NCT06076668|Drug|Saline|Patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.
75572980|NCT06076005|Other|Advanced lung cancer patients' group|Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis
75572981|NCT06075368|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
75572982|NCT06074211|Behavioral|Safety in Seconds mobile app: Safe Sleep Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education. This intervention will be testing the effectiveness of a newly developed educational module on safe sleep education.
75572983|NCT06074211|Behavioral|Safety in Seconds mobile app: Car Seat Safety Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education, including fire and car seat safety.
75724967|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
75877928|NCT05461833|Biological|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
75877929|NCT05461833|Drug|OTILONII BROMIDUM|OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment
75426379|NCT04202094|Diagnostic Test|Blood sample|A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.
75877930|NCT05461833|Dietary Supplement|multi-strain probiotic|multi-strain probiotic, oral, 1 capsule BID for 1 month
75426380|NCT04202094|Diagnostic Test|Semen analysis|A semen analysis to evaluate the ejaculate volumes, sperm concentration, sperm motility and sperm morphology. If sperm is found in the semen sample, an antisperm antibody test ((in)direct mixed anti-globulin reaction test) and a sperm DNA fragmentation test (sperm chromatin dispersion test) will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
75877931|NCT01560585|Drug|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
75572984|NCT06073041|Other|Invitation to adopt|All eligible Prisma Health clinics will be invited to adopt EIMG. Adopting clinics will first be sent an instructional video as a part of a low touch initial onboarding. After 4 months, clinics will then recieve an in-depth standardized onboard training.
75724968|NCT00928824|Dietary Supplement|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
75426381|NCT04199767|Drug|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
75426382|NCT04199767|Drug|40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
75426383|NCT04189939|Other|clinical assessments|"Behavioral tasks will be executed via a computer interface. Below, we provide an estimated timeline for each visit and subsequently provide detail for the relevant stages.~Each participant's visit will last approximately 4-5 hours. Each visit will consist of the following tasks (in this order):"
75426384|NCT04159506|Behavioral|mindfulness, emotion didactics, interpersonal skills, experiential learning|mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
75426385|NCT04148066|Diagnostic Test|ctDNA blood sample|every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
75426386|NCT04144231|Behavioral|iCBT-I|Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
75426387|NCT04144231|Behavioral|GCBT-I|Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
75426388|NCT04142476|Other|interview|interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
75572985|NCT06072521|Drug|Lactoferrin Bovine|Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
75572986|NCT06068881|Drug|Tazverik (Tazemetostat)|Oral Tablet
75572987|NCT06066671|Other|GCO (Experimental copaiba oil resin gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the GCO will receive the application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
75724969|NCT00816686|Biological|AGS-16M18|IV Infusion
75877932|NCT03603236|Diagnostic Test|preeclampsia|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
75877933|NCT03603236|Diagnostic Test|control|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
75724970|NCT00924768|Biological|20K EU CCRE|Inhalation of CCRE
75724971|NCT00584987|Drug|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
75724972|NCT00584987|Drug|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
75724973|NCT00584987|Drug|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
75724974|NCT00584987|Drug|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
75877934|NCT05462847|Drug|Ringer acetate|8ml/kg Ringer acetate over 10 minutes
75877935|NCT01376427|Drug|Dexamethasone|Dexamethasone
75877936|NCT01376427|Drug|Methotrexate|Methotrexate
75877937|NCT01376427|Drug|Vincristine|Vincristine
75877938|NCT03601598|Drug|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
75877939|NCT03601598|Drug|SHR6390|SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
75426389|NCT04141358|Diagnostic Test|Advanced ultrasound measurements|"Clinical interventions and procedures:~Consent at 0 week~Clinical data collection at 0 week~Strain for native artery at 0 week~Young's modulus for native artery at 0 week~Intimal medial thickness for native artery at 0 week~Ultrasound blood volume flow measurement at 0 week~Vessel diameter at 0 week~Blood pressure at 0 week~BMI at 0 week~Intra-operative blood volume flow measurement at AVF surgery time~Strain for native artery at 6 weeks~Young's modulus native artery at 6 weeks~Intimal medial thickness native artery arteries at 6 weeks~Ultrasound blood volume flow measurement at 6 weeks~Vessel diameter at 6 weeks~Blood pressure at 6 weeks~BMI at 6 weeks"
75426390|NCT04128696|Drug|feladilimab|feladilimab is available as an intravenous infusion.
75426391|NCT04128696|Drug|Pembrolizumab|Pembrolizumab is available as an intravenous infusion.
75426392|NCT04128696|Drug|Placebo|Placebo is available as an intravenous infusion.
75426393|NCT04125914|Behavioral|Behavioral Dietary Intervention|Record food intake
75426394|NCT04125914|Other|E-mail|Receive e-mails
75426395|NCT04125914|Behavioral|Exercise Intervention|Undergo exercise
75426396|NCT04125914|Other|Health Promotion and Education|Receive text messages
75426397|NCT04125914|Other|Internet-Based Intervention|Join Facebook page
75426398|NCT04125914|Other|Questionnaire Administration|Ancillary studies
75426399|NCT04125914|Behavioral|Telephone-Based Intervention|Receive telephone coaching
75426400|NCT04102579|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
75426401|NCT04102579|Drug|Placebo|non-active dosage form
75426402|NCT04093921|Behavioral|MET-based therapy|see previous
75426403|NCT04093921|Behavioral|Standard Care|To include all recommended outpatient treatments
75426404|NCT04093362|Drug|TAS-120|TAS-120 is an oral FGFR inhibitor
75572988|NCT06065241|Dietary Supplement|LLP-01|Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.
75572989|NCT06065241|Other|Placebo|Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
75572990|NCT06064812|Drug|FWD1802|"Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days."
75572991|NCT06064812|Drug|palbocilib|"The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days."
75572992|NCT06060028|Device|Interoceptive stimulation treatment with mechanical stimulation of C-LTMRs afferences|The intervention is a non-invasive interoceptive stimulation (affective touch) delivered to the left volar forearm. The stimulation is delivered using a device with a small tactile probe that touches the skin in a circular motion. The device is designed to induce maximum firing frequency in the peripheral C-Ts nervous afferents, which respond to low-force, low-velocity stimuli, specifically 3 cm/sec, 2.5mN. The stimulation will be delivered in 18 blocks, each consisting of 6 short periods of stimulation of varying durations presented in random order, with pauses of 6 seconds after every single stimulation, the entire stimulation protocol will have a total duration of 30 minutes.
75572993|NCT06060028|Device|Sham treatment|In the sham condition, patients will receive a similar stimulation with the interoceptive tactile device, however, the device will be turned on for only 3 seconds every minute, and consequently turned off for 57 seconds. The entire duration of the stimulation will be approximately 30 minutes, similar to the experimental condition.
75572994|NCT06055751|Device|TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473)|No intervention will be done as part of this prospective registry. Implantation of Boston Scientific Loop Recorder (LUX-Dx) will be performed regardless of this research and outside this research protocol per standard of care
75877940|NCT05462769|Device|Percutaneous vascular closure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
75877941|NCT05462691|Procedure|tuberosity suture|to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
75426405|NCT04093362|Drug|Cisplatin/Gemcitabine|Cisplatin/Gemcitabine is currently 1st line standard of care
75426406|NCT04077164|Other|No intervention, observational only.|No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
75426407|NCT04073420|Device|Surgical Heart Valve Repair Products|Surgical heart valve repair products.
75426408|NCT04073420|Device|Surgical Heart Valve Replacement Products|Surgical heart valve replacement products.
75426409|NCT04070027|Procedure|Total Hip Arthroplasty|Total hip arthroplasty following standard procedures.
75426410|NCT04070027|Other|Progressive Resistance Training|"Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the American College of Sports Medicine (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power."
75426411|NCT04061239|Drug|CPX-351|CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
75426412|NCT04061239|Drug|Daunorubicin|Daunorubicin is commercially available as a powder for reconstitution in 20 mg vials. In this trial, daunorubicin should be administered as an IV infusion over 60 min.
75426413|NCT04061239|Drug|Cytarabine|Cytarabine is commercially available as vials/bottles for preparation of diluted infusion solution. Cytarabine will be administrated intravenously. In this trial, cytarabine is administered as a continuous infusion.
75426414|NCT04061239|Drug|Azacitidine|Azacitidine at 75mg/m² for 7 days. Patients should receive a minimum of 2 and up to 6 cycles.
75426415|NCT04053452|Diagnostic Test|Peripheral nerve ultrasound|Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
75426416|NCT04053452|Diagnostic Test|Measurement of strength|Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
75572995|NCT06053983|Device|Turbox CRP kit|Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.
75572996|NCT06053983|Drug|rosuvastatin 20 mg,|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
75572997|NCT06053983|Drug|atorvastatin 40 mg|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
75724975|NCT00924846|Procedure|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
75724976|NCT00924924|Behavioral|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
75724977|NCT00924924|Behavioral|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
75724978|NCT05373537|Behavioral|Cognitive behavioral therapy for Insomnia|Caregiver with insomnia will receive CBT-Insomnia and will be trained to implement CBT-I tailored for their child with Autism Spectrum Disorder and Insomnia
75877942|NCT03597152|Dietary Supplement|WelTract|Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
75877943|NCT03597152|Dietary Supplement|Placebo|Inert placebo custom manufactured for the sponsor
76047886|NCT02478359|Behavioral|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
76047887|NCT01877668|Drug|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
76047888|NCT01877668|Drug|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
76047889|NCT01877668|Drug|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
75724979|NCT00727961|Drug|Pegylated Liposomal Doxorubicin hydrochloride|Caelyx Intravenous, 50 mg/m^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
76047890|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
76047891|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
75724980|NCT00568958|Behavioral|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
75877944|NCT03075501|Behavioral|Paired|Drug conditioning is assessed by pairing drug administration with a given context.
76047892|NCT01877278|Device|Wearable pulsed electromagnetic fields|
75426417|NCT04052191|Biological|MCRcI® stem cells|Intra-Coronary Administration of MCRcI® stem cells
75426418|NCT04050163|Biological|MiSaver®|Intravenous administration of MiSaver® Stem Cell via peripheral vein access.
75426419|NCT04037709|Procedure|scaling and root planing (SRP) + PDT placebo|Patientes will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
75426420|NCT04037709|Procedure|scaling and root planing (SRP) + PDT|patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done only on one side of mouth using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
75426421|NCT04036227|Drug|GS-248|GS-248 oral solution
75724981|NCT00568958|Drug|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
75426422|NCT04036227|Drug|Placebo|Placebo oral solution with the same composition to match active drug
75572998|NCT06053840|Drug|Chloral Hydrate|Participants will be involved in the trial for approximately 7-8 weeks, the first week to collect baseline data and complete screening and eligibility confirmation, the following two weeks they will administer IMP, and there will be a further 4 week observation period. All trial recruitment and follow-up procedures will be conducted remotely via telephone/video calls.
75572999|NCT06051968|Behavioral|Online hearing support for first-time hearing aid users|Participants get hearing rehabilitation according to common practice and the online hearing support consists of five chapters that aim to give information, support, and advice to the new hearing aid users. The participants are assigned a new chapter between each visit at the clinic.
75573000|NCT06051968|Behavioral|Hearing rehabilitation according to common practice.|Participants get hearing rehabilitation according to common practice.
75724982|NCT00568958|Drug|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
75573001|NCT06049693|Drug|Ferrous Gluconate 300 MG|Ferrous Gluconate 300 MG twice a day
75724983|NCT03540771|Other|Palliative Care|"The intervention will comprise an approach to render palliative care, as taught to hepatologists through an on-line learning platform, and as delivered by PC providers as routine care. The elements of the intervention, which will be guided by a checklist and implemented over the course of interactions with the patient and caregivers at the initial, 1, 2, and 3 month visits, to include:~Patient/caregiver understanding of diagnosis, illness and prognosis~Symptom assessment and management~Psychosocial assessment and management~Distress screening and management~Discussion of goals of care~Advanced directives"
75724984|NCT02590835|Procedure|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
75573002|NCT06049160|Drug|Misoprostol|All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
75877945|NCT03075501|Drug|Stimulant or sedative|CS+ for paired, CS0 for unpaired
75877946|NCT03075501|Drug|Placebo|CS- for paired, CS0 for unpaired
75877947|NCT03597074|Diagnostic Test|color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization|Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
76047893|NCT01906372|Drug|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
76047894|NCT01925170|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
75573003|NCT06047834|Drug|Standard of Care with Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 escalating dose levels (in terms of lofexidine base): low dose, mid dose, or high dose.
75573004|NCT06047834|Other|Standard of Care without Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care without lofexidine wilt receive non-pharmacologic measures and morphine when indicated.
75573005|NCT06046937|Drug|Monolaurin|applied thinly twice a day
75573006|NCT06046937|Drug|Mupirocin ointment|applied thinly twice a day
75573007|NCT06046443|Drug|LB54640|Oral daily administration
75573008|NCT06046443|Drug|Placebo|Placebo matched to LB54640
75426423|NCT04036136|Behavioral|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
75426424|NCT04036136|Behavioral|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
75426425|NCT04034004|Behavioral|Mindfulness|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
75426426|NCT04034004|Drug|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
75426427|NCT04034004|Other|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.
75573009|NCT06042088|Other|Regular Size Glove and Bigger One|Different sizes of surgical gloves will be worn by participants
75573010|NCT06041620|Biological|VGB-Ex01|CRISPR-Cas12b editing hematopoietic stem cells
75573011|NCT06041139|Diagnostic Test|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
75573012|NCT06041139|Diagnostic Test|Defocus Curve|Measurement of visual acuity performed from +1.00 to -4.00 in 0.50 diopter steps and with +0.25 and -0.25 added.
75573013|NCT06041139|Diagnostic Test|Halo and Glare testing|Measurement to quantify degree of visual loss caused by either halo and/or glare.
75724985|NCT02590835|Procedure|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
75724986|NCT00821912|Drug|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
76047895|NCT01925170|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
76047896|NCT01925170|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
76047897|NCT01925014|Diagnostic Test|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
75573014|NCT06041139|Other|Patient Questionnaires|Patients will complete a series of questionnaires to record self-reported visual disturbances, visual acuity satisfaction, level of spectacle independence and any issues with glare, halos, and/or starbursts.
75573015|NCT06038851|Procedure|Para-Sartorial Compartments (PACS) Block|"This intervention was selected because it has the potential to optimize analgesia by skin coverage of the upper third of the surgical incision. The intervention will be performed as follows:~The intermediate femoral cutaneous nerve will be visualized at the supralateral level of the sartorius muscle, in a duplicature of the fascia lata.~The needle will be inserted at the same puncture site as for the femoral triangle block, with a latero-medial orientation in the plane (intracanalar compartment).~In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed in addition, below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment)."
75573016|NCT06038851|Procedure|Femoral Triangle Block (FTB)|"The high frequency linear ultrasound probe will be positioned midway between the superior edge of the patella and the anterosuperior iliac spine. It will then be moved to visualize the apex of the femoral triangle, confirmed by visualization of the sartorius muscle laterally and the long adductor medially.~The needle will be inserted with a latero-medial orientation in the plane.~The initial injection will be a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle."
75724987|NCT00821912|Drug|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
75724988|NCT05690997|Other|Intensive treatment|If the mean home SBP preceding clinic follow-up is >130mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is <120mmHg, BP lowering treatment will be stepped down, until the target SBP of 120-129mmHg is achieved, or symptoms of hypotension prevent treatment to be further intensified.
75877948|NCT03596528|Procedure|Lung biopsy|Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
75877949|NCT05462535|Drug|Amosartan Plus Tab.|Amosartan Plus Tab., Once daily administered per the locally approved product information
75877950|NCT05764317|Drug|Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
76047898|NCT01925014|Diagnostic Test|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
76047899|NCT01876810|Drug|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
76047900|NCT01876810|Drug|Placebo|One lactose pill twice a day for two weeks.
76047901|NCT01876732|Drug|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
76047902|NCT01905592|Drug|niraparib|300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops
75573017|NCT06038851|Procedure|Infiltration between popliteal artery and capsule of the knee (IPACK) block|It will be performed in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
76047903|NCT01905592|Drug|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
75426428|NCT04034004|Behavioral|Meditation|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
76047904|NCT01876420|Device|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
75426429|NCT04033029|Device|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
75426430|NCT04033029|Drug|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
75426431|NCT04026503|Other|Live Long Walk Strong rehabilitation program|Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
75573018|NCT06036108|Drug|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered at least 10 hours of fasting. In Period 2, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal.
75573019|NCT06036108|Drug|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal. In Period 2, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered following at least 10 hours of fasting.
75573020|NCT06035211|Other|3D model pré-operative education|Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group
75573021|NCT06027034|Behavioral|Online program for psoriasis (GAIA-PSO-01)|The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.
75573022|NCT06026826|Device|transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
75426432|NCT04022746|Procedure|Magnetic Resonance Elastography|Undergo multiparametric MRI/MRE
75426433|NCT04022746|Procedure|Magnetic Resonance Imaging|Undergo multiparametric MRI/MRE
75426434|NCT04020185|Drug|IMSA101|IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
75573023|NCT06026826|Device|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
75877951|NCT05764317|Drug|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
76047905|NCT04608682|Drug|Sugammadex|The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
75573024|NCT06020950|Other|Control|Low-calorie diet with the use of placebo pearls (containing sunflower oil)
75573025|NCT06020950|Dietary Supplement|Omega-3 supplementation|Low-calorie diet with the use of marine omega-3 pearls (containing 1200 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid/day)
75426435|NCT04020185|Drug|Immune checkpoint inhibitor (ICI)|Administered according to product label
75573026|NCT06020950|Other|Chia seed|Low-calorie diet with the consumption of 30 grams of powdered chia seeds
75573027|NCT06018662|Other|A medication management mobile application|A mobile application to select the most appropriate drugs for anesthetics, antimicrobials and analgesics, in addition to dose calculations
76047906|NCT04608682|Drug|Saline|The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
75426436|NCT04020185|Drug|Immuno-oncology (IO) therapy|Administered according to product label
75573028|NCT06017180|Other|Myofascial Release Techniques|Volleyball players will perform these practices with a physiotherapist 3 days a week for 8 weeks (24 sessions), and their routine sports training will continue. Participants in the group will be shown how to use rolling materials. The application will be performed as 2 sets in a session using the body weight of the person, as 10 rolls in 1 minute. The application time will be 2 minutes in total for each session. There will be 30 seconds of rest between sets. The participation rate limit for the sessions was determined as 80%. The application rate will be controlled with a metronome. The pressure to be created using body weight will be controlled by a numerical pain scale. The technique will be applied to the biceps brachii, latissimuss dorsi, upper trapezius, pectoralis minor, pectoralis major, and thoracic extensor muscles. During the application, a foam roller and a rolling stick (Thera-Band, Hygienic Corporation, Akron, OH) will be used.
75573029|NCT06017180|Other|Sham myofascial release technique|It was planned to apply the sham myofascial release technique to the athletes in the control group. In this application; with the help of the palm of the hand, pressure will be applied to the surface of the relevant muscles, first without pressure for 1 minute, then after resting for 30 seconds. The given pressure will be 2 out of 10 (0: No pain/discomfort due to pressure, 10: Unbearable pain/discomfort due to pressure). This group will also be given the right to receive a myofascial relaxation program which the experimental group received, after the study period ended.
75573030|NCT06014047|Procedure|No-touch vein graft|Two No-touch saphenous vein grafts anastomose to the right coronary and left coronary system. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
75573031|NCT06014047|Procedure|Radial artery graft|One radial artery graft and one conventional saphenous vein graft anastomose to the right coronary or left coronary system basing on surgeons' decision. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
75724989|NCT05690997|Other|Standard treatment|If the mean home SBP preceding clinic follow-up is >140mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is <130mmHg, BP lowering will be stepped down, until the target SBP 130-140mmg is achieved or symptoms of hypotension prevent treatment being intensified.
75426437|NCT04007380|Other|Continuous positive airway pressure (CPAP) therapy|The participants will undergo CPAP therapy for 4 consecutive months in the management of moderate-to-severe SRBDs
75426438|NCT04000880|Behavioral|Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
75426439|NCT04000880|Other|Diet-Exercise|Diet-Exercise
75426440|NCT04000880|Other|Exercise-Diet|Exercise-Diet
75426441|NCT04000880|Other|Combined Diet and Exercise|Combined Diet and Exercise
75724990|NCT02593253|Other|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
75724991|NCT02593253|Other|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
75724992|NCT00816764|Biological|AGS-8M4|IV Infusion
75877952|NCT05764317|Drug|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
75426442|NCT03998579|Other|The CanMoRe programme|An exercise intervention in Primary Health Care
75426443|NCT03998579|Other|Home exercise|An active control group
75426444|NCT03995641|Drug|marcaine and kenalog|Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
75426445|NCT03977753|Drug|2LVERU® or 2LVERU® JUNIOR|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
75573032|NCT06009523|Device|Transcranial direct current stimulation|1 stimulation per day during 15 days.
75426446|NCT03977753|Drug|Placebo|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
75426447|NCT03969706|Drug|Abemaciclib 200 MG|Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
75426448|NCT03964259|Drug|Intravenous fluids|Administration of post HDMTX intravenous fluids (IVF)
75426449|NCT03957473|Device|Indigo Aspiration System|Indigo Aspiration System with CAT RX Aspiration Catheter and optional Indigo Separator 4
75573033|NCT06007677|Drug|STAR-0215|STAR-0215 will be administered as a subcutaneous injection.
75573034|NCT05988151|Other|New surgical approach|Patients were included in the study after obtaining informed consent for the new surgical approach inspired by the Fibonacci ratio.
75573035|NCT05986266|Drug|Carbetocin|To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
75573036|NCT05982132|Other|anthropometric measurement|Measurement of weight and other anthropometrics data
75573037|NCT05980728|Other|No Intervention|No Intervention
75724993|NCT05325905|Diagnostic Test|Gingival crevicular fluid sampling|GCF sampling and clinical periodontal measurements were performed
76047907|NCT01875874|Biological|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
75426450|NCT03952962|Device|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.
75426451|NCT03926312|Device|Smart device-based cardiac rehabilitation|A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
75426452|NCT03922984|Procedure|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
75426453|NCT03893279|Behavioral|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
75426454|NCT03891784|Drug|Abemaciclib|Given PO
75573038|NCT05979779|Drug|HU6|HU6 is being evaluated for its efficacy in improving liver fat content in obese subjects with Type 2 Diabetes at risk of Nonalcoholic Steatohepatitis (NASH)
75573039|NCT05979779|Other|Placebo|Placebo
75573040|NCT05978687|Drug|OPHTESIC LIDOCAINE HYDROCHLORIDE 20MG/G|"In group A, all patients will receive topical 2% lidocaine gel (ophtesic lidocaine hydrochloride 20 mg/G) prior to surgery.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
75724994|NCT00820976|Drug|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
75724995|NCT00727649|Drug|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
75724996|NCT00727649|Drug|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
75724997|NCT00987597|Behavioral|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
75724998|NCT00987597|Behavioral|conventional follow-up|nicotinic substitutes
75724999|NCT00568334|Biological|Varilrix (inactivated varicella vaccine)|subcutaneously injection
75725000|NCT04006041|Drug|Toripalimab|Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
76047908|NCT04619446|Device|Removable Twin Block|Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
75573041|NCT05978687|Drug|Xylocaine with Epinephrine|"In group B, all patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle. When asked for, patients will receive additional topical 1% lidocaine eye drops.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
75725001|NCT04006041|Drug|Paclitaxel/cisplatin|Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
76047909|NCT04619446|Device|Fixed Functional , AdvanSync Appliance|AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
75725002|NCT04006041|Radiation|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.
75725003|NCT04006041|Procedure|Esophagectomy|A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
76047910|NCT02500121|Other|Placebo|Normal saline
75573042|NCT05971082|Other|Follow-up|Follow-up study of progression/remission of liver disease
75573043|NCT05967598|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment
75573044|NCT05967598|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
76047911|NCT02500121|Drug|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
76047912|NCT01875250|Biological|PROSTVAC-F (Fowlpox)/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
76047913|NCT01875250|Biological|PROSTVAC-V (Vaccinia)/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
76047914|NCT01875250|Drug|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
76047915|NCT01904032|Drug|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
76047916|NCT01904032|Drug|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
75426455|NCT03868410|Device|New rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
75426456|NCT03868410|Device|Conventional rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be stimulated with high-frequency rTMS (5-Hz) using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
75426457|NCT03866954|Combination Product|EE-TP|Ecoli thymidine phoshorylase encapsulated within autologous erythrocytes
75426458|NCT03862950|Drug|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
75426459|NCT03862950|Drug|Metformin|Active medication
75426460|NCT03848065|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
75426461|NCT03848065|Biological|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
75426462|NCT03848065|Biological|Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)|Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
75725004|NCT00727571|Other|Observations|This is a non-interventional, observational study; no investigational product is being used
75725005|NCT00225277|Drug|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
75426463|NCT03846830|Device|Incremental Velocity Error (IVE)|A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.
75573045|NCT05967598|Device|Sham cyma conchae stimulation|The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.
75573046|NCT05961332|Device|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
75573047|NCT05961332|Device|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
75725006|NCT00225277|Drug|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
75725007|NCT00821054|Drug|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
75877953|NCT03596216|Other|PENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.
75725008|NCT04391673|Behavioral|Vestibular rehabilitation|Vestibular rehabilitation (treatment as usual).
75573048|NCT05961332|Device|Zeiss Clarus 700 imaging|Zeiss Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
75725009|NCT00567996|Drug|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
75725010|NCT00567996|Drug|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
75573049|NCT05961059|Biological|2.5 μg InvaplexAR-Detox|2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
75573050|NCT05961059|Biological|10 μg InvaplexAR-Detox|10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
75725011|NCT00567996|Drug|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
75725012|NCT00567996|Drug|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
75725013|NCT00821990|Drug|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
75573051|NCT05961059|Biological|0.1 μg of dmLT|0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
75573052|NCT05961059|Biological|Placebo|Placebo vaccination with commercially available saline solution.
75877954|NCT03596216|Other|TENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
76047917|NCT01903876|Behavioral|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
75573053|NCT05960994|Other|Intervention period|"During the intervention period, three interventions will be implemented through telemedicine.~A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.~A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.~A management intervention package will be implemented, with a specific focus on enhancing quality and safety."
75573054|NCT05948813|Drug|TY-9591|The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
75573055|NCT05948813|Drug|Osimertinib|The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
75573056|NCT05948267|Drug|ketamine- dexmeditomidine admixure|ketamine in anesthetic dose mixed with two different doses of dexmeditomidine
75725014|NCT00821990|Other|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
75725015|NCT04388319|Drug|Zonisamide|Zonisamide (100 mg/daily) for 12 weeks.
75877955|NCT05461443|Dietary Supplement|Probiotic|
76047918|NCT01903876|Behavioral|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
76047919|NCT01921348|Device|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
76047920|NCT01921348|Device|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
76047921|NCT01921270|Drug|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units"
75426464|NCT03846830|Behavioral|Traditional Vestibular Rehabilitation (VPT)|Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.
75426465|NCT03844750|Procedure|Hepatectomy|Undergo liver resection.
75573057|NCT05948267|Drug|Propofol, Lidocaine and fentanyl|Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
75573058|NCT05945303|Procedure|Coronary Artery Bypass Grafting surgery|Assessing the reliability of predicting fluid responsiveness in adults undergoing coronary artery bypass graft surgery using ultrasonography of the internal jugular vein for assessment of vessel distensibilty in relation to stroke volume variation (SVV) measured by electrical cardiometry.
75573059|NCT05944965|Drug|Atomoxetine 80 mg plus Oxybutynin 5 mg|80mg Atomoxetine and 5mg Oxybutynin administered 30mins prior to bed
75573060|NCT05944965|Drug|Atomoxetine 80 MG|80mg Atomoxetine administered 30 mins prior to bed
75573061|NCT05944965|Drug|Placebo|Placebo and placebo (sugar pill) administered 30 mins prior to bed
75573062|NCT05935085|Drug|ANB032|BTLA agonist antibody
75573063|NCT05935085|Drug|Placebo|Placebo
75573064|NCT05921149|Dietary Supplement|Fasting Mimicking Diet (Xentigen by L'Nutra)|L-Nutra Xentigen is a product which will provide all the food to be consumed by subjects during 3 days prior to chemotherapy and for 24 hours after chemotherapy. Xentigen is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients that are generally regarded as safe (GRAS) and comprises proprietary vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. The FMD consists of a 4-day regimen that provides approximately 1100 kilocalories for the first day and approximately 500 kilocalories per day for the second to the fourth day. Subsequently, a day 5 of transition diet (approximately 800 kilocalories) is provided to avoid the refeeding syndrome.
75573065|NCT05921149|Drug|Carboplatin|Given IV
76047922|NCT02325739|Drug|FGF401|FGF401 is a FGFR4 inhibitor.
76047923|NCT02325739|Biological|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
76047924|NCT05121922|Behavioral|Metacognitive Therapy|Psychological treatment provided by the patient's regular general practitioner
76047925|NCT01903720|Drug|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
76047926|NCT02366689|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
76047927|NCT02366689|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
75573066|NCT05921149|Drug|Paclitaxel|Given IV
75573067|NCT05921149|Dietary Supplement|Standard diet|Normal diet
75573068|NCT05918354|Device|Skin Prick Automated Test|Detection of sensitisation to specific allergens via the skin prick automated test.
76047928|NCT02366689|Drug|fluoride only toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
76047929|NCT02366689|Drug|Cetylpyridinium chloride mouthwash|Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
76047930|NCT02366689|Drug|Fluoride only mouthwash|Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
75426466|NCT03844750|Biological|Pembrolizumab|Given IV
75426467|NCT03844750|Drug|Vactosertib|Given orally once a day (QD) for cycle 1, and twice a day (BID) for cycle 2 and beyond
75426468|NCT03806803|Biological|Lyophilized fecal microbiota transplant|15 capsules
75426469|NCT03806803|Biological|Lyophilized sterile fecal filtrate|15 capsules
75426470|NCT03806166|Other|Shorter Systemic Antibiotics|Reduced duration of post-operative systemic antibiotic therapy
75426471|NCT03806166|Other|Standard treatment|Standard duration of systemic antibiotic treatment
75426472|NCT03792867|Drug|Doxorubicin|Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
75426473|NCT03781921|Other|No intervention|There is no intervention. Each group will conduct the same tasks and questionnaires and we will compare performances between groups.
75426474|NCT03765918|Biological|Pembrolizumab 200 mg|200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
75426475|NCT03765918|Radiation|Radiotherapy 60 Gray/day|Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
75426476|NCT03765918|Radiation|Radiotherapy 66 Gray/day|High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
75426477|NCT03765918|Radiation|Radiotherapy 70 Gray/day|Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
75426478|NCT03765918|Drug|Cisplatin 100 mg/m^2|100 mg/m^2 administered by IV infusion on Day 1 of each 21-day cycle
75426479|NCT03756896|Drug|Carfilzomib|Given IV
75426480|NCT03756896|Drug|Dexamethasone|Given PO
75426481|NCT03756896|Drug|Pomalidomide|Given PO
75573069|NCT05910502|Behavioral|Autism Family Empowerment Coaching and Training Program|Participants in the intervention group will be connected with Project AFECT Coaches who will provide: Coaching to (1) assure parents understand diagnosis, (2) assist parents in finding accurate, current information about autism, (3) guide parents to free online autism training resources, (4) empower parents to evaluate child's intervention plan holistically, and (5) provide emotional support to reduce stress; Navigation to (1) help family access autism treatments, and (2) connect to early intervention and educational services.
75573070|NCT05908253|Behavioral|sham neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.
75573071|NCT05908253|Behavioral|nonadaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.
75573072|NCT05908253|Behavioral|adaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
75573073|NCT05908058|Other|Emotional Changes Investigation|Emotional Changes between Emergency and Intensive care unit and On-site Counter Staffs after COVID-19 Infection and Exploring The Impact of Personnel Emotional Adjustment
75573074|NCT05903547|Device|Dermabond Prineo|For subjects in the Dermabond Prineo group, the Dermabond Prineo system will be applied to the skin for skin closure under manufacturer's guidelines.
75573075|NCT05903547|Other|Suture|For subjects in the Suture group, the skin will be closed with the standard subcuticular suture method.
75573076|NCT05898529|Diagnostic Test|Rapid antigen test|COVID-19 rapid antigen testing of nasal swab
75573077|NCT05895006|Device|alpha-frequency tACS|The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.
75573078|NCT05895006|Device|Random noise stimulation|The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).
75877956|NCT05461365|Drug|Insulin|Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
76047931|NCT01903252|Drug|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
75877957|NCT03602846|Dietary Supplement|Medical Nutrition Therapy|Only given medical nutrition therapy.
75877958|NCT03602846|Drug|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
75426482|NCT03741764|Device|Vivosorb|Resorbable implant device
75426483|NCT03737955|Drug|Gemtuzumab Ozogamicin|Receive IV
75426484|NCT03737955|Other|Quality-of-Life Assessment|Ancillary studies
75426485|NCT03737669|Biological|Mirasol-treated Fresh Whole Blood|Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
75426486|NCT03737669|Biological|Standard Fresh Whole Blood|Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
75426487|NCT03716128|Diagnostic Test|18F-PET|Bone biopsy and 18F-PET
75426488|NCT03686007|Other|Informational Intervention|Receive MSM intervention handbook
75426489|NCT03686007|Other|Informational Intervention|Receive MSM intervention research nurse coaching
75426490|NCT03686007|Other|Informational Intervention|Receive ASCO print materials
75426491|NCT03686007|Other|Informational Intervention|Receive CRA assistance
75426492|NCT03686007|Other|Media Intervention|View the MSM intervention videos
75426493|NCT03686007|Other|Media Intervention|View ASCO Cancer.net videos
75426494|NCT03686007|Other|Quality-of-Life Assessment|Ancillary studies
75426495|NCT03686007|Other|Questionnaire Administration|Ancillary studies
75725016|NCT04388319|Drug|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
75426496|NCT03683225|Combination Product|CTC-413|pramipexole ER, given with aprepitant
75725017|NCT04388319|Other|Halo G6 e-cigarette|G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
75426497|NCT03678389|Other|ESC|USE OF ENDOSPHENOIDAL COIL (ESC) TO OBTAIN MRI IMAGING OF THE PITUITARY GLAND
75426498|NCT03668223|Behavioral|Promoting Resilience in Stress Management (PRISM)|Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
75426499|NCT03642964|Drug|CTC-501|pramipexole IR, given with ondansetron
75426500|NCT03638999|Drug|Ketorolac Trometamol 30Mg/1mL Injection|Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.
75426501|NCT03638999|Drug|Normal saline|Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
75426502|NCT03636438|Other|No Intervention|No Intervention
75426503|NCT03635892|Drug|cabozantinib|cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
75426504|NCT03635892|Drug|nivolumab|Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
75725018|NCT04085627|Drug|Valsartan and Amlodipine Tablets|1 tablet contains Valsartan 80mg& Amlodipine 5mg
75725019|NCT00821210|Device|Sham CPAP|CPAP with pressure of 3cm H2O
75725020|NCT00821210|Device|CPAP of optimal pressure|CPAP of optimal pressure
75877959|NCT03602846|Drug|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
75877960|NCT02317991|Drug|nab-paclitaxel|nab-paclitaxel 125 mg/m^2 IV
76047932|NCT01903252|Drug|Asacol 400 mg|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
75426505|NCT03629223|Drug|Tepotinib TF2|Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
75426506|NCT03629223|Drug|Tepotinib TF3|Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
75426507|NCT03625765|Device|SmartGoggles|the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
75725021|NCT03970135|Other|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose < 3mmol/L) or symptoms of hypoglycemia
75426508|NCT03622775|Biological|Daratumumab|Given IV
75426509|NCT03614702|Biological|1-dose cIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
75426510|NCT03614702|Biological|1-dose sIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
75426511|NCT03614702|Biological|2-doses cIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
75426512|NCT03614702|Biological|2-doses sIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
75725022|NCT04086173|Dietary Supplement|Probiotics|Probiotics will be administered at night and will consist of 4 capsules
75725023|NCT04086173|Other|Placebo|Placebo
75725024|NCT04005261|Diagnostic Test|C-peptide concentrations|The patients will be grouped by their C-peptide concentrations
75725025|NCT00821288|Behavioral|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
75877961|NCT02317991|Biological|ramucirumab|Ramucirumab 8 mg/kg IV
75877962|NCT03602768|Behavioral|Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
75426513|NCT03614702|Biological|2-doses cIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
75426514|NCT03614702|Biological|2-doses sIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
75573079|NCT05894655|Behavioral|COVID-19 walk-up, on-site testing strategy|This strategy is a no-appointment, walk-up point-of-care PCR and rapid testing strategy for clinic patients and community members. It will be offered 5 days/week for 7 hours during the first 3 months of the trial at Clinic 1. The intensity will decrease over the trial ending with 1 SYH Medical Assistant overseeing the testing protocol. Bilingual research staff will be trained to oversee onsite testing.
75573080|NCT05894655|Behavioral|Community Health Worker (CHW) leading testing navigation and general preventive care reminders|This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.
75725026|NCT00821288|Behavioral|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
75426515|NCT03614702|Biological|1-dose cIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
75426516|NCT03614702|Biological|1-dose sIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
75426517|NCT03614702|Biological|2-doses cIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
75426518|NCT03614702|Biological|2-doses sIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
75426519|NCT03614702|Biological|2-doses cIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
75426520|NCT03614702|Biological|2-doses sIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
75426521|NCT03611933|Other|position change applied at different times|Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
75426522|NCT03568383|Drug|Delamanid (DLM)|"Adults and children ≥30 kg: delamanid 200 mg orally once daily.~Children ≥2.5 kg to <30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits."
75573081|NCT05894655|Behavioral|No-cost self-testing kit vending machines|This strategy includes vending machines that will provide interactive instructions for accessing free self-testing COVID-19 kits located outside of clinics for patients and community members to use anytime. The vending machines will be available 24 hours/day, 7 days a week.
75573082|NCT05886972|Behavioral|Awareness about propofol injection induced pain|The aim of the study is to observe the effect of patient awareness about the possibility of occurrence of pain during propofol injection on the rate of incidence and severity of pain during injection as a primary goal as the pain score of propofol injection pain is the main end point of the study .
75725027|NCT00224887|Behavioral|In home nutrition counseling|In home family-based behavioral counseling
76047933|NCT01920958|Other|TachoSil®|TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and tissue sealing in surgery.
75725028|NCT00224887|Other|standard nutrition education curriculum|video and lesson plans based on USDA Food Guide Pyramid
75426523|NCT03568383|Drug|Isoniazid (INH)|"Adults and children ≥24 kg: INH 300 mg orally once daily.~Children ≥2.5 kg to <24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted."
75573083|NCT05873959|Biological|HAV implantation|HAVs already implanted under humanitarian aid program to repair or reconstruct arteries following an extremity life- or limb-threatening traumatic injury.
75573084|NCT05867030|Drug|lenalidomide|lenalidomide is administered orally
75573085|NCT05867030|Drug|rituximab|rituximab is administered intravenously
75573086|NCT05867030|Drug|parsaclisib|parsaclisib is administered orally
75573087|NCT05863351|Procedure|Computed Tomography|Undergo CT
75877963|NCT03602768|Behavioral|Memory & Aging Program|Pre-recorded videos and activities combine psycho-education, memory strategy training, and social support to educate about normal memory change in aging, normalize the experience of participants going through it, and equip them to handle age-related memory change.
76047934|NCT04415398|Device|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=3 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over 4 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
76047935|NCT01613716|Drug|Ozurdex|Ozurdex .7 mg injected into the treated eye
75426524|NCT03568383|Dietary Supplement|Pyridoxine (vitamin B6)|All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
75426525|NCT03567473|Drug|Oral dexamethasone|Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later
76047936|NCT01872910|Drug|Placebo|Administered orally
75426526|NCT03567473|Drug|Nebulized Epinephrine|Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
75573088|NCT05863351|Procedure|Magnetic Resonance Imaging|Undergo MRI
75426527|NCT03567473|Drug|Oral placebo|Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.
75426528|NCT03567473|Drug|Nebulized normal saline|Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
75426529|NCT03567473|Drug|MDI Epinephrine|Two doses of Epinephrine given by MDI plus spacer at 625 mcg (5 actuations of 125mcg) 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
75573089|NCT05863351|Other|Questionnaire Administration|Ancillary studies
75426530|NCT03567473|Drug|MDI placebo|Two doses of inhaled placebo given by MDI plus spacer, 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
75426531|NCT03547908|Drug|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
75426532|NCT03547908|Drug|Placebo to match DTG|Tablet administered orally once daily, without regard to food
75573090|NCT05863351|Procedure|Stereotactic Ablative Radiotherapy|Undergo SAbR
75573091|NCT05863351|Procedure|Systemic Therapy|Given standard of care systemic therapy
75573092|NCT05862051|Procedure|Local Ablative Therapy|LAT modalities allowed include surgical resection, stereotactic radiotherapy (SRT), laparoscopic or percutaneous thermal ablation [radiofrequency ablation (RFA) or microwave ablation (MWA)]. The LAT modalities will be delivered by specialists in the field (surgeons, radiation oncologists and/or interventional radiologists). The precise mode of delivery and number of times the LAT modality is delivered is case-dependent and is determined at a multi-disciplinary meeting (MDM).
75877964|NCT03602768|Behavioral|Cambridge Brain Sciences|Commercial brain training software available for subscription to the general public and for research studies.
75877965|NCT00861549|Drug|Phencynonate hydrochloride|2mg/tablet
75877966|NCT03602690|Drug|Dolutegravir + Darunavir/ritonavir + optimized NRTI|Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
75877967|NCT01379547|Behavioral|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
75877968|NCT01379547|Behavioral|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
75877969|NCT02237612|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
76047937|NCT01872910|Drug|LY3023703|Administered orally
76047938|NCT01872910|Drug|Celecoxib|Administered orally
76047939|NCT01920568|Biological|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
76047940|NCT01920568|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance <=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
75426533|NCT03547908|Drug|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
75426534|NCT03547908|Drug|DTG|50 mg tablet administered orally once daily, without regard to food
75426535|NCT03547908|Drug|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
75426536|NCT03547908|Drug|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
75426537|NCT03539380|Drug|TRx0237|Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)
75426538|NCT03519685|Behavioral|Contraceptive Training and Education|Staff at the student health center and local health centers where they refer for contraceptive services will receive a CME-accredited education and training session and technical assistance. The one-day session emphasizes evidence-based and patient-centered contraceptive counseling and provision. Students attending colleges assigned to the intervention arm will receive materials and resources designed to educate young people about contraceptive methods and where to access services.
75426539|NCT03519685|Behavioral|Placebo Nutrition Education|Students attending colleges assigned to the nutrition education arm will receive materials and resources designed to educate young people about the impacts of sugar on health.
75426540|NCT03517579|Device|Cervical Collar Therapy Indicator (COTI)|"Study Device; The CoTI has 3 components;~A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~A cable that connects the collar unit to the Control Unit~A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131."
75426541|NCT03510104|Drug|MRX-2843|MRX-2843 capsules
75426542|NCT03500328|Other|Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy|Early Aggressive Therapy
75426543|NCT03500328|Other|Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod|Traditional Therapy
75877970|NCT02237612|Other|laboratory biomarker analysis|Correlative studies
75877971|NCT02978495|Drug|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
76047941|NCT01920568|Drug|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
75426544|NCT03469674|Radiation|Vaginal brachytherapy|Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks
75426545|NCT03469674|Radiation|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 48.6 Gy in 27 out-patients sessions over 5.5 weeks
75426546|NCT03469674|Other|Observation|No radiation therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
75426547|NCT03464760|Dietary Supplement|3.5g of spirulina per day in 1% silicone|5 tablets of 700mg per day
75877972|NCT02978495|Drug|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
76047942|NCT01920568|Drug|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
76047943|NCT01920568|Dietary Supplement|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
75877973|NCT02978495|Drug|Paclitaxel|80mg/m2 weekly for 12 weeks
75877974|NCT02978495|Drug|Cyclophosphamide|600mg/m2 4 cycles each 21 days
75877975|NCT02237690|Drug|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
75573093|NCT05862051|Procedure|Standard first-line systemic treatment|Standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
75573094|NCT05829785|Device|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vascular occlusion test
75573095|NCT05827081|Drug|Ribociclib|400 mg daily on days 1-21 of a 28 day cycle followed by 7 days rest
75725029|NCT04085393|Drug|GRANISETRON EXTENDED RELEASE INJECTION (GERSC)|GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
75426548|NCT03464760|Dietary Supplement|placebo|5 tablets per day of potato-based placebo
75426549|NCT03455608|Behavioral|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified
75426550|NCT03455608|Behavioral|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
75725030|NCT00987675|Other|pharmacological study|
75725031|NCT00987675|Other|questionnaire administration|
75725032|NCT00987675|Procedure|assessment of therapy complications|
75725033|NCT00987675|Procedure|high-intensity focused ultrasound ablation|
76047944|NCT01920568|Dietary Supplement|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
76047945|NCT01920178|Device|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
75426551|NCT03455608|Behavioral|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
75426552|NCT03450343|Drug|Oral azacitidine|Azacitidine can be taken with or without food at the same time every day.
75426553|NCT03450343|Drug|R-ICE|R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
75426554|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
75426555|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
75426556|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
75426557|NCT03435250|Drug|docetaxel|Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
75573096|NCT05827081|Drug|Letrozole|Letrozole 2.5 mg orally once daily continuously
75573097|NCT05827081|Drug|Ansastrozole|Anastrozole 1 mg orally once daily continuously.
75573098|NCT05827081|Drug|Goserelin|Goserelin 3.6 mg subcutaneously once every 4 weeks
75573099|NCT05827081|Drug|Leuprolide|Leuprolide 3.75 mg subcutaneously once every 4 weeks
75573100|NCT05825170|Device|FASY L|Subjects will receive FASY L in lips at level of their scar.
75725034|NCT00987675|Procedure|quality-of-life assessment|
75725035|NCT00928902|Drug|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
75725036|NCT00928902|Biological|melanoma vaccine|six melanoma vaccines given over a 6-week period
75725037|NCT00816920|Other|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
75725038|NCT04004949|Other|Assessment of scapular balance angle and upper extremity sensorimotor function|The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores & scapular balance angle test (SBA).
75426558|NCT03435250|Drug|nab-paclitaxel|Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
75426559|NCT03435250|Drug|gemcitabine|Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
75426560|NCT03425669|Device|Stochastic Vestibular Stimulation|Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
75426561|NCT03425669|Device|Sham stimulation|Patients will receive sham stimulation in place of active vestibular stimulation.
75426562|NCT03425669|Drug|Active medication|Patients will be examined with and without medication.
76047946|NCT01901848|Behavioral|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
75426563|NCT03420014|Drug|Doxorubicin|75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
75426564|NCT03420014|Combination Product|L19TNF plus doxorubicin|13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
75426565|NCT03395405|Drug|Nitazoxanide|One 500 mg tablet twice daily with food for 56 consecutive doses
75573101|NCT05801510|Behavioral|Cognitive Muscular Therapy for knee pain|Psychologically informed physiotherapy which uses biofeedback training to reduce muscle overactivity and improve postural control and also encourages people to change the way they react to pain.
75426566|NCT03395405|Other|Placebo|One tablet twice daily with food for 56 consecutive doses
75426567|NCT03393520|Drug|Placebo|oral capsules
75426568|NCT03393520|Drug|AVP-786|oral capsules
75426569|NCT03385005|Device|Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.|The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
75573102|NCT05801198|Dietary Supplement|Artemisia afra or Annua 10g oral infusion/tea per day for 14 days|Participants will be recruited after completing standard malaria treatment, and those who have a positive qRT-PCR for plasmodium gametocyte reservoirs will be randomly assigned to either artemisia afra tea, or artemisia annua tea or into the control group with no intervention
75725039|NCT00148759|Drug|LPV/r|LPV/r 800/200 mg once daily
75725040|NCT00925080|Device|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
75725041|NCT00717275|Drug|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
75426570|NCT03381248|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe.
75426571|NCT03381248|Other|Hyaluronic Acid Injection|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain.
75426572|NCT03381248|Other|Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain. After 6 months, qualifying subjects in this group will have the option to crossover to receive cooled radiofrequency treatment.
75426573|NCT03368625|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery before surgical resection of brain mets.
75426574|NCT03357757|Drug|Valproic Acid|The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.
75426575|NCT03357757|Biological|Avelumab|10 mg/kg IV
75426576|NCT03354663|Device|TactiCath SE|Ablation to achieve pulmonary vein isolation.
75426577|NCT03344458|Drug|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
75573103|NCT05795621|Biological|IBI311|10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
75573104|NCT05795621|Biological|placebo|4 does of placebo for phase II; 8 does of placebo for phase III.
75725042|NCT00822068|Device|anodal tDCS|anodal transcranial direct current stimulation
75725043|NCT00822068|Device|cathodal tDCS|cathodal transcranial direct current stimulation
75725044|NCT00822068|Device|sham stimulation|sham stimulation
75725045|NCT04006353|Drug|ABT|320 mg, Intravenous infusion
75725046|NCT04006353|Drug|RIF|600mg q.d.
75725047|NCT00925158|Procedure|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
75725048|NCT01075789|Drug|Lignocaine|Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
75725049|NCT01075789|Drug|Placebo|Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
75725050|NCT04515849|Drug|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
75725051|NCT04515849|Drug|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
75725052|NCT04515849|Drug|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
75573105|NCT05788094|Drug|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~Tafenoquine KOZENIS® 150 mg film-coated tablets will be purchased from GSK (Glaxo Smith Kline Pharmaceutical industry), 450 mg (3 tablets) will be given."
76047947|NCT01901848|Drug|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
75573106|NCT05788094|Drug|Chloroquine plus Tafenoquine (450 mg adult dose)|"Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~Tafenoquine KOZENIS® 150 mg film-coated tablets will be purchased from GSK (Glaxo Smith Kline Pharmaceutical industry), 450 mg (3 tablets) will be given."
75573107|NCT05786482|Behavioral|Online mind-body wellness program|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
75426578|NCT03312465|Device|AS Domelock System|Hemi or Total Shoulder Arthroplasty
75426579|NCT03305419|Drug|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
75426580|NCT03305419|Drug|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
75426581|NCT03288103|Drug|Norditropin|Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
75426582|NCT03287063|Other|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
75426583|NCT03273881|Drug|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
75426584|NCT03273881|Drug|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
75573108|NCT05786482|Behavioral|Online mind-body wellness program + Weekly Check-ins|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief weekly check-ins
76047948|NCT01901848|Drug|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
75426585|NCT03245242|Other|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
75426586|NCT03245242|Other|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
75573109|NCT05783908|Combination Product|With non-magnetic screen|Radiotherapy treatment with Linac MRI is performed with a non-magnetic screen that will guide the patient to block the breathing
75573110|NCT05779618|Other|no intervention|observational study, all data collected are binary
75573111|NCT05776602|Diagnostic Test|Fast MRI (Neuromix)|Diagnostic performance, correlation, agreement
75725053|NCT04515849|Drug|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
76047949|NCT01901848|Behavioral|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
75573112|NCT05764733|Drug|Bisphosphonate|Medicine used to treat bone problems, called osteopenia or osteoporosis.
75573113|NCT05764733|Behavioral|Resistance Training/Bone-Loading Exercise|Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.
75725054|NCT04515849|Drug|Placebo|Placebo administered subcutaneously
75725055|NCT03972241|Device|foot insole|arch support and toe extension
76047950|NCT01901848|Behavioral|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
76047951|NCT04415632|Other|low glycemic index diet|• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
75573114|NCT05764733|Other|Placebo|Capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.
75573115|NCT05756673|Drug|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
75725056|NCT04085159|Biological|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
75426587|NCT03233152|Drug|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
75725057|NCT00928980|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
75725058|NCT00928980|Drug|Optimal Medical Care|Therapeutic dose of antidepressant medication
75725059|NCT03972085|Other|Neural gliding exercises|"Neural gliding exercises: In addition to the Electrotherapy procedure, patients were asked to actively perform knee extension, ankle dorsiflexion and head extension in the slumped posture followed by simultaneous ankle plantar flexion together with knee and head flexion (10 repetitions in 1 minute). Patients performed the exercises under a home-based program for 5 days of the week during a total period of 3 weeks.~Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach."
75877976|NCT03601208|Diagnostic Test|Mitra|When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
75877977|NCT04788017|Drug|Ziresovir|"Planned treatments are:~Cohort 1: 300 mg of ziresovir~Cohort 2: up to 600 mg of ziresovir~Cohort 3: up to 900 mg of ziresovir"
75877978|NCT04788017|Other|Placebo|"Planned treatments are:~Cohort 1: 300 mg of placebo~Cohort 2: up to 600 mg of placebo~Cohort 3: up to 900 mg of placebo"
75426588|NCT03233152|Drug|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
75426589|NCT03190967|Drug|T-DM1|T-DM1 3.6 mg/kg intravenous (IV) every 21 days
75426590|NCT03190967|Drug|TMZ|Phase I: TMZ 30, 40 or 50 mg/m^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
75426591|NCT03188965|Drug|Elimusertib (BAY1895344)|Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
75426592|NCT03184571|Drug|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor
75573116|NCT05756673|Drug|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
75573117|NCT05756673|Drug|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
75573118|NCT05756673|Device|TePe Original Interdental Brush|Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.
75573119|NCT05745935|Drug|Oxytocin|This study will include 100 elective cesarean section in parous women who will be randomized into two groups each of 50 patients,
75573120|NCT05740813|Drug|ABBV-CLS-7262 Dose 1|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
75573121|NCT05740813|Drug|ABBV-CLS-7262 Dose 2|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
75573122|NCT05740813|Drug|Matching Placebo|Matching placebo is administered orally once per day for 24 weeks.
75725060|NCT03972085|Other|Electrotherapy sessions|Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
75877979|NCT03601130|Device|HydroxyColl Bone Graft Substitute|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
75877980|NCT03601130|Device|DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
75573123|NCT05720000|Device|Photobiomodulation|Patient will receive the application of the low-power 660 nm Newskin MMO red LED in the immediate postoperative period. The application will be made punctually over the entire length of the wire, which measures 5 cm, totaling 10 application points with 1 cm of distance between them. The LED application will be repeated twice a week, with a minimum interval of 48 hours, totaling 9 laser applications over 30 days.
75573124|NCT05720000|Procedure|PDO thread|The participant's face will be cleaned with a 0.2% chlorhexidine solution. 0.1 ml of injectable anesthetic (2% lidocaine hydrochloride without vasoconstrictor, XYlestesin) will be administered in the skin layer at the point of incision in the glabellar region with a 30-gauge needle. A subincision will be made with a 21-gauge cannula in the glabellar ridge and then an injectable thread will be applied in the deep dermal layer below the glabellar ridge in the same direction as it.
75725061|NCT00826046|Drug|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
75426593|NCT03176823|Device|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
75426594|NCT03176823|Other|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
75573125|NCT05718089|Other|Continuous aerobic exercise|"The Continuous aerobic exercise session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The  Continuous aerobic exercise intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
75725062|NCT00584909|Drug|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
75725063|NCT02551172|Drug|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
75725064|NCT02551172|Drug|HGP0816|Rosuvastatin
75725065|NCT02551172|Drug|Placebo of HCP1105|Soybean Oil
75725066|NCT02551172|Drug|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
75725067|NCT03947099|Drug|Ketamine Hydrochloride|Participants are treated with six one-hour infusions of ketamine hydrochloride over a three week period in hopes of treating symptoms of PTSD.
75725068|NCT00147823|Device|Vitoss Alone|Synthetic bone graft material
75725069|NCT00147823|Device|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
75725070|NCT05361915|Drug|Abivertinib|Abivertinib is a small molecule inhibitor
75725071|NCT05361915|Drug|Abiraterone|Hormone-based chemotherapy
75725072|NCT00929058|Drug|Bevacizumab|Intra-arterial infusion during 6 minutes
75725073|NCT03860246|Diagnostic Test|Portable ECG monitor|Recording of ECG rhythm on a portable monitor (Kardia Mobile)
75877981|NCT02942615|Other|limit heart dose|limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%
75877982|NCT03600974|Procedure|Stretta|Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
76047952|NCT04415632|Other|High glycemic index diet|Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
75426595|NCT03108196|Procedure|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
75426596|NCT03108196|Procedure|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
75426597|NCT03097939|Drug|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
75426598|NCT03097939|Drug|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
75426599|NCT03097874|Behavioral|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
75573126|NCT05718089|Other|High intensity interval training|"The High intensity interval training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The High intensity interval training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
75573127|NCT05718089|Other|Resistance training|"The Resistance training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The Resistance training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
75725075|NCT00925314|Biological|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
75725076|NCT00822146|Device|CRT|classified
75877983|NCT03600974|Procedure|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
75877984|NCT03600974|Drug|Probiotic Agent|Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
75877985|NCT03600974|Drug|PPI|PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
75877986|NCT03600974|Drug|Prokinetic Motility Agents|Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
75877987|NCT03600974|Drug|Neuromodulators|Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
75573128|NCT05702515|Other|Digital ECG Data Collection|synchronized digital data collected from the G4 and ECG machines during the PICC insertion procedure
75426600|NCT03097874|Behavioral|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
75426601|NCT03096782|Biological|Anti-Thymocyte Globulin|Given IV
75573129|NCT05695313|Drug|OnLife®|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. The OnLife supplement will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
75573130|NCT05695313|Other|Placebo|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. Placebo will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
75573131|NCT05693077|Biological|10E4 NTCD spores|in capsule for oral ingestion.
75426602|NCT03096782|Drug|Busulfan|Given IV
75426603|NCT03096782|Drug|Clofarabine|Given IV
75426604|NCT03096782|Drug|Cyclophosphamide|Given IV
75426605|NCT03096782|Biological|Filgrastim-sndz|Given SC
75573132|NCT05693077|Biological|10E7 NTCD spores|in capsule for oral ingestion.
75573133|NCT05693077|Other|placebo|in capsule for oral ingestion.
75573134|NCT05693077|Drug|Vancomycin Oral Capsule|4 times a day 250mg
75573135|NCT05692271|Drug|Propranolol|40 mg teva-propranolol taken twice daily for 12 weeks
75573136|NCT05692271|Drug|Placebo|Matching placebo
75573137|NCT05683925|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
75426606|NCT03096782|Drug|Fludarabine|Given IV
75426607|NCT03096782|Drug|Melphalan|Given IV
75426608|NCT03096782|Drug|Mycophenolate Mofetil|Given IV or PO
75426609|NCT03096782|Biological|Rituximab|Given IV
75426610|NCT03096782|Drug|Tacrolimus|Given IV
75426611|NCT03096782|Radiation|Total-Body Irradiation|Undergo total body irradiation
75426612|NCT03096782|Procedure|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
75426613|NCT03093831|Drug|Ibrutinib|560mg administered orally once daily.
75426614|NCT03081806|Drug|X0002|Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
75573138|NCT05683925|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
75573139|NCT05683925|Device|Noninvasive transcutaneous earlobe stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
75426615|NCT03070236|Other|Survey|Select questions will be ask in the survey
75573140|NCT05680922|Biological|LB2102|DLL3 directed autologous Chimeric Antigen Receptor T-cells
75573141|NCT05679726|Behavioral|massage|reflexology foot massage
75573142|NCT05664711|Drug|Bupivacaine Injection|"Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug."
75725077|NCT00816998|Procedure|Physical therapy|Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
75725078|NCT00816998|Procedure|Physical Therapy|Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
75426616|NCT03055013|Procedure|Nephrectomy|Undergo nephrectomy
75426617|NCT03055013|Biological|Nivolumab|Given IV
75426618|NCT03055013|Other|Patient Observation|Undergo observation
75426619|NCT03055013|Other|Quality-of-Life Assessment|Ancillary studies
75725079|NCT00907452|Drug|melphalan-prednisone-thalidomide|
75426620|NCT03055013|Other|Questionnaire Administration|Ancillary studies
75426621|NCT03052049|Device|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
75426622|NCT03036657|Device|MAC acupuncture needles|"Sterile single-use MAC acupuncture needles (0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea. Used for Manual Acupuncture~Used for: Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
75573143|NCT05652933|Diagnostic Test|Software for identifying vessel occlusion, infarct volume and penumbra|Assessment of the AI tool software
75573144|NCT05651360|Diagnostic Test|low-dose CT|Low-dose CT scan will be performed, not exceeding 30% radiation dose of the standard CT. Low-dose CT images will be reconstructed with TrueFidelity high. The low-dose CT will be performed directly after the standard CT to avoid bias from differences in the timing of the contrast phase.
75573145|NCT05648045|Behavioral|Behaviour intervention targeted for Lifestyle modification|An intervention to strengthen resilience that controls self-efficacy, self-esteem and optimism.
75573146|NCT05647889|Drug|Jet lidocaine|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
75426623|NCT03036657|Device|Electrostimulator 6c.Pro, Pantheon Research, Venice, CA|"Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture~Used for Interventions:~Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min"
75426624|NCT03033446|Radiation|Y-90 Radioembolization|Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
75573147|NCT05647889|Combination Product|Ice|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
75573148|NCT05647889|Other|Standard PVC procedure|Standard PVC procedure will be applied
75573149|NCT05645341|Diagnostic Test|screening system for ocular surface malignant tumors|Develop an intelligent screening system for ocular surface malignant tumors, apply it to the mobile terminal for real-world verification and large-scale general screening, and test its effect on assisting doctors in the diagnosis and treatment of rare diseases.
75573150|NCT05634044|Device|eNose Device|Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.
75725080|NCT00907452|Drug|lenalidomide-dexamethasone|
76047953|NCT01901614|Procedure|LALAK|"A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
75426625|NCT03033446|Drug|Nivolumab|21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
75573151|NCT05631756|Other|Lung Ultrasound|Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
75573152|NCT05622279|Procedure|Percutaneous tenotomy + PRP|The patients will receive a percutaneous ultrasound-guided treatment including a needle tenotomy followed by a PRP injection in the plantar fasciitis.
75573153|NCT05606237|Device|Low-level Red Light Therapy Device|The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
75725081|NCT00822224|Drug|MEOPA|inhalation of MEOPA during the painful care
75725082|NCT00907530|Drug|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
75426626|NCT03019536|Drug|LY3303560 - IV|Administered IV
75426627|NCT03019536|Drug|Placebo - IV|Administered IV
75426628|NCT03019536|Drug|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
75426629|NCT03019536|Drug|Flortaucipir F18|Administered IV during the PET scan performed during the study.
75426630|NCT02966665|Other|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
75725083|NCT00907530|Drug|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
75725084|NCT05331885|Biological|Suvratoxumab|Monoclonal antibody
75573154|NCT05597345|Drug|Selinexor|Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
75573155|NCT05576974|Drug|Pegsitacianine|Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
75725085|NCT05331885|Drug|Placebo|Placebo contains only excipients
75573156|NCT05576129|Device|TGP-tACS|"38 min and 20s of 4mA peak-to-peak theta-gamma stimulation with 75 Hz-gamma coupled to the peak of 6Hz-theta waves. 3s ramp-up at the beginning of stimulation and 3s ramp-down at the end of stimulation.~Administered using a Starstim® device and 5 gel electrodes with a πcm² area."
75725086|NCT00717197|Drug|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
75725087|NCT00929136|Biological|USP endotoxin|Continuous intra-arterial infusion
75725088|NCT00925392|Drug|Doripenem|Intravenous 500 mg every (q) 8 hours for 3 doses
75725089|NCT00925392|Drug|Doripenem|Intravenous 1000 mg q 8 hours for 3 doses
75725090|NCT05315271|Drug|Bupivacaine-ketamine injection|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
75725091|NCT05315271|Drug|Bupivacaine injection with intravenous ketamine infusion|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
75725092|NCT00147745|Drug|Colesevelam|Colesevelam 3.8g for 12 weeks
75573157|NCT05576129|Device|Sham-tACS|38 min and 20s of alternation between 10s of 4mA peak-to-peak TGP- tACS and a 6 min 30s stimulation-free interval. Each stimulation consists of 3s ramp-up, 4s TGP stimulation and 3s ramp-down. Administered using a Starstim® device and 5 gel electrodes with a πcm² area.
75573158|NCT05551455|Other|Nutritional/dietary intake manipulation ('Normal')|Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.
75573159|NCT05551455|Other|Nutritional/dietary intake manipulation ('Low')|Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
75573160|NCT05535361|Device|Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome|The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
75573161|NCT05530863|Behavioral|Assisted Therapy|The participant will receive coaching calls and support
75573162|NCT05530863|Behavioral|Sleep Hygiene|Standard Sleep Hygiene instructions.
75573163|NCT05526469|Procedure|Serratus anterior plane block|patients in this group will receive ultrasound guided single shot serratus anterior plane block for pain control intra and postoperative
75573164|NCT05526469|Procedure|erector spinae plane blocks|patients in this group will receive ultrasound guided single shot erector spinae plane block for pain control intra and postoperative
75573165|NCT05526469|Drug|Bupivacaine 0.25% Injectable Solution|Patients in both group will receive 0.5 ml/kg bupivacaine 0.25% injected locally in the muscle plane
75573166|NCT05523622|Device|Tono-Vera tonometer|The tonometer measures intraocular pressure with a small rebound probe, similar to those used with other tonometers currently on the market, such as the iCare.
75426631|NCT02966665|Drug|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
75426632|NCT02966665|Drug|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
75426633|NCT02966665|Drug|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
75426634|NCT02966665|Other|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
75426635|NCT02966665|Drug|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
75426636|NCT02966665|Drug|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
75426637|NCT02962167|Biological|Modified Measles Virus|Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
75573167|NCT05523622|Device|Goldman Applanation Tonometry|This is the current gold standard for measuring eye pressure.
75573168|NCT05521568|Diagnostic Test|Index test: Abbott ID NOW STREP A 2|The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.
75725093|NCT00147745|Drug|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
75725094|NCT00147745|Drug|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
75725095|NCT04542486|Procedure|"Excision of gingival hyperplasia using Soft tissue trimmer ."|Gingivoplasties and removal of excess gingival tissues using Soft tissue trimmer.
75426638|NCT02962167|Biological|Modified Measles Virus Lumbar Puncture|Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
75426639|NCT02945241|Drug|Vancomycin|Intravenous
75426640|NCT02945241|Other|Cystatin C dosing algorithm|Expressed in milliliters per minute
75426641|NCT02945241|Other|Creatine clearance dosing algorithm|Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
75426642|NCT02939573|Drug|Colchicine|Randomized to colchicine 0.6 mg x 2/day
75426643|NCT02939573|Drug|Dapsone|Randomized to dapsone 150 mg/day
75426644|NCT02939573|Drug|Azathioprine|Randomized to azathioprine 2 mg/kg/day
75426645|NCT02938299|Drug|L19IL2 + L19TNF|Mixture of L19IL2 and L19TNF once weekly
75426646|NCT02938299|Procedure|Surgery|Surgical resection of melanoma tumor lesions
75426647|NCT02934568|Drug|LEE011|Single agent LEE011 or in combination with other treatments
75426648|NCT02924818|Other|Clinical assessment|
75426649|NCT02924818|Behavioral|questionnaires|
75426650|NCT02924818|Other|pulmonary function test|
75426651|NCT02924818|Biological|blood test|
75426652|NCT02924818|Biological|microbiology|
75426653|NCT02924818|Biological|histology|
75426654|NCT02924818|Other|imaging|
75426655|NCT02877316|Other|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
75426656|NCT02877316|Other|safety plan on paper|Standard treatment with safety plan on paper
75426657|NCT02847468|Other|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
75426658|NCT02847468|Other|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
75426659|NCT02804087|Device|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
75426660|NCT02804087|Other|Sham Implantation|Sham Implantation
75426661|NCT02798276|Procedure|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
75573169|NCT05521568|Diagnostic Test|Reference standard test: Composite of culture and PCR-based tests based on a throat swab|"Throat samples will be obtained by use of a double-swab collection-transportation system :~Swab #1 will be used to perform the rapid antigen detection test (see below)~Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test."
75426662|NCT02798276|Other|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
75426663|NCT02773030|Drug|CC-220|Specified dose on specified days
75426664|NCT02773030|Drug|Dexamethasone|Specified dose on specified days
75426665|NCT02773030|Drug|Daratumumab|Specified dose on specified days
75426666|NCT02773030|Drug|Bortezomib|Specified dose on specified days
75426667|NCT02773030|Drug|Carfilzomib|Specified dose on specified days
75426668|NCT02763033|Drug|Bob's Red Mill®|Standard bone marrow transplant (BMT) diet + potato-based starch
75426669|NCT02763033|Other|Starch Placebo|Standard bone marrow transplant (BMT) diet + corn-based starch
75426670|NCT02681211|Other|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
75877988|NCT03075267|Drug|PT010 (BGF MDI) 320/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
75725096|NCT04542486|Procedure|Excision of gingival hyperplasia using the conventional scalpel technique|Excision of gingival hyperplasia in gingivoplasties using the conventional technique reverse bevel using 15c blade.
75426671|NCT02681211|Drug|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
75426672|NCT02681211|Drug|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
75426673|NCT02681211|Drug|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
75426674|NCT02681211|Drug|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
75426675|NCT02673775|Other|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
75426676|NCT02673775|Other|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
75426677|NCT02666768|Drug|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
75426678|NCT02632708|Drug|AG-120|
75426679|NCT02632708|Drug|AG-221|
75426680|NCT02632708|Drug|cytarabine|
75426681|NCT02632708|Drug|daunorubicin|
75426682|NCT02632708|Drug|idarubicin|
75725097|NCT00929292|Other|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
75725098|NCT00929292|Other|Modilac 1|Infant formula used for non breastfed children
75725099|NCT01326169|Behavioral|Brief intervention|Telephone-delivered counseling
75426683|NCT02632708|Drug|mitoxantrone|
75426684|NCT02632708|Drug|etoposide|
75725100|NCT01326169|Behavioral|Standard care|No intervention
75725101|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
75877989|NCT03075267|Drug|PT010 (BGF MDI) 160/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
75426685|NCT02617277|Drug|AZD1775|AZD1775 (adavosertib) is available in capsules for oral administration.
75426686|NCT02617277|Drug|MEDI4736|MEDI4736 (durvalumab) will be administered by IV infusion.
75426687|NCT02611570|Other|LDCT|LDCT at enrollment, annually for two years and biennially for 6 years if no lung cancer is detected
75426688|NCT02594124|Drug|nusinersen|Administered by intrathecal (IT) injection
75426689|NCT02548546|Device|ECHO|Imaging
75426690|NCT02548546|Device|ECG-gated MRA|Imaging
75426691|NCT02489617|Other|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
75725102|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
75725103|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
75725104|NCT00642902|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
75725105|NCT05313477|Drug|Ergocalciferol Capsules|Depend on initial 25(OH) vitamin D level If <10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If >20 ng/mL, 20000U of Ergocalciferol capsule per week
75725106|NCT05313477|Drug|Calcium carbonate|1000mg of Calcium carbonate daily
75725107|NCT02531815|Biological|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
75573170|NCT05521568|Diagnostic Test|Comparator test: Rapid antigen detection test (usual care)|As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
75573171|NCT05520034|Behavioral|Health Education|The participants will receive a 45mins, face-to-face group health education before discharge and during the 6th month by a nurse and a physiotherapist. Participants will be received refresher health education over the phone call , if the patient and family caregiver cannot come for any reason. They will also receive a digital BP machine, a salt-measurement spoon, a medication box, and a recording notebook for monitoring. The intervention group receives health education above and reminder telephone calls provided by research assistant nurses every month (1st month to 3rd month: twice a month, and 4th month to 12th month: once a month)
75573172|NCT05517083|Diagnostic Test|Ultarthin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
75573173|NCT05514340|Drug|Normal Saline along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
75573174|NCT05514340|Drug|Sovateltide along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
75573175|NCT05504018|Procedure|ACL reconstruction|Anterior cruciate ligament reconstruction surgery
75426692|NCT02471144|Biological|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
75426693|NCT02471144|Biological|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
75725108|NCT02531815|Drug|Placebo|Placebo for PF-06741086, single dose
75725109|NCT00826124|Procedure|Epidural steroid injection|Injection based solely on history and physical exam
75725110|NCT00826124|Procedure|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
75426694|NCT02471144|Biological|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(<25 kg, 25- <50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
75573176|NCT05498480|Biological|Relatlimab|Specified dose on specified days
75573177|NCT05498480|Biological|Nivolumab|Specified dose on specified days
75725111|NCT00826124|Procedure|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
75725112|NCT00224107|Drug|Silodosin|8 mg daily for 12 weeks
75725113|NCT00224107|Other|Placebo|1 capsule daily for 12 weeks
75725114|NCT00822302|Drug|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
75725115|NCT00822302|Drug|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
75426695|NCT02471144|Biological|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
75426696|NCT02448420|Drug|Palbociclib|"Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles."
75426697|NCT02448420|Drug|Trastuzumab|Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
75426698|NCT02448420|Drug|Endocrine therapy|Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
75426699|NCT02448420|Drug|Chemotherapy|Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
75573178|NCT05496556|Other|Test Leeds Food Preference Questionnaire (LFQP-France)|"The version of this questionnaire has been adapted to French eating habits. and based on the presentation of food photos, each representing one of the four categories below : salty-high in fat / salty-low fat / sugary-high fat / sweet-low fat The answers given to the LFQP predict a more or less caloric food intake. This tool makes it possible to objectify changes in eating behavior according to the nutritional status and protein status of patients.~The implied wanting score for salty-high-fat, salty-low-fat, sweet-high-fat, and sweet-low-fat foods is calculated based on the frequency and speed of choice for one food type out of 150 combinations.~For each of the food modalities, the software will return a score with its standard deviation. The modality preferred by the patient is the one with the highest score"
75573179|NCT05490511|Drug|Tacrolimus single dose|5 mg once
75573180|NCT05490511|Drug|Epidiolex single dose|Epidiolex 5 mg/kg
75573181|NCT05490511|Drug|Epidiolex steady-state and tacrolimus single dose|Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
75725116|NCT04004871|Drug|Nab-paclitaxel, Cisplatin and Fluorouracil|Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
75725117|NCT04004871|Radiation|concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
75725118|NCT00826358|Drug|ABT-143|Once, please see Arm Description for more details.
75725119|NCT00826358|Drug|ABT-335|Once, see Arm Description for more detail
75725120|NCT00826358|Drug|rosuvastatin|once, see Arm Description for more detail
75877990|NCT03075267|Drug|PT003 (GFF MDI) 14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
75426700|NCT02448420|Drug|Antibody-Drug Conjugates|3.6 mg/kg iv every 3 weeks
75426701|NCT02438306|Biological|Autologous cell therapy|Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.
75426702|NCT02438306|Other|Sham|An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
75426703|NCT02420002|Drug|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
75426704|NCT02420002|Other|Use of Hypnosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
75426705|NCT02420002|Procedure|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
75877991|NCT03600896|Drug|CYT107|"Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~5 mcg/kg/dose for 3 doses~10 mcg/kg/dose for 3 doses~20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II."
75877992|NCT03600662|Other|TriRec|Trileaflet Reconstruction of the Aortic Valve
75877993|NCT03600662|Other|Aortic valve replacement|Biological Prosthesis, Device: St. Jude Medical Trifecta GT
75573182|NCT05488067|Drug|atorvastatin|Oral atorvastatin treatment for ALGS children with xanthoma
75573183|NCT05465434|Drug|Zinc Supplement|Zinc sulphate 50 mg
75877994|NCT03600584|Procedure|Modified one-layer duct-to-mucosa Pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
75877995|NCT03600584|Procedure|Invagination pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
75877996|NCT03600506|Drug|Dexmedetomidine|Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.
75426706|NCT02408471|Device|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
75426707|NCT02403674|Drug|Doravirine, Tenofovir, Lamivudine|One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
75426708|NCT02403674|Drug|ATRIPLA™|One ATRIPLA™ tablet taken q.d. by mouth
75573184|NCT05461326|Procedure|Quad tendon|quadriceps tendon autograft
75573185|NCT05461326|Procedure|BTB|patellar tendon autograft
75573186|NCT05453227|Drug|Zinc|To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
75573187|NCT05451836|Other|Patient education leaflets|Patients who attend the emergency department with upper respiratory tract infections will be provided with patient education leaflets on appropriate antibiotic use and antimicrobial resistance. The leaflets are available in the four national languages in Singapore.
75573188|NCT05451836|Other|Physician feedback|All physicians working in the emergency department will receive a text message from their department head on their antibiotic prescribing rates every two months.
75573189|NCT05447156|Behavioral|Tailored QuitGuide app|This is an app not available to the public. It was developed/tailored based on an app available to the public and can be downloaded.
75573190|NCT05447156|Behavioral|Standard QuitGuide app|This is an app available to the public.
75573191|NCT05437250|Drug|Non interventional study|CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
75877997|NCT03600506|Drug|Placebo|Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
75877998|NCT05266677|Other|blend of glycerides at certain proportions|combination of glycerides in specific proportions in a liquid oral supplement
75573192|NCT05433688|Device|Robotic assisted gastric bypass surgery|The product under investigation and the conventional suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
75573193|NCT05425251|Diagnostic Test|GFAP and UCH-L1|2x5mL blood samples will be used to determine the performance of the automated VIDAS TBI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
75573194|NCT05423210|Combination Product|Atezolizumab + FSRT radiation|Atezolizumab 840mg IV every 2 weeks Fractionated Stereotactic Radiotherapy
75573195|NCT05419362|Drug|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 3x10^11 colony-forming units (CFU)
75426709|NCT02403674|Drug|Placebo|Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
75426710|NCT02375802|Biological|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
75573196|NCT05419362|Drug|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
75426711|NCT02375802|Drug|Adipose-derived stromal cells|
75426712|NCT02354781|Biological|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
75573197|NCT05414812|Behavioral|Multi-component oncofertility care intervention|"The intervention includes:~Young breast cancer patients presenting to oncology visits will complete a clinic-based oncofertility needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future, ii) need for contraception, and iii) sexual health/menopause symptoms.~A women's health survivorship care plan (SCP) in Spanish and English encompasses content on screening and management strategies for a) fertility concerns/pregnancy health; b) contraception; c) hot flashes and d) sexual health.~Oncofertility navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's oncofertility needs, ii) review the women's health SCP, iii) provide support with the goal of engaging in oncofertility care.~Oncofertility consultation as indicated via telehealth or in person will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
75725121|NCT03972007|Device|Fotobiomodulation|A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
75877999|NCT05266677|Other|glycerides used in current formulas|glycerides used in current formulas in a liquid oral supplement
75426713|NCT02352948|Drug|MEDI4736 (durvalumab)|MEDI4736 (durvalumab) treatment by intravenous infusion
75426714|NCT02352948|Drug|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
75426715|NCT02352948|Drug|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
75725122|NCT00987909|Biological|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
75426716|NCT02352948|Drug|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
75426717|NCT02352948|Drug|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
75426718|NCT02352948|Drug|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
75426719|NCT02337452|Other|Questionnaire Administration|Ancillary studies
75573198|NCT05408780|Drug|AC-OLE-01-VA|formulation of tricaprilin or matching placebo
75573199|NCT05374174|Diagnostic Test|Tardieu Scale for Spasticity|The clinician will rotate the elbow joint at various speeds while the participant sits relaxed.
75725123|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
75725124|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
75725125|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
75725126|NCT00822380|Dietary Supplement|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
75725127|NCT00822380|Dietary Supplement|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
75725128|NCT00822380|Dietary Supplement|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
75725129|NCT00822380|Dietary Supplement|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
75725130|NCT00822380|Dietary Supplement|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
75878000|NCT03593486|Device|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
75426720|NCT02337452|Behavioral|Web Site|Communicate via family outreach program website
75426721|NCT02331914|Procedure|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
75426722|NCT02331914|Procedure|Tumor biopsy|Tumor biopsy after disease progression
75573200|NCT05365919|Other|Family Talk Intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
75573201|NCT05359731|Drug|Bupivacaine Hydrochloride|Patients will receive a total volume of 30 ml of bupivacaine 0.5% in an axillary block with a double puncture.
75573202|NCT05359731|Drug|Bupivacaine Hydrochloride with Dexamethasone|Patients will receive a total volume of 30 ml of bupivacaine 0.5% with Dexamethasone 4 mg in an axillary block with a double puncture.
75573203|NCT05355337|Drug|Pramipexole|9 weeks of treatment with Pramipexole
75573204|NCT05355337|Drug|Placebo|9 weeks of treatment with Placebo
75725131|NCT00720083|Drug|cisplatin|Given IV
75878001|NCT03593486|Device|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
75878002|NCT03593330|Other|Transitional Care Programme|These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
75878003|NCT03590834|Behavioral|Center-based Intervention|"Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~Staff training and technical assistance~Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~Health contests~Gross motor and physical activity program~Miranos! activity cards based on children storybooks"
75426723|NCT02315326|Drug|Ibrutinib|"Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A."
75725132|NCT00720083|Drug|vandetanib|Given orally
75725133|NCT00720083|Radiation|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
75725134|NCT00209131|Drug|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
75725135|NCT00209131|Drug|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
75725136|NCT00925626|Procedure|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
75725137|NCT00925626|Procedure|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
75573205|NCT05348083|Procedure|ESPB|Echo-guided bilateral ESPB performed at T9 level at the end of surgery with a mixture of ropivacaine 0.375% and epinephrine 5 mcg/mL 20 mL each side.
75573206|NCT05341817|Drug|Letrozole|Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.
75725138|NCT04044950|Biological|E7 TCR|The injection will be approximately 3x10^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 mL of volume.
75573207|NCT05341817|Drug|Mifepristone|Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
75573208|NCT05341232|Behavioral|Lego Robot Programming Active Challenges|Participants will adapt their own Lego robot programs to achieve specific task goals.
75573209|NCT05341232|Behavioral|Lego Robot Programming Procedural Methods|Participating will undergo Lego robot programming training that engages them to follow fixed programming coding steps.
75573210|NCT05341232|Behavioral|Board Games|Participants will play board games with each other.
75573211|NCT05336435|Diagnostic Test|Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin|The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
75725139|NCT00907608|Drug|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
75573212|NCT05334173|Procedure|Roux-en-Y Gastric Bypass (RYGB) measuring the lengh of the common limb|The patients are randomized to Type 1 laparoscopic RYGB (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic RYGB (70cm alimentary limb and 150cm biliopancreatic limb). In both groups, the total intestinal length is measured to determine the size of the common limb. We introduce a 10 cm ruler into the abdominal cavity to measure the bowel and then extract it. LRYGB is made with linear stapler anastomosis.
75573213|NCT05301543|Behavioral|Experimental: Behavioral approach 1|Includes changing sleep habits and cognitions around sleep from a mental level
75573214|NCT05301543|Behavioral|Comparator: Behavioral approach 2|Includes changing sleep habits and awarenes of sleep from a perception level
75725140|NCT00224029|Drug|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
75878004|NCT03590834|Behavioral|Home-based Intervention|"Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars"
75878005|NCT03590834|Behavioral|Active Control|"Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention."
75878006|NCT03600272|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia during labor is a labor analgesia technique which reported maybe associate with a shorter labor duration compared to the traditional epidural labor analgesia.
75878007|NCT03600272|Procedure|Epidural analgesia|Epidural analgesia is a well-accepted technique using for pain relief during labor.
75573215|NCT05296473|Device|ADHD Therapy|investigational game-play therapy
75573216|NCT05296473|Device|Control Therapy|control game-play therapy
75878008|NCT05082597|Device|Low energy ESWT|Therapeutic sessions: 4(once a week, for 4 weeks) Total dosage: 2500 shoots over axillary cord lesion (1000 over most fibrotic area, 500 over upper arm, 500 over forearm, 500 over other area) Energy: 0.056-0.065mJ/mm2
75573217|NCT05296317|Drug|Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|"- Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
75573218|NCT05296317|Drug|Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)|"- Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
75725141|NCT00826592|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
75725142|NCT04085081|Other|E-mail|Receive brief motivational text or email messages
75725143|NCT04085081|Behavioral|Exercise Intervention|Receive personalized walking program plus strength exercises
75725144|NCT04085081|Other|Quality-of-Life Assessment|Ancillary studies
75725145|NCT04085081|Other|Questionnaire Administration|Ancillary studies
75725146|NCT04085081|Behavioral|Telephone-Based Intervention|Receive intervention coaching sessions via telephone
75573219|NCT05290090|Drug|Rituximab, Lenalidomide, Zanubrutinib and RCHOP|"chemo free period (21 days as a cycle, a total of 2 cycles): rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~Immunochemotherapy period: RCHOP regimen (21 days as 1 cycle, a total of 4 cycles): rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
75426724|NCT02315326|Drug|HD- Methotrexate (MTX)|Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
75573220|NCT05279534|Dietary Supplement|Probiotic|Combination of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, twice daily for 15 days
76047954|NCT01901614|Procedure|IEK|"A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
75725147|NCT04085081|Other|Text Message|Receive brief motivational text or email messages
75426725|NCT02315326|Drug|Rituximab + HD- Methotrexate (MTX)|Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
75426726|NCT02315326|Drug|procarbazine|Arm D: THIS IS THE ONLY ARM RECRUITING: : Oral procarbazine (100mg/m2/day) will be given on Day 1 through 7 during each cycle. Patients will be maintained on a tyramine-free diet during procarbazine administration.
75426727|NCT02303431|Drug|Edoxaban low dose|Edoxaban low dose
75426728|NCT02303431|Drug|Edoxaban high dose|Edoxaban high dose
75426729|NCT02248597|Drug|fludarabine phosphate|Given IV
75426730|NCT02248597|Drug|busulfan|Given IV
75426731|NCT02248597|Drug|cyclophosphamide|Given IV
75426732|NCT02248597|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo myeloablative or reduced intensity allogeneic stem cell transplant
75573221|NCT05279534|Other|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0, twice daily for 15 days
75573222|NCT05278741|Procedure|Surgery for unilateral breast reconstruction|"Before the surgery, patient will be completed two questionnaire DASH and BREAST-Q. Two tests will be performed (isokinetic test and EMG).~After the surgery, at one month : 2 Questionnaires (DASH / BREAST-Q) will be performed At three months and six months : 2 questionnaires + two tests will be perfomed"
75573223|NCT05278260|Dietary Supplement|Hydrogen tablets|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that releases molecular hydrogen, for the duration of the radiation therapy
75573224|NCT05278260|Dietary Supplement|Control|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that does not release any molecular hydrogen, for the duration of the radiation therapy
75725148|NCT03969979|Diagnostic Test|Shear wave elastography|shear wave elastogrophy will be performed
75725149|NCT00817154|Behavioral|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
75725150|NCT02591381|Procedure|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
76047955|NCT01901614|Drug|Retrobulbar Block or General Anesthesia|
76047956|NCT01901614|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
75426733|NCT02248597|Drug|tacrolimus|
75426734|NCT02248597|Drug|mycophenolate mofetil|
75426735|NCT02246621|Drug|Abemaciclib|Administered orally
75426736|NCT02246621|Drug|Anastrozole|Administered orally
75878009|NCT03600038|Behavioral|Experimental smoking cessation smartphone app|The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.
75573225|NCT05275725|Drug|Sildenafil|Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
75573226|NCT05266313|Behavioral|Oncosexology program|Thematic workshops throughout the year
75573227|NCT05260021|Drug|Tirzepatide Dose 1|Administered SC
75573228|NCT05260021|Drug|Tirzepatide Dose 2|Administered SC
75573229|NCT05260021|Drug|Placebo|Administered SC
75725151|NCT00929370|Drug|Glycine Transporter-1 inhibitor|GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
75573230|NCT05259319|Drug|Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]|Treatment given every 21 days during 24 months or until progression
75426737|NCT02246621|Drug|Letrozole|Administered orally
75573231|NCT05259319|Drug|Tiragolumab|Treatment given every 21 days during 24 months or until progression
75426738|NCT02246621|Drug|Placebo|Administered orally
75426739|NCT02227823|Drug|Pyridostigmine Bromide|
75573232|NCT05259319|Radiation|Stereotactic body radiation therapy (SBRT)|Radiothérapy is delivered as a hypofractionated schedule of 3 doses of 8Gy (idealy on Monday, Wednesday and Friday, or 3 sessions over a week, respecting at least 24 hours between each fraction)
75573233|NCT05254886|Other|NEMO nurse-led program|"The NEMO nurse-led program will consist of a single nursing consultation conducted on the day of the inclusion visit during which the nurse will:~Report the presence of pre-existing comorbidities/EIMs~Detect the presence of risk factors~Implement recommendations for the detection and/or management of comorbidities/EIMs."
75573234|NCT05247853|Procedure|Blood collection|Blood collection at enrollment visit
75573235|NCT05247853|Procedure|Oral, cervicovaginal and anal specimen collection|Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits
75573236|NCT05247853|Procedure|Anoscopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent anal HPV16/18+ in WLWH
75573237|NCT05247853|Procedure|Colposcopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV
75573238|NCT05247853|Procedure|Ablative Treatment|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy
75573239|NCT05247853|Procedure|LEEP (Loop Electrosurgical Excision Procedure)|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy that ablation ineligible
75725152|NCT00817232|Device|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
75725153|NCT03967795|Drug|N2-L-Alanyl-L-Glutamine (Substance)|20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
75725154|NCT04086251|Other|Gaido|Patients will participate for up to 21 days. Over the course of the study, 25-100 patients will be enrolled.
75725155|NCT00907764|Drug|regadenoson|400 ug, IV
75725156|NCT02550314|Drug|fiblast,gelatin sponge,fibrin glue|
75725157|NCT00987987|Procedure|donor lymphocyte infusion|regulatory T cells depletion
75725158|NCT01073527|Drug|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
75725159|NCT01073527|Drug|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
75725160|NCT00822458|Drug|vismodegib|Given orally
75725161|NCT00822458|Other|laboratory biomarker analysis|
75426740|NCT02197234|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
75426741|NCT02197234|Drug|Simvastatin|Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
75426742|NCT02197234|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
75426743|NCT02197234|Procedure|Pharmacokinetic sampling - simvastatin|Blood sampling to measure simvastatin levels
75426744|NCT02197234|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
75426745|NCT02177292|Radiation|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
75426746|NCT02129543|Procedure|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.
75725162|NCT00822458|Other|pharmacological study|
75725163|NCT00223795|Device|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
75878010|NCT03600038|Behavioral|Standard of care smoking cessation smartphone app|The control intervention uses a standard of care smartphone smoking cessation app.
75878011|NCT03913286|Device|Cortimo|The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
75878012|NCT04856943|Procedure|Smartconsent application|Patients asigned to smartconsent group will sign informed consent through a Tablet.
75878013|NCT04856943|Other|Control group|Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice
76047957|NCT01901614|Drug|Topical Anesthesia|
76047958|NCT01901614|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
75725164|NCT02538432|Drug|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
75725165|NCT02538432|Drug|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
75878014|NCT03599336|Procedure|Reverse Total Shoulder Arthroplasty (rTSA)|Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components as per standard surgical care and routine postoperative rehabilitation.
75426747|NCT02125461|Drug|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
75426748|NCT02125461|Other|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
75426749|NCT02114229|Drug|alisertib|Alisertib will be administered orally at 80 mg/m^2 per day for enteric coated tablet formulation and 60 mg/m^2 per day for oral solution formulation.
75426750|NCT02114229|Drug|methotrexate|Methotrexate will be given at a dose of 5 g/m^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m^2/dose.
75426751|NCT02114229|Drug|cisplatin|Cisplatin will be given intravenously (IV): 75 mg/m^2 IV infusion.
75426752|NCT02114229|Drug|carboplatin|Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
75426753|NCT02114229|Drug|cyclophosphamide|Cyclophosphamide will be given 1.5 g/m^2 IV infusion during induction and consolidation.
75426754|NCT02114229|Drug|etoposide|"Etoposide will be given 100 mg/m^2 IV infusion.~In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day."
75426755|NCT02114229|Drug|topotecan|Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL*hr.
75426756|NCT02114229|Drug|vincristine|Vincristine will be given 1 mg/m^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
75426757|NCT02114229|Procedure|Surgical resection|"For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a second-look operation is encouraged if and may be performed prior to consolidation therapy."
75426758|NCT02114229|Radiation|Radiation therapy|The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children < 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age > 36 months.
75426759|NCT02102529|Procedure|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
75573240|NCT05243966|Device|Myriad Matrix™ and Myriad Morcells™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
75573241|NCT05243680|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
75725166|NCT01563627|Other|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
75725167|NCT01563627|Device|Magnetic Resonance Imaging|
75878015|NCT03599336|Other|Nonoperative Treatment|Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
75878016|NCT03074331|Drug|SOF/VEL|400/100 mg FDC tablet(s) administered orally once daily
76047959|NCT01901302|Drug|CB-5945|
76047960|NCT01901302|Drug|Placebo|
75725168|NCT00826670|Drug|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
75725169|NCT00826670|Drug|Placebo (Decolonization)|Placebo
75725170|NCT05238519|Behavioral|Motivational interview (MI)|"The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH."
75426760|NCT02096042|Drug|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
75426761|NCT02096042|Drug|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
75573242|NCT05242848|Behavioral|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is >13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
75725171|NCT00719849|Biological|anti-thymocyte globulin|30mg/Kg Days -6 to -4
75725172|NCT00719849|Drug|cyclophosphamide|50 mg/Kg Day -6
75725173|NCT00719849|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
75725174|NCT00719849|Drug|fludarabine phosphate|40mg/m2 Days -6 to -2
75725175|NCT00719849|Drug|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
75725176|NCT00719849|Procedure|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
75725177|NCT00719849|Radiation|total body irradiation|200 cGy Day -1
75725178|NCT02549612|Device|Moniri Otovent|Please see arm description.
75426762|NCT02087033|Dietary Supplement|ritmonutra|2 tablets a day by mouth for 4 weeks
75426763|NCT02087033|Dietary Supplement|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
75426764|NCT02036931|Device|Metal on Polyethylene articulation|G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)
75426765|NCT02036931|Drug|Ceramic on Polyethylene articulation|G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
75725179|NCT03775239|Behavioral|Mindfulness in Sex Therapy and Intimate Relationships (MSIR)|"Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing & Exploring Week 3: Avoidance & Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning"
75573243|NCT05231915|Genetic|HOXB13 c.853delT mutation|Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
75573244|NCT05231460|Drug|Active Comparator: narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~IV Dilaudid 1mg q3h for breakthrough pain"
75573245|NCT05231460|Drug|Active Comparator: narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~IV Dilaudid 1mg q3h for breakthrough pain"
75573246|NCT05231460|Drug|non-narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~Toradol 15mg q6h~Tylenol 1000mg q8h~Gabapentin 100mg three times a day"
76047961|NCT04606420|Behavioral|Lifestyle medicine|"Diet: A low fat (10-15%) whole foods vegan diet, high in complex carbs and low in refined carbs (fruits, vegetables, whole grains, legumes, soy, seeds & nuts). Calories unrestricted. Multivitamin, fish oil, curcumin, vitamin C, B12, CoQ10, lion's mane, probiotic, and magnesium. 21 meals/week and supplements provided to participants and caregivers at no cost to them.~Exercise: Aerobic (e.g., walking) and strength training 30 minutes/day based on a personalized prescription from an exercise physiologist or certified personal trainer and registered nurse.~Stress Management: Meditation, gentle yoga-based poses, progressive relaxation, breathing exercises, and meditation (with optional glasses) 1 hour per day, supervised by a certified stress management specialist.~Group Support: Participants and their spouses/caregivers participate in a support group one hour/session, 3 days/week, supervised by a licensed mental health professional in a supportive, safe environment."
75573247|NCT05231460|Drug|non-narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~Toradol 15mg q6h~Tylenol 1000mg q8h~Gabapentin 100mg three times a day"
75573248|NCT05229770|Dietary Supplement|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
75573249|NCT05215223|Device|whole body vibration|the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session
75573250|NCT05215223|Device|Treadmill|Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
75878017|NCT03599024|Procedure|PCEA|The patients were able to control the administration of analgesics by themselves.
75878018|NCT03599024|Procedure|Non-PCEA|The patients were receiving analgesics according to the physician's prescription.
75878019|NCT03599024|Procedure|Total hip replacement|All patients enrolled in the study were indicated for total hip replacement surgery.
75878020|NCT02237924|Drug|endostar|Endostar 7.5mg / m2, 2 cycles of continuous intravenous pumping for ten days,and 2 cycles of maintenance therapy after radiotherapy
75878021|NCT02237924|Drug|DDP|DDP:100mg/m2 for 2-3 cycles
75878022|NCT02237924|Radiation|IMRT|IMRT:70-74Gy for 2-3 cycles
76047962|NCT04415242|Other|positioning|different positioning prior surgery
76047963|NCT01919398|Drug|LY2940680|Administered orally
76047964|NCT04626154|Diagnostic Test|Objectively monitoring thoracoabdominal asynchrony|Objectively monitoring thoracoabdominal asynchrony
75426766|NCT02036931|Device|Ceramic on Ceramic articulation|G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
75426767|NCT02027233|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses (VRS, SARS-CoV-2 and others).
76047965|NCT02500043|Drug|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
75573251|NCT05214430|Other|3 months exclusive enteral nutrition after surgery|patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.
75573252|NCT05213208|Drug|Propofol|Using > 200 mg of propofol sedation colonoscopy is performed. 90-120 minutes after colonoscopy subjects go home. Within 1 week patients will be asked about their condition and satisfaction for colonoscopy.
75573253|NCT05206409|Diagnostic Test|Ultrasound|Fetal head position determination using ultrasound
75725180|NCT03775239|Behavioral|Treatment-as-usual|"The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy."
75725181|NCT00907842|Device|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
75725182|NCT00822536|Drug|Aspirin and Clopidogrel|Aspirin <= 325 mg/j Clopidogrel = 75 mg /j
76047966|NCT02500043|Drug|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
76047967|NCT02499575|Drug|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
76047968|NCT02499575|Drug|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
75573254|NCT05204290|Drug|Pembrolizumab|Pembrolizumab will be delivered at the discretion of the patient's medical oncologist within 6 weeks after finishing SBRT. If a patient is already receiving pembrolizumab at the time of enrollment, then SBRT should not start sooner than 5 days after the last pembrolizumab infusion.
75573255|NCT05204290|Radiation|Stereotactic Body Radiation Therapy|patients will undergo CT simulation and will be immobilized in either a BodyFix® or long thermoplastic mask depending on the location of the lesion. 1.25mm slices will be acquired. Dose and fractionation will be at the discretion of the treating radiation oncologist (as will the constraint to the spinal cord).
75573256|NCT05204290|Other|Blood draws|Patients will have a blood draw at baseline and at 2-months post-SBRT, and 6 months post-stereotactic body radiation therapy.
75573257|NCT05202626|Diagnostic Test|Nasopharyngeal Endoscopy image-guided Biopsy|For each participant presenting with a suspicious nasopharyngeal lesion, the attending physician will assess the lesion and determine the appropriate biopsy approach. The physician may decide on multiple biopsies from the lesion area, including one sample from within the lesion itself, another from 5-8 mm outside the lesion, and a third from 8-10 mm beyond the lesion. Alternatively, a single biopsy may be deemed sufficient based on the clinical judgment. Each of these specimens will undergo pathological examination to confirm whether they are carcinomatous or non-carcinomatous.
75573258|NCT05197426|Drug|Oral Azacitidine|Specified dose on specified days
75573259|NCT05197426|Other|Placebo|Specified dose of specified days
75725183|NCT00822536|Drug|Aspirin|Aspirin : <= 325 mg/j
75725184|NCT04015752|Diagnostic Test|culture from infected site|ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
75573260|NCT05193227|Drug|ST-01|Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
75573261|NCT05193227|Drug|Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)|Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
75573262|NCT05188404|Behavioral|Choice of cannabis product|Participants choose and purchase their own cannabis product
75725185|NCT00826826|Procedure|Catheter ablation|(Pulmonary vein isolation)
75725186|NCT00826826|Drug|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
75725187|NCT00826826|Drug|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
75725188|NCT00925860|Procedure|non positive pressure mechanical ventilatory support|
76047969|NCT02065791|Drug|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
76047970|NCT02065791|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily
76047971|NCT01654289|Other|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
75426768|NCT02019628|Dietary Supplement|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
75426769|NCT02003924|Drug|Enzalutamide|160 mg by mouth once daily
75725189|NCT05217615|Behavioral|ezParent|The ezParent Program is a 6-module web-based adaptation of the group-based Chicago Parent Program (CPP). ezParent uses multiple strategies to promote skill development in parents. Each module includes (a) video narrator descriptions of parenting strategies, (b) video vignettes of parents and children as examples of how parenting strategies work, (c) questions following each vignette for parents to reflect upon, (d) interactive activities for parents to complete, (e) knowledge questions to assess parent understanding of the strategies, and (f) practice assignments. To tailor to the former VPT population, developmental tips are included. Parents are instructed to complete the 6 modules over 10-weeks, approximately 1 module every 1.5 weeks. At the end of each module, parents receive a practice assignment linked to the module content. To encourage and support program completion, parents receive automated text messages and badges.
76047972|NCT01654289|Other|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
76047973|NCT02499029|Drug|N-acetylcysteine|NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
75573263|NCT05158764|Device|Venous compression system of the lower limbs stage C6 / C6r of the CEAP classification|Etiological treatment of venous disease of the lower limbs stage C6 / C6r
75426770|NCT02003924|Drug|Placebo|Sugar pill to mimic enzalutamide
75426771|NCT01940471|Drug|TAF|25 mg tablet administered orally once daily
75573264|NCT05126992|Biological|AZD1222|Covid-19 AstraZeneca Vaccine
75573265|NCT05126082|Behavioral|PedsBP CDS|The PedsBP CDS is a sophisticated web-based electronic health record (EHR)-linked tool that can be used to address barriers and improve the identification and management of elevated blood pressure (BP) and hypertension (HT) in children and adolescents by providing patient-specific clinical care recommendations in real time and in accordance with national guidelines for BP management in youth.
75573266|NCT05125328|Drug|Remifentanil|First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate>100bpm and arterial blood pressure>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR<50bpm and ABP<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
75573267|NCT05124184|Device|GORE® PROPATEN® Vascular Graft|Patients that have had treatment with GORE® PROPATEN® Vascular Graft
75573268|NCT05124184|Device|GORE-TEX® Vascular Grafts|Patients that have had treatment with GORE-TEX® Vascular Grafts
75426772|NCT01940471|Drug|TDF|300 mg tablet administered orally once daily
75426773|NCT01940471|Drug|TAF Placebo|Tablet administered orally once daily
75426774|NCT01940471|Drug|TDF Placebo|Tablet administered orally once daily
75426775|NCT01902693|Other|No intervention for this study|No intervention
75426776|NCT01860456|Drug|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
75426777|NCT01848639|Drug|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
75573269|NCT05112900|Behavioral|Text Messaging (TM)|[see arm/group descriptions]
75573270|NCT05112900|Behavioral|Text Messaging + Health Navigation (TM+HN)|[see arm/group descriptions]
75426778|NCT01848639|Drug|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
75426779|NCT01765400|Drug|Prasugrel 10 mg daily x 2 weeks|
75426780|NCT01765400|Drug|Clopidogrel 75 mg daily x 2 weeks|
76047974|NCT02499029|Drug|Placebo|Identical looking placebo pills were administered each week.
76047975|NCT04968353|Device|Incisally-beveled attachment|Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
75725190|NCT05217615|Behavioral|Coaching calls|The purpose of the brief (~15 min) telephone coaching calls is to provide parents with clarification of program content, encouragement and reinforcement of program completion, and support tailoring of intervention content (ezParent or Active Control)for their child. Coaching calls are guided by a semi-structured script aimed at supporting parent learning and motivation. Calls will be scheduled every week for 10 weeks. Each call will include an opportunity for parents to identify and discuss:(a) questions regarding the materials and content received in their respective groups,(b) identification of potential barriers and strategies to overcome barriers for completion of intervention (ezParent or control) content in their respective group, and (c)follow up on discussion points from previous calls. In both conditions, coaches will have access to a web-based usage portal to guide the discussion.
75725191|NCT05217615|Behavioral|Active Control|The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
75573271|NCT05097599|Drug|lorlatinib|This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
75573272|NCT05097599|Drug|encorafenib + binimetinib|This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
76047976|NCT04968353|Device|Gingivally-beveled attachment|Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
76047977|NCT04968353|Device|Optimized attachment|Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
76047978|NCT04968353|Device|Horizontal attachment|Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
76047979|NCT02065713|Drug|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
76047980|NCT02065713|Drug|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
76047981|NCT02065713|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
76047982|NCT04701489|Device|Splenic ultrasound|GE LOGIQ E10 device with C1-6 ultrasound probe
76047983|NCT02497781|Drug|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
76047984|NCT02497781|Drug|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
76047985|NCT02497469|Drug|Vedolizumab|Vedolizumab infusion
76047986|NCT02497469|Drug|Adalimumab placebo|Adalimumab placebo-matching injection
75426781|NCT01751906|Device|Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
75573273|NCT05097599|Drug|talazoparib|This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
75573274|NCT05097599|Drug|fam-trastuzumab deruxtecan-nxki|This arm of the Strata PATH trial will assess the clinical benefit of Enhertu® (fam-trastuzumab deruxtecan-nxki) in patients with advanced solid tumors harboring HER2 over-expression, as detected by Strata testing (HER2 Expression Score positive [HER2 ES-positive]), excluding breast cancer, gastric cancer, or gastroesophageal junction (GEJ) cancer.
75573275|NCT05097599|Drug|enfortumab vedotin|This arm of the Strata PATH trial will assess the clinical benefit of Padcev® (enfortumab-vedotin) in patients with advanced solid tumors and are Nectin-4 Expression Score High (Nectin-4 ES-H), as detected by Strata testing, excluding urothelial cancer.
75573276|NCT05097599|Drug|sacituzumab govitecan|This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
75573277|NCT05097599|Drug|pembrolizumab|This arm of the Strata PATH trial will assess the clinical benefit of pembrolizumab in patients with advanced solid tumors and are Immunotherapy Response Score High (IRS-H), as detected by Strata testing, excluding approved pembrolizumab indications.
75573278|NCT05097599|Drug|axitinib|This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
75573279|NCT05097144|Device|Lens A (fanfilcon A)|Daily wear for one month
75573280|NCT05097144|Device|Lens B (asmofilcon A)|Daily wear for one month
75573281|NCT05068947|Drug|GV101|GV101 administered once orally.
75573282|NCT05068947|Drug|Placebo|Matched placebo
75573283|NCT05058196|Radiation|Whole breast radiotherapy|Whole breast radiotherapy after surgery
75573284|NCT05058196|Radiation|Intra Operative Radiotherapy|Intra Operative Radiotherapy
75573285|NCT05058157|Dietary Supplement|different ketogenic formulae|The research product may be in a form of powder to reconstitute or in a ready-to-drink format.
75573286|NCT05048719|Drug|LY3502970|Administered orally
75573287|NCT05048719|Drug|Dulaglutide|Administered subcutaneously
75573288|NCT05048719|Drug|Placebo|Administered orally
75725192|NCT02592941|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
75725193|NCT00817388|Other|No intervention|No intervention
75725194|NCT05013996|Behavioral|MIDSA|Multidimensional Inventory of Development, Sex, and Aggression
75573289|NCT05048719|Drug|Placebo|Administered subcutaneously
75573290|NCT05048498|Drug|NEX-18a injection|"In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection."
75573291|NCT05048498|Drug|Azacitidine Injection|In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
75725195|NCT05013996|Behavioral|Usual methods of evaluation|Usual methods of evaluation of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
75725196|NCT00822614|Drug|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
75725197|NCT00822614|Drug|Opioid|Current optimized BTP treatment
75725198|NCT00907920|Other|laboratory biomarker analysis|Correlative studies
75725199|NCT04087967|Drug|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1~5, intravenous infusion; Homoharringtonine:1mg/d,d3~16,intravenous infusion; Aclarubicin:10mg/d, d3~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection;"
75573292|NCT05030207|Diagnostic Test|Real-time Gated 4DCT|Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.
75573293|NCT05030207|Diagnostic Test|Conventional 4DCT|Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
75573294|NCT05028114|Drug|AC-1202|Tricaprilin formulated as AC-1202
75573295|NCT05028114|Drug|AC-OLE-01|Tricaprilin Formulation
75573296|NCT05028114|Drug|AC-OLE-02|Tricaprilin Formulation
75725200|NCT04087967|Drug|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
75725201|NCT03735693|Diagnostic Test|Ulstrasound|measurement of right femoral cross-section
75725202|NCT02549456|Procedure|natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
75725203|NCT02549456|Procedure|Laparoendoscopic resection|"Endoscopic phase: Transanal platform is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.~Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed."
75725204|NCT04087577|Other|conventional physical therapy|includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
75725205|NCT04087577|Other|mirror therapy|mirror therapy
76047987|NCT02497469|Drug|Adalimumab|Adalimumab injection
75426782|NCT01751906|Device|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
75573297|NCT05028114|Drug|AC-OLE-03|Tricaprilin Formulation
75573298|NCT05028114|Drug|AC-OLE-04|Tricaprilin Formulation
75573299|NCT05028114|Drug|AC-OLE-05|Tricaprilin Formulation
75573300|NCT05028114|Drug|AC-OLE-06|Tricaprilin Formulation
75725206|NCT04196751|Other|Clinical Supervision|After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6&12 month with pre-specified tools.
75725207|NCT00926016|Drug|Pioglitazone (Actos)|pioglitazone 45 mg a day
75426783|NCT01730937|Drug|Sorafenib|By mouth (PO)
75426784|NCT01730937|Radiation|stereotactic body radiation therapy|Intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are allowed.
75573301|NCT05028114|Drug|AC-OLE-07|Tricaprilin Formulation
75573302|NCT05028114|Drug|AC-OLE-08|Tricaprilin Formulation
75573303|NCT05028114|Drug|AC-OLE-09|Tricaprilin Formulation
75573304|NCT05028114|Drug|AC-OLE-010|Tricaprilin Formulation
75573305|NCT05028114|Drug|AC-OLE-P|Placebo to tricaprilin formulation
75573306|NCT05020197|Diagnostic Test|self-questionnaires on attachment and PTSD|The questionnaires (attachement type, PTSD symptoms) are administered face to face at the inclusion visit (at D0-D3). Validated self-questionnaires in French will be sent to the patients, either electronically or by post, according to their choice at D30 and D90. To describe the characteristics of the subjects, socio-demographic data, lifestyle, and medical history will be collected. The questionnaires will be administered three times to study the evolution of the parameters over time.
75573307|NCT05017779|Behavioral|Unstuck & On Target: High School|Unstuck & On Target: High School (UOT:HS) is a group-based curriculum for high school students that targets executive function skills using Cognitive Behavior Therapy (CBT) techniques. UOT:HS focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Lessons are delivered by school personnel within the school setting. Home extension activities are provided to parents.
75573308|NCT05017779|Other|Treatment as Usual|Participants in schools assigned to the Treatment as Usual (TAU) condition will continue to receive the standard school-based IEP accommodations and school supports that would typically be provided. Data will be collected on the types of supports TAU schools offer, and what supports TAU students receive.
75573309|NCT05009862|Drug|Rivaroxaban 2.5 Mg Oral Tablet|rivaroxaban 2.5 milligrams twice daily
75573310|NCT05009862|Drug|Placebo|placebo
75573311|NCT05009862|Drug|Aspirin 81Mg Ec Tab|aspirin 81 milligrams
75426785|NCT01569581|Biological|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
75426786|NCT01569581|Biological|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
75426787|NCT01569581|Biological|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
75426788|NCT01569581|Biological|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
75426789|NCT01560416|Drug|Fulvestrant|
75426790|NCT01560416|Drug|Ganetespib|
75426791|NCT01551823|Biological|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
75426792|NCT01551823|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
75426793|NCT01551810|Biological|Influenza Virus Vaccine|Influenza Virus Vaccine 0.5ml intramuscular injections
75426794|NCT01551810|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
75426795|NCT01512706|Biological|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
75426796|NCT01512706|Biological|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
75426797|NCT01512706|Biological|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
75426798|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
75426799|NCT01512706|Biological|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
75426800|NCT01512706|Biological|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
75426801|NCT01512706|Biological|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
75426802|NCT01512706|Biological|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
75426803|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
75426804|NCT01512706|Biological|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
75426805|NCT01512706|Biological|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
75573312|NCT05003180|Procedure|Surgical stabilization|The surgical stabilization can be either open or minimally invasive. The recommended procedure is posterior fixation with pedicle screws and rods. Both short and long segment fixation are allowed in the study. It is up to the treating surgeon to decide on fusion or decompression. If feasible, pedicle screws are inserted in the fractured vertebra.
75573313|NCT04994886|Procedure|Device implantation|The intervention involves the insertion of 2 lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) epidurally over the dorsal aspect of the spinal cord through 2 laminectomies and two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) in the abdomen of the participant.
75573314|NCT04972227|Drug|CY6463|oral tablets
75573315|NCT04972227|Drug|Placebo|oral tablets
75573316|NCT04962997|Other|Data collection|"Investigator will ensure the completion of a hetero-administered questionnaire which will be carried out in French, English, Portuguese or Spanish depending on the language spoken by the participant, including informations related to Demography and socio-economic conditions, Addictions, Work and studies, Housing, Health coverage, Gender and sexuality, Vulnerabilities and violence, Recourse to care, State of physical health, Mental Health, Prevention and Sexually Transmitted Infections (STIs), Checkup, Transition path and clinical complications and Dermatological problems.~Investigator will collect the data relating to the clinical examination, dermatological examination and the search for STIs (blood and / or urine) carried out in the routine care of the participant in a case report form (CRF).~The estimated duration of the interviews and the consultation is approximately 1 hour and 30 minutes per patient."
75573317|NCT04954001|Drug|FCN-159|FCN-159 is administered orally in once daily schedule for 28 days a cycle.
75573318|NCT04949802|Device|ViaLase Laser|ViaLase Laser System to create an aperture through the trabecular meshwork for the reduction of IOP in subjects with primary open-angle glaucoma
76047988|NCT02497469|Drug|Vedolizumab placebo|Vedolizumab placebo-matching infusion
76047989|NCT02497391|Drug|Evacetrapib|administered orally
75426806|NCT01512706|Biological|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
75426807|NCT01512706|Biological|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
75426808|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
75426809|NCT01512706|Biological|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
75426810|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
75426811|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
75573319|NCT04949737|Biological|Helicobacter Pylori detection|"Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.~Additional data will be collected through a questionnaire."
75573320|NCT04945915|Other|blood sampling|There was no intervention because this reasearch is observational study.
75573321|NCT04938583|Biological|Oregovomab|"Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg).~2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes"
75573322|NCT04938583|Drug|Bevacizumab|15mg/Kg Day 1 (every 21 days) until progression
75573323|NCT04938583|Drug|Paclitaxel|175 mg/m^2, Day 1 x 6 cycles (every 21 days)
75573324|NCT04938583|Drug|Carboplatin|AUC 5 IV Day 1 x 6 cycles (every 21 days)
75573325|NCT04925856|Other|blood sample|"•Blood sample:~1 heparinized tube (4 mL) for collection of plasma and storage~1 heparinized tube (4 mL) for immunophenotyping,~4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
75573326|NCT04918082|Other|Quality of life questionnaires|Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.
75725208|NCT04017104|Diagnostic Test|18F-FDG PET/CT|"For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
75725209|NCT04017104|Diagnostic Test|68Ga-DOTATOC PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
75725210|NCT04017104|Diagnostic Test|18F-DCFPyL PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
75725211|NCT05237531|Behavioral|Standardized Preoperative Education|"The standardized preoperative education includes a brief video, an interactive quiz, and a written handout.~The video will provide information on the proper use and common side effects of opioid pain medications, the expected effects of a peripheral nerve block, and the concept of multimodal postoperative pain management with non-opioid medications and non-pharmaceutical pain management strategies. The interactive quiz will reinforce the critical components of the video in a question-and-answer format which requires active participation. The written handout will summarize the educational content in a form which can be easily referenced by patients at home."
75878023|NCT04855227|Procedure|robotic-assisted ventral hernia repair|"Laparoscopic ventral hernia repair With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.~Robotic-assisted ventral hernia repair With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care."
75878024|NCT02238002|Procedure|cataract surgery|The patients of both groups underwent cataract surgery
75878025|NCT04615533|Other|Frail older adults, assessment|Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
75573327|NCT04913142|Other|Fecal and oral samples|oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
75573328|NCT04888416|Behavioral|I-STROM|I-STROM is a combination of the following implementation strategies: (a) initial and ongoing training, (b) learning collaboratives/knowledge sharing meetings, and (c) outcome measure champions
75573329|NCT04878575|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
75573330|NCT04878575|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
75573331|NCT04876989|Procedure|US-SGB|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.
75573332|NCT04876989|Procedure|US-TPVB|Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
75725212|NCT05237531|Behavioral|Standard of care|Education per provider preference (no standardization, current standard of care)
76047990|NCT02476175|Drug|Mirabegron|Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
76047991|NCT02065557|Biological|Adalimumab|Subcutaneous (SC) injection
75426812|NCT01345539|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.
75573333|NCT04873674|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
75426813|NCT01345539|Drug|Chemotherapy|Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
75426814|NCT01288066|Procedure|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
75573334|NCT04873674|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
75573335|NCT04871672|Other|Pilates Exercises|basic five pilates intermediate workout based on the principles of Pilates
75573336|NCT04871672|Other|Home Exercise program|home exercise
75573337|NCT04858269|Drug|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle
75573338|NCT04858269|Drug|Carboplatin|Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle
75573339|NCT04858269|Drug|Paclitaxel|Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.
75725213|NCT05237531|Behavioral|Preoperative and postoperative questionnaires|Preoperative questionnaire: Demographic questions plus specific questions about chronic pain, prior opioid use, and mental health diagnoses Postoperative questionnaire: Questions about pain control after surgery, satisfaction with pain control, healthcare contact since surgery, opioid consumption since surgery, and satisfaction with education
75725214|NCT04015206|Other|Group Interpersonal Psychotherapy|Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
75725215|NCT04799223|Other|Four-foods eating guidelines|To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.
75725216|NCT04799223|Other|No designed-foods eating guidelines|To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
76047992|NCT02065557|Biological|Placebo|Subcutaneous (SC) injection
76047993|NCT02065245|Biological|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion
76047994|NCT02065245|Biological|Placebo|Placebo administered by peripheral intravenous infusion.
76047995|NCT02065245|Biological|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.
76047996|NCT02043015|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
75725217|NCT04765449|Drug|Cytotoxic T Lymphocytes|Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
75878026|NCT04561089|Diagnostic Test|COVIDSeq Test|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
75878027|NCT03825302|Diagnostic Test|Methacholine challenge|Methacholine inhalation challenge will be administered to both male and females with asthma
75878028|NCT03825302|Diagnostic Test|Mannitol challenge|Mannitol inhalation challenge will be administered to both male and females with asthma
75426815|NCT01288066|Procedure|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
75426816|NCT01279850|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
75426817|NCT01257269|Other|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
75426818|NCT01217281|Procedure|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
75426819|NCT01068327|Drug|gemcitabine hydrochloride|Given IV
75426820|NCT01068327|Drug|leucovorin calcium|Given IV
75725218|NCT00827138|Drug|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
75725219|NCT00907998|Drug|APL180|
75725220|NCT00907998|Drug|APL180|
75725221|NCT00907998|Drug|Placebo|
75426821|NCT01068327|Drug|fluorouracil|Given IV
75426822|NCT01068327|Drug|nelfinavir mesylate|Given PO
75725222|NCT02549378|Device|confocal microscopy|microvessel diameter measured by confocal microscopy
75878029|NCT04851795|Other|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
75878030|NCT04851795|Other|unsupervised physical exercise|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
75878031|NCT02238392|Procedure|Adenosine test|Testing dormant conduction after PVI
75878032|NCT02238392|Procedure|Termination of AF|Testing AF iducibility and ermination of
75878033|NCT02260193|Drug|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
75426823|NCT01068327|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
75573340|NCT04797442|Drug|WST01 strain product|orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5*10^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
75573341|NCT04797442|Drug|placebo powder|orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
75725223|NCT03907683|Behavioral|Short Message with Text and Optional Image|"Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
75725224|NCT00929604|Other|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
75725225|NCT02549534|Procedure|Axon Reflexes|"*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33*C.~Heat Ramp: Increasing the heat in the heat probe to 42*C at approx. 0.1*C/10 sec.~Skin Heating: Heating the skin of the toe for 30 minutes 42*C.~Heat Ramp: Increasing the heat in the heat probe to 44*C at 0.1*C/10 sec..~Skin Heating: Heating the skin for an additional 5 minutes at 44*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
75426824|NCT01068327|Radiation|hypofractionated radiation therapy|Undergo radiotherapy
75878034|NCT02260193|Drug|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
76047997|NCT02043015|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
76047998|NCT02043015|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
75426825|NCT01068327|Procedure|therapeutic conventional surgery|Undergo surgery
75426826|NCT01035463|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
75426827|NCT01035463|Drug|Carmustine|Given IV
75573342|NCT04768153|Biological|Serology|Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
75426828|NCT01035463|Drug|Cytarabine|Given IV
75426829|NCT01035463|Drug|Etoposide|Given IV
75426830|NCT01035463|Drug|Lenalidomide|Given PO
75426831|NCT01035463|Drug|Melphalan|Given IV
75426832|NCT01035463|Biological|Rituximab|Given IV
75426833|NCT00936390|Drug|bicalutamide|Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
75426834|NCT00936390|Drug|flutamide|Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
75426835|NCT00936390|Drug|LHRH agonist (antagonist) therapy|LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
75573343|NCT04763564|Drug|Liraglutide Pen Injector|Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.
75573344|NCT04763564|Drug|Placebo Pen Injector|Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
75573345|NCT04743505|Drug|APL-101|-Provided by Apollomics
75573346|NCT04743505|Drug|Osimertinib|-Given standard of care
75573347|NCT04742504|Biological|BENRALIZUMAB|The decision of the patients treatment with benralizumab (Fasenra®, Astra Zeneca) included in the study will not come in any case influenced by their participation in the study but will be made in accordance with the clinical criteria established by the Asthma Multidisciplinary Unit (UMA).
75426836|NCT00936390|Radiation|Dose-Escalated Radiation Therapy|External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
75573348|NCT04730154|Behavioral|Pain Neuroscience Education (PNE)|PNE is a cognitive behavioural intervention, including educating patients that pain is an output product of the brain resulting from input from multiple central and peripheral nervous system processes and leading to threat perception. Transferring that knowledge to patients, allows them to understand, accept and effectively cope with their pain. In order to obtain the targeted behavioural change, motivational interviewing is used as the communication process throughout PNE.
75573349|NCT04730154|Behavioral|Motivational Interviewing (MI)|Motivational interviewing is a directive, collaborative, patient-centered communication approach for eliciting and enhancing motivation for behaviour change by helping clients to resolve ambivalence and uncertainty.
75573350|NCT04730154|Behavioral|Biomedically-focused education|The traditional biomedical-focused education programme explains patient's pain experience from a tissue (injured versus healthy tissue) and biomechanical perspective.
75573351|NCT04719832|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
75573352|NCT04719832|Drug|Placebo|Matching placebo will be administered as a normal saline using a pre-filled syringe.
75426837|NCT00572234|Drug|bupropion SR|12 week course of bupropion SR 150 mg, BID
75573353|NCT04718870|Drug|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
75573354|NCT04718103|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
75426838|NCT00534430|Drug|busulfan|
75426839|NCT00534430|Drug|cyclosporine|
75426840|NCT00534430|Drug|etoposide|
75426841|NCT00534430|Drug|mycophenolate mofetil|
75573355|NCT04718103|Biological|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
75573356|NCT04708860|Behavioral|Prolonged Nightly Fasting|Restriction of consumption of calorie-containing food/drinks after 8pm
75573357|NCT04708860|Behavioral|Exercise|Personalized moderate-intensity, aerobic exercise and strength training
75878035|NCT02260193|Drug|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
76047999|NCT02043015|Drug|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
76048000|NCT02043015|Other|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
75573358|NCT04705220|Dietary Supplement|MERIVA® Tablets|The treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
75573359|NCT04705220|Other|Placebo Tablets|The composition of placebo includes the same components of the treatment tablets, except for the active substance.
75573360|NCT04696887|Behavioral|Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities|• 8-week Tele Tai Chi intervention, participants will use a tablet or computer to join a small-group, online class (1hr, twice weekly) from home; during each session, participants will exercise as a group along with the pre-recorded video lessons and have the opportunity for social interaction (via video chat) before and after class.
75426842|NCT00534430|Procedure|allogeneic bone marrow transplantation|
75426843|NCT00534430|Procedure|allogeneic hematopoietic stem cell transplantation|
75725226|NCT02549534|Procedure|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
75426844|NCT00534430|Procedure|peripheral blood stem cell transplantation|
75573361|NCT04691557|Other|Mobile Health Application|YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.
75426845|NCT00534430|Radiation|total-body irradiation|
75426846|NCT00497926|Biological|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
75426847|NCT00411138|Radiation|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
75426848|NCT00411138|Drug|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
75426849|NCT00411138|Drug|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
75426850|NCT00411138|Drug|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
75426851|NCT00149149|Other|Zinc Carnosine coadministered with Indomethacin|
75426852|NCT00149149|Other|Placebo coadministered with Indomethacin|
75426853|NCT00085202|Biological|filgrastim|Given subcutaneously
75573362|NCT04691557|Other|Usual Care|Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
75573363|NCT04691232|Biological|Regulatory T cells|Autologous, ex vivo expanded, regulatory T cells
75573364|NCT04683315|Drug|mFOLFIRINOX Treatment Regimen|This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
75573365|NCT04683315|Drug|Gemcitabine/Nab-paclitaxel Treatment Regimen|This regimen will be nab-paclitaxel and gemcitabine.
75573366|NCT04683315|Radiation|Chemoradiation|50.4 Gy in 28 fractions.
75725227|NCT02549534|Procedure|Self-Reported Signs & Symptoms of CIPN|Self-reported signs & symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
75426854|NCT00085202|Drug|cisplatin|Given IV
75426855|NCT00085202|Drug|cyclophosphamide|Given IV
75426856|NCT00085202|Drug|vincristine|Given IV
75426857|NCT00085202|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
75426858|NCT00085202|Radiation|radiation therapy|Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
75426859|NCT01469312|Other|modified pasta|50 grams carbohydrate as a single breakfast meal
75573367|NCT04677790|Behavioral|assigned period of specific dietary restrictions|Step by step gradual introduction of egg containing food products
75426860|NCT01469325|Other|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
75426861|NCT01469325|Other|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
75426862|NCT01469338|Drug|cabazitaxel|Given IV
75426863|NCT01469338|Drug|prednisone|Given PO
75426864|NCT01469338|Drug|octreotide pamoate|Given IM
75426865|NCT01469338|Other|questionnaire administration|Ancillary studies
75426866|NCT01469338|Drug|octreotide acetate|Given SC
75573368|NCT04673617|Drug|AB-101|NK cell therapy
75573369|NCT04673617|Drug|Rituximab|Anti-CD20 antibody therapy
75573370|NCT04673617|Drug|Interleukin-2|Immune cytokine
75573371|NCT04673617|Drug|Cyclophosphamide|Lymphodepleting chemotherapy
75573372|NCT04673617|Drug|Fludarabine|Lymphodepleting chemotherapy
75573373|NCT04673617|Drug|Bendamustine|Chemoimmunotherapy
75725228|NCT04173195|Other|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
75878036|NCT05763147|Device|Intravenous Access Device Flushing|locking and flushing the end of catheter line at the intervals of different drug treatment.
75878037|NCT03587402|Other|Transcutaneous perineal stimulation|Surface stimulation
75725229|NCT00929682|Drug|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
75426867|NCT01469351|Drug|Liraglutide|"Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used."
75573374|NCT04649229|Drug|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
75573375|NCT04649229|Drug|Placebo|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
75573376|NCT04649229|Drug|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
75426868|NCT01469351|Drug|non-active study drug|placebo
75573377|NCT04649229|Drug|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
75725230|NCT03659721|Behavioral|FACAM|Support person
76048001|NCT02043015|Behavioral|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
76048002|NCT02043015|Behavioral|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
76048003|NCT02064231|Device|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
76048004|NCT02064231|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
75573378|NCT04649229|Drug|Aprepitant|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
75573379|NCT04645732|Behavioral|Personalized exercise therapy and self-management support program|See description under Arms
75573380|NCT04645732|Other|Usual care|See description under Arms
75573381|NCT04645667|Drug|Tacrolimus|Patients will be enrolled into this group if they receive tacrolimus per standard of care. This is an observational study and no interventions will be made.
75573382|NCT04644029|Drug|Islatravir|Oral 60 mg tablet administered once monthly during Part 1.
75573383|NCT04644029|Drug|Placebo to FTC/TDF|0 mg tablet administered once daily during Part 1.
75573384|NCT04644029|Drug|FTC/TDF|Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
75573385|NCT04644029|Drug|Placebo to ISL|0 mg tablet administered orally once monthly in Part 1.
75725231|NCT03659721|Behavioral|Care as Usual|Usual care
75725232|NCT03659721|Behavioral|COS-P|Attachment based therapy
76048005|NCT02064231|Device|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
75573386|NCT04640077|Other|No Intervention|No intervention
75573387|NCT04640077|Drug|donanemab|Administered IV
75573388|NCT04626297|Drug|Lebrikizumab|Given SC
75573389|NCT04626297|Drug|Placebo|Given SC
75573390|NCT04621526|Drug|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
75426869|NCT01469403|Behavioral|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
75426870|NCT01469416|Drug|Rosuvastatin|Rosuvastatin 20 mg PO x 1
75573391|NCT04621526|Drug|dexmedetomidine- propofol|patients will receive combination from 0.5 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
75573392|NCT04599010|Other|Dietary intervention|energy-restricted diet appropriate for resting metabolic rate using FFM as proxy
75573393|NCT04592809|Drug|Ketamine Hydrochloride|infused over a 40 minute period
75573394|NCT04592809|Drug|Midazolam Hydrochloride|infused over a 40 minute period
75725233|NCT04015674|Other|Exercise group|Aerobic exercise on a stationary bicycle
75426871|NCT01469416|Drug|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
75426872|NCT01469429|Other|placebo|Receive lozenge placebo PO
75426873|NCT01469429|Other|laboratory biomarker analysis|Correlative studies
76048006|NCT02064231|Device|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
75426874|NCT01469429|Other|questionnaire administration|Ancillary studies
75426875|NCT01469429|Drug|chemoprevention|Receive LBR lozenge PO
75573395|NCT04584255|Drug|Niraparib|Predetermined dosage PO Daily
75573396|NCT04584255|Drug|Dostarlimab|Predetermined Dosage, IV,q3 weeks
75573397|NCT04567407|Drug|Bilateral erector spinae blocks using ropivacaine|Bilateral chest wall nerve blocks using ropivacaine.
75573398|NCT04566978|Drug|89Zr-DFO-REGN3767|89Zr-DFO-REGN3767 is comprised of the anti-LAG-3 antibody, REGN3767 labeled with the positron-emitter zirconium-89 (89Zr) through the chelator-linker DFO. REGN3767 is an investigational monoclonal antibody that target LAG-3 receptors.
75573399|NCT04566978|Diagnostic Test|PET/CT|"A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution.~Part A patients will be imaged at three time points post-injection to allow for selection of optimal imaging time and dosimetry determination. For these patients, top of skull to feet scans will be acquired:~Within one to four hours following injection of tracer on Day 1~24-72 hours post-injection (Day 2-4)~20-168 hours post-injection (once during days 5-7)"
75573400|NCT04533165|Behavioral|Exercise|12 week exercise prescription targeting 3 days of at least 30 min of aerobic exercise and 2 days of resistance exercise per week. Adapted to individual abilities, goals, and needs. Exercise intensity targets a 6-7 out of 10 on a 0-10 rate of perceived exertion scale.
75573401|NCT04532177|Radiation|Stereotactic Body Radiation Therapy (SBRT)|fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
75725234|NCT04015674|Other|Control group|In a rest
75725235|NCT00929760|Behavioral|specialised renal care|"Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
75725236|NCT00817466|Drug|Racemic adrenaline|"For inhalation.~Dosing (as in previous study):~1) 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number."
75725237|NCT00817466|Drug|Isotonic saline|2ml NaCl 9mg/ml.
75878038|NCT03587402|Other|Anal stimulation|Intra-cavitary stimulation
76048007|NCT02064231|Device|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
76048008|NCT02063217|Drug|Sodium Oxybate|Sodium oxybate h.s.
76048009|NCT02063217|Behavioral|Sleep deprivation|36hr sleep deprivation
75573402|NCT04529408|Device|EarSats Pulse Oximeter Probe|Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
75426876|NCT01469429|Drug|chemoprevention|Receive LBR Saliva Substitute PO
75426877|NCT01469429|Other|placebo|Receive Saliva Substitute placebo PO
75426878|NCT01469442|Procedure|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
75426879|NCT01469455|Drug|DT01|"DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions."
75426880|NCT01469468|Drug|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
75426881|NCT01469468|Drug|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
75426882|NCT01469481|Drug|PF-04991532|a single oral dose of [14C]PF-04991532 (450 mg/100 uCi suspension)
75426883|NCT01469494|Procedure|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
75426884|NCT01469494|Procedure|SIEA flap breast reconstruction|"The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast."
75573403|NCT04500964|Device|TAVR|Trancatheter aortic valve replacement
75573404|NCT04465097|Drug|Tucidinostat|Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26
75573405|NCT04465097|Drug|Exemestane|Exemestane: 25 mg QD from week 1 to week 26.
75573406|NCT04465097|Drug|Ovarian function suppression|If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.
75426885|NCT01469507|Device|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
75426886|NCT01469507|Drug|Hyaluronan|3 weekly injections
75573407|NCT04462588|Drug|Cipro 400 MG in 200 ML Injection|medical tratment group
75573408|NCT04462588|Drug|Flagyl I.V. RTU|medical tratment group
75725238|NCT00926250|Dietary Supplement|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
75725239|NCT00926250|Dietary Supplement|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
75573409|NCT04462588|Procedure|appendectomy (open or laparascopic)|appendectomy (open or laparascopic)
75573410|NCT04440150|Procedure|Appendectomy|Open or Laparascopic Surgery
75573411|NCT04437823|Biological|Intravenous Infusions of Stem Cells|Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
75573412|NCT04433065|Device|Intrepid™ TTVR System|Device: Intrepid™ TTVR System
75426887|NCT01469520|Drug|Epivir®, Retrovir® and Viramune®|12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
75573413|NCT04429243|Device|GORE® VIABAHN® Stent Graft|On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.
75878039|NCT02035514|Biological|Bone marrow autologous mesenchymal stem cells transplantation|
75426888|NCT01469520|Drug|Lamivudine, Zidovudine and nevirapine|20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
75426889|NCT01469520|Drug|Lamivudine, zidovudine, nevirapine|Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
75426890|NCT01469533|Other|Spinal mechanical manipulation intervention|Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
75426891|NCT01469533|Other|Sham manipulation intervention|Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
75426892|NCT01469559|Drug|Novolin Toronto insulin|Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
75426893|NCT01469559|Drug|Normal saline|Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
75426894|NCT01469572|Drug|Pasireotide|Pasireotide is given as an injection.
75573414|NCT04418011|Device|Repetitive Transcranial Magnetic Stimulation|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
75725240|NCT04582370|Behavioral|theater program|10-week theory-based theater program designed to improve their physical functioning and reduce emotional stress.
75725241|NCT00908154|Drug|Placebo|Tablets to match GSK1014802
75725242|NCT00908154|Drug|GSK1014802|Sodium channel blocker
75725243|NCT00830648|Biological|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
75725244|NCT00926406|Drug|lead chelation therapy|Patients with lead poisoning (BLL> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL < 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
75725245|NCT04708899|Behavioral|arabic version of differential processing training program|comprehensive training program for central auditory processing disorder contains auditory and linguistic tasks (language organization, phonemic and phonetic awareness, dichotic listening,temporal patterning and auditory discrimination).
75878040|NCT04819035|Diagnostic Test|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
75878041|NCT02238236|Drug|Alesion®|Dry Syrup
75878042|NCT04306029|Other|Postpartum Family Planning Package|"Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
76048010|NCT02497001|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])
76048011|NCT02497001|Drug|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
75573415|NCT04418011|Device|Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
75573416|NCT04418011|Device|Repetitive Transcranial Magnetic Stimulation (Sham)|Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
75426895|NCT01469572|Procedure|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
75573417|NCT04409119|Device|HIS/LBB pacing|3830 lead to HIS or LBB
75573418|NCT04409119|Device|LV pacing|LV lead in a CS branch
75426896|NCT01469572|Drug|Everolimus|Given orally every day for the duration of the study
75573419|NCT04404140|Drug|Ipatasertib|Ipatasertib will be administered at a dose of 400 mg, as per the dosing schedule described above.
75725246|NCT04708899|Behavioral|Arabic computer based auditory traing program(CBAT)|comprehensive computer based traing program for central auditory processing disorder contains auditory memory, temporal processing, dichotic listening , selective attention and phonemic awareness games.
75426897|NCT01469598|Drug|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
75426898|NCT01469611|Biological|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
75426899|NCT01469624|Drug|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
75426900|NCT01469676|Device|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
75426901|NCT01469689|Other|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
75426902|NCT01469689|Other|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
75426903|NCT01469702|Drug|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
75426904|NCT01469702|Drug|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
75426905|NCT01469702|Drug|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
75426906|NCT01469728|Procedure|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
75426907|NCT01469728|Procedure|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
75426908|NCT01469741|Behavioral|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
75725247|NCT00930072|Drug|Cervical Sympathetic Block (bupivicaine, clonidine)|12-15ml solution of bupivicaine .5% containing 50 mcg of clonidine for cervical sympathetic block administered in a single injection.
75725248|NCT00626522|Drug|Aclidinium bromide and formoterol|once daily
75725249|NCT00626522|Drug|Aclidinium bromide and formoterol placebo|once daily
75573420|NCT04404140|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg, as per the dosing schedule described above.
75573421|NCT04404140|Drug|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m^2, as per the dosing schedule described above.
75725250|NCT00926562|Drug|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
75725251|NCT00926562|Drug|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
75725252|NCT04366791|Radiation|Low Dose Radiation Therapy|Undergo low-dose radiation therapy
75725253|NCT00926640|Drug|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
75426909|NCT01469793|Drug|DMOT4039A|DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.
75725254|NCT00926640|Drug|Cisplatin|6 cycles at 60mg/m2 IV on day 2
75878043|NCT02849678|Drug|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
75573422|NCT04349358|Other|FDG and FCH PET/CT|"during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)~just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams"
75426910|NCT01469806|Device|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
75426911|NCT01469845|Device|3% hypertonic saline|4 ml dose to be administered every 6 hours
75426912|NCT01469858|Device|Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla|functional magnetic resonance imaging
75573423|NCT04346654|Drug|Eltrombopag|Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
75426913|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
75426914|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepore Pro dressing after hip surgery.
75426915|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepilex Border dressing after hip surgery.
75426916|NCT01469884|Drug|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
75426917|NCT01469884|Drug|Cyclosporine|Trough level should be between 100 and 200ng/ml.
75573424|NCT04346654|Drug|Dexamethasone|Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
75426918|NCT01469884|Drug|Tacrolimus|Trough level should be between 5 and 10ng/ml.
75573425|NCT04319094|Behavioral|PEERS|Peer mentors deliver depression care that include social support and coping skills, focused on goal setting and small behavioral changes.
75426919|NCT01469286|Device|TEA|Electroacupuncture at ST36
75426920|NCT01469286|Device|Sham-TEA|Electroacupuncture at sham-points
75426921|NCT01469910|Drug|Simotinib Hydrochloride|Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
75573426|NCT04319094|Other|Social interaction|Study staff will provide a combination of 8 social interaction visits and phone calls to the participants randomized to this condition.
75573427|NCT04291508|Drug|Intravenous Acetaminophen (room temperature)|Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs < 50 kg) every six hours for 5 days (20 doses)
75573428|NCT04291508|Drug|Intravenous Vitamin C (refrigerated)|Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)
75573429|NCT04291508|Drug|5% Dextrose (room temperature)|Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses)
75725255|NCT00926640|Drug|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
75725256|NCT04656171|Radiation|MRI of the hand and forearm,|MRI of the hand and forearm,
75725257|NCT00830726|Drug|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
75725258|NCT00830726|Procedure|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
75725259|NCT00830726|Procedure|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
75725260|NCT00830726|Procedure|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
75426922|NCT01469910|Drug|Placebo|Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
75426923|NCT01469923|Drug|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
75426924|NCT01469923|Drug|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
75426925|NCT01469936|Dietary Supplement|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~First Week of intervention : 1/2 stick per day~Second to 5th Week : 1 stick per day"
75573430|NCT04291508|Drug|5% Dextrose refrigerated|Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses)
75426926|NCT01469936|Dietary Supplement|PLACEBO|"Duration : 5 weeks +/- 1 week.~Dosage:~First Week : 1/2 stick per day~Second to 5th Week : 1 stick per day"
75573431|NCT04256759|Drug|Dupilumab 300Mg Solution for Injection|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
75573432|NCT04255823|Other|General practitioner and Patient receive informations related to PPI deprescribing.|"General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.~Their patients will receive any informations (patient information material on PPI deprescribing)"
75573433|NCT04255823|Other|Only General practitioner receive informations related to PPI deprescribing.|"General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.~Their patients will not receive any informations."
75426927|NCT01469949|Other|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
75426928|NCT01469975|Drug|OTSA101-DTPA-90Y level 1|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
75426929|NCT01469975|Drug|OTSA101-DTPA-90Y level 2|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
75573434|NCT04242498|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
75573435|NCT04242498|Other|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
75573436|NCT04242342|Radiation|Adaptative MR-Guided Stereotactic Body Radiotherapy|"If lesion near organs at risk:~Prescription of 50 Gy in 5 fractions of 10 Gy~3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment~If lesion far of organs at risk:~Prescription of 60 Gy in 6 fractions of 10 Gy~3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment"
75573437|NCT04240158|Drug|IW-6463|IW-6463 Tablet
75573438|NCT04240158|Drug|Matching Placebo|Matching Placebo Tablet
75573439|NCT04169191|Drug|Sildenafil Citrate|Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
75573440|NCT04160325|Dietary Supplement|postoperative 3-month exclusive enteral nutrition|postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months
75573441|NCT04160325|Drug|azathioprine|azathioprine
75573442|NCT04160325|Other|normal diet|normal diet
75573443|NCT04154189|Drug|Lenvatinib|"Lenvatinib 14 milligrams per square meter (mg/m^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules."
76048012|NCT02497001|Drug|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
76048013|NCT02497001|Drug|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
75426930|NCT01469975|Drug|OTSA101-DTPA-90Y level 3|"Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data."
75426931|NCT01469988|Drug|Testosterone|Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
75426932|NCT01470040|Drug|discontinuation of aspirin therapy|discontinuation of aspirin therapy
75573444|NCT04154189|Drug|Ifosfamide|Ifosfamide 3000 milligrams per square meter per day (mg/m^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
75573445|NCT04154189|Drug|Etoposide|Etoposide 100 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
76048014|NCT04182555|Device|Bilirubin estimates from Smartphone Application|Bilirubin estimates through color analysis of digital images obtained through smartphone application.
75426933|NCT01470040|Drug|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
75426934|NCT01470053|Drug|mometasone furoate plus azelastine HCl|
75426935|NCT01470053|Drug|mometasone furoate|
75426936|NCT01470053|Drug|azelastine HCl|
75426937|NCT01470092|Drug|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
75426938|NCT01470157|Drug|Ketamine|5mg/kg as oral suspension
75426939|NCT01470157|Drug|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
76048015|NCT04182555|Diagnostic Test|Bilirubin concentration measured in standard blood samples|Bilirubin measured in total serum bilirubin.
76048016|NCT04182555|Device|Bilirubin estimates from standard transcutaneous device|Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
76048017|NCT04182555|Other|Visual assessment of jaundice|Degree of jaundice will be assessed by Kramer scale
75426940|NCT01470209|Drug|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
75573446|NCT04154189|Drug|Lenvatinib|Lenvatinib 14 mg/m^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors [RECIST] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
75573447|NCT04115527|Procedure|Extended Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes
75426941|NCT01470209|Drug|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
75573448|NCT04115527|Procedure|Standard Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
75573449|NCT04108481|Drug|Durvalumab|Immunotherapy
75573450|NCT04108481|Radiation|Yttrium-90 RadioEmbolization|Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
75573451|NCT04083859|Other|mPATH-Lung|A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
75573452|NCT04083859|Other|Lung health video|Web-based video about guideline recommended exercise for lung health
75725261|NCT00931398|Drug|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
75725262|NCT00931398|Drug|Placebo|Matched placebo for all Concerta doses.
75426942|NCT01470222|Other|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
76048018|NCT04733079|Other|Cleanweb electronic messaging ePro|Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
75426943|NCT01470287|Biological|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
75573453|NCT04073303|Biological|Botulinum Toxin Type A|Day 1 Administration of bilateral intramuscular injections into the masseter
75573454|NCT04073303|Other|Placebo|Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
75573455|NCT04068441|Other|no intervention|No intervention
75573456|NCT04048161|Drug|Tacrolimus|"The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is < 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
75573457|NCT04048161|Drug|Mycophenolate Mofetil|"The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20~30mg/kg/day，BID. The concentration for MPA-AUC is 30~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
75573458|NCT04032964|Drug|L19TNF|L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
76048019|NCT04733079|Other|Usual follow-up|Adaptation and follow-up of ULT according to referring physician's habits
76048020|NCT02366143|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
75725263|NCT00827216|Drug|Placebo|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
76048021|NCT02366143|Drug|Bevacizumab|Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
76048022|NCT02366143|Drug|Carboplatin|Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
75573459|NCT04032964|Drug|DOXORUBICIN|Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
75573460|NCT04011722|Device|Portico™ NG (Navitor) Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
75573461|NCT04011722|Device|Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
75573462|NCT03976193|Behavioral|BfitBwell program|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
75573463|NCT03976193|Behavioral|6 bi-weekly PA Behavior Change counseling sessions|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
75573464|NCT03964233|Drug|BI 907828|Film-coated tablets
75573465|NCT03964233|Drug|ezabenlimab|Solution for infusion
75573466|NCT03964233|Drug|BI 754111|Solution for infusion
75573467|NCT03949673|Drug|Fasinumab|Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
75573468|NCT03949673|Drug|Naproxen|Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
75573469|NCT03949673|Drug|Diclofenac|Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
75573470|NCT03949673|Drug|Celecoxib|Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
76048023|NCT02366143|Drug|Paclitaxel|Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
75426944|NCT01470300|Other|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit & vegetables, decreased fat, added plain water).
75426945|NCT01470313|Drug|PD-0360324|Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
75426946|NCT01470313|Drug|Placebo|Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
75426947|NCT01470326|Drug|Bazedoxifene|For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
75426948|NCT01470339|Drug|duloxetine|duloxetine 60mg once a day for 5 weeks
75426949|NCT01470352|Drug|Doluxetine|30 mg/d
75426950|NCT01470352|Drug|Placebo|suger pill 30mg/d
75426951|NCT01470365|Procedure|quality-of-life assessment|Ancillary studies
75573471|NCT03949673|Drug|Placebo|Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
75573472|NCT03922529|Behavioral|MACRO-I|MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format [site transitioning to home]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.
75426952|NCT01470365|Radiation|intensity-modulated radiation therapy|Undergo IMRT
76048024|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
75426953|NCT01470365|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
75426954|NCT01470378|Procedure|Thigh Surgery|Circumferential thigh surgery post bariatric surgery
75426955|NCT01470391|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
75426956|NCT01470391|Procedure|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
75573473|NCT03922529|Other|Usual Care|Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
75573474|NCT03919955|Drug|Atomoxetine|Atomoxetine 80 mg, per mouth, before bed
76048025|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
75725264|NCT00827216|Drug|Erythromycin|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
75725265|NCT00931476|Drug|somatropin|
75725266|NCT00931476|Drug|placebo|
76048026|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
75426957|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
75426958|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
75426959|NCT01470456|Drug|SAR3419|Pharmaceutical form:solution for infusion Route of administration: Intravenous
75426960|NCT01470456|Drug|rituximab|Pharmaceutical form:solution for infusion Route of administration: intravenous
75426961|NCT01470482|Procedure|No use of tourniquet|Tourniquet is not applied i 25 pts
75426962|NCT01470482|Procedure|Tourniquet|Use of tourniquet
75426963|NCT01470495|Other|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
75426964|NCT01470495|Other|RFA|treat Recurrent HCC with RFA
75573475|NCT03919955|Drug|Oxybutynin|Oxybutynin 5 mg, per mouth, before bed
75426965|NCT01470508|Behavioral|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
75426966|NCT01470508|Behavioral|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
75725267|NCT00827294|Behavioral|Mirror Therapy|The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
75426967|NCT01470521|Biological|Hookworm larvae|Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
75426968|NCT01470521|Biological|Placebo|Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
75426969|NCT01470534|Dietary Supplement|carbohydrate drink|carbohydrate drink
75426970|NCT01470534|Procedure|Muscle biopsy|Open muscle biopsy
75426971|NCT01470534|Procedure|Blood sampling|Venopuncture
75426972|NCT01470534|Dietary Supplement|Placebo|
75573476|NCT03919955|Drug|Placebo|Placebo, per mouth, before bed
75573477|NCT03909919|Procedure|Standard Care or Usual Clinical Practice|The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
75725268|NCT03760692|Device|i-gel|Evaluation of clinical performance in terms of insertion, ventilation and complications
75725269|NCT03760692|Device|Ambu AuroGain|Evaluation of clinical performance in terms of insertion, ventilation and complications
75725270|NCT05097729|Device|Transcranial Magnetic Stimulation|The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
75573478|NCT03905512|Drug|SEL-212|Administered as specified in the treatment arm
75573479|NCT03905512|Drug|KRYSTEXXA®|Administered as specified in the treatment arm
75725271|NCT00822848|Drug|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
76048027|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
76048028|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
75426973|NCT01470560|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
75426974|NCT01470560|Behavioral|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
75426975|NCT01470573|Procedure|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
75426976|NCT01470586|Procedure|Surgery for colorectal cancer|Surgical resection of colorectal cancer
75426977|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
75573480|NCT03891875|Combination Product|Subcutaneous elamipretide through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
75573481|NCT03891875|Combination Product|Subcutaneos placebo through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
75573482|NCT03871036|Drug|Tremelimumab|See experimental arm description for more details.
75573483|NCT03871036|Drug|Durvalumab|See experimental arm description for more details.
75573484|NCT03871036|Drug|Paclitaxel|See experimental arm description for more details.
75426978|NCT01470690|Drug|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
75426979|NCT01470690|Drug|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
75426980|NCT01470703|Device|ECMO (Quadrox®, Jostra®, Maquet®)|ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure <25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level <25 cm H2O and low pressure level ≥10 cm H2O
75573485|NCT03856827|Drug|IW-6463|IW-6463 Tablet
75573486|NCT03856827|Drug|Matching Placebo|Matching Placebo Tablet
76048029|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
76048030|NCT02041923|Behavioral|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
76048031|NCT02041923|Other|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
76048032|NCT02365519|Biological|LME636 ophthalmic solution|
76048033|NCT02365519|Biological|LME636 Vehicle|Inactive ingredients used as a placebo comparator
76048034|NCT04700163|Biological|C144-LS and C-135-LS|A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
76048035|NCT02061813|Drug|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
76048036|NCT02061813|Drug|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
76048037|NCT02061813|Drug|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
76048038|NCT02061813|Drug|Placebo|
76048039|NCT02096835|Device|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
75426981|NCT01470703|Other|conventional care|Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 <80% for >6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
75573487|NCT03850678|Device|Hearing Aid|Hearing Aid
75573488|NCT03849898|Procedure|Surgery|Surgical fracture treatment
76048040|NCT02096835|Device|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
76048041|NCT02096835|Drug|Tropisetron|will be given at the start of skin closure
76048042|NCT02096835|Drug|Dexamethasone|will be given after induction
76048043|NCT02294773|Procedure|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
75426982|NCT01470729|Other|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
75573489|NCT03849898|Other|Non-Surgical fracture treatment|Non-Surgical fracture treatment
75573490|NCT03847051|Diagnostic Test|MRI|Brain MRI without intravenous contrast
76048044|NCT02294773|Drug|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
76048045|NCT02294773|Drug|Letrozole|Patient is to take letrozole during cycle days 3-7.
76048046|NCT02365285|Drug|Galantamine|16 mg po prior to the infusion of intralipid
76048047|NCT02365285|Drug|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
76048048|NCT02365285|Drug|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
76048049|NCT02365285|Drug|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
76048050|NCT02041299|Drug|Deferiprone|
76048051|NCT02041299|Drug|Deferoxamine|
76048052|NCT01645735|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
75573491|NCT03834064|Behavioral|Oral health promotion strategy|The proposed intervention is comprised of four components : (a) planned action including a behavioral contract Activity 1) with caregivers and action planning for oral health (Activity 2), (b) caregiver capacity building with didactic training (Activity 3), observational learning and caregiver practice (Activity 4); (c) environmental adaptations with location of oral health activities and reminder posters - physical environment (Activity 5) and administrative oral health support- (social environment (Activity 6); and (d) reinforcement with caregiver coaching (Activity 7).
75725272|NCT00822848|Drug|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
75725273|NCT00822848|Drug|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
76048053|NCT01645735|Drug|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
76048054|NCT02365207|Drug|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
76048055|NCT01645111|Drug|Clevidipine|
76048056|NCT02364037|Behavioral|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
76048057|NCT02364037|Behavioral|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
76048058|NCT02364037|Device|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
76048059|NCT01919164|Drug|Sprifermin|Participants received Sprifermin as intra-articular injection.
75426983|NCT01470742|Drug|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
75426984|NCT01470742|Drug|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
75426985|NCT01470768|Other|Amino Acid-based Formula with high DHA and ARA|
75426986|NCT01470768|Other|Amino Acid-based Formula with lower DHA and ARA|
75426987|NCT01470794|Biological|Toca 511 vector|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antifungal 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, patients will begin courses of oral Toca FC at pre-specified intervals, depending on cohort, during the approximately 30 week study.
75426988|NCT01470794|Drug|Toca FC|
75426989|NCT01470807|Device|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
75573492|NCT03830164|Drug|Atorvastatin|Given PO
75573493|NCT03830164|Drug|Pentoxifylline|Given PO
75573494|NCT03830164|Dietary Supplement|Vitamin E Compound|Given PO
75725274|NCT00822848|Other|immunoenzyme technique|
75725275|NCT00822848|Other|immunohistochemistry staining method|
76048060|NCT01919164|Drug|Placebo|Participants received Placebo matched to sprifermin as intra-articular injection.
76048061|NCT01901224|Drug|Metformin 1000 mg|
76048062|NCT01901224|Drug|Placebo|
76048063|NCT05109676|Other|Questionnaire|A questionnaire will be offered to patients and identify the schedules of administration of progesterone, the day and time of blood samples taken as part of the care, the potential adverse events associated with this administration.
76048064|NCT01901146|Drug|ABP 980|ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
76048065|NCT01901146|Drug|Trastuzumab|Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
76048066|NCT01901146|Drug|Paclitaxel|Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
76048067|NCT01901146|Procedure|Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection|
75725276|NCT00822848|Other|laboratory biomarker analysis|
75725277|NCT00822848|Procedure|adjuvant therapy|Preoperative administration has been the preference at our institution.
75725278|NCT00822848|Procedure|neoadjuvant therapy|
75725279|NCT00822848|Procedure|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
75725280|NCT00822848|Radiation|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. *Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
75725281|NCT00931554|Procedure|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
75725282|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
76048068|NCT01644643|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
76048069|NCT01644643|Drug|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
76048070|NCT01644643|Drug|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
76048071|NCT01864564|Other|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
75573495|NCT03795311|Drug|FOLFIRINOX Bevacizumab|"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."
75573496|NCT03776136|Drug|lenvatinib|Administered orally once a day during each 21-day cycle.
75573497|NCT03776136|Biological|pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
75878044|NCT02849678|Drug|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
75878045|NCT04295577|Other|Niraparib|Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15[13].
75878046|NCT02238158|Drug|Atrovent® inhalets|
76048072|NCT01864174|Drug|Metformin XR|
76048073|NCT01864174|Drug|Metformin IR|
76048074|NCT01864174|Drug|Placebo matching with Metformin XR|
76048075|NCT01864174|Drug|Placebo matching with Metformin IR|
76048076|NCT01900444|Biological|IMOJEV|0.5 mL, Subcutaneous
76048077|NCT02294227|Biological|Secukinumab|Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.
76048078|NCT02294227|Other|Placebo|Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
75573498|NCT03769181|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75573499|NCT03769181|Drug|cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75725283|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
75573500|NCT03766672|Diagnostic Test|Intervention Arm|The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
75878047|NCT02238314|Drug|Tipranavir low dose|
76048079|NCT02496767|Drug|Tirasemtiv|
75426990|NCT01470820|Other|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
75426991|NCT01470833|Procedure|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
75426992|NCT01470846|Procedure|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
75573501|NCT03722407|Drug|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
75725284|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
75878048|NCT02238314|Drug|Tipranavir high dose|
75878049|NCT02238314|Drug|Ritonavir|
75878050|NCT02238314|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
75878051|NCT02238314|Drug|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
75725285|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
75725286|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
75725287|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
75725288|NCT00823004|Drug|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
75725289|NCT00823004|Drug|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
75725290|NCT00823004|Drug|GnRH agonist (buserelin)|50 µg SC twice daily
75725291|NCT00823004|Drug|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
75878052|NCT03587168|Other|the timed 360° turn test|Turning ability is assessed by using the timed 360° turn test.
75878053|NCT03587168|Other|Berg Balance Scale|Functional balance is assessed by using the Berg Balance Scale.
75878054|NCT03587168|Other|Four Square Step Test|The Four Square Step Test measures dynamic balance.
75878055|NCT03587168|Other|Functional Reach Test|The Functional Reach Test assesses limits of stability.
75878056|NCT03587168|Other|Trunk Impairment Scale|Trunk performance is assessed by using the trunk impairment scale.
75878057|NCT03587168|Other|Timed Up and Go Test|Functional mobility is assessed by using the timed up and go test.
75878058|NCT03587168|Other|Hoehn and Yahr Scale|Disease stage is assessed by the Hoehn and Yahr Scale.
75878059|NCT03587168|Other|Unified Parkinson's Disease Rating Scale|The Unified Parkinson's Disease Rating Scale assesses disease severity.
75878060|NCT03629769|Drug|Proxelan|Administration of one suppository of proxelan once a day for 30 days
76048080|NCT02496767|Drug|Placebo tablets|
76048081|NCT02496533|Procedure|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
76048082|NCT02496221|Drug|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
76048083|NCT02496221|Drug|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
75573505|NCT03684460|Device|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
75573506|NCT03684460|Device|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
75573507|NCT03676478|Other|delayed start enteral support @ POD5|"instead of caloric suppletion, participants will receive mls of water over the jejunostomy feeding tube daily equivalent to the rate of increase of infusion of the control group as to preserve the same amount of fluid administration through the GI route as the control group.~This is continued until POD5 12.00h when enteral feeding is started according to the incremental regimen as defined for the SOC group. During the intervention, water is used as to maximize stimulation of the enteral route, however without giving nutritional support and need to prolong iv-infusion for maintaining the fluid balance in the participants. Also subjects in this interventional arm will end up with a caloric suppletion of 1.000kCal/24h by the end of postoperative day 7."
75573508|NCT03657628|Other|Exercise Intervention|Strength training and moderate-intensity, aerobic exercise
75573509|NCT03638297|Drug|PD-1 antibody + cox inhibitor|"BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."
75725292|NCT00823004|Drug|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
75725293|NCT00930150|Behavioral|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
75426993|NCT01470846|Procedure|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
75426994|NCT01470898|Device|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
75426995|NCT01470911|Drug|SB010|"Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL."
75573510|NCT03623490|Other|managment of oral therapy|Initial consultation with a trio oncologist / pharmacist / nurse
75573511|NCT03621696|Drug|Cisplatin|-100 mg/m^2 intravenous push bolus (IVPB)
75573512|NCT03621696|Radiation|Intensity modulated radiation therapy|-IMRT or IMPT can be used
75573513|NCT03621696|Radiation|Intensity modulated proton therapy|-IMRT or IMPT can be used
75725294|NCT00930150|Behavioral|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
75725295|NCT00930150|Behavioral|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
75573514|NCT03621696|Procedure|Surgery|-Standard of care
75573515|NCT03621696|Other|FACT-H&N|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
75725296|NCT00930150|Behavioral|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
75725297|NCT00827450|Dietary Supplement|Ctl|Control, isocaloric diet; no coffee
75725298|NCT00827450|Dietary Supplement|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
75725299|NCT00827450|Dietary Supplement|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
75725300|NCT00827450|Dietary Supplement|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
75725301|NCT00827450|Dietary Supplement|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
75573516|NCT03621696|Other|MD Anderson Dysphagia Inventory|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
75426996|NCT01470911|Drug|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
75573517|NCT03621696|Other|University of Michigan Xerostomia Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
75573518|NCT03621696|Other|Scale of Subjective Total Taste Acuity|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
75573519|NCT03621696|Other|Neck Dissection Impairment Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
75573520|NCT03594747|Drug|Tislelizumab|Administered intravenously as described
75573521|NCT03594747|Drug|Paclitaxel|Administered intravenously as described
75573522|NCT03594747|Drug|Nab-paclitaxel|Administered intravenously as described
75573523|NCT03594747|Drug|Carboplatin|Administered intravenously as described
75573524|NCT03592641|Drug|Savolitinib|Given PO
75725302|NCT00827528|Procedure|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
76048084|NCT02496221|Drug|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
75426997|NCT01470937|Drug|Acarbose|acarbose 100 mg PO once daily
75426998|NCT01470937|Drug|Placebo|acarbose placebo
75426999|NCT01470950|Procedure|Motionmaker|3 times per week, FES Training on the Motionmaker device, for 6 months
75427000|NCT01470963|Other|Implementation of referral template|Implementation of referral template at the GP office
75427001|NCT01470976|Other|Goal-directed Resuscitation Therapy (GDT)|"A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~The final step will be red blood transfusion to reach a hematocrit higher than 28%."
75427002|NCT01470976|Other|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
75573525|NCT03565783|Biological|Cemiplimab|Given IV
75573526|NCT03538119|Other|High Intensity Interval Training Program|"The HIIT group performed 4 × 4-minute high-intensity intervals at 85%-95% HRpeak followed by a 1-minute recovery interval at 40% HRpeak, predicted with a supervised graded exercise test on a treadmill with the Bruce protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
75725303|NCT00827528|Procedure|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
75878061|NCT03589742|Device|AblaView® Ablation Catheter|The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
75878062|NCT02238470|Drug|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
76048085|NCT02475629|Biological|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
75427003|NCT01471002|Device|Galil Medical patented 17G Cryoablation Needles|
75427004|NCT01471067|Drug|Melphalan|140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
75427005|NCT01471067|Drug|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
75427006|NCT01471067|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
75427007|NCT01471067|Drug|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
75427008|NCT01471067|Procedure|Cord Blood Infusion|Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
75427009|NCT01471067|Drug|Rituximab|375 mg/m^2 by vein on Day -10 for B cell malignancy.
75427010|NCT01471067|Drug|ATG|"1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3."
75427011|NCT01471067|Drug|Busulfan|Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
75427012|NCT01471067|Drug|Clofarabine|30 mg/m^2 IV Day -7 to Day -4;
75427013|NCT01471067|Radiation|Total Body Irradiation (TBI)|2 Gy in AM of Day -3.
75427014|NCT01471080|Procedure|RFA|using RFA to treat cavernous hemangiomas
75427015|NCT01471080|Procedure|hepatectomy|using hepatectomy to treat cavernous hemangiomas
75427016|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
75427017|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
75427018|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
75573527|NCT03538119|Other|Moderate Intensity Continuous Training Program|"The MICT protocol (usual care) consisted of a continuous bout of moderate-intensity exercise to elicit 70-75% HRpeak, rating of perceived exertion 3 to 5 (fairly light to somewhat hard), for 27.5 minutes to equate the energy expenditure with the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
75725304|NCT04015284|Procedure|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
75725305|NCT04015284|Procedure|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
75427019|NCT01471119|Biological|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
75573528|NCT03504397|Drug|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
75427020|NCT01471132|Drug|Oxaliplatin|Oxaliplatin 345mg/m2,43℃，30mins
75427021|NCT01471132|Drug|Paclitaxel|Paclitaxel 260mg/m2,43℃，30mins
75427022|NCT01471145|Drug|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
75573529|NCT03504397|Drug|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
75725306|NCT00930306|Drug|AZD2066|12 doses, Given as capsule, 2 mg & 8 mg
75427023|NCT01471158|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
75427024|NCT01471158|Drug|Dorzolamide/timolol Maleate Fixed Combination (COSOPT)|Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
75427025|NCT01471184|Device|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
75427026|NCT01471184|Device|Placebo|Placebo Eye Drops/Nasal Spray
75427027|NCT01471210|Drug|Urelumab (BMS-663513)|
75573530|NCT03504397|Drug|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion
75573531|NCT03504397|Drug|folinic acid|Folinic acid will be administered as a 2-hour IV infusion.
75573532|NCT03504397|Drug|fluorouracil|Fluorouracil will be administered as IV bolus over 5-15 minutes and continuous IV infusion over 46-48 hours.
75573533|NCT03468985|Drug|Cabozantinib|Given PO
75573534|NCT03468985|Biological|Ipilimumab|Given IV
75573535|NCT03468985|Biological|Nivolumab|Given IV
75573536|NCT03447912|Behavioral|Intervention Condition|The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in public indoor and and outdoor spaces.
75573537|NCT03434418|Drug|osimertinib|80 mg oral administration daily
75427028|NCT01471236|Device|Agili-C Bi-phasic Implant|"The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner."
75573538|NCT03417336|Radiation|prostatic boost in brachytherapy with high dose rate (HDR)|prostatic boost in brachytherapy with high dose rate (HDR)
75573539|NCT03414905|Device|Aspira Catheter|"15.5Fr catheter~Standard of care"
75573540|NCT03414905|Procedure|Ultrasound|Standard of care
75427029|NCT01471236|Procedure|mini-arthrotomy|"The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded."
75573541|NCT03386539|Drug|Everolimus|Everolimus tablet
75573542|NCT03386539|Drug|Tacrolimus|Tacrolimus capsule or liquid suspension
75573543|NCT03386539|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil capsule or liquid suspension
75725307|NCT00930306|Drug|Caffeine|2 doses, Given as Tablet, 2x50 mg
76048086|NCT02475629|Drug|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
76048087|NCT02475395|Device|TRAK device|Use of TRAK to attain sperm concentration measurement
75427030|NCT01471262|Procedure|Right hepatectomy|Right liver resection
75427031|NCT01471262|Procedure|Extended right hepatectomy|Right hepatectomy involving 5 or more segments
75427032|NCT01471275|Drug|Metformin|250 mg or 500mg three times a day
75427033|NCT01471275|Drug|Jiangtangtiaozhi decoction|15 grams each time, twice a day, with boiled water
75573544|NCT03376659|Drug|Durvalumab|750mg IV q2 weeks
75573545|NCT03376659|Biological|CV301|"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."
75573546|NCT03376659|Drug|Capecitabine|1000mg orally twice a day, Monday - Friday Weekly
75427034|NCT01471314|Behavioral|Headache day versus non-headache day|
75573547|NCT03376659|Drug|Bevacizumab|5mg/kg IV q2weeks
75573548|NCT03366103|Biological|Navitoclax|Given PO
75573549|NCT03366103|Drug|Vistusertib|Given PO
75573550|NCT03314337|Device|Pancreatic stent: PSOF COOK®|After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
75725308|NCT00930306|Drug|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
75573551|NCT03307109|Other|Quality of life|Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
75573552|NCT03304821|Drug|GM-CSF|Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.
75725309|NCT00930306|Drug|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
75725310|NCT00930306|Drug|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
75573553|NCT03304821|Drug|Placebo|Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
75725311|NCT00830882|Drug|levosalbutamol|2 puffs four times a day for 2 weeks
75725312|NCT00830882|Drug|racemic salbutamol|2 puffs four times a day for 2 weeks
75427035|NCT01471327|Biological|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
75573554|NCT03267121|Drug|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
75573555|NCT03267121|Drug|Tegafur Gimeracil Oteracil Potassium Capsules|25mg/㎡ bid p.o. every day for 14 days as a cycle
75573556|NCT03253679|Drug|Adavosertib|Given PO
75573557|NCT03222999|Other|No intervention planned|No intervention planned
76048088|NCT01653743|Drug|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa [recombinant human Chorionic Gonadotropin, r-hCG]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of >=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
75725313|NCT00830882|Drug|placebo|2 puffs four times a day for 2 weeks
75427036|NCT01471327|Other|Placebo|Saline IV, single dose at Day 1
75427037|NCT01471366|Dietary Supplement|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
75725314|NCT04044092|Other|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
75427038|NCT01471366|Dietary Supplement|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
75725315|NCT04044092|Other|ELDOA stretching exercise|Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
75427039|NCT01471366|Dietary Supplement|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
75427040|NCT01471366|Dietary Supplement|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
75725316|NCT00823160|Procedure|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
75725317|NCT00823160|Procedure|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
75725318|NCT03584724|Drug|Norflo Oro|Norflo Oro is highly bioavailable curcumin complexed into phytosomes
75725319|NCT03584724|Drug|Placebo for Norflo Oro|Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
75725320|NCT00823238|Drug|ceftazidime and tobramycin|
75878063|NCT03581708|Other|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
75427041|NCT01471392|Device|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
75427042|NCT01471418|Drug|PET/CT with 18-FDG|FDG uptake
75573558|NCT03208010|Behavioral|Diabetes Prevention Intervention|"Educational sessions with emphasis on physical activity, healthy cultural diets, and strategies to promote positive behavioral changes.~Specific goals set for weight loss and physical activities~Fitbits provided for monitoring physical activity goals~Weekly review of and feedback on effects of physical activity (Fitbits) and dietary changes (checklists)~15 biweekly support group sessions plus 3 booster sessions every 6 months thereafter~Note: In response to the COVID-19 pandemic, a remote version of the intervention was designed to provide the program remotely instead of via the usual in-person group format. This alternative strategy is designed to replace the biweekly support groups, which in the past focused on similar content, i.e., reviewing key educational content, demonstrations of healthy Mexican American recipes."
75573559|NCT03208010|Other|Enhanced Usual Care|"Monitoring by existing personal physicians~Feedback on lab results~Referrals to physicians or clinics, if needed~Diabetes prevention educational materials"
75573560|NCT03187340|Behavioral|Sleep education and relaxation 1|Sleep hygiene and relaxation training; Sleep education and relaxation 1
75573561|NCT03187340|Behavioral|Sleep education and relaxation 2|Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
75573562|NCT03181477|Device|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
75725321|NCT00823238|Drug|inhaled tobramycin|
75725322|NCT00931788|Drug|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
75725323|NCT00931788|Other|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
75725324|NCT00831038|Procedure|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
75725325|NCT00827684|Drug|Irinotecan|
75725326|NCT00827684|Drug|Temsirolimus|
75573563|NCT03155906|Other|Health care delivery|Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
75573564|NCT03149822|Drug|Cabozantinib|Pharmaceutical form: tablets Route of administration: oral
75573565|NCT03149822|Drug|Pembrolizumab|Pharmaceutical form: solution Route of administration: injection
75573566|NCT03099148|Drug|Reference Formulation (R)|Administered PO
75725327|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
75725328|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
75725329|NCT00927030|Drug|supplemental liquid melatonin|Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
75725330|NCT00927030|Drug|flavored liquid or liquid supplemental melatonin|Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
75725331|NCT00827762|Drug|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
76048089|NCT01653743|Drug|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of >=18 mm; not more than 3 follicles each with a mean diameter of >=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
76048090|NCT01653743|Drug|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
75573567|NCT03099148|Drug|LY3337641 (T1)|20 mg PO
75573568|NCT03099148|Drug|LY3337641 (T2)|20 mg PO
75573569|NCT03099109|Drug|LY3321367|Administered IV
75573570|NCT03099109|Drug|LY3300054|Administered IV
75573571|NCT03095352|Biological|Pembrolizumab|200 mg Given IV
75573572|NCT03095352|Drug|Carboplatin|Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
75573573|NCT03095352|Biological|Trastuzumab|For HER2+ patients: IV every 3 weeks using standard approved dosing
75573574|NCT03088813|Drug|Irinotecan liposome injection|IV
75573575|NCT03088813|Drug|Topotecan|IV
75573576|NCT03061474|Drug|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
75573577|NCT03061474|Drug|Placebo Comparator|Oral Tablet
75573578|NCT03040726|Drug|Netupitant|Given PO
75573579|NCT03040726|Drug|Palonosetron|Given PO
75573580|NCT03040726|Drug|Palonosetron Hydrochloride|Given PO
75573581|NCT03040726|Other|Placebo|Given PO
75573582|NCT03040726|Other|Questionnaire Administration|Ancillary studies
75573583|NCT02936453|Procedure|Device implantation|"Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~Implantation of Activa RC neurostimulator"
75573584|NCT02932501|Procedure|Conservative treatment|Disinfectant mouth rinses, Antibiotic therapy, Antifungal therapy
75573585|NCT02932501|Procedure|Surgical treatment|Superficial debridement, Complete removal of necrotic bone, Complete bone resection, When applicable revision and soft tissue coverage
75725332|NCT00931866|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
75725333|NCT00931866|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
75725334|NCT00831116|Device|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
76048091|NCT02293993|Drug|SGI-110|
75427043|NCT01471431|Other|spontaneous breathing trial|"The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia <100 for >15 seconds or oxygen saturation by pulse oximetry <85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met."
75427044|NCT01471470|Drug|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
75427045|NCT01471496|Procedure|prophylactic injection therapy|Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
75427046|NCT01471509|Other|water, glucose with or without amino acid|240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
75427047|NCT01471535|Drug|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
75427048|NCT01471548|Drug|TKI258|
75878064|NCT04119375|Behavioral|Keheala Mobile Health Platform and Behavioral Interventions|"Keheala is a mobile health company that delivers powerful behavior change interventions from the social sciences across basic feature phones or smartphones to address the nonmedical drivers of disease, which exist away from health facilities.~The intervention includes automated reminders, remote self-verification of doses, accessible TB information and individualized follow-up."
76048092|NCT02322775|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
75427049|NCT01471600|Procedure|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
75427050|NCT01471613|Procedure|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
75427051|NCT01471613|Drug|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
75427052|NCT01471613|Biological|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
75427053|NCT01471613|Other|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
76048093|NCT02322775|Biological|Placebo|Placebo administered subcutaneously every 4 weeks
75427054|NCT01471652|Drug|Nutraceutical supplements|"CoEnzyme Q10: oral gel capsule bid~Acetyl L-carnitine: oral capsule bid~Alpha Lipoic Acid: oral tablet qd~Docosahexaenoic acid: oral gel capsule bid"
75427055|NCT01471652|Drug|Placebo|"Capsule form to imitate the following nutraceuticals:~Placebo 1: oral gel capsule bid~Placebo 2: oral capsule bid~Placebo 3: oral tablet qd~Placebo 4: oral gel capsule bid"
75427056|NCT01471665|Drug|GSK2190915 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
75427057|NCT01471665|Drug|Placebo|Placebo will be administered once daily for up to 16 days.
75427058|NCT01471678|Drug|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
75427059|NCT01471678|Drug|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
75427060|NCT01471678|Drug|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
75427061|NCT01471704|Drug|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
75427062|NCT01471704|Drug|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
75878065|NCT04119375|Behavioral|Social and Behavior Change Communication (SBCC)|Automated reminders, remote self-verification of doses and accessible TB information. All interactions are behaviorally-informed but do not include regular adherence support/follow-up from study team members as the Keheala intervention does.
75878066|NCT04119375|Behavioral|SMS Reminder|Patients receive a single daily SMS message to take their medication.
76048094|NCT04888273|Behavioral|Transition Intervention|Each adolescent-parent pair will be invited to complete 5 components of the intervention (peer support session, parent education session, transition meeting with healthcare providers, family doctor contact, and reading a transition navigation guide) over a 3-month period. These intervention components were designed with the intention of making the transition process transparent for the duo, preparing the adolescent to take responsibility of their own health as it relates to their disorder, and helping the parent step back from the process to help the adolescent integrate to adult care better.
75427063|NCT01471704|Drug|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
75427064|NCT01471288|Drug|Carum Cravi|40mg/kg of body weight
75427065|NCT01471288|Drug|Placebo|Placebo
75427066|NCT01471717|Drug|INX-08189 50 mg QD X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
75427067|NCT01471717|Drug|INX-08189 / Victrelis 800 mg TID X three days|Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
75427068|NCT01471717|Drug|Victrelis 800 mg TID x 3 days|In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
75427069|NCT01471717|Drug|Victrelis 800 mg TID with INX-08189 50 mg QD|Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
75427070|NCT01471717|Drug|Placebo with Victrelis 800 mg|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
75427071|NCT01471717|Drug|Cohort 2: Victrelis 800 mg with Placebo|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
75427072|NCT01471730|Drug|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 [mm] - MCF [mm]) * body weight [kg] / 140 [m] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
75427073|NCT01471730|Drug|Saline solution|Normal saline will be administered to control patients.
75427074|NCT01471730|Drug|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds [M1] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
75427075|NCT01471743|Dietary Supplement|Impact Advance Recovery (R)|
75427076|NCT01471743|Dietary Supplement|Ensure Plus (R)|
75573586|NCT02932501|Procedure|Adjuvant non-surgical treatment|Hyperbaric oxygen therapy Pentoxifylline and tocopherol Ozone therapy Low level laser therapy Pain relief Anti-inflammatory treatment Platelet rich plasma Parathyroid hormone and teriparatide Bone morphogenetic protein
75573587|NCT02899728|Drug|Carboplatin|Given IV
75573588|NCT02899728|Drug|Cediranib|Given PO
75573589|NCT02899728|Drug|Cediranib Maleate|Given PO
75573590|NCT02899728|Drug|Cisplatin|Given IV
75573591|NCT02899728|Drug|Etoposide|Given IV
75573592|NCT02899728|Drug|Olaparib|Given PO
76048095|NCT02322229|Drug|Ocriplasmin 0.125 mg in a 0.1 mL volume|
76048096|NCT02362789|Biological|Secukinumab|150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
76048097|NCT02362789|Biological|Placebo|Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
75573593|NCT02899065|Diagnostic Test|Procalcitonin|Procalcitonin is a blood test used to differentiate between viral and bacterial infections. This test is expected to aid in determining the best course of treatment for patients enrolled into this arm.
75725335|NCT04885452|Other|biobank|"Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5"
75427077|NCT01471756|Procedure|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
75427078|NCT01471769|Behavioral|Pain management video|6-minute video
75427079|NCT01471769|Behavioral|Falls Prevention Video|6-minute video
75427080|NCT01471808|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
75573594|NCT02899065|Other|Pharmacist-Led Education|Pharmacists will interpret the results of the Roche Cobas Liat Flu/RSV assay and procalcitonin test (if available) and provide the treating physician with recommendations for antibiotic therapy based on these results.
75878067|NCT04119375|Other|Standard of Care|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
75427081|NCT01471808|Drug|CSII, Metformin, Pioglitazone|CSII for 2~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
75427082|NCT01471808|Drug|CSII, Sitagliptin|CSII for 2~4 weeks combined with sitagliptin 100mg/d for 3 months
75573595|NCT02894177|Procedure|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
75573596|NCT02893930|Drug|Sapanisertib|Given PO
75573597|NCT02840890|Procedure|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
75573598|NCT02840890|Procedure|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
75725336|NCT00823394|Behavioral|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
75725337|NCT00823394|Other|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
75725338|NCT00823394|Behavioral|Self-help Materials|Information on how to lower risk for developing cancer.
75427083|NCT01471821|Drug|antiretroviral treatment|antiretroviral treatment
75427084|NCT01471847|Drug|BEZ235 + Trastuzumab Phase l/Phase ll)|"Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy)."
75573599|NCT02796781|Biological|Lung stem cells|Patients will receive clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
75573600|NCT02785562|Other|Assessment of PDL1 expression|Intervention : 2 biopsy slides will be analyzed in central laboratory.
75725339|NCT00831194|Behavioral|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
75725340|NCT04366544|Other|Part A1: Survey|Online
75725341|NCT04366544|Other|Part A2: Sample collection|Blood and Stool
75725342|NCT04366544|Other|Part B:|EEG and fMRI
75725343|NCT00930462|Device|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
75725344|NCT00827840|Drug|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
75725345|NCT00827840|Drug|Risperidone|1 to 6 mg of risperidone once or twice a day
75725346|NCT05280288|Device|Bone@BC app|Participants in the intervention group will be asked to use the Bone@BC app daily it will take them 1-3 minutes to answer the daily questions in the app concerning symptoms and physical activity. They will have access to a Questionnaire Prompt List in the app Bone@BC.
75878068|NCT03586934|Drug|Acetaminophen|Acetaminophen Tablet
75878069|NCT03586934|Drug|Celecoxib 200mg|Celecoxib Tablet
75878070|NCT03586934|Drug|Celecoxib 400 mg|Celecoxib Tablet
75878071|NCT03586934|Drug|Ropivacaine|Ropivicaine nerve block (injection)
75573601|NCT02783664|Other|Questionnaires to Evaluate Anxiety Related to Genetic Testing|"A health team member will outline the study parameters to the patient prior to the genetic counseling visit.~Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.~Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.~Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total."
75573602|NCT02780804|Drug|Entinostat|Given PO
75573603|NCT02780804|Other|Laboratory Biomarker Analysis|Correlative studies
75725347|NCT00927108|Other|Progenitor Stem Cell Culture|
76048098|NCT01646827|Drug|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
75427085|NCT01471847|Drug|Lapatinib + Capecitabine (Phase II)|"If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start"
75427086|NCT01471860|Device|BAROSTIM NEO System|
75427087|NCT01471860|Drug|Medical Management|
75427088|NCT01471873|Procedure|Corneal Collagen Cross-linking (CXL)|"The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well."
75427089|NCT01471886|Drug|Ketorolac Tromethamine|Every 8 hours for 4 days.
75427090|NCT01471886|Drug|Naproxen|Every 8 hours for 4 days.
75427091|NCT01471899|Drug|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
75427092|NCT01471899|Drug|Naproxen|2 tablets every 8 hours for 4 days
75427093|NCT01471912|Procedure|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
75427094|NCT01471925|Drug|Nexium®|
75427095|NCT01471925|Drug|Esomeprazol (40mg) + Sdium Bicarbonate (721mg)|
75573604|NCT02780804|Other|Pharmacological Study|Correlative studies
75878072|NCT03586934|Drug|Ketorolac|ketorolac injection
75878073|NCT03586934|Drug|Acetaminophen Injectable Product|Acetaminophen injection
75427096|NCT01471951|Other|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
75427097|NCT01471964|Drug|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
75427098|NCT01471977|Other|education,counseling, default tracers,quality of care|these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
75427099|NCT01471990|Drug|Pituitary Adenylate Cyclase-Activating Polypeptide-38|10 pmol/kg/min over 20 mins
75427100|NCT01471990|Drug|Vasoactive Intestinal Peptide|8 pmol/kg/min over 20 mins
75427101|NCT01472003|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
75878074|NCT03586934|Drug|Oxycodone|oxycodone tablet
75878075|NCT03586934|Drug|Tramadol|Tramadol tablet
76048099|NCT02293837|Drug|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
75427102|NCT01472003|Drug|ABT-806i|ABT-806i will be administered by intravenous infusion.
75427103|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
75427104|NCT01472016|Drug|docetaxel|Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
75427105|NCT01472016|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
75427106|NCT01472016|Drug|cetuximab|Cetuximab will be administered by intravenous infusion weekly.
75427107|NCT01472016|Drug|erlotinib|Erlotinib will be taken orally daily.
75427108|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
75573605|NCT02772562|Biological|PROSTVAC-V/F|"0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.~0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141."
76048100|NCT02293837|Drug|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
75725348|NCT02549300|Other|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
75725349|NCT00930618|Drug|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
75878076|NCT03586934|Drug|Morphine Injectable Solution|Morphine Patient Controlled Analgesia
75725350|NCT00930618|Drug|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
75878077|NCT03586934|Drug|hydrocodone bitartrate and acetaminophen|Norco tablet
75427109|NCT01472029|Drug|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Trastuzumab 4 mg/kg BW (6 mg loading dose at 1st administration), iv over 1 h on day 1 of each 14 day cycle~Docetaxel 50 mg/m², iv over 2 h on day 1 of each 14 day cycle~Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h on day 1 of each 14 day cycle~Leucovorin 200 mg/m² in 250 ml NaCl 0,9%, iv over 1 h on day 1 of each cycle~5-FU 2600 mg/m², iv over 24 h on day 1 of each 14 day cycle"
75427110|NCT01472029|Drug|Post-operative treatment trastuzumab mono therapy|"Trastuzumab mono therapy for 9 cycles:~Trastuzumab 6 mg/kg BW, iv over 1 h on day 1 of each 21 day cycle"
75427111|NCT01472042|Other|Banyan Biomarkers|Biomarkers to detect specific proteins.
75427112|NCT01472055|Drug|Fludarabine|"Fludarabine 40 mg/m^2 once a day intravenous administration over 30 min~Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr~Population pharmacokinetics analysis~Comparative analysis of population pharmacokinetics in pediatric and adult patients~Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate"
75573606|NCT02710968|Device|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
75573607|NCT02688959|Behavioral|Tai Chi|
75573608|NCT02688959|Behavioral|Exercise|
75573609|NCT02644941|Biological|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
75573610|NCT02644941|Device|ePTFE graft|Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
75878078|NCT03586934|Drug|Morphine|morphine injection
75878079|NCT03586934|Drug|Oxycodone Hydrochloride|oxycodone hydrochloride tablet
75878080|NCT03586934|Drug|Meloxicam|meloxicam tablet
75878081|NCT01596257|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
75878082|NCT01596257|Device|CliniMACS|
75878083|NCT02084121|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
75878084|NCT03577964|Diagnostic Test|Glucose Measurements,|Measurement of glucose Levels in bronchio alveolar secretions
76048101|NCT02293837|Other|Standard of Care|Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
76048102|NCT02361307|Procedure|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
76048103|NCT02361307|Procedure|Conventional ADL training|The control group receive the conventional ADL training programme
76048104|NCT02320903|Device|VillageWhere App|
75878085|NCT04749017|Dietary Supplement|Experimental product consumption|Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days
75878086|NCT04749017|Other|Control product consumption|Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
75878087|NCT02035592|Other|Full dose blueberry|"Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
75878088|NCT02035592|Other|Half dose blueberry|"Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
75427113|NCT01472068|Device|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
76048105|NCT02320123|Behavioral|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
76048106|NCT02360995|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
75573611|NCT02629393|Drug|ORGN001 (formerly ALXN1101)|
75573612|NCT02622581|Other|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
75573613|NCT02604459|Device|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
75573614|NCT02604459|Device|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
75878089|NCT02035592|Other|Control|"Control: 26g of placebo comparator material to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
75878090|NCT02051673|Biological|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
75878091|NCT03586856|Device|Nasal mask interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
75878092|NCT03586856|Device|Nasal prongs interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
75573615|NCT02604459|Procedure|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
76048107|NCT02360995|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
76048108|NCT02360995|Drug|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
76048109|NCT02360995|Drug|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
76048110|NCT02360995|Drug|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
75427114|NCT01472133|Other|Recording of 12 lead ECG|Recording of 12 lead ECG
75427115|NCT01472133|Other|Recording of lying and standing blood pressure|Recording of lying and standing blood pressure
75427116|NCT01472133|Other|Recording of chest wall movement|Recording of chest wall movement
75427117|NCT01472133|Other|Recording of heart rate variability|Done during deep breathing and a valsalva manoeuvre
75427118|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform at rest|For 10 mins
75427119|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform during exercise|Recording of ECG and Pulse oximeter waveform during exercise
75573616|NCT02604459|Procedure|General anesthesia|General anesthesia will be used in both groups
75573617|NCT02604459|Drug|propofol|propofol per protocol
75573618|NCT02604459|Drug|fentanyl|fentanyl per protocol
75573619|NCT02604459|Drug|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
75573620|NCT02548351|Drug|Obeticholic Acid|
75573621|NCT02548351|Drug|Placebo|
75878093|NCT05763069|Other|Home surveillance of pregnancies at risk|Offer women with pregnancies at risk home surveillance instaed of more frequent hospital out-patient visits and/or hospitalisation: cardiotocographia (CTG), patient measurements of CRP, temperature, blood pressure, and clinical signs of infection or severe forms of preeclampsia.
75878094|NCT03586154|Combination Product|Platelet rich plasma|combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
76048111|NCT04197037|Procedure|Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.|Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
76048112|NCT02360605|Behavioral|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
75573622|NCT02543268|Biological|Ad26.ZEBOV-Batch #1|Ad26.ZEBOV - Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
75725351|NCT00827996|Drug|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
75725352|NCT00936780|Device|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
75725353|NCT00823550|Drug|Entecavir|entecavir 0.5 mg QD
75573623|NCT02543268|Biological|Ad26.ZEBOV-Batch #2|Ad26.ZEBOV - Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
75573624|NCT02543268|Biological|Ad26.ZEBOV-Batch #3|Ad26.ZEBOV - Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
75573625|NCT02543268|Biological|MVA-BN-Filo|MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57.
75725354|NCT00823550|Drug|Lamivudine|lamivudine 100 mg QD
75573626|NCT02543268|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
75725355|NCT00937014|Other|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
75725356|NCT00937014|Other|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
75725357|NCT00828152|Behavioral|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
75725358|NCT00828152|Behavioral|On line discussion group|Placebo. On line discussion group.
75725359|NCT00932100|Drug|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
75725360|NCT00932100|Drug|Heparin|IV dose per standard of care at the local institution
75725361|NCT00828230|Drug|budesonide|One application of 2mg budesonide once daily for 8 weeks
75878095|NCT03586154|Drug|ketamine and bupivacaine injection|1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
75878096|NCT04658693|Device|Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode|See arm description
75878097|NCT03975621|Behavioral|Supportive Care|"Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence."
75427120|NCT01472146|Drug|Zo-Nantax|"Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg [loading dose] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"
75573627|NCT02535338|Drug|Erlotinib Hydrochloride|Given PO
75573628|NCT02535338|Other|Laboratory Biomarker Analysis|Correlative studies
75573629|NCT02535338|Drug|Onalespib Lactate|Given IV
75573630|NCT02535338|Other|Pharmacological Study|Correlative studies
75573631|NCT02500797|Biological|Ipilimumab|Given IV
75573632|NCT02500797|Other|Laboratory Biomarker Analysis|Correlative studies
75573633|NCT02500797|Biological|Nivolumab|Given IV
75725362|NCT00828230|Drug|Placebo foam|One application of placebo foam once daily for 8 weeks
75725363|NCT02548988|Other|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
75725364|NCT04469556|Drug|Folfirinox|Chemotherapy
75878098|NCT01413815|Dietary Supplement|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
75725365|NCT04469556|Drug|Gemcitabine/nab-paclitaxel|Chemotherapy
75725366|NCT00540423|Drug|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
75878099|NCT01413815|Other|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
75878100|NCT03585920|Behavioral|Expanded Corn Snack|A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
75878101|NCT04646603|Drug|MRG-001|Subjects will receive subcutaneous MRG-001 injections.
75878102|NCT04646603|Drug|Placebo|Subjects will receive subcutaneous placebo injections.
75573634|NCT02500797|Other|Quality-of-Life Assessment|Ancillary studies
75573635|NCT02136147|Drug|methylphenidate medication|
75573636|NCT02136147|Drug|atomoxetine medication|
75573637|NCT02136147|Drug|lisdexamphetamine medication|
75573638|NCT02136147|Drug|guanfacine medication|
75573639|NCT02090101|Drug|ANAKINRA|
75573640|NCT02047461|Drug|ORGN001 (formerly ALXN1101)|IV infusion
75573641|NCT02017704|Radiation|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
75573642|NCT02017704|Drug|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
75878103|NCT03579992|Behavioral|60-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 60 minutes per session
75427121|NCT01472159|Behavioral|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
75573643|NCT02017704|Radiation|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
75878104|NCT03579992|Behavioral|90-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 90 minutes per session
75573644|NCT02017704|Drug|FOLFOX6|"Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion."
75573645|NCT02017704|Procedure|Surgery|"After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis."
75725367|NCT00540423|Drug|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
75725368|NCT00540423|Drug|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
75725369|NCT00540423|Drug|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
75725370|NCT00932178|Behavioral|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
75725371|NCT04014504|Diagnostic Test|Neonatal Hearing Screening Test|neonatal hearing screening test results will be evaluated.
75573646|NCT02014415|Procedure|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
75573647|NCT02005471|Drug|Bendamustine|Bendamustine will be administered at a dose of 70 mg/m^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
75573648|NCT02005471|Drug|Venetoclax|"Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy."
75573649|NCT02005471|Drug|Rituximab|"Rituximab will be administered at a dose of 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle."
75573650|NCT01977651|Drug|Enzalutamide|Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
75573651|NCT01949311|Drug|Dupilumab|
75573652|NCT01933932|Drug|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
75725372|NCT03710850|Dietary Supplement|Inulin|Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
75725373|NCT00932256|Drug|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
75725374|NCT00932334|Behavioral|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
75878105|NCT03579992|Behavioral|90-min movement MyCI training|EMG-controlled in-lab training without restraint for 90 minutes per session
75573653|NCT01933932|Drug|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
75573654|NCT01933932|Drug|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
75878106|NCT03629847|Drug|Everolimus|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
75878107|NCT01330589|Drug|Placebo|Non-active placebo for 7 days: PO/TID
75573655|NCT01933932|Drug|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
75573656|NCT01892722|Drug|Interferon beta-1a|Administration once weekly via i.m. injections.
75573657|NCT01892722|Drug|Fingolimod|"Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less."
75573658|NCT01892722|Drug|Placebo capsule|Matching placebo capsule required for double-dummy masking to blind formulations.
75725375|NCT00932334|Behavioral|TALK Standard|Participants receive and educational video and booklet about living kidney donation
75725376|NCT00932334|Behavioral|Usual Care|Participants receive their usual care
75725377|NCT00937092|Drug|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
75725378|NCT00937092|Drug|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
75725379|NCT04124601|Radiation|Chemoradiotherapy|Capecitabine tablet with fractionated radiotherapy
75725380|NCT04124601|Drug|Ipilimumab|Infusion
75725381|NCT04124601|Drug|Nivolumab|Infusion
75725382|NCT00930696|Procedure|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
75725383|NCT00930696|Procedure|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
75725384|NCT00937170|Device|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
75878108|NCT01330589|Drug|St. Johns Wort|For 7 days: 300mg PO/TID
75878109|NCT03577886|Drug|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
75573659|NCT01892722|Drug|Placebo i.m. injection|Matching placebo i.m. injection required for double-dummy masking to blind formulations.
75573660|NCT01872260|Drug|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.
75573661|NCT01872260|Drug|Letrozole|Letrozole 2.5 mg/day
75573662|NCT01872260|Drug|BYL719|BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
75573663|NCT01711658|Radiation|IMRT|Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy
75573664|NCT01711658|Drug|Cisplatin|100 mg/m^2 administered intravenously on days 8 and 29
75573665|NCT01711658|Drug|placebo|1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
75573666|NCT01711658|Drug|Lapatinib|1500 mg lapatinib by mouth or by feeding tube daily starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
75725385|NCT00937170|Device|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
75725386|NCT00937170|Device|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
75878110|NCT03577886|Drug|Placebo|Phosphate Buffer Diluent oral solution
75878111|NCT01314833|Drug|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC*6"
75573667|NCT01698008|Other|Diabetes Doctor Mobile app|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
75573668|NCT01622868|Other|Laboratory Biomarker Analysis|Correlative studies
75573669|NCT01622868|Drug|Lapatinib Ditosylate|Given PO
75573670|NCT01622868|Radiation|Stereotactic Radiosurgery|Undergo SRS
75573671|NCT01622868|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
75573672|NCT01518556|Drug|Idarubicin|"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
75573673|NCT01516190|Behavioral|Exercise|Supervised exercise sessions and independent exercise
75573674|NCT01516190|Behavioral|Surgical preparation program|Book, tapes, CD
75573675|NCT01513408|Other|immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio|For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
75573676|NCT01421095|Drug|recombinant FSH|Each participant will recieve recombinant FSH (150 IU) intravenously
75573677|NCT01351103|Drug|LGK974|
75573678|NCT01351103|Biological|PDR001|
75573679|NCT01137643|Other|biologic sample preservation procedure|All samples collected during routine clinical care.
75573680|NCT01137643|Other|cytology specimen collection procedure|All Samples collected during routine clinical care.
75573681|NCT00566345|Biological|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
75573682|NCT00566345|Other|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
75573683|NCT00463814|Drug|AZD6244|oral capsule
75573684|NCT00317720|Drug|Trastuzumab|"Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose."
75573685|NCT00317720|Drug|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
75573686|NCT00540033|Dietary Supplement|infloran|Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
75573687|NCT00540033|Dietary Supplement|infloran|Study group was fed with infloran [Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)] and Bifidobacteria bifidum [(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)]; Laboratorio Farmaceutico S.I.T S.r.I ITALY] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
75725387|NCT00932412|Drug|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
75725388|NCT00932412|Drug|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
75427122|NCT01472172|Device|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
75427123|NCT01472211|Device|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
75427124|NCT01472211|Device|placebo filter|filter purifies water
75427125|NCT01472211|Other|disinfection tablets|government promoted tablets disinfect water
75427126|NCT01472237|Other|Nutritional intervention|Modification of diet
75427127|NCT01472250|Drug|Clinical chemo-drugs|"Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel"
75427128|NCT01472263|Drug|Pentoxifylline|Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules
75427129|NCT01472263|Drug|Placebo|Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
75427130|NCT01472276|Behavioral|Web-based program|Provided with the web-based program
75427131|NCT01472302|Device|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
75573688|NCT04661345|Other|Proteomic analysis of synovial fluids|Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
75573689|NCT04661345|Other|Proteomic analysis of the isolated coagulase-negative Staphylococci|Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
75573690|NCT00540072|Drug|daptomycin|
75427132|NCT01472302|Device|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
75427133|NCT01472315|Drug|medroxyprogesterone acetate|MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
75573691|NCT03759405|Biological|iPS differentiated cardiomyocytes|Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
75573692|NCT04661111|Device|Hymovis® ONE (32 mg/4 ml)|Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
75573693|NCT04660916|Drug|Isotretinoin|The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
75573694|NCT00540111|Dietary Supplement|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
75725389|NCT05046639|Drug|10 mL 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
75725390|NCT05046639|Drug|10 mL preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
75427134|NCT01472315|Drug|Placebo|Placebo pills were taken in same way as active comparator
75427135|NCT01472354|Behavioral|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
75573695|NCT04660838|Other|ACB intervention|Stopping and/or switching ACB medication to an alternative
75573696|NCT00540150|Biological|specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)|We treat each patient with mite-allergen following the two different protocols.
75573697|NCT05102253|Procedure|Dense cranial electroacupuncture stimulation (DCEAS)|"DCEAS will be conducted for 2 sessions per week for 12 consecutive weeks. Electrical stimulation will be conducted on six pairs of forehead acupoints located on the frontal, parietal, and temporal scalp areas. The acupoints includes: Bai-Hui (GV20), Yin-Tang (EX-HN3), left and right Si-Shen-Cong (EX-HN1), Tou-Lin-Qi (GB15), Shuai-Gu (GB8), Tai-Yang (EX-HN5) and Tou-Wei (ST8).~Disposable acupuncture needles will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation, followed by electrical stimulation. The stimulation intensity will be adjusted to a level at which patients felt most comfortable. Each session of treatment will last 30 min."
75573698|NCT05102253|Procedure|Transcutaneous electrical acupoint stimulation (TEAS)|"TEAS will be done for 3 times per week for 12 consecutive weeks by participants at home. A training workshop will be conducted to instruct participants how to use TEAS stimulator. Briefly, TEAS will be delivered on the bilateral Nei-Guan (PC6), which is located on the anterior forearm, between the tendons of the palmaris longus and ﬂexor carpi radialis, at the junction of the distal sixth and proximal ﬁve sixths of the line connecting the middle points of the wrist and elbow crease.~Constant current electrical impulses will be produced from a TEAS apparatus. Two electrode pads will be adhered onto the acupoint skin. The pulse amplitude will be adjusted to a level at which the perception of 'strong but comfortable' is achieved. Each session of treatment will last 30 min."
75573699|NCT05102253|Other|Wait-list control: Routine care|The routine care may include medications, advocacy intervention, and CBT. Post-trial treatment of TEAS+DCEAS will be offered to serve as a compensation for their participation.
75573700|NCT04660604|Device|Graston Technique®|Graston technique, one of the soft tissue mobilization techniques, has also been found to be effective method that affects muscle strength, performance and endurance through activation of muscle and nervous systems.
75573701|NCT04660253|Behavioral|LTP Plus Dads|
75725391|NCT04565613|Dietary Supplement|Enteral protein supplementation|"The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue."
75725392|NCT04014036|Device|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
75725393|NCT05007951|Biological|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 and 28 (stage1)
75725394|NCT05007951|Biological|ChAdOx1-S not less than 2.5 × 10^8 infectious units|injection volume of 0.5mL on days 0 and 28 (stage1)
75725395|NCT05007951|Biological|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 (stage2)
75725396|NCT04014816|Other|MDR bacteria positivity|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
75725397|NCT04014816|Other|negative fluid balance|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
75427136|NCT01472393|Dietary Supplement|Creatine supplementation|The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
75427137|NCT01472393|Dietary Supplement|dextrose (placebo)|The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
75427138|NCT01472406|Device|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
75725398|NCT00932490|Behavioral|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
75725399|NCT00932724|Drug|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
75573702|NCT04660292|Other|Maitland's mobilization|Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
75725400|NCT00932724|Drug|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
75427139|NCT01472406|Device|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
75878112|NCT01314833|Drug|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF*3-T*3"
75427140|NCT01472406|Device|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
75427141|NCT01472406|Device|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
75427142|NCT01472406|Device|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
75427143|NCT01472458|Behavioral|Quality improvement|The primary intervention in this project will be a multi-faceted quality improvement plan targeting improved predictions of neurological outcome and survival after cardiac arrest.
75427144|NCT01472484|Other|586/8x87 white|2 x 50 g
75427145|NCT01472484|Other|586/8x87 brown|2 x 50 g
75427146|NCT01472484|Other|BAT 881|2 x 50 g
75573703|NCT04660292|Other|Traditional Physical therapy|BASELINE TREATMENT INCLUDES TENS and Hot PACKS
75573704|NCT00540189|Procedure|Initial appendectomy|
75725401|NCT00931008|Drug|SID530, Taxotere|75mg/m2
75725402|NCT01563705|Procedure|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
75725403|NCT01563705|Procedure|Manual dexterity assessment|Purdue pegboard test
75725404|NCT00932802|Drug|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
75725405|NCT03439449|Device|CLEOS software program|Computer-assisted history taking program
75427147|NCT01472484|Other|586/8|2 x 50 g
75427148|NCT01472497|Drug|Pioglitazone|pioglitazone (15mg) once a day for 24 weeks
75573705|NCT00540189|Procedure|Interval appendectomy|
75573706|NCT04660409|Diagnostic Test|Blood test for serum Adropin|Blood test for serum Adropin
75573707|NCT01208233|Drug|PF-03049423|1 mg of PF-03049423 daily for 90 days
75573708|NCT01208233|Drug|PF-03049423|3 mg of PF-03049423 daily for 90 days
75573709|NCT01208233|Drug|PF-03049423|6 mg of PF-03049423 daily for 90 days
75573710|NCT01208233|Other|Placebo|Placebo of PF-03049423 daily for 90 days
75725406|NCT03439449|Procedure|Physician taken history|Conventional history taking by physicians
76048113|NCT02360605|Behavioral|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
76048114|NCT02360605|Behavioral|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
75427149|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
75725407|NCT00932880|Drug|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
75725408|NCT00932880|Drug|Norvasc|10 mg dose (Pfizer, USA)
75725409|NCT05360199|Behavioral|PROMs|evaluate the impact of recall bias on post proms scores
75725410|NCT00937482|Drug|cediranib maleate|Given orally
75725411|NCT00937482|Radiation|whole-brain radiation therapy|Undergo whole-brain radiotherapy
75725412|NCT01563861|Genetic|RNA analysis|
75427150|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
75573711|NCT04660565|Drug|Prednisone and Belimumab|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months. Belimumab will start at the same time as the prednisone induction.
75573712|NCT04660565|Drug|Prednisone|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months.
75573713|NCT04319341|Other|To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS|ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
75725413|NCT01563861|Genetic|gene expression analysis|
75725414|NCT01563861|Other|immunohistochemistry staining method|
75725415|NCT01563861|Other|laboratory biomarker analysis|
75725416|NCT00931086|Drug|belimumab|IV 10mg/kg q28days
75725417|NCT00933036|Device|Crosstrees Pod system for PVA|Minimally invasive spine surgery
75725418|NCT04453839|Drug|ZYESAMI (aviptadil acetate)|Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
75725419|NCT04004559|Other|No interventions|As this is a patient registry, there are no interventions.
75725420|NCT00566982|Drug|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
75725421|NCT00566982|Drug|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
75725422|NCT00624338|Drug|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
75427151|NCT01472536|Behavioral|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
75427152|NCT01472614|Drug|DLBS3233|Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
75427153|NCT01472627|Procedure|Blood draws|Blood draws
75427154|NCT01472640|Drug|liraglutide|1.8 mg sc QOD
75427155|NCT01472640|Drug|placebo|1 U sc QOD
75427156|NCT01472653|Drug|cisplatin|cisplatin 30 mg/m2/week I.V. during radiotherapy
75427157|NCT01472653|Radiation|radiotherapy|3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks
75427158|NCT01472653|Drug|cetuximab|cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
75427159|NCT01472666|Dietary Supplement|High content of MC-SFA|12 weeks dietary intervention
75427160|NCT01472666|Dietary Supplement|Whey|12 weeks dietary intervention
75573714|NCT04660136|Biological|contrast enhanced ultrasound|We injected the second generation, ultrasonic contrast agent (SonoVue, Bracco, Milan, Italy) as a bolus of 0.03 ml/kg through a three-way 20-gauge catheter in an antecubital vein, followed by a bolus of 5 ml saline solution (0.9% NaCl).CEUS was performed with a 7.5MHz linear probe and contrast-tuned technology, based on allow mechanical index and a real-time scan to ensure the preservation of the contrast agent. A low acoustic power setting was used, expressing a low mechanical index (MI), 0.09-0.14, of a 7.5 MHz linear probe.
75725423|NCT00624338|Drug|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
75725424|NCT00624338|Other|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
75725425|NCT00933114|Procedure|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
75725426|NCT00933192|Device|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
75427161|NCT01472666|Dietary Supplement|Low content of MC-SFA|12 weeks dietary intervention
75427162|NCT01472666|Dietary Supplement|Casein|12 weeks dietary intervention
75427163|NCT01472731|Other|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
75573715|NCT01208038|Drug|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
75573716|NCT00540267|Other|No Intervention|No Intervention
75573717|NCT04659980|Device|hilotherapy|continuous cooling of hands and feet at a constant temperature
75573718|NCT04659980|Device|frozen gloves|cooling of hands and feet using frozen gloves
75573719|NCT04659785|Drug|Fluzoparib|Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
75573720|NCT04659785|Drug|Apatinib|Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
75573721|NCT03609021|Procedure|Screening Mammography|Provide bilateral mammogram
75573722|NCT03609021|Procedure|Biospecimen Collection|Undergo collection of blood sample
75725427|NCT03977454|Procedure|Nerve Block|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA"
75725428|NCT03977454|Procedure|Periarticular Injection (PAI)|"Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA"
75725429|NCT03977454|Drug|Ropivacaine|60 ml 0.2% ropivacaine
75725430|NCT03977454|Drug|Dex|10 mg DEX/ 80 mg MPA
75427164|NCT01472731|Drug|GC1008|5 mg/kg intravenous use
75573723|NCT04659395|Other|Emergency nurses|Emergency nurses who are trained for one-day in ultrasound-guided femoral nerve block
75573724|NCT01207687|Biological|bevacizumab|Given IV
75573725|NCT01207687|Other|laboratory biomarker analysis|Correlative studies
75573726|NCT01207687|Procedure|quality-of-life assessment|Ancillary studies
75573727|NCT04659434|Drug|Sintilimab|"Patients receive sintiliman+R-GemOx three weeks for a cycle, detailed as follows:~Combination therapy~Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 4 cycles~R-GemOx: Rituximab 375mg/m2, d1; Gemcitabine 1000mg, d2; Oxaliplatin 100mg/m2, d2; every 3 weeks for a cycle, 4 cycle as protocol specified.~Monotherapy:~-Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 8 cycles"
75573728|NCT01207453|Drug|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
75573729|NCT01207453|Drug|Placebo|
75573730|NCT00540345|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
75427165|NCT01472744|Behavioral|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
75427166|NCT01472744|Behavioral|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
75427167|NCT01472744|Behavioral|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
75573731|NCT00540345|Drug|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
75573732|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
75573733|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
75573734|NCT04659356|Other|Patients admitted in Intensive Care Units|Data will be collected computerized patient records by the clinicians in charge of the patient.
75725431|NCT00828386|Procedure|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
75573735|NCT01207414|Drug|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
75573736|NCT00540384|Drug|Placebo|Placebo
75725432|NCT02549066|Procedure|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
75427168|NCT01472744|Behavioral|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
75725433|NCT02549066|Drug|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) < 12 %."
75725434|NCT00831350|Drug|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
75878113|NCT01314833|Drug|Epirubicin Cyclophosphamide Paclitaxel|"1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC*4-P*4"
75573737|NCT00540384|Drug|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
75573738|NCT01207219|Behavioral|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
75573739|NCT01207219|Behavioral|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
75573740|NCT04659551|Drug|Epirubicin|Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
75573741|NCT04659551|Drug|Cyclophosphamide|Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
75573742|NCT04659551|Drug|Triptorelin|Triptorelin 3.75 mg i.m. every 4 weeks until surgery
75573743|NCT04659551|Drug|Exemestane|Exemestane 25 mg oral continuous daily dose until surgery
75573744|NCT04659551|Drug|Nivolumab|Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
75573745|NCT04659668|Device|MMG-23-04-2019|"The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot."
75573746|NCT01206517|Drug|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
75573747|NCT01206517|Drug|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
75427169|NCT01472770|Drug|Gemcitabine + Capecitabine|Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
75427170|NCT01472783|Drug|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
75427171|NCT01472796|Dietary Supplement|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
75427172|NCT01472796|Drug|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
75573748|NCT01206517|Drug|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
75573749|NCT00540462|Procedure|gastric bypass|
75573750|NCT00540462|Procedure|sleeve gastrectomy|
75573751|NCT04659473|Other|Online survey|This study aims to apply a rapid online survey to determine the Spanish situation in this third wave of the pandemic.
75573752|NCT01206439|Drug|nebivolol|nebivolol 5 or 10 mg oral, daily
75573753|NCT01206322|Drug|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
75573754|NCT01206322|Drug|Placebo|The acute effects of intranasal sterile saline.
75573755|NCT04659200|Diagnostic Test|Venous blood was collected for biochemistry testing.|For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
75573756|NCT01206166|Drug|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
75573757|NCT00540501|Drug|Oseltamivir and Intravenous Zanamivir|"Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes."
75878114|NCT05763927|Drug|Fruquintinib|Fruquintinib 5mg 2w on/1w off, 21d/cycle, totally 4 cycle.
75427173|NCT01472809|Drug|ZYGK1|"ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
75427174|NCT01472809|Drug|Placebo|Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
75427175|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
75427176|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
75427177|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
75573758|NCT04659239|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
75427178|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
75427179|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
75427180|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
75427181|NCT01472861|Procedure|AECC (Autologous endometrial coculture)|endometrial biopsy with autologous endometrial coculture
75427182|NCT01472861|Other|no endometrial biopsy or Autologous endometrial coculture (AECC) performed|routine procedures with out biopsy
75427183|NCT01472900|Device|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
75573759|NCT04659239|Biological|Placebo|The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
75573760|NCT04659083|Device|Neurally adjusted ventilatory assist ventilation mode|This technique uses the electrical activity of the diaphragm (Edi) to control respiratory support and the NAVA level as an amplification factor that converts the Edi signal into a proportional pressure.
75878115|NCT05763927|Drug|Toripalimab|Toripalimab 200mg d1, 21d/cycle, totally 4 cycle.
75427184|NCT01472900|Drug|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
75725435|NCT00933348|Drug|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
75427185|NCT01472913|Drug|Fibrin sealant|Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
75573761|NCT03511248|Dietary Supplement|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
75725436|NCT00933348|Drug|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
75878116|NCT05763927|Radiation|Short-course radiotherapy|25 Gy in 5 fraction, d22-26.
75878117|NCT05763927|Procedure|TME|Surgical resection of the primary tumour in the rectum, 2-4weeks after the last dose of fruquintinib
75573762|NCT03511248|Dietary Supplement|Nitrate-deplete Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
75725437|NCT00823628|Drug|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
75427186|NCT01472913|Drug|Saline water|Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
75427187|NCT01472926|Drug|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
75427188|NCT01472926|Drug|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
75427189|NCT01472978|Drug|metronidazole|Metronidazole, 500 mg three times a for 10 days
75725438|NCT00823628|Drug|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
75725439|NCT00937872|Drug|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
75725440|NCT00937872|Drug|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
75725441|NCT00938184|Drug|Paroxetine 12.5 milligrams tablet|Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
75725442|NCT00938184|Drug|Paroxetine 25 milligrams tablet|Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
75878118|NCT03579836|Drug|BEY1107|Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
75878119|NCT03579836|Combination Product|Gemcitabine|Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
75878120|NCT04577781|Drug|GLPG3970|GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
75878121|NCT04577781|Drug|Placebo|Placebo powder and solvent for oral solution to be reconstituted prior to use.
75427190|NCT01473017|Behavioral|CBT-based Guided Self-Help|CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
75427191|NCT01473043|Drug|Axitinib|5mg twice daily [BD] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
75427192|NCT01473056|Drug|JTK-853|Tablets, twice a day for 3 days
75427193|NCT01473056|Drug|Dose 2 JTK-853|Tablets, twice a day for 3 days
75427194|NCT01473056|Drug|Dose 3 JTK-853|Tablets, three times a day for 3 days
75427195|NCT01473056|Drug|Dose 4 JTK-853|Tablets, twice a day for 3 days
75573763|NCT04658810|Other|Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)|Patients identified as women with cytomegalovirus (CMV) seroconversion during pregnancy will be called on the phoned and ask to participate to the study and to answer the Perinatal Post-traumatic Stress Disorder
75878122|NCT02737826|Drug|Buprenorphine Initiation - Phase I|In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.
75878123|NCT02737826|Drug|Gabapentin + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
75427196|NCT01473056|Drug|Placebo|Tablets, twice a day or three times a day for 3 days
75573764|NCT00540618|Drug|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
75573765|NCT00540618|Other|Placebo|
75573766|NCT00540618|Drug|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
75573767|NCT00540618|Drug|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
75573768|NCT04658459|Procedure|Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis|
75573769|NCT00557453|Drug|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
75427197|NCT01473069|Drug|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
75427198|NCT01473069|Drug|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
75427199|NCT01473082|Device|PFNA Augmentation (Synthes)|Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
75427200|NCT01473082|Device|PFNA (Synthes)|Proximal Femoral Nail Antirotation (PFNA)
75427201|NCT01473095|Drug|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
75427202|NCT01473121|Other|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
75427203|NCT01473147|Drug|Exenatide|Exenatide 5 microgram bid sc.
75427204|NCT01473147|Drug|Normal saline|Normal saline 2 u bid sc.
75427205|NCT01473173|Drug|CJ-12420|
75427206|NCT01473173|Drug|Esomeprazole 40mg|
75427207|NCT01473225|Other|Calorie information|Nutrition label featuring calorie information will be provided.
75573770|NCT00557453|Drug|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
75573771|NCT01207102|Drug|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
75573772|NCT01207102|Drug|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
75573773|NCT04658732|Drug|Administration of Alprazolam , Gabapentin , Dexmedetomidine|Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.
75573774|NCT00540696|Drug|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
75573775|NCT04658615|Procedure|Non-surgical periodontal therapy|A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
75573776|NCT04658420|Drug|Ketamine Hydrochloride|Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes
75573777|NCT04658420|Other|Music|"A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF"
75573778|NCT00540735|Procedure|photodynamic therapy|
75573779|NCT00557531|Device|BL-1040|2 mL of BL-1040
75573780|NCT04658264|Dietary Supplement|Wheat-Barley Composite flour|A combination of wheat and barley flour with 0.5% food grade xanthan gum as replacement for lost gluten, tested for sensory properties, nutrient profile, and rheology
75573781|NCT04657913|Other|cold water spray application|It will be sprayed into the mouth of patients every hour.
75725443|NCT00938184|Drug|Paroxetine 50 milligrams tablet|Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
75725444|NCT00938262|Drug|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
75427208|NCT01473225|Other|No calorie information|No nutrition label will be provided in this condition.
75427209|NCT01473238|Other|Evaluation form|A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
75427210|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
75573782|NCT04657913|Other|cold saline spray application|It will be sprayed into the mouth of patients every hour.
75427211|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
75427212|NCT01473251|Drug|Lucentis|0.5 mg monthly for 4 months
75427213|NCT01473264|Drug|recombinant human CC10 (rhCC10)|5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
75427214|NCT01473264|Drug|recombinant human CC10 (rhCC10)|1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
75427215|NCT01473264|Drug|placebo|Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
75427216|NCT01473277|Drug|BT-A (Dysport 500U), Triamcinolone acetonide|"All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment."
75427217|NCT01473290|Dietary Supplement|live freeze-dried lactic acid bacteria probiotic|Given orally (PO)
75427218|NCT01473290|Other|placebo|Given PO
75427219|NCT01473303|Biological|ganitumab|Given IV
75573783|NCT04657874|Other|Bromelains and Escin Oral Tablet|Supportive care after oral surgery
75573784|NCT04657874|Other|Placebo|Oral tablet without the active principle
75573785|NCT03324438|Behavioral|Home Telehealth T1D C2oYoT1-HR|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
75725445|NCT00933426|Drug|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
75725446|NCT00933426|Drug|Paclitaxel|50 mg/m^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
75427220|NCT01473303|Drug|fluorouracil|Given IV
75427221|NCT01473303|Drug|irinotecan hydrochloride|Given IV
75427222|NCT01473303|Drug|leucovorin calcium|Given IV
75427223|NCT01473303|Drug|oxaliplatin|Given IV
75427224|NCT01473303|Other|placebo|Given IV
75427225|NCT01473303|Other|questionnaire administration|Completed on paper
75427226|NCT01473316|Drug|GDC-0980|Single oral dose
75427227|NCT01473316|Drug|Ketoconazole|Repeating Oral Dose
75427228|NCT01473329|Other|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
75427229|NCT01473342|Behavioral|Mila Blooms|Behavioral intervention will be administered to 30 adolescent childhood cancer survivors & their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting & participation. During the 9th week (Week 17), participants complete one final survey & accelerometer wear.
75427230|NCT01473433|Procedure|Pericardial adipose pedicle (adiFLAP) transposition.|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.
75573786|NCT03324438|Behavioral|Personalized Behavioral Health|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
75573787|NCT03324438|Behavioral|Personalized Adherence Feedback|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
75573788|NCT00540813|Device|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
75878124|NCT02737826|Drug|Placebo + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
75878125|NCT02737826|Drug|Buprenorphine taper - Phase II|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
75427231|NCT01473433|Other|Control|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
75427232|NCT01473446|Procedure|Goal directed fluid therapy guided by LiDCOrapid|"Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.~Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV <10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding >1000ml. By fall in blood pressure and SVV <10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h."
75427233|NCT01473459|Procedure|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
75573789|NCT04658030|Device|VR 360 video surgery preparation|Preparing children on the surgery by a virtual reality 360 degrees video tour from the pediatric ward to the surgery room. In this video all information is given necessary for the surgery. This takes a maximum of 30 minutes and will be performed 1 time.
75427234|NCT01473459|Procedure|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
75427235|NCT01473472|Drug|Truvada|2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
75427236|NCT01473472|Drug|Placebo|2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
75427237|NCT01473485|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
75427238|NCT01473498|Other|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients."
75573790|NCT04658030|Other|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
75573791|NCT00540852|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging
75573792|NCT00540891|Drug|ALFUZOSIN|
75427239|NCT01473498|Other|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
75427240|NCT01473511|Behavioral|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focussed on skill learning for parents
75427241|NCT01473537|Drug|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
75427242|NCT01473550|Behavioral|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
75427243|NCT01473576|Dietary Supplement|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
75878126|NCT03367715|Drug|Nivolumab|study treatment on Day 1 with one dose of nivolumab 3 mg/kg
75878127|NCT03367715|Drug|Ipilimumab|study treatment on Day 1 with one dose of ipilimumab 1mg/kg
75427244|NCT01473576|Dietary Supplement|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
75427245|NCT01473615|Behavioral|Mindfulness Based Cognitive Therapy|A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
75573793|NCT04658225|Procedure|0.12% chlorhexidine|the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
75573794|NCT00540930|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
75878128|NCT03367715|Radiation|Radiation Therapy (RT)|total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
75427246|NCT01473654|Behavioral|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
75427247|NCT01473667|Procedure|Superficial Cervical Plexus Block (SCP) block|SCP block using 10-15ml of 1% Ropivacaine
75427248|NCT01473667|Procedure|Local site infiltration|Local site infiltration using 2% lidocaine
75427249|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
75427250|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
75427251|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
75427252|NCT01473693|Other|MRI Screening Form, MRI, Demographic / Medical Data form|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes."
75573795|NCT04657952|Procedure|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine & adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.
75878129|NCT03963063|Procedure|Goal-directed fluid therapy|"Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~individualized optimised stroke volume by mini-fluid challenge first~keep mean arterial pressure ≧65 mmHg~keep systolic blood pressure ≦140 mmHg~keep cardiac index ≧ 2.5 L/min/cm2"
75878130|NCT03963063|Procedure|Non goal-directed fluid therapy|"Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~keep mean arterial pressure ≧65 mmHg~keep systolic blood pressure ≦140 mmHg"
75878131|NCT03577808|Other|Biopsy|Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.
75725447|NCT04014582|Behavioral|Communal Coping Intervention|This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
75878132|NCT05762913|Other|Manual Diaphragm Release Technique|The therapist passes his fingers under the costal arch, during inspiration the therapist accompanies the movement of the ribs, while during expiration he takes his fingers deeper, increasing his pressure. The therapist progresses progressively deeper into the costal arch with each breath. The maneuver will be performed in two sets of 10 deep breaths. The diaphragm release technique will be applied in 3 sessions, with 2 days of rest in between.
75427253|NCT01473693|Other|MRI Screening Form, MRI. Demographic / Medical Data|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.~MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes"
75878133|NCT03585218|Biological|Inhalation of essential oils|"Intervention Inhalation of essential oils: From the T1 (2nd Cycle CT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the CT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment."
75878134|NCT01330667|Dietary Supplement|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
76048115|NCT02360293|Behavioral|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
75573796|NCT04657952|Drug|Medical Treatment|Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
75725448|NCT04014582|Behavioral|Diabetes Education|Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
75878135|NCT04064931|Diagnostic Test|Detection of niacin and other vitamins in plasma|Detection of niacin and other vitamins in plasma
75878136|NCT03577652|Drug|Ticagrelor|Ticagrelor, 90mg, 90mg twice daily
76048116|NCT02360293|Behavioral|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
76048117|NCT02359903|Drug|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
76048118|NCT02359903|Drug|Infliximab (Remicade)|
76048119|NCT02291419|Drug|ticagrelor|ticagrelor 90 mg bid
75725449|NCT04013958|Drug|IV Ketamine|IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
75725450|NCT04013958|Drug|IM Ketamine|IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
75725451|NCT00933504|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks.
75725452|NCT00933582|Drug|JNJ-39439335; Placebo; Naproxen|
75725453|NCT00933660|Other|ERC-training by instructor|Standard way of training with an instructor
75878137|NCT03620513|Drug|Decongestant (oxymetazoline 0.05%)|As described in arm/group
76048120|NCT02291419|Drug|aspirin|aspirin 81 mg daily
76048121|NCT02319031|Drug|Daclatasvir|
76048122|NCT02319031|Drug|Sofosbuvir|
76048123|NCT02319031|Drug|Ribavirin|
75573797|NCT00541008|Drug|sunitinib malate|
75573798|NCT04657796|Device|High Flow Nasal Cannula|use of high flow nasal cannula as a weaning mode from invasive mechanical ventilation to deliver oxygen
75573799|NCT03256227|Behavioral|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
75573800|NCT03256227|Behavioral|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
75725454|NCT00933660|Other|Web-based training only|Experimental way of training with a web based training application
75725455|NCT00933660|Other|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
75427254|NCT01473706|Other|Consumer Mini Nutritional Assessment|A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
75573801|NCT04657718|Device|KODEX-EPD system|Cardiac pacing leads implantation for PM, ICD, CRT, HBP and LBBP
75573802|NCT00541086|Drug|anastrozole|1 mg per day, orally
75573803|NCT00541086|Drug|exemestane|25 mg per day, orally
75573804|NCT00541086|Drug|letrozole|2.5 mg per day, orally
75573805|NCT00541086|Drug|tamoxifen citrate|20 mg per day, orally
75573806|NCT04657484|Drug|Medium dose prednisolone|Same as arm description
75725456|NCT00938418|Radiation|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
75725457|NCT00938574|Drug|Atu027|
75725458|NCT00938730|Drug|YM150|oral
75725459|NCT00938730|Drug|Warfarin|oral
75427255|NCT01473719|Behavioral|motivational intervention|7-session individual motivationally-based intervention
75427256|NCT01473719|Behavioral|health education|7 individual sessions focusing on health education
75427257|NCT01473771|Behavioral|Caring Letter (email)|"Participants will be emailed letters for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period."
75427258|NCT01473797|Drug|Cladribine|Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
75427259|NCT01473810|Biological|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
75573807|NCT04657484|Drug|Low dose prednisolone|Same as arm description
75573808|NCT00541125|Biological|bevacizumab|
75573809|NCT00541125|Biological|filgrastim|
75573810|NCT00541125|Drug|fluorouracil|
75573811|NCT00541125|Drug|irinotecan hydrochloride|
75573812|NCT00541125|Drug|leucovorin calcium|
75573813|NCT00541164|Drug|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
75573814|NCT00541164|Dietary Supplement|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
75573815|NCT04657757|Other|Intraoral apparatus|Eight platelets with different material composition and surface properties are fastened in a holder (carrier rondell) with 15 mm diameter and inserted into the braces. Braces are to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures. Platelets then are removed and analyzed. After a first course the braces are to be cleaned in chlorhexidine solution in an ultrasonic bath; followed by a second identical course (Braces to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures).
75573816|NCT04657601|Device|DiLumen C2 Endolumenal Interventional Platform|Dual balloon accessory to an endoscope and related instruments
75573817|NCT03231072|Device|Electrical Impedance Tomography record|Monitoring of pleural effusion evacuation by means of EIT
75725460|NCT00933816|Drug|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
75725461|NCT00538785|Biological|Motavizumab|15 mg/kg IM administered at monthly intervals
75725462|NCT00538785|Biological|Palivizumab|15 mg/kg IM administered at monthly intervals
75725463|NCT02058459|Device|Holaira™ Lung Denervation System with energy delivery|
76048124|NCT02318797|Behavioral|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
76048125|NCT02318797|Behavioral|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
75427260|NCT01473810|Biological|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
75427261|NCT01473810|Biological|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
75427262|NCT01473810|Biological|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
75427263|NCT01473823|Dietary Supplement|Omega-3 LCPUFA|Dosage is 5 ml daily until age 3 years.
75427264|NCT01473888|Drug|T89(Dantonic)|capsule, 225mg B.I.D.
75427265|NCT01473901|Drug|BKM120 + temozolomide|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
75573818|NCT04656977|Other|VR|The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.
75573819|NCT04656977|Other|TAU|The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.
75573820|NCT03221322|Behavioral|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
75878138|NCT03620513|Drug|Anesthesia (Lidocaine 15%)|As described in arm/group
76048126|NCT02359435|Drug|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
75427266|NCT01473901|Drug|BKM120 +temozolomide with/without radiotherapy|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
75427267|NCT01473914|Dietary Supplement|Low dose: supplemental zinc, selenium and vitamin E|"ZINC 25mg (AS ZINC SULFATE)~SELENIUM 50 mcg (AS SODIUM SELENITE)~VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
75878139|NCT03620513|Drug|Decongestants and Anesthesia (oxymetazoline and lidocaine)|As described in arm/group
75878140|NCT03620513|Drug|Normal saline|Spray of normal saline as premedication
76048127|NCT02359435|Drug|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
75573821|NCT04656938|Behavioral|Pre-frail intervention|Pre-frail partiipants will undergo 4 month intervention consisted of group-based physical exercise and nutritional classes.
75573822|NCT00541281|Drug|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
75573823|NCT00541281|Drug|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
75878141|NCT03585062|Drug|S1,|S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
75878142|NCT03585062|Drug|Paclitaxel-albumin|Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
76048128|NCT02318719|Drug|Placebo|Placebo
76048129|NCT02318719|Drug|DS-5565|
76048130|NCT01870726|Drug|INC280|"Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily."
75573824|NCT00541281|Drug|prednisone|2x5 mg a day
75573825|NCT04656860|Dietary Supplement|Juice Plus+|Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
75573826|NCT00541320|Drug|GW813893|
75573827|NCT04657172|Drug|Pilocarpine Ophthalmic|Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
76048131|NCT01870726|Drug|Buparlisib|Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
75427268|NCT01473914|Dietary Supplement|Standard renal vitamin: B and C renal vitamin|"BIOTIN 300 MCG~D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~FOLIC ACID 1 MG~NIACINAMIDE 20 MG~VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~VITAMIN B12(CYANOCOBALAMIN) 6 MCG~VITAMIN B2 (RIBOFLAVIN) 1.7 MG~VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~VITAMIN C (ASCORBIC ACID) 100 MG~INERT FILLER (CORNSTARCH)"
75427269|NCT01473914|Dietary Supplement|Medium dose: supplemental zinc, selenium and vitamin E|"ZINC 50 mg (AS ZINC SULFATE)~SELENIUM 75 mcg (AS SODIUM SELENITE)~VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
75427270|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
75573828|NCT04657172|Drug|Placebo|Vehicle ophthalmic solution administered with the Optejet microdose dispenser
75573829|NCT03199794|Biological|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
75573830|NCT04656821|Drug|Control Rx|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed
75573831|NCT04656821|Procedure|Erector Spinae Block|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
75573832|NCT04656821|Procedure|Thoracic Paravertebral Block|Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography
75573833|NCT04656509|Other|4-s sprint inertial load training|A program employing 30 bouts of 4s inertial load sprint training with progressively reduced recovery time (30 to 15 s) between sprints is effective for improving blood volume, VO2peak and maximal power.
75573834|NCT00541359|Drug|bortezomib|Given IV
75573835|NCT00541359|Drug|topotecan hydrochloride|Given IV
75573836|NCT00541359|Other|immunohistochemistry staining method|Correlative studies
75573837|NCT00541359|Other|pharmacological study|Correlative studies
75573838|NCT04656743|Procedure|intra-articular injection|The injection will be performed under ultrasound guidance by placing the patient's knee in approximately 90° of flexion with the leg hanging off the side of the bed (left). A high-frequency linear transducer ultrasound probe is placed in the superolateral corner of the patella, directed medially toward the patellofemoral joint space. In the extended leg, from anterior to posterior, the right image shows the quadriceps femoris tendon (QF), suprapatellar fat pad (SF), suprapatellar bursa (SB), prefemoral fat pad (PF), and femur (F). When the knee is flexed to 90°, the size of the suprapatellar bursa image is increased. Using an in-plane approach, the needle will be directed into the suprapatellar joint space, and 20 ml of bupivacaine 0.25% will be injected.
75725464|NCT02058459|Device|Holaira™ Lung Denervation System without energy delivery|
76048132|NCT04599868|Drug|Magnesium sulfate|"Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed."
76048133|NCT01900054|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
76048134|NCT01612156|Drug|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
76048135|NCT01612156|Drug|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
76048136|NCT01899742|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
76048137|NCT01899742|Drug|Tiotropium 18 mcg|Inhalation Powder
76048138|NCT04602988|Device|EEG|EEG monitoring of brain rhythms
75725465|NCT00990015|Drug|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
75725466|NCT00990015|Drug|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
76048139|NCT01615822|Drug|OZ439 100mg|OZ439 100mg oral suspension, single dose
76048140|NCT01615822|Drug|OZ439 400mg|OZ439 400mg oral suspension, single dose
76048141|NCT01615822|Drug|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
76048142|NCT01615822|Drug|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
75573839|NCT04656743|Procedure|genicular nerve block|The transducer will be first placed parallel to the long bone shaft and moved up or down to identify the epicondyle of the long bone. The genicular arteries will be identified near the periosteal areas, confirmed by color Doppler ultrasound. Accordingly, genicular nerve block target points should be next to each genicular artery. After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view. a gentle aspiration will be performed and a 2 mL injection volume will be administered.
75573840|NCT03111927|Other|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
75573841|NCT03111927|Other|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
75573842|NCT04656782|Other|Imaging survey|Participation as expert panelist in the imaging survey.
75573843|NCT04656782|Other|Facilitation|Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
75573844|NCT00541398|Behavioral|Implementation of guideline|Outreach visits with interactive education for health staff
75573845|NCT04656626|Behavioral|brief mindfulness based intervention|The 20 minute daily mindfulness sessions for 2 weeks consist of the following guided meditation practices: 1. Bring your attention to a primary object of focus 2. Maintain a moment-moment awareness 3. When your mind naturally drifts into thinking (mind wandering); just notice you are thinking, and then bring your attention back to your object of focus 4. When a strong sensation arises, again, notice the sensation or emotion and return to your breath. 5. As you gain confidence, you may practice maintaining this focus while observing thoughts flowing through your mind or sensations in your body while showing no concern for the content 6. You may even label your thoughts 7. Thank yourself for your efforts and for taking this time.
75573846|NCT04656626|Behavioral|Progressive muscle relaxation|"Control group:~Control group will be given an mp3 audio recording of a 20-minutes of progressive muscle relaxation will be sent directly as SMS messages and emails to be heard by the participants through their personal device of their choice, such as a smart phone."
75725467|NCT04237545|Device|T3 short and restoration (prosthesis)|A qualified patient will be treated with a T3 short implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
75725468|NCT04237545|Device|T3 standard length and restoration (prosthesis)|A qualified patient will be treated with a T3 standard length implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
76048143|NCT01615822|Drug|Placebo|
76048144|NCT01898884|Drug|VP 20629|
76048145|NCT01898884|Drug|Placebo|
76048146|NCT01613326|Drug|NVA237|NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
76048147|NCT01613326|Drug|Tiotropium|Tiotropium 18 μg once a day delivered via HandiHaler® device
76048148|NCT01613326|Drug|Placebo to tiotropium|Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
76048149|NCT01613326|Drug|Placebo to NVA237|Placebo to NVA237 50 μg once a day delivered via SDDPI
76048150|NCT01613326|Drug|salbutamol/albuterol|salbutamol/albuterol given as a rescue medication via inhaler when needed
75427271|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
75427272|NCT01473966|Dietary Supplement|coffee|patients will receive a cup of coffee at room temperature orally twice daily
76048151|NCT01613248|Drug|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
76048152|NCT01613248|Drug|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
75427273|NCT01473966|Dietary Supplement|coffee rectally|patients receive an enema of two cups of coffee at room temperature once daily
75573847|NCT03456921|Other|"End-of-life conversation game called Hello"|To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
75427274|NCT01473979|Procedure|Surgical closure of the poststernotomy wound infection|"Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone."
75427275|NCT01474005|Device|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
75573848|NCT04658069|Other|no specific interventions|no specific interventions
75573849|NCT04656704|Drug|hyaluronidase injected intradermally|Patients will receive 200 units of hyaluronidase injected intradermally to the cutaneous lips on Weeks 0, 4, 8, 12, and 16, and 20
75427276|NCT01474031|Other|Biomechanics|"Time interval: pre-op - 3m - 6m - 12m~Assessment of all subjects:~XR~Gait analysis with surface EMG and trunk markers:~Unipodal standing: 3 trials Right and 3 trials Left on FP~Level walking: 3 trials Right and 3 trials Left on FP~Chair rise: 3 trials, both legs on FP~Stair ascent: 3 trials Right and 3 trials Left on first FP~Stair descent: 3 trials Right and 3 trials Left on first FP~Squat: 3 trials, both legs on FP~Bipodal squat: 3 trials Right and 3 trials Left on FP~Functional scores (HHS, UCLA, HOOS, SF-36)"
75573850|NCT03096249|Drug|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
75573851|NCT03096249|Other|Placebo|Placebo spray: single dose (3 puffs per nostril).
75427277|NCT01474044|Drug|Gastropylor Complex Capsules|3 pills, three times a day, after meal
75427278|NCT01474044|Other|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
75427279|NCT01474057|Behavioral|DESTRESS-PC|"An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician."
75427280|NCT01474057|Other|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
75427281|NCT01474070|Device|Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT
75427282|NCT01474096|Other|implementation strategy of Breastfeeding|implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
75878143|NCT03854331|Behavioral|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
75427283|NCT01474161|Drug|GFT505 120mg - old formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
75427284|NCT01474161|Drug|GFT505 120mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
75573852|NCT04656548|Device|HydroPICC|PICC lines
75573853|NCT04656665|Drug|Aspirin|For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy
75878144|NCT03584906|Procedure|DGG Harvesting approach|An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
75573854|NCT03014622|Biological|Botulinum Toxins, Type A|Intramuscular injection
75573855|NCT03014622|Biological|Placebos|Intramuscular injection
75573856|NCT04656314|Diagnostic Test|Functional MRI scan|Functional MRI scan: Phase contrast, BOLD, Arterial Spin Labeling, Diffusion weighted MRI, T1 mapping, T1rho mapping
75573857|NCT04656119|Other|there is no intervention in our study|there is no intervention in our study
75725469|NCT05360121|Other|Muscle energy technique of erector spinae muscle|"Therapist will develop cross hand position left hand on lower thoracic and right hand on sacrum. Patient will asked to lift shoulder out of couch to contract the lumber erector spinae and apply force twenty percent against therapist force and keep this position of muscle contraction 7 to 10 seconds then 5 second relax .~Then therapist will take new position of muscle restriction by slacking and will hold 30 second that position at the end of restriction then will finally end stretch with three repetition. Muscle energy technique of erector spinae muscle."
75878145|NCT03584906|Procedure|ET harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
75427285|NCT01474161|Drug|GFT505 180mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
75878146|NCT03584906|Procedure|TDT harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
75427286|NCT01474161|Drug|GFT505 240mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
75427287|NCT01474161|Drug|GFT505 300mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
75427288|NCT01474161|Drug|Placebo|hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
75427289|NCT01474174|Biological|trivalent influenza vaccine|Given IM
75427290|NCT01474174|Other|laboratory biomarker analysis|Correlative studies
75427291|NCT01474187|Drug|Irinotecan|initial from 50mg/m2/week and increased by 15mg/m2/week
75427292|NCT01474187|Drug|Capecitabine|625mg/m2,bid,d1-5,qw
75427293|NCT01474187|Radiation|Radiotherapy|50Gy for whole pelvis
75878147|NCT03584906|Procedure|MT harvesting approach|An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
75878148|NCT03584906|Procedure|Root coverage procedure|A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
75427294|NCT01474226|Dietary Supplement|Amino Acid Crystalline Lysine Amino Acid Mix|crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.
75573858|NCT04656197|Other|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
75878149|NCT05436587|Genetic|The whole-exome sequencing|Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.
75878150|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and placebo
75878151|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and betamethasone
75573859|NCT04655846|Behavioral|Nursing intervention outcome: Breastfeeding Counseling (5244)|"Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~Educational Session: Explain the extraction and conservation of breast milk.~Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding."
75573860|NCT04655846|Behavioral|Nursing education about maternal care and usual education in maternity preparation course|Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
75573861|NCT04655534|Other|Inspiratory Muscle Warm-up (IMW)|The IMW protocol applied before each inspiratory muscle training (IMT) session by using a threshold inspiratory muscle trainer. The IMW protocol consists of 2 sets of 30 breaths in 40% of the maximal inspiratory pressure (MIP), with 1 min rest between sets. The intensity of MIP adjusted by two weekly MIP measurements.
75725470|NCT05360121|Other|Muscle energy technique of quadratus lumborum muscle|Therapist will take step over the patient off leg and squeezes gently with their thigh. Patient will abduct leg with 20 percent force against the resistance of therapists thigh for 7 to 10 second. the therapist gently and passively will move patient leg towards adduction by squatting down slowly. Therapist at same time with both hands cradling the iliac crest of pelvic for 30 second stretch and 3 repetition.
75878152|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and propionate de clobetasol
75427295|NCT01474226|Dietary Supplement|Cooked Rice containing Lysine|Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
75573862|NCT04655534|Other|Inspiratory Muscle Training (IMT)|The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.
75573863|NCT04655534|Other|Respiratory exercises and aerobic exercise program|Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.
75573864|NCT04655807|Drug|JNJ-64304500|JNJ-64304500 will be administered as SC injection.
75878153|NCT01330745|Other|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
75573865|NCT04655807|Drug|Placebo|Matching placebo will be administered as SC injection.
75573866|NCT04655807|Drug|Adalimumab|Adalimumab will be administered as SOC biological therapy.
75878154|NCT02809443|Biological|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
75878155|NCT03584282|Behavioral|Text Messaging|The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
75878156|NCT03584282|Behavioral|Peer Navigation|The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
75725471|NCT05360121|Other|Stretching of erector spinae muscle|The therapist standing on the side in a way to place his elbow placed on erector spine and apply stretching on the muscle belly in the direction of longitudinal or transverse plane( figure 1).Duration of stretch will be 15 seconds and four repetition.
75878157|NCT01330823|Dietary Supplement|L-Carnitine|L-Carnitine, 4g/day, orally (Juice)
75878158|NCT01330823|Dietary Supplement|Placebo|tartaric acid same dose like L-Carnitine as placebo
75878159|NCT03636191|Dietary Supplement|Probiotic strain|Lactobacillus
75427296|NCT01474252|Drug|RSI|"All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg"
75427297|NCT01474265|Drug|Varenicline|0.5-2 mg per day, oral use
75427298|NCT01474265|Drug|Placebo|1-2 tablets per day, oral use
75573867|NCT04655807|Drug|Ustekinumab|Ustekinumab will be administered as SOC biological therapy.
75573868|NCT04655417|Drug|Sodium Tetradecyl Sulfate|DRUG WILL BE INJECTED TO ALLAPTIENTS ACCORDING TO STANDARD PROTOCOL
75573869|NCT00541515|Device|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
75573870|NCT04655729|Drug|Infliximab|Blood collection
75573871|NCT02937831|Biological|RIXUBIS|
75573872|NCT00541554|Drug|Abilify (aripiprazole)|
75725472|NCT05360121|Other|Stretching of quadratus lumborum muscle|Placing patient's legs to one side of the table and upper body also move to the same side in lateral flexion. This position generate a basic gentle stretch of the muscle. The therapist use elbow on tight/ flat part of muscle belly to stretch out the muscle(figure 2). Duration of stretch will be 15 seconds and four repetition
75725473|NCT05360121|Other|Back strengthening exercises|"Supine Abdominal Draw In~Supine Butt Lift with Arms at Side~Abdominal Draw In with Heel Slide~Abdominal Draw In with Knee to Chest~Abdominal Draw In with feet on the ball~Abdominal Draw In with feet on the ball- add movement"
75878160|NCT03636191|Dietary Supplement|Placebo|Placebo
75427299|NCT01474265|Drug|Nicorette TX|10-15 mg per day, transdermal use (patches)
75427300|NCT01474278|Drug|Placebo|Single dose
75427301|NCT01474278|Drug|RO5028442|Single dose
75427302|NCT01474304|Drug|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
75427303|NCT01474330|Drug|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
75427304|NCT01474330|Drug|Placebo|Placebo capsule
75427305|NCT01474343|Genetic|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
75427306|NCT01474356|Other|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
75427307|NCT01474369|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
75427308|NCT01474369|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
75427309|NCT01474369|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
75591974|NCT06078696|Procedure|Stem Cell Infusion|Standard institutional procedures should be followed for the processing and administration of stem cell products for infusion. The infused graft under no circumstances is to be irradiated. No in-line leukocyte filter should be used and no medications or fluids should be given piggyback through the catheter lumen used for infusion of stem cells. Vital signs should be monitored before beginning the infusion and periodically during administration and in accordance with institutional guidelines. Pre-medications prior to the graft infusion will be according to the institutions standard practice. Benadryl, epinephrine, hydrocortisone, and oxygen be available at the bedside, as well as an emergency medical code cart available in the vicinity of the patient, for emergency use in case of an infusion reaction.
75878161|NCT03579758|Drug|Capecitabine|Given PO
76048153|NCT01613248|Drug|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans or other medication not explicitly excluded."
76048154|NCT01898806|Drug|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
75427310|NCT01474382|Drug|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
75427311|NCT01474382|Other|Sham injection|No drug administered, simulation of injection used in same manner as drug
75427312|NCT01474395|Drug|D-serine|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
75427313|NCT01474395|Drug|placebo|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
75573873|NCT04655339|Drug|Bilateral abdominal Lap-TAP|A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
75573874|NCT04655105|Device|root canal rotary files|post operative pain evaluation using different rotary file system
75573875|NCT04655183|Drug|Niraparib|Niraparib will be administered orally, once daily.
75573876|NCT04655183|Drug|M4344|M4344 will be administered once daily or on an intermittent schedule in combination with niraparib.
75573877|NCT04655183|Drug|Niraparib|Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.
75725474|NCT05360121|Other|Thermotherapy|Ten minute duration of hot pack given on low back for local superficial heat.
75725475|NCT01563939|Drug|Remifentanil|"Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg."
75725476|NCT04004715|Dietary Supplement|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
76048155|NCT01898806|Drug|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
75725477|NCT04004715|Dietary Supplement|Whey Protein|commercially available whey protein isolate
75725478|NCT04004715|Dietary Supplement|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
75878162|NCT03579758|Drug|Cisplatin|Given IV
75878163|NCT03579758|Drug|Gemcitabine|Given IV
75878164|NCT03636113|Device|Clarity RMS Electronic Sensor|The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
75878165|NCT03577574|Procedure|retrobulbar anesthesia|2% lidocaine 4ml injected into retrobulbar space
75878166|NCT03577574|Procedure|peribulbar anesthesia|2% lidocaine 4 to 8ml injected into peribulbar space
76048156|NCT01898806|Drug|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
75573878|NCT04655183|Drug|M4344|M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.
75573879|NCT04655183|Drug|Niraparib|Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.
75427314|NCT01474395|Behavioral|Sensory Based remediation paradigm|Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
75573880|NCT04655183|Drug|Niraparib|Niraparib will be administered as single agent at the approved dose.
75573881|NCT00541710|Dietary Supplement|genistein|pills of 27 mg, twice per day for 12 months
75573882|NCT00541710|Dietary Supplement|placebo|sugar pills twice per day for 12 months
75573883|NCT04654871|Dietary Supplement|Chondroitin Sulfate|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
75573884|NCT04654871|Procedure|Resistance exercise training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
75573885|NCT04654871|Procedure|Manual therapy / Joint Mobilization|Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
75427315|NCT01474408|Behavioral|interval training day 1|
75573886|NCT04654871|Procedure|THE therapy|Interferential and Heating for 20 min
75573887|NCT00541749|Drug|rhuMAb IFNalpha|Intravenous repeating dose
75573888|NCT04654793|Device|Robot assisted inclined bed treatment and FES|FES was performed at the same time as the robot-assisted inclined bed treatment once a day for 30 minutes, 5 days a week for 4 weeks.
75573889|NCT04654793|Device|conventional inclined bed treatment|conventional inclined bed treatment for 30 minutes once a day for 4 weeks, 5 days a week
75427316|NCT01474408|Behavioral|Moderate exercise day 2|
75573890|NCT04654520|Other|Drug therapy concurrent radiotherapy for primary tumor omitted CTV|Thoracic intensity modulated radiotherapy for primary tumor omitted CTV+Chemotherapy or Targeted drug therapy
75573891|NCT00541788|Other|Administration of Common Sage|Administration of Common Sage
75573892|NCT04654598|Other|BPA levels|BPA (bisphenol A) in urine, blood and follicle fluid samples
75573893|NCT02731716|Behavioral|New Payment Model|Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
75573894|NCT02731716|Behavioral|Social Comparisons|Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
75573895|NCT02731716|Behavioral|A1c Member/Provider Incentive|Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
75573896|NCT04654481|Device|HCFWO|The Afflovest device is a High Frequency Chest Wall Oscillation (HFCWO) device, a medical vest that uses vibrations to loosen and mobilize mucus in the lung secretions and help clear the airways.
75573897|NCT04654481|Other|Standard Care Plus Monitoring|Monitoring via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
75573898|NCT04654676|Drug|Vildagliptin|Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin
75573899|NCT04654637|Behavioral|Nutrition and Exercise Strategies|Multiple Interactive with Nutrition and Exercise Strategies
75573900|NCT00541905|Drug|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
75591975|NCT06078696|Drug|Cyclophosphamide 50mg|Cyclophosphamide will be given on days +3 and +4 at a dose of 50 mg/kg. Hydration prior to cyclophosphamide should be given according to standard institutional practice. Day +3 dose should occur between 60 and 72 hours after graft infusion and day +4 post-transplant should occur approximately 24 hours after prior dose. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume or as per institutional standard practice. Cyclophosphamide will be dosed according to adjusted ideal body weight (AIBW) in patients weighing > 125% ideal body weight (IBW).
75591976|NCT06078696|Drug|Mesna|Mesna is to be given starting 1 hour prior to cyclophosphamide at the same dose (50 mg/kg) as a continuous infusion over 24 hours.
75427317|NCT01474408|Behavioral|Control day 3|
75427318|NCT01474447|Behavioral|Grinberg Method|The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
75878167|NCT03577574|Procedure|two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
76048157|NCT01898806|Drug|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
76048158|NCT02291029|Drug|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
76048159|NCT02291029|Drug|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
75427319|NCT01474460|Dietary Supplement|phytonadione|Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
75427320|NCT01474473|Device|CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.~CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days"
75427321|NCT01474473|Device|Placebo and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.~Placebo is applied on the wound for 10 minutes every 3 to 4 days"
75427322|NCT01474499|Drug|Glycerine|
75427323|NCT01474499|Drug|Docusate sodium and sorbitol rectal solution|
75573901|NCT04654403|Drug|Camrelizumab|Eligible patients receive Camrelizumab 200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 4 cycles.Imaging will be performed 2-3 weeks after the 4th Camrelizumab administration.Patients who achieve PD and SD will be not included in the data statistics of this trial.The follow-up treatment according to investigator's and patients's choice(chemotherapy, Camrelizumab plus chemotherapy or Camrelizumab monotherapy).Other patients whose BOR is in remission (CR+PR) will be randomly assigned in a 1:1 ratio to receive Camrelizumab (200 mg every 2 weeks), or Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
75573902|NCT04654559|Other|Unobtrusive data collection using wearable non-invasive sensors|Two wearable non-invasive sensors will be mounted to the patients skin (lateral rib cage and foot). These wearable non-invasive sensors are measuring unobtrusively skin based parameters (no diagnosis will be made), which will be used for fever detection algorithm development..
75878168|NCT03070431|Radiation|High-precision RT 5x5 Gy in 1 week|Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
75878169|NCT02238548|Biological|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
75878170|NCT02238548|Other|Raw milk|
76048160|NCT02291029|Drug|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
76048161|NCT02291029|Drug|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
76048162|NCT02291029|Drug|CFZ533 active -Cohort 3|multiple doses of CFZ533 s.c. injection
76048163|NCT02291029|Drug|CFZ533 active - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
76048164|NCT02290873|Drug|Remimazolam|For induction and maintenance of sedation
76048165|NCT02290873|Drug|Midazolam|For induction of maintenance and sedation
76048166|NCT02290873|Drug|Placebo|Inactive control arm
75573903|NCT00541983|Drug|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
75573904|NCT00541983|Drug|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
75573905|NCT01205776|Device|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
75573906|NCT01205776|Procedure|CABG|Those patients receiving CABG
75573907|NCT04654715|Procedure|Gracilis flap interposition for rectouretral fistula management|Gracilis flap interposition is a surgery for rectouretral fistula
75573908|NCT00542022|Drug|MK0812 / Duration of Treatment: 12 Weeks|
75573909|NCT00542022|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
75573910|NCT04654442|Diagnostic Test|TestNPass|Patients will undergo saliva sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).
75573911|NCT00542061|Device|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
75573912|NCT01205581|Biological|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
75573913|NCT01205581|Biological|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
75573914|NCT00557648|Behavioral|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
75573915|NCT00557648|Behavioral|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
75573916|NCT00542100|Device|PCMRI|
75573917|NCT01205269|Drug|AZD8683, 50 mcg|Dry powder for inhalation, single dose
75573918|NCT01205269|Drug|Placebo|Dry powder for inhalation, single dose
75573919|NCT01205269|Drug|AZD8683, 200 mcg|Dry powder for inhalation, single dose
75573920|NCT04654286|Procedure|Nerve transfer procedure|"Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~Donor nerve is checked for its viability with an electric stimulator during surgery~Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis."
75573921|NCT04654286|Procedure|Nerve transfer with HAM-AdMSC composite wrapping|When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
75573922|NCT02888431|Device|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
75573923|NCT00542139|Drug|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
75573924|NCT00542139|Drug|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
75878171|NCT01330901|Drug|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
75878172|NCT03584204|Diagnostic Test|imaging|computed tomography, magnetic resosnance imaging, ultrasound
75573925|NCT04653974|Behavioral|Needle-free injection|"This study was performed among children aged 4-11 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 70 patients were evaluated in accordance with the exclusion criteria and 56 children (31 girls and 25 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the Wong-Baker Pain Scale at three time points: immediately after injection (Pain 1), during treatment (Pain 2), and at the end of the treatment (Pain 3)."
75573926|NCT00542217|Biological|Imprime PGG|
75878173|NCT02428647|Dietary Supplement|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
76048167|NCT02290405|Behavioral|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
75573927|NCT04654247|Behavioral|Quality audit and feedback|Endoscopists received quality report generated by Endo.Adm.
75725479|NCT05360043|Device|laser treatment|All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.
76048168|NCT02359045|Drug|D1400147|Treatment A
76048169|NCT02359045|Drug|D14000136|Treatment B
76048170|NCT02359045|Drug|D14000137|Treatment C
76048171|NCT02359045|Drug|Epanova®|Treatment D
76048172|NCT02358343|Behavioral|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
76048173|NCT02358343|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
76048174|NCT02358343|Drug|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
76048175|NCT02356783|Device|Pedometer|Wireless pedometer
76048176|NCT02289469|Other|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
76048177|NCT02318095|Drug|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
75573928|NCT04654247|Behavioral|Control|None feedback.
75573929|NCT04654091|Procedure|Cryoteraphy with liquid nitrogen|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of cryotherapy with liquid nitrogen will be carried out using CryoPen b® (HO Equipment, Hhislenghien-Belgium). To analyze the homogeneous application in all the patients in the study, perform 2 applications of 15 seconds per session, with an interval of 30 seconds between each application, such and as manufacturers recommend. The number of sessions in which the product is applied will be a maximum of 5, following the procedure of previous studies."
75878174|NCT02428647|Dietary Supplement|preventive zinc supplement|7 mg zinc daily as dispersible tablet
75878175|NCT02428647|Dietary Supplement|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
75573930|NCT04654091|Procedure|Nitric-zinc complex|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of nitric acid-zinc complex with Verrutop® (Isdin, Barcelona-Spain) will be carried out. The preparation is applied by making small touches with the applicators included in the product.~The number of sessions in which the product is applied will be a maximum of 5, following the recommendations of the manufacturers in the product data sheet."
76048178|NCT02318095|Radiation|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
76048179|NCT02318095|Other|Sugical resection|Surgical resection of the pancreas post radiation therapy
75573931|NCT04654169|Procedure|Ultrasound-guided IAI|Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.
75878176|NCT02428647|Dietary Supplement|preventive placebo supplement|dispersible daily placebo tablet
75878177|NCT02428647|Dietary Supplement|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
75573932|NCT04654169|Procedure|Ultrasound-guided SSNB|Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
75725480|NCT04004637|Drug|CD7 CAR-T cells infusion|"Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10^6/kg."
75725481|NCT03287271|Drug|VS-6063|"Phase 1:~First 3 patient cohort: VS-6063 200 mg PO twice daily~IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
75878178|NCT02428647|Dietary Supplement|placebo powder|placebo powder
75878179|NCT01071395|Drug|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
75878180|NCT01071395|Drug|Placebo|Sugar pill given 3 times daily
76048180|NCT02318095|Drug|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
75573933|NCT00542256|Device|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
75878181|NCT02970942|Drug|Semaglutide|Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
75878182|NCT02970942|Drug|Placebo|Once daily administration subcutaneously ( s.c., under the skin)
75878183|NCT05433311|Other|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
75878184|NCT03577496|Other|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares.
75878185|NCT05429723|Drug|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.
75878186|NCT05429723|Drug|HS-10383 Placebo|Placebo for HS-10383
76048181|NCT02317705|Drug|OTL38|
76048182|NCT02317705|Device|Near infrared camera imaging system|Near infrared camera imaging system
76048183|NCT02317705|Procedure|Laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
76048184|NCT02474069|Drug|Secukinumab|
76048185|NCT02317627|Drug|KD025|
76048186|NCT02517905|Drug|Bupivacaine liposome|Local administration
76048187|NCT02517905|Drug|Placebo|Local administration
76048188|NCT02473913|Drug|Milk Thistle|
76048189|NCT02473913|Drug|Placebo|
76048190|NCT02316847|Drug|diazepam nasal spray|
75725482|NCT03287271|Drug|Paclitaxel|"Phase 1:~First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
75725483|NCT03287271|Drug|Carboplatin|"Phase 1:~First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
75725484|NCT00538629|Other|no intervention|no intervention
75725485|NCT00538629|Other|no intervention|no intervention
75725486|NCT03163095|Device|Open Abdomen Management with ANPPT dressing|"The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.~The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.~Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment."
75725487|NCT03163095|Other|Closed Abdomen Management|"Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).~This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.~Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment."
75725488|NCT04232163|Behavioral|Arm Boot Camp|The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.
75725489|NCT00990405|Drug|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
75725490|NCT00990639|Drug|candesartan for hepatic fibrosis|"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"
75725491|NCT04211727|Diagnostic Test|Capillary finger prick blood sample|Patients will have a blood finger prick sample
75725492|NCT03742947|Diagnostic Test|peripartum haemostasis|Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
75725493|NCT04003935|Other|Juice Plus+ Complete|Plant-based smoothie; maintaining habitual diet.
75725494|NCT04003935|Dietary Supplement|Juice Plus+ Premium|Fruit and vegetable juice concentrate; maintaining habitual diet.
75725495|NCT00990717|Biological|NK-92 cells|"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~Level I: 1x10^9 cells/m^2~Level II: 3x10^9 cells/m^2~Level III: 5x10^9 cells/m^2"
76048191|NCT02473523|Other|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
76048192|NCT02473523|Other|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
75725496|NCT04004013|Dietary Supplement|Lifenol®|"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
75573934|NCT00542256|Device|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
75573935|NCT04653935|Behavioral|Self-management app with all intervention components|A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.
75573936|NCT04653935|Behavioral|Self-management app with Information component only|self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
75573937|NCT00542295|Drug|alverine citrate and simeticone|
75573938|NCT00542295|Drug|placebo|
75573939|NCT03454841|Drug|Prasugrel|Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
75573940|NCT03454841|Drug|Ticagrelor|Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
75573941|NCT03454802|Diagnostic Test|Passive Leg Raising|See above
75725497|NCT04004013|Dietary Supplement|Placebo|"Maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
75725498|NCT05359497|Diagnostic Test|Liver Multiscan sequences baseline|Additional Liver Multiscan sequences at baseline besides standard care MRI liver /MRCP prior to ERCP.
75725499|NCT05359497|Device|MRCP+ analysis baseline|Post processing tool (Software) for quantifying MRCP images after MRCP is performed. Patient involvement is not necessary during this procedure.
75725500|NCT05359497|Device|Liver Multiscan analysis baseline|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
75573942|NCT03454763|Drug|PRRT every 5 weeks|PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
75573943|NCT03454763|Drug|PRRT every 8-10 weeks|PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
75573944|NCT04653506|Drug|Paracetamol 1000 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
75573945|NCT04653506|Drug|Ibuprofen 400 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
75725501|NCT05359497|Diagnostic Test|MRI liver with MRCP|An extra MRI liver with contrast and MRCP is performed 8 weeks after the ERCP following standard care protocol
75573946|NCT00542412|Drug|Riluzole|
75573947|NCT04653701|Combination Product|Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter|We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
75573948|NCT04653623|Procedure|High tibial osteotomy|Treatment option for medial compartment osteoarthritis of knee
75573949|NCT04653623|Drug|Tranexamic acid|Medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation
75573950|NCT00542529|Biological|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
75573951|NCT04653740|Procedure|specimen sample collection|"Before and during treatment, and at progression, collection of :~Blood~Exhaled air~Saliva~Sweat~Tears~Urine"
75573952|NCT02015832|Device|Coronary stent|
75725502|NCT05359497|Diagnostic Test|Liver Multiscan sequences follow-up|Additional Liver Multiscan sequences are performed at 8 weeks after ERCP.
75725503|NCT05359497|Device|MRCP+ analysis follow up|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
75725504|NCT05359497|Device|Liver Multiscan analysis follow up|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences from the follow up scan are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
75573953|NCT02015832|Radiation|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
76048193|NCT02473523|Device|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
75427324|NCT01474525|Device|Home Blood Glucose Telemonitoring System|"The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers."
75427325|NCT01474564|Other|Blood draw|Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
75427326|NCT01474577|Other|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
75427327|NCT01474603|Dietary Supplement|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
75427328|NCT01474616|Other|Sit-to-Stand Activity|Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
75725505|NCT05279079|Diagnostic Test|Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis|Panel of microRNA and pancreatic enzyme biomarkers
76048194|NCT02473523|Device|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
75427329|NCT01474629|Dietary Supplement|probiotic-based dietary supplement|24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day
75427330|NCT01474629|Dietary Supplement|placebo|24 trained men receive a placebo for 16 weeks with same dosage compared to active group
75427331|NCT01474642|Drug|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
75573954|NCT02015832|Device|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
75573955|NCT02015832|Device|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
75573956|NCT02015832|Device|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
75573957|NCT00542568|Biological|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
75573958|NCT04653779|Drug|Evogliptin 5mg/Metformin 1000mg|Size reduction of a tablet formulation
75573959|NCT00542607|Drug|levocetirizine dihydrochloride|
75573960|NCT00542646|Procedure|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
75725506|NCT00990795|Drug|cyclosporine|Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
76048195|NCT02473523|Other|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
76048196|NCT02473523|Other|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
76048197|NCT02473523|Other|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
75427332|NCT01474642|Drug|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
75573961|NCT04653428|Device|Interventional treatment of tricuspid regurgitation|Interventional treatment for tricuspid regurgitatin with CE-certified products, e.g. edge-to-edge repair
75573962|NCT04685031|Drug|Nitroglycerin ointment|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
75573963|NCT04685031|Drug|Clobetasol Topical|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
75573964|NCT01972932|Dietary Supplement|Bio K+® 2 capsules orally (or via nasogastric tube)|Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
75573965|NCT01972932|Dietary Supplement|Placebo|Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
75573966|NCT04653311|Device|Endomina®|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
75573967|NCT00542763|Drug|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
75725507|NCT00990795|Drug|saline solution|Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
75725508|NCT00622700|Drug|Teriflunomide|Film-coated tablet Oral administration
75725509|NCT00622700|Drug|Placebo|Film-coated tablet Oral administration
75878187|NCT03073005|Other|Simulation-based Mastery Learning (SBML)|The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
76048198|NCT02473523|Other|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
76048199|NCT02316769|Procedure|King Vision video laryngoscope|Patient intubated with the King Vision Video Laryngoscope
76048200|NCT02316769|Procedure|McGrath MAC video laryngoscope|Intubation with the McGrath MAC video laryngoscope
75573968|NCT04653155|Behavioral|Cognitive behavioural therapy for insomnia|Cognitive behavioural therapy for insomnia
75573969|NCT00557804|Device|MUSE clinical system|non-invasive external monitoring device
75725510|NCT00538473|Biological|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
75573970|NCT01854684|Drug|Temoporfin|Given IV
75573971|NCT01854684|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
75573972|NCT01854684|Drug|Photodynamic Therapy|Undergo intraoperative PDT
75573973|NCT01854684|Other|Laboratory Biomarker Analysis|Correlative studies
75573974|NCT01854684|Other|Pharmacological Study|Correlative studies
75725511|NCT00538473|Biological|Fluarix™|Single dose, intramuscular injection
75725512|NCT04004091|Biological|Spermine|Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
75725513|NCT00990873|Genetic|gene expression analysis|
75725514|NCT00990873|Genetic|microarray analysis|
75725515|NCT00990873|Genetic|reverse transcriptase-polymerase chain reaction|
75725516|NCT00990873|Other|laboratory biomarker analysis|
75725517|NCT04025229|Behavioral|HIIT exercise|High intensity interval training (4 to 6 sessions) prior to surgery
75427333|NCT01474655|Procedure|Pars plana vitrectomy and removal of epiretinal membrane|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. Visualization of the fundus was achieved using a wide-angle viewing system. After core vitrectomy, induction of a posterior vitreous detachment was conducted using a 23-gauge angulated dissecting needle in cases without presence of a posterior vitreous detachment. The epiretinal membrane and internal limiting membrane was removed in all eyes. In most cases, internal limiting membrane was removed without the assistance of staining dye. Indocyanine green dye was used to facilitate the removal of internal limiting membrane in some of the cases.
75725518|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
75725519|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
75725520|NCT00831506|Drug|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
75725521|NCT02548130|Other|MELD score|introduction of MELD score
75725522|NCT00990951|Drug|Senna alexandrina and associations|"Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day"
75427334|NCT01474668|Drug|GDC-0941|Single oral dose\n \n\n\n\n
75725523|NCT00828620|Other|Imaging study|PET-CT
75878188|NCT03577340|Other|implant of cardiac device as per guidelines|Observation of performance to validate matrix
75427335|NCT01474694|Other|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
75427336|NCT01474707|Behavioral|Group one|Group 1 will view the knowledge-based video only
75427337|NCT01474707|Behavioral|Group two|Group two will view the motivational video only
75427338|NCT01474707|Behavioral|Group three|Group three will view both knowledge-based and motivational videos
75427339|NCT01474707|Behavioral|Group four|Group four will view the printed educational pamphlet and will not view either video
75725524|NCT02842359|Drug|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
75725525|NCT02842359|Drug|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
75725526|NCT02842359|Drug|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
75725527|NCT00823784|Procedure|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
75725528|NCT00823784|Procedure|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
75725529|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT"
75878189|NCT03582878|Drug|Sirolimus Oral Product|Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
75878190|NCT03582878|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
75878191|NCT01331057|Other|NEEL test|An assessment for children in French with items extracted from the NEEL test
75878192|NCT01331057|Other|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
75573975|NCT04653077|Other|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
75573976|NCT01827579|Biological|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
75573977|NCT04653233|Device|3D Systems Touch Haptic Simulator|This simulator is computer-aided and allows us to see this application on the computer screen while practicing with a haptic arm. It gives real-like feedback in hand manipulations. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option.
76048201|NCT02473445|Drug|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
76048202|NCT02473367|Drug|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
76048203|NCT02473367|Drug|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
76048204|NCT02473367|Drug|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
75427340|NCT01474720|Drug|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
75427341|NCT01474733|Other|educational intervention|series of lectures and workshops on health literacy
75427342|NCT01474759|Behavioral|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
75573978|NCT00542802|Drug|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
75573979|NCT00542802|Drug|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
75573980|NCT04652648|Drug|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID or 41 observation for 10 days
75573981|NCT00542841|Procedure|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
75573982|NCT00542958|Drug|NK012|9.0, 12.0, 16.0, 21.0, 28.0 mg/m^2, and to be determined. Intravenous infusion
76048205|NCT02316613|Drug|Rituximab|
76048206|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
76048207|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
76048208|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
76048209|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
76048210|NCT02355691|Device|PREVENA|The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
76048211|NCT02473289|Drug|Sirukumab 50 mg|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
76048212|NCT02473289|Drug|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
76048213|NCT02354599|Drug|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
76048214|NCT02354599|Drug|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
76048215|NCT02354599|Drug|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
75427343|NCT01474759|Behavioral|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
75573983|NCT04652492|Drug|Tislelizumab in combination with cTACE|On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
75573984|NCT01185210|Dietary Supplement|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
75573985|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
75573986|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
75573987|NCT04652336|Procedure|laparoscopic sleeve gastrectomy|Comparator arm - will receive standard laparoscopic sleeve gastrectomy
75573988|NCT04652336|Procedure|ligamentum teres cardiopexy with sleeve gastrectomy|experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
75573989|NCT00543036|Device|H-Coil deep TMS|
75573990|NCT04652297|Drug|HS-10356|Single dose of HS-10356
75573991|NCT04652297|Drug|Placebo|Single dose of Placebo
75427344|NCT01474759|Other|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
75573992|NCT04652297|Drug|HS-10356|Multiple doses of HS-10356
75573993|NCT04652297|Drug|Placebo|Multiple doses of Placebo
75573994|NCT04652024|Device|Anorectal manometry|, patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
75573995|NCT00543075|Drug|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
75573996|NCT04651907|Other|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
75573997|NCT04651907|Other|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints.
75878193|NCT01331057|Other|Interview|For parents of children include in the study: A semi -structured interview
75427345|NCT01474759|Behavioral|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
75427346|NCT01474785|Drug|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
75427347|NCT01474785|Other|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
75427348|NCT01474785|Procedure|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
75427349|NCT01474837|Behavioral|Intervention: Exercise and motivational interviewing|12 sessions of exercise with MI
75573998|NCT00543114|Drug|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
75573999|NCT00543114|Drug|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
75574000|NCT00543114|Drug|Rituximab|Given intravenously on Day 1 of each 28 day cycle
75574001|NCT03454724|Device|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
75725530|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT"
75427350|NCT01474850|Procedure|lung recruitment maneuver|RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
75427351|NCT01474902|Drug|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
75427352|NCT01474928|Behavioral|patient role played community video|Group two viewed the patient role played community video
75574002|NCT03454724|Device|Xience EES Everolimus Eluting Coronary Stent System|Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
75574003|NCT00543153|Behavioral|Interview|Interview lasting approximately 30-45 minutes.
75574004|NCT04652258|Drug|Actemra|Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
75574005|NCT01014546|Drug|Arsenic Trioxide|Given PO
75574006|NCT01014546|Dietary Supplement|Ascorbic Acid|Given PO
75574007|NCT01014546|Other|Laboratory Biomarker Analysis|Correlative studies
75574008|NCT01014546|Other|Pharmacological Study|Correlative studies
75574009|NCT04652141|Diagnostic Test|AsthmaTuner|AsthmaTuner consists of a treatment-adjusting algorithm that gives patient immediate feedback on the status of symptom control (i.e. controlled, partly controlled or uncontrolled) and a treatment recommendation with an image of the correct inhaler or other type of medication and the dose based on lung function (FEV1) and symptom scores (0-4 points).
75574010|NCT04651946|Diagnostic Test|DNA methylation testing|Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum
75574011|NCT00845442|Device|pacemaker|Placement of pacemaker over the chest wall to stimulate the larynx in the neck via a tunneled electrode
75574012|NCT04651829|Other|oral food challenge 1|First oral food challenge after a short period of several weeks of avoidance of CMP to confirm diagnosis of CMPA
75574013|NCT04651829|Other|oral food challenge 2|Second oral food challenge to test tolerance after 4 months of age if confirmed CMPA
75574014|NCT04651517|Device|XACT ACE Robotics study arm|Subjects will undergo lung procedures with the physician utilizing the XACT ACE Robotic System.
75574015|NCT00543231|Drug|G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide|
75574016|NCT00557843|Drug|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
75574017|NCT00557843|Drug|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
75725531|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT"
75427353|NCT01474928|Behavioral|both videos group|Group three viewed both the knowledge and community videos
75427354|NCT01474928|Behavioral|Pamphlet group|Group four read an educational pamphlet only
75427355|NCT01474928|Behavioral|physician-led knowledge video|Group one viewed a physician-led knowledge video
75427356|NCT01474928|Behavioral|Community video group|Group two viewed the patient role played community video
75427357|NCT01474928|Behavioral|knowledge video|Group one viewed a physician-led knowledge video
75427358|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks
75427359|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks
75574018|NCT04651478|Behavioral|Action Observation+Motor Imagery through BCI|Patients will undergo the treatment through the NeuRow platform. NeuRow is a gamified Brain-Computer Interface training paradigm in Virtual Reality (or neurogame) that allows patients to perform the same actions as they would do in real-life by imaging the movement. In NeuRow, patients will see a boat and two high fidelity virtual arms gripping two oars in the first-person view. Patients will have to imagine the movement of each corresponding hand to rotate each oar and progress, observing the movement imagined on screen. The goal of the task is to collect as many flags as possible in a fixed amount of time. In order to improve adherence, the number of flags collected will be recorded in each session. It will be able to adapt the boat speed, turn speed, and cut-off angle, to help patients not to deviate in excess from the target. The treatment itself will be performed for 20 minutes each session, divided into 4 series of 5 minutes to prevent fatigue.
75725532|NCT01564017|Biological|Allergovac depot|"depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT"
75725533|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT"
75725534|NCT01564017|Biological|Allergovac depot|"Sterile suspension for subcutaneous injection.~Same number of administration as the active groups"
75427360|NCT01474941|Drug|PF-04620110 or Placebo|Repeat Arm 1 or Arm 2
75427361|NCT01474967|Drug|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
75725535|NCT00828698|Other|No intervention|
75725536|NCT04044014|Device|Gellan sheet|Gellan sheet.
75725537|NCT04044014|Device|Gellan fluid gel|Gellan fluid gel.
75725538|NCT04044014|Device|Mepitel One|Control dressing-- Mepitel One.
75427362|NCT01474967|Drug|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
75427363|NCT01475006|Drug|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
75427364|NCT01475019|Drug|Orlistat|Tablet, 120 mg, three times daily, for six months
75427365|NCT01475019|Drug|Sibutramine|Tablet, 10 mg, once daily, for six months
75574019|NCT04651478|Behavioral|Action Observation through non-related with movement illustrations|The same configuration will be applied to simulate a BCI task, but playing a video about graphic illustrations, people's faces, and landscapes, never related to human movement. They will address interesting and changing topics to avoid patient's boredom. The control session will last 20 minutes, also divided into 4 series of 5 minutes and the therapist will give the instructions of observing and relax.
75878194|NCT03579524|Procedure|Erector Spinae Plane Block|At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
75574020|NCT00419328|Drug|NGR-hTNF|"Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~starting dose: 0.2 μg/m2~following doses: 0.4, 0.8 and 1.6 μg/m2.~number of patients: 4 per dose level~Step 2:~starting dose: 3.2 μg/m2~following doses: 6.4 and 12.8 μg/m2~number of patients: 3 per dose level~Step 3:~starting dose: 19.2 μg/m2~following doses: 28.8, 43.2 and 64.8 μg/m2~number of patients: 3 per dose level~Step 4:~starting dose: 86.2 μg/m2~following doses: 114.6 and 152.4 μg/m2~number of patients: 3 per dose level"
75725539|NCT00991107|Drug|HE3286|HE3286 20 mg (10 mg BID) for 28 days
75725540|NCT00828776|Biological|Heparin sodic - Cristália|5000UI/mL
75725541|NCT00828776|Biological|heparin - Liquemine (Roche)|5000UI/mL
75427366|NCT01475019|Behavioral|Diet and physical exercise|Hypocaloric diet and regular physical exercise
76024533|NCT03541512|Behavioral|Mindfulness + Education|"Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
75427367|NCT01475032|Drug|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
75427368|NCT01475032|Drug|Beclomethasone (BDP)|Beclomethasone (BDP) for 12 weeks
75427369|NCT01475032|Drug|Beclomethasone (BDP) + Formoterol Fumarate (FF)|free combo Beclomethasone (BDP) + FF for 12 weeks
75427370|NCT01475084|Device|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|"The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way."
75427371|NCT01475149|Other|Phlebotomy|Subjects will have blood drawn at each of the 3 study visits.
75427372|NCT01475188|Drug|Allergovit|commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
75725542|NCT00622466|Drug|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
75427373|NCT01475188|Other|placebo|placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
75427374|NCT01475201|Behavioral|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
75427375|NCT01475201|Behavioral|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
75725543|NCT00622466|Drug|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
75725544|NCT02617251|Other|No intervention|
75725545|NCT02550158|Procedure|Educational program EDU-MICI|
75725546|NCT04043858|Drug|Midodrine 2.5 mg tab|Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
75725547|NCT05359419|Combination Product|aminolevulinic acid hydrochloride gel, 10%|10% ALA with Red Light
75574021|NCT04651751|Behavioral|Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial|Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
75574022|NCT00543270|Device|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
75878195|NCT03579524|Procedure|Serratus Anterior Plane Block|At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
76048216|NCT02316223|Behavioral|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
76048217|NCT02286895|Biological|pentavalent rotavirus vaccine (PRV)|Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
75574023|NCT00543270|Procedure|Open Surgery|Open surgical abdominal aortic aneurysm repair
75574024|NCT04651556|Drug|Magnesium Sulfate & bupivacaine|intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
76048218|NCT02286895|Biological|measles vaccine (MV)|A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
76048219|NCT02286895|Biological|yellow fever vaccine (YFV)|A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
75427376|NCT01475227|Drug|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
75427377|NCT01475227|Drug|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
75427378|NCT01475266|Drug|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
75427379|NCT01475266|Drug|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
75427380|NCT01475279|Drug|Warfarin; Dantonic|Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
75427381|NCT01475292|Drug|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
75574025|NCT04651556|Drug|paracetamol & ketorolac|parenteral analgesics
75574026|NCT02587767|Device|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
75574027|NCT02587767|Device|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
75427382|NCT01475292|Drug|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
75427383|NCT01475292|Drug|Placebo|Placebo administered via a nebuliser once daily for 14 days
75427384|NCT01475318|Drug|mifepristone|200 mg mifepristone on day 1
75427385|NCT01475318|Drug|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
75427386|NCT01475318|Drug|Misoprostol|misoprostol 800mcg PV on day 3
75574028|NCT04651322|Device|upper robot Robot assisted upper arm training(RAT)|"The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~*Robot Assisted Arm training + Conventional occupational therapy"
75574029|NCT04651322|Behavioral|Conventional therapy|The control group received the usual conventional therapy *Only Conventional occupational therapy
75574030|NCT03456765|Diagnostic Test|Ultrasound|US will be made to assess kidneys
75574031|NCT04651049|Drug|propranolol|This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.
75574032|NCT04651049|Device||
75574033|NCT02497443|Biological|Autologous mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
75574034|NCT04651205|Dietary Supplement|vitamin B1 and magnesium supplements|vitamin B1 - 100 mg/day magnesium - 400 mg/day
75878196|NCT02238704|Dietary Supplement|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
75878197|NCT02238704|Dietary Supplement|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
75878198|NCT03577262|Other|[11C]-UCB-J|IV radioligand given prior to and during positron emission tomography (PET) scan
75878199|NCT01331135|Drug|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
75878200|NCT03577184|Drug|Metformin/Vildagliptin|Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.
75878201|NCT02849171|Device|PET scan|
75878202|NCT02849171|Radiation|C-Choline|
75878203|NCT03888885|Behavioral|Sport Education Model|A total number of 25 lecturers participated in the 12-hour CPD workshop on Sport Education curriculum on June 2018. The content of the workshop focused on the development of a Sport Education season, the changing roles of teachers and students, the assessment of personal and social responsibility, and the application of sport education season and related pedagogies on handball, badminton, swimming and physical conditioning. The Sport Education courseware and class materials were then designed by the eligible lecturers. The intervention was lasted for 10-lesson, 1-day per week and the duration for each lesson was around 90 minutes. The specific five phases in Sport Education model of team selection, teacher-directed, pre-season, formal competition and cumulating event were included. The eligible lecturers led the lessons according to the designated course wares and lesson plans for each sport.
75878204|NCT02848664|Device|Dysphagia retraining with device|Patients used the device for 60 trials of retraining swallowing at home each day and also had the device turned on throughout the day in automatic mode to intermittently trigger every few minutes to trigger a swallow for saliva control
75574035|NCT03456648|Drug|apixaban|non-vitamin K oral anticoagulant (NOAC)
75574036|NCT04651283|Other|Traditional seat group|"Each child in the control group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~Building towers and shapes with different textures weights and bright colors.~Inserting different shapes in the correct hole.~Dropping pellets.~Stringing beads.~Copying square and triangle.~Opening the bottle and close it.~Folding and Crumpling paper.~Cutting paper by scissors.~Tracing line and connecting dots.~Reaching above the level of shoulder.~Reaching across the midline.~Squeezing water out of a sponge.~Buttoning and unbuttoning button.~Playing clapping games.~Turning pages in a book.~Lacing string.~Picking up a small piece of food and bringing it into the palm.~Moving a penny from the palm to the fingers.~Removing socks.~Brush the teeth."
75725548|NCT05359419|Combination Product|aminolevulinic acid HCl topical solution, 20%|20% ALA with Blue Light
75725549|NCT00823862|Drug|SD-101|Intramuscular (IM)
75878205|NCT03635879|Other|MCTprocal medical food|32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
75878206|NCT03635879|Other|Milk/tricaprilin oil blend|154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
75725550|NCT00823862|Drug|ribavirin|oral, 2 times per day, for 2 months
75725551|NCT00991263|Genetic|gene expression analysis|
75725552|NCT00991263|Genetic|polymerase chain reaction|
75725553|NCT00991263|Other|laboratory biomarker analysis|
75725554|NCT02548598|Procedure|Endoscopic sinus surgery|This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
75878207|NCT03635879|Other|AC-1207|AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
75878208|NCT03635879|Other|AC-1205|AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
75878209|NCT03635879|Other|AC-1206|AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
75725555|NCT00828932|Drug|Lorcaserin|
75725556|NCT00537771|Drug|Anastrozole|1 mg once daily oral dose
75725557|NCT00537771|Drug|Tamoxifen|20 mg once daily oral dose
75725558|NCT00829088|Drug|AZD2066|1 dose oral solution
75878210|NCT03635879|Drug|AC-1202|AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
75878211|NCT02238860|Drug|Entacavir|Entacavir-0.5 mg ,OD,for
75574037|NCT04651283|Other|Adaptive seating equipment group|"Each child in the study group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~Building towers and shapes with different textures weights and bright colors.~Inserting different shapes in the correct hole.~Dropping pellets.~Stringing beads.~Copying square and triangle.~Opening the bottle and close it.~Folding and Crumpling paper.~Cutting paper by scissors.~Tracing line and connecting dots.~Reaching above the level of shoulder.~Reaching across the midline.~Squeezing water out of a sponge.~Buttoning and unbuttoning button.~Playing clapping games.~Turning pages in a book.~Lacing string.~Picking up a small piece of food and bringing it into the palm.~Moving a penny from the palm to the fingers.~Removing socks.~Brush the teeth."
75574038|NCT02428491|Biological|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
76048220|NCT02286895|Biological|meningitis conjugate vaccine (PsA-TT-5μg)|A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
75574039|NCT00557921|Drug|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
75574040|NCT00557921|Drug|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
75574041|NCT03456609|Drug|shenqifuzheng injection|500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
75574042|NCT03456609|Drug|Sodium Chloride Injection 0.9%|500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
75574043|NCT02346162|Behavioral|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI </=25, and when pregnant, weight gain within IOM guidelines.
75574044|NCT02346162|Other|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
75574045|NCT02324283|Drug|desflurane|"Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia."
75574046|NCT02324283|Drug|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
75574047|NCT00557960|Drug|Mixed salts of a single-entity amphetamine|
75574048|NCT00557960|Drug|Atomoxetine hydrochloride|
75574049|NCT00543426|Drug|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
75574050|NCT00543426|Drug|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
75574051|NCT00543465|Drug|MK0782|
75574052|NCT00557999|Other|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
75574053|NCT00558077|Drug|Metformin plus clomiphene citrate|Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
75574054|NCT00558077|Procedure|Laparoscopic ovarian drilling|Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
75574055|NCT00558116|Device|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
75574056|NCT04650971|Biological|UniFluVec|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
75574057|NCT04650971|Biological|Placebo|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
76048221|NCT02472977|Drug|Ulocuplumab|
76048222|NCT02472977|Drug|Nivolumab|
76048223|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
75574058|NCT00543504|Drug|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
75427387|NCT01475344|Drug|Human Fibrinogen Concentrate|"intravenous infusion over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
75574059|NCT00543504|Drug|Sorafenib|200 mg By Mouth Daily for 28 Days
75574060|NCT00543504|Drug|Erlotinib|50 mg By Mouth Daily for 28 Days.
75427388|NCT01475344|Drug|Placebo|"intravenous infusion over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
75574061|NCT00543504|Drug|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
75725559|NCT00831740|Other|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
75427389|NCT01475357|Other|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
75427390|NCT01475357|Other|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
75427391|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
75574062|NCT00543504|Drug|Lapatinib|250 mg By Mouth Daily for 21 Days.
75574063|NCT00543504|Drug|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
75574064|NCT00543504|Drug|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
75574065|NCT04651127|Drug|Toripalimab + Chidamide|In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
75878212|NCT02238860|Drug|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
75878213|NCT01333709|Drug|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
76048224|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
75574066|NCT04650776|Other|Heat strain|The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
75574067|NCT00543621|Other|daily enteral nutritional product and/or behavioral changes|
75574068|NCT00543660|Procedure|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
75574069|NCT04650737|Drug|single shot ESBP with dexmedtomidine|Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
75574070|NCT04650737|Drug|continous ESPB|Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
75574071|NCT00543738|Drug|MK0767|
75574072|NCT04650503|Other|No intervention|No intervention
75725560|NCT00831740|Other|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
75725561|NCT00831896|Biological|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
75427392|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1.
75878214|NCT01333709|Other|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
76048225|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
75427393|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1
75427394|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
75427395|NCT01475396|Behavioral|exercise|
75427396|NCT01475409|Biological|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
75574073|NCT00543816|Drug|MK0767|
75574074|NCT04650620|Device|Plenhyage® thin|0.75%
75725562|NCT00823940|Drug|GSK1362885|5 - 100mg of GSK1362885 or placebo
75725563|NCT00823940|Drug|GSK1362885|100 - 600mg or placebo
75725564|NCT00823940|Drug|Glucagon|0.5mg IV bolus
75878215|NCT01333709|Radiation|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
75574075|NCT04650620|Device|Plenhyage® medium|2%
75574076|NCT04650620|Device|Plenhyage® strong|2.5%
75725565|NCT00823940|Drug|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
75725566|NCT03857828|Other|semen sample|• seminal sample for measuring clusterin level.
76048226|NCT02059395|Other|Mastery based learning|Participants are allowed to follow the course content at their own speed
76048227|NCT02059395|Other|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
75574077|NCT04650386|Behavioral|Psychosocial support determined by adaptive treatment algorithm|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
75725567|NCT04043546|Behavioral|aerobic+resistance exercise training program|Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
76048228|NCT02059239|Drug|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
76048229|NCT02059239|Drug|Carmustine|300 mg/m2 on Day -6
76048230|NCT02059239|Drug|Etoposide|100 mg/m2 on days -5 to -2
75574078|NCT00665769|Other|Hypercapnia|transcutaenous CO2 50-60 mm Hg
75574079|NCT00665769|Other|Normocapnia|transcutaneous CO2 35-45 mm Hg
76048231|NCT02059239|Drug|Melphalan|140mg/m2 on Day -1
76048232|NCT02059239|Drug|Cytarabine|200 mg/m2 on days -5 to -2
75725568|NCT00831974|Drug|masitinib (AB1010)|3 mg/kg/day
75725569|NCT00831974|Drug|masitinib (AB1010)|6 mg/kg/day
75427397|NCT01475422|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
76048233|NCT02059239|Drug|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
75878216|NCT01333709|Radiation|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
76048234|NCT02059239|Biological|Autologous Stem Cell Transplantation|
76048235|NCT02059239|Biological|Allogeneic Stem Cell Transplantation|
75427398|NCT01475422|Behavioral|Usual Care|Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
75427399|NCT01475435|Procedure|non- surgical periodontal treatment|scaling and root planning
75427400|NCT01475435|Procedure|Prophylaxis|Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
75427401|NCT01475448|Other|Long distance training|Long distance training during four months, 3 times per week
75427402|NCT01475448|Other|Walking training|Walking training during four months, three times per week
75427403|NCT01475526|Other|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
75427404|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
75427405|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
75427406|NCT01475539|Biological|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
75574080|NCT04650308|Diagnostic Test|Neuropeptide Y examination|This examination was conducted by drawing blood serum from research subjects and performing centrifugation with 2000-3000 revolutions per minute (RPM) for 20 minutes. Furthermore, we carried out blood serum tests to check neuropeptide Y levels using the Human Neuropeptide Y Enzyme-link Immunosorbent Assay (ELISA) kit
76048236|NCT02059239|Drug|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
75574081|NCT00543933|Drug|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
75574082|NCT04650347|Procedure|visualized internal urethrotomy|incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.
75574083|NCT00543972|Drug|AVE9633|Intravenous Infusion
75574084|NCT04650230|Device|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices|
75725570|NCT00829322|Drug|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
75725571|NCT00829322|Drug|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
75725572|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
75725573|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
75725574|NCT02513667|Drug|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
76048237|NCT04722783|Behavioral|Parent-Child-Interaction Therapy adapted for children with autism spectrum disorder (PCIT-A)|PCIT is a behavioral family therapy approach emphasizing the integration of traditional child play therapy techniques within a behavioral framework of parent-child therapy and was developed by Eyberg (1988). It is based on attachment theory, social learning theory, and parenting styles theory. Recently, the intervention was adapted to children with ASD by our team (McNeil, Quetsch, & Anderson, 2019). PCIT-A will last about 8 months, 1 day per week, 60min per day (see Study Protocol, Fig. 2).
75574085|NCT02909010|Device|BIS™ Brain Monitoring System|The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
75574086|NCT02909010|Other|RASS|control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
75574087|NCT04649762|Behavioral|activating consciousness technique (hypnosis)|activating consciousness technique (hypnosis)
75725575|NCT02513667|Radiation|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
75878217|NCT01333709|Procedure|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
75878218|NCT02239172|Biological|PA83-FhCMB|
75427407|NCT01475552|Drug|Abciximab|Patients, who showed PRU >270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
75427408|NCT01475552|Drug|control|"Patients,who showed PRU >270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.~Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd"
75427409|NCT01475578|Drug|STA-1|STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
75427410|NCT01475578|Drug|Ergoloid Mesylates tablet|Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
75574088|NCT00544011|Biological|bevacizumab|
75574089|NCT00544011|Drug|capecitabine|
75574090|NCT00544011|Drug|fluorouracil|
75574091|NCT00544011|Drug|irinotecan hydrochloride|
75574092|NCT00544011|Other|diagnostic laboratory biomarker analysis|
75574093|NCT04650113|Combination Product|MTA material|Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
75574094|NCT00544050|Drug|Levetiracetam|
75574095|NCT04649996|Procedure|Appendectomy|comparison between operative and conservative treatment
75574096|NCT02908971|Behavioral|soy based formula at infancy|The intervention is only past history of soy consumption
75574097|NCT04649723|Drug|Rifampin|single oral dose, 600 mg, fasted.
75574098|NCT04649723|Drug|SHR1459|single oral dose, 200 mg, fasted.
75725576|NCT00829400|Behavioral|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
75725577|NCT00829400|Behavioral|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
75725578|NCT00829478|Behavioral|Decision Aid for Atrial Fibrillation|Single contact educational session
75574099|NCT02908893|Behavioral|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
75574100|NCT04649684|Device|Conventional robot-assisted gait training|They got conventional robot-assisted gait training, guidance force given equally to both limbs, and then gradually reduce the degree of guidance force to the extent that the patient is tolerable equally .during 4- week treatment session
75574101|NCT04649684|Device|Lower CIMT robot-assisted gait training group|They got robot-assisted gait training based on CIMT concept; 100% guidance force is given on the unaffected side and then verbal ques are given not to contract unaffected muscle voluntarily as much as possible are provided, automatically according to the predetermined joint trajectory. In contrast at the affected side, gradually reduce the degree of guidance force to the extent that the patient is tolerable.
75574102|NCT02909088|Drug|Ecopipam 50mg|
75574103|NCT02909088|Drug|Ecopipam 100mg|
75574104|NCT04649528|Behavioral|Effective endurance 4x4 training - Supervised|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
75574105|NCT04649528|Device|Effective endurance 4x4 training - APP|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
75574106|NCT04649645|Other|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
75574107|NCT04649645|Other|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
75574108|NCT04649645|Other|NOT SMOKING|Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
75574109|NCT00544128|Drug|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
75725579|NCT00829478|Other|Usual Care|Usual Care
75725580|NCT00991419|Drug|[18F]AZD4694|[18F]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
75725581|NCT00829556|Device|Integuseal|
75725582|NCT03823911|Drug|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|All approved direct-acting antivirals for hepatitis C will be used as the intervention.
75574110|NCT00544128|Drug|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
75574111|NCT00544206|Other|standard enteral feeding product|16 hrs daily x 5 days
75725583|NCT03823911|Procedure|Cardiac MRI|Cardiac MRI to assess for myocardial function and fibrosis
75725584|NCT00829634|Drug|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
75725585|NCT00829634|Drug|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
75574112|NCT00544206|Other|Diabetes specific feeding product|16 hrs daily for 5 days
75574113|NCT02908854|Other|Adding spices and herbs to school lunch vegetables|Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
75574114|NCT01240915|Drug|placebo|once every 7 days for 1- 3 doses
75574115|NCT01240915|Drug|MultiStem low dose|1-3 doses
75574116|NCT01240915|Drug|placebo|Single dose at week 8
75574117|NCT01240915|Drug|MultiStem low dose|Single dose at week 8
75574118|NCT01240915|Drug|placebo|Single dose Day 1
75574119|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
75574120|NCT01240915|Drug|placebo|Single dose at week 8
75574121|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
75574122|NCT01240915|Drug|placebo|Single dose Day 1
75574123|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
75574124|NCT01240915|Drug|placebo|Single dose at week 8
75725586|NCT05277753|Biological|Antigen-specific T cells CAR-T/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
75878219|NCT05202717|Device|PHENIX U4+|The newly developed domestic PHENIX U4+ is relatively small in size. In addition to the smooth muscle stimulation function of the traditional therapy device, its electrical stimulation waveform setting can also stimulate the striated muscle, and adds more than 10 A3 reflex treatment options, which can inhibit Urinary reflex, resulting in symptoms related to urinary incontinence in the patient.
75878220|NCT05202717|Device|Traditional pelvic floor treatment instrument|Traditional pelvic floor treatment instrument commonly used in clinical practice
75878221|NCT02969382|Drug|SEP-363856|One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
75878222|NCT02969382|Drug|Placebo - Cap|One Placebo capsule daily for 4 weeks
75427411|NCT01475591|Behavioral|Web-based multimodal rehabilitation based on cognitive based principles|The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
75427412|NCT01475604|Device|Ivivi Torino II|Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
75427413|NCT01475604|Device|Ivivi Torino II|Sham treatment for 4 weeks post-surgery
75427414|NCT01475617|Dietary Supplement|AquaVanta Chewable Tablet|AquaVanta Chewable Tablet (proprietary formulation of vitamin and minerals) 2 times a day for 6 months
75427415|NCT01475617|Dietary Supplement|Flinstones Complete|Flinstones Complete Multivitamin 2 times a day for 6 months
75427416|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
75427417|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
75574125|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
75427418|NCT01475617|Dietary Supplement|Twin Labs Iron Caps|Twin Labs Iron Caps (Ferrous Fumarate) 18 mg per day for menstruating women for 6 months
75427419|NCT01475617|Dietary Supplement|Rexall Vitamin B12 Tablet|Rexall Vitamin B12 Tablet (Cyanocobalamin 500 mcg)per day for 6 months
75427420|NCT01475630|Procedure|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
75427421|NCT01475630|Procedure|control|relaxation
75574126|NCT00544245|Behavioral|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
75878223|NCT03579368|Device|Symfony implantation|Bilateral Symfony IOL Implantation
76024534|NCT03541512|Behavioral|Education|"Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
75427422|NCT01475656|Drug|levetiracetam|Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
75427423|NCT01475669|Biological|Fibrinogen Concentrate (Human) (FCH)|Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
75427424|NCT01475669|Biological|Placebo|Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
75427425|NCT01475695|Drug|14C GSK2251052|1500 mg iv dose GSK2251052
75427426|NCT01475708|Drug|Doxycycline|100 mg PO bid, 14 days
76024535|NCT03530267|Drug|Aflibercept + mLV5FU2|Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
75427427|NCT01475760|Other|K2CG chewing gum (20mg chitosan)|All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14
75427428|NCT01475760|Other|K2CG chewing gum (60mg chitosan)|"Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:~Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).~If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42"
75427429|NCT01475799|Device|Replacement of the Aortic Stenotic Valve|Treatment for patients with Severe Aortic Stenosis.
75427430|NCT01475812|Other|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
75427431|NCT01475864|Procedure|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
75427432|NCT01475877|Drug|Bromfenac|Bromfenac 0.09% 1 drop in study eyes q day
75427433|NCT01475890|Dietary Supplement|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
75427434|NCT01475890|Dietary Supplement|Placebo|Once a day for 12 months.
75427435|NCT01475903|Procedure|Longitudinal sleeve gastrectomy|The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
75427436|NCT01475916|Behavioral|Educational program: consultation with paediatric pulmonologist|Longitudinal prospective study
75427437|NCT01475929|Dietary Supplement|Probiotic supplement|A single strain probiotic supplement given at two doses
75427438|NCT01475942|Dietary Supplement|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
75574127|NCT00558155|Drug|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
75574128|NCT00558155|Drug|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
75574129|NCT00558155|Drug|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
75574130|NCT00558155|Drug|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
75574131|NCT05476432|Procedure|HAIC|The microcatheter was advanced into the hepatic artery, and patients were transferred to the inpatient ward for drug infusion via the hepatic artery
75427439|NCT01475968|Other|Ultrafine Air Pollution Particulate Matter|Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
75427440|NCT01475968|Other|Filtered Air|Filtered Air
75427441|NCT01475981|Drug|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
75427442|NCT01475994|Other|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
75427443|NCT01475994|Other|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
75427444|NCT01476007|Drug|oral Cobalamin (vitamin B12)|Intervention group: oral Optovite® B12 1000 gammas.
75427445|NCT01476007|Drug|intramuscular Cobalamin (vitamin B12)|Control group: intramuscular Optovite® B12 1000 gammas.
75725587|NCT00824096|Procedure|Bronchoscopy|The patients in our ICU intubated for > 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3~4 days even with CLV <24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
75725588|NCT00991497|Device|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
75725589|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
75725590|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
75427446|NCT01476033|Dietary Supplement|nutraceutical group|6 capsules of supplement or placebo for 8wk
75427447|NCT01476046|Drug|GSK1995057 single dose|Single intravenous dose
75574132|NCT05476432|Drug|FOLFOX 2d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
75574133|NCT05476432|Drug|FOLFOX 1d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 23 hours
75574134|NCT02908815|Device|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
75574135|NCT02908815|Device|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
75574136|NCT01239745|Drug|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
75574137|NCT01239472|Drug|Everolimus|Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
75725591|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
75725592|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
75725593|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
75427448|NCT01476046|Drug|Placebo|Single intravenous dose
75427449|NCT01476059|Other|Telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
75427450|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
75427451|NCT01476072|Other|MRI scan|MRI scan only, methodology study with no other intervention
75427452|NCT01476085|Radiation|ML10|[18F]ML10 radioligand apoptosis biomarker
75427453|NCT01476098|Drug|Placebo|SB-705498 placebo
75427454|NCT01476098|Drug|SB-705498|400 or 600mg oral SB-705498
75427455|NCT01476124|Drug|morphine Placebo|Morphine Placebo
76048238|NCT04722783|Behavioral|Early Start Denver Model (ESDM) intervention|ESDM intervention provides intensive teaching by trained therapists and parents during natural play and relationship-focused daily routines. It is evidence-based and uses principles of developmental psychology and applied behavior analysis. It was designed for toddlers and preschoolers with autism spectrum disorder by Rogers and Dawson (2010). The first intensive part of ESDM intervention (20h per week) will last 40 weeks of intervention within a period of 12 months. It includes 2 days per week for 6h a day clinic therapy, and 5 days per week for 1h homework tasks, and 2 days per week for 1.5h an early special needs education at home. After the first 12 months, children receive the second lower intensity part of ESDM (7 hours per week). It includes 1 days every two weeks 1h day clinic therapy, and 5 days per week for 1h homework tasks, and 1 days per week for 1.5h an early special needs education at home (see Study Protocol, Fig. 2).
76048239|NCT04722783|Behavioral|1-hour ESDM|The active control group for PCIT-A stays in the ESDM day clinic therapy for the 12 hours per week while the PCIT-A group will receive 11 hours of ESDM day clinic therapy and 1 hour PCIT-A per week (see Study Protocol, Fig. 2).
76048240|NCT04722783|Behavioral|Early special needs education (ESNE)|The wait-list control group will receive early special needs education. It consists of a 90-minute visit at participants' homes once a week by an employee educated in early special needs education. As soon as space in ESDM is available children will receive the ESDM intervention (stepped-wedge design, see Study Protocol, Fig. 2).
75427456|NCT01476124|Drug|GEn 600 mg|Gabapentin enacarbil 600 mg
75427457|NCT01476124|Drug|Morphine|morphine extended release 60 mg
75427458|NCT01476124|Drug|GEn Placebo|Gabapentin enacarbil placebo
75427459|NCT01476137|Drug|GSK1120212|MEK inhibitor
75427460|NCT01476137|Drug|GSK2110183|AKT inhibitor
75427461|NCT01476163|Drug|migalastat HCl|150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl
75427462|NCT01476176|Drug|Experimental paracetamol|experimental paracetamol with caffeine
75427463|NCT01476176|Drug|Paracetamol marketed formulation|marketed formulation containing caffeine
75427464|NCT01476189|Drug|Experimental paracetamol formulation|experimental
75427465|NCT01476189|Drug|Marketed paracetamol|Marketed paracetamol
75427466|NCT01476189|Drug|Higher dose marketed paracetamol|Higher dose marketed paracetamol
75427467|NCT01476215|Drug|Paracetamol fast dissolution suspension|
75427468|NCT01476215|Drug|Paracetamol medium dissolution suspension|
75427469|NCT01476215|Drug|Paracetamol slow dissolution suspension|
75427470|NCT01476215|Drug|Paracetamol|
75427471|NCT01476228|Device|EEG recording|EEG recording
75427472|NCT01476241|Procedure|PEG tube placement|Percutaneous endoscopic gastrostomy
75427473|NCT01476280|Drug|palonosetron|0.075mg immediately before induction of anesthesia
75427474|NCT01476280|Drug|Ramosetron|0.3mg immediately before induction of anesthesia
75427475|NCT01476306|Other|Telemedicine|Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
75427476|NCT01476306|Other|Usual care|Patients in this group will receive care as they usually do with the physician.
75427477|NCT01476319|Other|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
75427478|NCT01476332|Drug|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
75427479|NCT01476332|Drug|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
75427480|NCT01476332|Drug|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
75427481|NCT01476358|Dietary Supplement|Vitamin A (retinyl palmitate).|"Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth"
75427482|NCT01476371|Behavioral|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here & Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
75427483|NCT01476384|Dietary Supplement|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
75427484|NCT01476384|Dietary Supplement|Placebo|250 ml water
75427485|NCT01476410|Drug|brentuximab vedotin|Given IV
75574138|NCT04649450|Other|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed just before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days at the neurosurgical ward they will receive music twice a day for 30 minutes.
75574139|NCT00544284|Drug|bortezomib|
75427486|NCT01476410|Drug|doxorubicin hydrochloride|Given IV
75427487|NCT01476410|Drug|vinblastine|Given IV
75574140|NCT00544284|Drug|temozolomide|
75574141|NCT00544284|Other|pharmacological study|
75427488|NCT01476410|Drug|dacarbazine|Given IV
75427489|NCT01476410|Procedure|quality-of-life assessment|Ancillary studies
75427490|NCT01476410|Genetic|DNA analysis|Optional correlative studies
75427491|NCT01476410|Genetic|RNA analysis|Optional correlative studies
75427492|NCT01476410|Radiation|fludeoxyglucose F 18|Correlative studies
75427493|NCT01476410|Procedure|positron emission tomography|Correlative studies
75427494|NCT01476410|Other|laboratory biomarker analysis|Optional correlative studies
75427495|NCT01476410|Other|immunohistochemistry staining method|Optional correlative studies
75574142|NCT02888275|Drug|Dexmedetomidine|
75574143|NCT02888275|Drug|normal saline|
75725594|NCT00824174|Behavioral|Questionnaire|1 questionnaire, about 15-20 minutes.
75427496|NCT01476410|Genetic|polymorphism analysis|Optional correlative studies
75574144|NCT03456531|Device|pulsed radiofrequency|The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes
75574145|NCT03456531|Drug|"NSAIDs ibubrofen,Aspirin"|"medical treatment as NSAIDs ibubrofen,Aspirin"
75574146|NCT02909049|Drug|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
75574147|NCT02909049|Drug|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
75574148|NCT02909049|Drug|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
75427497|NCT01476423|Drug|activated recombinant human factor VII|A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
75427498|NCT01476436|Other|Low carbohydrate dietary advice|Dietary advice
75427499|NCT01476436|Other|Continue usual diet|Dietary advice
75427500|NCT01476488|Drug|tacrolimus|
75427501|NCT01476514|Other|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
75427502|NCT01476527|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
75427503|NCT01476540|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
75574149|NCT02909049|Drug|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
75574150|NCT04649216|Drug|PCO371|PCO371 Capsule
75574151|NCT04649216|Drug|[14C]PCO371|[14C]PCO371 Oral solution
75574152|NCT04649216|Drug|[14C]PCO371|[14C]PCO371 Solution for infusion
75725595|NCT04003467|Drug|EBP05|tablets
75725596|NCT04003467|Drug|Placebo of EBP05|tablets
75725597|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
76048241|NCT02059161|Drug|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
75427504|NCT01476553|Procedure|Extensive Intraperitoneal Lavage (EIPL)|"EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius)."
75427505|NCT01476566|Behavioral|Educational intervention|Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
75427506|NCT01476579|Device|Cardiac Computer Tomography|Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
75427507|NCT01476592|Dietary Supplement|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
75427508|NCT01476605|Procedure|Dextrose prolotherapy|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
75427509|NCT01476605|Procedure|PrT-DMS|PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
75427510|NCT01476605|Procedure|Platelet Rich Plasma injection|Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
75427511|NCT01476618|Other|No Intervention|No Intervention
75427512|NCT01476631|Behavioral|Walking|"7 days prior to baseline participants must wear a blinded pedometer~At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale."
75427513|NCT01476657|Drug|IPI-145 (duvelisib)|Oral Twice A Day (BID) Dosing
75427514|NCT01476670|Other|Monitoring|Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
75427515|NCT01476683|Drug|Racecadotril|Film-coated tablet
75427516|NCT01476683|Drug|Racecadotril|Racecadotril Powder Blend
75427517|NCT01476683|Drug|Racecadotril|Marketed Capsule
75427518|NCT01476683|Drug|Racecadotril|Marketed Film-coated Tablet
75574153|NCT01229449|Drug|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
75574154|NCT01229449|Drug|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
75574155|NCT01229449|Drug|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
75574156|NCT01229449|Drug|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
75574157|NCT01229449|Drug|Placebo|Two placebo tablets, single dose taken orally with 300 ml water
75725598|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
75574158|NCT04648865|Drug|LY3537031|Administered SC.
75574159|NCT04648865|Drug|Placebo|Administered SC.
75574160|NCT04648982|Other|Admission to inpatient psychiatric unit|All persons in the study are hospitalized at the only inpatient mental health hospital in Rwanda - Ndera. Data will be collected when the person is being discharged.
75574161|NCT01239316|Other|Laboratory Biomarker Analysis|Correlative studies
75574162|NCT01239316|Other|Pharmacological Study|Correlative studies
75725599|NCT05361057|Drug|Venetoclax, Azacitidine|The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;
75427519|NCT01476735|Other|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
75574163|NCT01239316|Drug|Vismodegib|Given PO
75574164|NCT01239160|Device|Flexitouch System|"A segmental, programmable, gradient pneumatic compression device. It consists of a controller and garment set. The garments are constructed of nylon and have 27-32 chambers, depending upon garment size. The pressure setting is variable between normal and increased. The device is intended to be used for 60 minutes per day"
75574165|NCT01239160|Device|Hydroven FPR|The FH is an intermittent sequential external pneumatic compression system. The garment contains 3 compression chambers. The pressure range of the compressor device is 30-100 mmHg. It is intended to be used for 60 minutes per day.
75574166|NCT01239121|Other|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
75574167|NCT01239121|Other|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
76048242|NCT02059161|Drug|Lantus™|Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
76048243|NCT02059161|Drug|Prandial Insulin|Participants will continue their prandial insulin during the study.
75427520|NCT01476761|Device|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
76048244|NCT04417647|Device|VZ powder (purified clinoptilolite)|VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).
76048245|NCT04417647|Procedure|Standard of care (SoC)|wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.
75427521|NCT01476774|Drug|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
75427522|NCT01476774|Drug|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
75574168|NCT01239043|Biological|Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
75574169|NCT01239043|Biological|Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75574170|NCT01238848|Drug|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
75574171|NCT01238848|Drug|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
75574172|NCT02908542|Genetic|genetic analysis with massively parallel sequencing|
75574173|NCT01238575|Other|placebo|Administered for up to 8 weeks.
75574174|NCT01238575|Drug|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
75574175|NCT00544323|Device|oral implant|
75574176|NCT02888158|Other|Robotic assistance|Robotic assistance will be implemented during Pelvic Trainer training sessions.
75574177|NCT02888158|Other|Pelvic Trainer|The standard Pelvic Trainer simulator for surgical training.
75574178|NCT06022445|Other|CARPET prognostic model|For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.
75574179|NCT06022432|Other|Video of a patients testimonial|The intervention is a prerecorded video of a re-enacted patient-therapist interaction whereby the patient gives a testimonial about the treatment process while either reducing negative expectations or maximizing positive expectations about therapy, respectively.
75427523|NCT01476800|Drug|YM178 OCAS|oral
75574180|NCT06022432|Other|Writing Task|Participants write freely about their current treatment expectations / apprehensions to seek treatment
75574181|NCT06022419|Procedure|Lucerne Cast|Patients receiving reduction of fractured finger and subsequent customization of a lucerne cast. Duration of cast treatment is determined with 4 weeks.
75574182|NCT06022419|Procedure|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
75725600|NCT05361057|Drug|Venetoclax, daunorubicin, cytarabine|The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
75427524|NCT01476800|Drug|Ketoconazole|oral
76048246|NCT01897714|Drug|Melflufen|
75427525|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
75427526|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
75427527|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
75427528|NCT01476813|Drug|Comparator|comparison of different dosages of drug versus comparator
75574183|NCT06022367|Diagnostic Test|Head Turn Activation Technique|Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
75574184|NCT06022367|Diagnostic Test|Head Raise Activation Technique|Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
75574185|NCT06022354|Drug|SIM0278 Injection/Placebo|SIM0278 Injection/Placebo
75574186|NCT06022341|Other|Multiomic characterization|Multiomics analysis include targeted-NGS with a 400-genes panel, RNA-seq and methylome. All the genomic libraries will be constructed at the genomic facility of Angers University Hospital and the sequencing will be performed on a NovaSeq6000 in the GenoBIRD Platform in Nantes. Bioinformatic analysis will be performed and will derive for each sample: SNV/Indel and CNV from DNA sequencing, expression of mRNA and lncRNA, genes fusion and splicing events from RNA-seq, and methylation beta-values from methylome.
75574187|NCT06022341|Other|In vitro drug screening|The drug screening will be performed on the 'NEXT-AML' platform at St-Louis Hospital, Paris. This platform uses a multiparametric screening strategy based on flow cytometry measurements of cell viability, cell differentiation and stem cell compartment. Primary patient cells will be cultured in a specific niche-like medium with amino-acids, cytokines and stromal cells (Dal Bello et al. 2022). Twenty-five drugs at 6 concentrations covering a 1000-fold concentration range will be studied for each sample.
75574188|NCT06022328|Biological|Assessment of the epigenetic age|Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis
75725601|NCT00832286|Drug|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
75725602|NCT00991653|Procedure|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
76024536|NCT03530267|Drug|mFOLFOX7|Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
76024537|NCT03515811|Device|Signia™ Stapling System|Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri- Staple™ 2.0 Intelligent Reloads.
76024538|NCT03512418|Behavioral|PrEPsteps|Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
76048247|NCT01897714|Drug|Dexamethasone|
75427529|NCT01476878|Device|Frameless Stereotactic Radiosurgery with radiation mask|Linac-based radiosurgery using a thermoplastic mask (single treatment)
75427530|NCT01476891|Other|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
75574189|NCT06022315|Combination Product|caloric restrction high carbohydrate low fat diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold. The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the high CHO-low FAT diet, carbohydrates, fat, and protein will provide 60%, 25%, and 15% of individually predicted daily energy intake, respectively. Variety (n=7) of daily menus for calorie-restricted high FAT-low CHO diet will be provided and menus for high CHO-low FAT diet on pasta, rice, oats, fruit, and vegetable.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
75574190|NCT06022315|Combination Product|caloric restrction high fat low carbohydrate diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold.The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the low CHO-high FAT diet, the proportion of energy provided by CHO, fat, and protein will consist of 25%, 60%, and 15%, respectively. Variety (n=7) of daily menus for calorie-restricted low CHO-high FAT diet will be provided and menus for high FAT-low CHO group will be based on meat, fish, cheese, butter, and nuts.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
75725603|NCT00829946|Behavioral|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of ~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
75725604|NCT02548520|Other|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
75725605|NCT04016792|Drug|Placebo|Placebo will be administered once daily
75725606|NCT04016792|Drug|200 mg SPN-812|200 mg SPN-812 will be administered once daily and compared to Placebo
75725607|NCT04044170|Drug|Poziotinib|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
75878224|NCT01333787|Dietary Supplement|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
75878225|NCT03574922|Other|Balance exercises|Balance Exercises
75725608|NCT00832364|Drug|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
75725609|NCT00832364|Drug|Placebo|Placebo capsules
75427531|NCT01476891|Other|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
75427532|NCT01476917|Device|Attune Sleep Apnea System|Observation of Attune Sleep Apnea System for use during sleep.
75427533|NCT01476930|Procedure|cupping and serkangabin syrup|wet cupping serkangabin syrup
75427534|NCT01476930|Drug|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
75427535|NCT01476956|Other|Observational study|RA patients on standard DMARD therapy
75427536|NCT01476969|Device|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
75427537|NCT01476982|Device|ClearView Scan|Assessment with ClearView device
75427538|NCT01477021|Drug|cyclophosphamide|Given IV
75725610|NCT00832364|Biological|Etanercept|Injectable Biologic
75725611|NCT00832442|Drug|Beta blocker|as determined by individual study
75725612|NCT00832442|Other|Placebo|in addition to usual care
75725613|NCT00824330|Behavioral|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
75725614|NCT00830414|Drug|medroxyprogesterone acetate|IM Injection
75878226|NCT03574922|Other|Core Stabilization exercises|Core Stabilization exercises
75427539|NCT01477021|Biological|NY-ESO-1-specific T cells|Given IV
75427540|NCT01477021|Other|laboratory biomarker analysis|Correlative studies
75574191|NCT06022289|Drug|Pemigatinib|Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
75574192|NCT06022276|Drug|Nimotuzumab|Nitozumab injection 400mg/cycle, every 21 days/cycle, until disease progression, intolerable toxicity or death, or subject decision to withdraw from the study.The molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Nitozumab+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
75574193|NCT06022263|Drug|Lactic Acid|180 mg of STA363 will be slowly injected into a symptom-generating herniated lumbar disc
75574194|NCT06022263|Drug|Placebo|1.5 mL of Omnipaque in water for injection will be slowly injected into a symptom-generating herniated lumbar disc
75878227|NCT04869137|Drug|Lenvatinib Oral Product|20mg of Lenvatinib will be taken orally once daily
75427541|NCT01477034|Dietary Supplement|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
75427542|NCT01477060|Drug|Lapatinib|1250 mg/ die, os
75427543|NCT01477060|Drug|Metformin|1500 mg/die, os
75427544|NCT01477073|Drug|FSH-GEX™|
75427545|NCT01477073|Drug|recombinant FSH|
75427546|NCT01477073|Drug|urinary FSH|
75427547|NCT01477073|Drug|Placebo|
75427548|NCT01477099|Device|Toothbrushing with a manual brush|Toothbrushing with a manual brush
75427549|NCT01477112|Dietary Supplement|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
75427550|NCT01477112|Dietary Supplement|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
75427551|NCT01476397|Other|Control infant formula|partially hydrolyzed whey infant formula consumed ad libitum throughout study
75574195|NCT06022250|Drug|JS207|Patients will receive specific dose of JS207 via intravenous infusion.
75574196|NCT06022237|Drug|Ibandronate|Ibandronate 150 mg once monthly.
75574197|NCT06022237|Drug|Calcium|Calcium 500 mg twice daily
75574198|NCT06022237|Drug|Vitamin D3|Vitamin D3 - 1000 IU daily
75878228|NCT04869137|Drug|Pembrolizumab|200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
76024539|NCT03512418|Device|Digital pill|The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
75574199|NCT06022198|Procedure|Bronchoalveolar Lavage|Bronchoalveolar Lavage
75574200|NCT06022133|Behavioral|Dietary sodium restriction|Selfemployed dietary sodium restriction
75427552|NCT01476397|Other|Test infant formula|partially hydrolyzed whey formula with probiotic
75427553|NCT01477125|Behavioral|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
75574201|NCT06022120|Behavioral|An integrated health literacy intervention|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish contexts among students at risk of poorer health outcomes compared to their peers with stronger literacy skills.
75574202|NCT06022094|Other|2 months of reduced carb menus|Participants will eat a reduced carb menu for 2 months
75427554|NCT01477138|Procedure|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
75427555|NCT01477151|Drug|Volatile anesthetic|"The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration."
75725615|NCT00830414|Drug|medroxyprogesterone acetate|IM injection
75725616|NCT00830492|Drug|clomiphene citrate|100 mg from cycle day 3 through 7
75725617|NCT00830492|Procedure|Ultrasound|cycle day 8
75725618|NCT00830492|Drug|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
75725619|NCT00830492|Drug|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
75725620|NCT00830492|Drug|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
75725621|NCT00830492|Drug|rFSH|150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
75427556|NCT01477164|Behavioral|High intensity aerobic exercise|Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at ~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
75427557|NCT01477164|Behavioral|Resistance exercise training|Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
75427558|NCT01477164|Behavioral|Combined|The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
75427559|NCT01477190|Drug|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
75427560|NCT01477190|Drug|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
75427561|NCT01477203|Drug|Escitalopram|2-4 weeks, 5-10mg, max 20mg
75427562|NCT01477216|Other|ELSA 1-9|Measuring GI and II values for Finnish foods
75427563|NCT01477242|Drug|Ondansetron|2mg (5mL) in < 15 kg and 4mg (10mL) in 15kg to 30kg
75427564|NCT01477255|Behavioral|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
75427565|NCT01477268|Drug|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
75427566|NCT01477281|Drug|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
75427567|NCT01477281|Drug|Venaflon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
75574203|NCT06022055|Other|Blood and tissue collection|"Blood will be collected for group 1 during (i) the enrolment visit, (ii) in the 24 hours following a seizure, (iii)before the surgery and (iv) in the 36 months following the surgery. The left-over tissue, not useful for diagnostic purpose, will be kept for research.~Blood will be collected for group 2 right before the surgery and in the 36 months following the surgery. The left-over tissue not useful for diagnostic purpose will be kept for research."
75574204|NCT06022042|Device|On1 two-stage abutment and one-stage abutment|the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.
75574205|NCT06021951|Drug|Bempedoic Acid 180 MG Oral Tablet|Bempedoic Acid 180 MG Oral Tablet [Nexletol]
75878229|NCT02239250|Device|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
75427568|NCT01477294|Drug|Caffeine|5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
75427569|NCT01477294|Drug|Placebo|Malt dextrin (5 mg/kg body mass) twice a day during 4 days
75427570|NCT01477307|Other|Hypocaloric diet|Eurodiet,standardized hypo-caloric diet, during 3 weeks
75574206|NCT06021951|Drug|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet [NEXLIZET]
75427571|NCT01477346|Other|Nurse intervention|Complex package of care involving patient information and advice concerning lifestyle modification and recommended drug therapy.
75427572|NCT01477346|Other|Standard care|Continuing standard General Practitioner led care.
75427573|NCT01477372|Behavioral|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
75574207|NCT06021912|Drug|Immunotherapy|Sublingual immunotherapy
75725622|NCT00830570|Other|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
75725623|NCT00837356|Drug|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
75725624|NCT00837356|Drug|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
75574208|NCT06021899|Other|modified constraint induced movement therapy|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
75574209|NCT06021873|Procedure|SADI-S|Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
75574210|NCT06021847|Other|Ozonated water|ozonated water was prepared with a concentration of (2-4 mg/l) ozone for 1 min. in a 25 mg of double distilled water 37o C employing an Ozone generator (Ozone generator type N 1888A, China.)
75574211|NCT06021847|Other|Chlorhexidine mouthwash|Commercial available chlorhexidine mouthwash in the market was used.
75427574|NCT01477385|Procedure|Resin Infiltration|After cleaning the proximal surface with caries lesion, it will be performed the local infiltration anesthesia and adaptation of the rubber dam. The adjacent tooth will be protected by plastic or metal strip. Hydrochloric acid 15% will be applied on the lesion, which will be washed and dried. The surface should be dried by applying 95% ethanol and air-way syringe. The resin infiltration (Icon, DMG) will be applied on the lesion. The resin will be polymerized and applied again and polymerized.
75878230|NCT03651414|Other|Clinical data collection|There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
75427575|NCT01477385|Procedure|30% Silver Diammine Fluoride|It will be cleaned like group I. Soft tissues will be protected with petroleum jelly. The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
75427576|NCT01477385|Procedure|Dental Flossing|In this group, the patient will perform only mechanical removal of biofilm to floss daily.
75427577|NCT01477385|Procedure|Resin Infiltration Placebo|In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
75427578|NCT01477385|Procedure|30% Silver Diammine Fluoride Placebo|Soft tissues will be protected with petroleum jelly. The patient will receive sterile water application with a disposable microbrush for 3m. Then the surface will be washed for 30s.
75427579|NCT01477398|Device|QED-100|Use of the QED-100 results in mild hypercapnia during emergence
75427580|NCT01477411|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
75574212|NCT06021834|Other|rehabilitation|The subjects will be invited to attend the program three times per week.
75574213|NCT06021821|Other|SoundMind App|he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.
75574214|NCT06021821|Other|Spotify Playlist|"Participants will listen to a calm vibes playlist by Spotify."
75574215|NCT06021782|Other|All subjects-Observation|The sonographer or study team member will scan the lateral vaginal walls (Left and right) directing the probe slightly caudad in direction of the ischial spine (IS). The IS is very echogenic and easily identifiable (bony landmark). Anatomically, the pudendal nerve courses underneath the IS and travels with the vascular bundle of the pudendal artery and pudendal vein. The artery and the vein will be identified using color flow Doppler at the time of the scan. These landmarks, IS, pudendal artery and vein will serve as the basis for the identification of the pudendal nerve.
75574216|NCT06021769|Other|Observational only|No intervention
75574217|NCT06021756|Drug|Intervention: Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
75574218|NCT06021730|Behavioral|Standardized After Visit Instructions Only|The intervention took a standardized approach to after visit instructions which included a customizable template that would review patients conditions, changes in any medications, and any future labs, imaging, or referrals.
75878231|NCT00493961|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
75878232|NCT03077789|Procedure|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
75427581|NCT01477411|Drug|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
75427582|NCT01477424|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
75427583|NCT01477424|Drug|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
75427584|NCT01477437|Other|Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention|"The content will be delivered on a password-protected website, as part of the About Kids Health interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention."
75574219|NCT06021730|Behavioral|Standardized After Visit Instructions & Teach Back|This intervention included the Standardized After Visit Instructions and included teach back, a process by which patients restate in their own words their understanding of their condition, what was discussed in the visit, and what potential changes were made
75574220|NCT06021717|Drug|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
75878233|NCT00175136|Device|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
76024540|NCT03512418|Drug|Truvada|Participants receive once daily Truvada as PrEP to prevent HIV.
75574221|NCT06021717|Drug|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
75574222|NCT06021691|Behavioral|Acquired nurturing environment|Superimposed effects of intrauterine high-sugar environment exposure and postnatal nurturing environment exposure
75427585|NCT01477476|Drug|Anakinra|Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.
76048248|NCT05131737|Procedure|High altitude exposure|Exposure to 2500m of altitude
75574224|NCT06021665|Other|Fortetropin supplement|Test Formulation: 10g serving Calories: 64.8g Carbohydrates: 0.45g Fats: 5.5g Protein: 3.38g
75878234|NCT03649776|Other|Mental Health First Aid|Mental Health First Aid (MHFA) is listed in the Substance Abuse and Mental Health Services Administration's National Registry of Evidence-based Programs and Practices. The program also teaches the common risk factors and warning signs of specific types of illnesses like anxiety, depression, substance use, bipolar disorder, eating disorders, and schizophrenia. Participants are introduced to local mental health resources, national organizations, support groups, and online tools for mental health and addictions treatment and support.
75878235|NCT02589509|Behavioral|Direct-attention training using web-based BrainHQ|"BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame."
75427586|NCT01477476|Other|Placebo Comparator|A placebo will be given to 7 subjects.
75878236|NCT02589509|Behavioral|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
75878237|NCT02903238|Drug|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
75878238|NCT02903238|Drug|Placebo Oral Tablet|Lactose capsule
75574225|NCT06021665|Other|Cheese protein|"The cheese powder will act as the control product. Cheese powder has been chosen as it matches the macronutrient content of the test product, but without the active ingredient.~Control Formulation: 20g serving Calories: 93g Carbohydrates: 8g Fats: 5g Protein: 3g"
75574226|NCT06021652|Device|MindCotine Virtual reality|Virtual reality platform
75427587|NCT01477489|Drug|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
75427588|NCT01477489|Radiation|Standard radiation treatment|Limited to 60 Gy.
75427589|NCT01477502|Other|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
75427590|NCT01477502|Other|standard treatment without homeopathy|participants receive standard UTI prophylaxis
75427591|NCT01477541|Other|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
75574227|NCT06021587|Drug|Levosimendan|Initiation of levosimendan 48 hours before surgery
75574228|NCT06021587|Drug|No Levosimendan|Without Levosimendan Infusion
75574229|NCT06021574|Drug|VDJ001|a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody
75574230|NCT06021574|Drug|Placebo|Placebo
75574231|NCT06021548|Other|Blood sample|Finger stick blood spots will be collected at V0 and M12
75574232|NCT06021548|Other|Saliva sample|Saliva sample will be collected at V0
75574233|NCT06021548|Other|Hair sample|Hair sample will be collected at V0 (optional)
75574234|NCT06021535|Other|No intervention|No intervention
75574235|NCT06021522|Drug|Ecopipam|Selective dopamine D1 and D5 receptor antagonist
75574236|NCT06021509|Device|NovoClasp® transcatheter mitral valve clip and steerable guide catheter|The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.
75878239|NCT01331369|Behavioral|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
75878240|NCT01331369|Other|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
75427592|NCT01477554|Other|PRONTO training|PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
75427593|NCT01477580|Biological|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
76048249|NCT05131737|Procedure|Low altitude exposure|Exposure to 490 m
75427594|NCT01477580|Biological|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
75427595|NCT01477580|Biological|Medium-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
75427596|NCT01477580|Biological|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
75427597|NCT01477580|Biological|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
75427598|NCT01477580|Biological|Medium-dose V180 with Alhydrogel™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
75427599|NCT01477580|Biological|High-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
75427600|NCT01477580|Biological|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
75427601|NCT01477580|Biological|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
75427602|NCT01477580|Biological|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
75427603|NCT01477580|Biological|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
75427604|NCT01477580|Biological|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
75427605|NCT01477580|Biological|Placebo|Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
75427606|NCT01477593|Procedure|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
75878241|NCT03621852|Device|Endoultrasound guided FNB|EUS FNB with Aquire TM device
75574237|NCT06021496|Behavioral|face to face health education|Face-to-face health education with home visit
75574238|NCT06021496|Behavioral|online health education|online health education with video call
75574239|NCT06021470|Behavioral|Cognitive rehabilitation intervention|The intervention comprises a five-week group-based cognitive rehabilitation intervention delivered by a clinical neuropsychologist, with home activities tailored to each stroke survivor's identified goals. Sessions involve four patients and are delivered once per week lasting 2.5 hours with breaks.
75878242|NCT03651024|Device|ED surgery|The surgical implant for ED treatment
75574240|NCT06021405|Procedure|Tape stripping|a small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema
75878243|NCT01329809|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
76024541|NCT03463265|Drug|nab-sirolimus|nab-sirolimus, single agent
76024542|NCT03463265|Drug|nab-sirolimus + temozolomide|temozolomide, combination
76024543|NCT03463265|Drug|nab-sirolimus + bevacizumab|bevacizumab, combination
76024544|NCT03463265|Drug|nab-sirolimus + lomustine|lomustine, combination
76024545|NCT03463265|Drug|nab-sirolimus + marizomib (MRZ)|marizomib (MRZ), combination
76024546|NCT03463265|Drug|nab-sirolimus + temozolomide + radiotherapy|temozolomide + radiotherapy, combination
76024547|NCT03459092|Drug|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
76024548|NCT03459092|Procedure|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
76024549|NCT03453931|Drug|Corticosteroid injection|Intravenous high dose corticosteroids
75427607|NCT01477593|Procedure|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
75574241|NCT06021327|Procedure|Erector spinae plane block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 3 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact the tip of the T4 transverse process , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. Adequacy of the block will be confirmed by ultrasonographic visualization of fluid spread (seen as a lifting of the erector spina muscles in both block) and after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
75574242|NCT06021327|Procedure|Retrolaminar block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 1 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact T4 lamina of the vertebra , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. And after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
75574243|NCT06021314|Other|Brace|Cheneau type scoliosis brace due to brace indication for adolecant idiopatic scoliosis
75574244|NCT06021288|Other|Effluent dose of CRRT|The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
75574245|NCT06021262|Other|exposure to organophosphates|organophosphates are esters of phosphoric acids or Thio phosphoric acids that exist in pesticides, where patients can be chronically or acutely exposed to such compounds.
75574246|NCT06021249|Procedure|Traditional ventilation strategies|"Tidal volume：10ml/kg predicted body weight（PBW）；~0 cm H2O positive end expiratory pressure（PEEP）；~negative pressure extubation"
75574247|NCT06021249|Procedure|Traditional lung-protective ventilation strategies|"Tidal volume：6ml/kg PBW；~5cmH2O PEEP；~Ventilator-controlled recruitment manoeuvre；~CPAP；~negative pressure extubation"
75574248|NCT06021249|Procedure|Innovative lung-protective ventilation strategies|"Tidal volume：6ml/kg PBW；~5cmH2O PEEP；~positive pressure extubation；~postoperative breathing training"
75574249|NCT06021249|Procedure|Lung-protective ventilation|"Tidal volume：6ml/kg PBW；~5cmH2O PEEP；"
75878244|NCT02847260|Drug|Remodulin|Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
75878245|NCT02872571|Drug|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
75427608|NCT01477593|Procedure|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
75574250|NCT06021249|Procedure|negative pressure extubation|The suction tube is inserted into the endotracheal tube, continuous negative pressure suction, and at the same time that the balloon is completely deflated, the suction tube, dental pad and endotracheal intubation are pulled out at the same time, and then the patient is instructed to cough independently and remove sputum.
75574251|NCT06021249|Procedure|positive pressure extubation|The adjustable pressure limiting（APL）was adjusted to 30cm H2O, and after the patient breathed spontaneously until the peak airway pressure reached 30cm H2O, and after maintaining this level for 10s, the balloon was quickly cut off to remove the endotracheal tube, so that the patient had an autonomous coughing action, and then the oral sputum was removed.
75574252|NCT06021249|Procedure|postoperative breathing training|Inhale deeply through the nose, hold the breath for 5s, and then slowly spit out the breath through the mouth, cycle 5-6 times, and inflate the balloon. The above steps need to be performed 15 times within 24 hours after surgery.
75878246|NCT03650946|Diagnostic Test|Ga-68 PSMA PET|Ga-68 PSMA PET
75427609|NCT01477606|Drug|Midostaurin|"Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year."
75574253|NCT06021236|Behavioral|mindfulness-based intervention|Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing
75574254|NCT06021236|Other|CIED procedure routine care|CIED procedure home care guidance
75574255|NCT06021223|Dietary Supplement|Chicken extract supplement (high-dose)|140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
75574256|NCT06021223|Dietary Supplement|Chicken extract supplement (low-dose)|140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
75427610|NCT01477606|Drug|Cytarabine|"Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2)."
75574257|NCT06021223|Other|Placebo|140ml of placebo to be consumed daily for 2 weeks
75725625|NCT00832754|Device|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
75878247|NCT01331447|Drug|exemestane|25 mg tablet
75427611|NCT01477606|Drug|Daunorubicin|"Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)"
75574258|NCT06021210|Drug|Letermovir Pill|Letermovir is the world's first and only new drug approved for the prevention of CMV infection. In 2017, it was approved by the U.S. Food and Drug Administration (FDA) for the prevention of CMV infection and disease in CMV-seropositive adult recipients (R+) of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It was approved in China on December 31, 2021.
75574259|NCT06021171|Dietary Supplement|Partially hydrolyzed guar gum + bifidobacterium lactis|Synbiotic Supplement: Contains 5 grams of prebiotic fiber (Sunfiber®) and 8 billion active probiotics (Bifidobacterium lactis).
75427612|NCT01477619|Drug|Tasimelteon|20mg single dose on Day 1
75427613|NCT01477632|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
75427614|NCT01477632|Drug|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
75427615|NCT01477632|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
75574260|NCT06021171|Dietary Supplement|Partially hydrolyzed guar gum|5 g Partially hydrolyzed guar gum
75574261|NCT06021171|Dietary Supplement|Maltodextrin|5 g Maltodextrin
75574262|NCT06021132|Device|cochlear implant|Insertion of a electrode into the cochlear with the aim of providing deaf and severe hearing handicapped with the ability to hear speech.
75574263|NCT06021119|Drug|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors with Iftar meal
75574264|NCT06021106|Other|Breathing exercise application with virtual reality glasses|In adapting breathing exercises to virtual reality glasses; The exercise video was first shot by the researcher in front of a green screen. Then, a 3d background design was made by a software developer, a 360-degree printout was taken and transformed into a viewable form with these glasses. The exercise video is prepared as 20 minutes. The exercises will be done in the homes of the patients by making home visits. It is planned that the exercises will be done three times a week in a total of 24 sessions.
75574265|NCT06021106|Other|routine treatment and care|routine treatment and care
75574266|NCT06021067|Biological|Death mesenchymal stem cell|A standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4~6 weeks.
75878248|NCT03574844|Dietary Supplement|Saccharomyces cerevisiae, dose 500|Experimental arm
75878249|NCT03574844|Dietary Supplement|Saccharomyces cerevisiae, dose 1000|Experimental arm
75878250|NCT03574844|Dietary Supplement|Placebo|Placebo comparator arm
75878251|NCT03649620|Dietary Supplement|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
75878252|NCT03649620|Dietary Supplement|Placebo|Placebo for 12 weeks
75878253|NCT02968563|Drug|Tirabrutinib|Tablets administered orally
75878254|NCT02968563|Drug|Idelalisib|Tablets administered orally
75878255|NCT02968563|Drug|Obinutuzumab|Administered intravenously
75878256|NCT01329887|Drug|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
75878257|NCT03579212|Device|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
75574267|NCT06021028|Procedure|complex proximal carious cavities in posterior teeth.|Selective enamel etching with 37% phosphoric acid for 30 second will be done then the bonding agent will be applied following the manufacturer's instructions.
75725626|NCT00832754|Other|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
75427616|NCT01477697|Dietary Supplement|Omega-3|50 mg/kg per day of omega-3 fatty acids
75427617|NCT01477697|Dietary Supplement|Placebo|50 mg/kg per day of placebo equivalent
75574268|NCT06021015|Device|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
75574269|NCT06021015|Device|Irinotecan and HepaSphere Microspheres|Irinotecan and HepaSphere Microspheres
75574270|NCT06021002|Drug|R848|Nasal R848 administration
75574271|NCT06021002|Drug|Saline|Nasal saline administration
75725627|NCT00824486|Behavioral|Injury prevention education (TIPP)|using TIPP materials
75725628|NCT00824486|Behavioral|Injury prevention education (safe home)|using safe home model
75725629|NCT00832832|Other|Eyelid closure|Eyelid will be closed after eye drop instillation
75725630|NCT00832832|Other|No intervention will be assigned|No intervention will be assigned to this arm
75725631|NCT00824642|Device|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
75725632|NCT00824642|Device|placebo|placebo TENS applied prior to exercise
75725633|NCT00837746|Drug|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
75725634|NCT04043702|Drug|The intervention being studied|Intervention Other Names have not been specified
75725635|NCT00832988|Other|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
75725636|NCT02550080|Drug|Dapsone|For the HLA-B*1301 positive subjects, dapsone will not be administrated.
75725637|NCT02550080|Genetic|HLA-B*1301|The prospective genetic screening group will be tested before administrating dapsone
75725638|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
75878258|NCT01334099|Biological|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
75427618|NCT01477723|Other|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
75427619|NCT01477736|Drug|Oxybutynin|5 mg of immediate-release oxybutynin orally 3 times daily
75427620|NCT01477736|Drug|Botulinum toxin A|300 U intradetrusor injection
75427621|NCT01477775|Drug|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
75427622|NCT01477775|Drug|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
75574272|NCT06020989|Drug|Lazertinib+Pemetrexed+Carboplatin|Arm A will receive Lazertinib and Pemetrexed, Carboplatin combination. Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity. Pemetrexed(500 mg/m2) will be administered IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Carboplatin(AUC5) will be administered IV infusions on Day 1 of each 21-day cycle until 4 cycles.
75574273|NCT06020989|Drug|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
75574274|NCT06020989|Drug|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
75574275|NCT06020976|Diagnostic Test|liver biobsy|all pationt will be subjected yo liver biobsy to confirm diagnosis
75725639|NCT00833066|Biological|Placebo|placebo entero-coated capsules
75725640|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
75725641|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
75725642|NCT02547272|Procedure|Nasal and rectal bacterial samples|Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
75725643|NCT00838058|Drug|CE-224,535|one 250mg tablet, once in the morning in fasted state
75725644|NCT00838058|Drug|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
75878259|NCT01334099|Radiation|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
75878260|NCT03650868|Procedure|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
76048250|NCT01861522|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
75725645|NCT00838058|Drug|CE-224,535|4x250mg tablets, once in the morning, in fasted state
75725646|NCT00838058|Drug|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
75725647|NCT00838058|Drug|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
75725648|NCT00838058|Drug|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
75725649|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
75427623|NCT01477801|Drug|CHOLECALCIFEROL|"Standard guideline based therapy plus cholecalciferol:~Loading dose 300.000 U then 50.000 U every month for six months"
75574276|NCT06020963|Procedure|Low Intensity Shockwave Therapy (LiSWT)|Low Intensity Shockwave Therapy (LiSWT) has been used for many years. Its mechanism is to use shock wave energy to promote angiogenesis to achieve the functions of tissue repair and cell regeneration.
75574277|NCT06020963|Drug|Tamsulosin|Tamsulosin is a selective alpha-1 blocker, its main function is to relax the smooth muscles of the base of the prostate, urethra, and bladder, and improve lower urinary tract symptoms.
75725650|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
75725651|NCT02550392|Behavioral|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
75725652|NCT02547350|Drug|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
75725653|NCT00838214|Drug|budesonide|3mg capsule, 3x per day for 6 months
75878261|NCT03579134|Device|partial overlay denture|removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
75427624|NCT01477801|Drug|PLACEBO|Standard guideline based therapy plus placebo
75427625|NCT01477814|Behavioral|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
75427626|NCT01477814|Behavioral|chart reminder, educational mat'ls, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
75427627|NCT01477814|Behavioral|CR,ed mat'ls, FIT, phone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
75427628|NCT01477827|Other|None - observational study|
75427629|NCT01477840|Drug|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
75427630|NCT01477866|Dietary Supplement|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
75427631|NCT01477866|Other|conventional therapy|conventional therapy for colon-rectal cancer
75574278|NCT06020924|Other|No intervention|This study is a retrospective observational study without intervention.
75574279|NCT06020911|Drug|Biodentine|17 primary second molars of 17 children will be capped with Biodentine
75574280|NCT06020911|Drug|Theracal light cured|17 primary second molars of 17 children will be capped with Theracal light cured
75574281|NCT06020898|Drug|Sodium valproate|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
75725654|NCT00838214|Drug|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
75725655|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
75878262|NCT03579134|Other|fixed temporary crowns|fixed crowns made from temporary material placed to the newly altered vertical dimension
75878263|NCT01331525|Biological|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
75878264|NCT03650790|Diagnostic Test|Blood test|For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
75725656|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
75427632|NCT01477879|Other|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
75574282|NCT06020898|Drug|Normal saline|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
76048251|NCT01861522|Drug|Placebo|Two Placebo tablets will be taken orally twice a day
76048252|NCT01860976|Drug|Abatacept|
75725657|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
75725658|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
75878265|NCT03792165|Other|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
75878266|NCT03792165|Other|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
75427633|NCT01477879|Other|placebo (versabase gel only)|versabase gel only
75427634|NCT01477931|Drug|Bupropion extended release|300mg once a daily, PO, 8weeks
75427635|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
75427636|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
75725659|NCT00838292|Dietary Supplement|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
76048253|NCT01860976|Drug|Placebo|
76048254|NCT01860040|Drug|Cisplatin|Alkylating antineoplastic agent (Chemotherapy)
76048255|NCT01860040|Drug|Pemetrexed|Antimetabolite antineoplastic agent (Chemotherapy)
76048256|NCT01860040|Drug|Gemcitabine|Antimetabolite antineoplastic agent (Chemotherapy)
76048257|NCT04618744|Drug|ORMD-0801 (Insulin) capsule 8 mg BD|8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
76048258|NCT04618744|Other|Placebo|Matching Placebo
76048259|NCT01896934|Drug|Sertraline|50-200mg daily
76048260|NCT02039505|Drug|Vedolizumab|Vedolizumab intravenous infusion
76048261|NCT02039505|Drug|Vedolizumab placebo|Vedolizumab placebo
76048262|NCT02095197|Drug|Triamcinolone 80mg|C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
76048263|NCT02039427|Drug|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
76048264|NCT02039427|Other|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
76048265|NCT02039427|Drug|Placebo|Normal saline 2 ml
76048266|NCT02094885|Biological|Bioseal Fibrin Sealant|
76048267|NCT02094885|Other|Manual Compression|
75427637|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
75574283|NCT06020885|Radiation|Split-course hypo-CCRT|"Split-course hypo-CCRT is administered at the following three dose levels:~Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course."
75574284|NCT06020885|Drug|Induction chemo-immunotherapy|All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.
75574285|NCT06020885|Drug|Concurrent chemotherapy|Concurrent capecitabine was administered orally at 1000mg/m2 twice daily within half an hour after meals concurrently with radiotherapy.
75574286|NCT06020872|Other|Health literacy program|Health literacy program was the health education related to healthy plate.
75574287|NCT06020859|Device|undergo NaviEC-2000Pro Gastro Scan mode|Patients undergo NaviEC-2000Pro Gastro Scan mode.
75574288|NCT06020859|Device|NaviEC-2000Pro Routine gastric examination|Patients undergo NaviEC-2000Pro Routine gastric examination mode.
75574289|NCT06020859|Device|NaviEC-1000 Routine gastric examination|Patients undergo NaviEC-1000 Routine gastric examination mode.
75427638|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
75427639|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
75574290|NCT06020833|Drug|Roxadustat in combination with retinoic acid|Roxadustat 150mg po qod combined with retinoic acid 20mg po bid
75574291|NCT06020820|Other|Cervical Rehabilitation program (Intervention Group) Group A|"(Positional release technique on trapezius muscle): the therapist locate and apply pressure along the tender points in the upper fibers of the trapezius. Lateral flexion of subject's head toward the side of a tender point held for 90 seconds.~(Suboccipital muscle release): The therapist places both his palms under the sub occipital region of the subject with his curled-up fingers and places an upward pressure causing a stretch and distraction for 30 seconds,This technique was performed 3 times in one session.~Stretching of pectoralis muscle:~Pectoralis muscle stretch were performed once daily, completing three repetitions on each side with a 30-second hold. Stretching with repetition of five, three times a day for 1week neck and soulder ROMs"
76048268|NCT01896856|Drug|SGI-110 Dose Escalation|"Dose level 1 (DL1): 45 mg/m^2 administered as a subcutaneous injection~Dose level 1G (DL1G): 45 mg/m^2 administered as a subcutaneous injection + growth factor support~Dose level -1 (DL-1): 30 mg/m^2 administered as a subcutaneous injection~Dose level -1G (DL-1G): 30 mg/m^2 administered as a subcutaneous injection + growth factor support"
76048269|NCT01896856|Drug|Regorafenib|160 mg taken orally
75574292|NCT06020820|Other|control group group B|"Relax shoulders and neck sufficiently~look down~turn face to the right~turn face to the left~incline head to the right~incline head to the left~turn shoulders round and round~slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening)."
75574293|NCT06020794|Behavioral|Exercise|quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors
75574294|NCT06020794|Biological|LP-PRP|The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
75427640|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
75427641|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
75427642|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
75725660|NCT00838292|Other|nutrition counseling|
76024550|NCT03438552|Radiation|Stereotactic Body Radiotherapy|This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.
76024551|NCT03374800|Drug|Placebo (0.9% saline)|normal saline
76024552|NCT03374800|Drug|Pantoprazole|40 mg powder for injection reconstituted with 0.9% saline
76024553|NCT03373968|Drug|Givinostat|suspension of givinostat (10 mg/mL)
76048270|NCT01896856|Drug|TAS-102|35 mg/m^2 taken orally
76048271|NCT01896856|Drug|SGI-110|45 mg/m^2 administered as a subcutaneous injection
76048272|NCT01896856|Drug|Irinotecan|125 mg/m^2 administered IV
75427643|NCT01477996|Procedure|27-gauge|27-gauge needle for IVT
75427644|NCT01477996|Procedure|30-gauge|30-gauge needle for IVT
75427645|NCT01478022|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
75427646|NCT01478022|Drug|Ibuprofen|Ibuprofen 200 mg daily, capsules
75574295|NCT06020768|Other|the bed-head was raised to an angle of 0, 20, 30 and 45 degrees|With each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.
75574296|NCT06020742|Procedure|Autologous USC mitochondrial oocyte transplantation|Mitochondria are isolated from urine derived stem cells from fresh middle urine of the subjects, and injected into the cytoplasm of mature oocytes together with sperm
76048273|NCT02038959|Other|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
76048274|NCT01896700|Drug|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
75574297|NCT06020729|Other|General Exercises without occlusion training|General Exercises as bench press, squats , maximum sprint, leg power without occlusion training
75878267|NCT03649542|Other|Fluidotherapy plus exercise|The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
75878268|NCT01334177|Drug|TLR8 agonist VTX-2337|Given SC
75427647|NCT01478022|Other|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
75427648|NCT01478061|Device|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
75427649|NCT01478074|Drug|G-CSF|5 mcg/kg daily from day -7 until post-nadir ANC > 1000
75427650|NCT01478074|Drug|Cytarabine|2 g/m2 daily from day -6 through -2
75427651|NCT01478074|Drug|Fludarabine|30 mg/m2 daily from day -6 through -2
75427652|NCT01478074|Biological|Donor Natural Killer (NK) cells|Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10^6 cells/Kg
75427653|NCT01478074|Biological|ALT-801|0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
75427654|NCT01478126|Drug|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
75878269|NCT01334177|Biological|cetuximab|Given IV
75427655|NCT01478126|Drug|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2*weight/24. Infusion starts in operating room and ends next day after the surgery.
75427656|NCT01478139|Procedure|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
75878270|NCT01334177|Other|laboratory biomarker analysis|Correlative studies
75878271|NCT01334177|Other|pharmacogenomic studies|Correlative studies
75878272|NCT03578978|Other|No intervention|No intervention will be given to study subjects. Only blood will be obtained from study subjects.
75878273|NCT03574766|Behavioral|Meditation|Daily meditation
75878274|NCT03649386|Device|Heated and humidified breathing circuit on|Heated and humidified breathing circuit will be turned on.
76048275|NCT01896700|Drug|Placebo|Escalating matched dose of placebo
76048276|NCT02352493|Drug|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
76048277|NCT02352493|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
76048278|NCT02286193|Behavioral|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
75427657|NCT01478139|Procedure|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
76048279|NCT01896232|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
75725661|NCT00838370|Drug|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD*2A. Patients heterozygous or homozygous mutant for DPYD*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
76048280|NCT01896232|Drug|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
76048281|NCT01896232|Drug|Oral Placebo|Administered orally once a day.
76048282|NCT01896232|Drug|Intravenous Placebo|Administered intravenously (IV) three times per week.
75574298|NCT06020729|Other|Occlusion Training|In experimental sessions players will perform with occlusion training which is blood flow resistance training, 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time.This training will also improve and increase muscular strength as well as speed and physical performance in players.
75574299|NCT06020716|Drug|Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution|Three times daily
75725662|NCT00838448|Behavioral|Exercise|Exercise performed on a treadmill for 20-30 minutes
75725663|NCT00510718|Drug|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
75574300|NCT06020716|Drug|Placebo|Three times daily
75574301|NCT06019091|Device|Compass Health TENS 3000, 3 mode Analog Unit|The TENS unit Compass Health TENS 3000, 3 mode Analog Unit will be configured based on randomization to 20 Hz, 50 Hz, or 100 Hz. Pulse width 200 microseconds, Normal (N) Mode. It will be used on the posterior tibial nerve via a patch that is supplied each day for 30 minutes of the day. These 30 minutes of intervention will occur at the participants most painful time of the day for their pain.
75574302|NCT06018740|Dietary Supplement|Daily Balance Gummy|Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
75725664|NCT00537381|Drug|Docetaxel|Docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks.
75725665|NCT00537381|Drug|Prednisone|Prednisone 5 mg orally twice daily.
76048283|NCT02460224|Drug|LAG525|LAG525 was administered via intravenous (i.v.) infusion
76048284|NCT02460224|Drug|PDR001|PDR001 was administered via i.v. infusion
76048285|NCT02094573|Drug|Brigatinib|Brigatinib tablets
76048286|NCT01859494|Device|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
76048287|NCT01858636|Device|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
76048288|NCT02058849|Drug|Beetroot|10g Beetroot powder mixed with 4-8 oz.
76048289|NCT02058849|Other|Placebo|Placebo
76048290|NCT01858558|Biological|aMIL|On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
76048291|NCT01858558|Drug|No aMIL|On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
76048292|NCT02058537|Drug|Bethanechol|Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
76048293|NCT01612000|Biological|PanBlok|Intramuscular injection
76048294|NCT01612000|Biological|rHA adjuvant|Intramuscular injection
76048295|NCT01895608|Behavioral|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
75878275|NCT03649386|Device|Heated and humidified breathing circuit off|Heated and humidified breathing circuit will be turned off.
76048296|NCT01895608|Behavioral|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
76048297|NCT01895608|Behavioral|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
76048298|NCT01895608|Behavioral|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
75427658|NCT01478152|Other|Drug-like Medical Device: Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
75427659|NCT01478165|Drug|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
75427660|NCT01478165|Drug|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
75427661|NCT01478230|Drug|Nicotine|Nicotine 5 mg Inhaler
75427662|NCT01478230|Drug|Nicotine|Nicotine 10 mg Inhaler
75427663|NCT01478282|Drug|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
75725666|NCT00537381|Biological|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
75427664|NCT01478282|Drug|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
75427665|NCT01478295|Behavioral|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
75427666|NCT01478295|Other|Control Group/Usual Care:|"Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education"
75725667|NCT00537381|Drug|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
75878276|NCT03574688|Dietary Supplement|Water|Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
75878277|NCT05763537|Behavioral|Standard Doula Care Plus PMAD Intervention|Doulas trained in the DONA training, and the PMAD-focused training will provide care to perinatal people.
75878278|NCT05763537|Behavioral|Standard Doula Care|Doulas trained in the DONA training will provide care to perinatal people.
75878279|NCT05761821|Device|Leadless pacemaker|All enrolled patients were implanted with leadless pacemaker.
75878280|NCT05762523|Biological|VAC∆6 vaccine - оnce at a dose of 10⁶ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
75878281|NCT05762523|Biological|VAC∆6 vaccine - once at a dose of 10⁷ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁷ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
76048299|NCT02409680|Drug|Low dose aspirin|Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
76048300|NCT02409680|Drug|Placebo|Placebo
76048301|NCT04618354|Other|No interventions|This clinical study is a retrospective study, and no interventions have been implemented for patients.
76048302|NCT01895452|Drug|ALKS 9072, Low Dose|Intramuscular injection, given monthly
76048303|NCT01895452|Drug|ALKS 9072, High Dose|Intramuscular injection, given monthly
75427667|NCT01478308|Drug|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
75427668|NCT01478308|Drug|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
75427669|NCT01478308|Drug|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
76048304|NCT02094417|Drug|AMG531|Subcutaneous, weekly injection
75427670|NCT01478334|Behavioral|high intensity interval training|"First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.~Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period."
75427671|NCT01478334|Behavioral|Control|"First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.~Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion."
75725668|NCT00833300|Drug|Haloperidol|"2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Discontinue current drug therapy and select one of:~Quetiapine up to 100 mg/day~Risperidone up to 6 mg/day~Loxapine up to 50 mg/day~Methotrimeprazine up to 75 mg/day~Reassess in 24 hours.~Delirium absent - Continue for 24 hours then discontinue.~Delirium present - Treatment at discretion of attending physician."
76048305|NCT01894984|Drug|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
75427672|NCT01478386|Other|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
75427673|NCT01478386|Device|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
75878282|NCT05762523|Biological|VAC∆6 vaccine - twice at a dose of 10⁶ PFU|15 volunteers vaccinated twice spaced 28 days apart, intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
76048306|NCT01894984|Drug|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
75427674|NCT01478386|Device|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
76048307|NCT02375672|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
76048308|NCT02375672|Drug|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~Oxaliplatin 85 mg/m^2 IV with~Leucovorin 400 mg/m^2 IV followed by~5FU 400 mg/m^2 bolus and then 2400 mg/m^2 via continuous infusion"
75427675|NCT01478399|Drug|PB1023 Injection|90 mg Dose
75427676|NCT01478412|Other|Polymer based fiducial placement|Fiducial marker placement with rectal ultrasound imaging.
75427677|NCT01478425|Device|Lipidic Microemulsion|Topical nasal, twice a day
75427678|NCT01478425|Device|Saline|Topical Nasal, twice a day
75427679|NCT01478438|Device|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
75427680|NCT01478451|Behavioral|Exercise|Exercise will be performed for 10 minutes at the left or right trapezius (randomized)
75427681|NCT01478451|Other|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
75427682|NCT01478464|Other|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
75427683|NCT01478490|Drug|mirabegron|oral
75427684|NCT01478490|Drug|metoprolol|oral
75427685|NCT01478503|Drug|mirabegron OCAS|oral
75427686|NCT01478503|Drug|Placebo|oral
76048309|NCT01894516|Drug|GLPG0634|GLPG0634 capsules.
75427687|NCT01478516|Procedure|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
75427688|NCT01478529|Drug|mirabegron OCAS|oral administration
75427689|NCT01478529|Drug|mirabegron|iv administration
75427690|NCT01478568|Drug|mirabegron|oral
75427691|NCT01478568|Drug|desipramine|oral
76048310|NCT01894516|Drug|Placebo|Placebo capsules.
76048311|NCT02491463|Biological|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
76048312|NCT02491463|Biological|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
76048313|NCT02491463|Biological|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
75427692|NCT01478607|Drug|QUTENZA|A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
75427693|NCT01478633|Drug|Galantamine|8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
75427694|NCT01478646|Other|conventional breathing therapy|duration: 60 minutes.
75427695|NCT01478646|Other|reflectory breathing therapy|duration: 60 minutes.
75427696|NCT01478659|Dietary Supplement|Control study food with no added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
75427697|NCT01478659|Dietary Supplement|Study food with added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
75427698|NCT01478672|Procedure|Health Coaching and Life-long Monitoring|Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
75427699|NCT01478685|Drug|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
75427700|NCT01478685|Drug|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
75427701|NCT01478685|Drug|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2
75427702|NCT01478711|Other|Clinical Decision Support Tool|A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
75427703|NCT01478724|Dietary Supplement|Milk proteins fraction|capsules, one per day, 24 months
75725669|NCT00833300|Drug|Olanzapine|"2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Discontinue current drug therapy and select one of:~Quetiapine up to 100 mg/day~Risperidone up to 6 mg/day~Loxapine up to 50 mg/day~Methotrimeprazine up to 75 mg/day~Reassess in 24 hours.~Delirium absent - Continue for 24 hours then discontinue.~Delirium present - Treatment at discretion of attending physician."
75878283|NCT05762523|Biological|Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine|15 volunteers vaccinated by the two-step vaccination method: Step 1 - the first vaccination once subcutaneously with 1 dose (0.5 ml) of the inactivated smallpox vaccine OspaVir® in the area of the left shoulder 8-10 cm below the shoulder joint; Step 2 - the second vaccination once by the method of multiple puncture into the outer surface of the shoulder 8-10 cm below the shoulder joint with a live smallpox vaccine at a dose of 1x 106 PFU 7 days following the first vaccination with OspaVir®.
76048314|NCT02491463|Drug|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
76048315|NCT02038881|Biological|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
75427706|NCT01478750|Dietary Supplement|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
75427707|NCT01478750|Procedure|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
76048316|NCT01857622|Drug|DU-176b 15mg|oral DU-176b 15mg once daily
76048317|NCT01857622|Drug|DU-176b 30mg|oral DU-176b 30mg once daily
76048318|NCT01857622|Drug|DU-176b 60mg|oral DU-176b 60mg once daily
76048319|NCT01857310|Dietary Supplement|5 mg folic acid and 30 mg elemental zinc|
75574303|NCT06018402|Other|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity).
75574304|NCT06018402|Other|physical therapy + espb|"the same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
75574305|NCT06018376|Drug|Systemic oncological treatment|Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
75574306|NCT06018155|Other|Spine surgery|Cohort of patients suffering from low back pain and candidate to a spine surgery included in a database previously constituted
75725670|NCT00833378|Drug|Eltrombopag|Eltrombopag 100 mg single oral dose
75725671|NCT00833378|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
75725672|NCT00833378|Drug|Eltrombopag and Lopinavir/Ritonavir|Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
75427708|NCT01478776|Dietary Supplement|omega-3|4 cap 1 gr omega-3 per day for 10 weeks
75427709|NCT01478776|Dietary Supplement|placebo|patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
75427710|NCT01478789|Dietary Supplement|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
75427711|NCT01478789|Dietary Supplement|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
75427712|NCT01478789|Dietary Supplement|placebo|100g/d yogurt with no added plant sterol
75574307|NCT06018012|Device|MRS and ABR|Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry
75574308|NCT06016192|Behavioral|Aerobic Exercise Training|Physical activity performed as controlled aerobic exercise training on ergometer
75591977|NCT06078696|Drug|Sirolimus Oral Tablet|Sirolimus will be given orally with a loading dose of 12 mg, then followed by 4 mg orally daily. Dosage will be adjusted to a therapeutic target of 10 - 15ng/ml in first 3 months post transplant and 3-10 after 3 months. Sirolimus should be started on day +5. It will be continued until at least day 180. Sirolimus can be tapered or continued according to the treating physician discretion and the presence of absence of GVHD and/or degree of donor chimerism. Sirolimus should be continued if donor chimerism is less than 50% to prevent graft loss.
75591978|NCT06078696|Drug|Rituximab or Biosimilar|Rituximab (375 mg/m2/dose) will be administered on Days -14 and -6. In those subjects receiving ongoing renal replacement therapy, rituximab should be administered several hours after hemodialysis. The first rituximab solution for infusion should be administered intravenously at an initial rate of 50 milligrams/hour (mg/hr). The rate may be escalated by 50mg/hr every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions may be started at 100 milligrams/hour (mg/hr) and titrated by 100 mg/hr every 30 minutes to a maximum of 400mg/hr if the subject tolerated the first infusion.
75427713|NCT01478802|Device|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
75427714|NCT01478802|Device|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
75427715|NCT01478815|Behavioral|contingency management|Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
75591979|NCT06078683|Dietary Supplement|C8 Ketone Supplement|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the supplement twice a day for 6 weeks. The supplement is a C8 Ketone Diester supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein. For the proposed studies all participants will drink 5.4 oz of supplement, delivering 50g of C8 Ketone Supplement daily in a split serving fashion where half will be consumed in the morning with breakfast, and the other half with lunch."
75591980|NCT06078683|Dietary Supplement|Placebo|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the placebo twice a day, once at breakfast, and once around lunch time for 6 weeks. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any ketones (BHB), which will be replaced with a similar caloric content of fat in the form of canola oil."
75591981|NCT06078683|Dietary Supplement|Ketone Ester Acute|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink two servings of the supplement at once (50g total C8 Ketone Supplement), and images obtained before and after consumption. The supplement is a C8 Ketone Supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein."
75574309|NCT06015191|Behavioral|Remote Cardiac Rehabilitation|Participants will engage in a ramp-up period (weeks 0-2) where participants will attend 1-on-1 live, remote in-home exercise sessions (20-35 min./session, 3-days/wk.) delivered by a health coach via telehealth video conferencing. Participants will be provided a tablet computer and a small set of equipment. Following the ramp-up period, participants will be asked to attend live, in-home, group-based exercise sessions (weeks 3-12, 3-5 participants/group, 45-min, 3-days/wk. minimum). Sessions will be offered 4-days/wk. in the afternoons and early evenings allowing participants to select the most convenient 3 days per week to attend. Sessions will include a variety of dynamic aerobic and anaerobic (resistance) exercises with a target heart rate corresponding to 60-75% of VO2peak. In the group-based exercise sessions, participants will be able to see, hear, and verbally interact with the health coach and the other participants, allowing for supervision and encouraging social support.
75427716|NCT01478815|Other|Standard Care|Standard Care
75574310|NCT06015191|Behavioral|Active Control|Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
75574311|NCT06014814|Procedure|Catheter ablation|Catheter ablation of atrial fibrillation
75574312|NCT06014294|Behavioral|HIIT|Participants will receive a 16-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 34 to 40 minutes with progression of training. Each HIIT section will include ten combined exercises with self-weight. For Weeks 1-2, the HIIT section will include 10 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 9 intervals of 60 seconds of active recovery.
75574313|NCT06014294|Behavioral|Baduanjin|As a typical MICT, Baduanjin Qigong will be performed. The instructor will provide group teaching with individual instructions on specific movements. The same training principles of individuality and progression used in the HIIT group will also be applied to Baduanjin Qigong group.
75574314|NCT06014294|Behavioral|Workshop|Participants in the non-exercise control group will receive a series of workshops related to daily recreation.
75574315|NCT06014021|Behavioral|Pelvic floor muscle training with biofeedback device|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure.
75574316|NCT06014021|Behavioral|Pelvic floor muscle training|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature.
75574317|NCT06014021|Behavioral|Information about pelvic floor and communication with health professionals|Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.
75574318|NCT06012656|Device|MiniMAX|Total or Partial Hip Arthroplasty
75725673|NCT05359341|Drug|Sitagliptin 50 mg|Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
75878284|NCT02796261|Drug|Eflornithine|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
75878285|NCT02796261|Drug|Lomustine|Lomustine 90 mg/m2 administered orally once every 6 weeks
75427717|NCT01478841|Drug|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
75427718|NCT01478841|Drug|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
75427719|NCT01478867|Other|Detection of gluten in feces|Detection of Gluten in Feces
75427720|NCT01478880|Procedure|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
75725674|NCT05359341|Drug|Empagliflozin 12.5 MG|Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
75725675|NCT05359341|Drug|Sitagliptin 50 mg + Empagliflozin 12.5 MG|Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
75878286|NCT02796261|Drug|Lomustine|Lomustine 110 mg/m2 administered orally once every 6 weeks
75878287|NCT02904096|Device|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
75725676|NCT05359341|Drug|Empagliflozin 12.5 MG + Sitagliptin 50 mg|Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
75725677|NCT00824954|Procedure|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
76048320|NCT01857310|Drug|Placebo Comparator: Placebo|
75427721|NCT01478880|Procedure|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
75574319|NCT06009185|Drug|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.
75574320|NCT06006793|Drug|SY-5933|KRAS p.G12C inhibitor
75574321|NCT06006754|Other|Observational study|No intervention: observational study
75574322|NCT06004739|Drug|Start Antibiotics / Continue Antibiotics for treatment of bacteriuria|Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician [MRP]). Antibiotics choice to be selected by the MRP.
75574323|NCT06004739|Other|No Antibiotics for treatment of bacteriuria|Participants will be randomized to no antibiotics
75574324|NCT06004232|Behavioral|Prenatal Yoga to Prevent Postpartum Depression (PRY-D) intervention|The PRY-D curriculum is a mindfulness-based prenatal yoga intervention which utilizes techniques to build both embodiment and mindfulness, and has previously been shown to reduce depression in a small sample of pregnant women with clinical depression.
75574325|NCT06004232|Behavioral|Treatment as Usual (TAU)|TAU involves routine prenatal care, during which time all patients are given information on the importance of physical activity during pregnancy.
75574326|NCT06003010|Behavioral|Yoga|6 yoga videos to be done 2-3x a week for 6 weeks before and after surgery.
76048321|NCT02472353|Drug|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
76048322|NCT02472353|Drug|Doxorubicin|Standard of care treatment with doxorubicin
76048323|NCT02491073|Other|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
75574327|NCT05994027|Behavioral|ATTACH™ Online Platform Parenting Program|ATTACH Online Platform: Preserving and promoting optimal RF in parents who are experiencing adversities, enables parents to appropriately attribute affective states to their children and respond accurately to meet their children's needs, thus promoting sensitive/ responsive parent-child relationships.
76048324|NCT02314117|Drug|Ramucirumab|Administered IV
76048325|NCT02314117|Drug|Capecitabine|Administered orally
75574328|NCT05993182|Drug|Ephedrine 5mg|Patients received 5mg bolus dose of ephedrine Intravenous after the first hypotension [ Base line time or starting point is first hypotension]
75574329|NCT05993182|Drug|Ephedrine 10mg|Patients received 10mg bolus dose of ephedrine Intravenous after the first hypotension [ Base line time or starting point is first hypotension]
75574330|NCT05993182|Drug|Ephedrine 15mg|Patients received 15mg bolus dose of ephedrine Intravenous after the first hypotension [ Base line time or starting point is first hypotension]
75427722|NCT01478893|Biological|SEL-068|Sub-cutaneous injection, multiple dose
75574331|NCT05989217|Device|Occlusal Splint|Occlusion Splint
75574332|NCT05989217|Radiation|Laser Therapy|Laser Therapy
75878288|NCT01569711|Procedure|Deep brain stimulation of nucleus accumbens|"Day0 : surgical placement of electrodes~M1 : stimulation of nucleus accumbens~M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
75427723|NCT01478893|Biological|Saline|Sub-cutaneous injection, multiple dose
75878289|NCT05202171|Other|Cervical Stabilization Exercise|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
76048326|NCT02314117|Drug|Cisplatin|Administered IV
76048327|NCT02314117|Drug|Placebo|Administered IV
75427724|NCT01477905|Device|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
75427725|NCT01477905|Device|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
76048328|NCT02314117|Drug|Fluorouracil|Administered IV
76048329|NCT01893346|Drug|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
75427726|NCT01478945|Device|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
75427727|NCT01478984|Procedure|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
75427728|NCT01478984|Procedure|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
75427729|NCT01478997|Dietary Supplement|Flexsure Capsules|Flexsure - 3 capsules once a day in the absence of meals (at least 30 min prior to meals) for 56 days
75574333|NCT05989113|Other|Administration of the IPAQ-SF questionnaire|Administration of the IPAQ-SF questionnaire at the patient's consultation and upon return home
75574334|NCT05988866|Behavioral|lipodia|Participants will receive access to the digital health intervention lipodia in addition to TAU.
75427730|NCT01478997|Dietary Supplement|Placebo Capsules|Carboxy Methyl Cellulose
75427731|NCT01479023|Drug|64Cu-DOTA-U3-1287|
75427732|NCT01479023|Drug|U3-1287 (unlabeled)|
75427733|NCT01479036|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
75574335|NCT05982847|Diagnostic Test|Blood pressure screening|Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.
75574336|NCT05981924|Other|Perioperative Music Therapy|Music therapist will play customized music in the perioperative period on the basis of oxycodone analgesia
75725678|NCT05398731|Other|Covid_19|Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19
75878290|NCT05202171|Other|Standard treatment|standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
75427734|NCT01479036|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
75427735|NCT01479049|Drug|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
75427736|NCT01479049|Drug|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
75427737|NCT01479062|Behavioral|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
75427738|NCT01479062|Behavioral|Usual Care|Placebo Control
75427739|NCT01479088|Drug|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value <180 pg/mL as tolerated by the patient
75427740|NCT01479101|Other|MammaPrint 70-gene expression profile|
75427741|NCT01479101|Other|BluePrint 80 gene expression profile|
75427742|NCT01479114|Drug|rh-GCSF|10 ug/kg/day intravenously for 3 days
75427743|NCT01479153|Procedure|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
75574337|NCT05978843|Behavioral|Monetary benefit to purchase fruits and vegetables|Participants will receive varying benefit amounts to purchase fruits and vegetables.
75725679|NCT00838760|Drug|TMC558445; TMC310911; Darunavir; Placebo|
75725680|NCT05384301|Other|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
75725681|NCT00825032|Procedure|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
75725682|NCT00825032|Procedure|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
75725683|NCT03791398|Drug|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
75725684|NCT03791398|Drug|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
75725685|NCT03791398|Drug|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
75574338|NCT05976477|Other|educational intervention|"four short videos (about one-minute/one-minute and half duration) concerning the topic of reducing dietary salt intake to control the blood pressure in elderly hypertensive patients: the mini-videos will be designed with a common thread starting from providing general information regarding diet to enhance awareness of the amount of salt that is usually introduced with the diet, up to give suggestions on which products to choose/avoid during grocery shopping and how to behave during the preparation and consumption of food at home to reduce salt intake;~Four images informing participants about the risk of excessive salt intake and health benefits of a low-sodium diet and tips on how to reduce daily salt intake;~Four recipes for tasty easy-to-prepare meals, avoiding added salt."
75574339|NCT05975580|Drug|Topiramate|Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
76048330|NCT02490371|Device|Low frequency rTMS|1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
75427744|NCT01479179|Drug|AMG 479|"Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
75427745|NCT01479179|Drug|Trastuzumab|"Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle."
75427746|NCT01479192|Drug|Fenretinide|100mg (2cps/day) for 5 years
75427747|NCT01479192|Other|Placebo|2 cpr/day of matched placebo for 5 years
75427748|NCT01479218|Device|Occlutech PDA occluder|Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
75427749|NCT01479231|Drug|dexlansoprazole|Dexlansoprazole 60 mg daily for 6 weeks
75427750|NCT01479244|Biological|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
75427751|NCT01479244|Biological|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
76048331|NCT02490371|Behavioral|structured physiotherapy upper limb training|Structural Physiotherapy upper limb training for 30-minutes
75427752|NCT01479257|Behavioral|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
75427753|NCT01479257|Device|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
75574340|NCT05975580|Drug|Phentermine|Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine
75427754|NCT01479257|Device|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
75427755|NCT01479283|Drug|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered."
75574341|NCT05975580|Drug|Placebo|Placebo is an inactive substance.
75574342|NCT05969340|Diagnostic Test|ultra-high-resolution CT-scan|Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
75574343|NCT05963347|Drug|Golidocitinib|Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.
75574344|NCT05963347|Drug|CHOP Regimen|CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
75574345|NCT05948917|Behavioral|Mind-Body Skills Groups|The mind-body skills groups consist of supportive small group sessions with about 8-10 participants per group. Participants of these groups learn and practice mind-body techniques including: meditation, self-expression through drawings, autogenics and biofeedback, guided imagery, body awareness, and genograms.
75574346|NCT05945121|Other|Cardio-oncology program|Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
75574347|NCT05943964|Behavioral|Virtual exercise and rehabilitation program|"Participants will have two 30-minute sessions per week for 12 weeks. The program will focus on aerobic exercises and stretching exercises. When applicable, stretching exercises will focus on areas of contractures, and joints with limited range of motion (ROM).~Sessions will be completed by a team of Physical Therapists using the established telemedicine platform at Children's Healthcare of Atlanta, as used routinely in the blood and marrow transplant clinic for clinical care (Epic). Adherence to the program will be encouraged during monthly standard clinic visits."
76048332|NCT02058147|Drug|Insulin glargine/lixisenatide Fixed Ratio Combination|Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
76048333|NCT02058147|Drug|Insulin glargine (HOE901)|Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
76048334|NCT02058147|Drug|Lixisenatide (AVE0010)|Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
76048335|NCT02058147|Drug|Metformin|Pharmaceutical form: Tablet; Route of administration: Oral administration.
76048336|NCT02489981|Drug|Spiriva|60 puffs
76048337|NCT04205045|Diagnostic Test|Lactose Breath Test|Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.
76048338|NCT04205045|Other|Gut permeability test|A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.
75427756|NCT01479283|Drug|5-Days Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered."
75427757|NCT01479296|Biological|VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)|Given intramuscularly
75427758|NCT01479296|Biological|rAd5 env A|Given intramuscularly
75427759|NCT01479296|Biological|rAd5 env B|Given intramuscularly
75427760|NCT01479296|Biological|rAd5 env C|Given intramuscularly
75574348|NCT05943288|Device|OIP-1|Olympus Endoscopy Computer-Aided Detection (CADe) system
76024554|NCT03329300|Behavioral|Family-based Behavioral Treatment (FBT)|Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
75427761|NCT01479296|Biological|rAd5 gag-pol|Given intramuscularly
75427762|NCT01479296|Biological|Placebo Vaccine|Given intramuscularly
75427763|NCT01479361|Drug|Atovaquone 750 mg twice daily|
75427764|NCT01479361|Drug|Atovaquone 1500 mg twice daily|
75427765|NCT01479387|Drug|[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received In-111 Zevalin.
76048339|NCT04205045|Other|Milk Test|Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
76048340|NCT04415554|Diagnostic Test|echocardiography|echocardiography exam of the infant
75427766|NCT01479452|Procedure|Bariatric surgery|Gastric banding, vertical banded gastroplasty, gastric bypass
75574349|NCT05937724|Other|Family Caregiving|Family caregiving and sibling inclusive
75574350|NCT05934747|Device|DBS|Deep Brain Stimulation
75574351|NCT05932966|Device|Insulin closed-loop delivery system|Insulin closed-loop delivery system
75574352|NCT05928026|Behavioral|Financial Support|A debit card will be loaded with $500 and can be used like a typical debit card.
75574353|NCT05912049|Drug|9MW3811 Injection|Single dose intravenously infused on day 1
75725686|NCT00838838|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 18yrs in medical practices fulfilling all criteria for documentation.
76048341|NCT02471183|Drug|Selexipag|Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
75427767|NCT01479452|Other|Usual care|Non-surgical obesity treatment
75427768|NCT01479491|Other|Data collection|Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
75427769|NCT01479504|Drug|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
75574354|NCT05912049|Drug|Placebo|Single dose of matching placebo intravenously infused on day 1
75574355|NCT05885438|Behavioral|ACT workshop|This workshop is a brief behavioral intervention that teaches acceptance and commitment therapy skills (e.g., values clarification, acceptance, committed action) to approach healthy living.
75574356|NCT05880147|Device|Consent App|Family will receive their study information and consent form in an app on a tablet
75574357|NCT05880147|Other|Traditional paper-based consent|Patient/family will receive their study information and consent on a traditional paper form
75574358|NCT05857748|Drug|lifitegrast|patient newly started on medication will be followed for 6 months
75574359|NCT05847517|Drug|Metoprolol Injection|"A dilution of 15 mg Metoprolol tartrate in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure or heart rate, the infusion shall be stopped and the infusion noted."
75574360|NCT05847517|Drug|saline 0.9%|"A dilution of 0.9% sodium chloride in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure below 110 mmHg or heart rate below 60 bpm, the infusion shall be stopped and the infusion noted."
75725687|NCT00838994|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
75725688|NCT05360979|Drug|envafolimab|Envafolimab: 300 mg, D1, Q3W, subcutaneously administered
76024555|NCT03304210|Drug|PIPAC with Abraxane|Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
76024556|NCT03297346|Other|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
76024557|NCT03289741|Drug|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
76048342|NCT01855828|Drug|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
75878291|NCT05763381|Device|Photobiomodulation Therapy (PBMT)|Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.
76024558|NCT03289741|Drug|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
76048343|NCT01855828|Drug|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
75427770|NCT01479504|Drug|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
76048344|NCT01855828|Drug|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
76048345|NCT01855828|Drug|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
75427771|NCT01479504|Drug|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
75427772|NCT01479504|Drug|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
75427773|NCT01479556|Drug|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
76024559|NCT03289741|Behavioral|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
76024560|NCT03246529|Drug|BL-8040 1.25 mg/kg + G-CSF|Up to 2 SC injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
75427774|NCT01479556|Drug|Placebo|150mg BID p.o.
75427775|NCT01479569|Procedure|Pericardiocentesis|
75427776|NCT01479582|Drug|Access to unlicensed cord blood units|
75427777|NCT01479634|Drug|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
75574361|NCT05828615|Other|Group A|"Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
75591982|NCT06078683|Dietary Supplement|Placebo Acute|Participants will undertake a controlled feeding intervention where they will drink two servings of the placebo at once (50g total placebo), and images obtained before and after consumption. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any BHB, which will be replaced with a similar caloric content of fat in the form of canola oil.
76024561|NCT03246529|Drug|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
76048346|NCT01855828|Drug|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
76048347|NCT01855828|Drug|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
76048348|NCT04417335|Biological|BCG vaccine|Bacille Calmette-Guérin is a live attenuated strain of Mycobacterium bovis developed in 1921 to prevent tuberculosis and other mycobacterial related infections.
76048349|NCT04417335|Biological|Placebo|0.9% NaCl
76048350|NCT02489279|Behavioral|Sustained Attention Control (SAC) Method|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
76048351|NCT02489279|Behavioral|Scrabble|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
76048352|NCT04417491|Device|Dry Needling|Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
75427778|NCT01479634|Drug|Study-Provided ART|"Study provided drugs:~Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate [TDF] and emtricitabine [FTC]) PLUS~Efavirenz [EFV]"
75725689|NCT00991731|Behavioral|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
75725690|NCT00991731|Behavioral|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
75427779|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
75725691|NCT00833534|Biological|rituximab|Given IV
75725692|NCT00833534|Drug|lenalidomide|Given orally
75725693|NCT00833612|Device|Counterpulsation with IAB|IABC pre-reperfusion PCI
75725694|NCT05591001|Drug|ketamine and dexmeditomidine combination|Dexmedetomidine( 0.4 -0.6 μg/.kg /.hr)) ketamine,( 1 -2m/.kg/.hr) infusion
75427780|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
75725695|NCT05591001|Drug|Propofol|propofol (100 ug /kg/min) infusion
75725696|NCT00517192|Drug|Tipranavir|
75725697|NCT00517192|Drug|Darunavir|
75725698|NCT00517192|Drug|Ritonavir|
75725699|NCT05283369|Device|Videogame therapy|The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.
75725700|NCT05283369|Other|Conventional therapy|The usual dose of physical and occupational therapy, for 8 weeks.
75725701|NCT00625820|Drug|6R BH4|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
75725702|NCT00625820|Dietary Supplement|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
75725703|NCT00145327|Drug|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
75725704|NCT00145327|Drug|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
75725705|NCT05408793|Device|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.
75725706|NCT00833768|Drug|Sevelamer carbonate|800mg tablets to be taken orally with meals three times per day
75574362|NCT05828615|Other|Group B|"The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
75725707|NCT00833768|Drug|Placebo for sevelamer carbonate|Placebo tablets to be taken orally with meals three times per day
75427781|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
75427782|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
75427783|NCT01479647|Drug|PH-797804|Tablet, 24 mg, single dose
75427784|NCT01479660|Other|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
75427785|NCT01479660|Drug|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
75725708|NCT01009606|Other|Usual strategy|Usual strategy
75725709|NCT01009606|Other|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
75725710|NCT05590611|Other|Dietary Intervention with Brown Bread|The participants in this group will be asked to replace all their habitual bread intake by standard brown bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
75725711|NCT05590611|Other|Dietary Intervention with Sourdough Bread|The participants in thisgroup will be asked to replace all their habitual bread intake by wholemeal sourdough bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
75725712|NCT05358405|Other|Müller maneuver|The Müller maneuver allows maximum inspiratory pressure measurement via a one-way valve connected to the intubation tube and is currently used in routine care for diaphragmatic assessment. Ventilation through the one-way valve results in forced inspiration for about 20 seconds. The endothoracic depression induced by this test is likely increasing venous return and cardiac output in patients with preload reserve, i.e. in preload-dependent patients. The observation of an increase in cardiac output during a Müller maneuver could reflect the existence of a dependent preload state, i.e. with a reserve of preload, and de facto lower risk of pulmonary oedema. This test would be an easy alternative to the passive leg raising test used in current practice to evaluate the preload dependency and the risk of weaning induced pulmonary edema.
75725713|NCT05590533|Other|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the F-2-MS
75725714|NCT00510484|Drug|Pancrelipase Delayed Release|24000 unit Capsule
75725715|NCT00510484|Drug|Placebo Comparator|Placebo
75725716|NCT00839228|Drug|Perhexiline|100mg o bd for 3 months
75725717|NCT00839228|Drug|Placebo|Placebo one tablet bd for 3 months
75878292|NCT05763381|Device|Sham-Photobiomodualtion Therapy (Sham-PBMT)|Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
75725718|NCT05408637|Device|Transcranial Phoobiomodulation (tPBM)|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
75725719|NCT00839384|Device|Advisa IPG|Implantable Pulse Generator will be implanted
75725720|NCT05408481|Diagnostic Test|Serum cortisol level|Biochemical test
75725721|NCT00839462|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
75725722|NCT00839462|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
75725723|NCT01009996|Procedure|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
75725724|NCT05590143|Drug|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
75878293|NCT04053348|Procedure|Home-based rehabilitation program using mobile app|Home-based rehabilitation program
75878294|NCT03648762|Behavioral|Aerobic Exercise Intervention|Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
75725725|NCT05590143|Drug|Placebo|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
75725726|NCT01789983|Behavioral|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
75574363|NCT05826860|Behavioral|Mindfulness Practice|Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
75574364|NCT05826860|Behavioral|Storytelling Workshop|Participants attend 2 (90 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
75574365|NCT05799976|Behavioral|Text message nudge|The text message nudge will be sent to patients 3 days and 1 day prior to a visit with the primary care practices and notify them of up to 3 care gaps based on electronic health record data. Care gaps will be selected based on availability and ranked in this order: influenza vaccination, pneumococcal vaccination, breast cancer screening, colorectal cancer screening, hemoglobin A1 testing, or statin therapy.
75574366|NCT05797623|Drug|Trappa ethanolamine tablets ; ciclosporin|Trappa ethanolamine tablets combined with ciclosporin
75574367|NCT05797623|Drug|Placebo ; ciclosporin|Placebo combined with ciclosporin
75574368|NCT05791227|Diagnostic Test|Sonographer Evaluation|A sonographer will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
75574369|NCT05791227|Diagnostic Test|AI Evaluation|An AI model will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
75574370|NCT05774288|Device|Cera™ patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
75574371|NCT05774288|Device|Another patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
75574372|NCT05753007|Drug|Cannabidiol (CBD)|Custom-formulated full-spectrum solution high in cannabidiol
75574373|NCT05753007|Drug|Placebo|Placebo solution
75574374|NCT05747573|Drug|GB1211|Hard tablet or capsules for oral use
76048353|NCT04417491|Device|Sham Needling|Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
76048354|NCT02489045|Drug|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
76048355|NCT02488109|Other|Higher Calorie Refeeding|
75574375|NCT05746065|Drug|PrEP|Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.
75574376|NCT05739448|Other|nutritional intervention|The nutritional intervention will be based on the following 4 elements: nutritional follow-up by a dietician, fortified meals, tender and juicy meat dishes and fish dishes
75574377|NCT05739448|Other|physical activity|The physical activity intervention will be based on the following 2 elements: Follow-up with a trainer for adapted exercise and physical exercise instruction sheets
75725727|NCT01789983|Other|Collect Blood, GA and Other Survey Tools|"Geriatric Assessment (GA) (Version 5)~Functional Assessment of Cancer Therapy-General (FACT)~Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~Outcome Expectations for Exercise (OEE) scale29~Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
75725728|NCT00622388|Drug|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
75725729|NCT01156389|Drug|Ritonavir and Pyramax|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
76048356|NCT02488109|Other|Lower Calorie Refeeding|
75427786|NCT01479673|Dietary Supplement|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
75427787|NCT01479686|Procedure|iMRI|3.0TiMRI guided resection in adults with glioma
75427788|NCT01479686|Procedure|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
75427789|NCT01479699|Dietary Supplement|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
75427790|NCT01479712|Procedure|Normal Saline Irrigation|Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
75427791|NCT01479738|Procedure|Capitate bone grafting|Capitate bone graft transfer for PIP joint reconstruction
75427792|NCT01479751|Drug|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
75427793|NCT01479751|Drug|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
75427794|NCT01479751|Drug|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
75574378|NCT05736770|Other|Respiratory rehabilitation and out of bed mobilization|The Respiratory rehabilitation and out of bed mobilization group will perform following exercises: pre operative out of bed mobilization, active cycle breathing techniques, forced expiratory technique and volume based incentive spirometery
75574379|NCT05736770|Other|conventional treatment|The conventional exercise program group will perform :Flow based Incentive spirometery, Chest percussion if needed
75574380|NCT05735080|Drug|INX-315|Oral administration
75574381|NCT05726617|Behavioral|Avatar Intervention|8 weekly sessions of 60 minutes.
75725730|NCT01156389|Drug|Pyramax|Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
76048357|NCT02351167|Drug|Combination NRT (Nicotine patch, Nicotine lozenge)|
76048358|NCT02351167|Drug|Varenicline|
76048359|NCT02351167|Drug|Placebo|
76048360|NCT02351167|Behavioral|Intensive smoking counseling|
76048361|NCT02350309|Drug|Lemborexant 5 mg|Lemborexant 5 mg tablet.
76048362|NCT02350309|Drug|Lemborexant 10 mg|Lemborexant 10 mg tablet.
76048363|NCT02350309|Drug|Lemborexant-matched placebo.|Lemborexant-matched placebo tablet.
76048364|NCT02350309|Drug|Flurazepam 30 mg|Flurazepam 30 mg capsule.
76048365|NCT02038647|Drug|Alisertib|Alisertib tablets
76048366|NCT02038647|Drug|Placebo|Placebo matching tablets
76048367|NCT02038647|Drug|Paclitaxel|Paclitaxel intravenous injection
76048368|NCT02058069|Device|Robotic Arm Assisted Total Knee Arthroplasty|The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
76048369|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
76048370|NCT02057835|Drug|BI 691751 high dose|BI 691751 high dose
76048371|NCT02057835|Drug|BI 691751 middle dose|BI 691751 middle dose
76048372|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
75574382|NCT05716386|Dietary Supplement|Low salt diet|Low salt diet less than 2 gram per day
75574383|NCT05714462|Other|meals consisting of primarily animal protein sources|an omnivorous diet
75574384|NCT05714462|Other|meals consisting of plant protein sources|an herbivorous diet
75574385|NCT05714332|Other|Advanced practice physiotherapy and orthopedic surgeon management|Management of their musculoskeletal condition by an advanced practice physiotherapist and an orthopedic surgeon.
75574386|NCT05714332|Other|Orthopedic surgeon management|Management of their musculoskeletal condition by an orthopedic surgeon.
75574387|NCT05708989|Procedure|Caudal Block|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
75725731|NCT04043624|Drug|Lidocaine|regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
75725732|NCT04043624|Drug|Saline|IV bolus of saline, followed by continuous infusion of saline
75725733|NCT01105767|Drug|Chlorhexidine gluconate|Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
75725734|NCT01105767|Other|Supplemental training, education and hygiene|Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
75427795|NCT01479790|Device|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
75427796|NCT01479803|Procedure|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
75427797|NCT01479829|Drug|ESC + CBX|Escitalopram (ESC) 10 mg twice day given orally twice a day plus Celecoxib (CBX) 200 mg twice daily.
75725735|NCT00834002|Biological|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
75427798|NCT01479829|Drug|ESC + PBO.|• Escitalopram (ESC) 10 mg twice per day plus Placebo (PBO)administered twice daily.
75427799|NCT01479829|Drug|ESC+CBX|• Escitalopram 10 mg given twice day plus Celecoxib 200 mg twice daily.
75427800|NCT01479881|Drug|tacrolimus|a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).
75427801|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
75427802|NCT01479881|Drug|cyclosporine|A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).
75427803|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
75427804|NCT01479907|Dietary Supplement|Synbiotics|12 gr in 250 cc of water once daily X 15 days
75574388|NCT05708989|Procedure|Ultrasound-guided Pudendal Block|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
75725736|NCT05589987|Device|power mobility|"Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded."
75725737|NCT00834158|Procedure|TACE|1 time
75725738|NCT00834158|Procedure|PVE|1 time
75878295|NCT03648762|Behavioral|Combined Aerobic and Strength Exercise Intervention|Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
75427805|NCT01479907|Dietary Supplement|Placebo|12 gr in 250 cc of water once daily X 15 days
75427806|NCT01479920|Drug|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
75574389|NCT05708989|Drug|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
75878296|NCT03648762|Behavioral|Inspiratory Muscle Training Exercise Intervention|Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
75574390|NCT05708989|Drug|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
75427807|NCT01479920|Procedure|DCEAS (Hwato®/ Dongbang®)|"Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable."
75574391|NCT05705440|Biological|RSVPreF3 vaccine|No intervention is administered in this extension study. Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of RSVPreF3 vaccine except in RSV MAT-011 study, where some participants received a second dose as well.
75427808|NCT01479920|Procedure|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
75427809|NCT01479933|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
75427810|NCT01479933|Dietary Supplement|Placebo|Inactive placebo
75427811|NCT01479933|Dietary Supplement|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
75574392|NCT05705440|Other|Control|No intervention is administered in this extension study. Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of any control (placebo, Tdap or influenza vaccine).
75574393|NCT05694507|Other|Mental Well-being Chatbot|The chatbot contents are developed by Clinical psychologists and well-being promotion officers. Content includes relationships, stress, value, emotion, and positive psychology.
75427812|NCT01479946|Drug|Electrochemotherapy|bleomycin together with electroporation
75427813|NCT01479959|Device|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
75427814|NCT01479972|Biological|VPM1002|Tuberculosis vaccine
75574394|NCT05682079|Other|TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity|"The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device."
75725739|NCT05589909|Diagnostic Test|IL27, PCT, CRP, Blood culture|magnetic bead multiplex platform
75725740|NCT03693430|Drug|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
75725741|NCT03693430|Drug|Placebo (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
75725742|NCT00625742|Behavioral|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
75725743|NCT00625742|Behavioral|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
75725744|NCT00625742|Drug|Melatonin|20 mg by mouth (PO) Daily
75725745|NCT00625742|Dietary Supplement|Juven|90 calories of Juven, twice a day.
75427815|NCT01479972|Biological|BCG|commercially available live vaccine BCG
75427816|NCT01479998|Other|standard care|standard care plus nicotine replacement therapy
75725746|NCT00625742|Drug|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate >110 beats/min) or resting energy expenditure (REE) > 110% of predicted.
75725747|NCT00625742|Drug|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
75725748|NCT00834314|Procedure|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
75878297|NCT02586675|Drug|Tamoxifen|Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
75878298|NCT02586675|Drug|Ribociclib|"Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD)."
75725749|NCT00834314|Procedure|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
75725750|NCT05589441|Drug|salbutamol|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
75427817|NCT01479998|Other|standard care plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
75878299|NCT02586675|Drug|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
75878300|NCT03648528|Drug|cholecalciferol|
75878301|NCT03648528|Drug|placebo|
75878302|NCT03648294|Other|adrenalectomy for primary addosteronism|All of the clinical and biological data were retrospectively compiled from the patient computerized record. The variables analyzed were: age, sex, body mass index (BMI), PAH discovery circumstances, pre- and postoperative systolic and diastolic blood pressure assessments, number of pre-hypertensive antihypertensive drug - and postoperatively, the laterality, the size and nature of the lesions, the operating time, the surgical technique used. The biological data evaluated were pre- and postoperative plasma and plasma creatinine, preoperative serum aldosterone concentrations, plasma renin activity, and preoperative aldosterone / renin ratio. Hypokalemia was defined as serum concentration below 3.5 mmol / L.
75427818|NCT01480011|Drug|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
75878303|NCT05202015|Drug|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|MRI of the liver accoring to our institutional daily routine protocol
75427819|NCT01480050|Drug|temozolomide|standard of care drug
75427820|NCT01480050|Other|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
75427821|NCT01480050|Other|pharmacological study|
75427822|NCT01480050|Drug|Mibefradil|
75427823|NCT01480063|Drug|Fampridine|Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
75427824|NCT01480102|Drug|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
75878304|NCT03648216|Behavioral|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
75427825|NCT01480102|Other|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
75725751|NCT05589441|Drug|Insulin|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
75725752|NCT00825188|Drug|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
75878305|NCT05201625|Diagnostic Test|real time PCR|real time PCR
75878306|NCT04053114|Other|DNA and RNA extraction from FFPE or frozen tissue sample|Next generation sequencing (NGS)
75878307|NCT03629691|Other|lung cavitation|apatinib treated patients developed lung cavitation
75878308|NCT03648138|Behavioral|Sugary drink warning labels|This information appears in the description of the study arms.
76048373|NCT02057835|Drug|BI 691751 low dose 1|BI 691751 low dose 1
75574395|NCT05682014|Behavioral|Mindful Breastfeeding Program|"A web-based Mindful Breastfeeding Program, which is applied to pregnant women in groups of 5, consisting of 8 sessions, 2 sessions per week for 4 weeks.~Mindful breastfeeding program will consist of breastfeeding education, introduction to the concept of mindfulness, mindful breastfeeding, practical suggestions to pregnant women by the researcher, providing a discussion environment for them to share their experiences, and homework on the content of the program.~A web site with written material, video and audio recordings will be created and presented to the participants as a support element.~In order for them to use mindfulness practices in their daily lives, motivational WhatsApp short messages will be sent by the researcher daily during the training, weekly during the post-training period, and daily in the postpartum period."
75878309|NCT03161405|Drug|TAK-906 Maleate|TAK-906 capsule
76048374|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
76048375|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
76048376|NCT02057835|Drug|BI 691751 low dose 2|BI 691751 low dose 2
76048377|NCT02057757|Drug|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
75427826|NCT01480115|Other|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
75427827|NCT01480128|Procedure|Single-port|Single-port laparoscopic colon resection
75427828|NCT01480128|Procedure|Multi-port|Multi-port laparoscopic colon resection
75427829|NCT01480141|Drug|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
75427830|NCT01480167|Device|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
75427831|NCT01480167|Other|Non-operative Management|Conservative Care
75725753|NCT00825188|Drug|eplerenone|Eplerenone 25-50mg daily x 8 weeks
75878310|NCT03161405|Drug|Itraconazole|Itraconazole solution
75427832|NCT01480180|Drug|turoctocog alfa pegol|Administered i.v.
75427833|NCT01480193|Other|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
75427834|NCT01480193|Other|Integrative Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
75427835|NCT01480245|Drug|GSK2402968|6mg/kg/week
75427836|NCT01480271|Drug|2 ng GSK2445053|2ng GSK2445053 administered intranasally
75427837|NCT01480271|Drug|20ng GSK2445053|20ng GSK2445053 administered intranasally
75725754|NCT00825188|Drug|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
75725755|NCT00825188|Drug|amlodipine|amlodipine 5-10mg daily for 8 weeks
75878311|NCT03648060|Device|Digital kinematic biofeedback system|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
76024562|NCT03205657|Procedure|auto transplant followed by allo transplant|patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL
76024563|NCT03183609|Other|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
76048378|NCT02057757|Drug|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
76048379|NCT02037477|Drug|Vonoprazan|Vonoprazan tablets
75427838|NCT01480271|Drug|100ng GSK2445053|100ng GSK2445053 administered intranasally
75427839|NCT01480271|Drug|200ng GSK2445053|200ng GSK2445053 administered intranasally
76024564|NCT03183609|Other|Rice Flour in Protein Shake|15 Grams Rice Flour BID
76024565|NCT03142711|Other|No Medical Intervention|Validation of phone ePRO
76048380|NCT02037477|Drug|Esomeprazole|Esomeprazole capsules
76048381|NCT02037477|Drug|Rabeprazole sodium|Rabeprazole sodium tablets
76048382|NCT02057523|Drug|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
76048383|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
76048384|NCT02037165|Drug|Pregabalin|Pregabalin hard capsule
76048385|NCT02037165|Drug|BI 1026706|BI 1026706 oral solution
76048386|NCT02037165|Drug|Celecoxib|Celecoxib hard capsule
76048387|NCT02470403|Drug|LIK066|LIK066 25 mg tablets
76048388|NCT02470403|Drug|Placebo|Matching placebo tablets
76048389|NCT01855750|Drug|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
76048390|NCT01855750|Drug|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
75574396|NCT05678972|Other|Self-help online mindfulness-based intervention|"This self-help online mindfulness-based intervention is comprised of four weekly modules on education about mindfulness, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and videos are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice.~Participants will be asked to meditate daily and complete a daily log on their mindfulness practice during this 8-week period."
75574397|NCT05670795|Drug|Recombinant Follicle Stimulating Hormone|clinical pregnancy rates
76048391|NCT01855750|Drug|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
75574398|NCT05670795|Drug|Recombinant Follicle Stimulating Hormone and Clomiphene Citrate|clinical pregnancy rates
75574399|NCT05669833|Drug|Guselkumab|Guselkumab (GUS) subcutaneous injection
75574400|NCT05669833|Drug|Golimumab|Golimumab (GOL) subcutaneous injection
75574401|NCT05669833|Drug|Placebo|Guselkumab (GUS) matching placebo subcutaneous injection
75574402|NCT05661097|Procedure|Suture mode|Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.
75574403|NCT05660577|Device|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
76048392|NCT01855750|Drug|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
76048393|NCT01855750|Drug|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
76048394|NCT01855750|Drug|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
75427840|NCT01480271|Drug|400ng GSK2445053|400ng GSK2445053 administered intranasally
75427841|NCT01480271|Drug|1000ng GSK2445053|1000ng GSK2445053 administered intranasally
75427842|NCT01480271|Drug|2000ng GSK2445053|2000ng GSK2445053 administered intranasally
75427843|NCT01480271|Drug|4000ng GSK2445053|4000ng GSK2445053 administered intranasally
75427844|NCT01480271|Drug|Placebo|Placebo administered intranasally
75427845|NCT01480310|Drug|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
75574404|NCT05657496|Drug|Triamcinolone Acetonide 40 mg/ml Inj, Susp|Prepared in clinic by physician or medical staff
75574405|NCT05657496|Biological|Platelet-rich plasma Inj|Produced from participant's whole blood venous draw of approximately 15 mL. Prepared by centrifuge in clinical office
75574406|NCT05642455|Genetic|Afamitresgene autoleucel|Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to <40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells/kg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion
75574407|NCT05627063|Drug|ABSK121-NX|In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.
75878312|NCT01813929|Drug|Metformin|Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
75878313|NCT01813929|Drug|Placebo|Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
75427846|NCT01480310|Drug|Placebo|may receive up to 3 subcutaneous doses of placebo
75427847|NCT01480323|Drug|Interleukin-2|intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases
75427848|NCT01480323|Drug|Ipilimumab|IV infusion, 3 mg/kg, day 2, 23, 44, 65
75878314|NCT05284968|Drug|Cell injection|All subjects will be treated with cell injection
76048395|NCT01855750|Drug|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
75427849|NCT01480336|Drug|Amiodarone Plus Ranolazine|Ranolazine 500mg by mouth twice daily
75427850|NCT01480336|Drug|Amiodarone with Placebo|stabel dose of amiodarone as prescribed by cardiologist
76048396|NCT04963439|Drug|Macitentan|Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.
75427851|NCT01480362|Device|Negative Pressure Wound Therapy|"Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations."
75427852|NCT01480362|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
75427853|NCT01480375|Device|Smartbx™ system.|The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
75427854|NCT01480388|Drug|Placebo/JNJ-39758979 (300 mg/d)|Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
75427855|NCT01480388|Drug|JNJ-39758979 (10 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
75427856|NCT01480388|Drug|JNJ-39758979 (30 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
75427857|NCT01480388|Drug|JNJ-39758979 (100 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
75427858|NCT01480388|Drug|JNJ-39758979 (300 mg)|Form = tablet, route = oral adminstration once daily for 48 weeks
75427859|NCT01480414|Biological|4times injection|bone marrow derived mono nuclear stem cell
75427860|NCT01480414|Biological|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
75427861|NCT01480453|Device|Trabecular Metal Humeral Stem|Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
75574408|NCT05609929|Drug|Multiple administration of omeprazole Single administration of AB-106|Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour
75574409|NCT05607459|Other|Dry Needling|"Dry needling consists of a skilled intervention which uses a thin filiform needle (as those used in acupuncture) to penetrate the skin and stimulate underlying myofascial trigger points (defined as a hyperirritable spot in skeletal muscle that is associated with a hypersensitive palpable nodule in a taut band which is painful on manual compression and can give rise to characteristic referred pain, referred tenderness, motor dysfunction and autonomic phenomena.)~This intervention will be performed targeting the upper trapezius and cervical multifidus muscles"
75574410|NCT05607459|Behavioral|Therapeutic Exercise|Patients will include a supervised therapeutic exercise program in their daily life, based on strengthening exercises for neck muscles.
75574411|NCT05607459|Other|Manual Therapy|Patients will receive a manual compression (30 seconds) over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus muscle.
75878315|NCT03650166|Other|MyBP|This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
75427862|NCT01480466|Other|Obesity tools in the electronic health record|The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
75427863|NCT01480492|Drug|Telbivudine|600mg,1/d,one year
75427864|NCT01480505|Procedure|Pars plana vitrectomy with gas tamponade|"A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment."
75427865|NCT01480518|Genetic|DNA analysis|
75427866|NCT01480518|Genetic|comparative genomic hybridization|
75878316|NCT03650166|Other|Personal BP monitor|Battery-powered BP monitor for personal use
75427867|NCT01480518|Genetic|gene expression analysis|
75878317|NCT04059822|Other|Slow and deep breathing|Please see arm description
75878318|NCT04053738|Device|Anti-snoring bed|The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
75878319|NCT05285046|Other|No intervention|No intervention
75574412|NCT05607459|Other|Sham Dry Needling|"For the sham DN intervention, a similar approach will be used, but the skin will be not pierced since the material used will be a telescopic Park's sham device.~The guide tube will be pressed against the skin mark and the sham needle will be allowed to drop. The handle will be tapped briskly, but the (blunted) needle tip will not not break the skin."
75427868|NCT01480518|Genetic|mutation analysis|
75427869|NCT01480518|Genetic|polymerase chain reaction|
75427870|NCT01480518|Genetic|polymorphic microsatellite marker analysis|
75427871|NCT01480518|Other|laboratory biomarker analysis|
75427872|NCT01480531|Drug|Clevidipine|"Clevidipine administration begins in the ER or ICU~Clevidipine is again administered post op when blood pressure control is required.~Clevidipine will be administered by an infusion pump via either a central line or a peripheral IV as follows:~Clevidipine will be initiated at an infusion rate of 0.4 μg•kg-1•min-1 and will be titrated as tolerated in doubling increments every 90 s up to 3.2 μg•kg-1•min-1.~Infusion rates above 3.2 μg•kg-1•min-1 will be guided by the patient's response and permitted in serial increments of 1.5 μg•kg-1•min-1.~Infusion rates between 4.4 and 8.0 μg•kg-1•min-1 will be administered for no longer than 2 h.~As blood pressure approaches goal, increase dose by less than double and lengthen time between does adjustments to every 5-10 minutes (a 1-2 mg/hr increase will generally result in a 2-4 mm Hg reduction in SBP)"
75427873|NCT01480544|Other|Experimental: Treatment 1|Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
75427874|NCT01480544|Other|Experimental: Treatment 2|Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
75427875|NCT01480557|Procedure|liquefaction|Cataract extraction surgery type
75427876|NCT01480557|Procedure|Torsional ip|A type cataract surgery using torsional ip technology
75574413|NCT05607407|Drug|Methimazole|Starting dose: Methimazole 15 mg/d. Six participants will receive this dose. If they achieve a 10% increase in peripheral blood H2S concentrations, an additional 13 participants will receive this dose to accrue a total of 19 participants for which a preliminary estimate of PFS6 can be calculated. If the first 6 participants do not achieve a 10% increase in peripheral blood H2S concentrations, the dose will be increased to the second and final dose level of 25 mg/d at which 19 participants will be treated.
75725756|NCT05407623|Behavioral|PAX Good Behavior Game|"PAX GBG is packaged into ten specific tools that the teachers are trained to introduce in in their classroom management practice. The program introduces verbal and visual cues that facilitate prosocial and attentive behaviors One of the core elements of the program is the PAX-game, meaning that the children - while focusing on ordinary school tasks like math - get to play a game in teams where each team tries to make as few classroom rules infractions as possible during a certain period of time. The teams that succeed in achieving predetermined goals get a reward (often a fun and desirable activity) that serves as a reinforcer of prosocial and task-oriented behaviors.~Supervision is performed individually with each teacher and included that the PAX-trainer observes a lecture given by the teacher before each supervision session."
76048397|NCT04939103|Device|TRUS-FNA|Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
76048398|NCT01855126|Other|Blue light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
76048399|NCT01855126|Other|Red light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
76048400|NCT01622673|Drug|Raltegravir|"Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
75427877|NCT01480609|Drug|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
75427878|NCT01480622|Drug|TDF tablets|"White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331"
75427879|NCT01480648|Drug|BI 144807 Placebo|Placebo that represents BI drug
75427880|NCT01480648|Drug|BI 144807|single dose (low to high dose)
75427881|NCT01480661|Drug|Roflumilast|Roflumilast 500 µg, once a day in the morning during 6 months
75427882|NCT01480661|Drug|Placebo of Roflumilast|Placebo 500 µg, once a day in the morning during 6 months
75427883|NCT01480661|Radiation|Functional Respiratory Imaging|CT scan of thorax, at baseline and after 6 months
75427884|NCT01480687|Dietary Supplement|DHA-EPA|1800 mg/day
75427885|NCT01480687|Drug|Ciprofibrate|100 mg/day
75427886|NCT01480700|Other|Nutritional study|subjects consume 2 eggs per day during 4 months
75427887|NCT01480713|Drug|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
75574414|NCT05607407|Procedure|Recurrent Glioblastoma Surgical Resection|The purpose of resection is to remove as much tumor as possible to alleviate mass effect and to obtain brain tissue for experimental analysis.
75427888|NCT01480713|Drug|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
75427889|NCT01480726|Procedure|Surgery|
75574415|NCT05607407|Diagnostic Test|Pharmacodynamic Assays|Pharmacodynamic assays are intended to investigate drug and downstream drug-induced effects.
76048401|NCT01622673|Drug|TUMS® Ultra Strength|"3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
75427890|NCT01480739|Drug|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
75427891|NCT01480739|Drug|100 mg Placebo|Twice daily for 7 days
76048402|NCT01622673|Drug|MINTOX® Maximum Strength|"20 mL MINTOX® Maximum Strength (MS)~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
76048403|NCT01855048|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
75427892|NCT01480752|Drug|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
76048404|NCT01855048|Other|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
75427893|NCT01480752|Drug|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
75574416|NCT05600036|Drug|ESK-001|Oral tablet
75574417|NCT05600036|Drug|Placebo|Oral tablet
75427894|NCT01480752|Drug|no injection|inject nothing after inferior alveolar injection and before root canal therapy
75427895|NCT01480765|Drug|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
75574418|NCT05594628|Other|Neuromuscular training|"Neuromuscular training is designed as 8 weeks and 2 times a week, and approximately 20 minutes per session for Neuromuscular training+usual basketball training group. Other group is only going to keep attending usual basketball training.~Neuromuscular training consisted 3 exercises:~First exercise is passing the ball to side to side on bosu with standing on one leg. 60-90 seconds on time, 30-60 seconds off time. 2 sets for both passing sides and bilaterally.~Second exercise is standing on bosu unilaterally and while standing stabilized, switching basketball hand to hand as dribbling on the floor. Exercise will be on for 60-90 seconds and off for 30-60 seconds, 2 sets for each side Third exercise is jumping with one stance/leg, and landing with double stance while a therabant is attached to the belly and pulling with a minimum/medium force from one side. Changing legs after one jump, 6 times for both side is equal to 1 set of the exercise. It will be done 2 sets for both sides."
76048405|NCT02469857|Drug|AB103 0.5 mg/kg|
75427896|NCT01480765|Drug|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
75427897|NCT01480765|Drug|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
75427898|NCT01480765|Drug|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
75427899|NCT01480778|Drug|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
75427900|NCT01480778|Drug|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
75427901|NCT01480791|Drug|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
75427902|NCT01480791|Drug|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
75427903|NCT01480804|Other|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
76048406|NCT02469857|Other|NaCl 0.9%|
76048407|NCT04960865|Other|Kinesio Taping under tension.|Kinesio tape will be applied to participants under tension.
76048408|NCT04960865|Other|Kinesio Tape without tension|Kinesio tape will be applied to participants without any tension.
76048409|NCT04960865|Other|Rigid Taping|Rigid Taping will be applied.
76048410|NCT02036853|Drug|Triheptanoin|"Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established."
76048411|NCT02469623|Device|Dipole Density Mapping with AcQMap followed by ablation|
75878320|NCT01502085|Drug|Vorinostat, Lenalinomide and Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
75574419|NCT05594563|Drug|DFMO|DFMO orally twice a day
75574420|NCT05594563|Drug|Placebo|Placebo orally twice a day
75574421|NCT05593029|Drug|SEP-363856|Tablet
75574422|NCT05593029|Other|Placebo|Placebo
75427904|NCT01480817|Drug|Sorafenib|Sorafenib 400mg po bid
75427905|NCT01480817|Procedure|TACE for HCC with portal vein invasion|The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
75574423|NCT05591755|Drug|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
75574424|NCT05591755|Drug|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)
75725757|NCT05407623|Behavioral|Count on Me!|"Count on me! is set in adventure game where the child has an avatar that travels thru different worlds/platforms by using their mathematical skills. The child starts of in the home of the avatar, in a house like environment, where the child discovers a magical map that brings the child into a different world called Numberia. During the adventures in Numberia the child learns that it has certain skills, called the mathemagical powers, that will be used to liberate Numberia from the evil Prince Claw that has captured all the beautiful things (e.g., the birds that used to sing in the forest).~Count on me! was developed within a behavior analytic framework using a nonlinear programming process."
75878321|NCT04052802|Other|Fissure sealing|The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
75574425|NCT05591755|Drug|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)
75878322|NCT03648684|Behavioral|Caffeine-Based Expectancy Challenge|Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
75878323|NCT03648684|Behavioral|Placebo-Based Expectancy Challenge|Intervention to alter expectancies (expectancy modification only)
75878324|NCT03647982|Drug|Meditoxin|injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
75878325|NCT03647982|Drug|Botox|injection of Botox into the intradermal of each contralateral upper back in equal doses
75878326|NCT03647904|Behavioral|SEMS Project|TThe intervention is a culmination of five empirically supported interventions: (1) The MS Wellness Program aimed at developing lifestyle strategies to enhance quality of living and cope with various aspects of MS; (2) The FACETS intervention, which aims to reduce fatigue and improve self-efficacy; (3) The Modified Story Memory technique, which improves new learning and memory; (4) The Speed of Processing training, which improves performance on measures of processing speed in persons with MS. Finally, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, a cognitive behavioral intervention, which improves psychological functioning and functional outcomes.
75878327|NCT03650010|Procedure|Total ankle replacement|total ankle prosthesis through a lateral or an anterior approach
75878328|NCT02901054|Drug|Ondansetron|A single 15-min intravenous infusion of ondansetron
75878329|NCT03068715|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
75427906|NCT01480830|Device|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
75427907|NCT01480856|Procedure|Cobedding|Newborn twins are settled in a singe bed: this is cobedding
75574426|NCT05591755|Drug|Experimental: Vehicle ophthalmic solution (n = 56)|Experimental: Vehicle ophthalmic solution (n = 56)
75574427|NCT05591144|Drug|Prednisone tablet|The dose selection of oral prednisone is the maximum daily dose for 5 days, followed by a taper every 2 days
75574428|NCT05591144|Drug|Ginkgo Biloba Extract|Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
75427908|NCT01480856|Procedure|Single-bedding|Newborn twins are settled in two single beds : this is single-bedding
75427909|NCT01480869|Drug|calcium and cholecalciferol|Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
75427910|NCT01480869|Drug|calcium and cholecalciferol|"Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level < 10 ng/mL~100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level < 20 ng/mL~100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level < 30 ng/mL"
75574429|NCT05587478|Drug|EDP-323|Oral administration
75574430|NCT05587478|Drug|Placebo|Placebo to match EDP-323, oral administration
75574431|NCT05585229|Drug|Psilocybin-assisted Psychotherapy|Participants will complete a 8-week structured psychotherapeutic intervention involving administration of 25mg and 37.5mg PEX010 on two separate occasions.
75574432|NCT05579730|Drug|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo
75574433|NCT05579730|Drug|Ketotifen fumarate ophthalmic solution 0.035%|Ketotifen fumarate ophthalmic solution 0.035%
75574434|NCT05579730|Drug|Brimonidine tartrate ophthalmic solution 0.025%|Brimonidine tartrate ophthalmic solution 0.025%
75574435|NCT05579730|Drug|Vehicle ophthalmic solution|Vehicle ophthalmic solution
75574436|NCT05579262|Dietary Supplement|Beetroot juice|Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation
75574437|NCT05557071|Behavioral|Digital Health Behaviour Change Platform|"Participants will gain access to 6 weekly lessons.~A series of 6 weekly educational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as corresponding behaviour change techniques and a number of other tools and strategies, such as reflection activities, quizzes, and worksheets. Mini podcasts are available to supplement the concepts introduced in the modules. The content is tailored for early career professionals. There will be an emphasis on tactics (e.g., mindfulness, acceptance, emotion regulation) to assist with overcoming incidental affect."
75574438|NCT05548361|Combination Product|active chlorhexidine and placebo probiotic|the randomized patients will be receive active chlorhexidine rinse and placebo probiotic
75574439|NCT05548361|Combination Product|placebo chlorhexidine and active probiotic|the randomized patients will receive placebo chlorhexidine rinse and active probiotic
75574440|NCT05548361|Combination Product|active chlorhexidine and active probiotic|the randomized patients will receive active chlorhexidine rinse and active probiotic
75574441|NCT05542667|Combination Product|Giomer varnish|After dryness and isolation are accomplished, Giomer varnish ( PRG coat barrier, by Shofu) will be applied once at the first treatment visit, one drop of PRG Coat Barrier ACTIVE will be added to the container provided in the package containing PRG Coat Barrier BASE the materials will be mixed together with a disposable tip provided by the kit a thin layer is to be applied and left untouched for 3 seconds according to manufacturer instructions and finally varnish is to be light-cured.
75878330|NCT03068715|Device|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
75878331|NCT03068715|Device|Open label TBS-DLPFC|"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
75878332|NCT04053036|Drug|MDMA|Participants will be given 1.5mg/kg of MDMA
75878333|NCT04053036|Drug|Placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
75878334|NCT03647670|Drug|PF-04965842|orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
75878335|NCT03647670|Drug|Midazolam|substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
75427911|NCT01480882|Procedure|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
75427912|NCT01480882|Device|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
75427913|NCT01480895|Behavioral|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
75427914|NCT01480908|Procedure|Echocardiography at rest|Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
75574442|NCT05542667|Combination Product|Fluoride varnish|After dryness and isolation are accomplished, fluoride varnish (Biflourid 10, by Voco ) single-use type, the foil in the single-use Bifluorid 10 will be pierced using Micro-Tim brush, then a thin layer of the varnish is to be applied using a micro brush for four sessions at a frequency of one session each week, the varnish will be left undisturbed for 10-20 seconds then air-dried according to manufacturer instructions.
75574443|NCT05537428|Behavioral|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
75574444|NCT05533671|Procedure|medial patellofemoral reconstruction|Surgery to correct dislocated (knocked out of place) knee cap. This surgery anchors the kneecap back into the correct position and supports the kneecap.
75427915|NCT01480908|Procedure|Echocardiography during exercise|TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
75427916|NCT01480908|Procedure|MRI at rest|Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
75427917|NCT01480908|Procedure|Exercise testing|Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
75878336|NCT05202951|Other|questionnaires|Electronic case report form integrating questionnaires on chronic pain related to haemophilia, associated-comorbidities, sociodemographic characteristics and analgesic treatments used.
75878337|NCT02966340|Drug|Prazosin|2mg Prazosin
75878338|NCT02966340|Drug|Placebo|Placebo
75878339|NCT05200689|Device|Kinesiotaping (KT)|"Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin."
75878340|NCT03647748|Device|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment.
76048412|NCT02469077|Behavioral|6 week aerobic exercise intervention|"Participants randomly assigned to the 6 week aerobic exercise intervention will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks).~Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out."
75878341|NCT05207007|Procedure|Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation|Phacomulsification lens removal cataract surgery with IOL implantation in both two groups
75574445|NCT05533671|Procedure|Non-operative group|Physical therapy by following a specific regimen.
75574446|NCT05532189|Procedure|ACL reconstruction with BTB autograft with internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft), and the graft will be fortified by suture tape during the surgery in order to strengthen it.
75574447|NCT05532189|Procedure|ACL reconstruction with BTB autograft without internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft). The graft will not be fortified by suture tape in this group. It will be used as is without any modification.
75574448|NCT05532189|Other|Standardized Rehabilitation Protocol|Participants will undergo a standardized rehabilitation protocol with twice weekly physical therapy
75574449|NCT05532150|Procedure|Arthroscopic Bankart repair|Participants in this group will undergo minimally invasive surgery to repair their shoulder with a technique called a Bankart repair.
75574450|NCT05532150|Procedure|Physical therapy|Participants in this group will follow a specific physical therapy rehabilitation protocol
76048413|NCT02469077|Drug|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
75725758|NCT05407623|Behavioral|Collegial Learning Community|"Collegial learning community is a feasible way of professional learning for teachers according to the five cyclical steps. The teachers go through the first step that is to assess the skill or knowledge gaps for students, using various data sources (for example testing, grades, surveys, student interviews). The second step is to reflect upon what skills the teacher needs to acquire in order to help the students to meet the goals. The third step is to deepen the professional knowledge and skills. The fourth step is engaging the students in the new practice, and in the fifth step to evaluate the impact the new practice has had on student outcomes.~In Collegial learning community teachers take help from their peers in each of these steps in a structured way. For example, way of deepening tacit or procedural knowledge (in step two) is to visit a colleague during class and make observations on their classroom practice."
75725759|NCT00834392|Behavioral|Exercise|Walking exercise
75725760|NCT00834470|Drug|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
76048414|NCT02469077|Drug|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
76048415|NCT02469077|Drug|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
76048416|NCT02486627|Drug|plazomicin|
76048417|NCT02486627|Drug|meropenem|
76048418|NCT02486627|Drug|levofloxacin (oral)|
76048419|NCT01644565|Biological|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
75725761|NCT03997864|Drug|Prazosin|"Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks."
76048420|NCT01644565|Biological|Recombinant fimbrial adhesin dscCfaE|
76048421|NCT01644565|Biological|Modified E. coli heat labile enterotoxin LTR192G|
75878342|NCT05284734|Procedure|Regional anesthesia intervention|Ultrasound-guided caudal and erector spinae blocks were administered
75878343|NCT05206851|Other|Manual Lymphatic Drainage and Hot Pack|"Application of hot pack for 20 minutes at low back in sitting, and then the participant will perform deep diaphragmatic breathing for 10 minutes, following these steps:~Sitting in comfortable position~One hand is placed over chest and other on abdomen.~Inhale deep through the nose.~Exhale through mouth, completely, counting back from 4 to 1. Application rotary or stationary circle over low back in side lying position, in pregnant females. A session of 20-30 minutes of Manual Lymphatic Drainage will be given biweekly.~And at the end of Manual Lymphatic Drainage application, deep breathing for 10 minutes will be performed again."
75878344|NCT05206851|Other|Hot Pack|Hot pack will be applied at low back, for 20 minutes as home based protocol.
75574451|NCT05528588|Combination Product|Furoscix|"Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours)."
76048422|NCT02485925|Device|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
76048423|NCT04936217|Other|Data collection|For each patient, the following data will be collected and analyzed: age at operation, sex, Body Mass Index (BMI), ASA score, ASIA score, type of bladder dysfunction assessed by urodynamic evaluation, urinary abnormalities assessed by morphological examination (ultrasound and / or computed tomography) and cystoscopy, creatinine clearance, operative indications, initial mictional mode, surgical assembly, immediate and later complications.
76048424|NCT04936217|Other|Interview using a validated questionnaire|A telephone survey will be conducted by means of a questionnaire in order to evaluate the patient's quality of life.
75574452|NCT05528588|Drug|Diuretic Therapy|Patients will receive home dose oral furosemide or oral furosemide per standard of care.
75574453|NCT05524532|Dietary Supplement|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.
75725762|NCT03997864|Drug|Placebos|Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
75725763|NCT05407467|Dietary Supplement|Curcumin and virgin coconut oil extract (KurCo Smart)|we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
75725764|NCT04043468|Other|Audit and feedback|Audit and feedback (A&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
75725765|NCT01010152|Drug|Codeine Sulfate|30 mg Tablet
75725766|NCT00834548|Procedure|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
75878345|NCT03067311|Behavioral|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
75878346|NCT03067311|Behavioral|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
75878347|NCT05185713|Other|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.
75878348|NCT05762289|Other|Thrust Manipulation (in weight bearing and non weight bearing)|Pain and Range of cervical motion was assessed before and after manipulation in both groups.
76048425|NCT02282293|Drug|Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|
76048426|NCT02282293|Drug|Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)|
76048427|NCT01854658|Drug|GFF MDI (PT003)|GFF MDI administered as two puffs BID
76048428|NCT01854658|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
76048429|NCT01854658|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
76048430|NCT01854658|Drug|Placebo|
76048431|NCT01892020|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
76048432|NCT01892020|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
76048433|NCT02485691|Drug|cabazitaxel XRP6258|Pharmaceutical form: solution Route of administration: intravenous
76048434|NCT02485691|Drug|enzalutamide|Pharmaceutical form: capsule Route of administration: oral
75574454|NCT05524532|Dietary Supplement|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules
75574455|NCT05501717|Drug|ALXN2030|ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
75574456|NCT05501717|Drug|Placebo|Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
75574457|NCT05481684|Other|Normal Progesterone group|No progesterone supplementation
75574458|NCT05481684|Other|Low Progesterone group|Progesterone level <10 ng/mL on ET day. If serum progesterone levels were <10 ng/ml at ET day, vaginal pills (Lutinus 2*1) or SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day. Progesterone supplementation was discontinued if there was no pregnancy. Progesterone supplementation at the same dose was continued until 10 gestational weeks for viable pregnancies.
75574459|NCT05477420|Other|Decision Aid|Participants in the experimental group would be asked to use the decision aid developed by the study. The decision aid tool will ask participants their preferences on traditional face-to-face and online psychotherapies and how they rank different treatment attributes.
75574460|NCT05473715|Drug|Aflibercept(BAY86-5321, Eylea)|2mg, intravitreal (IVT) injection
75574461|NCT05470933|Drug|WJ01075|"Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials."
75574462|NCT05468970|Other|NO Intervention|NO Intervention
75574463|NCT05455008|Behavioral|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
75725767|NCT05589129|Dietary Supplement|Whey Protein Supplement|Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
75574464|NCT05437172|Procedure|injectable platelet rich fibrin with demineralized dentin graft|after atraumatic extraction, collection of whole venous blood (9 ml) in sterile vacutainer tubes will be done without anticoagulant added, vacutainer tubes will be then placed in a centrifugal machine at 700 revolutions per minute (rpm) for 3 min with a tube filled with water to maintain the balance during the centrifuging process. ADDG particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze. Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.
75574465|NCT05437172|Procedure|demineralized dentin graft|"after atraumatic extraction, ADDG particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze.~Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures."
75574466|NCT05431686|Behavioral|SMA visits|SMA visit once every 3 months over a 12 month period
75725768|NCT05589129|Dietary Supplement|Carbohydrate Placebo Control|Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
75725769|NCT00839774|Other|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
75725770|NCT00839774|Other|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
75574467|NCT05431140|Device|CloudCare|Only eligible subjects to whom CloudCare is introduced as part of their new standard care will be enrolled. Participants will not be subjected to extra procedures on top of their standard of care, except that they will be asked to fill out short questionnaires about their treatment satisfaction and the emotional burden caused by diabetes, which are not standard in the participating study locations.
75725771|NCT00839774|Other|White wheat flour|White wheat flour will be administered at 50 g/day
75725772|NCT02549846|Drug|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
75725773|NCT01888653|Behavioral|Attention Bias Modification (ABM)|The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.
75725774|NCT01888653|Behavioral|Attention control training (ACT)|In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
75725775|NCT00840008|Other|Educational intervention|As per detailed protocol.
75725776|NCT05407155|Combination Product|bevacizumab plus nab-paclitaxel and platinum|Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
75725777|NCT00840242|Drug|Nicotine gum|8-12 pieces per day, maximum 24 daily
75725778|NCT00840242|Drug|Placebo gum|8-12 pieces per day, maximum 24 daily
75427918|NCT01480921|Behavioral|Home-based exercise training|"Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:~5-10 min warm-up~30 min aerobic interval training (walking or stationary bicycle)~10 min cool-down~Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study."
75427919|NCT01480921|Behavioral|Supervised hospital-based exercise training|"Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:~5-10 min of warm-up~30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers~10 min of cool down~Exercise will be tracked by the participant in exercise log books."
75427920|NCT01480947|Drug|Bio-three|oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
75427921|NCT01480960|Other|Pulmonary rehabilitation + whole body vibration training|standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
75574468|NCT05415956|Behavioral|Walking exercise therapy|Moderate-to-high intensity walking exercise therapy (7 weeks, 14 session) with progression in duration and intensity.
75591983|NCT06078670|Drug|CVL218|Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.
75427922|NCT01480973|Radiation|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
75725779|NCT00840242|Drug|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
75725780|NCT00840242|Drug|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
75725781|NCT00621296|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
75878349|NCT05174949|Device|Transcranial direct current stimulation (high-definition)|"Three conditions:~anodal stimulation over the ipsilesional primary motor cortex~cathodal one over the contralesional premotor cortex~Sham"
75725782|NCT00840320|Drug|1278863|15mg, 25mg, 50mg, 150mg
75427923|NCT01480986|Drug|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m^2，ivgtt，90min，D1 Cisplatin 50 mg/m^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
75427924|NCT01481025|Drug|Cimicifuga + Hiperico|"1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months"
75574469|NCT05410132|Other|Internet-delivered Mindfulness Based Training (iMBT)|"The iMBT developed for this study will be adapted from our team's previous study and the manual of mindfulness based cognitive therapy. The program is designed to be brief in nature, for example, participants will be asked to practice meditations for 15 minutes a day instead of the original 45 minutes a day, and each module is shortened to approximately 1 hour instead of the original 2.5 hours.~This iMBT is comprised of six weekly modules on education about mindfulness, guidance on using mindfulness skills to manage symptoms, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and graphics are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice."
75574470|NCT05403450|Drug|Tolinapant|Capsule for oral administration
75574471|NCT05403450|Drug|Decitabine + Cedazuridine|Tablet for oral administration
75574472|NCT05388708|Device|ECMO support|ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
75574473|NCT05388708|Other|PROSpect protocolized therapies|"PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure.~The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure <28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 < 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine."
75574474|NCT05384951|Dietary Supplement|HMB + Vitamin D3|The supplement will be taken orally twice daily. Participants will take 2 blended HMB + Vitamin D3 tablets in the morning and 2 tablets in the evening for 12 weeks.
75574475|NCT05376215|Device|Experimental hearing aid|This hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and by use with a mobile application.
75574476|NCT05361109|Drug|Baricitinib|The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
75574477|NCT05359276|Drug|Olipudase alfa|GZ402665
75591984|NCT06078657|Drug|IBI110+Sintilimab|"IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years."
75725783|NCT00840320|Drug|Placebo|matching placebo
75591985|NCT06078644|Other|respiratory exercise diary|Patients in the intervention group will be asked to perform breathing exercises in the form of using a spirometer 10 times every hour during the preoperative period while they are awake for three days, starting from the first day after the surgery. Patients in this group will be given a breathing exercise diary.
75725784|NCT00840398|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
75725785|NCT00840398|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
75427925|NCT01481025|Drug|Cimicifuga Herbarium|"2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months"
75591986|NCT06078605|Other|Nicotinamide(Mitovita)|Nicotinamide(VitaminB3)
75725786|NCT00537303|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
75725787|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
75725788|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
75427926|NCT01481025|Drug|Aplause®|4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
75427927|NCT01481064|Behavioral|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
75427928|NCT01481090|Procedure|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
75427929|NCT01481103|Procedure|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
75427930|NCT01481142|Device|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
75574478|NCT05355389|Behavioral|Cognitive training|For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
75574479|NCT05355389|Behavioral|Motor training|For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
75574480|NCT05344300|Other|Temperature-measurement in lungs under sauna bath|Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.
75574481|NCT05343975|Procedure|biopsy with audio-guided Meditation|biopsy with audio-guided Meditation
75574482|NCT05341700|Behavioral|Impact Load Exercises|Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
75574483|NCT05341700|Behavioral|No Impact Load Exercises|Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
75574484|NCT05340426|Device|UKidney|The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
75574485|NCT05338619|Drug|Lazertinib|Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
75427931|NCT01481155|Procedure|ablative CO2 laser therapy|CO2 laser therapy
75725789|NCT00840554|Other|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
76048435|NCT02485691|Drug|abiraterone acetate|Pharmaceutical form: tablet Route of administration: oral
75427932|NCT01481155|Procedure|photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²
75725790|NCT00840554|Other|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
75427933|NCT01481168|Device|Pacemaker implantation (Medtronic)|DDD+/-R pacing
75427934|NCT01481168|Device|Pacemaker implantation (Medtronic)|ODO pacing
75427935|NCT01481168|Device|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
75427936|NCT01481181|Dietary Supplement|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
75427937|NCT01481194|Drug|Doxorubicin|50 mg/m2 IV on day 1 of a 21-day cycle
75427938|NCT01481194|Drug|Bortezomib|1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
75427939|NCT01481194|Drug|Lenalidomide|15 mg orally on days 1-14 of a 21-day cycle
75427940|NCT01481194|Drug|Dexamethasone|20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
75427941|NCT01481194|Drug|Cyclophosphamide|750 mg/m2 IV on day 1 of a 21-day cycle
75574486|NCT05329610|Dietary Supplement|Beta-alanine|Slow-release beta-alanine.
75574487|NCT05329610|Dietary Supplement|Placebo|Taste and appearance-matched placebo (tapioca starch).
75574488|NCT05320380|Drug|Anti-CD123 ADC IMGN632|Given IV
76048436|NCT02485691|Drug|prednisone|Pharmaceutical form: tablet Route of administration: oral
75574489|NCT05320380|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
75574490|NCT05320380|Drug|Cytarabine|Given IT and IV
75574491|NCT05320380|Drug|Fludarabine Phosphate|Given IV
75574492|NCT05320380|Drug|Hydrocortisone Sodium Succinate|Given IT
75574493|NCT05320380|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
75574494|NCT05320380|Drug|Methotrexate|Given IT
75574495|NCT05320380|Drug|Prednisolone|Given IT
75574496|NCT05320146|Other|MRI-PDFF|Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.
75725791|NCT02548286|Drug|Candesartan 8mg|PO, 1day or 22day
76048437|NCT02517515|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
75427942|NCT01481220|Drug|Eltrombopag|In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
75574497|NCT05316389|Procedure|Breast reconstruction|Muscle sparing Latissimus Dorsi Flap or prothesis
75574498|NCT05309590|Drug|Dose|We are looking at the outcomes of prescribing half of the topical steroid (i.e. fluticasone [Flovent] and Swallowed viscous budesonide [Pulmicort]) in relation to the patient's remission. These patients will have already achieved remission on a full dose of the steroid.
75574499|NCT05306886|Other|ICB Medical Insoles|After the foot analysis of the participants in the intervention group, special insoles will be designed in a computer program. In these insoles, 3-6 mm medial wedge support, 1-3 mm heel wedge support, 2-4 mm medial longitudinal arch support will be provided. These values will be determined according to the needs of each participant. A single physiotherapist will design all insoles. All drawings will be made by a single physiotherapist. After the design of the insoles is completed, insoles will be produced by transferring them to a Computer Numerical Control (CNC) machine. Ethyl vinyl acetate (EVA), the use of which has been found useful before, will be used as the material in the insoles molds. After processing, 1mm thick fabric will be used for the top coating. All insoles will be produced by the same physiotherapist.
75574500|NCT05306886|Other|ICM Insoles|As in the intervention group, insoles will be designed for the participants in the control group, processed by CNC machine and the production will be completed. Only 2mm medial longitudinal arch support will be given to the insoles of the people in this group.
75574501|NCT05292950|Drug|ARO-MUC5AC|single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
75574502|NCT05292950|Drug|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
75574503|NCT05291208|Combination Product|Combined tACS and Cognitive Training Program|The program contemplates 12 WM training sessions based on tasks of storage and manipulation of verbal and visuospatial information, with a frequency of twice a week during six weeks (total of 12 sessions). Patients will receive real electrical stimulation for 10 minutes during verbal working memory task. This includes 10s periods of phase-in and 10 s of phase-out and will be done in parallel with the cognitive intervention program in sessions 3, 4, 5, 6, 7, 8, 9, and 11. The electrical stimulation will be applied with two 3x1 arrays of electrodes. The central stimulation electrodes will be positioned in F3 and CP3 (10-20 system). The AC stimulation will be one mA from the baseline to the stimulation peak. The stimulation will have a gamma sine waveform (80Hz) over the positive phase of the theta oscillation (between 4 and 8 Hz, adjusted by each subject, Reinhart et al, 2019) phase-locked between arrays with impedances always under 10 kOhm.
75725792|NCT02548286|Drug|Amlodipine 5mg|PO, 1day or 22day
75427943|NCT01481233|Drug|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
75427944|NCT01481259|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
75591987|NCT06078605|Other|Placebo|Placebo
75591988|NCT06078592|Drug|BRIDIN-plus Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
75591989|NCT06078592|Drug|Combigan Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
75725793|NCT02548286|Drug|CKD-330 8/5mg|PO, 1day or 22day
75725794|NCT00834704|Drug|PEGPH20|PEGylated recombinant human hyaluronidase
75591990|NCT06078579|Diagnostic Test|Leptin|Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls
75591991|NCT06078527|Device|Cheung-Bearelly Aesthesiometer|The Cheung-Bearelly Aesthesiometer will be used to deliver a range of calibrated stimuli through the channeled flexible laryngoscope to assess sensation of the laryngopharynx.
75725795|NCT05360433|Drug|Oxycodone oral capsule|Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
75725796|NCT00834782|Procedure|IOP measurement|Measuring IOP
75591992|NCT06078527|Procedure|Transnasal Laryngoscopy|A procedure to examine your larynx (voice box)
75591993|NCT06078527|Other|Questionnaires|Patient-reported health and behavioral outcomes measures will be administered
75591994|NCT06077942|Device|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
75591995|NCT06077526|Behavioral|P.E.A.K. Rx|Pain Education + Physical Activity Group Based Intervention
75591996|NCT06077526|Other|Usual Care|Participants will receive the community hospital's usual care.
75574504|NCT05291208|Behavioral|Traditional Cognitive Training Program|Participants will start a cognitive intervention program identical to the intervention group. Still, unlike the intervention group, they will receive placebo electrical stimulation, i.e., an electrical current will be applied for a short period at the beginning of the session (30 seconds), and then the stimulation will be stopped. This procedure induces a sensation in the skin similar to the real stimulation without generating a detectable impact on the brain state. They will be performed in parallel to the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10.
75427945|NCT01481259|Other|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
75427946|NCT01481311|Device|medical Body Composition Analyzer seca 514/515|Current of 100 µA
75725797|NCT00989391|Drug|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
75427947|NCT01481311|Procedure|Deuterium and Sodium Bromide dilution methods|Orally administered to the subject in a solution with 100 ml tap water.
75574505|NCT05288218|Device|Leak-free Bronchoscope Adapter|A novel leak-free bronchoscope adapter will connect to the ventilation circuit in place of a standard adapter.
75725798|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
75725799|NCT00989391|Drug|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
75878350|NCT05200611|Diagnostic Test|Fecal Immunochemical Test|Participants with positive fecal immunochemical test results were further examined by colonoscopy.
75878351|NCT04040673|Procedure|thyroid lobectomy|routine surgical removal of thyroid for biopsy
75878352|NCT04040673|Device|Raman spectroscopy probe measurement|The measurement of Raman spectra from the excised tissue
75427948|NCT01481337|Procedure|Colonic polypectomy or endoscopic mucosal resection (EMR)|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
75427949|NCT01481350|Drug|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
75427950|NCT01481363|Behavioral|The Talking Sense manual|Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
75427951|NCT01481363|Behavioral|Treatment as usual - communication information and advice|Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
75427952|NCT01481389|Dietary Supplement|Theobromine|200 ml drink with added theobromine (no cocoa added)
75427953|NCT01481389|Dietary Supplement|Cocoa|200 ml drink with cocoa (no theobromine added)
75574506|NCT05288218|Device|Standard Bronchoscope Adapter|Commercially available bronchoscope adapter (Smiths Medical)
75574507|NCT05285865|Other|Conventional Treatment|Thrice a day for complete length of stay. This is Conventional treatment The total duration of session will be of 15-20 mins.
75574508|NCT05285865|Other|Scapular Mobilization|Thrice a day for complete length of stay including two sets of repetitions with a rest interval of 30 seconds between sets. Grade 1-3 As reported in a study Scapular mobilization (SM) i.e., Scapular superior, inferior glides, upward and downward rotations and scapular distraction, along with Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
75574509|NCT05254951|Diagnostic Test|Tidal Volume Challenge|Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
75574510|NCT05230888|Other|Questionnaires about symptoms|The CGA and VES-13 questionnaires will be conducted at baseline. Immune-related adverse events (irAEs) will be investigated at 3 and 6 months using a Patient Knows Best symptom tracker form (local Trust created).
76048438|NCT02517515|Drug|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
75574511|NCT05206058|Procedure|venipuncture|Plan to enroll 240 health people who are 20-35 years of age. People with received veinpuncture. Blood will be collected at time and drawn into Heparin-coated tube.
76048439|NCT02466659|Device|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
75725800|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
76048440|NCT01891864|Drug|GP2015 Etanercept|Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
75427954|NCT01481389|Dietary Supplement|Cocoa and theobromine|200 ml drink with added cocoa and theobromine
76048441|NCT01891864|Drug|Enbrel|Enbrel is used as reference product to GP2015.
76048442|NCT02485301|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
76048443|NCT02485301|Drug|Placebo|A single dose administrated intramuscular
75427955|NCT01481389|Dietary Supplement|Placebo|200 ml drink (no added theobromine or cocoa)
75427956|NCT01481402|Drug|Liothyronine|Liothyronine 40 microgram per day
75427957|NCT01481402|Drug|Liothyronine|3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
75878353|NCT05206461|Other|Trunk Control Measurement Scale|Trunk Control Measurement Scale, easy and simple to use, was used to evaluate trunk control
75427958|NCT01481441|Drug|SonoVue|2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
75427959|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
75427960|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
75427961|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
75574512|NCT05191355|Biological|blood test|Blood spot collection for sampling
75574513|NCT05186168|Device|MiniHip Stem|The MiniHip stem is a titanium femoral stem (Ti-6Al-4V) coated with a layer of hydroxyapatite applied over a layer of pure titanium
75574514|NCT05186168|Device|Trinity Acetabular Cup System|The Trinity Acetabular System is a modular acetabular cup system consisting of a press fit, titanium alloy shell
75878354|NCT05206149|Drug|Intranasal glugagon|Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
75574515|NCT05177393|Other|Assessment of patient-reported outcomes (PROs)|Questionnaires will be administered to participants
76048444|NCT02484911|Drug|Olanzapine|5mg,twice a day orally on day 1 to day 4
76048445|NCT02484911|Drug|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
76048446|NCT02484911|Drug|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
76048447|NCT02484911|Drug|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
76048448|NCT04306367|Drug|Pembrolizumab|200 mg given intravenously.
76048449|NCT04306367|Drug|Olaparib|300 mg given orally.
76048450|NCT04925609|Drug|Brigatinib|Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
76048451|NCT02466425|Drug|SHP465|12.5mg and 25mg capsules (one capsule daily)
76048452|NCT02466425|Drug|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
75427962|NCT01481454|Biological|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
75427963|NCT01481467|Behavioral|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
75427964|NCT01481480|Procedure|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
75427965|NCT01481480|Procedure|Arthroscopic repair|Arthroscopic repair
75427966|NCT01481493|Biological|BT061|subcutaneous administration of the monoclonal antibody BT061
75427967|NCT01481493|Biological|Placebo|subcutaneous injection of placebo
75427968|NCT01481506|Procedure|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
75427969|NCT01481519|Drug|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
75427970|NCT01481519|Drug|Artificial Tears|artificial tears 1 drop, 4 times per day
75427971|NCT01481584|Dietary Supplement|Protein drink - protein isolate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
75427972|NCT01481584|Dietary Supplement|Protein drink - protein hydrolyzate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
75427973|NCT01481597|Drug|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
75427974|NCT01481597|Drug|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
75427975|NCT01481597|Drug|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
75427976|NCT01481597|Drug|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
75427977|NCT01481597|Drug|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
75427978|NCT01481610|Drug|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
75427979|NCT01481610|Drug|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
75427980|NCT01481623|Other|Constitution of a biological bank|Blood samples for the constitution of a biobank (DNA, RNA, serum)
75427981|NCT01481623|Other|Metabolic studies|oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
75427982|NCT01481662|Device|Diffusion tensor magnetic resonance imaging of the brain|Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
75427983|NCT01481688|Other|Exercise|Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.
75427984|NCT01481688|Other|Extra time|An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
75427985|NCT01481701|Drug|Oxaliplatin|85 mg/m² / 14days
75427986|NCT01481701|Drug|oxaliplatin|oxaliplatin
75427987|NCT01481714|Drug|Sodium picosulphate, magnesium oxid and citric acid|"A sachet mixed with 250 mL of water at 18:00 pm~A sachet mixed with 250 mL of water at 21:00 pm~A minimum of 4 litres of fluid were recommended throughout the preparation"
75427988|NCT01481714|Drug|Sodium picosulphate/magnesium oxide and citric acid|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
75427989|NCT01481727|Device|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (>18mmHg) for at least six hours, nocturnal ventilation.
75427990|NCT01481727|Device|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
75427991|NCT01481753|Procedure|pancreaticoduodenectomy without Braun enteroenterostomy|no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy
75427992|NCT01481753|Procedure|Braun enteroenterostomy|addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
75427993|NCT01481766|Dietary Supplement|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
75427994|NCT01481766|Dietary Supplement|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
75427995|NCT01481766|Behavioral|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
75427996|NCT01481818|Drug|EGCG|Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
75725801|NCT00989391|Drug|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
75725802|NCT00989391|Drug|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
75427997|NCT01481831|Drug|Palonosetron Hydrochloride|0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
75427998|NCT01481831|Drug|Palonosetron Hydrochloride|0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
75427999|NCT01481844|Drug|Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole|use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
75878355|NCT05206149|Drug|Intranasal placebo|Intranasal placebo (represented by isotonic saline solution) is administered.
75428000|NCT01481844|Drug|Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline|this combination is standard of care as H pylori second line treatment
75428001|NCT01481857|Other|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
75428002|NCT01481857|Other|Segmental trunk exercise|Segmental trunk exercise
75428003|NCT01481870|Drug|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
75428004|NCT01481870|Drug|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
75428005|NCT01481909|Drug|Rupatadin|20 mg, 28 days over 60 days
75428006|NCT01481922|Device|whitacre 24 gauge|Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
75878356|NCT05206071|Biological|CD19+22 CAR-T cells|Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
75428007|NCT01481922|Device|whitacre 22 gauge|Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
75428008|NCT01481948|Behavioral|Food, Fun, & Fitness Internet Program for Girls|This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
76048453|NCT04925453|Combination Product|active tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
75725803|NCT00834860|Drug|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
75574516|NCT05159739|Genetic|Blood Draw or Saliva/Cheek Cell Sample:|Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
75725804|NCT00834938|Other|No intervention|No intervention
75574517|NCT05156047|Drug|Pitolisant Oral Tablet|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
75725805|NCT00835016|Behavioral|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
75725806|NCT00825422|Drug|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
75725807|NCT04003545|Radiation|LED Photobiomodulation|A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.
75574518|NCT05156047|Drug|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
75574519|NCT05155098|Other|secukinumab|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.
75574520|NCT05134649|Drug|BOTOX|Intramuscular Injection
75574521|NCT05124275|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
75574522|NCT05124275|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
75574523|NCT05124275|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
75574524|NCT05124275|Drug|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
75725808|NCT04003545|Other|Placebo LED Photobiomodulation|For the placebo group, the procedures will be the same, however the LED equipment will remain off.
75725809|NCT00835250|Procedure|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
75725810|NCT00835250|Procedure|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
75428009|NCT01481961|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
75428010|NCT01481987|Procedure|Epiretinal Membrane Surgical treatment|epiretinal membrane peeling
75428011|NCT01482000|Other|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
75428012|NCT01482000|Other|usual care|The control group will get the usual care with some additional tests for the study.
75428013|NCT01482013|Drug|HPP854|Oral, once a day for 28 days.
75428014|NCT01482013|Drug|Placebo|Oral, once a day for 28 days.
75428015|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
75428016|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
75428017|NCT01482039|Procedure|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
75574525|NCT05121636|Device|MetaFix Collared Stem|Patients received the MetaFix Collared stem during there Total Hip Arthroplasty
75574526|NCT05113953|Drug|Centanafadine|Sustained-release oral tablets
75574527|NCT05113953|Drug|Placebo|Oral tablets
75725811|NCT03853226|Procedure|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
75428018|NCT01482039|Procedure|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
75428019|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
75428020|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
75428021|NCT01482104|Drug|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
75428022|NCT01482104|Drug|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
75428023|NCT01482117|Drug|Clopidogrel|single oral administration of 300mg of clopidogrel
75428024|NCT01482117|Drug|Cilostazol|single oral administration of 100mg cilostazol
75428025|NCT01482117|Drug|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
75428026|NCT01482130|Behavioral|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
75428027|NCT01482130|Behavioral|recommendations|"The control group will be encouraged to follow a training program according to recommended exercise guidelines:~Weight bearing activities (walking, jogging or strength training)~30 - 60 minutes, 3 - 5 times each week~A total of 2 - 3 hours each week should be achieved"
75428028|NCT01482143|Drug|AFQ056|
75574528|NCT05093972|Drug|Ulonivirine|Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
75574529|NCT05092360|Biological|Nemvaleukin and Pembrolizumab Combination|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
75574530|NCT05092360|Biological|Pembrolizumab|Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
75574531|NCT05092360|Biological|Nemvaleukin|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes
75574532|NCT05092360|Drug|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
75574533|NCT05092360|Drug|Paclitaxel|80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min
75574534|NCT05092360|Drug|Topotecan|4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min
75428029|NCT01482156|Drug|RAD001 + BEZ235|RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
75428030|NCT01482234|Behavioral|TXT Me|text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
75428031|NCT01482247|Dietary Supplement|L-Arginine|Dietary Supplement
75428032|NCT01482247|Dietary Supplement|Placebo Supplement|Dietary Supplement
76048454|NCT04925453|Combination Product|sham tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
75428033|NCT01482260|Procedure|Biopsy|Biopsy
75428034|NCT01482273|Procedure|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
76048455|NCT04616014|Drug|ORMD-0801 QD|8 mg, QD
76048456|NCT04616014|Drug|ORMD-0801 BD|8 mg, BD
76048457|NCT02451917|Drug|Glargine insulin|The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained
76048458|NCT02451917|Drug|NPH insulin|The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
76048459|NCT02349451|Biological|adalimumab|
75428035|NCT01482273|Procedure|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
75428036|NCT01482299|Drug|RAD001|"RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability."
75428037|NCT01482338|Drug|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
75574535|NCT05092360|Drug|Gemcitabine|1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
75725812|NCT05358015|Procedure|vascularized bone graft for scaphois nonunion|vascularized bone graft for scaphois nonunion
75878357|NCT03629457|Behavioral|Mindfulness and Mindful Self-Compassion|Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
76048460|NCT02349451|Biological|ABT-122|
76048461|NCT04956731|Other|Pharmacist Provision of Medication Abortion|Pharmacists providing start to finish medication abortions
76048462|NCT04956263|Drug|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China."
75574536|NCT05082077|Device|LIVERguard|The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.
75574537|NCT05072301|Behavioral|Contingency Management|The treatment group will receive a onetime offer of $80 (a reactive carrot) to forego all abstinence (contingency management) reward payments in the future.
75725813|NCT04043780|Device|Decompression prototype splint for carpal tunnel syndrome|This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
75574538|NCT05072301|Behavioral|Control|The control group will receive contingency management payments and other monetary benefits for completing the trial.
75574539|NCT05055778|Behavioral|SmokefreeTXT|"The program is identical to the publicly available program available through the National Cancer Institute Smokefree.gov Initiative but has been set up to be delivered through a research account. The program will send 3-5 messages a day over 7 weeks, with one week to prepare for a quit attempt and 6 weeks of cessation support messages. Participants can get real time support for cravings, mood, and slips by texting keywords to the program. They keywords are CRAVE, MOOD, and SLIP. Participants can also re-set their quit date by texting NEW. The program asks questions each week to ask about smoking status and about mood and cravings."
75574540|NCT05054400|Drug|F18 Fluciclovine|Given by IV
75574541|NCT05054400|Other|Standard of Care|Standard of care
75725814|NCT04043780|Device|Standard splint for carpal tunnel syndrome|This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
75725815|NCT00505414|Drug|Tapentadol in the Titration Phase|
75574542|NCT05033054|Drug|SGLT2 inhibitor|Participants will ingest a standard dose of SGLT2i prescribed by the standard of care physician.
75725816|NCT00505414|Drug|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
75878358|NCT03629379|Drug|Ustekinumab|Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
75574543|NCT05017818|Other|Observational retrospective data|Non-intervention
75574544|NCT05009927|Drug|Imatinib tablets|Imatinib interruption
75574545|NCT05005442|Biological|Pembrolizumab/vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
75725817|NCT00505414|Drug|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
75725818|NCT00505414|Drug|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
75725819|NCT00505414|Drug|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
75428038|NCT01482338|Drug|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
75428039|NCT01482364|Device|Integrated hemodynamic management (IHM) - HOTMAN System|Therapeutic approach according to HOTMAN System measurement(ICG)results .
75428040|NCT01482364|Device|Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System|Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
75725820|NCT00840788|Procedure|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
75725821|NCT00840788|Procedure|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
75725822|NCT02549924|Drug|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
75428041|NCT01482377|Drug|RO5479599|RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
75428042|NCT01482377|Drug|Cetuximab|Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m^2 for the first infusion, followed by doses of 250 mg/m^2 for subsequent infusions.
75428043|NCT01482377|Drug|Erlotinib|Erlotinib, at a dose of 150 mg will be administered.
75725823|NCT02549924|Drug|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
75428044|NCT01482377|Drug|zirconium-89-labeled RO5479599|Single dose of radiolabeled drug will be administered.
75428045|NCT01482416|Drug|Estrogens, Conjugated (USP)|Experimental group will use 0.625mg/day during 30 days
75428046|NCT01482416|Drug|Placebo|Placebo group will use placebo once/day during 30 days
75428047|NCT01482442|Drug|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
75428048|NCT01482442|Drug|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
75574546|NCT05002322|Other|Systems Analysis and Improvement Approach|"Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel."
75574547|NCT04994301|Diagnostic Test|Lung T1 MRI|Evaluation of lung T1 MRI to Assess Lung Disease
75574548|NCT04989569|Dietary Supplement|Nutritional intervention|In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
75574549|NCT04974645|Device|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
75574550|NCT04974645|Other|Education|The education arm will receive digitally delivered psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
75574551|NCT04966065|Device|Parietex Parastomal mesh|Laparoscopic Modified Sugarbaker technique for repair of parastomal hernias in end-colostomies
75428049|NCT01482468|Drug|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
75428050|NCT01482468|Drug|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
75428051|NCT01482559|Drug|Dopamine hydrochloride|Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
75428052|NCT01482559|Drug|Dextrose 5%|IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
75428053|NCT01482572|Procedure|biopsy|percutaneous lung biopsy and aspiration
75428054|NCT01482585|Other|CT, PET, copy number alteration|Duel-energy CT, PET, copy number alteration
75428055|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
75428056|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
75428057|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
75428058|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
75428059|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
75428060|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
75428061|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
75428062|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
75574552|NCT04956224|Biological|VLA2001|"whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain)~2 vaccinations 28 days apart~Booster Vaccination on Visit B1"
75574553|NCT04953910|Drug|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
75574554|NCT04925570|Device|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
75574555|NCT04925570|Other|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
75574556|NCT04915157|Device|Spinal Cord Stimulator|All patients will receive an implanted spinal cord stimulator.
75574557|NCT04915027|Other|a usual follow-up with Rehabkompassen®|Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.
75574558|NCT04915027|Other|a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®|Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
75725824|NCT01813227|Drug|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
75725825|NCT01813227|Drug|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
75878359|NCT03629379|Drug|Vedolizumab|Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
75878360|NCT03629301|Behavioral|ID-DPP group|This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
75878361|NCT03629301|Other|Wait-list Group|This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
75878362|NCT05123079|Drug|Darigabat|Tablets
75878363|NCT05129163|Behavioral|Exercise|The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
76048463|NCT04956263|Drug|Dapagliflozin|Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
76048464|NCT02409368|Drug|Nivolumab|
75428063|NCT01482624|Device|Hyaluronan (0.5%, 5 mg/10 ml)|Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
75428064|NCT01482624|Procedure|Standard arthroscopic meniscal surgery|Standard arthroscopic meniscal surgery without add-on treatment.
75428065|NCT01482650|Device|supraglottic airway placement and use|The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
75428066|NCT01482663|Behavioral|Healthy Skin Clinic|"The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).~Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.~Finally, a counselling consultation with a nurse, trained within dermatology."
75428067|NCT01482689|Dietary Supplement|Fish oil capsule (specially manufactured for the study)|One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.
75428068|NCT01482689|Dietary Supplement|Multivitamin tablet of type: Vitaplex ABCD|One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
75428069|NCT01482702|Behavioral|weight loss intervention|Behavioral weight loss intervention
75428070|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
75428071|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
75428072|NCT01482728|Drug|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
75574564|NCT04902261|Drug|Tislelizumab|Tislelizumab 200 mg every three weeks
75428073|NCT01482728|Drug|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
75574565|NCT04902261|Drug|Nab paclitaxel|Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks
75725826|NCT01813227|Drug|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
75725827|NCT00825578|Device|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
75574566|NCT04902261|Drug|Gemcitabine|Gemcitabine 1000mg/m2 on d1 and d8 every three weeks
75725828|NCT01012882|Biological|sublingual immunotherapy with allergen extract|sublingual application
75725829|NCT01012882|Biological|sublingual immunotherapy with placebo|sublingual application
75574567|NCT04884100|Other|Validating and improving PPG-based algorithms|Our project aims at validating and improving PPG-based algorithms that were previously developed during the time course of a preceding study mini-Holter, accepted by the CER-VD in 2015. The developed features might help improve our understanding of the physio-pathological expression of cardiac arrhythmias. Indeed, current evidence demonstrates that PPG signals contain rich information on diverse cardiovascular mechanisms and properties
75574568|NCT04873596|Drug|Nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine.
75574569|NCT04873596|Drug|Nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam.
75574570|NCT04868357|Behavioral|Hypnosis|Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.
75725830|NCT00841022|Other|Information with comics|Information of children with comic leaflet
75725831|NCT00989469|Drug|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
76048465|NCT01853878|Biological|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
75725832|NCT04709458|Biological|TBX-2400|Hematopoietic stem cells transplantation
75725833|NCT02546882|Biological|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
76048466|NCT01853878|Biological|Placebo|Intramuscular administration
76048467|NCT04891484|Drug|Ondansetron group|patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
76048468|NCT04891484|Drug|Saline group|patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
76048469|NCT02342678|Behavioral|Yoga Therapy|
76048470|NCT02342678|Behavioral|Physical Conditioning|
75428074|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
75428075|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
75428076|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
75574571|NCT04868357|Behavioral|Relaxation|Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
75574572|NCT04847635|Device|Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)|The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.
75574573|NCT04847635|Device|Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)|The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
75574574|NCT04842786|Other|Coconut oil|Coconut oil, Parachute oil composition: 92% lauric (C12) fatty acid, 6% oleic fatty acid, 2% linoleic fatty acid
75574575|NCT04841434|Drug|Voraxaze Injectable Product|High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to <40 mL/min, or in the case of decreased GFR, the decrease is >50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing >100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
75574576|NCT04838301|Drug|Allopregnanolone|Allopregnanolone 4mg IV via 30-minute infusion, once per week.
75574577|NCT04838301|Other|Placebo|Normal saline solution IV via 30-minute infusion, once per week
75574578|NCT04817189|Drug|NEPA (300mg netupitant/0.5mg palonosetron)|Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
76048471|NCT02342288|Procedure|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
75574579|NCT04817189|Drug|Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)|Standard of care will be administered on Day 1 of each cycle.
75574580|NCT04817189|Drug|Dexamethasone, 8 mg (oral) or equivalent IV dose|Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
75574581|NCT04811703|Drug|Combined PIPAC / IV chemotherapy treatment|Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
75574582|NCT04805645|Other|No intervention (Retrospective Cohort Observational)|No intervention as this study is a Retrospective Cohort Observational
75574583|NCT04772989|Drug|AB308|Administered intravenously (IV) as specified in the treatment arm
75428077|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
75428078|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
75574584|NCT04772989|Drug|Zimberelimab|Administered IV as specified in the treatment arm
75428079|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
75428080|NCT01482754|Drug|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
75428081|NCT01482780|Device|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
75428082|NCT01482793|Procedure|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
75574585|NCT04755361|Behavioral|Housing Outreach Project Collaboration (HOP-C)|HOP-C has several components: HOP-C Case management is outreach-based (emphasizing community and home contacts) and participant goal-driven, providing coaching and skill building in key functional domains and assistance with navigating various systems (justice, housing, employment, health, education). The mental health component has two parts. One is a weekly, 90-minute, mental health and wellness-oriented group. The group acts, for most, as a stepped care approach, with members moving on to access individual psychotherapy as needed. Peer support is provided by youth with a history of lived experience of homelessness who have successfully achieved housing stability and progress in major life domains. Peers receive extensive training and are formally hired into these roles with their being 2-3 peers on the team.
75725834|NCT02546882|Drug|saline|1 ml saline was injected for 1 cm2 area.
75725835|NCT00989547|Other|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
75428083|NCT01482806|Behavioral|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
75428084|NCT01482806|Behavioral|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
75428085|NCT01482832|Behavioral|Interpersonal therapy-based treatment|Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
75428086|NCT01482845|Drug|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
75428087|NCT01482845|Drug|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
75428088|NCT01482858|Dietary Supplement|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
75428089|NCT01482858|Other|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
75574586|NCT04743479|Diagnostic Test|high-resolution MRI/CT examinations|Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).
75574587|NCT04735575|Biological|EMB-06|EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.
75725836|NCT01010308|Drug|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
75725837|NCT04002687|Drug|ATV-PG 1000-400 mg + AQ 612 mg|The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
75725838|NCT02548052|Drug|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
75725839|NCT02548052|Drug|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
75428090|NCT01482871|Drug|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
75428091|NCT01482871|Drug|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
75428092|NCT01482871|Drug|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
75428093|NCT01482871|Drug|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
75574588|NCT04725916|Other|Showering|Patients will be instructed to shower after surgery with drains in place
75574589|NCT04725916|Other|Restriction of Showering|Patients will be restricted from showering post operatively if they have drains in place
75574590|NCT04724837|Drug|Zibotentan|Participants will receive zibotentan as per the arms they are randomized.
75574591|NCT04724837|Drug|Dapagliflozin|Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
75574592|NCT04724837|Drug|Placebo|Participants will receive placebo as per the arms they are randomized to.
75428094|NCT01482897|Drug|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
75428095|NCT01482897|Drug|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
75428096|NCT01482897|Drug|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
75428097|NCT01482923|Behavioral|Treatment as usual|Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.
75428098|NCT01482923|Behavioral|AIR (Aspirations, Inspiration, Respiration)|Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
75428099|NCT01482936|Drug|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
75428100|NCT01482949|Drug|AGS-003|Autologous Dendritic Cell Immunotherapy
75428101|NCT01482975|Other|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
75428102|NCT01482975|Other|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
75574593|NCT04714047|Other|Progressive Resistance Training and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime."
75725840|NCT02548052|Drug|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
75725841|NCT02548052|Drug|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
75725842|NCT02548052|Drug|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
75725843|NCT02548052|Drug|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
75725844|NCT03630328|Dietary Supplement|Cogni.Q|AGN
75725845|NCT03630328|Other|Placebo|Placebo
75725846|NCT04590417|Drug|Estradiol valerate 2 mg, cyproterone acetate 25 mg|The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
75428103|NCT01483001|Drug|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
75428104|NCT01483014|Drug|imatinib mesylate|
75428105|NCT01483040|Device|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
75428106|NCT01483053|Drug|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
75428107|NCT01483053|Drug|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
75428108|NCT01483066|Device|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
75428109|NCT01483092|Dietary Supplement|inulin|20g/day for 4 weeks
75428110|NCT01483092|Dietary Supplement|maltodextrin|20g/day for 4 weeks
75428111|NCT01483131|Other|Exercise training|12 weeks of resistance training twice a week.
75428112|NCT01483131|Other|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
75428113|NCT01483157|Other|vascular occlusion with exercise trainig|twelve weeks of resistance training with vascular occlusion twice a week
75428114|NCT01483157|Other|high intensity resistance training|twelve weeks of resistance training twice a week
75428115|NCT01483170|Drug|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
75428116|NCT01483170|Drug|Placebo|Placebo fexinidazole
75428117|NCT01483196|Procedure|ultrasound imaging|Undergo TCD
75428118|NCT01483196|Other|questionnaire administration|Complete neurocognitive questionnaires
75428119|NCT01483196|Procedure|assessment of therapy complications|Undergo TCD
75428120|NCT01483196|Procedure|quality-of-life assessment|Ancillary studies
76048472|NCT02342288|Procedure|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
75428121|NCT01483196|Procedure|magnetic resonance imaging|Undergo MRI
75428122|NCT01483222|Device|QUIKDRAW Pro, Aspen Medical Products|Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
75428123|NCT01483222|Device|MUELLER 4581, Mueller Sports Medicine|Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
75725847|NCT00825656|Drug|Sinol or Sinol-M nasal spray|"One spray in each nostril up to a maximum of 12 times / day on an as needed basis"
75725848|NCT01010386|Procedure|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
75725849|NCT01010386|Procedure|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
75428124|NCT01483235|Behavioral|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
75725850|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
75725851|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
75725852|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
75725853|NCT02548208|Device|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
75428125|NCT01483235|Behavioral|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
75428126|NCT01483248|Biological|conventional therapy plus MenSC transplantation|"patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1*10E6 MSC/kg body for 2 weeks."
75428127|NCT01483248|Drug|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
75428128|NCT01483261|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
75428129|NCT01483274|Biological|Vaccine|Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
75428130|NCT01483287|Dietary Supplement|Alpha-Galactosidase|"The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time)."
75428131|NCT01483300|Drug|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
75574594|NCT04714047|Other|Progressive Resistance Training and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime without supervision."
76048473|NCT01853644|Drug|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
75428132|NCT01483300|Drug|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
75428133|NCT01483339|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
75428134|NCT01483339|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
75428135|NCT01483365|Drug|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
76048474|NCT01853254|Drug|Peginterferon alfa-2a|Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
75428136|NCT01483391|Behavioral|Enhanced Care|The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
75428137|NCT01483391|Behavioral|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
75878364|NCT05129163|Behavioral|Nutrition activities|The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
75878365|NCT05084157|Diagnostic Test|Echocardiography|Patients will undergo Doppler echocardiography
75428138|NCT01483404|Procedure|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
75878366|NCT05055999|Drug|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day
75878367|NCT05205837|Drug|Letrozole 2.5mg, hCG|Drug -Treatment Intramuscular injektion - Treatment
75428139|NCT01483417|Procedure|Single incision Laparoscopic hysterectomy|SILS port
75428140|NCT01483417|Procedure|Conventional laparoscopic hysterectomy|3-4 conventional ports
75428141|NCT01483430|Drug|Ginseol Kg1 (low dose)|1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
75428142|NCT01483430|Drug|Ginseol Kg1(high dose)|1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
75878368|NCT05205837|Drug|Placebo|Drug - Placebo Intramuscular injektion - placebo
75428143|NCT01483430|Drug|Placebo|1 capsule/day (starch), Duration: 8 weeks
75428144|NCT01483443|Procedure|Oophrectomy|Both oophrectomy
75428145|NCT01483456|Other|"The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)"|"The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:~Identification of patient's fall risk,~Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),~Get up workshop and morbidity and mortality conferences related to fall cases"
75725854|NCT02548208|Device|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
75878369|NCT05761665|Other|Evaluation|Kinesiophobia=Tampa scale Balance=Berg Balance Scale Falling=The Fall Activity Scale( Tinetti) Walking speed=Timed Get Up and Walk Test ,Two-Minute Walking Test Fragility=Frail Fragility Questionnaire, Clinical Fragility Scale
75878370|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
75878371|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
75878372|NCT05043285|Biological|SCTV01C|intramuscular injection
75428146|NCT01483469|Drug|RO4917523|orally daily, 14 days
75428147|NCT01483469|Drug|RO5011232|[11C]-RO5011232 intravenously
75428148|NCT01483482|Procedure|Conservative Treatment|Simple Sling
75428149|NCT01483482|Procedure|Surgical treatment|Superior Locking plate
75428150|NCT01483508|Other|Flavanol- and procyanidins-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomer] and procyanidins [dimers to decamers]
75428151|NCT01483508|Other|Procyanidins-containing drink|Single oral intake of a ocoa-based dairy drink containing procyanidins [dimers to decamers]
75428152|NCT01483508|Other|Flavanol-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomers]
75725855|NCT01010464|Procedure|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
75725856|NCT00841256|Biological|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
75725857|NCT00841256|Drug|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
75428153|NCT01483521|Other|Clinical home visitation|Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
75428154|NCT01483534|Device|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
75428155|NCT01483547|Device|Bispectral Index (BIS Vista, Covidien)|BIS values at LOC, PI, ROC.
75574595|NCT04714047|Other|Neuromuscular exercise and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home without supervision."
75878373|NCT05043285|Other|Placebo|Intramuscular injection
75878374|NCT05042115|Other|Education in pain neurosciences and clinical hypnosis|Will be performed education in pain neurosciences and clinical hypnosis, in 4 sessions during 4 weeks
75878375|NCT05042115|Other|Education in pain neurosciences and clinical hypnosis plus osteopathic manipulative treatment|Will be performed education in pain neurosciences and clinical hypnosis, and only for this group will be delivered osteopathic manipulative treatment, in 4 sessions during 4 weeks
75878376|NCT04380519|Drug|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
75878377|NCT04380519|Drug|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)
75428156|NCT01483573|Other|neural mobilization|stretch the nerve
75428157|NCT01483573|Other|straight leg raise|stretch the hamstring
75428158|NCT01483586|Drug|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
75428159|NCT01483586|Drug|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
75428160|NCT01483638|Drug|axitinib|5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
75428161|NCT01483638|Drug|placebo|will be administered orally with the same schedule of axitinib
75428162|NCT01483677|Other|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
75428163|NCT01483677|Other|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
75574596|NCT04714047|Other|Neuromuscular exercise and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home."
75574597|NCT04694794|Other|Educational Brochure|Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
75574598|NCT04605822|Device|3D imaging Total Body Photography Vectra® WB360|3D Total Body Photography Vectra® WB360 (Canfield Scientific, Parsippany, New Jersey, USA) and its digital dermoscopic camera (VISIOMED® D200evo dermatoscope) and scoring of pigmented skin lesions. All participants of this study will undergo 3D TBP at baseline and the follow-up visits up to month 24.
75574599|NCT04605822|Device|2D imaging FotoFinder ATBM® Master imaging system|2D imaging with FotoFinder® Mole Analyzer and scoring of pigmented skin lesions. All participants of this study will undergo 2D imaging FotoFinder ATBM® Master imaging system at baseline and the follow-up visits up to month 24.
75574600|NCT04605822|Device|Smartphone application (SkinVision®)|Smartphone application for all dermatoscopically documented pigmented skin lesions in all study participations and record of risk assessment of the health application (low, medium or high risk) to compare the app's accuracy in risk assessment with the AI tools and the dermatologist. The SkinVision® smartphone app is CE certified.of skin lesions. All participants of this study will undergo Smartphone application (SkinVision®) at baseline and the follow-up visits up to month 12.
75574601|NCT04605822|Other|Standard-of-care clinical assessment of the skin|Clinical skin examination with dermatoscope by an experienced dermatologist and risk assessment of pigmented lesions (melanoma vs. naevus). All participants of this study will undergo Standard-of-care clinical assessment of the skin at baseline and the follow-up visits up to month 24.
75878378|NCT04380519|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
75878379|NCT05760963|Other|Collection of datas|"Analysis lumbar echographies results by Trident ans Shamrock techniques.~Costiform processes on T12 to L5 were spotted and noted. For Trident technique, quality of image, depth of lumbar plexus and presence of vessels were noted.~Shamrock technique was performed, the projection of C line (line obtained with a probe put on the iliac crest) was noted with the invisible ink pen. Then the probe was oriented cephalically (for line >C) and caudally (line <C). For each lines, quality of image, depth of lumbar plexus and presence of vessels were also noted.~The projections of C, >C, <C on the costiform processes were noted."
75878380|NCT05004051|Other|ViTAA Analysis|Imaging Analysis Software
75878381|NCT04980573|Other|Aromatherapy|The aromatherapy intervention consists of inhaling a fragrant oil extracted from citrus peels, plant resins, and leaves.
75878382|NCT04980573|Other|Placebo|The placebo intervention consists of inhaling an oil extracted from inert plant matter.
75878383|NCT02847182|Biological|Cord Blood Infusion|
75428164|NCT01483716|Behavioral|Rehabilitation|
75428165|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 1, single oral dose
75428166|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 2, single oral dose
75428167|NCT01483729|Drug|danoprevir|Reference Phase 2 Tablet Formulation, single oral dose
75428168|NCT01483729|Drug|ritonavir|Test Formulation 1, single oral dose
75428169|NCT01483729|Drug|ritonavir|Test Formulation 2, single oral dose
75428170|NCT01483729|Drug|ritonavir|Reference Formulation, single oral dose
75428171|NCT01483755|Procedure|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
75574602|NCT04603001|Drug|LY3410738|Oral LY3410738
75574603|NCT04603001|Drug|Venetoclax|Oral venetoclax
75574604|NCT04603001|Drug|Azacitidine|Subcutaneous or intravenous azacitidine
75574605|NCT04602741|Behavioral|A4i Intervention|6 months of the provision of A4i on the individual's own device.
75574606|NCT04588922|Drug|GFH009|In the dose escalation part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the expansion part, patients will be assigned based on tumor type(s).
75428172|NCT01483755|Procedure|Percutaneaous intervention|Conventional primary percutaneaous intervention
75428173|NCT01483768|Procedure|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
75428174|NCT01483781|Drug|Canagliflozin|Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
75428175|NCT01483781|Drug|Placebo|Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
75878384|NCT02847182|Biological|Placebo|
75428176|NCT01483833|Drug|Iferanserin|Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
75428177|NCT01483833|Drug|Placebo|Placebo ointment applied intra-anally twice daily for 14 days
75428178|NCT01483846|Drug|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
75428179|NCT01483846|Drug|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
75428180|NCT01483859|Other|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
75428181|NCT01483885|Device|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
75428182|NCT01483885|Device|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
75878385|NCT03578900|Drug|Xeros|
75878386|NCT03578900|Drug|Citric Acid based Mouthwash|
75878387|NCT03576872|Other|Psychoeducational|Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
75574607|NCT04588922|Drug|GFH009|In the dose escalation part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the expansion part, patients will be assigned based on tumor type(s).
75725858|NCT05360355|Procedure|total face reconstruction surgery and intraoperative indocyanine green angiography|Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
75878388|NCT02550002|Drug|Aflibercept|Intravitreal injection
75878389|NCT03574376|Drug|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
75878390|NCT03574376|Drug|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
75428183|NCT01483885|Procedure|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
75428184|NCT01483911|Biological|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
75574608|NCT04588922|Drug|GFH009, venetoclax, azacitidine|Group 3. Patients with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens
75725859|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
75428185|NCT01483911|Biological|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
75428186|NCT01483976|Other|Oral medical nutritional supplement|orally over a three hour period
75428187|NCT01483976|Other|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
75428188|NCT01483989|Other|SYSTANE® Gel Drop lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
75428189|NCT01484002|Device|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
75725860|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
75428190|NCT01484015|Drug|cefepime hydrochloride|Given IV
75725861|NCT00989703|Drug|placebo|oral solution, daily for 14 days
75725862|NCT00989703|Drug|GLPG0259|oral solution
75574609|NCT04581733|Drug|MT1621|All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.
75725863|NCT00989703|Drug|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
75725864|NCT01012960|Drug|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
75725865|NCT04572009|Other|Bio-mathematical model|bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
75574610|NCT04576715|Behavioral|TEaM Intervention|"Multi-setting mTBI (mild traumatic brain injury) Evaluation and Management Intervention incorporates provider education and information technology support systems, based on the best available evidence and tailored to a specific environment (acute care setting vs primary care clinic). Facilitates linkages between providers (ED/UC to primary care) and systems (healthcare to school).~Provider Training Modules: Training includes decision-making support alerted by positive triage screening and concussion-specific eMR template~Management based on current best practices (however, may have additional education from the provider training)~Return to school letters~Primary Care Follow Up"
75574611|NCT04576715|Behavioral|Standard of Care|"Continue with CHOA current best practices for mTBI:~No TEaM Provider training (but will be offered to all providers at end of study)~Will not be trained on utilization and implementation of the concussion screening alert and eMR template"
75574612|NCT04576364|Drug|Magnesium sulfate for 12 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
75725866|NCT04572009|Other|Without bio-mathematical model|No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
75725867|NCT03610906|Procedure|Tumor and Blood Specimens|If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
75574613|NCT04576364|Drug|Magnesium sulfate for 24 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
75574614|NCT04547790|Dietary Supplement|Psyllium|One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water
75574615|NCT04547790|Dietary Supplement|Wheat Dextrin|One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water
75574616|NCT04542317|Behavioral|REACH VN|4-6 sessions delivered over the course of 2-3 months.
75574617|NCT04542317|Behavioral|Enhanced control|A single session providing education about dementia
75574618|NCT04538976|Drug|Sildenafil|Sildenafil in standard dosage
75725868|NCT01683825|Drug|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
75725869|NCT00841334|Behavioral|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
75725870|NCT00841334|Behavioral|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
75725871|NCT02547116|Drug|Rifampin|Addition of Rifampin to standard anti-Staphylococcal treatment regimen
75725872|NCT05377047|Radiation|SABR|Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
75725873|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
75574619|NCT04537351|Biological|CYP-001|The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.
75574620|NCT04529967|Other|no interventions|it is a observational study, do not have interventions.
75574621|NCT04522544|Drug|Tremelimumab|300 mg Tremelimumab C1D1
75574622|NCT04522544|Drug|Durvalumab|1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
75574623|NCT04522544|Procedure|Y-90 SIRT|Locoregional therapy will be performed as a standard-of-care procedure
75574624|NCT04522544|Procedure|DEB-TACE|Locoregional therapy will be performed as a standard-of-care procedure
75574625|NCT04521686|Drug|LY3410738|Oral LY3410738
75574626|NCT04521686|Drug|Gemcitabine|Intravenous gemcitabine
75574627|NCT04521686|Drug|Cisplatin|Intravenous cisplatin
75574628|NCT04521686|Drug|Durvalumab|Intravenous durvalumab
75725874|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
75725875|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
75725876|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
75574629|NCT04487678|Dietary Supplement|Ketone ester supplement|Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.
75725877|NCT00835562|Procedure|Non-surgical management|Non-surgical management (physiotherapy and self-training)
75725878|NCT00835562|Procedure|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
75878391|NCT03576794|Drug|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
75878392|NCT03576794|Drug|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
75878393|NCT02846558|Other|Frequent Patient Interaction|Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.
75878394|NCT02846558|Behavioral|Timing Restriction|Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.
75574630|NCT04482036|Other|Mobile Phone Application Assessments|"The BrainCare Notes app was designed to be installed on the caregiver's phone. It has the capacity to send Neuropsychiatric Inventory Questionnaire (NPI-Q) assessments to the caregiver. If the answers to the behavioral and psychological symptoms rise above the threshold, the clinicians will be notified, and a care plan will be enacted, in order to keep the patient and caregiver safe.~The application also has the ability to send and receive private messages between caregiver and the patient's clinical care team."
75574631|NCT04482036|Other|Standard Assessments|The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.
75574632|NCT04447794|Behavioral|Step Away Chatbot|"The Step Away chatbot utilizes AI technology to provide mobile, web-based, person-centered, behavioral-based interventions and timely support for individuals seeking to reduce their alcohol use. Participants interact with the chatbot through interactive text.~The Step Away chatbot is informed by the following theoretical constructs: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. It uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. It proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
75574633|NCT04447794|Behavioral|Step Away App|"The Step Away app is a smartphone-based mobile intervention system.~It is informed by three theoretical constructs that are considered the most important active ingredients for person-centered, behavioral-based intervention and treatment in addictions: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. Step Away uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. Step Away proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
75574634|NCT04444518|Behavioral|VAX-MOM Intervention|The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
75725879|NCT00835562|Procedure|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
75574635|NCT04444518|Behavioral|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
75574636|NCT04437043|Other|quality of life questionnaires|pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
75878395|NCT02846558|Device|LoseIt! Smartphone Application|Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
75878396|NCT04362813|Drug|Canakinumab|Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
75878397|NCT04362813|Drug|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
75428191|NCT01484067|Device|Patch ( Compeed© Total CareTM Cold Sore Patch)|A cold sore patch containing zinc sulfate
75428192|NCT01484080|Drug|BIBF + Paclitaxel|"Priming Period:~Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.~One week washout is planned before starting the treatment phase.~Treatment Phase:~Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days)."
75428193|NCT01484080|Drug|Paclitaxel|Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
75428194|NCT01484106|Other|Fluid Resuscitation|"In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR)."
75428195|NCT01484106|Other|Standard of Care|Standard of Care
75428196|NCT01484145|Drug|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
75428197|NCT01484171|Drug|idarubicin|idarubicin 10-12 mg/m2 for three days
75428198|NCT01484171|Biological|microtransplantation|idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
75428199|NCT01484184|Drug|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
75574637|NCT04431635|Drug|Copanlisib|Copanlisib IV: day 1, 8, 15 every 28 days
75428200|NCT01484223|Behavioral|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
75428201|NCT01484249|Device|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
75428202|NCT01484262|Drug|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
75574638|NCT04431635|Drug|Nivolumab|Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
75574639|NCT04431635|Drug|Rituximab|Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
75574640|NCT04422015|Other|No intervention|No intervention
75574641|NCT04420962|Diagnostic Test|Visual Acuity|Best corrected visual acuity utilizing the Snellen method
75574642|NCT04373928|Procedure|Drug guided by Mini-PDX/PDX|Chemotherapeutic agents guided by Mini-PDX/PDX will be applied to PC patients and the efficiency will be studied.
75574643|NCT04350775|Other|RE-IADL|RE-IADL program is to conduct trainings related to instrumental activities of daily living. For example,using communication appliance, moving in community, financial management, health care, housework, prepare meals and clear ,and shopping.
75574644|NCT04350775|Other|General community rehabilitation|General community rehabilitation contains the activities in psychiatric rehabilitation center.
75574645|NCT04343820|Procedure|Breast reconstruction|Breast reconstruction by prepectoral positioned implant after lipo-preparation of the wall.
75574646|NCT04324307|Drug|PD-L1/CTLA4 BsAb|PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W
75725880|NCT05359107|Behavioral|"The Free From Pain Exercise Book"|Contains educational information and exercises to improve musculoskeletal pain and reduce sarcopenia.
75428203|NCT01484262|Drug|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
75428204|NCT01484353|Behavioral|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
75428205|NCT01484366|Procedure|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
75428206|NCT01484366|Procedure|plating|Surgical plating of both bonforearm fractures
75428207|NCT01484379|Procedure|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
75428208|NCT01484405|Procedure|posterior approach|Surgical approach for Total Hip Arthroplasty
75428209|NCT01484405|Procedure|anterolateral approach|anterolateral surgical approach
75428210|NCT01484418|Behavioral|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
75428211|NCT01484418|Behavioral|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
75428212|NCT01484457|Device|Closed-loop session|"Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose < 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.~Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.~After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia."
75428213|NCT01484470|Biological|StemEx|"For patients allocated to StemEx® arm:~Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~Day 1: StemEx® transplantation.~Day 2 to 3 years: Post transplant follow-up."
75574647|NCT04324307|Combination Product|GP|Gemcitabine 1000mg/m2, iv, D1,8,15, 28days/cycle; nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle;
75574648|NCT04324307|Combination Product|FOLFIRINOX|Fluorouracil 2400mg/m2，iv，D1, 14days/cycle; Oxaliplatin 68-85mg/m2，iv, D1,14days/cycle;Irinotecan135-180mg/m2，iv, D1, 14days/cycle;Calcium Folate 400mg/m2，iv, D1, 14days/cycle;
75574649|NCT04298151|Drug|Zirconomer Improved|glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
75574650|NCT04298151|Drug|Ketac Molar quick Aplicap|highly viscous glass ionomer with improved mechanical properties than the conventional GI
75574651|NCT04268173|Other|Community-Based, Client-Centered Prevention Home|Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
75725881|NCT05359107|Behavioral|"The Back Book"|Contains advice and guidance on how to deal with and reduce back pain.
75725882|NCT03971695|Drug|BI 706321|Capsule or Oral Solution
75574652|NCT04251130|Drug|2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine|A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.
75725883|NCT03971695|Drug|Placebo|Capsule or Oral solution
75725884|NCT02549690|Drug|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
75725885|NCT02549690|Drug|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
75725886|NCT05357937|Behavioral|standard physiotherapy program|A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups
75878398|NCT03578822|Drug|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
75574653|NCT04217395|Behavioral|Obese or overweight health subjects involved in the X-Ailes program (at least one contact with the health system navigator)|"The X-Ailes program is a face-to-face or telephone-based support program by health-system navigators and developed by a patients and public association to support overweight or obese care users.~The main objective of the study is to evaluate the efficacy of the X-ailes program on quality of life of overweight and obese people involved in the program.~Secondary objectives are to assess their overall health status, their health literacy level and their empowerment. The implementation study is guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance; Glasgow, Vogt, & Boles, 1999) theoretical framework to determine whether the intervention objectives are being met and to understand the mechanisms of action of the device."
75574654|NCT04216628|Other|Amniotomy|Artificial rupturing of membranes and IV infusion of Oxytocin
75574655|NCT04210284|Dietary Supplement|Ensure|"Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains:~160 Calories, 20 from fat~2g Total fat~0.5g Saturated fat~20mg Cholesterol~135mg Sodium~170mg Potassium~19g Total carbohydrate~<1g Fiber~4g Sugar~16g Protein~Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously.~Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control (NO ENSURE) and oral supplementation (ENSURE) arms for the aforementioned baseline and perioperative variables"
75428214|NCT01484522|Biological|FluMist|Administered at the manufacture's recommended dose
75428215|NCT01484522|Biological|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
75574656|NCT04192019|Drug|Micro-glucagon|Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
75428216|NCT01484522|Biological|Fluzone|Vaccine administered at manufacturer's recommended dose
75574657|NCT04192019|Drug|Mini-glucagon|Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
75878399|NCT03578822|Drug|Aspirin|Aspirin 300mg is taken orally at the beginning of thrombolysis.
75428217|NCT01484535|Procedure|Ankle Aspiration|Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.
75725887|NCT02549768|Drug|Dexmedetomidine|At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
75428218|NCT01484535|Procedure|Ankle aspiration Standard Anterolateral|Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
75428219|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
75428220|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
75428221|NCT01484548|Biological|LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
75428222|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
75428223|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
75428224|NCT01484587|Drug|CNTO 1959|CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
75428225|NCT01484587|Drug|Placebo|Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
75428226|NCT01484600|Drug|REGN668: Injection Rate 1|Subjects will receive REGN668 via SC injection
75428227|NCT01484600|Drug|REGN668: Injection Rate 2|Subjects will receive study drug via alternate delivery (if necessary)
75725888|NCT02549768|Drug|Sodium Chloride 0.9%|Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
75725889|NCT04551651|Device|ApplTree|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
75725890|NCT04551651|Device|Google Calendar|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
75428228|NCT01484613|Device|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
75428229|NCT01484639|Other|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
75725891|NCT00841646|Biological|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
75725892|NCT04464213|Other|Single dose experiments|In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time.
75725893|NCT04464213|Other|Multi-dose experiments|In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.
75428230|NCT01484639|Other|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
75574658|NCT04174170|Drug|Brexpiprazole|Up to 3 mg pill
75574659|NCT04174170|Drug|Sertraline|Up to 150 mg pill
75574660|NCT04174170|Other|Placebo|Pill
75574661|NCT04172779|Drug|Erlotinib Hydrochloride|Oral administration of erlotinib 25mg tablet
75725894|NCT00841724|Drug|Fludarabine, Busulfan, Thymoglobuline|
75725895|NCT00843362|Drug|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
75574662|NCT04165343|Radiation|Positron Emission Tomography (PET) on EXPLORER|"Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive tracer (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you."
75574663|NCT04165343|Diagnostic Test|Magnetic Resonance Imaging|MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
75574664|NCT04165343|Diagnostic Test|Echocardiogram and Electrocardiogram|You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
75574665|NCT04165343|Diagnostic Test|Blood test|We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
75574666|NCT04146298|Drug|Cyclophosphamide|Cyclophosphamide will be administered prior to cell infusion.
75574667|NCT04146298|Drug|Fludarabine|Fludarabine will be administered prior to cell infusion.
75428231|NCT01484665|Other|PROCASE Decision-Aid|"VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study."
75428232|NCT01484717|Behavioral|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
75428233|NCT01484717|Drug|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)].
75574668|NCT04146298|Biological|Mutant KRAS G12V-specific TCR transduced autologous T cells|After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
75574669|NCT04146298|Drug|Anti-PD-1 monoclonal antibody|During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
75428234|NCT01484717|Behavioral|Telephone counseling|Participants receive brief twice weekly telephone counseling.
75428235|NCT01484743|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
75428236|NCT01484756|Dietary Supplement|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
75428237|NCT01484756|Dietary Supplement|Placebo|calcium carbonate 500 mg
75574670|NCT04144738|Diagnostic Test|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
75574671|NCT04144738|Diagnostic Test|FIT test|Stool samples will be collected by the subject for the FIT test.
75574672|NCT04144738|Procedure|Colonoscopy|Subjects will undergo a screening colonoscopy.
75574673|NCT04126590|Biological|KN044|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg."
75574674|NCT04124614|Drug|Brexpiprazole|Up to 3 mg pill
75574675|NCT04124614|Drug|Sertraline|Up to 150 mg pill
75574676|NCT04124614|Other|Placebo|Pill
75725896|NCT00843362|Drug|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
75574677|NCT04104243|Other|Men-Tailored DPP (Power-Up)|Evaluating whether a diabetes prevention program (DPP) tailored for men (Power-Up) will show better or similar percent weight loss and retention than a standard mixed-gender DPP
75574678|NCT04099797|Genetic|C7R-GD2.CART cells (ICV infusion)|"Dose levels in the current phase of study are ICV infusion followed by IV infusion (DL 1b, 2b, 3b, 4b)~Dose level 1b ICV: 5 x 10^6 cells/dose (followed by standard IV dose)~Dose level 2b ICV: 1 x 10^7 cells/dose (followed by standard IV dose)~Dose level 3b ICV: 2 x 10^7 cells/dose (followed by standard IV dose)~Dose level 4b ICV: 5 x 10^7 cells/dose (followed by standard IV dose)"
75428238|NCT01484782|Behavioral|Interactive Voice Response (IVR) automated calls|Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
75574679|NCT04099797|Genetic|C7R-GD2.CART cells (IV infusion)|Standard IV dose: 30 million cells/m2 divided into two doses given at least 5 days and no greater than 10 days apart.
75574680|NCT04089488|Other|Medical Chart Review|Correlative studies
75574681|NCT04089488|Other|Survey Administration|Respond to surveys
75574682|NCT04042935|Drug|Alpha Lipoic Acid|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
75574683|NCT04038060|Behavioral|WhatsApp Group|Participants will receive peer adherence support through WhatsApp groups
75574684|NCT04038060|Behavioral|2-way SMS|Participants will receive healthcare worker adherence support through 2-way SMS
75574685|NCT04038060|Behavioral|Drug level feedback|Participants will receive adherence counseling based on tenofovir drug levels
75574686|NCT04038060|Behavioral|Monthly counseling sessions|Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence
75725897|NCT04003233|Device|SDS|The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
75725898|NCT04003233|Device|MID-C|The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
75725899|NCT00841802|Drug|Prednisone|Prednisone 30mg once daily x 5 days
75725900|NCT05300295|Behavioral|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
75725901|NCT00989859|Device|Plethysmographic monitoring|Plethysmographic monitoring
75725902|NCT00621140|Drug|linagliptin|active
75725903|NCT00621140|Drug|placebo|placebo
75574687|NCT04009291|Combination Product|TransCon PTH|TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
75574688|NCT04009291|Combination Product|Placebo for TransCon PTH|Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
75574689|NCT03997305|Device|AltaValve|Transcatheter Mitral Valve Replacement
75574690|NCT03990506|Procedure|Epi-on PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; < 45D, 7.2J/cm2; 45-50D, 10J/cm2; > 50D, 15 J/cm2.
75574691|NCT03990506|Procedure|Epi-Off PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; < 45D, 7.2J/cm2; 45-50D, 10J/cm2; > 50D, 15 J/cm2.
75574692|NCT03954431|Diagnostic Test|Dedicated breast CT(BCT)|The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.
75428239|NCT01484795|Device|BILEVEL (Respironics)|Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
75574693|NCT03953131|Procedure|Computed Tomography|Undergo PET/CT
75428240|NCT01484795|Device|Continuos positive airway pressure (Respironics)|CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
75428241|NCT01484821|Device|ARFI|Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
75428242|NCT01484847|Drug|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
75428243|NCT01484860|Drug|AUY922|AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
75428244|NCT01484886|Other|Red blood cell transfusion|10cc/kg weight RBC transfusion as needed according to hemoglobin level
75574694|NCT03953131|Radiation|Gallium Ga 68-DOTATATE|Given IV
75574695|NCT03953131|Procedure|Positron Emission Tomography|Undergo PET/CT
75574696|NCT03947424|Device|LP Er:YAG|LP Er:YAG applied to oral mucosa
75574697|NCT03947424|Device|SMOOTH mode Er:YAG|SMOOTH mode Er:YAG applied to oral mucosa
75574698|NCT03947424|Device|sham|Er:YAG laser applied to oral mucosa with no energy
75574699|NCT03938571|Procedure|Duodenal Switch|
75574700|NCT03936517|Drug|Prednisolone|Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
75574701|NCT03936517|Drug|Hydrocortisone|Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
75574702|NCT03889795|Drug|Metformin|Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
75574703|NCT03889795|Drug|Simvastatin|Simvastatin oral pill will be taken daily in the evening.
75574704|NCT03889795|Drug|Digoxin|Digoxin oral pill will be taken once daily.
75574705|NCT03839108|Other|Paraffin wax|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
75574706|NCT03839108|Drug|Prolotherapy|. Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
75725904|NCT00207727|Drug|CNTO 1275|
75725905|NCT00841880|Drug|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
75725906|NCT00841880|Drug|Ramipril|10 mg once a day
75574707|NCT03819075|Device|Lightwalker Laser (Fotona)|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.
75574708|NCT03819075|Other|standard|Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
75574709|NCT03808025|Behavioral|opioid education|see arm/group descriptions
75725907|NCT00841880|Drug|Ramipril|5mg once a day
75725908|NCT03971851|Other|Frailty risk groups|Patients older than 65 will be separated into groups of varying frailty risk
75428245|NCT01484886|Other|Red blood cell transfusion|10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
75428246|NCT01484964|Drug|ASP015K|oral
75574710|NCT03802084|Drug|vactosertib/imatinib combination|"Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)"
75574711|NCT03790280|Diagnostic Test|HFO analysis|We hypothesize that the strategy of incorporating HFO data to a standard ECoG-guided resection in pediatric epilepsy surgery will result in improved postoperative seizure outcome than the traditional approach.
75725909|NCT00835874|Drug|Probiotics|Lactobacillus acidophilus, b.lactis capsule. Once daily.2X 10 by the power of 10 bacteria per dose.
75725910|NCT03969745|Behavioral|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
75725911|NCT03969745|Behavioral|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
75725912|NCT00835952|Drug|ATX-101|ATX-101 single doses
75725913|NCT03971773|Other|hypnosis|patient with cancer will undergo sessions of hypnosis
76048475|NCT01853254|Drug|Ribavirin|For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing < 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
75725914|NCT00843440|Drug|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
75725915|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet once daily
75725916|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet once daily
75725917|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet two times a day
76048476|NCT02373098|Drug|Fingolimod 0.5 mg|66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
76048477|NCT01853176|Drug|Liposomal Injection Bupivacaine (Exparel)|
76048478|NCT01853176|Drug|Standard bupivicaine|
75428247|NCT01484990|Drug|Levodopa-Carbidopa|Intestinal Gel
75428248|NCT01485003|Biological|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
75725918|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet two times a day
75725919|NCT00504556|Drug|warfarin|warfarin tablets
75725920|NCT05274009|Other|No cooling (control)|Participants are exposed to 35°C, 60% relative humidity for 8 hours.
75428249|NCT01485029|Procedure|Nasopharyngeal (NP) aspirate|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
75428250|NCT01485042|Drug|Pazopanib and TH-302|Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
75428251|NCT01485068|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
75428252|NCT01485081|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
75428253|NCT01485107|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
75428254|NCT01485146|Drug|ETC-1002|escalating doses
75428255|NCT01485159|Procedure|Spirometry|assessment of lung function by spirometry
75428256|NCT01485185|Drug|Gabapentin lower dose|Repeat, oral dose
75725921|NCT05274009|Other|Recommended cooling|Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (~23°C, ~50% relative humidity), and then return to the heat for a final 3 hours.
75725922|NCT05274009|Other|Hybrid cooling|Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (~23°C, ~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
76048479|NCT02372396|Behavioral|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
75428257|NCT01485185|Drug|Donepezil|Repeat, oral dose
75574712|NCT03777462|Drug|Neoadjuvant gemcitabine plus nab-paclitaxel|Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. Surgical resection will be performed after neoadjuvant chemotherapy.
75574713|NCT03777462|Drug|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
75574714|NCT03777462|Drug|Neoadjuvant S-1 plus nab-paclitaxel with SBRT|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
75574715|NCT03745326|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
75574716|NCT03745326|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2/day IVPB daily over 30 minutes for 5 days.
75725923|NCT00836030|Other|No treatment given|No treatment given
76048480|NCT02372396|Behavioral|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
75428258|NCT01485185|Other|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
75428259|NCT01485185|Other|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
75428260|NCT01485185|Drug|Gabapentin higher dose|Repeat, oral dose
75428261|NCT01485198|Procedure|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
75428262|NCT01485198|Drug|Acetaminophen|Acetaminophen (750mg orally TID) administration
75428263|NCT01485211|Drug|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
75428264|NCT01485224|Drug|Thalidomide|"Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~8 additional weeks of treatment after the achievement of complete response~16 additional weeks of treatment after the achievement of partial response~24 weeks of treatment completed without response~unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
75428265|NCT01485237|Other|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
75574717|NCT03745326|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
75725924|NCT00206323|Drug|Topiramate (drug)|Topiramate 25 mg titrated to 200 mg
75725925|NCT00206323|Drug|placebo/sugar pill|placebo
75725926|NCT00841958|Procedure|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
75725927|NCT03903159|Behavioral|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
75428266|NCT01485276|Procedure|DBS Surgery|
75428267|NCT01485302|Drug|SAR228810|"Pharmaceutical form:solution~Route of administration: intravenous"
75428268|NCT01485302|Drug|SAR228810|"Pharmaceutical form:solution~Route of administration: subcutaneous"
75574718|NCT03745326|Biological|anti-KRAS G12D mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
75574719|NCT03730181|Drug|Rifapentine|Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.
75574720|NCT03730181|Drug|Isoniazid|Isoniazid. 25mg/kg
75574721|NCT03701568|Drug|dC/dT|Collection of retrospective data from TK2 patients previously treated with dC/dT
75574722|NCT03698487|Other|Intervention|Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
75574723|NCT03679559|Other|Best Practice|Continue usual physical activity
75574724|NCT03679559|Behavioral|Exercise Intervention (home walking program and resistance training)|Complete home-based walking program and resistance training
75725928|NCT04043000|Dietary Supplement|Super 13 Pro & Prebiotics|"Super 13 Pro & Prebiotics was given three times a day for four weeks."
75878400|NCT03578822|Drug|rhPro-UK simulation agent|Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
75878401|NCT03578822|Drug|Aspirin simulation agent|Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
75878402|NCT03578744|Procedure|Conventional Flap surgery|After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
75878403|NCT03576638|Drug|Accordion Pill Carbidopa/Levodopa|AP 50/500 TID days 2-7
75878404|NCT03576638|Drug|Sinemet CR 25Mg-100Mg Extended-Release Tablet|25/100 1.5 pills five times/day
75878405|NCT04284657|Drug|Pravastatin|Pravastatin 40 mg QD
75574725|NCT03679559|Behavioral|Exercise Intervention (home-based Zumba program and resistance training)|Complete home-based Zumba program and resistance training
75574726|NCT03679559|Behavioral|Exercise Intervention (HIIT program and resistance training)|Complete HIIT program and resistance training
75574727|NCT03679559|Other|Informational Intervention|Watch video
75574728|NCT03679559|Other|Laboratory Biomarker Analysis|Correlative studies
75574729|NCT03679559|Device|Monitoring Device|Wear Fitbit
75574730|NCT03679559|Other|Quality-of-Life Assessment|Ancillary studies
75574731|NCT03679559|Other|Questionnaire Administration|Ancillary studies
75725929|NCT02546804|Procedure|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
75725930|NCT02546804|Procedure|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
75725931|NCT02546804|Procedure|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
75878406|NCT04284657|Drug|sodium citrate|sodium citrate up to 30 ml TID
75878407|NCT03578666|Other|Massage|The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
75878408|NCT03578666|Other|Cold water immersion|The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
76048481|NCT01835548|Drug|NT0102|NT0102 (methylphenidate polistirex [MPP] extended release [XR] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
75428269|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
75428270|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
75428271|NCT01485328|Drug|AMARGOL®|per oral solution, 40 mL single dose
75428272|NCT01485341|Dietary Supplement|gluten|gluten is administered once a day at 10g/day for 15 days
75428273|NCT01485341|Dietary Supplement|rice starch|rice starch is administered once a day at 10 g/day for 15 days
75574732|NCT03674671|Drug|Intravenous Ketamine|Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
75574733|NCT03674671|Procedure|Electroconvulsive Therapy|Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
75574734|NCT03668119|Biological|Nivolumab|Specified dose on specified days
75574735|NCT03668119|Biological|Ipilimumab|Specified dose on specified days
75574736|NCT03659799|Drug|Insulin FiAsp|An insulin bolus of FiAsp will be given 5 minutes before breakfast
75428274|NCT01485367|Drug|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand & extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand & extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right & left forearms.
75574737|NCT03659799|Drug|Insulin Aspart|An insulin bolus of Aspart will be given 5 minutes before breakfast
75574738|NCT03659799|Other|60-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
75574739|NCT03659799|Other|120-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
75574740|NCT03653364|Drug|Baloxavir Marboxil|"Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age.~Participants will be recruited in parallel to the following three cohorts:~Cohort I: ≥ 3 months to < 12 months old (minimum 8 participants): 2 mg/kg~Cohort II: ≥ 4 weeks to < 3 months old (minimum 4 patients): 1 mg/kg~Cohort III: birth to < 4 weeks old (minimum 4 patients): 1 mg/kg"
75574741|NCT03624244|Drug|Aromatase Inhibitors|Maintenance of AI versus interruption of AI
76048482|NCT01835548|Drug|Placebo|Matching ODT placebo was given once daily.
75428275|NCT01485406|Biological|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
75428276|NCT01485406|Biological|Synflorix™|1 dose administered intramuscularly
75428277|NCT01485432|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
75428278|NCT01485445|Drug|Fluticasone Furoate (200mcg unit strength)|inhalation powder
75428279|NCT01485445|Drug|Fluticasone Furoate/Vilanterol (200/25mcg unit strength)|inhalation powder
75428280|NCT01485458|Procedure|Early surgery|Surgery within 24 hours after admission
75428281|NCT01485458|Procedure|Delayed surgery|Surgery more than 2 weeks after injury
75428282|NCT01485510|Behavioral|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
75428283|NCT01485510|Behavioral|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
75725932|NCT00205855|Device|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
75725933|NCT01013038|Procedure|Thrombus aspiration followed by stent implantation|Export aspiration catheter 6F (Medtronics)
76048483|NCT01852942|Drug|Losartan|Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
76048484|NCT01852942|Drug|Placebo|one tablet by mouth daily
75725934|NCT01013038|Procedure|conventional PCI|balloon angioplasty and/or stent implantation
76048485|NCT01852162|Drug|Dabigatran|Dabigatran 150mg
76048486|NCT01852162|Drug|Placebo|Matching placebo tablets
76048487|NCT04596124|Device|fitostimoline plus|randomized controlled multicentric study
75725935|NCT04526704|Drug|Pexidartinib|200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
75878409|NCT05205135|Behavioral|SHARE Programme|"SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting."
75428284|NCT01485523|Other|Nasal provocation test|"TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites."
75725936|NCT00842114|Biological|R+CVP+IFN|Immunochemotherapy
75878410|NCT03576560|Other|Retrospective Chart Review|Retrospective Chart Review
75878411|NCT03574220|Drug|Pembrolizumab|200mg IV every 21 days over 6 months
75878412|NCT03574220|Radiation|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
75878413|NCT03574142|Drug|Epanova|A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days.
76048488|NCT01835470|Drug|Abatacept|
75428285|NCT01485562|Drug|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
75428286|NCT01485562|Other|placebo|4 tablets, administered sublingually if the woman experiences a PPH
75428287|NCT01485575|Procedure|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
76048489|NCT02451137|Drug|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75428288|NCT01485601|Biological|MT10109|Single dose intramuscular injection MT10109 vs Botox®
75725937|NCT00842192|Drug|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
75725938|NCT00536991|Dietary Supplement|Calcitriol|Given PO
75725939|NCT00536991|Drug|Ketoconazole|Given PO
75725940|NCT00536991|Other|Laboratory Biomarker Analysis|Correlative studies
75725941|NCT00536991|Other|Pharmacological Study|Correlative studies
75725942|NCT00536991|Drug|Therapeutic Hydrocortisone|Given PO
75725943|NCT00842270|Drug|AB1010|3 mg/kg/day
75725944|NCT00842270|Drug|AB1010|4,5 mg/kg/day
75725945|NCT00842270|Drug|AB1010|6 mg/kg/day
75725946|NCT00842270|Drug|placebo|matching placebo to AB1010 dosages
76048490|NCT02451137|Drug|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
76048491|NCT02451137|Drug|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
76048492|NCT02451137|Drug|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
76048493|NCT02372006|Drug|afatinib|
76048494|NCT02406248|Drug|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
75428289|NCT01485653|Drug|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
75428290|NCT01485679|Other|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
75428291|NCT01485692|Drug|haloperidol+promethazine|haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
75428292|NCT01485692|Drug|haloperidol + midazolam|haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
75428293|NCT01485692|Drug|olanzapine|olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
75428294|NCT01485692|Drug|Ziprasidone|ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
75428295|NCT01485705|Other|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|"When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic optimal or not of initial medical care is then determined by the independent experts blinded from issue of the care."
75428296|NCT01485718|Dietary Supplement|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
75428297|NCT01485718|Dietary Supplement|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
75428298|NCT01485731|Drug|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
75428299|NCT01485731|Drug|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
75428300|NCT01485731|Radiation|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
75428301|NCT01485731|Radiation|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
75428302|NCT01485731|Procedure|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
75428303|NCT01485731|Procedure|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
75428304|NCT01485731|Procedure|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
75428305|NCT01485731|Procedure|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
76048495|NCT02450903|Drug|LDK378|Oral LDK378 750mg once daily
76048496|NCT02371616|Device|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
75428306|NCT01485731|Procedure|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
75428307|NCT01485731|Procedure|Proctoscopy|Optional. Pre-Treatment
75428308|NCT01485731|Procedure|Cytoscopy|Optional. Pre-Treatment
75428309|NCT01485731|Procedure|Renal Ultrasound|Optional. Pre-Treatment
76048497|NCT02371616|Other|Sodium fluoride|1426 ppm fluoride as sodium fluoride
76048498|NCT02371616|Other|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
76048499|NCT02370914|Device|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
75428310|NCT01485731|Procedure|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
75428311|NCT01485731|Procedure|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
75428312|NCT01485744|Drug|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
75428313|NCT01485757|Drug|L-arginine|All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
75428314|NCT01485822|Procedure|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
75428315|NCT01485822|Drug|Travoprost 0.004% ophthalmic solution|
75428316|NCT01485835|Drug|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
75428317|NCT01485835|Drug|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
75428318|NCT01485835|Drug|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
75574742|NCT03620019|Drug|Denosumab|A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
75428319|NCT01485848|Drug|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
75428320|NCT01485848|Drug|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
75428321|NCT01485900|Drug|SAR407899A|"Pharmaceutical form:capsule~Route of administration: oral"
75428322|NCT01485913|Other|intensive education intervention using a network of involved diabetic patients (peer educators)|the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
75428323|NCT01485926|Drug|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
75574743|NCT03620019|Drug|Pembrolizumab|Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
75574744|NCT03620019|Drug|Nivolumab|Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
76048500|NCT02370914|Behavioral|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
76048501|NCT02370602|Drug|TAK-063|TAK-063 tablets
76048502|NCT02370602|Drug|[^11C]T-773|[^11C]T-773 IV solution
75574745|NCT03591770|Biological|SHINGRIX|"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
75574746|NCT03569813|Behavioral|PrEP@Home System|"The PrEP@Home system includes a home care kit mailed quarterly to participants. The kit has components for self-collection of urine, rectal and pharyngeal swabs, microtube blood collection, and materials for return shipping. Biological tests routinely performed at PrEP follow-up (FU) visits will be done on the specimens. At months 6 and 12, the kit will include materials to assess for protective levels of emtricitabine triphosphate (FTC-TP).~The system includes a study app through which participants may track the mailing of home testing kits, access quarterly surveys, and communicate with study clinicians. The surveys will include domains that physicians assess at PrEP care quarterly FU visits (sexual risk, illicit substance use, PrEP adherence, side effects).~Study Clinicians will review Lab and survey results and if the results show no contraindications for PrEP continuation, the clinician may renew a participant's PrEP prescription. Telemedicine visits will be scheduled as needed."
75574747|NCT03569813|Other|Standard of Care|Control participants will receive clinic-based PrEP follow-up. After the baseline assessment, control participants will receive active linkage to standard, clinic-based PrEP care for their next PrEP care follow-up visit. Participants will also download the control version of the study app, which will contain only research elements pertinent to their participation in the control arm of the study including quarterly surveys. At months 6 and 12, control arm participants will be sent materials for DBS self-collection and return shipping to allow for measurement of the study outcome, emtricitabine triphosphate (FTC-TP).
75574748|NCT03559647|Drug|Atezolizumab|Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
75574749|NCT03557502|Other|Heat Therapy Group|30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session
75574750|NCT03557502|Other|Aerobic Exercise Group|30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak
75428324|NCT01485926|Drug|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
75725947|NCT00836108|Behavioral|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
75428325|NCT01485939|Other|placebo patch applied|Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
75428326|NCT01485939|Other|5% lidocaine patch|Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
75428327|NCT01485952|Drug|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
75428328|NCT01485952|Drug|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
75428329|NCT01485952|Drug|Placebo|Once daily administration (immediate release capsule)
75428330|NCT01485965|Drug|SEN0014196|100 mg, immediate release tablets, once daily administration
75428331|NCT01485978|Drug|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
75725948|NCT00504166|Drug|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
75725949|NCT00504166|Other|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
75725950|NCT02547584|Procedure|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
75725951|NCT04342520|Other|Dyads Patient / caregiver|adult patient / caregiver couples, patient are 55 years of age or older and have Alzheimer's disease or a related disease
75725952|NCT01013116|Biological|modified allergen extract of house dust mites|subcutaneous injections
75725953|NCT01013116|Biological|placebo|subcutaneous injections
75725954|NCT04002765|Diagnostic Test|pulmonary function tests|"Lung function tests (standard of care)~Dynamic and static volumes (FVC, FEV1, TPC, RV)~Lung diffusion capacity for CO (DLCO)~Chest Xrays~High resolution CT scanner (HRCT)"
75725955|NCT02546648|Drug|Tranexamic Acid|
75725956|NCT02546648|Drug|Tranexamic Acid Placebo|
76048503|NCT02370368|Device|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
75725957|NCT02546648|Drug|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
75725958|NCT03997942|Other|Effect of exercise|Once the data are available, we hope to have information about which of the exercise practices included in the rehabilitation program of acute upper extremity burn patients is more effective.
76048504|NCT02370368|Other|Agility Ladder Drills|Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
76048505|NCT04897256|Behavioral|TURN-IT exercise program|Based on the exercise motor learning principles, participants spend 10-15 minutes at each Exercise Station that focuses on particular constraints of turning ability. The stations will focus on important underlying aspects of turning, such as weight-shifting and increasing axial rotation during functional turning tasks. Each station will be progressed across levels to make more challenging (such as adding a dual task). Initially participants will be supported in an overhead body-weight support system (ZeroG) to allow them to practice challenging exercises without the risk of falling.
75428332|NCT01485978|Drug|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
75428333|NCT01485978|Drug|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
75428334|NCT01486004|Drug|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
75428335|NCT01486004|Drug|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
75428336|NCT01486017|Drug|ASP015K|oral
75428337|NCT01486030|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
75428338|NCT01486082|Other|OCA 10|A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
75428339|NCT01486095|Device|AXXESS + Biomatrix Biolimus Eluting stent|NAP
75428340|NCT01486095|Device|Culotte technique with Xience V or Xience Prime stents|NAP
75428341|NCT01486108|Procedure|dorsal column stimulator|test different settings of stimulation
75428342|NCT01486121|Other|Therapy strategy|Sedation & mechanical ventilation
75428343|NCT01486134|Procedure|Multipolar Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
75428344|NCT01486147|Behavioral|Visual nutrient profiling tool|Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.
75428345|NCT01486147|Behavioral|Nutrient ratings table|Showed nutrition information and had to match to fiber and protein ratings from a table.
75428346|NCT01486186|Drug|Traditional Chinese Medicine|A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
75428347|NCT01486186|Drug|placebo chinese medicine|There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
75428348|NCT01486225|Device|Innothera's brand Stockings|15 patients having used Innothera branded Stocking
75428349|NCT01486225|Other|Stockings other than Innothera's brand|15 patients having used any other brand than Innothera's brand stockings
75428350|NCT01486251|Drug|axitinib|"Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
75428351|NCT01486290|Behavioral|Behavioral|the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
75574751|NCT03489057|Behavioral|Prostate Cancer Education and Resources for Couples (PERC)|PERC uses mHealth technologies to dramatically increase couples' accessibility to posttreatment supportive care whenever and wherever they feel comfortable accessing it. PERC aims to improve QOL for both patients and partners by enhancing positive appraisals of illness and boosting self-efficacy, social support from multiple sources, and healthy behaviors for symptom self-management at home.
75428352|NCT01486303|Procedure|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
75428353|NCT01486329|Biological|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
75428354|NCT01486329|Biological|Placebo|Drink solution
75725959|NCT00843596|Procedure|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
75428355|NCT01486342|Radiation|PET-CT scan|"PET-CT imaging with [18F]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.~A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames."
75428356|NCT01486355|Biological|Measles vaccine|Edmonston-Zagreb measles vaccine
75428357|NCT01486381|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin)
75428358|NCT01486394|Other|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
75428359|NCT01486420|Procedure|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
75725960|NCT00842426|Behavioral|Self-management program (SM)|"Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management."
75878414|NCT03578588|Drug|Banapenem|Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed
75428360|NCT01486420|Procedure|Open surgery|Open A1-pulley release
75428361|NCT01486433|Drug|Simvastatin|40 mg (1 tablet) simvastatin once a day
75428362|NCT01486433|Drug|acetylsalicylic acid (ASA)|81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
75428363|NCT01486433|Drug|omefas|4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
75428364|NCT01486459|Drug|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
75428365|NCT01486472|Drug|S-1|Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
75428366|NCT01486485|Drug|heparinized saline priming group|
75428367|NCT01486485|Drug|nafamostat infusion after heparinized saline priming|
75428368|NCT01486511|Procedure|Liver resection|Hepatectomy including both minor and major.
75428369|NCT01486511|Radiation|Computed Tomography|Computed Tomography +/- pulmonary angiography
75878415|NCT04876677|Drug|Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium|Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB
75878416|NCT02966028|Drug|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
75878417|NCT02966028|Drug|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
75878418|NCT03578432|Drug|Everolimus|Given PO
75878419|NCT03578432|Other|Laboratory Biomarker Analysis|Correlative studies
75878420|NCT03578432|Other|Survey Administration|Ancillary studies
75878421|NCT03578354|Drug|4-aminopyridine|an oral drug to be swallowed
75878422|NCT03578354|Drug|Atenolol|an oral drug to be swallowed
75428370|NCT01486550|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
75428371|NCT01486550|Drug|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
75428372|NCT01486563|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
75428373|NCT01486563|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
75428374|NCT01486576|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
75428375|NCT01486576|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
75428376|NCT01486602|Drug|carboplatin|IV
75428377|NCT01486602|Drug|paclitaxel|IV
75574752|NCT03489057|Behavioral|usual care plus NCI website|The usual care plus NCI website provides generic information about prostate cancer treatment options, research, causes, and statistics; coping resources that are not prostate cancer-specific; support from non-providers via a toll free phone and LiveHelp Online Chat about cancer-related questions, clinical trials, and quitting smoking.
75574753|NCT03360643|Diagnostic Test|Point-of-care ultrasound prior to radiology ultrasound|Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound
75574754|NCT03360643|Diagnostic Test|Radiology-performed ultrasound|Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
75574755|NCT03321734|Drug|Caffeine|Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
75428378|NCT01486602|Radiation|radiation therapy|Defined per the protocol
75574756|NCT03321734|Drug|Placebos|SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
75428379|NCT01486641|Procedure|Anterolateral approach|Anterolateral approach acording to Gammer for hip arthroplasty.
75428380|NCT01486654|Device|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
75428381|NCT01486654|Device|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
75428382|NCT01486654|Device|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
75428383|NCT01486667|Drug|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
75725961|NCT00842426|Behavioral|Care management program (CM)|"In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support."
75725962|NCT01010620|Behavioral|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
75725963|NCT00842504|Drug|Micafungin|3 mg/kg IV once over 1 hour
75725964|NCT00842582|Drug|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
75725965|NCT00842582|Drug|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
75725966|NCT00842582|Drug|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
75725967|NCT00843908|Device|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
75878423|NCT03578354|Other|Placebo|a masked placebo to be swallowed
75878424|NCT02239718|Procedure|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
75428384|NCT01486667|Drug|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
75428385|NCT01486680|Procedure|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
75574757|NCT03316196|Behavioral|COGENT COGNITIVE TRAINING|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
75428386|NCT01486680|Procedure|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
75574758|NCT03316196|Behavioral|Non training computer condition|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
75725968|NCT00843908|Device|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
75725969|NCT00842660|Drug|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
75725970|NCT00509236|Drug|Sitagliptin|25 mg (one 25-mg tablet) once daily
75428387|NCT01486706|Drug|Gabapentin|100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day
75878425|NCT02239718|Procedure|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
75878426|NCT02925741|Other|Silk-Like Linens|Synthetic moisture-wicking fabric
75428388|NCT01486706|Drug|Solifenacin Succinate|5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab
75428389|NCT01486706|Drug|Placebo drugs|will titrate medications similar to the active drug group
75428390|NCT01486719|Procedure|Sensate Dorsal Digital Island Flap|This article reports repair of the finger pulp defect using the dorsal digital island flap. Both dorsal branches of the proper digital nerves (PDNs) were used for maximal sensory restoration.
75725971|NCT00509236|Drug|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
75878427|NCT03576482|Other|Transport on foot|Patients go to operating room walking with their families and with their normal clothes
75428391|NCT01486732|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
75428392|NCT01486732|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
75574759|NCT03306316|Dietary Supplement|Prebiotic|Prebiotic experimental group
75574760|NCT03306316|Dietary Supplement|Dextrose Control|Dextrose Control
75574761|NCT03261830|Drug|Cefazolin|Primary intervention
75574762|NCT03261830|Drug|Clindamycin|For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
75574763|NCT03261830|Drug|Saline|Placebo Intervention
75725972|NCT00836420|Procedure|no intervention|the value of the clinical use of microdialysis monitoring of the brain
75725973|NCT00842738|Behavioral|Mindfulness meditation|Mindfulness meditation
75725974|NCT00842738|Other|No meditation|Health care services as usual
75725975|NCT00842738|Other|Controls|No intervention
75725976|NCT00842816|Drug|ST101|10 mg; administered once/day
75725977|NCT00842816|Drug|ST101|60 mg; administered once/day
75725978|NCT00842816|Drug|ST101|120 mg; administered once/day
75725979|NCT00842816|Drug|Placebo|placebo tablets to match ST101 tablets
75725980|NCT00842894|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
75878428|NCT02239796|Device|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
75878429|NCT02239796|Device|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
75878430|NCT02964312|Device|Nasal Implant|Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
76048506|NCT02340806|Device|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
75574764|NCT03237182|Drug|Individualized TB treatment with multiple drugs|"Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
75574765|NCT03237182|Drug|Standardized TB treatment with multiple drugs|"Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
75725981|NCT00842894|Drug|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
75725982|NCT02546726|Behavioral|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
75725983|NCT02546726|Behavioral|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
75725984|NCT04043390|Diagnostic Test|CRP and Molbio Truenat MTB|A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
75725985|NCT04043390|Diagnostic Test|CRP and Xpert ULTRA MTB/RIF|A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
75725986|NCT04043390|Diagnostic Test|standard test Xpert|The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
75428393|NCT01486732|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
75428394|NCT01486771|Drug|Macugen ® (pegaptanib sodium)|"Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection."
75878431|NCT04155333|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
76048507|NCT01835158|Drug|Cabozantinib S-malate|Given PO
75428395|NCT01486797|Drug|NOX-A12|"Pilot Group (NOX-A12 single agent, and combined with BR):~3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX-A12 in combination with BR):~Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
75428396|NCT01486823|Drug|MLDL1278A|Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
75428397|NCT01486823|Drug|MLDL1278A|Single subcutaneous dose of 360 mg MLDL1278A.
75428398|NCT01486875|Drug|biphasic insulin aspart 30|Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
75574766|NCT03224819|Drug|Emerfetamab|Administered by intravenous (IV) infusion.
76048508|NCT01835158|Other|Laboratory Biomarker Analysis|Correlative studies
75725987|NCT04043390|Diagnostic Test|Culture as reference standard|The investigators will use culture to assess the sensitivity of schemes 1 and 2
75428399|NCT01486888|Drug|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
75428400|NCT01486901|Drug|isophane human insulin|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
75574767|NCT03215043|Dietary Supplement|Eriocitrin|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
75725988|NCT00843128|Device|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
75725989|NCT00843128|Device|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
75574768|NCT03215043|Other|Placebo|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
75574769|NCT03064568|Drug|Misoprostol 100Mcg Tab|
75574770|NCT03064568|Drug|Placebo|
75574771|NCT03048786|Behavioral|Control|Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
75574772|NCT03048786|Behavioral|Peer Mentoring|"Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date."
75574773|NCT02885142|Procedure|Local excision for early rectal cancer|
75574774|NCT02879201|Procedure|Slow efficiency dialysis|Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
75725990|NCT00508924|Drug|Argatroban|
75725991|NCT00508924|Drug|Argatroban|
75725992|NCT00508924|Drug|Argatroban|
75725993|NCT00508924|Drug|Heparin|
75725994|NCT00836576|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
75725995|NCT00836576|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
75725996|NCT00836654|Biological|Catumaxomab (Removab)|Puncture free survival
75725997|NCT00836654|Procedure|paracentesis|
75725998|NCT00836732|Procedure|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
75725999|NCT00844064|Drug|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
75726000|NCT04003077|Device|laser meridian massage|The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm^2; power density, 300mW/cm^2; pulsed wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm^2.
75726001|NCT05221593|Drug|Lithium Carbonate|400 mg tablet in controlled released formula
75428401|NCT01486914|Drug|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
75428402|NCT01486940|Drug|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
75428403|NCT01486940|Drug|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
75428404|NCT01486940|Drug|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
75428405|NCT01486940|Drug|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
75428406|NCT01486953|Drug|Desflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
76048509|NCT01835158|Drug|Sunitinib Malate|Given PO
75428407|NCT01486953|Drug|Sevoflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
75428408|NCT01486979|Drug|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
75428409|NCT01486979|Drug|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
75428410|NCT01486992|Drug|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
75574775|NCT02836522|Behavioral|Assessment of Health-Related Quality|Demographic Questionnaire, ANCHOR HRSI, FACT-G, MDASI, Patient ECOG PS, PGIC
76048510|NCT02337764|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
75574776|NCT02785042|Device|Heidelberg Spectralis OCT|OCT imaging
75726002|NCT00844142|Drug|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
75726003|NCT00844142|Drug|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
75428411|NCT01487018|Procedure|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
75428412|NCT01487018|Procedure|Traditional Surgery|To compare with the experamental group.
75428413|NCT01487031|Other|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
75428414|NCT01487031|Other|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
75428415|NCT01487044|Drug|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only."
75574777|NCT02785029|Device|OCT|
75574778|NCT02783950|Other|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
75574779|NCT02773004|Other|EPClin genomic test|
75726004|NCT00837044|Drug|Treximet|Treximet
75726005|NCT00837044|Drug|Migraine rescue medication of choice|Migraine rescue medication of choice
75726006|NCT01013272|Drug|Entecavir|Entecavir 0.5mg orally daily
75726007|NCT01013272|Drug|Lamivudine|Lamivudine 100mg orally, daily
75726008|NCT02546024|Drug|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
75726009|NCT01010698|Drug|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
75726010|NCT00851162|Biological|Trinity multipotent stem cells|Enough to fill voids which vary in size
75726011|NCT00851162|Biological|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
75726012|NCT03541486|Drug|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.
75574780|NCT02691078|Other|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
75574781|NCT02549573|Drug|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
75878432|NCT05204979|Other|Vaginal Versus Sublingual misoprostol|Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
75428416|NCT01487070|Drug|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only."
75574782|NCT02549573|Behavioral|Physical Therapy|All subjects will participate in a standardized PT intervention
75428417|NCT01487096|Drug|Teriflunomide|"film-coated tablet~oral administration"
75428418|NCT01487096|Drug|Placebo (placebo for teriflunomide)|"film-coated tablet~oral administration"
75428419|NCT01487122|Radiation|Continuous microwave|Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
75428420|NCT01487122|Radiation|Pulsed microwaves|Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
75878433|NCT03576404|Other|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
75878434|NCT03647514|Drug|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
76048511|NCT04420442|Procedure|Scar Transformation Group|Surgical excision of the NSSI scars followed by IntegraTM transplantation and wound closure with a negative pressure wound system. After 21 days the silicone layer of the IntegraTM will be removed and split thickness skin will be transplanted. After suture removal a compression therapy by individually tailored garments will be started for 12 months.
76048512|NCT01834222|Biological|Non-intervention|Non-intervention
76048513|NCT01833832|Drug|Cisplatin|Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
75428421|NCT01487122|Procedure|Sham microwaves|Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks
75428422|NCT01487135|Drug|EVP-6124|A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
75428423|NCT01487135|Drug|Placebo|Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
75428424|NCT01487135|Drug|Moxifloxacin|A moxifloxacin 400 mg tablet administered orally on Day 1
75574783|NCT02542657|Drug|Clarithromycin|Given PO
75574784|NCT02542657|Drug|Dexamethasone|Given PO
75574785|NCT02542657|Drug|Ixazomib Citrate|Given PO
75574786|NCT02542657|Drug|Pomalidomide|Given PO
75574787|NCT02503423|Drug|ASTX660|described above
75574788|NCT02485418|Drug|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
75574789|NCT02378181|Behavioral|Health Education Toolkit|An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.
75574790|NCT02378181|Behavioral|Treatment-as-usual|Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
75574791|NCT02371460|Dietary Supplement|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
75574792|NCT02371460|Combination Product|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
75574793|NCT02346838|Dietary Supplement|Inulin|The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
75574794|NCT02346838|Dietary Supplement|Placebo|The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
75428425|NCT01487187|Procedure|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord
75574795|NCT02301663|Other|Handgrip|Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand
75574796|NCT02301663|Other|Altitude simulation|Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.
75574797|NCT02301663|Other|Leg exercise|Subjects will perform leg exercise to increase metabolic demand.
75428426|NCT01487187|Procedure|immediate umbilical cord clamping|immediate cord clamping without milking as per standard practice
75428427|NCT01487213|Other|Home self assessment of complete medical abortion|Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
75428428|NCT01487226|Drug|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks * 6 cycles
75428429|NCT01487226|Drug|Cisplatin 50mg/m2|"Cisplatin 50mg/m2~Repeat every 3 weeks * 6 cycles"
75428430|NCT01487239|Drug|[14C]-GDC-0980|100 uCi of [14C]-GDC-0980 in total dose of 10 mg GDC-0980
75428431|NCT01487252|Behavioral|At home saliva sampling|Saliva samples taken every half an hour in evening before bedtime.
75574798|NCT02229968|Drug|Amicar (ε-aminocaproic acid)|
75574799|NCT02229968|Drug|normal saline|
75574800|NCT02222844|Other|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
75574801|NCT02201108|Drug|Teriflunomide|Pharmaceutical form:film-coated tablet, Route of administration: oral
75574802|NCT02201108|Drug|Placebo|Pharmaceutical form:tablet, Route of administration: oral
75574803|NCT02180243|Behavioral|Mindfulness meditation/Acupuncture|Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
75574804|NCT02180243|Other|Gulf War Health Education|Participants randomized to this group will take part in a health education group.
75428432|NCT01487278|Drug|misprostol|600 mcg misoprostol oral
75428433|NCT01487278|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
75428434|NCT01487304|Drug|Marketed low dose hormone replacement therapy|A low dose of marketed HRT products prescribed at the discretion of the treating physician
75428435|NCT01487317|Drug|Rivastigmine transdermal patch|One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity < 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity < 10, the active treatment will be stopped
75574805|NCT02153229|Radiation|Photodynamic Therapy|
75574806|NCT02153229|Procedure|Radical Pleurectomy|
75574807|NCT02153229|Radiation|Chemotherapy|
75574808|NCT02153229|Drug|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
75574809|NCT01975597|Procedure|Bone marrow aspirates and biopsy|
75574810|NCT01864460|Behavioral|lifestyle modification|Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management
75574811|NCT01842204|Device|Magnetic field therapy device|Therapy device for 1 week.
75574812|NCT01842204|Device|Non magnetic field therapy device.|Non-active device for 1 week.
75574813|NCT01816100|Other|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
75574814|NCT01816100|Behavioral|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
75726013|NCT03541486|Drug|Gemcitabine|600 mg/m2 once weekly for up to weeks
75428436|NCT01487317|Drug|placebo patch|One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity < 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity < 10, the placebo treatment will be stopped
75428437|NCT01487330|Device|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
75574815|NCT01789879|Drug|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
75574816|NCT01789879|Drug|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
75574817|NCT01789879|Drug|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
75726014|NCT03541486|Radiation|radiation therapy|Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
75428438|NCT01487343|Behavioral|questionnaire and interview|Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
75428439|NCT01487356|Other|No intervention|Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
75726015|NCT00851240|Drug|BTT-1023|intravenous
75726016|NCT00851240|Drug|Placebo|Intravenous
75428440|NCT01487369|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
75428441|NCT01487382|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
75878435|NCT03647514|Drug|Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
75878436|NCT05759871|Other|GnRH antagonist|The GnRH antagonist in the control group (standard therapy) is administered from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day and is injected each time immediately after the injection of FSH.
75428442|NCT01487395|Drug|Donepezil .|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
75878437|NCT02239952|Drug|Sunitinib|50 mg once daily, oral use for 14 days
75428443|NCT01487395|Drug|Placebo|the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
75428444|NCT01487408|Drug|insulin aspart|Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
75574818|NCT01772563|Drug|volasertib|Solution for infusion
75574819|NCT01772563|Drug|itraconazole|capsules
75726017|NCT00620750|Drug|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
75726018|NCT04884243|Drug|CBT-006|Cyclodextrin
75726019|NCT02547896|Drug|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
75574820|NCT01771900|Behavioral|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
75726020|NCT02547896|Drug|Diclofenac|The patients will receive only diclofenac
75878438|NCT02239952|Drug|vandetanib|300 mg, once daily, oral use for 14 days
75878439|NCT02239952|Drug|Erlotinib|150 mg, once daily, oral use for 14 days
75878440|NCT03647436|Other|Comprehensive Geriatric Assessment. Both groups.|Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
75878441|NCT04089423|Device|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
75878442|NCT03576326|Behavioral|Drawing Incentive|The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
75878443|NCT04739475|Procedure|Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
75878444|NCT03647280|Drug|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
75878445|NCT03647280|Drug|Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
75428445|NCT01487421|Drug|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
75428446|NCT01487421|Drug|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
75574821|NCT01771900|Behavioral|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
76048514|NCT01833832|Procedure|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
75726021|NCT04002999|Device|3D printed ceramic bracket and tray|The 3D ceramic bracket being investigated is the only available customized ceramic bracket. This will be a first for the orthodontic speciality. This will also be the first and only customized bracket system that includes customization of the bracket base. This helps in the control of first order orthodontic movements and allows brackets to be bonded on any labial surface of the tooth while maintaining an ideal prescription. As 3D printing is not limited by the mold-ejection in CIM, [24] the bracket system being tested here has the potential to achieve a more accurate slot dimension.
75726022|NCT04002999|Device|Stock ceramic bracket + 3D printed tray|Traditionally, indirect bonding, starts with creating a mold of all the teeth as an exact replica of the mouth of the patient. From there, in the lab, the orthodontist positions each bracket precisely where it should go on each tooth and then creates a custom tray that allows transfer of the brackets from the lab model to the patient's teeth. By taking the time to place the brackets in a proper position on the lab model, orthodontists eliminate the inaccurate process of placing orthodontic brackets directly on the teeth. It theoretically also takes less chairside time and is more comfortable for the patient. It is however more technique sensitive. In this study, indirect bonding setup will be done virtually using commonly-available orthodontic software. The trays/jigs will then be 3-D printed
75726023|NCT04002999|Device|Stock bracket, no tray|Direct bonding is the traditional way of placing orthodontic brackets, in which orthodontists clinically eyeball the tooth and place the bracket where they deem most appropriate
75878446|NCT03576248|Device|In-phase 6 Hz prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
76048515|NCT01833832|Drug|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
75428447|NCT01487434|Behavioral|Check & Connect|Structured mentoring and case management
75428448|NCT01487447|Other|Customized sound|treatment with customized sound therapy
75428449|NCT01487447|Other|Regular Masker|treatment with white noise
75428450|NCT01487460|Drug|TAP311|
75574822|NCT01765439|Dietary Supplement|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
75574823|NCT01622725|Procedure|Placing the resorbable mesh|Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
75428451|NCT01487473|Behavioral|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
75574824|NCT01622725|Procedure|Non-resorbable synthetic mesh.|Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
75878447|NCT03576248|Device|Sham prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
75878448|NCT03576248|Device|2 mA left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
75428452|NCT01487486|Drug|IVF Antagonist Protocol|"Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle >14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
75428453|NCT01487512|Drug|Treatment A: Hydromorphone 8 mg|type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
75428454|NCT01487512|Drug|Treatment B: Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
75428455|NCT01487512|Drug|Treatment C: Hydromorphone 32 mg|type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
75428456|NCT01487512|Drug|Treatment D: Hydromorphone 64 mg|type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
75428457|NCT01487551|Drug|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
75428458|NCT01487564|Drug|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
75428459|NCT01487590|Other|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
75428460|NCT01487590|Other|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
75428461|NCT01487629|Drug|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
75574825|NCT01622127|Device|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
75726024|NCT01564251|Drug|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
75726025|NCT01564251|Drug|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m^2 and/or 500 mg/m^2.
75878449|NCT03576248|Device|Sham left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
76048516|NCT01833520|Drug|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
76048517|NCT01850602|Drug|PA21|
75428462|NCT01487629|Drug|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
75428463|NCT01487642|Device|Standard 15-minute telephone counselling|Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
75428464|NCT01487642|Device|Proactive telephone counselling|subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
75574826|NCT01543789|Procedure|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
75574827|NCT01543789|Procedure|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
75726026|NCT00844220|Procedure|CT/MR|CT/MRI-directed clinical management strategy
75726027|NCT00844220|Procedure|Catheterization|Standard clinical management directed by conventional coronary angiography
75726028|NCT00508144|Drug|Alimta|500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks
75726029|NCT00844454|Procedure|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
75726030|NCT00844454|Procedure|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
75726031|NCT02545712|Other|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
75726032|NCT02545712|Other|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
76048518|NCT01850602|Drug|Sevelamer hydrochloride|
76048519|NCT01832818|Device|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
76048520|NCT02405780|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
75574828|NCT01517945|Behavioral|AIM materials and assessments|"Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over < 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session."
75574829|NCT01445171|Device|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
75574830|NCT01316523|Drug|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
75574831|NCT01316523|Drug|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
75428465|NCT01487642|Device|Interactive web-based smoking cessation programme|Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
75428466|NCT01487642|Device|Self-help material|Participants receives self-help materials and on request information on other smoking cessation services if they wish.
75428467|NCT01487694|Drug|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
75428468|NCT01487694|Drug|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
75428469|NCT01487707|Behavioral|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
75428470|NCT01487707|Behavioral|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
75574832|NCT01307657|Other|high fat meal|Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
75574833|NCT01258933|Drug|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
75574834|NCT01200927|Other|Physical therapy|Perceptual motor therapy, comparing twice weekly to once weekly home program
75574835|NCT01109771|Device|permanent mesh fixation|Permanent mesh fixation will be used.
75574836|NCT01109771|Device|absorbable mesh fixation|Absorbable mesh fixation will be used.
75428471|NCT01487707|Behavioral|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
75428472|NCT01487720|Drug|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
75428473|NCT01487733|Genetic|gene expression analysis|
75428474|NCT01487733|Genetic|in situ hybridization|
75574837|NCT01042561|Dietary Supplement|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
75574838|NCT01042561|Dietary Supplement|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
75428475|NCT01487733|Other|immunohistochemistry staining method|
75428476|NCT01487733|Other|laboratory biomarker analysis|
75574839|NCT00959244|Other|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
75574840|NCT00959244|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
75574841|NCT00959244|Other|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
75726033|NCT02545712|Other|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
75726034|NCT02545712|Other|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
75726035|NCT02545712|Other|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
75726036|NCT02545712|Other|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
75726037|NCT02545712|Other|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
75726038|NCT02545712|Other|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
75574842|NCT00959244|Other|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
75574843|NCT00848328|Biological|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
75726039|NCT02545712|Other|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
75726040|NCT02545712|Other|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
75726041|NCT01011010|Drug|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
75726042|NCT01011010|Drug|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
75878450|NCT04721769|Procedure|Endoscopic strip craniectomy (with lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
75878451|NCT04721769|Procedure|Endoscopic strip craniectomy (without lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
76048521|NCT02405780|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
76048522|NCT02369510|Drug|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
75428477|NCT01487759|Dietary Supplement|Oligofructose enriched inulin|
75428478|NCT01487759|Dietary Supplement|Maltodextrin|
75428479|NCT01487785|Drug|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
75574844|NCT00848328|Drug|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
75574845|NCT00573339|Other|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
75574846|NCT00573027|Procedure|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
75574847|NCT00569543|Other|high performance liquid chromatography|urine analysis
75574848|NCT00569543|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
75574849|NCT00569543|Other|mass spectrometry|The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.
75574850|NCT00569543|Other|medical chart review|Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.
75726043|NCT01011010|Drug|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
75726044|NCT01011010|Other|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
76048523|NCT02369510|Drug|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
76048524|NCT02369510|Drug|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
75428480|NCT01487798|Drug|biphasic human insulin 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
75428481|NCT01487798|Drug|biphasic insulin aspart 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
75428482|NCT01487811|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin)
75428483|NCT01487837|Drug|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
75428484|NCT01487850|Biological|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
75428485|NCT01487876|Biological|HBV DNA vaccine|HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
75574851|NCT00492050|Drug|Bortezomib|1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22.
75574852|NCT00492050|Drug|Rituximab|375 mg/m^2 IV on Day 8 and 22.
75574853|NCT00492050|Drug|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
75574854|NCT01237951|Drug|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
75574855|NCT01237951|Drug|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
75574856|NCT01237951|Drug|Gemcitabine|1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
75574857|NCT01237951|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
75428486|NCT01487876|Other|Placebo|Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
75428487|NCT01487889|Other|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
75428488|NCT01487902|Drug|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
75428489|NCT01487902|Drug|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
75726045|NCT01011010|Other|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
75726046|NCT05357391|Device|The Pressure Injury Prediction and Education model using a mobile application system|Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
75726047|NCT00851708|Drug|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
75726048|NCT01011088|Other||Not any artificial interventions were given
75428490|NCT01487915|Drug|GCb|Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
75428491|NCT01487915|Drug|GemOx|Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
75574858|NCT01237951|Drug|Melphalan|60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
75574859|NCT01237951|Procedure|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
75574860|NCT01237951|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
75574861|NCT02908581|Drug|Placebo|Administered orally once daily
75574862|NCT02908581|Drug|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
75574863|NCT00544362|Biological|cetuximab|
75574864|NCT00544362|Drug|cisplatin|
75574865|NCT00544362|Drug|fluorouracil|
75574866|NCT00544362|Procedure|conventional surgery|
75726049|NCT01011166|Drug|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
75726050|NCT01011166|Drug|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
75726051|NCT01011166|Biological|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
75428492|NCT01487967|Other|Preference and Goal Instrument|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
75428493|NCT01487980|Procedure|Cord clamping|Early vs Delayed
75428494|NCT01487993|Drug|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
75428495|NCT01487993|Behavioral|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
75428496|NCT01488006|Device|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
75428497|NCT01488058|Other|OxIGen + iCBT|OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
75428498|NCT01488058|Other|Waitlist Control|Waitlist will receive iCBT at week 11
75428499|NCT01488084|Procedure|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
75428500|NCT01488084|Procedure|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
75428501|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an active nasal probe.
75428502|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an inactive nasal probe.
75574867|NCT02908776|Dietary Supplement|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
75574868|NCT02908776|Other|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
75574869|NCT04648943|Procedure|Ex-Press mini shunt insertion|
75428503|NCT01488123|Behavioral|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
75574870|NCT04648943|Procedure|Trabeculectomy|
76048525|NCT01650194|Drug|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
75428504|NCT01488136|Drug|Diazoxide|Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
75428505|NCT01488136|Drug|Placebo|Lactose Ph capsules (Placebo)
75428506|NCT01488175|Procedure|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
75428507|NCT01488175|Procedure|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
75574871|NCT02908503|Other|Placebo Film|placebo vaginal films
75574872|NCT04648670|Behavioral|Cognitive stimulation|The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
75428508|NCT01488201|Drug|Placebo|
75428509|NCT01488201|Drug|KHK4827|
75428510|NCT01488214|Other|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
75428511|NCT01488227|Dietary Supplement|Vitamin D|4000 IU of Vitamin D daily for 6 months
75428512|NCT01488227|Dietary Supplement|Placebo|Acts as a control for the Vitamin D intervention
75428513|NCT01488253|Drug|Sirolimus|Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
75574873|NCT01239394|Drug|ofatumumab|Weekly infusion for 8 weeks
75574874|NCT00553293|Drug|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
75574875|NCT00553293|Drug|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
75574876|NCT04648514|Procedure|Using of hydraulic lifter device for closed sinus lifting|Using of recent closed minimally invasive technique (hydraulic left technique) by hydraulic lifter device for closed sinus lifting then evaluation of the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement for patients with posterior edentulous maxilla .
75574877|NCT04648514|Behavioral|patient satisfaction evaluation after using hydraulic lifter device|Evaluation of patient satisfaction numerically will be done after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
75574878|NCT00544401|Other|Hypnopuncture (Hypnosis+Acupuncture)|hypnosis and acupuncture
75574879|NCT02908737|Device|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
75574880|NCT04648397|Other|Low glycaemic load, high fibrous product|Test-lunch of 370 grams of chickpeas, seasoned with a herb- and spice mix to increase palatability. Glycaemic load 18.5. Consumed in duplicate.
75574881|NCT04648397|Other|High glycaemic load, low fibrous product|Test-lunch of 257 grams of brown rice, seasoned with rice-oil and a herb- and spice mix to increase palatability. Glycaemic load 44.9. Consumed in duplicate.
75574882|NCT00544518|Drug|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
75574883|NCT00544518|Drug|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
75726052|NCT01011166|Drug|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
75428514|NCT01488253|Drug|Tacrolimus|Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
75878452|NCT03646032|Behavioral|SAAFE|After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.
75428515|NCT01488266|Drug|Aripiprazole|patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
75428516|NCT01488266|Drug|switching to different class of antidepressant|Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
75428517|NCT01488292|Behavioral|RECAP social skills and reading program|weekly individual and group sessions
75428518|NCT01488305|Dietary Supplement|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
75428519|NCT01488305|Other|AAMA project activities (HFP and IYCF BCC)|This is the existing AAMA program
75574884|NCT04648592|Dietary Supplement|Low salt diet plus sodium chloride supplements|Patients will receive a low salt diet plus salt supplements.
75574885|NCT04648592|Dietary Supplement|Low salt diet plus placebo|Patients will receive a low salt diet plus placebo.
75574886|NCT02908698|Drug|Prednisone|"Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
75574887|NCT02908698|Drug|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
75726053|NCT00621842|Drug|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
75726054|NCT00621842|Drug|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
75726055|NCT05356143|Drug|Rupatadine|Oral single dose 10 mg tablet
75726056|NCT01013428|Other|Ultrasound|Ultrasound will be used to evaluate tendons.
75726057|NCT04849455|Drug|0.2% ropivacaine local anesthetic continuous erector spinae plane block|Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)
75726058|NCT04849455|Drug|0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block|Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
75726059|NCT04849455|Drug|Spinal Morphine|200-300 mcg of spinal morphine
75574888|NCT00544596|Drug|R-(-)-gossypol acetic acid|Given orally
75574889|NCT00544596|Drug|cisplatin|Given IV
75574890|NCT00544596|Drug|etoposide|Given IV
75428520|NCT01488344|Drug|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
75428521|NCT01488383|Drug|Purified extract of Rebaudina Stevia-Stevioside|volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
75428522|NCT01488383|Drug|Sodium saccharin|Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
75428523|NCT01488396|Drug|0.05%cyclosporin eye drop|use twice daily for 6 months
75428524|NCT01488422|Behavioral|Stress Reduction|We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.
75428525|NCT01488435|Dietary Supplement|Cow's milk|Powdered whole cow's milk
75428526|NCT01488435|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
75428527|NCT01488461|Genetic|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
75428528|NCT01488474|Procedure|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
75428529|NCT01488500|Other|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
75428530|NCT01488513|Drug|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
75428531|NCT01488526|Drug|TDF treatment|About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
75428532|NCT01488552|Drug|Gemcitabine|1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
75428533|NCT01488552|Drug|nab-paclitaxel|125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
75428534|NCT01488552|Drug|FOLFIRINOX|"The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients)."
75428535|NCT01488552|Genetic|Immunohistochemistry (IHC) Analysis|Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
75428536|NCT01488552|Drug|Metformin|Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
75574891|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
75574892|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
75574893|NCT00544635|Device|no intervention|no intervention
75574894|NCT00544635|Device|light|scars will be treated with light
75574895|NCT00558233|Behavioral|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
75574896|NCT00558233|Behavioral|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
75574897|NCT02908425|Other|Statin user|Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
75574898|NCT02908191|Drug|ABI-H0731|
75574899|NCT02908191|Drug|Placebo for ABI-H0731|
75574900|NCT02908191|Drug|Entecavir|Used to treat adults with chronic hepatitis B virus
75574901|NCT02908191|Drug|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
75574902|NCT02908191|Drug|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
75574903|NCT02908191|Drug|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
75574904|NCT04648007|Diagnostic Test|Kaihani Score|Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
75726060|NCT02545010|Drug|Paclitaxel|"All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician."
75428537|NCT01488552|Drug|mFOLFIRI|5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
75726061|NCT02545010|Radiation|LDWART (Low Dose Whole Abdominal Radiation Therapy)|"LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator."
75878453|NCT03646032|Behavioral|Control|This group will receive dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
75878454|NCT03578120|Biological|Pre-school booster vaccine|Routine vaccination with pre-school booster vaccine
75428538|NCT01488565|Drug|Azacitidine and eltrombopag|Standard: azacitidine D1-5, 8&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
75428539|NCT01488604|Device|Polymeric Nasal Spray|Experimental nasal spray
75878455|NCT03646578|Other|State of anxiety|"Patient anxiety assessment by STAI-Y-A self-assessment questionnaire provided before and after pediatric interview.~The assessment is given to patients upon arrival in the hospitalization service of pregnancies and again after the pediatric interview. This pediatric interview should take place between 1 and 7 days after admission to the hospital ward.The second part includes a 6-week inclusion period with assessment of patients' state of anxiety by a STAI-Y-A self-assessment questionnaire given before and after pediatric interview associated with the delivery of a written document. on prematurity."
75878456|NCT03576170|Other|aromatherapy|aromatherapy by inhalation and/or therapeutic massage
75428540|NCT01488604|Device|Sham Nasal Spray|Sham nasal spray
75428541|NCT01488630|Other|STaRS|The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
75428542|NCT01488656|Dietary Supplement|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
75428543|NCT01488656|Dietary Supplement|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
75428544|NCT01488669|Procedure|robot assisted neck dissection via retroauricular approach|A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.
75574905|NCT00544752|Other|16|indoor temperature of 16 degrees celcius
75574906|NCT00544752|Other|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
75574907|NCT00544752|Other|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
75574908|NCT00544791|Drug|melatonin|5 mg, oral, daily dose for 6 months
75574909|NCT00544791|Drug|placebo like melatonin tablets|
75574910|NCT04647812|Behavioral|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology and home-based telerehabilitation
75574911|NCT04647812|Behavioral|Conventional rehabilitation|Traditional multidisciplinary in-patient rehabilitation
75574912|NCT04647773|Drug|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
75574913|NCT04647773|Drug|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
75878457|NCT01566747|Drug|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
75574914|NCT04647773|Drug|HSK16149 60mg BID|HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
75428545|NCT01488669|Procedure|Conventional neck dissection|A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
75428546|NCT01488682|Procedure|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
75574915|NCT04647773|Drug|HSK16149 80mg BID|HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
75428547|NCT01488682|Procedure|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
75428548|NCT01488695|Device|GlideScope Groove|GlideScope Groove
75428549|NCT01488695|Device|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
75428550|NCT01488734|Dietary Supplement|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
75428551|NCT01488734|Dietary Supplement|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
75428552|NCT01488734|Dietary Supplement|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
75428553|NCT01488734|Dietary Supplement|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
75428554|NCT01488734|Drug|Placebo|Placebo for the fortified mushroom arms
75574916|NCT04647773|Drug|Pregabalin 150mg BID|Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
75574917|NCT04647773|Drug|Placebo BID|Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
75574918|NCT01237678|Drug|IMGN901|Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
75726062|NCT05356065|Other|survey administration|Outcome Measures
75428555|NCT01488747|Dietary Supplement|Coromega Omega-3 Squeeze|660 mg EPA, 434 mg DHA
75428556|NCT01488747|Dietary Supplement|Coromega Nectar|660 mg EPA, 436 mg DHA
75726063|NCT01013506|Drug|IGF-1R inhibitor OSI-906|Given orally
75726064|NCT01013506|Drug|erlotinib hydrochloride|Given orally
75726065|NCT01013506|Drug|goserelin|Given subcutaneously
75428557|NCT01488747|Dietary Supplement|Barleans Swirl|660 mg EPA, 660 mg DHA
75428558|NCT01488747|Dietary Supplement|Nordic Omega-3 Softgel|660 mg EPA, 440 mg DHA
75574919|NCT01237678|Drug|Carboplatin and Etoposide|Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
75574920|NCT04647461|Drug|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
75574921|NCT04647461|Drug|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
75574922|NCT04684992|Device|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
75726066|NCT01013506|Drug|letrozole|Given orally
76048526|NCT01650194|Drug|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
75428559|NCT01488773|Drug|first prescription of montelukast|The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
75574923|NCT01229371|Biological|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
75726067|NCT00855452|Procedure|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
75726068|NCT00844688|Drug|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease.~The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs.~Withdrawal of consent for any reason."
75878458|NCT03621462|Device|Artificial Intelligence Dermatology Assistant (AIDA™)|The Artificial Intelligence Dermatology Assistant (AIDA™) collects conventional demoscopic images and images at various spectral bands. Following image acquisition, the AIDA™ software presents users with (1) similar lesion images from the International Skin Imaging Collaboration archive, (2) Hypodermoscopy™ images, and (3) images providing an indication of lesion depth, based on the spectral data.
75428560|NCT01488773|Drug|first prescription of salmeterol|The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
75726069|NCT00844688|Drug|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 & 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
75726070|NCT04541680|Drug|Nintedanib 150 MG [Ofev]|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
75726071|NCT04541680|Other|Placebo|Placebo
75726072|NCT00855530|Drug|amibegron (SR58611A)|oral administration of 300 mg twice daily
75726073|NCT03883191|Other|L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
75726074|NCT03883191|Other|Placebo|Taking 1 pack of placebo powder three times a day before meals for three months.
75726075|NCT00855608|Drug|adalimumab|intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
75726076|NCT00851864|Drug|Tinzaparin|"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy."
75726077|NCT00851942|Drug|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
75878459|NCT03578042|Drug|Losartan and amlodipine and hydrochlorothiazide|this is a fixed combination containing the 3 drugs
75878460|NCT03578042|Drug|Standard of care|any free triple combination therapy for hypertension given as 2 or 3 pills
75878461|NCT03646500|Procedure|Retrobulbar Block|Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure
75878462|NCT03646500|Procedure|Remifentanil|Remifentanil administered as intravenous infusion prior to transcleral diode procedure
75878463|NCT03574064|Other|Glucagon-Like Peptide-2 (GLP-2)|Glucagon-Like Peptide-2 (GLP-2) injection.
75878464|NCT03574064|Other|Glucose-dependent insulinotropic polypeptide (GIP)|Glucose-dependent insulinotropic polypeptide (GIP) injection.
75878465|NCT03574064|Other|GLP-2+GIP|GLP-2+GIP injection.
75574924|NCT01229371|Biological|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
75574925|NCT02908230|Behavioral|Enhanced Care|8-week (nutrition, physical activity, and mental health) summer curriculum/program
75878466|NCT03574064|Other|Placebo|Placebo injection.
76048527|NCT01650194|Drug|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
75574926|NCT02908230|Behavioral|Standard Care|8-week (nutrition and physical activity) summer curriculum/program
75574927|NCT02908230|Behavioral|Active Control|8-week (non-nutrition, physical activity or mental health) summer curriculum/program
75574928|NCT02908152|Dietary Supplement|curcumin|"1500 mg~1 capsule / day for 12 weeks"
75574929|NCT02908152|Dietary Supplement|placebo|"1500 mg~1 capsule / day for 12 weeks"
75574930|NCT01237327|Drug|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
75574931|NCT01237327|Drug|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
75574932|NCT02907021|Drug|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
75574933|NCT01237054|Drug|18-NaF PET|The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
75574934|NCT01237054|Other|DCE-MRI|An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
75574935|NCT01237054|Drug|18-FDG PET/CT|The 18F-FDG injection procedure will be injected and be followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
75574936|NCT02906982|Other|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
75574937|NCT02906982|Other|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
75878467|NCT03918408|Combination Product|PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
75428561|NCT01488786|Device|BrainPort Vision Device|2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
75428562|NCT01488799|Behavioral|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
75428563|NCT01488825|Behavioral|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
75428564|NCT01488838|Drug|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
75428565|NCT01488838|Radiation|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
75574938|NCT04319536|Other|no intervention|self-sampling
75574939|NCT04647695|Drug|Interferon beta-1b|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
75574940|NCT04647695|Drug|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
75574941|NCT02908113|Behavioral|collection data|
75574942|NCT02908113|Behavioral|IRM|
75574943|NCT04647305|Other|Closed face shield with Surgical face mask use|Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.
75574944|NCT04647305|Other|Surgical face mask use only|Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
75574945|NCT04647344|Drug|AK104 plus Carboplatin and Pemetrexed|Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
75574946|NCT04647344|Drug|AK104 plus Carboplatin and paclitaxel|Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
75574947|NCT02906748|Procedure|injection with a syringe in new-site for parathyroid autografting|new-site for parathyroid autografting, close to the antecubital vein
75726078|NCT04190186|Device|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
75574948|NCT02906748|Procedure|injection with a syringe in traditional site for parathyroid autografting|traditional-site for parathyroid autografting,not intensively close to the antecubital vein
75574949|NCT04647149|Behavioral|Dietary Approach|Dietary approaches with energy restriction performed at different times of the day.
75574950|NCT02906865|Other|Proximal hamstring tendons repair|Proximal hamstring tendons repair
75574951|NCT04647266|Procedure|endoscopic submucosal dissection|endoscopic submucosal dissection
75574952|NCT02907957|Device|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
75574953|NCT02907957|Procedure|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
75574954|NCT04646954|Diagnostic Test|Host DNA methylation testing|Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample
75574955|NCT04646954|Diagnostic Test|Cervical cytology and/or high-risk human papillomavirus assays|Cervical cytology and/or high-risk human papillomavirus assays
75574956|NCT04647188|Other|Robotic assisted surgery with IDR data capture|Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology
75574957|NCT04646876|Drug|Magnesium Sulfate|Prospective , comparative , double blind study
75574958|NCT04646876|Drug|Placebo|Prospective , comparative , double blind study
75574959|NCT04646915|Other|Day surgery|Patients with CuRC who meet the standards will be assigned to day surgery center for surgery
75574960|NCT02906904|Other|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
75428566|NCT01488864|Behavioral|Applied Relaxation (AR)|"AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.~During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.~The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation."
75574961|NCT02906904|Other|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
75574962|NCT02908035|Drug|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
75574963|NCT02908035|Drug|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
75574964|NCT04646759|Drug|Fulvestrant combined with Pyrotinib|Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily
75574965|NCT04646759|Drug|Capecitabine combined with Pyrotinib|Capecitabine 1000mg/m^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
75574966|NCT02906826|Device|Video game|Video game operated by performing therapy correctly
75726079|NCT02545790|Procedure|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
75726080|NCT02545790|Biological|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
75878468|NCT03573986|Biological|[18F]fluoromisonidazole|positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
75574967|NCT04646798|Other|Hemiarthroplasty|standard surgical approaches to repair of fractured elbows
75574968|NCT04646798|Other|Total elbow arthroplasty|standard surgical approaches to repair of fractured elbows
75574969|NCT02907801|Behavioral|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
75574970|NCT04646525|Diagnostic Test|Physical examination|Pediatric patients diagnosed with COVID-19 and who have had infection will be examined, adenoid and tonsillar tissues will be evaluated in terms of hypertrophy, chronic, or recurrent infection.
75574971|NCT02906514|Drug|Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)|1000mL used for cardiopulmonary bypass priming
75574972|NCT02906514|Drug|Sodium Chloride 0.9% (Fresenius)|1000mL used for cardiopulmonary bypass priming
75574973|NCT02906475|Other|standardized skin care regimen|"Application of a standardized daily skin care regimen:~milk lotion once daily and~application of addendum for bathing as needed"
75574974|NCT02907723|Device|Sleep Recording|the device records movements during patients' sleep
75574975|NCT02907567|Drug|CT1812|Active study drug
75574976|NCT02907567|Drug|Placebo|non-active study drug
75574977|NCT04646018|Other|Lumbar Spine Manipulation|Lumbar non-thrust manipulation is a passive movement that is performed with a rhythm and a grade in a manner in which the patient is able to prevent the technique from being performed.
75574978|NCT04646018|Other|Sham Manipulation|Lumbar non-thrust manipulation without force applied
75574979|NCT02906436|Device|Xvivo Chamber|
75574980|NCT04646135|Drug|Lorazepam 4 mg/ml|Lorazepam will be administered intravenously according to the scheduled sequences.
75574981|NCT02906553|Drug|Glyceryl Trinitrate|
75574982|NCT02906553|Drug|Placebo|
75574983|NCT04646291|Device|Insemination with the Mosie Baby Kit|The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
75574984|NCT02907684|Dietary Supplement|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
75574985|NCT02907684|Dietary Supplement|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
75574986|NCT04646096|Device|MAKO THA 4.0 System|"Measure how the accuracy and precision of robotic arm-assisted total hip arthroplasty (THA) for placement accuracy of implant position in both the anterior and posterior approach.. The intervention will assess the precision of the MAKO system in placing hip components according to plan. It will compare hip angles executed by the Mako system intraoperatively with the 'gold standard' of 3D computer tomography (CT) scans.~The postoperative CT scan can show the precision of the MAKO system by accurately determining the location of hip replacements in patients after surgery."
75574987|NCT04681989|Behavioral|Moving On After Breast Cancer|"After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~Instructions on how to use the physical therapy-based education materials by a research staff member~a range of motion wand~a small ball~MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment."
75574988|NCT04646447|Dietary Supplement|L-serine|"L-Serine Arm L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320.~All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.~The L-Serine will be manufactured, packaged, labeled and/or distributed by NUTRICIA or delegated contractors. It will be presented in a powdered form of 100 gr of the amino acid L-serine. For oral use.~Sufficient L-serine will be dispensed at home considering the dose according the weight of the patient."
75428567|NCT01488942|Other|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
75428568|NCT01488955|Drug|Ibuprofen|400 mg oral once a day from day 0 for 3 days
75428569|NCT01488955|Drug|Fosfomycin-Trometamol|8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
75428570|NCT01488968|Radiation|Standard Radiation Treatment|39 radiation treatments
75428571|NCT01488968|Radiation|Hypofractionated radiation treatment|25 radiation treatments
75428572|NCT01488981|Other|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
75428573|NCT01488981|Device|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
75574989|NCT04682184|Drug|Propranolol|Administered orally.
75574990|NCT04682184|Drug|Pseudoephedrine|Administered orally.
75574991|NCT04682184|Device|Wearable Biosensor Patch Device|Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.
75574992|NCT02907450|Device|TwiCare®.|
75574993|NCT04645901|Drug|Drug: SYHA1805 tablets|Oral tablets of SYHA1805 with several doses
75574994|NCT04645901|Drug|Placebo|Oral tablets of placebo with matching several doses
75574995|NCT04645940|Drug|fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole|"fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
75574996|NCT04645940|Drug|fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole|"fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
75574997|NCT02906280|Device|EBUS-TBNA needle|tissue sampling
75574998|NCT02906085|Drug|Endothelin-1|
75574999|NCT02906085|Drug|Placebo|Isotonic saline
75575000|NCT00558506|Drug|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
75575001|NCT02907411|Other|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
75575002|NCT00558545|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
75575003|NCT02907645|Behavioral|Local educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
75575004|NCT02907645|Behavioral|National educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
75575005|NCT00558623|Dietary Supplement|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
75575006|NCT02905968|Device|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
75575007|NCT00558662|Device|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
75575008|NCT00558662|Device|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
75575009|NCT02906046|Device|Weight in Lower Limbs|
75575010|NCT00558740|Other|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
75575011|NCT02907528|Biological|Bone|Furcation defect regenerated with bone graft material
75428574|NCT01489033|Biological|Subcutaneous immunotherapy with Phleum pratense pollen extract|Increasing doses up to a maximum dose of 500 TSU
75575012|NCT02907528|Biological|EMD|Furcation defect regenerated with EMD
75575013|NCT04645472|Device|CT-Ultrasound|For patients with kidney stones who are planning to undergo PCNL, perform a preoperative simulated CT-ultrasound fusion examination to further clarify the condition of the kidney stones and simulate and optimize the puncture route. Apply CT- Ultrasound fusion precise positioning to guide the intraoperative PCNL puncture process.
75575014|NCT02905890|Drug|Norethisterone enantate|Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
75575015|NCT02905890|Device|Condoms|Latex male condoms
75575016|NCT02906163|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.
75575017|NCT02906163|Drug|SoC (tyrosine kinase inhibitor)|In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
75575018|NCT04645745|Dietary Supplement|myo-inositol, alpha-lactalbumin, folic acid|Evaluating the improvement vs the baseline after three and six months of treatment
75575019|NCT02907060|Device|Mechanical cervical ripening|"The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon.~It will be used in accordance with user manual"
75726081|NCT00503776|Behavioral|exercise intervention|Patients undergo low weight resistance training.
75726082|NCT00503776|Drug|amifostine trihydrate|Given subcutaneously
75726083|NCT00503776|Procedure|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
75428575|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
75428576|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
75428577|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
75428578|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
75428579|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
75428580|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
75428581|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
75428582|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
75428583|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
75428584|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
75575020|NCT02907060|Drug|Pharmacological cervical ripening|"The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).~It will be used in accordance with Summary of Product Characteristics"
75575021|NCT02905851|Other|Feedback group|Monitoring ability to use teledermatology to modify antibiotic burden
76048528|NCT02367716|Device|CRT|The study will include the Quartet™ family of left heart leads or any newer St. Jude Medical quadripolar CRT systems, including CRT-P systems, that China Food and Drug Administration (CFDA) might approve in the future
75878469|NCT03573986|Drug|Bevacizumab|Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
76048529|NCT02366936|Device|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
76048530|NCT05369936|Other|Aromatherapy|Lavender will be inhaled through three phases
76048531|NCT05369936|Other|Placebo|Vapors of the distal water will be inhaled through three phases
76048532|NCT01648166|Other|Environmental sampling|Soil, water, blood, urine, hair and radon testing in homes in Appalachia
76048533|NCT02404220|Drug|Entospletinib|
76048534|NCT02404220|Drug|Vincristine|
76048535|NCT02404220|Drug|Dexamethasone|
75428585|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
75428586|NCT01489124|Drug|Imipenem|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
75428587|NCT01489137|Drug|remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml."
75575022|NCT02905851|Other|Non Feedback group|To use as control to see if antibiotic burden has been reduced in the active feedback group
75575023|NCT04645043|Other|US_Eso|After applying ultrasound guided esophageal pressure, the peak inspiratory pressure increased from 10cmH2O to 24cmH2O (increased by 2 cmH2O) during mask ventilation.
75575024|NCT02905695|Drug|Chirocaine|
75575025|NCT02905695|Other|Placebo|
75575026|NCT04645238|Other|Static Stretching|Static hamstring stretching exercise lasting 30 seconds and 10 repetitions under the supervision of the physiotherapist
75575027|NCT04645238|Other|PNF Stretching|PNF hold-relax stretching technique that consists of 10 seconds isometric contraction, 30 seconds hamstring stretching and 10 repetitions under the supervision of the physiotherapist
75726084|NCT00852020|Dietary Supplement|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
76048536|NCT02404220|Drug|CNS Prophylaxis|
75428588|NCT01489163|Behavioral|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
75726085|NCT04002531|Other|General and Neurological examination|Information about your general health, neurological symptoms and current medications with be collected
75726086|NCT04002531|Other|Vital signs|Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
76048537|NCT02335658|Drug|DSP-5423P|40-80mg/day
76048538|NCT02366468|Drug|ranibizumab 0.5 mg|intravitreal injection
76048539|NCT02366312|Drug|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
75726087|NCT04002531|Procedure|12 lead electrocardiogram|A non-invasive test that measures the electrical activity of the heart
75726088|NCT04002531|Procedure|Echocardiogram|A non-invasive sonogram of the heart
75726089|NCT04002531|Procedure|Blood draw|Blood will be drawn to evaluate general health and renal function (kidney health)
76048540|NCT05370560|Other|Plasma transthyretin concentration|Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
76048541|NCT02335346|Drug|Duloxetine|Administered orally
76048542|NCT04908020|Other|Follow-up patients|The intervention consists in the assessment of some psychological aspects (post traumatic stress symptoms and coping) of cancer patients in follow-up care, through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
75726090|NCT04002531|Procedure|Urine collection|Urine will be collection to evaluate renal function (kidney health)
76048543|NCT02403206|Device|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
76048544|NCT02403206|Procedure|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
75575028|NCT02907333|Behavioral|Advice to use condoms|
75428589|NCT01489202|Device|platinum chromium everolimus-eluting stent|An everolimus-eluting stent with a platinum chromium platform
75428590|NCT01489202|Device|cobalt chromium everolimus-eluting stent|An everolimus-eluting stent with cobalt chromium platform
75428591|NCT01489215|Behavioral|"presence"|"constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the checking method if the child is actively protesting or crying."
75428592|NCT01489215|Behavioral|"checking"|putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
75428593|NCT01489228|Drug|E1224|100 mg tablets
75428594|NCT01489228|Drug|Benznidazole|100mg tablets
75428595|NCT01489228|Drug|Placebo|tablets
75428596|NCT01489241|Procedure|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
75428597|NCT01489267|Other|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).
75575029|NCT00558779|Procedure|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
75428598|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
75428599|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
75878470|NCT03573986|Radiation|positron emission tomography (PET/CT).|PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
75428600|NCT01489319|Drug|Salsalate|4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
75575030|NCT00558779|Procedure|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
75575031|NCT04645082|Diagnostic Test|x-ray examination|A total of 40 individuals who underwent an axial x-ray examination of the lower extremity following ankle sprain were included.
75575032|NCT02905773|Other|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
75575033|NCT02905773|Other|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
75726091|NCT04002531|Procedure|2-hour Holter Monitor|A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
75428601|NCT01489319|Drug|Salsalate|4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
75428602|NCT01489332|Drug|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).~Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
75428603|NCT01489345|Drug|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
75428604|NCT01489345|Drug|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
76048545|NCT02333630|Other|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
75428605|NCT01489371|Other|Laboratory Biomarker Analysis|Correlative studies
75428606|NCT01489371|Biological|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given IP
75428607|NCT01489371|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75428608|NCT01489397|Device|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
75428609|NCT01489410|Drug|Drug-Eluting Beads (DEB) with Doxorubicin|One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
75428610|NCT01489410|Drug|Lipiodol Ethanol Mixture|One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
75428611|NCT01489423|Genetic|RNA analysis|
75428612|NCT01489423|Genetic|in situ hybridization|
75428613|NCT01489423|Genetic|polymerase chain reaction|
75428614|NCT01489423|Other|enzyme-linked immunosorbent assay|
75428615|NCT01489423|Other|flow cytometry|
75428616|NCT01489423|Other|immunohistochemistry staining method|
75428617|NCT01489423|Other|laboratory biomarker analysis|
75428618|NCT01489436|Procedure|Single-port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.
75726092|NCT04002531|Other|Brief Pain Inventory questionnaire|A questionnaire about daily pain
76048546|NCT02333630|Other|Asthma education|A website with links to written asthma education and videos
76048547|NCT02401412|Device|Test Ostomy Barrier|
76048548|NCT02401412|Device|Control Ostomy Barrier|
75575034|NCT04644848|Diagnostic Test|Ultrasonographical tattooing of suspicious axillary lymph nodes.|"Patients with clinically negative axillae scheduled for sentinel lymph node biopsy (SLNB) will have axillary ultrasonographical imaging of the ipsilateral axilla with a high-frequency linear probe. Suspicious lymph nodes are identified according to any of the following criteria:~Round shape.~Cortical thickness > 3 mm~Eccentric cortical thickness.~Loss of hilum.~For each patient, node dimensions and the presence of each of the above-mentioned criteria are recorded. Tattooing of all suspicious nodes is done using I ml of sterile liquid charcoal."
75575035|NCT04644848|Procedure|Sentinel lymph node biopsy|Sentinel node biopsy is performed with peri-areolar subdermal injection of 3 ml methylene blue 5%. The lymphatics are tracked to the first blue lymph node. All blue, enlarged and /or tattooed nodes are separately biopsied and labelled as SLN and/or tattooed node.
75575036|NCT04644848|Diagnostic Test|Histopathological examination of the axillary nodes|"All tattooed nodes are excised and sent to frozen section examination; labelled tattoo node.~All enlarged or blue stained nodes are excised and sent to frozen section examination; labelled sentinel node.~All nodes are bisected and a single 5 um section examined. All frozen section examinations are followed by routine paraffin section examination."
75575037|NCT04644848|Procedure|Further axillary management|Further axillary management is performed as per institutional guidelines. If SLNB is negative, no further surgery is required. Axillary lymph node dissection is performed if sentinel lymph node is positive or not identified. Management of positive SLNB as per the American College Of Surgeons' Oncology Group (ACOSOG) Z0011 protocol is not currently adopted on routine basis at the investigators' institution. In this study, patients with tattooed nodes with positive histopathological findings are offered full axillary dissection even if their sentinel nodes are negative.
75575038|NCT02907294|Drug|PBF-999 / 160 mg|2 capsule 80 mg x 8 days
75575039|NCT02907294|Drug|PBF-999 / 320 mg|4 capsule 80 mg x 8 days
75575040|NCT02907294|Drug|Placebo|2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
75575041|NCT04644887|Other|Dietary intervention: Healthy diet|Dietary guidance in the intervention group is based on the Nordic and Finnish nutrition recommendations with an emphasis on the quality of dietary fat. The aims for the intake of fatty acids will be SFA < 10 % of energy intake (E%) and mono- and polyunsaturated fatty acids (UFA) >2/3 of the total fat intake. The key food products such as vegetable oil-based spread, liquid margarine and canola oil are provided to the participants. The participants are recommended to use fat free (e.g. milk, sourdough milk and yogurt) and low fat (e.g. cheese ≤ 17%) dairy products and low-fat meat, poultry, and fish as well as natural nuts and seeds.
75575042|NCT04644887|Other|Dietary intervention: Control diet|The control diet corresponds to the average nutrient intake in the Nordic countries, i.e. the intake of SFA about 15 E% and the proportion of UFA about 50 % of total fat intake. The participants of the control group will get butter-based spread for bread and cooking. They are recommended to use semi-skimmed milk (1,5 %), normal fat yogurt (~2%), normal fat cheese (~24-35 %) and avoid consumption of vegetable oils. They are allowed to eat a portion of fish and nuts once a week.
75575043|NCT00553371|Other|biomarker analysis|
75575044|NCT00553371|Procedure|computed tomography|
75726093|NCT04002531|Other|Quality of Life questionnaire|A questionnaire about the impact of disease on their activities of daily living and quality of life
75428619|NCT01489436|Procedure|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
75428620|NCT01489462|Behavioral|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
75575045|NCT04644926|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
75575046|NCT04682262|Procedure|Cervical dilatation|Patients undergo to cervical dilatation prior to the hysteroscopy under general anaesthesia with using Hegar dilator (no.10)
75575047|NCT00558818|Drug|Clevudine|clevudine 30 mg qd
75575048|NCT02907138|Other|Medical Yoga|
75575049|NCT02907138|Other|Treatment as Usual (physical therapy)|
75575050|NCT04644341|Combination Product|cardiovascular and respiratory systems monitoring|only one group of individuals to observe the impact of COVID-19 on their cardiovascular and respiratory systems in long term.
75575051|NCT04681911|Drug|Inetetamab|Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
75575052|NCT04681911|Drug|Pyrotinib|Pyrotinib: 400mg, oral, every day.
75575053|NCT04681911|Drug|Capecitabine|Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
75575054|NCT04681911|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle
75726094|NCT02545634|Dietary Supplement|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
76048549|NCT02365298|Device|etafilcon A|etafilcon A soft contact lens
76048550|NCT02365298|Device|nelfilcon A|nelfilcon A
75575055|NCT04681911|Drug|Vinorelbine|Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle
75575056|NCT04681911|Drug|Carboplatin|Carboplatin, AUC = 6, 3-week cycle
75575057|NCT04681911|Drug|Albumin paclitaxel|Albumin paclitaxel, 100 mg/m2, weekly
75575058|NCT04681911|Drug|Eribulin|Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle
75575059|NCT04644302|Diagnostic Test|microcirculation recording|non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
75575060|NCT02907255|Device|Oximetry monitor|Wireless respiratory monitoring system
75575061|NCT04644458|Other|Measuring the ulna length using meauring tape|the left ulna will be measured with a measure tape from the olecranon to mid point of styloid process.
75575062|NCT02905656|Behavioral|Brief Advice|Psychoeducation
75575063|NCT02905656|Behavioral|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
75575064|NCT02905656|Behavioral|Rate Reduction|Reducing the number of cigarettes consumed.
75575065|NCT02905656|Drug|Pharmacological|Nicotine Replacement Therapy in the form of gum.
75575066|NCT02905656|Behavioral|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
75575067|NCT00558857|Device|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
75575068|NCT02905539|Drug|Iron Isomaltoside 1000|
75575069|NCT02905539|Drug|Ferric Carboxymaltose|
75575070|NCT02905734|Drug|Nicotine patch|Single administration of an active treatment (nicotine patch)
75575071|NCT02905734|Other|placebo patch|Single administration of a placebo treatment
75726095|NCT02545634|Other|Placebo|
75726096|NCT00852098|Procedure|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
75726097|NCT00852098|Procedure|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
75726098|NCT05356689|Other|mechanical traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
75726099|NCT00855686|Drug|Memantine|20mg once daily oral dose
75726100|NCT00855686|Drug|Placebo|Daily oral dose
76048551|NCT02365064|Device|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
75575072|NCT04644380|Device|INVOcell|Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
75575073|NCT04644107|Drug|Marizomib|Marizomib will be administered via IV
75575074|NCT02899572|Procedure|Sexology consultation|a sexology consultation is planned in the 15 days after inclusion
75428621|NCT01489462|Behavioral|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
75575075|NCT04644146|Genetic|GENETIC|It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
75575076|NCT04644185|Drug|SCTA01|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
75575077|NCT04644185|Other|Placebo|all SCTA01 excipients without active component+best supportive care
75575078|NCT02899494|Other|Antenatal classes|
75575079|NCT02899494|Other|Physical and psychic preparation|
75575080|NCT02899260|Device|Peanut Exercise Ball|A Peanut shaped exercise ball.
75575081|NCT04643756|Other|conventional physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound.
75575082|NCT04643756|Other|conventional physiotherapy plus kinesiotaping|Conventional physiotherapy plus kinesiotaping
75575083|NCT02905461|Behavioral|Contraceptive text messages|
75726101|NCT04041908|Other|Experimental Product|2 sachets per day
75726102|NCT04001283|Drug|Sodium Nitrite|Intravenous drug infusion
75428622|NCT01489462|Behavioral|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
75726103|NCT04001283|Drug|0.9% Sodium-chloride|Matched placebo
75726104|NCT02546414|Other|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
75726105|NCT00991965|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
75878471|NCT05204433|Other|no intervention|no intervention
75878472|NCT03573674|Behavioral|CE - Cognitive Ergonomics (KERGO)|"CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
75428623|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter [mg/mL], i.e. 16 mL) under fasting conditions
75428624|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
75428625|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
75575084|NCT02905461|Other|Text messages not about contraception|
75575085|NCT04643873|Other|physical activity counseiling +pilates exercise group|It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
75575086|NCT04643873|Behavioral|physical activity counseiling group|During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
75575087|NCT02899533|Drug|[18F] FES|[18F] FES PET/CT scan, imaging tracer
75575088|NCT02905383|Other|Exercise|A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
75575089|NCT04643717|Other|Electronic pupillometer analysis|Electronic pupillometer analysis
75575090|NCT02907840|Device|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
75575091|NCT04643522|Other|Clinical assessment|Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).
75575092|NCT02905305|Device|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
75575093|NCT02905305|Device|Contour Advance electrode|Standard Contour Advance electrode
75575094|NCT04643444|Diagnostic Test|Blood sampling|Testing for the presence of SARS-CoV-2 antibodies
75575095|NCT04643444|Other|Online Questionnaire|Questions on working place, risk profiles and PPE
75575096|NCT02899182|Drug|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
75575097|NCT02899182|Other|O2|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
75575098|NCT00558935|Dietary Supplement|Red Wine|20g alcohol daily/red wine for 4 weeks
75575099|NCT02905227|Drug|CVT-427 (zolmitriptan inhalation powder)|Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
75575100|NCT04643600|Drug|L-Arginine, 500 Mg Oral Capsule|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
75575101|NCT02899455|Drug|HGP0904|
75428626|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
75575102|NCT02899455|Drug|HGP0608|
75575103|NCT02899455|Drug|HGP0816|
75575104|NCT02899455|Drug|HGP0904 Placebo|
75726106|NCT00844922|Drug|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
75726107|NCT00844922|Drug|Placebo|Placebo
75726108|NCT04534335|Device|SNOO Smart Sleep from Happiest Baby, Inc|Data related to the use of the SNOO itself (collected electronically) such as the amount of movement provided by the SNOO, etc., will be examined with the hemodynamic data obtained during the use of the SNOO. Clinical care data as it relates to the child will also be evaluated as it pertains to the use of the SNOO (this information will focus on the amount and frequency of narcotics administered to the infant). feasibility of use is the device intervention.
75726109|NCT00619112|Drug|temozolomide|single arm study
75726110|NCT00845156|Dietary Supplement|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
75575105|NCT02899455|Drug|HGP0816 Placebo|
75878473|NCT03573674|Behavioral|RS - Recovery Support (KUORMA)|"RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
75878474|NCT03959592|Drug|Lutein, zeaxanthin and mesozeaxanthin|The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
75878475|NCT03959592|Other|Placebo|This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
75575106|NCT04643561|Other|Travelan OTC|5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
75575107|NCT02898909|Device|nuclear lens fragmentation in 8 pieces|
75575108|NCT02898909|Device|nuclear lens fragmentation in 16 pieces|
75428627|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
75428628|NCT01489501|Procedure|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
75575109|NCT04643483|Drug|Certolizumab pegol|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous~Subjects will receive certolizumab pegol in a pre-specified sequence during the Treatment Periods."
75575110|NCT04643483|Drug|Adalimumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous~Subjects will receive adalimumab in a pre-specified sequence during the Treatment Periods."
75575111|NCT04643483|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods."
75575112|NCT02905071|Other|filling of Serenat at baseline (T1)|Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.
75575113|NCT02905071|Other|Serenat at baseline T1 and 3 others questionnaires|Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.
75575114|NCT02905071|Other|filling of Serenat, HADS, STAY-Y and BDI at baseline T1|Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
75575115|NCT00559052|Drug|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
75575116|NCT02899104|Drug|Xofigo (Radium-223 dichloride, BAY88-8223)|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
75726111|NCT04001985|Other|No clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
75726112|NCT04001985|Other|Clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
75428629|NCT01489514|Other|Epicutaneous skin prick testing|"Epicutaneous skin prick testing will be performed utilizing the following extracts:~Histamine control purchased from Greer.~Saline control purchased from Greer.~Standard Peanut Extract purchased from Greer.~Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A & T.~Sterile extract prepared from roasted & blanched but untreated peanuts. This is prepared by North Carolina A & T.~Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A & T. This is not classified as a drug and is~Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.~Sterile extracts containing peanuts that have been treated with alcalase"
75878476|NCT04087395|Device|RHA®4 with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
75428630|NCT01489540|Device|laser Doppler imager (Moor)|The laser Doppler imager measures the blood flow of the skin/burn
75428631|NCT01489566|Drug|Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
75428632|NCT01489566|Drug|the placebo ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
75428633|NCT01489592|Drug|curcuma longa|oral administration of 6 grams of curcumin
75428634|NCT01489605|Device|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
75428635|NCT01489605|Device|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
75726113|NCT00856154|Biological|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.~Gag150 RLLNAWVKV~Gag433 FLGKIWPV~Env 67 NIWATHACV~Pol606 KLGKAGYVV~Vpu66 ALVEMGHHV~Vif101 GLADQLIHL~Vif23 SLVKHHMYV~Gag298 KRWIILGLNKIVRMY~gp41 VWGIKQLQARVLAVERYLKD~Padre AKXVAAWTLKAAA"
75726114|NCT00852332|Dietary Supplement|Curcumin|
75726115|NCT00852332|Drug|Taxotere|
75726116|NCT00992043|Dietary Supplement|creatine|
75726117|NCT00992043|Other|Exercise training|
75428636|NCT01489618|Biological|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
75428637|NCT01489618|Biological|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
75428638|NCT01489631|Drug|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
75428639|NCT01489631|Drug|marcaine|bupivacaine 0,125%
75428640|NCT01489631|Drug|sufentanil|sufentanil 1mcg/ml
75428641|NCT01489631|Drug|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
75428642|NCT01489644|Drug|repaglinide|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
75726118|NCT00845234|Behavioral|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
75726119|NCT00852410|Drug|1% lidocaine with 1:100,000 adrenaline|high dose
75575117|NCT00559130|Device|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
75575118|NCT04643132|Drug|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
75575119|NCT04643132|Drug|S-ketamine (low-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
75575120|NCT04643132|Drug|S-ketamine (high-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
75575121|NCT02904993|Other|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
75428643|NCT01489644|Drug|metformin|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
75575122|NCT02904993|Other|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
75575123|NCT04643171|Device|high intensity elliptical training|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
75575124|NCT04643171|Device|electrocaupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
75726120|NCT00852410|Drug|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
75726121|NCT00992121|Drug|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
75726122|NCT00992121|Drug|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
75726123|NCT00992121|Drug|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
75428644|NCT01489644|Drug|repaglinide and metformin combination tablet|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
75428645|NCT01489683|Drug|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
75575125|NCT02899143|Drug|Antibiotic|Targeted antimicrobial therapy
75575126|NCT04643288|Procedure|open flap debridement|open flap debridement for managing two and three walls intrabony periodontal defects
75575127|NCT04643288|Procedure|n-HA bone graft|Nanocrystalline Hydroxyapatite bone graft substitute for managing two and three walls intrabony periodontal defects
75575128|NCT02899026|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
75726124|NCT00852488|Procedure|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
75726125|NCT04002609|Other|oxygen|oxygen supplementation during brronchoscopy
75726126|NCT02545946|Device|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I&D
75726127|NCT02545946|Other|traditional I&D with or without packing|abscess will be drained with a traditional I&D with or without packing (as deemed appropriate by ER doctor)
75575129|NCT02899026|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
75575130|NCT02899026|Drug|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
75575131|NCT04643054|Dietary Supplement|Ovotransferrin|Administering 200 mg of ovotransferrin orally in addition to the standard of care therapy for 10 days
75575132|NCT02904837|Behavioral|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
75575133|NCT02904837|Behavioral|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
75575134|NCT04643210|Behavioral|F2F MoB EI|"The MoB F2F EI will comprise a total of 12 educational F2F sessions. Each session will have a duration of 1.5 hours and the maximum number of participants in the groups will be 12 patients.~The intervention group will receive the MoB F2F EI on group or personal form according to the participant's choice. The implementation methodology of the MoB F2F EI will include videos and power point presentations, as well as interactive learning methods such as role-playing, empowerment exercises, live discussions."
75575135|NCT04643210|Other|MoB DP|This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
75575136|NCT02904798|Drug|Polypodium Leucotomos|- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
75575137|NCT00559169|Drug|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
75575138|NCT02898948|Biological|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
75575139|NCT02898831|Other|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
75726128|NCT03131193|Other|Physician|Study primary health centers will be staffed with an additional physician
75726129|NCT03131193|Other|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
75726130|NCT03131193|Behavioral|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
75575140|NCT02904876|Radiation|Diffusion Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
75726131|NCT04420299|Drug|Bemiparin|Bemiparin at therapeutic dose for 10 days
75726132|NCT04420299|Drug|Bemiparin|Bemiparin at prophylactic dose for 10 days
75726133|NCT00619502|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
75726134|NCT00992199|Drug|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
75726135|NCT04041986|Device|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
75726136|NCT00992277|Procedure|Ablation and skin resurfacing|
75726137|NCT00856310|Biological|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
75726138|NCT02773485|Radiation|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
75726139|NCT02773485|Drug|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
75726140|NCT04042220|Drug|Glucocorticoids|Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
75726141|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1%|
75726142|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
75726143|NCT02545556|Procedure|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
75726144|NCT04341909|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
75726145|NCT00852566|Drug|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
75428646|NCT01489683|Drug|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
75575141|NCT04642664|Drug|Apatinib plus Camrelizumab|Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
75428647|NCT01489696|Drug|mirabegron|oral
75428648|NCT01489696|Drug|tamsulosin|oral
75428649|NCT01489709|Drug|Vesicare|oral
75575142|NCT04642742|Dietary Supplement|Chewable plant sterol|Chewable plant sterol (gummy)
75575143|NCT02904759|Drug|Desmopressin|
75575144|NCT02904759|Drug|Placebo|
75575145|NCT02898792|Drug|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
75575146|NCT02904642|Behavioral|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
75726146|NCT00852566|Drug|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
75726147|NCT00852722|Other|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
75726148|NCT00856622|Drug|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
75878477|NCT04087395|Device|RHA®4-Lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
75878478|NCT03573596|Drug|Dasatinib|CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
75575147|NCT02904642|Behavioral|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
75575148|NCT04642313|Other|Magnesium and/ or Potassium|Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
75575149|NCT02904447|Other|x-ray and pedobar foot pressure mapping|
75575150|NCT04642157|Other|ELIOS|"ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~A systematic initial contact with an ELIOS web-clinician~Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician"
75428650|NCT01489722|Drug|AZD1208|Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
75428651|NCT01489761|Device|percutaneous coronary intervention|drug eluting stent implantation
75428652|NCT01489774|Drug|Placebo|single and multiple dose
75428653|NCT01489774|Drug|CJ-12406|single and multiple dose
75428654|NCT01489787|Procedure|HIFU|"The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient."
75428655|NCT01489787|Procedure|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
75575151|NCT04642157|Other|other resources contacts|"Three types of resources will be suggested via the ELIOS website:~The General Practitioner (GP)~The closest medico-psychologic center (CMP)~The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation."
75575152|NCT02904525|Device|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
75726149|NCT00856622|Drug|timolol 0.5% ophthalmic solution|one drop in the morning and evening
75878479|NCT03621618|Diagnostic Test|dobutamine|evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure
76048552|NCT02401256|Drug|Efavirenz|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
76048553|NCT02401256|Drug|Bupropion|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
76048554|NCT02401256|Drug|Rosuvastatin|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
75428656|NCT01489787|Procedure|HIFU|"Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient"
75428657|NCT01489800|Behavioral|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
75575153|NCT04642118|Procedure|Pulmonary recruitment maneuver|Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
75575154|NCT04641884|Other|Not concerned|Not concerned
75726150|NCT00856622|Drug|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
75428658|NCT01489839|Other|Periodontal therapy|All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
75575155|NCT04641923|Other|Adhesion barrier|Adhesion barrier application at the time of first surgery
75575156|NCT02904564|Drug|MMP with 5-FU|MMP with 5-FU using tattoo device
75575157|NCT02904564|Drug|MMP with Saline infusion|MMP with saline infusion using tattoo device
75726151|NCT00856700|Drug|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
75726152|NCT00618956|Drug|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily [BID]), oral administration.
75726153|NCT00618956|Drug|Placebo|Placebo
75726154|NCT00852800|Drug|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
75726155|NCT00852800|Drug|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
75726156|NCT00845546|Drug|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
75575158|NCT04642040|Other|Pulmonary Rehabilitation|Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
75726157|NCT00852878|Behavioral|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
75878480|NCT03621618|Diagnostic Test|norepinephrine|evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
75575159|NCT02904486|Behavioral|change behavior|Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
75726158|NCT00852878|Behavioral|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
75726159|NCT00852956|Drug|Betahistine|"The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00"
75428659|NCT01489852|Drug|17beta-estradiol|Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
75428660|NCT01489865|Drug|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
75428661|NCT01489904|Biological|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
75428662|NCT01489917|Other|Patent hemostasis and heparin|Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
75428663|NCT01489930|Behavioral|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
75428664|NCT01489930|Behavioral|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for ~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
75575160|NCT04642001|Other|Photon Laser III-DMC (without radiation emission) + My First- Colgate|Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
75575161|NCT04642001|Other|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK|Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
75878481|NCT04038333|Other|No intervention|This is an observational study without any interventions.
75878482|NCT05204277|Other|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
75878483|NCT05204277|Other|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
75726160|NCT00853034|Dietary Supplement|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
75726161|NCT00853034|Dietary Supplement|AXOS|"arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
75878484|NCT05204277|Other|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
75878485|NCT03619278|Other|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 doses of 10-1074 antibodies and 3 doses of romidepsin
75726162|NCT00716417|Drug|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
75726163|NCT00716417|Drug|BIBW 2992|low to high dose, daily
75878486|NCT03619278|Other|placebo|Participants will receive 5 vaccines of placebo of HIVACAR01, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
75878487|NCT05204121|Drug|Elpida|elsulfavirine, capsules
75575162|NCT04642001|Radiation|Photon Laser III-DMC (with irradiation emission) + My First- Colgate|Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
75428665|NCT01489930|Behavioral|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
75428666|NCT01489943|Drug|GSK1605786 500 mg|Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.
75428667|NCT01489943|Drug|Midazolam 3 mg|Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.
75428668|NCT01489943|Drug|Pioglitazone 15 mg|Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.
75428669|NCT01489943|Drug|Omeprazole 40 mg|Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.
75428670|NCT01489943|Drug|Rosuvastatin 10 mg|Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
75575163|NCT04642001|Combination Product|Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK|Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
75575164|NCT02904681|Other|No intervention. Observational and descriptive study|
75575165|NCT02904408|Behavioral|psychotherapy|Group psychotherapy
75575166|NCT04641845|Other|Cork inlay wedge|
75726164|NCT02592863|Drug|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
76048555|NCT02401256|Drug|Montelukast|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
75428671|NCT01489982|Device|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
75428672|NCT01489982|Behavioral|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
75428673|NCT01489982|Drug|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
75428674|NCT01489982|Device|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
75575167|NCT04641689|Device|Desk Only|Provision of height-adjustable desk
75575168|NCT04641689|Behavioral|Program Only|Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
75575169|NCT02898753|Drug|VAL-1221|VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
75726165|NCT02592863|Drug|Placebo|Patients will take placebo 3 times per day for 12 weeks
75726166|NCT00719537|Drug|Aspirin|Aspirin 81 mg once a day
75428675|NCT01489995|Drug|A (migalastat)|150 mg migalastat HCl in the fasting state (reference arm)
75428676|NCT01489995|Drug|B (migalastat)|150 mg migalastat HCl with simultaneous consumption of a glucose drink
75428677|NCT01489995|Drug|C (migalastat)|150 mg migalastat HCl 1 hour before consumption of a high fat meal
75575170|NCT02898753|Drug|RhGAA|Active comparator
75575171|NCT04641572|Other|Choose comfortable position|Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions will be taken by the participant during labor.Then the researcher will register the time ( minutes/hours) will be taken and which that will be more preferable by the participant
75726167|NCT00719537|Drug|Placebo Oral Tablet|Placebo 1 tab Daily
75726168|NCT00719537|Drug|Progesterone|Oral Progesterone 200 mg Twice Daily
75726169|NCT02591459|Other|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
75575172|NCT02898324|Other|KiVa program|KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
75575173|NCT04641533|Procedure|L-PRF + DPSC|After surgical removal of impacted mandibular third molars, extraction sockets were filled with L-PRF membranes + DPSCs.
75575174|NCT04641533|Procedure|L-PRF|After surgical removal of impacted contralateral mandibular third molars, each extraction sockets were only filled with L-PRF membranes.
75575175|NCT02898675|Device|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
75575176|NCT02898675|Device|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
75428678|NCT01489995|Drug|D (migalastat)|150 mg migalastat HCl 1 hour before consumption of a light meal
75575177|NCT02898558|Behavioral|Magnification hand size|Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
75575178|NCT02898558|Device|magnifying lenses|
75575179|NCT04641494|Dietary Supplement|Conjugated linoleic acid|CLA Mixture capsule (50:50, c9, t11-CLA: t10, c12-CLA)
75575180|NCT04641494|Dietary Supplement|High oleic acid safflower oil capsules|
75575181|NCT02898636|Other|autopsy|At autopsy achieving adequate sampling of lesions and healthy skin
75575182|NCT02898363|Other|Information campaign|During a two-year information program, physicians, mainly general practitioners, carers in and outside institutions, associations and families will be informed on cancer frequency, on cancer particularities and on cancer detection in persons with intellectual disabilities by means of documents, mails and e-mails, meetings and a website providing all available useful information on cancer in persons with intellectual disabilities.
75575183|NCT04641377|Other|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
75575184|NCT04641377|Other|Health Education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
75575185|NCT02898441|Device|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
75575186|NCT04641455|Drug|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
76048556|NCT02349295|Drug|Placebo|Administered SC
75428679|NCT01489995|Drug|E (migalastat)|150 mg migalastat HCl 1 hour after consumption of a light meal
75428680|NCT01490008|Drug|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
75428681|NCT01490008|Other|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
75428682|NCT01490021|Procedure|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
75428683|NCT01490021|Procedure|rTMS/Placebo TBS|rTMS/Placebo TBS
75428684|NCT01490034|Behavioral|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
75428685|NCT01490034|Behavioral|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
75575187|NCT04641455|Drug|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
75428686|NCT01490034|Behavioral|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
75428687|NCT01490034|Behavioral|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
75428688|NCT01490047|Drug|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
75428689|NCT01490047|Drug|Liposomal doxorubicin|Infusion over 60 minutes
75428690|NCT01490047|Drug|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
75575188|NCT04641455|Drug|Water|Administration of water before upper endoscopy
75575189|NCT02898480|Procedure|Remote ischemic conditioning|Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
75726170|NCT00853190|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
75726171|NCT00853190|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
76048557|NCT02349295|Drug|Ixekizumab 80 mg Q4W|Administered SC
75428691|NCT01490047|Drug|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
75428692|NCT01490099|Drug|insulin detemir|One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
75428693|NCT01490112|Drug|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
75428694|NCT01490177|Drug|Food proteins|Oral ingestion of Food proteins
75428695|NCT01490203|Drug|Gd-EOB-DTPA|"Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
75428696|NCT01490203|Drug|Gd-EOB-DTPA|"Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
75428697|NCT01490203|Procedure|MRI|"Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
75575190|NCT04641182|Other|Prone position|Prone position as indicated by the treating physician as specified in the institutional protocol
75575191|NCT02898402|Procedure|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
75726172|NCT02591225|Drug|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
76048558|NCT02349295|Drug|Ixekizumab 80 mg Q2W|Administered SC
75575192|NCT00559286|Drug|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
75575193|NCT02898519|Other|cohort|Blood sampling
75726173|NCT02591225|Drug|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
75726174|NCT03962153|Diagnostic Test|Obstetric Ultrasonography|Obstetric Ultrasonography
75726175|NCT04085003|Procedure|Endovascular repair or Open surgery|The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
75726176|NCT02590679|Device|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
75428698|NCT01490203|Procedure|MRI|"Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
75428699|NCT01490216|Drug|lisdexamfetamine|20mg q.d. to 70mg b.i.d
75428700|NCT01490229|Drug|Ezetimibe|os, 10 mg, once daily, 1 year
75428701|NCT01490229|Drug|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
75428702|NCT01490255|Drug|Ranolazine|os, 750 mg, twice per day, for 15 days
75428703|NCT01490255|Drug|Amlodipine|os, 10 mg, once daily, 15 days
75428704|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
75428705|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
75428706|NCT01490281|Behavioral|water-based exercise|Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
75428707|NCT01490281|Behavioral|land-based exercise intervention|Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
75428708|NCT01490307|Behavioral|Family Check-Up|The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
75428709|NCT01490320|Behavioral|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
75428710|NCT01490320|Behavioral|Play Nicely Program|Multimedia program available at www.playnicely.org.
75428711|NCT01490320|Other|Control Group|Standard care in primary care clinic.
75428712|NCT01490333|Dietary Supplement|Vitamin D3|The vitamin D3 will be taken daily.
75428713|NCT01490346|Drug|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
75428714|NCT01490398|Drug|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is > 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
75428715|NCT01490411|Drug|Placebo|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
75428716|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
75428717|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
75428718|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
75428719|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
75575194|NCT00559403|Behavioral|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
75428720|NCT01490437|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
75575195|NCT00559403|Behavioral|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
75726177|NCT05302895|Device|All-in-one health monitoring device|The staff will use the new monitoring device to carry out the health monitoring on every day during the 12-week period. After each round of health monitoring by the traditional and the new devices, the staff will need to fill in log sheets designed by HKU to document the time consumed for the entire process.
75726178|NCT04085939|Other|Online survey|Anonymous survey using the online survey tool, JotForm
75726179|NCT03951389|Other|Non-interventional|Non-interventional
75726180|NCT02590445|Device|deep brain stimulation system|
75726181|NCT04086095|Device|Neofact application aid|The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
75428721|NCT01490437|Drug|Cisplatin|Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
75428722|NCT01490437|Drug|Dexamethasone|Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
75428723|NCT01490437|Drug|Vitamins|Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
75428724|NCT01490476|Drug|RAD001|10 mg per os / day or 05mg per os / day with 12 month
75428725|NCT01490489|Other|blood sample and doppler Ultrasound of uterine arteries|"36 ml of blood samples (serum and plasma) will be collected~After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch"
75428726|NCT01490515|Procedure|non-invasive metabolomic profiling|non-invasive metabolomic profiling of IVF human embryos
75575196|NCT02898285|Behavioral|Team sports|Participants will choose from a list of team sports and will be signed up with the team.
75575197|NCT02898285|Behavioral|Individual sport condition|Participants will choose from a list of individual sports.
75878488|NCT04697901|Device|Active Transcranial Direct Current Stimulation (tDCS)|"Active simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
76024566|NCT03125343|Procedure|endoscopy|"Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~PET-CT is optional, but can be performed at inclusion~Pelvic MRI including diffusion weighted imaging according to appendix C.~Clinical examination~Endoscopy (flexible sigmoidoskopy) with photodocumentation~CEA~After two years the patients will be followed every six month with:~Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~Clinical examination~Endoscopy with photodocumentation~CEA"
75428727|NCT01490515|Other|morphological evaluation|Simple microscopic observation of embryos and evaluation of morphological characteristics
75428728|NCT01490554|Procedure|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
75428729|NCT01490567|Drug|Donepezil|5 mg/day
75575198|NCT02898285|Behavioral|Night out|"Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children)."
75726182|NCT05325827|Procedure|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 ~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
75726183|NCT00715949|Other|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
75428730|NCT01490567|Drug|placebo|placebo 5mg/d
75428731|NCT01490593|Behavioral|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
75428732|NCT01490606|Other|knee OA project|"physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy."
75428733|NCT01490606|Other|conventional PT|12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
75428734|NCT01490619|Behavioral|Healthy Thinking In Teens|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
75428735|NCT01490619|Other|Advanced Diabetes Education.|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
75428736|NCT01490658|Drug|repaglinide|Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
75575199|NCT04640870|Drug|Afatinib|Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC
75575200|NCT04640558|Device|Muscle strength measurement|The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
75575201|NCT02898168|Device|WA group|Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
75575202|NCT02898168|Other|Control|Conventional rehabilitation therapy and gait training without WA.
75575203|NCT04640207|Device|Facial skin treatment|Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
75575204|NCT02897934|Drug|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
75575205|NCT04640129|Drug|PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate|Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
75726184|NCT04084535|Other|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
75726185|NCT04084535|Other|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
76024567|NCT03125343|Procedure|Surgery|Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
75575206|NCT04640129|Drug|Tenofovir Disoproxil Fumarate|TDF monotherapy
75575207|NCT02898012|Drug|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
75575208|NCT02898012|Drug|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage > grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
75726186|NCT00503698|Drug|somatropin|20 mcg/kg/day, injected s.c. (under the skin)
75726187|NCT00503698|Drug|placebo|Placebo injected s.c (under the skin)
75428737|NCT01490658|Drug|metformin|Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
75428738|NCT01490658|Drug|repaglinide and metformin combination tablet|Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
75428739|NCT01490671|Drug|1% tenofovir gel|One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
75428740|NCT01490671|Drug|Placebo gel|One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
75428741|NCT01490710|Other|collection of clinical and biological parameters|Investigation focal lies in hemodynamic monitoring during the last 10 minutes (Cardiac Index Assessment and clinico-biological parameters as: ventilatory and respiratory parameters, NIRS, GDS, Omega Score, heart rate, blood pressure, lactate, BNP, perfusion coefficient…)
75575209|NCT04640324|Drug|Nutraceutical therapy|Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
75575210|NCT02897895|Biological|levels of CNI in whole blood|
75575211|NCT02897895|Biological|Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)|
75575212|NCT04640285|Other|RELX ENDS Tobacco Flavor|Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
75575213|NCT04640285|Other|RELX ENDS Menthol Flavor|Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions
75575214|NCT04640285|Other|Usual Brand Cigarette|Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions
75726188|NCT02589899|Other|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
75575215|NCT04640285|Other|Nicorette White Ice Mint nicotine polacrilex gum|Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
75575216|NCT02898129|Other|Questionnaire|
75726189|NCT00573794|Biological|adalimumab|adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
75726190|NCT00715793|Drug|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
76024568|NCT03125343|Device|MRI|
76024569|NCT03109210|Behavioral|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
75428742|NCT01490710|Other|assign optimal ventilatory mode|End of study: At the end of the second session, clinician will assign optimal ventilatory mode regarding patient clinical response.
75428743|NCT01490736|Drug|Lemuteporfin|lemuteporfin topical solution, 1%
75428744|NCT01490749|Drug|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
75428745|NCT01490749|Drug|XELOX|Patients will receive two cycles of XELOX.
75428746|NCT01490749|Drug|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
75428747|NCT01490749|Radiation|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
75428748|NCT01490762|Drug|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
75428749|NCT01490762|Drug|Regular Human Insulin|Subcutaneous injection
75428750|NCT01490775|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
75575217|NCT02898129|Device|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
75575218|NCT00559442|Other|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
75575219|NCT00559481|Drug|dexamethasone|
76048559|NCT04877587|Drug|Ascorbate|"A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~2 60 g/m2 IV Days (1,2,8,9,15,16)~1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~1 30 g/m2 IV Days (1,2,8,9,15,16)"
75428751|NCT01490775|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
75428752|NCT01490801|Genetic|DNA analysis|
75428753|NCT01490801|Genetic|RNA analysis|
75575220|NCT00559481|Drug|ketoconazole|
75726191|NCT00715793|Drug|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
75726192|NCT00715793|Procedure|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
75726193|NCT04085549|Device|Berry Oil Cream|Cream containing berry and plant oils and humectants; a medical device product in development
75726194|NCT04085549|Other|Reference Cream|Commercial refence cream not containing berry and plant oils.
76024570|NCT03109210|Behavioral|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
76024571|NCT03086798|Procedure|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
76024572|NCT03086798|Procedure|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
76048560|NCT04877587|Drug|Gemcitabine|Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
76048561|NCT02281357|Biological|Tralokinumab|Tralokinumab dose
76048562|NCT02281357|Other|Placebo|Placebo dose
76048563|NCT02284243|Drug|Intranasal Dexmedetomidine|
76048564|NCT02284243|Drug|Intranasal Placebo|
76048565|NCT02284009|Biological|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
76048566|NCT02284009|Biological|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
76048567|NCT02284009|Biological|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
76048568|NCT02280499|Device|standard PROMOS prosthesis|
76048569|NCT02400476|Drug|Neratinib|
76048570|NCT02400476|Drug|Loperamide|
76048571|NCT02400476|Drug|Colestipol|2 g twice daily with or without food for one 28 day cycle
75428754|NCT01490801|Genetic|cytogenetic analysis|
75428755|NCT01490801|Genetic|in situ hybridization|
75428756|NCT01490801|Genetic|mutation analysis|
75428757|NCT01490801|Genetic|polymerase chain reaction|
75428758|NCT01490801|Genetic|western blotting|
75428759|NCT01490801|Other|flow cytometry|
75428760|NCT01490801|Other|immunohistochemistry staining method|
75575221|NCT00559481|Drug|therapeutic hydrocortisone|
75575222|NCT00559481|Procedure|pharmacological study|
75575223|NCT02897739|Procedure|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
75575224|NCT02897739|Biological|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
75575225|NCT02897739|Radiation|PET CT|PET study for metabolic pathway study
75575226|NCT02897739|Behavioral|Psychological assessment|Assessment by a psychologist
75575227|NCT00559520|Dietary Supplement|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
76024573|NCT03083652|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
76024574|NCT03083652|Other|Sham|Conventional physiotherapy with NMES device NOT activated
75878489|NCT04697901|Device|Sham Transcranial Direct Current Stimulation (tDCS)|"Sham simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Sham stimulation will consist of active stimulation for 120s, including the ramping up to 2 mA and down to no stimulation. Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
75878490|NCT02899962|Drug|LEO 90100 aerosol foam|LEO 90100 aerosol foam twice weekly
76048572|NCT02400476|Drug|Budesonide|9 mg extended release tablets once daily with or without food for 28 days
76048573|NCT02363738|Drug|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
76048574|NCT02363738|Other|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
75575228|NCT00559520|Dietary Supplement|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
75575229|NCT01236352|Drug|BMS-911543|
75575230|NCT02897856|Drug|Buccal midazolam|Study subject will receive Buccal midazolam, Intramuscular placebo.
75575231|NCT02897856|Drug|Intramuscular midazolam|Study subject will receive Intramuscular midazolam,Buccal placebo
75428761|NCT01490801|Other|medical chart review|
75428762|NCT01490853|Drug|Interpheron alpha|Long term outcom after interferon alpha discontinuation or not
75428763|NCT01490879|Drug|Nexagon® Low Dose|Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
75428764|NCT01490879|Drug|Nexagon® Medium Dose|Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
75428765|NCT01490879|Drug|Nexagon® High Dose|Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
75428766|NCT01490879|Drug|Nexagon® vehicle|Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
75428767|NCT01490905|Other|Theramine (A medical food)|Theramine two capsules twice daily for 28 days.
75428768|NCT01490905|Drug|Theraprofen|Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
75428769|NCT01490905|Drug|Ibuprofen|Ibuprofen 400mg once daily for 28 days.
75428770|NCT01490944|Drug|Iron, Folic acid and Cyanocobalamin|"Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks~Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks"
75428771|NCT01490944|Drug|Iron and Folic Acid|Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
75428772|NCT01490957|Other|Database|Database
75428773|NCT01490970|Other|Database|Database
75428774|NCT01490983|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
75428775|NCT01490983|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
75428776|NCT01490996|Drug|Oral complex C3 curcumin + chemotherapy|Daily oral capsule(s)
75428777|NCT01490996|Drug|Chemotherapy only|Standard care chemotherapy
75428778|NCT01491009|Drug|Remifentanil|IV infusion
75428779|NCT01491009|Drug|Midazolam|IV infusion
75428780|NCT01491048|Procedure|THA Physiotherapy|Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
75428781|NCT01491048|Procedure|No physiotherapy after THA|No physiotherapy after THA
75428782|NCT01491061|Drug|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
75428783|NCT01491061|Drug|Placebo|os, two doses 12 hours apart prior to PCI
75575232|NCT00559559|Device|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
75575233|NCT00559559|Procedure|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
75575234|NCT00559598|Genetic|proteomic profiling|
75575235|NCT00559598|Other|medical chart review|
75575236|NCT02897661|Procedure|WMT|Washed microbiota transplantation (WMT) through mid-gut
75575237|NCT02897661|Dietary Supplement|EEN|Exclusive enteral nutrition (EEN) through feeding tube
75575238|NCT03454685|Other|without intervention type|Without intervention,this study is just an observational study.
75575239|NCT02897505|Behavioral|Music Workshop|At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
75575240|NCT04639934|Genetic|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
75575241|NCT02897544|Behavioral|Individualized Manualized Health Education Intervention|
75575242|NCT04640090|Behavioral|Smartphone app (Wysa)|The commercially available smartphone application, Wysa, offers evidence-based wellness tools such as supportive listening, deep breathing techniques, guided meditation, yoga, and more. Users can communicate via text to a virtual artificial intelligence (AI) chatbot and/or a human well-being coach.
75575243|NCT02897622|Other|Case management|Case management by Eira unit
75575244|NCT04639739|Biological|anti-CD19 CAR NK|2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
75575245|NCT04639700|Behavioral|Psycho-educational intervention|"Participant will be sent a baseline survey, and will then be contacted by the interventionist to complete 4 sessions, which feature the following areas:~Session 1: Identifying CG Needs for Information & Support, Communication with Healthcare Team~Session 2: Communication with Patient and Family~Session 3: Self-care: Emotional & Spiritual Needs, Self-care: Physical Needs~Session 4: Re-Assessing Needs, Planning for the future"
75575246|NCT01236118|Drug|LY2439821|Administered subcutaneously
75575247|NCT02897583|Procedure|YAG vitreolysis|
75575248|NCT04206631|Drug|Doxycycline Capsule|Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
75575249|NCT04206631|Procedure|Comedone extraction|Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
75575250|NCT04639817|Drug|Levofloxacin|Levofloxacin administration
75878491|NCT02899962|Drug|LEO 90100 aerosol foam vehicle|LEO 90100 aerosol foam vehicle twice weekly
75428784|NCT01491074|Drug|Tocilizumab 280 mg|Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
75428785|NCT01491074|Drug|NaCl 0.9% 100 ml|Placebo
75428786|NCT01491087|Biological|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
75428787|NCT01490385|Device|LED Phototherapy|
75428788|NCT01491100|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
75575251|NCT04639817|Drug|trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole administration
75878492|NCT03647202|Drug|Milademetan Treatment A|Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
75878493|NCT03647202|Drug|Milademetan Treatment B|Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
75428789|NCT01491139|Drug|olaparib|Given twice daily. Exposure will escalate by daily dose and duration.
75428790|NCT01491139|Drug|cisplatin|Dose will be 35mg/m2 i.v. once weekly.
75428791|NCT01491139|Radiation|Intensity Modulated Radiotherapy|Total dose will be 70Gy in 35 fractions over 7 weeks.
75428792|NCT01491152|Device|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
75428793|NCT01491165|Procedure|stem cell transplantation through interventional procedures|one time interventional procedures
75428794|NCT01491191|Dietary Supplement|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
75428795|NCT01491191|Dietary Supplement|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
75428796|NCT01491204|Drug|Paclitaxel+HM30181|oral, 3times for 4weeks
75575252|NCT02897154|Diagnostic Test|In-vitro|
75575253|NCT05496634|Behavioral|Sedantary|An informative presentation
75575254|NCT05496634|Behavioral|Exercise therapy|Pilates exercise therapy
75575255|NCT02897193|Device|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
75575256|NCT02897193|Device|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
75575257|NCT02897193|Device|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
75575258|NCT02897193|Device|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
75575259|NCT04639856|Procedure|Coronary Artery Bypass Grafting|on-pump vs off pump Coronary artery Bypass Grafting
75575260|NCT01236001|Drug|Lacosamide|
75878494|NCT03647202|Drug|Milademetan Treatment C|Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
75878495|NCT03646344|Drug|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
75575261|NCT04639349|Behavioral|exercise group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
75575262|NCT04639349|Other|control group|the control group will not be trained
75575263|NCT02897466|Other|Direct Antimicrobial Susceptibility Testing|An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
75575264|NCT04639544|Dietary Supplement|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
75575265|NCT04639544|Dietary Supplement|Lactobacillus strain|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
75575266|NCT02897232|Other|Survey|Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
75575267|NCT01229254|Drug|Amiodarone|Patients on Amiodarone
75575268|NCT01229254|Drug|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
75575269|NCT01229254|Drug|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
75575270|NCT01229254|Drug|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
75575271|NCT04639232|Dietary Supplement|Placebo|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
75575272|NCT04639232|Dietary Supplement|Prob-milk|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
75575273|NCT04639232|Dietary Supplement|Voluntas-Prob|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
75575274|NCT02897388|Other|breast milk consume promotion|(1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling & promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
75575275|NCT01235728|Drug|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
75726195|NCT00924014|Drug|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
75726196|NCT00924014|Drug|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
75726197|NCT00924014|Drug|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
75726198|NCT02591303|Other|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
75428797|NCT01491217|Drug|Paclitaxel|HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
75575276|NCT01235728|Drug|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
75575277|NCT01235728|Drug|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
76048575|NCT04894526|Other|Alternating Energy Intake|To alternate between caloric overconsumption (130% of usual total energy needs) and caloric underconsumption (70% of usual total energy needs) on a daily basis for 6 days/week followed by one ad libitum day for 4 weeks.
75575278|NCT00559676|Drug|capecitabine|
75575279|NCT00559676|Drug|fluorouracil|
75575280|NCT00559676|Drug|irinotecan hydrochloride|
75575281|NCT00559676|Drug|leucovorin calcium|
75878496|NCT03646344|Drug|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
76048576|NCT04894526|Other|Regular Energy Intake|To consume the usual energy intake (100% of total energy needs) on a daily basis for 6 days/week, also followed by one ad libitum day for 4 weeks.
75575282|NCT00559676|Drug|oxaliplatin|
75575283|NCT00559676|Other|laboratory biomarker analysis|
75575284|NCT00559676|Other|pharmacological study|
75575285|NCT04639271|Drug|Pyrotinib Plus And|Pyrotinib::400mg/d,qd,po
75575286|NCT04639271|Drug|Trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle
75428798|NCT01491243|Drug|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
75428799|NCT01491243|Drug|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
75428800|NCT01491256|Drug|Pre-procedural High dose atorvastatin loading|Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention
75428801|NCT01491256|Drug|No pre-procedural high-dose atorvastatin loading|atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
75428802|NCT01491282|Other|Enabling and disabling VNS|No intervention
75428803|NCT01491295|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
75428804|NCT01491295|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
75575287|NCT04639271|Drug|Abraxane|Abraxane 125mg/M2, qw iv
75575288|NCT02896764|Device|Cone-beam CT|
75575289|NCT02896959|Procedure|Arthroscopic rotator cuff repair|
75575290|NCT04639076|Behavioral|Behavioral Weight Loss Program|The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.
75726199|NCT00853268|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
75726200|NCT00853268|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
76048577|NCT02331680|Drug|OPC-41061|
75726201|NCT01011244|Biological|ADIPOPLUS|"autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula"
75726202|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
75726203|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
75575291|NCT04639076|Behavioral|Personalized Behavioral Weight Loss Program|The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
75575292|NCT02896725|Device|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
76048578|NCT02331680|Drug|OPC-41061|
76048579|NCT02331680|Drug|Placebo|
76048580|NCT02331446|Behavioral|Physical exercise intervention|
76048581|NCT02349061|Drug|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
76048582|NCT02349061|Drug|Placebo Infusion|Placebo intravenously at Week 0.
76048583|NCT02349061|Drug|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
75726204|NCT00845780|Drug|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
76048584|NCT02349061|Drug|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
75428805|NCT01491308|Other|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
75428806|NCT01491321|Procedure|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~1st week : SC 0.2cc/day, 2days/week~2nd week : SC 0.4cc/day, 2days/week~3rd week : SC 0.8cc/day, 2days/week"
75428807|NCT01491321|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
75428808|NCT01491321|Procedure|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~1st week : SC 0.2cc/day, 2days/week~2nd week : SC 0.4cc/day, 2days/week~3rd week : SC 0.8cc/day, 2days/week"
75726205|NCT00853424|Procedure|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
75726206|NCT00853424|Other|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
76048585|NCT02349061|Other|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
76048586|NCT02331368|Procedure|Autologous Stem Cell Transplant|
76048587|NCT02331368|Drug|Melphalan|140-200 mg/m^2
76048588|NCT02331368|Drug|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
75428809|NCT01491360|Procedure|LaserACE(R)|Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.
75428810|NCT01491373|Device|rhBMP-2/ACS/LT-CAGE® Device|rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
75428811|NCT01491373|Device|Autograft/LT-CAGE® Device|LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
75428812|NCT01491438|Procedure|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|"PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing"
75428813|NCT01491438|Procedure|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
76048589|NCT02331368|Drug|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
76048590|NCT02362724|Device|Sapphire|silicone hydrogel contact lens
75428814|NCT01491477|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
76048591|NCT02362724|Device|Pearl|silicone hydrogel contact lens
75428815|NCT01491477|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
75428816|NCT01491503|Drug|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
75428817|NCT01491503|Drug|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
75428818|NCT01491503|Drug|Montelukast & levocetirizine|Montelukast sodium 10mg & levocetirizine dihydrochloride 5mg PO. Single dose.
75428819|NCT01491581|Dietary Supplement|food bar|milk based food bar enriched with micronutrients
75428820|NCT01491594|Drug|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
75428821|NCT01491659|Dietary Supplement|Idoform Plus|orally once daily
75428822|NCT01491659|Dietary Supplement|Placebo|orally once daily
75428823|NCT01491698|Procedure|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
75726207|NCT00853502|Drug|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
76048592|NCT02362646|Biological|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
76048593|NCT02362646|Drug|Control Solution|
76048594|NCT04907162|Diagnostic Test|Beck depression inventory fast screen|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
76048595|NCT04907162|Diagnostic Test|German Pain Inventory|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
75428824|NCT01491698|Procedure|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
75575293|NCT02896725|Device|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
76048596|NCT04907162|Diagnostic Test|Brief Pain Inventory|Validated questionnaire for pain.
76048597|NCT04907162|Diagnostic Test|Fatigue Severity and Disability Scale (FSS)|Validated questionnaire for perceived fatigue
75575294|NCT04639154|Procedure|Erector spinea plane block|ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
75726208|NCT00853736|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
75575295|NCT04681053|Drug|Ivermectin Powder|- Administration through inhalation (6mg) BID for 3 days
75575296|NCT04639193|Drug|Acetazolamide|Acetazolamide tablet (encapsulated)
75575297|NCT04639193|Drug|Eszopiclone|Eszopiclone tablet (encapsulated)
75575298|NCT04639193|Drug|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone
75575299|NCT04639193|Drug|Venlafaxine|Venlafaxine capsule
76048598|NCT04907162|Diagnostic Test|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
76048599|NCT04907162|Diagnostic Test|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
75726209|NCT00853736|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
75726210|NCT00857168|Drug|Testosterone MD-Lotion|
75726211|NCT00857324|Drug|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
76048600|NCT04907162|Diagnostic Test|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
75575300|NCT01235689|Biological|Adalimumab|If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
75575301|NCT01235689|Drug|Prednisone|The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
75575302|NCT01235689|Drug|Azathioprine|Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
75575303|NCT04680819|Dietary Supplement|Anatolian Propolis|Health workers who agree to participate in the study will be accepted as the study group, and healthcare professionals who do not agree to participate in the study will be considered as the control group. The study group will be asked to take 20 drops of Propolis drop form twice a day in the morning / evening, and the control group will not receive any treatment and both groups will be followed. In this process, patients diagnosed with COVID-19 will be determined. PCR test positivity taken from the throat for the diagnosis of COVID-19 will be accepted. The research will cover a period of 1 month. At the end of 1 month, patients diagnosed with COVID-19 in the study and control groups will be compared. Thus, the protective properties of Anatolian propolis will be determined.
75726212|NCT04043078|Other|Exercise|The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
75726213|NCT00857402|Dietary Supplement|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
76048601|NCT04907162|Diagnostic Test|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
76048602|NCT04907162|Diagnostic Test|Myotonometer Assessment|Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
76048603|NCT04907162|Diagnostic Test|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
75726214|NCT00857402|Dietary Supplement|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
76048604|NCT04907162|Diagnostic Test|Borg Scale|the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
76048605|NCT02280421|Drug|ASP2151 400mg + 100mg ciclosporin|
75726215|NCT00853814|Behavioral|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
75726216|NCT00853892|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
75575304|NCT04638764|Other|Aerobic interval training combined with high intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 70 %- 80 % of one repetition maximum (1-RM)).
75575305|NCT04638764|Other|Aerobic interval training combined with low intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 30 %- 40 % 1-RM).
75575306|NCT04638764|Other|Aerobic interval training|Patients enrolled in arm of the study will perform 12 weeks of aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing).
75575307|NCT04680858|Other|DECT|Use of a digital enhanced telecommunication headset for team communication
75575308|NCT04680429|Drug|RP7214|Participants will receive single and multiple ascending doses of RP7214
75575309|NCT04680429|Drug|Placebo|Participants will receive single and multiple ascending doses of matching placebo
75575310|NCT02896842|Drug|Posology dose modification|
75575311|NCT02896842|Other|active comparator|
75575312|NCT04638530|Other|Education on breaking bad news to family members remotely|Participants will receive a combination of surveys, pre- and post-tests, lectures and didactics to increase their awareness of techniques to communicate difficult topics with patients remotely as well as skill building exercises.
76048606|NCT02280421|Drug|ASP2151 1200mg + 100mg ciclosporin|
76048607|NCT04906382|Procedure|Biopsy|Undergo biopsy
75575313|NCT00559715|Drug|bevacizumab|1.25 mg intravitreally monthly/on demand
75575314|NCT00559715|Drug|ranibizumab|0.5 mg intravitreally monthly/on demand
75575315|NCT02896998|Procedure|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
75575316|NCT02896998|Procedure|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
75575317|NCT00559832|Other|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
75575318|NCT02896803|Drug|mFLOX|5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
76048608|NCT04906382|Drug|Carboplatin|Given IV
76048609|NCT04906382|Drug|Paclitaxel|Given IV
76048610|NCT04906382|Biological|Tislelizumab|Given IV
75575319|NCT02897037|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
75575320|NCT02897037|Drug|heparin|heparin monotherapy
75575321|NCT00559871|Drug|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
75575322|NCT00559910|Drug|PH-797804|PH-797804 at four dose levels
75575323|NCT00559910|Drug|Placebo|Placebo
75575324|NCT02896530|Other|No intervention. Description study|
75575325|NCT04680624|Procedure|Fecal sample collection|During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected.
75575326|NCT04638608|Other|EMBRACE (relatives)|Online support program for both relatives
75575327|NCT04638608|Other|EMBRACE (Health care providers)|Online support program for health care providers
75575328|NCT00553683|Drug|cyclophosphamide|
75575329|NCT00553683|Drug|poly ICLC|
75575330|NCT00553683|Procedure|hepatic artery embolization|
75575331|NCT00553683|Radiation|3-dimensional conformal radiation therapy|
75575332|NCT04638179|Other|Not intervention.Use retrospective case contrl study.|Use retrospective case contrl study.
75575333|NCT01229176|Biological|Vi-CRM197 vaccine|
75575334|NCT01229176|Biological|Vi Polysaccharide (PS) vaccine|
75726217|NCT00853892|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
75575335|NCT01229176|Biological|Pneumococcal conjugate vaccine|
75878497|NCT01569945|Drug|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
75878498|NCT01569945|Drug|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
75575336|NCT02896686|Radiation|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
75575337|NCT02896686|Other|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
75575338|NCT02896686|Procedure|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
75575339|NCT04638101|Behavioral|Mindfulness-based intervention|Mindfulness-based intervention: The proposed MBI was designed based on well-known MBI programs including Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy and adapted to adolescents' needs and language. The program consisted of 8 weekly sessions in groups of up to 8 participants, lasting 1h30. Two MBI groups were offered per week (Wednesdays and Fridays) and participants had the possibility to choose the most convenient day for them. Two instructors were present for each group throughout the intervention.For each session one theme was addressed, such as attention and the stabilisation of the focus of attention, bodily sensations, breath, emotions, thoughts, compassion, stress, stress reactivity and coping strategies.
75575340|NCT01228747|Drug|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
75575341|NCT01228747|Drug|Placebo|Matching oral placebo tablets twice daily for 28 weeks
75575342|NCT02896413|Drug|Dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
75575343|NCT02896413|Drug|Control group|0.9% saline infusion
75575344|NCT01228591|Device|Acuvue Advance Plus|Silicone hydrogel contact lens.
76048611|NCT04892719|Diagnostic Test|Fluoroscopic chest imaging with 4Dx technology software analysis|4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
75575345|NCT01228591|Device|Acuvue Advance|Silicone hydrogel contact lens
75575346|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
75575347|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
75575348|NCT00553722|Drug|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
75575349|NCT00553722|Drug|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
75575350|NCT01235338|Drug|LDX + Venlafaxine XR|"Day 1-5 LDX 30mg~Day 6-10 LDX 50mg~Day 11-15 LDX 70mg~Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~Day 31-34 Venlafaxine XR 150mg daily~Day 35-38 Venlafaxine XR 75mg daily."
75575351|NCT01235338|Drug|Venlafaxine XR + LDX|"Day 1-5 Venlafaxine XR 75mg~Day 6-10 Venlafaxine XR 150mg~Day 11-15 Venlafaxine XR 225mg~Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~Day 21-25 Venlafaxine XR and LDX 50mg daily~Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~Day 31-34 Venlafaxine XR 150mg~Day 35-38 Venlafaxine XR 75mg."
75575352|NCT04638296|Other|Interviews|The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
76048612|NCT02362412|Drug|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
75575353|NCT02896491|Radiation|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
75575354|NCT04638023|Device|Arabin pessary|Arabin pessary was inserted intravaginally electively in women with cervical insufficiency (history based) or as emergency in those with short cervix on ultrasound.
75575355|NCT01234675|Drug|Milnacipran|50 mg twice daily
75575356|NCT01234675|Drug|Placebo|50 mg twice daily
75726218|NCT02546336|Device|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
75726219|NCT00854126|Drug|GDC-0980|Escalating repeating dose
75726220|NCT00857480|Drug|NRL972|Single intravenous administration of 2 mg NRL972
75575357|NCT02895984|Behavioral|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
75575358|NCT04638452|Behavioral|Video & movements recording|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test
76048613|NCT02280187|Procedure|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
76048614|NCT02347813|Drug|Pioglitazone|15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
75428825|NCT01491711|Drug|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
76048615|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
75575359|NCT04638452|Behavioral|Questionnaires|Passing self and hetero questionnaires of emotion felt and perceived.
75575360|NCT02896101|Drug|Pimecrolimus Cream, 1%|
75575361|NCT02896101|Drug|Elidel® (pimecrolimus) Cream|
75575362|NCT02896101|Drug|Placebo of Pimecrolimus Cream, 1%|
75575363|NCT04637789|Behavioral|the whole body vibration|most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.
75575364|NCT04637789|Behavioral|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
75575365|NCT04638218|Device|Rehabilitation Training System|The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
75575366|NCT02896062|Behavioral|sleep-coaching|Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
75575367|NCT04638257|Biological|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14|Daily oral Lactobacilli starting at =<18 weeks of gestation in singleton pregnancy
75575368|NCT04638257|Other|Placebo|Daily oral placebo starting at =<18 weeks of gestation in singleton pregnancy
75726221|NCT00857480|Drug|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
76048616|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
76048617|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
75575369|NCT02896179|Device|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
75726222|NCT00857480|Drug|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
75428826|NCT01491711|Drug|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
75428827|NCT01491750|Behavioral|GUIDED IMAGERY|DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
75428828|NCT01491750|Behavioral|PLACEBO|DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
75726223|NCT00857558|Drug|saxagliptin|orally administration at 1 mg once a day for 12 weeks
76048618|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
75428829|NCT01491828|Device|Kai Strap|Medical device component that vibrates on a subject's neck.
76048619|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
75428830|NCT01491867|Drug|travoprost 0.003%|Instillation of travoprost 0.003% 1/die in both eyes for 3 months
75428831|NCT01491880|Behavioral|Therapist-Assisted by Telephone|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
75428832|NCT01491880|Behavioral|Self-Help|Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
75428833|NCT01491906|Behavioral|Text Messaging and Behavior Counseling|"Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group starter counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring."
75575370|NCT02896179|Device|GEO|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
75575371|NCT04637906|Dietary Supplement|Bioarginina®|Food supplement based on 1,66 grams of L-arginine
75575372|NCT02896023|Drug|human menopausal gonadotropin|Induction of ovulation followed by ICSI
75575373|NCT04637750|Behavioral|Educational intervention|The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).
75575374|NCT02896140|Other|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
75726224|NCT00857558|Drug|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
75726225|NCT00857558|Drug|saxagliptin|orally administration at 5 mg once a day for 12 weeks
75726226|NCT00857558|Drug|placebo|orally administration once a day for 12 weeks
75878499|NCT03645876|Drug|SHR-1210|200mg
75726227|NCT00857636|Behavioral|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
75726228|NCT00718523|Drug|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
75726229|NCT00718523|Drug|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
75726230|NCT02590367|Drug|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks."
75726231|NCT02590367|Drug|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
75726232|NCT02590367|Drug|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
75726233|NCT02590913|Dietary Supplement|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
75575375|NCT04637633|Drug|topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,|topical preservative free artificial tears Q.I. D.
75726234|NCT02590913|Dietary Supplement|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
75575376|NCT02896218|Other|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
75575377|NCT04637867|Other|Collection of blood, salivary and nasopharyngeal samples.|"Each visit M6 and M12~Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)~Salivary sample~Nasopharyngeal sample"
75726235|NCT02589743|Device|Sealant|Application of preventive agent
75726236|NCT02589743|Device|Adhesive and Sealant|Application of preventive agent and technique for control moisture
75878500|NCT03645876|Drug|BP102|7.5mg/kg
75878501|NCT03645876|Drug|oxaliplatin|130mg/m2
75878502|NCT03645876|Drug|capecitabine|1000mg/m2
75575378|NCT01228318|Drug|Zoledronic acid|"A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes."
75575379|NCT02895867|Other|Full fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
75575380|NCT02895867|Other|Low fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
75575381|NCT02895867|Other|Control|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
75575382|NCT04637828|Drug|GNS561|study drug
75575383|NCT04206475|Other|rehabilitation|"the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes."
75575384|NCT04206475|Other|Intensive Memory-Focused Training Program (IM-FTP)|During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
75575385|NCT05512624|Behavioral|Common Elements Treatment Approach|"For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion."
75575386|NCT02895828|Other|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
75575387|NCT02895828|Other|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
75428834|NCT01491997|Behavioral|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
75428835|NCT01491997|Behavioral|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
75428836|NCT01492010|Dietary Supplement|whey protein|25 g whey protein
75428837|NCT01492010|Dietary Supplement|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
75575388|NCT02895672|Drug|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
75575389|NCT04637711|Procedure|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision|Only visible lesions and necrotic tissues, such as abscess cavity, sinus tract and fistula, were removed intraoperatively, while normal glands and fat were retained. Preoperative ultrasound was used to locate the lesion area and then the surgical incision was designed. Intraoperative ultrasound examination of latent small lesions, resection of lesions visible under ultrasound, and then a full breast exploration, one finger page incision interval.Radially cut from the base to the subcutaneous, lesions were found and treated locally. After removal of lesion, fully using the syringe, in turn, use of 3% hydrogen peroxide solution, 1% eniodine, saline water is widely jet pulse washing, and around the lesions base. After rinsing, soak in 1% active iodine for 10min, then rinse with normal saline until the liquid is clear. Breast tumor Surgery (Oncoplastic Breast Surgery, OBS) core technology (volume replacement and volume replacement).
75575390|NCT02895516|Device|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
75575391|NCT04637516|Device|"Animation program BlinkBlink"|Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
75575392|NCT01227967|Drug|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
75575393|NCT01227967|Drug|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
75575394|NCT02895555|Procedure|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested aulograft.
75878503|NCT03645798|Behavioral|"Three good things therapy"|"To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?"
75575395|NCT02895555|Procedure|Allograft|Approx 50 g of allograft bone in the fused site
75575396|NCT00560027|Other|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
75575397|NCT00560144|Drug|RG1507|3mg/kg iv weekly
75575398|NCT00560144|Drug|RG1507|9mg/kg iv weekly
75575399|NCT00560144|Drug|RG1507|Pharmacokinetic-derived dose, <=16mg/kg iv weekly
75575400|NCT02895477|Device|hearing aid|
76048620|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
75575401|NCT04317391|Behavioral|Pain management program|Mindfulness based stress reduction
75575402|NCT00553761|Device|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
75575403|NCT04637477|Behavioral|Virtual ELM|Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.
75575404|NCT04637204|Drug|Cabozantinib|oral therapy
75575405|NCT04637204|Drug|Axitinib|oral therapy
75575406|NCT02895633|Other|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
75575407|NCT02895633|Other|CT scan|With injection of Iomeron 400
75575408|NCT02895633|Other|MRI|With injection of gadolinium (Multihance)
75575409|NCT04637126|Other|Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography|Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
75428838|NCT01492010|Dietary Supplement|whey protein supplemented with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
75428839|NCT01492023|Behavioral|neuropsychological rehabilitation|attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
75428840|NCT01492049|Behavioral|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
75428841|NCT01492049|Behavioral|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
75575410|NCT01227928|Drug|Pazopanib|Pazopanib 800 mg daily for 24 months
75575411|NCT01227928|Drug|Placebo comparator|Placebo 800 mg daily for 24 months
75575412|NCT02895438|Dietary Supplement|gluten|
75575413|NCT04637360|Drug|Cinacalcet Tablets|All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.
75575414|NCT04637360|Drug|calcitriol|All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
75575415|NCT04317703|Drug|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
75575416|NCT04317703|Drug|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
75575417|NCT02895399|Other|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
75575418|NCT05656846|Device|PulseNmore ES™|The patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.
75726237|NCT00715559|Drug|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
75726238|NCT00620282|Drug|liraglutide|Stepwise dose increase, s.c. (under the skin) injection, once daily
75726239|NCT00620282|Drug|placebo|Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
76048621|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
75428842|NCT01492049|Behavioral|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
75428843|NCT01492062|Device|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
75726240|NCT00620282|Drug|glimepiride|Tablets, 1 - 4 mg daily
76048622|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
76048623|NCT02328326|Other|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
75428844|NCT01492075|Drug|PCRA (Intermittent injection)|Intermittent injection of LA intraabdominally
75575419|NCT05656846|Device|Standard Ultrasound|These patients will not receive the additional intervention and will use the Standard Ultrasound. A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
75428845|NCT01492114|Dietary Supplement|Resveratrol|"Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
75726241|NCT05684861|Drug|Isotretinoin|systemic isotretinoin was given to all 90 patients , dose was prescribed according to weight for 3 months
75428846|NCT01492114|Dietary Supplement|resveratrol|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
75428847|NCT01492127|Biological|Blood test|Blood test
75428848|NCT01492140|Procedure|Subdermal Injection|Injection of dermal filler
75428849|NCT01492140|Device|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
76048624|NCT02328326|Other|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
76048625|NCT01649804|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
76048626|NCT02397278|Drug|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
76048627|NCT02360228|Device|tACS (alpha)|
76048628|NCT02360228|Device|tDCS|
76048629|NCT02359994|Device|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.
75428850|NCT01492153|Drug|biphasic human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
75428851|NCT01492153|Drug|isophane human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
75575420|NCT04317352|Procedure|MVR|Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
75575421|NCT00624598|Behavioral|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
75575422|NCT02895126|Behavioral|"Appui Parental program"|
75428852|NCT01492153|Drug|human soluble insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
75428853|NCT01492166|Drug|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
75575423|NCT02895126|Behavioral|Regular parental support|
75575424|NCT04636892|Other|MindMics earbud|Novel noninvasive wearable infrasound sensor
75428854|NCT01492179|Drug|Normal saline|Normal saline would be administered intravenously and intra-abdominally.
75575425|NCT05656690|Other|Exposure to disability|Disability status assessed by functional measures
75575426|NCT05656612|Other|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
75575427|NCT05656612|Other|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
75575428|NCT05656612|Other|Written, Oral and Visual Education|"Before the initial training was given, state anxiety levels were measured with a questionnaire.~The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale."
76048630|NCT02359994|Device|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
75575429|NCT04636580|Behavioral|parent accompanying the child during treatment|After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
75575430|NCT05656456|Other|Y-BOCS or FAS online survey, interview|Y-BOCS or FAS and online survey will be administered interview will be conducted
75575431|NCT05656339|Dietary Supplement|CHO+WP|Oral supplement containing carbohydrates plus whey protein
75575432|NCT05656339|Dietary Supplement|CHO|Oral supplement containing carbohydrates
75575433|NCT05656339|Dietary Supplement|Fast|Fast condition of 12 hours
75575434|NCT05656300|Diagnostic Test|MRI scan using USPIO particles|Diagnostic imaging
75575435|NCT04636541|Behavioral|Goal Management Training|Goal Management Training® (GMT) has been developed to improve executive functions. It was validated in patients presenting executive dysfunction following many conditions: acquired traumatic brain injury, neurodevelopmental spina bifida, attention deficit and hyperactivity disorder (ADHD), subjective cognitive complaints and multiple sclerosis. GMT includes self-instruction strategies, self-monitoring exercises, cognitive training techniques, psychoeducation on cognitive processes, mindfulness exercises and assignments between sessions. It has been shown to increase patient awareness of deficits and improve cognitive control in goal-directed behaviors. The original GMT is a nine-week program administered to dysexecutive patients in 90-to-120-minute group sessions. Thus, it might be suitable for PD-MCI patients presenting with executive dysfunction.
75428855|NCT01492179|Drug|Intravenous Lidocaine|Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
75428856|NCT01492179|Drug|Intra-abdominal Lidocaine|Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
75428857|NCT01492192|Drug|18F-RGD-PET-CT and perfusion CT scans on 3 occasions|"Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions"
75428858|NCT01492205|Drug|insulin human|All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
75575436|NCT04636541|Behavioral|Psychoeducation|See the Arm section for full details. For a justification of how we designed this intervention: Many clinical guidelines include general recommendations about giving information to PD patients and family so they can take part into decision process. However, few standardized psychoeducation interventions are available, and they don't include information on PD cognitive decline. Some studies investigated Mindfulness Based Stress Reduction (MBSR) and other related mindfulness interventions in PD patients. In this approach, formal meditative exercises are included to develop non-judgmental attention to experiences in the present moment. In elderly patients with MCI unrelated to PD, mindfulness interventions show positive effects on cognitive functioning, including attention, executive functioning and memory (Gard et al., 2014). Therefore, non-pharmacological interventions for PD-MCI including both education on cognitive symptoms, as well as mindfulness exercises, are promising.
75575437|NCT02895009|Device|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
75575438|NCT02895009|Device|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
75575439|NCT04638959|Other|collect gastric tissue and stool samples|collect gastric tissue and stool samples
75575440|NCT00624637|Other|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
76048631|NCT04905446|Other|Deuterated nicotinamide (D4-NAM) IV infusion|Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.
76048632|NCT04905446|Procedure|Skeletal muscle biopsy|Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.
76048633|NCT04905446|Procedure|Skin tissue biopsy|This procedure is used to sample skin tissue from the upper thigh via a punch biopsy.
76048634|NCT02326298|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
76048635|NCT02326298|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use"
76048636|NCT02396420|Device|Embosphere Microspheres|
76048637|NCT02279719|Drug|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
76048638|NCT02279719|Drug|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
76048639|NCT02279719|Drug|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
76048640|NCT02279407|Drug|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
75428859|NCT01492218|Drug|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
75428860|NCT01492257|Other|Shared Decision Making Intervention|Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
75726242|NCT05684861|Diagnostic Test|ELISA Assays of Serum TWEAK.|: From each subject, 5mL of blood was collected into vacutainers before and after treatment with isotretinoin. The blood samples were centrifuged at 3000g for 10 min at a temperature of 4°C, then . Quantitative determinations for serum TWEAK were achieved using the corresponding commercially available ELISA kit supplied by the AssayMax
75428861|NCT01492270|Procedure|Prostate HistoScanning|Advanced Ultrasound assessment of the prostate
75428862|NCT01492270|Procedure|Multi-parametric MRI|Multi-sequence Magnetic resonance imaging of the prostate
75575441|NCT05656144|Device|Cadonilimab|AK104, 6mg/kg, Q2W
75575442|NCT05656066|Behavioral|The Vibration Intervention|The vibration frequency of the massager, which accelerates blood circulation, is 6000 / min, it works with a 1.5 volt battery. Can be used easily with one hand. The vibration simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
75575443|NCT05656066|Behavioral|The Pressure Intervention|Pressure was placed in the ıntramuscular area properly 30 seconds before injection. Then the injection process was completed.
75726243|NCT02591069|Device|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
75726244|NCT04042688|Drug|intraarticular administration of tranexamic acid|Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
75428863|NCT01492270|Procedure|Transperineal prostate mapping biopsy|Needle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
75428864|NCT01492270|Procedure|Image guided biopsies|Biopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained
75726245|NCT02590133|Drug|Recombinant Human Endostatin Injection (Endostar)|15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
75726246|NCT02590133|Drug|Fluorouracil (5-Fu)|200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
75726247|NCT02590133|Drug|Nedaplatin|80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
75726248|NCT00854204|Drug|TMC114; TMC41629|
75726249|NCT02590991|Other|Prebiotics|To study the long term effect of supplementation in early life
75428865|NCT01492283|Other|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
75428866|NCT01492283|Other|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
75428867|NCT01492296|Procedure|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
75428868|NCT01492296|Procedure|conventional fasting|patients were evaluated after fasting for 8 hours
75428869|NCT01492322|Radiation|TRODAT|Smoker will receive a TRODAT injection
75428870|NCT01492335|Behavioral|Cognitive Report|Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
75428871|NCT01492335|Behavioral|Treatment As Usual|Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
75575444|NCT04680663|Diagnostic Test|Peripheral Perfusion index|Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue
75575445|NCT04680663|Diagnostic Test|serum lactate level|Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
75575446|NCT00560222|Dietary Supplement|bovine lactoferrin|1gm of lactoferrin will be given each day
75575447|NCT00560222|Dietary Supplement|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
75575448|NCT04317508|Drug|Topicale GelPatch (Benzocaine 18%)|Intervention group
75726250|NCT02590991|Other|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
75726251|NCT00854282|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
75726252|NCT02590211|Behavioral|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
75726253|NCT00854438|Other|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
76048641|NCT02279407|Drug|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
76048642|NCT02279407|Drug|Dapagliflozin|10 mg administered as 10 mg tablet
75575449|NCT04317508|Drug|Benzocaine oral gel 20%|control group
75575450|NCT05655988|Diagnostic Test|inguinal ultrasonography|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
75575451|NCT04636658|Other|Incentive spirometer training|Incentive spirometer training 5 sessions a week, each session of 15 minutes, for 4 weeks
75575452|NCT04636658|Other|diaphragmatic resistance exercises|"Incentive spirometer with diaphragmatic resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient.~Digital spirometer training for 15 minutes. diaphragm breathing exercises with resistance for 30 minutes. 5 sessions a week, for 4 weeks"
75575453|NCT05655910|Dietary Supplement|Ensure Surgery Immunonutrition shake|Nutrition shake to support immune health and recovery from surgery.
75575454|NCT04636463|Procedure|Intraoperative Music|Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
75575455|NCT04636736|Diagnostic Test|HIV drug resistance testing|HIV drug resistance testing in people newly diagnosed in HIV in Poland
75575456|NCT04680702|Diagnostic Test|Sims Score|Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
75575457|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
75575458|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
75575459|NCT00560300|Drug|1 alpha D2|Vitamin D sterol
75575460|NCT00560300|Drug|1,25 dihydroxy vitamin D3|Active vitamin D sterol
75575461|NCT00560300|Drug|Sevelamer HCl|Phosphate binder
75575462|NCT00560300|Drug|Calcium Carbonate|Phosphate binder
75726254|NCT00857870|Drug|Metformin|"Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose."
75726255|NCT00857870|Drug|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of <5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
75878504|NCT03645798|Behavioral|Normal psychological instruction|Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
76048643|NCT02279407|Drug|Placebo|Placebo matching to dapagliflozin 10 mg
75575463|NCT02895243|Other|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
75575464|NCT02904369|Drug|Emtricitabine|
75575465|NCT02904369|Drug|Tenofovir alafenamide|
75575466|NCT02904369|Drug|Tenofovir disoproxil|
75575467|NCT02904330|Drug|K1-70 intramuscular or K1-70 intravenous|Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
75575468|NCT00560378|Drug|Tacrolimus ointment 0.1%|Topical
75575469|NCT00560456|Other|Chronic sleep restriction and driving simulator|"One night of normal sleep~Driving simulator~Night 1: night of total sleep deprivation~Night 2: night of sleep recovery~Night 1 to 5: nights of sleep restriction~Driving simulator after night 1 to 5~Night 6: night of sleep recovery~Driving simulator"
75575470|NCT00560534|Procedure|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
75575471|NCT04636424|Other|assesment of gait|speed and weight distribution during gait
75575472|NCT04636346|Behavioral|Acceptance and Commitment Therapy|Seven group sessions
75575473|NCT04636346|Other|Questionnaires|Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two follow-up time points.
75575474|NCT02895321|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
75575475|NCT02895321|Other|Colgate, Protection Caries|a fluorine-based toothpaste gels
75575476|NCT02895321|Other|Placebo gel|a glycerin and water gel
75575477|NCT04636385|Other|Observational study no intervention|No intervention
75575478|NCT02894970|Device|Pulmonary PPG|Five minutes check with a lights source with two wave lengths of infrared and a detector.
75428872|NCT01492348|Behavioral|STEPS UP|"The STEPS UP intervention enhances RESPECT-Mil in several ways:~Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.~Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, & primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.~Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.~Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components."
75575479|NCT02904174|Behavioral|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question & answer session were included in the group education.
75575480|NCT02894931|Dietary Supplement|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
75726256|NCT00848432|Drug|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
75726257|NCT00854516|Procedure|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|"Procedure Schedule: The total duration for study participation will be 14 days (8 visits).~Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days."
75726258|NCT04043156|Radiation|High-precision RT|18 x 2.33 Gy of high-precision RT in 3.5 weeks
75726259|NCT00854750|Drug|ACTHAR|SQ weekly injections
75726260|NCT00854750|Drug|ACTHAR|SQ weekly injections
75726261|NCT00854750|Drug|ACTHAR|SQ weekly injections
75726262|NCT00854750|Drug|ACTHAR|SQ weekly injection
75726263|NCT00858026|Other|Breastmilk|Exclusively breastfed babies
75726264|NCT00858026|Other|Standard milk|Weaning babies fed with the standard formula
75726265|NCT00858026|Other|Fermented milk|Weaning babies fed with the fermented formula
75726266|NCT00848666|Drug|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
75726267|NCT00858104|Procedure|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
75726268|NCT00858182|Drug|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
75726269|NCT00858182|Drug|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
75726270|NCT00854984|Behavioral|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
75726271|NCT04123340|Diagnostic Test|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
75726272|NCT02545244|Dietary Supplement|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
75726273|NCT02545244|Dietary Supplement|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
75726274|NCT02545244|Drug|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
75726275|NCT00858260|Genetic|blood sample|Searching for Klotho variants in DNA
75726276|NCT00858338|Procedure|Potentially curative surgery|"Surgery:~Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.~Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy."
75878505|NCT03646266|Drug|Rocuronium Bromide|Titration with rocuronium bromide until tidal volume 6ml/kg PBW
76048644|NCT02326220|Drug|Placebo|
76048645|NCT02326220|Drug|Alirocumab|
75575481|NCT02894931|Dietary Supplement|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
75575482|NCT02894931|Dietary Supplement|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
75575483|NCT02894931|Dietary Supplement|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
75575484|NCT02894931|Other|Control- water|Chilled water flavored with lemon juice as control
75575485|NCT04635956|Drug|Drug therapy|6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
75575486|NCT02904018|Other|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
75575487|NCT02903979|Other|HVGIC|In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
75575488|NCT02903979|Other|Indirect pulp capping|In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
76048646|NCT02279173|Drug|Romiplostim|Romiplostim subcutaneous weekly injection
75428873|NCT01492348|Behavioral|OUC|"Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist."
75428874|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
75575489|NCT04635488|Procedure|lateral lymph node dissection|All participted would receive lateral lymph node dissection for rectal cancer.
75575490|NCT02895204|Dietary Supplement|Fermented Maillard reacted whey protein (F-MRP)|6g of powder containing 4.2g fermented maillard reacted whey protein
75575491|NCT02895204|Dietary Supplement|Placebo|6g of maltodextrin
75575492|NCT04635371|Device|Non-invasive Monitoring|Wearable, wireless, non-invasive chest-patch devices will be attached to the patients following recruitment and aigning an informed consent form, and from that moment on, vitals will be collected automatically and analyzed retrospectively.
75575493|NCT02894892|Drug|(A)Bismuth|
75726277|NCT00858338|Drug|Floxuridine (IP)|"Adjuvant IP Chemotherapy:~week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy."
75726278|NCT00858338|Procedure|Adjuvant Chemoradiation therapy|"Adjuvant Chemoradiation therapy:~week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days."
75726279|NCT00855140|Other|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
75726280|NCT00848900|Behavioral|Outdoor activity|Adding 1 hour outdoor time into school curricula
75726281|NCT00858416|Device|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
75726282|NCT00858416|Device|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
75726283|NCT00848978|Behavioral|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity ~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
75726284|NCT00858572|Drug|STA-9090 (ganetespib)|Chemotherapy agent
75428875|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
75428876|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
75428877|NCT01492374|Drug|Placebo matching BMS-241027|Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
75575494|NCT02894892|Drug|(B)Bismuth|
75575495|NCT02894892|Drug|(C)Bismuth|
75575496|NCT02894892|Drug|(D)Esomeprazole and Bismuth|
75575497|NCT02894892|Drug|(E)Esomeprazole and Bismuth|
75575498|NCT02894892|Drug|(F)Esomeprazole and Bismuth|
75575499|NCT02894892|Other|(G)Control|
75428878|NCT01492387|Other|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
75428879|NCT01492413|Behavioral|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
75428880|NCT01492452|Other|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
75428881|NCT01492465|Drug|AMG 876|Ascending single doses of study drug administered SC, with one cohort administered IV
75428882|NCT01492491|Device|SUPRA-HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
75575500|NCT04635566|Drug|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
75575501|NCT04635566|Drug|Placebo|Placebo one time/day at the evening.
75575502|NCT02894853|Genetic|Liquid (blood) biopsies and tumor biopsy (optional)|Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)
75428883|NCT01492504|Drug|Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)|Observational study - No Intervention [(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)]
75428884|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone for 2 hours
75428885|NCT01492517|Other|Diesel exhaust|Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3
75428886|NCT01492517|Other|Ozone18|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
75428887|NCT01492517|Other|Clean Air|Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
75428888|NCT01492530|Behavioral|Men of African American Legacy Empowering Self|Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
75428889|NCT01492530|Behavioral|Standard HIV Education & Risk Reduction|Single, individual counseling and education session. Lasting 20-30 minutes.
75428890|NCT01492543|Drug|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
75575503|NCT04635293|Procedure|preoperative infusion of levosimendan|the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
75428891|NCT01492556|Drug|Etoposide|Lastet (Etoposide Capsules, 25mg*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
75575504|NCT04635293|Procedure|no preoperative infusion of levosimendan|the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
75575505|NCT02894736|Device|Soterix tDCS machine|Soterix tDCS machine - miniCT supervised neuromodulation system
75575506|NCT04635215|Device|Sensura Mio Bodyfit technology ostomy pouches|The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
75575507|NCT02903862|Behavioral|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support & assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
75878506|NCT02899338|Drug|BI695501 Prefilled syringe|
75726285|NCT00858650|Other|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
75726286|NCT00515086|Drug|Everolimus|Tablets taken once a day with a full glass of water.
75726287|NCT00515086|Procedure|Surgery|Salvage surgical resection
75726288|NCT00849134|Drug|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
75878507|NCT02899338|Drug|BI695501Autoinjector|
75428892|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS at sham point
75575508|NCT02903862|Device|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
75428893|NCT01492569|Other|questionnaire administration|Ancillary studies
75428894|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS
75428895|NCT01492608|Drug|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
75726289|NCT00861224|Other|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
75726290|NCT00861302|Behavioral|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
75726291|NCT01011322|Drug|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
75726292|NCT01011322|Drug|placebo|placebo
75726293|NCT00858806|Drug|Imatinib|"Intermittent Imatinib administration.~1 week on / 1 week off for the 1st month(weeks 1-4)~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
75726294|NCT02545088|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
75726295|NCT02545088|Other|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
75726296|NCT02545088|Other|2nd control group|The 2nd control group will not receive an intervention.
75575509|NCT04635410|Other|ULTRASOUND IMAGING|SCAN LABOURING WOMEN BY ULTRASOUND
75575510|NCT01227889|Drug|GSK2118436|150 mg twice daily
75575511|NCT01227889|Drug|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
75575512|NCT02894814|Behavioral|One-Stop Dispensing|Use of own medication, review of the patient's medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
75575513|NCT02894814|Behavioral|One-Stop Dispensing and focused dialogue|Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
75726297|NCT00849368|Drug|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets"
75726298|NCT02544932|Drug|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
75726299|NCT02544932|Drug|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
75726300|NCT02544932|Drug|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
75878508|NCT04052100|Other|Usual care|The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.
75428896|NCT01492621|Drug|Desvenlafaxine|Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
75428897|NCT01492634|Other|Prescription of post-dialytic weight based on BCM device|"Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).~The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.~Prescription steps will be calculated weekly for all study patients. TAFO < -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO > 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week."
75428898|NCT01492647|Drug|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
75428899|NCT01492647|Drug|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
75428900|NCT01492647|Drug|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
75428901|NCT01492660|Device|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
75428902|NCT01492660|Device|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
75428903|NCT01492699|Drug|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
75428904|NCT01492712|Drug|Propofol|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
75428905|NCT01492712|Drug|Propofol|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
75428906|NCT01492725|Device|Intra-arterial Clot Retrieval with Solitaire device|Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
75428907|NCT01492725|Genetic|intravenous tissue plasminogen activator (tPA)|Standard care IV tPA therapy administered as per registered product information
75428908|NCT01492738|Procedure|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
75428909|NCT01492751|Behavioral|Quality of life assessment and Clinical evaluation|"quality of life assessed by the Expanded Prostate Cancer Index Composite (EPIC), the Medical Outcomes Study 36-Item Short Form (SF-36) version 2, the Functional Assessment of cancer Therapy, General and Prostate specific (FACT-G and FACT-P, respectively), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIES). Quality of Life questionnaires are administered centrally by telephone interview before treatment and during follow-up at 1, 3, 6, and 12 months after treatment the first year, then annually until 10 years, and every 5 years thereafter.~Demographic and clinical characteristics at baseline are recorded at clinical sites and include age, Prostate Specific Antigen (PSA), Gleason grading, prostate volume, risk group and use of neoadjuvant hormonal treatment. According tho the national health guidelines participants are visited every 6-12 months after treatment."
75726301|NCT02544854|Drug|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~First 15 minutes: 15 mg/kg/min~16 to 30 minutes: 13 mg/kg/min~31 to 60 minutes: 11 mg/kg/min~61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~5, 15 and 25 minutes of starting infusion,~1, 3, 5, 7, 9 and 12 minutes of bolus and,~5, 25, 60 and 120 minutes of infusion ended."
75726302|NCT00861458|Drug|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
75726303|NCT00861536|Drug|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
75726304|NCT00861536|Drug|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
75726305|NCT00849446|Device|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
75726306|NCT02544776|Drug|Clomifene citrate ( clomid 50 mg )|
75726307|NCT02544776|Drug|Amlodipine|
75726308|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
75428910|NCT01492751|Procedure|Radical retropubic prostatectomy surgery|The surgery group underwent radical retropubic prostatectomy. The surgery is performed by a technique based on a modification of the radical retropubic prostatectomy described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible, controlling the vessels with titanium clips, and avoiding any kind of coagulation to decrease the risk of neurovascular bundle damage. The bladder neck may be preserved on surgeon criteria. Lymph node dissection is rarely performed due to the extremely low risk of metastatic involvement in this subset of patients. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 1 to 3 weeks to facilitate bladder emptying.
75428911|NCT01492751|Radiation|External beam radiotherapy|External beam radiation is carried out with the 3D conformal technique. Patients are treated in a supine position by immobilizing feet and legs. Data from a computed tomography (CT) scan performed with the patient in the treatment position were entered into a 3D treatment-planning system to outline prostate, bladder, and rectum on each slice. Seminal vesicles and regional lymphatics are also contoured if a high risk of involvement was suspected. Applied margins are used to calculate prostate planning target volume (PTV). Custom blocking with Cerrobend blocks or multileaf collimators are designed using beam's eye view, and additional margins were adjusted to provide a minimum dose of 95% to the prostate PTV. Treatment is delivered in 1.8 to 2.0 Gy daily fractions, 5 days per week. Off-line setup control is assessed weekly by comparing orthogonal portal images with the corresponding digitally reconstructed radiographs.
75428912|NCT01492751|Radiation|Prostate Brachytherapy|Brachytherapy is performed by pre-planned procedure. Under epidural anaesthesia, the patient is placed in the lithotomy position (forced lithotomy position larger prostate volumes) and, after probing the patient, the best prostate spatial location is searched, proceeding then to prepare the sterile field and bladder catheterization. A prostate volumetry with a three-dimensional reconstruction is performed and automatically transferred to the scheduler, which processes the images and outlines the prostate, urethra and rectum in each of the sections. In LDR prostate brachytherapy, the prostate gland corresponds to the PTV. The standard dose for 100% isodose is 145 Gy according to the TG-T43 for I-125 sources. Dosimetry calculation of the automatically prescribed dosage is then estimated, with a final manual optimization.
75428913|NCT01492790|Procedure|Emergency cholecystectomy first|The intervention is an emergency cholecystectomy without prior common bile duct imaging
75575514|NCT04635332|Behavioral|Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)|"Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity."
75575515|NCT04635332|Behavioral|Developed health promotion intervention materials (booklet).|In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
75575516|NCT02894541|Drug|CKD-519 100mg|
75575517|NCT02894541|Drug|CKD-519 200mg|
75575518|NCT02894541|Drug|CKD-519 100mg|
75575519|NCT02894541|Drug|CKD-519 200mg|
75726309|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
75726310|NCT00859196|Drug|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
75428914|NCT01492790|Procedure|Sequential common bile duct imaging/cholecystectomy|This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
75575520|NCT02888392|Other|Kiwifruit|2 green kiwifruit cultivar 'Hayward'
75575521|NCT02888392|Dietary Supplement|Psyllium|Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
75575522|NCT04635020|Procedure|iStent|2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork
75575523|NCT04635020|Procedure|SLT-laser|1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)
75575524|NCT04635020|Procedure|Cataract surgery|Conventional cataract surgery
75575525|NCT05655871|Other|Transtheoretic Model Based Video Exercise Training|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. Participants 10-12. No application will be made between weeks and the last test will be done in the 12th week.
75575526|NCT05655871|Other|Standard Maintenance Practice|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. The final test will be done at week 12.
75575527|NCT04681716|Other|ELDOA|For Spinal Segment L4-L5 and L5-S1 proper ELDOA position was instructed to the experiment group patients.ELDOA stands for Elongation Longitudinaux Avec Decoaption Osteo Articulaire, or LOADS (Longitudinal Osteo-articular De-coaptation Stretching). ... They can be described as fascial stretch that localizes tension at the level of a specific spinal segmental.
76048647|NCT02282917|Drug|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
75575528|NCT04681716|Other|CONVENTIONAL PHYSIOTHERAPY|"Transcutaneous Electrical Nerve Stimulation (TENS):~120Z dual channel TENS unit made in Japan was used in the research. Electrodes of TENS were placed on lumbar region and TENS was given for 15 minutes on Constant mode. Intensity was adjusted according to patient's comfort.~Hot pack was applied on the lumbar region for 10 - 15 minutes.Lumbar Mobilization (CPA) was given on spinous process of L1- L5 vertebrae and L5-S1. For every session given 3 sets of 10 repetitions of each lumbar vertebra was performed."
75726311|NCT00859196|Drug|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
75726312|NCT00849602|Drug|Placebo|Placebo bid for three days
75726313|NCT00849602|Drug|Chloroquine|Chloroquine bid for three days
76048648|NCT02358668|Drug|BTI320|BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
76048649|NCT02358668|Drug|BTI320 matching placebo|Placebo
76048650|NCT02282605|Drug|XF-73 nasal gel|
76048651|NCT02282605|Drug|Placebo nasal gel|
75726314|NCT00859274|Drug|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
75726315|NCT00859352|Drug|AZD1981|oral tablets during 14 consecutive days.
76048652|NCT02282605|Other|Chlorhexidine gluconate 2% topical cloths|
76048653|NCT02282527|Biological|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
76048654|NCT02282527|Biological|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
76048655|NCT05650099|Device|One or two dental implants (Biomet3I dental implant system) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of missing posterior teeth and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
76048656|NCT02278939|Behavioral|Filipinos Fit and Trim Weight Loss Program|This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
76048657|NCT02278471|Drug|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
75428915|NCT01492803|Dietary Supplement|Probiotics|"Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)"
75428916|NCT01492803|Dietary Supplement|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
76048658|NCT05565235|Drug|patients will receive intraoperative serratus block with bupivacaine|no additives
76048659|NCT05565235|Drug|serratus block with bupivacaine /magnesium|magnesium added
75575529|NCT04681521|Other|Hot and Cold compress, nursing interventions|using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
75575530|NCT04634942|Device|Cryos REF 0971 Cold Spray|Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
75428917|NCT01492816|Behavioral|Community Mobilization|The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
75428918|NCT01492829|Behavioral|individual and group-based, community health worker delivered|Pre-test will be individual, tablet-based; participants will receive correct information for incorrect HIV/STI knowledge responses and will watch a brief HIV/STI educational video. This will be followed by participants attending 6 weeks of group educational sessions focused on: HIV, STI, interpersonal relationships, communication and decision-making, mental health and coping, creating social change
75428919|NCT01492855|Procedure|Arthroscopy|Arthroscopy is offered for the patients who do not benefit from conservative treatment.
76048660|NCT05565235|Drug|serratus block with bupivacaine with nalbuphine|nalbuphine added
76048661|NCT04420039|Device|Endoscopic biliary transmural drainage|"Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent."
75575531|NCT04634942|Device|ShotBlocker BIONIX Press Firmly USA|ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
75428920|NCT01492855|Behavioral|Non-invasive treatment|All patients will receive information and supervised exercises by a physiotherapist.
75575532|NCT01227577|Drug|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
75575533|NCT04681599|Device|Filter|Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases
75575534|NCT04681599|Device|Scavenger face tent|A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria
76048662|NCT02278003|Other|memory test|
75428921|NCT01492881|Drug|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
75428922|NCT01492881|Drug|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
75428923|NCT01492881|Drug|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
75428924|NCT01492894|Drug|Cyclosporins/Tacrolimus|Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
75428925|NCT01492894|Drug|Sirolimus|Change from current calcineurin inhibitor to Sirolumus
75428926|NCT01492907|Radiation|MeIQx|On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
75428927|NCT01492907|Procedure|Pancreatectomy|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
76048663|NCT02278003|Drug|Propofol|
76048664|NCT02277769|Drug|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
76048665|NCT02277769|Drug|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
75428928|NCT01492920|Dietary Supplement|Acetyl-L-Carnitine Hydrochloride|Given orally
75428929|NCT01492920|Other|Placebo|Given orally
75428930|NCT01492920|Other|Questionnaire Administration|Ancillary studies
75428931|NCT01492920|Other|Quality-of-Life Assessment|Ancillary studies
75428932|NCT01492959|Drug|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
75428933|NCT01492985|Biological|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
75428934|NCT01492985|Biological|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
75428935|NCT01492998|Other|guggulsterone, a natural FXR antagonist.|Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
75428936|NCT01493011|Device|chemotherapy & WBH|standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
75428937|NCT01493037|Device|PICSO (Pressure-controlled Intermittent Coronary Occlusion|The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
75428938|NCT01493050|Drug|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
75428939|NCT01493050|Drug|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
75428940|NCT01493076|Device|Primary cannulation/precut sphincterotomie with the Baby-S|"At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the Albaran-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome."
75575535|NCT04635137|Procedure|Ablation and Cementoplasty|Percutaneous thermal ablation with subsequent cementoplasty in a single procedure
75575536|NCT05655793|Diagnostic Test|Tear Fluid collection (Schirmer's strip)|Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
75575537|NCT05655793|Diagnostic Test|Retinal imaging|The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
75575538|NCT00624676|Drug|Lipo Hydroxy Acid|Twice a day
76048666|NCT01641991|Biological|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
75575539|NCT00624676|Drug|5% benzoyl peroxide gel|Once a day
75575540|NCT04634903|Behavioral|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
75575541|NCT04634903|Behavioral|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
75575542|NCT04634903|Behavioral|Growth Mindset SSI|Online, 30-minute self-administered program for youth
75575543|NCT05655754|Drug|Methohexital|anesthesia during ECT
76048667|NCT01641991|Biological|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
76048668|NCT05649709|Drug|L-VA dual therapy|1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
76048669|NCT05649709|Drug|H-VA dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
76048670|NCT05649631|Dietary Supplement|Sodium|50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.
76048671|NCT02277691|Drug|TAK-536TCH tablet|TAK-536TCH tablets
75428941|NCT01493102|Drug|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
75575544|NCT05655754|Drug|Ketofol|anesthesia during ECT
75575545|NCT02894385|Drug|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
75575546|NCT05655715|Radiation|Stereotactic body radiotherapy|8 Gray x 3
75575547|NCT05655715|Drug|Ipilimumab Injection [Yervoy]|1 mg/kg IV Q3W for four doses,
75428942|NCT01493102|Drug|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
75428943|NCT01493115|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75428944|NCT01493115|Drug|Insulin glargine - New formulation HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75428945|NCT01493154|Biological|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
75428946|NCT01493154|Drug|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
75575548|NCT05655715|Drug|Nivolumab Injection [Opdivo]|Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W
75575549|NCT05655715|Procedure|Biopsies|From soft tissue metastases.
75575550|NCT05655676|Drug|89Zr-NY008|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
75575551|NCT04634864|Device|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously
75575552|NCT04634864|Device|sham tDCS|The stimulator was switched off after 2 minutes of stimulation.
75575553|NCT02894463|Other|questionnaire|
75575554|NCT04317235|Drug|Ropivacaine 0.5% Injectable Solution|Is to put 3 ml or 5 ml and show the difference
75575555|NCT00560690|Drug|Metformin|500 mg oral three times a day for 6 months
75575556|NCT00560690|Drug|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
75575557|NCT00560690|Drug|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
75575558|NCT01227421|Drug|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
75575559|NCT01227421|Drug|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
75575560|NCT01227421|Drug|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
75575561|NCT05655559|Other|Questionnare|Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
75575562|NCT05655559|Device|Moxy Muscle Oxygen Monitor|Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
76048672|NCT02277691|Drug|TAK-536CCB tablet|TAK-536CCB tablets
76048673|NCT02277691|Drug|HCTZ 12.5 mg tablet|HCTZ tablets
76048674|NCT02395172|Drug|Avelumab|Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
76048675|NCT02395172|Drug|Docetaxel|Participants received 75 mg per square meter (m^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
76048676|NCT04876027|Drug|GLP-1 RAs|GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
76048677|NCT04876027|Other|calorie restricted diet|Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
76048678|NCT04859101|Other|Gum|2 minutes of gum chewing prior to procedure
76048679|NCT04859101|Other|Control|2 swallows prior to procedure
76048680|NCT02275819|Other|Exercise|Exercise (walking 3 times a week for 60 minutes) or Inspiratory Muscle Therapy (breathing against an inspiratory resistive load 3 times a week for up to 60 minutes)
76048681|NCT02358044|Drug|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
76048682|NCT02358044|Biological|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
76048683|NCT02358044|Drug|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
76048684|NCT02358044|Drug|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
75575563|NCT00560729|Dietary Supplement|Renutryl 500|
75575564|NCT00560729|Dietary Supplement|Generique|
75575565|NCT00560729|Dietary Supplement|Generique + Renutryl 500|
75575566|NCT02903901|Drug|Melatonin|10 mg liquid Melatonin IR-SL at 7 pm for 1 week
75575567|NCT02903901|Drug|Placebo|10 mg liquid placebo at 7 pm for 1 week
75575568|NCT00560768|Device|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:~A right ventricular defibrillation lead~In case of use of a dual chamber ICD a right atrial pacing lead~A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
75575569|NCT02904213|Biological|ComBe Five (Liquid)|
75575570|NCT01227265|Drug|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
75575571|NCT01227265|Drug|Placebo|Preladenant-matching placebo oral tablet taken twice daily
75575572|NCT00560807|Procedure|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
75575573|NCT04319302|Procedure|Isolated Vascularized Gastric Tube (IVGT) graft|A conduit was created by tubularising a vascularized segment of the greater curve of the antrum of the stomach and this was used between the remaining common hepatic duct and the duodenum.
76048685|NCT02275117|Biological|ALD403|
76048686|NCT02275117|Biological|Placebo|
76048687|NCT04869553|Other|Management pain with distraction methods ABC|"Every patient will receive :~The usual pain management of their ward (Treatment A),~The usual pain management of their ward with a hypnosis session (Treatment B)~The usual pain management of their ward with a virtual reality session (Treatment C)"
76048688|NCT04869553|Other|Management pain with distraction methods BCA|"Every patient will receive :~The usual pain management of their ward with a hypnosis session (Treatment B)~The usual pain management of their ward with a virtual reality session (Treatment C)~The usual pain management of their ward (Treatment A)"
76048689|NCT04869553|Other|Management pain with distraction methods CAB|"Every patient will receive :~The usual pain management of their ward with a virtual reality session (Treatment C)~The usual pain management of their ward (Treatment A)~The usual pain management of their ward with a hypnosis session (Treatment B)"
76048690|NCT05649319|Procedure|ERAS protocol|The ERAS protocol involves a pre-admission patient education using audiovisual videos, the reduction of perioperative fasting time with administration of preoperative carbohydrate loading and early resumption of oral feeding after surgery, multimodal postoperative nausea and vomiting prevention, early removal of the nasogastric tube and urinary catheter, and multimodal analgesia to minimize opioid consumption after surgery.
75726316|NCT00859352|Drug|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
76048691|NCT05649241|Drug|Nicotine patch|Nicotine replacement therapy patch
76048692|NCT05649241|Drug|Nicotine gum|Nicotine replacement therapy gum
76048693|NCT05649241|Behavioral|Medication Therapy Management|Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
76048694|NCT05507827|Drug|Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)|CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
76048695|NCT05507827|Drug|Treg CD34+HSPC (Orca-T)|Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
76048696|NCT05649007|Device|hip arthroplasty with prosthesis|Use of femoral stem and acetabular cup for hip arthroplasty
76048697|NCT02274493|Device|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
75428947|NCT01493193|Other|Endurance training with constant work load|Endurance training with constant work load(n=15): 31min at 65-75% HRmax
75428948|NCT01493193|Other|Pyramid-Training|Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
75428949|NCT01493193|Other|High-intensity interval training|HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
75428950|NCT01493206|Radiation|intraoperative radiotherapy|intraoperative radiotherapy
75428951|NCT01493232|Other|buccalized occlusion|Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
76048698|NCT02274493|Procedure|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
76048699|NCT02274493|Procedure|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
76048700|NCT02274493|Behavioral|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
75428952|NCT01493245|Drug|JNS020QD|During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
75726317|NCT00861770|Other|Ultrafiltration|Ultrafiltration based on standard of care.
75726318|NCT00861770|Other|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
75726319|NCT00618410|Device|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
75726320|NCT00618410|Other|Placebo|Nasal placebo
75726321|NCT00861926|Drug|Ventolin|Ventolin : salbutamol sulfate 100µg
75726322|NCT00861926|Drug|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
75575574|NCT05655403|Behavioral|Step training program|The program will consist of 3 phases: (1) getting familiar, (2) increasing complexity, and (3) consolidating skills. In Phase 1, the participants will be asked to use one foot to step on single-colored stepping panels located in a specific region of the plastic mat (e.g., upper quadrant). In Phase 2, the exercise will progress by introducing the following 4 cognitively challenging stepping tasks. After finishing the 4 stepping tasks in Phase 2, the exercises will progress to Phase 3, which will consolidate the participants' stepping and cognitive skills. The following 4 additional stepping tasks will be introduced. The instructor will tailor the exercises for each participant, based on their training performance.
75575575|NCT04634981|Procedure|anesthesia of emergency cesarean section|compare General versus spinal anesthesia
75575576|NCT05655286|Drug|38% SDF treatment|Children with active caries will receive 38% silver diamine fluoride treatment
75575577|NCT05655286|Behavioral|not to rinse for at least 30 minutes after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked not to rinse their mouths for at least 30 minutes.
75575578|NCT05655286|Behavioral|rinse mouth immediately after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked to rinse their mouths immediately.
75575579|NCT02904252|Other|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F>2).
76048701|NCT02273167|Drug|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
76048702|NCT02273167|Drug|NER1006,1-Day Morning Split-Dosing|"The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid."
76048703|NCT02273167|Drug|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
76048704|NCT02272777|Drug|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
75428953|NCT01493258|Other|iCOPE Intervention group|The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
75428954|NCT01493297|Other|Labeled iron solutions|Labeled iron as FeSO4 (4 mg/test meal)
75428955|NCT01493310|Drug|mifepristone|"Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"
75428956|NCT01493310|Drug|placebo|Given orally
76048705|NCT02272777|Drug|Nilotinib|Nilotinib 300mg BID or 400mg QD
75428957|NCT01493310|Drug|nab-paclitaxel|"Given by intravenous infusion (IV)~Dose of 80 mg/m2"
75726323|NCT04041518|Procedure|Autotransplantation|Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
75726324|NCT04041752|Behavioral|SOLID|condition with a classical meal served using solid food items
75428958|NCT01493323|Behavioral|Assessment of personality traits|suicide behaviour , psychic pain, social exclusion, decision making...
76048706|NCT05648929|Other|Patient Satisfaction Questionnaire|During regular clinical examinations patient will go through a short questionnaire at week 4, 16 and 24 to check patient satisfaction with expanders
75428959|NCT01493323|Behavioral|Assessment of suicidal act|suicide behaviour , psychic pain, social exclusion, decision making...
75575580|NCT04318990|Procedure|Distal radial artery access|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
75575581|NCT04318990|Procedure|Proximal radial artery surgery|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
75575582|NCT04319107|Other|ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.|Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.
75575583|NCT00553449|Drug|rabeprazole|
75575584|NCT04319263|Drug|induction regimen of intravesical BCG|intravesical instillation of 6 weekly doses of BCG
75726325|NCT04041752|Behavioral|LIQUID_P|condition with a liquid meal served using a powder solution
75575585|NCT05655169|Procedure|Piezosurgery and GaALAs diode laser|"One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.~After six weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) 10 seconds per point will be applied."
75575586|NCT05655169|Procedure|Piezosurgery|One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.
76048707|NCT05648929|Diagnostic Test|Pregnancy test|Pre-op; to sufficiently check pregnancy as exclusion criteria
76048708|NCT05648929|Procedure|Blood draw|pre- expander implantation, alongside anaesthesia pre- expander explantation and exchange with definite implant alongside anaesthesia - no additional vein irritation needed
75726326|NCT04041752|Behavioral|LIQUID_L|condition with a pre-prepared meal served using a liquid solution.
75726327|NCT04041206|Device|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated [Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)]. The acupoint microcirculation will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
75726328|NCT00849992|Drug|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
75726329|NCT00849992|Procedure|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
75428960|NCT01493323|Behavioral|Assessment of depression|suicide behaviour , psychic pain, social exclusion, decision making...
75428961|NCT01493323|Procedure|Cyber ball game|functional neuroimaging
75428962|NCT01493323|Procedure|Iowa Gambling Task|functional neuroimaging
75428963|NCT01493323|Procedure|Microcomputer|functional neuroimaging
75428964|NCT01493323|Procedure|blood sample|blood sample
75428965|NCT01493336|Drug|capecitabine RTD|single oral dose
75575587|NCT05655169|Other|Fixed orthodontic appliance|"After the levelling and alignment phase is completed, the rectangular stainless steel archwires (0.019 × 0.025) will be inserted, then after two weeks, the en masse retraction will be started via closed nickel-titanium coil springs applying 250 g of force per side."
75575588|NCT04634630|Genetic|Exposure to lung cancer stem cells|The exposure to lung cancer stem cells was measure as the percentage of Aldehyde dehydrogenase (ALDH) on all viable cells extracted from surgically resected tumor specimens
75575589|NCT02903589|Other|observational|
75575590|NCT05658406|Drug|Ringer's Lactate|infusion of 15 mL/kg/hour Ringer's lactate intraoperative
75575591|NCT05658406|Drug|Ringer's Lactate|infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
75575592|NCT05658406|Drug|Ringer's Lactate|infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
75575593|NCT05658406|Drug|normal Saline|standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
75575594|NCT05658367|Procedure|Aromatherapy massage with sesame- lavender oil mixed|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame- lavender oil mixed for 15 minutes with classical massage manipulations.
75575595|NCT05658367|Procedure|Aromatherapy massage with sesame oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame oil for 15 minutes with classical massage manipulations.
75428966|NCT01493336|Drug|capecitabine [Xeloda]|single oral dose
75428967|NCT01493336|Drug|capecitabine [Xeloda]|standard treatment
75428968|NCT01493388|Drug|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
75428969|NCT01493401|Procedure|Midurethral slings (MUS)|Retropubic, Transobturator, and Single incision MUS can be used.
75428970|NCT01493440|Drug|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
75575596|NCT05658367|Procedure|Massage with parraffin oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with paraffin oil for 15 minutes with classical massage manipulations.
75575597|NCT04319146|Procedure|robot-assisted radical prostatectomy|robot-assisted radical prostatectomy as first-line treatment
75575598|NCT04206592|Device|Oropharyngeal leak pressure during pneumoperitoneum.|Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
75575599|NCT02894697|Device|Angiography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
75428971|NCT01493479|Drug|90Y Ibritumomab tiuxetan|2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
76048709|NCT05648929|Procedure|Expander based breast reconstruction|implantation of 2 different expanders intraindividually
75428972|NCT01493479|Drug|Rituximab|"All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.~In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to <= 20% to enter the main treatment phase of the trial."
75428973|NCT01493518|Drug|AMG 557 or PLACEBO|Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.
75575600|NCT02894697|Device|Optical coherence tomography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
75726330|NCT00862004|Procedure|VATS|video-assisted thoracoscopic surgery (VATS) major pulmonary resection with systematic node dissection (SND) for clinical stage IIIA non-small cell lung cancer
75726331|NCT03846128|Biological|blood sample|blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1
75726332|NCT00859664|Other|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
75726333|NCT00859742|Procedure|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
75726334|NCT00618722|Drug|Deoxycholic Acid Injection|
75428974|NCT01493570|Drug|BI 409306|High dose film-coated tablet
75428975|NCT01493570|Drug|BI 409306|Low dose film-coated tablet
75428976|NCT01493570|Drug|BI 409306|Low dose film-coated tablet
75428977|NCT01493570|Drug|BI 409306 Placebo|Film-coated tablet
75428978|NCT01493570|Drug|BI 409306|Medium dose film-coated tablet
75428979|NCT01493609|Behavioral|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
75428980|NCT01493622|Drug|minocycline|variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
75726335|NCT00618722|Drug|Placebo|
75726336|NCT02546180|Other|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
76048710|NCT05648929|Procedure|Ultrasound of breast|Measurement of capsular thickness pre- expander removal
76048711|NCT05648929|Other|S(AE )monitoring|(S)AE evaluation will be performed from Visit 1 (Day 0 = Expander implantation) to Visit 15 (Day 168-196 = Reoperation) according to visit plan.
75428981|NCT01493622|Drug|placebo|variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
75428982|NCT01493635|Other|analgesic ladder|Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
75428983|NCT01493635|Other|analgesic ladder|Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
75428984|NCT01493648|Drug|Vitamin D|Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
75428985|NCT01493648|Drug|Placebo|Participants will receive placebo (lactose 100 mg) for 3 months.
75428986|NCT01493661|Other|Chronic Sleep Restriction|All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
76048712|NCT02357810|Drug|Pazopanib Hydrochloride|Given PO
76048713|NCT02357810|Drug|Oral Topotecan Hydrochloride|Given PO
76048714|NCT02357810|Other|Laboratory Biomarker Analysis|Correlative studies
75428987|NCT01493674|Dietary Supplement|folic acid|two 5-mg tablets of folic acid
75428988|NCT01493700|Procedure|heated circuit|use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
76048715|NCT04858243|Other|Home-Based ART|Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.
76048716|NCT04858243|Other|Facility-Based ART|Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.
76048717|NCT02357576|Drug|Intralipid 20% I.V. Fat Emulsion|
76048718|NCT01850446|Drug|Ergoferon|Safety and Efficacy
75428989|NCT01493700|Procedure|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
76048719|NCT01850446|Drug|Oseltamivir|Safety and Efficacy
76048720|NCT02465567|Drug|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
76048721|NCT02465567|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
76048722|NCT02465567|Drug|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
76048723|NCT02465567|Drug|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
76048724|NCT01644175|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
76048725|NCT01644175|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
75575601|NCT04634474|Behavioral|Suction|Is DAS an accurate pain descriptor for every application in intensive care unit?;. This question guides the study. This study was planned with the thought that the result may be misleading in applications such as eye care and aspiration that will trigger reflex movements in intensive care. In addition, creating new evidence on whether endotracheal suction is a painful application is the basis of the application.
75575602|NCT05658250|Device|CRE8 polymer-free Amphilimus-eluting stent|Percutaneous coronary intervention using a Cre8 stent for long lesions
76048726|NCT01644175|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
76048727|NCT02357420|Drug|Relamorelin|Double blind relamorelin was given subcutaneously BID for 12 weeks.
75428990|NCT01493713|Other|Evaluate the correlation of overall different objective response.|Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
75428991|NCT01493726|Drug|ALKS 9072, Low dose|IM injection, given monthly
75428992|NCT01493726|Drug|ALKS 9072, Med dose|IM injection, given monthly
75575603|NCT05469997|Behavioral|Mediterranean-Ketogenic Diet|In the MeDi-KD group, the participants will adhere to a modified Mediterranean-ketogenic diet. The ketogenic component of the diet will require limiting the intake of carbohydrates to about 10% of all calories consumed in a day, while obtaining most of the energy from healthy fats, mostly from plant-based sources (~70-75% of your daily caloric intake) and lean proteins (~15-20% of your daily caloric intake). The ketogenic ratio (the ratio of fat to carbohydrates) will be gradually increased during the first week from 1:1 to 3:1. The Mediterranean component of the diet will encourage the participants to consume more green leafy vegetables, nuts, and olive oil, while limiting the consumption of processed or fried food, red meat, full-fat dairy, and sweets.
75726337|NCT02546180|Other|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
75726338|NCT02544698|Biological|One dose of PCV13a vaccine|
75726339|NCT02544698|Biological|One dose of PCV13a vaccine|
76048728|NCT02357420|Drug|Placebo|Placebo given subcutaneously for 12 weeks.
76048729|NCT05648461|Radiation|Five fraction of post operative radiotherapy|Target volume will include tumor bed & ipsilateral level I-III levels.
76048730|NCT04856761|Drug|S-1|S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
75428993|NCT01493726|Drug|ALKS 9072, High dose|IM injection, given monthly
75428994|NCT01493726|Drug|Placebo|Dosed matched placebo IM injection, given monthly
75428995|NCT01493752|Dietary Supplement|beetroot juice|250mls daily beetroot juice
75428996|NCT01493765|Other|Simulator training with expert scoring|Residents will be trained using surgical simulation
75428997|NCT01493791|Drug|CDB-2914|
75428998|NCT01493817|Other|laboratory biomarker analysis|Correlative studies
75726340|NCT02544698|Biological|three doses of PCV13a vaccine|
75726341|NCT02544698|Biological|three doses of PCV13a vaccine|
76048731|NCT04856761|Drug|Capecitabine|Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
76048732|NCT01832038|Drug|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 [NCT01710657], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
76048733|NCT05648383|Behavioral|mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
75575604|NCT05469997|Dietary Supplement|Mediterranean diet supplemented with medium-chain triglyceride oil|"The participants will adhere to the Mediterranean diet. In addition, they will be asked to take two daily doses of medium-chain triglyceride oil (MCT oil).~The MCT oil supplement (Nutiva MCT oil, Nutiva Inc.) is approved by Health Canada (NPN: 80086912) and will be used according to its approved condition of use (i.e., source of medium-chain fatty acids which supports energy production in the body at a cellular level [ATP]). Each serving of this product provides 130 Calories from MCTs (14 g) with a C8-C10 ratio of 60:40. Nutiva MCT oil can be mixed into any beverage of choice, but cannot be used for cooking.~participants will start the intervention by taking 5 mL of MCT oil twice daily for the first day to acclimate their bodies to the supplement and gradually increase the dose to 14 g BID by the end of week 1. The participants may be asked to increase the dose to 20 mL of MCT twice daily if tolerability remains positive."
75726342|NCT03845816|Behavioral|Self-Compassion Scale (SCS) questionnaire|all included patients with chronic pain will answer the Self-Compassion Scale (SCS) questionnaire
76048734|NCT05648383|Behavioral|Standard care|Participants will receive standard care, including lifestyle recommendations.
75575605|NCT04633967|Drug|Alemtuzumab Injection|"This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol~Premedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion.~Premedication with 50 mg of prednisone orally for 5 days before the infusion.~During Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion.~Post Infusion Medication~Post-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion.~Post-medication with 50 mg of prednisone orally for 5 days after the infusion.~Medications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed"
75575606|NCT00560846|Dietary Supplement|Impact|Preoperative 5 day oral Impact and early post-operative enteral Impact
76048735|NCT05369689|Other|No interventions|As this is a prognosis evaluation study, there are no interventions.
75726343|NCT00862160|Device|ROCsafeTM|using minimized perfusion circuit while CABG
75726344|NCT00850148|Procedure|Anwar|Anwar surgical method
75726345|NCT00850148|Procedure|Melles|Melles surgical method
76048736|NCT01849588|Drug|Sorafenib|
76048737|NCT05648305|Procedure|Root Canal Treatment/ Re-treatment|The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
76048738|NCT02357342|Drug|Sirolimus|intravitreal injection
75428999|NCT01493830|Genetic|fluorescence in situ hybridization|
76048739|NCT02357342|Drug|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
75575607|NCT00560846|Dietary Supplement|Glucose load|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
76048740|NCT02271529|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
76048741|NCT02325518|Drug|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
75429000|NCT01493830|Genetic|gene expression analysis|
75429001|NCT01493830|Genetic|microarray analysis|
75429002|NCT01493830|Genetic|mutation analysis|
75429003|NCT01493830|Genetic|protein analysis|
75429004|NCT01493830|Other|immunohistochemistry staining method|
75429005|NCT01493830|Other|laboratory biomarker analysis|
75429006|NCT01493830|Other|microscopy|
75429007|NCT01493843|Drug|pictilisib|Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
75575608|NCT04634006|Device|Home-based transcranial direct current (tDCS) device|tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
75575609|NCT04633850|Drug|Dexamethasone|Intravenous dexamethasone 8 mg. Given once at the end of surgery.
75575610|NCT04633850|Drug|Bupivacain|"Bupivacaine dose according to weight. <60 kg: Total dose 100mg 60-90kg: Total dose 150mg >90kg: Total dose 200mg~Given once at the end of surgery."
75429008|NCT01493843|Drug|Placebo|Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
75429009|NCT01493843|Drug|bevacizumab|Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
75575611|NCT04633538|Device|Smartphone app|Use of smartphone app to measure 6 minute walk test (6MWT)
76048742|NCT02325518|Drug|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
75726346|NCT00862238|Behavioral|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
76048743|NCT02325518|Drug|Subject's habitual PGA monotherapy|
76048744|NCT02270983|Drug|Linaclotide 145 micrograms|
75429010|NCT01493843|Drug|carboplatin|Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
75429011|NCT01493843|Drug|paclitaxel|Paclitaxel will be administered at 200 milligrams per square meter (mg/m^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
75429012|NCT01493856|Drug|Cresto|tablet, rosuvastatin 20mg
75429013|NCT01493856|Drug|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
75429014|NCT01493856|Drug|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
75726347|NCT00862238|Other|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, & C
76048745|NCT02270983|Drug|Linaclotide 290 micrograms|
75429015|NCT01493869|Drug|cabozantinib|3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
75429016|NCT01493882|Drug|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
75429017|NCT01493882|Drug|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
75429018|NCT01493882|Drug|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
75429019|NCT01493882|Drug|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
76048746|NCT02270983|Drug|Placebo|Matching placebo
76048747|NCT02449889|Drug|highly purified human chorionic gonadotropin|
76048748|NCT02449889|Drug|recombinant human chorionic gonadotropin|
76048749|NCT01831804|Drug|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
76048750|NCT01831804|Drug|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
76048751|NCT02270671|Behavioral|ABMT|Attention Bias Modification Training
76048752|NCT02270671|Other|Placebo|Placebo Training
76048753|NCT04415164|Drug|Xueshuantong lyophilized powder|Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
75726348|NCT00860054|Dietary Supplement|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
75429020|NCT01493895|Device|standard hoem treatment|"All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method."
76048754|NCT04415164|Drug|Placebo|Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
76048755|NCT04415164|Other|Guidelines-based standard care|Guidelines-based standard care for acute ischemic stroke
75429021|NCT01493895|Device|LLLT-808 B-cure laser machine|"From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.~All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.~The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards."
75429022|NCT01493908|Drug|High price|Acetaminophen label as high price
75429023|NCT01493908|Drug|Low price|Acetaminophen label as low price
75429024|NCT01493908|Drug|Low price participants aware paying part|Acetaminophen label as low price; participants aware they are paying part of the full price
75429025|NCT01493908|Drug|No price|acetaminophen. No price - price issue not introduced to participants.
75429026|NCT01493908|Drug|Free of charge|Acetaminophen. participants aware the product is free of charge
75429027|NCT01493921|Drug|SR-T100 gel|Patient will be instructed to self-apply approximately 0.3~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
75429028|NCT01493921|Drug|Vehicle gel|Patient wil be instructed to self-apply approximately 0.3~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
75575612|NCT02903784|Device|fMRI|Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)
75726349|NCT00850226|Behavioral|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
76048756|NCT04875481|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
76048757|NCT04875481|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
75429029|NCT01493934|Drug|injection of 6-DIG|Unique injection dose of 92.5 MBq
76048758|NCT02324270|Drug|Diclofenac epolamine|Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
75429030|NCT01493973|Drug|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
75429031|NCT01493973|Drug|Placebo|Placebo
75429032|NCT01493986|Drug|Ropivacaine|Dosage. Onset time
76048759|NCT02324270|Other|Placebo|Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
75429033|NCT01493999|Drug|Clopidogrel reloading|Up to three times 600 mg clopidogrel
75429034|NCT01493999|Drug|Prasugrel|60 mg prasugrel in patients with HPR
75575613|NCT02903784|Procedure|tractography|Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)
75575614|NCT02903784|Other|neuropsychological examination|Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination
75575615|NCT04633382|Combination Product|Enhanced recovery after biliary tract surgery|Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
75575616|NCT02903628|Behavioral|eye health education|give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
75575617|NCT02903706|Other|Measure of Plasmodium prevalence (PCR)|
76048760|NCT02270515|Other|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
75429035|NCT01494012|Radiation|stereotactic body radiation therapy|Undergo SBRT
75575618|NCT04633733|Drug|HL237 tablet|HL237 400mg will be administered orally twice a day.
75575619|NCT04633733|Drug|tacrolimus capsule|tacrolimus 5mg will be administered orally once a day.
75429036|NCT01494012|Procedure|positron emission tomography|Undergo FDG-PET/CT
75575620|NCT02903745|Other|observational|
75878509|NCT04052100|Other|Multimodal prehabilitation|"The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App."
75878510|NCT04052178|Device|rTMS active and sham|Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
75429037|NCT01494012|Procedure|computed tomography|Undergo FDG-PET/CT
75429038|NCT01494012|Other|questionnaire administration|Ancillary studies
75429039|NCT01494012|Drug|fludeoxyglucose F 18|Undergo FDG-PET/CT
75575621|NCT04633265|Device|ECG-I Mapping of Atrial Fibrillation|Catheter ablation of Atrial Fibrillation guided by ECG-I
75575622|NCT05427942|Drug|Adalimumab|Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
75575623|NCT04632875|Behavioral|Loving-Kindness Meditation|Approximately 15-minute sessions are administered 6 days per week
75575624|NCT04632875|Behavioral|Relaxation Meditation|Approximately 15-minute sessions are administered 6 days per week
75575625|NCT05427903|Procedure|Cryotherapy|Ice packs application for 5 minutes after IANB injection
75575626|NCT05427903|Procedure|Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine|Buccal infiltration after IANB
75575627|NCT04633109|Procedure|taste bud biopsy|Taste buds will be surgically removed a) during a planned and medically induced elective surgery under full anesthesia; b) by local anesthesia in subjects without a medically induced surgery
75429040|NCT01494025|Behavioral|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
75429041|NCT01494077|Other|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
75575628|NCT04633109|Diagnostic Test|oral glucose tolerance test|75g glucose will be applied in drinking water following blood sample collection to evaluate glucose, insulin and C-peptide level.
75575629|NCT04633109|Diagnostic Test|Taste sensitivity|Subjects are given taste strips with 4 concentrations per each taste quality of sweet, sour, salty, bitter and umami in a pseudo-randomized manner. Subjects are asked to identify the taste quality, state the intensity, preference and certainty.
75575630|NCT04633109|Diagnostic Test|olfactory function|Subjects will be presented 16 different sniffing sticks in a randomized order, each for about 4seconds. People are then asked to identify the smell by choosing one out of 4 options (forced choice).
75575631|NCT04633109|Diagnostic Test|taste bud density|The number of taste buds on the anterior tongue will be determined by colouring the tongue surface with food colour. Taste buds will apply more reddish as compared to non-taste tissue. Based on a digital photography the number of taste buds per subjects is counted manually.
75575632|NCT04633109|Diagnostic Test|anthropometry|Anthropometric data collection will include measures of body height, body weight, arm-, upper- and lower leg circumferences, waist- and hip circumferences and a bioimpedance analysis to obtain data about body composition.
75575633|NCT04633109|Other|biospecimen collection|Blood and saliva samples will be taken as well as a tongue swab.
75575634|NCT04633109|Other|questionnaires|Through the use of several questionnaires, data about eating behavior, food preferences, life style factors and other will be obtained.
75429042|NCT01494090|Drug|Rosuvastatin|5 or 20 mg per day during 6 months
75429043|NCT01494090|Drug|Placebo|5 or 20 mg per day during 6 months
75429044|NCT01494116|Other|900 mL of 0.9% Normal Saline|"The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered."
75575635|NCT04633070|Behavioral|Gamification|Gamification (including, but not limited to a ranking system, badges and achievements, points, social media interaction, and leveling up) within mobile and web-based applications (also referred to as 'apps') for lifestyle modification (diet, physical activity, smoking cessation etc).
75575636|NCT05427747|Drug|cefotaxime|"One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~Decrease of peritoneal fluid PMN count to < 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture."
75575637|NCT04633031|Device|Boston|
75575638|NCT04633031|Device|Cheneau|
75575639|NCT04632914|Other|trunk stabilizing exercise|trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.
75575640|NCT04632914|Other|cardiac rehabilitation programe|all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
75726350|NCT00850226|Behavioral|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
75726351|NCT00862316|Device|Oxford Unicompartmental Knee|Knee Arthroplasty
75726352|NCT02544620|Other|Does fulfil of discharge criteria on the day of the surgery|
75429045|NCT01494155|Drug|Capecitabine|825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
75429046|NCT01494155|Drug|Hydroxychloroquine|400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
75726353|NCT02544620|Other|Does not fulfil of discharge criteria on the day of the surgery|
75726354|NCT02546258|Device|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
75429047|NCT01494155|Radiation|Proton or Photon Radiation Therapy|Daily, beginning Week 2 for 5 consecutive days
75726355|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
75429048|NCT01494168|Procedure|Bariatric surgery (Roux-en-y bypass or sleeve gastrectomy)|Bariatric surgery
75429049|NCT01494194|Other|Air Structuring Protein|A novel food protein preparation
75575641|NCT05427591|Procedure|"The chemomechanical caries removal agent BRIX3000® in group (1A)"|"In group(1A), the chemomechanical caries removal agent BRIX3000® was used for caries removal in primary molars."
75575642|NCT05427591|Procedure|The traditional surgical treatment in group (1C)|In group(1C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
75575643|NCT05427591|Procedure|"The chemomechanical caries removal agent Carie-CareTM in group (2B)"|"In group(2B), the chemomechanical caries removal agent Carie-CareTM was used for caries removal in primary molars."
75726356|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
75726357|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
75726358|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
75726359|NCT02544542|Device|Rectum cooling system|
75726360|NCT02544542|Device|Hyper-hypothermia blanket|
75726361|NCT00862472|Drug|DuoTrav APS|DuoTrav APS QD AM
75726362|NCT00862472|Drug|DuoTrav|DuoTrav QD AM
75726363|NCT00860210|Device|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
75726364|NCT00850304|Drug|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
75429050|NCT01494194|Other|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
75429051|NCT01494207|Behavioral|Wellness counseling|Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
75429052|NCT01494220|Device|Bispectral index monitoring (BIS)|BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
75429053|NCT01494246|Other|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
75575644|NCT05427591|Procedure|The traditional surgical treatment in group (2C)|In group(2C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
75575645|NCT04632602|Other|physiological effects of awake prone position in COVID 19 patients|"Study of physiological effects of awake prone position in COVID 19 patients on lung inhomogeneity assessed by Electrical Impedance Tomography (EIT), gas exchange and dyspnea score (Borg Scale).~Measurements will be performed at baseline (on supine position), then patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours. EIT records will be performed during the last 30 minutes of each period, blood gas and dyspnea score at the end of each period."
75429054|NCT01494259|Drug|Bupivacaine|Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
76048761|NCT02448875|Device|CyPass Micro-Stent|Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
76048762|NCT02448875|Device|Viscoelastic|Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
75429055|NCT01494259|Drug|Saline|Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
75575646|NCT02903316|Procedure|Fluids|
75429056|NCT01494285|Drug|ARK-E021 5%|Topically applied once daily at bedtime
75575647|NCT02903199|Dietary Supplement|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
75575648|NCT02903199|Dietary Supplement|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
75878511|NCT04052178|Device|PES active and sham|Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
75726365|NCT00850304|Drug|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
75726366|NCT00850382|Drug|Dasatinib|"Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
75726367|NCT00850382|Drug|daunorubicin|"Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3"
75726368|NCT00850382|Drug|Cytarabine|"Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours."
75878512|NCT04052178|Dietary Supplement|Capsaicin active and placebo|Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
75878513|NCT03645642|Drug|Midodrine|Midodrine 5 mg thrice daily
75429057|NCT01494285|Drug|ARK-E021 10%|Topically applied once daily at bedtime
75429058|NCT01494285|Drug|Placebo|Topically applied once daily at bedtime
75575649|NCT02903199|Dietary Supplement|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
75575650|NCT02903433|Other|High-intake avocados|Families will receive 14 avocados on a weekly basis.
75878514|NCT03645642|Biological|Albumin|Albumin 20g/l
75575651|NCT02903433|Other|Low-intake avocados|Families will receive 3 avocados on a weekly basis.
75575652|NCT02903433|Behavioral|Diet tips|Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.
75575653|NCT02903433|Behavioral|Avocado consumption advice|Recipe book with healthy recipe suggestions that include avocado.
75575654|NCT00445406|Drug|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
75575655|NCT00445406|Drug|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
75575656|NCT00445445|Other|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
75575657|NCT00445445|Other|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
75575658|NCT00445445|Procedure|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
75575659|NCT00445445|Procedure|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
75878515|NCT03645642|Drug|Diuretics|Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
75878516|NCT05284266|Procedure|Liposuction early|Liposuction 6-9 months after inclusion
75878517|NCT05284266|Procedure|Liposuction late|Liposuction 18-21 months after inclusion
75575660|NCT00445445|Procedure|study of high risk factors|"Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis."
75878518|NCT05284266|Other|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, including compression garment and exercise program, Self-care program"
75429059|NCT01494311|Drug|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
75429060|NCT01494311|Drug|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
75429061|NCT01494311|Drug|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
75575662|NCT00445523|Biological|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
75878519|NCT05284266|Other|Standard conservative treatment with Intermittent Pneumatic Compression (IPC)|Physical therapy, including compression garment and exercise program, Self-care program and Intermittent Pneumatic Compression (IPC)
75878520|NCT05284422|Procedure|Traditional Peripheral venous catheter insertion|Insertion of a short catheter in a peripheral vein with the help of visualization palpation
75878521|NCT05284422|Procedure|Ultrasound-guided insertion of a peripheral venous catheter|Insertion of a short catheter in a peripheral vein with the help of an ultrasound device
75575663|NCT00445523|Drug|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
75575664|NCT05427357|Other|Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)|"Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats."
75575665|NCT02903082|Biological|Residue of blood further to NFS|
75575666|NCT02903082|Biological|Residue of blood further to preoperative workup|
75575667|NCT02903082|Biological|Bone marrow collected during a myelogram carried out for hematological pathology workup|
75726369|NCT00860366|Drug|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
75726370|NCT00860366|Other|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
75878522|NCT03066609|Drug|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
75878523|NCT03066609|Drug|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
75429062|NCT01494311|Drug|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
75429063|NCT01494337|Procedure|HOLEP|USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
75429064|NCT01494337|Procedure|PVEP-XPS|Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
75429065|NCT01494363|Drug|Fluorouracil|5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
75429066|NCT01494363|Drug|Leucovorin|Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
75429067|NCT01494363|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
75429068|NCT01494363|Drug|Irinotecan|Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
75575668|NCT02903082|Biological|Bone marrow collected during myelogram routinely performed during hospitalization in ICU|
75575669|NCT00445562|Other|biologic sample preservation procedure|
75575670|NCT00445562|Other|informational intervention|
75575671|NCT02903004|Drug|Trabectedin|
75575672|NCT02903004|Drug|Pegylated Liposomal Doxorubicin|
75575673|NCT02903004|Drug|Topotecan|
75575674|NCT02903004|Drug|Gemcitabine|
75726371|NCT02544464|Drug|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
75726372|NCT02544464|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
75726373|NCT00862550|Other|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
75726374|NCT00862628|Drug|Rebamipide|100mg tid, 4 or 8 weeks
75726375|NCT00507442|Drug|VELCADE (bortezomib)|bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
75726376|NCT00507442|Drug|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
75429069|NCT01494402|Drug|D961S|Oral gelatine capsule
75429070|NCT01494402|Drug|Esomeprazole|Oral HPMC capsule
75429071|NCT01494402|Drug|Buffered acetylsalicylic acid|Tablet
75429072|NCT01494415|Drug|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
75429073|NCT01494415|Drug|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
75726377|NCT00507442|Drug|cyclophosphamide|cyclophosphamide 500 mg/m^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
75575675|NCT02903004|Drug|Weekly Paclitaxel|
76048763|NCT05648149|Behavioral|hierarchical multi-dimensional cognitive training scheme based on computer|The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
76048764|NCT05648071|Drug|Sintilimab|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus Bevacizumab until disease progression or intolerable toxicity.
75726378|NCT00507442|Drug|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
75726379|NCT00850616|Biological|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
76048765|NCT01831726|Drug|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
75726380|NCT00850616|Biological|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
75726381|NCT00862706|Drug|Telbivudine/LDT600A|Oral once daily
75575676|NCT02903004|Drug|Carboplatin|
75726382|NCT00860444|Behavioral|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
75726383|NCT00860444|Behavioral|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
75726384|NCT00860522|Drug|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
75575677|NCT00445718|Procedure|computed tomography|
75575678|NCT00445718|Procedure|3-Tesla magnetic resonance imaging|
75575679|NCT00445718|Procedure|Abdominal Sonogram|Sonogram of the abdomen area
75575680|NCT00445757|Procedure|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
75575681|NCT00445757|Radiation|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
75575682|NCT04699175|Drug|HR021618|Treatment group A:HR021618; high dose
75726385|NCT00860522|Drug|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
75726386|NCT02544386|Procedure|MRI and 3D CT scan|Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
75726387|NCT04041362|Biological|UB-421|Monoclonal antibody by IV infusion plus standard ART
75726388|NCT04041362|Other|Antiretroviral Therapy (ART)|Standard ART
75726389|NCT02546102|Biological|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
75575683|NCT04699175|Drug|HR021618|Treatment group B:HR021618; low dose
75726390|NCT02546102|Biological|Placebo|Control, autologous monocytes-enriched PBMC.
75726391|NCT00860678|Other|Physical activity|
75878524|NCT03066609|Drug|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
75575684|NCT04699175|Drug|Placebo|Treatment group C: HR021618 blank preparation.
75575685|NCT03277781|Other|Screening|Screening for AAA
75575686|NCT02902887|Device|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
75575687|NCT00445796|Drug|Artesunate|
75575688|NCT00445796|Drug|Amodiaquine|
75726392|NCT00860678|Other|no Intervention|
75575689|NCT01225822|Drug|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
76048766|NCT04868617|Device|ATTRACT-I|The aim of this investigation is to evaluate the performance and safety of an ostomy baseplate with a novel skin protection technology and its ability to reduce peristomal skin complications compared to SenSura® Mio. The subject will be randomized to either test product or comparator at enrollment. The subject will wear the test product for approximately 35 days and then cross-over to the comparator (or vice-versa) for approximately 35 days. At each baseplate change, the subject will answer questions about their skin, and take pictures of their stoma and used baseplate. They will also answer quality of life questionnaires at each study visit.
76048767|NCT05464069|Device|Nerivio|Nerivio is a Remote Electrical Neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
75878525|NCT03645486|Genetic|Infusion of lentiviral TYF-CGD-modified autologous stem cells|Infusion of lentiviral TYF-modified autologous stem cells at 1~10x10^6 gene-modified cells per kg body weight
75878526|NCT03646110|Procedure|Minimally invasive esophagectomy|Minimally invasive esophagectomy is a surgical procedure for esophageal resection
76048768|NCT01831258|Device|SensAwake On|
76048769|NCT01831258|Device|SensAwake Off|
76048770|NCT01849276|Drug|metformin hydrochloride|Given orally
75575690|NCT01225822|Drug|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
75575691|NCT01225822|Drug|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
75575692|NCT01225822|Drug|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
75575693|NCT01225822|Drug|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
75575694|NCT00445835|Other|Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
75575695|NCT00445835|Other|Conservative arm|Conservative medical approach
75878527|NCT05204043|Other|Peter Hess® sound massage|The Peter Hess® sound massage uses sound vibrations generated by therapeutic singing bowls. Peter Hess' methods act far from a traumatised area, far from the pain. It will be given on the patient's bed for 30 minutes.
75878528|NCT05204043|Other|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation in bed for 30 minutes.
76048771|NCT01849276|Drug|cytarabine|Given IV
76048772|NCT01849276|Other|laboratory biomarker analysis|Correlative studies
76048773|NCT02465489|Drug|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
76048774|NCT02465489|Drug|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
76048775|NCT01829464|Drug|Placebo|TAK-875 placebo-matching tablets
76048776|NCT01829464|Drug|TAK-875|TAK-875 tablets
76048777|NCT01829464|Drug|TAK-875|TAK-875 tablets
76048778|NCT04953923|Drug|Cedazuridine|Tablet for oral administration
76048779|NCT04953923|Drug|Placebo|Capsule for oral administration
75575696|NCT00445874|Drug|Ketotifen with a Contact Lens (no generic name)|
75575697|NCT02902731|Drug|PLACEBO|subcutaneous injection of placebo every day during 16 weeks
75575698|NCT02902731|Drug|ANAKINRA|subcutaneous injection of anakinra every day during 16 weeks
75726393|NCT00860756|Other|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
75878529|NCT05204043|Other|Questionnaires|"State Trait Anxiety Inventory (STAI)~Pain assessment - Visual Analogic Scale (from 0 to 10)."
76048780|NCT04953923|Drug|Moxifloxacin|Tablet for oral administration
76048781|NCT01847092|Drug|AZD1722|
76048782|NCT01847092|Drug|Placebo|Placebo for AZD1722
75575699|NCT00445913|Biological|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
75575700|NCT00445913|Biological|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
75575701|NCT02902926|Behavioral|Low FODMAPs Diet|Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
75575702|NCT02902926|Behavioral|Diet instruction|Answer the doubt and help the patient get the diet knowlege about the IBS.
75575703|NCT00445952|Other|clinical observation|
75575704|NCT00445952|Procedure|management of therapy complications|
75575705|NCT01225549|Drug|AZD5423|Suspension for nebulisation once daily 7 days
75575706|NCT01225549|Drug|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
75575707|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
75575708|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
75726394|NCT00850772|Dietary Supplement|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
75726395|NCT00850850|Drug|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
75726396|NCT00850850|Drug|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
75726397|NCT03845426|Other|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
75726398|NCT00860834|Behavioral|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
75726399|NCT00860834|Behavioral|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
75878530|NCT03611790|Device|NeVa VS|mechanical dilatation
75575709|NCT05469685|Drug|Vonoprazan|Potassium-competitive acid blocker
75878531|NCT05757921|Device|Perisolv (A)|Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.
75575710|NCT05469685|Drug|Amoxicillin|Antibiotic for H. pylori eradication
75575711|NCT02956772|Drug|TACE|After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
75575712|NCT02956772|Drug|Arsenic trioxide|Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
75726400|NCT00860912|Procedure|Collagen Matrix|surgical/reinforcing material
75726401|NCT00860990|Other|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
75726402|NCT00619892|Drug|quetiapine XR|Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.
75726403|NCT00619892|Drug|placebo|Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
75726404|NCT04040972|Other|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
75726405|NCT00507130|Biological|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
75726406|NCT00507130|Biological|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
75726407|NCT00507130|Biological|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
75726408|NCT00507130|Other|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
75726409|NCT00863096|Biological|Gardasil|HPV vaccine
75726410|NCT00863174|Drug|SPARC147709|SPARC147709 injection
75726411|NCT00863174|Drug|Reference147709|Reference147709 injection
75726412|NCT00870272|Drug|Misoprostol|400mcg misoprostol taken sublingually or buccally
75726413|NCT00863252|Drug|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
75726414|NCT00863252|Drug|angiotensin blockade|Continuation of angiotensin blockade
75575713|NCT04680234|Procedure|DMEP kit|Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C
75726415|NCT00503308|Procedure|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
75575714|NCT04680234|Device|Dermapen|Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
75575715|NCT01225159|Drug|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
75726416|NCT00870350|Biological|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
75878532|NCT05757921|Other|Standard (B)|Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
75878533|NCT03946761|Device|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
75878534|NCT02964234|Behavioral|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
75878535|NCT02964234|Behavioral|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
75429074|NCT01494415|Radiation|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
75429075|NCT01494480|Procedure|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
75878536|NCT03921255|Other|Cognitive Bias Modification|There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark & Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark & Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey & Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
75878537|NCT03645252|Procedure|Vein interruption before any other surgical manipulation|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner."
75429076|NCT01494519|Procedure|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
75726417|NCT00870350|Biological|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
75726418|NCT04040894|Biological|Teprotumumab|Treatment with 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
75726419|NCT00863564|Dietary Supplement|Caseine|
75726420|NCT00863564|Dietary Supplement|Cod|
75726421|NCT00863564|Dietary Supplement|Gluten|
75726422|NCT00863564|Dietary Supplement|Whey Isolate|
75429077|NCT01494519|Procedure|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
75429078|NCT01494558|Other|Chemoradiotherapy Regimen between PC and PE|etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
75878538|NCT03645252|Procedure|Arteries interruption before vein interruption|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above."
76048783|NCT01601821|Drug|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
76048784|NCT01601821|Drug|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
76048785|NCT02323646|Drug|Placebo|Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
76048786|NCT02323646|Drug|Telapristone Acetate|Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
76048787|NCT01846624|Drug|Decitabine|Given IV
75429079|NCT01494597|Drug|isavuconazole|oral
75429080|NCT01494597|Drug|cyclosporine|oral
75726423|NCT03893565|Drug|GSK2831781 - Double Blind Phase|GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
75878539|NCT03645174|Device|Using long tube|Fiberoptic-guided intubation through LMA, using long tube
75726424|NCT03893565|Drug|Placebo|Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
75429081|NCT01494623|Device|repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain regions.
75429082|NCT01494636|Drug|GSK2339345 (solution)|3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
75575716|NCT01225159|Drug|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
75575717|NCT00446069|Drug|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
75726425|NCT03893565|Drug|GSK2831781 - Open Label phase|GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
75726426|NCT00863642|Procedure|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
75726427|NCT00863642|Procedure|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
75726428|NCT00865358|Behavioral|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
75726429|NCT00502996|Drug|Methotrexate|>=15 mg po/week
75726430|NCT00502996|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
75878540|NCT03645174|Device|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
75878541|NCT03773328|Biological|CK0801|CK0801 (Cord blood-derived T-regulatory cells)
75878542|NCT03645018|Diagnostic Test|diagnosis with tomosynthesis|Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
76048788|NCT01846624|Drug|Midostaurin|Given PO
76048789|NCT05647915|Drug|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
75726431|NCT00865436|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
75726432|NCT00865436|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
75878543|NCT03644394|Device|Implantation of IMES sensors|Surgical implantation of IMES sensors during routine surgery to improve prosthetic control
75878544|NCT05203809|Device|TempTraq temperature monitor|All participants will wear both TempTraq temperature monitor and CORE temperature monitor.
75429083|NCT01494636|Drug|GSK2339345 (nebulised)|25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
75878545|NCT03644940|Diagnostic Test|CustomSight|Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
75429084|NCT01494636|Drug|Placebo (0.9% sodium chloride solution)|Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
75429085|NCT01494636|Drug|Lidocaine|40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
75429086|NCT01494675|Other|procalcitonin measurement|"The patients assigned to the procalcitonin group had procalcitonin and C reactive protein levels measured at day 0 (bacteremia), 5 or 7 (if positive blood culture) and then every 48 hours until hosptital discharge, death or until the antibiotics were stopped. A predefined procalcitonin protocol was used together with the clinical outcome, to guide the physician´s decision to discontinue antibiotics.~The procalcitonin protocol encouraged the physician to discontinue the antibiotics when: 1)procalcitonin dropped more than 90% from the baseline peak level or 2)an absolute value below 0,5ng/mL was reached. Cases in which the antibiotic treatment was continued against what the PCT values indicated were categorized as  antibiotic discontinuation overruling"
75429087|NCT01494688|Drug|Paclitaxel|Paclitaxel, at a dose of 80 mg/m^2 will be administered QW for up to 12 weeks.
75429088|NCT01494688|Drug|RO5509554|RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
75575718|NCT02902692|Other|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
75726433|NCT00870506|Behavioral|video|5-minute video compared (intervention) to no video and no other intervention (control)
75726434|NCT00870662|Device|AFS System|AFS System with patient specific flow rate
75726435|NCT00715403|Drug|BIBF 1120|
75726436|NCT01013584|Dietary Supplement|cholecalciferol|daily dose
75726437|NCT00863954|Device|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
75726438|NCT00864110|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
75726439|NCT00864110|Radiation|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
75878546|NCT03864081|Device|Phase Signal Recorder|The Phase Signal Acquisition (PSAQ) System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms. The PSAQ System consists of two components that work together to acquire and transmit the phase signals and patient specific data to a secured, cloud-based repository. The PSAQ System is comprised of: 1) the Phase Signal Recorder (PSR) which is a portable instrument, and 2) the Phase Signal Data Repository (PSDR) which is a cloud based data repository. Data collected during this study will not be used to guide treatment.
75878547|NCT01345188|Drug|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
75878548|NCT01345188|Drug|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
75726440|NCT00864110|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
75726441|NCT00864188|Dietary Supplement|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
75878549|NCT03852459|Drug|S-Ibuprofen|Topical Gel 5%
75429089|NCT01494701|Drug|nusinersen|Administered by intrathecal (IT) injection
75429090|NCT01494714|Drug|JNJ 10229570-AAA 1.2% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
75429091|NCT01494714|Drug|JNJ 10229570-AAA 2.4% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
75429092|NCT01494714|Drug|JNJ 10229570-AAA 3.6% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
75878550|NCT03852459|Drug|Vehicle|Vehicle Gel
75878551|NCT03580902|Behavioral|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
75429093|NCT01494714|Drug|Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
75429094|NCT01494714|Drug|Petroleum jelly|A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
75429095|NCT01494727|Drug|CJ Amlodipine/Valsartan 10/160mg|single dose
75429096|NCT01494727|Drug|Novartis Exforge 10/160mg|single dose
75429097|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
75429098|NCT01494740|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
75429099|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
75429100|NCT01494766|Dietary Supplement|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
75575719|NCT05464459|Procedure|Novel elbow procedure|A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.
75575720|NCT01224925|Procedure|Direct pulp capping with Dycal|Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling
75575721|NCT01224925|Procedure|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
75575722|NCT02902653|Drug|Oral misoprostol|hourly titrated misoprostol
75575723|NCT02902653|Drug|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
75575724|NCT02902653|Drug|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
75575725|NCT00446303|Drug|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."
75575726|NCT04680351|Procedure|phrenic stimulation|measurements of the hemodynamic effects of phrenic stimulation
75726442|NCT00864188|Dietary Supplement|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
75726443|NCT00864188|Dietary Supplement|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
75726444|NCT00864188|Dietary Supplement|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
75878552|NCT03580902|Drug|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
75429101|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
75429102|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
75429103|NCT01494792|Device|In Vitro Diagnositc aid for diagnosis|
75429104|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
75429105|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
75429106|NCT01494805|Other|Control (ranibizumab alone)|Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
75429107|NCT01494831|Behavioral|TF-CBT|15 sessions of group-based, trauma-focused cognitive behavioral therapy
75575727|NCT01223404|Drug|Placebo|Participants are administered a placebo patch and a placebo capsule
75575728|NCT01223404|Drug|Nicotine|Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
75575729|NCT01223404|Drug|Mecamylamine|Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
75575730|NCT00446342|Drug|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
75575731|NCT05657821|Dietary Supplement|Pumpkin seeds extract capsules|the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks
75575732|NCT00446381|Drug|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
75575733|NCT00446381|Drug|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
75575734|NCT04680273|Drug|[14C]-GDC-9545|Participants will receive a single oral dose of [14C]-GDC-9545 capsule, 30 milligrams (mg) (not more than [NMT] 4.6 megabecquerel [MBq]; 124 microcurie [μCi]) with approximately 240 millilitres (mL) water in the fasted state.
75575735|NCT04680273|Drug|GDC-9545 Solution for Infusion|Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
75429108|NCT01494844|Device|Respiratory monitor patient interface.|Wear each interface for 20 minutes
75575736|NCT04680273|Drug|GDC-9545/F12 Capsule|Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
75575737|NCT04680273|Drug|GDC-9545/F18 Capsule|Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
75575738|NCT00446420|Drug|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
75878553|NCT03644862|Device|etafill|Etafill is a HA formulation intended to be used in opthalmic anterior segment cataract surgery.
75878554|NCT03744390|Drug|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
75878555|NCT03644316|Device|BandGrip skin closure device|topical skin closure device
75726445|NCT05325749|Genetic|Screening|Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
75726446|NCT05325749|Genetic|Family history record|Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
75429109|NCT01494857|Drug|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
75429110|NCT01494870|Procedure|PCI|urgent PCI on admission
75429111|NCT01494883|Behavioral|Mindfulness Based Stress Reduction|A weekly training of eight sessions lasting two and a half hours.
75429112|NCT01494909|Dietary Supplement|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
75429113|NCT01494935|Behavioral|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
75429114|NCT01494935|Behavioral|Control diet|Normal fat, normal fat diet
75429115|NCT01494948|Other|allergen challenge|nasal challenges with antigen to which they are sensitive to
75575739|NCT00446498|Device|CPAP and Non Invasive Ventilation|
75575740|NCT04679922|Procedure|Soft Tissue Enhancement around dental implant|Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants *. Group II (Experimental Group): FLA **+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
75575741|NCT00446537|Procedure|Methylphenidate|
75575742|NCT05426889|Procedure|subdural hematoma burr hole drainage|For patients with larger hematoma, remove the hematoma by burr hole drainage
75575743|NCT05426889|Drug|drug conservative treatment|The patient did not receive surgical treatment and chose conservative treatment
75726447|NCT05325749|Other|Questionnaire survey|Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
75726448|NCT05325749|Genetic|Diagnostic|The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
75726449|NCT05325749|Genetic|Selective screening|The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
75726450|NCT00864266|Drug|Chemotherapy|Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
75726451|NCT00918515|Drug|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
75726452|NCT00865592|Drug|dutogliptin|dutogliptin 400 mg, once daily tablet
75878556|NCT03629145|Behavioral|Live Music Therapy|Investigator will begin play live guitar and voice music.
75878557|NCT03629145|Behavioral|Recorded Music Therapy|Investigator will play recorded music.
75878558|NCT05283876|Device|Excimer light|Excimer light sessions
75575744|NCT00446576|Drug|Epoetin Alfa|
75575745|NCT02902419|Other|Wound dressing removal.|
75575746|NCT00446615|Behavioral|computer decision support tool|
75429116|NCT01494961|Behavioral|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
75429117|NCT01494974|Device|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
75429118|NCT01494974|Device|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
75429119|NCT01495026|Drug|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
75429120|NCT01495026|Drug|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
75429121|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
75429122|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
75575747|NCT00446615|Behavioral|audit and feedback|
75575748|NCT00446615|Behavioral|group learning session|
75575749|NCT02902341|Dietary Supplement|Nutrition Therapy|Nutrition based on measured caloric needs.
75429123|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
75429124|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
75429125|NCT01495026|Drug|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
75575750|NCT02902341|Dietary Supplement|Control|Standard protocol nutrition based on calculated caloric needs.
75726453|NCT04084223|Other|Ultrasound|"An Ultrasound exam (not performed in routine care) will be performed at Baseline, 1, 3 and 6 months for protocol.~All patients will also have CRP dosage (for DAS28 assessment), RAPID-3 and PROs (performed in routine care but analyzed for the study)."
75726454|NCT00865670|Drug|Azithromycin Monohydrate 600 mg Tablets|
75726455|NCT00865670|Drug|Zithromax (azithromycin dihydrate) 600 mg Tablets|
75726456|NCT00864344|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
75726457|NCT00864344|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
75429126|NCT01495026|Drug|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
75429127|NCT01495026|Drug|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
75429128|NCT01495039|Drug|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
75726458|NCT00870974|Drug|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]F-PEB
75726459|NCT00864422|Behavioral|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
75429129|NCT01495052|Dietary Supplement|organic naked oat with whole germ (ONOG)|The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
75429130|NCT01495065|Drug|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
75726460|NCT00864422|Behavioral|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
75726461|NCT00864500|Drug|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
75429131|NCT01495065|Drug|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
75429132|NCT01495065|Drug|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
76048790|NCT05647915|Behavioral|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
76048791|NCT01829230|Device|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
75726462|NCT00864500|Drug|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
75726463|NCT02588963|Other|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
75726464|NCT02588963|Other|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
75429133|NCT01495065|Drug|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
75429134|NCT01495065|Drug|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
75878559|NCT05759715|Other|Iris Color Measurement , LF/HF Measurement|Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
75575751|NCT03277664|Behavioral|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
75575752|NCT02902302|Drug|Ibuprofen 400 mg/10 mL oral suspension|
75575753|NCT02902302|Drug|MOMENT 400 mg coated tablet|
75726465|NCT02588963|Other|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
75726466|NCT00864734|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
75878560|NCT03644784|Diagnostic Test|Standardized protocol for assessing aortic regurgitation using videodensitometry|Standardized protocol for assessing aortic regurgitation using videodensitometry
75429135|NCT01495065|Drug|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
75429136|NCT01495078|Procedure|Telemonitoring|"Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses."
75726467|NCT00864734|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
75726468|NCT04084691|Other|Physical exercice - moderate intensity|standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
75726469|NCT04084691|Other|Physical exercice - high intensity|standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
75726470|NCT04084691|Other|Physical exercice - workout|standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes
75726471|NCT04084691|Other|Normal meal|- Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.
75878561|NCT05283798|Device|IUD|Postpartum intra-caesarean section insertion of copper T380 versus multiload 375
75726472|NCT04084691|Other|Normalized meal|"- Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned."
75726473|NCT04084691|Other|Fasting|non meal in the hour before exercise
75726474|NCT00864812|Drug|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
75726475|NCT00864812|Drug|tiotropium|COPD patients treated with tiotropium
75878562|NCT02896296|Drug|RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
75878563|NCT03643614|Procedure|Injection of autologous regenerative cells of adipose tissue|Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
76048792|NCT02269657|Device|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
76048793|NCT04588714|Behavioral|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
75429137|NCT01495104|Drug|RO4917838|Multiple doses
75429138|NCT01495104|Drug|valproate|Multiple doses
76048794|NCT02269423|Biological|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
76048795|NCT02269423|Other|Placebo|Normal saline placebo.
76048796|NCT05647837|Diagnostic Test|lumper puncture|lumper puncture
75429139|NCT01495117|Drug|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
75429140|NCT01495117|Drug|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
75429141|NCT01495130|Procedure|ultrasound imaging|Undergo transrectal ultrasound
75429142|NCT01495130|Procedure|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
75726476|NCT02590055|Drug|gemcitabine/docetaxel combination|
75726477|NCT00864890|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
75429143|NCT01495143|Procedure|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
75726478|NCT00864890|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
75726479|NCT00919295|Drug|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
75726480|NCT00919295|Drug|placebo|placebo
75726481|NCT00865748|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
75726482|NCT00865748|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
75726483|NCT00865826|Other|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
76048797|NCT01827670|Drug|Stannous fluoride|Test dentifrice containing 0.454% SnF
76048798|NCT01827670|Drug|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate [1000 parts per million (ppm) fluoride]
76048799|NCT02267317|Drug|Eritoran|Pharmacologic inhibitor of TLR4 receptors.
76048800|NCT02267317|Drug|D5W|5% Dextrose Water = Vehicle
76048801|NCT01844830|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
75575754|NCT03277625|Procedure|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
76048802|NCT01844830|Drug|Placebo|Inactive ingredients supplied in identical nasal sprayer
75878564|NCT05262348|Device|adaptive DBS delivered through AlphaDBS IPG System|"The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive real-time fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable."
76048803|NCT05426473|Other|QuickDASH form|Patients have to complete these two forms, Quick DASH and SF-36, before surgery then 6 weeks after
75429144|NCT01495156|Drug|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."
75575755|NCT02902458|Other|Individual interview with a qualified psychologist|Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
75575756|NCT02957318|Dietary Supplement|FiberBind|Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
75575757|NCT02957318|Dietary Supplement|RG-I fiber|Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.
75878565|NCT05262348|Device|conventional DBS delivered through AlphaDBS IPG System|The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
76048804|NCT04874467|Procedure|Supportive periodontal therapy|"A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit."
76048805|NCT01827592|Drug|Elobixibat 10 mg|Elobixibat 10 mg/day
76048806|NCT01827592|Drug|Elobixibat 5 mg|Elobixibat 5 mg/day
76048807|NCT01827592|Drug|Placebo|Placebo
76048808|NCT02323334|Drug|LY3202626|administered orally
76048809|NCT02323334|Drug|Placebo (Part A, B, C)|administered orally
76048810|NCT02323334|Drug|Itraconazole|administered orally
76048811|NCT02448719|Drug|TAK-792 30 mg|TAK-792 30 mg was administered in the morning after a fast.
76048812|NCT02448719|Drug|TAK-792 30 mg placebo|TAK-792 30 mg placebo was administered in the morning after a fast.
76048813|NCT02448719|Drug|TAK-792 100 mg|TAK-792 100 mg was administered in the morning after a fast.
76048814|NCT02448719|Drug|TAK-792 100 mg placebo|TAK-792 100 mg placebo was administered in the morning after a fast.
76048815|NCT02448719|Drug|TAK-792 250 mg|TAK-792 250 mg was administered in the morning after a fast.
75575758|NCT02957318|Dietary Supplement|Placebo|Low-fiber control
75726484|NCT00865982|Drug|Docetaxel, Cisplatin, Capecitabine|"3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks."
76048816|NCT02448719|Drug|TAK-792 250 mg placebo|TAK-792 250 mg placebo was administered in the morning after a fast.
76048817|NCT02448719|Drug|TAK-792 500 mg|TAK-792 500 mg was administered in the morning after a fast or after breakfast.
75575759|NCT01223365|Drug|Hydrocodone ER|Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
75575760|NCT02956811|Drug|Dapagliflozin|SGLT2 inhibitor
75575761|NCT02956811|Drug|Placebo|Matching Placebo
75726485|NCT00866060|Drug|Memantine|20mg memantine
76048818|NCT02448719|Drug|TAK-792 500 mg placebo|TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
76048819|NCT02448719|Drug|TAK-792 750 mg|TAK-792 750 mg was administered in the morning after a fast.
76048820|NCT02448719|Drug|TAK-792 750 mg placebo|TAK-792 750 mg placebo was administered in the morning after a fast.
76048821|NCT02448719|Drug|TAK-792 1250 mg|TAK-792 1250 mg was administered in the morning after a fast.
76048822|NCT02448719|Drug|TAK-792 1250 mg placebo|TAK-792 1250 mg placebo was administered in the morning after a fast.
76048823|NCT02322866|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
76048824|NCT02322866|Drug|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
75726486|NCT00866060|Drug|Donepezil|10mg donepezil
76048825|NCT04198376|Procedure|Group A The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
76048826|NCT04198376|Procedure|Group B Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
76048827|NCT02463071|Drug|AZD0585|1g soft capsule
76048828|NCT02463071|Drug|AZD0585 placebo|1g soft capsule
75429145|NCT01495156|Drug|Placebo/Adjunctive SGA treatment|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."
75726487|NCT00866060|Drug|Placebo donepezil|Placebo donepezil
75726488|NCT00866060|Drug|Placebo memantine|Placebo memantine
75726489|NCT00871052|Drug|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
75726490|NCT00866138|Drug|masitinib (AB1010)|masitinib 9 mg/kg/day per os
75726491|NCT00502840|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
75878566|NCT03643536|Other|12-WPEP|The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
75878567|NCT03644706|Drug|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
75575762|NCT04319419|Dietary Supplement|Supplement with micronutrients|Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.
75575763|NCT04319419|Other|Nutrition education|Group received nutrition education program during 6 months
75575764|NCT05657782|Biological|PanChol|PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
75575765|NCT05426694|Other|Scapular clock exercises|In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
75429146|NCT01495169|Drug|iloperidone (oral tablet)|iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
75429147|NCT01495182|Other|Dietary fiber|A proprietary fiber will be given to subjects
75429148|NCT01495195|Drug|High-dose donepezil|Donepezil titrated to 22.5 mg daily
75575766|NCT05426694|Other|Stretching and strengthening exercises|Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
75575767|NCT00446693|Device|EndoFast Reliant™ system for Pelvic Organ Prolapse repair|The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
75575768|NCT04319029|Behavioral|Pharmaceutical care plan|"The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study."
75575769|NCT05657704|Drug|The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype|Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
75575770|NCT04319185|Other|Assistance to perform Peritoneal Dialysis (PD) at home|The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
75575771|NCT00446732|Device|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
75575772|NCT00446771|Drug|Mannitol|
75575773|NCT01222078|Biological|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
75575774|NCT03277586|Drug|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
75575775|NCT03277586|Drug|Placebo|Identically formulated and packaged inactive substance
75575776|NCT02902536|Other|No interventions|
75429149|NCT01495195|Drug|Low-dose donepezil|Donepezil titrated to 10 mg daily
75429150|NCT01495195|Drug|Selegiline|Transdermal selegiline, 6 mg daily
75429151|NCT01495195|Drug|Placebo|microcrystalline cellulose
75429152|NCT01495208|Drug|Aflibercept|intravitreal aflibercept injection 2mg
75429153|NCT01495260|Drug|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
75429154|NCT01495260|Drug|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
75429155|NCT01495260|Drug|vitamin E|vitamin E, 150-300 mg daily for 2 months
75429156|NCT01495273|Procedure|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
75429157|NCT01495273|Procedure|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
75429158|NCT01495299|Device|Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish|Phacoemulsification (standard cataract extraction surgery)
75575777|NCT04317157|Dietary Supplement|Caffeine|Specific dosage of caffeine for each participant (6 mg.kg-1).
75575778|NCT04317157|Other|Placebo|Placebo pill.
75575779|NCT04318873|Other|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
75575780|NCT04317079|Dietary Supplement|Hydroxytyrosol|Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
75878568|NCT03644706|Drug|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
75878569|NCT03740919|Drug|LY900014|Administered SC
75878570|NCT03740919|Drug|Insulin Lispro|Administered SC
75878571|NCT03740919|Drug|Insulin Glargine|Administered SC
75878572|NCT03740919|Drug|Insulin Degludec|Administered SC
75429159|NCT01495312|Device|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
75575781|NCT04317079|Other|Diet|Consultation by a dietitian was offered to all participants
75575782|NCT03277430|Procedure|Live donor uterus transplantation|Transplantation of uterus from a living donor.
75575783|NCT03277430|Procedure|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
75878573|NCT01335685|Drug|Ixazomib|Ixazomib capsules
75429160|NCT01495325|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
75429161|NCT01495325|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
75429162|NCT01495338|Drug|AC-170 0.17%|1 drop in one eye at one timepoint
75429163|NCT01495338|Drug|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
75429164|NCT01495338|Drug|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
75429165|NCT01495338|Drug|Olopatadine hydrochloride 0.2%/Tears Naturale II|1 drop in one eye at one timepoint
75575784|NCT03277430|Drug|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
75575785|NCT02902575|Procedure|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
75575786|NCT05657431|Other|essential oils (Ylang ylang oil)|inhaler aromatherapy
75575787|NCT05657431|Other|placebo (saline solutions)|placebo saline solutions
75575788|NCT05657431|Other|essential oils (lemon oil)|inhaler aromatherapy
75575789|NCT04699214|Drug|Endostar (recombinant human endostatin injection)|The experimental group is Endostar combined with AI
75575790|NCT04699214|Drug|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
75575791|NCT02902380|Drug|dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
75575792|NCT02902380|Drug|control group|0.9% saline infusion
75878574|NCT01335685|Drug|Melphalan|Melphalan tablets
75878575|NCT01335685|Drug|Prednisone|Prednisone tablets
75878576|NCT01335763|Drug|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
75878577|NCT02926209|Device|Aer-O-Scope (Colonoscopy)|"Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope."
75878578|NCT02926209|Procedure|Colonoscopy (Conventional Colonoscope)|"Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope"
75878579|NCT04466163|Behavioral|Schema Therapy and the Healthy Adult|The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen & Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
75575793|NCT03277235|Behavioral|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
75575794|NCT05426577|Diagnostic Test|ELISA, LAMP, Cytokine Release Assay|"IgG1 ELISA: ELISA that employs soluble Leishmania lysate or protein antigen.Results are recorded as antibody titres, which are measured by the absorbance values of products generated using enzyme conjugated anti-human antibodies.~Cytokine release assay (CRA): In this assay whole blood is stimulated for 24 hours with leishmania antigen. Cytokine levels are then assessed in the plasma fraction using flow cytometry with the BD™ Cytometric Bead Array for Human Cytokines or standard ELISA kits for human cytokines commercialized by Sigma-Aldrich (RAB0268-IL-2, RAB0222-IFN-g, RAB0224-IL-10, RAB0476-TNF-a, RAB0119-IP-10).~LAMP test for VL: We will use the LoopampTM Leishmania Detection Kit, CE-marked and produced Eiken Chemical Co., Japan."
75878580|NCT03635671|Diagnostic Test|Optical Coherence Tomography Angiography|Retinal scans will be acquired at each follow up visit
75878581|NCT04462965|Combination Product|Toripalimab|Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
76048829|NCT02266381|Procedure|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
76048830|NCT02266381|Procedure|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
76048831|NCT02266381|Procedure|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
76048832|NCT01827046|Drug|rt-PA|Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
75575795|NCT01221727|Drug|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
75575796|NCT01221727|Drug|Midazolam|All subjects will receive two oral dose administrations of midazolam.
75575797|NCT03277157|Dietary Supplement|B. lactis B94|A probiotic dose of 15 billion per capsule.
75575798|NCT03277157|Dietary Supplement|Placebo|Placebo capsule
75429166|NCT01495351|Drug|ABT-888/Bortezomib|ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
75429167|NCT01495364|Biological|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
75575799|NCT02902614|Procedure|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
75575800|NCT02902614|Procedure|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
75575801|NCT05657392|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment. Last few decades, it has been revealed that rTMS accelerates motor recovery and may reduce stroke-related symptoms.
75878582|NCT04462965|Combination Product|Temozolomide|Placebo：Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
76048833|NCT02356562|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir
75429168|NCT01495364|Other|placebo|matching placebo
75429169|NCT01495377|Drug|Remifentanil|Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
75429170|NCT01495377|Drug|Placebo|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
75429171|NCT01495377|Drug|Technetium|37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
76048834|NCT02356562|Drug|Sofosbuvir|tablet
76048835|NCT02356562|Drug|Ribavirin|tablet
76048836|NCT02448563|Behavioral|Nutrition and physical activity education|Eight weekly in-person groups
76048837|NCT02266225|Other|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
75575802|NCT05657392|Other|32 electrode electroencephalography (EEG)|32-electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting
75575803|NCT03277118|Device|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
75575804|NCT01221181|Drug|Eculizumab|Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
75575805|NCT05657314|Dietary Supplement|Active Comparator|Consists of 15 grams of pea protein
75429172|NCT01495377|Device|Dynamometer (Jamar)|portable hydraulic hand dynamometer to assess grip strength.
75429173|NCT01495429|Procedure|Central venous catheter|Placement of a peripherally inserted central venous catheter
75575806|NCT03277079|Drug|statin + ezetimibe|Combination of two drugs
75429174|NCT01495429|Procedure|Central venous catheter|Placement of a centrally inserted central venous catheter
75429175|NCT01495442|Device|modified Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
75575807|NCT03277079|Drug|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
75575808|NCT05657236|Other|medical treatment|traditional medical treatment and regular follow-up
75878583|NCT01339585|Device|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
75878584|NCT04004325|Drug|FT-4101|FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
75429176|NCT01495442|Device|standard Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
75575809|NCT05657236|Other|plyometric exercise|Each session starts with a 5-minute warm-up of flexibility exercises (active range motion and stretching exercises).The main plyometric exercise set will be applied for 20-30 minutes and consisted of 10 exercises directed at the lower body that gradually progress by increasing the set/repetition number in two exercise blocks, each continue for 1 month .The cool down period is 5 minutes and includes walking at self-preferred speed and static stretches of the major muscle groups.
75575810|NCT02902224|Dietary Supplement|Tap water|300ml tap water via nasogastric tube
75575811|NCT02902224|Dietary Supplement|Glucose|300ml tap water with 75g glucose via nasogastric tube
75878585|NCT04004325|Drug|FT-4101 placebo|FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
75878586|NCT04004325|Other|Deuterated Water|Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
75878587|NCT05208489|Other|there is no intervention involved in this study|there is no intervention involved in this study.
75878588|NCT05185063|Diagnostic Test|Point of Care blood test|The pH will be incorporated into the MIRACLE2 score in a pre-hospital setting. The patients will continue to be treated with standard of care.
76048838|NCT02354690|Drug|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
75878589|NCT01339663|Drug|cyclophosphamide|Given IV
75878590|NCT01339663|Biological|aldesleukin|Given SC
75878591|NCT01339663|Biological|autologous tumor cell vaccine|Receive T-APC via IV
76048839|NCT02354690|Drug|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
76048840|NCT02354690|Drug|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
75575812|NCT02902224|Dietary Supplement|Fructose|300ml tap water with 25g fructose via nasogastric tube
75575813|NCT01220557|Behavioral|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
75575814|NCT01220557|Behavioral|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
75575815|NCT04317001|Drug|Modafinil|Treatment will be with 100mg of modafinil for the two week primary phase of the study
75575816|NCT04317001|Drug|Placebo|placebo
75575817|NCT03277040|Other|CSA membership|Bi-weekly fresh food delivery
75878592|NCT01339663|Other|laboratory biomarker analysis|Correlative studies
75878593|NCT01339663|Other|immunologic technique|Correlative studies
75878594|NCT01339663|Other|immunohistochemistry staining method|Correlative studies
75878595|NCT01339663|Genetic|polymerase chain reaction|Correlative studies
75878596|NCT01339663|Biological|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
75878597|NCT03066999|Procedure|Cystoscopy|Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
75878598|NCT03066999|Device|DirectVision|Patients will assign to either Group DirectVision (catheter placement via DirectVision)
75878599|NCT00092599|Drug|MK0653, ezetimibe|
76048841|NCT02354690|Drug|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
75878600|NCT00092599|Drug|Comparator: ezetimibe, placebo|
75878601|NCT01335841|Device|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
75878602|NCT03737565|Device|Optimax stent®|Percutaneous coronary intervention with Optimax stent®
75878603|NCT02889133|Drug|Iron-dextran|Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
76048842|NCT02354222|Drug|Canagliflozin|
76048843|NCT02354222|Drug|Teneligliptin|
76048844|NCT02354222|Drug|Placebo|
75575818|NCT02887339|Other|Training Website|Additional training website can be found at gtextraing.org
75575819|NCT02887339|Other|Control|Standard training given by OPOs and GTEx staff
75575820|NCT05426499|Drug|Patients requiring cefotaxime treatment|Dosage according to SmPC
75575821|NCT05426499|Drug|Patients requiring meropenem treatment|Dosage according to SmPC
75575822|NCT05426499|Drug|Patients requiring fluconazole treatment|Dosage according to SmPC
75575823|NCT05426499|Drug|Patients requiring isavuconazole treatment|Dosage according to SmPC
75575824|NCT05426499|Drug|Patients requiring anidulafungin treatment|Dosage according to SmPC
75575825|NCT05658094|Device|Exosome|Each patients will receive 4 injection with an interval of 14 days during two months
75575826|NCT01220401|Behavioral|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
75878604|NCT02889133|Drug|Saline|Salt water IV - 500 mL, one pint normal saline.
76048845|NCT04904276|Drug|Fostamatinib|Fostamatinib disodium
76048846|NCT02353442|Other|Posterior shoulder mobilizations|A second investigator performed 5min of posterior capsule shoulder mobilization for the experimental group, 3times/week during 4 weeks.
76048847|NCT02353442|Other|External rotators strengthening|Individuals performed 3x10 repetitions of external rotators strengthening in sidelying position 3times/week during 4 weeks.
76048848|NCT02353442|Other|Placebo ultrasound|A second investigator performed 5min of placebo ultrassound for the control group, 3times/week during 4 weeks.
75429177|NCT01495468|Biological|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
75429178|NCT01495494|Device|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
75575827|NCT00446810|Drug|Benfotiamine|
75575828|NCT00446810|Drug|Placebo|
75878605|NCT02889133|Procedure|Blood Donation|Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
75878606|NCT02889133|Procedure|24-hour PTR|"The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation."
75878607|NCT01333423|Drug|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
75878608|NCT01333423|Drug|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
75429179|NCT01495494|Device|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
75429180|NCT01495507|Procedure|MPFL- Reconstruction|
75429181|NCT01495520|Drug|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
75429182|NCT01495520|Drug|Placebo|os, pill, b.i.d., 30 days
75575829|NCT05657197|Behavioral|Exercise intervention|A 12-week exercise program consisting of three times per week 1-hour sessions, including 30-minutes aerobic- and 30-minutes progressive resistance training. The intensity of training will be adjusted to each individual, based on a cardiopulmonary exercise test. Training sessions will be performed in groups of 10 participants under supervision of a sports physical therapist.
75575830|NCT05657197|Other|Usual care|Usual care, including general advice concerning chronic fatigue.
75575831|NCT00446888|Behavioral|Standardized Meals for Diet Stabilization|Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
75575832|NCT00446888|Dietary Supplement|Forticare|400 ml of commercially-available nutritional supplement.
75575833|NCT00446888|Dietary Supplement|Product 4808|400 ml Forticare, to which has been added extra protein and the amino acid leucine.
75575834|NCT02887300|Behavioral|Mantra Meditation|"Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
75575835|NCT05657158|Other|Brolucizumab|Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included
75429183|NCT01495546|Other|Early loading|Patients stepping down immediately after THA
75429184|NCT01495546|Other|Late loading|Patients stepping down after three weeks of HTA
75429185|NCT01495624|Other|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
75575836|NCT01220167|Drug|Ondansetron 8 mg ODFS without water|Single dose of Ondansetron 8 mg (ODFS) administered without water
75575837|NCT01220167|Drug|Ondansetron 8 mg ODFS with water|Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water
75575838|NCT01220167|Drug|Zofran ODT (ondansetron 8 mg) without water|Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water
75429186|NCT01495624|Other|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
75575839|NCT00447044|Behavioral|Resistance Exercise|Subjects will lift weights with their legs.
75575840|NCT00447044|Dietary Supplement|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
75575841|NCT00447044|Dietary Supplement|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
75575842|NCT02902185|Drug|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
75575843|NCT02902185|Drug|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
75575844|NCT00447161|Drug|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10^9 of Bacillus clausii spores, orally suspension in water
75726492|NCT00515008|Behavioral|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
75878609|NCT03554187|Device|Ultrasonic periodontal Debridement, with appropriate device|Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.
75878610|NCT03554187|Biological|Analyzes of periodontopathogenic bacteria|Collection of plaque, to analyze the bacteria in the pocket
76048849|NCT02353442|Other|Scapular squeezing|Individuals performed 3x10 repetitions scapular squeezing exercise 3times/week during 4 weeks.
76048850|NCT02353442|Other|Upper trapezius stretching|Individuals performed 3x30s of upper trapezius stretching, 3times/week during 4 weeks.
76048851|NCT02353442|Other|Posterior Capsule Stretching|Individuals performed 3x30s of posterior capsule stretching, 3times/week during 4 weeks.
76048852|NCT02351960|Drug|Dexlansoprazole|Dexlansoprazole capsules
76048853|NCT02351180|Drug|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
76048854|NCT02351180|Drug|Placebo|Placebo will serve as a control treatment
76048855|NCT02350478|Drug|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
76048856|NCT02350478|Drug|Placebo|The subject will receive placebo orally once daily for 12 weeks.
76048857|NCT02349542|Drug|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
75575845|NCT00447161|Drug|Placebo|Matched placebo
75575846|NCT00447200|Procedure|Esophagus Doppler monitoring|
75575847|NCT00447200|Procedure|Fluid optimization|
75575848|NCT00447239|Procedure|glucontrol (insulin therapy)|
75575849|NCT02901873|Device|Electrical Impedance Spectroscopy|
75575850|NCT00447317|Behavioral|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
75575851|NCT00447317|Behavioral|Attention control|Standard peritoneal dialysis dietary education
75575852|NCT05425914|Drug|Vitamin D|New treatment option for dry eye patients with low serum vitamin D Level
75575853|NCT05425914|Drug|Artificial tear|Conventional dry eye treatment
75575854|NCT00447356|Drug|recombinant interferon alfa|
76048858|NCT02321930|Drug|tofacitinib 5mg po bid|
76048859|NCT01647542|Drug|TAK-875|TAK-875 tablets
76048860|NCT01647542|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
76048861|NCT02321462|Drug|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
76048862|NCT02321462|Drug|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
75878611|NCT03554187|Genetic|IL1B test|susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)
75878612|NCT03554187|Biological|Salivary Sampling|Salivette to chew. To analyse salivary microbiota
75878613|NCT03554187|Device|Halitosis measure|With appropriate device : halimeter
75878614|NCT01333579|Other|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
75575855|NCT02902068|Device|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
75575856|NCT00447434|Drug|Natto extract (Nattokinase)|
75575857|NCT00447473|Drug|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
76048863|NCT02391584|Device|XprESS|Balloon dilation of the Eustachian tube
76048864|NCT02391584|Other|Control|Continued medical management
76048865|NCT02266147|Drug|SD-101|
76048866|NCT02266147|Radiation|Radiation therapy|
76048867|NCT04873843|Behavioral|Functional digital game training group|Functional digital game training group is divided in 16 participants. In one session, participants in the functional digital game training group completed 40 minutes of intervention using various functional digital game such as working memory, memory, and attention. (Total 10 session)
76048868|NCT04873843|Behavioral|Individual cognitive training|Functional digital game training group is divided in 16 participants. In one session, participants in the individual cognitive training group completed 40 minutes of intervention using various cognitive training such as working memory, memory, and attention. (Total 10 session)
76048869|NCT05647135|Other|Medical food|enteral formulas with different protein composition
75878615|NCT00092209|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium|
76048870|NCT05402917|Procedure|Erector Spinae Plane Block|Interfascial plane (area) blocks are blocks in which the local anesthetic agent is injected into the potential area between the two fasciae. The ESPB we used in our study is a member of interfascial plane blocks. The erector is applied between the spinal muscle and the transverse process, spreading the drug from the injection site to both cranial and caudal. Unlike other defined interfascial plane blocks, ESPB can show paraspinal block characteristics since the injection site is above the transverse process.
76048871|NCT02264977|Device|GORE® TAG® Thoracic Branch Endoprosthesis|
76048872|NCT02264821|Drug|ropivacaine infiltration|wound infiltration
76048873|NCT02264821|Drug|intrathecal morphine|100 µg added to the spinal anaesthesia
76048874|NCT02264821|Drug|placebo|placebo in spinal anaesthesia and in wound infiltration
76048875|NCT05386147|Device|Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)|see arm description
75878616|NCT00092209|Drug|Comparator: placebo, losartan, hydrochlorothiazide|
75878617|NCT04399473|Behavioral|Pain Neuroscience Education (PNE)|Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
75878618|NCT01339741|Dietary Supplement|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
75878619|NCT01339741|Drug|Placebo|Placebo, oral route, 12 weeks
75429187|NCT01495650|Behavioral|Tailored program of PA and nutritional counseling|Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
75429188|NCT01495663|Drug|I-131-CLR1404|"Description:~Dosimetry: IV, 5 mCi, single dose, 6-day duration~Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"
75429189|NCT01495715|Drug|Idebenone|
75429190|NCT01495715|Drug|Placebo|
75429191|NCT01495728|Procedure|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
75429192|NCT01495728|Procedure|Sham Manipulation|Mid and Upper Thoracic Spine
75429193|NCT01495754|Other|coffee|Comparison of different amounts of coffee
75429194|NCT01495767|Other|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
75429195|NCT01495780|Behavioral|Remote Health Monitoring|1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
75429196|NCT01495806|Drug|Glucomannan|2 x 5g
75429197|NCT01495806|Drug|placebo|glucose 5 g
75429198|NCT01495832|Other|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
75429199|NCT01495832|Other|Control Group|The control group will consume comparator foods for 12 weeks.
75429200|NCT01495845|Other|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
75429201|NCT01495871|Dietary Supplement|Amino Acids|15 grams amino acids two times per day for 6 weeks
75429202|NCT01495871|Dietary Supplement|Placebo of inert compounds|Placebo two times per day for 6 weeks
75429203|NCT01495871|Dietary Supplement|Valine|2.5 grams valine supplementation two times a day for 6 weeks
75429204|NCT01495884|Drug|non-pegylated liposomal doxorubicon (Myocet™)|
75429205|NCT01495884|Drug|Lapatinib (Tyverb™)|
75429206|NCT01495897|Device|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
75429207|NCT01495897|Device|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
75575858|NCT00447473|Drug|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
75878620|NCT05184829|Other|selective lymph node dissection|selective lymph node dissection
75429208|NCT01495910|Drug|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
75575859|NCT00447473|Drug|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
75575860|NCT05425602|Drug|MAX-40279-01: 50mg/70mg|[Stage 1]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. [Stage 2]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.
76048876|NCT04854889|Drug|Decitabine|Demethylating agents
76048877|NCT02261467|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
75429209|NCT01495936|Procedure|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
75429210|NCT01495936|Procedure|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
75429211|NCT01495949|Drug|etomidate|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
75429212|NCT01495949|Drug|thiopentone|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
75429213|NCT01495962|Drug|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
75429214|NCT01495962|Drug|Placebo|Placebo (Normal Saline)
75429215|NCT01496001|Procedure|Lumpectomy, axillary block dissection, breast conserving surgery|Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.
75429216|NCT01496001|Other|Radiotherapy|Adjuvant radiotherapy carried out by institutional protocols.
75429217|NCT01496040|Drug|rAAV2/4.hRPE65|"One injection in on eye~Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP~Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.~Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP."
75429218|NCT01496053|Dietary Supplement|AndoSan|AndoSan 30 ml x 2 for 21 days
75429219|NCT01496053|Dietary Supplement|Sugar Extract|Sham comparator
75429220|NCT01496092|Drug|Keto Acid|12 tablets per day
76048878|NCT02261467|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
75429221|NCT01496105|Drug|Lidocaine|
75429222|NCT01496105|Drug|saline|
75429223|NCT01496144|Procedure|Manual therapy and active exercises|"Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises"
75429224|NCT01496144|Procedure|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
75429225|NCT01496170|Drug|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
76048879|NCT05646823|Dietary Supplement|Probiotic blend|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
76048880|NCT05646823|Dietary Supplement|Placebo|vehicle only - Maltodextrin gluten free
76048881|NCT05646667|Other|interscalene with Erector spinae plane block group|patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and US guided Erector spinae plane block at T2 using 10 ml of bupivacaine 0.5%.
76048882|NCT05646667|Other|Interscalene group|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
75429226|NCT01496170|Drug|Placebo|Placebo capsules, orally, once per day for 7 days
75575861|NCT00447512|Drug|ghrelin|acylated ghrelin
75429227|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
75429228|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
75575862|NCT00553488|Drug|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
75575863|NCT00553488|Drug|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
75575864|NCT00447551|Drug|Poly-L-Lactic Acid|Deep dermal injection
75726493|NCT00515008|Behavioral|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
75726494|NCT03326830|Device|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher&Paykel, New-Zealand).
75726495|NCT03326830|Device|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
75726496|NCT01013662|Procedure|glycemic control|exogenous insulin
75726497|NCT01011790|Behavioral|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
75726498|NCT00514540|Drug|Docetaxel|75 mg/m^2 IV over 60 Minutes on Day 1 of 21 day cycle.
75726499|NCT00514540|Drug|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.
75878621|NCT05184829|Other|Systemic Lymph Node Dissection|Systemic Lymph Node Dissection
75575865|NCT00447629|Drug|PPM-204|
75575866|NCT00553527|Procedure|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
75575867|NCT00447668|Behavioral|Yoga|Yoga for back pain
75575868|NCT00447668|Behavioral|Exercise|exercises for back pain
75575869|NCT00447668|Behavioral|Self-care book recommendations|Self-care book for back pain
75575870|NCT05425407|Dietary Supplement|whey protein|Daily 45g of whey protein supplementation during a three week eccentric training period
75575871|NCT05425407|Dietary Supplement|whey protein + collagen peptide|Daily 15g of whey protein and 20g collagen peptide supplementation during a three week eccentric training period
75726500|NCT00514540|Drug|Etoposide|120 mg/m^2 daily for 3 days of 21 day cycle.
75726501|NCT00514540|Drug|Cisplatin|25 mg/m^2 for 3 days of 21 day cycle.
75878622|NCT01482195|Biological|Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.
75878623|NCT01341613|Dietary Supplement|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
75878624|NCT01341613|Dietary Supplement|Placebo capsule|Twice per day (BID), 9 weeks
75575872|NCT00447707|Behavioral|Positive Choice|
75878625|NCT00003777|Drug|amifostine trihydrate|
75429229|NCT01496209|Biological|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
75429230|NCT01496209|Biological|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
75429231|NCT01496235|Dietary Supplement|Dark chocolate|Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
75878626|NCT00003777|Drug|cisplatin|
75429232|NCT01496235|Dietary Supplement|White chocolate|Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
75429233|NCT01496261|Drug|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
75878627|NCT00003777|Drug|fluorouracil|
75878628|NCT00003777|Procedure|surgical procedure|
75878629|NCT00003777|Radiation|radiation therapy|
75878630|NCT01339819|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
75429234|NCT01496261|Drug|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
75575873|NCT03455322|Drug|norepinephrine versus midodrine & octreotide|either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6h.
75575874|NCT00447746|Procedure|D1 or D2 lymphadenectomy for gastric cancer patients|
75429235|NCT01496300|Procedure|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
75575875|NCT05425368|Drug|Silver diamine fluoride|First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
75575876|NCT05425368|Drug|Mineral trioxide aggregate|First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.
75726502|NCT03121534|Drug|Blinatumomab|"Patients will receive blinatumomab as a continuous IV infusion, commencing on day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week .~blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28. This will be followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days.blinatumomab treatment-free interval."
75726503|NCT03121534|Drug|Dexamethasone|Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
75429236|NCT01496300|Procedure|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
75429237|NCT01496326|Drug|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
75429238|NCT01496326|Drug|placebo|2 grams of placebo cream for 14 days
75429239|NCT01496339|Biological|MenSCs transplantation|1×10^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
75429240|NCT01496339|Drug|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
75878631|NCT01339819|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
75878632|NCT05208255|Other|Exercise|"NEP is a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercises are progressed from simple to complex tasks. Varied equipment (such as different sized balls, rackets, tulles, exercises balls, eye bands, ropes etc.) is used during different exercises containing cross-limb movements, throwing, jumping, walking, and cognitive tasks. Although the stages of the NEP and exercise selection are the same for each participant, the use of materials or cognitive tasks selection may differ according to the age and skill of the participant. The cognitive tasks were performed by using different visual (colored cards, numbered cards etc.) or auditory cues.~Motor Imagery Program: Motor imagery (MI) is a dynamic mental state during which the representation of a given motor movement is rehearsed in working memory without overt motor output. MI training will be performed in the form of imagined NEP exercises in the last 15 minutes of the session."
75878633|NCT02963922|Drug|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
75878634|NCT02963922|Drug|Placebo|Injected subcutaneously (s.c., under the skin) once daily
75575877|NCT02901522|Other|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
75575878|NCT02901522|Other|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
75575879|NCT02901522|Other|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
75726504|NCT03121534|Drug|Ibrutinib|Ibrutinib treatment will commence on cycle 1, day 1 at 420mg/d. Dose reductions to 280mg/d or 140mg/d are allowed per treating physician discretion, but the reason must be documented in the medical record. Ibrutinib will be given continuously until disease progression or toxicity.
75575880|NCT02901522|Other|Teleconsultation|The general practioner received phone call to asthma care.
75575881|NCT00447824|Procedure|Introduction of better conditions during blood sampling|
75575882|NCT04681326|Device|biological prosthesis|retro-muscular positioning of a swine dermal collagen prosthesis
75726505|NCT03121534|Drug|Nivolumab|Patients will receive nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.
75726506|NCT01012102|Biological|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
75726507|NCT01012102|Biological|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
76048883|NCT01643473|Behavioral|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
76048884|NCT01643473|Other|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
76048885|NCT05646277|Other|e-Consultation|first orthodontic consultation in remote
76048886|NCT05646277|Other|Consultation|first orthodontic consultation in face-to-face
75429241|NCT01496378|Behavioral|Problem-Solving Skills Training|Parents will receive 8, 1-hour sessions of individual problem-solving therapy over 8 weeks. Caregivers will complete the first training session and at least 3 subsequent sessions in person. Remaining sessions will be completed via telephone. In session 1, parents will be introduced to the PSST program and a rationale and explanation for problem solving strategies will be provided. During sessions 2-8, parents will identify a problem that they wish to work on. The therapist will use the primary cognitive-behavioral strategies of modeling, behavioral rehearsal, performance feedback, and generalization of skills in the process of teaching problem solving skills to parents. Parents will complete homework assignments to practice using the problem-solving skills in real-life situations
75429242|NCT01496404|Procedure|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
75429243|NCT01496404|Procedure|Scalpel|Incising skin (epidermis and dermis) with scalpel.
75726508|NCT01012102|Biological|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
75726509|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
75726510|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
76048887|NCT05344651|Device|Surgery/implantation|The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
76048888|NCT05341843|Drug|sertraline|sertraline at the intended dose of 50 mg twice daily for 8 weeks.
75429244|NCT01496417|Drug|Belatacept|Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
75429245|NCT01496443|Drug|TAK-875 and Glimepiride|
75429246|NCT01496482|Other|Only measurements done on subjects in both groups.|As study compared specific diagnostic procedures, no intervention was done or compared.
75429247|NCT01496495|Drug|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
75575883|NCT00447863|Drug|Levonorgestrel/Ethinyl Estradiol|
75575884|NCT02901600|Other|Detection of the expression of DMTB1 by immunohistochemistry|
75575885|NCT00447941|Drug|SCA-136|
75575886|NCT05425329|Dietary Supplement|I3.1|Capsule containing bacterial strains Lactobacillus plantarum (CECT7484 and CECT7485) and Pediococcus acidilactici (CECT7483) at a ratio of 1:1:1.
75575887|NCT05425329|Dietary Supplement|Placebo treatment|Capsule containing maltodextrin.
75575888|NCT00448097|Drug|cetuximab|No verifiable data available, PI relocated
75575889|NCT00448097|Drug|docetaxel|No verifiable data available, PI relocated
75726511|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
75726512|NCT01013818|Drug|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
75726513|NCT01013896|Behavioral|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
76048889|NCT05341843|Drug|placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
76048890|NCT02320058|Drug|Ipilimumab|
75575890|NCT03455283|Drug|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
75429248|NCT01496508|Device|mechanical ventilation (SLE 5000, Servo-i-Maquet)|Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
75429249|NCT01496521|Drug|Aspirin|100mg qd for 6 months.
75429250|NCT01496521|Dietary Supplement|Tea Polyphenols|300mg bid for 6 months.
75429251|NCT01496534|Drug|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
75575891|NCT03455283|Other|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
75575892|NCT00448214|Drug|YM150|Oral
75575893|NCT00448214|Drug|warfarin|Oral
75575894|NCT02901639|Other|counseling|
75575895|NCT00448253|Biological|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."
75575898|NCT00448292|Drug|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
75575899|NCT00448292|Drug|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
75575900|NCT00553566|Procedure|medical chart review|
75575901|NCT00553566|Procedure|questionnaire administration|
75575902|NCT00553566|Procedure|study of socioeconomic and demographic variables|
75726514|NCT01013896|Other|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group."
75726515|NCT01013974|Drug|GSK573719 250 μg|Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
75726516|NCT01013974|Drug|GSK573719 500 μg|Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
75726517|NCT01013974|Drug|GSK573719 1000 μg|Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
76048891|NCT02320058|Drug|Nivolumab|
75575903|NCT02901561|Drug|misoprostol 200|
75575904|NCT02901561|Drug|misoprostol 400|
75575905|NCT00448409|Biological|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
75575906|NCT00448409|Drug|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
75575907|NCT02901678|Device|Intrusion by 400 g|using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
75575908|NCT02901756|Dietary Supplement|Antemig|Participants were instructed to take one tablet every morning for three months.
75575909|NCT00448526|Behavioral|low protein diet|
75575910|NCT05424939|Procedure|Colectomy|Colon resection
75575911|NCT05424939|Procedure|Stoma procedures|Any type of colostomy or ileostomy with or without bowel resection
75575912|NCT05424939|Procedure|By-pass/laparotomy/laparoscopy/biopsy|Any palliative surgery without bowel resection
75575913|NCT05424705|Diagnostic Test|OCT, NIRS|
75575914|NCT03276884|Other|Experimental Infant Formula|amino acid-based infant formula powder
75575915|NCT03276884|Other|Control Infant Formula|amino acid-based infant formula powder
75878635|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample~on pre-operative d-1/d, post-operative d1 and d5(+/-2),~one month post-operative,~at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
75575916|NCT02901366|Drug|14C-FYU-981|14C-FYU-981, (Oral single dosing)
75726518|NCT01013974|Drug|GSK573719 matching Placebo|Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
75726519|NCT04615624|Drug|Furosemide|Furosemide, a loop diuretic
75878636|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample~before starting the therapy~at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~at the end of the study or at the date of disease progression."
75878637|NCT01340131|Drug|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
76048892|NCT02319668|Drug|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
75878638|NCT01340131|Drug|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
75878639|NCT00090181|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
76048893|NCT02319668|Drug|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
76048894|NCT02092467|Drug|tofacitinib|Oral tablet, 5 mg BID
76048895|NCT02092467|Drug|tofacitinib|Oral tablet, 10 mg BID
76048896|NCT02092467|Biological|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
75575917|NCT03276806|Behavioral|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
76048897|NCT02092467|Biological|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
75575918|NCT03276806|Behavioral|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
75726520|NCT04615624|Other|Placebo|Normal saline
75726521|NCT00713609|Drug|Benzoyl peroxide gel|5% benzoyl peroxide in a gel applied topically once a day
75726522|NCT00713609|Drug|Clindamycin gel|1% clindamycin phosphate applied topically once a day
75878640|NCT00090181|Drug|Comparator: diclofenac / Duration of Treatment: 4 weeks|
75878641|NCT05207787|Drug|HS-10365|Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
75878642|NCT03643380|Device|AHLeveeS System|AHLeveeS System for treatment of overactive bladder
75878643|NCT01336075|Procedure|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
75878644|NCT01336075|Procedure|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
75575919|NCT03276806|Other|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
75575920|NCT03276806|Other|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
75575921|NCT03276767|Other|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
75726523|NCT00713609|Drug|Tazarotene cream|0.1 % tazarotene in a cream applied topically once a day
76048898|NCT02462759|Drug|Nusinersen|Administered by intrathecal injection.
75726524|NCT00713609|Drug|Vehicle gel|Vehicle gel is an identical gel without the active ingredients
75726525|NCT00713609|Drug|Vehicle cream|Vehicle cream is an identical cream without the active ingredients
75726526|NCT00513682|Drug|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
76024575|NCT03035877|Behavioral|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
76048899|NCT02462759|Procedure|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
76048900|NCT04420871|Drug|150 mg of Xeloda®|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.
75429252|NCT01496534|Drug|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
75726527|NCT00493012|Dietary Supplement|vitamin D|6 drops of a vitamin D containing oil
75726528|NCT00918593|Drug|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
75726529|NCT00918593|Radiation|Radiotherapy|Radiotherapy according to hospital procedures.
75726530|NCT00918593|Drug|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
75726531|NCT04084847|Dietary Supplement|berberis vulgaris=barberry|10 grams of barberry powder will be consumed daily for 8 weeks.
75575922|NCT05424666|Procedure|Harvesting method and Fat graft preparation method|"The procedure begins by identifying the areas where the fat will be collected Then the sample is collected by micro-incision using a fine suction cannula or during conventional liposuction. The fat cells are taken from an area of the body where there is a reserve (generally, in the abdomen, hips, knees, inner thighs, buttock) The collected fat cells are then subjected to a sterile centrifugation for a few minutes so as to separate the cells that will be injected (intact fat cells) from the elements that must not be injected (fat cells destroyed by the sample, non-fat cells such as than blood cells).~Injection of fat cells into the breasts The reinjection of fat (lipofilling) is performed using micro-cannulas allowing incisions of the order of 1-2 mm in different angles and in multiple directions so as to increase the contact area between the grafted cells and the recipient tissues allowing a good grip of the injection."
75726532|NCT04084847|Dietary Supplement|Placebo|Placebo powder
75726533|NCT04084457|Dietary Supplement|Wild Blueberry powder|Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
75726534|NCT04084457|Dietary Supplement|Placebo|Identical formulation as the treatment matched for fibre and vitamin C
75726535|NCT05163431|Device|Hallux Valgus orthosis|Custom designed orthosis and manufactured by 3D printing.
75575923|NCT03276689|Drug|Duloxetine|The patients will take duloxetine for 8 weeks.
75726536|NCT04083833|Drug|Tetrodotoxin|A single TTX dose in a dose ascending study
75726537|NCT04083833|Drug|Placebos|matching placebo comparator
75726538|NCT05155241|Behavioral|online health promotion video|Participants will watch an online health promotion video tailored to their current stage of change related to seasonal influenza vaccination uptake once every two weeks for four times (at week 0, 2, 4, and 6)
75726539|NCT05155241|Behavioral|Control (same online health promotion video)|Participants will watch a same online video providing general advices related to seasonal influenza vaccination at week 0, 2, 4, and 6
76024576|NCT03035877|Behavioral|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
75429253|NCT01496547|Drug|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
75429254|NCT01496573|Other|laboratory biomarker analysis|Correlative studies
75726540|NCT05144477|Behavioral|FAID Fear Intervention|Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
75726541|NCT05135663|Drug|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
75726542|NCT05135663|Drug|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
76024577|NCT03017560|Behavioral|Computerized cognitive treatment|Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
75575924|NCT03276689|Drug|Pregabaline|The patients will take pregabaline for 8 weeks.
75575925|NCT03276689|Other|Placebo|The patients will take placebo for 8 weeks.
75575926|NCT03276650|Other|data collection|biological, administrative, clinical, outcome date
75429255|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
75429256|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
75575927|NCT04699370|Other|cognition-targeted exercise|"All Standardized physical therapy exercises will be performed in a time-contingent .~Goal setting is essentially done together with the patient, focussing on functionality instead of fatigue relief. Progression to a next level of (more difficult) exercises will be preceded by an intermediate phase of motor imagery.~The treating physical therapist will be advised to address patients' cognitions about their problems during the cognition-targeted exercise training, so that patients will have positive perceptions regarding their illness and treatment outcome.~The treating physical therapist will be advised to discuss the patient's perceptions about each exercise. This include discussion of the anticipated consequences of the exercises and challenging the patient's cognitions in relation to the exercises"
75878645|NCT05214261|Other|Safety and efficiency of post operative analgesia between laparoscopic-assisted TAP block and epidural analgesia|"Patients in the TAP group will be given a laparoscopic-assisted TAP block with a total of 2mg/kg of 0.25% bupivacaine in the bilateral subcostal region into four spots of the bilateral subcostal region, two on both sides of the lateral abdomen between the anterior iliac spine and lower costal arch. The TAP block is performed after the first trocar placement before the insertion of other trocars and the beginning of the surgical intervention.~In the control group epidural catheters will be placed using landmark- and loss-of-resistance techniques while the patient is on the operating table. Infusions of 4ml/h containing 0.125% levobupivacaine and 5.5 μg/mL fentanyl will be started with a CADD Solis VIP-infusion pump at the time of anesthesia induction."
75878646|NCT03644238|Diagnostic Test|Oral Glucose Tolerance Test|75g of glucose is consumed
75726543|NCT05684237|Procedure|HiSMILE treatment option|The non-CE labeled VisuMax treatment option HiSMILE is able to modify the lenticule shape in a way that should lead to a change in spherical aberration postoperatively.
75726544|NCT02589587|Procedure|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
75726545|NCT02589587|Other|no intervention|lean control group
75726546|NCT05246813|Other|Blood and bone marrow cell collection|Collection of blood and bone marrow
75726547|NCT05238233|Drug|Tropicamide|One drop will be given to participants
75878647|NCT03644238|Behavioral|Inactivity|Lying or sitting down.
75878648|NCT03644238|Behavioral|Physical activity|20 minutes of fixed intensity exercise on a bicycle ergometer.
75575928|NCT04699370|Behavioral|Cognitive behavioral therapy|In the first and second sessions, patients will learn about fatigue-related symptoms as well as Cognitive behavioral therapy and its effectiveness. The third and fourth sessions will be devoted on the introduction of behavioral strategies. The fifth session will introduce cognitive strategies to decrease fatigue. The last three sessions will be about how to adopt the proposed strategies consistently.
75575929|NCT04699370|Other|Standardized physical therapy|The standardized physical therapy will consist of eight half-hour individualized face to face physiotherapy sessions, over a 4-week period. this program will consist of twice-weekly supervised general aerobic, strengthening and flexibility exercise sessions .This exercise program is reflective of the general exercises typically undertaken within routine clinical practice.
75575930|NCT02901210|Procedure|Modified delorme procedure|
75575931|NCT04699448|Other|Nutritional intervention.|Diets designed for body weight loss, based on different macronutrient content.
75575932|NCT01220128|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
75575933|NCT01220128|Drug|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
75575934|NCT01220128|Drug|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
75726548|NCT05238233|Drug|1% Pilocarpine|One drop will be given to participants
75726549|NCT05238233|Drug|Proparacaine Hydrochloride|One drop will be given to participants
75726550|NCT05238233|Device|Tono pen AVIA|Participant intraocular pressures measured
75575935|NCT01220128|Drug|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75575936|NCT01220128|Drug|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
75575937|NCT01220128|Drug|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75575938|NCT01220128|Drug|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75575939|NCT01220128|Drug|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
76048901|NCT04420871|Drug|150 mg of capecitabine|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
75575940|NCT01220128|Drug|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
76048902|NCT02349386|Drug|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
76048903|NCT02349386|Drug|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
76048904|NCT04935047|Other|Multilingual Support|Multilingual Support is a classroom intervention, which is designed to be delivered in classes of adult learning of a new language. The intervention involves the use of a language assistant, who is at minimum independent user (B1) in the language to be learned (in this case Norwegian), according to the language proficiency scale of the Common European Framework of Reference (CEFR) for languages, learning, teaching, assessment (Little, 2006). The language assistant will be in the classroom for seven hours a week, collaborating with the teacher in providing language training. In classrooms where participants have different primary languages, the language assistant(s) must cover all languages represented in the classroom.
76048905|NCT04934891|Drug|ION547|ION547 will be administered by SC injection.
76048906|NCT04934891|Drug|Placebo|ION547-matching placebo will be administered by SC injection.
76048907|NCT04892888|Biological|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
76048908|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
75429257|NCT01496651|Procedure|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.~There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
75878649|NCT03619785|Drug|Bupivacaine|Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.
75878650|NCT03619785|Drug|Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen|Oral or IV pain medication as needed.
75878651|NCT03643302|Device|Version BF-1T26 electronic bronchoscope|Interventions involving the therapy of airway clearance and bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
75878652|NCT02881567|Drug|Daclizumab|High yield formulation
75878653|NCT02962674|Device|prostaFix System|
75575941|NCT01220128|Drug|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75575942|NCT01220128|Drug|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75726551|NCT05238233|Device|VG4 Gonio|Participant iridocorneal angle measured
75726552|NCT05238233|Device|Reichert phoropter|Participant screened for hyperopia >+1 diopter
75726553|NCT05685017|Diagnostic Test|Nur Aisiyah Widjaja|Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
75878654|NCT03280797|Procedure|Blood sample|2ml blood taken into TruCulture tube
75878655|NCT05184595|Other|Carfilzomib delivered in OH only|Patients receive the whole treatment en OH.
75878656|NCT05184595|Other|Carfilzomib delivered in OH and HaH combined|Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.
75878657|NCT05213793|Diagnostic Test|multi-delay arterial spin labeling|Multi-delay arterial spin labeling is a new method to evaluate the degree of the cerebral perfusion. It can obtain three parameters including CBF,CBV and ATT without radiation,which is similar to the traditional technology. Multi-delay ASL can provide more information of the acute stroke patients.
75878658|NCT03643068|Drug|KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).
75878659|NCT03643068|Drug|KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
75878660|NCT05184517|Drug|Oph1|0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
76048909|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
76048910|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
76048911|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
76048912|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
76048913|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
76048914|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
76048915|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
76048916|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
75429258|NCT01496651|Procedure|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
75575943|NCT04699409|Other|stroke educational campaign: FAST|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
75575944|NCT04699409|Other|stroke educational campaign: STROKE 112|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
75726554|NCT00918905|Device|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
75726555|NCT04083443|Other|Additional blood sampling|Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
75726556|NCT04083677|Device|SONAR|A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.
75726557|NCT00919373|Procedure|Substrate modification|Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
75726558|NCT00919373|Procedure|VT ablation|Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
76048917|NCT02036775|Drug|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
76048918|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
76048919|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
75429259|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to elderly subjects
75726559|NCT00919373|Procedure|ICD Implantation|Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
75726560|NCT05314439|Drug|ION904|ION904 will be administered by SC injection.
75726561|NCT05314439|Drug|Placebo|Placebo will be administered by SC injection.
75726562|NCT00617708|Biological|cixutumumab|Given IV
75726563|NCT00617708|Drug|erlotinib hydrochloride|Given PO
75726564|NCT00617708|Drug|gemcitabine hydrochloride|Given IV
76048920|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
76048921|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
76048922|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
76048923|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
76048924|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
76048925|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
76048926|NCT02034591|Drug|Apixaban|
75429260|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to younger group (18-45 years old)
75429261|NCT01496690|Drug|Pregabalin|Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
75429262|NCT01496690|Drug|Pregabalin Placebo Capsules|Parallel to Active Comparator
75429263|NCT01496703|Other|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
75429264|NCT01496716|Procedure|Hip arthroplasty|The purpose of hip arthroplasties is to reduce pain and increase mobility.
75429265|NCT01496729|Procedure|Transversus abdominis plane (TAP) block|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.
75429266|NCT01496729|Procedure|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
75429267|NCT01496742|Drug|Placebo|Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
75878661|NCT05184517|Drug|Restasis|0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
75878662|NCT05207475|Device|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 years after enrollment.
75429268|NCT01496742|Drug|RO5490258|15 mg/kg iv, Day 1 of each 21-day cycle
75429269|NCT01496742|Drug|bevacizumab [Avastin]|15 mg/kg iv, Day 1 of each 21-day cycle
75429270|NCT01496742|Drug|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
75726565|NCT04083209|Behavioral|Opioid counseling|The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
75429271|NCT01496742|Drug|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
75429272|NCT01496742|Drug|pemetrexed|500 mg/m2, Day 1 of each 21-day cycle
75429273|NCT01496755|Drug|Placebo|Single/multiple doses
75429274|NCT01496755|Drug|RG7667|Single/multiple ascending doses
75429275|NCT01496768|Dietary Supplement|Leucine|7,2 g/day during 3 months
75429276|NCT01496768|Dietary Supplement|Alanine|7,2 g/day during 3 months
75429277|NCT01496781|Procedure|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
75429278|NCT01496781|Procedure|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
75726566|NCT02589119|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
75726567|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
75726568|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
75726569|NCT05227586|Procedure|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
75726570|NCT05227586|Procedure|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
75726571|NCT00871130|Procedure|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
75726572|NCT00876044|Drug|aflibercept (AVE0005)|Intravenous route
75726573|NCT00876044|Drug|placebo|Intravenous route
76048927|NCT02034591|Dietary Supplement|Boost Plus|
75429279|NCT01496820|Dietary Supplement|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
76048928|NCT02391116|Drug|Copanlisib (Aliqopa, BAY80-6946)|Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
76048929|NCT02091921|Drug|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
76048930|NCT02447081|Device|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
75429280|NCT01496820|Dietary Supplement|Placebo|placebo 1500mg/day for 12weeks
75429281|NCT01496833|Device|Ankura Branched/Fenestrated Stent Graft|Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
75429282|NCT01496859|Device|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
75429283|NCT01496911|Drug|Levocetirizine|a single oral dose of 5 mg
75429284|NCT01496911|Drug|Hydroxyzine|a single oral dose of 50 mg
75429285|NCT01496911|Drug|Placebo|a single oral dose
75429286|NCT01496924|Other|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
75429287|NCT01496937|Drug|GLPG0974|
75429288|NCT01496937|Drug|GLPG0974|
75429289|NCT01496950|Device|10Hz active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
75429290|NCT01496950|Device|Placebo|10Hz placebo rTMS delivered to the vertex
75429291|NCT01496989|Biological|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
75429292|NCT01496989|Biological|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
75726574|NCT04040114|Device|Molemap Skin Cancer Triage Artificial Intelligence Device|This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
75878663|NCT03644628|Procedure|Laparoscopic repair of anterior and apical pelvic organ prolapse|Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
75726575|NCT00876122|Drug|GDC-0941|Escalating oral dose
75726576|NCT00866216|Drug|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
75878664|NCT01336153|Drug|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
75878665|NCT01336153|Drug|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
75726577|NCT00866216|Drug|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
75726578|NCT00871208|Drug|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
75726579|NCT00871208|Drug|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
75726580|NCT04039802|Procedure|Single-stage surgery|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
75726581|NCT04039802|Other|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
75726582|NCT00876278|Device|*AT.Smart 46LC|Primary implantation of *AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
75878666|NCT03629067|Drug|Treatment T|Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
75878667|NCT03629067|Drug|Treatment R|Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
75878668|NCT05182333|Other|Examination|History taking, examination of upper limb
75878669|NCT03644082|Behavioral|Luminosity Trial Memory Match|Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
75726583|NCT04083521|Dietary Supplement|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10^9 CFU once a day for 90-days.
75726584|NCT00871364|Drug|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
75726585|NCT00871364|Drug|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
75726586|NCT00876356|Dietary Supplement|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
75429293|NCT01496989|Biological|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
75726587|NCT00876356|Dietary Supplement|Olive oil|Olive oil 4.5g/day x 12 weeks
75726588|NCT04083053|Procedure|Perianal Exam|Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
75726589|NCT04083053|Procedure|high-resolution anoscopy (HRA) with biopsy|The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
75726590|NCT05227274|Other|Items completion with or without a MFM-Play|Patients will completed 3 MFM during the follow-up, two times using the MFM-Play, and one without the MFM-Play Delay between each MFM completion will be 1 month ± 15 days
75726591|NCT00866450|Dietary Supplement|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
76048931|NCT02391038|Drug|MLN0264|MLN0264 IV.
76048932|NCT02260921|Device|iovera°|
75429294|NCT01496989|Biological|Ad35-GRIN/ENV|(2x10^10vp) Delivered intramuscularly by standard needle injection
75726592|NCT00866450|Dietary Supplement|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
75878670|NCT03644082|Behavioral|Luminosity Trial Memory Matrix|The purpose id to remember the location of squares on a grid
75878671|NCT03644082|Behavioral|Luminosity Trial Famliar Faces|The purpose is to create associations between visual and verbal information
75726593|NCT03894969|Biological|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
75726594|NCT03894969|Biological|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
75726595|NCT00876434|Drug|Sirolimus|
75726596|NCT00871442|Other|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
75878672|NCT03644082|Behavioral|Luminosity Trial Brain Shift|The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
75878673|NCT03644082|Behavioral|Luminosity Trial Star Search|The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
75878674|NCT03644082|Behavioral|Luminosity Trial Word Bubbles|"The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking."
75878675|NCT03644082|Behavioral|Luminosity Trial Color Match|The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
76048933|NCT02260921|Device|Sham Comparator|
75429295|NCT01497002|Drug|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
75429296|NCT01497002|Biological|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
75429297|NCT01497028|Procedure|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
75726597|NCT00871442|Other|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
75726598|NCT00871442|Drug|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
75878676|NCT03644082|Behavioral|Luminosity Trial Ebb and Flow|Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
75726599|NCT00871520|Other|no specific interventions|There are no specific interventions in this observational study
75726600|NCT02588729|Other|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
75726601|NCT05355597|Drug|Exparel Injectable Product|Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
75726602|NCT05355597|Drug|Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)|Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
75878677|NCT03644082|Behavioral|Luminosity TrialChalk Board Challenge|purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
75726603|NCT05684003|Other|Neuromuscular exercise based injury-prevention program|Neuromuscular exercise based injury-prevention program
75726604|NCT00866528|Drug|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
75726605|NCT00866528|Drug|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
75726606|NCT05355519|Other|Electronic curriculum and instructor-led course, then placebo|Electronic curriculum and instructor-led course
75726607|NCT05355519|Other|Placebo, then electronic curriculum and instructor-led course|Electronic curriculum and instructor-led course
75575945|NCT05424588|Diagnostic Test|clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection|Total body dual-energy X-ray absorptiometry (DEXA) was taken BN and AN to measure total (FM) and segmental fat (truncal FM), visceral adipose tissue (VAT) and lean mass (LM). Tetra-polar dual frequency BIA (InBody 120; Cerritos, USA) was used BPP, BN and AN to measure weight and to estimate FM, FFM, and MM. Impedance measurements were performed. CPET was carried out on a cycle ergometer with clip-on pedals. Blood samples were collected in the morning BPP, BN, AN. Biochemical parameters considered in this study were: ALT, AST, creatinine, 25-hydroxy vitamin D, total cholesterol, HDL, LDL, triglycerides concentrations. We isolated CPCs from heparinized blood, as previously reported (14). After the collection of peripheral blood mononuclear cells (PBMCs) by a gradient centrifugation. (15). Differentiating Human Skeletal muscle cells were cultured with or without pooled sera of participants at 5% final concentration. 146b and 34a miRNAs were extracted from PBMCs.
75575946|NCT04698941|Drug|Albumin Paclitaxel|Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m^2 on Day 1 of each 21-day cycle.
75726608|NCT05031767|Other|Usual care|"Conventional follow-up strategy with blood tests, patient-reported outcomes, and pre-scheduled visits at the hospital every 6th month.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
75726609|NCT05031767|Other|Remote monitoring|"Hospital health professionals perform remote monitoring of frequent patient-reported outcomes, blood test results, and physical activity data available on a digital platform.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital ."
75878678|NCT03644082|Behavioral|Luminosiuty Follow that Frog|The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
75726610|NCT05031767|Other|Patient-initiated care|"No pre-scheduled visits or remote monitoring.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
75429298|NCT01497041|Drug|Docetaxel|Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
75429299|NCT01497041|Drug|Oxaliplatin|Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
75429300|NCT01497093|Drug|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
75726611|NCT00871598|Drug|BTT1023|intravenous, three infusions over three weeks
75726612|NCT00871598|Drug|Placebo|intravenous, three infusions over three weeks
75726613|NCT00871598|Drug|BTT1023|Test challenge
75429301|NCT01497093|Drug|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
75429302|NCT01497093|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
75575947|NCT04698941|Drug|Simvastatin|20mg daily oral tablet taken.
75575948|NCT04206202|Device|3D-Printed Patient-Specific Intramedullary Guide|The 3D-printed patient-specific intramedullary guide is used in TKA to control femoral component rotation.
75726614|NCT04082741|Drug|BMS-986318|Specified dose on specified days
75726615|NCT04082741|Other|Placebo|Placebo Matching BMS-986318
75726616|NCT00992667|Drug|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
75726617|NCT00992745|Drug|123-I-MIP-1072|Single 10 mCi intravenous injection
75726618|NCT00992745|Drug|111-In capromab pendetide|Single 5 mCi intravenous injection
75726619|NCT00992745|Drug|123-I-MIP-1072|Single 5 mCi intravenous injection
75878679|NCT03644082|Behavioral|Luminosity Train of Thought|purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
75429303|NCT01497106|Behavioral|Calorie Restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
75429304|NCT01497106|Behavioral|Control (normal living)|Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
75429305|NCT01497119|Drug|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
75429306|NCT01497119|Drug|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
75429307|NCT01497119|Drug|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
75429308|NCT01497132|Drug|Vitamin D3|Oral drops 30000 IU weekly
75429309|NCT01497132|Drug|Placebo|Matching placebo
75429310|NCT01497145|Drug|KRN321|
75575949|NCT02901288|Drug|Isoniazid|Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
75575950|NCT02901288|Drug|Rifampicin|Rifampicin is a widely used anti-tuberculosis medication.
75575951|NCT02901288|Drug|Pyrazinamide|Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
75878680|NCT01340287|Dietary Supplement|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
76048934|NCT02462603|Drug|PTC-589|PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
75726620|NCT05171972|Drug|Ofatumumab|This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
76048935|NCT02034513|Drug|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
75429311|NCT01497158|Other|Self-help brochure|Self help brochure given at baseline visit.
75429312|NCT01497158|Other|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
75429313|NCT01497223|Drug|MGCD290|1 Oral Dose Administration
75575952|NCT02901288|Drug|Ethambutol|Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
75575953|NCT02901288|Drug|Levofloxacin|Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
75726621|NCT00992823|Drug|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
75726622|NCT00992823|Biological|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
75726623|NCT00871676|Behavioral|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
76048936|NCT02034513|Drug|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
75429314|NCT01497236|Dietary Supplement|Dietary Supplement: Nutrition supplement with RUTF or MNP|"14 days nutritional supplementation with either~a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier"
75429315|NCT01497249|Dietary Supplement|A dietary fiber (FCHO)|15 g twice per day in beverage
76048937|NCT02034513|Drug|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
76048938|NCT05370248|Other|Tidal volume 6 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
76048939|NCT05370248|Other|Tidal volume 10 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
76048940|NCT02348840|Device|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
76048941|NCT02462057|Other|Email message regarding the HealthyFood benefit|
76048942|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
75429316|NCT01497249|Dietary Supplement|Placebo|Placebo drink
75429317|NCT01497288|Drug|INFS (Intranasal Fentanyl Spray)|Intranasal Fentanyl Spray
75726624|NCT00871676|Behavioral|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
75726625|NCT00876746|Procedure|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
76048943|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
75726626|NCT03894813|Drug|"Probiotics and Metronidazole"|Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)
76048944|NCT02034435|Other|Low Salt diet plus Placebo tablet|
76048945|NCT02034435|Other|Low Sodium diet plus Salt tablet|
75429318|NCT01497301|Behavioral|Group Visits|"During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants."
75429319|NCT01497314|Other|Low Lactose Infant Formula|Low Lactose Infant Formula
75429320|NCT01497327|Drug|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
75726627|NCT03894813|Drug|Metronidazole Vaginal|Metronidazole Suppositories,qd, 7 days
75726628|NCT00615992|Drug|Tiotropium|
76048946|NCT02034435|Drug|Epleronone|50mg daily
75429321|NCT01497327|Drug|PSI-7977|PSI-7977 400mg QD for seven days
75726629|NCT04001361|Procedure|Laser Cell Therapy|Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
75726630|NCT02588183|Device|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
76048947|NCT02034435|Drug|Amlodipine|5mg daily
76048948|NCT04691427|Device|Virtual Eye Rotation Vision Exercises (VERVE)|A video game designed with elements of vision therapy will be delivered to participants utilizing consumer-available virtual reality headsets (VIVE Pro Eye).
76048949|NCT02033889|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
76048950|NCT02033889|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
76048951|NCT02033889|Drug|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
76048952|NCT02033889|Other|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
75575954|NCT00448643|Radiation|Vaginal Brachytherapy|High-Dose Rate [HDR] or Low-Dose Rate [LDR], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
75575955|NCT00448643|Drug|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
75575956|NCT00448643|Radiation|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated [2-Levels]; 6 -8 hours after administration of Cisplatin chemotherapy
75575957|NCT03276455|Genetic|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
75575958|NCT00448799|Radiation|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of [123I] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
75575959|NCT02901327|Procedure|Lumbar Stabilisation Exercise|"McGill protocol starting with:~'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~'curl-up' exercise 10 repetitions with 7 seconds hold each~'side-bridge' exercise 10 repetitions with 7 seconds hold each~'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
75575960|NCT02901327|Procedure|treadmill walk exercise|"Bruce protocol~This include:~'5 minutes warm up' at zero degree inclination.~'20 minutes active exercise with increasing speed and inclination'~'5 minutes cool down'"
75575961|NCT05424393|Drug|YISAIPU® ( An etanercept biosimilar)|YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
75726631|NCT00876824|Drug|Amphotericin B Lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
75726632|NCT00876824|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
75726633|NCT00992979|Procedure|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
75878681|NCT01340287|Dietary Supplement|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
75575962|NCT05424393|Drug|csDMARDs|csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
75575963|NCT05424354|Device|Altrazeal (R) Transforming Powder Dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with Altrazeal TPD.
75575964|NCT05424354|Other|Standard of Care burn dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with the institution's standard of care burn dressing.
75575965|NCT00448838|Biological|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
75726634|NCT00992979|Procedure|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
75726635|NCT00866684|Drug|Sirolimus|Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month
75429322|NCT01497340|Other|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
75429323|NCT01497340|Other|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
75429324|NCT01497353|Procedure|Position at introitus level|After birth: Weigh at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec then another Weigh will be obtained after clamping
75429325|NCT01497353|Procedure|position at Maternal Abdomen|After birth: Weight at 10 + 2 sec then the baby will be placed at maternal abdomen and Cord clamping will be performed at 120 sec and new Weigh will be obtained after clamping
75429326|NCT01497379|Procedure|surgical implantation of subretinal device|surgical implantation of subretinal device
75429327|NCT01497379|Procedure|surgical implantation of subretinal device|intra-individual implant OFF
75429328|NCT01497405|Behavioral|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
75429329|NCT01497405|Biological|Test, Treat, Retain(TTR) only|TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
75429330|NCT01497431|Dietary Supplement|Selenium|Given PO
75429331|NCT01497431|Other|Placebo|Given PO
75429332|NCT01497431|Other|Laboratory Biomarker Analysis|Correlative studies
75575966|NCT00448838|Drug|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
75726636|NCT00866684|Drug|Azathioprine|Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
75726637|NCT00866684|Drug|Mycophenolate|Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
75726638|NCT00866684|Drug|Ciclosporin|Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
75726639|NCT00866684|Drug|Tacrolimus|Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
75726640|NCT05356455|Behavioral|motivational interview technique|Difference between pre-test and post-test
75726641|NCT05225948|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.
75575967|NCT00448838|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
75726642|NCT05225948|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.
75726643|NCT00993057|Drug|Insulin|Adjustable insulin infusion scale with loading doses
75726644|NCT00866762|Drug|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
75726645|NCT04001907|Behavioral|Resistance exercise|effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.
75726646|NCT04001907|Dietary Supplement|β-hydroxy-β-methylbutyrate|
75726647|NCT04001907|Dietary Supplement|placebo|
75878682|NCT05207319|Other|integrated Moral Reasoning Development Intervention (MRDI)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
75878683|NCT01341691|Other|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
75429333|NCT01497431|Other|Pharmacological Study|Correlative studies
75429334|NCT01497431|Drug|Methylselenocysteine|Given PO
75575968|NCT03455244|Device|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
75575969|NCT03276338|Behavioral|HOLA|To increase condom use and HIV testing
75878684|NCT05213403|Diagnostic Test|Evaluation with new scoring system|"Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes"
76048953|NCT02033889|Drug|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
75575970|NCT01219933|Drug|methylprednisolone|starting dose >/= 1 mg and </= 20 mg orally daily, according to dose-reduction schedule
75726648|NCT00876902|Drug|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg [approximately 0.27 mg/kg] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
75429335|NCT01497444|Drug|hypoxia-activated prodrug TH-302|
75878685|NCT05213325|Diagnostic Test|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)
76048954|NCT02033889|Biological|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
75429336|NCT01497444|Drug|sorafenib tosylate|
75429337|NCT01497457|Procedure|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
75429338|NCT01497470|Drug|Custirsen, paclitaxel and carboplatin|Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
75575971|NCT01219933|Drug|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
75575972|NCT00448877|Device|fNIR light emitting and sensing device|
75575973|NCT05368441|Drug|Midazolam|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.
75878686|NCT03166371|Dietary Supplement|Liposomal Glutathione (GSH)|Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
76048955|NCT02033889|Drug|Metformin|Metformin >=1500 mg/day, orally, once a day
76048956|NCT02447003|Biological|Pembrolizumab|IV infusion of 200 mg.
76048957|NCT01844284|Device|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
76048958|NCT01844284|Device|Absorb™ BVS|Subjects receiving Absorb™ BVS
75429339|NCT01497483|Drug|Pravastatin alone|Pravastatin 40 mg with placebo.
75429340|NCT01497483|Drug|Pravastatin and Cyclosporine|Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
75429341|NCT01497522|Drug|Vildagliptin|vildagliptin 50 mg twice daily
75429342|NCT01497522|Drug|Placebo|Matching Placebo of vildagliptin 50 mg twice daily
75575974|NCT05368441|Drug|Saline|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
75575975|NCT00448955|Drug|ARD-0403|ARD-0403
75429343|NCT01497535|Drug|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
75429344|NCT01497535|Drug|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
75575976|NCT05657080|Device|Cytosponge-TFF3|Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
75575977|NCT02901015|Behavioral|Assessment battery A|"Social cognition tests version A are administered to the patients"
75575978|NCT02901015|Behavioral|Assessment battery B|"Social cognition tests version B are administered to the patients"
75575979|NCT04316845|Diagnostic Test|18F-fluorocholine PET/CT|Patients undergo both 18F-fluorocholine PET/CT and Single isotope dual phase Tc-99m sestamibi scan (both planar scan and SPECT/CT)
75575980|NCT05423886|Other|Personalized screening invitation interval|Time to receive the next invitation for fecal immunochemical testing screening, will depend based on individuals risk determined by fecal Hemoglobin concentration
75575981|NCT00449228|Procedure|-preoperative education and total hip replacement|-preoperative education and total hip replacement
75575982|NCT01218802|Drug|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
75575983|NCT01218802|Drug|Placebo|participants will take a sugar pill daily for 96 weeks
76048959|NCT02054715|Behavioral|print educational intervention|print educational intervention
76048960|NCT02054715|Behavioral|multimedia psychoeducational intervention|multimedia psychoeducational intervention
75429345|NCT01497548|Drug|Methylphenidate|Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
75575984|NCT00449267|Device|Intraocular Lens|Phacoemulsification with in the bag implantation of the IOL
75575985|NCT02887222|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
75575986|NCT01218646|Biological|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
75575987|NCT01218646|Biological|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
75575988|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
75575989|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
75575990|NCT02901171|Behavioral|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
75575991|NCT02901171|Behavioral|ACT group treatment|
75575992|NCT02901171|Behavioral|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
75575993|NCT00449345|Procedure|Blood test for Quantiferon-GOLD assay|
75575994|NCT02900937|Device|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
75575995|NCT00449384|Behavioral|Diagnostic Screening|
75575996|NCT00449423|Drug|acipimox|
75575997|NCT05423847|Diagnostic Test|POCUS|POCUS of lungs, pericardium and abdomen
76048961|NCT02446769|Device|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
75429346|NCT01497548|Drug|Placebo|Placebo given on morning (0800) and noon (1200)daily
75429347|NCT01497561|Drug|insulin detemir|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
75429348|NCT01497561|Drug|insulin NPH|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
75575998|NCT00449462|Procedure|consumption of CLA enriched food|
75575999|NCT00449501|Drug|Budesonide/formoterol pMDI|
75576000|NCT00449501|Drug|Budesonide HFA pMDI|
75726649|NCT00876902|Drug|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
75429349|NCT01497574|Drug|insulin detemir|On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
75576001|NCT03276299|Other|six minute walking test|six minute walking test
75576002|NCT03276299|Other|six minute walking test|six minute walking test with encouragement
75726650|NCT04039646|Combination Product|ERAS treatment|The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
75726651|NCT00993135|Drug|methotrexate|
75726652|NCT00993135|Other|medical chart review|
75726653|NCT00993135|Procedure|assessment of therapy complications|
75726654|NCT00876980|Device|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
75429350|NCT01497574|Drug|insulin glargine|On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
75429351|NCT01497587|Drug|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
75429352|NCT01497600|Drug|insulin detemir|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
75429353|NCT01497600|Drug|insulin NPH|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
75576003|NCT04680078|Procedure|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. The sutures are removed 1 week after the surgery.
75726655|NCT00993213|Procedure|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
75726656|NCT00993213|Other|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
75726657|NCT00877136|Device|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
75726658|NCT00993369|Other|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
75726659|NCT00866996|Drug|Methylphenidate extended-release; Atomoxetine|
75726660|NCT02588495|Other|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
75429354|NCT01497626|Drug|Lapatinib and bortezomib|"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."
75429355|NCT01497639|Device|Interleaving stimulation mode (Medtronic)|Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
75429356|NCT01497639|Device|Double monopolar stimulation mode (Medtronic)|Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
75429357|NCT01497652|Drug|Rasagiline/Placebo|Will receive placebo pills each day for the entire 14 weeks.
75429358|NCT01497652|Drug|Rasagiline|0.5 mg for two weeks, then 1 mg for 12 weeks.
75726661|NCT00871910|Drug|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
75726662|NCT00871910|Drug|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
75726663|NCT00871910|Drug|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
75878687|NCT03166371|Other|Placebo|Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
75878688|NCT05207241|Other|provides guidance on gravitationally assisted breastfeeding|Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
75878689|NCT02962908|Biological|FLU-v|Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH
75576004|NCT04680078|Procedure|Conventional Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is then removed .
75576005|NCT03276260|Device|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
75576006|NCT02900820|Other|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
75429359|NCT01497678|Device|Extracellular Matrix|Extracellular Matrix
75429360|NCT01497691|Device|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
75429361|NCT01497691|Device|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
75429362|NCT01497691|Device|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
75429363|NCT01497717|Drug|Adalimumab (Humira)|"Open label pilot trial.~The study includes 3 phases :~Open label treatment period of 24 weeks.~Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks."
75429364|NCT01497730|Device|Total Knee Replacement|"Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices."
75429365|NCT01497743|Drug|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
75429366|NCT01497769|Biological|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10^7 pfu and intradermal saline placebo
75429367|NCT01497769|Biological|Intradermal MVA85A|Intradermal MVA85A 1 x 10^7 pfu and inhaled aerosol saline placebo
75429368|NCT01497782|Other|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
75878690|NCT02962908|Biological|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
75429369|NCT01497821|Drug|AMG 172|AMG 172 is an antibody drug conjugate
75429370|NCT01497210|Device|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
75878691|NCT02962908|Biological|Saline|Subcutaneous injection in the upper arm with 0.5ml of saline
75878692|NCT02962908|Biological|Adjuvanted placebo|Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
75576007|NCT02900820|Other|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
75576008|NCT03276182|Device|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
75878693|NCT03642756|Device|different intra-arterial catheter size|in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
75878694|NCT02962284|Drug|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
75878695|NCT03642600|Dietary Supplement|dietary advice plus myo-inositol and folic acid|dietary advice and lifestyle interventions and myo-inositol
75429371|NCT01497873|Drug|Topotecan|1.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
75429372|NCT01497873|Drug|Belotecan|0.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
75429373|NCT01497886|Behavioral|Hip Hop Stroke educational program|Three one-hour sessions, conducted over three consecutive days
75576009|NCT01188772|Drug|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
75576010|NCT01188772|Drug|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
75576011|NCT01188772|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
75576012|NCT01188772|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
75576013|NCT00449579|Device|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
75878696|NCT03642600|Drug|dietary advice plus Liraglutide Pen Injector|dietary advice and lifestyle interventions and liraglutide pen injector
75576014|NCT04679883|Drug|5% GLH8NDE|5% GLH8NDE as eye drops
75726664|NCT00871910|Drug|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
75726665|NCT00871910|Drug|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
76048962|NCT02420093|Device|"Pelvis Support Assembly"|"Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2."
75576015|NCT04679883|Drug|Placebo|Placebo as eye drops
75576016|NCT01188655|Drug|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
75576017|NCT02900703|Biological|stool samples|
75576018|NCT00449618|Drug|Aspirin 100 mg|dose of 100 mg administered on awakening or at bedtime
75576019|NCT00449618|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
75576020|NCT00449618|Procedure|Chronotherapy, timing of medication|Dosing on awakening versus bedtime
75576021|NCT00449618|Drug|Placebo|Use of placebo on awakening versus bedtime
75576022|NCT01188538|Drug|Epiduo gel|Once daily application on the face in the evening for 12 weeks
75576023|NCT01188538|Drug|BPO|Once daily application on the face in the evening for 12 weeks
75726666|NCT00871910|Drug|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
75726667|NCT00871910|Drug|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
75726668|NCT05355441|Drug|Analgesic|Routine clinical practice treatments recommended by the medical team involved
75576024|NCT04316767|Behavioral|App Intervention|Participants will receive access to a self-care app for use on their smartphone. The app provides a suite of tools based on cognitive behavioral therapy and mindfulness. The app guides users through a variety of short lessons (3-5 minutes) that teach users to self-manage stress, mood, anxiety, and depression. Participants will be encouraged to use the app on a daily basis and will be able to use the app at their discretion.
75576025|NCT00449657|Drug|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
75576026|NCT00449657|Procedure|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.~Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
75576027|NCT00449657|Drug|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 & 9
75576028|NCT00449657|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 & 9
75576029|NCT04318444|Drug|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
75576030|NCT04318444|Drug|Placebo oral tablet|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
75726669|NCT01564329|Drug|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
75726670|NCT05213481|Drug|Tepotinib Hydrochloride Hydrate|Participants will receive Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
75726671|NCT05213481|Drug|Carbamazepine|Participants will receive Carbamazepine tablet with break-line twice daily at the same time each day in the morning and evening from Day 8 to Day 32.
75726672|NCT00872066|Device|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
75726673|NCT00872066|Device|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
75576031|NCT02900898|Other|Dynamic exercise and Mediterranean diet|DE, MD
75576032|NCT02900898|Other|Dynamic exercise|DE
75576033|NCT02900898|Other|Mediterranean diet|MD
75576034|NCT02900898|Other|Control|Control
75576035|NCT03276143|Drug|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
75576036|NCT03276143|Drug|Apixaban|2.5 mg apixaban administered as tablet orally twice daily
75576037|NCT03276143|Drug|BAY1213790|Single dose of BAY1213790 administered as intravenous infusion
75576038|NCT05423574|Procedure|robotic Trans Abdomino Pre Peritoneal prothesis repair|The treatment of primary and incisional ventral hernia using the robotic assisted laparoscopy technique
75726674|NCT00993525|Drug|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
75726675|NCT00993603|Behavioral|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
75429374|NCT01497886|Behavioral|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
75576039|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
75576040|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
75576041|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
75576042|NCT00449774|Drug|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
75576043|NCT00449774|Drug|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
75576044|NCT02900742|Drug|YiQiFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
75576045|NCT02900742|Drug|YangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
75576046|NCT02900742|Drug|YiQiYangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
75726676|NCT00993681|Biological|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
75726677|NCT00993681|Biological|TD Vaccine System|placebo
75726678|NCT03892707|Drug|Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum|"Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
75726679|NCT05132049|Drug|DA-5211|single dose administration (DA-5211 one tablet once a day)
75429375|NCT01497912|Drug|Atorvastatin|Atorvastatin 80mg once daily for 8 weeks
75576047|NCT02900742|Drug|Gemcitabine®|"Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops."
75576048|NCT02900742|Drug|Pemetrexed®|"Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops."
75576049|NCT02900742|Drug|Docetaxel®|"Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
75576050|NCT02900742|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
75576051|NCT00449813|Drug|Pantoprazole|40 mg Pantoprazole
75576052|NCT01188226|Device|Denture teeth|Denture teeth made of nano hybrid composite material
75576053|NCT02900547|Other|Patients with systolic heart failure|
75576054|NCT05423067|Procedure|bilateral permanent occlusion of uterine arteries|bilateral permanent Occlusion of uterine arteries through abdominal route
75726680|NCT05132049|Drug|DA-5211-R1 + DA-5211-R2|single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
75726681|NCT00993759|Drug|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
75726682|NCT00513604|Biological|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
75429376|NCT01497912|Drug|Placebo|Placebo tablet once daily for 8 weeks
75429377|NCT01497925|Drug|ADI-PEG 20|Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
75429378|NCT01497951|Other|Aminolaevulinic acid|Photodynamic therapy
75726683|NCT00513604|Biological|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10^11 lymphocytes (minimum of 1 x 10^9), day 0
75429379|NCT01497951|Other|Methylcellulose Placebo|Methylcellulose
75429380|NCT01497964|Drug|cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
75429381|NCT01497977|Drug|phytoestrogens|The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
75429382|NCT01497977|Drug|phytoestrogens|The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
75429383|NCT01497990|Drug|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
75429384|NCT01498003|Drug|tirofiban|10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
75429385|NCT01498003|Drug|normal saline solution|same use as tirofiban
75576055|NCT01218100|Drug|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
75576056|NCT01218100|Drug|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
75576057|NCT01218100|Drug|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
75576058|NCT01218100|Drug|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
75576059|NCT02900508|Other|Exergaming training|
75576060|NCT02900508|Other|Physical therapy intervention|
76048963|NCT02419937|Drug|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
76048964|NCT02419937|Drug|Placebo|Saline injection
75726684|NCT00513604|Drug|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
75726685|NCT00513604|Drug|Fludarabine phosphate|Given intravenously 25 mg/m^2/day over 15-30 minutes, day -5 to -1
75429386|NCT01498016|Drug|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
75429387|NCT01498029|Procedure|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
75576061|NCT02900196|Other|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
75726686|NCT00513604|Radiation|Total body irradiation|600 cGy
75726687|NCT00872144|Drug|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
75726688|NCT05355129|Drug|TT-00920|Tablets
75726689|NCT05355129|Drug|TT-00920 Placebo|Tablets
76048965|NCT04594018|Drug|Finlândia Association + finasteride placebo|Finlândia association hair lotion + finasteride placebo
76048966|NCT04594018|Drug|Minoxidil + finasteride|Minoxidil hair lotion + Finasteride 1 mg
75429388|NCT01498029|Device|Cartilage Autograft Implantation System (CAIS)|The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
75429389|NCT01498081|Drug|AZD2115|AZD2115 administered via inhalation
75429390|NCT01498081|Drug|Placebo|Placebo administered via inhalation
75726690|NCT00872222|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
75726691|NCT00877526|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
75726692|NCT00867152|Drug|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
76048967|NCT02054481|Drug|BI 655066|Medium dose
76048968|NCT02054481|Drug|BI 655066|High dose
76048969|NCT02054481|Drug|Ustekinumab|
76048970|NCT02054481|Drug|BI 655066|Low dose
76048971|NCT01610752|Behavioral|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
75429391|NCT01498081|Drug|Indacaterol|Indacaterol administered via inhalation
76048972|NCT02054325|Drug|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
76048973|NCT02054325|Drug|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
76048974|NCT02446691|Biological|MenACWY|Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
75429392|NCT01498081|Drug|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
75429393|NCT01498094|Procedure|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
75576062|NCT02900196|Other|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
75576063|NCT02900313|Other|cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
75576064|NCT00449852|Behavioral|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
75576065|NCT04681209|Behavioral|DRT Condition|"Children were asked to provide five descriptors of two children who each engaged in defending behaviors. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what friendship heroes are like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity."
75576066|NCT04681209|Behavioral|Empathy Condition|Children in the empathy-based condition were asked to provide five descriptors of how two children who were bullied would fee. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what being bullied feels like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.
75576067|NCT05423028|Procedure|Ultrasound-guided nerve hydrodissection|Peri- median nerve injection for hydrorelease and decompression
75429394|NCT01498094|Other|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
75576068|NCT02900235|Drug|MT-3995|
76048975|NCT02091375|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
76048976|NCT02091375|Drug|Placebo control|Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
76048977|NCT04690335|Biological|MV-012-968|MV-012-968 is a recombinant, live attenuated RSV vaccine.
75576069|NCT00449969|Device|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
75576070|NCT00449969|Device|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
75576071|NCT05422989|Diagnostic Test|X-ray, CT|Just a diagnostic procedure to confirm the diagnosis
75726693|NCT00867152|Drug|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
75726694|NCT00867152|Drug|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
76048978|NCT04690335|Other|Placebo|Saline solution
76048979|NCT02032875|Drug|Daclatasvir|
76048980|NCT02032875|Drug|Sofosbuvir|
76048981|NCT02032875|Drug|Ribavirin|
76048982|NCT02032407|Drug|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
76048983|NCT04689867|Behavioral|Cognitive Behavioral Suicide Prevention for psychosis CBSPp)|Cognitive and behavioral approach to suicide prevention among individuals with psychosis
76048984|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 6
76048985|NCT01843972|Drug|BI 691751|oral solution
76048986|NCT01843972|Drug|Placebo|placebo solution
76048987|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 2
76048988|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 5
76048989|NCT01843972|Drug|BI 691751|1 tablet
76048990|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 3
76048991|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 4
75429395|NCT01498107|Behavioral|SilverCloud Platform|The SilverCloud online intervention will be provided as an alternative choice to paper manuals to support guided self-help for depression in a primary care mental health service. Participants will receive up to eight progress reviews on a weekly or fortnightly basis as agreed with their therapist with the intervention running not more than three months.
75726695|NCT00867152|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
76048992|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 7
75429396|NCT01498133|Procedure|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
75576072|NCT00450008|Drug|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
75576073|NCT00450008|Drug|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
75576074|NCT00450008|Drug|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
75576075|NCT02900469|Biological|denosumab|denosumab: 120 mg subcutaneous injection
75576076|NCT02900469|Procedure|Surgery|Surgery: approximately 2-4 weeks after dosing of denosumab
75576077|NCT00450047|Device|Speed-feedback therapy system with a bicycle ergometer|
75576078|NCT00450047|Device|Ergometer at conventional settings|
76048993|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 1
75576079|NCT00450086|Drug|Budesonide|9 mg per day
75576080|NCT00450086|Drug|Mesalazine|3 g per day
75576081|NCT00450086|Drug|Placebo|0 g per day
75576082|NCT05422950|Other|Relationship between physical condition and functionality in post-covid patients|Correlation study between the physical condition and functionality of patients after intubation due to covid 19
75576083|NCT05422911|Drug|Abiraterone acetate|YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist [unless the Veteran has had prior bilateral orchiectomy].
76048994|NCT01826422|Dietary Supplement|EPA and DHA|Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
76048995|NCT01826422|Dietary Supplement|Placebo Comparator|Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
76048996|NCT01843660|Drug|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
75576084|NCT05422911|Drug|Apalutamide|Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist [unless the Veteran has had prior bilateral orchiectomy].
75576085|NCT05422911|Drug|Enzalutamide|Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist [unless the Veteran has had prior bilateral orchiectomy].
75576086|NCT00450125|Other|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
75576087|NCT00450125|Other|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
75576088|NCT00450164|Procedure|esofagic varices ligation|
75726696|NCT00867152|Drug|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
75726697|NCT00993837|Procedure|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
75726698|NCT00867230|Drug|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
76048997|NCT02090283|Drug|SD-101 dermal cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
76048998|NCT02032173|Drug|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
75429397|NCT01498159|Behavioral|Pharmacist disease/medication management|
75429398|NCT01498159|Behavioral|Pharmacist-patient encounters|
75429399|NCT01498159|Behavioral|Pharmacist medication intensification and adherence support|
75429400|NCT01498159|Behavioral|Pharmacist communication with primary care physicians|
75429401|NCT01498159|Behavioral|Pharmacist documentation in electronic medical record|
75429402|NCT01498159|Behavioral|Health promoter-patient encounters in-person or by phone|
75576089|NCT00450164|Drug|Nadolol|
75429403|NCT01498159|Behavioral|Health promoter medication and lifestyle support|
75576090|NCT00450164|Drug|Isosorbide mononitrate|
75576091|NCT00450164|Drug|Prazosin|
75576092|NCT02900430|Other|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
76048999|NCT04712409|Procedure|Single anastomosis duodeno-ileal bypass|Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion
76049000|NCT04712409|Procedure|Biliopancreatic diversion with duodenal switch|Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.
75429404|NCT01498159|Behavioral|Health promoter communication with pharmacists|
75429405|NCT01498172|Biological|MAGE-A3 ASCI|5 doses every 3 weeks
76049001|NCT04712409|Procedure|SADI-S as a revisional procedure|In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery
76049002|NCT04712409|Procedure|BPD-DS as a revisional procedure|In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery
76049003|NCT04689477|Device|Vascular occlusion test|The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.
76049004|NCT02031471|Drug|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
75429406|NCT01498172|Biological|BCG|1 intravesical dose /week for 6 weeks
75429407|NCT01498198|Procedure|Rotator Cuff Repair Surgery|Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
75429408|NCT01498198|Other|Non Operative Treatment|Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
75429409|NCT01498211|Procedure|Biopsy|3 mm punch biopsy of the skin at the distal leg.
75576093|NCT02900430|Drug|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
76049005|NCT02461589|Drug|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
76049006|NCT02461589|Drug|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
75429410|NCT01498224|Device|ReSure Sealant|Comparison of ReSure Sealant to suture(s)
75429411|NCT01498224|Procedure|Sutures|
75429412|NCT01498237|Device|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
75429413|NCT01498237|Procedure|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
75576094|NCT05422833|Other|Evaluation and analysis of clinical data|Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
75576095|NCT02900040|Other|kidney transplantation|
75576096|NCT00450203|Biological|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
75576097|NCT00450203|Drug|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
75576098|NCT00450203|Drug|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
76049007|NCT02461589|Drug|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
76049008|NCT04420793|Other|Questionnaire|3 voice recording tasks and 1 text entry task will be performed.
75576099|NCT00450203|Drug|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
75726699|NCT05093543|Behavioral|physical rehabilitation/physiotherapy and psychosocial group sessions|physical rehabilitation/physiotherapy and psychosocial group sessions
75429414|NCT01498302|Other|diagnostic laboratory biomarker analysis|
75429415|NCT01498302|Other|flow cytometry|
75429416|NCT01498315|Other|Ultrasound examination|Ultrasound examination following hysterectomy
75429417|NCT01498354|Procedure|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
75429418|NCT01498354|Procedure|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
75429419|NCT01498367|Procedure|Telemonitoring of patients with diabetes type 2|Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
75429420|NCT01498380|Drug|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease < 20% or blood pressure decrease/increase < 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease >/= 20% or SBP/DBP/MAP decrease or increase >/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
75429421|NCT01498406|Dietary Supplement|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
75429422|NCT01498432|Drug|Heliox21|For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
75576100|NCT00450203|Procedure|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
75576101|NCT00450203|Procedure|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
75576102|NCT00450203|Procedure|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
75576103|NCT00450203|Drug|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
75576104|NCT05422677|Drug|Hanmi Tams® Capsule|Hanmi Tams®, Once daily administered per the locally approved product information
75576105|NCT00450281|Genetic|chromogenic in situ hybridization|
75726700|NCT05014841|Behavioral|Speech Tasks|Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
75726701|NCT04039958|Drug|Soviredia|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
75429423|NCT01498432|Drug|Air O2|For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
75429424|NCT01498497|Drug|EUR-1100|
75429425|NCT01498497|Drug|Placebo|
75429426|NCT01498510|Behavioral|Web-based CBT for chronic pain|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
75576106|NCT00450281|Genetic|gene expression analysis|
75576107|NCT00450281|Genetic|mutation analysis|
75576108|NCT00450281|Genetic|polymerase chain reaction|
75576109|NCT00450281|Genetic|polymorphism analysis|
75576110|NCT00450281|Other|fluorescent antibody technique|
75576111|NCT00450281|Other|immunohistochemistry staining method|
75726702|NCT04039958|Drug|Harvoni (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
75726703|NCT04039958|Drug|Harvoni (Second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
75726704|NCT00534105|Other|Total Cholesterol|
75429427|NCT01498523|Other|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
75429428|NCT01498523|Other|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
75429429|NCT01498523|Other|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
75576112|NCT00450281|Other|laboratory biomarker analysis|
75576113|NCT00450281|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
75576114|NCT00450281|Other|study of socioeconomic and demographic variables|
75576115|NCT00450281|Procedure|study of high risk factors|
75576116|NCT02900274|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
75576117|NCT05421390|Other|Reduced fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. Skim milk, fat-free yogurt, and ≤22 % fat cheese
75576118|NCT05421390|Other|Regular fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. 3.25% fat milk, ≥2% fat yogurt, and ≥28% fat cheese
75726705|NCT00534105|Other|Triglyceride|
75429430|NCT01498523|Other|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
75429431|NCT01498536|Behavioral|aerobic exercise|3 times per week for 12-weeks
75429432|NCT01498562|Drug|Gefitinib and Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
75576119|NCT04699097|Drug|Azithromycin|250 mg tablet, 5 ml / 200 mg 30 ml suspension
75576120|NCT02900001|Procedure|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
75726706|NCT00534105|Other|HDL|
75576121|NCT02900001|Procedure|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
75576122|NCT02899923|Other|Data collection|
75576123|NCT00450320|Drug|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
75726707|NCT00534105|Other|LDL|
75726708|NCT00872378|Drug|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
75726709|NCT00872378|Drug|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
75726710|NCT00994071|Drug|Temozolomide|
75726711|NCT00994071|Drug|ABT-888|
76049009|NCT04934189|Behavioral|Empowerment Self Defense Training|We have contracted with Prepare, Inc., the New York City chapter of IMPACT International to deliver the tailored ESD violence prevention intervention. IMPACT is an international ESD violence prevention organization with chapters across the United States. Prepare, Inc. will provide facilitators who have completed IMPACT's nationally standardized ESD violence prevention program requirements that include receipt of over 100 hours of training. IMPACT training is open to trans and cisgender women. The extensive training of IMPACT facilitators promotes intervention efficacy, while the risk of potential bias conferred by their experience with a pre-existing curriculum is mitigated by our community-engaged approach (i.e.,TW community members, service providers, and scientists [PI and Co-I] collectively shape the content of the final tailored ESD intervention, and TW co-facilitators will be present in every training session).
76049010|NCT02089737|Drug|Panitumumab|Panitumumab for intravenous infusion
76049011|NCT04688853|Biological|TEG002|TEG002 cells are autologous T cells transduced with a specific γδTCR
75429433|NCT01498562|Drug|Gefitinib|Mono-therapy group: Gefitinib(250mg daily)
75429434|NCT01498614|Behavioral|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
75429435|NCT01498627|Biological|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
75576124|NCT05421234|Other|diagnostic test and sperm analysis|"Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test."
76049012|NCT02460575|Biological|Lactobacillus reuteri 17938|probiotic
75576125|NCT00450359|Procedure|breast imaging study|
76049013|NCT02460575|Biological|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
76049014|NCT02089347|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
75726712|NCT00877682|Procedure|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
75726713|NCT05084885|Other|Online therapy|Standard counseling provided over the internet.
75429436|NCT01498627|Other|Data collection|PGRx information system
75726714|NCT00994149|Drug|Diazoxide|10mg/kg/d divide every 8 hours
76049015|NCT02089347|Biological|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
76049016|NCT02419469|Drug|Cytarabine|"Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.~Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.~Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11."
75726715|NCT00994149|Drug|Ora-plus|placebo, give every 8 hours.
75726716|NCT00573248|Drug|Nicotine|"21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days"
75726717|NCT00573248|Other|Placebo|Placebo Patch
75726718|NCT00994227|Procedure|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
76049017|NCT02419469|Drug|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
75429437|NCT01498666|Dietary Supplement|L. reuteri protectis|1 tablet once daily for 4 weeks
75726719|NCT04039880|Drug|Olorofim|single oral dose (120 mg, 3.7 MBq)
75726720|NCT04083989|Other|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
75726721|NCT00994305|Drug|N-acetylcysteine|600 mg bid po 0-7 PO
75726722|NCT00994305|Drug|control|No treatment: standard care provided. No N-acetylcysteine administration.
75726723|NCT00877760|Drug|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
75726724|NCT00877760|Drug|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
75429438|NCT01498666|Dietary Supplement|Placebo tablet|1 tablet once daily for 4 weeks
75429439|NCT01498705|Other|Procalcitonin level|PCT level upon admission and on days 1, 3, and 5 following baseline level
75576126|NCT00450359|Procedure|comparison of screening methods|
75576127|NCT00450359|Procedure|radiomammography|
75576128|NCT00450398|Drug|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
75576129|NCT00450398|Drug|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
75576130|NCT05421195|Drug|corticosteroids therapy|Oral corticosteroids
75726725|NCT04083911|Drug|Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF|"Decitabine:20mg/m2/d, d1~5, intravenous infusion; Homoharringtonine:1mg/d,d3~9,intravenous infusion; Aclarubicin:10mg/d, d3~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection;"
75726726|NCT05354895|Device|Transcranial infrared laser stimulation|non-invasive, non-pharmacologic photobiomodulation device
75726727|NCT00877838|Drug|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
76049018|NCT02419469|Drug|Vincristine|"Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.~Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.~Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.~Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.~Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.~Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days."
75429440|NCT01498718|Biological|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
75429441|NCT01498718|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
75429442|NCT01498731|Behavioral|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
75576131|NCT05421195|Other|Olfactory training|repeat and deliberate sniffing of a set of odorants
75576132|NCT00450476|Device|Hi-Lo Evac Endotracheal Tube|
75726728|NCT00877838|Drug|Placebo|Gelatin capsules resembling the ones containing the active substance
75429443|NCT01498783|Drug|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
75429444|NCT01498796|Drug|Ketorolac|
75429445|NCT01498796|Drug|Normal Saline|
75429446|NCT01498809|Drug|Midodrine|Single 10 mg dose
75429447|NCT01498835|Drug|Sunitinib|"Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual."
75576133|NCT00450515|Drug|capecitabine|
75576134|NCT00450515|Drug|vinflunine|
75576135|NCT05420259|Behavioral|Combined Exercise and Dietary Intervention (CEDI)|The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.
75576136|NCT05420259|Behavioral|Standard Care|Standard Care
75726729|NCT00995241|Drug|Raltegravir|Raltegravir 800 mg / 24 hours.
75726730|NCT00867542|Other|no intervention|no intervention
75576137|NCT02899845|Other|postural task|
75576138|NCT02899845|Other|walk task|
75576139|NCT03276104|Procedure|IOL repositioning|Intraocular lens repositioning by scleral suturing
75576140|NCT03276104|Procedure|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
75576141|NCT03275987|Behavioral|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
75576142|NCT03275987|Behavioral|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
75576143|NCT03275987|Behavioral|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
75429448|NCT01498848|Dietary Supplement|Cooking oils|Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
75576144|NCT02956850|Other|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
75576145|NCT02956850|Drug|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
75878697|NCT03642522|Device|repetitive transcranial magnetic stimulation|rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
75429449|NCT01498861|Drug|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
75878698|NCT03642444|Device|Cane|Assistive walking device
75878699|NCT03642444|Device|Elasticated worn orthotic-garment|Assistive walking device -elasticated worn orthotic garment
75878700|NCT03642288|Drug|Gastrografin|Patients with CRE-induced SBO or ASBO both received GG challenge.
75576146|NCT04699019|Other|Four speeds|Four speeds ranging from a set walking speed up to 9 mph
75576147|NCT04699019|Other|Foot Strike Pattern|Foot strike sequences (rearfoot strike, midfoot strike, forefoot strike)
75726731|NCT00872612|Procedure|EUS-FNA/EBUS-TBNA + BAL|"EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.~EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.~BAL = bronchoalveolar lavage"
75726732|NCT00872612|Procedure|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
75726733|NCT00994383|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg
75726734|NCT00877994|Behavioral|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
75429450|NCT01498861|Drug|Dolutegravir|Dolutegravir is an experimental HIV drug
75726735|NCT00877994|Behavioral|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
75726736|NCT02588417|Drug|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
75726737|NCT02588417|Drug|Levobupivacaine|levobupivacaine 2.5 mg
75726738|NCT00532935|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an ~32 wk treatment period
75726739|NCT00532935|Drug|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an ~32-wk treatment period.
75726740|NCT00878150|Behavioral|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
75878701|NCT03641352|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
75878702|NCT03641352|Drug|Placebo|Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
75576148|NCT04698863|Device|Oxygen reserve index|eveluating oxygen reserve in blood
75726741|NCT00878150|Behavioral|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
75726742|NCT00994539|Drug|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
76049019|NCT02419469|Drug|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
75429451|NCT01498861|Drug|Placebo|Placebo is a tablet with no drug in it
75429452|NCT01498874|Drug|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
75429453|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
75429454|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
75429455|NCT01498900|Drug|repaglinide|Prescription according to the product labelling at the physicians' discretion
75429456|NCT01498913|Drug|repaglinide|Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
75429457|NCT01498926|Drug|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
75576149|NCT02899806|Other|Written Information|A written information on peridural anesthesia is delivered
75576150|NCT02899806|Other|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
75576151|NCT00450593|Genetic|gene expression analysis|
75576152|NCT00450593|Genetic|microarray analysis|
75576153|NCT00450593|Genetic|molecular genetic technique|
75429458|NCT01498926|Drug|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
76049020|NCT02419469|Drug|PEG asparaginase|"Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.~Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.~Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.~Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.~Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3."
75429459|NCT01498939|Drug|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
75576154|NCT00450593|Genetic|mutation analysis|
75576155|NCT00450593|Other|laboratory biomarker analysis|
75576156|NCT00450593|Procedure|mutation carrier screening|
75726743|NCT00872846|Device|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
75726744|NCT00878306|Drug|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
76049021|NCT02419469|Drug|Ofatumumab|"Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.~Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3."
76049022|NCT02419469|Drug|Rituximab|"Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.~Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3."
76049023|NCT02419469|Drug|Methotrexate|"Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses."
76049024|NCT02419469|Drug|Cyclophosphamide|"Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1."
76049025|NCT02419469|Drug|Mercaptopurine|"Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly."
76049026|NCT02419469|Drug|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
75429460|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
75429461|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
75429462|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
75429463|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
75429464|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B2|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
75429465|NCT01499004|Drug|tofacitinib (CP-690,550) immediate-release formulation|A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
75429466|NCT01499017|Drug|PF-06291874 or placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.
75576157|NCT00450593|Procedure|study of high risk factors|
75576158|NCT05419713|Other|Visual Stimuli for Space Perception|The visual environment (e.g., target locations and texture backgrounds) will be varied and human behavioral responses (judged distances) will be measured to reveal the space perception and cognitive processes underlying space perception and navigation.
75576159|NCT00450671|Procedure|Collagen Plug Placement|
75576160|NCT00450671|Procedure|Seton placement|
75726745|NCT00878306|Drug|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
76049027|NCT02419469|Drug|Dexamethasone acetate|"Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.~Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days."
76049028|NCT02419469|Drug|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
75576161|NCT05419167|Behavioral|STEP-COVID|The program is offered by two facilitators to groups of three to six women, online in a synchronous mode. The intervention is divided into two phases, each including three sessions. The first 3 sessions aim to explore how the participants feel, to better understand what makes them feel this way, to allow them to exchange with other people who are going through similar experiences, and to support the ability to manage stress and more unpleasant emotions. The following three sessions aim to enable participants to refocus on their experience of pregnancy and motherhood by giving them the opportunity to reflect upon how they wish to be as mothers, upon how their personal history influences their experience of pregnancy and motherhood, upon the moments that, as mothers, might be the most pleasant and those that will require more adaptations, and upon identifying the needs they have or expect to have after childbirth as well as the resources available to them to meet these needs.
75576162|NCT00450710|Procedure|ileal interposition with a sleeve gastrectomy|
76049029|NCT04687761|Drug|Azacitidine|AZA 75 mg/m2/daily SC days 1 to 7 or on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle
76049030|NCT04687761|Drug|Venetoclax|Venetoclax (ramp-up) 400 mg/daily oral days 1 to 28
75576163|NCT04698824|Procedure|Hypnosis session|"At least one session of hypnosis in the internal medicine unit at the hospital Groupe Hospitalier Mutualiste de Grenoble"
75576164|NCT00450827|Biological|bevacizumab|
75576165|NCT00450827|Biological|filgrastim|
75726746|NCT00878306|Drug|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
76049031|NCT04687761|Drug|Quizartinib|Quizartinib 40 mg/daily oral, days, 8 to 28
76049032|NCT04687761|Drug|Cytarabine|Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10
76049033|NCT04687761|Drug|Venetoclax|Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28
75429467|NCT01499017|Drug|PF-06291874 or Placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
76049034|NCT04687761|Drug|Quizartinib|Quizartinib 40 mg/daily oral, days 8 to 28
76049035|NCT02419313|Drug|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
76049036|NCT02419313|Drug|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
75429468|NCT01499056|Biological|stem cell injection|intra articular inection of mesenchymal stem cell
75576166|NCT00450827|Procedure|autologous hematopoietic stem cell transplantation|
76049037|NCT04730193|Drug|Caffeine|Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient
76049038|NCT04730193|Drug|Placebo|Placebo pill will be formulated with a non active ingredient such as rice flour powder
76049039|NCT02419001|Drug|Period 1 - Treatment Sequence AB|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
75429469|NCT01499069|Drug|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|"Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months"
75429470|NCT01499108|Drug|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
75576167|NCT00450827|Radiation|iodine I 131 monoclonal antibody 3F8|
75576168|NCT00450905|Device|PRIMA Device|
75576169|NCT00450944|Biological|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
75576170|NCT05417607|Behavioral|P-ESDM informed caregiver coaching|Caregiver coaching informed by P-ESDM done remotely (via telehealth)
75576171|NCT00451061|Drug|Alfuzosin|
75576172|NCT00451061|Drug|Tamsulosin|
75576173|NCT03455127|Other|FSI ECD|Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
75576174|NCT02931578|Other|Glucose100|
75576175|NCT02931578|Other|Glucose50|
75576176|NCT02931578|Other|Glucose42|
75576177|NCT02931578|Other|Oral Glucose Tolerance Test|For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
75576178|NCT02931344|Dietary Supplement|Dietary Supplement: Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
75726747|NCT00878306|Drug|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
76049040|NCT02419001|Drug|Period 1 - Treatment Sequence AC|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
76049041|NCT02419001|Drug|Period 2 - Treatment Sequence AB|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
76049042|NCT02419001|Drug|Period 2 - Treatment Sequence AC|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
76049043|NCT02031237|Radiation|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
76049044|NCT02031237|Radiation|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
75576179|NCT02931383|Drug|Liraglutide 3 mg (Saxenda)|
75576180|NCT02931383|Drug|Liraglutide 3 mg placebo|
75576181|NCT02931422|Behavioral|Financial incentive|Conditional cash transfer upon HIV testing
75429471|NCT01499121|Drug|Sunitinib|The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop > grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
75429472|NCT01499186|Other|Local Vibration|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
75429473|NCT01499212|Procedure|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
75429474|NCT01499225|Drug|YH14642 500mg Tab|YH14642 500mg per day(once a day)
75429475|NCT01499225|Drug|YH14642 500mg Tab|YH14642 1000mg per day(twice a day)
75429476|NCT01499225|Drug|YH14642 500mg Tab|YH14642 2000mg per day(three times a day)
75576182|NCT02931461|Procedure|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration|
75576183|NCT04593641|Biological|CT-P59|administered
75576184|NCT04341441|Drug|Hydroxychloroquine - Daily Dosing|"The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
75576185|NCT04341441|Drug|Hydroxychloroquine - Weekly Dosing|"The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
75726748|NCT00878384|Drug|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of <80bpm and <110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
75429477|NCT01499225|Drug|INSADOL[Zea mays L. extract] 35mg Tab|"[Initiation dose : 4weeks after administraion] INSADOL[Zea mays L. extract] 210mg TAB per day~[Maintain dose : Between 4weeks and 8weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day~[Maintain dose : Between 8weeks and 12weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day"
75429478|NCT01499225|Drug|DENTISTA[Doxycycline hyclate] 20mg Cap|DENTISTA[Doxycycline hyclate] Cap 40mg per day
75429479|NCT01499225|Drug|Placebo|Placebo
75429480|NCT01499238|Device|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
75429481|NCT01499238|Device|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
75429482|NCT01499251|Drug|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
75429483|NCT01499251|Drug|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
75429484|NCT01499251|Drug|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
75429485|NCT01499264|Device|MySkin patch|Hydrogel and polyurethane film
76049045|NCT02031237|Radiation|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
75429486|NCT01499264|Device|Traditional Dressing|Gauze and Patch
76049046|NCT02031237|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
75429487|NCT01499316|Procedure|High Flow oxygen|10 minute shigh flow oxygen
75576186|NCT04341441|Other|Placebo oral tablet|"Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..~Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.~Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected."
75576187|NCT04341441|Diagnostic Test|Monitoring Visit - Baseline|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
76049047|NCT02088957|Drug|Brivaracetam intravenous solution|"Active Substance: Brivaracetam~Pharmaceutical Form: Solution for infusion~Concentration: 10 mg/mL~Route of Administration: Intravenous bolus use"
76049048|NCT02088957|Drug|Brivaracetam oral tablets|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~Route of Administration: Oral use"
76049049|NCT02088957|Drug|Phenytoin intravenous solution|"Active Substance: Phenytoin~Pharmaceutical Form: Solution for infusion~Concentration: 50 mg/mL~Route of Administration: Intravenous use"
76049050|NCT02088957|Drug|Phenytoin oral tablets|"Active Substance: Phenytoin~Pharmaceutical Form: Tablet~Concentration: Weight based~Route of Administration: Oral use"
75429488|NCT01499316|Procedure|Room Air|Room air breathing
75429489|NCT01499407|Device|ClearWay RX catheter|
75576188|NCT04341441|Diagnostic Test|Monitoring Visit - Week 4|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
75726749|NCT00878384|Procedure|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
75726750|NCT04082975|Drug|NVP-1203|Oral dose for 7 days
75726751|NCT04082975|Drug|NVP-1203-R|Oral dose for 7 days
75726752|NCT04082975|Drug|NVP-1203 placebo|Oral dose for 7 days
75726753|NCT04082975|Drug|NVP-1203-R placebo|Oral dose for 7 days
75726754|NCT00994617|Drug|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
75726755|NCT00994617|Drug|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
76049051|NCT02418845|Drug|SYM-1219|
76049052|NCT02418845|Drug|Placebo|
75429490|NCT01499407|Drug|Abciximab|
75429491|NCT01499433|Drug|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
75429492|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
75429493|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
75429494|NCT01499446|Drug|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
75429495|NCT01499446|Drug|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
75429496|NCT01499459|Genetic|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
75429497|NCT01499472|Device|shock wave therapy|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
75429498|NCT01499472|Device|dermagold shockwave|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
75429499|NCT01499472|Procedure|standard of care|regular care including debridement and bandaging.
75429500|NCT01499485|Drug|Acetazolamide|"Daily morning ABGA:~If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of acetazolamide 500 mg .~If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of acetazolamide 500 mg.~If actual bicarbonate <= 26 mmol/L: omit treatment that day."
75576189|NCT04341441|Diagnostic Test|Monitoring Visit - Week 8|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
75576190|NCT04341441|Other|Weekly Assessment|Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 &7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.
75429501|NCT01499485|Drug|Placebo|"Daily morning ABGA:~If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of placebo.~If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of placebo.~If actual bicarbonate <= 26 mmol/L: omit treatment that day."
75726756|NCT00995397|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
75726757|NCT00995397|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
75726758|NCT00919451|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
76024726|NCT05745025|Other|Rehabilitation|"Rehabilitation will consist of education, value-based goal setting, Graded Motor Imagery (GMI) (3 components described below), and graded activity. Subjects will complete activities at treatment sessions and be asked to perform certain treatment activities at home.~Week 1: Pain education, functional value-based goal setting, laterality training (first component of GMI), one task for graded activity (task-based on patient goals)~Week 2: Continue week 1 activity, add graded motor imagery (second component of GMI), progress 1st graded activity, and initiate 2nd graded activity exercise.~Week 3- Mirror therapy (third component of GMI), assess knowledge and update education as needed, progress graded activity 1 and 2, and add 3rd graded activity if appropriate based on patient goals.~Week 4- Continue with week 3 activities. Discuss experience with meditation and progress graded activity as tolerated"
76049053|NCT02088177|Drug|Long-acting injectable naltrexone|Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
75429502|NCT01499537|Device|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
75429503|NCT01499537|Device|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
75429504|NCT01499550|Device|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
75429505|NCT01499550|Other|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
75429506|NCT01499589|Procedure|regional anesthesia|regional anesthesia procedure
75429507|NCT01499602|Drug|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
75429508|NCT01499602|Drug|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
75429509|NCT01499615|Device|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
75429510|NCT01499641|Drug|Methylprednisolone|Epidural methylprednisolone 40 mg or none
75576191|NCT04525937|Other|Patient Questionnaire|Patient Questionnaire
75576192|NCT04525937|Other|Provider Questionnaire|Provider Questionnaire
75576193|NCT01187953|Drug|Prograf (tacrolimus)|Administered per current product labeling
75576194|NCT01187953|Drug|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
75726759|NCT05684393|Other|frequency distribution type|One group is fitted using channel filterbank frequency distribution based on anatomy data extracted from post-OP CT measurements. The second (control) group is fitted with the standard frequency distribution used in MAESTRO 9 fitting software.
75726760|NCT04968743|Device|Transcranial magnetic stimulation (TMS)|TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.
75726761|NCT03016312|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
75726762|NCT03016312|Drug|Enzalutamide|Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
75726763|NCT05061953|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
75726764|NCT05059223|Drug|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
75576195|NCT05381259|Behavioral|hortitherapy in people living with Alzheimer's taking place in three different day care|"6 users benefiting from the horticultural workshop and 6 others from a usual workshop (control group) This control group will benefit from its usual workshop while the other group will participate in the horticultural workshop.~If it is impossible to carry out the workshops outdoors (rain or high heat), the day reception centers will provide a room to allow the workshops to be carried out. They will be adapted in terms of activities and materials."
76049054|NCT02030535|Drug|olodaterol|free combination with tiotropium
75726765|NCT05059223|Drug|Placebo|Placebo tablets, taken twice daily
75429511|NCT01499693|Drug|Magnesium Pantoprazole 20 mg|oral dose, twice a day
75429512|NCT01499693|Drug|Magnesium Pantoprazole 40 mg|oral dose, once a day (morning)
75429513|NCT01499693|Drug|Placebo|"oral dose, once a day (night)~Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group)."
75429514|NCT01499706|Behavioral|1-session of telephone-administered motivational interviewing|Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
75429515|NCT01499706|Behavioral|4-session telephone-administered motivational interviewing|Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
75429516|NCT01499719|Behavioral|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
75429517|NCT01499745|Behavioral|Pulmonary Rehabilitation|"Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation"
75429518|NCT01499758|Drug|Atorvastatin|80 Mg tablets
75429519|NCT01499771|Drug|Atorvastatin|80 Mg tablets
75429520|NCT01499784|Behavioral|pelvic floor muscle training|behavioral modification and pelvic floor muscle training
75429521|NCT01499797|Other|The CareWell programme|"The CareWell programme contains the following components:~multidisciplinary primary care teams~working with proactive care plans integrating cure, care and welfare~advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~medication review~case-management~guidelines for consultation of in-hospital geriatric experts~guidelines for transfers from primary care to home-based facilities and hospital and back~practice guidelines for management of common geriatric conditions"
75429522|NCT01499836|Other|PVB|paravertebral block
75429523|NCT01499875|Drug|Phenoxymethylpenicillin|mixture, 25 or 50 mg/kg taken once.
75429524|NCT01499901|Procedure|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
75429525|NCT01499901|Procedure|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
75576196|NCT02900157|Biological|MEDI9090|MEDI9090 will be administered by IV infusion
75576197|NCT02900157|Biological|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
75576198|NCT02931305|Drug|Epimedium Prenylflavonoids Extract|Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
75576199|NCT02931305|Drug|Placebo|Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
75429526|NCT01499914|Biological|influenza vaccination|Influenza vaccination in patients with cystic fibrosis
75429527|NCT01499927|Other|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
75576200|NCT04262817|Drug|Nicotine form|participants will receive 36mg/ml nicotine salt and freebase nicotine
75576201|NCT04262817|Other|E-cigarette experimental flavor|Participants will receive menthol and tobacco flavored e-cigarettes
75726766|NCT00919607|Drug|quetiapine fumarate extended-release|200mg,oral,single dose
75726767|NCT00919607|Drug|quetiapine fumarate extended-release|300mg,oral,single dose
75726768|NCT01014052|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
76024727|NCT01981096|Behavioral|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
76024728|NCT01981096|Behavioral|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
76024729|NCT02394613|Drug|ANX776|Single intravenous injection
75576202|NCT04679259|Diagnostic Test|Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood|Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.
75576203|NCT04679259|Diagnostic Test|Neurocognitive test|Neurocognitive test is performed before surgery and at 7 day after surgery
75726769|NCT05188391|Diagnostic Test|Deltoid Gap Sign|At first deltoid sign test will be performed and the result of the test will be noted for the patients who are already scheduled open medial ankle surgery due to diagnosed as ankle fracture. During the open surgery, the test results will be evaluated.
75576204|NCT04679259|Diagnostic Test|Assessment of delirium|Postoperative delirium is assessed daily during 7 days after surgery.
75576205|NCT02931149|Drug|Platelet-rich plasma|Submucosal injection with PRP was performed prior to endoscopic resection
75726770|NCT01014130|Radiation|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
76049055|NCT02030535|Drug|tiotropium|free combination with olodaterol
76049056|NCT02030535|Drug|Placebo|
76049057|NCT02030535|Drug|tiotropium|fixed dose combination with olodaterol
75429528|NCT01499966|Procedure|Plaster of Paris/ Tubigrip|"After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks"
75576206|NCT04679766|Procedure|Ice cream cone technique with immediate implant as a flapless bone regenerative method in management of patients with labial plte dehiscence|Atraumatic extraction will be done The extraction socket will be debrided to remove any residual debris using surgical curettes Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence. Implant placement will be done. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability Resorbable collagen membrane will be cut confirming to the size and shape of the defect of labial bone plate dehiscence. The membrane will be placed against internal surface of the extraction socket against the remaining buccal plate of bone. The gap between the collagen membrane and the implant fixture will be filled with xenograft particulates.The membrane will be folded in palatal direction to seal the socket in an ice cream cone shape, then will be secured using non-resorbable sutures
75576207|NCT02931188|Drug|Anacetrapib|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
75576208|NCT02931188|Drug|Statin|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
75576209|NCT02931188|Drug|Placebo|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
75576210|NCT01217944|Drug|Ranibizumab|0.5 mg ranibizumab intravitreal injection
75726771|NCT01014130|Radiation|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
75726772|NCT05187221|Behavioral|CVS Group|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.
76049058|NCT02030535|Drug|olodaterol|fixed dose combination with tiotropium
75726773|NCT02587637|Device|Dorsal Root Ganglion Stimulation|
75726774|NCT00512902|Drug|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
75726775|NCT00512902|Drug|Imatinib|Up to 600 mg QD PO for up to 1 year.
75726776|NCT01014364|Drug|hydrocortisone|50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
75726777|NCT01014364|Drug|isotonic saline|intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
75429529|NCT01499979|Procedure|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
75576211|NCT01217944|Drug|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
75576212|NCT01217944|Drug|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
75576213|NCT01217944|Drug|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
76049059|NCT04710537|Other|AlloDerm|Enrolled patients will have one of their breasts reconstructed with AlloDerm at the time of their breast reconstruction surgery.
76049060|NCT04710537|Other|DermACELL|Enrolled patients will have one of their breasts reconstructed with DermACELL at the time of their breast reconstruction surgery.
76049061|NCT02029989|Device|Glucose and lipids|"Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids"
75429530|NCT01499992|Procedure|Standard physical therapy program PLUS aquatic physical therapy|2. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
75429531|NCT01499992|Other|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
75429532|NCT01500005|Drug|Baby D3 drops|2000-4000 iu per day
75429533|NCT01500018|Drug|TC-5214|Single oral dose of 2 mg
75429534|NCT01500018|Drug|TC-5214 Placebo|Single oral dose
75429535|NCT01500018|Drug|Ketamine|Single oral dose of 100 mg
75429536|NCT01500018|Drug|Phentermine|Single oral dose of 45 mg
75429537|NCT01500018|Drug|TC-5214|Single oral dose of 8 mg
75429538|NCT01500018|Drug|TC-5214|Single oral dose of 16 mg
75726778|NCT04082351|Dietary Supplement|Nanotechnology structured water ( Magnalife)|Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
75726779|NCT04082351|Dietary Supplement|ordinary water|Ordinary bottled water
76049062|NCT02029989|Device|Glycosylated Hemoglobin A1c|"Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c"
76049063|NCT02029989|Device|Blood Pressure and Heart Rate|"Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate"
76049064|NCT02029989|Device|Body mass index|Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
76049065|NCT02029989|Device|Waist and Hip circumference|"Measurement for Central Obesity~Waist and Hip circumference"
76049066|NCT02029989|Behavioral|Comprehensive Medication Management|Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
75429539|NCT01500018|Drug|Phentermine|Single oral dose of 90 mg
75429540|NCT01500070|Device|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
75429541|NCT01500122|Drug|RhuDex|"Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions."
76049067|NCT02048241|Behavioral|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
76049068|NCT02048241|Other|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
76049069|NCT02048241|Drug|Intuniv|Weekly administration of medication in doses as per protocol
76049070|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
76049071|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
76049072|NCT02087943|Drug|Placebo|Orally twice a day (BID)
76049073|NCT02087943|Drug|Placebo|Orally twice a day (BID)
75429542|NCT01500148|Device|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
75429543|NCT01500161|Drug|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
75429544|NCT01500161|Drug|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
75429545|NCT01500161|Drug|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
75726780|NCT01015300|Drug|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
75726781|NCT04082507|Diagnostic Test|Serum alpha-fetoproteine|Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
76049074|NCT02029521|Dietary Supplement|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
76049075|NCT02029521|Dietary Supplement|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
76049076|NCT04685811|Drug|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.
76049077|NCT04709211|Procedure|Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca block using 50 ml 0f Bupivacaine 0.25%
75576214|NCT04238013|Other|Whole Body Vibration (WBV)|The WBV session will consist of 8 bouts of 45s vibration (50Hz) with a minute of rest in between each bout.
75576215|NCT04238013|Other|Electrical Stimulation|The electrical stimulation intervention serves to account for any effects of standing and/or of repeated performance of the sit-to-stand behavior on neurophysiological outcomes. In the electrical stimulation intervention, participants will receive electrical stimulation while standing on the vibration platform for 8 bouts for 45s with a minute of rest in between without vibration.
75576216|NCT04689737|Drug|Doravirine|Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
75429546|NCT01500161|Drug|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
75726782|NCT01015378|Procedure|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
75576217|NCT05342220|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning through inflation of a blood pressure cuff to systolic blood pressure values > 200mmHg for 5 minutes (3 times) each before electrocardioversion Electrical cardioversion for atrial fibrillation (100, 150, 200 Joule)
75576218|NCT05342220|Procedure|Sham preconditioning|Inflation of a blood pressure cuff to systolic blood pressure values ~ 20mmHg for 5 minutes (3 times) each before electrocardioversion
76049078|NCT04709211|Procedure|Anterior Quadratus Lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using 50 ml 0f Bupivacaine 0.25%
75576219|NCT04689815|Drug|Oral Arsenic Trioxide Formulation|Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
76049079|NCT04709211|Drug|bupivacaine|bupivacaine
75429547|NCT01500161|Drug|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
75429548|NCT01500161|Drug|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
75726783|NCT01015456|Drug|mycophenolate sodium|per oral, twice daily, for 12 months
75726784|NCT01015456|Drug|cyclophosphamide|intravenous, monthly, for 6 months
75726785|NCT00919841|Other|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
75726786|NCT02589041|Procedure|intraneural sciatic nerve injection|"A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication."
76049080|NCT02443883|Drug|Ramucirumab|Administered IV
76049081|NCT02460263|Device|Tablo Hemodialysis System|
76049082|NCT02443805|Biological|300 IR|300 IR tablet of HDM Allergen Extracts
76049083|NCT02443805|Biological|Placebo|Placebo tablet
76049084|NCT01652885|Drug|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
76049085|NCT02459951|Other|clenched fist|Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
75429549|NCT01500161|Drug|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
75429550|NCT01500174|Device|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
75429551|NCT01500174|Device|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
75429552|NCT01500265|Biological|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
75429553|NCT01500291|Other|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
75576220|NCT05341557|Drug|BPI-371153|Subjects will receive BPI-371153 until disease progression
75576221|NCT01187446|Radiation|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
76049086|NCT04931927|Behavioral|Making Connections Intervention-Telehealth (MCI-T)|Single session telehealth engagement intervention plus telehealth treatment as usual (TAU) [MCI-T +TAU]
75576222|NCT01187446|Drug|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
75576223|NCT02931110|Drug|CBL0137|CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
75576224|NCT04224285|Other|Dayzz app|Personalized sleep training app that evaluates sleep issues and offers a complete, holistic sleep improvement solution
75576225|NCT02930993|Biological|anti-mesothelin CAR T cells|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
75576226|NCT02931227|Procedure|temperature obtained by the non-invasive method of zero-heat flux|
75576227|NCT02931227|Procedure|esophageal temperature|
75429554|NCT01500304|Procedure|Minimally invasive inguinal lymph node dissection|Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
75429555|NCT01500330|Procedure|cupping massage|the upper back is covered in massage oil the cupping glass is drawn along the back muscles
75429556|NCT01500330|Procedure|Progressive muscle relaxation|standardized programme on muscle relaxation according to Jacobson
75429557|NCT01500343|Drug|Saccharomyces boulardii|1 gram per day, during 3 months
75576228|NCT02931227|Procedure|intracerebral temperature|
75576229|NCT02931227|Procedure|arterial temperature|
75726787|NCT02589041|Drug|Ropivacaine 1%|
75726788|NCT00919139|Other|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
76049087|NCT04931927|Behavioral|Treatment as usual (TAU)|Telehealth treatment as usual without the single session telehealth engagement intervention
76049088|NCT04922957|Drug|ALLOCETRA-OTS|The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
75429558|NCT01500356|Behavioral|Behavioral weight loss intervention|Weight loss intervention that focuses on reducing energy intake.
75429559|NCT01500356|Behavioral|Diet Plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
75429560|NCT01500356|Behavioral|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
75576230|NCT04191798|Behavioral|Telerehabilitation using the KinexConnect system for rehabilitation after TKA.|KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.
75576231|NCT04191798|Behavioral|Traditional outpatient PT for rehabilitation after TKA.|Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
75576232|NCT02931071|Drug|filgrastim|G-CSF (12 μg/Kg/12 h) 8 days.
75576233|NCT02931071|Drug|plerixafor|Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
75576234|NCT02931032|Procedure|Sampling of dental plaque / infected dentine|A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
75576235|NCT01187407|Drug|LY2216684|
75576236|NCT01187407|Drug|Placebo|
75576237|NCT01187407|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
75576238|NCT00554034|Drug|periopatch|Patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study.
75726789|NCT00492232|Drug|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
75726790|NCT00492232|Drug|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
75576239|NCT02930681|Dietary Supplement|Glucosanol 500mg|
75576240|NCT02930681|Dietary Supplement|Placebo|
75429561|NCT01500369|Other|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
75576241|NCT05310058|Dietary Supplement|C6 ketone di-ester|C6 ketone di-ester
75576242|NCT05308576|Biological|SCTV01E|D0; intramuscular injection
75576243|NCT05308576|Biological|Placebo|D0; intramuscular injection
75576244|NCT02930876|Behavioral|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
75576245|NCT05329311|Procedure|ERATS protocol applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying the ERATS protocol will be investigated.
75576246|NCT05329311|Procedure|ERATS protocol not applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying without the ERATS protocol will be investigated.
75576247|NCT01186978|Radiation|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
75576248|NCT04506905|Drug|MK-8189|MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
75576249|NCT04506905|Drug|Placebo|Oral tablets of dose-matched placebo to MK-8189 according to randomization
76049089|NCT04922957|Other|Placebo|Ringer's lactate solution
75429562|NCT01500369|Other|standard of care|Placebo Comparator
75429563|NCT01500395|Procedure|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
75429564|NCT01500408|Drug|Interferon beta-1a (current approved manufacturing process invloving FBS)|Single dose of 60 mcg given Intramuscularly (IM)
75576250|NCT05326230|Device|Paradise™ (PRDS-001) Renal Denervation Ultrasound System|Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control
75726791|NCT02587871|Drug|Cytarabine|Given IV
75726792|NCT02587871|Other|Laboratory Biomarker Analysis|Correlative studies
75576251|NCT05326230|Device|Renal Angiogram|Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure
75726793|NCT02587871|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
75576252|NCT01186939|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m^2/day.
75726794|NCT02587871|Biological|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
75726795|NCT02587871|Biological|G-CSF mobilized peripheral blood cells|microtransplantation
75726796|NCT05683379|Diagnostic Test|AAV8 DetectCDx|An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
75576253|NCT04318483|Other|survey|parents' telephone interview to collect medical history
75576254|NCT00554112|Behavioral|Exercise|Exercise
75576255|NCT05463172|Other|abdominal strengthening exercises|abdominal strengthening exercises
75576256|NCT05463172|Other|pelvic floor muscles strengthening exercises|to strengthen pelvic floor muscles
75576257|NCT05461105|Drug|rencofilstat, 75 mg|1 softgel capsule
75576258|NCT05461105|Drug|rencofilstat, 150mg|2 softgel capsules
75576259|NCT05461105|Drug|rencofilstat, 225 mg|3 softgel capsules
75576260|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
75726797|NCT02587793|Other|not interventional study|
75726798|NCT04082273|Device|Femtosecond Laser for Cataract Surgery|Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment
76049090|NCT02087241|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
75429565|NCT01500408|Drug|Interferon beta-1a (new process, manufactured without FBS)|Single dose of 60 mcg given Intramuscularly (IM)
75429566|NCT01500421|Device|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
75576261|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
75576262|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
75429567|NCT01500421|Device|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
75429568|NCT01500421|Device|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
75429569|NCT01500486|Device|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
75429570|NCT01500499|Genetic|gene expression analysis|
75429571|NCT01500499|Genetic|gene rearrangement analysis|
75429572|NCT01500499|Genetic|polymerase chain reaction|
75429573|NCT01500499|Genetic|protein analysis|
75429574|NCT01500499|Genetic|western blotting|
75429575|NCT01500499|Other|laboratory biomarker analysis|
75429576|NCT01500499|Other|mass spectrometry|
75429577|NCT01500512|Other|Clinical Observation|Undergo observation
75576263|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
75576264|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
75576265|NCT04447040|Drug|Placebo|Placebo tablets administered as a single two-tablet dose.
75429578|NCT01500538|Drug|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
75576266|NCT02930642|Behavioral|Mindful Eating|Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.
75576267|NCT02930642|Other|Nutrition DVD|Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
75576268|NCT03455205|Drug|shenqifuzheng|500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.
75576269|NCT03455205|Drug|0.9%sodium chloride|500ml sodium chloride（0.9%）daily（at day 1-7 and day22-28）through intravenous infusion.
75576270|NCT02930954|Drug|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
75576271|NCT02930954|Drug|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
75576272|NCT02930954|Drug|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
75726799|NCT04082273|Other|Conventional Cataract Surgery|Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
75726800|NCT00919919|Drug|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
75726801|NCT00919919|Drug|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
75429579|NCT01500564|Device|anodal tDCS (device) Eldith DC-Stimulator|tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
75429580|NCT01500564|Device|Sham tDCS|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
75429581|NCT01500577|Drug|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
75429582|NCT01500577|Drug|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
75429583|NCT01500577|Other|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
75429584|NCT01500590|Drug|Renin-angiotensin system blockers|ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
75429585|NCT01500590|Drug|non-renin angiotensin system blockers|amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
75429586|NCT01500603|Device|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
75576273|NCT05290467|Behavioral|Online antenatal care|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Messages, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
75576274|NCT02930759|Drug|BAY987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-096)
75726802|NCT04082195|Other|Fooya mobile game|An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.
75726803|NCT04082195|Other|Uno board game|A popular board game which is not a mobile app.
76024730|NCT02394691|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
76024731|NCT02652767|Biological|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
75726804|NCT04807595|Other|None (Observational study)|The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
75878703|NCT03641274|Other|Case-management intervention for frequent users of the emergency department|The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
76024732|NCT02652767|Device|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
76024733|NCT04480333|Drug|Drug: NA-831 - 0.10 mg/kg|NA-831 in nanoparticle inhalation formulation
76024734|NCT04480333|Drug|Placebo- 0.10 mg/kg|Placebo in nanoparticle inhalation formulation
75429587|NCT01500603|Device|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
75576275|NCT03457649|Biological|ARGX-113|
75576276|NCT03457649|Biological|Placebo|
75726805|NCT02587091|Behavioral|Portable obstetric ultrasound|This intervention was advertised at the cluster level
75726806|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
75726807|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
75726808|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
75726809|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
75576277|NCT04141917|Combination Product|Point-of-care molecular testing and treatment of influenza|Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged <12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
75576278|NCT02930525|Other|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
75726810|NCT00491764|Drug|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
75726811|NCT00491764|Drug|Placebo|Placebo for 24 weeks.
75726812|NCT04082039|Other|convetional PCA method unsing only 1-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
75726813|NCT04082039|Other|utilizing 2-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
75726814|NCT02586311|Drug|CKD-330 16/5mg|Once a day, 8 weeks
75878704|NCT03644004|Other|frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.|"Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data."
75576279|NCT02930525|Other|Standard respiratory care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
75576280|NCT04117659|Other|withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients|discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
75576281|NCT02930798|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z46-116)"
75576282|NCT02930408|Procedure|electrocardiogram|
75576283|NCT02930408|Procedure|Echocardiography|
75576284|NCT04116606|Drug|Active JNJ-54175446|JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
75726815|NCT02586311|Drug|Amlodipine 5mg Placebo|Once a day, 8 weeks
75726816|NCT02586311|Drug|CKD-330 16/5mg Placebo|Once a day, 8 weeks
75726817|NCT02586311|Drug|Amlodipine 5mg|Once a day, 8 weeks
75726818|NCT02586467|Behavioral|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
75726819|NCT02586467|Behavioral|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
75726820|NCT02586467|Behavioral|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
75878705|NCT03643926|Procedure|Arthroscopic Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view
76024735|NCT04480333|Drug|Drug: NA-831 - 0.20 mg/kg|NA-831 in nanoparticle inhalation formulation
75576285|NCT04116606|Drug|Placebo|Matching placebo containing the same excipients
75576286|NCT02930915|Device|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
75576287|NCT02930447|Device|Autologous glue|Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
75429588|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
75429589|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
75429590|NCT01500044|Procedure|Program targeting the opening of foramen|Rehabilitation intervention that specifically targets the opening of the intervertebral foramen
75429591|NCT01500044|Procedure|Conventional Rehabilitation Program|Program used in previous randomized clinical trials in this population
75429592|NCT01500642|Biological|Slit One|slit one sublingual immunotherapy 200 stu
75429593|NCT01500642|Biological|Slit One|slit one vestibular immunotherapy 200 stu
75429594|NCT01500642|Biological|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
75429595|NCT01500655|Procedure|Regional nerve block|a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
75429596|NCT01500655|Procedure|Catheter|After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
75429597|NCT01500668|Drug|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
75429598|NCT01500668|Drug|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
75726821|NCT02586467|Behavioral|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
75429599|NCT01500707|Drug|SCH 900800|SCH 900800, one 20 mg tablet, orally
75429600|NCT01500785|Drug|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
75429601|NCT01500785|Drug|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
75576288|NCT04679571|Biological|Albumin|Patients with serum albumin <3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin >3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin >3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.
75726822|NCT02586467|Behavioral|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
75726823|NCT00491608|Biological|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
75726824|NCT01018888|Device|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
75726825|NCT04678583|Procedure|Resection of colorectal liver metastases|Comparison of two liver surgery methods
75726826|NCT03996928|Other|Exercise|
75429602|NCT01500811|Biological|cell injection|Intra articular injection of chondrocyte
75429603|NCT01500824|Drug|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
75429604|NCT01500837|Drug|association of RIFAMPIN + CLINDAMYCIN|association of RIFAMPIN + CLINDAMYCIN
75429605|NCT01500837|Drug|association of LEVOFLOXACIN+ CLINDAMYCIN|association of LEVOFLOXACIN+ CLINDAMYCIN
75429606|NCT01500850|Drug|nph insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
75429607|NCT01500850|Drug|human insulin|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal"
75429608|NCT01500850|Drug|Insulin Glargine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
75429609|NCT01500850|Drug|Insulin glulisine|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal"
75429610|NCT01500863|Drug|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
75429611|NCT01500863|Drug|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
75429612|NCT01500863|Drug|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
75576289|NCT04679571|Drug|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year."
75576290|NCT02930369|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
75576291|NCT02930486|Device|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
75576292|NCT02930486|Device|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
75429613|NCT01500863|Drug|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
75878706|NCT03643926|Procedure|Open Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
76024736|NCT04480333|Drug|Placebo- 0.20 mg/kg|Placebo in nanoparticle inhalation formulation
75429614|NCT01500863|Drug|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
75429615|NCT01500863|Drug|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
75429616|NCT01500876|Radiation|4D-CT pre-treatment scan|Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
75429617|NCT01500889|Procedure|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
75576293|NCT04679415|Drug|hzVSF-v13|Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7
75576294|NCT04679415|Drug|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7
75576295|NCT02930330|Behavioral|INT|"5 min warm-up (40% Pmax*)~30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~10 min cool-down (30% Pmax)~Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
75576296|NCT02930330|Behavioral|CONT|"5 min warm-up (40% Pmax*)~30 min moderate intensity continuous training (60% Pmax)~10 min cool-down (30% Pmax)~Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
75726827|NCT04675775|Other|Medically-tailored meals (MTM)|After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.
75726828|NCT04675775|Dietary Supplement|Protein supplements|"A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving."
75576297|NCT02929940|Other|No intervention|No Intervention, observational
76049091|NCT02087241|Drug|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
76049092|NCT02087241|Drug|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
76049093|NCT02087241|Drug|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
76049094|NCT02087085|Drug|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
75576298|NCT02930057|Drug|Celestone|all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
76024737|NCT04480333|Drug|Drug: GS-5734 - 1.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
76049095|NCT02087085|Other|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
76049096|NCT02443337|Drug|LY3023414|Administered orally
76049097|NCT02443337|Drug|Necitumumab|Administered IV
76049098|NCT04684251|Procedure|Coil embolisation of hemorrhoidal arteries.|Coil embolisation of hemorrhoidal arteries as previously described.
76049099|NCT02443103|Drug|Guanabenz acetate|
75576299|NCT02930057|Procedure|pulsed radiofrequency treatment|all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
75576300|NCT02930057|Drug|Control|all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
75576301|NCT05238363|Drug|HLX07|HLX07 1500mg ivgtt Q3W
75576302|NCT02930135|Procedure|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
75726829|NCT04675775|Behavioral|Nutrition education handout|A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
75726830|NCT02586545|Other|Shared care|
76024738|NCT04480333|Drug|Placebo- 1.00 mg/kg|Placebo in nanoparticle inhalation formulation
76024739|NCT04480333|Drug|Drug: GS-5734 - 2.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
76049100|NCT02022657|Drug|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
76024740|NCT04480333|Drug|Placebo- 2.00 mg/kg|Placebo in nanoparticle inhaled formulation
76024741|NCT04480333|Combination Product|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
76024742|NCT04480333|Combination Product|Placebo 0.10 mg + 1.00 mg/kg|The combined placebo are in nanoparticle inhaled formulation
75576303|NCT04080492|Other|QOL Survey|The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
75429618|NCT01500889|Procedure|GroupII: V-Y advancement flap|"GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide."
75726831|NCT04932785|Other|Regular diet|Regular diet
75726832|NCT04932785|Other|Clear Liquid Diet|Clear Liquid Diet
75429619|NCT01500889|Procedure|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
75429620|NCT01500902|Other|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
75429621|NCT01500902|Other|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
75429622|NCT01500915|Drug|Ranibizumab|0,5mg intravitreal ranibizumab
75429623|NCT01500928|Device|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
75429624|NCT01500941|Dietary Supplement|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
75429625|NCT01500941|Other|maltodextrin|sachets
75429626|NCT01500967|Other|Shi-style cervical manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
75429627|NCT01500967|Other|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
75429628|NCT01500980|Biological|P. falciparum infection|P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
75429629|NCT01500980|Drug|Chloroquine|Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
75429630|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 post ITV infection
75429631|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
75429632|NCT01500993|Drug|Capecitabine|Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
75429633|NCT01500993|Drug|5-FU|4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
75429634|NCT01501019|Other|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
75576304|NCT04049721|Procedure|HBO|2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks.
75726833|NCT02587715|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
75878707|NCT03640884|Drug|Xueshuantong-Injection|Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
75726834|NCT02587715|Other|Liberation therapy|
75726835|NCT04777721|Biological|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
75429635|NCT01501032|Device|MD-logic artificial pancreas system|The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
75429636|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
75429637|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
75429638|NCT01501058|Behavioral|parent-assisted social skills training program for adolescents with autism spectrum disorder|The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
75429639|NCT01501058|Behavioral|Delayed intervention|Intervention is provided to Waitlist Control Group after waiting for 14 weeks
75429640|NCT01501071|Device|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
75429641|NCT01501084|Drug|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
75429642|NCT01501084|Drug|Normal saline .2cc subcutaneous injection|sterile saline injection
75429643|NCT01501097|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
75429644|NCT01501123|Drug|Haloperidol|5mg IM
75576305|NCT04049721|Other|Standard of Care|20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
75726836|NCT00615836|Drug|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
75429645|NCT01501123|Drug|Midazolam|IM midazolam
75429646|NCT01501136|Other|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
75429647|NCT01501136|Other|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
75726837|NCT05139212|Procedure|Optimum time for intravenous cannulation in children premedicated with dexmedetomidine|The optimum time for intravenous cannulation after the induction of anesthesia with sevoflurane, oxygen, and nitrous oxide in children with intranasal dexmedetomidine premedication will be searched in children undergoing elective surgery.
75726838|NCT04040270|Behavioral|Live drama+DVD+Worksheets|"Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
75429648|NCT01501136|Other|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
75726839|NCT04040270|Behavioral|DVD+Worksheets|"The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
75726840|NCT00872924|Drug|sumatriptan 100mg|
75576306|NCT02930252|Device|Niti-S Biliary ComVi Stent|Endoscopic placement of biliary fully covered metal stents
75576307|NCT02930252|Device|Niti-S stent (D type)|Endoscopic placement of biliary uncovered metal stent
75576308|NCT04017000|Diagnostic Test|Bladder Shape Test|Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
75576309|NCT04017000|Other|Calibration images|Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
75576310|NCT04007406|Drug|DP13|DP13 systemic administration
75576311|NCT02929901|Dietary Supplement|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
75726841|NCT00867776|Behavioral|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
75726842|NCT00878540|Drug|mirtazapine|30 mg mirtazapine once daily for 7 days
75726843|NCT04039334|Other|Conventional Chest Physiotherapy|Conventional chest physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), teaching of respiratory control, relaxing and coughing techniques.
75726844|NCT04039334|Other|Creative Dance Based Exercise Training|Creative dance based exercise training will be given under the supervision of a physiotherapist who takes creative dance instructor training 2 days and 60 minutes per week.
75726845|NCT04018274|Drug|PF-06651600|50 mg by mouth (PO) once daily (QD)
75726846|NCT04018274|Drug|Ethinyl estradiol (EE) and levonorgestrel(LN)|Oral tablet containing 30 ug EE and 150 ug of LN
75726847|NCT00873002|Drug|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
75726848|NCT00873002|Drug|sorafenib tosylate|400 mg PO BID
75726849|NCT00491530|Drug|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
75726850|NCT00491530|Drug|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
75726851|NCT00491530|Drug|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
75878708|NCT03641040|Diagnostic Test|Video-oculography|measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
76049101|NCT02418455|Drug|UX003|solution for intravenous infusion
76049102|NCT02417753|Drug|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
75429649|NCT01501136|Other|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
75429650|NCT01501136|Radiation|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
75576312|NCT02929901|Dietary Supplement|caffeine|caffeine plus placebo
75576313|NCT02929901|Dietary Supplement|chlorogenic acid|chlorogenic acid plus placebo
75576314|NCT02929901|Dietary Supplement|placebo|placebo plus placebo
76049103|NCT02417441|Device|Eeva|Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.
76049104|NCT02021643|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
75429651|NCT01501149|Drug|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
75576315|NCT05237661|Dietary Supplement|Moon Balance|Moon Balance is a blend of 6 food ingredients
75576316|NCT02929784|Device|Intervention|Device: neuroConn_CE_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
75576317|NCT02929784|Device|Sham|no meaningful stimulation will be given.
75576318|NCT02929706|Genetic|Pre-genotype NUDT15 and optimize azathioprine dosage|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
75576319|NCT03993132|Drug|Empagliflozin|new users (initiators) of Empagliflozin
75726852|NCT00491530|Drug|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
75878709|NCT03641040|Diagnostic Test|Alternative prism cover test|measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
75878710|NCT03641976|Drug|A-FOLFOXIRI|"Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV"
75726853|NCT04040660|Drug|NexoBrid|NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)
75726854|NCT04313062|Behavioral|Educational Intervention|"An educational intervention based on the PM ACTIVAS' model and a  Falling Prevention Kit , both in a home visit by the trainees. Also, a telephone follow-up and a last house call 12 months after recruiting to assess the changes implemented by the person and their family, to conduct the final survey and to ask for the  Falls and Events Calendar  ."
75726855|NCT00867854|Other|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
75726856|NCT00873158|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
75878711|NCT03641976|Drug|Arm II (A-FOLFOX/A-FOLFIRI)|"Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV"
75878712|NCT01069692|Drug|SBR759A|SBR759A 6g daily
75576320|NCT03993132|Drug|Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA)|initiators of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA)
75576321|NCT02929628|Device|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
75576322|NCT00553878|Drug|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
75576323|NCT04407689|Drug|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
75576324|NCT04407689|Drug|Placebo|Intramuscular (IM) placebo (normal saline) at the same frequency
75726857|NCT00919685|Biological|blood sample|from rest of blood sample collected for other measurements
75576325|NCT05225064|Behavioral|Incentives to be vaccinated|Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
75576326|NCT05225064|Device|Mask|Individuals are given cloth masks
75726858|NCT00617240|Drug|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
75726859|NCT00617240|Drug|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
75726860|NCT04775927|Other|education|premarital education
75726861|NCT04039490|Device|SCENERGY|Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
75726862|NCT00878618|Drug|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
75726863|NCT00878618|Drug|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
75576327|NCT05225064|Behavioral|Encouragement to wear a mask|Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
75576328|NCT05225064|Behavioral|Vaccination made more convenient|Vaccines are conducted at the household-level rather than the village-level
75576329|NCT05225064|Behavioral|Social mobilization campaign to be vaccinated|Village-level social mobilization campaign to be vaccinated
75878713|NCT01069692|Drug|SBR759A|Placebo Comparator 0g daily
75878714|NCT01069692|Drug|SBR759A|SBR759A 3g daily
75878715|NCT01069692|Drug|SBR759A|9g daily
75878716|NCT01069692|Drug|SBR759A|12g daily
75878717|NCT03621228|Device|MindfulGarden|MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
75726864|NCT05676281|Behavioral|Healthy Together (Control)|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~6 Sessions with a Wellness Coach~4-8 sessions with a Dietician~4-8 sessions of Physical Theraphy~1 session during month 1 or 2 Streetwyze Training~Safety Net Referrals"
76049105|NCT02021643|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
76049106|NCT02021643|Drug|PEG|Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
76049107|NCT02415959|Drug|Creon IR|
76049108|NCT02415959|Drug|Creon® (DR/GR)|
76049109|NCT02021565|Behavioral|Immediate Intervention Group|Assistive Technology (AT) Specialists, experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform three activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, AT Specialists also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, AT Specialists provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
76049110|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
76049111|NCT05370677|Genetic|ARMS|amplification refractory mutation system
76049112|NCT02021331|Device|immediate implant placement without provisionalization|
75576330|NCT05222919|Dietary Supplement|Bare performance supplement|dietary supplement
76049113|NCT02021331|Device|immediate implant placement with immediate provisionalization|
76049114|NCT04682535|Other|Social relationships|Exposure to social interactions with spouse, friends, and family. Perceived loneliness, emotional strain, and emotional support.
76049115|NCT02085135|Drug|ALKS 5461|Sublingual tablet taken once daily
75429652|NCT01501149|Drug|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
76049116|NCT02441309|Drug|Mifamurtide|
76049117|NCT02441309|Drug|Ifosfamide|
75429653|NCT01501175|Other|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
75429654|NCT01501188|Other|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
75429655|NCT01501188|Other|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
75576331|NCT05222919|Dietary Supplement|Placebo|Placebo
75576332|NCT02929862|Drug|LYC-55716|For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
75576333|NCT04381052|Drug|Clazakizumab|Dose is 25mg intravenously over 30 minutes.
75576334|NCT04381052|Other|Placebo|Intravenously administered over 30 minutes.
75576335|NCT03956940|Device|Intplex test|Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
76049118|NCT02027025|Drug|SPARC1103 low dose|once daily
75576336|NCT00624325|Drug|interferon alfa-2b|12 MU daily continuously subcutaneous
75576337|NCT00624325|Drug|interferon alfa-2b|9 MU daily continuously subcutaneous
75576338|NCT00624325|Drug|interferon alfa-2b|6 MU daily continuously subcutaneous
75576339|NCT02929745|Procedure|Skin biopsy|Four 4-5 mm punch biopsies of the skin
75576340|NCT02929745|Procedure|Blood draw|Blood will be drawn to test for HLA-cw6 status
75576341|NCT05204823|Other|Experimental product|Chocolate milk shakes
75576342|NCT05204823|Other|Control product|Glucose
75576343|NCT04322279|Diagnostic Test|Serology|SARS-CoV-2 serology
75576344|NCT04322279|Genetic|Sequencing|Whole exome sequencing
76049119|NCT02027025|Drug|SPARC1103 high dose|once daily
76049120|NCT02027025|Drug|SPARC Placebo|
76049121|NCT01652729|Drug|Exenatide once weekly suspension|
76049122|NCT01652729|Drug|Sitagliptin|
76049123|NCT01652729|Drug|Placebo|Placebo oral capsule once daily
76049124|NCT02083965|Biological|rFVIIIFc|Administered as specified in the treatment arm.
76049125|NCT02438813|Drug|Deoxycholic acid|Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
76049126|NCT02438813|Procedure|Surgical Procedures|Surgical procedures for treatment of SMF as per standard of care in clinical practice.
76049127|NCT02438813|Procedure|Laser Liposuction|Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
75429656|NCT01501214|Drug|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
75429657|NCT01501214|Drug|Normal saline|Normal saline given
75429658|NCT01501227|Device|Taper Guard Endotracheal Tube|comparison of two different endotracheal tubes
75429659|NCT01501227|Other|Conventional endotracheal tube|Sham Comparator
75429660|NCT01501253|Drug|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
75429661|NCT01501253|Drug|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
75429662|NCT01501253|Drug|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
75429663|NCT01501279|Procedure|Pudendal nerve block|the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
75429664|NCT01501292|Other|Fixation and staining|Fixation and staining by MitiTracker Green FM
75429665|NCT01501292|Other|Observation by laser microscopy|Observation with Laser scanning confocal microscopy
75429666|NCT01501305|Dietary Supplement|Mineral solution|Rehydration mineral solution
75429667|NCT01501305|Dietary Supplement|Carob powder with probiotics|7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
75429668|NCT01501318|Behavioral|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
75429669|NCT01501318|Behavioral|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
75429670|NCT01501331|Device|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
75429671|NCT01501344|Dietary Supplement|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
75429672|NCT01501357|Behavioral|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
75429673|NCT01501357|Behavioral|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
75429674|NCT01501370|Drug|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
75429675|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
75726865|NCT05676281|Behavioral|Healthy Together + Promotora Support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~6 Sessions with a Wellness Coach~4-8 sessions with a Dietician~4-8 sessions of Physical Theraphy~1 session during month 1 or 2 Streetwyze Training~Safety Net Referrals~16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)"
75429676|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
75429677|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
75429678|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
75429679|NCT01501396|Drug|Megestrol Acetate|
76024743|NCT04480333|Combination Product|Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
75429680|NCT01501396|Drug|Mirtazapine|
75429681|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
75429682|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
75429683|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
75429684|NCT01501422|Drug|Estrogen patch|50 microgram estrogen patch weekly
75429685|NCT01501422|Drug|Placebo|Placebo patch for 8 weeks
75429686|NCT01501435|Drug|CJ-30039|single dose
75429687|NCT01501435|Drug|fenofibric acid|single dose
75429688|NCT01501448|Drug|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
75429689|NCT01501448|Drug|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
75878718|NCT03641898|Procedure|FFR-guided PCI|After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or >90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR >0.80 are defined as FNLs and should result in deferral of PCI.
75878719|NCT03641898|Diagnostic Test|Intravascular ultrasound|After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
75878720|NCT01344876|Drug|OPB-51602|once daily during the treatment period
75878721|NCT03641586|Drug|BGB-283|
75878722|NCT05183178|Drug|Prasugrel 10 mg p.o|Prasugrel 10 mg once daily p.o. Patient >75 years of age or <60 kg will receive 5 mg prasugrel OD.
75878723|NCT05183178|Drug|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily p.o.
75878724|NCT03640806|Other|PHYSICAL ACTIVITY|3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
75878725|NCT03572426|Other|genotyping all subjects|genotyping using SNaPshot genotyping method.
75878726|NCT02846324|Drug|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
75878727|NCT02846324|Drug|Placebo|Placebo capsules
75878728|NCT02240342|Drug|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
75878729|NCT03576092|Diagnostic Test|Lung Ultrasound|Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
75878730|NCT03161093|Drug|Fasinumab|Solution for injection in pre-filled syringe
75878731|NCT03161093|Drug|Naproxen|Pharmaceutical form: Capsule
75878732|NCT03161093|Drug|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
75878733|NCT03161093|Drug|Naproxen-matching placebo|Capsule
75878734|NCT02847650|Drug|Placebo|
75429690|NCT01501461|Procedure|Harvesting and implantation of stem cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.
75576345|NCT03934398|Diagnostic Test|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
75878735|NCT02847650|Drug|PF-06649751|
75878736|NCT03573440|Other|mindful education on eating|Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
75878737|NCT03573284|Diagnostic Test|fractional exhaled nitric oxide(FeNO)|FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
75429691|NCT01501487|Drug|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
75429692|NCT01501487|Drug|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
75576346|NCT03934398|Diagnostic Test|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.
75576347|NCT03934398|Diagnostic Test|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
75576348|NCT03934398|Diagnostic Test|Emotional/Behavioral Assessments|Participants and parents will fill out questionnaires for emotional/behavioral assessments
75576349|NCT02929550|Other|Well-controlled|Both groups got treatment but well-controlled reached target of LDL-C<1.8 mmol/l
75429693|NCT01501487|Drug|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
75576350|NCT02929511|Procedure|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
75576351|NCT02929511|Procedure|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
75878738|NCT03573284|Diagnostic Test|impulse oscillometry(IOS)|The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
75878739|NCT03576014|Biological|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2~4 weeks after the transplant.
75429694|NCT01501487|Drug|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
75429695|NCT01501487|Drug|T + trastuzumab followed by CEF + trastuzumab|"Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.~Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr"
75429696|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).~Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week."
75429697|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
75576352|NCT02929511|Procedure|Active comparator Protaper multi-file system|
75576353|NCT03934281|Device|Honey dressing Melectis G|"The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
75576354|NCT03934281|Device|HAS recommendation dressing|"Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
75576355|NCT04689893|Drug|68Ga-Dotatate|68Ga-Dotatate was injected into the patients before the PET/CT scans
75576356|NCT04689893|Drug|68Ga-DOTA-JR11|68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
75576357|NCT03922854|Other|Non-interventional data collection only|There is no clinical intervention. This study is just capturing data from devices used part of routine clinical care. The results of this data collection will be analysed to inform study results.
75576358|NCT05184426|Diagnostic Test|Echocardiogram|Ultrasound study to assess cardiac anatomy and function
75726866|NCT05676281|Behavioral|Healthy Together + Parenting Training|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~6 Sessions with a Wellness Coach~4-8 sessions with a Dietician~4-8 sessions of Physical Theraphy~1 session during month 1 or 2 Streetwyze Training~Safety Net Referrals~6-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
75726867|NCT05676281|Behavioral|Healthy Togethers + Parenting Training + Promotora support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~6 Sessions with a Wellness Coach~4-8 sessions with a Dietician~4-8 sessions of Physical Theraphy~1 session during month 1 or 2 Streetwyze Training~Safety Net Referrals~16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)~8-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
75726868|NCT05102942|Behavioral|Attentional Control Training Program|The 317 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 106), Group B: ACTP sham training delivered via a smartphone application + TAU (n = 106), or Group C: TAU only (n = 106). Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks). Patients in Group C will receive only the primary treatment for AUD.
75878740|NCT03575858|Device|Barrel shaped interdental brush|Barrel shaped interdental brush Size SS 0.8mm
75878741|NCT03575858|Device|Tapered interdental brush|Tapered interdental brush Size SS 0.6mm
75878742|NCT03575780|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
75878743|NCT01334255|Drug|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
75878744|NCT03575624|Behavioral|Nutritional and goal-setting education, yoga|"This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice"
75878745|NCT03573128|Behavioral|Students with Autism Accessing General Education|With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
75878746|NCT03573128|Other|Enhanced Services As Usual|Teaching staff access in-service presentations and print materials with no active study team coaching.
75878747|NCT01334333|Drug|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
76049128|NCT02438813|Device|Energy Devices|Energy Devices for the treatment of SMF as per standard of care in clinical practice.
76049129|NCT02438813|Other|Other Treatments|Other treatments for SMF as per standard of care in clinical practice.
76049130|NCT02437409|Device|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
76049131|NCT02459093|Device|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
76049132|NCT02459093|Device|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
75429698|NCT01501487|Drug|PTH followed by dose dense AC of FEC|"Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel."
75576359|NCT05184426|Diagnostic Test|Cardiac magnetic resonance|MR to assess cardiac anatomy, function and tissue damage
75878748|NCT01334333|Drug|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
76049133|NCT02458469|Drug|Buspirone|The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
75429699|NCT01501500|Drug|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
75429700|NCT01501500|Drug|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
75576360|NCT05184426|Diagnostic Test|Coronary angiography|Cathteterization to assess coronary anatomy. Intravascular ultrasound to obtained a detailed assessment of vessels anatomy. Guidewire pressure to assess microcirculation
75576361|NCT05184426|Diagnostic Test|Endomyocardial biopsy|Optic microscopy, immunofluorescence, transmission electron microscopy
75576362|NCT04689425|Drug|Umbilical cord blood mononuclear cell gel（MNC）|Local wound treatment by combination of PRP and MNC, once;
75576363|NCT04689425|Drug|The platelet rich plasma（PRP）|Local wound treatment by PRP alone, once.
75878749|NCT03573050|Drug|RIV-TDS 13.3 mg/24 h|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
75878750|NCT03573050|Drug|Exelon® 13.3 mg/24 hours transdermal patch|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
75878751|NCT03572894|Device|PVI and RPVI measurements|"PVI and RPVI measurements during variations of the tidal volume (Vt challenge) and a recruitment maneuver in anesthetized and mechanically ventilated patients.~T0 : Vt 6 mL/kg of predicted body weight (PBW) during 5 minutes~T1 : Vt 8 mL/Kg of PBW during 5 minutes~T2 : Vt 10 mL/kg of PBW during 5 minutes~T3 : Vt 6 mL/kg of PBW during 5 minutes~T4 : A single recruitment maneuver~Data will be recorded at each step."
75878752|NCT03575312|Drug|Enrofloxacin|dermal application, inhalation rsp. oral administration of Enrofloxacin
76024744|NCT04480333|Combination Product|Placebo 0.20 mg + 2.00 mg/kg|Placebo 0.10 mg + 1.00 mg/kg
76024745|NCT03166891|Drug|Chiauranib|Take 50mg orally once daily
76024746|NCT04969601|Biological|vaccine COMIRNATY® (BNT162b2)|two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
75429701|NCT01501539|Procedure|Standard Hydrocolloid Dressing|Treatment placed over insertion site.
75429702|NCT01501539|Procedure|Silver Hydrocolloid Dressing|Place dressing against skin under gastrostomy tube
76024747|NCT01980940|Drug|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
76024748|NCT01980940|Drug|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
76024749|NCT01980940|Drug|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
75576364|NCT05184192|Drug|Gabapentin gelatin capsules 300mg|Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
75576365|NCT05184192|Drug|Placebo|lactose monohydrate NF
75576366|NCT04689581|Other|Ultrasound guided bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
75576367|NCT04689581|Other|Ultrasound guided modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
75576368|NCT03887676|Drug|Arbaclofen|Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg
75576369|NCT03887676|Other|Placebo|Administered orally as disintegrating tabs, round, white and beveled edges
75576370|NCT04689620|Device|laser|treating the venous ulcer with laser
75576371|NCT02929472|Behavioral|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
75429703|NCT01501552|Other|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
75429704|NCT01501552|Other|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
75429705|NCT01501552|Other|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
75429706|NCT01501565|Procedure|Postoperative transverse abdominal plain (TAP) blockade|Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
75429707|NCT01501591|Drug|Hydroxizine|25 mg orally, one time on two different days, 72 hours apart
75429708|NCT01501591|Other|Placebo|Matching placebo once on two different days, 72 hours apart.
75576372|NCT02929472|Behavioral|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
75576373|NCT02929433|Other|Cycloergometer|Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
75576374|NCT04291469|Drug|Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)|The probiotic compound will consist of tables containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).
75576375|NCT04291469|Dietary Supplement|Prebiotics (Combined inulin and maltodextrin tables)|The prebiotic compound will consist of tables containing inulin and maltodextrin (oral,daily for 14 weeks)
75429709|NCT01501591|Drug|hydroxyzine/placebo|25 mg hydroxyzine or placebo once on two different days, 72 hours apart
75429710|NCT01501604|Drug|BKM120|100 MG PO QD in cycles of 28 days
75576376|NCT04291469|Dietary Supplement|maltodextrin|Maltodextrin tables (oral,daily for 14 weeks)
75576377|NCT03882294|Other|Probiotics|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
75576378|NCT03882294|Other|Placebo|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
75576379|NCT02929121|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
75576380|NCT02929121|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
75576381|NCT02929277|Other|blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires|
75576382|NCT03871998|Other|Skin barrier protection in the first 2 months of life|Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
75576383|NCT02929394|Drug|Trabectedin|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
75576384|NCT05159037|Behavioral|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
75576385|NCT05159037|Behavioral|Music Booster|Participants listen to a musical track they ranked as highly liked before a stressful situation
75576386|NCT02929316|Drug|Vedolizumab|IV infusion week 0, 2 and 6
75878753|NCT05186441|Other|DMPFC iTBS|The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
76049134|NCT02458469|Drug|Trazodone|100 mg dose before bed-time
75576387|NCT03841539|Behavioral|Mediterranean Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.
75576388|NCT03841539|Dietary Supplement|Study Supplement|Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
75576389|NCT03841539|Behavioral|Low-fat Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
75576390|NCT02929238|Other|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
75576391|NCT02929238|Other|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
75576392|NCT05152836|Device|Vibrotactile stimulation at tremor frequency|Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
75576393|NCT05152836|Device|Vibrotactile stimulation at tremor frequency*1.5|Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
75576394|NCT05152836|Device|Vibrotactile stimulation at continuous stimulation|Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
75726869|NCT02587559|Procedure|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
75726870|NCT00615290|Drug|tipranavir|
76049135|NCT02458469|Drug|Placebo|One placebo pill before bed-time
75429711|NCT01501617|Biological|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
75429712|NCT01501617|Device|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
75429713|NCT01501630|Device|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
75576395|NCT05152836|Device|Vibrotactile stimulation 10% below and above step frequency|This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
75576396|NCT02929199|Other|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
75576397|NCT02929199|Other|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
75576398|NCT03791112|Drug|BPI-16350|BPI-16350 capsules administered orally
75576399|NCT02929355|Other|carotid assesment by duplex ultrasonography|
75576400|NCT02929043|Other|air puffs|
75576401|NCT02928926|Other|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
75576402|NCT05099211|Procedure|Muscle biopsies|"Optional~In pre-training:~Biopsy performed during the digestive surgery procedure~Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department."
76024750|NCT01980940|Drug|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
76024751|NCT01980940|Drug|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
76024752|NCT01980940|Drug|Placebo|Placebo gel applied topically.
75429714|NCT01501643|Device|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
75429715|NCT01501643|Device|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
76024753|NCT01980940|Drug|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
76024754|NCT01980940|Drug|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
76049136|NCT01843348|Drug|Everolimus|
75576403|NCT05099211|Other|Muscle Strengthening|3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.
75576404|NCT05099211|Biological|Blood and urine samples|fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
75726871|NCT02587169|Drug|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
75576405|NCT05099211|Other|Aerobic Training|"3 sessions per week for 18 weeks. Duration: 1 hour Training on a classic pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities."
75576406|NCT05099211|Other|Evaluation 1 pre-surgery|"Carried out at least 15 days before surgery~st visit:~Nutritional assessment~Body composition~Psychometric tests of quality of life + IPAQ Test~VO2pic~nd visit:~Neuromuscular tests~Functional tests"
75576407|NCT05099211|Other|Evaluation 2 post-surgery|"st visit:~Body composition~Nutritional assessment~Psychometric tests of quality of life~nd visit:~neuromuscular tests~Functional tests~Familiarization with training equipment if patient participates in re-training"
75576408|NCT05099211|Other|Intermediate Evaluation 3|performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6
75726872|NCT00873236|Biological|bevacizumab|Given IV
75726873|NCT00873236|Biological|recombinant interferon alpha-2a|Given SC
75726874|NCT04039724|Drug|HCP0605 + HGP0816|
75726875|NCT04039724|Drug|HCP1305|
75726876|NCT00878696|Procedure|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
75878754|NCT05186441|Other|DLPFC iTBS|The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
75576409|NCT05099211|Other|Final post-training evaluation 4|Tests identical to evaluation 1 + TM6
75576410|NCT02928809|Device|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
75576411|NCT02928809|Other|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
75576412|NCT03731598|Procedure|bed rest|Volunteers will be physically inactive on bed rest at the clinical research center
75726877|NCT00878774|Biological|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
75726878|NCT00878774|Biological|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
75726879|NCT00868010|Drug|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
75726880|NCT00868010|Drug|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
75726881|NCT05683301|Drug|Amlodipine + Perindopril|Single pill combination of dual antihypertensive agent
75726882|NCT05683301|Drug|Perindopril + Indapamide|Single pill combination of dual antihypertensive agent
75726883|NCT05683301|Drug|Amlodipine + Indapamide|Single pill combination of dual antihypertensive agent
75878755|NCT03572816|Device|Settner shoe|custom-made heel-unloading orthosis ('Settner shoe') in aftercare of calcaneus fractures (used according to manufacturer), certified 'CE' product with more than 10 years experience
75878756|NCT02847494|Drug|metoclopramide|metoclopramide 10mg intravenous infusion over 15 minutes
75878757|NCT02847494|Drug|Dexamethasone|dexamethasone 10mg intramuscular injection
75878758|NCT02847494|Drug|methylprednisolone acetate|methylprednislone acetate 160mg intramuscular injection
75429716|NCT01501669|Drug|Irinotecan, Capecitabine|"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"
75878759|NCT02559401|Other|MRI|
75878760|NCT02559401|Other|Neurocognitive battery|
75878761|NCT03572270|Diagnostic Test|AMH test|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
75878762|NCT03572270|Diagnostic Test|pelvic ultrasound|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
75576413|NCT02928731|Other|Questionnaires set 1|Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.
75878763|NCT02554253|Drug|Ketamine|Ketamine used for induction
75878764|NCT02554253|Drug|Propofol|Propofol for induction
75429717|NCT01501695|Drug|5LGr|Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
75429718|NCT01501695|Drug|tiapride|"dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Total duration:8 weeks."
75429719|NCT01501695|Drug|placebo|mimetic granule: same with 5LGr mimetic tablet: same with tiapride
75576414|NCT02928731|Other|Questionnaires set 2|Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
75576415|NCT02928965|Drug|Minocycline|Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
75878765|NCT02239484|Drug|Tadalafil|
75576416|NCT02928965|Drug|Placebo|Matching placebo with appearance of over - encapsulated minocycline
75576417|NCT04679220|Procedure|Preheating|For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
75576418|NCT02928692|Drug|Minocycline|
75576419|NCT02928692|Drug|Placebo|
75576420|NCT04679142|Drug|Baclofen Tablets|Enrolled patients will receive treatment and evaluations for their disease as determined by their physicians in accordance with local standard of care. Visits will be scheduled by their physician according to patient-specific needs and national clinical practice.
75878766|NCT02239484|Drug|Tamsulosin|
75878767|NCT02239484|Drug|Tadalafil + Tamsulosin|
75878768|NCT01331759|Device|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
75878769|NCT03575234|Drug|Cyclophosphamide|Given IV
75576421|NCT02928653|Dietary Supplement|Beverage|Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
75576422|NCT02928419|Drug|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
75576423|NCT02928419|Other|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
75576424|NCT02928419|Drug|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
75726884|NCT05081648|Procedure|CT MuST|Multiple Single Cannulation Technique (MuST): Experimental technique
75726885|NCT05081648|Procedure|Rope-ladder cannulation technique|Standard cannulation technique( Rope-ladder)
75429720|NCT01501708|Drug|Caspofugin based combination therapy|"Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given."
75726888|NCT05068856|Drug|HRS2543|"Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC."
75429721|NCT01501721|Behavioral|Exercise|Home-based exercise program
75429722|NCT01501721|Behavioral|Diet|Nutritional counseling aiming to reduce suggar intake
75576425|NCT00554151|Device|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
75576426|NCT02928614|Drug|Liraglutide 3 mg (Saxenda)|
75576427|NCT02928614|Drug|Liraglutide 3 mg placebo|
75576428|NCT02928458|Drug|Omnipaque|
75576429|NCT02928458|Drug|MD-Gastroview|
75576430|NCT03685500|Drug|Symtuza® (TAF/FTC/DRV/c)|Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
75726889|NCT04770467|Drug|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
75576431|NCT03685500|Drug|ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
75726890|NCT04770467|Drug|Placebo|Placebo given by intravenous administration
75878770|NCT03575234|Biological|IRX-2|Given SC
75878771|NCT03575234|Biological|Nivolumab|Given IV
75576432|NCT02928575|Drug|Sunitinib|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
75576433|NCT02928575|Drug|Temozolomide|Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
75429723|NCT01501734|Device|watch-pat|"The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.~The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.~Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea."
75429724|NCT01501747|Drug|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
75576434|NCT02928575|Radiation|Radiation Therapy|Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
75576435|NCT05052918|Behavioral|Exercise|1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks
75576436|NCT02928302|Other|TVU CL screening|Transvaginal ultrasound cervical length screening
75576437|NCT02928263|Other|Non-Interventional|Other
75576438|NCT02928146|Procedure|Hernia Repair|
75576439|NCT04276415|Drug|DS-6157a|Administered as a single agent intravenously (IV) every 3 weeks
75576440|NCT02928068|Behavioral|Occupational Performance Coaching (OPC)|OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
75878772|NCT03575234|Procedure|Surgery|Undergo surgery
75576441|NCT02927951|Drug|Pregabalin|150mg bid
75576442|NCT02927951|Drug|Placebo|150mg bid
75576443|NCT02927678|Other|white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging|
75576444|NCT03457532|Drug|Glumetinib for tablet|25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
75576445|NCT02927600|Other|Low GI Breakfast|Intake of low GI breakfast
75576446|NCT02927600|Other|High GI Breakfast|Intake of high GI breakfast
75576447|NCT02927600|Other|Low GI Dinner|Intake of Low GI dinner
75726891|NCT00873314|Behavioral|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
75726892|NCT00873314|Behavioral|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
75726893|NCT00878852|Behavioral|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
75878773|NCT01337531|Drug|Gonal-F, Fostimon|dosage form
75429725|NCT01501747|Drug|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
75878774|NCT01337531|Drug|Gonal-F, Fostimon|injection, daily, 10-15 days
75878775|NCT03572114|Diagnostic Test|3Tesla MRI|"A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content~Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).~1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)~conventional FLAIR sequence"
75429726|NCT01501760|Drug|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
75429727|NCT01501760|Drug|NaCl|Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
75429728|NCT01501773|Biological|Autologous bone marrow stem cell|Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
75429729|NCT01501786|Drug|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
75429730|NCT01501786|Drug|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
75429731|NCT01501786|Drug|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
75576448|NCT02927600|Other|High GI Dinner|Intake of high GI dinner
75576449|NCT02927561|Other|Diabetic Retinopathy screening|Diabetic Retinopathy screening
75576450|NCT02927405|Drug|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
75576451|NCT02927405|Procedure|TAP Block|a procedure done anesthetize the anterior abdominal wall
75576452|NCT02927444|Biological|NBP606|A single intramuscular injection into the thigh
75576453|NCT02927444|Biological|Prevnar13|A single intramuscular injection into the thigh
75576454|NCT04967820|Other|resilience and institutional support|psychological inherent resilience and institutional support during COVID-19 outbreak
75576455|NCT02927483|Dietary Supplement|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
75576456|NCT02927483|Dietary Supplement|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
75576457|NCT02927210|Drug|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
75576458|NCT02927210|Drug|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
75576459|NCT04679649|Other|Manual spinal mobilisation physiotherapy|Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
75576460|NCT02927522|Drug|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
75576461|NCT02927522|Drug|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
75576462|NCT04679688|Other|descriptive|Those who apply for IVF treatment and have an antral follicle number of 4-10 will be included in the treatment. The reason for including patients with this number of antral follicles in the study is to determine the follicle locations and to determine each growing follicle separately on the day of hCG and egg collection.
75576463|NCT04679493|Drug|XC7 100 mg single|The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
75576464|NCT04679493|Drug|XC7 200 mg single|The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
75576465|NCT04679493|Drug|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 capsules once)
75576466|NCT04679493|Drug|XC7 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
75576467|NCT04679493|Drug|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
75576468|NCT02927132|Behavioral|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
75726894|NCT00878852|Behavioral|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
75726895|NCT05226806|Other|Measurement of cardiorespiratory performance in 3 different settings|"The study is divided into three examinations days, which extend over a maximum of 2 weeks:~Day 1: Inclusion examination, time required: 1.5 hours Taking anamnesis, medical examination and blood drawing, determination of PROCAM score, Framingham score, ESC score, anthropometric measurements, questionnaires (IPAQ-physical activity, health status / quality of life (SF 36)), pulmonary function test, resting ECG, echocardiography, heart rate variability measurement (VO2max determination), spiroergometry (modified Bruce protocol) on the treadmill incl. inquiries about the BORG scale~Day 2: 1 km test trail, Time required: 1 hour: Completion of a 1 km cardio test path including mobile spiroergometry~Day 3: 8 km hike, time required approx. 3.5 hours: Participation in a guided cardio hike over 8 km, if applicable, including spiroergometry Afterwards (In Austria only): Logging of physical activity, physical motivation and accompanying circumstances over a period of 3 weeks"
75576469|NCT02927132|Behavioral|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
75576470|NCT02927054|Other|Sepsis Education|Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
75576471|NCT04938648|Behavioral|Pharmacist-led deprescribing intervention|1) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
75576472|NCT02926976|Drug|Risperidone with Clozapine|Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
75576473|NCT02926976|Drug|Aripiprazole with Clozapine|Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
75576474|NCT02926976|Drug|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
75429732|NCT01501799|Drug|adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
75576475|NCT02926976|Device|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
75576476|NCT02926976|Device|Magnetic seizure therapy(MST) with Clozapine|Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
75878776|NCT03572114|Behavioral|Burke-Fahn-Marsden Dystonia Rating scale|internationally standardized examination/quantification of dystonia
75429733|NCT01501799|Drug|EPIDUO|EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
75429734|NCT01501799|Drug|Placebo (Vehicle Gel)|Vehicle Gel
75429735|NCT01501812|Behavioral|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
75429736|NCT01501825|Device|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
75429737|NCT01501825|Device|five channels Multiway deep Transcranial Magnetic Stimulation|"During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)"
75429738|NCT01501864|Behavioral|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
75429739|NCT01501877|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.
75576477|NCT02926976|Device|clozapine|clozapine may be used in the treatment of treatment-resistant schizophrenia
75576478|NCT04917393|Device|iRF System Multi-organ Denervation|If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
75576479|NCT04917393|Other|Control Procedure|If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
75576480|NCT03455166|Diagnostic Test|Serum Markers|Serum Markers
75576481|NCT02927015|Other|Purple Majesty potato chips|Purple Majesty potato chips
75576482|NCT02927015|Other|Mountain Rose potato chips|Mountain Rose potato chips
75726896|NCT05226806|Other|GENERAL CARDIO HIKES AS PART OF GENERAL TOURIST OFFER OF MUNICIPALITIES|General cardio hikes (WITHOUT spirometric breathing gas analysis) on the selected hiking trails. Measurement of the heart rate as well as the route, time and walking speed using GPS geotracking using an anonymized user profile. User survey regarding the user-friendliness of the application.
75429740|NCT01501877|Behavioral|Standard smoking cessation intervention|Standard smoking cessation intervention based on clinical practice guidelines.
75576483|NCT02927015|Other|White potato chips|White potato chips
75576484|NCT02927015|Other|Crackers|Crackers
75878777|NCT03572114|Behavioral|MDS-United Parkinsons Disease Rating Scale, Part III|most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society
75878778|NCT03572114|Behavioral|Beck Depression Inventory|internationally standardized examination to quantify traits of anxiety and depression
75878779|NCT03572114|Behavioral|MoCA: Montreal Cognitive Assessment:|internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism
75878780|NCT04563611|Other|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
75878781|NCT04563611|Other|Askling L-Protocol|he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
75878782|NCT04563611|Other|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.
75878783|NCT04563611|Other|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
75429741|NCT01501890|Drug|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
75429742|NCT01501890|Drug|Placebo|0.9% NaCl
75429743|NCT01501903|Procedure|Standard|FNA in a single plane
75429744|NCT01501903|Procedure|Fanning|FNA in multiple planes
75429745|NCT01501916|Dietary Supplement|Vitamin D3|daily dosage of 50 µg Vitamin D3 for 8 weeks
75576485|NCT02926820|Behavioral|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
75576486|NCT04910412|Device|transcranial direct current stimulation|Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training
75726897|NCT00868088|Procedure|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
75429746|NCT01501916|Dietary Supplement|Placebo|daily intake of placebo
75576487|NCT02926781|Device|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
75576488|NCT00553956|Behavioral|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
75726898|NCT00873392|Drug|Transdermal nicotine|Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
75726899|NCT00873392|Other|Usual drug treatment of Parkinson's disease|Usual drug treatment of Parkinson's disease
75726900|NCT04039256|Device|percutaneous ventricular restoration using heartech® device|Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.
75429747|NCT01501942|Drug|AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide|AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
75429748|NCT01501942|Drug|Buffered Saline|The matching placebo is an oral solution of phosphate buffered saline
75429749|NCT01501968|Drug|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
75429750|NCT01501968|Drug|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
75576489|NCT02926742|Device|EkoSonic Endovascular System|Ultrasound catheter-directed thrombolysis.
75576490|NCT04887246|Biological|COVID-19 vaccines|COVID-19 vaccines available at Colombia
75576491|NCT02926703|Other|Serum lactate and CK concentrations in blood samples|Serum lactate and CK concentrations in blood samples were measured routinely at admission
75576492|NCT04878549|Diagnostic Test|5-gene transcription signature|This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
75726901|NCT02587013|Procedure|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
75576493|NCT02926664|Other|measurement of qSOFA|qSOFA will be measured at H0, H1 and H3
75576494|NCT02926625|Behavioral|Systematic follow-up|"Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.~HEW advice and procedures~Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick~Children who are getting worse should come back immediately or at any time for a re-assessment~All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.~HEW should fill out a loose child assessment form~If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre."
75576495|NCT02926625|Behavioral|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
75576496|NCT02926508|Dietary Supplement|Bimuno (BGOS)|"The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink."
75576497|NCT02926508|Other|Maltodextrin|"Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention."
75576498|NCT02926469|Device|Virtual Reality|Using Virtual Reality during labor
75576499|NCT04680195|Drug|Thalidomide|"The patients were treated with thalidomide tanken orally every night for 4 months, and the treatment period was divided into induction period and maintenance period, as follows:~Induction period:~The oral dose of thalidomide started at 50 mg, and increased to 100 mg after one week if tolerable, and maintain 100 mg for three weeks. The medication time was 1 month.~Maintenance period: The oral dose of thalidomide was 50-75mg/d. The medication time was 3 months."
75576500|NCT02926313|Other|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
75576501|NCT04864431|Dietary Supplement|Vitamin D|Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180
75576502|NCT04864431|Other|Placebo|Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180
75576503|NCT02926118|Dietary Supplement|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
75576504|NCT02926118|Dietary Supplement|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
75576505|NCT00553995|Drug|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
75429751|NCT01501994|Other|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
75576506|NCT00553995|Drug|Placebo|
75726902|NCT02587013|Procedure|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
75726903|NCT04040036|Behavioral|Children watch applications by wearing the virtual headset during the blood draw.|wearing the virtual headset
75726904|NCT03933371|Device|Colon Capsule Endoscopy|The capsule endoscopy will be ingested by the participant. This device captures images along the large bowel. This images are stored in an external memory and afterwards they are downloaded in a computer
75726905|NCT00879008|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
75726906|NCT04081181|Procedure|Microwave ablation|CT_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
75576507|NCT02926430|Biological|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).
75576508|NCT02926430|Biological|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).
75576509|NCT02926430|Drug|Placebo|Participants will receive placebo as formulation buffer.
75726907|NCT00873470|Procedure|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
75726908|NCT00873548|Device|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:~Positioning of the patient~Definition of the CCD-angle~Fracture reduction~Determination of the nail diameter~Incision~Insertion of the device"
75429752|NCT01501994|Other|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
75429753|NCT01501994|Procedure|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
75576510|NCT04798287|Drug|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
75576511|NCT04798287|Drug|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
75576512|NCT02926157|Behavioral|Life Style and Sleep Intervention|
75726909|NCT02586935|Drug|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
75576513|NCT04798209|Drug|ACT-777991 (SAD)|ACT-777991 administered as hard capsules for oral use.
75576514|NCT04798209|Drug|ACT-777991 (MAD)|ACT-777991 administered as hard capsules for oral use, once daily.
75576515|NCT04798209|Drug|Placebo (SAD)|ACT-777991 matching placebo administered as hard capsules for oral use.
75576516|NCT04798209|Drug|Placebo (MAD)|Matching placebo administered as hard capsules for oral use, once daily.
75726910|NCT02586935|Other|Placebo|Administered orally after dispersion in approximately 100 ml of water
75726911|NCT00868400|Dietary Supplement|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
75576517|NCT04798209|Drug|14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer, administered intravenously.
75576518|NCT04798209|Drug|Microtracer matching placebo (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
75576519|NCT04798209|Drug|14C-ACT-777991 microtracer (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer, oral solution..
75576520|NCT04798209|Drug|Microtracer matching placebo (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
75726912|NCT00868400|Dietary Supplement|flavored water|will be given in doses equal to those of high-carbohydrate beverage
75726913|NCT00868478|Drug|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
75726914|NCT04079699|Diagnostic Test|Liquid Biopsy|Measuring biomarkers in blood and urine samples
75878784|NCT02240420|Behavioral|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
75878785|NCT04508855|Drug|Low molecular weight heparin|Switch from direct oral anticoagulants to low molecular weight heparin
75429754|NCT01502007|Other|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
75576521|NCT04784013|Procedure|Conventional CLOSE-guided pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.
75576522|NCT04784013|Procedure|High power short duration pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
75576523|NCT02926040|Procedure|Irreversible electroporation|
75726915|NCT04079699|Diagnostic Test|Standard biopsy|Histological examination of tissue biopsies
75726916|NCT00879164|Drug|bupivacaine hydrochloride|
75726917|NCT00879164|Other|questionnaire administration|
75726918|NCT00919997|Genetic|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
75726919|NCT00919997|Genetic|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
75726920|NCT00919997|Other|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
75576524|NCT04783350|Device|Transcranial alternating current stimulation (tACS)|tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.
75576525|NCT02925767|Device|311-nm Ti:Sapphire laser|Pallas, LaserOptek, South Korea
75576526|NCT02925767|Device|308-nm excimer laser|XTRAC, PhotoMedex, US
75576527|NCT04764708|Behavioral|Compassion and Metacognition Based Therapy|The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).
75576528|NCT04764708|Behavioral|Cognitive Behavioral Therapy|Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
76049137|NCT01843348|Drug|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
75429755|NCT01502007|Other|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
75429756|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
75429757|NCT01502020|Drug|Vehicle Cream|Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
75429758|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
75576529|NCT02925962|Other|Clinical Decision Support System (CDSS)|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
75576530|NCT02925962|Other|Clinic Decision Sup System + Pharmacist|Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
75576531|NCT04748445|Diagnostic Test|SARS-CoV-2/Influenza/RSV RT-PCR|nasal swab
76049138|NCT01843348|Drug|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
75726921|NCT00919997|Other|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
75726922|NCT00919997|Other|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
76049139|NCT01843348|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
75726923|NCT00919997|Procedure|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
76049140|NCT01843348|Drug|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
76049141|NCT01843348|Drug|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
76049142|NCT01843348|Drug|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
76049143|NCT01843192|Device|Endocutter|
76049144|NCT01825876|Drug|Evacetrapib|Oral administration
75429759|NCT01502046|Drug|delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.
75429760|NCT01502046|Drug|Placebo|Placebo, One spray per day, up to a maximum of 12 sprays per day.
75429761|NCT01502059|Other|Pilates|Pilates training - twice a week (one hour per class) during 90 days
75726924|NCT02586779|Other|whatsApp|whatsApp application will be used for consultations.
75429762|NCT01502098|Procedure|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
75429763|NCT01502098|Other|Sling|Sling for 4 weeks
75429764|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
75429765|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
75429766|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
75576532|NCT02925845|Device|Neuromuscular electrostimulation|The device CompexTheta 400i provided with various developmental programs rehabilitation exercise with different phases, types and current is used. an adaptive program (heating, toning, muscular atrophy, strength-endurance) will be established for each patient during the study period. It shall apply at the level of the muscle bellies of the flexor and extensor muscles of the forearm dela upper extremity AV created. Electrodes are positioned at the anatomical reference positions. The intensity of the current will increase until a tolerable muscle contraction and painless by the patient.
75726925|NCT02586779|Other|without whatsApp|whatsApp application will be not used for consultations.
75878786|NCT03575078|Drug|ARQ761, Olaparib|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
75429767|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
75429768|NCT01502150|Other|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
75429769|NCT01502150|Other|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
75429770|NCT01502163|Device|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
75429771|NCT01502163|Device|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
75429772|NCT01502189|Other|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
75726926|NCT04079777|Drug|Clinical treatment|Liquid Resuscitation, Anti-infection
75726927|NCT04079543|Other|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
75429773|NCT01502202|Drug|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
75429774|NCT01502202|Drug|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
75429775|NCT01502202|Drug|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
75429776|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
75429777|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
75429778|NCT01502241|Drug|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
75429779|NCT01502241|Radiation|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
75429780|NCT01502254|Other|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
75429781|NCT01502267|Drug|High dose IVIG and B cell depleting agents|"IVIG(2g/kg two times on day 1, 30)~Rituximab(375mg/m2 on day 3)~Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
75878787|NCT02259842|Drug|BI 34021 FU2 solution|
75576533|NCT04679454|Radiation|Phase I|To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
75726928|NCT04079543|Other|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
75726929|NCT04593251|Biological|CALY-002|1-hour intravenous infusion
75726930|NCT04593251|Biological|Placebo|1-hour intravenous infusion
75726931|NCT02585687|Device|liver Perfusion MRI|
75878788|NCT02259842|Drug|BI 34021 FU2 tablet|dose group 4 only
75878789|NCT02259842|Drug|Placebo|
75878790|NCT02259842|Other|High fat, high calorie breakfast|only for dose groups 3 and 5
75878791|NCT03377036|Diagnostic Test|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
75878792|NCT03377036|Diagnostic Test|2D-FFDM|2D full-field digital mammography
76049145|NCT01825876|Drug|Warfarin|Oral administration
75429782|NCT01502319|Behavioral|Cognitive therapy|Interventional studies conducted by the consortium focus on a range of cognitive and cognitive-behavioral techniques including cognitive therapy.
75429783|NCT01502345|Biological|Vaccine/device combination for prevention of HFRS|PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
75429784|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
75429785|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
75429786|NCT01502358|Biological|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
75429787|NCT01502384|Other|neurological examination|motor and cognitive functions
75429788|NCT01502449|Behavioral|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
75429789|NCT01502449|Other|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
75429790|NCT01502488|Procedure|Fat Harvesting and Stem Cell Injection|Cells will be harvested through a local liposuction and injected via IV delivery
75429791|NCT01502501|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
75429792|NCT01502514|Procedure|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
75429793|NCT01502527|Dietary Supplement|Femarelle|Twice daily oral treatment with Femarelle
75429794|NCT01502553|Device|Comparison Test to Yuyue Medical BP Meter, YYBP-212|DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
75429795|NCT01502566|Behavioral|Education Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
75429796|NCT01502592|Procedure|Cryoablation|"OncCore Biopsy (+ Cryo) Date*~Pre- and post- cryo MRI~Core biopsy x ≥3~Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.*"
75429797|NCT01502592|Biological|Ipilimumab|"Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date*~MRI~Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery."
75429798|NCT01502605|Drug|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
75429799|NCT01502618|Behavioral|Focus Group|N/A. Protocol is the focus group
75429800|NCT01502657|Device|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
75429801|NCT01502670|Drug|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
75429802|NCT01502683|Procedure|No aortic clamping|No aortic clamp used in this group. The aortic clamp is a standard cardiac surgical instrument used during cardiac operations, not a specific device used for this study.
75429803|NCT01502683|Procedure|partial occluding clamp|The partial-occluding clamp is a standardized instrument used during coronary artery bypass surgery, it is not a specific device for this study.
76049146|NCT01842958|Device|Straumann Bone Level Implants, 4.1 mm implant diameter|Straumann Bone Level Implants, 4.1 mm implant diameter
75726932|NCT00920543|Drug|Placebo|Twice daily dosing
75726933|NCT00920543|Drug|FP 100mcg|Twice daily dosing
75726934|NCT00920543|Drug|FP 500mcg|Twice daily dosing
75726935|NCT00920543|Drug|FP 250mcg|Twice daily dosing
75726936|NCT00920543|Drug|FSC 100/50mcg|Twice daily dosing
75726937|NCT00920543|Drug|FSC 250/50mcg|Twice daily dosing
75726938|NCT00920543|Drug|FSC 500/50mcg|Twice daily dosing
75726939|NCT04731155|Drug|PCSK9 inhibitor （Alirocumab）plus standard medications|PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
75726940|NCT04731155|Drug|standard medications|standard medications was giving to subjects according guidelines
75726941|NCT04080011|Device|NP-PWD|Application of NP-PWD device.
75726942|NCT02584439|Drug|ivabradine|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
75576534|NCT04679454|Radiation|Phase II|The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
75576535|NCT02925728|Other|Finger-Food|Finger-Food at lunch and having diner
75576536|NCT02925728|Other|Without Finger-Food|Without finger-food
75726943|NCT02584439|Drug|lactose capsule (placebo)|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
76049147|NCT01842958|Device|Straumann Bone Level Implants, 3.3 mm implant diameter|Straumann Bone Level Implants, 3.3 mm implant diameter
75429804|NCT01502683|Procedure|single cross clamp|The proximal anastomoses performed under single clamp is an alternative method during coronary artery bypass surgery. The single clamp essentially means that whole operation is done using the cross clamp, which is a standard instrument during cardiac operations, not a specific device for this study.
75429805|NCT01502683|Procedure|cross clamp and partial occluding clamp|Both an aortic cross clamp and partial occluding clamp are used in this arm. Neither the cross clamp nor the partial clamp are specific devices for this study but are standard cardiac surgical instruments used during coronary artery bypass surgery and cardiac surgery.
75429806|NCT01502696|Biological|PEG IFN alfa-2b|3µg/kg weekly injections
75576537|NCT02925884|Device|Gunnar OTC Glasses Condition|Gunnar Over-The-Counter Computer Glasses have optical power of 0.5 diopter for reducing accommodation demands at typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
75576538|NCT04744974|Behavioral|Diet intervention|Participants will be given dietician counseling on their assigned diet
75576539|NCT04242251|Other|SPARKLE Model of care|Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.
75576540|NCT04725786|Other|thoracic echography|The research intervention corresponds to the performance of a thoracic echography to diagnose an incipient pulmonary interstitial syndrome.
75576541|NCT04723524|Combination Product|Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
75576542|NCT04723524|Other|Placebo Comparator|Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
75576543|NCT02925806|Other|Non-interventional study - retrospective database review|
75576544|NCT04706754|Other|Questionnaires|Prospectively enrolled participants will be provided with survey packets comprised of different questionnaires at the initial/baseline visit and every 3 months and/or whenever there is an update in their treatment protocol
75726944|NCT04729049|Procedure|Erector Spinae plane Block|Ultrasound-guided interfascial technique, aiming to block the anterior and posterior branches of the spinal nerves for multi-dermatomal analgesia. Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve a craniocaudal distribution along several vertebral levels.
75726945|NCT04729049|Drug|Patient controlled analgesia with intravenous morphine|Patient-controlled intermittent boluses of morphine 1 mg (maximum once every 15 minutes).
75726946|NCT04722107|Drug|rAAV2/8-hCYP4V2|rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
75878793|NCT03572504|Other|critically ill children|Compare a series of measurement or size estimation techniques to the WHO standard to identify the most reliable method (s) of pediatric resuscitation.
75878794|NCT03157583|Other|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
75878795|NCT03157583|Other|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
75878796|NCT03157583|Other|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
75878797|NCT03157583|Other|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
76049148|NCT02413229|Drug|DSXS1411|DSXS (Taro Pharmaceuticals Inc.)
76049149|NCT02413229|Drug|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
75429807|NCT01502722|Behavioral|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
75429808|NCT01502735|Biological|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
75576545|NCT04689308|Drug|MH048|Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
75576546|NCT04672122|Device|Transcranial direct current stimulation|Cathodal tDCS will be applied for 20 mins.
75576547|NCT04689191|Biological|Experimental Group A and C meningococcal polysaccharide vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
75429809|NCT01502735|Biological|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
75429810|NCT01502748|Other|endovascular sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
75429811|NCT01502774|Drug|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
75576548|NCT04689191|Biological|Control Group A and C meningococcal polysaccharide vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
75576549|NCT04671498|Procedure|Biospecimen Collection|Undergo collection of blood sample
75576550|NCT04671498|Procedure|Droplet-BC Test|Undergo Droplet-BC Test
75576551|NCT04671498|Other|Electronic Health Record Review|Medical records are reviewed
76049150|NCT01825798|Drug|Metformin|Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
75576552|NCT04689113|Behavioral|Incontinence Health Belief Development Program|After the applied interventions, it is desired to develop kegel exercise behavior in women.
75429812|NCT01502774|Drug|Placebo|One single intravenous bolus injection of Placebo
75576553|NCT02925572|Other|Cycling exercises|All measurements are performed before and after the training program (12 weeks)
75576554|NCT04664673|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy originally developed for hemiplegic children.
75576555|NCT04664673|Behavioral|Regular care|customary or usual treatment given to any adult stroke survivor
75429813|NCT01502774|Procedure|Echocardiography|1 year after AMI
75429814|NCT01502800|Drug|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
75576556|NCT02925377|Behavioral|Neuromuscular warm-up|The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
75576557|NCT02925377|Behavioral|Standard warm-up|Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
75576558|NCT04654299|Procedure|External biliary stent|The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
75576559|NCT02925299|Device|FlorenceM (US) and FlorenceX (UK)|"The automated closed loop system (FlorenceM in US) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature.~The automated closed loop system (FlorenceX in UK) will consist of:~The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
75576560|NCT02925299|Device|Insulin pump therapy|Subjects will continue using their own insulin pump for 6 months.
75576561|NCT02925416|Drug|oritavancin|
75576562|NCT02925416|Drug|placebo (D5W)|
75576563|NCT02925533|Drug|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
75576564|NCT02925533|Drug|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
75726947|NCT02585765|Drug|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
75726948|NCT02585765|Drug|Placebo|8 weeks of daily placebo capsules.
75878798|NCT03157583|Other|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
75576565|NCT02925260|Other|MRI with ileal pouch contrast and enema.|Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
75576566|NCT02917889|Drug|Caffeine|Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
75576567|NCT02917889|Drug|Placebo|Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
75576568|NCT02917889|Other|Cardiopulmonary test|"assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~."
75429815|NCT01502800|Drug|ARQ 761 Weekly Administration|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
75429816|NCT01502800|Drug|Bi-Weekly Administration of ARQ 761|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
75429817|NCT01502800|Drug|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
75576569|NCT02917889|Other|Treadmill aerobic exercise|30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
75576570|NCT04573842|Other|Ultrasound assessment of SCV|An ultrasound examination of the SCV will be performed before anesthesia induction. Apart from this, the protocol does not differ at all from the ordinary fashion
75576571|NCT04564092|Drug|DaTSCAN™ Ioflupane (123I) Injection|Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
75726949|NCT02584361|Procedure|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
75726950|NCT02584361|Procedure|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
75726951|NCT02584283|Procedure|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
75726952|NCT02584283|Device|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
75726953|NCT02584283|Procedure|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
75726954|NCT02584283|Drug|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
75726955|NCT04080401|Device|Game-based rehabilitation exercise|4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
75878799|NCT03157583|Other|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
75576572|NCT02917967|Drug|Botulinum toxin injection|"BoNT-A will be injected into two hamstring and/or gastrocnemius muscles under the guidance of ultrasonography or electrical stimulation.~Maximal total dose and dose regimen for each muscle would follow the recommendation of international consensus.~A. Semitendinosus 5 to 7.5 units/kg of body weight B. Semimembranosus 5 to 7.5 units/kg of body weight C. Gastrocnemius 10 units/kg of body weight D. Maximal total dose per patient : unilateral injection 500 units, bilateral injection 1,000 units E. The dosage of two hamstring muscles will depend on the severity of spasticity and gait abnormalities of children with CP"
75576573|NCT04536909|Other|Non-surgical|We have constructed a training program with help from physiotherapists from Rikshospitalet in Oslo, tailored for kyphotic- and scoliotic patients.
75576574|NCT04536909|Procedure|Surgical|Surgery for correction of kyphotic- or scoliotic deformity.
75576575|NCT04688840|Procedure|hip arthropalsty|follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
75726956|NCT04080401|Other|Conventional brochures of rehabilitation exercise|4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
75726957|NCT04634669|Drug|AXS-05 (dextromethorphan-bupropion)|- AXS-05 tablet, taken daily (up to 15 months)
75726958|NCT02585531|Drug|Hypertonic Saline 3%|"The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours ."
75726959|NCT02585531|Drug|Epinephrine and Dexamethasone|"The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours."
75726960|NCT04572503|Procedure|Barbed Suture Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
75878800|NCT03157583|Other|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
75429818|NCT01502826|Dietary Supplement|standardized mixed meal|All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
75429819|NCT01502839|Other|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
75429820|NCT01502878|Dietary Supplement|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
75429821|NCT01502878|Dietary Supplement|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
75429822|NCT01502878|Dietary Supplement|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
75726961|NCT00920153|Biological|bleomycin sulfate|Given IV
75726962|NCT00920153|Drug|ABVD regimen|Given IV
75726963|NCT00920153|Drug|carmustine|Given IV
75726964|NCT00920153|Drug|cisplatin|Given IV
75726965|NCT00920153|Drug|cytarabine|Given IV
75878801|NCT03570710|Drug|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
76024755|NCT02394223|Procedure|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
76024756|NCT04857437|Drug|PF-07202954 Repeat Dose|10, 30, 100, 300, 600, 1200 milligrams (mg)
75726966|NCT00920153|Drug|dacarbazine|Given IV
75726967|NCT00920153|Drug|dexamethasone|Given orally
75726968|NCT00920153|Drug|doxorubicin hydrochloride|Given IV
75726969|NCT00920153|Drug|etoposide|Given IV
75726970|NCT00920153|Drug|gemcitabine hydrochloride|Given IV
75726971|NCT00920153|Drug|ifosfamide|Given IV
75726972|NCT00920153|Drug|melphalan|Given IV
75726973|NCT00920153|Drug|methylprednisolone|Given IV
75726974|NCT00920153|Drug|mitoguazone|Given IV
75726975|NCT00920153|Drug|vincristine sulfate|Given IV
75726976|NCT00920153|Drug|vindesine|Given IV
75429823|NCT01502891|Other|Decision Aid|The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
75429824|NCT01502904|Device|Sirolimus-eluting stent|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
75726977|NCT00920153|Drug|vinorelbine tartrate|Given IV
75726978|NCT00920153|Procedure|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
75726979|NCT00920153|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
75726980|NCT04080713|Drug|Budesonide|Budesonide 9 mg prolonged release tablet
75726981|NCT04080557|Other|Surgery|All patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
75576576|NCT04688879|Procedure|intra-arterial urokinase thrombolysis|Under local anaesthesia, the right femoral artery was punctured in accordance with the Seldinger technique, and a 6-Fr sheath, 10 cm in length, was implanted. Selective catheterization of the SMA was performed with 4-Fr catheter. The SMA angiography was performed to identify the filling defect. Thrombolysis was performed using a 5-Fr multiple-sideport infusion catheter (100cm with sideport of 7cm, 14 ports or 100cm with sideport of 15cm, 30 ports, Cook, Bloomington, IN, U.S.A). The tip of the microcatheter was embedded in the thromboembolism, which was fragmented at the time of thrombolysis. Thrombolysis was performed locally in the SMA with a bolus of urokinase
75576577|NCT04688957|Procedure|oseodensification sinus lifting|application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.
75576578|NCT04688957|Procedure|osteotome sinus lifting|drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
75576579|NCT04517721|Other|Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)|The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
75576580|NCT02917733|Drug|LY3039478|Administered orally
75576581|NCT02917655|Behavioral|Womac|Answer WOMAC at baseline, 6, 12 and 24 months.
75576582|NCT02917655|Behavioral|Lequesne|Answer Lequesne at baseline, 6, 12 and 24 months.
75576583|NCT02917655|Behavioral|Numerical Rating Scales (NRS)|Answer NRS at baseline, 6, 12 and 24 months.
75576584|NCT02917655|Behavioral|IPAQ|Answer IPAQ at baseline, 6, 12 and 24 months.
75726982|NCT02585453|Device|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
75726983|NCT02585453|Device|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
75726984|NCT02585453|Device|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
75726985|NCT02586701|Other|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
75726986|NCT04079309|Behavioral|Lavender/Orange|A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.
75878802|NCT03570710|Drug|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
75878803|NCT03570710|Drug|Normal saline|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
75576585|NCT02917655|Behavioral|STS30|Perform the STS30 at baseline, 6, 12 and 24 months.
75576586|NCT02917655|Behavioral|TUG|Perform the TUG at baseline, 6, 12 and 24 months.
75576587|NCT02917655|Behavioral|Six-minute Test|Perform the six-minute test at baseline, 6, 12 and 24 months.
75576588|NCT02917655|Behavioral|Two days of lectures|Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
75576589|NCT02917655|Behavioral|Session with the psychologists|Participate in a extra session group with the psychology team about their experiences with the program
75576590|NCT02917655|Behavioral|Sessions with the physical therapy team|Participate in a extra session group with the physical therapists
75576591|NCT02917655|Behavioral|Sessions with the physical educators team|Participate in a extra session group with the physical educators
75576592|NCT02917655|Behavioral|Nutritional habits to be improved|Attend 3 extra meetings about nutrition.
75576593|NCT02917655|Behavioral|Tampa Scale for Kinesiophobia (TSK)|Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
76024757|NCT04857437|Drug|PF-07202954 Single Dose|10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
75726987|NCT02583503|Radiation|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
75726988|NCT02584205|Device|Powerbreathe|"In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea."
75726989|NCT04550039|Device|Body-weight-supported treadmill|Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist
75726990|NCT04550039|Device|Ekso Bionics EksoNR exoskeleton|Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
75726991|NCT02585297|Other|no intervention|
75726992|NCT02584127|Behavioral|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
75429825|NCT01502904|Device|Biolimus-eluting stents|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
75726993|NCT02584127|Behavioral|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
75429826|NCT01502904|Drug|pravastatin 20mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
75429827|NCT01502904|Drug|pitavastatin 2mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
75429828|NCT01502904|Drug|Non-ARB /day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
75429829|NCT01502904|Drug|Eposartan 600mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
75576594|NCT02917538|Procedure|RFA|Both groups will receive radiofrequency ablation treatment
75576595|NCT04485273|Device|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
75576596|NCT04485273|Drug|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
75576597|NCT04485273|Procedure|Subtenon's Block|Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.
75576598|NCT04485273|Drug|Local Anesthetic Solution and Dexmedetomedine|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
75576599|NCT04485273|Drug|Local Anesthetic Solution|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
75726994|NCT00501046|Drug|Placebo|9g /day (3 times a day)
75726995|NCT00501046|Drug|AST-120|9g /day (3 times a day)
75726996|NCT01018966|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
75726997|NCT01019044|Procedure|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
75429830|NCT01502930|Behavioral|IRT|Internet-based IRT with therapist support during 6 weeks
75429831|NCT01502930|Behavioral|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
75429832|NCT01502943|Drug|Louxiangdan Tongxin granules|"TCM treatment:~Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
75429833|NCT01502943|Drug|TCM granules placebo|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
75576600|NCT02205528|Drug|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
75726998|NCT04546061|Behavioral|Project Uplift|Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
75576601|NCT02205528|Drug|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
75726999|NCT04078685|Procedure|Standard catheter ablation|Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
75878804|NCT01315379|Behavioral|Prolonged Exposure Therapy|This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
75878805|NCT01337765|Drug|BEZ235 + MEK162|
75429834|NCT01502943|Drug|Chixiangshen Tongxin granules|"TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
75429835|NCT01502943|Drug|TCM granule placebo plus western basis treatment|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
75429836|NCT01502943|Drug|Western basis treatment|Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
75429837|NCT01502969|Biological|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
75429838|NCT01502969|Biological|cell culture medium in absence of virus|Placebo
75429839|NCT01502982|Drug|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
75429840|NCT01502995|Device|Laser light (U-Step Walking Stabilizer with laser light)|Use of a laser light on a rolling walker during episodes of freezing of gait.
75429841|NCT01503008|Device|Proteus Sustained Behavior Change system|The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
75576602|NCT02205528|Drug|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
75576603|NCT02205528|Drug|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
75576604|NCT03532022|Drug|Chronocort®|Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
75576605|NCT03532022|Drug|Standard Care|The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
75576606|NCT02205099|Drug|SKL15508|
75576607|NCT02205099|Drug|Placebo|
75576608|NCT02200380|Drug|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
75576609|NCT02200380|Drug|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
75576610|NCT02196792|Device|E-Poly liner|E-Poly liner with a titanium cup
75576611|NCT02196792|Device|ArComXL liner|ArComXL liner with a titanium cup
75576612|NCT02196792|Device|32 mm femoral head|Stem with a 32 mm CoCr femoral head
75727000|NCT04078685|Procedure|Contact Force-sensing-based catheter ablation|Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
76024758|NCT04857437|Drug|Placebo|Matching Placebo
75576613|NCT02196792|Device|36 mm femoral head|Stem with a 36 mm CoCr femoral head
75576614|NCT02917499|Device|TMS|Transcranial magnetic stimulation
75576615|NCT02191878|Drug|TKM-080301|TKM-080301 intravenous infusion
75429842|NCT01503008|Drug|Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)|Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
75429843|NCT01503047|Dietary Supplement|Tonalin®|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
75576616|NCT03411083|Procedure|Total or unicompartmental knee replacement|Fast-track Knee replacement surgery including same day surgery
75576617|NCT02187003|Drug|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
75576618|NCT02187003|Other|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
75576619|NCT03330509|Other|SPARK intervention|An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
75576620|NCT00554814|Drug|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
75576621|NCT00554814|Drug|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
75576622|NCT00554814|Drug|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
75727001|NCT03928223|Other|exploratory survey on Itch modification by color viewing|"Patients relate their itch to a color of the Manchester Color Wheel (MCW) and choose a color of the MCW aimed at counteracting their itch. They complete the ItchyQoL (German version), which is a standard tool to assess itch-related quality of life. Then patients look at their antipruritic monochrome color for five minutes on a lap-top screen. Itch intensity (0-10 NRS) will be assessed at baseline and again after the patients looked at this color for 5 minutes."
75727002|NCT05519189|Drug|Ropivacaine|Peri-anal infiltration of Ropivacaine
76024759|NCT02394379|Device|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
75576623|NCT02161419|Drug|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
75576624|NCT02161419|Drug|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
75576625|NCT02917616|Other|Alkaline drinking-water|
75576626|NCT02917616|Other|Neutral drinking-water|
75576627|NCT02160678|Drug|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
75576628|NCT02160678|Drug|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
75576629|NCT02160678|Drug|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
75576630|NCT02917304|Biological|GC3110A vaccine|0.5mL, Intramuscular
75576631|NCT02917226|Other|Clinical decision support and monitoring system|
75576632|NCT02153502|Drug|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
75576633|NCT02153502|Drug|Placebo|Placebo capsules administered twice a day over a 10-week period
75576634|NCT02917343|Behavioral|mirror therapy and repetitive task training|
75576635|NCT02917148|Other|Peripheral Venipuncture or Blood draw from Central Line|
75576636|NCT02151474|Drug|INCB047986|
75429844|NCT01503047|Dietary Supplement|Placebo|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
75429845|NCT01503060|Behavioral|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
75576637|NCT02151474|Drug|Placebo|
76024760|NCT05229575|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
75429846|NCT01503060|Behavioral|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
75429847|NCT01503060|Drug|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
75429848|NCT01503060|Drug|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
75429849|NCT01503060|Drug|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
75429850|NCT01503060|Drug|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
75429851|NCT01503112|Other|No intervention, observational study|
75429852|NCT01503138|Behavioral|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
75429853|NCT01503151|Behavioral|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
75429854|NCT01503151|Behavioral|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
75429855|NCT01503151|Behavioral|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
75576638|NCT02917070|Other|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
75576639|NCT02144181|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75576640|NCT02917109|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
75576641|NCT02916992|Radiation|CT scan of the thorax|A low dose CT scan of the thorax (2mSv) wil be performed once.
75576642|NCT02916992|Genetic|blood sample for FLCN mutation analyses|A venous punction in order to withdraw 16ml blood is undertaken once.
75576643|NCT02916914|Other|Q2 feeding|Infants are going to be fed every 2 hours
75576644|NCT02130687|Drug|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
75727003|NCT05519189|Other|Failure to perform peri-anal ropivacaine infiltration|Failure to perform peri-anal ropivacaine infiltration
75429856|NCT01503151|Behavioral|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
75429857|NCT01503177|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
75429858|NCT01503177|Other|laboratory biomarker analysis|Correlative studies
75727004|NCT04080323|Drug|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
75727005|NCT04080323|Drug|placebo|1 vaginal tablet of placebo 60 minutes before surgery
75727006|NCT03930017|Biological|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
75727007|NCT00533949|Biological|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
75727008|NCT00533949|Drug|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
75727009|NCT00533949|Drug|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
75878806|NCT01334489|Device|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
75727010|NCT00533949|Radiation|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
75429859|NCT01503177|Procedure|single photon emission computed tomography|Correlative studies
75429860|NCT01503177|Procedure|computed tomography|Correlative studies
75727011|NCT00533949|Radiation|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
75727012|NCT00485134|Biological|240 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
75878807|NCT02842736|Device|Cerene(R) Cryotherapy Device|
75878808|NCT01307033|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
75878809|NCT01307033|Drug|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
75878810|NCT01307033|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
75576645|NCT02130687|Drug|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
75576646|NCT02130687|Drug|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
75576647|NCT02130687|Other|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
75576648|NCT02916836|Other|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
75576649|NCT02916836|Other|No Use of therapeutic drug conciliation sheet (TDC)|
75727013|NCT00485134|Biological|480 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
75727014|NCT00485134|Biological|690 Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
75727015|NCT00485134|Other|Shigella challenge strain|300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
75878811|NCT01307033|Drug|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
76049151|NCT01825798|Drug|Placebo|The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
76049152|NCT01824472|Device|CPAP|Treatment for sleep apnea
76049153|NCT01824472|Behavioral|CBT|Treatment for insomnia
76049154|NCT01824472|Device|sham CPAP|Placebo for sleep apnea
76049155|NCT01824472|Behavioral|CC|Placebo (sham) for insomnia
75576650|NCT02916758|Other|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
75576651|NCT01228656|Drug|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
75576652|NCT01228656|Drug|Mometasone furoate|Dermatologic ointment applied once a day
75576653|NCT02916641|Drug|Fuzhenghuayu|
75576654|NCT02916641|Drug|UDCA|
75576655|NCT02916680|Procedure|Pancreatic islet transplantation in the anterior chamber|Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
75576656|NCT02125266|Drug|V404|Sustained Release
75576657|NCT02916524|Behavioral|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
75576658|NCT02116998|Biological|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~GB104: ABC transporter, substrate-binding protein~GB144: Maltose/maltodextrin binding protein, ABC transporter~GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
75576659|NCT02116998|Biological|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
75576660|NCT02116998|Biological|Streptococcus pneumoniae inoculation|Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
75727016|NCT05514353|Drug|PBI-100 Topical Cream|PBI-100 Topical Cream in 1 of 3 dose levels
75727017|NCT05514353|Drug|Vehicle Cream|The Vehicle Cream formulation contains the same excipients as the active cream
75878812|NCT02844920|Device|Intrauterine ultrasound guided radio-frequency ablation|Radiofrequency ablation for the treatment of uterine fibroids
75878813|NCT04446143|Behavioral|Mindfulness meditation|Mindfulness meditation
75878814|NCT02244398|Other|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
75878815|NCT02244398|Other|FP services|VHTs in the control arm only provide family planning services
75727018|NCT02585141|Device|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
75727019|NCT02585141|Procedure|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
75727020|NCT02585141|Drug|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
75576661|NCT02916329|Other|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
75727021|NCT04443101|Other|different types of intracular lens|different types of intracular lens
75576662|NCT02110368|Drug|Testosterone Topical Gel, 1.62% Metered Pump|
75576663|NCT02110368|Drug|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
75576664|NCT02916485|Device|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
75576665|NCT01709214|Drug|Cebranopadol (GRT6005) Low-Dose Range|Capsules
75576666|NCT01709214|Drug|Cebranopadol (GRT6005) High-Dose Range|Capsules
75727022|NCT02583347|Device|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
75727023|NCT04079231|Drug|Brolucizumab|Intravitreal Injection
75727024|NCT04079231|Drug|Aflibercept|Intravitreal injection
75727025|NCT00994695|Biological|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
75727026|NCT05350293|Other|Molded abutment|"The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner."
75727027|NCT05350293|Other|3D printed abutment|A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
75727028|NCT02584985|Procedure|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
75727029|NCT02584985|Procedure|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
75878816|NCT04475705|Drug|propofol|intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
75878817|NCT04475705|Drug|sevoflurane|sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
76049156|NCT02412761|Drug|Lisinopril|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
75429861|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
75429862|NCT01503203|Other|Core training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
75429863|NCT01503203|Other|Physical Virtual Training|The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
75429864|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
75429865|NCT01503203|Other|Core Training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
75429866|NCT01503216|Dietary Supplement|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
75576667|NCT01709214|Drug|Placebo|Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
75576668|NCT01709214|Drug|Oxycodone CR|Capsules containing oxycodone CR 10 or 20 milligrams
75576669|NCT02916602|Drug|HCP1401|amlodipine, Losartan, Chlorthalidone FDC
75576670|NCT02916602|Drug|HCP0605|amlodipine, Losartan FDC
75576671|NCT02110212|Procedure|U/S Surgery and CCC|Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
75576672|NCT02110212|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
75576673|NCT02916797|Other|Stepping training with feedback|Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
75429867|NCT01503216|Dietary Supplement|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
75576674|NCT02916290|Drug|Fuzhenghuayu|
75576675|NCT02916290|Drug|UDCA|
75576676|NCT01708551|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75576677|NCT02916251|Drug|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
75576678|NCT02916251|Drug|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
75429868|NCT01503216|Dietary Supplement|Placebo|Placebo
75429869|NCT01503242|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
75429870|NCT01503242|Drug|Cyclosporine|Given PO
75429871|NCT01503242|Drug|Fludarabine Phosphate|Given IV
75429872|NCT01503242|Drug|Mycophenolate Mofetil|Given IV or PO
75429873|NCT01503242|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
75429874|NCT01503242|Radiation|Total-Body Irradiation|Undergo TBI
75429875|NCT01503242|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
75429876|NCT01503255|Behavioral|cognitive behavioral group therapy|6 weekly 90-minute group sessions
75429877|NCT01503255|Behavioral|health education group|6 weekly 90-minute group sessions
75576679|NCT01707264|Drug|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
75576680|NCT02916095|Drug|Kanitinib|Oral administration of Kanitinib tablets.
75576681|NCT02106546|Drug|Carboplatin|Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
75576682|NCT02106546|Drug|Veliparib|Capsules taken orally twice a day, 12 hours apart.
75576683|NCT02106546|Drug|Paclitaxel|Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
75429878|NCT01503268|Device|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
75429879|NCT01503268|Procedure|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
75576684|NCT02106546|Drug|Placebo to veliparib|Capsules taken orally twice a day, 12 hours apart.
75429880|NCT01503268|Procedure|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
75429881|NCT01503281|Other|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
75576685|NCT02916173|Drug|Recombinant Human Chorionic Gonadotrophin|250 unit intramuscular
75576686|NCT02916173|Drug|human chorionic gonadotrophin + gonadotrophin releasing hormone agonist|250 unit intramuscular + 1 mg subcutaneous
75429882|NCT01503320|Dietary Supplement|Enteral glutamine|Dosage of glutamine: 0.57g/kg, ~ 30g/day= 3sachets
75429883|NCT01503320|Dietary Supplement|Placebo|Similar appearing nutritional supplement without glutamine.
75429884|NCT01503346|Drug|DaHuang GanTsao Tang|"Intervention group~2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~each package was given to each patient four times a day (three time after meal and one time before sleep);~each patient received the usual medication of the hospice ward at the same time;~record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
75429885|NCT01503359|Dietary Supplement|Sarcosine|"Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months."
75429886|NCT01503372|Drug|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
76024761|NCT04842929|Device|Transcranial magnetic stimulation|The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
75429887|NCT01503372|Drug|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
75576687|NCT02916134|Procedure|Laparoscopic +/- Open Appendicectomy|Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
75576688|NCT02916134|Drug|Antibiotic treatment|"Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics."
75576689|NCT02916212|Other|Optimized alarm profiles|
75576690|NCT04688606|Diagnostic Test|Circulating tumor cell capture technology|CTCBIOPSY® automatic testing platform
75576691|NCT02104245|Drug|Ciprofloxacin dispersion for inhalation|
75576692|NCT02104245|Drug|Placebo|
75576693|NCT04688489|Dietary Supplement|Carbloading and maltodextrin|The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
75576694|NCT01699737|Drug|JTT-851|
76024762|NCT02699983|Behavioral|Behavioral Dietary Intervention|Use SparkPeople web-based program
75429888|NCT01503385|Drug|Celecoxib|400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
75429889|NCT01503398|Drug|Olanzapine|Olanzapine Tablets, 5 mg
75429890|NCT01503424|Drug|Olanzapine|Olanzapine Tablets, 5 mg
75429891|NCT01503437|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
75429892|NCT01503450|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
75576695|NCT01699737|Drug|Glimepiride|Encapsulated Glimepiride tablets
75576696|NCT01699737|Drug|Placebo for Active|
75576697|NCT01699737|Drug|Placebo for comparator|
75429893|NCT01503463|Procedure|Home telemonitoring of patients with CHF|"Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified."
75576698|NCT04688723|Drug|Dabigatran + Ticagrelor|Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.
75576699|NCT04688723|Drug|Dabigatran + clopidogrel|Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.
75576700|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
75576701|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
75576702|NCT01699464|Drug|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
75576703|NCT04688645|Drug|Balanced crystalloid solution|Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
75727030|NCT04521803|Drug|high dose Rifampicin (RIF)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
75727031|NCT00920465|Drug|mifegyne and cytotec|One day dosage versus two days dosage
75429894|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
75576704|NCT04688645|Drug|Normal saline|0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
75576705|NCT00555282|Device|central venous catheter|coated central venous catheter
75576706|NCT00555282|Device|central venous catheter|standard central venous catheter
75576707|NCT04688372|Other|Surge Index|See study description above
75576708|NCT02104050|Drug|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
75576709|NCT02104050|Drug|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
75576710|NCT02915861|Other|Non-invasive eschar samples + blood|EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).
75576711|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+blood|EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).
75576712|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
75727032|NCT04078919|Dietary Supplement|Nut consumption|daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)
75727033|NCT04078919|Other|Low calorie diet|Low calorie diet
75727034|NCT02583035|Other|Nurse telephone contact|Nurse will contact patient 3 days before consultation
75727035|NCT00994773|Drug|Simvastatin|daily doses for 14 days
75727036|NCT00994773|Drug|Tenofovir|
75727037|NCT00994773|Drug|Entecavir|Entecavir
75727038|NCT05405543|Drug|MYK-224|Specified dose on specified days
75727039|NCT05405543|Other|Placebo|Specified dose on specified days
75727040|NCT00995631|Procedure|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
75429895|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
75576713|NCT02915861|Other|Blood+Skin sample|Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
75576714|NCT03200132|Diagnostic Test|Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.
75576715|NCT01694277|Drug|Masitinib|12 mg/kg/day
75576716|NCT01694277|Drug|Sunitinib|50 mg/day
75576717|NCT02100150|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
75727041|NCT00995787|Drug|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
75727042|NCT00995787|Drug|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
75727043|NCT04079153|Device|Mandibular advancement Appliance|Advances the mandible at desired range at a fixed vertical dimension
75727044|NCT00994851|Drug|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
75878818|NCT03569150|Other|Cultural adaptation/implementation COMFORT CC|The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
75429896|NCT01503502|Drug|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
75429897|NCT01503502|Drug|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
75727045|NCT00994851|Drug|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
75727046|NCT04411745|Other|No intervention, observational study|
75429898|NCT01503528|Procedure|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
75429899|NCT01503528|Procedure|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
75429900|NCT01503541|Genetic|DNA analysis|
75429901|NCT01503541|Genetic|RNA analysis|
75429902|NCT01503541|Genetic|gene expression analysis|
75429903|NCT01503541|Genetic|mutation analysis|
75429904|NCT01503541|Genetic|polymerase chain reaction|
75429905|NCT01503541|Other|laboratory biomarker analysis|
75576718|NCT02100150|Drug|Placebo|Strawberry flavored solution 0.5% v/v in Water for Injection
75576719|NCT03103490|Drug|18F-FSPG|Patients receive 8mCi of 18F-FSPG and undergo PET/MRI imaging (or PET/CT for patients with metal implants) to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation.
75727047|NCT04001127|Other|High Intensity Functional Training|"The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing)."
75576720|NCT01669980|Drug|Ceftaroline fosamil|"Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~Subjects < 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~PO clindamycin 13 mg/kg/dose~PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
75429906|NCT01503554|Behavioral|Combined Social Worker and Pharmacist Program|"Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.~Pharmacist will be available to patients should they have any medication-related questions post-discharge"
75576721|NCT01669980|Drug|IV Ceftriaxone and Vancomycin|"IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~PO clindamycin 13 mg/kg/dose~PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
75576722|NCT02915666|Drug|Digoxin Combination|Digoxin 0.25 mg PO daily will be given for 8-week cycles
75576723|NCT02915666|Drug|Dabrafenib|dabrafenib 150mg PO twice daily for 8-week cycles
75727048|NCT04078607|Behavioral|Rapid Visual Information Processing task|A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
75727049|NCT04078607|Behavioral|None or Control condition|Participant were instructed to eat at will during a 15-minute duration.
75727050|NCT05198505|Drug|TQB2868 Injection|TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
75429907|NCT01503554|Behavioral|No Intervention: Usual Care|Patient receives usual care upon discharge from the hospital.
75429908|NCT01503567|Other|No treatment given|Subject will only fill out a questionaire
75429909|NCT01503580|Drug|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
75429910|NCT01503593|Device|Calcium Phosphate, Calcium Sulphate|1cc of Calcium Phosphate and 1cc of Calcium Sulphate
75429911|NCT01503619|Other|laboratory biomarker analysis|Correlative studies
75429912|NCT01503658|Drug|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
75429913|NCT01503671|Drug|Atorvastatin|Atorvastatin 40 mg/day
75576724|NCT02915666|Drug|Trametinib|trametinib 2 mg PO daily for 8-week cycles
75576725|NCT02915822|Procedure|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique for hallux valgus correction
75727051|NCT04078841|Dietary Supplement|ReaLife+ (RLP)|RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
75429914|NCT01503684|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
75429915|NCT01503723|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
75429916|NCT01503736|Drug|ferric citrate|0g/day ferric citrate capsule, TID for 56 days
75576726|NCT02915822|Procedure|Open Scarf/Akin osteotomy|Open technique for Hallux Valgus correction
75576727|NCT02098473|Drug|RPC4046|
75576728|NCT02098473|Drug|Placebo|
75727052|NCT04078841|Other|Inert Brown powder|Brown powder Inert brown powder to look similar to RLP
75727053|NCT03742869|Combination Product|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
75727054|NCT02583191|Drug|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
75878819|NCT03158311|Drug|QVM149|Indacaterol acetate / glycopyrronium bromide / mometasone furoate
75878820|NCT03158311|Drug|Salmeterol/fluticasone plus tiotropium|Free triple arm of salmeterol / fluticasone plus tiotropium
75429917|NCT01503736|Drug|ferric citrate|4g/day ferric citrate capsule, TID for 56 days
75878821|NCT01331915|Biological|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."
75429918|NCT01503736|Drug|ferric citrate|6 g/day ferric citrate capsule, TID for 56 days
75429919|NCT01503762|Other|Mirror therapy|mirror therapy
75429920|NCT01503762|Other|Classical rehabilitation techniques|splinting, tendon gliding, active range of motion, activities of daliy living
75429921|NCT01503788|Drug|Midazolam|participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
75429922|NCT01503801|Drug|Nitric Oxide|The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
75429923|NCT01503801|Device|respiratory support|Routine respiratory support.
75429924|NCT01503814|Other|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
75429925|NCT01503827|Radiation|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
75878822|NCT02244866|Drug|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
75429926|NCT01503840|Drug|sugammadex|sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
75429927|NCT01503840|Drug|Sodium chloride solution|Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
75429928|NCT01503892|Dietary Supplement|Metanx|Metanx- one tablet twice daily for twelve months
75878823|NCT02244866|Drug|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
75429929|NCT01503892|Drug|Placebo|Placebo- one tablet twice daily for twelve months.
75429930|NCT01503905|Drug|Docetaxel|75mg/m2, iv injection, day1, every 21 days
75429931|NCT01503905|Drug|epirubicin|80mg/ m2, iv injection, day1, every 21 days
75429932|NCT01503905|Drug|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
75429933|NCT01503905|Procedure|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
75429934|NCT01503905|Drug|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
75429935|NCT01503905|Drug|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
75429936|NCT01503905|Drug|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
75429937|NCT01503905|Radiation|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
75429938|NCT01503905|Drug|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
75429939|NCT01503905|Drug|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
75429940|NCT01503918|Drug|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
75878824|NCT01334567|Drug|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
75878825|NCT03570398|Other|unenhanced abdomino-pelvic CT scan|unenhanced abdomino-pelvic CT scan
75878826|NCT03570398|Other|abdominal ultrasound|abdominal ultrasound
75576729|NCT02915627|Device|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
75576730|NCT02915588|Other|early isometric loading after rotator cuff surgery|
75576731|NCT02915588|Other|passive motion after rotator cuff surgery|
76049157|NCT02412761|Drug|Amlodipine|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
75429941|NCT01503918|Drug|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
75429942|NCT01503957|Device|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
75429943|NCT01503957|Device|Saline solution|Nasal spray, 2 sprays in each nostril
75429944|NCT01503970|Device|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
75429945|NCT01503983|Drug|Trastuzumab|Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
75429946|NCT01503983|Drug|Capecitabine|Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
75576732|NCT02915510|Dietary Supplement|Glycomacropeptide-based protein substitute|
75576733|NCT02098278|Drug|CAT-2003|
75576734|NCT02098278|Drug|Placebo|
75878827|NCT01337843|Other|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
75878828|NCT01337843|Other|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
76049158|NCT02412761|Drug|Hydrochlorothiazide|Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
76049159|NCT01842334|Behavioral|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
76049160|NCT01842334|Drug|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
75429947|NCT01503983|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
75429948|NCT01503996|Behavioral|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
75429949|NCT01504009|Other|Muscle training|12 weeks of strength training 2-3 times/week
75429950|NCT01504022|Other|Telecare, selfmonitoring, lifestyl behaviour|Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
75429951|NCT01504035|Device|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
75576735|NCT02915471|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
75576736|NCT04677894|Device|Laryngoscopy|During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
75576737|NCT02915276|Procedure|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
75576738|NCT02915276|Procedure|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
75576739|NCT02915315|Dietary Supplement|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
75576740|NCT02092935|Drug|SMT19969|
76049161|NCT02457611|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
75727055|NCT02583191|Drug|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~Enoxaparin 1 mg/kg BW twice daily~Tinzaparin 175 I.E./kg BW once daily~Dalteparin 200 I.E./kg BW once daily"
75727056|NCT04000893|Other|Resistance exercise session|Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
75878829|NCT04398329|Drug|HTX-034|HTX-034, low dose
75878830|NCT04398329|Drug|HTX-034|HTX-034, high dose
75878831|NCT04398329|Device|Luer lock applicator|Applicator for instillation
75878832|NCT04398329|Drug|Bupivacaine HCl|Bupivacaine HCl, 50 mg
75878833|NCT00449111|Drug|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
75429952|NCT01504035|Device|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
75429953|NCT01504048|Procedure|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
75429954|NCT01504061|Other|Mederma N&I|Topical gel applied three times a day for eight weeks.
75878834|NCT03568916|Drug|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
75429955|NCT01504061|Other|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
75429956|NCT01504074|Behavioral|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
75576741|NCT02092935|Drug|Vancomycin|
75576742|NCT02915237|Dietary Supplement|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
75576743|NCT02915237|Dietary Supplement|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
75576744|NCT01666977|Drug|AMG 386|15mg/kg
75576745|NCT01666977|Drug|AMG 386|30 mg/kg
75576746|NCT01666977|Drug|AMG 386 Placebo|AMG 386 Placebo
75576747|NCT01666977|Drug|Pemetrexed|Pemetrexed 500 mg/m2
75576748|NCT01666977|Drug|Carboplatin|Carboplatin AUC 6
75576749|NCT02915354|Drug|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
75576750|NCT01661634|Drug|Ularitide|
75727057|NCT04078217|Device|Jintronix|Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.
75727058|NCT04078217|Other|Booklet|Home-based exercise program using a paper booklet (not the technology).
75727059|NCT02582723|Other|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
75727060|NCT02582723|Other|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
75727061|NCT02582723|Other|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
75576751|NCT01661634|Drug|Placebo|
75576752|NCT02915081|Other|Blue light|"Illumination: High illumination lighting will be instituted with a Day*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period."
75429957|NCT01504126|Drug|Chemotherapy|Undergo standard chemotherapy
75878835|NCT03568916|Drug|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
75576753|NCT02914847|Behavioral|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
75576754|NCT01661166|Drug|Fesoterodine|4 mg
75576755|NCT01661166|Drug|Placebo oral tablet|Placebo
75576756|NCT02915003|Behavioral|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
75727062|NCT05347329|Dietary Supplement|Tongkat Ali Maca Plus|Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
75878836|NCT03568916|Drug|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
75878837|NCT01334645|Other|Copeptin|"Patients with hyponatremia < 135 mmol/L or troponin > 1 μg/L are released study.~Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.~Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.~The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected"
75878838|NCT03571880|Device|Biodex-assisted isometric strength testing|The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
75429958|NCT01504126|Drug|Propranolol Hydrochloride|Given PO
75429959|NCT01504126|Other|Quality-of-Life Assessment|Ancillary studies
75429960|NCT01504126|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
75429961|NCT01504139|Drug|hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase|when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
75429962|NCT01504139|Drug|hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase|hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
75429963|NCT01504139|Drug|LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase|LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
75576757|NCT01659138|Drug|SAR339658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
75576758|NCT01659138|Other|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75576759|NCT02915042|Drug|Dexmedetomidine|Analgesic Efficacy
75576760|NCT02915042|Drug|Placebo|Saline placebo
75576761|NCT01658826|Drug|AIC316|100 mg oral administration
75576762|NCT01658826|Drug|Valacyclovir|500 mg oral administration
75576763|NCT02914769|Drug|Ayahuasca|patients will receive a single dose of ayahuasca.
75576764|NCT02914769|Drug|placebo|patients will receive a single dose of a passive placebo.
75878839|NCT03635593|Drug|CBD|Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.
75878840|NCT03635593|Drug|CBD+THC|Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
75576765|NCT04677582|Behavioral|Vidas Activas, famiLias saludablEs (VALE)|Families and Children allocated to the intervention will receive weekly group-based meetings over a 10-week period consisting of education and activities on healthy lifestyles. Graduate students/Research Assistants trained in nutrition, exercise and clinical psychology will lead the meetings. All activities will be culturally relevant (i.e. cooking healthy Latino recipes) and Spanish speaking students will be recruited to deliver the intervention. Participants will be involved on deciding activities and projects and while some sessions will meet as a family group with parents/guardians, others will meet separately.
75727063|NCT02582567|Other|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
75429964|NCT01504139|Drug|vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase|The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
75429965|NCT01504152|Behavioral|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
75429966|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
75878841|NCT03635593|Other|Placebo|Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
75878842|NCT05213247|Device|electronic apparatus (visocor OM50).|Measurement of blood pressure and heart rate
75429967|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
75429968|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
75878843|NCT04373915|Behavioral|Remote Bedside Rounding|Parents of infants on the medical team utilizing remote rounding will have the opportunity to participate in rounds by video conferencing at the infant's bedside. Participation will be tracked and surveys regarding stress, satisfaction, and attachment will be completed by parents in both groups.
75878844|NCT03571490|Drug|Ropivacaine|Single shot of ropivacaine 0.325%
75429969|NCT01504165|Drug|cilengitide 1000mg|A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
75429970|NCT01504165|Drug|cilengitide > 1000mg and up to 2000mg|A single dose of cilengitide > 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
75429971|NCT01504178|Drug|duloxetine|administration during 28 days
75429972|NCT01504178|Drug|placebo of duloxetine|administration during 28 days
75429973|NCT01504178|Drug|injection of apomorphine|injection performed at D28
75429974|NCT01504178|Drug|injection of placebo of apomorphine|performed at D28
75429975|NCT01504178|Drug|L-Dopa|performed at D28
75429976|NCT01504178|Drug|injection of placebo of L-Dopa|performed at D28
75576766|NCT02914925|Device|ArmeoSpring/CIT|Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
75576767|NCT02092077|Drug|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
75878845|NCT03571490|Drug|Saline|Single shot of saline 0.9%
75576768|NCT02092077|Drug|somatropin|Dose may be adjusted as required
75878846|NCT05754801|Drug|Yunzhi Essence|Yunzhi Essence capsule
75878847|NCT05754801|Other|Placebo|Placebo capsules
75878848|NCT01331993|Drug|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
75878849|NCT01331993|Drug|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
75878850|NCT01331993|Drug|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
75878851|NCT03424694|Radiation|HDR brachytherapy as monotherapy|
75576769|NCT01651143|Drug|SAR100842|"Pharmaceutical form: tablets~Route of administration: oral"
76049162|NCT04593628|Behavioral|Connect for Caregivers|The STAR Center developed Connect for Caregivers to help improve connectedness among older caregivers of individuals with Alzheimer's Disease and Related Dementias (ADRD). Connect for Caregivers includes three components: (1) psychoeducational materials on the importance of connectedness for health and well-being; (2) a card sort-based 'discussion prioritization tool' that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; (3) personalized resources to address the identified barriers/targets. We will tailor Connect for Caregivers for Hispanic/Latino and Spanish-speaking caregivers guided by the Selective and Directed Treatment Adaptation Framework. The intervention is given once during the study.
75429977|NCT01504191|Behavioral|Internet-based CBT|"The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.~A psychologist will communicate with the participants through internal text-messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc."
75429978|NCT01504256|Drug|catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel|"Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)"
75576770|NCT01651143|Drug|Placebo (for SAR100842)|"Pharmaceutical form: tablets~Route of administration: oral"
75576771|NCT02914886|Drug|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
75727064|NCT05347017|Procedure|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by HCL acid and inserted as demineralized dentin block graft in the socket
75727065|NCT05347017|Procedure|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non restorable tooth, then the autogenous bone block graft will be harvested from the maxillary tuberosity and reshaped and inserted into the socket
76049163|NCT04931381|Other|Chemotherapy guided by organoid drug sensitivity test|Chemotherapy guided by organoid will be given to advanced pancreatic cancer patients.
76049164|NCT02457065|Behavioral|"Melanoma Survivor plaque"|The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
75429979|NCT01504256|Drug|Fluorouracil, leucovorin, oxaliplatin, docetaxel|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
75576772|NCT02914886|Drug|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
75576773|NCT01650051|Drug|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
75576774|NCT01650051|Drug|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
75576775|NCT01643226|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
75576776|NCT01643226|Drug|placebo solution|0.0% riboflavin ophthalmic solution
75576777|NCT01643226|Device|KXL System|30 mW/cm2
75576778|NCT02089425|Drug|K-103-IP|
75576779|NCT02089425|Drug|Placebo|Placebo comparator
75576780|NCT02914652|Drug|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
75429980|NCT01504282|Drug|mitomycin-C|
75429981|NCT01504282|Drug|Placebo|balanced salt solution (BSS)
75429982|NCT01504295|Drug|Metadoxine|Improve Liver Function and Reduce ALcohol Use
75576781|NCT02914652|Drug|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
75576782|NCT02081703|Drug|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
75429983|NCT01504308|Device|MR-HIFU treatment|A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
75429984|NCT01504308|Device|Sham treatment|A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
75429985|NCT01504321|Drug|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
75429986|NCT01504321|Drug|Placebo|Encapsulated lactose powder
75576783|NCT02081703|Drug|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
75576784|NCT02081703|Drug|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
75576785|NCT02081703|Drug|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
75576786|NCT02914691|Drug|Dapagliflozine 10 mg once daily tablet treatment|
75727066|NCT04403009|Other|no intervention|no intervention
75727067|NCT00998907|Device|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
75576787|NCT02914691|Drug|Placebo identical once daily tablet treatment|
75576788|NCT02081118|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
75576789|NCT02081118|Drug|Placebo|Placebo for HM11260C
75576790|NCT02078310|Drug|ITI-007|ITI-007 for Part 1
75576791|NCT02078310|Drug|Placebo|ITI-007 for Part 1
75576792|NCT02078310|Drug|ITI-007|ITI-007 for Part 2
75576793|NCT02078310|Drug|Placebo|Placebo for Part 2
75727068|NCT00998907|Device|PDS II|polyglactin 910 suture material for abdominal wall closure
75727069|NCT03084237|Biological|HLX02|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
75727070|NCT03084237|Biological|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
75727071|NCT03084237|Drug|docetaxel|75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
75727072|NCT02584907|Other|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
75727073|NCT04615715|Behavioral|CMV Risk-Reduction Intervention|CMV Risk-Reduction Intervention
75727074|NCT04615715|Behavioral|Stress Reduction Messaging|Stress Reduction Messaging
75576794|NCT02914574|Other|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
75576795|NCT02077881|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
75576796|NCT02077881|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
75576797|NCT02077881|Drug|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
75576798|NCT02914418|Device|Transcranial Magnetic Stimulation using iTBS Paradigm|TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for ~200sec and can promote changes in neural activity.
75576799|NCT04677699|Diagnostic Test|Combined Risk Score|Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
75576800|NCT02074410|Drug|OMS643762|
75576801|NCT02074410|Drug|Placebo|
75576802|NCT02914340|Device|Spiration Valve System|
75576803|NCT02914262|Drug|AKB-4924|Comparison of different dosages of AKB-4924
75576804|NCT02914262|Other|Placebo|Placebo comparator
75576805|NCT02915900|Other|Gonadotropin removal test|Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
75576806|NCT02915900|Other|Routine IVF method|Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
75429987|NCT01504334|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
75429988|NCT01504334|Drug|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
75727075|NCT00996021|Drug|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
75429989|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
75429990|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
75727076|NCT00996021|Drug|Placebo Suspension|Placebo is a liquid with no drug in it.
75727077|NCT00996021|Drug|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
75727078|NCT00996099|Device|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
75429991|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
75429992|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
75429993|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
75429994|NCT01504386|Procedure|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
75429995|NCT01504386|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
75429996|NCT01504438|Device|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
75576807|NCT01632228|Drug|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
75576808|NCT01632228|Drug|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
75576809|NCT01632228|Drug|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
75576810|NCT02914223|Drug|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
75727079|NCT00996099|Other|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
75727080|NCT02582645|Procedure|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
76024763|NCT02699983|Behavioral|Exercise Intervention|Use Fitbit monitor and SparkPeople web-based program
75576811|NCT01628094|Drug|RO5024048|
75576812|NCT01628094|Drug|RO5190591|
75576813|NCT01628094|Drug|RO5466731|
75576814|NCT01628094|Drug|ribavirin [Copegus]|
75429997|NCT01504438|Device|STAR Total Ankle Replacement|STAR Total Ankle Replacement
75429998|NCT01504451|Device|ILR insertion|Insertion of implantable loop recorder
75429999|NCT01504451|Procedure|AF ablation|AF ablation
75430000|NCT01504464|Biological|mesenchymal stem cell|intra articular injection of mesenchymal stem cell
75430001|NCT01504464|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
75430002|NCT01504490|Drug|CS-7017 and Bexarotene|"CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
75430003|NCT01504503|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
75430004|NCT01504503|Drug|Aricept|Aricept 10 mg Tablets
75430005|NCT01504516|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
75430006|NCT01504516|Drug|Aricept|Aricept 10 mg Tablets
75430007|NCT01504542|Biological|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
75430008|NCT01504542|Biological|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
75576815|NCT01628094|Drug|ritonavir|
75576816|NCT02914106|Other|Observational Study|Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
75576817|NCT01627314|Biological|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
75576818|NCT01627314|Biological|Untreated CB|Cord Blood
75576819|NCT03026504|Drug|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
75727081|NCT02582645|Procedure|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
75727082|NCT02584751|Drug|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
75727083|NCT02584751|Device|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
75727084|NCT02584751|Procedure|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
75727085|NCT02584751|Procedure|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
75727086|NCT02584751|Procedure|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
75727087|NCT02584751|Procedure|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
76024764|NCT02699983|Device|Activity Monitoring Device|Wear Fitbit activity monitoring device
75430009|NCT01504542|Biological|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
75430010|NCT01504568|Other|Treatment|Adults: ≥40 kg:250mg every eight hours Children: <40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
75430011|NCT01504581|Biological|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
75430012|NCT01504581|Biological|HM10660A placebo|Single dose of HM10660A Placebo
75576820|NCT02073123|Drug|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~If > 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~If >1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If >1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
75576821|NCT02073123|Drug|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
75727088|NCT02584751|Procedure|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
75878852|NCT01340365|Behavioral|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
75878853|NCT01340365|Behavioral|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
75878854|NCT01337999|Other|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
75878855|NCT03571412|Device|repetitive Transcranial Magnetic Stimulation|Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
75878856|NCT01341769|Other|Dietary Intervention|
75878857|NCT01341769|Other|Dietary Intervention|
75878858|NCT01341769|Other|Dietary Intervention|
75430013|NCT01504581|Biological|Pegasys|Single dose of Pegasys 180ug
75430014|NCT01504594|Procedure|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
75430015|NCT01504607|Procedure|Congenital Cataract Surgery|Congenital cataract surgery with IOL implantation
75430016|NCT01504620|Other|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
75430017|NCT01504620|Drug|insulin infusion|i.v. infusion of insulin
75430018|NCT01504633|Dietary Supplement|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
75430019|NCT01504646|Dietary Supplement|Lyprinol|8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
75430020|NCT01504646|Dietary Supplement|Placebo (Olive Oil)|8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
75576822|NCT02073123|Drug|Nivolumab|Nivolumab administered intravenously at 240 mg every 2 weeks.
75576823|NCT02073123|Drug|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
75576824|NCT02914145|Drug|Dihydroartemisinin-piperaquine|Mass drug administration
75576825|NCT02913989|Other|Smoking habits characterization|
75727089|NCT00999219|Drug|FK199B|oral
75727090|NCT00999219|Drug|Zolpidem|oral
75727091|NCT00996177|Drug|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
75727092|NCT00996177|Drug|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
75727093|NCT04079933|Other|Oral tobacco-derived nicotine product (OTDN)|
75727094|NCT02584595|Device|ICD/CRT-D with NIPS or EP Study|ICD/CRT-D implanted patients are tested for inducible MMVT during electrophysiology (EP) Study or Non-Invasive Programmed Stimulation (NIPS) Study
75727095|NCT00996255|Drug|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
75878859|NCT01341769|Other|Dietary Intervention|
76024765|NCT01960114|Drug|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
76024766|NCT01960114|Drug|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
75576826|NCT00554892|Procedure|bowel preparation|oral laxatives, retrograde enemas
75430021|NCT01504659|Drug|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
75576827|NCT00554892|Procedure|no preparation bowel|no preparation bowel
75576828|NCT01626573|Drug|Itacitinib|
75576829|NCT01626573|Drug|Itacitinib Placebo|
75576830|NCT02913950|Other|validation of pediatric stool scale|validation of pediatric stool scale
75576831|NCT01621152|Other|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
75576832|NCT01621152|Other|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
75576833|NCT02914028|Procedure|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
75576834|NCT02914028|Drug|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
75576835|NCT02913911|Other|feedback|Sit to stand training with external feedback
75576836|NCT02065284|Other|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
75576837|NCT02913833|Other|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
75576838|NCT02913755|Behavioral|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
75576839|NCT02064426|Drug|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
75878860|NCT04344431|Combination Product|Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)|One session per day of HBOT in addition to the standard treatment with normobaric oxygen
76049165|NCT02083653|Drug|Sym004 (12 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
75576840|NCT02064426|Biological|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
75430022|NCT01504659|Drug|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
75430023|NCT01504685|Procedure|Banded Laparoscopic Roux-en-Y gastric bypass|"A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
75576841|NCT00899301|Other|biologic sample preservation procedure|Tissue, urine and blood collection.
75430024|NCT01504685|Procedure|Unbanded Laparoscopic Roux- en-Y gastric bypass|"A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
75576842|NCT02913677|Dietary Supplement|nutrition|Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
75576843|NCT02913716|Drug|defactinib|Single oral dose of 400 mg [14C]-defactinib
75576844|NCT02063997|Drug|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
75576845|NCT02063997|Drug|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
75576846|NCT02063997|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
75576847|NCT02063997|Drug|Placebo|Placebo tablets once daily for 12 weeks
75576848|NCT02063997|Drug|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
75576849|NCT02913443|Drug|RO7051790|RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
75576850|NCT00585507|Drug|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
75878861|NCT05709080|Other|family-professional collaboration practice model|Online instructional sessions will be conducted in two sessions for six hours (3 hours per session) for the physical therapists in the experimental group. The instructional session focus on explaining the specific strategies and process to implement the Family-professional Collaboration (four step process) Model as ( Step 1: Mutually agreed-upon goals, Step 2: Shared planning, Step 3: Shared implementation and Step 4: Shared evaluation of child and family outcomes.
75878862|NCT05184127|Drug|MIR 19 ®|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
76049166|NCT02083653|Drug|Sym004 (9/6 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
75576851|NCT02913287|Dietary Supplement|Aquamin/Aquamin MG|Marine-based nutraceutical
75576852|NCT02913287|Other|Maltodextrin Placebo|Maltodextrin Placebo
75576853|NCT02063685|Drug|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
75576854|NCT02063685|Drug|Observation|not maintenance therapy and followed-up with MRD monitoring.
75576855|NCT02063685|Drug|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
75576856|NCT02063685|Drug|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
75576857|NCT02063685|Drug|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
75430025|NCT01504698|Procedure|Advice and exercise-based treatment plus joint manipulation|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
75576858|NCT02913248|Procedure|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
75576859|NCT02063295|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
75727096|NCT04080089|Combination Product|Surgical treatment, drug therapy, remote cognitive training|"Surgical treatment：Children with OSAHS who had surgical indications and informed consent from the parents underwent tonsillectomy and adenoidectomy.~drug therapy：For children whose parents only agree to receive medical treatment, montelukast sodium tablets are given for 6 months to reduce the inflammatory response of adenoids, tonsils, etc.~remote cognitive training:For children whose parents did not agree to undergo surgery or medication, the cognitive function was evaluated at the time of enrollment, and cognitive training was performed. Individualized training programs were developed according to the cognitive assessment system, and cognitive function was evaluated again after one course of treatment."
75727097|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
75430026|NCT01504698|Procedure|Advice and exercise-based treatment|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
75576860|NCT02063295|Drug|ZGN-440 for injectable suspension|
75576861|NCT02913170|Dietary Supplement|Nattokinase|
75576862|NCT02913170|Dietary Supplement|Placebo|
75576863|NCT02057172|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
75576864|NCT02057172|Drug|liraglutide|Liraglutide is a GLP-1 agonist.
75878863|NCT05184127|Combination Product|Standard COVID-19 therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
75878864|NCT01338077|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
75878865|NCT01338077|Drug|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
75430027|NCT01504724|Drug|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
75430028|NCT01504737|Other|Aerobic Exercise Training|12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.
75430029|NCT01504737|Other|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
75576865|NCT02057172|Drug|Placebo|Placebo
75576866|NCT02913404|Procedure|ACL Reconstruction|standard surgical procedure
75576867|NCT02913404|Procedure|ACL Recon. extra-articular-tenodesis|standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
75576868|NCT02053116|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
75576869|NCT02053116|Drug|Placebo|Tablet, 0 mg, twice daily, 2 weeks
75576870|NCT02912975|Other|Mirror treatment|The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
75576871|NCT02912975|Other|Tactile treatment|In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
75576872|NCT02894307|Drug|Rivaroxaban|In patients with mechanical valves and unstable INR
75576873|NCT02913014|Other|No AAD post Ablation.|Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
75430030|NCT01504750|Procedure|dynamic daylight and atmosphere lighting|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
75430031|NCT01504763|Procedure|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
75430032|NCT01504776|Drug|Panobinostat|Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat
75430033|NCT01504776|Drug|Bortezomib|
75430034|NCT01504828|Drug|Ramipril|Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
75430035|NCT01504906|Drug|cyclosporine|Oral tablets, 600 mg , single dose
75430036|NCT01504906|Drug|ticagrelor|Oral tablets, 180 mg, single dose
75430037|NCT01504932|Dietary Supplement|BRB Lozenge|ARM I: Patients will be instructed to begin BRB administration and continue daily for up to 6 months.
75430038|NCT01504932|Other|Survey Administration|Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
75430039|NCT01504932|Other|Laboratory Biomarker Analysis|Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
75430040|NCT01504932|Other|pharmacological study|Correlative studies
75430041|NCT01504945|Other|RBC transfusion|1 bag of packed red blood cells
75430042|NCT01504945|Other|Normal saline infusion|500 mL of normal saline infusion
75430043|NCT01504984|Drug|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
75430044|NCT01504984|Drug|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I&II D1(crossover)
75430045|NCT01505023|Dietary Supplement|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
75430046|NCT01505023|Dietary Supplement|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
75430047|NCT01505023|Dietary Supplement|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
75430048|NCT01505036|Other|SMARTCARE service|U-Healthcare service
75430049|NCT01505049|Drug|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
75430050|NCT01505075|Radiation|Hypofractionated radiation|40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
75430051|NCT01505088|Drug|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
75430052|NCT01505088|Drug|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
75430053|NCT01505088|Drug|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
75430054|NCT01505088|Drug|Placebo Eyedrops|Placebo Eyedrops
75430055|NCT01505101|Behavioral|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
75430056|NCT01505101|Behavioral|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
75430057|NCT01505127|Drug|TAK-438|
75430058|NCT01505127|Drug|Lansoprazole|
75430059|NCT01505127|Drug|Amoxicillin|
75430060|NCT01505127|Drug|Clarithromycin|
75430061|NCT01505140|Other|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
75576874|NCT02052648|Drug|Indoximod|
75576875|NCT02052648|Drug|Temozolomide|
75576876|NCT02052648|Drug|Bevacizumab|
75576877|NCT02052648|Radiation|Stereotactic Radiation|
75576878|NCT02913053|Behavioral|Aerobic exercise|Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week
75430062|NCT01505153|Biological|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
75430063|NCT01505192|Device|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
75727098|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
75727099|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
75430064|NCT01505218|Drug|Propofol sedation by nurse anaesthestist|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.~Propofol sedation by nurse anaesthetists:"
75727100|NCT02582801|Drug|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
75727101|NCT05388695|Biological|Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells|Single or sequential injection of CD19, CD20 and CD22 CAR T cells.
75430065|NCT01505218|Drug|Patient-controlled propofol sedation|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
75430066|NCT01505231|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement.
75430067|NCT01505231|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
75430068|NCT01505244|Behavioral|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
75576879|NCT02913053|Behavioral|Non-aerobic exercise|Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
75576880|NCT02894112|Dietary Supplement|non-fat milk|1 serving of non-fat fluid milk
75576881|NCT02894112|Dietary Supplement|carbohydrate control beverage|1 serving of carbohydrate control beverage (Carbohydrate powder + water)
75576882|NCT02894112|Dietary Supplement|caloric control beverage|1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
75576883|NCT01186744|Drug|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
75576884|NCT01186744|Drug|CP-690,550|10 mg oral BID
75576885|NCT01186744|Drug|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
75576886|NCT01186744|Drug|CP-690,550|5 mg oral BID
75727102|NCT04078451|Procedure|preserve the main cystic artery|The experimental group preserve the main cystic artery, and the control group cut off the main cystic artery
75727103|NCT00583115|Drug|Gleevec|260 mg/M2/day, given once daily by mouth
75878866|NCT03570320|Other|Modification of opioid prescription method|Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
75878867|NCT01315561|Other|acupuncture, injection|MSAT and intramuscular injections of diclofenac(NSAID)
75878868|NCT04328129|Procedure|Human biological samples|"Blood sample~Nasopharyngeal swab."
75576887|NCT02912936|Dietary Supplement|Ketogenic medium chain triglyceride drink (MCT drink)|10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
75576888|NCT02912936|Dietary Supplement|Placebo|10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
75576889|NCT02044341|Drug|AR01|drops administered an needed for pain
75576890|NCT02044341|Drug|Glycerin ear drops|placebo drops administered for ear pain
75576891|NCT02912819|Other|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
75430069|NCT01505257|Behavioral|END-DSD|Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
75576892|NCT00555399|Drug|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
75878869|NCT01336309|Behavioral|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
75430070|NCT01505270|Other|Retrospective case study|Retrospective case study
75430071|NCT01505283|Drug|NaCl 0.9%|epidural administration of 6 ml of NaCl 0.9%
75430072|NCT01505283|Drug|Sufentanil|epidural administration of sufentanil 10 µg
75430073|NCT01505283|Drug|lidocaine|epidural administration of lidocaine 50 mg
75430074|NCT01505296|Drug|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
75430075|NCT01505296|Procedure|Catheter ablation|Complete PVI
75430076|NCT01505309|Device|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
75878870|NCT03571178|Other|Physical Therapy|Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
75878871|NCT04266665|Drug|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
75878872|NCT04266665|Other|Normal saline|Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
75878873|NCT03571100|Drug|Chlorhexidine|Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
75878874|NCT03571100|Drug|Povidine-Iodine|Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
75878875|NCT01338311|Drug|salbutamol|200mcg twice daily for a total of 7 doses
75576893|NCT00555399|Drug|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m^2/day PO x 21 days; Level -I = 100 mg/m^2/day PO x 21 days; Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days."
75576894|NCT00555399|Procedure|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
75576895|NCT00555399|Drug|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
75430077|NCT01505335|Device|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
75576896|NCT03454932|Other|Blood sampling|
75576897|NCT02912663|Drug|Verapamil and Magnesium Sulfate|Single dose strategy will be used
75727104|NCT05371223|Drug|Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine|"Each combined course is constituted by two consecutive 28-day cycles of systemic chemotherapy (three adminstrations per cycle: days 1,8 and 15) and one cycle of PIPAC administered within 10-13 days from the last administration of systemic chemotherapy. Between each combined course a 7-10 days pause is observed.~The recommended dose of Nabpaclitaxel in combination with Gemcitabine is 125 mg/m2 administered endovenous over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. The concurrent recommended dose of Gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Nabpaclitaxel administration on Days 1, 8 and 15 of each 28-day cycle.~A pressurized aerosol containing Nabpaclitaxel at the dose of 112,5 mg/m2 diluted in a total volume of 200 ml of NaCl 0.9% is applied through the nebulizer inside the abdominal cavity during laparoscopy."
75430078|NCT01505348|Other|Overnight fast|Overnight fast from 21:00 h
75878876|NCT01338311|Drug|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
75878877|NCT01336387|Drug|retinoid 9cUAB30|Given PO
75878878|NCT01336387|Other|placebo|Given PO
75878879|NCT01336387|Other|pharmacological study|Correlative studies
75430079|NCT01505361|Biological|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
75430080|NCT01505361|Biological|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
75878880|NCT01336387|Other|laboratory biomarker analysis|Correlative studies
75878881|NCT01336387|Other|cancer prevention|Disease prevention
75878882|NCT01334879|Drug|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
75878883|NCT05354492|Other|Program to Support Well-Being after Adversity|You will be asked to meet on Zoom weekly for 6 weeks with our trained program facilitators along with the other 6-10 members of the intervention group. Meetings will last approximately 75-90 minutes each, and will involve a variety of discussions and activities related to navigating the changes you may face after experiencing a difficult life event. These sessions will be audio-recorded for research purposes and to ensure that facilitators are doing a good job delivering the program.
75878884|NCT03570242|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
75430081|NCT01505413|Drug|Erlotinib|Erlotinib 100 mg po qd daily
75430082|NCT01505413|Drug|Gemcitabine|Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
75430083|NCT01505413|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
75430084|NCT01505426|Drug|ASP1941|oral
75430085|NCT01505426|Drug|metformin|oral, concomitant use
75430086|NCT01505426|Drug|Placebo|oral
75430087|NCT01505439|Drug|solifenacin|oral
75430088|NCT01505504|Drug|mirtazapine|30 mg at bedtime
75430089|NCT01505582|Other|Inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
75576898|NCT02912663|Other|Placebo|Single matching dosing strategy will be used
75576899|NCT02026401|Biological|NGM282|
75576900|NCT02026401|Biological|Placebo|
75576901|NCT02912741|Drug|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
75576902|NCT02912741|Drug|resin infiltration|low viscous light cure resin applied in layers and cured
75878885|NCT01315795|Drug|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
75576903|NCT05355298|Drug|AMP945 ascending doses|Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
75576904|NCT05355298|Drug|AMP945 RP2D|Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
75576905|NCT04318522|Device|Transcranial Direct Current Stimulator|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
75576906|NCT02894151|Drug|Depot medroxyprogesterone acetate|
75576907|NCT02894151|Device|LNG-IUS|
75576908|NCT02912858|Device|geko plus R-2|"The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.~The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies."
75727105|NCT04079075|Other|Cognitive training|"This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will."
75727106|NCT04079075|Behavioral|Physical activity|This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
75727107|NCT04079075|Behavioral|Nutrition education|"This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared."
75430090|NCT01505582|Other|Sham inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
75430091|NCT01505595|Other|Proprioceptive training|12 weeks
75430092|NCT01505595|Other|Sham proprioceptive training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
75430093|NCT01505621|Other|L[ring-13C6]phenylalanine|Oral drink composed of essential amino acids including L[ring-13C6]phenylalanine
75576909|NCT02894229|Behavioral|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
75576910|NCT02894229|Behavioral|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
75576911|NCT02021370|Drug|BAY85-3934|25mg Tablet
75576912|NCT02021370|Drug|Placebo|Matching placebo tablet
75576913|NCT02912702|Drug|Pegaspargase|2000U/m2 day5
75576914|NCT02912702|Drug|doxorubicin hydrochloride liposome injection|25 mg/m2 day 1
75576915|NCT02912702|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
75727108|NCT04079075|Behavioral|Adaption to memory loss|This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
75727109|NCT04079075|Diagnostic Test|Diagnosis of hearing impairment|Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
75727110|NCT05370443|Behavioral|Life Skills education program|"The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations."
75878886|NCT03570164|Drug|Sevoflurane|End-tidal concentration of sevoflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
75576916|NCT02912702|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
75576917|NCT02912702|Drug|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
75576918|NCT02912702|Drug|dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
75576919|NCT02894073|Device|skin transilluminator|VeinViewer
75576920|NCT02912585|Biological|Oropharyngeal administration of own mother's colostrum|
75576921|NCT02912585|Other|Oropharyngeal administration of sterile water (placebo)|
75576922|NCT02912585|Biological|Oropharyngeal administration of donor human milk|
75576923|NCT02016534|Drug|AMG 337|AMG 337 300mg orally daily.
75576924|NCT02912429|Device|Patellofemoral Arthroplasty|
75576925|NCT02010333|Drug|Ha44 Gel 0.74% w/w|HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
75576926|NCT02912390|Procedure|Cerclage|Macdonald cerclage placed in standard fashion
75576927|NCT02912390|Other|Expectant management|placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
75576928|NCT02894346|Other|Teachers|Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
75576929|NCT02912273|Other|Baseline Participant Assessment|"Section 1 contains demographic questions~Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months~Section 3 has the participant list all medication~Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)~Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very~Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
75727111|NCT02582411|Device|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
75878887|NCT03570164|Drug|Desflurane|End-tidal concentration of desflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
75878888|NCT05181943|Device|Simpler diode laser|Non-contacting irradiation for 30 seconds on three intraoral sites repeated four times
75878889|NCT05181943|Drug|Conventional symptomatic treatment|Conventional treatment using oracure, BBC spray, miconaz three times daily
75430094|NCT01505660|Behavioral|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at ~9 and 12 months after enrollment.
75430095|NCT01505686|Procedure|MRI scan|MRI scan with a 1,5 T MRI scanner
75430096|NCT01505699|Genetic|RNA analysis|
75430097|NCT01505699|Genetic|cytogenetic analysis|
75430098|NCT01505699|Genetic|microarray analysis|
75430099|NCT01505699|Other|laboratory biomarker analysis|
75430100|NCT01505712|Genetic|gene expression analysis|
75430101|NCT01505712|Other|laboratory biomarker analysis|
75430102|NCT01505738|Other|bacterial samples|bacterial samples taken
75430103|NCT01505777|Drug|Probiotics (Medirac)|10/mosapride 10mg three times a day, P.O. 4week
75430104|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 10mg three times a day, P.O. 4week
75430105|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 15mg three times a day, P.O. 4week
75430106|NCT01505777|Drug|Probiotics (Medirac)|30/mosapride 15mg three times a day, P.O. 4week
75430107|NCT01505777|Drug|Probiotics (Medirac) placebo/mosapride placebo|three times a day, P.O. 4week
75430108|NCT01505790|Drug|PRASUGREL|60 mg the first day then 10 mg per day during one month
75430109|NCT01505790|Drug|Clopidogrel|"600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP <50%. No more than 3 * 600mg of clopidogrel will be authorized in this protocol.~Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least."
75430110|NCT01505803|Dietary Supplement|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
75430111|NCT01505803|Dietary Supplement|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
75430112|NCT01505803|Dietary Supplement|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
75430113|NCT01505816|Device|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
75430114|NCT01505842|Procedure|Colonoscopy with Indigo-Carmine chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
75430115|NCT01505842|Procedure|Conventional white-light colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
75430116|NCT01505855|Drug|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
75576930|NCT02912273|Other|Baseline Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
75727112|NCT02582411|Device|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
75727113|NCT00532779|Drug|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
75727114|NCT00532779|Drug|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
75727115|NCT00532779|Drug|Placebo|
75430117|NCT01505894|Drug|BI 409306|High dose film-coated tablet
75727116|NCT00532779|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
75727117|NCT02583737|Procedure|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
75727118|NCT02583737|Procedure|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
75727119|NCT04489355|Procedure|coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)|
75727120|NCT04078763|Behavioral|Rehabilitation protocol with visual-auditory feedback|The rehabilitation protocol with visual-auditory feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will always have a visual-auditory feedback
75878890|NCT01315951|Biological|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
76049167|NCT02083653|Other|Best Supportive Care (BSC)|BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
76049168|NCT02083653|Drug|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
75430118|NCT01505894|Drug|BI 409306|High dose film-coated tablet
75430119|NCT01505894|Drug|BI 409306 Placebo|Placebo film-coated tablet
75430120|NCT01505894|Drug|BI 409306|Low dose film-coated tablet
75430121|NCT01505894|Drug|BI 409306|Medium dose film-coated tablet
75430122|NCT01505907|Drug|CXB909|CXB909
75430123|NCT01505920|Procedure|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
75430124|NCT01505920|Procedure|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
75430125|NCT01505946|Other|TGA (Thrombin generation Assay)|"TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period"
75430126|NCT01505959|Device|CPAP treatment|Usual CPAP treatment
75430127|NCT01505959|Device|CPAP treatment|CPAP treatment with telemedicine system
75430128|NCT01505985|Dietary Supplement|Oral nutritional Supplement|Specialized nutritional supplement for seniors
75430129|NCT01505985|Dietary Supplement|Placebo|placebo product with no specific nutrients
75430130|NCT01505998|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
75430131|NCT01506011|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
75430132|NCT01506024|Procedure|Total hip arthroplasty direct lateral approach|
75430133|NCT01506024|Procedure|Total hip arthroplasty posterior approach|
75878891|NCT01391234|Radiation|STAT RT planning and delivery workflow|"Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
75727121|NCT04078763|Behavioral|Rehabilitation protocol with visual feedback|The rehabilitation protocol with visual feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will only have a visual feedback.
75576931|NCT02912273|Other|Follow-up Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions~Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~Section 3 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
75727122|NCT04078763|Behavioral|SPHERE protocol|"Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value"
75727123|NCT04078763|Behavioral|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.
75727124|NCT04078763|Behavioral|Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire|15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.
75727125|NCT04001673|Behavioral|Pharmacist's intervention|Information about bDMARDs management.
75727126|NCT00500266|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
75430134|NCT01506024|Procedure|Total hip arthroplasty, anterior approach|
75430135|NCT01506037|Drug|Desloratadine|Desloratadine ODT 5 mg
75430136|NCT01506050|Drug|Desloratadine|Desloratadine ODT 5 mg
75430137|NCT01506063|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
75430138|NCT01506076|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
75430139|NCT01506089|Other|36 degrees Celsius|Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
75576932|NCT02912273|Other|Follow-up Healthcare Provider Assessment|"Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
75727127|NCT00996411|Drug|Salvinorin A|This is an initial dose ranging study
75430140|NCT01506102|Device|Thromboelastography|Thromboelastography during labor and after delivery
75430141|NCT01506115|Drug|Photofrin|Photodynamic therapy: Intravenous Photofrin at a dose of 2 mg/kg body weight, 48 hours before photoactivation by intraluminal light illumination
75430142|NCT01506128|Other|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
75430143|NCT01506154|Drug|MRX-7EAT|Once daily application of a patch for 14 days
75430144|NCT01506167|Drug|Bevacizumab|Bevacizumab was administered as part of standard first-line treatment
75430145|NCT01506167|Drug|Capecitabine/Oxaliplatin|Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
75430146|NCT01506167|Drug|Fluorouracil/Folinic Acid/Oxaliplatin|Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
75430147|NCT01506167|Drug|Capecitabine|Capecitabine was administered along with bevacizumab as part of standard first-line treatment
75430148|NCT01506167|Drug|Fluorouracil/Folinic Acid/Irinotecan|Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
75576933|NCT02912273|Other|End-of-study Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions~Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~Section 3 contains multiple questions about the participant's concern about falling with answers ranging from 1=Not at all to 4=Very~Section 4 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
75727128|NCT00996567|Drug|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
75878892|NCT05184049|Drug|Epalrestat,Mecobalamin|Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.
75430149|NCT01506167|Drug|Fluorouracil +/- Folinic Acid|Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
75430150|NCT01506219|Procedure|Geriatrician-performed CGC|Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
75727129|NCT02583581|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
75430151|NCT01506245|Behavioral|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
75430152|NCT01506258|Procedure|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
75878893|NCT05184049|Drug|Mecobalamin|Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.
75878894|NCT01336543|Drug|Chemotherapy following concurrent Chemoradiotherapy|"NSCLC (Non-Small Cell Lung Cancer)~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~Radiation 59.4 Gy with 2 cycles of PE~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
75878895|NCT03570086|Diagnostic Test|diagnostic|using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
75878896|NCT01341847|Procedure|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
75878897|NCT01341847|Procedure|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
75878898|NCT03568370|Other|olive oil|Evaluate the effectiveness of olive oil and human milk in the prevention of nipple cracking, nipple pain and maternal satisfaction in lactating women during the first 3 days of treatment and the 7th and 10th day after delivery.
75878899|NCT03568214|Other|Exercise|The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
75878900|NCT03568136|Drug|Secukinumab 300 mg|Solution for injection in pre-filled syringe
75878901|NCT03568136|Drug|Placebo|Solution for injection in pre-filled syringe
75878902|NCT01336621|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
75878903|NCT05187481|Drug|Jianpi Huatan dispensing granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
75878904|NCT05187481|Drug|Placebo granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
75878905|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
75878906|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
75878907|NCT00383435|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
75878908|NCT00383435|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
75727130|NCT02583581|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
76049169|NCT02083653|Drug|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
76049170|NCT02436239|Drug|Vilazodone|Vilazodone tablets, once daily, oral administration
76049171|NCT02026011|Drug|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
76049172|NCT02026011|Drug|Placebo|Sugar pill, matched to the active study medication in capsule size and color
75430153|NCT01506258|Procedure|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
75430154|NCT01506284|Procedure|Forced oscillatory technique (FOT) and laser interferometry (LIR).|"FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient."
76049173|NCT02436005|Device|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
76049174|NCT02436005|Device|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
75430155|NCT01506310|Behavioral|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
75727131|NCT02852655|Drug|MK-3475|
75727132|NCT00500110|Drug|Docetaxel|30 mg/m^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
75878909|NCT00383435|Drug|Placebo|Placebo MDI twice a day for 26 weeks
75878910|NCT01336699|Other|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
75878911|NCT01336699|Biological|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
75878912|NCT01336699|Biological|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
75878913|NCT01340521|Drug|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
76049175|NCT02456909|Device|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
76049176|NCT02456909|Device|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
76049177|NCT02456909|Drug|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
76049178|NCT04199273|Procedure|Magnetic stimulation|Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
76049179|NCT04199273|Procedure|Electric stimulation|Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
76049180|NCT02025621|Drug|Levosimendan|
76049181|NCT02025621|Drug|Placebo|matching placebo
75576934|NCT02912273|Other|End-of-study Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
75576935|NCT02008344|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
75576936|NCT02008344|Drug|placebo|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
75576937|NCT02912546|Procedure|MRI|A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
75576938|NCT02912156|Drug|Vaway FC Tablets 200mg (Voriconazole)|
75576939|NCT02912156|Drug|VFEND FC Tablets 200mg (Voriconazole)|
75576940|NCT03455049|Other|Andrographis Paniculata Ext|Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
75576941|NCT02912234|Drug|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
75430156|NCT01506310|Other|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
75430157|NCT01506310|Other|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change"
75727133|NCT00500110|Drug|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
76049182|NCT04729023|Procedure|Pars plana vitrectomy combined with cataract surgery.|In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.
76049183|NCT04729023|Procedure|Pars plana vitrectomy with subsequent cataract surgery.|In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.
76049184|NCT02020941|Drug|carfilzomib|Given IV
76049185|NCT02020941|Drug|dexamethasone|Given IV or PO
76049186|NCT02020941|Other|laboratory biomarker analysis|Correlative studies
76049187|NCT02024529|Biological|4 mL injection of Ampion|4 mL injection of Ampion
75430158|NCT01506336|Drug|masitinib|masitinib 12 mg/kg/day
75430159|NCT01506336|Drug|sunitinib|sunitinib 50 mg/day
75430160|NCT01506349|Dietary Supplement|gluten|4 grams of gluten.
75430161|NCT01506349|Dietary Supplement|Placebo|
75430162|NCT01506375|Biological|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
75430163|NCT01506375|Biological|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
75430164|NCT01506388|Device|foley catheter|foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours
75430165|NCT01506388|Drug|Misoprostol|misoprostol 50 Ug , vaginally every 4-6 hours
75430166|NCT01506388|Drug|Vaginal IMN|IMN vaginal 40 mg every 4-6 hours
75576942|NCT02912234|Drug|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
75576943|NCT04676139|Drug|Fluoxetine|Fluoxetine 10 mg capsules once daily for 12 months
75576944|NCT04676139|Drug|Placebo|placebo for 12 months
75576945|NCT01999764|Drug|QLT091001|QLT091001 administered orally at multiple time points.
75576946|NCT01999764|Other|Placebo|Placebo is administered orally at multiple time points.
75576947|NCT02912039|Device|TetraGraph|A sequence of 3 sets of Train of four (TOF) stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
75727134|NCT00500110|Drug|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
75727135|NCT00500110|Drug|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
75727136|NCT02582333|Other|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
75727137|NCT05335551|Diagnostic Test|Patients monitored with TruGraf and TRAC Liver testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC Liver results will be utilized in conjunction with standard of care assessments to determine patient management in the study arm.
76049188|NCT02024529|Drug|4 mL Injection of Placebo|4 mL Injection of Placebo
75576948|NCT02912039|Device|TOF Watch|A sequence of 3 sets of TOF stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
75576949|NCT02911961|Drug|Acetaminophen|1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
75576950|NCT01998828|Drug|Momelotinib|Momelotinib tablet administered orally once daily
75576951|NCT02912000|Behavioral|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
75430167|NCT01506401|Device|SensorMedics 3100B High Frequency Oscillatory Ventilator|High Frequency Oscillation
75430168|NCT01506401|Procedure|Lung Protective Ventilation|Tidal Volume 6ml/kg; plateau pressure < or = 35cmH20; Prescribed PEEP/FiO2 chart
75430169|NCT01506414|Drug|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
75430170|NCT01506427|Radiation|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
75878914|NCT03698123|Other|Dietary Modification|Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
76049189|NCT02020863|Device|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
75430171|NCT01506440|Procedure|cognitive assessment|Given cognitive assessments
75430172|NCT01506440|Procedure|quality-of-life assessment|Ancillary studies
75430173|NCT01506466|Other|blood test/ additional measurement|blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
75430174|NCT01506492|Behavioral|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
75430175|NCT01506505|Drug|Cardiovascular Agents|Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
75430176|NCT01506531|Procedure|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
75430177|NCT01506531|Procedure|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
75430178|NCT01506544|Drug|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
75430179|NCT01506557|Dietary Supplement|cholecalciferol|dose 800 IU/day for 6 month
75430180|NCT01506557|Dietary Supplement|placebo|oil capsules
75430181|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10^3 plaque-forming unit [PFU] of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
75430182|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
75576952|NCT04676061|Drug|Norethindrone acetate (NTA)|norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks
75576953|NCT04676061|Drug|Placebo|Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
75576954|NCT04675944|Drug|BIA 5-1058|200 mg (2 x 100 mg tablets), oral route
75576955|NCT04675944|Drug|treprostinil|1 mg (1 extended-release tablet), oral route
75576956|NCT02911766|Drug|Chlorhexidine 0.2% Mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
75576957|NCT02911766|Drug|Chlorhexidine 0.12% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
75576958|NCT02911766|Drug|Chlorhexidine 0.06% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
75576959|NCT01993641|Drug|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
75878915|NCT01340599|Dietary Supplement|defined green tea catechin extract|Given PO
75878916|NCT01340599|Other|placebo|Given PO
75878917|NCT01340599|Other|immunohistochemistry staining method|Correlative studies
75878918|NCT01340599|Other|immunoenzyme technique|Correlative studies
75430183|NCT01506570|Biological|Placebo|One SC injection at Day 0 and Day 180 of placebo
75430184|NCT01506622|Drug|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
75430185|NCT01506622|Drug|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
75430186|NCT01506622|Drug|Administration of saline|Saline will be administered to control group at the end of anesthesia.
75576960|NCT01993641|Drug|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
75727138|NCT04358237|Drug|Lurbinectedin|"Lurbinectedin will be presented as a lyophilized powder for concentrate for solution for infusion in 4-mg vials. Before use, the 4-mg vial will be reconstituted with 8 mL of sterile water for injection, to give a solution containing 0.5 mg/mL of PM01183. For administration to patients as IV infusion, reconstituted vials will be diluted with glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) solution for infusion.~PM01183 will be administered as a 1 hour IV infusion Q3W, in a minimum volume of 100 mL of solution for infusion (either 5% glucose or 0.9% sodium chloride), or a minimum volume of 250 mL if through a peripheral line, always at a fixed rate and through a pump device."
75878919|NCT01340599|Other|questionnaire administration|Ancillary studies
75430187|NCT01506635|Drug|Timolol|
75430188|NCT01506635|Drug|Placebo|artificial tear twice a day
75430189|NCT01506661|Drug|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
75430190|NCT01506687|Behavioral|Health counselling by nurse navigator|Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
75430191|NCT01506687|Behavioral|Usual primary care counselling|Usual care health counselling on colorectal cancer and screening options
75576961|NCT01993641|Drug|Decitabine|"All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks."
75576962|NCT00555516|Other|EW02|"Name: EW02~Dosage form: capsule.~Dose(s): 350mg per capsule, 2 capsule tid.~Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3."
75576963|NCT01991184|Drug|GDC-0853|Multiple escalating doses
75430192|NCT01506700|Device|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
75576964|NCT02911727|Procedure|Fast-track discharge|As described above
75430193|NCT01506713|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
75430194|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
75727139|NCT04358237|Drug|Pembrolizumab|Pembrolizumab will be supplied as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
75878920|NCT01340599|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
75727140|NCT04358159|Device|Ventralex|Repair of the hernia by a Ventralex patch in sublay position
76049190|NCT01824394|Device|nMARQ Navigation Catheters|
75430195|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
75430196|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
75430197|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
75430198|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
75430199|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
75430200|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
75430201|NCT01506765|Drug|N-Acetyl-Cysteine (NAC)|Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
75576965|NCT02911883|Device|Optical Coherence Tomography Angiography|
75727141|NCT04358159|Device|Progrip|Repair of the hernia by a Progrip mesh in onlay position
75727142|NCT03925649|Biological|HB-adMSCs|single infusion of HB-adMSCs
75727143|NCT05304533|Drug|MYK-224|Specified dose on specified days
75878921|NCT01340599|Other|high performance liquid chromatography|Correlative studies
75878922|NCT01340599|Other|mass spectrometry|Correlative studies
75878923|NCT01335035|Drug|deferasirox|
76049191|NCT01824394|Device|NaviStar ThermoCool Catheters|
75430202|NCT01506778|Device|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
75430203|NCT01506791|Drug|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
75878924|NCT01340677|Drug|Canagliflozin, 50 mg|Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
76049192|NCT01823536|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
76049193|NCT01841554|Device|Cardioband|
75430204|NCT01506804|Other|methylprednisolone|Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
75430205|NCT01506817|Procedure|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
75576966|NCT04675905|Other|no intervention (cohort study)|Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged >= 65 years
75576967|NCT02911649|Other|Wearable Technology - Garmin Vivosmart|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
75576968|NCT02911649|Other|Online Educational Group|A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
75727144|NCT05304533|Drug|Itraconazole|Specified dose on specified days
75878925|NCT01340677|Drug|Canagliflozin, 300 mg|Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
75878926|NCT01340677|Drug|Canagliflozin, 100 mg|Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
75430206|NCT01506830|Procedure|Relative isolation with cotton rolls|Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
75878927|NCT05164315|Procedure|Tailored surgery|Procedure: Tailored surgery based on intraoperative local excision/biopsy
75878928|NCT05164315|Procedure|Total mesorectal excision (TME)|Procedure: Total mesorectal excision for all allocated patients
75878929|NCT01335269|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
75878930|NCT05183815|Other|slow stroke massage and murrotal quran|murrotal quran and slow stroke massage
75878931|NCT01335347|Biological|ND1.1|adenovirus with the dsRNA adjuvant, dried and put into capsules
75576969|NCT02911649|Other|Wearable Technology - FitBit Alta|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
75576970|NCT02911649|Other|Wearable Technology - Polar Loop 2|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
75727145|NCT05304533|Drug|Verapamil|Specified dose on specified days
75727146|NCT00534495|Biological|Rilonacept|2.2 mg/kg subcutaneously
75430207|NCT01506830|Procedure|Absolute isolation with rubber dam|Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
75576971|NCT01989429|Drug|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
75727147|NCT04077827|Drug|Propofol|Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
75727148|NCT00999375|Behavioral|Education|
75727149|NCT00999375|Behavioral|Problem Solving|
75727150|NCT00999375|Behavioral|Social Learning|
75727151|NCT00999375|Behavioral|Behavior Modification|
75727152|NCT00996645|Other|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
75727153|NCT00996723|Drug|vandetanib and dasatinib|Two oral investigational agents (vandetanib [VEGFR2, RET, and EGFR inhibitor] and dasatinib [bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
75878932|NCT01335347|Biological|Placebo control|Capsules of the same size and shape as experimental groups
75878933|NCT05164003|Drug|CORETOX®|Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
75878934|NCT05164003|Drug|BOTOX®|Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
75878935|NCT05163535|Drug|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
75878936|NCT05163535|Other|ELPIDA®|Elsulfavirine capsules
75878937|NCT01338467|Device|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
75878938|NCT01340755|Procedure|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
75878939|NCT04434209|Device|Subject management guided by NephroCheck® test|NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
75878940|NCT04434209|Other|Standard of Care|Standard of Care patient management
75878941|NCT01341925|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
76024767|NCT04752527|Drug|venetoclax combined with decitabine|combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio. (On day 1 of cycle 1, decitabine 20 mg/m2 will be given intravenously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 28 day cycle is finished. For patients with high FLT3-ITD allelic ratio, sorafenib was administered at a dose of 400mg orally twice daily, on days 3 through 28.
75576972|NCT02911532|Procedure|Tissue engineering conjunctiva transplantation|During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
75727154|NCT00999453|Other|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
75727155|NCT01019122|Radiation|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
75727156|NCT05332587|Drug|Rituximab|The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
75727157|NCT04078529|Other|5 day falls prevention training|Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
75727158|NCT04078529|Other|Home exercise programme|A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
75727159|NCT04078529|Other|Environmental Assessment|Use of the Homefast assessment tool to reduce risk of falls at home.
75727160|NCT00996879|Drug|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
75430208|NCT01506843|Biological|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
75727161|NCT00996879|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
75576973|NCT01989234|Drug|YKP10811|
75576974|NCT01989234|Drug|Placebo|
75727162|NCT02581397|Drug|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
75727163|NCT02581397|Drug|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
75576975|NCT02911493|Behavioral|Reducing Sedentary Behavior|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
75576976|NCT02911493|Behavioral|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
75576977|NCT04675671|Other|Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]|The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
75576978|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
75576979|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
75576980|NCT01984788|Drug|BCX4161|
75576981|NCT01984788|Drug|Placebo|
75576982|NCT02911337|Dietary Supplement|lifestyle modification|Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
75576983|NCT01983306|Drug|SP-333 1 mg|Tablet
75727164|NCT02581397|Drug|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
75727165|NCT02582177|Drug|Candicort®|Apply on the affected area and around it twice a day
75727166|NCT02582177|Drug|Nizoral®|Apply on the affected area and around it twice a day
75727167|NCT02582177|Drug|Baycuten N®|Apply on the affected area and around it twice a day
75727168|NCT02582177|Drug|Canesten®|Apply on the affected area and around it twice a day
75727169|NCT00999531|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
75727170|NCT00999531|Drug|Placebo|Inhaled Placebo, sterile saline
75727171|NCT00996957|Biological|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
75576984|NCT01983306|Drug|SP-333 3 mg|Tablet
75576985|NCT01983306|Drug|SP-333 6 mg|Tablet
75576986|NCT01983306|Drug|Placebo|Tablet
75576987|NCT02911220|Genetic|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
75576988|NCT02911454|Other|Infant formula|
75727172|NCT04099667|Drug|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
75727173|NCT04099667|Drug|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
75727174|NCT04099667|Drug|Phase 2; Placebo|Intramuscular injections on Day 1
75727175|NCT04099667|Drug|Phase 3; MYOBLOC|Intramuscular injections on Day 1
75727176|NCT04099667|Drug|Phase 3; Placebo|Intramuscular injections on Day 1
75727177|NCT00997191|Procedure|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
75727178|NCT00997191|Drug|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT>275um
75727179|NCT00997191|Drug|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT>275um
75430209|NCT01505972|Other|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
75576989|NCT01982175|Biological|Alemtuzumab|"Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~--------------------------------------------------------------------------------"
75430210|NCT01505972|Other|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
75430211|NCT01506895|Drug|darapladib|Experimental compound 160 mg dose
75430212|NCT01506895|Drug|placebo|Placebo to match
75576990|NCT01975818|Drug|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
75576991|NCT01975818|Biological|Epoetin alfa/beta|
75576992|NCT02911259|Device|Suction is set to -2 cmH2O|Post-operative suction is set to -2 cmH2O (intervention).
75576993|NCT02911259|Device|Suction is set to -10 cmH2O|Post-operative suction is set to -10 cmH2O (standard treatment).
75576994|NCT04676919|Device|phonophoresis therapy with pulsed mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
75576995|NCT04676919|Device|phonophoresis therapy with continuous mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
75576996|NCT04676919|Device|sham ultrasound|sham ultrasound therapy, five days a week for three weeks
75576997|NCT02911415|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
75576998|NCT02911181|Other|BIVA measurement|
75576999|NCT02910947|Procedure|ultrasound guided quadratus lumborum or Transversus Abdominis plane block|The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
75577000|NCT01973049|Drug|Daclatasvir|
76024768|NCT05229497|Drug|AK112|IV infusion,Specified dose on specified days
76024769|NCT05229497|Drug|AK117|IV infusion,Specified dose on specified days
75430213|NCT01506921|Drug|Racemic ketamine|0.6 mg/kg
75430214|NCT01506921|Drug|S-ketamine|0.3 mg/kg
75430215|NCT01506934|Drug|linifanib|"Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)~Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)"
75430216|NCT01506999|Biological|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
75430217|NCT01507012|Dietary Supplement|Berry Polyphenols|
75430218|NCT01507012|Dietary Supplement|Placebo|Placebo control containing sugar and artificial flavouring.
75430219|NCT01507038|Drug|YH14617|1mg once weekly
75430220|NCT01507038|Drug|YH14617|1.6mg once weekly
75430221|NCT01507038|Drug|YH14617|2mg once biweekly
75430222|NCT01507038|Drug|Placebo|Once weekly
75430223|NCT01507064|Drug|Sorafenib|tablets 200mg dosage: 400mg bid duration: 4 weeks
75577001|NCT01973049|Drug|Asunaprevir|
75577002|NCT01973049|Drug|BMS-791325|
75577003|NCT01973049|Drug|Ribavirin|
75577004|NCT01973049|Drug|Placebo matching Ribavirin|
75577005|NCT01185964|Biological|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
75577006|NCT01185964|Drug|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
75577007|NCT02910869|Genetic|Pathway Genomics FIT test|
75577008|NCT01972854|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
75577009|NCT01972854|Drug|placebo solution|0.0% riboflavin ophthalmic solution
75577010|NCT01972854|Device|KXL System|30mW/cm2
75577011|NCT01217476|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
75577012|NCT04677075|Procedure|mastectomy|mastectomy either simple or modified radical
75577013|NCT04318756|Behavioral|Translation and cultural adaptation go the cancer worry scale|To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.
76024770|NCT05229497|Drug|Carboplatin|IV infusion,Specified dose on specified days
76024771|NCT05229497|Drug|Cisplatin|IV infusion,Specified dose on specified days
76024772|NCT05229497|Drug|5-Fluorouracil|IV infusion,Specified dose on specified days
76024773|NCT02005276|Behavioral|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
75430224|NCT01507064|Procedure|laser ablation (LA)|"For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
75430225|NCT01507077|Drug|ZGN-440|Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
76049194|NCT01823224|Drug|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
75430226|NCT01507077|Drug|ZGN-440 sterile diluent|Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
76049195|NCT01823224|Drug|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
76049196|NCT01840228|Drug|Micronized progesterone suppository|
75577014|NCT02888002|Behavioral|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
75430227|NCT01507116|Other|No treatment given|Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
75430228|NCT01507168|Drug|Placebo|iv Days 1 and 8, and every 2 weeks thereafter
75430229|NCT01507168|Drug|GC33|1600 mg iv Day 1 and 8, and every 2 weeks thereafter
75430230|NCT01507194|Drug|Ondansetron|Single IV dose
75430231|NCT01507194|Drug|Vestipitant|Single IV dose
75430232|NCT01507207|Procedure|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
75430233|NCT01507259|Other|cocoa|70% versus 34%
75430234|NCT01507272|Drug|liraglutide|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
75430235|NCT01507272|Drug|liraglutide|Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
75577015|NCT04675437|Other|Aerobic exercise|12-weeks aerobic exercise program
75577016|NCT02605538|Biological|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
75727180|NCT02581319|Procedure|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
75430236|NCT01507272|Drug|placebo|Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
75430237|NCT01507272|Drug|placebo|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
75727181|NCT05315739|Device|Non-invasive transcutaneous vagus nerve stimulation (tVNS)|tVNS delivers an electrical current to the cervical branch of the vagus nerve. Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2) are performed. The two periods are separated by a 2 weeks wash-out period.
76049197|NCT01839916|Biological|therapeutic allogeneic lymphocytes|Given IV
75430238|NCT01507311|Drug|liraglutide|A single dose injected subcutaneously (under the skin)
75430239|NCT01507311|Drug|placebo|A single dose injected subcutaneously (under the skin)
75430240|NCT01507337|Drug|liraglutide|A single dose of 1 mg administered subcutaneously (under the skin)
76049198|NCT01839916|Other|laboratory biomarker analysis|Correlative studies
75577017|NCT04677192|Combination Product|Microwave Ablation combination with chemotherapy|Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
75430241|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
75430242|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
75430243|NCT01507363|Drug|Placebo|Placebo tablets for 7 days, starting on the day of surgery
75727182|NCT05315739|Device|Sham vagus nerve stimulation|"The sham device produces a slight vibrating sound, but does not produce an electical current and hence, does not activate the vagus nerve.~Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period."
75430244|NCT01507376|Drug|recombinant hCG|recombinant hCG(250 µg Ovitrell)
75430245|NCT01507376|Drug|recombinant hCG|recombinant hCG(500 µg Ovitrell)
75430246|NCT01507376|Drug|urinary hCG|10,000 IU urinary hCG
75430247|NCT01507389|Drug|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
75430248|NCT01507402|Drug|REGN1033(SAR391786)|Administration method A
75430249|NCT01507402|Drug|REGN1033(SAR391786)|Administration method B
75430250|NCT01507402|Drug|Placebo|(inactive substance)
75727183|NCT00997269|Dietary Supplement|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
76049199|NCT01823146|Drug|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
75430251|NCT01507428|Drug|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
75727184|NCT00997269|Dietary Supplement|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
75430252|NCT01507428|Drug|Carboplatin|Given IV
75430253|NCT01507428|Procedure|Computed Tomography|Undergo FDG PET/CT
75727185|NCT02582099|Drug|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
75430254|NCT01507428|Procedure|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
75430255|NCT01507428|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
75430256|NCT01507428|Drug|Fludeoxyglucose F-18|Undergo FDG PET/CT
75430257|NCT01507428|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
75430258|NCT01507428|Other|Laboratory Biomarker Analysis|Correlative studies
75430259|NCT01507428|Drug|Paclitaxel|Given IV
75727186|NCT02582099|Drug|Normal saline nasal irrigation|Nasal wash with normal saline solution
75727187|NCT00997347|Drug|Mifepristone and misoprostol|"200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone"
75727188|NCT00997581|Drug|apremilast|apremilast 20 mg taken twice daily by mouth
76049200|NCT01823146|Drug|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
75430260|NCT01507428|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
75430261|NCT01507428|Procedure|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
75430262|NCT01507441|Genetic|gene mapping|
76049201|NCT02083185|Drug|Relugolix|Relugolix tablets
76049202|NCT02083185|Drug|Leuprorelin|Leuprorelin subcutaneous injection
76049203|NCT04417023|Other|B3 for NMD: Bench to Bedside and Back|Transformative discoveries leading to improved care in Neuromuscular Disease
75430263|NCT01507441|Genetic|microarray analysis|
75430264|NCT01507441|Genetic|mutation analysis|
75430265|NCT01507441|Genetic|nucleic acid sequencing|
75430266|NCT01507441|Other|laboratory biomarker analysis|
75430267|NCT01507454|Drug|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
75430268|NCT01507467|Radiation|Accl. RT|Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
75430269|NCT01507467|Radiation|Accl. radiotherapy + Nimorazole|Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
75430270|NCT01507480|Drug|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
75430271|NCT01507506|Radiation|Radiotherapy|"Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
75577018|NCT02550470|Device|Carbon Dioxide Absorbents|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
75577019|NCT02550470|Device|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
75577020|NCT02550470|Drug|Sevoflurane|
76049204|NCT02019927|Device|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
75727189|NCT00997581|Drug|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
75430272|NCT01507506|Radiation|Experimental arm|"Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
76049205|NCT02019927|Device|Sham|Sham
76049206|NCT04185441|Drug|Tanzânia association|Tanzânia association capsule
75727190|NCT04001439|Drug|Experimental drug|All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
75430273|NCT01507519|Device|Sirolimus Eluting Coronary Stent System (Biomime)|Coronary Artey PTCA
76049207|NCT04185441|Drug|Omnic Ocas|Tamsulosin 0,4 mg
75727191|NCT05301153|Diagnostic Test|real time PCR , ELISA|Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39. Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA
75727192|NCT05183139|Drug|Ixazomib|Ixazomib capsules
75430274|NCT01507532|Other|pharmacokinetic monitoring|pharmacokinetic monitoring
75727193|NCT05183139|Drug|Pomalidomide|Pomalidomide capsules
75727194|NCT05183139|Drug|Lenalidomide|Lenalidomide capsules
75727195|NCT05183139|Drug|Dexamethasone|Dexamethasone tablets
76024774|NCT02005276|Behavioral|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
76024775|NCT02005276|Behavioral|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
76049208|NCT04185441|Other|Omnic Ocas placebo|Tamsulosin placebo
76049209|NCT04185441|Other|Tanzânia association placebo|EMS association placebo
76049210|NCT04416945|Other|Household Reactive Case Detection|Within 7 days of the index case notification, all members of the index case's household and everyone in the neighboring five households will then be invited to participate in the study. After consenting, a finger stick blood sample will be collected for each consenting individual for testing with the HS-RDT for P. falciparum, a standard combination RDT, and four blood spots on filter paper.
76049211|NCT04416945|Other|RACD of cases' co-workers/co-travelers|"Index cases will be screened by the VMW at their households at the time of case investigation to determine if they have traveled or worked in a forest or forest-fringe area within the past 30 days. If eligible, the case will trigger two reactive recruitment strategies to screen and treat others who recently traveled or worked with the case in a forest or forest-fringe location:~Peer-referral RACD (PR-RACD): In this strategy, the case will identify specific co-travelers or co-workers resident in their village who had spent the night with the case at a forest or forest-fringe area and spent the night there in the past 30 days.~Venue-based RACD (VB-RACD): In this strategy, co-workers will be recruited directly from (accessible) forest or forest-fringe work sites where the index case worked and spent at least one night in the past 30 days."
76024776|NCT03169777|Biological|avelumab|Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
75577021|NCT04688216|Other|risk factors of infection with multidrug-resistant organisms|"General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs"
75577022|NCT04675359|Procedure|Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint|Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis
75577023|NCT04675203|Procedure|Tooth extraction|Tooth extraction
75430275|NCT01507558|Procedure|Administration of dexamethasone to SFA/popliteal adventitia|Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
75430276|NCT01507571|Other|Dignity Therapy|"Dignity Therapy is a brief psychotherapeutic intervention consisting of:~a tape-recorded session with the patient using the DT question protocol~Transcription of the interview, which is then edited~A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by."
75430277|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
75727196|NCT00999843|Drug|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
75577024|NCT02910518|Drug|Insulin glulisine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75577025|NCT02910518|Drug|Insulin glulisine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75577026|NCT02910518|Drug|Insulin aspart|"Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous"
75577027|NCT02910518|Drug|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75577028|NCT02910518|Drug|Glucagon|"Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous"
75577029|NCT02910518|Drug|Glucose|"Pharmaceutical form: solution~Route of administration: intravenous"
75727197|NCT03830567|Other|Pharmacist prescription|Pharmacist prescribed hormonal contraception (initiation or continuation).
75727198|NCT03830567|Other|Clinician prescription|Clinician prescribed hormonal contraception (initiation or continuation).
75727199|NCT00997659|Dietary Supplement|chromium picolinate|1000 mg per day
75727200|NCT00997737|Device|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
75430278|NCT01507597|Drug|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
75577030|NCT02910518|Drug|Heparin|"Pharmaceutical form: solution~Route of administration: intravenous"
75577031|NCT01217437|Biological|Bevacizumab|Given IV
75577032|NCT01217437|Drug|Irinotecan Hydrochloride|Given IV
75577033|NCT01217437|Drug|Temozolomide|Given PO
75577034|NCT02910479|Device|E-Celsius thermometer|comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
75577035|NCT02910479|Device|Rectal thermometer|
75577036|NCT02910479|Device|Esophageal thermometer|
75577037|NCT02910479|Device|Vital sense capsule thermometer|
75577038|NCT00624364|Drug|biphasic insulin aspart|
75577039|NCT00624364|Drug|metformin|
75577040|NCT02910596|Drug|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
75577041|NCT02910596|Device|early bladder training|early bladder training start on 3rd - 5thpostoperative day
75727201|NCT05300919|Other|Measurement based care|Measurement-based care based on arm.
75727202|NCT03827213|Drug|Exparel|A shot of long acting local anesthetic for post operative pain management
75727203|NCT03827213|Device|Indwelling Interscalene Catheter|ropivacaine, given through a catheter inserted between the shoulders
75727204|NCT00999999|Procedure|Craniotomy supra- or infratentorial, dural closure|After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
75430279|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
75430280|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
75577042|NCT02910596|Other|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
76049212|NCT04416945|Other|Case Management and Follow-up|"All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions."
75577043|NCT02910596|Other|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
75577044|NCT04316377|Drug|Hydroxychloroquine Sulfate|400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
75577045|NCT04677036|Other|No intervention is given|No intervention given
75577046|NCT02886988|Drug|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
75577047|NCT02886988|Drug|normal saline|0.1mlof normal saline will be injected with a 30G needle.
75577048|NCT02887144|Device|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
75577049|NCT02887144|Device|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
75577050|NCT06227455|Procedure|Maxillary alveolar ridge augmentation|The surgical procedure involves careful flap reflection, autogenous graft harvesting, and placement and fixation of the barriers over mixture of Autogenous graft and xenograft particles.
75577051|NCT06227442|Diagnostic Test|KDIGO criteria of 2010|They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.
75577052|NCT06227429|Drug|Nitisinone|According to prescription
75577053|NCT06227416|Other|Biopsy|punch biopsy (2-4 mm) depending on the size of the AK lesion.
75577054|NCT06227403|Behavioral|Leadership, Engagement, and youth Activism Program with Mindfulness|The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP-M) was designed and co-created with youth to improve youth wellbeing by enhancing civic engagement and leadership opportunities and by developing mindfulness in day-to-day life. LEAP-M seeks to foster these improvements in youth of color as a strategy to combat structural racism encountered at school- and neighborhood-levels and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
75577055|NCT06227403|Behavioral|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential transition skills and digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
75577056|NCT06227390|Procedure|partial pulpotomy|2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
76049213|NCT02412371|Drug|Paclitaxel|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
76049214|NCT02412371|Drug|Placebo for Veliparib|Capsule for oral administration
75430281|NCT01507623|Device|Capnography (Phillips MP20 monitor)|"In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures"
75577059|NCT06227364|Diagnostic Test|MCI patients|patients with mild cognitive impairment submitted to Magnetic Resonance, neuropsychological evaluation, neurological assessment
75577060|NCT06227364|Diagnostic Test|metabolic patients|patients with obesity and metabolic dysfunction submitted to haematological tests, psychological and neuropsychological evaluation and endocrinologu assessment
75577061|NCT06227351|Procedure|completely limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to the zygoma anatomy-guided approach classification and previously planned surgery using Cone beam C.T lateral window and sinus foor lifting will be decided to be done or not.~After securing the surgical templates in its proper position, sequential osteotomy drilling will be performed in a steady in and out movement under copious sterile saline irrigation.The drills will be entering the maxilla palatally and puncturing the alveolar crest to reach the buccal side.The drills will be visualized through the bony window created until it reaches the zygomatic bone.Sequential drills with the uses of guided tubes,sleeves and keys will be used to guarantee that the implant have been placed in a fully completely guided manner.Afterwards the zygomatic implants will be placed."
75577062|NCT06227351|Procedure|Partially limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full -thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to zygoma anatomy-guided approach classification and previously planned surgery using cone beam C.T.lateral window and sinus floor lifting will be decided to be done or not.After securing the surgical templates,The first drill only will be used using the guide then it will be removed and the other drills will be completed in a free hand without the use of guide to guarantee that the implant will be placed in partially guided manner.Afterwards the zygomatic implants will be placed."
75577063|NCT06227338|Drug|Indocyanine green|"Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg)."
76049215|NCT02412371|Drug|Carboplatin|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
75430282|NCT01507636|Other|Occupational Therapy|Occupational therapy using a special arm function training.
75430283|NCT01507636|Other|Physical therapy|Physical therapy for arm force training.
75430284|NCT01507649|Behavioral|telephone-based cognitive-behavioral intervention|The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
75430285|NCT01507701|Drug|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
75430286|NCT01507714|Procedure|Preventive transobturator tension free vaginal tape|during the vaginal wall repair surgery, a TVT-O procedure will be done
75577064|NCT06227325|Drug|RC48 combined with Sintilimab and XELOX|RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1；Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks
75577065|NCT06227312|Device|LADY 1 Pro, New Life Balance|whole-body vibration training on the platform
75577066|NCT06227312|Other|exercises|calf raises and modified drop jumps
75577067|NCT06227286|Device|EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, initiates with 0.030MPa.
75430287|NCT01507727|Drug|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
75430288|NCT01507727|Drug|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
75430289|NCT01507740|Drug|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
75430290|NCT01507740|Drug|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
75430291|NCT01507740|Drug|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
75577068|NCT06227286|Device|Sham-EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, constant to 75 mmHg.
76049216|NCT02412371|Drug|Veliparib|Capsule for oral administration
76049217|NCT02412371|Radiation|Radiotherapy|Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks
76049218|NCT02411747|Behavioral|Testing|
76049219|NCT02411747|Behavioral|Directed self-regulated simulation training|
76049220|NCT01822756|Drug|ruxolitinib|
75430292|NCT01507753|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
75430293|NCT01507753|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
75430294|NCT01507753|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
75430295|NCT01507766|Drug|early enteral nutrition|The enteral nutrition was started within 48h after admission
75430296|NCT01507766|Drug|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
75577069|NCT06227273|Dietary Supplement|Hydrogen water|Daily consumption of hydrogen water for 16 weeks.
75577070|NCT06227260|Other|Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice|Interventions among the 3 studies were categorized as other.
75577071|NCT06227247|Behavioral|Meals4Moms Intervention|A community-based, healthy living program including continued gestational diabetes (GDM) education, physical activity level monitoring, and delivery of medically-tailored GDM meals for the management of gestational diabetes in pregnant people.
75577072|NCT06227234|Other|Dechoker|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
75577073|NCT06227234|Other|LifeVac|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
75577074|NCT06227234|Other|Abdominal Thrusts|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
76049221|NCT01822756|Drug|gemcitabine|Other names: Gemzar®
76049222|NCT01822756|Drug|nab-paclitaxel|Other names: Abraxane®
75430297|NCT01507792|Drug|iron sulphate|1 or 2 330 mg/daily iron sulphate oral tablets
75430298|NCT01507792|Drug|antiH1-histamine, proton pump inhibitor|This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
75430299|NCT01507805|Device|EA preconditioning|EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
75430300|NCT01507805|Device|sham EA preconditioning|Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
75430301|NCT01507818|Device|Ivivi Torino II|Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0>
75430302|NCT01507818|Device|Inactive Sham device|The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
75430303|NCT01507844|Device|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
75727205|NCT00997815|Drug|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
75727206|NCT00997815|Drug|Normal saline injection|Using normal saline 2.5 ml injected in control side
75727207|NCT04078139|Drug|The MP/RP group|Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
75727208|NCT04078139|Drug|The RP group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
75727209|NCT04077983|Drug|combined therapy using nab-paclitaxel and gemcitabine chemotherapy|"Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~Three weeks is a course of treatment with a total of 4 courses."
75727210|NCT00997971|Other|Modilac Rose 1|Infant formula used for non-breastfed children
75727211|NCT03823469|Behavioral|CCTP|Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.
75727212|NCT03823469|Behavioral|Nutritional counseling|Two 30-minute nutritional counseling sessions
75430304|NCT01507857|Biological|400U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
75430305|NCT01507857|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
75430306|NCT01507870|Procedure|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
75430307|NCT01507922|Drug|Fenoverine|Fenoverine 100mg three times a day for 8 weeks
75430308|NCT01507922|Drug|Timebutine|Timebutine maleate 150mg three times a day for 8 weeks
75430309|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
75430310|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
76024777|NCT03169777|Biological|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
75430311|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
75430312|NCT01507948|Behavioral|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
75430313|NCT01507974|Drug|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
75430314|NCT01507974|Drug|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
75430315|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
75577075|NCT06227221|Drug|Sorafenib|Subjects receive sorafenib 400mg once daily. Insulin therapy will be continued as a routine therapy.
75577076|NCT06227221|Drug|Placebo|Subjects receive placebo 400mg once daily. Insulin therapy will be continued as a routine therapy.
75577077|NCT06227208|Device|Continuous vital sign monitoring|Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.
75727213|NCT04000191|Procedure|MAC|Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
75727214|NCT04000191|Other|Perianal ice application|Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
75727215|NCT03822845|Drug|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
75727216|NCT01000233|Dietary Supplement|Phytine (phytate)|300 mg tid * 24 months
75727217|NCT01000233|Dietary Supplement|Placebo|Phytine (Phytate)
75430316|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
75430317|NCT01507974|Drug|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
75430318|NCT01507974|Drug|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
75430319|NCT01508000|Drug|FOLFOX6|5-FU, folinic acid, oxaliplatin
75430320|NCT01508000|Biological|Bevacizumab|Targeted therapy
75430321|NCT01508000|Biological|Panitumumab|Targeted therapy
75430322|NCT01508000|Procedure|Surgery|
75430323|NCT01508039|Other|Chitin Micro Particle|"The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)"
75430324|NCT01508065|Device|Glucometer CGM-305|The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
75430325|NCT01508091|Behavioral|energy restricted mediterranean-type diet|Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women
75430326|NCT01508091|Behavioral|25 % calorie restriction|25 % calorie restriction respect total energy expenditure
75727218|NCT04075955|Drug|Zyprexa® (OLANZapine 5MG)|"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"
76024778|NCT03169777|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75430327|NCT01508104|Drug|BEZ235|dose escalation 400mg- 1000mg per day
75430328|NCT01508104|Drug|Everolimus|dose escalation 2.5 to 5 mg per day
76024779|NCT03169777|Biological|cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
75430329|NCT01507610|Drug|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
75430330|NCT01508143|Drug|Misoprostol 400 micrograms|Misoprostol 400 micrograms each 6 hours for 8 dose
75430331|NCT01508143|Drug|Misoprostol 800 micrograms|Misoprostol 800 micrograms each 12 hours for 4 doses
75430332|NCT01508156|Drug|IDX719|IDX719 liquid suspension (1 - 100 mg) taken by mouth.
75430333|NCT01508156|Drug|Placebo|Placebo liquid suspension matching IDX719 taken by mouth.
75430334|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
75430335|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
75430336|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
75430337|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
75577078|NCT06227182|Diagnostic Test|Muscle ultrasound with surface electromyography and dynamometry|The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.
75577079|NCT06227182|Diagnostic Test|MRI scan|In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.
75577081|NCT06227156|Drug|Disitamab Vedotin Injection|2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle or every 3 weeks is a treatment cycle
75577082|NCT06227143|Procedure|Anesthesia depth monitoring|Anesthesia depth monitoring during opioid-free anesthesia
75430338|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
75430339|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
75430340|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
75430341|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
75577083|NCT06227130|Behavioral|MindYou|A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work.
76024780|NCT03169777|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
76024781|NCT03169777|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
76024782|NCT03169777|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
75577084|NCT06227117|Drug|Disitamab Vedotin Injection （18 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
75430342|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
75430343|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
75430344|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
75430345|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
75430346|NCT01508208|Other|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
75430347|NCT01508247|Biological|inactivated vaccine (Vero Cell) against EV71|inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
75430348|NCT01508247|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, on day0, 28
75430349|NCT01508260|Procedure|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
75430350|NCT01508260|Drug|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
75430351|NCT01508273|Behavioral|Exercise Program|Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
75430352|NCT01508273|Behavioral|Website|Website access given that allows participant to track exercise behavior and help to set goals.
75430353|NCT01508273|Behavioral|Exercise DVD|Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
75430354|NCT01508273|Behavioral|Survey|"Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake."
75430355|NCT01508273|Behavioral|Self-Report Assessments|Self-report assessments given about quality of life and physical assessments of balance and coordination.
75430356|NCT01508286|Drug|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
75430357|NCT01508286|Drug|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
75577085|NCT06227117|Drug|Toripalimab （18weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
75577086|NCT06227117|Drug|Carboplatin|AUC 3 Q2W or AUC1.5 QW intravenous infusion
75577087|NCT06227117|Drug|Disitamab Vedotin Injection （12 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
75577088|NCT06227117|Drug|Sequential Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
75577089|NCT06227117|Drug|Sequential CTX|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
75430358|NCT01508286|Drug|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
75430359|NCT01508299|Procedure|skin test|skin test with the Suspected raw food
75430360|NCT01508338|Dietary Supplement|Placebo|An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
75430361|NCT01508338|Dietary Supplement|HMB|A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
75430362|NCT01508338|Dietary Supplement|Peak ATP and HMB|One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
75430363|NCT01508338|Dietary Supplement|ATP|One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
75430364|NCT01508364|Drug|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
76024783|NCT03169777|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
75430365|NCT01508377|Behavioral|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
75727219|NCT04075955|Drug|Emend® (Aprepitant)|"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"
75727220|NCT04076033|Other|functional compressive bandage|"The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers."
75727221|NCT03814187|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
75727222|NCT00484198|Drug|Pioglitazone|45 mg over-encapsulated tablet administered orally, once daily
75727223|NCT00484198|Drug|Placebo|Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
75727224|NCT00484198|Drug|Rivoglitazone|1.0 mg tablet administered orally, once daily
75727225|NCT00484198|Drug|Rivoglitazone|1.5 mg tablet administered orally, once daily
75430366|NCT01508377|Behavioral|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
75430367|NCT01508429|Other|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
75430368|NCT01508429|Drug|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
75430369|NCT01508468|Drug|symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)|Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
75430370|NCT01508468|Drug|experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)|NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
75430371|NCT01508494|Drug|Galantamine|16 mg galantamine daily P/O
75577090|NCT06227117|Drug|Toripalimab （12weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed.
75577091|NCT06227104|Device|Convection-based Hemodiafiltration|Convection-based Hemodiafiltration with pre substitution fluid
75577092|NCT06227091|Dietary Supplement|Beetroot juice|acute dose of beetroot juice
75577093|NCT06227091|Dietary Supplement|Placebo|depleted nitrate beetroot juice
75727226|NCT04077905|Drug|Pegylated liposomal doxorubicin|35mg/m² ivgtt on day 1
75727227|NCT04077905|Drug|Etoposide|100mg/m² ivgtt on day 1
75727228|NCT04077905|Drug|Methylprednisolone|2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
75727229|NCT04076501|Procedure|Oxygen application|Oxygen application Supplemental oxygen via mask
75727230|NCT04076501|Procedure|Sham room air|Room air applied via mask
75727231|NCT04077749|Biological|Femdophilus probiotic|Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.
75727232|NCT04077749|Other|Normal Saline|50 mL normal saline at room temperature
75727233|NCT01015846|Other|Exercise|Redcord (sling exercise) and traditional exercise
75727234|NCT01015846|Other|Core stability exercise|Traditional core stability exercise
75727235|NCT04471246|Drug|Cephalexin|1000 mg PO QID for 7 days
75430372|NCT01508494|Drug|placebo|placebo
75577094|NCT06227078|Device|Kinesiotaping|"Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results."
75577095|NCT06227065|Drug|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
75727236|NCT04471246|Drug|Cephalexin|500 mg PO QID plus oral placebo for 7 days
75727237|NCT04278521|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
75727238|NCT04276259|Drug|Buprenorphine|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~6 hours) and an oral placebo tablet.
76024784|NCT03169777|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
76024785|NCT03169777|Biological|nivolumab|Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
75430373|NCT01508546|Procedure|axillary dissection|Conservative breast surgery with or without axillary dissection
75430374|NCT01508572|Drug|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
75430375|NCT01508585|Behavioral|Telephone Based Cognitive Behavioral Therapy|6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
75430376|NCT01508611|Other|30% silver diammine fluoride|"The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.~Anteroposterior toothbrushing technique will be explained to the children."
75430377|NCT01508611|Behavioral|Oral hygiene|With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique
76024786|NCT03169777|Drug|Lovaza|Omega-3-acid ethyl esters
76024787|NCT03169777|Drug|oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
75430378|NCT01508624|Other|Interaction|Participants in this condition will interact with nurses during their surgery. The nurses will not touch the patient's hand during treatment as this intervention looks at interaction with another person, in the absence of tactile stimuli.
75430379|NCT01508624|Other|Music|Participants will be offered a choice of music to listen to from a selection at the clinic, they will also have the opportunity of bringing or selecting their own music which can be streamed from the internet. They will listen to the music through headphones
75577096|NCT06227065|Drug|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
75577097|NCT06227065|Drug|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
75430380|NCT01508624|Behavioral|Touch - stress balls|Participants will be provided with two stress balls which they will be encouraged to squeeze during their surgery and administration of the local anaesthetic
75430381|NCT01508624|Behavioral|DVD|participants will be given a choice of DVDs to watch during their procedure. A wall mounted screen will be positioned so that participants can comfortably view the screen during their procedure. they will listen to the accompanying audio through wireless headphones.
75430382|NCT01508637|Other|Diesel Exhaust|Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
75430383|NCT01508637|Other|Filtered Air|Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
75577098|NCT06227065|Drug|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
75727239|NCT04276259|Drug|Naltrexone|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours) and a saline IM injection.
75430384|NCT01508637|Drug|Terazosin|2 mg by mouth, 90 minutes prior to exposure initiation
75430385|NCT01508637|Drug|placebo|capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
75430386|NCT01508663|Device|Everolimus Eluting Stent or Zotalolimus Eluting Stent|Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)
75430387|NCT01508663|Drug|ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.|one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
75430388|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars first|First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
75430389|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars second|First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
75430390|NCT01508715|Other|Shoulder resistive exercise|"Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks."
75577099|NCT06227052|Device|Num Vapocoolant Spray|This is the study arm. Partipants in this arm will receive Num vapocoolant spray during their gynecologic procedure. They will receive the spray on their cervix right before the paracervical block. Num Vapocoolant spray is currently FDA approved to be used on skin prior to injections. We are using it in the same fashion but in the vagina on the cervix to help with the pain of the paracervical block injection.
75727240|NCT04276259|Drug|Oral Placebo|Oral placebo: to match the oral naltrexone.
75727241|NCT04276259|Drug|IM Placebo|IM saline placebo: to match the i.v. buprenorphine.
76024788|NCT03169777|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
76024789|NCT03169777|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
75577100|NCT06227052|Other|Placebo|This is the placebo. This group will receive Natures tear normal saline spray.
75727242|NCT04276259|Device|Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.|Participants will receive two blocks of each TBS form. During the first block, stimulation intensity will be gradually escalated in 5% increments (from 80% to 110% rMT) in order to enhance tolerability. In all conditions, the investigators will apply 600 pulses of theta burst at 110% RMT. Each block of iTBS will consist of 20 trains, each lasting 2s with intertrain intervals of 8s, for a total of 192s. Each block of cTBS will consist of one continuous train of 40s. The sTBS will make use of two surface electrodes placed on the scalp.
75727243|NCT03797651|Drug|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
75878942|NCT01341925|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
75430391|NCT01508728|Device|ORTHOSENS orthosis|with active vibration
75430392|NCT01508728|Device|ORTHOSENS orthosis|with placebo vibration
75430393|NCT01508741|Dietary Supplement|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
75430394|NCT01508741|Dietary Supplement|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
75430395|NCT01508754|Procedure|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
75430396|NCT01508767|Other|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
75430397|NCT01508780|Device|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
75577101|NCT06227039|Other|Vibroacoustic stimulation on|Mechanical stimulus is provided to the patient through a vibroacoustic device via vibration around the neck.
75577102|NCT06227039|Other|Augmented Reality on|Visual stimulus is provided through augmented reality glasses in the form of a game.
75577103|NCT06227039|Other|Vibroacoustic stimulation off|Vibroacoustic device is worn but turned off.
75577104|NCT06227039|Other|Augmented reality off|Augmented reality glasses are worn but turned off.
75430398|NCT01508780|Device|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
75430399|NCT01508793|Behavioral|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
75577105|NCT06227026|Biological|Anti-CD19 CAR-T cells|Anti-CD19 CAR-T cells are autologous T cells, engineered to express an extracellular single chain variable fragment (scFv) derived from a murine anti-human CD19 hybridoma clone FMC63 linked in frame to hinge region derived from human CD8, transmembrane domain derived from Tumor Necrosis Factor Receptor Super Family 19 (TNFRSF19) the transactivation costimulatory domain 4-1BB, and CD3 zeta signaling domain (Miltenyi Biotec Inc). Anti-CD19 CAR-T cells will be cryopreserved in infusible cryomedia for a later infusion. Anti-CD19 CAR-T cells will be administered in 1 to 3 bags. Bag aliquoting, cell content and cryomedia composition will be done according to specifications in the CMC.
75577106|NCT06227013|Behavioral|Whistleblowing intervention|the participated nurses will receive session about Whistleblowing
75727244|NCT03797651|Drug|Very-short DAPT less than 1 month after PCI|Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
75727245|NCT05062109|Behavioral|Multimodal geriatric prehabilitation|"Multimodal prehabilitation will be carried out over a period of 6 weeks in a day admission (once a week) and at home, and will include:~Muscle rehabilitation developed with a physiotherapist or physical activity monitor~Nutritional support (dietitian at the 1st, 3rd, and 6th day admission (DA))~Cognitive and physical stimulation Exergame~Psychological support by a psychologist~Information in the form of videos on the main risks and important points to know and prepare before and after surgery~Assessment of patient satisfaction, any limitations encountered, the possible performance of exercises at home and the occurrence of any adverse effects.~One session of adapted physical activity at home of one hour per week by a physical trainer from the Siel Bleu association"
75430400|NCT01508806|Drug|liraglutide|Single dose of 0.75 mg, administered as a subcutaneous injection
75430401|NCT01508819|Other|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
75430402|NCT01508845|Dietary Supplement|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
75727246|NCT00499486|Drug|sirolimus|Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
75430403|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
75430404|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
75430405|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
75430406|NCT01508858|Drug|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
75430407|NCT01508858|Drug|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
75430408|NCT01508858|Drug|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
75430409|NCT01508871|Other|Observational study, no intervention|No intervention
75727247|NCT03794375|Other|Telehealth|After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
75878943|NCT01341925|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
75878944|NCT01338623|Drug|Tansulosine|capsule 0,4 mg
75430410|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
75430411|NCT01508884|Drug|Imiquimod|pretreatment with topical imiquimod cream to the injection site before vaccination
75430412|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
75430413|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
75727248|NCT03794375|Other|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
75430414|NCT01508884|Biological|influenza vaccine|single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
75430415|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
75430416|NCT01508923|Drug|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
75430417|NCT01508923|Drug|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
75430418|NCT01508975|Other|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
75430419|NCT01508988|Drug|ONO-9054|Eye drops 0.3 µg/mL both eyes on Day one
75430420|NCT01508988|Drug|ONO-9054|Eye drops 1 µg/mL both eyes on Day one
75430421|NCT01508988|Drug|ONO-9054|Eye drops 3 µg/mL both eyes on Day one
75430422|NCT01508988|Drug|ONO-9054|Eye drops 10 µg/mL both eyes on Day one
75430423|NCT01508988|Drug|ONO-9054|Eye drops 20 µg/mL both eyes on Day one
75430424|NCT01508988|Drug|ONO-9054|Eye drops 30 µg/mL both eyes on Day one
75430425|NCT01508988|Drug|ONO-9054|Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
75430426|NCT01509001|Drug|Metformin|750 to 2500 mg/day, two times a day during 4 months
75727249|NCT01019278|Radiation|proton beam radiation therapy|Undergo external proton beam radiation
75727250|NCT01019278|Radiation|radiation therapy treatment planning/simulation|
75727251|NCT01019278|Drug|cisplatin|Given IV
75430427|NCT01509001|Drug|Glimepiride|1 to 8 mg/day , two times a dya, during 4 months.
75727252|NCT02581241|Device|tilt table|"Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
76049223|NCT01822756|Drug|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
75727253|NCT01014520|Drug|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
75878945|NCT01340833|Drug|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK2118436, starting 1.75 hours after the oral dose
75577107|NCT06227000|Behavioral|Living Longer and Stronger with SCI|Study staff will schedule a brief zoom training session with each person assigned to the intervention to ensure that they are able to download and use the Zoom platform. Once a weekly session day and time has been determined the 8-week LLS intervention program will begin. LLS group participants will participate in 2-hour weekly sessions co-facilitated by a study investigator and one of the study's senior advisors. Participants will be encouraged to set a health-oriented goal and complete weekly action plans. They will be provided with materials each week with health-related information and resources. Participants will also be asked to complete a short survey each week to rate the session. After completing the 8 sessions, a link to the post-test survey and some questions to evaluate the LLS program will be sent to the participants. Finally there will be follow up survey to be completed at 4 months post intervention.
75577108|NCT06227000|Behavioral|Control|Participants will be sent links to the three surveys at the same time as those assigned to the LLS group but they will not attend any of the zoom calls. They will be offered all study materials at the end of the study.
75577109|NCT06226987|Diagnostic Test|68Ga-DOTATATE PET/MRI|PET/MRI scanning
75577110|NCT06226974|Other|Static Stretching|"Shoulder extension - shoulder extension with the hand resting on a door;~Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~Shoulder flexion - arms above the head against a wall;~Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
75577111|NCT06226961|Device|cupping|The dynamic cupping will be performed for ten minutes, at a slow pace, and consisted of applying a small amount of massage cream (ATL®) over the entire shoulder (to obtain the ideal sliding surface for cupping application), insufflation of the suction cup, with two pumps, and sliding it in the direction of the muscle fibers around the shoulder and also in the transversal direction.
75577112|NCT06226948|Device|CGM|Patients will wear CGM monitors for 10 days.
75577113|NCT06226948|Diagnostic Test|Visualization|Enriched visualization of SCORE2 CVD risk.
75727254|NCT04040699|Biological|KN026 combined with KN046|KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
75727255|NCT01015924|Procedure|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
75727256|NCT01015924|Procedure|ESIN|Elastiv stable intramedullary nailing
75878946|NCT01332383|Drug|Naratriptan|
75878947|NCT01338701|Procedure|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
75878948|NCT01338701|Procedure|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
76049224|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
76049225|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
76049226|NCT01822678|Drug|Placebo|Placebo
76049227|NCT01822366|Behavioral|Trauma-focused Cognitive Behavioral Therapy|
76049228|NCT01838590|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
75878949|NCT01338701|Other|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
75878950|NCT01340911|Drug|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
75878951|NCT01340911|Drug|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
75878952|NCT01340989|Procedure|alteration of the insufflation gas|addition of 4% oxygen
75878953|NCT01340989|Procedure|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~humidification~set temperature of 32°C"
75577114|NCT06226922|Other|No intervention|No intervention
75577115|NCT06226909|Procedure|different types of ultrasound technique|Shear-wave elastography-guided or B-mode ultrasound-guided
75878954|NCT01340989|Procedure|standard pneumoperitoneum|no intervention besides the use of CO2
75878955|NCT01337011|Other|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
75878956|NCT05162209|Dietary Supplement|Synbiotic|Oral sachet, for 12 weeks
75577117|NCT06226883|Drug|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
75577118|NCT06226883|Drug|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
75577119|NCT06226870|Other|biodentin|Pulp capping material
75577121|NCT06226844|Device|Music therapy walking program|In the experimental group (PEMA BeatMove), patients will benefit from an outpatient walking training program with app-based performance monitoring, combined with music therapy (BeatMove device). The program comprises 36 walking training sessions, with 30
76024790|NCT03169777|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
76024791|NCT03169777|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
76024792|NCT03169777|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
75577122|NCT06226831|Other|Structured interview|In-person structured interviews will be performed by the investigators.
75430428|NCT01509014|Behavioral|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
75577123|NCT06226818|Other|completion of scales and questionnaires|"Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances."
75577124|NCT06226805|Drug|BB-031|Solution for injection
75577125|NCT06226805|Drug|Placebo|0.9% sodium chloride for injection
75430429|NCT01509027|Behavioral|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
75430430|NCT01509027|Behavioral|Standard care|standard care
75430431|NCT01509027|Behavioral|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
75577126|NCT06226779|Behavioral|Baduanjin exercsie|The Baduanjin exercise consists of 8 postures, with emphasis on different body parts. The exercise is commonly practiced as follows: (1) 2 hands holding up the heavens, (2) drawing the bow to shoot the eagle, (3) separating the heaven and earth, (4) wise owl gazing backwards, (5) swaying the head and shaking the tail, (6) 2 hands holding the feet to strengthen the waist, (7) clenching the fists and glaring fiercely, and (8) bouncing on the toes.
75577127|NCT06226779|Behavioral|Brisk walking|The brisk walking will be gradually increased physical exertion from light to moderate of intensity. During the training period, the heart rate of participants will be monitored.
75577128|NCT06226779|Behavioral|Health education|Health education will include lecture classes. Video watching will watch videos which were not aim at improving physical exertion, such as sports games or sports related variety shows
75878957|NCT01342159|Procedure|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
75577129|NCT06226766|Drug|JSKN033 Injection|JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
75430432|NCT01509066|Other|Diet|Dietary approaches for PCOS
75577131|NCT06226740|Other|Single Visit Non Surgical Root Canal Treatment Protocol|The current study aimed to compare the effects of different obturation techniques on postoperative pain level and radiographic healing in non-surgical endodontic treatment applied in a single visit in teeth with single root canal and apical periodontitis.
75577132|NCT06226727|Drug|BR1019|One tablet administered alone
75577133|NCT06226727|Drug|BR1019-1|One tablet administered alone
75577134|NCT06226727|Drug|BR1019-2|One tablet administered alone
75577135|NCT06226714|Biological|MCV4|1 dose of MCV4 on Day 0
75878958|NCT01342237|Drug|HDCT 1(TTC), HDCT2(MEC)|"TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
75878959|NCT01337323|Drug|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
75878960|NCT03157037|Biological|Imlifidase|One dose of 0.25 mg/kg body weight imlifidase on study day 1
76024793|NCT03169777|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
76024794|NCT03169777|Biological|GI-4000|RAS yeast vaccine
76024795|NCT03169777|Biological|GI-6207|CEA yeast vaccine
76024796|NCT03169777|Biological|GI-6301|Brachyury yeast vaccine
75430433|NCT01509092|Procedure|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole"
75430434|NCT01509131|Drug|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
75430435|NCT01509131|Drug|2L PEG-ASC|Patients will asked to take PEG-ASC according to labeling instructions
75430436|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
75430437|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
75430438|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
75430439|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
75430440|NCT01509144|Biological|Na Cl Placebo vaccine|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
75577136|NCT06226714|Biological|MPSV4|1 dose of MSPV4 on Day 0
76049229|NCT01838590|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75577137|NCT06226701|Device|Cryolipolysis device|"-Cryolipolysis device~1max cool shaping device ( inform china korean technology).Is used for fat lipolysis ,with no harm to the skin.The device consist of Cool sculptor applicator head , cool gel pad its alarge gel pad it should be adherent to the area to be treated before applying the cool sculptor applicator to protect the skin from bruising or ecchymosis. The device uses vacuum suction which can be adjusted according to the patient tolerance. Duration of session 45min at each of treatment session ,1session every 2weeks for 3months."
75577138|NCT06226688|Procedure|Biofeedback device and other group control group|Intervention 1 :-Using the biofeedback device with dumble to strength affected arm post mastectomy
75577139|NCT06226688|Procedure|Control group|Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc
75577140|NCT06226675|Procedure|PENG Block|To apply local anesthetic under psoas tendon
75577141|NCT06226675|Procedure|LFCN block|to apply local anesthetic around lateral femoral cutaneous nerve
75878961|NCT04830943|Drug|Cerebrolysin|Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
75430441|NCT01509157|Device|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
75878962|NCT01341145|Behavioral|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
75878963|NCT01341145|Behavioral|Relaxation|12-week progressive muscle relaxation program (active control)
76049230|NCT01611454|Device|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
75878964|NCT03067610|Radiation|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
76049231|NCT01611454|Device|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
75430442|NCT01509157|Procedure|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
75430443|NCT01509196|Drug|HIP0901 / Lipidilsupra|HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
75430444|NCT01509209|Drug|Pseudoephedrine / Levocetirizine|tablet, BID everyday
75430445|NCT01509222|Behavioral|Personalized nutrition counseling|
75430446|NCT01509235|Procedure|Chest physiotherapy|The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
75878965|NCT03067610|Drug|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
75430447|NCT01509261|Drug|Ilaprazole|20mg/Tap, QD
75430448|NCT01509261|Drug|Lansoprazole|30mg/Tap, QD
75577144|NCT06226649|Behavioral|Digital Dyadic Empowerment|"The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~Access to CKD Health Education Information;~Supportive Information for Significant Others;~Physiological Values Logging for Self-Monitoring;~Reminders for Clinical Appointments and Daily Self-Management Tasks;~Kidney Health Diary for Lifestyle Modification Progress Tracking;~Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers."
75577145|NCT06226636|Other|salt|After ≥8 hr overnight fasting, participants will be required to ingest 780 mg of sodium (2 g salt) and BP measured every 10 minutes for 2 hours to determine IPROS. For SSBP, Participants are put on low salt (50 mmol Na/day) followed by seven days of high salt diet (250 mmol Na/day). Participants' mean arterial pressure (MAP) difference between low- and high-salt diet will be used to define salt sensitivity (MAP≥8 mmHg) and salt resistance (MAP≤5 mmHg).
75577147|NCT06226610|Drug|Dupilumab|injection every two weeks while on study
75577148|NCT06226610|Other|Placebo|injection every two weeks while on study
75577149|NCT06226597|Device|Fitbit device|Daily use of a fitbit wearable activity tracker device.
75727257|NCT04267367|Behavioral|Dietitian-led dietary approach to management of diabetes|In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process[27]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
75727258|NCT04266574|Device|Near Infrared Spectroscopy (NIRS)|"The anesthesiologist will apply optodes before induction of anesthesia and before preoxygenation, to detect baseline NIRS level, NIRS will be monitored continuously up to post-anaesthesia care unit (PACU) discharge, or up to three the investigator's after ICU admission.~When a decrease in NIRS value over 10% is detected, or if NIRS value is below 60%, patients will start hemodynamic optimization, to reverse the reduction in NIRS and return to baseline values, according to a predefined protocol."
75430449|NCT01509274|Biological|Plasma|3 ml plasma injected once into the plantar fascia
75727259|NCT04266574|Device|Standard Care|Controls will be treated according to standard of care, maintaining a MAP≥65 and an adequate cardiac output according to the hemodynamic monitoring chosen by the anesthesiologist (invasive blood pressure monitoring or pulse contour monitors). NIRS will be recorded also in controls, but caring anesthesiologists will be blinded to NIRS.
75878966|NCT01338935|Drug|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage *.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.~*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
75430450|NCT01509274|Biological|Saline|3 ml of saline injected once into the plantar fascia
76024797|NCT03169777|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
76024798|NCT02306915|Drug|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
76024799|NCT04105907|Device|GentleWave|Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth
75430451|NCT01509274|Other|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
75430452|NCT01509300|Biological|anti-thymocyte globulin|On days -10 to -9
75577150|NCT06226584|Dietary Supplement|multiple-strain probiotics|Juice HA capsule which contains more than one strain of probiotics
76024800|NCT03167047|Procedure|Caudal block|Caudal epidural
76024801|NCT03167047|Procedure|Nerve Block|Peripheral nerve block
75430453|NCT01509300|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
75430454|NCT01509300|Radiation|Total body irradiation|2Gy D-6 to D-4
75430455|NCT01509300|Drug|Fludarabine|30mg/M2 once daily IV on days -8 to -4
75430456|NCT01509300|Drug|cyclophosphamide|60 mg/kg IV on day-3 and -2
75430457|NCT01509300|Drug|Tacrolimus|begin on 0
75430458|NCT01509300|Drug|Mycophenolate mofetil|begin on 0
75430459|NCT01509300|Drug|Rituximab|375mg/m2 on day +21
75430460|NCT01509313|Device|hysteroscopic morcellator (TruClear)|It can be used to treat uterine pathology with a mechanical cutting edge
75727260|NCT01016002|Drug|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
75430461|NCT01509313|Device|Bipolar Electrical resectoscope (Versapoint)|It can be used to treat uterine pathology with an electrical cutting edge
75430462|NCT01509326|Other|chiropractic treatment|12 sessions over 4 weeks
75430463|NCT01509326|Device|Dr. Zaxx pillow|Daily use of an acupressure pillow
75430464|NCT01509352|Procedure|esophageal stitches during fundoplication|placement of esophageal stitches with fundoplication
75430465|NCT01509352|Procedure|no esophageal stitches placed during fundoplication|no esophageal stitches are placed during the fundoplication procedure
75577151|NCT06226571|Drug|SNDX-5613|Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
75577152|NCT06226571|Drug|Chemotherapy Regimen|Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
75577153|NCT06226571|Drug|HiDAC|Consolidation: Participants will receive HiDAC IV.
75577154|NCT06226545|Drug|LASN01|Low dose of LASN01 will be administered intravenously.
75577155|NCT06226545|Drug|LASN01|High dose of LASN01 will be administered intravenously.
75577156|NCT06226545|Drug|Placebo|Placebo will be administered intravenously.
75577157|NCT06226532|Drug|lidocaine spray|Group SL: Spray 10% lidocaine for 4 puffs at the endotracheal tube cuff, also prepare for spray at the laryngeal inlet for 4 puffs (total approximately 1.5mg/kg)
75577158|NCT06226532|Drug|Intravenous Lidocaine|2% lidocaine 1.5 mg/kg IV will be given 2 minutes after cisatracurium injection (3 minutes prior intubation).
75727261|NCT01016080|Drug|glutathione|250 mg capsules, twice daily, orally
75727262|NCT01016080|Drug|placebo|250 mg capsules, twice daily, orally
75577159|NCT06226519|Diagnostic Test|11C-MET-PET/RMN|60 children and/or adolescents (≤18 years) with a diagnosis of brain tumor (medulloblastoma, other embryonal tumors or high-grade gliomas), who have followed the contemporary adjuvant therapy protocol of post-surgical chemo and radiotherapy and completed radiotherapy for at least 6 months will undergo a brain MET-PET/MRI.
75577160|NCT06226506|Drug|Test (T) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.
75577161|NCT06226506|Drug|Reference (R) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.
75577163|NCT06226467|Behavioral|Neurobehavioral Affective Control Training|"The N-ACT program comprises a series of eight training sessions, lasting one hour each, over two months. N-ACT sessions will be guided by a cognitive training coach (supervised by a licensed mental health clinician), who will explain intervention procedures and rationale, offer relevant psychoeducation, and use motivational interviewing principles to provide encouragement and support. In addition to coach-led content, participants will spend about half of each weekly training session (~30 minutes) practicing two computer-based adaptive training tasks targeting affective control."
75577164|NCT06226454|Drug|VX-993|Suspension for oral administration.
75727263|NCT01019434|Drug|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
75727264|NCT01019434|Drug|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
75727265|NCT01016158|Drug|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
75727266|NCT04024631|Other|75g glucose beverage (Glucola, Trutol, or similar brand)|Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
76024802|NCT03167047|Drug|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
76024803|NCT01980706|Drug|Baclofen|Baclofen is a GABA-B agonist
75430466|NCT01509365|Drug|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
75430467|NCT01509365|Drug|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
75430468|NCT01509391|Drug|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
75430469|NCT01509417|Other|ad lib feedings after pyloromyotomy|ad lib feedings after pyloromyotomy
75430470|NCT01509417|Other|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
75430471|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
75430472|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
75577165|NCT06226454|Drug|Placebo|Suspension for oral administration.
75430473|NCT01509443|Other|Exercise|Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
75577166|NCT06226441|Procedure|Continuous Renal Replacement Therapy|CRRT
75577167|NCT06226428|Other|Bed cyclo-ergonometry|The MotoMed Letto 2 device will be used, with a progressive pattern, starting at 5 minutes and lasting up to 30 minutes. It will be performed once a day, during weekdays (Monday to Friday) until discharge from the intensive care unit, and at a modified Borg intensity of 2-3 (Light).
75430474|NCT01509456|Dietary Supplement|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
75577168|NCT06226428|Other|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.
75727267|NCT04024631|Other|DXA, whole body|Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
75727268|NCT00499252|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
76049232|NCT01611298|Biological|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
76049233|NCT01822132|Drug|Extended release naltrexone|
75430475|NCT01509469|Dietary Supplement|Casein|Ileal infusion of low dose casein (5 gram)
75430476|NCT01509469|Dietary Supplement|Casein|Ileal infusion of high dose casein (15 gram)
75727269|NCT00499174|Procedure|conventional surgery|Radical prostatectomy
75727270|NCT00499174|Radiation|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
75727271|NCT00499174|Radiation|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
75577169|NCT06226428|Other|Progressive upper and lower limb strength training|Performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells.
75727272|NCT00499174|Procedure|Biopsies|Periodic repeat biopsies
75727273|NCT01019512|Other|questionnaire administration|Ancillary studies
75727274|NCT01019512|Other|lymphedema management|
75727275|NCT01019590|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
76024804|NCT01980706|Drug|Placebo|Pill containing no pharmacologically active substance.
75430477|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
75430478|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
75430479|NCT01509469|Other|Saline|Ileal infusion with saline (180mL in total)
75430480|NCT01509469|Dietary Supplement|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
75430481|NCT01509482|Other|blood samples|blood samples to test for primary and secondary outcome measures
75430482|NCT01509482|Other|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
75430483|NCT01509495|Device|Akern BIA101 and Custom Device|Impedance Measurement every 4 hours
75727276|NCT01019590|Drug|Benicar HCT ® Tablets 40 mg/25 mg|
75727277|NCT03775421|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
75727278|NCT04130620|Diagnostic Test|Applied Kinesiology|An Applied Kinesiology muscle test will be supplemented by a single blood draw for validation.
75727279|NCT01016314|Device|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
75727280|NCT01016314|Device|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
75727281|NCT01014676|Dietary Supplement|Probiotic|
75727282|NCT01014676|Other|Placebo|
75727283|NCT00532155|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
75727284|NCT00532155|Drug|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
75727285|NCT00532155|Drug|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
76024805|NCT02402803|Other|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
76024806|NCT02092571|Drug|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
75878967|NCT01338935|Drug|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study."
75430484|NCT01509508|Drug|Immediate ARV treatment initiation with TDF/FTC/EFV|"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."
75430485|NCT01509508|Other|South African recommendation guided ARV (TDF/FTC/EFV) initiation|"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~WHO clinical stage 3 or 4 irrespective of CD4 count~MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."
75727286|NCT00532155|Drug|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
76049234|NCT01822132|Drug|Placebo|
75727287|NCT01019668|Drug|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
75727288|NCT01019668|Drug|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
75727289|NCT04076345|Diagnostic Test|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
75727290|NCT01019746|Drug|propofol|propofol administration
75727291|NCT03764033|Behavioral|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
75727292|NCT03764033|Behavioral|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
75727293|NCT00205777|Drug|Bazedoxifene Acetate|BZA 20mg, daily, oral
75727294|NCT00205777|Other|Placebo|Placebo, daily, oral
75727295|NCT03762395|Drug|CXA-10|6 weeks of treatment with 150 mg/day of orally administered CXA-10
75430486|NCT01509521|Drug|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
75430487|NCT01509521|Drug|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
75577172|NCT06226402|Drug|Hypertonic saline 3% nebulizer|Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
75727296|NCT03762395|Drug|Matching Placebo|6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
75878968|NCT01338935|Drug|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
75727297|NCT01000389|Device|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
75577173|NCT06226402|Drug|Intravenous hypertonic saline 3%|Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
75727298|NCT05674097|Other|no intervention|no intervention
75727299|NCT01004055|Device|Procellera™ Antimicrobial Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed
75727300|NCT01004055|Drug|ACTICOAT™ Antimicrobial Barrier Dressing|Dressing changes every 2-3 days, more frequently if needed
75727301|NCT01004055|Drug|Mepilex® Ag Silver Foam Dressing|Dressing changes every 2-3 days, more frequently if needed
75727302|NCT03748511|Other|fibroscan and stool sample|patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
75878969|NCT04455295|Device|Transdermal Vagus Nerve Stimulation (tVNS)|Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.
75577174|NCT06226389|Procedure|4 different bulk-fill composite|Posterior cavities either class 1/2
75727303|NCT00483652|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
75577175|NCT06226376|Device|EXOPULSE Mollii Suit Stimulation|"We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes."
75727304|NCT00483652|Drug|Placebo|placebo (sugar pill)
75430488|NCT01509560|Drug|Everolimus|"Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.~Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16"
75430489|NCT01509573|Behavioral|Family Strengthening Intervention in Rwanda (FSI-R)|"Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.~8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material."
75430490|NCT01509599|Procedure|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy: cooling gel wrap during the home-based intervention
75430491|NCT01509599|Procedure|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
75430492|NCT01509651|Drug|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
75430493|NCT01509690|Other|Multidisciplinary, intensive and collaborative care|"No specific study drugs, devices or procedures are involved.~Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access [arteriovenous (AV) fistula or graft] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications."
75430494|NCT01509703|Procedure|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
75430495|NCT01509729|Procedure|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
75430496|NCT01509729|Procedure|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
75430497|NCT01509742|Drug|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
75430498|NCT01509742|Drug|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
75430499|NCT01509755|Drug|placebo|Once daily injection, under the skin (s.c.) for 12 weeks
75577176|NCT06226363|Drug|LNF1901 Monoclonal Antibody Injection|LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
75878970|NCT03567902|Device|C-MAC videolaryngoscope intubation|C-MAC videolaryngoscope intubation
75878971|NCT03567902|Device|Direct laryngoscope intubation|Direct laryngoscope intubation
75430500|NCT01509755|Drug|liraglutide|Once daily injection, under the skin (s.c.) for 12 weeks
75430501|NCT01509755|Drug|glimepiride|Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
75430502|NCT01509781|Procedure|Insertion of suction drain(s) following mastectomy|One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
75727305|NCT04000425|Combination Product|AVENIO ctDNA surveillance kit|AVENIO circulating tumor DNA (ctDNA) Analysis Kits is a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit.
75727306|NCT03742791|Drug|TS-134|5 mg to 80 mg oral solution
75727307|NCT03742791|Drug|Placebo|Matched Placebo oral solution
75878972|NCT05186701|Other|Kinesio Tape|"Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis."
75878973|NCT05186701|Other|Conventional Physical Therapy|Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
75430503|NCT01509781|Procedure|Adaptive skin sutures.|Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
75430504|NCT01509794|Other|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
75727308|NCT04245683|Procedure|Bowel/rectal resection|surgical removal of the portion of the rectum where the tumor was originally identified
75727309|NCT04245683|Other|non-operative follow up|patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
75727310|NCT00998283|Drug|HM10460A 5μg/kg|Subcutaneously administrate at 0 hour on Day 1
75727311|NCT00998283|Drug|HM10460A 15μg/kg|Subcutaneously administrate at 0 hour on Day 1
75727312|NCT00998283|Drug|HM10460A 45μg/kg|Subcutaneously administrate at 0 hour on Day 1
75727313|NCT00998283|Drug|HM10460A 135μg/kg|Subcutaneously administrate at 0 hour on Day 1
75727314|NCT00998283|Drug|HM10460A 350μg/kg|Subcutaneously administrate at 0 hour on Day 1
75727315|NCT00998283|Drug|Placebo|Subcutaneously administrate at 0 hour on Day 1
75727316|NCT01014832|Drug|Intensive insulin therapy|Intensive insulin therapy
75878974|NCT03570008|Behavioral|9 days spa residential program|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~Sp-Ex: spa residential program including physical activity~Sp-alone: spa residential program alone~Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
75430505|NCT01509794|Other|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
75430506|NCT01509833|Drug|rFSH|Administration of rFSH for ovarian stimulation.
75430507|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
75430508|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
75430509|NCT01509859|Device|PFNA proximal femur nail device (Synthes)|"synthes PFNA proximal femur nail device"
75430510|NCT01509859|Device|INTERTAN proximal femur nail device (Smith&Nephew)|"Smith&Nephew INTERTAN proximal femur nail device"
75430511|NCT01509898|Device|Water jet|use of water jet for a month
75430512|NCT01509911|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
75430513|NCT01509911|Drug|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
75430514|NCT01509924|Other|Physical activation on Prescription|The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
75430515|NCT01509937|Device|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
75430516|NCT01509937|Device|Device|participants in control arm will not receive BCM measurement.
75430517|NCT01509963|Other|no intervention : measure of score|To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
75430518|NCT01509976|Other|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
75430519|NCT01510002|Procedure|Total thyroidectomy|Extracapsular total thyroidectomy
75430520|NCT01510002|Procedure|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
75430521|NCT01510015|Drug|Risperidone|variable dose
75577177|NCT06226350|Drug|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
75577178|NCT06226337|Other|listen music|During hysterosalpingography, women were listened to the Acemaşiran maqam as music via MP4 players and headphones.
75577179|NCT06226324|Other|neuropsychological test|The subjects were evaluated for memory, cognition, mood and sleep
75727317|NCT03996473|Drug|Radium-223 dichloride (Xofigo, BAY 88-8223)|Intravenous (IV) injection, every 6 weeks for up to 6 administrations
75727318|NCT03996473|Drug|Pembrolizumab|IV infusion, every 3 weeks for a maximum of up to 35 administrations
75727319|NCT04075565|Behavioral|Terrestrial altitude|Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.
75430522|NCT01510041|Other|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
75430523|NCT01510041|Other|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
75430524|NCT01510080|Behavioral|Computer-assisted live supervision|8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
75430525|NCT01510080|Behavioral|Delayed video-based supervision|12 video-based sessions (each 50 minutes) during treatment of 2 patients
75577180|NCT06226311|Other|Data collection|Collection of sociodemographic, lifestyle and health data; Child anthropometry (weight, height and head circumference) at the ages of 3-4 and 5-6 years Child neurodevelopment scores at the ages of 3-4 and 5-6 years
75577181|NCT06226311|Other|Diagnostic Test: Urinary|Trichloro-pyridinol (TCPy) and 3-phenoxybenzoic acid (3-PBA) Environemental oligoelements including Lithium (7Li), Arsenic (75As), Cadmium (111Cd), Lead (208Pb) and Mercury (80Hg)
75727320|NCT04075565|Behavioral|Cloud 9|"Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined."
75878975|NCT03570008|Behavioral|3 sessions of 10 minutes per day of physical exercise|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~Sp-Ex: spa residential program including physical activity~Sp-alone: spa residential program alone~Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
75878976|NCT02246426|Other|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
75878977|NCT02246426|Other|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
75878978|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
75430526|NCT01510093|Drug|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
75430527|NCT01510132|Drug|Travoprost/timolol fixed combination (Travacom)|Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
75430528|NCT01510171|Drug|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
75577182|NCT06226298|Device|Xiaxi postural hammock|Lie in the Xiaxi postural hammock for 10 minutes for 5 days.
75577183|NCT06226298|Behavioral|Yoga mat|Lie in the Yoga mat for 10 minutes for 5 days.
75577184|NCT06226285|Device|TechQoL4Carers Platform|"The TechQoL4Carers platform is a technological solution that has been designed and developed by the research team in collaboration with the end users. A website and a mobile application integrate the platform. The services offered are: summary of the person's state of health; training content, advice and personalised recommendations based on their situation in terms of quality of life, provision of care, occupational balance, self-management of health and empowerment. It also allows synchronisation with the Xiaomi Smart Band 7/8 activity wristband.~The intervention has a duration of three months. Participants will use the services of TechQoL4Carers and wear the Xiaomi Smart Band 7/8 wristband on a regular basis.~It is expected that caregivers will access and use the TechQoL4Carers platform, at least once a week, to answer the weekly questionnaire and they will consult, at least once a month, the training contents for self-care and for the provision of care."
75577185|NCT06226272|Device|Spinal Fusion|Cervical Spinal Fusion
75577186|NCT06226272|Device|Spinal Fusion|Thoracic / Lumbar Spinal Fusion
75577187|NCT06226272|Device|Spinal Deformities Correction|Spinal Deformities Correction
76049235|NCT04593004|Device|Teledermatology|Patients will be assessed and followed-up by trained physicians through a store-and-forward system (teledermatology online service - Evita® app), which allows patients to upload pictures of skin areas affected by acne as well as their symptoms or questions related to their disease.
75878979|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
75878980|NCT00381485|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
75878981|NCT05183269|Device|Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)|Use of the Oncomfort virtual reality monitor
75878982|NCT01335503|Dietary Supplement|AN-PEP|Endoprotease enzyme (AN-PEP)
75430529|NCT01510171|Drug|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
75430530|NCT01510223|Dietary Supplement|Olive oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase."
75430531|NCT01510223|Dietary Supplement|Olive oil and fish powder|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase."
75577192|NCT06226233|Other|Juniver program|The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evidence-based curriculum, interactive tools, and moderated peer support groups.
75727321|NCT01004211|Procedure|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
75727322|NCT01004211|Procedure|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
75727323|NCT02580461|Behavioral|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
75727324|NCT01004289|Procedure|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
75727325|NCT01004289|Procedure|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
75727326|NCT03745079|Other|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
75727327|NCT03745079|Other|Spoton Temporal|Mesuring temperature on skin near to temporal artery using Spoton
75878983|NCT01341379|Drug|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
75878984|NCT01332539|Other|no intervention|non-interventional study
75878985|NCT01335659|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
75878986|NCT01335659|Device|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
75878987|NCT05182957|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)
75577193|NCT06226220|Procedure|Sacral neuromodulation|Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as >50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.
75727328|NCT03745079|Other|Spoton Carotid|Mesuring temperature on skin near to carotidl artery using Spoton
75878988|NCT05182957|Drug|Lenalidomide|Lenalidomide 25mg qd po d1-d10 (/21d)
75878989|NCT05182957|Drug|Azacitidine|Azacitidine 75mg/m2 i.v d1-d7 (/21d)
75878990|NCT02840474|Biological|VRC-HIVMAB080-00-AB|VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
75430532|NCT01510223|Dietary Supplement|Olive oil and macadamia oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase."
75430533|NCT01510223|Dietary Supplement|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
75577194|NCT06226181|Procedure|Dacryocystorhinostomy and amniotic membrane|Dacryocystorhinostomy surgery with amniotic membrane placement on the osteotomy site.
75727329|NCT01000545|Drug|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
75878991|NCT02840474|Biological|VRC-HIVMAB075-00-AB|VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
75878992|NCT00092651|Drug|MK0653A, ezetimibe (+) simvastatin|
75577195|NCT06226181|Procedure|Conventional dacryocystorhinostomy|Conventional dacryocystorhinostomy surgery without adding amniotic membrane
75577196|NCT06226168|Other|exercise and environmental conditions|Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.
75577197|NCT06226168|Other|exercise and environmental conditions|Passive exposure to normobaric hypoxia conditions. No training intervention. There will be a measurement of selected somatic indices and a quantitative measurement of bone mass indices (bone mineral density). A blood draw for biochemical analysis will be performed.
75727330|NCT01000545|Drug|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
75727331|NCT03992729|Drug|Pregnant women exposed to tildrakizumab|Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
75727332|NCT03992729|Drug|Pregnant women not exposed to tildrakizumab|Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
75727333|NCT00483574|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
75878993|NCT00092651|Drug|Comparators: simvastatin and ezetimibe|
75878994|NCT04777981|Dietary Supplement|CBDRA60 supplement|CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans [15, 16]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,
75878995|NCT04777981|Dietary Supplement|Placebo|Placebo
75878996|NCT01335737|Behavioral|aerobic training|12 weeks of aerobic training, 4 times/week
75878997|NCT01335737|Behavioral|Wait list|wait list control condition
75878998|NCT04889599|Drug|BH009 (Docetaxel injection)|75mg/m2
75878999|NCT04889599|Drug|Docetaxel injection|75mg/m2
76049236|NCT04593004|Other|Face-to-face consultation|Patients will be assessed and followed-up by trained physicians through regular face-to-face outpatient consultations.
76049237|NCT01821898|Drug|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
76049238|NCT01821898|Other|Elimination diet|This group will receive an elimination diet
75430534|NCT01510236|Behavioral|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
75430535|NCT01510262|Behavioral|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.~Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:~A. The STI strengths-based prevention case management, or B. Standard care.~Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.~Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~Conduct cost effectiveness analyses of intervention compared to the standard."
75577198|NCT06226155|Behavioral|TENDAI4PrEP|An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
75577199|NCT06226155|Other|Enhanced treatment as usual|"Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy.~safety during pregnancy/postpartum, and PrEP availability at the ANC."
75577200|NCT06226142|Procedure|Percutaneous dilatational tracheostomy|Percutaneous dilatational tracheostomy
75577201|NCT06226129|Drug|Gadopiclenol|Gadopiclenol for contrast enhanced MRI
75727334|NCT00483574|Biological|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
75727335|NCT00483574|Biological|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
75577202|NCT06226116|Procedure|socket preservation|After the tooth extraction the investigator will select two sockets, one will be assigned as the experimental side and we will preserve it with cold-processed autologous dentin. The second will be designated the control group and we will only stabilize the blood clot.
75577203|NCT06226116|Procedure|placement of experimental implants|After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
75727336|NCT00483574|Biological|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
75727337|NCT01000623|Drug|venlafaxine|Given orally
76049239|NCT02411591|Drug|Necitumumab|Administered IV.
75727338|NCT01000623|Drug|placebo|Given orally
75727339|NCT01000623|Procedure|hypnotherapy|Practice hypnosis
76049240|NCT02411591|Drug|Abemaciclib|Administered orally.
76049241|NCT02454959|Device|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
76049242|NCT02454959|Device|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
76049243|NCT01821118|Biological|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
76049244|NCT01821118|Other|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
76049245|NCT01650779|Biological|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
75430536|NCT01510262|Behavioral|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
75430537|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
75430538|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
75430539|NCT01510288|Drug|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
75430540|NCT01510301|Device|Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)|"To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;~Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;~Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence."
75430541|NCT01510314|Biological|C-reactive protein and procalcitonin dosages|
75430542|NCT01510340|Behavioral|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
75430543|NCT01510353|Device|Radiation monitoring device|Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
75430544|NCT01510392|Device|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
75430545|NCT01510405|Other|Tissue Collection|Tissue sample collection
75430546|NCT01510431|Drug|PROCHYMAL (remestemcel-L)|intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter
75430547|NCT01510483|Behavioral|Obesity Prevention|Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
75430548|NCT01510483|Behavioral|Tobacco Prevention|Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
75430549|NCT01510496|Procedure|Inguinal herniorraphy.|Inguinal herniorraphy (non laparoscopic).
75430550|NCT01510496|Procedure|Hysterectomy.|Hysterectomy: Vaginal and abdominal.
75577204|NCT06226116|Procedure|histological sample collection|"Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long."
75727340|NCT01000623|Procedure|mind-body intervention procedure|Practice focused attention
75727341|NCT00998361|Procedure|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
75727342|NCT00483184|Biological|Veldona,|Very low dose oral natural human interferon alpha lozenges
75879000|NCT03476213|Procedure|Group TCI|Induction and anesthesia will be done by using Gepth model for sufentanil and Schnider effect model for propofol. Anesthetics will be aplicated using infusion pump Agilia (Fresenius Kabi). Another titration will be according to target value of entropy between 40 and 60 and surgical pleth index below 35.
75879001|NCT03476213|Procedure|Group TIVA|Induction of anesthesia will be done by titrating of propofol to the dose of 1.2 mg/kg and sufentanil 5-10 ug according to body weight, maintaining of anesthesia using continuous infusion of propofol 5 mg/ kg/hour and sufentanil 35 ug/hour to reach the target value of entropy between 40 and 60 and surgical pleth index below 35.
75430551|NCT01510496|Procedure|Thoracotomy .|Thoracotomy (non laparoscopic).
75430552|NCT01510509|Device|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
76049246|NCT02411201|Drug|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
75430553|NCT01510509|Device|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
75430554|NCT01510522|Drug|Glucophage|Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: > 1.700mg/day for 6 month
75430555|NCT01510522|Drug|Glucophage|"Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: > 1.700mg/day for 6 month"
75430556|NCT01510535|Drug|Placebo|First 2 weeks Placebo(2ml) once weekly in experimental group
75430557|NCT01510535|Drug|Hyruan Plus|Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
75430558|NCT01510535|Drug|LBSA0103|at third week LBSA0103(60mg) once in experimental group
75430559|NCT01510548|Biological|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
75430560|NCT01510561|Drug|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
75430561|NCT01510561|Drug|90Y-hPAM4|
75727343|NCT00998439|Device|SeQuent® Please|"6 F, 7 F, or 8 F guiding catheters have to be used~after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~ISR must be predilated with uncoated balloon~balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~inflation time has to be ≥ 30 sec~select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~each Paclitaxel-eluting balloon catheter is allowed for single use only~additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
75727344|NCT00998439|Device|SeQuent® II|"6 F, 7 F, or 8 F guiding catheters have to be used~after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~ISR must be predilated with uncoated balloon~balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~inflation time has to be ≥ 30 sec~select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~each Paclitaxel-eluting balloon catheter is allowed for single use only~additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
75727345|NCT01000779|Drug|Propranolol|upto 320mg/day maximum
75727346|NCT01000779|Device|multi band ligator for esophageal varices|to obliterate esophageal varices
75879002|NCT03567746|Procedure|Underwater EMR|Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
75430562|NCT01510561|Drug|90Y-hPAM4 + gemcitabine|
75879003|NCT03567746|Procedure|Conventional EMR|It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
75430563|NCT01510574|Drug|Misoprostol|3 x 200mcg tablets of oral misoprostol
75430564|NCT01510574|Drug|placebo|3 x placebo tablets resembling misoprostol taken orally
75430565|NCT01510587|Behavioral|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
75430566|NCT01510587|Behavioral|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
75430567|NCT01510600|Genetic|DNA analysis|
75430568|NCT01510600|Genetic|polymerase chain reaction|
75430569|NCT01510600|Other|laboratory biomarker analysis|
75430570|NCT01510600|Other|medical chart review|
75430571|NCT01510613|Drug|Pomalidomide and Dexamethasone|Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
75430572|NCT01510626|Dietary Supplement|Food proteins|Food proteins
75430573|NCT01510626|Drug|Omalizumab|Drug
76049247|NCT01838044|Drug|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
75727347|NCT00998595|Other|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
75727348|NCT04075643|Drug|Reference drug|D935 Cap. 1 Cap., single oral administration under fasting condition
75727349|NCT04075643|Drug|Test drug|CKD-385 Tab. 1 Tab., single oral administration under fasting condition
76049248|NCT01838044|Drug|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
75430574|NCT01510639|Biological|Platelet Rich Plasma|The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
75430575|NCT01510665|Dietary Supplement|Magnesium citrate|Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
75430576|NCT01510665|Dietary Supplement|Placebo|Identical appearing placebo with inactive ingredients, two pills once daily.
75430577|NCT01510665|Behavioral|Dietary modification|Nutritionist counseling session and advice on following a magnesium rich diet
75430578|NCT01510730|Drug|eradication treatment of Helicobacter pylori infection|Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
75727350|NCT01000857|Drug|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
75727351|NCT01004445|Drug|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
76049249|NCT02410811|Other|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
76049250|NCT02435381|Drug|Carisbamate|600mg Orally on days 2-4
75430579|NCT01510743|Procedure|Catheterization of subclavian vein|Catheterization of subclavian vein
75430580|NCT01510743|Procedure|Catheterization of internal jugular vein|Catheterization of internal jugular vein
75430581|NCT01510782|Drug|Placebo to BI 655064|intravenous infusion of escalating doses
75577205|NCT06226103|Other|Aerobic Exercise and Computerized Cognitive Training|"Aerobic Exercise (AE) included walk briskly, increasing intensity and duration progressively. The first week they had to walk 30 min per day, 3 days per week, up to 9-10 on the Borg Rating of Perceived Exertion Scale (BRPES; Borg, 1982) perceived as light intensity; during the second week, the duration was increased to 45 min and the intensity 9-10 and frequency (3 days per week) were maintained; the following 10 weeks they maintained the duration (45 min) and frequency (3 days per week) and increased the intensity up to 12-14 on BRPES perceived as moderate-high effort.~Computerized Cognitive Training (CCT) included a multidomain computer-based cognitive training using the brainHQ software in sessions of 45 min, 3 days per week for 12 weeks. Cognitive tasks targeted attention, recognition, colour and shape, identification, calculation, visual perception, visual spatial processing, memory, and executive function."
76049251|NCT02435381|Drug|Placebo|Placebo treatment only
75430582|NCT01510782|Drug|Placebo to BI 655064|subcutaneous injection of escalating doses
75430583|NCT01510782|Drug|BI 655064|intravenous infusion of escalating doses
75430584|NCT01510782|Drug|BI 655064|subcutaneous injection of escalating doses
75430585|NCT01510795|Drug|spironolactone|Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
75430586|NCT01510808|Procedure|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
75430587|NCT01510821|Other|Use of Maquet Vasoshield Pressure-limiting syringe on SVG|Use of Maquet Vasoshield Pressure-limiting syringe on SVG
75430588|NCT01510821|Other|Use of non-regulated syringe on SVG|Use of non-regulated syringe on SVG
75577206|NCT06226103|Other|Conventional Exercises and Brain health lectures|Participants were exposed to balancing, coordination, stretching, and core exercises. Additionally, they attended brain health lectures to provide a comparative non-interactive cognitive engagement. Both the exercises and lectures were scheduled similar to the intervention group over 12 weeks
75727352|NCT01004445|Drug|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
75727353|NCT01004445|Drug|Placebo|Two aerosol treatments per day (one treatment every 12hr)
75430589|NCT01510847|Drug|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
75577207|NCT06226090|Drug|TG103 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
75577208|NCT06226090|Drug|Placebo 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
75727354|NCT02580695|Biological|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
75727355|NCT02580695|Drug|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
75727356|NCT04075019|Behavioral|The Raising Healthy Children intervention, including teacher training, child skill development, and parent training|
75430590|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|250 mg
75430591|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|500 mg
75577209|NCT06226090|Drug|TG103 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
75577210|NCT06226090|Drug|Placebo 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
75577211|NCT06226090|Drug|TG103 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
75577212|NCT06226090|Drug|Placebo 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
75727357|NCT03672929|Device|RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years.
75727358|NCT02581553|Drug|lesinurad/allopurinol 200/300 FDC tablets|
75727359|NCT02581553|Drug|lesinurad 200 mg|
75727360|NCT02581553|Drug|allopurinol 300 mg|
75727361|NCT02581553|Drug|lesinurad/allopurinol 200/200 FDC tablets|
75727362|NCT02581553|Drug|allopurinol 200 mg|
75727363|NCT04077203|Behavioral|Biofeedback / No biofeedback|Biofeedback / No biofeedback
76049252|NCT01837966|Other|Lavender oil|2 drops for aromatherapy
76049253|NCT01837966|Other|Placebo|2 drops unscented mineral oil for aromatherapy
75577213|NCT06226077|Behavioral|sleep extension intervention|The sleep intervention aims to increase sleep duration by one-hour (15 minutes/week) over the course of 4-weeks using components from Cognitive Behavioral Therapy for Insomnia. More specifically, the intervention consists of psychoeducation, sleep extension, sleep hygiene, and stimulus control. Participants will meet with Dr. Wu or a trained staff member once a week over the course of 4-weeks via Zoom. The intervention will be adapted based on feedback from the community, knowledge gained during previous interviews.
75577214|NCT06226077|Behavioral|contact control intervention|The control condition is a contact-control intervention whereby participants will meet with Dr. Wu or a trained staff member once-week over the course of 4-weeks to receive education materials from the Healthy Homes intervention developed by the UT School of Public Health.
75727364|NCT03944915|Drug|Carboplatin|Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
75727365|NCT03944915|Drug|Paclitaxel|"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."
75879004|NCT01342627|Drug|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
75430592|NCT01510873|Other|HRQOL evaluation|"Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start."
75430593|NCT01510899|Drug|RO4917838|Single dose of RO4917838
75430594|NCT01510899|Drug|RO4917838|Single dose of RO4917838
75430595|NCT01510938|Dietary Supplement|L. acidophilus DDS-1, B. lactis UABLA-12|1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
75577215|NCT06226064|Drug|VES001|VES001 is an oral, blood brain barrier penetrating ligand of sortilin.
75577216|NCT06226064|Drug|Placebo|A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
75727366|NCT03944915|Drug|Nivolumab|Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
75577217|NCT06226051|Device|PEAPOD Infant Body Composition measuring device|PEAPOD is a device to that collects body composition measurements.
75727367|NCT03944915|Radiation|Radiation|Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
75727368|NCT03944915|Drug|Hydroxyurea Pill|One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
75727369|NCT03944915|Drug|5-fluorouracil|5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
75727370|NCT03944915|Drug|Filgrastim Injection|Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
75577218|NCT06226038|Other|Magnet disc|Magnetic field promote proliferation and stimulate osteoblast differentiation
75577219|NCT06226038|Other|Stainless steel|For control
75879005|NCT04384393|Biological|ThisCART19 cells|0.2-60 x 10^6 CAR T cells per kg body weight.
75879006|NCT03570944|Procedure|HRS, KRS|Elective HRS or KNR in adult patients, with any ERAS compliance
76049254|NCT02435147|Drug|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
75430596|NCT01510938|Dietary Supplement|Placebo|1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
75430597|NCT01510951|Drug|AMG 811 or Placebo|Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
75430598|NCT01510964|Behavioral|prompt-sheet|"Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology."
75577222|NCT06226012|Device|pulsed magnetic field|Children in this group received pulsed magnetic therapy in addition to traditional exercise program
75577223|NCT06226012|Device|Low level laser|Children in this group received low level laser therapy in addition to traditional exercise program
75577224|NCT06225999|Drug|Irinotecan liposome injection (S095013)|Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
75577225|NCT06225999|Drug|Oxaliplatin|Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
75577226|NCT06225999|Drug|LLV (levoisomer form of leucovorin)|LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
75727371|NCT03944915|Drug|Cisplatin|Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
75727372|NCT05674019|Other|MRI exam|Brain MRI Morphometric exam
75727373|NCT00482170|Device|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
75727374|NCT00482170|Device|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
75727375|NCT05228249|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood ASCT
75727376|NCT05228249|Drug|Carmustine|Given IV
75727377|NCT05228249|Drug|Cytarabine|Given IV
75727378|NCT05228249|Drug|Etoposide|Given IV
75727379|NCT05228249|Biological|Loncastuximab Tesirine|Given IV
75727380|NCT05228249|Drug|Melphalan|Given IV
75879007|NCT01343641|Drug|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
75430599|NCT01510964|Behavioral|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
75430600|NCT01510977|Drug|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
75430601|NCT01510977|Drug|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
75430602|NCT01510990|Drug|Gefitinib|gefitinib 250mg/day daily
75430603|NCT01511003|Drug|Tacrolimus|oral
75430604|NCT01511029|Drug|Dexpramipexole|300 mg - Oral Tablets
75430605|NCT01511029|Drug|Dexpramipexole|600 mg Oral Tablets
75430606|NCT01511029|Drug|Dexpramipexole Placebo|Placebo - Oral Tablet
75577227|NCT06225999|Drug|5- FU (5-Fluorouracil)|5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
75430607|NCT01511029|Drug|Moxifloxacin|400 mg - Oral Tablet
75879008|NCT01343641|Drug|Placebo|Inactive Pill used as a comparator
75577228|NCT06225986|Behavioral|LMH-4-DCP|Reminiscence-based intervention for family caregiver-PwD dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.
75577229|NCT06225986|Behavioral|LMH-4-DCP access without reminiscence activities|Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
75879009|NCT03155945|Drug|Olorinab|Olorinab active treatment for 8 weeks.
75879010|NCT03570866|Diagnostic Test|Positron emission tomography and computed tomography|Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.
75879011|NCT03570866|Procedure|Surgical treatment|Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
75879012|NCT01342705|Procedure|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
75430608|NCT01511094|Procedure|Goniocurettage|Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
75577230|NCT06225973|Drug|TL-925|TL-925 is an eye drop.
75430609|NCT01511120|Drug|Tetraspan|
75430610|NCT01511120|Drug|acetated Ringer's solution|
75430611|NCT01511133|Procedure|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
75430612|NCT01511133|Procedure|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
75430613|NCT01511146|Drug|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
75430614|NCT01511146|Drug|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
75430615|NCT01511159|Drug|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
75430616|NCT01511159|Drug|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
75430617|NCT01511159|Drug|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
75577231|NCT06225973|Other|Placebo|The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.
75879013|NCT03570788|Procedure|Amputation|Major amputation defined as at or above ankle
75879014|NCT01342783|Genetic|DNA analysis|
75879015|NCT01342783|Genetic|RNA analysis|
75879016|NCT01342783|Genetic|mutation analysis|
75879017|NCT01342783|Genetic|nucleic acid sequencing|
75879018|NCT01342783|Other|laboratory biomarker analysis|
75879019|NCT03569930|Drug|flavonoid-based supplements|Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
75879020|NCT03569930|Drug|Centella Complex|The components are: Centella Asiatica, Beta-glucan, Arnica, Aloe Vera, Menthol, Devil's claw, perform actions useful to alleviate the painful symptomatology, restore the tone of the venous wall, assist the treatment of microcirculatory damage.
75879021|NCT03569930|Behavioral|standard of care|diet rich in water and vegetable fibers, hygienic and anal dilator
75879022|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
75430618|NCT01511159|Drug|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
76049255|NCT02435069|Drug|Dose Response - NS and USP Glycerin - First Intervention|This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
75577233|NCT06225934|Behavioral|Exercise and home program to increase lateral flexion and rotation angles|Suggestions will be made to the parent/caregiver of the baby diagnosed with congenital muscular torticollis (CMT) participating in the study to increase the baby's decreasing lateral flexion and rotation angles, and parents/caregivers will be advised to integrate these suggestions into their daily routine as much as possible.These suggestions; It includes holding-carrying-breastfeeding (feeding) principles, active-passive lateral flexion and active stretching of the child and activities that will increase joint range of motion for the SCM muscle, environmental arrangements, games that enable the development of active symmetrical movements and prone activities. The home program to be implemented by parents/caregivers will continue for 6 weeks. During the evaluations, the demographic characteristics of the babies (gender, gestational age, birth weight, parental information, mother's pregnancy type, pregnancy history, Apgar score, ultrasonography values, etc.) will be recorded.
75577234|NCT06225921|Drug|Adebrelimab|Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.
75577235|NCT06225921|Drug|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
75727381|NCT02580383|Procedure|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
75577236|NCT06225921|Drug|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
76049256|NCT02435069|Drug|Effectiveness - NS and USP Glycerin - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
75577237|NCT06225908|Procedure|Serratus posterior superior intercostal plane block|application of local anestesic under serratus posterior superior muscle at the level of second costa
75727382|NCT02580227|Drug|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
75727383|NCT02580227|Other|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
75430619|NCT01511159|Drug|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
75430620|NCT01511159|Drug|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
75430621|NCT01511159|Drug|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
75430622|NCT01511172|Drug|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
75430623|NCT01511172|Drug|metformin|1000 mg daily, administered orally
75430624|NCT01511172|Drug|placebo|Metformin placebo administered orally. 1000 mg daily
75430625|NCT01511172|Drug|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
75430626|NCT01511172|Drug|glimepiride|Individually adjusted dose, administered orally
75430627|NCT01511185|Drug|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
75430628|NCT01511185|Drug|placebo|A single dose administered subcutaneously in random order
75430629|NCT01511198|Drug|liraglutide|Injected subcutaneously once daily
75577238|NCT06225895|Drug|normal saline|patients will receive a sham block with 20 ml of normal saline on each side followed by general anesthesia.
75727384|NCT04076267|Other|Tool assessing symptoms validation|Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
75727385|NCT03883113|Biological|MVA-NP+M1|Trial Vaccine
75879023|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
75879024|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
75430630|NCT01511198|Drug|metformin|1000 mg twice daily, administered orally
75879025|NCT01343719|Drug|BI 661051|low dose solution for oral administration
76049257|NCT04917731|Drug|Botulinum toxin type A|Botox injected at digital artery
76049258|NCT02454101|Procedure|cord milking|milking of the cord 5 times toward the neonate
75577239|NCT06225895|Procedure|Erector spinae plane block|patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
75577240|NCT06225895|Procedure|a rhomboid intercostal nerve block|patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
75577241|NCT06225895|Drug|Bupivacaine|20 ml of bupivacaine 0.25%
75727386|NCT03883113|Biological|Saline|Sodium Chloride Placebo
75727387|NCT03883113|Biological|H3N2 (A/Belgium/2417/2015)|Challenge Agent
76049259|NCT02454101|Procedure|delayed cord clamping|delay clamping of the cord for 120 seconds
75430631|NCT01511211|Drug|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
75430632|NCT01511211|Drug|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
76049260|NCT02409719|Other|Schedule|Illustrative daily planner to point the day that the exercise was performed
75430633|NCT01511237|Drug|Nevirapine, zidovudine, lamivudine|"Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:~NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake~AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).~3TC syrup 2 mg/kg every 12 hours for four weeks."
75430634|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
75430635|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG|"Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.~EGCG, 675 mg/day, oral, for one year."
75577242|NCT06225882|Drug|Oxaluria evolution.|To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
75727388|NCT04218695|Drug|Ceftriaxone|Antibiotic
75727389|NCT04218695|Drug|Normal saline|50cc intravenous once daily
75727390|NCT01000935|Other|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
75727391|NCT03967639|Procedure|Elective cardiac surgery|Elective cardiac surgery
75727392|NCT05674331|Procedure|Extraction site development technique|The technique is described by Molnar et al. in 2019. The aim is to reconstruct the buccal bony wall with a xenogenic membrane with a slow absorption rate properties. This technique aims to stabilizate and enlarge the blood clot .
75879026|NCT01343719|Drug|BI 661051|low dose solution for oral administration
75879027|NCT01343719|Drug|BI 661051|low dose solution for oral administration
76049261|NCT02409719|Other|Verbal Information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
76049262|NCT01820572|Drug|Belatacept|
76049263|NCT01820572|Drug|Tacrolimus|
76049264|NCT01820572|Drug|Cyclosporine|
76049265|NCT01820260|Drug|Ingenol mebutate gel|
76049266|NCT01820260|Drug|placebo|
76049267|NCT01819480|Procedure|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
76049268|NCT01610596|Drug|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
76049269|NCT01610596|Drug|Placebo|
75727393|NCT05674331|Device|autogenous tooth bone graft|ATB was invented by Kim et al. in 2011. The extracted tooth is grinded and goes throw a sterilization procedure by the manufacturer's recommendation. The graft material can be used immediately for ARP.
75727394|NCT05674331|Procedure|Socket seal technique|After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.
75727395|NCT00998673|Device|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
76049270|NCT01818700|Drug|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
75727396|NCT00998673|Device|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
75727397|NCT03967561|Other|Progressive water-based aerobic training|The intervention will comprise walking/running in shallow pool with progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
75727398|NCT03967561|Other|Non-progressive aerobic training|The intervention will comprise walking/running in shallow pool without progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
75430636|NCT01511276|Behavioral|Diet|Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
75430637|NCT01511276|Behavioral|Mainly exercise induced weight loss|"Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.~Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day."
75430638|NCT01511289|Drug|Imatinib|400mg/Tab, QD
75430639|NCT01511289|Drug|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
75430640|NCT01511302|Drug|RNS60|RNS60, 2ml, nebulized twice daily.
75430641|NCT01511302|Drug|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
75577243|NCT06225869|Behavioral|Assessments in ON and OFF levodopa state|Neurological assessment, neuropsychological assessment, and fMRI in ON and OFF levodopa state
75577245|NCT06225843|Biological|Sotevtamab|Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU)
75577246|NCT06225843|Combination Product|FOLFOX|FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.
75727399|NCT01001013|Drug|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
75727400|NCT01004523|Genetic|fluorescence in situ hybridization|
75727401|NCT01004523|Genetic|loss of heterozygosity analysis|
75727402|NCT01004523|Genetic|polymerase chain reaction|
75727403|NCT01004523|Other|flow cytometry|
75727404|NCT01004523|Other|immunohistochemistry staining method|
76049271|NCT01817764|Drug|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
76049272|NCT01817764|Drug|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
75727405|NCT00490282|Radiation|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
75727406|NCT00490282|Radiation|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
75727407|NCT03646877|Drug|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
75727408|NCT03646877|Other|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
75727409|NCT00998751|Drug|oral masitinib|7.5 mg/kg/day
75727410|NCT02580929|Radiation|radiotherapy|radiotherapy before surgery
75577247|NCT06225830|Device|Eksobionics Eksoskeleton NR|During treatment sessions, the therapist will guide the participant's progress using a specific plan. The therapist will set a trajectory for each leg, determining the appropriate step height and length, and program it into the Ekso device. The Ekso will then assist the participant by following this trajectory, with varying levels of assistance for each step. As the participant improves, the therapist will gradually reduce the assistance provided until the participant reaches a point where they no longer require assistance or reach a plateau. In the final phase, the trajectory will be removed, and the participant will walk using their own movements. The therapist may add resistance or assistance based on the participant's needs, but it will be in line with their self-generated movements rather than a predetermined path.
75577248|NCT06225817|Dietary Supplement|Open-label placebo pills|The placebo pills in this study are empty capsules without any ingredients inside. The capsules are made of microcrystalline cellulose.
75577249|NCT06225804|Drug|ABSK112|In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
75727411|NCT01016470|Dietary Supplement|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
75727412|NCT01016470|Dietary Supplement|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
76049273|NCT01817764|Drug|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
75430642|NCT01511302|Drug|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
75430643|NCT01511341|Behavioral|Telenursing|The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
75430644|NCT01511367|Drug|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
75430645|NCT01511367|Drug|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
75577250|NCT06225791|Behavioral|MMS (90x2) + BCC or expanded BCC|Provision of 90-count bottles x 2, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
75727413|NCT01004601|Drug|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
75430646|NCT01511367|Drug|Flixotide|50ug 2 puffs twice daily
75430647|NCT01511380|Behavioral|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
75727414|NCT01004601|Drug|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
75727415|NCT03640793|Device|Implantation|Implantation of 6 PPIS implants
75727416|NCT00998829|Other|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
75727417|NCT01001247|Drug|TMC278; Omeprazole|
75727418|NCT03923543|Diagnostic Test|Neutrophil to lymphosit ratio|
75727419|NCT04205357|Drug|Sulfasalazine|Sulfasalazine combined with stereotactic radiosurgery
75879028|NCT01343719|Drug|BI 661051|high dose solution for oral administration
76049274|NCT04726618|Drug|Hyperpolarized 129-xenon gas and Perfluoropropane gas|"Hyperpolarized 129-xenon gas will be used as a contrast agent for MRI. Xenon will be inhaled by the participant at a maximum dose volume of 1/6 of the participant's total lung capacity.~Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane)."
76049275|NCT01803880|Device|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
75577251|NCT06225791|Behavioral|MMS (180x1) + BCC or expanded BCC|Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
75577252|NCT06225778|Other|Exercise|6-week online exercise group
76049276|NCT01803880|Device|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
76049277|NCT01803646|Drug|AM-101|AM-101 gel for intratympanic injection
76049278|NCT01803646|Drug|Placebo|Placebo gel for intratympanic injection
76049279|NCT01817530|Other|Elagolix placebo|oral coated tablet
75430648|NCT01511380|Behavioral|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
75430649|NCT01511406|Behavioral|cognitive behavioral therapy|Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
75430650|NCT01511432|Drug|telaprevir formulation A|A single 1125-mg dose administered orally
75430651|NCT01511432|Drug|telaprevir Formulation B|A single 1125-mg dose administered orally
75430652|NCT01511432|Drug|telaprevir Formulation C|A single 1125-mg dose administered orally
75577253|NCT06225765|Procedure|Transoral endoscopic thyroidectomy vestibular approach (TOETVA)|Remote access thyroid surgery
75577254|NCT06225765|Procedure|Traditional Open Thyroidectomy|Open thyroidectomy via trans-cervical approach
75577255|NCT06225752|Drug|Probucol|Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
75430653|NCT01511432|Drug|telaprevir Formulation D|A single 1125-mg dose administered orally
75430654|NCT01511471|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
75430655|NCT01511484|Behavioral|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
75577256|NCT06225752|Drug|Placebo probucol|Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
75577257|NCT06225726|Procedure|urethral bladder resection|urethral bladder resection. Per-operative bladder ultrasound elastography and simultaneous cystometry
75577258|NCT06225713|Device|focused power ultrasound mediated inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
75577259|NCT06225713|Device|sham-control group|Participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
76049280|NCT01817530|Drug|Elagolix|oral coated tablet
76049281|NCT01817530|Drug|0.5 mg estradiol / 0.1 mg norethindrone acetate|oral hard capsule
75577260|NCT06225687|Other|Heat Application|The researcher will conduct daily measurements of gastric residual volume (GRV) and abdominal circumference, listen to bowel sounds, and assess distension from the first day of enteral nutrition initiation. Additionally, they will record the frequency of vomiting/defecation. Subsequently, a 15-minute hot application will be applied to the abdominal/lumbar region.
75727420|NCT01004757|Other|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
76049282|NCT01817530|Drug|1 mg estradiol / 0.5 mg norethindrone acetate|oral hard capsule
76049283|NCT01817530|Drug|E2/NETA placebo|oral hard capsule
76049284|NCT01816984|Drug|PI3K inhibitor BKM120|Given PO
75577261|NCT06225674|Device|Episealer Talus implant|This is an observational study, no intervention will be done. The aim for the clinical investigation is to collect data from approximately 25 adult subjects who were treated for focal osteochondral defect with Episealer Talus implant in 6 clinics (Sweden and Germany) since January 2020.
75577262|NCT06225661|Behavioral|SAFE Intervention|Manualized individual youth and family psychotherapeutic intervention. Weekly individual and family sessions with a therapist for 6 weeks. Participants will continue to receive usual care.
75577263|NCT06225661|Behavioral|NAV (Telephone Navigation)|Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed. Participants will continue to receive usual care.
75577264|NCT06225648|Other|threonine|There are 7 different threonine test levels ranging from 5 to 45 mg of threonine per kilogram body weight per day.
75577265|NCT06225635|Drug|Ezerosu(monolayer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
75430656|NCT01511484|Behavioral|Generic appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
75577266|NCT06225635|Drug|Ezerosu(double layer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
75577267|NCT06225622|Drug|Irinotecan Liposome|"In dose escalation study, irinotecan liposome injection will be administered by an intravenous infusion at three doses of 60 mg/m2, 70 mg/m2 and 80 mg/m2, d1, 14 days per cycle. In expansion study, irinotecan liposome injection will be administered by an intravenous infusion at the dose of RP2D, d1, 14 days per cycle.~Until the disease progresses or surgery is possible."
75430657|NCT01511484|Behavioral|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
75727421|NCT01004757|Other|Low Fat diet|traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
75727422|NCT02580773|Drug|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
75727423|NCT02580773|Drug|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
75430658|NCT01511497|Biological|PF-04427429|Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
75430659|NCT01511497|Other|Normal saline|Intravenous, normal saline
75430660|NCT01511510|Drug|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
75727424|NCT05032937|Drug|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
75727425|NCT01008813|Biological|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (3,8 microgram) adjuvanted with AS 03A
75430661|NCT01511510|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
75727426|NCT01008813|Biological|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (15 microgram)
75879029|NCT01343719|Drug|BI 661051|high dose solution for oral administration
75430662|NCT01511510|Drug|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
75577268|NCT06225622|Drug|Oxaliplatin|85 mg/m2, intravenously infusion, d1, 14 days per cycle, up to 12 cycles.
75577269|NCT06225622|Drug|5-FU|2400mg/m2, intravenous infusion, d1-2, 14 days per cycle. Until the disease progresses or surgery is possible.
75577270|NCT06225622|Drug|LV|400mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.
75577271|NCT06225622|Drug|Bevacizumab|5mg/kg, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.It is used to patients in dose escalation phase and with gene mutation in extension phase.
75577272|NCT06225622|Drug|Cetuximab|500mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.For wild-type patients in extended phase studies.
75577273|NCT06225609|Procedure|Ghost ileostomy|Laparoscopic or robotic surgery with ghost ileostomy
75879030|NCT01343719|Drug|BI 661051|low dose tablet
75430663|NCT01511510|Drug|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
75430664|NCT01511510|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
75430665|NCT01511523|Dietary Supplement|RGMA001|3 capsules administered BID once a day.
75430666|NCT01511523|Dietary Supplement|Sugar Pill|Placebo
75577274|NCT06225609|Procedure|No ileostomy|Laparoscopic or robotic surgery with no ileostomy
75577275|NCT06225596|Drug|BT8009|Participants will receive BT8009 IV on days 1, 8 +/- 15 schedule of every 21-day cycle.
75577276|NCT06225596|Drug|Pembrolizumab|Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.
75577277|NCT06225596|Drug|Gemcitabine + cisplatin Or carboplatin|Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.
75727427|NCT01001481|Other|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
75727428|NCT03999645|Procedure|Early laparoscopic cholecystectomy|within 72h from symptom onset
75727429|NCT03999645|Procedure|Late laparoscopic cholecystectomy|after 72h up to seven days from symptom onset
75727430|NCT05195801|Device|USG|Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
75727431|NCT01005069|Drug|DLBS-32|DLBS-32 50 mg once daily and lifestyle modification
75430667|NCT01511549|Drug|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
75430668|NCT01511549|Drug|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
75430669|NCT01511562|Drug|carmustine|Given IV
75430670|NCT01511562|Drug|cytarabine|Given IV
75577278|NCT06225596|Drug|Avelumab|After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.
75577279|NCT06225570|Drug|Isotretinoin|This arm aims to study the effectiveness, side effects and patient satisfaction of taking isotretinoin on a weekly basis as opposed to current standard daily dosing.
75577280|NCT06225570|Drug|Tetracycline|This arm aims to serve as the comparison group. Tetracycline antibiotics are the current standard of care for the treatment of moderate acne.
75577281|NCT06225557|Other|ERAS community recommendation|Enhanced recovery techniques including opioid sparing anesthesia in elective cesarean section
75577282|NCT06225557|Other|Traditional postoperative care|Usual anesthesia and analgesia in elective cesarean section.
75577283|NCT06225544|Drug|Lumasiran|Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
75577285|NCT06225518|Behavioral|Individualized physical activity management system|Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
75577286|NCT06225505|Diagnostic Test|ctDNA monitoring|For each patient included, a ctDNA detection assay will be performed in blood samples every 3 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.
75577287|NCT06225505|Diagnostic Test|68Ga-FAPI-46-PET-CT|). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
75879031|NCT01343719|Drug|Placebo|solution for administration
75430671|NCT01511562|Drug|etoposide|Given IV
75430672|NCT01511562|Drug|thiotepa|Given IV
75430673|NCT01511562|Procedure|stem cell transplant|
75430674|NCT01511562|Drug|G-CSF|
75430675|NCT01511575|Genetic|RNA analysis|
75430676|NCT01511575|Genetic|reverse transcriptase-polymerase chain reaction|
75430677|NCT01511575|Other|laboratory biomarker analysis|
76049285|NCT01816984|Biological|cetuximab|Given IV
76049286|NCT01816906|Device|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
75727432|NCT01005069|Drug|DLBS-32|DLBS-32 100 mg once daily and lifestyle modification
75727433|NCT01005069|Drug|DLBS-32|DLBS-32 200 mg once daily and lifestyle modification
75727434|NCT01005069|Drug|DLBS-32|DLBS-32 300 mg once daily and lifestyle modification
75727435|NCT01005069|Drug|Placebo capsule|Placebo capsules once daily and lifestyle modification
75727436|NCT01009125|Other|$2 cash|$2 cash incentive will be included in the mailed survey
75727437|NCT01009125|Other|$5 cash|$5 cash incentive will be included in the mailed survey
75727438|NCT02580851|Other|diagnostic test - cardiac magnetic resonance imaging|
76049287|NCT01816906|Device|Footwear: MCP|One group of patients will receive footwear with MCP insoles
75430678|NCT01511627|Drug|General Anesthesia + Spinal anesthesia combined|"All patients will receive a preoperative multimodal analgesic regime:~Tylenol® 975mg per os~Naproxen® 500 mg per os~Patients will receive a spinal anesthetic with:~Bupivacaine 0.5% 10 mg~Fentanyl 10ug~Epidural Morphine 150ug~After the spinal, a general anesthetic will be induced using:~Midazolam 1 - 2 mg intravenously~Fentanyl 1 - 2 ug/kg intravenously~Propofol 1-3 mg/kg intravenously~Rocuronium 0.3 - 0.9mg/kg intravenously~followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.~Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~Dexamethasone 4mg and Ondansetron 4mg intravenously~Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU)."
75430679|NCT01511627|Drug|General Anesthesia (control group)|"All patients will receive a preoperative multimodal analgesic regime:~Tylenol® 975mg per os~Naproxen® 500 mg per os~Group I (General anesthetic) patients will receive a general anesthetic :~Midazolam 1 - 2 mg intravenously~Fentanyl 1 - 2 ug/kg intravenously~Propofol 1-3 mg/kg intravenously~Rocuronium 0.3 - 0.9mg/kg intravenously~followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.~Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~Dexamethasone 4mg and Ondansetron 4mg intravenously~Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously~Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU)."
75430680|NCT01511666|Device|Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS|ECLS states for extracorporeal life support.
75430681|NCT01511666|Other|Standard care|Standard care as per recent guidelines will be provided.
76049288|NCT01816594|Drug|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
75430682|NCT01511692|Drug|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
75430683|NCT01511692|Drug|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
75430684|NCT01511692|Drug|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
75430685|NCT01511692|Drug|glimepiride|Dose individually adjusted, administered orally for 4 weeks
75430686|NCT01511705|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
75430687|NCT01511705|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
75430688|NCT01511718|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
75430689|NCT01511718|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
75430690|NCT01511731|Drug|Famotidine|Famotidine Tablets 40 mg
75430691|NCT01511731|Drug|Pepcid|40mg tablets
75430692|NCT01511744|Biological|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
75430693|NCT01511757|Drug|Fluconazole|Fluconazole Tablets, 200 mg
75727439|NCT02580851|Other|diagnostic test - coronary angiography|
75727440|NCT01005147|Drug|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
75430694|NCT01511757|Drug|Fluconazole|fluconazole 200 mg
75430695|NCT01511770|Drug|Fluconazole|Fluconazole Tablets, 200 mg
75727441|NCT01005147|Other|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
75430696|NCT01511770|Drug|Fluconazole|Fluconazole 200 mg tablets
75430697|NCT01511783|Drug|E2609|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
75430698|NCT01511783|Drug|Placebo|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
76049289|NCT01816594|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
75430699|NCT01511796|Other|upper limb rehabiliation|3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
75430700|NCT01511822|Drug|Drospirenone Ethinyl estradiol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
75430701|NCT01511822|Drug|Drospirenone Ethinyl estradiol Myo-inositol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
75430702|NCT01511822|Drug|placebo|
75430703|NCT01511835|Dietary Supplement|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
75727442|NCT01001793|Device|Levacor Ventricular Assist Device|Surgical procedure
75879032|NCT01343719|Drug|BI 661051|medium dose tablet
75577290|NCT06225479|Behavioral|Exercise|"An individualized 12-week exercise intervention that will follow American College of Sports Medicine guidelines to ensure a gradual safe increase in frequency and intensity. The exercise goals for participants in the intervention arm are to increase minutes/week of aerobic exercise, build strength and muscle mass, and improve flexibility, core strength, and balance progressively over the course of 12 weeks. The participants are prescribed 3 sessions of aerobic exercise lasting 45-75 minutes each, including warm up and cool down; 2 resistance training sessions per week, and at least 3 flexibility and balance sessions per week.~Intervention arm receives the following: Control arm Successful Aging newsletter plus additional educational materials related to exercise, heart rate monitor and resistance bands, and two 90-minute sessions and ten 30-minute phone sessions over 12 weeks with an exercise coach (the first two sessions include a resistance training session)."
75430704|NCT01511835|Dietary Supplement|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
75577291|NCT06225479|Other|Calls and Newsletter|"A 12-week remote health education program developed by the study team to provide a control for the exercise intervention. Participants in this arm will receive a summary of the American College of Sports Medicine guidelines (self-directed and time-based), a twice-monthly Successful Aging newsletter with suggestions for health diet, stress reduction, and social engagement, and twice-monthly phone calls to reinforce and discuss topics in the newsletter and to review adverse events and change in medications."
75577292|NCT06225466|Drug|Rocuronium|After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.
75577293|NCT06225466|Drug|Sugammadex|When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.
75577294|NCT06225466|Other|Anesthesia without neuromuscular blockade|Anesthesia without rocuronium or sugammadex
75577295|NCT06225453|Other|Individualized perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at more than -20% of the baseline values of each patient.
75430705|NCT01511835|Drug|Folic Acid|Folic Acid 400mcg; 1 cp/die
75430706|NCT01511848|Drug|DFP (ferriprox) and deferasirox (ICL 670)|"Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670"
75430707|NCT01511848|Drug|DFP, DFO|"Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days"
75430708|NCT01511874|Drug|ELIGARD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
75430709|NCT01511887|Drug|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
75577296|NCT06225453|Other|Conventional perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at ≥65 mmHg and ≥90 mmHg, respectively, in all patients.
75577297|NCT06225440|Dietary Supplement|Levagen+® Palmitoylethanolamide (PEA)|Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.
75577298|NCT06225440|Dietary Supplement|Placebo|Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.
75577299|NCT06225427|Procedure|Biopsy|Undergo tissue biopsy
75727443|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
75430710|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
75430711|NCT01511900|Drug|Placebo|Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
75430712|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
75430713|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
75430714|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
75430715|NCT01511900|Drug|CAT 1004|Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
75430716|NCT01511952|Other|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
75430717|NCT01511952|Other|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
75430718|NCT01511965|Other|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
75430719|NCT01511991|Drug|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
75430720|NCT01512004|Drug|Propiverine Hydrochloride|drug of oral capsule
75430721|NCT01512004|Drug|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
75430722|NCT01512017|Device|Crystalline cellulose simple occlusive dressing|A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
75430723|NCT01512017|Device|Vaseline|External use
75430724|NCT01512043|Behavioral|Breathing control|Practice of device guided breathing control twice a day for four weeks.
75430725|NCT01512056|Drug|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
75430726|NCT01512069|Behavioral|Web-based Health Planner on diet and exercise|"URL is closed~The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors."
75430727|NCT01512069|Behavioral|Non-tailored booklet on exercise and diet|The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
75430728|NCT01512082|Device|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
75430729|NCT01512082|Device|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
75430730|NCT01512134|Device|Deep Brain Stimulation Device|Deep brain stimulation surgery
75577300|NCT06225427|Procedure|Biospecimen Collection|Undergo blood sample collection
75577301|NCT06225427|Procedure|Computed Tomography|Undergo CT scan
75577302|NCT06225427|Procedure|Echocardiography|Undergo echocardiography
75577303|NCT06225427|Drug|Gilteritinib|Given PO
75577304|NCT06225427|Procedure|Magnetic Resonance Imaging|Undergo MRI
75577305|NCT06225427|Other|Questionnaire Administration|Ancillary studies
75727444|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
76049290|NCT01816594|Drug|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
75577306|NCT06225414|Other|Usual Care|The usual care includes a provider flag in electronic medical record (EMR) on patients' eligibility for LCS if their smoking history is complete.
75577307|NCT06225414|Behavioral|Brief Patient Education|Brief one-page education material on lung cancer screening benefits and risk
75430731|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|"We will include following general anesthesia techniques:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.~After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.~After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.~Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr."
75430732|NCT01512173|Drug|propranolol gel|Topical administration twice daily
75430733|NCT01512173|Drug|Placebo|Topical administration twice daily
75430734|NCT01512199|Drug|U3-1287|U3-1287: 18 mg/kg administered intravenously once every three weeks
75577308|NCT06225414|Behavioral|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
75577309|NCT06225414|Behavioral|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
75577310|NCT06225414|Behavioral|Patient Reminders|within 2 weeks prior to appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss lung cancer screening with their provider.
75577311|NCT06225414|Behavioral|Provider Reminders|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for lung cancer screening and their reported barriers.
75577312|NCT06225401|Other|Simcapture PRE|Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom
75727445|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
75879033|NCT03569852|Behavioral|Time Restrictive Feeding|Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.
75879034|NCT03569852|Behavioral|Traditional Eating Pattern|Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.
76049291|NCT01816594|Drug|BKM120 Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
76049292|NCT01802320|Drug|Akt Inhibitor MK2206|Given PO
76049293|NCT01802320|Other|Laboratory Biomarker Analysis|Correlative studies
76049294|NCT01802320|Other|Pharmacological Study|Correlative studies
76049295|NCT02453711|Drug|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
75430735|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
75577313|NCT06225401|Other|Simcapture POST|Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
75727446|NCT01001871|Dietary Supplement|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
76049296|NCT02453711|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
75430736|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
75430737|NCT01512199|Drug|U3-1287|The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
75430738|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
75430739|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
75430740|NCT01512199|Drug|Placebo|Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
75430741|NCT01512212|Procedure|biopsy|fnab
75430742|NCT01512238|Other|Pharmaceutical care|Information about medicine, sideeffect, adherence
75430743|NCT01512277|Biological|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
75430744|NCT01512290|Other|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
75430745|NCT01512303|Behavioral|Sudarshan Kriya Yoga|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
75430746|NCT01512303|Behavioral|Mindfulness-Based Stress Reduction|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
75430747|NCT01512329|Behavioral|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
75430748|NCT01512329|Behavioral|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
75430749|NCT01512342|Behavioral|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
75430750|NCT01512342|Behavioral|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
75430751|NCT01512355|Drug|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
76049297|NCT02453711|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
75430752|NCT01512355|Drug|placebo group|normal saline_02mcg/kg/hr
75430753|NCT01512381|Device|Implantation of CRT device|RV lead of CRT system is implanted into the middle part of interventricular septum
75430754|NCT01512381|Device|Implantation of conventional VVI(R) pacemaker|RV lead is implanted into the middle part of interventricular septum
75430755|NCT01512394|Procedure|standard bowel prep|standard bowel prep
75430756|NCT01512394|Procedure|no bowel prep|no bowel prep
75430757|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
75430758|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
75430759|NCT01512433|Procedure|Ture acupuncture|Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
75430760|NCT01512433|Procedure|Sham acupuncture|"The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling."
75430761|NCT01512459|Drug|Venlafaxine|Venlafaxine MR Capsules 150 mg
75430762|NCT01512472|Drug|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
75577314|NCT06225349|Dietary Supplement|Dietary supplementation with Microencapsulated Magnesium|Volunteers will be provided with the product Microencapsulated Magnesium. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
75727447|NCT01001871|Dietary Supplement|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
76049298|NCT02453555|Drug|Linagliptin|
76049299|NCT02453555|Drug|Empagliflozin placebo + linagliptin placebo low dose|Matching placebo empagliflozin + linagliptin
76049300|NCT02453555|Drug|Empagliflozin + linagliptin low dose|tablet
76049301|NCT02453555|Drug|Linagliptin placebo|Matching placebo linagliptin
76049302|NCT02453555|Drug|Empagliflozin + linagliptin high dose|tablet
75879035|NCT01316731|Other|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
75430763|NCT01512485|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
75879036|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
75879037|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
76049303|NCT02453555|Drug|Empa + lina highdose placebo|
75430764|NCT01512511|Procedure|nitrous oxide use for pneumoperitoneum creation|use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
75430765|NCT01512524|Other|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
75430766|NCT01512537|Radiation|Narrowband UVB|UVB 3 times a week
75430767|NCT01512537|Dietary Supplement|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
75430768|NCT01512550|Procedure|GF hip guide|Using GF hip guide to measure and control the peroperative positioning of the hip stem
75430769|NCT01512550|Procedure|Stryker Navigation System|Using Orthomap Modular Hip Software to navigate the operation
76049304|NCT02453321|Procedure|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
76049305|NCT02453321|Procedure|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
76049306|NCT02453321|Procedure|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
75430770|NCT01512550|Device|ABG II modular femoral component|A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
76049307|NCT02453321|Drug|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
75430771|NCT01512563|Device|Biliary stent|palliative treatment for malignant patients
75430772|NCT01512576|Other|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
75430773|NCT01512576|Behavioral|relaxation|1 treatment session of 30 minutes
75430774|NCT01512602|Behavioral|DBT|16 weeks DBT treatment
75430775|NCT01512602|Behavioral|CAMS|CAMS-informed psychotherapy
75430776|NCT01512615|Other|Complex Cardiac rehabilitation|Complex Cardiac Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
76049308|NCT01610284|Drug|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
76049309|NCT01610284|Drug|BKM120|BKM120 100 mg once daily
76049310|NCT01610284|Drug|BKM120 matching placebo|BKM120 matching placebo, once daily
75430777|NCT01512615|Other|Control group|Usual care, clinical control as provided by treating heart centre
75430778|NCT01512628|Drug|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
75430779|NCT01512641|Other|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
75430780|NCT01512641|Other|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
75577315|NCT06225349|Dietary Supplement|Dietary supplementation with Magnesium Oxide|Volunteers will be provided with the product Magnesium Oxide. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
75577316|NCT06225349|Dietary Supplement|Dietary supplementation with Magnesium Citrate|Volunteers will be provided with the product Magnesium Citrate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
75577317|NCT06225349|Dietary Supplement|Dietary supplementation with Magnesium Bisglycinate|Volunteers will be provided with the product Magnesium Bisglycinate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
76049311|NCT02452463|Biological|Durvalumab|Given IV
76049312|NCT02452463|Drug|Nintedanib|Given PO
76049313|NCT02452463|Other|Placebo|Given PO
76049314|NCT02452463|Procedure|Quality-of-Life Assessment|Ancillary studies
76049315|NCT02432105|Drug|EXE844 Sterile Otic Suspension, 0.3%|
76049316|NCT02432105|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
75430781|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
75577320|NCT06224855|Drug|DXC006|"Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose."
75430782|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
76049317|NCT02431793|Behavioral|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.
76049318|NCT02431793|Behavioral|SMS Text Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
76049319|NCT03628391|Drug|Haloperidol|haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
76049320|NCT03628391|Drug|Placebo|placebo for ICU delirium, titrated on validated screening tool-based diagnosis
76049321|NCT01801930|Drug|OCV-103 and OCV-104|0.3 mg of each
76049322|NCT01801930|Drug|OCV-103 and OCV-104|1 mg of each
76049323|NCT01801930|Drug|OCV-103 and OCV-104|3 mg of each
75430783|NCT01512680|Behavioral|Education to Functional Insulin Therapy|"Intake of Continuous Glucose Monitor for 5 to 7 days~Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~3 months after the training: Blood sampling, vital signs and data on diabetes~6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~9 months after the training: Blood sampling, vital signs and data on diabetes~1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
75430784|NCT01512719|Procedure|POEM|Per Oral Endoscopic Myotomy for achalasia
75430785|NCT01512771|Other|CPAP|6 weeks of CPAP
75577321|NCT06224725|Other|dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)|Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.
75577322|NCT06224595|Drug|CS32582 capsule|Participants receive CS32582 orally single or multiple doses
75577323|NCT06224595|Drug|Placebo capsule|Participants receive placebo matching CS32582 orally single or multiple doses
75577324|NCT06224517|Other|Rehabilitation|The intervention includes daily physical and occupational therapy sessions tailored to each patient's functional status. In this study, stroke patients will undergo a four-week rehabilitation therapy program comprising 60-minute daily sessions of physical and occupational therapy. The physical therapy includes balance training, mobility and strengthening exercises, while occupational therapy covers sensorimotor and fine motor training, and ADL activities.
75577325|NCT06224322|Other|Assesment Scale|Caregiving burden will be assessed with Turkish validated scoring tools such as the Zarit scale and the Pediatric Quality of Life Inventory (PEDSQL) Family Impacts module before and after surgery.
75727448|NCT02580071|Dietary Supplement|Sheng-Yu-Tang|"Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)"
76049324|NCT01801930|Drug|OCV-103 and OCV-104|6 mg of each
75879038|NCT03160703|Other|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
76049325|NCT01610206|Drug|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
76049326|NCT01610206|Drug|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
76049327|NCT04414462|Other|exergaming training|"HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)"
75430786|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
75430787|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
75577326|NCT06224166|Diagnostic Test|Collection and use of tissue samples, blood and saliva|"For tissue collection, tumor and surrounding tissues will be used healthy specimens taken during surgical removal, according to clinical practice. Blood and saliva sampling will be carried out at different times:~i) the day before surgery; ii) the day after surgery (only for blood); iii) at the time of patient discharge (approximately 15 days after surgery); iii) during the check-up visit scheduled to monitor the follow-up (FU)"
75430788|NCT01512823|Behavioral|Education|"Interactive educational intervention:~4 hour education session (with notes and 'evidence packs'); presentations, small group discussion tasks and practice of particular skills - 2 hour session (1 week later)~Emailed notes from second session~Telephonic/email follow-up (reminders)~Didactic educational intervention:~- 4 hour education session (with notes and 'evidence packs'; questions answered but no discussion or application of skills"
75430789|NCT01512836|Behavioral|Case Management|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:~Formulation and implementation of care plans together with the patient~Monitoring of individual status and care plan effectuation~Overall coordination between health care providers~Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)~Regular telephone consultations and home visits~Promote disease-self management through coaching"
75577327|NCT06224101|Behavioral|Simulation-based training|simulation training consists of practicing diagnostic coronary angiography with 3D printed simulator-SimulHeart.
75430790|NCT01512862|Drug|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
75577328|NCT06224023|Diagnostic Test|Determination of presepsin levels in ascites|A diagnostic paracentesis will be performed and presepsin level will be determined in ascites.
75577331|NCT06223854|Dietary Supplement|Iodized salt|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
75577332|NCT06223854|Dietary Supplement|Experimental: Iodized salt with lower-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
75577333|NCT06223854|Dietary Supplement|Experimental: Iodized salt with higher-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
75879039|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
75879040|NCT03569774|Procedure|One-lung ventilation with individualized PEEP|During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
75727449|NCT05673941|Other|Creative physical training|The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
75430791|NCT01512862|Drug|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
75430792|NCT01512901|Drug|Betamethasone Microsphere (DE-102） Low Dose|
75430793|NCT01512901|Drug|Betamethasone Microsphere (DE-102） High Dose|
75430794|NCT01512901|Drug|Sham|
75727450|NCT01001949|Dietary Supplement|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
75430795|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
75430796|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
75430797|NCT01512914|Drug|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
75430798|NCT01512914|Drug|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
75577339|NCT06223373|Device|Blood Flow Restriction|In the BFR group, the tourniquet will be pressurized to 50% limb occlusion pressure (LOP), which is the pressure necessary for occluding 50% of arterial limb flow in the upper extremity.
75577340|NCT06223373|Device|"sham Blood Flow Restriction"|In the sham BFR group, the tourniquet will be pressurized to 0% occlusion pressure, while maintaining enough pressure to keep the tourniquet in place.
75577342|NCT06221813|Biological|PHV02|Nipah virus vaccine
75577343|NCT06221813|Biological|Lactated Ringer's|Placebo
75577344|NCT06220916|Behavioral|Dance training in Classical Ballet and Contemporary Dance|Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
75727451|NCT01001949|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
75577345|NCT06220422|Procedure|Standard Department procedure for managing direct-acting oral anticoagulants|Standard Department procedure for managing direct-acting oral anticoagulants (NACO < 50 ng/mL) in the management of fractures before September 2021
75577346|NCT06220422|Procedure|New Department procedure for managing direct-acting oral anticoagulants|New Department procedure for managing direct-acting oral anticoagulants (NACO < 100 ng/mL) in the management of fractures after September 2021
75577347|NCT06219252|Device|Intraoperative aberrometer|the patient intraocular lens will be optimized during the aphakic period after cataract extraction and before intraocular lens implantation, this will produce a possible change in the dioptric power of the intraocular lens
75577348|NCT06219252|Other|Preoperative intraocular lens calculation|the intraocular lens in this group will be calculated preoperatively with Barrett Universal II formula
75577349|NCT06219226|Procedure|Chlorine dioxide mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
75577350|NCT06219226|Procedure|Chlorhexidine mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
75430799|NCT01512940|Procedure|Laparoscopic Greater Curvature Plication|"The greater curvature of the stomach is separated from the greater omentum. At least two rows of at least five continuous stitches will be placed about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure. The two tissue bites of an individual stitch will be centered about the intended fold line.~Subsequent stitches will be uniformly spaced distally along the length of the fold. The second row of sutures will be placed across the fold line created by the previous row of sutures in the same fashion as the first row. Up to 2 additional rows may be added as required to achieve this result (for a total of up to 4 rows). Upon completion of the procedure, the section of the stomach infolded by the sutures will be inspected using the endoscope."
75430800|NCT01512953|Drug|Lansoprazole|Lansoprazole 30 mg once a day
75727452|NCT01002027|Behavioral|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
75577351|NCT06219031|Other|no intervention|no intervention
75577352|NCT06218836|Other|Pre-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Then, the cuff will be inflated to 40 cm of H2O to gain full stretch inflation.Thereafter the cuff will be deflated with the help of cuff inflator-deflator device to maintain intracuff pressure of 4 cm H2O The external cuff balloon will be obliterated with a soft clamp to ensure that at the time of passage of tube through the glottic-inlet, the tube cuff does not get deflated due to pressure equalization with the external balloon.
75577353|NCT06218836|Other|Non-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Thereafter the endotracheal intubation will be done.
75577354|NCT06218238|Device|Powered prosthetic knee joint|Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
75577355|NCT06218238|Device|Conventional prosthetic knee joint|Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
75577356|NCT06214143|Biological|T3011 high dose|T3011 high dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
75577357|NCT06214143|Biological|T3011 middle dose|T3011 middle dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
75577358|NCT06214143|Biological|T3011 low dose|T3011 low dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
75879041|NCT03569774|Procedure|One-lung ventilation with low PEEP|Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
75727453|NCT01005381|Dietary Supplement|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
75879042|NCT01342861|Dietary Supplement|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
75879043|NCT03567668|Procedure|mitral valvuloplasty|Commissural plication was the most commonly used technique to repair mitral insufficiency, which was selectively supplemented by a specific combination of one or more of the following procedures: cleft closure, chordal shortening, transposition or replacement, edge-to-edge repair, leaflet augmentation, or division of papillary muscles, depending on the individual etiology and anatomy.
76024807|NCT02402959|Other|individualized treatment|Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
75727454|NCT01005381|Dietary Supplement|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
75430801|NCT01512966|Biological|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
75430802|NCT01512992|Procedure|Home telehealth|"Patients receive tailored intervention according to their clinical complexity.~All patients in the intervention group receive:~Personalised care plan~Education on self-management~Access to a personalized online health folder~Access to Call center~Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).~Patients with LOW complexity additionally receive:~Daily videoconferences for the 1st week after discharge~Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.~Patients with HIGH complexity additionally receive:~Videoconferences for at least 1 month after discharge, scheduled on an individual basis.~Remote monitoring for respiratory parameters.~One monthly phone call from the call centre to promote and assess patient self-management."
75430803|NCT01513005|Procedure|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~position of 4 trocars and insertion of a nasogastric tube~dissection and mobilization of the greater curvature of the stomach~preparation of the stomach for division~gastric partition~extraction of the gastric remnant~postoperative surveillance"
75727455|NCT01005381|Dietary Supplement|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
75727456|NCT01005381|Dietary Supplement|Calcium Placebo|"Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily."
75727457|NCT05080335|Other|Short videos|"As an educational RCT, the didactic content will be the same across the four arms, but its deliver will vary by:~TRANS- vs CIS-gender female instructors~With or without short videos of transgender youth embedded into the didactic [TV or CV]; for the group with no embedded videos [NV], the same videos will be shown AFTER completion of the post measures)~No-intervention control, in which TV will be delivered *after* collection of pre/post measures."
75727458|NCT01002183|Drug|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
75727459|NCT05734209|Behavioral|Virtual food|Virtual food eaten using immersive virtual reality equipment
75727460|NCT05734209|Behavioral|Real food|Real food eaten using regular utensils
75727461|NCT05154279|Drug|Terlipressin|intramyometrial terlipressin vs carbitocin vs saline as placebo
75727462|NCT05734131|Other|Bio-psychosocial assessment|Kinematic parameters were analyzed by two functional tests, the 10-Meter Walking Test (10MWT) and the Time Up&Go test (TUG).
75727463|NCT01005537|Biological|aldesleukin|Given IV and orally
76024808|NCT02085863|Drug|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
75879044|NCT01316965|Behavioral|Multifaceted prevention program HELP(Hospital Elder Life Program)|"A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium."
75879045|NCT01332617|Drug|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"Simvastatin 80 mg PO daily starting day -2 through day 10.~Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
75879046|NCT03569696|Biological|nivolumab|The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
75879047|NCT01343797|Other|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
75430804|NCT01513018|Other|high tidal volumes|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
75727464|NCT01005537|Biological|therapeutic autologous lymphocytes|Given IV
75879048|NCT00092573|Drug|MK0653, ezetimibe|
75879049|NCT00092573|Drug|Comparator: fenofibrate monotherapy|
75727465|NCT01005537|Drug|cyclophosphamide|Given IV
75727466|NCT01005693|Other|questionnaire administration|
75727467|NCT01005693|Procedure|cognitive assessment|
75727468|NCT01005693|Procedure|examination|
75727469|NCT01005693|Procedure|management of therapy complications|
75727470|NCT01002417|Drug|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
75727471|NCT01002417|Drug|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
75727472|NCT01002417|Drug|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
75577359|NCT06213766|Diagnostic Test|Cognitive assessment|"Group 1: Cognitively healthy subject:~After signing the consent form, during the only visit of the study, the investigator will administer to cognitively healthy subjects two cognitive screening tests to ensure that they meet the criteria for group 1. If performance on the cognitive scales prove to be borderline or below current standards (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15) for at least one of the 2 tests, the participant will prematurely end the study and may be offered an in-depth cognitive assessment as part of routine care.~Group 2: Patients suffering from Alzheimer's disease:~After signing the consent form, during the only visit of the study, the investigator will administer to patients the Montreal Cognitive Assessment to assess cognitive status."
75577360|NCT06213766|Other|Questionnaires|"For every participants (group 1 and 2):~During the only visit of the study and after the intervention 1, the participants will answer questionnaires about:~Demographic data such as age, gender, weight, height, education level;~Lifestyle habits such as usual mode of transport, sense of direction, use of GPS device, and video game practice;~Quality of sleep over the previous month and the previous night;~Cognitive reserve questionnaire from Rami et al., 2011;~Concomitant treatment and comorbidities."
75727473|NCT01002495|Biological|VM202|Endocardial injections on Day 0.
75879050|NCT01342939|Other|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
75430805|NCT01513018|Other|low tidal volume|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
75879051|NCT01342939|Other|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
75430806|NCT01513031|Other|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
76049328|NCT04414462|Other|training - Group II|"Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks."
76049329|NCT01816048|Drug|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
75430807|NCT01513044|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
75430808|NCT01513044|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
75430809|NCT01513057|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
75430810|NCT01513057|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
75430811|NCT01513070|Drug|Quick-Acting Heart Reliever|Quick-Acting Heart Reliever，200mg，tid，po. for six months
75430812|NCT01513070|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate，10mg，tid，po. for six months
75430813|NCT01513070|Drug|Placebo of Isosorbide Dinitrate|Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
75727474|NCT01005771|Drug|GF-001001-00|GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
75727475|NCT01005771|Drug|Placebo|Matching placebo
75727476|NCT01005849|Dietary Supplement|Protecflor|1 Capsule to be taken once a day during the entire study period
75727477|NCT01005849|Dietary Supplement|Placebo|1 Capsule to be taken once a day during the entire study period
75727478|NCT01005927|Dietary Supplement|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
76049330|NCT01816048|Radiation|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
76049331|NCT01816048|Procedure|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
76049332|NCT01816048|Procedure|Computed Tomography|Undergo 18F NaF PET/CT scan
76049333|NCT01612858|Drug|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
76049334|NCT01612858|Drug|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
75430814|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
75577361|NCT06213766|Device|Spatial navigation task with eye-tracking.|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1 and 2, the participants will complete the spatial navigation task with eye-tracking.~The participants will play the Sea Hero Quest video game and take on the role of the captain of a small boat that has to find its way through an aquatic environment. At the start of each level, the player is shown a map of the environment, with the boat's initial position and the buoys it must reach as quickly as possible in a set order. Once the map has been memorised, it disappears and the navigation begins.~Participants will play 6 levels of Sea Hero Quest (two training levels and four different navigation levels). This intervention will be proposed by a trained team member and participants will play on a digital tablet connected to an eye-tracker. The total duration of the task is 30 min (training phase + assessment sequences)."
75727479|NCT03742713|Drug|CPC634 (CriPec® docetaxel)|Docetaxel containing CriPec® nanoparticles
75727480|NCT01002651|Dietary Supplement|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
75727481|NCT01002651|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
75727482|NCT05733429|Other|eye cervical re-education|patients will receive eye-cervical re-education in the form of 10 exercises at three phases; the first phase will include stimulation of ocular mobility, the second phase will consist of Cervical mobility exercise with restricted eye movement and the third phase will include stimulation of eye and neck movement co-ordination
75727483|NCT05733429|Other|motor imagery therapy|the patients will receive motor imagery therapy for four weeks; the first week will receive kinesthetic imagery, the second week will receive visual imagery, the third week will receive action observation exercises with motor imagery and the fourth week will receive motor control exercises in front of a mirror.
75879052|NCT01342939|Dietary Supplement|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
75879053|NCT01342939|Other|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
75879054|NCT01342939|Other|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
75430815|NCT01513070|Drug|Placebo of Quick-Acting Heart Reliever|Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months
75430816|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
75430817|NCT01513083|Drug|trastuzumab emtansine|Multiple intravenous doses
75430818|NCT01513096|Drug|itopride|itopride, 10mg, twice per day, for 1 day
75430819|NCT01513109|Biological|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|i.m. administration
75430820|NCT01513135|Biological|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
75430821|NCT01513135|Biological|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
75430822|NCT01513161|Drug|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
75727484|NCT05733429|Other|conventional physical therapy|the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
75727485|NCT01002729|Other|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI < 30 given Oseltamivir
75727486|NCT01002729|Other|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI > 40 given Oseltamivir
75879055|NCT03392090|Other|More Good Days video&brief questionnaire|Help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments
75879056|NCT04376983|Behavioral|Telerehabilitation for patients with a cardiac resynchronisation device|Using the device-measured physical activity to create tailored motivational messages and tips to the patients to increase physical activity
75430823|NCT01513161|Drug|Placebo|
75430824|NCT01513174|Drug|Gefitinib|Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
75430825|NCT01513174|Drug|Gefitinib plus olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
75430826|NCT01513200|Drug|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
75727487|NCT01002807|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
75727488|NCT01002807|Drug|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
75727489|NCT01002807|Drug|Glucophage|Tablets, Oral, 1000 mg, Single Dose
75727490|NCT01002963|Drug|PF-04418948|solution, 30 mg, single
75727491|NCT01002963|Drug|PF-04418948|solution, 100 mg, single
75727492|NCT01002963|Drug|PF-04418948|solution, 300 mg, single
75577362|NCT06213766|Biological|Blood sampling|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1, 2 and 3, a state-qualified nurse will take venous samples from 3 tubes of 4ml each.~These blood samples will be frozen and stored until the end of the study when they will be analysed:~Sample 1: plasmatic Quanterix p-tau217 assay;~Sample 2: apolipoprotein E genotyping;~Sample 3: measurement of plasmatic creatinine levels. Neither the cognitively healthy subjects, nor the patients, nor the clinicians in charge of the patients included will be informed of the results of these biological assays (absence of clinical interest established at the present time of the APOE genotype and the p-tau217 protein level, absence of modification of the care pathway, in adequacy to the bioethics law of August 02, 2021. Creatinine level is used in this study as an adjustment variable to interpret the p-tau217 protein level and will not be used for clinical interpretation."
75430827|NCT01513200|Drug|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
75430828|NCT01513200|Drug|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
75430829|NCT01513226|Other|Cycled light|lights on at daytime, lights off at nighttime
75430830|NCT01513252|Behavioral|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
76049335|NCT04585984|Dietary Supplement|Experimental - Probiotic|Patients in the experimental group will take one compound (pill) a day for 21 days, containing a 50% combination of two probiotics: Lactobacillus rhamnosus and Bifidobacterium longum, at a dose of 10^9 cfu/day. The carrier of lyophilized probiotics is maltodextrin and the mixture is encapsulated in hypromellose capsules.
75430831|NCT01513265|Other|Pharmaceutical care plan, mostly based on the RASP|Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
75430832|NCT01513278|Drug|APN201|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
75577363|NCT06212349|Other|therapeutic-educational physiotherapy and pain education program|The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
75879057|NCT01332695|Drug|ST101|tablets for oral administration
75879058|NCT01332695|Drug|Placebo|placebo to match
75879059|NCT03569540|Drug|Glibenclamide|Placebo-controlled; Double blind test
75879060|NCT03569540|Other|Placebo|Amylum
75879061|NCT04376437|Drug|medical cannabis|inhalation by using a Portable Metered-Dose Cannabis Inhaler
76049336|NCT04585984|Dietary Supplement|Placebo|Patients in the control group will take one unit of placebo a day for 21 days.
76049337|NCT01612780|Device|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
75577364|NCT06212349|Other|pain education program|They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
75577365|NCT06208787|Behavioral|Neurofeedback training|Neurofeedback training involving auditory feedback upon measurement of non-harmonic alpha-theta ratios during focused attention meditation
75430833|NCT01513278|Drug|Placebo|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
75577366|NCT06208787|Behavioral|Sham Training|Sham neurofeedback involving auditory feedback at random timepoints during focused attention meditation such that no learning can take place
75577367|NCT06208592|Device|Sevoflurane with AnaConDa|Sevoflurane administered with AnaConDa device
75577368|NCT06207877|Drug|Cagrilintide|Cagrilintide will be administered subcutaneously.
75577369|NCT06207877|Drug|Semaglutide|Semaglutide will be administered subcutaneously.
75577370|NCT06207877|Drug|Placebo|Placebo will be administered subcutaneously.
75577371|NCT06207110|Behavioral|Regulation of Cues|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to improve satiety responsiveness and decrease food cue responsiveness. This arm will include an experiential component, including hunger monitoring during a meal or snack and participating in exposure exercises.
75577372|NCT06207110|Behavioral|Family Based Behavioral Treatment|FBT provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.
75430834|NCT01513304|Procedure|Manual therapy|
75430835|NCT01513356|Drug|BKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
75430836|NCT01513369|Drug|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
75430837|NCT01513369|Drug|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
75430838|NCT01513382|Procedure|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
75577373|NCT06207110|Behavioral|Regulation of Cues +|ROC+ includes all of the skills provided in ROC but integrates nutrition education and reducing energy intake
75577374|NCT06207110|Behavioral|Health Education|The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
75577375|NCT06206460|Other|Online Assessment|"Online Assessment which consists of:~Sociodemographic data (life changes, medical and gynaecological history)~German PMS symptom diary retrospectively for last menstrual cycle~Quality of Life Inventory (SF-12)~Expectancy of relief"
75577376|NCT06206005|Other|Observational study|evaluate implant survival, peri-implant outcome of 4 implant retained mandibular OVD after 10 years of function.
75577377|NCT06205628|Drug|ADX-850|siRNA duplex oligonucleotide
75577378|NCT06205628|Drug|Placebo|Saline
75577379|NCT06205628|Drug|Angiotensin Receptor Blockers|Angiotensin receptor blocker
75577380|NCT06205407|Drug|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris|Manufactured at Viatris
75577381|NCT06205407|Drug|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.|Manufactured at Neolpharma.
75727493|NCT01002963|Drug|PF-04418948|solution, 1000 mg, single
75727494|NCT01002963|Drug|PF-04418948|solution, 3000 mg, single
75879062|NCT01335893|Drug|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
75727495|NCT01002963|Drug|PF-04418948|solution, 4500 mg, single
75727496|NCT01002963|Drug|PF-04418948|solution, 6000 mg, single
75727497|NCT01006161|Drug|SCH 527123|Low dose
75727498|NCT01006161|Drug|SCH 527123|Medium dose
75727499|NCT01006161|Drug|SCH 527123|High dose
76024809|NCT02085863|Drug|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
75577382|NCT06205368|Device|Combine mobile app|"HIV/STI testing: learn more about testing options; create a plan to test 1-4 times in the coming year; locate places for those tests and/or order at-home test kits; and schedule reminders for periodic testing~Pre-exposure prophylaxis: PrEP self-assessment at first app use; monthly rescreening for PrEP eligibility; recommendation for PrEP based on Centers for Disease Control and Prevention (CDC) criteria; PrEP provider locator.~Behavioral risk assessment: e.g. HIV risk behaviors; sex while drunk or high, condomless anal intercourse with a positive or unknown HIV status partner, multiple sex partners, recent STI diagnosis, use of drugs) and protective behaviors~Non-occupational post-exposure prophylaxis (nPEP): information about nPEP; self-assessment; locator; referral to PrEP for men who evaluate multiple exposures for nPEP indication~Product ordering: participants can order condoms, condom-compatible lubricants, and at-home STI specimen collection kits."
75577383|NCT06205368|Behavioral|Motivational interview|The interview will be grounded in the Social Cognitive Theory of self-regulation (SCT) to reflect the underlying theory of the Combine app. It will be designed to enhance the effectiveness of the app by highlighting app features (e.g., frequently asked questions, product ordering, testing locators) and discussing strategies for following through on goals related to sexual health (e.g., creating and adhering to a testing plan)
75577384|NCT06205368|Diagnostic Test|HIV/STI testing|Participants will be able to order free HIV/STI self-test kits; they will be able to order up to two sets of kits during each of years 1 and 2 of follow-up. HIV and STI test kit orders are independent: ordering an HIV test kit does not trigger shipment of an STI kit and vice versa. When an order is placed, kits containing biospecimen self-collection tools are shipped directly to the participant along with written instructions and a link to video instructions on how to collect each of the samples (e.g., urine, rectal, blood). Return packaging is enclosed with instructions for participants to locate a drop-off location to return their samples to the lab.
75577385|NCT06203847|Drug|Combination group|Combination of epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)
75577386|NCT06203847|Drug|Standard group|standard doses of epinephrine (Adrenaline® 1mg/vial) every 3 minutes
75577387|NCT06202040|Procedure|Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.|The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.
75577388|NCT06202040|Procedure|Bilateral Rectus Sheath Block (RSB) will be performed.|When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.
75430839|NCT01513395|Behavioral|Interval bladder emptying|"Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time."
75727500|NCT01006161|Drug|SCH 527123|Placebo to match SCH 527123
75430840|NCT01513421|Procedure|Percutaneous drainage of intra-abdominal collection|"Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist"
75727501|NCT05733195|Other|OGTT test|The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.
75727502|NCT05733117|Drug|Vitamin D|cholecalciferol
75727503|NCT01003119|Behavioral|Addiction CHESS|Smartphone with ACHESS application loaded onto the phone.
75727504|NCT01006239|Other|No study intervention|The is no study related intervention.
76049338|NCT01612702|Drug|Dexamethasone|Dexamethasone 10 mg intravenous administration
75430841|NCT01513434|Procedure|transtibial technique|Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.
75430842|NCT01513434|Procedure|Transportal technique|Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.
75430843|NCT01513434|Procedure|anterior cruciate ligament reconstruction|femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
75727505|NCT01006317|Behavioral|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
75430844|NCT01513486|Behavioral|immobilization|
75727506|NCT01006317|Behavioral|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
75879063|NCT03567278|Device|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
75430845|NCT01513499|Drug|Oxytocin|Intranasal oxytocin 24 IU single-dose administration
75879064|NCT01339169|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
75430846|NCT01513499|Drug|Placebo|Intranasal Placebo single-dose administration
75879065|NCT05251441|Dietary Supplement|Breast Milk Fortifier supplements|Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
75430847|NCT01513525|Drug|liraglutide|Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
75430848|NCT01513564|Drug|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
76024810|NCT02402725|Drug|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
75430849|NCT01513564|Drug|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
75430850|NCT01513577|Other|Pedicle screws|The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
75430851|NCT01513577|Other|Percutaneous stab incisions|The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
75430852|NCT01513603|Drug|CLAG-M|IV times 5 days
75430853|NCT01513603|Drug|CLAG-M|Chemotherapy
75430854|NCT01513616|Other|Pulmonary rehabilitation|8-week program, 3 supervised session per week
75430855|NCT01513616|Other|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
75430856|NCT01513642|Behavioral|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
75727507|NCT01006317|Other|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
75727508|NCT01006395|Drug|Zoledronic acid|yearly infusion
75727509|NCT01006395|Drug|Placebo|yearly infusion
75727510|NCT03999801|Genetic|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab
75577389|NCT06201689|Dietary Supplement|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
75577390|NCT06201689|Dietary Supplement|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
75879066|NCT03567200|Behavioral|Single-Arm Feasibility|Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
75879067|NCT01332773|Procedure|Artery first procedure|early identification of SMA to evaluate infiltration
75430857|NCT01513655|Device|LTNIV|LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
75430858|NCT01513668|Drug|Acetaminophen|Extended release Gel tabs 650 mg
75430859|NCT01513681|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
75430860|NCT01513681|Drug|Lamictal®|Lamictal® 200 mg Tablets
75430861|NCT01513694|Procedure|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
75577391|NCT06201689|Dietary Supplement|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
75430862|NCT01513720|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
75430863|NCT01513720|Drug|Lamictal®|Lamictal® 200 mg Tablets
75430864|NCT01513733|Drug|tasquinimod|tasquinimod 0.25 mg continuously
75430865|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
75430866|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
75430867|NCT01513772|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
75430868|NCT01513772|Drug|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
75430869|NCT01513785|Drug|Rabeprazole and Amoxicillin|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
75430870|NCT01513785|Drug|Amoxicillin and Rabeprazole|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
75430871|NCT01513798|Behavioral|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
75577392|NCT06199466|Drug|Gemcitabine|Given by IV
75577393|NCT06199466|Drug|Nab-paclitaxel|Given by IV
75577394|NCT06199466|Drug|YL-13027|Given by PO
75577395|NCT06199297|Drug|Atezolizumab combined with Bevacizumab|Atezolizumab 1200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
75879068|NCT01332773|Procedure|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
75879069|NCT04371679|Other|No interventions planned|No interventions planned. Observational.
75879070|NCT03567512|Behavioral|Smoking hygiene intervention|The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (~20 minutes), 2 week telephone counseling (~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (~20 minutes), and 4 month telephone counseling (~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).
75879071|NCT03567512|Behavioral|Placebo intervention|"The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (~20 minutes), 2 week telephone counseling (~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (~20 minutes), and 4 month telephone counseling (~20 minutes)."
76049339|NCT02431559|Drug|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
76049340|NCT02431559|Drug|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
76049341|NCT02431559|Drug|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
75430872|NCT01513798|Behavioral|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
75430873|NCT01513811|Drug|Polyethylene glycol electrolyte solutions|Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
75430874|NCT01513811|Drug|Itopride and Polyethylene glycol electrolyte solutions|Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
75430875|NCT01513811|Drug|itopride and polyethylene glycol electrolyte solutions|Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
75430876|NCT01513824|Behavioral|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
75430877|NCT01513850|Drug|Hepabulin IV|I.V.
75577396|NCT06199297|Drug|Sintilimab combined with Bevacizumab|Sintilimab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
76049342|NCT02388269|Device|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
76049343|NCT01652573|Drug|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
76049344|NCT01652573|Drug|Saline Nasal Spray Placebo|
75430878|NCT01513863|Drug|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
75430879|NCT01513863|Drug|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
76049345|NCT02388191|Drug|Naproxen sodium|550 mg, oral, on day 1. Number of Cycles: 1
76049346|NCT02388191|Other|Placebo tablet|
76049347|NCT01815736|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
76049348|NCT01815736|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
76049349|NCT01815736|Drug|EFV/FTC/TDF|600/200/300 mg FDC tablet administered orally once daily
76049350|NCT01815736|Drug|RTV|100 mg tablet administered orally once daily
76049351|NCT01815736|Drug|ATV|300 mg capsule administered orally once daily
76049352|NCT01815736|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
75430880|NCT01513863|Drug|Placebo|Placebo applied to affected area once a day for 70 days
75430881|NCT01513915|Other|Group cognitive behavioral intervention|A Group cognitive behavioral intervention _based on parent training component of FRIENDS program_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
75430882|NCT01513928|Drug|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
75430883|NCT01513928|Drug|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
75430884|NCT01513928|Drug|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
75430885|NCT01513941|Drug|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
75430886|NCT01513941|Drug|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
75430887|NCT01513941|Drug|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
75430888|NCT01513980|Procedure|self-monitoring for patients with severe COPD|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients"
75430889|NCT01513980|Procedure|nurse-monitoring for patients with severe COPD|A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
75430890|NCT01513993|Procedure|Telemonitoring for patients with Congestive Heart Failure|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms."
75430891|NCT01514019|Drug|Acebutolol|Acebutolol
75430892|NCT01514019|Drug|Placebo|Placebo capsule(Capsules filled up with lactose)
75430893|NCT01514032|Procedure|Extracorporal shockwave lithotripsy|Extracorporal shockwave lithotripsy
75430894|NCT01514032|Procedure|Retrograde intrarenal surgery|Retrograde intrarenal surgery
75577397|NCT06199297|Procedure|Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy|The chemoembolization process employed 30 mg/m2 of epirubicin and 2-10 mL of lipiodol. This was followed by FOLFOX-based HAIC, including 85 mg/m2 of oxaliplatin, 400 mg/m2 of leucovorin, and an initial bolus of 400 mg/m2 of 5-FU for 2 h, which was then followed by a sustained infusion of 1200 mg/m2 5-FU for 23 h.
75430895|NCT01514058|Procedure|EUS-FNA first, followed by CRCP with bilinary stenting|EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)
75577398|NCT06194461|Biological|AZD5851|Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.
75577399|NCT06192563|Drug|Dupilumab|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
75577400|NCT06192017|Diagnostic Test|WomEC|The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.
75727511|NCT01003353|Behavioral|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
75430896|NCT01514058|Procedure|ERCP with stent placement, followed by EUS-FNA|ERCP with stent placement, followed by EUS-FNA
75430897|NCT01514071|Behavioral|Pop-up picture|"An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will pop-up when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either meets criteria or does not meet criteria in order to close the animated picture window."
75430898|NCT01514110|Drug|RAD001|Pharmacology of RAD001 as a combination partner for conventional agents.
75430899|NCT01514123|Drug|VGX-100|VGX-100 will be administered by IV infusion once every week
75430900|NCT01514123|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
75430901|NCT01514175|Drug|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
75430902|NCT01514175|Drug|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
75430903|NCT01514188|Drug|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
75430904|NCT01514188|Drug|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
75430905|NCT01514214|Device|WInged perimeter biliary stent insertion (Viaduct)|Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
75430906|NCT01514214|Device|traditional polyethylene stent insertion (Cotton Huibregtse)|insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
75430907|NCT01514227|Drug|Aspirin or thienopyridine|Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
75430908|NCT01514227|Drug|Aspirin and thienopyridine|Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
75577401|NCT06190093|Biological|bevacizumab|1.25 mg, intravitreal injection
75577402|NCT06190093|Biological|ranibizumab|0.5mg, intravitreal injection
75577403|NCT06180356|Drug|Niraparib oral tablets|Niraparib: 300 or 200 mg, according to body weight or platelet count. Tablets will be taken orally, once daily, continuously (in 28-day cycles).
75577404|NCT06177912|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
75727512|NCT05732805|Biological|BCD-217|Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
75727513|NCT05732805|Biological|BCD-100|Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
75727514|NCT05732805|Biological|Placebo|Placebo
76049353|NCT01815736|Drug|COBI|150 mg tablet administered orally once daily
75430909|NCT01514253|Drug|Glucose 25%|1 ml glucose 25%, once
75430910|NCT01514253|Dietary Supplement|Materna RTF Stage 1|1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
75430911|NCT01514253|Other|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
75430912|NCT01514266|Drug|Curcumin+Bioprine|The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
75430913|NCT01514266|Drug|Placebo|
75430914|NCT01514331|Other|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
75430915|NCT01514331|Other|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
75430916|NCT01514409|Dietary Supplement|5-Hydroxytryptophan|"Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia."
75430917|NCT01514409|Dietary Supplement|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
75577405|NCT06177912|Biological|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
75577407|NCT06174480|Other|Cryostimulation|Cryostimulation (-50°C, forced ventilation for 3 minutes) during 20 sessions over 2 weeks.
75577408|NCT06170788|Biological|MK-2870|IV infusion
75577409|NCT06170788|Biological|Pembrolizumab|IV infusion
75577410|NCT06169371|Drug|Abemaciclib|Week 1 50mg orally BID
75577411|NCT06169371|Drug|Abemaciclib|Week 2 100mg orally BID
75577412|NCT06169371|Drug|Abemaciclib|Week 3 150mg orally QAM, 100mg orally QHS
75577413|NCT06169371|Drug|Abemaciclib|Week 4 150mg orally BID
75430918|NCT01514435|Device|Electroconvulsive therapy|treatment for major depression
75430919|NCT01514435|Device|18-Fluoro-desoxy-glucose positron emission tomography|"intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique."
75430920|NCT01514487|Drug|liraglutide|One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
75430921|NCT01514500|Drug|somapacitan|Administered s.c. (subcutaneously, under the skin)
75430922|NCT01514500|Drug|placebo (somapacitan)|Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
75430923|NCT01514526|Drug|Dovitinib|"Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.~The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal."
75430924|NCT01514539|Other|cross-sectional|"Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity."
75430925|NCT01514578|Drug|TRV130A|Intravenous infusion of 1 hour duration
75430926|NCT01514578|Drug|Dextrose in Water|Intravenous infusion of 1 hour duration
75430927|NCT01514617|Procedure|Diffusion -and perfusion weighted MRI including iv contrast agent injection|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patients before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for reason not eligible for the study.~During the MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
75430928|NCT01514695|Drug|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
75430929|NCT01514695|Drug|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
75430930|NCT01514695|Other|Placebo|One dose of saline (2ml)
75577414|NCT06169072|Drug|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
75577415|NCT06169072|Device|Technetium99|Technetium99 +/- blue dye is injected per routine as a comparator and as back up.
75577416|NCT06168058|Diagnostic Test|Transcatheter Venography|Venographic assessment of ovarian veins and internal iliac veins
75727515|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous [IV] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
76024811|NCT02054351|Drug|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
76024812|NCT02394145|Drug|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
75430931|NCT01514708|Biological|AdimFlu-S Influenza Vaccine|Suspension for injection
75577417|NCT06168058|Procedure|Bilateral ovarian vein embolization|Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.
76024813|NCT02394145|Drug|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
75430932|NCT01514721|Drug|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
75577418|NCT06166732|Behavioral|Music-based Mindfulness|The participants will receive a single 20-minute music-based mindfulness session in person. The participants will listen to instrumental music during the session.
75577419|NCT06166732|Behavioral|Control Group|The participants will receive a single 20-minute information session in person. The information session will introduce the definition, history, basic concepts, and benefits of mindfulness practice.
76049354|NCT01651949|Biological|9vHPV Vaccine|9vHPV, V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
76049355|NCT02387957|Drug|Fovista®|
76049356|NCT02387957|Drug|bevacizumab|
76049357|NCT02387957|Drug|ranibizumab|
75430933|NCT01514799|Procedure|gastric bypass|two techniques of gastric bypass for studying the effects of making a long BP-limb
75430934|NCT01514812|Drug|YM150|oral - modified release formulation of YM150
75430935|NCT01514812|Drug|placebo|oral
75430936|NCT01514812|Drug|digoxin|oral
75430937|NCT01514825|Drug|YM150|oral
75430938|NCT01514825|Drug|Placebo|oral
75430939|NCT01514838|Drug|ASP1941|oral
75430940|NCT01514838|Drug|acarbose|oral
75430941|NCT01514838|Drug|Placebo|oral, used only during placebo run-in period
75430942|NCT01514851|Drug|Lanthanum carbonate (BAY77-1931)|
75430943|NCT01514851|Drug|Calcium carbonate|
75430944|NCT01514877|Drug|Icotinib|Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
75430945|NCT01514916|Device|mechanical anastomosis without suture|The Vascular Join device is intended to be used to create sutureless end-to-end anastomosis between an artery and a venous or synthetic graft conduit. Any type of e-PTFE and Dacron conduits can be used.
76049358|NCT02387957|Drug|aflibercept|
76049359|NCT01800916|Device|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
76049360|NCT01800916|Device|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
75430946|NCT01514929|Drug|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
76049361|NCT01800916|Device|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
76049362|NCT01800916|Device|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
76049363|NCT01815580|Drug|Atripla or Stribild|Antiretroviral therapy
76049364|NCT01799590|Drug|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
76049365|NCT04902131|Drug|A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL|Single dose cross-over bioequivalence trial
76049366|NCT04902131|Drug|A MENOPUR powder including solvent for solution for injection, 75 IU|Single dose cross-over bioequivalence trial
76049367|NCT01815424|Drug|placebo|placebo BID for 16 weeks and then re-randomized into active groups
76049368|NCT01815424|Drug|CP-690,550|CP-690,550 5mg BID for 52 weeks
76049369|NCT01815424|Drug|CP-690,550|CP-690,550 10mg BID for 52 weeks
76049370|NCT02431247|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
76049371|NCT02431247|Drug|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
75430947|NCT01514929|Drug|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
75430948|NCT01514929|Drug|Moxifloxacin|400mg oral pill given once
75430949|NCT01514929|Drug|Placebo|Placebo oral pill given once
75430950|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
75430951|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
75430952|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
75430953|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
76049372|NCT02431247|Drug|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
76049373|NCT02431247|Drug|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
76049374|NCT02431247|Drug|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
76049375|NCT02431247|Drug|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
76049376|NCT01814878|Drug|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl [75 mg]/acetaminophen [650 mg]) will be administered at 0, 12, 24 and 36 hours
76049377|NCT01814878|Drug|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl [37.5 mg]/acetaminophen [325 mg]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
75577430|NCT06155344|Other|Food Frequency Questionnaire|We will obtain a global index of vegetalization of the diet (the Plant based Diet Index: PDI) from data obtained using semi-quantitative questionnaires on food frequency (Food Frequency Questionnaire (FFQ)) validated on the national ELFE cohort (French Longitudinal Study from Childhood (https://www.elfe-france.fr)) and completed by women in the 1st trimester of pregnancy (T1) and at delivery.
75577431|NCT06155344|Other|Collection of 4 mL maternal blood|One tube collection of 4 mL maternal blood in the first trimester and at delivery.
75577432|NCT06154824|Other|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
75577433|NCT06154824|Other|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
75577434|NCT06153966|Drug|ION717|ION717 will be administered by IT injection.
75577435|NCT06153966|Drug|Placebo|Placebo-matching ION717 will be administered by IT injection.
75577436|NCT06153693|Drug|Placebo|Placebo once daily (QD) for 12 weeks
75577437|NCT06153693|Drug|lorundrostat Dose 1|50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
75577438|NCT06153693|Drug|lorundrostat Dose 2|50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
76049378|NCT02407457|Device|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
76049379|NCT02407457|Device|FDA Approved EVAR AAA Graft Systems|
76049380|NCT01814800|Biological|RI-002|Immune Globulin Intravenous (IGIV)
76049381|NCT01814332|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
75727516|NCT00615056|Drug|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous [IV] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
76049382|NCT01814332|Drug|Placebo|Placebo compound treatment for comparison with IP
75430954|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
75430955|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
75430956|NCT01514955|Radiation|Gold seeds insertion to detect movements at pelvis|
75430957|NCT01514955|Radiation|Image guided MRI based RT (IMRT+Brachytherapy)|
75430958|NCT01514968|Drug|cyclosporine|Single oral dose
75577443|NCT06148974|Dietary Supplement|Polar lipid 1|15g plant polar lipids from plant source 1. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
75577444|NCT06148974|Dietary Supplement|Polar lipid 2|15g plant polar lipids from plant source 2. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
75577445|NCT06148974|Dietary Supplement|Non-polar lipids|15g non-polar plant lipids from plant source 1. The lipids supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
75577446|NCT06148974|Other|No lipids|A commercial white wheat flour bread as a source of available carbohydrates (50 g), without added lipids.
76049383|NCT02407223|Drug|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
75430959|NCT01514968|Drug|danoprevir|Single oral dose
75430960|NCT01514968|Drug|ritonavir|Single oral dose
75430961|NCT01514981|Drug|AMG 761|Single dose of AMG 761 on study day 1.
75430962|NCT01514981|Drug|Placebo|Single dose of placebo on study day 1.
75430963|NCT01514994|Device|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
75430964|NCT01515020|Drug|vancomycin monotherapy|intravenous therapy by vancomycin
75430965|NCT01515020|Drug|daptomycin monotherapy|intravenous therapy by daptomycin
75577447|NCT06141369|Biological|individualized mRNA neoantigen vaccine (mRNA-0523-L001)|Individualized mRNA neoantigen vaccine (mRNA-0523-L001) will be injected intramuscularly every 21 days for 9 cycles. Dose escalation will be administered in 3 patients. 18 additional patients will be recruited and administered at the maximum tolerated(MTD) dose for all nine cycles.
76049384|NCT02407223|Drug|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
76049385|NCT02407223|Drug|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
76049386|NCT01797562|Diagnostic Test|Panels 1.3, 2.2 and 3.2 experimental allergens|Three allergen panels will be applied to the upper backs of study subjects and will be worn for 48 hours. Allergen test sites will be evaluated at 3, 4, 7(±1) and 21(±2) days post application.
76049387|NCT04602754|Drug|BERLIM 25/20 ASSOCIATION|Berlim 25/20 association coated tablet.
75430966|NCT01515033|Other|aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
76049388|NCT04602754|Other|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
76049389|NCT04602754|Other|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin calcium placebo coated tablet.
76049390|NCT04602754|Drug|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
75577448|NCT06136624|Drug|MK-5684|Administered orally
75727517|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
76049391|NCT04602754|Drug|ROSUVASTATIN CALCIUM|Rosuvastatin 20 mg coated tablet.
76049392|NCT04602754|Other|BERLIM 25/20 ASSOCIATION PLACEBO|Berlim 25/20 association placebo coated tablet.
76049393|NCT01813474|Drug|olaparib|tablet oral
76049394|NCT01868542|Drug|insulin detemir|Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
76049395|NCT01797094|Biological|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
75430967|NCT01515085|Procedure|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
75577449|NCT06136624|Drug|Abiraterone acetate|Administered orally
75577450|NCT06136624|Drug|Enzalutamide|Administered orally
75577451|NCT06136624|Drug|Hydrocortisone|Administered orally or IM as a rescue medication
75577452|NCT06136624|Drug|Fludrocortisone acetate|Administered orally
75577453|NCT06136624|Drug|Prednisone|Administered orally
75430968|NCT01515163|Behavioral|Exercise training|Aerobic exercise training, two times a week
75430969|NCT01515202|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
75430970|NCT01515202|Drug|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
75430971|NCT01515202|Drug|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
75727518|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion [IV] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
75879072|NCT01339325|Procedure|Cholecystectomy|"Standard laparoscopic cholecystectomy The first cannula is inserted with an open laparoscopy technique. LCs are performed with either HF or US energized dissection, standard or fundus-first gallbladder dissection, closure of the artery by ligature/clip or US, closure of cystic duct by ligature/clip.~Laparo-endoscopic single site cholecystectomy~The TriPort device is inserted at the navel site through a 15 to 25 mm incision with an open laparoscopy technique. Two working instruments are inserted (one grasper and one energised device) through the TriPort. A further 1.8 or 3 mm instrument inserted through the larger gel valve, parallel to a 5 mm dissecting instrument, is used in some cases to enhance exposure. Gallbladder dissection is accomplished either after preparation of the cystic duct and artery or with a fundus-first technique, by means of HF electrosurgery or US shears.The cystic artery is divided between clips or by US scissors. The duct is divided between clips."
75879073|NCT03569462|Behavioral|"Mobile WeChat intervention"|Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
76049396|NCT01797094|Biological|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
76049397|NCT02383589|Drug|Mycophenolate Mofetil Placebo|MMF matching placebo will be administered orally Q12H.
76049398|NCT02383589|Drug|Mycophenolate Mofetil|MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
75430972|NCT01515202|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
75430973|NCT01515202|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
75430974|NCT01515215|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
75430975|NCT01515228|Device|Xience Prime|everolimus-eluting stent implantation
75430976|NCT01515228|Device|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent implantation
75430977|NCT01515254|Behavioral|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
75727519|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
75879074|NCT03569462|Behavioral|Control condition|Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
76049399|NCT02383589|Drug|Rituximab|Rituximab will be administered at a dose of 1000 mg via IV infusion.
76049400|NCT02383589|Drug|Rituximab Placebo|Rituximab matching placebo will be administered via IV infusion.
76049401|NCT01810432|Drug|Evacetrapib|Administered orally
75430978|NCT01515293|Procedure|Single Incision Laparoscopic Appendectomy|
76049402|NCT01810432|Other|High-fat Meal|Administered orally, at breakfast.
76049403|NCT01796860|Other|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
76049404|NCT01796548|Drug|Oxybutinin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
76049405|NCT02406677|Other|Study voucher card|Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
76049406|NCT02404805|Drug|dolutegravir|dolutegravir tablets 50mg, once daily x 7 days.
76049407|NCT02404805|Drug|simeprevir|simeprevir tablets 150mg, once daily x 7 days.
76049408|NCT02430311|Drug|Olaparib|Tablet-150mg, Oral
76049409|NCT02430311|Drug|Paclitaxel|Injection
76049410|NCT02430311|Drug|Olaparib|Tablet-100mg, Oral
76049411|NCT02404649|Device|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
75430979|NCT01515293|Procedure|Conventional appendectomy|
75430980|NCT01515358|Drug|Placebo|Administered orally
75430981|NCT01515358|Drug|LY3000328|Administered orally
75430982|NCT01515371|Drug|IncobotulinumtoxinA|"Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.~For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection."
75430983|NCT01515371|Drug|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
75430984|NCT01515384|Drug|18F-AV-133|IV injection, 7.6 mCi (281.2 MBq)
75577454|NCT06136624|Drug|Dexamethasone|Administered orally as rescue medication
75577455|NCT06136598|Drug|MK-5684|Tablets to be taken orally.
75577456|NCT06136598|Drug|Dexamethasone|Tablets to be taken orally
75727520|NCT00615056|Drug|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
76049412|NCT02404649|Device|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
76049413|NCT02383355|Drug|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
75727521|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous infusion [IV] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
75727522|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
76049414|NCT02383355|Drug|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
76049415|NCT02381795|Drug|Nasal Carbon Dioxide|
76049416|NCT02404493|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
76049417|NCT02404493|Drug|1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
75430985|NCT01515397|Drug|Gelofusine balanced|Gelofusine balanced combined with Sterofundin ISO
75430986|NCT01515397|Drug|Gelofusine 4%|Gelofusine 4% combined with NaCl 0.9%
75430987|NCT01515436|Other|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
75430988|NCT01515436|Other|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
75577457|NCT06136598|Drug|Fludrocortisone|Tablets to be taken orally.
75577458|NCT06136598|Drug|Hydrocortisone|Tablet to be taken orally as a rescue medication.
75577459|NCT06132360|Drug|RN0191|This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
75577460|NCT06132256|Drug|Axatilimab|Administered as intravenous (IV) infusion
76024814|NCT03167827|Other|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
76024815|NCT03167827|Other|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
76024816|NCT03167827|Other|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
76024817|NCT03166657|Procedure|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
76024818|NCT04103099|Dietary Supplement|HLNatural Immune|Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
76024819|NCT02692417|Device|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
75430989|NCT01515501|Procedure|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
75430990|NCT01515553|Drug|liraglutide|Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
75430991|NCT01515579|Drug|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
75577461|NCT06132256|Other|Placebo|Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
75577462|NCT06131203|Device|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
76024820|NCT04091555|Dietary Supplement|HLNatural Tension|Understand the impact of the supplement on Tension Headaches
76024821|NCT02393911|Dietary Supplement|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
75430992|NCT01515579|Drug|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
75430993|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
75879075|NCT05708690|Drug|Tranexamic Acid 100 MG/ML|Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
75727523|NCT01003431|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
75727524|NCT01003431|Biological|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
75879076|NCT05708690|Drug|normal saline|Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
76024822|NCT02004886|Drug|MK-0893|10 mg and 100 mg tablets
76024823|NCT02004886|Drug|Metformin|500 mg metformin tablets
76024824|NCT02004886|Drug|Placebo|Placebo tablets matching MK-0893
76024825|NCT02004886|Drug|Placebo|Placebo tablets matching metformin
76024826|NCT02393989|Procedure|posterior restoration|restorations for caries effected teeth
75430994|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
75430995|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
75430996|NCT01515592|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
75430997|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin I
75430998|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin II
75430999|NCT01515644|Other|Powder based infant formula|Powder based infant formula without Inulin
75431000|NCT01515683|Behavioral|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
75577470|NCT06109662|Diagnostic Test|Cystatin C eGFR|Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.
75577471|NCT06109662|Other|Bioimpedance Analysis (Body composition analysis)|Participants will stand on a bioimpedance analysis machine which will measure different components of body composition
75577472|NCT06107413|Drug|ABBV-400|Intravenous (IV) Infusion
75577473|NCT06107413|Drug|Bevacizumab|IV Infusion
75577474|NCT06107413|Drug|Folinic Acid|IV Infusion
75577475|NCT06107413|Drug|Fluorouracil|IV Infusion
75577476|NCT06107413|Drug|Irinotecan|IV Infusion
75577477|NCT06104371|Device|Magtrace|Sentinel lymph node tracer and metastatic lymph node clip
76024827|NCT04065893|Procedure|Catheter ablation of ventricular arrhythmia|PVC or VT ablation
75431001|NCT01515683|Behavioral|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
76049418|NCT02380859|Behavioral|Prism adaptation|Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
75431002|NCT01515683|Behavioral|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
75431003|NCT01515683|Behavioral|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
76049419|NCT02380703|Behavioral|Aggression Prevention Training (APT)|
76049420|NCT02380703|Other|Enhanced Usual Primary Care (EU-PC)|
76049421|NCT02379923|Device|Crossing of Coronary Artery CTO|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires"
76049422|NCT04916171|Other|incidence|It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.
76049423|NCT02379221|Drug|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
76049424|NCT02379221|Drug|Topical|4% Topicaine gel
76049425|NCT02404103|Drug|Flunisolide HFA|
76049426|NCT02404025|Drug|Eltrombopag|Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
75431004|NCT01515722|Behavioral|Health education intervention (HEI)|"<Part 1> Understanding OAB~<Part 2> Behavioral/lifestyle modification~<Part 3> Bladder training~<Part 4> Understanding antimuscarinics"
75431005|NCT01515761|Procedure|Postero-lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
75577480|NCT06101264|Device|Virtual Reality Intervention|Participants will be given a virtual reality (VR) intervention following corrective scoliosis surgery for adolescent idiopathic scoliosis. The VR intervention will utilize a commercial device manufactured by Oculus. The intervention will utilize a software that simulates a low-physical load environment for the user. Starting on postoperative day 1, the participant will receive a 20-minute VR intervention 30 minutes prior to each physical therapy session. There will be two physical therapy sessions daily. Outcome measures will be assessed before and after every VR intervention and after the physical therapy session. The VR interventions will continue for each postoperative day until the participant is discharged from the hospital.
76049427|NCT02404025|Drug|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
76049428|NCT02404025|Drug|CsA|CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
76049429|NCT02377817|Device|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side."
76049430|NCT02377817|Device|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
75577485|NCT06094608|Device|Morning light treatment|Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.
75879077|NCT01343875|Procedure|tear of the distal tendon in the biceps muscle|
76049431|NCT02403635|Drug|Midazolam|
75577486|NCT06094608|Behavioral|Treatment-as-usual|Participants will not make modifications to their activities or sleep schedule.
75727525|NCT01003431|Biological|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
75727526|NCT01006473|Other|Exercise training|
75727527|NCT01006551|Drug|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
75727528|NCT00873626|Drug|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
75431006|NCT01515761|Procedure|Antero-Lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
75727529|NCT01003509|Procedure|modified shouldice and double|one arm modified shouldice, other one is double repair
75727530|NCT00879242|Drug|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
75727531|NCT05732493|Drug|Serplulimab|Serplulimab 300mg, d1, q3w
75727532|NCT05732493|Radiation|short-term radiotherapy|radiation: 25Gy/5Fx
76049432|NCT02403635|Drug|ASP2151|
75577488|NCT06091930|Drug|BI 765049|BI 765049
75577489|NCT06091930|Drug|Ezabenlimab|Ezabenlimab
75727533|NCT05732493|Drug|Oxaliplatin|130mg/m2 d1 q3w
75727534|NCT05732493|Drug|Capecitabine|1000mg/m2 d1-14 q3w
75727535|NCT00873704|Other|supplemental postoperative oxygen|
75879078|NCT04851821|Drug|Quercetin|Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
76049433|NCT04907903|Other|internet-based intervention|Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).
75577490|NCT06090370|Device|N95 Respirator|The participants in this group will be provided with N95 respirator masks to protect from dust and debris while working in the brick kiln and trained on proper usage.
75727536|NCT01003587|Behavioral|District health information package|"The intervention package consists of:~A report on disease burden, disease control priorities and health system performance in India~Condensed fact sheet based on the report~District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~Customized speech for district level officials detailing key actions to reduce deaths~Reminder materials including poster version of the DRCs and video on key points and actionable messages"
75727537|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
76049434|NCT02402933|Drug|Nasal Glucagon|3 mg nasal glucagon powder
75727538|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
75431007|NCT01515774|Drug|Mirapex ER|Change Requip or Mirapex to Mirapex ER
75879079|NCT03567122|Other|Internal Focus of Attention|Information already included in arm/group descriptions.
75879080|NCT03567122|Other|External Focus of Attention|Information already included in arm/group descriptions.
76049435|NCT05370365|Procedure|Below elbow cast|Patients will be stay with a below elbow cast for 4 or 6 weeks
76049436|NCT01796470|Drug|Entospletinib|Entospletinib tablets administered orally twice daily
76049437|NCT01796470|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
75431008|NCT01515800|Behavioral|Text message reminder|Receive text message
75431009|NCT01515813|Drug|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
75431010|NCT01515813|Drug|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
75577491|NCT06090370|Device|Protective Eyewear|The participants in this group will be provided with eye wear to protect the eyes from dust and debris while working in the brick kiln and trained on proper usage
75727539|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
75879081|NCT03567122|Other|Control|Information already included in arm/group descriptions.
75431011|NCT01515813|Drug|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
75577492|NCT06090370|Other|Baseline Survey|A quantitative, cross-sectional survey will be distributed to enrolled participants to understand baseline worker perceptions on silicosis and personal protective equipment (PPE).
75577493|NCT06090370|Other|Design of Workshop|A co-creation human centered design workshop to elicit feedback on PPE training prototypes and types of PPE.
75577494|NCT06090370|Other|Training Workshop Pilot|Qualitative workshops will be held to elicit feedback on the piloted PPE training program.
75577495|NCT06087302|Behavioral|child-Parent Relationship Therapy (CPRT)|The Child Parent Relationship Therapy (CPRT) is an evidence-based intervention program that trains parents/caretakers to help their children with social, emotional, attachment, and behavioral difficulties
76049438|NCT05102890|Other|ESOGER|For patients in the intervention group, ESOGER will be administered by phone by a member of the clinic team prior to their virtual or in-persons consultation with their primary care provider. ESOGER is already available on an online platform for data entry. Based on feedback our team obtained from interviews with current users of ESOGER, administration of the tool is expected to take between 5 and 10 minutes. A report summarizing the health and social status of the patient along with flagged potential vulnerabilities will be generated automatically by the online ESOGER platform. This report will then be uploaded to the patient's electronic chart by a member of the clinic and made available for the primary care provider at the time of the consultation.
76049439|NCT01868074|Device|Insole|Custom-molded arch-supporting insole
76049440|NCT04414852|Drug|Apatinib Mesylate|All the subjects will be administrated with 250mg apatinib on day 1
76049441|NCT04171024|Device|Sham electrical stimulation|A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
75431012|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)|One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
75431013|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)|One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
75431014|NCT01515839|Dietary Supplement|Multivitamin Supplement intervention|"We recommend the following protocol:~2 tablets of a high quality multivitamin BID~2 capsules of omega 3 fish oil BID for a total of 3 grams daily~3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg~Weight loss"
75431015|NCT01515852|Procedure|general anesthesia in stereotactic biopsy|stereotactic biopsy
75431016|NCT01515852|Procedure|local anesthesia in stereotactic biopsy|stereotactic biopsy
75431017|NCT01515878|Device|Hemocontrol|Blood Volume Tracking system using biofeedback
75577498|NCT06081894|Drug|Aficamten|Oral Tablet
75577499|NCT06081894|Drug|Placebo|Oral Tablet
75727540|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
75577502|NCT06066944|Other|Self-Thai Foot Massage|It is a specific technique and pressure to the feet and lower legs to promote relaxation, improve circulation, and enhance overall well-being. It is a traditional therapeutic practice originating from Thailand and is often performed by trained practitioners. Self-Thai foot massage is often based on traditional Thai massage techniques but adapted for self-application.
75577504|NCT06066047|Other|TOUCH ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~5 minutes bilateral touch on external malleolus~5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~5 minutes bilateral touch on acromion, for midline, centring diaphragms~Throughout the treatment, the practitioner maintained a focused attention on touch by voluntarily and constantly directing attention to the sensation/perception of the hands, perceiving texture, density, temperature, reactivity and motility of the tissue."
75727541|NCT00868634|Drug|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
75879082|NCT03379727|Drug|Midostaurin|Orally administered inhibitor of multiple tyrosine kinases
75879083|NCT03569384|Combination Product|Tele Rehab|The intervention group will obtain telerehabilitation
75431018|NCT01515917|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
75431019|NCT01515917|Drug|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
75431020|NCT01515917|Other|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
75431021|NCT01515917|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
75431022|NCT01515930|Behavioral|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding monitoring diabetes care.
75431023|NCT01515930|Behavioral|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding diabetes care.
75431024|NCT01515930|Behavioral|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
75879084|NCT01343953|Procedure|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
75431025|NCT01515969|Drug|Erlotinib hydrochloride|Given PO
75431026|NCT01515969|Drug|Dovitinib lactate|Given PO
75431027|NCT01515982|Behavioral|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
75431028|NCT01515982|Behavioral|Control Group|All participants were asked not to commence any new exercise regimen.
75431029|NCT01516021|Dietary Supplement|intake of high or low fat yoghurt|intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
75431030|NCT01516047|Drug|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
75431031|NCT01516047|Drug|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
75431032|NCT01516060|Drug|Efavirenz|400mg qd; 2 x 200mg
75431033|NCT01516060|Drug|Efavirenz|600mg qd; 3 x 200mg qd
75879085|NCT05140291|Other|Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
75879086|NCT05140291|Other|Sham Dry Needling|Needle handles inside of guide tubes will be tapped in a way similar to an actual needle being set but the sham needles will be blunted.
75431034|NCT01516099|Other|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).
76049442|NCT04171024|Device|Transcutaneous diaphragm electrical stimulation|A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
75431035|NCT01516099|Other|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
75431036|NCT01516138|Drug|GIK|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
75431037|NCT01516138|Drug|Control|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
75431038|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
75431039|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
75431040|NCT01516151|Dietary Supplement|CaPre™|2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
75577505|NCT06066047|Other|AUDITORY ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~5 minutes bilateral touch on external malleolus~5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~5 minutes bilateral touch on acromion, for midline, centring diaphragms~During the treatment, the operator's attention was focused on acoustic signals delivered through earphones. The beeps were delivered at random intervals between 0.5 and 2.0 seconds. The operator had to count the number of acoustic signals produced during the treatment period."
75577506|NCT06063720|Device|Endoscreen QC|Artificial intelligence monitoring of effective withdrawal time
75431041|NCT01516151|Drug|Lipid Lowering Medication|Patient will be treated as per the Standard of care.
75431042|NCT01516151|Dietary Supplement|CaPre™|4 capsules of 1 g total per day for 8 weeks.
75431043|NCT01516164|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
75431044|NCT01516229|Drug|somatropin|Prescription of somatropin at the discretion of the physician
75431045|NCT01516242|Other|No treatment given|Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
75431046|NCT01516255|Drug|liraglutide|0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
75577507|NCT06062368|Behavioral|Rate of Entry|The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.
75431047|NCT01516255|Drug|placebo|Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
75577508|NCT06059651|Procedure|Metabolic & Bariatric Surgery|Roux-en-Y metabolic and bariatric surgery
75577509|NCT06055985|Other|Placebo|Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
75577510|NCT06055985|Drug|UCB0022|Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
75879087|NCT03567044|Diagnostic Test|Blood Draw|Eligible subjects will have blood draws at the following times: baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks.
75879088|NCT02247128|Drug|Aspirin + clopidogrel|
75879089|NCT02247128|Drug|Aspirin monotherapy|
75879090|NCT02247128|Drug|OAC + clopicogrel|
75879091|NCT02247128|Drug|OAC monotherapy|
76049443|NCT01810042|Drug|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
76049444|NCT02424539|Drug|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
75431048|NCT01516255|Drug|moxifloxacin|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control
75431049|NCT01516255|Drug|placebo|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
75431050|NCT01516255|Procedure|electrocardiogram (ECG)|24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide
75431051|NCT01516255|Procedure|electrocardiogram (ECG)|Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected
75431052|NCT01516294|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
75431053|NCT01514903|Drug|HIP0908|SINGLE DOSE , CROSS OVER
75431054|NCT01514903|Drug|viagra|single dose, cross over
75431055|NCT01516320|Procedure|Roux-en-Y Gastric Bypass|A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
75431056|NCT01516320|Procedure|Laparoscopic adjustable gastric banding|A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
75431057|NCT01516320|Procedure|Vertical Sleeve Gastrectomy|A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
75431058|NCT01516333|Other|High GL 107|Three meals a day
75431059|NCT01516333|Other|Medium GL 76|Three meals a day
75431060|NCT01516333|Other|Medium GL 68|Three meals a day
75431061|NCT01516333|Other|Low GL 48|Three meals a day
75431062|NCT01516372|Drug|GEn 1200mg|1200 mg of Gen administered as a single dose
76049445|NCT02424539|Other|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
75431063|NCT01516372|Drug|Gen 6000 mg|6000 mg of Gen administered as a single dose
75431064|NCT01516372|Drug|GEn Placebo|Placebo to match GEn Tablets
75431065|NCT01516372|Drug|Moxifloxacin Placebo|Placebo to match Moxifloxacin
75431066|NCT01516372|Drug|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
75431067|NCT01516411|Behavioral|Mobile Intervention for Lifestyle Eating/Exercise @ Stanford|Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
75577511|NCT06055608|Drug|Sirolimus|Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight <40 kg will receive 3mg/m^ 2, with maintenance dose of 1 mg/m^2 divided BID - weight >= 40kg will receive 6mg/m^ 2, with maintenance dose of 2 mg daily
75577512|NCT06055608|Biological|Belatacept|Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24
75577513|NCT06055608|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil-MMF will be initiated at 600 mg/m^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m^2 BID
75879092|NCT01339481|Drug|abatacept|Intravenous Infusion
75431068|NCT01516450|Drug|GSK1550188 IV|Single IV dose of belimumab 200 mg
75431069|NCT01516450|Drug|GSK1550188 SC|Single SC dose of belimumab 200mg
75431070|NCT01516463|Drug|Collagenase Santyl|Applied topically (2 mm thickness once daily)
75577514|NCT06055608|Drug|Tacrolimus (Group1)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant
75577515|NCT06055608|Drug|Anti-Thymocyte Globulin (ATG)|Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function
75577516|NCT06055608|Drug|Tacrolimus (Group 2)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels
75879093|NCT01344031|Drug|Akt Inhibitor MK2206|Given PO
76049446|NCT01809262|Drug|single dose of 5 mcg|solution for inhalation
76049447|NCT01809262|Drug|single dose of placebo|solution for inhalation
76049448|NCT01809262|Drug|single dose of 40 mcg|solution for inhalation
75431071|NCT01516463|Biological|Bacitracin|Applied topically (2 mm thickness) once daily
75431072|NCT01516489|Behavioral|Stage 1|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
75431073|NCT01516489|Behavioral|Stage 2|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
75431074|NCT01516502|Other|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
75431075|NCT01516515|Drug|Vehicle gel|placebo
75431076|NCT01516515|Drug|SR-T100 with 2.3% of SM|2.3% of SM in Solanum undatum plant extract
76049449|NCT01809262|Drug|single dose of 20 mcg|solution for inhalation
75879094|NCT01344031|Drug|Anastrozole|Given PO
75879095|NCT01344031|Drug|Fulvestrant|Given IM
76049450|NCT01809262|Drug|single dose of 2 mcg|solution for inhalation
76049451|NCT01809262|Drug|single dose of 10 mcg|solution for inhalation
76049452|NCT04915703|Procedure|Flushing of PTBD catheter|flushing of internal external PTBD catheter 3 times a day
76049453|NCT01808248|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
75431077|NCT01516528|Procedure|Spirometry|Assessment of lung function by spirometry
75431078|NCT01516554|Drug|Testosterone undecanoate|40 mg twice daily
76049454|NCT01808248|Drug|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
75431079|NCT01516554|Drug|placebo|twice daily
75431080|NCT01516567|Drug|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
75431081|NCT01516580|Drug|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
75577518|NCT06048744|Procedure|external oblique intercostal block|U S guided external oblique intercostal block after induction.
75431082|NCT01516580|Drug|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
75431083|NCT01516645|Drug|KHK2898|injection
75577519|NCT06048744|Procedure|Erector Spine block|US guided erector spine block after induction
75577520|NCT06048718|Drug|Trastuzumab-Deruxtecan (T-DXd)|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
75577521|NCT06045806|Biological|idecabtagene vicleucel|Specified dose on specified days
75577522|NCT06045806|Drug|Lenalidomide|Specified dose on specified days
75577523|NCT06045806|Drug|Fludarabine|Specified dose on specified days
75577524|NCT06045806|Drug|Cyclophosphamide|Specified dose on specified days
75577525|NCT06044311|Drug|Vactosertib|200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.
75577526|NCT06044311|Drug|Standard of Care Chemotherapy|Neoadjuvant chemotherapy treatment as per standard of care.
75577527|NCT06044311|Radiation|Concurrent Radiation|Neoadjuvant radiation treatment as per standard of care.
75577528|NCT06042478|Drug|Remibrutinib|Active treatment
75577529|NCT06042478|Drug|Placebo to remibrutinib|Placebo followed by active treatment
75577530|NCT06042478|Drug|Placebo to omalizumab|Placebo followed by active comparator
75577531|NCT06042478|Drug|Omalizumab|Active comparator
76049455|NCT01808248|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
76049456|NCT02424383|Device|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
76049457|NCT01867294|Drug|Doxycycline|Given PO
76049458|NCT01867294|Procedure|Management of Therapy Complications|Moisturizer given topically
75431084|NCT01516658|Device|Hydrogel coil|at least one Hydrogel coil have to use for embolization
75431085|NCT01516658|Device|Bare platinum coil|only bare platinum coil have to use for embolization
75431086|NCT01516697|Procedure|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
76049459|NCT01867294|Other|Placebo|Given topically
76049460|NCT01867294|Other|Questionnaire Administration|Ancillary studies
76049461|NCT01867294|Drug|Spironolactone|Given topically
75577535|NCT06039826|Drug|LY3437943|Administered SC.
75577536|NCT06039826|Drug|Ethinyl Estradiol|Administered orally
75577537|NCT06039826|Drug|Drospirenone|Administered orally
75577538|NCT06038591|Behavioral|Sleep Tight|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
75879096|NCT01344031|Other|Laboratory Biomarker Analysis|Correlative studies
75879097|NCT01332929|Drug|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
76049462|NCT01867294|Drug|Sunscreen|Given topically
76049463|NCT01867294|Drug|Therapeutic Hydrocortisone|Given topically
76049464|NCT02424149|Drug|Phenazopyridine|
76049465|NCT02423291|Drug|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
76049466|NCT02401529|Drug|IV dexamethasone|0.15 mg/kg
76049467|NCT02401529|Drug|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
75577539|NCT06036836|Biological|favezelimab/pembrolizumab|IV infusion
75577540|NCT06036836|Biological|pembrolizumab|IV infusion
76049468|NCT02401529|Drug|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
76049469|NCT02401529|Drug|IV saline|IV saline
75431087|NCT01516697|Procedure|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
75431088|NCT01516710|Procedure|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
75431089|NCT01516710|Procedure|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
75431090|NCT01516723|Device|Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)|Recanalization of totally occluded coronary arteries
75431091|NCT01516762|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
75431092|NCT01516775|Other|clear fluid ingestion|drinking of clear fluid in preoperative period
76049470|NCT01867216|Drug|Placebo|Administered orally as capsules
75431093|NCT01516788|Other|Phototesting|Single MED dose on Day 2
75431094|NCT01516801|Other|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
75431095|NCT01516814|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
75577541|NCT06036836|Drug|lenvatinib|Oral administration of capsule
76049471|NCT01867216|Drug|LY2922470|Administered orally as capsules
75431096|NCT01516814|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
75879098|NCT04660279|Diagnostic Test|Dynamic Whole-Body parametric PET/CT|Dynamic whole-body PET/CT imaging protocol
76049472|NCT01866826|Drug|Rifaximin|subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)
76049473|NCT01866826|Other|Placebo|subject will receive three capsules of placebo by mouth twice daily.
75431097|NCT01516814|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
75431098|NCT01516827|Behavioral|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
75431099|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily for 21 days, followed by 15 mg once daily
75431100|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
75431101|NCT01516840|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
75431102|NCT01516840|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
75431103|NCT01516853|Device|Non-contrast MRI|Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
75431104|NCT01516866|Procedure|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
75431105|NCT01516905|Drug|NM404|injection of either 2.0mCi or 5.0mCi I-124 NM404
75577542|NCT06035120|Device|AeriSeal System|The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
75577544|NCT06029270|Procedure|Biospecimen Collection|Undergo blood sample collection
75577545|NCT06029270|Procedure|Bone Scan|Undergo bone scan
75577546|NCT06029270|Drug|Carboplatin|Given IV
75577547|NCT06029270|Drug|Cisplatin|Given IV
75879099|NCT01316029|Procedure|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
75879100|NCT05185193|Device|radiofrequency|Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times
76024828|NCT04065893|Drug|Intensified medical therapy|Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
76024829|NCT05744713|Other|Observational|Observational
76024830|NCT05228561|Other|Mobile Application Supported Nutrition and Diabetes Education|With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
76024831|NCT05228483|Device|CO2 fractional laser|CO2 fraction laser
75577548|NCT06029270|Procedure|Computed Tomography|Undergo CT or PET/CT
75577549|NCT06029270|Drug|Gemcitabine|Given IV
75577550|NCT06029270|Procedure|Magnetic Resonance Imaging|Undergo MRI
75577551|NCT06029270|Biological|Nivolumab|Given IV
75577552|NCT06029270|Procedure|Positron Emission Tomography|Undergo PET/CT
75431106|NCT01516931|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
75577553|NCT06029270|Biological|Relatlimab|Given IV
76049474|NCT04579276|Procedure|Thoracic paravertebral block|Intrathoracic method undergone through video assisted surgery (VATS
76049475|NCT04579276|Procedure|thoracic epidural analgesia|locoregional analgesia under ultrasound control
75577556|NCT06008197|Drug|Finerenone|Oral finerenone
75577557|NCT06008197|Drug|Placebo|Matching oral placebo
75577558|NCT06007521|Other|interview with neurologist|interview with neurologist
75577559|NCT06004037|Drug|Delpazolid|"Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks.~After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total."
75577560|NCT06001788|Drug|Ziftomenib|Oral administration
75727542|NCT05232357|Drug|Sodium thiosulfate and Methylene blue solution|Take a methylene blue injection (2ml:20mg), add 18ml distilled water and mix well. Add NaS2O3.5H2O800mg to the methylene blue solution 10ml, add 4 drops of dilute hydrochloric acid, heat the water bath until the dark blue fades, the solution is milky and turbid, adjust the PH to about 3.5. Put the prepared solution into a glass bottle with a rubber stopper, which is wrapped in tin foil, sealed and protected from light, and stored in a refrigerator at-20 ℃. It can be used after high-pressure sterilization before operation. Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent. During gastroenteroscopy, DMB staining solution was locally sprayed on the surface of gastrointestinal lesion mucosa or injected into the lesion mucosa.
75727543|NCT00879476|Drug|Ramipril 10mg capsules|
75727544|NCT01003743|Device|endolumenal tissue approximation|
75431107|NCT01516931|Behavioral|counseling|Placebo monthly by general counseling for 12 months.
75431108|NCT01516983|Drug|icotinib|"Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.~Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.~Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.~Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity."
75431109|NCT01516983|Radiation|Whole brain radiotherapy|Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
75431110|NCT01516996|Drug|docetaxel and cisplatin|"The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.~CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT"
75577561|NCT06001788|Drug|Fludarabine|Intravenous infusion
75577562|NCT06001788|Drug|Idarubicin|Intravenous infusion
75577563|NCT06001788|Drug|Cytarabine|Intravenous Infusion
75577564|NCT06001788|Drug|Gilteritinib|Oral administration
75577565|NCT06001788|Biological|Granulocyte colony-stimulating factor|Subcutaneous injection
75577566|NCT05998408|Drug|Ruxolitinib|Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
75577567|NCT05991817|Procedure|Surgery/general anesthesia|Adult patients between the ages of 30 and 50 who are to undergo elective surgery under general anesthesia will have their spatial memory tested and interleukin 1beta and alpha tumor necrosis measured before and after surgery.
75577568|NCT05987592|Behavioral|Brain Education and WELLness with Migraine Group A|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
75577569|NCT05987592|Behavioral|Brain Education and WELLness with Migraine Group B|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
75577570|NCT05987033|Drug|NVDX3|NVDX3 is implanted during a single surgical intervention.
75577571|NCT05986851|Drug|Azeliragon|Oral capsule
75577574|NCT05985655|Drug|GTAEXS617|GTAEXS617 tablets daily
76049476|NCT04584970|Device|Applied VR|The Applied VR device is a lightweight mobile virtual reality headset with embedded software, creating an immersive experience. The Applied VR is specifically designed for medical use.
76049477|NCT04584970|Device|Apple iPad|The Apple iPad is a tablet device controlled by touch screen with a variety of games and applications.
76049478|NCT01791244|Drug|Rebif®|
75879101|NCT05185193|Device|sham stimulation|The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
76049479|NCT01865812|Drug|Obeticholic Acid|All participants were treated with OCA (oral administration, 10 mg, once daily [QD]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
76049480|NCT04600258|Dietary Supplement|Dark Chocolate|The patients will receive 40g per day of dark chocolate for 2 months
76049481|NCT01808092|Drug|ceftazidim-avibactam (CAZ-AVI, experimental product)|2000mg ceftazidime plus 500mg avibactam
75577577|NCT05963763|Behavioral|Career Navigator Coaching|"The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~Career pathway navigation~Employee benefit maximization~Financial literacy and wealth building~Services funds for resources that mitigate specific barriers or needs."
75879102|NCT02247986|Drug|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
76049482|NCT01808092|Drug|meropenem (active comparator)|1000mg of Meropenem
76049483|NCT04584814|Device|No intervention|Basal analysis
76049484|NCT04584814|Device|scare ventilator at 20|To set scare ventilator by 20 cycles per minute
76049485|NCT04584814|Device|scare ventilator at 40|To set scare ventilator by 40 cycles per minute
76049486|NCT01774084|Dietary Supplement|Experimental: PreOp, NutriciaNordica AB|
76049487|NCT01774084|Dietary Supplement|Placebo Comparator: Water|
76049488|NCT01807234|Drug|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
76049489|NCT01807234|Drug|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
76049490|NCT01807234|Drug|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
76049491|NCT01790932|Drug|BKM120|
75431111|NCT01516996|Radiation|IMRT|"IMRT is administered with chemotherapy from week 7 to week 13~GTV（primary tumor）：68-70Gy/35~38 F，once a day, 5 times per week~CTV（Clinical target）：56-66Gy/30~36f，once a day, 5 times per week~GTV-ln（positive neck region）：66-70Gy/33~36 F，once a day, 5 times per week~CTV-ln（negative neck region）：50-54Gy/28~30F, once a day, 5 times"
76049492|NCT02377427|Drug|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
75577579|NCT05959473|Device|Idylla EGFR_IUO/3.20 Mutation Test|Clinical Performance Study Protocol for Idylla EGFR_IUO/3.20 Mutation Test The EGFR_IUO/3.20 is automated on the Idylla™ Platform, which executes the entire process from sample to result including sample liquefaction, cell lysis, real-time PCR amplification/detection, and data analysis and reporting.
75577580|NCT05955170|Drug|Tucatinib in Combination of Oral VP16 and trastuzumab|Combination of tucatinib-Oral VP16-trastuzumab
76049493|NCT02421887|Drug|Antioxidant Supplement|An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
75577582|NCT05952856|Drug|MK-0616|Oral tablet
75577583|NCT05952856|Drug|Placebo|Oral tablet
75577584|NCT05948293|Device|Machine learning model called IDoser|Patients in the intervention arm will be prescribed the first dose of FSH by IDoser, that will take into account the age of the patient, BMI, AFC and AMH. These data will be retrieved from the patient's clinical file after their first visit to the clinic, after providing the patient with informed consent documentation.
75577585|NCT05948293|Procedure|Standard clinical practice|Patients in the control group will be prescribed their first dose of FSH by the clinician according to standard clinical practice.
75577586|NCT05947071|Biological|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
75577587|NCT05947071|Biological|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
75431112|NCT01516996|Biological|Nimotuzumab|Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13~14 weeks
75577588|NCT05946733|Procedure|Group A|After induction of general anesthesia, oblique subcostal TAP blocks will be done(14) under the guidance of Sonosite ,superficial probe ,14-15 MHz ultrasound transducer
75577589|NCT05946733|Procedure|Group B|After induction of general anesthesia, bilateral lateral TAP block will be performed (15) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz)
75577590|NCT05946733|Other|Group C|the analgesia will be maintained using a morphine patient-controlled analgesia (PCA) device set to give 1.5 mg bolus administration of morphine without a basic rate and 15 min lock-out time. The total amount of morphine administration will be recorded for the subsequent 24 h
75577591|NCT05943535|Drug|Placebo|Placebo administered QID
75577592|NCT05943535|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
76049494|NCT02421887|Other|Placebo|Placebo
75577593|NCT05943535|Device|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
75577594|NCT05940402|Drug|Emraclidine|Oral tablets
75577595|NCT05934292|Drug|MK-0616|Single oral dose
75577596|NCT05931796|Other|NON-ERAS pathway|All patients received best of care practice, with standardization of preoperative and postoperative care
75431113|NCT01517009|Drug|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
75879103|NCT04580953|Device|CardiaCareTM RR2|Treatment with CardiaCareTM RR2
75879104|NCT03569306|Device|ENB|ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
76049495|NCT01609582|Drug|TAK-875|TAK-875 tablets
76049496|NCT01609582|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
76049497|NCT01789606|Drug|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
76049498|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
76049499|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
76049500|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
75431114|NCT01517009|Drug|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
75431115|NCT01517009|Drug|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
75431116|NCT01517009|Procedure|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
75431117|NCT01517022|Drug|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
75431118|NCT01517035|Procedure|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
75431119|NCT01517165|Drug|Pioglitazone|
75431120|NCT01517165|Drug|Placebo|
75431121|NCT01517204|Device|Direct laryngoscope (Macintoish laryngoscope)|Direct laryngoscope was used to facilitate the intubation of left-sided DLT.
75431122|NCT01517204|Device|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
75431123|NCT01517217|Procedure|No girdle|No girdle is used for the first five postoperative days
75431124|NCT01517217|Procedure|Girdle|Girdle the first five postoperative days
75431125|NCT01517230|Behavioral|Local radio campaign to reduce under-five child mortality|"The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years."
75431126|NCT01517256|Behavioral|Living Everyday Above-and-beyond Pain (LEAP)|8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.
75431127|NCT01517256|Other|Wait-listed|Patients are wait-listed while awaiting participation to the LEAP program.
75431128|NCT01517269|Behavioral|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
75431129|NCT01517269|Behavioral|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
75431130|NCT01517308|Drug|pegylated interferon alpha 2a + ribavirin|Comparison of different duration of drugs (48 weeks vs. 24 weeks)
75727545|NCT04925102|Other|Standardized treatment protocol for cerebral palsy|Passive and active range of motion (ROM) exercises of all joints, prone positioning, slow prolonged manual stretching (30 minutes daily), standing frame for children with GMFCS IV-V, supported sitting, supported walking, lower limb serial casting (if needed), active strength training, progressive resistance training, functional exercises, sensory integration: therapeutic activities to organize sensation from the body and environment, bimanual training: repetitive task training in the use of two hands together, context-focused therapy: changing the task or the environment, the occupational therapy, cognitive behaviour therapy and home programmes.
76049501|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
75431131|NCT01517321|Drug|MK-0431/ONO-5435|Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
75727546|NCT00879554|Biological|CVX-045|Weekly, intravenous dose
76049502|NCT01773226|Device|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
75431132|NCT01517321|Drug|Placebo, MK-0431/ONO-5435|Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
75431133|NCT01517334|Drug|Minocycline HCl Microspheres|
75431134|NCT01517347|Drug|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
75431135|NCT01517360|Drug|Oxytocin|Oxytocin 40 IU, intranasal inhalation
75431136|NCT01517360|Other|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
75431137|NCT01517360|Behavioral|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
75431138|NCT01517386|Procedure|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
75431139|NCT01517399|Drug|tivantinib|three oral 120 mg tablets administered twice a day
75431140|NCT01517399|Drug|omeprazole|One 40 mg oral capsule once alone and once again with tivantinib
75577597|NCT05931796|Other|ERAS pathway|ERAS pathway ERAS consist of approximately 15 elements (or components) that include preoperative, intraoperative, and postoperative interventions .
75727547|NCT00868946|Drug|Virazole (Ribavirin)|"Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.~Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses)."
75431141|NCT01517399|Drug|s-warfarin|One 10 mg oral tablet once alone and once again with tivantinib
75431142|NCT01517399|Drug|caffeine|One 200 mg oral tablet once alone and once again with tivantinib
75577598|NCT05923333|Dietary Supplement|B. infantis Rosell®-33|B. infantis Rosell®-33 + maltodextrin
75727548|NCT00874016|Device|Airtraq|Intubation using Airtraq
75727549|NCT00874016|Device|Direct Laryngoscopy|Intubation using direct laryngoscopy
75879105|NCT03569306|Device|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
75431143|NCT01517399|Dietary Supplement|vitamin K|One oral 5 mg tablet on multiple days when and around warfarin administration
75431144|NCT01517399|Drug|digoxin|One oral 0.25 mg tablet once alone and once again with tivantinib
75431145|NCT01517399|Drug|midazolam|Intravenous 1.5 mg dose once alone and once again with tivantinib
75431146|NCT01517438|Behavioral|agitation|agitation score after desflurane anesthesia
75431147|NCT01517464|Genetic|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
75431148|NCT01517490|Other|Insulin pump|Insulin pump therapy
75431149|NCT01517490|Other|Multiple daily insulin injections|Multiple daily insulin injections
75727550|NCT00482014|Drug|pemetrexed|"Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase"
75727551|NCT00482014|Drug|cisplatin|"Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles"
75431150|NCT01517490|Procedure|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
75431151|NCT01517490|Other|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
75727552|NCT00482014|Drug|carboplatin|"Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter*minute (mg/mL*min), administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - dosed at AUC 5 mg/mL*min, administered intravenously, every 21 days for 3 cycles"
75879106|NCT03566888|Device|Blood pressure assessment|Validation of an automated blood pressure device
75879107|NCT05708534|Drug|Belatacept|Switching from anticalcineurins to belatacept in a cohort of kidney transplant recipients seropositive for CMV
75879108|NCT03159611|Drug|Tenoten for children|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
75879109|NCT03159611|Drug|Placebo|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
75879110|NCT03000374|Drug|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
75879111|NCT03000374|Drug|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
75577599|NCT05923333|Dietary Supplement|Placebo|Maltodextrin
75577600|NCT05921955|Device|Optiflow high-flow nasal cannula system|Using the Optiflow high-flow nasal cannula system to supply oxygen for maternal.
75577601|NCT05919472|Dietary Supplement|Oral iron supplementation (pre-treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 1-56
75577602|NCT05919472|Biological|COVID-19 vaccine|Johnson & Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
75577603|NCT05919472|Biological|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
75577604|NCT05919472|Dietary Supplement|Oral iron supplementation (simultaneous treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 28-56
75577605|NCT05919472|Biological|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
75727553|NCT00482014|Radiation|radiation therapy|"Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51~Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45"
75727554|NCT00879788|Drug|Ramipril 10mg capsules|
75727555|NCT03595553|Drug|Ridinilazole|ridinilazole (200 mg bid)
75431152|NCT01517503|Behavioral|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
75727556|NCT03595553|Drug|Vancomycin|vancomycin (125 mg qid)
75879112|NCT03000374|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
75577606|NCT05918094|Drug|Experimental dose: modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
75577607|NCT05918094|Drug|Standard dose: standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
75431153|NCT01517503|Behavioral|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
75577608|NCT05917470|Drug|ONCT-534|ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
75727557|NCT00874172|Drug|Rapid optimized analgesic strategy|"Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
75727558|NCT00874172|Drug|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
75727559|NCT04119154|Diagnostic Test|Contrast Microhalography (CEM)|Fine needle aspirates evaluated by CEM device
75727560|NCT00614822|Drug|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
75879113|NCT03000374|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
75577609|NCT05909904|Drug|Tislelizumab|Administered intravenously
76049503|NCT01773070|Drug|ABT-450/ritonavir|ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.
75577610|NCT05909904|Drug|BGB-A425|Administered intravenously
76024832|NCT05228483|Combination Product|5-aminolevulinic acid (5-ALA) with red light illumination|5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).
76049504|NCT01773070|Drug|ABT-333|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
76049505|NCT01773070|Drug|ABT-267|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
75431154|NCT01517542|Other|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
75431155|NCT01517555|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
75431156|NCT01517555|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
75431157|NCT01517555|Drug|paracetamol|One single dose of 1 g. Tablet
75431158|NCT01517568|Drug|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
75431159|NCT01517607|Other|Mesalazine|Patient's treated with oral Mesalazine
75431160|NCT01517620|Drug|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
75431161|NCT01517633|Device|BirthSign|When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
75431162|NCT01517646|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
75577611|NCT05909904|Drug|LBL-007|Administered intravenously
76049506|NCT01772368|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments."
75577615|NCT05905068|Drug|RN0191 INJECTION|a sterile solution in each bottle for subcutaneous (SC) injection
75727561|NCT04861298|Drug|standard of care for COVID-19 as per the hospital guidelines|Hospital standard of care treatment for COVID-19
75577617|NCT05900245|Other|Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）|EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.
75727562|NCT04861298|Dietary Supplement|Quercetin Phytosome (QP)|Daily dose of 600 mg of Quercetin for 1st week and then 400 mg for the 2nd week
76024833|NCT05228483|Drug|Mometasone furoate (MMF) 0.1% ointment|0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
76024834|NCT01959880|Device|The Contour Profile Gel (CPG) breast implants|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.~The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study."
76049507|NCT01772368|Drug|FS MDPI|FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
76049508|NCT01772368|Drug|Advair Diskus|ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
76049509|NCT01772368|Drug|Albuterol|Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
75431163|NCT01517672|Behavioral|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
76049510|NCT01788046|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
76049511|NCT01788046|Drug|Placebo|Administered intravenously (IV) three times per week.
76049512|NCT01806298|Drug|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
76049513|NCT01772134|Drug|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
76049514|NCT01772134|Drug|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
75431164|NCT01517685|Dietary Supplement|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
75431165|NCT01517685|Dietary Supplement|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
75431166|NCT01517724|Drug|Bortezomib|1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
75431167|NCT01517789|Device|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|"Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.~Flash and steady state visual evoked potential are measured during the surgical procedure at different times."
75431168|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
75431169|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
75431170|NCT01517828|Drug|Sedation by ketamine|"Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
75431171|NCT01517828|Drug|Sedation with Midazolam|"Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
76049515|NCT01772134|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
76049516|NCT01772134|Drug|Placebo|Inhalation Powder, Placebo
76049517|NCT01994889|Drug|Tafamidis|Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
75431172|NCT01517854|Drug|Sildenafil|20 mg Revatio (sildenafil citrate) three times a day
75431173|NCT01517854|Drug|Placebo|Placebo identical to Revatio (sildenafil citrate) three times a day
76049518|NCT01994889|Drug|Tafamidis|Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
75727563|NCT00869102|Drug|GLP-1|intravenous, 124,5 pmol/kg body weight
76049519|NCT01994889|Drug|Placebo|Placebo in soft gel capsules administered once a day for 30 months
76049520|NCT02082483|Other|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
76049521|NCT02017899|Biological|S. sonnei 1790GAHB|
76049522|NCT02017899|Biological|Placebo|
76049523|NCT01993329|Drug|Gefapixant 50 mg|Gefapixant 50 mg tablet administered orally
76049524|NCT01993329|Drug|Gefapixant 300 mg|Gefapixant 300 mg tablet administered orally
76049525|NCT01993329|Drug|Placebo to mimic 50 mg tablets|Sugar pill manufactured to mimic gefapixant 50 mg tablets
75577622|NCT05898607|Other|continuous Thoracic paravertebral block|continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
75577623|NCT05898607|Other|continuous Erector spinae plane block|continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure
75577624|NCT05892744|Drug|Sertraline|50-200mg/day
75577625|NCT05891171|Drug|AB598|Administered as specified in the treatment arm
75577626|NCT05891171|Drug|Zimberelimab|Administered as specified in the treatment arm
75577627|NCT05891171|Drug|Carboplatin|Administered as specified in the treatment arm
75577628|NCT05891171|Drug|Pemetrexed|Administered as specified in the treatment arm
75577629|NCT05891171|Drug|Fluorouracil|Administered as specified in the treatment arm
75431174|NCT01517906|Behavioral|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
75431175|NCT01517906|Behavioral|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
75577630|NCT05891171|Drug|Leucovorin|Administered as specified in the treatment arm
75577631|NCT05891171|Drug|Oxaliplatin|Administered as specified in the treatment arm
75577632|NCT05889182|Drug|Upadacitinib|Oral Tablets
75577633|NCT05889182|Drug|Placebo|Oral Tablets
75577634|NCT05884931|Device|Nexpowder|Hemostatic powder for endoscopy after colonoscopy polypectomy
75577635|NCT05884931|Procedure|Conventional Treatment|Standard hemostatic procedure
75879114|NCT04323943|Device|Ankle Foot orthosis (AFO)|"The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~6MWT where energy cost will be measured~5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed"
75577636|NCT05882071|Drug|Sodium/glucose cotransporter-2 inhibitors (SGLT2i)|Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
75577637|NCT05879887|Behavioral|UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)|UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.
76049526|NCT01993329|Drug|Placebo to mimic 300 mg tablets|Sugar pill manufactured to mimic gefapixant 300 mg tablets
76049527|NCT04417101|Drug|Chinese Herb|The participants will be instructed to take their JBT and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
75577640|NCT05877547|Drug|Efinopegdutide|Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg
75577641|NCT05877547|Drug|Semaglutide|SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg
76049528|NCT02016183|Drug|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
76049529|NCT02377349|Biological|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
76049530|NCT02377349|Drug|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
76049531|NCT02421419|Drug|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
75577642|NCT05877547|Drug|Placebo|SC injection of matching placebo
75577643|NCT05873439|Radiation|Genomically Guided Radiation Therapy (RT)|Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.
75577644|NCT05864118|Diagnostic Test|Respiratory pathogen panel PCR test|Respiratory pathogen panel PCR test and COVID-19 antibody test.
75577645|NCT05864118|Diagnostic Test|COVID-19 antibody test|COVID-19 antibody test
75577646|NCT05860036|Biological|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10^6 anti-BCMA CAR+T cells/kg.
76049532|NCT02421419|Drug|Xylocaine|a local anesthetic agent
76049533|NCT02421419|Drug|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
75577647|NCT05860036|Drug|VRd|Bortezomib, Lenalidomide and Dexamethasone
75577648|NCT05850013|Device|Lifelight Junior|Lifelight® is an app developed by xim that measures VS including heart rate, respiratory rate and blood pressure. All you need to do to have these vital signs measured is look at your smartphone or tablet camera for 20-40 seconds. The app has used data from over 1 million heartbeats to learn how to measure these vital signs in adults. The technology is already available for doctors and nurses to use with adult patients in some specific scenarios
75431176|NCT01517919|Behavioral|Peer-Led Self-Management|"The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants."
76049534|NCT02016105|Drug|GP2017 Adalimumab|
75431177|NCT01517932|Drug|dexmedetomidine|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery"
76049535|NCT02016105|Drug|Humira ® Adalimumab|
76049536|NCT02400905|Device|BioMimics 3D Vascular Stent System|Femoropopliteal stenting
76049537|NCT02400749|Drug|Apremilast|"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
75577653|NCT05847582|Behavioral|Standard inpatient psychiatric care|All participants involved in this study will receive standard of care treatment at Duke University Medical Center's Behavioral Health Inpatient Program.
75577654|NCT05847582|Behavioral|Inpatient Skills Training|Inpatient skills training will be completed while participants are receiving inpatient treatment at BHIP. Skills training includes content designed to improve emotional regulation skills.
75577655|NCT05847582|Behavioral|mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)|mSTARS includes inpatient skills training and a mobile health (mHealth) telephone app designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.
75577656|NCT05845814|Biological|Coformulated favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
75577657|NCT05845814|Biological|Coformulated vibostolimab/pembrolizumab|Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
75577658|NCT05845814|Combination Product|EV|1.25 mg/kg IV infusion
75577659|NCT05845814|Biological|Pembrolizumab|200 mg IV infusion
75577660|NCT05845710|Device|Neuroguard IEP Direct System|carotid artery stenting, direct access with blood flow redirection
75577661|NCT05845645|Drug|UCB0599|Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
75727564|NCT03582917|Drug|Alphacalcidol|Alphacalcidol 0,5mg tablet
75727565|NCT05226728|Drug|pembrolizumab|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
76049538|NCT02400749|Drug|Placebo|Placebo tablets will be provided to sites in blister cards.
76049539|NCT02420327|Drug|Placebo patch & placebo capsule|On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
76049540|NCT02420327|Drug|Placebo patch & galantamine capsule|On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
75577662|NCT05845645|Other|Esomeprazole|Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.
75577663|NCT05845645|Other|Placebo|Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.
75879115|NCT03566654|Device|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.
75431178|NCT01517932|Drug|saline placebo|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery"
75431179|NCT01517958|Other|Respiratory Distress Group|Diagnostic lung ultrasound.
75431180|NCT01517958|Other|Control Group|Lung ultrasound
75431181|NCT01517971|Other|laboratory biomarker analysis|Correlative studies
75577664|NCT05839041|Drug|AVD-104|Intravitreal injection
75577665|NCT05839041|Drug|Avacincaptad|Intravitreal injection of 2 mg avacincaptad
75577666|NCT05838495|Other|formulated liquid diet|will be fed exclusively the pediatric enteral study formula with a feeding tube
75577667|NCT05837091|Drug|Low Sodium Oxybate|Titrated according to standard of care and continued on stable dose for 3 months
75577668|NCT05837091|Diagnostic Test|24-hour polysomnography|Performed in a sleep study lab, recording of body functions including brain activity, eye movements, muscle activity, heart rhythm and blood oxygen levels while asleep and awake for a 24-hour period
75577669|NCT05837091|Device|Nextsense EEG earbuds|Ear buds used to record sleep staging worn for a 24-hours period
75577670|NCT05837091|Device|Axivity device|Wristband that records activity level worn for approximately one month to track sleep and steps/activity.
75577671|NCT05836584|Biological|Atezolizumab|Given IV
75577672|NCT05836584|Procedure|Biospecimen Collection|Undergo collection of blood samples
75577673|NCT05836584|Drug|Capecitabine|Given PO
75577674|NCT05836584|Procedure|Computed Tomography|Undergo CT or PET/CT
75577675|NCT05836584|Drug|Docetaxel|Given IV
75577676|NCT05836584|Procedure|Echocardiography|Undergo ECHO
75577677|NCT05836584|Drug|Fluorouracil|Given IV
75577678|NCT05836584|Drug|Leucovorin Calcium|Given IV
75577679|NCT05836584|Procedure|Lymphadenectomy|Undergo lymphadenectomy
75577680|NCT05836584|Procedure|Magnetic Resonance Imaging|Undergo MRI
75879116|NCT03566654|Device|ambulatory blood pressure monitoring|A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
75577681|NCT05836584|Drug|Oxaliplatin|Given IV
75577682|NCT05836584|Procedure|Positron Emission Tomography|Undergo PET/CT
75577683|NCT05836584|Procedure|Surgical Procedure|Undergo surgery
75577684|NCT05836090|Behavioral|Family Spirit Strengths (FSS)|The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).
75577685|NCT05836090|Behavioral|Family Spirit Nurture|The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.
75577686|NCT05828823|Device|Hemodialysis twice weekly|Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
75577687|NCT05828823|Other|Hemodialysis thrice weekly|Conventional hemodialysis regimen
75577688|NCT05815160|Drug|Debio 0123|Administered as capsules.
75577689|NCT05815160|Drug|Etoposide|Administered as IV infusion.
75577690|NCT05815160|Drug|Carboplatin|Administered as IV infusion.
75727566|NCT00869180|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
75727567|NCT00869180|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
75727568|NCT00874328|Drug|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
75727569|NCT00874328|Drug|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
75879117|NCT03566654|Device|Sham remote ischemic conditioning|Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
75431182|NCT01517997|Procedure|Paclitaxel coated balloon angioplasty.|Infrapopliteal angioplasty using a paclitaxel coated balloon.
75431183|NCT01517997|Procedure|Infrapopliteal Primary Drug Eluting Stenting|Infrapopliteal primary stenting using drug-eluting stent(s)
75431184|NCT01518010|Behavioral|Play game|Participants engage in non-game activity (establish baseline) 7 * 1 hr weekly; play single-player game 7 * 1 hr weekly; play multi-player game 7 * 1 hr weekly.
75431185|NCT01518023|Other|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
75431186|NCT01518036|Drug|somatropin|2.9 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
75431187|NCT01518036|Drug|somatropin|4.3 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
75879118|NCT03635359|Diagnostic Test|blood test|analysis of cell-free DNA in maternal plasma
75431188|NCT01518062|Drug|somatropin|4 IU/m^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
75727570|NCT00874328|Drug|TS-1 (S-1)|TS-1 po D1~D14 q 3 weeks until maximum 6 cycles
75727571|NCT00879866|Biological|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
75879119|NCT03566576|Drug|Anlotinib|Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
75879120|NCT03566576|Drug|Pemetrexed|Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
75879121|NCT03566576|Drug|Docetaxel|Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
76024835|NCT05228405|Other|All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness|All of the different type of disabled children's caregivers (cerebral palsy, muscular dystrophy, spina bifida and down syndrome) will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
75431189|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
76024836|NCT04255277|Drug|Combined oral contraceptives (COC)|A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
76024837|NCT04255277|Drug|Moxifloxacin 400mg|A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
75431190|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface, the second year and finally 8 IU/m^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
75431191|NCT01518062|Drug|oestrogen|Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
75727572|NCT00879944|Other|Blood pressure|Blood pressure will be measured once while patient is seated
75727573|NCT00879944|Other|Height|Height will be measured in centimeters at the time of enrollment
75727574|NCT00879944|Other|Weight|Weight will be measured in kilograms at enrollment
76024838|NCT04255277|Drug|Cenerimod 0.5 mg|This will be administered orally as a film-coated tablet in the morning.
76024839|NCT04255277|Drug|Cenerimod 4 mg|This will be administered orally as a film-coated tablet in the morning.
76024840|NCT04255277|Other|Charcoal, activated|Granules for oral suspension will be used and administered open-label.
75431192|NCT01518075|Other|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
75431193|NCT01518075|Other|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
76049541|NCT02420327|Drug|Nicotine patch & placebo capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
76024841|NCT04255277|Drug|Matching Placebo|Cenerimod matching placebo tablets will be administered once daily orally in the morning.
76049542|NCT02420327|Drug|Nicotine patch and galantamine capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
76049543|NCT04898465|Other|Social Paediatric Intervention|Family will meet the hospital's social-paediatrician and social worker. Together they will evaluate the need for social support, risk for neglect and refer families for local social services if needed. The visit will contain primary and secondary prophylaxis of child abuse and neglect.
76049544|NCT04420559|Other|Intramuscular Injection|Intramuscular Benzathine Penicillin Injection Procedure
76049545|NCT02374853|Drug|Vancomycin|Topical prophylactic antibiotic
76049546|NCT02374853|Other|No Vancomycin|Placebo: Sterile water. No Vancomycin.
76049547|NCT02015793|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
76049548|NCT02015793|Biological|Placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
75431194|NCT01518088|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to study foods
75431195|NCT01518101|Drug|Vildagliptin/ Metformin|Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
76049549|NCT02347631|Device|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first."
75431196|NCT01518101|Drug|Liraglutide|1.2 mg once daily by commercially available injection pens
75431197|NCT01518101|Drug|Metformin|1000 mg tablets twice daily
75727575|NCT00879944|Other|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
75727576|NCT00879944|Other|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
75727577|NCT00874406|Drug|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
76024842|NCT05228093|Procedure|Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap|"Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. And the reconstruction of the nasopharyngeal defect use the nasal septum and floor mucoperiosteum flap. Antibiotic therapy based on the result of bacterial cultivation before the surgery was administered for 5-7 days after surgery. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid, and endoscopic nasal cleanup was performed every 2-4 weeks until the flap was completely epithelialized and the entire defect was relined.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
75577697|NCT05806294|Behavioral|Digital Metabolic Rehabilitation|Digital Metabolic Rehabilitation combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise Protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 20 based on physical ability and stage of COPD. Intervention has 3 phases. In phase 1, weekly videoconferences with the kinesiologist and dietitian and monthly sessions with psychologist and respiratory therapist are held for the first 3 months. Phase 2 lasts from months 4 to 6 and has biweekly videoconferences with health professionals. Phase 3 starts in month 6 and has monthly group sessions with health professionals.
75431198|NCT01518114|Behavioral|Exercise Training|Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
75577698|NCT05805384|Device|SEDA|Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.
75577699|NCT05798650|Behavioral|facial dissatisfaction|"Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs."
75577701|NCT05794555|Behavioral|Enhanced Usual Care|Patients will be provided and counseled on two methods which will enhance care. The first is a handout on nutrition recommendations and protein supplementation. This will include the recommendation of both high protein snacks during the daytime (e.g., protein bars) and a high-protein night-time snack (e.g., peanut butter and crackers). The second will be to counsel participants on falls prevention methods that can be enacted in day-to-day life. All participants will be provided with a standard hand-out of Centers for Disease Control and Prevention (CDC)-endorsed fall-risk reduction measures.
75577702|NCT05794555|Drug|Lactulose|"Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2."
75727578|NCT00874406|Drug|folfox4|folfox4 will be done within 28 days after liver resection
75727579|NCT04840628|Other|Resistance of the respiratory system|increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
75431199|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
75431200|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
75431201|NCT01516944|Drug|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
75431202|NCT01518127|Other|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
75431203|NCT01518140|Device|Oxygen Delivery Devices|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
75727580|NCT00880178|Drug|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
75727581|NCT00880178|Drug|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
75727582|NCT04038866|Other|rehabilitation gait with dual task|
75727583|NCT04038866|Other|rehabilitation gait without dual task|
75431204|NCT01518140|Behavioral|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
75431205|NCT01518166|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
75577703|NCT05794555|Behavioral|Investigator recommended exercise|Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.
75577704|NCT05794555|Behavioral|TeleTai-Chi (virtual)|TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.
75577705|NCT05794022|Other|MRI|1 MRI at 1 month with gadolinium injection
75577706|NCT05794022|Biological|Biocollection|Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
75577707|NCT05794022|Behavioral|Quality of life questionaries|EQ-5D-5L and HAD questionaries at 1 month and 1 year.
75577708|NCT05792020|Device|Focused Ultrasound Stimulation|This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.
75577709|NCT05791032|Device|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
75577710|NCT05787106|Other|Cyberball task|"The game consists of ball throws between animated characters lasting about 50 throws. In the rejection condition, after 2 or 3 throws, the participant no longer receives the ball (no more passes). In the control conditions (all included), the participant receives the ball as often as the others."
75577712|NCT05781750|Drug|zetomipzomib|Subcutaneous injection of zetomipzomib
75727584|NCT00529659|Drug|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
75727585|NCT00529659|Drug|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
75727586|NCT05726565|Other|multidisciplinary cardiac rehabilitation|A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
75431206|NCT01518166|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
75431207|NCT01518166|Drug|atorvastatin|One single dose of 40 mg. Tablet
75431208|NCT01518166|Drug|lisinopril|One single dose of 20 mg. Tablet
75431209|NCT01518166|Drug|griseofulvin|One single dose of 500 mg. Tablet
75431210|NCT01518166|Drug|digoxin|One single dose of 1 mg. Tablet
75577713|NCT05781750|Drug|placebo|Subcutaneous injection of placebo
75727587|NCT04076969|Behavioral|Integrated educational session|The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
75727588|NCT04077125|Drug|Rifaximin|to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
75727589|NCT05707689|Behavioral|Entertainment gaming|If needed, gaming schedule will be tailored based on the participants' individual needs (working, studying, family issues) as long as the total gaming hours will be achieved. Participants are encouraged not to play video games during the study period. Participants' gaming interventions will be monitored carefully and recorded after each gaming session in specific gaming diary.
75727590|NCT05172401|Device|Oxulumis® suprachoroidal microcatheterization administration of Triesence®|Suprachoroidally administered Triamcinolone acetonide (Triesence) 2.4mg/60µl
75879122|NCT04377997|Drug|Enoxaparin|Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
75879123|NCT03566498|Dietary Supplement|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements
75879124|NCT03566498|Dietary Supplement|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
75879125|NCT01336049|Drug|Nimotuzumab|Nimotuzumab 200mg/week
75879126|NCT04758949|Drug|FL-101|200 mg administered intravenously every 2 weeks prior to surgery.
75879127|NCT04758949|Drug|Nivolumab|240 mg administered intravenously every 2 weeks prior to surgery.
75879128|NCT04758949|Drug|Placebo|200 mg administered intravenously every 2 weeks prior to surgery.
75879129|NCT04320979|Radiation|internal mammary nodal irradiation|chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
75879130|NCT04320979|Radiation|no internal mammary nodal irradiation|chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
75879131|NCT03564860|Procedure|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
75879132|NCT03565016|Other|no interventional study|no interventional study
75879133|NCT05708456|Other|Mobile application with symptom management|In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.
75879134|NCT01344343|Other|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
75879135|NCT03566186|Other|Phototherapy|Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
75577717|NCT05776225|Procedure|Right heart catheterization (RHC)|RHC to evaluate pulmonary hemodynamics
75577718|NCT05773989|Drug|CYP2C19 genotype guided P2Y12 monotherapy|Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
75577719|NCT05773989|Drug|Clopidogrel|Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
75577720|NCT05767346|Drug|Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)|Aficamten (CK-3773274) tablets administered orally
75577721|NCT05767346|Drug|Placebo to match aficamten|Placebo for aficamten (CK-3773274) administered orally
75577722|NCT05767346|Drug|Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)|Metoprolol succinate tablets administered orally
75727591|NCT05167877|Other|No intervention will be given to the participants|This is an observational feasibility study with no intervention.
75431211|NCT01518179|Device|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
75431212|NCT01518179|Other|Routine follow up and treatment|Control
75431213|NCT01518205|Device|LDL-apheresis|"The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
75431214|NCT01518231|Procedure|autologous hematopoiesis stem cell transplantation|Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
75431215|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
75431216|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial);
75431217|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
75431218|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt.
75431219|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
75431220|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial)
75431221|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
75727592|NCT01006785|Drug|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
75727593|NCT01006785|Drug|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
75879136|NCT03566186|Other|Placebo|The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
75879137|NCT03566186|Other|Passive recovery|Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
75431222|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt
75431223|NCT01518283|Drug|Cabazitaxel 10 mg/m2|Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
75431224|NCT01518296|Device|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
75577723|NCT05767346|Drug|Placebo to match metoprolol succinate|Placebo for metoprolol succinate administered orally
75577724|NCT05764239|Drug|SYNB1934v1|SYNB1934v1 IMP consists of powder for oral suspension packaged in sachets. During dose preparation, the powder will be resuspended in water or apple juice prior to administration.
75577725|NCT05764239|Drug|Placebo|A placebo will be manufactured using an inactive powder that is color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo will be packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
75577726|NCT05763004|Drug|IOS-1002|monotherapy
75577727|NCT05763004|Drug|IOS-1002 + KEYTRUDA® (pembrolizumab)|combination therapy
75727594|NCT00143455|Drug|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
75727595|NCT00143455|Drug|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
75727596|NCT05166551|Procedure|Acupressure|"This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine."
75727597|NCT05166551|Procedure|Placebo Acupressure|Placebo Acupressure
75727598|NCT01006863|Drug|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
75577728|NCT05760794|Procedure|Non-barbed delayed absorbable suture|The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
75577729|NCT05760794|Procedure|Barbed delayed absorbable suture|The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
75577730|NCT05756725|Other|Practice-Level Implementation Strategies|The intervention is implementation of new population health management tools that may better leverage patient navigation and other staff resources to ensure timely abnormal follow up of breast and colorectal cancer screening. The research team will work with CHCs to select implementation strategies that will best facilitate integration of the new tools into practice. The team will use electronic health record data (analyzed at the population level) to determine the impact of the new tools on screening outcomes and qualitative data from up to 3 staff and 2 patients per CHC to evaluate integration of the tools into practice.
76049550|NCT02347631|Device|Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first."
75577731|NCT05751941|Drug|Abiraterone|1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
75577732|NCT05751941|Drug|Enzalutamide|160 mg of Enzalutamide will be given orally daily ending at week 4
75879138|NCT01344421|Procedure|Minimally invasive approach for Periacetabular osteotomy|A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
76049551|NCT02015637|Drug|Delafloxacin|single dose
76049552|NCT02015637|Drug|Ceftriaxone|single dose
76049553|NCT02347085|Drug|GFF MDI (PT003)|
76049554|NCT02347085|Drug|Placebo MDI|
75431225|NCT01518335|Procedure|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
75431226|NCT01518335|Procedure|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
75431227|NCT01518348|Biological|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
75431228|NCT01518387|Drug|Lanthanum Carbonate (BAY77-1931)|
75431229|NCT01518413|Drug|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
75431230|NCT01518413|Drug|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
75431231|NCT01518426|Device|EEG Recording (Emotiv)|"Record EEG during auditory oddball paradigms:~with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)"
75431232|NCT01518439|Device|Alpha 200®|inspiratory capacity is increased with the use of constant pressure device: Alpha 200®
75431233|NCT01518439|Device|Alpha 200® + physiotherapist|inspiratory capacity is increased with the use of constant pressure device (Alpha 200®) combined with the manual pressures techniques to increase cough by the physiotherapist
75577733|NCT05751941|Drug|Apalutamide|240 mg of Apalutamide will be given orally daily ending at week 4
75577734|NCT05751941|Drug|Sipuleucel-T|Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
75879139|NCT03566030|Drug|Tenofovir disoproxil fumarate 300mg|Administered Tenofovir disoproxil fumarate 300 mg QD
75879140|NCT03566030|Drug|Tenofovir Alafenamide 25 mg|Administered Tenofovir Alafenamide 25 mg QD
76049555|NCT02374463|Behavioral|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
75577735|NCT05746897|Drug|NM1F Injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
75577736|NCT05746897|Drug|Pembrolizumab injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
75577738|NCT05741528|Drug|SEP-363856|SEP-363856 tablet
75879141|NCT04312711|Diagnostic Test|3D-TOF-MRA|"The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases."
76049556|NCT02374463|Behavioral|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
76049557|NCT02015481|Drug|Cabaletta|
75431234|NCT01518439|Device|Cough Assist®|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®)
75431235|NCT01518439|Device|Cough Assist® + physiotherapist|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®) combined with the manual pressures techniques to increase cough by the physiotherapist
75431236|NCT01518439|Other|physiotherapist|manual pressures techniques to increase cough applied by the physiotherapist
75431237|NCT01518452|Behavioral|Cogmed JM working memory training|daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
76049558|NCT02374307|Other|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
76049559|NCT02397473|Drug|Galcanezumab|Administered SC
75431238|NCT01518452|Behavioral|Cogmed JM working memory training after waiting|Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
75431239|NCT01518465|Drug|dalteparin|Given SC
75577739|NCT05741060|Drug|S-equol|Experimental drug
75577740|NCT05741060|Drug|Placebo|Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.
75577741|NCT05740982|Biological|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.
75577742|NCT05729477|Device|miCOR System|The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.
75577743|NCT05729477|Device|Phaco Subject Cohort|Phaco Subject Cohort
75577744|NCT05726305|Procedure|Live donor uterus transplantation|Transplantation of uterus from a living donor.
75431240|NCT01518465|Drug|lenalidomide|Given PO
75431241|NCT01518465|Drug|dexamethasone|Given PO
75431242|NCT01518465|Other|laboratory biomarker analysis|Correlative studies
75431243|NCT01518478|Drug|Fluzone® Intradermal (Sanofi Pasteur Inc.)|"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."
75431244|NCT01518491|Drug|NanoDOX Hydrogel|NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
75431245|NCT01518491|Other|VAC Alone|Patients will receive VAC therapy three time weekly for eight weeks
75431246|NCT01518504|Other|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
75431247|NCT01518504|Other|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
75431248|NCT01518569|Drug|ulinastatin|ulinastatin 5000 unit/kg iv before the initiation of CPB
75431249|NCT01518569|Drug|placebo|placebo (the same amount of normal saline) iv before the initiation of CPB
75431250|NCT01518582|Device|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
75577745|NCT05726305|Procedure|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
75577748|NCT05721144|Drug|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
75879142|NCT03565952|Other|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
75431251|NCT01518595|Drug|bosentan|pts. will receive bosentan for 3 months
75431252|NCT01518595|Drug|Placebo|pts. will receive placebo for 3 months
75431253|NCT01518608|Drug|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|"Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.~Pentothal 4mg/kg Rocuronium 0.6 mg/kg"
75431254|NCT01518621|Radiation|Radiation|Whole brain radiation
75431255|NCT01518621|Drug|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
75431256|NCT01518634|Drug|Imipramine treatment|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
75431257|NCT01518634|Drug|Placebo|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
75431258|NCT01518647|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
75431259|NCT01518660|Behavioral|Training|Bi-weekly progressive resistance training
76049560|NCT02397473|Drug|Placebo|Administered SC
76049561|NCT02344745|Other|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
75577752|NCT05709132|Behavioral|iPeer2Peer Program|Behavioral: iPeer2Peer Support Mentorship Program iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
75577753|NCT05708859|Drug|Tirzepatide|Tirzepatide 15mg Subcutaneous Solution
75577754|NCT05708859|Drug|Placebo|Volume matched Subcutaneous Solution
75577756|NCT05706129|Drug|[68Ga]Ga-DPI-4452|[68Ga]Ga-DPI-4452, administered as IV injection.
75577757|NCT05706129|Drug|[177Lu]Lu-DPI-4452|[177Lu]Lu-DPI-4452, administered as IV infusion.
75577758|NCT05699525|Behavioral|Personalized MAYA Mobile App|All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
75879143|NCT03565952|Other|Control group|The control group does not receive treatment
75431260|NCT01518686|Device|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
75431261|NCT01518712|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
75431262|NCT01518712|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
75431263|NCT01518725|Dietary Supplement|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
75431264|NCT01518725|Dietary Supplement|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
76049562|NCT02344745|Other|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
76049563|NCT02370641|Dietary Supplement|PomX|1000 mg POMx daily for 4 weeks
76049564|NCT01621191|Drug|Duloxetine|Administered Orally
76049565|NCT02343263|Drug|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
75431265|NCT01518738|Behavioral|breath attention training|4 week training
75431266|NCT01518738|Behavioral|working memory attention training|4 week training
75431267|NCT01518764|Dietary Supplement|Red Wine Polyphenols 600mg/day|
75431268|NCT01518764|Dietary Supplement|placebo|
75431269|NCT01518777|Other|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
75431270|NCT01518790|Drug|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
75431271|NCT01518803|Dietary Supplement|Mediterranean-style breakfast|"The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight."
75577759|NCT05699525|Behavioral|General MAYA Mobile App|New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.
75577760|NCT05698199|Drug|ITI-1001|ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.
76049566|NCT02343263|Biological|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
76049567|NCT02081859|Device|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
76049568|NCT02081859|Other|Conventional Criteria|
76049569|NCT04420715|Other|Training on coronary angiography using 3D coronary artery simulator|Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.
76049570|NCT04897451|Other|Questionnaire|EQ5D-5L questionnaire self-reported 3 months after delivery
76049571|NCT02342639|Drug|Rifaximin|550mg pills
76049572|NCT02342639|Drug|Placebo|Placebo pill
76049573|NCT01625091|Drug|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
76049574|NCT01625091|Drug|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
75431272|NCT01518803|Dietary Supplement|Western-style breakfast|The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
75727599|NCT01006863|Drug|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
75727600|NCT01006863|Drug|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine [group 5 (n=30)] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
75727601|NCT05688189|Device|different starting temperature setting of HFNC|The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
75879144|NCT03565796|Behavioral|Personalized active referral plus financial incentive|Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
75727602|NCT03967093|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
75879145|NCT03565796|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
75727603|NCT01006941|Biological|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
75879146|NCT03565796|Behavioral|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
75879147|NCT03565796|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
75879148|NCT03565796|Behavioral|COSH booklet|A general smoking cessation self-help booklet
75879149|NCT04256005|Other|Exercise|Participants will complete one of two exercise conditions (50% Delta GET or 105% VO2peak).
75879150|NCT05353946|Device|Percutaneous coronary intervention (PCI)|Optimal stent expansion by IVUS-guided PCI.
75879151|NCT03565718|Behavioral|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
75879152|NCT03565718|Behavioral|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
75879153|NCT01344499|Procedure|Carbon dioxide|standard pneumoperitoneum with 100% CO2
75879154|NCT01344499|Procedure|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
75879155|NCT01344499|Drug|Adept|instillation of 1 liter of fluid at the end of laparoscopy
75879156|NCT01344499|Drug|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
75879157|NCT03565562|Other|Promotion of the e-health tool by local authorities|Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.
75879158|NCT03565562|Other|Promotion of the e-health tool by local authorities and GPs|In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
75879159|NCT05065879|Biological|COVAX|2 doses of Covid-19 vaccine
75879160|NCT01339715|Procedure|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
75879161|NCT01333085|Drug|carboplatin|
75879162|NCT01333085|Drug|RAD001|
75879163|NCT01333085|Drug|paclitaxel|
75879164|NCT01344655|Drug|Atimos®|Formoterol 12 μg pMDI
75879165|NCT01344655|Drug|Serevent™|Salmeterol 25 µg pMDI
75879166|NCT01344655|Drug|Placebo|placebo
76049575|NCT02396849|Device|Continuous Positive Airway Pressure (CPAP)|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
76049576|NCT02396849|Device|Continuous Positive Airway Pressure (CPAP) Sham|Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
75879167|NCT03565484|Drug|susceptibility guided therapy|Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
75879168|NCT03565484|Drug|personal medication history guided therapy|Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
75879169|NCT03565484|Drug|salvage treatment for failed eradication|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
76049577|NCT02370251|Drug|Omegaven|Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB <2 mg/dL) occurs.
75431273|NCT01518842|Biological|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
76049578|NCT02396537|Drug|Lidocaine|Administered intranasally prior to Midazolam administration.
75577764|NCT05693558|Biological|NVD-003, an autologous 3D scaffold free osteogenic graft|Bone correction and grafting surgery
75577765|NCT05688852|Drug|VTX958|Dose A VTX958
76049579|NCT02396537|Drug|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
76049580|NCT02396537|Drug|0.9% Saline|Administered intranasally prior to Midazolam administration.
76049581|NCT04891367|Other|Cognitive behavioral therapy|The G-CBT manual for adolescents has been developed in the OCD-clinic in Aarhus and pilot tested in Aarhus. The G-CBT manual is based on the NordLOTS I-CBT manual in overall content and structure, with a few additional elements added with inspiration from previous individual and group CBT literature as well as the author's ideas. The main therapeutic ingredient is exposure and response prevention. The manual is made up of three individual family sessions, 13 weekly adolescent group sessions, three parent group sessions and two adolescent group booster sessions.The manual contains detailed guiding of therapists for each session and a comprehensive collection of working sheets for the adolescents to be used during sessions.
75577766|NCT05688852|Drug|VTX958|Dose B VTX958
75577767|NCT05688852|Drug|VTX958 Placebo|Placebo
75577768|NCT05688423|Behavioral|SIRI Team|"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~Medications for SUD as integral to management of infectious complications~Integration of ID and SUD care~Longitudinal care with familiar providers~Multidisciplinary care and care coordination~Tailored antibiotic options and care settings~Harm reduction"
75431274|NCT01518855|Drug|Nifedipine (Adalat, BAYA1040)|
75431275|NCT01518855|Drug|Amlodipine (Norvasc)|
75431276|NCT01518855|Drug|Diovan|
75431277|NCT01518881|Drug|TKM-100201|IV Infusion
75727604|NCT03534167|Behavioral|TODAY! App and Coaching|"The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based."
75727605|NCT02531347|Behavioral|Telemedical home blood pressure measurements|
75727606|NCT02531347|Behavioral|Conventional blood pressure monitoring|
75431278|NCT01518881|Drug|Placebo|IV infusion
75727607|NCT04075175|Drug|S315|Human monoclonal antibody against Diphtheria Toxin
75431279|NCT01518894|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
75431280|NCT01518894|Drug|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
75431281|NCT01518894|Drug|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
75431282|NCT01518894|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
75431283|NCT01518907|Biological|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Subdermal dose
75431284|NCT01518920|Drug|PF-04958242|PF-04958242 0.35 mg oral solution
75431285|NCT01518920|Drug|PF-04958242|PF-04958242 0.27 mg oral solution
75431286|NCT01518920|Drug|Placebo|Placebo oral solution
75431287|NCT01518933|Drug|Silibinin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
75879170|NCT01336127|Behavioral|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
76049582|NCT02342171|Other|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
75431288|NCT01518933|Drug|Saline|Placebo
75431289|NCT01518959|Drug|Cholecalciferol|180.000 IU monthly
76049583|NCT01624467|Biological|Necitumumab|800 mg necitumumab, administered once per week IV
75431290|NCT01518959|Drug|oleum neutralicum|Placebo comparator, 9 ml monthly
76049584|NCT01624233|Drug|80 mg ixekizumab|Administered SC
75727608|NCT04075175|Drug|0.9% Sodium Chloride (NaCl)|Placebo 0.9% Sodium Chloride (NaCl)
75727609|NCT05550051|Procedure|Awake nasal fiberoptic intubation|Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
75431291|NCT01518985|Drug|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
75431292|NCT01518985|Drug|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
75431293|NCT01518985|Other|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
75431294|NCT01518998|Drug|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
75431295|NCT01519011|Drug|oral azacitidine|oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
75727610|NCT03967015|Other|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
75727611|NCT05012007|Other|Reminder Phone|Standard reminder via phone (audiocare)
76049585|NCT01993017|Other|Cognitive Behavioral Therapy (CBT)|"The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement ."
75431296|NCT01519011|Drug|oral azacitidine|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
75431297|NCT01519037|Drug|Cinacalcet 60 MG|one dose of oral cinacalcet, 60mg
75431298|NCT01519037|Drug|Placebo oral tablet|one tablet of placebo
75431299|NCT01519050|Behavioral|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
75431300|NCT01519076|Device|Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)|The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
76049586|NCT01993017|Drug|Antidepressant Medication|"The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated."
76049587|NCT01993017|Other|Standard Care|Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
76049588|NCT01993017|Other|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
75431301|NCT01519102|Device|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
75431302|NCT01519115|Other|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
75431303|NCT01519115|Other|usual care|one physical therapy visit in hospital following ACF surgery
76049589|NCT01993017|Other|No intervention|
76049590|NCT01992549|Biological|Human-cl rhFVIII|
75431304|NCT01519128|Drug|Treatment A: Digoxin|Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
75431305|NCT01519128|Drug|Treatment B: TMC278|Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
76049591|NCT01992159|Drug|Romosozumab|Administered by subcutaneous injection
76049592|NCT01992159|Drug|Placebo|Administered by subcutaneous injection
76049593|NCT01988493|Drug|Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
76049594|NCT01988493|Drug|Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
76049595|NCT01988493|Drug|Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
76049596|NCT01988493|Drug|Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
75431306|NCT01519154|Drug|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
75431307|NCT01519154|Drug|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
75577769|NCT05688423|Behavioral|Treatment as Usual|Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
75577770|NCT05687903|Drug|TAK-861|TAK-861 tablets
75577771|NCT05687903|Drug|Placebo|TAK-861 placebo matching tablets
76049597|NCT01988493|Drug|Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
76049598|NCT02081079|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
76049599|NCT02081001|Drug|Novo Nordisk GlucaGen®|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
76049600|NCT02081001|Drug|G-Pump™ (glucagon infusion)|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
76049601|NCT02080221|Drug|FOLFOXA|
76049602|NCT02079909|Drug|T-817MA-H|224 mg or 448 mg T-817 MA once daily
75577772|NCT05687032|Drug|inotuzumab ozogamicin|Given IV
75577773|NCT05677451|Drug|LOU064 (blinded)|LOU064 (blinded) active treatment
75577774|NCT05677451|Drug|placebo|matching active drug
75577775|NCT05673460|Drug|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg
75727612|NCT05012007|Other|Reminder Text|reminder via text (VEText)
76049603|NCT02079909|Drug|T-817MA-L|224 mg T-817 MA once daily
76049604|NCT02079909|Drug|Placebo|Placebo
75431308|NCT01519193|Behavioral|Narrative Exposure Therapy for violent offenders (NETvo)|During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
75431309|NCT01519219|Radiation|Hepatic Irradiation|Patients who take part in this study are required to be scheduled for hepatic irradiation. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy
75431310|NCT01519232|Radiation|Liver Irradiation|Patients already scheduled to undergo radiation treatment
75431311|NCT01519258|Other|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
75431312|NCT01519258|Device|NAVA|Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
75431313|NCT01519297|Drug|Irbesartan|150mg orally for one dose
75431314|NCT01519310|Other|Antibiotic (metronidazole and ciprofloxacin)/probiotic|"Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks."
75431315|NCT01519336|Drug|danoprevir|100 mg q12h
75431316|NCT01519336|Drug|darunavir|600 mg q12h
75431317|NCT01519336|Drug|ritonavir|100 mg q12h
75431318|NCT01519388|Other|Spontaneous breathing|study of the swallowing of boluses of water and yogurt under spontaneous breathing
75431319|NCT01519388|Device|Elysée 150®|Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
75727613|NCT03741439|Device|Treatment|Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
75727614|NCT03741439|Device|Sham|Sham treatment
75431320|NCT01519401|Drug|3 mg drospirenone and 20 µg ethinyl-estradiol|
75431321|NCT01519401|Drug|3 mg drospirenone and 30 µg ethinyl-estradiol|
75577776|NCT05670405|Other|The Trauma PORTAL|"Participants will have 9 weeks to complete the 8 modules which each take on average 45 minutes to complete. Each module consists of psychoeducational handouts, videos, interactive exercises, and discussion topics that has been adapted from the R&R curriculum. The participants will also receive a pdf of the handouts from the modules, which can be used to take notes or refer back to in the future.~There will be an optional 60-minute weekly virtual group session for participants to engage with other participants in their group and for group facilitator providers to discuss the materials covered and answer any questions. Participants will join a Zoom video group visit to access the group. Each weekly group will be facilitated by 2 clinicians specializing in trauma-focused therapy within the WCH TTP who have extensive experience with in-person and virtual synchronous R&R."
75727615|NCT03529955|Drug|Apremilast 30mg|Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
75727616|NCT00142909|Drug|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
75727617|NCT00142909|Drug|Placebo|Lofexidine Placebo
75431322|NCT01519479|Other|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
75431323|NCT01519479|Other|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
75431324|NCT01519492|Drug|AFN-12520000|Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
75431325|NCT01519505|Behavioral|Lifestyle intervention|INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
75431326|NCT01519531|Drug|Placebo|Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
75431327|NCT01519531|Drug|VIA-3196|Oral, daily dosing for 14 days
75431328|NCT01519544|Drug|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
75431329|NCT01519544|Drug|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
75431330|NCT01519557|Drug|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
75431331|NCT01519557|Drug|Placebo|Placebo
75727618|NCT03885245|Drug|L-ctirulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
75431332|NCT01519596|Procedure|quality-of-life assessment|Ancillary studies
75431333|NCT01519596|Other|counseling intervention|Receive lifestyle-related counseling
75727619|NCT03885245|Drug|Matching Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
75727620|NCT01007019|Drug|YH4808 30mg|YH4808 30mg (single dose)
75727621|NCT01007019|Drug|YH4808 50mg|YH4808 50mg (single dose)
75727622|NCT01007019|Drug|YH4808 100mg|YH4808 100mg (single dose)
75431334|NCT01519596|Behavioral|exercise intervention|Undergo physical activity intervention
75727623|NCT01007019|Drug|YH4808 200mg|YH4808 200mg (single dose)
75727624|NCT01007019|Drug|YH4808|YH4808 400mg (single dose)
75431335|NCT01519596|Other|educational intervention|Receive educational materials
75431336|NCT01519596|Procedure|standard follow-up care|Undergo usual care
75431337|NCT01519609|Drug|bowel prep before endoscopy|bowel prep before colonoscopy
75431338|NCT01519622|Other|Questionnaire|Questionnaire to be distributed among sick elderly in the community
75431339|NCT01519687|Drug|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
75431340|NCT01519726|Drug|Midazolam|
75431341|NCT01519739|Device|MediGuide™|MediGuide™ system will be used to guide CRT implants
75431342|NCT01519752|Drug|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
75431343|NCT01519752|Drug|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
75431344|NCT01519752|Drug|Placebo|Placebo applied to affected area once a day for 28 days
75431345|NCT01519830|Drug|Iron carboxymaltose (Ferinject)|Intravenous iron
75727625|NCT01007019|Drug|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
75431346|NCT01519830|Drug|Placebo|0.9% NaCl solution
75431347|NCT01519856|Drug|piribedil (Clarium)|oral tablets, 50 mg
75431348|NCT01519895|Behavioral|Telephone intervention|counseling and education support
75431349|NCT01519908|Device|CRT-D (Medtronic)|Biventricular implantable cardioverter defibrillator, post marketing release
75727626|NCT01007019|Drug|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
75727627|NCT01007019|Drug|YH4808 600mg|YH4808 600mg
75727628|NCT01007019|Drug|YH4808 800mg (single dose)|YH4808 800mg (single dose)
75727629|NCT01007019|Drug|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
75727630|NCT01007019|Drug|Placebo|10 volunteers will be administered matched placebo.
75727631|NCT01007019|Drug|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
75727632|NCT05673863|Behavioral|Psychological Resilience Program|The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
75727633|NCT02579993|Procedure|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
75727634|NCT02579993|Procedure|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
75879171|NCT03565406|Drug|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
75431350|NCT01519973|Radiation|SPECT/CT processed with Evolution for CardiacTM software|SPECT/CT to be compared with PET/CT
75431351|NCT01519986|Dietary Supplement|Vitamin D3|Supplement of vitamin D3
75431352|NCT01519986|Dietary Supplement|Placebo|Placebo
75431353|NCT01519999|Behavioral|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
75727635|NCT04075097|Behavioral|Aerobic exercise|1 session
75727636|NCT04075097|Behavioral|Iyengar yoga|1 session
75727637|NCT01007175|Biological|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
75727638|NCT01007175|Biological|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
75879172|NCT03565406|Drug|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
75879173|NCT01333163|Biological|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
75879174|NCT01333163|Biological|Isotone NaCl|2 hours IV infusion.
75879175|NCT04734379|Drug|Fasudil|Oral fasudil 180 mg/day
75879176|NCT03565250|Other|self understanding interview|semi-structured interview designed for assessment of identity according to Damon & Hart's 7-dimension develomental model
75879177|NCT05352620|Other|Implant assisted maxillary overdenture|For each patient, an implant assisted maxillary overdenture will be fabricated using a minimally invasive flapless surgical technique with OT-Equator and Smart Box attachment
75879178|NCT04163887|Procedure|hepatectomy|Resection colorectal liver metastases using a laparoscopic approach or an open approach.
75727639|NCT01007175|Biological|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
75727640|NCT01007175|Biological|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
75879179|NCT01333241|Behavioral|Lifestyle behavior interventon grop|
75727641|NCT01007175|Biological|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
75727642|NCT04076189|Procedure|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
75879180|NCT01333241|Other|Placebo Comparator: Control group|
75879181|NCT03565094|Drug|Lu AF28996 solution|"Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses"
75879182|NCT03565094|Drug|Lu AF28996 capsule|hard capsule orally QD: one dose lower than the highest dose level in part A
75727643|NCT04076189|Procedure|No endotracheal suctioning|Procedure includes: immediate initiation of positive pressure ventilation without intubation and tracheal suctioning
75727644|NCT03508739|Drug|Sacubitril/Valsartan 200mg (blinded)|study day 2 for AB and study day 3 for BA
75727645|NCT03508739|Drug|Valsartan 160mg (blinded)|study day 3 for AB and study day 2 for BA
75727646|NCT03882437|Biological|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
75727647|NCT00205699|Drug|risperidone|randomized to begin 12 week trial of risperidone
75727648|NCT00205699|Drug|olanzapine|randomized to begin 12 week trial of olanzapine
75727649|NCT00205699|Drug|aripiprazole|randomized to 12 week trial of aripiprazole
75431354|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
75431355|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
75431356|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
75431357|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
75431358|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
75431359|NCT01520025|Radiation|PET MPI imaging with 18F-Fluorodeoxyglucose|"Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)"
75431360|NCT01520051|Drug|Mepolizumab|3 monthly intravenous infusions of 750 mg
75431361|NCT01520051|Drug|Placebo|3 monthly intravenous infusions with saline
75431362|NCT01520077|Drug|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
75431363|NCT01520103|Drug|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
75431364|NCT01520103|Drug|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
75431365|NCT01520116|Drug|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
75431366|NCT01520116|Drug|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
75431367|NCT01520116|Drug|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
75431368|NCT01520116|Drug|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
75431369|NCT01520116|Drug|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
75431370|NCT01520116|Drug|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
75431371|NCT01520116|Drug|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
75431372|NCT01520116|Drug|Timoptic|0.5%
75727650|NCT03503513|Drug|Gentamicin Sulfate|Gentamicin will be compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Participants will do daily instillations of 30 milliliters of solution
75727651|NCT03882801|Drug|Gefapixant|In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.
75727652|NCT03882801|Drug|Placebo|In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
75727653|NCT01073917|Other|Spontaneous Breathing|
75727654|NCT01073917|Other|Pressure Controlled Ventilation|
75727655|NCT01073917|Other|Pressure Support Ventilation|
75727656|NCT01582399|Drug|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
75727657|NCT03880227|Device|Active anodal tDCS|active anodal tDCS with behavioral tasks to assess visual attention
75727658|NCT03880227|Device|Sham tDCS|sham tDCS with behavioral tasks to assess visual attention
75727659|NCT04000113|Device|laser acupuncture|low level laser emission on specific acupuncture points
75727660|NCT04000113|Device|Sham laser|Sham laser
75577777|NCT05665608|Device|Implantable cardioverter-defibrillator (ICD)|"A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing.~The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs."
75577778|NCT05665608|Drug|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure"
75727661|NCT03999567|Other|Pen and Paper Digit Symbol Substitution Test (DSST)|The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
75727662|NCT03999567|Other|Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)|Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
75431373|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
75431374|NCT01520142|Drug|JNJ-26528398|In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
75431375|NCT01520142|Drug|Placebo|In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
75431376|NCT01518218|Behavioral|laying-on-of-hands|The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
75577781|NCT05664243|Biological|Autologous genetically modified gamma-delta T cells|Arm A: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance
75577782|NCT05664243|Biological|Allogeneic genetically modified gamma-delta T cells|"Phase 1b and Arm B: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with D1 of TMZ 150mg/m2~Arms C: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance"
75727663|NCT02580149|Drug|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
75879183|NCT01339871|Drug|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
75879184|NCT01339871|Drug|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
75431377|NCT01520181|Drug|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
75431378|NCT01520194|Other|women attending reproductive health clinics|women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al
75431379|NCT01520194|Other|medical records|medical chart review of patients assisted January 2009 to December 2010
75431380|NCT01520220|Drug|LY2784544|LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
75431381|NCT01520233|Genetic|RNA analysis|
75431382|NCT01520233|Genetic|gene expression analysis|
75431383|NCT01520233|Other|laboratory biomarker analysis|
75431384|NCT01520246|Genetic|gene expression analysis|
75431385|NCT01520246|Other|laboratory biomarker analysis|
75431386|NCT01520285|Drug|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
75431387|NCT01520285|Drug|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
75577784|NCT05661734|Drug|VX-548|Tablets for oral administration.
75879185|NCT01339949|Device|IRay|low voltage external beam radiosurgery
75879186|NCT01339949|Device|IRay|low voltage external beam radiosurgery
75431388|NCT01520298|Drug|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
75577786|NCT05660486|Other|Aromatherapy|Participants in this group will receive 2-3 drops of 100% pure Lavandula angustifolia essential oil applied to a surgical mask pre-procedure for aromatherapy.
75727664|NCT02580149|Drug|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
75727665|NCT01007331|Behavioral|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10^10 colony forming units pr day of probiotics
75727666|NCT04996017|Drug|Atezolizumab 1200 mg in 20 ML Injection|Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
75727667|NCT04996017|Drug|Placebo|Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
76049605|NCT04178031|Device|IUD insertion|"Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman."
76049606|NCT02014467|Drug|Denosumab|Injection
75727668|NCT03483935|Other|Microwave treatment|Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
75431389|NCT01520298|Drug|Acetaminophen IV|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
75577787|NCT05660486|Other|Placebo|Participants in this group will receive 2-3 drops of water applied to a surgical mask pre-procedure.
75577788|NCT05656196|Other|Chinese herbal tea VGH-DESJS-1|Chinese herbal tea VGH-DESJS-1.
75727669|NCT00530439|Other|Lifestyle intervention|Dietician counselling and physical training
76049607|NCT02014467|Drug|Placebo|Injection
76049608|NCT02014467|Dietary Supplement|Elemental Calcium|Oral, at least 600 mg
76049609|NCT02014467|Dietary Supplement|Vitamin D|Oral, at least 400 IU
76049610|NCT02013765|Drug|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
76049611|NCT02013687|Biological|Pfs25 VLP- FhCMB|
75577789|NCT05653999|Device|Hearing Aids|Hearing aids will be used by infants with a diagnosed sensorineural hearing loss.
75727670|NCT00530439|Other|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
75727671|NCT00530439|Behavioral|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
75879187|NCT04693429|Drug|Bepotastine Besilate|Bepotastine Besilate 1.5% QID (quater in die) for 7 days
76049612|NCT02013609|Drug|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
76049613|NCT01988337|Device|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
76049614|NCT01988337|Other|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
75727672|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
76049615|NCT02013531|Drug|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
75727673|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
75727674|NCT04994223|Drug|Rivaroxaban 10 MG Oral Tablet [Xarelto]|rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival
75727675|NCT04962633|Other|Probiotic Pasta|Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
75431390|NCT01520311|Device|eSVS Mesh|Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
75727676|NCT04962633|Other|Control Pasta|Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
76049616|NCT01988103|Drug|Apremilast|20 mg tablet BID for 68 weeks
75431391|NCT01520337|Device|oral tablet dye for detection of polyps during colonoscopy|oral tablet dye for improved detection of
75431392|NCT01520350|Drug|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
75431393|NCT01520350|Drug|placebo|Placebo
75431394|NCT01520376|Behavioral|Counselling|Visit by a psychiatrist at day-30 and day-180 after discarge
75431395|NCT01520389|Drug|MM-151|MM-151
75431396|NCT01520389|Drug|MM-151 + irinotecan|MM-151 + irinotecan
75431397|NCT01520415|Drug|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
75431398|NCT01520415|Drug|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
75431399|NCT01520428|Behavioral|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
75431400|NCT01520441|Drug|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
75431401|NCT01520467|Drug|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
75727677|NCT01007565|Procedure|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
75727678|NCT00497146|Drug|paricalcitol|2 µg capsule
75727679|NCT00497146|Drug|placebo|placebo capsule
75727680|NCT01016548|Biological|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
76049617|NCT01988103|Drug|Apremilast|20 mg tablet BID for 68 weeks
76049618|NCT01988103|Drug|Placebo|Placebo tablet BID for 16 weeks
76049619|NCT02013375|Procedure|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
76049620|NCT02013375|Drug|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
75431402|NCT01520467|Drug|Placebo|1 placebo tablet /day administered orally for 18 months.
75431403|NCT01520493|Other|Submaximal exercises|Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
75431404|NCT01520571|Procedure|Non-Computer Assistance TKA|Non-Computer Assistance Total Knee Arthroplasty
75431405|NCT01520571|Procedure|Computer Assistance TKA|Computer Assistance Total Knee Arthroplasty
75431406|NCT01520584|Dietary Supplement|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
75431407|NCT01520623|Other|Serum concentration /Serum inflammatory|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
75431408|NCT01520636|Procedure|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
75431409|NCT01520636|Procedure|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
75431410|NCT01520649|Drug|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
75431411|NCT01520649|Drug|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
75431412|NCT01520662|Other|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
75431413|NCT01520675|Procedure|surgery|Drainage procedure
75431414|NCT01520675|Procedure|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
75431415|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
75431416|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
75431417|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
75431418|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast and lunch
75431419|NCT01520753|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at dinner
75431420|NCT01520766|Device|prefabricated titanium post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
75431421|NCT01520766|Device|prefabricated glass fiber reinforced composite post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
75431422|NCT01520792|Drug|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
75727681|NCT01019824|Drug|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
76049621|NCT02013375|Radiation|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
76049622|NCT02013375|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
76049623|NCT02013375|Drug|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
76049624|NCT02079519|Drug|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
75577796|NCT05651841|Drug|Tezepelumab|"Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
75577797|NCT05651841|Other|placebo|"APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
75577798|NCT05646121|Device|Suprasorb® A + Ag wound dressing and rope|Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressings / Packing Rope are soft, conformable wound coverings with a high mannuronic acid content (mass per unit area ≥100 g/m2). The silver impregnated calcium alginate fibres react with wound exudate or blood to form a gel which creates a moist wound environment. The silver contained in the wound dressing has broad antimicrobial activity, including against MRSA and VRE. Antimicrobial action (>3 log steps) associated with the ionic silver from the silver alginate fibres (1.5%) is observed in vitro after just 24 h and this remains stable for up to seven days
76049625|NCT01987557|Behavioral|rate group|walking with a high cadence (steps per minute)
75727682|NCT01016626|Drug|CKD-4101 tablet|"CKD-4101 tablet 1000 mg~500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
75431423|NCT01520805|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
76049626|NCT01987557|Behavioral|magnitude treadmill group|
76049627|NCT01987557|Behavioral|regular treadmill walking|
75727683|NCT01016626|Drug|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg~250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
75727684|NCT01016704|Behavioral|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
75727685|NCT00489970|Procedure|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
75879188|NCT05353712|Other|SUCROSE|50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
76049628|NCT02078817|Drug|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
76049629|NCT02011893|Device|Tonic Stimulation|Prodigy Neurostimulation System with associated components
76049630|NCT02011893|Device|Burst Stimulation|Prodigy Neurostimulation System with associated components
75431424|NCT01520818|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m^2 will receive BIAsp 50
76049631|NCT02011113|Drug|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
76049632|NCT02011113|Drug|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
76049633|NCT01807156|Drug|Tivozanib|Oral medication given daily. No placebo.
76049634|NCT01987479|Drug|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
76049635|NCT01987479|Drug|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
76049636|NCT01987479|Drug|Methotrexate|Methotrexate will be administered per investigator's discretion.
76049637|NCT01620489|Drug|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
75577803|NCT05640102|Drug|Zanubrutinib|Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling
75577804|NCT05634057|Drug|Anisodamine hydrobromide combined with heparin|The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
75431425|NCT01520818|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m^2 will receive BIAsp 70
75431426|NCT01520818|Drug|biphasic human insulin 30|Administered subcutaneously (s.c., under the skin), twice a day
75577805|NCT05630885|Drug|CVC 150 mg|Administered as one 150-mg tablet by mouth once a day with food.
75577806|NCT05630885|Drug|CVC 300 mg|Administered as two 150-mg tablets by mouth once a day with food.
75431427|NCT01520831|Drug|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
75431428|NCT01520831|Drug|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
75577807|NCT05630885|Other|Placebo for CVC 150 mg|Administered as one 150-mg matching placebo tablets by mouth once a day with food.
75577808|NCT05630885|Other|Placebo for CVC 300 mg|Administered as two 150-mg matching placebo tablets by mouth once a day with food.
75431429|NCT01520831|Drug|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
75727686|NCT00489970|Biological|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
75431430|NCT01520831|Drug|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
75431431|NCT01520844|Biological|blood sampling|blood sampling
75431432|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
75431433|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
75577809|NCT05630703|Behavioral|Mindfulness-based Attention Training in IBS|The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
75577810|NCT05630703|Other|Low FODMAP Diet|Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
75577811|NCT05626114|Biological|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
75577812|NCT05625698|Drug|MagTrace only|see information in arm descriptions
75727687|NCT00489970|Biological|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
76049638|NCT01620489|Drug|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
75431434|NCT01520896|Drug|NKTR-118|Oral 25 mg
75431435|NCT01520896|Drug|Ketoconazole|Oral 400 mg
75577813|NCT05625698|Combination Product|MagTrace and Magseed|see information in arm descriptions
75577814|NCT05624749|Drug|ianalumab|ianalumab s.c. monthly
75577815|NCT05624749|Drug|placebo|placebo s.c. monthly
75577816|NCT05624112|Drug|Dupilumab|Dupilumab solution in a pre-filled syringe for Subcutaneous injection
76049639|NCT02076165|Behavioral|Acceptance and the Behavioral Changes to Treat Insomnia|Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.
75577818|NCT05617014|Radiation|Neuraceq|Amyloid PET imaging with Florbetaben (Neuraceq) injection
75577819|NCT05617014|Radiation|Amyvid|Amyloid PET imaging with Amyvid (Florbetapir) injection
75577820|NCT05617014|Radiation|Tauvid|Tau PET imaging with Tauvid (Flortaucipir) injection
75577821|NCT05617014|Radiation|MK-6240|Tau PET imaging with MK-6240 injection
75577822|NCT05617014|Radiation|NAV4694|Amyloid PET imaging with NAV4694 injection
75577823|NCT05617014|Radiation|PI-2620|Tau PET imaging with PI-2620 injection
75577824|NCT05615870|Other|Winix 5500-2 HEPA filtration units|To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.
75727688|NCT01020058|Procedure|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
75879189|NCT05353712|Other|CONTROL|35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
76049640|NCT02076165|Behavioral|Cognitive behavioral therapy for insomnia|Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
75727689|NCT02798471|Drug|Edoxaban|15 or 30 mg tablets for participants 12 years of age to <18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
75727690|NCT02798471|Drug|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
75879190|NCT05353712|Other|ARA20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
75879191|NCT05353712|Other|ARA40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
75879192|NCT05353712|Other|TAG20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
75879193|NCT05353712|Other|TAG40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
76049641|NCT01620255|Drug|Placebo|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
76049642|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
76049643|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
76049644|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
76049645|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
76049646|NCT02010567|Drug|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
76049647|NCT02010567|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
76049648|NCT02010567|Radiation|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if <T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume."
76049649|NCT02010567|Procedure|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
76049650|NCT01806064|Drug|TRC105 and Axitinib|
75577825|NCT05612425|Behavioral|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
75577826|NCT05612425|Behavioral|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
75577827|NCT05612100|Other|Electronic Health Record Review|Ancillary studies
75577828|NCT05612100|Other|Questionnaire Administration|Complete alopecia questionnaires
75577829|NCT05612100|Other|Survey Administration|Complete alopecia surveys
75577830|NCT05609968|Biological|Sacituzumab Govitecan|IV infusion
75577831|NCT05609968|Biological|Pembrolizumab|IV infusion
76049651|NCT01806064|Drug|Axitinib|
75879194|NCT01336283|Other|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
76049652|NCT01804582|Other|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
75431436|NCT01520935|Other|Data collection|"The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).~Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed."
75431437|NCT01520948|Behavioral|Exercise-based behavioral therapy|Pelvic floor muscle exercise training, bladder training, fluid management, constipation management
75431438|NCT01520948|Behavioral|Behavioral control|Mirrored star drawing
76049653|NCT01787188|Drug|Meloxicam Test Capsules|
76049654|NCT01787188|Drug|Meloxicam Test Capsules|
76049655|NCT01787188|Drug|Placebo Capsules|
75577836|NCT05601414|Device|BIO-Z|a novel cuffless continuous BP wrist monitor
75727691|NCT03443765|Diagnostic Test|Detection of Plasma levels of 25(OH) vitamin D by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
75727692|NCT03443765|Diagnostic Test|Detection of Total serum immunoglobulin E by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
75879195|NCT01336283|Other|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
75879196|NCT01336283|Other|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
76049656|NCT01787032|Drug|BI 113608|tablet
75577837|NCT05601414|Device|Finapres Nova|a cuffless continuous BP monitor
76049657|NCT01787032|Drug|BI 113608|tablet
76049658|NCT01787032|Drug|BI 113608|tablet
76049659|NCT01787032|Drug|Ketoconazole|tablet
76049660|NCT01787032|Drug|Voriconazole|tablet
76049661|NCT01737268|Drug|FK949E|Oral tablet
76049662|NCT01769404|Biological|LY2605541|
75879197|NCT03916549|Device|Acupuncture|The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
75879198|NCT05353634|Diagnostic Test|Effects of mNGS on infected patients|The impact of mNGS on infected patients, including diagnostic value, drug selection, treatment prognosis, economic burden, etc.
75879199|NCT03564704|Drug|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.
75727693|NCT03441893|Diagnostic Test|parasitological diagnostics (coproscopy)|Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
75727694|NCT03441893|Drug|Nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
75727695|NCT03441893|Drug|Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
75727696|NCT03441893|Drug|Mesalazine 250Mg|Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
75727697|NCT03441893|Drug|Placebo tabletes|Tab. Placebo (shugar pills) will be given to the participants
75727698|NCT03848663|Behavioral|Traditional Remapping|Shifting text outside of scotoma
75727699|NCT03848663|Behavioral|Personalized Remapping|Shifting text based on individual letter-based perimetry
75727700|NCT03440177|Drug|Ramipril|Patients are tested for their normal prescription ramipril medication
75727701|NCT00489736|Drug|dronedarone (SR33589)|oral administration
75727702|NCT00489736|Drug|amiodarone|oral administration
75727703|NCT02774759|Device|Accelerometer|Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
75727704|NCT02774759|Behavioral|Questionnaires|"Questionnaires completed at baseline regarding quality of life and diet.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
75727705|NCT02774759|Behavioral|Fitness Test|Fitness test given covering various physical activities at baseline and at 6 month visit.
75879200|NCT03564704|Drug|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
75879201|NCT03564704|Drug|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
75879202|NCT03564704|Drug|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
75879203|NCT03564704|Drug|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
75879204|NCT03564704|Drug|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.
75879205|NCT03564704|Drug|Methotrexate|Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
76049663|NCT01769404|Biological|Insulin Glargine|
76049664|NCT04562662|Device|mediVR KAGURA|Approximately 20 min mediVR KAGURA-guided rehabilitation
76049665|NCT01769326|Other|Conventional hand exercise|Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
76049666|NCT01769326|Device|MusicGlove|The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
76049667|NCT01769326|Other|Conventional Arm Exercise|Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
76049668|NCT01769326|Device|Resonating Arm Exerciser|The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
76049669|NCT01786330|Device|Procare abdominal binder|
76049670|NCT01786330|Other|Standard of Care|
76049671|NCT01786174|Drug|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
75577839|NCT05590728|Drug|Apramycin (EBL-1003)|A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
75727706|NCT02774759|Behavioral|Resistance Training|Physical activity guidelines workbook distributed along with activity monitor. Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member. Information from wireless scale and Fitbit sent to Fitbit website to monitor levels.
75727707|NCT02774759|Behavioral|Aerobic Exercise|Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor.
75727708|NCT02774759|Behavioral|Telephone Coaching/Phone Calls|Participants called 4 times during the first month, 2 times during the second month, and 1 time per month for the rest of the study. Participants also receive a follow-up call at the end of the study.
75727709|NCT02774759|Behavioral|Video Chat Sessions|Video chatting between the research team and participants occurs 2 times per month during the first and third months, when new exercises are introduced. Video chatting offered monthly as needed by participants during months 2, 4, 5, and 6.
75727710|NCT00617084|Device|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
75727711|NCT00617084|Device|Abbott Xience V|Abbott Xience V
75727712|NCT02758847|Device|Angiogram, Medtronic DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
75727713|NCT02758847|Device|Angiogram, Bard DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
75727714|NCT01016860|Drug|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
75727715|NCT01016860|Drug|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
75727716|NCT04075877|Behavioral|FOCUS|See prior section.
75879206|NCT03564704|Drug|6-mercaptopurine.|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
75879207|NCT03564704|Drug|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.
75879208|NCT03564704|Drug|Cytarabine|AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.
76049672|NCT01786174|Other|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
76049673|NCT01736566|Other|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
75577840|NCT05588843|Drug|SAR443122|oral capsule
75577841|NCT05588843|Drug|Placebo|oral capsule
76049674|NCT01736566|Other|Family History Only|Doctors and their patients receive a Family History report.
76049675|NCT01768858|Drug|Adalimumab|Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
76049676|NCT01736254|Drug|Evacetrapib|
76049677|NCT01736254|Drug|Gemfibrozil|
76049678|NCT01767376|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
76049679|NCT01767376|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
76049680|NCT01767142|Device|The Zeltiq System with Modified Belt Applicator|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
76049681|NCT01785628|Dietary Supplement|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
76049682|NCT01785628|Dietary Supplement|Placebo Capsule|Placebo is dextrin composition.
76049683|NCT01785472|Drug|LCZ696|LCZ696 200 mg tablet
76049684|NCT01785472|Drug|Olmesartan|Olmesartan 20 mg capsule
76049685|NCT01785472|Drug|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
76049686|NCT01785472|Drug|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
76049687|NCT01785160|Drug|Raltegravir|low dose oral administration
76049688|NCT01785160|Drug|Raltegravir|low dose oral administration
75577842|NCT05581602|Device|Wearing bracelets (3-Axis Logging Accelerometer)|Participants will be required to wear wristbands containing an accelerometer on each wrist. The bracelets will be kept on both wrists for 7 days with permission to remove them from time to time.
75727717|NCT00874484|Drug|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
75727718|NCT00869492|Drug|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
75727719|NCT00869492|Drug|nadifloxacine|Nadifloxacine 1% cream twice dailly
75727720|NCT00489424|Drug|Placebo|
75727721|NCT00489424|Drug|Acetaminophen|
76049689|NCT01785160|Drug|Faldaprevir|medium dose oral administration
76049690|NCT01736176|Drug|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
75727722|NCT00489424|Drug|Fluvastatin|
75879209|NCT03564704|Procedure|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
76049691|NCT01736176|Procedure|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
76049692|NCT01736176|Drug|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
76049693|NCT01735630|Drug|ELND005|
76049694|NCT01735630|Drug|Placebo|
76049695|NCT04575922|Drug|Nivolumab|Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.
76049696|NCT04575922|Drug|Ipilimumab|Administered into vein by intravenous infusion day 1 of each 6 week study cycle.
76049697|NCT04575922|Radiation|Radiation Therapy|3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
76049698|NCT01735396|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
76049699|NCT01766206|Biological|MenACWY-CRM (Menveo)|One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
76049700|NCT01734850|Drug|Busulfan|Intravenous busulfan
75727723|NCT05325359|Behavioral|L test|"It is an expanded version of the TUG and is designed to assess advanced functional ambulation with more detail available elsewhere. It is recorded when the participant gets up from the chair, walks 3 m to a cone, turns 90° to the right, continues to walk 7 m to the next cone, turns 180° left around the cone, then returns to the chair the same way. The test time is recorded, starting with the word go and ending with the participant's back touching the back of the chair."
75727724|NCT00869570|Drug|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
75727725|NCT00869570|Drug|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
75727726|NCT00869570|Radiation|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
76049701|NCT01734850|Biological|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
76049702|NCT01734850|Biological|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
76049703|NCT01766050|Drug|Caffeine|
76049704|NCT01766050|Drug|Losartan|
76049705|NCT01766050|Drug|Omeprazole|
76049706|NCT01766050|Drug|Dextromethorphan|
76049707|NCT01766050|Drug|Midazolam|
76049708|NCT01766050|Biological|Belatacept|
76049709|NCT02341625|Drug|BMS-986148|
75431439|NCT01520974|Other|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
75431440|NCT01520974|Other|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
75431441|NCT01521000|Device|Garment Sleeve|compression sleeve (20 to 30 mm of Hg)
75431442|NCT01521013|Behavioral|Supported self-care|"Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook."
75727727|NCT00880412|Drug|EHT 0202 etazolate|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
75727728|NCT00880412|Drug|Placebo|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
75727729|NCT05673707|Diagnostic Test|Thyromental Height|its measure between thyroid and mentum
75727730|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
75727731|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
75431443|NCT01521013|Behavioral|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
76049710|NCT02341625|Biological|Nivolumab|
75879210|NCT03564704|Procedure|Intrathecal injection|Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.
75879211|NCT03564704|Radiation|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.
76049711|NCT02370095|Drug|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
76049712|NCT02370095|Drug|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
76049713|NCT05370053|Diagnostic Test|ELF Test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
75431444|NCT01521052|Device|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
75431445|NCT01521065|Device|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
75431446|NCT01521078|Behavioral|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
75431447|NCT01521130|Drug|Levetiracetam|Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
75431448|NCT01521156|Other|1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
75431449|NCT01521156|Other|2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).|2 = Intervention 2 (1 test product/day)
75431450|NCT01521169|Other|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
75431451|NCT01521169|Other|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
75431452|NCT01521169|Other|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
75431453|NCT01521182|Other|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
75431454|NCT01521182|Other|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
75431455|NCT01521195|Device|Extracorporeal blood flow via ECMO machine|"Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.~Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%"
75431456|NCT01521208|Device|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
75431457|NCT01521208|Other|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
75431458|NCT01521221|Other|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
75879212|NCT03564704|Genetic|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.
75879213|NCT03564704|Procedure|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.
75879214|NCT03564704|Diagnostic Test|Flow-MRD|Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.
75879215|NCT03564704|Diagnostic Test|FISH|FISH will be added to PDT-ALL-LBL for bone marrow samples.
75879216|NCT03564704|Diagnostic Test|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.
76049714|NCT01783678|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
76049715|NCT01783678|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
76049716|NCT01734772|Drug|dabigatran etexilate|multiple doses of dabigatran
76049717|NCT01734772|Drug|dabigatran etexilate|medium dose dabigatran
76049718|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
76049719|NCT01734772|Drug|ticagrelor|multiple doses of ticagrelor
75577849|NCT05571579|Biological|blood and/or csf collection|"blood and/or collection~Only once :~1 tube of blood of 4 mL on dry tube with or without gel,~2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection."
75577850|NCT05569551|Device|Adhesive pouch|Is a barrier dressing categorized under class C medical device. It is used to seal up the umbilical stump to prevent contamination until its cord detachment. It has an adhesive film that sticks to skin with a centrally located non-adhesive pouch ensuring that zero pressure is applied on the umbilicus. It is made of polyurethane, the same material as transparent intravenous cannula dressings making it hypoallergenic waterproof and breathable.
75577851|NCT05568888|Drug|BE1116|4-Factor Prothrombin Complex administered by intravenous (IV) infusion
75577852|NCT05568888|Drug|Placebo|Administered by intravenous (IV) infusion
76049720|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
76049721|NCT01734772|Drug|dabigatran etexilate|single dose of dabigatran
76049722|NCT02340221|Drug|Taselisib|Taselisib 4 mg was administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
76049723|NCT02340221|Drug|Placebo|Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
75727732|NCT03412643|Drug|Doxorubicin|60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
75727733|NCT03412643|Drug|Cyclophosphamide|600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
75431459|NCT01521234|Behavioral|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
75431460|NCT01521247|Other|Asthma Transition Program|Asthma Education.
76049724|NCT02340221|Drug|Fulvestrant|Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
76049725|NCT02395133|Drug|Dupilumab|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
75727734|NCT03412643|Drug|Weekly Paclitaxel|80 mg/m2 IV weekly for 12 doses
75727735|NCT03412643|Drug|Trastuzumab|loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4
75727736|NCT03412643|Drug|Pertuzumab|loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4
75727737|NCT03412643|Diagnostic Test|Celcuity CELx HSF|Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
75431461|NCT01521273|Other|Bean varieties|10 x 50 g/ arm
75431462|NCT01521286|Other|Data collection|HZ and PHN booklet questionnaire and zoster brief pain inventory (ZBPI) questionnaire.
75431463|NCT01521299|Drug|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
75431464|NCT01521312|Drug|saxagliptin|5mg a day for 11-14 weeks
75431465|NCT01521312|Other|placebo pill|one tablet a day for 11-14 weeks
75431466|NCT01521325|Drug|Amatuximab|Subjects will receive one infusion of radiolabeled amatuximab.
75879217|NCT03564704|Diagnostic Test|Karyotyping|Karyotyping will be performed in PDT-ALL-LBL protocol.
75879218|NCT03564704|Drug|Chidamide|HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.
76049726|NCT02395133|Drug|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
75431467|NCT01521377|Drug|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
75431468|NCT01521377|Drug|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
76049727|NCT02395055|Drug|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
76049728|NCT02395055|Drug|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
76049729|NCT02369159|Drug|Peramivir|
75577864|NCT05563272|Drug|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
75577865|NCT05563246|Drug|LY3473329|Administered orally
75577866|NCT05563246|Drug|Placebo|Administered orally
75577867|NCT05561166|Other|EPIDREAM Questionnaire|EPIDREAM Questionnaire (questionnaire about dreams and epileptic seizures)
75577868|NCT05559697|Device|Sponsor incisional negative pressure wound therapy device and dressing|A sponsor incisional dressing placed on the knee and connected to a sponsor disposable negative pressure therapy device
75577869|NCT05559697|Device|Standard of Care incisional negative pressure wound therapy system|The control incisional negative pressure wound therapy system represents the standard of care system and market leader. It consists of a disposable negative pressure therapy device and incisional dressing.
75577870|NCT05558696|Drug|bomedemstat|Oral tablet
75727738|NCT05125744|Diagnostic Test|Assisted Ventilation|patients will be invasively ventilated in assisted mode. In all enrolled patients ventilated in assisted mode. Diaphragmatic activity will be evaluated through ultrasound (primary end point) and electrical activity of the diaphragm (optional) at stepwise decreasing of PEEP level. Also, the activity of remaining respiratory muscles will be assessed through sonography at the same levels of PEEP (secondary end point).
75727739|NCT00614744|Procedure|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
75727740|NCT00614744|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
75727741|NCT01017094|Drug|silversulfadiazine|apply once a day
75727742|NCT04074239|Other|Video triage|The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
76049730|NCT02369159|Drug|Oseltamivir|
76049731|NCT02368691|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
76049732|NCT02394665|Radiation|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
76049733|NCT02394665|Drug|Temozolomide|"Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~Concurrent during Radiation Therapy: 75 mg/m^2 orally for 6 weeks;~Post-radiation, adjuvant therapy: 150 mg/m^2 - 200 mg/m^2 orally daily on days 1 - 5 of each cycle."
76049734|NCT02394665|Behavioral|Functional Assessment of Cancer Therapy-Brain (FACT-Br)|FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
76049735|NCT02394665|Radiation|Stereotactic Radiosurgery Boost|"Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy."
76049736|NCT02394665|Radiation|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
76049737|NCT02394665|Device|3D MRSI|Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
75431469|NCT01521377|Drug|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
75431470|NCT01521377|Drug|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
76049738|NCT02367911|Drug|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
75577879|NCT05556447|Behavioral|Internet delivered pain coping skills training|Participants in the intervention group will complete 8 weeks of pain coping skills training delivered online
75727743|NCT01020214|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
76049739|NCT02367911|Drug|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
76049740|NCT02339285|Device|tACS (alpha)|
75431471|NCT01521377|Drug|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
75431472|NCT01521377|Drug|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
75431473|NCT01521390|Drug|GSK573719 62.5 mcg (one strip)|GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
76049741|NCT02339285|Device|tACS (gamma)|
76049742|NCT02367833|Drug|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
76049743|NCT02367833|Drug|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
75431474|NCT01521390|Drug|GSK573719 62.5 mcg(two strips)|GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
75431475|NCT01521390|Drug|GSK573719 125 mcg (one strip)|GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
75431476|NCT01521390|Drug|GSK573719 125 mcg(two strips)|GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
75431477|NCT01521390|Drug|Placebo|Placebo, no active ingredient
75727744|NCT01020214|Drug|Benicar HCT® Tablets 40 mg/25 mg|
75577893|NCT05550376|Other|Registry|Non-interventional registry
75727745|NCT02733029|Drug|Sonazoid|Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
75727746|NCT02733029|Device|contrast enhanced ultrasonography|Injection of intravenous ultrasound contrast
75727747|NCT01017172|Other|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
75727748|NCT02715323|Other|Cross-sectional study|
75727749|NCT02578433|Behavioral|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
75727750|NCT02578433|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
75431478|NCT01521416|Other|Data collection|"Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated."
75431479|NCT01521442|Behavioral|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
75431480|NCT01521442|Behavioral|Wait-list Control|Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
75431481|NCT01521455|Drug|HCP0910|250/50, BID for 2 weeks
75431482|NCT01521455|Drug|Seretide Diskus|250/50, BID for 2 weeks
75431483|NCT01521481|Other|Triple inguinal nerve block.|Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.
75431484|NCT01521481|Other|Unilateral subarachnoid anesthesia|Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
75431485|NCT01521520|Drug|ferumoxytol|Ferumoxytol at a dose of between 1 and 6 mg iron/kg body weight (maximum 510 mg/injection) will be administered via intravenous injection. Ferumoxytol will be administered with each series of MRIs.
75431486|NCT01521533|Drug|NOX-A12|"Pilot Group (NOX A12 single agent, and combined with VD):~3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX A12 in combination with VD):~Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
75577894|NCT05540717|Biological|PQ Grass|Suspension for Injection
75879219|NCT03564704|Diagnostic Test|PET-CT scan|PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
75577895|NCT05540717|Biological|Placebo|Solution for injection
75577896|NCT05536752|Drug|QA102/Placebo|Capsules
75577897|NCT05536752|Drug|QA102|Capsules
75577898|NCT05536752|Drug|Placebo|Capsules
75577899|NCT05515536|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
75577900|NCT05514054|Drug|Imlunestrant|Administered orally.
75577901|NCT05514054|Drug|Tamoxifen|Administered per local approved label.
75577902|NCT05514054|Drug|Anastrozole|Administered per local approved label.
75577903|NCT05514054|Drug|Letrozole|Administered per local approved label.
75577904|NCT05514054|Drug|Exemestane|Administered per local approved label.
75727751|NCT04919993|Behavioral|Cognitive Behavioral Therapy-Insomnia|Group presentation
75727752|NCT00565812|Drug|SD-6010|200 mg tablets once a day for 2 years
75727753|NCT00565812|Drug|SD-6010|50 mg tablets once a day for 2 years
75879220|NCT03564548|Drug|PPP001|Group assigned to PPP001
75577905|NCT05513027|Device|Augmented Whole-body Scanning via Magnifying PET|-Added at the end of the SOC FDG-PET/CT scan. Will take approximately 3-5 minutes longer.
75577906|NCT05513027|Device|FDG-PET/CT|-Standard of care
75727754|NCT00565812|Drug|Placebo|Placebo tablets once a day for 2 years
75577907|NCT05513027|Drug|18F- fluorodeoxyglucose|-Standard of care given with FDG-PET/CT
76049744|NCT02367833|Drug|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
75577909|NCT05507580|Drug|Upadacitinib|Oral tablet
75577910|NCT05506670|Other|Diagnostic test and phone call|Viral diagnostic test will be performed at inclusion. In case of RSV positive results, follow up phone calls will be scheduled at day 14 and day 30 to collect data.
75431487|NCT01521572|Drug|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
75577911|NCT05506670|Diagnostic Test|Diagnostic test|Viral diagnostic test will be performed at inclusion. In case of RSV negative result, no more intervention will be required.
75577912|NCT05502315|Drug|Cabozantinib|40 mg taken orally
75577913|NCT05502315|Drug|Nivolumab|480 mg by infusion
75577914|NCT05500417|Drug|ALFQ|ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
75577915|NCT05500417|Biological|CJCV2|Vaccine comprised of C. jejuni capsule conjugated to Cross-Reactive Material 197 (CRM197), a non-toxic mutant protein of diphtheria toxin. CJCV2 will be reconstituted in 1 mL of sterile water for injection (SWI). The resuspended CJCV2 product will be diluted with sterile 0.9% Sodium Chloride for Injection. 3 dosages for administration: 1 microgram, 3 micrograms, and 10 micrograms.
75431488|NCT01521585|Drug|SEN0014196|50 mg oral once daily tablet
75577916|NCT05493241|Behavioral|Behavioral Activation for Independence in Older Veterans (ACTIVaTE)|6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.
75577917|NCT05493241|Behavioral|Attention control|An attention control (AC) group will be used to control for the social interaction and educational aspects of ACTIVaTE. The AC arm will consist of 6 weekly one-hour VVC-delivered sessions including friendly social conversation plus education on remaining active within the physical, cognitive, and social domains during older adulthood. During each session, the interventionist will review a relevant handout or other educational materials with the participant. AC interventionists will not be trained in the ACTIVaTE intervention, and the investigators will assess whether any key features of ACTIVaTE (activity monitoring/planning, values exploration, problem-solving) are incidentally incorporated into this arm during fidelity assessment.
75577918|NCT05489926|Drug|Pamiparib|Pamiparib, 60mg PO BID
75727755|NCT03974334|Behavioral|OWL-Hypertension 8 Wk Trial|Our Whole Lives - Hypertension is an innovative online community and self-management program that provides access to stress reduction, mind-body techniques, nutrition, exercise, and peer support. OWL-H provides educational materials including videos of clinician-led talks (stress reactivity, nutrition, movement, etc.). OWL-H also provides subjects a facilitated community blog, private journal, peer support, and an extensive resource library. It will be tested by 26 patients with hypertension, to refine the platform based on patient feedback and outcomes.
75727756|NCT03970824|Biological|CT-P17|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
75727757|NCT03970824|Biological|US-licensed Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
75727758|NCT03970824|Biological|EU-approved Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
75727759|NCT00933894|Drug|Telaprevir; Escitalopram|
75431489|NCT01521585|Drug|SEN0014196|200 mg oral once daily tablet
75431490|NCT01521585|Drug|Placebo|oral once daily tablet
75431491|NCT01521611|Radiation|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
75431492|NCT01521624|Drug|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
75431493|NCT01521637|Procedure|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
75577919|NCT05485961|Drug|CSL300|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
75577920|NCT05485961|Drug|Placebo|0.9% w/v NaCl
75577921|NCT05485961|Drug|Placebo|Part 2 (Phase 3): Matching the excipient content and concentration of the CSL300 product, minus the active ingredient
75431494|NCT01521637|Procedure|Sham-treatment: no NMES|Sham comparator
75431495|NCT01521650|Dietary Supplement|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
75431496|NCT01521676|Genetic|molecular alteration|research of molecular alteration
75577922|NCT05479643|Device|Surface Electromyography|Surface ElectroMyoGraphy (SEMG) is a non-invasive technique for measuring muscle electrical activity that occurs during muscle contraction and relaxation cycles. Electrodes will be attached with a AgCl gel to muscles used for articulation.
75727760|NCT00933972|Drug|RO4998452|20mg po single dose
75727761|NCT00564486|Drug|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
75727762|NCT00564486|Drug|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
75727763|NCT00564486|Drug|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
75727764|NCT00564486|Drug|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
75879221|NCT03564548|Drug|Morphine sulfate or Hydromorphone or Oxycodone|Group assigned to morphine sulfate or hydromorphone or oxycodone
75879222|NCT03159455|Drug|BI 1467335|Duration - 28 days
75879223|NCT03159455|Drug|Placebo|Duration - 28 days
75879224|NCT05353010|Drug|Tacrolimus|Tacrolimus 5mg (1 mg * 5 capsules)
75879225|NCT05353010|Drug|IN-A001(Tegoprazan)|IN-A001 50mg(Tegoprazan 50mg* 1 tablet)
75879226|NCT05353010|Drug|IN-A001(Tegoprazan) + Tacrolimus|IN-A001 50mg(Tegoprazan 50mg*1 tablet) and Tacrolimus 5mg(1mg * 5capsules)
76049745|NCT02367521|Combination Product|Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)|"LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.~Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength."
75431497|NCT01521689|Drug|Rituximab|Low doses of sub cutaneaous rituximab
75431498|NCT01521702|Drug|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
75431499|NCT01521702|Procedure|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
75577923|NCT05478681|Device|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
75577925|NCT05472909|Other|Standardized Relaxation Music|Participants listen to standardized relaxation music during surgery.
75727765|NCT00481078|Drug|vorinostat|Given PO
75727766|NCT00481078|Drug|paclitaxel|Given IV
75727767|NCT00481078|Drug|carboplatin|Given IV
75727768|NCT00481078|Other|placebo|Given PO
75727769|NCT00481078|Other|laboratory biomarker analysis|Correlative studies
75879227|NCT05352854|Drug|0.5% pilocarpine eye drops|Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
75879228|NCT01841177|Drug|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
75431500|NCT01521715|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
75431501|NCT01521728|Other|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
75431502|NCT01521728|Other|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
75431503|NCT01521728|Other|Stretching/Range-of-Motion|"Stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
75431504|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of extended release capsules
75431505|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
75431506|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
75431507|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
75431508|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
75727770|NCT00934206|Behavioral|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
75727771|NCT00934284|Other|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
75879229|NCT03564782|Biological|PVSRIPO|The live, attenuated, oral (Sabin), serotype 1 poliovirus vaccine booster will be administered 1 week before PVSRIPO injection. The study drug, PVSRIPO, is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). It will be given at a dose of 1x10^8 TCID50 (tissue culture infectious dose) directly into the breast tumor.
75431509|NCT01521793|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
75577926|NCT05472909|Other|Personal Choice of Music|Participants listen to their preferred music during surgery.
75577927|NCT05470491|Drug|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Prednisone tapering doses given orally daily: -days -14 through -12: 1mg/kg/day -days -11 and -10: 0.75 mg/kg/day -days -9 and -9: 050 mg/kg/day -day -7: 0.25 mg/kg/day Pentostatin 4 mg/m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4. Busulfan IV AUC targeted dose of 14.8-23.0 mg*h/L, on days -3 and -2.
75577928|NCT05470491|Drug|GVHD prophylaxis|Cyclophosphamide 50 mg/kg IV daily Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion Mesna 50 mg/kg IV concomitant with cyclophosphamide
75431510|NCT01521806|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to snack foods
75577929|NCT05470491|Procedure|allo HCT|bone marrow transplant
75577930|NCT05470491|Drug|Plerixafor|In phase 1 dose level 3 and phase 2 only: Plerixafor 240 (Micro)g/kg subcutaneously every other day, starting day +1 through day +21
75577931|NCT05470491|Drug|Maraviroc|Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
75879230|NCT01336361|Other|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
75879231|NCT02838134|Other|Rocuronium|A bolus of 0.7 mg/kg rocuronium is administered just after tracheal intubation and then an infusion of rocuronium (0.3 to 0.4 mg/kg) is started when post-tetanic count (PTC) is more than 0 and titrated towards PTC 1-2.
75431511|NCT01521819|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
75431512|NCT01521819|Drug|Lucentis|Intravitreal injection of Lucentis as needed.
75431513|NCT01521832|Drug|SEN0014196|5 mg single oral dose
75431514|NCT01521832|Drug|SEN0014196|25 mg single oral dose
75431515|NCT01521832|Drug|SEN0014196|75 mg single oral dose
75431516|NCT01521832|Drug|SEN0014196|150 mg single oral dose
75431517|NCT01521832|Drug|SEN0014196|300 mg single oral dose
75431518|NCT01521832|Drug|SEN0014196|600 mg single oral dose
75431519|NCT01521832|Drug|SEN0014196|300 mg single oral dose (females)
75431520|NCT01521832|Drug|SEN0014196|100 mg multiple oral dose
75431521|NCT01521832|Drug|SEN0014196|300 mg multiple oral dose
76049746|NCT02367521|Device|Sham Comparator: Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
75577933|NCT05458297|Biological|Zilovertamab vedotin|IV infusion
75577934|NCT05458297|Drug|Nemtabrutinib|65 mg once daily (QD) orally
75879232|NCT02838134|Other|No additional Rocuronium|No additional rocuronium is administered after tracheal intubation.
75879233|NCT03150589|Drug|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
75431522|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose
75431523|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose (females)
75431524|NCT01521910|Dietary Supplement|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses >= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
76049747|NCT02338193|Drug|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
76049748|NCT02338193|Drug|DAPA|10 mg dapagliflozin QD for 20-24 weeks
75577937|NCT05453578|Other|Placebo|0.9 percent sodium chloride
75577938|NCT05453578|Biological|WRAIR-PAM-CF1|Bacteriophage combination composed of the following phages: PaWRA01Phi11, PaWRA01Phi39, PaWRA02Phi83, and PaWRA02Phi87.
75577939|NCT05446870|Biological|Pembrolizumab|200 mg by IV infusion on Day 1 of each 21-day cycle
75577940|NCT05446870|Drug|Paclitaxel|175 mg/m^2 by IV infusion on Day 1 of each 21-day cycle
75577941|NCT05446870|Drug|Carboplatin|AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
75577942|NCT05446870|Biological|Avastin|According to local practice and at the choice of the investigator.
75577943|NCT05446870|Biological|MK-4830|800 mg by IV infusion on Day 1 of each 21-day cycle
75577944|NCT05446870|Drug|Docetaxel|75 mg/m^2 by IV infusion on Day 1 of each 21-day cycle
76049749|NCT02338193|Drug|MET XR|1000 mg Metformin XR BID for 20-24 weeks
76049750|NCT01783444|Drug|Capecitabine|Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
75879234|NCT03150589|Drug|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
75879235|NCT05708300|Drug|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
76049751|NCT01783444|Drug|Exemestane|Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
76049752|NCT01783444|Drug|Everolimus|Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
75431525|NCT01521910|Dietary Supplement|normal protein diet|"The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period."
75431526|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (lower dose)
75431527|NCT01521936|Other|pharmacological study|Correlative studies
75431528|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (higher dose)
75431529|NCT01521936|Other|laboratory biomarker analysis|Correlative studies
75431530|NCT01521962|Drug|Alogliptin|Alogliptin tablets
75431531|NCT01521962|Drug|Insulin|Insulin injection
75431532|NCT01521975|Drug|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
75431533|NCT01521988|Procedure|Atrial flutter ablation|Radiofrequency ablation of Atrial flutter
75431534|NCT01521988|Procedure|Atrial flutter ablation and pulmonary vein isolation|Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
75431535|NCT01522001|Behavioral|Shared Care model|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~Examination by the patient´s general practitioner 8-12 weeks after discharge."
75431536|NCT01522014|Device|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
76049753|NCT02367131|Drug|Jardiance|Empagliflozin
75879236|NCT05708378|Other|Rocker board training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
75879237|NCT05708378|Other|Stable surface training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
75879238|NCT05340452|Drug|Klaribact 125mg/5ml Suspension|one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
75431537|NCT01522014|Device|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
75431538|NCT01522027|Procedure|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
75431539|NCT01522040|Drug|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
75431540|NCT01522040|Drug|Placebo|Simple saline drip, without active drug
75431541|NCT01522053|Procedure|Catheter-over-needle|Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
75431542|NCT01522053|Procedure|Catheter-through-needle|Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
75431543|NCT01522066|Procedure|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
75431544|NCT01522066|Procedure|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
75431545|NCT01522079|Procedure|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
75577948|NCT05442515|Biological|CD19/CD22-CAR-transduced T cells|CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen
75577949|NCT05442515|Drug|cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
75879239|NCT05340452|Drug|Klaricid 125mg/5ml Suspension|one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
75431546|NCT01522092|Drug|escitalopram|5mg-20mg, tablet, od, 12 months
75431547|NCT01522105|Drug|Daptomycin|One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
76049754|NCT02394275|Biological|Fecal Microbiota Transplant|All eligible patients will receive fecal microbiota transplant
76049755|NCT01608724|Drug|Saxagliptin|oral, 5 mg once a day (Q.D.)
76049756|NCT02366195|Drug|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 4.0 mL of 10^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10^8 PFU/mL.
76049757|NCT04905251|Drug|Mifepristone-Misoprostol|Non interventional design.
76049758|NCT02364947|Drug|Nalmefene hydrochloride|As-needed; tablets, orally
76049759|NCT02364947|Drug|Placebo|As-needed; tablets, orally
75431548|NCT01522118|Device|ExAblate 2100; InSightec|"Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.~MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens"
75431549|NCT01522144|Behavioral|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
75431550|NCT01522157|Dietary Supplement|Low-fat Diet|Low-fat Diet is provided for a breakfast and a lunch.
75431551|NCT01522157|Dietary Supplement|Low-carbohydrate Diet|Low-carbohydrate Diet is provided for a breakfast and a lunch.
75431552|NCT01522157|Dietary Supplement|Mediterranean Diet|Mediterranean Diet is provided for a breakfast and a lunch.
75431553|NCT01522209|Procedure|Liver Surgery|R0 Resection of Liver Metastases after Planning with preoperative imaging data and comparison with intraoperative contrast enhanced ultrasound
75431554|NCT01522209|Device|Contrast Enhanced Ultrasound|The contrast enhanced Ultrasound imaging is performed before and during the operation using Sonovue contrast agent (2.5ml iv preop, 4.5ml iv intraop)
76049760|NCT02392481|Procedure|Biofluid sampling|
75431555|NCT01522209|Radiation|CT Scan (standard)|A staging CT of the liver/abdomen with the minimal possible dosage for aquiring sufficent triphasic data in a 64-line helical scan
75431556|NCT01522209|Radiation|Primovist MRI (3 Tesla)|an MRI scan of the liver with Primovist contrast agent including late phase as addition to the preop staging according to the protocol
75431557|NCT01522222|Procedure|continuous, mechanical ventilatory support|Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
75431558|NCT01522261|Other|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
75431559|NCT01522261|Other|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
75431560|NCT01522274|Behavioral|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
75431561|NCT01522274|Behavioral|Health education|Videos
75431562|NCT01522287|Behavioral|Computer-Assisted Cognitive Behavior Therapy (BT STEPS)|BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
75431563|NCT01522300|Other|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
75431564|NCT01522300|Other|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
75431565|NCT01522326|Drug|Ibuprofen|Ibuprofen 400mg tablet. Take one dose by mouth.
75431566|NCT01522326|Drug|Metoclopramide|Metoclopramide 10mg tablet. Take one tablet by mouth.
76049761|NCT02392403|Device|Nucleus CI532 cochlear implant|
76049762|NCT02392247|Device|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
76049763|NCT02337725|Drug|TVP-1012|TVP-1012 1mg Tablets
76049764|NCT02337725|Drug|Placebo|Placebo tablets
76049765|NCT02337491|Drug|Pembrolizumab|
76049766|NCT02337491|Drug|Bevacizumab|
75431567|NCT01522352|Procedure|Aortic valve replacement by bioprosthesis|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
75431568|NCT01522378|Drug|123 iodine metaiodobenzylguanidine|10 millicurie (mCi) (370 MBq)
75431569|NCT01522430|Procedure|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
75431570|NCT01522430|Procedure|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
75431571|NCT01522482|Dietary Supplement|High saturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
75431572|NCT01522482|Dietary Supplement|Saturated fatty acids and fish oil meal|"Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.~The dose of fish oils was equivalent to two portions of oily fish."
75431573|NCT01522482|Dietary Supplement|High unsaturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
75431574|NCT01522495|Device|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
75431575|NCT01522495|Device|SPY Imaging|SPY Imaging to assess tissue perfusion
75431576|NCT01522508|Procedure|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
75431577|NCT01522521|Drug|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
75431578|NCT01522521|Drug|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
75577950|NCT05442515|Drug|fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).
75431579|NCT01522534|Drug|Mepivacaine|mepivacaine 1% 20 ml corresponding to 200 mg
75431580|NCT01522534|Drug|Morphine|Morphine alone with a placebo nerve block
75577951|NCT05433662|Behavioral|Pandemic Acceptance and Commitment Therapy (Pan-ACT)|Pan-ACT is a 10-session, closed group, transdiagnostic intervention for older adults.
75577952|NCT05424978|Other|Standardized green channel treatment methods for stroke|The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.
75577953|NCT05424380|Drug|GSK3745417|GSK3745417 will be administered
75577954|NCT05424081|Behavioral|EMBER|Self-help tool to increase weight management engagement
75431581|NCT01522547|Drug|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
75431582|NCT01522560|Other|Feedback group|"Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF)."
75431583|NCT01522560|Other|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
75577955|NCT05424081|Behavioral|Control|List of weight management programs
75577956|NCT05422794|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
75577957|NCT05422794|Procedure|Biopsy|Undergo biopsy
75879240|NCT02835092|Other|Take Shape For Life Program|The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 & 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
76049767|NCT01765582|Drug|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
76049768|NCT01765582|Drug|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
76049769|NCT01765582|Drug|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
76049770|NCT01765582|Drug|irinotecan|Participants will receive IV infusion of 165 mg/m^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
76049771|NCT01765582|Drug|folinic acid|Participants will receive IV infusion of 200 mg/m^² (Arm A) or 400 mg/m^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m^2 in the maintenance therapy.
76049772|NCT01765582|Drug|oxaliplatin|Participants will receive 85 mg/m^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
76049773|NCT04413838|Drug|NIVOLUMAB|IV injection within 30 minutes of 24ml file (=240 mg) containing NIVOLUMAB BMS(Bristol-Myers Squibb) 10mg/ml (immune check point inhibitor targeting PD-1) on top of routine standard of care for COVID-19 infection
76049774|NCT04413838|Other|Routine standard of care|No intervention is planned in this arm. Patients will follow routine standard of care for the COVID-19 treatment
76049775|NCT01649375|Drug|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
76049776|NCT01649375|Drug|Placebo|Placebo
76049777|NCT01649375|Drug|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
76049778|NCT02336555|Drug|MK-8291|MK-8291 oral tablets
76049779|NCT02336555|Drug|Placebo|Placebo oral tablets
76049780|NCT01648283|Drug|IV racemic methadone HCl|IV racemic Methadone HC1 6 mg
76049781|NCT01648283|Drug|Oral racemic methadone HCl|oral d5-methadone HCl 11 mg
76049782|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
75431584|NCT01522573|Procedure|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
75431585|NCT01522586|Drug|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
75431586|NCT01522586|Drug|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
75431587|NCT01522599|Other|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
75431588|NCT01522599|Other|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
75431589|NCT01522612|Drug|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
75577958|NCT05422794|Procedure|Biospecimen Collection|Undergo collection of blood samples
76049783|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
76049784|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
76049785|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
76049786|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
76049787|NCT01649297|Drug|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
76049788|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
76049789|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
76049790|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
76049791|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
76049792|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
76049793|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
76049794|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
76049795|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
76049796|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
76049797|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
76049798|NCT01649297|Drug|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
75879241|NCT02835092|Other|Medifast Direct Program|The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 & 2 & 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
75879242|NCT02835092|Other|Self-directed Control|The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
75879243|NCT03564392|Behavioral|Acceptance Based Behavioral Intervention|This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
75879244|NCT03145207|Drug|Lidocaine patch|lidocaine patch
75879245|NCT02836652|Device|HeartMate II (HMII)|Left Ventricular Assist Device
76049799|NCT01649297|Drug|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
76049800|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
76049801|NCT01649297|Drug|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
76049802|NCT01648205|Drug|Placebo|Matching Placebo will be given for first month.
75879246|NCT02836652|Drug|Warfarin|(INR Target 2.0-2.5, median 2.25, per standard of patient care)
76049803|NCT01648205|Drug|Ranolazine|Patients will receive ranolazine 1000mg bid for subsequent 5 months.
76049804|NCT04894253|Biological|SRAS-CoV-2 vaccination immunological response|"Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.~Intervention includes immunological analysis on additional volume of blood collected as part of routine care."
76049805|NCT02362451|Biological|Autologus elutriated monocyte placebo vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
76049806|NCT02362451|Biological|Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
76049807|NCT01734382|Drug|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants < 30 kg) or 8 mg/kg (for participants >/=30 kg) Q2W/Q3W/Q4W.
76049808|NCT02391311|Device|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
75431590|NCT01522612|Drug|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
75431591|NCT01522612|Drug|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
75431592|NCT01522625|Drug|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
75431593|NCT01522625|Drug|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
75431594|NCT01522664|Drug|DEDN6526A|Multiple ascending doses
75577959|NCT05422794|Procedure|Computed Tomography|Undergo CT
75879247|NCT02836652|Drug|acetylsalicylic acid (ASA) therapy|(81mg/day)
75879248|NCT04335175|Other|None - observational study|None - observational study
75879249|NCT01344811|Procedure|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
76049809|NCT01765426|Biological|TDV|TDV suspension for intradermal administration
75879250|NCT01344811|Other|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
75879251|NCT02836496|Drug|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
76049810|NCT01765426|Drug|Placebo|Phosphate buffered saline (PBS)
76049811|NCT01765270|Drug|Saxagliptin|one 5-mg saxagliptin tablet daily
76049812|NCT01765270|Drug|Placebo|5mg placebo tablet daily
76049813|NCT01733758|Drug|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
76049814|NCT01733758|Drug|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
75577960|NCT05422794|Procedure|Magnetic Resonance Imaging|Undergo MRI
76049815|NCT01733758|Drug|Placebo|Albiglutide matching placebo will be available as a pen injector
76049816|NCT01733758|Drug|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
76049817|NCT01607554|Drug|Irinotecan|"180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician"
75727772|NCT00934284|Other|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
75577961|NCT05422794|Drug|Nab-paclitaxel|Given IV
75879252|NCT02836496|Drug|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
76049818|NCT01607476|Drug|C11 PiB|One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
75431595|NCT01522677|Drug|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
75431596|NCT01522690|Other|Different walk tests with an accelerometer device|Subjects will performed three walk tests of 50 meter at different speeds, a six minute walk test, a walking test of 30 seconds then a test to measure the maximum force of extension and knee flexion on each leg. The walk tests will be performed with the accelerometer device (Locometrix) worn in a belt
75431597|NCT01522716|Biological|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
75577962|NCT05422794|Biological|Pembrolizumab|Given IV
76049819|NCT01607476|Drug|F18 Flutametamol|One time intravenous administration of 3-7 mCi F18 Flutametamol.
75577963|NCT05420844|Other|Kintsugi voice journaling application|Participants will use the Kintsugi voice journaling phone application for three months.
76049820|NCT01765192|Drug|Roflumilast|Roflumilast was supplied in tablets.
76049821|NCT01765192|Drug|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
76049822|NCT01765192|Drug|Montelukast|Montelukast was supplied in tablets.
75431598|NCT01522729|Drug|Fentanyl|Single-dose of intrathecal fentanyl [25ug] Duration of fentanyl : 3.5 hours
75577967|NCT05406401|Biological|Zilovertamab Vedotin|IV infusion
75577968|NCT05406401|Drug|Cyclophosphamide|IV infusion
75577969|NCT05406401|Drug|Doxorubicin|IV infusion
75727773|NCT00938808|Dietary Supplement|day formula diet|The Cambridge Programme. Formula diet
75727774|NCT00480532|Drug|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
76049823|NCT01733680|Drug|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
76049824|NCT01733680|Behavioral|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
76049825|NCT04892498|Radiation|Hypofractionated radiotherapy|10-24Gy/5-8Gy/2-3f
76049826|NCT04892498|Drug|PD-1 inhibitor|q3w, until PD
76049827|NCT04892498|Drug|GM-CSF|200μg, D1-D7, ≥8 cycles
76049828|NCT04892498|Drug|IL-2|at a dose of 2 million IU, D8-D14, ≥8 cycles
75577970|NCT05406401|Biological|Rituximab|IV infusion
75577971|NCT05406401|Biological|Rituximab Biosimilar|IV infusion
75577972|NCT05406401|Drug|Prednisone|IV or oral administration (per local guidelines)
75577973|NCT05406401|Drug|Prednisolone|IV or oral administration (per local guidelines)
75577974|NCT05405426|Other|Red blood cell transfusion|The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.
76049829|NCT02336165|Drug|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
75577975|NCT05398809|Drug|Ruxolitinib|Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
75577976|NCT05393037|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
75577977|NCT05393037|Biological|Placebo|Saline in each 0.5 mL sterile solution
75879253|NCT02836496|Drug|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
76049830|NCT02336165|Radiation|Standard radiotherapy|Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.
76049831|NCT02336165|Biological|Bevacizumab|Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
76049832|NCT02360111|Drug|Cyclophosphamide|
76049833|NCT02334683|Device|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
76049834|NCT02334683|Device|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
75431599|NCT01522729|Drug|Placebo comparator|placebo [NaCl]
75431600|NCT01522794|Drug|NOX-H94|single i.v. infusion
75431601|NCT01522794|Drug|Placebo solution|single i.v. infusion
75431602|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
75431603|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
75431604|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
75431605|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
75577978|NCT05393037|Biological|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
75577979|NCT05393037|Biological|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
75577980|NCT05384262|Drug|AZD0780|Subjects will receive AZD0780 orally as a single ascending dose.
75577981|NCT05384262|Drug|AZD0780|Subjects will receive AZD0780 orally as a multiple ascending dose.
75577982|NCT05384262|Drug|AZD0780|Subjects will receive AZD0780 orally as a single and multiple ascending dose.
75577983|NCT05384262|Drug|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
75577984|NCT05384262|Drug|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
75577985|NCT05384262|Drug|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
75577986|NCT05384262|Drug|Rosuvastatin|Subjects will receive rosuvastatin orally.
75727775|NCT00480532|Drug|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
75727776|NCT00480532|Drug|Oracea|40-mg tablet daily for 84 days
75727777|NCT00480532|Drug|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
75727778|NCT00480532|Drug|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
75431606|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
75577987|NCT05382286|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
75577988|NCT05382286|Drug|Pembrolizumab|Administered intravenously
75727779|NCT00480532|Drug|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
75727780|NCT00480532|Drug|placebo daily|Placebo daily for the first 84 days of the study
75577989|NCT05382286|Drug|Paclitaxel|Administered intravenously
75577990|NCT05382286|Drug|nab-Paclitaxel|Administered intravenously
75577991|NCT05382286|Drug|Gemcitabine|Administered intravenously
75727781|NCT04013880|Drug|CDA Inhibitor E7727/Decitabine Combination Agent ASTX727|Given by mouth
75577992|NCT05382286|Drug|Carboplatin|Administered intravenously
76049835|NCT02319044|Drug|MEDI4736|MEDI4736 monotherapy
76049836|NCT02319044|Drug|Tremelimumab|Tremelimumab monotherapy
76049837|NCT02319044|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
76049838|NCT01649765|Drug|belimumab 10mg/kg|belimumab 10mg/kg IV monthly
75727782|NCT04013880|Drug|IDH-1 Inhibitor FT-2102|Given by mouth
75727783|NCT00934518|Radiation|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
75727784|NCT00934518|Drug|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
75879254|NCT02836496|Drug|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
76049839|NCT01649765|Other|placebo|Normal Saline 250 ml
76049840|NCT02317562|Drug|I10E|Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
76049841|NCT02317016|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
76049842|NCT02317016|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
75727785|NCT00496366|Drug|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
75727786|NCT00496366|Drug|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
75431607|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
75431608|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
75431609|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
75431610|NCT01522820|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
75431611|NCT01522820|Other|Laboratory Biomarker Analysis|Correlative studies
75431612|NCT01522820|Other|Pharmacological Study|Correlative studies
75431613|NCT01522820|Drug|Sirolimus|Given PO or PEG
75431614|NCT01522846|Drug|Heparin|Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
75577996|NCT05370079|Biological|Collection of biological sample (blood and/or CSF)|"Blood sample will be collected one time for each patient:~2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml)."
75577997|NCT05367245|Drug|Cal-Mag Butyrate|Supplements
75577998|NCT05367245|Drug|Placebo|Only Cal-Mag but no Butyric acid
75727787|NCT00934674|Drug|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
75727788|NCT00934752|Device|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
75727789|NCT01020292|Drug|Nelfinavir|
76049843|NCT02317016|Drug|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
76049844|NCT02317016|Procedure|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
76049845|NCT02317016|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
76049846|NCT02311478|Device|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
76049847|NCT02388932|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
76049848|NCT02388932|Device|Positron Emission Tomography|Undergo PET/CT
76049849|NCT02388932|Device|Computed Tomography|Undergo PET/CT
76049850|NCT02388932|Other|Quality-of-Life Assessment|Ancillary studies
76049851|NCT02388776|Device|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
76049852|NCT02316548|Radiation|Intensity-Modulated Radiation Therapy|Postoperative adjuvant IMRT radiotherapy 50.4 Gy in 28 fractions. In patients not getting postoperative adjuvant chemotherapy the radiation treatment must begin within 140 days after cystectomy. For patients getting adjuvant chemotherapy radiation treatment must start within 49 days of completing chemotherapy.
75431615|NCT01522859|Device|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
76049853|NCT02281760|Drug|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
75431616|NCT01522872|Drug|TH-302|
75431617|NCT01522872|Drug|TH-302 and Dexamethasone|
75431618|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
75431619|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
75431620|NCT01522885|Device|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
75431621|NCT01522885|Procedure|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
75431622|NCT01522898|Procedure|AV nodal ablation|Percutaneous catheter ablation of the AV node.
75431623|NCT01522898|Drug|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
75431624|NCT01522911|Device|WATCHMAN LAA system (Percutaneous left atrial appendage closure)|The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
75431625|NCT01522989|Drug|PD-0332991|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
75431626|NCT01522989|Drug|5-FU|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
75577999|NCT05367076|Behavioral|Web-based Aerobic Exercise Program|"Community based FTTs will use a web-based platform to deliver a 12-week exercise training program (120-minute group sessions of aerobic activity 3 times/week). Each session will include:~Warm-up activities~Aerobic activities and fitness training in a game-like fashion~Organized sports/games~Cool down activity~Snack/reward time"
75578000|NCT05364944|Drug|Debio 4126|Intramuscular (IM) injection
75578001|NCT05364944|Drug|Sandostatin LAR|Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
75727790|NCT01017406|Device|PSU heel cushion and plantar fascia specific stretching exercise|"Wear heel cushion during daily activity~Plantar fascia stretching exercise 3 times per day"
75727791|NCT04014426|Other|Blood sample|"Exposed group:~15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)"
75727792|NCT04014426|Other|Urinary sample|"Exposed group:~15 to 30 min before the PIPAC procedure (T0)~2hours after the end of the procedure (T1)~The next morning after the procedure (T2)~Non-exposed group:~- During the morning (8 to 10 a.m) (T0)"
75879255|NCT04213807|Biological|MAA868 Cohort 1|Subcutaneous injection: low dose
75879256|NCT04213807|Biological|MAA868 Cohort 2|Subcutaneous injection: high dose
75879257|NCT04213807|Biological|MAA868 Cohort 3|Subcutaneous injection: Dose to be determined.
75879258|NCT04213807|Other|Placebo|Subcutaneous injection: Placebo
76049854|NCT02281760|Drug|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
76049855|NCT02390531|Drug|Bevacizumab|Varying dosages in 10µl
75431627|NCT01522989|Drug|Oxaliplatin|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
75431628|NCT01523015|Other|preoperative chemo- and chemoradiotherapy|2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
75431629|NCT01523015|Procedure|Surgical resection|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
75431630|NCT01523028|Other|Soluble Coffee|"Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~200 mL coffee or~200 mL coffee + 2 bread rolls + honey~200 mL coffee + 1 bread roll + peanut butter"
75431631|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
75431632|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
76049856|NCT02390219|Drug|Lumacaftor|
75431633|NCT01523041|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin)
75431634|NCT01523054|Drug|Metoprolol- Toprol XL|Extended release tablet, 200mg once daily for 4 days
75431635|NCT01523054|Drug|Metoprolol- Lopressor|Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
75431636|NCT01523067|Drug|Vasomera (PB1046)|Single dose of Vasomera
75431637|NCT01523067|Drug|0.9% Sodium Chloride|Placebo injection
75727793|NCT03117582|Other|Stool specimen|"The following stool specimen will be collected for this study:~4, 3mL stool specimen from patient~1, 25mL stool aliquot from donor"
75727794|NCT00488644|Drug|Levothyroxine|75 mcg by mouth (PO) Daily for 8 Weeks
75727795|NCT00488644|Drug|Liothyronine|15 mcg PO Daily for 8 Weeks
75727796|NCT00934830|Drug|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
75727797|NCT00934830|Other|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
76049857|NCT02390219|Drug|Ivacaftor|
76049858|NCT02334215|Drug|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
76049859|NCT02334215|Behavioral|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
76049860|NCT02334215|Behavioral|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
76049861|NCT02359877|Drug|BCD-054|
76049862|NCT02359877|Drug|Rebif|
76049863|NCT02359877|Drug|Avonex|
76049864|NCT02389829|Drug|Hydromorphone|
76049865|NCT02389829|Drug|Prochlorperazine|
76049866|NCT02389829|Drug|Diphenhydramine|
75578002|NCT05364944|Drug|Somatuline ATG|Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
75578003|NCT05359783|Drug|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.
75578004|NCT05352672|Drug|Fianlimab|Intravenous (IV) infusion
75578005|NCT05352672|Drug|Cemiplimab|IV infusion
75578006|NCT05352672|Drug|Pembrolizumab|IV infusion
75578007|NCT05352672|Drug|Placebo|IV infusion
75578008|NCT05350345|Other|Root-cause analysis|The first part of this study involves a report with a root-cause analysis done by the students. The second part is a gamification in which they have to evaluate each other and give feedback.
75578009|NCT05348863|Behavioral|SPARK|The SPARK digital platform provides support to the patient (shown as an app) as well as provides the possibility for the health care provider to review and give feedback on blood glucose levels through the care giver interface of the platform.
75727798|NCT00934908|Dietary Supplement|Green Tea|Green tea capsules taken twice a day.
75727799|NCT00934908|Other|Placebo|"Non-active sugar pill."
75879259|NCT05065099|Device|Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)|Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
75879260|NCT01344967|Drug|Zoledronic acid|Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
75431638|NCT01523080|Drug|Acetaminophen|Extended release Gel tabs 650 mg
75431639|NCT01523093|Drug|Ondansetron|Orally Disintegrating Tablets 8mg
75431640|NCT01523106|Drug|L-carnitine|dietary supplement
75578010|NCT05342636|Biological|Pembrolizumab|200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)
75431641|NCT01523106|Other|Placebo|Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
75727800|NCT02575404|Drug|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
75727801|NCT02575404|Drug|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
75879261|NCT05250661|Other|Aqueous propolis extract|The patients gargled 4 times a day after meals and 5 ml each time. Patients were instructed to keep the propolis solution in their mouth for one minute, to touch all structures in the mouth, and not to eat or drink anything orally for one hour after spitting.
75879262|NCT04176913|Drug|LUCAR-20S CAR-T cells|An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
75431642|NCT01523119|Drug|Ondansetron|Orally Disintegrating Tablets 8 mg
75431643|NCT01523145|Behavioral|Rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
75431644|NCT01523145|Other|Control Group|usual follow-up Standard follow-up at the participating heart center
75431645|NCT01523158|Biological|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
75431646|NCT01523197|Device|BiPAP ventilation, auto-trilevel ventilation|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
75431647|NCT01523210|Other|physiotherapy|thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
75431648|NCT01523236|Drug|Mometasone furoate|50 mcg/actuation Nasal Spray
75578011|NCT05342636|Biological|Coformulation favezelimab/pembrolizumab|800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W
75578012|NCT05342636|Biological|MK-4830|800 mg administered via IV infusion Q3W
75578013|NCT05342636|Drug|Lenvatinib|20 mg administered via oral capsules each day
75578014|NCT05342636|Drug|Irinotecan|180 mg/m^2 administered via IV infusion on day 1 of every 14-day cycle.
75578015|NCT05342636|Drug|Paclitaxel|80-100 mg/m^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
75578016|NCT05338697|Diagnostic Test|Transcranial Magnetic Stimulation (TMS)|No intervention used. This study is using TMS to obtain motor evoked potential (MEP), a prognostic biomarker. The TMS procedure is being conducted during the first week of hospitalization, which required registration under an IDE. Only TMS devices that have received 510(k) clearance from the FDA are used in this study, consisting of MEGA-TMS and MagStim 200-2.
75578017|NCT05333471|Drug|MTP 101-LF|Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product. Participants will receive approximately 32 mL via colonoscopy.
75578018|NCT05331729|Radiation|FMISO-PET Protocol|"injection of 18F-FMISO~Monitoring for 2 h~PET scan (30 min) 2h post injection~Monitoring for 2h~PET (30min) 4h post injection~Discharge of the subject with appropriate recommendations after a PET/CT"
75578019|NCT05327010|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
75727802|NCT00564018|Drug|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
75727803|NCT00564018|Drug|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
75578020|NCT05327010|Procedure|Biopsy|Undergo tumor biopsy
75578021|NCT05327010|Procedure|Biospecimen Collection|Undergo blood sample collection
75578022|NCT05327010|Procedure|Diagnostic Imaging|Undergo diagnostic imaging
75727804|NCT00564018|Drug|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
75578023|NCT05327010|Drug|Talazoparib|Given PO
75578024|NCT05319730|Drug|Paclitaxel|80-100 mg/m2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
75578025|NCT05319730|Drug|Irinotecan|180 mg/m2 IV infusion, administered on day 1 of every 14-day cycle.
75727805|NCT04013724|Behavioral|Group tobacco cessation interventions|"Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented."
75727806|NCT00934986|Other|Surface expression of functional biomarkers of the NK cell|"An extra blood sample of 40 ml is required :~Stage A patient who does not require a treatment: one sample the day of enrollment.~Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment."
75578026|NCT05319730|Biological|Pembrolizumab|200 mg IV infusion, administered every Q3W.
75578027|NCT05319730|Biological|MK-4830|800 mg IV infusion, administered Q3W up to 35 infusions.
75578028|NCT05319730|Drug|Lenvatinib|20 mg oral administration every day.
75578029|NCT05319730|Biological|MK-2870|4 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.
75578030|NCT05319730|Drug|Antihistamine|Administered per product label.
75578031|NCT05319730|Drug|H2 Receptor Antagonist|Administered per product label.
75727807|NCT00935142|Drug|[18F]VM4-037|Bolus IV injection of [18F]VM4-037
75431649|NCT01523236|Drug|Nasonex®|50 mcg/actuation Nasal Spray
75431650|NCT01523236|Drug|Placebo|Nasal Spray
75431651|NCT01523249|Device|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
75431652|NCT01523262|Procedure|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
75431653|NCT01523262|Procedure|Normal surgery, with sham intervention without inflating arm cuff|
75578032|NCT05319730|Drug|Acetaminophen (or equivalent)|Administered per product label.
75578033|NCT05319730|Drug|Dexamethasone (or equivalent)|Administered per product label.
75578034|NCT05309733|Genetic|VOR33|VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
75578035|NCT05308446|Biological|Cetuximab|Given IV
75727808|NCT04013412|Dietary Supplement|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake [any of 4 flavors] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
75727809|NCT00935298|Drug|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*1 type and CYP3A5*1/*3 type administer 0.15mg/kg/d，CYP3A5*3/*3 type administer 0.08mg/kg/d).
75879263|NCT04172467|Other|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
75879264|NCT03268213|Biological|Fecal Microbial Transplantation|"Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy"
76049867|NCT02358863|Drug|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
76049868|NCT02358863|Drug|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
75578036|NCT05308446|Drug|Encorafenib|Given PO
75727810|NCT04014192|Drug|Dapagliflozin|Treated with dapagliflozin 10mg/d for one week.
75727811|NCT04014192|Drug|Empagliflozin|Treated with empagliflozin 10mg/d for one week.
75578037|NCT05308446|Biological|Nivolumab|Given IV
75578038|NCT05306834|Procedure|Retinal Imaging|Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
75578039|NCT05306834|Genetic|Blood sample|Analyses of molecular biomarkers including
75727812|NCT04014192|Drug|Canagliflozin|Treated with canagliflozin 100mg/d for one week.
75727813|NCT00935376|Behavioral|Sleep Education Program|Treatment as usual.
75879265|NCT05050279|Drug|Delgocitinib capsule|oral capsule
75879266|NCT05050279|Drug|Placebo capsule|oral capsule
75879267|NCT03074227|Other|Allogeneic faecal transplantation|"Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor."
75879268|NCT03074227|Other|Autologous faecal transplantation|Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
76049869|NCT02358863|Drug|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
76049870|NCT02358863|Drug|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
76049871|NCT02358863|Drug|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
75578040|NCT05306834|Procedure|Evaluation of cardiovascular risks|Measurement of blood pressure and arterial stiffness
75578041|NCT05306834|Procedure|Brain imaging (MRI)|3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
76049872|NCT02358863|Drug|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
76049873|NCT02358863|Drug|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
75727814|NCT00935376|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
75578042|NCT05306834|Other|Cognitive Tests|Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
75578043|NCT05306834|Other|Geriatric Depression Scale (GDS)|15 items
75578044|NCT05306834|Other|Instrumental Activities of Daily Living (IADL)|Instrumental Activities of Daily Living (IADL)
75578045|NCT05306834|Diagnostic Test|Unipodal standing test|Unipodal standing test
75727815|NCT00935376|Behavioral|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
75727816|NCT00935454|Procedure|Hepatocyte matrix implantation|"First operation:~Removal of liver tissue and biopsy of pancreas~Second operation:~Implantation of hepatocyte matrix implant into small bowel mesentery"
75727817|NCT00935610|Dietary Supplement|Immunocal|20 grams per day of Immunocal for 135 days.
75727818|NCT00935610|Dietary Supplement|Casein|20 grams per day for 135 days
75727819|NCT04013646|Drug|Umbilical cord blood infusion|The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
75727820|NCT04013646|Drug|Erythropoietin injection|Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
75727821|NCT04013646|Drug|Placebo umbilical cord blood infusion|Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
75727822|NCT04013646|Drug|Placebo erythropoietin injection|Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
75727823|NCT04013646|Procedure|Active rehabilitation|Physical therapy and occupational therapy are performed daily.
76049874|NCT02358863|Drug|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
75727824|NCT03381287|Drug|HTD1801 Tablets, 500 mg|500 mg/day (250 mg BID)
75727825|NCT03381287|Drug|HTD1801 Tablets, 1000 mg|1000 mg/day (500 mg BID)
75727826|NCT03381287|Drug|HTD1801 Tablets, 2000 mg|2000 mg/day (1000 mg BID)
75727827|NCT03381287|Drug|Placebo to match 500 mg HTD1801|2 tablets/day (1 tablet BID)
75879269|NCT01345201|Biological|OMP-18R5|IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.
76049875|NCT02358473|Biological|mogamulizumab|Mogamulizumab will be administered by IV infusion.
76049876|NCT02358473|Drug|Docetaxel|Docetaxel will be administered by IV infusion.
76049877|NCT02357459|Drug|FX006|Single 5 mL IA injection
76049878|NCT02357459|Drug|Placebo|Single 5 mL IA injection
75431654|NCT01523314|Drug|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
75431655|NCT01523314|Other|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
75431656|NCT01523327|Other|measuring protein creatinin ratio,serum uric acid|"A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method."
75431657|NCT01523353|Behavioral|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
75578046|NCT05306834|Other|Walking speed measurement|over 5 meters
75578047|NCT05302908|Behavioral|NuestraSaludSegura|It blends peer navigation and mHealth
76049879|NCT02357459|Drug|TCA IR 40|Single 1 mL IA injection
75578049|NCT05293106|Biological|Platelet Transfusion|All platelet transfusions will be given as 10mL/kg as is considered standard of care.
75578050|NCT05292846|Drug|Direct-acting oral anticoagulation|Apixaban Dabigatran Edoxaban Rivaroxaban
75727828|NCT03381287|Drug|Placebo to match 1000 mg HTD1801|4 tablets/day (2 tablet BID)
75727829|NCT03381287|Drug|Placebo to match 2000 mg HTD1801|8 tablets/day (4 tablet BID)
76049880|NCT04902599|Procedure|Renuvion/j-Plasma procedure using blunt dissection technique|Renuvion/j-Plasma procedure using blunt dissection technique
76049881|NCT04902599|Procedure|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique.
75578052|NCT05282342|Diagnostic Test|Diagnostic tests|No intervention will be carried out. Participants of the whole groups will be underwent the same tests.
75578053|NCT05282121|Drug|Avenciguat (BI 685509)|Avenciguat (BI 685509)
75578054|NCT05282121|Drug|Empagliflozin|Empagliflozin
75727830|NCT04074473|Drug|propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
75727831|NCT04074473|Procedure|Esophageal varice ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
75727832|NCT04074473|Other|DC propranolol|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
75879270|NCT04072861|Drug|RBT-9|intravenous administration
75879271|NCT05250349|Diagnostic Test|Echocardiography|Transthoracic echocardiography with standard measurements
75879272|NCT05250349|Diagnostic Test|Doppler sonography|Transcarotid and transcranial Doppler sonography
75431658|NCT01523379|Drug|Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row
75431659|NCT01523379|Drug|Placebo|NaCl i.v. two times a day, two days in an row
75431660|NCT01523418|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) & 5 weeks (THR)
75431661|NCT01523431|Drug|Irinotecan Injection [Camptosar]|CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 *1/*1 or heterozygous UGT1A1*1/*28 or *1/*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1*28/*28, *6/*6 or *28/*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
75431662|NCT01523431|Drug|5-fluorouracil|The 5-FU dosage will remain the standard.
75431663|NCT01523431|Drug|Leucovorin|The LV dosage will remain the standard.
75431664|NCT01523470|Device|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
75431665|NCT01523483|Drug|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
75578055|NCT05270837|Drug|Pegvaliase|Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
75578056|NCT05270837|Other|Diet Only|Diet Control
75578057|NCT05269355|Drug|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm description.
75578058|NCT05269355|Drug|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm description.
75578059|NCT05269355|Other|Placebo|Placebo will be administered as per the schedule specified in the arm description.
75578060|NCT05268315|Behavioral|Brief Psychoeducational Intervention|The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
75578061|NCT05237648|Other|Online Voice quality education module|The novel online module the authors developed consists of a patient education on acoustic-perceptual rating of voice quality (CAPE-V), practice rating sample recordings of others' voices, and the patient's self-rating of their own voice in real time during a standard sentence-reading task. The module also includes the Self-Efficacy Scale for Voice Therapy.
75727833|NCT03093480|Biological|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
75727834|NCT00616928|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
75727835|NCT00616928|Biological|Placebo|Two intramuscular injections at Days 0 and 21.
75727836|NCT00939042|Procedure|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
75727837|NCT00939042|Procedure|BMNC therapy|Injection of BMNC after common PCI
75727838|NCT02578511|Drug|Ixazomib|Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
75727839|NCT00935688|Other|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
75727840|NCT00869648|Procedure|Extension|After anaesthesia induction the head is placed in extension
75727841|NCT00869648|Procedure|Neutral head position|After anaesthesia induction the head is placed in neutral position
75879273|NCT05250349|Diagnostic Test|Neuropsychological tests|Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
75879274|NCT04044781|Drug|BPN14770, T2310|Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
75879275|NCT04044469|Behavioral|Immunization-enhancement|This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.
76049882|NCT02332889|Biological|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be > 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
75879276|NCT04044469|Behavioral|Immunization-inhibition|This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.
75431666|NCT01523483|Drug|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
76049883|NCT02332889|Drug|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
76049884|NCT02357147|Drug|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
76049885|NCT02357147|Drug|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
75431667|NCT01523509|Device|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
75431668|NCT01523522|Other|Myoblast injection|Autologous myoblast injection in the anal sphincter
75431669|NCT01523522|Procedure|saline solution injection|saline solution injection in anal sphincter
75431670|NCT01523535|Behavioral|repeated cycles of short sleep|- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
75431671|NCT01523548|Drug|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
75431672|NCT01523561|Behavioral|dance group|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
75431673|NCT01523574|Drug|Vitamin E|Vitamin E 400mg PO orally
75431674|NCT01523574|Drug|Placebo|Placebo, given orally
75431675|NCT01523600|Behavioral|Whole body vibration training|The intervention comprises a 10-week individually supervised, progressive WBV training done twice a week on a side-alternating device with simultaneous body transferring and slight squatting exercises. At the week one, the duration of a single training bout is 1 x 1 min, and the number of 1 min bouts is weekly increased by one until five bouts is reached. During weeks 4 - 10, the training comprises 5 x 1 min bouts with 1 min rest periods between. During weeks 1 to 3, vibration frequencies are 12 and 18 Hz, which are used alternately. Thereafter, also 26 Hz may be used instead of 18 Hz. In addition, the amplitude of vibration is increased progressively according to a specified protocol. A detailed training diary is kept.
75431676|NCT01523600|Behavioral|Wellness group|The intervention comprises a 10-week supervised group training done once a week with the focus on stretching and flexibility exercises done mostly in a sitting position. The duration of a single training session is 45 minutes. A training diary is kept.
75431677|NCT01523626|Other|Total body Computed Tomography.|"The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.~The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT."
75431678|NCT01523626|Other|Conventional imaging and selective CT scanning.|"The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.~Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers."
75879277|NCT04044469|Behavioral|Control group|This group receives no further information after watching the videotaped doctor's report.
75879278|NCT04634383|Device|WFMA - wireless floating microelectrode array|Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
75879279|NCT01345279|Drug|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
75879280|NCT01345279|Drug|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
76049886|NCT02357147|Drug|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
75879281|NCT01345279|Drug|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
75879282|NCT00577577|Drug|rhIGF-I/rhIGFBP-3|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
75431679|NCT01523639|Drug|Metformin/Placebo|"The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks"
75879283|NCT00577577|Drug|placebo|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
75879284|NCT02833844|Drug|Evolocumab|Dose of subcutaneous evolocumab QM
75879285|NCT02833844|Drug|Placebo|Dose of matching placebo QM
75431680|NCT01523678|Drug|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
75431681|NCT01523678|Drug|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
75879286|NCT01345357|Drug|CEP-9722|CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
75879287|NCT01345357|Drug|Gemcitabine|Gemcitabine will be administered at 1250 mg/m^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
75431682|NCT01523678|Drug|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
75431683|NCT01523691|Behavioral|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
75431684|NCT01523691|Behavioral|Control sleep|Regular amounts of sleep across study protocol
75431685|NCT01523730|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.
75431686|NCT01523730|Device|Sham Repetitive Transcranial Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
75879288|NCT01345357|Drug|Cisplatin|Cisplatin will be administered at 75 mg/m^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
75879289|NCT01333631|Drug|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
75431687|NCT01523769|Procedure|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
75431688|NCT01523795|Other|Motion-controlled video gaming|Play of motion-controlled video games for one hour
75431689|NCT01523795|Other|Traditional video gaming|Participants played traditional video games for one hour
75431690|NCT01523795|Other|Television watching|Participants watched television for one hour
75431691|NCT01523847|Drug|MBVD (Myocet+BVD)|"MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15"
75431692|NCT01523860|Drug|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
75431693|NCT01523912|Device|Radiofrequency ablation of dysplastic mucosa (HALO)|Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
75431694|NCT01523925|Behavioral|dCIT|This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
75431695|NCT01523925|Behavioral|BAT|The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
75431696|NCT01523925|Behavioral|Control intervention group|The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
75431697|NCT01523925|Behavioral|Functional electrical stimulation|
75431698|NCT01523938|Behavioral|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
75431699|NCT01523990|Drug|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
75431700|NCT01523990|Drug|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
75431701|NCT01524003|Procedure|cryotherapy|cryotherapy treatment of the uterine cervix
75431702|NCT01524003|Procedure|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
75431703|NCT01524016|Drug|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
75431704|NCT01524042|Procedure|Pants for colonoscopy|We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
75431705|NCT01524055|Device|Single-Balloon-Enteroscopy with Air as insufflation gas.|Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
75431706|NCT01524055|Device|Single-Balloon-Enteroscopy with CO2 as insufflation gas.|Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
75431707|NCT01524068|Drug|Standard Steroid Treatment|One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
75879290|NCT05014789|Device|Control-IQ technology 2.0|All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
76049887|NCT02357147|Drug|Cisplatin|Combination Phase - Cisplatin 75 mg/m^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
75578062|NCT05237648|Other|Vocal hygiene module|The generic online patient education module on vocal hygiene during the waiting period between their initial evaluation and their first therapy session that also includes the Self-Efficacy Scale for Voice Therapy
75578063|NCT05232708|Drug|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
75578064|NCT05232708|Drug|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
75431708|NCT01524068|Drug|The Standard Steroid Treatment, Plasma Exchange and rituximab|The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
75431709|NCT01524081|Drug|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~- Cefuroxime in 100ml saline~- Metronidazole in 500ml saline"
75431710|NCT01524081|Drug|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~- 2x amoxicillin in 100ml saline~- Fluconazole in 500ml saline"
75578065|NCT05232708|Drug|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
75578066|NCT05232708|Drug|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
75578067|NCT05230758|Drug|Metformin hydrochloride (HCl) 500mg tablet|"Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API) and are white, round, biconvex, film-coated tablets, with a score line on one face and debossed with HMR on the other. Each tablet contains the non-medicinal ingredients magnesium stearate and povidone. Tablet coating is comprised of hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide."
75431711|NCT01524081|Drug|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~- 100ml saline solution~- 500ml saline solution"
75431712|NCT01524081|Drug|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~- 2x 100ml saline solution~- 500ml saline solution"
75431713|NCT01524094|Drug|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
75431714|NCT01524094|Procedure|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
75431715|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
75578068|NCT05230758|Drug|Placebo|Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
75578069|NCT05229107|Device|Cereset Research|Device: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
75578070|NCT05226494|Drug|fb-PMT|Daily dosing based on patient weight
75727842|NCT00869648|Procedure|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
75879291|NCT01345435|Procedure|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
75879292|NCT01345435|Procedure|Telemonitoring & Telemedicine|The Telemonitoring & Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
75879293|NCT01345435|Other|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
75879294|NCT04611763|Drug|Flurbiprofen axetil preoperatively|give Flurbiprofen axetil 15 min before surgery
75879295|NCT04611763|Drug|Flurbiprofen axetil postoperatively|give Flurbiprofen axetil at the end of surgery
75879296|NCT05329064|Biological|BNT162b2 Pfizer-BioNTech/Comirnaty|"The study will use 10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose.~Two doses will be given at 2 months apart between doses."
75879297|NCT05186935|Device|Injectable Hydrogel treatment|The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
75578071|NCT05224531|Drug|CS1 Administration|CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
75578072|NCT05222828|Drug|Carbocaine Injectable Product|One injection per patient
75578073|NCT05217108|Device|FitBit|All participants in each study group will receive a Fitbit. Participants will be asked to wear a Fitbit every day for 8 weeks to record the number of steps you take
75727843|NCT00563784|Drug|Erlotinib|150 mg by mouth daily for 7 Weeks
75727844|NCT00563784|Drug|Carboplatin|2 AUC by vein weekly for 7 Weeks
75727845|NCT00563784|Drug|Paclitaxel|45 mg/m^2 by vein weekly for 7 Weeks
75727846|NCT00563784|Radiation|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
75578074|NCT05212246|Drug|5% Imiquimod cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
75578075|NCT05212246|Drug|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
75578076|NCT05212090|Diagnostic Test|EOS X-Ray|Repeated AP Pelvis x-ray and Lateral Lumbar EOS x-ray
75578077|NCT05206500|Drug|Antibiotic|FDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC >0 and <10,000
75578078|NCT05206500|Device|Next Gen|Next Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.
75578079|NCT05192954|Device|LigaSureTM vessel sealing device|Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
75578080|NCT05191680|Drug|Apalutamide Oral Tablet [Erleada]|Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.
75578081|NCT05191680|Drug|Placebo|Placebo to match apalutamide
75578082|NCT05178901|Biological|PHV02|live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection
75578083|NCT05178901|Other|Placebo|Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection
75727847|NCT00869882|Procedure|Circumferential arthrodesis|"Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI."
75879298|NCT04568629|Other|Advice from the PiPS-B14 prognostic tool|"Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction."
75879299|NCT04568629|Other|Advice from another clinician|"Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor."
75879300|NCT04973917|Procedure|respiratory support|respirators for invasive mechanical ventilation
75879301|NCT03985033|Other|leucocyte and platelet-rich fibrin (L-PRF)|The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
75879302|NCT01341782|Drug|paricalcitol|
75879303|NCT01341782|Drug|maxacalcitol|
75578084|NCT05170399|Biological|Fluzone|Annual Influenza Vaccine
75578085|NCT05170399|Biological|Shingrix|Recombinant, adjuvanted Zoster Vaccine (RZV)
75578086|NCT05170399|Biological|Flucelvax|Annual Influenza Vaccine
75578087|NCT05170399|Biological|Afluria|Annual Influenza Vaccine
75578088|NCT05170399|Biological|PREVNAR 13|Pneumococcal Conjugate Vaccine (PCV13)
75578089|NCT05170399|Biological|Heplisav -B|Recombinant, adjuvanted Hepatitis (HepB-CpG)
75578090|NCT05170399|Biological|Pfizer-COVID-19 Vaccine|COVID-19 Vaccine
75578091|NCT05170399|Biological|FluLaval|Annual Influenza Vaccine
75578092|NCT05170399|Biological|Fluarix|Annual Influenza Vaccine
75578093|NCT05170399|Biological|PNEUMOVAX 23|Pneumococcal Polysaccharide Vaccine (PPSV23)
75578094|NCT05170399|Drug|PREVNAR 20|Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
75578095|NCT05170399|Drug|AREXVY, ABRYSVO|Respiratory Syncytial Virus Vaccine
75578096|NCT05161507|Procedure|Magseed|Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.
75578097|NCT05161507|Procedure|Magtrace|Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.
75578098|NCT05161507|Procedure|Axillary lymph node metastasis - needle biopsy|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
75431716|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
75727848|NCT00869882|Procedure|Posterolateral fusion with instrumentation|"Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~Central stenosis: decompression is performed including medial facectomy, laminectomy;~Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed."
75727849|NCT03291509|Behavioral|Video Conference Meetings|Individual video conferencing with a health educator using an iPad.
75879304|NCT01341782|Drug|paricalcitol placebo|
75879305|NCT01341782|Drug|maxacalcitol placebo|
75879306|NCT01345747|Device|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
75879307|NCT05150509|Diagnostic Test|Oral Squamous Cell Carcinoma|To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
75879308|NCT02250157|Drug|Oratecan|
75879309|NCT03952429|Behavioral|Anti Alcohol App with Active Cognitive Bias|The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.
76049888|NCT02356211|Other|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
75431717|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
75431718|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
75431719|NCT01524146|Procedure|Photodynamic Therapy|"PDT is a therapeutic approach that specifically targets neoplastic cells.~• PDT involves three components:~Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.~Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis~Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.~Technique:~Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.~Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months."
75578101|NCT05149534|Behavioral|Written Exposure Therapy|Narrative written disclosure of trauma administered in an evidence-based protocol.
75578102|NCT05149534|Device|repetitive transcranial magnetic stimulation|Noninvasive magnetic neuromodulation device
75578103|NCT05147805|Drug|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
75578104|NCT05147805|Drug|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
75578105|NCT05139017|Biological|Zilovertamab vedotin|Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg
75578106|NCT05139017|Biological|Rituximab|IV Infusion 375 mg/m^2
75578107|NCT05139017|Drug|Gemcitabine|IV Infusion 1000 mg/m^2
75578108|NCT05139017|Drug|Oxaliplatin|IV Infusion 100 mg/m^2
75578109|NCT05139017|Drug|Bendamustine|IV Infusion 90 mg/m^2
75727850|NCT03291509|Behavioral|In-person Meetings|Individual face-to-face (FTF) meetings with a health educator.
75879310|NCT03952429|Behavioral|Inactive Cognitive Bias Modification|The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
75879311|NCT01345825|Other|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
75879312|NCT01345903|Procedure|therapeutic conventional surgery|Undergo robotic-assisted surgery
75879313|NCT05063149|Drug|Broncho-Vaxom|Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
75879314|NCT05063149|Other|Placebo|Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
75879315|NCT01341470|Drug|LY2495655|administered intravenously or subcutaneously
75879316|NCT01341470|Drug|Placebo|administered intravenously or subcutaneously
76049889|NCT02332655|Drug|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
76049890|NCT02388737|Drug|Vonoprazan|Vonoprazan tablets
76049891|NCT02388737|Drug|Lansoprazole|Lansoprazole capsules or tablets
76049892|NCT02388737|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
75431720|NCT01524159|Dietary Supplement|bromelain capsule|Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
76049893|NCT02388737|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
75431721|NCT01524159|Dietary Supplement|placebo (wheat starch)|Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
75431722|NCT01524172|Behavioral|Yoga Based Psychotherapy Group|YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
75578116|NCT05117502|Device|intermittent Theta Burst Stimulation|intermittent Theta Burst Stimulation (iTBS) is a type of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered by the MagVenture MagPROX100 with MagOption Stimulator and MagPro Cool Coil B65 A/P. The MagPro Cool Coil B65 A/P can be switched from active to placebo.
75431723|NCT01524172|Behavioral|Standard Mental Health Treatment|Trauma and evidence informed therapy
75431724|NCT01524185|Behavioral|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
75578117|NCT05117502|Device|Placebo intermittent Theta Burst Stimulation|The placebo coil magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active iTBS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e. clicking) nearly identical to that of the active coil.
76049894|NCT02355743|Drug|rtPA lock therapy|"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."
76049895|NCT02388347|Drug|Placebo SC|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
76049896|NCT02388347|Biological|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
75431725|NCT01524185|Behavioral|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
76049897|NCT02388347|Biological|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
76049898|NCT02388347|Biological|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
76049899|NCT02388347|Biological|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
75578123|NCT05096403|Drug|Pegcetacoplan|Pegcetacoplan taken twice weekly as subcutaneous injection
75578124|NCT05091788|Device|Venus Aime|Venus Aime is a micro-coring device of the skin that can potentially help reduce moderate to severe facial wrinkles.
75578125|NCT05079256|Device|595 nm Pulsed dye laser (Candela V-beam perfecta)|595 nm pulsed dye laser therapy. 2 treatments Fluence ~ 6 - 9 J/cm^2 Pulse duration ~ 0.45 - 3.0 ms 33% overlap.
75879317|NCT03564158|Drug|meropenem-vaborbactam|Meropenem-Vaborbactam being studied for effects on TQT
75879318|NCT03564158|Drug|Placebo|Placebo
75879319|NCT03564158|Drug|Moxifloxacin|Active Comparator
76049900|NCT02355665|Drug|Nicotine Spray|Nicotine Spray
76049901|NCT02355665|Drug|Placebo|Placebo to match nicotine spray
76049902|NCT02010255|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
76049903|NCT02010255|Drug|RBV|RBV tablets administered orally in a divided daily dose
76049904|NCT02354417|Biological|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
75578126|NCT05070793|Behavioral|Culturally adapted interpersonal psychotherapy|Individual psychotherapy based on Brief Interpersonal Psychotherapy, culturally adapted for transgender and nonbinary individuals.
75578127|NCT05069974|Drug|Linezolid 600 mg|After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days or 1 tablet of of Linezolid every 24hours during 5 days.
75578128|NCT05069974|Drug|Benzathine Penicilllin G|After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
75578129|NCT05068414|Diagnostic Test|Blood panel|"Thrombin generation test~Residual plasma concentration of dabigatran, rivaroxaban and/or apixaban (direct oral anticoagulants)~International Normalized Ratio (if anti-vitamin K therapy is prescribed)~Platelet aggregation test"
75578130|NCT05065411|Drug|Enobosarm & Abemaciclib Combo|Subjects will receive a combo of Enobosarm & Abemaciclib
75578131|NCT05065411|Drug|non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant|Non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant
75578132|NCT05055570|Other|No intervention|No intervention
75578133|NCT05053997|Behavioral|NAVIGATE|Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
76049905|NCT02332187|Device|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
76049906|NCT02332187|Device|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
75727851|NCT03291509|Behavioral|Enhanced Stop Light Diet|Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
75879320|NCT02677298|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
76049907|NCT02330549|Drug|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
75431726|NCT01524237|Drug|LY2979165|Capsules administered orally
75431727|NCT01524237|Drug|LY2140023|Tablets administered orally
75431728|NCT01524237|Other|Placebo|Administered orally
75431729|NCT01524237|Other|Ketamine|Administered intravenously (IV)
76049908|NCT02330549|Drug|Placebo|Placebo-matching CVC administered orally once daily and taken every morning with food.
76049909|NCT02009865|Drug|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
75431730|NCT01524250|Drug|corticosteroids|1250mg of oral prednisone daily for 3 days
75431731|NCT01524250|Drug|corticosteroids|1000mg IV methylprednisolone daily for 3 days
75431732|NCT01524315|Drug|Vitamin B1-ratiopharm|300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
76049910|NCT02009865|Drug|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
75879321|NCT02677298|Drug|Placebo|Injection, sodium chloride 0.9 mg divided in five 0.1mL i.m. injections into glabellar area
75879322|NCT02677298|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles
75879323|NCT03143101|Biological|FluMist trivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
75431733|NCT01524315|Drug|Placebo|100 ml normal saline, intravenous, preoperative
75431734|NCT01524341|Drug|KAE609|KAE609 was supplied as capsules for oral use.
75578139|NCT05026177|Drug|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.
75431735|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
75578140|NCT05026177|Drug|Placebo|Matching placebo given b.i.d. for 76 weeks
75727852|NCT03291509|Behavioral|Physical Activity|Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
75727853|NCT00203047|Drug|Glatiramer Acetate|20mg glatiramer acetate (GA) administered by daily subcutaneous injections
75727854|NCT00203047|Drug|Placebo|Placebo for prednisone given daily
75727855|NCT00203047|Drug|Prednisone|Prednisone 1250 mg taken daily
75727856|NCT00870038|Device|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
75879324|NCT03143101|Biological|FluMist Quadrivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
75879325|NCT03143101|Biological|FluMist Quadrivalent (2017-2018)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
75879326|NCT01345981|Drug|Lidocaine|dosage 20 mg and 40 mg
75431736|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
75578141|NCT05018299|Biological|FB704A placebo|Placebo
75578142|NCT05018299|Biological|FB704A|Anti-IL-6 antibody
75578143|NCT05017545|Biological|carfilzomib|"Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant."
76049911|NCT01620177|Drug|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
76049912|NCT01620177|Drug|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
75431737|NCT01524367|Drug|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
75727857|NCT00870038|Device|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
75727858|NCT00870038|Device|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
75727859|NCT04074551|Drug|HCP1701|HCP1701
75727860|NCT04074551|Drug|Losartan|Losartan
75727861|NCT04074551|Drug|Amlodipine|Amlodipine
75727862|NCT04074551|Drug|Rosuvastatin and Ezetimibe|Rosuvastatin and Ezetimibe
75879327|NCT00871351|Drug|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
75879328|NCT00871351|Drug|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
75879329|NCT00871351|Drug|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
75431738|NCT01524367|Drug|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
75431739|NCT01524380|Drug|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
75431740|NCT01524380|Drug|Placebo|twice a day, 10 weeks
75431741|NCT01524406|Drug|HPP593|Oral, twice a day.
75431742|NCT01524406|Drug|Placebo|Oral, twice a day.
75727863|NCT00870116|Radiation|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
75727864|NCT00870116|Radiation|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
75727865|NCT00870116|Radiation|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
75727866|NCT02608385|Radiation|Stereotactic body radiotherapy (SBRT)|Patients will receive 3 or 5 doses of SBRT to the chosen metastases.
75727867|NCT02608385|Drug|Pembrolizumab|Pembrolizumab (200 mg) given every 3 weeks.
75879330|NCT00871351|Drug|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
75879331|NCT04920331|Biological|Erenumab|140mg single intravenous administration (60 minutes)
75879332|NCT02745080|Biological|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
75879333|NCT02745080|Biological|Adalimumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
75879334|NCT01346137|Drug|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
75879335|NCT04537507|Procedure|Coronary angiography|
75879336|NCT00521599|Drug|Mometasone furoate dry powder inhaler|
75879337|NCT00521599|Drug|Placebo|
75578144|NCT05017545|Biological|belatacept|Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
75578145|NCT05017545|Procedure|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been >4 weeks since the previous bone marrow aspiration.
75578146|NCT05005416|Behavioral|GOALS Intervention|Weekly treatment sessions are comprised of a graded activity program focused on goal setting in 4 treatment domains: therapeutic exercise, aerobic activity, functional activity, and pain coping skills. Instruction in cognitive behavioral coping skills for pain include: explaining pain (pain neuroscience education), pacing, soliciting positive social support, cognitive restructuring, present mindedness, and symptom self-management planning.
75578147|NCT05005416|Behavioral|Usual Care Physical Therapy|Usual care will be characterized by extracting the following variables from participants' electronic health record: date of physician referral to physical therapy for neck or low back pain diagnosis (index referral), attendance of at least one PT visit (adherence), dates of first and last PT visits for index referral (duration of care), number of PT visits attended across an 8-week episode of care for the index referral (number of visits), clinic where PT services were provided (service location), and CPT billing codes issued during the episode of care for the index referral (type and frequency of treatments provided).
75578148|NCT05000645|Behavioral|Grocery delivery|Each food delivery will contain approximately $35 worth of fresh fruits, vegetables, dairy products, and whole grain foods. These foods are not meant to supplant regular meals, rather make healthy eating more convenient.
75727868|NCT00142519|Drug|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
76049913|NCT02075541|Biological|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
76049914|NCT02075541|Drug|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
75879338|NCT00442897|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
75879339|NCT00442897|Drug|Comparator: atorvastatin|atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
75431743|NCT01524432|Drug|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
75431744|NCT01524432|Drug|Placebo|No drug loaded microcapsules socks
75431745|NCT01524445|Other|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
75431746|NCT01524458|Procedure|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
75431747|NCT01524471|Procedure|Per Oral Endoscopic Myotomy|
75431748|NCT01524497|Drug|Trazodone|75mg tablet/150 mg tablet
75431749|NCT01524497|Drug|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
75431750|NCT01524510|Radiation|CT scan|low dose radiation scan without contrast without and with MRA
75431751|NCT01524510|Device|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
75578149|NCT05000645|Behavioral|Unsweetened beverage delivery|Participants will receive unsweetened beverages to replace normal sugar-sweetened beverage intake.
75578150|NCT04993625|Procedure|avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla
75727869|NCT00142519|Drug|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
75727870|NCT03714776|Drug|Placebo|Placebo matching solution administered as SC injection.
75727871|NCT03714776|Drug|ISIS 757456|Administered as SC injection.
75727872|NCT00141817|Drug|pantoprazole for approximately 9 weeks.|
75879340|NCT01346215|Biological|heparin sodium|5000 UI/mL
75578151|NCT04992728|Other|Restricted Spectrum Magnetic Resonance Imagining|Restriction Spectrum Magnetic Resonance Imaging (RS-MRI), which uses magnetism instead of x-rays to build up a picture of the inside of the body. The scan is completely painless but can be rather noisy and requires the patient to lie very still inside the center of a large, doughnut-shaped magnet for approximately 30-60 minutes complete the imaging.
75431752|NCT01524575|Drug|gemcitabine and oxaliplatin|Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
75578152|NCT04989816|Drug|Trastuzumab Deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
75578153|NCT04989699|Drug|OTX-TKI/Sham|OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
75578154|NCT04989699|Drug|Aflibercept/Sham|Aflibercept administered every 8 weeks
75578155|NCT04987307|Drug|Efavaleukin alfa|Efavaleukin alfa will be administered by subcutaneous (SC) injection.
75578156|NCT04987307|Drug|Placebo|Placebo will be administered by SC injection.
75431753|NCT01524601|Drug|Rosuvastatin|20 mg rosuvastatin for 4 weeks
75727873|NCT00573170|Drug|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg)
76049915|NCT02330081|Device|Mirasol treatment of whole blood|"Subject will be infused with two products at the same time:~radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~radio-labeled platelets derived from subject's untreated fresh whole blood."
76049916|NCT01986855|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
75727874|NCT00573170|Drug|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) [currently marketed as Fioricet]
75727875|NCT00573170|Drug|placebo|placebo
75727876|NCT03967171|Other|before uterine incision oxytocin|blood loss during elective cesarean section
75727877|NCT03967171|Other|after clamping the umbilical cord oxytocin|blood loss during elective cesarean section
75727878|NCT03971383|Drug|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
76049917|NCT01986855|Drug|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
76049918|NCT01986855|Drug|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
75727879|NCT03971383|Drug|Placebo|3 tablets one time, 3 times a day(tid)
75727880|NCT01077349|Procedure|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being <35 ml/kg/h (or a maximum of 3500 ml/h).
75727881|NCT01077349|Procedure|standard care|"extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~Serum creatinine > 350 micromol/L or increase x3.0 from pre-operative value OR~Diuresis < 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~Or serum urea > 36 mmol/l OR~Or life threatening hyperkalemia"
75727882|NCT03966937|Other|Dry needling|"Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points."
75431754|NCT01524614|Procedure|nasal mask|nasal mask use instead of face mask
75578157|NCT04987086|Diagnostic Test|PSMA PET|PSMA PET may have influence on the clinical decision-making of the patients with renal cancer
75727883|NCT03966937|Other|Control|Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
75727884|NCT00880646|Dietary Supplement|Oolong tea containing L-arabinose and indigestible dextrin|
75727885|NCT00880646|Dietary Supplement|Oolong tea (Placebo)|
75727886|NCT00880724|Device|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
75727887|NCT03967327|Drug|Buprenorphine transdermal patches|It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
75727888|NCT03967327|Drug|Morphine Sulfate Sustained-Release Tablet|It will be administered orally twice (q12h) daily.
75727889|NCT01075945|Drug|Dihydroartemisinin- piperaquine|three tablets per day
75431755|NCT01524640|Biological|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
75431756|NCT01524640|Biological|Placebo|1.5 ml oral administration on day 0 and day 14
75431757|NCT01524653|Drug|Rosuvastatin|20 mg po od
75727890|NCT01075945|Drug|artemether- lumefantrine|twenty tablet in eight doses
75727891|NCT00882752|Procedure|molecular analysis|bowel disease
76049919|NCT01986855|Drug|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
76049920|NCT02075463|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
76049921|NCT02075463|Drug|Placebo|Matching placebo tablet for GSK1278863
76049922|NCT02353871|Biological|Botulinum toxin type A|A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
75578158|NCT04980300|Behavioral|Expanded Intervention|Participants in the Expanded Intervention arm will receive five virtual consultation sessions, delivered by a physical therapist over 12 weeks (at Weeks 1, 2, 4, 7, and 10) and lasting approximately 45-60 minutes each. Each session will focus on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis. Participants will be provided with an exercise manual, tracking log, educational manual, and a step counter. Participants will be prescribed up to 6 exercises (quadriceps, hip abductor/gluteal, hamstrings/gluteal, calf, balance) and daily walking step goals. Progression will be a joint decision by the participant and physical therapist. Education will include information on knee osteoarthritis, managing pain, being active, weight loss, dealing with setbacks, and progressing activity. The physical therapist will also discuss barriers and facilitators to meeting and progressing goals as appropriate.
75578159|NCT04980300|Behavioral|Brief Intervention|Participants in the Brief Intervention arm will receive access to a study-specific website that navigates them to a variety of web-based resources on knee osteoarthritis. Topics for the various resources include an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis. Sessions range from 20 - 70+ minutes.
76049923|NCT02353871|Drug|Placebo|A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
75578161|NCT04965493|Drug|Pirtobrutinib|Oral
75578162|NCT04965493|Drug|Venetoclax|Oral
75578163|NCT04965493|Drug|Rituximab|Intravenous (IV)
75578164|NCT04951778|Drug|CC-91633|Administered orally according to the assigned treatment schedule
75578165|NCT04948749|Device|Drug Eluting Stent implantation|The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
75578166|NCT04948749|Drug|Aggressive medical treatment|Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).
75578167|NCT04948749|Behavioral|Risk factor management|Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
75727892|NCT00874562|Drug|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
75431758|NCT01524653|Drug|Placebo|20 mg po od
75431759|NCT01524718|Radiation|Imaging with two X-ray image intensifiers|Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
75431760|NCT01524731|Drug|Saline|Normal Saline
75578168|NCT04948749|Drug|Standard medical treatment|Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
75578169|NCT04943042|Drug|Avatrombopag|According to prescription
76049924|NCT02009397|Drug|Ipilimumab|
75727893|NCT00874562|Drug|Rapamycin|Taken orally mixed with water or orange juice
75727894|NCT00874640|Biological|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
75727895|NCT00882830|Procedure|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
75727896|NCT00874718|Behavioral|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
75431761|NCT01524731|Drug|Dexamethasone|4 mg
75431762|NCT01524731|Drug|Dexamethasone|8 mg
75727897|NCT00874718|Behavioral|General education|Non-specific educational program for general health.
75431763|NCT01524744|Drug|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
75431764|NCT01524744|Drug|Adcortyl|triamcinolone acetonide 0.1% in orabase
75431765|NCT01524757|Drug|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
75727898|NCT00201643|Drug|Betamethasone or Dexamethasone (2nd course of ACS)|Course of Betamethasone or Dexamethasone
75727899|NCT00201643|Drug|Placebo|Course of Placebo (NS)
75727900|NCT03798314|Biological|Nivolumab|Given IV
76049925|NCT02009397|Drug|GM-CSF|
75431766|NCT01524809|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
75431767|NCT01524809|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
75431768|NCT01524848|Drug|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
75431769|NCT01524861|Drug|Placebo|a placebo tablet bis in die for 12 months
75431770|NCT01524861|Drug|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
75431771|NCT01524861|Drug|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
75431772|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
75431773|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
75431774|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
75578175|NCT04927663|Procedure|Computed Tomography|Undergo CT imaging
75578176|NCT04927663|Procedure|Magnetic Resonance Imaging|Undergo MRI
75578177|NCT04927663|Procedure|Positron Emission Tomography|Undergo PET imaging
75578178|NCT04927663|Drug|11C-YJH08|Given IV
75578179|NCT04921358|Drug|Tislelizumab|administered intravenously
75578180|NCT04921358|Drug|Docetaxel|administered intravenously
75578181|NCT04921358|Drug|Sitravatinib|administered orally
76049926|NCT04666311|Diagnostic Test|Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB|"CAD4TB version 6 and 7: Software tool for detecting lung abnormalities in computer tomogram images (pulmonary abnormalities) and frontal chest radiograph images (tuberculosis abnormalities) ; availability is guaranteed by Delft Imaging System; EC 0344 Certificate (vs.6); CE mark pending (vs.7). Will be performed by a registered and qualified radiographer in accordance with national regulations.~Afinion AS100 Analyzer and Afinion CRP: In vitro diagnostic to determine the amount of CRP in human whole blood, serum or plasma; CE-mark ; Will be performed by qualified, GCP-trained study personnel."
75879341|NCT01346215|Biological|heparin sodium|5000 UI/mL
75879342|NCT02834390|Drug|Quizartinib|"[Induction period, Cycle 1] Once-daily repeated oral administration Day 8 to Day 21.~[Induction period, Cycle 2] Once-daily repeated oral administration Day 6 to Day 19.~[Consolidation period] Once-daily repeated oral administration Day 6 to Day 19."
75879343|NCT02834390|Drug|Cytarabine|"[Induction period, Cycle 1] Once-daily intravenous injection of 100 mg/m^2 cytarabine on Day 1 to 7.~[Induction period, Cycle 2] Once-daily intravenous injection of 100 mg/m^2 cytarabine on Day 1 to 5.~[Consolidation period] Twice-daily intravenous injection of 3.0 g/m^2 cytarabine at 12-hour intervals on Days 1, 3, and 5."
75879344|NCT02834390|Drug|Idarubicin|"Either Idarubicin or Daunorubicin will be used [Induction period, Cycle 1] Once-daily intravenous injection of 12 mg/m^2 idarubicin on Day 1 to 3.~[Induction period, Cycle 2] Once-daily intravenous injection of 12 mg/m^2 idarubicin on Day 1 and 2."
75879345|NCT02834390|Drug|Daunorubicin|"Either Idarubicin or Daunorubicin will be used [Induction period, Cycle 1] Once-daily intravenous injection of 60mg/m^2 daunorubicin on Day 1 to 3.~[Induction period, Cycle 2] Once-daily intravenous injection of 60mg/m^2 daunorubicin on Day 1 and 2."
75879346|NCT03141151|Behavioral|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
75578184|NCT04908423|Drug|Xeomin®|To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.
75578185|NCT04895358|Biological|pembrolizumab|Intravenous (IV) infusion
75578186|NCT04895358|Drug|paclitaxel|IV infusion
75727901|NCT03798314|Drug|Pomalidomide|Given PO
75727902|NCT01077427|Device|Gemcitabine + Cisplatin + regional hyperthermia|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)~Cisplatin: 25 mg/m² as iv-infusion on days 2, 3* and 16, 17* of each course (Total dose: 600 mg/m²)~Regional hyperthermia: 60 minutes on days 2, 3*, and 16, 17* of each course~* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17"
75727903|NCT01077427|Drug|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles"
75431775|NCT01524939|Drug|immunoglobulin G|Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
75431776|NCT01524952|Device|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
75431777|NCT01524965|Procedure|Immediate mobilisation after locking-plate osteosynthesis|"Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
75578187|NCT04895358|Drug|nab-paclitaxel|IV infusion
75879347|NCT03141151|Behavioral|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
75879348|NCT01317433|Drug|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
75879349|NCT01317433|Drug|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
75879350|NCT01358708|Drug|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
75879351|NCT01358708|Drug|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
75578188|NCT04895358|Drug|liposomal doxorubicin|IV infusion
75578189|NCT04895358|Drug|capecitabine|oral administration
75879352|NCT01346449|Behavioral|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
75879353|NCT01346449|Behavioral|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
75879354|NCT01346449|Behavioral|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
75578190|NCT04895358|Drug|normal saline|IV infusion
75578191|NCT04895358|Drug|dextrose|IV infusion
75578192|NCT04894591|Drug|Zepzelca|Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.
75578193|NCT04892017|Drug|DCC-3116|Oral Tablet Formulation
75578194|NCT04892017|Drug|Trametinib|Oral Tablet Formulation
75578195|NCT04892017|Drug|Binimetinib|Oral Tablet Formulation
75578196|NCT04892017|Drug|Sotorasib|Oral Tablet Formulation
75727904|NCT05204654|Other|In-office fabricated appliance|A 0.022 Slot MBT™ second molar mini tube that has been modified to have a 2 mm length will be placed on the maxillary first molar and a 0.018 slot MBT™ maxillary canine bracket will be placed on the maxillary canine, with a 0.016x0.022 stainless-steel wire spanning from the maxillary first molar to the maxillary canine. A bayonet bend will be placed mesial to the molar tube. A curve will be bent into the wire, so that the wire is able to passively rest on the buccal surface of the maxillary canine. A stainless-steel closed coil will span the molar to canine and lay flush to the mesial portion of the molar tube and the distal portion of the canine bracket. The wire will be cinched mesial to the maxillary canine tie-wing and also 2-3 mm distal to the maxillary first molar to ensure that the molar can rotate during treatment, if needed. A stainless-steel tie will be used to secure the wire into the canine bracket. AP correction will be completed following CMA protocol
75879355|NCT01346449|Behavioral|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
75879356|NCT03563768|Procedure|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
75879357|NCT01317511|Dietary Supplement|Protein|Protein drink
75431778|NCT01524965|Procedure|Standard mobilisation after locking plate osteosynthesis|"Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
75431779|NCT01524965|Device|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
75879358|NCT03563924|Other|"Setting up a specific care path AlloTC for management of TVE in patients with cancer"|"Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)"
75879359|NCT03563846|Drug|RP-G28|RP-G28 is a purified galacto-oligosaccharide (GOS) product
75879360|NCT03635281|Procedure|Recruitment manoeuvers|"Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~set FIO2 at 1.0~Ppeak limit at 45 cmH2O~Respiratory rate set at 6~I:E set at 1:1~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~If the maximum VT is set without rasing the Pplat, raise PEEP~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
75879361|NCT03635281|Procedure|incremental PEEP|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
75431780|NCT01525004|Drug|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
75727905|NCT05204654|Device|Carriere Motion Appliance|A bar spanning from the maxillary first molar to canine with a ball and socket joint at the molar and a canine pad at the canine. A slight bend is present between the molar and canine bracket. The ball and socket is designed to allow the molar to rotate to -15 degrees along it's longitudinal axis. The appliance claims that it allows for Class II correction with minimal secondary tooth movements when used with mandibular anchorage.
75727906|NCT00883064|Drug|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)|
75727907|NCT00883064|Drug|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)|
75879362|NCT01346761|Behavioral|Telephone Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
75879363|NCT01346761|Behavioral|In-Person Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
76049927|NCT04666311|Diagnostic Test|CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection|"CAD4COVID: Non-commercial product. Software tool for detecting pneumonia-related features to be expected in COVID-19 patients; availability is guaranteed by Delft Imaging System; CE certified. Will be performed by a registered and qualified radiographer/health professional in accordance with national regulations. Analysis in combination with differential white blood cell count.~SD Biosensor, STANDARDTM Q COVID-19 Ag Test (rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2)"
75431781|NCT01525004|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
75431782|NCT06053606|Device|cryoablation of atrial fibrillation using only 28 mm size balloon|all applications in all PVs are done with 28 mm balloon
75431783|NCT06053606|Device|cryoablation of atrial fibrillation using expandable balloon (28 / 31 mm)|first applications in LSPV and RSPV are done with 31 mm balloon
75431784|NCT06053593|Device|Testing of self collected urine|Each PWD will test their self-collected urine.
75431785|NCT06053593|Device|Labeling Evaluation|Each PWD will complete a labeling evaluation.
75431786|NCT06053593|Device|Urine Control testing|Each PWD will test four urine control solutions.
75431787|NCT06053580|Drug|Valsartan 40 mg|Valsartan 40mg twice daily for 24 weeks.
75431788|NCT06053580|Drug|Placebo|Placebo twice daily for 24 weeks.
75431789|NCT06053528|Drug|Antibiotic|Effect if treatment
75431790|NCT06053346|Behavioral|Pay For Performance (PFP)|Wraparound mental health, psychosocial, and addiction treatment services provided by contractor under an schedule of rewards or penalties that was agreed to with Santa Clara County.
75431791|NCT06053346|Behavioral|Usual Care (UC)|Outpatient and inpatient mental health and psychosocial services delivered by Santa Clara County services and systems.
75431792|NCT06053333|Other|Non-Interventional Study|Non-interventional study
75431793|NCT06053320|Device|Prism adaptation therapy (PAT) + Electrical stimulation (E-stim)|PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).
75431794|NCT06053320|Device|Prism adaptation therapy (PAT) + Sham Stimulator|Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.
75431795|NCT06053320|Other|Gait Training|After PAT, participants will complete multiple 30-seconds to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts.
75431796|NCT06053203|Other|Exposure of interest - Moderate or High-risk Preeclampsia|No intervention
75578200|NCT04889924|Radiation|Axillary Radiotherapy|Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
75578201|NCT04889924|Procedure|Lymphadenectomy|Axillary Lymph node dissection
75727908|NCT01077505|Biological|albiglutide|albiglutide 50mg weekly subcutaneous injection
75727909|NCT01077505|Drug|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
75727910|NCT01073995|Drug|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
75727911|NCT01074073|Drug|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
75727912|NCT00883220|Behavioral|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
75727913|NCT00874874|Drug|sorafenib tosylate|
75578204|NCT04869943|Drug|Enobosarm|Oral Enobosarm 9mg per day
75578205|NCT04869943|Drug|Exemestane|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)
75578206|NCT04849728|Drug|IVA337|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
75578207|NCT04849728|Drug|Placebo|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
75578208|NCT04847466|Drug|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every 4 weeks (1 week after starting treatment with the PDL-1 CAR-NK cells).
75578209|NCT04847466|Drug|Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30-minute IV infusion every 6 weeks. Pembrolizumab will be administered on the same day as the PD-L1 CAR-NK cells.
75578210|NCT04847466|Biological|PD-L1 t-haNK|PD-L1 CAR NK cells (2x109) will be administered by IV infusion over approximately 30 minutes every week. After the week 6 treatment, these cells will be given every 2 weeks.
75431797|NCT06053190|Behavioral|Sentence stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
75431798|NCT06053190|Behavioral|Speaking style|The sentences will be presented either in A. conversational speaking style, or B. hyper-articulated clear speech style. Clear and conversational speech samples will be elicited from a single male talker. In the conversational speech condition, which will be recorded first, the talker will be instructed to read the sentences as they would in everyday conversation. In the clear speech condition, the talker will be instructed to produce the sentences as if they would if they were talking to a person with hearing loss.
75578211|NCT04840823|Drug|Enoxacin|Oral 200mg tablet
75727914|NCT01076257|Behavioral|Modified Constraint-induced Movement Therapy|"Home based CIT~Restriction of the less affected limb~Intensive practice using affected limb~Positive experience~Functional task (task)"
75727915|NCT01076413|Behavioral|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
75727916|NCT01076413|Behavioral|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
75727917|NCT05204264|Behavioral|Acceptance and Commitment Therapy (ACT)|This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.
75578212|NCT04840823|Drug|Placebo|Oral tablet
75879364|NCT01356602|Drug|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
75879365|NCT01356602|Drug|Canakinumab lyophilized powder|Canakinumab lyophilized powder
75879366|NCT01356602|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide
75879367|NCT01356602|Drug|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
75578213|NCT04840602|Procedure|Biospecimen Collection|Undergo blood sample collection
75578214|NCT04840602|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
75578215|NCT04840602|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
75578216|NCT04840602|Procedure|Computed Tomography|Undergo CT or PET/CT
75578217|NCT04840602|Drug|Ibrutinib|Given PO
75578218|NCT04840602|Procedure|Positron Emission Tomography|Undergo PET/CT
75578219|NCT04840602|Biological|Rituximab|Given IV
75578220|NCT04840602|Drug|Venetoclax|Given PO
75578221|NCT04838743|Drug|IDegLira|"Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study."
75578222|NCT04832932|Biological|COVID-19 vaccines|Emergency-use authorized COVID-19 vaccines
76049928|NCT02312219|Drug|Folic Acid|1 mg folic acid once daily
76049929|NCT02312219|Drug|Placebo|placebo once weekly
76049930|NCT02312219|Drug|Low Dose Methotrexate|An anti-inflammatory drug
75578223|NCT04832282|Device|Napoleon|The Micro-Tech Endoscopic Measurement Device named Napoleon is a small catheter with a 30mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA. The device was originally intended to measure polyps. However, it is used off-label in this study and is considered investigational.
75578224|NCT04832282|Other|Visual estimation|For each case, endoscopists will first visually estimate the diameter of the GJA by comparing its size to the upper endoscope.
75578225|NCT04830111|Device|heart rate variability biofeedback Application (Eureka iDestressor)|heart rate variability biofeedback protocol duration time is 10 min twice/day for 5days
75879368|NCT01347775|Device|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
75578226|NCT04827979|Biological|daratumumab|"Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.~Definition of highly sensitized: Potential kidney transplant recipients with either:~calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or~cPRA >98% (with >5 years of waiting time) awaiting living donor transplant"
75879369|NCT01347775|Device|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
75879370|NCT01347853|Drug|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
75879371|NCT01347853|Drug|Placebo|Intranasal post-surgery for up to 5 days total
75879372|NCT01346917|Drug|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
75879373|NCT01346917|Drug|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
75879374|NCT01343017|Other|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
75879375|NCT03563612|Device|cpap|application of cpap to the non-dependent lung, during one lung ventilation
75879376|NCT01348009|Drug|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
75879377|NCT03620305|Other|Description of treatment of septic pseudarthrosis|description of chirurgical 2 steps management of septic pseudarthrosis
75879378|NCT01343173|Drug|Imatinib stop|To stop imatinib after inclusion.
75879379|NCT01346995|Other|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
75879380|NCT01346995|Other|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
75578227|NCT04827979|Biological|belatacept|Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.
75578228|NCT04827979|Procedure|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been >4 weeks since the previous bone marrow aspiration.
75879381|NCT02830880|Drug|FACBC PET-CT|Anti-3-[18F]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
75578229|NCT04821375|Drug|bazedoxifene plus conjugated estrogens|6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
75578230|NCT04821141|Drug|Bazedoxifene and Conjugated Estrogens|BZA (20 mg) plus CE (0.45 mg) taken together once daily
75578231|NCT04820790|Other|Mobile applications|Monitoring of patients with home oxygen through a mobile application
75578232|NCT04815291|Device|Receives SCOUT at biopsy|SCOUT Reflector
75578233|NCT04810091|Drug|Placebo Administration|Given PO
75578234|NCT04810091|Other|Questionnaire Administration|Ancillary studies
75578235|NCT04810091|Drug|Telotristat Ethyl|Given PO
75578236|NCT04801368|Drug|Randomization of two local anesthetics.|Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
75578237|NCT04799301|Behavioral|Diet with no soda|Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane
75578238|NCT04799301|Behavioral|Diet with 50% of carb intake from soda|Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
75578239|NCT04799301|Behavioral|Diet with 20% of carb intake from soda|Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
75578240|NCT04794894|Behavioral|outpatient rehabilitation|Treatment provided after completion of inpatient, acute rehabilitation.
75578241|NCT04792099|Procedure|Continuous positive airway pressure|After study entry, CPAP will be provided via mask or binasal prongs in order to have a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery. A PEEP of 5 will be used for uniformity.
75578242|NCT04792099|Procedure|Nasal Cannula|After study entry, flow will be set to 0.5 L/kg with 1L maximum while on NC during the study period to reduce the risk of inadvertent PEEP with higher flows. Initial FiO2 can be titrated to achieve target saturations, and may be increased up to 100% while on NC.
75578243|NCT04791865|Behavioral|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
75578244|NCT04791865|Behavioral|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
75727918|NCT05204264|Behavioral|Mindfulness-based Emotional Regulation (MER)|This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.
75578245|NCT04782336|Other|Sample Collection|"Sample Collection - Adult Population:~Two (2) Nasal AND/OR~Two (2) Throat Swabs AND/OR~One (1) Saliva Sample~Sample Collection - Paediatric Population:~Two (2) Nasal OR~Two (2) Throat Swabs AND/OR~One (1) Saliva Sample"
75879382|NCT02830880|Other|MRI, CT, or Bone Scan|Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.
75578246|NCT04777435|Diagnostic Test|Therapeutic orientation test for TMA|Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.
75578247|NCT04763746|Device|Lifelight Data Collect Sub-protocol 1|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period, noting down the first reading displayed at 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will operate the automatic sphygmomanometer upon hearing from study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing the heart rate measurements and note the reading displayed after 0, 30 and 60 seconds. The three heart rate readings should be averaged to generate a single, average heart rate reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate and oxygen saturation measurements and three concurrent video datasets."
75727919|NCT04017884|Combination Product|Remin Pro Forte|a combination of chemicals with natural products cream .
75727920|NCT04017884|Combination Product|Remin Pro|a combination of chemicals
75727921|NCT00880880|Other|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
75727922|NCT00880958|Dietary Supplement|Mixture of various probiotics and fermentation products|
75727923|NCT00880958|Dietary Supplement|Placebo|
75879383|NCT03141307|Behavioral|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
75879384|NCT03141307|Behavioral|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
75578248|NCT04763746|Device|Lifelight Data Collect Sub-protocol 2|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period noting down the first reading displayed at 0, 30 and 60 seconds timepoints. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will be directed by the announcement of study nurse 1 to begin and end manually counting observed inspirations by watching chest rises throughout the full 60-second period. According to the results of the quality improvement initiative, Study nurse 2 may place their hand on the participant's chest to increase the accuracy of their manual counting.~This sub-protocol will be repeated once more to generate two sets of respiratory rate and oxygen saturation measurements and two concurrent video datasets."
75578249|NCT04763746|Device|Lifelight Data Collect Sub-protocol 3|"The study nurse will observe the oxygen saturation measurements during this 60-second measurement period indicated by the timer on the software. They will note down the first reading displayed after 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading for the 60-second period.~This sub-protocol will be repeated once more to generate two sets of oxygen saturation measurements and two concurrent video datasets."
75727924|NCT04489628|Drug|Vitamin D3 or Placebo|): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
75727925|NCT04489628|Device|Doctella telehealth monitoring|Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
75727926|NCT00130039|Drug|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
75727927|NCT00130039|Drug|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
75727928|NCT00875030|Drug|artesunate sachets|single dose 50 mg (2 X 25 mg) artesunate sachets
75727929|NCT00875030|Drug|Arsuamoon|single dose 50 mg arsuamoon tablet
75727930|NCT00883298|Drug|temozolomide and bevacizumab|oral temozolomide 100 mg/m2 days 1-5 & 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 & 5 every 28-day cycle
75727931|NCT03969277|Other|Graded Motor Imagery|"The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks."
75727932|NCT03969277|Other|Standard Rehabilitation|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
75727933|NCT03969277|Other|Home Exercise Program|Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
75727934|NCT03969277|Other|Cold Application|Cold application around the elbow joint for 15 minutes in every session.
75431799|NCT06053151|Behavioral|exercise counselling|. The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy. The goal of the first phase was to start regular exercise, and the goal of the second phase was to continue regular exercise.
75431800|NCT06053138|Dietary Supplement|Ketone monoester|Supraphysiological levels of ketosis acutely, part 1, and intermittently and longer lasting, part 2, as obtained by ingestion of a ketone monoester dietary supplement
75431801|NCT06053138|Dietary Supplement|Placebo|The placebo vehicle is matched to the ketosis intervention in the experimental arm with regards to taste, volume, viscosity, appearence, and packaging
75431802|NCT06053112|Other|New infant formula with 6 HMOs blend|Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
75431803|NCT06053112|Other|Standard infant formula without 6 HMOs blend|Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
76049931|NCT01986231|Drug|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
76049932|NCT02312063|Drug|Sitagliptin|
76049933|NCT02312063|Drug|Glimepiride|
76049934|NCT02353169|Drug|Dexmedetomidine|
76049935|NCT02353169|Drug|Saline|
76049936|NCT02009163|Drug|Lisdexamfetamine dimesylate|SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
76049937|NCT02009163|Other|Placebo|Placebo capsule once per day (double-blind period)
76049938|NCT01983969|Drug|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
76049939|NCT01983969|Drug|Vorinostat|1000 mg by vein on Day -11 through Day -2.
75431804|NCT06053099|Other|Plasma ctDNA|"Plasma ctDNA before surgery (optional)~Plasma ctDNA post-surgery : 4 to 8 weeks post-surgery, before starting adjuvant chemotherapy (if given) and before starting adjuvant osimertinib (if given)~Plasma ctDNA every 6 months~Plasma ctDNA at relapse"
76049940|NCT01983969|Drug|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
76049941|NCT01983969|Drug|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
76049942|NCT01983969|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
76049943|NCT01983969|Drug|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
76049944|NCT01983969|Other|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
76049945|NCT01983969|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
76049946|NCT01983969|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
76049947|NCT01983969|Drug|Rituximab|375 mg/m2 by vein on Days -9.
76049948|NCT02008773|Drug|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
76049949|NCT02008773|Drug|placebo|placebo capsules 6/day oral for 16 weeks
76049950|NCT02257567|Drug|Bendamustine|Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
76049951|NCT02257567|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
76049952|NCT02257567|Drug|Polatuzumab vedotin (Liquid)|Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
76049953|NCT02257567|Drug|Rituximab|Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
76049954|NCT02257567|Drug|Polatuzumab vedotin (Lyophilized)|Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
76049955|NCT04419961|Behavioral|Educational program|"The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants."
76049956|NCT05330299|Behavioral|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. It consists of 11 online modules and is therapist-supported.
76049957|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
76049958|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
76049959|NCT01642615|Drug|Placebo|Dexlansoprazole placebo-matching capsules
75431805|NCT06053099|Other|FFPE blocks|"Surgery FFPE blocks~FFPE blocks at relapse (optional)"
75431806|NCT06053086|Radiation|Treatment ETHOS radiotherapy|• Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
75431807|NCT06053086|Radiation|Conventional IMRT|• Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
75578250|NCT04763746|Device|Lifelight Data Collect Sub-protocol 4|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will manually count observed inspirations by watching chest rises throughout the 60-second period. They may place their hand on the participant's chest to increase the accuracy of manual counting.~Study nurse 2 will operate a standard automatic sphygmomanometer and clinical finger clip sensor upon hearing from Study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing these measurements and note the readings displayed after 0, 30 and 60 seconds. The three heart rate and three oxygen saturation readings will each be averaged to generate a single, average reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate, respiratory and oxygen saturation measurements and three concurrent video datasets."
75578251|NCT04757922|Procedure|Opportunistic salpingectomy / bilateral salpingectomy|An opportunistic salpingectomy refers to removal of the salpinges without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases. Therefore, a so-called opportunistic salpingectomy is a method of female sterilization.
75727935|NCT04038788|Device|HD hf-tRNS|See detail in arm/group descriptions regarding the intervention.
75727936|NCT00881114|Drug|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
75727937|NCT00881114|Drug|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
75727938|NCT00875186|Other|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
76049960|NCT02311361|Biological|Durvalumab|10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
76049961|NCT02311361|Biological|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
75431808|NCT06053073|Device|Cervical rippening at home|The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction
75431809|NCT06053073|Device|Cervical rippening in the hospital|The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction
75431810|NCT06053060|Other|Randomisation Standard Dynacup or Dynacup One C|Randomisation
75727939|NCT00875186|Other|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
75727940|NCT04687436|Device|mechanical cervical ripening|mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
76049962|NCT02311361|Radiation|Sterostatic body radiation therapy (SBRT)|8 Gray (Gy) x 1; 5Gy x 5
76049963|NCT02352779|Dietary Supplement|Omega-3 Fatty Acid|Given PO
76049964|NCT02352779|Other|Placebo|Given PO
76049965|NCT02352779|Other|Questionnaire Administration|Ancillary studies
76049966|NCT02352779|Other|Laboratory Biomarker Analysis|Correlative studies
75578252|NCT04747834|Device|MICOR-304|The MICOR-304 offers a mechanical approach to lens fragmentation and aspiration which provides an alternative to phacoemulsification with no cavitation, no thermogenic energy in the eye, which can eliminate generation of heat inside the eye while maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.
75578253|NCT04742439|Device|Sham transcranial direct current stimulation|Participants will receive 30 seconds of ramp up and down stimulation at the start and end of the 20 minute stimulation period.
75578254|NCT04742439|Device|Individualized transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at the individualized dose (maximum of 4mA).
75578255|NCT04742439|Device|2mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 2mA dose.
75578256|NCT04742439|Device|4mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 4mA dose.
75727941|NCT00475852|Drug|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
75727942|NCT00475852|Drug|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
75727943|NCT00875264|Drug|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
75879385|NCT03141307|Behavioral|Control|Standard of care, paper-based brochure
75431811|NCT06053034|Device|Solio alpha cure plus|The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
75431812|NCT06053008|Other|The relationship between pain perception, temporomandibular joint disorder severity and spine health|The relationship between pain perception, temporomandibular joint disorder severity and spine health
75431813|NCT06052995|Drug|Elidel 1% Topical Cream|Elidel® 1% is a non-steroid cream for cutaneous use containing pimecrolimus. It is indicated for mild or moderate AD.
75431814|NCT06052982|Procedure|Drainage|At the end of the knee arthroplasty, a drain is placed or not at the surgical site depending on randomization result
75578257|NCT04734106|Drug|Desert Harvest Aloe Vera Capsules|600 mg pure, freeze-dried aloe vera super-concentrate with a minimum of 200 mg glycosaminoglycan per capsule.
75578258|NCT04734106|Other|Placebo Capsules|550mg of Avicel microcrystalline cellulose per two-piece, hard-shelled gelatin capsule.
75578259|NCT04729413|Behavioral|Couples Counseling|Psychoeducational counseling on relationships and maternal and child health in the context of HIV.
75578260|NCT04729413|Other|Enhanced Standard of Care|Enhanced standard of care with education on pregnancy and postpartum health, similar to what is presented to women at routine antenatal and postpartum care.
75727944|NCT01017484|Other|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
75727945|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
75727946|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
75727947|NCT00141271|Drug|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
75879386|NCT01347151|Device|The glidescope video laryngoscopy|
75879387|NCT01347151|Device|The Pentax airwayscope|
75727948|NCT01017640|Other|Laboratory Biomarker Analysis|Correlative studies
75879388|NCT01348243|Drug|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
75879389|NCT01348243|Drug|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
75879390|NCT01347229|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
75578261|NCT04727944|Other|Reach and grasp tasks in healthy participants using MEG technique (Experiment 1)|"Human participants will perform reach and grasp movements to various objects (e.g. a cube, sphere, or rod) driven either by perceived action affordances, or instruction cues. A rotating carousel will be used to present subjects with various objects affording different types of grasps (e.g. a precision pinch, a whole hand 'power' grasp, or a tripod grasp).~Prior to the experiment, subjects will be tested outside the scanner by asking them to grasp each object as they would naturally to ensure that each object elicits the expected grasp type. Subject-specific, 3D-printed head-casts will be created based on high resolution MRI scans from each subject, and worn by subjects during the MEG experiment (Experiment 1) to reduce within-session head movement associated with reaching and grasping.~At the end of this session an experimental task is added: detection of tons in presence of multitonal masks, in order to verify how beta peaks might be generated by a stimulus auditory."
75578262|NCT04727944|Other|Reach and grasp tasks in healthy participants using EEG technique (Experiment 2)|Experiment 2 consists of a task of reaching for and grasping several objects (e.g. a cube, sphere, or rod) ; the task used for experiment 2 is the same as that used for experiment 1. EEG signals will be measured.
75578263|NCT04712851|Biological|Pembrolizumab|Given IV
75578264|NCT04702425|Drug|VOB560|Powder for concentrate for solution for infusion
75879391|NCT01348321|Drug|Levamisole|Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
75431815|NCT06052930|Device|HTC Vive™ Pro|"A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week.~Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session)."
75431816|NCT06052917|Other|DECIdE|DECIdE is a decision aid. Its a communication tool to help health providers as general practitioners or community pharmacists, to practice shared medical decision about optional prescription drug. DECIdE provide robust scientific data about benefit and risks associated to the drug under consideration. DECIdE was built based on the consensus of potentials users ( care providers and patients ), tested on users testing and finally validated by a expert consensus ( DELPHI method).
75578265|NCT04702425|Drug|MIK665|Concentrate for solution for infusion
75727949|NCT01017640|Drug|Mitomycin|Given IV
75727950|NCT01017640|Drug|Veliparib|Given PO
75578266|NCT04700124|Biological|Pembrolizumab|200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.
75578267|NCT04700124|Biological|Enfortumab vedotin (EV)|1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.
75727951|NCT00614120|Drug|liraglutide|0.6 mg/day, s.c. (under the skin) injection
75727952|NCT00614120|Drug|placebo|Glimepiride placebo, capsules
75578268|NCT04700124|Procedure|RC + PLND|Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
75727953|NCT00614120|Drug|liraglutide|1.2 mg/day, s.c. (under the skin) injection
75727954|NCT00614120|Drug|liraglutide|1.8 mg/day, s.c. (under the skin) injection
75727955|NCT00614120|Drug|glimepiride|Capsules, 4.0 mg/day
75727956|NCT00614120|Drug|metformin|Tablets, 1.5-2.0 g/day
75727957|NCT00614120|Drug|placebo|Liraglutide placebo, s.c. (under the skin) injection
75727958|NCT00496054|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 & P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
75727959|NCT00881192|Procedure|IABP|preoperative IABP placement
75727960|NCT00495820|Drug|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
75727961|NCT00495820|Other|Placebo|Standard inactive pill.
75578269|NCT04700124|Drug|Gemcitabine|1000 mg/m^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
75578270|NCT04700124|Drug|Cisplatin|70 mg/m^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
75727962|NCT04387240|Drug|Artemisinin / Artesunate|testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative
75727963|NCT04387240|Other|placebo|placebo or sham drug will be given to the second arm
75727964|NCT05203328|Device|Vapotherm|Monitored anesthesia care with oxygen supplementation through a high-flow nasal cannula
75727965|NCT05203328|Device|Regular nasal canula|Monitored anesthesia care with oxygen supplementation through a regular nasal cannula
75727966|NCT00495586|Drug|Placebo|One pill to be taken every eight hours for 8 days
75727967|NCT00495586|Drug|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
75727968|NCT00881270|Drug|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
75727969|NCT00881348|Drug|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
75431817|NCT06052865|Behavioral|SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants. Additionally, for very preterm infants with advanced neurological injury, additional 1-2 sessions of weekly motor therapy are added to the SENSE-II program
75431818|NCT06052865|Behavioral|SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants.
75578271|NCT04698876|Procedure|Self-tonometry by means of ICareHOME|Outpatient measurement of intraocular pressure at home
75578272|NCT04698876|Procedure|Intraocular measurement by means of rebound tonometry or Goldmann applanation tonometry|Stationary measurement of intraocular pressure in a clinic
75578273|NCT04698876|Procedure|Blood pressure|Blood pressure measurement for 24 h
75578274|NCT04697628|Drug|tisotumab vedotin|2.0 mg/kg every 3 weeks (Q3W)
75578275|NCT04697628|Drug|topotecan|1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days
75578276|NCT04697628|Drug|vinorelbine|30 mg/m2 IV on Days 1 and 8, every 21 days
75578277|NCT04697628|Drug|gemcitabine|1000 mg/m2 IV on Days 1 and 8, every 21 days
75727970|NCT00613730|Drug|Gemcitabine|Intravenous administration
75727971|NCT00613730|Drug|panitumumab|Intravenous administration
75431819|NCT06052865|Other|Reference/ Standard of care|Infants in the Unexposed group receive the NICU standard of developmental care throughout hospitalization.
75431820|NCT06052852|Drug|BDC-3042|Dectin-2 agonist antibody
75578278|NCT04697628|Drug|irinotecan|100 or 125 mg/m2 IV weekly for 28 days, every 42 days
75578279|NCT04697628|Drug|pemetrexed|500 mg/m2 IV on Day 1, every 21 days
75578280|NCT04682197|Device|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
75578281|NCT04681677|Radiation|Radiation: Intra-operative Radiation Therapy - IORT|Single fraction, Intra-operative Radiation Therapy at the time of surgical resection of recurrent GBM followed by Bevacizumab 28-56 days after surgery.
75431821|NCT06052852|Drug|Pembrolizumab|Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells
75431822|NCT06052839|Drug|Pembrolizumab|Immunotherapy that works by helping the immune system to kill cancer cells by targeting and blocking a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
75578282|NCT04681677|Drug|Bevacizumab|Bevacizumab
75578283|NCT04680065|Biological|AAV2-GDNF gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
75578284|NCT04680065|Procedure|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dural penetration
75578285|NCT04674813|Drug|CC-95266|Specified dose on specified days
75578286|NCT04674813|Drug|Fludarabine|Specified dose on specified days
75578287|NCT04674813|Drug|Cyclophosphamide|Specified dose on specified days
75578288|NCT04674813|Drug|Bendamustine|Specified dose on specified days
75578289|NCT04662515|Procedure|Type of surgery|surgical or non-surgical extraction one or more teeth
75578290|NCT04662515|Drug|Dabigatran|
75727972|NCT05200754|Other|Convalescent/Vaccine-boosted Plasma (CP/PVP)|"Plasma from apheresis obtained from donors, who have recovered from SARS-CoV-2 infection or received a successful vaccination against SARS-CoV-2.~CP/PVP infusion is administered on two following days. Each CP/PVP bag contains approx. 238 - 337 ml anti-SARS-Cov-2 CP/PVP for infusion."
75431823|NCT06052839|Drug|Carboplatin|A chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
75431824|NCT06052839|Drug|Paclitaxel|A chemotherapeutic agent used as a treatment for various cancers; paclitaxel is a mitotic inhibitor.
75431825|NCT06052826|Other|Best Practice|Undergo standard of care
75431826|NCT06052826|Other|Cognitive Intervention|Receive delirium prevention education
75578291|NCT04662515|Drug|Rivaroxaban|
75578292|NCT04662515|Drug|Apixaban|
75578293|NCT04662515|Drug|Edoxaban|
75578294|NCT04662515|Drug|Warfarin|
75578295|NCT04650854|Drug|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
75578296|NCT04643457|Drug|UCB9741|- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
75431827|NCT06052826|Other|Comprehensive Geriatric Assessment|Undergo geriatric assessment
75431828|NCT06052826|Other|Nutritional Intervention|Undergo nutritional optimization
75431829|NCT06052826|Procedure|Physical Therapy|Undergo physical function optimization
75431830|NCT06052826|Other|Questionnaire Administration|Ancillary studies
75431831|NCT06052813|Drug|BN104|Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
75578297|NCT04643457|Drug|Intravenous Placebo|- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
75578298|NCT04643457|Drug|Subcutaneous Placebo|Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
75578299|NCT04626518|Biological|Pembrolizumab|Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
75578300|NCT04626518|Biological|MK-4830|Administered via IV infusion at a dose of 800 mg Q3W
75578301|NCT04626518|Drug|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
75578302|NCT04626518|Drug|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
75578303|NCT04626518|Biological|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
75578304|NCT04626518|Biological|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
75578305|NCT04626479|Biological|Pembrolizumab|Administered via IV infusion at a dose of 400 mg Q6W
75578306|NCT04626479|Biological|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
75578307|NCT04626479|Drug|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
75578308|NCT04626479|Drug|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
75578309|NCT04626479|Biological|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
75431832|NCT06052761|Other|Making Toys from Medical Materials|"Rabbit Making: The two fingers and the palm of the medical glove will be filled with cotton and the bottom part will be tied. The finger part of the glove will form the rabbit's ears, and the palm part will form its face. After the glove is shaped, the rabbit's eyes and mouth will be drawn with a pencil.~Cat Making: Three abeslangs will be cut to appropriate sizes to create the cat. The cut pieces will be combined to form the cat's head, feet, and tail. After the assembly process is completed, the cat's eyes, nose and beard will be drawn with a pencil.~Plane Making: The 10 cc syringe and needle tip removed from its packaging will be combined. Children will be asked to color the two abeslangs given to them in the color they want. The abeslangs painted by the children will be fixed to the syringe with a plaster, one on the bottom and the other on the top."
75431833|NCT06052748|Drug|AD-223A|PO, Once daily(QD), 8weeks
75431834|NCT06052748|Drug|AD-223B|PO, Once daily(QD), 8weeks
75431835|NCT06052748|Drug|AD-223C|PO, Once daily(QD), 8weeks
75578310|NCT04626479|Drug|Vibostolimab/Pembrolizumab|Administered via IV infusion at a dose of 200 mg/200 mg Q6W
75578311|NCT04624243|Drug|MK-8189|MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.
75578312|NCT04624243|Drug|Risperidone|Risperidone administered QD at a dose of 6 mg via oral capsule.
75578313|NCT04624243|Drug|Placebo to MK-8189|MK-8189-matching placebo administered QD via oral tablet.
75431836|NCT06052748|Drug|AD-223A Placebo|PO, Once daily(QD), 8weeks
75431837|NCT06052748|Drug|AD-223B Placebo|PO, Once daily(QD), 8weeks
75431838|NCT06052748|Drug|AD-223C Placebo|PO, Once daily(QD), 8weeks
75431839|NCT06052735|Other|Correlation research|The relationship among pain perception, temporomandibular disorder severity and spine health
75578314|NCT04624243|Drug|Placebo to risperidone|Risperidone-matching placebo administered QD via oral capsule.
75578315|NCT04623554|Behavioral|Prehabilitation program|The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
75578316|NCT04621890|Behavioral|LOAN2DOSE and COIN2DOSE|This is a behavioral economics intervention designed to help improve meal time bolusing behaviors in youth with type 1 diabetes.
75578317|NCT04598399|Behavioral|Mindfulness Based Relapse Prevention|7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.
75578318|NCT04598399|Behavioral|Relaxation/ meditation|7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants
75727973|NCT00613574|Drug|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
75727974|NCT00881426|Drug|Cefprozil 500 mg Tablets (Sandoz GmbH)|
76049967|NCT04893395|Other|Pharmacogenomic Screening|"First telehealth appointment:~Pharmacogenomics education and informed consent~Medical history~Sample collection~Second telehealth appointment:~Results of pharmacogenomic testing~Utility and limitations of pharmacogenomic testing~Patient-specific potential impacts on current or future medication therapies~Answering of patient questions~Referral to mental health provider(s) for treatment-specific recommendations"
76049968|NCT02257489|Drug|ACE-083|recombinant fusion protein
75431840|NCT06052722|Other|Correlation assessment|The relationship between the Premenstrual Syndrome Impact Scale and the Fonseca Anamnestic Index will be examined for individuals with premenstrual syndrome. The relationship between Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea Score and Fonseca Anamnestic Index will be examined for individuals with primary dysmenorrhea.
75431841|NCT06052709|Other|Occupational balance assessment|There is no intervention. The presence and severity of temporomandibular disorders, occupational balance, and stress levels of individuals will be evaluated.
75727975|NCT00881426|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
75727976|NCT00883532|Drug|budesonide|budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 < 30% or is extubated
75727977|NCT00883532|Drug|surfactant and air (placebo)|receive surfactant and air as control through endotracheal route
75727978|NCT00875498|Procedure|active iTBS|"Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.~80% MT, 20 sessions of 6 minutes, 2 per day"
75727979|NCT00875498|Procedure|sham iTBS|iTBS placebo (placebo coil)
75879392|NCT03772951|Other|Cognitive Remediation Therapy|Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.
75879393|NCT03772951|Drug|Clozapine|the course of disease is more than 2 years, the condition is stable for more than one month
76049969|NCT05645809|Device|MONOFIX® PGCL|An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
75578319|NCT04585269|Behavioral|Bright IDEAS-YA|Bright IDEAS-YA is a manualized problem-solving skills training intervention conducted by a trainer who teaches the participant the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach.
75578321|NCT04576117|Procedure|Biospecimen Collection|Undergo blood sample collection
75578322|NCT04576117|Procedure|Magnetic Resonance Imaging|Undergo MRI
75578323|NCT04576117|Other|Quality-of-Life Assessment|Ancillary studies
75578324|NCT04576117|Other|Questionnaire Administration|Ancillary studies
75578325|NCT04576117|Drug|Selumetinib Sulfate|Given PO
75578326|NCT04576117|Drug|Vinblastine Sulfate|Given IV
76049970|NCT05645809|Device|Quill Monoderm™|An absorbable suture made of polyglactin used for soft tissue suture.
76049971|NCT02329223|Biological|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
76049972|NCT02329223|Other|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
75578327|NCT04570579|Device|Vivity Extended Depth of Focus Intraocular Lens|Patients selected to have bilateral sequential cataract surgery using the Vivity (spherical and/or toric where applicable) intraocular lens implant will subsequently be offered enrollment into this observational study. Visual outcomes will be recorded at postoperative day 1, week 1, month 1 and month 3.
76049973|NCT05645419|Behavioral|personalized chronoprevention|Chronobiological variables: dynamic and static position of the planets of the solar system, moon, sun, constellations; angles/degrees of celestial objects above/below the horizon; angular interactions between celestial objects; the moment/time of the patients' birth; moment/time of MI occurrence; latitude / longitude of the place of birth of the patients, as well as the occurrence of MI (event); the degree of influence of celestial objects in relation to the constellations, where they were at a particular personal event / points of the patient.
76049974|NCT01641601|Device|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
75431842|NCT06052696|Drug|Gardasil 9 Suspension for Injection|"After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations~First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
75879394|NCT01343329|Drug|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
76049975|NCT02350127|Behavioral|Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
75431843|NCT06052696|Drug|Placebo|"After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
76049976|NCT02350127|Behavioral|Usual Care|Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
75578335|NCT04531904|Device|EMBOVAC Aspiration Catheter|The EMBOVAC Aspiration catheter is used to treat acute ischemic stroke. The catheter can be used to facilitate introduction of diagnostic or therapeutic agents and is also intended for use in removal/aspiration of emboli and thrombi from selected blood vessels in the neuro vasculature.
75578336|NCT04527926|Behavioral|STEPuP Intervention|"Project STEPup has 4 components designed to address barriers to MAT and EBP adoption: 1) a hub and spoke remotely-supported provider education and training program, 2) addiction teleconsultation support, 3) case management and telepsychiatry support, and 4) a partnership with health system administrators and payers to address administrative and reimbursement related needs."
75879395|NCT01343329|Drug|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
76049977|NCT02256553|Biological|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
76049978|NCT02256553|Biological|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
76049979|NCT02256553|Drug|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
76049980|NCT05305807|Other|Postural exercises|Postural correction exercises are effective in improving forward head posture and it effectively decrease neck pain and increase ROM Exercise training and ergonomic guidelines concerning the use of touchscreen smartphones will reduce the risk of developing upper extremity musculoskeletal disorders
76049981|NCT05302297|Drug|Cemiplimab|Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
75578337|NCT04527926|Behavioral|Usual Care|Standard of Care
75578338|NCT04510506|Device|Artificial Pancreas (AP)|The AP system used in this trial is the Tandem t:slim insulin pump with Control-IQ Technology. This system is FDA approved for use starting at age 14 years.
76049982|NCT02349425|Drug|Gefapixant|Gefapixant 7.5 and 50mg tablets administered orally
76049983|NCT02349425|Drug|Placebo (for gefapixant)|Placebo to gefapixant 7.5 and 50mg tablets administered orally
75578339|NCT04502862|Drug|SAR231893|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
75578340|NCT04502862|Drug|Placebo|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
75578341|NCT04470921|Procedure|Opportunistic Salpingectomy|An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.
75578342|NCT04467502|Other|cognitive-behavioral therapy for gambling disorder|6 sessions of cognitive-behavioral therapy for gambling disorder
75578343|NCT04467502|Other|imaginal exposure therapy focus on gambling cues|6 sessions of imaginal exposure therapy focus on gambling cues
75578344|NCT04467502|Other|virtual reality exposure therapy focus on gambling cues|6 sessions of virtual reality exposure therapy focus on gambling cues
76049984|NCT02310581|Drug|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
76049985|NCT02310581|Drug|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
75431844|NCT06052683|Radiation|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant|Low-dose rate brachytherapy with Iodine-125 to a total dose of 144 Gy
75431845|NCT06052683|Radiation|Stereotactic Body Radiation Therapy to the prostate|Prostate Stereotactic Body Radiation Therapy using 36.25 Gy in 5 fractions
75578345|NCT04463368|Procedure|Isolated hepatic perfusion|The procedure is performed under general anaesthesia. The caval vein is isolated infrahepatically above the renal veins and suprahepatically between the diaphragm and the pericardium. A catheter is placed in the retrohepatic portion of the caval vein for perfusion outflow. The portal vein is clamped and the proper hepatic artery is cannulated via the gastroduodenal artery. The liver perfusion is performed at a rate of 8- 9 ml/kg/min with a target liver temperature of 40 degrees Celsius. The leakage from the system was continuously recorded using Technetium labelled albumin (Vasculosis) injected into the perfusion circuit. Melphalan (1 mg/kg bodyweight divided into two doses, given 30 minutes apart) is added to the perfusion system. The perfusion is then continued for 60 minutes, after which the perfusion was discontinued.
75578346|NCT04463368|Drug|Ipilimumab|4 courses of ipilimumab 3mg/kg every third week
75727980|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
75727981|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
75879396|NCT01317589|Drug|fentanyl|"T = 0~start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~if necessary increase dose strong opioid with 50%~T=2 3 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T=3 5 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%"
75879397|NCT01317589|Drug|methadone|"T = 0~start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~if necessary increase dose strong opioid with 50%~T=2 3 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T=3 5 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%"
76049986|NCT04892693|Drug|Talazoparib Oral Capsule|- Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
76049987|NCT02309723|Device|Beta amyloid imaging|
75431846|NCT06052670|Diagnostic Test|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|pressure wire-based fractional flow reserve (FFR); intravascular ultrasound (IVUS)-based ultrasonic flow ratio (UFR)
75431847|NCT06052605|Behavioral|Healthy Aging in People with Epilepsy Program|This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
75431848|NCT06052436|Biological|Allogeneic thyTreg 5.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
76049988|NCT02309411|Drug|Rivaroxaban (Xarelto, BAY59-7939)|With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
75431849|NCT06052436|Biological|Allogeneic thyTreg 10.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
75431850|NCT06052423|Drug|HS-20093|HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
75431851|NCT06052345|Device|Garmin smartwatch|"Physical activity (Activity sessions, type and length of activity, activity intensity estimations)~Meal detection and meal characteristics (accelerometry and gyroscope data)~Oxygen saturation (pulse oximetry)~Number of steps (pedometer)~Stress level indicators (based on heart-rate analytics)~Sleep patterns (sleep and wake-up time, sleep quality)"
75431852|NCT06052345|Other|REBECCA Mobile application|"GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection)~Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3~Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)"
75578347|NCT04463368|Drug|Nivolumab|4 courses of nivolumab 1mg/kg every third week
75578348|NCT04460053|Procedure|Neurofilament light protein measurement in Isolated limb perfused patients|A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
75578349|NCT04454528|Radiation|Hypofractionated radiotherapy|Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
75578350|NCT04454528|Drug|Pembrolizumab infusion|Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.
76049989|NCT02008227|Drug|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
75431853|NCT06052345|Other|REBECCA PC plug-in|"the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram).~These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites"
75578351|NCT04454528|Procedure|Blood and tissue sampling|Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
75879398|NCT01347385|Procedure|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
75879399|NCT01347385|Procedure|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
75879400|NCT01348477|Procedure|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
76049990|NCT02008227|Drug|Docetaxel|75 mg/m^2 IV infusion on Day 1 of each 21-day cycle
75879401|NCT02825420|Drug|trabectedin|
76049991|NCT04867551|Drug|KDT-3594|oral administration, dose titration
75431854|NCT06052332|Radiation|Short course radiotherapy|Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.
75431855|NCT06052332|Drug|Adjuvant chemotherapy (optional)|The choice of the adjuvant chemotherapy is to the investigator's discretion.
75578352|NCT04421963|Drug|Olaparib|300 mg olaparib (2×150 mg tablets) twice daily
75578353|NCT04420884|Drug|Dazostinag|Dazostinag intravenous Infusion.
76049992|NCT04862871|Behavioral|Physical Activity - Pediatric Pain Rehabilitation Center|While admitted to the Pediatric Pain Rehabilitation Center program, patients receive 1-3 hours of individual and group physical therapy 5 times per week and completed a 30-60 minute home exercise program 9 times per week. The median length of stay for the program is 5 weeks. The amount of aerobic exercise prescribed is individualized to each patient and ranged from 10-20 minutes per session. The duration of aerobic exercise prescribed progressed by 5-10 min weekly until the child reached 20-30 minutes. Patients are instructed to reach a moderate to vigorous intensity of exercise (defined at 5-7/10 rate of perceived exertion). The mode of exercise varied dependent on patient ability and interest. Typical modes of exercise included: walking, running, stationary biking, swimming, sports (i.e., soccer, dance), and online aerobic workouts. Patients were prescribed an individualized 30-60 minute discharge home program using the same structure upon completing the program.
76049993|NCT02006979|Other|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
76049994|NCT02348723|Drug|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0
75431856|NCT06052332|Procedure|Total mesorectal excision|"Surgery must be performed according to the principles of total mesorectal excision. A watch & wait approach is allowed for those subjects who have clinical complete response according to the local assessment."
75578354|NCT04420884|Drug|Pembrolizumab|Pembrolizumab intravenous Infusion.
75578355|NCT04420884|Drug|Platinum|Carboplatin or Cisplatin intravenous infusion
75578356|NCT04420884|Drug|5-fluorouracil|5-fluorouracil intravenous infusion
75578357|NCT04385485|Procedure|Active mobilisation|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
75578358|NCT04385485|Procedure|Passive mobilisation with place and hold|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
75578364|NCT04369131|Device|Functional electrical stimulation|Randomized placement of FES pads in one of four locations during each session. Locations include: (a) none, (b) calves only, (c) quads and abdominals only, and (d) calves, quads, and abdominals.
75578365|NCT04350138|Biological|Meningococcal Group B Vaccine|A combination vaccine consisting of rMenB and OMV NZ.
75578366|NCT04350138|Other|Placebo|150mM sodium chloride (0.9% saline solution).
75431857|NCT06052332|Combination Product|Total neoadjuvant therapy|"The choice of the TNT is left to the investigator's discretion.~If RAPIDO:~SCRT (5 fractions of 5 Gy), followed by~Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If RAPIDO light:~SCRT (5 fractions of 5 Gy), followed by~Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If OPRA with induction chemotherapy:~Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by~CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~If OPRA with consolidation chemotherapy:~CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine) followed by~Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)"
75879402|NCT01347463|Procedure|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
75879403|NCT01347619|Other|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
75879404|NCT01347619|Other|Toolkit, Periodic Audit/Feedback, Educational Messages|"Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis."
76049995|NCT02348723|Drug|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
76049996|NCT01967277|Device|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
76049997|NCT01967277|Device|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
76049998|NCT04411095|Other|Measuring thoracic rotation mobility|Measuring the thoracic rotation mobility with a goniometer, from a standardized position
75578367|NCT04349501|Other|Restriction Spectrum Imaging Magnetic Resonance Imaging|RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
76049999|NCT02326883|Behavioral|Care Management|The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
75578369|NCT04337021|Behavioral|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
75578370|NCT04330664|Drug|MRTX849|KRAS G12C Inhibitor
76050000|NCT02326883|Behavioral|Skills Training|The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
76050001|NCT02326883|Behavioral|Usual Care|Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
75578371|NCT04330664|Drug|TNO155|SHP2 Inhibitor
75578372|NCT04315181|Drug|Opioid Agonist|Active opioid agonist or placebo, administered orally
75578373|NCT04315181|Drug|Sedatives|Active sedative or placebo, administered orally
76050002|NCT02006667|Drug|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
76050003|NCT02006667|Drug|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
76050004|NCT02006667|Drug|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
76050005|NCT01983111|Drug|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
76050006|NCT01983111|Drug|tramadol/acetaminophen|"Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
76050007|NCT02348489|Drug|SGI-110 (guadecitabine)|Investigational medicinal product
75879405|NCT01347619|Other|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
75727982|NCT04262258|Dietary Supplement|Blueberry enriched diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
75727983|NCT00881582|Drug|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 & 4: 48 weeks; genotypes 2 & 3: 24 weeks)
75727984|NCT00875654|Genetic|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume<100ml) less than 6 weeks after stroke
75727985|NCT00881738|Drug|Clarithromycin 250 mg Tablets (Geneva, USA)|
75727986|NCT00881738|Drug|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
75727987|NCT00613106|Drug|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
75879406|NCT01343563|Procedure|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
76050008|NCT02348489|Drug|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
75431858|NCT06052280|Other|Telerehabilitation exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the TrE group will continue with prescribed self-training at home through telerehabilitation, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The TrE arm will be supported by a telerehabilitation device which will be installed and tested at the patients' home immediately after the outpatient intensive program. The device will track any access and exercise duration, so that the physiotherapists will be able to remotely monitor both the actual duration of each session and their weekly frequency. One session per week will be directly and online supervised by a physiotherapist, while the other two will be recorded only."
76050009|NCT02309099|Device|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
76050010|NCT01966107|Drug|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
75578379|NCT04305054|Biological|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
75578380|NCT04305054|Biological|Vibostolimab|Administered via IV infusion at a specified dose on specified days
75578381|NCT04305054|Biological|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
75578382|NCT04305054|Drug|Lenvatinib|Administered via oral capsule at a specified dose on specified days
75727988|NCT00613106|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
75727989|NCT00883844|Drug|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
75879407|NCT01348555|Drug|Bronchodilatator|
75727990|NCT00883844|Drug|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
75879408|NCT01348555|Drug|Bronchodilatator|
76050011|NCT01966107|Drug|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
75578383|NCT04305054|Biological|Favezelimab/Pembrolizumab|Administered via IV infusion at a specified dose on specified days
76050012|NCT01982331|Biological|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
76050013|NCT01982331|Other|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
76050014|NCT02326025|Drug|Olaratumab|Administered IV
76050015|NCT02326025|Drug|Doxorubicin|Administered IV
76050016|NCT01619865|Drug|68Ga-DOTATOC PET/CT|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
75578384|NCT04305054|Drug|ATRA|Administered via oral capsule at a specified dose on specified days
75578385|NCT04303169|Biological|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
75727991|NCT00875732|Device|Bi Ventricular Pacing|
75727992|NCT00875732|Device|Right Ventricular Pacing|
76050017|NCT02006121|Drug|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
76050018|NCT02006121|Drug|Placebo|Sodium chloride 9 mg/ml
76050019|NCT02005887|Drug|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
75727993|NCT00881816|Drug|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
75727994|NCT03712904|Radiation|Stereotactic Body Radiation Therapy|Undergo radiation
76050020|NCT02005887|Drug|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
75727995|NCT03712904|Biological|Ziv-Aflibercept|Given IV
75727996|NCT00875888|Device|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
75727997|NCT00881972|Behavioral|Exercise|walking/running/cycling
76050021|NCT02005887|Drug|letrozole|Letrozole 2.5 mg orally every day for 6 cycles
75578386|NCT04303169|Biological|Vibostolimab|Administered via IV infusion at a specified dose on specified days
75578387|NCT04303169|Biological|Gebasaxturev|Administered via IT injection at a specified dose on specified days
75578388|NCT04303169|Biological|MK-4830|Administered via IV infusion at a specified dose on specified days
75578389|NCT04303169|Biological|Favezelimab + Pembrolizumab|Administered via IV infusion at a specified dose on specified days
75578390|NCT04303169|Drug|ATRA|Administered via oral capsules at a specified dose on specified days
76050022|NCT01982253|Drug|Fasiglifam|Fasiglifam tablets
76050023|NCT01982253|Drug|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
76050024|NCT01981473|Other|no intervention|
76050025|NCT01981473|Other|no intervention|
76050026|NCT01981473|Other|no intervention|
76050027|NCT02005029|Drug|Erythromycin|
75578391|NCT04294667|Drug|DZP|Subjects will receive dapirolizumab pegol at prespecified time-points.
75578392|NCT04294667|Other|Placebo|Subjects will receive placebo at prespecified time-points.
75727998|NCT04038554|Diagnostic Test|Feces and saliva analysis|Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
76050028|NCT02005029|Drug|placebo|
76050029|NCT02325791|Drug|Suptavumab 30 mg/kg|Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
76050030|NCT02325791|Drug|Placebo Matched to Suptavumab|Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
76050031|NCT02325791|Drug|Suptavumab 30 mg/kg- 1 Dose|Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
76050032|NCT02325791|Drug|Suptavumab 30 mg/kg - 2 Doses|Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
76050033|NCT02004873|Device|Micra Pacemaker Implant|
75578393|NCT04291573|Device|HD-tDCS|Real stimulation (2mA, 20min) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes ~4cm away
75431859|NCT06052280|Other|Home self-exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the HSE group will continue with prescribed self-training at home, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The HSE arm will be given a booklet containing detailed explanations and pictures of the assigned exercises, in order to guide them in the correct execution of the requested movements. Subjects in this group will be asked to fill in a training diary to keep track of the training sessions and their duration. Once a week a physiotherapist will contact patients to discuss possible problems encountered in performing the exercises and to help in solving them."
75431860|NCT06052254|Drug|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
75431861|NCT06052254|Drug|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
75431862|NCT06052254|Drug|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
75578394|NCT04291573|Device|Sham HD-tDCS|Sham stimulation (2mA, ramp up and down phases of 30s) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes ~4cm away
75431863|NCT06052241|Drug|shampoos and scalp serums|shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
75431864|NCT06052215|Behavioral|Online Information Cards Education|Providing family planning education to women through online information cards
75431865|NCT06052202|Behavioral|CRC mHealth|Participants receive text messages that contain information about colorectal cancer and screening. Some text messages include links to videos that are intended to reduce barriers to colorectal cancer screening. Other text messages include links to brief web-based assessments. Responses to assessment questions are used to make sure each man receives only the information relevant to his needs. The main educational content is completed in the first 6 weeks. Additional educational and motivation text messages continue for up to 4 more months if a participant reports not having completed colorectal cancer screening.
75578395|NCT04282018|Drug|BGB-10188|Administered as specified in the treatment arm
75578396|NCT04282018|Drug|Zanubrutinib|Administered as specified in the treatment arm
75578397|NCT04282018|Drug|Tislelizumab|Administered as specified in the treatment arm
76050034|NCT02347787|Behavioral|IMPaCT|"The IMPaCT intervention has three stages:~Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group."
76050035|NCT02347787|Other|Usual care|
75578405|NCT04268641|Other|Arm 1|"Materials used for the course :~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair + Seat back + Positioning cushion + Belt"
75727999|NCT00875966|Drug|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
75728000|NCT00875966|Drug|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
75431866|NCT06052202|Behavioral|Control|Participants receive text messages that include links to videos and/or brochures developed by the Centers for Disease Control. This information is designed to educate the public about colorectal cancer and motivate screening. Text messages are sent every 2-3 days for 6 weeks.
75578406|NCT04268641|Other|Arm 2|"Materials used for the course :~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair + Seat back + Positioning cushion"
75578407|NCT04268641|Other|Arm 3|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair"
75578408|NCT04268641|Other|Arm 4|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion + Belt"
75578409|NCT04268641|Other|Arm 5|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion"
75578410|NCT04268641|Other|Arm 6|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair"
75728001|NCT04142294|Dietary Supplement|Histidine|ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
75728002|NCT00141037|Drug|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)~Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
75431867|NCT06052189|Procedure|Ultrasound|Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.
75431868|NCT06052163|Drug|Bumetanide|Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
75431869|NCT06052163|Drug|Placebo|A placebo has no active properties and is taken orally.
75578411|NCT04242329|Procedure|Surgical metastasectomy|Surgical removal of metastases aimed at R0 resection.
75431870|NCT06052150|Procedure|Dental exam and periodontal cleaning if needed|Dental exam and periodontal cleaning if needed
75431871|NCT06052124|Device|Augmented Reality Device|AR device will be used to determine where to place SEPS drain
75578412|NCT04242329|Drug|Immunotherapy|Continued PD1-inhibitor treatment according to current treatment standards.
75578413|NCT04241185|Drug|Pembrolizumab|400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
75578414|NCT04241185|Radiation|Conventional Radiotherapy (Bladder only)|64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
75578415|NCT04241185|Radiation|Conventional Radiotherapy (Bladder and pelvic nodes)|64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
75728003|NCT00141037|Drug|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
75728004|NCT00141037|Drug|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40 kg and 1.5 mg/kg/day in subjects weighing >40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
75728005|NCT00141037|Drug|Tacrolimus|Taken orally from immediately preoperatively to those>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects <age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) &5-7 ng/mL >= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 & 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
76050036|NCT04416399|Drug|Budesonide dry powder inhaler|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
76050037|NCT01979835|Device|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
76050038|NCT02282345|Other|Laboratory Biomarker Analysis|Correlative studies
76050039|NCT02282345|Drug|Talazoparib|Given PO
76050040|NCT01732822|Drug|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
76050041|NCT01732822|Drug|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
75431872|NCT06052111|Drug|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
75431873|NCT06052111|Drug|Group D (dexmedetomidine group)|The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
75431874|NCT06052085|Other|Pain Neuroscience Education|Four sessions of Pain Neuroscience Education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.
75431875|NCT06052085|Other|Biomedical Pain Education|4 sessions of Biomedical Pain Education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.
75431876|NCT06052085|Other|Standard Physiotherapy Program|Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks. Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks.
75431877|NCT06052007|Behavioral|LC-Based Debriefing|LC-based debriefing encourages reflection by allowing learners to identify and explore topics of particular interest. The model is defined as a structured post-event LC, which is useful for improving competence, professional development, and clinical judgment among intensive care unit and trauma nurses. The model is useful not only for one recipient by allowing reflection on positive and negative experiences but also for the whole group by allowing them to make connections to their own practice that day or to previous experiences, supporting teamwork. It also helps them understand what good practice is by doing their own self-assessment with peers' benchmarking.
75578416|NCT04241185|Radiation|Hypofractionated Radiotherapy (Bladder only)|55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
76050042|NCT02004093|Drug|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
75578417|NCT04241185|Drug|Cisplatin|35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
75578418|NCT04241185|Drug|Fluorouracil (5-FU)|5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
75578419|NCT04241185|Drug|Mitomycin C (MMC)|MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
75578420|NCT04241185|Drug|Gemcitabine|Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
75578421|NCT04241185|Drug|Placebo to Pembrolizumab|Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
76050043|NCT02004093|Drug|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
76050044|NCT02004093|Drug|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
76050045|NCT02004093|Drug|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
76050046|NCT01641367|Drug|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day [200 mg per day])
75431878|NCT06052007|Behavioral|3D Model-Based Debriefing|The model has three parts: defusing, discovering, and deepening. The experiential learning theory on which this model is based facilitates learning goals. This model allows its participants to create new mental models for future practice, develop critical thinking skills, and identify knowledge gaps. In the model, a debriefing session starts with preliminary information and ends with a summary of what has been learned. Participants' gaps in understanding and learning are identified, and how they can apply their learnings to practice is discussed.
75431879|NCT06051994|Device|AI-guided VA ablation|Ablation of ventricular arrhythmia as guided by the ablation index, using Carto 3 electroanatomic mapping system, QDOT Micro ablation catheter, and multipolar mapping catheters (Optrell, Decanav)
75879409|NCT04437277|Diagnostic Test|Hepatitis C, serology|Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
75578422|NCT04239625|Drug|ALK-001|Oral administration of a pill for up to 24 months
76050047|NCT01641367|Drug|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
75431880|NCT06051981|Drug|5% sodium fluoride|a flavored xylitol-sweetened, 5% sodium fluoride in a resin carrier delivered in a 1.2 ml syringe or in a 0.4 ml unit, Ultradent, USA) will be applied on all teeth according to the manufacturer's instructions.
75431881|NCT06051981|Drug|Intensive 5% sodium fluoride|Intensive FV will be applied three times a week for a week (every two days).
75431882|NCT06051981|Drug|Casein Phosphopeptide-Amorphous Calcium Phosphate|for 12 weeks. A thin layer from Tooth Mousse™ will be applied to the teeth after daily brushing with traditional toothpaste and left intact for 180 seconds before rinsing with distilled water
75431883|NCT06051981|Drug|Resin infiltration|resin infiltration will be applied as specified by the manufacturer.
75431884|NCT06051955|Other|oral sodium sulfate|All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.
75431885|NCT06051942|Device|Robotic Waterjet Treatment|The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System. During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.
75578423|NCT04238819|Drug|Abemaciclib|Administered orally
75578424|NCT04238819|Drug|Irinotecan|Administered IV
75431886|NCT06051929|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
75431887|NCT06051916|Other|residual urine|The study includes two group, A and B. Se previously
75578425|NCT04238819|Drug|Temozolomide|Administered orally or IV
75578426|NCT04238819|Drug|Dinutuximab|Administered IV
75578427|NCT04238819|Drug|GM-CSF|Administered subQ
75578428|NCT04234360|Drug|5 days of systemic corticotherapy (prednisone)|Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
76050048|NCT01641367|Drug|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
75578429|NCT04234360|Drug|5 days of placebo|Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
76050049|NCT01641367|Drug|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
76050050|NCT01641367|Drug|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
76050051|NCT01641367|Drug|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
76050052|NCT01641367|Other|SOC adherence versus SOC+CPI adherence|"not participating in the adherence randomization; OR~randomized to SOC adherence; OR~randomized to SOC+CPI adherence."
76050053|NCT02325713|Drug|Oral dispersible tablet of praziquantel (ODT-PZQ)|Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
76050054|NCT02325713|Drug|Cysticide|Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
75879410|NCT00687986|Radiation|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
75879411|NCT00687986|Procedure|primary surgery|an anatomical surgical resection with lymph node dissection
76050055|NCT02325713|Drug|ODT-PZQ|Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
75578441|NCT04211961|Drug|Scopolamine|The treatment group will receive a 100ml infusion of Scopolamine ( dose 4μg/kg) at 4 visits during the study
75578442|NCT04211961|Other|Placebo|The placebo group will receive a 100ml infusion of saline at 4 visits during the study
75728006|NCT00141037|Drug|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
75431888|NCT06051890|Drug|Extended-Release Buprenorphine (XRB)|XRB (Sublocade) will be delivered as a pre-filled 2cc subcutaneous monthly injection, using a 300mg starting dose in most cases (100mg starting doses are available per the study team's clinical judgement). XRB consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades. Prior to an initial injection, the participant must be stable for several days or longer on sublingual buprenorphine (SLB) at doses of 8mg/day or higher. Participants will receive at least one XRB monthly injection prior to release, which investigators anticipate to usually be the 300mg dose. Some participants will be recruited earlier during the incarceration (or experience delayed release dates and then longer than anticipated incarcerations); XRB will be continued monthly from the time of induction to the day of release.
75578443|NCT04210115|Biological|pembrolizumab|IV infusion
75578444|NCT04210115|Drug|placebo|IV infusion
75578445|NCT04210115|Drug|cisplatin|IV infusion
75578446|NCT04210115|Drug|5-FU|IV infusion
75578447|NCT04210115|Radiation|radiotherapy|external radiation
75578448|NCT04210115|Drug|leucovorin|IV infusion
75578449|NCT04210115|Drug|levoleucovorin|IV infusion
75578450|NCT04210115|Drug|oxaliplatin|IV infusion
75578451|NCT04206787|Drug|Afatinib|drug
75578452|NCT04206436|Drug|Cftr Modulators|CFTR modulators are drugs used to treat cystic fibrosis
75431889|NCT06051890|Drug|Sublingual Buprenorphine (SLB)|Maintenance of existing SLB prescription (treatment as usual).
75431890|NCT06051851|Drug|Penpulimab|"Penpulimab 200mg IV D1~1 cycle every 21 days"
75431891|NCT06051851|Drug|Anlotinib|"Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days"
75578453|NCT04201782|Drug|There are no disallowed treatments|Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
75578454|NCT04195477|Behavioral|vDPP|virtual Diabetes Prevention Program
75578455|NCT04190563|Behavioral|Pain De-Catastrophizing|Experimenter-administered education and skill practice.
75728007|NCT00141037|Drug|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
75431892|NCT06051851|Drug|Nab paclitaxel|"Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days"
75578456|NCT04190563|Behavioral|Pain Education|Experimenter-administered education.
75578457|NCT04176562|Device|RTI Spine products|"Interbody fusion devices - intended to help facilitate fusion by providing a platform for bone growth, while maintaining height and decompression.~Supplemental fixation and/or stabilization devices - are intended to stabilize the spine to allow for fusion to occur, maintain current spinal movement, correct deformities or curvature, treat trauma, spinal stenosis, tumor and pseudarthrosis.~Bone graft substitute - is intended to aid in fusion."
75578458|NCT04165486|Drug|ION464|ION464 will be administered by IT injection.
75578459|NCT04165486|Drug|Placebo|ION464-matching placebo will be administered by IT injection.
76050056|NCT02325713|Drug|ODT-PZQ|Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
75578460|NCT04154683|Device|Cellvizio®|use of the Cellvizio® optical biopsy
75578461|NCT04137380|Drug|Mirikizumab - IV|Administered IV
75578462|NCT04137380|Drug|Mirikizumab - SC|Administered SC
75578463|NCT04137380|Drug|Placebo - IV|Administered IV
75578464|NCT04137380|Drug|Placebo - SC|Administered SC
75728008|NCT00141037|Drug|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
75879412|NCT00306098|Drug|islets|Islet transplantation
75431893|NCT06051851|Drug|Gemcitabine|"Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days"
75431894|NCT06051838|Procedure|surgery|if the patients is TD positive, we recommond careful surgery and pathological examination.
75431895|NCT06051825|Diagnostic Test|Blood specimen collection for C-reactive protein (CRP) and WBC (white blood cells). Saliva specimen collection for analysis of CRP levels|Blood analysis of CRP and WBC levels Saliva analysis of CRP levels
75431896|NCT06051799|Other|Myofascial trigger points pressure release|Patient lying down in the supine position, Therapist do a first and second finger pincer grasp is performed on the myofascial trigger points located on the upper trapezius muscle and sternocleidomastoid muscle, this pressure will be increased as the therapist perceives a reduction in soft tissue resistance under the finger over a period of 90 seconds. Previous studies indicate no difference between 60 and 90 seconds of pressure. It will be performed on as many trigger points as we find in each muscle associated with the study.
75431897|NCT06051799|Other|Therapeutic exercise and postural hygiene|"Therapeutic exercise and postural hygiene: A progression of exercises with contraction of the deep neck flexor muscles will be included in the first session. Subjects will be taught to perform a slow and controlled craniocervical flexion. Subjects will then be trained to be able to progressively maintain craniocervical flexion through feedback from an air device (Stabilizer™, Chattanooga Group Inc., Chattanooga, TN) placed behind the neck. This sensor monitors the slight flattening of the cervical curve that occurs with contraction of the craniocervical deep flexor musculature. It should be performed at least once a day during the treatment regimen.~Also Postural correction exercises carried out regularly throughout the day, especially when seated. Indications are given to avoid pelvic retroversion and maintain a natural lumbar lordosis while performing retraction and adduction of the scapulae and gently lengthening the spine."
75728009|NCT04612946|Behavioral|Referral to Telemedicine LCS Counseling Visit|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit, and asked for permission to be referred directly to the LCS navigator to help schedule an appointment. They will also be given the option to directly contact the LCS navigator. Telemedicine counseling visits will be conducted using established clinical procedures for virtual or telephone visits at Penn Medicine. In accordance with reimbursement policies for lung cancer screening, these visits will be conducted by a physician or nurse practitioner within the Lung Cancer Screening Program at Penn Medicine. Counseling visits are covered without co-pay as standalone visits according to USPSTF guidelines and costs will not be covered by the study. LCS is an evidence-based practice and considered standard of care for those who are eligible and desire to be screened. Clinicians retain full control on how to conduct LCS counseling or LDCT in this trial.
75578465|NCT04122690|Behavioral|PDAE|Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
75578466|NCT04122690|Behavioral|WAE|The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
76050057|NCT02325713|Drug|ODT-PZQ|Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
76050058|NCT02325713|Drug|Cysticide|Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
75728010|NCT04612946|Behavioral|Usual Care|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their providers.
75728011|NCT04602884|Diagnostic Test|Breath biopsy sampling using the ReCIVA Breath Sampler|Breath biopsy sampling using the ReCIVA Breath Sampler
75728012|NCT00140413|Drug|Nutropin AQ|Daily injection. Dosage dependent on weight.
75728013|NCT04039178|Device|BQ|The BQ device (BrainQ Technologies Ltd., Israel), a Brain Computer Interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in EEG measurements of healthy/non healthy subjects. These patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.
75728014|NCT04039178|Device|Sham|Sham BQ device
75728015|NCT04038398|Procedure|Non-invasive ventilation with different FiO2 settings|CPAP therapy applied with different order of FiO2 settings.
75728016|NCT01582555|Drug|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
75728017|NCT01582555|Drug|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
76050059|NCT04877639|Drug|Esmketamine,Dexmedetomidine|Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
76050060|NCT02325401|Drug|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
76050061|NCT02325401|Drug|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
75578471|NCT04086485|Drug|Lu-177-DOTATATE|Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
75578472|NCT04086485|Drug|Olaparib|Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
76050062|NCT02325401|Radiation|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
76050063|NCT02324699|Drug|Prednisone|
76050064|NCT02324699|Drug|Placebo|
76050065|NCT02324699|Drug|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
75879413|NCT04422925|Procedure|Living Donor Hepatectomy|On living donor hepatectomy (preoperative), the first following day of surgery, 3rd day, and 7th day, blood will be taken for the measurement of S100β, NSE, and GFAP levels in the postoperative period. The plasma of the blood taken will be separated and stored at -800C. Values will be measured by the ELISA method. During the hospitalization, the delirium status of the patients will be evaluated with the delirium evaluation scale (Delirium Rating Scale-Revised - 98 Turkish version). Functional and cognitive information and other results will be collected at each follow-up point.
75431898|NCT06051786|Drug|azelastine/fluticasone 137/50 mcg nasal spray|AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).
75431899|NCT06051786|Drug|Dymista™|Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
75431900|NCT06051773|Other|muscle involvement|evaluation of muscle involvement
75431901|NCT06051760|Biological|NV-001|NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.
76050066|NCT01764256|Biological|P2-VP8 subunit rotavirus vaccine|P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
76050067|NCT01764256|Other|placebo|Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
76050068|NCT01979523|Other|Laboratory Biomarker Analysis|Correlative studies
76050069|NCT01979523|Other|Pharmacological Study|Correlative studies
76050070|NCT01979523|Drug|Trametinib|Given PO
76050071|NCT01979523|Drug|Uprosertib|Given PO
75578473|NCT04086485|Diagnostic Test|Ga dotatate scanning|Ga68-DOTATATE PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
75578474|NCT04086485|Diagnostic Test|FDG-PET scanning|F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
75578475|NCT04086485|Drug|Amino Acid infusion|Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
75879414|NCT03563378|Drug|Lactated Ringer|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
76050072|NCT02255461|Drug|palbociclib isethionate|Given PO
76050073|NCT02255461|Other|pharmacological study|Correlative studies
76050074|NCT02255461|Other|laboratory biomarker analysis|Correlative studies
76050075|NCT01764022|Drug|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
76050076|NCT01764022|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
76050077|NCT02003391|Drug|Beta-blocker monotherapy|Per participant's current prescribed therapy
76050078|NCT02003391|Drug|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
76050079|NCT04852627|Behavioral|Brisk walking|Walking
76050080|NCT04658901|Device|ERA-C70,ERA-C30 and ERA-G5|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) to treat varicose veins of lower extremity
76050081|NCT04658901|Device|ClosureFast™ and ClosureRFG™|use ClosureFast™ and ClosureRFG™ which has the indication of the treatment of varicose veins of lower extremity approved by NMPA
76050082|NCT02254681|Drug|Gemcitabine|
76050083|NCT02254681|Drug|Cisplatin|
75431902|NCT06051747|Procedure|Three-dimensional patient-specific bioprinting trachea implantation|The intervention entails the creation of a 3D cell-printed tracheal organ, achieved through the fusion of biopolymer materials and the bioprinting (3D cell printing) technique. This process involves distribution of nasal cavity stem cells (hNTSCs) and nasal septum cartilage cells (hNCs) within hydrogel matrices, culminating in the formation of a personalized tracheal structure.
76050084|NCT02254681|Radiation|low dose radiotherapy|Whole liver and portal lymph node basin low dose radiotherapy
75578476|NCT04076683|Device|Algodrep|Algorithm computing the volume of blood to be transfused and the interval between apheresis which are necessary to maintain an individual objective of HbS percentage.
75578477|NCT04075825|Biological|Darvadstrocel|Allogenic expanded adipose-derived stem cells (eASCs) 5 million cells/ml - suspension for injection darvadstrocel received in previous ADMIRE-CD II study. No drug administration in this study.
75578478|NCT04075292|Drug|Acalabrutinib|acalabrutinib 100 mg twice daily orally
75578479|NCT04075292|Drug|Rituximab|Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
75578480|NCT04075292|Drug|Chlorambucil|Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
75578481|NCT04068194|Drug|Avelumab|Given IV
75431903|NCT06051721|Drug|CYB004|CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog.
75431904|NCT06051721|Behavioral|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
75578482|NCT04068194|Procedure|Biopsy|Undergo biopsy of tumor
75728018|NCT03966313|Device|ventricular assist device implantation|"Blood sampling in patients under surgery for ventricular assist device implantation at five time points:~After anesthetic induction~Before starting the device~2h, 6h and 48h after starting the device"
75728019|NCT03741361|Other|anxiety and depression|Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
75431905|NCT06051708|Other|standard AKI care bundle|AKI care bundle include use of iv fluids, diuretics, antihyperkalemic drugs, sodium bicarbonate, antibiotics in septic patients.
75728020|NCT00884000|Drug|Genotropin|
76050085|NCT01965327|Drug|Interferon Gamma-1b|"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection."
76050086|NCT05651191|Drug|Human CD19 Targeted DASH CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
76050087|NCT02002689|Drug|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
76050088|NCT01639729|Drug|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
75431906|NCT06051708|Other|standard care for hospitalized patients|this includes iv fluids, diuretics, antibiotics in septic patients, other measures according to original disease
76050089|NCT01639729|Drug|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
75431907|NCT06051682|Device|Artificial intelligence|Artificial intelligence software : Boneview. It analyzes the x-rays, gives an assessment of the presence of fractures at the examination level and locates the fractures on each image by presenting them to the practitioner directly on their screen, without any other logistical constraints for the doctor.
76050090|NCT01639729|Drug|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
76050091|NCT01639729|Drug|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
76050092|NCT02002533|Behavioral|Brief Behavioral Therapy|Undergo BBT intervention
75431908|NCT06051682|Procedure|Emergency physician|the emergency physician analyzes the x-rays
75431909|NCT06051630|Drug|Lidocaine intravenous|Perioperative lidocaine intravenous administration
75431910|NCT06051630|Drug|Serum saline intravenous|Perioperative serum saline intravenous administration
75431911|NCT06051578|Other|Abdominal wall tension measurement|"All patients will have the tension of their abdominal wall measured during surgery using a tension scale or tensiometer."
75578483|NCT04068194|Procedure|Biospecimen Collection|Correlative studies
75578484|NCT04068194|Procedure|Computed Tomography|Undergo CT scan
76050093|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo BBT intervention
76050094|NCT02002533|Other|Educational Intervention|Undergo HEAL
76050095|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo HEAL
76050096|NCT02002221|Drug|Vildagliptin (LAF237)|Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
76050097|NCT02002221|Drug|Placebo|Matching placebo of vildagliptin 50 mg twice daily
75578485|NCT04068194|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
75578486|NCT04068194|Drug|Peposertib|Given PO
75578487|NCT04047862|Drug|Ociperlimab|Administered as an intravenous (IV) injection
75578488|NCT04047862|Drug|Tislelizumab|Administered as an IV injection
75578489|NCT04047862|Drug|Pemetrexed|Administered in accordance with local guidelines, prescribing information/summary of product
75578490|NCT04047862|Drug|Paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
75578491|NCT04047862|Drug|Nab paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
75578492|NCT04047862|Drug|Carboplatin|Administered in accordance with local guidelines , prescribing information/summary of product
75578493|NCT04047862|Drug|Cisplatin|Administered in accordance with local guidelines , prescribing information/summary of product
75578494|NCT04047862|Drug|Etoposide|Administered in accordance with local guidelines , prescribing information/summary of product
75578495|NCT04047862|Drug|5fluorouracil|Administered in accordance with local guidelines , prescribing information/summary of product
75578496|NCT04047862|Drug|Oxaliplatin|Administered in accordance with local guidelines , prescribing information/summary of product
75578497|NCT04047862|Drug|Capecitabine|Administered in accordance with local guidelines , prescribing information/summary of product
75728021|NCT00884000|Drug|Zomacton|
76050098|NCT02002221|Drug|Insulin|"Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion."
76050099|NCT02002221|Drug|Metformin|Patients continued their prescribed metformin dose, if applicable.
75728022|NCT00884078|Other|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
75728023|NCT00885716|Behavioral|patient training in shared decision making|
76050100|NCT01639495|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
76050101|NCT05651113|Other|SCID Screening|The addition of newborn bloodspot screening for severe combined immunodeficiency
76050102|NCT05642143|Diagnostic Test|Dual Energy X-ray Absorbtiometry scan|Evaluation of body composition and bone mass density
76050103|NCT05642143|Diagnostic Test|High-resolution peripheral quantitative computed tomography|High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.
75728024|NCT00885716|Behavioral|cognitive training|
75728025|NCT03948932|Device|Transvaginal sonography|Measurement of cervical length via transvaginal sonography prior to labor induction.
76050104|NCT05642143|Diagnostic Test|Microindentation|Measures Bone Material Strength Index (BMSi) of cortical bone.
76050105|NCT05642143|Diagnostic Test|Thermal perception thresholds|Heat and cold perception thresholds
76050106|NCT05642143|Diagnostic Test|Nerve conduction studies|Nerve conduction and amplitude of sural nerve
75431912|NCT06051461|Dietary Supplement|Oral lipid emulsions|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).
75431913|NCT06051370|Procedure|Ultrasound-guided glenohumeral space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach
75431914|NCT06051370|Procedure|Ultrasound-guided subacromial space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the subacromial space through the anterolateral approach
75728026|NCT03948932|Device|Pressure watch|Measurement of inflation pressure in a cervical ripening balloon is PSI units.
75728027|NCT02543684|Other|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
76050107|NCT05642143|Diagnostic Test|Composite Autonomic Symptom Score 31|A validated self-assessment questionnaire quantifying the severity and distribution of autonomic symptoms across six domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor functions) by scoring 31 clinically selected questions
76050108|NCT05642143|Diagnostic Test|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
76050109|NCT05642143|Diagnostic Test|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
75728028|NCT02543684|Other|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
75728029|NCT02543684|Other|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
75728030|NCT02543684|Other|oral glucose load|glucose load providing 50g of carbohydrates
75728031|NCT02543762|Procedure|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
76050110|NCT05642143|Diagnostic Test|Assessment of cardiovascular autonomic neuropathy|Electrocardiographic recordings at rest and during cardiovascular autonomic reflex tests.
76050111|NCT05642143|Diagnostic Test|Handgrip strength|Evaluation of muscle strength
76050112|NCT05642143|Diagnostic Test|Force plate platform|Evaluation of balance while standing still
76050113|NCT05642143|Diagnostic Test|Biospecimen collection|Biochemistry including bone turnover markers, glycemic status, inflammation markers i.e
76050114|NCT05642143|Diagnostic Test|Isometric leg extension strength|Evaluation of muscle strength
76050115|NCT05642143|Diagnostic Test|Michigan Neuropathy Screening Instrument|MNSI is used to assess status of peripheral neuropathy. It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes.
75728032|NCT00923312|Biological|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
75879415|NCT03563378|Drug|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
75578498|NCT04036331|Behavioral|Brenner FIT Standard|After referral, families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and physical activity specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, physical activity, and parenting. Specialized visits with the physical activity specialist or dietician are scheduled as pertinent issues arise. Clinic visits include individualized goal setting (for behaviors family/clinician have agreed to address), healthy eating and physical activity education, and behavioral counseling to implement changes at home.
75578499|NCT04036331|Behavioral|By Design Essentials|A dietitian provides each participant with a detailed program manual that describes the prescribed diet. The dietitian utilizes standard behavioral techniques to promote lifestyle behavior changes that enable participants to implement and maintain behaviors necessary to adhere to the dietary prescription. Participants also receive a standard exercise program designed to promote exercise energy expenditure of approximately 600 kilocalories*/week. The exercise prescription includes resistance training for 2 days per week and aerobic training for 3 days per week, to meet a 600 kilocalories*/week expenditure goal. Behaviorists meet with participants to provide individual and group-based counseling to learn the skills necessary to adopt the prescribed dietary pattern and exercise plans. Group sessions will be delivered consecutively over 6 months (20 total; 1.5 hours each).
75578500|NCT04036331|Behavioral|Dyad Plus|"This will include all components of the standard Brenner FIT program and By Design Essentials.~In addition, group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. Dyads will attend 6 meetings that will last approximately 1 hour each."
75728033|NCT04038710|Drug|Triple combination therapy|Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
75728034|NCT00923390|Genetic|2G-1 TCR Retroviral Vector-Transduced lyn|
75728035|NCT00923390|Drug|Aldesleukin|
75431915|NCT06049004|Other|Activities of Daily Living Protocol|The protocol is a performance-based objective measurement method based on repetition of daily activities. Participants are asked to perform the activities defined in the protocol at the same speed they do at home. The Londrina Protocol includes 5 stations: Station 1 Arranging Objects on the Table, Station 2 Walking with Bags, Station 3 Organizing Shelves, Station 4 Clothesline Task, Station 5 Walking. The completion time of the protocol is recorded.
75728036|NCT00923390|Drug|Cyclophosphamide|
75728037|NCT00923390|Drug|Fludarabine|
75728038|NCT00923390|Drug|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
75728039|NCT00882596|Device|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
75728040|NCT00882674|Drug|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
75728041|NCT00888524|Procedure|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
75728042|NCT00888524|Procedure|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
75879416|NCT01352455|Procedure|Hemodialysis|5 days per week hemodialysis
75879417|NCT02829944|Drug|Ropivacaine|
75879418|NCT02829944|Drug|Ketorolac|
75879419|NCT02829944|Drug|Placebo|
75431916|NCT06048289|Other|Blood samples, tumor biopsy specimens will be collected|Blood samples, tumor biopsy specimens at baseline will be collected
75431917|NCT06047743|Other|Alternating unilateral Isometric Handgrip Exercise|Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
75728043|NCT04038242|Other|Resilience promotion program|Resilience Promotion Program consists of eight sessions. Except the first orientation session and the last review session, other six sessions focus on cultivating the five internal resiliency factors (physical, behavioral, cognitive, emotional and spiritual). There are two sessions for behavioral factor, including one special to deal with the relationships between parents and children.
75728044|NCT00885794|Drug|Ranibizumab|3 intravitreal injection every 5 weeks
75728045|NCT00888602|Dietary Supplement|3.4 g psyllium|3.4 g psyllium served with meal
75728046|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium served with a meal
75728047|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium
75728048|NCT00888602|Other|Meal|meal
75728049|NCT02543450|Other|Cardiovascular and task-oriented training|
75728050|NCT02543450|Other|Upper limb strength training program|
75879420|NCT03563300|Other|Wheat flour|Wheat flour will be administered once daily for 7 days
75879421|NCT03563300|Other|Placebo Comparator|Placebo will be administered blindly versus wheat flour for 7 days
75879422|NCT04014842|Device|RapidShock|Use of the Reconfirmation Analysis Mode algorithm
75879423|NCT04014530|Drug|Ataluren + Pembrolizumab|Ataluren and Pembrolizumab combination therapy
75879424|NCT03563534|Drug|Silver Diamine Fluoride|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
75431918|NCT06047743|Other|Dominant knee extension Isometric Exercise|Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
75431919|NCT06046430|Other|Assessment|The same assessments will be made to participants in both groups.
75431920|NCT06046261|Other|ACP board game for life|The research subjects will be assigned to the experimental group or the control group according to their wishes. Those who are willing to participate the ACP board game will be assigned to the experimental group. The intervention time for each board game is around 2 hours. There are 60 cards in this ACP board game; the focus of the game is to know the participants' thoughts on the card options. Questionnaires need to be filled in before and after intervention.
75578501|NCT04032587|Behavioral|Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)|First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).
75578502|NCT04032587|Behavioral|Mindfulness-based interventions (e.g. body scan)|Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.
75578503|NCT04024540|Dietary Supplement|isocaloric dietary restriction|Very low caloric diet
75578504|NCT04024540|Procedure|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
75578505|NCT04021537|Device|non-invasive nerve stimulation|Electrical stimulation will be provided via a TENS unit.
75728051|NCT00885872|Drug|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
76050116|NCT05262439|Device|New generation CPAP mask|All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
75431921|NCT06046248|Drug|Belumosudil|200mg PO QD x 24 cycles (28-day cycle)
75431922|NCT06046248|Drug|Rituximab|375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
75431923|NCT06045702|Procedure|Epididymal sample|During a planned surgical procedure carried out by the Urology and Medically Assisted Reproduction (MAP) department at Brest University Hospital in the patients included in the study, a remnant epididymal sample (between ½ and ¼ of a cc) will be kept for research purposes. These patients suffer from male infertility, leading them to undergo surgery in order to check for the presence of spermatozoa in the epididymis, and to recover spermatozoa which will be frozen and flaked in the AMP department of the CHU Brest, in the event of future procreation by in vitro fertilisation.
75578506|NCT04013152|Other|Clinical database|Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
75578507|NCT04011644|Behavioral|A-CHESS self-monitored|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a research team member. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
75578508|NCT04011644|Behavioral|A-CHESS peer-supported|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a counselor. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
75728052|NCT00888758|Device|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
75728053|NCT00888758|Device|everolimus|200 patients with STEMI will be treated with PROMUS DES.
75728054|NCT04037150|Diagnostic Test|Circulating tumor DNA|Circulating tumor DNA
75728055|NCT02542436|Other|No intervention|No intervention administered in this study
75879425|NCT03563534|Drug|Glass Ionomer|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
75578509|NCT04011644|Behavioral|A-CHESS clinically-integrated|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a health coach. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
75578510|NCT04000061|Other|medical chart review|data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
75578511|NCT04000061|Other|data generated by direct IT export|data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
75578512|NCT03965468|Drug|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
75578513|NCT03965468|Drug|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
75578514|NCT03965468|Drug|Paclitaxel|A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
75578515|NCT03965468|Radiation|Stereotactic body radiation therapy (SBRT)|SBRT of all oligo-metastatic lesions
75578516|NCT03965468|Procedure|Surgical resection - definitive local treatment.|Surgical resection of primary tumour for patients with single station, non-bulky tumours.
75578517|NCT03965468|Radiation|Radical radiotherapy - definitive local treatment.|Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.
75578518|NCT03965468|Drug|Tremelimumab|Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.
75578519|NCT03944941|Drug|Avelumab|Given IV
75578520|NCT03944941|Drug|Cetuximab|Given IV
75578521|NCT03936777|Drug|ZX008 (Fenfluramine Hydrochloride)|Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.
75578522|NCT03929666|Drug|ZW25 (Zanidatamab)|"Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~Part 2: RD identified in Part 1"
75728056|NCT00888836|Procedure|Bariatric surgery: Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
76050117|NCT05640661|Device|Oculus Quest II|"active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~During the realization of the exposure with VRi they will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
75578523|NCT03929666|Drug|Capecitabine|Administered orally twice daily (PO bid)
75578524|NCT03929666|Drug|Cisplatin|Administered IV
75578525|NCT03929666|Drug|Fluorouracil|Administered IV
75578526|NCT03929666|Drug|Leucovorin|Administered IV
75578527|NCT03929666|Drug|Oxaliplatin|Administered IV
75578528|NCT03929666|Drug|Bevacizumab|Administered IV
75578529|NCT03929666|Drug|Gemcitabine|Administered IV
75578530|NCT03924895|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
75578531|NCT03924895|Procedure|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
75578532|NCT03924895|Drug|Enfortumab Vedotin|Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
76050118|NCT05640661|Device|Oculus Quest II|active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.
76050119|NCT04871971|Dietary Supplement|10 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.
76050120|NCT04871971|Dietary Supplement|20 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.
76050121|NCT04871971|Dietary Supplement|10 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.
76050122|NCT04871971|Dietary Supplement|20 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.
76050123|NCT04871971|Dietary Supplement|50 g Glucose|To determine the glycaemic response and insulinaemic response to 50g Glucose
75431924|NCT06045637|Behavioral|Group included in a psychoeducational program based on the cognitive behavioral approach (experiment)|The 9-session cognitive behavioral approach-based psychoeducation program will last 5 weeks. Sessions; It will be carried out in the form of acquaintance, recognition of trauma and its effects, emotion and thought behavior analysis, cognitive errors, automatic thoughts and alternative thought generation, cognitive emotion regulation strategies, coping with negative emotions, instilling hope and termination session.
76050124|NCT05651035|Other|oral feeding|"In experimental group infants: Preterms in this group will be breastfed by their own mother.~In control group infants: Preterms in this group will be fed by the researcher by putting the baby's own mother's milk in the bottle. During feeding, the preterm will be placed on the lap by the researcher in a standing position on the same mother's breast, and will be given a raised side-lying position. In this position, the preterm's head and body will be elevated 45-60 degrees with the help of a small pillow. While the researcher will support the preterm's head, neck and shoulder with one hand, he will control the bottle with the other hand. By touching the preterm's nipple to the preterm's lips, the preterm will be prepared for feeding, and the bottle will be placed in the baby's mouth with the mouth opening and the tongue lowering. During feeding, stimulating movements such as pushing the bottle back and forth in the mouth, which will lead the newborn to suck faster, will not be made."
75431925|NCT06045481|Drug|administration of single dose of doxycycline|Postexposure prophylaxis with Single Dose doxycycline
75431926|NCT06045143|Device|Patients undergoing DDD pacemaker implantation|compare the effect right ventricular apical versus septal pacing on left ventricular function by deformation imaging using 2D speckle tracking echocardiography.
75431927|NCT06044727|Procedure|Minimally invasive non surgical periodontal therapy|using Magnifying loupes
75578535|NCT03919929|Drug|Semaglutide 3mg and 7mg [Rybelsus]|Once daily oral tablet of semaglutide for 4 months
75578536|NCT03919929|Other|Weight loss diet|Prescribed weight loss diet to match weight loss in Drug arm
75578537|NCT03910478|Device|DBS Self-Collection Kit|Kit for self-collection of Dried Blood Spot (DBS) samples
75578538|NCT03910478|Other|Standard Control Strategy|Standard of care with office-based testing.
75578539|NCT03904862|Drug|CX 4945|CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
75578540|NCT03900221|Other|No intervention|No intervention
76050125|NCT05260177|Device|Light Therapy System (LTS): Active Setting|Exposure for 1 hour á day for consecutive days
76050126|NCT05260177|Device|Light Therapy System (LTS): Sham Setting|Exposure for 1 hour á day for consecutive days
76050127|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation A (Treatment A)|A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
75728057|NCT00888836|Procedure|Bariatric surgery: Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
76050128|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation B (Treatment B)|A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
76050129|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation C (Treatment C)|A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
76050130|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation D (Treatment D)|A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
76050131|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation C (Treatment E)|A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
76050132|NCT05650801|Other|Music Therapy|Therapy using a traditional music originally from Indonesian culture
76050133|NCT05650723|Drug|Zanubrutinib Pill|320 mg once per day by mouth
76050134|NCT05650723|Drug|Venetoclax Pill|400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
76050135|NCT05650723|Drug|Obinutuzumab Injection|1000 mg IV given every 28 days
75431928|NCT06044727|Procedure|Conventional subgingival instrumentation|Conventional subgingival instrumentation
75431929|NCT06044220|Behavioral|Intervention|The intervention group was given training on male reproductive health and testicular self-examination after the pretest. Posttest was administered after the training. He was reminded to perform TSE for 3 months after the training. After the reminders, a follow-up test was applied.
75431930|NCT06044220|Other|Control|Pretest and posttest were administered to the control group at the same time as the intervention group. After reminding the intervention group to perform TSI for 3 months, a follow-up test was performed in the control group.
75431931|NCT06043388|Biological|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
76050136|NCT05636215|Biological|IBI354|Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
75431932|NCT06043388|Biological|Placebo|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
75431933|NCT06040801|Behavioral|Frailty intervention measures|"Providing management and recommendations based on the specific impairment domain.~Assessment domain:~Functional status~Nutrition~Comorbidity~Mobility/Falls~Mood~Cognition~Polypharmacy~Social support."
75578544|NCT03894566|Other|No intervention - birth cohort study|There are no interventions because it is a birth cohort study
75578545|NCT03893916|Procedure|MEG - EEG HR|"MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools."
75578546|NCT03879395|Procedure|Abdominal surgery with metastasectomy|Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
75578547|NCT03872284|Other|oculomotor movement recordings, neurovisual assessment|Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
75879426|NCT02824562|Behavioral|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
75431934|NCT06030388|Other|Strength training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
75431935|NCT06030388|Other|High-intensity aerobic training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
75431936|NCT06025708|Device|Diagnostic Test: Quantra QStat Cartridge|Whole blood coagulation testing system
75431937|NCT06024785|Procedure|Vertebropexy|"microsurgical (i.e., the use of a microscope or magnifying glasses during decompression) lumbar laminotomy with partial removal of the medial facet joint by preserving the midline structures (supraspinous-interspinous ligament complex); approach: bilateral or ipsilateral with cross-over to the contralateral side.~Stabilization of the spine will be achieved with a biological ligament (for instance semitendinosus donor allograft) which will be pulled through a drilled hole in the spinous process of two adjacent vertebra in a looping technique and tendon ends fixed by an anchor knot after baseball stitches in a standardized fashion. Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia). Passive stability in clinically important directions of motion such as flexion-extension and shear movements will be provided, yet without stiffening other directions of motion."
75431938|NCT06018961|Other|Post-operative ileus surgery|Collection of ileus events, items of IFEED score and surgical complications
75578548|NCT03861897|Other|KRP-NI + KM|Non instrumental pleural chest physiotherapy (KRP-NI), 2 sessions a day on weekdays and 1 session a day on weekends and mobilization physiotherapy (KM), 1 session per day except weekend during the hospitalization. The combination of the two physiotherapy is KRP-NI + KM. Afterward, 3 sessions per week, renewable until M3 of non instrumental pleural respiratory physiotherapy. If necessary the doctor can prescribe sessions of mobilization physiotherapy
75578549|NCT03861897|Other|KM|Mobilization physiotherapy (1 session per day except weekend) during the hospitalization. Afterward, if necessary the doctor can prescribe sessions of mobilization physiotherapy(KM).
75578550|NCT03843008|Dietary Supplement|Melatonin|Participants in the Melatonin Group will receive 3mg of melatonin each evening for up to seven days for a maximum total of 21mg of melatonin.
75578551|NCT03838536|Dietary Supplement|Whole Egg Powder|Breastfeeding mothers will consume the equivalent of 5 whole eggs per week for 3 months.
75578552|NCT03838536|Dietary Supplement|Egg White Powder|Breastfeeding mothers will consume the equivalent of 5 egg whites per week for 3 months.
75728058|NCT00888836|Behavioral|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (<30% total fat and <10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
75879427|NCT02824562|Behavioral|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
75879428|NCT02744066|Device|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
75879429|NCT03563456|Behavioral|structured combined exercise|A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
75431939|NCT06015490|Other|Conditioned Stimulus: Sucrose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
75431940|NCT06015490|Other|Conditioned Stimulus: Glucose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of glucose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
75431941|NCT06015490|Other|Conditioned Stimulus: Fructose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of fructose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
75431942|NCT06015490|Other|Conditioned Stimulus: Sucrose (aim 2)|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
75578553|NCT03836040|Drug|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
75578554|NCT03836040|Drug|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
75578555|NCT03836040|Drug|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
75578556|NCT03836040|Other|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
75578557|NCT03833622|Other|Shared Decision Aid Assessment|Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
75578558|NCT03832998|Drug|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
75578559|NCT03832998|Drug|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
75578560|NCT03832998|Drug|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
75578561|NCT03832998|Other|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
75578562|NCT03829475|Drug|Bezlotoxumab|This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).
75578563|NCT03829475|Drug|Placebo|placebo is an infusion of normal saline.
75578564|NCT03829475|Drug|Fecal Microbiota Transplantation|FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
75578565|NCT03824444|Device|PODS|Percutaneous Osseointegrated device for transhumeral patients
75578566|NCT03819985|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
75578567|NCT03819985|Other|Quality-of-Life Assessment|Ancillary studies
75578568|NCT03819985|Other|Questionnaire Administration|Ancillary studies
75578569|NCT03811886|Drug|Natalizumab|"Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study."
75578570|NCT03807401|Behavioral|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to perform pointing movement toward visual target.
75578571|NCT03807401|Behavioral|Virtual reality device|The lateral displacement will be simulated thanks to a virtual reality environment. Participants will wear an Oculus Rift instead of the prismatic goggles and will perform pointing movement as well.
75578572|NCT03807401|Behavioral|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to mentally perform pointing movement toward visual target. There will be no concurrent movement execution.
75431943|NCT06015490|Other|Conditioned Stimulus: High Fructose Corn Syrup (aim 2)|Participants will consume flavored beverage solutions containing 110 calories of high fructose corn syrup in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
75578573|NCT03805477|Drug|Nintedanib|Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
75728059|NCT00888992|Behavioral|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
76050137|NCT05249647|Other|Instrument based Fascial abrasion technique|Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place & the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping. Fascial Abrasion tool was washed in alcohol-based sanitizer before and after every treatment session and all norms of COVID-19 precautions were maintained. Myofascial trigger points were marked with a 1×1 cm piece of tape/under wrap to confirm consistency of subsequent treatments.
76050138|NCT05249647|Other|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
76050139|NCT05247697|Drug|Mirtazapine 7.5 MG Oral Tablet once daily at bedtime|Mirtazapine 7,5 mg capsule
76050140|NCT05247697|Drug|Placebo oral tablet once daily at bedtime|Matching placebo
76050141|NCT05650489|Other|assessment|correlation between Autistic features, motor function and quality of life
76050142|NCT05232175|Drug|ALT-BB4|Recombinant Hyaluronidase
76050143|NCT05232175|Drug|0.9%NaCl|Normal Saline
76050144|NCT05193331|Drug|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
76050145|NCT02001987|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
76050146|NCT02001987|Drug|Methotrexate|Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
76050147|NCT02001987|Drug|csDMARDs|csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
76050148|NCT01363765|Other|Xpert MTB/Rif|Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
76050149|NCT01363765|Other|Smear microscopy|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
76050150|NCT02001051|Procedure|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
76050151|NCT02001051|Other|Observation|Observation for 6 months prior to surgery
75578581|NCT03793166|Procedure|Biospecimen Collection|Undergo blood sample collection
75578582|NCT03793166|Drug|Cabozantinib|Given PO
75578583|NCT03793166|Procedure|Computed Tomography|Undergo CT scan
75578584|NCT03793166|Biological|Ipilimumab|Given IV
75578585|NCT03793166|Procedure|Magnetic Resonance Imaging|Undergo MRI
75578586|NCT03793166|Biological|Nivolumab|Given IV
75578587|NCT03793166|Other|Quality-of-Life Assessment|Ancillary studies
75578588|NCT03793166|Other|Questionnaire Administration|Ancillary studies
75879430|NCT03563456|Behavioral|cardiorespiratory exercise|Once per week continuous cardiorespiratory training of moderate intensity
75578589|NCT03777267|Device|Active CR|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
75578590|NCT03761563|Device|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
75578591|NCT03744468|Drug|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
75578592|NCT03744468|Drug|Tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
75578593|NCT03744468|Drug|LBL-007|Human anti LAG-3 IgG4-kappa antibody
75578594|NCT03739814|Biological|Blinatumomab|Given IV
75578595|NCT03739814|Biological|Inotuzumab Ozogamicin|Given IV
75728060|NCT00888992|Behavioral|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
76050152|NCT05577013|Other|kinesiotaping|It will be applied by kinesiotape certified physiotherapist on tendons in the direction of extensor muscle to facilitate range of motion by stretching 50%. At first it will be applied on extensor pollicis longus and extensor pollicis brevis muscles of hand, extensor digitorum and extensor indicis of last 4 fingers of hand. Triceps brachii in arm and Supraspinatus and Infraspinatus muscles to stabilize the gelnohumeral joint
75578596|NCT03732898|Device|New Programming Paradigm|A new programming paradigm will be evaluated.
75578597|NCT03725007|Drug|Upadacitinib|Upadacitinib is administered as an oral solution or tablet as described in protocol.
75578598|NCT03711032|Biological|Pembrolizumab|Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization
75578599|NCT03711032|Biological|BCG|BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
75578600|NCT03685890|Drug|Nivolumab|One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
75578601|NCT03685890|Procedure|Isolated limb perfusion (ILP)|Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
75578602|NCT03670680|Device|Use of the Lina LibrataTM|Use of the Lina LibrataTM
75728061|NCT04038320|Drug|Sofosbuvir/ledipasvir (SOF/LDV)|"SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients <75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients."
75728062|NCT00563706|Drug|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
75879431|NCT03563144|Drug|Gemcitabine|Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
75578603|NCT03632473|Diagnostic Test|multimodal evoked potentials (mmEP)|combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
75578604|NCT03613532|Drug|Venetoclax|Part 1: 6-7 total doses depending on dose level assigned
75578605|NCT03613532|Drug|Fludarabine|Given once daily for 4 days
75578606|NCT03613532|Drug|Busulfan|Given twice daily for 4 days
75578607|NCT03613532|Drug|Venetoclax|Part 2 and Part 3: 14 doses for 8-12 cycles depending on dose level assigned
75578608|NCT03613532|Drug|Azacitidine|Part 2: 5 doses for 8-12 cycles depending on dose level assigned
75578609|NCT03613532|Drug|Decitabine/cedazuridine|Part 3: 3 doses for 8 cycles
75578610|NCT03605927|Drug|BMS-986004|BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.
75578611|NCT03605927|Drug|Sirolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
75578612|NCT03605927|Drug|Tacrolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
75578613|NCT03595293|Device|fNIRs-based Neurofeedback|Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.
75578614|NCT03595293|Device|Sham feedback|Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.
75578615|NCT03531450|Behavioral|Cognitive Behavioral Therapy|Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
75728063|NCT00563706|Drug|risperidone|
75728064|NCT00563706|Other|placebo|
75728065|NCT02543606|Drug|Esomelone|powder for injection/ infusion Esomeprazole 40mg
75728066|NCT02543606|Drug|Nexium|powder for injection/ infusion Esomeprazole 40mg
75728067|NCT04038632|Other|Decentralization of Childhood TB Diagnosis|The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
75728068|NCT00935844|Drug|TAK-901|"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
75879432|NCT03563144|Drug|Nab-paclitaxel|NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
75578616|NCT03504241|Biological|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
75578617|NCT03504241|Drug|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
75578618|NCT03504241|Drug|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
75578619|NCT03504241|Drug|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
75578620|NCT03504241|Drug|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
75578621|NCT03504241|Drug|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
75578622|NCT03504241|Drug|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
75578623|NCT03501706|Behavioral|Sequenced Recall of Digits--Auditory|Auditory digit sequence AT memory component.
75578624|NCT03501706|Behavioral|Sequenced Reverse Recall of Digits--Auditory|Reversed auditory digit sequence AT memory component.
76050153|NCT05577013|Other|motor relearning program|Stacking up blocks Stacking up polystyrene cups Folding piece of cloth Using cutlery Pouring water into glass Closing/opening lid of bottles turning the pages of books or newspaper writing on paper Squeezing of ball Coloring in different shapes
75578625|NCT03501706|Behavioral|Sequenced Recall of Words--Visual|Visual word sequence AT memory component
75578626|NCT03501706|Behavioral|Verbal Memory--Visual|word recognition AT memory component
75578627|NCT03471247|Device|In-Bed Cycle Ergometer|Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.
75578628|NCT03471247|Other|Routine PT|Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
75431944|NCT06015490|Other|Conditioned Stimulus: Sucrose + Non-nutritive Sweetener (aim 2)|Participants will consume flavored beverage solutions containing a non-nutritive sweetener and 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
75728069|NCT02543372|Behavioral|Behavioral Couples Therapy (BCT)|BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
75728070|NCT02543372|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
75728071|NCT00939588|Drug|Aliskiren/ Valsartan|
75728072|NCT00939588|Drug|Telmisartan/ Ramipril|
75728073|NCT02543138|Device|Trocar|Closed thoracostomy using the new trocar
75431945|NCT06000254|Device|High energy density pulse electromagnetic field|The treatment coil is positioned over the area of the shoulder that experiences the most pain, and it remains in place for a duration of 9 minutes. The patient is subjected to a high-energy high-PEMF with a frequency of 3 pulses per second during the session.
76050154|NCT05429437|Biological|Injectable platelet rich fibrin .|i-PRF with maxillary canine retraction that will be performed two times on intervention sides according to a standardized protocol.
75578629|NCT03467243|Behavioral|Cognitive Behavioral Social Skills Training|CBSST is a more recovery-oriented psychosocial rehabilitation intervention that helps Veterans with SMI set goals, correct errors in thinking, and build communication skills to improve social functioning
75578630|NCT03467243|Behavioral|Social Skills Training|SST is an evidence-based, manualized, goal setting curricula that teaches social skills, for example: communication skills and listening skills for Veterans with Serious mental Illness.
76050155|NCT05429437|Biological|Injectable platelet rich fibrin .|i-PRF that will be performed four times on intervention sides according to a standardized protocol.
75578631|NCT03467243|Behavioral|Treatment as usual|TAU is when Veterans continue to receive their usual care.
75578632|NCT03454035|Drug|Ulixertinib|Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
75578633|NCT03454035|Drug|Palbociclib|Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
75578634|NCT03448393|Biological|CD19/CD22 CAR T-Cells|CD19/CD22 cells will be infused on Day 0 after induction chemotherapy regimen.
75578635|NCT03448393|Drug|Fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)
75578636|NCT03448393|Drug|Cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.
75578637|NCT03399773|Biological|Dilanubicel|Given IV
75578638|NCT03399773|Drug|Cyclophosphamide|Given IV
75578639|NCT03399773|Drug|Fludarabine|Given IV
75578640|NCT03399773|Drug|Thiotepa|Given IV
75578641|NCT03399773|Radiation|Total-Body Irradiation|Undergo TBI
75578642|NCT03399773|Procedure|Umbilical Cord Blood Transplantation|Given IV
75578643|NCT03399773|Other|Laboratory Biomarker Analysis|Correlative studies
75578644|NCT03399773|Procedure|Biospecimen Collection|Undergo blood sample collection
75728074|NCT00935922|Dietary Supplement|Flaxseed|Flaxseed omega-3 fatty acids and lignans
75728075|NCT00936000|Dietary Supplement|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
76050156|NCT04850677|Other|Observational Cohort|Observational study
76050157|NCT01763164|Drug|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
76050158|NCT01763164|Drug|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
76050159|NCT01782742|Drug|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
75578645|NCT03399773|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspirate and biopsy
75578646|NCT03399773|Procedure|Bone Marrow Biopsy|Undergo bone marrow aspirate and biopsy
75578647|NCT03399773|Procedure|Multigated Acquisition Scan|Undergo MUGA
75578648|NCT03399773|Procedure|Electrocardiography|Undergo ECHO
75578649|NCT03399773|Procedure|Computed Tomography|Undergo CT
75578650|NCT03376126|Other|Minimal-invasive isolated limb perfusion|Minimal-invasive isolated limb perfusion
75578651|NCT03353805|Behavioral|questionnaire|questionnaire
75578652|NCT03326596|Drug|Tranexamic Acid 1000 mg/10ml normal saline infusion|Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
75578653|NCT03323905|Device|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
75578654|NCT03320304|Device|Vagal Nerve Simulation (VNS) Therapy|A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
75578655|NCT03318939|Drug|Poziotinib|"The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~Cohorts 1-3: 16 mg QD~Cohort 4: 8 mg BID~Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~Cohorts 6 and 7: 8 mg BID"
75578656|NCT03310905|Procedure|Abdominal Wall Transplant with another solid organ transplant|Transplant of abdominal wall in combination with another solid organ transplant.
75578657|NCT03310905|Procedure|Abdominal Wall Transplant alone|Abdominal Wall Transplant alone
75578658|NCT03295682|Device|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
75578659|NCT03283085|Drug|25 mg Ontamalimab|Ontamalimab sterile aqueous buffered solution will be administered in dose of 25 mg subcutaneously.
75578660|NCT03283085|Drug|75 mg Ontamalimab|Ontamalimab sterile aqueous buffered solution will be administered in dose of 75 mg subcutaneously.
75728076|NCT00889148|Drug|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
76050160|NCT01782742|Drug|Placebo|
75879433|NCT03563144|Drug|Aldoxorubicin HCl|Albumin-binding prodrug of doxorubicin HCl
75879434|NCT03563144|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
75578661|NCT03266276|Other|PSOPC pathway approach|"The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral."
75578662|NCT03224767|Drug|Vemurafenib|Given PO
75578663|NCT03224767|Drug|Cobimetinib|Given PO
75879435|NCT03563144|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
75879436|NCT03563144|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
75879437|NCT03563144|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
75879438|NCT03563144|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
76050161|NCT01782664|Drug|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
76050162|NCT01782664|Drug|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
76050163|NCT01782664|Drug|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
76050164|NCT01782664|Drug|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
75578664|NCT03224767|Other|Laboratory Biomarker Analysis|Correlative studies
76050165|NCT04414072|Procedure|sleeve gastrectomy with loop bipartition|operations to decrease weight
76050166|NCT01732588|Drug|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
76050167|NCT01732588|Drug|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
76050168|NCT01732588|Drug|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
76050169|NCT01781962|Other|No Treatment|No Treatment was given in this study.
75578665|NCT03224767|Other|Quality-of-Life Assessment|Ancillary studies
75578666|NCT03204786|Drug|Vasopressin (USP) Injectable Solution [Vasostrict]|Nasal Spray
75578667|NCT03204786|Drug|Placebo|Placebo Nasal Spray
75578668|NCT03202602|Other|Telemonitoring of CPAP treatment|Telemedicine technology allows for monitoring of CPAP pressure, air leaks, apnea-hypopnea index (AHI) and compliance on a daily basis.
75578669|NCT03202602|Other|Standard care|Office visits and monitoring of CPAP treatment at each visit.
75879439|NCT03563144|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
75879440|NCT03563144|Biological|GI-6207|CEA yeast vaccine
75879441|NCT03563144|Biological|GI-6301|Brachyury yeast vaccine
76050170|NCT04560790|Drug|BD111 Adult single group Dose|3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
76050171|NCT04574830|Other|No Intervention|No Intervention
76050172|NCT01639339|Biological|Placebo plus standard therapy|Placebo plus standard therapy
75728077|NCT00889148|Other|Placebo|Half the patients will be randomized to placebo
75879442|NCT03563144|Biological|haNK|NK-92 [CD16.158V, ER IL-2]
75879443|NCT03563144|Drug|Avelumab|Avelumab
75879444|NCT03563144|Drug|Bevacizumab|Bevacizumab
75879445|NCT03563144|Drug|Capecitabine|Capecitabine
75879446|NCT03563144|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75879447|NCT03563144|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
75879448|NCT03563144|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
75879449|NCT03563144|Drug|Oxaliplatin|Oxaliplatin
75879450|NCT04835636|Behavioral|Diabetes Prevention Program|This program is a 1 year lifestyle modification program focused on reducing calories and fat calories and increasing physical activity to achieve a 7% weight loss. This study utilized the first 16 sessions (6 months) of the program
75879451|NCT03831074|Device|Implantation of an intraocular lenses: iMics 1 NY-60 & NY-60G|
76050173|NCT01639339|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
76050174|NCT01639339|Drug|Standard therapy|"The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
76050175|NCT02000817|Biological|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
76050176|NCT02000817|Biological|Placebo|Placebo is available 0.9% w/v sodium chloride
76050177|NCT01641133|Biological|Synflorix (3-Dose)|3 doses administered intramuscularly
76050178|NCT01641133|Biological|Synflorix (2-Dose)|2 doses administered intramuscularly
75578670|NCT03198416|Device|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
75578671|NCT03181399|Drug|Triheptanoin|. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
76050179|NCT01641133|Biological|Synflorix (Single Dose)|1 dose administered intramuscularly
76050180|NCT01641133|Biological|Prevenar 13 (Single Dose)|1 dose administered intramuscularly
76050181|NCT01641133|Biological|Prevenar 13 (2-Dose)|2 doses administered intramuscularly
75431946|NCT06000254|Other|physiotherapy|Physiotherapy includes a range of activities such as passive and active-assisted shoulder range of motion (ROM) exercises, Pendulum exercises, Codman's exercises, and Cross-body reach exercises. These exercises are conducted under the supervision of a physiotherapist and each training session lasts approximately 30 minutes.
75578672|NCT03181061|Other|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
75578673|NCT03173950|Drug|Nivolumab|Participants will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
75578674|NCT03142893|Drug|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
75578675|NCT03142893|Drug|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
75578676|NCT03142893|Drug|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
75578677|NCT03142893|Drug|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
75578678|NCT03142893|Drug|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
75578679|NCT03142893|Drug|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
75578680|NCT03142893|Drug|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
75578681|NCT03142893|Drug|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
76050182|NCT04849429|Biological|Platelet rich plasma (PRP) with exosomes|Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
75431947|NCT06000254|Device|sham High energy density pulse electromagnetic field|The sham treatment coil is positioned over the area of the shoulder where maximum pain is experienced, and it remains in place for a duration of 9 minutes. The parameters are consistent with those used in the experimental group. The key distinction lies in the fact that the energy output is not delivered to the patient.
75578682|NCT03142893|Drug|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
75578683|NCT03142893|Drug|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
75578684|NCT03142893|Drug|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
75578685|NCT03142893|Drug|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
75578686|NCT03094312|Procedure|Dynamic Spectral Imaging (ISD)|cerebral stimulation: dynamic spectral imaging (ISD)
75578687|NCT03073304|Drug|Crystalloid based prime solution|Crystalloid based prime solution
75578688|NCT03073304|Drug|Erythrocyte based prime solution|Erythrocyte based prime solution
75578689|NCT02999022|Drug|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
75578690|NCT02999022|Drug|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
75578691|NCT02996955|Behavioral|social support|behaviour change intervention
75578692|NCT02996955|Behavioral|treatment of illness perceptions|educational interview
75578693|NCT02996955|Device|Activ8|wearing a move monitor
75578694|NCT02996955|Other|activity advice|walking or cycling 5 days a week during at least half an hour
76050183|NCT04849429|Drug|Normal Saline|placebo : 2 ml normal saline para discal administration
76050184|NCT05112757|Other|Smartphone application use|Use of a smartphone application
76050185|NCT04419259|Drug|AMG 334|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
76050186|NCT04835311|Procedure|surgical perineal repair|women who have undergone surgical perineal repair (codes CCAM JMMA002 and/or HKCA005)
76050187|NCT02000427|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
76050188|NCT05382013|Drug|Avatrombopag|Patients will receive treatment of oral avatrombopag 20mg per day for the first 5 days
75578695|NCT02927301|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
75578696|NCT02907398|Device|Inspire therapy|
75578697|NCT02907398|Other|No intervention|
75578698|NCT02892123|Drug|ZW25 (Zanidatamab)|ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
75578699|NCT02892123|Drug|Paclitaxel|Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
75578700|NCT02892123|Drug|Capecitabine|Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
75578701|NCT02892123|Drug|Vinorelbine|Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
75578702|NCT02892123|Drug|Tucatinib|Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
75578703|NCT02892123|Drug|Tucatinib|Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
75728078|NCT00936156|Drug|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
75728079|NCT00129961|Drug|sirolimus|
75431948|NCT05999214|Diagnostic Test|99mTc-H7ND SPECT/CT imaging performed|99mTc-H7ND SPECT/CT imaging positive (+) was defined as the presence of at least one measurable lesion and the uptake of the lesion was greater than that of normal liver in the experimental group, and patients were divided into SD+ and SD-. According to the guidelines and routine clinical practice, SD- patients were treated with the original regimen or maintenance treatment, and SD+ patients were divided into continuation of the original regimen or second-line treatment according to the MDT discussion results.
75578704|NCT02754323|Device|Apparatus CODESNA|The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
75728080|NCT00129961|Drug|cyclosporine or tacrolimus|
75728081|NCT00528567|Drug|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
75728082|NCT00528567|Drug|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
75431949|NCT05990751|Biological|GD2 CAR T cells|The GD2 CAR T cells target GD2 positive cells. The cells also express transgenes that aim to increase their resistance within the tumour microenvironment.
75578705|NCT02737878|Behavioral|Aerobic Training|"Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
75578706|NCT02737878|Behavioral|Resistance Training|"Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
76050189|NCT05382013|Other|Artificial Liver Support System|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
75578707|NCT02737878|Behavioral|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
75879452|NCT03825224|Procedure|Diagnostic Test: Myostrain|This test measures the contraction of the heart muscle in one to three heartbeats per plane. It's a pulse sequence that produces images that reveal the underlying contraction fo the muscle of a healthy heart and associated weaknesses in case of disease.
76050190|NCT05382013|Other|Comprehensive internal medical treatment.|Patients will receive comprehensive internal medical treatment.
75431950|NCT05990075|Behavioral|self-monitoring|This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
75431951|NCT05973851|Drug|Esketamine Nasal Product|See arm description
75431952|NCT05973851|Drug|Ketamine Hydrochloride|See arm description
75431953|NCT05973851|Drug|Esketamine hydrochloride|See arm description
75431954|NCT05973851|Drug|Second-line Antidepressants|See arm description
75728083|NCT00936234|Drug|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
75728084|NCT00886028|Drug|Liposomal doxorubicin|"Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
75728085|NCT00886028|Drug|Cisplatin|"Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
75728086|NCT00889304|Device|Position HTO system|open wedge high tibial osteotomy
75879453|NCT03824600|Diagnostic Test|Fractional Flow Reserve Motorized Pullback|A pullback device (Volcano R 100, San Diego CA, USA), adapted to grip the coronary pressure wire (PressureWire X, St Jude Medical, Minneapolis, USA), set at a speed of 1 mm/sec to pullback the pressure-wire until the tip of the guiding catheter during continued pressure recording.
75728087|NCT00936468|Biological|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
75728088|NCT02543216|Dietary Supplement|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
75728089|NCT00939666|Procedure|Wait&see or TEM with intensive follow-up|Wait&see or TEM with intensive follow-up
75879454|NCT04705766|Other|Urine Collection|A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.
76050191|NCT04678921|Drug|TJ210001|human anti-C5aR monoclonal antibody
76050192|NCT04673851|Device|Horyzons USA|Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.
75431955|NCT05973786|Drug|Escitalopram|ATC code: N06AB10
75431956|NCT05973786|Drug|Sertraline|See arm description
75431957|NCT05973786|Drug|Duloxetine|See arm description
75431958|NCT05973786|Drug|Venlafaxine|See arm description
75431959|NCT05973786|Drug|Lithium|See arm description
76050193|NCT04845217|Drug|Peppermint oil|Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
76050194|NCT04845217|Drug|Coconut Oil|Enteric coated coconut oil taken by mouth three times daily for 8 weeks
75431960|NCT05973786|Drug|Lamotrigine|See arm description
75431961|NCT05973786|Drug|Valproate acid|See arm description
75431962|NCT05973786|Drug|Quetiapine|See arm description
75431963|NCT05968638|Other|Regular Diet|Regular Diet
75578708|NCT02737878|Behavioral|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
76050195|NCT04419883|Device|McMurray Enhanced Airway|Provider Satisfaction of a New, Flexible Extended-Length Pharyngeal Airway to Relieve Upper Airway Obstructive During Deep Sedation: A Pilot Study
75431964|NCT05968638|Other|Ketogenic Diet|Ketogenic Diet
75431965|NCT05958875|Drug|Clozapine|Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
75431966|NCT05958875|Drug|Second-line Antipsychotics (treatment as usual)|Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
75578709|NCT02735109|Other|photographies|cells description by taken photographies vith confocal microscope (VivaScope 3000)
75578710|NCT02735109|Procedure|biopsy normal area|biopsy done to compare with abnormal area
75431967|NCT05954949|Procedure|Adenomas detection rate with the different observation methods|Films performed in white light high definition, NBI and indigo-carmine dye, will be compared blindly to detecte number of adenomas with the different observation methods
75431968|NCT05935618|Behavioral|ACT-ING program ( Activity-based skill- and strength training to improve ingestion)|The intervention is based on a client-centered Occupational therapy task-oriented approach, in which real objects are employed in a realistic context. The intervention uses the effortful swallowing in combination with advancing steps of liquid and food items as resistive forces to challenge the swallow in a safe environment during eating and drinking activities. Progression is realized based on pre-determined progression rules to ensure the right challenges in combination with safety (Hansen et al, 2023).
75431969|NCT05930587|Other|Cold water immersion|Cold water immersion (15 degree celsius, 20 minutes)
75578711|NCT02720874|Behavioral|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
75578712|NCT02720874|Behavioral|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
75578713|NCT02720874|Behavioral|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
75728090|NCT03835364|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using the Aptus Home, anaemia home monitoring system.
75728091|NCT00936546|Drug|Rituximab|Mabthera, Rituximab 1000 mg I.V.
75728092|NCT00889460|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
75728093|NCT00889460|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
75728094|NCT00936624|Drug|SOTB07|SOTB07 100mg
75728095|NCT00936624|Drug|SOTB07|SOTB07 200mg
75728096|NCT00936624|Drug|placebo|placebo
75728097|NCT00936624|Drug|montelukast|montelukast 10mg po, bid, 12week
75728098|NCT00889538|Drug|placebo|50 mL of 1/2 normal saline IV
75578714|NCT02720874|Behavioral|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
75578715|NCT02720874|Behavioral|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
75578716|NCT02669394|Behavioral|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
75578717|NCT02669394|Behavioral|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
75578718|NCT02659930|Drug|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
75578719|NCT02659930|Drug|pomalidomide|pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
75578720|NCT02653976|Drug|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
75578721|NCT02611037|Drug|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
75578722|NCT02611037|Drug|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m^2).
75578723|NCT02611037|Drug|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
75578724|NCT02611037|Other|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
75578725|NCT02607202|Drug|nab-paclitaxel|
75578726|NCT02607202|Drug|Carboplatin|
75578727|NCT02607202|Drug|Gemcitabine|
75578728|NCT02573441|Behavioral|Jump Math|Jump Math is a workbook based program aimed at improving math skills
75578729|NCT02573441|Behavioral|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
75578730|NCT02573441|Behavioral|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
75728099|NCT00889538|Drug|glutathione|glutathione 600 mg IV
75728100|NCT00889538|Drug|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
75728101|NCT04012476|Drug|Indocyanine Green|Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
75431970|NCT05905094|Other|Postural correction exercises|Exercises to improve posture like shoulder shrugging, chin tuckin, neck isometrics
75431971|NCT05891262|Drug|BMS-986196|Specified dose on specified days
75431972|NCT05891262|Drug|Loestrin|Specified dose on specified days
75431973|NCT05888454|Other|Integrative Group Program|The integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.
75431974|NCT05888454|Other|Conventional treatment for T2DM|Conventional medical treatment for T2DM
75431975|NCT05878587|Other|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes
75431976|NCT05878587|Other|thermotherapy+ TENS+ low intensity high repetition exercises|The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.
75431977|NCT05877469|Other|Mat pilates Training|In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
75578731|NCT02560662|Behavioral|Physical activity|"Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call."
75578732|NCT02446236|Drug|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
75578733|NCT02446236|Drug|Ibrutinib|560 mg PO daily
75578734|NCT02446236|Drug|Rituximab|375 mg/m2 IV Day 1
75578735|NCT02429479|Behavioral|Making Your Wishes Known|Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
75578736|NCT02429479|Behavioral|Standard advance care planning|This is a online simple living will form.
75578737|NCT02402660|Drug|ALK-001|Daily, oral administration for 24 months
75578738|NCT02402660|Drug|Placebo|Daily, oral administration for 24 months
75578740|NCT02347228|Drug|OB318 capsule|Oral qd, at least 30 minutes before breakfast
75578741|NCT02309840|Behavioral|choice architecture|"Place vegetables at the beginning of the lunch line.~Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.~Promote fruits and vegetables with prominently displayed signage and images.~Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level."
75578742|NCT02309840|Other|Chef-enhanced meals|meals prepared by a professional chef with enhanced palatability
75578743|NCT02208375|Drug|Capivasertib|Given PO
75578744|NCT02208375|Other|Laboratory Biomarker Analysis|Correlative studies
75578745|NCT02208375|Drug|Olaparib|Given PO
75578746|NCT02208375|Other|Pharmacological Study|Correlative studies
75728102|NCT00138151|Biological|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
75728103|NCT00138151|Drug|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
75578747|NCT02208375|Drug|Vistusertib|Given PO
75728104|NCT00138151|Drug|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
76050196|NCT05359393|Combination Product|a combination therapy including tislelizumab|"Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v)."
75578764|NCT02162420|Drug|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
75578765|NCT02162420|Drug|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
75578766|NCT02162420|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
75728105|NCT02543060|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
75728106|NCT02543060|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
75728107|NCT04012788|Dietary Supplement|Synbiotic mixture|A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)
75728108|NCT04012788|Other|Placebo comparator|Placebo powder
75578767|NCT02162420|Radiation|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
75578768|NCT02162420|Biological|Stem Cell Transplant|Stem cell transplant on day 0.
75578769|NCT02162420|Drug|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
75578770|NCT02040376|Drug|Metformin|Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
75578771|NCT02040376|Drug|Placebo|Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
75728109|NCT00889616|Drug|BSAM2/Alhydrogel + CPG 7909|
75728110|NCT00138073|Device|Web-based waveform interpretation guide|Use of an educational website.
75728111|NCT04038164|Behavioral|Dog-Assisted Therapy and pharmacological treatment|The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
75728112|NCT04013490|Dietary Supplement|Cassava dietary fiber capsule|Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
75728113|NCT04037306|Behavioral|Butyrate Feedback|Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
75728114|NCT04037306|Behavioral|Fiber Feedback|Estimated fiber consumption from menu records of weight loss facility.
75728115|NCT02581631|Biological|Nivolumab|
75728116|NCT02581631|Drug|Brentuximab Vedotin|
75728117|NCT00884546|Drug|BMS-833923|Capsule, Oral, Once daily, 6 months
75728118|NCT00884546|Drug|Lenalidomide|Capsule, Oral, Once daily, 6 months
75728119|NCT00884546|Drug|Dexamethasone|Capsule, Oral, Once a week, 6 months
75728120|NCT00884546|Drug|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
75728121|NCT04970277|Other|drinking water group|Those randomized to drink water group were asked to drink 200 mL colorless water every 10 minutes, starting at the time of capsule ingestion until three times in total.
75728122|NCT04970277|Other|control group|Those randomized to control group were asked not to drink extra water after capsule ingestion.
75728123|NCT05444049|Device|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
75578772|NCT01944761|Behavioral|Exercise Program|"Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) [10 mins], ii) aerobic training/fitness games [30 mins], iii) organized sports [30 mins], iv) cool down (i.e. stretching, low intensity games) [10 mins] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week."
75578773|NCT01850888|Drug|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
75728124|NCT00886106|Drug|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
75728125|NCT00886106|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
75728126|NCT00939978|Drug|rhEPO|recombinant human erythropoietin(rhEPO)
75728127|NCT00889694|Drug|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
75578774|NCT01850888|Drug|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
75728128|NCT00889694|Drug|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
75578775|NCT01850888|Drug|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000).
75578776|NCT01850888|Procedure|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum > 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum >2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
75728129|NCT00889694|Drug|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
75728130|NCT04012320|Other|No intervention, observational study|No intervention, observational study
75728131|NCT05278910|Other|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour
75728132|NCT05278910|Dietary Supplement|Fish oil + Roasted wheat flour|Assign fish oil and roasted wheat flour
75728133|NCT05278910|Dietary Supplement|Soybean oil + Vegetable and fruit extracts|Assign soybean oil and vegetable and fruit extracts
75728134|NCT05278910|Dietary Supplement|Fish oil + Vegetable and fruit extracts|Assign fish oil and vegetable and fruit extracts
75728135|NCT00940212|Drug|AZD2423|oral, single administration
75728136|NCT00940212|Drug|Placebo|oral administration and single dose
75728137|NCT00529035|Drug|Interleukin-2|Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
75728138|NCT04421664|Drug|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
75728139|NCT04421664|Drug|Placebo oral tablet|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
75728140|NCT02578043|Drug|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
75728141|NCT02578043|Drug|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
75431978|NCT05877469|Other|Functional Training|In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
75431979|NCT05877183|Device|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 45-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
75431980|NCT05877183|Device|Sham device|The sham device is also a wristwatch, which consists of an accelerometer, a gyroscope sensor, and a rechargeable battery that supports up to 72 hours of continuous use. The device will monitor the participant's arm activity, but it will not emit any reminders or be connected to a telerehabilitation system. The participants were instructed to perform the exercises from the pictorial handout for the recommended therapy dose and received a weekly therapy consultation as well.
75431981|NCT05874570|Drug|Esomeprazole|Proton pump inhibitor
75431982|NCT05874570|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
75431983|NCT05874570|Drug|Tetracycline|Antibiotics for H. pylori eradication
75431984|NCT05874570|Drug|Doxycycline|Antibiotics for H. pylori eradication
75431985|NCT05874570|Drug|Metronidazole|Antibiotics for H. pylori eradication
75431986|NCT05874531|Diagnostic Test|End-expiratory occlusion test|15 seconds end-expiratory occlusion
75578777|NCT01785316|Procedure|IHP|
75578778|NCT01719055|Device|neurostimulation system|Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
75578779|NCT01652092|Drug|Alemtuzumab 0.3 mg|0.3 mg/kg intravenously (IV) on days -12 through -10
75578780|NCT01652092|Drug|Cyclophosphamide|cyclophosphamide 50 mg/kg IV on days -9 through -6
75578781|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
75578782|NCT01652092|Biological|Stem Cell Transplantation|"Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be > 5.0 x 10^7 nucleated cells/kg."
75728142|NCT02578043|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
75578783|NCT01652092|Drug|Fludarabine phosphate 40 mg|40 mg/m^2 IV on days -5 through -2 (for children < 6 months and/or < 10 kg weight dose at 1.33 mg/kg)
75578784|NCT01652092|Drug|Melphalan|140 mg/m^2 IV on day -3
75578785|NCT01652092|Drug|Alemtuzumab 0.2 mg|0.2 mg/kg intravenously (IV) on days -14 through -10
75578786|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
75578787|NCT01652092|Drug|Fludarabine phosphate 30 mg|fludarabine 30 mg/m^2 IV on days -8 through -4
75578788|NCT01652092|Drug|MESNA|administered as per the standard institutional protocol.
76050197|NCT04833439|Other|Fasting Mimicking Diet|Low-caloric, low-protein, plant-based diet regiment for 3 days
76050198|NCT04178707|Device|OnZurf Probe, Senzime AB, Uppsala, Sweden|Probe is inserted into the fistula and measurements are made of the inner environment.
76050199|NCT04650919|Procedure|Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).|"The procedure consists of 2 operating times:~Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.~Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety."
75728143|NCT04037384|Behavioral|Eye yoga|Eye yoga exercises at home given by a trained instructor
75728144|NCT04037384|Behavioral|Passive Reading|Passive reading at home
75728145|NCT00940056|Procedure|Endoscopic ablation of AF|"The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care."
75728146|NCT00940056|Drug|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
75728147|NCT00889850|Drug|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
75728148|NCT00889850|Drug|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
75431987|NCT05854316|Diagnostic Test|Comprehensive Biomechanical assessment|Magnetic resonance images, electromyography and dynamometry data will be used, together with data from the gait assessment and clinical questionnaires/measures, to characterize the biomechanics of the participants, and to develop and inform personalised musculoskeletal models
75431988|NCT05853081|Diagnostic Test|Bioelectrical impedance analysis|The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.
75431989|NCT05848076|Other|TNE|McGill exercise focuses on the ability of the spine to stabilize in different positions 3 sets of 3 repletion with of each of muscle and briefly explains the patient about their pain
75431990|NCT05848076|Other|core stability|McGill exercises for the low back.
75578795|NCT01621594|Device|The Toshiba Aquilion ONE CT system|To test the diagnostic accuracy of low-radiation dose CT coronary angiography for detecting significant coronary artery stenosis and to determine the prognostic value of low-radiation dose CT coronary angiography for discriminating patient risk of death or major adverse cardiac events.
75578797|NCT01566695|Drug|Oral Azacitidine|300 mg daily, days 1 to 21 of each 28-day treatment cycle
75578798|NCT01566695|Drug|Placebo|Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
75728149|NCT04074317|Drug|PRAM9|SC injection
75728150|NCT04074317|Drug|Regular Insulin + Pramlintide|Separate SC injections
75728151|NCT04074317|Drug|Regular Insulin|SC injection
75578799|NCT01566695|Other|Best Supportiv Care (BSC)|BSC included and was not limited to packed RBC (packed red blood cell [pRBC] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
76050200|NCT01600885|Drug|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
76050201|NCT01600885|Drug|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
75728152|NCT00941148|Drug|Insulin Glargin|
75728153|NCT00941148|Drug|NPH insulin|
75728154|NCT00941148|Drug|Insulin detemir|
75431991|NCT05840276|Device|Cryoneurolysis|The VISUAL-ICE uses a combination of argon and helium, to create a highly localized cold zone with temperatures between -20 and -100°C. A probe will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization to accurately determine the location of the nerve and to account for adjacent neurovascular structures and variations in anatomical structures. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Cryoneurolysis at each target site requires 2 freeze cycles with a duration of 3 mins, and with thaw cycles between 20-40 seconds.
75431992|NCT05840276|Other|Sham|A sham needles will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Sham will simulate cryoneurolysis at each target site for 2 freeze cycles with a duration of 3 mins, and also simulate thaw cycles between 20-40 seconds. No temperature changes will actually occur although the experience and sounds will be similar to cryoneurolysis
75728155|NCT00941148|Drug|metformin|metformin (2000 mg/day)
75728156|NCT02541500|Drug|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
75431993|NCT05834114|Other|Mckenzie protocol|"In this group 20 participants will receive McKenzie protocol with conventional physical therapy. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). Subsequently, the participant will be requested to return to the original position while the therapist one hand's forefinger placed alongside the participant's mandible (to stabilize the head at full retraction position), and the heel of the other hand placed on the first or second dorsal vertebra (to provide posterior-anterior force). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week."
75578802|NCT01506141|Drug|Idursulfase-IT|Participants will receive Idursulfase-IT once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
75578803|NCT01506141|Drug|Elaprase|Participants will receive weekly IV infusions of commercially available Elaprase.
75578804|NCT01468883|Procedure|M|Modified radical mastectomy
75728157|NCT04073849|Drug|EPOGEN® (epoetin alfa)|Active drug
75728158|NCT04073849|Other|Normal Saline|Placebo
75728159|NCT05280210|Other|PTC drug screening|PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.
75728160|NCT05221203|Behavioral|TR-30|Bodyweight training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
75728161|NCT05221203|Behavioral|TR-45|Bodyweight training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
75728162|NCT03263429|Drug|Glutaminase Inhibitor CB-839|Given by mouth
75728163|NCT03263429|Biological|Panitumumab|Given by vein
75728164|NCT03263429|Drug|Irinotecan Hydrochloride (phase I only)|Given by vein
75728165|NCT03263429|Other|Laboratory Biomarker Analysis|Correlative studies
75728166|NCT03263429|Other|Pharmacological Study|Correlative studies
75728167|NCT03263429|Device|Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans|During phase II at baseline and day 28 of cycle 1
75728168|NCT00609674|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
75728169|NCT00609674|Drug|Placebo|Placebo
75728170|NCT00940134|Biological|PYY 3-36|0.8 pmol/kg/min x 3 hours
75728171|NCT00940134|Biological|GLP-1|1.0 pmol/kg/min x 3 hours
75728172|NCT00940134|Biological|saline infusion|saline infusion x 3 hours
75728173|NCT00941382|Drug|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
75728174|NCT00941382|Drug|Sibutramine|15 mg per day for 180 days
75728175|NCT00941382|Drug|Metformin|Metformin 850 mg per day for 180 days
76050202|NCT04625257|Other|Saliva based assay: crude RNA extraction|Crude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.
76050203|NCT04625257|Other|Validation of the NGS method|Compare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.
75728176|NCT00137839|Drug|Erlotinib|
75728177|NCT02542982|Device|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
75728178|NCT00941460|Drug|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
75578805|NCT01468883|Radiation|X|Excisional biopsy plus radiation
75578806|NCT01451502|Biological|Umbilical Cord Blood (UCB)|Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
75578807|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|"Target defined using both fMRI during hallucinations occurence and tractography.~Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session"
75578808|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
75431994|NCT05834114|Other|Rhythmic Stabilization technique|In this group participants will receive Rhythmic stabilization, with Conventional physiotherapy treatment the flexion , extension exercises performed. During flexion pattern the experimenter stood at the right side of patient and used his tip of fingers at chin. The experimenter then put his left hand at anterior side of head to apply resistance. then extension pattern is resisted and asked patient to match my resistance. The experimenter provided resistance against right rotation and lateral flexion provided during the exercise in order to induce strong muscle contractions. 3 sessions of 45 minutes a week, over a period of 10 weeks.
75431995|NCT05824650|Other|Observational|Individuals will be evaluated observationally in a 45-minute period in one day.
75578809|NCT01212029|Behavioral|Behavioral measures|Behavioral tasks/ questionnaires
75578810|NCT01212029|Device|fNIRS Devices &amp; Application|Device 1- fNIRSoft and Device 2 - NIRScout
75578811|NCT01212029|Other|Physiological measures|A set of tasks.
76050204|NCT04625257|Other|Validation of the LAMP assays|The RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.
75578813|NCT01081951|Drug|olaparib|Tablets Oral BID
75578814|NCT01081951|Drug|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
75431996|NCT05811260|Other|Myofascial Release technique|on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
75578815|NCT01081951|Drug|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
75578816|NCT01081951|Drug|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
75578817|NCT01081951|Drug|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
75728179|NCT00941460|Drug|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
75578818|NCT00777582|Drug|AZD2281|Oral single dose formulation
75578819|NCT00736385|Drug|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
75578820|NCT00736385|Drug|Placebo|placebo 2000 mg daily for 12 months
75578821|NCT00392327|Drug|Carboplatin|Given IV
75578822|NCT00392327|Drug|Cisplatin|Given IV
75578823|NCT00392327|Drug|Cyclophosphamide|Given IV
75578824|NCT00392327|Biological|Filgrastim|Given IV or SC
75578825|NCT00392327|Drug|Isotretinoin|Given PO
75578826|NCT00392327|Other|Laboratory Biomarker Analysis|Correlative studies
75578827|NCT00392327|Other|Quality-of-Life Assessment|Ancillary studies
75578828|NCT00392327|Radiation|Radiation Therapy|Undergo radiation therapy
75578829|NCT00392327|Drug|Vincristine Sulfate|Given IV
75578830|NCT00357565|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
75578831|NCT00357565|Drug|busulfan|Administered 1.1 mg/kg if <12 kg intravenous (IV) every 6 hours (0.8 mg/kg if >12 kg IV every 6 hours on Days -8 through -5.
75578832|NCT00357565|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of >200 ng/mL. For children < 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
75578833|NCT00357565|Drug|fludarabine phosphate|Administered 25 mg/m^2 intravenous (IV) over 60 minutes on Days -4 through -2.
75578834|NCT00357565|Drug|melphalan|Administered 60 mg/m^2 intravenous (IV) over 30 minutes on Days -4 through -2.
75728180|NCT02542904|Procedure|mesenteric excision|
75728181|NCT04013178|Behavioral|Accentuated eccentric loading + electromyostimulation|An innovative training intervention to optimize muscle strength and muscle mass
75728182|NCT04013178|Behavioral|Conventional resistance training|A conventional approach to resistance training
75728183|NCT00886184|Procedure|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
75728184|NCT00886184|Procedure|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
75431997|NCT05811260|Other|Post facilitation stretch .|static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
75431998|NCT05808608|Drug|AK104|Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
75431999|NCT05808608|Drug|Axitinib|An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
75432000|NCT05803200|Drug|No intervention|No intervention was given as this is an observational study.
75432001|NCT05790031|Device|Intelligent Nighttime Brace|Participants will be invited to undergo a fitting session of intelligent nighttime brace. After the fitting, participants will join a 6-month wear trial of the intelligent nighttime brace. Participants are required to wear the intelligent nighttime brace for 8 hours a day during sleeping and compliance will be recorded by an intelligent monitoring system. Participants will be invited to undergo assessments before the wear trial, after the trials of 3 months and after the trial of 6 months. The measure outcomes of the assessment include 1)ultrasound scanning image, 2)3D body scanning, 3)garment pressure, 4) questionnaires
75432002|NCT05782309|Drug|Flavanol|Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
75432003|NCT05782309|Drug|Placebo|Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
75432004|NCT05781321|Radiation|Accelerated Hypofractionated Radiation Therapy|Undergo short course RT
75432005|NCT05781321|Procedure|Computed Tomography|Undergo CT simulation
75432006|NCT05781321|Drug|Fluorodopa F 18|Given IV
75432007|NCT05781321|Procedure|Magnetic Resonance Imaging|Undergo MRI
76050205|NCT04625257|Other|Validation of the POCT Antigen and Antibody tests|Rapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.
75432008|NCT05781321|Procedure|Positron Emission Tomography|Undergo PET
75432009|NCT05781321|Other|Quality-of-Life Assessment|Ancillary studies
75432010|NCT05781321|Other|Questionnaire Administration|Complete questionnaires
75432011|NCT05781321|Radiation|Radiation Therapy|Undergo standard course RT
75432012|NCT05781321|Drug|Temozolomide|Given PO
75432013|NCT05781243|Drug|Lactated Ringer Solution|Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
75432014|NCT05781243|Drug|Normal saline|Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
75432015|NCT05774509|Biological|Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells|Repeated (X3) intravenous infusions of the extracellular vesicle-enriched secretome of cardiovascular progenitor cells (differentiated from human induced pluripotent stem cells)
75432016|NCT05768035|Biological|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors 6 days after haplo HSCT and 2 days after the last administration of cyclophosphamide
76050206|NCT05369455|Procedure|erector spinae plane block|determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
75578835|NCT00357565|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients <45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
75578836|NCT00357565|Procedure|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
75578837|NCT00352534|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo radiotherapy
75578838|NCT00352534|Biological|Dactinomycin|Given IV
75578839|NCT00352534|Drug|Doxorubicin Hydrochloride|Given IV
75578840|NCT00352534|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75578841|NCT00352534|Drug|Vincristine Sulfate|Given IV
75432019|NCT05739890|Other|Embryo genome sequencing|This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.
75432020|NCT05739890|Other|Parents genome sequencing|Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.
75728185|NCT02542670|Genetic|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
75728186|NCT00890240|Drug|JNJ-31001074|
75728187|NCT00890318|Drug|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
75432021|NCT05735847|Procedure|Total Knee Arthroplasty (TKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.
75432022|NCT05735847|Procedure|Unicompartmental Knee Arthroplasty (UKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.
75432023|NCT05729984|Behavioral|Paula exercises|The patients will perform Paula exercises after the cesarean delivery
75432024|NCT05729984|Behavioral|Gum chewing|The patients will be given chewing gum and will be asked to chew it after the cesarean delivery
75432025|NCT05700396|Behavioral|Breast Cancer Survivor Education Program|Weekly sessions via Zoom platform with study staff.
75432026|NCT05695820|Other|Blood Flow Restriction training|It is a method that involves reducing blood flow to a muscle by the application of an external constricting device, such as a blood pressure cuff or tourniquet, to provide mechanical compression of the underlying blood vessels. BFR is applied aiming to enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet
75432027|NCT05695131|Device|GlenXRose Virtual Reality Speech Therapies|Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
75432028|NCT05694741|Drug|AZD0186|Subjects will receive AZD0186 orally.
75432029|NCT05694741|Drug|Placebo|Subjects will receive placebo orally.
75432030|NCT05675709|Behavioral|Training and Education|Undergo group and online trainings
75432031|NCT05672355|Procedure|Biospecimen Collection|Undergo blood sample collection
75432032|NCT05672355|Biological|mRNA COVID-19 Vaccine|Given IM
75432033|NCT05672355|Biological|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM
75432034|NCT05672121|Drug|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
75432035|NCT05671887|Procedure|Double Lung Transplantation|To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.
75432036|NCT05663112|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy will be performed.
75432037|NCT05663112|Procedure|Breast massage|Breast massage will be performed for a duration of 5 minutes.
75432038|NCT05663112|Procedure|Blue dye injection|Isosulfan blue dye will be injected in the subareolar region of the breast
75432039|NCT05661344|Drug|BI 1015550|BI 1015550
75728188|NCT00890318|Other|ketoconazole|Tablet, see Arm Description for intervention information.
75728189|NCT00890318|Drug|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
75728190|NCT00563316|Drug|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
75728191|NCT00563316|Drug|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
75728192|NCT04037774|Drug|Dexmedetomidine|comparision of different doses of dexmedetomidine used intrathecally
76050207|NCT05369455|Procedure|ultrasound guided caudal block|determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
75432040|NCT05643183|Other|Astmakompas|The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
76050208|NCT01732510|Drug|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
76050209|NCT01732510|Drug|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
76050210|NCT05369377|Drug|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
75432041|NCT05616949|Behavioral|Treatment as Usual (TAU) (Arm 1)|Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
75578844|NCT00018044|Drug|Clofazimine|
76050211|NCT05369377|Drug|Eltrombopag|eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
76050212|NCT04832269|Other|Exposure to methylprednisolone during pregnancy|Exposure to methylprednisolone during pregnancy in the context of an MS relapse therapy
75578847|NCT00001721|Drug|Cholesterol Suspension|
75578848|NCT00001721|Drug|CRH|
75578849|NCT00001721|Drug|Cholesterol|
75728193|NCT04037774|Other|placebo|addition of placebo with local anesthetic to create a control group
75728194|NCT00890474|Procedure|Moxibustion of the BL67 acupoint|Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
75728195|NCT01529736|Procedure|High torque insertion|Osseotite implant placed with high insertion torque forces
76050213|NCT05353153|Other|hypnosis|Hypnosis-based intervention with two sessions of hypnosis (focusing on the treatment of anxiety)
76050214|NCT05353153|Other|standart care|no intervention no hypnosis
76050215|NCT04608331|Drug|Dexmedetomidine|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
76050216|NCT04608331|Drug|Placebo|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
76050217|NCT04065295|Drug|BI 1356225|Oral Dose
76050218|NCT04065295|Drug|Placebo|Oral dose
76050219|NCT05348941|Dietary Supplement|TECADRIOL|Food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
76050220|NCT04842097|Behavioral|Mindfulness-based stress reduction|An online mindfulness-based stress reduction intervention will be administered in a group format of maximum 15 participants, once a week for 120 minutes for 8 weeks by an experienced therapist trained in MBSR. Sessions will include sitting and lying meditation, hatha yoga and a body scan where attention is sequentially focused on different parts of the body. Individual autonomous practice between 30-45 minutes, 6 times / week will also be recommended. To support individual autonomous practice, a daily diary and two guided videos (around 35 minutes/each) were created.
76050221|NCT01637077|Drug|pregabalin|Given PO
76050222|NCT01637077|Drug|placebo|Given PO
76050223|NCT01637077|Other|questionnaire administration|Ancillary studies
76050224|NCT02308163|Drug|Peficitinib|oral
76050225|NCT02308163|Drug|Placebo|oral
76050226|NCT02308163|Biological|Etanercept|subcutaneous injection
76050227|NCT05347537|Other|Mulligan mobilization|Mulligan Mobilization designed to reduce pain and improve the patient's range of motion. Mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
76050228|NCT05347537|Other|clamshell exercise|As a general exercise, the clamshell can help strengthen your medial glutes, bringing more power and stability to your hips. This group treated with mulligan's mobilization with movement and clamshell exercises.
75432042|NCT05616949|Behavioral|Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)|Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
75432043|NCT05603702|Drug|Lacosamide|Study Visit 1: Baseline study assessments will be made and questionnaires completed in person, on day 0. Drug treatment days will then occur on days 1-7. Study Visit 2: Following completion of the 7-day drug treatment period, participants will have a face-to-face clinic visit on day 8 (with a 3 day grace period), where similar assessments and questionnaires will again be completed. Participants will return all unused drug at this visit, for disposal and to monitor compliance. A follow-up phone visit will occur on day 21 (with a 3 day window) to assess for adverse events and medication changes
75432044|NCT05558865|Behavioral|somnovia|Participants receive access to the digital health application somnovia
75432045|NCT05548036|Device|OPEP|OPEP (Aerobika (tm)
75432046|NCT05546606|Device|ECCO2R|ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.
75432047|NCT05526313|Drug|Prilinostat Mesylate 1.2mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
75432048|NCT05526313|Drug|Prilinostat Mesylate 2.4mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
76050229|NCT04819711|Behavioral|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is an evidence-based intervention that is based on principles of cognitive behavioral therapy. It includes strategies that incorporate behavioral activation, active listening, collaboration with the family, guided discovery, and homework. The adapted THP consists of 5 integrated sessions. Session 1 introduces the programme and focuses on engagement of participants, introduction of THP, and breathing exercises. Session 2 focuses on psychoeducation and problem solving. Session 3 focuses on the mother's well-being and introduces activities such as physical exercises, good sleep practices and ensuring a balanced diet. Session 4 focuses on the mother's relationship with the unborn baby. Session 5 focuses on activating social support from family, friends and peers and provides closure of therapy.
76050230|NCT04556851|Drug|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
76050231|NCT04556851|Drug|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
76050232|NCT04556851|Drug|Placebo|Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
75432049|NCT05526313|Drug|Prilinostat Mesylate 4.0mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
75432050|NCT05526313|Drug|Prilinostat Mesylate 6.0mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
75432051|NCT05526313|Drug|Prilinostat Mesylate 8.4mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
75432052|NCT05526313|Drug|Prilinostat Mesylate 11.2mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
75432053|NCT05526313|Drug|Prilinostat Mesylate 15mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
75432054|NCT05515159|Other|electroconvulsive therapy|electrical stimulation of the brain while the patient is under anesthesia.
75432055|NCT05513716|Other|Retrospective tissue sample analysis|Archival formalin-fixed, paraffin-embedded (FFPE) tumour tissue from colorectal cancer peritoneal metastasis and paired primary tumours, where available - taken as standard care
75432056|NCT05509101|Other|commercially available control algorithm|Control of the prosthesis/orthosis is based on clinical standard of care using commercially available control algorithms.
75432057|NCT05509101|Other|experimental control algorithm|Control of the orthosis is based on residual muscle activity mapped to intended movement using high density electromyography and artificial intelligence control algorithms.
75432058|NCT05508854|Genetic|prenatal genetic counselling|Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb in terms of genetic diseases, the tests and risks that can be done for the diagnosis of the disease, the test results and information about the disease in case of illness and the presentation of options.
75432059|NCT05498883|Other|Score completion|completion of the SRI score
75578850|NCT02910440|Drug|DCL-101 vs Golytely|
75432060|NCT05494593|Drug|ELAPRASE|Participants will receive 0.5 milligram per kilogram (mg/kg) of body weight of ELAPRASE, intravenous, infusion for 104 weeks.
75578851|NCT04676997|Biological|Camrelizumab|200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion.
75432061|NCT05494593|Drug|Rituximab|Participants will receive 375 milligram per square meter per dose (mg/m^2/dose) of intravenous rituximab weekly for 4 weeks in 5-week cycle.
75578852|NCT04676997|Drug|Nab paclitaxel|125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion.
75578853|NCT04676997|Drug|Epirubicin|90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
75578854|NCT04676997|Drug|Cyclophosphamide|600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
75578855|NCT01217047|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
75578856|NCT01217047|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
75578857|NCT01217047|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
75728196|NCT01529736|Procedure|Low torque insertion|Osseotite implant placed with low insertion torque forces
75728197|NCT02542748|Drug|Norepinephrine|norepinephrine injection
76050233|NCT04039399|Procedure|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).
75432062|NCT05494593|Drug|Methotrexate|Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.
75432063|NCT05494593|Drug|Intravenous Immunoglobulin (IVIG)|Participants will receive 500 mg/kg of IVIG every 4 weeks in 5-week cycle.
75432064|NCT05491356|Drug|Tissue Plasminogen Activator|Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile
75432065|NCT05491356|Drug|Placebo|0.9% saline solution, intra-catheter administration, sterile
75432066|NCT05481151|Drug|P1101 (Ropeginterferon alfa-2b-njft)|Ropeginterferon alfa-2b-njft
75432067|NCT05481151|Drug|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft
75432068|NCT05473013|Behavioral|Behavioral Therapy for Eating Disorders|Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
75432069|NCT05473013|Behavioral|Skills Monitoring On|Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
75432070|NCT05473013|Behavioral|Automated Reminder Messages|Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
75578858|NCT01217047|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
75578859|NCT00624403|Device|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
75578860|NCT00624403|Device|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
75728198|NCT02542748|Drug|Ephedrine|Ephedrine injection
75728199|NCT00941616|Biological|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
75728200|NCT00941616|Biological|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
75728201|NCT04037540|Procedure|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
75728202|NCT04037540|Procedure|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
75728203|NCT00941694|Behavioral|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
75578861|NCT02910128|Behavioral|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
75728204|NCT00941694|Behavioral|placebo group|3 phone calls not related to asthma self-management
76050234|NCT04039399|Procedure|Sham Ischemic Conditioning|There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
76050235|NCT04419727|Procedure|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, the arterial tissues will be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using Trizol reagent (Invitrogen, Milan Italy), according to the manufacturer's instructions. The expression of ER-alpha, ER-beta,and GPER will be quantified by real-time PCR using the Step One ™ sequence detection system (Applied Biosystems Inc. Milan, Italy), following the manufacturer's instruction
75578862|NCT01968720|Drug|CAT-2003|
75578863|NCT01968720|Drug|Placebo|
75578864|NCT02910206|Drug|Etomidate|etomidate is given intravenously
75728205|NCT02542592|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
75728206|NCT02542592|Drug|Isotonic Sodium Chloride|Placebo
76050236|NCT04554745|Radiation|Ultrasound|ultrasound assessment of pregnant women
76050237|NCT04038697|Procedure|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
75432071|NCT05473013|Behavioral|JITAIs|Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
75432072|NCT05470400|Biological|FP conjugate vaccine (25 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
75432073|NCT05470400|Biological|FP conjugate vaccine (200 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
75578865|NCT02910206|Drug|propofol|propofol is given intravenously
75578866|NCT02910206|Drug|Sufentanil|sufentanil is given intravenously
75578867|NCT02910206|Drug|Cisatracurium|Cisatracurium is given intravenously
75578868|NCT04675086|Drug|alpha1-proteinase inhibitor|Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
75728207|NCT00941772|Other|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
75728208|NCT03178487|Drug|Upadacitinib|Tablet
75432074|NCT05470400|Biological|Trimer 6931 (100 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
75578869|NCT04675086|Drug|Antiviral Agents|a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
75578870|NCT02909972|Drug|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
75578871|NCT02909972|Drug|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
75578872|NCT01961778|Device|Radio-Frequency Ablation|
75578873|NCT01961778|Device|Cryotherapy|
75728209|NCT03178487|Drug|Placebo|Tablet
75578874|NCT04687943|Combination Product|PELOID therapy, kinesio tape, exercise|126 patients diagnosed with lateral epicondylitis will be divided into 3 groups. Totally 15 sessions of peloid therapy for 42 patients in 1 group for 3 weeks, 5 days a week, 2 sessions of muscle and fascia correction techniques for 3 weeks in the second group for 3 weeks, and 3 sets per day for 42 patients in the third group for 3 weeks. You will be given 10 repetitive home workouts.
75578875|NCT04674657|Drug|blood drug concentration|blood drug concentration
75578876|NCT04688060|Diagnostic Test|Falls Efficacy Scale-International (FES-I)|The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
75578877|NCT04674735|Drug|APSLXR|Oral coated tablets once a day for 60 days.
75578878|NCT00555594|Drug|Bevacizumab (Avastin)|One dose of 0.1cc of subconjunctival Bevacizumab was applied
75728210|NCT02542826|Other|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
76050238|NCT04038697|Procedure|Ischemic Conditioning Sham|Ischemic conditioning sham consists of the same setup as ischemic conditioning, which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 10 mmHg for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. 10 mmHg is a sufficient inflation pressure for study participants to perceive some cuff tightness, but is not high enough to occlude blood flow. In our study, participants assigned to the IC Sham + Treadmill Training groups will undergo twelve sessions of ischemic conditioning sham over a four-week period.
75432075|NCT05470400|Biological|Trimer 6931 (200 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
75578879|NCT02910050|Drug|Bicalutamide|50mg once a day orally
75578880|NCT02910050|Drug|Aromatase Inhibitor|participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
75578881|NCT04674930|Other|Exercise program|Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
75578882|NCT02909933|Drug|liraglutide|
75432076|NCT05470400|Biological|Trimer 4571 (200 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
75432077|NCT05470400|Biological|Trimer 4571 (100 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
75578883|NCT02909933|Drug|metformin and liraglutide|
75578884|NCT01960686|Biological|Low dose RSV F Antigen|
75578885|NCT01960686|Biological|High dose RSV F Antigen|
75578886|NCT01960686|Biological|Dose 1 of Aluminum Adjuvant|
75728211|NCT04430036|Drug|AGEN1884|A fully human monoclonal Anti-PD-1 Antibody
75728212|NCT04430036|Drug|AGEN2034|A fully human monoclonal Anti-PD-1 Antibody
75728213|NCT04430036|Drug|Cisplatin|Alkylating antineoplastic agent
75432078|NCT05451862|Device|Holmium-166 treatment|Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.
75879455|NCT04784624|Behavioral|Lifestyle program|The cardiometabolic and weight loss program is based on The Wellness Institute clinically validated lifestyle medicine program and will be delivered virtually using a digital platform and artificial intelligence that is supported by a health coach. The program focuses on building individual's self-efficacy, motivation and importance to make and sustain healthy choices. The 16-week program begins with a health risk assessment and a personalized wellness plan. The plan includes a personalized exercise plan and nutrition strategy. Each user will regularly check-in with their personal health coach whose role is to provide expert advice and also empower, support and help make the user accountable as they build a healthy lifestyle. Coaching includes identifying obstacles to changing behaviors and how to develop new behaviors that will become the norm.
75879456|NCT04763720|Behavioral|Dyadic Developmental Psychotherapy|DDP involves approximately twenty sessions with the family, conducted by a trained DDP therapist. DDP is developed to treat trauma-related and attachment difficulties. DDP is not a manualized treatment but involves using a set of core communication techniques (termed PACE; Playfulness, Acceptance, Curiosity and Empathy).
75879457|NCT01338818|Drug|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
75879458|NCT05310110|Drug|10% lidocaine spray|10% lidocaine spray 3 puff for the throat before induction
75879459|NCT05310110|Drug|Placebo of lidocaine spray|Normal saline spray 3 puff for the throat before induction
75879460|NCT05310110|Drug|Cisatracurium|Intravenous cisatracurium 0.12 mg/kg during induction
75879461|NCT05310110|Drug|Placebo of cisatracurium|Intravenous normal saline during induction
75728214|NCT04430036|Drug|Gemcitabine|Antimetabolite antineoplastic agent
75578887|NCT01960686|Biological|Dose 2 of Aluminum Adjuvant|
75728215|NCT00528957|Drug|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants > 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to > 37 kg may be switched from the oral powder to the tenofovir DF tablet.
75728216|NCT00528957|Drug|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry (pediatric participants < 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
75728217|NCT00528957|Drug|Stavudine|Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m^2 every 8 hours; pediatric participants > 12 years of age: 300 mg twice daily).
75728218|NCT00890630|Procedure|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
75728219|NCT00890630|Drug|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
75432079|NCT05451862|Device|Holmium-166 work-up|Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
75432080|NCT05438836|Radiation|online adaptive radiotherapy|Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy
75432081|NCT05433948|Diagnostic Test|Simultaneous EEG and CRT|"EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal."
75432082|NCT05427578|Other|fNIRS measurement|measurement using functional near-infrared spectroscopy
75578888|NCT01960686|Biological|Dose 3 of Aluminum Adjuvant|
75578889|NCT01960686|Biological|Dose 4 of Aluminum Adjuvant|
75578890|NCT01960686|Biological|Placebo|
75578891|NCT02910245|Drug|Mercaptopurine (Purinethol)|
75578892|NCT02910245|Drug|Placebo|
75578893|NCT02910245|Drug|Mesalamine|
75578894|NCT02910245|Drug|Prednisone|
75578895|NCT04674891|Other|baseline physical therapy treatment|Group A was control group and the patients received Conventional treatment protocol for 4 weeks which included 3 sessions per week. Patients received hot pack for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises will be performed in sitting (10sec hold,10 to 15 reps)
75728220|NCT00890708|Drug|Voriconazole (therapeutic drug monitoring)|dosage adjustment according to trough level of voriconazole in plasma
75728221|NCT00890786|Drug|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
75728222|NCT00890786|Drug|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
75432083|NCT05423184|Other|Exercise Therapy For Lower Extremities|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg raise with theraband, squat, lunge walk and static balance exercises. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
75728223|NCT00890786|Drug|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
75432084|NCT05423184|Other|Exercise Therapy For Myofascial Chains|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their structered exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg and arm raise with theraband, squat with arm participation using theraband, lunge walk with arm participation using theraband and static balance exercises with arm participation using theraband. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
75432085|NCT05415787|Other|Blood sample|2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
75879462|NCT05310110|Drug|Propofol|The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.
75879463|NCT02823470|Drug|LUM/IVA|LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
75879464|NCT02823470|Device|activated smart device|
75879465|NCT02823470|Device|de-activated smart device|
75879466|NCT04748510|Procedure|Functionally Aligned Total Knee Arthroplasty|Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
75728224|NCT00560508|Drug|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
75728225|NCT00560508|Drug|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
75728226|NCT05127759|Drug|HLX208|HLX208 450mg bid po
75728227|NCT00890864|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
76024843|NCT05228093|Procedure|Conservative treatment|"Debridement guided by nasopharyngeal endoscopy and excision of the radiation-induced necrotic tissues were performed every 1 or 2 weeks. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid. Other conservative treatment included daily nasopharynx rinsing with 2% aquae hydrogeniidioxide (5-10 mL each time) or saline (50-100 mL each time) and antibiotic therapy (metronidazole or ornidazole) guided by the culture results was also performed synchronously. Intravenous nutrition and systematic antibiotic therapy were also performed if indicated and necessary. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
76024844|NCT01980628|Drug|ibrutinib|
75728228|NCT00890942|Drug|naloxone|naloxone 0.4mg.(1 ml) intramuscular
75728229|NCT00890942|Drug|normal saline|normal saline 1 ml IM
75578896|NCT04674891|Other|Cervical Stabilization exercises|"Group B was experimental group and received baseline physiotherapy treatment in addition to Cervical Stabilization exercises. Pillow was placed beneath cervical spine in supine position and guided patients to nod head as though they said 'yes' and asked them to hold for 10 seconds. 10 repetitions were done before progressing to the next target level.~4 weeks (3 sessions per week)~Hot pack: 10 min~TENS: 10 min~Cervical isometric exercises in sitting (10sec hold,10 to 15 reps)~Cervical Stabilization exercises (10 sec hold, 10 reps)~On eligible participants baseline assessment was taken on day 1, post intervention assessment was taken at the end of 4th week."
75578897|NCT01185340|Drug|LY2216684|
75578898|NCT01185340|Drug|Placebo|
75578899|NCT01185340|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
75578900|NCT02910284|Biological|Observational|
75578901|NCT01959282|Drug|Placebo|Participants will receive placebo once daily
75578902|NCT01959282|Drug|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
76050239|NCT04038697|Procedure|Treadmill Training|Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
75578903|NCT01959282|Drug|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
75578904|NCT01959282|Drug|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
75432086|NCT05415787|Other|Urine sample|Urine sample is taken during the consultation carried out for the patient's care
75578905|NCT01959282|Drug|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
75578906|NCT01216189|Radiation|Preoperative radiotherapy|Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.
75578907|NCT02909738|Other|Volunteer to pedal a bicycle|
75578908|NCT04674696|Other|Approach|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
75728230|NCT05125887|Other|Questionnaire|Patients diagnosed positive for COVID on an outpatient basis will respond to a questionnaire by mail, at 24 month of diagnosis. This questionnaire will make it possible in particular to collect intercurrent events (hospitalization, emergencies, etc.).
75728231|NCT04037852|Device|robotic assisted nipple sparing mastectomy|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
76024845|NCT01255943|Behavioral|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
76024846|NCT04007705|Behavioral|Anti-inflammatory and low FODMAPs diet|Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
76024847|NCT04007705|Behavioral|General healthy eating|Healthy eating counseling according to the World Health Organization
75432087|NCT05415397|Drug|Celecoxib 400mg|Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
75432088|NCT05415397|Drug|Placebo|Placebo add-on to treatment as usual (standard antidepressant treatment)
75432089|NCT05414201|Drug|Adalimumab|Subcutaneous Injection
75432090|NCT05413733|Behavioral|Digital care pathway|"Sessions of the digital neuropsychological program:~Subjective functional ability and goals~Fatigue after ABI~Attention and concentration~Memory~Memory strategies~Working memory and executive functions~Emotional reactions~Summary and future goals"
75432091|NCT05413733|Behavioral|Care as usual|The standard care of patients with ABI including all necessary outpatient rehabilitation visits. Neuropsychological visits may include a short period of psychoeducation with a clinical neuropsychologist.
75432092|NCT05410288|Device|Acu-TENS|A TENS stimulator will be used (NeuroTrac TENS; Verity Medical Ltd., Wexford, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral SP6, PC6 and HT7) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
75578909|NCT02909699|Other|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
75578910|NCT01958853|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
76024848|NCT03978533|Behavioral|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
75432093|NCT05410288|Other|acupressure+SHP|Participants in the acupressure group will receive acupressure coupled with SHP. The acupressure protocol was developed based on a protocol recommended by a review and will comprise the following: (1) applying consistent finger-tip pressure of 3-5 kg, with rotational movements; (2) counterclockwise and then clockwise circular motions for 2.5-min each; (3) confirming the precision of the acupressure based on participants feeling pain, numbness, distension, or warmth at the point of application; and (4) an acupoint sequence from the leg to the head, first on the left side of the body and then on the right side of the body; and (5) a 5-min treatment on each acupoint (i.e., bilateral SP6, PC6, and HT7) in each 30-min session. The SHP is the same with Acu-TENS+SHP group.
75432094|NCT05410288|Other|placebo stimulation+SHP|Participants in the placebo stimulation + SHP group will receive 30-minute placebo stimulation from identical-looking TENS devices with the electrical circuit disconnected inside.
75728232|NCT04037852|Procedure|Endoscopic assisted nipple sparing mastectomy|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
75728233|NCT04037852|Procedure|Conventional nipple sparing mastectomy|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
75728234|NCT00941850|Procedure|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
76050240|NCT04819477|Behavioral|Fact box|"All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot."
76050241|NCT04819477|Behavioral|Cates plot|In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
76050242|NCT04818775|Device|HemaClear|HemaClear Model A
76050243|NCT04818775|Device|Pneumatic Tourniquet|Pneumatic Tourniquet
76050244|NCT04966273|Device|Microcatheter|Only to be used if Biosensor Microcatheter does not perform accordingly
75432095|NCT05410288|Other|sleep hygiene program(SHP)|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
75432096|NCT05397665|Drug|AT-007|AT-007, aldose reductase inhibitor
75432097|NCT05397665|Drug|Placebo|Liquid oral suspension
75432098|NCT05386810|Biological|Experimental vaccine|Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
75578911|NCT01185301|Biological|adalimumab|Pre-filled syringe every other week
75578912|NCT01185301|Drug|methotrexate|weekly oral capsule dosing
75578913|NCT02909855|Other|No intervention|Participants in this study will not receive any interventions as part of the study.
75578914|NCT01957722|Procedure|Microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
75578915|NCT01957722|Biological|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
75578916|NCT02909660|Other|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
75578917|NCT02909894|Other|Prolonged Sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow investigators to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. Following this, a lunch meal will be provided and investigators will continue taking blood samples and blood pressure at 30, 60, 120 and 180 minutes after this lunch meal. In total, 10 blood samples will be taken over the 7 ½ hour testing period. There will also be a cognitive test in the morning and afternoon.
75578918|NCT02909894|Other|Light arm ergometry breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of light intensity arm ergometry on a desktop arm ergometer every 30 minutes following breakfast and lunch. In total they will do 12 five minute arm ergometry breaks throughout the 7 ½ hour test period (60 minutes of arm ergometry in total). In total 10 blood samples will be taken on the day.
75578919|NCT01955616|Drug|RM-131|
75578920|NCT01955616|Drug|Placebo|
75578921|NCT02909621|Dietary Supplement|FLEXOFYTOL®|The product FLEXOFYTOL® is bio-optimized curcumin.
75578922|NCT02909621|Other|PLACEBO|
75578923|NCT04675008|Drug|Dacomitinib|Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
75578924|NCT02909543|Other|Observation and Interviwe|The research data will be conducted by using a semi structured interview of the participants in the study.
75578925|NCT01954173|Radiation|3D conformal radiation therapy|Undergo conformal radiation therapy
75578926|NCT01216072|Drug|Fingolimod|0.5 mg/day oral capsule
75578927|NCT01216072|Drug|Standard MS DMTs|
75578928|NCT02909582|Procedure|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
75728235|NCT04963179|Device|Womed Leaf|"Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated during approximately 5 days. It is degraded and discharged naturally through the cervix and vagina in less than 30 days."
75578929|NCT01940991|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
76050245|NCT05344105|Device|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
75578930|NCT01940991|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
75578931|NCT02909465|Drug|Midazolam|Using Midazolam as a premedication for reducing ketamine-induced agitation
75728236|NCT04938986|Diagnostic Test|IMMUNOSCORE®|recommendation for patient care according to the result of the IMMUNOSCORE®
75728237|NCT00942006|Drug|doxycycline|100 mg bid, 14 days
75578932|NCT02909465|Drug|Haloperidol|Using Haloperidol as a premedication for reducing ketamine-induced agitation
75578933|NCT02909465|Drug|placebo|distilled water
75578934|NCT02909465|Drug|Ketamine|Ketamine is routinely used for all procedural sedation in the patients.
75578935|NCT04312555|Drug|Alprostadil|Alprostadil intravenous administration. (0.5 mg/1ml of Alprostadil + 49cm saline 0.9%) and 4 cm direct intravenously / 8 hours
75578936|NCT04674579|Device|MRI|magnetic resonance imaging
75578937|NCT01184989|Drug|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
75578938|NCT02909192|Device|Light Therapy Device|
75578939|NCT04674423|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide treatment for 144 weeks
75578940|NCT02909387|Behavioral|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
75578941|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
75578942|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
75578943|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
75728238|NCT00942006|Drug|ceftriaxone|2g x 1 iv, 14 days
75728239|NCT00886418|Drug|muscle relaxant|muscle relaxant administration throughout anesthesia
75728240|NCT00886418|Drug|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
75728241|NCT00942240|Drug|ACU-4429|administered orally once a day for 14 days
75578944|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
75432099|NCT05386810|Biological|IPV control vaccine|Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
75432100|NCT05386810|Biological|single-person sIPV control vaccine|"Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd.~Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection."
75432101|NCT05376462|Diagnostic Test|Quantra System with the QStat Cartridge|Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.
75432102|NCT05376462|Diagnostic Test|Standard Laboratory Tests|Laboratory tests that provide information about a patient's coagulation status.
75432103|NCT05376345|Biological|LCAR-BCDR cells product|Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen
75432104|NCT05368090|Procedure|EUS-RFA of left adrenal gland|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
75578945|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
75578946|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
76050246|NCT04533373|Procedure|DIEP Flap Neurotization|"We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new source) that is being transferred and attaching it to a nerve in the chest wall."
76050247|NCT04018807|Other|Resource pamphlet|The pamphlet will list violence prevention, mental health, and substance abuse services.
76050248|NCT04018807|Behavioral|Remote Therapy|Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
75578947|NCT02909426|Device|Ultrasonography|Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
75578948|NCT02909426|Device|Digital mammography|Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
75578949|NCT00555867|Drug|Anastrozole|oral
75578950|NCT02909309|Device|JAWAC system + Capnoline + Spo2|measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
75578951|NCT01932099|Device|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
75578952|NCT03457376|Diagnostic Test|Hand Grip Force|Hand Grip Force
75578953|NCT03457376|Diagnostic Test|Maximal Inspiratory Pressure|Maximal Inspiratory Pressure
75578954|NCT03457376|Diagnostic Test|Maximal Expiratory Pressure|Maximal Expiratory Pressure
75578955|NCT00555945|Procedure|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
75578956|NCT00555945|Procedure|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
75578957|NCT02909270|Device|Mediclore|to apply mediclore fully around thyroid gland
75578958|NCT00555984|Drug|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
75578959|NCT00555984|Drug|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
75578960|NCT01917825|Drug|MDT-15|
75432105|NCT05368090|Procedure|adrenalectomy|Patients in the adrenalectomy group will be admitted in the Dept. of Endocrine surgery. They will undergo laparoscopic transabdominal total adrenalectomy according to routine. The patients will be monitored in the postoperative unit 4-6 hours before returning to the ward. If no complications occur, the patients are usually discharged day 2 after surgery.
75578961|NCT01912560|Drug|CAT-2003|
75432106|NCT05364788|Other|Retrospective tissue sample analysis|Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
75578962|NCT01912560|Drug|Placebo|
75578963|NCT01912560|Drug|Statin|All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
75578964|NCT01910025|Drug|ADI-PEG 20|
75578965|NCT03457337|Drug|S-1 plus Gefitinib|S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
75578966|NCT03457337|Drug|Gefitinib|Gefitinib: 250mg, 1 day, orally
75578967|NCT04674540|Other|No Intervention|No Intervention
75578968|NCT04674501|Procedure|Cardiac evaluation and blood sampling|"Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets."
75578969|NCT03455010|Other|Increased load|Participants walk with 120% body weight achieved with a weight vest
75578970|NCT03455010|Other|Reduced load|Participants walk with 80% body weight achieved by a dynamic unloading system
75578971|NCT05311280|Other|high intensity interval training plus myotherapy|"High intensity interval training (HIIT) has been proved its same effect on lower down body fat as moderate intensity continuous training (MICT). In addition, HIIT has the additional benefit of being a time-efficient program which can increase exercise adherence and the participants were more likely to intend to continue. Previous two studies show that HIIT could improve the severity of OSA in both obese adults and obese children.~Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas."
75578972|NCT05311280|Other|home exercise plus myotherapy|Home exercise: ambulation by patients themselves Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas.
75728242|NCT00942240|Drug|matching placebo tablet|administered orally once a day for 14 days
75728243|NCT05398185|Behavioral|WiseApp|The Intervention group will receive the WiseApp that delivers medication adherence reminders
75578973|NCT01908738|Drug|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
75578974|NCT01908738|Drug|10%lidocaine spray|
75728244|NCT02542124|Biological|NM-IL-12 and TSEBT|The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
75728245|NCT00942318|Drug|Detemir insulin, Aspart insulin, Metformin|Insulin doses adapted by patients according to self monitoring blood glucose results.
75728246|NCT04037618|Drug|[14C]-EYP001a|Oral drinking suspension
75728247|NCT00942396|Device|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
75728248|NCT00891098|Behavioral|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
75728249|NCT00891098|Behavioral|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
75728250|NCT04819269|Drug|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
75728251|NCT04819269|Drug|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
76024849|NCT03840707|Behavioral|LIFEwithIBD|"LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease"
75432107|NCT05345951|Behavioral|e-PBI+|The e-PBI+ is a preventive parent-based intervention emphasizing parent-teen communication on drinking/risks of alcohol abuse, with the addition of data-driven cannabis content to guide parent communications with their students (e.g., cannabis content focusing on the endocannabinoid system; acute and chronic cannabis use effects on the brain, cognition, and development; THC potency in present-day cannabis; cannabis use effects on mental and physical health, including psychosis, depression, and anxiety; respiratory/cardiovascular/sleep problems; cannabidiol (CBD) content, myths; and cannabis effects on psychosocial function). Together the goals are to reduce alcohol and cannabis use in college students.
75578975|NCT04673955|Drug|Encorafenib|Observation of real-life treatment with encorafenib and cetuximab
75578976|NCT04673955|Drug|Cetuximab|Observation of real-life treatment with encorafenib and cetuximab
75578977|NCT04673838|Other|neurodevelopmental therapy|Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
75578978|NCT04673838|Other|Lower extremity sensory training|Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
75578979|NCT05298293|Device|ONCOLAXY Follow-up|"The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard."
75578980|NCT01904409|Drug|Placebo|
75578981|NCT01904409|Drug|Rifaximin SSD 40 mg IR tablet|
75578982|NCT01904409|Drug|Rifaximin SSD 80 mg IR tablet|
75578983|NCT01904409|Drug|Rifaximin SSD 40 mg SER tablet|
75578984|NCT01904409|Drug|Rifaximin SSD 80 mg SER tablet|
75578985|NCT01904409|Drug|Rifaximin SSD 80mgIR/80mgSER tablet|
75578986|NCT02277158|Drug|Chemoradiotherapy|S-1 CCRT
75578987|NCT01902381|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
75578988|NCT04673916|Drug|Healing evaluation|Treatments were topically applied for 5 days
75578989|NCT05294276|Other|no intervention related|no intervention related
75578990|NCT01887366|Drug|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
75578991|NCT01887366|Drug|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
75578992|NCT01887366|Drug|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
75578993|NCT04674072|Other|Reverse Nordic curl exercise|The reverse Nordic curl is a body-weight exercise which mainly works the quadriceps and hip flexors. It has a large eccentric component, meaning the muscles are working whilst lengthening.
75578994|NCT04674072|Other|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
75728252|NCT00944580|Biological|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
75728253|NCT05280054|Drug|AV-101|360 mg capsules
75728254|NCT05280054|Drug|Probenecid|1000 mg oral
75578995|NCT04674150|Device|ARISE with AR|An augmented reality game for mobile devices with AR experiences enabled
75728255|NCT00891254|Device|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
75578996|NCT04674150|Device|ARISE without AR|An augmented reality game for mobile devices with AR experiences disabled as an control
75578997|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks
75879467|NCT04748510|Procedure|Mechanically Aligned Total Knee Arthroplasty|Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
75879468|NCT05238584|Procedure|Partial omentectomy|Partial omentectomy: with preservation of the greater omentum at >2 cm from the gastroepiploic arcade.
75879469|NCT04645862|Diagnostic Test|CT scans|4D CTA imaging
75879470|NCT03562910|Other|HelpSteps application|Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
75578998|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks
75578999|NCT01885260|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks
75579000|NCT01876719|Drug|AR08|
75579001|NCT01876719|Drug|Placebo|
75579002|NCT05285540|Drug|DT-216|DT-216 will be administered by intravenous (IV) injection
75579003|NCT05285540|Drug|DT-216 matching Placebo|Placebo will be administered by intravenous (IV) injection
75579004|NCT04673799|Drug|MV088 injection|MV088 injection (60mg) by subcutaneous injection once on the first day
75579005|NCT04673799|Drug|Prolia® injection|Prolia® injection (60mg) by subcutaneous injection once on the first day
75579006|NCT04673487|Diagnostic Test|1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test|Evaluation of 11 different Typhoid Rapid Diagnostic Tests that are commercially available internationally and use Blood culture as standard for comparison
75728256|NCT00942474|Device|Facilitate nerve stimulation lead placement with the nerve access tool|
75728257|NCT03999099|Drug|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
75579007|NCT01873677|Drug|M518101|
75728258|NCT03999099|Drug|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
75728259|NCT03999099|Drug|Placebo oral tablet|Placebo
75728260|NCT03962790|Device|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with a new manufacturing technology
75728261|NCT03962790|Device|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with the current manufacturing technology
75728262|NCT05323695|Behavioral|Depression Screening Intervention|All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
75728263|NCT04013022|Behavioral|Exercise History|The groups will be divided based on their exercise history
75579008|NCT01873677|Drug|Vehicle|
75579009|NCT05236400|Device|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.
75579010|NCT05236400|Procedure|Manual phlegm suction system|Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
75728264|NCT01007799|Dietary Supplement|vitamin D placebo|12 weeks of placebo
75728265|NCT01007799|Dietary Supplement|Vitamin D|12 weeks supplementation based on serum vitamin D levels
75728266|NCT01007877|Other|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
75728267|NCT00609518|Drug|pemetrexed|500 mg/m^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
75879471|NCT03562754|Procedure|reduced systemic heparin anticoagulation|receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
75579011|NCT04673526|Procedure|Laparoscopic intersphincteric resection|Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
75432108|NCT05345951|Behavioral|e-PBI|"The e-PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the e-PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
75432109|NCT05328440|Drug|Pyrotinib Maleate|once a day, 125mg each time, taking for 3 weeks, stopping for 1 week, 4 weeks as a cycle. It is recommended to take medicine at about the same time every day, take it with warm water, and fast at least 1 hour before and after taking medicine
75432110|NCT05328440|Drug|Dalpiciclib Isethionate Tablets|400mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 28 days as a cycle
75432111|NCT05328440|Drug|Inetetamab|the initial dose is 8mg / kg and the subsequent dose is 6mg / kg. It is administered intravenously for 21 days.
75432112|NCT05328440|Drug|Fulvestrant|fluvestrant is administered intravenously on the 1/15 day of the first cycle, and then on the first day of each cycle, 500mg / time, intravenously
75432113|NCT05304858|Procedure|Biopsy|Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
75432114|NCT05300087|Drug|Albuterol Sulfate Inhalation Aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
75432115|NCT05300087|Drug|Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation|MDI, 2 puffs, single dose, fasting
75579012|NCT04673526|Procedure|Laparoscopic abdomino-perineal procedures|Abdominoperineal resection + colostomy in left iliac fossa or perineum
75728268|NCT00609518|Dietary Supplement|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
75432116|NCT05296577|Drug|anlotinib and vinorelbine|anlotinib 12mg orally ,2 weeks on/1 week off ,Q3W; vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
75728269|NCT00609518|Dietary Supplement|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
75728270|NCT00609518|Dietary Supplement|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
75879472|NCT03562754|Procedure|Regional Citrate Anticoagulation|intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
75432117|NCT05296577|Drug|Vinorelbine injection|vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
75432118|NCT05296564|Drug|CYCLOPHOSPHAMIDE and FLUDARABIN|1. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
75432119|NCT05296564|Drug|Cyclophosphamide|CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
75432120|NCT05296564|Biological|HBI 0201-ESO TCRT|HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.
75432121|NCT05296564|Drug|Aldesleukin|Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
75432122|NCT05290025|Drug|Nicotine patch|> 20 cigarettes per day: 21 mg nicotine/ 24 hours 10-20 cigarettes per day: 14 mg nicotine/ 24 hours 5-10 cigarettes per day: 7 mg nicotine/ 24 hours
75432123|NCT05290025|Drug|Nicotine gum|Nicotine chewing gum will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 chewing gums per day
75432124|NCT05290025|Drug|Nicotine lozenge|Nicotine lozenges will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 lozenges per day
75579013|NCT01215955|Drug|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
75579014|NCT01215955|Drug|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
75579015|NCT01873404|Drug|BG00010|As specified in the treatment arm
75579016|NCT01873404|Drug|Placebo|As specified in the treatment arm
76050249|NCT04830787|Other|no intervention|there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
76050250|NCT04018729|Device|Zephyr Endobronchial Valve|Endoscopic lung volume reduction therapy.
75432125|NCT05290025|Behavioral|Smoking cessation counselling|Once a week patients are asked about progress in cessation attempt. Sigaretts smoked the last week are recorded. Goal is set for the next week. Information on typical nicotine withdrawal symptoms and ameliorating techniques.
75432126|NCT05290025|Other|Screening for use of tobacco products|At the initiation of the trial screening questions about cigarett use for the last day and week.
75432127|NCT05290025|Other|Screening for interest in smoking cessation|At the initiation of the trial all smoking participants are asked if the are interested in changing their smoking habits. They are given three alternatives: will make cessation attempt; will make reduction attempt; not certain.
75432128|NCT05284045|Other|Detailed information|Subjects in this arm will receive usual information + detailed information on side effects
75432129|NCT05274321|Device|Nanodropper|Device used for administering eye drops
75728271|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
75432130|NCT05274321|Device|Standard Eye Dropper|Standard Eye Dropper used for administering eye drops
75879473|NCT02259920|Drug|KUC 7483 CL, immediate release tablet|
75579017|NCT05212220|Behavioral|EMA-based intervention|A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
75579018|NCT05212220|Behavioral|EMA-based intervention|Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
75579019|NCT04677270|Behavioral|Digital problem solving tool|Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
75579020|NCT02887105|Other|Standard neuropsychological assessment|
76050251|NCT04018729|Biological|Marrow-derived mesenchymal stromal cell|Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
75432131|NCT05259475|Other|Lifestyle Advice|Maintain a weekly healthy diet and regular exercise.
75432132|NCT05259475|Other|Diet Intervention|Calorie-restricted meals (lunch and dinner)
75432133|NCT05259475|Other|OCFA Meal-Based Diet-Intervention|OCFA-containing food product
75432134|NCT05255835|Device|Semiconductor Knee Sleeves|semiconductor elements germanium and carbon within the cotton fabric
75432135|NCT05255835|Device|Cotton Knee Sleeves (Placebo)|cotton fabric knee sleeves
75432136|NCT05252429|Drug|Docetaxel|Docetaxel 75mg/m2; q21
75579021|NCT02887105|Other|Brain MRI|
75579022|NCT01871415|Drug|aleglitazar|150 mcg orally daily
76050252|NCT04817371|Device|Volatile Organic Compounds analysis (e-noses)|VOC analysis in exhaled air with e-noses.
76050253|NCT04817371|Other|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
76050254|NCT04817371|Device|Volatile Organic Compounds analysis (mass spectrometry)|VOC analysis in exhaled air with mass spectrometry.
76050255|NCT04817371|Device|Volatile Organic Compounds analysis in sweat (mass spectrometry)|VOC analysis in sweat with mass spectrometry.
76050256|NCT05408533|Device|2-Way Foley Urethral Urinary Catheter|Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
75579023|NCT01871415|Drug|metformin|pre-existing background regimen and dose
75579024|NCT01871415|Drug|placebo|matching aleglitazar placebo orally daily
76050257|NCT04001647|Drug|Acetylcholine|Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
76050258|NCT04001647|Drug|Sodium Nitroprusside|Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
76050259|NCT04001647|Drug|Ascorbic Acid|The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
75432137|NCT05252429|Drug|Pembrolizumab|Pembrolizumab 200mg, q21
75432138|NCT05249309|Drug|Ketamine|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
75879474|NCT02259920|Drug|KUC 7483 CL, particulate formulation|
75432139|NCT05224271|Other|Electronic Health Record Review|Medical records are collected
75432140|NCT05224271|Other|Medical Device Usage and Evaluation|Fitbit information is collected
75432141|NCT05224271|Other|Survey Administration|Complete surveys
75432142|NCT05220202|Behavioral|Behavioral Intervention Group (MOTIVATE)|Behavioral: Behavioral Intervention Group (MOTIVATE) The behavioral intervention is designed for older Veterans with musculoskeletal pain and depression and will include 8 individual telephone sessions delivered by health coaches (for up to 5 months total), accounting for additional time between sessions (if needed).
75432143|NCT05199480|Other|Tobacco flavored liquid type 1|A commercially available cartridge-based device with tobacco flavored liquid.
75432144|NCT05199480|Other|Tobacco flavored liquid type 2|A commercially available cartridge-based device with tobacco flavored liquid.
75432145|NCT05198336|Biological|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
75579025|NCT05189717|Drug|HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus|During HRS-8080 monotherapy period, the dose of HRS-8080 would be increasing. In the combination therapy period, HRS-8080 will be administered at flat dose of RP2D-1 and RP2D.
75579026|NCT05182463|Drug|Peginterferon Alfa-2B|Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
75579027|NCT05182463|Drug|Nucleoside Analogs|Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
75728272|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
75879475|NCT02259920|Drug|KUC 7483 CL, solution formulation|
76050260|NCT04419571|Procedure|Emergency Laparotomy|All adult patients undergoing emergency laparotomy
75579028|NCT04673643|Device|Transcutaneous Auricular Vagus Nerve Stimulation|to use taVNS to treat Reflux Esophagitis
75728273|NCT01008033|Drug|IDP-108|Topical application once a day for 48 weeks
75728274|NCT01008033|Drug|Vehicle|Topical application once a day for 48 weeks
75728275|NCT01008111|Drug|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
75879476|NCT02259920|Device|Enterion™ capsule|
75879477|NCT04353674|Device|Control group|Patients randomized into this group will receive standard of care for COVID-19 infection
75879478|NCT04353674|Device|SLEDD with a L-MOD|Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
75879479|NCT01371656|Drug|levofloxacin|Given PO or IV
75579029|NCT05125484|Other|experimental Bowen Technique|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
75579030|NCT05125484|Other|Experimental Myofacial release technique|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
75579031|NCT04673097|Other|Icon® resin infiltration|low viscosity resin that can flow through the pores in the enamel surface
75579032|NCT04673097|Other|MI paste plus|s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
75579033|NCT05108129|Procedure|M-TAPA block|"After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25% bupivacaine will be injected between the transversus abdominis muscle and the lower aspect of the costal cartilage. The same procedure will be repeated on the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
75579034|NCT05108129|Procedure|OSTAP block|"The patients will receive oblique subcostal TAP block in the supine position immediately after the endotracheal intubation. The anesthesiologist of the operating room will place the ultrasound with a linear probe subcostally and from the xiphoid to the right iliac crest obliquely. Rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin. The needle will be directed to the transversus abdominis fascia. Local anesthetic solution of 25 ml 0.25% will be injected to between rectus abdominis and transversus abdominis muscles along the oblique subcostal line. The same procedure will repeated to the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
75579035|NCT01854294|Drug|GM604|GM604 treated group subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
75579036|NCT01854294|Drug|Placebo comparator|Placebo comparator group subject will receive a slow IV bolus injection (~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
75579037|NCT02277197|Drug|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)"
75879480|NCT01354106|Device|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
76024850|NCT03670121|Device|Bronchoscopic Thermal Vapor Ablation (BTVA)|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
76024851|NCT04435925|Drug|Remifentanil|Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
76024852|NCT04435925|Drug|Fentanyl|Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
76024853|NCT03648281|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
76024854|NCT01979614|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
76024855|NCT01979614|Other|Placebo|5% v/v glucose solution
76024856|NCT05205707|Diagnostic Test|ACE serum levels|Circulating ACE2 level will be measured
75432146|NCT05193019|Other|Parenteral antiplatelet agents|Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice
75432147|NCT05186337|Behavioral|FROA-BD programme|The experimental group (n=42) will receive a 4-month intervention consisting of 32 sessions of treatment.
75432148|NCT05176964|Radiation|split-course HFRT|7Gy/F, d7, q3w, 5 cycles
75432149|NCT05176964|Drug|CAPOX chemotherapy|CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
75579038|NCT02277197|Drug|Cetuximab|"Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended."
75579039|NCT00555087|Drug|Testosterone Undecanoate and/or PDE-5|Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
75579040|NCT04672902|Procedure|Single-operator cholangioscopy guided electrohydraulic lithotripsy|Single-operator cholangioscopy guided electrohydraulic lithotripsy has the advantage of providing direct visualization of the bile ducts, enabling a single physician to diagnose and perform the therapeutic intervention in a single procedure.
75432150|NCT05176964|Drug|Tislelizumab|Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
75879481|NCT01354028|Other|Massage therapy|An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
75432151|NCT05174702|Radiation|Irradiation collected at the end of the operation on the active dosimeter|Mesure of the irradiation collected at the end of the operation on the active dosimeter for the surgeon, the patient and the operating team
75432152|NCT05150028|Behavioral|Patient participation|Questionnaire
75432153|NCT05150028|Other|Clinician barrier reports|How many times a 7 question Survey on medication education practices is opened
75432154|NCT05149040|Other|"survey Intensive care of very elderly: What do they wish for themselves?"|self-administered mailed survey
75432155|NCT05136287|Drug|GLP-1 receptor agonist|Patients are included after GLP1 agonists prescription , at the first dispensation
75579041|NCT04673253|Other|Passive leg Raise|The intervention will be performed immediately after spinal anesthesia, and passive leg raise will be performed using two standard pillows placed under the heel so that the leg is approximately 30 cm above the horizontal plane of the table. The passive leg raising position will continue until the cord is clamped.
75879482|NCT03065582|Other|Topical Product A|topical application sunscreen containing topical antioxidants and sunscreen filters
75879483|NCT03065582|Other|Topical Product B|topical application of product A without topical antioxidants
75432156|NCT05116644|Other|NONE - this is a cross-sectional survey design|NONE - this is a cross-sectional survey design
75879484|NCT03065582|Other|Topical Product C|Topical application of antioxidants only
76050261|NCT04490161|Other|intravenous reinstallation of cerebrospinal fluid|10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
75432157|NCT05095571|Dietary Supplement|EH301 (Nicotinamide Riboside/Pterostilbene)|For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
75432158|NCT05090111|Drug|ALG-055009|Single or multiple doses of ALG-055009
75432159|NCT05090111|Drug|Placebo|Single or multiple doses of Placebo
75432160|NCT05077098|Drug|ADXS-504|ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
76050262|NCT04923997|Behavioral|Health Coaching|6 months of integrative health coaching, goal setting, survey administration and physical assessments.
76050263|NCT04829461|Device|Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal|Procedure using a single-use cystoscope for stent removal
75432163|NCT05063916|Drug|AK104|Given By IV
76050264|NCT04829461|Device|Standard of care reusable cystoscope used for stent removal|Procedure using a reusable cystoscope for stent removal
76050265|NCT03876457|Device|Endovascular Thrombectomy|Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
75432164|NCT05034458|Dietary Supplement|Crohn's disease exclusion diet|Patients will receive, in addition to their normal treatment, polymeric formula + diet
75432165|NCT05017025|Drug|Aurora A Kinase Inhibitor LY3295668|Given PO
75432166|NCT05017025|Drug|Osimertinib|Given PO
75432167|NCT05003739|Procedure|Hip arthroplasty with Logica Mirror femoral stem|Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
75579042|NCT04673253|Other|control|The controlled group was positioned in the normal supine position.
75579043|NCT05096897|Other|Self-administrated questionnaires|GOHAI, IBD-Q, IBD-disk
75579044|NCT04673214|Drug|Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
75579045|NCT04673214|Drug|Azithromycin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
75579046|NCT04672473|Biological|DC-CTL|DAC combined with Ag-CTL
75579047|NCT05040113|Drug|CBP-307|CBP-307 capsules oral administration
75579048|NCT01845987|Drug|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
75579049|NCT01845987|Drug|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
75579050|NCT00556023|Drug|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
75432168|NCT04992208|Biological|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
75432169|NCT04987320|Drug|Olpasiran|Subcutaneous injection
75432170|NCT04979728|Other|At Home Self-Collections|Directly observed at home self-collection of blood samples
75579051|NCT05011214|Drug|Sevoflurane|All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
75879485|NCT03065582|Other|Control|No product applied
75432174|NCT04966000|Behavioral|Prism Adaptation Therapy|Participants wear goggles with built-in prisms (a 20-diopter lens) that shift the visual scene to the right. While wearing the googles they reach to and cross out 60 lines/circles, requiring them to learn to reach more leftward than the visual targets appear. Participants can only see the end of their movements.
75432175|NCT04959240|Drug|Velmanase Alfa|
75432176|NCT04941664|Drug|0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELVA90) of cases of the aforementioned local anesthetic (LA), in order to produce the surgical anesthesia of the patients scheduled for shoulder surgeries. Based on the principal investigator's clinical experience, the initial volume of 8ml will be used. Depending on the success or failure of the superior trunk block, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 2ml. The upper dose limit of the study to minimize the potential for local anesthetic systemic toxicity will be 16ml and the lower dose limit will be 4ml, which will be of no clinical importance."
75432177|NCT04918420|Device|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
75879486|NCT04541888|Drug|CsA Ophthalmic Gel|The CsA eye gel of 0.3 g: 0.15 mg
75579052|NCT05011214|Drug|Esketamine|All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
75579053|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
75579054|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
75579055|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
75579056|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
75579057|NCT04672668|Diagnostic Test|duplex ultrasound for the common femoral artery|duplex ultrasound for the common femoral artery before and after the angiography
75579058|NCT04676841|Device|Conventional ventilation + instrumental tables with integrated laminar airflow|Surgical instruments protected from contamination by local laminar airflow
75579059|NCT04676841|Device|Conventional ventilation + standard instrumental tables|Control
75579060|NCT04676841|Device|Laminar airflow ventilation + standard instrumental tables|Control
75579061|NCT04949438|Drug|AZD4831|Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
75579062|NCT04676763|Drug|Substance P|Participants will receive Substance P
75579063|NCT04676763|Drug|Normal Saline|Participants will receive normal saline as Negative control
75579064|NCT04676763|Drug|Histamine|Participants will receive histamine as Positive control
75579065|NCT04944563|Procedure|Segmentectomy|Patients receive segmentectomy
75579066|NCT04944563|Procedure|Lobectomy|Patients receive lobectomy
75579067|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|32 mg
75579068|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|48 mg
75579069|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|64 mg
75728276|NCT01008111|Drug|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
75728277|NCT00886496|Biological|recombinant human mannose-binding lectin|
75728278|NCT00884858|Drug|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
75579070|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|80mg
75579071|NCT04932083|Drug|Bupivacaine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added."
75579072|NCT04932083|Drug|Fentanyl|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added."
75579073|NCT04932083|Drug|Nalbuphine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added."
75579074|NCT04932083|Drug|Midazolam|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added."
75579075|NCT04672629|Device|echocardiography|follow up echocardiography
75579076|NCT00555126|Device|Forced Air Warming|Warming after Randomization
75579077|NCT00555126|Device|Warming with endovascular catheter + forced air warming|Warming after Randomization
75728279|NCT05272293|Biological|NK cell infusions|Three doses of expanded haploidentical NK cells (30-100 x 10^6 cells /kg).
75728280|NCT00891332|Drug|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
75728281|NCT02541344|Device|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
75728282|NCT02541344|Device|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
75879487|NCT04541888|Drug|Placebo|Placebo
75879488|NCT04541888|Drug|Hypromellose Eye Drop|Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
75879489|NCT01354964|Drug|Vitamin D|
75879490|NCT01354964|Drug|Placebo|
75879491|NCT03562676|Other|weightlessness|parabolic flight
75879492|NCT02673476|Drug|ALS-008176|ALS-008176 tablets
75579078|NCT04920071|Device|Visual acuity and contrast sensitivity measurement|Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
75579079|NCT04672785|Behavioral|SF36 questionary|patients who underwent a posterior fossa craniectomy for a cerebellar hematoma at Grenoble University Hospital between 01/01/2010 and 01/01/2020 were enrolled in this study. The main objective is to assess the level of disability and the quality of life of patients who have had a posterior cranial fossa craniectomy.
75879493|NCT02673476|Drug|Placebo|Identical placebo tablets
75579080|NCT01825980|Drug|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
75579081|NCT01825980|Drug|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
75728283|NCT02541344|Device|Placebo|"Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102."
75579082|NCT01825980|Drug|Placebo|Placebo
75579083|NCT04672200|Other|Group exercise|Weekly group exercises delivered online and face to face
75579084|NCT04676685|Drug|E2730|E2730 capsules.
75579085|NCT04676685|Drug|E2730-matched placebo|E2730-matched placebo capsules.
75579086|NCT04672317|Drug|Immunotherapy combined with chemotherapy|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
75579087|NCT04791878|Drug|Mesenchymal stem cells|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
75579088|NCT04672278|Dietary Supplement|Shanzha Fruit drink or placebo drink|The dosage of Shanzha fruit drink or the placebo is 3 cans per day
75728284|NCT00609362|Drug|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
75728285|NCT00609362|Drug|Placebo pill|One encapsulated placebo pill a day for 14 weeks
75728286|NCT02541266|Other|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
75728287|NCT05278832|Drug|QLS31905|QLS31905 injection
75728288|NCT00886574|Drug|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
75728289|NCT00886574|Drug|Aspirin|100 mg once a day
75879494|NCT01354496|Drug|LY2409021 Reference Form|Administered orally
75879495|NCT01354496|Drug|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
75879496|NCT01354496|Drug|LY2409021 Test-High Formulation (high particle size)|Administered orally
75432178|NCT04911790|Biological|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
75432179|NCT04899908|Radiation|Stereotactic Radiation|Focused radiation beams to treat tumors
75432180|NCT04899908|Drug|AGuIX gadolinium-based nanoparticles|Intravenous injection
75432181|NCT04899908|Other|Placebo|Intravenous infusion
75432182|NCT04890002|Device|Far-infrared emitting pyjamas|Clothing made in far infrared (FIR) - based textiles could be a sustainable way for alleviating sleep problems with many advantages. Firstly, the proposed far infrared textiles are made of man-made profiled fibers without the addition of chemicals such as ceramic additives or other related coatings.
75879497|NCT01354496|Drug|LY2409021 Test-Low Formulation (low particle size)|Administered orally
76024857|NCT04649476|Drug|Camrelizumab|The participants will receive camrelizumab (200 mg) intravenous infusion each 2-week cycle for 3 cycles prior to surgery.
76024858|NCT04649476|Drug|Camrelizumanb plus TPF|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
76024859|NCT04671784|Other|EUS-E|EUS-E
75579089|NCT04676568|Procedure|Extravesical VVF repair|Both standard transvesical and extravesical approach for VVF repair will be utilised
75579090|NCT04676295|Behavioral|Face-to-face and web-based lifestyle intervention|Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.
75728290|NCT00886652|Other|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
75728291|NCT00891566|Procedure|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
75728292|NCT00885014|Behavioral|CBT|Telephone cognitive-behavioral therapy
75728293|NCT00885014|Behavioral|EAP|Employees Assistance Program
75728294|NCT00611858|Drug|Cetuximab|
75728295|NCT00611858|Drug|5-Fluorouracil|
75728296|NCT00611858|Radiation|Radiation|
75728297|NCT00137449|Drug|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
75728298|NCT00886730|Behavioral|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
75879498|NCT04164134|Other|blood draw|"Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible."
75432183|NCT04890002|Device|Sham-pyjamas|The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function.
75432184|NCT04888858|Drug|Epidural analgesia (0.125% bupivacaine/2mcg fentanyl solution)|As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
75432185|NCT04873687|Device|External Counter Pulsation (ECP) therapy|ECP therapy consist of 36 session, each session @1 hour/day, five days a week with initial pressure of 300mmHg
75432188|NCT04859842|Other|Pulse Electromagnetic Field|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with PEMF in prone position. Each session will be 45 minute long with a 15 minute PEMF therapy and a 30 minute conventional therapy program.
75432189|NCT04859842|Other|Interferential Current|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with Interferential current in prone position. Four interferential electrode will be placed on low back region. Each session will be 45 minute long with a 15 minute interferential current and a 30 minute conventional therapy program.
75432190|NCT04859842|Other|Sham|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with conventional therapy and sham electrotherapy. Sham application will be performed on prone position with four electrodes and electrodes will stay for 15 minutes on this region.
75432191|NCT04854291|Other|Administration of donor FMT|Intracaecal infusion of FMT
75579091|NCT01655225|Drug|LY3023414|Administered orally. Dose of 20 to 600 mg, as determined in Part A.
75579092|NCT01655225|Drug|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
75579093|NCT01655225|Drug|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
75579094|NCT01655225|Drug|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
75579095|NCT01655225|Drug|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
75879499|NCT02259998|Drug|Persantin® new formulation|
75432192|NCT04854291|Other|Administration of placebo|Intracaecal infusion of carrier solution
75432193|NCT04837716|Biological|Bevacizumab|Given IV
75432194|NCT04837716|Drug|Carboplatin|Given IV
75432195|NCT04837716|Drug|Ensartinib|Given PO
75432196|NCT04837716|Drug|Pemetrexed|Given IV
75432197|NCT04823650|Device|COHORT A: Actigraph|The ActiGraph CentrePoint Insight Watch is a small worn activity monitor designed for documenting physical movement associated with applications in physiological monitoring.
75579096|NCT01655225|Drug|Abemaciclib|Administered orally
75579097|NCT01655225|Drug|Letrozole|Administered orally
75579098|NCT00555165|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
75579099|NCT03457298|Device|Ossix Volumax|Ossix Volumax is intended to be used for Lateral ridge augmentation
75579100|NCT03457298|Device|FDBA with collagen membrane|freeze-dried bone allograft (FDBA) with collagen membrane
75579101|NCT04759625|Other|Novel biscuit enriched with mushroom powder containing 3g of β-glucans|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
75579102|NCT04759625|Other|Placebo biscuit|Daily consumption of placebo biscuit
75579103|NCT04671888|Other|exercises|COPD patients will be asked to wear a data logger system to collect EMG data and respiration parameters during exercise that simulate daily activity (i.e., walking, cycling)
75579104|NCT04722653|Drug|NNC0194-0499|1 single dose administered subcutaneously (s.c. - under the skin)
75579105|NCT04722653|Drug|Placebo (NNC0194-0499 )|1 single dose administered subcutaneously (s.c. - under the skin).
75579106|NCT01818921|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
75579107|NCT01818921|Drug|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
75579108|NCT01818921|Drug|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
75579109|NCT04700345|Device|Onyx|Embolization of the Middle Meningeal Artery using the liquid embolic material
75579110|NCT04700345|Procedure|Burr-hole|Burr-hole drainage of subdural hematoma
75879500|NCT02259998|Drug|Persantin® commercial formulation|
75879501|NCT04009460|Drug|ES101|ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
76024860|NCT05117957|Drug|Sorafenib|Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
75579111|NCT04700345|Other|Medical Management|best medical management
75579112|NCT01815450|Drug|BLI1100|BLI1100 topical cream
76050266|NCT03876457|Other|Medical Management|Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
76050267|NCT04193917|Diagnostic Test|Conjunctival swab|A conjunctival swab of both eyes will be taken at the same time together with an extensive questionnaire.
75432198|NCT04823650|Device|Panoramic Bracelet and GENEActiv|"Panoramic Bracelet:~The Panoramic Digital Health Bracelet is a wearable inertial measurement unit intended for use by researchers and healthcare professionals for high frequency or continuous collection of physical data in home and professional healthcare settings during research studies. It includes a 3 axis accelerometer and gyroscope, as well as magnetometer, pressure, and temperature sensors. The bracelet has no interface or screen for participants to interact with.~GENEActiv:~The GENEActiv device is a wearable inertial measurement unit designed for public health research and clinical trials. The device is a circular unit with attachable wrist-bands, and has no interface or screen for participants to interact with. The GENEActiv device is FDA 510(k) exempt. The device records acceleration data and can collect data remotely for up to 1 month."
75432199|NCT04803734|Drug|Albuterol Sulfate inhalation aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
75879502|NCT02035826|Behavioral|Behavioral Economics Intervention|Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
76050268|NCT04828681|Diagnostic Test|Cardiac magnetic resonance imaging|Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.
75432200|NCT04803734|Drug|Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation|MDI, 2 puffs, single dose, fasting
75432201|NCT04799964|Device|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
75432202|NCT04799964|Device|Tubridge (MicroPort)|Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.
75432203|NCT04784247|Drug|Lenvatinib|20mg daily (two 10mg lenvatinib capsules) taken orally
75432204|NCT04784247|Drug|Pembrolizumab|(200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
75432205|NCT04771650|Other|CAMI|The CAMI is a culturally adapted motivational interview. It is a single 75 minute session that focuses on promoting motivation to change drinking and drug use behavior.
75579113|NCT01815450|Drug|BLI1100 - modified formulation|BLI1100 topical cream
75579114|NCT01815450|Drug|Placebo|Placebo topical cream
75579115|NCT01810575|Drug|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
75579116|NCT01810575|Drug|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
75579117|NCT01810575|Drug|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
75579118|NCT04671524|Other|Exercise protocol|a combination of stretching, range of motion, and strengthening exercise.
75579119|NCT04671849|Drug|SIM1803-1A|SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.
75579120|NCT04664777|Device|Masimo Model RDS7A|Masimo monitoring platform equipped with Radical-7 Pulse CO-Oximeter fingertip probe for measurement non-invazive hemoglobin level (SpHb) an perfusion index (PI)
75579121|NCT01785771|Drug|ITCA 650 (exenatide in DUROS)|
75579122|NCT04664582|Procedure|Sentinel Lymph Node Biopsy|see intervention group description
75579123|NCT04671537|Drug|Preloading with crystalloid fluid|crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
75579124|NCT00556101|Procedure|Whole body magnetic resonance angiography|
75579125|NCT04620356|Device|DryNites Pyjama Pants|DryNites Pyjama Pants are disposable, absorbent youth pants designed to help children manage bed wetting by absorbing involuntary urine loss and protecting the child's garments and bedding. DryNites Pyjama Pants are underwear-like alternatives that can be discreetly worn beneath pyjamas or nightwear during the bedwetting phase.
75579126|NCT01784874|Biological|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
75579127|NCT01784874|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
75579128|NCT01784133|Drug|omiganan|
75579129|NCT01784133|Drug|placebo|
75579130|NCT04607252|Drug|Metformin plus Megestrol acetate|metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
75728299|NCT00886730|Behavioral|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
75728300|NCT00886730|Behavioral|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
75432206|NCT04766073|Procedure|Niche prevention suture|This group will have the uterus sutured in two layers using a new technique.
75432207|NCT04763161|Procedure|Decompressive hemicraniectomy|Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident
75432208|NCT04763161|Procedure|neurosurgical operation|neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
75579131|NCT04607252|Drug|Megestrol Acetate|megestrol acetate 160mg per day, oral
75579132|NCT01782729|Drug|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
75579133|NCT04671264|Device|Sallowing VC during six weeks|"follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl)."
75579134|NCT04671303|Drug|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
75579135|NCT01780428|Drug|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
75579136|NCT01780428|Drug|Placebo|
75579137|NCT04578392|Procedure|high ligation of ileocolic artery|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
75579138|NCT04578392|Procedure|mesenteric sparing|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
75579139|NCT04671420|Drug|HLX01|Patients will receive HLX01 intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
75579140|NCT04671420|Drug|Mabthera®|Patients will receive Mabthera® intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
75579141|NCT04573556|Drug|Lemborexant|Lemborexant oral tablets.
75432209|NCT04730570|Behavioral|Essential Coaching for Every Mother|Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
75728301|NCT00886808|Drug|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
75432210|NCT04714086|Drug|Avapritinib|Avapritinib will be administered orally at 300 mg QD.
75728302|NCT00891644|Other|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
75579142|NCT04671108|Device|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
75579143|NCT04573166|Procedure|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation|After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
75728303|NCT00891644|Other|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
75728304|NCT00891644|Other|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
75579144|NCT01779453|Drug|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
75579145|NCT01779453|Drug|Placebo|Placebo once daily for 8 weeks
75728305|NCT00886886|Drug|MDMA|125 mg, single dose
75728306|NCT00886886|Drug|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
75728307|NCT00886886|Drug|Placebo|capsules identical to MDMA or Reboxetine
75879503|NCT02035904|Drug|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
75579146|NCT01779453|Drug|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
75879504|NCT02035904|Drug|saline|patient controlled infusion from the 2nd day after surgery
75879505|NCT02035904|Drug|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
75879506|NCT02035904|Device|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
75728308|NCT04036760|Behavioral|Research transitional care coordination|Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
75728309|NCT04036916|Other|Virtual Reality Sensorimotor Training|Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
75579147|NCT04687982|Biological|modified donor lymphocytes infusion (mDLI)|"The planned number of mDLI is 3.~Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
76050269|NCT04828369|Procedure|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|(1) Standard diagnostic endoscopy was first performed. Fundal varices were assessed using the classification of Sarin's. (2) intraluminal water filling of the gastric fundus to use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. (3) Punctured the gastric fundal variceal vein at the lower esophagus near the cardia and placed the coil into the shunt and immediately injected with sclerosant and cyanoacrylate under the guidance of EUS. (4) Sclerosant and cyanoacrylate were injected into the gastric fundal varices by a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. (5) After the injection, use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
75579148|NCT04671147|Procedure|Preoperative traction|Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
75728310|NCT00891722|Other|biologic sample preservation procedure|
75728311|NCT00891722|Other|laboratory biomarker analysis|
75879507|NCT02035904|Drug|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
75432211|NCT04681287|Drug|inetetamab and PD-1 inhibitor combined with chemotherapy.|"Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued."
75432212|NCT04681131|Biological|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
75432213|NCT04681131|Biological|PD-1 inhibitor|PD-1 inhibitor
75432214|NCT04645277|Device|Scanning with magnetic resonance imaging|Facial nerves and adjacent blood vessels are scanned using MRI in the patients with hemifacial spasm (HFS). Then multiplanar reconstruction (two dimensional), along with curved planar reconstruction and magnetic resonance virtual endoscopy (three dimensional), will be performed in the different groups of HFS.
75432215|NCT04641741|Drug|Mepolizumab 100 MG|Discovery of predictive/prognostic biomarkers of response to mepolizumab using flow cytometry, transcriptomic, and proteomic technologies.
75579149|NCT04571723|Behavioral|Diabetes Prevention Program|This is the established Diabetes prevention program curriculum.
75432216|NCT04626141|Drug|Abaloparatide|Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
75432217|NCT04626141|Drug|Placebo|Placebo will be dispensed as a 30-day supply of disposable pen injections.
75432218|NCT04625959|Behavioral|Behavioral Therapy for Eating Disorders|Change behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
75579150|NCT04571723|Behavioral|Health Mindset modified diabetes prevention program|This is the established diabetes prevention program curriculum with the addition of curriculum focused on the role of mindset in health.
75728312|NCT00891722|Other|questionnaire administration|
75728313|NCT00891800|Device|Brachytherapy|SIR-Sphere contains radiation of Y-90.
75728314|NCT00891800|Device|SIR-Sphere|Brachytherapy Radiation seeds
75728315|NCT00886964|Biological|Intradermal HBV 1 course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
75879508|NCT02035904|Drug|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
75879509|NCT04110080|Procedure|multimodal pain management|Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.
75432219|NCT04625959|Behavioral|MABT: Mindful Awareness|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically mindful awareness, designed to enhance self-regulation. Mindful awareness strategies include developing inner and outer wisdom, formal meditation, and shifting awareness to the present moment. Mindful awareness skills also include increasing awareness of thoughts, feelings, physical sensations, and hunger and fullness cues.
75579151|NCT01776606|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
75579152|NCT01776606|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
75579153|NCT04670952|Other|Low Pressure Laparoscopic Cholecystectomy|Low Pressure Laparoscopic Cholecystectomy (10mmHg) is set as the experimental group.
76050270|NCT04828369|Procedure|balloon-occluded retrograde transvenous obliteration|(1)A balloon occlusive catheter was inserted into the shunt via the right femoral vein. (2)Investigators performed angiography to evaluate the size and location of GV and the shunt during balloon occlusion. Shunt was occluded by Fogarty balloon. The diameter of the balloon was chosen according to the diameter of shunt. (3)Then investigators injected sclerosant into the portosystemic shunt. (4)Finally, the balloon left in place for 24 hours was gradually deflated when complete occlusion of blood flow of the target shunt was achieved.
75579154|NCT04670952|Other|Standard Pressure Laparoscopic Cholecystectomy|Standard Pressure Laparoscopic Cholecystectomy (14mmHg) is set as the control group.
75579155|NCT01774578|Drug|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
76050271|NCT04408729|Other|PrEP My Way|"Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, and 6 via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 6 and as needed (e.g., treatment for positive tests).~This intervention aims to increase adherence/persistence on PrEP. We hypothesize that removing the structural barriers and stigma associated with going to the clinic, women may be more likely to continue on PrEP."
75432220|NCT04625959|Behavioral|MABT: Values|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically values, designed to enhance self-regulation. Values skills include identifying and clarifying values, living a values life, making values-consistent decisions, addressing competing values, values awareness, and using values to address negative moods.
75432221|NCT04625959|Behavioral|MABT: Emotion Modulation|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically emotion modulation, designed to enhance self-regulation. Emotion modulation skills include long-term habits for emotion regulation, coping strategies, crisis management, and cognitive reappraisal.
75579156|NCT01774578|Biological|HyperAcute®-Lung Immunotherapy|"HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells."
75728316|NCT00886964|Biological|Intramuscular HBV I course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
75728317|NCT00887042|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, & -6)
75579157|NCT01774578|Drug|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
75579158|NCT01774578|Drug|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
75728318|NCT00892112|Drug|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
75728319|NCT00892112|Drug|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
75728320|NCT00887120|Drug|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|"BW 6-7.9 kg: 1.5 mL oral q 12 hr~BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~BW > 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
75728321|NCT00887120|Drug|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|"BW 6-7.9 kg: 1.0 mL oral q 12 hr~BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~BW > 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
75579159|NCT04545593|Behavioral|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) was designed to provide a single, integrated program that could address the dual challenges of mental health and disability among minority elders. PMSB-E seeks to improve mood symptoms, identify and correct negative distortions or cognitions, promote behavioral activation through engaging the participant in pleasant activities, and encourage developing supportive relationships. All sessions are tailored to the participant's needs using a collaborative approach.
75579160|NCT04545593|Behavioral|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. Research staff will call the participant 4 times over the course of 6 months to administer mental health items, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group.
75728322|NCT00892190|Drug|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
75432222|NCT04625959|Behavioral|MABT: Distress Tolerance|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically distress tolerance, designed to enhance self-regulation. Distress tolerance skills include psychological acceptance, uncoupling, willingness, and dealing with dirty distress.
75432223|NCT04613440|Other|Family Letter (Standard of Care)|The family letter is given to probands in the standard of care arm and provides information on the familial mutation and serves to encourage first degree relatives to complete genetic testing.
75432224|NCT04613440|Other|Educational Video|The educational video is provided by the clinical genetic testing laboratory and explains the importance and implications of genetic testing. This educational video is shared with first degree relatives in the intervention arm
75728323|NCT00892190|Drug|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
75728324|NCT00887276|Drug|Moxifloxacin|"intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~20 ml physiologic saline solution (placebo) (over 30 min)~20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2 capsules Placebo~2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days"
75432225|NCT04613440|Other|Mailed Saliva Kit for Genetic Testing|The FDR's email will be sent to the genetic testing lab, Invitae, which will allow them to log on to the online portal, create a unique account, and order a genetic testing saliva kit free of charge. The FDR will receive the kit and instructions in the mail. The FDR will collect the saliva sample and send the sample back to the genetic testing laboratory.
76050272|NCT04402489|Drug|Placebo|Placebo
75432226|NCT04613440|Other|Telephone Counseling|The FDR's will be contacted and receive post genetic testing phone counseling
75432227|NCT04609852|Drug|E8001|Intravenous infusion.
75879510|NCT04110080|Other|goal directed fluid management|Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.
75879511|NCT04110080|Other|preoperative carbohydrate loading|Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.
75879512|NCT04110080|Procedure|Donor nephrectomy|All patient will have laparoscopic nephrectomy procedure with transplant surgery.
75879513|NCT04110080|Procedure|regional anesthesia|transabdominal plane and rectus sheath nerve block
75879514|NCT03562520|Behavioral|Behavior change counseling|"Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers."
75879515|NCT02035982|Drug|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
75879516|NCT02035982|Drug|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
75879517|NCT05707832|Drug|Amphotericin B cholesteryl Sulfate Complex for Injection|Intravenous injection (IV), once a day after reaching the recommended dose of 3.0-4.0 mg/kg for treatment. Subjects will receive ABCD intravenous therapy for at least 2 weeks, and the longest course of treatment will not exceed 6 weeks.
75879518|NCT02822222|Drug|Magnesium citrate, tribasic anhydrous soft gelatin capsule|110 mg elemental magnesium/capsule
75432228|NCT04609852|Drug|Placebo|Intravenous infusion.
75879519|NCT02822222|Drug|Placebo soft gelatin capsule|0 mg elemental magnesium/capsule
75879520|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
75432229|NCT04603495|Drug|Pelabresib|"Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF."
75728325|NCT00887276|Drug|Ampicillin;Amoxicillin|"intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~2 capsules Amoxicillin (0,5 g)~2 capsules Amoxicillin (0,5 g)~2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days"
75728326|NCT00528879|Drug|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
75728327|NCT00528879|Drug|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
75728328|NCT00528879|Drug|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
75879521|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
75879522|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
75879523|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
75579161|NCT01756482|Drug|GS-5806|GS-5806, powder for oral solution
76050273|NCT04402489|Drug|MT-7117 Low Dose|MT-7117 Low Dose
76050274|NCT04402489|Drug|MT-7117 High Dose|MT-7117 High Dose
75579162|NCT01756482|Drug|Placebo|
75579163|NCT04543994|Drug|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
75579164|NCT04543994|Drug|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
75432230|NCT04603495|Drug|Ruxolitinib|Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
75432231|NCT04603495|Drug|Placebo|Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
75579165|NCT04543994|Other|Placebo|Normal saline
75579166|NCT04519697|Drug|Mesenchymal Stem Cells|Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.
75579167|NCT04519697|Other|Placebo|Normal Saline
75579168|NCT04670601|Drug|Flurbiprofen Test 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
75579169|NCT04670601|Drug|Flurbiprofen Reference 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
75728329|NCT00608894|Drug|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
75728330|NCT00608894|Drug|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
75879524|NCT02821910|Drug|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
76050275|NCT04827199|Device|Artificial Urinary Sphincter implantation|"Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~Perineal approach and bulbar urethral dissection~Inguinal approach~Cuff implantation around the urethra~Transmission cable passing~Surgery test procedure~Implantation of the Control Unit~Closure of the inguinal incision~Closure of the perineal incision~Implant disabled mode activation"
76050276|NCT04399369|Device|SDF|38% silver diamine fluoride solution
76050277|NCT04399369|Device|NaF|5% sodium fluoride varnish
75432232|NCT04597619|Other|Novel Nonopioid Pathway|The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
75728331|NCT00892268|Procedure|acupuncture therapy|Undergo acupuncture
75728332|NCT00892268|Procedure|pain therapy|Receive standard care
75728333|NCT00892346|Procedure|Single ASCT with Thalidomide maintenance|"Single ASCT with Thalidomide maintenance:~Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)"
75728334|NCT00892424|Drug|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
76050278|NCT04840147|Device|JointRep®|JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.
75432233|NCT04593940|Drug|Infliximab|study drug or matching placebo
75432234|NCT04593940|Drug|Abatacept|study drug or matching placebo
75432235|NCT04593940|Drug|Remdesivir|Standard of Care
75432236|NCT04593940|Drug|cenicriviroc (closed to enrollment as of 3-Sep-2021)|study drug or matching placebo
75579170|NCT04670913|Drug|Camrelizumab|A human anti-PD-1 monoclonal antibody
75579171|NCT04670913|Drug|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
75579172|NCT04671069|Drug|MGL-3196|Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
75579173|NCT04671069|Drug|Clopidogrel|After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
75579174|NCT04374539|Biological|Plasma exchange|"Plasma exchanges with 5% human albumin and fresh frozen plasma in patients with quick <50% or only with 5% albumin in patients with quick of 50% or more. We will exchange between 1.2 and 1.5 plasma volumes, that will vary according to sex, weight, height and hematocrit.~Polyclonal immunoglobulin will be administered at a dose of 100 mg / kg ev after each plasma exchange.~Standar Medical treatment Kaletra:~lopinavir/ritonavir: 2c/12h 7 days~Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~Tocilizumab 400 mg (weight <75Kgs) or 600 mg (weight ≥ 75 Kg)~Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~Clexane 40-60 mg/d"
75879525|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
75879526|NCT03819452|Diagnostic Test|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
75579175|NCT04374539|Drug|Standar medical treatmen|"Kaletra: lopinavir/ritonavir: 2c/12h 7 days~Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~Tocilizumab 400 mg (weight <75Kgs) or 600 mg (weight ≥ 75 Kg)~Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~Clexane 40-60 mg/d"
75879527|NCT05707910|Biological|EBV immunological agent|Low-dose group:2*10^7 Medium-dose group:5*10^7 High-dose group:2*10^8
75879528|NCT05707676|Drug|LB4330|LB4330
76050279|NCT04840147|Procedure|Microfracture|Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
76050280|NCT04419415|Dietary Supplement|Breakfast with high protein dairy|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.
76050281|NCT04419415|Other|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
75579176|NCT01753167|Drug|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
75579177|NCT01753167|Drug|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
75579178|NCT01753167|Drug|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
76050282|NCT04419415|Other|Skipping breakfast|Participants will be asked to skip breakfast.
76050283|NCT04815109|Other|Encephalography measurement|Encephalography measurement and partially aggravated sedation.
76050284|NCT01999335|Drug|Oprozomib|Extended release (ER) tablets administered orally
75579179|NCT01741194|Drug|AC-1204|AC-1204 taken once daily, by mouth
75728335|NCT02541032|Procedure|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
75728336|NCT02541032|Procedure|Standard dental treatment|Supragingival mechanical scaling and polishing.
75879529|NCT03972956|Other|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
75879530|NCT02817776|Device|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
75579180|NCT01741194|Drug|Placebo|Placebo taken once daily, by mouth
75579181|NCT04363346|Drug|FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
75579182|NCT04670718|Device|Optical Coherence Tomography Probe|Use of OCT probe for examination of gastrointestinal tract
75579183|NCT04332458|Behavioral|A focus group interview|this is a qualitative study using focus group interviewing.
75579184|NCT01823016|Drug|Placebo|Placebo tablet, taken once daily
75579185|NCT01823016|Drug|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
75579186|NCT04670211|Device|maxillary distractor|the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor
75728337|NCT02541032|Drug|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
75728338|NCT00557856|Drug|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
75728339|NCT00892502|Drug|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
75879531|NCT03138655|Drug|Vedolizumab|Vedolizumab IV infusion.
75879532|NCT02036138|Procedure|Laparoscopic Sleeve Gastrectomy|
75879533|NCT02036138|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
76050285|NCT01999335|Drug|Pomalidomide|Capsules for oral administration
76050286|NCT01999335|Drug|Dexamethasone|Tablets for oral administration
76050287|NCT01978119|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
76050288|NCT01978119|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
75432237|NCT04584294|Behavioral|MyPath Web-Based Informational and Decision Support Tool|"The MyPath Decision Support Tool includes the following sections and features:~Questions to capture reproductive goals and orientations towards a potential pregnancy~Education modules about the menstrual cycle, fertility, and prepregnancy health with the opportunity to flag topics that are relevant and of interest to the patient~A contraceptive decision module that provides education, elicits patient preferences about different aspects of contraception, and suggests methods most appropriate based on the patient's preferences~A feature for adding free-text questions that patients may have for their provider~An email with a summary page that the patient can bring to a visit to guide discussions with primary care providers about reproductive needs"
75432238|NCT04566900|Behavioral|Neurofeedback|Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
75579187|NCT04322123|Drug|Hydroxychloroquine Oral Product|Hydroxychloroquine 400 mg BID
75579188|NCT04322123|Drug|Hydroxychloroquine + azithromycin|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
75579189|NCT04670328|Diagnostic Test|not required|Diagnostic tests( hematological parameters) were assessed.
75579190|NCT04670367|Behavioral|Walk 30mins|aerobic exercise
75579191|NCT04670367|Behavioral|Walk plus Baduanjin|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
76050289|NCT01999179|Drug|Heparin, Low-Molecular-Weight, or direct oral anticoagulants|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
76050290|NCT01977729|Drug|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
76050291|NCT01977729|Behavioral|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
75579192|NCT04670367|Other|usual care|routine care
75728340|NCT00892502|Drug|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
75728341|NCT01008189|Behavioral|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
76050292|NCT01998477|Biological|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain [A/H1N1-like, A/H3N2-like, and B-like]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
76050293|NCT01998477|Biological|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain [A/ H1N1-like, A/H3N2-like, and B-like]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
76050294|NCT01998399|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
76050295|NCT01998399|Drug|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
76050296|NCT01781572|Drug|LEE011|LEE011 will be administered orally once daily
76050297|NCT01781572|Drug|MEK162|MEK162 will be administered orally twice daily
76050298|NCT01998243|Device|Intragastric Balloon (IGB), group A|the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
76050299|NCT01998243|Other|diet, control group B|the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
75432239|NCT04566900|Other|Placebo|Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
75432240|NCT04562831|Dietary Supplement|EH301 (Nicotinamide Riboside/Pterostilbene)|Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.
75579193|NCT04670367|Behavioral|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
75728342|NCT01008189|Behavioral|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
75728343|NCT00885404|Drug|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
75728344|NCT00892580|Drug|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
75728345|NCT00191113|Drug|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
75728346|NCT00191113|Drug|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
76050300|NCT01977573|Drug|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
76050301|NCT01977573|Drug|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
75432241|NCT04548648|Drug|Acalabrutinib|Acalabrutinib at 100 mg is taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
75432242|NCT04548648|Drug|Isavuconazole|Prophylactic treatment with isavuconazole includes loading dose of 372 mg (2 capsules) administered orally every 8 hours for 6 doses (48 hours), followed by maintenance administration of 372 mg (2 capsules) once daily as long as the subject is on study treatment.
75432243|NCT04544111|Drug|Trametinib|"2mg by mouth daily~*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube"
75432244|NCT04544111|Drug|Dabrafenib|150 mg twice daily (OR at dose the patient previously tolerated)
75432245|NCT04544111|Drug|PDR001|400mg IV every 4 weeks
75728347|NCT00191113|Drug|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
75728348|NCT00608582|Device|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
75432246|NCT04539483|Drug|HDIT101 (blinded therapy)|Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
75432247|NCT04539483|Drug|Placebo (blinded therapy)|Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
75432248|NCT04539483|Behavioral|Photo documentation of orolabial herpes lesions|Patients will be asked to document their orolabial lesions with photos by using their smart phone
75432249|NCT04539483|Behavioral|Completion of questionnaires (patient-reported outcomes)|Patients will be asked to document their health status in questionnaires by using their smart phone
75879534|NCT02036138|Drug|Advanced Medical Therapy|
75879535|NCT03562442|Behavioral|Smoking cessation|Smoking cessation with or without professional / medical support
75432250|NCT04539483|Procedure|28-day swabbing of orolabial region|Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions
75432251|NCT04539483|Procedure|Blood drawings|Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
75432252|NCT04531969|Other|Spa therapy and conventional physical therapy|"HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day."
75432253|NCT04524208|Drug|Cabozantinib|Cabozantinib is administered orally at the dose of 60 mg per day..
75432254|NCT04522739|Drug|Spironolactone|The initial dose of spironolactone will be 25mg and will be increased to 50 mg after 2 weeks provided the following criteria are present: 1) systolic blood pressure (SBP) >110 mm Hg, 2) diastolic blood pressure (DBP) > 60 mm Hg, and no reported symptoms of hypotension (dizziness or weakness). Participants will take one capsule by mouth per day.
75432255|NCT04522739|Drug|Placebo|A placebo to match spironolactone will be taken orally once per day.
75432256|NCT04522336|Drug|Docetaxel|Given IV
75432257|NCT04522336|Drug|Fluorouracil|Given IV
75579194|NCT04313348|Behavioral|eMobilize-Uganda application|"Arm 1 is the Control arm. Participants will receive no SMS reminders nor social supporter notifications. Arm 2, Scheduled SMS arm: Will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda CommCare application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery will be sent to participants. The content of the SMS reminders will be customized at enrolment. Arm 3 social support engagement arm: Will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information through the eMobilize-Uganda CommCare application or messaging + weekly SMS reminders + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for all the study follow-up period."
75579195|NCT04670289|Drug|TenoMiR (Low Dose)|Mimic of miR29a
75579196|NCT04670289|Drug|TenoMiR (Medium Dose)|Mimic of miR29a
75579197|NCT04670289|Drug|TenoMiR (High Dose)|Mimic of miR29a
75579198|NCT04670289|Drug|Placebo|0.9% saline
75579199|NCT04259138|Biological|Treatment Algorithm A|"Participants who are treatment-naïve at randomization will follow treatment algorithm A. Participants, upon entry into the study, will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (with optional oral corticosteroid in combination) will be initiated.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
75432258|NCT04522336|Drug|Oxaliplatin|Given IV
75432259|NCT04522336|Biological|Pembrolizumab|Given IV
75579200|NCT04259138|Biological|Treatment Algorithm B|"Participants who are taking non-biologic UC therapies at randomization will follow treatment algorithm B.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
75579201|NCT04259138|Biological|Treatment Algorithm C|"Participants who are taking anti-TNF, tofacitinib or ustekinumab therapy at randomization will follow treatment algorithm C.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
75579202|NCT01741155|Drug|SPI-1620|SPI-1620 11 μg/m2 administered intravenously over one minute.
75879536|NCT05707520|Drug|enteric-coated mycophenolate (MPAs)|Immunosuppression protocol with enteric-coated mycophenolate sodium
75432260|NCT04522336|Radiation|Radiation Therapy|Receive radiation therapy
75432261|NCT04517487|Biological|Vaginal Microbiome Transplantation (VMT)|Healthy donors vaginal fluid is introduced into recipients' vagina to replace their indigenous disease-associated microbiome
75432262|NCT04517487|Biological|Placebo|Placebo
75579203|NCT01741155|Drug|Docetaxel|Docetaxel: 75 mg/m2 administered as IV infusion.
75432263|NCT04517370|Device|Fractional/Pixel CO2 laser|"The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation)."
75432264|NCT04487041|Biological|Standard dose influenza vaccination|Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle
75432265|NCT04487041|Biological|High dose influenza vaccination|4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle
75432266|NCT04478708|Biological|AMG 133|Participants will receive AMG 133 as a single dose in Part A and multiple doses in Part B and C.
75432267|NCT04478708|Drug|Placebo|Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
75432268|NCT04478006|Genetic|RNA-seq|Gene expression and fusion transcripts analysis
75432269|NCT04478006|Genetic|whole exon sequencing|Genetic alternation analysis
75432270|NCT04478006|Other|Cytogenetics test|Remission and relapse are monitored by cytogenetic analyses.
75879537|NCT05707520|Drug|None MPA|Immunosuppression protocol without enteric-coated mycophenolate sodium
75432271|NCT04461899|Biological|Blood test|additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
75432272|NCT04455048|Other|Cervicothoracic thrust manipulation|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.
75432273|NCT04455048|Other|Cervicothoracic thrust manipulation sham|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
75432274|NCT04442828|Diagnostic Test|Use of 3D echocardiography in patient follow-up|Patients will undergo clinical and echocardiographic examination including detailed 3D echocardiography at study inclusion and at least one follow-up visit.
75432275|NCT04419818|Behavioral|Virtual Reality|Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Participants will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.
75432276|NCT04402346|Procedure|Radiofrequency-assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a radio frequency device
75432277|NCT04402346|Procedure|Stapler assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a stapler device with/without seamguard
75432278|NCT04397484|Drug|0.5% Levobupivacaine|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
75579204|NCT04244630|Combination Product|Antioxidants|Over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses
75579205|NCT04670406|Behavioral|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
75579206|NCT04239053|Drug|Bupivacaine|Measuring the plasma concentration level of bupivacaine after applying ESPB
75879538|NCT04412785|Drug|Cyclosporine|• The initial dose will be 9 mg/kg/day oral divided q12h. For IV, the dose will be 3mg/kg/day by continuous IV infusion.
75879539|NCT03689101|Procedure|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
75579207|NCT04670250|Diagnostic Test|non invasive markers|non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
75579208|NCT00556179|Drug|Lactoserum (Dermacyd Femina®)|Once a day during three months
75579209|NCT04687592|Procedure|reduction and fixation|"Reduction: one trial of closed reduction under anaesthesia and image control. Open reduction will be done by anterolateral or lateral approach if closed reduction failed~Fixation: internal fixation of the fracture by appropriate implant according to the fracture state"
75579210|NCT01718145|Drug|Daclatasvir|
75728349|NCT03965052|Drug|PRO 179|"Generic name: Travoprost~Distinctive denomination: Bristrio® (PRO-179)~Active principles: Travoprost 0.004%.~Pharmaceutical form: Ophthalmic solution~Presentation: multi-dose dropper bottle, 2.5 milliliters.~Prepared by: Sophia Laboratories, S.A. of C.V.~Description of the solution: transparent solution, free of visible particles.~Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
75879540|NCT02820038|Behavioral|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
75879541|NCT02820038|Behavioral|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
75879542|NCT02820038|Behavioral|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
75579211|NCT01718145|Drug|Asunaprevir|
75579212|NCT01718145|Drug|Ribavirin|
75579213|NCT01718145|Biological|pegIFNα-2b|
75579214|NCT01718145|Drug|Telaprevir|
75579215|NCT04687748|Device|Electromographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength. Electromyographic biofeedback is a specific form of biofeedback. The device records muscle activity through application of vaginal probe will be inserted in vagina and the reference surface electrode would be placed over the right anterior superior iliac spine.
75579216|NCT04687748|Other|PFM exercises|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds. Three attempts would be made with 40 seconds rest in between each contraction. The exercises would be performed with the patient initially in supine position, with hip and knee flexed at 30 and 90 degrees.
75579217|NCT00556257|Drug|Cyclosporine|Standard of care
75579218|NCT00556257|Drug|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
75728350|NCT03965052|Drug|Travatan 0.004 % Ophthalmic Solution|"Generic name: Travoprost~Distinctive denomination: Travatan®~Active ingredients: Travoprost 0.004%~Pharmaceutical form: Ophthalmic solution.~Presentation: multi-dose dropper bottle, 2.5 milliliters.~Prepared by: Alcon Laboratories Inc.~Description of the solution: transparent solution, free of visible particles.~Consult information to prescribe."
75579219|NCT04687787|Other|Core Stabilization exercises|. Each session will be given for 40 mins (20 mins for TENS and 20 Mins for exercise) Core Stability Exercises include Kegel Exercises, Modified V-sit, opposite Arm Leg Raise, Seated Side bends poses, Dumbell Side bends and Pelvic Tilt. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
75579220|NCT04687787|Other|Routinely prescribed exercises|Each session will be given for 40 mins ( 20 mins for TENS and 20 Mins for exercise Routinely prescribed exercises composed of Hamstring stretches, hip flexor stretches, hip extensor stretches, calf stretches, and back extensor stretches. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
75579221|NCT01712451|Drug|salmeterol xinafoate, fluticasone propionate|LIPO-102
75579222|NCT01712451|Drug|Placebo|Placebo
75579223|NCT01712451|Drug|salmeterol xinafoate|Salmeterol
75579224|NCT00541268|Device|ICD|Intracardioverter defibrillators from 2 different manufacturers
75579225|NCT00541268|Other|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
75579226|NCT01712217|Drug|AT13387|HSP90 inhibitor
75728351|NCT05265117|Procedure|HIPEC|HIPEC is given after primary or interval debulking surgery.
76024861|NCT04671628|Behavioral|Relaxing music|Participants will be asked to listen to relaxing music for 30 minutes each day. They will allowed to choose between several playlists based on their preference.
76024862|NCT04671238|Device|SPECT CT|SPECT/CT scan of the spine as part of a vertebroplasty
76024863|NCT02654717|Drug|DFD-07 Cream|
76024864|NCT02654717|Drug|Placebo Cream|
75579227|NCT01712217|Drug|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
75579228|NCT04046237|Other|Periodontal treatment|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
75579229|NCT00555243|Procedure|Laparoscopic Simulation training|five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
75579230|NCT00555243|Procedure|Traditional Surgical Education|Traditional surgical teaching (no simulator)
75579231|NCT04014764|Other|This is a non-interventional study|N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
75579232|NCT04669821|Drug|HSK3486|Loading Dose：0.1 mg/kg，Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
75579233|NCT04669821|Drug|Propofol|Loading Dose：0.5 mg/kg，Maintenance Dose：Maintenance is started at1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5mg/kg/h.
75579234|NCT04670055|Drug|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
75579235|NCT00532025|Drug|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
75579236|NCT04669119|Dietary Supplement|Bromelain/Boswellia Serrata Casperome|Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
75579237|NCT04669119|Dietary Supplement|Centella Asiatica/Vitamins|Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
75579238|NCT04669119|Dietary Supplement|Placebo|Placebo
75579239|NCT04669080|Behavioral|Health care provider cost navigation training|Health care providers and asthma educators in a pediatric asthma clinic will receive an online training about the importance of cost of care conversations, how to start cost of care conversations with families, how to refer families to cost navigation resources, and how to lead asthma specialty care teams in cost navigation.
75579240|NCT03954080|Device|Intraspinal-optimal stim therapy|During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
75432279|NCT04397484|Drug|2% Xylocaine with adrenaline 1:200,000|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
75432280|NCT04396600|Behavioral|MinnRAP Peer Support Program|"The behavioral intervention consists of 1) pairing healthcare workers into Battle Buddies who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals."
75432281|NCT04372641|Drug|p97 Inhibitor CB-5339 Tosylate|Given PO
75432282|NCT04352296|Procedure|Individualized blood pressure|Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit
75432283|NCT04352296|Procedure|Standard blood pressure|Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure <140 mm Hg, and treatment of hypertension defined by a systolic blood pressure > 180 mm Hg or diastolic blood pressure >105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
75579241|NCT04669353|Drug|Platelet rich plasma|approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.
75432284|NCT04313881|Drug|Magrolimab|Administered intravenously
75432285|NCT04313881|Drug|Azacitidine|Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
75432286|NCT04313881|Drug|Placebo|Placebo to match magrolimab administered intravenously
75432287|NCT04304911|Behavioral|Blended intervention (UP-APP)|Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP)
75432288|NCT04304911|Behavioral|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
75432289|NCT04288635|Biological|Whole blood samples|Whole blood samples at admission, from day one to three after admission
75432290|NCT04262843|Drug|Cyclophosphamide|Given IV
75579242|NCT00532064|Procedure|Biospecimen Collection|Undergo collection of blood
75579243|NCT00532064|Other|Questionnaire Administration|Ancillary studies
75579244|NCT04669977|Dietary Supplement|Mulberry juice|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. Also, a reminder of the next clinical visit is attached. They are expected to finish the mulberry juice in 10 to 11days instead of 12 days.
75579245|NCT04668807|Device|Connected Medical Device|Monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) with a Connected Medical Device (DMC) in the operating room
75579246|NCT04668807|Device|Traditional transmission system|Monitoring of physiological parameters with a traditional wired transmission system between the sensor and the data processing device in the operating room
75579247|NCT03849248|Other|Maternal scent cloth|The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
75432291|NCT04262843|Drug|Fludarabine|Given IV
75432292|NCT04262843|Drug|Fludarabine Phosphate|Given IV
75432293|NCT04262843|Biological|Granulocyte Colony-Stimulating Factor|Growth factor therapy
75432294|NCT04262843|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
75432295|NCT04262843|Procedure|Intensity-Modulated Radiation Therapy|Undergo TMLI
75432296|NCT04262843|Drug|Mycophenolate Mofetil|Immunosuppressive therapy
75432297|NCT04262843|Drug|Tacrolimus|Immunosuppressive therapy
75432298|NCT04215679|Other|Three-dimensional immersive virtual reality application|In this group, individuals will be included in a game program that will last for 3 days a week for a total of 6 weeks and 45 minutes a day. Individuals will use the IVR to rehabilitate functions that are frequently used in daily life through task-oriented games. The IVR device will be placed on the head of the individual by closing the eyes of the individual and the Leap Motion device will be used to enable individuals to see their own hands in a virtual reality environment. In order to ensure the safety of individuals, practices shall be carried out with the individual sitting in the chair and leaning against the back. A total of 3 different games will be used for upper extremity function, each game will be 15 minutes and the total session time will be 45 minutes.
75432299|NCT04215679|Other|Motor imagery|Motor imagery will be performed with the eyes closed. In addition, for the safety of the individual, the individual will sit comfortably in a chair in a quiet environment and sit back. In the motor imagery group, individuals will be shown videos of the 3 games for 2 times in the IVR group and will be asked to imagine that they perform the same functions in the IVR games. The motor imagery will be 3 days a week for a total of 6 weeks and 45 minutes per day (including rest periods).
75432300|NCT04215679|Other|Conventional physiotherapy|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
75432301|NCT04185935|Other|Biospecimen Collection|Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
75432302|NCT04185935|Other|Questionnaire Administration|Ancillary studies
75432303|NCT04150497|Biological|UCART22|Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
75579248|NCT04669392|Drug|70% Ethanol Alcohol|"Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time."
75879543|NCT01348867|Other|Structured care led by a nurse consultant|"For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit."
75432304|NCT04150497|Biological|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
75432305|NCT04116723|Device|Flexible brace|Participants will be invited to undergo a fitting session of a flexible brace. After the fitting session, participants will join a two-hours wear trial of the flexible brace. Participants are required to wear the brace for two-hours and undergo assessments before and after the wear trial. The measurement outcomes of the assessment include 1) X-ray scan, 2) 3D body scan, 3) garment pressure, and 4) questionnaire.
75432306|NCT04116164|Drug|111In-DOTA-h11B6|4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
75879544|NCT01352611|Drug|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
75432307|NCT04112173|Behavioral|perturbation-based fall-recovery training|Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
75579249|NCT00532142|Drug|Intravitreal Triamcinolone|
75579250|NCT00532142|Procedure|Radial Optic Neurotomy|
75579251|NCT00532142|Other|Placebo - Sham Intravitreal Injection|
75579252|NCT04668963|Device|MIRROR THERAPY|patients were seated on a chair, with the mirror positioned between the upper limbs perpendicular to the subject's midline and with the unaffected upper limb facing the reflective surface. Following the physiotherapist indications, the patients observed the reflection of their unaffected limb while performing the following movements with the both arms, the affected one as good as possible: flexion and extension of the shoulder, elbow, wrist and finger, prone supination of the forearm.
75579253|NCT04865627|Device|activity monitor|Both groups will wear three different activity monitors for one week. There is one observation moment which consists of four minutes lying, sitting, standing, walking and taking stairs. Participants will be filmed during this moment.
75728352|NCT03964974|Behavioral|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
75879545|NCT01352689|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
75579254|NCT04775264|Procedure|Pulsed Electric Field Ablation|catheter ablation of ganglionated plexi structures on the epicardial surface of the heart during cardiothoracic surgery
75879546|NCT01352689|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
75879547|NCT03688399|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
75879548|NCT03688399|Device|IOL implantation comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
75879549|NCT01357213|Drug|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
75879550|NCT01357213|Other|Placebo|Normal saline 100 ml
75879551|NCT01348945|Other|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
75879552|NCT01357291|Behavioral|Recidivism Reduction Program|Assigned to the 21-module Recidivism Reduction Program
75879553|NCT01357291|Behavioral|Business-as-usual|Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
75432308|NCT04091295|Drug|DeltaRex-G|Intravenous infusions of DeltaRex-G for treatment of advanced pancreatic cancer and sarcoma that have failed standard therapies
75432309|NCT04074746|Biological|Anti-CD30/CD16A Monoclonal Antibody AFM13|Given IV
75879554|NCT01352767|Device|InsuPad|Heating pad
75879555|NCT02819804|Drug|Dasatinib|Given PO
75879556|NCT02819804|Other|Laboratory Biomarker Analysis|Correlative studies
75879557|NCT02819804|Biological|Nivolumab|Given IV
75879558|NCT02819804|Other|Pharmacological Study|Correlative studies
75432310|NCT04074746|Drug|Cyclophosphamide|Given IV
75432311|NCT04074746|Drug|Fludarabine|Given IV
75432312|NCT04074746|Drug|Fludarabine Phosphate|Given IV
75432313|NCT04074746|Biological|Genetically Engineered Lymphocyte Therapy|Given AFM13-NK cells IV
75432314|NCT04053075|Other|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
75579255|NCT04669626|Other|Use of Ocetnilin|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~Removal of old dressing~Applying a soaked gaze with Octenilin® on the wound (5 minutes)~Mechanical debridement if necessary~Wound cleansing with Octenilin®~Application of new dressing (according to the wound healing phases, medical prescription)"
75879559|NCT02819726|Biological|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
75728353|NCT03964974|Behavioral|Sleep Hygiene Education (SHE)|The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
75879560|NCT02819726|Biological|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
75879561|NCT02819726|Biological|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
75879562|NCT02816138|Drug|Nicotine|Open-label transdermal nicotine patch
75879563|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
75879564|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d|Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
75432315|NCT04053075|Other|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
75879565|NCT02815670|Drug|Idarucizumab|
75879566|NCT02037152|Behavioral|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
75879567|NCT02036918|Drug|Sipuleucel-T|
75879568|NCT02036918|Procedure|Lymph Node Biopsy|
75432316|NCT04038619|Procedure|Fecal Microbiota Transplantation|Undergo FMT via colonoscopy
75432317|NCT04038619|Drug|Loperamide|Given PO
75432318|NCT04033497|Device|MRI|Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
75879569|NCT02809976|Drug|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
75879570|NCT02036528|Drug|Gentamicin Topical Gel|
76050302|NCT01963767|Drug|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract*~Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
76050303|NCT01963767|Dietary Supplement|Placebo|
75432319|NCT04031560|Behavioral|Integrative treatment|The experimental group (62 patients) will take part on the integrative group program consisting of 12-sessions, 90 minutes each, once a week (4 focused on psychoeducation, 1 directed to the family relatives, 3 on mindfulness and 4 on functional remediation)
75432320|NCT04030507|Device|MRI|MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
75879571|NCT02036528|Drug|Ciprofloxacin|
75432321|NCT03987386|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75879572|NCT02036528|Drug|Doxycycline|
75879573|NCT02047682|Behavioral|Biopsychosocial|
75879574|NCT02047682|Behavioral|Reference|
75879575|NCT02880865|Biological|Live attenuated SA 14-14-2 Japanese Encephalitis vaccine|Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
75879576|NCT02880865|Biological|Measles, mumps, rubella vaccine|Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
75579256|NCT04669626|Other|Use of NaCl 0.9%|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~Removal of old dressing~Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~Mechanical debridement if necessary~Wound cleansing with NaCl 0.9% solution~Application of new dressing (according to the wound healing phases, medical prescription)"
75579257|NCT04669470|Procedure|bariatric endoscopy, mainly intragastric baloons, plication of stomach too|bariatric endoscopy, mainly intragastric baloons, plication of stomach too
75579258|NCT04669431|Other|Xbox kinect Training|Xbox kinect 360, Tennis player, Joy riding, Rally ball. Tennis player in first 2 weeks, Joy riding in 3rd and 4th weeks, and all 3 games in 5th and 6th weeks 35 minute/3 days a week for 6 weeks with Conventional physical therapy, 25 minute
75728354|NCT00892658|Drug|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
75879577|NCT01352923|Other|blood test|preparation of blood platelets
75432322|NCT03987386|Other|Quality-of-Life Assessment|Ancillary studies
75432323|NCT03987386|Other|Questionnaire Administration|Ancillary studies
75432324|NCT03987386|Radiation|Radiation Therapy|Undergo conventional radiation therapy
75432325|NCT03983577|Other|Point of service delivery model|Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.
75432326|NCT03967834|Other|Patient with Soft Tissue Sarcoma|"Tumor specimens will be collected for the study at diagnosis.~A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.~Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years."
75432327|NCT03960723|Other|Questionnaire|A questionnaire asking the patients for several questions related to the Informed Consent Form they have signed before surgery, will be administered.
75432328|NCT03951831|Drug|REGN2810|Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
75579259|NCT04669431|Other|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living( eating, grooming, folding of towel, basket lifting, turn key into lock, reaching forward, sideways reach, ball grasping, picking up small blocks and lifting cane and pencil) 35 minute/3 days a week for 6 weeks
75579260|NCT00533312|Drug|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
75579261|NCT00533312|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
75579262|NCT00533312|Drug|Comparator : niacin / Duraton of Treatment: 4 Weeks|
75728355|NCT00892736|Other|Laboratory Biomarker Analysis|Correlative studies
75728356|NCT00892736|Other|Pharmacological Study|Correlative studies
75728357|NCT00892736|Drug|Veliparib|Given PO
75728358|NCT03966235|Drug|Melatonin 3 mg|Melatonin was taken daily for 6 months.
75728359|NCT03966235|Drug|Placebo|Placebo tablet was taken daily for 6 months.
75728360|NCT00892814|Radiation|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
75728361|NCT00892814|Radiation|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
75432329|NCT03951831|Drug|Degarelix|Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
75579263|NCT04668612|Device|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.
75579264|NCT04668612|Device|Standard bolus|Standard boluses for all meals
75728362|NCT03966469|Other|Preoperative support person present|Participants who bring a support person to their preoperative appointment.
75432330|NCT03951831|Drug|Leuprolide Acetate|Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.
75579265|NCT04669314|Procedure|Liver resection or enucleation for liver hemangioma|Operations in which the hemangioma is selectively removed from the liver parenchyma border are named enucleation, and the operations in which the hemangioma is removed anatomically or non-anatomically with some liver parenchyma surrounding it are named liver resection
75579266|NCT00533390|Drug|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
75728363|NCT03966469|Other|Patient Present Only|Patient presents to their preoperative appointment without a support person.
75728364|NCT01077661|Drug|Nebivolol|patients administrated Nebivolol according to the prescribing information
75432331|NCT03951831|Drug|Docetaxel|Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
75879578|NCT03635125|Drug|Nebivolol I|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg
75879579|NCT03635125|Drug|Nebivolol II|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg
75432332|NCT03911687|Behavioral|CONCERN CDS system notification|"The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months"
75432333|NCT03897270|Procedure|Photoacoustic Imaging|Undergo photoacoustic imaging of the breast
75579267|NCT00556296|Drug|NRP104|NRP104 30mg capsule once daily in a.m.
75579268|NCT00556296|Drug|NRP104|NRP104 50mg capsule once daily in a.m.
75579269|NCT00556296|Drug|NRp104|NRP104 70mg capsule once daily in a.m.
75579270|NCT00556296|Drug|Placebo|Placebo
75728365|NCT00606320|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
75728366|NCT03966079|Drug|recombinant tissue plasminogen activator|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
75728367|NCT02540486|Other|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
75728368|NCT02540486|Other|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
75879580|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
75879581|NCT01854385|Drug|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
75879582|NCT02809118|Drug|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
75879583|NCT02809118|Drug|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
75879584|NCT02809118|Other|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
75432334|NCT03884972|Drug|Trabectedin|Given IV
75432335|NCT03884972|Drug|Venetoclax|Given PO
75432336|NCT03872453|Drug|Zavegepant|A single dose of zavegepant
75432337|NCT03872453|Drug|Zavegepant matching placebo|A single dose of placebo matched to zavegepant
75432338|NCT03872453|Device|Intranasal Aptar Pharma Unit Dose System|A single-dose intranasal device
75579271|NCT04709003|Diagnostic Test|Serologic test|A blood test to check antibodies type and amount
75579272|NCT04709003|Diagnostic Test|Respiratory swabs|PCR test to Covid-19
75579273|NCT00556335|Procedure|manual aspiration|air aspiration
75579274|NCT00556335|Procedure|conventional drainage|drainage, pneumocath
75579275|NCT04668456|Drug|Dexmedetomidine|the drug administered either subtenon ot iv
75579276|NCT04668456|Drug|lidocaine 2%|subtenon injection
75728369|NCT03966859|Drug|Atorvastatin 20mg|oral dose, once daily for 7 days
75728370|NCT03966859|Other|Lactose placebo|oral dose, once daily for 7 days
76050304|NCT01731886|Procedure|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.
76050305|NCT01731886|Drug|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
75728371|NCT00528411|Drug|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
75432339|NCT03869463|Other|Computerized Cognitive Training|Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.
75432340|NCT03869463|Other|Control|This group will not receive computerized cognitive training.
75432341|NCT03819517|Dietary Supplement|Resveratrol|Over the counter supplementation
75432342|NCT03819517|Other|Placebo|Empty white colored soft vegetarian capsule
75432343|NCT03803761|Drug|Copanlisib|Given IV
75432344|NCT03803761|Drug|Fulvestrant|Given IM
75432345|NCT03772834|Behavioral|Exercise Intervention|Undergo resistance training and walking
75432346|NCT03772834|Drug|Methylphenidate|Given PO
75432347|NCT03772834|Other|Placebo|Given PO
75579277|NCT04668456|Drug|bupivacine 0.5%|subtenon injection
75579278|NCT04668456|Drug|Normal saline|either subtenon or iv
75579279|NCT04668417|Behavioral|Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with a direct scheduling link included, enabling the patient to directly schedule a flu vaccination only visit
75579280|NCT04668417|Behavioral|Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with no direct scheduling link included
75432348|NCT03772834|Other|Quality-of-Life Assessment|Ancillary studies
75728372|NCT00528411|Drug|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
75728373|NCT00528411|Drug|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
75728374|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
75728375|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
75728376|NCT00136357|Behavioral|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
75432349|NCT03772834|Other|Questionnaire Administration|Ancillary studies
76050306|NCT01731886|Drug|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
76050307|NCT01731886|Procedure|Stem cell collection|Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is >2500 x 109 cells/liter; platelet count is >20 x 103/mm3.
75432350|NCT03772834|Other|Stretching|Undergo stretching
75432351|NCT03739073|Other|OCTA (angiography by tomography in optical coherence)|The study concerns patients with intermediate stenosis of the left anterior descending artery (LDA). A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed; it's a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina and then ophthalmological examination data will correlate with coronary angiography.
75432352|NCT03735095|Drug|Porfimer Sodium|Given IV
75579281|NCT04686968|Procedure|Greenhouse Technique|First, the high-strength sutures were passed through the teared tendon, and then Crimson duvet procedure was performed on the footprint from the articular margin of the humeral head to the apex of the greater tubercle, followed by a lateral row anchor.
75579282|NCT04686968|Procedure|Microfracture Combined With Suture Bridge Technique|A three-line anchor suture method is used as in the greenhouse technique, except that the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
75579283|NCT00556413|Biological|cetuximab|
75579284|NCT00556413|Drug|fluorouracil|
75579285|NCT00556413|Drug|irinotecan hydrochloride|
75579286|NCT00556413|Drug|leucovorin calcium|
75579287|NCT00556413|Drug|oxaliplatin|
75579288|NCT04687085|Other|10 minute mindful meditation recording|10 minute mindful meditation recording
75432353|NCT03735095|Procedure|Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy|Undergo EBUS-TBN guided I-PDT
75579289|NCT04668573|Other|Trunk exercise|Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
75579290|NCT04686695|Device|taVNS|taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
75579291|NCT04668690|Drug|Mitoxantrone Hydrochloride Liposome Injection|Drug: Liposomal mitoxantrone hydrochloride (20 mg/m2) administered as an intravenous infusion on day 1 of each 28-day cycle.
75579292|NCT04668690|Drug|Chidamide|Drug: Chidamide tablet (30 mg) is given to the patients p.o. 30 minutes after breakfast, twice per week with 3-day intervals.
75579293|NCT04668534|Device|taVNS 10|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
75579294|NCT04668534|Device|taVNS 25|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
75579295|NCT04668534|Device|Control|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
75579296|NCT04658979|Other|Pulmonary tele-rehabilitation|All the participant will by include in a tele-rehabilitation program who will be based on an 12-week intervention including therapeutic education and self-management sessions and training sessions, delivered through a videoconferencing application. All interventions will be under the supervision of a rehabilitation professional from the Pavillon de prévention des maladies cardiovasculaire (PPMC) and modeled according to the recommendations of the ATS/ERS.
75579297|NCT04593992|Device|HTEMS|high-tone external muscle stimulation
75579298|NCT04593992|Device|Placebo|Placebo stimulation
75579299|NCT04668729|Other|Chiropractic Manipulation|"Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position."
75579300|NCT00533585|Drug|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
75728377|NCT00895700|Behavioral|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
75728378|NCT00129649|Behavioral|Telephone reminder call|
75432354|NCT03726879|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
75432355|NCT03726879|Drug|Placebo|Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
75432356|NCT03726879|Drug|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
75728379|NCT00895778|Other|Neuromuscular blockade with rocuronium and reversal with sugammadex|
76050308|NCT01731886|Drug|Melphalan|Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
76050309|NCT01731886|Drug|G-CSF|Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
76050310|NCT01731886|Drug|Cyclophosphamide|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
76050311|NCT01731886|Drug|Mesna|Mesna will be provided with the cyclophosphamide.
75432357|NCT03726879|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
75432358|NCT03726879|Drug|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
75432359|NCT03726879|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
75432360|NCT03726879|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
75432361|NCT03726879|Drug|Trastuzumab Emtansine|Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
75432362|NCT03723187|Other|normal saline|experimental group use normal saline sealing tube
75432363|NCT03723187|Other|normal saline+heparin|normal saline+heparin(Currently, Regular used in hospital)
75432364|NCT03721835|Device|CONQUEST FN Femoral Neck Fracture System|Fracture fixation device consisting of a single plate and three screws
75579301|NCT00533585|Drug|Paclitaxel|200 mg/m^2 By Vein Over 3 Hours on Day 1.
75579302|NCT00533585|Drug|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
75432365|NCT03716843|Other|Pressure monitoring system|"The pressure measurement undergarment will be given to all consenting AIS patients who have received their own thoraco-lumbo-sacral orthosis (TLSO) rigid brace. Each patient will wear the undergarment first and the TLSO brace on top. FBG sensors embedded in the undergarment will measure each pressure signal at approximately 2 minutes. The average force reading will be calculated.~Then, the experiment will be repeated once, but the anisotropic textile brace will replace the TLSO brace. The pressure measurement system will be used to obtain an accurate and adequate comparison of the forces applied to the patients. The effectiveness of the anisotropic textile brace will be evaluated through X-ray radiography, and its correction effect with be compared with that of the TLSO brace."
75432366|NCT03712462|Behavioral|Acceptance-Based Behavioral Weight Loss Therapy for BED|ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
75579303|NCT00533585|Drug|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
75579304|NCT04585100|Drug|FM101 tablet|Bio-equivalent test (tablet vs oral solution)
75579305|NCT04585100|Drug|FM101 oral solution|Bio-equivalent test (tablet vs oral solution)
75579306|NCT04585100|Drug|Placebo|Placebo BID for 28 days
75579307|NCT04585100|Drug|FM101 150 mg|FM101 (150 mg) BID for 28 days
75579308|NCT04585100|Drug|FM101 300 mg|FM101 (300 mg) BID for 28 days
75432367|NCT03712462|Behavioral|Standard Behavior Therapy|SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
75432368|NCT03697096|Other|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
75579309|NCT04659252|Other|n/a - samples collected along routine care samples only|This is a non-interventional study.
75579310|NCT04668378|Other|Time restricted eating|TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.
75579311|NCT04668378|Other|Normal Diet|ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
75879585|NCT01353001|Behavioral|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
76050312|NCT01759420|Drug|Ondansetron|4mg of intravenous ondansetron
75579312|NCT04668222|Drug|Yu-Ping-Feng formula|Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
75579313|NCT04668222|Drug|Xiang-Sha-Liu-Jun formula|Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
75579314|NCT04668222|Drug|Liu-Wei-Di-Huang formula|Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
75579315|NCT04668222|Drug|"Placebo for Deficiency of Qi and Yang"|"Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula"
75579316|NCT04668222|Drug|"Placebo for Deficiency of Qi and Yin"|"Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula"
75579317|NCT04659057|Drug|Nebulized Lidocaine|will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).
75579318|NCT04659057|Drug|Nebulized dexmedetomidine|will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).
75579319|NCT04659057|Drug|Nebulized lidocaine and dexmedetomidine|will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.
75579320|NCT04659057|Other|Placebo|will receive nebulized saline 0.9% (5 ml) as control group.
75579321|NCT04668261|Other|Advanced imaging investigation|MRI imaging
75579322|NCT04658745|Device|Intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients, by using a butterfly shape coil.
75579323|NCT04658745|Behavioral|Mirror Therapy|Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
75579324|NCT04658745|Device|Sham intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. However, a sham coil will be used, which is not associated with any stimulation effect on the brain.
75728380|NCT00895856|Other|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
75728381|NCT00896246|Drug|Klean-Prep®|Four litres of solution administered orally as a divided dose.
75728382|NCT00896246|Drug|Moviprep®|Two litres of solution administered orally as a divided dose
75879586|NCT01353001|Behavioral|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
75879587|NCT01353001|Behavioral|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
75879588|NCT01349023|Other|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
75879589|NCT02036606|Behavioral|questionary|
75879590|NCT02047838|Other|Anti-mullerian hormone (AMH) level dosage.|
75432369|NCT03697096|Other|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having a UTI due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
75728383|NCT00187135|Drug|Fentanyl|"Fentanyl - 1 mcg/kg in 3 ml normal saline~Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
75879591|NCT02047838|Other|Follicle-stimulating hormone (FSH) level dosage.|
75579325|NCT04658745|Behavioral|Sham mirror Therapy|In sham mirror therapy, the mirror will be covered. Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to move the non-affected hand. The participants cannot receive mirror visual feedback of the paretic upper extremity movement during the therapy. Same as mirror therapy, the movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
75579326|NCT00533741|Drug|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
75579327|NCT00533741|Drug|Placebo|Saline for injection.
75579328|NCT00533741|Biological|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
75579329|NCT04658511|Device|Ultrasound|On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
75579330|NCT04668027|Diagnostic Test|impulse oscillation（IOS）|The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
75432370|NCT03697070|Other|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
75432371|NCT03697070|Other|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
75432372|NCT03691051|Drug|Pyrotinib plus Capecitabine|Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.
75432373|NCT03653598|Other|Atrial Fibrillation|Data collection on Atrial Fibrillation
75579331|NCT04668027|Diagnostic Test|bronchial provocation test(BPT)|Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
75728384|NCT00187135|Drug|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
75728385|NCT00187135|Drug|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
75728386|NCT00187135|Drug|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
75728387|NCT00896324|Behavioral|Cognitive Rehabilitation|The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
75432374|NCT03630042|Drug|Pembrolizumab|200 mg IV dose given on day 1 of a three week cycle
75432375|NCT03630042|Drug|Rituximab|375 mg/m2 IV dose given up to 8 times in the trial
75879592|NCT02047838|Other|Antral follicle count (AFC).|
75432376|NCT03565991|Drug|Avelumab|IV treatment
75432377|NCT03565991|Drug|Talazoparib|Oral treatment
75879593|NCT01318681|Drug|cetirizine 10 mg|cetirizine 10 mg over encapsulated
75879594|NCT01318681|Drug|fluticasone furoate|nasal spray 25ug per dose
75879595|NCT01318681|Drug|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
75432378|NCT03535142|Procedure|Bariatric surgery|Roux en y gastric bypass or gastric sleeve operation
75432379|NCT03504488|Biological|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
75432380|NCT03504488|Biological|PD-1 inhibitor|PD-1 inhibitor
75432381|NCT03465813|Behavioral|CaringGuidance After Breast Cancer Diagnosis|CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
75432382|NCT03461276|Biological|ABvac40|ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminium hydroxide as adjuvant.
75432383|NCT03461276|Biological|Placebo|Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminium hydroxide) without the conjugate.
75432384|NCT03391362|Radiation|Stereotactic Radiation|Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
75579332|NCT04668027|Diagnostic Test|bronchial dilation test(BDT)|The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
75728388|NCT00896324|Behavioral|Active Neurofeedback Training|Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
75728389|NCT00896324|Behavioral|Neurofeedback Training (placebo / Sham)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
75728390|NCT00528021|Drug|Placebo|Vehicle Only
75728391|NCT00528021|Drug|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
76050313|NCT01781026|Drug|Vemurafenib|Single arm trial
76050314|NCT01607398|Drug|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
76050315|NCT01607398|Drug|Placebo|Placebo inhalation, twice daily, from week0 -12.
76050316|NCT01779856|Device|REVEAL Insertable Cardiac Monitor (ICM)|
75579333|NCT00533819|Other|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
75579334|NCT04658589|Procedure|Laparoscopic versus open distal gastrectomy|Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
75579335|NCT04545671|Other|trifocal lens|not applicable as patients are already implanted with the trifocal lens
75579336|NCT04658394|Other|Reminiscence therapy|Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes) · Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
75579337|NCT04667988|Diagnostic Test|JAK expression|JAK2 assessment in blood by PCR
75579338|NCT04536116|Device|Virtual Reality headset|MRI simulation with a Virtual Reality headset
75728392|NCT00896402|Drug|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
75879596|NCT02036684|Behavioral|Prehabilitation (PREHAB)|
76050317|NCT01729156|Drug|Metformin|1000 mg metformin twice daily in 3 months
76050318|NCT01729156|Drug|Placebo|2 tablets twice daily in 3 months
76050319|NCT01779700|Drug|Fingolimod|0.5mg each day of 8 week cycle
76050320|NCT01779700|Drug|placebo|1 tablet each day of 8 week cycle
76050321|NCT01778530|Drug|TRC105|Intravenous infusion.
76050322|NCT01778062|Drug|Indacaterol|Indacaterol 150µg once daily oral inhalation
76050323|NCT01778062|Drug|Control|Placebo once daily oral inhalation
76050324|NCT01757704|Procedure|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
75432385|NCT03364868|Drug|Oral Insulin|treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
75432386|NCT03364868|Other|Placebo|treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
75432387|NCT03354897|Drug|Torasemide 5Mg Tablet|16 weeks treatment
75432388|NCT03332251|Device|Posture Correction Girdle|Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
75432389|NCT03308929|Device|G7 Dual Mobility hip|Total hip arthroplasty and implantation of the G7 device
75432390|NCT03186638|Drug|Ibuprofen|Given PO
75432391|NCT03186638|Other|Placebo|Given PO
75432392|NCT03186638|Other|Questionnaire Administration|Ancillary studies
75879597|NCT03562286|Procedure|Fetoscopy|Performing a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair of the fetal neural tube defect.
75432393|NCT03165292|Radiation|mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
75432394|NCT03165292|Drug|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
75432395|NCT03165292|Drug|Thiotepa|Day 1-3 Thiotepa
75579339|NCT04668183|Procedure|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
75432396|NCT03165292|Procedure|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
75579340|NCT04668183|Procedure|Dorsal penile nerve block group|Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
75879598|NCT03604159|Drug|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
75432397|NCT03140423|Drug|Arm 1. Routine Care (Mupirocin/CHG)|The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
75432398|NCT03140423|Drug|Arm 2. Iodophor/CHG Decolonization|The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
75432399|NCT03075072|Radiation|Whole brain radiation|Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
75432400|NCT03075072|Radiation|Stereotactic radiation (SRS)|Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
75432401|NCT03045744|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
75432402|NCT03010657|Other|Intervention|Subjects will be asked to consume certain foods during chemotherapy treatment.
75432403|NCT02998385|Drug|Cisplatin|intravenous, concomitant to irradiation
75432404|NCT02998385|Radiation|radiotherapy|66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week
75432405|NCT02958007|Behavioral|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
75579341|NCT04521998|Device|electroacupuncture|Electroacupuncture used to reduce the inflammation was proved previously.
75579342|NCT04521998|Device|TENS|Patients who unlike needles would like to choose TENS as treatment for pain relief.
75432406|NCT02958007|Behavioral|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
75728393|NCT00896402|Drug|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
75432408|NCT02876302|Drug|Ruxolitinib|15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
75432409|NCT02876302|Drug|Paclitaxel|80 mg/m2, IV (in the vein) weekly for 12 weeks.
75432410|NCT02876302|Drug|Doxorubicin|60 mg/m2, IV (in the vein) every 14 days for 4 doses.
75579343|NCT04658706|Other|A supervised exercise program|is a 12-week exercise program supervised by specially trained instructors combining moderate to high intensity aerobic and strength exercises (three 1 hour sessions a week).
75579344|NCT04658706|Other|exercise prescription|they will receive a prescription concerning healthy lifestyles and a personalized exercise plan
75579345|NCT04520555|Device|Laryngeal mask airway|LMA Flexible is a supraglottic airway device, which can be moved out of the surgical field without displacement of the cuff, or loss of seal for the anesthetist
75579346|NCT04520555|Device|Endotracheal tube|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
75579347|NCT00533858|Drug|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
75728394|NCT00560352|Drug|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
75879599|NCT03604159|Drug|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
75879600|NCT03686930|Drug|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
75432411|NCT02876302|Drug|Cyclophosphamide|600 mg/m2, IV (in the vein) every 14 days for 4 doses.
75432412|NCT02853747|Behavioral|Physical Activity, 20-meter shuttle run|cross-sectional physical activity assessment and medical screeening
75432413|NCT02846623|Drug|Atezolizumab|Given IV
75432414|NCT02846623|Other|Laboratory Biomarker Analysis|Correlative studies
75432415|NCT02846623|Biological|Obinutuzumab|Given IV
75432416|NCT02846623|Drug|Venetoclax|Given PO
75432417|NCT02691663|Dietary Supplement|Oral bicarbonate supplementation|
75432418|NCT02691663|Dietary Supplement|Placebo|
75432419|NCT02649868|Procedure|TAE|Transarterial embolization
75432420|NCT02649868|Radiation|RFA|Thermal ablation
75432421|NCT02649868|Device|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
75432422|NCT02639065|Drug|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
75432423|NCT02620072|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
75579348|NCT04658355|Other|Chlorhexidine Gluconate|4% Chlorhexidine Gluconate vaginal cleansing solution as a surgical preparation.
75579349|NCT04658355|Other|Povidone-iodine|10% povidone-iodine vaginal cleansing solution as a surgical preparation.
75579350|NCT04498442|Behavioral|Simha Kriya|Simha-Kriya involves deep breathing exercises and meditation. It is the practice of extending the breath, expanding our lung capacity and mental concentration and energizing the body. Simha Kriya, when practiced intentionally will unite the mental, physical, and spiritual body through the breath. For the purpose of this study we advocate practice of Simha Kriya at least once a day.
75728395|NCT00560352|Drug|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m^2 QD, 1.3 mg/m^2 QD
75728396|NCT00560352|Drug|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
75728397|NCT00892892|Drug|Rilmenidine|1 mg Rilmenidine per day versus
75728398|NCT00892892|Drug|Nitrendipine|20 mg Nitrendipine per day
75879601|NCT03686930|Drug|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
75728399|NCT04037696|Behavioral|General Health Promotion Approach|"The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
75728400|NCT04037696|Behavioral|Control|The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
75728401|NCT00944736|Dietary Supplement|VSL#3|1 packet BID
75728402|NCT00944736|Dietary Supplement|Placebo|1 inactive packet BID
75728403|NCT00887900|Procedure|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
75728404|NCT00887900|Procedure|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
75728405|NCT00944814|Dietary Supplement|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
75728406|NCT00944814|Dietary Supplement|LNS without zinc|LNS containing no zinc
75728407|NCT00527787|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
75432424|NCT02620072|Other|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
75432425|NCT02589106|Device|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
75432426|NCT02566785|Other|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
75432427|NCT02532257|Drug|Ibrutinib|Given PO
75432428|NCT02532257|Other|Laboratory Biomarker Analysis|Correlative studies
75879602|NCT03686930|Drug|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
75879603|NCT03686930|Drug|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
75879604|NCT01353235|Drug|Prednisolone|Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
75879605|NCT01353235|Drug|usual care|no drug administered
75432429|NCT02532257|Drug|Lenalidomide|Given PO
75432430|NCT02532257|Biological|Rituximab|Given IV
76050325|NCT01757704|Procedure|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
75432431|NCT02441101|Device|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
75432432|NCT02441101|Device|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
75432433|NCT02420860|Biological|Elotuzumab|Given IV
75432434|NCT02420860|Drug|Lenalidomide|Given PO
75432435|NCT02420860|Other|Questionnaire Administration|Ancillary studies
75432436|NCT02398786|Other|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
75432437|NCT02344537|Behavioral|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
75432438|NCT02236429|Biological|vaginal flora transplant|
75432439|NCT02113657|Drug|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
75879606|NCT02048228|Drug|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
76050326|NCT01757392|Biological|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
76050327|NCT01756846|Other|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
75432440|NCT02004704|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion"
75432441|NCT01892371|Drug|Azacitidine|Given SC or IV
75432442|NCT01892371|Drug|Cytarabine|Given SC
75432443|NCT01892371|Other|Pharmacodynamic Study|Correlative studies
75432444|NCT01892371|Drug|Quizartinib|Given PO
75432445|NCT01415882|Drug|Cyclophosphamide|Given PO
75432446|NCT01415882|Biological|Daratumumab|Given IV
75432447|NCT01415882|Drug|Dexamethasone|Given PO or IV
75432448|NCT01415882|Drug|Ixazomib Citrate|Given PO
75432449|NCT01415882|Other|Laboratory Biomarker Analysis|Correlative studies
75432450|NCT01303341|Other|Laboratory Biomarker Analysis|Correlative studies
75432451|NCT01303341|Other|Pharmacological Study|Correlative studies
75432452|NCT01303341|Drug|Riluzole|Given PO
75579351|NCT04498442|Behavioral|Reading a Book|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. Reading a book is often inculcated into mindfulness research due to it's impact on the personality and attitude. The simple act of reading a book can have a significant impact on their attitudes and can help them cope better with stress. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely for 15 minutes each day. Reading a book could potentially be substituted with sitting idle for 15 minutes if participants wishes to.
75579352|NCT04667598|Drug|Modified Wenxin Decoction|Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
75728408|NCT00527787|Drug|Naproxen|Naproxen (500 mg) dosed twice daily (bid) orally
75728409|NCT00893048|Drug|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
75728410|NCT00893048|Drug|Placebo Oral Tablet|Placebo
75432453|NCT01303341|Drug|Sorafenib Tosylate|Given PO
75432454|NCT01254942|Other|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
75432455|NCT01254942|Other|Usual Care|
75432456|NCT01092702|Drug|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
75432457|NCT01057134|Device|Cutera Ultrasound Device|Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.
75432458|NCT00926848|Behavioral|Partners Together in Health (PaTH) Intervention|Patients and partners in the PaTH experimental group participated in 18-36 exercise and 18 educational sessions in a structured cardiac rehabilitation program. Patients in the Usual care group also participated in 18-36 exercise and 18 educational sessions; partners, however, only participated in the educational sessions.
75432459|NCT00690352|Behavioral|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
75432460|NCT00667121|Drug|citalopram hydrobromide|
75432461|NCT00667121|Drug|escitalopram oxalate|
75432462|NCT00667121|Drug|gabapentin|
75432463|NCT00667121|Drug|sertraline hydrochloride|
75432464|NCT00667121|Drug|tamoxifen citrate|
75432465|NCT00667121|Drug|venlafaxine|
75432466|NCT00667121|Genetic|molecular genetic technique|
75432467|NCT00667121|Other|high performance liquid chromatography|
75432468|NCT00667121|Other|laboratory biomarker analysis|
75432469|NCT00667121|Other|pharmacological study|
75432470|NCT00667121|Procedure|adjuvant therapy|
75432471|NCT00658879|Drug|Somavert (Pegvisomant)|"Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
75432472|NCT00591851|Drug|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
75432473|NCT00336024|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC resuce
75432474|NCT00336024|Drug|Carboplatin|Given IV
75432475|NCT00336024|Drug|Cisplatin|Given IV
75432476|NCT00336024|Drug|Cyclophosphamide|Given IV
75432477|NCT00336024|Drug|Etoposide|Given IV
75432478|NCT00336024|Biological|Filgrastim|Given IV or SC
75432479|NCT00336024|Other|Laboratory Biomarker Analysis|Correlative studies
75432480|NCT00336024|Drug|Leucovorin Calcium|Given IV or orally
75432481|NCT00336024|Drug|Methotrexate|Given IV
75432482|NCT00336024|Other|Quality-of-Life Assessment|Ancillary studies
75432483|NCT00336024|Drug|Thiotepa|Given IV
75432484|NCT00336024|Drug|Vincristine Sulfate|Given IV
75432485|NCT00133705|Drug|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
75432486|NCT00133705|Drug|Inert Capsule|sugar pill
75432487|NCT01525017|Biological|Combig-DC (allogeneic dendritic cells) Cancer Vaccine|Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
75432488|NCT01525043|Drug|Naproxen|Naproxen 500mg BID for the first 2 weeks
75432489|NCT01525043|Drug|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
75432490|NCT01525043|Drug|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
75432491|NCT01525043|Drug|Naproxen|500mg bid
75432492|NCT01525043|Drug|Synera|Topical appication of single patch to elbow for 12hrs/day
75432493|NCT01525043|Drug|Synera|Single patch applied to elbow for 4hrs/twice daily
75432494|NCT01525056|Radiation|ct and mri scans|ct and mri scan preradiation and postradiation
75432495|NCT01525056|Radiation|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
75432496|NCT01525056|Radiation|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
75432497|NCT01525108|Behavioral|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
75432498|NCT01525108|Other|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
75579353|NCT04667676|Device|acupoint TENS|TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
75579354|NCT00533936|Biological|trastuzumab|
75579355|NCT00533936|Drug|cyclophosphamide|
75579356|NCT00533936|Drug|doxorubicin hydrochloride|
75579357|NCT00533936|Drug|fluorouracil|
75579358|NCT00533936|Drug|paclitaxel|
75579359|NCT00533936|Procedure|adjuvant therapy|
75579360|NCT00533936|Procedure|conventional surgery|
75579361|NCT00533936|Procedure|neoadjuvant therapy|
75579362|NCT04686539|Drug|CBD|CBD oil not containing THC, to be administered sub-lingual.
75579363|NCT04686539|Drug|Placebo|Placebo Oil
75579364|NCT00557544|Drug|metoclopramide|metoclopramide 0,15 mg/kg
75728411|NCT00940368|Dietary Supplement|Provision of capsules containing ginger powder or placebo|"The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram."
75879607|NCT02048228|Drug|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
75728412|NCT00608426|Behavioral|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
75728413|NCT00557076|Behavioral|Familiar Auditory Sensory Training|Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
75579365|NCT00557544|Drug|placebo|placebo per os
75579366|NCT00557544|Drug|ketoprofen|ketoprofen 1 mg/Kg
75579367|NCT04667871|Procedure|cataract surgery|Eyes for cataract surgery
75579368|NCT04667832|Diagnostic Test|selective coronary artery angiography|Radial approach, invasive selective coronary angiography with selective contrast injection and filming in coronary arteries
75579369|NCT04667910|Drug|601 1.25mg|Solution for injection (intravitreal use)
75579370|NCT04667910|Drug|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
75728414|NCT00557076|Behavioral|Sham Auditory Sensory Training|The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
75879608|NCT01349179|Device|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
75879609|NCT05701046|Procedure|Interbody fusion surgery|Interbody fusion surgery
75579371|NCT04404608|Diagnostic Test|Complete blood picture, bone marrow aspiration cytology|none except the regular routine investigations in such cases
75579372|NCT04668105|Other|High volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again.Group 1 will do the Nordic hamstring exercise with protocol 3 repetitions × 3sets× 3 times for 4 weeks.
75879610|NCT03046927|Drug|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
75879611|NCT03046927|Other|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
75879612|NCT02036762|Other|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
75879613|NCT01357369|Procedure|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
75879614|NCT02037308|Dietary Supplement|Bread|
75879615|NCT01349257|Drug|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
75879616|NCT03813446|Device|Device: RhythmPadBP|"Detection of heart rhythm and measurement of blood pressure~Intervention:~Patients will start by wearing a consumer SmartWatch (Huwaei SmartWatch 2, which has a CE mark) and a 60 second reading of their wrist Photoplethysmyograph (PPG) will be recorded. This will enable us to compare the PPG from the wrist with the fingertip data collected from the RhythmPadBP.~The watch will be cleaned with alcohol wipe in the same manner that the RhythmPadBP is cleaned between subjects use.~Patients will be asked to place their palms of both hands on RhythmPadBP and then the underlying heart rhythm and BP will be recorded. 12-lead ECG and BP reading will be obtained by standard devices for comparison."
75879617|NCT03589105|Drug|Ocrelizumab 300 mg|Two doses of 300 mg infusion administered 14 days apart.
75579373|NCT04668105|Other|Low volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again. Group 2 will do the Nordic hamstring exercise with protocol 3 repetitions × 3 sets × 1 times for 4 weeks.
75579374|NCT04333043|Diagnostic Test|audiological test, cognitive questionnaires|administration of cognitive and quality of life questionnaires and audiological test
75579375|NCT04667286|Procedure|Prone Position (PP)|Prone the patients on oxygen for at least 10 hrs a day
75579376|NCT04657965|Drug|LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
75579377|NCT00534014|Dietary Supplement|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
75579378|NCT04658004|Drug|NKG2D CAR T-cells|Each subject receive NKG2D CAR T-cells by intravenous infusion
75579379|NCT00534053|Other|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
75579380|NCT04658043|Other|Intervention on socioemotional functioning|"A culturally sensitive intervention based on the train the trainer (or coach the coach) model for enhancing the social adaptive functioning of young children (aged 3-6) with ASD in China, via providing training for parents"
75579381|NCT04657848|Procedure|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
75579382|NCT04657614|Other|Neutral Alignment|Alignment that is a neutral replicate of the participants prescribed prosthesis.
75579383|NCT04657614|Other|Anterior Alignment|Alignment that is anterior displaced pylon.
75579384|NCT04657614|Other|Posterior Alignment|Alignment that is posteriorly displaced pylon.
75579385|NCT00534170|Dietary Supplement|Probiotic (Yakult)|It is a dietary supplement ,65 ml containing 15 billion lactobacillus
75579386|NCT04244513|Device|Deep brain stimulation|the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
75728415|NCT00942864|Drug|ranibizumab|ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
75728416|NCT00943020|Dietary Supplement|Nutricia PreOp nutritional supplement|nutritional supplement
75728417|NCT00943020|Dietary Supplement|Lipid|Drink
75728418|NCT00943020|Dietary Supplement|Glutamine|Drink
75728419|NCT04017728|Device|Conventional Percutaneous Vertebroplasty|The cement is injected into the bone metastases directly.
75728420|NCT04017728|Device|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
75879618|NCT03589105|Drug|Ocrelizumab 600 mg|A single does of 600 mg infusion administered 24 weeks after the initial dose.
75879619|NCT03813368|Procedure|Whipples pancreatico-duodenectomy|Classic whipples and pylorus preserving
75728421|NCT00945048|Device|electrical velocimetry|determination of cardiac output by electrical velocimetry
75728422|NCT00945048|Device|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
75432499|NCT01525121|Other|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
75432500|NCT01525134|Device|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
75432501|NCT01525134|Device|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
75432502|NCT01525147|Biological|YHB1411-2: Level 2|IV infusion
75432503|NCT01525147|Biological|YHB1411-2: Level 3|IV infusion
75432504|NCT01525147|Biological|YHB1411-2: Level 4|IV infusion
75879620|NCT02048306|Behavioral|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
75432505|NCT01525147|Biological|YHB1411-2: Level 5|IV infusion
75432506|NCT01525147|Biological|Placebo|IV infusion
75432507|NCT01525147|Biological|YHB1411-2: level 1|IV infusion
75432508|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
75879621|NCT02048306|Behavioral|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
75879622|NCT01357447|Drug|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
75879623|NCT01357447|Drug|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
76050328|NCT01756846|Other|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
75432509|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
75432510|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
75432511|NCT01525212|Drug|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
75432512|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
75432513|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
75432514|NCT01525264|Behavioral|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
75432515|NCT01525264|Behavioral|Healthy Wife Control Group|Intervention group of couples who received education about importance of Healthy diet
75432516|NCT01525290|Drug|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
75432517|NCT01525290|Drug|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
75728423|NCT00945048|Device|spirometry|spirometry for testing the ventilatory function
75728424|NCT00945048|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
75728425|NCT00896558|Drug|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
75728426|NCT00896558|Drug|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
75728427|NCT00943176|Drug|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
75879624|NCT02048384|Drug|metformin alone (Arm A)|metformin alone
75879625|NCT02048384|Drug|metformin (Arm B)|rapamycin + metformin
75879626|NCT02048384|Drug|rapamycin (Arm B)|rapamycin + metformin
75879627|NCT01353391|Drug|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
75879628|NCT01353391|Drug|Placebo Comparator|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
75879629|NCT01349335|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
75579387|NCT04657536|Device|high frequency fulguration equipment|All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
75579388|NCT04657536|Drug|promestriene vaginal soft capsules|Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
75728428|NCT00896636|Procedure|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
75728429|NCT00896636|Other|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
75728430|NCT00129259|Biological|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
75728431|NCT00129259|Other|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
75728432|NCT00129259|Dietary Supplement|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
75728433|NCT00896714|Device|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
75879630|NCT01349335|Drug|Tolvaptan|tablet, 30 mg, Qd, 7 days
75879631|NCT01349335|Drug|placebo|tablet, 30 mg, Qd, 7days.
75432518|NCT01525303|Behavioral|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
75432519|NCT01525368|Behavioral|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
75432520|NCT01525433|Behavioral|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
75432521|NCT01525433|Behavioral|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
75432522|NCT01525446|Radiation|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
75432523|NCT01525459|Procedure|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
75728434|NCT00943254|Other|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
75728435|NCT00943254|Other|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
75879632|NCT03040921|Procedure|Uterine transposition.|Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
75879633|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
75879634|NCT03009487|Drug|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
76050329|NCT01963611|Drug|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
76050330|NCT01963611|Drug|Copaxone 20 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
75728436|NCT04017572|Procedure|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
75879635|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
75432524|NCT01525459|Other|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
75432525|NCT01525511|Drug|A|"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~Dosage: 2 tablets~DHA-PQP:~1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~Dosage: 3 tablets"
75432526|NCT01525511|Drug|B|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~Dosage: 2 tablets~DHA-PQP:~1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~Dosage: 3 tablets"
75432527|NCT01525524|Device|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
75432528|NCT01525537|Drug|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
75432529|NCT01525537|Drug|sufentanil|sufentanil was given at standard practise
75432530|NCT01525576|Behavioral|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
75728437|NCT00896792|Other|counseling intervention|
75432531|NCT01525654|Behavioral|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
75432532|NCT01525680|Other|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
75432533|NCT01525680|Other|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
75432534|NCT01525706|Drug|Ethanol and Paclitaxel Injection|Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL [3mg/ml diluted in normal saline from original concentration of 6mg/mL] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
75432535|NCT01525719|Drug|Everolimus|10 mg everolimus
75432536|NCT01525732|Procedure|Per Oral Endoscopic Myotomy|
75432537|NCT01525758|Drug|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
75432538|NCT01525758|Drug|microcrystalline cellulose|identical number of tablets to active drug groups
75728438|NCT00896792|Other|questionnaire administration|
75728439|NCT00896792|Other|survey administration|
75728440|NCT00896792|Procedure|end-of-life treatment/management|
75728441|NCT00896792|Procedure|psychosocial assessment and care|
75728442|NCT00940524|Drug|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) *continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC > 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) *continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
75728443|NCT00186901|Drug|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
75728444|NCT00186901|Other|Placebo|Placebo
75728445|NCT00893126|Procedure|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
75579389|NCT04236206|Behavioral|Mobile Phone Short Message Service|"SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~Patients will be encouraged to send messages/call the researcher for any queries encountered."
75579390|NCT04657653|Procedure|core decompression|:The procedure was performed under general anesthesia with the aid of image intensifier. All patients were positioned in supine position on a fracture table. The core decompression was performed using the direct lateral approach with 2 cm skin incision. A fluoroscope guided large single drill with 8 mm diameter over a guide wire was used to remove the necrotic tissues from the femur head through the lateral cortex distal to trochanteric tubercle. After the removal of the core necrotic bone, the track was filled with 5 ml synthetic bone paste substitute (tricalcium phosphate) and an intraoperative fluoroscope was used to confirm the adequacy of the decompression and grafting.
75579391|NCT04686617|Diagnostic Test|Mechanical Vibration|Oral B HummingBird device (Procter&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
76050331|NCT01963611|Drug|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
76050332|NCT01963611|Drug|Plovamer acetate 10 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
76050333|NCT01963611|Drug|Plovamer acetate 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
76050334|NCT04662645|Other|Palliative Therapy|Undergo embedded palliative care
75432539|NCT01525771|Other|Docetaxel|"The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.~Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)~Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days~Cisplatin 60mg/m2 IV (D1) every 21 days"
75432540|NCT01525810|Drug|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention [subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)]
75579392|NCT04657419|Other|survey|"Self-questionnaires will be completed by the participants :~General health and mental health~Fatigue~Burn-Out~Sleepiness~Sleep hygiene~Symptoms of COVID"
75728446|NCT00945126|Other|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
76050335|NCT04662645|Other|Questionnaire Administration|Ancillary studies
76050336|NCT01975701|Drug|BGJ398|Capsule for oral use.
76050337|NCT01962987|Drug|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
75432541|NCT01525823|Drug|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
75432542|NCT01525823|Drug|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
75432543|NCT01525836|Drug|rituximab; recombinant human thrombopoietin (rhTPO)|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 29th day)
75432544|NCT01525836|Drug|Rituximab|patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
75432545|NCT01525888|Procedure|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
75432546|NCT01525914|Drug|Dutasteride|dutasteride 0.5mg daily
75879636|NCT02048540|Biological|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
76050338|NCT01962987|Other|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
76050339|NCT01962441|Drug|SOF|400 mg tablet administered orally once daily
76050340|NCT01962441|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76050341|NCT01962441|Drug|Peg-IFN|180 µg administered via subcutaneous injection once weekly
76050342|NCT01638013|Drug|Peficitinib|Oral Tablet
76050343|NCT01637623|Drug|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
75579393|NCT00556569|Other|CHAM JAM|"CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity"
75579394|NCT04184804|Behavioral|Behavioral Intervention|"The intervention package will be consisted of:~Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~Signs in school areas about organic fruits and vegetables~Workshops and interactive games for children~Seminars for parents"
75579395|NCT00556608|Device|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
75579396|NCT00556608|Device|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
75579397|NCT00534287|Drug|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
76050344|NCT01637623|Drug|Allopurinol|Allopurinol 300 mg daily for 6 weeks
75579398|NCT00534287|Drug|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
75579399|NCT00556647|Procedure|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
75579400|NCT00556647|Procedure|conventional diagnosis|out-patient diagnosis
75579401|NCT00534326|Procedure|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
75579402|NCT00534326|Procedure|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirating
75579403|NCT04686656|Other|nasal oxygen|Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.
76050345|NCT01637623|Drug|Placebo|Placebo capsule daily for 6 weeks
76050346|NCT01962207|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
75432547|NCT01525940|Device|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
75432548|NCT01525953|Drug|Chemotherapy|Chemotherapy according to standard
75432549|NCT01525953|Radiation|Radiotherapy|Radiotherapy according to local standard
75432550|NCT01525979|Behavioral|Task-related unilateral arm training|The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.
75579404|NCT04686656|Other|buccal oxygen|Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
75579405|NCT04168502|Drug|Glasdegib|After randomization patients in both arms will be randomized to maintenance with glasdegib vs clinical observation
75579406|NCT04168502|Drug|Gemtuzumab Ozogamicin|Both arms, before randomization, will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
75579407|NCT04666896|Other|Tailored home-based exercise therapy|exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
75579408|NCT04666896|Other|Standard home-based exercise therapy|The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
76050347|NCT04844827|Genetic|Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily|Interventions will consist of a diagnostic and symptomatic videothoracoscopy in patients with pleural metastasis under general anesthesia, as part of a standard of care procedure. Fragments of these pleural biopsies (one for routine diagnosis and two for scientific purposes) will enrich the biocollection. Five blood samples will be taken at the time of surgery (3 to 5 ml / tube). These biological samples will be stored in the HCL CRB tumor bank. At the same time, patient demographic data will be collected and anonymized. In the long term, the biological material will be used by IARC for carrying out multi-omics and bioinformatics analyzes
75579409|NCT04666935|Other|The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program|Sport Injury Prevention Program.
75579410|NCT04666935|Other|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
76050348|NCT01995825|Drug|Brand lamotrigine|Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
76050349|NCT01995825|Drug|Generic lamotrigine|Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
76050350|NCT04829929|Device|Omega™LAA Occluder implantation|Left Atrial Appendage closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk by Omega™LAA Occluder using Omega™ Delivery System
76050351|NCT03777943|Procedure|Sampling peritoneal tissue|Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
76050352|NCT01995357|Device|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
75579411|NCT00534443|Procedure|Endoscopy of upper GI tract|"Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines."
75432551|NCT01525979|Behavioral|Task-related bilateral arm training|This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.
75432552|NCT01525979|Behavioral|Robot-assisted bilateral arm training|The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.
75432553|NCT01525979|Behavioral|Robot-assisted unilateral arm training|The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
75432554|NCT01525992|Behavioral|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
75579412|NCT04667091|Other|Physiotherapy|"Treatment will be given in 3 sessions per week for 6 weeks with home exercise program and participants will be provided with exercises sheets to remember the exercises.~The selected outcome measure will be taken on baseline (initial visit) and 6th week (post intervention)"
75579413|NCT00534482|Behavioral|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
75879637|NCT02048540|Drug|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
75879638|NCT02048540|Procedure|Gastrectomy|
76050353|NCT01995357|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
76050354|NCT01995357|Device|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
76050355|NCT04838353|Device|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
75879639|NCT01353469|Drug|Insulin human/Insuman Comb 25 (HR1799)|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
76050356|NCT05270239|Behavioral|N-back Cognitive Training|N-back task mainly trains working memory and information processing speed. This training lasts 10 days (1 hour per day).
76050357|NCT05270239|Behavioral|Virtual Reality Motor and Cognitive Training|"Virtual Reality Ball Task mainly trains inhibitory control, attention, working memory and motor functions. This training lasts 10 days (30 minutes per day)"
76050358|NCT04307563|Behavioral|Mindfulness session|1.5 hour weekly session with health educator
75432555|NCT01525992|Other|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
75579414|NCT00534482|Behavioral|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
75579415|NCT00534482|Behavioral|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
75579416|NCT00534482|Behavioral|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
75579417|NCT04667052|Drug|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
75579418|NCT04667052|Drug|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
75579419|NCT04136522|Procedure|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
75432556|NCT01526005|Drug|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
75579420|NCT04136522|Procedure|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
75728447|NCT00888056|Procedure|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
75728448|NCT00943332|Procedure|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
75432557|NCT01526005|Drug|Transdermal Placebo Patch|1 patch per day; 8 weeks total
75432558|NCT01526018|Behavioral|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
75728449|NCT04036370|Procedure|PECS group|Pecs block performed using ultrasound guidance. Standard pain follow up and monitorization will be performed.
75432559|NCT01526031|Procedure|1:10,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)~2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)~3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)~4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)"
75432560|NCT01526031|Procedure|1:30,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)~2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)~3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)~4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)"
75728450|NCT04036370|Other|Control group|Standard pain follow up and monitorization will be performed.
75432561|NCT01526031|Procedure|normal saline injection|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)~2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)~3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)~4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)"
75432562|NCT01526031|Procedure|physiotherapy|"Physiotherapy treatment will be provided at each visit after bee venom or saline injection.~transcutaneous electrical nerve stimulation (TENS) for 15 minutes~transcutaneous infrared thermotherapy (TDP) for 15 minutes~manual physical therapy for 15 minutes~simple home exercise program"
75432563|NCT01526044|Device|Freestyle Navigator|Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
76050359|NCT04817761|Drug|Calaspargase pegol (S95015)|"Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2.~Patients aged 40 to < 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2."
76050360|NCT03706963|Other|Phone Call|-phone call 7 days (+/- 2 days) into preoperative period
75579421|NCT04667130|Behavioral|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes. Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
75728451|NCT00943410|Radiation|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
75728452|NCT00943410|Drug|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
75728453|NCT00896948|Genetic|Southern blotting|
75728454|NCT00896948|Genetic|TdT-mediated dUTP nick end labeling assay|
76050361|NCT04267081|Drug|Venetoclax|Ex vivo venetoclax sensitivity testing is used for patient selection.
76050362|NCT04258267|Procedure|Early mobilization|Patients will wear an adduction sling to immobilize the shoulder during the first 4 weeks post-operative
75432564|NCT01526070|Drug|Intravitreal injection of Aflibercept|
75432565|NCT01526083|Other|Lacosamide|Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days
75432566|NCT01526083|Other|Warfarin|"Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period~In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.~Duration: single dose"
75432567|NCT01526109|Behavioral|Strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
75432568|NCT01526109|Behavioral|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
75432569|NCT01526109|Behavioral|Whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
75432570|NCT01526122|Drug|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg & Aspirin 100mg in 1 capsule), PO
75728455|NCT00896948|Genetic|gene expression analysis|
75728456|NCT00896948|Genetic|protein expression analysis|
75728457|NCT00896948|Other|flow cytometry|
75728458|NCT00896948|Other|fluorescent antibody technique|
75728459|NCT00896948|Other|immunoenzyme technique|
75728460|NCT00896948|Other|immunohistochemistry staining method|
75728461|NCT00896948|Other|immunologic technique|
75579422|NCT01215916|Drug|LY573636|"Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid [350 micrograms (µg) to 1000 µg orally, daily], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone [4 milligrams (mg) orally, twice daily or equivalent]."
75579423|NCT01215916|Drug|Pemetrexed|"375 to 500 milligrams per square meter (mg/m^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent)."
76050363|NCT04258267|Procedure|Delayed mobilization|Patients will wear an abduction sling to immobilize the shoulder during the first 4 weeks post-operative, followed by an adduction sling for 2 weeks.
75728462|NCT00186121|Drug|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
75432571|NCT01526122|Drug|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets & Aspirin 100mg 2 capsules, PO
75432572|NCT01526161|Drug|inhaled fluticasone propionate|100 micrograms
75728463|NCT00186121|Drug|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
75879640|NCT01353469|Drug|Insulin human/Novolin® 30R|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
76050364|NCT05309005|Behavioral|VR TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT. The stimulus material in the Virtual Reality version is perceived through a head mounted display. This allows the test person to watch the scenes in three dimensions and a 360 degree angle, increasing the sense of social presence.
76050365|NCT05309005|Behavioral|DT TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT, with identical content as the VR TASIT. The stimulus material in the desktop version is perceived on a two dimensional desktop computer screen.
76050366|NCT04814173|Other|One-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the one-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the maxillary arch between the roots of 2nd premolar and 1st molar and closer to the molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals).
75432573|NCT01526161|Drug|salmeterol|50 m
75432574|NCT01526161|Drug|Montelukast|Double blind double dummy
75432575|NCT01526174|Drug|Golimumab|Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
75432576|NCT01526200|Procedure|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
75432577|NCT01526226|Device|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
75432578|NCT01526226|Device|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
75432579|NCT01526239|Other|Colorectal cancer screening pamphlet|Colorectal cancer screening pamphlet
75579424|NCT00534521|Device|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
75728464|NCT00897026|Drug|cyclophosphamide|
75728465|NCT00897026|Drug|doxorubicin hydrochloride|
75728466|NCT00897026|Drug|paclitaxel|
75728467|NCT00897026|Genetic|fluorescence in situ hybridization|
75728468|NCT00897026|Other|immunohistochemistry staining method|
75728469|NCT00897182|Genetic|microarray analysis|
75728470|NCT00897182|Genetic|polymerase chain reaction|
75728471|NCT00186043|Drug|Quetiapine/Seroquel|Quetiapine/Seroquel
75728472|NCT00186043|Drug|Placebo|Placebo
75879641|NCT03562208|Biological|Adult Bone Marrow Stem Cells|Autologous Bone Marrow Stem Cells Transplant
75879642|NCT03562130|Drug|Teduglutide|Daily sub cutaneous injection 0,05 mg/kg/day
75879643|NCT02050178|Drug|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
75432580|NCT01526265|Behavioral|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
75579425|NCT00534521|Device|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
75432581|NCT01526265|Behavioral|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
75432582|NCT01526265|Behavioral|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
75579426|NCT04666818|Device|Use of Flash Glucose Monitoring|Participants in the intervention group were advised to monitor glucose levels by means of flash glucose system.
75579427|NCT00534560|Drug|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
75579428|NCT00534560|Drug|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
75728473|NCT00897260|Drug|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~Fludarabine dose adjustment:~70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion"
75728474|NCT00897260|Radiation|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
75728475|NCT00897260|Procedure|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
75879644|NCT02050256|Other|continuing medical education and electronic decision support|
75879645|NCT02050256|Other|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
76050367|NCT04814173|Other|Two-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the tow-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the mandibular arch between the 2nd premolar and 1st molar, then, a class II elastics 3/16 and 6.5oz will be use from the TAD to the hook of canines brackets).
75432583|NCT01526265|Behavioral|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
75579429|NCT00534560|Drug|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
75579430|NCT01184872|Drug|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
76050368|NCT04814173|Other|en-mass retraction|A group of patients in which participants will be undergo to the en-mass retraction with first premolars extraction with mini-implants in the maxillary arch inserted between the 2nd premolar and 1st molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals .
75579431|NCT01184872|Drug|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
75579432|NCT04666779|Other|Chiropractic care|Care provided by chiropractors, based on manual therapy, exercise prescription and patient advice/education/reassurance
75579433|NCT02887924|Device|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
75579434|NCT01215721|Drug|Vesicare|5 mg daily
75728476|NCT00897338|Other|flow cytometry|laboratory analysis
75728477|NCT00897338|Other|fluorescence activated cell sorting|laboratory analysis
75728478|NCT00897338|Other|immunohistochemistry staining method|laboratory analysis
75728479|NCT00897338|Other|immunologic technique|laboratory analysis
75879646|NCT02037074|Drug|Drug: EVP-6308|Arms 1, 2, 3
75879647|NCT02037074|Drug|Placebo|Arm 4
75879648|NCT02048618|Drug|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
75879649|NCT02048618|Drug|Placebo|placebo oral tablets, intake once daily for 20 weeks
76050369|NCT03698071|Biological|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
76050370|NCT03698071|Biological|urine sample|6 ml
75579435|NCT02886910|Other|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
75579436|NCT02886910|Other|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
75579437|NCT02887027|Behavioral|Exercise4Mood Intervention|The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
75579438|NCT04113239|Diagnostic Test|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
75579439|NCT04113239|Genetic|DNA-microarray genotyping|Taking a saliva sample for genotyping
75728480|NCT00897338|Other|biomarker analysis|laboratory analysis
75728481|NCT00185965|Drug|CPG 7909|6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
75728482|NCT00607880|Procedure|vascular access device placement|
75728483|NCT01076491|Drug|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
76050371|NCT04792567|Drug|BAF312|taken orally once per day (dose depends on CYP2C9 genotype)
75728484|NCT02541890|Behavioral|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
76050372|NCT04792567|Drug|Baseline disease modifying therapies (DMTs)|DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
75432584|NCT01526265|Behavioral|Collaborative Rewards|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
75879650|NCT02047448|Procedure|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
75432585|NCT01526278|Drug|Maxmarvil®|Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
75432586|NCT01526304|Other|no intervention|No intervention, only observational study
75879651|NCT02050412|Other|Cat fur scratch test|
76050373|NCT04825171|Drug|Bryophyllum 50 % Chewing Tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
76050374|NCT04235335|Behavioral|Indigenous Mother's Empowerment Program & Indigenous Kid's Club Program|Weekly groups administered to mothers and children simultaneously but separately for 10 weeks
75432587|NCT01526317|Drug|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
75432588|NCT01526330|Drug|YH14618|A mg/disc
75432589|NCT01526330|Drug|YH14618|B mg/disc
76050375|NCT04419025|Drug|N-acetylcysteine|Oral formulation: 600 mg capsules of N-acetylcysteine
75579440|NCT04666506|Other|Virtual reality|"The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog)."
75728485|NCT01076569|Other|laboratory biomarker analysis|Correlative studies
75879652|NCT02048696|Other|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
75879653|NCT02048774|Behavioral|Designation of Social Positioning|
75879654|NCT02048852|Other|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
75432590|NCT01526330|Drug|YH14618|C mg/disc
75432591|NCT01526330|Drug|Placebo|0mg/disc
75432592|NCT01526369|Drug|Trastuzumab|
75432593|NCT01526369|Drug|Paclitaxel|
75432594|NCT01526369|Drug|Lapatinib|
75579441|NCT04072211|Biological|Engerix-B|Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
75579442|NCT00534677|Drug|Terlipressin|2 mg stat & then 1 mg q6h iv and Placebo of Octreotide
75728486|NCT00893282|Device|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
75879655|NCT02048852|Other|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
75432595|NCT01526382|Device|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
75432596|NCT01526382|Procedure|central venous catheter|patients in this arm can receive central venous catheter
75432597|NCT01526395|Drug|Propofol|"The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week."
75432598|NCT01526421|Other|monetary reinforcer|Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
75432599|NCT01526447|Procedure|Craniosacral Therapy|Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding
75728487|NCT00893282|Device|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
75728488|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
75432600|NCT01526447|Procedure|Sham Craniosacral Therapy|Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
75432601|NCT01526460|Drug|Atorvastatin|80 mg
75879656|NCT02048852|Other|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
75879657|NCT02048852|Other|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
75879658|NCT03561974|Device|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
75879659|NCT02048930|Device|Budesonide Easyhaler|
75879660|NCT02048930|Device|Budesonide dry powder inhaler|
76024865|NCT05117879|Procedure|Cold snaring polypectomy/ Cold EMR/Hot EMR|"Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove [small colonic polyps] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue."
76024866|NCT05117801|Device|Petale|The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
76024867|NCT03094871|Behavioral|FACE-PC|
75728489|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
75579443|NCT00534677|Drug|Octreotide|Octreotide 50mcg/hr infusion & a placebo of Terlipressin
75432602|NCT01526460|Drug|Rosuvastatin|40 mg
75432603|NCT01526460|Drug|Placebo|no statin loading dose
75432604|NCT01526473|Biological|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
75432605|NCT01526486|Procedure|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
75432606|NCT01526486|Procedure|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
75432607|NCT01526499|Drug|Docetaxel and Cyclophosphamide (TC)|Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
75432608|NCT01526499|Drug|Docetaxel (T)|Docetaxel 75mg/m2 IVGTT D1;every 21days
75432609|NCT01526512|Drug|metroCX|cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
75432610|NCT01526525|Drug|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
75579444|NCT00556764|Drug|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
75579445|NCT00556764|Drug|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
75579446|NCT00556803|Procedure|radiofrequency ablation|radiofrequency ablation
75579447|NCT00556803|Procedure|TACE after RFA|TACE after RFA within one month
75579448|NCT00556959|Drug|high dose clonidine HCl sustained release|high dose clonidine HCl sustained release tablets for 8 weeks
75432611|NCT01526525|Drug|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
75579449|NCT00556959|Drug|low dose clonidine HCl sustained release|low dose clonidine HCl sustained release tablets for 8 weeks
75579450|NCT00556959|Drug|placebo|placebo tablets for 8 weeks
75728490|NCT00127933|Drug|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
75728491|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
75728492|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
75579451|NCT04008641|Other|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
75579452|NCT00557037|Drug|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
75579453|NCT01184326|Drug|pazopanib|
75579454|NCT01184326|Drug|everolimus|
76050376|NCT04837417|Diagnostic Test|Pathologic group|"Voluntary Activation level will be determined with the interpolate twitch technique (ITT), both during isometric contractions (knee at 40° flexion) and during isokinetic contraction at angular velocity equal to 100°/s.~Vastus Medialis and Soleous H-reflex will be measured. Cortical excitability and interhemispheric connectivity will be measured through transcranial magnetic stimulation (TMS).~Tests of balance in standing will be performed using the EquiTest platform. Individuals will be requested to perform three different tasks: Sensory Organization test, Adaptation Test upward/downward, Motor Control test backward/forward. Surface electromyography from lower limbs will be recorded.~Through TMS driven by neuronavigation, the cortical representation of the Quadriceps muscle will be studied.~Gait analysis will be performed on a treadmill mounted on force sensors. Participants will walk at increasing velocities from 0.4 m/s to 1.6 m/s. Speed will be increased of 0.2 m/s every 30 s."
75432612|NCT01526525|Drug|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
75432613|NCT01526525|Drug|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
75432614|NCT01526525|Procedure|sedation|If the patient had sedation score >2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
75432615|NCT01526525|Procedure|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
75432616|NCT01526525|Drug|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
75432617|NCT01526525|Drug|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
75579455|NCT04666350|Other|to assess the consistency and reproducibility of two consecutive direct skin feeding assays (DSFA) at 24-hour interval.|"The results from this experimental medicine study will inform whether the preferred Before-After trial design in which each human volunteer serves as their own internal control can be utilized for a follow-on Phase 2b trial."
75579456|NCT01215253|Drug|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
75579457|NCT03898115|Behavioral|CHG Education|"The CHG educational intervention will include educational outreach and audit and feedback implementation strategies"
75579458|NCT04666233|Procedure|Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection
75579459|NCT04666233|Procedure|Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
75579460|NCT01184053|Drug|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
75579461|NCT04206241|Diagnostic Test|Point of care early infant diagnosis (POC EID)|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
76050377|NCT04837339|Other|Collection of biological samples|Blood sample, biopsies sample, hair sample.
75432618|NCT01526564|Drug|Acetylcarnitine|Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or >4 hours for 8 weeks
75432619|NCT01526564|Drug|Placebo|3 t.i.d, two plates per time
75432620|NCT01526590|Drug|Definity Contrast|While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
75432621|NCT01526616|Drug|Metformin|Metformin 850 mg twice a day for six months
75579462|NCT03895814|Behavioral|Protective Step Training|Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
75579463|NCT04666194|Procedure|Cold forceps|
75579464|NCT04666194|Procedure|Cold snare|
75579465|NCT04666194|Procedure|Hot snare|
75579466|NCT03870698|Procedure|Laparoscopic group|The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
75728493|NCT03875313|Drug|CB-839|CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
75728494|NCT03875313|Drug|Talazoparib|Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
75728495|NCT01008345|Drug|ezetimibe|Patients will receive 10 mg/day of ezetimibe for 8 weeks
75579467|NCT04666077|Behavioral|Home-based MT through Supervised, Supported Singing (H3S)|"Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity."
75579468|NCT04666077|Behavioral|Individualized Music Therapy (IMT)|The Individualized Music therapy (IMT) conducted by the LACMM staff. It will be administered by a certified music therapist twice weekly for 45 minutes. The sessions will employ extensive clinical improvisation based on the songs of kin utilized in the H3S condition. Compliance will be measured with a weekly log which will record dates and times of each condition.
75579469|NCT04666077|Other|Attention Control (AtCon)|"The attention control (AtCon) will meet with the LACMM team for an interview in which they will be asked about music preferences and music experiences. They will answer any questions from participant and caregiver about music experiences. Study staff will contact the members of this group at the same schedule as the H3S group to assess music activity engagement. This will measure unplanned exposure and minimize drop-in music activity which could contaminate the control condition."
75579470|NCT04666116|Dietary Supplement|Dietary supplementation in patients with covid disease admitted to hospital|Dietary supplementation in patients with covid disease admitted to hospital
75579471|NCT03813875|Drug|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
75579472|NCT03813875|Other|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
75879661|NCT02049008|Other|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
75432622|NCT01526616|Drug|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
75432623|NCT01526642|Device|Non Invasive Ventilation|NIV during night
75432624|NCT01526655|Procedure|Abdominal total hysterectomy|Abdominal total hysterectomy through a low transverse abdominal wall incision
75432625|NCT01526655|Procedure|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
75432626|NCT01526694|Drug|Bendamustine|Bifunctional alkylating agent consisting of a purine and amino acid antagonist (a benzimidazole ring) and an alkylating nitrogen mustard moiety.
75432627|NCT01526694|Drug|Thalidomide|Thalidomide can directly inhibit the growth and survival of myeloma cells, by oxidative damage to DNA mediated by free radicals. The drug can induce apoptosis even in drug resistant myeloma cells. Thalidomide modulates cell adhesion molecule expression, so it may interfere with the mutually stimulatory interactions between myeloma cells and the bone marrow microenvironment.
75432628|NCT01526694|Drug|Dexamethasone|It's a corticosteroid.
75432629|NCT01526707|Drug|inhaled steroid|inhaled budesonide for 7 days
75432630|NCT01526746|Drug|Tasimelteon|20mg capsule, once
75579473|NCT03813875|Drug|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
75728496|NCT06089850|Other|Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft.|"Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data~CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires~Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires~D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant"
76050378|NCT04813003|Other|Functional Brain Imaging and neurobehavioural tasks|"Combination of 3 neurobehavioural tasks:~Task 1 consists in subjective value rating of 64 food items. Participants are asked to rate how much they would want to eat the presented food item while fMRI (functional magnetic resonance imaging ) scanning is performed.~Task 2 consists in rating of subjective nutrient factor of the same 64 food items. Participants will answer the following four categorical questions in randomized order for each item: low or high in added sugar/protein/fat and healthy or unhealthy.~Task 3 consists of a decision-making task. Participants will be presented with two food items (out of the 64 food items), and asked to choose which of the two items they prefer to consume at the end of the experiment."
76050379|NCT01638559|Drug|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
76050380|NCT04210999|Other|Homebased resistance training|Resistance training at home instructed via a smart phone training app
76050381|NCT04210999|Other|Supervised heavy slow resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist
76050382|NCT05259787|Drug|Sedation Etomidate combined with propofol|Drug IV within 10 second during anesthesia induction.
75432631|NCT01526746|Drug|Tasimelteon|20mg, once
76050383|NCT05259787|Drug|Sedation Propofol|Drug IV within 10 second during anesthesia induction.
76050384|NCT04809571|Other|Photoacoustic imaging and Confocal Raman spectroscopy measurement|All subjects will first have their basic history and clinical measurements taken, followed by skin physiology measurements and photoacoustic mesoscopic imaging as well as confocal Raman spectroscopy measurements.
76050385|NCT05226325|Drug|Dexmedetomidine|patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
76050386|NCT04418635|Dietary Supplement|Prosta-OK® Neo or Prosta-OK® Neo-matched placebo|the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
75432632|NCT01526759|Dietary Supplement|LM pectin (10%)|15 days 1 daily consumption of a drink with 10g pectin added
75432633|NCT01526759|Dietary Supplement|gelatin|15 days 1 daily consumption of a drink with 10g gelatin added
75432634|NCT01526772|Procedure|Endoscopy|Transoral endoscopy versus transoral endoscopy
75432635|NCT01526798|Device|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
75432636|NCT01526798|Device|Conventional high-flux dialyzer|
75879662|NCT02049008|Other|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
75879663|NCT02808338|Device|Philips BiPAP AutoSV Advanced System One|Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
75432637|NCT01526811|Device|Endurant Stent graft|Endurant Stent graft implantation
75432638|NCT01526824|Dietary Supplement|omega-3 polyunsaturated fatty acids (Lovaza)|Lovaza, 1 gram orally daily
75432639|NCT01526837|Drug|Avastin|Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
75432640|NCT01526850|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
75879664|NCT02808338|Device|Modified Philips BiPAP ASV|This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
75432641|NCT01526850|Drug|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
75579474|NCT03813875|Drug|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
75432642|NCT01526863|Dietary Supplement|HA egg|Daily dose of HA egg or placebo for 6 months
75728497|NCT06089837|Drug|EC5026 oral tablet|"2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)"
75728498|NCT06089837|Drug|Placebo oral tablet|2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
75432643|NCT01526876|Drug|clevidipine butyrate|intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
75728499|NCT06089811|Dietary Supplement|Prebiotic|Group 1 (prebiotic and placebo L-tryptophan): prebiotic (oligofructose, Orafti®P95, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day)
75728500|NCT06089811|Dietary Supplement|L-Tryptophan|Group 2 (placebo prebiotic and L-tryptophan): L-tryptophan (3g/day) and placebo prebiotic (microcrystalline cellulose, 20g/day)
75432644|NCT01526915|Procedure|Bone curettage + PRF|Bone curettage and PRF insertion
75432645|NCT01526915|Procedure|Bone curettage alone|Bone curettage without PRF insertion
75432646|NCT01526941|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
75432647|NCT01526941|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
75432648|NCT01526954|Device|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
75432649|NCT01526980|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
75728501|NCT06089811|Dietary Supplement|Placebo|Group 3 (placebo prebiotic and placebo L-tryptophan): placebo prebiotic (microcrystalline cellulose, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day).
75579475|NCT03813875|Drug|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
75432650|NCT01526980|Drug|biphasic insulin aspart 70|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
75432651|NCT01526980|Drug|biphasic human insulin 30|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
75728502|NCT06089785|Device|elastography|evaluation of degree of spleen stiffness in liver cell failure patient by elastography.
75728503|NCT06089772|Other|Comparing to Manipulation and Myofascial Release Techniques|Randomized Controlled Trials
75728504|NCT06089746|Other|NIPT|Coordinated suite of DME and training to support continuous maintenance of flexion posture during the 6 week trial.
75728505|NCT06089733|Drug|Part A ABSK201 and Itraconazole|Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
75879665|NCT02808338|Device|ResMed S7 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
75728506|NCT06089733|Drug|Part A ABSK201 and Rifampicin|Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
75879666|NCT02808338|Device|ResMed S9 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
75432652|NCT01527019|Drug|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
75432653|NCT01527019|Drug|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
75579476|NCT03813875|Drug|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
75579477|NCT01183858|Drug|Erlotinib [Tarceva]|Single daily oral dose
75432654|NCT01527019|Drug|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
75432655|NCT01527032|Drug|melphalan, thalidomide and dexamethasone|
75728507|NCT06089720|Device|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|nine orthodontic patients each one will receive 2 coated zinc oxide nanoparticle molar tubes in split-mouth manner and will assess for antimicrobial effect on s. mutans & lactobacillus after two weeks, in addition to evaluation of bond failure rate after three months.
75728508|NCT06089720|Device|orthodontic molar tubes (control)|nine orthodontic patients each one will receive two uncoated molar tubes in split-mouth manner and will assess for antimicrobial effect on S. mutans & lactobacillus after two weeks, also, evaluation of the bond failure rate after three months period.
75728509|NCT06089707|Drug|Naloxone Nasal Spray|IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
75879667|NCT02050646|Other|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
75879668|NCT02050646|Other|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
75879669|NCT02037386|Device|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
75879670|NCT02049086|Behavioral|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
75432656|NCT01527058|Drug|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
75432657|NCT01527084|Procedure|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
75432658|NCT01527097|Drug|Atorvastatin|Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
75579478|NCT04665882|Procedure|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
75579479|NCT04686344|Drug|intermittent boluses of Hypertonic saline|intermittent boluses every 6 hours over 30 min for 48 hours
75579480|NCT04686344|Drug|continuous infusion of Hypertonic saline|continuous infusion over a period of 48 hours
75579481|NCT05450536|Other|Video Model and Role Play|Video clips and role-play will be utilized to teach self-advocacy skills to autistic college students.
75579482|NCT05349136|Other|Synchronous telerehabilitation group|This group will receive Action Observation Treatment with a synchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under the supervision of a physiotherapist via videoconferencing.
75579483|NCT05349136|Other|Asynchronous telerehabilitation group|This group will receive Action Observation Treatment with an asynchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under parental supervision.
75728510|NCT06089655|Device|CGMS|The Intervention group is to use CGMS to estimate the effect on blood glucose (HbA1C).
75728511|NCT06089655|Behavioral|AI diet application|The Intervention group is to use an AI diet application to estimate the effect on blood glucose (HbA1C).
75728512|NCT06089642|Device|Virtual reality|Virtual reality based on distraction and Virtual Reality based on focussed attention
75728513|NCT06089629|Procedure|Lingual frenuloplasty|Surgical release of ankyloglossia with suture reorientation of the wound to improve lingual mobility, done under local or general anesthesia
75432659|NCT01527097|Drug|Atorvastatin placebo|Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
75728514|NCT06089603|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed)
75728515|NCT06089603|Drug|Conventional pharmacological treatment|Usual treatment of the patient
75579484|NCT04316416|Procedure|T7 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T7 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T7 spinous process.~After imaging of erector spina musceles and transvers process of 7 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge & 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
75728516|NCT06089603|Other|Sleep ,diet and life style recomendations|Daily recomendatios
75728517|NCT06089590|Other|Non-interventional|This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
75728518|NCT06089564|Behavioral|Skit video, Pictorial, Sign language|Three oral health educational intervention groups, group A (skit video), group B (pictorial) and group C (sign language) by using Sequentially Numbered Sealed Opaque Envelopes (SNOSE). Children picked a sealed envelope randomly and assigned to oral health education intervention group A, B and C. Participants in group A were assigned a skit video method of oral hygiene intervention and shown 5 minute video on what to eat and how to brush their teeth. The video included that what is good and bad for teeth, and how to brush which includes method, time and duration of tooth brushing. Participants assigned to group B and C was provided same instructions for tooth brushing and eating habits in the form of pictures and sign language respectively. The children of Group A received instructions in the form of laminated cards and asked to take with them at home. Participants in group C were received instructions in sign language in the presence of teacher.
75728519|NCT06089551|Drug|SmofKabiven|Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
75432660|NCT01527123|Drug|GSK2585823|CLDM1%/BPO3%
75432661|NCT01527175|Other|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
75432662|NCT01527188|Biological|100IR|100IR sublingual tablet of
75432663|NCT01527188|Biological|300IR|300IR sublingual tablets of
75432664|NCT01527188|Biological|500IR|500IR sublingual tablet of
75432665|NCT01527188|Other|Placebo|Placebo sublingual tablet of
75432666|NCT01527201|Procedure|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
75579485|NCT04316416|Procedure|T9 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T9 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T9 spinous process.~After imaging of erector spina musceles and transvers process of 9 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge & 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
75579486|NCT04316416|Drug|control group|24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
75579487|NCT05449522|Other|Vitamin D|High dose of vitamin D is given in divided dose orally or enterally via a feeding tube
75579488|NCT05449522|Other|Placebo|Placebo
76050387|NCT05394883|Behavioral|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week. Each session will consist of: 5-min flexibility warm-up and cool-down; 40 min of moderate intensity calculated as 40-59% Heart Rate Reserve (HRR) along with Rating of Perceived Exertion (RPE) between 13-14; and 20 minutes of resistance with an additional 30 minutes of unsupervised home aerobic activity per week. The women will be given their choice of aerobic equipment or walking either track/ treadmill to achieve a total of 40 minutes of moderate intensity exercise. The Supervised Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
75579489|NCT04665804|Dietary Supplement|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
75728520|NCT06089538|Diagnostic Test|mEEG battery|The 2 groups will be assessed twice : in the acute phase of acute respiratory distress syndrome (ARDS) at patient's bedside in the intensive care unit (ICU) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and a simple clinical neuropsychological assessment ; 6 months ± 2 weeks later using the same mEEG battery and a multi-domain clinical neurocognitive and psychological assessment battery
75728521|NCT06089512|Procedure|paravertebral block group|Paravertebral block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
75728522|NCT06089512|Procedure|Mid point transverse process block group|Mid point transverse process block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
75579490|NCT04665804|Dietary Supplement|Glucosamine and Chondroitin sulfate supplementation|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
75579491|NCT04665804|Other|Supervised Exercise training|"Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
75579492|NCT04665804|Other|Home Exercise Program|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
75579493|NCT04665804|Procedure|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
75579494|NCT04665804|Procedure|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
75579495|NCT05434468|Other|Sustained neutral apophyseal glides|gong mobilization
75579496|NCT04316455|Other|Integrative Yoga Therapy|Participants having an hour in-person weekly session with qualified yoga therapist for 6-weeks. At each session, the personalised yoga practices including straightening and relaxing posture of yoga, yoga breathing, Combinations of sound and imagery yoga practices were given and asked to continue practice at home during the week.
75579497|NCT05431192|Behavioral|Mindfulness Training + Enhanced Usual Care|"Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice."
75579498|NCT05431192|Other|Enhanced Usual Care|"Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study."
75579499|NCT00534755|Other|Breast Cancer database|prospective breast cancer database
75579500|NCT00534872|Drug|SB-649868|10 mg
75579501|NCT04665414|Diagnostic Test|MRI|preoperative MRI
75579502|NCT04665414|Diagnostic Test|transvaginal ultrasound|preoperative transvaginal ultrasound
75579503|NCT04665414|Diagnostic Test|transvaginal ultrasound elastography|preoperative transvaginal ultrasound elastography
75579504|NCT00534911|Behavioral|Cognitive Behavioral Therapy|"Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.~Other Name: Primary and secondary coping enhancement training (PASCET)"
75579505|NCT00534911|Behavioral|Supportive Non-directive Therapy (SNDT)|SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
75728523|NCT06089512|Procedure|Control group|Only general anesthesia was applied to the patients.
75728524|NCT06089499|Behavioral|Get Palliative Care: four educational learning module videos|Organizational Sponsored public domain educational videos
75879671|NCT02049086|Behavioral|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
75879672|NCT02049242|Procedure|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
75432667|NCT01527214|Radiation|CT scan and education|GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
75432668|NCT01527227|Other|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
75432669|NCT01527240|Drug|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
75879673|NCT02049242|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
75432670|NCT01527240|Drug|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
75432671|NCT01527253|Other|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
75432672|NCT01527266|Dietary Supplement|Carbohydrate drink|sucrose beverage
75432673|NCT01527266|Dietary Supplement|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
75579506|NCT04665609|Drug|Anlotinib and TQB2450 solution|Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
75432674|NCT01527279|Drug|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
75579507|NCT04665609|Drug|TQB2450 solution|TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
75579508|NCT03737981|Drug|Ibrutinib|Given PO
75579509|NCT03737981|Biological|Obinutuzumab|Given IV
75579510|NCT03737981|Other|Observation|Undergo observation
75579511|NCT03737981|Drug|Venetoclax|Given PO
75579512|NCT04665492|Diagnostic Test|EEG recording 1|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). EEG device usbamp (company Guger Technologies, Austria) will be used."
75579513|NCT04665492|Diagnostic Test|EEG recording 2|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). This intervention will take place six month after EEG recording 1. EEG device usbamp (company Guger Technologies, Austria) will be used."
75579514|NCT04665492|Diagnostic Test|Sensory Test|Test for mechanical sensations of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. Semmes-Weinstein Monofilaments will be used
75579515|NCT04665492|Diagnostic Test|Brief Pain Inventory 1|This questionnaire that ask about any acute or chronic pain
75579516|NCT04665492|Diagnostic Test|Multidimensional health locus of control|Questionnaire that test personal belief about control of one's own health
75579517|NCT04665492|Diagnostic Test|Sensory test thermal|"Test of thermal sensations (thermal roller) of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. A Somedic SenseLab Rolltemp device will be used"
75579518|NCT04665492|Diagnostic Test|Neuropathic pain symptoms|Questionnaire that test for neuropathic pain symptoms
75879674|NCT02049320|Drug|Remifentanil|
75879675|NCT02050724|Drug|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
75432675|NCT01527279|Drug|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
75432676|NCT01527305|Drug|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
75432677|NCT01527318|Drug|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
75579519|NCT04665492|Diagnostic Test|McGill pain questionnaire|Questionnaire assess three separate components of experiencing pain; the sensory intensity, the emotional impact and the cognitive evaluation of pain.
75579520|NCT04665492|Diagnostic Test|Pain Catastrophising Scale|Questionnaire use to identify individual pain experience.
75579521|NCT04665219|Behavioral|HBM-based text messages|"The intervention in the test group will consist of a set of text messages developed based on the HBM to be sent to the parents regularly in the following 48 weeks.~During the first 24 weeks, parents will receive a text message (and feedback if deemed appropriate) each week. In the next 24 weeks, the parents will receive a text message every 4 weeks, altogether 30 messages will be sent to the parents. All messages will be sent to the parents individually through free mobile App by a research assistant."
75579522|NCT04665219|Behavioral|Standard text message|Parents in the control group will receive an oral health education pamphlet produced by the Oral Health Education Division in the Department of Health, the Government of Hong Kong SAR. In order to maintain a double-blind design in the present study, the pamphlet will be distributed in an electronic form and sent via a text message.
75579523|NCT04665102|Other|Image classification using deep learning algorithm|Image classification using deep learning algorithm
75579524|NCT04665141|Biological|Mepolizumab|Mepolizumab will be prescribed freely by the treating physician according to real-life conditions.
75879676|NCT02050724|Device|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
75879677|NCT02050724|Device|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
75879678|NCT02260076|Drug|PEG 400|
75879679|NCT02260076|Drug|Placebo|
75432678|NCT01527331|Behavioral|video decision aid|cpr video decision aid
75432679|NCT01527409|Behavioral|Tailored health partnership program|"When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement."
75579525|NCT04665141|Biological|Omalizumab|Omalizumab will be prescribed freely by the treating physician according to real-life conditions.
75579526|NCT04665141|Biological|Reslizumab|Reslizumab will be prescribed freely by the treating physician according to real-life conditions.
75579527|NCT04665141|Biological|Benralizumab|Benralizumab will be prescribed freely by the treating physician according to real-life conditions.
75579528|NCT04665141|Biological|Dupilumab|Dupilumab will be prescribed freely by the treating physician according to real-life conditions.
75579529|NCT04665063|Biological|Auto CAR-T|Biological: Auto CAR-T
75579530|NCT04665063|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
75879680|NCT02807948|Device|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
75879681|NCT02050802|Drug|Moxifloxacin 400 mg|
75879682|NCT02050802|Drug|Macitentan 10 mg|
75879683|NCT02050802|Drug|Macitentan 30 mg|
75879684|NCT02050802|Other|Placebo|
75879685|NCT02051504|Behavioral|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
75879686|NCT02051504|Dietary Supplement|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
75579531|NCT04665063|Procedure|Leukapheresis|Leukapheresis
75579532|NCT00534950|Radiation|5 vs 6 weekly fraction of RT|Chemotherapy
75579533|NCT04664868|Procedure|Sphinkeeper™|Sphinkeeper™ prostheses are self-expandable solid prostheses, made of inert Hyexpan (polyacrylonitrile) and are inserted into the intersphincteric anal groove.
75579534|NCT04664712|Dietary Supplement|Tendisulfur Pro|Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) [17, 18], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
75579535|NCT04664712|Device|Focused shock wave|We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
75879687|NCT02051504|Procedure|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
75728525|NCT06089473|Other|Intervention Group: Exercise, Nutritional, and Psychological Support|"Exercise Intervention: 12-weeks of supervised, individualized virtual exercise sessions, delivered by an accredited kinesiologist. Independent unsupervised sessions start at week 5. After 12 weeks, a 5-month maintenance phase is followed, continuing to exercise three times weekly for 30 minutes per session.~Nutritional Intervention: this will include a comprehensive nutrition assessment by a dietitian, followed by a visit with a nutritionist to address individual needs and convey recommendations (in-person for those in Quebec, and online for those in Alberta).~Psychological Intervention: this will include an initial in-person consultation to identify participants' needs. If anxiety or depression are identified, participants will be referred to a web-based resource with evidence-bases strategies and resources to help develop coping skills. Some participants may be referred to a psychiatrist if this has not already been done by the transplant team."
75728526|NCT06089473|Other|Usual Care Only|Usual Care for kidney transplant candidates, which may include medical visits, nutrition, and psychological support.
75879688|NCT02051504|Procedure|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
75879689|NCT02051504|Procedure|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
75879690|NCT02051504|Procedure|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
75879691|NCT02051504|Other|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
75432680|NCT01527409|Behavioral|Usual care and health education workshop|"While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group."
75579536|NCT03663725|Drug|Intensified protocol|Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
75579537|NCT03663725|Drug|Stupp protocol|RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
75579538|NCT04664439|Diagnostic Test|CT-FFR|CCTA examination will be performed by qualified medical imaging technicians, and patients will be scanned with 256rows of CT, according to standard operating norms. The coronary artery physiological function evaluation software(Keya Medical Technology, Beijing, China)will be configured in the core laboratory in advance, and the relevant imaging analysts will be trained. The core laboratory will receive the CCTA inspection data and evaluate the CCTA image quality. According to the standard operation flow of the software specification, the CT-FFR analysis will be carried out on the images that meet the requirements, and the CT-FFR value of the lesions will be measured.
75579539|NCT04664595|Drug|Propofol Fresenius|final dose of Propofol (mcg/kg) to reach the target effect-site concentration
75579540|NCT04665024|Procedure|preoperative chest physiotherapy|"The patients were approached to partake in the investigation after they got full clarifications about the point of study. They were allocated into two groups and reassurance was achieved about the absence of any side effects.Furthermore, the examination was approved by the ethical committee.~Effects of preoperative chest physiotherapy were compared between two groups, by measuring the lung functions, oxygen saturation, pulmonary complications and length of hospital staying. Lung functions were completed by utilizing spirometry parameters, oxygen saturation was measured by pulse oximeter and pulmonary complications were diagnosed by specialist doctors."
75579541|NCT04665024|Procedure|postoperative chest physiotherapy|"Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days."
75579542|NCT01215175|Biological|Prevnar™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
75579543|NCT01215175|Biological|V114, Aluminum Adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
75579544|NCT01215175|Biological|V114, Aluminum Nonadjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
75728527|NCT06089460|Other|Beef|Fresh, locally-sourced, grass-fed, grass-finished ground beef sufficient to meet protein needs based on body weight for 8 weeks
75728528|NCT06089460|Other|Meat analogue|Commercially-available and purchased meat analogue sufficient to meet protein needs based on body weight for 8 weeks
75879692|NCT02051582|Procedure|Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
75579545|NCT04664283|Device|DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography|DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
75579546|NCT03580148|Drug|Cortisone|Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
75579547|NCT03580148|Biological|Bone Marrow Aspirate|Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
75579548|NCT04664517|Procedure|Flexible intramedullary nail (FIN)|Both bone FIN
75579549|NCT04664517|Procedure|Reduction auder general anesthesia and long arm cast|Reduction and cast
75579550|NCT01215097|Drug|Linagliptin|once a day
75579551|NCT01215097|Drug|placebo|once a day
75579552|NCT04664322|Device|non invasive ventilation and high flow nasal canulae oxygen therapy|patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy
75579553|NCT04318795|Procedure|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
75579554|NCT04318795|Procedure|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
75579555|NCT03527576|Drug|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
75728529|NCT06089460|Other|Beans/legumes|Canned beans/legumes sufficient to meet protein needs based on body weight for 8 weeks
75432681|NCT01527422|Drug|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
75432682|NCT01527448|Drug|Quetiapine XR (seroquel)|During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
75432683|NCT01527474|Drug|escitalopram|participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presences of depressive symptoms and side effects up to a maximum of 20mg/day.
75432684|NCT01527539|Drug|biphasic insulin aspart 30|Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
75432685|NCT01527552|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
75432686|NCT01527565|Drug|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
75432687|NCT01527604|Other|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
75432688|NCT01527604|Other|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
75432689|NCT01527617|Other|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
75432690|NCT01527617|Other|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
75432691|NCT01527630|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
75432692|NCT01527643|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
75432693|NCT01527656|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
75432694|NCT01527669|Drug|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
75579556|NCT03527576|Drug|NaCl 0.0308 MEQ/ML Injectable Solution|Intravenous injection of NaCl 0.9% before the surgery.
75728530|NCT06089447|Behavioral|A story based intervention called 'The Shadow of Tallystick Valley'|'The Shadows of Tallystick Valley' is a story based intervention for CYP aged 7 - 14 years aimed at supporting the psychological wellbeing and resilience of those affected by familial substance misuse. It has been designed by Book of Beasties, a developer of games and educational content, in collaboration with the charity Change Grow Live, who support those experiencing substance misuse and CYP affected by familial substance misuse in the UK. The wellbeing resource harnesses protective factors, such as respectful and caring conversations with professionals (Wangansteen and Westby, 2019), to facilitate a safe and supportive environment aimed towards understanding the CYPs experience, support their psychological wellbeing and building resilience and coping skills. It uses fictional narratives, including characters that represent particular topics which act as drivers for engagement.
75432695|NCT01527669|Drug|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
75432696|NCT01527695|Drug|ER tablet 25 mg AZD3241|2 tablets twice daily for Day 1
75432697|NCT01527695|Drug|ER tablet 100 mg AZD3241|1-6 tablets twice daily from Day 2 until Day 56±3 days
75432698|NCT01527695|Drug|Placebo for AZD3241 25 mg|2 tablets twice daily for Day 1
75432699|NCT01527695|Drug|Placebo for AZD3241 100 mg|1-6 tablets twice daily from Day 2 until Day 56±3 days
75579557|NCT04664010|Drug|Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Atomized inhalation of 5 million U α-interferon and 2 mL sterilized water, twice a day; 0.2 g arbidol, three times a day, treatment course no more than 10 days; intravenous administration of ribavirin 500 mg, once every 12 hours, treatment course no more than 10 days; intravenous administration of 10 g immunoglobulin C, once a day, 3-5 days. Anti-bacterial infection treatment is given to the patients who have yellow sputum and increased levels of procalcitonin and other bacterial infection specific indicators.
75579558|NCT04664010|Drug|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Buzhong Yiqi plus and minus formula: 1 dose once, twice a day, taking with warm water. Huhuang Detoxicity Paste: One dose once, twice a day, taking with warm water; Baimu Qingre Jiedu Paste: One dose once, twice a day, taking with warm water; Fumigation/inhalation of Chinese herbs and vitamin C: 30-40 minutes once, 3-7 times a day. Patients take vitamin E capsule and folic acid every day. plus invention 1
75579559|NCT04664010|Drug|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment|invention 1 plus invention 2 plus 100 mL of 5% glucose containing vitamin C (10 g/60 kg body mass) is intravenously administered twice a day.
75579560|NCT00534989|Procedure|FDG PET|FDG PET
75579561|NCT04664127|Drug|Kagocel+Valacyclovir|"Group 1-patients with simple severe herpes (HSV-infection orolabial and / or genital localization) treatment [Valacyclovir + Kagocel ° ] (n= 25).~Treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (the rate of suppressive therapy). * Kagocel®, 24 mg orally (2 tablets of 12 mg): 3 times per day, 5 days continuously.~* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months"
75579562|NCT04664127|Drug|Valacyclovir|"Group 2 -patients with simple severe herpes (HSV-infection orolabial and/or genital localization) receiving treatment [Valacyclovir] (n= 20).~Scheme of treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (a course of suppressive therapy)*.~* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months."
75579563|NCT04664049|Dietary Supplement|NRICM101|"Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
75579564|NCT00535028|Drug|AER 001|AER 001 25 mgs s.c. once daily for 28 days
75579565|NCT00535028|Drug|placebo|sterile saline
75579566|NCT04664088|Procedure|Acupuncture|"Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary."
75579567|NCT04664088|Drug|Venlafaxine|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
75432700|NCT01527708|Procedure|Corneal Collagen Cross-linking (CXL)|Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
75728531|NCT06089421|Other|Genetic Information Assistant|Participants assigned will receive a link to Genetic Information Assistant for pre-test counseling.
75579568|NCT00535067|Behavioral|Questionnaire|Questionnaires taking 60 minutes total to complete.
75579569|NCT00557115|Other|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
75579570|NCT00535106|Device|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
75579571|NCT00535106|Device|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
75728532|NCT06089421|Other|Telegenetics with UVA genetic counselor|Participants assigned will have a pre-test counseling session via a telegentics visit with a genetic counselor.
75728533|NCT06089408|Other|Best Practice|Use a regular blanket
75728534|NCT06089408|Other|Supportive Care|Use a weighted blanket
75728535|NCT06089408|Other|Survey Administration|Ancillary studies
75728536|NCT06089382|Drug|Sintilimab|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles or tumour recurrence）
75728537|NCT06089382|Drug|Lenvatinib|8mg orally once a day for 1 year
75728538|NCT06089382|Procedure|Transarterial Chemoembolization (TACE)|One cycle of TACE postoperatively
75579572|NCT00535106|Other|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
75728539|NCT06089369|Biological|Sintilimab|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）
75728540|NCT06089369|Procedure|Transarterial Chemoembolization (TACE)|One cycle of TACE postoperatively
75728541|NCT06089356|Drug|zolmitriptanee|zolmitriptane tablet daily
75728542|NCT06089356|Drug|topiramate|topiramate once daily
75728543|NCT06089356|Drug|Valproate|valproate once daily
75879693|NCT02051582|Procedure|Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
75879694|NCT02051660|Behavioral|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
75432701|NCT01527721|Procedure|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
75728544|NCT06089343|Diagnostic Test|Coronary CT angiography|Comprehensive hemodynamic and plaque features derived from CTA and verified by OCT of all culprit and non-culprit lesions to predict ACS.
75728545|NCT06089330|Drug|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
75728546|NCT06089330|Drug|SG001|240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
75728547|NCT06089330|Drug|Irinotecan|180mg/m^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).
75728548|NCT06089330|Drug|Regorafenib (Stivarga)|160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
75728549|NCT06089317|Combination Product|TCM ultrasonic atomization treatment with herbal Compound Decoction (CD)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the CD group is TCM compound decoction.~The prescription of atomization solution in the CD group contains Honeysuckle flower (金銀花) 5g, Chrysanthemum flower (菊花) 5g, Pale betterflybush flower (密蒙花) 5g, Mild mint herb (薄荷) 5g, Barbary wolfberry fruit (枸杞子) 10g, and Ophiopogon japonicus (麥冬) 5g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
75879695|NCT02051660|Behavioral|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
75879696|NCT02051738|Drug|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
75879697|NCT02051738|Drug|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
75879698|NCT02050958|Drug|OXP001|
75579573|NCT04663854|Drug|Trehalose|Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
75579574|NCT04664244|Combination Product|Combination of nimotuzumab and radiotherapy|Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.
75579575|NCT04663815|Behavioral|Animal-assisted activity|The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
75579576|NCT04663815|Other|Control intervention|The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
75579577|NCT04663581|Other|Left Sided Colonoscopy|Starting colonoscopy with the patient in left decubitus
75579578|NCT04663581|Other|Right Sided Colonoscopy|Starting colonoscopy with the patient in right decubitus
75728550|NCT06089317|Combination Product|TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
75432702|NCT01527721|Procedure|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
75579579|NCT04663698|Other|Baseline|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
75579580|NCT04663698|Other|MESH-Resistor 5|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
75579581|NCT04663698|Other|MESH-Resistor 10|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow
75579582|NCT04663698|Other|Perforated Resistor 7|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
75432703|NCT01527734|Drug|Tetrodotoxin|15ug and 30ug once or twice a day for 1 or 2 days.
75432704|NCT01527734|Drug|placebo|1ml once or twice a day for 1 or 2 days.
75432705|NCT01527760|Drug|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
75432706|NCT01527786|Drug|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
75579583|NCT04663698|Other|Perforated Resistor 11|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
75579584|NCT04663659|Other|no intervention|no intervention
75579585|NCT04663971|Procedure|Any surgery|Any surgical procedures performed for inflammatory bowel diseases
75579586|NCT04663971|Procedure|Any medical treatment|Any treatment (including non-surgical) performed for inflammatory bowel diseases
75728551|NCT06089317|Combination Product|TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
75879699|NCT02050958|Drug|Ibuprofen|
75879700|NCT02037464|Dietary Supplement|Capsaicin Supplement (Cayenne by Nature's Way)|One capsule of the supplement to be taken twice daily.
75728552|NCT06089317|Combination Product|Placebo TCM ultrasonic atomization treatment (PA)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
75432707|NCT01527812|Procedure|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
75432708|NCT01527825|Biological|Trivalent influenza vaccine (seasonal)|"Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~An A/California/7/2009 (H1N1)pdm-like virus~An A/Perth/16/2009 (H3N2)-like virus*~A B/Brisbane/60/2008-like virus * A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season."
75432709|NCT01527825|Biological|Normal saline|0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
75728553|NCT06089317|Drug|Artificial Tears (AT)|The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
75879701|NCT02879383|Procedure|DMR Procedure|The DMR procedure consists of hydrothermal ablation of the duodenum using the Revita System
75579587|NCT04663386|Drug|Budesonide-Formoterol|Dry powder inhaler
75432710|NCT01527838|Biological|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
75579588|NCT04663542|Procedure|immobilization duration|brace immobilization duration after open surgery for Achilles tendon rupture
75579589|NCT03503630|Drug|COMPOUND 2055269|COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
75579590|NCT03503630|Radiation|Radiation Therapy|Radiotherapy 25 Gy to be given on Days 1-5
75579591|NCT03503630|Drug|mFOLFOX|Given every 2 weeks for 6 cycles
75579592|NCT03503630|Procedure|Total Mesorectal Excision|Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
75579593|NCT04663269|Drug|4mg PF Dexamethasone|analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone
75579594|NCT04663269|Drug|Control Test|Peritubal block - standard local analgesic administration
75579595|NCT03465020|Other|Observation|Safety and efficacy outcomes of patients on different treatments
75879702|NCT02879383|Procedure|Sham Procedure|The sham procedure consists of placing the Revita Catheter into the stomach for 30 minutes and then removing it from the patient.
75879703|NCT02049554|Other|Preconception Care Screener|
75579596|NCT04686500|Device|Tidal volume measured by spirometer and DIBH surface from CT image|The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
75879704|NCT02049710|Behavioral|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
75579597|NCT03303339|Drug|Onvansertib|Onvansertib orally
75879705|NCT02049710|Behavioral|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
75879706|NCT01353625|Drug|CC-115|"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
75579598|NCT03303339|Drug|Cytarabine|subcutaneously
75579599|NCT03303339|Drug|Decitabine|intravenously
75879707|NCT01357603|Biological|Glargine|dosage form: Subcutaneous injection
75579600|NCT04686461|Drug|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
75579601|NCT03422471|Other|Hyperinsulinemic Hypoglycemic Clamp|Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
75728554|NCT06089304|Device|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
75728555|NCT06089291|Device|Persona IQ|"Persona IQ is a system comprised of the following subsystems:~RTM utilizing mymobility® patient application and care team dashboard,~PPK System with~CTE Extension Implant and Instrumentation,~Surgical Base Station System,~Home Base Station System,~Canary CDMP,~Canary CMGP software module, and~The ZBEdgeTM Connected Artificial Intelligence data platform.~The system combines physical components, electronics, software, and user interfaces to collect, store, analyze, transmit, and display patient data for use by both physicians and patients."
75728556|NCT06089252|Drug|walnut extract|Four times a day over a 10-day period
75728557|NCT06089213|Other|real-time intervention|An individual exercise program will be carried out at home, supervised remotely via videoconference.
75579602|NCT03299946|Drug|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
75879708|NCT02051894|Drug|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
75579603|NCT03299946|Drug|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
75579604|NCT03399929|Other|Post Acute Rehabiltation|
75728558|NCT06089200|Procedure|Transversus Abdominal Plane Block|20 cc of bupivacaine 0.2% was given to the transversus abdominis plane
75728559|NCT06089200|Procedure|Spinal Morphine|100 µg was administered intrathecally preoperatively
75728560|NCT06089174|Other|Ultra-trail|Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)
75728561|NCT06089148|Diagnostic Test|contrast enhanced digital mammography, tomosyntheis and MRI|
75728562|NCT06089122|Biological|IVIG|Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. At Visit 4, at least 20 patients will perform the PK assessment, collecting additional blood samples.
75879709|NCT01357681|Drug|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
75879710|NCT01357681|Drug|Placebo|Placebo
75879711|NCT02049788|Behavioral|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
75879712|NCT02049788|Behavioral|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
75432711|NCT01527864|Drug|pegylated endostatin and Paclitaxel-Carboplatin|Dosage：10mg/m2
75432712|NCT01527864|Drug|Placebo and Paclitaxel-Carboplatin|Dosage：10mg/m2
75579605|NCT00535340|Drug|SR58611A|
75579606|NCT00535379|Drug|Sunitinib|Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
75579607|NCT00535418|Drug|Letrozole|
75579608|NCT03288948|Other|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
75579609|NCT03307382|Device|SpyGlass DS Cholangioscopy|SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
75432713|NCT01527877|Drug|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
75579610|NCT04679064|Drug|Niraparib|PARP-inihibitor
75579611|NCT04679064|Drug|Dostarlimab|PD-1 inihibitor
75432714|NCT01527890|Drug|Fentanyl|intravenous patient-controlled analgesia
75728563|NCT06089109|Behavioral|Kentucky Violent Death Reporting System|The Kentucky Violent Death Reporting System (KYVDRS) addresses the need for accurate surveillance and data analysis by combining data from death certificates, coroner/medical examiner reports, police reports, crime laboratory reports, toxicology reports, and child fatality review team reports.
75728564|NCT06089109|Behavioral|Implementation and Effectiveness of VIP Corps Training|Implement and evaluate the effectiveness of VIP Corps training aimed at students enrolled in helping professions in their last program year. intervention efficacy to change in students' knowledge, attitudes, and practices of intimate partner violence (IPV) screening, detection, and referrals; participant practices will be the primary, longer-term outcome; while changes in knowledge and attitudes will be short-term outcomes. Secondary outcomes will include changes in detecting symptoms of a) SU/D and b) depression and/or anxiety and providing appropriate resources.
75728565|NCT06089096|Diagnostic Test|Home Sleep Apnea test (HSAT)|Patient will received HSAT at baseline
75728566|NCT06089044|Drug|Dalbavancin Injection|Dalbavancin as long-term suppressive therapy.
75432715|NCT01527903|Drug|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
75432716|NCT01527903|Drug|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
75728567|NCT06089031|Diagnostic Test|Coronary Function Test|Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
75728568|NCT06089005|Device|Instrument Assisted Soft Tissue Mobilization device|Application of IASTM tool on specific muscle areas twice daily for intervention protocol of 7 days
75432717|NCT01527929|Drug|Cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
75579612|NCT04679064|Drug|Pegylated liposomal doxorubicin|Chemotherapy drug
75579613|NCT04679064|Drug|Paclitaxel|Chemotherapy drug
75579614|NCT04679064|Drug|Gemcitabine|Chemotherapy drug
75579615|NCT04679064|Drug|Topotecan|Chemotherapy drug
75579616|NCT04679064|Drug|Bevacizumab|Chemotherapy drug
75728569|NCT06088953|Diagnostic Test|VRB test|"V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise.~V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation."
75432718|NCT01527955|Other|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
75432719|NCT01527968|Drug|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
75432720|NCT01527968|Drug|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
75432721|NCT01527968|Drug|Normal Saline|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
75432722|NCT01527981|Behavioral|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
75432723|NCT01527994|Drug|Aprepitant|Aprepitant 125 mg oral tablets
75432724|NCT01527994|Drug|Placebo pill|Placebo oral pill- inactive compound
75432725|NCT01528007|Drug|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
75579617|NCT03292289|Procedure|Pre- and post-operative consultation|Before and between the two interventions
75728570|NCT06088940|Dietary Supplement|Multistrain Probiotic|The probiotic capsule contains Lactobacillus and Bifidobacterium strains, ingested orally once daily.
75579618|NCT03292289|Procedure|Stomatherapy consultation|Clinical exam. At one and six months after the 2nd intervention
76050388|NCT05394883|Behavioral|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking program including tips for walking indoors and outdoors, exercise handouts for warm-up/cool-down activities, demonstrations for resistance training activities and an exercise log. Women assigned to Home Exercise group will be contacted once per week to discuss their progress, barriers/challenges faced, ask questions, and strategies to achieve the exercise guidelines. The Home Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
75432726|NCT01528007|Drug|Placebo|Placebo pill with no active ingredients.
75432727|NCT01528020|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
75432728|NCT01528020|Behavioral|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
75432729|NCT01528059|Procedure|Stomach-small intestine reconstruction|Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
75432730|NCT01528085|Drug|Nilotinib|Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)
75432731|NCT01528137|Biological|talactoferrin|Given PO
75432732|NCT01528137|Other|laboratory biomarker analysis|Correlative studies
75579619|NCT03292289|Procedure|Questionnaires|"QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)~Stoma-QoL before and after the 2nd intervention~LARS score at 1, 3, 6 and 12 months after the 2nd intervention"
75579620|NCT01183780|Biological|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
75728571|NCT06088940|Other|Placebo|Placebo is composed of maltodextrin, that is an identically formulated and packaged inactive substance
75728572|NCT06088927|Device|Conduction system pacing|Conduction system pacing (His Bundle Pacing or Left Bundle Branch Area Pacing)
75728573|NCT06088914|Device|Anodal transcranial direct current stimulation|Anodal tDCS will be delivered for 5 consecutive days. Participants will receive 2 mA of stimulation for 20 minutes with the anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
75432733|NCT01528163|Drug|Cabazitaxel|from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
75432734|NCT01528163|Drug|Methotrexate|From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
75432735|NCT01528176|Drug|10,000 IU of cholecalciferol for a total of 8 weeks|Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
75432736|NCT01528202|Dietary Supplement|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
75432737|NCT01528202|Dietary Supplement|Fruit juice cordial|fruit flavoured juice concentrate
75432738|NCT01528241|Drug|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
75432739|NCT01528267|Other|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
75432740|NCT01528267|Other|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
75579621|NCT01183780|Biological|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
75579622|NCT01183780|Drug|Irinotecan|180 milligrams/square meter (mg/m^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
75579623|NCT01183780|Drug|Folinic Acid|400 mg/m^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
75432741|NCT01528280|Biological|Vaccination against hepatitis A|Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
75432742|NCT01528280|Other|No Intervention|No Intervention
75432743|NCT01528306|Biological|HP802-247|"Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each"
75432744|NCT01528306|Other|Placebo|"Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each"
75432745|NCT01528371|Drug|Midazolam|"Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~Investigators inject an additional sedative agent and the dental treatment is started."
75432746|NCT01528371|Drug|Normal Saline Solution (NSS)|"Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~Investigators inject an additional sedative agent and the dental treatment is started."
75432747|NCT01528384|Drug|ADI-PEG 20|4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
75432748|NCT01528397|Procedure|pedicled nerve graft|A pedicled nerve graft harvested from the dorsal branch of the PDN can be used for reconstruction of such defects. The graft is based on the second dorsal metacarpal artery.
75432749|NCT01528410|Device|ALFApump removal of ascites|Implanted ALFApump, removing produced ascites according to programmed schedule
75432750|NCT01528410|Procedure|Large volume paracentesis for removal of ascites|Large volume paracentesis - standard of care, removing ascites according to patient need
75579624|NCT01183780|Drug|5-Fluorouracil|400 mg/m^2 bolus immediately followed by 2400 mg/m^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
75579625|NCT04662957|Dietary Supplement|Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo|Oral supplementation with multi-strain probiotic preparation
75579626|NCT04662957|Dietary Supplement|Maltodextrin|Maltodextrin as placebo
75579627|NCT00535457|Other|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
75579628|NCT04679103|Biological|Eculizumab (JSC GENERIUM, Russia)|Eculizumab
75579629|NCT04663191|Procedure|anatomical resection|Anatomical resection with systematic lymph-node dissection
75579630|NCT00535535|Dietary Supplement|Fructose|Fructose, 0.5 g/kg
75579631|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
75579632|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
75579633|NCT04678713|Dietary Supplement|investigate the nutritional determinants of MFO in moderate to well-train individuals|The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.
75879713|NCT02037932|Device|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
75432751|NCT01528423|Procedure|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
75432752|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
75432753|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
75728574|NCT06088914|Device|Sham transcranial direct current stimulation|Sham tDCS will be delivered for 5 consecutive days. Participants will receive sham stimulation for 20 minutes with the current intensity ramping down after 30 seconds of stimulation. The anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
76050389|NCT01756300|Device|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
75432754|NCT01528475|Behavioral|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
76050390|NCT03543631|Other|Survey|Online survey
75432755|NCT01528488|Other|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
75432756|NCT01528488|Other|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
75432757|NCT01528501|Drug|Panobinostat (LBH589)|
75432758|NCT01528514|Dietary Supplement|Curcuminoids|Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
75432759|NCT01528514|Other|Placebo|Placebo in capsule form, 4 capsules 4 times/day
75432760|NCT01528540|Drug|Placebo|This group will include placebo.
75728575|NCT06088849|Procedure|Venipuncture|The lactating mother will be asked to collect milk samples and donate 2 blood samples, which is not a part of their normal follow-up/treatment. We will also aks the parents if we can collect a blood sample fo the infant (0-6 months).
76050391|NCT04811131|Drug|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
76050392|NCT04811131|Drug|ARQ-252 Vehicle cream|ARQ-252 Vehicle cream
75432761|NCT01528540|Drug|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
75432762|NCT01528553|Device|8plate|12 mm or 16 mm plate. 24 mm or 36 mm screw
75432763|NCT01528553|Device|Staples (Richards, Smith & Nephew)|Staples (3 on each side)
75432764|NCT01528566|Behavioral|Tai Chi|The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.
75432765|NCT01528566|Behavioral|Attention control|The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
75579634|NCT04678713|Other|Investigate the physiological determinants of MFO in moderate to well-train individuals|Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.
75579635|NCT00535574|Drug|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
75579636|NCT00535574|Drug|bexarotene|75 mg/day 6 weeks
75579637|NCT04678830|Drug|Placebos|Placebos
75579638|NCT04678830|Drug|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
75579639|NCT01183468|Biological|Aralast NP 45 mg dose|- 45 mg/kg/week
75579640|NCT01183468|Biological|Aralast NP 90 mg dose|- 90 mg/kg/week
76050393|NCT04811131|Device|NB-UVB phototherapy active treatment|NB-UVB phototherapy active treatment
76050394|NCT04811131|Device|NB-UVB phototherapy sham treatment|NB-UVB phototherapy sham treatment
75579641|NCT01183468|Biological|Aralast NP 180 mg dose|- 180 mg/kg/week
75579642|NCT03245021|Drug|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
75579643|NCT04678791|Drug|Nimotuzumab|Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
75579644|NCT04678791|Drug|Cisplatin|Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
75579645|NCT04678791|Radiation|External-beam radiation|Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
75579646|NCT04678791|Radiation|Brachytherapy|Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 ~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
75579647|NCT01183390|Drug|Anastrozole|1 mg Tablets
75432766|NCT01528579|Other|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
75728576|NCT06088810|Other|CoMPoSER intervention group|Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.
75728577|NCT06088810|Other|Sleep Education|Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
75728578|NCT06088797|Other|METRIC COMPARISON Tasks : Tactile PVSE test|"Tactile PVSE test The tests are presented in 6 independent booklets, each of which tests a distinct skill: comparison of lengths, comparison of sizes, comparison of obliques, perception of environments, comparison of relative positions in relation to a frame and comparison of relative positions with distractors.~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
75728579|NCT06088797|Other|METRIC COMPARISON Tasks : Classic PVSE test|"Classic PVSE test Use of the standardized PVSE test printed on thick white paper in 6 separate booklets each containing a subtest (length, size, oblique, middle, relative position and relative position with distractor)~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
75879714|NCT01543633|Drug|Propofol|Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
75879715|NCT03561740|Drug|capecitabine|additional metronomic chemotherapy of capecitabine
75432767|NCT01528579|Behavioral|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
75432768|NCT01528579|Other|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
75432769|NCT01528618|Drug|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
75432770|NCT01528618|Drug|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
75432771|NCT01528631|Other|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
75579648|NCT01183390|Drug|Anastrozole|1 mg Tablets
75579649|NCT02887807|Drug|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
75579650|NCT02887807|Drug|Single intravenous bolus of placebo at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
75879716|NCT03494647|Device|Cheetah Heel Cup|The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.
75879717|NCT03494647|Device|The X Brace|The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
75879718|NCT02037698|Device|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
75432772|NCT01528631|Other|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
75579651|NCT04663035|Drug|Tislelizumab|200mg, iv. drip, Q3W. Tislelizumab will start within 3-7 days after ablation treatment. The longest course of treatment is 12 months.
75579652|NCT04663035|Procedure|Ablation|After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).
75579653|NCT04662762|Other|Nursing intervention programme|educational information
75579654|NCT03191942|Device|Modified ortho-k lenses|KETT MC lens
75579655|NCT03191942|Device|Ortho-k lenses|KATT BeFree lens
75579656|NCT04662606|Behavioral|Consumption of a standard meal prior to the fMRI data collection|Consumption of a standard meal prior to the fMRI data collection
75579657|NCT03058952|Behavioral|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
75579658|NCT03058952|Behavioral|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
75579659|NCT04662528|Drug|Placebo|4 x 1g capsules/day
75579660|NCT04662528|Drug|MAT9001 (omega-3 pentaenoic acid)|4 x 1g capsules/day
75728580|NCT06088797|Other|Mental imagery task|This involves answering questions concerning the position or identity of 2 or 3 objects on the basis of the mental representation of a grid by auditory guidance. Each grid must be constructed mentally with the verbal description of the path and the objects encountered.
75579661|NCT02830997|Device|Stereotactic guidance system|
75579662|NCT03098706|Procedure|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
75579663|NCT03098706|Procedure|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
75579664|NCT02802488|Procedure|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care."
75579665|NCT04662333|Procedure|Transcrestal approach for sinus lift|After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.
75879719|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
75432773|NCT01528644|Dietary Supplement|alginate beads containing ferrous gluconate|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
75579666|NCT04662333|Procedure|Xenograft application|Before implant placement, xenogenic collagen membrane and bone granules will be pushed under the Schneiderian's membrane through the surgical site.
75579667|NCT05300672|Drug|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
75579668|NCT03098589|Drug|Revlimid|Revlimid
76050395|NCT04724161|Diagnostic Test|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits using national standards and commercially available malaria rapid diagnostic tests
76050396|NCT05221021|Drug|Vaginal estrogen|0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
76050397|NCT05221021|Drug|Mirabegron 50 MG [Myrbetriq]|50mg oral Mirabegron once daily
75432774|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
75579669|NCT05298137|Procedure|Passive Leg Raise|A passive leg raise (PLR) is defined as raising a patient's legs to a 45-degree angle at the hip while supine.
75579670|NCT04662177|Drug|Dexmedetomidine|The study participants are divided into two groups: Group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by con-tinuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Group 2 receives the standard anaesthesia management.
75579671|NCT05292560|Other|Training in positivity|The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.
75728581|NCT06088797|Other|Proprioceptive spatial representation tasks|"16 configurations of 3 objects with direct or indirect passive exploration of their relative positions.~Each grid is presented 3 times with the following 3 questions to which the subject answers yes or no by forced choice~a single measure of the number of correct answers which will be the sum of the correct answers obtained to each of the 3 questions in the direct vs indirect condition"
75579672|NCT03076008|Other|Observational|No intervention
75579673|NCT03026517|Drug|Dabrafenib|
75579674|NCT03026517|Drug|Trametinib|
75728582|NCT06088797|Other|Tasks assessing number sense based on relative positions or lengths|"Pointing exercises on a digital line of 50 cm paper tape: the participant points with his finger to a position on the tape, according to the verbal request of the experimenter~Measures the intermanual gap during requests for evaluation of 5 times the wand, subtracting the length of a wand, then dividing this length by 2."
76050398|NCT03164473|Drug|Rituximab|pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
76050399|NCT03164473|Drug|Azathioprine|oral tablets : 2 mg/kg/day for 24 months
76050400|NCT03164473|Drug|Placebo-rituximab|4 infusions for 18 months
76050401|NCT03164473|Drug|Placebo-azathioprine|oral tablets for 24 months
76050402|NCT03162289|Other|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
75579675|NCT03026517|Drug|Phenformin|
75579676|NCT00537953|Drug|Miltefosine , meglumine antimoniate|
75579677|NCT02971098|Procedure|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
75432775|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
76050403|NCT03162289|Other|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
75432776|NCT01528644|Dietary Supplement|alginate beads with ferrous gluconate in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
75432777|NCT01528657|Other|Ventricular Pace Suppression (Vps)|Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.
75432778|NCT01528657|Other|Intrinsic rhythm support (IRSplus)|All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
75432779|NCT01528683|Radiation|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
75432780|NCT01528722|Drug|Bupivacaine|0.25% 20ml administered intraperitoneal
75432781|NCT01528722|Other|Normal saline|sodium chloride 0.9% solution
75432782|NCT01528748|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
75579678|NCT05259449|Behavioral|Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
75579679|NCT05259449|Other|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
75579680|NCT05259449|Other|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
75728583|NCT06088797|Other|WISC V Similarity and Span Test|The Wechsler Intelligence Scale for Children - Fifth Edition, Australian Standard (WISC-V) is an individually administered and comprehensive clinical instrument used to assess the general thinking and reasoning skills of children aged six years to 16 years. Test results include a Full-Scale Intelligence Quotient (IQ) score as well as age-equivalent rankings and scores for Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory and Processing Speed composites
75879720|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
75879721|NCT02053454|Drug|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
76050404|NCT05218915|Drug|Dulaglutide|Dulaglutide once weekly subcutaneous
75728584|NCT06088797|Other|WISC V Arithmetic subtest|The WISC-V is an individually administered, comprehensive clinical instrument for assessing the intelligence of children. The primary and secondary subtests are on a scaled score metric with a mean of 10 and a standard deviation (SD) of 3. These subtest scores range from 1 to19, with scores between 8 and 12 typically considered average.
75728585|NCT06088771|Biological|Dupilumab|Dupilumab will be administered at the recommended initial dosage of 600 mg (two 300 mg injections) on Day 1.
75728586|NCT06088771|Biological|Cemiplimab|Cemiplimab will be administered at the recommended dosage of 350 mg, as an intravenous infusion, over 30 minutes on Day 1.
75728587|NCT06088758|Device|Normothermic machine perfusion (NMP) of steatotic liver|Steatotic liver grafts that are selected will be run on NMP to assess quality of graft and determine whether it meets criteria for transplantation
75728588|NCT06088745|Biological|Recombinant Herpes Zoster Vaccine|The active ingredient of the recombinant herpes zoster vaccine is varicella-zoster virus glycoprotein E fusion protein expressed in CHO cells by gene recombination technology. The LZ901 cell line carrying this gene is cultured in chemically defined medium. The harvest cell culture is purified by multi-step liquid chromatography. After Low pH incubation and virus removal filter package Nanofiltration inactivation/virus removal process, the bulk containing high-purity recombinant herpes zoster virus glycoprotein E is obtained. Finally, an alumina adjuvant is added to the formulated final product.
76050405|NCT05218915|Drug|Insulin Degludec|Insulin degludec once daily
76050406|NCT05218915|Device|Continuous glucose monitor|Dexcom G6 CGM system
75728589|NCT06088745|Biological|Recombinant Herpes Zoster Vaccine Placebo|Alumina adjuvant
75432783|NCT01528761|Behavioral|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
75432784|NCT01528761|Other|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
75579681|NCT04661943|Drug|Tucidinostat|Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
75579682|NCT05252000|Device|mechanical debridement|subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
75579683|NCT05252000|Device|adjunctive aPDT|Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
75728590|NCT06088719|Procedure|axillary surgery|one group undergoes axillary surgery
75432785|NCT01528774|Other|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
75432786|NCT01528800|Drug|Vitamin K1|10mg orally three times a week for 12 months
75432787|NCT01528800|Drug|Microcrystalline Methylcellulose|10mg orally three times a week for 12 months
75579684|NCT05252000|Device|sham aPDT|subjects will receive saline and non-light emitting laser on the tooth
75879722|NCT02053454|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
75879723|NCT02052050|Other|core stability|
75879724|NCT02931097|Device|Deep brain stimulation|Stimulating deep brain electrodes and pulse generator
75879725|NCT02931097|Device|Sham stimulation|
75879726|NCT02052128|Drug|onapristone|
75879727|NCT01349413|Drug|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
75879728|NCT01349413|Other|Placebo|Identical looking placebo
75879729|NCT01349647|Biological|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
75728591|NCT06088706|Procedure|Intra-articular injection of ozone|the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
75579685|NCT04662138|Drug|directly acting antivirals|Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
75579686|NCT00557154|Device|ultrasound|ultrasound used to identify target vein
75579687|NCT00557154|Device|standard technique for venipuncture|routine equipment
75579688|NCT05237414|Device|Active tDCS|20 minutes of 2.0 mA direct current applied over the right DLPFC
75579689|NCT05237414|Device|Sham tDCS|15 seconds of 2.0 mA direct current applied over the right DLPFC
75579690|NCT05237414|Behavioral|Active CT|Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).
75579691|NCT05237414|Behavioral|Sham CT|Sham memory inhibition CT (i.e., participants have to categorize alcoholic and non-alcoholic images but they do not have to inhibit the memories related to these images).
75579692|NCT05226299|Biological|Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
75579693|NCT05226299|Biological|Saline|Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.
75579694|NCT00557232|Drug|bevacizumab|1.25mg/month
75579695|NCT02797119|Drug|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
75579696|NCT02797119|Drug|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
75579697|NCT02797119|Drug|Saline Solution (TA0)|
75579698|NCT05173259|Behavioral|F|The participant will be asked to chew the two-coloured chewing gum naturally.
75579699|NCT05173259|Behavioral|R|The participant will be asked to chew the two-coloured chewing gum on the right-side.
75579700|NCT05173259|Behavioral|L|The participant will be asked to chew the two-coloured chewing gum on the left-side.
75579701|NCT05173259|Behavioral|G05|The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
75579702|NCT05173259|Behavioral|G15|The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.
75579703|NCT05173259|Behavioral|G25|The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
75579704|NCT00557388|Dietary Supplement|Protein/Amino Acids|Casein Whey Leucine
75728592|NCT06088680|Device|Glycar Pericardial Patch|Glycar Bovine pericardial patch with AldeCaptm Technology (aka SJM with EnCaptm technology)
75432788|NCT01528813|Device|Er:YAG laser + amorolfine lacquer|To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
75432789|NCT01528813|Drug|Amorolfine lacquer|To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
75432790|NCT01528826|Drug|vinorelbine plus oxaliplatin|Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
75432791|NCT01528839|Drug|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
75432792|NCT01528839|Drug|Placebo|
75432793|NCT01528865|Drug|Lamivudine|"Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks."
75432794|NCT01528865|Drug|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
75432795|NCT01528930|Drug|Amikacin|500 mg, once daily for 2 years
75432796|NCT01528943|Drug|Prostacycline|Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
75432797|NCT01528943|Drug|Isotonic saline|same volume as the group that are allocated to prostacycline
75432798|NCT01528956|Genetic|DNA methylation analysis|
75432799|NCT01528956|Genetic|RNA analysis|
75579705|NCT00557388|Other|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
75579706|NCT05161208|Drug|OC-01 (varenicline 0.6mg/ml) Nasal Spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
76050407|NCT05237089|Other|Electroacupuncture|Regular acupuncture will be applied at the main and the additional acupoints with 0.25mm*40mm or 0.30mm*75mm needles. The main acupoints include Shangwan (CV13), Zhongwan (CV12), Jianli (CV11), Xiawan (CV10), bilateral Quchi (LI11), Hegu (LI4), Liangmen (ST21), Tianshu (ST25), Daheng (SP15), Fujie (SP14), Shuidao (ST28), Zusanli (ST36), Fenglong (ST40), Wailing (ST26), Guilai (ST29). Additional acupoints include bilateral Shangjuxu (ST37) and Neiting (ST44), bilateral Yinlingquan (SP9) and Shuifen (CV9), Qihai (CV6) and Guanyuan (CV4). Acupuncturists will use all main acupoints and choose the combined acupoints based on the patients' patterns during each treatment session. The EA apparatus will be connected to the needles at the bilateral ST21, ST25, SP15, using continuous wave type, frequency at 3 Hz, and intensity of 4-5 mA based on the endurance of each patient. Needles will be retained for 30 minutes before removal.
75579707|NCT05161208|Drug|Placebo (vehicle) nasal spray|Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
75579708|NCT00537992|Procedure|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
75579709|NCT00538070|Dietary Supplement|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
75579710|NCT04662021|Other|Aerobic Exercises|Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)
75579711|NCT00538109|Drug|Glivec®/Gleevec®|Chemotherapy
75579712|NCT04661904|Device|Continuous theta burst stimulation (cTBS)|Our active treatment will consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
75579713|NCT04661904|Device|Sham stimulation|The sham stimulation group will receive a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 4 days) with the coil set at 90 against the skull. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
75728593|NCT06088667|Other|Fascial mobilization group|In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments for 4 weeks.
75728594|NCT06088654|Drug|IPH6501|phase 1 (dose finding) and phase 2 (dose expansion)
75728595|NCT06088628|Diagnostic Test|Facial expression; Electroencephalogram; MRI|Recording facial expressions of participants, EEG recordings, and MRI scans.
75879730|NCT01349647|Biological|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
75879731|NCT02806232|Drug|Biltricide (racemate praziquantel) oral tablets|Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
75879732|NCT02806232|Drug|Racemate Praziquantel ODT|Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
75432800|NCT01528956|Genetic|gene expression analysis|
75432801|NCT01528956|Genetic|nucleic acid sequencing|
75432802|NCT01528956|Genetic|polymorphism analysis|
75432803|NCT01528995|Device|Medtronic Interstim II-3058|impulse generator
75432804|NCT01528995|Procedure|Anal bulking injection|"Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa"
75432805|NCT01529073|Drug|Nitazoxanide|Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
75728596|NCT06088602|Procedure|Cryoneurolysis|Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.
75432806|NCT01529099|Device|SIGMA HP PARTIAL KNEE|SIGMA HP PARTIAL KNEE
75432807|NCT01528436|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
75432808|NCT01528436|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
75432809|NCT01528436|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
75432810|NCT01529125|Drug|zidovudine, lamivudine, nevirapine|
75432811|NCT01529138|Drug|Axitinib|Combination treatment with temsirolimus and axitinib
75432812|NCT01529138|Drug|Temsirolimus|Combination treatment with temsirolimus and axitinib
75579714|NCT04661865|Other|Health Information Package Program (HIP program )|"Fifteen minutes PowerPoint presentation will be introduced to women to increase women's educational experience and raise their level of engagement and commitment.~The principal investigator will narrate the video record with PowerPoint slides and it was recorded as a video and will include information regarding the introduction to pregnancy, causes and predisposing factors of iron deficiency anemia during pregnancy, signs and symptoms, prevention, management of iron deficiency anemia during pregnancy that includes iron therapy, iron supplementation, dietary management. Content validity for the information in the video will be done by sending it to three experts in maternity nursing. Iron supplementation will be given to all participants who will start by sixteen weeks of pregnancy and they will receive information regarding the proper usage of iron supplements."
75432813|NCT01529151|Other|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
75432814|NCT01529151|Other|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
75579715|NCT00538148|Drug|Telithromycin|
75579716|NCT04661553|Device|"Mueller's polarimetric colposcopy Group 1"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation."
75879733|NCT02806232|Drug|Levo Praziquantel ODT|Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
75879734|NCT02908087|Drug|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
75879735|NCT02908087|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
75879736|NCT01357837|Drug|Matching Placebo|2 capsules of matching placebo once a day, in the morning, for a total of 28 days
75432815|NCT01529164|Drug|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
75432816|NCT01529164|Drug|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
75432817|NCT01529164|Drug|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
75432818|NCT01529164|Drug|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
75432819|NCT01529177|Drug|Metformin / clomid / hCG|Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
75432820|NCT01529177|Drug|Clomiphene citrate / hCG|Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
75432821|NCT01529190|Drug|Pregabalin|Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
75879737|NCT01357837|Drug|GRT6005|2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
75879738|NCT01357837|Drug|GRT6005|2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
75579717|NCT04661553|Device|"Mueller's polarimetric colposcopy Group 2"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth."
75579718|NCT05150873|Other|CTA evaluation|Any pre-operattive CTA of the patients of the cohort will be carefully evaluated to determine the theoric anatomical feasibility of an off the shelf Endograft, particularly in patients with an angulated and short aortic neck
75579719|NCT05134025|Other|Pump settings|Alteration in the pump setting prior to exercise commencement
75579720|NCT04661670|Device|occlusal stabilization splints|an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
75728597|NCT06088602|Procedure|Sham|The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.
75432822|NCT01529190|Drug|Placebo|placebo
75432823|NCT01529216|Device|DIAMOND System|Electrical stimulation to the fundus
75432824|NCT01529229|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
75432825|NCT01529229|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
75432826|NCT01529242|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
75432827|NCT01529242|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
75579721|NCT02470884|Device|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
75579722|NCT05114174|Other|mami-educ|The intervention corresponds to sending 3 messages a week through Telegram, with nutritional information, for 12 consecutive weeks (a different nutritional topic each week). The messages address the three domains of learning, cognitive, affective, and psychomotor for each topic.
75579723|NCT04661826|Drug|Oncofid-P-B|Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
75579724|NCT05110391|Drug|Hormonal Therapy Agent|Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
75579725|NCT04661631|Diagnostic Test|Lung ultrasound|Lung ultrasound during the screening process for SARS-CoV-2 infection in patients with an indication for urgent surgery.
75579726|NCT00538187|Drug|obatoclax mesylate|Given IV
75579727|NCT00538187|Drug|bortezomib|Given IV
75579728|NCT00538187|Other|laboratory biomarker analysis|correlative study
75579729|NCT00538187|Other|pharmacological study|correlative study
75579730|NCT04661709|Drug|Wen Xin granule|one dose daily, two times per day.
75579731|NCT04661709|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
75579732|NCT04661709|Drug|Atorvastatin Calcium|20 mg tablet, one tablet each night.
75579733|NCT04661709|Drug|Isosorbide Mononitrate Tab 20 MG|one tablet， twice daily.
75728598|NCT06088589|Behavioral|Mismatch negativity|"Event related potentials are compared between frequent and infrequent speech sounds (i.e., ba vs da)."
75579734|NCT04661709|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg, two times daily.
75579735|NCT04661709|Drug|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
75579736|NCT04661709|Drug|WXG placebo|one dose daily, two times per day.
75579737|NCT04661709|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
75728599|NCT06088576|Other|Together|"Tchat : limited to 20-30 minutes per day. With a member of the team Together. For teleconsultations : First teleconsultation, during the first month (1 to 4 sessions/month), are made by nurse and/or educator. After that, it is psychologists who do the teleconsultations (2 to 4 sessions/month). It's during 30 to 45 minutes.~Home visits, individual or group interviews on site are possible after 4 month."
75879739|NCT01357837|Drug|GRT6005|2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
75579738|NCT04661709|Drug|glyceryl trinitrate|be taken when angina pectoris attacks.
75579739|NCT00538226|Device|External Electric Muscle Stimulation|
75728600|NCT06088550|Dietary Supplement|BCAA|a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine & 1.25 gm valine).
75728601|NCT06088550|Other|home-based graded exercise program|home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
75728602|NCT06088524|Other|Social Media Fatigue|Mental Fatigue creation protocol: It has been reported that at least 30 minutes of social media use causes mental fatigue and impairs lower extremity and decision-making performance (Fortes et al., 2021). For mental fatigue with social media, participants will be created with 45 minutes of continuous use of social media (instagram, facebook, twitter, youtube) on smartphones by concentrating with headphones.
75728603|NCT06088498|Behavioral|Updating Existing Smartphone App|Participants will be asked to use a recently developed study smartphone application to reduce cravings to smoke for a 1-week period. Through the app, participants will be exposed to smoking extinction trials daily. Participants will be encouraged and reminded to complete 2-5 extinction sessions per day. Each session will present 3-10 cues, and each cue will be presented for 30-60 seconds (average amount of extinction per day will be about 17 minutes). Participants will be encouraged to conduct the extinction sessions when high cravings are expected.
75728604|NCT06088498|Behavioral|Quitline Services|Quitline coaches use cognitive behavioral therapy, reinforcement, and principles of self-efficacy to promote effective behavior change. The quitline approach includes 5 key elements: setting a quit date, coping with triggers, effectively using medications, tobacco proofing, and social support. Individuals who enroll in the quitline's multi-call program receive phone calls and NRT.
75728605|NCT06088498|Behavioral|Quitline Services and Smartphone App|In addition to quitline services, participants will download a study app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, those in the intervention group will be exposed to smoking extinction trials through the study smartphone app.
75728606|NCT06088472|Biological|TIL injection|Autologous tumor infiltrating lymphocyte injection
75432828|NCT01529255|Drug|telbivudine (ROADMAP)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
75432829|NCT01529255|Drug|Telbivudine (Standard of Care)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
75432830|NCT01529281|Dietary Supplement|Branch Chain Amino Acid (BCAA)|Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with ~300 ml of water.
75432831|NCT01529281|Dietary Supplement|Placebo - asparmate|Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with ~300 ml of water.
75432832|NCT01529294|Drug|Iloperidone|
75432833|NCT01529307|Drug|TAS266|TAS266 IV infusions given weekly
75432834|NCT01529320|Drug|Adventan® (methylprednisolone aceponate 0,1%)|Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
75579740|NCT02466867|Drug|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
75579741|NCT02466867|Drug|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
75579742|NCT02462850|Drug|CL-108|
75579743|NCT00538265|Drug|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
75728607|NCT06088459|Biological|1mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
75728608|NCT06088459|Biological|4mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
75728609|NCT06088459|Biological|8mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
75728610|NCT06088433|Drug|Ticagrelor|Comparison of 12 month of ticagrelor SAPT（90mgBID*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD * 1 month, followed by clopidogrel 75mgQD)
76050408|NCT05237089|Other|Sham acupuncture|Patients will receive superficial acupuncture treatment at the same main acupoints as EA group with 0.22*0.25mm needles. The electroacupuncture apparatus will connected to the needles at the bilateral Liangmen (ST21), Tianshu (ST25), Daheng (SP15) without current output. Needles will be retained for 30 minutes before removal. The treatment will be given 3 times a week in week 1-12, 2 times a week in week 13-20, and once a week in week 21-24, totaling 56 sessions of real or sham acupuncture.
75579744|NCT00538265|Drug|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)"
75579745|NCT00538265|Drug|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
75579746|NCT02462811|Drug|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
75579747|NCT02462811|Drug|Placebo|
75579748|NCT02462811|Drug|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
75579749|NCT00538382|Drug|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
75579750|NCT00538421|Drug|Propofol|Infusion intravenously (IV) 0-10 mg/kg/h
75579751|NCT00538421|Drug|Sevoflurane|0,7-1,5 MAC
75579752|NCT04661475|Drug|Dexmedetomidine Injection [Precedex]|ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.
75432835|NCT01529333|Device|Middle Ear Implant with MET V Transducer|The MET V System is indicated for use in addressing the amplification needs of adults, 18 years of age and older, who have mixed hearing loss.
75432836|NCT01529359|Dietary Supplement|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
75432837|NCT01529359|Dietary Supplement|Placebo|Placebo 2 gelules per days for 6 weeks
75579753|NCT04661475|Drug|Normal saline|while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
75579754|NCT04661436|Diagnostic Test|Contrast-Enhanced Ultrasound|"The research will study the qualitative analysis indicators of contrast-enhanced ultrasound, including: enhancement uniformity, enhanced range, presence or absence of enhancement defect area, presence or absence of nourishing blood vessels, etc.; and quantitative analysis indicators, including: peak time, peak intensity, rising slope, Area under the curve, etc., analyze the correlation between the changes of various parameters before and after neoadjuvant treatment（NAT） and the pathological response of patients, and try to find indicators and cut-off values that can predict and early evaluate the efficacy.~This study will study the qualitative and quantitative parameters of MRI-enhanced scanning and the changes of DWI parameters, analyze the correlation between the parameters of patients before and after NAT and pathological response, and try to find indicators and cut-off values that can predict and early evaluate the efficacy."
75579755|NCT00554268|Drug|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
75579756|NCT00538499|Drug|Fentanyl citrate|
75579757|NCT00538499|Drug|Bupivacaine hydrocloride|
75579758|NCT00538499|Procedure|videothoracoscopy|
75579759|NCT00554307|Device|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
75579760|NCT00538538|Drug|vitrectomy with subretinal lucentis|A gas bubble will be placed in the eye after the gel has been removed.
75579761|NCT00538538|Drug|vitrectomy with subretinal lucentis|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
75579762|NCT00554346|Drug|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
75579763|NCT04661046|Drug|Traditional Chinese Medicine|Chinese medicine prescription
75579764|NCT00538655|Drug|modafinil|400mg vs. 200mg (PO) daily
76050409|NCT05237089|Other|Health education|The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
75432838|NCT01529372|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
75432839|NCT01529398|Other|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
75579765|NCT04661319|Procedure|video editing training|"The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~Select a random experimental group.~For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation."
75579766|NCT00538694|Drug|daptomycin|
75579767|NCT02436096|Drug|TNX-102 SL Tablet, 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
75579768|NCT02436096|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
75579769|NCT00538772|Other|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
75579770|NCT02435121|Drug|SAR125844|Pharmaceutical form:Concentrate for solution Route of administration: intravenous
75579771|NCT00538811|Drug|interferon alpha-2b, ribavirin, interferon-gamma,|
75579772|NCT00538811|Drug|interferon alpha-2b, ribavirin, amantadine|
76050410|NCT03462511|Behavioral|HABIT Intervention|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
76050411|NCT03424603|Drug|STRO-001|intravenous antibody drug conjugate
75579773|NCT04660773|Device|NB UVB phototherapy|ultraviolet phototherapy sessions
76050412|NCT04706689|Behavioral|SWADOC tool|"The tool explores some oral and pharyngeal components of swallowing as well as a range of prerequisite and related components of swallowing in DOC patients.~It is composed of an average of 50 qualitative items and a subsection named SWADOC-scored comprising 8 quantitative items."
75432840|NCT01529398|Other|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
75579774|NCT04660773|Drug|Pregabalin|oral medication
75579775|NCT00538889|Drug|Lecozotan SR|
75579776|NCT00538889|Drug|Citalopram|
75579777|NCT02413827|Drug|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
75579778|NCT02413827|Drug|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
75579779|NCT00538928|Other|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
75879740|NCT02053532|Procedure|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
75879741|NCT02053688|Device|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
75879742|NCT02053688|Device|Toric Soft Contact Lenses|astigmatism correction using toric optics
75879743|NCT01349725|Drug|ARRY-502|Oral; multiple dose, escalating
75879744|NCT01349725|Drug|Placebo|Oral; matching placebo
75432841|NCT01529398|Other|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
75432842|NCT01529411|Drug|Vinflunine|Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min).
75432843|NCT01529411|Other|Undefined (standard care)|All the current interventions used by each institution for the study disease.
75432844|NCT01529437|Drug|sublingual immunotherapy|Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
75432845|NCT01529437|Drug|placebo sublingual immunotherapy|SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
75432846|NCT01529476|Drug|Levofloxacin|levofloxacin 500 mg,QD,7~10 days
75432847|NCT01529476|Drug|Nemonoxacin|Nemonoxacin 500mg,QD,7~10 days
75879745|NCT02037854|Other|Nutrient formulation|
76050413|NCT04706689|Behavioral|FOTT-SAS|"Facial Oral Tract Therapy Swallowing Assessment of Saliva : the results of the SWADOC-scored in one of the sessions will be compared to the FOTT Swallowing Assessment of Saliva (FOTT-SAS) (27). The test is based on 7 questions under which if items 1-4 are answered Yes and items 5-7 are answered No, oral intake should be initiated. The FOTT-SAS includes items that can be scored based on the administration of the SWADOC tool. In that respect, no additional administration will be required"
75728611|NCT06088433|Drug|Clopidogrel|Comparison of 12 month of ticagrelor SAPT（90mgBID*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD * 1 month, followed by clopidogrel 75mgQD)
75728612|NCT06088433|Drug|Aspirin|Comparison of 12 month of ticagrelor SAPT（90mgBID*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD * 1 month, followed by clopidogrel 75mgQD)
76050414|NCT05384197|Drug|Enhanced regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
75728613|NCT06088420|Drug|intrathecal morphine for intrathecal morphine group . bupivacaine 0.25% for Quadratus Lumborum and Erector Spinae nerve block groups .|Intrathecal morphine Group: All members of this group will receive spinal anesthesia with 12 mg 0.5% (2.2ml) hyperbaric bupivicane with intrathecal morphine(100mcg). QLB Group: All members of this group will receive bilateral quadratus lumborum block after spinal anesthesia at end of operation. The QLB will be performed by using bupivacaine 0.25% .ESB Group: All members of this group will receive bilateral erector spinae block after spinal anesthesia at end of operation. The ESB will be performed by using bupivacaine 0.25% (15 ml in each side) .
75879746|NCT01353781|Drug|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
75432848|NCT01529489|Other|Resisted/Aerobic physical training|COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.
75432849|NCT01529489|Other|Interval physical training in elliptical equipament|Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.
75432850|NCT01529489|Other|Interval physical training in elliptical equipament|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
75432851|NCT01529489|Other|Resisted/Aerobic physical training|Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
75432852|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
75432853|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
75579780|NCT04660656|Diagnostic Test|5 repetition sit-to-stand test|"The sit-to-stand test with five repetitive movements is used as standard in our clinical routine to determine the patient's mobility objectively. The first measurement is performed preoperatively during surgery (baseline). The follow-up measurement is performed six weeks after the operation and one year after the operation in the clinic.~A stool with a fixed height is used for this purpose. The patient should cross his arms over the chest and then slowly stand up until the knees are full of space. Then the patient sits down again, of course without support of the arms. The duration of the five movements is recorded using a stopwatch. The complete movement starts after the Go command and ends when the patient is fully upright after the fifth movement. This duration is written down as the patient's score."
75432854|NCT01529528|Drug|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
75579781|NCT00538967|Drug|doxycycline|2 weeks once daily
75579782|NCT04660851|Behavioral|Coached|10-weeks of diet coaching weekly by telephone to improve dietary protein intake
75579783|NCT02410356|Drug|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
75579784|NCT02410356|Drug|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
75579785|NCT00539084|Device|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
75579786|NCT04660734|Procedure|Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.|Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
75579787|NCT00539123|Behavioral|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
75579788|NCT00539123|Behavioral|abstinence-contingent buprenorphine (ACB)|Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.
75432855|NCT01529541|Drug|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
75432856|NCT01529541|Drug|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
75432857|NCT01529554|Drug|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
75432858|NCT01529554|Drug|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
75432859|NCT01529567|Behavioral|Cognitive Behavioral Therapy without exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
75728614|NCT06088407|Drug|with Tranexamic acid|Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively
75432860|NCT01529567|Behavioral|Cognitive Behavioral Therapy with exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
75432861|NCT01529580|Behavioral|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:~One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
75432862|NCT01529619|Drug|Rivastigmine transdermal patch|
75579789|NCT02385201|Device|Senza|Spinal Cord Stimulation
75579790|NCT00539318|Procedure|Blood drawing|Once when enroll in study
75579791|NCT02382510|Drug|TRN-157|
75728615|NCT06088394|Device|Acupuncture|"Participants will be asked to assume supine lying position on the plinth and the following points will be located then needles will be inserted:~CV3,4 &5-40 mm needles at a depth of 1 cun perpendicular insertion.~ST 25 bilaterally-40 mm needles at a depth of 1 cun oblique insertion.~SP6 & 9, K13&7 bilaterally-25 mm needles at a depth of 0.5 cun perpendicular insertion. A total of 13 needles will be inserted at each session."
75728616|NCT06088394|Other|pelvic floor exercises|pelvic floor muscle exercises can help strengthen pelvic floor muscle, which provides better control of urinary urgency by interfering with urethral-detrusor reflexes and inhibiting detrusor contractions
75728617|NCT06088368|Procedure|in-plane needle guidance|Ultrasound -guided lumbar plexus block with in-plane needle guidance using the Shamrock method
75728618|NCT06088368|Procedure|out-of-plane needle guidance|Ultrasound -guided lumbar plexus block with out-of-plane needle guidance using Shamrock method
75728619|NCT06088316|Drug|group A : Amoxicillin Esomeprazole HDDT|"Group A - Amoxicillin 1gm 8 hourly after meal & esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.~Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal & Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days."
75728620|NCT06088316|Drug|group-B : Levofloxacin triple therapy|Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal & Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
75579792|NCT02382510|Other|Placebo|
75579793|NCT02382510|Drug|Tiotropium|
75579794|NCT00539357|Device|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
75579795|NCT00539396|Drug|Technosphere Insulin|
76050415|NCT05384197|Drug|Extended regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)"
76050416|NCT01995201|Drug|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
75432863|NCT01529658|Procedure|Renal hypothermia|"Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery."
75432864|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
75432865|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
75432866|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
75432867|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
75432868|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension BID
75432869|NCT01529684|Drug|radio-labeled OSI-906|Part A: oral solution of 14C-OSI-906
75432870|NCT01529684|Drug|OSI-906|Part B: oral tablets OSI-906
75432871|NCT01529697|Behavioral|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
75432872|NCT01529710|Drug|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
75432873|NCT01529788|Drug|Right lateral orbital injection of Botox Cosmetic or Dysport|Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
75432874|NCT01529788|Drug|Left lateral orbital injection of Botox Cosmetic or Dysport|Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
75432875|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
75432876|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
75432877|NCT01529892|Drug|A single oral 5 mg of duterium labeled methamphetamine|
76050417|NCT01995201|Drug|methotrexate|stable dose
75728624|NCT06088264|Drug|BMS-986322|Specified dose on specified days.
76050418|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
76050419|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
76050420|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
76050421|NCT05383651|Device|bellavista 1000|observational use of Bellavista 1000 ventilator in adult ventilated patients
75432878|NCT01529918|Other|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
75432879|NCT01529931|Device|Hair2Go|Hair2Go treatment once a month for 6 months
75432880|NCT01529957|Drug|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
75432881|NCT01530022|Drug|Lacosamide (LCM)|"LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period"
75432882|NCT01530022|Drug|Carbamazepine Immediate Release (CBZ-IR)|"CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period."
75579796|NCT04660695|Device|EUS-guided gastroenterostomy|Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
75879747|NCT03805880|Diagnostic Test|cerebral desaturation monitoring and cognitive examination|Before general anesthesia, continuous monitoring of cerebral oxygenation(rSO2) was started using an INVOS 5100 (Somaneic, Tro, MI) .Patient cognitive function was assessed using Mini-Mental State Examination (MMSE) on the day before surgery (baseline) and then after 1 day after surgery.
75879748|NCT03561662|Dietary Supplement|Alpro soya drinks|12 weeks
75432883|NCT01530035|Other|physical training|training
75432884|NCT01530048|Drug|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
75432885|NCT01530074|Procedure|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
75432886|NCT01530126|Biological|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
75579797|NCT03456986|Behavioral|PATH neurotraining|Tunes up the center of the motion discrimination (dorsal stream) working range
75579798|NCT03456986|Behavioral|Orientation Discrimination|Tunes up the ventral stream most sensitive to high contrast and colored patterns.
75728625|NCT06088251|Behavioral|Nutri Training|Nutri Training will begin with 1) a presentation of diet counseling evidence and best practices for advising patients, along with information about nutrition recommendations for patients with chronic illness and 2) tools supporting the patient for follow-up. This content will be delivered via a live demonstration of the Nutri interactive software and case demonstration, a novel approach to delivering the learning objectives of standard nutrition education for residents.
75728626|NCT06088251|Behavioral|Standard Nutrition Education|Standard Nutrition Education Standard Nutrition Training will present an overview of 1) nutrition recommendations for patients with chronic disease and 2) cover the role of a registered dietitian and referrals.
75728627|NCT06088225|Device|distance-image screen|Distance-image screen is a screen make each image at distance of 6-meters to reduce the accommodation and convergence for eyes during the reading and learning with screens.
75728628|NCT06088121|Device|ATNC MDD-V1 (Real TMS + Real Cog)|Synchronized TMS and cognitive stimulation to 6 brain areas.
75879749|NCT02051036|Procedure|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
75879750|NCT02053766|Drug|Sevoflurane|Sevoflurane up to 8% will be administered to study subjects
75432887|NCT01530126|Biological|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
75432888|NCT01530126|Biological|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
75432889|NCT01530139|Behavioral|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
75432890|NCT01530139|Behavioral|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
75432891|NCT01530139|Behavioral|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
75432892|NCT01530139|Behavioral|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
75579799|NCT02376465|Drug|BLI4600 bowel preparation|Oral bowel preparation for colonoscopy
75579800|NCT02376465|Drug|PEG based bowel preparation|Oral bowel preparation for colonoscopy
75579801|NCT00539435|Procedure|Intravenous Insulin on cardiac disease in diabetic pts|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
75579802|NCT04660578|Procedure|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
75579803|NCT00539474|Procedure|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
75432893|NCT01530152|Procedure|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.~The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
75579804|NCT04660266|Diagnostic Test|Liver Ultrasound|liver ultrasound examination, including gray-scale and seven Doppler examination
75579805|NCT00539630|Drug|Docetaxel|
75579806|NCT04660461|Drug|Lansoprazole 30mg|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
75579807|NCT04660461|Drug|Placebo|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
75579808|NCT04685330|Procedure|Ultrasound guided procedure|Single-arm, open-label device efficacy study to enroll 200 patients who have been ordered to have an ultrasound-guided procedure by the MGH Interventional Radiology department, including paracentesis, thoracentesis, biopsy, or ultrasound-guided drain placement. Patients will be restricted to adults who can consent.
75579809|NCT04685330|Device|Portable ultrasound|The FDA approved Healcerion SONON portable ultrasound (linear and curved) will be used during clinically indicated standard ultrasound-guided procedures following clinical standard of care. A standard clinical ultrasound will subsequently be used for image guidance as the gold standard. Images will be compared and improved. The efficacy of the portable ultrasound will be monitored by the clinical user and any complications within 30 days will be determined by chart review.
75579810|NCT00539669|Drug|Docetaxel|
75579811|NCT00554424|Drug|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
75579812|NCT00554424|Drug|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
75579813|NCT00539708|Procedure|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
75579814|NCT04660305|Drug|AT278|Concentrated rapid acting insulin aspart
75432894|NCT01530165|Behavioral|Life style counseling|The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat <30 proportion of total energy, saturated fat <10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
75432895|NCT01530204|Procedure|Physical Therapy for knee OA|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
75432896|NCT01530204|Behavioral|Cognitive Behavioral Therapy for Pain CBT-P|8-12 session pain-focused Cognitive Behavioral Therapy
75579815|NCT04660305|Drug|NovoRapid|Rapid acting insulin aspart
75579816|NCT00554502|Drug|supportive therapy with: ACE-inhibitor / ARB / Statin|"Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~Other antihypertensive medications depending on the clinical decision and following current guidelines.~Statin therapy~Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day."
75579817|NCT00554502|Drug|supportive and immunosuppressive therapy|"supportive therapy as outlined above~depending on GFR:~methylprednisolone and prednisolone~cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~Concomitant medication with the immunosuppressive treatment following current clinical practice"
75579818|NCT00539786|Drug|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
75579819|NCT00539825|Drug|GSK704838|
75879751|NCT02053766|Drug|Dexmedetomidine|Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
75579820|NCT04660071|Other|ultrasonographic Assessment,|Ultrasound assessment was performed on rectus femoris (RF), vastus intermedius (VI), vastus medialis (VM) and vastus lateralis (VL) muscles using with an ultrasound-imaging device (Philips Medical Systems EPIQ 5 Release 5.0.2, Amsterdam).
75579821|NCT04660071|Other|Echo intensity Measurements|All images were analysed using the Image J software (Version 1.48v, National Institutes of Health, Bethesda, MD, USA) by two different analysers (five years and one-year of experience in US image analysis).
75579822|NCT00554541|Other|Ankle Brachial Index Venous physiologic study|Assessment of lower extremity venous disease
75579823|NCT00540020|Other|Rehabilitation|
75579824|NCT00554580|Procedure|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
75432897|NCT01530204|Other|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
75432898|NCT01530217|Drug|Ibuprofen.|Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
75579825|NCT00554580|Procedure|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
75579826|NCT02359227|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
75728629|NCT06088121|Device|ATNC MDD-V1 (Sham TMS + Real Cog)|Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
75728630|NCT06088108|Device|Cornell treadmill exercise protocol|Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
75728631|NCT06088095|Other|Mobility group|Patients will be mobilized in accordance with the gradual mobilization procedure 12 hours after the angiography procedure.
75432899|NCT01530230|Drug|oxytocin|Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
75579827|NCT00540098|Drug|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
75579828|NCT00540098|Drug|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
75579829|NCT00540098|Drug|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
75728632|NCT06088082|Drug|Bupivacaine Hydrochloride|Patients will be randomly assigned to receive a TAP and PRS blocks with 34 mL of 0.25% bupivacaine (study group) or standard hospital analgesia protocol (control group).
75879752|NCT02053766|Drug|Propofol|Propofol up to 50 mcg/ kg/min will be administered to study subjects.
75879753|NCT02053844|Other|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
75879754|NCT02053844|Other|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
76050422|NCT05383651|Device|bellavista 1000 neo|observational use of Bellavista 1000 ventilator in neonatal ventilated patients
76050423|NCT04690699|Biological|Lerapolturev|Lerapolturev administered via intravesical instillation once
75432900|NCT01530269|Drug|C11-Sodium Acetate|PET Imaging with C11-Sodium Acetate
75432901|NCT01530282|Other|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
75432902|NCT01530282|Other|Non invasive method|Non_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
75432903|NCT01530295|Drug|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
75432904|NCT01530308|Drug|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
75432905|NCT01530308|Drug|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
75432906|NCT01530321|Other|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
75579830|NCT00540098|Drug|Placebo + relaxation|placebo pill once daily + regular relaxation training
75579831|NCT00540137|Drug|nevirapine|400mg once daily
75728633|NCT06088056|Drug|Combination use of SRT with T-DXd|"Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg"
76050424|NCT04690699|Other|5% DDM|5% DDM and saline washes
75432907|NCT01530321|Other|Light Massage|5 minutes of light pressure massage to the neck and upper back
75432908|NCT01530347|Device|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
75432909|NCT01530360|Device|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
75432910|NCT01530386|Drug|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
75432911|NCT01530412|Other|Pulmonary Rehabilitation|Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
75432912|NCT01530438|Other|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|"At T0 and T9 or 12 monts, are performed :~Imaging : fMRI at rest and anatomical MRI~Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ..."
75432913|NCT01530451|Drug|Desmopressin|120mg OD
75432914|NCT01530451|Drug|Placebo|one tab OD
75579832|NCT00540137|Drug|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
75579833|NCT04660110|Drug|IPT with Dihydroartemisinin Piperaquine|A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
75579834|NCT00540176|Drug|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
75579835|NCT02341560|Drug|QPI-1007 Injection - 1.5 mg|
75579836|NCT02341560|Drug|QPI-1007 Injection - 3.0 mg|
75432915|NCT01530490|Drug|Cabergoline and Hydroxyethyl Starch|0.5mg
75432916|NCT01530490|Drug|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
75728634|NCT06088017|Drug|CKD-391(2)|QD, PO
75728635|NCT06088017|Drug|CKD-331, D337|QD, PO
75728636|NCT06087965|Drug|Fingolimod|0.5mg/day oral fingolimod over a course of 3 consecutive days
75728637|NCT06087952|Other|Randomised treatment advice (discontinue vs continue after 3 months)|Randomisation to continue or discontinue anticoagulant therapy in 1:1 ratio stratified on risk category of L-TRRiP and VTE-BLEED score
76050425|NCT04638387|Dietary Supplement|PB125|Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.
76050426|NCT04638387|Dietary Supplement|Placebo|Placebo comparator to P125
75432917|NCT01530503|Drug|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
75579837|NCT02341560|Other|Sham Injection Procedure|Sham Procedure
75579838|NCT00540215|Other|Glucagonlike peptide|450 nmol native form, synthetic
75579839|NCT00540254|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
75579840|NCT00540254|Other|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
75579841|NCT00540332|Drug|Placebo|Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
76050427|NCT01728454|Drug|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
76050428|NCT01728454|Drug|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
76050429|NCT04568590|Behavioral|educational intervention|If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average > 3), they will be given the informational handout along with a brief script.
75579842|NCT00540332|Drug|palifermin|120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
75579843|NCT02336685|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
75728638|NCT06087952|Diagnostic Test|VTE-BLEED score|Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score
75728639|NCT06087952|Diagnostic Test|L-TRRiP score|Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score
75728640|NCT06087952|Other|Advise to continue anticoagulant treatment after 3 months|Advise to continue anticoagulant treatment after 3 months for patients with high VTE recurrence and low bleeding risk
75728641|NCT06087952|Other|Advise to discontinue anticoagulant treatment after 3 months|Advise to discontinue anticoagulant treatment after 3 months for patients with low VTE recurrence risk
75728642|NCT06087939|Device|Mechanical ventilation|Mechanical ventilation (MV) is a life support technique that is routinely used in the intensive care units (ICUs) for patients with life-threatening conditions.
75728643|NCT06087926|Device|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. TMS is FDA approved for the treatment of depression and other neuropsychiatric disorders and is regularly used in neurologic and psychiatric research.~ITBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatment lasts approximately 3 minutes."
75728644|NCT06087913|Drug|TAF/EVG vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
75728645|NCT06087913|Drug|Matching Placebo vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
75432918|NCT01530503|Drug|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
75728646|NCT06087900|Other|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
75879755|NCT02053922|Drug|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
76050430|NCT04568044|Procedure|Blood sample|Peripheral blood sample will be obtained.
76050431|NCT01636687|Drug|Placebo|2 injections of placebo to secukinumab 150mg per dose
75432919|NCT01530516|Device|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
75432920|NCT01530516|Device|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
75432921|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
75432922|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
75432923|NCT01530529|Drug|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
75432924|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
75432925|NCT01530542|Drug|oxycodone hydrochloride|oxycodone hydrochloride 5 mg tablet under fasted conditions
75432926|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
75432927|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
75432928|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
75432929|NCT01530542|Drug|marketed oxycodone hydrochloride|1 x oxycodone hydrochloride 15 mg tablet under fed conditions
75579844|NCT02336685|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
75579845|NCT02336685|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
75579846|NCT02336685|Drug|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
75579847|NCT00540410|Drug|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
75579848|NCT00540410|Drug|Coartem® (arthemether+ lumefantrine)|"Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days"
75579849|NCT00540488|Other|Adult enteral formula|
75579850|NCT04659837|Behavioral|No-Added-Sugar Diet|All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
75579851|NCT00540527|Drug|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
75579852|NCT00540527|Drug|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
75579853|NCT04659720|Device|Hydrolic lifter device|evaluation of implant stability after closed sinus lifting by hydraulic lift technique using hydraulic lifter device
75579854|NCT04659720|Behavioral|Patient satisfaction evalution using hydraulic lifter device|patients satisfaction will be evaluated numerically after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
75579855|NCT00540605|Drug|Tenofovir 1% vaginal gel|topical gel containing 1% tenofovir
76050432|NCT01636687|Drug|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
75432930|NCT01530555|Drug|Rabbit ATG, Thymoglobuline (Genzyme)|"Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months"
75432931|NCT01530568|Other|Xpert|This arm receives the GeneXpert test
75432932|NCT01530568|Other|Smear|This arm receives smear microscopy
75579856|NCT04659915|Drug|Metformin 500 mg Oral Tablets + Prednisone 20mg Tablets|"During one phase of the study: Metformin 500mg Day 1 1-0-0 Day 2 1-0-0 Day 3 1-0-1 Day 4 1-0-1 Day 5 2-0-1 Day 6 2-0-1 Day 7 4-0-0~In combination with prednisone 20mg: day 1 to day 7 1.5-0-0."
75579857|NCT04659915|Drug|Placebo 500 mg Tablets + Prednisone 20mg Tablets|During another phase of the study: identical looking placebo pills starting day 1 500mg 1-0-0, day 2 500mg 1-0-0, day 3 500mg 1-0-1, day 4 500mg 1-0-1, day 5 500mg 2-0-1. day 6 2-0-1, day 7 4-0-0. In combination with prednisone 20mg: day 1 to day 7 1.5-0-0.
75579858|NCT00557427|Drug|hypericum|250mg tablets twice daily for 8 weeks
75579859|NCT00557427|Drug|fluoxetine|20mg - 40mg daily for 8 weeks
75579860|NCT00540800|Drug|docetaxel|given in combination with epirubicin or capecitabine
75432933|NCT01530581|Procedure|G-PB Transplant|G-PB Transplant
75432934|NCT01530581|Procedure|G-BM Transplant|G-BM Transplant
75432935|NCT01530594|Drug|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
75432936|NCT01530594|Drug|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
75579861|NCT00540800|Drug|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
75432937|NCT01530594|Drug|Lenalidomide|Lenalidomide/Low dose Dex (LLD
75432938|NCT01530607|Drug|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
75432939|NCT01530607|Drug|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
75432940|NCT01530620|Drug|Propiverine hydrochloride ER (extended release)|45 mg capsule (1x1/d)
75432941|NCT01530620|Drug|Propiverine hydrochloride IR (immediate release)|15 mg tablet (3x1/d)
75579862|NCT00540800|Drug|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
75579863|NCT00540878|Drug|SB-751689 oral tablets (400 mg)|
75728647|NCT06087900|Other|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
75728648|NCT06087900|Other|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
75728649|NCT06087900|Other|Control|The CON group did not have any intervention but usual care.
75728650|NCT06087887|Other|no interventions|no interventions
75579864|NCT00540917|Procedure|cooling spray during laser treatment|skin temperature measurement
75579865|NCT04659876|Diagnostic Test|clinical features and laboratory values|Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
75879756|NCT02053922|Drug|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . [Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
76050433|NCT01636687|Drug|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
75579866|NCT00540956|Drug|cytarabine|
75579867|NCT00540956|Other|laboratory biomarker analysis|
75579868|NCT04678596|Device|EonAligner|EonAligner system is one stage system.
75579869|NCT04678596|Device|Clearfix|Clearfix system is three-stage system.
75579870|NCT00541073|Dietary Supplement|vitamin B12|
75579871|NCT00541073|Drug|cisplatin|
75579872|NCT00541073|Drug|pemetrexed disodium|
75579873|NCT00541073|Genetic|gene expression analysis|
75579874|NCT00541073|Other|laboratory biomarker analysis|
75579875|NCT00541073|Other|pharmacological study|
75579876|NCT04678323|Drug|Lifestyle Management|Participants in this group will receive lifestyle management.
75579877|NCT00541112|Biological|cetuximab|
75432942|NCT01530646|Behavioral|Weight loss|-750kcal/d
75579878|NCT00541112|Drug|capecitabine|
75579879|NCT00541112|Drug|fluorouracil|
75728651|NCT06087874|Dietary Supplement|Vivomixx®|The probiotic group participants will receive 1 sachet of probiotic product daily from 36weeks of gestation up to 7th day of postpartum while placebo groups will 1 sachet placebo prepared with the same colour, taste, and packaging with Vivomixx® daily for the same duration of probiotic groups. Vivomixx® is a non-genetically modified (GMO), gluten-free, high potency microbiotic food supplement, containing eight strains (Streptococcus thermophilus DSM24731® / NCIMB 30438, Bifidobacterium breve DSM24732® / NCIMB 30441, Bifidobacterium longum DSM24736® / NCIMB 30435, Bifidobacterium infantis DSM24737® / NCIMB 30436*, Lactobacillus acidophilus DSM24735® / NCIMB 30442, Lactobacillus plantarum DSM24730® / NCIMB 30437, Lactobacillus paracasei DSM24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM24734® / NCIMB 30440) of live bacteria (450 billion bacteria per sachet).
75879757|NCT02053922|Drug|Misoprostol|Misoprostol (200 mcg Tablet) [Misotac, Sigma Pharmaceutical Industries, SAE, Egypt] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
75879758|NCT02052206|Procedure|Shoulder replacement surgery|
75879759|NCT02054000|Drug|Tirofiban|Intracoronary administering of Tirofiban
75432943|NCT01530646|Dietary Supplement|Soy|2 x 25g/d SPC
75432944|NCT01530646|Dietary Supplement|Whey|2 x 25g/d WPI
75728652|NCT06087874|Dietary Supplement|Placebo|A maltose- containing product with a similar phenotype with Vivomixx®.
75432945|NCT01530672|Device|MBIO POC combined HIV syphilis test ( SnapEsi)|Venipuncture for routine ANC screening plus additional for device validation purposes.
75879760|NCT02054000|Other|Placebo|Intracoronary serum physiologic
75879761|NCT02054078|Drug|Bevacizumab|Bevacizumab200mg by intrapleural administration
75879762|NCT02054078|Drug|Pulvis talci|Pulvis talci 4g by intrapleural administration
75432946|NCT01530685|Dietary Supplement|Glycabiane|2 gelule per day for 4 months
75432947|NCT01530685|Dietary Supplement|placebo|2 gelules per day for 4 months
75432948|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
75432949|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
75432950|NCT01530711|Drug|Terlipressin and albumin|"Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase < 10 mmHg and the creatinine values decrease <25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.~Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day."
75579880|NCT00541112|Drug|leucovorin calcium|
75579881|NCT00541112|Drug|oxaliplatin|
75579882|NCT00541112|Procedure|adjuvant therapy|
75579883|NCT00541112|Procedure|conventional surgery|
75579884|NCT00541112|Procedure|neoadjuvant therapy|
75579885|NCT00541112|Radiation|radiation therapy|
75579886|NCT04678011|Procedure|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
75579887|NCT00541151|Device|MiniArc|sling system
75579888|NCT04659447|Drug|Platelet-Rich Plasma|36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
75579889|NCT05086523|Device|Programmable Hypertension Control (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
75579890|NCT05086523|Device|Pacing (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
75728653|NCT06087861|Radiation|External Beam Radiotherapy|Radiation will be delivered by external beam techniques to the tumor and areas of possible microscopic disease at a dose of 30 Gy divided into 5 equal fractions of 6 Gy (administered over a total of 5 to 10 business day
75879763|NCT02052284|Other|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
75879764|NCT02051192|Behavioral|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
75432951|NCT01530724|Other|Weight-loss diet strategy (+) exercise (PA)|Weight-loss diet strategy with a free gym membership; monthly 60-minute educational workshops; 3 sessions of workout per week of mostly aerobic training
75432952|NCT01530724|Other|weight loss (-) exercise (PA)|Weight-loss diet strategy without exercise
75432953|NCT01530737|Drug|Antithrombin III|Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
75579891|NCT04659525|Drug|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
75579892|NCT04659525|Drug|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
75579893|NCT04659525|Drug|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
75579894|NCT03456908|Combination Product|18F-TFB-PET|Infusion of F-18 TFB and PET / CT imaging
75579895|NCT02333643|Drug|CLS003|
75579896|NCT02333643|Drug|Furosemide|
75579897|NCT02333643|Drug|Digoxin|
75579898|NCT02333643|Drug|Vehicle topical|
75579899|NCT03456869|Device|Patient Specific Implant|The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
75579900|NCT04659330|Behavioral|Online education (BdandMe) for injection technique|patients were referred to the relevant modules on BD and Me™ (for online education)
75579901|NCT04659330|Device|4mm needles|Providing a supply of needles for single use of 4mm insulin injection needle.
75579902|NCT00541424|Procedure|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
75579903|NCT02330445|Drug|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
75579904|NCT00541463|Drug|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
75728654|NCT06087848|Biological|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
75879765|NCT02051192|Other|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
75879766|NCT02052362|Drug|ABT-450/r/ABT-267|ABT-450, ABT-267 and ritonavir
75432954|NCT01530737|Other|Saline Placebo|Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
75579905|NCT00541463|Drug|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
75579906|NCT04659486|Behavioral|Home-based exercise training|Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
75579907|NCT02324985|Drug|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
75579908|NCT02324985|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
75579909|NCT00541541|Procedure|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
75579910|NCT02314299|Drug|MTP-131|
75579911|NCT04659681|Diagnostic Test|PVI Guided fluid management during surgery for (PVI<12) colloid bolus will be given .|PVI probe attached to finger in PVI Group
75579912|NCT04659681|Diagnostic Test|CVP Guided Fluid management during surgery for CVP<10 cms H2O colloid bolus will be given|Placement of central venous catheter
75432955|NCT01530763|Drug|Ceftaroline fosamil|"Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children < 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)"
75432956|NCT01530763|Drug|Ceftriaxone|"Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)"
75432957|NCT01530763|Drug|amoxicillin clavulanate|"Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)"
75728655|NCT06087809|Behavioral|Education and feedback|"Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email."
75879767|NCT03561506|Drug|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
75879768|NCT03561506|Drug|0.9% Normal Saline|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
75432958|NCT01530776|Behavioral|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
76050434|NCT05213377|Procedure|Preoperative warming|Patients enrolled in surgery who will not receive 30 minutes of pulsed air thermal blanket warming prior to induction of anesthesia (3M™ Bair Hugger™ Adult Integral Blanket, Model 300 Dimensions: 213 cm x 91 cm)
76050435|NCT01634659|Device|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
75579913|NCT04659642|Drug|Dexmedetomidine Injection [Precedex]|the drug is given 15 minutes before the estimated end of surgery
75579914|NCT04659642|Drug|Fentanyl Citrate Injection|the drug is given 15 minutes before the estimated end of surgery
75579915|NCT04659642|Combination Product|dexmedetomidine and fentanyl|the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
75579916|NCT00541736|Drug|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
75579917|NCT02306811|Drug|Vatelizumab|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
75579918|NCT00541814|Drug|Cyclosporine|Target drug level 50-100 ng/ml or cyclosporine withdrawal
75579919|NCT04659564|Device|User of Dayspring device|The Dayspring™ device is a novel FDA-cleared wearable solution that is portable and easy-to-use sequential compression system.
75579920|NCT00541853|Drug|Candesartan|Candesartan upto 8mg
75579921|NCT00541853|Drug|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
75579922|NCT00541853|Drug|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
75579923|NCT02301234|Drug|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
75579924|NCT02301234|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
75579925|NCT02301234|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
75579926|NCT02301234|Drug|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
76050436|NCT01634659|Device|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
76050437|NCT05652985|Behavioral|Inter-professional Collaboration Training|the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration
75579927|NCT02301234|Drug|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
75579928|NCT00541892|Other|Medium with no human serum albumine added|See above
75579929|NCT00541892|Other|Conventional medium|See above
75579930|NCT00542048|Drug|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
75579931|NCT02300142|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
75579932|NCT02300142|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
75579933|NCT02300142|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
75579934|NCT02300142|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
75579935|NCT02300142|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
75579936|NCT00539903|Behavioral|Physical activity (PA) and immigrants|
75432959|NCT01530802|Procedure|clipping of uterine arteries during laparoscopic myomectomy|For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
75579937|NCT01214668|Drug|LY573636-sodium|"Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met."
75728656|NCT06087809|Behavioral|Clinical decision support|"Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration."
75728657|NCT06087796|Drug|Betamethasone Valerate 0.1% Cream|Topical treatment modality for alopecia areata.
75728658|NCT06087796|Drug|Pentoxifylline|Topical treatment modality for alopecia areata.
76050438|NCT05165641|Procedure|segmental spinal anesthesia|Spinal anesthesia was performed at a lower thoracic level with the patient in the sitting position. After local anesthesia with 1% lidocaine, the spinal puncture was done in the 10th thoracic intervertebral space (T 10) through a median approach. A 27 Gg pencil-point needle with an introducer was used (marquee). To identify T 10, the vertebra prominens (C7) was palpated and the spinous processes were palpated caudally [ref}. Two senior anesthesiologists performed all the spinal punctures. The progression of the spinal needle was cautious and soft. The effort was made to stop the needle progression just after the tactile perception of the dura mater. Once the flow of cerebrospinal fluid was obtained, 1.5 ml of hyperbaric bupivacaine 5mg/ml (=7.5 mg) mixed with 0.5 ml of fentanyl 50 µg/ml (= 25 µg) was injected and the spinal needle removed.
76050439|NCT04796467|Drug|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
75579938|NCT01214668|Drug|Liposomal Doxorubicin|"40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
75579939|NCT00542126|Drug|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
75579940|NCT02886832|Dietary Supplement|Prostate Health formulation|
76050440|NCT04796467|Drug|68Ga-P16-093|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
76050441|NCT05814471|Device|Cable fastening system and 3d printed straps|The participants will wear a Odra knee brace held in place with by a cable fastening system and 3d printed straps for 2 weeks.
76050442|NCT05814471|Device|Velcro straps system|The participants will wear a Odra knee brace held in place with by a velcro straps system for 2 weeks.
76050443|NCT05814458|Device|tDCS|Patients will be receiving twice a day tDCS (applied current at 2mA) stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
75579941|NCT02293941|Drug|JKB-122 5mg|Participants were randomized to receive JKB-122 5mg for 12 weeks
75579942|NCT02293941|Drug|JKB-122 15mg|Participants were randomized to receive JKB-122 15mg for 12 weeks
75728659|NCT06087796|Drug|Metformin|Topical treatment modality for alopecia areata.
75728660|NCT06087783|Dietary Supplement|Experimental product - Fortifit® Powder|Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
75728661|NCT06087783|Other|Standard of care|Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement
75579943|NCT02293941|Drug|JKB-122 35mg|Participants were randomized to receive JKB-122 35mg for 12 weeks
75579944|NCT02293941|Drug|Placebo|Participants were randomized to receive comparable placebo for 12 weeks
75879769|NCT01336439|Drug|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography."
75432960|NCT01530815|Drug|Bupivicaine Infusion|Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
76050444|NCT05814458|Device|Placebo|Patients will be receiving twice a day sham stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
76050445|NCT05814445|Other|Neuromuscular exercise program|Participants will complete a neuromuscular program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and training to improve hip and knee muscles strength, proprioception, and core stability.
76050446|NCT05814445|Other|Institutional exercise program|Participants will complete an institutional exercise program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and concentric and eccentric knee exercises.
76050447|NCT05814432|Drug|Liposomal Amphotericin B|Single high dose (10mg/kg) Standard treatment on 14 days (3mg/kg)
76050448|NCT05814380|Radiation|99mTc-DPD scintigraphy|99mTc-DPD scintigraphy
75432961|NCT01530841|Device|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
75432962|NCT01530893|Dietary Supplement|Flavanone - supplement|acute single optimal dose
75432963|NCT01530893|Other|Flavanone - food|acute single dose
75432964|NCT01530893|Other|Flavanone - placebo|acute single dose (flavanone free)
75432965|NCT01530893|Dietary Supplement|Isoflavone - supplement|acute single optimal dose
75432966|NCT01530893|Other|Isoflavone - food|acute single optimal dose
75432967|NCT01530893|Other|Isoflavone - placebo|acute single dose (isoflavone free)
75432968|NCT01530893|Dietary Supplement|Isoflavone - metabolite supplement|acute single optimal dose of commercial product
75432969|NCT01530893|Dietary Supplement|Flavan-3-ol - supplement|acute single optimal dose
75432970|NCT01530893|Other|Flavan-3-ol - food|acute single optimal dose
75579945|NCT00542165|Drug|Alfuzosin|
75579946|NCT02289846|Drug|IW-9179|
76050449|NCT05814380|Diagnostic Test|Collection of blood samples and echocardiography|Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
75579947|NCT02289846|Drug|Matching Placebo|
75432971|NCT01530893|Other|Flavan-3-ol - placebo|acute single dose (flavan-3-ol free)
75432972|NCT01530893|Dietary Supplement|Anthocyanin - supplement|acute single optimal dose
75432973|NCT01530893|Other|Anthocyanin - food|acute single optimal dose
75432974|NCT01530893|Other|Anthocyanin - placebo|acute single dose (anthocyanin free)
75432975|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
75579948|NCT00542204|Behavioral|Online disease management|The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
75879770|NCT01336595|Device|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
75432976|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
75579949|NCT04648800|Drug|BCG-10 vaccine|"The BCG-10 anti-tuberculosis vaccine~powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~lyophilised BCG vaccine~one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain."
75579950|NCT04648800|Drug|0.9% saline|0.9% saline
75432977|NCT01530919|Procedure|Minimally invasive radioguided parathyroidectomy|After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
76050450|NCT05814328|Other|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
76050451|NCT05814302|Drug|Paracetamol|Emergency physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I)
76050452|NCT05814289|Other|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
76050453|NCT05814276|Behavioral|Training on non-pharmacological therapies' methodology|"The San Rocco study encompasses a training on the non-pharmacological therapies' methodology. It allows the professional caregiver to methodological definition of the non-pharmacological interventions and a comparison of shared readings of the challenging behaviors by the group of colleagues. Participants will follow:~Five meetings, lasting 11 hours overall, on the multidimensional assessment, the shared readings of behavioral disorders of each person and identification of the objectives through the discussion of cases, and administration of non-pharmacological therapies within the framework of the personalization of the interventions~Five meetings, lasting five and a half hours, for the supervision of the staff which implement the non-pharmacological therapies.~As usual control group Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training."
75432978|NCT01530958|Behavioral|CKD Registry|"Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~identify patients with CKD~notify PCPs of a patients' CKD status~provide PCP outreach with NKDEP guidelines and patient educational materials"
75432979|NCT01530958|Behavioral|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
76050454|NCT05814263|Device|HIS/LBB pacing|3830 lead to HIS or LBB
75579951|NCT00542243|Drug|Finasteride|Finasteride (5mg) will be given once per day for 6 months.
75579952|NCT00542243|Drug|Placebo|Placebo will be given once a day for 6 months.
75728662|NCT06087744|Behavioral|NeuroN-QI|Skin-to-skin contact (SSC) lasting 2 hours with an auditory sensory stimulation followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.
76050455|NCT05814263|Device|LV pacing|LV lead in a CS branch
75728663|NCT06087744|Behavioral|SSC alone|Skin-to-skin contact (SSC) lasting 2 hours
76050456|NCT05814237|Other|Data collection|Data collection from study participants to characterise diagnostic and therapeutic practices.
75728664|NCT06087718|Device|Maastro applicator|The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size < 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.
75432980|NCT01530958|Behavioral|Usual care|"Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care."
75432981|NCT01530971|Drug|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
75432982|NCT01530984|Drug|Ipilimumab|Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
75579953|NCT02286804|Device|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
75579954|NCT02286765|Device|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
75579955|NCT00542360|Behavioral|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
75579956|NCT02283957|Drug|CNTX-4975|
75579957|NCT02283957|Other|Placebo|
75579958|NCT04648995|Device|High energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
75432983|NCT01530984|Drug|GM-CSF|GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
76050457|NCT05814224|Diagnostic Test|Liquid biopsy and CT scan|"CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation"
76050458|NCT05814185|Device|Periodontal distractor|different activation protocols of periodontal distractor
75432984|NCT01531010|Device|Ventilation protocol delivered by the SLE5000 ventilator|"In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
75432985|NCT01531036|Device|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
75579959|NCT04648995|Device|Low energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
76050459|NCT05814315|Behavioral|HOPE Intervention|Participants used the Health Checkins Platform for 12 weeks for emotional support and to obtain pain management tools
76050460|NCT05814120|Behavioral|BLS training program|BLS training program was in accordance with the 2020 AHA cardiopulmonary resuscitation (CPR) guidelines. The BLS training program adopts 4D teaching techniques, namely description (Describe), demonstration (Demo), implementation (Do), feedback (Debriefing).
76050461|NCT05814094|Other|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.
75879771|NCT01336595|Device|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
76050462|NCT05814094|Other|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
76050463|NCT05814081|Procedure|Position/Ventilation|Positioning and ventilation mode adjustments were made to the patients.
75432986|NCT01531049|Drug|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
75432987|NCT01531049|Drug|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
75432988|NCT01531049|Drug|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
75432989|NCT01531049|Other|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
75432990|NCT01531062|Drug|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
76050464|NCT05814068|Drug|antihypertensive drug treatment|Patients with hypertension will be treated for it by their physician
75432991|NCT01531062|Dietary Supplement|black sticky rice|300 mg capsule bid, 56 days
75579960|NCT00542399|Drug|Levemir (insulin detemir)|Levemir once a day
75579961|NCT00542399|Drug|Levemir twice a day|Levemir twice a day
75579962|NCT04648722|Procedure|Hemithyroidectomy|We investigated patients who received a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism, Medical University of Vienna between 1994 and 2018.
75579963|NCT00542516|Drug|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
75879772|NCT01336751|Drug|Insulin glargine|solution for subcutaneous injection
75579964|NCT00542516|Drug|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
75432992|NCT01531075|Biological|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
75432993|NCT01531075|Biological|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
75579965|NCT02266719|Device|Fenestrated CMD|"The CMD that will be used in this IDE is structurally the same as the commercially available Zenith Fenestrated AAA Endovascular Graft.~In general, the Zenith® Fenestrated AAA Endovascular Graft is a modular system constructed of full- thickness woven polyster fabric sewn to self-expanding stainless steel z-stents with braided polyster and monofilament polypropylene sutures. In this study, fenestrated grafts with usually up to 4 fenestrations may be used.~Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms."
75728665|NCT06087705|Device|Intra-articular injection of hyaluronic acid|"The injection must necessarily be performed by a practitioner in compliance with the rules of asepsis.~Procedure of use:~Before the injection, a rigorous prior disinfection of the area to be treated will be carried out.~Check the integrity of the sterility protector.~Take the syringe and remove the protective tip.~Hold the syringe body and insert a sterile intra-articular injection needle into the Luer-Lock system.~Gently turn the needle clockwise to secure the needle in the Luer-Lock system.~A visual check of the attachment of the needle will be carried out.~Remove the needle cap.~Inject slowly."
75728666|NCT06087692|Other|Exercise|-based game therapy applied in addition to aerobic exercise
75728667|NCT06087666|Procedure|FICare|The Family Integrated Care (FICare) programme has been developed in a multicenter cluster randomised controlled trial, with 26 tertiary NICUs from Canada, Australia and New Zealand, comparing standard NICU care (which was mainly care by nurses) (891 infants) to FICare programme (895 infants). FICare model and showed that the involvement of parents in the direct care improved weight gain and increased breastfeeding rates in the preterm infants. In addition, their parents had lower rates of stress and anxiety. These results were confirmed in a cluster-randomised controlled trial. Subsequent studies carried out so far have shown promising positive effects on a variety of domains. Maturation profiles have been shown to accelerate with the FICare intervention as a shorter time to achieve exclusive enteral nutrition as well as oral nutrition has been shown in the preterm infants included in FICARE programmes compared to control babies
75432994|NCT01531088|Behavioral|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
75432995|NCT01531101|Behavioral|Individual psychodynamic psychotherapy|Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
75728668|NCT06087653|Drug|Lenalidomide|Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone
75728669|NCT06087588|Drug|0.9%sodium chloride|PENG sham block with 20ml 0,9% normal saline
75728670|NCT06087588|Drug|95% ethanol|PENG neurolysis with 2.5ml of 95% ethanol
75728671|NCT06087575|Device|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
75728672|NCT06087562|Drug|Ropivacaine 0.5% Injectable Solution 20mL|Ultrasound-guided iPACK block with 20mL of 0,5% ropivacaine
76050465|NCT05814003|Drug|hydroxylate flavones solid dispersion application|this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing
76050466|NCT05814003|Other|Placebo|Dough inert material without any therapeutic action
75432996|NCT01531114|Drug|ticagrelor|Patients will be randomized to this arm to receive loading dose of ticagrelor
75432997|NCT01531114|Drug|prasugrel|Patients will be randomized to this arm to receive loading dose of prasugrel
76050467|NCT05813977|Device|tritube|The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
76050468|NCT05813951|Drug|Linezolid|linezolid either continues infusion or standard intermittent dose
75432998|NCT01531140|Drug|polyethylene glycol +Bisacodyl|Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
75432999|NCT01531140|Drug|Polyethylene glycol|Polyethylene glycol p.o.: 60 ml/kg/days
75433000|NCT01531140|Drug|Sennosides|Sennosides 1tbl/8kg for 2 days
75433001|NCT01531166|Drug|pegylated Interferon-alpha 2a|Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
75433002|NCT01531179|Drug|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
75433003|NCT01531179|Drug|Placebo|Placebo for 3 months
75433004|NCT01531192|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
75879773|NCT01336751|Drug|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
75879774|NCT01336829|Drug|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
76050469|NCT05813938|Device|LabTest Checker|A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
75728673|NCT06087562|Drug|0,9% normal saline 20mL|Ultrasound-guided placebo block with 20mL of 0,9% normal saline
75728674|NCT06087341|Other|NKG2D-CAR memory T cell|Patients will be allocated in two groups: Arm A and Arm B. Both groups will receive an intravenous infusion of NKG2D-CAR memory T cells. Additionally, patients on Arm B will receive an intratumoral dose of NKG2D-CAR memory T cells (in accessible primary tumor and metastases). The distribution of patients on one arm or other will depend on their clinical characteristics described in the inclusion/ exclusion criteria. All patients will receive lymphodepleting chemotherapy prior to the infusion of NKG2D-CAR memory T cells according to the usual clinical practice in our center. Some patients will also receive low dose radiotherapy prior to infusion.
75433005|NCT01531192|Drug|Nystatin|50000 unit/3 times a day, both for orally and by orogastric route
75433006|NCT01531218|Drug|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
75433007|NCT01531218|Drug|Placebo|
75433008|NCT01531244|Biological|dactinomycin|Given via ILI
75728675|NCT06086821|Diagnostic Test|Periodontal Re-Evaluation|Recording of the periodontal charting
75728676|NCT06086535|Procedure|Intercostal nerve cryoanalgesia vs BRILMA blockade|For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery
75728677|NCT06086015|Device|transcranial alternating current stimulation (tACS)|2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)
75433009|NCT01531244|Drug|melphalan|Given via ILI
75433010|NCT01531244|Biological|Conditionally replicative adenovirus 3/5-delta|Given via ILI
75728678|NCT06085729|Drug|ADI-PEG 20|Given by Injection
75728679|NCT06085729|Drug|Cabazitaxel|Given by IV (vein)
75728680|NCT06085729|Drug|Carboplatin|Given by IV (vein)
75728681|NCT06085651|Procedure|Selective thoracolumbar fusion (STLF) surgery|Selective thoracolumbar fusion (STLF) surgery, is an established corrective surgical technique for spinal deformities with excellent outcomes over time
75728682|NCT06084832|Biological|blood microsampling|blood microsampling for the measure of Phosphatidylethanol
75728683|NCT06084377|Genetic|Preimplantation Genetic Screening|Non-invasive technique to investigate the presence of genetic disorders.
75728684|NCT06083922|Drug|Cyclophosphamide|Days 1, 8 and 15, Cycles 1-8
76050470|NCT05813886|Other|biodex balance system|The balance tests of the patients were performed 2 to24 WEEKS after their recovery from the disease, which was confirmed by the evaluations of the Covid-19 staff and negative polymerase chain reaction test.
75433011|NCT01531283|Drug|unacylated ghrelin|IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
75433012|NCT01531283|Drug|acyl ghrelin|IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
75433013|NCT01531283|Drug|combined acyl and desacyl ghrelin|IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
75433014|NCT01531283|Drug|saline|IV, saline, one time, for the duration of the study visit(approximately 5 hours)
75433015|NCT01531309|Drug|AGO178|AGO178 is administered as a sublingual tablet.
75433016|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
75433017|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
75879775|NCT01336829|Drug|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
75879776|NCT01336829|Drug|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
75728685|NCT06083922|Drug|Bortezomib|Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+
75579966|NCT02266719|Device|Type I - III TAAA|"Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms. Devices will be implanted in patients with type I-III thoracic abdominal aneurysms.~The branches in this study will be constructed as internal/external cuffs, axially oriented and caudally or cranially directed, as necessary . Branch position will be determined by the anatomic location of the target vessels using a consistent craniocaudal and circumferential cuff position."
75728686|NCT06083922|Drug|Dexamethasone|Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8
75728687|NCT06083922|Drug|Daratumumab|Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+
75433018|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
75879777|NCT01336829|Drug|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
75879778|NCT01340183|Drug|AZD5099|IV Dose
75579967|NCT02266719|Device|Arch cohort|Arch branched devices may be designed using one of two configurations: (1) Zone 0 device with two inner antegrade branches for the innominate artery and the left common carotid artery with or without a retrograde left subclavian artery branch and (2) Zone 1-2 device with a single retrograde subclavian artery branch with double or triple wide scallop for the left common carotid artery. These devices are designed for a of proximal landing/fixation zone of at least 20 mm of healthy aortic segment or a previous graft.
75579968|NCT03456830|Drug|ALLN-177|ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
75433019|NCT01531348|Other|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
75579969|NCT03456830|Drug|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
75579970|NCT02265393|Drug|OTO-104|
75579971|NCT02265393|Drug|Placebo|
75579972|NCT00542555|Drug|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
75579973|NCT00542555|Drug|Naproxcinod 375 mg|
75728688|NCT06082947|Device|CliniMACS®|CliniMACS® αβT cell/CD19+B cell depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
75728689|NCT06082908|Diagnostic Test|Diagnostic test|Subjective and objective measurement will be performed in older adults.
75879779|NCT01340183|Drug|Placebo|IV Dose
75879780|NCT02960490|Drug|E6011|subcutaneous administration
75879781|NCT02960490|Drug|Placebo|subcutaneous administration
75433020|NCT01531361|Drug|Crizotinib|Given PO
75433021|NCT01531361|Other|Laboratory Biomarker Analysis|Correlative studies
75433022|NCT01531361|Other|Pharmacological Study|Correlative studies
75433023|NCT01531361|Drug|Sorafenib Tosylate|Given PO
75433024|NCT01531361|Drug|Vemurafenib|Given PO
75433025|NCT01531400|Other|self-selected music|Investigators played self-selected background music in the music group
75579974|NCT00542555|Drug|Naproxen|
75879782|NCT02804750|Drug|CORT125134|
75879783|NCT05184491|Drug|Naïve patients - ACO therapy|Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
75879784|NCT05184491|Drug|Naïve patients - LNDL therapy|Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
75879785|NCT05184491|Drug|Naïve patients - MNDL therapy|Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
75879786|NCT05184491|Drug|Treatment-experienced patients- LNDL therapy|Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
75879787|NCT05184491|Drug|Treatment-experienced patients- MNDL therapy|Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
75879788|NCT01340339|Device|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
75579975|NCT00542555|Drug|Naproxcinod 750 mg|
75579976|NCT04648488|Other|Experimental early mobilisation|early activ assisted exercises treatment
75579977|NCT04648488|Other|Aktive comparator standrad treatmnet|standard treatment with a plaster 3 weeks and then active assisted exercises
75579978|NCT04685018|Device|fMRI acquisition|Participants from the two groups will perform an avoidance-relief task inside an MRI scanner
75433026|NCT01531413|Other|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
75433027|NCT01531426|Device|near infrared spectroscopy (INVOS®, Covidien)|Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
75579979|NCT02260674|Drug|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
75579980|NCT02260674|Drug|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
75579981|NCT02260674|Drug|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
75579982|NCT00542711|Drug|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
75579983|NCT04679025|Other|Exposure - postoperative hyperglycemia|Postoperative hyperglycemia (blood or capillary glucose > 10.0 mmol/L) within 72 hours of a surgical procedure
75433028|NCT01531452|Drug|Oxaliplatin|130mg/m2 d1,repeated q21d
75579984|NCT04678128|Behavioral|Dance4Healing Telehealth Live Zoom Sessions|"Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class."
75579985|NCT04678128|Behavioral|Dance Buddy|"Following randomization (beginning of intervention period) half of the participants will be assigned a dance buddy, and will be asked to dance with their buddies using the Dance4Healing TLVP at least 2 additional times/week. This group will have 24/7 access to Dance4Healing Platform during the intervention and post-intervention periods."
75728690|NCT06082830|Behavioral|Intervention|"The intervention arm includes five components:~Personalized goal: Participants will complete an interview with a registered dietitian to review their baseline diet quality data and establish their personalized dietary goals.~Meal timing: Participants will receive information on why eating later at night is detrimental and specific strategies on how to limit eating past 8pm in the evening.~Nutrition skills: Participants will receive nutrition education and cooking skills text messages, using adolescent specific guidance from the Dietary Guidelines for Americans.~Home food environment: Participants will receive text messages on how to better select and prepare foods in the home environment (e.g., fruit and vegetable availability).~Engagement strategies: Researchers will design and implement text messages that recognize participant time and effort (e.g., text badges in recognition of completing the first study week)."
75728691|NCT06082544|Other|mini-screw implant|JEIL SCREW 1.6* 8 MM 16-G2-008 or JEIL SCREW 1.6*10 MM 14-G2-010
75728692|NCT06082544|Device|removable partial denture|Acrylic removable partial denture
75728693|NCT06080204|Drug|Octreotide LAR|Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
75728694|NCT06079307|Other|Oxygenated Mouthwash|Will be comparing the impact of using oxygenated mouthwash with other groups.
75433029|NCT01531452|Drug|s1|80mg/m2/d, d1-14,repeated q21d
75433030|NCT01531465|Other|Pulmonary Function Testing & esophageal pressure monitoring|Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
75433031|NCT01531465|Other|Pulmonary function testing and esophageal pressure|Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
75579986|NCT00542906|Other|localization|localization of the several types of somatosensory stimuli
75579987|NCT04678674|Procedure|tooth root augmentation|Autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement.
75579988|NCT00542945|Device|ICD|Implantation of an ICD
75579989|NCT00542945|Other|Optimal medical treatment|ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
75433032|NCT01531478|Other|Unique medical visit of the study|"The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia)."
75433033|NCT01531491|Procedure|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
75433034|NCT01531491|Procedure|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
75433035|NCT01531504|Device|ViKY UP|laparoscopic-assisted hysterectomy procedure
75433036|NCT01531517|Drug|Royal Jelly and Panthenol (PedyPhar® Ointment)|"the following will be done to each patient depending on the number of the visit:~Assessment of the patient for inclusion/exclusion criteria~Informed consent process~Medical history of the patient~Blood withdrawn for investigation~Drainage of the ulcer if there is a collection~Revascularization as needed and indicated by APSV done at visit 0.~Swab from the ulcer for culture and micro-organism count: on detailed visits only.~Debridement as needed.~Dressing:~Inspection and assessment of the ulcer~Irrigation using 500 ml of saline or as required.~Drying of the ulcer (leave to dry)~Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~Fix the dressing to the ulcer"
75433037|NCT01531517|Drug|Panthenol Ointment|"the following will be done to each patient depending on the number of the visit:~Assessment of the patient for inclusion/exclusion criteria~Informed consent process~Medical history of the patient~Blood withdrawn for investigation~Drainage of the ulcer if there is a collection~Revascularization as needed and indicated by APSV done at visit 0.~Swab from the ulcer for culture and micro-organism count: on detailed visits only.~Debridement as needed.~Dressing:~Inspection and assessment of the ulcer~Irrigation using 500 ml of saline or as required.~Drying of the ulcer (leave to dry)~Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~Fix the dressing to the ulcer"
75433038|NCT01531530|Biological|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|The vaccine is mixed with salt water and given by mouth.
75433039|NCT01531530|Other|Placebo|Corn starch and baking soda are mixed with salt water and given by mouth.
75433040|NCT01531543|Device|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
75433041|NCT01531569|Other|BeneFlax - 38% secoisolariciresinol diglucoside (SDG)|0.8g of BeneFlax (contains 300mg SDG) given once by mouth
75433042|NCT01531595|Drug|Bevacizumab plus alternating Xelox/Xeliri|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
75433043|NCT01531621|Other|Biomarker sampling|Blood samples every 8-12 weeks
75433044|NCT01531634|Behavioral|Dynamic Cognitive Intervention Group|Twelve meetings of a Dynamic Cognitive Intervention group.
75433045|NCT01531647|Drug|danoprevir|100 mg q12h Days 8-21
75433046|NCT01531647|Drug|raltegravir|400 mg q12h Days 1-4 and 18-21
75433047|NCT01531647|Drug|ritonavir|100 mg q12h Days 8-21
75433048|NCT01531660|Behavioral|step-up jogging program|
75579990|NCT04677933|Drug|A: OLP-1002|10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002
75579991|NCT04677933|Drug|B: OLP-1002|10 patients will receive 10 µg OLP-1002 BIW OLP-1002
75579992|NCT04677933|Drug|C: Placebo|10 patients will receive Placebo BIW
75579993|NCT00542984|Drug|teriparatide 20 micrograms/day subcutaneous|
75728695|NCT06079307|Other|Oxygenated mouth foam|will be comparing the impact of using oxygenated foam to other groups.
75579994|NCT00542984|Drug|salmon calcitonin 100 IU/day subcutaneous|
75579995|NCT02257983|Drug|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
75579996|NCT02257983|Drug|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
75728696|NCT06077929|Other|No intervention done|No interventions done
75728697|NCT06076473|Diagnostic Test|Untargeted metabolomics|Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.
75728698|NCT06075732|Behavioral|Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccine hesitancy and increase willingness and uptake in Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccination.
75579997|NCT00543023|Drug|teriparatide 20 micrograms/day subcutaneous|
75433049|NCT01531686|Procedure|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
75433050|NCT01531712|Drug|Gemcitabine|1000mg/m2 / / 40mg/m2
75879789|NCT01340339|Device|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
75433051|NCT01531712|Radiation|Radiotherapy|50.4 Gy
75433052|NCT01531712|Drug|Tarceva|100mg/day
75433053|NCT01531712|Drug|Oxaliplatin|100mg/m2 (only in QT)
75433054|NCT01531751|Device|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
75433055|NCT01531751|Drug|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
75728699|NCT06075433|Device|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
75728700|NCT06075420|Device|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
75728701|NCT06072768|Drug|Oral prednisone Taper|The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.
75728702|NCT06072768|Drug|150-day taper prednisone|The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.
75879790|NCT05184179|Drug|Olmesartan Medoxomil|Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
75879791|NCT02051270|Other|Descriptive study|More than 65 years old elders
75879792|NCT05187299|Other|observer tool|The observer tool is paper-based and is divided in columns (each column filled out for a dyad observed) with lines representing the above-described steps of learning and presented with visual incremental actions to be performed. The observer tool will only be used to reinforce learning and will not be used for summative evaluation. Instructors have already been involved in previous simulation studies performed in our center, and especially those in which an observer tool has been assessed (one study published, two manuscripts in preparation).
75433056|NCT01531764|Drug|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 & 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
75433057|NCT01531777|Drug|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
75433058|NCT01531777|Drug|apatinib|750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
75579998|NCT00543023|Drug|salmon calcitonin 100 IU/day subcutaneous|
75579999|NCT04648917|Drug|Caffeic acid|40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight >50kg, 200mg per time, weight < or =50kg, 100mg per time)
75580000|NCT00543179|Drug|Somatuline (Lanreotide Autogel®)|
75580001|NCT04648527|Procedure|arthroscopic synovectomy and thermocoagulation|An diagnostic arthroscopy and an arthroscopic synovectomy and thermocoagulation of the dorsal hypertrophic synovial will be performed
75580002|NCT00543218|Drug|teriparatide 20 micrograms/day subcutaneous|
75433059|NCT01531790|Drug|Carboplatin|d1, AUC 5, i.v.
75433060|NCT01531790|Drug|Pemetrexed|d1, 500 mg/m2, i.v.
75433061|NCT01531790|Drug|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
75433062|NCT01531790|Drug|Centrum|1 tablet/day
75433063|NCT01531816|Device|Early Rehabilitation intervention|"Passive mobility: cycle ergometer~Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention."
75433064|NCT01531829|Drug|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
75580003|NCT00543218|Drug|calcitonin 100 IU/day subcutaneous|
75879793|NCT02054312|Behavioral|Family Based Interpersonal Psychotherapy (FB-IPT)|
75879794|NCT02054312|Behavioral|Client Centered Therapy (CCT)|
75879795|NCT01341509|Procedure|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
75879796|NCT01341509|Procedure|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
76050471|NCT05813821|Behavioral|Antimicrobial stewardship in surgery|"Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment >7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team."
76050472|NCT05813808|Diagnostic Test|ultra-low-dose computed tomography|7 ultra-low-dose computed tomography imaging
76050473|NCT05813782|Behavioral|Baby Massage|Baby massage training (30 minutes) was given to primiparous mothers before they were discharged from the hospital. Baby massage training consists of sections that explain the importance of massage, preparation for massage, stages of baby massage and situations that need attention. Primiparous mothers were told to do this massage to their babies in the postpartum period. Baby massage video CD, brochure and baby oil were given to primiparous mothers for an effective baby massage.
75580004|NCT00543257|Other|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
75580005|NCT00543257|Other|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
75580006|NCT02252835|Drug|Arhalofenate|800 mg once daily orally for four weeks
75580007|NCT02252835|Drug|Febuxostat|40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
75580008|NCT02252835|Drug|Arhalofenate|600 mg once daily orally for four weeks
75580009|NCT02252835|Drug|Febuxostat|80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
76050474|NCT05813756|Other|Post-diagnosctic psychoeducational intervention|Participants are randomized to the intervention group. In this group, the participant receives 10 one-hour individual sessions of psychoeducational intervention, bi-monthly, with an evaluation at mid-term (T1:T0+~2.5 months), at the end of the intervention (T2 : T0+~5 months) and 3 months after the intervention (T3 : T0+~8 months). At the same time psychological questionnaires and scales will be completed
76050475|NCT05813704|Device|Coronary Crossing System of Shanghai MicroPort Rhythm|The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
75580010|NCT02252835|Drug|Colchicine|0.6 mg daily
76050476|NCT05813691|Diagnostic Test|Meridan Bioscience Point of Care test against HCV antibodies|Point of care evaluation of antibodies against HCV obtaining a drop of capillary blood via puncture of the fingertip. If antibodies were detected, HCV RNA assay will be performed.
76050477|NCT05813665|Drug|Narlumosbart|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
75580011|NCT03456752|Drug|Dexamethasone|Dexamethasone 8mg intravenously prior to induction of anesthesia
76050478|NCT05813665|Drug|Denosumab|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
75580012|NCT03456752|Drug|Normal saline|Normal saline 1.6ml intravenously prior to induction of anesthesia
75728703|NCT06072703|Device|Magstim Rapid2 System|"The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction."
75728704|NCT06071741|Procedure|Percutaneous Coronary Intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
75580013|NCT02227290|Drug|Naftin Cream|
75580014|NCT02227290|Drug|Placebo Cream|
75580015|NCT03456713|Biological|LY3074828|Administered SC
75580016|NCT04648137|Diagnostic Test|study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)|single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.
75580017|NCT04648137|Diagnostic Test|Control intervention: Placebo|Identical placebo (only mannitol) capsules
75580018|NCT03456674|Device|LaseMD System|A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
76050479|NCT05813652|Other|Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
76050480|NCT05813652|Other|Peri-pandemic time period (March 13, 2020 to December 3, 2021)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
76050481|NCT05813639|Procedure|Lumbar medial branch cryo ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
75580019|NCT04648332|Drug|Bupivacaine Hydrochloride|compartment psoas block
75580020|NCT03456596|Other|ENABLE|This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
75580021|NCT04647981|Other|Xpert® Bladder Cancer Monitor Test|The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
75580022|NCT03456557|Radiation|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
75728705|NCT06070220|Behavioral|traditional occupational therapy intervention and client-centered intervention|"Traditional occupational therapy intervention and client centered intervention were given to the participants.~CC intervention is a dynamic approach that involves a systematic therapy process, that is, in which the participant and the therapist are active in the treatment process. In the current study, a treatment program was designed over a maximum of 5 occupations in which participants evaluated after THA indicated problems in activities of daily living according to COPM. This systematic and dynamic program consists of 4 phases: (1) client-centered goal setting, (2) negotiating an intervention plan, (3) the actual intervention, (4) an evaluation of the outcome and finally reporting to relevant others."
75879797|NCT01341509|Procedure|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
76050482|NCT05813639|Procedure|Lumbar medial branch radiofrequency ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
75879798|NCT02051348|Biological|Pylopass|Pylopass
75879799|NCT02051348|Biological|Placebo|Placebo
75879800|NCT02052518|Behavioral|Experimental|These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
75879801|NCT03640962|Other|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
75580023|NCT04648566|Procedure|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
75879802|NCT02052674|Device|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
75879803|NCT02052674|Device|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
76050483|NCT05813639|Procedure|Endoscopic denervation of fazet joint|The procedure is based on positive lumbar Z- joint testing followed by decapsulation of the facet joint through an endoscopic approach
75433065|NCT01531829|Drug|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
75433066|NCT01531842|Procedure|Conj flora Antibiotic resistance|Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).
75433067|NCT01531855|Other|Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose|Dosage after exercise
75580024|NCT04648566|Procedure|Intrauterine administration of sperm washing medium|Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
75580025|NCT05078411|Behavioral|Test treatment|"Test treatment will consist of a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on periodontal risk level (as calculated with the PerioRisk tool proposed by Trombelli et al. 2009) and profile (i.e., the magnitude of the contribution of each PerioRisk parameter to generate the patient risk level); (iii) information on treatment plan and oral hygiene instructions, with emphasis to treatment goals based on the PerioRisk output.~The operators will be trained to administer test treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
75728706|NCT06070220|Behavioral|Traditional occupational therapy intervention|"The following training procedure, which included exercise, transfer activities and home arrangements, was followed in common in both groups:~st day: After the operation, exercises to strengthen the muscles of the participants (thigh, hip and trunk muscles) were explained verbally and visually. Each exercise consists of 3 sets of 12 repetitions. Exercises were updated in bed, sitting or standing, depending on the participant's functional status, pain and fatigue. Additionally, transfer activities training was provided.~nd day: The exercises taught to the participants on the first day were repeated. Following these exercises, participants were given verbal instructions on gait training, and then gait training began. According to the pain and fatigue status of the participants, gait exercises were continued.~rd day: The work done on the first and second day was repeated. Pre-discharge home arrangements training was provided."
75879804|NCT05163834|Biological|Efgartigimod|intravenous infusion of efgartigimod
75879805|NCT05163834|Other|Placebo|intravenous infusion of placebo
76050484|NCT05813626|Drug|Toripalimab|Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
75879806|NCT05163834|Biological|PNEUMOVAX 23|PNEUMOVAX 23 vaccine
75879807|NCT05182619|Procedure|ultrasound-guided stellate ganglion block|under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
76050485|NCT05813600|Drug|Nirmatrelvir/Ritonavir|Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature >38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.
76050486|NCT05813561|Drug|DWP14012|DWP14012 40mg
76050487|NCT05813522|Drug|Furmonertinib Mesilate Tablets|160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
75433068|NCT01531868|Other|Video|Video of physician
75433069|NCT01531868|Other|Video|Video of physician
75433070|NCT01531868|Other|Video|Video of physician
75433071|NCT01531868|Other|Video|Video of physician
75433072|NCT01531868|Other|Video|Video of physician
75433073|NCT01531868|Other|Video|Video of physician
75728707|NCT06069882|Behavioral|Cognitive Rehabilitation|"Cognitive Rehabilitation is a person-centred, goal-oriented, problem-solving therapy aimed at managing or reducing functional disability, mitigating excess disability, and maximising engagement and social participation (Clare et al., 2019, p. 710). For this multiple-baseline SCED, there will be a baseline phase where participants will be assessed on goal attainment without an intervention. This phase will be either 3, 4, 5 weeks long and be determined for the participants using an electronic randomiser programme. Thereafter, facilitators will help participants devise personal rehabilitation plans to achieve one of these goals using evidence-based rehabilitative methods. These methods may include the use of environmental adaptations and prompts, introduction of compensatory strategies, procedural learning of skills, and methods for learning or relearning relevant information. The personal rehabilitation plan is put into practice for 6 weeks during the intervention phase of the study."
75728708|NCT06066476|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
75879808|NCT01065012|Drug|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
75879809|NCT01065012|Drug|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
75580026|NCT05078411|Behavioral|Control treatment|"Control treatment will consist in a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on treatment plan and oral hygiene instructions, and treatment goals. Although the general concept of risk of periodontitis incidence/progression will be explained, no mention will be made to the patient risk level as calculated with PerioRisk or any other tool.~The operators will be trained to administer control treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
75580027|NCT04648176|Device|Moses technology|Using Holmium laser with Moses technology or conventional one
75433074|NCT01531907|Other|Study visit procedures|"Anthropometric measurements to include:~Weight, height, and BMI.~Waist and hip circumference~Triceps skinfold thickness~Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours."
75433075|NCT01531920|Drug|alcohol + placebo|Part A alcohol + placebo
75433076|NCT01531920|Drug|alcohol + perampanel|Part A: alcohol + perampanel
75580028|NCT00543335|Drug|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
75580029|NCT00543335|Procedure|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
75580030|NCT02223039|Biological|AbGn-168H|AbGn-168H monoclonal antibody
75580031|NCT02223039|Biological|Placebo|Placebo of AbGn-168H
75580032|NCT00543413|Drug|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
75580033|NCT00543413|Drug|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
75580034|NCT00543413|Drug|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
75879810|NCT01065012|Drug|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
75433077|NCT01531920|Drug|perampanel + alcohol|Part B: perampanel + alcohol
75433078|NCT01531920|Drug|placebo + alcohol|Part B: placebo + alcohol
75433079|NCT01531933|Drug|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
75580035|NCT00554658|Drug|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
75580036|NCT00543452|Other|Oxygen|4 liters of oxygen a minute
75580037|NCT00543452|Other|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
75580038|NCT00543491|Drug|MK0767|
75580039|NCT00543530|Drug|MK0831|
75580040|NCT00554736|Biological|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
75580041|NCT00543608|Drug|iclaprim|
75580042|NCT00543608|Drug|vancomycin|
75580043|NCT00554775|Drug|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
75580044|NCT00554775|Drug|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
75580045|NCT00543647|Drug|Fenofibrate 160 mg tablet|
75580046|NCT00543647|Drug|Placebo|
75580047|NCT04647747|Other|Self measurement with pulse oximeter|Participant will measure peripheral saturation at home, conduct physiotherapy if desaturation occurs, and contact hospital if desatuation persists
75580048|NCT04647669|Drug|Remdesivir|200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
75580049|NCT04647669|Drug|Acalabrutinib|100 mg capsules twice daily every 12 h for 10 days taken with or without food.
75433080|NCT01531933|Drug|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
75580050|NCT04647669|Drug|Interferon beta-1a|Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
75580051|NCT04647669|Other|Standard of Care|Treatment according to local hospital protocol
75580052|NCT00543686|Drug|Montelukast|Intake of Montelukast
75879811|NCT01065012|Drug|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
75433081|NCT01531946|Procedure|MRI Scan|"Patients will have to spend additional 10min in the scanner.~Additional scan modalities used:~Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.~Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.~An overall 20min scan period."
75433082|NCT01531972|Drug|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
75580053|NCT00543686|Drug|Fluticasone|Intake of Fluticasone
75580054|NCT04647864|Device|Transcatheter Aortic Valve Implantation|Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
75580055|NCT00543842|Drug|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
75580056|NCT00543842|Drug|Capecitabine|Starting Dose 650 mg/m^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
75580057|NCT00543842|Drug|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
75580058|NCT00543842|Radiation|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
75433083|NCT01531972|Drug|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
75433084|NCT01532011|Drug|Erlotinib|"Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
75580059|NCT00543842|Procedure|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
75580060|NCT04638816|Device|Restylane Volyme|Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).
75580061|NCT04638816|Device|Restylane Lyft Lidocaine|Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).
75580062|NCT00543881|Device|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
75580063|NCT00543881|Device|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
75580064|NCT04638855|Device|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)
75580065|NCT04638855|Device|Placebo|No device after hysteroscopy surgery
75580066|NCT00543920|Drug|MK0777|
75580067|NCT04638738|Device|SensiumVitals wearable patch sensor|Wearable sensor which measures heart rate, respiratory rate, and temperature continuously.
75580068|NCT00543959|Drug|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
75580069|NCT00543959|Drug|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
75580070|NCT00543959|Drug|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
75580071|NCT04638972|Device|working length determination techniques|A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.
75580072|NCT00543998|Device|Optical Measurement transillumination|Optical Measurement of sinus
75580073|NCT04638777|Device|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
75580074|NCT04638777|Device|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and sham repetitive transcranial magnetic stimulation with H-coil over PFC
75580075|NCT04638777|Device|rTMS with H-coil|Sham repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
75580076|NCT00544037|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
76050488|NCT05813509|Device|Organoid culture|Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
75433085|NCT01532011|Drug|Pralatrexate|"Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
75433086|NCT01532024|Other|Microdose of NAP|Delivery of NAP at microdose (<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
75433087|NCT01532037|Other|Cognitive behavioural therapy based self help|Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
75433088|NCT01532037|Other|Treatment as usual|Usual care from healthcare professionals with regard to patients symptoms of fatigue
75433089|NCT01532050|Device|Mandibular Advancement Device ( MAD)|
75433090|NCT01532063|Procedure|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
75433091|NCT01532076|Procedure|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
75433092|NCT01532076|Procedure|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
75580077|NCT04647357|Drug|SHR-1316|Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
76050489|NCT05813496|Drug|Alpha-Lipoic Acid (ALA)|Oral tablet
76050490|NCT05813496|Drug|Placebo|Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.
75433093|NCT01532102|Drug|AP611074|
75433094|NCT01532102|Drug|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
75433095|NCT01532115|Drug|BIA 9-1067|50 mg and 800 mg of BIA 9-1067 (single-dose)
75433096|NCT01532115|Drug|Placebo|single-dose
75580078|NCT00544154|Drug|CDP870|
75580079|NCT04638582|Drug|Pembrolizumab|Neoadjuvant pembrolizumab 200 mg IV every 3 weeks, given on cycle day 1. Adjuvant pembrolizumab 400 mg IV every 6 weeks, given on cycle day 1.
75580080|NCT04638582|Drug|Carboplatin|Carboplatin AUC 6 IV (maximum dose: 900 mg) for squamous cell carcinoma, and AUC 5 IV (maximum dose: 750 mg) for non-squamous cell carcinoma, every 3 weeks, given on cycle day 1.
75433097|NCT01532115|Drug|moxifloxacin|400 mg moxifloxacin (single-dose)
75433098|NCT01532154|Drug|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
75580081|NCT04638582|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks, given on cycle day 1. Only given to participants with squamous cell carcinoma.
75580082|NCT04638582|Drug|Pemetrexed|Pemetrexed 500 mg/m2 every 3 weeks, given on cycle day 1. Only given to participants with non-squamous cell carcinoma.
75580083|NCT00544193|Drug|gemcitabine hydrochloride|
75580084|NCT00544193|Genetic|polymerase chain reaction|
75580085|NCT00544193|Other|immunohistochemistry staining method|
75580086|NCT00544193|Procedure|conventional surgery|
75580087|NCT00544193|Radiation|intraoperative radiation therapy|
75580088|NCT00544193|Radiation|radiation therapy|
75580089|NCT00544232|Drug|Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
75580090|NCT00544232|Drug|Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
75580091|NCT04647318|Behavioral|Compassion focused imagery, relaxation imagery and control task|Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
75580092|NCT00544271|Biological|INFANRIX|
75580093|NCT00544271|Biological|BOOSTRIX|
75580094|NCT00544271|Biological|HAVRIX|
75728709|NCT06060470|Behavioral|Virtual reality based dance group|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
75433099|NCT01532180|Device|aura6000 System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
75433100|NCT01532193|Other|Decreased oxygen concentration|"The oxygen concentration is decreased during the in Vitro embryo culture."
75433101|NCT01532206|Other|Blood pressure cuff insufflation|Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
75433102|NCT01532219|Behavioral|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
76050491|NCT05813483|Other|Skinceuticals skin care product(CE)|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
75433103|NCT01532219|Behavioral|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
75580095|NCT01191268|Drug|Insulin Glargine|
75580096|NCT01191268|Drug|LY2189265|
75580097|NCT01191268|Drug|Insulin Lispro|
75580098|NCT04647552|Drug|Drug Steroid|hydrocortisone injection
75580099|NCT04647279|Diagnostic Test|Dual-emission X-ray Absorptiometry|The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.
75580100|NCT00544310|Biological|Anti adhesion agent|Adhesions prevention
75580101|NCT00544349|Biological|cetuximab|
75580102|NCT00544349|Drug|fluorouracil|
75580103|NCT00544349|Drug|leucovorin calcium|
75580104|NCT00544349|Drug|oxaliplatin|
76050492|NCT05813483|Other|fraxel laser therapy|fraxel laser therapy combined with routine moisturizing and sun protection
75580105|NCT01191190|Drug|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
75580106|NCT00544388|Drug|levocetirizine dihydrochloride|
75728710|NCT06060470|Behavioral|Active Comparator: Control|Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
75728711|NCT06058455|Behavioral|IDEA3 Sexual Assault Resistance Intervention|Internet-delivered EAAA (IDEA3), adapted from an in-person sexual assault resistance education intervention: Enhanced Assess, Acknowledge, Act (EAAA) intervention that was found in a randomized trial to reduce sexual assault victimization by about 50% at follow-up. IDEA3 designed for female identifying university students and focuses on resisting sexual assault committed by males in 4, 3-hour units: 1-ASSESS builds ability to detect risk with male acquaintances and develop risk reduction strategies. 2-ACKNOWLEDGE explores overcoming emotional barriers preventing women from acknowledging risk and employing effective resistance strategies with males. 3-ACT shows effectiveness of resistance strategies and teaches verbal and physical self-defense in common situations. 4-RELATIONSHIPS & SEXUALITY adapts the Our Whole Lives curriculum to increase women's comfort in talking about sex/sexuality and identify sexual values/desires.
75580107|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
75580108|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
75728712|NCT06058455|Behavioral|Consent Workshop|Participant pairs assigned to the control arm will receive a 60-minute session consisting of a 60-min interactive, virtual consent workshop. The workshop will include information on a) what consent is, including the idea that consent is about bodily autonomy and applies to interactions beyond sex, b) how to give and ask for consent, and c) examples of what it looks like to ask for and give/not give consent. This presentation will be given by a well-trained Research Assistant.
75728713|NCT06058130|Drug|Anticoagulant Oral|Anticoagulation alone
75580109|NCT00544505|Drug|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
75580110|NCT00544583|Procedure|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
75580111|NCT00544583|Procedure|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
75879812|NCT01065012|Drug|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
75879813|NCT01065012|Drug|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
75879814|NCT01315691|Drug|Liposomal amikacin for inhalation|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment."
75879815|NCT01315691|Drug|Placebo for liposomal amikacin for inhalation|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~Administration procedures, volume and administration time are the same as for Arikace™.~Placebo will be administered for 28 days."
75879816|NCT02038244|Other|Multimodal integrative medicine inpatient treatment program|
75879817|NCT05654090|Drug|cefoperazone sodium and sulbactam sodium|Pharmacokinetic study under fasting conditions
75879818|NCT01340729|Drug|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
76050493|NCT05813470|Biological|Omalizumab (CinnaGen)|Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection
75433104|NCT01532232|Drug|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
75580112|NCT00544622|Procedure|structured therapeutic chain of stroke treatment|
75580113|NCT00544700|Biological|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
75580114|NCT00544700|Other|no maintenance|No treatment until progression
75580115|NCT00559884|Drug|GSK189075 (Modified and immediate release formulations)|
75728714|NCT06058130|Drug|Anticoagulation combined with antiplatelet therapy|Anticoagulation combined with antiplatelet therapy
75728715|NCT06057467|Drug|Anticoagulation Agents|Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
75728716|NCT06057155|Diagnostic Test|ultrasound optic nerve sheath diameter assessment|ultrasound optic nerve sheath diameter assessment
75580116|NCT05824676|Device|Variable Angle LCP Patella Plating System|FDA approved device, 510K number of, K210408. The Variable Angle LCP Patella Plating System is a device that can be formed to a patients specific need with various anchoring points to best fix what is needed for fixation.
75728717|NCT06057142|Behavioral|Fun activities for reciting Tang poems|The students will participate in three weekly sessions of Tang poem classes and one session of performance show. Each session lasts for 1.5 hours. Parents can sit in the class. A total of six poems will be taught by two experienced Chinese teachers.
75879819|NCT02052830|Behavioral|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
75580117|NCT05824676|Device|Traditional Fixation|Traditional fixation methods for patellar fracture (screws, suture fixation, wire fixation, other plates).
75580118|NCT05824663|Drug|HBM1020|Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
75879820|NCT02959866|Other|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
75879821|NCT05183711|Behavioral|Questionnaires|The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
75879822|NCT02054468|Drug|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
75879823|NCT02054468|Drug|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
76050494|NCT05813470|Biological|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
76050495|NCT05813405|Other|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors
76050496|NCT05813379|Combination Product|exosime injection|Treatment- exosome injection
75433105|NCT01532232|Drug|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
75433106|NCT01532245|Other|two lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
75433107|NCT01532245|Other|one lung ventilation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
75433108|NCT01532245|Other|One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
75433109|NCT01532284|Other|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
75433110|NCT01532297|Device|Citrate dialysate (CiDi)|Use during chronic dialysis 3x/week
75433111|NCT01532297|Device|Standard dialysate (StDi)|Use during chronic dialysis 3x/week
75433112|NCT01532323|Other|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
75433113|NCT01532336|Drug|NVC-422 Solution, 0.3%|NVC-422 Ophthalmic Solution dropped onto the eye
75433114|NCT01532336|Drug|NVC-422 Vehicle Solution|NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
75433115|NCT01532375|Dietary Supplement|Kochujang|Kochujang (32g/day) for 12weeks.
75433116|NCT01532375|Dietary Supplement|placebo|placebo(32g/day) for 12weeks
75433117|NCT01532401|Other|sodium chloride|sodium chloride 500mg
75433118|NCT01532401|Other|Methylcellulose crystalline|Methylcellulose 37 ml
75433119|NCT01532466|Drug|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
75433120|NCT01532531|Device|"GEMORE Multi-Function Electrotherapy Stimulator"|"The Collateral Meridian Therapy (CMT) group patients received, according to the CMT protocol described previously (5), CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
75433121|NCT01532544|Drug|Ilomedin and Integrilin|Continuous infusion
75433122|NCT01532544|Drug|low molecular weight heparin.|
75433123|NCT01532583|Other|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
75433124|NCT01532596|Behavioral|Mindfulness-Based Stress Reduction|8-week standardized mindfulness meditation training program
75433125|NCT01532622|Dietary Supplement|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days
75433126|NCT01532622|Other|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
75433127|NCT01532661|Other|observational study|data collected by investigators
75433128|NCT01532674|Device|Antimicrobial photodynamic therapy (Periowave) and scaling and root planing|"ROOT PLANNING PROCEDURE:~The procedure is the same as in the control group~APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :~The photosensitive agent : Formulation Periowave Treatment Kit-2ml~Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.~Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.~All the periodontal pockets will be treated subgingivally~Elimination of the photosensitive by irrigation"
75433129|NCT01532674|Procedure|scaling and root planing|"ROOT PLANNING PROCEDURE:~An unique operator ( independent from the explorer) will do the root planing for both the test and control group.~Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.~* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque."
75433130|NCT01532713|Procedure|oxygen administration|nasal O2 5L/min via nasal cannula
75433131|NCT01532726|Drug|ESL|ESL 400/800/1200 mg tablets once daily
75879824|NCT02054468|Drug|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
75879825|NCT02054468|Drug|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
75879826|NCT02054468|Drug|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
75879827|NCT02054468|Drug|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
75879828|NCT02054468|Drug|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
75879829|NCT02054468|Drug|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
75879830|NCT02054468|Drug|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
75879831|NCT01340807|Other|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
75879832|NCT03640650|Combination Product|Dropless Therapy|The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
75879833|NCT03640650|Drug|Usual Care|In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
75879834|NCT05183555|Drug|68Ga-DOTATOC PET/CT|68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
75879835|NCT03618966|Device|Neuromuscular magnetic stimulation (NMMS)|It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
75433132|NCT01532739|Behavioral|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
75433133|NCT01532765|Procedure|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
75433134|NCT01532765|Procedure|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
75433135|NCT01532765|Procedure|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
75728718|NCT06056557|Device|VARIPULSE™ catheter ablation|"Subjects will arrive to the electrophysiology laboratory for their ablation procedure and will undergo preparation for the procedure per standard protocol.~The purpose of an ablation procedure is to scar or destroy the heart tissue causing the atrial fibrillation. The current FDA approved ablation treatments commonly use freezing, radio frequency, or laser, delivered through a catheter that is threaded through blood vessels to the heart, as the energy source to destroy the abnormal tissue.~The BWI IRE VARIPULSE ablation system used in this study uses a type of energy source called pulse field.~Pulse field ablation applies ultra-rapid (less than 1 second) electrical fields to the heart muscle to destroy the abnormal tissue. This type of energy is thought to safer and more effective at treating atrial fibrillation.~● For a lesion set that cannot be performed using the VARIPULSE catheter technology, a conventional FDA-approved RF ablation"
75879836|NCT05187143|Device|DENTAL IMPLANT|The study implants were 3.5, 3.75 or 4.5 mm implant diameter, Straumann® BLX implant SLActive® Roxolid® (Institut Straumann AG, Basel, Switzerland) and the abutment was a 0 °, 2.5 mm of height Straumann® Screw-retained Abutment. The length of the implants was 6, 8 and 10 mm. The 6 mm implant is only commercially available in 3.75 and 4.5 diameter.
75728719|NCT06054880|Drug|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
75728720|NCT06054880|Other|Saline injection 0.9%|Placebo
75728721|NCT06053021|Drug|aspirin, clopidogrel, cilostazol, and dipyridamole|Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
75728722|NCT06049940|Biological|Investigational tetanus vaccine, adsorbed|The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.
75728723|NCT06049940|Biological|Control tetanus vaccine, adsorbed|The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.
75879837|NCT02052908|Other|Laboratory Biomarker Analysis|Correlative studies
75879838|NCT02052908|Drug|Naproxen|Given PO
75879839|NCT02052908|Other|Placebo Administration|Given PO
75879840|NCT03640572|Diagnostic Test|Bone marrow analysis to identify disseminated tumour cells|Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.
75879841|NCT01336985|Drug|Irinotecan|
75879842|NCT01336985|Procedure|Chemoembolization|
75879843|NCT01336985|Device|Drug-Eluting Beads|
75433136|NCT01532804|Drug|bevacizumab, oxaliplatin and 5FU combination|"Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.~Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)"
75433137|NCT01532804|Drug|Bevacizumab, oxaliplatin and raltitrexed combination|"Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.~Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min"
75433138|NCT01532843|Drug|PegIFN alfa-2b|Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
75433139|NCT01532856|Drug|Thalidomide, Cyclophosphamide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
75433140|NCT01532856|Drug|Thalidomide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
75433141|NCT01532856|Drug|Thalidomide, Melphalan, Prednisone|thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
75433142|NCT01532882|Drug|Diosmin|tablet, 600mg, PO, 1 tab per day during 28 days
75879844|NCT01336985|Procedure|Biopsy|
75879845|NCT03640494|Device|Optical Coherence Tomography|This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.
76050497|NCT05813366|Other|Acupuncture|Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.
75433143|NCT01532882|Drug|Placebo|tablet, PO, 1 per day during 28 days
75433144|NCT01532895|Drug|Hydromorphone HCI OROS|type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
75433145|NCT01532947|Procedure|post placement|placement of an endocanalar post
75433146|NCT01532960|Biological|poly-ICLC|poly-ICLC
75433147|NCT01532960|Biological|9 Peptides from Her-2/neu, CEA, & CTA|9 synthetic peptides derived from Her-2/neu, CEA & CTA derived breast cancer proteins.
75433148|NCT01532960|Biological|Peptide-tet|A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
75433149|NCT01533012|Procedure|Pressure difference|Peak inspiratory pressures difference between two lungs
75433150|NCT01533025|Procedure|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
75433151|NCT01533090|Drug|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
75433152|NCT01533090|Drug|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
75433153|NCT01533129|Drug|Testogel 50 mg transdermal gel|50mg testosterone gel implementation on every night
75433154|NCT01533129|Drug|Testosterone 250mg injection|The testosterone 250mg ester IM injections performed in three weeks.
75433155|NCT01533142|Procedure|Bariatric surgery|"Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass"
75728724|NCT06048510|Diagnostic Test|Pregnant women|"Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).~The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.~Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin."
75728725|NCT06048159|Device|HD-tACS|High definition tACS will be applied during speech therapy.
75728726|NCT06048159|Device|Sham HD-tACS|Sham high definition tACS will be applied during speech therapy.
75433156|NCT01533142|Procedure|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
75433157|NCT01533155|Drug|Nektar 118|Oral 25 mg tablet
75433158|NCT01533155|Drug|Quinidine|Oral 200 mg tablet
75433159|NCT01533155|Drug|Quinidine placebo|Oral Tablet
75433160|NCT01533155|Drug|Morphine|10 mg/ml, intravenously
75433161|NCT01533168|Genetic|cytogenetic analysis|
75433162|NCT01533168|Genetic|nucleic acid sequencing|
75433163|NCT01533168|Other|diagnostic laboratory biomarker analysis|
75433164|NCT01533168|Other|laboratory biomarker analysis|
76050498|NCT05813366|Other|Tryptophan-Rich Diet|"All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed."
76050499|NCT05813366|Other|Vitamin B6 Supplementation|All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.
75433165|NCT01533168|Other|medical chart review|
75433166|NCT01533194|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
75433167|NCT01533194|Biological|Wild-type Reovirus|Given IV
75433168|NCT01533220|Drug|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 03 days
75433169|NCT01533220|Drug|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 03 days
75433170|NCT01533233|Procedure|thoracoscopic lobectomy and mediastinal lymph node dissection|
75580119|NCT05824624|Other|ANIMAL-ASSISTED INTERVENTION|It will be ensured that the child is introduced to the goldfish when he is lying in the observation room, that the child will name the fish, and that he will communicate and feed the fish during his stay. Thus, it is aimed to turn the attention of the child to the goldfish while in the emergency room, to distract the child with the fish while all nursing interventions are presented, and to reduce the fear.
75580120|NCT05824624|Other|Routine Care|Routine nursing care will be provided.
75580121|NCT05824585|Drug|DZD8586|DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
75580122|NCT05824520|Other|ITS plus OMT|Invasive treatment strategy plus optimal medical therapy
75580123|NCT05824520|Other|OMT|Optimal medical therapy alone
75728727|NCT06045819|Biological|Blood sampling for venetoclax drug dosage (venous puncture)|8 blood samples for venetoclax and azole antifungal drugs identification and dosage will be taken by venous and capillary punctures throughout management of patients
75728728|NCT06032715|Behavioral|BI (Brief Intervention)|Short structured individual behavioral intervention to reduce inappropriate usage of Z-hypnotics
75728729|NCT06025305|Diagnostic Test|Intravascular imaging test|Coronary artery disease patients first underwent CCTA and then intravascular imaging test within 3 months
75433171|NCT01533272|Drug|Tenofovir, emtricitabine, maraviroc|experimental drug
75433172|NCT01533272|Drug|Tenofovir, emtricitabine, lopinavir/r|Lopinavir/r 400mg BID
75433173|NCT01533285|Biological|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
75433174|NCT01533285|Biological|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
75433175|NCT01533298|Drug|CombiflexOmega peri|intravenously over 3 days infusion
75433176|NCT01533298|Drug|SmofKabiven peripheral|intravenously over 3 days infusion
75433177|NCT01533324|Drug|S-1 combined with Leucovorin|S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
75433178|NCT01533363|Procedure|Stapled hemorrhoidopexy|
75433179|NCT01533363|Procedure|Milligan Morgan|
75433180|NCT01533376|Drug|Timolol|0.5% timolol maleate ophthalmic gel-forming solution applied once
75433181|NCT01533376|Drug|Preservative free artificial tear gel.|Preservative free artificial tear gel applied topically twice a day.
75580124|NCT05824481|Drug|Cadonilimab|Injectable solution
75580125|NCT05824481|Drug|Lenvatinib|Capsule
75580126|NCT05824468|Drug|Zimberelimab|Injectable solution
75580127|NCT05824468|Drug|Lenvatinib|Capsule
75580128|NCT05824455|Combination Product|JS109 combine with irinotecan|JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
75580129|NCT05824442|Biological|Blood sample for multiplex QPCR technique|Blood sampling specifically for qPCR Echino at inclusion and one year after
75580130|NCT05824429|Other|Urotherapy|Urotherapy is an umbrella term that includes components such as information about bladder function and problem, lifestyle changes including the regulation of voiding and fluid intake times, correct toilet positions, information about bladder irritants, and motivation. All participants included in our study will be given urotherapy training before starting PFM exercises and CTM with their families.
75580131|NCT05824429|Other|Diaphragmatic Breathing Exercises|In our research, diaphragm breathing exercises will be applied to both groups before starting PFM exercises in sessions for 8 weeks, 3 days a week.
75580132|NCT05824429|Other|PFM Exercises|PFM exercises will be started after children learn to contract and relax their PFM in isolation without the use of auxiliary muscles. In the exercises, fast and slow contractions targeting type 1 and type 2 muscle fibers will be taught to increase both strength and endurance of PFM.
75580133|NCT05824429|Other|Connective Tissue Manipulation|"CTM is a reflex treatment technique that is applied manually by physiotherapists to the skin area and acts on some cells and connective tissue by making short and long pulls (. In our study, CTM will be applied to our study group, where CTM and PFMR will be applied together, 3 days a week, for a total of 8 weeks.~The application will be made to the basic region (sacral), lower thoracic, abdominal and anterior pelvic region."
75580134|NCT05824390|Drug|rituximab group|Rituximab is a human-mouse chimeric monoclonal antibody specifically targeting B cell surface antigen CD20. CD20 may act as a calcium channel to play a certain signal role and participate in the regulation of B cell maturation and differentiation. Once combined with CD20, RTX consumed CD20 + B fines through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis. Recent studies have shown that B cell depletion therapy has a certain effect on many autoantibodies-mediated kidney diseases ( such as membranous nephropathy, lupus nephritis, etc. ). Therefore, rituximab combined with CD20 antigen on the surface of B cells can exhaust B cells that produce antibodies and play a therapeutic role by reducing antibody production, so this therapy also has potential therapeutic value for IgAN patients.
75580135|NCT05824312|Drug|Tyrosine kinase inhibitor drugs.|TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
75580136|NCT05824286|Other|HbA1c prediction|HbA1c prediction model was developed based on fasting capillary blood glucose and postprandial capillary blood glucose from self-monitoring blood glucose. Since HbA1c was measured once every 3 month, self-monitoring blood glucose records were transferred to predicted HbA1c by prediction model every month.
75580137|NCT05824247|Device|68Ga-FAPI-PET-CT|a new technology that using Fibroblast activation protein （FAP）inhibitor as the tracer of PET-CT
75580138|NCT05824234|Other|Implementation of a training centered around the notions of recovery with mental health services first year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
75580139|NCT05824234|Other|Implementation of a training centered around the notions of recovery with mental health services second year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
75580140|NCT05824221|Device|rTMS|Non invasive brain stimulation in Cocaine Use Disorder
76050500|NCT05813340|Procedure|Vascularized inter-positional periosteal connective tissue flap|It is a vascularized pedicled flap derived from the hard palate that can be used as a barrier to prevent in growth of soft tissue in guided bone regeneration and to increase soft tissue quantity
75580141|NCT05824156|Biological|5 mg/kg CM-101|CM-101, Monoclonal Ab blocking CCL24
75580142|NCT05824156|Other|Placebo|Placebo
75580143|NCT05824117|Other|Individual Placement and Support (IPS)|"IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults.~Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning."
75580144|NCT05824091|Drug|MK-7762 (TBD09)|Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
75580145|NCT05824091|Other|Placebo|A subset of participants from each of the 6 dosing cohorts will receive placebo.
75580146|NCT05824065|Drug|OMA102|1 mg
76050501|NCT05813249|Drug|Rybelsus Oral Product|Oral Semaglutide
75580147|NCT05824065|Drug|OMA102|2 mg
76050502|NCT05813249|Drug|Ozempic Injectable Product|Subcutaneous Semaglutide
76050503|NCT05813249|Drug|Tocopherol and/or Actos|Vitamin E and/or Pioglitazone
75728730|NCT06017713|Behavioral|tDCS + symptoms provocation|The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
76050504|NCT05813210|Diagnostic Test|Exercise in combination with biomarkers and pharmacological stress CMR test|A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.
76050505|NCT05813197|Behavioral|My Choice - My Way!|Support intervention for adolescents (15+) in out-of-home care (foster care, group home care, supported living, institutional care, etc). 16-19 sessions with a MCMW coach, 4-8 months, weekly to bi-weekly sessions.
76050506|NCT05813197|Behavioral|Usual services|Usual services
75433182|NCT01533389|Drug|Silodosin|"Drug: silodosin dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo"
76050507|NCT05813184|Drug|Antibiotics|Any antibiotic therapy administered > 7 days
76050508|NCT05813171|Dietary Supplement|Allicor|Participants will take Allicor capsules in addition to standard treatment for a year.
76050509|NCT05813171|Drug|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
76050510|NCT05813145|Drug|Placebo|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
76050511|NCT05813145|Drug|Fenofibrate 160mg|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
76050512|NCT05813106|Drug|Dexmedetomidine Hydrochloride|Intravenous dexmedetomidine 0.2 mcg/kg
76050513|NCT05813106|Drug|normal saline|normal saline
76050514|NCT05813093|Device|rTMS|Accelerated iTBS treatment
76050515|NCT05813054|Dietary Supplement|HA matrix ingredient|1 capsule/day
76050516|NCT05813054|Dietary Supplement|Placebo|1 capsule/day
76050517|NCT05813028|Other|a Mobile Application|Patients will use the mobile application for 6 weeks after receiving the first course of chemotherapy. The Multidimensional Scale of Perceived Social Support, Memorial Symptom Rating Scale, EORTC QLQ-C30 Quality of Life Scale and QLQ-CR29 Module, Beck Anxiety Scale will be administered when they come to the hospital for their 2nd course of chemotherapy. Patients will use the mobile application for 6 more weeks after receiving the second chemotherapy course. 3. The scales will be reapplied when they come to the hospital for a chemotherapy course. Patients will continue to use the mobile application for three more weeks after receiving their 4th and final cure. When the patients come to the outpatient clinic control in the 12th week, the use of the mobile application will be terminated and the Mobile Application Efficiency Evaluation Form will be applied together with the other scales.
76050518|NCT05813015|Drug|Docetaxel|Docetaxel 40mg/m2，every 21 days，6 cycles.
76050519|NCT05813015|Drug|Tegafur-Gimeracil-Oteracil|S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.
75433183|NCT01533389|Drug|Placebo|dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks
75433184|NCT01533402|Behavioral|therapist support|Weekly therapist support without CBT-interventions
75433185|NCT01533402|Behavioral|Internet-delivered CBT|Internet-delivered cognitive behavioural therapy with therapist support
75580148|NCT05824065|Drug|Placebo|OMA102 - Placebo
75580149|NCT05823935|Procedure|Bakay purse string|After developing the bladder flap, Vicryl polyglactin 910 sutures (Ethicon, Inc, Somerville, NJ) will be placed on the line between the cervicovaginal junction and the bladder starting at either 4 to 3 o'clock or 8 to 9 o'clock, as anchor sutures. Paying attention not to get closer than 1 cm to the bladder, the first suture will be passed from 4 o'clock to 3 o'clock and continued circumferentially in a full-thickness purse string fashion through 3, 1, 10, 8, 7, 5 o'clock completing a circle while including both uterosacral ligaments.
76050520|NCT05813002|Other|standard neural mobilization|is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
76050521|NCT05813002|Other|Distal to proximal neural mobilization|is a distal to proximal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
75580150|NCT05823935|Procedure|Cuff closure via vaginal route group|After the uterus will be removed via vaginal route, vaginal cuff ends will be grasped via vaginal approach and sutured continuous locked sutures using Vicryl polyglactin 910 sutures in one layer.
75879846|NCT01337063|Other|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
76050522|NCT05813002|Other|proximal to distal neural mobilization|is a proximal to distal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
75433186|NCT01533415|Device|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of <1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
75433187|NCT01533415|Device|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
75580151|NCT05823909|Device|fabian Therapy evolution ventilators with PRICO (Predictive Intelligent Control of Oxygenation)|12 hours Automated PRICO FiO2 control
75433188|NCT01533441|Dietary Supplement|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
75433189|NCT01533454|Other|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
75433190|NCT01533467|Device|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
75433191|NCT01533480|Drug|Zirgan|0.15% ganciclovir gel(Zirgan)
75433192|NCT01533480|Drug|genteal gel|0.3% Hypromellose gel
75433193|NCT01533506|Drug|stiripentol|Stiripentol up to 30 mg/kg/day to control seizures
75433194|NCT01533519|Drug|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
75433195|NCT01533532|Drug|KLH-2109|
75433196|NCT01533532|Drug|KLH-2109|
75433197|NCT01533532|Drug|KLH-2109|
75433198|NCT01533532|Drug|placebo|
75433199|NCT01533545|Drug|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
75433200|NCT01533545|Drug|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
75580152|NCT05823909|Device|fabian Therapy evolution ventilators with manual FiO2 control|12 hours Manual PRICO FiO2 control
75580153|NCT05823883|Drug|DW6014|"Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition"
75433201|NCT01533558|Drug|caspofungin|normal dosage for caspofungin, not adapted for the study
75580154|NCT05823870|Drug|DW6014|"Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast"
75580155|NCT05823792|Diagnostic Test|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
75580156|NCT05823779|Other|Blood draw|We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR
75580157|NCT05823766|Behavioral|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
75433202|NCT01533571|Procedure|Immediate implant placement with simultaneous bone grafting|"Flapless surgery is used for surgical implant installation.~Implant is placed in the cingulum position of adjacent teeth incisal edge.~After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.~Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .~Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material."
75433203|NCT01533610|Procedure|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
75433204|NCT01533623|Device|Mandibular Advancement Device|Nightly wearing time
75580158|NCT05823766|Procedure|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
75433205|NCT01533649|Behavioral|Andrews/Reiter approach to epilepsy|"The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline."
75433206|NCT01533649|Behavioral|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
76050523|NCT05812937|Procedure|Intraabdominal ultrasound|To assess the diagnostic value of the intraoperative intrabaabdominal ultrasound (IIUS) for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
75580159|NCT05823766|Behavioral|Clinical Visit|Patients who screen positive for PTE will have an in-depth clinical visit
75580160|NCT05823766|Procedure|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
75879847|NCT03640416|Device|Fitbit® Charge HR smart watch|The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
76050524|NCT05812898|Other|exercises|strengthening of the gluteus maximus and medius, calf muscles stretching for calf and hamstring muscles
75433207|NCT01533662|Drug|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
75580161|NCT05823766|Procedure|EEG|An EEG will be performed on patients who screen positive for PTE at the clinical visit
75580162|NCT05823766|Behavioral|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
75580163|NCT05823740|Other|Bioelectrical impedance Analysis (BIA)|Bioelectrical impedance analysis (BIA) is a method for estimating body composition, in particular, body fat and muscle mass, where a weak electric current flows through the body and the voltage is measured in order to calculate the impedance (resistance) of the body. BIA will be done at baseline, during the study related to routine medical imaging, and end of the study.
75879848|NCT01337141|Other|Control|7 face-to-face visits.
75879849|NCT01337141|Device|Telecare system|5 telematic visits and 2 face-to-face visits.
75879850|NCT03640338|Device|Cold-Therapy System|After surgery, participants assigned to this group will receive the cold-therapy system to use at the hospital and during the first 2 weeks following discharge.
75879851|NCT05186831|Behavioral|Texting|Patients will be asked to text their BP. They will receive an automated response to their texts.
75879852|NCT05186831|Behavioral|Online patient portal|Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
76050525|NCT05812898|Other|myofascial release|myofascial release using instrument assisted soft tissue mobilization
75433208|NCT01533662|Drug|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
75433209|NCT01533675|Other|Hydrogen peroxide|Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator
75433210|NCT01533675|Other|Saline|Once daily topical application of normal saline, using a cotton-tipped applicator
75433211|NCT01533701|Other|Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling|Fetal blood sampling is conducted when a non reassuring cardiotocographic pattern occurs to detect fetal hypoxia during labor. Amniotic fluid, maternal blood is sampled in cases of fetal blood sampling. Umbilical cord blood sampling is conducted at delivery.
75433212|NCT01533727|Drug|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
75580164|NCT05823740|Other|D3-Creatine Dilution (D3Cr)|The D3-Creatine dilution method is a safe and noninvasive measure of skeletal muscle mass that has previously been validated in adults, neonates, healthy children, and children. D3-Creatine Dilution will be done at baseline, during the study related to routine medical imaging, and end of the study.
75879853|NCT01337375|Drug|peginterferon alfa 2a [Pegasys]|sc weekly
75879854|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv weekly
75879855|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|sc twice weekly
75879856|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv twice weekly
76050526|NCT05812872|Drug|Toothgraft|Particulate dentin
76050527|NCT05812872|Drug|Allograft|Mineralized corticocancellous allograft
76050528|NCT05812872|Drug|Alloplast|Beta tri-calcuim phosphate
76050529|NCT05812833|Behavioral|Education|Pregnant women will be given online baby care training
76050530|NCT05812781|Drug|VTX2735|Dose A
76050531|NCT05812781|Drug|VTX2735|Dose B
75879857|NCT03635411|Dietary Supplement|Nicotinamide Riboside and Pterostilbene|Nicotinamide riboside and pterostilbene manufactured by Basis
76050532|NCT05812768|Device|Suture-Tight Suture Delivery System|Implantation of the Suture-Tight Suture in the deployment of multiple nitinol sutures to provide augmented fixation and sealing between endovascular aortic graft and the native artery.
76050533|NCT05812729|Behavioral|resiLIR Basic|"Each module contains psychoeducational elements as well as practical exercises.~Week 1: Introduction + Stress and resilience~Week 2: Optimism~Week 3: Mindfulness~Week 4: Sense of coherence and values~Week 5: Acceptance~Week 6: Self-compassion + Conclusion"
76050534|NCT05812716|Behavioral|resiLIR Healthcare Professionals|"Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life."
76050535|NCT05812677|Drug|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
75433213|NCT01533727|Drug|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
75433214|NCT01533740|Drug|fluorouracil/irinotecan/levo-folinic acid/bevacizumab|standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks
75879858|NCT03635411|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Basis supplement.
75433215|NCT01533766|Drug|CombiflexOmega|intravenously over 5 days infusion
75433216|NCT01533766|Drug|SmofKabiven|intravenously over 5 days infusion
75580165|NCT05823740|Other|6-Minute Walk Test (6MWT)|Cardiovascular fitness will be measured with the 6-minute walk test (6MWT). 6MWT will be done at baseline, during the study related to routine medical imaging, and end of the study.
75879859|NCT02748512|Drug|FAI Insert administered using the Mk II inserter|
75879860|NCT02748512|Drug|FAI Insert administered using the Mk I inserter|
75580166|NCT05823740|Other|Timed Up and Go (TUG)|Balance and mobility will be assessed by the timed-up-and-go test (TUG). TUG will be done at baseline, during the study related to routine medical imaging, and end of the study.
75580167|NCT05823740|Other|30-second Sit-to-Stand (STS)|Strength and muscular function will be evaluated by modified 30-second sit-to-stand (STS). STS will be done at baseline, during the study related to routine medical imaging, and end of the study.
75580168|NCT05823740|Other|Hand Grip Strength (GS)|Strength and muscular function will be evaluated by grip strength (GS). GS will be done at baseline, during the study related to routine medical imaging, and end of the study.
75728731|NCT06017440|Behavioral|EXERCISE|Participants will receive at 08:00 am a calibrated breakfast of 500kcal. They should not perform physical exercise during the day. They will be asked at 11 a.m. to cycle for 30 minutes at 65% of the maximal capacities and their energy expenditure will be measured by indirect calorimetry. At 11 a.m., teenagers will receive a calibrated meal of 800 kcal respecting the nutritional recommendations for this age. Questionnaires on feelings of hunger will be distributed to them at regular intervals. They will also be asked to complete a 10-minute computer exercise to assess their relationship to food before and after lunch (LFPQ. Leeds Food Preference Questionnaire, Liking/ wanting). Finally, from 60 minutes after the midday test meal, teenagers will have access to an ad libitum buffet for one hour.
75728732|NCT06017440|Behavioral|CONTROL|Teenagers should not perform any physical activity during the day and they will be asked to stay at 11 a.m., for 30 minutes, resting in a semi-supine position.
75728733|NCT06016959|Other|Dietetic intervention|Dietetic intervention involves individualised and tailored dietary advice to patients struggling with their nutrition. This includes optimising energy and protein intake to improve malnutrition & also giving dietary advice to support with nutrition impact symptoms e.g. bloating.
75728734|NCT06016959|Other|Diet sheet (placebo)|Patients randomised into the group receiving a diet sheet will be sent out Royal Brompton & Harefield Hospital's Poor Appetite diet booklet which involves general strategies to improve nutritional status (energy and protein)
75728735|NCT06014775|Drug|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
75728736|NCT06012669|Dietary Supplement|High dose Human Lactoferrin|Dietary Supplement and Food Ingredient
75879861|NCT04816799|Behavioral|Startle Adjuvant Rehabilitation Therapy (START)|Exposure to loud acoustic stimulus during training of motor task (in this case speech).
75580169|NCT05823740|Other|PBTL p16 expression|Peripheral Blood biospecimen for PBTL p16 expression will be used for the assessment of biological aging. Blood biospecimens will be collected at baseline and end of the study for PBTL p16 analysis.
75580170|NCT05823740|Other|CT, MR and PET Imaging|Participants will undergo routine imaging with either computed tomography (CT), Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan. Skeletal muscle mass and fat mass will be calculated at several different vertebral levels from imaging studies.
75580171|NCT05823714|Drug|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day*7days."
75728737|NCT06012669|Dietary Supplement|Low dose Human Lactoferrin|Dietary Supplement and Food Ingredient
75728738|NCT06012669|Dietary Supplement|Active Control Bovine Lactoferrin|Dietary Supplement and Food Ingredient
75728739|NCT06007651|Drug|LY3885125|Administered SC
75728740|NCT06007651|Drug|Placebo|Administered SC
75879862|NCT04875455|Device|POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
75580172|NCT05823701|Drug|Chidamide|20 mg (4 capsules), d1, d4, d8, d11 orally per cycle
75879863|NCT02748356|Drug|Lactobacillus|Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
75728741|NCT06005038|Behavioral|pSOPT|computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)
75728742|NCT06005038|Behavioral|MLA|computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.
75728743|NCT06001814|Behavioral|One-Mind One-Heart|One-Mind One-Heart will include mindfulness and behavior change skills to address psychological distress, physical activity, diet, and substance use.
75728744|NCT06001814|Other|Education|Education will be provided on behavioral cardiovascular disease risk reduction strategies, such as increasing physical activity, reducing salt intake in diet, and reduce/stop alcohol and tobacco-use.
75728745|NCT05999994|Drug|Ramucirumab|Administered IV
75728746|NCT05999994|Drug|Cyclophosphamide|Administered orally
75728747|NCT05999994|Drug|Vinorelbine|Administered IV
75728748|NCT05999994|Drug|Gemcitabine|Administered IV
75728749|NCT05999994|Drug|Docetaxel|Administered IV
75728750|NCT05999994|Drug|Abemaciclib|Administered orally
75728751|NCT05999994|Drug|Irinotecan|Administered IV
75728752|NCT05999994|Drug|Temozolomide|Administered orally
75433217|NCT01533792|Procedure|Supra/subgingival scaling using periodontal curette scraping|The experimental group received supra and subgingival therapy with periodontal curettes
75580173|NCT05823701|Drug|Azacitidine|100mg d1- d5 subcutaneous injection per cycle
75580174|NCT05823701|Biological|obinutuzumab|1000mg d4 intravenous infusion per cycle
75580175|NCT05823701|Drug|Liposomal mitoxantrone|20mg/m2 d5 intravenous infusion per cycle
75433218|NCT01533792|Procedure|Supra and subgingival scaling|The experimental group received supra and subgingival scaling.
75433219|NCT01533805|Other|Pilates exercises with stabilization|This group will focus on exercises with core stabilizing muscles. The frequency will be 16 sessions lasting 1 hour.
75433220|NCT01533805|Other|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine. The frequency will be 16 sessions lasting 1 hour.
75433221|NCT01533818|Drug|Amoxicillin|"80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0"
75433222|NCT01533818|Drug|Sugar Syrup|It will be given 2 times/day for 7 days
75433223|NCT01533857|Dietary Supplement|hot water|Hot water and placebo capsule
75433224|NCT01533857|Dietary Supplement|Black tea and phenolic acids|Black tea extract and capsule with phenolic acids
75580176|NCT05823649|Dietary Supplement|Early feeding/intervention group|The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.
75879864|NCT02052986|Other|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
75580177|NCT05823610|Diagnostic Test|ultrasound|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
75433225|NCT01533870|Drug|NKTR-118|Oral 25 mg
75580178|NCT05823597|Behavioral|Sugar Intensive Treatment|see arm description
75580179|NCT05823597|Behavioral|General Health Control|see arm description
75580180|NCT05823519|Device|Endologix Ovation Alto Endograft|Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
75433226|NCT01533870|Drug|Rifampin|Oral 600 mg
75433227|NCT01533896|Behavioral|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
75433228|NCT01533961|Drug|SCYX-7158|
75433229|NCT01533961|Drug|Placebo|
75433230|NCT01533987|Dietary Supplement|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
75433231|NCT01534000|Procedure|Cardiac computed tomographic angiography (CCTA)|Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
75433232|NCT01534026|Drug|Aspirin|Current dose
75433233|NCT01534026|Other|withdrawal of aspirin|Stopping current dose of aspirin
75433234|NCT01534039|Device|Sur-Fit Natura|ConvaTec Moldable Skin Barrier for ostomy patients
75433235|NCT01534039|Device|FormaFlex|Hollister skin barrier for ostomy patients
75879865|NCT02054624|Behavioral|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
75433236|NCT01534091|Behavioral|Pedometer with supervision|
75879866|NCT02054624|Behavioral|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
75433237|NCT01534091|Behavioral|Pedometer without supervision|
75433238|NCT01534117|Biological|Platelets|1 unit of platelets
75580181|NCT05823493|Behavioral|Schroth exercise therapy|The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.
75728753|NCT05993091|Other|mirror therapy (MT)|Each participant will practice two different MT protocols: UMT and BMT. During UMT, the affected hand is static, whereas during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements (i.e., shoulder flexion, elbow flexion/extension, forearm pronation/supination, and wrist flexion/extension and circumduction), fine motor movements (i.e., opposition, grasp, and release), and object manipulation (i.e., reaching out to grasp a cup, flipping coins).
75433239|NCT01534117|Drug|DDAVP|Desmopressin 0.3mcg/kg IV x 1
75433240|NCT01534130|Device|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
75433241|NCT01534130|Device|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
75433242|NCT01534169|Drug|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
75580182|NCT05823493|Device|laser therapy|Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
75433243|NCT01534221|Device|Biomatrix drug eluting stent|Biomatrix drug eluting stent
75433244|NCT01534234|Device|PARADYM RF SONR|SonR CRT Optimization
75433245|NCT01534234|Device|PARADYM RF SONR|Echocardiography Optimization
75433246|NCT01534247|Drug|CAZ-AVI|Infusion
75433247|NCT01534247|Drug|metronidazole|Infusion
75433248|NCT01534247|Drug|CAZ-AVI + metronidazole|Infusion
75433249|NCT01534286|Drug|Theramine|Theramine 2 capsules 3 times per day
75433250|NCT01534286|Drug|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
75433251|NCT01534312|Drug|CGMP protein|Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
75433252|NCT01534312|Drug|Maximal oral 5ASA|4800 grams/day of Mesalazine (Asacol/Mezavant)
75433253|NCT01534325|Device|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
75433254|NCT01534325|Device|Control|"The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance."
75580183|NCT05823428|Procedure|Augmentation with subacromial bursa + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
75580184|NCT05823428|Procedure|Rotator cuff debridement + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
75580185|NCT05823415|Procedure|Laterally Closed Tunnel with CTG|A novel minimally invasive surgical approach laterally closed tunnel technique (LCT) has been recently introduced for the management of isolated gingival recession. The laterally closed tunnel technique ensures predictability by tunneling and mobilization of flap for graft coverage.
75580186|NCT05823415|Procedure|CAF with CTG|Gold standard surgical technique
75580187|NCT05823389|Procedure|Re-instrumentation with flapless Emdogain application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
75580188|NCT05823389|Procedure|Re-instrumentation with placebo application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
75580189|NCT05823350|Other|Abdominal massage|Abdominal massage after colonoscopy
75580190|NCT05823324|Behavioral|Therapeutic play group|The dramatization method with teddy bear, one of the TP methods, was applied during the PIVC intervention
75580191|NCT05823285|Drug|QLS31903|0.01μg/kg-2.16 μg/kg QLS31903 for injection
75580192|NCT05823272|Other|ONS|oral nutritional supplement
75580193|NCT05823246|Drug|QLF31907|Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
75580194|NCT05823194|Procedure|Fertility sparing surgery|Sparing the uterus and/or ovaries of the patients suffering from gynecologic malignancies to keep the patients' fertility
75580195|NCT05823181|Device|laparoscopy|laparoscopic exploration of common bile duct
75580196|NCT05823168|Drug|Antiepileptic Drug|we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
75580197|NCT05823155|Procedure|Detailed penicillin allergy evaluation|The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
75580198|NCT05823103|Diagnostic Test|Shawki Septum Scoring System|Utilising the novel scoring system to facilitate feasibility and safety of hysteroscopic metroplasty for uterine septum
75433255|NCT01534325|Device|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
75433256|NCT01534338|Behavioral|Mindfulness Meditation|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
75433257|NCT01534338|Behavioral|Sleep Education|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
75433258|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
75433259|NCT01534377|Behavioral|Interpersonal Psychotherapy for Adolescents|Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.
75433260|NCT01534377|Behavioral|Enhanced Care|Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
75433261|NCT01534390|Device|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
75433262|NCT01534429|Procedure|Quantitative Sensory Testing|Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
75433263|NCT01534442|Drug|Atropine|1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
75433264|NCT01534442|Drug|Placebo|
75433265|NCT01534455|Drug|Lapatinib + 1,23 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
75433266|NCT01534455|Drug|Lapatinib + 1,76 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
75433267|NCT01534468|Biological|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
75433268|NCT01534546|Drug|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
75433269|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
75433270|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
75433271|NCT01534559|Other|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
75433272|NCT01534572|Dietary Supplement|Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
75580199|NCT05823103|Diagnostic Test|ESHRE ASRM Classification|Utilising the current classification before performing hysteroscopic metroplasty
75580200|NCT05823051|Other|VASIDS-TP and Counseling Practice|VASIDS-TP will be implemented online as an individual training to the intervention group through the Microsoft Teams program, to be completed in 5 days-5 sessions in the time frames determined by the participants. The consultancy practice will start with a pre-test and participants will be assured that they can call the researcher 24/7, and the consultancy practice will be continued by phone call or messaging.
75879867|NCT02054624|Behavioral|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
75433273|NCT01534572|Dietary Supplement|Bifidobacterium|Intervention (2 weeks) with a strain of Bifidobacterium
75433274|NCT01534585|Drug|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.~Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
75580201|NCT05822999|Device|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
75433275|NCT01534585|Radiation|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
75433276|NCT01534585|Drug|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
75433277|NCT01534585|Other|Quality of life|The EORTC QLQ-C30 and H&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
75433278|NCT01534585|Genetic|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
75433279|NCT01534702|Drug|clofarabine, cytarabine, idarubicin|"Treatment is stratified according to patients age (< 60 years vs. ≥ 60 years).~Medication:~Patients < 60 years:~idarubicin 7.5 mg/m2 iv, days 1 + 3~cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~idarubicine 6 mg/m2 iv, days 1 + 3~cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~level -1: 15 mg/m2 iv, days 1 to 5~level 1: 20 mg/m2 iv, days 1 to 5~level 2: 25 mg/m2 iv, days 1 to 5~level 3: 30 mg/m2 iv, days 1 to 5~level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1."
75433280|NCT01534715|Drug|IMGN529|
75433281|NCT01534741|Other|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
75433282|NCT01534741|Device|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
75433283|NCT01534754|Drug|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
75433284|NCT01534754|Drug|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
75879868|NCT02054624|Behavioral|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
75879869|NCT01341041|Biological|chlorine dioxide|one time wash with 50ppm CD solution
76050536|NCT05811624|Behavioral|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.|"14 weeks, 18 treatment sessions~This includes:~3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day."
75433285|NCT01534754|Drug|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
75433286|NCT01534754|Drug|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
75433287|NCT01534780|Procedure|laparoscopic ventral herniotomy|Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
75433288|NCT01534780|Device|Protack|fixation of mesh with protack
75433289|NCT01534780|Device|Securestrap|fixation of mesh with Securestrap
75580202|NCT05822999|Device|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
75580203|NCT05822973|Device|3.0 monocryl suture|incision will be closed with absorbable suture
75580204|NCT05822973|Device|3.0 nylon suture|incision will be closed with non-absorbable suture
75879870|NCT01341041|Biological|saline|one time wash with 50-100 cc normal saline
75879871|NCT02053064|Genetic|SAF-301|
75879872|NCT04805021|Other|no intervention|no intervention
75879873|NCT02053142|Drug|Acyclovir|Single dose of acyclovir 200mg was given for pk study
75879874|NCT02053142|Drug|Placebo|
75879875|NCT01316471|Behavioral|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
75879876|NCT01316471|Other|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
76050537|NCT05811624|Behavioral|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.|"14 weeks, 18 treatment sessions~This includes:~3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful."
76050538|NCT05810987|Other|RESTORE|"Virtual educational curriculum organized into the following modules:~Module Specific Communication Strategies~Introduction~Preparing for and introducing a conversation [Consider personal bias /Building rapport /Ask permission]~Assessing understanding [Avoid correcting /Open ended questions]~Giving information [Give a warning shot /Using silence /Wish/worry/wonder]~Explore goals [Reflective listening /Naming, validating emotion~Summarizing and recommending a plan [Values-based recommendation /Aligning with goals /REMAP (Reframe, Expect emotion, Map goals, Align, Propose plan)]"
76050539|NCT05810987|Behavioral|Medical Interaction and Coaching|Skills sessions with standardized patients (SPs) along with coaching feedback.
76050540|NCT05810025|Behavioral|RealRisks|RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
75879877|NCT01316549|Drug|Fludarabine|Given as injection
75879878|NCT02054780|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
76050541|NCT05809687|Drug|DKP21102_C|Placebo
75433290|NCT01534780|Device|Glubran|fixation of mesh with Glubran
75433291|NCT01534793|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
75433292|NCT01534806|Drug|Ketorolac|Ketorolac(0.5mg/kg) IV push
75433293|NCT01534806|Drug|Placebo|Sodium Chloride 0.9% - 10 mL IV push
75433294|NCT01534832|Device|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
75433295|NCT01534845|Drug|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
75580205|NCT05822947|Other|Active manual therapy|Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).
75433296|NCT01534858|Device|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
75433297|NCT01534884|Biological|rituximab|1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
75433298|NCT01534923|Behavioral|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
75433299|NCT01534949|Biological|rituximab|375 mg/m2 by intravenous [IV] infusion
75433300|NCT01535027|Drug|teriparatide|teriparatide 20 ug/day, sc.
75433301|NCT01535027|Drug|teriparatide and raloxifene|teriparatide 20 ug/day sc. raloxifene 60mg oral daily
75433302|NCT01535027|Drug|teriparatide and alendronate|teriparatide 20 ug/day sc. alendronate 70mg oral weekly
75433303|NCT01535079|Drug|Placebo|Single administration
75433304|NCT01535079|Drug|Ibuprofen 35 mg|Single administration
75433305|NCT01535079|Drug|Ibuprofen 25 mg|Single administration
75580206|NCT05822947|Other|Control manual therapy|Light touch and a breathing exercise (3 to 4 minutes).
75580207|NCT05822908|Drug|VO659|VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
75580208|NCT05822882|Procedure|Epidural anesthesia|Postoperative pain management by epidural anesthesia via epidural catheter and pain pump
75580209|NCT05822804|Device|Vascular Closure Device (Tonbridge)|Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).
76050542|NCT05809687|Drug|DKP21102_B|Treatment
75433306|NCT01535079|Drug|Ibuprofen 15 mg|Single administration
76050543|NCT05809687|Drug|DKP21102_A|Active Control
75433307|NCT01535079|Drug|Strefen|Single administration
75433308|NCT01535092|Drug|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
75433309|NCT01535092|Drug|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
75433310|NCT01535144|Device|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
75433311|NCT01535144|Device|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
75580210|NCT05822804|Device|EXOSEAL Vascular Closure Device (Codis Corporation)|Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).
75580211|NCT05822778|Device|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
75580212|NCT05822778|Device|"Q-MED RESTYLANE"|Dermal filler injection to facial areas
76050544|NCT05809570|Diagnostic Test|Clinical examination|"A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient."
75580213|NCT05822739|Drug|BBM-P002|Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
75580214|NCT05822726|Diagnostic Test|Prostate biopsy|"Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme)."
75433312|NCT01535157|Drug|Fenretinide/LXS + Ketoconazole|Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
75433313|NCT01535170|Dietary Supplement|bovine Lactoferrin|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17].
75580215|NCT05822713|Drug|Amisulpride|5mg/2ml
75728754|NCT05993091|Other|augmented reality (AR)|The training program with different levels of difficulty provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg, etc.), activities of daily living training (i.e., reaching to grasp functionally relevant objects), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
75433314|NCT01535183|Drug|Irinotecan combination chemotherapy|"Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)~VCR 2㎎/㎡ d0 IV push~Etoposide 100㎎/㎡ d0-d2 IV over 1hr~Carboplatin 450㎎/㎡ d0 IV over 8hrs~Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna"
75433315|NCT01535196|Drug|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
75433316|NCT01535209|Radiation|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
75580216|NCT05822713|Drug|Amisulpride Placebo|2ml
75580217|NCT05822700|Procedure|Kirschner wire|Transfixing femoral head Kirschner wire
75580218|NCT05822687|Behavioral|Education|This is a constant component; all participants will get a psychoeducation digital module.
76024868|NCT05191043|Other|Kinesio Taping Technique|Kinesio taping is a thin, stretchy, elastic cotton strip with an acrylic adhesive that is approximately the same thickness as the epidermis of the skin. When the taping method is followed correctly, the tape effects on the muscle by facilitating a weakened muscle or relaxing an over-used muscle,decreasing pain, fatigue and increasing tissue recovery. Kinesio Taping facilitation technique will be used with fifty percent stretch on rhomboids bilaterally.
76050545|NCT05809531|Drug|Pegcetacoplan|Complement (C3) Inhibitor
76050546|NCT05808582|Drug|chidamide，fulvestrant|chidamide combined with fulvestrant
76050547|NCT05808400|Biological|MSC-derived exosomes|The total volume of MSC-derived exosomes is 5ml, and exosome concentration in preparation is 1*10^9 particles/ml.
75580219|NCT05822687|Behavioral|Reappraisal Coping|This digital module will teach reappraisal coping skills.
75580220|NCT05822687|Behavioral|Distraction Coping|This digital module will teach distraction coping skills.
75580221|NCT05822687|Behavioral|Relaxation Coping|This digital module will teach relaxation coping skills.
75580222|NCT05822674|Drug|Sitagliptin/metformin ( 50/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
75879879|NCT02054780|Behavioral|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH."
75580223|NCT05822674|Drug|Empagliflozin/metformin(10/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
75580224|NCT05822661|Dietary Supplement|Black Seed Oil|Dietary supplement
75879880|NCT01316627|Behavioral|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
75580225|NCT05822661|Dietary Supplement|Placebo|placebo capsules same odor, color and size as the drug but without the active ingredient
75580226|NCT05822622|Other|echocardiography|to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
75580227|NCT05822609|Drug|Semaglutide|1.0 mg
75580228|NCT05822609|Other|Placebo|Placebo
75879881|NCT01316627|Behavioral|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
75879882|NCT03439657|Biological|HZ/su vaccine GSK1437173A|2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
75879883|NCT03439657|Biological|Prevenar13|1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
75879884|NCT02053220|Biological|Colo-Ad1|Oncolytic virus
75879885|NCT02056028|Procedure|Hepatic resection|
75879886|NCT01341743|Drug|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
75580231|NCT05820425|Other|LFP and EEG recording|STN LFP and EEG recording during the OFF and ON medication condition
75728755|NCT05993091|Other|Control intervention|Participants will perform 90 minutes of therapist-mediated conventional therapy. The treatment protocols will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. Specifically, the affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques will be used to alleviate functional deficits. In addition, the therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
75879887|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
75879888|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
75433317|NCT01535209|Radiation|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
75580232|NCT05820360|Behavioral|CoMBI-SMI|The first step is analysis of the behavioral problem because the core need is insufficiently compensated by the current environment or counteracted by the behavior of people within that environment. Step 2 is to choose the right core need based on this analysis. CoMBI-SMI describes the patient's self-image, the image of others, the triggering events and the problematic behavior of the patient based on personality disorders as classified by the Diagnostical and Statistical Manual of Mental Disorders. Step 3 is to choose the nursing intervention that is easily deployable so that Healthcare providers can identify the underlying core need and reduce the behavioral problems and burden on the healthcare providers. The fourth and final step is to draw up a CoMBI plan. The CoMBI-SMI is a cyclical process where it is important that the entire team is aligned with the patient's behavioral approach. Interventions are carried out by the entire team and evaluated after an agreed period of time.
75580233|NCT05819294|Procedure|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
75580234|NCT05819008|Diagnostic Test|Neuropsychological Assessment|"To validate Mindmore Distance (MD), the following standard neuropsychological tests will be used in a testing session with a psychologist:~Wordlist 1 and 2 from WMS-III (Wechsler, 1997). Equivalent to RAVLT in MD~Coding from WAIS-IV (Wechsler, 2008). Equivalent to SDPT in MD~Block Span from WMS-III (Wechsler, 1997). Equivalent to CBT in MD~Trail Making Test from D-KEFS (Delis et al., 2001). Equivalent to TMT-Click in MD~Color-Word Interference Test from D-KEFS. Equivalent to Stroop in MD~Verbal fluency from D-KEFS. Equivalent to FAS in MD~All participants will complete some questionnaires: Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983); Insomnia Severity Index (Bastien, Vallieres, & Morin, 2001); Cognitive Failure Questionnaire (Broadbent, Cooper, FitzGerald, & Parkes, 1982); Perceived Stress Scale (Levenstein et al., 1993); Multidimensional Fatigue Inventory (Smets, Garssen, Bonke, & De Haes, 1995)."
75580235|NCT05817474|Drug|lidocaine (2 %) 2 ml and tranexamic acid|lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed
75580236|NCT05812560|Other|postural changes|application of a protocol of postural changes every 30-60 min or at least two postural changes in one hour during labor.
75728756|NCT05985382|Other|Lower Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
75728757|NCT05985382|Other|Upper Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
76024869|NCT05191043|Other|Routine Physical Therapy|"routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes."
76050548|NCT05805787|Other|Acupressure|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
76050549|NCT05800002|Procedure|Intravascular ultrasound|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.
76050550|NCT05800002|Procedure|Angiography|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
75433318|NCT01535300|Procedure|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
75433319|NCT01535313|Device|OnControl BM-Biopsy system|Bone marrow biopsy at posterior iliac crest
75879889|NCT02054858|Procedure|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
75879890|NCT01341197|Other|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
75879891|NCT01341275|Biological|hepatitis B vaccine|10 ug dose, one-time administration
75879892|NCT01341275|Biological|hepatitis B vaccine|20 ug dose, one-time administration
75879893|NCT02852161|Device|Magnet assissted capsule endoscopy|Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
75879894|NCT01353937|Drug|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
75879895|NCT04720001|Drug|Florbetaben F18|A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
75580237|NCT05812170|Behavioral|Educational online session about PF|The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
75580238|NCT05811013|Device|Transcranial static magnetic field stimulation (tSMS)|Patients will be randomly assigned to either real or sham tSMS. Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 12 +12 months. Patients will choose whether to undergo stimulation at home or in the hospital on an outpatient setting. Real tSMS will be delivered with two cylindrical neodymium magnets (grade N45) of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), applied with south polarity, each pointing toward the motor cortex. To discharge the weight of the helmet from the head during the sessions, patients will be instructed to rest the back of head and helmet on an inclined surface in a comfortable position. They will be also instructed to rest, minimizing movement, and not to watch audiovisuals during the stimulation sessions.
75728758|NCT05984316|Other|Exercise|"Dual task exercises are defined as the appropriate direction of attention during two activities performed at the same time. Dual task performance is required during many activities in daily life. Multitasking is complicated to understand because it is divided into social, physical, and psychological branches.~The simultaneous occurrence of movement and cognitive processes is seen as a part of social participation. Considering that one task affects the other, dual task is defined as the simultaneous performance of two tasks that can be performed independently, can be evaluated separately, and have different purposes.~Each task must be incompatible and measurable, achievable alone or in different combinations. The increased need for information processing alone does not constitute dual-tasking."
75879896|NCT04720001|Device|PET|PET Scan for brain imaging
75879897|NCT02878213|Device|D700 System|Atrial Fibrillation Ablation Procedure
75879898|NCT04705883|Drug|Prasterone (DHEA), Micronized|Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
75728759|NCT05981768|Drug|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
75728760|NCT05980793|Procedure|PIP joint denervation|Surgical denervation of the PIP joint
75728761|NCT05980793|Procedure|Patient education plus exercise|An education plus exercise program
75879899|NCT04677491|Drug|Ospemifene 60 mg|Ospemifene vs placebo
75879900|NCT04677491|Behavioral|fMRI experiments|Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.
75879901|NCT02053298|Drug|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
75879902|NCT04653545|Diagnostic Test|HbA1c|"Blood will be taken as per requirement for patients being admitted to hospital. A small sample will be sent to the biochemistry department for measurement of HbA1 (by HPLC method).~All patients who are diagnosed with diabetes (or known to have diabetes) will have a foot examination and retinal and renal screening and cardiovascular assessment for diabetes complications."
75879903|NCT02054936|Drug|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
76050551|NCT05796804|Procedure|ERECTOR SPINAE PLANE BLOCK|ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
76050552|NCT05796804|Procedure|Peng block + lateral femoral cutaneous nerve block|ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
75879904|NCT02054936|Drug|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
75433320|NCT01535352|Behavioral|Mom-Net|"The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration."
75433321|NCT01535352|Behavioral|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
76050553|NCT05796804|Procedure|spinal anesthesia|bupivacaine 0.5% 2.2 ml
76050554|NCT05788887|Other|Authentic Ladotyri Mytilinis PDO cheese|Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
75433322|NCT01535391|Drug|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
76050555|NCT05788887|Other|Control|Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
76050556|NCT05788874|Diagnostic Test|18F-FAPI and 18F-FDG PET/CT|18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer
75580239|NCT05811013|Device|Sham Transcranial static magnetic field stimulation (tSMS)|Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 12 +12 months. Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain).
76050557|NCT05788289|Drug|Tafasitamab|Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
76050558|NCT05788289|Drug|Lenalidomide|Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
76050559|NCT05775887|Biological|UQSC2 Vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373. The Study will be unblinded after Day 29, to enable subjects who received the investigational vaccine (UQSC2 vaccine) to seek vaccination with a TGA (Therapeutic Goods Administration) approved COVID-19 booster vaccine if indicated by public health authorities.
75433323|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
75433324|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
75433325|NCT01535417|Drug|Shinbaro Capsule|Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)
75433326|NCT01535417|Drug|Celebrex|
75433327|NCT01535456|Procedure|FLT-PET scans|FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
75580240|NCT05808179|Device|Light|Broad-spectrum white light flashes are ~4000 lux, 2 msec long, occur every 20 s
75580241|NCT05808179|Behavioral|CBT|Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing
75728762|NCT05977660|Diagnostic Test|Cumberland ankle instability tool for diagnose to determine ankle instability and its severity|CAIT is a Patient-reported measures of outcome (PROM) and it is very simple, reliable, and valid measurement tool that is used without comparing with the contralateral ankle, which consists of 9 questions and is scored between 0 and 30, developed by Hiller and her colleagues in 2006 to measure the severity of functional ankle instability. Low scores of the participants indicate poor ankle stability, while high scores indicate good ankle stability.
75879905|NCT02802878|Device|Hybrid Training using Electrodes and Joint Motion Sensors|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
75879906|NCT02802878|Device|Isokinetic Training with Isokinetic Dynamometer|Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
76050560|NCT05775887|Biological|NVX-CoV2373 vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373
75580242|NCT05808179|Device|Sham Light|Broad-spectrum white light flashes are ~4000 lux, 2 msec long, occur once
75580243|NCT05805150|Device|Control Contact Lens (stenfilcon A)|One week wear
75728763|NCT05973019|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|6 times/per week for 2 weeks, total 12 times rTMS with 10 Hz.
76050561|NCT05774431|Other|There was no intervention necessary.|There was no intervention necessary.
76050562|NCT05766189|Behavioral|Wastewater vaccine prompts|Social media communications showing levels of SARS-CoV-2 in wastewater
76050563|NCT05760560|Drug|Sugammadex|At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
75433328|NCT01535469|Drug|Fluconazole|Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
75433329|NCT01535482|Behavioral|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
75433330|NCT01535482|Behavioral|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
75580244|NCT05805150|Device|Test Contact Lens (senofilcon A)|One week wear
75433331|NCT01535495|Drug|Propranolol|Propranolol XL 120mg by mouth once daily
75433332|NCT01535521|Device|Sleep Position Trainer (SPT)|
75580245|NCT05805137|Device|WoundWatch wound management system|eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch wound management system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
75433333|NCT01535547|Drug|isavuconazole|oral
75580246|NCT05797480|Other|Real Dry needling|Real dry needling will be applied to the pelvic floor, hip and lower back muscles.
75728765|NCT05966948|Drug|Dextrose Solution|Prolotherapy is a regenerative tissue therapy that is considered efficacious for reducing the symptoms and morbidity of Knee Osteoarthritis (KOA) using hypertonic dextrose as an injectable substance. Treatment will be given two times, on day 1st and 30th day.
75728766|NCT05966948|Drug|Normal Saline|Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
75728767|NCT05966688|Drug|SPR720|Multiple oral doses of SPR720 capsules.
75728768|NCT05966688|Drug|Azithromycin|Multiple oral doses of azithromycin.
75433334|NCT01535547|Drug|tacrolimus|oral
75433335|NCT01535586|Device|CPAP versus MAD|Cross over design
75433336|NCT01535612|Device|PaQ™ insulin infusion device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
75728769|NCT05966688|Drug|Ethambutol|Multiple oral doses of ethambutol.
75879907|NCT04782791|Drug|Nivolumab plus SOX|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA<1.25 m2, 40mg; 1.25<BSA<1.50 m2, 50mg; BSA>1.50 m2, 60mg. Day 15 to day 21 is the rest period.
75580247|NCT05797480|Other|Non penetrating dry needling|Sham non penetrating dry needling (fixed needle in an introducer tube) will be applied to the pelvic floor, hip and lower back muscles.
75580248|NCT05780567|Drug|TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|"TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors.~Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer."
75580249|NCT05780567|Drug|Placebo capsules, Letrozole, Anastrozole, Tamoxifen|Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.
75580250|NCT05751629|Drug|Dostarlimab|Dostarlimab was administered.
76050564|NCT05758090|Procedure|NIPE monitor|Procedure/Surgery: NIPE protocol. Give intraoperative fentanyl according to NIPE value. NIPE score 50-70 indicates optimal narcotic effect. NIPE score > 70 indicated overdosage of narcotic and narcotic should be withheld. NIPE score < 50 indicates inadequate narcotic and narcotic should be given.
76050565|NCT05758090|Procedure|Control|Procedure/Surgery: Standard protocol. Give intraoperative fentanyl according to vital signs.
76050566|NCT05757388|Drug|Parecoxib + paracetamol|Administers after induction of anesthesia.
75433337|NCT01535625|Device|Momo stent|Patients with PCI
75433338|NCT01535651|Behavioral|Teen Outreach Program with Media Enhancement (TOP4ME)|Persons participating in TOP will receive text messages weekly in addition to TOP
75433339|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fasted|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
75580251|NCT05751629|Drug|Bevacizumab|Bevacizumab was administered.
75433340|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fasted|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
75433341|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fed|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
75433342|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fed|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
75580252|NCT05751629|Drug|Niraparib|Niraparib was administered.
75580253|NCT05744271|Device|FES+VFBT|Standing balance training with the FES+VFBT system will occur 3x/week for six weeks (i.e. 18 sessions). Electrodes will be placed on the participants' plantarflexors and dorsiflexors bilaterally and FES will be administered using the device, MyndSearch, during the balance training exercises. Each session will last one hour, including 15 min to identify motor thresholds and maximum tolerable stimulation levels, 5 min to don/doff the safety harness, 5 min to calibrate the FES+VFBT exercises, 20 min to complete the FES+VFBT exercises, and 10-15 min to take rest breaks between exercises as needed.
75433343|NCT01535690|Other|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
75879908|NCT04782791|Drug|Nivolumab|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.
75879909|NCT04782791|Procedure|Gastrectomy|A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
75879910|NCT04773197|Behavioral|Beating the Blues (BtB)|Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
75879911|NCT04773197|Behavioral|Entertain Me Well (EMW)|Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
75433344|NCT01535716|Behavioral|hemodynamic optimization strategy driven by the ECOM|"goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) & cardiac index (CI).~goals:~SVV < 11%~IC > 2,2 ml/min/m²~During the anesthesia"
75433345|NCT01535716|Behavioral|standard management strategy|"goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~Diuresis > 0,5ml/kg/h~Blood pressure , PAM > 65 mmHg~Pulse pressure variation~CVP 8 to 12 cmH20~Visual aspect of the heart~Overload signs During the anesthesia"
75580254|NCT05736640|Drug|Denosumab|
75580255|NCT05736640|Drug|Placebo|
75580256|NCT05734014|Behavioral|Healthy Relationship|The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.
75580257|NCT05728294|Procedure|Femoral nerve block with ropivacaine 0.5%, 20 ml|Femoral nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
75580258|NCT05728294|Procedure|Sciatic nerve block with ropivacaine 0.5%, 20 ml|Sciatic nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
75728770|NCT05960513|Behavioral|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
75728771|NCT05956405|Behavioral|AIR + Mindfulness|AIR + Mindfulness program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
75728772|NCT05956405|Behavioral|Relaxation condition|Relaxation program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
75879912|NCT04773197|Behavioral|Coaching|A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
75879913|NCT01341353|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
76050567|NCT05757388|Drug|Normal saline|Administers after induction of anesthesia.
75879914|NCT01341353|Drug|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
76050568|NCT05755334|Drug|Ropivacaine|Administration of Ropivacaine
76050569|NCT05746299|Behavioral|Congruent vs. Incongruent|The Congruent vs. Incongruent intervention relates to the feature-based structure of the novel categories (Modular or non-Modular) and whether there is (Congruent) or is not (Incongruent) a match between what was previously learned and the final target category.
76050570|NCT05746299|Behavioral|Immediate vs. Awake vs. Asleep|Immediate, Awake, and Sleep refer to either no break, 2.5 hours awake, or 2 hours asleep plus a 30-minute post-nap break to account for sleep inertia between learning and target category.
76050571|NCT05746299|Behavioral|Targeted memory reactivation (TMR)|Targeted memory reactivation (TMR) is the systematic presentation of sounds during sleep that were associated with certain stimuli during learning and will be administered either during slow wave sleep (SWS) or rapid eye movement (REM) sleep.
76050572|NCT05741606|Drug|Sodium pentaborate pentahydrate|Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
75433346|NCT01535742|Device|Ambu Aura-i size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
75433347|NCT01535742|Device|air-Q ILA size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
75433348|NCT01535742|Device|Ambu Aura-i size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
75879915|NCT02056106|Drug|antidepressant therapy|
75433349|NCT01535742|Device|air-Q ILA size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
75433350|NCT01535755|Device|protocol|In this group, the patients were weaned as the protocol.
75433351|NCT01535755|Other|physician's orders|In this group, the patients were weaned as the clinicians' order.
75879916|NCT05183087|Diagnostic Test|3T Connectome MRI|MRI scan of structural connectivity
75879917|NCT05183087|Diagnostic Test|7 Tesla MRI|MRI scan of functional connectivity
76050573|NCT05741606|Drug|Placebo|Placebo capsules
76050574|NCT05729334|Device|Clinicgram Euclides|"Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~for EUCLIDES 3D, a two reference points selected by the investigator."
76050575|NCT05717205|Diagnostic Test|technetium scitigraphy|patients will have a technetium scintraphy confirming or ruling out gastroparesis. Then the patients will have a gastroscopy with tissue samples from antrum and fundus. During gastroscopy an endo-flip ballon will meassure the distensibility in pylorus.
75433352|NCT01535768|Drug|Aqueous Suppressant Eye Drops|"Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)"
75433353|NCT01535781|Drug|Tranexamic Acid|1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
76050576|NCT05707182|Drug|18F-rhPSMA-7.3|18F-rhPSMA-7.3 PET/MR
76050577|NCT05704322|Other|Wim Hof Methode|The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
76050578|NCT05701891|Combination Product|Physiotherapy with integrated Virtual Reality|A 12-week personalised, VR-integrated physiotherapy intervention.
76050579|NCT05701891|Other|Physiotherapy (usual care)|A 12-week usual physiotherapy care intervention.
76050580|NCT05692921|Other|Remote Home Monitoring (RHM)|A Virtual platform will be used to provide education and support for ACS patients within the community after a patient is discharged home
75433354|NCT01535781|Drug|Placebo|Identical syringe and drip used as in the intervention, to ensure blinding.
75580259|NCT05725577|Other|care via the telemedicine system|Care via the telemedicine system
75580260|NCT05725577|Other|Routine care|Routine care
75879918|NCT05183087|Diagnostic Test|TSPO PET|PET scan of neuroinflammation
75879919|NCT05183087|Diagnostic Test|Tau PET|PET scan of tau deposition
75879920|NCT05183087|Diagnostic Test|Cognitive and Behavioral Assessments|Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
75879921|NCT05183087|Diagnostic Test|Blood Biomarkers|Blood-based assessments of proteomic and metabolic biomarkers of brain injury
75879922|NCT02056184|Drug|Adalimumab|
75879923|NCT01341431|Drug|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
75879924|NCT02056262|Other|Dental cavity evaluation|The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
75433355|NCT01535820|Drug|Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
75433356|NCT01535820|Drug|Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
75879925|NCT02056262|Biological|Saliva sampling|A saliva sample will be harvested.
75879926|NCT02056262|Biological|Plaque sampling|Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
75580261|NCT05704829|Drug|Trastuzumab deruxtecan|T-DXd i.v.
76050581|NCT05692921|Other|Rapid Response Nursing|A Rapid Response Nurse will be used to provide education and support for ACS patients within the community after a patient is discharged home.
76050582|NCT05691140|Other|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
76050583|NCT05688735|Other|Isosorbide Diester Moisturizer|Isosorbide Diesters (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5% ointment
76050584|NCT05688735|Other|Control Moisturizer|Topical vehicle (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5 % ointment
75580262|NCT05704829|Drug|Standard-of-Care|Chemotherapy+T+P
75580263|NCT05676840|Procedure|orthodontic treatment with fixed appliances|comprehensive orthodontic treatment with fixed orthodontic appliances for the correction of misaligned teeth.
75580264|NCT05657366|Procedure|Peritoneal lavage|Continuous abdominal flushing with normal saline
76050585|NCT05627596|Behavioral|Ask-Advise-Refer|All patients will be asked if they smoke, advised to quit, and referred to the state quitline
75433357|NCT01535833|Procedure|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
75433358|NCT01535846|Behavioral|Conscious food tasting intervention|Six weekly 2-hour workshops
75433359|NCT01535859|Drug|Cabergoline|Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
75879927|NCT02801396|Device|Etafilcon A Design 1 (Test 1)|
75879928|NCT02801396|Device|Etafilcon A Design 2 (Test 2)|
75879929|NCT02801396|Device|Etafilcon A (Control)|
75879930|NCT02800928|Drug|CERC-501|CERC-501
75879931|NCT02800928|Drug|Placebo|Placebo
75879932|NCT02056418|Dietary Supplement|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
75879933|NCT02056418|Drug|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
75879934|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
76050586|NCT05627596|Drug|Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release|14 mg transdermal nicotine patch
76050587|NCT05627596|Drug|Nicotine lozenge|4mg nicotine lozenge
75433360|NCT01535859|Drug|Placebo|1 tablet daily for 8 days.
75433361|NCT01535872|Dietary Supplement|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
76050588|NCT05619198|Behavioral|High Intensity Interval Exercise|"High Intensity Interval Exercise:~5 minutes resting phase @ 0 watts.~5-minute warm up phase @ 20 watts.~40 minutes of interval work consisting of eight bouts of 1-minute cycling at a power output corresponding to ~85% of VO2max interspersed with 4-minute recovery periods at 20 watts.~5 minutes resting phase @ 0 watts."
75580266|NCT05638347|Drug|HRS-7085 tablets|Single oral administration
75580267|NCT05638347|Drug|Placebo tablet|Single oral administration
75580268|NCT05636748|Diagnostic Test|18F-GP1 PET/CT|Patient will receive 1 18F-GP1 PET/CT
76050589|NCT05619198|Behavioral|Moderate Intensity Continous Exercise|"Moderate Intensity Continous Exercise:~5 minutes resting phase @ 0 watts.~5-minute warm up phase @ 20 watts.~40 minutes of MICE 65% VO2max.~5 minutes resting phase @ 0 watts."
76050590|NCT05593588|Drug|Fisetin|20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
76050591|NCT05593588|Drug|Placebo|Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
76050592|NCT05591066|Behavioral|PFC I-PASS Intervention|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
75879935|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
75879936|NCT02056574|Drug|NA-1|
75879937|NCT02056574|Drug|Placebo|
75879938|NCT02058680|Biological|PSA/IL-2/GM-CSF|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
76050593|NCT05591066|Behavioral|PFC I-PASS+ Intervention|PFC I-PASS+ builds on PFC I-PASS to make it better and focus on the special needs of patients who speak languages other than English. PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters during and after rounds, cultural humility training, and provider communication skills training.
76050594|NCT05590871|Device|FlashPoint renal denervation system|Radio-frequency ablation of renal arterial sympathetic nerves
76050595|NCT05588882|Procedure|Wavefront-guided LASIK|Topography-guided utilizes topography mapping to perform the ablation
76050596|NCT05588882|Procedure|Wavefront-guided|Wavefront-guided utilizes aberrometry to perform the ablation
76050597|NCT05585749|Other|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
75433362|NCT01535885|Biological|Cytotoxic T Lymphocytes|Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
75433363|NCT01535898|Other|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
75433364|NCT01535989|Drug|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
75433365|NCT01535989|Drug|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
75433366|NCT01536002|Drug|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
75433367|NCT01536028|Drug|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
75580269|NCT05636748|Diagnostic Test|Agitated Contrast Echocardiogram|Agitated saline and ultrasound contrast will be performed to assess for intracardiac shunts and left ventricular thrombus.
75879939|NCT02058758|Device|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
75879940|NCT02058914|Dietary Supplement|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
75879941|NCT02058914|Dietary Supplement|High Glucose sweetened beverage|HG-sweetened beverage
75879942|NCT02055014|Drug|Liraglutide|
75879943|NCT02055014|Device|Duodenal-jejunal bypass liner - Endobarrier device|
75879944|NCT03148691|Drug|A-101|Topical Solution
75879945|NCT02059226|Behavioral|cognitive behavioural therapy|Internet-based CBT
75879946|NCT02059226|Other|Internet-based resource page|Static webpage
75879947|NCT02059304|Device|Measurement of cervical length with embryo transfer catheter|
75879948|NCT03148067|Procedure|Intramedullary nailing for fracture fixation|
75879949|NCT02059382|Behavioral|ChiRunning training|
75879950|NCT02059382|Behavioral|unblinded accelerometer|
75879951|NCT02059382|Behavioral|participation in online social network|
75879952|NCT02059382|Behavioral|participation in study website|
75879953|NCT02059382|Behavioral|Technology support for behavior change|
75879954|NCT02055170|Drug|finasteride 5mg oral daily|
75879955|NCT04552925|Other|Rehabilitation|Exercises and rehabilitation for massive rotator cuff tears
75879956|NCT02055326|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
76050598|NCT05585294|Behavioral|Exercises|Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
76050599|NCT05582798|Drug|Alpha 1-Proteinase Inhibitor 180mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
75879957|NCT02055326|Behavioral|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
75879958|NCT02055326|Behavioral|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
75879959|NCT03561116|Dietary Supplement|XAN|Daily intake of a sachet containing 12 mg of XAN
75879960|NCT03561116|Dietary Supplement|Placebo|Daily intake of a sachet containing excipient
75580270|NCT05636748|Diagnostic Test|MRI Head|Where necessary, if the CT head is normal or the clinical diagnosis of a stroke is not definite, a research MRI head will be undertaken if this has not already been performed as part of standard care.
75580271|NCT05636748|Diagnostic Test|ECG Monitoring|All patients who do not have evidence of atrial fibrillation or atrial flutter on their 12-lead ECG will undergo an ECG Holter monitor for up to 7 days. This will be part of their standard care. If this has not been arranged by the usual care team this will be performed as a research procedure.
75728773|NCT05955326|Drug|Sovateltide|Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
75433368|NCT01536028|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
75879961|NCT04490993|Drug|APL-1202 in combination with Epirubicin|"Induction period: APL-1202 is administered for 12 consecutive weeks~Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
75879962|NCT04490993|Drug|Placebo in combination with Epirubicin|"Induction period: placebo is administered for 12 consecutive weeks~Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
75879963|NCT02055482|Drug|Molidustat (BAY85-3934)|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
75879964|NCT02055482|Biological|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
76050600|NCT05582798|Drug|Alpha 1-Proteinase Inhibitor 120mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
76050601|NCT05582798|Drug|Sodium chloride|Sodium chloride 09.% intravenous infusion
76050602|NCT05574322|Other|Progressive foot strengthening protocol|"This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :~Maximum muscle strength of the foot~Foot muscle morphology"
76050603|NCT05574322|Other|Control group|The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.
75879965|NCT04465565|Procedure|9% Sodium Chloride (NaCl) IV|9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
75879966|NCT04395755|Behavioral|Generalized Anxiety Disorder-7 (GAD-7)|The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.
76050604|NCT05574309|Device|Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer|Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
75433369|NCT01536028|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
75433370|NCT01536028|Drug|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
75433371|NCT01536054|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
75433372|NCT01536054|Drug|sirolimus|Given PO
75433373|NCT01536054|Other|laboratory biomarker analysis|Correlative studies
75433374|NCT01536054|Biological|sargramostim|Given SC
75580272|NCT05633017|Combination Product|CereVu Objective Dyspnea Score|Small forehead wearable and mobile app
75580273|NCT05628142|Radiation|Pelvic CT Scan|Pelvic CT-Scan between 6-12 months post-op
76050605|NCT05574309|Device|GAITRite Device|Walking parameter measured during a 10 m walking test with GaitRite device
75879967|NCT04395755|Behavioral|Patient Health Questionnaire-9 (PHQ-9)|The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
76050606|NCT05567640|Behavioral|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
75433375|NCT01536106|Other|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
76050607|NCT05567640|Behavioral|Space for depression|Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
75580274|NCT05591586|Behavioral|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 6 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and 6) solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be <15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
75728774|NCT05955326|Other|Normal Saline|Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.
76050608|NCT05567640|Behavioral|Space for resilience|This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
76050609|NCT05552196|Drug|Ponesimod|Ponesimod tablet will be administered orally.
76050610|NCT05552196|Drug|Carbamazepine|Carbamazepine tablet will be administered orally.
75433376|NCT01536106|Other|Placebo control|Intracoronary infusion of autologous peripheral blood.
75433377|NCT01536132|Drug|Levosimendan|0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
75433378|NCT01536132|Drug|Placebo|Placebo (same appearance than active drug) is administered with the same dosing regime
75433379|NCT01536158|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
75879968|NCT04743947|Other|No intervention; observational study|no intervention
75879969|NCT02059460|Drug|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
75879970|NCT02059460|Drug|placebo|
75879971|NCT02055716|Drug|Sulforadex|
75879972|NCT02055716|Drug|alpha-cyclodextrin|
75879973|NCT04739735|Procedure|Dental Local Anaesthesia|lower primary molar teeth indicated for extraction will be given a local anaesthetic injection according to the random allocation to one of the two arms mentioned previously
76050611|NCT05538247|Drug|Indomethacin|Immediate release oral capsules 50 mg, 3 times a day for 6 days
76050612|NCT05538247|Dietary Supplement|S. boulardii CNCM I-745|Two 250 mg capsules orally twice daily for 14 days
76050613|NCT05538247|Drug|Placebo|Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days
76050614|NCT05536258|Other|Fluid|The investigators will titrate fluid administration to maintain a RI > 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI > 90 over at least 85% of the intraoperative period.
75433380|NCT01536158|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
75433381|NCT01536210|Drug|YY-162|YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
75433382|NCT01536210|Drug|Placebo|Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
75433383|NCT01536223|Drug|PF (cisplatin and 5-fluorouracil) group|the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
75879974|NCT02059538|Other|Adipose tissue biopsies (omental and subcutaneous) liver|
76050615|NCT05533632|Drug|Semaglutide|Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.
76050616|NCT05531916|Other|Pressurized gloves and foot caps|Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).
76050617|NCT05496192|Drug|Nivolumab/rHuPH20|Specified dose on specified days
76050618|NCT05496192|Drug|Nivolumab|Specified dose on specified days
76050619|NCT05493072|Other|RxConnect|Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.
76050620|NCT05477758|Behavioral|Collaborative care|Participants in the intervention group were allocated a receive a low-intensity programme of behavioural activation specifically designed for adults ≥65 with subthreshold depression. An allocated case manager (primary care mental health worker/ Improving Access to Psychological Therapy) delivered collaborative care for an intended 8-10 weeks. This ran alongside general practitioner (GP) usual care. Collaborative care in both CASPER and CASPER+ trial included weakly telephone/ face-to-face support, active surveillance and symptom monitoring
75433384|NCT01536223|Drug|TPF (docetaxel plus cisplatin and 5-fluorouracil) group|"3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2."
75433385|NCT01536236|Device|ANS Eon™ Implantable Pulse Generator (Permanent Implant)|Appropriate programming based on subject's preference of programs.
75433386|NCT01536236|Device|Placebo|Placebo
75433387|NCT01536249|Drug|Dexpramipexole|Single Oral Dose
75580275|NCT05591586|Behavioral|mobile video interpreting (mVI) access|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
75879975|NCT02059538|Radiation|CT-scan|
75879976|NCT02059538|Other|Stools sampling|
75433388|NCT01536249|Drug|Cimetidine plus Dexpramipexole|Multiple Oral Doses
75433389|NCT01536288|Drug|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
75433390|NCT01536288|Drug|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
75433391|NCT01536301|Drug|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
75433392|NCT01536301|Drug|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
75879977|NCT02059538|Other|DNA sampling|
75879978|NCT02059538|Other|Blood sampling|
75879979|NCT02059538|Other|Urine sampling|
75879980|NCT02059538|Radiation|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
75879981|NCT01341899|Procedure|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
75879982|NCT02059616|Drug|Amlodipine 5mg|Daily oral administration for 8 weeks
75879983|NCT02059616|Drug|Amlodipine 10mg|Daily oral administration for 8 weeks
75879984|NCT02059616|Drug|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
75879985|NCT02059616|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
75879986|NCT04724681|Device|WARD CSS|Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well
75879987|NCT02055794|Procedure|Suturing of the perineal skin|
75433393|NCT01536314|Drug|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
75433394|NCT01536314|Drug|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
75433395|NCT01536353|Drug|AGSAV301|tablet, q.d.
75433396|NCT01536353|Drug|Exforge 10/160|Tablet, q.d.
75580276|NCT05564221|Drug|YH35324|Subcutaneous injection of YH35324
75580277|NCT05564221|Drug|Placebo|Subcutaneous injection of None of active ingredient
75580278|NCT05564221|Drug|Omalizumab|Subcutaneous injection of Omalizumab
75580279|NCT05557357|Procedure|Electroacupuncture (EA)|"Electroacupuncture (EA) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are Tinggong (SI19) and Yifeng (TE17) of the affected side, Baihui (GV20) and Yintang (GV24+), bilateral posterior temporal line (MS11), and Zhongzhu (TE3) and Zusanli (ST36) of the affected side.~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11."
75580280|NCT05557357|Procedure|Electroacupuncture Combined With Warm Needling (EAWN)|"Electroacupuncture combined with warm needling (EAWN) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are SI19 and TE17 (affected side), GV20 and GV24+, bilateral MS11, and TE3 and ST36 (affected side).~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.~For warm needling (WN), two moxa sticks will be ignited and attached one by one to the needle handle of each acupoint of SI19 and TE17."
75879988|NCT02055794|Procedure|Closing perineal skin with surgical glue|
75879989|NCT02055794|Procedure|No suturing of the perineal skin|
75879990|NCT02059694|Drug|Hyaluronidase|
75879991|NCT02059694|Other|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
75879992|NCT02055872|Drug|Intravenous albumin|
75433397|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
75433398|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
75433399|NCT01536431|Drug|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
75433400|NCT01536444|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
75879993|NCT02055872|Drug|Normal saline|
75879994|NCT03146741|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
75879995|NCT03561038|Device|Franseen Needle|Comparing 2 needles designed for tissue acquisition
75879996|NCT03561038|Device|Fork-tip Needle|Comparing 2 needles designed for tissue acquisition
75879997|NCT02056730|Drug|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
75879998|NCT05162573|Drug|177Lu-PSMA-617|Dose-escalation of 177Lu-PSMA-617 (3, 6 or 9 GBq) combined with external beam radiotherapy (EBRT)
75879999|NCT05162573|Radiation|EBRT|External Beam Radiotherapy
75880000|NCT02056808|Drug|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
75880001|NCT02055950|Procedure|Storage of kidney in refrigerated solution|
75880002|NCT02055950|Procedure|Kidney perfused by pulsatile machine|
75880003|NCT01337219|Drug|Tobramycin|
75880004|NCT03560804|Drug|Olmesartan|Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
75880005|NCT03560804|Drug|Chlorthalidone|Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
75880006|NCT02056886|Procedure|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
76050621|NCT05477758|Other|Usual General Practitioner (GP) care|Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.
75580281|NCT05557357|Other|Waitlist Control|No treatment will be provided during the 10-week waiting period after baseline assessment.
75580282|NCT05556564|Drug|observational study|No intervention, observational study
76050622|NCT05477758|Behavioral|Behavioral Activation Self-Help guide|Participants in the intervention arm were provided with a self-help booklet based on clear principles of BA for depression. The purpose of the booklet was to introduce simple behavioural strategies for improving mood. Participants were encouraged to (1) re-establish their daily routine, (2) increase meaningful activities and (3) reduce avoidance behaviours. Participants also received 3 phone calls at week 1, 3 and 6 designed to check the booklet had arrived and to encourage the use of the materials. All participants received their usual GP care
75880007|NCT03150719|Drug|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
75880008|NCT03150719|Drug|Ivacaftor|IVA 150 mg tablet.
75880009|NCT03150719|Drug|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
75880010|NCT03150719|Drug|Placebo|Placebo matched to IVA tablet.
75880011|NCT02038400|Device|KINETUBE medical Device|
76050623|NCT05472623|Drug|Adagrasib|Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.
76050624|NCT05472623|Combination Product|Adagrasib/Nivolumab|Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.
76050625|NCT05466110|Device|Spinal Cord Stimulation|Epidural application of electrical current to the spinal cord
76050626|NCT05466110|Procedure|Spinal Fusion Surgery|screw-rod system based spinal instrumentation
76050627|NCT05442775|Drug|Reldesemtiv|Oral tablet
75433401|NCT01536470|Other|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
75433402|NCT01536470|Other|Ephedryne chorydrate|
75580283|NCT05550896|Diagnostic Test|Echocardiogaphy|Assessment of high velocity low amplitude signals on Doppler echocardiography
75580284|NCT05540886|Behavioral|TEACH CLEAN|"The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities."
75728775|NCT05955053|Other|Midwifery care applied in line with Midwife-Pregnant cooperation|Pregnant women who apply to the obstetrics clinic will be informed about the research by the doctor and the pregnant woman whose labor has started will be sent to the delivery room. The researcher will be welcomed by the midwife from the first time the pregnant woman arrives in labor (delivery room), and firstly she will be informed about the purpose of the research and an informative consent form and a pregnant identification form will be filled in that she agrees to participate in the research. During labor and labor, the research midwife (HYY) will be with a pregnant woman until she gives birth and care will be given according to the items in the midwifery care checklist prepared based on the partnership model. After giving birth to a pregnant woman and applying the scales, another pregnant woman will be transferred and care will be given in the same way according to the midwifery care model checklist.
75728776|NCT05948007|Device|Neurofeedback training|12 training sessions within 6 weeks will be provided. In each training session, participants will have neurofeedback training for five 3-minute training periods.
75880012|NCT02038400|Device|insertion of tympanic ventilation tubes (tympanostomy)|
75880013|NCT01343927|Behavioral|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
75880014|NCT01343927|Behavioral|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
75880015|NCT01343927|Behavioral|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
76050628|NCT05438394|Drug|melphalan hydrochloride for injection|Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
76050629|NCT05407610|Procedure|Conventional Radiofrequency ablation of the genicular nerves|Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
75880016|NCT02057120|Procedure|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
75880017|NCT02057120|Device|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
75880018|NCT02057354|Behavioral|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
75880019|NCT02057354|Behavioral|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
75880020|NCT04828187|Diagnostic Test|Comparison of the proposed artificial network with the ground truth|"Both eyes will be included for each study participant. Participants watched a 4-10-minute video in standard mesopic environmental lighting conditions at 3.5m viewing distance. Simultaneously, all blinking moves will be recorded through a web infrared camera.~The proposed system was tested on the 8 different subjects. Several metrics of blink detection and classification accuracy were calculated against the ground truth, which was generated by 3 independent experts, whose conflicts were resolved by a senior expert. Two independent blink identifications are assumed to be in agreement, if and only if there is sufficient temporal overlapping and the type of blink is the same between the DLED system and the ground truth."
75580285|NCT05517460|Other|Auricular acupressure|The participant in Intervention period will receive acupressure on ear Shenmen point, ear Large intestine point, ear Rectumn point and ear San Jiao point.
75728777|NCT05948007|Device|Sham-neurofeedback training|The Sham group has the same training dosage as the neurofeedback group.
75728778|NCT05948007|Behavioral|Pain management protocol|The treatment components include sleep psychoeducation, sleep hygiene education, exercise consultation, and cognitive-behavioral pain management, i.e., practice in changing dysfunctional thoughts, setting and working toward behavioral goals, relaxation skills
75728779|NCT05941494|Drug|Propofol|Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
75580286|NCT05517460|Other|health education|health education for self-care and medication adherence
75580287|NCT05511792|Procedure|TAVR for BAV Using Down Sizing with the Evolut Pro platform|Down sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
75728780|NCT05941494|Drug|Sevoflurane|Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
75728781|NCT05941494|Drug|Ephedrine|The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
75728782|NCT05941494|Drug|Phenylephrine|Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
75880021|NCT02057432|Device|intra-operative MRI|Patients will undergo an MRI during surgery.
75880022|NCT01344005|Other|caregiver-related intervention or procedure|
75880023|NCT01344005|Other|questionnaire administration|
75880024|NCT01344005|Procedure|quality-of-life assessment|
75880025|NCT01344005|Procedure|radiography|
75880026|NCT02059772|Drug|ranibizumab|
75880027|NCT02059772|Procedure|micropulse diode laser|
75880028|NCT01344083|Drug|T1210|2 drops T1210 once a day
75880029|NCT01344083|Drug|Olopatadine hydrochloride|2 drops once a day Olopatadine
76050630|NCT05407610|Procedure|Cooled Radiofrequency ablation of the genicular nerves|Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
76050631|NCT05407610|Procedure|Sham procedure|Sham procedure with placing of needles subcutaneously.
76050632|NCT05407129|Behavioral|Family safety reporting intervention|Family safety reporting intervention for patients/families
76050633|NCT05386030|Combination Product|saypha® VOLUME Lidocaine|Crosslinked hyaluronic acid (HA) 23 mg/mL + 0.3% lidocaine hydrochloride.
76050634|NCT05386030|Combination Product|Juvéderm® Voluma™ XC|Crosslinked HA 20 mg/mL + 0.3% lidocaine hydrochloride
76050635|NCT05368493|Other|MRI task|Task fMRI (Simon) [ Time Frame: Children will undergo MRI scans when they are 6-11 years of age. ] Children will also complete a task, which will allow exploratory analyses of the functionality of attention-related neural circuits. The Simon fMRI task is a non-verbal task equivalent to the Stroop that tests sustained attention and inhibitory control and discriminates children with and without ADHD. Exploratory fMRI time-series data for each participant will be modeled using a general linear model with 3 predictors: congruent correct, incongruent correct, and incorrect. Contrast images for each participant (e.g., incongruent-minus-congruent) will be generated and entered into a group-level random-effects model. Analyses are exploratory, and will focus on frontal lobe activity during each type of trial.
76050636|NCT05349331|Procedure|Liver Resection|Surgical resection treatment: laparoscopic or open liver resection is performed, and targeted and immunotherapy are not continued after surgery.
76050637|NCT05345730|Diagnostic Test|3 DImensional Late Enhanced Gadolinium cardiac MRI scan|A cardiac MRI scan is made using late gadolinium enhancement to detect atrial fibrosis in the left atrium.
75433403|NCT01536483|Drug|Butyrate enemas|"Seven enemas~Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~The study remains blinded for the investigation team through the intervention of a clinical research nurse~According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~Installation time and retention is setted at 15 minutes~Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist"
75580288|NCT05511792|Procedure|TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform|Traditional sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
75580289|NCT05501561|Biological|Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational IIV-A Investigational Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
75728783|NCT05937893|Other|Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans|Following baseline scans, the participant will orally consume the keto-ester, for subsequent scans which will include repeated BHB MRSI acquisitions to dynamically measure BHB labeling in the brain, followed by a final GABA MRSI acquisition.
75728784|NCT05932238|Other|Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF)|commercially available eye drops
75728785|NCT05932238|Other|Polyethylene glycol 400 and propylene glycol solution/drops - Preserved|commercially available eye drops
75880030|NCT04039217|Drug|Biktarvy|Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
75880031|NCT02059850|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
75880032|NCT02059850|Drug|Cyclophosphamide|Given IV
75880033|NCT02059850|Other|Laboratory Biomarker Analysis|Correlative studies
75880034|NCT01342055|Drug|Apetrol ES|sequences of administered drugs
75433404|NCT01536509|Behavioral|Telehealth Behavioral Treatment (TBT)|Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
75580290|NCT05501561|Biological|Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
75580291|NCT05501561|Biological|Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-C Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
75728786|NCT05931432|Other|Comprehensive Well-Being Intervention|The intervention group will receive an 18-month comprehensive suite of services including: 1) monthly automated text messaging reminders about wellbeing resources focused on a range of topics (e.g. mindfulness, stress management, childcare support, racial trauma, diversity and inclusion) and assignment to a one-hour quarterly peer support group with an expectation of regular attendance. Half of these sessions will be self-directed discussion topics and half will be facilitated discussions. The content of monthly text messaging resources and discussion topics for the peer-support groups will be informed by the Aim 1 qualitative findings.
75728787|NCT05930730|Biological|Comvigen (Bivalent, ChulaCov19 BNA159.2)|single dose of COMVIGEN at 50 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
75728788|NCT05930730|Biological|BIVALENT Pfizer/BNT vaccine|single dose of BIVALENT of Pfizer/BNT Bivalent vaccine at 30 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
75880035|NCT02038478|Biological|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
75880036|NCT00982111|Drug|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
75880037|NCT00982111|Drug|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
75880038|NCT00982111|Biological|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
76050638|NCT05330611|Device|Cryoneurolysis of Intercostal Nerves|"Patients will be offered a minimally invasive intervention procedure for pain control called cryoneurolysis using an ultrasound-guided device called the Iovera Smart Tip 190.~The direct application of cold to the intercostal nerves via Iovera device produces lesions in peripheral nervous tissue to block the pain caused by rib fractures.~This procedure is particularly beneficial for patients who are not candidates for surgical stabilization of their rib fractures.~Application of cryoneurolysis as an analgesic will reduce the amount of narcotics patients might need and instead provide them short- or long-term pain control with minimal risk.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
76050639|NCT05330611|Other|Standard of Care|"Patients will be provided regular standard of care at the Stanford Hospital with short- or long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.~Standard of care for patients with rib fractures that are not eligible for surgical stabilization includes multi-modal pain therapy and pulmonary toilet.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
76050640|NCT05289089|Behavioral|Positive Psychology Intervention|Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
75433405|NCT01536509|Behavioral|Education Only (EO)|Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
75433406|NCT01536548|Procedure|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
75433407|NCT01536548|Procedure|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
75433408|NCT01536600|Drug|biphasic insulin aspart 30|The insulin dose and regimen was individualised at the physician's discretion
75580292|NCT05501561|Biological|Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
75728789|NCT05929482|Behavioral|Infección de Amor (Infectious Love)|"Infectious Love is a filmed dramatized story (telenovela/soap opera) culturally tailored for US Latinas and delivered online.~IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
75728790|NCT05928091|Other|Phone call to an expert team|Patients will be treated as the expert said when the investigator called him
75728791|NCT05926453|Other|Maximal cardiorespiratory exercise test|previously described
75728792|NCT05924191|Device|Photobiomodulation|Intra-oral irradiations wll be performed with a low intensity Laser device at 4 anatomical points, with a wavelength of 660 nm. The extraoral FBM will be applied with 1 cluster (20cm2) with a wavelength of 630nm. Subsequently, the same region will be irradiated with the same cluster, using the 4 LEDs with a wavelength of 850 nm 1 hour before performing the surgery.
75728793|NCT05924191|Drug|Placebo Corticosteroid|Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
75880039|NCT05615090|Procedure|Arm I (Prepectoral),|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
75580293|NCT05491200|Drug|Prasugrel based short DAPT|Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus
75433409|NCT01536613|Drug|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
75580294|NCT05491200|Drug|Prasugrel based standard DAPT|Prasugrel based DAPT for 1 year
75880040|NCT05615090|Procedure|Arm II (Subpectoral)|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
75880041|NCT02957682|Drug|Praluent (Alirocumab)|
75880042|NCT02957682|Drug|Placebo|
75433410|NCT01536626|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
75433411|NCT01536639|Drug|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
75880043|NCT02057822|Procedure|Cytokins assay in tears|
75880044|NCT03057951|Drug|Empagliflozin|once daily
75880045|NCT03057951|Drug|Placebo|once daily
75880046|NCT02060240|Behavioral|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
75880047|NCT02038556|Behavioral|cognitive behaviorial therapy -Insomnia|
75433412|NCT01536652|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
75433413|NCT01536665|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
75433414|NCT01536665|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
75580295|NCT05491200|Device|OCT guided revascularization|OCT guided revascularization of the non-culprit lesions
75580296|NCT05491200|Device|Angio guided revascularization|Angio guided revascularization of the non-culprit lesions
75580297|NCT05490888|Drug|PHIN-214 Subcutaneous injection|Single or multiple subcutaneous injection(s) with PHIN-214 terlipressin derivative, single ascending dose or multiple ascending dose
75580298|NCT05489081|Behavioral|Positive Behavior Management Toolkit|The Positive Behavior Management Toolkit, or the implementation strategy resource package, is a set of resources provided to teachers in the intervention group that aims to support their use of positive behavior management practices in the classroom, particularly with students with hyperactive, inattentive, or impulsive behaviors.
75580299|NCT05468996|Drug|Remimazolam|A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
75580300|NCT05431179|Drug|Zilovertamab|After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
75580301|NCT05431179|Drug|Ibrutinib|All participants will receive oral Ibrutinib (560mg) daily.
75580302|NCT05431179|Drug|Placebo|After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
75580303|NCT05410301|Device|Static Magnetic and Electric (sBE) device|Home-based Static Magnetic and Electric (sBE) device that is slept in
75580304|NCT05410301|Drug|Lomustine|Chemotherapy drug
75580305|NCT05410301|Drug|Bevacizumab|Chemotherapy and targeted therapy drug
75728794|NCT05924191|Device|Simulation Photobiomodulation|The irradiation simulations will be practiced in the same anatomical points described in the experimental group. This protocol will be carried out 1 hour before the surgical procedure (Baseline). The Laser device will be disconnected and its beep sound will be recorded and run on simulating the irradiation.
75433415|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
75433416|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
75433417|NCT01536691|Drug|ramosetron|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
75433418|NCT01536691|Drug|ondansetron|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
75433419|NCT01536717|Drug|Articaine hydrochloride 2% solution|"4 ml/h periosteal wound infusion~duration of 72 h"
75433420|NCT01536717|Drug|Sodium Chloride|Placebo Sodium chloride 0,9%
75728795|NCT05924191|Drug|Corticosteroid|The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
75728796|NCT05923606|Device|Active tACS|Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
75728797|NCT05923606|Device|Placebo tACS|Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
75880048|NCT02057900|Biological|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
75880049|NCT02060318|Drug|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
75880050|NCT01318837|Drug|solifenacin|oral
75433421|NCT01536730|Behavioral|Homework Intervention Strategy|"Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention."
75880051|NCT03146663|Drug|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
75880052|NCT03146663|Drug|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
75880053|NCT01350037|Drug|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
75880054|NCT01350037|Drug|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
76050641|NCT05287191|Drug|Magnesium sulfate and then Digoxin|We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast AF persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance <60 ml/min measured by the MDRD formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone will be administered as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
75880055|NCT02060006|Drug|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
75880056|NCT01350193|Device|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
75880057|NCT01350193|Other|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
76050642|NCT05287191|Drug|Amiodarone|We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
75433422|NCT01536743|Drug|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
75580306|NCT05409989|Device|FRED™ X™|The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.
75580307|NCT05400434|Behavioral|Standard Parent-Child Interaction Therapy (PCIT)|PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
75580308|NCT05400434|Behavioral|Natural Helpers (NH)|Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
75880058|NCT03640182|Other|Health management model of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
75880059|NCT03620435|Drug|Atezolizumab|Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
75880060|NCT01357993|Drug|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
75580309|NCT05390450|Device|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block. Prior to Popliteal plexus block, the proximal end of the adductor canal will be identified. The transducer will be slid distally along the femoral artery until the artery deviated away from the sartorius muscle in the distal part of the adductor canal towards the adductor hiatus. The nerve block needle will be inserted from the anterolateral end of the transducer and advanced in-plane through the medial vastus muscle. The endpoint of injection will be inside the distal end of the adductor canal close to the adductor hiatus. The injection will be adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle. The Popliteal plexus block will be carried out with 10 mL of local anesthetic mixture, containing 50 mg of bupivacaine and 0.05 mg of epinephrine.
75880061|NCT03618888|Other|Instructor-led training|The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
76050643|NCT05280652|Behavioral|Nutritional and culinary intervention|Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).
75580310|NCT05390450|Device|Ultrasound-Guided Fascia Iliaca block|Patients will be placed in a supine position, and the skin will be cleaned aseptically. The inguinal ligament from the anterior superior iliac spine to the pubic tubercle will be drawn on the skin and divided into 3 parts. The injection point was 1 cm caudally from the point where the lateral and middle part of the inguinal ligament met. The skin and deep tissues were infiltrated with 1% lidocaine. A 18G nerve block needle will be inserted into the skin perpendicularly until the first (fascia lata) and second loss of resistance (fascia iliaca) will be felt. Following aspiration to exclude intravascular injection, 40 mL of 0.25% bupivacaine (1-1.5 mg/kg), which will be prepared under aseptic conditions, and then injected. Sensorial block will be evaluated using the pinprick test 20 minutes after injection for areas of the thigh innervated by the femoral, lateral cutaneous and obturator nerves.
76050644|NCT05280652|Behavioral|Nutritional intervention|Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
76050645|NCT05278052|Radiation|Local consolidative radiation therapy|Local consolidative radiation therapy (LCRT) to all oligo-metastatic sites in addition to primary disease site
76050646|NCT05278052|Drug|Standard maintenance therapy as decided by the treating medical oncologist|Standard maintenance therapy/Observation
75580311|NCT05387694|Other|Thrombotic risk assessment|Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +/- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.
75728798|NCT05923593|Dietary Supplement|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil.
75728799|NCT05916144|Behavioral|Interaction-Based Early Education Program|The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
75728800|NCT05912088|Behavioral|Intervention Group|Subjects will participate in groups of about 14 to implement the program.
75728801|NCT05912088|Behavioral|Control Group|Subjects will receive the usual care advice
75880062|NCT03618888|Other|Self-learning training|The self-learning training contents a standard kit for self-directed training in BLS
76024870|NCT05190029|Diagnostic Test|Series of questions to parents of children in a virtual form.|A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).
76050647|NCT05268094|Device|Ductal Arterial Stent|Drug-eluting ductal arterial stents will be placed by transcatheter method.
76050648|NCT05268094|Procedure|Systemic-to-Pulmonary Artery Shunt|A surgical connection will be made between a systemic artery and the pulmonary artery.
76050649|NCT05259046|Dietary Supplement|Menaquinone-7 (MK-7) tablet (333 µg)|One MK-7 tablet containing 333 µg MK-7 per day
76050650|NCT05259046|Dietary Supplement|Placebo tablet|One placebo tablet per day
76050651|NCT05230212|Other|Pecan Breakfast Shake|The pecan breakfast shake contains 68 grams of blended raw pecans. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
75880063|NCT01317017|Drug|Actimmune|"All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.~Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.~Patients will return at one to two weeks for suture removal.~Clinical assessments done at every visit.~Patients will also be evaluated at each visit for any adverse events."
75728802|NCT05910268|Behavioral|NIATx + ECHO|Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
75880064|NCT05637554|Procedure|Laparoscopic appendectomy using clipping.|Laparoscopic appendectomy using clipping to secure the base of the appendix.
76050652|NCT05230212|Other|Cream Breakfast Shake|The cream breakfast shake contains 138 grams of heavy whipping cream. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
76050653|NCT05221632|Device|Accelerated transcranial magnetic stimulation with real coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation.
76050654|NCT05221632|Device|Transcranial magnetic stimulation with real coil|The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .
76050655|NCT05221632|Device|Transcranial magnetic stimulation with sham coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
76050656|NCT05217537|Drug|Omadacycline Injection [Nuzyra]|Single dose of 100 mg omadacycline IV in 100 mL of normal saline
76050657|NCT05217537|Drug|Omadacycline Oral Tablet|Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
76050658|NCT05216042|Dietary Supplement|Study diet|Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)
76050659|NCT05216042|Other|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
76050660|NCT05216042|Other|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
76050661|NCT05216042|Other|Glucose Challenge|Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
76050662|NCT05208216|Device|Geko device|A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
75433423|NCT01536756|Other|Exercise Intervention -- Physical Rehabilitation Program|"The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise."
75433424|NCT01536756|Other|Wait List Control Group|The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
75580312|NCT05377411|Device|tDCS|During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
75728803|NCT05908084|Biological|HAV|HAV implantation
75580313|NCT05377411|Behavioral|cognitive training|Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
75728804|NCT05908084|Other|AVF|AVF creation procedure
75728805|NCT05882305|Biological|(Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate|Patients will receive approximately （2.5-10）x10^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
75728806|NCT05869266|Device|professional fitting vs. self fitting|Licensed professional fits the hearing aid fitting using professional programing tools and thresholds obtained from the traditional audiometry vs. subject performs self-fitting of the hearing aids using the Tuned App.
75728807|NCT05866835|Other|Manufacture of custom-made IOP|"Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~digital recording of the maxillary and mandibular dental arches~mandibular wedging performed with an inter-arch piece~digital recording of the inter-arch position"
75728808|NCT05866835|Other|Ventilation tests|"Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~At rest, standing still.~During a 4 minute run on a treadmill at 50% of MAS.~During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS"
76050663|NCT05208216|Device|Flowtron DVT|A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
76050664|NCT05207891|Device|Intervention mattress|The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
76050665|NCT05206682|Drug|Leuprorelin|Leuprorelin will be used to postpone period after vaginal repair.
76050666|NCT05204082|Device|Single Use Vein Entry Indicator Device|Electronic pressure sensing device, integrated to a conventional needle catheter, and which indicates continuously during intravenous cannulation whether the tip of the needle is inside or outside of a vein, to assist a clinician in intravenous cannulation.
76050667|NCT05201937|Drug|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
76050668|NCT05192564|Other|Exercise for bilateral or unilateral vestibular hypofunction patients|Physical Activity intervention with balance exercises, multidirectional displacements, and strength with postural control, implementing 8-10 exercises integrating the main muscle groups and motor patterns, aerobic exercise on bicycle (15 min) developed progressively in intensity (R1-mild, R2-moderate, R3-vigorous) implementing an intervallic design in low volume.
76050669|NCT05192564|Other|Conventional rehabilitation treatment|Vestibular rehabilitation exercises counseling
76050670|NCT05153629|Device|TENS|TENS device used four times a day for 60 minutes each time
76050671|NCT05137236|Biological|mRNA-1283|Sterile liquid for injection
76050672|NCT05137236|Biological|mRNA-1283.211|Sterile liquid for injection
75580314|NCT05375877|Device|iATROS|"The digital eHealth platform of iATROS in combination with a wearable will be used independently by the subjects of the study. In particular, the reminder function is used to remind patients to record their ECGs, take medication and perform other tasks they may have created themselves, or to use other iATROS functions, such as teleconsultation or remote medical data reporting. Furthermore, the designed training program for atrial fibrillation patients teaches them how to deal with their own disease.~If unhealthy or dangerous vital signs are detected during the use of these medical devices over a longer period of time, the patient receives feedback through the application for medical presentation. This includes the detection of atrial fibrillation recurrences."
75580315|NCT05369273|Other|intra-articular injection|intra-articular injection
75580316|NCT05369273|Radiation|RMI SCANS|AT 1 MONTHS BEFORE THE INTERVENTION
75580317|NCT05369273|Other|RMI SCANS|AT 1MONTH AFTER THE INTERVENTION
75580318|NCT05369273|Other|RMI SCAN|AT 6 MONTHS AFTER THE INTERVENTION
75580319|NCT05366439|Drug|AT-752|Parallel Assignment
76050673|NCT05137236|Biological|mRNA-1273|Sterile liquid for injection
76050674|NCT05137236|Biological|mRNA-1283.529|Sterile liquid for injection
75580320|NCT05366439|Drug|Placebo Comparator|Parallel Assignment
75728809|NCT05866835|Other|Evaluation of comfort level:|Collection from participants (self-questionnaire)
76050675|NCT05136612|Other|conventional physiothrapy|Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.
76050676|NCT05136612|Other|robotic rehabilitation|The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
76050677|NCT05130177|Drug|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
76050678|NCT05130177|Drug|Domvanalimab|Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
75580321|NCT05365230|Other|On-demand personalized follow-up care|On-demand personalized follow-up care (on demand access to a WBCP nurse and an annual follow-up by telephone.
75580322|NCT05365230|Other|Guideline-based follow-up care (standard of care)|Follow-up care based on current standard of care guidelines.
75728810|NCT05863819|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
75728811|NCT05860439|Procedure|Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Patients previously treated were reassessed for long-term follow-up.
75728812|NCT05858710|Drug|DPPG2-TSL-DOX|DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.
75728813|NCT05852873|Drug|Nirmatrelvir/ritonavir|Participants in the intervention arm will receive a standard 5-day treatment course Paxlovid (nirmatrelvir plus ritonavir) in addition to standard of care.
75728814|NCT05852873|Drug|Placebo|Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.
75880065|NCT05637554|Procedure|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
75580323|NCT05348226|Diagnostic Test|Additional Cardiac Magnetic Resonance Scan|Standard of care medical treatment with sacubitril/valsartan (Entresto). Additional Cardiac Magnetic Resonance Imaging (CMR) Scan after 4-6 months of treatment.
76050679|NCT05129748|Drug|Sodium Thiosulfate + Mannitol|Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.
76050680|NCT05127746|Drug|Aricept 5mg Tablet|1 tablet once daily
75433425|NCT01536782|Procedure|Bolus|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
75433426|NCT01536782|Procedure|Gravity|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
75580324|NCT05339893|Device|In Motion Rehabilitation Robot|Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.
75580325|NCT05330793|Dietary Supplement|Oral probiotic|an oral probiotic intervention with or without a novel ADP1 toothpaste
75580326|NCT05330793|Dietary Supplement|Placebo|placebo without Oral probiotic or toothpaste
75728815|NCT05849259|Other|Dementia Care Quality at Home|Each of the two HBPC practices will identify at least two trained Dementia Care Quality at Home Champions who will be trained in the intervention comprised of 1) a standardized assessment tool to assess PLWD and caregiver needs; 2) seven modules created to optimize the well-being of the PLWD and their caregiver; and 3) regular team-based review of persons participating in the program to address care challenges and a team-based case conference approach to solve these challenges.
75728816|NCT05847530|Device|Potenza|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
75728817|NCT05847530|Device|Icon|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
75728818|NCT05845359|Drug|Methadone|One group will receive 10mg of methadone upon induction, while the other will receive a saline solution as placebo. We will see the effectiveness of methadone on postoperative pain management, while monitoring for opioid-related side effects.
75728819|NCT05838222|Behavioral|Solution Focused Intervention|A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges
76050681|NCT05127746|Drug|Aricept 10mg Tablet|1 tablet once daily
76050682|NCT05127746|Drug|DA-5207 A|1 patch once weekly
76050683|NCT05127746|Drug|DA-5207 B|1 patch once weekly
75880066|NCT03640104|Behavioral|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
75880067|NCT03640104|Behavioral|Nutrition guidelines|Nutritional recommendations based on international guidelines
75433427|NCT01536782|Device|Pump|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
75580327|NCT05306977|Device|Open-label accelerated 1 Hz repetitive transcranial magnetic stimulation|Patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right intraparietal sulcus. Subjects will receive a continuous train of 1 Hz stimulation. They will receive a total of 600 pulses per train. Trains will be separated by ~50 min rest intervals.
75880068|NCT04686773|Biological|AZD1222|"AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box."
75580328|NCT05297578|Biological|24-Valent Pneumococcal Conjugate Vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
75580329|NCT05297578|Biological|Pneumococcal 20-valent Conjugate Vaccine|0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
75728820|NCT05838222|Other|Treatment as Usual|The patient receives standardized care from primary care team without the SFBT intervention
75728821|NCT05837533|Other|Communication model|During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
75728822|NCT05837169|Other|Mindfulness-based stress reduction|The control group will be assessed with the study surveys at baseline, will not receive MBSR intervention for the following 8 weeks, and will subsequently be reassessed with the study surveys at the same time points as the intervention group. At the end of the recruitment and follow-up of all the participants, the study will end and the control group will be able to receive the MBSR intervention free of charge according to the preference of the participants.
75728823|NCT05834946|Other|Megagen implant placement|Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface
75880069|NCT04686773|Biological|rAd26-S|"Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box"
75880070|NCT02058056|Radiation|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
75728824|NCT05834946|Other|Biomate-Swiss implant|Biomate-Swiss implant with precision dimension laser (PDL) surface
75728825|NCT05829824|Behavioral|CareConnect|A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)
75880071|NCT05162495|Device|BioStation T101 and TeraTube|Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
75880072|NCT02956278|Drug|Allopurinol|
75880073|NCT02956278|Other|Placebo|lactose placebo pill
75880074|NCT02058134|Device|cardioPAT cell saver|
75880075|NCT02060396|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
75433428|NCT01536808|Other|Cardiac RMI|Cardiac RMI
75433429|NCT01536808|Other|Analysis telomere|Analysis telomere
75433430|NCT01536808|Other|Stress test|Stress test
75433431|NCT01536808|Other|echocardiography|echocardiography
75433432|NCT01536834|Device|Medical Device|
75880076|NCT01358071|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
75880077|NCT01358071|Drug|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
75880078|NCT01358071|Drug|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
75880079|NCT04827719|Drug|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
75880080|NCT02058212|Drug|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
75880081|NCT02957136|Device|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
75880082|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
75880083|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
75880084|NCT02060474|Drug|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
75880085|NCT03561272|Other|Smart Phone Application|Oral medication adherence phone application.
75880086|NCT03561272|Other|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
75880087|NCT03640260|Behavioral|breathing regulation with physical activity|The subjects will have education leaflets with breathing and oximetry level evaluation training.
75880088|NCT01354171|Device|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
75880089|NCT04668443|Other|Graphical Informed Consent (GIC)|The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.
76024871|NCT05190029|Other|Intervention by teachers|"The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas."
75433433|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
75433434|NCT01536847|Other|Dietary Intervention|300 mL of liquid food product
75433435|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
75728826|NCT05829824|Other|AutoReach|Phone call / SMS Text
75728827|NCT05829824|Procedure|Biospecimen samples|Saliva and breath sample
75728828|NCT05826496|Other|Exercise|The supervised high-intensity interval training is conducted on bicycle ergometers at 85-95% maximal workload. The high-intensity interval sequences will be separated by two steady state sequences. Blood samples are collected at baseline, 2 min and 60 min post-exercise.
75728829|NCT05820711|Drug|MSC|"Injection of MSCs into submandibular glands at pre-specified dose level:~Dose -1: 5 (4 - 6) x10^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml)~Dose 0: 10 (8 - 12) x10^6 MSCs per gland (1 ml)~Dose 1: 20 (16 - 24) x10^6 MSCs per gland (2 ml)"
75728830|NCT05816070|Drug|IVIEW-1201|Four times per day for day 1-2 and three times per day for day 3-7
75728831|NCT05816070|Drug|Ofloxacin Eye Drops|Four times per day for day 1-2 and three times per day for day 3-7
75728832|NCT05795413|Procedure|Mastectomy with PECS blocks|Approximately half of patients recruited will receive a PECS block with Liposomal bupivacaine and half will not receive a block.
76024872|NCT05190029|Procedure|Physiotherapeutic evaluation|"A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1)."
75433436|NCT01536873|Drug|Dolutegravir|Eligible patients will receive DTG 50 mg given orally BID
76050684|NCT05062824|Behavioral|Baby Feed|Baby Feed web portals can (1) Quickly and easily evaluate infant diet using a validated Infant Food Frequency Questionnaire (infant FFQ) developed by our group14. [Parental FFQ portal]; (2) Provide automatic results to healthcare professionals on nutrients and foods/beverages consumed above or below the recommended levels to discuss with parents for improving the infant's diet. Also, to provide recommendations for amounts of foods/beverages that the infant should be consuming by age [Clinician Portal]; (3) Give online access to parents to these diet recommendations to implement at home, with an easy tracking component [Parent's Portal].
75433437|NCT01536977|Other|quality-of-life assessment|Ancillary studies
75433438|NCT01536977|Other|questionnaire administration|Ancillary studies
75580330|NCT05267496|Device|oscillating positive expiratory pressure device|Patients randomized to the experimental arm of the study will receive an AEROBIKA oscillating positive expiratory pressure device in addition to the standard pulmonary rehabilitation program. The patient will receive instructions pertaining to the use of the device during the first evaluation visit to the rehabilitation service and this information will be reinforced at each follow-up visit. The patient will receive a log book in order to record date and time of use to assess treatment compliance and an instructions and maintenance booklet will be handed out to ensure adequate use of the device.
76050685|NCT05054218|Biological|mRNA-1273|Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.
76050686|NCT05048316|Behavioral|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
75433439|NCT01536977|Behavioral|management of therapy complications|Undergo BBT-I
75433440|NCT01536977|Behavioral|cognitive assessment|Ancillary studies
75580331|NCT05267496|Procedure|Pulmonary rehabilitation|"Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~Directed ventilation~Physical conditioning Post-surgical rehabilitation~Diaphragmatic mobilization~Thoracic expansion through incentive flow spirometry"
75580332|NCT05265715|Other|Low AGE diet|"The recommended daily AGE intake will be either:~7,500 kilounits [ku], which is a 50% reduction from the average 15,000 ku consumed by most adults or~a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)"
75580333|NCT05265715|Procedure|Research blood draw|Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
75580334|NCT05260944|Device|Acapella device|patients will receive a two supervised sessions using acapella device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
76050687|NCT05007808|Drug|G001 Topical Gel|Non-steroidal anti-inflammatory drug for topical administration
75580335|NCT05260944|Device|Power lung device|Group B. patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
75580336|NCT05260944|Other|routine Physical Therapy program|Group C. Thirty patients will receive only routine physical Therapy program
75728833|NCT05795413|Drug|Liposomal bupivacaine|All of the PECS blocks performed at this institution have liposomal lupivacaine as the anesthetic. Investigators will examine quality of recovery and pain control in patients who receive a PECS block versus those who do not receive one.
75728834|NCT05795192|Drug|SB17170|Taking SB17170 orally once a day
76050688|NCT05007808|Drug|Vehicle|Vehicle Gel for topical administration
75433441|NCT01536977|Behavioral|educational intervention|Undergo BBT-I
75433442|NCT01537003|Device|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
75433443|NCT01537003|Device|Coban 2 layer|Compression bandage
75433444|NCT01537016|Device|PROMOGRAN|PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
75433445|NCT01537016|Device|Tielle|Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
75433446|NCT01537055|Drug|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
75433447|NCT01537055|Drug|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
75433448|NCT01537094|Dietary Supplement|Placebo|
75580337|NCT05260112|Other|ERICA|"Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses."
76050689|NCT05006040|Device|Hybrid Closed Loop System|Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system [25, 26]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days [30].
76050690|NCT04988477|Behavioral|Chronic care management|Quarterly brief provider intervention (the 5As) and 3 quarterly outreach calls over 3 months.
76050691|NCT04974619|Behavioral|Online survey|Aim 1 Participants will be asked to complete a Qualtrics survey to identify knowledge gaps, health beliefs, attitudes, and educational learning preferences.
76050692|NCT04974619|Behavioral|Focus groups|Focus groups will be conducted in-person or remotely to evaluate the newly created educational materials about HPV vaccination. Individual interviews and/or focus groups (n=24) with young Latino men who have sex with men (YLMSM) (12 in Puerto Rico and 12 in Florida) will be conducted to gain feedback on the education intervention. The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference and aesthetics of the theoretically informed, HPV education target for Spanish-speaking YLMSM.
76050693|NCT04974619|Behavioral|Interviews|In-depth interviews (n=20) will be conducted with key stakeholders (10 in PR and 10 in FL) eliciting feedback to inform intervention content and delivery methods and identify potential facilitators and barriers to intervention implementation.
75728835|NCT05795192|Drug|Placebo|Taking Placebo orally once a day
75433449|NCT01537094|Dietary Supplement|Vitamin C 250 mg once daily|
75433450|NCT01537094|Dietary Supplement|Vitamin C 1,000 mg once daily|
75728836|NCT05788081|Drug|BMS-986369|BMS-986369 is an orally administered Cereblon-modulating compound
75728837|NCT05788081|Drug|Nivolumab 10 MG/ML|Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.
75728838|NCT05788081|Drug|Rituximab|Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions
76050694|NCT04944784|Drug|Reldesemtiv|Reldesemtiv Oral Tablet
75433451|NCT01537107|Drug|vismodegib|Given PO
75433452|NCT01537107|Drug|sirolimus|Given PO
75728839|NCT05786222|Behavioral|CSH-Delivered Overdose Prevention Support|Corporation for Supportive Housing (CSH) will deliver technical support for overdose (OD) prevention in the participating PSH buildings using a package of core implementation strategies: PSH Overdose Prevention (POP) Toolkit (an implementation manual/blueprint for overdose prevention practices); Implementation Champions (staff and tenants in each PSH building will be selected as implementation champions who support implementation and sustainment of OD prevention practices in their buildings); practice facilitation (the practice facilitator [a trained CSH employee] will work with the tenant and staff champions in small group workshops and coaching sessions, building their capacity and supporting their work toward implementation of building OD prevention practices); learning collaboratives (PSH buildings starting the intervention at the same time will attend learning collaborative meetings).
76050695|NCT04944784|Drug|Placebo|Placebo Oral Tablet
75433453|NCT01537107|Procedure|positron emission tomography|Correlative studies
76050696|NCT04936750|Other|Analysis of body composition|The cross section of the third lumbar spine in the CT scan images of the patients was analyzed to obtain the parameters related to the body composition of the patients
75433454|NCT01537107|Procedure|computed tomography|Correlative studies
75433455|NCT01537107|Other|pharmacological study|Correlative studies
75433456|NCT01537107|Other|laboratory biomarker analysis|Correlative studies
75433457|NCT01537107|Radiation|fludeoxyglucose F 18|Correlative studies
75433458|NCT01537146|Drug|Ropivacaine|Bolus infusion via catheter/6H for 24H
75433459|NCT01537146|Drug|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
75880090|NCT03561194|Dietary Supplement|Omegaven|After the diagnosis of PNALD is made, patients who are followed by the Neonatal Intensive Care Unit, NICU, will contact Dr. Honrubia and Dr. Swarup. Cases may also include referrals of patients with PNALD from other healthcare facilities or self-referrals. If the patient's parents or guardians agree to participate in the study, informed consent will be obtained. The history of present illness and past medical history will be reviewed with the guardian and pertinent demographic and medical information will be recorded on data collection forms. This form will be used to record all laboratory results, nutritional history, and descriptions of any liver biopsies performed.
75880091|NCT03618810|Drug|PEGCSF first level prophylactic use|6mg (≥45kg) or 3mg (<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
75880092|NCT03618810|Drug|PEGCSF second level prophylactic use|6mg (≥45kg) or 3mg (<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
75880093|NCT01354249|Dietary Supplement|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
75880094|NCT02058446|Drug|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
75880095|NCT02236650|Behavioral|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
75880096|NCT02236650|Other|Treatment as Usual|Treatment as Usual for 4 weeks
75880097|NCT01354327|Dietary Supplement|Limicol|3 tablets / day during 4 months
76050697|NCT04932486|Device|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation of the upper airway muscles
76050698|NCT04930887|Drug|Exparel (Bupivacaine Liposome)|Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
76050699|NCT04930887|Drug|Saline|Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
76050700|NCT04930666|Other|BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease|BREATHE-ALD utilizes the patient's nurse practitioner (NP) to deliver a brief intervention using motivational interviewing and shared decision making, in a one-time 9-minute intervention. The NP will follow a 4-step script tailored to specific ALD self-management discussed during the most recent visit with the patient's pulmonologist. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
76050701|NCT04875065|Behavioral|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
76050702|NCT04863248|Drug|Trilaciclib|Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
75433460|NCT01537159|Device|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
75728840|NCT05776966|Behavioral|Gender-specific digital intervention (GSDI)|The GSDI is a digital intervention that incorporates factors that are more prevalent in women with opioid use disorder that may affect their treatment outcomes. The content for the intervention was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes.
75728841|NCT05776966|Other|Treatment as usual|Participants will receive treatment as usual for opioid use disorder which is a mix of medication treatment and individual and group therapy services across various levels of care.
75728842|NCT05774665|Drug|Omega 3|Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)
75728843|NCT05774665|Other|Placebo|Placebo consisting of soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)).
75728844|NCT05772533|Procedure|Serratus anterior plane block|The latissimus dorsi muscle between the midaxillary line and the posterior axillary line will be located under ultrasound guidance. The needle will be inserted into the plane from top to bottom until the serratus anterior surface, and the injectate will be slowly administered.
76050703|NCT04863248|Drug|Placebo|Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
76050704|NCT04863248|Drug|Docetaxel|Docetaxel administered IV on Day 1 of each 21-day cycle.
76050705|NCT04815902|Drug|Fisetin|Oral Fisetin 20 mg/kg taken for 10 days total.
75728845|NCT05772533|Procedure|PENG block|"Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed Between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
75880098|NCT01354327|Dietary Supplement|Placebo|3 tablets / day during 4 months
75880099|NCT05160311|Drug|Optimized Medical Treatment (OMT)|Optimized Medical Drug Treatment
75880100|NCT05160311|Device|Drug Eluting Stent (DES) Coronary Angioplasty|Percutaneous Angioplasty with DES
75880101|NCT02058524|Biological|fecal microbiota transplantation|
75880102|NCT02058602|Other|Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months|Patients are receiving no treatment on this study and there is no investigational product involved.
75880103|NCT02715141|Behavioral|Collection of stool sample|Collection of stool sample prior to the scheduled surveillance colonoscopy.
75880104|NCT02031666|Drug|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
75880105|NCT02031666|Drug|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
75880106|NCT01354405|Drug|Lanreotide|120 mg every 28 days intramuscular
75880107|NCT03363035|Drug|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
76050706|NCT04815902|Drug|Losartan|12.5 mg oral Losartan taken for 30 days total.
76050707|NCT04815902|Drug|Placebo - Losartan|Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
76050708|NCT04815902|Drug|Placebo Fisetin|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
75433461|NCT01537172|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
75580338|NCT05256836|Other|Tablet computer-based cognitive training program|"The subject of the study executes a program mounted on a tablet personal computer (PC) (Samsung Galaxy Tab S6 Lite) and performs a cognitive training task by touching the screen with the index finger.~It consists of 10 tasks related to the activity of daily living: 1) taking medicine, 2) making a phone call, 3) taking a shower, 4) doing laundry, 5) finding directions, 6) riding the bus, 7) buying goods, 8) Money management, 9) ingredient sorting, 10) meal preparation.~It is involved in cognitive functions in various domains such as attention, working memory, processing speed, problem solving, visuospatial ability, verbal and visuospatial memory.~There are three levels of difficulty for each task, high, medium, and low, and the difficulty becomes more difficult as session 1 to 36 progresses.~One cognitive training session lasts about 30 minutes."
75728846|NCT05772078|Other|Assess compliance rate and demographics|Records to evaluate attendance rate
75728847|NCT05770869|Device|ALIBIRD mHealth platform|Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
75728848|NCT05768347|Biological|Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)|Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.
75728849|NCT05765448|Other|Soy control|Soy isolate control meal
75728850|NCT05765448|Other|Intervention (Laver/nori (Porphyra umbillicus) macroalgae whole biomass)|Laver/nori (Porphyra umbillicus) macroalgae whole biomass treatment meal
75728851|NCT05765448|Other|Intervention (Laver/nori macroalgae (Porphyra umbillicus) protein isolates)|Laver/nori macroalgae (Porphyra umbillicus) protein isolates treatment meal
75728852|NCT05765448|Other|Intervention (Chlorella microalgae (Chlorella vulgaris) whole biomass)|Chlorella microalgae (Chlorella vulgaris) whole biomass treatment meal
75728853|NCT05765448|Other|Intervention (Chlorella microalgae (Chlorella vulgaris) protein isolates)|Chlorella microalgae (Chlorella vulgaris) protein isolates treatment meal
75728854|NCT05762536|Drug|Darolutamide|Darolutamide 600 mg b.i.d. until the end of the last taxane cycle
75880108|NCT03363035|Drug|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
76050709|NCT04807140|Drug|Toripalimab, nab-paclitaxel, carboplatin|"Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
76050710|NCT04807140|Drug|Toripalimab|"Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
76050711|NCT04807140|Procedure|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
75433462|NCT01537172|Drug|Placebo|Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
75433463|NCT01537224|Other|Measure of the electrophysiological activity of the subthalamic nucleus|Local field recording of the subthalamic nucleus by mean of externalized electrodes in the immediate postoperative periode.
75433464|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
75433465|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
75433466|NCT01537250|Drug|Nemonoxacin 3 tablets|oral form,once daily,7~10 days
75880109|NCT03363035|Drug|Enoxaparin|Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
75880110|NCT02060084|Drug|a control group|the same dose of luke warm water
75880111|NCT02060084|Drug|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live>0.5*107CFU), twice per day, for 2 weeks
75880112|NCT05211843|Other|Drinking water|The intervention will compare the effects of a usual serving of drinking water with the effects of a usual serving of apple juice. Both beverages will also be assessed relative to the effects of not drinking anything at all.
75880113|NCT05211843|Other|Apple juice|apple juice
75880114|NCT03619122|Procedure|Second Examination|The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
75880115|NCT01350349|Behavioral|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
75880116|NCT01350349|Behavioral|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
75880117|NCT03618732|Other|Bilateral movement-based computer training|
75880118|NCT03618732|Other|Video-directed conventional training|
75433467|NCT01537263|Device|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
75728855|NCT05762536|Drug|Docetaxel or cabazitaxel|Docetaxel or cabazitaxel Q3W
75433468|NCT01537276|Procedure|diagnose under real-time fluoroscopy|radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
76050712|NCT04804566|Other|This is a non-interventional study|This is a non-interventional study
75433469|NCT01537289|Device|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
75433470|NCT01537289|Device|chest tube (28-French)|inserting chest tube to decompress pneumothorax
75433471|NCT01537328|Other|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
75433472|NCT01537341|Behavioral|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
75433473|NCT01537341|Behavioral|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
75433474|NCT01537354|Drug|Curosurf®|Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
75433475|NCT01537354|Drug|Survanta®|Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
75728856|NCT05757219|Drug|Itacitinib|Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
75880119|NCT03150485|Device|JJVC Fitting Guides|Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
75880120|NCT02060552|Drug|Diacerein|oral administration of IL-1βinhibitory
75880121|NCT02060552|Drug|Colchicine|"Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control"
75880122|NCT02060552|Drug|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
75880123|NCT01358149|Other|cocoa-based food|single intake of cocoa-based food
75880124|NCT01358149|Other|cocoa-based food|Single intake of cocoa-based food
75880125|NCT05384886|Diagnostic Test|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
75880126|NCT01350427|Dietary Supplement|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
75433476|NCT01537380|Drug|Cefazoline|Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
75433477|NCT01537406|Radiation|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
75580339|NCT05217004|Other|Dementia Talk mobile application|The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
75580340|NCT05217004|Other|CLEAR Dementia Care mobile application|The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
75580341|NCT05206487|Dietary Supplement|Polydextrose|PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
75728857|NCT05757219|Biological|Chimeric antigen receptor (CAR) T-cell therapy|Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
75728858|NCT05755815|Procedure|retrolaminar block|A high-frequency 12 MHz linear ultrasound probe will be used, patients will receive bilateral ultrasound-guided retrolaminar plane block with 20 mL of bupivacaine 0.25%. Their spines will be palpated from the vertebra prominens caudally to T7 and point will be marked to identify the spinous processes, which will be confirmed by ultrasound through counting from T12 with the characteristic last rib attached to its transverse process upward to the T7 lamina. The linear high frequency transducer (6-13 MHz) will be placed in the parasagittal plane one cm lateral to the midline. The needle will be inserted in the in-plane view of the ultrasound probe and will be advanced from downward to upward to target the T7 posterior lamina surface at an angle of 90˚ to the skin until the needle tip will be contacted the posterior surface of targeted lamina . After negative aspiration, 20 mL of bupivacaine 0.25% will be injected. The procedure was repeated following the same steps on the other side.
75728859|NCT05755815|Procedure|Peritoneal block|before giving an incision for the ports, 20 ml of 0.25% bupivacaine will be infiltrated subcutaneously over the port sites (6 ml will be infiltrated around each midline port site and 4 ml will be infiltrated around at the lateral port sites) and at the end of surgery and before the removal of trocars, 20 ml of 0.25% bupivacaine diluted in normal saline will be instilled by the surgeon intraperitoneally at gallbladder bed and under domes of both diaphragms under direct vision with a separate catheter passed through one of the trocars.. The pressure of the gas insufflation was kept within 10-12 mm Hg in all patients. At the end of surgery, CO2 was evacuated, and intraperitoneal anesthetic solution was left in situ.
75728860|NCT05755802|Procedure|PENG block|"A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
75728861|NCT05755802|Procedure|Shoulder block|The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it Will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. A 50 mm nerve block needle will be used in the long axis view for the block. After confirming extravascular placement of the needle, injectate will be given below the supraspinatus fascia and then during axillary nerve block,The posterior surface of the humerus will be visualised in the short axis view. So, the circumflex artery will be visualised longitudinally. After confirming extra-vascular placement of the needle, injectate will be given into space.
75728862|NCT05754073|Drug|1. Intranasal oxytocin spray|30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
75728863|NCT05754073|Drug|2. Intranasal placebo spray|30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase
75728864|NCT05754073|Drug|3. Intranasal Oxytocin spray|30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
75728865|NCT05747950|Other|Vibration|Vibration is used as an alternative to physical exercise in various areas to increase muscle performance and flexibility, improve balance and proprioception, reduce spasticity and increase bone density.
75433478|NCT01537471|Drug|Placebo|Placebo
75580342|NCT05203497|Drug|SPECT|One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
75433479|NCT01537471|Drug|Meclizine|Meclizine 12.5 mg
75433480|NCT01537471|Drug|Meclizine|Meclizine 25 mg
75433481|NCT01537484|Procedure|Massage Therapy|Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
75433482|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
75433483|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
75580343|NCT05181709|Drug|Sodium Chloride|Administered intranasal (IN) and intramuscular (IM) in combination
75880127|NCT01350427|Dietary Supplement|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
75880128|NCT01350427|Dietary Supplement|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
75880129|NCT05211765|Diagnostic Test|Superior vena cava transthoracic evaluation|The superior vena cava will be observed with a cardiac ultrasound machine, its diameter in different respiratory phases evaluated and compared with fluid response.
75880130|NCT05384574|Dietary Supplement|cholecalciferol|daily supplementation of cholecalciferol, 10 000 IU, during 14 days
75880131|NCT04355585|Drug|Colchicine Tablets|1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
75580344|NCT05181709|Biological|NDV-HXP-S IN low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108^8 EID50."
76050713|NCT04773691|Device|Active rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC"
76050714|NCT04773691|Device|Placebo rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation."
76050715|NCT04773691|Other|Questionnaires|questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
75728866|NCT05747950|Other|Modified Constraint-İnduced Movement Therapy|Compulsory use therapy is a form of treatment in which the movements of the healthy side are prevented and the use of the weak side is encouraged in the stroke patient.
76050716|NCT04773691|Device|Breathalyzer|estimation of blood alcohol level
76050717|NCT04761575|Other|Validation of the FFQ65+ via eNutri app|All participants will provide two eNutri FFQ datasets within a 14-day interval along with three 24-hour dietary recalls and dried blood spot samples.
76050718|NCT04759248|Drug|Atezolizumab + Trastuzumab + Vinorelbine|"Atezolizumab IV 1200 mg in combination with~Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and~Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV."
76050719|NCT04756726|Drug|CFT7455|oral CFT7455
75580345|NCT05181709|Biological|NDV-HXP-S IM low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10^8 EID50."
75580346|NCT05181709|Biological|NDV-HXP-S IN high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.
75580347|NCT05181709|Biological|NDV-HXP-S IM high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.
75728867|NCT05747950|Other|Conventional Therapy|Conventional exercises
75433484|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
75580348|NCT05166980|Dietary Supplement|Mutiply-fortified salt|Salt fortified with iron, zinc, vitamin B12, folic acid, and iodine
75580349|NCT05166980|Dietary Supplement|Iodized salt|Salt fortified with iodine
75433485|NCT01537497|Drug|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
76050720|NCT04756726|Drug|Dexamethasone Oral|oral dexamethasone [ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; >75 Years old: 20 mg QW on days 1, 8, 15, and 22]
75433486|NCT01537510|Behavioral|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
75580350|NCT05166460|Device|Kidney cooling device|renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.
75580351|NCT05110495|Drug|Xentuzumab|The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
75728868|NCT05746039|Drug|Semaglutide Pen Injector|Once weekly subcutaneous injection
75880132|NCT04355585|Drug|Placebo oral tablet|Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
75880133|NCT05189743|Procedure|Skin transplantation to heal burn injuries|"The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest."
75880134|NCT02061020|Drug|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
76050721|NCT04754932|Other|Cognitive Stimulation Therapy|Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.
76050722|NCT04708275|Procedure|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
75433487|NCT01537523|Procedure|community-care program|community nurse care, physiotherapy
75433488|NCT01537536|Drug|EndoTAG-1|EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
76050723|NCT04704505|Radiation|radium-223|Radium-223 is an alpha-particle-emitting bone-targeted therapy. All patients will receive Treatment with Radium-223 at a dose of 55 kBq per kilogram of body weight IV every 28 days, for 6 cycles,
76050724|NCT04704505|Drug|Bipolar Androgen Therapy (BAT)|All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
76050725|NCT04699435|Other|Control|"All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the Control group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
76050726|NCT04699435|Other|PreOx_3min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_3min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
76050727|NCT04699435|Other|PreOx_6min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_6min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 6-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
75580352|NCT05108883|Device|MR-proADM KRYPTOR|MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized
76050728|NCT04689555|Procedure|Novel method without manual compression|Novel method for femoral artery hemostasis without manual compression. After sheath removal, four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
75580353|NCT05094011|Biological|Aadipose-Derived Mesenchymal Stem Cells|Stereotactic intrastriatal implantation of 3×10^7 per hemisphere (total 6×10^7 cells) or 1×10^8 per hemisphere (total 2×10^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).
76050729|NCT04689555|Procedure|Standard method with manual compression.|Standard method for femoral artery hemostasis with manual compression.After sheath removal, manual compression was continued for at least 10 minutes or until hemostasis. After that four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
76050730|NCT04683692|Device|Magnetic Resonance Imaging (MRI)|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
76050731|NCT04683692|Other|Laboratory Testing|Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation
75580354|NCT05086276|Drug|FX-322|Active Comparator
75580355|NCT05086276|Drug|Placebo|Placebo
75728869|NCT05724082|Other|Clean Air Intervention|"Based on findings from preliminary focus groups/in-depth interviews, staff will introduce various components of established clean air interventions to each household. Each household will receive interventions, depending on their known risk factors, exposures, and willingness to trial the intervention.~Study staff will ask the primary cook to complete a time-activity diary during the intervention period that includes cooking episodes, duration of cooking, stove(s) used, type of food cooked, and number of people for whom the meal was cooked. Staff will continuously monitor use of the LPG/pellet stove and any other stoves owned by the household with the Berkeley Stove Use Monitoring System, a temperature logger attached to the stove to quantify the number of stove uses / time of use . Study staff will use similar loggers to monitor use of other devices installed including the air purifiers, lighting etc."
75728870|NCT05720611|Behavioral|Digitally delivered gardening and healthy eating course|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
75728871|NCT05718856|Drug|TPO-RAs|After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the TPO-RAs will stop until the platelet count <100×10^9/L.
75580356|NCT05065294|Drug|Psilocybin therapy|- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring
75580357|NCT05058287|Drug|Depo-Medrol 40Mg/Ml Suspension for Injection|40mg Depo-Medrol mixed with hemostatic matrix
75580358|NCT05058287|Drug|Placebo|1 mL of sterile normal saline mixed with hemostatic matrix
75580359|NCT05016375|Other|Interview|Interview with individuals with T2DM
75433489|NCT01537562|Other|Timing of IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
75580360|NCT04990609|Device|Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)|Endoscopic Ultrasound (EUS)-guided Radiofrequency Ablation (RFA) consists of the application of alternating current with a frequency of 350-500 kilohertz (kHz) to the target tissue via a special electrode located at the tip of an echoendoscope. The alternating current causes the vibratory movement of ionic particles in the abutting and adjoining tissue and results in the generation of heat. However, RFA induces not only local disruption of the tumor by heat, but it also produces localized coagulation necrosis of the tumor which induces the release of large amounts of cellular debris which represent a source of tumor antigens that can trigger a host adaptive immune response against the tumor.
75580361|NCT04990609|Drug|Neoadjuvant chemotherapy (NAC)|The NAC regimen will be determined clinically by the participant's physician [possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)].
75580362|NCT04968899|Drug|Neofordex®|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
75580363|NCT04968899|Drug|Intravenous immunoglobulins|IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
75580364|NCT04965818|Drug|Futibatinib and Binimetinib|Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
75580365|NCT04963205|Device|Adjustable bed backrest|The adjustable bed backrest facilitates for the individual high lying with a fowler (90 degrees raised head and trunk) and/or semi fowler position (30-45 degrees raised head and trunk) which enables patient's lung expansion. The diaphragm is pulled downwards by the gravity allowing for lung expansion and improved ventilation. In addition, the upper airways are stretched in order to prevent upper airway narrowing during sleep (flow limitation, snoring, obstructive sleep apnea). The position relaxes the tension of the abdominal muscles, allowing for improved breathing. Patients can define their own most comfortable position during the night. Elevated body position over 30 degrees from supine position is a requirement for the intervention group. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
75580366|NCT04963205|Other|Standard bed|Sleeping in a standard bed, in a position below 30 degrees from supine position. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
75580367|NCT04957693|Behavioral|vegan diet and lifestyle changes|vegan diet and lifestyle changes
75580368|NCT04941105|Drug|Evolocumab|A single subcutaneous administration of 140 mg evolocumab
75728872|NCT05718856|Drug|TPO-RAs combining anti-CD 20 monoclonal antibody|"After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24.~Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater.~Ps.Participants in the TPO-RAs monotherapy group who have platelet count < 20×10^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2 or Ortuzumab at 1000mg/ dose if weighing 45kg or greater."
75728873|NCT05715047|Behavioral|CBT for Fatigue|10, individualized counseling sessions with a behavioral health counselor via Zoom platform.
75728874|NCT05715047|Behavioral|Usual Care|Standard transplant care.
75728875|NCT05709470|Other|No-intervention|Observational cross-sectional study design with no intervention
75728876|NCT05700383|Behavioral|GetActive-Fitbit|GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
75880135|NCT02031744|Drug|erlotinib [Tarceva]|150 mg oral administration once daily
75433490|NCT01537575|Biological|intravenous immunoglobulins|One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
75433491|NCT01537575|Biological|Saline solution|Placebo
75433492|NCT01537588|Other|Autograft STG harvest from ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
75433493|NCT01537588|Other|Autograft harvest contralateral to ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
75580369|NCT04941105|Drug|Saline solution|A single subcutaneous injection of 1ml of 0,9% saline solution
75580370|NCT04925687|Biological|Intravitreal autologous CD34+ cells|Autologous CD34+ cells harvested from bone marrow injected intravitreal
75580371|NCT04922632|Behavioral|Transcendental Meditation (TM)|TM is a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
75580372|NCT04922632|Behavioral|Experience Resolution Methodology (ERM)|ERM is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
75580373|NCT04922632|Behavioral|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM)|TM + ERM is an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
75728877|NCT05700383|Behavioral|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
75880136|NCT02031744|Drug|Placebo|15 mg/kg intravenous administration every 3 weeks
75880137|NCT02031744|Drug|Onartuzumab [MetMAb]|15 mg/kg intravenous administration every 3 weeks
75880138|NCT04653389|Drug|Sintilimab Injection|Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
75728878|NCT05696158|Device|MHNA-003|6-week digital therapy program designed to reduce the severity of tinnitus symptoms
75728879|NCT05693766|Drug|Capecitabine|2000 mg taken by mouth twice daily for 7 days on, 7 days off
75728880|NCT05693766|Other|Endocrine-therapy|Endocrine therapy administered
75728881|NCT05693766|Other|MammoPrint ® and BluePrint assays|Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
75728882|NCT05691244|Drug|Drug: Normal Saline|Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
75728883|NCT05691244|Drug|Sovateltide|Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
75728884|NCT05681780|Biological|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
75880139|NCT04653389|Drug|TACE|The first TACE and Sintilimab Injection will be initiated simultaneously.
75880140|NCT04653389|Radiation|Radiotherapy|Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
76024873|NCT05117645|Diagnostic Test|Computed tomography|All patients will be examined by multislice CT scanner,Light speed 5X GE 8 detector elements scanner or GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) or Toshibe Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Axial scanns will be done commences at 1 cm above the diaphragm and ending at lesser trochanters then coronal and sagittal reconstruction images will be exposed.
76024874|NCT03343301|Biological|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
76024875|NCT03343301|Drug|Modified FOLFOX6|"Modified FOLFOX6 regimen consists of the following:~Oxaliplatin 85 mg/m² IV infusion over 120 minutes~Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours."
75433494|NCT01537614|Drug|COLIMYCINE inhalation|2 MILLION UI
75433495|NCT01537614|Drug|COLIMYCINE injectable|2 MILLIONS UI
75433496|NCT01537627|Other|Physical training|"Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.~Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months."
75433497|NCT01537627|Other|Physical training|Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
75433498|NCT01537640|Biological|SAR231893 (REGN668) DP1|Pharmaceutical form:solution Route of administration: subcutaneous
75433499|NCT01537640|Biological|SAR231893 (REGN668) DP2|Pharmaceutical form:solution Route of administration: subcutaneous
75433500|NCT01537653|Drug|SAR231893 (REGN668)|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
75433501|NCT01537653|Drug|placebo|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
75728885|NCT05681780|Drug|Nivolumab|Nivolumab (Opdivo®), 360 mg, IV infusion every 3 weeks prior to TIL infusion, and then after TIL infusion 480 mg ever 4 weeks for up to 12 months.
75728886|NCT05681780|Drug|Cyclophosphamide|Cyclophosphamide will be administered on days -7 and -6.
75433502|NCT01537679|Behavioral|Kirtan Kriya meditation|Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.
75433503|NCT01537679|Behavioral|Relaxation|Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
75433504|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 80mcg
75433505|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 320mcg
75433506|NCT01537692|Drug|BDP HFA Inhalation Aerosol (QVAR)|BDP HFA Oral 320mcg
75433507|NCT01537705|Drug|Neuron012703 (Medical Food)|2 capsules twice daily for sixty days.
75728887|NCT05681780|Drug|Fludarabine|Fludarabine will then be infused per institutional standard on Days -7 to -3.
75728888|NCT05681780|Other|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive a dose infusion TIL cells.
75728889|NCT05681780|Drug|Interleukin-2 (IL2)|Participants will receive IL-2 for up to 6 doses, based on participants tolerance and investigator judgement. This will be given after the infusion of the T-cells.
75433508|NCT01537718|Device|REPLY 200|REPLY 200 pacemaker
75433509|NCT01537731|Procedure|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
75433510|NCT01537744|Drug|oral 5-azacitidine in combination with romidepsin|"DOSING REGIMEN(S):~Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)~Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15~Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15~Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15~Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15~Level 4d MTD 8mg/m2 days 8, 15, and 22~Each cycle will last 28 days.~Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.~On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.~Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene."
75728890|NCT05945160|Drug|Alpha Lipoic Acid 300mg|A naturally occuring mitochondrial antioxidant
75728891|NCT05945160|Drug|Coenzyme Q10 200mg|A naturally occuring mitochondrial antioxidant
75728892|NCT05675059|Behavioral|Consultations with Moffitt Dietician|Participants will have an initial consultation and then biweekly follow-up visits (in-person or virtually) with a study dietician for 12 weeks.
75580374|NCT04922632|Behavioral|Treatment As Usual (TAU)|TAU is the existing Duke Health & Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
75433511|NCT01537757|Drug|MK-8931|Single dose, administered as oral capsules
75433512|NCT01537770|Procedure|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
75580375|NCT04922138|Drug|Aumolertinib|All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
75580376|NCT04906590|Drug|[18F] PI-2620|Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
75728893|NCT05675059|Behavioral|Daily Food Intake Diary with Fitbit Smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone app and wearing a Fitbit for 12 weeks.
75728894|NCT05675059|Behavioral|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at 4, 8, 12 and 16 weeks.
75728895|NCT05670223|Other|Fit&Strong Exercise Program|The Fit and Strong! Program (F&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F&S! exercise program assists older adults to improve strength and functioning.
75728896|NCT05661266|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
75580377|NCT04873102|Drug|Danazol Pill|"Danazol is a synthetic steroid derived from ethisterone, It suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. The pituitary-suppressive action of danazol is reversible. Danazol has been approved in treating endometriosis, fibrocystic breast disease, hereditary angioedema, thrombocytopenic purpura, and other conditions. It is metabolized and eliminated by renal and fecal pathways. The mean half-life of danazol in healthy males is 9.7 hours. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.~Adverse reactions from danazol include androgen like effects (i.e. weight gain, acne, mild hirsutism, edema, hair loss, voice change) and menstrual disturbances. The use of danazol in pregnancy is contraindicated. Other side effects include elevations in liver-enzyme levels and lipid abnormalities."
75728897|NCT05660525|Drug|4 weeks of Nicotine lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
75728898|NCT05660525|Drug|8 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
75728899|NCT05660525|Behavioral|QuitAid|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
75580378|NCT04871516|Other|Quality-of-Life Assessment|Ancillary studies
75580379|NCT04871516|Other|Questionnaire Administration|Ancillary studies
75580380|NCT04871516|Radiation|Radiation Boost|Undergo radiation therapy boost
75580381|NCT04871516|Procedure|Therapeutic Surgical Procedure|Undergo standard surgery
75580382|NCT04871516|Radiation|Whole Breast Irradiation|Undergo standard WBI
75580383|NCT04871516|Other|Breast MRI|A baseline breast MRI
75580384|NCT04870710|Device|transcranial electrical stimulation|Electrical stimulation to the extrastriate visual cortex.
75580385|NCT04860375|Procedure|Multidisciplinary patient care|A holistic, multidisciplinary, patient-centered care.
75580386|NCT04860375|Other|Standard care|Standard care in Sweden
75580387|NCT04860141|Drug|Gabapentin 600mg|The patient will take gabapentin 600mg 2 hours prior to the procedure
75580388|NCT04860141|Drug|Placebo|the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
75728900|NCT05660525|Behavioral|Smokefree TXT|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.
75728901|NCT05660525|Behavioral|Tobacco Quitline|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.
75580389|NCT04858802|Device|PROPEL Contour Sinus Implant|370 mcg mometasone furoate-coated sinus implant
75433513|NCT01537770|Procedure|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
75433514|NCT01537796|Behavioral|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
75433515|NCT01537796|Behavioral|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
75433516|NCT01537796|Behavioral|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
75433517|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
75433518|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
75580390|NCT04858802|Procedure|Balloon Sinus Dilation Alone|No PROPEL Contour Sinus Implant
75580391|NCT04857697|Procedure|Biopsy|Undergo biopsy
75580392|NCT04857697|Procedure|Biospecimen Collection|Undergo collection of blood, stool, and tissue samples
75580393|NCT04857697|Drug|Probiotic|Given PO
75580394|NCT04857697|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
75580395|NCT04834128|Drug|TCB008|administration of gamma delta T cells by IV bolus injection
75580396|NCT04823156|Dietary Supplement|Calcium|Daily calcium food supplement.
75880141|NCT05211687|Other|Smart-home for freezing of gait|"A projector, Kinect camera and computer are located 2 meters from the walking area. Participants walk nine times back and forth on the walking track, in each of three walking conditions:~Baseline: participants walk in a comfortable pace. The walking track consist a rectangle created by a white light projected on the floor. Based on in this walking condition, step width and cadence are calculated to determine the individual parameters of the cueing.~Light-stripes: The walking area consist of 4-5 white light-stripes. Space between the stripes is 110% of the participant step length. Participants are instructed to walk over the stripes.~Metronome: The walking track consist of a rectangle created by a white light projected on the floor, and in addition metronome beats are delivered by the computer. Beats frequency are 90% of the cadence. Participants are instructed to match their steps to the metronome beats.~Each walking condition up to 90 seconds."
75880142|NCT03134911|Drug|DOAC or VKA|6 months - 2 years
75580397|NCT04816825|Device|Alkit eSence|Home-based rehabilitation program including computer games and supervised by a physiotherapist.
75580398|NCT04816825|Other|Standard rehabilitation|Standard rehabilitation program at the COPD-Center
75580399|NCT04813653|Drug|cyclosporine in combination with carfilzomib and dexamethasone|patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
75433519|NCT01537822|Procedure|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith & Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
75880143|NCT03134911|Drug|VKA|6 months - 2 years
75880144|NCT04652843|Procedure|Rectosignoidoscopy|Rectosignoidoscopy for colonic biospsies collection
75433520|NCT01537822|Procedure|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
75580400|NCT04803747|Drug|Tranexamic acid (TXA)|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
75580401|NCT04803747|Drug|Placebo (0.9 % Saline)|Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
75580402|NCT04790474|Drug|ixazomib-pomalidomide-dexamethasone|"Cycles 1-3: during each 21-day cycle:~ixazomib 3 mg on Days 1, 4, 8 and 11~pomalidomide 4 mg on Days 1 through 14~dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~ixazomib 4 mg on Days 1, 8 and 15~pomalidomide 4 mg on Days 1 through 21~dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23"
75580403|NCT04789161|Procedure|double kissing crush stenting|Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
75728902|NCT05660525|Drug|4 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch.
75728903|NCT05660525|Drug|8 Weeks Nicotine Lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
75580404|NCT04789161|Procedure|double kissing culotte stenting|Patients with true bifurcation lesion treating with double kissing culotte stenting technique
75728904|NCT05659537|Drug|Dulaglutide|Administered SC
75728905|NCT05645146|Behavioral|Smoking Cessation treatment delivered by Tobacco Free Florida Quitline|Phone counseling with the state tobacco quitline
75728906|NCT05645146|Drug|Nicotine patch|Participants will be provided with a 12 week supply of nicotine patches
75728907|NCT05645146|Drug|Nicotine Lozenge|Participants will be provided with a 12 week supply of nicotine lozenges
75728908|NCT05645146|Behavioral|Motivation and Problem Solving (MAPS) intervention|MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
75880145|NCT04652843|Procedure|Coloscopy|Coloscopy for colonic biospsies collection
75880146|NCT05182593|Other|Diet moderate/high in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)
75880147|NCT05182593|Other|Diet low in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (<5 grams/day)
75880148|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
75880149|NCT02061098|Dietary Supplement|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
75880150|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
76050732|NCT04671186|Dietary Supplement|Culturelle (Lactobacillus rhamnosus strain GG)|Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily
75433521|NCT01537848|Procedure|EUS guided transmural drainage|Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
75433522|NCT01537861|Drug|Filgrastim|
75433523|NCT01537861|Drug|Bortezomib|
75433524|NCT01537861|Drug|Carfilzomib|
75580405|NCT04787055|Device|Receiver-in-canal hearing instrument|Receiver-in-canal hearing instrument
75580406|NCT04777617|Other|DD-cfDNA|We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study
75728909|NCT05635123|Other|No intervention|This is a prospective observational study with no intervention.
75728910|NCT05628636|Drug|AC-OLE-01-VA|formulation of tricaprilin
75728911|NCT05619692|Drug|SAGE-718|Softgel lipid capsules.
75880151|NCT02061098|Dietary Supplement|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
75580407|NCT04767529|Drug|EFX|Administered by subcutaneous injection
75728912|NCT05619692|Drug|SAGE-718-matching Placebo|Softgel lipid capsules.
75728913|NCT05612412|Other|Morning Exercise|Standardized treadmill exercise session starting at approximately 0700
75728914|NCT05612412|Other|Evening Exercise|Standardized treadmill exercise session starting at approximately 1800
76050733|NCT04671186|Other|Placebo|Placebo group will take 1 capsule of placebo orally once daily
75433525|NCT01537861|Drug|Dexamethasone|
75433526|NCT01537861|Drug|Cyclophosphamide|
75433527|NCT01537861|Drug|Thalidomide|
75433528|NCT01537861|Drug|Lenalidomide|
75433529|NCT01537861|Drug|Pomalidomide|
75433530|NCT01537874|Behavioral|Motivational Interview|30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques
75433531|NCT01537874|Behavioral|Usual best practices|Standard care delivered using informational materials
75580408|NCT04767529|Drug|Placebo|Administered by subcutaneous injection
75580409|NCT04743570|Drug|Placebo treatment|Active drug/placebo is given for the first 5 days of admission.
75580410|NCT04743570|Drug|Methylnaltrexone treatment|Active drug/placebo is given for the first 5 days of admission.
75728915|NCT05612074|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
75728916|NCT05600582|Biological|CodaLytic|CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009
75880152|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
75880153|NCT02061098|Dietary Supplement|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
75880154|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
76050734|NCT04651270|Device|SurroundScope|The study will evaluate standard laparoscopic surgery using the 270Surgical system. The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
76050735|NCT04617197|Device|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
76050736|NCT04588038|Biological|Efineptakin alfa|Given via intramuscular injection
76050737|NCT04548479|Device|PEP bottle|PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
75728917|NCT05594394|Behavioral|Orai: Master Public Speaking|"Participants will access the Orai: Master Public Speaking (Sani, Dhamani, & Gupta, 2020) platform with mobile and web-based applications. Communication skill-building moduleswill be assigned using exercises, case scenarios, and AI-assisted feedback debriefing through the Orai application.~Participants will also complete case scenarios created with specific nursing conflict issues a charge nurse may encounter in an acute care facility. Upon completion of the competency development program, participants will complete the CMCSS to determine the effect on confidence levels and a brief survey (Appendix C) to assess the amicability of the program."
75880155|NCT02061098|Dietary Supplement|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
75433532|NCT01537939|Behavioral|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
75433533|NCT01537965|Device|Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens|"Five ultrasounds exams are realised:~elastography with Fibroscan®~ultrasound elastography in supersonic mode with Aixplorer®~ultrasound analysis of the surface liver with QRS software,~quantification of acoustic structure with Aplio XG,~elastography ARFI with Acuson S2000."
75433534|NCT01537978|Other|Video gaming for enhanced function after spinal cord injury.|Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
75433535|NCT01537991|Radiation|Radiotherapy|All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
75433536|NCT01538017|Drug|Xiapex|Collagenase Clostridium Histolyticum
75580411|NCT04736030|Behavioral|Intervention|Twelve weekly sessions will be led by Ms. Schneider and Ms. Montañez supported by Drs. Arredondo and Ayala and student research assistants. Mothers and daughters will participate in weekly virtual 1.5-hour sessions that include didactic teaching, skill building (including PA parenting and communication skills training), interactive discussions, PA, and homework review (homework examples: 30-min walks, practicing communication strategies). Mothers and daughters will attend sessions together, with 10-12 mother-daughter dyads participating in each series. Sessions 2-12 will include at least 30 min PA. Sessions will discuss strategies to engage in PA outside the sessions (goal of 60-min MVPA daily).
75580412|NCT04718025|Drug|Ticagrelor 90mg|Up to day 30 after ACS, all enrolled patients will receive standard-dose ticagrelor 2x90mg as a part of dual antiplatelet therapy. Participants in SDTA arm will continue treatment with ticagrelor 2x90mg until 12 months post-ACS, while patients in LDTA and LDTP will be switched to low-dose ticagrelor 2x60 mg starting on day 31.
75580413|NCT04718025|Drug|Ticagrelor 60mg|Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.
75728918|NCT05586971|Drug|Tigulixostat|Xanthine Oxidase Inhibitor
75728919|NCT05586971|Drug|Allopurinol|Xanthine Oxidase Inhibitor
75728920|NCT05586971|Drug|Placebo|Matching placebo
75728921|NCT05578820|Biological|Intratumoral administration of Stimotimagene copolymerplasmid|Intratumoral administration of gene therapy drug Stimotimagene copolymerplasmid
75728922|NCT05578820|Drug|Intravenous administration of Ganciclovir (Cymeven®)|Intravenous administration of prodrug Ganciclovir (Cymeven®)
75728923|NCT05570058|Drug|RXC007|RXC007 will be administered in the form of oral capsules at 3 dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and 3 will receive RXC007 and 6 patients of cohorts 1B and 3B. The Dosage regimen is BID or QD.
75728924|NCT05570058|Drug|Placebo|The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and 3. In Cohorts 1B and 3B, the placebo will be received by 2 of the 8 patients. The Dosage regimen is BID or QD
75728925|NCT05566834|Drug|Minnelide|at the MTD dose level established for monotherapy or combination to confirm safety. With a sample of 12 patients, the probability is > 80% that a serious adverse event with at least a 16% incidence will be detected.
75728926|NCT05564754|Device|Feedback-controlled temperature device|If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.
75728927|NCT05564754|Other|High MAP|A MAP target of >85mmHg will be used. Vasopressors will be titrated to this target during 36h.
75728928|NCT05564754|Other|Deep sedation|Deep sedation for at least 36h
75433537|NCT01538017|Procedure|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
75433538|NCT01538043|Other|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
75433539|NCT01538069|Other|Exercise training|It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).
75433540|NCT01538069|Other|CPAP group|The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.
75433541|NCT01538069|Other|Exercise and CPAP group|The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
75433542|NCT01538095|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
75433543|NCT01538095|Other|Laboratory Biomarker Analysis|Correlative studies
75433544|NCT01538095|Other|Pharmacological Study|Correlative studies
75433545|NCT01538095|Biological|Trebananib|Given IV
75433546|NCT01538108|Device|PTA Balloon catheter with paclitaxel|patients treated by the NMB's PTA Balloon catheter with paclitaxel
75433547|NCT01538108|Procedure|Plain Balloon angioplasty (PBA)|PBA
75433548|NCT01538160|Drug|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
75580414|NCT04718025|Drug|Aspirin|Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.
75728929|NCT05564754|Other|Fever control without a device|Management of fever in the ICU without a device
75728930|NCT05564754|Other|Low MAP|A MAP target of >65mmHg will be used. Vasopressors will be titrated to this target during 36h.
75580415|NCT04711148|Other|placebo|placebo
75580416|NCT04711148|Drug|orelabrutinib|Orelabrutinib is a white, round, uncoated tablet
75580417|NCT04666948|Device|vancomycin model-informed precision dosing|A CE labelled dosing calculator is used for a priori and a posteriori calculation of vancomycin dose using a target AUC between 400-600 mg*h/L
75580418|NCT04666948|Drug|Vancomycin|Vancomycin treatment
75580419|NCT04660526|Other|Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators|EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
75580420|NCT04660526|Other|Systematic bystander resuscitation instruction by 911 operators|911 operators will be able to describe how to administer CPR over the phone.
75728931|NCT05564754|Other|Minimal sedation|A strategy of minimal sedation in the ICU, used only as needed to facilitate transport, imaging and invasive procedures.
75880156|NCT01344239|Procedure|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
75433549|NCT01538173|Drug|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
75433550|NCT01538173|Drug|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
75433551|NCT01538225|Drug|Sativex®|"THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks"
75433552|NCT01538225|Drug|Placebo|"Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks"
75433553|NCT01538238|Drug|pazopanib|pazopanib 800mg qd until progression or unacceptable toxicity
75433554|NCT01538251|Drug|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
75433555|NCT01538251|Drug|Placebo|Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
75433556|NCT01538277|Procedure|Contact Force during ablation|Radio Frequency Ablation procedure with real-time contact force information known to the operator
75433557|NCT01538277|Other|Standard ablation procedure|Standard ablation procedure
75433558|NCT01538316|Dietary Supplement|Quercetin supplement|500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.
75433559|NCT01538316|Dietary Supplement|Genistein supplement|100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.
75433560|NCT01538316|Dietary Supplement|Placebo|vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
75433561|NCT01538329|Drug|Amantadine|200mg / day once daily in the morning and at noon - oral administration -
75880157|NCT03618576|Procedure|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
75880158|NCT02061176|Procedure|Transanal Haemorrhoidal Dearterialization|
75880159|NCT02061176|Procedure|Open Haemorrhoidectomy|
75880160|NCT02061254|Device|Cutometer|3 measures by cutometer on each area: the mean value will be the final value
75880161|NCT02061254|Device|High resolution ultrasonography (echography)|Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)
75880162|NCT02061254|Device|Elastography|10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer
75880163|NCT02061254|Procedure|Skin biopsy|Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
75880164|NCT05189665|Procedure|Extraperitoneal high sacral ligament suspension surgery|The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .
75433562|NCT01538329|Drug|placebo|200mg / day once daily in the morning and at noon - oral administration -
75433563|NCT01538355|Other|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
75580421|NCT04660526|Other|Comprehensive community training of lay people in CPR and AED use.|Training of lay people regarding CPR and AED use.
75580422|NCT04660526|Other|Optimized first responder performance including earlier use of AEDs.|First responders will recognize where AEDs are located and use them appropriately
75728934|NCT05550246|Drug|Atomoxetine|Treatment given for 3 nights
75433564|NCT01538355|Other|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
75433565|NCT01538355|Other|Control diet|Patients stay on their regular diet.
75728935|NCT05550246|Drug|Oxybutynin|Treatment given for 3 nights
75880165|NCT05189665|Procedure|Sacrospinous ligament fixation|The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.
75880166|NCT01344395|Drug|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
75580423|NCT04630080|Device|Scalp cooling|Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
75580424|NCT04609176|Drug|Camrelizumab plus Apatinib and SOX|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
75580425|NCT04609176|Drug|Camrelizumab plus Apatinib|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
75433566|NCT01538381|Drug|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
75433567|NCT01538381|Other|Observation|Observation
75433568|NCT01538394|Drug|Varenicline|
75433569|NCT01538394|Drug|Nicotine patches|
75433570|NCT01538394|Drug|Placebo (nicotine patches)|
75580426|NCT04562090|Drug|mirabegron|Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
75580427|NCT04560920|Other|Availability of contextual PGD at the visit|Contextual PGD will be availability in a display at the visit.
75580428|NCT04560647|Other|No intervention - Psoriasis Subject|Not currently treated plaque psoriasis patients
75580429|NCT04560647|Other|No intervention - Control Subject|Control subjects without plaque psoriasis and no family history of psoriasis
75580430|NCT04557189|Drug|TAK-951|TAK-951 SC injection
75580431|NCT04557189|Drug|Ondansetron|Ondansetron IV injection
75433571|NCT01538407|Other|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
75880167|NCT01344395|Drug|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
75880168|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
75880169|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
75880170|NCT02062112|Other|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
75880171|NCT01342289|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.
75880172|NCT01342289|Drug|Fludarabine|Days -6, -5, -4, -3, and -2: 30 mg/m^2/day IV.
75880173|NCT01342289|Radiation|Total body irradiation|Day -1: 200 centigray in one fraction.
75880174|NCT01342289|Drug|Mycophenolate Mofetil|Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.
75433572|NCT01538420|Drug|GLPG0492|Oral solution
75880175|NCT01342289|Drug|Tacrolimus 60|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 60.
75880176|NCT01342289|Drug|Tacrolimus 90|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 90.
75880177|NCT01342289|Drug|Tacrolimus 120|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 120.
75880178|NCT01342289|Biological|Bone marrow transplant|Donor stem cells infused IV on Day 0.
75880179|NCT03134599|Device|etafilcon A|contact lens
75880180|NCT03134599|Device|methafilcon A - Interozzo|contact lens
75880181|NCT03134599|Device|methafilcon A - CVI (CooperVision)|contact lens
75433573|NCT01538420|Drug|Placebo|Placebo oral solution
75580432|NCT04557189|Drug|Ondansetron Placebo|Ondansetron placebo-matching IV injection
75580433|NCT04557189|Drug|TAK-951 Placebo|TAK-951 placebo-matching SC injection
75580434|NCT04556461|Drug|Tralokinumab|2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)
75580435|NCT05306197|Behavioral|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
75580436|NCT05306197|Behavioral|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
75580437|NCT05306197|Behavioral|Non-Contingent Feedback Training|Participants listen to a musical track they chose with no operant conditioning.
75580438|NCT04530838|Biological|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
75880182|NCT02062190|Drug|resveratrol|"100mg 2x/day~1 month"
76024876|NCT03297827|Other|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic & hemorrhagic stroke.
76024877|NCT05136365|Drug|Xiongdan Wan|Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.
76024878|NCT03251729|Procedure|Cervical cerclage|Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
76024879|NCT03251729|Drug|Vaginal progesterone|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
76024880|NCT03248843|Drug|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
76024881|NCT02696785|Drug|Ixekizumab|Administered SC
76024882|NCT02696785|Drug|Placebo|Administered SC
76024883|NCT02696785|Drug|Adalimumab|Administered SC
75433574|NCT01538446|Drug|Modification of Prasugrel based on a biological assay|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
75880183|NCT05128539|Drug|JS001(Toripalimab)+JS002|"Part A: In this phase, 3 dose levels will be preliminarily set up. The dose level of Toripalimab is fixed as 240 mg, intravenous infusion, Q3W. The dose levels of JS002 are fixed at 75 mg,150 mg and 300 mg subcutaneously, and the traditional 3+3 design will be used for dose escalation with 21 days as entire treatment cycle. In addition, the period of 21 days after the first administration is defined as the DLT observation period.~Part B: Based on the data of the safety, PK and preliminary efficacy in Part A patients, the dosage will be determined for advanced tumor patients who had received at least first-line therapy in this part. Two to three groups with different tumor types will be further enrolled, and about 30 patients will be included in each group (the specific number and cohort will be adjusted according to the research progress). Toripalimab is a humanized IgG4κ mAb specific against human PD-1."
75433575|NCT01538446|Drug|prasugrel / clopidogrel|fixed dose of prasugrel 5 mg
75580439|NCT04530838|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
75580440|NCT04474054|Device|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation will be performed using catheter ablation
75580441|NCT04442919|Drug|Ticagrelor followed with Methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
75580442|NCT04442919|Drug|Ticagrelor followed with Morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
75580443|NCT04442919|Drug|Ticagrelor alone|patients who received ticagrelor without any analgesia due to unstable angina
75580444|NCT04435197|Drug|Pembrolizumab Injection|Pre-operative Pembrolizumab+chemoradiotherapy
75580445|NCT04424901|Drug|Placebo|Daily dose while hospitalized up to 9 days
75580446|NCT04424901|Drug|Dipyridamole Tablets|Daily dose while hospitalized up to 9 days
75880184|NCT01319071|Other|Blood sample|Extraction of blood sample from top-level athletes
75880185|NCT03618498|Procedure|ILM flaps insertion techniques or free ILM flaps.|The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
75880186|NCT05109273|Procedure|Transcatheter ablation|Three-dimensional electroanatomic mapping and radiofrequency ablation with irrigated catheter
75880187|NCT02060708|Device|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
75880188|NCT04194606|Procedure|Use of radial artery for access for a coronary angiography or intervention|After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
75880189|NCT05211531|Other|Measuring number of post-operative steps|Measuring the number of post-operative steps that inpatients take.
75433576|NCT01538446|Device|Verify Now|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
75433577|NCT01538459|Drug|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
75433578|NCT01538459|Drug|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
75433579|NCT01538485|Drug|Cholecalciferol|weekly dose (based on 70IU KG body weight/day)
75433580|NCT01538511|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
75433581|NCT01538511|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
75580447|NCT04415060|Drug|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
75580448|NCT04415060|Drug|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
75580449|NCT04410445|Biological|Bempegaldesleukin|Specified dose on specified days
75580450|NCT04410445|Biological|Nivolumab|Specified dose on specified days
75580451|NCT04392440|Behavioral|DIAL-SDM|Communication intervention for nephrologists and coaching intervention for patients.
75580452|NCT04392440|Other|usual care|regular nephrology care
75728936|NCT05548491|Drug|AZR-MD-001 ointment/semi-solid drug|ointment/semi-solid drug
75728937|NCT05546697|Other|Online- Yoga-based Intervetion|See arms description
75728938|NCT05546697|Behavioral|Online- BA|See arms description
75728939|NCT05545852|Procedure|GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
75728940|NCT05545852|Procedure|COT(Conventional Open Thyroidectomy)|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
75728941|NCT05544799|Other|No intervention|No intervension
75580453|NCT04381091|Drug|Idebenone 150 MG Oral Tablet|idebenone 900 mg/day
75580454|NCT04372498|Drug|Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)|This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
75580455|NCT04342494|Behavioral|Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback."
76050738|NCT04529278|Drug|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
75580456|NCT04342494|Device|Headspace app + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices."
75580457|NCT04342494|Device|Headspace app + Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices."
75580458|NCT04342494|Device|SilverCloud + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
75728942|NCT05536518|Behavioral|Mid-Ohio Farmacy (produce prescription) + WW International Coaching (In person and/or Virtual)|All study participants are members of the Mid-Ohio Farmacy produce prescription program. All participants are food insecure and will be enrolled and participate in WW coaching sessions for 24 weeks.
75728943|NCT05534633|Other|Choice of STBBI test(s)|Participants may receive a point of care HIV test, and/or point of care HCV test, and/or dry blood spot test, which can test for HIV, HCV, and syphilis, at the participants' choice.
75728944|NCT05534100|Device|Biostrap EVO Wristband|Participants in both groups will wear the Biostrap wearable device
75728945|NCT05531591|Drug|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
75728946|NCT05531591|Drug|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
75728947|NCT05531591|Drug|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
75728948|NCT05531591|Drug|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
75728949|NCT05531591|Drug|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
75728950|NCT05529654|Device|Impella 5.5 with SmartAssist|For subjects enrolled in the Trial, the Impella 5.5 will be placed intra-operatively during the index cardiac surgical procedure
75880190|NCT01354483|Biological|Umbilical Cord Blood Mononuclear Cell|
75880191|NCT01354483|Biological|Methylprednisolone|30mg/kg i.v. methylprednisolone
75880192|NCT01354483|Drug|Lithium Carbonate Tablet|6 weeks
76050739|NCT04503148|Drug|Propofol|Propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
76050740|NCT04503148|Drug|Inhaled General Anesthetics|Sevoflurane or desflurane for induction and maintenance of anesthesia
75880193|NCT02061410|Device|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
75580459|NCT04342494|Device|SilverCloud app +Enhanced Feedback +Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
75580460|NCT04340921|Biological|COVID-19 exposure|Observation only
75880194|NCT05211453|Procedure|atrioventricular node ablation|atrioventricular node ablation
75880195|NCT03560726|Behavioral|Cognitive Behavioral Stress Management|Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
75880196|NCT03376152|Behavioral|Electric Kettle Promotion|Provision of free electric kettles and promotional materials/information
75880197|NCT05211375|Procedure|Duodenojejunal bypass|Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.
75880198|NCT05211375|Procedure|Sleeve gastrectomy|Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.
75880199|NCT03618264|Drug|Miscible liquid of dexamethasone and ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
75880200|NCT03618264|Drug|Ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
75880201|NCT05089617|Drug|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699."
75580461|NCT04314817|Drug|Any drug used to treat Covid-19|lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
75580462|NCT04312269|Other|Targeted Memory Reactivation (TMR)|Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
75580463|NCT04307030|Diagnostic Test|Heart Auscultation and Echocardiography|Heart auscultation will be done by cardiovascular pediatrician and echocardiography by echocardiologist
75728951|NCT05527405|Device|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
75728952|NCT05524935|Drug|Pembrolizumab|Pembrolizumab Day 1 of each 21 day (3 week) cycle
75728953|NCT05524935|Drug|Olaparib|Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
75728954|NCT05522036|Combination Product|Metvix + Dermaris|Photodynamic Therapy
75728955|NCT05508594|Drug|CT001|Intranasal
75728956|NCT05508594|Drug|Placebo|Intranasal
75580464|NCT04294563|Dietary Supplement|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
75580465|NCT04294563|Other|Standard Care by Surgeon and Physical Therapist|Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
75728957|NCT05508594|Drug|Sufentanil|Intranasal
75728958|NCT05508594|Drug|Ketamine|Intranasal
75728959|NCT05505630|Drug|Ketamine|A single dose of IV ketamine will be administered.
75433582|NCT01538537|Drug|rigosertib sodium|ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
75880202|NCT03628911|Device|Tetanizing Burst Therapy|Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock
75580466|NCT04284969|Behavioral|PROADAPT program|"A pre-intervention activity by telephone follow-ups every week for 12 weeks and then every month.~Pre-operative physical training including strength, endurance and breathing exercises.~A nutrition activity.~An activity to educate patients (on nutrition, exercise).~The implementation of standardised intervention procedures, established in agreement with the surgeons' representatives.~A pharmaceutical drug conciliation activity: optimization of the patient's different treatments with pharmaceutical expertise.~A transition activity from the hospital to the home, and a telephone follow-up up to 12 weeks after the surgery."
75728960|NCT05505630|Drug|Midazolam|A single dose of IV midazolam will be administered
75728961|NCT05505630|Drug|Dexmedetomidine|A single dose of IV dexmedetomidine will be administered
75728962|NCT05505630|Drug|Saline|A single dose of IV saline will be administered
75880203|NCT03617016|Drug|Domperidone|Participants will receive domperidone tablets orally.
75880204|NCT03617016|Drug|Placebo|Participants will receive matching placebo to domperidone tablets orally.
75580467|NCT04242953|Drug|SCO-120|"Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)"
75880205|NCT03798938|Other|plant-based diet|subjects will be placed in plant-based diet and the effect of plant-based diet to the endothelial function will be monitored
75433583|NCT01538550|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
75580468|NCT04242953|Drug|matching placebo|"Part A: single oral administration~Part C: multiple oral administration (14 day dosing)"
75580469|NCT04226898|Biological|Synbiotic Supplement|Synbiotic supplement 1 powder stick by mouth daily
75433584|NCT01538550|Procedure|iFOBT|Biennial screening with iFOBT
75580470|NCT04226898|Biological|Inert Compound|Synbiotic supplement identical placebo 1 powder stick by mouth daily
75580471|NCT04225312|Drug|Personalized extended interval dosing of natalizumab|Personalized extended interval dosing of natalizumab with a schedule from every 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
75580472|NCT04225312|Drug|Standard interval dosing|Standard interval dosing in control group and historic group
75580473|NCT04209205|Drug|AIN457 6 mg/kg i.v.|AIN457 6 mg/kg delivered by i.v. infusion
75580474|NCT04209205|Drug|Placebo|Matching placebo to AIN457 i.v. infusion
75580475|NCT04209205|Drug|AIN457 3 mg/kg|AIN457 3 mg/kg delivered by i.v. infusion
75580476|NCT04193787|Other|EPIC-P|EPIC-P is a brief, bio-behavioral intervention based on the information-motivation-behavioral skills (IMB) model framework, which integrates i) a biomedical component (i.e., PrEP), ii) behavioral components (i.e., drug- and sex-related primary HIV prevention), and iii) mHealth technology (i.e., text messaging PrEP reminders).
75728963|NCT05500885|Device|PEMF device, Quantum Tx, Singapore|The options of the appliance will be adjusted to 1.5mT, 10Hz on the diseased leg for 10 minutes.
75728964|NCT05500885|Other|Standard rehabilitation and sham PEMF therapy for CAI|Balance training and muscle strengthening
75728965|NCT05498441|Device|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.
75880206|NCT05210829|Diagnostic Test|stationary and trait anxiety scale|survey
75880207|NCT02062268|Behavioral|health education & law enforcement|
75880208|NCT02031822|Procedure|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
75433585|NCT01538563|Drug|rigosertib sodium|Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
75433586|NCT01538576|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
75880209|NCT02060786|Drug|generic clopidogrel (Plavitor® )|
75880210|NCT02060786|Drug|original clopidogrel (Plavix® )|
75580477|NCT04193046|Other|Blood Sample|Prevalent (existing) and incident (new) participants who are found to either have PH or not by RHC will provide blood sample for the establishment of a biomarker signature of PH.
75580478|NCT04158908|Behavioral|Oncolo-GIST|"Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~Principles of introducing prognosis in the setting of worsened scan results~Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you)~Addressing informational needs and psychological reactions~Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
75728966|NCT05498441|Drug|Antipsychotics, mood stabilizers, etc.|During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
75880211|NCT03628833|Device|Incontinence Management System|Incontinence detection device
75880212|NCT03616938|Procedure|Cardiopulmonary resuscitation|2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
75880213|NCT02060864|Dietary Supplement|AN-PEP|Two pills are consumed in the morning with a breakfast
75580479|NCT04157595|Other|Reproductive Genetic Carrier Screening|Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
75880214|NCT02060864|Dietary Supplement|Placebo|
75880215|NCT03560414|Procedure|simple plasma exchange|simple plasma exchange treatment
75880216|NCT03560414|Procedure|conventional PDF treatment group|conventional PDF treatment group
75880217|NCT03560414|Procedure|less plasma PDF treatment group|less plasma Plasma diafiltration treatment
75880218|NCT02062424|Other|DIPI|
75880219|NCT03798704|Diagnostic Test|IFA, LIAISON|Comparison of two diagnostic serological tests - IFA and LIAISON.
75580480|NCT04129086|Drug|Ketamine plus usual care|Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
75580481|NCT04129086|Drug|Usual Care|Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
75580482|NCT04117685|Other|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
75728967|NCT05492201|Drug|LY3873862|Administered orally.
75728968|NCT05492201|Drug|Placebo|Administered orally.
75728969|NCT05491551|Behavioral|Mindfulness-Based Treatment-Regulation of Craving|"Participants will be trained in using the MBT-based mindfulness strategy as described above (notice craving and accept the feeling without judgment or reaction). Participants will then be instructed to think of accepting and non-reactive responses when they see the instruction ACCEPT during ROC-T. On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see ACCEPT and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale."
75880220|NCT05384418|Radiation|HDP-Tc99m bone scintigraphy|HDP-Tc99m bone scintigraphy
75880221|NCT03153137|Drug|Macitentan 10 mg|film-coated tablet; oral use
75880222|NCT03153137|Drug|Placebo|film-coated tablet; oral use
75880223|NCT05654558|Device|Auxiliary cantilever intrusion arches on initial archwires|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
75880224|NCT05654558|Device|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
75880225|NCT03616626|Radiation|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
75880226|NCT03616626|Radiation|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
75728970|NCT05491551|Behavioral|Cognitive-Based Therapy-Regulation of Craving|"Participants will be trained in using the CBT strategy by first considering and reading about the negative consequences of drinking. Participants will then be instructed to think of those negative consequences (Focus on the negative consequences associated with drinking) when they see the instruction REFRAME during ROC-T.On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see REFRAME and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale"
75728971|NCT05487820|Device|IscAlert|Insertion of a CO2- and temperature sensor(s) in the reconstructed flap.
75728972|NCT05483062|Other|galla chinensis|toothpaste
75728973|NCT05483062|Other|Stannous fluoride|Toothpaste
75728974|NCT05481034|Device|SMA bolus option|SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.
75728975|NCT05481034|Device|Exactly estimated carbohydrate content bolus option|The carbohydrate content of meals is estimated in grams of carbohydrates prior to a meal bolus
75433587|NCT01538589|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
75433588|NCT01538641|Drug|Rituximab, Gemcitabine, Oxaliplatin|Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
75433589|NCT01538654|Procedure|enteral protein tube feeding in obese|The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
75433590|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
75580483|NCT04103632|Diagnostic Test|EVH test|"Spirometry~Skin prick test~Peripheral blood test~FeNO measurement"
75580484|NCT04062448|Drug|Ibrutinib|Ibrutinib 420 mg will be administered orally.
75580485|NCT04062448|Drug|Rituximab|Rituximab 375 mg/m^2 will be administered intravenously.
75433591|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
75433592|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
75433593|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
75580486|NCT04040764|Procedure|Tritanium uncemented Total Knee Replacement|This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
75580487|NCT04013295|Other|Prize-linked savings|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
75728976|NCT05477134|Other|Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus|On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
75728977|NCT05474989|Drug|LSD|Moderate to high dose LSD
75728978|NCT05474989|Drug|Active placebo|Low dose LSD
75728979|NCT05469802|Biological|Purified Inactivated Zika Virus Vaccine (PIZV)|PIZV vaccine with aluminium hydroxide adjuvant IM injection.
75728980|NCT05469802|Other|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
75728981|NCT05459376|Other|Exercises and dry cupping|Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
75728982|NCT05458674|Drug|Tucatinib|taken orally
75728983|NCT05458674|Drug|Eribulin|taknen intravenously
75728984|NCT05458674|Drug|Trastuzumab|taken intravenously
75728985|NCT05456477|Other|Beef|Beef entrees
75880227|NCT03616626|Radiation|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
75880228|NCT03617484|Drug|Bortezomib|Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle.
75880229|NCT03617484|Drug|Ibrutinib|Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
75880230|NCT01344473|Device|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
75880231|NCT02063204|Drug|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
75880232|NCT03617406|Diagnostic Test|Volume Challenge|Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
75880233|NCT01344551|Dietary Supplement|Cocoa Drink|High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
75880234|NCT03618108|Drug|Doxycycline Capsule|doxycycline capsule
75880235|NCT03618108|Drug|Azithromycin Capsule|azithromycin capsule
75880236|NCT03618108|Drug|Rifabutin Oral Capsule|rifabutin capsule
75880237|NCT03618108|Drug|Placebo oral capsule|Placebo oral capsule identical in size and form to doxycycline
75880238|NCT03618108|Drug|Placebo Oral Tablet|Placebo oral capsule identical in size and form to azithromcyin
75880239|NCT03618108|Drug|Placebo oral capsule|Placebo oral capsule identical in size and form to rifabutin
75880240|NCT03138473|Diagnostic Test|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, creatinine clearance (CrCl) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of CrCl below 60 ml/min/1.73 m2 (1 point for CrCl between 59 and 50, 2 points for CrCl between 49 and 40 and 3 points for CrCl between 39 and 30 ml/min/1.73 m2). The CrCl is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
76050741|NCT04484766|Other|Primary data collection|"Primary data collection takes place via questionnaires outside the study centre.~All other investigations take place at the study centre:~Physical examination: height, weight, BMI, blood pressure~Cardiac examination: cardiac output~Vascular measurements: Carotid intima media thickness, total peripheral resistance, blood pressure, flow-mediated vascular dilatation, critical flicker frequency, pulse wave velocity, augmentation index~Serum analysis: basic laboratory, multiplex analysis (human vascular inflammation, human angiogenesis and adhesion molecule panel)"
76050742|NCT04429516|Drug|Morphine Sulfate|over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
76050743|NCT04429516|Drug|Placebo oral tablet|capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
76050744|NCT04417452|Other|Basic data collection (online survey or written form)|Basic data collection is carried out by means of a questionnaire that participants can fill in outside the study centre. It contains questions about the current life situation, sleep and activity behaviour.
75580488|NCT04006665|Diagnostic Test|Lung Ultrasonography (Baseline)|Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
75580489|NCT04006665|Diagnostic Test|Lung Ultrasonography ( At the end of surgery)|Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
75728986|NCT05456477|Other|Poultry|Poultry entrees
75880241|NCT03138473|Diagnostic Test|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-[rSS/bSS]) ×100.
75580490|NCT04000555|Drug|Oral Vancomycin|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
75580491|NCT04000555|Other|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
75728987|NCT05445414|Device|"SteWARdS Antibiotic Defense app"|"The SteWARdS Antibiotic Defense app is an evidence-based serious game app developed by the study team. The app uses gamification theories to increase user engagement and to deliver bite-sized information to participants. For example, players will learn about the uses of antibiotics through the messages delivered through the game and the cost of tackling antibiotic-resistant infections through purchasing an expensive antibiotic with the virtual currency earned from the games."
75728988|NCT05438940|Behavioral|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
75728989|NCT05438940|Behavioral|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth
75728990|NCT05438940|Behavioral|Survey|Participants will take a survey at baseline and weeks 4,8,12 & 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
75880242|NCT02031900|Device|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
76050745|NCT04417452|Other|Physical examination|The physical examination takes place at the study centre and includes the measurement of height, current weight and body fat, as well as the recording of heart and circulation parameters (e.g. blood pressure measurement or determination of vascular health by means of ultrasound). General metabolic and hormonal parameters are analysed by means of a blood sample. In addition, a sugar test for diabetes diagnosis will be carried out.
76050746|NCT04417452|Behavioral|Psychometric examination|Psychometric examination is carried out at the study centre with the help of a RIAS (Reynolds Intellectual Assessment Scales and Screening) test.
76050747|NCT04417452|Diagnostic Test|Recording of the adrenergic stress reaction (saliva test)|The adrenergic stress reaction is recorded by a saliva test.
76050748|NCT04371263|Other|Emotional Change of Nursing Manpower in Emergency and Critical Unit After Keen Election And What's The Influence of Emotional Change|use the emotion regulation questionnaire (ERQ) to realize the influence in duty work
76050749|NCT04357951|Drug|d-cycloserine|D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
75580492|NCT03994822|Device|Mechanical Thrombectomy using the pRESET Thrombectomy device|Clot removal using the pRESET Thrombectomy device
75580493|NCT03994822|Device|Mechanical Thrombectomy using the Solitaire Revascularization Device|Clot removal using the Solitaire Revascularization Device
75580494|NCT03994393|Drug|Tremelimumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
75728991|NCT05438927|Behavioral|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
75728992|NCT05438927|Behavioral|Nutrition Counseling|Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
75728993|NCT05438927|Behavioral|Fact G Survey|Participants will take a survey at baseline and weeks 4,8,12 & 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
76050750|NCT04357951|Drug|Placebo pill|A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
76050751|NCT04357951|Behavioral|Behavior Therapy|All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
76050752|NCT04323293|Other|Cold Water Bath|immersion of the hand for 2-5min in 2-10°C water
76050753|NCT04323293|Other|Neutral Water Bath|immersion of the hand for 2-5min in 32±2°C water
76050754|NCT04285229|Drug|Ixekizumab|Administered SC
76050755|NCT04285229|Drug|Placebo|Administered SC
76050756|NCT04282668|Drug|TAS1440|Form: Capsule or Tablet Route of Administration: Oral
76050757|NCT04282668|Drug|TAS1440 + ATRA|Form: Capsule or Tablet Route of Administration: Oral
76050758|NCT04263454|Drug|Endotoxin, Escherichia Coli|Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
76050759|NCT04263454|Procedure|Magnetic Resonance Spectroscopy|MRI is a non-invasive imaging technique and does not utilize ionizing radiation.
75880243|NCT04903704|Diagnostic Test|1 Minute Sit to Stand Test|Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
75728994|NCT05438927|Behavioral|General Anxiety Disorder (GAD)-7|Participants will take a survey at baseline and weeks 4,8,12 & 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
75728995|NCT05438927|Behavioral|Patient Health Questionnaire (PHQ)-9|Participants will take a survey at baseline and weeks 4,8,12 & 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
75728996|NCT05436808|Radiation|Partial Chest Wall Radiation Therapy|Patients will receive radiation therapy (30 Gray in 5 fractions) to the affected chest wall, delivered on consecutive days or every other day
75728997|NCT05425615|Device|Transcranial Magnetic Stimulation|Deymed DuoMag XT-35 rTMS
75880244|NCT01342601|Device|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
75880245|NCT01342601|Device|Placebo products|Nasal Spray and Eye drops without Ectoin
76050760|NCT04259060|Drug|Hydroxocobalamin with Butyrate|"In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2."
75433594|NCT01538680|Drug|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
75433595|NCT01538693|Drug|escitalopram oxalate|10 mg 4.5 hours prior to testing
75433596|NCT01538693|Drug|Cyproheptadine|8mg 4.5 hours prior to testing
75433597|NCT01538693|Drug|sugar pill|4.5 hour prior to testing
75728998|NCT05422339|Device|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
75728999|NCT05388604|Device|RF device|The entire defined treatment area will then be treated by delivering adjacent pulses with minimal overlap of 10% or less. Parameters may be adjusted throughout the treatment in order to increase subject comfort.
75433598|NCT01538693|Other|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
75433599|NCT01538706|Other|Hospital-based home care|Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
75433600|NCT01538732|Drug|alitretinoin|30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
75433601|NCT01538758|Other|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
75433602|NCT01538758|Other|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
75433603|NCT01538771|Drug|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
75433604|NCT01538771|Drug|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
75729000|NCT05388604|Device|Microneedling device|"Test spots may be performed prior to the first treatment. Test spots may be performed prior to the first treatment. It will follow a similar procedure to treatment but only in an inconspicuous place, such as behind the ear, in an area no larger than 2in x 2in.~The tip will be placed in contact with the skin, and parameters may be adjusted throughout the treatment and will determined by the Clinician."
75729001|NCT05379946|Drug|D-1553|D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation
75729002|NCT05379946|Drug|IN10018|IN10018 orally once daily at approximately the same time each day
75729003|NCT05378464|Biological|Dendritic Cell (DC1) Vaccine|Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
75729004|NCT05378464|Drug|Trastuzumab|Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
75880246|NCT03616548|Diagnostic Test|Endoscopic surveillance|Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
75880247|NCT04349657|Device|Supera Peripheral Stent System treatment group|Percutaneous endovascular stenting with the Supera Peripheral Stent System
75880248|NCT04349657|Procedure|Endarterectomy treatment group|Surgical treatment through endarterectomy
75880249|NCT03616392|Drug|D308, CKD-501|"D308~CKD-501: Lobeglitazone sulfate 0.5mg"
75880250|NCT04894968|Diagnostic Test|Assessment of the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016|"Patient will be screened for the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016.~This requires patients to fulfill all of the four criteria listed below:~Symptoms of heart failure (e.g. dyspnea on extertion)~Preserved ejection fraction (Left ventricular ejection fraction ≥50%~NT-proBNP ≥125 pg/mL~Echocardiographic signs for structural heart disease or diastolic dysfunction (at least one of the criteria below)~Left atrial volume index >34 mL/m²~Left ventricular mass index ≥115 g/m² for males or ≥95 g/m² for females~E/e' ≥13~Septal e' <9 cm/s"
75433605|NCT01538784|Drug|YF476|"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:~Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth~Groups A & B were dosed alternately, at weekly intervals"
75580495|NCT03994393|Drug|Durvalumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
75880251|NCT03615378|Dietary Supplement|5000 IU D3|Daily
75580496|NCT03991624|Diagnostic Test|cognitive assessment|"MMSE : Mini-Mental State Examination~5 words of Dubois~Direct Assessment of Functional Status~Trail Making Test~BREF : Fast Front End Efficiency Battery~short battery of praxies~Quality of Life in Alzheimer's Disease"
75729005|NCT05378464|Drug|Pepinemab|Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
75729006|NCT05378464|Biological|T-Cell therapy|Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
75729007|NCT05370508|Combination Product|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS
75729008|NCT05368246|Device|UCon|The subjects self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
75729009|NCT05358522|Other|Opioid Prescribing Report Cards|"Initial comparison: Clinicians will receive an initial peer comparison feedback report by email in which their post-operative opioid prescribing for patients undergoing their top 3 procedures is compared to the guideline recommended doses and the mean prescribing doses by other University of Pennsylvania Health System (UPHS) prescribers for each of those 3 procedures since the start of the baseline period.~Furthermore, in an attached report, for each of the 3 procedures, the mean patient reported ability to manage pain one week at home after the procedure will be displayed for those who received guideline compliant dosages of opioids relative to those who received higher than guideline recommended amounts.~Monthly comparison: On a monthly basis clinicians will get a report providing similar peer comparison feedback as above but with a monthly trend line of their performance since the start of the intervention."
75729010|NCT05347914|Behavioral|Mindfulness|Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
75729011|NCT05338879|Other|Non-Interventional|No study treatment will be administered on this study.
75729012|NCT05334381|Behavioral|Adapted-STAT ED|Patient navigator assigned to provide culturally informed motivational interviews, brief case management, psychoeducation and telephone contacts
75880252|NCT03615378|Dietary Supplement|1000 IU D3|Daily
75433606|NCT01538797|Drug|YF476|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100 mg), placebo and ranitidine 150 mg. There were at least 7 days between consecutive Treatment Days.
75433607|NCT01538797|Drug|Ranitidine|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100mg), placebo and ranitidine 150mg. There were at least 7 days between consecutive Treatment Days.
75880253|NCT03615378|Dietary Supplement|Placebo|lactose/sugar tablet
75880254|NCT03617250|Other|Disease Activity Score-28|Assessment of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio and their association with Disease Activity Score-28
75433608|NCT01538836|Behavioral|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
75433609|NCT01538836|Behavioral|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
75433610|NCT01538849|Drug|Esomeprazole 40mg|1 tablet = Esomeprazole 40 mg
75433611|NCT01538849|Drug|YH4808 A mg|1 tablet = YH4808 A mg
75433612|NCT01538849|Drug|YH4808 B mg|1 tablet = YH4808 B mg
75433613|NCT01538849|Drug|YH4808 C mg|YH4808 C mg = 2 x YH4808 B mg
75433614|NCT01538875|Drug|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
75433615|NCT01538875|Drug|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
75433616|NCT01538888|Procedure|WHOLE BODY VIBRATION|03 MONTHS, TWICE PER WEEK
75433617|NCT01538901|Other|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
75433618|NCT01538901|Drug|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
75433619|NCT01538914|Procedure|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
75433620|NCT01538914|Procedure|PCA|Postoperative pain is controlled with intravenous PCA.
75433621|NCT01538927|Drug|Fibrin Sealant|Fibrin Sealant 4ml (Baxter Tisseel)
75433622|NCT01538927|Drug|Suture|Black silk 000
75433623|NCT01538940|Biological|Intradermal vaccine|15ug
75729013|NCT05334381|Behavioral|Standard Enhanced Treatment|Follow up phone calls following discharge from the emergency department to confirm mental health treatment referral recommendations
75880255|NCT03616314|Device|stepping verticalization plus functional electrical stimulation|patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
75880256|NCT03616314|Device|stepping verticalization|patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
75433624|NCT01538940|Biological|Intramuscular vaccine|15ug
75433625|NCT01538953|Other|handwashing|participants received weekly in-home handwashing promotion and soap as needed
75433626|NCT01538953|Other|flocculent-disinfectant for water treatment|participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
75433627|NCT01538953|Other|water treatment with sodium hypochlorite|participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
75433628|NCT01538979|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
75433629|NCT01538979|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
75433630|NCT01538979|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
75433631|NCT01538992|Device|Standard steerable Marinr RF ablation Catheter (5F or 7F)|Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
75433632|NCT01539018|Drug|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
75433633|NCT01539018|Drug|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
75433634|NCT01539044|Drug|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
75433635|NCT01539044|Drug|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
75729014|NCT05332639|Behavioral|Personalized Risk Estimation for Crohn's Disease (PRE-CD) tool|We will develop a web-based, personalized risk estimation for CD (PRE-CD) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI), smoking history, NSAID use, intake of fruit, vegetables, and fiber, oral contraceptive use (females), and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
75880257|NCT03616314|Other|conventional physiotherapy|patients are treated only with 60 minutes/day of conventional physiotherapy
75880258|NCT02236728|Drug|Pramipexole|
75880259|NCT01344707|Drug|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
75580497|NCT03991624|Other|Inhibition evaluation|"Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button)."
75880260|NCT03615300|Diagnostic Test|serum NGAL|serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
75880261|NCT04254653|Behavioral|American Indian and Alaska Native What Can I Eat?|Participants will engage in 5 ~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
75880262|NCT01344785|Procedure|Intramedullary nailing|All patients will be treated with Intramedullary nailing
75880263|NCT03136861|Biological|AIN457|anti IL-17a monoclonal antibody
75880264|NCT03136861|Drug|AIN457 Placebo|Placebo matching AIN457
76050761|NCT04259060|Drug|Placebo with Butyrate|"In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day."
76050762|NCT04251195|Behavioral|Cognitive Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
76050763|NCT04251195|Behavioral|Active Control Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
75433636|NCT01539057|Drug|Fibrinogen|"The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts"
75580498|NCT03991624|Other|Assessment of mental flexibility|"a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli."
75729015|NCT05332639|Behavioral|Standard Crohn's Disease Education|The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-CD tool as well.
75729016|NCT05332379|Diagnostic Test|Pulsed Wave Doppler USG examination|Pulsed Wave Doppler USG examination of the posterior tibial artery on the left or right lower extremity will be performed before spinal anesthesia, at the 5th and 10th minutes after the spinal anesthesia. Blood flow velocities and vessel diameters will be measured.
75880265|NCT03482856|Behavioral|MNA plus CBT-I|MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.
76050764|NCT04218240|Drug|Pregabalin 200 MG capsules|oral pregabalin 200 mg capsules given with a taper on day 5
76050765|NCT04218240|Drug|Placebo oral tablet|oral Placebo
76050766|NCT04218240|Drug|Lofexidine 0.18Mg Tab|lofexidine 0.18 tab given with a taper starting on day 5
76050767|NCT04212793|Drug|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery
76050768|NCT04212793|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
76050769|NCT04212260|Behavioral|Oropharyngeal exercises|Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.
75433637|NCT01539057|Drug|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
75580499|NCT03991624|Other|Evaluation of the update|"an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters."
75880266|NCT03482856|Behavioral|MNA alone|MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.
75580500|NCT03991624|Other|working memory|"the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on."
75580501|NCT03991624|Other|episodic memory|- A recognition task with a Remember/Know paradigm
75729018|NCT05312632|Drug|Safinamide Mesilate|Safinamide Mesilate oral tablets.
76050770|NCT04212260|Behavioral|Sham control|Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
75433638|NCT01539096|Procedure|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
75880267|NCT01342679|Drug|dasatinib|100mg QD
75580502|NCT03970733|Biological|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
75580503|NCT03970733|Biological|Placebo|PBS (Phosphate Buffered Saline)
75580504|NCT03961438|Biological|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.
75729019|NCT05301114|Behavioral|Community Health Worker support|Participant will receive weekly or monthly support (via phone or in person) from a community health worker. The community health worker will be responsible for continuously assessing the patient's social needs, providing referrals to community based organizations, and assisting with the patient's non-medical needs as they progress through survivorship (e.g. social support, referrals, etc). Individuals who identify no risk factor will receive monthly phone calls, while individuals who identify 1-3 risk factors will receive monthly home visits with interim phone calls for 6 months. Those who identify 4 or more risk factors or have intensive needs such as behavioral health will receive the same services as the medium risk group and will also be connected with the social work teams within each institution.
75880268|NCT04852926|Other|Self-administered questionnaires|"6 self-administered questionnaires (EORTC-QLQ-C30, RSE, BIS, HAD, FSFI, DAS-4) completed by the patients at every usual follow-up consultation.~1 (FSFI) or 2 (MSHQ, PEP) self-administered questionnaires completed by the partner (respectively female or male) between every usual follow-up consultation.~Follow-up usual consultations :~T0 (at inclusion) : before disease + since diagnosis~C4 (chemotherapy course n°4)~C6 (chemotherapy course n°6)~M3 (3 months after chemotherapy)~M6 (6 months after chemotherapy)~A1 (1 year after chemotherapy)~A2 (2 years after chemotherapy)"
75880269|NCT03616080|Behavioral|soccer play program|once a week for an hour of a soccer program for 8 weeks
76050771|NCT04187547|Drug|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)"
76050772|NCT04187547|Drug|Placebo|Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
76050773|NCT04175678|Other|Diet|Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.
75880270|NCT01342835|Drug|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
76050774|NCT04175678|Other|Exercise|Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.
76050775|NCT04175678|Other|Standard care|Observational
76050776|NCT04159662|Behavioral|Cognitive Intervention|In each of the 6 visits, participants will be completing some computerized tasks for a period of about 40 minutes. At the end of each session, there will be 10-15 minutes of bridging discussion between the research therapist and the participants. (More details about each condition will be added after study completion to protect the blinding of our participants) .
75433639|NCT01539096|Behavioral|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
75433640|NCT01539096|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
75433641|NCT01539109|Behavioral|Rehabilitation|Patients will receive training upon tasks of daily living. Patients will perform these exercises in our laboratory under the supervision of qualified personnel.
75433642|NCT01539109|Procedure|Noninvasive brain stimulation: tDCS|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 2 weeks in conjunction with therapy for the affected hand.
75433643|NCT01539109|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
75433644|NCT01539161|Device|Implantable Cardiac Monitor|9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
75433645|NCT01539161|Procedure|Standard of Care|Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
75433646|NCT01539174|Biological|rituximab|Given IV
75433647|NCT01539174|Drug|cyclophosphamide|Given IV
75433648|NCT01539174|Drug|doxorubicin hydrochloride|Given IV
75433649|NCT01539174|Drug|vincristine sulfate|Given IV
75433650|NCT01539174|Drug|prednisone|Given PO
76050777|NCT04159662|Behavioral|Active Control Intervention|In each of the 6 visits, participants will be completing some computerized tasks for a period of about 40 minutes. At the end of each session, there will be 10-15 minutes of bridging discussion between the research therapist and the participants. (More details about each condition will be added after study completion to protect the blinding of our participants) .
75433651|NCT01539174|Other|laboratory biomarker analysis|Correlative studies
75433652|NCT01539174|Other|pharmacological study|Correlative studies
75580505|NCT03961438|Biological|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
75580506|NCT03943017|Other|Inspection and safety evaluation by 3 longstanding experience physicians of early clinical researches|Adjudicate each ARC's observations according to the 3 physicians perceived medical importance regarding safety; first, adjudications are performed separately. Then disagreements are settled during a final adjudication meeting between them.
75729020|NCT05287594|Behavioral|Integrated Exercise Program|"Neuromuscular warm-up: Each participant will perform a series of dynamic stretches, core stability, balance, and medicine ball exercises. The dynamic stretches include 8 repetitions of 6 stretches targeting the hip and thigh musculature, followed by 3 core stability isometric exercises (curl-up, side bridge, and bird dog). Participants will then perform 2 sets (per leg) of hop-to-stabilization (with a reach) balance exercises, followed by 3 separate medicine ball exercises emphasizing explosive full-body movements.~High Intensity Interval Training (HIIT): HIIT will include a series of high intensity exercise bouts on a stationary bike that includes a 1:1 work-to-rest ratio. Training intensity will be determined from the peak power output obtained during the baseline VO2 peak assessment and progressively increased by the number of bouts and intensity. The number of work bouts will increase from 5 to 8 bouts and the intensity will increase from 90 to 110% of peak power output."
75433653|NCT01539187|Device|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
75580507|NCT03921411|Biological|Nemolizumab|Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
75880271|NCT03616002|Other|Hookah smoking|ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
76050778|NCT04155463|Other|Organic Diet|Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.
76050779|NCT04155463|Other|Conventional Diet|Participants receive one week of conventionally grown (non-organic) food.
75433654|NCT01539200|Dietary Supplement|ONS+JDR|Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
75433655|NCT01539200|Dietary Supplement|JDR|Jacques-Delacroze Eurythmic training with placebo ONS
76050780|NCT04117347|Device|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
76050781|NCT04117347|Device|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
76050782|NCT04117347|Device|Light therapy C via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
76050783|NCT04084951|Biological|SQZ-PBMC-HPV|antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16
76050784|NCT04084951|Drug|Atezolizumab|programmed cell death ligand 1 (PD-L1) blocking antibody
76050785|NCT04084951|Drug|Ipilimumab|cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
76050786|NCT04084951|Drug|Nivolumab|programmed cell death 1 (PD-1) blocking antibody
76050787|NCT04083898|Biological|Isatuximab|Isatuximab will be administered on a 28-day cycle
76050788|NCT04083898|Drug|Bendamustine|Bendamustine will be administered on a 28-day cycle as follows
76050789|NCT04083898|Drug|Prednisone|Prednisone will be administered on a 28-day cycle as follows
76050790|NCT04058665|Device|Floseal|Hemostatic agent
76050791|NCT04056611|Drug|JNJ-53718678 250 mg|JNJ-53718678 250 mg will be administered orally.
76050792|NCT04056611|Drug|Placebo|Matching placebo will be administered orally.
76050793|NCT04056611|Drug|JNJ-53718678 125 mg|JNJ-53718678 125 mg will be administered orally.
76050794|NCT04040686|Drug|Injection of 99mTc-NM-02|Patient will be injected with microdose (<100ug) of 99mTc-NM-02 radiotracer
76050795|NCT04035837|Drug|pegylated interferon-alfa|All the patients in this study will receive pegylated interferon for all course.
75433656|NCT01539213|Drug|secukinumab (AIN457)|anti-IL-17 antibody
75433657|NCT01539252|Procedure|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
75580508|NCT03906851|Behavioral|Activity and diet|Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
75580509|NCT03855475|Behavioral|Aerobic exercise|Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle
75880272|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
75880273|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
76050796|NCT04022135|Dietary Supplement|Folic acid|Participants will supplement with 0.6mg/day for 16 weeks.
76050797|NCT04022135|Dietary Supplement|(6S)-5-methyltetrahydrofolic acid|Participants will supplement with 0.625mg/day for 16 weeks.
75433658|NCT01539252|Procedure|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
75433659|NCT01539265|Drug|silodosin|
75433660|NCT01539265|Drug|silodosin|
75433661|NCT01539265|Drug|placebo|
75433662|NCT01539278|Procedure|Adenotonsillectomy|Tonsils and adenoids are surgically removed
75433663|NCT01539278|Other|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
75433664|NCT01539304|Drug|CITUS Dry Syrup|Pranlukast 10% dry syrup, b.i.d.
75433665|NCT01539304|Drug|Placebo|Placebo dry syrup, b.i.d
76050798|NCT04011254|Procedure|haemodialysis|Routine haemodialysis session
76050799|NCT04001803|Drug|CAB LA+RPV LA|Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
76050800|NCT04001777|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
76050801|NCT04001777|Drug|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
76050802|NCT03994913|Biological|CAR-CD19 T Cells|"The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion."
76050803|NCT03987802|Drug|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
76050804|NCT03984994|Other|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
76050805|NCT03984994|Other|Strength training|3 months of center-based, supervise strength training
76050806|NCT03983668|Drug|CMP-001|Immunostimulatory therapeutic agent
76050807|NCT03983668|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy
75880274|NCT01354561|Procedure|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
75880275|NCT02666183|Behavioral|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
75880276|NCT02666183|Behavioral|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
75880277|NCT02666183|Behavioral|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
75880278|NCT03316950|Device|IntraGen RF|IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
75880279|NCT03316950|Device|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
75880280|NCT03316950|Device|Placebo (DIVA/IntraGen combined)|"(DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner."
75880281|NCT03139279|Drug|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
75880282|NCT03139279|Other|Saline placebo|Intravenous saline/placebo
75880283|NCT03139279|Drug|Propofol|Propofol titrated intravenous boluses
75880284|NCT02562599|Drug|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
75880285|NCT02562599|Radiation|Intensity-modulated radiotherapy (IMRT)|Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
76050808|NCT03977012|Drug|Buprenorphine|5~20 mcg
76050809|NCT03968055|Other|Integration with Epic|Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
75580510|NCT03855475|Behavioral|Stretching|Participants will complete 12 weeks of supervised stretching, 3 times per week
75580511|NCT03798639|Biological|Ipilimumab|Given IV
75580512|NCT03798639|Biological|Nivolumab|Given IV
75880286|NCT01358227|Drug|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
75880287|NCT03311958|Drug|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
75580513|NCT03798639|Radiation|Radiation Therapy|Receive radiation therapy
75880288|NCT01370642|Drug|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
76050810|NCT03940066|Device|Biomonitor-2 and Kardia mobile|Implantable cardiac monitor and Smart-phone based electrocardiogram recording
76050811|NCT03940066|Other|No Intervention|No intervention
76050812|NCT03915964|Drug|Baricitinib|Administered orally.
76050813|NCT03915964|Drug|TNF Inhibitor|Administered SC
76050814|NCT03907423|Drug|Rosuvastatin10 mg tablet|Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
76050815|NCT03907423|Drug|Placebo Oral Tablet|Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
75580514|NCT03774901|Drug|Avelumab|intravenous 10 mg/kg every 2 weeks
75880289|NCT01370642|Drug|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
75880290|NCT01370642|Biological|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
75880291|NCT01370642|Drug|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
75880292|NCT02873208|Drug|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
75880293|NCT03138967|Drug|Rocuronium|Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
75880294|NCT03138967|Drug|Sugammadex|Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
75880295|NCT03138967|Drug|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
75880296|NCT03138967|Drug|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
75880297|NCT01358305|Other|Protein Blend|Single intake of approximately 20 grams of total protein
75880298|NCT01547117|Radiation|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
75580515|NCT03762018|Drug|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
75880299|NCT01547117|Radiation|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
75880300|NCT01547117|Procedure|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
75880301|NCT01547117|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
75433666|NCT01539330|Drug|Voriconazole|"At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po"
75880302|NCT01358383|Drug|naproxen|250mg, oral dose
75880303|NCT01358383|Drug|esomeprazole|20mg, oral dose
75433667|NCT01539330|Other|microdialysis|long-term microdialysis over study days 1-4 (visits 1-7)
75433668|NCT01539343|Drug|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
75433669|NCT01539369|Other|Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day|"Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided."
75580516|NCT03762018|Drug|Pemetrexed|Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
75580517|NCT03762018|Drug|Bevacizumab|Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
75580518|NCT03762018|Drug|Atezolizumab|Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
75880304|NCT03560336|Drug|Liraglutide|Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
75880305|NCT04847388|Drug|Substance like alcohol, marijuana, etc.|Cohort study
75880306|NCT03136159|Device|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
75880307|NCT03615768|Combination Product|Adapalene-Clindamycin Combination Gel|5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
75880308|NCT03615768|Drug|Adapalene Gel|Differin 0.1% Gel, applied nightly for 12 weeks
75880309|NCT03615768|Drug|Clindamycin Gel|Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
75880310|NCT02061644|Other|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
75880311|NCT04178135|Drug|rLH|rLH supplement from day 1 of stimulation
75880312|NCT04178135|Drug|rLH|rLH supplement from day 6 of stimulation
75880313|NCT04958070|Other|MPS I|MPS I, symptoms of disease onset , ERT
75880314|NCT01318291|Behavioral|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
75880315|NCT01318291|Behavioral|Control|Medical treatment alone
75880316|NCT03793400|Drug|Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)
75880317|NCT03614988|Other|Evening Levothyroxine Administration|Bedtime levothyroxine intake, with 60-minute meal-free interval
75880318|NCT03614988|Other|Morning Levothyroxine Administration|Morning levothyroxine intake, 60 minutes before breakfast.
75880319|NCT01318369|Drug|Namisol|Single dose delta-9-tetrahydrocannabinol
75880320|NCT01318369|Drug|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
75880321|NCT02061722|Radiation|PET Imaging with [18F]MNI-659|"The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
75880322|NCT01345097|Device|Total Hip Arthroplasty|Total Hip Arthroplasty
75433670|NCT01539382|Procedure|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow >2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
75433671|NCT01539395|Other|MSDx Complex-1 Biomarker Test|A biomarker test for the level of MSDx Complex-1
75433672|NCT01539408|Drug|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
75580519|NCT03750825|Device|NIDA Standard Research E-cigarette (SREC)|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
75580520|NCT03747146|Device|Continuous Adductor Canal Catheter (ACC)|At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
75880323|NCT01350739|Procedure|intraumbilical incision|vertical, intraumbilical incision
75880324|NCT01350739|Procedure|infraumbilical incision|incision at the inferior boarder of the umbilicus, circular
75880325|NCT03479684|Other|Gene-directed dosage of warfarin|the first day given model prediction dose * 1.5 times（<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
75880326|NCT03479684|Other|standard dosage of warfarin|the first day given 4.5mg; adjusted dose based on INR from the second day
75880327|NCT01316003|Other|Optical coherence tomography|Optical coherence tomography
75433673|NCT01539408|Procedure|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
75433674|NCT01539421|Behavioral|Use of Home exercise computer program|After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
75880328|NCT01318447|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
75880329|NCT01986933|Drug|nemolizumab (CIM331)|
75880330|NCT01986933|Other|Placebo|
75880331|NCT05251103|Other|time-restricted feeding trial|The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.
75880332|NCT03614052|Drug|Tamsulosin Hydrochloride 0.4 milligrams|Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
75880333|NCT03614052|Drug|Placebo Oral Tablet|Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
75880334|NCT01318525|Drug|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
76050816|NCT03906409|Other|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
75880335|NCT01318525|Drug|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
75880336|NCT02062892|Drug|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
76024884|NCT05117567|Combination Product|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
76024885|NCT02004262|Biological|GVAX Pancreas Vaccine|
76024886|NCT02004262|Biological|CRS-207|
75880337|NCT02062892|Drug|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
75880338|NCT02063360|Drug|BMS-663068|BMS-663068
75880339|NCT02063360|Drug|Darunavir (DRV)|Darunavir (DRV)
75880340|NCT02063360|Drug|Ritonavir (RTV)|Ritonavir (RTV)
75880341|NCT02063360|Drug|Etravirine (ETR)|Etravirine (ETR)
75880342|NCT01358461|Biological|Blood sampling|Blood sampling
75880343|NCT01358461|Other|ECG-Holter 24 h tape and sino-carotid stimulation test|ECG-Holter 24 h tape and sino-carotid stimulation test
75880344|NCT03614832|Drug|Ticagrelor 90 mg|half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
75880345|NCT03614832|Drug|Clopidogrel 150 mg|double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
75880346|NCT05210595|Drug|Clopidogrel 75 mg|75 mg/day as maintenance dose.
75433675|NCT01539434|Behavioral|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
75433676|NCT01539434|Behavioral|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
75880347|NCT05210595|Drug|Ticagrelor 60mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.
75880348|NCT05210595|Drug|Ticagrelor 45 mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
75880349|NCT01358539|Behavioral|Pain education|Patients receiving pain education
75880350|NCT03560570|Biological|Coagulation assay|Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin
75880351|NCT03560570|Other|Clinical data collection|At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
75880352|NCT03614754|Diagnostic Test|Somatosensory evoked potentials|Stimulation of the pudendal nerve while recording at the sensory cortex.
75880353|NCT02061800|Device|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
75880354|NCT02061800|Drug|Thiotepa|Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
75880355|NCT02061800|Drug|Cyclophosphamide|Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
75433677|NCT01539460|Procedure|minimally invasive surgery|Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
75433678|NCT01539473|Drug|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
75580521|NCT03747146|Device|Adductor Canal block with sham catheter|Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
75580522|NCT03728582|Device|Active tDCS plus Speech-Language Therapy|1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
75580523|NCT03728582|Device|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
75580524|NCT03614234|Drug|pegunigalsidase alfa|Recombinant human alpha galactosidase A
75580525|NCT03613077|Procedure|surgical placement of an endosteal implant|Subjects, male or female at least 18 years old, with the need of dental implant therapy and restoration according to the cleared indications for the implant
75580526|NCT03593395|Other|Peer Mentoring [PM]|Virtual Peer Mentoring
75433679|NCT01539473|Drug|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
75433680|NCT01539551|Other|check BNP and lactate|we will collect patients's blood samples on Day 0, Day1 and Day2
75433681|NCT01539564|Drug|Minocycline HCl Microspheres|
75433682|NCT01539577|Drug|dexamethasone 700 μg intravitreal implant|dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
75880356|NCT02061800|Drug|Alemtuzumab|Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
75880357|NCT02061800|Drug|Tacrolimus|Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
75880358|NCT02061800|Drug|Melphalan|Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
75880359|NCT02061800|Drug|Busulfan|Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
75880360|NCT02061800|Drug|Fludarabine|Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
75880361|NCT02061800|Drug|Methylprednisolone|Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
75880362|NCT01354795|Procedure|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
75880363|NCT01354795|Procedure|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
75433683|NCT01539603|Device|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
75880364|NCT01350817|Drug|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
75433684|NCT01539603|Device|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
75580527|NCT03593395|Other|Structured Education Based Transition Program STE|Education-based program
75433685|NCT01539616|Drug|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
75580528|NCT03579680|Behavioral|ADT ORDER CHECK ATTESTATION (OR)|Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior.
75580529|NCT03579680|Behavioral|PROVIDER SCRIPT (SC)|The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior.
75580530|NCT04501328|Behavioral|CIC+VA-CRAFT|CIC+VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
75580531|NCT04501328|Behavioral|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
75580532|NCT03566017|Drug|pegunigalsidase alfa|Recombinant human alpha galactosidase A
75580533|NCT03555279|Behavioral|PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm|HIV Prevention Behavioral Health Intervention delivered by Probation Staff
75580534|NCT03555279|Behavioral|PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm|HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
75880365|NCT01350817|Drug|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
75880366|NCT02063438|Procedure|Pericostal suture technique|
75880367|NCT02063438|Procedure|Intracostal suture technique|
75880368|NCT01986075|Behavioral|Computer-assisted behavior therapy|TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
75880369|NCT01986075|Drug|Mixed-Amphetamine Salts- Extended Release (MAS-ER)|80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT
75880370|NCT01986075|Drug|Placebo|Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
75880371|NCT04753710|Drug|Ocular gel|Instillation
75880372|NCT02061878|Drug|Bexarotene|Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
75880373|NCT02061878|Drug|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
75433686|NCT01539616|Drug|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
75433687|NCT01539616|Drug|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
75433688|NCT01539616|Drug|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
75433689|NCT01539629|Device|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
75433690|NCT01539655|Drug|vandetanib|Oral tablets, 300 mg, single dose
75433691|NCT01539655|Drug|omeprazole|Oral capsules, 40 mg, multiple doses
75433692|NCT01539655|Drug|ranitidine|Oral tables, 150 mg, multiple doses
76050817|NCT03906409|Other|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
76050818|NCT03903874|Behavioral|Deep south Interactive voice response system supported Active Lifestyle (DIAL)|12 months of automated telephone physical activity counseling with community health worker support
76050819|NCT03897621|Drug|Tranexamic Acid|tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
75580535|NCT03548467|Biological|VB10.NEO|VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).
75580536|NCT03548467|Drug|Bempegaldesleukin|0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
75880374|NCT01358617|Other|diagnostic laboratory biomarker analysis|Correlative studies
75880375|NCT00394355|Drug|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
75580537|NCT03525990|Other|Questionnaires|Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
75880376|NCT00394355|Drug|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
75880377|NCT00394355|Drug|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
75580538|NCT03490669|Biological|MSC-1|humanized monoclonal antibody for intravenous administration
75880378|NCT00394355|Drug|montelukast|10 mg given once daily in the evening by mouth for 1 year.
75729021|NCT05282212|Diagnostic Test|Ultrasound Scan|Within 90 days before the revision surgery, a calibrated examiner will ultrasonically scan the implants. The ultrasound device has been validated for its usability and design on human subjects in our recent clinical study (the University of Michigan Institutional Review Board under the number HUM00139630 and was registered with the National Institutes of Health U.S. National Library of Medicine database for clinical trials (clinicaltrials.gov) under the following identifier: NCT03558282) Coupling will be achieved with commercially available sterilized US gel (Sterile Aquasonic, Fairfield, NJ). The US probe will be mounted on an adjustable arm attached to a fixed stand. The probe is navigated by a calibrated examiner at the implant of interest and then will execute a total ±5 mm linear mesio-distal and coronal-apical translations to create 3D cross-sectional and transverse volumes, respectively and stored as an imageframe series, i.e., a DICOM format cineloop.
75880379|NCT01822743|Procedure|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
75880380|NCT01822743|Procedure|sham comparator|
75880381|NCT02797808|Drug|Sertraline|Impact of sertraline on functional brain connectivity
76050820|NCT03897621|Drug|Placebo|Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
76050821|NCT03882671|Device|EpiTel Epilog|EEG recording device
75880382|NCT02797808|Other|No Intervention|Healthy control non-intervention
75880383|NCT01800669|Other|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
75880384|NCT01800669|Other|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
75580539|NCT03456882|Drug|RNS60|normal saline plus oxigen in nanobubble
75580540|NCT03433807|Drug|Idebenone|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
75729022|NCT05272813|Drug|MS-553|MS-553
76024887|NCT02004262|Drug|Chemotherapy|Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
76024888|NCT02004262|Drug|cyclophosphamide|
76024889|NCT05117411|Diagnostic Test|OCTA and pseudophakin cystoid edema|Patients underwent OCT angiografia after cataract surgery
76024890|NCT01675427|Other|Interleukin 28B testing|Blood sampling for ILB28 genotyping
76024891|NCT02394067|Other|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
76024892|NCT03166267|Device|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
76024893|NCT02393833|Procedure|Blood samples collection|"Blood samples to be collected at the following time points:~Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~Months 12, 18 and 36 after start of induction chemotherapy~At time of confirmatory evidence of progression"
76024894|NCT02393599|Drug|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
76024895|NCT02393599|Drug|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
75880385|NCT05251025|Other|Passive sustained stretching|"The Group A received Passive Stretching Technique. Along with the Passive Stretching Technique, this group also received certain conventional treatments which included resistive exercises, gait training exercises, bridging and exercises in other functional positions were also undertaken by the included individuals.~All the exercises mentioned above were performed for 30 minutes and there was not any specific division of time for all these mentioned activities. The patients used to perform these conventional treatments and exercises on their motor control basis. The exercises were performed for 30 minutes and been done for 5 days in a week for consecutive 6 weeks."
75880386|NCT05251025|Other|Myofascial Release|The Group B received Myofascial Release Technique and along with conventional treatments. The Myofascial Release Technique for hamstrings was given to the patient in prone position. The technique was applied either by the crossed hands or thumbs. This total treatment was given for 30 minutes consecutively. After the technique the Myofascial structures were stretched and then were hold for straight 120 seconds so that the tissues get softened. The technique was given to patients with 6 repetitions and with a hold for 120 seconds. The treatment was continued for 5 days a week for straight 6 weeks.
76050822|NCT03882671|Device|Empatica E4|PPG, sweat level, temperature and accelerometry recording device
76050823|NCT03882671|Device|GENEActiv|Temperature, light level and accelerometry recording device
76050824|NCT03880656|Biological|Intramuscular administration of autologous BM-MNCs|Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
75433693|NCT01539681|Drug|Sorafenib (Nexavar, BAY43-9006)|Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
75433694|NCT01539707|Drug|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
75433695|NCT01539720|Drug|Ulipristal acetate|30 mg tablet
75729023|NCT05267587|Radiation|Hypofractionated Stereotactic Radiosurgery|Participants will be given hypofractionated stereotactic radiosurgery (fSRS) in 9 Gray Units (Gy) per fraction x 3 consecutive daily fractions (27 Gy total) to the index metastasis that will be resected.
75729024|NCT05265364|Radiation|IMRT with SIB|moderate hypofractioation using 2.5gy/fr in prostate cancer patients usig IMRT SIB technique
75433696|NCT01539720|Device|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
75433697|NCT01539733|Drug|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
75433698|NCT01539733|Drug|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
75580541|NCT03416179|Drug|glasdegib|"Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
75729025|NCT05263180|Biological|EMB-09|EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
75729026|NCT05260671|Drug|Penpulimab combined with cetuximab|PD-1 antibody combined with EGFR inhibitors, biweekly
75433699|NCT01539785|Procedure|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
75880391|NCT02796560|Drug|Brand name travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
75880392|NCT02796560|Drug|Generic travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
76050825|NCT03874507|Other|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
76050826|NCT03859167|Other|Stress Test|Participants will reach maximum exercise on a treadmill and results will be collected and recorded.
76050827|NCT03849118|Diagnostic Test|89Zr-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
76050828|NCT03846726|Procedure|standard TME surgery|radical resection for rectal cancer
76050829|NCT03821506|Device|Dynamic Light|Dynamic Lighting system
75433700|NCT01539785|Procedure|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
75433701|NCT01539798|Other|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
75880393|NCT01316081|Dietary Supplement|Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine|"Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets"
76050830|NCT03821506|Device|Usual care|Standard lighting system
76050831|NCT03819192|Diagnostic Test|microbiome analysis|"From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~directly after hospitalization~5-7 days after beginning of antibiotic treatment~24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium."
76050832|NCT03819192|Diagnostic Test|Conventional cultures|For every sample taken for microbiome analysis, a conventional culture is taken as control.
76050833|NCT03819192|Diagnostic Test|CAAP48 measurement|CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).
75880394|NCT05735301|Procedure|Endovascular therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA"
75880395|NCT05735301|Drug|Drug|Drug conservative therapy could be uesd in patients who with no indication of surgery
75880396|NCT02062970|Biological|blood draw|
75880397|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
75880398|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
75880399|NCT02063048|Behavioral|Text Message Based Weight Loss Support|
75880400|NCT05007405|Other|Groups/Cohortes|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
75880401|NCT01343069|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
75433702|NCT01539798|Other|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
75880402|NCT03560492|Other|Exercises|5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
75880403|NCT03560492|Device|Posture garment|Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
75880404|NCT01343147|Other|Microwave diathermy|Deep tissue heating via microwave diathermy
75880405|NCT01343147|Other|Superficial hyperthermia|Superficial heating via hot pack application
75880406|NCT05210127|Procedure|Scarf osteotomy for Hallux Valgus deformity|An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol
75880407|NCT01345331|Behavioral|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
75880408|NCT02062034|Drug|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
75880409|NCT02062034|Drug|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
75880410|NCT02062034|Drug|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
75880411|NCT03620357|Device|CGM|CGM Group: Dexcom G6 CGM
75880412|NCT03620357|Device|SMBG|SMBG Group: Blood Glucose Meter
75880413|NCT02063594|Drug|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
75880414|NCT02063594|Drug|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
75880415|NCT00344487|Drug|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
76050834|NCT03809884|Behavioral|Dietary Counselling|Individually tailored strategy to increase potassium in the diet.
76050835|NCT03809884|Drug|Potassium Citrate|Dosing of 50 to 100 mmol of potassium citrate per day (as 25 to 50 ml of the liquid solution).
76050836|NCT03804138|Other|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
75580542|NCT03416179|Drug|daunorubicin + cytarabine|"'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');"
76050837|NCT03785366|Drug|VeraCept|VeraCept Intrauterine Device (IUD)
76050838|NCT03785366|Drug|ParaGard|ParaGard intrauterine copper contraceptive
75433703|NCT01539824|Biological|Mycobacterium obuense|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
75880416|NCT03789968|Drug|bictegravir/emtricitabine/tenofovir alafenamide|Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
75433704|NCT01539824|Radiation|SBRT|The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
75880417|NCT05089643|Drug|Anlotinib|Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.Continuous oral administration for 2 weeks stopped for 1 week, that is, 3 weeks (21 days) as a treatment cycle, until disease progression or adverse reactions become intolerable.In case of missing medication, confirm that the time before the next medication is less than 12 hours, no refill.
75880418|NCT05089643|Drug|Capecitabine|Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
75880419|NCT02871492|Drug|Pritelivir 5% w/w ointment|
75880420|NCT02871492|Drug|Pritelivir ointment matching placebo|
75880421|NCT02871492|Drug|Zovirax® cream|
75580543|NCT03416179|Drug|azacitidine|Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
75880422|NCT01345487|Other|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
75880423|NCT01345487|Other|Animal protein|Protein in the form of minced pork/beef
75880424|NCT02063126|Dietary Supplement|ReConnect (NADH plus CoQ10)|"ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)"
75880425|NCT02063126|Dietary Supplement|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
75880426|NCT04959435|Other|biological samples collection|samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa
75880427|NCT02032056|Dietary Supplement|Probiotic (10^9 CFU/day)|
75580544|NCT03416179|Drug|Placebo|"Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
75880428|NCT02032056|Dietary Supplement|Probiotic (10^8 CFU/day)|
75880429|NCT02032056|Other|Placebo|
75880430|NCT05591300|Diagnostic Test|Microparticles research|The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).
75880431|NCT03615612|Other|QuickSee refractive error assessment + glasses|QuickSee refractive error assessment + glasses
75880432|NCT02063750|Other|strengthening exercises using a Swiss ball|"This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM)."
75433705|NCT01539850|Device|OMS102|Subjects will receive implanted OMS102 System.
75433706|NCT01539876|Procedure|Fine needle aspiration assessing tumour TNFa levels|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
75880433|NCT02063750|Other|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
75880434|NCT05209113|Other|Education|A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
75880435|NCT03143855|Drug|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
75880436|NCT03143855|Drug|Placebo|Placebo will be administered twice daily for for 5 days
75880437|NCT03615456|Procedure|Conventional thyroidectomy|Thyroid vessels are ligated with sutures and divided
75880438|NCT03615456|Procedure|Harmonic scalpel thyroidectomy|Thyroid vessels are sealed using harmonic scalpel device
75880439|NCT02878603|Biological|Caplacizumab|
75880440|NCT02878603|Other|Standard of Care|• PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
75880441|NCT03613974|Drug|Lidocaine|patients will receive different lidocaine concentrations
75880442|NCT01343225|Drug|atripla|once a day
75433707|NCT01539889|Radiation|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
75433708|NCT01539902|Biological|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
75880443|NCT01343225|Drug|darunavir ritonavir raltegravir|as directed
76050839|NCT03768427|Combination Product|EZ 10 mg/Ator 10 mg|FDC of EZ10 mg/Ator 10mg
75433709|NCT01539902|Drug|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
75433710|NCT01539915|Drug|BCT194|Topically applied BCT194 cream (0.5%)
75580545|NCT03416179|Drug|Placebo|Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
75580546|NCT03416179|Drug|glasdegib|"Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.~Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first."
75880444|NCT01317251|Other|Dietary intervention (without dairy products)|Control diet without dairy products
75880445|NCT01317251|Other|Dietary intervention (high milk content)|Diet with a high content of milk (~1200 mg Ca/d from milk)
75880446|NCT01317251|Other|Dietary intervention (high cheese content)|Diet with a high content of cheese (~1200 mg Ca/d from cheese)
75880447|NCT05078333|Other|dry needle|dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
75880448|NCT05078333|Device|high intensity laser therapy|High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
75880449|NCT04736511|Other|Star Excursion Balance Test|"The subject will be in unipodal support (only one foot on the ground) on the tested lower limb in the center of the platform. Three lines forming a Y will be arranged according to the lower limb in charge in three directions : anterior (ANT), posteromedial (PM) and posterolateral (PL). The goal is then to reach the longest distance possible in all three directions with the tip of the foot in relief before returning to the starting position. The subject will have 4 training trials per direction on each lower limb then 3 trials will be recorded in order to keep the average."
75880450|NCT04736511|Other|Single leg Drop Vertical Jump|The subject will drop from a step and land on one leg, then jump as high as possible and stabilize again on the same leg. The height of the step is 30 cm. The subject will perform 3 consecutive jumps in the strictest respect of the instructions: drop to the level of the mark on the ground and bounce as high as possible while spending a minimum of time on the ground. The subject must stabilize for 3 seconds during the second contact with the ground so that the instructions and measurements are reproducible.
76050840|NCT03768427|Combination Product|EZ 10 mg/Ator 20 mg|FDC of EZ10 mg/Ator 20mg
76050841|NCT03768427|Drug|Atorvastatin|Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
75433711|NCT01539928|Other|Dual FDG-PET/CT|Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
76050842|NCT03768427|Drug|Placebo for FDC EZ/Ator|A single placebo tablet administered orally QD for 84 days
76050843|NCT03768427|Drug|Placebo for atorvastatin|Two placebo tablets matching atorvastatin administered orally QD for 84 days
75880451|NCT04736511|Other|Unplanned sidestep cutting manoeuvre|"The objective is to create an unanticipated playing situation, close to the daily actions of the subjects in the practice of handball. The subject will make sidestep cutting manœuvre in front of an opponent simulated by a dummy used during usual training.~The subject will sprint in a straight line and then at the force platform will make a rapid change of direction on the side of his shooting arm or will continue his run in a straight line. A light signal randomly will indicate to the player the direction in which he must carry out his manoeuvre. A computer reconstruction of the kinematics and dynamics (knee moment) will be performed."
76050844|NCT03758781|Drug|IRX 2|IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.
76050845|NCT03758781|Drug|Nivolumab|Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
76050846|NCT03747718|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
76050847|NCT03747718|Other|Placebo|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
76050848|NCT03746080|Drug|Plerixafor|Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
76050849|NCT03746080|Drug|Temozolomide|Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
75433712|NCT01539941|Behavioral|Medication integration protocol|MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
75433713|NCT01539967|Procedure|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~position of 4 trocars and insertion of a nasogastric tube~dissection and mobilization of the greater curvature of the stomach~preparation of the stomach for division~gastric partition~extraction of the gastric remnant~postoperative surveillance"
75433714|NCT01540006|Other|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
75433715|NCT01540019|Drug|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
75880452|NCT04736511|Other|Tendon vibration|The subject will be asked to stand, motionless in bipodal (both feet on the ground) support on a stable and unstable ground (foam). A tendon vibration (80Hz) will be randomly applied to the subject in the Achilles tendons or paravertebral muscles. This vibration will cause an alteration of proprioceptive information in the vibrated area leading to a disruption of postural balance. Thus, according to the amount of displacement of the center of pressure (CoP), the proprioceptive weighting ratio (dRPW) is calculated to deduce therefrom the weight assigned by the CNS to the various proprioceptive inputs during the postural task.
75880453|NCT05250635|Device|electronic stethoscope|It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
75880454|NCT01370408|Drug|Palonosetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
76050850|NCT03746080|Radiation|Whole-Brain Radiotherapy (WBRT)|Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
76050851|NCT03746080|Radiation|Radiation Therapy|Radiotherapy consists of 30 Gy in 15 fractions
76050852|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
75880455|NCT01370408|Drug|ondansetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
75880456|NCT01370408|Drug|Dexamethasone|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
75880457|NCT04769388|Drug|Osimertinib|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
75880458|NCT04769388|Drug|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
75880459|NCT01345565|Drug|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
75880460|NCT03294109|Drug|Abdominal wall block with liposomal bupivicaine|Abdominal wall block with liposomal bupivicaine
75433716|NCT01540032|Behavioral|Low salicylate diet|Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
75433717|NCT01540032|Behavioral|Normal diet|Patients will eat their usual diet.
75433718|NCT01540058|Other|Cancer Type ID test|"CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).~CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York."
75433719|NCT01540058|Other|No test Empiric strategy|Empiric strategy
75580547|NCT03416179|Drug|cytarabine|Consolidation with single agent cytarabine 3 g/m2 IV for adults <60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
75580548|NCT03416179|Procedure|HSCT|If required, and done per standard of care post Induction(s).
75580549|NCT03408964|Other|biological samples collection and analysis|Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
75580550|NCT03406767|Other|GLA:D Canada Program|The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
75880461|NCT01345643|Other|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
75880462|NCT01345643|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
75880463|NCT03517488|Biological|XmAb20717|Monoclonal bispecific antibody
75880464|NCT04727931|Behavioral|Neuropsychological assessement and questionnaires|Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
75880465|NCT02065466|Drug|nab-paclitaxel|
75880466|NCT02065466|Drug|Temozolomide|
75880467|NCT02065466|Drug|Bevacizumab|
75880468|NCT01358773|Other|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
75880469|NCT03970811|Procedure|Immediate Implants|dental implants are immediately placed after tooth extraction
75880470|NCT03970811|Procedure|temporary restoration|temporary restoration will be placed immediately after implant placement
75880471|NCT03970811|Procedure|final restoration|final restoration (loading) will be placed 3 months postsurgical
75880472|NCT02064062|Biological|Autologous Mesenchymal Stem Cells|
75880473|NCT03963869|Other|Malaria Camps|The Govt. of India Malaria Control Programme (MCP) of Odisha provides ITNs and IRS, and trains community health workers (ASHAs) on the diagnosis and treatment of malaria, providing them with antimalarial drugs so that malaria treatment is available even in remote villages. Faced with a persistent burden of malaria in forest villages, the MCP recently introduced malaria camps (MCs) combining focused screening and treatment in villages with intensified vector control. The program includes one round of testing and treatment for the whole village population before the monsoon season, followed by one round of screening and treating of fever cases only during the monsoon season.
75880474|NCT05208801|Drug|Percutaneous injection|A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
75880475|NCT05208801|Drug|Morphine|Intrathecal injection of morphine 400mcg
75880476|NCT05208801|Drug|Morphine+Bupivacaine|Intrathecal injection of 5mg of 0.5% bupivacaine chloride
75880477|NCT03614598|Procedure|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
75880478|NCT03614598|Procedure|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
75880479|NCT03614598|Procedure|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
75880480|NCT02064140|Drug|Rocuronium|
75880481|NCT03963011|Diagnostic Test|Bowel Ultrasound|Ultrasound imaging of the bowel
75880482|NCT03628755|Behavioral|Digital Manipulation of Thyroid cartilage|"Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60."
75880483|NCT03628755|Behavioral|Fluency Shaping Therapy|FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
75880484|NCT03628755|Behavioral|combination Group|combination group intervention of DMT + FST
75880485|NCT01355029|Behavioral|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
75433720|NCT01540084|Drug|propofol|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
75880486|NCT02065544|Behavioral|behavioral weight loss and exercise|Weight loss and exercise counseling
75880487|NCT05190627|Drug|Loratadine|Loratadine 10mg/day added to rapamycin for 12 months
76050853|NCT03724149|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
75433721|NCT01540110|Drug|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
75433722|NCT01540123|Dietary Supplement|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
75433723|NCT01540123|Dietary Supplement|Control|Sugar matched control containing berry flavouring and no phytochemicals
75433724|NCT01540136|Drug|Nedaplatin|Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
75580551|NCT03406767|Other|JointEffort Program|The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
75433725|NCT01540136|Drug|Cisplatin|Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
75580552|NCT03372902|Device|Breast MRI|Participants with dense breast tissue will get a mammogram and MRI
75580553|NCT03372902|Device|Breast Mammogram|State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.
75580554|NCT03372902|Other|Blood draw|Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.
75729027|NCT05253924|Diagnostic Test|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1, Piezo1, Piezo2, TRPV1 andTRPM8) will be investigated. Saliva sample will be collected for PT and FT. Genomic DNA will be extracted from aliquots of 0. 4 ml of each saliva sample with the Oragene OG575 (DNA Genotek) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
75880488|NCT05190627|Drug|Placebo 10mg/day added to rapamycin for 12 months|Placebo in the same type of capsule than the experimental drug
75580555|NCT03372902|Procedure|Breast Biopsy|Tissue specimens from the biopsy of the BI-RADS 4 mammographic lesion and (among women undergoing surgical excision) the surgical specimen(s) will be subjected to genomic profiling at GRAIL, Inc. or MSKCC. The tumor specimens from the participants diagnosed with cancer during the follow-up period will also undergo molecular profiling.
75580556|NCT03372902|Behavioral|online participant reported questionnaire|Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.
75580557|NCT03361215|Other|Biosampling for molecular analysis|Observational study with no therapeutic intervention. Biosampling for molecular analysis
75580558|NCT03349528|Biological|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily
75580559|NCT03349528|Biological|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
75880489|NCT02064218|Drug|Anti-hypertensive drugs|
75880490|NCT01345799|Drug|TRK-170|
75880491|NCT01345799|Drug|Placebo|
75880492|NCT03614520|Other|Administration of olive oil|25 mL of extra virgin olive oil
75880493|NCT03614520|Other|Administration of red wine|150 mL or Red Wine
75580560|NCT03338764|Drug|SM-1|SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
75880494|NCT03614520|Other|Combination of red wine and olive oil|150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
75880495|NCT03614520|Other|Water|Mineral water will be given as placebo
76050854|NCT03724149|Drug|Epclusa|Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
76050855|NCT03720002|Dietary Supplement|HF2|placebo
76050856|NCT03595228|Biological|BN-Brachyury plus radiation|MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
76050857|NCT03572933|Drug|ganaxolone|active drug
75580561|NCT03338764|Drug|Placebo|Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
75580562|NCT03313544|Drug|Nivolumab|NIVOLUMAB
75880496|NCT03614520|Other|Dark beer|250 mL of IPA beer (alcohol 8.5% vol)
75880497|NCT03614520|Other|Light Beer|250 mL of blonde ale beer (alcohol 4,5% vol)
75433726|NCT01540175|Other|Blood samples obtained|Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
75433727|NCT01540188|Behavioral|Family Intervention to Address Drug Use and HIV in Vietnam|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
75433728|NCT01540201|Other|Conventional I:E ratio|conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
76050858|NCT03572933|Drug|Placebo|inactive
75880498|NCT03614520|Other|Alcohol free Beer|250 mL of alcohol free beer (alcohol 0.0% vol)
75433729|NCT01540201|Other|I:E = 1:1 ratio|I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
75880499|NCT01358851|Procedure|Cryotherapy|1-2 times during the treatment time
75880500|NCT01358851|Drug|LAS41005|once daily
75580563|NCT03313544|Device|MRI|Cardiac MRI 6 MONTHS
75580564|NCT03313544|Biological|BLOOD SAMPLES|biological (BNP and troponin)
75580565|NCT03313544|Device|trans-thoracic echocardiography|1, 3 and 6 months
75880501|NCT02065778|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
75580566|NCT03309579|Other|Liberal RBC Transfusion Strategy|RBC transfusion is triggered by a Hemoglobin value of ≤100g/L
75580567|NCT03309579|Other|Restrictive RBC Transfusion Strategy|Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
75880502|NCT03619941|Dietary Supplement|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
75880503|NCT03619941|Dietary Supplement|Placebo|Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
75880504|NCT01343303|Drug|Placebo|Placebo tablet/capsule every 12 hours for 21 days
75880505|NCT01343303|Drug|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
75880506|NCT01343303|Drug|Naproxen|500 mg capsule every 12 hours for 21 days
75880507|NCT01343303|Drug|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
75880508|NCT03614442|Other|slopped shoulder implant|different implant design to enhance soft and hard tissue outcome
75880509|NCT04418115|Other|Acupuncture; based on Tradidtional Chinese Medicine|Acupuncture is a form of treatment that involves inserting very thin needles through a person's skin at specific points on the body, to various depths. Research suggests that it can help relieve pain, and it is used for a wide range of other complaints.
76050859|NCT03558152|Drug|UTTR1147A|UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
76050860|NCT03558152|Drug|UTTR1147A Placebo|The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
76050861|NCT03558152|Drug|Vedolizumab|Vedolizumab will be administered IV, as specified in the prescribing information.
76050862|NCT03558152|Drug|Vedolizumab Placebo|The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.
76050863|NCT03768999|Diagnostic Test|Non-contrast magnetic resonance coronary angiography (MRCA)|Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
75433730|NCT01540214|Other|Pre- and postoperative evaluations|"At baseline before surgery and at 6 and 12 months after surgery: questionnaires, bladder diary, pelvic examination with additional ultrasound (one extra outpatient clinic visit at 6 months compared to standard care).~At baseline before surgery and at 12 months after surgery: urodynamics with additional urine sampling (one extra outpatient clinic visit at 12 months compared to standard care).~At time of surgery: additional cystoscopy."
75433731|NCT01540227|Drug|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes"
75433732|NCT01540240|Drug|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
75433733|NCT01540240|Drug|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
75580568|NCT03251859|Drug|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
75580569|NCT03251859|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg daily
75580570|NCT03156660|Behavioral|Weight gain prevention (Group 1)|"Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~Daily self-monitoring of steps and number of Small Changes~Daily weight self-monitoring on the BodyTraceTM e-scale~Fit Bit Alta activity trackers to self-monitor steps"
75580571|NCT03156660|Behavioral|Weight loss intervention (Group 2)|"Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~Tailored calorie and fat goals based on their baseline weight.~Daily dietary intake and physical activity self-monitoring using a website or app.~Daily weight self-monitoring on the BodyTraceTM e-scale~Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~Fit Bit Alta activity trackers to self-monitor steps"
75580572|NCT03156660|Behavioral|Self-guided intervention (Group 3)|"Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~EatingWell Diet book.~Daily weight self-monitoring on the BodyTraceTM e-scale"
75580573|NCT03118349|Drug|MVT-1075|MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
75580574|NCT03118349|Drug|MVT-5873|MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
75880510|NCT01343381|Drug|Hepalean Heparin|400 units per kilogram bolus prior to initiation of CPB
75433734|NCT01540292|Biological|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
75433735|NCT01540305|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
75433736|NCT01540305|Device|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
75880511|NCT01343381|Drug|PPC Heparin|400 unit per kilogram bolus prior to initiation of CPB
75433737|NCT01540318|Procedure|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
75433738|NCT01540331|Device|"model 1000 PNT vacuum controller (the vacuum device for ocular suction)"|A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
75433739|NCT01540344|Procedure|CRS|complete macroscopic cytoreduction (CC-0/1)
75433740|NCT01540344|Drug|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
75580575|NCT03053115|Drug|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
75880512|NCT03620149|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Denosumab 120 mg, SC, on day 1 of every 12-week cycle
75880513|NCT02064686|Other|Exhaled breath temperature|
75880514|NCT03614286|Diagnostic Test|culture and pcr|The swab immersed in Diamond's Modified medium culture tube and squeezed for cultivation and examined daily with a light microscope to identify T. vaginalis Samples from culture will be placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample , and the preparation was mixed, incubated at room temperature for 10 min, and stored at -70°C until tested.
75880515|NCT04369755|Other|MRI|A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
75880516|NCT01343537|Other|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
75880517|NCT02064374|Drug|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
75880518|NCT02064374|Drug|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
75880519|NCT02064374|Drug|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
75880520|NCT03614208|Behavioral|Home-care rehabilitation group (HCRG)|The exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week.
75880521|NCT05188365|Other|true acupuncture|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
75880522|NCT05188365|Other|sham acupuncture|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days
76050864|NCT03482141|Device|Whole Exome Sequencing (WES)|The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
76050865|NCT03461406|Biological|Fibrin Sealant Grifols|The FE Grifols solution was applied topically via drip or spray application.
76050866|NCT03461406|Biological|EVICEL|The EVICEL solution was applied topically via drip or spray application.
75880523|NCT05061251|Drug|BAY 2402234|Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
76050867|NCT03431974|Drug|LD-Aminopterin oral capsule|anti-folate treatment
75580576|NCT03053115|Drug|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
75580577|NCT03053115|Drug|Placebos|Controls will take placebo two hours after dinner
75580578|NCT03049969|Device|tDCS stimulation|up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
76050868|NCT03431974|Drug|Placebo oral capsule|Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
76050869|NCT03416335|Drug|DSP-0509|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
75580579|NCT03003026|Other|Novel task-specific bike skills training program|Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.
75880524|NCT01351129|Drug|Formulation 1|150-mg immediate release tablet (single dose)
75880525|NCT01351129|Drug|Formulation 2|150-mg modified release capsule, short duration (single dose)
75880526|NCT01351129|Drug|Formulation 3|150-mg modified release capsule, long duration (single dose)
75580580|NCT03003026|Other|Parent-led home-based bike skills training program|The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
75880527|NCT02064452|Other|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
76050870|NCT03416335|Drug|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
75580581|NCT02932332|Other|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
75580582|NCT02932332|Other|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
75580583|NCT02932332|Other|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
76050871|NCT03416335|Drug|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
75580584|NCT02932332|Other|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
75580585|NCT02918409|Drug|Colistin|
75580586|NCT02918409|Drug|Tobramycin|
75880528|NCT02064452|Behavioral|Placebo Comparator|Enhanced Usual Community Care-Waitlist
75880529|NCT02236884|Procedure|no-scar transanal total mesorectal excision(TME)|
75880530|NCT01355263|Drug|iron and vitamin a|
75880531|NCT04415177|Device|EaseVRx headset with active intervention|VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.
75880532|NCT04415177|Device|EaseVRx headset without active intervention|VR software developed by AppliedVR with neutral non-interactive content.
75880533|NCT02065856|Biological|AVANZ Salsola|AVANZ Salsola
75880534|NCT03613428|Drug|Ruxolitinib|Dose escalation up to 80 mg administered orally
75880535|NCT03613428|Drug|Vincristine|1.4 mg/m2 i.v. weekly for 4 weeks
75880536|NCT03613428|Drug|Prednisone|1 mg/kg orally 5 consecutive days per week for 4 weeks.
76050872|NCT03408899|Drug|PC-1005 gel|PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
75433741|NCT01540357|Behavioral|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
75433742|NCT01540357|Behavioral|Treatment after waiting time|Treatment was performed after completion of the active arm.
75580587|NCT02901574|Device|Anodal or Cathodal tDCS|2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
75729028|NCT05253924|Diagnostic Test|EEG acquisition|Both PT and FT infants will have their EEG signal recorded during mother-baby interaction according to a modified version of the Still Face paradigm; the EEG signal will be recorded by means of the medical system eego mylab (AntNeuro), using special headphones equipped with 32 electrodes and suitable to acquire the EEG signal since early childhood. After spectral analysis of the EEG signal, the difference in signal strength in the alpha band recorded by two homologous electrodes (or electrode clusters) (i.e. right alpha - left alpha) will be calculated to obtain the FAA index. Because the alpha frequency band is associated with cortical inhibitory activity, a lower asymmetry reflects less left hemisphere activation than right hemisphere activation. The analysis of EEG data will be performed in MatLab environment using the eeglab software and algorithms developed ad hoc.
75729029|NCT05233527|Procedure|Episiotomy Closure|indicated episiotomy with Novosyn® Quick after spontaneous vaginal delivery
75880537|NCT03290521|Procedure|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
76050873|NCT03348956|Diagnostic Test|EPR Oximetry|Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
76050874|NCT03328546|Other|Dietary intake|Dietary intake converted into dietary pattern scores.
75880538|NCT03290521|Procedure|No washing|no washing
75880539|NCT02065934|Other|cardio-pulmonary resuscitation|
76050875|NCT03311308|Drug|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
75880540|NCT01343615|Procedure|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
75433743|NCT01540383|Behavioral|Intensive integrative aphasia therapy|Intensive language therapy (3 weeks, 5 days/week, >=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment
75433744|NCT01540383|Behavioral|Waiting list control group|Control group starts intensive language therapy after a 3-week waiting period.
75433745|NCT01540396|Behavioral|Dietary modification and medications|Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
75433746|NCT01540435|Drug|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
75580588|NCT02901574|Device|Sham|2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
75880541|NCT01343615|Procedure|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
75880542|NCT03613350|Diagnostic Test|Pad test|20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.
75880543|NCT02064530|Drug|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
75880544|NCT02064530|Drug|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
75880545|NCT02064530|Drug|serum physiologic|21 ml serum physiologic is applied interfasially
75880546|NCT01358929|Drug|Placebo|Placebo to RO6807952
75880547|NCT01358929|Drug|RO6807952|Escalating subcutaneous dose
75880548|NCT01345877|Procedure|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
75880549|NCT01568229|Drug|AMG 747|Three dose levels once-daily oral administration
75880550|NCT01568229|Drug|Placebo|Once-daily oral administration
75880551|NCT03613896|Procedure|conventional dentures|conventional dentures
75880552|NCT03613896|Procedure|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
75880553|NCT02066012|Other|dysmetabolic iron overload syndrome|
75580589|NCT02901574|Behavioral|Computerized naming therapy|Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
75880554|NCT05384028|Other|Nurse -led case management|This study would apply case management to the whole course management of AMI patients from admission to 6 months after discharge. Pharmacists, nutritionists, rehabilitation specialists and psychiatrists led by nurse would take the initiative to conduct individualized assessment and health guidance, and case managers would participate in the whole process of inpatient diagnosis and treatment. Coordinating multidisciplinary medical resources to jointly implement diagnosis and treatment and rehabilitation for patients can improve the quality of care.
75880555|NCT05384028|Other|Routine inpatient care and post-discharge follow-up management|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
75580590|NCT02868450|Biological|Blood Sample|
75729030|NCT05233371|Other|Parenting Stress Index (PSI)|"collected by self-questionnaire during the follow-up carried out within the framework of the usual care (at 4, 9, 24 months of corrected age, +/- 18 months according to the neurodevelopmental evolution).~Parental stress will be measured at each visit with the same parent (father or mother)."
75880556|NCT01355341|Drug|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
75729031|NCT05233371|Other|Collection of health care consumption|"Type and number of health professionals consulted between the different visits scheduled as part of the usual follow-up of the Dijon Bourgogne University Hospital,~Frequency and duration of rehabilitation sessions by type of health professionals,~Follow-up methods (institutional or private),~Consumption of care will be evaluated by means of self-questionnaires given to parents during follow-up consultations as part of the usual care."
75433747|NCT01540448|Procedure|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
75580591|NCT02868411|Other|Rectal Swab|
75580592|NCT02868346|Other|Anal swab|
75580593|NCT02866565|Drug|adipose-derived regenerative cells (ADRCs)|injection of the experimental treatment
75580594|NCT02866201|Other|Rectal swab|
75880557|NCT02066090|Device|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
75880558|NCT02066090|Device|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
75880559|NCT01351207|Other|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
75880560|NCT05250557|Diagnostic Test|Fractional flow reserve|Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
75880561|NCT03613194|Procedure|Sampling|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~Peritoneal liquid~none tumoral peritoneum~Portal blood~Peripheral blood~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
75880562|NCT04519437|Drug|REGN10933+REGN10987|Administered subcutaneous (SC) every 4 weeks (Q4W)
75880563|NCT04519437|Drug|Placebo|Administered subcutaneous (SC) every 4 weeks (Q4W)
75880564|NCT02064608|Drug|AZD2014|mTOR inhibitor
76024896|NCT02393599|Drug|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
75433748|NCT01540448|Procedure|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
75433749|NCT01540448|Procedure|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
75433750|NCT01540461|Drug|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
75433751|NCT01540500|Drug|Tasimelteon|5.66 mg dose on Day 1 and Day 8
75433752|NCT01540500|Drug|Fluvoxamine|50 mg Dose on Days 2-8
75433753|NCT01540526|Drug|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
75580595|NCT02861768|Biological|Pharyngeal swab|
75729032|NCT05233371|Other|Assessment of parent satisfaction|"their level of information, their child's follow-up, and the support provided by the professionals.~Satisfaction will be evaluated by means of a self-questionnaire (Likert scale) given to parents during follow-up consultations as part of their usual care."
75433754|NCT01540539|Drug|REGN1154 or placebo|Participants will receive active drug or placebo
75433755|NCT01540552|Other|medical chart review|
75433756|NCT01540552|Procedure|computed tomography|
75580596|NCT02859792|Drug|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
75580597|NCT02859792|Drug|Placebo|placebo capsules 25 or 50 mg
75580598|NCT02859792|Biological|Blood Samples|v1;v2;v3;v4
75580599|NCT02858687|Other|Nasopharyngeal swab|
75580600|NCT02858661|Other|Nasopharyngeal swab|
75580601|NCT02858609|Other|Nasopharyngeal Swab|
75729033|NCT05223413|Device|RIPC|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to 200 mmHg to stop blood flow in the arm.
75580602|NCT02851771|Other|Nasopharyngeal Swab|
75729034|NCT05223413|Device|Simulated RIPC (Sham)|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to a low pressure not stopping blood flow in the arm.
75580603|NCT02846753|Procedure|trans catheter heart valve replacement|trans catheter heart valve replacement
75580604|NCT02842333|Other|Additional biological samples|Blood samples
76050876|NCT03311308|Drug|Metformin|500 mg, by mouth, twice a day for nine weeks.
75880565|NCT04299997|Other|Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.|"Ass of targeted suspect lesions~On each mpMRI,radiologist will contour lesions that were targeted at subsequent biopsy based on reports. Contours will be disclosed to readers who will assess,for each lesion:~Likert score(gut feelingie subjective ass of the likelihood that lesion is clinically significant prostate cancer(5-level scale))~PI-RADSv2, PI-RADSv2.1 score(by strictly applying the published PI-RADS criteria)~EPE score(ie the likelihood of extraprostatic extension;5-level subjective scale without predefined criteria)~Max diameter~Def of add suspect lesions Readers could define suspectadditional targets(AT);for each AT,they will provide the same criteria. It is expected that, for these suspect AT,at least one score is≥3~Ass of lobes Scores of prostate lobes will be automatically calculated based on 2 previous steps of reading. However,in lobes with no suspect lesion,readers could define whether same criteria are1or2,in peripheral zone and transition zone"
75880566|NCT03613584|Drug|Von Willebrand Factor|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
75880567|NCT03613584|Drug|Saline Solution|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
75880568|NCT03907943|Procedure|carotid endarterectomy|Surgical treatment of ICA stenosis.
75880569|NCT02066246|Device|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
75880570|NCT02066246|Device|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
75880571|NCT01359085|Drug|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
75880572|NCT01359085|Procedure|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
75880573|NCT04280523|Drug|ESR-specific PET scan|Lung ESR Density by PET: Investigators will use 18F-FES as an estrogen receptor (ESR)-specific PET tracer to determine lung ESR density. 18F-FES will be prepared according to published methods. Briefly, all subjects will be evaluated by PET imaging, using standardized protocols. Blood will be obtained just before FES injection to measure the endogenous estrogen level [estradiol (E2)], to rule out pregnancy in female patients, and some reserved for future studies of mechanism. Approximately 6 mCi (222 MBq) of 18F-FES will be administered intravenously over 1~2 minutes, with scanning initiated 1 hour after administration of the tracer. Emission scans will be performed of the chest. A multimodality computer platform (Syngo; Siemens) will be used for image review and manipulation.
75880574|NCT05384184|Procedure|Tumor /metastases removal|Tumor /metastases removal
75880575|NCT04322357|Drug|Prednisone|A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
75880576|NCT04322357|Behavioral|In-home Exercise Training|For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.
75880577|NCT04322357|Drug|Prednisone plus exercise|Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
76024897|NCT02393365|Other|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
75580605|NCT02828085|Biological|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
75580606|NCT02827175|Other|blood sample|
75580607|NCT02822807|Biological|Blood sampling|
75580608|NCT02820623|Behavioral|Self-report|
75580609|NCT02820623|Behavioral|Chart-Stimulated Recall|
75580610|NCT02820623|Behavioral|Behavioral Rehearsal|
75433757|NCT01540552|Procedure|computer-aided detection/diagnosis|
75433758|NCT01540578|Other|laboratory biomarker analysis|Correlative studies
75433759|NCT01540591|Drug|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
75880578|NCT01351285|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
75880579|NCT05189041|Other|Aneurysmal pulsation in functional MRI|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
75880580|NCT02032290|Procedure|Assessment of Coronary Flow Reserve|
75880581|NCT02032290|Procedure|Percutaneous coronary intervention|
75880582|NCT02032290|Drug|ticagrelor loading|
75880583|NCT02032290|Drug|Clopidogrel loading|
75880584|NCT01317329|Other|Clinically prescribed CPAP therapy|CPAP as prescribed by attending physician
75880585|NCT03560180|Diagnostic Test|Dutch score|leakage score (DUtch LeaKage, DULK), that consider several items (fever, heart rate, respiratory rate, urinary production, mental status, clinical conditions, signs of ileus, gastric retention, fascial dehiscence, abdominal pain, wound pain, leukocytosis, CRP, increase of urea or creatinine and nutrition status), to give a score
75433760|NCT01540591|Drug|Saline|Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
75433761|NCT01540604|Drug|CRD007|
75880586|NCT03560180|Diagnostic Test|Serum C-reactive Protein|see study protocol
75880587|NCT03560180|Diagnostic Test|serum Procalcitonin|see study protocol
75880588|NCT01351363|Device|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
75880589|NCT01351363|Device|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
75880590|NCT05384106|Dietary Supplement|(R)-1,3-butanediol|Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
75880591|NCT05050565|Behavioral|Experiences of stigma and psychological flexibility in chronic pain participants|Chronic pain participants will answer questionnaires at two points in time, two weeks apart. These questionnaires ask about stigma and psychological flexibility, as well as depression, catastrophizing, pain interference, and social adjustment. The data collected is only observational and does not include any intervention.
75880592|NCT03379428|Drug|Trastuzumab|8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
75880593|NCT03379428|Drug|Ibrutinib 560 mg|560 mg by mouth daily
75880594|NCT03379428|Drug|Ibrutinib 840 mg|840 mg by mouth daily
75433762|NCT01540643|Device|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
75580611|NCT02819232|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
75880595|NCT03379428|Drug|Ibrutinib 420 mg|420 mg by mouth daily
75880596|NCT03132805|Behavioral|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
75880597|NCT03132805|Behavioral|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
75433763|NCT01540656|Device|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|"A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
75880598|NCT03628131|Drug|Pazopanib|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
75880599|NCT03628131|Drug|Ifosfamide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
75880600|NCT03628131|Drug|Carboplatin|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
75880601|NCT03628131|Drug|Etoposide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
75880602|NCT02067884|Procedure|dynamic contrast-enhanced ultrasound imaging|Undergo CEUS
75433764|NCT01540669|Dietary Supplement|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
75433765|NCT01540669|Dietary Supplement|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
75433766|NCT01540669|Dietary Supplement|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
75433767|NCT01540669|Dietary Supplement|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
75433768|NCT01540682|Drug|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
75580612|NCT02819206|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
75880603|NCT02067884|Procedure|shear wave elastography|Undergo SWE
75880604|NCT02067884|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Participant will receive contrast agent by intravenous administration
75580613|NCT02819128|Other|Swabs skin, pharyngeal, and blood sample|Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).
75880605|NCT02067884|Device|Philips Shear Wave Elastography|Equipment used for SWE
75880606|NCT01317485|Procedure|Laparoscopic lavage and drainage|"[CLOSED] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~***This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
75880607|NCT01317485|Procedure|Sigmoidectomy with primary anastomosis|[OPEN] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
75580614|NCT02819128|Other|Collection of body lice|For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.
75580615|NCT02816307|Other|blood samples|
75880608|NCT01317485|Procedure|Sigmoidectomy with end-colostomy|[OPEN] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
75580616|NCT02774005|Drug|Idebenone|
75880609|NCT03612882|Other|Online questionnaire|Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
75880610|NCT03560024|Other|PACAP27|PACAP27 is vasodilator of cerebral vessels
75880611|NCT03560024|Other|Placebo|Saline
75880612|NCT05102643|Biological|SARS-CoV-2 DNA Vaccine|A novel vaccine developed for prophylaxis of COVID-19 based on HKU's PD-1-based DNA vaccine platform. It encodes a recombinant antigen comprising a soluble human PD-1 domain (i.e. programmed cell death protein, a member of the Cluster of Differentiation 28 (CD28) family) and the receptor binding domain (RBD) of SARS-CoV-2 (i.e. the key viral entry element).
75433769|NCT01540682|Drug|Cetuximab|~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
75433770|NCT01540682|Radiation|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of ~70 Gy.
75580617|NCT02747849|Device|TENS|Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
75880613|NCT05102643|Biological|Matching placebo|Solution for intramuscular injection
75580618|NCT02700828|Drug|Hydrocortisone|4 * 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
75580619|NCT02700828|Drug|Placebo|4 * 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
75880614|NCT01351441|Behavioral|Medication adherence consultation|Patients will be counseled in person on day 0 then telephonically every month after until day 365.
75580620|NCT02695771|Drug|Mitomycin C|Cancer chemotherapeutic agent
75580621|NCT02695771|Drug|Gemcitabine|Cancer chemotherapeutic agent
75580622|NCT02658032|Behavioral|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
75580623|NCT02658032|Behavioral|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
75880615|NCT01351441|Other|Medication problems assessment|Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
75880616|NCT01351441|Other|Beer's Criteria Assessment|The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
76050877|NCT03308006|Biological|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
76050878|NCT03279393|Drug|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
76050879|NCT03270098|Behavioral|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
76050880|NCT03270098|Behavioral|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
75580624|NCT02658032|Other|standard care|
76050881|NCT03266471|Diagnostic Test|Baseline blood sample|Blood sample for cytokine measurements and genetics.
76050882|NCT03266471|Diagnostic Test|Baseline intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
76050883|NCT03266471|Other|Crohn's disease activity index (CDAI)|To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.
76050884|NCT03266471|Diagnostic Test|Post treatment blood sample|Blood sample for cytokine measurements after patients have been on therapy for at least 6 weeks but no more than 52 weeks.
76050885|NCT03266471|Diagnostic Test|Post treatment intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 6 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
75580625|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
75580626|NCT02462460|Device|MRI|
76050886|NCT03266471|Diagnostic Test|Baseline stool sample|Stool sample for inflammatory markers or microbiome analysis.
75580627|NCT02462460|Behavioral|Optional Screening Questionnaire|
75580628|NCT02339701|Radiation|IMRT|
75580629|NCT02339701|Radiation|SBRT|
76050887|NCT03266471|Diagnostic Test|Post treatment stool sample|Stool sample for inflammatory markers or microbiome analysis.
75580630|NCT02209142|Other|blood prelevement|blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
75580631|NCT02209142|Other|psychometric data collection|
75580632|NCT02200276|Biological|Influenza|
75580633|NCT02190305|Device|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
75580634|NCT02167711|Drug|SIRT Yttrium-90|
75729035|NCT05221931|Procedure|Percutaneous coronary intervention|1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent [Boston Scientific, USA], Prevail [Medtronic, USA], or SeQuent Please, SeQuent Please NEO [B-Braun, Germany])
76050888|NCT03179449|Diagnostic Test|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
76050889|NCT03179449|Procedure|Surgery|Undergo surgical resection
76050890|NCT03179449|Drug|Ferumoxytol|Given IV
76050891|NCT03179449|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
75580635|NCT01975428|Device|DM Pgm + device|"Disease management program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
75580636|NCT01975428|Behavioral|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
75580637|NCT01941641|Drug|neoadjuvant FOLFOXIRI|
75580638|NCT01941641|Drug|Capecitabine|
75580639|NCT01792934|Drug|XELOX regimen according to standard procedures|
75880617|NCT01351441|Behavioral|Health Literacy Assessment|Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
75880618|NCT02260232|Other|exercise training|
75880619|NCT01319227|Procedure|Hip replacement|Hip arthroplasty with uncemented components
75880620|NCT02067962|Biological|Blood sample|Blood sample
75580640|NCT01792934|Drug|FOLFOX regimen according to standard procedures|
75880621|NCT03613272|Procedure|Subxiphoid approach extended thymectomy by VATS|Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
75880622|NCT03613272|Procedure|Intercostal approach extended thymectomy by VATS|Extended thymectomy performed through the traditional intercostal VATS approach
75880623|NCT05250479|Behavioral|Mindfulness education|44 primiparous pregnant women will receive mindfulness education
75880624|NCT01355653|Device|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
76050892|NCT02978196|Procedure|Injection of 99m-Tc-NM-01|Patient is injected with micro-dose of 99m-Tc-NM-01
75580641|NCT01792934|Procedure|Surgery|
75880625|NCT01355653|Device|marketed heatwrap|heatwrap, topical, one time application, 8 hour duration
75580642|NCT01792934|Other|radiofrequency ablation (RFA)|
75880626|NCT05033223|Other|PTSD evaluation of emergency room staff 9 and 12 months after the end of second lockdown in France during COvid-19 pandemic|PCL-5 autoquestionnaire to make the PTSD diagnosis
75880627|NCT02032368|Procedure|transarterial chemoembolization (TACE)|
76050893|NCT02915744|Drug|NKTR-102|
76050894|NCT02915744|Drug|Eribulin|
76050895|NCT02915744|Drug|Ixabepilone|
76050896|NCT02915744|Drug|Vinorelbine|
75580643|NCT01792934|Other|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
75580644|NCT01792934|Radiation|stereotactic body radiation therapy (SBRT)|
75580645|NCT01792934|Drug|Bevacizumab|may be added to both regimens according to standard procedures
75580646|NCT01792934|Procedure|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
75580647|NCT01751438|Other|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
75580648|NCT01751438|Other|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
75580649|NCT01751438|Behavioral|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
75580650|NCT01751438|Other|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
75580651|NCT01669915|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
75580652|NCT01669915|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
75580653|NCT01669915|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
75580654|NCT01669915|Dietary Supplement|Fish oil placebo|Fish oil placebo
75880628|NCT01351519|Drug|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
75880629|NCT03612492|Drug|Esmolol|Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
75880630|NCT03612492|Drug|Lidocaine|Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
75880631|NCT04970199|Device|laser application on acupoints|laser acupuncture
75880632|NCT05250401|Diagnostic Test|liver functions and thyroid functions|laboratory tests
75880633|NCT03612414|Dietary Supplement|Aqualief|Three tablets/day
75880634|NCT03612414|Dietary Supplement|Placebo|Three tablets/day
75880635|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
75880636|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
75880637|NCT04952493|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
75880638|NCT04952493|Drug|Sodium Iodide I 131|RAI treatment may shrink the tumor
75880639|NCT04952493|Drug|Penpulimab|Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
75880640|NCT01351597|Drug|docetaxel/ oxaliplatin|"docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
76024898|NCT02393365|Procedure|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
76024899|NCT02402491|Drug|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
76024900|NCT02402491|Drug|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
76050897|NCT02915744|Drug|Gemcitabine|
76050898|NCT02915744|Drug|Paclitaxel|
76050899|NCT02915744|Drug|Docetaxel|
76050900|NCT02915744|Drug|Nab-paclitaxel|
76050901|NCT02885363|Other|Clinical examination|
75880641|NCT04951245|Procedure|UC group: ultrasound-assisted CNSs guided|1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast. The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla. During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used. Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle . A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters. Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region. Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
75880642|NCT04951245|Procedure|GC group: CNSs plus ICG dual-tracer-guided|The preparation of CNSs mapping was identical to that of the UC group. 1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast. A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs. All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed. The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
75880643|NCT01347749|Behavioral|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
75880644|NCT01347749|Behavioral|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
75880645|NCT02793128|Drug|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
75580655|NCT01653223|Drug|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
75580656|NCT01549587|Drug|0.243% sodium fluoride|dentifrice: brush thoroughly twice daily
75580657|NCT01549587|Device|toothbrush|brush thoroughly twice daily
75580658|NCT01549587|Device|dental floss|floss the whole mouth once daily
75880646|NCT03612180|Drug|Metoprolol Succinate|Pharmacokinetics
75580659|NCT01549587|Drug|0.454% stannous fluoride|dentifrice: twice daily brush thoroughly for 2 minutes
75880647|NCT04400799|Drug|Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml|daily incetion s.c. for 14 days
76050902|NCT02885363|Other|Blood sample|
75580660|NCT01549587|Device|toothbrush|twice daily brush thoroughly for 2 minutes
75580661|NCT01549587|Drug|0.07% Cetylpyridinium chloride|mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
75580662|NCT01549587|Device|dental floss|floss the whole mouth once daily
75580671|NCT01047540|Drug|AIC316|Oral administration
75580672|NCT01047540|Drug|AIC316|Oral administration
75880648|NCT01359241|Procedure|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
75880649|NCT01359241|Drug|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
75580673|NCT01047540|Drug|AIC316|Oral administration
75580674|NCT01047540|Drug|AIC316|Oral administration
75580675|NCT01047540|Drug|Placebo|Oral administration
75580676|NCT00521222|Drug|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
75580677|NCT00521222|Drug|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
75580678|NCT00521222|Drug|Ipratropium HFA|Primary as-needed rescue medication in all treatment groups
75580679|NCT00521222|Drug|Albuterol HFA|Secondary as-needed rescue medication in all treatment groups
75580680|NCT00544856|Behavioral|complex cognitive training|
75580681|NCT00560001|Behavioral|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
75580682|NCT04647045|Dietary Supplement|Cultured milk drink|Each bottle contains 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose.
75580683|NCT00544934|Drug|GLY-230|125, 250 0r 375 mg bid for 14 days
75580684|NCT00544934|Other|Placebo|No drug administered
75580685|NCT04638348|Device|New Biofeedback|Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.
75580686|NCT00545012|Drug|Levetiracetam|
75880650|NCT05250323|Other|observational tests in face-to-face visit|All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
75880651|NCT04697238|Device|Weight vest|A vest weighing up to a maximum of 15 kg.
75880652|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
76024901|NCT02402491|Drug|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
76050903|NCT02885363|Procedure|Echocardiography|
75580687|NCT04647123|Other|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
75580688|NCT00545090|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
75580689|NCT00545207|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
75580690|NCT00545207|Drug|Placebo|po monthly for 2 years
75580691|NCT04647006|Procedure|thyroid|Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
75580692|NCT04638504|Other|ultrasonography|vascular and adipose tissue measurement by ultrasonography
75580693|NCT04684784|Device|Intervention-Dry Needling|Deep Dry Needling into the site of the latent TriggerPoint of the upper trapezius muscle. 1 session in upper trapezius muscle moving the needle up and down ten times.
75580694|NCT04684784|Device|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
75880653|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
75880654|NCT05383794|Other|Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
75880655|NCT02068040|Dietary Supplement|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
75880656|NCT02068196|Procedure|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
75880657|NCT02068196|Drug|Ipilimumab|
75880658|NCT03612570|Device|Nano-Pulse Stimulation Device|NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
75880659|NCT03142451|Drug|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
75880660|NCT03142451|Drug|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
75433771|NCT01540708|Drug|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
75580695|NCT00545246|Drug|aflibercept (AVE0005)|intravenous infusion
75880661|NCT04065789|Drug|Carfilzomib|Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
75580696|NCT00545246|Drug|docetaxel|intravenous infusion
75880662|NCT04065789|Drug|Daratumumab|Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
75880663|NCT04065789|Drug|Lenalidomide|Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
75880664|NCT04065789|Drug|Dexamethasone|Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
75880665|NCT03611478|Dietary Supplement|Probiotic formulation|Probiotic capsule
75880666|NCT03611478|Dietary Supplement|Placebo|Placebo capsule identical in taste and appearance to probiotic capsule
75880667|NCT02066558|Other|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
75880668|NCT02066558|Other|Placebo|
75880669|NCT04933773|Other|Movement artifact - knocking|60 seconds motion artifact simulation - knocking with sensors
75580697|NCT04638114|Procedure|Mini-open DAA|Direct anterior approach hip
75580698|NCT04638114|Procedure|Hip arthroscopy|arthroscopic treatment of hip pathology
75580699|NCT00545285|Procedure|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
75580700|NCT04637997|Device|compression stockings class I|Daily wearing of compression stockings class I for four weeks on the affected extremity.
75580701|NCT04637997|Device|compression stockings class II|Daily wearing of compression stockings class II for four weeks on the affected extremity.
75580702|NCT03456440|Diagnostic Test|MRI|MRI scan of the patients liver with DWI and acquisition of ADC value.
75580703|NCT03456401|Drug|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
75433772|NCT01540708|Drug|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
75880670|NCT04933773|Other|Movement artifact - tremor|60 seconds motion artifact simulation - tremor with sensors
75433773|NCT01540721|Drug|Marketed paracetamol|marketed formulation
75433774|NCT01540721|Drug|Experimental paracetamol formulation|Experimental formulation
75433775|NCT01540734|Drug|Marketed paracetamol|Marketed formulation
75433776|NCT01540734|Drug|Experimental paracetamol formulation|Experimental formulation
75433777|NCT01540747|Dietary Supplement|Myo-inositol + folic acid + melatonin|Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
75433778|NCT01540747|Dietary Supplement|Myo-inositol + folic acid|Myo-inositol (2000mg) + folic acid (200 mcg)
75580704|NCT04638192|Device|tACS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
75580705|NCT03456362|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
75729036|NCT05212727|Device|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
75729037|NCT05212428|Procedure|Biospecimen Collection|Undergo collection of saliva, blood, urine and stool samples
75433779|NCT01540760|Drug|MCAF5352A|Multiple ascending doses
75433780|NCT01540760|Drug|Placebo|Matching MCAF5352A, multiple doses
75580706|NCT04646538|Other|Regenerative Endodontics Procedures (REPs)|REPs was done for 10 mature maxillary necrotic teeth with periapical lesions. Instrumentation was done using Protaper Next system till size X3. Irrigation with 1.5 % NaOCl was done in the first visit. in the second visit, bleeding was induced in the canal by irritating the periapical area followed by the application of Biodentine as cervical plug then completion of the coronal restoration.
75729038|NCT05212428|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
75729039|NCT05212428|Other|Genetic Counseling|Receive genetic counseling
75729040|NCT05212428|Other|Questionnaire Administration|Complete family history
75729041|NCT05212428|Other|Questionnaire Administration|Ancillary studies
75880671|NCT04933773|Other|Artifact - ambient light|60 seconds artifact simulation - ambient light using sensor opening
75880672|NCT04933773|Other|Artifact - low perfusion|60 seconds artifact simulation - reduced perfusion using a cuff
75880673|NCT04933773|Other|SpO2 measurement|Two SpO2 measuring devices are active simultaneously on one hand during measurement.
75433781|NCT01540786|Procedure|High resolution urodynamic assessment|
75433782|NCT01540786|Procedure|Conventional urodynamic assessment|
75433783|NCT01540799|Device|ATI Neurostimulation System|ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
75433784|NCT01540812|Drug|Vincristine in induction|
75729042|NCT05198245|Drug|Rimegepant|Rimegepant 75mg
75729043|NCT05198245|Drug|Various|Various
75729044|NCT05198245|Other|No intervention|No intervention
76024902|NCT03166423|Drug|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
76050904|NCT02853643|Drug|ASN002|Single dose study with food effect
75433785|NCT01540812|Drug|Daunorubicin in induction|
75433786|NCT01540812|Drug|Prednisone in induction|
75433787|NCT01540812|Drug|Metotrexato in induction|
75433788|NCT01540812|Drug|Cytarabine in induction|
75433789|NCT01540812|Drug|Hydrocortisone in induction|
75433790|NCT01540812|Drug|Idarubicin in induction-2|
75433791|NCT01540812|Drug|Fludarabine in induction-2|
75433792|NCT01540812|Drug|Ara-C in induction-2|
75433793|NCT01540812|Drug|G-CSF in induction-2|
75433794|NCT01540812|Drug|Dexamethasone in consolidation-1|
75433795|NCT01540812|Drug|Vincristrine in consolidation-1|
75433796|NCT01540812|Drug|Metotrexato in consolidation-1|
75433797|NCT01540812|Drug|PEG-ASP in consolidation-1|
75433798|NCT01540812|Drug|Dexamethasone in consolidation-2|
75433799|NCT01540812|Drug|ARA-C in consolidation-2|
75433800|NCT01540812|Drug|PEG-ASP in consolidation-2|
75433801|NCT01540812|Drug|Dexamethasone in consolidation-3|
75880674|NCT01351831|Other|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
75880675|NCT01351831|Other|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
76050905|NCT02835638|Device|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
76050906|NCT02827955|Device|Gamma Knife® radiosurgery bilateral|
75580707|NCT03456323|Behavioral|Palliative Care Consultation|The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
75433802|NCT01540812|Drug|Vincristine in consolidation-3|
75433803|NCT01540812|Drug|Metotrexato in consolidation-3|
75433804|NCT01540812|Drug|PEG-ASP in consolidation-3|
75580708|NCT03456323|Other|Usual Care|Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
75580709|NCT04638270|Biological|anti-CD19 FasT CAR-T cells|Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion.
75580710|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
75580711|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
75580712|NCT00545519|Drug|thymoglobulin|
75433805|NCT01540812|Procedure|allogeneic HSCT|
75433806|NCT01540812|Procedure|Allo HSCT with reduced-intensity conditioning|
75580713|NCT04637685|Device|Centurion Phacoemulsification System|Infusion Pressure
75729045|NCT05197595|Behavioral|Attachment-based compassion therapy|Compassion program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
75729046|NCT05197595|Behavioral|Relaxation program|Relaxation program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
75433807|NCT01540877|Procedure|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
75880676|NCT03611634|Other|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
75880677|NCT02064842|Drug|TMC647055|TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
75880678|NCT02064842|Drug|TMC435|TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
75880679|NCT02064842|Drug|Placebo|Placebo capsule once daily taken orally on Day 1 in Part 1
75433808|NCT01540877|Procedure|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
75433809|NCT01540877|Procedure|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
75433810|NCT01540877|Procedure|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
75433811|NCT01540903|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
75433812|NCT01540903|Biological|Saline|Saline
75880680|NCT02064842|Drug|Ritonavir (RTV)|RTV 30 mg (ie, 0.38 mL oral solution of RTV [80 mg/mL strength]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
76050907|NCT02823327|Genetic|Laboratory Biomarker Analysis|Correlative studies
76050908|NCT02823327|Other|Medical Chart Review|Medical chart review is performed
76050909|NCT02803125|Behavioral|Psychosocial intervention|This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
76050910|NCT02803125|Behavioral|Support group control|The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
76050911|NCT02782949|Drug|Curcumin|Given PO
76050912|NCT02782949|Other|Laboratory Biomarker Analysis|Correlative studies
75433813|NCT01540916|Other|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
75433814|NCT01540916|Other|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
75433815|NCT01540942|Dietary Supplement|nutrition treat|intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;[W=weight（Kg）；H=height（cm）；A=age（year）]
75433816|NCT01540942|Other|surgery|bowel resection
76050913|NCT02782949|Other|Placebo Administration|Given PO
76050914|NCT02782949|Other|Quality-of-Life Assessment|Ancillary studies
75433817|NCT01540955|Behavioral|Improving Cognition with group intervention|Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
75580714|NCT00545558|Drug|Efavirenz|600 mg tablet taken orally daily
75580715|NCT00545558|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
76050915|NCT02736656|Drug|SPN-812|
75433818|NCT01540968|Behavioral|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
75433819|NCT01540994|Radiation|radiation therapy|Stereotactic Body Radiation Therapy
75580716|NCT04638426|Drug|HL237 tablet|Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
75580717|NCT04638426|Drug|Placebo of HL237 tablet|Placebo of HL237, twice a day
75580718|NCT00545597|Drug|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
75580719|NCT04646577|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
75433820|NCT01541007|Drug|Cabazitaxel|25 mg/m2 every three weeks
75433821|NCT01541007|Drug|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
75433822|NCT01541046|Biological|Biogaia L. reuteri DSM 17938|Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
75580720|NCT04646577|Device|Transcranial Direct Current Stimulation (tDCS|Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
75580721|NCT00545636|Other|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
75580722|NCT04646421|Behavioral|Motivational telephone intervention|Motivational telephone intervention to high-risk gamblers, aiming to stimulate them to reduce gambling, quit gambling, or to seek peer support or treatment.
76050916|NCT02528643|Drug|Enzalutamide|Oral capsule
76050917|NCT02528643|Drug|Placebo|Oral capsule
76050918|NCT02506933|Other|Laboratory Biomarker Analysis|Correlative studies
76050919|NCT02506933|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
76050920|NCT02506933|Other|Placebo|Given IM
75433823|NCT01541046|Biological|Probiotic Placebo|Description of Placebo: contains same excipients as Active Agent, without the active ingredient
75433824|NCT01541059|Drug|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
75433825|NCT01541059|Drug|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
75433826|NCT01541072|Drug|Pegfilgrastim|Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
76050921|NCT02409810|Drug|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
76050922|NCT02325804|Behavioral|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
76050923|NCT02206815|Drug|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
76050924|NCT02206815|Drug|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
76050925|NCT02186691|Other|MRI|
76050926|NCT02175680|Drug|PRO 140|CCR5 Antagonist
75580723|NCT04684667|Drug|Propranolol Therapy for Infantile Hemangioma|If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.
75880681|NCT04924881|Drug|COVID Rehab Formula granules|COVID Rehab Formula granules once daily for 8 weeks
75880682|NCT04924881|Other|Placebo granules|Placebo granules once daily for 8 weeks
75880683|NCT01355809|Drug|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
75880684|NCT01355809|Drug|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
75880685|NCT01355809|Drug|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
75880686|NCT03612102|Behavioral|Intensive Group Behavioral Treatment (IGBT)|IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
75880687|NCT04013139|Diagnostic Test|CPET|CPET
75880688|NCT03141905|Other|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
75880689|NCT03141905|Other|Usual Care|Standard clinical care
75580724|NCT04637919|Biological|IN-B001 EV71 A dose|Inactivated vaccine against EV71, three doses, 28 days interval
75580725|NCT04637919|Biological|IN-B001 CVA16 B dose|Inactivated vaccine against CVA16, three doses, 28 days interval
75580726|NCT04637919|Biological|IN-B001 Bivalent C dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
75580727|NCT04637919|Biological|Placebo|Placebo, three doses, 28 days interval
75880690|NCT05383638|Other|Health education|Intervention is achieved through health education. Analyze the factors that may affect patients' satisfaction with primary medical services through existing data, and carry out targeted health education.
75880691|NCT04917315|Drug|JLP-2002 A mg|administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
75580728|NCT00545675|Drug|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
75580729|NCT00545675|Drug|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
75580730|NCT00545831|Device|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
75580731|NCT00545831|Device|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
75580732|NCT04637958|Device|THA|Total hip arthroplasty
75880692|NCT04917315|Drug|Placebo|administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
75880693|NCT03612024|Behavioral|questionnaire|a standardized questionnaire was sent to all participants
75880694|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
76024903|NCT03166423|Device|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
76024904|NCT02402569|Device|32 channels Deep Brain Stimulator|
75433827|NCT01541072|Drug|Filgrastim|Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils >= 0.5 G/L)
75433828|NCT01541098|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
75433829|NCT01541098|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
75433830|NCT01541111|Drug|Magnesiun|75mg pills; each 12h; 12wk
75433831|NCT01541124|Drug|Opioid|10 mg/pill, po, each 6h, during 6m
75433832|NCT01541137|Drug|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
75880695|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
75880696|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
75880697|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
75880698|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
76050927|NCT02175680|Other|Historical data|Historical data (i.e., time to HIV-1 RNA viral load > 500 copies/mL of 29 days).
75880699|NCT04887597|Drug|Secukinumab|The study is composed of a single arm receiving secukinumab for the duration of 6 months.
76024905|NCT02402413|Procedure|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
76024906|NCT02402413|Procedure|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
76024907|NCT02402413|Device|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
76050928|NCT02151175|Device|LIFUP|
76050929|NCT02125981|Drug|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
76050930|NCT02125981|Drug|Placebo|taking placebo drug
76050931|NCT02114944|Device|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
76050932|NCT02114944|Device|CPAP|Patient treated, as per attending physician's decision, with CPAP
76050933|NCT02114944|Device|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
76050934|NCT02114944|Device|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
75433833|NCT01541137|Drug|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
75580733|NCT00545870|Drug|bevacizumab|intravitreal application
75580734|NCT00545870|Drug|Ranibizumab|intravitreal application
76050935|NCT01983462|Drug|Clonidine|
75580735|NCT04637451|Procedure|Root coverage treatment|Gingival unit graft Connective tissue graft
76050936|NCT01983462|Drug|Hydrochlorothiazide|
76050937|NCT01983462|Drug|Placebo|
76050938|NCT01936883|Radiation|HDR|High dose rate brachytherapy
76050939|NCT01936883|Radiation|LDR|Low dose rate brachytherapy boost
76050940|NCT01779375|Drug|Metformin|
76050941|NCT01779375|Drug|Glargine|
76050942|NCT01594723|Drug|120 mg LY2784544|Administered orally
75580736|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
75580737|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
75580738|NCT04637568|Diagnostic Test|Computerized tomography|Obtained CT scans involving the head region were analyzed retrospectively.
75580739|NCT04637412|Other|Menu label|Participants will be shown a sample of items from a restaurant menu, displayed with labels
75580740|NCT05050292|Other|Personalized cognitive stimulation|"Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity."
75880700|NCT01347905|Other|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
75880701|NCT04192266|Drug|Estradiol|2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
75880702|NCT04192266|Drug|Placebo oral tablet|2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
75729047|NCT05186948|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
75880703|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
75580741|NCT05050292|Other|Sham cognitive stimulation|"Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game."
75580742|NCT04646304|Other|Objective Feedback (Motion Capture)|Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
75729048|NCT05184569|Drug|Verdiperstat|Oral, extended release (ER) tablet
75729049|NCT05180422|Drug|AMG 510|Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.
75729050|NCT05180422|Drug|MVASI|Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).
75729051|NCT05179057|Drug|Posoleucel|Administered as 2-4 milliliter infusion, visually identical to placebo
75880704|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
75729052|NCT05179057|Drug|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel
75729053|NCT05176704|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
75729054|NCT05161533|Drug|Carboplatin|Given IV
75729055|NCT05161533|Drug|Cisplatin|Given IV
75729056|NCT05161533|Biological|Durvalumab|Given IV
75880705|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
75580743|NCT04645914|Behavioral|Use of nicotine product (smoking/vaping)|The smokers/vapers are consuming during the study one nicotine product of their own. The dose is the same as each individual is consuming regularly
75580744|NCT04684433|Other|Data extraction from medical files|Data extraction from medical files
75580745|NCT04646070|Procedure|Reduction mammaplasty|Breast reduction surgery
75580746|NCT00545987|Device|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
75580747|NCT00545987|Device|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
75580748|NCT00546026|Other|placental function assessment|Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
75580749|NCT00546065|Drug|esomeprazole treatment|concomitant esomeprazole treatment
75580750|NCT00558324|Procedure|LASIK|Mechanical microkeratome Hansatome 160 microns
75580751|NCT00558324|Procedure|LASIK|Mechanical microkeratome K 3000 130 microns
75580752|NCT00558324|Procedure|LASIK|Femtoseconds laser 100 microns
75580753|NCT00546143|Drug|Omalizumab|
75580754|NCT00546143|Drug|Omalizumab|
75580755|NCT00546143|Drug|Omalizumab|
75580756|NCT04645992|Device|active TENS|study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
75580757|NCT04645992|Device|sham TENS|control group will be treated with the same protocol as the study group but with the TENS unit is off .
75729057|NCT05161533|Drug|Etoposide|Given IV
75729058|NCT05161533|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75729059|NCT05161533|Other|Quality-of-Life Assessment|Ancillary studies
75729060|NCT05161533|Other|Questionnaire Administration|Ancillary studies
75880706|NCT05250245|Drug|Tolterodine Tartrate 4 MG|Tolterodine is actively being used in the treatment of over active bladder symptoms today
75880707|NCT05250245|Other|Continuous positive airway pressure therapy (CPAP)|The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy
75880708|NCT01347983|Drug|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
76050943|NCT01559935|Drug|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
75880709|NCT02068664|Behavioral|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
76050944|NCT01559935|Drug|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
76050945|NCT01559935|Drug|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
75433834|NCT01541137|Device|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
75880710|NCT01359475|Procedure|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
75880711|NCT03611400|Dietary Supplement|Probiotic|This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
75880712|NCT03611400|Dietary Supplement|Placebo|The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
76050946|NCT01559935|Drug|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
75433835|NCT01541150|Behavioral|neuropsychological questionnaires|Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
75433836|NCT01541176|Other|Absence of corticotherapy post-transplantation|No study treatment
75433837|NCT01541176|Drug|Corticotherapy post-transplantation|"Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~D1 to D14 : 20 mg/day,~D15 to M1 : 15 mg/day,~M1 to M3 : 10 mg/day,~M3 to M12 : 5 mg/day."
75433838|NCT01541189|Drug|Valsartan|80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
75580758|NCT00546221|Behavioral|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
75580759|NCT00546221|Behavioral|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
75880713|NCT05249933|Drug|Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8|Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
76050947|NCT01559935|Drug|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
76050948|NCT01559935|Drug|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
76050949|NCT01284699|Procedure|Gamma Knife radiosurgery|For patients presenting a contraindications for anaesthesia or electrode implantation, operate their brain without opening the skull without infection or bleeding risk.
76050950|NCT00981058|Biological|Necitumumab|"800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle.~Continues until progressive disease, toxicity, noncompliance, or withdrawal."
76050951|NCT00981058|Drug|Gemcitabine|"1250 mg/m2 on Days 1 and 8 of every 3 week cycle.~Continues for a maximum of six cycles."
76050952|NCT00981058|Drug|Cisplatin|"75 mg/m2 IV on Day 1 of every 3 week cycle.~Continues for a maximum of six cycles."
76050953|NCT00979043|Behavioral|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
75433839|NCT01541202|Drug|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
75433840|NCT01541202|Drug|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
76050954|NCT00979043|Behavioral|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
76050955|NCT00667069|Drug|triptorelin|
76050956|NCT00667069|Procedure|adjuvant therapy|
76050957|NCT00667069|Radiation|3-dimensional conformal radiation therapy|
76050958|NCT00565851|Biological|Bevacizumab|Given IV
75433841|NCT01541228|Device|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.~Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval."
75433842|NCT01541228|Procedure|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval."
75580760|NCT04646772|Procedure|Multivisceral resection|Multivisceral resection for locally advanced colon cancer.
75580761|NCT05037383|Other|Video recordings|The surgery of the patient will be recorded by cameras placed on the top of the displays used by the operating staff. The recordings will be only carried out while the patient is draped for the surgery, thus completely covered.
75580762|NCT00560079|Drug|Allopurinol|Allopurinol 600mg/day bid for 28 days
75580763|NCT00560079|Drug|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
76050959|NCT00565851|Drug|Carboplatin|Given IV
76050960|NCT00565851|Drug|Docetaxel|Given IV
76050961|NCT00565851|Drug|Gemcitabine Hydrochloride|Given IV
75580764|NCT00560079|Drug|Placebo|Placebo
76050962|NCT00565851|Other|Laboratory Biomarker Analysis|Correlative studies
76050963|NCT00565851|Drug|Paclitaxel|Given IV
76050964|NCT00565851|Other|Quality-of-Life Assessment|Ancillary studies
76050965|NCT00305227|Drug|Lactin-V|
75580765|NCT04646265|Other|periodontal treatment|non-surgical root debridement
75580766|NCT00560118|Drug|fotemustine|
75580767|NCT00560118|Genetic|gene expression analysis|
75580768|NCT00560118|Genetic|polymerase chain reaction|
75580769|NCT00560157|Dietary Supplement|Crucial (enteral tube feeding)|Evaluation of new enteral product, Crucial, in ICU patients
75580770|NCT00546299|Drug|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
75580771|NCT00558402|Behavioral|Meditation|meditation class 1/week for 8 weeks
75580772|NCT00558402|Behavioral|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
76050966|NCT00305227|Drug|Placebo|
76050967|NCT00238563|Drug|Triamcinolone injection, sub-tenon|
76050968|NCT00001070|Drug|Oral Vitamin C|
76050969|NCT04601467|Drug|AZD5718|Oral dose of AZD5718 (tablet) once daily for 12 months
76050970|NCT04601467|Drug|Placebo|Oral dose of matching placebo (tablet) once daily for 12 months
76050971|NCT01599793|Drug|cabozantinib|Given PO
76050972|NCT01599793|Other|laboratory biomarker analysis|Correlative studies
75433843|NCT01541267|Drug|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
75433844|NCT01541280|Drug|Azacitidine|Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of >15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of >1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
75433845|NCT01541280|Other|DLI|"Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of >grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.~If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too."
75580773|NCT00558402|Behavioral|Respite only|Respite care 90 mins per week for 8 weeks
75580774|NCT00546494|Drug|Effexor® (Venlafaxine)|
75580775|NCT04637607|Other|Auricular acupoints stimulation|Noninvasive auricular acupoints stimulation with seeds
75729061|NCT05156606|Drug|AndroGel|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
75580776|NCT00546533|Drug|Etanercept|
75580777|NCT00558441|Device|IVMRI|Intra Vascular Magnetic Resonance Imaging
75580778|NCT00558480|Drug|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
75729062|NCT05132439|Drug|Metformin ER|Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties
76050973|NCT01599793|Procedure|magnetic resonance imaging|Undergo MRI
76050974|NCT05209633|Drug|Granules Dendrobii|6g each, 3 times per day, total 18 weeks
76050975|NCT05209633|Drug|Placebo|placebo
76050976|NCT04499677|Drug|Favipiravir|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
76050977|NCT04499677|Drug|Lopinavir/ Ritonavir|Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
76050978|NCT04499677|Other|Favipiravir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
76050979|NCT04499677|Other|Lopinavir/ Ritonavir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
75433846|NCT01541293|Drug|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
75433847|NCT01541293|Drug|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
75433848|NCT01541332|Drug|Pomalidomide|Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.
75580779|NCT00558480|Drug|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
75580780|NCT05034146|Drug|68Ga-FAPI|68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).
75580781|NCT05034146|Device|PET/CT|68Ga-FAPI PET/CT scan were performed 20~60 min after 68Ga-FAPI (1.85-3.7MBq/kg) injection intravenously.
75580782|NCT04637100|Other|Mobile or tablet-based gaming applications|Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
75433849|NCT01541332|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle."
75433850|NCT01541332|Drug|Dexamethasone|Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
75580783|NCT04637100|Other|Stroke-related educational videos|Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
75580784|NCT00546611|Drug|PEP005|
75580785|NCT04637490|Device|patellar component|patellar resurfacing
75580786|NCT04645875|Other|Sit regimen|See Sit regimen arm description
75580787|NCT04645875|Other|SitLess regimen|See SitLess regimen arm description
75580788|NCT00546650|Drug|Sumatriptan succinate|NP101 iontophoretic transdermal system
75580789|NCT00546650|Drug|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
75580790|NCT04637373|Diagnostic Test|Hysteroscopy|adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
75433851|NCT01541410|Device|Vascutek Hybrid Graft|Single Group Assignment
75433852|NCT01541436|Device|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
75580791|NCT00546767|Behavioral|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
75580792|NCT00546767|Behavioral|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
75580793|NCT00546767|Behavioral|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
75580794|NCT00546767|Behavioral|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
75580795|NCT04645758|Combination Product|Dry needling and Extra corporeal Shock wave therapy|5 mins of dry needling and 1250 pulses of shockwave therapy on dominant forearm muscles
75580796|NCT00546806|Other|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
76050980|NCT05652751|Drug|nerve growth factor|The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
76050981|NCT05652751|Drug|physiological saline|Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
75433853|NCT01541462|Other|Weaning|Decrease assistance provided by the ventilator
75433854|NCT01541475|Drug|Bupropion, Escitalopram|Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
75433855|NCT01541475|Drug|Escitalopram|Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
75433856|NCT01541488|Drug|BI 1021958|tablet
75433857|NCT01541488|Drug|BI 1021958|drinking solution / tablet
75433858|NCT01541488|Drug|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
75580797|NCT04637178|Behavioral|Resistance training|Resistance training sessions twice a week for ten weeks
75580798|NCT04637178|Behavioral|Endurance training (habitual)|Endurance training for ten weeks (habitual routines)
75580799|NCT00546845|Device|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
75580800|NCT00546845|Device|Use of self-expanding Expert stent|Nitinol stent
75580801|NCT00546923|Drug|Venlafaxine XR|
75580802|NCT00560196|Other|Observation|
75433859|NCT01541501|Device|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
75433860|NCT01541527|Biological|blood test|One blood test entering in the usual follow-up of the patient
75433861|NCT01541540|Behavioral|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
75433862|NCT01541540|Behavioral|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
75729063|NCT05132439|Drug|placebo|Matched to active study drug
75433863|NCT01541579|Other|Cx601|120 million cells administered by intralesional injection.
75433864|NCT01541579|Other|Saline solution|24 mL saline solution by intralesional injection
75433865|NCT01541592|Other|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of ~1 tablespoon per hour so that the total infusion time will be 6 hours.
75580803|NCT04645563|Other|Sending thorax ct video images via smartphone applications|Video images of the patients will be sent via smartphone application to infectious disease specialist for consulting.
75729064|NCT05113667|Other|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program|Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
75880714|NCT02064998|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
75880715|NCT02064998|Behavioral|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
75580804|NCT04637217|Diagnostic Test|Optical Coherence Tomography|Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
75880716|NCT02064998|Behavioral|TeleCoach|Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
75880717|NCT02032602|Other|Deep Dry Needling|
75880718|NCT01359553|Other|Intra-articular ultrasound imaging of knee joint during arthroscopy|
76050982|NCT05652751|Device|EA|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
76050983|NCT05652751|Device|sham EA|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
75880719|NCT01359553|Other|Non-invasive ultrasound imaging of knee|
75880720|NCT01359553|Other|Quantitative MRI imaging of knee|
75880721|NCT01359553|Other|Contrast-enhanced CT imaging of knee|
75880722|NCT02068742|Other|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
75880723|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
76050984|NCT02909335|Drug|Tacrolimus|"Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~between 6 and 10 ng / ml during the first 2 months,~between 5 and 8 ng / ml from the start of the end M3 and M6,~and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
75433866|NCT01541605|Drug|methylphenidate|tablets for oral use
75433867|NCT01541605|Drug|Placebo|tablets for oral use
75433868|NCT01541618|Other|MSDX Complex-1 Biomarker test|MSDX Complex-1 Biomarker test
75433869|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
75433870|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
75729065|NCT05113316|Behavioral|Messy Memories App|"The Messy Memories mobile app is an intervention targeting stress-related problems based on practices with proven effectiveness, to overcome barriers and provide access to evidence-informed intervention strategies aimed to improve mental health in frontline healthcare workers.~The app allows the user to self-administer exposure therapy techniques outside of the traditional psychotherapy context. The Messy Memories app was initially released in a written form for self-help, but with widespread use of smartphones, a mobile application has the potential to further reduce barriers and increase access to care among frontline healthcare workers. The current study proposes to examine this newly developed application for usability and feasibility in a small sample of frontline healthcare workers (Phase I) and then test efficacy of the application in a larger-scale RCT (Phase II) where the application will be compared to a TAU condition."
75729066|NCT05108298|Other|Questionnaires|Patients will complete questionnaires online through EASEE-PRO. There will be a set of fixed questionnaires at each timepoint for both arms. The patients will be asked to rank the 15 types of PROs according to their importance. The participants randomized to the choice arm will be asked to choose 5 of the 15 PROs to complete. The participants randomized to the fixed arm will be given a fixed 5 of the 15 PROs at each time point.
75880724|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
75880725|NCT01348217|Radiation|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
75729067|NCT05100069|Drug|Brigatinib|Brigatinib Tablets
75729068|NCT05087550|Procedure|Liver Transplantation|Patients who underwent liver transplantation at Methodist Dallas Medical Center
75729069|NCT05086250|Drug|Ketamine|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
76050985|NCT02909335|Drug|Everolimus|"Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~between 6 and 10 ng / ml during the first 2 months,~between 5-8 ng / ml from the start of the end M3 and M6,~and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
76050986|NCT02909335|Drug|Mycophenolate mofetil|mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
76050987|NCT02909335|Drug|Prednisolone, Prednisone or Methylprednisolone|Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
75433871|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
75433872|NCT01541657|Other|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
76050988|NCT02893267|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
75729070|NCT05086250|Drug|Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
76050989|NCT02893267|Other|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
75729071|NCT05086250|Drug|Placebo|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
75880726|NCT01348217|Radiation|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
75880727|NCT01348217|Radiation|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
75880728|NCT01348217|Drug|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
75880729|NCT02065076|Drug|Sodium polystyrene sulfonate|
75880730|NCT02065076|Drug|Lactose with carob gum|
75433873|NCT01541657|Other|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
75433874|NCT01541657|Other|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
75433875|NCT01541670|Drug|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Intravenous injection
75433876|NCT01541683|Other|PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)|Patients will be instructed to drink 4 Liters of PEG solution (FORTRANS®) split into 2 days while sucking on sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy while continuously sucking on Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure while continuously sucking on Halls®)
75433877|NCT01541683|Other|PEG solution (Fortrans®)|4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
75580805|NCT04637061|Combination Product|intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis|Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.
75580806|NCT04637061|Diagnostic Test|Air Leak test|This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.
75580807|NCT04637061|Diagnostic Test|Evaluation of the anastomotic rings|The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete
75580808|NCT00558675|Biological|AlloStim|single intravenous infusion of 1 x 10^9 AlloStim cells
75580809|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7
75580810|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7 and day 14
75580811|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7, day 14 and day 21
75580812|NCT04637139|Drug|Vebicorvir (VBR)|300mg Vebicovir containing 2 µCi [14C]VBR.
75580813|NCT00547001|Drug|Estradiol|1mg during stabilization & then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
75580814|NCT05034107|Other|Aromatherapy|Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.
75580815|NCT04645485|Biological|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).|Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.
76050990|NCT02893267|Other|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
75433878|NCT01541774|Device|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
75433879|NCT01541852|Drug|Losmapimod|One tablet of Losmapimod 7.5mg twice daily
75433880|NCT01541852|Drug|Placebo|One tablet twice daily
75580816|NCT05030792|Other|Attention-restorative therapy (ART)-based virtual reality (VR)|The ART-based VR intervention will be provided using an Oculus Go™ which is a commercially available, all-in-one VR headset with a handheld controller.
75580817|NCT04636866|Other|NO intervention|NO intervention
75580818|NCT05016674|Device|LipoLife system|Abdominal Laser-Assisted Liposuction
75580819|NCT04645641|Device|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
75580820|NCT04636476|Procedure|Modified Nesbit's procedure and dorsal dartos flap|Modified Nesbit's procedure to correct the penile curvature and dorsal dartos flap to correct the associated penile torsion
75580821|NCT04645407|Drug|Fuzheng Huayu tablet|Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
75580822|NCT00547040|Other|no intervention|no intervention
75580823|NCT04645056|Other|Stretching and Mobility exercises for neck and shoulder|9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
75580824|NCT04684316|Other|Electronic survey with selective consultations|Participants complete an online questionnaire, after which the 20% employees that mostly need contact with the occupational physician (based on their survey score) are invited to a consultation with the occupational physician.
75880731|NCT02465593|Drug|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
75880732|NCT02465593|Drug|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
75880733|NCT02465593|Drug|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
75433881|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
75880734|NCT02465593|Procedure|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
75880735|NCT02465593|Radiation|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
75433882|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
75433883|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
75433884|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
75433885|NCT01541904|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
75433886|NCT01541085|Drug|Darunavir/Ritonavir (DRV/r)|Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
75880736|NCT02068898|Drug|XS003|
75880737|NCT02068898|Drug|Tasigna|
75880738|NCT03611322|Drug|Semaglutide, 0.25 mg|Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
75880739|NCT03611322|Drug|Semaglutide, 0.5 mg|Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
75880740|NCT03611322|Drug|Semaglutide, 1.0 mg|Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
75880741|NCT03611322|Device|DV3372|DV3372 device will be used for administration of semaglutide
75433887|NCT01541085|Drug|Efavirenz (EFV)|Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
75433888|NCT01541943|Drug|Atorvastatin|Once daily, administered orally, 8 week
75433889|NCT01541943|Drug|Losartan|Once daily, administered orally, 8 week
75433890|NCT01541943|Drug|Placebo|Once daily, administered orally, 8 week
75433891|NCT01541943|Drug|HL-040XC|Once daily, administered orally, 8 week
75433892|NCT01541956|Drug|Metformin|500 mg twice daily
75433893|NCT01541956|Drug|vildagliptin|Vildagliptin 50 mg twice daily
75580825|NCT04636788|Procedure|Venous sampling|venous sampling of 12ml
75580826|NCT00547235|Biological|therapeutic allogeneic lymphocytes|
75580827|NCT00547235|Procedure|allogeneic bone marrow transplantation|
75580828|NCT00547235|Radiation|total-body irradiation|
75580829|NCT04636749|Device|Erbium laser|Vaginal laser therapy
75580830|NCT04636749|Device|Sham laser|Sham laser therapy
75580831|NCT00547274|Drug|MK0767|
75580832|NCT00547352|Drug|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
75880742|NCT03611322|Device|PDS290 pen-injector|PDS290 pen-injector will be used for administration of semaglutide
75433894|NCT01542008|Behavioral|Customized Adherence Enhancement (CAE)|CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
75580833|NCT00547352|Drug|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
75580834|NCT04645095|Device|Transcutaneous electrical nerve stimulation|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
75580835|NCT04645095|Device|Hot pack|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
75580836|NCT00547391|Procedure|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
75729072|NCT05086250|Drug|Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
75729073|NCT05083923|Drug|Diroximel fumarate|Administered as specified in the treatment arm
75729074|NCT05070403|Drug|Afatinib 40 MG|Participants will receive 40 mg Afatinib, once daily.
75729075|NCT05064423|Behavioral|Clinical Trials Education Program|The Community Health Educator (CHE) will provide CT education and outreach to increase clinical trial knowledge and the importance of clinical trials research and participation. The clinical trials educational activities will include the use of NCI Colorectal Cancer resources and materials, including a PowerPoint presentation, clinical trials information, and online resources. The CHE will tailor the PowerPoint slides to ensure that they are culturally tailored, visually appealing, low-literacy, language appropriate and include appropriate visuals. The CTs educational sessions will be delivered in Spanish and English and will take approximately 45 minutes to 1 hour.
75580837|NCT00547391|Other|no intervention|No intervention (controls). Follow up started from the day of randomization.
75580838|NCT04636827|Biological|sIPV+DTaP+HepA|sIPV+DTaP+HepA at the age of 18 month old
75580839|NCT04636827|Biological|sIPV|sIPV at the age of 18 month old
75580840|NCT04636827|Biological|DTaP|DTaP at the age of 18 month old
75580841|NCT04636827|Biological|HepA|HepA at the age of 18 month old
75580842|NCT00547469|Drug|DDP733|
75580843|NCT04636515|Drug|F520|200mg，Q3W
75580844|NCT04636593|Drug|Almonertinib|All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
75580845|NCT02277275|Dietary Supplement|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
75580846|NCT02277275|Dietary Supplement|Placebo|Placebo will be provided to the other two arms for six months
75729076|NCT05064085|Drug|Cemiplimab|Participants will be given Cemiplimab 350 mg IV day 1 every 21 days
75729077|NCT05064085|Drug|Capecitabine|Participants will take Capecitabine at 2 dose levels: 800 mg/m^2 and 1000 mg/m^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
75729078|NCT05060016|Drug|Tarlatamab|Intravenous (IV) infusion
75880743|NCT02424019|Drug|ILUVIEN 0.19 MG|
75433895|NCT01542008|Behavioral|broadly-directed, non-individualized education (EDU)|"EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed."
75580847|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
75580848|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
75580849|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
75580850|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
75580851|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
75880744|NCT01346423|Behavioral|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
76050991|NCT02893267|Device|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
76050992|NCT04471909|Device|NEXUS Aortic Stent Graft System|"Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion."
76050993|NCT02805517|Device|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
76050994|NCT05652595|Drug|GP40141|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
76050995|NCT05652595|Drug|Nplate|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
75433896|NCT01542047|Drug|Carboplatin|Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
75433897|NCT01542047|Drug|Pazopanib|Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
75580852|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
75433898|NCT01542060|Drug|biphasic insulin aspart 30|Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
75580853|NCT00560274|Drug|Pegasys|As prescribed
75433899|NCT01542073|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
75580854|NCT00560274|Drug|Ribavirin|As prescribed
75729079|NCT05044832|Behavioral|Personalized Music|Personalized music delivered during the perioperative and post-operative periods. Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit.
75433900|NCT01542086|Procedure|Myocardial SPECT|
75580855|NCT00560274|Drug|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
75580856|NCT00547547|Dietary Supplement|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
75580857|NCT00547547|Drug|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
75580858|NCT00547547|Drug|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
75729080|NCT05036629|Device|MRI Protocol|"Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse,~NIRS Oxymon artinis medical system~tES (transcranial electrical stimulation, Neuroelectrics)"
75729081|NCT05035511|Device|tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
75433901|NCT01542086|Procedure|64-channel coronary CT angiography (CCTA)|
75433902|NCT01542099|Drug|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml."
75580859|NCT00547625|Drug|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
75580860|NCT00547625|Drug|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
75580861|NCT04645368|Drug|bovhyaluronidase azoxymer|3000 IU intramuscularly once every 5 days with a course of 15 injections
75580862|NCT00547664|Drug|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
75433903|NCT01542099|Drug|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml."
75433904|NCT01542112|Other|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
75580863|NCT00547664|Other|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
75580864|NCT04644939|Other|Phone calls|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions and a telephone call one day before the procedure to re-explain the instructions and the importance of bowel preparation
75433905|NCT01542112|Other|No treatment|Patients in this arm receive the usual routine in the department.
75580865|NCT04644939|Other|Standard bowel preparation|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions
75580866|NCT04644939|Other|Colonoscopy|Patients will undergo colonoscopy
75580867|NCT00547742|Procedure|PET/CT Scan|
75580868|NCT00547742|Procedure|phlebotomy|
76050996|NCT04418323|Procedure|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
75433906|NCT01542138|Drug|Desonide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
75433907|NCT01542138|Drug|Niacinamide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
75433908|NCT01542138|Drug|Placebo|Humectant placebo cream
75580869|NCT00560430|Drug|telmisartan|80 mg per day, orally, weeks 1-14
76050997|NCT05652517|Procedure|Vein of Marshall ethanol infusion|Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
75433909|NCT01542151|Other|Time of labor induction|Assigned time of labor induction - morning or evening
75433910|NCT01542190|Drug|Ketorolac Tromethamine|ketorolac tromethamine 0.4%
75580870|NCT00560430|Drug|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
75580871|NCT00560430|Drug|placebo|placebo; orally weeks 1-14
75580872|NCT00547781|Procedure|PGD|
75729082|NCT05030493|Drug|mFOLFOX6 + panitumumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
76050998|NCT05163847|Biological|Cam2020 M2SR H3N2 influenza vaccine|Administered intranasally on Day 1
75433911|NCT01542216|Behavioral|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
75433912|NCT01542216|Behavioral|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
75580873|NCT04644588|Diagnostic Test|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
75580874|NCT00547820|Other|placebo|
75580875|NCT00547820|Device|Urinary sensor|
75580876|NCT00560469|Other|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
75580877|NCT00560547|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
75580878|NCT04644510|Device|Lung ultrasonography|Standardized eight-point Lung ultrasonography
75580879|NCT04636047|Other|The method of gene mutation detection|All samples were detected by NGS CGP panel.
75580880|NCT00547937|Device|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
75580881|NCT04644900|Other|chewed mint gum|In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.
75729083|NCT05030493|Drug|mFOLFOX6 + bevacizumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
76050999|NCT05163847|Biological|Fluzone HD IIV|Administered intramuscularly on Day 1
76051000|NCT05163847|Other|IN Placebo|Administered intranasally on Day 1
75580882|NCT04644900|Other|Mouthwash|Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
75580883|NCT00547976|Drug|[C-11]PBR28|
75580884|NCT00548015|Behavioral|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
75580885|NCT04636125|Drug|Doxycycline 100 MG Oral Tablet|Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
75580886|NCT04636242|Procedure|Skin Biopsy|A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
75580887|NCT04636242|Drug|5 Aminolevulinic Acid + Phototherapy|5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
75580888|NCT00548054|Biological|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
75580889|NCT00548054|Biological|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
75580890|NCT04644822|Diagnostic Test|[18F] PSMA-1007 Injection|a novel [18F] PSMA radiotracer that is highly selective for PSMA.
75580891|NCT04644432|Drug|Medication (A specification is listed under each arm)|Study drugs and dosages are listed in the description of arms.
75580892|NCT04644432|Other|Patient reported outcomes measurement|"PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish."
75580893|NCT00548288|Drug|pamidronate|
76051001|NCT05163847|Other|IM Placebo|Administered intramuscularly on Day 1
75580894|NCT04644354|Drug|Nifedipine 10 mg|For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
75580895|NCT00548366|Other|Sodium restriction|4 gram sodium diet
75580896|NCT00548366|Other|Sodium restriction|2 gram sodium diet
75729084|NCT05026814|Other|Interview after one year or more from the treatment received|Questionnaires to evaluate the satisfaction with treatment, the motivations and expectations for the treatment, the general well-being, the sexual function and the genital selfimage
75729085|NCT05023382|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection
75580897|NCT04644081|Behavioral|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postpartum mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
75580898|NCT04644081|Behavioral|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
75580899|NCT04644081|Drug|TAU|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of mental health care).
75580900|NCT00548444|Biological|MVA85A|Vaccine. Dose: 1 x 10^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
75580901|NCT00548444|Other|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
75580902|NCT04636359|Behavioral|Acupuncture stimulation|The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
75580903|NCT00548483|Drug|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
75580904|NCT04635813|Procedure|Thyroidectomy|Thyroidectomy
75580905|NCT04635852|Drug|Fentanyl|
75580906|NCT04635852|Drug|Immediate release morphine|
75729086|NCT05021991|Drug|100 mg PRAX-944|Once daily oral treatment with titration
75729087|NCT05021991|Drug|60 mg PRAX-944|Once daily oral treatment with titration
76051002|NCT05203393|Device|Harmony Headset|"The Harmony headset is a non-invasive nonsignificant risk observational device to collect intracranial waveform data. The headset will be placed on normal study participants to collect data for a period of 3 minutes and transferred to investigators for analysis."
76051003|NCT04196569|Device|Alcon Trifocal and Trifocal Toric Intraocular Lenses|"Panoptix Model #TFAT00 for the UV Absorbing Trifocal IOL. Torics:~TFAT30, TFAT40, TFAT50, TFAT60"
75433913|NCT01542242|Drug|Liraglutide|Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
75433914|NCT01542268|Drug|pentoxifylline|Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
75433915|NCT01542268|Drug|pentoxifylline placebo|Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
75580907|NCT00548561|Drug|Dexrazoxane|
76051004|NCT05652361|Other|Additional visualisation of surgical assistance during surgery|Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
75580908|NCT00548600|Procedure|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
75729088|NCT05021991|Drug|Placebo|Once daily oral treatment
75729089|NCT05021991|Drug|Flexibly dosed 20 mg to 100 mg PRAX-944|Once daily oral treatment
75729090|NCT05018247|Procedure|Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention|Urgent revascularization via CABG or PCI combined with Optimal Medical Treatment
75433916|NCT01542281|Dietary Supplement|Whey protein and dietary supplements|Whey protein and dietary supplements in addition to pre-hab exercise
75433917|NCT01542281|Other|prehab exercise|minimum 4 weeks and maximum 8 weeks; 3 times a week
75433918|NCT01542294|Drug|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
75433919|NCT01542294|Drug|Oxaliplatin|130mg/m2 d1 repeated every 21 days
75433920|NCT01542320|Dietary Supplement|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
75729091|NCT05014672|Drug|Setanaxib|Oral tablets, 400mg per tablet
75729092|NCT05014672|Drug|Placebo|Oral tablets
75729093|NCT05014438|Drug|BMS-986166|Specified dose on specified days
76051005|NCT05651971|Behavioral|measurement group|Measurement of the distance between the origin of LCA (left colonic artery，LCA) and IMA (inferior mesenteric artery，IMA) root and the distance between IMA and IMV (inferior mesenteric vein，IMV) at the origin of LCA in rectal cancer patients
76051006|NCT04137211|Behavioral|Prolonged sitting with social break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
75580909|NCT00548600|Radiation|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
75580910|NCT04635618|Behavioral|Cognitive Behavioral Brief-Telepsychotherapy|Four sections of Cognitive Behavioral Brief-Telepsychotherapy plus personalized pre-recorded videos
75580911|NCT04635618|Behavioral|Brief Interpersonal Telepsychotherapy|Four sections of Brief Interpersonal Telepsychotherapy plus personalized pre-recorded videos
75580912|NCT04635618|Behavioral|Telepsychoeducation|A single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks
75580913|NCT04684355|Other|Real-time colonoscopic optical diagnosis for colorectal neoplasm|Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
75580914|NCT00548639|Other|Statin Choice Decision Aid|Paper based instrument with pictures indicating level of risk.
76051007|NCT04137211|Behavioral|Prolonged sitting with walk break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
75580915|NCT00548639|Other|Control Pamphlet|ADA Diabetes Sheet
75580916|NCT04635696|Drug|Ethyl chloride|Pressurized vapocoolant developed for acute, mild pain relief.
75580917|NCT04635696|Other|Tissue culture grade water|Pressurized water mist
75580918|NCT04644120|Drug|ABBV-47D11|Intravenous (IV) infusion.
75580919|NCT04644120|Drug|Placebo for ABBV-47D11|Intravenous (IV) infusion.
75580920|NCT04644120|Drug|ABBV-2B04|Intervenous (IV) Infusion
75729094|NCT05014438|Drug|Branebrutinib|Specified dose on specified days
75580921|NCT04644120|Drug|Placebo for ABBV-2B04|Intervenous (IV) Infusion
75580922|NCT00558909|Drug|BI 44847|
75580923|NCT00558909|Drug|placebo for BI 44847|
75729095|NCT05014438|Other|Placebo|Specified dose on specified days
75729096|NCT05014048|Dietary Supplement|Vitamin D3|20 mikrog vitamin D3 daily
75729097|NCT05014048|Dietary Supplement|Placebo|Placebo
75729098|NCT05010577|Drug|BX004-A|Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
75729099|NCT05010577|Drug|Placebo|Nebulized placebo
75580924|NCT04942145|Device|virtual reality in dental patients|"The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires"
75580925|NCT04643964|Behavioral|Entrée: Cognitive skills|In this condition, participants view a video-based intervention covering cognitive emotion regulation skills. This intervention asks participants to respond to questions and practice identifying and evaluating their own thoughts using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
75729100|NCT05008783|Drug|AK104|AK104 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward, AK104 will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
75433921|NCT01542320|Other|Placebo|Solution without active Lactobacillus reuteri
76051008|NCT04137211|Behavioral|Prolonged sitting with simple resistance activities|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
76051009|NCT05651815|Device|Graphene spectrum light wave therapy room|Undergo 30-min of graphene adjuvant therapy every day for 7 d.
75433922|NCT01542333|Genetic|gene expression analysis|
75433923|NCT01542333|Genetic|proteomic profiling|
75433924|NCT01542333|Genetic|reverse transcriptase-polymerase chain reaction|
75433925|NCT01542333|Genetic|western blotting|
75580926|NCT04643964|Behavioral|Entrée: Behavioral skills|In this condition, participants view a video-based intervention covering behavioral emotion regulation skills. This intervention asks participants to respond to questions and practice scheduling activities that might give them a sense of pleasure or accomplishment using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to schedule and engage in behaviors in line with the intervention skills.
75580927|NCT04643964|Behavioral|Entrée: Interpersonal skills|In this condition, participants view a video-based intervention covering interpersonal emotion regulation skills. This intervention asks participants to respond to questions and practice communicating effectively using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
76051010|NCT04132219|Behavioral|eHealth Intervention|Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
75433926|NCT01542333|Other|immunohistochemistry staining method|
75433927|NCT01542333|Other|laboratory biomarker analysis|
75433928|NCT01542333|Procedure|spectroscopy|
75433929|NCT01542346|Procedure|subcutaneous adaption|
75433930|NCT01542359|Other|Yogic practice|breathing, meditation, physical postures
75433931|NCT01542359|Other|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
75433932|NCT01542385|Procedure|Stent|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
75433933|NCT01542424|Drug|biphasic insulin aspart 30|Prescribed at the discretion of the physician
75433934|NCT01542424|Drug|insulin detemir|Prescribed at the discretion of the physician
75433935|NCT01542437|Drug|BIBW 2992|"All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug."
75433936|NCT01542450|Drug|insulin detemir|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
75433937|NCT01542450|Drug|insulin NPH|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
75433938|NCT01542463|Drug|insulin detemir|Prescribed at the discretion of the physician
75433939|NCT01542476|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
75580928|NCT04643964|Behavioral|Sampler skills|In this condition, participants view a video-based intervention covering three emotion regulation skills: cognitive, behavioral, and interpersonal skills. This intervention asks participants to respond to questions and practice using skills using intervention worksheets. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
75580929|NCT00548678|Drug|intravenous diclofenac sodium (DIC075V)|intravenous diclofenac sodium
75580930|NCT00548678|Drug|ketorolac|intravenous ketorolac
75580931|NCT00548678|Drug|oral diclofenac (Cataflam)|oral diclofenac (Cataflam)
75580932|NCT00548678|Drug|aspirin|oral aspirin
75580933|NCT00548834|Drug|CDP870|
75580934|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
75580935|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
76051011|NCT03998293|Drug|Somatostatin|infused to block endogenous insulin secretion over a 4 hour period
75580936|NCT00548951|Other|Control|Receive no sessions in a Snoezelen Room.
75580937|NCT04635501|Device|ABS 5.6.7|Patients whose access site will be closed with the ABS 5.6.7
75580938|NCT04684199|Dietary Supplement|Melatonin|Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
75729101|NCT05008783|Drug|Placebo|Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
75580939|NCT04684199|Dietary Supplement|Placebo|
76051012|NCT05651503|Dietary Supplement|Prodilac Oral, Frezyderm|In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two Experimental groups
76051013|NCT05651503|Dietary Supplement|placebo lozenges|In order to avoid possible bias, probiotics will be compared with placebo lozenges/no probiotic in two Control groups
76051014|NCT01755598|Biological|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
75433940|NCT01542489|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
75433941|NCT01542489|Drug|insulin aspart|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
75433942|NCT01542489|Drug|human soluble insulin|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
76051015|NCT01755598|Biological|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
76051016|NCT01606306|Drug|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
75580940|NCT04635267|Other|Prone position in patients with ARDS|Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
75580941|NCT00548990|Behavioral|cardiovascular exercise training|
75580942|NCT00548990|Behavioral|flexibility/balance control|
75580943|NCT00560586|Drug|Budesonide|1 puff each nostril (32 micrograms) at bedtime
75580944|NCT00560586|Drug|placebo|1 puff each nostril at bedtime
76051017|NCT01606306|Drug|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
76051018|NCT01606306|Drug|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
76051019|NCT01754194|Procedure|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
75580945|NCT00549029|Genetic|DNA|withdraw 5~10mL blood from vein only once during the whole design
76051020|NCT01754194|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
75580946|NCT00549068|Drug|Risedronate Sodium (Actonel)|
75580947|NCT04644198|Biological|Convalescent Plasma Infusion|250 mls of convalescent plasma on day 1 & 2.
75580948|NCT04643730|Other|Acupressure methods|Acupressure on the KI3 and St36 points applied to the babies in the acupressure group for a total of 7 minutes before the heel prick
75580949|NCT04643730|Other|Foot Reflexology Methods|Foot reflexology was applied to the babies in the foot reflexology group for a total of 7 minutes before the heel prick
75580950|NCT04643730|Other|Control Grup|No pre-application was made to the babies in the control group as a routine procedure.
75580951|NCT00549107|Drug|Levosimendan|
75580952|NCT00549107|Drug|Milrinone|
76051021|NCT01753570|Drug|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
75580953|NCT04635306|Diagnostic Test|Approved GEBT test meal|FDA-approve GEBT test meal
75580954|NCT00549146|Drug|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
75580955|NCT00549146|Drug|fluticasone propionate DISKUS 500mcg|
75580956|NCT04643496|Procedure|Laparoscopic or open Ileocolic resection|Laparoscopic or open Ileocolic resection
75580957|NCT00549185|Drug|SAR3419|Intravenous infusion
75580958|NCT04643847|Drug|Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
75580959|NCT00549263|Drug|SB797620|
75580960|NCT00549341|Drug|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
75729102|NCT05004090|Diagnostic Test|DNA methylation analysis|Genomic DNA will be extracted from 0.4 ml aliquots of each saliva sample using the kit manufacturer's suggested protocol, quantified with Qubit 2.0 (Invitrogen), and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed as described. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated and tabulated.
76051022|NCT01753570|Drug|RBV(24 weeks)|RBV: 600 - 1000mg/day based on body weight for 24 weeks
76051023|NCT01753570|Drug|IFN beta(24 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
76051024|NCT01753570|Drug|RBV(48 weeks)|RBV: 600 - 1000mg/day based on body weight for 48 weeks
76051025|NCT01753570|Drug|IFN beta(48 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
76051026|NCT01753336|Biological|Botulinum toxin type A|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
76051027|NCT01777282|Drug|Albiglutide|Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
76051028|NCT01777282|Drug|Sulfonylurea|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
76051029|NCT01777282|Drug|Biguanide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
76051030|NCT01777282|Drug|Glinide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
76051031|NCT01777282|Drug|Thiazolidinedione|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
75580961|NCT00549341|Other|Physiologic saline|Single injection.
75580962|NCT00549380|Device|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
75580963|NCT00549419|Drug|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
75880745|NCT01346423|Behavioral|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
75880746|NCT03610776|Device|Portion control plate|Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
75880747|NCT03610776|Device|Conventional plate|Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
75433943|NCT01542515|Procedure|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
75433944|NCT01542554|Other|Low glycaemic index diet|Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
75433945|NCT01542554|Other|Usual diabetic diet|Diabetic subjects will be given dietary advice without mention about glycaemic index
75433946|NCT01542567|Drug|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
75433947|NCT01542567|Drug|Placebo|Placebo suppositories
75433948|NCT01542593|Device|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|"During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
75433949|NCT01542606|Device|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
75433950|NCT01542619|Biological|rVIIa-FP|Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
75433951|NCT01542619|Biological|Placebo (0.9% normal saline)|Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
75580964|NCT00549419|Drug|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
75580965|NCT00549419|Drug|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
75580966|NCT04635540|Behavioral|Educational Brochure|Educational brochure on decreased empathy and emotion recognition in patients with neurodegenerative disease
75433952|NCT01542671|Behavioral|Intervention|"Lifestyle Counselor meetings at baseline, 6 months, and 12 months~Structured eating plan~Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~Monthly Motivational phone calls with Lifestyle Counselor for the first year~4 informational DVDs over the two year period~Feedback on submitted food and exercise journals"
75580967|NCT00549458|Behavioral|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
75880748|NCT01346579|Other|laboratory biomarker analysis|Correlative sciences
75880749|NCT03611088|Other|Kangaroo Position.|The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
75880750|NCT02066870|Drug|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
75880751|NCT02066870|Drug|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
75580968|NCT00549458|Procedure|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
75580969|NCT04635150|Behavioral|Close Collaboration with Parents|Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
75729103|NCT05004090|Diagnostic Test|Proteomics analysis|Urine samples are collected using non-invasive methods and are prepared according to a procedure preparatory to quantitative recovery of exosomes: once thawed and centrifuged at 17,000 x g for 10 min at 4°C, the recovered supernatants are separated and centrifuged at 200,000 x g for 1 hr at 4°C. Exosome pellets are separated, washed repeatedly and resuspended in buffer (NH4HCO3, 0.1 mM ph=7.8). Protein concentration is estimated with the SPNTM Protein Assay kit and each sample (50 ± 0.5 μg protein) is digested with trypsin using a 1:50 (w/w) enzyme/substrate ratio at 37 °C over night (o/w). A second tryptic digestion is performed with an enzyme:substrate ratio of 1:100 (w/w) for 4h. Digested samples, centrifuged at 13,000 × g for 10 min, are purified and concentrated using PepClean C-18 columns. The samples obtained are analyzed by reversed-phase liquid chromatography coupled to high-resolution mass spectrometry.
75880752|NCT05030363|Drug|ALDH enzyme supplementation|ALDH enzyme (PICOZYMEQ™)
75880753|NCT03635203|Device|CBCT|Observation of C-shaped root canal in mandibular first and second molars in Egyptian sub-population
75880754|NCT03611244|Device|Portable seat device devised to maintain lumbar lordosis|"The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained."
75880755|NCT04034355|Drug|Calmangafodipir (5 µmol/kg)|PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.
75880756|NCT04034355|Other|Placebo|Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
76051032|NCT01777282|Drug|Alpha-glucosidase inhibitor|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
75433953|NCT01542671|Behavioral|Control|"Lifestyle Counselor meetings at baseline, 6 months, and 12 months~Structured eating plan~5 informational NIDDK mailings over the two year period"
75880757|NCT05210699|Other|Product A|Usual Brand (UB) filtered, menthol combustible cigarette
75880758|NCT05210699|Other|Product B|Flavor variant P1211216 of a 1.5% nicotine ENDS product
75880759|NCT05210699|Other|Product C|Flavor variant P1211217 of a 2.4% nicotine ENDS product
76051033|NCT04169776|Device|Transcutaneous Auricular Vagus Nerve (taVNS) stimulation|Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
75433954|NCT01542697|Drug|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
75433955|NCT01542710|Drug|Ganfort|Bimatoprost/Timolol fixed combination
75433956|NCT01542710|Drug|Duotrav|Fixed combination of Travoprost and Timolol
75433957|NCT01542723|Drug|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
75880760|NCT05210699|Other|Product D|Flavor variant P1211222 of a 5.0% nicotine ENDS product
75580970|NCT03456050|Behavioral|FRC exercise|The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
75880761|NCT05210699|Other|Product E|Flavor variant P1213616 of a 1.5% nicotine ENDS product
75729104|NCT05004090|Diagnostic Test|Still Face Paradigm|During an observational session, a short video recording of the mother-child interaction of approximately 10 minutes will be made in a semi-structured setting to assess the child's emotional regulation and social behavior. The interaction will be structured in 5 different phases according to the Still Face paradigm (Tronick et al., 1978): Play, Still#1, Reunion#1, Still#2, Reunion#2. Play: Mothers will be invited to interact with their babies for 10 minutes; Still: mothers will be asked to remain still while maintaining an unresponsive expressionless face and not to smile, touch, or talk to the child for 2 minutes (Still#1: 2 minutes; Still#2: 2 minutes); Reunion: mothers will be asked to resume the play activity with their own for an additional 2 minutes (Reunion#1: 2 minutes; Reunion#2: 2 minutes).
75729105|NCT05000931|Device|Osia 2 System|Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.
75729106|NCT04996823|Drug|Ipilimumab|Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.
75729107|NCT04996823|Drug|Axitinib|Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)
75729108|NCT04993235|Behavioral|NEPSY-II|Participants with SS and BWS are administered with selected subtests assessing six different neuropsychological domains
75880762|NCT05210699|Other|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
75880763|NCT02066948|Other|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
75729109|NCT04993235|Behavioral|CBCL and AQ questionnaires|Parents of participants with SS and BWS are administered with questionnaires assessing behavioral problems and autistic traits
75729110|NCT04993235|Behavioral|BUT questionnaire and experimental tasks|A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups
75880764|NCT02066948|Other|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
75880765|NCT02066948|Other|meal pattern|skew or even
75880766|NCT02066948|Dietary Supplement|even|even amount of protein distributed between each meal
75880767|NCT02066948|Dietary Supplement|skew|a skewed amount of protein is distributed between each meal
75880768|NCT01317745|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
75580971|NCT03456050|Behavioral|Conventional Exercise|The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
75580972|NCT04643691|Drug|Losartan 50 mg and Spironolactone 25 mg pillules oral use|Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
75580973|NCT03456011|Other|Battlefield Acupuncture|Battlefield Acupuncture gold semi permanent needles
75580974|NCT03455972|Biological|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)
75580975|NCT03455972|Drug|Immunomodulatory drugs|Maintenance therapy
75580976|NCT03455933|Other|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
75580977|NCT03455933|Other|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
76051034|NCT04571632|Drug|Avelumab|"Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions < 0,5 cm to 2.0 mL for lesions > 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required."
75580978|NCT03455933|Other|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
75580979|NCT04634994|Drug|[F-18]SDM-8|PET radiopharmaceutical. Subjects will undergo [F-18]SDM-8 PET Scanning to measure synaptic density.
75580980|NCT00549497|Drug|GW870086X|
75880769|NCT01317745|Drug|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
75580981|NCT00549536|Dietary Supplement|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
75580982|NCT04643613|Dietary Supplement|Protison cancer nutritional formula (PCNF)|PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
75580983|NCT00549575|Drug|L ARG|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
75580984|NCT00549575|Drug|Placebo|After double blind randomization, patients received a placebo.
75580985|NCT00549614|Drug|acipimox|capsule, 250 mg, 4 times daily for 28 days
75580986|NCT00549614|Drug|placebo|capsule, 250 mg, 4 times daily for 28 days
75580987|NCT00558987|Behavioral|Discipline Video|"The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers."
75580988|NCT00558987|Behavioral|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
75580989|NCT00549653|Drug|GW856553|
75580990|NCT00560664|Procedure|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
75580991|NCT00560664|Procedure|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
75580992|NCT00549692|Drug|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
75580993|NCT00560742|Procedure|Control|Coronary artery bypass grafting without bone marrow cells injection
75433958|NCT01542762|Drug|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
75433959|NCT01542775|Behavioral|Aerobic Exercise Group|12 weeks Aerobic exercise
75433960|NCT01542775|Behavioral|Control Group|maintaining usual activities
75433961|NCT01542801|Drug|Norfloxacin|Norfloxacin 400 mg per day
75433962|NCT01542801|Drug|ciprofloxacin|Ciprofloxacin 750 mg per week
75580994|NCT00560742|Procedure|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
75580995|NCT00560742|Procedure|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
75580996|NCT00560781|Drug|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
75580997|NCT00559026|Biological|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
75580998|NCT00559026|Other|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
75580999|NCT00549809|Procedure|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
75729111|NCT04982367|Device|Sirolimus-eluting balloon catheter|Sirolimus-eluting balloon catheter designed and produced by Acotec
75433963|NCT01542814|Device|3Dimensional Mammography|The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.
75581000|NCT00549887|Drug|Analog or Human Insulin|prescribed in accordance with usual clinical practice
75581001|NCT00549926|Drug|Fluvastatin|
75581002|NCT00549926|Drug|Pravastatin|
75581003|NCT00549926|Drug|Pitavastatin|
75581004|NCT00549926|Drug|Atorvastatin|
75581005|NCT04634448|Procedure|Interval appendectomy|interval appendectomy at 2 to 3 months after the initial non-operative treatment
75581006|NCT04634448|Diagnostic Test|Follow-up MRI at 1 year|follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
75581007|NCT00549965|Drug|Risedronate Sodium|
75581008|NCT04634487|Other|No intervention|No intervention
75581009|NCT00550004|Drug|RP101|190 mg oral tablet
75581010|NCT00550004|Drug|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
75581011|NCT04634721|Drug|bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.
75729112|NCT04982367|Device|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter (trade name:DHALIA)
75729113|NCT04979442|Drug|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
75729114|NCT04979442|Drug|Trabectedin|1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks
75581012|NCT04643262|Procedure|Sleeve Gastrectomy|Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.
75581013|NCT04634565|Drug|PF-06651600|oral PF-06651600 tablet 200 mg once daily
75581014|NCT00550121|Drug|vitamin C|
75880770|NCT01317745|Biological|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
75880771|NCT03610932|Dietary Supplement|Vitamin C|Taken as 3 500mg capsules.
76051035|NCT04571632|Drug|Ipilimumab 5 MG/ML|"Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions < 0,5 cm to 2.0 mL for lesions > 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size"
75433964|NCT01542814|Device|2D FFDM|Standard of care screening mammogram.
75581015|NCT00550121|Drug|placebo|
75581016|NCT04643028|Other|Home exercise|Exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
75880772|NCT03610932|Other|Placebo|Taken as 3 500mg capsules.
75880773|NCT01355965|Biological|Autologous T cells|
75880774|NCT03610620|Procedure|Vivascope 2500 ex-vivo fluorescent confocal microscope|scanned with the Vivascope 2500
75880775|NCT01346657|Drug|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
75433965|NCT01542827|Other|Biofreeze|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
75880776|NCT01359709|Drug|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
75880777|NCT02067026|Dietary Supplement|Aleurone|
75880778|NCT02067026|Dietary Supplement|Placebo|
75880779|NCT04158336|Drug|ZN-c3|ZN-c3 is a study drug
75880780|NCT01346735|Other|No intervention|
75880781|NCT03940365|Device|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
75433966|NCT01542827|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
75433967|NCT01542866|Other|Health Management Tool (HMT)|Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
75433968|NCT01542892|Other|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
75433969|NCT01542892|Dietary Supplement|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
75433970|NCT01542905|Dietary Supplement|Korean Red Ginseng|Korean Red Ginseng Capsule (1g/day) for 8 Weeks
75581017|NCT04643028|Other|Mulligan mobilization|Mulligan mobilization: Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions.Sixty seconds of rest will be given between sets.
75880782|NCT01317823|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
75433971|NCT01542905|Other|Placebo|Placebo Capsule (1g/day) for 8 Weeks
75433972|NCT01542918|Drug|Lenalidomide|"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral"
75433973|NCT01542918|Drug|Rituximab|"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"
75433974|NCT01542931|Drug|TPF induction chemotherapy|Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
75433975|NCT01542944|Drug|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
75433976|NCT01542970|Dietary Supplement|Placebo|Olive oil
75581018|NCT04643028|Other|Cervical stabilization|Cervical stabilization group: In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
75433977|NCT01542970|Dietary Supplement|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
75729115|NCT04969887|Drug|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
75880783|NCT05539898|Device|ICD implantation|All included in the study will undergo ICD implantation for primary prevention of SCD
75880784|NCT02826486|Drug|BL-8040|BL-8040 subcutaneous(SC) injections
75433978|NCT01542970|Dietary Supplement|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
75433979|NCT01542970|Dietary Supplement|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
75433980|NCT01542983|Behavioral|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
75433981|NCT01542983|Behavioral|treatment as usual|Standard treatment for fatigue and insomnia
75880785|NCT02826486|Drug|Pembrolizumab|pembrolizumab will be given as a 30-minute IV infusion
75433982|NCT01543009|Other|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
75880786|NCT02826486|Drug|Chemotherapy of Onivyde|• IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
75433983|NCT01543022|Device|Symphony|The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.
75581019|NCT00550160|Drug|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
75433984|NCT01543022|Procedure|The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker|The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
75433985|NCT01543035|Drug|stop statin and switch to an antiretroviral drug with less impact on lipid metabolism|Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
75433986|NCT01543048|Other|Study Follow-Up|Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
75433987|NCT01543061|Device|OPTIVEtm Plus|1 drop in each eye four times a day for a period of 30 (± 3) days
75433988|NCT01543061|Procedure|No treatment|One month of contact lens wear with no eye drop use
75433989|NCT01543061|Device|Blink Contacts® Eye Drops|1 drop in each eye four times a day for a period of 30 (± 3) days
75433990|NCT01543100|Other|blood and bone marrow samples|"Specific tests of the study will be realized from :~Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.~Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.~In all cases, no additional sampling will be performed."
75433991|NCT01543139|Drug|Valproate+Cytidine-+Creatine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
75433992|NCT01543139|Drug|Valproate+Cytidine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
75433993|NCT01543139|Drug|Valproate|Valproate: Week0-8: 300mg/day
75433994|NCT01543165|Drug|Ketorolac and nefopam balanced analgesia|Sequential intravenous administration of ketorolac and nefopam
75729116|NCT04969887|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
75729117|NCT04968132|Other|Multicomponent opioid reduction and pain management pathway|Pre-operative pain education and expectation setting, identification and modification of risk factors in high risk patients, postoperative individualized analgesic prescriptions, and continued support for pan control and recovery facilitated by an interventions coordinator.
75729118|NCT04968132|Other|Standard care|Standard perioperative care, surgical treatment, and pain medications.
75433995|NCT01543165|Drug|Balanced analgesia using ketorolac and morphine|Sequential intravenous administration of ketorolac and morphine
75433996|NCT01543165|Drug|Pain control with single analgesics (ketorolac)|This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
75433997|NCT01543191|Drug|PUR118|low dose and high dose for 3 doses, BID
75581020|NCT00550199|Drug|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
75880787|NCT01359787|Drug|Mapracorat|Daily topical application
75581021|NCT04643301|Drug|Liraglutide Pen Injector|Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
75729119|NCT04968054|Drug|Arm I (Propofol)|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
75581022|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
75581023|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
75581024|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
75581025|NCT00550355|Drug|Placebo|3 doses of Placebo administered over 12 weeks
75581026|NCT04634292|Behavioral|EEG|EEG + walking task + auditory task
75581027|NCT00550433|Device|Bazedoxifene/Conjugated Estrogens|
75581028|NCT00559143|Other|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
75581029|NCT00550472|Dietary Supplement|probiotics|Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
75581030|NCT04634370|Biological|Natural Killer Cells infusion|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
75581031|NCT00550511|Radiation|Surgeon-performed ultrasound|After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
75581032|NCT04642989|Other|Sham Treatment|All movements of facial effleurage except applying pressure
75581033|NCT04642989|Other|Facial Effleurage|Facial massage to remove any lymphatic blockages
75581034|NCT04642989|Drug|Antibiotics|"Appropriate standard-of-care antibiotics as determined by the physician."
75581035|NCT04634058|Drug|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 monoclonal antibody combined with CTLA-4 monoclonal antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
75581036|NCT00550628|Genetic|DNA methylation analysis|
75581037|NCT00550628|Genetic|fluorescence in situ hybridization|
75581038|NCT00550628|Genetic|gene expression analysis|
75581039|NCT00550628|Genetic|polymerase chain reaction|
75581040|NCT00550628|Genetic|protein expression analysis|
75581041|NCT00550628|Genetic|reverse transcriptase-polymerase chain reaction|
75581042|NCT00550628|Other|diagnostic laboratory biomarker analysis|
75581043|NCT00550628|Other|immunoenzyme technique|
75581044|NCT00550628|Other|immunohistochemistry staining method|
75581045|NCT00550628|Procedure|biopsy|
75581046|NCT00550628|Procedure|therapeutic conventional surgery|
75433998|NCT01543217|Other|RT management|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
75433999|NCT01543217|Other|Ususal care|Routine respiratory care.
75581047|NCT00550628|Radiation|fludeoxyglucose F 18|
75581048|NCT00560820|Drug|Deferasirox|30 mg/kg/day
76051036|NCT04571632|Drug|Pembrolizumab 100 MG in 4 ML Injection|The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.
75581051|NCT00550784|Biological|filgrastim|
75581052|NCT00550784|Drug|cisplatin|
75581053|NCT00550784|Drug|cyclophosphamide|
75581054|NCT00550784|Drug|melphalan|
75581055|NCT00550784|Drug|paclitaxel|
75581056|NCT00550784|Drug|topotecan hydrochloride|
75581057|NCT00550784|Genetic|TdT-mediated dUTP nick end labeling assay|
75581058|NCT00550784|Genetic|gene expression analysis|
75581059|NCT00550784|Other|immunohistochemistry staining method|
75581060|NCT00550784|Other|pharmacological study|
75581061|NCT00550784|Procedure|peripheral blood stem cell transplantation|
75581062|NCT04633941|Other|Standard Care|Standard Care
75581063|NCT00550823|Device|Cardiac CT 0BRILLIANT 64|Cardiac CT
75729120|NCT04968054|Drug|Arm II (Remimazolam)|Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
75729121|NCT04954027|Behavioral|Questionnaires|"5 visits are planned during the study :~the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online~4 telephone interviews for follow-up by investigator"
75880788|NCT01359787|Drug|Vehicle without active|Daily topical application
75880789|NCT02067260|Device|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
75880790|NCT02067260|Device|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
75434000|NCT01543230|Device|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
75581064|NCT04633785|Other|No Intervention|There are no interventions in this study. The mercury sphygmomanometer and the wrist sphygmomanometer will be used in this study to collect blood pressure values from the study subjects.
75581065|NCT00550901|Drug|cisplatin|
75581066|NCT00550901|Drug|dexrazoxane hydrochloride|
75581067|NCT00550901|Other|high performance liquid chromatography|
75581068|NCT00550901|Other|laboratory biomarker analysis|
75581069|NCT00550901|Other|mass spectrometry|
75581070|NCT00550901|Other|pharmacological study|
75581071|NCT04633746|Diagnostic Test|measuring plasma Endostatin level|measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
75581072|NCT04633629|Other|Lung ultrasound|We will perform daily a lung ultrasound to evaluate pulmonary congestion by counting B-lines.
75581073|NCT04643223|Other|kinesio tape with tension|The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
75581074|NCT04643223|Other|kinesio tape without tension|The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
75581075|NCT00551018|Drug|Vicriviroc|one 30 mg tablet QD
75581076|NCT00551018|Drug|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
75581077|NCT00551057|Behavioral|Expression type|to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue
75581078|NCT00551096|Drug|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
75434001|NCT01543243|Device|Stochastic resonance whole-body vibration A|"Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1."
75434002|NCT01543243|Device|Stochastic resonance whole-body vibration B|"Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4."
75434003|NCT01543269|Drug|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
75581079|NCT00551096|Drug|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
75434004|NCT01543269|Drug|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
75581080|NCT00551096|Drug|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
75581081|NCT04642872|Other|Infant BIT|Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
75581082|NCT04642872|Other|Infant CIMT/BIT|Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.
75581083|NCT04642872|Other|Conventional therapy|Following the usual therapy in the baby.
75581084|NCT04642872|Other|infant cimt|use of unaffected hand containment to improve the use of affected hand with unimanual activities
75581085|NCT00551252|Drug|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
75581086|NCT04642716|Other|Saliva collection of patients and salivary free amino acids analysis|
75434005|NCT01543282|Device|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
75581087|NCT00551330|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily
75581088|NCT00551330|Drug|Placebo|One tablet of placebo once daily
75581089|NCT04642794|Other|observational study|patients admitted for AP with portosplenomesenteric vein thrombosis.
75581090|NCT04892966|Diagnostic Test|TXI Light Imaging|Standard Colonoscopy using TXI imaging
75581091|NCT04892966|Diagnostic Test|WLI Imaging|Standard Colonoscopy using White Light Imaging
75581092|NCT04642521|Device|Jamar hydraulic hand dynamometer|"The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg."
75581093|NCT00551486|Procedure|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
75581094|NCT04642248|Other|Personalized Run Practice|A combination of drills, flexibility, and strength activities combined with a gait retraining program
75434006|NCT01543321|Drug|Tetrabenazine|"Treatment with tetrabenazine consists in:~5-week titration to a maximum dose of 200 mg / day~5 weeks at stable dose~2 weeks in wash-out~The treatment will be blinded for patients and investigators"
75729122|NCT04951804|Procedure|EUS-CPN without bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to inject a neurolytic agent such as absolute alcohol around the base of the celiac artery.
75729123|NCT04951804|Procedure|EUS-CPN with bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to firstly inject bupivacaine and secondly a neurolytic agent such as absolute alcohol around the base of the celiac artery.
75880791|NCT03748485|Behavioral|wait and watch|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),without(wait and watch) adjuvant chemotherapy
75880792|NCT03748485|Drug|adjuvant chemotherapy|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
75880793|NCT02825940|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
75581095|NCT03455894|Device|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
75581096|NCT04642482|Dietary Supplement|Synbiotic (Rillus)|Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.
75581097|NCT04642482|Drug|Placebo|Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
75581098|NCT03455777|Drug|AKCEA-ANGPTL3-LRX|Single open-label cohort
75581099|NCT03455738|Other|vasoplegic syndrome|Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the norepinephrine dosage were included. Hemodynamic and uncalibrated pulse contour analysis (Volume view, FloTrac, Edwards Lifescience, Irvine) values were obtained before and after decreasing the norepineprhine dosage. Responders were defined by a >10% decrease in mean arterial pressure (MAP).
76051037|NCT04571632|Other|CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC|"CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions < 0,5 cm to 4.0 mL for lesions > 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size."
75581100|NCT04642209|Device|Aggregometry|"After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS <4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation."
76051038|NCT01975389|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
75581101|NCT01167374|Radiation|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
75581102|NCT01125761|Drug|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
75729124|NCT04941469|Device|Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types."
75729125|NCT04941469|Device|Plain off-the-counter foot orthosis (Medical grade foot orthosis)|The control device for this study would be the plain original Formthotics (Original Dual Hard).
76051039|NCT01975389|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
75434007|NCT01543321|Drug|Placebo|"Treatment with placebo consists in:~5-week titration to a maximum dose of 200 mg / day~5 weeks at stable dose~2 weeks in wash-out~The treatment will be blinded for patients and investigators"
75434008|NCT01543334|Biological|Blood sampling|Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
75434009|NCT01543347|Drug|Temocillin|Antibiotic treatment
75434010|NCT01543360|Procedure|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The same puncture material/devices will be used in both arms of the study.
75729126|NCT04940299|Biological|Ipilimumab|Given IV
75729127|NCT04940299|Biological|Nivolumab|Given IV
75729128|NCT04940299|Biological|Tocilizumab|Given SC
75729129|NCT04936204|Device|ConnettivinaBio Plus cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
76051040|NCT01974141|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
75880794|NCT02825940|Drug|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m^2 on Days 1 and 8.
75880795|NCT02825940|Drug|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m^2 on Day 1.
75880796|NCT02065232|Drug|Tilmanocept|
76051041|NCT01974141|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
76051042|NCT01945593|Biological|BAX855|Antihemophilic Factor (Recombinant), PEGylated
75729130|NCT04936204|Device|ConnettivinaBio cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
75729131|NCT04931771|Device|vFFR guided revascularization|3D-angio-based vessel FFR (CAAS, Pie Medical Imaging, Maastricht, The Netherlands) uses 3-Dimensional Quantitative Coronary Angiography (3D-QCA) for functional assessment of coronary stenosis. vFFR is calculated using two angiographic views with at least 30 degrees difference in rotation/angulation to generate the 3D reconstruction of the coronary artery.
75434011|NCT01543360|Procedure|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein). The same puncture material/devices will be used in both arms of the study.
75434012|NCT01543373|Device|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
75729132|NCT04931771|Device|FFR guided revascularization|Fractional flow reserve (FFR) is a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis (narrowing, usually due to atherosclerosis) to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle (myocardial ischemia)
75880797|NCT02065232|Drug|Sulfur Colloid|
75880798|NCT02304991|Drug|Liquid Peanut Extract|5000mcg/ml peanut protein
75434013|NCT01543373|Device|Bare Metal Stent|Bare metal coronary stent
75880799|NCT02304991|Drug|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
75880800|NCT04870281|Device|CRT-DX|Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
75880801|NCT01348295|Other|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
76051043|NCT01945281|Drug|Caspofungin|
76051044|NCT01945281|Drug|Amphotericin B Deoxycholate|
76051045|NCT01961349|Drug|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
76051046|NCT01961349|Drug|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
76051047|NCT01961349|Drug|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
76051048|NCT01973595|Dietary Supplement|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
76051049|NCT01973595|Other|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
75434014|NCT01543386|Drug|Curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
75581103|NCT01125761|Drug|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
75581104|NCT04642326|Device|Test Group: experimental - UVC Therapy applied|in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
75581105|NCT04642092|Behavioral|PsicAP protocol|The intervention will include: psychoeducation, relaxation and breathing techniques, thought management, tips to improve quality of life and relapse prevention. All of these activities will be based on scientific evidence and many of these aspects will be supported by mobile devices.
75581106|NCT04642092|Behavioral|Conventional treatment|Typical treatment that is currently given to patients with emotional disorders in Dominican primary care units.
75581107|NCT04641780|Drug|Brexpiprazole|"For the treatment of schizophrenia, the recommended starting dosage for Rexulti™ is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Rexulti™ dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg.~The recommended starting dosage for Rexulti™ as adjunctive therapy for MDD is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. It must be periodically reassess to determine the continued need and appropriate dosage for treatment."
75729133|NCT04915131|Device|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes."
75729134|NCT04910048|Other|POPOP (preoperative patient optimization program)|A 2 month structured program focused on reduction of BMI, body weight, visceral fat, body fat and improvement of lean body mass and intracellular fluid.
75729135|NCT04910048|Other|SOC (standard of care)|Referral to a dietician for two months of self-directed weight loss
75729136|NCT04897334|Device|tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
75880802|NCT02069132|Drug|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
75880803|NCT03715985|Drug|EVAX-01-CAF09b|The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
75880804|NCT04852029|Other|Low dose hCG|Patients will either maintain the current dose of have an increased dose prescribed based on randomization
75434015|NCT01543399|Drug|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
75434016|NCT01543399|Drug|Placebo|patients of the placebo group will use placebo one a day for 30 days
75434017|NCT01543412|Drug|FOLFIRI|Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
75434018|NCT01543438|Other|Video Prescription (additional education)|receives video prescriptions
75434019|NCT01543464|Drug|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
75434020|NCT01543529|Drug|RO4917838|Single dose of RO4917838
75434021|NCT01543529|Drug|Placebo to RO4917838|Single dose of placebo to RO4917838
75581108|NCT04641624|Other|ultrasound assessment|soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
75581109|NCT05431127|Device|IMT therapy using the Pr02 mobile device|Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
75581110|NCT04641546|Procedure|Therapeutic Exercise|Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
75581111|NCT04641546|Procedure|Occupation-Based Intervention|Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
75581112|NCT05427656|Radiation|[18F] TRACK|We propose to use the radiotracer [18F] TRACK to non-invasively image the concentration of TrkB/C in the living human brain with PET in the 3 cohorts. The different subgroups of healthy controls will be used to define the best quantification method for our TrkB/C ligands and to assess a possible age dependency of TrkB/C binding in the healthy population, and may be of particular importance for the future study of patients with Alzheimer's Disease or mild cognitive impairment. Each participantsubject will receive a single scan with 185 MBq [18F] TRACK injected into an antecubital vein. Dynamic PET data will be acquired in list mode for 90 minutes ([18F] TRACK) respectively on a CTI/Siemens HRRT PET scanner at the brain imaging center of the Montreal Neurological Institute following our published procedure for [18F] TRACK after a transmission scan.
75729137|NCT04897334|Device|sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
75729138|NCT04897334|Behavioral|Cognitive Therapy|During both the treatment and the sham intervention, participants will undero cognitive therapy training by performing the NBack task. In this sequential letter memory exercise participants are presented with sequential stimuli in the form of a series of letters. For each new stimulus they are asked to indicate if the current stimulus matches the stimulus from 2 trials prior. This exercise stimulates cognitive demand in working memory, executive function and attention and is correlated with dorsolateral prefrontal cortex activity.
75880805|NCT01352065|Drug|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
75729139|NCT04887337|Procedure|Arthroscopic stabilization|Early arthroscopic stabilization with Bankart repair
75729140|NCT04887337|Other|Rehabilitation including a period of immobilization followed by physical therapy|Rehabilitation including a period of immobilization followed by physical therapy
75880806|NCT01352065|Drug|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
75880807|NCT01352065|Drug|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
76051050|NCT01944969|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
76051051|NCT01961115|Drug|Epacadostat|Given PO
76051052|NCT01961115|Biological|MELITAC 12.1 Peptide Vaccine|Given ID/SC
76051053|NCT04661397|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.
75729141|NCT04879199|Diagnostic Test|Static stability measurement|"The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s."
75729142|NCT04879199|Diagnostic Test|Dynamic stability measurement|"The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized."
75729143|NCT04868565|Drug|Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]|"after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight."
75729144|NCT04858776|Combination Product|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
75729145|NCT04858776|Combination Product|Perivascular sham|Saline delivery around target vein segment(s)
75729146|NCT04849416|Drug|LOXO-305|Administered orally.
75729147|NCT04831476|Other|Patients with Benign Prostate Hyperplasia|patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin
75729148|NCT04825847|Device|BIS monitor|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
76051054|NCT04661397|Drug|Darunavir|Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.
75434022|NCT01543529|Other|Alcohol|Standard alcoholic drink
75434023|NCT01543542|Radiation|Whole Brain XRT 30Gy/10 fractions with|30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
75434024|NCT01543555|Drug|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
75729149|NCT04825847|Other|Control group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at [0.8-1.2] MAC.
75729150|NCT04815473|Procedure|Valvulotomy|Valvulotomy of the venous valves
75729151|NCT04806373|Drug|Cathflo Activase|Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
75729152|NCT04806373|Drug|Talc Slurry Pleurodesis|Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
75729153|NCT04804280|Genetic|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1) will be investigated. Cord blood will be collected at birth for PT and FT, only for PT a peripheral blood sample will be collected at hospital discharge, during routine clinical procedures. Genomic DNA will be extracted from aliquots of 0. 2 ml of each blood sample with the GeneElute Blood Genomic DNA kit (Sigma) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
75434025|NCT01543555|Drug|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
75434026|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
75434027|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
75434028|NCT01543724|Drug|Lithium|10mg/kg/day for 12 weeks
75434029|NCT01543737|Device|3ml hyaluronic acid (DUROLANE)|DUROLANE Hyaluronic acid 20mg/ml
75434030|NCT01543737|Device|2ml hyaluronic acid, (HYALGAN)|HYALGAN Hyaluronic acid 10mg/ml
75434031|NCT01543750|Drug|4-Aminopyridine|
75434032|NCT01543750|Drug|Placebo|Placebo
75434033|NCT01543802|Drug|pazopanib|Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
75434034|NCT01543815|Behavioral|Well-Being Therapy based on Web Mobile Technology|The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.
75434035|NCT01543815|Behavioral|Cognitive Behavior Therapy|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.
75434036|NCT01543815|Other|Standardized Care Management|CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
75434037|NCT01543854|Drug|RLX030|Intravenous infusion of RLX030 over 20 hrs
75434038|NCT01543854|Drug|Placebo|Intravenous infusion of placebo over 20 hours
75729154|NCT04804280|Diagnostic Test|Functional Magnetic Resonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. a trained experimenter will apply tactile stimulation associated with affective touch characteristics to the child with a soft brush on the right anterior tibial region in proximal and distal directions. The length of the stimulated area will be measured to cover approximately 15 cm, and tactile stimulations will be applied at a rate of 5 cm/s for 15s, with randomized intervals between stimuli of 10-15s (resulting in 5 stimulations in a 15s block). A regular audio signal will help the researcher to keep a constant stroke velocity. Audio commands will also be used to direct the experimenter. Infant must be asleep (natural sleep) during the fMRI acquisition.
75729155|NCT04796415|Behavioral|the DEMA-Pro intervention|Trained DEMA-Pro coaches will deliver six weekly, 1-hour telephone sessions. The first session is an orientation to the DEMA-Pro intervention and development of the initial Weekly Activity Plan based on the patient's self-identified meaningful activity. Over the next five weekly sessions, the coach uses problem-solving strategies to facilitate dyad collaboration to mutually identify meaningful activities and make a realist plan to achieve the patient-identified meaning activity goals. In each session, the patient and caregiver also select, review, and discuss one of six topics in the Self-Management Toolkit (e.g., planning meaningful activities; learning strategies for living with subjective cognitive impairment; finding resources, planning for the future).
75729156|NCT04786340|Drug|Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution|WST-057
75729157|NCT04786340|Drug|Placebo: WST-057 4mL topical solution|Placebo
75729158|NCT04763577|Other|Assay of Bradykinin-degradating enzymes.|Aminopeptidase P activity assay; Dipeptidyl peptidase IV activity assay; Angiotensin Converting Enzyme activity assay; MME gene polymorphisme exploration.
75581113|NCT05427656|Device|Measurement of Arterial Input Function|The non-invasive detector, hereinafter called NID, comprises of plastic scintillating fibers (BCF-12, St-Gobain, France) wrapped in a medical-grade acrylic heat-shrink tube (Vention Medical, USA). The scintillating fibers are coupled to 5 m long transmission fibers to bring the signal out of the PET detector. The fibers will be held in place using a 3D-printed structure composed poly-lactic acid. The NID is designed to measure both positrons and photons escaping the wrist. Post-processing software is used to calculate the arterial input function.
75581114|NCT04641585|Diagnostic Test|Patients affected by Brugada Syndrome 1|ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
75581115|NCT00559221|Drug|FLAG+IDA|Fludarabine, cytarabine, G-CSF
75581116|NCT05408312|Biological|Experimental Vaccine 1|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
75581117|NCT05408312|Biological|Experimental Vaccine 2|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
75581118|NCT05408312|Biological|Experimental Vaccine 3|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
76051055|NCT04661397|Drug|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.
75434039|NCT01543867|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
75434040|NCT01543880|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
75434041|NCT01543893|Behavioral|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
75434042|NCT01543893|Behavioral|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
75434043|NCT01543906|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
75434044|NCT01543932|Drug|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
75434045|NCT01543932|Drug|Prasugrel|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
75434046|NCT01543932|Drug|Ticagrelor|Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
75434047|NCT01543945|Drug|Dexamethasone|4 mg iv before induction for high and extremely high risk
75581119|NCT05408312|Biological|placebo|Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
75581120|NCT04641468|Procedure|DCB|OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
75581121|NCT04683497|Other|Contrast-enhanced Intraoperative Ultrasound|Intraoperative ultrasound with the administration of a contrast agent I.V.
75581122|NCT00559260|Device|Passive monitoring with pulse-oximetry, NIBP and ECG|
75581123|NCT04641117|Other|Exercise|Walking and Power Training
75581124|NCT04641390|Other|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
76051056|NCT04661397|Drug|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.
76051057|NCT01973439|Other|Intervention 1: PK assessment while on Twice Daily Abacavir|Week 0
75581125|NCT04641390|Other|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
75581126|NCT00559299|Drug|GSK163090|
75581127|NCT05358080|Drug|Entelon Tab. 50mg|twice daily for 24months
75581128|NCT05358080|Drug|Placebo|twice daily for 24months
75581129|NCT00559338|Drug|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
75581130|NCT00559338|Drug|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
75581131|NCT05352737|Diagnostic Test|methylmalonic acid testing|
76051058|NCT01973439|Other|Intervention 2: PK assessment while on Once Daily Abacavir|Week 4
76051059|NCT01973283|Drug|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
76051060|NCT01943799|Biological|GS-4774|Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
75581132|NCT04641429|Behavioral|Qigong exercise|Participants in the experimental group receive 12-week group-based Qigong exercise training.
75581133|NCT04641429|Behavioral|Stretching exercise|Participants in the control group receive 12-week group-based stretching exercise training.
75581134|NCT00559416|Drug|Cell Transfer|
75581135|NCT04640883|Behavioral|Inclusion of sprints during low-intensity cycling during a 14-day training camp (high training load)|Inclusion of 12x30-s maximal sprints during five low-intensity cycling sessions with long duration (>fours hours per session). Five sessions will be performed as low-intensity cycling-only (Controll sessions, distance matched). All other sessions will be performed as low-intensity sessions and adjusted according to each participants training load goal to reach an increase of ~50% in load compared to habitual training.
75581136|NCT04640883|Behavioral|Low-intensity cycling during a 14-day training camp (high training load)|Five low-intensity cycling sessions (>four hours per session), distance-matched to sprint group.
75581137|NCT04640883|Behavioral|Recovery for 10 days (low training load)|Habitual low-intensity cycling (>0.5-2 hours per session)
75581138|NCT00553124|Drug|selenium|
75434048|NCT01543945|Drug|Ondansetron|4 mg iv before ended surgery 30 min
75581139|NCT00553124|Drug|vitamin E|
75581140|NCT00553124|Procedure|biopsy|
75581141|NCT00553124|Procedure|chemoprevention|
75434049|NCT01543945|Drug|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
75434050|NCT01543971|Drug|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
75581142|NCT00553124|Procedure|cryopreservation|
75729159|NCT04739358|Drug|Tepotinib|Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
75729160|NCT04734743|Other|cystic fibrosis|Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
75729161|NCT04730167|Other|Neurological and neuropsychological assessments / MRI / PET scan / Video-oculography.|Essential data for this study are those collected during the concussion assessment, carried out as part of routine care at Princess Grace Hospital (medical background; history of sports practice and history of concussions; data extracted from clinical and neuropsychological evaluations, from imaging exams (MRI and PET-Scan) and from eye-tracking evaluation).
76051061|NCT01943799|Drug|OAV Regimen|Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
76051062|NCT01972659|Drug|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
75434051|NCT01543971|Drug|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
75434052|NCT01543984|Other|Tailored Physical Activity|Tailored Physical Activity (3*50 min/week in 10 weeks)
75434053|NCT01543984|Behavioral|Health Counselling|Health guidance (1,5h)
75434054|NCT01543997|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
75434055|NCT01543997|Behavioral|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
75434056|NCT01544010|Behavioral|Stage-Tailored Manual|Manual with 5 sections for each Stage of change delivered at baseline
75581143|NCT00553124|Procedure|cytology specimen collection procedure|
75581144|NCT00553124|Procedure|diagnostic procedure|
75581145|NCT00553124|Procedure|gene expression analysis|
75581146|NCT00553124|Procedure|immunohistochemistry staining method|
75581147|NCT00553124|Procedure|laboratory biomarker analysis|
75581148|NCT00553124|Procedure|medical chart review|
75581149|NCT00553124|Procedure|mutation analysis|
75581150|NCT00553124|Procedure|polymerase chain reaction|
75581151|NCT00553124|Procedure|quality-of-life assessment|
75581152|NCT00553124|Procedure|questionnaire administration|
75581153|NCT00553124|Procedure|study of socioeconomic and demographic variables|
75729162|NCT04728048|Procedure|Dural puncture epidural|already described
75729163|NCT04728048|Procedure|Standard epidural|already described
75729164|NCT04717635|Biological|Canakinumab|Provide as 150 mg/1 mL solution for subcutaneous injection and administer 4mg/kg every 4 weeks.
75729165|NCT04714411|Drug|Omadacycline|Omadacycline monotgherapy
76051063|NCT01972659|Drug|Magnesium Sulphate|"Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion"
76051064|NCT01972659|Drug|sugammadex|4 mg/kg iv bolus at the end of the surgery
75581154|NCT04640649|Other|Algorithm prediction|Patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion will be randomly assigned to a test group or control group. The test group will have their baseline data analyzed by an algorithm to predict the probability of conversion to wet AMD. If the probability is high for conversion at or before 3 months, patients will have earlier follow-up care than the control group (standard follow-up care every 6 months).
75581155|NCT05340335|Drug|Remimazolam|A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
75729166|NCT04713735|Dietary Supplement|Control: Placebo|Placebo
75434057|NCT01544010|Behavioral|Stage Tailored Feedback Report|Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
75434058|NCT01544010|Behavioral|Moderate TTM-Tailored Feedback Report|Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
75434059|NCT01544010|Behavioral|Full TTM-Tailored Feedback Report|Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
75434060|NCT01544010|Behavioral|Enhanced TTM+Addiction Tailored Feedback Report|Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
75729167|NCT04713735|Dietary Supplement|bovine lactoferrin supplement|600 mg
75729168|NCT04678557|Combination Product|VC-01 Combination Product|PEC-01 cells loaded into an Encaptra Drug Delivery System
75880808|NCT02065310|Other|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 & 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
75880809|NCT03610854|Device|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
75880810|NCT01356043|Drug|S-amlodipine 5mg,Telmisartan 80mg|S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
75729169|NCT04656873|Procedure|Biospecimen Collection|Undergo collection of cheek swab, blood, urine, stool, and tissue samples for research
75729170|NCT04656873|Other|Medical Chart Review|Periodic review of medical records for clinical parameters (labs, ICI dosing and frequency, occurrence, timing and type of irAE, irAE management, etc.) along with relevant demographic information (age, sex/gender, race/ethnicity, insurance type, etc.).
75729171|NCT04656873|Other|Questionnaires/Surveys|Periodic self-report questionnaires/surveys for symptom tracking, quality of life, perinatal outcomes, etc.
75434061|NCT01544036|Drug|perflutren|Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
75434062|NCT01544075|Behavioral|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
75434063|NCT01544075|Behavioral|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
75434064|NCT01544101|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
75434065|NCT01544101|Dietary Supplement|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
75581156|NCT04640805|Dietary Supplement|Protein supplementation|Liquid protein fortifier (Similac) will be added at 1ml per 25ml of PDHM at 130ml/kg/day of feed volume.
75434066|NCT01544140|Drug|Midazolam|Oral syrup 7.5 mg, single dose
75434067|NCT01544140|Drug|vandetanib|Oral tablets, 800 mg, single dose
75434068|NCT01544192|Drug|Gingko Biloba|2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
75434069|NCT01544192|Drug|α-tocopherol|2x300 mg α-tocopherol
75434070|NCT01544192|Drug|Placebo|control group did not receive oral neuroprotective agent
75434071|NCT01544192|Drug|Antioxidant formula|2x1 tablet AOF
75434072|NCT01544205|Other|fMRI-based neurofeedback|5 sessions lasting one hour each
75581157|NCT04640805|Other|Analysis with Miris Human Milk Analyzer|PDHM macronutrient content will be analyzed using the Miris Human Milk Analyzer and PDHM with fat content of 3.8g/dL or higher will be selected and provided.
75581158|NCT04640844|Biological|blood sample|measuring the expression and function of lymphocyte A2A receptors.
75581159|NCT04640610|Other|Storage of operating waste|Storage of operating waste of adenoidectomy / tonsillectomy
75581160|NCT05327075|Other|questionnaire|it is in the form of questionnaire and scoring tool
75880811|NCT01356043|Drug|S-amlodipine 5mg|S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
75880812|NCT02065388|Behavioral|Standard of care dosing for warfarin|
76051065|NCT01971723|Other|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
75880813|NCT02065388|Genetic|Genotype-guided dosingTaiwan algorithm for warfarin|
75880814|NCT02065388|Genetic|Genotype-guided dosing IWPC algorithm for warfarin|
76051066|NCT01971723|Other|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
75434073|NCT01544231|Biological|Plasma NGAL level|The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
75434074|NCT01544244|Procedure|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
75581161|NCT04640454|Procedure|nipple sparing mastectomy|The investigators categorized the incisions into radial, inframammary, and periareolar incisions with planned reconstruction types; direct to implant (DTI), transversus rectus abdominis myocutaneous (TRAM) flap, latissimus dorsi myocutaneous (LD) flap, or LD with implant.
75729172|NCT04652752|Device|CONNETTIVINA HI TECH patch|It is a medical device for topical application in the form of a patch with adhesive transparent polyurethane edge and a central pad impregnated with a solution of hyaluronic acid sodium salt, able to create a hydrating environment, such as to favor the natural healing process of tissue repair in case of bruises, abrasions, small cuts, superficial wounds, burns
76051067|NCT01942785|Drug|Brexpiprazole|2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
76051068|NCT01774786|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
76051069|NCT01774786|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
76051070|NCT01774786|Drug|Cisplatin|Participants will receive cisplatin 80 mg/m^2 IV q3w for 6 cycles.
75434075|NCT01544244|Procedure|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
75729173|NCT04647656|Device|Hyperbaric oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
75729174|NCT04647656|Device|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
76051071|NCT01774786|Drug|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
75434076|NCT01544257|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
75434077|NCT01544257|Procedure|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
75434078|NCT01544270|Dietary Supplement|Yogurt-like snacks|twice a day 120 g for four weeks
75581162|NCT04640181|Drug|Enoxaparin|Subcutaneous enoxaparin While hospitalized only.
75581163|NCT04640181|Drug|Rivaroxaban|Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
75581164|NCT04640103|Other|No interventions|No interventions
75581165|NCT00559455|Drug|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
75581166|NCT00559455|Drug|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
75581167|NCT00559455|Drug|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
75581168|NCT00559494|Drug|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
75729175|NCT04636905|Other|Questionnaires|Participants will be asked to complete a series of questionnaires assessing quality of life and other general health outcomes
75729176|NCT04620551|Device|Sub-clinical stimulation|The third night of recording will involve sub-clinical thresholds of stimulation in all subjects.
75729177|NCT04599946|Dietary Supplement|Infant formula and follow-on formula made from whole goat milk|Infant formula and follow-on formula made from whole goat milk
75581169|NCT00559494|Drug|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
75434079|NCT01544283|Drug|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
75581170|NCT00559494|Procedure|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
75581171|NCT00559494|Procedure|SCPP control|maintenance of Mean arterial pressure of >65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
75581172|NCT03455621|Procedure|Toothbrushing|Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
75581173|NCT00559533|Drug|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
75581174|NCT05286632|Device|KidneYou APP|KidneYou is a medical device designed to deliver digital therapy (DT) to patients. The DT utilizes high quality digital technologies to stimulate lifestyle changes in patients. KidneYou has been set up to improve the commitment of patients in following therapeutic directives (i.e. nutritional programs, daily/weekly physical activities) to manage their chronic diseases like CKD. Moreover, KidneYou can improve patient's awareness about his/her disease (mindfulness) so as to increase the individual human ability to be fully present at the ongoing disease's condition and react to it in active and positive manner. Particularly, the mindfulness program contained in this App has been designed to increase the patient's psychological and mental health, aiming at decreasing the perceived stress due to the underlying disease and to the attempts of life-style changes (i.e., healthy diet and physical activity) which may initially negatively affect the subject's natural attitudes.
75581175|NCT00559572|Behavioral|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
75729178|NCT04599946|Dietary Supplement|Infant formula and follow-on formula made from cow's milk ingredients|Infant formula and follow-on formula made from cow's milk ingredients
75729179|NCT04591808|Drug|Atorvastatin/Perindopril|1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.
75729180|NCT04591808|Drug|Atorvastatin|1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.
75434080|NCT01544283|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
75729181|NCT04591808|Drug|Perindopril|1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.
75434081|NCT01544296|Drug|KHK6188|
75434082|NCT01544296|Drug|Placebo|
75729182|NCT04589065|Device|Selective Cytopheretic Device|SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
76051072|NCT01774786|Drug|Placebo|Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
76051073|NCT01774786|Drug|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
75581176|NCT00559572|Other|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
75581177|NCT00559611|Procedure|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
75581178|NCT00559611|Procedure|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
75581179|NCT05208086|Diagnostic Test|Detection of monoclonal component|Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
75581180|NCT03454698|Other|Education|"Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group."
75581181|NCT05186675|Procedure|superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
75581182|NCT04639908|Other|Interview|interview with patient
76051074|NCT01960725|Biological|RV5 (Pentavalent Rotavirus Vaccine)|
75434083|NCT01544322|Drug|ME-344|"experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
75434084|NCT01544374|Other|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
75581183|NCT04639791|Other|No intervention|Observation only, no intervention
75581184|NCT04639557|Behavioral|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target maternal mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
75581185|NCT05165693|Other|Experimental Formula|Diabetes-specific study formula
75581186|NCT05165693|Other|Test Meal|Instant oatmeal
75729183|NCT04588545|Radiation|Radiation Therapy|Participants will receive radiation therapy (RT), either whole brain radiation therapy or focal brain/spine RT. The goal of RT is to palliate symptoms and improve the flow of Intrathecal (IT) therapy through the cerebrospinal fluid (CSF). As such, various RT schedules and targets are permitted. It is expected that the majority of patients will receive WBRT with 30 Gy in 10 fractions. However, shorter fractions of 20 Gy in 5 fractions of WBRT are permitted. In those patients who have more localized leptomeningeal disease in the spine, focal RT in up to 10 fractions may be administered with the exact dose left up to the discretion of the treating radiation oncologist.
75880815|NCT04835415|Procedure|Bilateral retrolaminar block|in lateral position and after skin sterilization. The spine is palpated from cervical (C7) downward toT7 and point marked to identify the spinous process. The linear high frequency transducer (6-13 MHz) will be placed parasagittal plane 1 cm lateral to the midline. The needle (18 gauge) is inserted in the plane view of the ultrasound probe to target the T7 and needle is advanced from downward to upward until the needle tip contacted the lamina. After negative aspiration, a 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side.
75434085|NCT01544387|Other|Bed Rest|"Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position~Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed~Subjects may have limited bathroom privileges"
75729184|NCT04588545|Drug|Pertuzumab|Participants will be treated at 1 of 4 dose levels of pertuzumab, beginning at 10 mg and increasing up to 80 mg or Maximum Tolerated Dose (MTD).
75729185|NCT04588545|Drug|Trastuzumab|Participants will be treated at a fixed dose of 80 mg trastuzumab.
75729186|NCT04551053|Drug|parsaclisib|parsaclisib will be administered QD orally
75729187|NCT04551053|Drug|ruxolitinib|ruxolitinib will be administered BID orally
76051075|NCT04654845|Procedure|Pulpotomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Wait until confirmation of absence of bleeding from the conducts. Placement of polytetrafluroethylene in pulp chamber. Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
75434086|NCT01544387|Other|Activity|"Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed~Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired."
75729188|NCT04551053|Drug|placebo|placebo will be administered QD orally
76051076|NCT04654845|Procedure|Pulpectomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Establishment of working length by means of Electronic Apex Locator and a number 8 K file.~Access to all conducts with a number 10 K file. Rotary instrumentation with one reciprocating system up to working length and up to an apical diameter of 25.~Placement of polytetrafluroethylene in pulp chamber. No intermediate medication will be filled into the conducts.~Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
75434087|NCT01544413|Procedure|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
75729191|NCT04545489|Behavioral|Intervention group|This is a intervention for 12 months which focuses on behavioral and medication management, led by a health coach (nurse or pharmacist)
75434088|NCT01544439|Procedure|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
75581187|NCT04639362|Drug|ibrutinib, venetoclax, obinutuzumab|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
75581188|NCT04639362|Drug|ibrutinib, venetoclax|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
75581189|NCT04683536|Procedure|Obturator nerve blockade|We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer
75581190|NCT04639401|Other|motor entrainment to auditory cues and music during walking on quality of movement|The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
75581191|NCT04683419|Device|Modified Thoracoscopic pleural Cryobiopsy|"Thoracoscopic pleural biopsy will be taken with a modified technique raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe"
75581192|NCT04639284|Drug|Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies|Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
75581193|NCT05103800|Behavioral|invasive interventions|listening the white noise during the invasive interventions
75581194|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
75581195|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
75581196|NCT05089214|Device|Intra oral cameras|Diagnostic comparison of two intra oral cameras
75581197|NCT04639440|Other|Adipose tissue|Adipose tissue sampling
75581198|NCT04629027|Drug|Immune checkpoint inhibitor|the patients receive necessary treatment without special intervention
75581199|NCT00561249|Procedure|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
75581200|NCT05076656|Dietary Supplement|Lactobacillus fermentum D3|Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.
76051077|NCT01942161|Drug|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
76051078|NCT01942161|Drug|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
76051079|NCT01942161|Drug|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
75581201|NCT05076656|Biological|Fecal microbiota transplant (FMT)|Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.
75581202|NCT05076656|Drug|Placebo|Placebo in a white, gelatin capsule (orally), with powder milk
75581203|NCT00561288|Drug|acetaminophen|2 x 1000 mg doses per day
75581204|NCT00561288|Other|cornstarch|2 x 1000 mg cornstarch per day
75729192|NCT04545489|Behavioral|Education control group|This group will receive education materials related to CVD risk reduction at each 4 month visit over the course of 12 months.
75434089|NCT01544439|Procedure|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
76051080|NCT01971645|Drug|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
76051081|NCT01971645|Drug|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
75434090|NCT01544452|Procedure|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
75434091|NCT01544452|Procedure|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
75434092|NCT01544465|Behavioral|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
75729193|NCT04544202|Drug|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~Dabrafenib, 150 mg, twice daily (BID);~Trametinib, 2.0 mg, once daily (QD)"
75729194|NCT04544202|Drug|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
76051082|NCT01941537|Drug|ILV-094|IV infusion of ILV-094
76051083|NCT01941537|Drug|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
75581205|NCT00561327|Drug|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
75581206|NCT05060939|Diagnostic Test|COVID-19 vaccinated people|Patients with at least one dose of COVID-19 vaccine tested for SARS-CoV-2 infection with RT-PCR on respiratory specimen. RT-PCR, serological testing and viral sequencing will be applied on patient's samples
75581207|NCT00561366|Drug|Placebo|Placebo t.i.d.
75581208|NCT00561366|Drug|Arimoclomol|capsule, 400 mg t.i.d.
75581209|NCT00561405|Behavioral|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
75581210|NCT00561405|Behavioral|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
75581211|NCT00561444|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
75581212|NCT05043974|Other|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
75434093|NCT01544465|Behavioral|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
75434094|NCT01544504|Drug|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
75581213|NCT05041088|Dietary Supplement|ProdromeNeuro Plasmalogen|The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
76051084|NCT01971567|Device|HIRREM|
76051085|NCT01960413|Drug|Montelukast added to Hydroxyurea|
76051086|NCT01960413|Drug|Placebo added to Hydroxyurea|
75434095|NCT01544517|Drug|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
75434096|NCT01544530|Other|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
75434097|NCT01544569|Genetic|DNA analysis|
75434098|NCT01544569|Genetic|fluorescence in situ hybridization|
75434099|NCT01544569|Genetic|gene expression analysis|
75434100|NCT01544569|Genetic|gene mapping|
75434101|NCT01544569|Genetic|microarray analysis|
75434102|NCT01544569|Genetic|polymerase chain reaction|
75434103|NCT01544569|Genetic|protein expression analysis|
75434104|NCT01544569|Other|laboratory biomarker analysis|
75434105|NCT01544569|Other|medical chart review|
75581214|NCT00561522|Drug|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
75581215|NCT00561522|Other|No other preventive treatment|No other preventive treatment
75581216|NCT05009264|Procedure|OMT|OMT will be performed on identified areas of trapezius trigger points
75581217|NCT03454659|Procedure|Craniotomy|Extracting the part of the sculpt
75581218|NCT03454620|Drug|irinotecan|GC1118 combination with irinotecan
75581219|NCT03454620|Drug|FOLFIRI|GC1118 combination with FOLFIRI
75581220|NCT04628559|Drug|Dexmedetomidine|dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
76051087|NCT04661241|Other|Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches|The proposed sequence (<15 minutes) will be added as a supplementary sequence only for the preoperative imaging for subjects who agree to participate: a 3D multi-echo GRE sequence will be performed during a preoperative MR imaging, using the following parameters: field of view = 220x170x75 mm3, matrix = 176x136x60, 1.25-mm isotropic resolution, flip angle = 22 degrees, TR = 92 ms, 20 TEs = 1.90 - 45.98 ms with echo spacing of 2.32 ms, bandwidth = 840 Hz/pixel.
76051088|NCT04661241|Other|Routine clinical MRI protocol|MRI will be performed using 3T scanner (Skyra, Siemens, Erlangen, Germany). All patients will undergo preoperative MRI of the brain including routine clinical MRI protocol (T1-/T2-weighted and diffusion imaging) under general anesthesia to reduce movement artifacts.
76051089|NCT01970475|Biological|ABP 501|Solution for subcutaneous injection in pre-filled syringe
75434106|NCT01544621|Other|Smoking cessation|Smoking cessation
75434107|NCT01544634|Drug|Propranolol|Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.
75434108|NCT01544634|Drug|Placebo|Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks
75434109|NCT01544634|Drug|Qvar 50|Qvar 50, 1 puff bd for 6 weeks
75434110|NCT01544634|Drug|Qvar 100|Qvar 100, 2 puffs bd for 6 weeks
75434111|NCT01544647|Other|Usual spa protocol|In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
75434112|NCT01544647|Other|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
75434113|NCT01544673|Drug|linezolid|600 mg oral tablet twice daily for 4.5 days
75434114|NCT01544673|Drug|Placebo|500 mg oral placebo twice daily for 4.5 days
75434115|NCT01544686|Device|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
75434116|NCT01544712|Procedure|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
75581221|NCT04628559|Drug|Ketamine|In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
75581222|NCT04628559|Drug|Saline|Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
75581223|NCT04683341|Drug|Tenofovir Alafenamide Tablets|Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm (Arm A), CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm (Arm B), CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA < 20 IU/mL) will be enrolled.
75581224|NCT04628793|Drug|PF-07258669|PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
75581225|NCT04628793|Drug|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
75581226|NCT04683302|Device|3DUS biplanar catheterization|biplanar view of both short and long axis view of the internal jugular vein improves anatomical awareness and potentially improves safety of venous catheterization
75581227|NCT04683302|Device|2D US catheterization|2D short axis internal jugular vein catheterization
75581228|NCT04683263|Other|Placebo|topical cream with same composition as Intervention but without active ingredients
75581229|NCT04683263|Other|Fisiocrem|a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
75581230|NCT04628676|Drug|tranexamic acid|Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.
75581231|NCT04628676|Drug|Epinephrine|Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
75581232|NCT00561561|Behavioral|Acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
75581233|NCT01214629|Drug|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
75581234|NCT01214629|Drug|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
75581235|NCT01214629|Drug|pegfilgrastim|6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
75581236|NCT04628325|Drug|Furosemide|Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
75581237|NCT04977869|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
75581238|NCT04977869|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
75581239|NCT04318600|Drug|human amniotic mesenchymal stem cell|human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
75729195|NCT04544202|Drug|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
75581240|NCT04657497|Drug|FOY-305|Specified Dosage and Duration of Treatment
75729196|NCT04543097|Behavioral|Vocational Support|"Participants randomised to receive vocational advice will all be offered:~Step 1, contact by phone to undertake an assessment with a trained Vocational Support Worker (VSW) to identify obstacles to Return to Work (RTW) and support RTW planning.~Step 2, face-to-face (in person or by videoconference) in-depth discussion of obstacles to RTW and further support for RTW planning.~Step 3, contact by the VSW (with participant consent) with the participants' workplace.~The frequency of contact will be individualised to the needs of participants and the offer of support continued until sustained RTW (defined as return to any work for at least 4 weeks) or until 6 months of absence, after which participants will be signposted to other services."
75729197|NCT04536038|Behavioral|Opt-out|A study coordinator will call the patient unless they opt-out. See arm description for more details.
75729198|NCT04536012|Behavioral|Gamification and Social Incentives|Participants in the intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
75434117|NCT01544712|Procedure|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
75434118|NCT01544725|Drug|Procedural sedation with ketamine-propofol combination|"K= Kétamine P= Propofol RSS= Ramsay Sedation Score~At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).~At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
75581241|NCT04657497|Drug|Placebo|Specified Dosage and Duration of Treatment
75581242|NCT01214434|Device|Promiseb Topical Cream|topical non steroidal cream, twice daily
76051090|NCT01970475|Biological|Adalimumab|Solution for subcutaneous injection in pre-filled syringe
75581243|NCT01214434|Other|Bland emollient|Eucerin cream twice daily
76051091|NCT04653753|Device|kneeSOFT500|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
76051092|NCT01939977|Drug|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
75434119|NCT01544725|Drug|Procedural sedation with ketamine alone|"K= Ketamine I= Intralipid placebo~At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).~At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
75434120|NCT01544738|Other|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
75434121|NCT01544738|Other|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
75434122|NCT01544751|Drug|Low dose metformin|500 mg twice a day
75434123|NCT01544751|Drug|Metformin|1000 mg twice a day
75434124|NCT01544751|Drug|Atorvastatin|20 mg/day
75434125|NCT01544764|Other|Assessment , Feedback, Incentives, and eXchange Program|The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
75434126|NCT01544777|Device|Study IOL|Aspheric IOL for correction of aphakia
75434127|NCT01544777|Device|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
75434128|NCT01544777|Device|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
75434129|NCT01544790|Procedure|Esophagectomy|In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
75434130|NCT01544803|Behavioral|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
75434131|NCT01544803|Behavioral|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
76051093|NCT01939977|Drug|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
76051094|NCT01939899|Drug|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
75434132|NCT01544816|Other|Snack Product|control food product
75434133|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 1
75434134|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 2
75434135|NCT01544829|Dietary Supplement|Theobromine|Single dose of theobromine
75434136|NCT01544829|Dietary Supplement|Theobromine|Multiple doses of theobromine
75434137|NCT01544829|Dietary Supplement|Placebo|Placebo capsules
75434138|NCT01544842|Drug|0.1 % tacrolimus ointment|applied topically to oral mucosa
75434139|NCT01544842|Drug|0.1 % triamcinolone paste|applied topically to oral mucosa
75434140|NCT01544842|Drug|Orabase paste|applied topically to oral mucosa
75434141|NCT01544855|Dietary Supplement|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
75581244|NCT04318639|Combination Product|Donepazil|"Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.~Cognitive remediation therapy (CRT): This study employs a computerized program (BrainHQ) for cognitive enhancement. Participants use their program for one hour per session, up to five sessions per week, over 13 weeks (maximum of 65 sessions). They may training on site or at another quiet location of their choice."
75581245|NCT04628403|Other|massage|clinical interventions, of mechanophysiological origin for the treatment of symptoms corresponding to DOMS, after exercise
75581246|NCT04628403|Device|lasertherapy|lasertherapy
75581247|NCT04628403|Device|shock waves|shock waves
75581248|NCT01214395|Drug|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
75581249|NCT04656834|Procedure|hand incision closure using monocryl sutures and skin glue|At the end of surgery, the investigator will close the incision using monocryl sutures and skin glue
75581250|NCT04656834|Procedure|hand incision closure using simple nylon sutures|At the end of surgery, the investigator will close the incision using simple nylon sutures
75581251|NCT01214239|Drug|Placebo|once a day
75581252|NCT01214239|Drug|Linagliptin|once a day
75581253|NCT04628520|Procedure|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
75434142|NCT01544868|Other|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
75434143|NCT01544881|Drug|Technosphere Insulin Inhalation Powder|Inhalation Powder using the Gen2C inhaler
75434144|NCT01544881|Drug|Rapid Acting Analog|Subcutaneous Injection
75434145|NCT01544894|Drug|Raloxifene|60 mg/d for one year
75434146|NCT01544894|Drug|Strontium ranelate|2 g/d, for one year
75434147|NCT01544907|Device|Conventional PTA|Use of conventional balloon for angioplasty only
75581254|NCT04628520|Procedure|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
75581255|NCT04628520|Procedure|Maintenance|Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
75581256|NCT01214200|Device|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
75729201|NCT04496154|Dietary Supplement|Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)|Triple Strength Omega-3 from Webber Naturals
75729202|NCT04490655|Behavioral|Active somatosensory training|Patients in the experimental group will be required to move the robotic handle using their paretic arm from the start position to a visual target shown on screen. However, patients' paretic arm will be occluded from vision throughout the training session. They will make the reaching movement by depending on their proprioception of the arm position in space, without relying too much on the vision of their arm. Haptic guidance will be provided as somatosensory cues while participants are actively moving. Positive reinforcement will also be given for each successful movement that reaches the target in the form of a pleasant audio tone, visual feedback, and a running score. Assessment will be performed before and after the completion of the whole 15 training sessions.
75729203|NCT04490655|Behavioral|Motor-based training|Patients in the control group will also be required to propel the robotic handle using their paretic arm to a target location. This training covers the same centre-out reaching movements but without any emphasis on proprioception, where the view of the paretic arm will not be occluded. However, no haptic guidance will be provided during the reaching movement. Positive reinforcement will still be given to inform the participants of their trial outcomes. Assessment will be performed before and after the completion of the whole 15 training sessions.
75729204|NCT04489433|Drug|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~Dabrafenib, 150 mg, twice daily (BID);~Trametinib, 2.0 mg, once daily (QD)"
75434148|NCT01544907|Device|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
75434149|NCT01544946|Drug|88% sucrose po|88% sucrose solution (Syrup B.P.)
75434150|NCT01544946|Drug|placebo po|sterile water
75434151|NCT01544959|Drug|fentanyl|Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
75434152|NCT01544959|Drug|beta-blocker (esmolol, metropolol)|esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
75434153|NCT01544972|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
75434154|NCT01544972|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
75434155|NCT01544985|Drug|88% sucrose po solution|88% sucrose solution (Syrup B.P.)
75434156|NCT01544985|Drug|placebo po|sterile water
75434157|NCT01545011|Other|Inspiratory muscle training|Inspiratory muscle training
75434158|NCT01545024|Drug|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
76051095|NCT01970397|Device|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
76051096|NCT01970397|Device|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
75434159|NCT01545037|Dietary Supplement|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®|Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.
75581257|NCT04967534|Behavioral|WB-EMS|Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 12 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping, and lower extremity strength will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by the rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one-on-one.
75729205|NCT04489433|Drug|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
75729206|NCT04489433|Drug|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
75729207|NCT04481451|Procedure|Erector spinae block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
76051097|NCT01970241|Drug|NPH|NPH given per study table based on steroid dose and patient weight in kg.
75434160|NCT01545037|Other|Placebo|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
76051098|NCT01970241|Drug|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
76051099|NCT01939353|Drug|CTN SR|CTN SR tablets
76051100|NCT01939353|Drug|Placebo|CTN SR-matching placebo tablets
76051101|NCT01970007|Device|Zilver Vena Venous Self-Expanding Stent|stenting
75434161|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
75729208|NCT04481451|Procedure|Quadratus lumborum block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
76051102|NCT01728376|Drug|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
75434162|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
75434163|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
75434164|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
75434165|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
75434166|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
75729209|NCT04481451|Drug|Ropivacaine|ropivacaine 0.2% nerve block injection
75729210|NCT04450797|Device|US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).|"US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).~Head not fixed, placed on horseshoe head holder, no preoperative navigation planning, catheter will be cut in length after positioning under real-time US guidance."
75729211|NCT04450797|Device|Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).|"Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).~Head fixed in head clamp, entry point, trajectory and catheter length planned based on preoperative computer tomography imaging, catheter placed using navigated stylet."
75434167|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
75434168|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
75581258|NCT04967534|Behavioral|social contact control group|Psycho-social intervention with participants randomized to the control group receiving (if wanted) the same social contact time (20-30 minutes/week) as the WB-EMS group. Depending on personal preferences and Covid-19 restrictions this will be done by phone or in-person one-on-one. Health-related topics and/or general chatting will be offered.
75880816|NCT04835415|Procedure|Thoracic epidural analgesia|In the lateral position, after skin sterilization, Ultrasound with high frequency linear probe (5-13 MHz). Thoracic intervertebral space (T7-8) will be identified by counting from the C7 to prominent thoracic spine (T7). The probe will be used in parasagittal plane 2 cm from midline. The probe will be directed medially to identify the dura matter at the T7-8 intervertebral space . the needle 18 gauage will be inserted in plane to target T7-8 intervertebral space ., after needle tip reached target space, loss of resistance technique then 20 ml bupivacaine 0.25% plus 5ug/ml adrenaline (1:200000) was injected after aspiration
75880817|NCT01317563|Dietary Supplement|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
76051103|NCT01728376|Drug|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
76051104|NCT01708174|Drug|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
76051105|NCT01708174|Drug|TMZ|Temozolomide capsules were obtained locally by the Investigator
76051106|NCT01605916|Drug|AZD6244|Tablet Oral bid
76051107|NCT02416609|Radiation|LDR|LDR will be delivered during each cycle of Gem-based doublets
75434169|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
75434170|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
75434171|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
75434172|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
75880818|NCT01317563|Dietary Supplement|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
76051108|NCT02416609|Drug|Gem-based doublets|4 cycles of Gem-based doublets
76051109|NCT02416609|Radiation|SBRT|SBRT will be administered after the fourth Gem-based doblet cycle, if no progression; three fractions will be administered
76051110|NCT02321137|Procedure|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
76051111|NCT02321137|Procedure|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
76051112|NCT02217709|Drug|phenelzine sulfate|Given by mouth
76051113|NCT02217709|Other|laboratory biomarker analysis|Correlative studies
76051114|NCT02217709|Other|questionnaire administration|Ancillary studies
76051115|NCT04791553|Drug|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
75434173|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
75434174|NCT01545089|Other|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
75434175|NCT01545089|Other|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
75434176|NCT01545154|Device|Transperineal Ultrasound|
76051116|NCT05651347|Other|Placebo|Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.
76051117|NCT05651347|Drug|Melatonin 10 MG|Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
76051118|NCT05651269|Drug|Milciclib Dose: 150 mg/day Mode of administration: oral|milciclib plus gemcitabine
76051119|NCT05647525|Diagnostic Test|Perform autoimmune encephalitis titer tests|We only follow up without intervention.
76051120|NCT04791163|Device|Socket evaluation|The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
76051121|NCT05638009|Dietary Supplement|Salt substitute 66%33%|Salt substitute composed of 66% potassium chloride and 33% sodium chloride
76051122|NCT05638009|Dietary Supplement|Salt substitute 33%/66%|Salt substitute composed of 33% potassium chloride and 66% sodium chloride
75434177|NCT01545167|Genetic|blood sampling|blood samples obtained to extract biomarkers and dna for analysis, questionnaires
75434178|NCT01545219|Dietary Supplement|Prebiotic|8g/day xylo-oligosaccharide
75434179|NCT01545219|Dietary Supplement|Bi-07|10^9 CFU B. lactis / day
75434180|NCT01545219|Dietary Supplement|Synbiotic|8g/day xylo-oligosaccharide + 10^9 CFU Bi-07
75434181|NCT01545219|Dietary Supplement|Placebo|8g/day maltodextrin
75434182|NCT01545258|Other|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
75581259|NCT01214044|Drug|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
75581260|NCT04628286|Other|Sham Laser|Sham Laser in plantar fascia
75729212|NCT04446273|Device|Bi-Manu-Track|The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
75729213|NCT04441203|Device|CardioMems|novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System
75729214|NCT04415333|Drug|Sodium Butyrate 5 mmol|Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
76051123|NCT05636683|Procedure|Root surface debridement|subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
76051124|NCT01635283|Biological|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
76051125|NCT01635283|Other|laboratory biomarker analysis|Correlative studies
75581261|NCT04628286|Other|Myofascial Induction|Myofascial Induction in plantar fascia
75434183|NCT01545284|Drug|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
75434184|NCT01545297|Drug|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
75434185|NCT01545297|Drug|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
75581262|NCT01213966|Drug|OZ439|po, single dose
75729215|NCT04415333|Drug|Sodium Butyrate 80 mmol|Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
75729216|NCT04409457|Other|fasting state|16 hours of fasting
75729217|NCT04409457|Other|fed state|fed a standardized meal
75729218|NCT04409457|Other|magnetic resonance imaging|neuroimaging with computational modeling
76051126|NCT01707004|Drug|decitabine|Given IV
76051127|NCT01707004|Drug|fludarabine phosphate|Given IV
76051128|NCT01707004|Drug|busulfan|Given IV
76051129|NCT01707004|Drug|cyclophosphamide|Given IV
76051130|NCT01707004|Drug|tacrolimus|Given PO or IV
75434186|NCT01545297|Drug|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
75581263|NCT04628598|Behavioral|Antenatal care and prenatal education with a home visit|Providing prenatal education and care by home visits to pregnant women
75729219|NCT04400253|Behavioral|SAATH Intervention|SAATH intervention is a physical activity intervention for South Asian mothers and daughters with group exercise classes and discussion groups.
75729220|NCT04388761|Drug|Allogeneic adipose derived mesenchymal stem cells|Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft
75729221|NCT04338893|Procedure|Device: Persona Total Knee|The choice of intervention is defined by surgeons standard use of device 'Persona' in their standard of care practice
75729222|NCT04338893|Procedure|Device: NexGen Total Knee|The choice of intervention is defined by surgeons standard use of device 'Nexgen' in their standard of care practice
76051131|NCT01707004|Drug|mycophenolate mofetil|Given PO
76051132|NCT01707004|Biological|filgrastim|Given SC
76051133|NCT01707004|Radiation|total-body irradiation|Undergo total-body irradiation
76051134|NCT01707004|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
76051135|NCT01707004|Other|laboratory biomarker analysis|Correlative studies
76051136|NCT01939197|Drug|ABT-450/r/ABT-267|tablet
75434187|NCT01545310|Drug|SLV354|One dose of ABT-354
75581264|NCT01213264|Other|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
75581265|NCT01213264|Drug|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
75729223|NCT04338893|Procedure|Device: Vanguard Total Knee|The choice of intervention is defined by surgeons standard use of device 'Vanguard' in their standard of care practice
75880819|NCT01359865|Procedure|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at <0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
76051137|NCT01939197|Drug|ABT-333|tablet
76051138|NCT01939197|Drug|ribavirin|tablet
76051139|NCT05182645|Behavioral|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of crohn's disease patients.
76051140|NCT05182645|Behavioral|waiting control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
75434188|NCT01545323|Genetic|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
75434189|NCT01545349|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
75434190|NCT01545349|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
75434191|NCT01545349|Biological|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
75434192|NCT01545362|Procedure|Total knee arthroplasty|Total knee arthroplasty
75434193|NCT01545401|Other|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~Global CV Risks Self-Management Booklets~CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention"
75434194|NCT01545414|Behavioral|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
76051141|NCT01969851|Drug|Lacosamide|"Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).~Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively."
75434195|NCT01545414|Behavioral|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
75434196|NCT01545427|Drug|Imatinib mesylate|200 mg bid for 6 months
75434197|NCT01545427|Other|Placebo|Placebo coated to match appearance of Gleevec identically.
75434198|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
75434199|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
75434200|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
76051142|NCT04661085|Diagnostic Test|Broader Medical history and clinical tests|Patients will be treated with standard care plus additional blood tests, urine culture and urine flow cytometry,
76051143|NCT04659759|Other|COVID-19 exposure|COVID-19 exposure during pregnancy
75434201|NCT01545440|Drug|placebo|subcutaneous dose every 4 weeks
75434202|NCT01545466|Behavioral|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
75434203|NCT01545479|Drug|captopril 25mg|renal blood oxygenation after captopril
75581266|NCT01213264|Drug|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
75581267|NCT04628247|Device|Spring gravity bar|"contain two wooden board length (160 cm) and width (15 cm)~contain pair of spring at every end of board~two wooden board connect in the middle"
75581268|NCT04628637|Other|Serum protein level analysis|Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.
75581269|NCT04628208|Diagnostic Test|Spartan COVID-19 v2 System|A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
75581270|NCT04656912|Procedure|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
75581271|NCT04657107|Drug|S-ketamine|K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
75581272|NCT04657107|Other|normal saline|Saline group: pregnant women received saline, intravenous drip
75581273|NCT04657107|Drug|S-ketamine|K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
75581274|NCT04937582|Diagnostic Test|Cognitive assessment|Complete cognitive and psychological assessment
75434204|NCT01544426|Procedure|Office hysteroscopy and endometrial snip|Office hysteroscopy with endometrial snip
75581275|NCT04937582|Diagnostic Test|Imaging|"Brain MRI~Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)"
75434205|NCT01544426|Procedure|Office hysteroscopy|Office hysteroscopy
75434206|NCT01545505|Behavioral|Neuropsychological assessment|"A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test."
75581276|NCT04937582|Diagnostic Test|Routine care|"Electroencephalogram (EEG)~Optional: polysomnography, lumbar puncture"
75581277|NCT04937582|Other|Psychiatric evaluation|Psychiatric consultation if necessary
75581278|NCT04937582|Other|Psychiatric evaluation|Psychiatric consultation if necessary (before the end of their participation in the study)
75581279|NCT04657029|Behavioral|Treadmill|30 minutes of moderate-high intensity treadmill training.
75581280|NCT04657185|Other|OR PathTrac Feedback Optimization|OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
75581281|NCT04906460|Drug|WVE-N531|WVE-N531 is an antisense oligonucleotide (ASO)
75581282|NCT04656483|Other|Telemedicine Video Feedback Intervention|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
75581283|NCT04656483|Other|Psychoeducational Booklet Intervention|Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
76051144|NCT04659759|Biological|COVID-19 vaccine|Receipt of any COVID-19 vaccine
75581284|NCT00561717|Drug|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
75434207|NCT01545531|Drug|Iohexol|Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration [13]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
75581285|NCT00561717|Drug|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
75581286|NCT00561717|Drug|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
75581287|NCT00561717|Drug|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
75581288|NCT04901351|Procedure|Smear|In addition to the routine gynecological follow-up including a cervico-vaginal smear and an HPV test (HPV-HR genome detection), the doctor will propose prospectively to all consecutive patients who meet the inclusion criteria, during a follow-up consultation (post treatment of cervical dysplasia), to participate in the study, that is to have 2 other anal and ENT samples for an HPV test
75581289|NCT00561756|Biological|plasmid DNA vaccine therapy|
75581290|NCT00561756|Other|flow cytometry|
75581291|NCT00561756|Other|immunoenzyme technique|
75729224|NCT04293939|Diagnostic Test|Functional Magnetic Risonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. MRI Protocol: T1 weighted image structural, T2 weighted image structural, fMRI task. Task fMRI: experiment will be implemented using the block design is as follow: 1.Rest (control condition): no touch; 2.Soft touch (stimulus condition): gentle strokes on infant's right leg (~15 cm area) with a soft brush at a velocity of ~5 cm/s Stimulus blocks will last for ~15s, allowing the blood-oxygen-level-dependen (BOLD) signal to reach the steady state. Control blocks duration will be randomized (10-18s) to avoid foresee activation phenomena. Condition will be administered multiple times (~10 times). Two run will be administered. The stimulus will be administered using a soft brush. A regular audio signal will help the operator to keep a constant stroke velocity. Audio commands will also be used to direct the operator. Infant must be asleep (natural sleep) during the fMRI acquisition.
75729225|NCT04293523|Drug|ELOCTA|Extended half-life factor VIII product
75880820|NCT02067338|Drug|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
76051145|NCT01938573|Drug|Cisplatin|Given IV
75434208|NCT01545570|Drug|GSK2376497|GSK2376497 Active Comparator
75434209|NCT01545570|Drug|0.9% sodium chloride|0.9% sodium chloride Placebo Comparator
75434210|NCT01545596|Behavioral|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
75434211|NCT01545609|Other|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
75581292|NCT04628052|Procedure|Colonoscopy|Music vs. No-Music
75581293|NCT04860401|Device|Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)|The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
75581294|NCT04628130|Other|Yoga Therapy|Yoga based self managed practices personalised to chronic pain patients
75581295|NCT04827485|Other|Gluteal squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
75581296|NCT04827485|Other|No squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will not perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
75581297|NCT04656756|Behavioral|Personalized Care|A clinical and standardized workflow was created for both experimental and control groups. This standardized workflow: consisted of services which included the management of basic medications, routine care regarding the postpartum period, newborn care and health education. After the standardized clinic workflow was formed, a personalized care plan was developed for the experimental group. Each care procedure was shared with the participants in the experimental group. Moreover, all potential alternative care plans were presented to the participants.
75581298|NCT04683107|Other|Eccentric protocol|Participants in this arm will perform progressive eccentric exercise protocol
75581299|NCT04683107|Other|Isometric protocol|Participants in this arm will perform progressive isometric exercise protocol
75581300|NCT04683146|Drug|Hand antisepsis with Propanolol- 1 60%.|"Pre-washing for one minute with neutral soap to remove the transient flora.~Hand antisepsis using Propanolol-1 60% in both hands.~Bacterial sample collection from right hand.~Sterile surgical glove in both hands.~Bacterial sample collection from left hand three hours later"
75581301|NCT04683146|Drug|Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.|"Pre-washing for one minute with neutral soap to remove the transient flora.~Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~Bacterial sample collection from right hand.~Sterile surgical glove in both hands.~Bacterial sample collection from left hand three hours later."
75581302|NCT04656717|Other|Measure of the total cost of performing next-generation sequencing (NGS)|Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
75729226|NCT04280978|Diagnostic Test|ABI ABC|"The assessor will administer ABaCo test through a computer device and she will marked the responses on a paper sheet. Video recordings are needed only to allow an impartial scoring. In fact, an external trained judge will do the scoring.~Furthermore the linguistic abilities will be assessed through the administration of some subtests of the Italian battery BVL 4-12. In particular, the researcher will administer the following subtests: naming, lexical comprehension and grammatical comprehension.~Moreover, some neuropsychological abilities will be analysed using the test BVN 5-11. In addition, the theory of mind and the non-verbal IQ will be assessed.~The Socio-Economic-Status of the family involved in the research will also be investigated, considering its importance on the rehabilitation outcomes."
75729227|NCT04279587|Behavioral|Residential camp|Intensive education at a residential camp.
75880821|NCT02067338|Drug|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
75880822|NCT01336764|Behavioral|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
75880823|NCT01336764|Behavioral|Control|Unguided listening to radio/music.
75880824|NCT04801173|Combination Product|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
75880825|NCT04801173|Behavioral|Low calorie standard diet|Low calorie standard diet with no specified dietary supplement addition
75434212|NCT01545635|Drug|Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|"Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT >90sec and FIBTEM A10>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min"
75434213|NCT01545635|Drug|Fresh Frozen Plasma blood type 0, A, B and AB|Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 <7mm and/or ExTEM CT>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
75434214|NCT01545661|Procedure|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
75434215|NCT01545661|Procedure|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
75434216|NCT01545687|Dietary Supplement|Lactobacillus brevis CD2 lozenge|Dissolved orally
75434217|NCT01545687|Other|placebo|Dissolved orally
75434218|NCT01545726|Drug|QAW039|QAW039 was supplied as capsules for oral administration.
75434219|NCT01545726|Drug|Placebo|Placebo was supplied as capsules for oral administration.
75434220|NCT01545739|Device|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
75434221|NCT01545752|Other|teaching by non-interactive CD|teaching book with non-interactive CD
75434222|NCT01545752|Other|Interactive CD|Teaching book with interactive CD
75434223|NCT01545778|Drug|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
75434224|NCT01545778|Drug|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
75581303|NCT00557583|Drug|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
75581304|NCT04627935|Behavioral|The COPD Assessment Test|Used to assess symptoms in COPD patients.
75581305|NCT04627935|Diagnostic Test|Navicular Drop Test|It is the test used to measure the amount of pronation in the foot.
75581306|NCT04627935|Behavioral|International Physical Activity Questionnaires (IPAQ)|The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.
75434225|NCT01545791|Drug|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
75581307|NCT04627935|Behavioral|COPD and Asthma Fatigue Scale (CAFS)|CAFS is a comprehensive, brief, patient-centered questionnaire developed to capture fatigue experienced by patients with asthma or COPD.
75581308|NCT04627935|Behavioral|Saint George Respiratory Questionnaire|Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
75581309|NCT04800302|Procedure|Continous Quadratum Lumborum Block III|Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum & psoas major muscles with ultrasound guidance.
75581310|NCT04800302|Procedure|Single dose Quadratum Lumborum Block III|Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
75434226|NCT01545804|Drug|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
75729228|NCT04253821|Other|muscle tonus, stiffness and elasticity,six-minute walk test, Pulmonary function tests, The neck disability index|The muscle tonus, stiffness and elasticity of upper trapezius (UT), semispinalis capistis (SSC), pectoral muscles (PM) and sternocleidomastoideus muscles (SCM) were measured by using MyotonPro® device. Functional capacity was measured with six-minute walk test. Pulmonary function tests was evaluated with spirometer. The neck disability index (NDT) was applied. The forward head posture was determined by measurements of craniovertebral angle (CVA). Physical activity levels of participants were evaluated by Physical Activity Index (FIT).
75434227|NCT01545830|Dietary Supplement|vitamin D3 (cholecalciferol)|Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
75434228|NCT01545856|Drug|levodopa|levodopa use
75880826|NCT01348451|Device|surgical implantation|human spinal cord stem cell implantation in ALS patients
75434229|NCT01545869|Procedure|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
75434230|NCT01545882|Drug|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
75434231|NCT01545908|Other|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
75581311|NCT04800302|Procedure|Intra-venous Morphine|Intra-venous Morphine [0.1 mg/kg] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
75880827|NCT03423290|Device|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
75434232|NCT01545908|Other|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
75581312|NCT04795037|Drug|CU06-1004, Single dose|"Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5"
75729229|NCT04249622|Other|Best Practice|Given standard of care pertuzumab-based chemotherapy
75729230|NCT04249622|Other|Questionnaire Administration|Ancillary studies
76051146|NCT01938573|Drug|Gemcitabine Hydrochloride|Given IV
76051147|NCT01938573|Drug|Sirolimus|Given PO
75729231|NCT04249622|Drug|Rifaximin|Given PO
75729232|NCT04249544|Drug|Pramipexole|1mg of pramipexole
75729233|NCT04249544|Drug|Placebo|1mg equivalent of placebo
75729234|NCT04230980|Drug|Gabapentin|Gabapentin 600mg tablet
75729235|NCT04230980|Drug|Placebo|Placebo tablet
75729236|NCT04218968|Drug|Carvedilol|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
75729237|NCT04216381|Diagnostic Test|Trauma Specific Frailty Index Questionnaire|questionnaire to assess patient's pre-injury health condition
75729238|NCT04208464|Drug|Baricitinib|4mg daily for 24 weeks from baseline
75729239|NCT04208464|Drug|Baricitinib|4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
75729240|NCT04201223|Behavioral|FLARE Intervention|[See arm/group descriptions]
75880828|NCT01352143|Drug|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
75880829|NCT01352143|Drug|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
75581313|NCT04795037|Drug|CU06-1004, Multiple doses|"Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD"
75581314|NCT04795037|Drug|Placebo|Placebo matched to CU06-1004, oral capsule
75581315|NCT04723706|Diagnostic Test|COVID-19 serology IgG|patients with SCT or CART who decide to get their vaccines we will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days after vaccination; 1 month +/- 10 days (after the first dose), 2 months +/- 10 days (after the 2nd dose), 3 months +/- 10 days, 6 months +/- 10 days and 12 months +/- 10 days
75581316|NCT04711304|Biological|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
75581317|NCT04711304|Device|Hyaluronic acid|Intraarticular injection
75581318|NCT04711304|Other|Saline|Intraarticular injection
75581319|NCT04710719|Drug|Triamcinolone Injection|Post surgical injection at site of keloid with TAC for 3 injections
75581320|NCT04710719|Drug|Triamcinolone Injection and 5-fluorouracil injection|Post surgical injection at site of keloid with TAC and 5FU for 3 injections
75581321|NCT04649372|Procedure|EndoVE|On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.
75729241|NCT04195685|Procedure|Neurofeedback (NFB)|Participants are seated in a comfortable chair and have common EEG electrodes with a pre-application of EEG adhesion conductive paste placed on scalp. The participant will receive coaching as they look at the game training screen and focus on the image. The game training screen provides almost instantaneous feedback (within 200 milliseconds) to participants about brain functioning. Twenty, one-hour, NFB training sessions will be provided by a trained NFB specialist over an 8-10-week period with up to 5-sessions but usually 3 sessions a week. The specific NFB special use system that will be used is the Cygnet NFB System from Bee Medic Corporation. The latest technological advances in this system has enabled training frequencies in the infra-low frequency range as well as in all other relevant frequency ranges which is a breakthrough capacity not available on any other NFB system. This will enable the individualized training to the person's brain training preference.
75729242|NCT04192344|Drug|ABSK021|ABSK021 oral capsule
75434233|NCT01545921|Other|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
75434234|NCT01545947|Drug|CC-223, erlotinib|"Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
75434235|NCT01545947|Drug|CC-223, oral azacitidine|"Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
75581322|NCT04683185|Drug|E6742|E6742 tablets.
75581323|NCT04683185|Drug|Placebo|E6742-matched placebo tablets.
75729243|NCT04188236|Device|Hernia Blocking System|Hernia Blocking System device implanted during a lumbar discectomy procedure
75729244|NCT04184882|Drug|Bocidelpar|Oral
75729245|NCT04184882|Drug|Placebo|Oral
75729246|NCT04164225|Behavioral|Qigong Exercise|"Participants with chronic low back pain will follow the free 5 elements Qigong healing class (estimate of 6 hours) at the Spring Forest Qigong center and then practice the 5 elements healing Qigong at home 3 times a week for 40 minutes with a freely available online video, for 12 weeks. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed."
75880830|NCT02260310|Other|Weizhong and Huantiao|
75880831|NCT02260310|Other|A-shi point|
75880832|NCT05188651|Behavioral|face masks|wearing face masks
75434236|NCT01545947|Drug|CC-223, oral azacitidine|"Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
75581324|NCT04656405|Other|Online real-time quality measurement and feedback video-based CPR training|"Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants."
75581325|NCT04656405|Other|Online real-time feedback video-based CPR training without quality measurement|"Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants."
75581326|NCT04656405|Other|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance."
75581327|NCT04656288|Drug|BI 764198 - Formula A|BI 764198
75880833|NCT01352299|Device|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
75880834|NCT01352299|Device|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
75880835|NCT01352299|Device|Miller|Laryngoscopy performed with Miller Laryngoscope
75434237|NCT01545960|Other|not applicable in this study|No actual interventions will be administered for this study.
75880836|NCT01352299|Device|TrueView|Laryngoscopy performed with TrueView laryngoscope
75434238|NCT01545973|Other|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
75581328|NCT04656288|Drug|BI 764198 - Formula B|BI 764198
75581329|NCT04656288|Drug|BI 764198 - Formula C|BI 764198
75581330|NCT04656288|Drug|BI 764198 - Formula D|BI 764198
75581331|NCT04592276|Dietary Supplement|PS128|Participants took two capsules with PS128 after dinner for 30 days.
75581332|NCT04592276|Dietary Supplement|placebo|Participants took two capsules without PS128 after dinner for 30 days.
75581333|NCT04627779|Drug|preemptive analgesia with flurbiprofen axetil|give flurbiprofen axetil 15 min before surgery
75581334|NCT04656327|Other|No intervention|There is no intervention in this study. It is a cross-section study evaluating the oral health and nutritional statuses of community-dwelling elders dependent for care for their activities of daily living.
75880837|NCT01348529|Behavioral|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
75880838|NCT02069210|Other|Blood transfusion|Intraoperative blood transfusion
75581335|NCT04627584|Combination Product|MW33 injection|a recombinant fully human antibody to coronavirus
75581336|NCT04627584|Combination Product|MW33 injection placebo|Placebo
75581337|NCT04537598|Procedure|Morphine patient controlled analgesia|30 patients will receive PCA only for postoperative analgesia
75581338|NCT04537598|Procedure|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia
76051148|NCT01938573|Procedure|Cystectomy|Undergo cystectomy when appropriate
76051149|NCT05496907|Behavioral|Diabetes specialist nurse-led collaborative care intervention|10 sessions with a diabetes nurse to help improve physical and mental health outcomes
76051150|NCT04777513|Procedure|CCTA (Coronary Computed Tomography Angiography)|Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
76051151|NCT04777513|Procedure|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
76051152|NCT04777513|Procedure|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
76051153|NCT04777513|Device|CNBP measurement|Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
76051154|NCT04777513|Device|Cardiolens FFR-CT Pro|Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
75581339|NCT04627467|Drug|Chloroquine|250mg tablet (150mg base chloroquine)
75880839|NCT05188573|Device|Early detection pancreatic cancer test|Blood collection and pancreatic cancer early detection testing with return of results
75880840|NCT05188573|Device|Early detection pancreatic cancer test and MRI Imaging|Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
76051155|NCT05169931|Biological|RegenerEyes|Biologic eye drop
75581340|NCT04656015|Device|MRI|"cMRI will be done only to patients presented with signs of HF, with raised cardiac biomarkers and echocardiographic signs of myocardial injury~The Lake Louise diagnostic criteria for CMR in myocarditis:~CMR findings are consistent with myocardial inflammation if at least two of the following criteria are present:~Regional or global myocardial signal intensity increase in T2-weighted images~Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted images~There is at least one focal lesion with non-ischemic regional distribution on late gadolinium enhancement Presence of left ventricular dysfunction or pericardial effusion provides additional, supportive evidence for myocarditis 6. Carotid du"
75581341|NCT04656093|Behavioral|Supportive counseling|"Participants in the control arm will receive 3 placebo sessions to control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes. The interventionist will review a patient education booklet for COPD self-management over the 3 sessions and address any question raised by the study subject."
75581342|NCT04656093|Behavioral|Education on SMB|Goal is to educate patient on SMB based on responses during 15-month interview and screener call, and assess patient's motivation for change.
75581343|NCT04656093|Behavioral|Psychoeducation on ATs for maladaptive beliefs (if applicable)|Goal is to educate patient on relationship between thoughts and SMB, and identify maladaptive beliefs, automatic thoughts, and cognitive distortions.
75581344|NCT04656093|Behavioral|Psychoeducation on emotional response (if applicable)|Goal is to educate patient on relationship between emotions and COPD + SMB, identify
75581345|NCT04531631|Drug|Dorzagliatin|tablet
75581346|NCT04531631|Drug|placebo|placebo
75581347|NCT04529447|Other|Survey|The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
76051156|NCT03522259|Drug|Rivaroxaban 10 MG Oral Tablet [Xarelto]|Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
76051157|NCT04788901|Other|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
76051158|NCT01937871|Drug|5 mg Tadalafil|Administered orally
76051159|NCT01937871|Drug|Placebo|Administered orally
76051160|NCT01937871|Drug|0.2 mg Tamsulosin|Administered orally
76051161|NCT04775875|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory wave form confirmation of cerebral arteries, and optical tracking technology (eg, AntNeuro Visor2 system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
76051162|NCT01341535|Radiation|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
76051163|NCT01341535|Radiation|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
76051164|NCT04775407|Procedure|blood sampling|IgM og IgG analysis
76051165|NCT05380063|Drug|De-escalated Dual Antiplatelet Therapy|ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
75581348|NCT04627623|Diagnostic Test|IgM and IgG antibodies assay|5 ml venous blood sample collection to assay IgM and IgM against COVID19
75581349|NCT04627740|Drug|Retroviral vector-transduced autologous T cells to express anti-ALPP CARs|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
75729247|NCT04164225|Behavioral|P.Volve Exercises|P.Volve exercise focuses on low impact core strengthening, core stabilization, and stretching. The program is similar in delivery as Qigong (i.e., online videos). An introductory class (estimate of 2.5h) will be given by the P.Volve team, the principal investigator, and a physical therapist who has experience with P.Volve exercises. Participants will access online videos for individual home practice in 40min/session, 3x/week for 12 weeks. Participants will receive a P.ball for some exercises, while other exercises are done with no equipment. Tailored videos will be available for those with cLBP. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.
75729248|NCT04147819|Drug|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
75880841|NCT03726333|Drug|lorlatinib|continued daily administration of 100 mg lorlatinib
76051166|NCT05380063|Drug|Dual Antiplatelet Therapy|Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.
75434239|NCT01545986|Behavioral|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
75434240|NCT01546012|Device|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
75434241|NCT01546012|Device|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
75434242|NCT01546025|Behavioral|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
75434243|NCT01546025|Behavioral|Relaxation training|One hour training in relaxation techniques
75581350|NCT04656366|Diagnostic Test|Coronary Angiography|Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)
75581351|NCT04525469|Behavioral|Narrative Exposure Therapy|"NET involves: 1) diagnostic interview and psychoeducation, 2) laying out the Lifeline, 3) NET therapy sessions (constructing the trauma narrative in context of the life course), 4) final session rituals. Laying out the Lifeline (using rope or string) allows participants to take a bird's eye view of the events of their life using simple items such as flowers to represent positive events and stones to represent traumatic events. The focus of NET sessions is to encourage participants to describe the details of traumas and integrating the cold memories (i.e., facts) with the hot memories (e.g., cognitions, emotions, physiological feelings, and sensory information). The therapist makes notes after each session narrating the details of the traumas (stones) and reads this at the beginning of each subsequent session. Final session rituals involve re-reading the trauma narrative, hopes for the future, and laying out the final Lifeline placing flowers for hopes and wishes for the future."
75581352|NCT04509167|Biological|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of ~500ug per peptide once a week for 8 weeks.
76051167|NCT02740699|Drug|Rosuvastatin|Participants will receive 20-40 mg once daily
75581353|NCT04627155|Drug|LY03003|Rotigotine,extended-release microspheres
75581354|NCT04508972|Device|Alexa Amazon|To test the use of the Amazon Alexa device as a tool to conduct screening of employees and patients at the point of entry into the Heart Failure (HF) Clinic of the McGill University Health Center.
76051168|NCT02740699|Drug|Atorvastatin|Participants will receive 40-80 mg once daily.
76051169|NCT02740699|Radiation|Cardiac Computed Tomography (CT)|Cardiac CT angiography (CCTA) provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Performed at baseline, 12 months 24 months, and 36 months.
75434244|NCT01546051|Drug|BCI-838|BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
75581355|NCT04656249|Drug|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing <60 kg and 12mg/d to those ≥60 kg.
75581356|NCT04656054|Procedure|liposuction|liposuction procedure and observation of the hematological changes on the patients
75581357|NCT04627350|Other|Response to pulmonary finding (nodule, mass)|Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
75581358|NCT04472156|Procedure|Transfer of mosaic embryo|Subjects will transfer a mosaic embryo transferred to their uterus
75581359|NCT04655859|Diagnostic Test|saliva cotton swab|evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
75729249|NCT04147819|Drug|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
75880842|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
75434245|NCT01546051|Drug|BCI-838|BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
75434246|NCT01546051|Drug|BCI-1038, BCI-1206 & BCI-1283|Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
75434247|NCT01546051|Drug|BCI-838|BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
75434248|NCT01546064|Device|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
75880843|NCT03726333|Drug|lorlatinib|continued daily administration of 100 mg QD lorlatinib
76051170|NCT02740699|Radiation|Cardiac Magnetic Resonance Image (MRI)|Provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Cardiac MRI may be performed at baseline, and 24 months (optional).
76051171|NCT01287091|Drug|GDC-0980|Oral tablet dose
76051172|NCT01287091|Drug|GDC-0980|Oral capsule dose
75434249|NCT01546064|Device|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
75434250|NCT01546077|Procedure|Placement of perineural catheters with Hydrolocalization technique using|Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
75434251|NCT01546090|Drug|Alprazolam|preoperative administration of an orally 0.50 mg single dose
75581360|NCT04682951|Procedure|Decompressive Craniectomy|
75581361|NCT04655898|Drug|[14C]CC-90001|Oral
75581362|NCT04682756|Diagnostic Test|The model of machine learning|Early diagnosis of NTEMI patients by machine learning model
75581363|NCT04682795|Device|Needle-free injector|Using needle-free injector as insulin carrier to treat T2DM
75434252|NCT01546090|Drug|placebo|placebo capsules were filled with starch
75434253|NCT01546103|Dietary Supplement|Cholecalciferol|1000 IU by mouth, once daily for 3 months.
75434254|NCT01546103|Dietary Supplement|Cholecalciferol|5000 IU by mouth, once daily for 3 months.
75434255|NCT01546116|Drug|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
75434256|NCT01546129|Device|Dianatal Obstetric Gel (Cross-linked polyacrylic acid)|Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
75581364|NCT04682795|Device|Insulin pen|Using insulin pen as insulin carrier to treat T2DM
75581365|NCT04627116|Drug|Tecarfarin|Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
75581366|NCT04655742|Device|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
75581367|NCT04395482|Other|Lung CT scan analysis in COVID-19 patients|This research project will evaluate the morphological characteristics of the lung by CT scan analysis in COVID-19 patients which will be identified as specific patterns using artificial intelligence technology and their impact on outcome.
75729250|NCT04140448|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML
75729251|NCT04140448|Device|Ultra-wide Fluorescein Angiography|Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
75729252|NCT04125589|Behavioral|Speaking Activity|Participants will engage in a speaking activity where they are given a topic to speak about.
75880844|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
76051173|NCT01287091|Drug|GDC-0980|Oral tablet dose in fed state
76051174|NCT01287091|Drug|GDC-0980|Oral repeating dose in fasting state
76051175|NCT01287091|Drug|GDC-0980|Oral repeating dose in fed state
76051176|NCT01287091|Drug|GDC-0980|Oral tablet in a fasting state
75434257|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
75581368|NCT04627233|Drug|Human Ezrin Peptide 1 (HEP1)|"HEP-1 will be administrated s.c. into the lower abdominal wall~induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days"
75581369|NCT04627233|Drug|Placebo|placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
75581370|NCT04655664|Diagnostic Test|not currently consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
75581371|NCT04655664|Diagnostic Test|consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
76051177|NCT01287091|Drug|rabeprazole|Oral repeating dose
75434258|NCT01546233|Behavioral|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
75434259|NCT01546233|Behavioral|standard education|standard education before and after chemotherapy
75434260|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
75729253|NCT04125589|Behavioral|Talking Activity|Participants will engage in a talking activity where they may talk about a topic of their choice.
75729254|NCT04120493|Genetic|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
75729255|NCT04120493|Other|Imitation (sham) surgery|Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull
76051178|NCT01269463|Drug|Methylphenidate Hydrochloride Extended Release Capsule|An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily
76051179|NCT01269463|Drug|Placebo|Capsule without active drug
75434261|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
75581372|NCT04365179|Drug|Nerofe|"Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1."
75581373|NCT04655508|Drug|Seretide|"For children between 6 to 11 years (< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
75581374|NCT04655508|Drug|Placebo|For children between 6 to 11 years (< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
75581375|NCT04355546|Other|Non-interventional|As this is a Non-interventional trial, only data obtained within the current routine management of COPD at outpatient respiratory centres or GP centres will be documented.
75581376|NCT04627272|Device|AutoDX-DR|AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.
75581377|NCT04655781|Procedure|idiopathic macular hole (MH) surgery|Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns
75729256|NCT04106570|Other|fatiguability of the knee extensors|fatiguability of the knee extensors (in N.m) measured with a dynamometer.
75729257|NCT04100174|Radiation|focal brachytherapy boost to SBRT|As above
75729258|NCT04087096|Drug|Denosumab|Denosumab will be administered at postoperative months 1, 7, and 13
76051180|NCT05362825|Drug|Neo-adjuvant Chemotherapy FOLFOXIRI Regimen|Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
76051181|NCT05362825|Procedure|synchronous resection surgery|Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
75434262|NCT01546272|Device|Insorb resorbable staples|Subcutanous suture using resorbable staples
75434263|NCT01546272|Device|Monocryl resorbable wire|Subcutanous suture using resorbable wire
75434264|NCT01546298|Other|Patch tests|Patch tests for allergic reaction
75434265|NCT01546311|Device|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
75434266|NCT01546324|Procedure|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
75434267|NCT01546350|Genetic|PGD|array CGH after blastocyst biopsy
75434268|NCT01546350|Procedure|PGD|PGD using blastocyst biopsy and testing of the biopsy by array CGH
75434269|NCT01546363|Other|Blood draw|phlebotomy
75434270|NCT01546376|Radiation|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
75434271|NCT01546376|Other|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
75434272|NCT01546389|Biological|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
75434273|NCT01546389|Drug|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
75434274|NCT01546415|Drug|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
75434275|NCT01546428|Drug|INC280|
75434276|NCT01546441|Behavioral|interprofessional assessment|assessment by interprofessional team
75434277|NCT01546441|Behavioral|usual care|usual care in primary care clinic
75729259|NCT04087096|Drug|Placebo|Placebo will be administered at postoperative months 1, 7, and 13
75729260|NCT04087096|Drug|Zoledronic Acid|Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
75581378|NCT04626999|Procedure|Single Bundle ACL Reconstruction|"Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft."
75434278|NCT01546467|Behavioral|Cognitive remediation|Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
75434279|NCT01546506|Drug|Gutron® treatment|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
75434280|NCT01546558|Drug|Metformin|Metformin 1000 mg bid on Days 1-10
75434281|NCT01546558|Drug|Ranolazine|Ranolazine 500 mg bid on Days 6-10
75434282|NCT01546597|Drug|Metformin|"Metformin 500 mg bid on Days 1-5~Metformin 850 mg bid on Days 6-10~Metformin 500 mg bid on Days 11-15~Metformin 850 mg bid on Days 16-20"
75434283|NCT01546597|Drug|Ranolazine|"Ranolazine 1000 mg bid on Days 11-15~Ranolazine 1000 mg bid on Days 16-20"
75434284|NCT01546610|Other|insoles intervention|EVA insole with arch support and bar retrocapital
75434285|NCT01546610|Other|placebo insole|EVA insole flat
75581379|NCT04626999|Procedure|Double Bundle ACL Reconstruction|"Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft."
75581380|NCT02906774|Biological|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
75581381|NCT02907008|Other|Polysomnography|
75581382|NCT04655040|Drug|Caffeine|100milligram (mg) tablet taken orally in period 1 and period 2
75581383|NCT04655040|Other|Ritlecitinib|200 milligrams (mg) taken orally once a day(QD) for 8 days
75581384|NCT02906735|Procedure|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
75434286|NCT01546662|Dietary Supplement|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
75434287|NCT01546662|Dietary Supplement|Placebo|1/ 2 capsules, twice daily for 12 weeks
75434288|NCT01546701|Drug|Buprenorphine|2 mg sublingual tablet
75434289|NCT01546701|Drug|Morphine|0.1 mg/kg IV morphine
75434290|NCT01546727|Behavioral|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
75434291|NCT01546727|Behavioral|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
75434292|NCT01546779|Device|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
75581385|NCT04626765|Drug|CD19 CAR-T|CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells
75581386|NCT04626765|Drug|CD22 CAR-T|CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells
75581387|NCT04626765|Drug|CD 19+22|CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells
75581388|NCT04626765|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
75581389|NCT04626765|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
75581390|NCT02906969|Other|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
75581391|NCT02906969|Other|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
76051182|NCT02539459|Drug|Everolimus|10 mg tablets
75581392|NCT02906891|Device|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
75581393|NCT04655274|Diagnostic Test|The Quality of Vision questionnaire|The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.
75581394|NCT04626648|Behavioral|Pause with a sugar containing drink|Three-minute long intraoperative pause, including a sugar-containing drink
75581395|NCT02906618|Drug|LY3039478|Administered orally
75581396|NCT02906618|Drug|3C 15N 2H-LY3039478 IV|Administered IV
75581397|NCT04626726|Drug|CD19 CAR-T|CD19 CAR-T infusion for patients with CD19 positive tumor cells
75581398|NCT04626726|Drug|CD22 CAR-T|CD22 CAR-T infusion for patients with CD22 positive tumor cells
75581399|NCT04626726|Drug|CD19+CD22 CAR-T|CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
75581400|NCT04626726|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
75581401|NCT04626726|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
75581402|NCT04655235|Genetic|Genotyping|Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
76051183|NCT01706926|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
76051184|NCT01706926|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
75581403|NCT04654962|Procedure|Anesthetic nerve block|iliac fascia block is an analgesic technique that uses local anesthesia, is effective and relatively safe in preoperative management. The target of this block is the femoral and lateral femoral cutaneous nerves; which innervate the anterior aspect of the thigh, as well as the muscle and periosteum that covers the femoral head, neck and proximal femur.
75581404|NCT04654884|Other|Auricular acupuncture (AA)|The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
75729261|NCT04075435|Drug|high CBD/low THC sublingual solution|Hemp derived solution to be administered sublingually twice daily.
76051185|NCT01706926|Biological|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
76051186|NCT01706926|Other|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
75434293|NCT01546792|Behavioral|Combined lifestyle intervention|Exercise training, dietary advice, behaviour change counselling
75434294|NCT01546805|Drug|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
75434295|NCT01546805|Drug|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
76051187|NCT01634113|Drug|tiotropium-bromide|IMP
76051188|NCT01634113|Drug|tiotropium-bromide|IMP
76051189|NCT01634113|Drug|placebo|placebo matching tiotropium
76051190|NCT01706770|Device|enfilcon A|
76051191|NCT01706770|Device|galyfilcon A|
76051192|NCT01016899|Radiation|electronic brachytherapy|Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
75434296|NCT01546818|Biological|SAV001-H|A whole-killed HIV
75434297|NCT01546844|Other|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
75434298|NCT01546896|Drug|buspirone+alprazolam|day 1~7: buspirone 10mg/d + alprazolam 0.5mg / day 8~28: buspirone 20mg/d + alprazolam 0.5mg / day 29~56: buspirone 20~30mg/d + alprazolam 0.5mg
75434299|NCT01546896|Drug|alprazolam|0.5mg/d
75434300|NCT01546909|Biological|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
75434301|NCT01546935|Drug|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
76051193|NCT04497454|Other|EIT-Group|A mechanical ventilation strategy with the main goal to maintain DP < 16 cmH2O
76051194|NCT04497454|Other|ARDSNet|Low PEEP-FiO2 table ARDS Network ventilation protocol
76051195|NCT01937715|Drug|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
76051196|NCT01937715|Drug|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
75729262|NCT04069299|Drug|68Ga-DOTATATE|The NETspot kit is 2 vials, Vial 1 contains 40 mcg dotatate, 5 mcg 1,10phenanthroline; 6mcg gentisic acid and 20 mg mannitol. Vial 2 contains 60 mg formic acid, 56.5 mg sodium hydroxide and water for injection
75880845|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
75880846|NCT01347125|Device|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
75880847|NCT05188495|Drug|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
75434302|NCT01546961|Drug|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
75581405|NCT02906501|Procedure|The Penn Web-Based Computerized Neurocognitive Battery|The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
75581406|NCT02906501|Procedure|The Iowa Gambling Test (IGT)|The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
75581407|NCT02906540|Procedure|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
75581408|NCT02906540|Procedure|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
75581409|NCT02906423|Other|PROMIS-10 questionnaire|Patient completed a PROMIS-10 questionnaire
75581410|NCT02906462|Other|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
75880848|NCT02069288|Drug|Fludrocortisone|50 µg of fludrocortisone per os
75434303|NCT01546974|Device|HME filter Twin Star 55, Drager Medical, Germany|
75581411|NCT02906462|Other|Usual practices|the centres applies their usual practices
75434304|NCT01546974|Device|Heated humidification|
75434305|NCT01547026|Behavioral|Implementation Intentions|In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
75880849|NCT02069288|Drug|Placebo|1 tablet of placebo per os
75880850|NCT01356121|Drug|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
75880851|NCT01356121|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
75880852|NCT05725161|Behavioral|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
75434306|NCT01547052|Behavioral|DBT for children|intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
75434307|NCT01547052|Behavioral|Enhanced Supportive-Educational therapy|weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
75434308|NCT01547078|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
75434309|NCT01547078|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
75729263|NCT04069299|Diagnostic Test|Positron Emission Tomography (PET) Scan|PET scan is an imaging test using radioactive tracers.
76051197|NCT01937715|Biological|Bevacizumab|5 mg/m^2 every 2 weeks or 7.5 mg/m^2 every 3 weeks
75434310|NCT01547091|Biological|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
75581412|NCT04654494|Procedure|Total proctocolectomy|excision of the whole large bowel including colon and rectum and end ileostomy fashioning
75434311|NCT01547091|Drug|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
75581413|NCT04654494|Procedure|Total colectomy|excision of the colon with preservation of the rectum
75581414|NCT04654494|Procedure|Segmental colectomy|excision of a segment of colon
75581415|NCT02906345|Device|Therapeutic Plasma Exchange (TPE)|All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
75581416|NCT04654572|Diagnostic Test|Myotonometric measurement|Myotonometric assessment can predict the muscle stiffness, tone and elasticity
75581417|NCT02906306|Behavioral|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
75581418|NCT02906306|Behavioral|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
75880853|NCT05725161|Behavioral|Wait-list control group with psychoeducation materials provided|The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
75581419|NCT04626531|Other|Web-Based Education|Participants in the intervention group had unlimited access to the Web site, free of charge. The Web site was designed to run on personal computers and smartphones.
75581420|NCT04626531|Other|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
75581421|NCT02906384|Radiation|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
75880854|NCT01336608|Drug|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
75434312|NCT01547091|Biological|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
75434313|NCT01547104|Drug|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
75434314|NCT01547104|Drug|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
75434315|NCT01547143|Drug|IST and/or alloHCT|"1) Patients will be categorized by their initial serum ferritin level.~Mild ( ferritin<3,000 μg/L): close observation~Moderate (ferritin: 3,000-10,000 μg/L):~Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)~continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.~Severe (ferritin>10,000 μg/L):~initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)~continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.~2) AlloHCT for refractory or reactivated cases."
75434316|NCT01547156|Device|Intervention group|
75434317|NCT01547169|Drug|Placebo Comparator|saline, taken twice per day for a 3 week duration
75434318|NCT01547169|Drug|insulin detemir|10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
75434319|NCT01547169|Drug|insulin detemir|20IU insulin detemir, administered intranasally twice per day for a 3 week duration
75581422|NCT04626414|Drug|Ferric maltol capsule|single dose of 30 mg capsule
75581423|NCT04626414|Drug|Ferric maltol suspension|single dose of 30mg (5ml) oral suspension
75581424|NCT02906267|Other|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
75581425|NCT04654611|Drug|preservative free tafluprost 0.0015%|preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
75581426|NCT02906228|Radiation|Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law|
75581427|NCT04654416|Drug|Corticosteroid with or without colchicine|We describe the clinical outcome of patients treated with corticosteroid and colchicine
75581428|NCT02906189|Radiation|MRI|
75581429|NCT02906150|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
75581430|NCT02906150|Drug|SoC (chemotherapy and platinum agent)|Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
75729264|NCT04067297|Other|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of ~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
75729265|NCT04057807|Drug|LPS|LPS (0.4 ng/kg)
75729266|NCT04052828|Device|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
75581431|NCT04626453|Behavioral|2-month home moderate-intensity exercise|The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
75581432|NCT00561990|Drug|Nimotuzumab|
75581433|NCT02906072|Behavioral|Low fat plant-based diet|Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.
75581434|NCT02906072|Behavioral|Lectures on health effects of a low fat plant-based diet.|Participants attend the lectures on health effects of a low fat plant-based diet.
75581435|NCT04654728|Procedure|Active Comparator: ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
75434320|NCT01547182|Behavioral|Caloric restriction|Caloric restriction
75581436|NCT02906111|Drug|estriol|"Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse"
75581437|NCT02906111|Procedure|vaginal surgery|Control Group
75581438|NCT00562029|Procedure|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
75581439|NCT02905916|Drug|PEG-rhG-CSF|
75581440|NCT04626492|Diagnostic Test|Quantitative MRI imaging|Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
75581441|NCT02905994|Drug|Volasertib|Polo-Like Kinase Inhibitor
75581442|NCT02905994|Drug|Cytarabine|Standard chemotherapy at dosage and schedule for 7+3 induction
75581443|NCT02905994|Drug|Idarubicin|Standard chemotherapy at dosage and schedule for 7+3 induction
75581444|NCT02905994|Procedure|Bone Marrow Biopsy|Bone marrow biopsy assessments scheduled during induction to assess response
75581445|NCT04626336|Procedure|Cystectomy|Cystectomy
75581446|NCT02905955|Device|Prevena, KCI, Acelity, NPWT|All patients will receive a Prevena NPWT (if inclusion criteria are met)
75581447|NCT04654767|Other|Tissue sampling|"Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls."
75581448|NCT02905877|Other|Behavioural study|reaching studies and other behavioural studies.
75581449|NCT04626180|Procedure|Extubation|Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
75581450|NCT04626180|Procedure|Manual Hyperinflation|Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
75581451|NCT02905682|Drug|Desmopressin|
75581452|NCT02905682|Drug|Placebo|
75434321|NCT01547182|Behavioral|Aerobic Training|Walking
75434322|NCT01547182|Behavioral|Resistance Training|Lifting weights
75434323|NCT01547195|Procedure|swim training|"Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.~Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training."
75434324|NCT01547195|Procedure|Training walk|"The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.~The training of walking will last 50 minutes, three times per week for 12 weeks.~At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes."
75434325|NCT01547208|Procedure|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
75434326|NCT01547208|Procedure|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
75434327|NCT01547221|Drug|clotrimazole|single application of 1%clotrimazole ear drop
75434328|NCT01547221|Drug|3% Boric acid|3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
75434329|NCT01547273|Procedure|bone graft inside socket only|bone graft inside socket only
75581453|NCT04654377|Other|Personalised education|Patients will be explained about their disease and possible outcomes based on clinical, biochemical and imaging data.
75581454|NCT04626258|Drug|Fluconazole|Fluconazol once a month 150 mg capsule
75880855|NCT01336608|Drug|Vilanterol|Inhaled long acting beta-agonist
75581455|NCT04626258|Other|L-Mesitran|The first month apply every day one sachet, the next five months apply every week one sachet.
75581456|NCT02905643|Other|Study subjects|This study does not include an intervention it is only observational.
75581457|NCT04626102|Behavioral|Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)|"The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session."
75434330|NCT01547273|Procedure|bone graft inside and outside socket|bone graft inside and outside socket
75434331|NCT01547273|Procedure|no bone graft|no bone graft
75434332|NCT01547312|Drug|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
75434333|NCT01547312|Procedure|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
75434334|NCT01547312|Procedure|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
75581458|NCT04626102|Behavioral|Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)|"This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below."
75880856|NCT01336608|Drug|Placebo|Placebo
75880857|NCT02069444|Procedure|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
75434335|NCT01547312|Procedure|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
75434336|NCT01547312|Drug|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
75434337|NCT01547312|Drug|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
75434338|NCT01547312|Drug|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
75581459|NCT02905604|Device|dmPFC iTBS|2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
75581460|NCT02905604|Device|dmPFC Sham iTBS|Sham iTBS
75434339|NCT01547312|Procedure|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
75434340|NCT01547325|Drug|NanoDOX 1% doxycycline monohydrate Hydrogel|1% doxycycline monohydrate hydrogel
75581461|NCT04626219|Other|Imaging|Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
75880858|NCT02069444|Procedure|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
75581462|NCT04626219|Behavioral|fast|hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
75581463|NCT04626219|Behavioral|regulated meals|standardized diet from noon until 9 a.m. the next day
75581464|NCT04626063|Drug|Magnesium|Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
75581465|NCT04626063|Drug|NSAID|Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
75880859|NCT03872999|Other|Functional brain imaging without any contrast agent|"During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
75880860|NCT03628521|Drug|Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin|Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
75434341|NCT01547325|Drug|placebo hydrogel|placebo hydrogel
75434342|NCT01547351|Other|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
75434343|NCT01547364|Drug|Saline|Injection of 10 ml of normal saline into the caudal epidural space
75434344|NCT01547364|Drug|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
76051198|NCT01937715|Drug|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
75581466|NCT04626063|Drug|paracetamol|Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
75729267|NCT04047563|Drug|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
75880861|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
75880862|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
75880863|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
75880864|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
76051199|NCT01937559|Biological|Tranexamic acid (TXA)|1.5g of TXA in 100ml normal saline solution
76051200|NCT01937559|Drug|Normal saline|
76051201|NCT04634331|Behavioral|Augmented Reality Multi-Modal Training|Training administered via an augmented reality headset.
75581467|NCT04681976|Behavioral|Telematic dance program|"Telematic dance program~The dance program will consist of 24 sessions distributed twice a week for a total period of 3 months. Each session will include:~A) Warm up: It will consist of analytical and global movements of increasing intensity and stretching exercises. It will also involve body awareness and motor control exercises.~B) Choreography part: the participants must follow and learn the choreographies. Intensity ranges shall vary between low and moderate. (3-4 in Borg's Modified Scale (0-10)).~C) Cool down: It will consist of global movements of decreasing intensity, stretching, breathing, and relaxing exercises."
75581468|NCT04625985|Drug|Metformin Glycinate|Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment
75581469|NCT04625985|Drug|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
75581470|NCT02905760|Drug|Furosemide|"Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)"
75581471|NCT02905760|Drug|Placebo filling|Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
75581472|NCT02905760|Drug|Placebo furosemide|"Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)."
75581473|NCT02905760|Drug|Vascular filling|Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
75581474|NCT04653987|Procedure|Percutaneous biliary drainage|
75880865|NCT02067494|Other|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
76051202|NCT04634331|Behavioral|Traditional Multi-Modal Training|Training administered via a 1:1 physical therapy session
75434345|NCT01547377|Dietary Supplement|zinc and selenium supplementation|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
75434346|NCT01547377|Other|rosuvastatin + placebo|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
75581475|NCT02905526|Behavioral|Contraceptive instant messages|Contraceptive Instant messages
75581476|NCT02905526|Other|Mobile phone app|Mobile phone app
76051203|NCT01960257|Device|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
75581477|NCT02905565|Drug|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
76051204|NCT01960257|Other|SOC DOT|
75581478|NCT02905565|Drug|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
75581479|NCT04654065|Drug|IN-C004|One time dose of IN-C004 taken orally.
75581480|NCT04654221|Diagnostic Test|mGFR by iohexol clearance|Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
75581481|NCT04654182|Drug|Chlorhexidine Gluconate|Product used in accordance with manufacturers Hand Hygiene instructions
75581482|NCT02905409|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
75581483|NCT04625712|Procedure|Cholecystectomy|Cholecystectomy within the first week after a mild acute biliary pancreatitis
75581484|NCT02905448|Other|Low fat plant-based nutrition|"Conventional low fat plant-based meals free from animal source foods three times daily.~Plant-based meal replacement with Herbalife European Free From Vanilla formula two times daily.~Herbal beverage two times daily. Dietary fiber supplements is taken three times daily (10-36w) and more high fat whole plant-based foods (avocado, tofu, seeds) Conventional food intake is taken ad libitum and no calorie counts or restrictions will be applied.~From 10 to 36 weeks we added vitamin B12 and EPA+DHA fatty acid"
75729268|NCT04047563|Drug|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
76051205|NCT01918371|Drug|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
75434347|NCT01547416|Drug|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|"Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
75729269|NCT04037397|Drug|Anti Arrhythmics|Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
75729270|NCT04037397|Procedure|Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation|Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
75729271|NCT04029974|Device|ErigoPro|Robotic tilt-stepper lower extremity movements at the cadence of 0, 40, and 80 steps/minute.
75729272|NCT04029233|Device|Occlutech PFO Occluder|The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.
75729273|NCT04023045|Device|Assist-Knee|Assist-Knee is an experimental lower limb knee prosthesis.
75729274|NCT04023045|Device|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
75880866|NCT02067494|Other|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
75880867|NCT01361347|Dietary Supplement|milk|milk for milk allergic children (1:25 dilution, whole milk)
75880868|NCT05697003|Drug|Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
75434348|NCT01547416|Drug|no epidural drug administered|"Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
75434349|NCT01547455|Drug|Atorvastatin(Lipitor)|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
75729275|NCT04015921|Other|No intervention|There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.
75729276|NCT04006769|Drug|Entacapone|Entacapone tablet
75729277|NCT04006769|Drug|Imatinib Mesylate|Imatinib Mesylate tablet
75880869|NCT05697003|Drug|ADVAIR DISKUS 100/50|2 inhalations in one study period
75880870|NCT01356199|Dietary Supplement|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
75880871|NCT01356199|Dietary Supplement|PLACEBO|PLACEBO. 6 per day for 8 months.
75880872|NCT02067572|Other|Saline mouthwash|
75880873|NCT02067572|Other|Salvia mouthwash|
75880874|NCT03775473|Diagnostic Test|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
75880875|NCT02069522|Other|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
75729278|NCT03999138|Diagnostic Test|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of < 3 minutes.
75729279|NCT03997383|Drug|Placebo|Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
75729280|NCT03997383|Drug|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
75729281|NCT03974061|Behavioral|Brief Acceptance and Commitment Therapy|Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
75729282|NCT03974061|Behavioral|Brief Alcohol Intervention|The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
75729283|NCT03936998|Combination Product|Vancomycin plus VE416 before PNOIT|Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks followed by PNOIT
75880876|NCT02069522|Other|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
75880877|NCT02033148|Drug|icotinib hydrochloride|Given PO
75434350|NCT01547455|Drug|Placebo|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
75880878|NCT02033148|Other|laboratory biomarker analysis|Correlative studies
75434351|NCT01547494|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
75434352|NCT01547494|Dietary Supplement|mixture of omega3 and vitamins|mixture of omega3 and vitamins
75434353|NCT01547507|Device|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
75880879|NCT02033148|Other|pharmacological study|Correlative studies
75880880|NCT01361425|Drug|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
75880881|NCT01361425|Drug|placebo|placebo 500mg 8/8h, orally
75880882|NCT02033226|Device|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
75434354|NCT01547520|Drug|Meperidine|intramuscular, 25 mg, 5 to 10 minutes before EGD
75434355|NCT01547520|Drug|normal saline|25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
75434356|NCT01547546|Drug|GDC-0084|Multiple doses
75434357|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp negative patients.
75434358|NCT01547559|Drug|part1:EAC-T|esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
75434359|NCT01547559|Drug|part1:EA-EMC-T|esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
75434360|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp positive patients.
75434361|NCT01547559|Drug|part2:GGA group|GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
75434362|NCT01547572|Procedure|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
75729284|NCT03936998|Combination Product|Vancomycin plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
75729285|NCT03936998|Combination Product|Placebo plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
75581485|NCT04653870|Other|cyriax manipulation lumber|"In group A patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Cyriax manipulation.~Exercises (Guided low back exercises, 3-5times/day). Ankle pumping (5-10 repetition with 15-20 second hold), Quads Isometric (5-10 repetition with 15-20 second hold), Hams & Calf stretching (5-10 repetition with 15-20 second hold), Bridging (5-10 repetition with 15-20 second hold), Prone Back extension (10 repetition) Precaution Prevent yourself from sitting low on ground, Sitting with support will be directed and be careful during driving and ascending stairs.~Cyriax Manipulation: 2-3 repetitions/session, 2 session/week Lumbar spinal manipulation Rotation Techniques Lumbar spinal manipulation Extension Techniques Lumbar spinal manipulation Antideviation Techniques total of 4 session were given. 2 session/week."
76051206|NCT01917747|Behavioral|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
75434363|NCT01547572|Procedure|The control group will receive a leaflet only|The control group will receive a leaflet only
75581486|NCT04653870|Other|lumber decompression|"Group B: In group B patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Decompression Session.~Conservative therapy: Same as Group A~Lumbar spine decompression:~30 Minutes Session (generalized time for every one) . On the account of MRI description level is recommended and acknowledged by MRI the level of disc protrusion, decompression is operated. Patient is lying on table facing upward. For locking of the patient's body it was secured by pelvis and thoracic straps. One part of the decompression table is immobile other is movable. Bottom extreme part of the table is mobile.~Estimation of weight of patient is first thing to do. We calculated it by division of whole weight by 5 and that 5th segment of weight was utilized as an interventional pound for decompression. ."
75581487|NCT02905292|Other|evaluation and treatment maneuver for BPPV|
75581488|NCT04654026|Drug|Aspirin/Clopidogrel|No intervention, only observational studies
75581489|NCT04681703|Behavioral|Nurse-led program on accuracy of blood pressure self-measurement|The training program was performed in accordance with current guidelines and consisted of a 1-h educational session led by one family nurse (FN) tasked with instruction of the patients. During the training program the FN emphasized that since morning and evening blood pressure (BP) values can widely differ, especially in patients taking medications, BP should be measured twice a day, in the morning and at evening, at specific fixed times (between 6:00 am and 9:00 am and between 6:00 pm and 9:00 pm) at least during the first week of monitoring. Thereafter, measurements can be taken before antihypertensive drugs are taken.
75581490|NCT02905253|Drug|AC-084|Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
76051207|NCT01917747|Behavioral|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
75581491|NCT02905253|Drug|Placebo|Placebo capsules matching AC-084 capsules
75581492|NCT04625868|Other|Educational video|Patients will watch a preoperative educational video on proper opioid use and disposal.
75581493|NCT02905175|Procedure|blood sample|
75581494|NCT02905175|Procedure|synovial tissue|synoviocytes from synovial tissue
76051208|NCT01597791|Device|Foley catheter|Foley catheter placement after CSE.
76051209|NCT01597791|Other|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
75434364|NCT01547585|Other|Standardized soy containing muffin|Standardized muffin containing two levels of soy
75434365|NCT01547611|Other|Customary treatment|The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
76051210|NCT01916967|Drug|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
75434366|NCT01547611|Other|Structured behavioural medicine program|The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
75434367|NCT01547624|Other|Neck specific exercises|Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
75434368|NCT01547637|Procedure|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
75434369|NCT01547637|Procedure|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
75581495|NCT04653909|Other|Rehabilitation|The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
75581496|NCT04625595|Drug|350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
75581497|NCT04625595|Drug|700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
75581498|NCT04625595|Drug|1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
75581499|NCT04625595|Drug|1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
75581500|NCT02905058|Drug|Ketoprofen|oral non-steroidal antiinflammatory drug
75581501|NCT02905058|Drug|placebo|
75581502|NCT00557661|Drug|CD-NP|24 hr intravenous infusion
75434370|NCT01547650|Other|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
75434371|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
75434372|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
75434373|NCT01547689|Biological|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
75581503|NCT02905136|Other|Fundamental research|serum, whole blood, cerebrospinal fluid
75581504|NCT03454854|Device|intelligent terminal APP|Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
75581505|NCT02905097|Procedure|Knee Replacement|Surgical replacement of arthritic knee with an implant
75581506|NCT03454815|Procedure|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
75581507|NCT02905019|Biological|R21 with Matrix-M1|Vaccine
75581508|NCT02905019|Biological|ChAd63 ME-TRAP|Vaccine
75581509|NCT02905019|Biological|MVA ME-TRAP|Vaccine
75581510|NCT03454776|Device|Unloader One brace|A knee brace used to unload affected compartments in osteoarthritic knees
75880883|NCT02033226|Device|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
75880884|NCT01356355|Drug|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
75581511|NCT03454776|Device|Placebo brace|A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
75581512|NCT02904941|Biological|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
75581513|NCT02904941|Device|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
75729286|NCT03936998|Combination Product|Placebo plus placebo with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by placebo for VE416 PO QD x 6 weeks with concomitant PNOIT
75880885|NCT01356355|Drug|Placebo|One capsule twice a day daily till ureteral stent in situ
75880886|NCT01356355|Drug|Tolterodine|One capsule twice a day daily till ureteral stent in situ
75880887|NCT02069600|Device|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
75880888|NCT03610542|Behavioral|Triggers for anxiety|Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
76051211|NCT01916967|Drug|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
76051212|NCT01936623|Behavioral|Computerized Brief Intervention|No additional information needed.
75581514|NCT02904941|Procedure|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
75880889|NCT03610542|Behavioral|Identifying and challenging negative thoughts|Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
76051213|NCT04625127|Device|Treadmill gait training with GaitBetter|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes.
76051214|NCT04625127|Other|Treadmill gait training with GaitBetter + Standard of care|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes. In addition, the investigators will record the number and duration of therapy sessions followed by the participant during standard of care.
76051215|NCT04625127|Other|Standard of care|Participants will follow their standard of care. The investigators will record the number and duration of therapy sessions followed during standard of care.
76051216|NCT01959243|Drug|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
75880890|NCT03610542|Behavioral|Relaxation|Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
76051217|NCT01959243|Drug|Vehicle|Ophthalmic solution to be applied as directed.
75434374|NCT01547702|Behavioral|Teacher Help for ADHD|"Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~Session 5: Help to use instructional interventions for ADHD~Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours"
75434375|NCT01547897|Drug|NOX-E36|0.5 mg/kg study drug or placebo as SC injections twice a week
75434376|NCT01547910|Dietary Supplement|Fish Oil|Fish oil given in supplementary dose
75434377|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
75434378|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
75434379|NCT01547949|Dietary Supplement|tart cultivar Montmorency cherry juice|
75434380|NCT01547949|Dietary Supplement|placebo cherry fruit drink|
75581515|NCT03454737|Procedure|mesenchymal stem cells|"Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration"
75581516|NCT03454737|Procedure|Pure platelet-rich plasma|"Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%."
75581517|NCT02904980|Behavioral|Technical Training|Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.
75581518|NCT02904980|Behavioral|Quiet Eye Training|Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
75434381|NCT01547962|Device|Gintuit|"Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture."
75434382|NCT01547962|Other|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
75434383|NCT01547988|Other|Balance Training Intervention|The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
75434384|NCT01548001|Drug|Iguratimod|25 mg/tablet, taken orally, 2 tablets/day (bid)
75434385|NCT01548001|Drug|Methotrexate|2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
75434386|NCT01548014|Dietary Supplement|VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).
75434387|NCT01548027|Procedure|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
75434388|NCT01548027|Procedure|TAP block|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
75880891|NCT03610542|Behavioral|Goal Setting|Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
75434389|NCT01548027|Other|No intervention|No intervention
75880892|NCT03610542|Behavioral|Overcoming avoidance|Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
75880893|NCT03634969|Drug|BMS-986224|Specified dose on specified days
75581519|NCT04625322|Other|HCV care provided by hospitalist during acute psychiatric admission|HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
76051218|NCT01959243|Drug|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
75581520|NCT02904824|Biological|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
75581521|NCT02904824|Biological|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
75434390|NCT01548053|Other|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
75581522|NCT04653519|Device|Virtually guided minimally invasive preparation|Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
75434391|NCT01548066|Drug|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
75434392|NCT01548066|Drug|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
75434393|NCT01548079|Drug|Ursodeoxycholic Acid (UDCA)|20mg/kg/day UDCA in three weeks
75581523|NCT02904746|Behavioral|Make It!|The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
75581524|NCT02904785|Device|Extracorporeal Shock Waves|
75581525|NCT02904785|Device|Sham Extracorporeal Shock Waves|
75581526|NCT02904785|Other|Physical activities|Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
75581527|NCT01212991|Drug|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
75581528|NCT01212991|Drug|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
75880894|NCT01356433|Drug|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
75880895|NCT01356433|Drug|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
76051219|NCT01959243|Drug|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
76051220|NCT01959165|Drug|MEDI7183 low dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
76051221|NCT01959165|Drug|MEDI7183 medium dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
76051222|NCT01959165|Drug|MEDI7183 high dose|MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
75880896|NCT02033460|Other|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
75880897|NCT02033460|Other|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
76051223|NCT01959165|Drug|Matching Placebo|Placebo will be administered by SC on Day 1, Week 2,4, and 8
76051224|NCT01916109|Drug|Gemcitabine|
76051225|NCT01916109|Drug|Carboplatin|
76051226|NCT01916109|Drug|Panitumumab|
76051227|NCT01916109|Procedure|radical cystectomy|
76051228|NCT01915095|Device|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
75434394|NCT01548092|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
76051229|NCT01915095|Device|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
76051230|NCT01915095|Other|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
76051231|NCT01915095|Other|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
76051232|NCT01958619|Drug|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
76051233|NCT01958619|Drug|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
76051234|NCT01958619|Drug|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
76051235|NCT01958619|Drug|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
76051236|NCT01752634|Drug|Secukinumab (AIN457)|Secukinumab (AIN457)
76051237|NCT01752634|Drug|Placebo|Placebo PFS for s.c. administration.
76051238|NCT01726270|Drug|tamsulosin|0.4 mg
76051239|NCT02102269|Device|actimove sling|
75434395|NCT01548105|Other|Blood draw for the study participants|"These will include:~Procollagen 1-N propeptide levels (PINP)~Matrix metalloproteinase (MMP9)~Plasma Vitamin C levels"
75434396|NCT01548118|Biological|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
75434397|NCT01548118|Biological|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
75434398|NCT01548118|Biological|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
76051240|NCT02102269|Device|shoulderlift|
76051241|NCT01914393|Drug|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
76051242|NCT01545271|Drug|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
76051243|NCT01545271|Device|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
76051244|NCT00559819|Drug|placebo|Placebo (orange juice), same volume as alcohol
76051245|NCT00559819|Drug|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
76051246|NCT01931865|Drug|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
75581529|NCT04625439|Behavioral|Personality Feedback Self-Management Intervention|The intervention is a personality feedback report that will tell participants whether they scored low (bottom third), average (middle third), or high (top third) on each of the five factor personality characteristics based on gender-matched norms. In addition to a description of general tendencies based on their level of each personality trait, the feedback will include information about how scoring in a given category may relate to an individual's cancer self-management or healthcare decision making. The feedback for each personality trait will include recommendations for how to improve key outcomes.
75880898|NCT02033460|Other|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
75880899|NCT03691727|Drug|tirofiban hydrochloride (AGGRASTAT®)|Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
75880900|NCT03691727|Diagnostic Test|MRI|Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
75880901|NCT03691727|Diagnostic Test|Neurological Exam|Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
76051247|NCT04646889|Drug|AR882 Single Dose|A single dose of AR882
76051248|NCT04646889|Drug|AR882 Multiple Dose|AR882 taken once daily for 14 days
76051249|NCT01617447|Drug|Placebo of Aripiprazole|administered orally once daily
75434399|NCT01548118|Biological|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
75434400|NCT01548131|Behavioral|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
75434401|NCT01548144|Drug|Crizotinib (Xalkori)|"Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1."
75434402|NCT01548144|Drug|Pazopanib|"Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1."
75434403|NCT01548144|Drug|Pemetrexed|"Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1."
75434404|NCT01548157|Drug|HCP1007 / omarco and crestor|HCP1007 / Rosuvastatin plus Omega-3
76051250|NCT01617447|Drug|Aripiprazole|Flexibly dose administered orally once daily
76051251|NCT00432679|Drug|Rosiglitazone (BRL49653C)|study drug
76051252|NCT05232487|Other|Swiss low back acupuncture (SLBA)|"Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes.~Swiss low back pain acupuncture The SLBA method is a further developed method from the Jiu Gong acupuncture technique, also known as the Nine Palace-Points on the spine. The following acupuncture points will be used: LV3/ LV5, Tai Xi (Kl 3), Fe Yang (BL 58), Tai Chong (LR 3), Guang Ming (GB 37), Tai Xi (Kl 3) and Fe Yang (BL 58)."
76051253|NCT05232487|Other|Standard acupuncture (SA)|Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes. The SA method is described in the acupuncture textbook for TCM in China and all acupuncture points are selected based on TCM principles, international literature, and the opinion of national and international TCM experts. The following points have been selected: Ming Men (GV 4), Zhi Shi (BL 52), Tai Xi (KI 3) Yao Guan (GV 3), Guan Yuan Shu (BL 26), Ge Shu (BL 17), Ci Liao (BL 32), Wei Zhong (BL 40), Ji Zhong (GV 6), Yao Yang Guan (GV 3), Shen Shu (BL 23), Da Chang Shu (BL 25) and A-Shi points.
75434405|NCT01548170|Drug|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
75434406|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
75434407|NCT01548170|Drug|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
75434408|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
75880902|NCT03691727|Behavioral|Questionnaires|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
75880903|NCT03691727|Diagnostic Test|Vital Signs|Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
75880904|NCT03691727|Other|Standard of Care Treatment|Participants will receive standard of care treatment and will not receive study drug.
76051254|NCT01600105|Drug|Perfusion MRI|1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
76051255|NCT01077895|Procedure|CVVH|"CVVH is started using following parameters:~Blood flow is started at 150 mL/min~Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
75434409|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
75434410|NCT01548183|Behavioral|Lifestyle counseling|Weekly SMS assessments of risky sexual encounters with feedback
75434411|NCT01548196|Procedure|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
75434412|NCT01548209|Drug|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
75434413|NCT01548209|Drug|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
75434414|NCT01548235|Drug|biphasic insulin aspart 30|Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
75434415|NCT01548248|Drug|insulin detemir|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
75434416|NCT01548248|Drug|insulin aspart|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
75581530|NCT02904551|Procedure|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
75581531|NCT02904551|Procedure|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
75581532|NCT04625400|Diagnostic Test|bronchoscope|Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
75434417|NCT01548261|Procedure|Donating oral mucosal cells|Donating oral mucosal cells
75434418|NCT01548274|Drug|Sarpogrelate|Sarpogrelate 300mg/day
75434419|NCT01548326|Drug|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
75434420|NCT01548326|Drug|placebo|one Placebo tablet orally per day for 10 days
75880905|NCT02069834|Drug|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
75880906|NCT02069834|Drug|Arm 2 (control)|Continuation of existing HAART at the time of randomization
75880907|NCT01360177|Procedure|124 PET/CT imaging|Standard of Care
75880908|NCT01360177|Drug|Na134I|25 to 150 mCi
75880909|NCT01360177|Drug|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
75880910|NCT01360177|Drug|Tri-iodothyronine|20 mg/day x 2
75880911|NCT02071940|Drug|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
75880912|NCT01348685|Other|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
75880913|NCT01348685|Other|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
75880914|NCT01348685|Other|The effect of solid vs. liquid forms of whey protein on food intake|
75880915|NCT01346371|Drug|Refresh Tears 0.5% Lubricant Eye Drops|
75880916|NCT01346371|Drug|Bepreve 1.5% Ophthalmic Solution|
75434421|NCT01548365|Other|Infusion therapy nursing expert service|"The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.~If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.~If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device."
75581533|NCT02904434|Other|Grapefruit Juice|On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
75581534|NCT04653792|Drug|Pregabalin 75mg|75 mg capsule
75581535|NCT04653792|Device|Placebo|75 mg
75581536|NCT02904473|Other|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
75581537|NCT04625010|Other|Swaddling|Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
75880917|NCT01348841|Other|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
75880918|NCT02069912|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
75880919|NCT01356511|Drug|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
75880920|NCT01356511|Drug|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
75880921|NCT03685487|Procedure|decolonization|current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
75434422|NCT01548378|Genetic|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
75434423|NCT01548378|Genetic|NL003|Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
75880922|NCT03685487|Other|compliance questionnaire|We asked if the patient has done the whole decolonization procedure
75880923|NCT02069990|Drug|Cholecalciferol|
75880924|NCT01347281|Procedure|Injection of [18F]HX4|"Injection of [18F]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~[18F]HX4 PET scans; 444 MBq (12 mCi) [18F]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of [18F]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): [18F]FDG PET in treatment position"
75581538|NCT04625010|Other|Maternal holding|Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
75581539|NCT02904668|Other|self-managmeent program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (…), which were complemented by a problem-based session.
75581540|NCT02904707|Other|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
75581541|NCT02904395|Other|observational (no intervention)|
75581542|NCT04653441|Behavioral|Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention|"The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy)."
75581543|NCT02904278|Other|Teen Pocket PATH® Mobile Application|Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
75581544|NCT02904278|Other|Control Group: Standard of Care|Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
75581545|NCT00557700|Drug|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
75581546|NCT00557700|Drug|Administration of placebo|Administration of placebo
75581547|NCT00557739|Drug|mometasone furoate|Topical 0.1% mometasone furoate
75581548|NCT00557739|Drug|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
75581549|NCT00557739|Drug|Vehicle (placebo)|Topical placebo
75581550|NCT02904122|Other|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
75581551|NCT02903888|Drug|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
75434424|NCT01548378|Genetic|NL003|Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
75581552|NCT02903927|Device|Implantation of CT LUCIA IOL|
75434425|NCT01548378|Other|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
75581553|NCT02903927|Device|Implantation of Acrysof IQ SN60WF IOL|
75581554|NCT04624542|Device|Electromyographic device|the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS
75434426|NCT01548391|Drug|HX-1171|20mg, 200mg, 500mg
75434427|NCT01548430|Drug|TTP4000|
75434428|NCT01548430|Drug|Placebo|
75434429|NCT01548443|Device|Medifoam H dressing|"Cover medifoam H on the wound for a week."
75434430|NCT01548443|Device|Duoderm THIN dressing|"Cover Duoderm THIN on the wound for a week"
75581555|NCT02904083|Behavioral|self assessment of adherence|
75581556|NCT04653168|Drug|LY3041658|Administered SC
75581557|NCT04653090|Diagnostic Test|Xray|Hip AP Xray
75434431|NCT01548456|Procedure|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
75434432|NCT01548456|Procedure|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
75434433|NCT01548469|Other|Bio Mineral toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
75581558|NCT04653012|Device|Intracranial macro-microelectrode recording|Additionnally to clinical macroelectrodes, Benkhe-Fried depth macro-microelectrodes will be implanted and recorded during the pre-surgical investigation of epileptic patients
75581559|NCT02903849|Behavioral|Drafting Motivational Messages|Write down three motivating messages
75434434|NCT01548469|Other|Perio Total Care toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
75434435|NCT01548482|Other|Laboratory Biomarker Analysis|Correlative studies
75434436|NCT01548482|Other|Pharmacological Study|Correlative studies
75434437|NCT01548482|Drug|Temsirolimus|Given IV
75434438|NCT01548482|Biological|Trebananib|Given IV
75434439|NCT01548508|Other|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
75581560|NCT02903849|Behavioral|Control Reminders|Receive standard reminders at three points during the challenge
75880925|NCT02072018|Drug|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
75880926|NCT02072018|Drug|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
76051256|NCT01077895|Procedure|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol~Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~Vasopressor or inotrope medication dose is increased by > 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV > 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
76051257|NCT01077895|Procedure|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
75434440|NCT01548508|Other|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
75434441|NCT01548521|Drug|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
75434442|NCT01548534|Dietary Supplement|Dietary supplementation with fish oil.|Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
75434443|NCT01548534|Dietary Supplement|Dietary supplementation with vegetable oil|Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
75434444|NCT01548547|Other|Simulation-based mastery learning|Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
75434445|NCT01548560|Drug|Dapivirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
75581561|NCT02903849|Behavioral|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
75581562|NCT04653129|Procedure|Autologous Fat Grafting|"The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin."
75581563|NCT04653129|Procedure|Primary Nerve Repair|Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
75880927|NCT01347359|Behavioral|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
75880928|NCT01347359|Behavioral|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
75880929|NCT02076308|Other|Electroacupuncture and physical therapy|real electroacupuncture
76051258|NCT04785079|Procedure|Graston Instrument assisted Soft tissue Mobilization|Instrument assisted soft tissue mobilization using the Graston tool and technique for 3 minutes on each of the three locations
75434446|NCT01548560|Drug|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
75434447|NCT01548586|Device|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
75434448|NCT01548612|Drug|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
75434449|NCT01548612|Drug|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
75434450|NCT01548664|Other|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
75434451|NCT01548664|Other|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
75581564|NCT04681547|Procedure|Genicular nerve Block|"After the administration of spinal anesthesia, the anatomical structures of the proximal and distal region of the knee will be explored through an M- ultrasound machine Turbo® with a high-frequency 6-13 MHz linear probe.~The ultrasound transducer will be placed in a coronal orientation to the axis of the knee in the corresponding area to be blocked according to anatomical landmarks of superior medial genicular nerve (SMGN), inferior medial genicular nerve block (IMGN), superior lateral genicular nerve (SLGN), inferior lateral genicular nerve (ILGN), and recurrent genicular nerve (RGN).~It should be noted that the visualization of the genicular arteries in the femoral epicondyles and in the area of the tibial plateau, represents an accurate guide to where the sensory afferents are, however; its display is not constant.~4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves."
75581565|NCT04681547|Procedure|Local Infiltration Analgesia|100 ml of ropivacaine 0.2% with 1 mg of epinephrine during the period of intraoperative ischemia and, before the closure of the surgical wound, 50 ml of ropivacaine 0.2%.
75581566|NCT04624464|Other|Rectal swabs - microbiological analysis|Microbial analyses will be performed from the rectal swabs obtained.
75434452|NCT01548677|Drug|trastuzumab|8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
75581567|NCT04624464|Other|Examination of patient room|Only performed for cohort 2
75729287|NCT03917407|Drug|DUR-928 (Moderate AH)|"A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion."
75729288|NCT03917407|Drug|DUR-928 (Severe AH)|"Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study."
75729289|NCT03901534|Device|Auto-CPAP|Use of Auto-CPAP
75729290|NCT03901534|Other|Withdrawal of Auto-CPAP|Withdrawal of Auto-CPAP
75729291|NCT03897673|Dietary Supplement|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
75729292|NCT03897673|Dietary Supplement|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
75729293|NCT03873805|Biological|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
75434453|NCT01548703|Drug|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
75729294|NCT03873805|Drug|Cyclophosphamide|Given IV
75729295|NCT03873805|Drug|Fludarabine|Given IV
75729296|NCT03873805|Drug|Fludarabine Phosphate|Given IV
75880930|NCT02076308|Other|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
76051259|NCT04797325|Drug|Vedolizumab|Repeatedly vedolizumab infusion at week 0, 2, 6, 14, 22
76051260|NCT04797325|Drug|Prednisolone|tablet prednisolone plus infliximab in severe cases.
75434454|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
75880931|NCT02070068|Device|PINPOINT System|
76051261|NCT02246647|Diagnostic Test|Permeability measurement|Saccharide excretion was compared between IBS-C and healthy volunteers
76051262|NCT02246647|Procedure|Esophagogastroduodenoscopy|Duodenal biopsies were collected from IBS-C and healthy volunteers
76051263|NCT02246647|Procedure|Flexible sigmoidoscopy|Colonic biopsies were collected from IBS-C and healthy volunteers
76051264|NCT00752245|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
75434455|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
75434456|NCT01548729|Procedure|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
75434457|NCT01548781|Behavioral|Impairment-based robotic intervention for reaching function|All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
75581568|NCT04681391|Device|transCranial direct current stimulation|In the present study, we applied DC Brain Stimulator Plus to stimulate right temporoparietal junction (rTPJ). The target electrode was placed over the location of rTPJ; on the other hand, the return electrode was placed over the left supraorbital area. That is, during anodal tDCS, the anode was placed over CP6, and the cathode was placed over left supraorbital area; conversely, during cathodal tDCS, the cathode was placed over CP6, and the anode was placed over left supraorbital area. For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. On the other hand, same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds. Therefore, participants could feel the skin sensation but did not have the after-effects of tDCS.
75581569|NCT04652817|Device|MMI-22-04-2019|A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
75581570|NCT04681586|Device|bright light therapy|using a bright light therapy device (10.000 lux) for 30min every morning for two weeks
75581571|NCT04681586|Device|dim red light|using the same device as the active group, but with an installed filter that dims light to <300 lux for 30min every morning for two weeks
75729297|NCT03853564|Behavioral|Video-Feedback Intervention|Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
76051265|NCT00752245|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
76051266|NCT00752245|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
76051267|NCT04771351|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
76051268|NCT04771351|Drug|Placebo|Diluent solution
75434458|NCT01548794|Procedure|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
75434459|NCT01548794|Procedure|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
75434460|NCT01548794|Procedure|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
75434461|NCT01548807|Drug|Everolimus (RAD001)|
75434462|NCT01548846|Radiation|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
75581572|NCT04624269|Drug|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
75434463|NCT01548859|Drug|Midazolam|0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
75581573|NCT02903810|Biological|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
75581574|NCT04652739|Drug|Lycopene Softgel, 10 Mg|Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.
75581575|NCT04652739|Drug|Prednisolone|Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
75729298|NCT03853564|Other|Phone-Call Intervention|Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
75434464|NCT01548859|Drug|Sevoflurane|end tidal concentration of % 0,5-8
75434465|NCT01548872|Drug|HTK solution|50 ml/kg bolus in 2 minutes
75434466|NCT01548872|Drug|crystalloid cardioplegia solution|30 ml/kg bolus in two minutes
75434467|NCT01548898|Device|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
75434468|NCT01548911|Drug|gemtuzumab ozogamicin|Given IV
75729299|NCT03836482|Device|Selective Cytopheretic Device|Treatment will be delivered for 6 hours a day for up to 6 consecutive days.
75729300|NCT03812302|Diagnostic Test|68-Ga HA-DOTATATE PET/CT|See arm description.
75434469|NCT01548911|Other|laboratory biomarker analysis|Correlative studies
75434470|NCT01548924|Drug|Dovitinib|Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
75434471|NCT01548924|Drug|Dovitinib + Paclitaxel|"Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days."
75434472|NCT01548937|Drug|I-123 ADAM|"This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
75434473|NCT01548950|Drug|Sildenafil singly or in association with Bosentan|Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
75434474|NCT01548963|Procedure|Intensive glycemia control|Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
75434475|NCT01549015|Other|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
75434476|NCT01549028|Behavioral|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
75434477|NCT01549054|Drug|10-mg dose of E5501 2G tablet|Treatment A: Single 10-mg dose of E5501 2G tablet
75434478|NCT01549054|Drug|10-mg dose of E5501 cyclodextrin oral solution|Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
75581576|NCT02904005|Other|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
75581577|NCT02903498|Drug|UFT|UFT 360mg/m2 qd po d1-14, q3w
76051269|NCT04770727|Behavioral|CBT workshop|The CBT based intervention for adolescents will include psychoeducation on food allergy and anxiety and also focus on providing skills, knowledge and support.
75434479|NCT01549054|Drug|10-mg dose of E5501-P21% powder|Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
75434480|NCT01549054|Drug|10-mg dose of E5501 lipid-based oral|Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
75434481|NCT01549080|Drug|Yisuishengxue Granule|Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
75434482|NCT01549093|Drug|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
75434483|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
75581578|NCT04624347|Behavioral|Access to video and movement curves|intervention of caregivers with access to videos and motion curves of the premature infant
75581579|NCT02903459|Other|Transversal Study so there is no intervention|
76051270|NCT05107687|Behavioral|Smoking cessation|"Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention."
76051271|NCT01933113|Device|Deep Brain Stimulation of the Lateral Hypothalamic Area|Deep Brain Stimulation of the Lateral Hypothalamic Area
75434484|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
75434485|NCT01549106|Drug|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
75434486|NCT01549106|Drug|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
75434487|NCT01549119|Biological|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
75434488|NCT01549119|Biological|Placebo|Comparison with experimental vaccine
75434489|NCT01549145|Device|Nimbus Multifunctional Stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
75434490|NCT01549158|Drug|torasemide-PR|Single oral dose of torasemide PR 10 mg
75434491|NCT01549158|Drug|Furosemide-IR|Single oral dose of furosemide IR 40 mg
75434492|NCT01549158|Drug|torasemide-IR|Single oral dose of torasemide IR 10 mg
75434493|NCT01549171|Drug|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
75434494|NCT01549171|Other|normal saline|Supplement with vehicle only no Iloprost.
75434495|NCT01549236|Drug|Benznidazole 12,5mg or 100mg|"All 80 subjects recruited into the study will receive treatment with:~- Benznidazole (Laboratório Farmacêutico do Estado de Pernambuco -LAFEPE - Recife - Brazil; tablet 12.5mg or 100mg), 7.5 mg/Kg/day PO (actual range of 5.5-8.5 mg/Kg/d), divided in two daily doses, for 60 days."
75434496|NCT01549249|Device|optical coherence tomography|spectral-domain optical coherence tomography
75581580|NCT04623957|Device|ForgTin©|"The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises."
75581581|NCT04652427|Drug|Dexmedetomidine Hydrochloride 0.1 MG/ML|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
75581582|NCT04652427|Drug|0.9% Sodium Chloride Injection|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
75581583|NCT02903576|Procedure|injection of hESC-RPE in suspension|The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
76051272|NCT04773067|Biological|UB-612|Around 3300 adult subjects and 330 adolescent subjects will receive 2 doses of 100 µg UB-612 vaccine. The subjects will be invited to have the 3rd dose after unblinded.
76051273|NCT04773067|Biological|Placebo|Around 550 adult subjects and 55 adolescent subjects will receive 2 doses of normal saline 0.9%.
76051274|NCT04784845|Biological|N. lactamica Y92-1009|Lyophilised N. lactamica reconstituted in phosphate-buffered saline
76051275|NCT04784455|Drug|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within 100 days of HSCT
76051276|NCT02244619|Drug|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
75434497|NCT01549262|Device|"Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)"|Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
75434498|NCT01549262|Device|Observe embryo development|Observe embryo development in the traditional manner
75434499|NCT01549288|Behavioral|modified Atkins diet|Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
75434500|NCT01549288|Other|no dietetic input|continuation of anti-epileptic medication without any dietetic input
75434501|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
75434502|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
75434503|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
75434504|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
75434505|NCT01549327|Other|Oncology Interactive Navigator|
75434506|NCT01549327|Other|Routine Care|
75434507|NCT01549353|Behavioral|gum chewing|
75434508|NCT01549366|Device|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
76051277|NCT02244619|Drug|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
76051278|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 2 of Cycles 3-6
75434509|NCT01549366|Device|Pedicle Screws|Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
75434510|NCT01549379|Radiation|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
75434511|NCT01549418|Drug|Aspirin (ASA)|Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
75434512|NCT01549418|Drug|Placebo|
75434513|NCT01549431|Drug|Panobinostat|"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~Standard 3+3 design~3 out of 4 weeks"
75434514|NCT01549431|Drug|Carfilzomib|"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~Standard 3+3 design~Days 1/2, 8/9 and 15/16 every 4 weeks"
75434515|NCT01549431|Drug|Dexamethasone|Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
75434516|NCT01549444|Other|presence of maternal risk factor for hypertension|
76051279|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 1 of Cycles 3-6
75581584|NCT02903576|Procedure|injection hESC-RPE seeded in a substrate|Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
75581585|NCT04623918|Other|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
75581586|NCT04623918|Other|Control rice|Control rice (C4), identical in appearance
75434517|NCT01549457|Other|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
75434518|NCT01549470|Biological|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
75434519|NCT01549470|Biological|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
75434520|NCT01549496|Drug|Amlodipine|amlodipine 2.5 mg QD
76051280|NCT02243371|Drug|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
76051281|NCT02243371|Biological|GVAX|5x10^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
75581587|NCT02903654|Other|observational|
75434521|NCT01549496|Drug|Diltiazem|diltiazem 120 mg qd
75434522|NCT01549509|Biological|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection in their upper arm of 1 x 10^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
75434523|NCT01549522|Behavioral|bulletin board or telephone depth interview (TDI)|experiential based research. anonymous participation.
75434524|NCT01549522|Behavioral|interview regarding experiences and opinions as to condition and treatment|not a drug trial. experential/opinion based research.
75434525|NCT01549535|Device|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
75434526|NCT01549548|Drug|Ponatinib|Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
75434527|NCT01549561|Behavioral|Parent Training|16 weeks of parent training led by a trained group facilitator
75581588|NCT04624308|Drug|Toripalimab|Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
76051282|NCT02243371|Drug|CY|200 mg/m^2 administered IV on Day 1 of Cycles 1 and 2
76051283|NCT01931475|Drug|Duloxetine|Administered orally
75434528|NCT01549561|Behavioral|Youth Skills Training|16 weeks of one-on-one sessions with a trained youth skills coach
75581589|NCT02903693|Other|cross sectional|
75581590|NCT04624425|Other|Segmental breathing exercises|Segmental breathing exercises along with the Conventional Treatment of buteyko breathing exercises for two weeks of duration. Segmental breathing exercises include 18-20 breaths in one session (6 breaths/min) with rest interval after every 6 breaths.
75581591|NCT04624425|Other|Buteyko breathing exercises|Buteyko exercises for two weeks of duration. Treatment session will be last for 10-15minutes.
75729301|NCT03803852|Device|Intraocular Lens Implantation|"Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impressinto the capsular bag using an injector, after removing of the human cristalline lens.~Implantation of the Alcon Clareon toric and Rayner RayOne EMV toric IOL on the axis according to the steep meridian of the cornea"
76051284|NCT01931475|Drug|Placebo|Administered orally
75581592|NCT02903771|Drug|Part A: Dose Escalation of Cantrixil|"Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug."
75581593|NCT02903771|Drug|Part B: Expansion Cohort of Cantrixil|Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
75581594|NCT04623879|Drug|Lumacaftor, Ivacaftor Drug Combination|
75581595|NCT04624035|Procedure|Implantable Collamer Lens (ICL) in treatment of myopia in adults.|ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.
75581596|NCT04624035|Procedure|Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.|IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
76051285|NCT04622787|Other|Knowledge translation|"A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).~The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.~Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.~Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings."
75434529|NCT01549574|Drug|crizotinib|Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
75434530|NCT01549574|Drug|esomeprazole|Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
75434531|NCT01549600|Dietary Supplement|psyllium|1 level tablespoon (~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
75434532|NCT01549600|Dietary Supplement|Microcrystalline Cellulose|1 level tablespoon (~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
75434533|NCT01549626|Dietary Supplement|Defatted flaxseed flour|30g defatted flaxseed flour per day for breakfast
75434534|NCT01549626|Dietary Supplement|Golden flaxseed flour|30 grams of golden flaxseed flour per day for breakfast
75581597|NCT02903732|Other|observational|registry
75581598|NCT04624386|Other|Thiol disulfide level|Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
75434535|NCT01549626|Dietary Supplement|Whole brown flaxseed flour|30 grams of whole brown flaxseed flour per day for breakfast
75581599|NCT04624191|Other|Saturation at home|Clinical benefit of taking saturation at home in interstitial lung disease
75581600|NCT02903264|Other|Gestational diabetes mellitus|
75729302|NCT03792841|Drug|acapatamab|Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
75729303|NCT03792841|Drug|Pembrolizumab|Combined with acapatamab for investigational treatment of mCRPC
75729304|NCT03792841|Drug|Etanercept|Prophylaxis for acapatamab-related cytokine release syndrome.
75729305|NCT03792841|Drug|Cytochrome P450 (CYP) Cocktail|Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
75581601|NCT04624152|Behavioral|Soccer heading|A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
75581602|NCT02903225|Behavioral|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
75581603|NCT00562068|Biological|alemtuzumab|
76051286|NCT01929993|Procedure|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
75434536|NCT01549665|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.
76051287|NCT01929993|Procedure|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
75434537|NCT01549678|Other|Total contact insole|EVA insole shaped on patient´s foot.
75434538|NCT01549678|Other|placebo insole|EVA insole flat
75434539|NCT01549691|Drug|Zopiclone|7.5 mg before sleep, the evening before surgery
75434540|NCT01549691|Drug|Alprazolam|0.5 mg at awakening, the day of surgery
75434541|NCT01549691|Drug|placebo|given night before surgery and at awakening, the day of surgery
75434542|NCT01549704|Drug|Ropivacaine|"Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).~Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine."
75434543|NCT01549704|Drug|Saline|please see intervention description for ropivacaine
75434544|NCT01549717|Device|Fitting of a wireless telemetry device|Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
75434545|NCT01549743|Drug|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
75434546|NCT01549743|Drug|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
75434547|NCT01549743|Drug|Celecoxib plus Rebamipide|"Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide"
75434548|NCT01549756|Behavioral|bulletin board and teleophone depth interview|qualitative based research
75581604|NCT00562068|Drug|cyclophosphamide|
75581605|NCT00562068|Drug|doxorubicin hydrochloride|
75581606|NCT00562068|Drug|prednisolone|
75581607|NCT00562068|Drug|vincristine sulfate|
75434549|NCT01549782|Dietary Supplement|Inulin and Fructo-oligosaccharide|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
75434550|NCT01549782|Dietary Supplement|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
75434551|NCT01549795|Procedure|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
75434552|NCT01549795|Radiation|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
75434553|NCT01549795|Radiation|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
75434554|NCT01549795|Drug|Capecitabine|Capecitabine - administered till liver transplantation
75434555|NCT01549795|Procedure|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
75581608|NCT00562068|Genetic|polymerase chain reaction|
75581609|NCT00562068|Other|flow cytometry|
75581610|NCT00562068|Other|laboratory biomarker analysis|
75581611|NCT00562068|Other|pharmacological study|
75581612|NCT02903342|Other|Leaflet|A leaflet designed from data obtained from previous qualitative and quantitative studies.
75581613|NCT04623606|Biological|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
75581614|NCT02903303|Other|Hypnosis|"It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~1st session : contact with the therapist, body scan, basic suggestions~2nd session : hypnosis induction followed by suggestions tu build a safe place~3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~4th session : very similar to the previous session for the content, focused on auto-hypnosis learning."
75434556|NCT01549808|Other|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
75434557|NCT01549808|Other|mobilization|sitting, standing and walking
75581615|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
75581616|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
75581617|NCT02903186|Behavioral|SMS|This is an intervention using short mobile messages (SMS)
75581618|NCT00562146|Procedure|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
75581619|NCT02903147|Behavioral|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
75581620|NCT02903147|Behavioral|The employer's training|
75581621|NCT02903108|Drug|SRP plus boric acid gel|SRP followed by 0.75% boric acid placement into intrabony defect
75581622|NCT02903108|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
75581623|NCT00562185|Drug|carboplatin|
75434558|NCT01549847|Drug|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
75581624|NCT00562185|Drug|doxorubicin hydrochloride|
75581625|NCT02902796|Device|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
75581626|NCT00562224|Drug|PCI-24781|"Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached."
75434559|NCT01549847|Drug|Placebo|Placebo PO BID
75434560|NCT01549899|Behavioral|In-person Cognitive Behavioral Therapy of Insomnia|In-person CBTi was be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consisted of 6-sessions and included the same efficacious and commonly used modules of CBTi (i.e., sleep education & hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive therapy).
75581627|NCT02902718|Device|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
75581628|NCT04623645|Device|ultrasound technique|evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve
75581629|NCT02902835|Behavioral|BUP_FAST|Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)
75581630|NCT02902835|Behavioral|Referral to treatment|Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
75581631|NCT04623762|Other|Yoga|yoga application
75581632|NCT02903069|Drug|MRZ|"MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.~MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.~IV hydration will be given prior to the MRZ infusion."
75434561|NCT01549899|Behavioral|Internet Cognitive Behavioral Therapy of Insomnia|The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology, with the PI (DJT) as the subject matter expert. The treatment consists of the same components as the in-person CBTi, but their mode of delivery was considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions was divided into lessons covering different aspects of each of the components. The lessons were presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components were included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
75434562|NCT01549938|Dietary Supplement|Cholecalciferol|20,000 IU cholecalciferol capsule, given once weekly for 16 weeks.
75581633|NCT02903069|Drug|TMZ|"TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment."
75581634|NCT02903069|Radiation|RT|Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
75581635|NCT02903069|Device|Optune|Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
75581636|NCT04623723|Other|PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips
75581637|NCT04623723|Other|Conventional (FS-407, EMS® Piezon, Switzerland)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)
75581638|NCT02902679|Drug|BMS-986177|
75581639|NCT04623840|Other|Tadalafil 5Mg Tab + continuous and interval exercise|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
75581640|NCT04623840|Drug|Tadalafil 5Mg Tab|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
75581641|NCT02902640|Drug|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
75581642|NCT02902640|Drug|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
75581643|NCT02902640|Drug|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
75581644|NCT04623528|Diagnostic Test|T1 and T2 relaxometry of the liver parenchyma|Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
75581645|NCT04623489|Behavioral|¡Vivir Mi Vida! Lifestyle Intervention|
75581646|NCT04624893|Drug|Polatuzumab Vedotin-Piiq|Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
75581647|NCT04623450|Other|Smoothie|Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.
75581648|NCT04623294|Procedure|Oxygen supply of high-low-high procedure|"The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
75729306|NCT03727724|Drug|Afatinib|Tablet
75729307|NCT03727724|Drug|Cetuximab|Injection
75434563|NCT01549938|Dietary Supplement|Placebo|Microcellulose capsule identical in appearance to treatment
75434564|NCT01549990|Drug|Sevoflurane|maintenance of general anesthesia with sevoflurane
75434565|NCT01549990|Drug|desflurane|maintenance of general anesthesia with desflurane
75434566|NCT01550016|Other|Observation|Clinical follow-up and laboratory investigations.
75434567|NCT01550029|Behavioral|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle."
75581649|NCT04623294|Procedure|Oxygen supply of low-high-low procedure|"The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
75581650|NCT02902523|Drug|Viread® tablet 300mg|Single dose administration(PO) in the fasted state
75581651|NCT02902523|Drug|HUG116 tablet 245mg|Single dose administration(PO) in the fasted state
75581652|NCT04623060|Other|Combination of Low-volume interval treadmill training and Resistance Training|"Low-volume interval training (LV-ITT) protocols included a 5 min warm-up (30%-50%VO2peak) up to 20min of LV-ITT and a 5 min cooling down (30%-50% VO2peak). The LV-ITT will repeat 60s bursts of fast treadmill walking at maximum tolerate speed (0% incline), alternate with pre-specified recovery periods about 4 minutes according to protocol. Each time the participants completed a burst successfully, treadmill speed will be increased by 0.1 mph for the next burst. The recovery periods will be 4 minutes. The intervention will be conducted for about 30 minutes.~Resistance training will be conducted by using a horizontal leg press machine. They are encouraged to focus on an explosive concentric movement and a controlled eccentric movement such that the time on each phase was in the ratio 1:2."
75581653|NCT02902562|Procedure|Contrast Enhanced Ultrasound (CEUS)|An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
75581654|NCT02902562|Procedure|Magnetic Resonance Imaging (MRI)|For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
75581655|NCT00562263|Behavioral|Lifestyle modification|Dietary modification and regular physical activity
75434568|NCT01550029|Behavioral|Counseling/Managing Mood|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
75434569|NCT01550055|Drug|CMAB009 plus Irinotecan|Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
75581656|NCT02902367|Other|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
75434570|NCT01550055|Drug|Irinotecan-only and sequential-CMAB009|First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
75434571|NCT01550068|Diagnostic Test|Echocardiography|
75434572|NCT01550081|Other|Rate of perceived exertion|Exercise intensity controlled by Borg scale
75434573|NCT01550081|Other|Heart rate monitor|Exercise intensity controlled by heart rate monitors
75581657|NCT02902367|Other|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
75581658|NCT04623255|Drug|OCTAPLAS|plasma exchange
75581659|NCT02902289|Drug|Ibuprofen 200 mg/5 mL oral suspension|
75729308|NCT03724110|Other|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
75434574|NCT01550107|Drug|Allopurinol|300mg b.d for 24 weeks
75581660|NCT02902289|Drug|MOMENT 200 mg coated tablet|
75729309|NCT03714555|Diagnostic Test|Safety Laboratories|Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
75729310|NCT03714555|Other|AE Assessment|Assessment of Adverse Events (AE)
75581661|NCT04623411|Behavioral|Neonatal resuscitation training with classical method and serious game simulation method|"After the theoretical training, the participants will be given technical information on the use of web-based neonatal resuscitation serious game simulation method.~Each participant will be asked to apply this method at least three times."
75581662|NCT04623411|Behavioral|Control Group|Neonatal resuscitation training with classical method
75581663|NCT02902133|Drug|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 5 days
75581664|NCT04623333|Drug|TQB2450|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
75434575|NCT01550107|Drug|Lactose tablets|matched placebo tablets b.d
75434576|NCT01550146|Drug|Dexamethasone acetate|iv. dexamethasone 0.1 mg/kg
75581665|NCT04623021|Drug|Nafamostat Mesilate|Administered intravenously as a continuous infusion
75729311|NCT03714555|Other|Physical Exam|Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
75729312|NCT03714555|Other|Concomitant Medication Review|Prior and Concomitant Medication Review
75729313|NCT03714555|Diagnostic Test|Tumor Imaging|Tumor CT or MRI
75729314|NCT03714555|Drug|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
75729315|NCT03714555|Drug|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
75434577|NCT01550146|Drug|Placebo|iv. Normal Saline 0.1 ml/kg
75434578|NCT01550172|Behavioral|Sleep Behavioral Therapy A and NHMS|"The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments."
75434579|NCT01550172|Behavioral|Sleep Behavioral Therapy B and NHMS|"The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy B uses primarily behavioral adjustments."
75729316|NCT03714555|Drug|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
75729317|NCT03701295|Drug|Azacitidine|Given IV or SC
75729318|NCT03701295|Drug|Pinometostat|Given IV
75434580|NCT01550211|Device|Magnetoencephalograph (MEG)|Conducting a brain scan during a series of perceptual and linguistic tasks
75434581|NCT01550250|Behavioral|Night-time compression system garment|Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
75434582|NCT01550250|Behavioral|Day-time compression sleeve|Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
75434583|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas."
75434584|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal."
75581666|NCT02902016|Drug|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
75581667|NCT04622748|Behavioral|Trier Social Stress Test|8-min oral calculation and 5-min speech
75581668|NCT04622826|Biological|immune plasma|immune covid 19 plasma infusion
75581669|NCT02901977|Drug|Ramipril|Antihypertensive therapy
75581670|NCT02901977|Drug|Doxazosin|Antihypertensive therapy
75581671|NCT02902094|Device|Drug eluting balloons|
75581672|NCT02902094|Device|Non drug eluting balloons|
75581673|NCT04681235|Other|Training on VR|The training is aimed at improving the functioning of the motor sphere, including balance, gait, and upper limb function, as well as increasing the level of motivation and reducing the level of anxiety and depression. Game applications were selected based on therapeutic tasks of motor recovery.
75581674|NCT00553553|Drug|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
75581675|NCT00553553|Drug|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
75581676|NCT04622982|Other|Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)|"Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) <30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist."
75581677|NCT02901938|Procedure|cemented femoral stem|The patients assigned even numbers will undergo implantation of cemented femoral stem.
75581678|NCT02901938|Device|cannulated compression screws|The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
75581679|NCT04622202|Drug|Pregabalin 150mg|oral capsule pregabalin 150 mg.
75581680|NCT04622202|Drug|multivitamin|oral placebo in the form of oral multivitamin capsule.
75581681|NCT02901782|Procedure|Personalized titanium plate|3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
75581682|NCT04622475|Biological|Fecal Microbiota Transplant (FMT) Capsule|When enrolled in the study, subjects will ingest 20 FMT capsules/day orally for 3 consecutive days. If the syndrome is not completely recovered or relapse 14 days after the first administration, the subject will receive a booster dose (20 capsules/day for 3 consecutive days).
75729319|NCT03698552|Biological|ADCT-602|Starting dose of ADCT-602: 30 μg/kg given by vein.
75581683|NCT04622358|Drug|AD-214-02|1 tablet administered before the breakfast during 7 days
75729320|NCT03697720|Drug|Naproxen|Participants will take naproxen 500mg BID before and for the first 3 days of their period.
75729321|NCT03635983|Biological|NKTR-214|Specified dose on specified days
75729322|NCT03635983|Biological|Nivolumab|Specified dose on specified days
75729323|NCT03626662|Drug|AMG 890|Ascending Single Doses of AMG 890
75729324|NCT03626662|Drug|Placebo|Calculated volume to match experimental drug.
75729325|NCT03610971|Drug|Ruxolitinib|Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
75729326|NCT03610971|Drug|BCR-ABL Tyrosine Kinase Inhibitor (TKI)|The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
75729327|NCT03596385|Drug|Beta blocker|long-term maintenance beta-blocker therapy
75581684|NCT04622358|Drug|Rabeprazole|1 tablet administered before the breakfast during 7 days
75434585|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation."
75434586|NCT01550276|Other|Placebo control|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
75434587|NCT01550302|Procedure|Superficial Cervical Plexus Block|"At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site."
75434588|NCT01550302|Drug|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
75434589|NCT01550354|Drug|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
75434590|NCT01550354|Drug|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
75581685|NCT02901665|Other|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
75581686|NCT00562341|Other|Bariatric Surgery|one time lapb-band gastric bypass surgery
75581687|NCT02901587|Drug|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
75581688|NCT02901587|Drug|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
76024908|NCT04440241|Procedure|regenerative treatment periimplantitis|"Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps."
76024909|NCT03166501|Drug|Lanicemine|Three 60 min parenteral infusions over a 5 day period
76024910|NCT03166501|Drug|Placebo|Three 60 min parenteral infusions over a 5 day period
76024911|NCT02402257|Behavioral|CVC Train the Trainer|Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
76051288|NCT04630821|Other|Dilute Sodium Hypochlorite solution|"Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.~While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers."
75434591|NCT01550354|Drug|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
75434592|NCT01550380|Drug|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
75581689|NCT02901587|Drug|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
75581690|NCT04622397|Drug|Tranexamic acid injection|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
75581691|NCT04622397|Drug|Saline|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
75581692|NCT02901704|Device|Renal Denervation System (AngioCare)|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
75581693|NCT02901704|Procedure|Sham procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 10 minutes prior to introducer sheath removal.
75581694|NCT02901743|Other|Scaling and Root planing|All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
75581695|NCT02901392|Procedure|AMS-800|Artificial urianry sphincter
75434593|NCT01550393|Genetic|proteomic profiling|
75581696|NCT02901392|Procedure|ADVANCE/ADVANCEXP|Male sling
75581697|NCT02901392|Procedure|VIRTUE|Male sling
75581698|NCT02901392|Procedure|INVANCE|Male sling
75581699|NCT02901353|Device|Sirolimus Eluting Coronary Stent System|Patient with Angina Pectoris will be enrolled for the intervention
75581700|NCT04621773|Procedure|Preimplantation Genetic Screening(exposure)|Preimplantation genetic screening (PGS) was developed in the late 1980s as an alternative to prenatal diagnosis for couples at risk of transmitting a genetic or chromosomal abnormality to their children. In embryos created through in vitro fertilisation (IVF), cells are biopsied and analysed using genetic tests such as polymerase chain reaction and fluorescent in situ hybridisation (FISH).
75581701|NCT02901119|Dietary Supplement|Whey protein|Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.
75434594|NCT01550393|Other|enzyme-linked immunosorbent assay|
75581702|NCT04621695|Procedure|RBL|Both arms are standard care procedures in the Netherlands
75581703|NCT04621695|Procedure|Hemorrhoidectomy|Both arms are standard care procedures in the Netherlands
75581704|NCT02901197|Behavioral|Education and Reminder Posters|See arm description
75581705|NCT02901197|Other|Policy Change|See arm description
75581706|NCT02901002|Other|Sensory testing in the two hand|spontaneous sensations while watching a hand
75581707|NCT02901002|Other|Neuropsychological evaluation|Score to anxiety-depression scale
75581708|NCT04621656|Combination Product|January Mobile Application (Sugar AI)|Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
75581709|NCT04681664|Other|High fat diet|50 % fat
75581710|NCT04621461|Dietary Supplement|Zinc Sulfate 220 MG|220mg once daily for 5 days
75581711|NCT04621461|Drug|Placebo|Once daily for 5 days
75581712|NCT02901236|Procedure|Standard Guarded Trabeculectomy|A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
75581713|NCT02901236|Drug|Mitomycin C|Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
75581714|NCT02901236|Drug|Bevacizumab|After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
75581715|NCT02900963|Other|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
75581716|NCT04621422|Biological|Subject carrying an amplification of nucleotide repeats in one of the following 9 genes FMR1, DMPK, ZNF9, SCA2, JPH3, HD, FXN, C9ORF72, RFC1|Biological/Vaccine: DNA Samples collection as part of usual care
76051289|NCT04645953|Combination Product|3mg AZ-010|Subject will receive a single inhaled dose (3mg)
75434595|NCT01550393|Other|laboratory biomarker analysis|
75434596|NCT01550393|Other|medical chart review|
76051290|NCT04645953|Combination Product|1mg AZ010|Subject will receive a single inhaled dose (1mg)
76051291|NCT04645953|Combination Product|Staccato Placebo|Subject will receive a single inhaled dose (Staccato Placebo)
75434597|NCT01550406|Device|Tachocomb|"A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
75434598|NCT01550406|Device|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
75434599|NCT01550419|Drug|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
75434600|NCT01550419|Drug|Placebo|The smell and shape of placebo are the same as atorvastatin
75434601|NCT01550445|Drug|Prednisolone|Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
75581717|NCT04621617|Drug|Albumin|Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
75581718|NCT04621617|Drug|Midodrine|Oral Midodrine will be given at a dose of 7.5 mg three times in a day
75581719|NCT04621617|Drug|Standard medical therapy (SMT)|SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
75581720|NCT02900924|Device|BioMimics 3D Stent|
75581721|NCT00562380|Biological|ganitumab|
75581722|NCT00562380|Other|laboratory biomarker analysis|
75581723|NCT00562380|Other|pharmacological study|
75581724|NCT00562380|Procedure|biopsy|
76024912|NCT03166579|Behavioral|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
75434602|NCT01550497|Other|supervised spinal stabilization exercises|Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
75434603|NCT01550523|Drug|IGF-1R/AS ODN|Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
75434604|NCT01550523|Device|biodiffusion chamber|The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
75434605|NCT01550588|Device|Device closure|PFO Amplatzer device closure
75434606|NCT01550588|Drug|Standard medical treatment|Standard Medical management using anti-coagulant therapy
75434607|NCT01550601|Procedure|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
75434608|NCT01550614|Genetic|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
75434609|NCT01550627|Other|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
75581725|NCT02900612|Other|Water aerobics training.|The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
75581726|NCT02900612|Other|Water resistance training.|The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
75581727|NCT02900612|Other|Control Group|The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
75581728|NCT01212757|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
75581729|NCT01212757|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
75581730|NCT01212757|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
75581731|NCT01212757|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
75581732|NCT00562419|Drug|CT-322|IV solution, weekly
75581733|NCT00562419|Drug|irinotecan hydrochloride|IV solution, biweekly
75581734|NCT02900768|Behavioral|Exercise|Combination of resistance and aerobic exercises for 100 days.
75581735|NCT00562458|Drug|anastrozole|
75581736|NCT02900729|Device|Radiofrequency ablation catheter|Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
75581737|NCT02900729|Drug|Amlodipine, losartan potassium and hydrochlorothiazide|Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
75581738|NCT00562536|Procedure|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
76024913|NCT01978912|Drug|KTP-001|KTP-001 is one time dose intradiscally.
76051292|NCT01912599|Device|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
76051293|NCT01912599|Device|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
76051294|NCT04645017|Behavioral|Intergenerational Music Program|Music activities will be lead by adolescent musicians for older adult participants.
75434610|NCT01550627|Other|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
75434611|NCT01550640|Drug|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
75434612|NCT01550653|Drug|liraglutide|Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
75581739|NCT01190410|Drug|certolizumab pegol|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
75581740|NCT01190410|Drug|certolizumab pegol|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
75581741|NCT01190254|Drug|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
76051295|NCT01929681|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
75581742|NCT01190254|Drug|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
76051296|NCT01646177|Drug|Placebo|Administered SC
75434613|NCT01550653|Drug|Placebo|
76051297|NCT01646177|Drug|50 mg etanercept|Administered SC
75434614|NCT01550666|Behavioral|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
75434615|NCT01550718|Behavioral|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
75434616|NCT01550718|Behavioral|ESML-Social (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session."
75434617|NCT01550770|Drug|propofol|peripheral IV of propofol at increasing dose levels
75581743|NCT01190254|Drug|placebo|asenapine-matched placebo tablets for sublingual administration
75581744|NCT04315987|Biological|NestaCell®|A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
76024914|NCT02393443|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
76024915|NCT02393443|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
75434618|NCT01550783|Other|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
75581745|NCT04315987|Biological|Placebo|Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
75581746|NCT04621383|Dietary Supplement|Whey protein plus collagen|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
75581747|NCT04621383|Dietary Supplement|Whey protein plus maltodextrin|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
75581748|NCT04621305|Other|normal saline|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
75581749|NCT04621305|Drug|Bolus Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
75581750|NCT04621305|Drug|Continuous Infusion Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
75581751|NCT00553592|Drug|Bicifadine|600mg/day
75581752|NCT00553592|Drug|Bicifadine|placebo tablet
75581753|NCT00553592|Drug|Bicifadine|1200 mg
75581754|NCT04620954|Drug|Oregovomab|2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.
75581755|NCT04620954|Drug|Nivolumab|480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).
75581756|NCT04620954|Drug|Chemotherapy|Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m^2 and 5 AUC (Area Under the Curve) respectively.
75581757|NCT04621032|Diagnostic Test|Polygraphy monitoring|All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.
75581758|NCT04621032|Diagnostic Test|laboratory tests|Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.
76051298|NCT01646177|Drug|80 mg ixekizumab|Administered SC
76051299|NCT01912287|Behavioral|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
75581759|NCT02900261|Other|No intervention|This study is observational and does not entail any intervention. Different methods to assess sodium and caffeine consumption will be compared.
75581760|NCT00562692|Drug|Nesiritide|Nesiritide 4 hour infusion
76051300|NCT01912287|Behavioral|Stress Education|Active control group (12 sessions)
76051301|NCT01912287|Behavioral|Yoga|12 sessions, mindfulness components
76051302|NCT01929135|Drug|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
76051303|NCT01929135|Drug|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
76051304|NCT01911819|Procedure|Sinus augmentation|
76051305|NCT01911819|Drug|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
76051306|NCT01911819|Drug|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
76051307|NCT01911819|Drug|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
75434619|NCT01550783|Other|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
75434620|NCT01550783|Other|Questionnaire Administration|Ancillary studies
75434621|NCT01550783|Procedure|Screening Method|Undergo standard of care Pap test screening
75434622|NCT01550783|Procedure|Screening Method|Undergo home-based HPV screening
75434623|NCT01550796|Behavioral|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
75434624|NCT01550822|Other|HEALS|
76051308|NCT02280863|Device|Medtronic Hybrid Closed-loop System - Android Platform|A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
76051309|NCT02280863|Device|Medtronic Hybrid Closed-loop Integrated System|A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
76051310|NCT01911429|Drug|Lurasidone 40 mg|Lurasidone 40 mg once daily
75434625|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Standard of care use of an embolic protection device
75581761|NCT00562692|Drug|Placebo|Placebo infusion
76051311|NCT01911429|Drug|Lurasidone 80 mg|Lurasidone 80 mg once daily
75581762|NCT02900534|Other|Internet-based self-help|10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
75581763|NCT04621110|Drug|intranasal dexmedetomidine|Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure. To assess the level of sedation the study will use Ramsay sedation scale.
75581764|NCT04621110|Drug|intranasal fentanyl|Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
75581765|NCT04621110|Drug|intravenous ketamine (ketalar®)|Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
75581766|NCT04621110|Drug|intravenous midazolam|Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
75581767|NCT04620720|Drug|capule gabapentin|neuropathic analgesic
75581768|NCT02900222|Procedure|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
75880932|NCT01347437|Behavioral|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
75581769|NCT04620642|Biological|Registry|No specific intervention. Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
76051312|NCT01911429|Drug|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
76051313|NCT02324465|Device|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
76051314|NCT02324465|Device|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
76051315|NCT02324153|Drug|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
75581770|NCT02900417|Drug|Sitagliptin|All the patients will receive sitagliptin 100mg daily
75434626|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
75434627|NCT01550848|Drug|Abraxane and Gemcitabine|"ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15"
75880933|NCT05076409|Drug|BI 425809|Period 1 and period 2
75880934|NCT05076409|Drug|fluconazole|Period 2
76051316|NCT02324153|Drug|Microcrystalline Cellulose|Placebo Comparator
76051317|NCT02324153|Drug|Riboflavin 100 mg|Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
76051318|NCT02280473|Drug|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
76051319|NCT02280473|Drug|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
76051320|NCT04420481|Drug|Somatropin|Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.
76051321|NCT04420481|Drug|Placebo|Placebo
76051322|NCT01911273|Drug|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
76051323|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
76051324|NCT01911273|Other|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
75880935|NCT02076386|Drug|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
75434628|NCT01550874|Behavioral|Physical activity behavior-change counselling|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
75434629|NCT01550887|Other|No intervention|No intervention will be performed on this study
75434630|NCT01550900|Drug|Metformin ER|Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
75434631|NCT01550900|Other|Placebo|Placebo tablets by mouth 1 time a day.
75434632|NCT01550913|Behavioral|Sober Network Interpersonal Psychotherapy (IPT)|IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
75434633|NCT01550913|Other|Treatment as Usual|Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
75880936|NCT01347515|Other|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
75434634|NCT01550926|Drug|120 mg orlistat|2 X60 mg capsule
75434635|NCT01550926|Drug|60 mg orlistat|60 mg orlistat
75434636|NCT01550926|Drug|orlistat experimental dose|experimental
75434637|NCT01550939|Device|Ophthalmic Biometer|One complete biometry examination
75434638|NCT01550978|Device|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
75434639|NCT01551004|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
75434640|NCT01551004|Other|Placebo|Matching placebo capsules will be given to 2 subjects of each cohort.
75434641|NCT01551043|Biological|CART-19|
75434642|NCT01551069|Drug|hydroxychloroquine (Z0188)|"Pharmaceutical form:tablet~Route of administration: oral"
75434643|NCT01551069|Drug|Placebo|"Pharmaceutical form:tablet~Route of administration: oral"
75434644|NCT01550458|Drug|mibefradil|25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
75434645|NCT01550458|Other|Placebo|1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
75581771|NCT04620876|Other|Bimodal high resolution imaging of the retina|The protocol consists of performing an Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT).The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
75581772|NCT04620408|Drug|SHR4640|Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
75434646|NCT01551108|Behavioral|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
75581773|NCT02900183|Drug|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
75581774|NCT02900495|Device|transcutaneous electric nerve stimulation|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
75581775|NCT04620837|Drug|Tislelizumab|Tislelizumab：200mg Q3W IV. There will be no dose reduction for Tislelizumab ， if there is no disease progression or serious Treatment Related adverse events(TRAE) , patients will receive Tislelizumab (200mg,Q3W) until progression or death
75581776|NCT04620837|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated. Depending tolerated dose reduction. Medication process: disease control and patients can tolerate the side effects, continued drug use; researchers believe the patient is not fit to continue medication or efficacy evaluation at the end of the clinical progression of medication.
75581777|NCT00562731|Drug|ARD-0403|Daily transdermal ARD-0403
75434647|NCT01551108|Behavioral|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
75434648|NCT01551121|Other|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
75581778|NCT02900027|Drug|APOC-III-L-Rx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
75581779|NCT02900027|Drug|Placebo Comparator|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
75581780|NCT04620447|Other|Intelligent Virtual Reality Therapy System (IVRTS)|The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.
75581781|NCT02900144|Behavioral|Modified Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
75581782|NCT02900144|Behavioral|Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
75581783|NCT04620018|Drug|Amoxicillin|Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
75581784|NCT02900105|Drug|Letrozole|Letrozole 2.5mg (1 tablet) once a day for 4 months
75581785|NCT02899910|Behavioral|Health education|Education on lifestyle changes for treatment of metabolic syndrome
76051325|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
75434649|NCT01551134|Procedure|Fundoplication|Primary fundoplication
75434650|NCT01551134|Procedure|Fundoplication|Primary fundoplication
75434651|NCT01551147|Drug|ONO-6950|200 mg QD for 8 days
75434652|NCT01551147|Drug|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
75434653|NCT01551147|Drug|Montelukast|10 mg Montelukast QD for 8 days
75581786|NCT02899910|Behavioral|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
75581787|NCT04619940|Diagnostic Test|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
75434654|NCT01551160|Other|A communication and team-working intervention|Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
75434655|NCT01551225|Drug|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
75434656|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
75434657|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
75581788|NCT04619940|Diagnostic Test|Standard Goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
75581789|NCT04619784|Other|Pilates Exercises|Patients will receive 12 sessions of pilates.
75581790|NCT04619784|Other|control|Their routine medical treatments were continued
75581791|NCT02899871|Other|diagnosis of joint|"The diagnosis of joint pain will be established by a rheumatologist and completed:~If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~serum assays of the anti-TNF administered, as well as screening for associated antibodies."
75581792|NCT04619667|Device|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
75581793|NCT04619667|Device|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
75880937|NCT05033353|Diagnostic Test|Monitoring of regional cerebral oxygenation|Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
75880938|NCT01347593|Drug|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
76051326|NCT02308007|Drug|Terconazole|
75581794|NCT02899832|Device|NIRS|Near Infra Red Spectroscopy
75581795|NCT04619862|Drug|Gabapentin|See arm descriptions
75581796|NCT04619862|Drug|Placebo|See arm descriptions
75581797|NCT05425121|Procedure|Core stability exercises|The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.
75581798|NCT05425121|Device|Biofeedback training|EMG biofeedback training will be administered to the participants in combination with core stability exercise training.
76051327|NCT02308007|Drug|Metronidazole|
76051328|NCT02308007|Drug|Terconazole/metronidazole|
75581799|NCT01190839|Biological|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
75581800|NCT01190839|Drug|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
75434658|NCT01551277|Other|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
75434659|NCT01551277|Other|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
75434660|NCT01551290|Drug|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
75434661|NCT01551290|Drug|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
75434662|NCT01551316|Drug|MN-221|This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
75434663|NCT01551316|Drug|Placebo|This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
75581803|NCT05425043|Biological|Granulocytes|Receive granulocytes for 7 consecutive days after engraftment post transplant
75581804|NCT02887261|Device|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
75581805|NCT02887261|Device|Conventional Port|not for power injection for contrast media.
75581806|NCT04619277|Device|drug-coated balloon|drug-coated balloon
75581807|NCT01190215|Biological|FluarixTM|One Intramuscular injection
75581808|NCT01190215|Biological|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
76051329|NCT02278367|Drug|Flortaucipir F18|IV injection, 370 MBq (10 mCi), up to two doses
76051330|NCT02278367|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain
76051331|NCT04886141|Behavioral|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
76051332|NCT01910181|Drug|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
76051333|NCT04885907|Biological|mRNA-1273 vaccine|COVID vaccine 3rd dose
75581809|NCT04619238|Diagnostic Test|King's Health Questionnaire|patients fulfilled questionnaire
75581810|NCT04619238|Diagnostic Test|the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form|patients fulfilled ICIQ-SF questionnaire
75581811|NCT05424965|Other|no intervention|no intervention
75581812|NCT04619394|Other|Aquatic exercise - own monitors program|"Supervision of own exercises by the Monitor with its own program. Two weekly sessions, both aquatic in small glass and large. The activity carried out will be aerobic; They will work with their own body weight and the lightweight floating material they offer in these pools. Exercises will be carried out that favor flexibility, elasticity, resistance and the strengthening of the muscular ligaments. The intensity of the exercises will be moderate and adapted in each month of gestation. We will eliminate positions and exercises that overload the pregnant woman, avoiding possible injuries and obstetric alterations.~The start of the program will be established in week 10-12 of the pregnancy and the end in week 37-41.~The total number of sessions of the program will be from 25 to 31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes and adherence to both experimental groups of ≥28 classes."
76051334|NCT04885907|Other|Normal Saline Placebo|Normal Saline Placebo
76051335|NCT04622241|Other|Eave Tubes|The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g. bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides. No additional screening will be done. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
75581813|NCT04619394|Other|Aquatic exercise - AIPAP program|"Supervised by a midwife with AIPAP method. AIPAP method is divided into 10 sessions of 50 minutes that are repeated cyclically with a total of 120 exercises. The sessions are divided into 5 groups with different objectives: 2 sessions of aerobic capacity improvement, 2 sessions of strength improvement, 2 sessions of pelvic elasticity, 2 coordination sessions and the last 4 sessions of the previous ones.~The beginning of the program will be established in week 10-12 of pregnancy and the end in week 37-41.~The total number of sessions of the program will be 25-31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes in both experimental groups. It will be necessary to obtain an adherence to both experimental groups of ≥28 classes."
75581814|NCT00553865|Drug|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
75581815|NCT00562770|Drug|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
75581816|NCT00562770|Drug|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
75581817|NCT04619550|Other|High tibial osteotomy|Realignment surgery
75581818|NCT05424692|Drug|5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
75581819|NCT04618965|Drug|control group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
75581820|NCT04618965|Drug|Intrathecal dexmedetomidine|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
76051336|NCT04622241|Other|Eave Ribbons|"Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial).~All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
75581821|NCT04618965|Drug|Intravenous dexmedetomidine|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
75729328|NCT03574974|Device|Experimental Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators believe that this feedback may help participants learn to control their PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
76051337|NCT04622241|Other|Full House Screening|"Full house screening includes screening eaves/ceilings, ventilation openings, and windows. Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials. or ceilings, if eaves are closed and ventilation openings. We are also filling in any gaps in the walls. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
75581822|NCT04618926|Device|Device intubating Laryngeal Tube Suction Disposable|Resuscitation in covid 19 patients
76051338|NCT04622241|Other|Partial House Screening|Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present. In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls. No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
76051339|NCT01957215|Drug|Indomethacin|Topical indomethacin
76051340|NCT01957215|Drug|Placebo|Placebo patch
75581823|NCT05424653|Device|Transcatheter Aortic Valve System|Procedure: Transcatheter Aortic Valve Replacement
75581824|NCT01190449|Biological|ofatumumab|Given IV
75581825|NCT00562809|Drug|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
75581826|NCT01190176|Procedure|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
75581827|NCT01190176|Biological|Cervarix|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
76051341|NCT02322749|Drug|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
76051342|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
75581828|NCT01190176|Biological|Placebo control|Subjects received 3 doses of the control [Al(OH)3] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
75434664|NCT01551329|Drug|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
75434665|NCT01551368|Drug|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
75581829|NCT04206280|Behavioral|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
75581830|NCT04206280|Behavioral|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
75581831|NCT04618848|Diagnostic Test|Fingerstick blood draw|Each participant shall be pricked twice in order to perform CBC test
75434666|NCT01551368|Drug|Placebo|Identical inactive tablets.
75434667|NCT01551381|Drug|EV-077|twice daily oral administration
75434668|NCT01551381|Drug|Placebo|twice daily oral administration
75581832|NCT04316065|Drug|YHP1906|YHP1906 Tab. 5 mg
76051343|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
76051344|NCT01957137|Device|InterStim® (Device Programming)|
75434669|NCT01551394|Drug|Meropenem|20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
75581833|NCT04316065|Drug|YHR1902|Comparator. YHR1902 Tab. 5 mg
75581834|NCT01190098|Drug|Lacosamide|"Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid"
75729329|NCT03574974|Device|Control Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators do not believe this feedback can help participants' PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
76051345|NCT01928433|Drug|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
76051346|NCT01928433|Drug|Finafloxacin placebo i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
75581835|NCT01190098|Drug|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
75581836|NCT04618887|Procedure|pallidotomy|deep brain nuclei lesion of GPi
76051347|NCT01928433|Drug|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
76051348|NCT01928433|Drug|Finafloxacin placebo tablets once daily|Administered as four tablets
76051349|NCT01928433|Drug|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
76051350|NCT01928433|Drug|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
76051351|NCT01928433|Drug|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
76051352|NCT01928433|Drug|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
76051353|NCT02322281|Drug|Rociletinib|
75434670|NCT01551394|Drug|Ampicillin + gentamicin or cefotaxime + gentamicin|"Ampicillin:~Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours~Gentamicin:~Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)~Cefotaxime:~Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days."
75434671|NCT01551407|Drug|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
75729330|NCT03564197|Other|18F-PD-L1|18F-PD-L1 PET/CT scan
76051354|NCT02322281|Drug|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
76051355|NCT02322125|Device|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
76051356|NCT02243293|Drug|ABT-493|Tablet
76051357|NCT02243293|Drug|ABT-530|Tablet
76051358|NCT02243293|Drug|ribavirin (RBV)|Tablet
76051359|NCT02243293|Drug|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
76051360|NCT02322047|Drug|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
76051361|NCT02322047|Drug|Naltrexone|Naltrexone Dosing Days 1-42: 50mg @ 9PM
76051362|NCT02322047|Drug|Placebo (Prazosin)|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
75581837|NCT04618887|Procedure|deep brain stimulation|deep brain stimulation of GPi
75581838|NCT02885857|Drug|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
75729331|NCT03551496|Combination Product|Drug Eluting Stent - Below the Knee|Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
75729332|NCT03551496|Device|Standard PTA Control Arm|The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
75729333|NCT03549000|Other|NZV930|NZV930, Specified dose on specified days, intravenous (IV)
75729334|NCT03549000|Other|PDR001|PDR001, Specified dose on specified days, intravenous (IV)
75729335|NCT03549000|Drug|NIR178|NIR178 Specified dose on specified days, Orally
75729336|NCT03517449|Drug|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
75729337|NCT03517449|Drug|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
75729338|NCT03517449|Drug|Paclitaxel|80 mg/m^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
75729339|NCT03517449|Drug|Doxorubicin|60 mg/m^2 administered by IV on Day 1 of each 21-day cycle.
76051363|NCT02322047|Drug|Placebo (Naltrexone)|Placebo Dosing Days 1-42: 50mg @ 9PM
76051364|NCT02254291|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
76051365|NCT02254291|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
76051366|NCT02254291|Drug|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
75581839|NCT04314739|Dietary Supplement|Resveratrol|Participants will consume one of the treatment types daily for a period of four weeks.
75581840|NCT04314739|Dietary Supplement|Placebo|Participants will consume one of the treatment types daily for a period of four weeks.
75581841|NCT00562848|Drug|GSK962040|GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
75581842|NCT00562848|Drug|Placebo|Subjects will receive placebo.
75729340|NCT03480360|Drug|Cyclophosphamide|14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
75729341|NCT03480360|Drug|Fludarabine|30 mg/m2 daily for 5 days
75729342|NCT03480360|Radiation|Total Body Irradiation|200 centigray (cGy) for one day (day -1)
75729343|NCT03480360|Drug|Tacrolimus|1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
75729344|NCT03480360|Drug|cellcept|dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
75729345|NCT03480360|Drug|g-csf|5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) > 1000/mcL for 3 days.
75729346|NCT03480360|Procedure|Peripheral Blood Transplant|cell dose goal: < 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
76051367|NCT02253433|Other|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
75434672|NCT01551433|Device|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
75581843|NCT02885740|Other|Quantification assay of adenosine and methionine cycle metabolites|
75581844|NCT02885740|Genetic|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
75581845|NCT02885740|Other|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
75581846|NCT02885740|Biological|Blood sample|
75581847|NCT05309785|Drug|Invokana 300 mg and 100 mg tablet|"Substudy 1 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 12+2 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12+2 weeks (phase 2) and then stopped. If not tolerated, the dose will be reduced to 100 mg until the end of follow-up.~Each phase of 12 weeks is followed by a 2-week window to ascertain surrogate efficacy outcomes.~Substudy 2 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 9 days."
75581848|NCT00562926|Procedure|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
75581849|NCT01190020|Drug|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
75581850|NCT01190020|Drug|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
75581851|NCT01189435|Drug|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
75581852|NCT05424614|Other|Functional outcome follow-up of patients|Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
75581853|NCT05306158|Other|CC+ECIG Condition|Participants will push CC- and ECIG-related pictures.
75581854|NCT05306158|Other|CC Condition|Participants will push CC-related images and push and pull ECIG-related pictures equally often.
75434673|NCT01551459|Drug|Dacarbazine|Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
75581855|NCT05306158|Other|Sham Condition|Participants will pull and push CC- and ECIG-related pictures equally often.
75434674|NCT01551459|Drug|Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
76051368|NCT02253433|Other|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
75581856|NCT05304286|Behavioral|Acceptance and Commitment Therapy|The aim of ACT is to address avoidance behaviors by increasing openness to difficult experiences, such as pain, and to develop an awareness of behavioral options that will aid to facilitate behavior change processes that are in accord with living a values-based life.
76051369|NCT02242981|Drug|LY2623091|Administered orally
75434675|NCT01551485|Drug|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
75434676|NCT01551485|Drug|Placebo|Pacebo tablet, blinded given on the first night after surgery
76051370|NCT02277743|Drug|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
76051371|NCT02277743|Drug|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
76051372|NCT02242903|Drug|LY3079514|Administered SC
76051373|NCT02242903|Drug|LY3079514|Administered IV
75581857|NCT01165996|Other|flow cytometry|Correlative studies
75581858|NCT01165996|Other|DNA methylation analysis|Correlative studies
75581859|NCT01165996|Other|cytogenetic analysis|Correlative studies
75581860|NCT01165996|Drug|decitabine|Given subcutaneously
75581861|NCT01165996|Genetic|microarray analysis|Correlative studies
75581862|NCT01165996|Genetic|gene expression analysis|Correlative studies
76051374|NCT02242903|Drug|Placebo|Administered SC
75581863|NCT01165996|Other|pharmacological study|Correlative studies
75581864|NCT01165996|Genetic|polymorphism analysis|Correlative studies
75581865|NCT04619433|Drug|Camrelizumab;Pemetrexed and Carboplatin; Famitinib;|"Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib"
75581866|NCT04619433|Drug|Camrelizumab;Pemetrexed and Carboplatin;Placebo|"Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo"
75581867|NCT02886871|Behavioral|Step Goal Delivery by Smartphone|
75581868|NCT05424536|Other|Bone measurement by DXA and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites plus femoral neck, one measurement will be performed by DXA to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
75581869|NCT04652388|Behavioral|Nutritional counseling|Nutritional counseling about mediterranean diet
75581870|NCT04619160|Drug|Propofol|TCI 4 µg/mL start until BIS-value of 50
75581871|NCT04619160|Drug|Sevoflurane|start 1 MAC, until BIS-value of 50
75581872|NCT01165684|Drug|insulin aspart|"Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted."
75581873|NCT01165684|Drug|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
75581874|NCT01165684|Drug|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
76051375|NCT02242903|Drug|Placebo|Administered IV
76051376|NCT02320721|Drug|Insulin Glargine (HOE901 - U300)|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
75581875|NCT04618731|Diagnostic Test|caries prevalence def ,DMF|the examination will carried out on dental chair using diagnostic set
75581876|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
75581877|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
76051377|NCT02320721|Drug|Insulin Glargine (HOE901 - U100)|Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
76051378|NCT02320721|Drug|Background therapy|Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
76051379|NCT02320487|Drug|Bendamustine|Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
76051380|NCT02320487|Drug|Obinutuzumab|Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
76051381|NCT04884659|Other|Time restricted feeding arm|80% of calories consumed before 2PM, remaining 20% consumed by 4PM. Fasting for 14-16 hours
76051382|NCT04884659|Other|usual feeding pattern arm|All meals consumed ad lib with 50% of calories consumed after 4PM
76051383|NCT02277119|Device|Maestro|OCT machines used for diagnostic purposes
76051384|NCT02277119|Device|iVue|OCT machines used for diagnostic purposes
75581878|NCT01189201|Drug|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
75581879|NCT01189201|Drug|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
75581880|NCT04652466|Device|farukcicekci2|To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition
75581881|NCT05424497|Other|Vignettes|Presenting vignettes with fictive cases
75581882|NCT01188967|Drug|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
75581883|NCT01188967|Drug|Placebo|Placebo
75880939|NCT02076464|Behavioral|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
75581884|NCT04316728|Device|VivaDiag™ COVID-19 lgM/IgG Rapid Test|VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma
75581885|NCT04652271|Procedure|Pancreatic surgery|Open, laparoscopic or robotic surgery of the pancreas
75434677|NCT01551498|Dietary Supplement|Anatabloc Supplement|Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
76051385|NCT02320253|Behavioral|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
75434678|NCT01551498|Dietary Supplement|Placebo|Placebo, as mint flavored lozenges, to be taken 3 times each day
75434679|NCT01551511|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
75434680|NCT01551511|Drug|Placebo|Identical step-up approach to the Namisol arm.
75581886|NCT02885935|Other|Recommended protein intake|Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
75581887|NCT02885935|Other|Elevated protein intake|Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
75581888|NCT05424458|Procedure|Anterior Implant Treatment|Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.
75729347|NCT03452826|Device|Antibiotic therapy according to the result of mPCR (device)|"Phone call at D28 and D90, unless the patient is still hospitalized;~Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~Collection of an additional respiratory tract sample for biological banking in both arms."
75729348|NCT03444948|Device|EUS-RFA using Habib Tm as a probe|3 EUS-RFA interventions at 1-month interval
75729349|NCT03444948|Procedure|EUS|Standard intervention
75729350|NCT03434548|Radiation|PET imaging|"PET imaging Radiation: Radioligand [¹¹C]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain.~PET imaging Radiation: Radioligand [¹¹C]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain."
75729351|NCT03434548|Other|Multi-modal MRI imaging|Multi-modal MRI imaging
75729352|NCT03422783|Device|Standardized tetanic stimulation|"The intervention is not a drug, but it is standardized electrical stimulus applied with a muscle relaxation monitor on the forearm of the anesthetized patient. The NoL index is registered in response to this stimulus in an observational manner.~Device: Device PMD200TM offering intraoperative NoL Index"
75729353|NCT03422783|Diagnostic Test|Catastrophizing score|Pre-operative catastrophizing score is correlated with post-operative pain and opioid consumption
75880940|NCT01360333|Other|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
75880941|NCT02072252|Behavioral|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
75434681|NCT01551524|Biological|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
75880942|NCT03672227|Behavioral|Mealtime Matters Training|This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
75434682|NCT01551537|Other|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
75434683|NCT01551537|Other|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
75880943|NCT01347671|Drug|GRT6005|25µg/day once daily
75581889|NCT04618380|Diagnostic Test|bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity|"The following clinical indexes are evaluated:~Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test."
75880944|NCT01347671|Drug|GRT6005|75 µg/day once daily
75581890|NCT05424107|Other|KIDMED|Pre-and post-intervention evaluation of the adherence to the Mediterranean diet and its effect on prediabetic state, as well as, other anthropometric values.
75729354|NCT03422783|Diagnostic Test|Nociceptive threshold|Nociceptive threshold for pressure, heat and electrical stimulation are associated with post-operative pain and will be assessed preoperatively to see if there is correlation between them and the NOL index response to the nociceptive stimulus (see intervention 1)
75729355|NCT03422783|Biological|Biomarkers|Some biomarkers of inflammation and endogenous opioids are associated with post-operative pain. Blood samples will be withdrawn at D0 before surgery starts, D1 (H24) and D2 (H48) after surgery to see if they correlate with NOL changes after the stimulus described in intervention 1 above
75729356|NCT03410836|Drug|intravenous lidocaine (IVL)|lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
75880945|NCT01347671|Drug|GRT6005|200 µg/day once daily
75880946|NCT01347671|Drug|Matching Placebo|Once daily
75880947|NCT01361659|Procedure|shockwave treatment|9 treatments in 3 months
75880948|NCT03671603|Drug|Iodixanol|Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
75880949|NCT02072330|Drug|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
75880950|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
75434684|NCT01551576|Device|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
75434685|NCT01551589|Radiation|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV（primary tumor）：66-70Gy/33~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33~35F，once a day, 5 times per week.
75434686|NCT01551589|Drug|docetaxel and cisplatin|Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
75434687|NCT01551589|Radiation|Elective Nodal Irradiation (ENI)|The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
75434688|NCT01551602|Drug|AK159|transdermal administration of teriparatide acetate
75434689|NCT01551602|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
75434690|NCT01551602|Drug|Placebo|Multiple administration of placebo AK159
75434691|NCT01551615|Drug|Metformin 1000 mg|2 x 500 mg oral tablets
75434692|NCT01551615|Drug|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
75581891|NCT04652232|Other|RV3466F lotion|"Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application"
75581892|NCT04652232|Other|Shampoo|"Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application"
75581893|NCT04652349|Drug|HGP1910|Take it once daily for 8 weeks orally.
75581894|NCT04652349|Drug|HCP1903|Take it once daily for 8 weeks orally.
75581895|NCT04652349|Drug|HGP1909|Take it once daily for 8 weeks orally.
75581896|NCT04652349|Drug|HGP1911|Take it once daily for 8 weeks orally.
75581897|NCT01188811|Drug|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
75581898|NCT01188811|Drug|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
75434693|NCT01551628|Drug|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
75434694|NCT01551641|Other|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
75581899|NCT01183234|Drug|SPD544|two 30mg capsules, single oral dose
75880951|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
75880952|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
75581900|NCT01183234|Drug|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
75581901|NCT04618497|Drug|Methoxyflurane|Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
75581902|NCT04618497|Drug|Ketorolac|Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
75581903|NCT05423873|Other|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants twice daily
75581904|NCT04618575|Drug|Ursodeoxycholic acid combined with total glucosides of paeony|Ursodeoxycholic acid combined with total glucosides of paeony
75434695|NCT01551641|Drug|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
75434696|NCT01551641|Other|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
75581905|NCT04618575|Drug|Ursodeoxycholic acid only|Ursodeoxycholic acid only
75581906|NCT04618419|Diagnostic Test|internal jugular vein distensibility index|It is a prospective observational clinical study to correlate hemodynamic monitoring between Electrical Cardiometry and internal jugular vein distensibility index by sonogram
75581907|NCT04680338|Diagnostic Test|CMR stress perfusion imaging|CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant
75581908|NCT04618536|Other|Inorganic sunscreen|Inorganic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
75880953|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
75880954|NCT05128643|Biological|Recombinant novel coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).
75434697|NCT01551654|Device|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
75434698|NCT01551667|Biological|Antibody assays for S. aureus|Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
75434699|NCT01551667|Biological|Basic blood work|Hemogramme + CRP on Days 0, 2, 4 and 7
75434700|NCT01551680|Radiation|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
75434701|NCT01551706|Dietary Supplement|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract
75434702|NCT01551706|Other|Placebo|Placebo
76051386|NCT02320253|Behavioral|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
75581909|NCT04618536|Other|Organic sunscreen|Organic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
75434703|NCT01551719|Behavioral|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
75434704|NCT01551732|Behavioral|ACT|10 session manualized cognitive behavioral anger control therapy
75434705|NCT01551732|Behavioral|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
75434706|NCT01551771|Drug|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
75434707|NCT01551771|Drug|GW824575 matched-placebo|Placebo
75434708|NCT01551797|Drug|Paracetamol 500 mg|Standard Paracetamol formulation
75434709|NCT01551797|Drug|Paracetamol 1000 mg|Paracetamol Sustained Release formulation
75434710|NCT01551797|Drug|Paracetamol 750 mg|Paracetamol Sustained Release formulation
75434711|NCT01551836|Drug|Paracetamol formulation 1|formulation 1
75434712|NCT01551836|Drug|Paracetamol formulation 2|Formulation 2
75434713|NCT01551862|Procedure|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
75581910|NCT04679987|Diagnostic Test|Holter ECG|all patients will be monitored for paroxysmal Af by holder ECG
75581911|NCT05423795|Other|Telemedicine-based intervention|Telemedicine-based intervention Multifaceted intervention including daily videoconferences with audit and feedback, educational interventions, and dissemination of published works
75880955|NCT02070224|Other|Serum and urine samples collections|Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
75880956|NCT02070224|Other|Imaging (x-rays and MRI)|MRI will be done at baseline and 12 month and x-rays will be done at baseline
75880957|NCT03660215|Other|mediation|support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
75434714|NCT01551901|Device|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
75434715|NCT01551914|Device|Ultrasonic Scissors (Ethicon)|Haemostasis using Ultrasonic scissors
75434716|NCT01551914|Device|Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)|bipolar, monopolar or clip coagulation techniques
75434717|NCT01551940|Drug|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
75434718|NCT01551940|Drug|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
75434719|NCT01551953|Behavioral|Tai chi|12 week tai chi class
75434720|NCT01551953|Behavioral|Mind-body breathing|12 week breathing class
75434721|NCT01551953|Behavioral|Education|12 week education class
75434722|NCT01551966|Device|Wireless esophageal capsule endoscopy ( PillCam Eso2)|"This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.~During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.~For to asses the tolerance, after they completed both exams, the patients will be asked to answer a comfort score questionnaire.~In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy."
75581912|NCT05423795|Other|Standard of care arm|Classic expertise (as routinely performed in the participating ICU)
75581913|NCT05423561|Procedure|exchange nailing with larger, thicker nail crossing corticalization|exchange nailing with larger, thicker nail crossing corticalization
75581914|NCT04651959|Drug|AVICOD 200 MG Film Tablet|AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
75581915|NCT04651959|Drug|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
75434723|NCT01551992|Procedure|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
75434724|NCT01552005|Drug|Saxagliptin|No Intervention
75581916|NCT01165216|Drug|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
75581917|NCT01165216|Drug|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
75581918|NCT01165216|Drug|Paclitaxel|IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
75581919|NCT01165216|Drug|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
75581920|NCT04651881|Drug|Reference drug|1 Cap., single oral administration under fed condition
75581921|NCT04651881|Drug|Test drug 1|1 Tab., single oral administration under fed condition
75581922|NCT04651881|Drug|Test drug 2|1 Tab., single oral administration under fed condition
75581923|NCT05367427|Dietary Supplement|Bifidobacterium longum consumption|Regular consumption in breakfast of inactivated B. longum
75581924|NCT05367427|Dietary Supplement|Placebo|Placebo pill with maltodextrin
75729357|NCT03410836|Other|Placebo|Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
75729358|NCT03390595|Combination Product|avelumab 10mg/kg with carboplatin/gemcitabine|"Dosage and schedule:~Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:~Intravenously every 2 weeks for two cycles.~During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.~Intravenously every 2 weeks until progressive disease or intolerance.~Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~Carboplatin 5AUC day +1.~Gemcitabine 1000mg/m2 day +1 and +8."
75434725|NCT01552018|Drug|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
75434726|NCT01552018|Drug|Placebo|Placebo, 1 tablet per day for 3 months.
75434727|NCT01552044|Drug|Spironolactone|25mg tablet once a day for 1 month
75434728|NCT01552044|Drug|Placebo|one tablet once a day for 1 month
75581925|NCT05423405|Other|Acupressure|selected acupoint pressure
75581926|NCT04652310|Device|TFNA extended-short nail (235 mm)|The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)
75581927|NCT04652310|Device|TFNA long nail (260-480mm)|The long version of the TFN-advanced proximal femoral nailing system (TFNA)
75581928|NCT05423288|Procedure|Distal pancreatectomy (DP)|Any scheduled distal pancreatectomy performed for any diagnosis
75581929|NCT04652115|Drug|Defibrotide|Deibrotide via IV
75434729|NCT01552070|Behavioral|Recruitment maneuver|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
75434730|NCT01552070|Other|without recruit maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
75434731|NCT01552083|Other|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
75434732|NCT01552122|Drug|Odanacatib|Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
75434733|NCT01552122|Drug|Alendronate|Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
75581930|NCT05423171|Other|Intensive bimanual therapy|60-hour intensive therapy promoting the use of both hands (ex: bimanual activities, games,...)
75581931|NCT01580553|Drug|Levocarnitine Injection|Levocarnitine Injection:5ml:1g
75581932|NCT01580553|Drug|Levocarnitine placebo|L-Carnitine injection placebo (5ml:1g)
76051387|NCT02320253|Behavioral|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
76051388|NCT04197089|Drug|Vitamin D|First dose of 10.000 IU Vitamin D at baseline visit for all patients; stratification of treatment (10.000 or 50.000 IU Vitamin D) depending base 25(OH)Vitamin D levels. Treatment weekly during 4 weeks before scheduled cystectomy
75581933|NCT05423054|Other|Abdominal massage|"Patients will be positioned on their back while their knees will be flexed.~Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~The PR will be standed on the right side of the patient during the massage practice.~The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
75581934|NCT04618107|Procedure|Wide awake surgery|Wide awake local anaesthesia was used to perform tendon repair surgeries.Local anaesthetic injections given using 27 gauze needle in subcutaneous tissue plane.Tendon repair performed using modified Kessler repair.Outcome of surgery assesed at sixth postoprative week.
75729359|NCT03390595|Combination Product|carboplatin/gemcitabine alone|"•Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~Carboplatin 5AUC day +1.~Gemcitabine 1000mg/m2 day +1 and +8."
75729360|NCT03387761|Drug|Ipilimumab|"For Cohort 1:~Day 1: Ipilimumab 3 mg/kg~Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~Day 1: Ipilimumab 3 mg/kg~Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~Day 1: Ipilimumab 1 mg/kg~Days 22: Ipilimumab 1 mg/kg"
75729361|NCT03387761|Drug|Nivolumab|"For Cohort 1:~Day 22: Nivolumab 1 mg/kg~Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~Days 1 and 22: Nivolumab 1 mg/kg~Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg"
75729362|NCT03367312|Drug|Hyperpolarized 129Xenon gas|Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
75729363|NCT03354169|Behavioral|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
75434734|NCT01552122|Other|Placebo (odanacatib)|One compressed tablet administered orally, once-a-week, for 24 months.
75729364|NCT03325946|Behavioral|ACQUIRE Therapy|Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
75581935|NCT04618107|Procedure|General anaesthesia|Tendon repair performed under general anaesthesia using modified Kessler repair.Outcomes of surgery assesed at sixth post operative week
75581936|NCT05423015|Dietary Supplement|Lactobacillus casei strain Shirota|Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.
75729365|NCT03288545|Drug|enfortumab vedotin (EV)|Intravenous (IV) infusion on days 1 and 8 every 21 days
75880958|NCT02072408|Drug|aflibercept|"Three monthly intravitreal aflibercept (2mg) injections~Five bimonthly intravitreal aflibercept (2mg) injections~Rescue treatment: Verteporfin photodynamic therapy~Loss of five ETDRS letters or one Snellen line of vision from baseline~Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~Presence of active polyp on indocyanine green angiography"
75434735|NCT01552122|Dietary Supplement|Cholecalciferol (Vitamin D3)|Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
75434736|NCT01552122|Dietary Supplement|Calcium carbonate|Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
75434737|NCT01552122|Other|Placebo (alendronate)|One compressed tablet administered orally, once-a-week, for 24 months.
75729366|NCT03288545|Drug|pembrolizumab|IV infusion on day 1 every 21 days
75729367|NCT03288545|Drug|cisplatin|IV infusion on day 1 every 21 days
75729368|NCT03288545|Drug|carboplatin|IV infusion on day 1 every 21 days
75729369|NCT03288545|Drug|gemcitabine|IV infusion on days 1 and 8 every 21 days
75434738|NCT01552148|Other|USguided bilateral TAP block|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
75434739|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8 min)
75581937|NCT05423015|Dietary Supplement|Lactobacillus casei strain Shirota plus inulin|The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.
75581938|NCT05423015|Dietary Supplement|Lactobacillus casei strain Shirota plus fructans from A. salmiana|The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
75434740|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8min)
75581939|NCT04618224|Diagnostic Test|DDART Testing|One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
75581940|NCT04618224|Diagnostic Test|wDDART Testing|One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
75581941|NCT04618146|Drug|Morphine Sulfate|intrathecal low dose morphine for early return to normal activity without opioid related complications.
75581942|NCT04618146|Drug|Bupivacaine Hydrochloride|intrathecal bupivacaine 0.5%
75581943|NCT05422898|Behavioral|Gist messages on COVID-19 vaccination|Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator
75581944|NCT05422898|Behavioral|COVID-19 vaccine information|Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group
75434741|NCT01552187|Drug|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (<70kg) 48 to 72 hours before surgery till 1 months after surgery
75434742|NCT01552187|Drug|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
75434743|NCT01552200|Procedure|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
75434744|NCT01552200|Procedure|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
75581945|NCT04651842|Device|PCI|Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
75581946|NCT05422859|Other|MobiDig|"The application will contain the following modules:~information and knowledge about heart failure;~vital sign diary, which can be sent to the certified HFU~pedometer (individualized step-goal), cardiac home training videos~frequently asked questions and connection to a certified HFU provider by a heart failure hotline"
75581947|NCT04651647|Procedure|Revision surgery with / without open bone graft|Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
75581948|NCT04651686|Other|Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
75434745|NCT01552226|Device|Continuous Preperitoneal Analgesia|Preperitoneal catheter placed at the completion of surgery in the standard fashion.
75434746|NCT01552226|Device|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion.
75434747|NCT01552239|Radiation|IMRT/IGRT, Tumor resection, Brachytherapy|"All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection"
75434748|NCT01552252|Dietary Supplement|apple juice|unaltered(0% POs-Ca) commercially available apple juice
75434749|NCT01552252|Dietary Supplement|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
75581949|NCT05421962|Drug|Ketamine|Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
75581950|NCT00557817|Drug|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to > 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases < 13 g/dL. If the Hb decreases to < 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
75581951|NCT00557817|Drug|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin > 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS > 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation < 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
75581952|NCT05421182|Other|Revised Impact of Event Scale|to measure the affect of routine life stress,everyday traumas and acute stress
75581953|NCT05421182|Other|Hospital Anxiety and Depression scale|to measure anxiety and depression
75581954|NCT05421182|Other|36-Item Short Form Survey|SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
75581955|NCT05421182|Other|satisfaction survey|satisfaction survey of the trusted person about the communication with ICU personal
75581956|NCT05421182|Other|semi-directed interview with trusted person on the general experience of the patient's medical evacuation|interview of the trusted person about the medical evacuation : evacuation announcement;organization of the medical evacuation,; concerns related to evacuations;reception and information by the center admitting the evacuated patient; arrangements of visit, patient repatriated
75581957|NCT05421182|Other|semi-directed interview with trusted person on the general experience of hospitalization in intensive care|interview of the trusted person about ICU hospitalization: reception in ICU; ICU organization; concerns related to ICU hospitalization, information and communication with ICU staff, arrangements of visit, context of ICU discharge
75581958|NCT04651530|Procedure|Phaco|phacoemulsification of cataract only
75581959|NCT04651530|Procedure|Phaco+ECP|Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
75581960|NCT05420480|Procedure|Two-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
75581961|NCT05420480|Procedure|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
75581962|NCT05420480|Procedure|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
75434750|NCT01552252|Dietary Supplement|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
75434751|NCT01552252|Dietary Supplement|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
75434752|NCT01552252|Dietary Supplement|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
75434753|NCT01552291|Dietary Supplement|Glutamine|30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
75434754|NCT01552291|Drug|Placebo|30g oral maltodextrin / day for 5 days before surgery
75434755|NCT01552304|Other|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
75434756|NCT01552304|Other|Control group|
75434757|NCT01552317|Other|OxSalt care bundle|A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
75434758|NCT01552330|Drug|Primaquine and Pyronaridine-artesunate|"Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
76051389|NCT02276807|Behavioral|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
75581963|NCT04651491|Drug|Kagocel|"The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days."
75581964|NCT03455231|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with complicated bone metastases
75581965|NCT04617873|Procedure|Bilateral STN-DBS and T10-T12 SCS|simultaneous stimulation of bilaterally-STN-DBS combined with spinal cord stimulation
75581966|NCT05419739|Other|Glasgow coma scale|This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
75581967|NCT00563004|Dietary Supplement|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
75581968|NCT00563004|Dietary Supplement|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
75581969|NCT05419583|Diagnostic Test|Coronary computed tomography angiography|CT scan of the heart arteries
75434759|NCT01552330|Drug|Primaquine and Pyronaridine-Artesunate|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
75434760|NCT01552421|Procedure|TV NOTES cholecystectomy|Transvaginal NOTES cholecystectomy
75434761|NCT01552447|Other|EpiFix|Dehydrated placental tissue
75581970|NCT05419583|Diagnostic Test|Invasive coronary angiography|Invasive coronary angiography via the radial or femoral approach
75581971|NCT05419583|Diagnostic Test|Transthoracic echocardiography|Ultrasound scan of the heart
75434762|NCT01552447|Other|Compression Therapy|Compression bandaging
75434763|NCT01552473|Behavioral|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
75581972|NCT05419583|Diagnostic Test|Cardiac MRI scan|An MRI scan to assess the heart structure and function
75581973|NCT05419583|Drug|Antiplatelet Drug (Aspirin or Statin)|Antiplatelet therapy for coronary artery disease
75581974|NCT05419583|Drug|Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)|Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
75581975|NCT05419583|Drug|Guideline directed heart failure therapy|Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
75581976|NCT05419583|Drug|Statins (Cardiovascular Agents)|Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
75434764|NCT01552473|Behavioral|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
75581977|NCT04651764|Device|ColubrisMX Endoluminal Surgical (ELS) System|Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
75581978|NCT04617600|Drug|MTA|Survival rate using MTA in cariously exposed vital primary molars
75581979|NCT04617600|Drug|TheraCal PT|Survival rate using TheraCal PT in cariously exposed vital primary molars
75434765|NCT01552486|Other|Chiropractic Spinal Manipulative Therapy|Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
75581980|NCT05408624|Procedure|ultrasound transvaginal drainage|Ultrasound-guided transvaginal drainage of TOA by a puncture under simple sedation or analgesia with/or under general anesthesia
75581981|NCT05408624|Procedure|laparoscopy|Laparoscopy for drainage of TOA under general anesthesia
75581982|NCT04651608|Behavioral|manuel acupressure|Acupressure was applied once by the researcher 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child. 3 fingers were placed on the child's wrist with their fingers and the region (point P6) between the flexor carpi radians and palmaris longus 1 cm below. Acupressure was applied to the wrist of the child by press for 2 minutes. The same procedure was applied to the other wrist. Then, data were recorded in accordance with the data collection procedure.
75581983|NCT04651608|Behavioral|sea-band acupressure|30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child, sea-band acupress was applied by the researcher. The P6 point on the wrist was identified and marked with the child's own fingers. A sea band was attached to both wrists of the child by the researcher. The attached sea-band was allowed to remain for 15 minutes and was removed by the researcher at the end of the period. Separate sea-band was attached to each child. Acupress wrist bands, which are produced in separate sizes for adults and children, were used during the application, taking into account the physical development of the child, pediatric for the age range of 5-12, and adult size sea-band for the age of 12. Acupress application with sea-band was done once. Then, data were recorded in accordance with the data collection procedure
75581984|NCT04651608|Behavioral|placebo manuel acupressure|Placebo manual acupress was applied in the next protocol for the child who was administered manual acupressure.
75581985|NCT04651608|Behavioral|placebo sea-band|Placebo sea-band was applied in the next protocol for the child who was administered sea-band acupressure.
75581986|NCT05406089|Other|Medication history|The study was retrospective and did not involve the application of interventions
75729373|NCT03274414|Drug|Cisplatin|Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m^2 (dose reductions after the first cycle allowed for toxicity)
75729374|NCT03274414|Radiation|Adjuvant Proton Radiotherapy|"Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology."
75729375|NCT03274414|Procedure|Endoscopic Resection|In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
76051390|NCT02276807|Other|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
75434766|NCT01552486|Other|Usual Care|Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
75434767|NCT01552499|Other|Standard of care|
75434768|NCT01552499|Other|Applications of EpiFix|
75434769|NCT01552512|Dietary Supplement|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
75434770|NCT01552512|Other|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
75434771|NCT01552538|Device|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
75581987|NCT04651335|Device|afferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The concentric direction moves the ball from the left to the center of the body.
75581988|NCT04651335|Device|efferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The efferent direction moves from the center to the right.
75581989|NCT04651023|Dietary Supplement|Nelumbo nucifera Leaf Extract|Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
75581990|NCT05395832|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions at sea|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) at sea Standard pharmacological treatment usually provided to patients with fibromyalgia."
75581991|NCT05395832|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions in nature|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) in nature Standard pharmacological treatment usually provided to patients with fibromyalgia."
75729376|NCT03274414|Drug|cisplatin and etoposide|If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
75729377|NCT03267316|Biological|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
75729378|NCT03267316|Drug|Cisplatin|Standard of care treatment
75729379|NCT03267316|Drug|Gemcitabine|Standard of care treatment
75729380|NCT03267316|Drug|Nab-paclitaxel|Standard of care treatment
75434772|NCT01552551|Behavioral|Assessment and education|PA Healthy Steps program
75729381|NCT03267316|Drug|Carboplatin|Standard of care treatment
75729382|NCT03267316|Drug|Pemetrexed|Standard of care treatment
75729383|NCT03257631|Drug|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
75729384|NCT03257631|Drug|Pomalidomide|Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
75880959|NCT02076542|Behavioral|Education - Diabetes and Sports|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Sports was created. The module covers specific and detailed aspects of the topic sports such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible."
75434773|NCT01552551|Behavioral|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
75434774|NCT01552551|Behavioral|Healthy Steps in Motion|Group exercise program
75434775|NCT01552564|Procedure|Index of microvascular resistance|
75880960|NCT03644849|Device|CO2RE® (Syneron Candela Corp, Wayland, MA)|The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.
75880961|NCT03644849|Other|Sham laser treatment|A physician who is not blinded will perform a sham laser treatment on blinded subjects.
75880962|NCT02070458|Drug|ixazomib|Given PO
75880963|NCT02070458|Drug|mitoxantrone hydrochloride|Given IV
75434776|NCT01552564|Other|Cardiac magnetic resonance|
75434777|NCT01552564|Other|Blood markers|
75880964|NCT02070458|Drug|etoposide|Given IV
75434778|NCT01552616|Procedure|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
75581992|NCT05395832|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
75581993|NCT04651062|Device|endocuff|Endocuff is a relatively new device which is intended to be attached to the end of the colonoscope.
75581994|NCT04651062|Procedure|no endocuff|colonoscopy is performed without endocuff.
75581995|NCT05394779|Device|DTXO APP|DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.
75880965|NCT02070458|Drug|cytarabine|Given IV
75880966|NCT03131479|Drug|LIK066|LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
75434779|NCT01552629|Drug|QGE031|
75581996|NCT05394779|Device|PLACEBO APP - Control group|The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
75729385|NCT03256812|Device|ICT-based ECG monitoring|Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.
75880967|NCT02076854|Behavioral|Text-Message Intervention|
75880968|NCT01348997|Behavioral|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
75880969|NCT01348997|Behavioral|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
75880970|NCT03620227|Other|Exercise|40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
75880971|NCT03620227|Dietary Supplement|Beetroot juice|Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.
75880972|NCT03620227|Dietary Supplement|Placebo|Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
75434780|NCT01552629|Drug|Placebo|
75434781|NCT01552629|Drug|Cyclosporine A|
75434782|NCT01552642|Behavioral|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
75434783|NCT01552655|Radiation|Dual-time PET/CT (low-dose)|4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
75434784|NCT01552668|Drug|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
75434785|NCT01552668|Drug|Placebo|Receive Placebo twice daily
75729386|NCT03256812|Device|Holter monitoring|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
75729387|NCT03164460|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT/IMPT
75729388|NCT03164460|Radiation|Proton Radiation|Undergo IMRT/IMPT
75729389|NCT03164460|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75581997|NCT04651101|Diagnostic Test|coronary angiography|extent of coronary artery disease in invasive coronary angiography
75880973|NCT02072564|Other|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
75880974|NCT02076932|Behavioral|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
75434786|NCT01552707|Biological|XCEL-MT-OSTEO-ALPHA|"Isolation and ex-vivo expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion."
75434787|NCT01552707|Procedure|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest
75434788|NCT01552733|Device|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
75434789|NCT01552733|Other|Standard of care|Rehabilitation Therapy
75581998|NCT04651257|Device|Contrast mammography (CEM)|Contrast mammography in pathological nipple discharge
75581999|NCT05387408|Behavioral|Best Practice Health and Employment Opioid-related Policies|The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
75582000|NCT05380700|Device|Virtual Reality Stimulation|Participants in the intervention group will be provided with up to 30 minutes of relaxing, 360-degree virtual reality (VR) stimulation and corresponding sounds, twice in 24 hours during their stay on the intermediate care unit.
75729390|NCT03152058|Drug|Certolizumab Pegol|"Certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
75880975|NCT02077010|Drug|Inhaled nebulized milrinone|inhaled nebulized milrinone 60mg/4ml
75434790|NCT01552759|Procedure|Postprandial responses|Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.
75434791|NCT01552759|Behavioral|Cold pressor test|Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.
75434792|NCT01552759|Behavioral|Test meal|Subjects are presented with an ad libitum buffet meal.
75434793|NCT01552785|Device|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
75434794|NCT01552798|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
75434795|NCT01552798|Drug|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
75880976|NCT01319461|Device|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
75434796|NCT01552798|Drug|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
75434797|NCT01552096|Drug|peritonsillar infiltration|1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
75729391|NCT03129139|Drug|Minnelide™Capsules|Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
75729392|NCT03122639|Drug|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
75880977|NCT01319461|Device|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
75880978|NCT02070536|Other|sRAGE|
75434798|NCT01552824|Procedure|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
75582001|NCT05376761|Drug|Dexmedetomidine|The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
75582002|NCT04617561|Drug|Ursodeoxycholic acid|Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)
75582003|NCT04617561|Drug|Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)|Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
75729393|NCT03122639|Drug|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
75434799|NCT01552824|Procedure|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
75434800|NCT01552837|Drug|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
75582004|NCT04617483|Biological|Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the commercial scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 26-45.
75582005|NCT04617483|Biological|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 18-59.
75582006|NCT04617483|Biological|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group above 60.
75434801|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation A capsule with water and under fed condition
75434802|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation B capsule with water and under fed condition
75434803|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation C capsule with water and under fed condition
75434804|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation D capsule with water and under fed condition
75729394|NCT03117920|Drug|Minnelide|Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
75729395|NCT03098459|Other|Non-interventional observational prospective cohort study|Non-interventional observational prospective cohort study
75729396|NCT03096054|Drug|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
75880979|NCT03180749|Other|Follow up per standard of care|Patients will come in 2 years post implantation and receive standard examinations
75880980|NCT02077088|Other|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
75880981|NCT01361815|Device|H-Coil Deep TMS in combination with SSRIs|The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
75434805|NCT01552850|Drug|Oxycodone|40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
75434806|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose
75434807|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation E, single dose
75582007|NCT04617288|Other|Ultrasound Therapy, SNAGs|
75582008|NCT04617249|Procedure|median anesthesia|giving median anesthesia
75582009|NCT04617249|Procedure|paramedian anesthesia|giving paramedian anesthesia
75434808|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation F, single dose
75582010|NCT05349383|Drug|Antibody-Drug Conjugate|"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
75582011|NCT05349383|Drug|Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate|We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
75729397|NCT03094793|Other|abnormal EEGs|"This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.~Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention."
75729398|NCT03055767|Drug|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
75729399|NCT03055767|Other|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
75582012|NCT05344820|Behavioral|Art based mandala|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
75729400|NCT03025308|Drug|Filgotinib|Tablet(s) administered orally once daily
75729401|NCT03025308|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
75729402|NCT02998567|Drug|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
75729403|NCT02998567|Drug|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
75434809|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation G, single dose
75434810|NCT01552863|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation TBD, single dose
75582013|NCT04617171|Drug|Benralizumab 30 MG/ML [Fasenra]|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
75582014|NCT04617171|Drug|Placebos|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
75729404|NCT02998567|Drug|ASTX727|In arm B2 (lung expansion) replacing guadecitabine
75729405|NCT02918864|Drug|Oxytocin|This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions.
75729406|NCT02918864|Behavioral|Social Cognitive Skills Training|Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
75729407|NCT02918864|Behavioral|Facilitated Play Therapy|The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
75729408|NCT02916979|Drug|Fludarabine|Fludarabine: 30 mg/m2 daily for 5 days
75729409|NCT02916979|Drug|Busulfan|Busulfan: 100 mg/m2 daily for 4 days
75434811|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation H, single dose
75434812|NCT01552941|Device|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
75434813|NCT01552967|Drug|Capecitabine|"Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles."
75582015|NCT04617054|Drug|AB-106|600mg QD for each subjects.
75582016|NCT05337488|Other|questionnaire with interview|They will be invited to complete a questionnaire and an individual semi-structured interviews.
75582017|NCT00557934|Other|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
75582018|NCT04679753|Device|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with iTBS
75582019|NCT04679753|Device|Brainsway DTMS with High Frequency (HF) Stimulation|Brainsway DTMS with HF
75582020|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
75582021|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
75582022|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
75582023|NCT04679714|Device|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
75582024|NCT00558090|Drug|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
75582025|NCT05323604|Other|Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
75582026|NCT00558129|Device|X-STOP®|Surgical implantation of X-STOP IPD device
75582027|NCT00558129|Procedure|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
75582028|NCT04616976|Biological|convalescent plasma|convalescent plasma was get from the patients who recovery from COVID-19
75582029|NCT05293847|Behavioral|Telerehabilitation exercises and postural skills|12 week based postural exercises and skills were applied to participants. The exercises were done 3 times a week. The exercises about cervical and thoracal region strengthening and stretching of muscles and structures.
75582030|NCT04616742|Drug|[14C]SHR6390|Patients will receive single dose of orally [14C]SHR6390 on Day 1.
75582031|NCT04616703|Radiation|CT imaging|CT of abdomen
75582032|NCT05292287|Device|Polar Ignite Wearable Activity Monitor|A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
75582033|NCT04651140|Behavioral|aerobic exercise|Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks
75582034|NCT05287217|Other|Comparison of medication administration for pain control|Measuring pain control following FESS surgery
75880982|NCT01349075|Radiation|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
75434814|NCT01552980|Drug|S-1 and Oxaliplatin|"Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;~Efficacy will be evaluated every three cycles."
75434815|NCT01552993|Drug|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
75434816|NCT01552993|Drug|sucrose|pacifier and sucrose
75434817|NCT01553006|Drug|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
75434818|NCT01553019|Radiation|Proton radiation|Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
75582035|NCT05278403|Other|Virtual reality and video games|Use of a software in stroke patients' rehabilitation.
75582036|NCT05278403|Other|Neurological physiotherapy|Application of conventional physical therapy techniques.
75582037|NCT04650906|Behavioral|Mindhelper - a national youth mental health promotion website|Mindhelper is a fully digital youth mental health service reaching out to a large number of young people when and where they need it, with full anonymity. Mindhelper was developed in 2014-2017 by Centre for Telepsychiatry in the Region of Southern Denmark in a partnership with four Danish municipalities. The development of the site was funded by the Danish foundation TrygFonden. The original idea behind the site was inspired by the Australian youth mental health promotion service ReachOut.com. The Mindhelper service was launched in September 2016. From January 2019 Mindhelper received permanent funding through a joint agreement between the five Danish Regions. Mindhelper is Denmark's most comprehensive youth mental health promotion website where young people can seek mental health information, advice, and self-help tools to improve their mental health and well-being. Since it was launched, the site has been very successful in attracting large numbers of visitors.
75582038|NCT05273255|Biological|Fecal Microbiota Transplantation (FMT)|Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of ICI.
75434819|NCT01553019|Drug|Gemcitabine|Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
75729410|NCT02916979|Biological|Rabbit ATG|"Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"
75729411|NCT02916979|Drug|Methotrexate|"Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"
75729412|NCT02716116|Drug|TAK-788|TAK-788 capsules.
75729413|NCT02702414|Biological|Pembrolizumab|Intravenous (IV) infusion
75729414|NCT02548559|Drug|Full-Spectrum Cannabidiol|Full-Spectrum Cannabidiol; total daily dose of 30 mg.
75729415|NCT02548559|Drug|Single-Compound Cannabidiol|Single-Compound Cannabidiol; total daily dose of 30 mg.
75729416|NCT02548559|Drug|Placebo|Placebo solution.
75880983|NCT02072720|Drug|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
75880984|NCT05077007|Procedure|Percutaneous nephrolithotomy|Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma
75434820|NCT01553097|Other|Neurocognitive impairment observation|None - observational
75434821|NCT01553123|Drug|Ulipristal Acetate|once daily, oral
75434822|NCT01553123|Drug|Iron|once daily, dried ferrous sulfate
75434823|NCT01553162|Genetic|DNA analysis|
75434824|NCT01553162|Genetic|RNA analysis|
75434825|NCT01553162|Genetic|gene expression analysis|
75434826|NCT01553162|Other|laboratory biomarker analysis|
75434827|NCT01553175|Genetic|DNA analysis|
75582039|NCT04650750|Drug|Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin|"Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect."
75582040|NCT04650750|Drug|Placebo|Similar placebo 4g twice a day for two months
75729417|NCT02491632|Drug|Dexamethasone|Given PO
75434828|NCT01553175|Genetic|gene expression analysis|
75434829|NCT01553175|Genetic|mutation analysis|
75434830|NCT01553175|Genetic|protein expression analysis|
75434831|NCT01553175|Other|immunohistochemistry staining method|
75582041|NCT05250128|Procedure|Catheterization|Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance
75582042|NCT04650711|Diagnostic Test|p16 protein expression|P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
75582043|NCT04650828|Drug|TDF|TDF combined with telbivudine (LDT) for 12 months
75582044|NCT04650828|Drug|Tenofovir Disoproxil Fumarate 300 MG|TDF monotherapy was continued for 12 months
75582045|NCT04650360|Behavioral|Postoperative Intervention Educational Program|The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
75582046|NCT05197556|Drug|HSG4112|Once-daily oral administration
75582047|NCT05197556|Drug|Placebo|Once-daily oral administration
75729418|NCT02491632|Behavioral|Exercise Intervention|Complete a graded resistance exercise program and a walking regimen
75729419|NCT02491632|Other|Laboratory Biomarker Analysis|Correlative studies
75729420|NCT02491632|Other|Quality-of-Life Assessment|Ancillary studies
75880985|NCT05077007|Procedure|Extracorporeal Shock Wave Lithotripsy|Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.
75880986|NCT01356745|Drug|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
75434832|NCT01553175|Other|laboratory biomarker analysis|
75434833|NCT01553227|Device|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
75434834|NCT01553266|Behavioral|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
75434835|NCT01553305|Other|Supervised high-intensity exercise programme|Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
75434836|NCT01553305|Other|Exercise programme|Supervised exercise programme
75434837|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
75582048|NCT04650555|Drug|BIO 300 Oral Powder|Amorphous solid dispersion of genistein milled into a powder
75582049|NCT04650477|Procedure|Fixation while forearm in extension-pronation position|Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
75582050|NCT00553904|Dietary Supplement|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
75582051|NCT05181683|Drug|Casirivimab+Imdevimab|Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
75582052|NCT04650516|Device|Virtual reality|20 minutes treatment in virtual reality
75582053|NCT04650516|Device|Digital control|20 minutes digital control movie on tablet without virtual reality
75729421|NCT02491632|Other|Questionnaire Administration|Ancillary studies
75729422|NCT02270580|Behavioral|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
75880987|NCT01356745|Drug|medical air|inhalation gas for inhalation use
75582054|NCT04650321|Drug|Ocrelizumab at home|Patients will receive ocrelizumab infusion at home.
75582055|NCT05153525|Drug|Intermittent boluses of Cisatracurium|Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
75582056|NCT05153525|Drug|Intravenous infusion of Cisatracurium for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
75582057|NCT04649931|Device|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
75434838|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
75434839|NCT01553357|Drug|Lenalidomide, dexamethasone|"Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.~Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study."
75434840|NCT01553370|Other|Increased Dairy Intake|3 additional servings of low fat dairy will be consumed
75434841|NCT01553370|Other|Supplemental carbohydrate|Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
75434842|NCT01553383|Device|"nasal peep valve Provent"|application of nasal peep valve vs dental device and cpap
75434843|NCT01553422|Other|Fluid therapy (Saline Normal)|Saline Normal 1 Lit. during 30 minutes
75434844|NCT01553422|Other|Fluid therapy (Saline Normal)|saline Normal 1 lit during 30 minutes
75582058|NCT04649970|Procedure|Antegrade double-J stent|After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.
75434845|NCT01553435|Drug|Dextromethorphan|The study medicines shall be administered via tube.
75434846|NCT01553435|Drug|Placebo|The study medicines shall be administered via tube.
75434847|NCT01553448|Genetic|gene expression analysis|
75434848|NCT01553448|Genetic|protein expression analysis|
75434849|NCT01553448|Other|enzyme-linked immunosorbent assay|
75434850|NCT01553448|Other|immunohistochemistry staining method|
75880988|NCT02072798|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
75880989|NCT01361893|Other|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
75582059|NCT05127863|Behavioral|social communication intervention (pragmatic)|10 sessions of group intervention in order to improve pragmatic/social communication. one session of one hour per week. Activities will included role play, conversations, etc.
75582060|NCT04649892|Drug|Naltrexone|Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
75880990|NCT03602885|Behavioral|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
75880991|NCT03602885|Behavioral|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
75880992|NCT01360567|Dietary Supplement|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
75434851|NCT01553448|Other|laboratory biomarker analysis|
75434852|NCT01553448|Other|medical chart review|
75434853|NCT01553487|Other|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
75434854|NCT01553500|Dietary Supplement|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
75434855|NCT01553500|Behavioral|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
75434856|NCT01553513|Other|[18F]-FDG positron emission computed tomography|"Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest."
75582061|NCT04649892|Drug|Placebo|Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
75582062|NCT04649892|Behavioral|Psychoeducational|Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
75582063|NCT04649892|Device|Eye-tracking|"The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~Before taking the first dose of naltrexone or placebo.~One hour after taking the first dose of naltrexone or placebo.~One week after continuous and daily use of naltrexone or placebo.~At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo."
75582064|NCT05125796|Drug|paracetamol|1000 mg intravenous paracetamol in 100 mL normal saline
75582065|NCT05125796|Drug|Dexketoprofen Trometamol|50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline
75582066|NCT05125796|Drug|Lidocaine topical|Application of 5 gr of 5% topical lidocaine
75582067|NCT05125796|Drug|Placebo|100 mL intravenous normal saline infusion+ placebo topical pomade application
75582068|NCT04649814|Other|Questionnaire|Questionnaire for all, interview for part of the respondents.
75582069|NCT04616859|Dietary Supplement|Alcohol and Energy Drink (AmED)|Multiple oral dose of alcohol mixed with ED
75434857|NCT01553513|Procedure|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
75582070|NCT04616859|Dietary Supplement|Alcohol and Energy drink Placebo|Multiple oral dose of alcohol mixed with ED placebo (soft drink)
75582071|NCT04616859|Dietary Supplement|Alcohol placebo and Energy drink|Multiple oral dose of alcohol placebo (water) mixed with ED
75582072|NCT04616859|Dietary Supplement|Alcohol placebo and energy drink placebo|Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
75582073|NCT04616937|Dietary Supplement|GOS|Prebiotic
75582074|NCT04616937|Dietary Supplement|Placebo|Placebo
75582075|NCT05053607|Behavioral|Digital Health Coaching Program|consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
75582076|NCT05053607|Device|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
75582077|NCT04616586|Drug|Siltuximab|11 mg/kg IV administered over 1 hour
75582078|NCT04616586|Other|Normal Saline|IV administered over 1 hour
75582079|NCT04616469|Procedure|Root canal treatment using TruNaomy rotary files|Trunatomy rotary files will be used for the process of cleaning and shaping of the root canal system
75582080|NCT04616469|Procedure|Root canal treatment using race rotary instruments|Race rotary files will be used for the process of cleaning and shaping of the root canal system
75582081|NCT05038787|Drug|LY3473329|Administered orally.
75582082|NCT05038787|Drug|Placebo|Administered orally.
75729423|NCT02270580|Behavioral|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
75880993|NCT01360567|Dietary Supplement|Placebo|500 mg . one capsule of placebo, 3 times per day
75582083|NCT00563043|Procedure|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
75582084|NCT00563121|Procedure|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
75582085|NCT04988321|Procedure|Prolonged continuous theta burst stimulation (pcTBS)|Non-invasive brain stimulation (transcranial magnetic stimulation or TMS) which consists of a stimulating coil being held over the head. When this coil delivers a painless magnetic pulse, it feels like a quick, light tap on the head. Two different coils will be used to perform TMS. One coil will be used to determine stimulation parameters for the pcTBS protocol. The second coil will be used to implement pcTBS, which is a repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on the head. Participants will receive two procedures during one session, one with active stimulation and one with inactive stimulation.
75729424|NCT02086188|Drug|Mirabegron|see detailed information in associated Arm Description
75729425|NCT02086188|Drug|Placebo|Sugar pill manufactured to mimic Mirabegron 25mg tablet.
75582086|NCT04616508|Behavioral|motor control assessment|Basic science study of control of reaching movements
75582087|NCT04616352|Other|Resistance to cefuroxime|Non susceptibility in vitro testing
75729426|NCT02022982|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
75729427|NCT02022982|Drug|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
76051391|NCT02252965|Drug|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
76051392|NCT02252965|Drug|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
76051393|NCT02242435|Biological|4 mL injection of Ampion|4 mL injection of Ampion
76051394|NCT02242435|Drug|4 mL Injection of Placebo|
75582088|NCT00553943|Drug|Rituximab|375 mg/m2 D1
75582089|NCT00553943|Drug|Cytarabine|50 mg D3
75582090|NCT00563160|Drug|gemcitabine, carboplatin|
75582091|NCT00563160|Procedure|surgery|
75582092|NCT00563199|Behavioral|nurse-delivered stage-matched smoking cessation counseling|
75582093|NCT00563238|Drug|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
75582094|NCT04679558|Drug|Chlorhexidine varnish added to the preventive protocol|Antibacterial agent varnish added to the preventive protocol
75582095|NCT04679558|Behavioral|Preventive protocol|Preventive protocol
75582096|NCT03454542|Device|Menicon Modified Lens Design|Randomized in a daily wear, single day (6 hours or more) evaluation
75582097|NCT04934228|Drug|Hydrochlorothiazide 12.5Mg Tab|"Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~Condition/disease indication(s): Hypertension~Subject population: Hypertension~Dose(s): 25 mg/day~Administration: Oral~Dosing regimen: 12.5 mg twice per day"
76051395|NCT02251717|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
76051396|NCT02242201|Drug|PNB Bupivacaine|Infusion
76051397|NCT02242201|Drug|PAI Ropivacaine|Injection
75582098|NCT04934228|Drug|Clonidine Pill|"Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~Condition/disease indication(s): Vascular function and blood flow~Subject population: Hypertension~Dose(s): 0.1 mg (oral)~Administration: Oral~Dosing regimen: 0.1 mg twice daily by mouth"
75582099|NCT04934228|Drug|Placebo|Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
75582100|NCT03454503|Drug|Imatinib|Film coated tablet contains 400 mg imatinib (as mesilate)
75582101|NCT03454464|Procedure|Conventional|Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure
75582102|NCT03454464|Procedure|central neck dissection first|central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
75729428|NCT01854229|Device|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
75729429|NCT01675440|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
75582103|NCT03454386|Behavioral|Stress Management and Resilience Training Program|"This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives."
75582104|NCT03454386|Behavioral|Self-Management Stress Reduction Program|Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
75582105|NCT04915781|Other|Not applicable, this is an observational study|Not applicable, this is an observational study
75582106|NCT04616157|Behavioral|ICBT-I|Cognitive-behavioral therapy for insomnia
75582107|NCT04900844|Device|CGuard Carotid Stent implantation|Implantation of CGuard carotid stent in the eligible patients
75880994|NCT02077244|Behavioral|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
75880995|NCT01361971|Procedure|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
75880996|NCT02880761|Procedure|Assessment guiding surgery and puncture for AVF|Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
75880997|NCT01356823|Biological|30μg HPV|Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
75880998|NCT01356823|Biological|60μg HPV|Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
75434858|NCT01553513|Procedure|Intravascular ultrasound and virtual histology|"During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.~A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.~Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque."
75880999|NCT01356823|Biological|90μg HPV|Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
75881000|NCT01356823|Biological|Hepatitis B vaccine|Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
75881001|NCT02070770|Dietary Supplement|Very low calorie diet|
75881002|NCT02070770|Other|Standard weight loss diet|
75881003|NCT01349153|Behavioral|Facebook-based Messages/Website|Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
75881004|NCT01349153|Behavioral|Facebook-based Self-help Comparison|Twelve weekly messages and a pedometer.
75881005|NCT03635047|Biological|AL002|Single-doses of AL002 in up to 9 dose-escalating cohorts
75881006|NCT03635047|Other|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
75881007|NCT02073032|Other|No intervention, only observation|
76051398|NCT02242201|Drug|PAI liposomal bupivacaine|Injection
76051399|NCT02242201|Drug|Epinephrine|Injection, weight-based dosage of 100 mcg - 300 mcg
76051400|NCT02242201|Drug|Ketorolac|Injection, 30 mg
75582108|NCT04616391|Device|insulin pump Medtronic 780G|"Patients from the AHCL group will use the MiniMed 780G AHCL system. This system is already CE-marked.~The AHCL system will be initiated first in Manual Mode (i.e. without AHCL control) with suspend before low feature (Visit 1).~The AHCL system will be initiated in Auto Mode (i.e. with AHCL control) at Visit 2 with the settings in the below table. The Insulin to Carb ratio (ICR) and the Active Insulin Time (AIT) may be adjusted by the physician during the study. The glucose target may not be adjusted, unless in case of safety concerns. The patients may not adjust system settings without consulting with the physician.~At each visit, the AHCL system data will be downloaded and reviewed by the physician. The patient interaction with the system will be evaluated, included sensor calibration, bolus management (before the meals and for corrections as needed), alarms and Auto Mode exits."
75582109|NCT03455153|Other|Physical activity monitoring|COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
75434859|NCT01553513|Other|Serum biomarkers|"A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers."
75582110|NCT04616430|Drug|Topical endoxifen|topical solution
75582111|NCT04616430|Drug|Placebo|topical
75582112|NCT04891796|Other|No intervention|No intervention
75434860|NCT01553565|Procedure|Cold polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
75434861|NCT01553578|Other|questionnaire administration|Ancillary studies
75582113|NCT04616040|Drug|Camrelizumab|The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.
75582114|NCT04616118|Other|Phone Visit|Participants randomized to this arm will receive usual care via telephone only
75582115|NCT04616118|Other|Video Visit|Participants randomized to this arm will receive usual care via video call
75582116|NCT00553982|Procedure|Patellar component|Resurfacing with onlay technique
76051401|NCT02242045|Drug|Idelalisib|150 mg tablet(s) administered orally twice daily
76051402|NCT02241889|Device|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
76051403|NCT02241889|Device|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
75434862|NCT01553578|Procedure|therapeutic touch|Receive healing touch therapy
75434863|NCT01553578|Behavioral|management of therapy complications|Receive healing touch therapy
75434864|NCT01553578|Behavioral|management of therapy complications|Receive guided imagery audiotapes
75434865|NCT01553578|Procedure|standard follow-up care|Receive standard care
75434866|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the first postoperative day
75434867|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the 6th postoperative day
75582117|NCT00553982|Procedure|No patellar component|Trimming of osteophytes when appropriate
75582118|NCT04615962|Drug|Hydrocortisone Acetate 1% Cream|Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.
75729430|NCT01361399|Drug|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
75582119|NCT04615962|Drug|Mometasone Furoate|Mometasone is a medium-strength corticosteroid.
75582120|NCT04615962|Drug|SNG100|A combination of low potency steroid and skin barrier repair agent
75582121|NCT04881929|Drug|KN026|KN026 in Combination With Docetaxel
75582122|NCT04615767|Dietary Supplement|D-chiro-inositol|as described previously
75582123|NCT04881227|Device|Chatbot on COVID-19 vaccine hesitancy|This intervention will provide to participants information on COVID-19 vaccine hesitancy consisting of the possibility of accessing a long series of questions and answers online about this vaccination.
75582124|NCT04881227|Other|Control intervention|This control intervention will provide to participants a brief text decribing the way vaccines works.
75582125|NCT04615494|Procedure|Position|Pneumoperitoneum with Steep Trendelenburg position
75582126|NCT04616001|Drug|IVIG|Patients will receive IVIG daily for four days.
75582127|NCT04615611|Drug|salbutamol|inhalation of salbutamol
75582128|NCT04615611|Drug|Placebo|administration of placebo
75582129|NCT04615728|Procedure|laparoscopic or open appendicectomy|Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
75582130|NCT04832165|Other|Inspiratory muscle strength training|Inspiratory muscle training during 8 weeks, 30 inspirations at 60% of the PIM (maximum inspiratory pressure), 2 times a day for 5 days per week.
75582131|NCT04798586|Drug|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
75729431|NCT01361399|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
75582132|NCT04798040|Other|cold application|To reduce pain, cold application is applied around the drain before the drain is removed.
75582133|NCT04798040|Other|lavender oil inhalation|To reduce pain, lavender oil is inhaled prior to drain removal.
75582134|NCT04798040|Other|oxygen administration|To reduce pain, oxygen is inhaled prior to drain removal.
75434868|NCT01553617|Drug|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
75434869|NCT01553617|Drug|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
75434870|NCT01553630|Procedure|RIA bone graft|Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
75434871|NCT01553630|Procedure|Surgery without bone graft|Plating of fracture without bone graft
75434872|NCT01553643|Drug|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
75582135|NCT00563277|Procedure|combined pterygium and cataract operation|
75582136|NCT00563277|Procedure|pterygium excision followed by cataract operation|
75582137|NCT04785053|Device|transcranial alternating current stimulation (tACS)|The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
75582138|NCT04614792|Device|Transcranial direct current stimulation|Non-invasive brain stimulation or neuromodulation.
75582139|NCT04776551|Procedure|Percutaneous fixation of acute Scaphoid fractures|Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw
75582140|NCT04614675|Procedure|Distal soft tissue procedure with TALR|TALR group: Transarticular lateral release as the distal soft tissue procedure
75582141|NCT04614675|Procedure|Distal soft tissue procedure with PCLR|PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
75582142|NCT04614285|Procedure|Partial excavation|"Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude."
75582143|NCT04614012|Other|treated with hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
75434873|NCT01553643|Drug|placebo|at a rate of 3g two times per day
76051404|NCT02241733|Behavioral|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
75434874|NCT01553656|Drug|cabozantinib capsules|cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
75434875|NCT01553656|Drug|cabozantinib tablets|cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
75434876|NCT01553669|Behavioral|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
75434877|NCT01553682|Behavioral|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
75582144|NCT04713371|Drug|Keytruda Injectable Product|"Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected."
75582145|NCT04713371|Drug|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected."
75582146|NCT04713371|Drug|Cytoxan|Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.
75582147|NCT04713371|Procedure|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.
75582148|NCT04713371|Drug|GM-CSF Injectable|Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
75582149|NCT04683614|Drug|Norepinephrine|5 mic/kg/hr norepinephrine
75582150|NCT04683614|Biological|Fresh frozen plasma|early administration of fresh frozen plasma
75582151|NCT04613895|Drug|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
75582152|NCT04613895|Drug|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
75582153|NCT04613700|Drug|Secretin|Native hormone
75582154|NCT04613700|Other|Placebo|Saline
75582155|NCT04613544|Device|Voice Assist Arrhythmia Monitoring (VAAM)|application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.
75582156|NCT00563355|Drug|erythropoietin|
75582157|NCT04672109|Device|Transcranial direct current stimulation|Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
75582158|NCT00563394|Drug|ofloxacin|400 mg twice a day for 14 days
75582159|NCT00563394|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
75582160|NCT04660877|Dietary Supplement|Cheddar Cheese|20g of protein from cheddar cheese
75582161|NCT04660877|Dietary Supplement|Milk|20g of protein from milk
75582162|NCT04653350|Other|High Intensity Exercises|Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
75582163|NCT04653350|Other|General Exercises|Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training & balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
75582164|NCT00563433|Drug|ofloxacin|400 mg twice a day for 14 days
75582165|NCT00563433|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
75434878|NCT01553682|Behavioral|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
76051405|NCT02241733|Behavioral|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
75434879|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
75434880|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
75434881|NCT01553721|Drug|udenafil|"Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)"
75434882|NCT01553721|Drug|placebo|Phase IIa - placebo Phase IIb - placebo
75434883|NCT01553760|Procedure|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
75434884|NCT01553760|Procedure|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
75434885|NCT01553773|Drug|isoflavone|treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
75434886|NCT01553773|Drug|Estradiol|a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
75434887|NCT01553786|Drug|Lenalidomide|Lenalidomide
75434888|NCT01553838|Device|MRI guided prostate biopsy and TRUS guided biopsy|MRI guided prostate biopsy
75434889|NCT01553877|Dietary Supplement|Pushti packet|A food composed of roasted rice, roasted lentil, molasses and soybean oil
75434890|NCT01553877|Dietary Supplement|Rice based Ready to Use Complementary Food Supplements|A rice based diet.
75582166|NCT04652102|Biological|CVnCoV|Intramuscular (IM) injection.
75582167|NCT04652102|Biological|Placebo|Intramuscular (IM) injection.
75582168|NCT04652102|Biological|Authorized/licensed vaccines for preventing COVID-19 (AV)|Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
75582169|NCT00563472|Drug|estetrol|10 mg orally per day for 28 days
75582170|NCT00563472|Drug|estetrol|20 mg orally per day for 28 days
75582171|NCT00563472|Drug|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
75582172|NCT00563472|Drug|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
75582173|NCT04679597|Drug|Capecitabine|comparison of two treatments
75582174|NCT00563511|Procedure|adherence intervention|
76051406|NCT02241343|Device|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
76051407|NCT04191577|Drug|CVN424 Low Dose|CVN424
76051408|NCT04191577|Drug|CVN424 High Dose|CVN424
76051409|NCT04191577|Drug|Placebo|Placebo
76051410|NCT02241187|Drug|PEGPH20|
75434891|NCT01553877|Dietary Supplement|Chick-pea based Ready to Use Complementary Food Supplements|A chick-pea based diet.
75434892|NCT01553890|Other|Blood sample|blood sample, venous blood, about 10 ml will be drawn from participants
75434893|NCT01553903|Drug|Tamoxifen,|Tamoxifen 20 mg/day during 5 years,
75434894|NCT01553903|Drug|Exemestane|Exemestane 25mg/day during 5 years
75434895|NCT01553903|Drug|Anastrozole|Anastrozole 1 mg/day during 5 years,
75434896|NCT01553903|Drug|Letrozole|Letrozole 2.5 mg/day during 5 years,
75434897|NCT01553929|Other|Physical Training and cognitive activity (EPC group)|The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
75434898|NCT01553929|Other|Physical training (EP group)|The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
75582175|NCT00563511|Procedure|intervention without adherence advice|
75434899|NCT01553929|Other|control group|no physical training and no cognitive activity
75434900|NCT01553942|Drug|Afatinib|induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
75582176|NCT00563511|Procedure|control|
75582177|NCT04613856|Other|Hydration protocol - 237 mL water bolus|Subjects consume 237 mL of water every 20 minutes during 2 hours of high intensity work in the heat.
75729432|NCT01361399|Drug|Lidocain|Single oral application of Lidocain (as lozenge)
76051411|NCT02241187|Drug|Cetuximab|
76051412|NCT02241187|Device|DW & DCE-MRI|
76051413|NCT02241187|Other|blood draws|Blood samples will be drawn at various time points.
76051414|NCT02249767|Drug|Tretinoin|Treatment of acne once daily in evening
76051415|NCT02239939|Behavioral|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
75582178|NCT04613856|Other|Hydration protocol - 500 mL water bolus|Subjects consume 500 mL of water every 40 minutes during 2 hours of high intensity work in the heat.
75582179|NCT04609397|Drug|Hemay005|Hemay005 tables 60mg bid p.o;
75582180|NCT04609397|Drug|Hemay005|Hemay005 tables 45mg bid p.o
75582181|NCT04609397|Other|Placebo|placebo to Hemay005 tables bid p.o
75582182|NCT04613193|Other|Blood presssure reduction|Patients will be uptitrated in antihypertensive treatment until the treatment target is achieved.
76051416|NCT02239939|Behavioral|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
76051417|NCT02248675|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
75434901|NCT01553942|Radiation|Radiation|Daily, Monday-Friday
75434902|NCT01553942|Drug|Cisplatin|Day 1 of each cycle, IV infusion over 60 minutes
75434903|NCT01553942|Drug|Pemetrexed|Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
75434904|NCT01553942|Procedure|Surgery|Surgery to remove tumor
75434905|NCT01553955|Procedure|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
75434906|NCT01553968|Other|Cycling|30 minutes of cycling at 50% of predetermined maximal performance
75434907|NCT01553981|Drug|Tadalafil|Tab. Tadalafil 20 mg every other day for 6 months
75434908|NCT01553981|Drug|Placebo|Shape , size, color and odor matched Tab. of inert material every other day for 6 months
75434909|NCT01554007|Other|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
75434910|NCT01554020|Dietary Supplement|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
75434911|NCT01554020|Dietary Supplement|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
75434912|NCT01554059|Drug|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
75434913|NCT01554059|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly * 6 doses 3-4 weeks after radical resection
75434914|NCT01554059|Drug|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
75434915|NCT01554059|Radiation|Radiotherapy|2GY daily *20次
75434916|NCT01554072|Other|Home based pulmonary rehabilitation with exercise|After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
75434917|NCT01554085|Drug|ALS-002158|ALS-002158
75434918|NCT01554085|Drug|Placebo|placebo
75582183|NCT04587947|Drug|sacubitril/ valsartan|Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment
75582184|NCT04613310|Diagnostic Test|Rapid Diagnostic Test vs PCR|4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
75582185|NCT04578080|Device|Transcranial direct current stimulation|Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
75582186|NCT04612998|Other|left lateral decubitus position|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
75582187|NCT04612998|Other|sitting position|Active control group consisted of patients performing CSEA in the sitting position.
75582188|NCT04612998|Drug|The use of intravenous ephedrine.|Intravenous ephedrine (6 mg) was used to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) during surgery.
75582189|NCT04612998|Drug|The use of intravenous atropine.|Intravenous atropine (1 mg) was given in case of bradycardia (the heart rate < 45 beats/minute) during surgery.
75582190|NCT04612998|Drug|The use of intravenous metoclopramide|When nausea and vomiting were observed, intravenous metoclopramide (10 mg) was administered.
75582191|NCT04545476|Device|Participants in this group will receive the experimental APIS Biomaterial on the Head.|One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
75582192|NCT04545476|Device|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.|One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
75582193|NCT04545476|Other|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
75434919|NCT01554098|Procedure|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
75434920|NCT01554098|Procedure|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
75434921|NCT01554111|Drug|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
75434922|NCT01554111|Drug|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
75434923|NCT01554111|Drug|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
75434924|NCT01554124|Drug|Meropenem|"40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
75434925|NCT01554137|Other|isokinetic strength training|The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
75434926|NCT01554137|Other|passive motion|The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
75582194|NCT04545476|Other|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
75434927|NCT01554150|Behavioral|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
75582195|NCT00563589|Drug|mycophenolate mofetil, methotrexate, cyclosporin|
75582196|NCT00563589|Drug|Methotrexate and cyclosporin|
75582197|NCT00563628|Device|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
75582198|NCT04492670|Procedure|Tui-na|For administering of Tui-na manipulation practice, responsible Tui-na CMP must have at least 2 years of clinical experience. The pre-trial workshops led by a senior practitioner will be organized to ensure standardization of Tui-na treatment manipulation and procedures.
75582199|NCT04492670|Drug|Du-Huo-Ji-Sheng-Tang (DHJST)|This study medication is derived from Du-Huo-Ji-Sheng-Tang (DHJST) and concentrated Chinese Medicine granules will be used.
75582200|NCT00563667|Procedure|pterygium excision|
75434928|NCT01554189|Drug|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
75582201|NCT04613037|Biological|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
75582202|NCT04612842|Behavioral|Motivational Interviewing|The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
75582203|NCT04612881|Drug|fitostimoline vaginal pessaries|vaginal pessaries
75582204|NCT04612881|Other|standard of care|standard of care
75582205|NCT04464161|Dietary Supplement|Ensure|Ensure protein is a complete nutritional drink with 10g, 240 calories, and 27 vitamins and minerals. It is often used as a nutritional supplementation in many hospitals.
75582206|NCT04612959|Other|Psychosexual care|The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions.The psychosexual caring program includes psycho-education and sexual counseling.
75582207|NCT04612803|Drug|Antihistamine|Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
75582208|NCT02204345|Drug|Carboplatin|Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
75582209|NCT02204345|Drug|Paclitaxel|Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
75582210|NCT02204345|Drug|RO5479599|RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
75582211|NCT04612647|Other|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)
75582212|NCT04612647|Behavioral|Physical Activities & Activity Booklets|expected to engage in physical activity at least 3 hours per week
75582213|NCT02187302|Drug|CRLX101|
75582214|NCT02187302|Drug|Bevacizumab|
75582215|NCT02187302|Drug|Standard of Care (Investigator Choice)|
75582216|NCT02179151|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
75582217|NCT02179151|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
75729433|NCT01361399|Drug|Placebo|Single oral application of Placebo (as lozenge)
75434929|NCT01554189|Drug|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
75582218|NCT02163746|Procedure|CO2 (carbon dioxide) laser|
75582219|NCT02163746|Procedure|Surgical Deroofing|
75582220|NCT02160665|Drug|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
75582221|NCT02160665|Drug|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
76051418|NCT02248675|Other|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
76051419|NCT04783441|Device|Dexcom G6|access to continuous glucose monitoring in the Dexcom G6 arm 24/7
75434930|NCT01554202|Behavioral|assessment of memory|
75434931|NCT01554202|Biological|circulating tPA dosage|
75434932|NCT01554202|Genetic|ApoE4|
75434933|NCT01554202|Other|Brain imaging examination MRI and PET examinations|
75434934|NCT01554215|Behavioral|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
75434935|NCT01554215|Behavioral|Mom Power Attentional Control Group|at home control, weekly mailings
75434936|NCT01554228|Other|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
75434937|NCT01554254|Drug|TXA127|300mcg/kg/day, subcutaneous injection for up to 28 days
75434938|NCT01554267|Device|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
75582222|NCT02160665|Drug|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
75582223|NCT04611984|Procedure|Piezocision|Piezocisions were performed on the mesial and distal sides of the right maxillary canines. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
75582224|NCT04611984|Procedure|Control|The mesial and distal sides of the left maxillary canines served as controls and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
75582225|NCT04633707|Device|adjunctive bright white light therapy in the morning|the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00~9:00) for 6 weeks.
75582226|NCT04633707|Device|adjunctive bright white light therapy in the afternoon|the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00~14:00) for 6 weeks.
75582227|NCT04633707|Device|adjunctive dim red light therapy in the afternoon|the participants received dim red light therapy (light intensity: <100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00~14:00) for 6 weeks.
75582228|NCT02138630|Dietary Supplement|Capsaicin|
75729434|NCT01332682|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
75582229|NCT02138630|Dietary Supplement|Placebo|Sugar capsule
75582230|NCT04612023|Other|Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)|Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
75582231|NCT02137343|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
75582232|NCT02137343|Drug|Placebo|Placebo
75434939|NCT01554280|Device|Fully coated, removable , self-expanding oesophageal stent|Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
75434940|NCT01554293|Drug|Matching placebo|Matching Placebo, single dose
75434941|NCT01554293|Drug|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
75434942|NCT01554332|Device|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
75434943|NCT01554345|Drug|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
75434944|NCT01554358|Behavioral|Lifestyle intervention|"The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~--------------------------------------------------------------------------------"
75434945|NCT01554384|Procedure|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
75582233|NCT02137343|Drug|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
75582234|NCT02137343|Drug|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
75582235|NCT02125253|Drug|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
75582236|NCT02125253|Drug|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
75729435|NCT01332682|Behavioral|Resistance Training and Nutrition Counseling|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
75729436|NCT01116622|Drug|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
75729437|NCT01116622|Drug|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
75729438|NCT01064479|Drug|Carboplatin|Given IV
75729439|NCT01064479|Drug|Cisplatin|Given IV
75729440|NCT01064479|Drug|Docetaxel|Given IV
75729441|NCT01064479|Drug|Erlotinib Hydrochloride|Given PO
75729442|NCT01064479|Other|Laboratory Biomarker Analysis|Optional correlative studies
75434946|NCT01554384|Procedure|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
75434947|NCT01554397|Radiation|Intensity Modulated Radiation Therapy (IMRT)|45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
75434948|NCT01554397|Drug|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
75434949|NCT01554423|Other|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
75729443|NCT01064479|Other|Pharmacological Study|Optional correlative studies
75729444|NCT01064479|Other|Placebo|Given PO
75582237|NCT02125253|Drug|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
75582238|NCT02116244|Drug|Civamide Nasal Spray|
75434950|NCT01554423|Behavioral|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
75434951|NCT01554423|Behavioral|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
75729445|NCT01064479|Other|Quality-of-Life Assessment|Ancillary studies
75729446|NCT00640978|Drug|RAD001|30 mg orally weekly for 4 weeks
75729447|NCT00640978|Drug|Erlotinib|150 mg by mouth daily for 28 Days
75434952|NCT01554436|Behavioral|neuropsychological assessment|"The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test"
75434953|NCT01554449|Procedure|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
75434954|NCT01554449|Procedure|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
75434955|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA + 650 mg DHA daily
75434956|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in ADHD group|Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
75729448|NCT00449748|Drug|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
75434957|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA and 650 mg DHA daily
75434958|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in healthy control group|Placebo contains MUFA in stead of PUFA, same energy value
75434959|NCT01554319|Drug|SB010|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL."
75434960|NCT01554319|Drug|Placebo (phosphate-buffered saline)|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board."
75729449|NCT00241098|Drug|valsartan|
75729450|NCT00171015|Drug|valsartan plus hydrochlorothiazide|
75729451|NCT03999255|Procedure|combined respiratory support (CRS)|combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
76024916|NCT01977898|Drug|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
76024917|NCT01977898|Drug|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
76051420|NCT04783441|Device|Dexcom G6 blinded sensor|retrospective access to continuous glucose profile after 10 days of wear
76051421|NCT02238379|Drug|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
76051422|NCT02238379|Other|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
76051423|NCT02238067|Drug|ESA|Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
76051424|NCT02238067|Other|Satisfaction Survey Questionnaire|Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
75434961|NCT01554540|Drug|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
75434962|NCT01554553|Procedure|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
75434963|NCT01554566|Dietary Supplement|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
75434964|NCT01554592|Drug|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
75434965|NCT01554592|Drug|Statin therapy|Participants will continue on stable statin therapy.
75434966|NCT01554631|Drug|Acarbose (Glucobay ODT, BAYG5421)|
75434967|NCT01554631|Drug|Acarbose (Glucobay, BAYG5421)|
76051425|NCT02237911|Other|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
75434968|NCT01554644|Device|Prontosan|Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
75434969|NCT01554644|Device|Saline|Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
75434970|NCT01554657|Other|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
76024918|NCT02393287|Other|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
76051426|NCT02237911|Other|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
76051427|NCT02234479|Biological|Hydrophor (Group A)|"Rehydrates dry, chapped or chafed skin~May be used alone as a skin lubricant or protectant"
76051428|NCT02234479|Biological|MediHoney (Group B)|"It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:~Maintain a balanced environment for healing.~Aids in reducing dermatitis.~Reduce affected area pH.2-3"
76051429|NCT02207491|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
76051430|NCT02207491|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
76051431|NCT02207491|Other|Placebo|1 drop QD, AM, OU
76051432|NCT02315066|Drug|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
75582239|NCT04633083|Other|Data collection|"Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data."
75434971|NCT01554657|Other|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
75434972|NCT01554670|Procedure|RF micro-tenotomy|an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
75434973|NCT01554709|Device|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
75434974|NCT01554722|Procedure|Needle placement|In plane versus out of plane needle placement techniques
75582240|NCT02114060|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
75582241|NCT02114060|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
75582242|NCT02114060|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
75582243|NCT02114060|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
75729452|NCT05225961|Drug|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
75729453|NCT05225961|Drug|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
75582244|NCT02114060|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
75582245|NCT02114060|Biological|Placebo|0.9% Normal Saline (NaCl)
75582246|NCT04677998|Procedure|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.
75582247|NCT00560898|Drug|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
75434975|NCT01554735|Behavioral|Exercise and diet|24 weeks of exercise and diet counselling
75582248|NCT00560898|Drug|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
75582249|NCT00560898|Drug|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
75582250|NCT00560898|Drug|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
75582251|NCT02104388|Drug|SJP-0035 Ophthalmic Solution|
75582252|NCT02104388|Drug|Vehicle of SJP-0035 Ophthalmic Solution|
75582253|NCT04611828|Device|Philips SmartSleep|closed-loop auditory stimulation
75434976|NCT01554748|Procedure|Total joint arthroplasty|
75434977|NCT01554761|Procedure|phacoemulsification|After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).
75729454|NCT00556998|Drug|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
75582254|NCT04678037|Behavioral|PROs assessment using sickle cell disease mobile app (SCD-app)|A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
75582255|NCT04633044|Dietary Supplement|Betaine|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
75582256|NCT04633044|Dietary Supplement|Placebo|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
75729455|NCT00528801|Behavioral|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
75729456|NCT00528801|Procedure|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
76051433|NCT02315066|Drug|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
76051434|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
75434978|NCT01554761|Device|Pentacam (Oculus,Germany)examination|Total corneal astigmatism is obtained by Pentacam at every visit.
75434979|NCT01554787|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus(AM)at a rate of 2.8g three times per day
75434980|NCT01554787|Other|Placebo|at a rate of 2.8g three times per day
75434981|NCT01554800|Drug|ACP-501|A single dose infusion
75434982|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
75434983|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
75434984|NCT01554813|Biological|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
75582257|NCT02104076|Device|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
75729457|NCT01564563|Drug|standard therapy|Standard treatment of bleeding
75729458|NCT01564563|Drug|placebo|Placebo
75729459|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
75582258|NCT04632849|Behavioral|GEM + CGM|Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
75729460|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
76051435|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
76051436|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
75582259|NCT04611438|Drug|Cannabidiol|"Intervention schedule for each patient is as follows:~Baseline Phase (2 weeks) Baseline Phase starts from the screening visit, where the patient and caregiver write permission to the trial and goes through laboratory, electroencephalography, and neuropsychological tests.~Treatment Period: Titration (2 weeks) + stabilization period (10 weeks) + maintenance period (12 weeks)~Titration: The patient would start cannabidiol on 5mg/kg/mg for 1 week and titrate dosage up to 10mg/kg/day for second week with the caregiver monitoring the patient's tolerability~Stabilization: caregiver monitoring the patient's tolerability, with no change in medication dosage~Maintenance: no change in medication dosage"
75582260|NCT02096666|Drug|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
75582261|NCT04632693|Procedure|CAF with SCTG and Vitamin C injection|Injection of vitamin C after CAF with SCTG aiming to increase gingival thickness in patients with RT1 gingival recession.
75582262|NCT04632693|Procedure|CAF with SCTG alone|Coronally advanced flap with subepithelial connective tissue graft.
75582263|NCT02093429|Drug|INCB047986|INCB047986 will be supplied as tablets.
75434985|NCT01554826|Biological|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
75582264|NCT00563745|Device|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
75434986|NCT01554826|Biological|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
75434987|NCT01554839|Behavioral|"Family of Heroes"|One hour online educational tool
75434988|NCT01554839|Behavioral|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
75434989|NCT01554852|Drug|Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
75582265|NCT04677764|Other|virtual reality|Wii Fit balance board (Nintendo Inc., Kyoto, Japan).
75582266|NCT04677764|Other|Standard of care|physical therapy and occupational therapy exercises either at their own home or a gym
75582267|NCT00563823|Drug|vatalanib|
75582268|NCT04677686|Behavioral|Bundle of Care|Hair removal with Clipper Glucose Control Preoperative antibiotics Repeat antibiotics after 4 Hours Optimize Body temperature Instrument change for colorectal anastomosis Use of wound protectors Experienced surgeon Preoperative showering
75582269|NCT00563862|Procedure|Conventional RT|
76051437|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
76051438|NCT02309372|Behavioral|Beating the Blues|Computerized depression treatment intervention
75582270|NCT00563862|Procedure|Accelerated RT|
75582271|NCT00563862|Drug|Cisplatin|
75582272|NCT00563862|Drug|5-fluorouracil|
75729461|NCT00945204|Other|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
75729462|NCT00945360|Drug|Letrozole (aromatase inhibitor)|Letrozole at a dose of 2.5 mg/day for 8 weeks.
75582273|NCT04677842|Drug|ART Therapy|
75582274|NCT04632342|Drug|HL301 tablet 300mg|"Experimental group 1 : 2 tablets at once, twice a day~Experimental group 2 : 2 tablets at once, three times a day"
76051439|NCT02276027|Drug|BYL719|BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
75434990|NCT01554852|Drug|Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
75582275|NCT04632342|Drug|Placebo of HL301 tablet|2 tablets at once, three times a day
75582276|NCT04611711|Drug|decitabine＋ TQB2450 injection|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
75729463|NCT00943566|Drug|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
76051440|NCT02276027|Drug|INC280|INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
76051441|NCT02276027|Drug|LDK378|LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
75434991|NCT01554852|Drug|Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1 & 2, 8 & 9, 15 & 16 - carfilzomib 20*/36 mg/m2** IV (*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; **carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 & 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
75434992|NCT01554852|Drug|Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
75434993|NCT01554852|Drug|Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
75434994|NCT01554852|Drug|Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Days 1, 4, 8 & 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 & 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
75582277|NCT04611711|Drug|decitabine＋ TQB2450 injection＋Anlotinib|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition. "
75582278|NCT00554879|Procedure|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
75582279|NCT00554879|Procedure|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
75582280|NCT04632537|Drug|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.
75582281|NCT04632537|Drug|Preservative-free saline|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
76051442|NCT02276027|Drug|MEK162|MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
76051443|NCT02309294|Device|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
76051444|NCT02309294|Device|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
76051445|NCT02309294|Device|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
76051446|NCT02309294|Device|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
75582282|NCT02092922|Drug|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
75582283|NCT02092922|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
75582284|NCT04611594|Behavioral|Fluid restriction|Ingestion of approximately 20 ml / kg of ideal weight,
75582285|NCT02092454|Drug|Benzocaine|topical otic solution
75582286|NCT02092454|Drug|Placebo|topical otic solution
76051447|NCT02309294|Device|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
75434995|NCT01554852|Drug|Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
75582287|NCT02083289|Drug|ONO-9054|
75434996|NCT01554852|Drug|Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 & 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
75434997|NCT01554852|Drug|High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)|High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
75434998|NCT01554865|Dietary Supplement|Optifast|1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
75582288|NCT02083289|Drug|Latanoprost|
75582289|NCT02081300|Drug|Oral testosterone undecanoate, LPCN 1021|
75582290|NCT02081300|Drug|Topical testosterone gel 1.62 %|
75729464|NCT00943566|Drug|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
75729465|NCT00943644|Device|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
75729466|NCT00943644|Device|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
76051448|NCT02233543|Drug|QVA149|Delivered once daily via single-dose dry powder inhaler
75434999|NCT01554865|Behavioral|Conventional diet counseling|
75435000|NCT01554878|Procedure|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
75729467|NCT01008657|Procedure|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
75435001|NCT01554917|Drug|Iguratimod|taken orally, 2 tablets/day (bid)
75435002|NCT01554930|Drug|Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)|Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
76051449|NCT02233543|Drug|QVA149 Placebo|Placebo delivered once daily via single-dose dry powder inhaler
75435003|NCT01554930|Drug|Xiyanping injection plus western therapy|Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
75435004|NCT01554943|Other|cardiac MRI|Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
75582291|NCT04611360|Other|Anodal Transcranial Direct Current Stimulation Group|"Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used"
76051450|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
75582292|NCT04611360|Other|Conventional Training Exercises Group|Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
75582293|NCT04677881|Other|Intervention group|intervention group: bread with sourdough control group: bread with yeast
75582294|NCT02074007|Drug|AR01|drops administered as needed for pain
75582295|NCT02074007|Drug|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
75582296|NCT00563979|Dietary Supplement|VitaluxPlus®|1 tablet daily
75582297|NCT00563979|Dietary Supplement|Omega 3|1 tablet daily
75582298|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
75582299|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
75582300|NCT04611204|Other|Descriptive cohort|NT-proBNP assay, electrocardiogram and transthoracic echocardiography before CTS surgery release. Pathological analysis for amyloid deposits of transverse carpal ligament of patients included.
75582301|NCT00554918|Drug|docetaxel|
76051451|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
76051452|NCT04761133|Drug|Povidone-Iodine pleural irrigation|Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
76051453|NCT02233309|Other|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
76051454|NCT02204917|Drug|OPTISON|Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
76051455|NCT02280044|Biological|Rifaximin intervention|Rifaximin administered then Challenge with C jejuni
76051456|NCT02280044|Biological|Placebo intervention|Placebo administered then Challenge with C jejuni
75435005|NCT01554969|Drug|capecitabine + ganetespib|"Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily."
75582302|NCT00554918|Drug|prednisolone|
75582303|NCT00554918|Drug|zoledronic acid|
75582304|NCT00554918|Procedure|quality-of-life assessment|
75582305|NCT00554918|Radiation|strontium chloride Sr 89|
75582306|NCT04632147|Other|Ujjayi pranayama, Nadi-Shodhana pranayama, Sukha pranayama|Ujjayi pranayama:It is a pranayamic application that is performed by slightly twisting the throat and breathing through the nose. Nadi shodhana pranayama is breathing alternately through the right and left nostrils.Sukha pranayama is inhaled through the nose for 5 seconds, then given through the nose for 5 seconds. Thus, 6 times of inspiration and expiration is done per minute.
75582307|NCT04632108|Drug|ASKB589 Injection|ASKB589 Injection with dose escalation stage of 0.3mg/kg up to10mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
75582308|NCT02061332|Biological|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
75582309|NCT04631874|Drug|CDFF0318, Champix|CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
75435006|NCT01554995|Drug|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
75582310|NCT02057315|Drug|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
75435007|NCT01554995|Drug|Linezolid|Linezolid 600 mg (Cohort 9) none
76051457|NCT04748653|Behavioral|Multi-component reintegration intervention|The intervention incorporates health education, psychosocial counseling, physiotherapy and economic investment.
76051458|NCT02308748|Drug|Dofetilide|"8 am: Placebo~12 pm (noon): 250 µg~5:30 pm: 250 µg"
76051459|NCT02308748|Drug|Mexiletine|"8 am: weight x 4 mg/kg~12 pm (noon): Same as at 8 am~5:30 pm: Same as at 8 am"
76051460|NCT02308748|Drug|Lidocaine|"9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes"
76051461|NCT02308748|Drug|Moxifloxacin|"9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)"
76051462|NCT02308748|Drug|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
75435008|NCT01555008|Drug|LX4211|Subjects will receive LX4211 once daily for 7 days
75435009|NCT01555008|Drug|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
75582311|NCT02057315|Drug|Placebo|One dose of matching placebo over 3 bilateral applications.
75582312|NCT04610931|Behavioral|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.~In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level."
75582313|NCT04610931|Behavioral|cognitive behavior therapy|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups."
75582314|NCT02053103|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
75582315|NCT02053103|Drug|Placebo|Tablet, 0 mg, twice daily, 6 weeks
75582316|NCT02049164|Drug|AR08|
75582317|NCT02049164|Drug|Placebo|
75435010|NCT01555021|Genetic|Genotyping assays|"Patients will provide blood samples at the beginning of the study. If the patient is in the AGT group (as opposed to the TAU group), their blood samples will be sent for genotyping immediately. AGT psychiatrists will be given the results of genotyping within 3-5 days in order to decide which antidepressants to use long-term and at what doses. Patients in the Treatment as Usual group will have their blood samples stored for future analysis. Both groups will provide saliva samples for GWAS analysis at a alter date; however, since the study was terminated early, GWAS testing for both groups and genotyping for the TAU group were not performed.~Patients will receive questionnaires to measure their mood, side effects, and symptoms.~Patients will be asked to participate in 3 follow-up phone calls (1 month, 3 months, and 6 months) to measure their mood."
75582318|NCT02047214|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
75435011|NCT01555034|Behavioral|movement therapy|exercise, nutrition, movement therapy
75435012|NCT01555034|Other|exercise plus nutrition|exercise, nutrition
75729468|NCT00940680|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
75729469|NCT00940680|Drug|Losartan|losartan 100mg q.d.
75729470|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
76024919|NCT02392975|Procedure|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
76051463|NCT02308748|Drug|Placebo|Placebo (#2 Gelcap or IV saline)
75435013|NCT01555047|Procedure|IUI|intrauterine insemination
75435014|NCT01555047|Procedure|IUI|intrauterine insemination
75435015|NCT01555060|Dietary Supplement|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
75435016|NCT01555086|Procedure|Limited pelvic Lymphadenectomy|approximately 10-14 lymph nodes are removed
75435017|NCT01555086|Procedure|Extended pelvic Lymphadenectomy|approximately 20 lymph nodes are removed
75435018|NCT01555099|Drug|AZD5423|oral inhaled
75435019|NCT01555099|Drug|Budesonide|oral inhaled
75435020|NCT01555099|Drug|Placebo|oral inhaled
75582319|NCT02047214|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
75729471|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
75729472|NCT01564719|Behavioral|Holistic health|The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
75729473|NCT00940758|Drug|PEP02|Dose escalation: 50-100 mg/m2 biweekly
76024920|NCT02392975|Procedure|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
76024921|NCT02003638|Drug|Niacin|Niacin titrated to 6000 mg daily
76024922|NCT02003638|Drug|Placebo|Placebo provided in the same pill quantity as niacin arm
76051464|NCT04745689|Drug|Durvalumab|"IV infusions through induction phase.~IV infusions through maintenance phase until PD or other discontinuation criteria."
76051465|NCT04745689|Drug|AZD2811|IV infusions through maintenance phase until PD or other discontinuation criteria.
76051466|NCT04745689|Drug|Carboplatin|IV infusions through induction phase if chosen by Investigator.
76051467|NCT04745689|Drug|Cisplatin|IV infusions through induction phase if chosen by Investigator.
76051468|NCT04745689|Drug|Etoposide|IV infusions through induction phase.
76051469|NCT04768543|Device|Upper airway stimulation (Inspire Medical Systems, Inc.)|phasic hypoglossal nerve stimulation device
75435021|NCT01555112|Drug|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
75435022|NCT01555190|Drug|myo-inositol 1500 gr|
75435023|NCT01555190|Drug|myo-inositol 2000 gr + folic acid 200 mcg|
75582320|NCT04632186|Device|EXOPULSE Mollii suit|"All sessions start with rated perceived pain with the NRS and the ShoulderQ questionnaire and assessed body function with the Fugl-Meyer UE scale, Ashworth scale and the Neuroflexor, before the start of the intervention.~Session 1. Stimulation with TENS according to best clinical practice. Session 2. Stimulation with the Mollii suit according to current best experienced practice with selective stimulation directed to the shoulder region Session 3. Stimulation using the full body Mollii suit according to current best experienced practice.~Outcome of each session is assessed with a pain drawing, the NRS (during and after treatment) and the Fugl-Meyer UE, Ashworth scale and the Neuroflexor (after treatment)."
75582321|NCT04631991|Diagnostic Test|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
75582322|NCT04631757|Drug|Camrelizumab + SOX + Radiotherapy|Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
75881008|NCT04943549|Drug|Bupivacain|Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
76051470|NCT01646216|Behavioral|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
76051471|NCT02308124|Drug|Midodrine|
76051472|NCT02308124|Drug|Pyridostigmine Bromide|
76051473|NCT02308124|Drug|Midodrine + pyridostigmine|
76051474|NCT02232061|Drug|Fingolimod|Fingolimod 0.5 mg tablet
76051475|NCT02275481|Drug|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
76051476|NCT02275481|Drug|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
75582323|NCT02032277|Drug|Cyclophosphamide|Cyclophosphamide
75582324|NCT02032277|Drug|Placebo|Placebo for Carboplatin
75582325|NCT02032277|Drug|Doxorubicin|Doxorubicin
75582326|NCT02032277|Drug|Paclitaxel|Paclitaxel
75582327|NCT02032277|Drug|Carboplatin|Carboplatin
75582328|NCT02032277|Drug|Veliparib|Veliparib
75582329|NCT02032277|Drug|Placebo|Placebo for Veliparib
75582330|NCT04611009|Behavioral|motor training|In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.
75582331|NCT04611009|Behavioral|mindfulness exercises|The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
76051477|NCT02204449|Behavioral|Cardiac Rehabilitation Peer Mentorship|
76051478|NCT02308046|Drug|Terconazole|
76051479|NCT02308046|Drug|Placebo|
76051480|NCT02318693|Drug|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
76051481|NCT02318693|Drug|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
76051482|NCT02230891|Drug|Carvedilol|Carvedilol is a non selective beta blocker
75582332|NCT00560976|Drug|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
76051483|NCT02230891|Drug|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
76051484|NCT02230891|Other|Usual care|standard care as per primary care provider
76051485|NCT01646138|Biological|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
75582333|NCT02026349|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
75582334|NCT02026349|Drug|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
75582335|NCT04611048|Diagnostic Test|Thermal QST (CDT, WDT, CPT, HPT) with the method of limits|The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
75582336|NCT04611048|Diagnostic Test|Thermal QST (cold and warm detection, heat pain) with the psi method|The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom & Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
75582337|NCT04611048|Diagnostic Test|Neurological examination|A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, & Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
76051486|NCT02204371|Drug|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
76051487|NCT02204371|Drug|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
75435024|NCT01555203|Behavioral|liveWell: A healthy foundation for life|"liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.~In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI."
75435025|NCT01555216|Drug|Single injection posterior tibial nerve block|5 ml of 0.5% ropivacaine
75435026|NCT01555216|Drug|Posterior tibial nerve catheter|5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
75435027|NCT01555229|Device|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
76051488|NCT02274857|Procedure|Standard PVI Ablation|Standard PVI procedure without FIRMap.
76051489|NCT02274857|Procedure|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
76051490|NCT02302859|Drug|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
76051491|NCT02302859|Behavioral|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
76051492|NCT02302859|Other|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
75435028|NCT01555229|Device|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
75435029|NCT01555242|Drug|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
75435030|NCT01555307|Other|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
75435031|NCT01555307|Other|Typical group|Seven typical exercises, 10 times each, 3 times a day
75435032|NCT01555320|Drug|Qishen Yiqi Dripping Pills|One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
75582338|NCT04611126|Drug|Ipilimumab|Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.
75729474|NCT01792752|Behavioral|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
75582339|NCT04611126|Drug|Cyclophosphamid|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
75582340|NCT04611126|Drug|Fludarabine Phosphate|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
75582341|NCT04611126|Biological|Tumor Infiltrating Lymphocytes infusion|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
75582342|NCT04611126|Drug|Nivolumab|Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
75582343|NCT04611126|Drug|Relatlimab|Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
75582344|NCT04611165|Drug|Nivolumab|"Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~EBRT begins 2-7 days after the first dose of nivolumab.~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
75435033|NCT01555320|Drug|Qishen Yiqi dripping pills dummy|One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
75435034|NCT01555333|Drug|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
76051493|NCT02302859|Behavioral|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time."
75582345|NCT02014649|Drug|20 mg laninamivir octanoate|
75582346|NCT02014649|Drug|Placebo|
75582347|NCT02014649|Drug|40 mg laninamivir octanoate|
75582348|NCT02014142|Drug|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
76051494|NCT02302859|Other|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
76051495|NCT02302859|Device|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
76051496|NCT02274311|Drug|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
76051497|NCT02316353|Biological|C1-esterase inhibitor|
76051498|NCT02273141|Drug|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
76051499|NCT02273141|Drug|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
76051500|NCT02314052|Drug|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety"
76051501|NCT02279732|Biological|Paclitaxel|
76051502|NCT02279732|Biological|Carboplatin|
76051503|NCT02279732|Biological|Ipilimumab|
76051504|NCT02279732|Other|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
76051505|NCT05650034|Radiation|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H&N SCCs ( pN0 or by PETCT).
76051506|NCT02279498|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
76051507|NCT02279498|Drug|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
75582349|NCT04631328|Other|Growing Together|Growing Together is a suite of free, online research-informed professional development modules to help early childhood educators promote deeper family engagement and enrich teacher-parent interactions.
75582350|NCT04631250|Drug|5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form|5-Aminolevulinic Acid was applied to both sides of the face.
75582351|NCT02009423|Drug|Masitinib|
75582352|NCT02009423|Drug|Placebo|
75582353|NCT04610619|Other|Immunological challenge|In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
75582354|NCT02006030|Drug|ADI-PEG 20|
75582355|NCT02006030|Drug|Transarterial chemoembolization|
75582356|NCT04631094|Other|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the serrated ball during the blood draw.
75582357|NCT04631094|Other|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the serrated ball during the blood draw.
75582358|NCT04631094|Other|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the smooth ball during the blood draw.
75582359|NCT04631094|Other|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the smooth ball during the blood draw.
75881009|NCT02070848|Other|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
76051508|NCT02307266|Behavioral|Standard of care + supplementary education|
76051509|NCT02307266|Behavioral|Standard of care + additional visits|
76051510|NCT02307266|Behavioral|Standard of care|
76051511|NCT02279420|Device|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
76051512|NCT04877132|Drug|olipudase alfa (GZ402665)|Patients will receive intravenous (IV) infusion of olipudase alfa
75435035|NCT01555372|Device|Hook Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
75435036|NCT01555372|Device|Locking Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
75435037|NCT01555385|Dietary Supplement|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
75435038|NCT01555398|Dietary Supplement|HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions|The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
75435039|NCT01555424|Dietary Supplement|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
75435040|NCT01555424|Dietary Supplement|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
75582360|NCT03455036|Other|Whole body vibration training|10 x 1 min whole body vibration exposure
75582361|NCT01998035|Drug|Romidepsin|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10, 14 mg/m2)"
75582362|NCT01998035|Drug|Oral 5-Azacitidine|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100, 200, 300 mg)"
75582363|NCT04630899|Other|Active joint mobilization|The participants bend his knees in a prone position. The physical therapist holds the medial malleolus with one hand and the lateral malleolus with the other. At the same time, the physical therapist touches the participant's soles to the sternum area and presses them in the dorsal direction. At this time, medial malleolus glides anterior and lateral malleolus glides posterior. The first procedure is to passively recognize movement. The second procedure is accompanied by active movement of the participant.
75881010|NCT02070848|Other|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
75881011|NCT02070848|Other|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
76051513|NCT02278328|Drug|STX209 (15mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose"
75582364|NCT04630899|Other|Passive joint mobilization|PJM uses Maitland's Mobilization method, grade III (high amplitude in the end range of the joint and 1 second vibration in the middle range through linear motion in which tissue resistance is felt). The participant is in a supine position, and the physical therapist holds the talus with one hand and the tibia with the other hand, and performs joint mobilization in the posterior direction with the hand holding the talus.
75582365|NCT01991210|Drug|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
75582366|NCT01991210|Drug|PLD|PLD will be administered at a dose of 40 mg/m^2 IV every 4 weeks.
75582367|NCT04611243|Biological|third dose vaccination with CoronaVac vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine
75582368|NCT04611243|Biological|third dose vaccination with BionTech vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine
75582369|NCT04611243|Biological|Vaccination with Coronavac vaccine|Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart
75582370|NCT04611243|Biological|Vaccination with BionTech Vaccine|Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
75582371|NCT01979939|Drug|DCV/ASV/BMS-791325|
75582372|NCT04610970|Drug|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
75582373|NCT04631172|Other|Coronavirus Anxiety Scale , COVID-19 Phobia Scale|Using two questionnaire completed in face-to-face interviews Participants were asked the Coronavirus Anxiety Scale (CAS), and the COVID-19 Phobia Scale (C19P-S).
75582374|NCT04677530|Drug|JNJ-40411813|JNJ-40411813 will be administered orally.
75582375|NCT04677530|Drug|Matching Placebo|Matching placebo will be administered orally.
75582376|NCT00564057|Drug|candesartan|tablet 8-16 mg once daily, one year
75582377|NCT00564057|Drug|lercanidipine|tablets 10-20 mg once daily, one year
75582378|NCT04630743|Behavioral|Cognitive and Behavioral intervention for the Management of Episodic Breathlessness|The cognitive and behavioral brief intervention comprises two parts: In a first module, the intervention and the study team is introduced, the definition of episodic breathlessness is given and the individual characteristics of breathlessness episodes are recorded. Goals of the intervention are discussed. In a subsequent module on patient education and the strategies, the patient and intervention executor discuss the patients' assumptions about episodic breathlessness including triggers and already used management strategies for breathlessness episodes. This follows the presentation of the non-pharmacological strategies: movement of air/ handheld fan, forward lean, diaphragmatic breathing, distraction, pursed lips breathing, long breaths out and relaxation training. The patient selects 2-3 strategies and trains them with the intervention executor.
75435041|NCT01555450|Other|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
75435042|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
75435043|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
75582379|NCT04630782|Diagnostic Test|PET-MRI scan|Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.
75582380|NCT04630704|Device|Pedra|Diffuse speckle contrast analysis perfusion system
75582381|NCT00564096|Device|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
76051514|NCT02278328|Drug|placebo|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
75435044|NCT01555515|Procedure|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
75435045|NCT01555515|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
75435046|NCT01555580|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
75582382|NCT00564096|Device|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
75582383|NCT04677452|Biological|JWCAR129|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
76051515|NCT02278328|Drug|STX209 (30mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose"
76051516|NCT02314637|Drug|Teneligliptin|Teneligliptin for 52 weeks
75435047|NCT01555593|Device|Cardioline Exp'air by Medi-soft - Sorinnes (B)|FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
75582384|NCT04677296|Other|VS002A|Amino acid based ORS/Medical food
75582385|NCT04677296|Other|WHO-ORS|WHO Oral rehydration solution, which is glucose based
75582386|NCT04610541|Drug|Remdesivir-HU|Remdesivir-HU 100 mg concentrate for solution for infusion
75582387|NCT04677335|Dietary Supplement|AB-LIFE with Monacolin K|Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
75582388|NCT04677335|Other|Placebo|Placebo capsules containing maltodextrin carrier only. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
75582389|NCT04630509|Procedure|traumatic cataract extraction|Irrigation/aspiration of traumatic cataract in children with posterior chamber intraocular lens implantation
75582390|NCT04677023|Other|GrandioSO x-tra® bulk|The prepared cavities will be restored with GrandioSO X-tra (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using using Elipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
75582391|NCT04677023|Other|Admira fusion X--tra® bulk|he prepared cavities will be restored with Admira fusion X-tra®️ bulk (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using usingElipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
75729475|NCT01792752|Behavioral|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
76051517|NCT02314637|Drug|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
76051518|NCT04877054|Behavioral|Adherence Treatment Program|4 telehealth sessions including a combination of psycho/medical education plus a motivational interviewing component.
76051519|NCT04877054|Behavioral|Education only|The control group will receive an education-only session. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
75582392|NCT04630548|Device|Intrauterine copper device|The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).
75582393|NCT01975610|Drug|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
75582394|NCT01975610|Drug|Placebo|Twice daily for 28 days
75582395|NCT04610424|Behavioral|"Cooperative Parent Mediated Therapy (CPMT)"|CMPT usually last 6 months, for a total amount of 15 sessions of 90 min; twelve core sessions (one session per week) are delivered in the first 3 months, followed by 3 monthly booster sessions. Each weekly core session had a specific focus and specific intervention strategies based on active parent coaching during parent-child interaction, and included the parent-child dyad with the parent being actively coached by a trained therapist. Live active coaching increases parents' competence in implementing strategies to enhance child development, and at the same time increases their confidence. This intervention has demonstrated evidence of effectiveness in socio-communicational improvement as measured by ADOS-G (Valeri, 2019) in a randomized controlled trial (RCT).
75582396|NCT04610424|Behavioral|As usual|Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
75582397|NCT04677101|Diagnostic Test|Liver Biopsy|Fine-needle liver biopsy
75881012|NCT04790695|Drug|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
75881013|NCT02073110|Device|Percutaneous Optical Biopsy (OCT and DRS)|
75881014|NCT01356979|Procedure|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
75881015|NCT02073188|Device|iBGStar|
75881016|NCT02073188|Device|Traditional Glucometer|
75881017|NCT01319305|Device|FinESS Sinus Treatment|balloon sinuplasty
76051520|NCT04876430|Drug|Meropenem|Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR < 50mL/min.
76051521|NCT01646645|Biological|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
76051522|NCT02272985|Other|[15O]H2O PET-CT scan|All participants will undergo 3 [15O]H2O PET-CT scans during the hemodialysis study session
76051523|NCT02272985|Other|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
75881018|NCT02073266|Procedure|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
75881019|NCT02073344|Procedure|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
75582398|NCT04630470|Behavioral|massage therapy with lavender oil|massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
75582399|NCT04630470|Behavioral|massage therapy with baby oil|massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
75582400|NCT04677062|Drug|GV-328|Patients with GV-328 treatment
75881020|NCT02073344|Other|no intervention|no renal replacement therapy
75881021|NCT04252105|Dietary Supplement|Antioxidant|Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
76051524|NCT01644149|Device|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
75881022|NCT02073422|Device|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
75881023|NCT02073422|Other|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
76051525|NCT01644149|Device|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
75582401|NCT04610463|Diagnostic Test|Cardiac flow measurement|Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
75582402|NCT04676984|Other|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
75582403|NCT01972178|Drug|PRC-4016|
75435048|NCT01555606|Other|No intervention|Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
75435049|NCT01555619|Device|CRT-D System|Implantation of a CRT-D System
75435050|NCT01555645|Behavioral|Stress management, in two steps|All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
75435051|NCT01555658|Drug|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)
75435052|NCT01555658|Drug|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)
75582404|NCT01972178|Drug|Placebo|
75582405|NCT01972178|Drug|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
75582406|NCT01972139|Device|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
76051526|NCT01644149|Biological|2011-2012 Fluzone trivalent inactivated influenza vaccine|
75582407|NCT01972139|Other|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
75582408|NCT01972139|Device|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
75582409|NCT04630665|Other|immediate implant placement|immediate implant placement in thin and thick buccal bony plates
75729476|NCT01792752|Behavioral|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
75582410|NCT01969838|Drug|Momelotinib|Momelotinib tablet administered orally once daily
75435053|NCT01555684|Procedure|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
75435054|NCT01555710|Drug|Carboplatin|AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
75435055|NCT01555710|Drug|Palifosfamide-tris|130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
75435056|NCT01555710|Drug|Etoposide|100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
75435057|NCT01555710|Drug|Carboplatin|AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
75435058|NCT01555736|Drug|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
75435059|NCT01555749|Drug|NNC172-2021|One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
75435060|NCT01555749|Drug|placebo|One injection administered subcutaneously (s.c., under the skin)
75435061|NCT01555775|Dietary Supplement|P-CHO supplement|In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
75435062|NCT01555775|Dietary Supplement|Fruit Milk Shake|The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
75435063|NCT01555788|Device|Artificial Pancreas for DiaPort system with Zone-MPC algorithm|Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
75435064|NCT01555801|Device|submucosal injection needle ; EUS|The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
75435065|NCT01555801|Device|ordinary endosonography(EUS)|These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
75435066|NCT01555814|Drug|Amisulpride|4-week open label amisulpride treatment
75582411|NCT01969838|Drug|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
75582412|NCT01969838|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
75582413|NCT01969838|Drug|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
75729477|NCT01792752|Behavioral|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
75881024|NCT02073500|Other|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
75582414|NCT04630314|Device|Percutaneus Coronary Intervention|Covered Stent
75582415|NCT01165177|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
75582416|NCT01165177|Biological|Placebo|Intramuscular injection
75582417|NCT04610385|Procedure|radical cystectomy with urinary diversion|surgical removal of the urinary bladder and other organs and perform a urinary shunt
75582418|NCT01967810|Drug|ANG1005|ANG1005 at a starting dose of 650 mg/m^2 or 600 mg/m^2 by intravenous infusion once every 3 weeks
76051527|NCT02313233|Dietary Supplement|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
75435067|NCT01555827|Other|Ophthalmological examination & Questionnaire|"The following examinations will be performed, after pupil dilation:~Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)~Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)~Wide-field colour and autofluorescence imaging (Optomap)~Measure of intra-ocular pressure (pneumotonometer)~The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:~Age, gender~educational level~smoking~cardiovascular diseases, current medications~scores at neuropsychological tests"
75435068|NCT01555840|Device|Magnetically Guided Capsule (MGCE)|"a) MGCE capsule The MGCE capsule is custom-made for observation of the stomach. It is 31 mm in length and 11 mm in diameter and equipped with two image sensors.~It contains a permanent magnet to enable magnetic guidance in the stomach by magnetic field. b) Guidance system The magnet guidance system is custom-made to guide the MGCE capsule inside the stomach. It has a footprint of 1m× 2m and generates a very low level magnetic fields. c) Conventional gastroscope"
75435069|NCT01555853|Drug|Abraxane|
75435070|NCT01555866|Drug|isavuconazole|IV
75435071|NCT01555879|Drug|Abatacept|As prescribed by a doctor for patient medical care.
75435072|NCT01555918|Drug|Isavuconazole|oral
75435073|NCT01555918|Drug|Isavuconazole (IV)|intravenous (IV)
75435074|NCT01555970|Drug|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
75435075|NCT01555970|Drug|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
75435076|NCT01556022|Device|ADRCs processed by the Celution System|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
75435077|NCT01556022|Device|Placebo Comparator: Lactated Ringer's and Subject's Blood|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
75435078|NCT01556035|Drug|Lenalidomide|Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
75435079|NCT01556048|Behavioral|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, & Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
75435080|NCT01556074|Behavioral|Yoga treatment|Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
75435081|NCT01556087|Behavioral|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
75435082|NCT01556087|Behavioral|Health Education|7 individual sessions with didactic health education information
75435083|NCT01556113|Other|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
75435084|NCT01556126|Device|Amphilimus Eluting Stent (CRE8)|Sirolimus formulated coronary eluting stent
75435085|NCT01556152|Drug|GRC 17536 (Medium Dose)|1 BD for 28 days
75729478|NCT01792752|Behavioral|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
75881025|NCT02073578|Procedure|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
76051528|NCT02313233|Dietary Supplement|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
76051529|NCT02313155|Drug|Subcutaneous injection of TAK-850|TAK-850 0.5 mL, Subcutaneous injection
75435086|NCT01556152|Drug|GRC 17536 (Low Dose)|1 BD for 28 Days
75435087|NCT01556152|Drug|Placebo|Matching Placebo for 28 Days
75435088|NCT01556191|Drug|Gefitinib|250 mg per day (oral)
76051530|NCT02313155|Drug|Intramuscular injection of TAK-850|TAK-850 0.5 mL, Intramuscular injection
76051531|NCT02204293|Drug|Canakinumab|Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
75435089|NCT01556191|Drug|Fulvestrant|500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
76051532|NCT02204293|Drug|Placebo|Matching placebo administered subcutaneously.
76051533|NCT02304926|Drug|Simvastatin|simvastatin (40 mg/day) for 4 weeks
76051534|NCT02304926|Drug|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
76051535|NCT02304926|Drug|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
75582419|NCT01967810|Drug|Bevacizumab|For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
75582420|NCT04610268|Device|transcranial direct current stimulation|Depending on the location of sEEG electrode implanted in the patient's head, the tDCS electrode (5 cm×7 cm each) was placed on occipital-frontal lobe or bilateral temporal lobe. Current intensity: 2 mA and 4 mA, Stimulus time: 3 min (each stimulus session).
75582421|NCT01966601|Drug|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
75582422|NCT01966601|Drug|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
75582423|NCT01966601|Drug|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
75582424|NCT01966601|Drug|Placebo|Placebo continuous intravenous infusion
75582425|NCT04610073|Behavioral|Interactive multimedia training and illustrated booklet|The experimental groups conducted interactive multimedia training and illustrated booklet
75582426|NCT03454269|Diagnostic Test|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
75582427|NCT01165138|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
75582428|NCT01165138|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
75582429|NCT01165138|Drug|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
75582430|NCT01963598|Drug|REGN1033 (SAR391786)|
75582431|NCT01963598|Drug|placebo|
75582432|NCT00561054|Drug|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
75582433|NCT04206358|Biological|OrienX010 combination with JS001|"OrienX010 Produced by Oriengene Biotechnology Co., Ltd. Strength: 1.0 mL/vial. Label claim: Titer 8.0 × 10^7Pfu/mL, NMT 1 × 10 particles11VP/mL.~JS001 Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package."
76051536|NCT01646255|Drug|Rotigotine|"Transdermal Patch~Content:~4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
75582434|NCT00561093|Drug|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
75582435|NCT00561093|Dietary Supplement|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
75582436|NCT00561093|Dietary Supplement|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
75582437|NCT00561093|Drug|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
75582438|NCT00561093|Dietary Supplement|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
75582439|NCT00561093|Dietary Supplement|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
75582440|NCT01960010|Drug|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
75582441|NCT01960010|Drug|Vehicle|Vehicle dosed BID
75582442|NCT01165021|Drug|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
75582443|NCT01165021|Drug|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
75582444|NCT01165021|Drug|Folic Acid|Administered orally.
75582445|NCT01165021|Drug|Vitamin B12|Administered Intramuscular injection.
75582446|NCT01165021|Drug|Dexamethasone|Administered orally.
75582447|NCT04314622|Drug|Supaglutide|Administered SC
75582448|NCT04314622|Drug|Placebo|Administered SC
75582449|NCT00561132|Dietary Supplement|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
75582450|NCT00561132|Other|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (<50 mg) twice daily for a period of 4 weeks
75582451|NCT02886754|Behavioral|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
75582452|NCT02886754|Behavioral|National e-learning programme only|National e-learning programme (COMPASS)
75582453|NCT02886754|Behavioral|Standard simulation|Paper based simulation cases
75582454|NCT01956812|Drug|IMMU-107|Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
76051537|NCT01646255|Drug|Placebo Patch|"Transdermal Patch~Size:~20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo received matching placebo patches"
75582455|NCT01956812|Drug|placebo|placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
75881026|NCT02077322|Device|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
76051538|NCT01646255|Drug|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release [in combination with benserazide or carbidopa]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
76051539|NCT04870229|Drug|Carnosine|
75582456|NCT01956812|Drug|Gemcitabine|Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
75582457|NCT01182844|Dietary Supplement|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
75582458|NCT01164865|Device|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
75729479|NCT00945516|Device|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
75881027|NCT02077322|Device|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
75881028|NCT02077400|Drug|Cephazolin|Cephazolin
75582459|NCT01164865|Device|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
75582460|NCT01164865|Device|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
75582461|NCT04630587|Procedure|Indirect restorations|see the Arm description
75582462|NCT01952990|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
75881029|NCT01362283|Other|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
75881030|NCT02077478|Device|Remifentanil and propofol administration using TCI|
75881031|NCT02077478|Device|Remifentanil and propofol administration using MCI|
76051540|NCT04870229|Drug|Placebo|Placebo
75582463|NCT04314310|Drug|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
75582464|NCT04314310|Drug|Placebo|equal volume of normal saline
75729480|NCT00945516|Device|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
75729481|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
75729482|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
75729483|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
75729484|NCT00943956|Drug|bicalutamide|
75729485|NCT00943956|Drug|everolimus|
75729486|NCT00943956|Drug|leuprolide acetate|
75729487|NCT00943956|Radiation|external beam radiation therapy|
75435090|NCT01556191|Drug|Erlotinib|150 mg per day (oral)
75435091|NCT01556217|Drug|JNJ-39393406|Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
75435092|NCT01556217|Drug|Placebo|Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
75435093|NCT01556282|Device|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
75435094|NCT01556308|Procedure|Taking of liquid and top of blisters|the liquid and the top of blisters will be took.
75435095|NCT01556321|Dietary Supplement|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
75435096|NCT01556321|Dietary Supplement|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
75435097|NCT01556334|Drug|Azithromycin|Azithromycin 1g po
75435098|NCT01556334|Drug|Erythromycin|Erythromycin IV then PO
75582465|NCT02886793|Drug|fludeoxyglucose|
75582466|NCT04610307|Procedure|buffered anesthesia|patients will undergo surgery under buffered local anesthesia
75582467|NCT01952132|Drug|OMS643762|
75729488|NCT01564797|Behavioral|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
75729489|NCT00945828|Behavioral|Annual Intervention Group|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
75881032|NCT02077556|Drug|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
75582468|NCT01952132|Drug|Placebo|
75582469|NCT00561171|Drug|SPP635|oral once daily
75582470|NCT01951742|Biological|ANT-1401|Active
75729490|NCT00945828|Behavioral|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
75729491|NCT01564875|Drug|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
75729492|NCT01564875|Drug|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
75881033|NCT02077556|Drug|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell < 4000/mcL)
75582471|NCT01951742|Biological|Vehicle|Vehicle
75582472|NCT04610229|Radiation|Hypofractionation guioded by dose painting|1
75582473|NCT01951235|Drug|Imeglimin|
75582474|NCT01951235|Drug|Placebo|
75582475|NCT04610502|Biological|Administration of Equine immunoglobulin anti SARS-CoV-2|The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.
75582476|NCT01949324|Biological|Ciliary neurotrophic factor (CNTF)|Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
75582477|NCT01949324|Procedure|Sham procedure|Sham surgery for Sham arm
75582478|NCT01949324|Device|NT-501 Implant|NT-501 encapsulated cell implant
75582479|NCT01949324|Procedure|NT-501 Implant procedure|Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
75881034|NCT02077556|Drug|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
75729493|NCT00944112|Biological|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
75729494|NCT00944112|Biological|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
75729495|NCT04012086|Other|Physical therapy|Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
75582480|NCT01164475|Drug|Granulocyte-colony stimulating factor (G-CSF)|
75881035|NCT02077556|Drug|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
75582481|NCT01164475|Drug|Fixed Dose Plerixafor|
75582482|NCT01164475|Drug|Weight-Based Plerixafor|
75582483|NCT04609995|Behavioral|Incentives|No financial incentive
75582484|NCT01942265|Drug|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
75582485|NCT01942265|Drug|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
75582486|NCT01942265|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
75582487|NCT01164007|Drug|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
75729496|NCT01529814|Device|Implant with new abutment connection|New abutment connection implant system
75729497|NCT01529814|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
75729498|NCT00944190|Behavioral|Self-management intervention|Brief counseling technique, self-management,
75729499|NCT00944190|Behavioral|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
75729500|NCT00945984|Procedure|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
75729501|NCT00944268|Drug|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
75881036|NCT02077556|Drug|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
75729502|NCT00944346|Drug|Metformin HCl|
75729503|NCT00527319|Drug|VT-122 low dose|VT-122 low dose, dose escalated
75729504|NCT00527319|Drug|VT-122 high dose|VT-122 high dose, dose escalated
75729505|NCT00562302|Device|Bio-Seal Plug|Deployment of the Bio-Seal plug in needle track
75729506|NCT00946062|Other|orientation and mobility training|orientation and mobility training
75582488|NCT01164007|Drug|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 28-day cycle.
75582489|NCT01941836|Drug|ETC-1002|Patients receive ETC-1002
75582490|NCT01941836|Drug|Ezetimibe|Patients receive ezetimibe
75729507|NCT04012632|Other|this study was an observational study and no interventions were given to the participants|the participants were recruited and the data as well as blood sample were collected.
75729508|NCT00134719|Biological|MenHibrix (Hib-MenCY-TT)|One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
75729509|NCT00134719|Biological|Infanrix® Penta|One intramuscular dose at 2, 4 and 6 months of age
75729510|NCT00134719|Biological|Prevenar®|One intramuscular dose at 2, 4 and 6 months of age
75881037|NCT02930941|Drug|Tranexamic Acid|TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
75582491|NCT04610151|Other|guided imagery|Guided Imagery CD: A guided imagery CD was prepared by a web designer with the recommendations of the researcher to include relaxing, soft and slow-paced, mixed nature sounds and photographs towards reducing pain in lower extremity surgical operation patients. The directives used for guidance, the audio recordings created as a result of literature review and the video lasted for 13 minutes (
75582492|NCT04630041|Behavioral|211 Referral|Patients with one or more reported social need will be referred to 211 for community based services. 211 will reach out and contact patients for follow-up.
75582493|NCT04629885|Drug|Oxytocin 400 IU vaginal gel|
75582494|NCT04629885|Drug|Placebo|Matching placebo gel with identical appearance to the test product, used as reference treatment.
75582495|NCT01939184|Drug|WC3055|12.5, 25, 50 or 75 mg dose
75582496|NCT01939184|Other|Placebo|Placebo
75582497|NCT04630119|Other|Questionnaires on quality of life, emotional health and presenteeism|After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
75582498|NCT04629768|Device|PuraStat|Purastat is applied to the EMR defect
75582499|NCT01163851|Biological|4 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
75582500|NCT01163851|Biological|0.5 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
75582501|NCT04609917|Procedure|trainee invlovement|Patients underwent selective biliary cannulation with trainee involvement
75582502|NCT02885662|Drug|CS-3150|CS-3150 2.5 to 5.0 mg , orally.
75582503|NCT00561210|Dietary Supplement|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
75582504|NCT00561210|Dietary Supplement|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
75582505|NCT01938599|Drug|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
75582506|NCT01938599|Drug|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
75582507|NCT04610034|Behavioral|"Resilient Caregivers"|"Resilient Caregivers is a 7-session group program developed for partner caregivers of patients with cancer (6 weekly sessions and 1 booster session). Each session takes place in groups of approximately 8 participants and lasts for two-and-a-half hours. Sessions 1 to 3 focuses on the caregiver and introduces the resilience components of coping strategies, meta-reflective skill and clarification of values. Sessions 4 and 5 focuses on these components in the relationship between the caregiver and the cancer patient and social support networks respectively, while Session 6 focuses on resilience in relation to self-care and care for the partner. A booster session will be scheduled one month after the end of Session 6 in order to follow-up on the intervention and allow participants to reflect on the benefits and challenges of the program."
75582508|NCT04610034|Other|Care as usual|The control arm will receive usual care, which implies no systematic support.
75729511|NCT00134719|Biological|ActHIB®|One intramuscular dose at 2, 4 and 6 months of age
75729512|NCT00134719|Biological|Meningitec®|One intramuscular dose at 2, 4 and 6 months of age
75582509|NCT01917383|Drug|Trabodenoson|Ophthalmic eye drop
75582510|NCT01917383|Drug|Latanoprost|Ophthalmic eye drop
75582511|NCT01917383|Drug|Timolol|Ophthalmic eye drop
75729513|NCT00134719|Biological|M-M-R®II|One subcutaneous dose at 12-15 months of age
75435099|NCT01555528|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
75435100|NCT01556373|Other|NA : non interventional study|NA : non interventional study
75582512|NCT00564135|Procedure|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
75729514|NCT00134719|Biological|Varivax®|One subcutaneous dose at 12 to 15 months of age
75729515|NCT00134719|Biological|PedvaxHIB®|One intramuscular dose at 12 to 15 months of age
75582513|NCT01163617|Device|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
75582514|NCT01163617|Device|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
75582515|NCT01163617|Device|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
75729516|NCT00940836|Drug|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
75729517|NCT00940836|Drug|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
75729518|NCT00940836|Drug|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
75729519|NCT03999177|Behavioral|Kinect-TOLF Training System|This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
75881038|NCT02930941|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
76051541|NCT05649761|Drug|QL1604 injection|Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
76051542|NCT05649566|Device|Virtual Reality game|"The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
75435101|NCT01555996|Behavioral|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
75582516|NCT01163617|Device|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
75582517|NCT01911767|Drug|Dimethyl fumarate|Administered as specified in treatment arm.
75582518|NCT01911767|Drug|Peginterferon beta-1a|Administered as specified in treatment arm.
75582519|NCT04629846|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
75729520|NCT05104827|Other|Complementary Integrative Medicine|30-minute individually tailored integrative medicine care, including acupuncture, acupressure, reflexology, movement therapies like QiGong or Feldenkrais as well as Anthroposophic Medicine and mind-body treatments.
75729521|NCT00940914|Drug|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
75729522|NCT00944424|Drug|Docetaxel + High dose Vitamin D2|Docetaxel + High dose Vitamin D2
75729523|NCT00944424|Drug|Docetaxel + Standard dose Vitamin D2|Docetaxel + Standard dose Vitamin D2
75881039|NCT02077634|Drug|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
75881040|NCT02077634|Drug|abiraterone acetate + prednisone|ormon therapy will be stopped
76051543|NCT02203591|Drug|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
76051544|NCT02203591|Drug|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
76051545|NCT02203591|Drug|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
76051546|NCT02203591|Drug|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
76051547|NCT01642277|Drug|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
76051548|NCT04869956|Other|Dietary pattern : High-fiber diet rich in PUFA|High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
76051549|NCT04869956|Other|Dietary pattern: Standard diet|standard nutritional recommendations
75582520|NCT04629846|Drug|QL1209|QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
75582521|NCT04629846|Drug|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
75582522|NCT04629846|Drug|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
75582523|NCT04629846|Procedure|surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
75582524|NCT01910012|Drug|ADI-PEG 20|
75582525|NCT01182337|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
75582526|NCT01182337|Drug|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
75582527|NCT04609527|Procedure|Management of placenta accreta spectrum|Conservative and radical (hysterectomy) treatment of placenta accreta. Follow up to the patients to detect the impact of treatment imposed A novel technique which early identification and repait of uterine wall defects resulted from invasion of the uterine wall by the placenta.
75582528|NCT01909427|Drug|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
75582529|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
75582530|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
75582531|NCT01909427|Drug|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
75582532|NCT01909427|Drug|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
75729524|NCT00944502|Drug|Dexamethasone|"Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days."
75729525|NCT04754295|Other|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
75729526|NCT04754295|Other|STANDARD|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
75729527|NCT00946140|Procedure|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
75729528|NCT00949962|Drug|antiandrogen therapy|Given systemically
75435102|NCT01555996|Behavioral|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
75435103|NCT01556464|Device|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
75435104|NCT01556477|Drug|Azacitidine|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
75729529|NCT00949962|Drug|leuprolide acetate|Given subcutaneously
75729530|NCT00949962|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
76051550|NCT02230189|Biological|Segmental airway allergen challenge|
75435105|NCT01556477|Drug|azacitidine + lenalidomide|"Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.~Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks."
75435106|NCT01556503|Device|VivaScope System|VivaScope System, Model#s 1500 and 2500
75582533|NCT01909427|Drug|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
75582534|NCT01909427|Drug|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
75582535|NCT04629573|Procedure|Lumber Epidural|Epidural procedure was performed by attending anesthesiologists who had completed at least 50 epidural procedures during their training. Patient was placed in the sitting position, the skin over the lumbar area was cleaned and a sterile technique was observed throughout the procedure. Skin and subcutaneous tissue were infiltrated with 1% lidocaine 2 mL at the intended site of epidural placement (L2-3 or L3-4 interspace). The lumbar epidural space was then located, using a midline approach with an 18 gauge Tuohy epidural needle via a loss of resistance technique with 2 mL of saline, 20 gauge epidural catheter was placed in each patient. We deliver an initial bolus of 20 ml bupivacaine 0.5% plus 100 mcg Fentanyl, followed by continuous infusion of bupivacaine 0.5% plus 1mcg/ml Fentanyl (3-5 ml/hr.).
76051551|NCT02230189|Procedure|Bronchoscopy|
76051552|NCT02230189|Diagnostic Test|Methacholine challenge test|
76051553|NCT02230189|Diagnostic Test|Spirometry|
76051554|NCT02230189|Diagnostic Test|Allergen skin prick test|
75435107|NCT01556529|Procedure|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
75582536|NCT04629573|Procedure|General anesthesia|Anesthesia was initiated with IV fentanyl 1 µg/kg, propofol 2 mg/kg and cisatracurium 0.15 mg/kg to facilitate endotracheal intubation. After tracheal intubation, anesthesia was maintained with sevoflurane in O2 and air (FiO2 of 0.5), cisatracurium 1µg/kg/min and fentanyl 0.5 µg/ kg /h were infused. Volume-Controlled ventilation was performed in all patients. Cisatracurium and fentanyl infusion was stopped at the end of surgery, neuromuscular blockade was reversed, and the patient was extubated and send to post-anesthesia care unit.
75582537|NCT01909232|Device|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
75582538|NCT01909232|Device|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
75881041|NCT01349309|Behavioral|Swallowing Exercise Group|"Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
75435108|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
75435109|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
75435110|NCT01556542|Device|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
75582539|NCT04609449|Procedure|Long biliopancreatic limb Roux-en-Y gastric bypass.|Long biliopancreatic limb Roux-en-Y gastric bypass.
75582540|NCT04609449|Procedure|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass
75582541|NCT01887002|Drug|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
75582542|NCT01887002|Drug|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
75582543|NCT00564174|Drug|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
75729531|NCT04115007|Radiation|Stereotactic Body Radiotherapy (SBRT) + Standard of care|"Definition of standard of care (prior to randomization):~Radiotherapy to the prostate in de novo metastatic patients~Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~Long term ADT +/- intermittent treatment~Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).~SBRT is delivered using the following regimen: 30 Grays (10 Gy x 3 fractions) for axial and appendicular bones and lymph node metastases if present. In case the dose cannot be safely delivered while maintaining a safe dose to the organs at risk, an alternate regimen (35 Gy in 5 fractions of 7 Gy) can be used."
75729532|NCT04115007|Drug|Standard of care|"Definition of standard of care (prior to randomization):~Radiotherapy to the prostate in de novo metastatic patients~Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~Long term ADT +/- intermittent treatment~Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel)."
75881042|NCT01365403|Drug|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
75881043|NCT01365403|Drug|carbamazepine|multiple oral doses, Days 1-24 of study period 2
76051555|NCT04196348|Procedure|Short BPL RYGB|Alimentary limb (AL) with 120 cm and BPL with 100 cm.
75435111|NCT01556542|Device|nitinol stent implantation|nitinol stent implantation
75435112|NCT05847660|Drug|Progesterone antagonist|Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.
75435113|NCT05847660|Drug|conventional antagonist protocol|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
75435114|NCT05847595|Other|Implicit motor training program|The implicit motor training aims to create a learning situation in which the learner is not (or minimally) aware of the underlying rules of the practiced motor skill. Cognitive-motor dual-task training will be used, which involves practicing hand-reaching and grasping in different locations in space while performing cognitive tasks associated with attention, memory, and executive function. The cognitive tasks include naming words, counting backwards, counting tones, counting days and months backwards, listening to a number and counting backwards by twos and threes, telling daily stories, spelling words backward, continuous subtraction of 7 from 100, and the Stroop task. The training will be tailored to the participant's abilities.
75582544|NCT00564174|Drug|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
75582545|NCT01878461|Drug|Vehicle|
75582546|NCT01878461|Drug|M518101|
75582547|NCT01163266|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
75582548|NCT01163266|Drug|Placebo|Vortioxetine placebo-matching capsules
75582549|NCT04629456|Other|neuromuscular electric stimulation|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
75582550|NCT04629456|Other|Exercises|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion
75582551|NCT01873703|Drug|pracinostat|Histone deacetylase inhibitor (HDACi)
75582552|NCT01873703|Drug|Placebo|Placebo
75435115|NCT05847595|Other|Explicit motor training program|"The explicit motor training aims to create a learning situation in which the learner is very aware of the learning process by providing detailed explicit instructions on each exercise. The Motion Guidance Shoulder Kit will be used for this intervention, which involves four exercises: Around the clock in flexion and abduction, Locate the Target in active range of motion, Butterfly in tracing small and large butterfly patterns, and Test your positional awareness in locating circles with eyes open and closed. The kit involves a strap around the forearm with a laser to guide the movement of the arm during the exercises."
75435116|NCT05847595|Other|Selected physical therapy program|The selected physical therapy program, which includes shoulder joint mobilization, graduated active exercises for shoulder muscles, hand weight bearing exercises, Approximation of the upper limb joints. While, the conventional physical therapy program for the lower extremity which includes gait training, strengthening exercises and balance training .
75582553|NCT01873703|Drug|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
75582554|NCT04629261|Behavioral|Use of ECOBICI (public bicycle sharing program)|Use of ECOBICI program with and without incentive.
75582555|NCT04629183|Other|integrated clinical evaluation|30-day follow-up (telephone/database query) to define outcome Patients will receive standard care, independent of study participation.
75582556|NCT01870505|Drug|BYL719|
75582557|NCT01870505|Drug|Letrozole|
75582558|NCT01870505|Drug|Exemestane|
75729533|NCT04012866|Behavioral|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
75729534|NCT04012866|Behavioral|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
75729535|NCT04012866|Behavioral|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
75729536|NCT00950040|Behavioral|Brief alcohol intervention|The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
75729537|NCT00950040|Behavioral|General health education|The intervention will consist of information about several general health behaviors.
75729538|NCT00946374|Drug|Immunochemotherapy|R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
76051556|NCT04196348|Procedure|Long BPL RYGB|AL with 120 cm and BPL with 200 cm.
75582559|NCT04629612|Procedure|Regional anesthesia|Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
75582560|NCT01868516|Drug|dexmecamylamine|
75582561|NCT01868516|Drug|Placebo|
76051557|NCT02304302|Drug|Memantine|Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
75729539|NCT00946374|Drug|High-dose BEAM plus autologous SCT|High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( > 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
75582562|NCT00564213|Drug|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
75582563|NCT01861847|Drug|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
75729540|NCT00946374|Other|HLA-identical allogenic SCT|Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
75729541|NCT04529577|Device|His-bundle pacing|"A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup."
75729542|NCT00950196|Drug|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
76051558|NCT02304302|Drug|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
75729543|NCT01565031|Procedure|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
75435120|NCT05847491|Diagnostic Test|IGRA/Tuberculin skin test|"All patients will receive:~Clinical evaluation;~Chest x-ray.~IGRA (or tuberculin skin test if immunocompromised)~Therapeutic proposal if eligible"
75435121|NCT05847413|Drug|Verapamil|Subjects will receive oral verapamil for 12 weeks
75435122|NCT05847335|Behavioral|Survey work|Childhood Trauma scale, Personality Beliefs questionnaire, Emotional Intelligence scale
75435123|NCT05847257|Drug|Letrozole tablets|letrozole 2.5mg twice weekly for 3 months
75435124|NCT05847257|Dietary Supplement|Coenzyme Q10 table|Coenzyme Q10 400 mg per day for 3 months
75582564|NCT01861847|Drug|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
75582565|NCT00564252|Drug|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
75582566|NCT04629144|Drug|Belimumab|"Belimumab administered subcutaneously 200mg weekly from week 0 to week 24.~Both arms will have the same corticosteroid tapering scheme, with an initial dose of 60 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~60 mg/day week (W)0-W4,~40 mg/day W4-W6~30 mg/day W6-W8,~20 mg/day W8-W10,~15 mg/day W10-W12,~10 mg/day W12-W14,~7.5 mg/day W14-W16,~5 mg/day W16-W18~2.5mg/day W18-W20.~Stopping glucocorticoid therapy at W20 At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
75582567|NCT04629144|Drug|Placebo|"Both arms will have the same corticosteroid tapering scheme, with an initial dose of 60 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~60 mg/day week (W)0-W4,~40 mg/day W4-W6~30 mg/day W6-W8,~20 mg/day W8-W10,~15 mg/day W10-W12,~10 mg/day W12-W14,~7.5 mg/day W14-W16,~5 mg/day W16-W18~2.5mg/day W18-W20.~Stopping glucocorticoid therapy at W20 At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
75582568|NCT01855880|Biological|AbGn-168H|
75582569|NCT01855880|Biological|placebo|
76051559|NCT02276612|Drug|E/C/F/TAF|150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
75435125|NCT05847218|Drug|RHN-001 (one tablet 750mg)|Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
75582570|NCT01851083|Biological|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10^6 cells/kg or 10x10^6 cells/kg weight.
76051560|NCT02301143|Drug|nab-Paclitaxel|
76051561|NCT02301143|Drug|Gemcitabine|
76051562|NCT02301143|Drug|Chemoradiation|
76051563|NCT02301143|Drug|Capecitabine|
76051564|NCT02301143|Procedure|Surgery|Surgical intervention
76051565|NCT02276222|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
75582571|NCT01851083|Other|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
75582572|NCT04609839|Other|Follow-up of patients with COVID-19|"The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.~The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients."
75582573|NCT01850381|Drug|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
75582574|NCT01850381|Drug|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
75582575|NCT00555074|Drug|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
75582576|NCT00555074|Drug|Placebo|Placebo, BID, oral route during 6 weeks
75582577|NCT04609488|Diagnostic Test|Surfactant assessment|To determine surfactant levels in lung fluid
75435126|NCT05847218|Drug|RHN-001 (750mg * 2 Tablets)|Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
75435127|NCT05847205|Drug|r-Hirudin|100 Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
75435128|NCT05847192|Diagnostic Test|[18F]-PI2620 PET scan|The PET scan will measure the regional distribution of tau aggregation in AD patients with and without psychosis compared to Cognitively Unimpaired Healthy participants with the PET radiotracer [18F]-PI2620.
75435129|NCT05847179|Drug|Progerinin|"This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.~. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase."
75435130|NCT05847166|Radiation|[99mTc]Tc-PSMA-T4|[99mTc]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The [99mTc]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product [99mTc]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.
75435131|NCT05847101|Procedure|Tracheoesophageal fistula repair|Tracheoesophageal fistula repair
75435132|NCT05847088|Drug|Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:|Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME.
75435133|NCT05847075|Other|Heat Therapy|Participants in the HT group will undertake whole body heat treatment according to previous methods. Participants will be housed in an environmental chamber initially set at 55.0oC on three non-consecutive days of the week during 12 weeks. Each session will last 60 min.
75582578|NCT04609605|Device|speckle tracking echocardiography|speckle tracking echocardiography of right ventricle
75582579|NCT01847573|Drug|HT-100|May be administered in either fed or fasted state
75582580|NCT01846793|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
75582581|NCT04609254|Drug|Paracetamol|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
75582582|NCT04609254|Drug|Dexketoprofen|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
76051566|NCT02276222|Drug|Spiriva® 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
75582583|NCT04609254|Drug|Ibuprofen|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
75582584|NCT01846481|Drug|RBP-8000 100 mg|RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
75582585|NCT01846481|Drug|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
75582586|NCT01846481|Drug|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
75582587|NCT01846481|Drug|RBP-8000 200 mg|RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
75881044|NCT01352663|Biological|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
75881045|NCT01352663|Biological|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
75881046|NCT01362361|Drug|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
75881047|NCT01362361|Drug|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
75881048|NCT02077712|Drug|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
75881049|NCT04949789|Other|Placebo without Exercise|2 Capsules to be taken 30 minutes before breakfast.
75881050|NCT04949789|Other|Placebo with Exercise|2 Capsules to be taken 30 minutes before breakfast.
75881051|NCT04949789|Other|IP I|2 Capsules to be taken 30 minutes before breakfast.
75881052|NCT04949789|Other|IP II|2 Capsules to be taken 30 minutes before breakfast.
75881053|NCT04949789|Other|IP III|2 Capsules to be taken 30 minutes before breakfast.
75881054|NCT05191771|Device|Neovis Total Multi|1 drop in each eye, 4 times per day
75435134|NCT05847075|Other|StrengthTraining|Participants will perform supervised exercise in a gym on three non-consecutive days of the week. Each session will last ~60 min and will consist of a warm up, the resistance training and a cool down. All sessions will be conducted by qualified sport and exercise scientists for 12 weeks.
75435135|NCT05847075|Other|Sedentary Control|Participants will not receive any intervention during 12 weeks.
75435136|NCT05847062|Procedure|reverse shoulder arthroplasty|The patient will be admitted to undergo reconstructive surgery of the arthropathy, by means of one of the two mentioned Inverted Arthroplasty implants. The patient will be operated following always the same surgical technique with the same protocol (position, anesthesia, antibiotic prophylaxis...) and by one of the three surgeons of the shoulder unit, being always at least two of them present in each of the interventions. Both the implants used and the complications occurring during surgery or in the immediate postoperative period will be recorded.
75881055|NCT05191771|Device|Systane Balance|1 drop in each eye, 4 times per day
75881056|NCT02073734|Drug|Dexamethasone|Dexamethasone 8mg/IV
75881057|NCT02073734|Drug|Placebo|Placebo given IV
75881058|NCT01365559|Drug|Group A: Carfilzomib & Non-IMiD Regimen|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
75881059|NCT01365559|Drug|Group B: Carfilzomib & IMiD containing regimen.|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
75881060|NCT03137537|Drug|Ivabradine|lower heart rate in heart failure patients.
75435137|NCT05847049|Other|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
75435138|NCT05847023|Behavioral|LUNA|see description above
75435139|NCT05846997|Diagnostic Test|Liquid biopsy and imaging|Liquid biopsy and imaging
75881061|NCT03137537|Drug|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
75881062|NCT02071004|Drug|DS-1040b|IV of 6 mg given once over 30 minutes
75881063|NCT02071004|Drug|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
76051567|NCT02275364|Device|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
76051568|NCT02275364|Device|Placebo strip|Placebo strip
75582588|NCT04609293|Combination Product|camrelizumab+apatinib+hyperfractionated radiotherapy|Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
75582589|NCT01844180|Drug|ONO-2952|
75582590|NCT01844180|Drug|ONO-2952 Matching Placebo|
75729544|NCT04012554|Procedure|avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung|Avoiding chest drainage tube placement after VATS of the lung in the experiment group.
75729545|NCT04012554|Procedure|Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung|Indewlling chest drainage tube after VATS of lung in the control group.
75729546|NCT01565109|Drug|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
75729547|NCT01565109|Radiation|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
75729548|NCT00526071|Drug|migalastat HCl|
76051569|NCT02275364|Other|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
75729549|NCT00525915|Drug|5-Fluorouracil|"Arm A = 250 mg/m^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m^2 IV over 48 hours on days 1 and 15."
75729550|NCT00525915|Drug|Oxaliplatin|"Arm A: 40 mg/m^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m^2 IV on Day 1 and 15"
75729551|NCT00525915|Radiation|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
75582591|NCT04609059|Drug|M201-A Injection|"Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
75881064|NCT02077790|Device|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
75435140|NCT05846971|Other|Educational materials on validated methylation assay|Educational materials include overall information on the assay including what the test does, how to use the test and report, and performance metrics on the test.
75435141|NCT05846958|Device|laser acupuncture|"Each patient in experimental group will receive laser acupuncture for 10 s with at least 4J/point for each point.10 minutes, three times per week for 4 weeks (total of 12 sessions)~nieght splint for 4 weeks ."
75729552|NCT00525915|Procedure|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
75582592|NCT04609059|Drug|Placebo|"Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
75582593|NCT04676750|Behavioral|Mindfulness-Based Stress Reduction|yoga, meditation and psycho education
75582594|NCT04601298|Other||
75729553|NCT05191329|Diagnostic Test|TPQue Greek version, NEI-VFQ-25 Greek version|Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
75729554|NCT00521079|Device|Therapy ON|Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
75435142|NCT05846958|Device|night splint|wearing night splint for 4 weeks
75435143|NCT05846945|Other|Threshold inspiratory muscle trainer device|The threshold inspiratory muscle trainer (IMT) device offers resistance to respiration through the spring-loaded valve.
75729555|NCT00521079|Device|Therapy OFF|Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
75729556|NCT03107117|Behavioral|Computer Counseling|two computer counseling online programs for a teen and a parent
75729557|NCT03107117|Behavioral|Standard Care|A referral for substance use counseling
75729558|NCT02579837|Device|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
75729559|NCT02579837|Device|Zeiss Cirrus|optical coherence tomographer (OCT)
75729560|NCT00521001|Drug|everolimus|
75729561|NCT00521001|Drug|temozolomide|
75729562|NCT04887701|Device|Non-hormonal vaginal device therapy|Experimental Active Therapy
75729563|NCT04887701|Device|Sham vaginal device therapy|Sham Comparator
75729564|NCT00134563|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
75881065|NCT05187559|Other|Standard physiotherapy|Neuromuscular exercise program with standard physiotherapy with no visual feedback
75881066|NCT05187559|Device|Biodex Balance SD and Biodex Gait Trainer|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
75435144|NCT05846945|Other|Adjusting mechanical ventilator trigger sensitivity|modifying the mechanical ventilator trigger sensitivity so that patients can only initiate inspiratory flow by producing more negative intrathoracic pressure
75435145|NCT05846945|Other|Chest physiotherapy|Conventional chest physiotherapy
75435146|NCT05846867|Drug|AK119|AK119 IV every 2 weeks.intravenous infusion
75435147|NCT05846867|Drug|AK112|AK112 IV every 2 weeks.intravenous infusion
75435148|NCT05846867|Drug|Oxaliplatin|Oxaliplatin: 85mg/m2, intravenous infusion
75435149|NCT05846867|Drug|Irinotecan|Irinotecan 180mg/m2, intravenous infusion
75435150|NCT05846867|Drug|Calcium folinate|Calcium folinate: 400mg/m2, intravenous infusion
75435151|NCT05846867|Drug|Fluorouracil|Fluorouracil 400mg/m2, intravenous injection
75582595|NCT04601181|Biological|ThisCART22 cells injection|"Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10^6 CAR-T cells per kg body weight.~Intervention study"
75582596|NCT04676828|Diagnostic Test|Single-photon-emission CT scan|SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung
75582597|NCT04676789|Drug|Pegaspargase|Pegaspargase 2500IU/m2 administered by intramuscular injection on Day 1
75729565|NCT00134563|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
75435152|NCT05846854|Other|Assessment for bleeding disorder with tailored post-operative care|Intervention will be expanded lab work-up for hematologic conditions, consultation by Hematology and tailored intra-operative and post-operative plan with aim to mitigate bleeding and hemorrhage risk, balancing thrombotic risk with this intervention.
75729566|NCT04019171|Behavioral|exercise training|6 weeks of physical exercise training. 3 sessions per week. Session duration : 40 minutes. Self-regulated exercise intensity using Borg's ratings of perceived exertion (RPE)
75729567|NCT03966547|Procedure|Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
75729568|NCT03966547|Procedure|Ganglion sphenopalatine block with placebo administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
75435153|NCT05846828|Other|Stanford Binet IQ test|"The Fourth Edition Stanford-Binet test which is based upon a four-factor model of intelligence, and its 15 subtests are partitioned into :~Verbal ability.~Abstract/Visual ability.~Quantaitive potential.~Short-Term Memory Scales"
75729569|NCT05189379|Other|Non-Alcoholic Odour|A chemical used in fragrances and flavouring with a smell close to a nutty, buttery structure. Used as a 1:100 deionised water dilution.
76024923|NCT05232253|Device|Cystoelastometer - Urodynamics Testing|The non-invasive cystoelastometer device connects to the drainage end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device a pressure measurement is recorded and stored in the device along with the time and date. The remaining urine is then evacuated through the catheter and device and the cystoelastometer records the volume of urine evacuated. The measurement(s) of bladder pressure and volume as well as the time and date can later be transmitted wirelessly to a smart phone that contains an app for the device.
75582598|NCT04676789|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1
75582599|NCT04676789|Radiation|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 50 Gy will be given in 25 days
75435154|NCT05846737|Biological|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10^6 anti-BCMA CAR+T cells/kg.
75435155|NCT05845736|Drug|Antihypertensive Agents|number of hypertensive drugs
75435156|NCT05843942|Other|Questionnaire|A food frequency questionnaire that was designed to assess folate, iron, and vitamin B12 intake will be administered. Furthermore a 24-hour recall food record will be administered and a complete blood count will be collected. Food frequency questionnaire data will be compared to recall food records and blood count data.
75582600|NCT04600713|Other|PT-X and IMT|The intervention consists of PT-X, including central circulatory exercise and muscle exercises, 2 times/week, 60 min/session for 12 weeks, and homebased exercises 2 times/week logged in an exercise diary. For IMT the Threshold Inspiratory Muscle Trainer (Threshold IMT) (Respironics Inc., Murrysville, PA, USA) will be used at 30 % of maximal expiratory pressure in 15 minutes 2 times a day during 12 weeks.
75582601|NCT01811576|Drug|TV-1106|
75582602|NCT01811576|Drug|Recombinant human growth hormone|Subcutaneous once daily
75582603|NCT04609371|Behavioral|self-care tools|self-care tools only
75582604|NCT04609371|Behavioral|lay telephone coaching|coaching
75729570|NCT05189379|Other|Alcoholic Odour|Alcoholic beverage beer / Alcoholic beverage red wine / Alcoholic beverage brandy / The type of the Alcoholic Odour intervention will be presented in a participant-preference basis.
75729571|NCT05189379|Other|Non-Alcoholic Images|Images of non-alcoholic items, namely; broom, duster, clothing iron, lightbulb, mat, mulch, penlight, rack, rock, kitchen scissors, trough, vent are presented in parallel with the non-alcoholic odour
75582606|NCT01810484|Device|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
75729572|NCT05189379|Other|Alcoholic Images|Images of alcoholic items, namely, beer, wine, schnapps are presented in parallel with the alcoholic odour
75729573|NCT01326325|Drug|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
75729574|NCT01326325|Drug|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
75435157|NCT05842148|Other|Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of pathological parameters (oncological radicality resection volume, locoregional extension / TNM / multifocality and tumor biological profile).
75435158|NCT05842148|Other|Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of post-surgical complications (dehiscence, liponecrosis, infection, seroma, hematoma, fibrosis, scar hypertrophy).
75435159|NCT05842148|Other|Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.|Control and review of technical analysis by the surgeon, and of psychosocial well-being, physical discomfort, adverse effects of radiotherapy by the patient collected through the administration of a questionnaire.
75435160|NCT05841173|Dietary Supplement|"PanTrek"|"The intervention is represented by the investigational product PanTrek, shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product PanTrek (per 1 dose):~Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg);~Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial);~Apple juice concentrated 2.5% - 7,5 g;~Potassium beta-hydroxybutyrate - 4,5 g;~Magnesium beta-hydroxybutyrate - 500 mg;~E211 sodium benzoate - no more than 5 mg;~E202 Potassium sorbate - no more than 3,6 mg;~Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021."
75435161|NCT05841173|Behavioral|Physical Trainings|Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).
75435162|NCT05841173|Other|Placebo|The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.
75435163|NCT05841173|Behavioral|Diet|The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
75582607|NCT01810484|Device|Ultherapy® treatment and CO2 laser treatment|"Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin."
75582608|NCT01810484|Device|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
75582609|NCT04600830|Procedure|Dry needling|Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.
75729575|NCT01326403|Drug|Tranexamic acid|"GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR."
75729576|NCT00520845|Drug|celecoxib|600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
75729577|NCT00520845|Drug|Docetaxel|75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
75729578|NCT00520845|Drug|pemetrexed disodium|500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
75729579|NCT00520845|Other|laboratory biomarker analysis|Blood collection
75729580|NCT00185731|Drug|Atorvastatin|80 mg orally once daily
75729581|NCT00582491|Drug|Modafinil|Modafinil 400mg orally every day for 16 days
75729582|NCT00582491|Drug|Placebo|Placebo orally everyday for 16 days
75729583|NCT00520767|Drug|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
75729584|NCT00520767|Drug|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
76024924|NCT02393131|Radiation|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
75729585|NCT00520767|Drug|melphalan|Melphalan 9 mg/m2/day days 1-4
75729586|NCT00520767|Genetic|microarray analysis|≤28 days prior to enrollment
75729587|NCT00520767|Other|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
75729588|NCT00520767|Other|laboratory biomarker analysis|≤28 days prior to enrollment
75729589|NCT00520767|Procedure|quality-of-life assessment|Start of each cycle
76024925|NCT02393131|Radiation|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
76024926|NCT02696317|Device|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
76024927|NCT02696317|Device|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
75582610|NCT04600869|Other|Naturalistic Decision-Making Model-based Oncofertility Care Education|We designed the education program according to Klein's NDM model, which explored the reasoning mechanism behind decision-making (Klein, 1993). It depends on the on-the-job training date in each unit. The education program consisted of the following: (1) Information accumulation: explanations of common cancer therapies related to subsequent infertility, psychological and mental change in cancer survivors with infertility, the necessity and method of early determination of fertility intention, and type of fertility preservation. (2) Sense-making: situational case sharing, emphasis on the guidance interaction between experienced and novice nurses to understand the patient's situation. (3) Decision-making: how to provide support, how to correspond, and attitudes toward people with strong fertility intention.
75582611|NCT01804829|Biological|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
75582612|NCT00565422|Drug|Escitalopram|10 mg/day
75582613|NCT01804088|Device|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
75582614|NCT04608747|Other|Tahini|Fifty grams of tahini were consumed by 20 healthy males
75729590|NCT02390453|Behavioral|Combined Cognitive and Physical|Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
75729591|NCT02390453|Behavioral|Cognitive|Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
75435164|NCT05840757|Device|HemoSphere ClearSight Module|The Clear Sight system consists of a finger cuff connected to a monitor It will be applied to the patients finger before and removed after the TAVI procedure.
75435165|NCT05840744|Diagnostic Test|complete blood count|Investigations done for identifying the risk factor which lead to thrombosis.
75435166|NCT05840705|Procedure|Small curved incision with apex lateral|Small curved incision with apex lateral
75435167|NCT05840692|Drug|Escitalopram 20 mg|Antidepressant
75435168|NCT05840692|Drug|Placebo|
75435169|NCT05840679|Drug|Irrigation Solution|Different concentrations of NaOCl are being used as the endodontic irrigant.
75435170|NCT05840653|Other|psychotherapeutic intervention|The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation
75435171|NCT05840640|Drug|Standard Medical Therapy|Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
75435172|NCT05840640|Drug|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
75435173|NCT05840640|Drug|G-CSF and NAC|Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
75435174|NCT05840627|Other|Fruit juice|Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
75435175|NCT05840614|Behavioral|The remote family support program|"Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.~Each session consisted of a lecture, followed by role playing and supportive group therapy. In the first session, we informed the participants about the symptoms of eating disorders and mechanism of IPT; in the second session, we shared details about the characteristics of adolescents; and during the third and fourth sessions, we provided information on effective communication according to IPT."
75582615|NCT01802723|Drug|Drug: salmeterol xinafoate|
75582616|NCT01802723|Drug|Drug: Placebo|
75582617|NCT04600908|Other|Characteristics of accidents|informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration
75582618|NCT01789736|Drug|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
75582619|NCT01789736|Drug|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
75582620|NCT01789736|Drug|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
75582621|NCT04600947|Drug|LP002|10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.
75582622|NCT01789268|Device|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
75582623|NCT00564330|Drug|Esomeprazole|20mg bid
75582624|NCT00564330|Drug|Placebo|Placebo bid
75582625|NCT01783808|Other|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
75582626|NCT04600635|Procedure|Bariatric surgery|Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
75582627|NCT00564369|Other|CDC HIV testing recommendations|Current vs. prior CDC recommendations
75582628|NCT01779947|Drug|Estradiol Vaginal Tablets 10 mcg|
75582629|NCT01779947|Drug|placebo|
75582630|NCT00564408|Drug|Carbachol|3 microgram per kg bodyweight infused intravenously
75582631|NCT01773785|Drug|SPI-1620|SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
75582632|NCT01773785|Drug|Docetaxel|Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
75582633|NCT04608864|Procedure|varicocelectomy|microsurgical subinguinal varicocelectomy
75582634|NCT01758458|Biological|Aldesleukin|Given SC
75582635|NCT01758458|Other|Laboratory Biomarker Analysis|Correlative studies
75582636|NCT01758458|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
75729592|NCT02390453|Behavioral|Physical|Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
75881067|NCT03137459|Behavioral|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
75435176|NCT05840601|Device|Pointdexter|Commercially available prosthetic hand modified with the investigational Pointdexter finger in place of the usual index finger.
75435177|NCT05840601|Device|Comparator|Unmodified commercially available prosthetic hand.
75435178|NCT05840588|Drug|Antibiotic Treatment|Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid
75435179|NCT05840588|Dietary Supplement|Probiotic Bifidobacterium breve PRL2020 treatment|Probiotic Bifidobacterium breve PRL2020
75582637|NCT01758458|Radiation|Radiation Therapy|Undergo radiation therapy
75729593|NCT02390453|Behavioral|Active Control|Control modules provide social contact for group discussion of health and successful aging.
75729594|NCT04074707|Dietary Supplement|Labeled iron solution (60mg and 120mg Ferrous Sulfate)|3 doses of 60mg iron as FeSO4 are given on 3 consecutive days (e.g., days 1-3); 3 doses of 120mg iron as FeSO4 are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as FeSO4 are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 100ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with daily, alternate-day or every-third day dosing.
75729595|NCT04679051|Behavioral|Sleep duration|Participants will be asked to alter time in bed to achieve specified sleep durations.
75582638|NCT01758458|Biological|Recombinant Interferon Beta|Given intralesionally
75582639|NCT04608981|Drug|Prednisolone 30 mg|Steroidal anti-inflammatory drug as a preoperative medication
75582640|NCT04608981|Drug|Diclofenac Potassium 50mg Tab|Non-steroidal anti-inflammatory drug as a preoperative medication
75582641|NCT04608981|Drug|Placebo|Starch
75582642|NCT04600557|Behavioral|Describing a shameful experience using a self-compassionate prompt|Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt
75582643|NCT04600557|Behavioral|Receiving compassionate responses from confederates|Following the participant's description of a shameful experience, two confederates will respond with compassionate responses
75582644|NCT04600557|Behavioral|Describing a shameful experience using a neutral prompt|Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
75582645|NCT04600557|Behavioral|Receiving no response from confederates|Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
75582646|NCT01737905|Drug|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
75729596|NCT03873987|Drug|Current Formulation of Oritavancin|Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
75729597|NCT03873987|Drug|Kimyrsa|New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
75582647|NCT01737905|Drug|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
75729598|NCT03018587|Device|TruSculpt|All subjects will receive 1 truSculpt radiofrequency treatment
75729599|NCT02359253|Other|Passive stretching|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.
75729600|NCT02359253|Other|Passive movement|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
75729601|NCT02359253|Other|IntelliArm|During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
75582648|NCT03454958|Other|Measurements of body composition|Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer & skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.
75582649|NCT01730768|Drug|AQW051|
75582650|NCT01730768|Drug|Placebo|
75582651|NCT04600245|Procedure|Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.|One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used
75582652|NCT04608708|Other|The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions|lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
75582653|NCT01730027|Drug|ADC3680|ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
75582654|NCT01730027|Drug|Placebo|Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
75729602|NCT02359253|Other|Hand robot|During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
75729603|NCT04072913|Other|Vaginal samples (biopsies + vaginal smear)|Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
75881068|NCT03137459|Other|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
75435180|NCT05840536|Drug|Furosemide plus Chlorothiazide|"Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs."
75435181|NCT05840536|Drug|Furosemide|Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
75435182|NCT05840523|Other|Proprioceptive Neuromuscular Facilitation exercises|The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
75435183|NCT05840523|Other|The Range Of Motion exercises|The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
75582655|NCT01730027|Drug|montelukast|montelukast for 12 weeks
75435184|NCT05840497|Other|Resistance exercise|"The intervention group will train 3 times per week (30 minutes with 15 min warm-up). The resistance exercise is described as the voluntary contraction of the skeletal muscle of a particular muscle group against some type of resistance, using light weights, elastic bands or the weight of the body itself.~Patients will be offered online sessions, they will receive a document with recommendations and a link to the videos with instructions.~."
75582656|NCT04600284|Drug|AD-2101|AD-2101 16/5mg
75582657|NCT04600284|Drug|AD-2102|AD-2102 25mg
75582658|NCT04600284|Drug|AD-2101 + AD-2102|AD-2101 16/5mg + AD-2102 25mg
75582659|NCT01715012|Biological|ST266|ST266 is applied daily by spray to burn wound and skin graft donor site
75582660|NCT01715012|Drug|Saline|Saline is applied daily by spray to burn wound and skin graft donor site
75582661|NCT04600401|Other|Mentis Plus+ (Experimental Group)|"Each factor can be considered a module, so it is a modular program. So, each module has 3 sessions to be carried out in full. It is a systematic program, so the order of the sessions is regulated by the letters A, B and C for each module. The modules to be worked on correspond to the low-level or languising factors identified after the application of the positive mental health questionnaire (PMHQ). After the application of the PMHQ, people are grouped with the same module to work."
75582662|NCT04600440|Biological|Convalescent plasma|Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
75582663|NCT00555191|Behavioral|diet restriction|each meal should contain less than 2 gm fructose
75582664|NCT04608669|Drug|Paracetamol|Give paracetamol or placebo and compare temperature
75582665|NCT00555230|Drug|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
75582666|NCT00555230|Drug|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
75582667|NCT01711346|Biological|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
75582668|NCT01711346|Biological|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
75729604|NCT02579213|Other|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
75881069|NCT02071160|Drug|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
75435185|NCT05840458|Procedure|PENG Block|Patient will be placed in the supine position and the ultrasound probe will be placed in the transverse plane over the anterior inferior iliac spine (AIIS) and aligned with the pubic ramus by rotating the probe counterclockwise by approximately 45 degrees. A 22-gauge, 100 mm needle will be inserted using the plane approach from lateral to medial, between the psoas tendon anteriorly and the pubic ramus posteriorly. Following a negative aspiration, 20 mL of 0.375% ropivacaine will be injected. The needle position will be confirmed by visualizing the separation of layers with the dispersion of the injected volume.
75435186|NCT05840445|Drug|Onabotulinum toxin A|Intramuscular application of onabotulinum toxin-A in the upper facial third.
75435187|NCT05840445|Drug|Prabotulinumtoxin A|Intramuscular application of prabotulinum toxin-A in the upper facial third.
75435188|NCT05840419|Device|Laparoscopic appendectomy|Laparoscopic appendectomy with Airseal or with standard insufflation
75435189|NCT05840406|Drug|Postoperative pain management with acetaminophen|During the 24 hours postoperatively, participants will receive 1 g acetaminophen intravenously (i.v.) three times a day. On the second and third postoperative days, participants will receive 1g acetaminophen per os three times a day.
75729605|NCT04072679|Drug|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
75881070|NCT01362673|Drug|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
75881071|NCT01362673|Drug|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
76051570|NCT02275052|Drug|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
76051571|NCT02275052|Drug|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
75435190|NCT05840406|Procedure|Bilateral TAP Block with levobupivacaine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine will be administered to the participant on each side.
75435191|NCT05840406|Procedure|Bilateral TAP Block with levobupivacaine and dexmedetomidine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine with the addition of 0,5 μg/kg dexmedetomidine will be administered to the participant on each side.
75435192|NCT05840406|Drug|Postoperative pain management with tramadol|During the 24 hours postoperatively, participants will receive 500 mg tramadol + 500 ml 0,9% NaCl i.v. continuously 30ml/h.
75435193|NCT05840406|Drug|Postoperative pain management with ketoprofen|During the 24 hours postoperatively, participants will receive 100 mg ketoprofen + 100 ml of 0,9% NaCl i.v. twice a day. The first dose will be administered in the theatre at the end of the surgical procedure.
75435194|NCT05840406|Drug|Postoperative pain management with ibuprofen|On the second and third postoperative days, participants will receive 600 mg ibuprofen per os three times a day.
75582669|NCT01710644|Drug|Burlulipase|Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
75582670|NCT01710644|Drug|Placebo (Caramel in sterile water)|Placebo will be taken with meals and snacks for 5 to 7 days
75582671|NCT04608942|Device|Jett Plasma Medical Lift|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
75582672|NCT04608942|Procedure|Mechanical Debridement|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
75582673|NCT04600089|Drug|Saline|Saline infusion
75582674|NCT04600089|Drug|Ketamine|Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
75881072|NCT01362673|Drug|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
75582675|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
75582676|NCT01704365|Biological|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
75582677|NCT01704365|Biological|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
75582678|NCT01704365|Biological|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
75582679|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
75582680|NCT01704365|Biological|Placebo|0.5mL IM Injection
75881073|NCT01362673|Drug|Placebo|Oral single dose as matching placebo
75881074|NCT01362673|Drug|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
75582681|NCT04600011|Other|Physical and occupational therapy (PT/OT)|"Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk."
75582682|NCT04600011|Other|Home Safety Evaluation (HSE)|The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
76051572|NCT02275052|Drug|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
75582683|NCT01698281|Drug|AEZS-108|"AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity."
75582684|NCT01698281|Drug|SCCC|"commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available."
75582685|NCT01698281|Drug|Dexamethasone|Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
75582686|NCT00565461|Biological|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
75582687|NCT01858883|Drug|itacitinib|
75729607|NCT02579291|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
75435195|NCT05840393|Other|Discharge training based on Roy adaptation model|The Roy Adaptation Model consists of four main areas of adaptation. In this study, the content of the discharge education given within the scope of the adaptation areas of the Roy Adaptation Model will be continued with information such as home nutrition process, pain, anxiety, fear, stress and coping methods, addressing changing roles and responsibilities, communication, problem solving and utilizing social support. A booklet will be prepared to increase the effectiveness of discharge training based on the Roy Adaptation Model and the booklet will be used as a guide in the training program.
75435196|NCT05840367|Behavioral|Partner present in the operation room|The partner (father, co-mother or other close relative present for the birth) is present in the operation room during the entire category 1 cesarean section. This is standard clinical practice in this particular hospital since June 2021.
75435197|NCT05840341|Drug|QingyiHuaji optimized formula|Qingyihuaji Optimization Formula each bag contains: (1)Scutellaria barbata D. Don (Banzhilian); (2) Hedyotis diffusa Willd. (Sheshecao); (3) Amorphophallus rivieri Durieu (Sheliugu); (4) Amomi Fructus Rotundus (Doukou); (5) Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan); (6) Semen Coicis (Yiyiren); (7) Ganoderma lucidum (Curtis) P. Karst. (Lingzhi). One bag at a time, twice a day, rinsing with boiling water, continuous administration, oral administration in the morning and evening, every 3 weeks as a cycle.
75435198|NCT05840328|Drug|Dexmedetomidine Injection [Precedex]|interventional drug will be administred either intravenously or epidurally
75881075|NCT01362673|Drug|Placebo|Oral multiple doses as matching placebo for 12 days
75435199|NCT05840328|Drug|Bupivacaine Injection|intervention drug will be administred epidurally
75582688|NCT01858883|Drug|Gemcitabine|
75582689|NCT01858883|Drug|nab-paclitaxel|
75729608|NCT02579291|Other|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
75729609|NCT00474760|Drug|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
75729610|NCT02579681|Drug|dimethyl fumarate|dimethyl fumarate administered as per the arm description
75729611|NCT00528645|Drug|saracatinib|Given orally
75881076|NCT02077868|Other|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
75881077|NCT02077868|Drug|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
75582690|NCT01858883|Drug|filgrastim|
75582691|NCT01697072|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
75582692|NCT01697072|Other|Placebo|Placebo
75582693|NCT01697072|Drug|Epirubicin|Epirubicin is an anthracycline cytotoxic agent.
75582694|NCT01697072|Drug|Cisplatin|Cisplatin is a non-cell cycle specific chemotherapeutic agent.
75582695|NCT01697072|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine.
75582696|NCT00565500|Drug|celecoxib|celecoxib capsules 200 mg bid for 1 week
75582697|NCT00565500|Drug|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
75582698|NCT00565500|Drug|placebo|placebo capsules tid for 1 week
75582699|NCT04608162|Other|Pulsed Electromagnetic Field (PEMF)|PEMF was administered to the whole body using a 1.8×0.6m mat
75582700|NCT04608162|Other|Exercise Program|Exercise program to facilitate bone health
75881078|NCT01360957|Dietary Supplement|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
76051573|NCT05649020|Drug|Dose of prilocaine|With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
76051574|NCT04869488|Drug|Fluzoparib|Fluzoparib Orally twice daily（Cohort 1、Cohort 4）
75435200|NCT05840315|Dietary Supplement|Basic intervention and nutritional intervention|"The training plan is divided into 3 parts with different sub-components. There will be ongoing enrollment until 10 participants have been recruited, after which the next sub-trial will start recruitment. The intervention from the respective sub-trials is described in the individual study phases.~Participants attend one-hour exercise sessions, 2 times/week for 8 weeks, in groups of 4-7 patients, supervised by 2-3 physio therapists.~After completion of the physical intervention all participants are given a nutritional supplement, being a 200ml cocoa(Chokolate milk), containing 7 grams of protein, 24grams of carbohydrates, 5 grams of fat and in total 166 kilocalories. If any participant has lactose intolerance or diabetes, they are advised to bring an egg and a piece of rye bread to secure an equal amount of protein and calories."
75582701|NCT04608162|Other|Placebo PEMF|Patients received placebo PEMF
75582702|NCT04608084|Biological|Autologous platelet rich plasma eye drops|Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops
75582703|NCT04600050|Other|usual care and exercise education|Provide exercise training materials after the education of exercise and health to enable home-based exercise
75582704|NCT04600050|Other|Eccentric exercise|Under the face-to-face supervisor, the eccentric exercise using a flywheel, and the self-directed home-based eccentric overload exercise using an elastic band are performed.
75582705|NCT01691846|Drug|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
75582706|NCT01691846|Drug|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
75582707|NCT04599543|Drug|IL3 CAR T-cells|Each subject receive IL3 CAR T-cells by intravenous infusion
75582708|NCT01670981|Biological|ixmyelocel-T|12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
75582709|NCT01670981|Other|Placebo|12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
75582710|NCT01658501|Drug|50 mg PB1023|
75582711|NCT01658501|Drug|70 mg PB1023|
75582712|NCT01658501|Drug|100 mg PB1023|
75582713|NCT01658501|Drug|Placebo (0.9% Sodium Chloride)|
75582714|NCT01658501|Drug|Victoza®|
75582715|NCT01658501|Other|Diet and Exercise|
75881079|NCT04912583|Device|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
75582716|NCT01658501|Drug|Metformin|
75582717|NCT01658501|Drug|Sulfonylurea|
75582718|NCT01658501|Drug|Metformin and Sulfonylurea|
75582719|NCT01656239|Drug|fedovapagon 1 mg|
75582720|NCT01656239|Drug|fedovapagon 2 mg|
75881080|NCT04912583|Device|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
75582721|NCT01656239|Drug|fedovapagon 4 mg|
75582722|NCT01656239|Drug|Placebo ( sugar pill)|
75881081|NCT03131713|Drug|Acetaminophen|Acetaminophen 1000mg
75582723|NCT01651871|Drug|S-555739 Dose 1|
75435201|NCT05840315|Procedure|Sit-to-stand|"First subtrial (participants 1-10):~Sit-to-stand-to-sit training: Participants will be instructed to do as many sit-to-stand repetitions as possible without using their arms in a 30 second window, followed by a 30 second rest. This sequence is repeated for a total of 10 sets (a total of 10 minutes). Standard seat height of chair is 46 cm.~Progression/regression: If a participant is unable to do at least 6 repetitions on the first sit-to-stand test, they are allowed to sit on a 6cm airex pillow while performing the exercise. When a single set of 12 chair rises are attained or total amount of repetitions reach 100 in 10 sets on an airex, the participant progresses to sitting on a 6-0,5cm wedge pillow, and again when the participant attains 12 rises, he/she progress to rising from the standard chair height."
75582724|NCT01651871|Drug|S-555739 Dose 2|
75435202|NCT05840315|Procedure|Leg press|"Second subtrial (participants 11-20):~In addition to the above intervention, progressive strength training is performed on a leg press, consisting of 3 sets of 8-12RM. Participants are instructed to do as many repetitions as possible, and the weight is increased if either 12 repetitions are performed on three consecutive sets or a single set or more than 14 repetitions are completed. If fewer than 6 repetitions are performed, the weight is reduced . There is a minimum of one minute break between each set of training on the leg press."
75881082|NCT03534011|Procedure|Resuscitative Balloon Occlusion of the Aorta|If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
75582725|NCT01651871|Drug|Cetirizine HCl Dose 1|
75435203|NCT05840315|Procedure|Hip abduction|"Third subtrial (participants 21-30):~In addition to interventions described in sub-trials 1 and 2, progressive strength training of the gluteal muscles is carried out in the form of hip abduction from a sitting position, using a hip abduction machine, consisting of 3 sets of 8-12RM using the same procedure as above mentioned for the leg press."
75582726|NCT01651871|Drug|S-555739 placebo|
75582727|NCT01651871|Drug|Cetirizine HCl placebo|
75582728|NCT01647308|Drug|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
75582729|NCT01647308|Drug|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
75582730|NCT04599582|Device|Hip Arthroplasty|Patients are operated with hip replacement.
75582731|NCT04599738|Other|Wheat muffin|Participants consumed a control muffin made of wheat flour.
75582732|NCT04599738|Other|Finger millet grain muffin|Participants consumed a test muffin made of finger millet grain and wheat flour.
75582733|NCT01643330|Genetic|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10^13 DNase Resistant Particles (DRP) MYDICAR
75582734|NCT01643330|Genetic|Placebo|Single intracoronary infusion
75582735|NCT01642550|Drug|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
75582736|NCT01642550|Drug|Placebo|
75582737|NCT04608123|Other|none (observational study)|DBS
75582738|NCT01641848|Device|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
75582739|NCT04607811|Behavioral|Gamification with social incentives|Participants will select a step goal that is 33%, 40%, or 50% above their baseline step value. Participants in this group will participate in a game with points and levels to help motivate participants to meet their daily step goal. Additionally, all participants will identify a support partner to receive weekly updates on their performance and offer positive encouragement to help the participant meet their step goal.
75881083|NCT03534011|Device|REBOA catheter|Catheter with a Resuscitative Balloon for Occlusion of the Aorta
75881084|NCT01361035|Other|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
75582740|NCT00555308|Other|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
75582741|NCT04608006|Drug|Bupivacaine-fentanyl|Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
75582742|NCT01640756|Device|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
75582743|NCT04599621|Diagnostic Test|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10) All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.
75582744|NCT01636817|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
75582745|NCT01636817|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
75435204|NCT05840172|Device|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
75582746|NCT00564525|Drug|Amitriptyline|Medication taken for 4 weeks
75582747|NCT00564525|Drug|Placebo|Medication taken for 4 weeks
75881085|NCT04894799|Other|Vestibular stimulation|In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
75881086|NCT04894799|Other|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
75881087|NCT05191693|Procedure|ERCP|endoscopic papillary balloon dilation (EPBD) with endoscopic sphincterotomy (EST
75582748|NCT01634087|Drug|Itacitinib|Itacitinib administered orally
75582749|NCT01634087|Drug|Placebo|Placebo administered orally
75582750|NCT03454230|Procedure|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
75582751|NCT04607733|Drug|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
75582752|NCT04607733|Drug|Mirikizumab Autoinjector|Administered SC by autoinjector
75582753|NCT01632137|Drug|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
75435205|NCT05840172|Device|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
75582754|NCT01632137|Drug|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
75582755|NCT00565539|Drug|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
75582756|NCT01626599|Device|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~is not implantable and no surgical procedure is required for a human subject to use the devices;~is not for use in supporting or sustaining a human life; and~is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
75881088|NCT02073812|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
76051575|NCT04869488|Drug|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）
75435206|NCT05840172|Device|Control NRL condom|IIn each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
75435207|NCT05840146|Other|Kinesiotaping|"Two I-strips were used:~The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.~The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension."
75881089|NCT03514121|Biological|FPA150|A monoclonal antibody against B7-H4
75881090|NCT03514121|Biological|Pembrolizumab|An anti-PD1 antibody
75881091|NCT02930005|Drug|Meclofenamic acid|
75881092|NCT02930005|Drug|Pentosan polysulfate sodium|
75881093|NCT02074046|Biological|cancer stem cell vaccine|
75881094|NCT02071238|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
75582757|NCT04607694|Radiation|Proton radiotherapy|Proton radiotherapy
75582758|NCT04607694|Radiation|Photon radiotherapy|Photon radiotherapy
75582759|NCT04599699|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
75582760|NCT01563731|Drug|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
75582761|NCT04599114|Behavioral|VIRTUES|VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
75582762|NCT04599426|Biological|Allogeneic NK cell regimen group|"10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10^6/kg d13，d15 ."
75881095|NCT02071238|Behavioral|Group Consultation|Informed consent discussion in group-format
75881096|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
75881097|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
75881098|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
76051576|NCT04869488|Drug|Fluzoparib Combined With Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
76051577|NCT05648942|Diagnostic Test|Anemia testing|Patients will undergo a point of care test to identify possible anemia
76051578|NCT02274038|Drug|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
75582763|NCT04599348|Dietary Supplement|HRG 80 Red Ginseng|A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.
75582764|NCT01516346|Drug|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
75582765|NCT01516346|Drug|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
75582766|NCT01516346|Drug|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
75729612|NCT04072757|Behavioral|Intervention Group|"Session One: Loving Food That Loves You Back - Food as Fuel~connection nutrition and health Session Two: Myth busting: Fruits and Vegetables - delicious and affordable~seasonal fruits & vegetables in the diet Session Three: No Time to Cook! Making nutritious meals that are fast and easy~quickly make delicious/nutritious meals using minimal ingredients Session Four: Don't Eat Food You Can't Pronounce Except Quinoa; Eat Quinoa~choose healthier foods Session Five: Taste Bud Rehab~reduce foods high in sugar and salt.Mind-body connection Session Six: Batch & One Ingredient Cooking~making large quantities to freeze; one ingredient cooking Session Seven: Sweet Tooth? Healthy Desserts~prepare healthier desserts Session Eight: Family Meal Practices~healthy eating habits in children Session Nine: Snacks as Mini Meals~make nutritious snacks to keep energy up all day Session Ten: Revamp Your Favorite Recipe~healthy up favorite recipes"
76051579|NCT02274038|Drug|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
75435208|NCT05840146|Other|Sham taping|A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.
75435209|NCT05840133|Diagnostic Test|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
75435210|NCT05840107|Biological|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously
75435211|NCT05840094|Drug|18F-FDG|18F-FDG is injected intravenously with a dose of 0.1mCi/kg.
75435212|NCT05840094|Device|MR STIR|The overall scanning time of MR is about 13min.
75435213|NCT05840094|Procedure|EBUS-TBNA|Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively
75582767|NCT04607304|Device|ABCA2 GIRMS|Two systems (ABCA-C and ABCA-D) with run order randomized
75582768|NCT04599387|Other|Remote Exercise Prescription|Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.
75582769|NCT04599387|Other|Usual Care|Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
75582770|NCT01303796|Drug|Sapacitabine|Oral sapacitabine capsules
75582771|NCT01303796|Drug|Decitabine|Decitabine intravenous
75435214|NCT05840081|Other|Milk or yogurt beverage|Commercially available milk or yogurt (depending on experimental arm) will be incorporated into flavored drinks/smoothies to minimize perceived differences among these items, preserving the double-blind nature of the study design.
75435215|NCT05840029|Procedure|VIDEO-ASSISTED THORACOSCOPIC SURGERY|A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
75435216|NCT05840003|Radiation|Ultra-Low-Dose thoraco-abdominopelvic scan|In addition to the usual management (i.e. standard dose Computed Tomography), an Ultra-Low-Dose thoraco-abdominopelvic scan will be routinely performed.
75435217|NCT05839977|Other|Individual telerehabilitation|The exercise will consist of strength and balance exercises using the Homebalance ® system
75435218|NCT05839977|Other|Home exercises based on videos|intervention include 12 video recordings of exercises created by a physiotherapist for home exercises, according to which they will also exercise
75435219|NCT05839964|Dietary Supplement|CBN and CBD|CBN and CBD in Gummy Format
75435220|NCT05839834|Diagnostic Test|Blood test|RNA sequencing of peripheral blood cells
75582772|NCT04598880|Drug|Polyethylene glycol + ascorbate|Pleinvue® is administered orally in 2 doses (3 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose is administered at 9 pm on the day before intervention (sachet 1: MACROGOL 3350 100 g + SODIUM SULFATE ANHYDROUS 9 g + SODIUM CHLORIDE 2 g + POTASSIUM CHLORIDE 1 g). Second dose is administered 5 hours before intervention and it is composed by 2 sachets (sachet A: MACROGOL 3350 40 g + SODIUM CHLORIDE 3,2 g + POTASSIUM CHLORIDE 1,2 g; sachet B: SODIUM ASCORBATE 48,11 g + ASCORBIC ACID 7,54 g).
75582773|NCT04598880|Drug|Sodium picosulfate + magnesium citrate|Citrafleet® is administered orally in 2 doses (2 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose (sachet 1) is administered at 9 pm on the day before intervention. Second dose (sachet 2) is administered 5 hours before intervention. Sachets 1 and 2 have the same composition: SODIUM PICOSULFATE 10 mg + MAGNESIUM OXIDE 3,5 g + CITRIC ACID 10,97 g.
75582774|NCT04598646|Behavioral|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
75582775|NCT04598646|Behavioral|Support|Behavioural support via professionals and peer support.
75435221|NCT05839821|Behavioral|noF-noRAS|resting state, that is, without finger-tapping and without listening to RAS
75435222|NCT05839821|Behavioral|F-noRAS|finger-tapping without listening to RAS
75582776|NCT04598646|Behavioral|Passive Behavioural Support|Passive behavioural support, either PAI-Score or recommended physical activity guidelines for cancer survivors, to encourage physical activity.
75582777|NCT04598958|Other|IMPROVE|Health system interventions that include: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees
75435223|NCT05839821|Behavioral|noF-100RAS|listening to RAS with the 100% of the baseline tempo and without finger-tapping
75435224|NCT05839821|Behavioral|F-100RAS|finger-tapping and listening to RAS with 100 % of baseline tempo
75582778|NCT04607655|Drug|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
75582779|NCT04607655|Drug|Placebo|Placebo is administered as inhalation once a day
75881099|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
75582780|NCT04607343|Device|Rehabilitation device based on electrical stimulation|Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
75582781|NCT04607265|Diagnostic Test|Cardiac MRI|Comparison of scar characteristics on cardiac MRI between the two groups.
75582782|NCT04598763|Other|smell the odors of the olfactory rehabilitation kit according to the classic or intensive method|regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
75881100|NCT01349387|Drug|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
75881101|NCT01365715|Procedure|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
75881102|NCT01365715|Procedure|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
75435225|NCT05839821|Behavioral|F-105RAS|finger-tapping and listening to RAS with 105 % of baseline tempo
75435226|NCT05839821|Behavioral|F-110RAS|finger-tapping and listening to RAS with 110 % of baseline tempo
75435227|NCT05839782|Procedure|Mitral valve repair (PLM)|A mitral valve plasty is performed to treat mitral regurgitation
75435228|NCT05839782|Procedure|Mitral valve replacement|A mitral valve replacement with a prosthesis is performed to treat mitral regurgitation
75435229|NCT05839704|Procedure|Bilateral Erector Spinae Plane Block|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the erector spinae plane at the level of T8.
75582783|NCT00564564|Drug|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
75582784|NCT00564564|Drug|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
75582785|NCT02894138|Drug|alteplase|
75582786|NCT02894138|Drug|Placebo|
75881103|NCT04913441|Other|Routine physical therapy|Patients in this group will get every session routine physical therapy of 30 minutes 3 times per week on alternative days for 12 weeks
75881104|NCT04913441|Other|Manual physical therapy with routine physical therapy|Patients in this group will get every session Manual physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
75435230|NCT05839704|Procedure|Abdominal Wall Blocks|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the subcostal transversus abdominus plane bilaterally and the serratus plane on the left side
75435231|NCT05839652|Drug|Midodrine Hydrochloride|Determine best drug and dose to increase and stabilize SBP during orthostatic tilt
75435232|NCT05839613|Diagnostic Test|Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)|Pharmacogenetics (PG) is the study of genetic differences in drug met-abolic pathways Therapeutic Drug Monitoring (TDM) is the quantification and interpre-tation of drug concentration in blood to optimize pharmacotherapy
75435233|NCT05839587|Procedure|Robotic TAPP|Robotic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of docking of the robot and port placement and part 4 consists of de-docking and skin closure
75582787|NCT00565656|Drug|BEVACIZUMAB|Administration of Bevacizumab
75582788|NCT02894021|Procedure|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
75881105|NCT04913441|Other|Stretching physical therapy with routine physical therapy|Patients in this group will get every session of Stretching physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
76024928|NCT02393053|Procedure|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
75582789|NCT02894021|Procedure|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
75881106|NCT01361191|Drug|R-MEGACHOP|"If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3)."
75881107|NCT03499613|Other|Multidisciplinary rehabilitation program|The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
76051580|NCT02274038|Drug|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
76051581|NCT02300558|Drug|Eleclazine|Tablets administered orally
75435234|NCT05839587|Procedure|Laparoscopic TAPP|Laparoscopic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of port placement only and part 4 consists of skin closure only.
75435235|NCT05839548|Drug|Mepivacaine 2% with epinephrine 1:100,000|Local Anesthesia
75435236|NCT05839548|Drug|Articaine (4%) with epinephrine 1:100,000|Local Anesthesia
75435237|NCT05839535|Behavioral|BDJ|BDJ is a mind-body intervention
75435238|NCT05839535|Device|tDCS|tDCS is a brain stimulation method.
75435239|NCT05839535|Device|sham tDCS|sham tDCS
75435240|NCT05839535|Other|exercise|exercise including stretching and other activities.
75582790|NCT00564603|Drug|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
75582791|NCT00564603|Other|0.9% Saline|Saline, in same volume of 2mL
75582792|NCT00565695|Device|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
75582793|NCT02894099|Other|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
75881108|NCT04905173|Other|Squat-to-stand maneuver|Subjects will squat for 5 seconds and then stand. The squat-to-stand exercise will be done up to 10 times, and then immediately undergo echocardiographic imaging.
76051582|NCT02300558|Drug|Eleclazine placebo|Tablets administered orally
76051583|NCT04882046|Other|Blood collection|Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
76051584|NCT04882046|Other|Data collection|collection of socio-demographic, clinical and biological data.
76051585|NCT02273960|Drug|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
76051586|NCT02273960|Drug|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
76051587|NCT02273960|Drug|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
75582794|NCT02894099|Other|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
75582795|NCT02894099|Other|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
75582796|NCT02894099|Other|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
75582797|NCT00555347|Drug|Armodafinil|Dosage 150-250 mg
75582798|NCT00555347|Drug|Placebo|Placebo
75881109|NCT04905173|Drug|Amyl nitrite inhalation|Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.
75435241|NCT05839522|Diagnostic Test|Point-of-care hepatitis C antibody test|Qualitative point-of-care test for hepatitis C antibodies (saliva sample)
75582799|NCT00564642|Drug|N Acetylcysteine|1200 mg, BD, 2weeks
75582800|NCT00555386|Dietary Supplement|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
75582801|NCT01580709|Procedure|Multiple brushings|Seven consecutive brush samples for cytology.
75582802|NCT01580709|Procedure|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
75582803|NCT02894294|Other|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine [SP] + Amodiaquine [AQ]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
75582804|NCT00565890|Drug|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
75582805|NCT02894060|Other|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
75881110|NCT04905173|Other|Valsalva|Subjects will undergo echocardiographic imaging while performing the Valsalva maneuver. This is according to current laboratory protocol and is part of standard of care.
75881111|NCT01362751|Other|No intervention|This study is an observational cohort study > no interventions
76051588|NCT02273960|Drug|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
75435242|NCT05839522|Diagnostic Test|Point-of-care hepatitis C RNA test|Hepatitis C Viral Load point-of-care test (fingerstick wholeblood sample)
75435243|NCT05839522|Diagnostic Test|Point-of-care hepatitis B surface antibody test|Qualitative hepatitis B surface antibody point-of-care test (fingerstick wholeblood sample)
75435244|NCT05839522|Diagnostic Test|Point-of-care hepatitis B surface antigen test|Qualitative hepatitis B surface antigen point-of-care test (fingerstick wholeblood sample)
75435245|NCT05839522|Diagnostic Test|Point-of-care HIV antibody test|Qualitative HIV antibody point-of-care test (saliva sample)
75582806|NCT02894216|Procedure|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
75582807|NCT02894255|Device|Coronary artery bypass grafting|
75582808|NCT02894255|Procedure|Percutaneous coronary intervention|
75582809|NCT00565929|Drug|Placebo|Sterile saline (0.9%).
75729613|NCT04072757|Behavioral|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
75435246|NCT05839522|Behavioral|Interview-style survey|Interview-style survey regarding demographics, risk behaviours, BBV testing and treatment history, and point-of-care testing acceptability
75582810|NCT00565929|Biological|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10^7 or 1X10^8 TCID 50.
75582811|NCT04676516|Drug|GSK3326595|GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
75582812|NCT04606758|Procedure|PCNL under fluoroscopic control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance
75729614|NCT00524745|Biological|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
75729615|NCT04073693|Dietary Supplement|Branched chain amino acids (BRCA)|They were with BRCA during the day apart of following the standard recommendations
75729616|NCT01017796|Drug|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
75435247|NCT05839509|Drug|GH001|GH001 administered via inhalation
75435248|NCT05839327|Diagnostic Test|Montreal cognitive assessment scale (MOCA)|Tests to evaluate cognitive disorders (MOCA), anxiety and depression (HADS) Pos-traumatic stress disorder (PCL-C) and quality of life (SF-36)
75729617|NCT01783535|Drug|vincristine|Given via minibag/gravity flow.
75729618|NCT01783535|Drug|topotecan|Given IV over 30 minutes.
75729619|NCT01783535|Drug|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is >2,000/µL on one occasion after the expected nadir.
75729620|NCT01783535|Drug|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is >2,000/µL on one occasion after the expected nadir.
75729621|NCT01783535|Drug|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
75435249|NCT05839275|Drug|Surufatinib|In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd.
75435250|NCT05839275|Drug|Sintilimab|200mg, d1, q3w
75435251|NCT05839275|Radiation|Radiotherapy|"BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.~Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy)."
75582813|NCT04606758|Procedure|PCNL under ultrasound control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance
75582814|NCT04676321|Other|Patient pathway|Investigation on the appropriateness and quality of NSCLC care among participating sites
75582815|NCT04598568|Device|balanSys UNI|Implantation of a balanSys UNI knee prosthesis implanted with a spacer block surgical technique
75582816|NCT04607031|Diagnostic Test|measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke|7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications
75729622|NCT01783535|Other|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
75729623|NCT01783535|Drug|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
75729624|NCT01783535|Drug|cyclophosphamide|Given IV.
75729625|NCT01783535|Drug|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
75729626|NCT01783535|Drug|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
75729627|NCT01783535|Procedure|enucleation|Eye removal due to advanced disease in Strata C and D participants.
75881112|NCT01361269|Drug|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
75881113|NCT01357187|Other|Scheduled removal of posterior instrumentation with AmnioFix|
75582817|NCT04676165|Device|Smart About Meds (SAM)|"SAM generates a patient-friendly list of prescribed and dispensed medications and offers several features:~Drug information: Patient-friendly monographs that describe treatment indications and the harms/benefits of medications.~Adherence alerts: Alerts users to non-adherence, such as when they fill prescriptions that were stopped at hospital discharge, don't fill prescribed medications, or buy medications at the incorrect dose.~Side-effect checker: Provides a list of side effects associated with individual medications and the patient's overall drug profile.~Rate my med: Allows patients to rate medications and describe experiences with a medication. Patients can view ratings given by users.~Caregiver connect: Provides patients' caregivers with access to the app.~Pharmacy connect: Allows patients to connect with their hospital pharmacist to ask questions regarding their medications and adherence alerts.~Other: pill images, daily pill reminders, weekly dosing schedule"
75582818|NCT04606953|Behavioral|Attention Process Training (APT-II)|The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
75881114|NCT01357187|Other|Scheduled removal of posterior instrumentation without AmnioFix|
75881115|NCT01362829|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
75435252|NCT05839262|Other|Conventional physical rehabilitation (CPR) / Active video games (AVG)|"In each session a routine of conventional exercises and active video games is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility).~AVG: Set of interactive video games available for the Nintendo Switch console."
75435253|NCT05839262|Other|Conventional physical rehabilitation (CPR)|"In each session a routine of conventional exercises is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility)."
75435254|NCT05839249|Other|JJ urological stents|recording complications of JJ stents during COVID19 pandemics
75435255|NCT05839236|Combination Product|Atorvastatin Calcium Tablets|The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
75582819|NCT04675658|Behavioral|CBPA + family support|Classroom Based Physical Activity + family support as described in the Arm
75435256|NCT05839223|Other|Education|"educational process (recommendations) about isotretinoin by a clinical pharmacist.~The information included: the degree of the importance of adherence to the drug and the recommendations, the correct method of taking it, the importance of doing periodic laboratory tests (lipid profile, liver enzyme test, and pregnancy test), common side effects, how to properly avoid and deal with side effects, precaution warnings they should pay attention to, and what are the cases in which the drug should be stopped."
75435257|NCT05839197|Procedure|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
75582820|NCT04675658|Behavioral|CBPA|Classroom Based Physical Activity
75582821|NCT04598490|Device|Space closure into old extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into healed bony socket
75582822|NCT04598490|Device|Space closure into recent extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into fresh bony socket
75881116|NCT01349543|Biological|RSV A Memphis 37|Intranasal administration
75881117|NCT01353209|Drug|Letrozole|2.5 mg daily for twelve months
75881118|NCT01353209|Drug|Placebo|sugar pill given daily for twelve months
75881119|NCT03637491|Drug|Avelumab|IV treatment
75881120|NCT03637491|Drug|Binimetinib|Oral treatment
75881121|NCT03637491|Drug|Talazoparib|Oral treatment
75881122|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
75582823|NCT04675697|Drug|Platinum-etoposide+Anlotinib|Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
75582824|NCT04606836|Drug|Bupivacaine Hydrochloride|See group descriptions
75582825|NCT04675814|Other|Adapted Physical Activity (APA)|Adapted Physical Activity (APA)
75729628|NCT01783535|Radiation|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
75881123|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
75881124|NCT01357265|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
76051589|NCT01646021|Drug|Ibrutinib|560 mg once daily continuous (without interruption) by mouth for 21-day cycles
76051590|NCT01646021|Drug|Temsirolimus|175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
76051591|NCT01750918|Drug|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
76051592|NCT01750918|Drug|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
75582826|NCT04598256|Procedure|Endoscopic procedure|Esophagogastroscopy and colonoscopy
75582827|NCT01163149|Drug|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
75582828|NCT01163149|Drug|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
75582829|NCT04676126|Dietary Supplement|Lumega-Z|Medical food which contains lutein, zeaxanthin, and meso-zeaxanthin
75582830|NCT04676126|Drug|Dorzolamide Hcl 2% Oph Soln|Topical carbonic anhydrase inhibitor
75582831|NCT04676126|Other|Placebo|Specially formulated non macular pigment-containing formulation which tastes similar to the commercial medical food being evaluated in this study
75881125|NCT04550455|Drug|Cladribine Tablets|Cladribine tablets will be administered according the current package insert guidelines
75881126|NCT03713463|Other|Oral Nutritional Supplement (ONS)|Per standard of care (SOC)
75881127|NCT01363141|Other|Regular AGE Diet|Regular AGE Diet
75881128|NCT01363141|Other|Low AGE Diet|One year reduction in dietary AGE intake.
75881129|NCT03675243|Diagnostic Test|sphincterometry|Sphincterometry is a method of the spincter function examination, which allows to assess the state of the anal sphincter muscle and its function
75582832|NCT04598373|Behavioral|interdisciplinary treatment|Interdisciplinary treatment (IDT) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
75582833|NCT04675619|Drug|Oral pirfenidone|Treatment
75582834|NCT04675619|Drug|Standard care|Treatment
75582835|NCT04675892|Procedure|A1 pulley division|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Wound closure with absorbable sutures and application of a light dressing."
75582836|NCT04675892|Procedure|A1 pulley division + Resection of one or both slips of the FDS tendon|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Palmar Bruner incision over the PIP joint. Distal dissection and resection of one or both slips of the FDS tendon.~Wound closure with absorbable sutures and application of a light dressing."
75582837|NCT04598100|Behavioral|FOCUS-EC|
75582838|NCT01163032|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
75582839|NCT01163032|Drug|Placebo|Placebo capsules, PO daily for 6 months
75582840|NCT04675736|Procedure|brushing force|Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface
75729629|NCT05001646|Device|In-home resonance-based electromagnetic field protection device|Participants will have an in-home EMF protection device
75729630|NCT00495040|Radiation|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
75881130|NCT01349699|Drug|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
75729631|NCT04073537|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
75729632|NCT04073537|Drug|Placebos|Anlotinib blank analog capsule.
75435258|NCT05839197|Drug|Camrelizumab plus Apatinib|"Apatinib(250 mg; p.o.; qd.); camrelizumab (200 mg; iv drip; q3w) If the liver function was grade Child-Pugh A, Camrelizumab was given intravenously once every 3 weeks (D1) on the same day, 200mg/, once every 3 weeks (D1).~Apatinib capsule was given orally to 250mg within half an hour after breakfast on the second day (D2) after the first HAIC. The drug was given continuously once a day and stopped on the same day of each HAIC."
75435259|NCT05839171|Behavioral|music and mandala coloring|Listening to music and coloring mandalas for women who have undergone embryo transfer and are waiting at home
75435260|NCT05839132|Procedure|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
75435261|NCT05839080|Behavioral|Gardens to Bellis|In FoodACT the school garden intervention that will be investigated is the well described and well-developed intervention called Gardens to Bellis. It involves pupils from 4th-5th grade and their teachers. The classes attend 8 school garden sessions distributed across two school years. The sessions start each year in March and ends in November. Pupils are divided into smaller groups, who gets a plot of which they are responsible for preparing, weed and harvest. The purpose is that pupils can cook their own food with the greens, fruits and berries they harvest in the garden and finds in the nature. The pupils and their families will hatch and harvest the school gardens between the session days.
75435262|NCT05839080|Behavioral|No intervention|Pupils are not receiving any intervention
75729633|NCT04073537|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV on Day 1 of each 21-day cycle.
75729634|NCT04073537|Drug|Carboplatin|Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
75729635|NCT03998631|Procedure|Carbon Dioxide and Saline Flush|The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.
75881131|NCT01349699|Drug|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
75881132|NCT01349699|Drug|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
76024929|NCT02393053|Procedure|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
75582841|NCT05305300|Biological|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A|receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.
75582842|NCT05305300|Biological|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B|receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
75582843|NCT04606719|Procedure|Advanced Platelet Rich fibrin|Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
75582844|NCT04187755|Drug|Ceftazidime Injection|Ceftazidime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 6 hourly)
75729636|NCT03998631|Procedure|Standard Saline Flush|Standard of care flushing of the TEVAR or TAVI device with normal saline.
75729637|NCT01020760|Behavioral|Face down posture|Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
75582845|NCT04187755|Drug|Cefepime Injection|Cefepime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 8 hourly)
75582846|NCT00555542|Drug|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
75582847|NCT04606563|Drug|Losartan|Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.
75582848|NCT04606563|Drug|Valsartan|Oral Valsartan 40 mg, stepped up to 80 mg and then up to 160 mg peak dose, as tolerated.
75582849|NCT04606563|Drug|Azilsartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
75729638|NCT04085133|Diagnostic Test|Gene Xpert Chest x ray and MSCT chest|Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis
75582850|NCT04606563|Drug|Candesartan|Oral Candesartan 8 mg, stepped up to 16 mg and then up to 32 mg peak dose, as tolerated.
75582851|NCT04606563|Drug|Eprosartan|Oral Eprosartan 400 mg, stepped up to 600 mg and then up to 800 mg peak dose, as tolerated.
75582852|NCT04606563|Drug|Irbesartan|Oral Irbesartan 75 mg, stepped up to 150 mg and then up to 300 mg peak dose, as tolerated.
75582853|NCT04606563|Drug|Olmesartan|Oral Olmesartan 10 mg, stepped up to 20 mg and then up to 40 mg peak dose, as tolerated.
75582854|NCT04606563|Drug|Telmisartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
75435263|NCT05839067|Behavioral|Care-HF|Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
75582855|NCT02885584|Device|High frequency percussive ventilation|
75582856|NCT00565968|Drug|melphalan|
75582857|NCT00565968|Drug|sorafenib tosylate|
75582858|NCT00565968|Genetic|gene expression analysis|
75729639|NCT01020916|Procedure|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
75582859|NCT00565968|Genetic|protein expression analysis|
76024930|NCT01959412|Drug|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
76024931|NCT01959412|Drug|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
75582860|NCT00565968|Genetic|western blotting|
75582861|NCT00565968|Other|pharmacological study|
75582862|NCT01162486|Drug|Rifampin & midazolam|rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
75729640|NCT01020916|Procedure|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
76024932|NCT01959412|Drug|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
76024933|NCT01959412|Drug|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
76024934|NCT01959412|Drug|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
75582863|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
75582864|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
75582865|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
75582866|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
75582867|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
75582868|NCT00555698|Device|Deep Brain Stimulations for Depression|Deep Brain Stimulations for Depression
75582869|NCT04314427|Procedure|Roux-en-Y gastric bypass|
75582870|NCT04314427|Procedure|Sleeve gastrectomy|
75435264|NCT05839054|Device|Virtual Reality audio and visual glass (Roller Coasters, group 1)|During the inhaler treatment, the child was shown Roller Coasters with VR glasses.
75582871|NCT04598607|Drug|Hypidone Hydrochloride tablets|30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
75582872|NCT04598607|Drug|Placebo|3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
75582873|NCT02885701|Other|No Splint|The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson & Johnson, New Brunswick, NJ) over the incision.
75582874|NCT02885701|Other|Removable Splint|The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
75582875|NCT02885701|Other|Non-removable Splint|The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
75729641|NCT02664363|Biological|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
75729642|NCT01020994|Drug|LAS41003|Once daily, topically
75582876|NCT00555737|Device|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
75582877|NCT01162135|Drug|Digoxin|"The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose."
75435265|NCT05839054|Device|Virtual Reality audio and visual glass (Wild Dolphins, group 2)|During the inhaler treatment, the child was shown Wild Dolphins with VR glasses.
75582878|NCT00555776|Drug|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
75582879|NCT00555776|Drug|placebo|placebo is given with the same definition as Gabapentin
75435266|NCT05839015|Behavioral|mHealth Intervention Based on Self-Compassion|Self-compassion techniques aim at developing compassionate skills for emotion regulation, such as self-kindness, recognition of common humanity, and mindfulness.
75435267|NCT05839015|Behavioral|Psychoeducation Intervention|Psychoeducational intervention promotes the learning of emotions, thoughts and behaviors through the description and explanation of psychological dimensions.
75435268|NCT05839002|Procedure|nCRT|ESCC patients that recieved surgery and nCRT.
75435269|NCT05838989|Device|Prefabricated Orthoses|Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.
75582880|NCT04675463|Drug|BGF Inhalation Aerosphere|Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time
75582881|NCT04675463|Drug|GFF Inhalation Aerosphere|Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
75582882|NCT04675112|Behavioral|Cognitive Behavioral Treatment (CBT) and Tinnitus Retraining Therapy (TRT)|"CBT is a psychologically informed treatment. Depending on individual patient needs, relevant areas of tinnitus education and management/self-management strategies, such as managing the emotional consequences of tinnitus, rapid relaxation, managing fear and avoidance behaviors and changing unhelpful thoughts and beliefs, are applied in accordance to a published manual [10].~TRT is based on the neurophysiological model focusing more on education and sound therapy than on analytical cognitive and behavioral interventions. A TRT program is usually included in a management scheme with hearing aids."
75582883|NCT01161628|Drug|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
75582884|NCT04598217|Other|anesthesiologist|non-interventional observational
76024935|NCT01959412|Drug|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
75582885|NCT04675502|Other|supervised Exercise training|warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
75582886|NCT04675502|Other|home exercise trainig|Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
75582887|NCT04314505|Drug|Opioid-Sparing Protocol|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. In the opioid-sparing group, a dose of Parecoxib sodium 40 mg was administrated through intravenous route before the incision. After the surgery, Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
75582888|NCT04314505|Drug|Opioid-Based Patient Controlled Analgesia|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
75582889|NCT04606641|Other|functional tasks with mirror therapy|In this group a mirror will be placed in the sagittal plane of patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror. Then the patient will be asked to perform functional tasks
75582890|NCT04606641|Other|functional tasks without mirror therapy|The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks
75582891|NCT02885467|Procedure|Total knee arthroplasty with Saphenous nerve burial|
75582892|NCT02885467|Procedure|Standard total knee arthroplasty|
75582893|NCT02885545|Device|Watchman|If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart
75582894|NCT02885545|Drug|Continued therapy with the prescribed oral anticoagulant|If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
75435270|NCT05838989|Other|general and lumbrical muscle stretching|Participants in this group will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks. The stretching exercises will be performed under the supervision of a trained therapist and will include a series of exercises designed to stretch the muscles in the hands, wrists, and forearms. In addition, participants will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist.
75582895|NCT04598412|Other|No intervention|Cross-sectional
75582896|NCT04675268|Diagnostic Test|oximetry|A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
76024936|NCT02402101|Device|Procedure: active tDCS|Intensity 2 mA during 20 minutes
76024937|NCT02402101|Device|Procedure: sham tDCS|sham condition as delivered by the stimulator
75435271|NCT05838989|Other|Placebo|Participants in this group will receive placebo treatment consisting of gentle wrist and hand movements. The movements will be performed under the supervision of a trained therapist and will consist of gentle range of motion exercises designed to mobilize the joints in the hands and wrists. Participants will not be provided with any orthoses to wear during the study.
76024938|NCT02402179|Other|Tryptophan|Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
76024939|NCT02401945|Drug|DE-120|
76024940|NCT02401945|Drug|Aflibercept|
75582897|NCT01161472|Drug|4mg fesoterodine|4mg tablet once daily for 6 days
75582898|NCT01161472|Drug|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
75582899|NCT01161472|Drug|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
75582900|NCT01161472|Drug|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
75435272|NCT05838976|Diagnostic Test|Shorter Version of the CTQ-SSS|The intervention in this study is the administration of the shorter version of the CTQ-SSS, a validated questionnaire designed to assess the severity of symptoms and functional limitations associated with carpal tunnel syndrome. The CTQ-SSS consists of 8 items related to symptom severity and 2 items related to functional status. The scores for each set of items are combined to generate symptom severity and functional status scores, which will be used to assess the validity and reliability of the CTQ-SSS in patients with carpal tunnel syndrome undergoing nonsurgical management.
75435273|NCT05838950|Other|high-intensity interval training intervention|Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.
75435274|NCT05838924|Other|PHYSICAL ACTIVITY + VIRTUAL REALITY|"The VR therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 VR exercises of Back School by manipulating visual proprioceptive information during all lumbar movements. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
75582901|NCT04606680|Device|Heat application at acupoints|"The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard. The hot sticker will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~The following lifestyle modification are recommended to help to establish healthy habits:~The proportion of three nutrients in total calories comprises of 55%-65% from carbohydrates, 20%-30% from oils and 15% from protein, and the energy of the whole day distributed to three meals will follow the proportion of 30% for breakfast, 40% for lunch and 30% for dinner. Meanwhile, low-to-moderate intensity physical activities will be instructed to them for at least 5 days per week continually, 30%-50% of the maximum heart rate reserve value will be required."
75729643|NCT01020994|Drug|LAS189962|Once daily, topically
75729644|NCT01020994|Drug|LAS189961|Once daily, topically
75729645|NCT00494026|Drug|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
75729646|NCT00494026|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
75729647|NCT00494026|Procedure|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
75582902|NCT04606680|Device|Medicated plaster at acupoints|"The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the ordinary sticker. They will be placed on the patient's acupoints for about 2 hours. The sticker has the same shape as the hot sticker, but it does not have the effect of thermal stimulation and infrared radiation. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~Lifestyle modification:It will be performed as the same as the heat application group."
75582903|NCT04606680|Device|Herb-partitioned moxibustion at acupoints|"The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard[18]. The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the hot sticker. They will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~Lifestyle modification:It will be performed as the same as the heat application group."
75729648|NCT01018108|Procedure|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
76024941|NCT01977820|Drug|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
76051593|NCT01750918|Drug|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
75435275|NCT05838924|Other|PHYSICAL ACTIVITY|"The 8 therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 exercises of Back School without VR. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
75435276|NCT05838898|Device|Specular microscopy|Non-contact Specular microscopy is a non-invasive method that allows for in vivo study of corneal endothelium.
75435277|NCT05838872|Device|Minuteful - Kidney Urine Analysis Test System|Urine samples were collected and tested by a lay user, using the Minuteful - Kidney test device. The lay user test results were compared to the results obtained by testing the same urine sample on the comparison device, the URiSCAN Optima.
76051594|NCT01750918|Device|5-fluorouracil|5-fluorouracil-based chemotherapy
76051595|NCT02300987|Drug|LEE011|
75729649|NCT01018108|Procedure|Acupuncture Therapy|Undergo acupuncture
75729650|NCT01018108|Other|Questionnaire Administration|Ancillary study
75729651|NCT01018108|Other|Laboratory Biomarker Analysis|Correlative Study
75729652|NCT00524589|Dietary Supplement|calcitriol|IV
75729653|NCT00524589|Drug|dexamethasone|Oral
76051596|NCT02300987|Drug|LEE011 Placebo|
75729654|NCT00524589|Genetic|protein expression analysis|Correlative Study
75729655|NCT00524589|Other|laboratory biomarker analysis|Correlative Study
75729656|NCT04074837|Drug|NNI-362|NNI-362 small molecule in liquid suspension.
75729657|NCT04074837|Drug|Placebo|Placebo liquid suspension
75729658|NCT01015066|Drug|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
75729659|NCT01015066|Drug|Naltrexone|Oral tables, 50 mg/d, once a day for six months
75729660|NCT01021072|Drug|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
75729661|NCT00472030|Drug|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
76024942|NCT01977820|Drug|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
76024943|NCT02402023|Behavioral|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
76024944|NCT02402023|Behavioral|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
75582904|NCT04675385|Drug|0.2% hyaluronic acid gel|In this split mouth study, 733 periodontal pockets of 28 patients with moderate to severe chronic periodontitis were chosen for investigation. They were divided into 2 groups: control group and experimental group. The experimental group received sub-gingival administration of 1 ml of 0.2% hyaluronic acid gel into each pocket immediately after root planing and then after 1 week, 2 weeks and 3 weeks. Clinical parameters were assessed at baseline and 6 weeks after root planing. Subgingival plaque was assessed at baseline and 6 weeks after root planing. Quantitative real-time PCR for Porphyromonas gingivalis (Pg), Treponema denticola (Td), Fusobacterium nucleatum (Fn) Tannerella forsythia (Tf) were performed at the same time.
75582905|NCT04598061|Drug|Dexmedetomidine IV|Dexmedetomidine IV
75582906|NCT01161043|Device|Sensor wear|All subjects to wear sensors
75729662|NCT00472030|Drug|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
75729663|NCT00127855|Biological|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
75729664|NCT00127855|Biological|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
75729665|NCT00127855|Biological|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
75729666|NCT00127855|Biological|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
75881133|NCT01349699|Drug|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
76024945|NCT02392897|Behavioral|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
76024946|NCT02392897|Behavioral|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
75582907|NCT04606875|Diagnostic Test|Campbell Score|The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.
75582908|NCT04674956|Drug|Camrelizumab|PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.
75582909|NCT04674956|Drug|Paclitaxel(Albumin Bound) and Gemcitabine|Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.
75582910|NCT04674956|Drug|Placebo|Placebo, 200mg, D1; every 21 days as a cycle.
75582911|NCT00564720|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
75582912|NCT00564720|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
75729667|NCT00127855|Biological|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
75729668|NCT00127855|Biological|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
75729669|NCT00127855|Biological|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
75729670|NCT00493636|Drug|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
75729671|NCT00493636|Drug|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
75729672|NCT00493636|Drug|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
76024947|NCT02003014|Drug|Pioglitazone|Pioglitazone Tablets
75582913|NCT00564720|Drug|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
75582914|NCT00564720|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
75582915|NCT04674917|Other|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy|"Group A which includes the acute group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~Hot Pack~TENSE~Mobilization ( on lumbar L1 toL5 ) Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
76024948|NCT03166345|Other|Treatment of Thin Endometrium|This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
75582916|NCT04674917|Other|Decompression + Hot pack , TENS , Mobilization , Exercise Therapy|"Group B which includes the chronic group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~Hot Pack~TENSE~Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
76051597|NCT01750840|Device|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
76051598|NCT01750840|Device|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
75435278|NCT05838846|Drug|Inhaled Milrinone|Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization (21-23), inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.
75435279|NCT05838846|Drug|IV Milrinone|Patients will receive intravenous milrinone - started after induction of anesthesia - infusion at dosage of 0.5 mcg/kg/min without loading dose (24), Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
75582917|NCT04674917|Other|Hot pack , TENS, Mobilization, Exercise therapy|"Group C which is our control group to compare it with the groups A and B to study the effects of decompression on lumbar radiculopathy The basic treatments are~Hot Pack~TENSE~Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine It is kept in mind that in this group we will not apply the decompression along with the above treatments."
76051599|NCT01750840|Device|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
76051600|NCT01606228|Drug|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
76051601|NCT01706536|Drug|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
76051602|NCT01706536|Drug|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
75435280|NCT05838833|Drug|INV-001|Patient will be assigned to one of three arms.
75582918|NCT04606485|Other|Acupressure|Acupressure is accepted as a non-invasive application that can easily be applied by trained nurses, which increases the quality of the medical care administered and contributes to physical and psychological recovery.
75729673|NCT00493636|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
75729674|NCT00524121|Drug|erlotinib hydrochloride|Oral
75729675|NCT00524121|Other|immunohistochemistry staining method|Correlative Study
75729676|NCT00524121|Radiation|radiation therapy|Radiation Treatment
75729677|NCT03996382|Diagnostic Test|DPD Scintigraphy|Confirms/Refutes diagnosis of cardiac amyloidosis.
76051603|NCT01706536|Drug|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
76051604|NCT01706536|Drug|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
76051605|NCT01706536|Drug|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
76051606|NCT02269943|Drug|CC-486|
76051607|NCT04882319|Drug|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously
76051608|NCT04882319|Drug|HP-5000 Placebo Patch|HP-5000, placebo and saline will be administered simultaneously
76051609|NCT04882319|Drug|Saline Patch|HP-5000, placebo and saline will be administered simultaneously
76051610|NCT01706458|Biological|sipuleucel-T|Given IV
76051611|NCT01706458|Biological|DNA Vaccine|Given ID
76051612|NCT02269787|Behavioral|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
75729678|NCT01018342|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
76051613|NCT01605370|Drug|Nebivolol|Nebivolol 2.5 mg once daily
76051614|NCT01605370|Drug|Metoprolol succinate|Metoprolol succinate 50 mg once daily
76051615|NCT02269709|Device|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
76051616|NCT02269475|Drug|MEDI3250|MEDI3250
76051617|NCT02269475|Drug|Placebo|Placebo
76051618|NCT01605136|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
76051619|NCT01605136|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months
76051620|NCT01706146|Drug|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
76051621|NCT04168450|Other|WiSAT System, Passive Feedback|The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
75435281|NCT05838820|Diagnostic Test|Nine-Hole Peg Test|The Nine-Hole Peg Test is a standardized test that measures manual dexterity and finger movement speed in individuals with hand impairments. The test involves the placement of nine pegs in a pegboard, one at a time, and then removal of each peg as quickly as possible using one hand. The test is timed, and the time required to complete the test provides an indication of manual dexterity and finger movement speed. The Nine-Hole Peg Test has been previously validated and is commonly used in clinical practice.
75582919|NCT01160770|Drug|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
76051622|NCT04168450|Other|WiSAT System, Active Feedback|The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
75435282|NCT05838820|Diagnostic Test|Jebsen-Taylor Hand Function Test|is a standardized test that assesses fine motor skills and functional abilities of the hand. The test involves the completion of seven subtests, including writing, simulated page turning, picking up small objects, stacking checkers, lifting large objects, simulated feeding, and stacking cans. Each subtest is timed, and the time required to complete each subtest provides an indication of hand function. The Jebsen-Taylor Hand Function Test has been previously validated and is commonly used in clinical practice.
75435283|NCT05838040|Other|General exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
75435284|NCT05838040|Other|General exercises with tranversus abdmoinis contraction|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. In addition to these exercises, the Back to Fitness Program includes the activation of the transverse abdominis muscle, which is an important stabilizing muscle in the core. The activation of this muscle is done through specific exercises and techniques, and is intended to improve core stability and reduce the risk of further back injuries.
75435285|NCT05837702|Procedure|ESPB|Erector spinae plane block
75435286|NCT05837702|Procedure|PVB|Paravertebral Block
75435287|NCT05837702|Procedure|CONTROL|No block has been done
75435288|NCT05837650|Behavioral|Emotional Awareness and Expression Therapy (EAET)|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
75582920|NCT00566007|Procedure|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
75582921|NCT00566007|Drug|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
75582922|NCT00566007|Drug|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
75582923|NCT04314154|Other|Monitoring PROM @ PREM data on participating patients|"125 patients (ages 18-55) admitted to SHALVATA mental health center and their clinicians will be recruited to participate in a prospective longitudinal assessment. Each will include PREMs, PROMs clinician rated outcomes and assessment of the degree to which clinical indicators (reflected processes of clinical guidelines) were carried out. The assessments will take place at admission, discharge and every 3 months for up for 9 months. The design is a repeated measures design with evaluating the interaction effect between assessed levels of indicators (between subject effect) and level of change in the PREMs, PROMs clinician along the research trajectory (within subject effect)."
75729679|NCT01018342|Drug|Macrobid® Capsules 100 mg|
75881134|NCT01370161|Procedure|TIPS treatment|"A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted."
76051623|NCT02269241|Drug|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
76051624|NCT01750684|Drug|AC105|
76051625|NCT01750684|Other|Placebo|
76051626|NCT01750294|Drug|Chlorthalidone|
76051627|NCT01749982|Other|Placebo|
76051628|NCT01749982|Drug|Choline bitartrate|
76051629|NCT01749982|Drug|Betaine|
76051630|NCT01749982|Drug|Choline bitartrate + Betaine|
76051631|NCT02269163|Biological|Immune Globulin Intravenous|Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product
76051632|NCT02269163|Biological|Prometic's Immune Globulin Intravenous 10%|Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
76051633|NCT01749826|Drug|Morphine Sulfate|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
75435289|NCT05837403|Procedure|Platelet rich plasma injection|venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
75582924|NCT04632719|Device|The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19|Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
75582925|NCT00566046|Drug|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
75582926|NCT00566046|Drug|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
75729680|NCT01074385|Behavioral|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
75729681|NCT03965767|Drug|Tranexamic Acid|comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
76051634|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
75729682|NCT00470626|Device|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
75729683|NCT03966001|Other|Transvaginal sonography at six months after cesarean section|In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
75729684|NCT03966001|Other|Transvaginal sonography at twelve months after cesarean section|In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
75729685|NCT01074541|Radiation|UVB|0.375 SED x 4 in a week
75582927|NCT01160614|Drug|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
75582928|NCT00566085|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
75582929|NCT04632407|Dietary Supplement|"Flax milk"|See above
76051635|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
76051636|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
76051637|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
76051638|NCT02267135|Biological|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
75435290|NCT05837403|Drug|Nitroglycerin ointment|application of the ointment twice daily
75582930|NCT04632407|Dietary Supplement|"Oat fibre milk"|See above
75582931|NCT04123639|Procedure|PTA|Percutaneous transluminal angioplasty
75582932|NCT02885233|Behavioral|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
75729686|NCT01074541|Radiation|UVB|0.75 SED x 4 in a week
75729687|NCT01074541|Radiation|UVB|1.5 SED x 4 in a week
75729688|NCT01074541|Radiation|UVB|3.0 SED x 4 in a week
75729689|NCT00132769|Drug|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
75729690|NCT00132769|Drug|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
75729691|NCT00520299|Drug|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
75729692|NCT02542683|Other|structured physical activity program|a structured modest physical activity program
75729693|NCT02518269|Procedure|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
75582933|NCT02885233|Behavioral|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
75729694|NCT02478255|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
76051639|NCT02267135|Biological|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
76051640|NCT02299427|Behavioral|dog safety|use of dog safety website at home for about 2 weeks
76051641|NCT02299427|Behavioral|transportation safety|use of transportation safety website at home for about 2 weeks
76051642|NCT05649371|Other|Prehabilitation|A multiphasic exercise prehabilitation program for alloHSCT candidates across each treatment phase, that includes behaviour change support
75435291|NCT05837208|Other|RV4369A cosmetic product|"The product is applied 1 or 2 times during the 2 study visits. The product is recovered by the technician after application of the product by the volunteer.~Application modalities:~Inclusion Assessment: The study product is given to the volunteer who applies it to his face (forehead) according to his usual habits.~After a waiting time and Multispectral camera measurements, the study product is again applied by the volunteer to his face according to his usual habits.~Final assessment: The study product is applied by the Clinical Research Technician on the subject's forearm on 4 delimited areas at specific quantities.~After a waiting period and Multispectral camera measurements on the forearm areas, the study product is given to the volunteer who applies it on his face according to the recommendations of use provided by the Technician."
75435292|NCT05836935|Radiation|Multislice CT scan of the paranasal sinuses.|MSCT scan using GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) , Toshiba Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Or Canon Aquilion Prime SP 160 -multidetector- row CT scanner (Canon Medical Systems, Tochigi, Japan) Thin slice Axial scans will be taken at 0.625-1.0 mm slice thickness, commencing from the hard palate till above the end of frontal sinuses, coronal and sagittal multiplanar reconstruction images will be obtained.
76051643|NCT05649215|Other|No intervention will be applied.|This is a questionnaire study.
76051644|NCT01724866|Drug|SPI-2012|SPI-2012 SC injection.
76051645|NCT01724866|Drug|Pegfilgrastim|Pegfilgrastim SC injection, per manufacturer's Prescribing Information.
75582934|NCT00566124|Drug|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
75582935|NCT00566124|Drug|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
76051646|NCT01724866|Drug|Docetaxel|Docetaxel given based on standard dose for chemotherapy.
76051647|NCT01724866|Drug|Cyclophosphamide|Cyclophosphamide given based on standard dose for chemotherapy.
76051648|NCT04419935|Procedure|lymphadenectomy|Lymphadenctomy according with ESTS guidelines
75582936|NCT00566124|Drug|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
75582937|NCT04632563|Other|Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)|A questionnaire regarding musculoskeletal past medical history and current symptoms.
76051649|NCT02266433|Drug|Ketorolac|"The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders."
76051650|NCT02266433|Drug|Dexamethasone|"Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites."
75582938|NCT01159912|Drug|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
75582939|NCT01159912|Drug|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
75729695|NCT02478255|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
75582940|NCT01159912|Drug|Placebo|Placebo inhalation powder
75582941|NCT04606368|Device|Thermage FLX|Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
75729696|NCT00132691|Drug|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
75729697|NCT00132691|Drug|oral corticosteroid with immunosuppressive agents as needed|Prednisone
75729698|NCT00125359|Drug|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
75435293|NCT05836935|Radiation|MRI examination of the paranasal sinuses|MRI imaging using Philips Achieva 1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea 1.5T MRI device (Siemens Healthineers, Germany) for suspected intracranial and orbital complications.
75435294|NCT05836610|Drug|Hydrocortisone|intravenous bolus hydrocortisone therapy during hypothermia treatment
75435295|NCT05835804|Drug|GCP intratumoral catheter|After local anaesthesia, intratumoral catheter will be place (one or several depending tumour criteria).The catheter placement could be guided by radiological imaging. Gemcitabine (200mg/l), carboplatin (100mg/l) and paclitaxel (20mg/l) will be each diluted in each in 160ml of NaCl0.9%. GCP will be administered successively for 8hours, at 20ml/h with a total duration of 24hours. The ITC will be done every 28 days for 6 times maximum in case of good response and tolerance. Nivolumab 240 mg IV will be started 1 to 7 days before the first intratumoral infusion and every 15 days, until progression or 2 until years in case of partial response, complete response or stabilization. Evaluation of tumour size will be done by CT-scan, or MRI 2every 2 months and PET-FDG every 3 months.
75582942|NCT04632368|Behavioral|Transcendental Meditation|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
75582943|NCT04632680|Device|PVI followed by targeting of drivers|Patients will undergo intraprocedural ECG-I mapping. The pulmonary veins will be isolated followed by targeting of drivers aiming to terminate AF.
75582944|NCT04606212|Drug|Losartan|administration of losartan (50 mg) (oral)
75582945|NCT04606212|Drug|Placebo Oral Tablet|administration of placebo (oral)
75582946|NCT04632446|Other|Early diagnosis|Early diagnosis. Upgrade program implementation.
75582947|NCT04606251|Other|Exercise|The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
75582948|NCT04606329|Drug|LuminoMark inj.(Conc. for fluorescence)|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
75582949|NCT04606329|Drug|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3~1mL once in this study.
75582950|NCT04632251|Device|SENSEI®|SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
75582951|NCT04597749|Diagnostic Test|PSG|In-lab sleep polysomnography test
75582952|NCT04597749|Diagnostic Test|Home Sleep Apnea Test with FDA cleared devices|In-lab HST test
75582953|NCT04597749|Other|Non-Contact Screening App|Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.
75582954|NCT04632797|Device|Hilotherm Chemo Care|Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
75582955|NCT04632212|Behavioral|Explicit Tax|"To impose an explicit tax on food and beverage items that are eligible for red stop-sign food logos (explained in Intervention 2) as less healthy foods. Explicit tax shows pre-tax prices and a label indicating that the price includes a corresponding tax on the less healthy products.~Food and Beverages: we will impose a 20% tax on sales price of the food items"
75729699|NCT00524043|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
75582956|NCT04632212|Behavioral|Food Labels (with the summary of healthiness of shopping baskets & targets)|"To provide the green circle 'healthy choice' food label to items with Nutri-Score A and B, the amber circle 'in between healthy and unhealthy choice' food label to items with Nutri-Score C, and the red stop-sign 'less healthy choice' food label to items with Nutri-Score D and E.~In the presence of food labels,~Video: subjects will watch a video briefly explaining the food labels on the store.~My Cart Summary: subjects will be provided a live visual indicator of the healthiness of shoppers' current basket with the recommended healthy baskets goals."
75582957|NCT04632212|Behavioral|Ordering|To order food items by Nutri-Score (high to low).
75582958|NCT04632212|Behavioral|Within-Group Substitution|To provide substitutes within corresponding food categories that are better than the items that subjects chose in terms of Nutri-Score based on the similarities of price, primary ingredients, flavor, and other characteristics.
75582959|NCT04606017|Drug|Caltrate Pill|VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
75582960|NCT04597866|Behavioral|Multimodal rehabilitation|A combination of exposure in vivo and interventions directly targeting the cortical reorganization for treating CRPS.
75582961|NCT04632095|Procedure|Aortic valve replacement due to sternotomy|conventional surgery of aortic stenosis
75582962|NCT04632095|Procedure|Aortic valve replacement due to parasternal right anterior mini-thoracotomy|surgery of aortic stenosis in minimally invasive technique
75591997|NCT06077123|Device|Contigo Application|Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
75729700|NCT00524043|Drug|Placebo|Once daily for 6 weeks
75729701|NCT00524043|Drug|Paliperidone ER|6 mg tablet once daily for 6 weeks
75729702|NCT03966703|Behavioral|mixing analysing test|The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
75729703|NCT01076725|Device|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
75729704|NCT01076725|Device|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
75435296|NCT05833048|Procedure|Rectus sheath block|Participants will receive an ultrasound guided rectus sheath block with local anesthetic
75591998|NCT06076980|Drug|Paracetamol|compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
75729705|NCT01076803|Drug|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
75435297|NCT05832944|Device|ultrasound guided hyomental distance|measuring the hyomental distance by ultrasound guidance
75435298|NCT05832866|Other|Clinical Based Isometric contraction strengthening Exercises using Thera band|Patients did isometric contraction exercises using thera band in the clinic physically. They did not need to be monitored by telephone
75435299|NCT05832866|Other|Telemonitored Home based Isometric Cntraction strengthening exercises using Thera band|Patients did isometric contraction exercises using thera band at home, they were monitored by telephone three times in a week for 8 weeks
75435300|NCT05830630|Drug|Bupivacaine methylene blue|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
75435301|NCT05830630|Drug|bupivacaine saline|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
75435302|NCT05827367|Device|Ultrasound|"The high-power pain threshold ultrasound (HPPTUS) In this technique, which be applied in continuous mode with intensity from t0.5 to 2 watt/cm to elicit pain threshold the US probe was kept motionless, and the intensity progressively increased until the maximum level of pain patient can endure was selected, it was maintained on this level for 3 to 4 seconds and then decreased to half intensity for 15 seconds the treatment process was repeated three times."
75435303|NCT05827367|Other|Myofascial release technique|Plantar fascia myofascial release Soluse muscle myofascial release Gastrocnmias muscle myofascial release
75435304|NCT05827367|Other|Strength and stretching|Plantar fascia stretching Interstice foot muscles strengthing
75435305|NCT05826132|Other|Adjusted Content Intervention|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman
75435306|NCT05826132|Other|Non-Adjusted Intervention Video|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics
75435307|NCT05823753|Drug|Cannabidiol|"The CBD product to be used in this study is Epidiolex (Jazz Pharmaceuticals/Greenwich), a plant-derived, highly purified CBD oral solution that is FDA approved for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.~Doses will be 300 mg/d or 900 mg/d according to participants' assigned condition. Participants will receive CBD or placebo oral solution twice daily (evenly split doses at morning and evening meals) for three days (to achieve steady state) following the baseline assessment (day 0), and in the morning of day 4 (before the post-test)."
75435308|NCT05823753|Drug|Placebo|Placebo solution (excipients only, also by Jazz Pharmaceuticals/Greenwich).
75435309|NCT05823402|Diagnostic Test|SPECT/CT|SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.
75591999|NCT06076980|Drug|Normal saline|as placebo
75592000|NCT06076733|Device|high definition-transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
75592001|NCT06076733|Device|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
75729706|NCT01076881|Behavioral|exercise training|
75729707|NCT00523419|Drug|Pemetrexed|500 mg/m^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
75729708|NCT03868059|Drug|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
75729709|NCT03998865|Device|Provisional abutment material|The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
76051651|NCT01748890|Device|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
76051652|NCT05648981|Other|Inferior Alveolar Nerve Block administration with laser irradiation|Patients will receive inferior alveolar nerve block local anesthesia followed by laser irradiation after completion of the operative procedure.
76051653|NCT05648981|Other|Inferior Alveolar Nerve Block administration|Patients will not receive any laser irradiation after administration of inferior alveolar nerve block local anesthesia.
76051654|NCT04869215|Other|EverVita Pro|EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.
76051655|NCT04869215|Other|Control bread|Bread baked with normal Bakers flour
76051656|NCT01747876|Drug|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
75582963|NCT04597788|Other|Protein supplemented very low calorie diet program|"Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss."
75582964|NCT04597788|Other|Conventional low calorie diet program|Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
75582965|NCT04597983|Dietary Supplement|2S-hesperidin|Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)
75582966|NCT04597983|Dietary Supplement|Placebo|Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.
75582967|NCT04631822|Procedure|Spinal anaesthesia|spinal anesthesia shall be conducted with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position.
76051657|NCT02273726|Drug|Epoetin Alfa|Epoetin alfa will be administered per dose and schedule specified in the arm.
76051658|NCT02273726|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
76051659|NCT04557358|Other|COVID-19 survey|A questionnaire locally developed to explore access to medical care and to medications, access to communication with their primary rheumatologist, and patients risk perception about COVID-19 disease
76051660|NCT04557358|Other|RAPID-3|The instrument measures function, pain, and patient global estimate of status, with correspond to activity disease
76051661|NCT04557358|Other|WHOQOL-BREF|The instrument measures the patient´s quality of life (4 dimensions: physics, phycological, social, and environment)
76051662|NCT04557358|Other|DASS-21 instrument (depression and anxiety)|The instrument measures the presence of depression and anxiety
75435310|NCT05822388|Procedure|Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care|Participants in this study will already be undergoing a DBS intervention, however, this is part of their standard clinical care. Pre-surgical DBS candidates that enroll in this study will consent to participate in 1) pre-operative neuroimaging including a high-resolution MRI scan, 2) collection of pre-operative neurocognitive data via chart review and 3) a 1-year postoperative neurocognitive assessment.
75435311|NCT05820464|Diagnostic Test|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
75435312|NCT05813158|Drug|Group 1(low concentration-high volume bupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive low concentration-high volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline} for each patient
75435313|NCT05813158|Drug|Group 2(high concentration-low volumecbupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive high concentration-low volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% } for each patien).
75435314|NCT05805683|Drug|Calcitonin|patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
75435315|NCT05805683|Drug|Placebo|patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
76051663|NCT04557358|Other|IER-R (posttraumatic stress)|The instrument measures the presence of posttraumatic stress
76051664|NCT01723228|Drug|Rasagiline|
76051665|NCT01723228|Drug|Placebo|
75435316|NCT05803057|Device|TMS stimulation treatment|Using the TMS treatment coli to stimulation with high frequency
75435317|NCT05803057|Device|TMS stimulation sham-treatment|Using the TMS sham-treatment coli to stimulation with high frequency
75582968|NCT04631822|Procedure|ultrasound-guided Adductor Canal Block + dexamethasone|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery. then, a 20-ml mixture of 0.25% bupivacaine, and 4 mg dexamethasone will be injected."
75881135|NCT01370161|Drug|Medical treatment|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
76051666|NCT02273180|Drug|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
76051667|NCT02273180|Drug|Humalog|Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
76051668|NCT02273180|Drug|Insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
75435318|NCT05799651|Biological|Glycovax-002|Intramuscular injection of vaccine against SARS-CoV-2
75435319|NCT05797051|Diagnostic Test|Microscopic hyperspectral imaging system|Microscopic hyperspectral imaging system
75435320|NCT05793996|Drug|Ferinject|The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.
75435321|NCT05793996|Other|Diet therapy|Patients will receive diet therapy to correct latent iron deficiency
75435322|NCT05793762|Device|Left virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual left hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
75729710|NCT04028115|Drug|Ixazomib|Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
75729711|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
75729712|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
75435323|NCT05793762|Device|Right virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual right hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
75435324|NCT05790005|Other|therapeutic play|2 days after the operation, 1 hour before the dressing, a warm-up game will be played with the child in the playroom of the pediatric surgery service, aiming to put the organs prepared by the researcher in their correct places on the picture for the first 10 minutes. Then, the teddy bear, which is given the appearance of an operation area by sewing a zipper on his stomach, will be given to the child and he will be asked to make the first dressing of the teddy bear. therapeutic game, in which the dramatization method is used, will last 20 minutes. During the 30-minute play practice, the child's questions will be answered.
75435325|NCT05779826|Other|Play dough|In the play dough group, play dough was used during the treatment of children receiving nebulizer therapy.
75435326|NCT05757856|Drug|NDX-3315|Oral solution
75729713|NCT00522951|Drug|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
75582969|NCT04631822|Procedure|ultrasound-guided Adductor Canal Block + dexmedetomedine|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine, and 0.5 Mg/kg dexmedetomidine will be injected."
75435327|NCT05749029|Behavioral|Four Week Self-Compassion Course|"This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~The Foundations of Self-Compassion~Developing your Compassionate Self~Deepening the Compassionate Relationship with Yourself~Self-compassion in Everyday Life."
75435328|NCT05748496|Behavioral|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training using breathing exercises and Yoga Nidra
75435329|NCT05746845|Biological|Blood sample|"Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)"
75435330|NCT05743491|Other|Standard Care|Cancer survivors assigned to this condition continue with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
75435331|NCT05743491|Behavioral|YOCAS©®|YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
75435332|NCT05731791|Radiation|Radiation Therapy to partial breast|Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment (Arm 1) and patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment (Arm 2).
75729714|NCT03865953|Drug|LAT8881|LAT8881 oral capsule
75729715|NCT03865953|Drug|Placebo|Placebo oral capsule
75881136|NCT01370239|Biological|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
75881137|NCT01801709|Genetic|intracerebral administration of AAVrh.10cuARSA|
75881138|NCT03628443|Diagnostic Test|Fibroblast Growth Factor 23|A sample of blood is tested for levels of fibroblast growth factor 23
75582970|NCT04605705|Combination Product|Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
75582971|NCT00560924|Drug|estradiol, 25 mcg|
75729716|NCT06028061|Procedure|Quadratus Lumborum Block III|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
76051669|NCT01746862|Drug|Saizen®|Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone [r-hGH]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
75582972|NCT04605900|Device|Orthopedic Footwear|The orthopedic footwear used by the OF Group was manufactured by the company J. Andrade Ferreira Neves Lda. with materials suitable for the diabetic foot, as registered with INFARMED under registration ID 279515.
75729717|NCT06028061|Procedure|Quadratus lumborum block III with Adjuvant|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
76051670|NCT01746862|Drug|Saizen®|Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
75435333|NCT05730933|Behavioral|Intervention|Subjects will receive a behavioral intervention with additional education in combination with more frequent follow up and patient reminders
75435334|NCT05725239|Device|Vagus Nerve Stimulation|All taVNS sessions will use the following parameters: 25Hz, 500us pulse width, on for 7 seconds, off for 12 seconds.The length of VNS treatment sessions will be identical to TMS treatment sessions and will have the same 30 minute break between each treatment session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active.
75435335|NCT05725239|Device|Transcranial Magnetic Stimulation|Participants will receive 20 trains of 30 pulses each for a total of 600 pulses per session. We will repeat this for 6 sessions each day, with at least 30 minutes between each session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active, so participants will get 24 TMS sessions over the course.
75435336|NCT05720689|Other|using relaxing music|music diffusion during dental care under MEOPA
75435337|NCT05720689|Other|No relaxing music|dental care under MEOPA without music
75435338|NCT05708924|Drug|FT538|FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.
75729718|NCT06027970|Drug|Terlipressin|After successful Endoscopic variceal ligation (EVL) The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days
75729719|NCT06027970|Other|0.9% normal saline (NS)|After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days
75582973|NCT04605900|Device|Standard Footwear|In the SF Group, it was recommended to use standard shoes more suitable for diabetic foot, with some specific characteristics, such as sports or walking shoes. The acquisition or not of a more suitable shoes by the participants was at the discretion of each individual.
76051671|NCT01745848|Drug|Roflumilast|
76051672|NCT01745380|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
76051673|NCT01745380|Drug|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
76051674|NCT01745146|Behavioral|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
76051675|NCT01745146|Behavioral|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
76051676|NCT04550104|Radiation|Radiotherapy|Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
76051677|NCT04550104|Drug|Olaparib Oral Tablet [Lynparza]|Oral tablet
75582974|NCT04605900|Device|Plantar Orthoses|The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.
76051678|NCT04550104|Drug|AZD1390|Oral tablet
76051679|NCT04550104|Drug|TBD Compound 1|
76051680|NCT04550104|Drug|TBD Compound 2|
76051681|NCT04550104|Drug|TBD Compound 3|
75729720|NCT06027957|Biological|anti-CD19 CAR T-cells|"For Biological: CD19 CAR T-cells~Dose: 1-2.10e6 cells/kg of weight~Route: intravenous infusion~For Chemotherapy Drug:~Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3.~Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3.~Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after."
75881139|NCT05191069|Other|Moringa Oleifera Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
75881140|NCT05191069|Other|Placebo Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
75435339|NCT05708924|Biological|Enoblituzumab|Enoblituzumab 15 mg/kg IV begin on Day -6 and continuing once every 3 weeks beginning on Day 22 until disease progression or unacceptable toxicity - refer to Section 7.2.1 for timing of the enoblituzumab dose on Day 22 if steroid pre-meds are needed due to an infusion reaction with the 1st enoblituzumab dose as there is a 14 day ban on corticosteroid use after the last dose of FT538
75435340|NCT05701085|Other|Educational Intervention|The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
75582975|NCT04605900|Behavioral|Education on foot self-care|"An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal."
75582976|NCT00560963|Drug|everolimus|
75582977|NCT04597515|Procedure|Robot Breast reduction surgery|Breast reduction surgery, using a robot by removing a breast disc at the base
75729721|NCT06027944|Other|Light exposure|Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)
75729722|NCT06027866|Device|SRAVI (Speech Recognition Application for the Voice Impaired)|Speech Recognition Application for the Voice Impaired (SRAVI) is a novel communication aid developed by Liopa (a company formed by Queen's University Belfast (QUB) and the Centre for Security Information Technologies (CSIT), QUB). SRAVI is an application-based lip-reading system, and the application ('app') can be downloaded onto any device with a standard forward facing camera (e.g., smartphone, tablet). When the device is held in front of a patient, it will track lip movement and identify phrases being mouthed.
75582978|NCT04631978|Diagnostic Test|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
75582979|NCT04597281|Other|Lifestyle intervention|The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
75582980|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
75582981|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
75582982|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose open label
75582983|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose
75729723|NCT06027853|Drug|CLL1 CAR-NK cell injection|"Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent"
75729724|NCT06027827|Procedure|Addition of fusion device lateral bone graft|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
75881141|NCT01353443|Procedure|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
75881142|NCT03628365|Dietary Supplement|HMB (beta-hydroxy beta-methylbutyrate)|1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
75881143|NCT01365871|Procedure|anesthetics injection|Basal injection of anesthetics or basal + apical injection of anesthetics.
75881144|NCT03040661|Procedure|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
75881145|NCT05683587|Other|ballet course, strength course|Include of two phase,first phase is strength course for three months and second phase is ballet course for three months.
75881146|NCT01349777|Drug|Pregrel®|Pregrel® 75mg daily for 12 months
75582984|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
75582985|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily low dose
75582986|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
75881147|NCT01349777|Drug|Plavix®|Plavix® 75mg daily for 12 months
75881148|NCT03446157|Drug|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
75582987|NCT04631627|Drug|Aspirin|With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
75435341|NCT05700799|Behavioral|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
75582988|NCT00564759|Drug|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
75582989|NCT04632017|Diagnostic Test|Computerized cardiotocography|To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing
75582990|NCT04314193|Drug|Methotrexate|Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
75582991|NCT04314193|Drug|Prednisolone|Oral prednisolone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
75582992|NCT04597398|Device|Evaluation of blood flow with indocyanine green|
75582993|NCT04631354|Drug|Radio-labelled S-770108|99mTc radio-labelled S-770108 supplied as a capsule containing 6 mg active pirfenidone for inhalation
75435342|NCT05693792|Other|Observational|No treatment regimen will be deployed in this follow-up study.
75582994|NCT04631354|Device|S-770108 Inhaler A1|Dry powder inhaler
75729725|NCT06027775|Drug|Targeted agent|The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
75435343|NCT05686005|Drug|Oral tranexamic acid|4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
75435344|NCT05686005|Drug|Intravenous tranexamic acid|15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.
75435345|NCT05682950|Radiation|online adaptive radiotherapy|CTV covers pelvis.
75435346|NCT05681923|Other|Questionnaires|Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.
75582995|NCT01159171|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
75582996|NCT01159171|Drug|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
75582997|NCT01159171|Drug|oxaliplatin|40 mg/m2 iv weekly
75729726|NCT06027736|Other|pharmacist-led education|A patient education protocol and an algorithm of pharmaceutical care in managing allergic rhinitis.
75729727|NCT06027710|Procedure|Extensive alveolar ridge augmentation with allogeneic bone blocks; dental implant insertion in allogeneic bone graft|Alveolar ridge augmentation procedure for extensive bone defect rehabilitation in the upper and/or lower jaw allogeneic bone blocks; dental implant insertion in allogeneic bone graft for oral rehabilitation after 6 month of healing
75582998|NCT04631315|Drug|Difluprednate Ophthalmic Emulsion 0.05%|1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
75729728|NCT06027697|Device|AccuFill® Porous Bone Substitute Material (BSM)|The patient will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the medical device AccuFill® Porous Bone Substitute Material (BSM).
75729729|NCT06027671|Behavioral|Structured Peer-delivered ART and Reentry Community Strategy|The intervention aims to circumvent clinic barriers by directly providing ART and build behavioral skills (planning, self-efficacy) through peer-facilitator led group sessions to improve care continuity following release from incarceration.
75881149|NCT03446157|Drug|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
75435347|NCT05681923|Other|Biospecimen collection|urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta
75435348|NCT05681923|Other|Neurodevelopmental assessment visit|"Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, between 60 and 66 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment."
75435349|NCT05681923|Other|DNA collection|If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken.
75435350|NCT05662852|Biological|Tdap|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Suspension manufactured by Sanofi Pasteur
75582999|NCT04631315|Drug|Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution|1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
75583000|NCT02885155|Other|Echocardiography|planned at regular intervals
75583001|NCT02885155|Other|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
75583002|NCT04631666|Biological|DZIF-10c|SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion
75583003|NCT04631666|Other|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
75729730|NCT06027658|Behavioral|RECREATION therapy|Dance as therapy program with speech and movement co-therapy via body activity.
75729731|NCT06027593|Behavioral|Mixed methods intervention|"Investigators will implement the intervention at the completion of the rapid user-centered design process and consultation with CDC collaborators.~During the rapid user-centered design process, the team will engage key stakeholders to create and optimize feedback reports that will fit the prescribing context, and determine appropriate implementation supports that will be needed to accompany the introduction of the feedback reports to each setting.~Following the initial awareness-building activities, investigators will circulate the antibiotic prescribing feedback reports. After the first 3 months (approximately) of report dissemination, the team will assess the feasibility and acceptability of the reports and implementation activities by administering a brief survey to prescribers and also conducting interviews with them. No direct identifiers will be collected."
75435351|NCT05658757|Other|Regular sweetened commercial foods|"This is your usual habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~If you eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat the regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as your usual habits if more often.~If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume these regular sweetened beverages as you usually do."
75583004|NCT02885194|Other|Laser-Evoked potential|Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
75583005|NCT04597203|Device|755-nm picosecond alexandrite laser with topical 2% hydroquinone|treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone
75583006|NCT04597203|Drug|topical 2% hydroquinone|treatment one side of the face with topical 2% hydroquinone
75583007|NCT04313842|Device|AVATAMED|tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response
75583008|NCT04631237|Other|Observational, no intervention|No intervention involved
75583009|NCT04631159|Behavioral|Health2Sync app and report blood glucose data weekly|Patients will need to download and use the Health2Sync app and report blood glucose data weekly
75583010|NCT04631159|Other|self-manage|Patients will be asked to self-manage and there is no intervention during the tracking process
75729732|NCT06027580|Device|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis use 2 hours per day for 6 months
75583011|NCT04605276|Other|No intervention|No intervention
76051682|NCT05648474|Diagnostic Test|Somatosensory evoked potential [SSEP] intraoperative monitoring|No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
75583012|NCT04596774|Procedure|Traditional Approach|Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
75583013|NCT04596774|Procedure|Enhanced Recovery After Surgery (ERAS) Approach|Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
75729733|NCT06027541|Procedure|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, GnRHa, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
76051683|NCT05648396|Other|FFRangio|Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
75435352|NCT05658757|Other|Allulose sweetened commercial foods|"This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits."
75435353|NCT05658757|Other|Whole and minimally processed and sweetened foods|"Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~If you eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as your usual habits if more often~If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that you usually do.~This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines."
75435354|NCT05654519|Drug|PENG/LFCN and QL Blocks|Bupivacaine 0.25% injection
75435355|NCT05643196|Device|PLIFUS|The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
75435356|NCT05643196|Device|Sham PLIFUS|Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
75435357|NCT05643196|Device|MRI|A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
75435358|NCT05624294|Drug|CS0159|Tablets administered orally
75435359|NCT05624294|Drug|Placebo|Tablets administered orally
75583014|NCT04630691|Procedure|Implantation|Patients received narrow diameter implants in posterior mandible or maxilla
75583015|NCT04631081|Procedure|coverage of the fingertips with bipedicled palmar island flap|The initial step is wound debridement. To design the flap, a longitudinal line is drawn at the junction of the volar and dorsal parts of the finger, starting from the distal part of the proximal interphalangeal joint flexion crease. It will be harvested from distal to proximal dissecting the digital canal plane. By releasing the Cleland and Grayson ligaments, the neurovascular bundle will be dissected. On the intermediate phalange, the dorsal branch of the neurovascular bundle must be preserved to maintain blood flow to the dorsal skin. Dissection is completed at the junction between the palmo-dorsal arteries and the collateral neurovascular bundles on both sides of the finger. A triangle may be resected at the distal edge of the flap to reshape of the pulp. Bone may be resected if needed to allow tension-free closure of the distal part of the flap. No Immobilization will be necessary.
75729734|NCT06027515|Behavioral|Prehabilitation Program|Multimodal prehabilitation program consisting of pre-surgical optimization of nutrition, physical function, and sleep health via individualized plans. Participants will also be supplied with Nestle Impact Advances Recovery Immunonutrition Drink.
75729735|NCT06027502|Behavioral|Passive Heating|20 minutes of baseline data collection, up to 45 minutes of immersion in the hot tub to achieve a core temperature of 38.5 degrees celsius, followed by up to 90 minutes of recovery.
75729736|NCT06027450|Other|NHIg prescription|Analysis of NHIg prescription
75729737|NCT06027424|Other||observational study, no intervention
75729738|NCT06027398|Diagnostic Test|SARS-CoV-2 RNA detection|SARS-CoV-2 RNA detection in used mask filters
76051684|NCT05648318|Drug|Lactulose oral solution|In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
76051685|NCT05648318|Drug|PEG|patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
75729739|NCT06027385|Diagnostic Test|molecular-based screening|Test for three mutations in the CTNS gene and one mutation in the SMA1 gene.
75881150|NCT04240925|Device|NIMV with sigh breaths|Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol
75881151|NCT04240925|Device|Standard NIMV|Will be treated by standard NIMV with no sigh
75881152|NCT04700007|Drug|Capsaicin|A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.
75729740|NCT06027372|Device|"LARGAN ECG Holter"|"wear LARGAN ECG Holter during sleep once after completion of pulmonary function test"
75729741|NCT06027346|Biological|Bio-008|The subjects in each dose group received the corresponding dose of BIO-008 monotherapy, administered intravenously (ivd) for a duration of 0.5 to 3 hours (the researchers can adjust the administration time according to the patient's tolerance). If there is an infusion reaction, the infusion can be suspended and completed within 12 hours. Administer on the first day of each cycle, once every 3 weeks (1 cycle, i.e. 21 days) (Q3W) until the criteria for termination of treatment or withdrawal from the study are met, whichever occurs first.
75729742|NCT06027294|Procedure|Ischemic Conditioning|A cuff will be inflated to a pressure of 225 mmHg.
75435360|NCT05590273|Behavioral|CALM Therapy|"The CALM intervention includes 3 to 6 individual therapy Zoom teletherapy sessions, each approximately 50-60 minutes in length biweekly, delivered over 3 months. Participants (caregivers) will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy (baseline) and immediately after the program (post-intervention)~In addition, after each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components.~Lastly, participants will complete an exit interview immediately following the end of the intervention."
75583016|NCT04631081|Other|occlusive dressing|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing. Skin proximal to the injury will be degreased to increase adherence of the dressing. Distally, the film leaves a pocket to collect wound exudate. During treatment, the foul-smelling liquid produced by the wound and clots collected in the occlusive dressing will not be removed. A gauze covers the occlusive dressing to protect the liquid pocket and cover potential smell.
75583017|NCT04596813|Device|CytoSorb 300 mL device|Intra-and postoperative CytoSorb hemoadsorption
75729743|NCT06027281|Other|Hamilton depression rating scale (HDRS)|Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.
75729744|NCT06027281|Other|Hamilton anxiety rating scale (HARS)|Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.
75881153|NCT04700007|Drug|Diphenhydramine|Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.
75881154|NCT04700007|Drug|Morphine Chloride|Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.
75881155|NCT04700007|Drug|Isotonic saline|injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
75881156|NCT04700007|Drug|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
76051686|NCT02203513|Drug|LY2606368|105 mg/m^2 intravenous (IV) once every 14 days of a 28 day cycle
75583018|NCT04630457|Device|Conventional ankle prosthesis|At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.
75583019|NCT04630457|Device|Meridium® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
75583020|NCT04630457|Device|RoFT® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
75583021|NCT01158118|Drug|Sargramostim|
75583022|NCT01158118|Drug|Plerixafor|
75583023|NCT04630340|Device|STEADES-2|In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
75729745|NCT06027281|Other|Mini international neuropsychiatric interview (MINI)|The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.
75729746|NCT06027281|Other|Minnesota Multiphasic personality Inventory (MMPI)|The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.
75729747|NCT06027281|Other|The Symptom Check-List-90-R (SCL-90-R)|The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.
75729748|NCT06027281|Other|Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)|An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.
75729749|NCT06027281|Other|The female sexual function index (FSFI)|The female sexual function index is a brief multidimensional scale for assessing sexual function in women.
76051687|NCT04881890|Behavioral|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits
75583024|NCT04596969|Other|Soluble Fiber Dextrin|Ingredient based on resistant starch
75729750|NCT06027203|Procedure|prostate biopsy|Prostate biopsy by either transrectal or transperineal technique
75729751|NCT06027164|Device|Portable Ultrasound System|EchoNous KOSMOS
75729752|NCT06027151|Drug|1ml of 1% metronidazole gel|1ml of 1% metronidazole gel subgingivally at baseline visit
75729753|NCT06027151|Drug|1ml of 2% minocycline gel|1ml of 2% minocycline gel sub gingivally at baseline visit
75729754|NCT06027151|Drug|1ml of combination of 1% metronidazole gel and 2% minocycline|1ml of the combination of 1% metronidazole gel and 2% minocycline subgingivally at baseline visit
75729755|NCT06027138|Other|blood flow resistance training|Muscle size and explosive power was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press ,vertical jump test and timed push ups and pull up tests .secondly treat the arm and thigh muscles to to blood flow resistance training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles.
76051688|NCT02299934|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
76051689|NCT02299934|Diagnostic Test|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
76051690|NCT01703260|Drug|Roflumilast|Roflumilast dose
75583025|NCT04313920|Other|Nutritional Supplement|50 g Carbohydrate
75881157|NCT01349855|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
76051691|NCT01703260|Drug|Pioglitazone|Pioglitazone dose
76051692|NCT01703260|Drug|Placebo|Pioglitazone placebo-matching dose
76051693|NCT01703260|Drug|Placebo|Roflumilast placebo-matching dose
75435361|NCT05585112|Drug|Lidocaine 2%|The child will be injected with lidocaine 2%,after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker faces pain rating scale
75435362|NCT05585112|Drug|Articaine 4%|The child will be injected with 4% Articaine, after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and Wong-Baker faces pain rating scale
75435363|NCT05560477|Drug|AM3101|Injectable drug product.
75435364|NCT05560477|Drug|Saline Placebo|2 mL 0.9% normal saline
75435365|NCT05559515|Behavioral|NDPP-Flex|NDPP + patient-centered goal setting
75435366|NCT05559515|Behavioral|NDPP|Usual care NDPP only
75583026|NCT00564837|Procedure|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
75435367|NCT05555004|Other|TEST1|Toddler milk with preconditioned L. reuteri and containing GOS
75583027|NCT00564837|Procedure|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
75583028|NCT01157845|Device|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
75583029|NCT00561041|Behavioral|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
75583030|NCT00561041|Behavioral|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
75583031|NCT00566241|Drug|recombinant human IGF-1|rhIGF-1
75583032|NCT00566241|Drug|Placebo|Placebo
75729756|NCT06027138|Other|slow motion strength training|We will use slow motion strength training method. Each exercise is performed by lifting weights for approximately 10 seconds, lowering the weight for another 10 seconds, and not resting between repetitions.before receiving treatment sample muscle size and explosive strength was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press (pre test).secondly treat the arm and thigh muscles to to slow motion weight training.weight training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles. (Post test).
75729757|NCT06027086|Drug|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.
75583033|NCT00564915|Dietary Supplement|Ketogenic diet|Ketogenic diet
75583034|NCT00561119|Drug|gemcitabine , paclitaxel|"Gemcitabine 1250 mg/m2 i.v. Day 1 & 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks"
75729758|NCT06027086|Drug|DRP-104|Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.
75729759|NCT06027073|Biological|omalizumab|adding omalizumab to anti asthmatic therapy
75583035|NCT00566280|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
75729760|NCT06027008|Device|Mechanical Insufflation-Exsufflation|"MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~severe ventilator instability (requiring > 12 cm H2O PEEP and dependency of > 60% FiO2);~severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~extra corporal membrane oxygenation (ECMO); and~deeply sedated patient (RASS score ≤ -4)."
75435368|NCT05555004|Other|TEST 2|Toddler milk with standard/non-preconditioned L. reuteri and not containing GOS.
75435369|NCT05552443|Drug|Hydromorphone 2.5 mcg/kg|2.5 mcg/kg intrathecal
75435370|NCT05552443|Drug|Hydromorphone 2.75 mcg/kg|2.75 mcg/kg intrathecal
75435371|NCT05552443|Drug|Hydromorphone 3 mcg/kg|3 mcg/kg intrathecal
75435372|NCT05552443|Drug|Hydromorphone 3.25 mcg/kg|3.25 mcg/kg intrathecal
75435373|NCT05552443|Drug|Hydromorphone 3.5 mcg/kg|3.5 mcg/kg intrathecal
75435374|NCT05552443|Drug|Hydromorphone 4 mcg/kg|4 mcg/kg intrathecal
75435375|NCT05552443|Drug|Hydromorphone 4.5 mcg/kg|4.5 mcg/kg intrathecal
75435376|NCT05552443|Drug|Hydromorphone 5 mcg/kg|5 mcg/kg intrathecal
75435377|NCT05551195|Device|WB001|WB001 is a digital therapeutic for postpartum depression.
75729761|NCT06026995|Drug|PEG-rhG-CSF|Subcutaneous injection with a fixed dose of 12 mg
75729762|NCT06026995|Drug|RhG-CSF|Inject rhG-CSF 5-10 μg/kg subcutaneously every day
75729763|NCT06026982|Dietary Supplement|probiotic and pickle|probiotic formula by Rugby Health that has Bacillus Coagulans spores 1billion CFU and inulin 250mg along with a pickle
75729764|NCT06026969|Other|Neurodevelopmental assessments and follow-up|All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
75729765|NCT06026956|Other|Tele-Assessment|Tele-Assessment
75435378|NCT05551195|Device|ED001|ED001 is a digital therapeutic for postpartum depression.
75435379|NCT05531253|Other|Data collection using the Optical Gas Analyser|To allow the OGA to acquire certain physiological data during the study it will be necessary to slightly vary the tension of oxygen and carbon dioxide for short periods. The changes involved will be of a lesser magnitude than those often seen due to natural variation over time in critically ill patients. The FiO2 will be increased by around 20% from baseline for several minutes; this is a far more modest increase than is seen with the practice of pre-oxygenation - a transitory increase in fraction of inspired oxygen ( FiO2) to 100% - performed regularly in ICU patients to make certain routine interventions safer. The end-tidal CO2 level will also briefly (1-2 min) be altered by around 1 kPa by transient adjustment of the ventilator settings.
75729766|NCT06026943|Device|DaRT seeds insertion|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
75435380|NCT05529641|Other|Diaphragmatic resistance training|6 weeks home exercise of diaphragmatic resistance training will be emphasized.
75729767|NCT06026930|Device|low-level laser therapy|LLLT and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
75729768|NCT06026904|Device|transcutaneous auricular vagus nerve stimulation|taVNS was developed as a non-invasive variant of VNS where the vagus nerve is stimulated through the skin of the auricle, which has become a promising avenue for research and, potentially, treatment of various disorders. Commonly, taVNS is applied via the ear targeting the auricular branch of the vagus nerve, where the stimulation elicits far-field potentials. In line with preclinical studies, acute taVNS enhances invigoration of effort and response inhibition capability.
75729769|NCT06026878|Drug|gemcitabine,nimotuzumab, toripalimab|same as before
75729770|NCT06026878|Drug|gemcitabine, cisplatin|same as before
75729771|NCT06026865|Dietary Supplement|S-Adenosyl-L-methionine (SAMe)|S-adenosyl-L-methionine 1200 mg/daily as 2400mg S-Adenosyl-L-methionine disulfate tosylate
75729772|NCT06026865|Other|Placebo|Placebo of identical appearance, smell and taste, with the same schedule.
75729773|NCT06026787|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added to the standard of care regimen of primary nephrotic syndrome patients
75729774|NCT06026761|Device|Skiin garment and pods|"Participants will be asked to wear two pieces of equipment to record physiological data:~A Skiin garment that contains IMU and ECG sensors~A Cosmed K5 metabolic cart that will record breathing rate data~Participants will then be asked to perform various tasks of daily living (e.g. watching TV, sweeping the floor), general strength exercises (e.g. squats, triceps dips, lunges), and aerobic exercises (e.g. walking, running) as instructed by researchers"
75729775|NCT06026748|Drug|XJ103 Injection|XJ103 is a humanized monoclonal antibody.
75729776|NCT06026748|Drug|Placebo|Placebo contains only excipients.
75729777|NCT06026735|Other|lung cancer with brain /leptomeningeal metastasis|Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.
75881158|NCT01318655|Drug|NKTR-118|Tablet, Oral, Once daily
75881159|NCT01318655|Drug|Placebo|Tablet, Oral, Once daily
76051694|NCT02203357|Biological|Hepatitis B vaccine|Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
75583036|NCT00561158|Behavioral|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~Rate Your Plate: determining high fat foods~Label Reading: reading food labels~Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~Recipe Modification: preparing old recipes in new ways to reduce fat~Eating Out: order healthier fast foods~Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~Substituting fat-modified foods for high fat foods~Avoiding fat as a seasoning or flavoring~Avoiding fried foods~Modifying meat~Replacing high fat foods with fruits, vegetables, grains and breads"
75583037|NCT00566319|Behavioral|PREPARE with pedometer|Structured educational programme with pedometer use
75583038|NCT00566319|Behavioral|PREPARE|Structured educational programme
75583039|NCT04630223|Diagnostic Test|endocan in umbilical cord blood|After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
75583040|NCT04605471|Drug|Iopromide(Ultravist, BAY86-4877)|The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
75583041|NCT04629989|Other|Standard Oxygen Delivery System|The standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
75583042|NCT04629989|Other|Double-Trunk Mask|The Double-Trunk Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
75583043|NCT04629989|Other|Surgical Mask|The Surgical Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
76051695|NCT02299388|Drug|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
76051696|NCT02202577|Drug|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
75435381|NCT05529641|Other|Cervical stabilization exercise|Participants will finish 6 weeks supervised cervical stabilization exercise in person by physical therapist. Dissociated movement and movement control will be emphasized during cervical stabilization exercise.
75435382|NCT05527483|Drug|[68Ga]PSMA|Patients will receive up to 6 mCi of [Ga-68]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
75435383|NCT05527483|Drug|Flourine-18 [F-18] Sodium Fluoride (NaF)|Patients will receive 8-12 mCi of [F-18]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
75435384|NCT05527483|Diagnostic Test|PET/CT|Patients will receive [68Ga]PSMA with a PET/CT and Flourine-18 [F-18] Sodium Fluoride (NaF) with a PET/CT
75435385|NCT05527470|Drug|Gemcitabine,Cisplatin|Induction chemotherapy: Patients receive 1000 mg/m2 gemcitabine intravenously on day 1and day 8， 80mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
75435386|NCT05527470|Radiation|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were > 66 Gy to the primary tumor and > 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
75435387|NCT05527470|Drug|Cisplatin|Concurrent chemotherapy: Patients received 100mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
75583044|NCT00566358|Procedure|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
75583045|NCT04629755|Behavioral|Intervention|The intervention was delivered via daily text messages to mobile phones during two weeks in the midst of the Covid-19 pandemic. Each message provided a link to a brief suggestion for an action or actions to take each day to improve relational closeness and well-being. Critical to the rationale for this intervention was the position that relationship science has developed key insights into what works and does not work to build and maintain closeness. These insights could be translated into brief and effective suggestions that individuals could implement daily, thereby quickly improving relational well-being and decreasing depression and loneliness at a critical time.
75583046|NCT04605042|Procedure|wet suction|Before pucturing the lesion, the stylet was removed and the needle was pre-flushed with 1-2 mL of saline using a 10-mL syringe, the endoscopist then punctured the lesion and replaced the 10-mL syringe with a 10-mL pre-vacuum syringe
75583047|NCT04605042|Procedure|standard negative pressure suction|after puncturing the lesion, the endoscopist removed the stylet and attached a 10-mL pre-vacuum syringe for aspiration.
75583048|NCT04596696|Biological|Rotavac|Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P[11], containing one bovine rotavirus gene P[11] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
76051697|NCT02202577|Drug|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
75583049|NCT00561197|Drug|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
75583050|NCT04596618|Device|Forearm cooling|forearm cooling will be performed for active cooling assessment.
75583051|NCT04596462|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
75583052|NCT04629638|Other|Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores|The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
75583053|NCT04605120|Procedure|Cervical fusion|1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
75583054|NCT04629560|Drug|Miracle Fruit|one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
75583055|NCT04605003|Device|Novel rig-S|A new device created to hold the high level disinfectant and automatically indicate when sterilisation process has been completed
75583056|NCT04605003|Device|Conventional Autoclave machine|The gold standard device to clean all medical instruments
75583057|NCT04629482|Other|Brain networks activity|The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.
75583058|NCT04596306|Procedure|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
75435388|NCT05519631|Other|electroencephalogram|The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.
75583059|NCT04629287|Drug|KPCXM18|KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
75583060|NCT04629287|Drug|Placebo|Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
75583061|NCT00564993|Drug|Dobutamin|10&20 µg/kg/min
75583062|NCT04629365|Other|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
75583063|NCT04629365|Other|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
75583064|NCT04629170|Drug|SYNB8802|SYNB8802 is formulated as a nonsterile solution intended for oral administration
76051698|NCT02299076|Behavioral|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
76051699|NCT02299076|Other|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
76051700|NCT01723072|Biological|Omalizumab|Humanized monoclonal antibody against human IgE
75583065|NCT04629170|Drug|Placebo|In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
75583066|NCT04629404|Drug|LY03003|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
76051701|NCT01723072|Drug|Placebo|Placebo to omalizumab
76051702|NCT01722994|Device|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
75583067|NCT04629404|Drug|Placebo|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
76051703|NCT01722994|Device|Chromic Gut Sterile absorbable Suture (Ethicon)|
76051704|NCT02228395|Drug|PF-04958242|Administered as specified in treatment arm
75583068|NCT04595916|Drug|Polyene phosphatidylcholine injection 930 mg QD|Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
76051705|NCT02228395|Drug|Placebo|Administered as specified in treatment arm
76051706|NCT02170051|Behavioral|CBSST-CCT|
76051707|NCT02170051|Behavioral|Goal focused supportive contact|
76051708|NCT02169739|Device|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
76051709|NCT02169505|Drug|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
75583069|NCT04595916|Drug|Magnesium Isoglycyrrhizinate injection 200 mg QD|Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
75435389|NCT05492435|Device|transcranial direct current stimulation|tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.
75435390|NCT05483920|Behavioral|One-time educational video|One-time educational video
75435391|NCT05483920|Behavioral|One-time educational video plus automated text messaging|Educational video plus automated text messaging
75435392|NCT05477485|Behavioral|Antiretroviral Improvement among Medicaid enrolleeS (patient)|Patient-level support will be offered to eligible Virginia Medicaid enrollees who have a late ART prescription refill(s) by >30-90 days. Patient-level support will involve direct linkages and referrals for participants with a late ART prescription refill(s) >30-60 days. Interventions will intensify as the gap in ART prescription(s) fills increases. For those with a late ART prescription refill(s) for >60-90 days, added patient-level support will include warm health technology via PositiveLinks, a mobile app program promoting better health through self-monitoring tools, educational resources, direct messaging with program staff, and a confidential user community board.
75435393|NCT05477485|Behavioral|Antiretroviral Improvement among Medicaid enrolleeS (provider)|Provider-level support will involve peer-to-peer provider consultations, which will be offered to providers of eligible Virginia Medicaid enrollees who have no record of a prior filled ART prescription.
75435394|NCT05475730|Procedure|bone and soft tissue augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel.A pouch is create between the bone and the membrane and the mixed bone chips and hyaluronic acid are inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
75435395|NCT05473988|Other|Admission to General Ward|Admission to General Ward
75583070|NCT00565071|Device|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
75583071|NCT04628819|Dietary Supplement|Babybiane Imedia or placebo|Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
75583072|NCT04604964|Other|Evaluation of anastomotic leakage occurrence|Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum
75583073|NCT04604886|Diagnostic Test|Passive Leg Raising|Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.
75583074|NCT04604886|Diagnostic Test|Dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
75583075|NCT04595877|Drug|Dipyrone administration|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
75583076|NCT04595877|Behavioral|Pain assessment|"Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain)."
75583077|NCT04595877|Biological|beta-endorphin immunoreactivity|Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.
75583078|NCT04595877|Other|Placebo administration|Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
75435396|NCT05473988|Other|Admission to Intensive Care Unit|Admission to Intensive Care Unit
75583079|NCT00561275|Biological|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
75583080|NCT04595955|Other|CMyLife|CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
76051710|NCT01909791|Procedure|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
75435397|NCT05473988|Other|30 Day Mortality|30 Day Mortality
75435398|NCT05472545|Behavioral|Neurofeedback|Real-time functional magnetic resonance imaging dyadic neurofeedback
75435399|NCT05471921|Behavioral|SBIRT|SBIRT is an evidence-based treatment for unhealthy alcohol and other drugs (AOD) use in non-humanitarian settings and can efficiently provide individuals with an appropriate level of care based on their symptoms. Participants randomized to SBIRT will receive an on-the-spot alcohol brief intervention (CETA-BI) and be categorized as low or moderate/high severity using the AUDIT scale. Participants who are moderate/high severity will be connected to a counselor and will begin full CETA treatment. CETA is a transdiagnostic approach that combines motivational interviewing with cognitive behavioral therapy to assist clients in considering changing their rates of AOD use. The intervention lasts 30-40 minutes and consists of 6 components including 1) screening; 2) identifying the impacts of unhealthy AOD use; 3) talking about change/goal-setting; 4) understanding the primary reason for drinking; 5) skill-building; and 6) referral for services.
75435400|NCT05471921|Behavioral|Treatment as usual|Mantapala health workers and supervisors were trained in mental health gap action program-humanitarian intervention guide (mhGAP-HIG), which is a mental health service provision guide for use in humanitarian settings; this training was led by staff from United Nations High Commissioner for Refugees. This training did not include evidence-based psychological interventions (e.g., CETA). Participants randomized to TAU will be referred to the existing services that exist in the health clinic located in Mantapala refugee settlement. More specialized services are referred to the District Hospital in Nchelenge.
75435401|NCT05467111|Other|Acute Exercise|Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines, as aerobic exercise, strength training or combined training) 24-48 hours prior to each cycle of anthracyclines.
75435402|NCT05466188|Diagnostic Test|CPC|CPC
75435403|NCT05465070|Device|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
75435404|NCT05465070|Device|Sham Control|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
75435405|NCT05462340|Drug|[18F]ASEM|[18F]ASEM demonstrated excellent imaging properties, as was recently confirmed by others. [18F]ASEM is the 1st validated α7 human PET radiotracer to examine α7-nAChR characteristics in the living brain of SCZ patients. Previous α7 studies in the SCZ literature were done using brains harvested post-mortem, and under variable storage conditions. The proposed studies will also determine α4β2-nAChR [18F]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with [18F]ASEM, which will be highly significant for understanding these receptors in SCZ.
75435406|NCT05462340|Drug|[18F]AZAN|The most widely used PET radioligand for human imaging of α4β2-nAChR is 2-[18F]FA. Because 2-[18F]FA exhibits very slow brain kinetics, the investigators developed [18F]AZAN, a highly α4β2 specific tracer with optimal brain kinetics. Therefore, the proposed studies will utilize [18F]AZAN to determine α4β2-nAChR [18F]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with [18F]ASEM, which will be highly significant for understanding these receptors in SCZ.
75435407|NCT05452278|Other|Product A|Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
75435408|NCT05452278|Other|Product B|Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
75435409|NCT05452278|Other|Product C|Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
75435410|NCT05452278|Other|Product D|Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
75435411|NCT05451485|Diagnostic Test|Blood speckle tracking|Blood speckle tracking measurements will be acquired of the carotid artery and superficial femoral artery
75435412|NCT05451485|Diagnostic Test|Ultrasound particle Imaging Velocimetry|Ultrasound particle imaging velocimetry will be acquired of the carotid artery and superficial femoral artery
75435413|NCT05451485|Diagnostic Test|4D flow MRI|4D flow MRI will be acquired of the carotid artery and superficial femoral artery
75435414|NCT05451485|Diagnostic Test|Conventional duplex|Conventional duplex measurements will be acquired of the carotid artery and superficial femoral artery
75435415|NCT05439356|Drug|Colchicine|Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
75881160|NCT04654533|Other|COSC|"COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, & Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study."
75881161|NCT04317521|Device|Use of EKO Core and EKO Duo electronic stethoscopes|Listen to heart murmurs
75881162|NCT03430869|Drug|F-18 AV-45|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
75881163|NCT03430869|Drug|F-18-THK-5351|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
75435416|NCT05439356|Drug|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
75435417|NCT05425004|Drug|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
75583081|NCT04628897|Behavioral|Exposures|"Total area of available floor space inside the home (m2)~Frequency that child plays outdoors~Total number of physical hazards in the home (presence of open stairwells, stove height)~Total number of fine-motor activity items available to the child~Presence of gross-motor activity items available to the child across each category (e.g., fixed, portable: ball equipment, push/pull equipment, riding equipment, rocking and twisting equipment)~Hemoglobin concentration (g/L)."
75583082|NCT00561509|Drug|SSRIs|Use within normal clinical practice
75583083|NCT00561509|Drug|Dual antidepressants|Use within clinical practice
75583084|NCT04604574|Other|Indigenous Healing and Seeking Safety|Indigenous Healing and Seeking Safety Intervention: Initial 90-minute meetings will be conducted with the participants; during these meetings, participants will receive information about IHSS, traditional healing, sharing circles, sweat lodge ceremonies, and program details. The sharing circles will take place at Benbowopka Residential treatment Centre in Blind River, Ontario. Each of the sharing circles will be cofacilitated by two Indigenous health-care workers. These facilitators will organize and lead sharing circles daily throughout the 28-day treatment cycle. Each sharing circle will be two hours long. The Seeking Safety program consists of up to 25 treatment topics that aim to teach participants a variety of skills. The majority of topics address the cognitive, behavioral, interpersonal, and case management needs of persons with SUD and posttraumatic stress disorders (PTSD) (Najavits, 2002a). The treatment will adhere to the concept of Two-Eyed Seeing and cultural sensitivity.
75583085|NCT00561548|Procedure|rectosigmoïdal biopsies|rectosigmoïdal biopsies
75583086|NCT04604730|Procedure|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
75583087|NCT04604730|Procedure|Anastomosis with protective stoma|Anastomosis with protective stoma
75881164|NCT01350011|Behavioral|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
75583088|NCT04604535|Dietary Supplement|Concentrated beetroot juice|70mL concentrated beetroot juice (400mg nitrate)
75583089|NCT04604535|Dietary Supplement|Placebo|70mL concentrated nitrate deplete beetroot juice (<0.01mmol/L nitrate)
75583090|NCT00566436|Procedure|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
75729778|NCT06026722|Behavioral|cognitive behavioral therapy for insomnia|CBT-I is a 4-session program built around 3 main axes: psychoeducation on sleep hygiene, cognitive therapy and behavioral stimulus control, sleep restriction and relaxation. Each of the 3 axes will be worked on over 3 sessions, the last one being a summary and consolidation session of the first 3. For ethical reasons, it has been decided that patients in the control arm will also follow CBT-I (on a waiting list). The control group will have the same follow-up as the experimental group, but will start the intervention 6 months after the experimental group. This will enable all patients to access CBT-I.
75729779|NCT06026709|Behavioral|MindWellness|"The online intervention MindWellness integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program."
75729780|NCT06026696|Other|follow-up|Long term follow-up
75729781|NCT06026631|Procedure|Lipidomic analysis for breast cancer patients|Lipidomic analysis for breast cancer patients
75729782|NCT06026605|Drug|WTX212A|WTX212A infusion once every 21 days
76051711|NCT01909791|Drug|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
76051712|NCT01909791|Procedure|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
75435418|NCT05413421|Drug|ORIC-944|ORIC-944 oral once daily for 28 days
76051713|NCT01909791|Drug|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
75583091|NCT00566436|Procedure|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
75729783|NCT06026592|Genetic|determination of circulating biomarkers of renal origin circulating biomarkers of renal origin|The extracted circulating DNA will be extracted and converted using the methylation kit. Finally, circulating DNA will be analyzed using the PCR mix developed by CGenetix, quantifying tubular and glomerular biomarkers (patented technology).
75729784|NCT06026566|Drug|Dos of Afentanil 20|the dosage of Afentanil is 20 ng/ml for TCI
75729785|NCT06026566|Drug|Dos of Afentanil 30|the dosage of Afentanil is 30 ng/ml for TCI
75729786|NCT06026566|Drug|Dos of Afentanil 40|the dosage of Afentanil is 40 ng/ml for TCI
75881165|NCT01350011|Behavioral|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
75881166|NCT01357343|Other|Chiropractic|Spinal manipulation and active and passive therapy.
75881167|NCT01357343|Other|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
75881168|NCT03430037|Dietary Supplement|Fisetin|Flavonoid Family
75881169|NCT03430037|Drug|Placebo oral capsule|Placebo
75881170|NCT01353599|Drug|Mometasone furoate|220mcg once daily, for eight weeks
76051714|NCT02202499|Drug|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
76051715|NCT02202499|Other|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
75881171|NCT01733147|Drug|Omega-3 polyunsaturated fatty acids|3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
76051716|NCT02202499|Other|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
75435419|NCT05413252|Other|Practice Facilitation|Practices will be assigned a practice facilitator who will support practices in implementing all practice redesign components associated with TBC for HTN management.
75435420|NCT05412979|Drug|ST-1891|ST-1891
75435421|NCT05412979|Drug|Levothyroxine|Levothyroxine
75435422|NCT05396846|Behavioral|Eating Plan 1|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
75435423|NCT05396846|Behavioral|Eating Plan 2|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
75435424|NCT05396846|Behavioral|Eating Plan 3|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
75435425|NCT05395624|Drug|18F-OP-801|18F Hydroxyl Dendrimer
75435426|NCT05386082|Other|Modified Delphi process|The study involves a brief demographics survey and Delphi process, i.e. three rounds of information and surveys, in which participants will be asked to score/rank potential metrics.
75435427|NCT05385458|Behavioral|ACT Intervention|Acceptance and Commitment Therapy
75435428|NCT05385458|Other|Usual Care|Usual Care Services
75583092|NCT04628702|Behavioral|tablet training|1.5 year training period
75583093|NCT00566475|Other|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
75583094|NCT04628975|Device|transillumination dispositif|infrared light
75583095|NCT00566514|Dietary Supplement|D-ribose|5 grams administered orally TID
75729787|NCT06026566|Drug|Dos of Afentanil 50|the dosage of Afentanil is 50 ng/ml for TCI
75729788|NCT06026566|Drug|Dos of Afentanil 60|the dosage of Afentanil is 60 ng/ml for TCI
75729789|NCT06026566|Drug|Dos of Afentanil 70|the dosage of Afentanil is 70 ng/ml for TCI
75729790|NCT06026566|Drug|Dos of Afentanil 80|the dosage of Afentanil is 80 ng/ml for TCI
75729791|NCT06026566|Drug|Dos of Afentanil 90|the dosage of Afentanil is 90 ng/ml for TCI
75729792|NCT06026566|Drug|Dos of Afentanil 100|the dosage of Afentanil is 100 ng/ml for TCI
75729793|NCT06026553|Drug|Ketorolac (Toradol)|IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
75729794|NCT06026553|Other|Placebo (saline)|IV Placebo (saline) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
75583096|NCT00566514|Other|dextrose|5 grams orally TID
75729795|NCT06026527|Drug|Magnesium sulfate|50 mg/kg Magnesium sulphate in 93-95 ml Normal Saline ( making a total of 100 ml solution )will be infused intravenously over 20-30 minutes in the participants allocated to M group starting from the moment of induction of anaesthesia
75729796|NCT06026527|Drug|Normal Saline|100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
75729797|NCT06026501|Drug|PE0116,PE0105|"PE0116: 4-1BB Agonist Antibody Drug~PE0105: PD-1 Monoclonal Antibody Drug"
75729798|NCT06026488|Other|Other|real world treatment and survival of DLBCL patients in China
75729799|NCT06026475|Procedure|Goal directed Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining SVV below 11
75729800|NCT06026475|Procedure|Conventional Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining CVP between 8-12 cms H20
75881172|NCT01733147|Drug|Placebo|3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
75881173|NCT02961881|Drug|blinatumomab|Blinatumomab used as both continuous IV infusion and subcutaneous injection
75881174|NCT03334539|Biological|HL036 ophthalmic solution|HL036 ophthalmic solution
75881175|NCT03334539|Other|Placebo vehicle solution|Placebo vehicle solution
75881176|NCT04308707|Other|Breaking bad news skills|Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
75881177|NCT01350089|Drug|Placebo (without alcohol, caffeine, energy drink)|(carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
76051717|NCT02202109|Behavioral|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
76051718|NCT02202109|Behavioral|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
76051719|NCT02227849|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 52 weeks
75435429|NCT05373836|Diagnostic Test|prognostic nutritional index calculated from laboratory parameters|Calculated nutritional index using laboratory results of serum albumin, lymphocyte count, and cholesterol
75435430|NCT05373511|Other|"3D/4D spine and posture analysis DIERS FORMETRIC 4D ,The Biodex Balance System SD-"|"3D/4D spine and posture analysis DIERS FORMETRIC 4D for postural analysis assessment~,The Biodex Balance System SD- for balance assessment"
75435431|NCT05360888|Behavioral|Tools for Life|Tools for Life focuses on empowering youth to learn more about their culture and their identity.
75435432|NCT05360888|Behavioral|Tools for Life + MISN|Tools for Life focuses on empowering youth to learn more about their culture and their identity. MISN focuses on helping youth get support from their community and social networks.
75435433|NCT05348538|Other|Medication review with follow up or MaJ? for the acronym in french|"MaJ? service will involve a pharmacist-patient face-to-face consultation with a 6-months interval during the study, it includes:~Educational training: pharmacists will attend a half a day course. They will inform pharmacy technicians of their tasks. They will also have available an online version of the training about the service and data collection.~Service provision: before the pharmacist-patient consultation (pharmacy technicians review the medication to identify the prescribed medication included in the treatment plan and to remove expired or medications non taken by the patient), during (pharmacist assess potential drug related problem) and after the consultation (to send a medication management plan to patients and doctors).~Practice change facilitation to support pharmacists: pharmacists will be follow-up by the research team during the study (1st, 2nd, 3rd, 6th, 12th and 15th months of the study) to support them through the delivery of the service."
75583097|NCT01157377|Drug|AGN-214868|AGN-214868 injected into the bladder.
75729801|NCT06026384|Other|text in non-narrative form|Participants will be asked to read a text and give feedback afterwards
75729802|NCT06026384|Other|text in narrative form|Participants will be asked to read a text and give feedback afterwards
75729803|NCT06026384|Other|animated video in non-narrative form|Participants will be asked to watch a video and give feedback afterwards
75583098|NCT01157377|Drug|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
75583099|NCT02885116|Device|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
75583100|NCT02885116|Device|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
75583101|NCT02885077|Device|High-intensity IMT + combined exercise|
75729804|NCT06026384|Other|animated video in narrative form|Participants will be asked to watch a video and give feedback afterwards
75881178|NCT01350089|Drug|Comparator 1 (with alcohol; without caffeine and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
75881179|NCT01350089|Drug|Comparator 2 (with alcohol and caffeine; without energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
75729805|NCT06026280|Behavioral|DRIVEN Application|Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.
75729806|NCT06026280|Other|Career Resources|Participants will receive weekly information about job-searching skills and resources from a study coordinator for six weeks.
75881180|NCT01350089|Drug|Comparator 3 (with alcohol and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
75435434|NCT05344872|Other|Weaning from mechanical ventilation|Weaning from mechanical ventilation post congenital cardiac surgery
75729807|NCT06026241|Other|Collecting data from the medical record|Patient's socio-demographic data (age, gender, residence), comorbidities, cause of death, date and frequency of care measures/treatments/paraclinical exams received before their death.
76051720|NCT02227849|Drug|GLP-1 analogue|
75729808|NCT06025838|Behavioral|positive feedback|The positive feedback game uses techniques relating to established therapies like Behavioral Activation and Acceptance and Commitment Therapy's valued living to encourage positive action in game and outside of the game.
75881181|NCT01357421|Drug|TT301|Single iv dose of TT301
76051721|NCT01927497|Procedure|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
76051722|NCT01927497|Procedure|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
76051723|NCT02169271|Drug|Aspirin|Given PO
76051724|NCT02169271|Other|Laboratory Biomarker Analysis|Correlative studies
76051725|NCT02169271|Other|Placebo|Given PO
76051726|NCT02202031|Behavioral|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
76051727|NCT02202031|Behavioral|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
75729809|NCT06024044|Behavioral|Mobilization Training|"The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients."
75729810|NCT06023628|Other|Danish Helicopter Emergency Service|Patients with traumatic cardiac arrest assessed by the Danish HEMS
75729811|NCT06023550|Other|Treatment with surgery and/or conservative measures|Patients will be treated according to established clinical practice with surgery and/or conservative measures.
75881182|NCT01357421|Drug|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
76051728|NCT01644188|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
76051729|NCT01644188|Drug|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
75435435|NCT05344274|Diagnostic Test|Indocyanine Green Angiography|Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
75435436|NCT05344274|Biological|Isocapnic Oxygen|Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
75435437|NCT05344274|Diagnostic Test|Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)|Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
75435438|NCT05340179|Procedure|Interlaminar cervical epidural injection|Fluoroscopy-guided interlaminar cervical epidural injection
75435439|NCT05340179|Procedure|Cervical selective nerve root block|Ultrasound-guided cervical selective nerve root block
75435440|NCT05325996|Diagnostic Test|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) using the Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures the visual field in an ophthalmic setting.
75435441|NCT05325996|Diagnostic Test|visuALL H|visuALL H a new portable perimeter measuring the visual field and acuity in a non ophthalmic setting.
75435442|NCT05325996|Diagnostic Test|iCare Home Tonometer|iCare HOME tonometer is a device developed for patients/subjects to measure their eye pressure at home.
75435443|NCT05325996|Diagnostic Test|Spectralis Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a computerized picture measuring the thickness of the inner layer of the retina that makes the optic nerve.
75729812|NCT06023420|Drug|4 Herbs Formula|4 herbs formula dose: 5g/day
75881183|NCT01350167|Procedure|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
75881184|NCT03137303|Device|Spirometry at initial visit|Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.
75881185|NCT03137303|Drug|Albuterol|The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
75881186|NCT03137303|Device|Spirometry at 12-month follow-up|At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.
76051730|NCT01644188|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
76051731|NCT01644188|Drug|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
75881187|NCT03296553|Drug|Valganciclovir|The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
75881188|NCT03296553|Drug|Antiretroviral Combinations|Patients will receive standard antiretroviral treatment as recommended
75881189|NCT03131167|Drug|SHP639 (n=60)|Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
75881190|NCT03131167|Drug|Placebo Comparator (n=24)|Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
75881191|NCT01365949|Genetic|microarray analysis|
75435444|NCT05323487|Drug|Bumetanide Injection|Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
75435445|NCT05307640|Behavioral|CG-Well|CG-Well is a web & phone based psychosocial intervention that teaches caregivers how to obtain information, education & support
75583102|NCT04628312|Other|Static footprint|The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
76051732|NCT01644188|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
75435446|NCT05307640|Behavioral|Information Support & Referral (ISR)|Attention control group that receives phone calls and modules from the Brain Injury Association of America.
75435447|NCT05307523|Device|Enriched Play Environment with Partial Body Weight Support Harness|A low-tech portable canopy with a partial-body weight harness system that allows a child and their caregiver to play freely in an 81 square foot space, which provides partial body weight offset to support movement and exploration.
75435448|NCT05307523|Other|Enriched Play Environment without Partial Body Weight Support Harness|Child and caregiver will play freely in the 81 square foot play space without being connected to the partial body weight support harness.
75583103|NCT00566553|Dietary Supplement|Grape Seed Extract|200 mg dose daily for 12 weeks.
75583104|NCT00566553|Dietary Supplement|Grape Seed Extract|400 mg dose daily for 12 weeks.
75583105|NCT00566553|Dietary Supplement|Grape Seed Extract|600 mg dose daily for 12 weeks.
75881192|NCT01365949|Genetic|protein analysis|
75881193|NCT01365949|Other|immunohistochemistry staining method|
75881194|NCT01365949|Other|laboratory biomarker analysis|
75881195|NCT01370551|Drug|Gynoflor|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
75881196|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
75881197|NCT01363375|Procedure|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
75881198|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
75881199|NCT01370707|Drug|Metformin|1000~1500mg/day, 24weeks
76051733|NCT02201953|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
76051734|NCT02201953|Drug|SOF|400 mg tablet administered orally once daily
76051735|NCT02201953|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75583106|NCT00566553|Dietary Supplement|Grape Seed Extract|800 mg dose daily for 12 weeks.
75583107|NCT01157182|Drug|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
75583108|NCT01157182|Drug|Activella®|1/0.5 mg Tablets
75583109|NCT04628390|Device|Laser|The laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
75583110|NCT04628390|Other|Placebo|Simulation laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
75583111|NCT01157065|Drug|AL-78898A|Investigational treatment
75583112|NCT01157065|Drug|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
75729813|NCT06023147|Procedure|E-TACE|The 100μm drug-loaded microspheres were loaded with 40mg-80mg anthracyclines at 1mL/2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded with 1mL/2mL chemotherapy drugs to embolize the tumor supplying arteries at different grades and diameters.
75729814|NCT06022068|Drug|Sirolimus|7 mg taken once per week during 26 weeks.
75729815|NCT06021743|Diagnostic Test|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
75435449|NCT05307302|Diagnostic Test|Force Sense|A measure of proprioception, using a handheld dynamometer (MicroFET2-hoggan Health Industries Inc.), in a sitting position in a standardized position of the elbow joint of the dominant upper extremity (90 degree of flexion). Measurement of the elbow joint flexion force sense will be expressed as percentages. Each of the targeted trials will be calculated as a percentage of the maximum voluntary contraction (MVC) reference measure. The difference between the targeted and the actual percentage of MVC for each of the trials will be then calculated as a percentage of the targeted MVC, to reflect the proportion of error.
75583113|NCT00566592|Other|oral ethanol, overnight|Oral ethanol before bedtime to achieve approximate BAL of 0.08%
75583114|NCT00566592|Other|IV ethanol|IV ethanol before bedtime to achieve approximate BAL of 0.08%
75583115|NCT00566592|Other|soda water|Oral Placebo before bedtime to achieve approximate BAL of 0.00%
75729816|NCT06021743|Diagnostic Test|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
75729817|NCT06021743|Diagnostic Test|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
75729818|NCT06021743|Diagnostic Test|Measurement of inflammatory cytokines|A panel of pro- and anti-inflammatory markers will be determined by flow cytometer microsphere-based assay.
75729819|NCT06021431|Device|MORE-VR|"An 8-session version of Mindfulness-Oriented Recovery Enhancement (MORE) delivered by virtual reality. The treatment involves training in mindfulness,reappraisal, and savoring techniques to address OUD.~Combination Product: Participants in this arm will also receive Treatment as usual (TAU) with medications for opioid use disorder (MOUD). Usual addictions treatment with medications such as buprenorphine or methadone plus psychological counseling."
75729820|NCT06021431|Other|Treatment as Usual|Participants will receive their usual treatment for OUD, including medications such as buprenorphine or methadone and any counseling they might already be receiving
75729821|NCT06021392|Procedure|Z plasty and minimal excision of pilonidal sinus|"The investigators will perform a  Z plasty  procedure and Minimal excision procedure for patients complaining of pilonidal sinus and the investigators will compare the outcomes and rate of recurrence of these two procedures"
75881200|NCT01370707|Drug|CJ-30001/CJ-30002|0.6/1500mg~0.9/1500mg/day, 24weeks
75435450|NCT05307302|Diagnostic Test|Joint Reproduction Sense|A measure of proprioception, using a smart phone goniometer (Android Clinometer) application, in a sitting position in a standardized position of the elbow joint of the dominant upper extremity. Measurement of the elbow joint position reproduction will be expressed as degrees of reproduced angle. Absolute Error (AE) score will be calculated by the absolute value of the difference in degrees of the angle reproduced after subtracting the angle targeted.
75729822|NCT06020807|Diagnostic Test|Bladder EpiCheck|Bladder EpiCheckTM (EpiCheck) is a urine test for monitoring of recurrence of NMIBC based on analysis of 15 informative DNA methylation biomarkers.
75729823|NCT06019910|Other|Snus with or without tobacco|At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.
75729824|NCT06018415|Behavioral|Early time-restricted eating (eTRE)|The eTRE group is instructed to consume all calories in early 8h eating window,
76051736|NCT02271854|Drug|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
76051737|NCT02271854|Drug|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
75435451|NCT05307302|Diagnostic Test|Seated Medicine Ball Throw|A measure of upper limb physical performance, using 2-kg medicine ball and a standardized protocol, throwing distance expressed in meters.
75435452|NCT05307302|Diagnostic Test|Closed Kinetic Chain Upper Extremity Stability Test|A measure of upper limb physical performance, using body weight and a standardized protocol, touches between hands expressed in number of touches.
75435453|NCT05307302|Diagnostic Test|Passing Accuracy|A measure of the basketball passing skills, passing of The American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) test battery will be used in a standardized protocol. Accurate passes will be expressed in points.
75435454|NCT05300685|Drug|Standard Buccal Harvest|Our institutions current anesthetic regimen. Comparison group
75435455|NCT05300685|Drug|Basic buccal procedure + Long acting local|Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
75435456|NCT05300685|Drug|Basic buccal procedure + Buccal block|Addition of long-acting local anesthetic as a buccal block after oral graft harvest
75583116|NCT00566592|Other|soda water|Oral Placebo to achieve approximate daytime BAL of 0.00%
75729825|NCT06018415|Behavioral|Late time-restricted eating (lTRE)|The lTRE group is instructed to consume all calories in late 8h eating window.
75881201|NCT04336735|Other|immunization app|A transplant specific immunization app will be trialed that 1) provides vaccine information and education, 2) stores vaccine records and 3) provides reminders when vaccines are due
76051738|NCT05296993|Dietary Supplement|Extracts found in the Extended Longevity supplements|Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.
75583117|NCT05268406|Device|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
75583118|NCT02885038|Other|Platelet concentrate transfusion|
76051739|NCT02296892|Drug|Remimazolam|For induction and maintenance of sedation
76051740|NCT02296892|Drug|Placebo|Inactive control arm
76051741|NCT02296892|Drug|Midazolam|For induction and maintenance of sedation
75435457|NCT05276817|Device|Epic Diode|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket while activating the diode laser.
75435458|NCT05276817|Drug|HP|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.
75435459|NCT05276817|Device|Sham|The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket. The diode laser will not be activated during the sham treatment. Coe-Pak periodontal dressing will be applied to the control quadrant to isolate it.
75435460|NCT05266807|Drug|oral capsulized Fecal Microbiota Transplantation|FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
75435461|NCT05266807|Drug|Vancomycin or Fidaxomicin|Vancomycin or Fidaxomicin per os as initially prescribed per SoC
75435462|NCT05254418|Drug|dulaglutide injection|All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
75583119|NCT04604457|Other|Palliative care contacts primary care|Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
75729826|NCT06017115|Device|Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)|Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
76051742|NCT02270684|Device|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
76051743|NCT05647928|Other|no intervention|no intervention
76051744|NCT02168803|Drug|Evacetrapib|Administered orally
76051745|NCT02201329|Drug|Azacitidine|Azacitidine (subcutaneous)
75435463|NCT05250284|Behavioral|WellBQ|National Institue for Occupational Safety and Health Worker Well-Being Questionnaire is comprised of 21 scales (multiple items assessing a single construct) and 31 single items that cover worker well-being. Domains include (i) work evaluation and experience, (ii) workplace policies and culture, (iii) workplace physical environment and safety climate, (iv) health status, and (v) home, community, and society.
75435464|NCT05250284|Behavioral|PROMIS|Patient-Reported Outcomes Measurement Information System is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.
75435465|NCT05233267|Other|Blood sample|Dosage of neopterin
75435466|NCT05233072|Other|Blood sample|Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0
75435467|NCT05227079|Device|MultCROC multibite forcep|Alligator style 2.4 mm diameter jaws that can hold up to six samples in one pass through endoscope.
75435468|NCT05227079|Device|Conventional double bite forcep|Use of conventional double bite forceps that can store up to two specimens in one pass through endoscope
75435469|NCT05222477|Behavioral|pelvic floor exercise|pelvic floor exercises(intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
75729827|NCT06012071|Device|Zirconia dental implants|Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
75729828|NCT06008951|Other|Listening to music|All participants will listen to self-chosen or researcher-chosen music with noise-cancelling headphones (JBL Tune 770NC). The music will be administered for 20 minutes before participants receive increasing electric pain stimuli.
76051746|NCT02201329|Drug|Volasertib|Volasertib escalating doses (intravenous)
76051747|NCT01927419|Drug|Nivolumab|
76051748|NCT01927419|Drug|Ipilimumab|
76051749|NCT01927419|Drug|Placebo|Matching nivolumab
75583120|NCT04628351|Behavioral|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
75583121|NCT01156792|Drug|FP 100|FP 100mcg BID
75583122|NCT01156792|Drug|GSK2190915 100|GSK2190915 100mg QD (AM)
75583123|NCT01156792|Drug|GSK2190915 300|GSK2190915 300mg QD (AM)
75583124|NCT01156792|Drug|montelukast|montelukast 10mg QD (PM)
75583125|NCT01156792|Drug|placebo|placebo BID
75583126|NCT01156792|Drug|FP/SAL 100/50|FP/SAL 100/50mcg BID
75729829|NCT06008951|Other|Listening to a podcast|ln the control condition, participants will listen to a podcast with noise-cancelling headphones (JBL Tune 770NC). The podcast will be administered for 20 minutes before participants receive increasing electric pain stimuli.
75729830|NCT06007430|Drug|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
76051750|NCT02168491|Drug|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
76051751|NCT02168491|Drug|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
76051752|NCT02225743|Other|Observation Of Temperature|Participants temperature will be recorded perioperatively.
76051753|NCT01721746|Biological|BMS-936558|
75435470|NCT05222477|Behavioral|Abdominal muscles exercise|abdominal exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
75435471|NCT05213520|Other|Alternate Day Intermittent Energy Restriction|It is a dietary intervention designed to alternate between full energy consumption on one day and 40% of daily energy requirement on the following day.
75435472|NCT05213520|Other|Reduced Calorie Diet|It is a dietary intervention designed to reduce daily calorie intake by 500-1000 kcal below an individual's daily calorie needs.
75583127|NCT04604145|Diagnostic Test|SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen|Obtain self-collected saliva sample, perform SARS-CoV-2 testing using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system on 30 samples associated with a positive and 30 samples associated with a negative NP sample, then compare saliva results to healthcare worker collected NP sample results evaluated on either the BioFire® FilmArray® Torch® system or the Cepheid® GeneXpert® (gold standard).
75583128|NCT04604223|Drug|Pioglitazone 45 mg|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
76051754|NCT01721746|Drug|Dacarbazine|
76051755|NCT01721746|Drug|Carboplatin|
76051756|NCT01721746|Drug|Paclitaxel|
75583129|NCT04628624|Dietary Supplement|Placebo control|8 week supplementation period, with participants consuming 2 capsules per day containing potato starch
75583130|NCT04628624|Dietary Supplement|GTE 1|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)
75583131|NCT04628624|Dietary Supplement|GTE 2|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
76051757|NCT02225665|Genetic|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
75583132|NCT01156714|Behavioral|Treadmill training with aerobic exercise|walk on treadmill for aerobic exercise
75583133|NCT01156714|Behavioral|Memory training with computerized memory program|memory testing and training on computer program
75583134|NCT01156714|Behavioral|Combination of treadmill training and computerized memory|both exercise and cognitive computer training
75583135|NCT00561314|Other|questionnaire administration|
75583136|NCT00561314|Procedure|biopsy|
75583137|NCT00561314|Procedure|high-intensity focused ultrasound ablation|
75583138|NCT00561314|Procedure|magnetic resonance imaging|
75583139|NCT00561314|Procedure|quality-of-life assessment|
75583140|NCT04595643|Other|Combination of different dysphagia training modalities|Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
75729831|NCT06007430|Other|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
75729832|NCT06006325|Device|electroacupuncture treatment|"Patients received acupuncture on both sides of the Zusanli (ST36) acupuncture points, and after Deqi , the needle was connected to an electro-acupuncture device (Hwato, Suzhou Medical ). The EA stimulation lasted for 30 min."
75435473|NCT05202418|Behavioral|Biofeedback Enhanced Treatment|The intervention involves biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. Participants will complete questionnaires before and after each session to measure autonomic reactivity, lifetime stress, depression, anxiety in response to stress induction, and coping strategies.
75583141|NCT04628273|Procedure|encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy|
75583142|NCT04604028|Drug|Lenalidomide [Leavdo®]|Complete remission and partial remission rate
75583143|NCT04595604|Procedure|Trimodal rehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
75583144|NCT04595604|Procedure|ERAS + nutritional prehabilitation|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
75583145|NCT00565149|Behavioral|PROOF|dietary overfeeding with high, low or normal protein content
75583146|NCT01156675|Device|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
75583147|NCT01156675|Device|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
75729833|NCT06006325|Device|sham electroacupuncture treatment|"The participants in the SHAM-EA group performed shallow punctures at the bilateral non-acupuncture points, did not perform the Deqi operation, and were connected to the electroacupuncture stimulator but not energized."
75729834|NCT06005012|Drug|Semaglutide|Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
75729835|NCT06005012|Drug|Placebo|Placebo
75435474|NCT05182359|Other|SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test|The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) test is used to predict the four-year likelihood of myocardial infarction, stroke, hospitalization for heart failure or death. It will be provided to the participant's ordering provider.
75729836|NCT06002724|Other||
75729837|NCT05997199|Dietary Supplement|Vitamin D replacement|Group 1 with vitamin D deficiency will be getting a standart vitamin D replacement of 50.000 IU/week for 8 weeks.
76051758|NCT02225665|Genetic|SB-728mR-T|- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
75435475|NCT05156996|Device|Supersaturated O2 Therapy of the Therox Downstream System®|SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient's left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.
75435476|NCT05156996|Procedure|PCI alone|Percutaneous Coronary Intervention for treatment of acute MI
75435477|NCT05154786|Other|Early Mobilization and endurance training|The early mobilization and endurance training will be conducted with grading exercise level. In the course of endurance training. After achieving patient's active participation in sitting on the bed, the goal will be to train for at least 20 min. If this is accomplished, exercise level and training period increased until a maximum of 7 on modified RPE. If these are well-tolerated and no contraindications as per medical prescription exist, the treatment will be further advanced to mobilizing participants to the bedside. After being able to sit for at least 10 min on the side of the bed, regardless of whether support is needed, participants will be moved into a chair with an individually adapted transfer according to the individual's resources.While sitting, functional tasks and activities of daily living will be performed and gradually increased to standing and walking exercises.
75435478|NCT05154786|Other|Usual Care|The weaning protocols, bed exercise, positioning, respiratory therapy, and early mobilization.
75435479|NCT05153330|Drug|BMF-219|BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.
75435480|NCT05141162|Behavioral|case and control group|randomized controlled experimental study
75435481|NCT05123989|Behavioral|Personalized move goals|Personalized move goals delivered by the Welltory mobile app
75435482|NCT05123989|Behavioral|Constant move goals|Static move goal delivered by the Welltory mobile app
75435483|NCT05117866|Drug|prasugrel Monotherapy|Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)
75435484|NCT05117177|Drug|Inupadenant|Oral administration
75435485|NCT05114031|Other|FB101|Microbial intervention using product FB101
75435486|NCT05114031|Other|Placebo|Saline water
75729838|NCT05995002|Other|Anthocyanin-rich diet|A weekly food plan aims to increase the consumption of anthocyanin-rich sources such as berries, black grapes (or currants), cherries, strawberries, pomegranates, and red onions.
75729839|NCT05992649|Other|physical therapy|Aquatic physiotherapy in warm water
76051759|NCT02225665|Drug|Cyclophosphamide|- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
76051760|NCT01721200|Other|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
75583148|NCT01156480|Drug|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
75583149|NCT01156480|Drug|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
75583150|NCT04595526|Procedure|Forced expiratory technique and induced sputum|The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.
75583151|NCT04595526|Procedure|Tracheal suction|Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
75583152|NCT02884960|Procedure|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
75583153|NCT04627961|Drug|TAS-102|Eligible patients who consent to participate will receive oral TAS-102 bid for days 1-5 and 8-12 of a 28 day cycle.
75583154|NCT04595253|Other|acupressure|"The acupressure involves the  Vaccaria Semen within skin-colored adhesive tape that placed on the Neiguan and Shenmen acupoints as an intervention measure. Continue to massage the acupoints with fingertips for 10 minutes, 3 times per day (8 and 12 in the morning, and 4 in the afternoon) . The adhesive tape will be retained in situ for 2 days."
75583155|NCT00561587|Drug|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
75729840|NCT05989776|Behavioral|Informational brochure for patients and brief training for oncologists|For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
75729841|NCT05987891|Diagnostic Test|Treadmill exercise stress test|Ellestad protocol will be applied in all subjects up to fatigue and recovery will be monitored.
75729842|NCT05987488|Biological|ShigETEC live, attenuated, oral vaccine|"Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses."
75583156|NCT04595487|Procedure|Left ventricular septal pacing|"In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion."
75435487|NCT05107284|Behavioral|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
75435488|NCT05107284|Behavioral|Delayed feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
76051761|NCT01721200|Other|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
75435489|NCT05106686|Dietary Supplement|Aureobasidium pullulans produced β-glucan group|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
75583157|NCT04595487|Procedure|Right ventricular pacing|In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
75583158|NCT01156363|Procedure|Dialysis|regular haemodialysis or peritoneal dialysis
75729843|NCT05987488|Other|Placebo|"Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart."
76051762|NCT02225587|Biological|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
75435490|NCT05106686|Dietary Supplement|placebo group|Placebo 300 mg/day for 12 weeks
75881202|NCT01363531|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
76051763|NCT02225587|Biological|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
76051764|NCT02225587|Biological|Placebo|Injections are to be administered into the deltoid muscle of the upper arm.
76051765|NCT02296424|Drug|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
76051766|NCT02296190|Drug|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
76051767|NCT02296190|Drug|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
76051768|NCT04875026|Drug|5-fluorouracil 4% (Tolak)|Application of Tolak once daily in the evening for 4 weeks
76051769|NCT04875026|Device|Dexeryl|Application of Dexeryl once daily in the morning for 8 weeks
76051770|NCT02296112|Drug|trametinib|Given PO
75435491|NCT05102136|Drug|REGN9933|Administered intravenously (IV) or subcutaneous (SC) per the protocol
75435492|NCT05102136|Drug|Placebo|Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol
75583159|NCT01156363|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
75881203|NCT01366105|Device|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
75881204|NCT01363609|Drug|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
75435493|NCT05095259|Drug|insulin human|Hyperinsulinemic glucose clamp studies require that insulin is administered at a steady continuous rate to achieve stable levels of hyperinsulinemia. To reach this, insulin needs to be infused intravenously using a standard intravenous pump system. The insulin dose will be adjusted according to the body surface area, aiming for insulin levels of ~170 mIU/l, which is within the physiological range. Thus, for a subject with a bodyweight of 70 kg, body length of 180 cm and - consequently - a body surface area of 1.936 m2, the required insulin infusion can be calculated as: 1.936 x 60 x 60 ÷ 1000 = 7.0 units per hour
75435494|NCT05095259|Drug|Epinephrin|Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50 ng∙kg-1∙min-1, for 20 minutes each. After each adrenaline infusion, substrate response will be measured by blood samples of glucose, lactate, free fatty acids, alanine, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
75435495|NCT05095259|Procedure|Muscle biopsy|With the study subject resting in the supine position, the skin is disinfected on the lateral side of the thigh around 15 cm above the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the muscle with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the muscle. A small piece (around 150 mg) of the muscle is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( ~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some muscular tenderness for 2-3 days corresponding to minor muscular trauma.
75583160|NCT00561626|Dietary Supplement|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
75729844|NCT05980702|Drug|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab, Carboplatin, albumin-bound paclitaxel:4 cycles"
75729845|NCT05980702|Drug|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab , Carboplatin, albumin-bound paclitaxel:2 cycles"
75729846|NCT05977634|Behavioral|Bladder training|Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom
75881205|NCT01363609|Drug|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration < 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
75583161|NCT00561626|Dietary Supplement|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
75583162|NCT02884921|Drug|Paracetamol|Paracetamol
75583163|NCT02884921|Drug|Paracetamol|Paracetamol
75583164|NCT02884921|Drug|Placebo|Placebo
75583165|NCT02884882|Other|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
75583166|NCT04595214|Other|TTTS cases are treated by intra-uterine laser for separation.|MC twin anaestemosis separatio by laser. Vasa previa and placenta accreta are treated with steroids or other protocols, Positive trisomies by NIPS undergoes CVS or amniocentesis
75583167|NCT00561704|Drug|losartan|losartan, 100mg daily,
75583168|NCT01156051|Drug|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
75729847|NCT05977634|Device|Transcutaneous tibial nerve stimulation|A combined electrotherapy device capable of applying transcutaneous electrical nerve stimulation will be used. Each session will take 30 minutes. Patient will visit the hospital twice a week for 6 weeks. An electrical current of 0-50 amperes with a frequency of 20 herz, and a duration of 200 micro seconds will be applied using 50x50 mm surface electordes. The aim is to create a tingling sensation without causing any pain on the tibial nerve, at the ankle level.
75881206|NCT01363609|Drug|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
75881207|NCT01363687|Device|remote ischemic postconditioning|Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
75583169|NCT01156051|Drug|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
75583170|NCT04595409|Drug|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
75583171|NCT04595409|Drug|Stelara® (Ustekinumab)|Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
75729848|NCT05976815|Behavioral|Combined Aerobic and Resistance Exercise|Apart from the neoadjuvant chemotherapy treatment (standard of care), participants allocated to the experimental group will additionally participate in a supervised physical exercise program that comprises 3 weekly sessions during the months that the patient is undergoing chemotherapy treatment. Each 75-minute session will comprise a 10-minute warm up, 30 minutes of strength training involving exercise for the major muscle groups, 30 minutes of aerobic training at 40-89% of heart rate reserve and a 5-minute cool down.
75729849|NCT05974748|Drug|Sodium hypochlorite 5.25%|The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.
75435496|NCT05095259|Procedure|Adipose tissue biopsy|With the study subject resting in the supine position, the skin is disinfected on one side of the abdomen around 5-10 cm lateral from the umbilicus to the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the adipose tissue with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the adipose tissue. A small piece (around 1 gram) of the adipose tissue is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( ~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some tenderness for 2-3 days corresponding to minor trauma.
76051771|NCT02296112|Other|laboratory biomarker analysis|Correlative studies
75583172|NCT04628000|Other|Vitamin D|Clinical Correlation
75881208|NCT03060447|Drug|Vesatolimod|Tablets Administered orally
75881209|NCT03060447|Drug|Placebo|Tablets Administered orally
76051772|NCT02296112|Other|pharmacological study|Correlative studies
76051773|NCT02295644|Device|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
75435497|NCT05095259|Drug|Glucagon|Glucagon is prepared in doses of 10 µg, 25 µg, and 50 µg and intravenously injected with intervals of 2 hours. After each glucagon injection, blood samples will be drawn to measure plasma glucose, glucagon, lactate, free fatty acids, alanine, amino-acids, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
75583173|NCT01156012|Drug|T2345|One drop of T2345
75583174|NCT01156012|Drug|Prostaglandin|One drop
75583175|NCT04627844|Dietary Supplement|Immediate Feeding|Standard tube feeds begun at an earlier time point
75583176|NCT04627844|Dietary Supplement|Delayed Feeding|Standard tube feeds begun at delayed time point
75583177|NCT04595136|Drug|Drug COVID19-0001-USR|COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2
75583178|NCT04595136|Drug|normal saline|0.9% NS via nebulization
75729850|NCT05974748|Drug|Propolis 20%|In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
75881210|NCT03060447|Drug|ART|ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.
75881211|NCT04623567|Drug|Jiangtang Tiaozhi recipe|The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)
75881212|NCT04623567|Drug|Metformin|The metformin tablets (500mg) will be administrated.
76051774|NCT02269670|Drug|everolimus|Given PO
76051775|NCT02269670|Drug|anastrozole|Given PO
76051776|NCT02269670|Drug|letrozole|Given PO
76051777|NCT02269670|Drug|tamoxifen citrate|Given PO
76051778|NCT02269670|Drug|fulvestrant|Given IM or PO
76051779|NCT02269670|Drug|megestrol acetate|Given PO
76051780|NCT02225353|Drug|Progesterone Cervical Pessary 6.3 g|Progesterone Cervical Pessary low dose
76051781|NCT02225353|Drug|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
76051782|NCT02225353|Drug|Progesterone Cervical Pessary 7.7 g|Progesterone Cervical Pessary high dose
76051783|NCT01641926|Biological|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
76051784|NCT01641926|Biological|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
76051785|NCT02295020|Drug|Standard treatment only|Standard treatment such as NSAIDs and injections
76051786|NCT02295020|Device|Standard treatment plus Bioskin Ten-7 knee brace|Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.
76051787|NCT02200939|Device|Bioinductive implant|
76051788|NCT02200939|Device|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
76051789|NCT05152381|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75583179|NCT04628117|Dietary Supplement|Oral nutritional supplementation for kidney disease|237 mls per day for 8 weeks.
75583180|NCT01155661|Drug|LY2216684 (edivoxetine)|12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
75583181|NCT01155661|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
75583182|NCT04627883|Other|Inspiratory-to-expiratory (I : E) ratio of 1:2|After preoxygenation and induction of anesthesia, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2 for 5 min before endotracheal intubation.
75583183|NCT04627883|Other|Inspiratory-to-expiratory (I : E) ratio of 2:1|After preoxygenation and induction of anesthesian, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1 for 5 min before endotracheal intubation.
75583184|NCT00565188|Drug|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
75583185|NCT04628078|Other|Use of echocardiography guidance for LAAC|Since August 2015, the echocardiography is routinely used by majority of operators to guide LAAC
75583186|NCT04603833|Drug|SHR3680+Docetaxel|Participants will receive SHR3680 combined with Docetaxel
75881213|NCT01712789|Drug|Pomalidomide|Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
75435498|NCT05095259|Device|IPRO 2 Medtronic Minimed|All potential subjects will receive a blinded continuous glucose sensor at Visit 1. At the following visits, the continuous glucose monitor (CGM) will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A blinded CGM will be installed a week before every visit.
75435499|NCT05095259|Procedure|7 Tesla (7T) Magnetic Resonance Imaging|Subjects will undergo a hyperinsulinemic euglycaemic glucose clamp, as mentioned above, in the MRI scanning room. After 30 minutes of stable normoglycaemia, subjects are taken into the MRI scanner (Philips Achieva 7.0 T) where brain, liver, thigh and calf muscle are scanned. After every anatomically different area, the subjects must be taken out of the scanner, while scanning coils are replaced. All subjects are advised to lie still and press the alarm button if necessary.
75583187|NCT04603833|Drug|SHR3680|Participants will receive SHR3680
75583188|NCT04603833|Drug|Docetaxel|Participants will receive Docetaxel
75583189|NCT04603716|Other|Eccentric Muscle Energy Technique|"Conventional Treatment given to both groups (Hot pack for 15 minutes, Mobilization, AROM Exercises 10 sets x 3days in a week)~Reciprocal inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) causing relaxation, patient force is minimal towards maximal therapist force, 5-7 repetition for 2-4seconds 3 days in a week up to 6 weeks.~Muscle is taken from shortened to lengthened position."
75583190|NCT04603716|Other|Concentric muscle energy technique|"Group B: Concentric Muscle Energy Technique: (Autogenic inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) patient force is greater than therapist force, 5-7repitition for 3-4seconds)Muscle is taken from lengthened to shortened position.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 1st 3rd and 6th week"
75583191|NCT04627532|Drug|PF-07304814|Participants will receive PF-07304814
75583192|NCT04627532|Drug|Placebo|Participants will recieve placebo
75583193|NCT04627766|Device|Monitoring with VTPatch (Connected device manufactured by VitalTracer)|Patients will be monitored for 24 consecutive hours and vital signs will be recorded with VTPatch and with standard of care
75583194|NCT01580748|Drug|Roflumilast|500 microgram once daily for 16 weeks
75583195|NCT04603872|Drug|CD19/BCMA Targeted CAR T-cells and dasatinib|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.
75583196|NCT04603872|Drug|CD19/BCMA Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
75881214|NCT01712789|Drug|Dexamethasone|Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
75881215|NCT01357499|Device|blood pressure cuff|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.
75583197|NCT04627688|Behavioral|Time restricted feeding|Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.
75729851|NCT05973279|Other|Tecno Body Prokin Isokinetic Balance System|It provides objectively measurable data in static and dynamic balance measurements. The moving balance platform of the system, which is driven by air piston servo motors, can measure at a working angle of 15 degrees in all directions. The results can be monitored and recorded live on the screen on the device. From these data, each individual's static and dynamic balance score is obtained by summing the forward-backward standard deviation and right-left standard deviation.
75881216|NCT01357499|Device|blood pressure cuff + electric muscle stimulator|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
75881217|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
75583198|NCT04627688|Behavioral|Standard dietary advices|Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.
75583199|NCT04603794|Drug|0.5% Povidone Iodine|Commercially Available Mouth Rinses and Over the Counter Standard Formulations
75583200|NCT04603794|Drug|0.12% Chlorhexidine Gluconate Mouth Rinse|Commercially Available Mouth Rinses
75583201|NCT04603794|Drug|1% Hydrogen Peroxide|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
75583202|NCT04603794|Drug|0.9% Normal Saline|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
75583203|NCT04603755|Device|Electrical Impedance tomography|Electrical Impedance tomography recording during 5 minutes every day during 7 days
75583204|NCT04627337|Drug|Saccharomyces Boulardii 250 MG|Probiotic yeast in capsules
75583205|NCT04627337|Behavioral|Dietary advice following a low fermentation diet|Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
75729852|NCT05973279|Other|Restorative Therapies RT300 leg/arm/cor:|RT300 is a motorised treatment system. In general there are 3 systems; Passive therapy, Active therapy and a combination of active therapy with some assistance from the motor. The device can be used from a chair, wheelchair or bed and there are two variants that can be used separately; Leg system, Arm system. Electrodes placed on the skin over specific muscle groups are connected via a cable or wirelessly to the RT300. These are used to stimulate peripheral motor nerves, causing the muscles to work. The software of the SAGE controller unit of the RT300 monitors the treatment process, including the stimulation patterns sent to the arms or legs, and the operation of the ergometer motor to produce smooth cycling motion. Contraindicated in the presence of lower limb fractures or pregnancy.
75583206|NCT04603638|Drug|Magnesium|40 mg/kg(peroperative), 40 mg/kg (postoperative 12 h)
75729853|NCT05973279|Other|CSMI (CYBEX) Humac Norm Isokinetic Test and Exercise System|22 isolated joint movement models, 4 resistance modes (isokinetic, isotonic, isometric and passive) and a large number of reports to meet the measurement and exercise needs of today's clinicians and researchers. The exercise modes of the device include; Continuous passive movement, multi-angle isometry, proprioception training, standard and eccentric focused isokinetic strengthening, deceleration training, dynamic isotonic training, strength training. Test modes of the device include; Proprioceptive, co-measured, standard isokinetic, concentric/eccentric isokinetic, intermittent stroke isokinetic test.
75729854|NCT05965739|Other|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
75729855|NCT05965739|Other|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
75729856|NCT05965739|Other|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention with demonstrated efficacy in improving attention and executive functions, among other cognitive domains.
75729857|NCT05965739|Device|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
75729858|NCT05965739|Device|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
75583207|NCT04603638|Drug|Isotonic|100 ml
75583208|NCT04627454|Procedure|Discectomy and insertion of dynamic cervical implant in cervical disc herniation|The surgical technique included the use of a conventional anterior cervical approach and discectomy and insertion of dynamic cervical implant after discectomy without fixation
75583209|NCT04603599|Diagnostic Test|serum soluble L1CAM (sL1CAM)|blood sample
75583210|NCT04627298|Behavioral|educational video game for preteens to support HPV vaccination|An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
75583211|NCT04603170|Other|DRUG|taking drug medication prescribed by psychiatrists for at least one month
75583212|NCT04627220|Diagnostic Test|taken venous sample|Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.
75583213|NCT04627259|Other|Thumb Disability Examination|Turkish Version of Thumb Disability Examination. The Turkish Version of Thumb Disability Examination consists of 20 questions related with thumb pain and functionality.
75729859|NCT05960318|Device|KalobaNaso spray|Nasal spray, 2 puff per nostril, 3 times a day
75729860|NCT05960318|Device|KalobaNaso junior spray|Nasal spray, 1 puff per nostril, 3 times a day
75729861|NCT05960292|Procedure|Laparoscopic and Vaginal Hysterectomy|To make a comparison between the Vaginal Vault complications after Hysterectomy
75881218|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
76051790|NCT02294786|Drug|Lapatinib|Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
76051791|NCT02294786|Drug|Capecitabine|Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
76051792|NCT02294786|Drug|Octreotide|Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
76051793|NCT04880876|Drug|25mg Eluxadoline|Oral Tablets
76051794|NCT04880876|Drug|100mg Eluxadoline|Oral Tablets
76051795|NCT05647694|Other|V-NAV indoor navigation prototype|Users will use the V-NAV prototype as an augmentation to their indoor navigation activities.
75435500|NCT05095259|Procedure|Indirect Calorimetry using Jaeger Oxycon Champion|Resting metabolic rate will be estimated, after reaching stable plasma glucose level, via a hyperinsulinemic euglycaemic clamp, as mentioned above. This will be done by indirect calorimetry, using a ventilated hood system (Jaeger Oxycon Champion, software version 4.3, Jaeger, Mijnhardt). Subjects are instructed to lie down and rest for a period of 30 minutes. Subjects are also instructed not to move, talk or sleep unless necessary during the period of measurement. The recorded measurement after 5 minutes to 30 minutes will be used for analysis.
75435501|NCT05095259|Procedure|Core temperature and thermography using Thermovision SC645|Thermography (Thermovision SC645, FLIR Systems, Wilsonville, OR, USA) is used to determine cutaneous vascular perfusion. Data is analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA).
75435502|NCT05095259|Device|Freestyle Libre 2|All potential subjects will receive a continuous glucose sensor at Visit 1. At the following visits, the CGM will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A CGM will be installed a week before every visit.
75435503|NCT05068284|Drug|ABBV-154|Intravenous (IV) Infusion; Subcutaneous Injection
75583214|NCT04603092|Behavioral|Digital Health Literacy Intervention|"Willing women participants will be provided equipment with instructions for the intervention, including a smartphone and a 4G Wifi gadget. The health literacy intervention, delivered to the experiment group, will last three months and will include a combination of the following four components:~Component 1: Health literacy video tutorial. Component 2: Virtual one-on-one weekly meetings. Component 3: Monthly group virtual meetings and Whatsapp group. Component 4: Provision and guidance of a self-management chart."
75583215|NCT01155583|Drug|azacitidine|Given by subcutaneous injection (SC)
75583216|NCT01155583|Drug|lenalidomide|Given orally
75881219|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
75881220|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)
76051796|NCT02269124|Device|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
75583217|NCT01155583|Drug|dexamethasone|Given orally
75583218|NCT01155583|Other|DNA methylation analysis|Correlative studies
75583219|NCT01155583|Other|gene expression analysis|Correlative studies
75583220|NCT01155583|Other|bone marrow aspiration|Correlative studies
75881221|NCT03387449|Device|Bimanual Arm Training|Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
75881222|NCT01350557|Other|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
76051797|NCT01927341|Drug|MEK162|Tablet for oral use, 45 mg (three 15 mg tablets), BID
76051798|NCT01927341|Drug|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
76051799|NCT02294474|Drug|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
75583221|NCT01155583|Other|immunohistochemistry staining method|Correlative studies
75583222|NCT01155583|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
75583223|NCT01155583|Other|flow cytometry|Correlative studies
75583224|NCT04603131|Biological|Inactivated Chikungunya virus vaccine 20 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
75729862|NCT05959850|Drug|Ambroxol|Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).
75881223|NCT01350557|Other|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
75881224|NCT04565379|Drug|NuSepin® 0.1 mg|NuSepin® 0.1 mg
75881225|NCT04565379|Drug|NuSepin® 0.2 mg|NuSepin® 0.2 mg
76051800|NCT02294474|Drug|Humalog|Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
76051801|NCT02294474|Drug|insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
75881226|NCT04565379|Drug|Placebo|Normal Saline
75435504|NCT05068284|Drug|Placebo|Intravenous (IV) infusion; Subcutaneous Injection
75435505|NCT05068284|Drug|ABBV-154|Subcutaneous Injection
75583225|NCT04603131|Biological|Inactivated Chikungunya virus vaccine 30 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
76051802|NCT02168101|Drug|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg."
75881227|NCT03074318|Drug|Avelumab|Given IV
75435506|NCT05068284|Drug|Placebo|Subcutaneous Injection
75435507|NCT05049278|Drug|Norepinephrine|"Continuous drug: norepinephrine 4mg * 1@ + D5W 200 mL (20 μg/mL)~Range: 0.03 ~ 0.09 μg/kg/min (= 0.1 ~ 0.3 mL/kg/h)"
75583226|NCT04603131|Biological|Inactivated Chikungunya virus vaccine 10 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
75881228|NCT03074318|Drug|Trabectedin|Given IV
75881229|NCT02071316|Drug|Hexacapron( Tranexamic acid)|1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
75881230|NCT02071316|Drug|esomeprazole|2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
75881231|NCT03318224|Other|none (observational study)|only assessments via questionnaires, no interventions
76051803|NCT02298179|Biological|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
76051804|NCT02298179|Biological|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
75435508|NCT05049278|Drug|Phenylephrine|"Continuous drug: phenylephrine 10mg * 5@ + D5W 200 mL (250 μg/mL)~Range: 0.42 ~ 1.26 μg/kg/min (= 0.1 ~ 0.3 mL/kg/h)"
75435509|NCT05032963|Behavioral|Overnight polysomnography examinations|sleep lab for overnight polysomnography examinations
75583227|NCT04603131|Biological|Placebo|3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
75583228|NCT04626908|Drug|GC022F CAR-T cells|Each subject receive GC022F CAR-T cells by intravenous infusion
75583229|NCT04627181|Drug|Ferric carboxymaltose|Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
75881232|NCT02071472|Other|DP medication reconciliation|
75881233|NCT02071550|Device|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
75583230|NCT04627181|Drug|Hydroxycobalamin|Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
75583231|NCT04627181|Drug|Placebo|Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
75435510|NCT04995237|Behavioral|PPP|Participants will be provided with a weekly bag of produce, information about how to cook the produce, assistance in setting quality of life goals, and individualized teaching to support meeting participant's set goals.
75435511|NCT04994054|Dietary Supplement|silkworms (Bombyx mori L.) pupae extracts group|silkworms (Bombyx mori L.) pupae extracts 2,400 mg/day for 12 weeks
75435512|NCT04994054|Dietary Supplement|Placebo group|Placebo 2,400 mg/day for 12 weeks
75435513|NCT04993729|Drug|T89 capsule|"T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID."
75881234|NCT02071550|Device|FORESIGHT and INVOS monitor|
76051805|NCT02298179|Biological|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
76051806|NCT02298179|Biological|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
76051807|NCT02298179|Biological|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
76051808|NCT02298179|Biological|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
76051809|NCT02298179|Biological|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
75435514|NCT04993729|Drug|Placebo capsule|Placebo capsules, p.o. TID.
75435515|NCT04982354|Drug|CPX-351|For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.
75435516|NCT04982354|Drug|Midostaurin|The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.
75435517|NCT04982354|Drug|Busulfan|0.8 mg/kg/dose every six hours x 12 doses administered intravenously
75435518|NCT04982354|Drug|Melphalan|70 mg/m2/day x 2 doses administered intravenously
75583232|NCT04627181|Drug|Placebo|Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
75583233|NCT04626830|Other|Mobile Application Intervention|Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
75583234|NCT04626557|Procedure|biopsy|biopsy of the endometrium
75583235|NCT04602897|Other|forced coughing|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
75583236|NCT04626752|Drug|BCMA CAR-T|Volunteers will be treated with BCMA CAR-T cells
75583237|NCT04626752|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
75729863|NCT05959850|Drug|Placebo|Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
75729864|NCT05955768|Procedure|Disposable cervical dilator stick combined with lidocaine hydrochloride injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing lidocaine hydrochloride. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
75881235|NCT02074202|Drug|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
75881236|NCT02074202|Drug|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
75435519|NCT04982354|Drug|Fludarabine|25 mg/m2/day x 5 doses administered intravenously
75435520|NCT04982354|Biological|CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor|Allogeneic stem cell transplant infused intravenously
75435521|NCT04981834|Other|Quality-of-Life Assessment|Ancillary studies
75435522|NCT04981834|Other|Questionnaire Administration|Ancillary studies
75583238|NCT04626752|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
75583239|NCT04602663|Device|Esophageal Variceal Band ligation|Band ligation of OV
75583240|NCT04602585|Behavioral|Psycho-education|Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
75583241|NCT01155466|Drug|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
75583242|NCT01155466|Drug|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
75583243|NCT01155466|Drug|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
75881237|NCT02074280|Drug|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
75435523|NCT04981834|Procedure|Radical Prostatectomy|Undergo RARP
75435524|NCT04981834|Procedure|Vesicopexy|Undergo vesicopexy
75583244|NCT01155466|Drug|Placebo to Preladenant Tablet|one tablet orally twice daily
75583245|NCT01155466|Drug|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
75583246|NCT01155466|Drug|Placebo to Rasagiline capsule|one capsule orally in AM
75583247|NCT00561860|Device|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
75881238|NCT02074592|Behavioral|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
76051810|NCT02298179|Biological|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
76051811|NCT02298179|Biological|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
76051812|NCT02298179|Drug|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
76051813|NCT02298023|Biological|allogenic adipose stem cell injection|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
76051814|NCT02298023|Biological|fibrin glue/normal saline injection|Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise
75435525|NCT04975633|Device|Bodyport Cardiac Scale|Patients will be instructed to take daily measurements for 90 days. Data will be transmitted to Bodyport and concerning findings (weight gain, change of impedance, elevated heart rate) will be reported back to the medical team. The medical team will either choose to act on the information given or continue to observe trends. Interventions may include titration of therapy, change in therapy, fluid restriction, sodium restriction and lifestyle modification
75881239|NCT02074592|Behavioral|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
75435526|NCT04959461|Behavioral|webCHAT|A self-guided, single session web intervention that utilizes a motivational interviewing style to prevent impaired driving
75435527|NCT04959461|Behavioral|Usual Care|6 hours of driver education
75583248|NCT04602351|Behavioral|Communication|policies on communication and informed consent in ICU
75583249|NCT00561899|Drug|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
75583250|NCT00561899|Drug|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
75583251|NCT00561899|Drug|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
75583252|NCT01155388|Drug|Ferumoxytol|Experimental: Ferumoxytol
75583253|NCT01155388|Drug|Oral Iron|Active Comparator: Oral iron
75583254|NCT04313725|Device|Tangible Boost|Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.
75583255|NCT04313725|Other|Placebo|Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
75583256|NCT04626440|Procedure|Diagnostic stage or the Clinical outcome|After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.
76051815|NCT02298023|Biological|normal saline injection|Total 1cc of normal saline injection and range of motion exercise
76051816|NCT02296931|Other|Saline|Standard IV Saline Fluids
76051817|NCT02296931|Drug|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
76051818|NCT02166697|Drug|candesartan cilexetil|candesartan cilexetil tablets
76051819|NCT01909479|Drug|MOD-4023|Individualized once weekly dose of MOD-4023
76051820|NCT01909479|Other|Placebo|Once weekly administration of placebo
76051821|NCT04760977|Drug|Drugs administration|Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents
75583257|NCT04313803|Device|CGM|Dexcom CGM system
75583258|NCT00565227|Drug|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
75583259|NCT00565227|Drug|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
76051822|NCT04760977|Device|Resuscitative endovascular balloon occlusion of the aorta|Resuscitative technique for exsanguinating traumas
75435528|NCT04935606|Behavioral|Usual Care|Usual Care participants will receive their standard medical care as usual and all study assessments. Providers will not receive information about their drug use. To reduce Hawthorne effect biases and to mask the study's purpose, RAs will provide the Usual Care arm patients with a cancer screening booklet and have them view a cancer screening Video Doctor. Participants will receive re-contact calls (5 min) to provide attentional control for the Usual Care arm, motivate continued trial participation by reminding next research assessment and study incentives, update contact information, and address participation barriers, but do not provide intervention. At study end, Usual Care will receive the QUIT video doctor and drug use reduction booklet materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
75583260|NCT00561938|Procedure|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
75583261|NCT00561938|Procedure|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
75583262|NCT04123756|Behavioral|standardized exercise therapy for knee OA patients|Standardized exercise therapy for 6-8 weeks (two times per week).
75583263|NCT02884726|Drug|BMS-986148|Specified dose on specified days
75583264|NCT04602273|Drug|Azacitidine Injection [Vidaza]|
75583265|NCT00562016|Device|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
75583266|NCT00562016|Device|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
75729865|NCT05955768|Procedure|Disposable cervical dilator stick combined with normal saline injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing normal saline. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
76051823|NCT04760977|Biological|Blood transfusions|Transfuion of transported blood products for exsanguinating traumas
75583267|NCT04313491|Other|Yoga|Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
75583268|NCT04313764|Drug|Bupivacaine Hcl 0.25% ESP block|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
75583269|NCT04313764|Drug|Bupivacaine Hcl 0.25% infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
75583270|NCT04602234|Diagnostic Test|Lung ultrasonography|Investigators performed lung ultrasonography on patients
75583271|NCT04313569|Procedure|Arthroscopic menisctomy|Arthroscopic medial menisctomy
75583272|NCT00624793|Other|Acupuncture|Standard Acup point protocol for treating nausea
76051824|NCT04760977|Other|Prehospital management|Stay and play strategy vs scoop and run
76051825|NCT04760977|Device|Prehospital eFAST|Prehospital thorax/abdomen extended focused assessment sonography for trauma
76051826|NCT01955733|Drug|BI 695500|
75435529|NCT04935606|Behavioral|QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)|"QUIT's core components include:~patient screening with the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST, score 4-26);~face-to-face brief clinician advice on reducing drug use (2-3 minutes);~video doctor reinforcing the clinician message;~drug use reduction brochure;~2- and 6-week telephone health coaching sessions to enhance self-efficacy in reducing drug use, via motivational interviewing and cognitive behavior therapy (CBT) techniques (20-30 minutes)."
75583273|NCT00624793|Other|Individualized Acup based on TCM diagnosis|Acup
75583274|NCT00624793|Other|Sham Acup|Sham Acup - Non-Active
76051827|NCT02197897|Drug|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
76051828|NCT02223793|Behavioral|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
75435530|NCT04935606|Behavioral|QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)|"The QUIT-Mobile intervention includes QUIT's core components and adds:~SMS/IVR/mobile-app self-monitoring survey prompts twice-weekly during the QUIT coaching through 6 weeks, and then weekly self-monitoring and automated feedback via SMS/IVR/app through 12-months.~Web-based dashboards will be used by coaches for monitoring of patients' self-monitoring data to enhance 2- and 6-week coaching sessions and for monitoring during the post-coaching self-management and monitoring period from 7-weeks to 12-months and intervening accordingly. The mobile platform will provide the same intervention functions (self-monitoring surveys and feedback messages) and robust data transfer protocols across three mobile technology platforms."
75881240|NCT02074670|Other|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
75881241|NCT02077946|Drug|liraglutide|No treatment given.
75881242|NCT02077946|Drug|sitagliptin|No treatment given.
75729866|NCT05952232|Dietary Supplement|PA-GH-01|1 capsule after breakfast once a day
75881243|NCT02078024|Drug|IVM plus ALB|
75881244|NCT02078024|Drug|IVM|
75881245|NCT03559790|Drug|tenofovir alafenamide|To evaluate of efficacy and safety in patients with TDF-TAF switch therapy
75881246|NCT02079896|Drug|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
75583275|NCT04626089|Drug|metformin glycinate|Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
75583276|NCT04626089|Drug|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
75583277|NCT04626323|Procedure|Roux-en-Y gastric bypass|"Pneumoperitoneum closed with Veress needle~Identification of Treitz angle~Measurement of biliary loop (50 cm)~Bowel transection with linear stapler (white load)~Measurement of the alimentary limb (100 cm)~Laterolateral Entero-anastomoses (white load)~Construction of gastric pouch distant about 3 cm from the esophageal-gastric junction with stomach section in the small curvature.~Linear cutting anastomosis (gastrojejunostomy) from about 1 to 1.2 cm~Anastomosis integrity evaluation by methylene blue test and/or perioperative air.~Expected surgical time: 60 minutes"
75583278|NCT04626323|Drug|Best medical treatment|Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
75583279|NCT04602039|Dietary Supplement|Bovine Colostrum|Bovine colostrum (Neovite)
75583280|NCT04601688|Drug|Bevacizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
75583281|NCT04601688|Drug|Bevacizumab Ophthalmic|Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
75729867|NCT05952232|Dietary Supplement|MK-GH-04|1 capsule after breakfast once a day
75729868|NCT05952232|Dietary Supplement|TSH-GH-03|1 capsule after breakfast once a day
75729869|NCT05952232|Dietary Supplement|PA-GH-02|1 capsule after breakfast once a day
76051829|NCT02223793|Behavioral|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
76051830|NCT02223793|Behavioral|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
76051831|NCT01926015|Biological|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
76051832|NCT01926015|Biological|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
75583282|NCT04626011|Procedure|Tooth extractions|After blood collection tests, Periodontal analysis, Orthopantomography and Anamnestic record each group will receive a full mouth disinfection and needed extractions.
75729870|NCT05946954|Procedure|Immediate Dentoalveolar Restoration|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
75881247|NCT02079896|Drug|Placebo|
75881248|NCT02079974|Drug|Pravastatin|20 mg pravastatin sodium daily for 3 months
75881249|NCT03559556|Other|CT angiography|CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
76051833|NCT02223715|Other|CDI Pts|
75881250|NCT01353755|Drug|Grass pollen specific immunotherapy|"Strength 1 (0.78μg/mL)~Strength 2 (6.25μg/mL)~Strength 3 (50μg/mL)~Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
75435531|NCT04932382|Drug|Misoprostol|will be used 3 h before IUD insertion
75435532|NCT04932382|Device|IUD|a copper T380A IUD
75435533|NCT04921475|Device|Regional oxygen saturation monitoring|Regional oxygen saturation of kidney is monitored using near infrared spectroscopy
75435534|NCT04910256|Drug|HuaTuo Zaizao pill|Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.
75435535|NCT04910256|Other|basic treatment|"It accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation."
75435536|NCT04909060|Device|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children between 1 and 3 years old, scheduled for elective adeno-tonsillectomy, tonsillectomy or adenoidectomy and with no neurological or cardiac congenital deficits, no cardiac arrythmias (non-sinus rhythm), no implanted pacemakers, nor with a history of prolonged resuscitation at birth, and chronic therapy with drugs that have known effects on sympathetic and parasympathetic activity, ASA physical status III or higher and parent/guardian refusal will have a NIPE placed on their electrocardiogram, at least 20 minutes before the expected end of the surgery, the NIPE monitor will be connected to the anesthesia monitor at the end of the surgery, when the patient is considered ready to be transferred to the PACU, the NIPE will be disconnected and reconnected to the patient monitor once in PACU. Values will be recorded until the patient meets the discharge criteria from PACU not before 2hours
75435537|NCT04906811|Device|AuraGen 1-2-3 with AuraClens system (BK190433)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: AuraGen 1-2-3 with AuraClens system
75435538|NCT04906811|Device|Revolve System (K120902)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: Revolve System
75583283|NCT04601766|Drug|APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
75435539|NCT04901715|Drug|Albuterol|Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.
75583284|NCT04601766|Drug|APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
75583285|NCT04625816|Device|whole body tilt device (Spine Balance 3D)|The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.
75729871|NCT05946954|Procedure|Ice cream cone technique|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
75435540|NCT04901715|Diagnostic Test|Technetium99m - Sulfur Colloid (Tc99m-SC)|Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 uCi deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive ¾ of the adult dose to account for the smaller lung volume.
75583286|NCT01154452|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
75583287|NCT01154452|Other|Laboratory Biomarker Analysis|Correlative studies
75583288|NCT01154452|Other|Pharmacological Study|Correlative studies
75881251|NCT01353755|Drug|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
75881252|NCT02080052|Device|Robot-assisted prostate biopsy|
75435541|NCT04895592|Drug|Dexamethasone|Given PO or IV
75435542|NCT04895592|Procedure|Resection|Undergo surgical resection
75583289|NCT01154452|Drug|Vismodegib|Given PO
76051834|NCT02196259|Drug|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
76051835|NCT02294396|Drug|Mirabegron tablet|orally administered at a dose of 1 tablet once daily after breakfast
76051836|NCT02294396|Drug|Solifenacin tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
75435543|NCT04895592|Radiation|Stereotactic Radiosurgery|Undergo SRS
75583290|NCT04625894|Radiation|Stereotactic Ablative Radiotherapy (SABR)|To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED > 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.
75435544|NCT04879927|Other|Resource Matching|Resource staff involved in the customized resource matching arm of the intervention will include staff from DFCI Patient Services and DFCI Financial Counseling. Financial counseling will support patients with financial resource needs. DFCI Patient Services will provide assistance for all other patient Social Determinants of Health needs.
75583291|NCT04625894|Drug|Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle|Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
75729872|NCT05944900|Procedure|Cyanoacrylate glue application|"The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.~Cyanoacrylate glue should be applied in accordance with the instructions for use.~Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly."
76051837|NCT02294396|Drug|Propiverine tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
76051838|NCT02294396|Drug|Imidafenacin tablet|orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
75729873|NCT05940025|Device|MORT-LBP|The MORT-LBP, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioral therapy for patients with chronic lower back pain.
75729874|NCT05940025|Other|treatment as usual (TAU)|In the control group, education and physiotherapy is delivered and self-exercise is recommended.
75435545|NCT04879927|Other|Usual Care|Patients randomized to the control group will receive a pre-existing pamphlet detailing DFCI resources.
75435546|NCT04876053|Behavioral|Healthy Food Delivery Intervention|Each weekly food box will include ~9,000 calories of food, equivalent to the amount the average household receives prorated per week from an average Arkansas food pantry. The boxes will be designed by a registered dietitian. The boxes will follow ADA's Create Your Plate method consistent with the meal pattern promoted in the American College of Physicians (ACP) DSMES. The foods will also reflect Feeding America's Detailed Foods to Encourage framework, developed by nutrition experts and food bank staff to represent USDA dietary guidelines with healthy food that can be made available by food banks.
75435547|NCT04861103|Drug|Lovenox|Three times a day dosing and measuring Xa peak and trough levels
75435548|NCT04855123|Other|retinal imaging|OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer
75435549|NCT04855123|Other|paraclinical surveillance|blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)
75435550|NCT04843761|Biological|Remdesivir|Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
75435551|NCT04843761|Drug|Remdesivir Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
75435552|NCT04843761|Biological|Aviptadil|Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.
75435553|NCT04843761|Drug|Aviptadil Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
75435554|NCT04843761|Drug|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
75435555|NCT04835129|Drug|Isatuximab (for run-in portion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles.
75729875|NCT05938699|Drug|NCX 470|NCX 470 0.1% vs Placebo
76051839|NCT02294396|Drug|Tolterodine capsule|orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
76051840|NCT01721044|Drug|Placebo|Administered orally
76051841|NCT01721044|Drug|Baricitinib|Administered orally
76051842|NCT01721044|Drug|cDMARD|Participants will continue to take background cDMARD therapy throughout study.
76051843|NCT02164981|Drug|sodium nitroprusside|intravenous
75435556|NCT04835129|Drug|Isatuximab (for expansion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles.
75435557|NCT04835129|Drug|Pomalidomide|4 mg PO days 1-21 of each cycle.
75435558|NCT04835129|Drug|Elotuzumab|10 mg/kg on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles.
75435559|NCT04835129|Drug|Dexamethasone|40 mg (20 mg if >75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
76051844|NCT02164981|Other|Placebo|Placebo
76051845|NCT02195869|Drug|Ibrutinib|
76051846|NCT01908699|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
76051847|NCT01908699|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
76051848|NCT01599637|Drug|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
76051849|NCT01599637|Drug|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
76051850|NCT02264639|Drug|Pegcetacoplan|Complement (C3) Inhibitor
76051851|NCT04881461|Drug|5-grass mix SLIT-drops|Sublingual allergy immunotherapy drops, for daily administration
75583292|NCT01154296|Behavioral|RESPECT-2 Counseling|Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
75583293|NCT04601025|Dietary Supplement|Yoghurt|200 ml plain full-fat yoghurt
75583294|NCT04601025|Dietary Supplement|Chickpea+Yoghurt|80 ml plain full-fat yoghurt + 70 gr cooked chickpea
75435560|NCT04797572|Device|Free Margin Cusp Sizer|The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
75435561|NCT04795635|Device|CMM + Axon Therapy|transcutaneous magnetic stimulation (tMS)
75435562|NCT04766190|Behavioral|Group 2: The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
75435563|NCT04766190|Behavioral|Group 1: Usual Care|Patients randomized to this arm will receive usual care.
75435564|NCT04766190|Behavioral|Group 3: The DISCO App + Booster|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. Then, 2 months later they will receive an intervention booster in the form of an individually-tailored email to remind patients of the contents of the intervention.
75435565|NCT04754711|Dietary Supplement|Oral Nutritional Supplement|We will propose to the patients of group 1 several different oral nutritional supplements according to taste, and consistency of each child in order to optimize observance. Each of those different oral nutritional supplements will be adapted to the nutritional survey and the age of children without exceeding recommended intake of proteins, carbohydrates, lipids and micronutrients. Those patients will consume the Oral Nutritional Supplement during 12 months.
75583295|NCT04601025|Dietary Supplement|Oat+Yoghurt|80 ml plain full-fat yoghurt + 100 gr cooked oat
75583296|NCT04625855|Drug|TBPM-PI-HBr|TBPM-PI-HBr (3 x 200 mg tablets) once
75583297|NCT02884570|Other|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
75583298|NCT04313452|Other|the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged|to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
75583299|NCT04313686|Behavioral|Mindfulness-based therapy|Based on randomization, those who first receive the mindfulness training program are the intervention group. Participants would meet weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
75729876|NCT05938699|Drug|Placebo|NCX 0.1% vs Placebo
76051852|NCT04881461|Drug|Placebo|Placebo
75729878|NCT05933382|Other|Corticosteroid Group|Conventional exercise and corticosteroid injection
75729879|NCT05933382|Other|Mulligan Group|Conventional exercise and mulligan mobilization
75729880|NCT05931315|Dietary Supplement|CaroRite™|One capsule to be taken immediately post-dinner / with dinner
75729881|NCT05931315|Dietary Supplement|Placebo|One capsule to be taken immediately post-dinner / with dinner
75729882|NCT05926349|Drug|Andexanet alfa|Andexanet is a recombinant version of human FXa
75435566|NCT04742881|Procedure|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
75435567|NCT04742881|Procedure|Low pressure + standard instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of standard instruments (5mm and 10mm instruments)
75435568|NCT04721925|Behavioral|Social media messaging|A motivational interviewing-based intervention delivered via private health coaching on social media for 8 weeks.
76051853|NCT05648903|Other|Total diet replacement|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly to 12 months. The TDR products will be provided to participants free of charge. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks but participants would have to self-fund these products.
75435569|NCT04720313|Drug|NXC-201 (formerly HBI0101)|NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
75435570|NCT04699604|Drug|Levocetirizine Dihydrochloride|At the end of the HILD assessment participants will be randomized to Levocetirizine Dihydrochloride or placebo. Children will be randomized by an investigational pharmacist to add-on either Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children >11 years per recommended doses) or placebo to their current asthma regimen.
75435571|NCT04699604|Drug|Placebo|Placebo
75583300|NCT04313686|Behavioral|No-intervention|Participants who were randomized into this group would continue to receive their usual follow-up care at the usual neurology outpatient clinic.
75583301|NCT04625933|Other|No intervention|No intervention
76051854|NCT05648903|Other|Low-carbohydrate diet|Participants who choose this intervention will be supported to undertake a low-carbohydrate diet. During the first 12 weeks of the programme patients will be supported to consume below 100g carbohydrate per day, whilst being encouraged to increase protein, choose predominantly unsaturated fats alongside a high intake of non-starchy vegetables and low-carbohydrate fruits. After 12 weeks patients will be able to increase their carbohydrate intake up to 130g per day. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 100g carbohydrate for an additional 4 weeks.
75435572|NCT04677660|Biological|TAK-919|TAK-919 intramuscular injection
75435573|NCT04677660|Biological|Placebo|Placebo intramuscular injection
75435574|NCT04665206|Drug|VT3989|25 or 100 mg capsules for oral administration.
75435575|NCT04664842|Other|Diaphragmatic Stretch Technique|Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.
75435576|NCT04664842|Other|Breathing Exercise Training|During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.
75435577|NCT04648215|Other|lavender oil|aromatherapy--two drops applied to a 2x2 gauze and pinned to subject's gown
75435578|NCT04648215|Other|Grapeseed Oil|aromatherapy--two drops applied to a 2 X 2 gauze and pinned to subject's gown
75435579|NCT04644419|Other|none (observational study)|This is an observational study and does not include intervention delivery.
75435580|NCT04633928|Biological|N-TEC: Autologous nasal chondrocytes and ECM proteins|Cells expanded in vitro and cultured in a collagen type I//III scaffold
75583302|NCT04600986|Other|Repeated dose of GnRH agonist|0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
75583303|NCT01154218|Drug|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
75583304|NCT04601142|Drug|Methylprednisolone|methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
75729883|NCT05926349|Drug|Usual Care|As per the label of the chosen usual care product(s) and/or usual care standards.
75729884|NCT05923775|Procedure|Impacted third molar surgey|The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.
75729885|NCT05921396|Procedure|Nasal patency - rhinomanometry|Nasal patency before and after the pituitary adenoma surgery will be assessed using rhinomanometry.
75729886|NCT05921396|Procedure|Nasal patency - nasal inspiratory peak flow|Nasal patency before and after the pituitary adenoma surgery will be assessed using nasal inspiratory peak flow..
75729887|NCT05920941|Drug|[14C]JAB-21822|Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
75729888|NCT05919862|Procedure|Robot system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan
75729889|NCT05919862|Procedure|Freehand surgery|Freehand implant placement by experienced surgeon.
75729890|NCT05911724|Other|Group I|Healthy Subjects
75729891|NCT05911724|Other|Group II|Stable Angina Patients
75729892|NCT05911724|Other|Group III|Heart Failure Patients
75881253|NCT03135119|Behavioral|TF-CBT|TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
75583305|NCT04625582|Behavioral|Face-to-face|"The intervention has been created specifically for this group of trainees, with the aim of acquiring or improving mediating personal skills in the processes of physical and mental well-being that help them cope with more motivation, enthusiasm and personal resources professional challenges.~It is based on conducting 4-hour face-to-face workshops, every four months throughout the period of specialized health training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing.~Audiovisual media (videos, presentations, recordings) will be used. They will be developed in person in a classroom equipped with the necessary means for training, including versatility of the space."
75583306|NCT04625582|Behavioral|Online|"The online intervention will pursue the same objectives and will be nourished by the same content as the face-to-face intervention. The theoretical content will be adapted for online use, with the flexibility of access and organization that this entails for the participants, including videos, presentations, recordings ...~Group techniques will be carried out online, every four months during the entire period of specialized health professional training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing."
75435581|NCT04605445|Procedure|1 visit root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
75729893|NCT05911451|Procedure|Arteriovenous fistula creation|It is recommended to create the arteriovenous fistula 3 to 6 months before the expected start of hemodialysis treatment using locoregional anesthesia. It is recommended to use minimal venous and arterial diameters of 2mm for radiocephalic fistulas and 3mm for brachiocephalic and brachiobasilic fistulas. It is recommended to avoid creating an arteriovenous fistula at the same side as a pacemaker, central venous catheter, or arterial stenosis. It is recommended to use the following order of preference for arteriovenous fistula creation: radiocephalic fistula as first choice, brachiocephalic fistula as second choice, and brachiobasilic fistula as third choice.
76051855|NCT05648903|Other|Intermittent fasting 5:2|"Participants will have the option to follow a 5:2 dietary approach whereby calories are significantly reduced on two days of the week to 500 calories per day for women and 600 calories per day for men. The placement of the fasting days can vary each week, but there must be two fasting days in each seven-day period. After 12 weeks, patients will have the option of continuing with the 5:2 approach for further weight loss or adopting a 6:1 approach whereby patients would only fast on 1 day in each seven-day cycle for weight maintenance. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 5:2 approach for an additional 4 weeks."
76051856|NCT01363011|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
75583307|NCT00565305|Behavioral|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
75583308|NCT00565305|Radiation|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
76051857|NCT01363011|Drug|COBI|COBI 150 mg tablet administered with food orally once daily
76051858|NCT01363011|Drug|ATV|ATV 300 mg tablet administered orally once daily
75583309|NCT04625348|Device|Ultracore Repose® mattress|residents will be placed on the Ultracore Repose® mattress for the daily care during 14 days
76051859|NCT01363011|Drug|DRV|DRV 800 mg tablet administered orally once daily
76051860|NCT01363011|Drug|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
75729894|NCT05911451|Procedure|Arteriovenous graft placement|It is recommended to implant the arteriovenous graft 2 weeks before the expected start of hemodialysis treatment under antibiotic prophylaxis. Implantation of an early-cannulation graft is recommended for patients who require more urgent start of hemodialysis to avoid the use of a temporary central venous catheter. It is recommended to use minimal arterial and venous diameters of 3mm and 4mm, respectively. It is recommended to avoid placing an arteriovenous graft at the same side as a pacemaker, central venous catheter, or arterial stenosis.
75435582|NCT04605445|Procedure|2 visits root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be started, or performed in another visit, lasting 2 visits. In the first visit cleaning and shaping is performed and a medication is put in place in the canals, and the tooth is temporized until the next visit at least one week apart. In the second visit the tooth is root filled and temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
75583310|NCT04625348|Other|experiences and perceptions of healthcare workers|Three focus groups will be set- up at the end of the study to provide insights into how caregivers think about the product and to provide a deeper understanding of the difference between the use of the Ultracore Repose® mattress (versus the Repose overlay mattress® and an alternating air mattress)
75583311|NCT04625543|Drug|Sintilimab Injection plus Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; Sintilimab Injection 200mg on day 22; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
75583312|NCT04625543|Drug|Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
75583313|NCT04601259|Combination Product|Orkla Corn Plaster with salicylic acid|Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
75583314|NCT04601259|Device|Orkla Corn Protector|Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
75583315|NCT04625309|Other|Adaptive sports|This will be the number of hours per week the subjects actively partake in adaptive sports teams.
75435583|NCT04587167|Other|Project ECHO|"Using proven adult learning techniques and interactive video technology, the ECHO Model promotes knowledge exchange between experts or specialists at centers of excellence (the hub) and primary care providers (the spokes), typically located in rural settings. Through regular real-time collaborative sessions, the spokes connect with the hub and with other spokes to discuss 1) best practices in care and 2) complex cases managed within their practice."
75583316|NCT00565383|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural
75583317|NCT00565383|Procedure|Intravenous fentanyl (50mcg)|Intravenous fentanyl
75881254|NCT03135119|Behavioral|TF-CBT+AAT|TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
76051861|NCT05648825|Device|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device. Using this device, myectomy could be performed in the beating heart via a mini-thoractomy approach. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. We are now conducting the study to explore the feasibility, the safety, and the efficacy of transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy.
75435584|NCT04587167|Other|Announcement Approach Training|Train physicians and their clinic staff to make strong HPV vaccine recommendations by using presumptive announcements. If parents show vaccine hesitancy, the Training train physicians a 3-step approach (Connect, Clarify, Counsel) to share effective, evidence-based messages about HPV vaccine.
75435585|NCT04587167|Other|Recall notices|Notify parents that their child is behind for HPV vaccination. Recall notices will include research-tested messages to specifically address parent concerns. Recall notices will be sent to parents via patient portal or email communication.
75435586|NCT04581616|Procedure|Intrathoracic Intercostal Nerve Block|Injection of local anesthetic into the subcostal groove, to achieve analgesia for chest region.
75583318|NCT04625387|Other|Dry Needle and Exercise|"A 0.25 X 15 mm acupuncture needle was used for sub occipital muscle and 0.25 X 40 mm needle was used for paraspinal and trapezius muscle. All the necessary precautions were maintained before inserting the needle. Therapists wore hand gloves for all purposes.~The exercise for the muscles of cervical group, for group A was carried out by elevating head from lying in supine position repeating 20 times in three sets and pressing a theraband forward in one set of 15 repetitions, to right side and to left side and back side"
75583319|NCT04625426|Device|3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant|Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant
76051862|NCT05648747|Other|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.
76051863|NCT05648669|Drug|Elagolix|200 mg tablet
76051864|NCT05648669|Drug|Elagolix placebo|Elagolix-matched Placebo tablet
76051865|NCT02263547|Drug|teriflunomide|
76051866|NCT02263547|Drug|Colestipol|
75583320|NCT04625426|Device|Conveen EasiCleanse and Conveen Critic Barrier|Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
75583321|NCT04625426|Device|Standard cleansing and Conveen Critic Barrier|Hospital's standard care for IAD management
75881255|NCT02078258|Behavioral|ABMT|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
75435587|NCT04581616|Procedure|Erector Spinae Plane Block|Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve analgesia for chest region.
75583322|NCT04625075|Diagnostic Test|Cardiac MRI|Cardiac MRI with gadolinium and manganese contrast
75435588|NCT04573582|Drug|Enasidenib|100 mg enasidenib (CC-90007)
75583323|NCT04625075|Diagnostic Test|Cardiac CT|Cardiac CT to assess coronaries
75729895|NCT05911451|Procedure|Central venous catheter placement|It is recommended to place a tunneled central venous catheter just before the start of hemodialysis treatment under local anesthesia, with conscious sedation if preferred by the patient. The catheter should preferably be placed in the right internal jugular vein with ultrasound-guided puncture and fluoroscopy control under sterile conditions. According to usual practice at the trial center, catheters may be implanted by surgeons, interventional radiologists, or nephrologists.
75729896|NCT05907694|Procedure|Transcatheter PFO closure|"Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient."
75729897|NCT05907694|Drug|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
75435589|NCT04571164|Drug|LY03003(Rotigotine,extended-release microspheres)|During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
75881256|NCT01317953|Dietary Supplement|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
75881257|NCT02078336|Drug|Midazolam Mylan|
75435590|NCT04571164|Drug|Placebo,extended-release microspheres|During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
75435591|NCT04559880|Drug|Tranexamic Acid Injection [Cyklokapron]|Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
75583324|NCT04625075|Diagnostic Test|Electrocardiogram (ECG)|ECG to assess rhythm
75583325|NCT04625075|Diagnostic Test|Blood samples|renal function liver function full blood count, hematocrit glucose
75583326|NCT04591548|Diagnostic Test|proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample|All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
75583327|NCT04625192|Procedure|Trephine osteotomy|"Using a trephine on a straight implant handpiece (at approximately 1800 rpm) with copious irrigation to avoid overheating the bone, a round bone cut will be made 4 -5 mm above the crest of the alveolar ridge.~The trephine is positioned perpendicular to the lateral wall, removing the outer cortex with a very gentle touch to avoid tearing the schneiderian membrane."
75583328|NCT04625114|Drug|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1->D5);
75583329|NCT04625114|Drug|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1->D5).
75881258|NCT02078336|Drug|Lorazepam Mylan|
75881259|NCT02078336|Drug|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
75435592|NCT04559867|Procedure|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP.
76051867|NCT05648513|Behavioral|Motivational Interwiev|Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the patients consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.
75435593|NCT04559867|Procedure|Sphincterotomy|A sphincterotomy uses a heated metal wire to cut the opening to the bile duct after a wire has been passed into it.
75435594|NCT04548193|Behavioral|Behavioral Dietary Intervention|Receive live phone call
75583330|NCT04625114|Drug|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6->D10);
76051868|NCT01925703|Drug|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
75435595|NCT04548193|Behavioral|Behavioral Dietary Intervention|Receive IVR phone messages
75435596|NCT04548193|Other|Educational Intervention|Receive educational materials
75435597|NCT04548193|Other|Questionnaire Administration|Ancillary studies
75435598|NCT04543838|Diagnostic Test|Intervention|Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP) intraoperative monitoring
75435599|NCT04543838|Other|Standard of Care BP management|If blood pressure (BP) control is determined to be necessary, standard of care practices to manage it will be implemented
75435600|NCT04542369|Drug|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Inductive/neoadjuvant therapy: Tislelizumab + EP Maintenance/adjuvant therapy: Tislelizumab + EP
75435601|NCT04533334|Procedure|FOB measurement|A FOB will be inserted after anesthesia induction and the distances will be measured by direct observation via the bronchoscope.
75435602|NCT04518995|Drug|CTP-543 matching placebo|Administered as tablets.
75435603|NCT04518995|Drug|CTP-543|Administered as tablets.
75435604|NCT04518995|Drug|CTP-543|Administered as tablets.
75435605|NCT04496596|Drug|Suramin|Suramin is administered via IV infusion as a single dose of 3 mg/kg
75435606|NCT04496596|Drug|Placebo|Placebo
75583331|NCT04625114|Drug|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6->D10).
75583332|NCT04592133|Diagnostic Test|Ultrasonography|Ultrasonography Examination
75583333|NCT04624880|Device|Giant magnetoresistive sensor (GMR)|Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.
75583334|NCT04591470|Diagnostic Test|Mar test|Study of antisperm antibodies
75583335|NCT04624841|Drug|Indocyanine Green|2.5-7.5 mg (0.05 mg/kg) injection
75435607|NCT04485286|Drug|[68Ga]CBP8|Up to 15 mCi of [68Ga]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
75583336|NCT04624607|Device|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive transspinal stimulation and non-invasive brain stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
75881260|NCT01353833|Drug|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
75881261|NCT01350635|Biological|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
75435608|NCT04474691|Behavioral|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract can be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available. Knowledge of performance feedback could describe either the desired articulator placement or the auditory quality of the target sound.
75583337|NCT04624607|Device|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive brain stimulation and non-invasive transspinal stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
75583338|NCT00567099|Drug|Aripiprzole|"Dosage form, dosage, frequency and duration:~Aripiprazole 5-30 mg tabs po qday x 3 months"
75729898|NCT05907252|Behavioral|Supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
75881262|NCT02080130|Dietary Supplement|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
75583339|NCT04624802|Behavioral|maternal exercise|The maternal exercise is broadly practiced by pregnant women in China. It is designed by a team led by Shen Shanmei, a professor of Maternity Exercises at Department of Obstetrics and Gynecology of First Hospital in Korea.
75729899|NCT05907252|Behavioral|Non-supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
75881263|NCT02080130|Dietary Supplement|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
75881264|NCT02080130|Other|Placebo|Placebo
75881265|NCT03366779|Device|6mm annular closure device|6MM Barricaid annular closure device implantation following standard lumbar discectomy
76051869|NCT01617681|Drug|VAL489|Valsartan 3mg/kg oral solution
76051870|NCT01617681|Drug|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
75583340|NCT00567177|Drug|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
75583341|NCT04624373|Other|Molecular analysis of surnatant|"The interventional pulmonologist selects the most suspect node. The corresponding TBNA is placed in Cytolyt and tagged using a sticker to indicate the specimen from which supernatant must be saved after the initial spin.~The supernatant is transferred to the Laboratoire de Biologie Médicale Oncologique where it undergoes a further hard spin. The remaining supernatant is stored at -80°C before to send it to Foundation One for DNA extraction from 3 ml of supernatant and genotyping.~Two 7,5 mL blood tubes are transferred to the laboratory to extract plasma. Plasma was stored at -80°C and then sent to Foundation One for DNA extraction from 2 mL of plasma and genotyping.~10 slides from the cell block are shipped to Foundation One. These specimens are tested by FoundationOne®CDX (tissue), and FoundationOne®Liquid (supernatant and plasma) for genomic and TMB analyses (hybrid-capture based next generation sequencing)."
75583342|NCT04591158|Device|Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
75583343|NCT03454607|Device|FREE robot|FREE robot to hold endoscope
75583344|NCT00567216|Drug|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
75881266|NCT03559478|Procedure|Sharp dissection with scalpel plus electrocautery to vessels|A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.
75881267|NCT03559478|Procedure|Electrocautery for all dissection|Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
75881268|NCT03355001|Device|Monosyn® Quick|"Mucosal sutures in the facial and oral~Dermal sutures, particularly in pediatrics~Episiotomy~Circumcision"
75881269|NCT03353675|Biological|TG4010|1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks
75881270|NCT03353675|Drug|Chemotherapy|"Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance"
75583345|NCT00562055|Drug|Atomoxetine|
75435609|NCT04474691|Behavioral|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum generated by the staRt app. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak or 'bump' on the visual display.
75435610|NCT04453462|Procedure|Endoscopic carpal tunnel release under local direct median nerve block|local direct median nerve block is performed by surgeon using the 1%xylocaine with adrenaline 12 mL(5 mL subcutaneous at incision site and 7 mL over median nerve) (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
75435611|NCT04453462|Procedure|Endoscopic carpal tunnel release under brachial plexus block|brachial plexus block under ultrasound-guided is performed by experienced single anesthesiologist using the 1%xylocaine with adrenaline 15 mL (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
75729900|NCT05907252|Behavioral|Non-supervised Individual-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
75729901|NCT05907031|Device|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
75435612|NCT04453007|Behavioral|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
75435613|NCT04453007|Behavioral|Feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
75435614|NCT04451057|Device|high flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
75583346|NCT00562055|Drug|PNU-165442G; [S,S]-reboxetine|
75729902|NCT05907031|Device|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
75583347|NCT04590729|Behavioral|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
75583348|NCT04590729|Behavioral|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
75881271|NCT03353675|Drug|Nivolumab|360 mg IV administration every 3 weeks
75881272|NCT02075060|Procedure|IPOI (pre-operative)|
75881273|NCT02075060|Procedure|IPOP (post-operative)|
75881274|NCT01350713|Drug|povidone iodine|one local application of 10% povidone iodine ointment
75881275|NCT02075216|Procedure|Myoblast Transplantation|For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
75881276|NCT02075216|Biological|Neonatal Cystourethroscope Injection|4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
75435615|NCT04451057|Device|low flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
75435616|NCT04441619|Behavioral|Delayed onset muscle soreness.|Participants will perform a fatiguing exercise protocol for the upper extremity (biceps muscles)
75583349|NCT04624022|Diagnostic Test|Anterior segment optical coherent tomography|Examination of the implanted perforated lacrimal plugs using anterior segment optical coherent tomography
75583350|NCT04590807|Device|Posterior spinal fusion with pedicle screws|Implanting pedicle screws and rods
75729903|NCT05892406|Device|Static guide|A static guide will be designed and fabricated based on CBCT and intra-oral scan. Implant will be placed under the assistance of statistic guide through the whole procedure.
75729904|NCT05892406|Device|Dynamic navigation|Implant will be placed under the assistance of dynamic navigation.
76051871|NCT02263079|Drug|Entecavir|Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
76051872|NCT02263079|Drug|Lamivudine|Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
76051873|NCT02263079|Drug|Pegylated Interferon Alfa-2A|Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m^2) BSA.
75435617|NCT04391374|Procedure|an arterial reconstructive procedure|
75435618|NCT04352452|Procedure|laparoscopic surgery|differences in musculoskeletal and cognitive stress
75435619|NCT04343521|Biological|Targeted Indoor Residual Spraying (TIRS)|Spraying of insecticide Actellic 300CS will start May-June and extend for 1-2 months. Residents will be asked to temporarily leave the house during treatment and wait 0.5-1 h for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed in CDC-Emory-UADY collaboration.
75435620|NCT04332783|Behavioral|psychophysics of sequential biases (no drug or patient work)|Psychophysical experiment on sequential effects in medical image perception. Observers, including clinicians, perform psychophysical continuous report match-to-sample and forced-choice discrimination judgments of medical images, including radiographs and photographs. Observer discrimination accuracy is measured on a trial-wise basis and sequential effects in those judgments are measured. Images can be presented with different interstimulus intervals and in different spatial locations and in different orders. Accuracy, and other signal detection metrics are computed as a function of these factors.
75435621|NCT04315883|Behavioral|Quality of Life Assessment|"Evaluation of change of HRQOL survey responses will be performed:~at baseline (time of treatment) and~1 month post treatment~6 months post treatment~12 months post treatment~5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
75435622|NCT04315883|Radiation|Transarterial Radioembolization|"Deliver catheter directed yttrium-90 directly to liver tumors and assess -Progression Free Survival - Local and Metastatic~Local Tumor Response by calculating the decreases in tumor size and enhancement after treatment. This will be assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST).~Resection Rate following treatment~Transplant Rate following treatment~Histologic Response by assessing tumor histopathology in patients who undergo tumor resection or liver transplant~Biologic Response by monitoring serum tumor markers (e.g. alphafetoprotein-AFP) in AFP secreting tumors~Review of clinical course post-treatment-rehospitalization rate"
75435623|NCT04312958|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
75729905|NCT05892406|Device|Robotic system|Implant will be placed under robotic arm and human collaboration.
75435624|NCT04312503|Drug|Lurasidone|Patients are treated with dosages according clinical practice
75435625|NCT04312503|Drug|aripiprazole, olanzapine, quetiapine or risperidone|Patients are treated with dosages according clinical practice
75583351|NCT04590807|Device|Anterior vertebral body tethering|Vertebral screws and cable
75583352|NCT00567294|Behavioral|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
75583353|NCT00567294|Behavioral|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
75583354|NCT00567294|Behavioral|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
75729906|NCT05891990|Procedure|immediate implant augmented with sticky tooth|"Topical anesthesia will be administered using an infiltration technique.~Atraumatic extraction will be done with the aid of periotome and Luxators.~The extraction socket will be debrided to remove any residual debris or granulation tissue.~Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~The gap between the implant and the defect of the facial bone will be filled with the sticky tooth to reach enough buccal bone supported and then will be covered with absorbable barrier collagen membranes.~Finally, the flap will be repositioned and sutured."
75583355|NCT04624412|Other|Continuous Aerobic Moderate Intensity Exercise|"Continuous Aerobic Moderate Intensity Exercise~5-10 min warm up~30 min moderate aerobic exercise (Treadmill walking exercise)~Constant intensity at 50% - 70% of max HR (3-6 METS)~5-10 min cool down"
75583356|NCT04624412|Other|Continuous Aerobic (Mild intensity Exercise)|"Continuous Aerobic (Mild intensity Exercise)~5-10 min warm up~30 min mild aerobic exercise (Treadmill walking exercise)~Constant intensity at 30-50 % of max HR (1-3 METS)~5-10 min cool down"
75583357|NCT04590924|Procedure|Hip arthroscopy|Patients that had hip arthroscopic surgery 5 years ago will be invited for 5 year follow up. The surgical procedures consisted of femoral osteoplasty, labral refixation and acetabular osteoplasty
75583358|NCT00567333|Other|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
75583359|NCT00567333|Other|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
75583360|NCT04623866|Drug|Huaiqinhuang|Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
76051874|NCT02295995|Behavioral|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
76051875|NCT02294981|Device|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
76051876|NCT02262377|Behavioral|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
76051877|NCT02260817|Drug|11C-choline Injection|"Choline C11 Injection for PET/CT Imaging Protocol:~15 - millicuries (mCi) 11C-choline IV Injection~PET images skull base to mid thigh with 3 min per bed position~Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol~Fusion of PET and CT images~Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:~No IV contrast~High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs~Fusion of coronal and PET images"
76051878|NCT05647967|Diagnostic Test|Ultrasound|Each patient underwent ultrasound after admission of ICU.
75435626|NCT04305444|Drug|DTRM-555|Oral once-daily administration
75583361|NCT04623866|Drug|valsartan|Valsartan granules 80mg/1.73m2 based qd 24 weeks
75583362|NCT00567372|Drug|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
76051879|NCT04873193|Device|Leo device|Children's respiratory flow and volume measurements will be continuously recorded using the Leo device during oscillometry and pneumotach procedures.
76051880|NCT01642589|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
76051881|NCT01642589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
75583363|NCT00562133|Drug|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
75583364|NCT00562133|Drug|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
75583365|NCT00567411|Drug|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
75583366|NCT00567411|Drug|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
75583367|NCT00562172|Drug|Insulin glargine|Once daily in the morning
75583368|NCT00562172|Drug|Glimepiride|Once daily in the morning
75583369|NCT00562172|Drug|Metformin|At least 1000 mg/day
75583370|NCT00567450|Drug|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
75583371|NCT00567450|Drug|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
75881277|NCT01318889|Drug|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
75881278|NCT02075294|Drug|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
75435627|NCT04297332|Behavioral|Behavioral Intervention|Complete active episodic thinking task
75435628|NCT04297332|Behavioral|Behavioral Intervention|Complete active future thinking priming task
75435629|NCT04297332|Behavioral|Behavioral Intervention|Complete control episodic future thinking task
75435630|NCT04297332|Behavioral|Behavioral Intervention|Complete control future thinking priming task
75435631|NCT04297332|Other|Informational Intervention|Provided with Forever Free relapse prevention booklet
75435632|NCT04297332|Drug|Nicotine Replacement|Receive nicotine patches, gum, or lozenges
75435633|NCT04297332|Other|Telephone-Based Intervention|Receive coaching call
75583372|NCT00562211|Drug|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
75881279|NCT02080208|Device|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
76051882|NCT05647499|Behavioral|The Back 2 School program for problematic school absenteeism|We will use the Danish version of the revised manual developed within the B2S study in Aarhus, Denmark. The B2S program consists of a 3 to 3,5 -hour initial clinical assessment, a clinical conference, 11 sessions where the youth and/or parent are attending, and a booster session after three months including youth and parent. The B2S manual comprise four school meetings with the child, parents, school staff and therapists present. In the Norwegian pilot study, we will add an extended school module to the B2S-program. The school module includes a pre-meeting interview with the schools in week 1 and session 1 with the school in week 2 or 3. The B2S counselor and the school will decide whether there is a need for an additional meeting between school meetings 1 and 2. There is also a booster session with the child, parents, the school and the B2S team 3 months after the program.
75583373|NCT00562211|Drug|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
75435634|NCT04290975|Other|Task-shifting of follow-up care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be shifted to be performed primarily by Community Health Workers (CHWs) with specialized epilepsy training
75729907|NCT05891990|Procedure|immediate implant augmented with autogenous tooth graft|"Topical anesthesia will be administered using an infiltration technique.~Atraumatic extraction will be done with the aid of periotome and Luxators.~The extraction socket will be debrided to remove any residual debris or granulation tissue.~Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~The gap between the implant and the defect of the facial bone will be filled with the autogenous demineralized dentin graft to reach enough buccal bone supported and then will be covered with collagen membranes.~Finally, the flap will be repositioned and sutured."
75729908|NCT05890846|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
75729909|NCT05890846|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
75729910|NCT05890846|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
75729911|NCT05890846|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
76051883|NCT05647421|Device|IOL implantation|after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .
76051884|NCT05647421|Device|IOL implantation|after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )
76051885|NCT01954251|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
75435635|NCT04290975|Other|Enhanced usual care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be performed primarily by physicians, with CHWs serving to collect standardized data regarding outcomes
75435636|NCT04288375|Radiation|Intensity-modulated radiation therapy (IMRT)|The prescribed dose of radiations for all patients will be 50 Gy in 25 fractions. 6MV energy photons will be used. Multi-beam IMRT plans, utilizing dynamic multileaf collimation, will be created based on the target tissue coverage and normal tissue avoidance.
75435637|NCT04282343|Behavioral|The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
75435638|NCT04282343|Behavioral|Usual Care|Patients randomized to this arm will receive usual care.
75435639|NCT04278131|Drug|BS01|Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
75435640|NCT04273841|Dietary Supplement|Military Energy Gum|Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
75435641|NCT04273841|Dietary Supplement|Placebo Gum|Pellet form placebo gum
75435642|NCT04267029|Diagnostic Test|TADPOL battery (deep clinicolaboratory profile)|"profile dimensions:~hemolytic~allergic~cardiorenal~inflammatory~leukoagglutinating~exploratory bioarchive"
75435643|NCT04256889|Device|nfant(R) feeding system|Use of nfant(R) technology feeding system as an adjunct to visual assessment and cue-based feedings for infants born less than 30 weeks GA
75435644|NCT04249063|Drug|Xylocaine 1 % and Normal Saline|3cc aliquots of local anaesthetic will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
75435645|NCT04249063|Drug|Normal Saline|3cc aliquots of normal saline will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
75435646|NCT04239040|Procedure|Tissue collection|Collection of cancerous tissue to create GVAX vaccine or irradiated GMCSF-secreting autologous neuroblastoma cell vaccine at time of clinically indicated surgical procedure
75435647|NCT04239040|Biological|GVAX vaccine|Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.
75583374|NCT00567528|Drug|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
75583375|NCT00567528|Drug|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
75583376|NCT01154140|Drug|treatment|crizotinib 250mg orally continuous twice daily dosing
75729912|NCT05888116|Device|Hidrante HA|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
75583377|NCT01154140|Drug|treatment|pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
75583378|NCT04623749|Procedure|US|Percutaneous Ultrasound guided FNAC
75583379|NCT04623749|Procedure|EUS|Endoscopic Ultrasound guided FNAC
75729913|NCT05888116|Device|Cumlaude Hidrante Interno®|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
75729914|NCT05886842|Other|Test-retest|Test-retest
76051886|NCT01954251|Biological|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
75729915|NCT05883748|Drug|DISC-1459|DISC-1459 dose level 1
75435648|NCT04239040|Drug|Nivolumab|"Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
75729916|NCT05883748|Drug|DISC-1459|DISC-1459 dose level 2
75729917|NCT05874973|Other|Time-controlled adaptative ventilation (TCAV)|Ventilation with TCAV set on the APRV mode on the ventilator.
75435649|NCT04239040|Drug|Ipilimumab|Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
75435650|NCT04237753|Behavioral|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
75435651|NCT04237753|Behavioral|MyHealtheBladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
75435652|NCT04229017|Procedure|Anterior Cervical Discectomy and Fusion|Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
75729918|NCT05874973|Other|Volume-controlled ventilation (VCV)|Ventilation with the VCV mode set on the ventilator.
76051887|NCT01644617|Drug|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
75435653|NCT04229017|Device|Posterior Cervical Stabilization System (PCSS)|Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.
76051888|NCT01644617|Drug|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
75729919|NCT05867420|Biological|ASKG915|ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
76051889|NCT01644617|Drug|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
76051890|NCT02294318|Behavioral|HealthCall+Motivational Interviewing|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
76051891|NCT02294318|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
76051892|NCT04643925|Drug|Ovitrelle|Ovitrelle 260 IE once daily for 8 weeks prior to IVF/ICSI
75435654|NCT04209127|Procedure|Microwave treatment via needle antenna|Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated
75435655|NCT04209127|Procedure|Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)|Embolization via percutaneous catheter
75435656|NCT04204252|Drug|Alpha 1-Antitrypsin|Kamada's alpha 1-antitrypsin product given by inhalation using the eFlow® electronic nebulizer manufactured by PARI Pharma GmbH
75435657|NCT04204252|Drug|Placebo|Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
75435658|NCT04203433|Drug|DLX105-DMP|1mg applied to target lesion
75435659|NCT04192955|Drug|Acetyl Salicylate|Tablets
75583380|NCT04590768|Other|Fermotein based meals|various meal products: bread, soup and an occasional burgers
75583381|NCT04590768|Other|Matching control meals with whey protein and wheat bran|various meal products: bread, soup and an occasional burgers
75583382|NCT04623788|Diagnostic Test|Cardiac MRI|Cardiac MRI with contrast
75583383|NCT04590612|Drug|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|25mg-100mg tablets to be taken orally three times a day on an empty stomach
75583384|NCT04590612|Drug|Citalopram|20 mg tablet to be taken orally once and at the same time of the day, daily.
75729920|NCT05860738|Other|sterilization|autoclaving using the rapid cycle (4 mins, 134 oC) and the universal cycle (20 mins, 121 oC). The autoclave used in this study is (Anthos A-17 Autoclave, Italy).
75729921|NCT05860387|Diagnostic Test|Next generation improvement of early invasive aspergillosis|Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
75729922|NCT05859386|Behavioral|Mindfulness maintenance program|"Four-week course to strengthen and extend skills learned in 8-week MBCT course. This will consist of four 2-hour sessions, occurring weekly for four weeks.~Monthly 1.5 hour meeting sessions. These will be led by an experienced MBCT teacher and will consist of a group meditation practice, a check-in time, and discussion of a topic relevant to the MBSR course.~Monthly check-in survey. This will be a brief (5 - 10 minute) survey (using Qualtrics) with questions about mood (PROMIS Depression and Positive Affect scales) and recent meditation practice."
75881280|NCT01357967|Drug|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
75881281|NCT01357967|Drug|Seroquel XR adjunctive|"Quetiapine group:~seroquel XR 50mg Day 1 --> 50mg Day 2 --> 150mg Day 3 --> 150mg Day 4 --> adjustment usually at hs but can be daytime"
75583385|NCT04623476|Procedure|Pathophysiological Excision for Crohn's disease|Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.
75583386|NCT04590378|Other|intensive care unit admission ratio|intensive care unit admission ratio
75583387|NCT04590339|Procedure|Guided inferior Alveolar Nerve lateralization|Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
75583388|NCT04623164|Drug|Cocktail from complex phytoadaptogens (CFA)|Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
75583389|NCT04623164|Procedure|Standard non-surgical periodontal treatment (NSPT)|Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
75583390|NCT00562250|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
75583391|NCT00562250|Drug|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
75583392|NCT00562250|Drug|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
75729923|NCT05852587|Drug|Xylitol|Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.
75881282|NCT02075372|Other|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
76051893|NCT02293499|Behavioral|PLASMA|"A structured asthma self-management manual (Let's Talk about Asthma [LTAA],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site."
76051894|NCT04628949|Device|aScope™ Duodeno endoscope and aBox™ Duodeno|"The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope."
75435660|NCT04184869|Drug|Belinostat|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A & B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
75435661|NCT04184869|Drug|Atazanavir|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir) Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
75435662|NCT04175262|Drug|sunitinib|Patients to receive sunitinib as second line therapy for mRCC
75435663|NCT04156997|Other|No intervention is involved in this study|No intervention is involved in this study
75435664|NCT04149899|Drug|WB007 0.05%|WB007 Ophthalmic Solution 0.05%
75435665|NCT04149899|Drug|WB007 0.15%|WB007 Ophthalmic Solution 0.15%
75435666|NCT04149899|Drug|WB007 0.4%|WB007 Ophthalmic Solution 0.4%
75435667|NCT04149899|Drug|Timolol 0.5%|Timolol Maleate 0.5% Ophthalmic Solution
75583393|NCT00562289|Drug|aspirin|during the follow up
76051895|NCT02257385|Drug|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
76051896|NCT02257385|Drug|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
76051897|NCT02257385|Drug|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
75583394|NCT00562289|Drug|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
75729924|NCT05852587|Drug|Sucralose|The placebo in this trial will be sucralose. Sucralose is alternate SA that is poorly absorbed and non-microbially metabolized by bacteria in the microbiome including C. difficile. Because this is a double-blind, controlled trial, the control will be presented in capsules that are identical in size, smell, texture, and appearance to those of the xylitol capsules. These will be produced by the BWH investigational drug service. Sucralose will be ordered from MEDISCA as well and will be 100% pure.
75583395|NCT00562289|Device|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
75583396|NCT01154101|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
75583397|NCT01154101|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
75583398|NCT04313218|Drug|Carbetocin|iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
75583399|NCT04590261|Other|Blood sampling|Peripheral Blood sampling, 25 mL
75583400|NCT04590261|Other|Nasal Brushing|Nasal Brushing, facultative
75583401|NCT00624871|Drug|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
75583402|NCT00624871|Drug|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
75583403|NCT00624871|Drug|Placebo|
75583404|NCT01153984|Drug|Erlotinib|Erlotinib 150 mg oral doses will be administered daily.
75583405|NCT02884375|Other|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~comorbidities (CIRS G)~polypharmacy (number of medications)~social environment (primary caregiver, support at home, friends , family, living alone)~urinary and/or fecal incontinence"
75583406|NCT04623203|Other|No intervention|No intervention
75583407|NCT05250271|Other|15 g dextrose|15 g dextrose tablets
75583408|NCT05250271|Other|5 g dextrose|5 g dextrose tablets
75583409|NCT05250271|Other|Protein bar|5 g carbohydrates + 10 g protein
75729925|NCT05845216|Device|ACTIVE Transcranial photobiomodulation (tPBM)|fMRI records before and after ACTIVE Transcranial photobiomodulation (tPBM)
75729926|NCT05845216|Device|SHAM Transcranial photobiomodulation (tPBM)|fMRI records before and after SHAM Transcranial photobiomodulation (tPBM)
75729927|NCT05843838|Procedure|Hypotension during spinal anesthesia for cesarean section|Hypotension, Mean Arterial Pressure<65 mmHg, or Systolic arterial pressure < 30% will be considered an initial value
75729928|NCT05843838|Diagnostic Test|Mini-mental test|"A Mini-Mental State test is a set of questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory).~At the end of the research, the mental test scores of the two groups will be compared and the effect of hypotension will be evaluated."
75729929|NCT05843838|Procedure|Spinal anesthesia|It is a neuraxial anesthesia technique in which local anesthetic is placed directly in the intrathecal space. Spinal anesthesia will be applied to both groups with heavy bupivacaine in usual doses.
76051898|NCT02257385|Drug|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
76051899|NCT02257385|Drug|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
76051900|NCT02257385|Drug|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
75583410|NCT04623359|Device|High resolution manometry|High resolution manometry
75583411|NCT01153633|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:~Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~Secondary dressing to be a semi occlusive dressing~Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
75881283|NCT02870855|Drug|intrauterine injection of HCG|intrauterine injection of HCG berore blastocyst transfer
75881284|NCT02075450|Device|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
75583412|NCT01153633|Device|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:~Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~Secondary dressing to be a semi occlusive dressing~Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
76051901|NCT02257385|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
75583413|NCT04590183|Drug|FK-506 (Drug)|Twice a day
75583414|NCT04590183|Drug|Prednisolone Acetate 1% Oph Susp|Four times a day
75583415|NCT04623281|Device|Sixty device|Prototype wearable hydration monitor to be worn by patient during dialysis and at night
75583416|NCT01153321|Drug|AZD2423|100mg Oral dose od
76051902|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
76051903|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
76051904|NCT01629667|Other|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
75583417|NCT01153321|Drug|AZD2423 Placebo|Oral dose od
75583418|NCT04590456|Other|PEMF|group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
75583419|NCT04589871|Other|Taping technique|Fixmull stretch and Leukotape (rigid tape) were used in taping to guide the patellar trajectory orientation while performing the movement. Individuals were asked to lay down in supine position with knee in a slightly bent position. Fixomull stretch was used as an adhesive pre-wrap to protect the skin and provide some of the checking force. The main check strap was provided by stripes of rigid tape (Leukotape). The knee cap was taped, started on the outer aspect of the knee cap and pulled inwards. Finished at the back of the inside of the knee. Two further pieces of tape (Fixomull Stretch and Leukotape) applied distal to the patella unloaded the infrapatellar fat pad.
75583420|NCT04589871|Other|A supervised exercise protocol|Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
75583421|NCT04622618|Drug|Gabapentin|Anticonvulsant, Antiemetic, Analgesic
75583422|NCT04589949|Biological|ConvP|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
75583423|NCT04589949|Biological|FFP|Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products
75583424|NCT04622852|Device|Open reduction internal fixation (ORIF) with an angular stable plate|Operative treatment of proximal humeral fracture
75881285|NCT02075450|Other|Just in Time Video|CPR Just in Time training video administered before the simulation case
75583425|NCT04589793|Behavioral|Life Style|Life Style intervention including physical activity, diet, sleep and stress
75583426|NCT04622891|Drug|Clarithromycin 500mg|clarithromycin 500
75583427|NCT04622891|Drug|Azithromycin|azithromycin group
75583428|NCT04622891|Drug|Placebo|control group
76051905|NCT01645280|Drug|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
76051906|NCT01645280|Drug|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
76051907|NCT01645280|Drug|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
76051908|NCT01645280|Drug|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
75729930|NCT05843838|Diagnostic Test|The Bromage scale|"The Bromage scale is the accepted tool for motor block examination. The classification of these scores~complete block: unable to move feet or knees~almost complete: able to move feet only~partial: just able to flex knees; free movement of feet~no block: full movement of knees and feet"
75881286|NCT02075528|Drug|Paliperidone ER|9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
75881287|NCT02075684|Procedure|Renal Biopsy|
75435668|NCT04137536|Drug|anti-EGFR-bispecific antibody armed activated T-cells|"Phase I:~First 3 participants, twice weekly infusions of 10^10 EGFR BATs infusions~If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10^10.~If >/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10^9 per infusion~If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~- 8 infusions of 7.5 x 10^9 or 10^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)"
76051909|NCT01645280|Drug|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
76051910|NCT02256917|Biological|Human cl rhFVIII|
75583429|NCT04622579|Drug|lenalidomide combined with rituximab|lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
75583430|NCT04590066|Behavioral|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
75583431|NCT04622501|Procedure|posterior spinal decompression and posterior spinal instrumented fusion|posterior spinal decompression and posterior spinal instrumented fusion performed on a patient with Spinal Epidural Lipomatosis
75583432|NCT04590105|Device|"Smartphone App SB Colonoscopy Prep"|We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.
75729931|NCT05843838|Drug|Heavy Bupivacaine for spinal anesthesia|Routine clinical heavy bupivacaine doses
75583433|NCT04590105|Other|Written Instruction|Written Instruction
75583434|NCT01153009|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
75881288|NCT02075762|Procedure|Transbronchial biopsy|
75435669|NCT04119115|Device|CT-V|CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.
75435670|NCT04119115|Other|Metabolites|Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.
75583435|NCT01153009|Drug|Duloxetine|Overencapsulated duloxetine delayed-release capsules
75729932|NCT05828095|Biological|INO-6160, 2 mg|ID EP at month 0,1,3 and 6
75729933|NCT05828095|Biological|Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)|IM at month 3 and 6
75881289|NCT02075762|Procedure|Cryoprobe biopsy|
75881290|NCT02075762|Procedure|VATS biopsy|
75435671|NCT04111029|Diagnostic Test|Cell Free DNA|Pre and post procedure plasma cell free DNA will be assessed for response to locoregional therapy
75583436|NCT01153009|Drug|Placebo|Placebo-matching capsules
75583437|NCT04622111|Drug|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
75583438|NCT04622111|Drug|Placebo|matching placebo tablet
75729934|NCT05824598|Behavioral|Multifunctional rehabilitation treatment|multidisciplinary approach with (OMT, psychological counseling, and therapists dedicated to swallowing disorders)
75729935|NCT05824364|Other|telerehabilitation|Telerehabilitation activites will be tested with the aim to provide 1) continuation of rehabilitative care, focused on physical training and patients'monitoring , and 2) information in the mid-term about study goals.
75729936|NCT05824364|Other|rehabilomic|blood withdrawal (10 ml of blood, two tubes of 5 ml for serum isolation): at the hospital admission at the Cardiac Rehabilitation Unit of IRCCS Fondazione Don Gnocchi of Milan (T0) and after the rehabilitative treatment (T1)
75881291|NCT02078804|Procedure|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
76051911|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
76051912|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
76051913|NCT04188223|Biological|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine produced by Bio Farma
76051914|NCT04188223|Biological|Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine produced by Bio Farma
76051915|NCT02256839|Device|CST_001|
75583439|NCT04622111|Drug|Metformin hydrochloride 750 mg|IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
75583440|NCT04589715|Other|electroacupuncture|the same as described in experimental arm.
75729937|NCT05821283|Procedure|exercise program consisting of supervised exercise and physical activity|The Physical Activity Group (PAG) included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking). Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions.The physical activity program was applied as moderate intensity (maximum heart rate 50-70%) walking exercise. The patients were recommended to walk for 30 minutes, 3 days a week (total of 90 minutes) for the first 3 weeks, and 30 minutes 5 days a week (total of 150 minutes) for the 2nd 3 weeks
75729938|NCT05821283|Procedure|exercise program consisting of only supervised exercises.|The Control Group (CG) included in the program consisting of only supervised exercises. Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions
75729939|NCT05817877|Other|phone use|There is no intervention.
75729940|NCT05816356|Drug|Decitabine|Oral administration of decitabine as a single dose to healthy male subjects
75435672|NCT04100122|Procedure|Blood drawing|Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)
75435673|NCT04087421|Device|Qufora Irrisedo Cone System|The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.
75435674|NCT04087421|Drug|"Glycerol OBA"|Rectal suppository. Stimulates the rectum and softens and loosens stool.
75435675|NCT04081883|Other|Biosensor algorithm|The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
75435676|NCT04080531|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
75435677|NCT04080531|Biological|Trivalent Influenza Vaccine|Given IM
75435678|NCT04077073|Device|ReIn-Hand|ReIn-Hand assists the hand opening
75729941|NCT05816356|Drug|Tetrahydrouridine|Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
75729942|NCT05815498|Biological|mRNA-1283.222|Sterile liquid for injection
75729943|NCT05815498|Biological|mRNA-1273.222|Sterile liquid for injection
75435679|NCT04077073|Device|Robot|Robot supports the shoulder load
75435680|NCT04073485|Procedure|Microwave ablation|Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
75435681|NCT04038684|Behavioral|Mindfulness-Based Weight Control (MBWC)|Mindfulness-Based Weight Control will be administered over 12 group-based sessions with weekly home practice (e.g., mindfulness exercises, dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Sessions will include BWC and mindfulness components. BWC components include: 1) a dietary plan based on a balanced, caloric deficit diet; 2) increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g., breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of emotions and their relation to emotional eating.
75583441|NCT04589715|Other|sham electroacupuncture|the same as described in sham comparator.
75583442|NCT02884843|Device|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
75583443|NCT02884843|Device|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
75583444|NCT01152814|Biological|Seasonal flu vaccine|This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
75583445|NCT04589442|Biological|Split thickness skin graft|standard of care graft
75583446|NCT04589442|Biological|microsurfaced split thickness skin graft|standard of care graft that has been microsurfaced
75583447|NCT04621994|Other|Dermabond|Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
75729944|NCT05813873|Other|Triflow|Triflow
75729945|NCT05813873|Other|Control|Exercise
75729946|NCT05808595|Dietary Supplement|AlphaWave® L-Theanine|One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
75729947|NCT05808595|Other|Placebo|One capsule of Placebo will be taken twice daily for 28 days.
75729948|NCT05805709|Other|Study Physician/Advance Practice Provider|The nephrologist and/or nephrology-associated advanced practice provider (APP) at each site will lead the intervention team for the duration of the study. The study physicians will fulfil two main roles: (a) Provide supervision to the rest of the study team and (b) conduct a discharge assessment to triage and make recommendations for follow-up care.
75729949|NCT05805709|Other|Nurse Navigator|The nurse navigator will be the primary contact for the participants assigned to the intervention group for the study. The navigator will obtain contact information, information about the patient's usual care providers and pharmacy, review medications, show the participant how to use the home blood pressure machine and scales and arrange for follow-up visits. The role of the nurse navigator will be to monitor the participant's medical condition; facilitate scheduling of needed medical follow-up including both routine (pre-scheduled) and ad hoc (urgent or emergency); enhance adherence with prescribed medical care and follow-up appointments; and serve as a resource to the patient to answer questions about their AKI-related management, facilitate medical and associated care and provide enhanced psychosocial support.
76051916|NCT02220907|Drug|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
75729950|NCT05805709|Other|Pharmacist|The pharmacist will complete the medication reconciliation and medication regimen review per the predetermined checklist, via telemedicine if agreeable to the patient. The goal of the patient/caregiver-pharmacist interaction is to cover the following: avoidance of nephrotoxins when possible and appropriate, appropriate dosing of renally cleared drugs, review for drug-drug interactions, monitoring appropriate use of chronic medications, medication adherence, monitor for adverse drug reactions, evaluation of non-prescription medication use, medication/disease education and social support.
75729951|NCT05805709|Other|Patient Education|Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
75729952|NCT05801757|Drug|Remimazolam|Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
75729953|NCT05801757|Drug|Propofol|propofol 2-3mg/kg/h
76051917|NCT02255981|Other|Acupuncture and massage|"Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself."
76051918|NCT01601873|Device|PROPATEN|Heparin-bonded graft implantation for hemodialysis vascular access
75435682|NCT04038684|Behavioral|Standard Behavioral Weight Control (SBWC)|Standard Behavioral Weight Control will be administered over 12 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Group sessions will include SBWC component, including: 1) a balanced, caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
75435683|NCT04014075|Drug|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
75435684|NCT04009109|Drug|Lenalidomide|Induction and Maintenance
75435685|NCT04009109|Drug|Ixazomib|Induction and Only Maintenance Arm B
75435686|NCT04009109|Drug|Daratumumab Injection|Induction and Only Maintenance Arm B
75435687|NCT04009109|Drug|Dexamethasone|Induction and Only Maintenance Arm B
75435688|NCT03983993|Drug|Niraparib|Given PO
75435689|NCT03983993|Biological|Panitumumab|Given IV
75435690|NCT03950661|Other|Walking|
75435691|NCT03944616|Behavioral|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
75435692|NCT03944616|Behavioral|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
75435693|NCT03921801|Other|Gait retraining|"Gait retraining using real-time electromyography biofeedback performed once per week for eight weeks.~During the gait retraining session the participant is walking on a treadmill while receiving information on calf muscle activation. A single session includes five bouts of walking each lasting for 5 minutes. During the first bout, the participant is receiving feedback (visual and auditive) on soleus muscle activation with the aim to increase it by 20% from their normal walking. During the second bout, the participant is receiving feedback (visual and auditive) on medial gastrocnemius muscle activation with the aim to decrease it by 20% from their normal walking. During the last three bouts, the participant is receiving feedback (visual and auditive) on the soleus to medial gastrocnemius muscle activation ratio with the aim to increase it by 20% from their normal walking. If hitting the target, the aim is increased by 5% for the subsequent bout."
75583448|NCT04621994|Other|Steri Strips|Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
75583449|NCT04205695|Procedure|CEMP (closed-ended multiport catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
75729954|NCT05799755|Drug|Nintedanib|Nintedanib 150 mg BID
75729955|NCT05799755|Drug|Placebo|Placebo comparator
75729956|NCT05799755|Drug|Standard of Care|Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
75881292|NCT02080286|Behavioral|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
75583450|NCT04205695|Procedure|OESP (open-ended single port catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
75583451|NCT04205695|Procedure|Patient-controlled analgesia|A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
75583452|NCT02884531|Other|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
75435694|NCT03921801|Other|Gait retraining + strength training|"Gait retraining using real-time electromyography biofeedback performed once per week and home-based calf muscle strength training performed three times per week for eight weeks.~The gait retraining is identical to the one intervention described for the intervention group Gait retraining.~The strength training is performed three times per week except for the first week in which it is performed two times. The session contained a warm-up (3x10 repetitions of two-legged heel raises) and maximal isometric calf muscle contractions. The maximal contractions are performed using a custom device with the ankle in dorsiflexion and the knee flexed by 100-120 degrees. Three sets of 10 repetitions (3-second contraction and 3-second rest) are performed with both legs and with maximal effort and 1-minute rest between the sets."
75583453|NCT02884531|Behavioral|Patient Education|Patient education (1/2 day)
75583454|NCT04589481|Other|Intake of 3 different candies against bad breath|Intake of 3 different candies against bad breath on three different days (2-days interval each) after artificially creating a temporary bad breath (by eating of chips and cheese); analysis of breathing during intake of candy both subjectively and objectively
75583455|NCT04621721|Behavioral|Gait/balance & resistive exercise|Walking forward and back, walking with head motion, static standing, Standing Partial Tandem, Tandem Standing heel to toe, Standing with head turns Single leg stance and March in place. Resistance exercises include: calf raises, lunges, supine leg curls and extensions.
75583456|NCT05244889|Behavioral|Digital CBT-I|"The digital CBT-I intervention (www.sleepio.com) consists of six weekly sessions of CBT-I delivered over the internet by an animated virtual therapist known as The Prof. The content includes behavioral (e.g. sleep restriction, stimulus control), cognitive (e.g. putting the day to rest, thought re-structuring, mindfulness) strategies, relaxation strategies (e.g., progressive muscle relaxation) and advice on lifestyle and bedroom factors (sleep hygiene). Although the sessions can be completed at the persons own pace, the shortest interval between individual sessions is 7 days, thus participants can complete the course in 6 weeks, or take as long as 12 weeks. As part of the SLEEPIO program, participants will be required to enter their sleep/wake patterns using electronic sleep diaries. There is no face-to-face contact throughout the intervention and all treatment sessions, support and reminders are provided through the online platform."
75583457|NCT05244889|Behavioral|Sleep Hygiene Education|Sleep Hygiene Education (SHE) has successfully been used as a control condition in other trials evaluating dCBT-I42. SHE does not have any therapeutic benefits for individuals with insomnia alone, but is often part of usual care. Consequently it is a credible alternative to dCBT-I. The sleep hygiene education will be provided on a website with access to information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). As with the dCBT-I group, participants will not be required to make any changes to their usual care.
75583458|NCT05244187|Device|OrthoCor Active System|The OrthoCor Active System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy for General Use of temporary pain relief, utilizing wraps that position the therapy, such as on the ankle, back, knee, wrist, elbow, shoulder, foot, or neck.
75583459|NCT04589520|Behavioral|HeartBot App|HeartBot is an app designed to enable people 14 years and older to use relaxation tools offered by Heartfulness to deal with daily stress and anxiety in a healthy, productive manner.
75881293|NCT02080286|Device|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
75583460|NCT04622033|Biological|Brodalumab|brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.
75583461|NCT01152580|Dietary Supplement|melatonin|3mg p.o. at bedtime daily
76051919|NCT01601873|Device|Standard Graft|non-heparin bonded conventional hemodialysis vascular access graft
75435695|NCT03909152|Drug|Onapristone ER|50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.
75435696|NCT03909152|Drug|Onapristone ER + Anastrozole|Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.
75435697|NCT03874169|Device|E4 wristband|A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
75435698|NCT03840174|Biological|V160|V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)
75435699|NCT03840174|Other|Placebo|Saline solution (0.9% sodium chloride [NaCl] administered as a 0.5 mL IM injection
76051920|NCT02194933|Drug|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
75435701|NCT03811873|Diagnostic Test|Dual x-ray absorptiometry|DEXA is a means of measuring bone mineral density (BMD) using spectral imaging. Two X-ray beams, with different energy levels, are aimed at the bones. Soft tissue absorption is subtracted out, then the bone mineral density (BMD) can be determined from the absorption of each beam by bone.
75435702|NCT03811873|Other|Vertebral Fracture Assessment|Lumbar/thoracic spine x-ray and labs assessed for bone turnover markers.
75435703|NCT03810898|Radiation|Radioligand [¹¹C]CHDI-00485180-R|Intravenous injection of radioligand in the arm with PET imaging of the brain.
75435704|NCT03810898|Radiation|Radioligand [¹¹C]CHDI-00485626|Intravenous injection of radioligand in the arm with PET imaging of the brain.
75435705|NCT03808766|Other|embolization|Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.
75435706|NCT03789721|Other|Medical Record Abstraction|Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
75435707|NCT03789721|Other|Biospecimen Sample Collection|Collect research samples, when feasible for those diagnosed with ALD.
75583462|NCT01152580|Dietary Supplement|sugar pill|lactose p.o. at bedtime daily
75583463|NCT02884453|Drug|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research & Development, LLC and Pharmacyclics Inc.
75583464|NCT02884297|Drug|Contrast agent: SonoVue®.|SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
75583465|NCT04621799|Drug|Fibrin sealant|The intra-annular delivery of non-autologous fibrin into the annulus
75583466|NCT02884336|Other|No intervention|
75583467|NCT04621370|Drug|Durvalumab|Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.
76051921|NCT05647109|Other|No intervention|No intervention
76051922|NCT04420247|Drug|Chloroquine|5 days of treatment with Chloroquine + Standard Care
76051923|NCT04420247|Drug|Hydroxychloroquine|5 days of treatment with Hydroxychloroquine + Standard Care
76051924|NCT04420247|Other|standard care|Standard Care according to Brazilian Guidelines for treating COVID-19
76051925|NCT01644890|Drug|NK105|IV, Weekly
76051926|NCT01644890|Drug|Paclitaxel|IV, Weekly
76051927|NCT04868006|Procedure|End-range Maitland mobilization + proprioception training|End-range Maitland mobilization performed in end position of internal rotation of the shoulder accompanied with 8--week long proprioception training
76051928|NCT04868006|Procedure|Non end-range Maitland mobilization + proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
75583468|NCT04621370|Drug|FOLFOX|"Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil."
75583469|NCT04621370|Radiation|Short Course Radiotherapy (Arm A)|25 Gray of photon radiation treatment delivered over 5 fractions.
75583470|NCT04621370|Radiation|Long course chemoradiation (Arm B)|50 Gray of photon radiation treatment delivered over 25 fractions.
75583471|NCT04621370|Drug|Capecitabine|Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
75435708|NCT03786718|Other|Patient-facing Diabetes Dashboard|The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
75435709|NCT03778424|Drug|Rufinamide|Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
75435710|NCT03776864|Biological|Pembrolizumab|Given IV
75583472|NCT01152385|Drug|AZD1656|Oral tablet administered twice daily during 4 months
75583473|NCT01152385|Drug|Placebo|administered twice daily during 4 months
75583474|NCT04621487|Drug|Amoxicillin|14 days 1 gr bid
75583475|NCT04621487|Drug|Metronidazole|14 days 500 mg bid
75583476|NCT04621487|Drug|Clarithromycin|14 days 500 mg bid
75729957|NCT05796089|Radiation|Thoracic Radiotherapy|"Participants will receive thoracic radiotherapy to a dose of 30 Gray (Gy) in 10 fractions (3 Gy per day) concurrently with cycle 3 or 4 of chemo-immunotherapy (Group 1).~Participants who are unsuitable for concurrent radiotherapy may receive consolidation radiotherapy. Consolidation thoracic radiotherapy will be administered to a dose of 30 Gy in 10 fractions, following 4 cycles of chemo-immunotherapy (Group 2).~Treatment fractions will be delivered daily, where treatment should be completed within 15 days (9-10 fractions a fortnight)."
75583477|NCT04621487|Drug|Pantoprazole 40mg|40 mg bid 14 days
75583478|NCT04621487|Drug|according to antibiogram|according to antibiogram
75583479|NCT01152190|Drug|Tadalafil|Administered orally, once daily for 8 weeks
75583480|NCT01152190|Drug|Placebo|Administered orally, once daily for 8 weeks
75583481|NCT04649853|Other|Standardized nursing care|All patients will receive standardized evidence based nursing care
75583482|NCT04621565|Drug|Normal saline|No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
75583483|NCT04621565|Drug|Hydrocortisone|"Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 & 100mg at 2000), the postoperative day 1 (100mg at 0800 & 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program."
75583484|NCT04650048|Device|Active HD-tDCS|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
75583485|NCT04650048|Device|Sham HD-tDCS|"Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS."
75729958|NCT05796089|Drug|Etoposide with Carboplatin or Cisplatin|"The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre.~Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles."
75729959|NCT05796089|Drug|Durvalumab|"The immunotherapy in this study is a standard treatment for ES-SCLC.~Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy.~A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy)."
75729960|NCT05795881|Other|Cyclic daytime enteral nutrition|The allocated feeding schedule is followed from the start of enteral nutrition after ICU admission until discharge from the ICU.
75435711|NCT03776864|Drug|Umbralisib|Given PO
75583486|NCT00562367|Drug|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
75583487|NCT01151410|Drug|Aliskiren|"Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg~Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg~High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg"
75435712|NCT03773575|Device|PREVENA™ PEEL & PLACE™ Dressing Kit|In combination with a negative pressure pump (V.A.C. ® Therapy Unit, KCI USA, Inc.), the Prevena dressing is designed to provide negative pressure wound therapy (NPWT) over surgical incisions (incisional NPWT).
75729961|NCT05794464|Procedure|Catheter ablation and/or electrical cardioversion|Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
75729962|NCT05791305|Behavioral|double duty intervention packages|The intervention employed in this study will serve as double-duty interventions. The WHO policy short report from 2017 and Hawkes et al2020 .'s were amended and used as the basis for the DDIs packages. The main components of the intervention packages are the promotion of a minimum level of dietary diversity, avoiding unwarranted harm from high-energy foods, and controlling market foods from the perspective of the consumer. The following central criteria will be used to evaluate the study's intervention packages.
76051929|NCT04868006|Procedure|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
76051930|NCT04865237|Biological|SARS-CoV-2 Virus|SARS-CoV-2, intranasally, (1x10^1 TCID50, 1x10^2 TCID50 and 1x10^3 TCID50 or higher, as necessary)
75881294|NCT02080286|Device|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
75881295|NCT02080442|Other|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
76051931|NCT04865237|Drug|Remdesivir|VEKLURY™
75435713|NCT03762759|Procedure|Computed Tomography|Undergo PET/CT
75435714|NCT03762759|Drug|Fluciclovine F18|Given IV
76051932|NCT01628965|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
75435715|NCT03762759|Radiation|Gallium Ga68-labeled PSMA-11|Given IV
75435716|NCT03762759|Procedure|Positron Emission Tomography|Undergo PET/CT
75435717|NCT03737266|Procedure|Sonographically assisted breast surgery|Sonography
75435718|NCT03737266|Procedure|Conventional breast surgery|Conventional
75435719|NCT03675412|Dietary Supplement|Caffeine tablet|Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
75435720|NCT03672877|Behavioral|Intensive exercise|Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.
75435721|NCT03664180|Drug|Bivalirudin|IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
75583488|NCT01151410|Drug|Enalapril|"Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg~Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg~High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg"
75583489|NCT04588896|Device|Continuous glucose monitoring|Abbott Freestyle Libre CGM for 8 weeks in adjunct to lifestyle modification programme
75583490|NCT04588896|Behavioral|Lifestyle modification programme|Lifestyle modification programme
75435722|NCT03664180|Drug|Enoxaparin|40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
75435723|NCT03664180|Drug|Unfractionated heparin|IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
75435724|NCT03664180|Drug|Bivalirudin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
75583491|NCT00562406|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
75583492|NCT00562406|Procedure|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
75729963|NCT05775081|Other|Regenerative endodontic procedues|Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
75729964|NCT05774366|Drug|Remimazolam|General anesthesia was induced with 12 mg/kg/hr of intravenous remimazolam. When loss of consciousness was achieved, the infusion rate of remimazolam was reduced to 1mg/kg/hr for maintenance. At the end of surgery, 0.2 mg of flumazenil is administered.
75583493|NCT04588974|Device|magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images|The patient will undergo both diagnostic tests within two days, a magnetic-assisted capsule endoscope system first and then conventional EGD will be carried on at least 4 hours afterward.
75583494|NCT04649658|Behavioral|Prone position|Prone position maintained at least 3 hours/day
75583495|NCT04621409|Biological|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
75583496|NCT04621409|Biological|Placebo|IV infusion of saline, approximately 5 hours
75583497|NCT04588935|Drug|Bisoprolol; Perindopril;|based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
76051933|NCT05647460|Procedure|computer guided screw holes locating guide and custom-made plates|"Virtual planning and guide fabrication for the study group:~Preoperative CT.~Virtual reduction of broken segments on software.~Gain occlusion.~Design surgical screw holes locating guide.~Design the custom-made plates.~Print the screw holes locating guide and the custom-made plate.~Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa."
75435725|NCT03664180|Drug|Enoxaparin placebo syringe|Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
75583498|NCT04691258|Behavioral|Experimental: Complete Group|"The participants performed the squat and Stiff exercises with the maximum range of motion. In the squats, the knees were completely flirted, even if the participant could not perform the movement with neutral vertebral posture. The heels were also not supported to the ground in some participants due to lack of flexibility. It was instructed that the participants tried to perform the Squats and Stiff keeping the lumbar lordosis neutral, with the best posture they could in all training sessions, but all should perform the exercise with as much range of motion as possible.~The positioning of the feet was also carefully controlled, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the upper iliac spines (EIAS). The direction of the knees was oriented pointing in the direction of the tip of the feet parallel throughout the cycle of the movement."
75583499|NCT04691258|Behavioral|Active Comparator: Restricted Group|"The conventional movement technique of the squat exercise was used, in which the participants performed with the range of motion restricted to the neutral vertebral posture, approximately 90º of movement of the knee joint. may increase the range of motion if the lumbar posture did not rectify.~The positioning of the feet in this group was carefully controlled, the participants performed the exercise with the joints of the hips abducted and rotated laterally. Having markings on the ground as a reference, the feet went rotated at 21º and the lateral edge of the heels were moved away from each other, approximately with the biacromial distance. The direction of the knees was oriented pointing in the direction of the tip of the feet throughout the cycle of the movement, aligned to the lateral rotation of the hip. In the first training session, with the aid of a goniometer and metric tape, adhesive marks were placed on the floor to ensure this positioning of the support base."
75583500|NCT00562523|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
75583501|NCT00562562|Other|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
75583502|NCT04649424|Device|CanSwab|New nasopharyngeal swab design.
75583503|NCT00562679|Other|There is no intervention|
75729965|NCT05774366|Drug|Desflurane|Desflurane (1 minimum alveolar concentration (MAC) of end-tidal desflurane concentration) is used for the maintenance of general anesthesia. Induction of general anesthesia is achieved with 1-2 mg/kg of intravenous propofol bolus.
75435726|NCT03664180|Drug|Unfractionated heparin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
75435727|NCT03662841|Procedure|Ablative chemoembolization (ACE)|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
75435728|NCT03652870|Drug|Nortriptyline|A medication used to treat conditions such as depression
75435729|NCT03652870|Drug|Escitalopram|A medication used to treat conditions such as depression
75435730|NCT03652870|Drug|Placebo|Lactose and magnesium stearate tablet to be used as a placebo.
75729966|NCT05763082|Drug|roflumilast cream 0.3%|test product
75729967|NCT05763082|Drug|Zoryve|RLD product
75729968|NCT05763082|Drug|Placebo|placebo
75729969|NCT05759156|Drug|Tranexamic acid injection|The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
75729970|NCT05745870|Dietary Supplement|Creatine Monohydrate Supplementation|Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
75729971|NCT05736484|Behavioral|Social Support Gamification|Participants sign a pre-commitment contract agreeing to try their best to achieve their daily step goal. Over the 26-week intervention period, participants are endowed 70 points (10/day) weekly and informed they will lose 10 points each day goal is not met. Points are replenished at start of each week. At the end of each week, if the participant has 40 points or more, they will advance a level, or drop a level if they have less than 40 points. The levels include blue (lowest), bronze, silver, gold, platinum (highest). Participants select a family member or friend as a support partner to receive weekly email on participants' progress (points, game level, and average step count). Participants will also work with a virtual health coach by attending group sessions organized by them with other participants through video calls once a month to discuss ways to motivate participants to increase their physical activity.
75729972|NCT05733962|Device|Use of the device DBL-4pen|"During the treatment period, the patient will use~the DBL-4pen device (consisting of a software hosting the Diabeloop algorithm installed on a smartphone)~the associated device #1: Dexcom G6, Continuous Glucose Monitoring (CGM)~the associated device #2: Two Mallya caps for their rapid- and long-acting insulin pens.~The regulation algorithm hosted by DBL-4pen software recommends insulin doses to be administrated by the patient."
75435731|NCT03652389|Behavioral|MJS Diabetes|patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
75435732|NCT03652389|Behavioral|Usual Care|Standard Diabetes Treatment
75435733|NCT03635060|Procedure|Dorsal Bridge Plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
75435734|NCT03635060|Procedure|Volar locking plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
75435735|NCT03634852|Drug|Moxifloxacin hydrochloride 0.5% eye drops|were prescribed four times a day for 1-month postoperatively
75583504|NCT04588779|Other|Graston|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Graston for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
75583505|NCT04588779|Other|Manual myofascial release|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Manual myofascial release for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
75729973|NCT05730543|Drug|Volbella or Juvederm Ultra XC filler|Hyaluronic acid filler
75729974|NCT05716451|Device|Device-assisted mobilisation with the sit/stand stabilizer Liana|Non-invasive device-assisted mobilisation with LIANA
75729975|NCT05712772|Other|Blue Light|Blue light exposure
75881296|NCT03137069|Drug|GDC-0853|GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
75881297|NCT03137069|Drug|Placebo|Matching Placebo will be administered orally, as per the dosing schedules described above.
75881298|NCT02080520|Dietary Supplement|Nattokinase|
75881299|NCT02080520|Dietary Supplement|Placebo|
75881300|NCT02080598|Behavioral|2 cigarettes in 15 minutes|
75881301|NCT01350869|Device|Xience|Patients with Xience
75881302|NCT01358045|Drug|Diclofenac|Application on the lesion 2 times a day 8 weeks.
75729976|NCT05712772|Other|Red Light|Red light exposure
75881303|NCT01358045|Drug|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
75881304|NCT01358045|Drug|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
75881305|NCT02076230|Drug|[14C] TH-302 (Label 1)|[14C]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
75881306|NCT02076230|Drug|[14C] TH-302 (Label 2)|[14C]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
75583506|NCT04621214|Device|Audio-Visual Triage System (AVT)|Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
75583507|NCT04649619|Procedure|GASTRIC BYPASS MODIFIED IN ROUX-EN-Y AS A THERAPEUTIC OPTION IN PATIENTS WITH INDICATION OF BARIATRIC AND / OR METABOLIC SURGERY|"Roux-en-Y gastric bypass:~Stapling and reduction of the gastric chamber of approximately 18 cm, followed by anastomosis with a deviated bowel, and another bowel anastomosis with a bowel in a lower portion, for deviation of biliopancreatic secretions. Maintenance of a gastro-gastric communication of approximately 1 cm between the functional gastric pouch and the excluded stomach for endoscopic access."
75583508|NCT04649697|Drug|Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer.
75583509|NCT04649697|Drug|Nanoparticulated Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer will be used in nanotechnology.
75729977|NCT05711095|Dietary Supplement|Fortified plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
75435736|NCT03634852|Drug|Dexamethasone 0.1% eye drops|were prescribed four times a day for 1-month postoperatively
75435737|NCT03634852|Drug|Intracameral Moxifloxacin 0.1%|"Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient."
75435738|NCT03634852|Drug|Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml|"Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure"
75435739|NCT03593811|Diagnostic Test|Questionnaires|Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.
75435740|NCT03593811|Diagnostic Test|4 channel electrogastrogram (EGG)|EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.
75583510|NCT04649697|Drug|Clobetasol Propionate|A corticosteroid drug used as a gold standard for treatment of methotrexate induced oral ulceration.
75583511|NCT04621097|Device|pulsed electromagnetic field|it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used
75583512|NCT04621097|Other|treadmill training|supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
75583513|NCT04621097|Drug|Medication|regular medications
75583514|NCT04588584|Other|Survey and Interviews|Survey and Interviews
75583515|NCT04621253|Drug|Novalgin|Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake
75583516|NCT04649463|Diagnostic Test|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
75583517|NCT04620902|Other|Tear sampling|Tear sampling using Schirmer's strips
75729978|NCT05711095|Dietary Supplement|Plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
75729979|NCT05711095|Dietary Supplement|Whey protein|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
75729980|NCT05708586|Behavioral|Control|This is the control condition and anxiety is addressed in a standard way of having the care taker calm the child during the intervention.
75729981|NCT05708586|Device|Virtual Reality (VR)|The child who is undergoing a procedure uses VR as a distraction during the intervention
75881307|NCT02076230|Drug|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
75583518|NCT04588701|Procedure|surgical procedures commonly done for anal fistula|Surgical procedures performed, including fistulotomy; fistulotomy with sphincter repair; seton; advancement flap; fistula plug;
75583519|NCT00567762|Drug|FK506|Opthalmic suspension
75583520|NCT00567762|Drug|placebo|placebo eye drops
75583521|NCT04620785|Other|methylene blue / IPL|therapeutic
75583522|NCT04620785|Other|IPL|therapeutic
75435741|NCT03593811|Diagnostic Test|36 channel high resolution electrogastrogram (HR-EGG)|HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.
75435742|NCT03593811|Diagnostic Test|Magnetogastrogram (MGG)|MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
75435743|NCT03593811|Diagnostic Test|Electrocardiogram (EKG)|Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin
75435744|NCT03593811|Drug|Ondansetron|Patients will be administered 4mg or 8 mg ondansetron dependent upon age in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.
75583523|NCT04620785|Other|saline|placebo
75583524|NCT00567801|Procedure|conventional embolectomy/thrombectomy|
75583525|NCT00567801|Procedure|embolectomy/thrombectomy with controlled reperfusion|
75583526|NCT04620590|Drug|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin is a stable, reversible, highly selective, and orally active inhibitor of human renal sodium glucose co-transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in the kidney. Patients will receive one tablet dapagliflozin 10 mg per day for a total period of 14±1 days. This dose is the recommended dose for monotherapy and for add-on combination therapy with other glucose-lowering medicinal products including insulin to improve glycaemic control in T2DM.
75583527|NCT04649268|Device|Group B|The C2 CARE C2 Physio 2019.2 has been developed for physiotherapy rehabilitation purposes including vestibular disorders. Virtual reality environments will be provided via the VR Oculus Quest headset as part of the OKS exposure incorporated within a customised VRT programme. Participants will attend 45 minute individualised supervised sessions once weekly for 8 weeks. Participants in this rehabilitation group will also have a home-based exercise programme to practise on days not attending clinic. The home-based programme will incorporate customised VRT exercises with exposure to VR environments using the VR Oculus Quest headset.
75881308|NCT03559712|Other|Collaborative care, Telemental health|Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
75881309|NCT02080754|Other|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
75583528|NCT04649268|Other|Group A|Optokinetic stimulation treatment delivered through visual motion DVDs. Individualised 45 minute supervised sessions will occur for this group also once weekly for 8 weeks together with a home-based customised VRT programme incorporation the DVD to practise on days not attending clinic. Participants will have to use the OKS DVD for their exercises at home daily for 8 weeks as part of the prescribed home exercise programme.
75583529|NCT04691219|Dietary Supplement|Mulberry leaves powder|Dried powder of mulberry leaves crude extract containing 12 mg of DNJ will be packed in a sealed packet with light and moisture protection. Participants will be instructed to mix 1 packet of the powder with a half glass (approximately 120 mL) of plain water and ingest thrice daily before meals. Additionally, they will be informed to rinse the glass with more water and drink to ensure that all of the powder will be taken.
75583530|NCT04691219|Behavioral|Diet control|Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
75881310|NCT02080754|Other|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
75881311|NCT01354067|Behavioral|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
75435745|NCT03593811|Drug|Cyproheptadine Oral Tablet|Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 4mg twice a day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients
75435746|NCT03575819|Drug|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
75583531|NCT04691063|Drug|SHR-1316; Carboplatin; Etoposide；Radiotherapy|SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）
75583532|NCT04691063|Drug|Palcebo; Carboplatin; Etoposide；Radiotherapy|Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）
75583533|NCT04588467|Other|Medical treatment|Pregnant women complaining thrombosed haemorrhoids will receive dietary modification (intake of at lest 3 liers of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application
76051934|NCT05647460|Procedure|conventional plates|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
75583534|NCT04588467|Procedure|Surgical treatment|Pregnant women complaining thrombosed haemorrhoids will receive local excision or thrombectomy under local anesthesia
75583535|NCT04620395|Diagnostic Test|Punch biopsy|A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
75583536|NCT01151215|Drug|AZD8931|Tablet, oral, bd
75583537|NCT01151215|Drug|anastrozole|Tablet, oral, od
75583538|NCT01151215|Drug|Placebo|Tablet, oral
75583539|NCT04588389|Drug|Ropivacaine injection Location 1|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1
75729982|NCT05705609|Other|Mandala art therapy|A mandala is a geometric configuration of symbols. In various spiritual traditions, mandalas may be employed for focusing attention of practitioners and adepts, as a spiritual guidance tool, for establishing a sacred space and as an aid to meditation and trance induction. Mandalas are used effectively in the field of art therapy. The possibility of using mandala in all age groups has contributed to the treatment process of different diseases and disorders, and its effectiveness has been presented to the scientific world with many researches around the globe. As a result of using mandala as an art therapy in adults, mandala has been used both in the treatment of psychiatric disorders and has been a tool used to observe the effects of the treatments. Art therapy which included drawing mandala, significantly reduced the severity of trauma symptoms in individuals with anxiety disorders and post-traumatic stress disorder.
75729983|NCT05692167|Drug|Topical dexmedetomidine|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
76051935|NCT05647382|Diagnostic Test|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
76051936|NCT01644734|Drug|Spiriva HandiHaler|
75435747|NCT03561103|Behavioral|Client-Centered Representative Payee|CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
75583540|NCT04588389|Drug|Ropivacaine injection Location 2|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2
75583541|NCT04588389|Drug|Multimodal Pharmacological Management|standard of care multimodal pharmacological management
75583542|NCT04620473|Drug|Anlotinib+Capeox|to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
75583543|NCT04620473|Drug|Capeox|to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
75583544|NCT00637234|Drug|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
75583545|NCT00637234|Drug|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
75583546|NCT04581720|Device|Train-of-four (TOF)|Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 ~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
75583547|NCT02883985|Radiation|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
75583548|NCT02940665|Other|ERAS|Patients in the ERAS group received the ERAS protocol
75583549|NCT04588194|Drug|Romiplostim|Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21
75729984|NCT05692167|Drug|Reginal dexmedetomidine|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
76051937|NCT02255279|Biological|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
76051938|NCT02255279|Biological|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
75729985|NCT05690594|Other|Self or straight administered questionnaire|"Self or straight administered questionnaire with 5 parts:~General questionnaire (to collect socio-demographic data)~ICIQ score to evaluate urinary continence~FLQI score to evaluate fecal continence~FSFI score to evaluate sexuality in women or IIEF-5 score to evaluate sexuality in men~SF-12 score to evaluate quality of life The questionnaire will be sent to patients by email and/or mail. Patients will be able to either complete the questionnaire alone and return it to the primary investigator, or to request a telephone interview to help them to complete the questionnaire. The questionnaire is administered only once and the estimated response time to the questionnaire is between 30 minutes and one hour."
76051939|NCT01643798|Procedure|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
75435748|NCT03560453|Behavioral|Project SEARCH Plus ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center (Daston et al., 2012). Students with developmental disabilities who participate in this model rotate through three 10-12 week internships within the business where they log approximately 720 hours of internship time learning marketable skills while receiving supported employment. They also get 180 hours of classroom time at the business for a total of approximately 900 hours embedded in the business setting. In addition to these important training components, Project SEARCH requires collaboration between multiple community partners to support students in attaining employment upon completion of the program. Collaborations include students with developmental disabilities and their family, a LEA, a local CRP, the state VR, and a host business.
75583550|NCT04588194|Drug|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
75583551|NCT04588194|Drug|Dexamethasone|40 mg IV/PO days 1-4
75583552|NCT04587921|Device|Digital oximeter monitoring|Digital oximeter and cardiac frequency monitoring.
76051940|NCT01643798|Procedure|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
75583553|NCT02940314|Drug|HIP1503|
75583554|NCT02940314|Drug|HGP1103|
75583555|NCT04581525|Device|transcranial direct current stimulation|
75729986|NCT05682261|Dietary Supplement|UNIMMAP-MMS|The study participants in this arm will receive the United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) containing 15 micronutrients including 30 mg of iron and 400 µg of folic acid.
75729987|NCT05682261|Dietary Supplement|IFA|The study participants in this arm will receive iron-folic acid supplements with 30 mg of iron and 400 µg of folic acid.
75729988|NCT05682261|Other|Placebo|The study participants in this arm will receive placebo made of sugar (lactose anhydrous).
75881312|NCT01354067|Behavioral|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
75881313|NCT01357811|Drug|eliglustat; digoxin|repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
75881314|NCT01357811|Drug|digoxin|oral 0.25mg dose of digoxin (single dose) on Day 1
75881315|NCT02079116|Other|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~60 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
75435749|NCT03552575|Drug|sacubitril/valsartan|Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
75729989|NCT05671965|Dietary Supplement|Xylitol|33.5g xylitol dissolved in 300mL tap water.
75729990|NCT05671965|Dietary Supplement|Sucrose|33.5g sucrose dissolved in 300mL tap water.
75881316|NCT02079116|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
75435750|NCT03552575|Drug|Valsartan|is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
75435751|NCT03535623|Other|remote ischemic preconditioning (RIPC)|RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion.
75729991|NCT05671965|Dietary Supplement|Acesulfame Potassium|0.1675g Ace-K dissolved in 300mL tap water.
75729992|NCT05671965|Dietary Supplement|Water|300mL tap water.
75881317|NCT01351181|Behavioral|Leaflet|Advice Leaflet
75881318|NCT01351181|Behavioral|Exercise Advice|Leaflet
75881319|NCT01351181|Behavioral|Normal Care|Normal Care
75435752|NCT03535623|Other|Sham-RIPC|Sham-RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion.
75435753|NCT03528902|Drug|Tamoxifen|Tamoxifen 20 mg po daily for 24 weeks.
75435754|NCT03528902|Drug|Placebo Oral Tablet|Placebo
75729993|NCT05670041|Behavioral|Intensified follow-up|Early, intensified follow-up after discharge from TAVI-procedure.
75881320|NCT02080910|Behavioral|Psychoeducation|
75881321|NCT04300985|Drug|Dexmedetomidine|Patients will start receiving dexmedetomidine 15 minutes before general anesthetic induction.
75881322|NCT04300985|Drug|Sham treatment|Patients will start receiving saline solution infusion 15 minutes before general anesthetic induction.
75881323|NCT04300985|Drug|Magnesium Sulfate|Patient will start receiving magnesium infusion (20 mg/kg/h) 15 minutes before general anesthetic induction.
75881324|NCT02079194|Drug|P2Y12 antagonist monotherapy|
75881325|NCT02079194|Drug|aspirin plus P2Y12 antagonist|
75881326|NCT01358279|Procedure|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
75435755|NCT03522714|Device|Fluid Immersion Simulation System|Dolphin Fluid Immersion Simulation® System Mattress will be used
75435756|NCT03522714|Device|Air Fluidized Bed System|Air Fluidized Bed (Clinitron) will be used.
75583556|NCT04620083|Other|Integrative Learning Program for Old People with Dementia|The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
75583557|NCT04620044|Other|Kaledo game|Before starting the study, the height and weight of the children in the play group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the game sessions were started.Game sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
75583558|NCT04620044|Other|Education|Before starting the study, the height and weight of the children in the education group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the education sessions were started.education sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
75583559|NCT04620044|Other|No intervention|Body mass indexes were calculated by measuring the height and weight of the students.Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.The same measurements and scale applications were repeated after 12 weeks.
76051941|NCT05647031|Other|Qualitative study. Pain in competitive athletes with physical disabilities and techniques for its management.|"This study used a qualitative, exploratory and descriptive methodology, with a semi-structured interview technique. The purpose was to respond to the specific objectives set out in this research from the perspective of competitive athletes and sports agents (physiotherapist, coach and psychologist). The thematic cores that served as a script for the interview were for the athletes and sports agents 1) sporting characteristics of the professionals; 2) perception of how pain affects this type of athlete and what repercussions it has on the development of their sporting career, and 3) knowledge of techniques and/or strategies for pain management (athlete, coach and psychologist).~The interviews were conducted via skype. After transcription of all the interviews, validation by the interviewees was applied for the reliability of the research. Two types of triangulation were applied to ensure the quality of the data."
76051942|NCT05647226|Combination Product|Digital therapeutic and intensive lifestyle programme|Initial 12-week LED and behaviour education app.
75583560|NCT04620122|Other|Progressive Muscle Relaxation Training and Music Therapy|Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
75729994|NCT05669846|Drug|Fecal Microbiota Transplant (FMT)|FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by performing a colonoscopy and sigmoidoscopy. The FMT consists of introducing normal bacterial flora contained in the stool collected from a donor into the small intestine. In this case, the donors are patients with advanced metastatic non-small cell lung cancer (NSCLC) who have undergone PD-1 therapy (nivolumab or pembrolizumab) and are currently in a durable remission that is ongoing. The FMT will be performed on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.
75729995|NCT05669846|Drug|Pembrolizumab|Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.
75729996|NCT05658718|Procedure|refractive surgery|refractive surgery
75729997|NCT05655364|Other|Mobile application|Breastfeeding Supportive Mobile Application
75435757|NCT03511339|Device|TecTraum device|"A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck."
75435758|NCT03495388|Drug|Oxycodone|Post-op pain management medication
75435759|NCT03463408|Drug|nivolumab|240 mg every 2 weeks
75435760|NCT03463408|Drug|ipilimumab|1 mg/kg every 6 weeks
75435761|NCT03462238|Procedure|Blood collection for Ppi assay|A 4.5 ml blood sample will be taken with a citrate vacuum tube.
75435762|NCT03462238|Radiation|CT Scan|A scanner will be performed
75435763|NCT03420144|Drug|Standard Medical Therapy|Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
75435764|NCT03420144|Drug|Growth Hormone|GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
75583561|NCT04581213|Procedure|General anesthesia|Children under general anesthesia for an elective surgery, aged between 6 months and 5 years old, ASA 1-2.
75583562|NCT04581291|Other|Moderate Intensity Aerobic Exercises|Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
75583563|NCT04620317|Dietary Supplement|Synbiotic|10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
75583564|NCT04620317|Dietary Supplement|Placebo|Non-active ingredients - Maltodextrins
75583565|NCT04620863|Other|t-DCS group|All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
75583566|NCT04620863|Other|Sham group|The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
75583567|NCT04588155|Device|Functional assessment|Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
75729998|NCT05650775|Drug|Concerta|3-week trial of oral methylphenidate extended release
75729999|NCT05650775|Drug|Adderall-XR|3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
75730000|NCT05646030|Diagnostic Test|TAP-II|The TAP-II device will be compared to lancet capillary sampling and the venipuncture
75730001|NCT05646030|Diagnostic Test|Lancet capillary sampling|The lancet capillary sampling will be compared to TAP device and the venipuncture
75435765|NCT03415425|Other|Current Version of the Influenza Alert|Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
75435766|NCT03415425|Other|Alternate Modifications of the Influenza Alert|Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
75435767|NCT03409744|Drug|evinacumab|Intravenous (IV) administration
75435768|NCT03408314|Other|PediQUEST Response|PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.
75435769|NCT03408314|Other|Usual Cancer Care|Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
75730002|NCT05646030|Diagnostic Test|Venipuncture|The venipuncture will be compared to TAP device and the lancet capillary sampling
75730003|NCT05645458|Other|mobile application ( PEG Assist )|The mobile application is used for PEG care. İt gives some information to caregivers related to PEG, PEG care, etc. Also, the researcher can monitor all feeding times with this application.
75730004|NCT05634954|Drug|GEH121224 (18F) Injection|Single GEH121224 (18F) Injection
75583568|NCT04588155|Other|Clinical assessment|"Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution"
75583569|NCT01151137|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
75583570|NCT01151137|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
75583571|NCT02940470|Other|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
75583572|NCT02940470|Other|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
75583573|NCT01151098|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
75730005|NCT05634954|Diagnostic Test|Dynamic and Static - PET/CT Scan|Group 1: Dynamic whole-body PET/CT scan will start at the time of injection (8 sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 120 minutes and 240 minutes after injection.
75730006|NCT05634954|Diagnostic Test|Static - PET/CT Scan|Group 2: Static whole-body scans
75730007|NCT05631132|Procedure|BAL + PAP|May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
75730008|NCT05630222|Drug|Ibuprofen 800 mg|Ibuprofen from Caspian Taamin Company
75881327|NCT01351259|Device|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
75881328|NCT01351493|Drug|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
75881329|NCT01351493|Drug|placebo|placebo Gel, once or twice per day, 12weeks
75583574|NCT04619771|Behavioral|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
75583575|NCT04581252|Device|Non-invasive cardiac system|Non-invasive cardiac system
75583576|NCT04619888|Diagnostic Test|HeartLogic|In case of HeartLogic index ≥16, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment. The management will be standardized across centers according to the Manage-HF protocol.
75583577|NCT04619849|Diagnostic Test|EMG|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
75435770|NCT03400943|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily up to 2 x 12 weeks
75435771|NCT03400943|Drug|Placebo|Matching placebo was administered to group B1 and B2.
75435772|NCT03384784|Drug|Galantamine|The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
75435773|NCT03384784|Drug|Placebo|Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
75435774|NCT03383094|Drug|Pembrolizumab|Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
75435775|NCT03383094|Radiation|Radiation therapy|70 Gy in 33-35 fractions
75583578|NCT04619849|Diagnostic Test|Palmaris Longus Test|Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
75583579|NCT04587960|Procedure|Delayed primary closure of skin incision in Caesarean section in experimental group|Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group
75583580|NCT04587960|Procedure|Primary closure of skin incision in Caesarean section in active comparator group|Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
75583581|NCT04619576|Behavioral|Occupational health workers|Questionnaire online
75730009|NCT05630222|Drug|Morphine Sulfate|Morphine Sulfate from Darupakhsh Company
75730010|NCT05630222|Drug|Ibuprofen 400 mg plus Acetaminophen 1000 mg|Both from Caspian Taamin Company
75730011|NCT05618730|Device|punctum plug insertion|"EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily."
75881330|NCT02829671|Other|Clinical and biological assessment|Blood sample, clinical assessment with questionnaires
75881331|NCT01354379|Biological|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
75881332|NCT01354379|Biological|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
75583582|NCT01151020|Device|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
75583583|NCT04619810|Other|Nurse intervention program|Implementation of a specific care program for patients receiving immunotherapy for lung cancer
75583584|NCT01150474|Drug|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
75583585|NCT01150474|Drug|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
75583586|NCT05088044|Other|training porogram|training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
75583587|NCT04587804|Device|rPMS+RF|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of the device will be applied over umbilicus and visible muscle contractions along with heating of the subcutaneous fat will be induced by the device.
75583588|NCT04619459|Other|Kangaroo Mother Care (KMC)|Kangaroo mother care is a method of care of infants. The method involves infants being carried, usually by the mother, with skin-to-skin contact. Kangaroo mother care (KMC). early after delivery have better success at breastfeeding and achieve this success sooner. In this method The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. The KMC session was continued for 3 hours.
75583589|NCT04580901|Behavioral|Group Interpersonal Psychotherapy|15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 6 weeks (acute phase) then every other week for 6 weeks (maintenance phase)
75583590|NCT04619303|Drug|Dexamethasone intravitreal implant|Intravitreal injection of 0.7mg dexamethasone implant
75583591|NCT04619303|Drug|Bevacizumab Injectable Product|Invtravitreal injection of 1.25mg/0.05mL bevacizumab
75583592|NCT01150357|Drug|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
76051943|NCT05647226|Other|Standard of care|Standard of care.
75583593|NCT01150357|Drug|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
75583594|NCT01150357|Drug|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
75583595|NCT04587765|Behavioral|Extra-curricular sports|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
75583596|NCT04619537|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
75730012|NCT05618730|Drug|Eye Drops, Lubricant|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
75730013|NCT05605249|Device|Cue X|The Cue X movement training module includes several games that can be performed in someone's home environment. The games are designed based on known physiotherapy guidelines and evidence for improving motor symptoms for people with PD and delivered in AR. Some of the games also have integrated cueing to allow people with more severe mobility impairments to participate. Feedback of performance can be given using the movement data of the AR headsets.
75730014|NCT05603494|Device|NuvoAir|Use of NuvoAir in pulmonary function monitoring during asthma attack
75730015|NCT05603481|Device|Continuous Glucose Monitor|Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
75730016|NCT05598619|Dietary Supplement|Vitamin C|Colon delivered vitamin C (ascorbic acid) for 12 weeks
76051944|NCT02194699|Biological|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
75583597|NCT04587414|Behavioral|eHealth +counselling contacts|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
75583598|NCT04587414|Behavioral|eHealth|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
76051945|NCT02194699|Other|Placebo|Placebo subcutaneous injection
76051946|NCT04867070|Diagnostic Test|NAS score|Participants will be recorded according to the NAS and W-BAS pain scores
76051947|NCT04866524|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
75435776|NCT03383094|Drug|Cisplatin|100 mg/m2 Weeks 1, 4, and 7.
75435777|NCT03374475|Drug|JNJ-42847922 20mg|Participants will swallow 20 mg (2*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
75435778|NCT03374475|Drug|JNJ-42847922 40mg|Participants will swallow 40 mg (2*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
75435779|NCT03374475|Drug|Placebo|All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
75435780|NCT03373032|Other|Stiper|"Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes."
75435781|NCT03373032|Other|Acupuncture|Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.
75435782|NCT03373032|Other|Exercise|Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
75435783|NCT03373032|Other|Follow Up|Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.
76051948|NCT04866524|Other|Physical development and General Health|Physical development and General health examination
76051949|NCT04866524|Other|Developmental Red flags|Developmental Red flags Questionnaires
76051950|NCT05647148|Behavioral|Progressive Relaxation Exercises|"In the first part of this audio material, which consists of three parts; The definition of deep relaxation, its purpose and points to be considered during exercise are included.~The second part, consisting of an average of thirty minutes, includes the explanation of relaxation exercises with verbal commands accompanied by the sound of the stream.~In the last part, there is only relaxation music without any commands."
76051951|NCT05369858|Drug|[14C] SKLB1028|A single 150 mg oral dose of [14C] SKLB1028 containing approximately 120 microcurie of [14C] SKLB1028
76051952|NCT02293538|Drug|FID 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
75583599|NCT04587414|Behavioral|Usual care|Usual care and councelling given to type 2 diabetics within the primary health care setting.
75730017|NCT05598619|Other|placebo|Colon delivered placebo once a day for 12 weeks
75730018|NCT05597891|Device|Viper Catheter System|Treatment with the Viper Catheter System for thromboembolectomy
76051953|NCT02293538|Drug|Saline control eye drops (15 ml)|Saline eye drops (15 ml)
76051954|NCT02293538|Device|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
76051955|NCT02194621|Drug|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
76051956|NCT02194621|Drug|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
76051957|NCT02194621|Drug|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
76051958|NCT02220205|Other|PelvicSim|
76051959|NCT02220205|Device|Manufacturer model|
75583600|NCT04580862|Other|Non-surgical endodontic retreatment in single visit|Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
75583601|NCT04587609|Behavioral|Free Phone Mounts|Participants will receive free phone mounts
75730019|NCT05595317|Device|Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. In the non-immersive virtual reality application, Microsoft Kinect Xbox 360 Adventures games will be applied at the light level exercise level under the supervision of a physiotherapist. The participant will play a game in which he stands in a standing boat in a boat going on a flowing river and has to overcome obstacles by jumping, crouching and stepping left and right (River rush game).
75435784|NCT03373032|Other|Observation|The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
75435785|NCT03344419|Drug|CI-581a|Medication infusion intravenously over 1 hour.
75435786|NCT03344419|Drug|CI-581b|Medication infusion intravenously over 1 hour.
75435787|NCT03344419|Behavioral|Motivational Enhancement Therapy (MET)|Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
75435788|NCT03344419|Behavioral|Mindfulness Based Relapse Prevention|Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
75435789|NCT03321526|Drug|JNJ-42847922|Participants will receive JNJ-42847922 capsule orally.
75881333|NCT02079272|Other|Helical tomotherapy for breast cancer|"At baseline, before helical tomotherapy is performed, for each included woman will have:~measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)~cardiologic examination including echocardiography for measurement of strain and strain rate~a CT coronary angiogram for measurement of coronary plaque indexes~Helical tomotherapy will be performed for all women included in the cohort.~At the end of tomotherapy, follow-up will include:~measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~A CT coronary angiogram 24 months after radiotherapy"
75881334|NCT03558698|Other|Good ventilation|Good ventilation with a low concentration of CO2
75881335|NCT03558698|Other|Ventilation CO2|CO2 High and Good ventilation
75881336|NCT03558698|Other|Poor Ventilation|Poor ventilation with high concentrations of CO2 and bio effluents
75881337|NCT01318187|Drug|paracetamol|1 gr
75881338|NCT01318187|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
75881339|NCT01318187|Drug|Paracetamol|1 gr intravenous
75881340|NCT01318187|Drug|Paracetamol|intravenous 1 gr
75881341|NCT01318187|Drug|Morphine|0.1 mg/kg intravenous
75881342|NCT01358435|Biological|30% Regular Insulin Human Neutral and 70%Isophane Insulin|Total Dose per subject is 0.4 IU/Kg given subcutaneously.
75881343|NCT01358435|Biological|Novolin 70/30|Total Dose per subject is 0.4IU/Kg given Subcutaneously.
75881344|NCT03558620|Procedure|mask ventilation|mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
75435790|NCT03321526|Drug|Placebo Matching to JNJ-42847922|Participants will receive placebo capsule matching to JNJ-42847922 orally.
75435791|NCT03321526|Drug|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
75583602|NCT04587609|Behavioral|Commitment Contract|Participants will develop and sign a personalized commitment contract where they will create their own weekly goals for phone use reduction, and plan potential future obstacles that may hinder them from reaching their goal and how and plan to overcome that obstacle.
75583603|NCT04587609|Behavioral|Personalized Habit Tips|Participants will receive weekly habit formation tips by text message. These messages will be tailored to encourage use of phone mounts, setting up do not disturb while driving, and include their personal obstacles and plans they developed to overcome.
75730020|NCT05595317|Device|Sham Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. As a sham application, the participants will sit in a chair in front of the screen and try to prevent the balls sent from the opposite direction by using their upper extremities while their bodies are fixed with the help of a belt, under the supervision of a physiotherapist (Rally ball game).
75435792|NCT03321526|Drug|Placebo Matching to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
75881345|NCT01318265|Drug|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
75881346|NCT01354457|Drug|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
75881347|NCT02079350|Drug|%6 HES and %4 Gelofusine|
75881348|NCT02081066|Other|cardiovascular risk factors|
76051960|NCT02266706|Drug|Ceftolozane/Tazobactam 1000/500 mg|A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
76051961|NCT02266706|Drug|Ceftolozane/Tazobactam 30/15 mg/kg|A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
75435793|NCT03321526|Drug|Selective Serotonin Reuptake Inhibitor (SSRI)|Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
75435794|NCT03321526|Drug|Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
75435795|NCT03297593|Drug|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
75435796|NCT03297593|Drug|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
75583604|NCT04587609|Behavioral|Social Gamification Feedback|"Each week of the intervention period, the participant will be notified whether they met their prior week's goal, stayed about the same, or backslid. Participants will all start with 100 points, and can gain/maintain/lose points each week in the intervention period. Levels are as follows:~Copper: 0-40 points Bronze: 50-80 points Silver: 90-120 points Gold: 130-160 points Platinum: 170-200 points~Social competition: participants will be placed in groups of 10 based on similarity of baseline phone use. Weekly leaderboard reports will be sent via email, with SMS reminder. In the leaderboard they'll see themselves as You."
75583605|NCT04587609|Behavioral|"Contest Financial Incentives"|"Participants who finish in the platinum level will receive equal share of a prize, or a small amount will be awarded each week over the course of the intervention period to the weekly Safest Driver in each of the social competition cohorts."
75583606|NCT04619381|Behavioral|CORONARY ARTERY DISEASE AND CLOPIDOGREL: PATIENT SURVEY|Survey is a non-standardized assessment of demographics, medication compliance and reasons for non- compliance.
75583607|NCT00568464|Drug|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
75583608|NCT04618835|Diagnostic Test|40-Steps-test|40 steps performed on the spot
75583609|NCT04587063|Behavioral|Fear Appeals|Email
76051962|NCT02266706|Drug|Ceftolozane/Tazobactam 20/10 mg/kg|A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
76051963|NCT02266706|Drug|Ceftolozane/Tazobactam 18/9 mg/kg|A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
75435797|NCT03240653|Other|Stratified response to Enzyme Therapy|Observational study involves review of retrospective and prospective data of participants' medical history, pathology, imaging and health questionnaires.
75435798|NCT03217669|Drug|Epacadostat|Epacadostat tablet: 100mg or 300mg
75435799|NCT03217669|Drug|sirolimus|Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
75435800|NCT03196427|Drug|Vedolizumab|Vedolizumab intravenous infusion
75583610|NCT04587063|Behavioral|Message about Future Healthcare Costs|Email
75435802|NCT03185819|Drug|Intranasal Placebo|Participants will receive placebo as intranasal dose to match intranasal esketamine.
75435803|NCT03185819|Drug|Midazolam Placebo Solution|Participants will receive placebo as oral dose to match midazolam drug.
75583611|NCT04587063|Behavioral|Endorsement from a Doctor|Email
75583612|NCT04587063|Behavioral|Comparison Table|Email
75583613|NCT04587063|Behavioral|Highlighting Cost Savings and Convenience|Email
75583614|NCT00568503|Drug|QAX028|
75583615|NCT00568503|Drug|Placebo|
75583616|NCT00568503|Drug|Tiotropium bromide|
75583617|NCT00568503|Drug|QAX028|
75583618|NCT00568503|Drug|QAX028|
75583619|NCT04619030|Other|Augmented Reality|The patient leaflet has an Augmented Reality model that appears out of the leaflet when viewed with a smartphone
75435804|NCT03185819|Drug|Midazolam|Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
75435805|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 28 mg as intranasal solution.
75435806|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 56 mg as intranasal solution.
75435807|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 84 mg as intranasal solution.
75583620|NCT04619030|Other|Traditional leaflet|Traditional leaflet with no Augmented Reality capability
75583621|NCT00568542|Drug|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
76051964|NCT02266706|Drug|Ceftolozane/Tazobactam 12/6 mg/kg|A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
75583622|NCT00568542|Drug|placebo|35 I.E. kg body weight placebo to erythropoetin beta
75881349|NCT01351649|Behavioral|middle school physical activity intervention for girls|"Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model."
75881350|NCT02079428|Other|No interventions|
76051965|NCT02293460|Drug|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
76051966|NCT04419974|Diagnostic Test|Molecular Diagnosis|Double-blind molecular diagnosis for the SCA3/MJD mutation.
75881351|NCT03062540|Drug|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
76051967|NCT04419974|Diagnostic Test|Clinical Scales - Baseline|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
75730022|NCT05590767|Procedure|Patients scheduled to undergo shoulder rotators repair surgery|Patients scheduled to undergo shoulder rotators repair surgery, and received combined general anesthesia and interscalene block
75730023|NCT05588752|Other|TAP block|TAP block under ultrasound
75435809|NCT03153111|Drug|Macitentan|macitentan 10 mg; film-coated tablet; oral use
75881352|NCT03062540|Drug|Placebo SL Tablet|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
76051968|NCT04419974|Diagnostic Test|Blood Draw - Baseline|"Blood collection on baseline for evaluation of~Candidate genes expression~Serum proteins~Lymphocytic proteins"
76051969|NCT04419974|Diagnostic Test|Quality of Life Assessment - Baseline|Participants fill out 2 self-reported quality of life questionnaires.
76051970|NCT04419974|Diagnostic Test|Clinical Scales - Follow-up 12 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
75583623|NCT00568620|Procedure|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
75583624|NCT00568620|Procedure|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
75583625|NCT04587102|Other|whole body viberation|vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform
75730024|NCT05580939|Other|Intervention group|They use Web-based Simulation Application for 4 weeks
76051971|NCT04419974|Diagnostic Test|Blood Draw - Follow-up 12 months|"Blood collection 12 months after baseline for prospective evaluation of~Candidate genes expression~Serum proteins~Lymphocytic proteins"
75435810|NCT03153111|Drug|Placebo|film-coated tablet (identical to the macitentan tablet); oral use
75435811|NCT03151629|Other|Standard of Care|Drugs routinely administered for metastatic prostate cancer per local standard.
75435812|NCT03144921|Behavioral|psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
75435813|NCT03126435|Drug|EndoTAG-1|twice weekly
75435814|NCT03126435|Drug|Gemcitabine|once weekly
75435815|NCT03123809|Device|Gastric Electrical Stimulation (GES) System|Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.
75435816|NCT03119584|Drug|linaclotide or placebo|
75435817|NCT03084939|Biological|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
75730025|NCT05579899|Drug|EVO101|Topical Cream
75730026|NCT05576012|Biological|SOL-116|Participants will receive SC injection in a double-blind manner
75730027|NCT05576012|Biological|Placebo|Participants will receive SC injection in a double-blind manner
75730028|NCT05570136|Behavioral|Functional Exercise|Treatment group will receive the 12-week STEP by a trained interventionist. During the intervention period, an occupational therapist will help the participant to learn the STEP exercise and principles and help the older adults to be more independent on functional exercising.
76051972|NCT04419974|Diagnostic Test|Quality of Life Assessment - Follow-up 12 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
76051973|NCT04419974|Diagnostic Test|Clinical Scales - Follow-up 24 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
75583626|NCT04587102|Other|Traditional program(balance exercises and resisted exercises)|balance exercises and resisted exercises
75583627|NCT04619147|Other|No intervention|This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.
76051974|NCT04419974|Diagnostic Test|Blood Draw - Follow-up 24 months|"Blood collection 24 months after baseline for prospective evaluation of~Candidate genes expression~Serum proteins~Lymphocytic proteins"
75435818|NCT03084939|Drug|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
75435819|NCT03084939|Drug|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
75583628|NCT00568659|Procedure|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
75583629|NCT02940353|Device|TREFOIL concept|
75583630|NCT04587258|Behavioral|Informational videos and social media campaigns encouraging cancer screening.|Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
75583631|NCT00562835|Drug|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25*‡ 0.25 mg/kg/day; Days 26 to 28*‡ 0.125 mg/kg/day~*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
75583632|NCT00562835|Other|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc [prednisolone + diluting fluid], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
75583633|NCT04587180|Procedure|Arthroscopic suture-bridge rotator cuff repair|Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
75730029|NCT05570136|Behavioral|Education|In the education group, participant will receive weekly health newsletters containing general health aging materials. A staff member will call the control group participants weekly to document any new exercise programs from usual community services.
75435820|NCT03047005|Drug|NB medication (Naltrexone Bupropion combination)|NB medication
75583634|NCT04587219|Biological|Gam-COVID-Vac|combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
75583635|NCT00568737|Drug|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
75583636|NCT00568737|Drug|Placebo|0.9% sodium chloride
75730030|NCT05565768|Drug|HZN-457|HZN-457 will be given in one subcutaneous administration
76051975|NCT04419974|Diagnostic Test|Quality of Life Assessment - Follow-up 24 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
75435821|NCT03047005|Other|Placebo|Placebo
75435822|NCT03011684|Drug|Tamoxifen|For ER Positive Randomization
75435823|NCT03011684|Drug|Letrozole|For ER Positive Randomization
75435824|NCT03003299|Device|Edwards SAPIEN 3/SAPIEN 3 Ultra THV|Edwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
75435825|NCT02968108|Drug|Ustekinumab|Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects <40 kg or 130 mg for subjects >= 40 kg in Group 1 and 9 mg/kg for subjects < 40 kg or 390 mg for subjects >= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at Week 8.
75730031|NCT05565768|Drug|Placebo|Placebo will be given in one subcutaneous administration
75730032|NCT05564806|Drug|YH004|All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
75435826|NCT02957149|Other|Autologous Platelet-Rich Plasma|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
75435827|NCT02957149|Device|Angel Concentrated Platelet Rich Plasma System|
75583637|NCT00562874|Dietary Supplement|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
75583638|NCT00562874|Dietary Supplement|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
75583639|NCT00562874|Dietary Supplement|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
75583640|NCT04587141|Drug|Sucrosomial iron|This is an oral iron formulation commercially available as an integrator
75583641|NCT04587141|Drug|Ferric Gluconate|This is a commercially available iron formulation for parenteral administration
75730033|NCT05564793|Device|Pre-implantation planning|ECGi mapping using the CE marked Amycard 01C device and a contrast enhanced CT
76051976|NCT05647070|Procedure|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, ~1 cm× ~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
76051977|NCT02266004|Device|Transcranial Direct Current Stimulation (tDCS)|Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
76051978|NCT02266004|Other|locomotor training|An individualized dual-task walking program for approximately 30 minutes.
75435828|NCT02947347|Drug|ibrutinib|ibrutinib 560mg administered orally
75435829|NCT02947347|Drug|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
75435830|NCT02947347|Drug|rituximab|rituximab 375mg/m^2 IV
75435831|NCT02870907|Other|Observation|no post operative chemotherapy
75583642|NCT04587141|Drug|Ferric carboxymaltose|This is a commercially available iron formulation for parenteral administration
75583643|NCT04619342|Device|GSMs-TACE|TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)
75583644|NCT04619342|Procedure|Surgical Resection|Surgical Resection of PVTT
75583645|NCT04586790|Drug|Midodrine Oral Tablet|midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
75583646|NCT04586790|Drug|Minirin oral tablet|Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
75583647|NCT04586790|Drug|Nor-Adrenaline|control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
75583648|NCT00568815|Drug|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
75583649|NCT00568893|Drug|drotrecogin alfa (activated)|
75583650|NCT00568971|Drug|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
75435832|NCT02870907|Drug|Etoposide|100 mg/m²/d, IV (in the vein) from D1 to D5.
75583651|NCT04586322|Other|No intervention, (observational study).|"From every participant the following information was recorded for further analysis:~BEWE score- Basic erosive tooth wear examination (from 2 calibrated examiners) to diagnose the presence of erosive tooth wear.~Their answer to a validated questionnaire assessing the dietary habits based in the frequency of acidic diet.~2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (in Volume loss per mm3) using Wearcompare software."
75583652|NCT02277405|Device|Shikani Optical Stylet|Optical intubation
75583653|NCT02277405|Device|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
75435833|NCT02870907|Drug|Vincristine|1, 5 mg/m²/d, IV at D1.
75435834|NCT02870907|Radiation|Orbital irradiation|45 Grays (Standard or external beam radiotherapy).
75435835|NCT02870907|Drug|Carboplatin|160 mg/m²/d, IV from D1 to D5.
75435836|NCT02870907|Drug|Vincristine|1,5 mg/m²/d, IV at D22 and D26
75730034|NCT05564793|Device|Post-implantation assessment|ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
75730035|NCT05561127|Combination Product|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
75730036|NCT05561127|Other|Control|Standard of Care Endoscopic Dilation
75730037|NCT05561114|Combination Product|GIE Medical ProTractX3 TTS DCB|Paclitaxel Coated Balloon
75730038|NCT05561114|Other|Control|Standard Endoscopic Dilation
75881353|NCT01351883|Dietary Supplement|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
75583654|NCT00562913|Drug|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
75583655|NCT00569088|Drug|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
75583656|NCT00569088|Drug|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
75583657|NCT02940158|Other|1/4 cup- Small red lentil|
75730039|NCT05553119|Behavioral|Home Rehabilitation Monitoring System|Established home-based pulmonary rehab system consists of three commercial devices (Garmin Vívofit™ activity monitor, Nonin 3150 WristOx2® Pulse Oximeter, Android tablet) and two software applications for telemonitored home pulmonary rehabilitation.
75730040|NCT05553119|Behavioral|Health coaching calls|Coaching calls based on motivational interviewing principles will occur weekly for twelve weeks following a standard protocol, lasting no more than 5-10 minutes.
75730041|NCT05552638|Other|Telecare|The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
75730042|NCT05546554|Drug|Suvorexant|5 mg (and up to 20 mg) Suvorexant given orally
75730043|NCT05546554|Drug|Placebo|Matching Placebo given orally
75435837|NCT02870907|Drug|Cyclophosphamide|300 mg/m²/d, IV from D22 to D26.
75435838|NCT02870907|Drug|Carboplatin|560 mg/m²/d, IV at D1.
75435839|NCT02870907|Drug|Etoposide|100 mg/m²/d, IV from D1 to D5
75583658|NCT02940158|Other|1/4 cup- Small green lentil|
75583659|NCT02940158|Other|1/4 cup- corn|
76051979|NCT04864652|Device|CHILLS Procedure|CHILLS Cryotherapy procedure
76051980|NCT02292719|Drug|OBV/PTV/r|Tablet
76051981|NCT02292719|Drug|Sofosbuvir|Tablet
75435840|NCT02870907|Drug|Carboplatin|160 mg/m²/d,IV from D1 to D5
75583660|NCT02940158|Other|1/4 cup- macaroni|
75583661|NCT02940158|Other|1/4 cup- white potato|
75583662|NCT02940158|Other|1/4 cup- white rice|
75435841|NCT02870907|Drug|Thiotepa|15 mg, intrathecal Thiotepa injection at D1.
75435842|NCT02870907|Drug|Vincristine|1,5 mg/m²/d), IV at D22
75583663|NCT02940158|Other|1/2 cup- small red lentil|
75583664|NCT02940158|Other|1/2 cup- small green lentil|
75583665|NCT02940158|Other|1/2 cup- corn|
75583666|NCT02940158|Other|1/2 cup- macaroni|
75583667|NCT02940158|Other|1/2 cup- white potato|
75583668|NCT02940158|Other|1/2 cup- white rice|
75583669|NCT00569244|Drug|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
75583670|NCT00569244|Drug|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
75730044|NCT05540574|Drug|Zolpidem|5mg (and up to10mg) Diphenhydramine given orally
75730045|NCT05540574|Drug|Placebo|Matching Placebo given orally
75730046|NCT05538234|Diagnostic Test|Laboratory values - baseline|Baseline laboratory values will be obtained
75730047|NCT05538234|Other|Medical information 12 hours before organ harvesting|"average hourly diuresis~hypotension MAP<65 Torr longer than 30 minutes (YES/NO)~Furosemide administration (YES/NO)~Mannitol administration (YES/NO)~administration of anti-diuretic hormone (YES/NO)~administration of vasopressors (YES/NO)~polyuria >3ml/kg/h (YES/NO)~nephrotoxic agents during hospitalization (YES/NO)"
75730048|NCT05538234|Diagnostic Test|Laboratory values - 12 hours after reperfusion|Laboratory values will be obtained 12 hours after reperfusion
75730049|NCT05538234|Diagnostic Test|Laboratory values - 48 hours after reperfusion|Laboratory values will be obtained 48 hours after reperfusion
76051982|NCT02292719|Drug|Ribavirin (RBV)|Tablet
76051983|NCT02291861|Drug|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
75583671|NCT03458156|Biological|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
75583672|NCT03458156|Biological|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
75583673|NCT03458156|Other|the control group|The patients will be assigned to the control group.
76051984|NCT02291861|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
76051985|NCT02291549|Drug|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
75435843|NCT02870907|Drug|Cyclophosphamide|1000 mg/m²/d, IV from D22 à D24.
75435844|NCT02870907|Procedure|Cytapheresis|Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamid.
75435845|NCT02870907|Drug|Carboplatin|AUC : 7/d, IV from D-8 to D-6.
75435846|NCT02870907|Drug|Etoposide|250 mg/m²/d, IV from D -5 to D-3.
75583674|NCT04586361|Combination Product|RegenLab PRP|PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.
76051986|NCT02291549|Drug|Mometasone furoate nasal spray|Mometasone furoate nasal spray (200mcg) once daily
75435847|NCT02870907|Drug|Thiotepa|300 mg/m²/d, IV from D-5 to D-3.
75583675|NCT04586361|Combination Product|hyaluronic acid|Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.
75881354|NCT03060980|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
75583676|NCT04586361|Other|normal saline|In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
75881355|NCT03060980|Drug|Empagliflozin (oral)|10 mg/day and 25 mg/day
75435848|NCT02870907|Procedure|Peripheral bood stem cell transplantation|at D0
75435849|NCT02823574|Biological|Nivolumab|
75435850|NCT02823574|Biological|Ipilimumab|
75583677|NCT04618952|Drug|Calcium D|calcium D supplementation given to postmenopausal females
75730050|NCT05538234|Diagnostic Test|Laboratory values - 7 days after reperfusion|Laboratory values will be obtained 7 days after reperfusion
75730051|NCT05538234|Diagnostic Test|Laboratory values - 90 days after reperfusion|Laboratory values will be obtained 90 days after reperfusion
75730052|NCT05538234|Other|Medical information during organ harvesting/transplantation|"Medical information during organ harvesting/transplantation~hypotension MAP 65 Torr > 5 minutes (YES/NO)~vasopressor support (YES/NO, duration in minutes)"
75730053|NCT05538234|Procedure|Organ harvesting|Organ harvesting for transplant
75881356|NCT03060980|Drug|Glimepiride (oral)|1-6 mg/day
75435851|NCT02823574|Other|Placebo|
75435852|NCT02746809|Device|CoreValve Evolut 34R TAVR system|"The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~Evolut 34R Transcatheter Aortic Valve (TAV)~EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~EnVeo R Loading System (LS)"
75435853|NCT02641028|Drug|CERC-501|CERC-501
75435854|NCT02641028|Drug|Placebo|Placebo
75435855|NCT02525796|Drug|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
75435856|NCT02525796|Drug|amiloride|amiloride, titrated up to a maximum of 10mg BID
75583678|NCT04618952|Drug|Placebo|Placebo
75583679|NCT00569283|Biological|therapeutic allogeneic lymphocytes|
75583680|NCT04619069|Radiation|SBRT|SBRT to all sites of metastatic disease as seen on PSMA PET scan
75583681|NCT04619069|Drug|Hormone therapy|Intermittent Hormone Therapy per physician discretion (Min. 8 months)
75583682|NCT00569322|Procedure|BG Test|
75730054|NCT05538234|Procedure|Organ transplantation|Transplantation of the harvested organ
75730055|NCT05528471|Other|Dietary intervention|To compare an iso-caloric, low fructose diet (~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
75881357|NCT01358591|Dietary Supplement|High calcium milk|High calcium milk (9 mg/kgBM)
75881358|NCT01358591|Dietary Supplement|Control|Regular Milk
75583683|NCT04618796|Other|vaccine|Effect of COVID-19 pandemic on vaccination compliance among children attending Assiut University Children Hospital and what is the degree of that.
75583684|NCT00569361|Procedure|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
75583685|NCT04580550|Other|Axial length variability|Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
75583686|NCT04618640|Biological|DTaP-IPV combination vaccine|Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
75583687|NCT04580706|Other|this is an observational study with none intervention|this is an observational study with none intervention
75730056|NCT05527574|Other|Resistance Exercise|Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months
75730057|NCT05527171|Behavioral|Virtual Reality Mindfulness Meditation|Participants will be immersed in a virtual environment of their choosing. While in the virtual environment, participants will follow a guided mindfulness meditation script. Participants will complete the intervention 3 times a week over the course of 8-weeks.
75435857|NCT02525796|Drug|Placebo|
75730058|NCT05527171|Behavioral|Virtual Reality Sham|Participants will be immersed in a virtual environment of their choosing, such as at a beach, forest, or lake.
75730059|NCT05527041|Device|EyeBOX Lens (EBLens)|"The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:~Gaze coordinates~Pupil sizes~Accelerometer data~Gyroscopic data~Rotation data~Blink data"
75730060|NCT05526664|Other|Genetic testing and Omics analysis|Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
76051987|NCT02291549|Procedure|Sham|In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
75435858|NCT02525796|Drug|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
75583688|NCT04586439|Drug|JNJ-73763989|JNJ-73763989 will be administered (high or low dose) as single SC injection.
75583689|NCT02940197|Behavioral|MediterrAsian diet|no other description
75583690|NCT04585932|Drug|Apalutamide|Given PO
75583691|NCT04585932|Drug|Degarelix|Given SC
75583692|NCT04585932|Drug|Leuprolide Acetate|Given IM
75583693|NCT04585932|Other|Quality-of-Life Assessment|Ancillary studies
75583694|NCT04585932|Other|Questionnaire Administration|Ancillary studies
75583695|NCT04585932|Radiation|Radiation Therapy|Undergo RT
75583696|NCT02940119|Device|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
75583697|NCT00569400|Drug|human insulin|
75583698|NCT02939963|Procedure|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O during 30 minutes then 30 minutes of basal pressure support then 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O
75583699|NCT02939963|Procedure|Pressure support 7 cm H2O PEP 4 cm H2O then ATC|30 minutes with pressure support 7 cm H2O PEP 4 cm H2O then 30 minutes of basal pressure support then 30 minutes with spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O
75881359|NCT01358747|Drug|BEACOPPesc|
75881360|NCT01358747|Drug|BEACOPPesc - ABVD - PET2|
75881361|NCT03124459|Drug|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
75881362|NCT03124459|Drug|Placebo|Recombinant fusion protein or buffer solution
75583700|NCT00569439|Drug|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
75583701|NCT00569439|Drug|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
75583702|NCT00569439|Drug|NS|Normal Saline solution at 125 cc/hr
75583703|NCT04618445|Behavioral|some risk factors that might be correlated with TMD|Fonesca questionnaire
75435859|NCT02452697|Biological|NK Cell enriched-DLI only|"The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.~If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started."
75730061|NCT05525390|Behavioral|Extended Reality-Enhanced Behavioral Activation|"Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc."
75583704|NCT04585971|Diagnostic Test|Signal intensity gradient|"Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A [Xa] along the arterial contour line) and at the inner point (Φb; signal intensity at position B [Xb]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
75583705|NCT04618367|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
75881363|NCT02081144|Other|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of ~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
75730062|NCT05525390|Behavioral|Traditional Behavioral Activation|Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
75881364|NCT02081144|Drug|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
75730063|NCT05523986|Other|Vitamin D|Vitamin D (2000IU/day) for 6 months
75881365|NCT02081144|Drug|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
75881366|NCT02081144|Behavioral|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
75881367|NCT01351961|Biological|blood sampling|take a sample of blood, 46 ml
75881368|NCT01351961|Procedure|brain MRI and TEP cerebral|magnetic resonance imaging
76051988|NCT05651165|Device|Pharmacoactive balloon angioplasty. Lutonix®|Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
75435860|NCT02452697|Biological|NK-DLI + DUK-CPG-001|"DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.~On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI."
75435861|NCT02360280|Drug|ketamine|sedative
75583706|NCT04618367|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75583707|NCT04618367|Drug|Sintilimab|200mg intravenously every 3 weeks
75583708|NCT00569478|Other|rehabilitation|Nursing consultations and physical training
75583709|NCT00569517|Behavioral|CBT|6-CBT based sesions
75730064|NCT05523986|Other|Placebo|Placebo
75730065|NCT05521789|Drug|ESB Thoracic|Erector spinae thoracic block with bupivacaine
75730066|NCT05520255|Drug|18F-PSMA-1007|18F-PSMA-1007 intravenous injection
75730067|NCT05509855|Genetic|Genetic: WU-CART-007|No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy
75730068|NCT05506215|Device|SynPath Acellular Dermal Matrix plus Off-loading Device|Application of SynPath
75730069|NCT05506215|Device|Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device|Application Wound Dressing composed of Collagen and Alginate
75730070|NCT05501678|Drug|Diphenhydramine|25mg (and up to 50mg) Diphenhydramine given orally
75730071|NCT05501678|Drug|Placebo|Matching Placebo given orally
75730072|NCT05501522|Biological|GBP510 adjuvanted with AS03|injection volume of 0.5mL on Day 0
75730073|NCT05501522|Other|Placebo (Normal Saline)|injection volume of 0.5mL on Day 0
75730074|NCT05497596|Other|Vitamin D|Vitamin D (2000IU/day) for 6 months
75730075|NCT05497596|Other|Placebo|Placebo
75730076|NCT05495204|Drug|Ibalizumab|Participation in clinical trials vs. routine care in OPERA
75881369|NCT01351961|Other|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
75435862|NCT02360280|Drug|midazolam|sedative
75583710|NCT00569517|Other|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
75881370|NCT01351961|Other|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
76051989|NCT05651165|Device|Mimetic stent.Supera®|Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
76051990|NCT02264990|Drug|Paclitaxel|Administered by Intravenous infusion on Day 1 of each 21-day cycle
75435863|NCT02201251|Drug|Topiramate|Topiramate weight based dosing for participants 2 to <10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
75435864|NCT02201251|Drug|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
75435865|NCT02192021|Drug|Micro needle array-Doxorubicin (MNA-D)|MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
76051991|NCT02264990|Drug|Carboplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
75435866|NCT02174575|Drug|Sevoflurane|Sevoflurane is administered during anesthesia in Sevoflurane group.
75435867|NCT02174575|Drug|Desflurane|Desflurane is administered during anesthesia in Desflurane group.
75435868|NCT02153814|Procedure|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
76051992|NCT02264990|Drug|Cisplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
75435869|NCT02153814|Procedure|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
75435870|NCT02027545|Behavioral|Decision Aid|Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise
75435871|NCT02027545|Behavioral|Provider Education|Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
75435872|NCT02027545|Behavioral|Performance Measure Modification|The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
75435873|NCT02027545|Behavioral|Simple Informational Booklet|A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
75435874|NCT01937039|Procedure|Sample collection|Blood, tissue, urine, and other samples may be collected
75583711|NCT00562952|Drug|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
75583712|NCT00562952|Drug|placebo|no intervention
75881371|NCT01351961|Procedure|Vascular explorations|Pulse wave velocity, VWF, IMT
75881372|NCT01351961|Biological|Urine sample|
75881373|NCT02083328|Dietary Supplement|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
75881374|NCT02083328|Dietary Supplement|Placebo (Mannitol)|Mannitol filled in gelatine capsules
75881375|NCT01354535|Procedure|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
75881376|NCT01354535|Procedure|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
75583713|NCT04585347|Drug|ALZ-801 170 mg Fasting|
75583714|NCT04585347|Drug|ALZ-801 205 mg Fasting|
75583715|NCT04585347|Drug|ALZ-801 205 mg After Food|
75583716|NCT04585347|Drug|ALZ-801 342 mg Fasting|
75881377|NCT02079506|Drug|Candesartan|
75881378|NCT02079506|Drug|Rosuvastatin|
76051993|NCT02264990|Drug|Veliparib|Oral capsule, administered twice daily for 7 days in each 21-day cycle
76051994|NCT02264990|Drug|Pemetrexed|Administered by Intravenous infusion on Day 1 of each 21-day cycle
76051995|NCT05646914|Other|Complex training exercises|Squats and drop jumps, Barbell step-ups and hops, Bench press and plyometric press-up, Barbell lunge and box jumps were performed.
75583717|NCT00569556|Other|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
75583718|NCT00562991|Device|measurement of exhaled NO is used to guide treatment|exhaled NO
75583719|NCT00569595|Behavioral|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
75583720|NCT00569595|Behavioral|Fighting Cancer with Advice|"Patient health counseling program by lay health educators entitled Fighting Cancer with Advice."
75730077|NCT05494723|Drug|YB-1113|Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
75583721|NCT04618601|Drug|Spironolactone|Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is >5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
75583722|NCT00567918|Drug|FK506|Ophthalmic suspension
75583723|NCT00569634|Procedure|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always < 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
75730078|NCT05491603|Biological|DBI-001|Topically administered
75730079|NCT05491603|Biological|DBI-002|Topically administered
75730080|NCT05491603|Biological|Aqueous Gel|Topically administered
75730081|NCT05489588|Device|GORE® VIAFORT Vascular Stent|Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.
75730082|NCT05489120|Other|Consumption of FLAVIS|Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.
75730083|NCT05488405|Drug|Mesalamine Oral Product|Mesalamine oral suspension for oral use
75435875|NCT01889810|Dietary Supplement|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
75730084|NCT05470140|Biological|WU-NK-101|WU-NK-101 administered on Day 1, Day 8, and Day 15.
75730085|NCT05468697|Drug|Belzutifan|40 mg tablet administered orally at a dose of 120 mg.
75730086|NCT05468697|Drug|Palbociclib|75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
75435876|NCT01888198|Behavioral|(EORTC QLQ-C30) questionnaire|
75435877|NCT01888198|Behavioral|EuroQol EQ-5D 7-item questionnaire|
75730087|NCT05464602|Other|Intervention group Lavender|This group received inhalation aromatherapy 2 drops of lavender oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
75730088|NCT05464602|Other|Intervention group Geranium|This group received inhalation aromatherapy 2 drops of geranium oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
75435878|NCT01867242|Other|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
75435879|NCT01867242|Other|Snus|Winterchill or Robust flavors
75435880|NCT01860560|Device|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
75435881|NCT01860560|Device|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
75435882|NCT01858688|Device|Multiparametric MRI|an MRI of the prostate will be performed
75435883|NCT01858688|Procedure|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
75435884|NCT01840592|Drug|Sorafenib|
75730089|NCT05463380|Other|standard of care|The patient will be treated following the satndard of care in the participating units
75730090|NCT05456152|Drug|Sublingual Tablet|Sublingual zolpidem - 1 sublingual tablet 30 minutes before bed time.
75730091|NCT05454033|Device|JUVÉDERM® VOLITE™|Injection, intradermal
75435885|NCT01840592|Drug|Doxorubicin|
75435886|NCT01831895|Device|MobiusHD™|Implant that is placed in the carotid sinus to control hypertension.
75435887|NCT01734694|Drug|Vancomycin|"Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;"
75583724|NCT00569712|Drug|budesonide/formoterol fumarate dihydrate inhalation aerosol|
75583725|NCT00569712|Genetic|DNA methylation analysis|
75583726|NCT00569712|Genetic|comparative genomic hybridization|
75583727|NCT00569712|Genetic|microarray analysis|
75583728|NCT00569712|Other|bronchoalveolar lavage|
75583729|NCT00569712|Other|immunoenzyme technique|
75730092|NCT05454033|Other|Control|No-treatment control
75730093|NCT05445635|Device|Iriscope|The use of Iriscope to improve the diagnostic yield of bronchoscopy in the setting of peripheral lung nodules
75730094|NCT05441332|Other|EOS Radiation|One EOS exam of lower extremities
75730095|NCT05441332|Behavioral|Semi-structured interview|Semi-structured interview to identify factors influencing patient adherence behavior for a sub-group of 15 patients. By phone, between 1 to 3 months after inclusion.
75881379|NCT01370941|Dietary Supplement|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
75583730|NCT00569712|Other|laboratory biomarker analysis|
75583731|NCT00569712|Procedure|bronchoscopy|
75583732|NCT00569751|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
75583733|NCT04618562|Other|Revival Active Program|Program comprised of physical activities, group play, mind games, reasoning and discussion on sleeted topics, breath work and relaxation techniques, 60 minutes all together.
75730096|NCT05441241|Device|Leap Motion Controller|The Leap Motion Controller is an infrared device that digitalizes in real-time the movements of the hand above it. This signal will be converted into Musical Instrument Digital Interface (MIDI) and then translated into a sound of a pitch that depends on the distance between the hand and the device. The software is set to produce a pentatonic scale, so every melody created by the patient will sound consonant, and the timbre will be warm, calm and in human vocal range (similar to a cello). The operator will do an example, playing a melody, and will invite the patient to imitate him. When the patient gains confidence with the device, after a limited time lapse (from 30 seconds to 3 minutes), while they are playing it with one hand, the venipuncture is done on the other arm
75730097|NCT05441241|Other|Traditional distraction techniques|Common distraction techniques will be used (i.e., visual stimulation, lecture)
75730098|NCT05440903|Behavioral|Headspace|A smartphone application that provides users with mindfulness and meditation sessions.
75730099|NCT05440903|Behavioral|TEDTalk|A smartphone application that provides users with psychoeducational audio recordings from TEDTalk.
75730100|NCT05439941|Drug|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
75881380|NCT01370941|Dietary Supplement|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
75881381|NCT02081222|Procedure|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
75881382|NCT02940548|Drug|Nifedipine GITS|Nifedipine GITS 30~60mg/day for 8 weeks
75881383|NCT02940548|Drug|Amlodipine besylate|Amlodipine besylate 5~10mg/day for 8 weeks
75881384|NCT01366183|Procedure|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
75881385|NCT01366183|Drug|Carboplatin|Undergo chemotherapy
75881386|NCT01366183|Biological|Filgrastim|Undergo chemotherapy
76051996|NCT05646914|Other|Plyometric training exercises|Drop Jumps, Hops, Plyometric press-up, Box Jumps were performed.
76051997|NCT02291237|Drug|Eleclazine|Tablet (s) administered orally once daily
75583734|NCT00569790|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
75583735|NCT00567957|Drug|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
75435888|NCT01734694|Drug|Ceftaroline|"Dose based on package insert labeling~CrCL > 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL < 15mL/min: 200 mg q12h;"
75435889|NCT01734694|Drug|Daptomycin|"Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL < 30 mL/min: 6 - 10 mg/kg IV q48h"
75435890|NCT01734694|Drug|Linezolid|600 mg IV/PO q12h
75435891|NCT01599234|Drug|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
75435892|NCT01599234|Drug|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
75435893|NCT01393301|Behavioral|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
75881387|NCT01366183|Drug|Paclitaxel|Undergo chemotherapy
75881388|NCT01366183|Other|Pharmacological Study|Correlative studies
75881389|NCT01366183|Other|Quality-of-Life Assessment|Ancillary studies
75435894|NCT01393301|Behavioral|Control|Enhanced standard smoking cessation treatment and NRT.
75730101|NCT05434598|Device|ChromoSeq|Novel, streamlined whole genome sequencing approach
75730102|NCT05430438|Other|dialysis with low dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
75730103|NCT05430438|Other|dialysis with standard dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
75730104|NCT05421078|Drug|Obicetrapib|tablet
75730105|NCT05421078|Drug|Obicetrapib|No active ingredient
75730106|NCT05415137|Drug|Efzofitimod 3 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
75730107|NCT05415137|Drug|Efzofitimod 5 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
75881390|NCT01366183|Other|Questionnaire Administration|Ancillary studies
76051998|NCT02291237|Drug|Placebo|Placebo to match eleclazine administered orally once daily
75583736|NCT00567957|Drug|Saline|same volume iv bolus before induction followed by same volume infusion
75583737|NCT04618094|Other|bicycle ergometer training with different intensities|Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
75583738|NCT00569829|Behavioral|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
75583739|NCT02940002|Drug|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
75583740|NCT02940002|Drug|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
75583741|NCT02940002|Drug|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
75730108|NCT05415137|Drug|Placebo|Placebo IV infusion every 4 weeks for a total of 12 doses
75730109|NCT05413174|Behavioral|Hypnoanalgésia|"Use of Ericksonienne hypnosis in the medical field, aiming to dissociate the patient from the intervention in order to modify his or her perception of pain and limit anxiety.~Ericksonienne hypnosis will use during ultrasound-guided biopsy in radiology ward."
75730110|NCT05408663|Drug|EXT608|EXT608 is an investigational drug administered via subcutaneous injection
75730111|NCT05408663|Other|Placebo|matching placebo administered via subcutaneous injection
75730112|NCT05402449|Other|Placebo|Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin.
76051999|NCT02292446|Drug|Ruxolitinib|supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
76052000|NCT02290925|Drug|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
76052001|NCT02290925|Dietary Supplement|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
75435895|NCT01339546|Other|no intervention|
75435896|NCT00716625|Drug|sunitinib malate|"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
75583742|NCT04580745|Drug|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
75435897|NCT00713817|Drug|Sativex®|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
75730113|NCT05402449|Dietary Supplement|Probiotics|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive).
75730114|NCT05396495|Device|NeurolyserXR|Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
75730115|NCT05396040|Procedure|LOLLI METHODE|WEEKLY SCREENING WITH POOLED SALIVA PCR TEST
75730116|NCT05388981|Biological|SBT115301|Immunomodulatory dimeric fusion protein
75730117|NCT05388981|Biological|Placebo|Matched placebo
75730118|NCT05372809|Biological|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
75730119|NCT05372809|Other|Control|"Standard care is defined in this protocol to include the following:~Debridement~Collagen-alginate primary wound dressing~Local offloading with felt pad for wounds on weight bearing surfaces~Foam~Multi-layer compression dressing~Off-loading device such as a full-length boot or total contact cast (if full-length boot cannot accommodate the patient) or surgical shoe for ulcers in non-weight bearing locations"
75730120|NCT05369871|Device|Closed-loop system|Closed-loop system consisting of a terminal including the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the Accu-Chek Insight insulin pump.
76052002|NCT05651087|Drug|LACUDY|LACUDY:Insert 2mL twice a week for 4 weeks before going to bed
76052003|NCT02290691|Biological|Influenza Vaccine|Influenza Vaccine
75435898|NCT00713817|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
76052004|NCT02292212|Device|ViE-21|The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
75730121|NCT05369871|Device|Open-loop system|Open-loop system consisting of a terminal without the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the usual insulin pump.
75730122|NCT05361902|Radiation|Adaptive radiotherapy according to UPRATE protocol|According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description
75881391|NCT03134183|Drug|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D&E
76052005|NCT02291510|Drug|Met DR|metformin delayed-release tablets
75435899|NCT00713323|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
75435900|NCT00713193|Drug|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
75435901|NCT00713193|Drug|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
75435902|NCT00710554|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
75435903|NCT00710554|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
75583743|NCT04580745|Drug|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
75583744|NCT04618328|Drug|all trans retinoic acid|ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks
75583745|NCT04585659|Other|Qigong|Mind-body movement art that includes specific movements, breath exercises, stretching and meditation.
75583746|NCT04617782|Combination Product|Donepezil TDS|Transdermal Delivery System
75583747|NCT04617782|Drug|Aricept|Oral
75583748|NCT04617704|Biological|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
75583749|NCT00569985|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
75730123|NCT05351749|Behavioral|New-prescription Alert|An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
75730124|NCT05351749|Behavioral|New-prescription Alert with referral option|An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
75881392|NCT03134183|Drug|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D&E
75881393|NCT02083484|Biological|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
76052006|NCT02291510|Drug|Met XR|metformin extended-release tablets
76052007|NCT02291510|Drug|Met IR|metformin immediate-release tablets
76052008|NCT02290223|Behavioral|Behavioral Based Treatment Model|Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
75435904|NCT00710424|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
75583750|NCT00569985|Drug|carmustine|Given IV
75583751|NCT00569985|Drug|cyclophosphamide|Given IV
75583752|NCT00569985|Drug|etoposide|Given IV
75583753|NCT00569985|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
75730125|NCT05351749|Behavioral|Existing-prescription notification to prescriber|Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
76052009|NCT05646407|Device|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
75583754|NCT02939768|Other|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit ~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed ~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
75583755|NCT02939768|Other|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
75435905|NCT00710424|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
75435906|NCT00674609|Drug|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
75730126|NCT05351749|Behavioral|Existing-prescription notification to pharmacist|Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
76052010|NCT02289833|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
75435907|NCT00674609|Drug|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
76052011|NCT05646329|Behavioral|Motivational Interview|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
75435908|NCT00674609|Drug|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
75435909|NCT00562549|Drug|SLx-2101|
75435910|NCT00289107|Device|Total Knee Arthroplasty|Rotating Platform (RP) Cruciate Substituting Knee System
75435911|NCT00289107|Device|Total knee replacement|Fixed Cruciate Substituting Knee System
75583756|NCT02939768|Other|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
75583757|NCT04617665|Other|One-handed mask ventilation|Using one-handed mask ventilation techniques during induction of general anesthesia
75583758|NCT04617665|Other|Two-handed mask ventilation|Using two-handed mask ventilation techniques during induction of general anesthesia
75730127|NCT05333783|Behavioral|Augmented Reality Exposure Therapy Based on ExposXR software|The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
75881394|NCT01354613|Drug|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
76052012|NCT01702558|Drug|Capecitabine|Capecitabine will be administered at de-escalating doses (starting from 750 mg/m^2) to determine the MTD.
76052013|NCT01702558|Drug|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
75435912|NCT00118846|Dietary Supplement|25 gm soy protein supplement|25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)
75435913|NCT00118846|Other|Placebo|Milk protein administered twice daily
75435914|NCT01556568|Drug|MEK162|
75435915|NCT01556607|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period at 3 visits
75435916|NCT01556607|Drug|Placebo|
75435917|NCT01556646|Drug|Tolvaptan|15 to 30mg qd titrated to sodium concentration
75435918|NCT01556659|Drug|Absence of Acenocoumarol|Dual anti-platelet therapy without the addition of Acenocoumarol.
75435919|NCT01556672|Drug|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
75583759|NCT00570024|Procedure|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
75583760|NCT00570024|Procedure|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
75583761|NCT00570102|Dietary Supplement|A highly hydrolyzed formula|Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
75583762|NCT00570102|Dietary Supplement|A regular cow's milk based formula|Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
75583763|NCT04617626|Drug|Azithromycin|Single dose of azithromycin suspension
75730128|NCT05324020|Behavioral|Medication adherence eHealth intervention|"The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies)."
75730129|NCT05320393|Drug|PrabotulinumtoxinA-Xvfs|One treatment of 40 units
75881395|NCT01354613|Drug|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
75881396|NCT01317719|Procedure|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
75881397|NCT05189405|Device|INVOcell IVC|Embryo development in intravaginal incubation
75881398|NCT02083640|Drug|Palbociclib Formulation Reference|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
75881399|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
75881400|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
75435920|NCT01556672|Device|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
75435921|NCT01556685|Other|clinical and neurological evaluation|The day of the usual IFN beta 1a IM injection
75435922|NCT01556685|Other|Blood Sample|For evaluation of interferon-related Nab
75881401|NCT01352039|Biological|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
75881402|NCT01352039|Biological|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
75435923|NCT01556685|Genetic|Blood Sample|genetic evaluation - predisposition to Nab generation
75881403|NCT02083718|Biological|PBSC|
75881404|NCT02083718|Biological|MSCs|
75881405|NCT05189327|Other|No intervention|Non-interventional study
75881406|NCT02083796|Procedure|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
75881407|NCT02083796|Procedure|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
75881408|NCT02083796|Procedure|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
75881409|NCT02083796|Procedure|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
75881410|NCT01363921|Device|HCO 1100|Dialysis treatment with HCO1100
76052014|NCT01702558|Drug|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.
75435924|NCT01556698|Drug|NVN1000|
75435925|NCT01556698|Drug|Vehicle|Placebo
75435926|NCT01556737|Dietary Supplement|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
75435927|NCT01556737|Dietary Supplement|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
75435928|NCT01556789|Biological|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
75435929|NCT01556802|Drug|Minocicline|Minocicline 100mg oral twice a day for 5 days
75583764|NCT04585230|Drug|CBD|CBD oil Roll-On Stick
75583765|NCT04585230|Drug|Mineral Oil|Mineral Oil- Roll on Stick
75583766|NCT04585230|Drug|Placebo|Roll- On stick with no CBD and no Mineral Oil
75583767|NCT04617899|Diagnostic Test|Intravascular imaging|Use of imaging catheter
76052015|NCT01702558|Drug|Capecitabine|Capecitabine will be administered at the MTD determined in Cohort 1.
75583768|NCT04584840|Procedure|Surgical treatment|"Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment~Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~Secure a two layered waterproof closure without tension (simple or with local flaps).~Samples will be sent for Pathological and microbiological analysis.~Stitches removal after two weeks~Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
75583769|NCT02939690|Device|UVC|UVC insertion depth calculated by [(3× birth weight (Kg) + 9)/2+1)]
75583770|NCT02939690|Device|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
75583771|NCT02939690|Device|Ultrasound|
75730130|NCT05320393|Drug|OnabotulinumtoxinA|One treatment of 20 units
75435930|NCT01556802|Drug|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
75435931|NCT01556815|Procedure|Transarterial Chemoembolization (TACE)|Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
75435932|NCT01556815|Other|Sorafenib in combination with TACE|"Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.~Procedure: TACE~TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated ."
75435933|NCT01556841|Biological|TroVax®|"Pre-amendment 10:~Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.~Post-amendment 10:~Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity."
75435934|NCT01556841|Biological|Placebo|"Pre-amendment 10:~Matched placebo will be administered as above.~Post-amendment 10:~TRI-70 onwards received TroVax only."
75583772|NCT04580784|Radiation|Weekly hypofractionation for early breast cancer|Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
75583773|NCT02939729|Other|Walking Programme|Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
75583774|NCT02939729|Device|Incentive Spirometer|An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
75730131|NCT05320393|Drug|PrabotulinumtoxinA-Xvfs|One treatment of 20 units
75583775|NCT02939729|Other|Deep Breathing Exercises|Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
75730132|NCT05301803|Device|Electrophysiology procedure|Electrophysiology testing and cardiac ablation of arrhythmia
75730133|NCT05283980|Drug|0.25% Bupivacaine|The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
75730134|NCT05273658|Drug|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
75730135|NCT05273658|Drug|Alcohol|Participants will ingest alcohol to achieve the target breath alcohol level
75730136|NCT05273190|Device|Vibrotactile Stimulation|Small electric motors, similar to a vibrating cell phone or gaming joystick, deliver vibration to the throat. Participants will assess cough symptoms throughout the study period.
75730137|NCT05272501|Behavioral|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
75730138|NCT05272254|Drug|10% povidone iodine + FV|applied to children's teeth
75730139|NCT05272254|Other|Placebo +FV|applied to children's teeth
75730140|NCT05270083|Diagnostic Test|NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)|Participants will receive an intravenous (IV) dose of 300 MBq of Neuraceq™ in a volume of 10 mL or less. A 30 minute duration PET image will be acquired starting immediately after Neuraceq™ injection. A second 20-minute duration PET image will be acquired starting 90 minutes after Neuraceq™ injection.
75583776|NCT00570180|Drug|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
75583777|NCT02939807|Drug|ABC294640|"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."
75583778|NCT04585074|Procedure|Robotic or endoscopic nipple sparing mastectomy|Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.
75583779|NCT04585074|Procedure|Conventional mastectomy (including nipple sparing mastectomy, skin sparing mastectomy)|Cases or Patients who underwent conventional mastectomy and immediate reconstruction are enrolled in this arm. Conventional mastectomy should not be performed using robotic or endoscopic surgical systems. Any incisions can be performed for this procedure. Conventional mastectomy includes also Nipple-sparing mastectomy and Skin sparing mastectomy. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases without immediate reconstruction are excluded.
75583780|NCT02939846|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
75583781|NCT02939495|Drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
75730141|NCT05269498|Device|CORTEXPLORER MED|The CORTEXPLORER MED system is a platform that enables surgical navigation using real-time radiological images of patients. The application software formats patient-specific computed tomography or magnetic resonance images taken before surgery. These are displayed on the screen and through mixed reality from different perspectives (axial, sagittal, coronal, diagonal). Before surgery, the surgeon can then create, save and simulate the course along one or more surgical trajectories. As a visualization aid, the surgeon can also create and edit one or more 3D models of the anatomy. During surgery, the system tracks the position of specific surgical instruments in or on the patient's anatomy and continuously updates the position of the instruments on these images.
75435935|NCT01556867|Other|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
75435936|NCT01556867|Other|Cord care with the use of antiseptics|"For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care."
75435937|NCT01556880|Behavioral|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
75435938|NCT01556893|Device|LenSx Laser|The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
75435939|NCT01556919|Procedure|Standard of care endoscopy|standard of care endoscopy
75435940|NCT01556945|Biological|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
75730142|NCT05264896|Drug|5-FU, Leucovorin, Oxaliplatin, Docetaxel|FLOT 4 cycles pre and post radical gastrectomy
76052016|NCT05650931|Procedure|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and pain modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
75435941|NCT01556945|Biological|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
75435942|NCT01556945|Other|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
76052017|NCT05650931|Procedure|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation.|SNS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites in the cervical thickening (C5-T1). Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
75730143|NCT05264896|Drug|XELOX|XELOX 8 cycles post radical gastrectomy
76052018|NCT05650931|Procedure|EEG to search for phantom pain biomarkers|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) when patient's pain returns to its preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
76052019|NCT02287883|Other|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
75435943|NCT01556945|Other|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
75435944|NCT01556971|Drug|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
75435945|NCT01556971|Drug|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
75583782|NCT04584879|Behavioral|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
75583783|NCT04584879|Behavioral|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
75583784|NCT04584879|Behavioral|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
75583785|NCT00570219|Drug|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
75583786|NCT04584957|Device|VAC therapy|Prophylactic ciNPWT therapy (Prevena® KCI) entails placement of the device over a closed incision immediately post-operatively. Prevena® KCI may be left in place with no additional intervention for up to 7 days.
76052020|NCT01743040|Diagnostic Test|CADence|"Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.~CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report."
76052021|NCT02194465|Drug|LY2623091|Administered orally
76052022|NCT02194465|Drug|Tadalafil|Administered orally
76052023|NCT02194465|Drug|Spironolactone|Administered orally
76052024|NCT02194465|Drug|Placebo|Administered orally
76052025|NCT02287025|Drug|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
76052026|NCT02287025|Other|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
75435946|NCT01556984|Other|DSA assay|All patients with diabetic foot perform a DSA assay. Before and after DSA, endothelial function will be measured.
75435947|NCT01557010|Drug|DWP05195|Tablets, oral administration, 100mg
75435948|NCT01557010|Drug|DWP05195|Tablets, oral administration, 200mg
75435949|NCT01557010|Drug|DWP05195|Tablets, oral administration, 300mg
75435950|NCT01557010|Drug|Control|Tablets, oral administration, Placebo
75435951|NCT01557023|Drug|barrier methods|
75435952|NCT01557023|Drug|barrier methods|
75435953|NCT01557036|Device|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
75435954|NCT01557049|Other|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
75435955|NCT01557049|Other|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
75583787|NCT04610957|Drug|Rosafem (FEMININE FORMULA)|Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
75583788|NCT00570375|Drug|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
75583789|NCT04617509|Drug|Formulation A GS-248|Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
75583790|NCT04617509|Drug|Formulation B GS-248|Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
75583791|NCT00570414|Device|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
75730144|NCT05259306|Device|Insightec Exablate Neuro MR-guided focused ultrasound transducer|This study will be utilizing the Insightec Exablate Neuro MR-guided focused ultrasound transducer to deliver low-intensity ultrasonic energy precisely and safely to the target region of the brain. MRgFUS has been FDA approved at high-intensity to treat essential tremor and Parkinson's disease associated tremor. Device premarket approval number (PMA) is P150038, and FDA approval notice was July 11, 2016. This study will be using this device not to make any lesions in the brain (as it is currently FDA approved), but instead to use the precision and non-invasive nature of the device to target the MD thalamus region of the brain at intensities currently approved by the FDA for transcranial ultrasound.
75730145|NCT05259176|Device|transcranial Direct Current Stimulation (tDCS)|Direct current transcranial stimulation will be applied for 20 minutes over the left posterior parietal cortex with an intensity set to 2 mA.
75730146|NCT05259176|Device|Sham stimulation (sham-tDCS)|The same positioning of electrodes as the stimulation condition will be used, but the current will be applied for 30 seconds and then progressively reduced.
75435956|NCT01557062|Other|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
75435957|NCT01557062|Other|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
75583792|NCT00570414|Device|Endotracheal tube|Airway management by the use of endotracheal tube
75730147|NCT05259176|Device|Behavioural|Treatment for upper limbs ideomotor apraxia (Smania et al., 2000)
76052027|NCT02287025|Other|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
76052028|NCT01720264|Drug|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
76052029|NCT04564846|Drug|ORMD-0801|8 mg capsules of ORMD-0801 (Oral Insulin)
76052030|NCT04564846|Other|Placebo|Placebo capsule (Fish Oil)
76052031|NCT01702246|Drug|Simvastatin|40 mg, orally, once daily for 3 months
76052032|NCT01631227|Drug|Eprosartan|Eprosartan 450 mg
75583793|NCT04617431|Behavioral|Mobile health application and social media|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
75583794|NCT00568035|Drug|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
75583795|NCT04611113|Dietary Supplement|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
75583796|NCT04611113|Dietary Supplement|Control Nutritional Support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
76052033|NCT01631227|Drug|Eprosartan Mesylate|Eprosartan mesylate 600 mg
76052034|NCT01631227|Drug|Placebo Eprosartan mesylate|Placebo Eprosartan mesylate
76052035|NCT01631227|Drug|Placebo Eprosartan|Placebo Eprosartan
75435958|NCT01557062|Other|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
76052036|NCT05645861|Procedure|Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
76052037|NCT01719172|Device|Veriset™ Hemostatic Patch|Topical Hemostat
76052038|NCT02286947|Drug|Eteplirsen|Eteplirsen solution for IV infusion
76052039|NCT02286713|Behavioral|Patient Decision Aid|Participants will receive study materials including a video to watch about lung cancer screening
76052040|NCT02286713|Behavioral|Standard Educational Information|Participants will receive study materials including a booklet to read about lung cancer screening.
76052041|NCT02286713|Behavioral|Follow-Up Assessments: Questionnaires|Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
76052042|NCT05650385|Drug|B1962|B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
75583797|NCT00568074|Drug|repaglinide|
75583798|NCT00568074|Drug|Glurenorm®|
75583799|NCT00568074|Drug|Glucobay®|
75583800|NCT00568113|Drug|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
75583801|NCT04617392|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.
75583802|NCT04617392|Other|Strength endurance training|Patients included in the active cohort arm with physical activity will undergo three months of strength endurance training under the supervision of a professional physiotherapist
75583803|NCT00568152|Dietary Supplement|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
75583804|NCT00568152|Dietary Supplement|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
75583805|NCT00568152|Drug|Aspirin|75mg dispersable aspirin taken daily for 14 days
75583806|NCT04610879|Drug|Carbamazepine|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
75583807|NCT04610879|Drug|Levetiracetam|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
75435959|NCT01557075|Drug|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Atorvastatin 40 mg daily for 12 months after randomization"
75583808|NCT04610879|Behavioral|Parent based sleep (PBS) intervention|The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
75583809|NCT04617236|Behavioral|Cultivando La Salud|"A lay health worker delivered educational intervention for breast and cervical cancer screening.~In total, the Intervention Group subject participation will take approx. up to four hours (1 hour for interview, 1 hour for the second interview, and 1-2 hours for the CLS intervention) and Control Group up to four hours (One hour for interview, one hour for the second interview, up to two hours for educational intervention after the second interview).~Follow-up data was collected 4-6 months post education session (intervention group) or post-baseline survey (control group)."
75435960|NCT01557075|Drug|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization"
75435961|NCT01557088|Other|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
75435962|NCT01557088|Procedure|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
75583810|NCT04584489|Other|iron stores assessment.|assessment of iron stores by measuring serum ferritin level (mandatory), serum iron and transferrin saturation.
75583811|NCT00570570|Procedure|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
75583812|NCT00570570|Other|conventional physiotherapy|trice a week during 6 weeks
76052043|NCT02285855|Drug|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
76052044|NCT02285855|Other|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
75730153|NCT05248919|Drug|Epclusa (nucleotide HCV NS5B polymerase inhibitors).|Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
75583813|NCT04617119|Device|Threshold IMT device|10 breaths X 3 sets, two times a day for 2 weeks. starting intensity 10 % of pre-measured maximal inspiratory pressure.
75583814|NCT04617119|Other|Conventional physical therapy|daily
75583815|NCT00570609|Other|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
75583816|NCT00570648|Drug|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
75583817|NCT00570726|Drug|Ranibizumab (Lucentis)|
75583818|NCT04584450|Other|Questionnaire|data collection using questionnaire
75583819|NCT00570804|Behavioral|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
75583820|NCT00570804|Behavioral|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
75583821|NCT04584606|Diagnostic Test|Lab workup (on admission and regularly during follow up).|"Complete blood count with differential leucocytic count. Absolute lymphocytic and neutrophilic count. Liver functions: Aspartate transaminase and Alanine transaminase . Renal functions: Blood urea nitrogen, serum Creatinine. HbA1C. C-reactive protein (quantitative). Serum ferritin level. D - dimer level (quantitative). Coagulation profile (Prothrombin time/ Partial thromboplastin time/ International normalized ratio).~Troponin level. Arterial blood gases when needed."
75583822|NCT00570843|Drug|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
75730154|NCT05248802|Drug|Placebo caplet of DLBS2411|1 caplet of placebo DLBS2411, twice daily
76052045|NCT02285855|Radiation|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
75583823|NCT00570843|Drug|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
75583824|NCT00563069|Drug|Midazolam|
75583825|NCT04584411|Diagnostic Test|Cardiac Magnetic resonance imaging|"The following basic sequences will be conducted:~Cine imaging using SSFP sequence for cardiac structure and function.~Tissue characterization imaging, T1 and T2.~Myocardial perfusion imaging.~Late gadolinium enhancement.~Diagnosis of myocarditis will be based on the modified Lake Louise criteria:~T2-weighted: any of the following standard T2 sequences: regional high signal standard T2 sequences: global signal intensity ratio (myocardium/skeletal muscle) ≥2 T2 mapping: increased T2 relaxation times T1-weighted: any of the following late enhancement imaging: non-ischemic (subepicardial or mid myocardial) late enhancement native T1 mapping: increased T1 relaxation times or extracellular volume supportive criteria: signs of pericarditis: effusion or pericardial late enhancement regional or global wall motion abnormalities[5]"
75583826|NCT04580355|Procedure|One-Stage Full Mouth Debridement|Periodontal debridement
76052046|NCT02285777|Biological|Meningococcal ABCWY|One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
75583827|NCT04580355|Drug|Amoxicillin 500mg|Administration of Amoxicillin 500mg prescribed on the day of treatment tid for 7 days.
75583828|NCT04580355|Drug|Metronidazole 400mg|Administration of Metronidazole 400mg prescribed on the day of treatment tid for 7 days.
75583829|NCT04580355|Drug|Amoxicillin Placebo|Administration of Placebo on the day of treatment tid for 7 days.
75583830|NCT04580355|Drug|Metronidazole Placebo|Administration of Placebo on the day of treatment tid for 7 days.
76052047|NCT02285777|Biological|Placebo|One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
76052048|NCT02285153|Drug|Acetylsalicylic acid lysinate|100mg intravenously administered Acetylsalicylic Acid lysinate per day
75583831|NCT00563108|Drug|Basiliximab|
75435963|NCT01557101|Procedure|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
75435964|NCT01557101|Procedure|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
75435965|NCT01557114|Drug|Ipilimumab|"Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.~Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy"
75435966|NCT01557114|Radiation|Radiotherapy|Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
75435967|NCT01557127|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
75435968|NCT01557140|Drug|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
75583832|NCT00563108|Drug|Placebo|
75583833|NCT00570882|Drug|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
75583834|NCT00570882|Drug|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
75583835|NCT00563147|Drug|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
75583836|NCT00570999|Drug|Palifermin|60 mg/kg/day
75583837|NCT00570999|Other|Placebo|1,2 mL once daily
75583838|NCT04616261|Behavioral|Training|6 weeks of training
75583839|NCT04616261|Drug|Formoterol|inhalation of 54 microg formoterol
75583840|NCT04616261|Drug|Placebo|inhalation of placebo
75583841|NCT04616222|Drug|CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
75583842|NCT04616222|Drug|Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
75583843|NCT04584177|Behavioral|Arm-hand BOOST program|The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
75583844|NCT04584177|Behavioral|Control program|A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
75583845|NCT00563225|Drug|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
75583846|NCT04580316|Behavioral|Parental active presence|The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.
76052049|NCT02285153|Drug|0.9% sodium-chloride solution|Placebo, intravenously administered, daily
76052050|NCT02284373|Other|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
76052051|NCT02284373|Other|Routine wound care for venous ulcers and lymphedema|wound care /dressings
76052052|NCT02284373|Device|Flexitouch pneumonic compression|pneumonic compression only
76052053|NCT01632241|Biological|Placebo plus standard therapy|Placebo plus standard therapy
76052054|NCT01632241|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
76052055|NCT01632241|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
76052056|NCT02263508|Drug|Talimogene Laherparepvec|Talimogene laherparepvec administered by intratumoral injection
76052057|NCT02263508|Drug|Pembrolizumab|Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
76052058|NCT02263508|Drug|Placebo|Administered by intratumoral injection
76052059|NCT02291432|Biological|autologous muscle-derived cells (AMDC)|Cell treatment
75583847|NCT04580316|Behavioral|Parent passive presence|Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
75583848|NCT00563264|Behavioral|KAN-DO|"The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children."
75583849|NCT03454490|Procedure|Postoperative pseudoaneurysm of the greater palatine artery|Patients had an autogenous connective tissue gingival graft.
75583850|NCT00571077|Device|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
75583851|NCT03454373|Behavioral|Incentive for linkage to care|"Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care"
75583852|NCT04584216|Other|Steam Eye Mask with acupoints stimulation|A participant needs to use SEM with acupoints stimulation once a day for 10 days and use hands to massage the acupoints on the eyebrows for the first 3 minutes, total application time at least for 20 minutes.
75583853|NCT04584216|Other|Steam Eye Mask|A participant needs to use SEM once a day for 10 days, total application time at least for 20 minutes.
75583854|NCT04615793|Other|PILATES EXERCISES|The experimental group will receive Pilates exercises focusing on lower limb strength, flexibility and coordination in addition to exercises given to control group. Exercises or movements were done on a mat, on an exercise ball or in standing position while emphasizing on spinal and pelvic alignment, maintaining core contraction and the rhythm of respiration. All exercises were done for 10 repetitions with a rest period of two minutes before commencing the next exercise, and lasted for about 45 minutes. All the groups will receive the above mentioned interventions thrice in a week for a period of 10 week
75583855|NCT04584060|Combination Product|ERAS protocols|ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter
75730155|NCT05248802|Drug|DLBS2411|1 caplet of DLBS2411 250 mg, twice daily
75730156|NCT05240924|Behavioral|Exposure and Response Prevention|ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.
75730157|NCT05240924|Other|Stress Management Training|The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
76052060|NCT05369780|Dietary Supplement|Hydrolyzed Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
76052061|NCT02290340|Drug|Placebo|Participants will receive placebo intramuscularly.
75435969|NCT01557153|Drug|Amlodipine|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
75435970|NCT01557153|Drug|Placebo|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
75435971|NCT01557179|Device|Hyalofemme|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
76052062|NCT02290340|Drug|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
76052063|NCT02290340|Drug|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
75435972|NCT01557179|Device|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
76052064|NCT02290340|Drug|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
76052065|NCT05647187|Diagnostic Test|Serum Interleukin 17 levels|Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)
75435973|NCT01557192|Device|Low Field Magnetic Stimulation Device|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
75435974|NCT01557218|Other|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
75435975|NCT01557218|Other|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
75583856|NCT04584060|Combination Product|Early oral feeding|Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward
75583857|NCT04584060|Combination Product|Prophylaxis against DVT|Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
75583858|NCT04615637|Device|MEG recordings|"Classical MEG recordings (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).~MEG recordings with our OPM He4 prototype (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli)."
75583859|NCT04584021|Device|Xiaomi MiBand3|Recording of sleep, activity and heart rate data to study their association with stress.
75583860|NCT04584021|Other|Socio-demographic questionnaire|Self-made questionnaire to be filled by the participants at the beginning of the study with the following personal data: age, gender, marital status, residential environment, cohabitation unit, educational level, socio-economic level, contract, working hours, overtime or not, number of overtime hours in a day, overtime frequency and perceived stress level
75583861|NCT04584021|Other|EuroQol-5D-5L|Quality of life questionnaire to be filled by the participants at the beginning, mid-term and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
75583862|NCT04584021|Other|Pittsburgh Sleep Quality Index (PSQI)|Questionnaire to be filled by the participants whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning, mid-term, and completion of the study.
75583863|NCT04584021|Other|State-Trait Anxiety Inventory (STAI)|Questionnaire to be filled by the participants which measures the anxiety level. To be given at the beginning, mid-term and completion of the study.
75583864|NCT04584021|Other|Perceived Stress Scale-10 (PSS-10)|Questionnaire to be filled by the participants which measures the stress level. To be given at the beginning, mid-term and completion of the study.
75583865|NCT04584021|Other|Stress questionnaire|Questionnaire designed by a work stress psychologist professional from the research group which is focused on stress and daily functioning. This questionnaire was given for the participants to fill. It is composed by 3 daily items and 4 weekly items.
75583866|NCT04615598|Behavioral|Action observation|The idea is to show some videos with the aim of improving patients' tongue strength.
75583867|NCT04615598|Behavioral|Placebo group|The idea is to show some videos of vegetation with the aim of having an intervention time but ineffective.
75730158|NCT05228574|Dietary Supplement|Sodium chloride (NaCl)|Sodium chloride capsules 6 grams per day for 4 weeks.
76052066|NCT05647187|Radiation|NB-UVB|patients will be exposed to narrow band UVB twice weekly for three months
76052067|NCT02290028|Device|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
76052068|NCT01741792|Drug|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
76052069|NCT02289950|Drug|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
76052070|NCT02289950|Drug|Placebo|Placebo will be administered intravenously (IV) weekly
76052071|NCT01741012|Drug|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
76052072|NCT02288312|Drug|BIA 2-093|
76052073|NCT01740388|Drug|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
76052074|NCT01740388|Drug|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
75730159|NCT05228574|Dietary Supplement|Placebo|Placebo capsules, 6 grams per day for 4 weeks.
76052075|NCT01740154|Procedure|transcranial magnetic stimulation|Undergo TMS
76052076|NCT01740154|Procedure|electromyography|Undergo EMG
76052077|NCT01740154|Other|survey administration|Ancillary studies
76052078|NCT01740154|Drug|sunitinib malate|Given PO
76052079|NCT02287922|Biological|ALX-0061|
76052080|NCT02287922|Biological|Placebo|
76052081|NCT02287922|Biological|Tocilizumab|
76052082|NCT02287610|Drug|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
75583868|NCT00571116|Drug|Disulfiram|Given PO
75730160|NCT05228574|Drug|Amiloride Hcl 5mg Tab|Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.
76052083|NCT05646212|Other|Project ECHO|Project Extension for Community Healthcare Outcomes® (ECHO): This EBP, tested originally to facilitate HCV care into non-specialty settings, is based on established educational theories of social learning & behavior change in where non-specialists collaborate with specialists, resulting in an innovative healthcare delivery model that results in equivalent quality care for patients in non-specialty settings.
75583869|NCT00571116|Drug|Arsenic trioxide|Given IV
76052084|NCT05646212|Other|Payment for Performance|"P4P in healthcare, endorsed by 3 IOM reports, gives financial incentives to clinicians for adhering to clinical guidelines and achieving better health outcomes. One 2007 IOM report recommended physician incentives so that profitability and improved healthcare delivery is aligned with patient safety goals and strengthen the business case for healthcare quality and safety."
76052085|NCT05646134|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation therapy that modulates brain excitability.
76052086|NCT05646134|Device|Sham Transcranial Magnetic Stimulation|During Sham Transcranial Magnetic Stimulation the coil will be facing the wall making the stimulation inactive
76052087|NCT05646056|Device|Software|Observation only
76052088|NCT04873466|Dietary Supplement|Enzyme-rich malt extract|Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
75583870|NCT04615676|Other|Follow-up phone call|Follow-up phone call after month to detect which patient have been hospitalized
75583871|NCT00571155|Drug|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
75583872|NCT04615481|Other|Elliptical Training Group|The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
75583873|NCT04615481|Other|Ergo-metric Training Group|The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
75583874|NCT04580433|Behavioral|Time-Restricted Feeding|"The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day."
75583875|NCT04584723|Other|Observation of flap survival and complications|We will report the flap survival and complications in this population group underwent to microsurgical procedures in a private practice setting
75583876|NCT04615169|Behavioral|Multi-component cognitive intervention with simulated everyday tasks (MCI-SET)|"2 hours per session: consisted primarily of modified everyday cognitive tasks, which were adjusted for individuals and for the group by the group leader to provide an error-reduction learning environment. Each session consisted of: (1) Warm-up: a 15-30 minute dual task of motor-cognitive exercises that increase arousal level and provide cognitive stimulation. For example, at the beginning of the group, the members would sing a song, mimic dance movement of the group leader, and clap hands when specific words occur in the song.~(2) 30-minutes guided and repetitive practices of contextually-relevant simulated everyday cognitive tasks with one 15 to 20- minute break in between; Cognitive tasks addressed complex attention, visual scanning, auditory attention, visual and motor memory, auditory memory, prospective memory, executive functioning, problem solving, etc."
75583877|NCT04615208|Diagnostic Test|suspected of COVID-19 infection|suspected of COVID-19 infection
75583878|NCT04614857|Other|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
75583879|NCT04583865|Other|teleconsultation|In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
75583880|NCT04614818|Other|Non-intervention research|Non-intervention research
75583881|NCT04614623|Device|AHCL pump|Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia
75583882|NCT04614623|Other|Video conferencing Application|Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
76052089|NCT02262728|Drug|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
76052090|NCT02262728|Drug|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
76052091|NCT02262728|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
75583883|NCT00571350|Procedure|tvt-o operation|transvaginal tention free obturator tape
75583884|NCT00571350|Procedure|tvt o operation|transobturator vaginal tape insertion
75730161|NCT05214443|Procedure|POEM + F|POEM would first be performed as per usual technique. Upon completion of the myotomy, a 2cm incision would be created over the adventitial layer at the level of gastro-esophageal junction (GEJ), allowing scope entry into the peritoneal cavity. The anterior part of the gastric fundus would be located, grasped with endoscopic forceps and pulled towards the esophageal myotomy site. The intended anterior fundus would then be anchored to the edge of the muscle at the GEJ, with the use of X-TackTM system. After confirming adequate hemostasis and secure anchorage of fundus to the esophagus, the mucosal entry site for the submucosal tunnel would be closed with endoscopic clips as per usual POEM technique.
75730162|NCT05195541|Drug|CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml
76052092|NCT02262260|Drug|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
76052093|NCT02262260|Drug|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
75583885|NCT04583631|Procedure|Adenoidectomy surgery|All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
75583886|NCT00571467|Drug|PRTX-100 (Staphylococcal protein A)|"4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
75730163|NCT05177107|Biological|Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
75730164|NCT05177107|Other|Placebo|Placebo (normal saline)
75730165|NCT05176873|Drug|DZD8586|Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
75730166|NCT05176873|Drug|Placebo|A single oral dose of placebo will be given.
75435976|NCT01557218|Other|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
75435977|NCT01557218|Other|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
75435978|NCT01557218|Other|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
75435979|NCT01557218|Other|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
75435980|NCT01557218|Other|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
75435981|NCT01557218|Other|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
75435982|NCT01557257|Drug|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
75435983|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
75435984|NCT01557257|Drug|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
75730167|NCT05176509|Drug|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
75730168|NCT05176509|Drug|YH001|YH001 will be administered intravenously over 60 minutes every 21-day cycle.
75730169|NCT05176509|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
75730170|NCT05176288|Drug|Axitinib|Taken Orally
75730171|NCT05176288|Drug|Palbociclib|Taken Orally
75730172|NCT05176288|Drug|Avelumab|Intravenous infusion
75435985|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
75583887|NCT04583553|Diagnostic Test|Vikor Scientific Urine-IDTM|Urine samples will be collected for both standard laboratory culture at KUMC Lab and expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will cover all costs associated with sample delivery. If insufficient urine volume is collected for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will be preferentially used for standard laboratory culture at KUMC Lab.
75583888|NCT00563303|Drug|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
75583889|NCT00563303|Drug|NaCl|48mL from Day 1 to Day 6
75583890|NCT00571506|Drug|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
75583891|NCT00571506|Drug|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
75583892|NCT04614077|Other|ex vivo organ bath testing, preservation of vein sections without contact to patient|1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath
75583893|NCT00571545|Behavioral|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
75583894|NCT00571545|Behavioral|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
75583895|NCT04583397|Other|radio frequency electromagnetic fields|Exposure system delivers emissions comparable to those from a WiFi access Point close to the bed or sham (no exposure)
75583896|NCT00571584|Drug|activated recombinant human factor VII|
75583897|NCT04614272|Behavioral|Prayer|Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.
75583898|NCT04614272|Behavioral|Reading a poem|Reading is a distraction tool for pain management
75730173|NCT05173415|Device|Sirius Pintution|The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
75730174|NCT05173415|Device|HydroMARK (C) Clip|The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
75730175|NCT05167565|Other|MRI/DTI|High resolution MRI scans will be acquired from each infant at three time points (~3, 6, and 12 months), while they are naturally asleep to measure the progressive myelination of the major brain fiber tracks, grey matter maturation, and to create generative models for source reconstruction of EEG sensor data.
75730176|NCT05167565|Other|EEG|EEG will be used to record infant brain activity during reaching and grasping actions to analyze beta activity
76052094|NCT02285270|Device|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
76052095|NCT01717768|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
76052096|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
76052097|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
75435986|NCT01557257|Drug|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
75435987|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
75435988|NCT01557270|Drug|dexmedetomidine|ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
75583899|NCT04583436|Device|Endovascular recanalization|Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
75583900|NCT04583436|Other|Open surgery|Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
75583901|NCT04613999|Drug|Ralinepag|"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."
75583902|NCT04583202|Other|Exposure to placebo|Patients are exposed to a placebo for 4h in the Alyatec EEC
75583903|NCT04583202|Other|Exposure to allergen|Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
75583904|NCT04613609|Device|Electronic Cigarette containing nicotine|Non-smokers used an electronic cigarette containing nicotine
75583905|NCT04613609|Device|Electronic Cigarette without nicotine|Non-smokers used an electronic cigarette without nicotine
76052098|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~Continue prednisone 10 mg/day to week 96"
75435989|NCT01557270|Drug|saline|ropivacaine + saline placebo, single shot perineural application
75435990|NCT01557296|Dietary Supplement|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
75583906|NCT00571623|Other|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
75583907|NCT00571740|Biological|bevacizumab|Given IV
75583908|NCT00571740|Biological|cetuximab|Given IV
75583909|NCT00571740|Drug|fluorouracil|Given IV
75583910|NCT00571740|Drug|leucovorin calcium|Given IV
75583911|NCT00571740|Drug|oxaliplatin|Given IV
75435991|NCT01557296|Radiation|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
75435992|NCT01557296|Other|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
75730177|NCT05167565|Other|Eye Tracking|Infants will be presented with the experimental stimuli, which will consist of images of adults displaying different facial expressions and non-social images (e.g. a cross, a geometric pattern). This procedure is based on commonly used eye tracking paradigms designed to assess attention biases in infancy. Infant eye movement and position will be measured during stimuli presentation.
75435993|NCT01557296|Biological|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
75435994|NCT01557335|Drug|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
75730178|NCT05167565|Other|Ages and Stages Questionnaire (ASQ)|"The parents will be asked to complete the ASQ questionnaire (Developmental questionnaire).~ASQ-3 has 5 aspects: Communication, Gross motor, Fine motor, Problem solving and Personal-Social Each aspect has 6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. ASQ-3 average = average score of 5 aspects."
76052099|NCT02260934|Drug|Methylprednisolone|"Week 0 and Week 2:~Solumedrol (100 mg) IV"
75435995|NCT01557335|Drug|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
75435996|NCT01557361|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
75435997|NCT01557361|Other|Standard RRT initiation|"Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~Serum potassium ≥6.0 mmol/L, or~Serum bicarbonate ≤ 10 mmol/L, or~Evidence of severe respiratory failure, based on a PaO2/FiO2 <200 and bilateral infiltrates on the chest x-ray, or~By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization"
75435998|NCT01557374|Drug|Tocilizumab, Abatacept|Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
75435999|NCT01557374|Drug|Decrease Tocilizumab, Abatacept|"The decrease pattern is established on 4 consecutive stages :~IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):~Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop~SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):~Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop~If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.~If DAS 28 > 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage~If DAS 28 > 3,2 : return to previous stage, (relapse according to European expert consensus)~In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study."
75436000|NCT01557387|Other|Endoscopic techniques|All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
75583912|NCT04613687|Device|Compression bandage|Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
75583913|NCT00571779|Device|AtriCure Bipolar System|
75583914|NCT00563342|Drug|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
75583915|NCT00563420|Procedure|Bronchoscopy|
76052100|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
76052101|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
76052102|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
76052103|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
76052104|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~Continue prednisone 10 mg/day to week 96"
76052105|NCT02260934|Drug|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
76052106|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
75583916|NCT04580082|Behavioral|Mindfulness lessons|14 lessons on mindfulness, each lasting approximately 20 minutes.
75583917|NCT00563498|Drug|Glutamine|
75583918|NCT04583046|Drug|normal saline inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).
75583919|NCT04583046|Drug|iloprost inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
75583920|NCT00563537|Radiation|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
76052107|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
75583921|NCT04613765|Behavioral|Measure adherence behaviors|"Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings."
75583922|NCT04582929|Drug|Neuronox ® Injection|Neuronox ® 50 or 100 unit intramuscular injection
75583923|NCT04613726|Drug|ondansetron|group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline
75583924|NCT04613726|Drug|Granisetron|Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline
75583925|NCT04613726|Drug|Saline|Control group consisted of patients receiving IV 10 ml normal saline
75730179|NCT05167565|Other|Infant Behavior Questionnaire Revised (IBQ-R)|"The parents will be asked to complete the IBQ-R questionnaire (Developmental questionnaire).~The 191-item instrument provides scores on 14 temperament scales which in turn cluster into 3 overarching factors: Positive Affectivity/Surgency, Negative Emotionality, and Orienting/Regulatory Capacity. Items are rated on a 7-point scale."
75730180|NCT05167565|Other|Beck Depression Inventory (BDI)|"The parents will be asked to complete the BDI questionnaire (Mental health questionnaire).~Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression."
75730181|NCT05167565|Other|The Brief Fear of Negative Evaluation Scale (BFNE)|"The parents will be asked to complete the BFNE questionnaire (Mental health questionnaire).~The BFNE measures anxiety associated with perceived negative evaluation. This scale is composed of 12 items describing fearful or worrying cognition. Scores from for each item are added up to obtain the total score."
75730182|NCT05167565|Other|Edinburgh Postnatal Depression Scale|"The parents will be asked to complete the Edinburgh Postnatal Depression Scale (Mental health questionnaire).~This is a set of 10 screening questions that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child. The total score is calculated by adding the numbers selected for each of the 10 items. If the parent's score is 10 points or above, they should speak to a health professional about those symptoms."
76052108|NCT02260934|Biological|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
75436001|NCT01557413|Procedure|Intramedullary nail|the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.
75436002|NCT01557413|Procedure|Locked plate|the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
75436003|NCT01557426|Other|Ultrasound|A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
75436004|NCT01557439|Drug|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
75436005|NCT01557478|Drug|Melatonin|20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
75436006|NCT01557478|Drug|match placebo|placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
75436007|NCT01557491|Procedure|Straight Incision|The incision will be made at a 90 degree angle to the surface of the scalp
75436008|NCT01557491|Procedure|Bevelled Incision|The Incision will be made at a 45 degree angle to the surface of the scalp.
75436009|NCT01557543|Other|Cell Therapy|Intramyocardial Injection of BMSCs
75583926|NCT00568230|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
75583927|NCT04613804|Drug|Toripalimab Injection|"Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle."
75583928|NCT00568269|Procedure|Open repair|Open repair is according to the Lichtenstein technique
75583929|NCT00568269|Procedure|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
75583930|NCT04613258|Dietary Supplement|SCAR Porridge|The treatment group was given SCAR porridge supplementation in the form of a soft porridge (a mixture of 50 g dry powder porridge added to 200 mL of hot water) along with nutritional counseling. The control group only received nutritional counseling and no SCAR porridge supplementation. A 50 g portion of SCAR porridge was provided once a day for 14 days. The SCAR porridge was monitored and administered by a researcher once a week to inquire about adherence to the supplementation consumption and perceived side effects. All research subjects went through a clearance period of one week and were requested not to consume any supplements.
75583931|NCT04613258|Other|Counseling|21 subjects in the control group (C) who only received dietary counseling
75583932|NCT03453957|Other|Professional development program|Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
75583933|NCT04613102|Drug|AVCN583601 (3% Cannabidiol cream)|Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
75583934|NCT04582851|Other|some risk factors correlated with TMD|exposure factors causing TMD
75583935|NCT04613219|Drug|Tofacitinib 5 MG [Xeljanz]|Treatment with Tofacitinib
75583936|NCT00563615|Drug|Tegaserod|
75583937|NCT04582656|Device|Targeted microwave ablation|Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
75583938|NCT00563654|Drug|Alfuzosin GITS (Xatral XL)|
75436010|NCT01557608|Procedure|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
75436011|NCT01557608|Procedure|Placebo treatment|"For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment."
75583939|NCT04612985|Device|XACT Robotic System|CT-guided Minimally Invasive Procedures e.g., Biopsies
75583940|NCT00571896|Drug|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
75583941|NCT00571896|Drug|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
75583942|NCT04613180|Drug|Montelukast Sodium|Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
75583943|NCT04613180|Drug|Placebo|placebo containing no active substance
75583944|NCT00571935|Drug|insulin aspart|
75583945|NCT00571935|Drug|soluble human insulin|
75730183|NCT05162326|Biological|BC-101|Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.
75583946|NCT04613063|Other|Diagnostic laparoscopy|A diagnostic laparoscopy was performed where a dilated jejunum was encountered with impaction of fecal content. Surgery was converted to open surgery, where a longitudinal enterotomy of 5 cm after the transition zone was created, evacuating manually the fecal material with mucous secretion.
75583947|NCT04612634|Biological|Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
76052109|NCT04879862|Combination Product|Epidural stimulation + Stand Training|Participants may use a standing apparatus or a less assistive device such as walker or cane. In case of upper limbs and trunk control insufficient for safely using the standing apparatus, participants will be placed on the treadmill, and a body weight support system. In this case, the level of body weight support will be continuously reduced as the individuals increase their ability to bear weight. A trainer positioned behind the participant will aid in pelvis and trunk stabilization. Trainer(s) positioned at the lower limb will provide manual facilitation for knee extension during standing. Manual facilitation at the trunk-pelvis and at the legs will be used only when needed.Participants will be encouraged to stand for as long as possible throughout the training session, with the goal to stand for 60 minutes with the least amount of assistance.
75583948|NCT04612634|Biological|Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
75583949|NCT04612634|Biological|Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
76052110|NCT04879862|Combination Product|Epidural stimulation + Step Training|Participants may be placed on the treadmill in an upright position and suspended in a harness. All trainers are careful to provide manual assistance only when needed. A trainer positioned behind the research participant will aid in pelvis and trunk stabilization, as well as appropriate weight shifting and hip rotation during the step cycle. Trainers positioned at each limb will provide manual assistance to promote knee extension and knee flexion and toe clearance. Research participants will step at various body weight load and speed. Research participants will take a break and rest at any time they feel the need to during the session. If independence is achieved during stepping, some training might be performed overground with appropriate assistive device and manual assistance to maintain participant safety. Participants will be encouraged to step for 60 minutes with the least amount of assistance. Seated or standing resting periods will occur when requested by the individuals
75436012|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Phone/Mail Group|Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
75583950|NCT00572052|Device|NovoFine® needle 6 mm|
75583951|NCT00572052|Device|Ultra-Fine needle 12.7 mm|
75583952|NCT04612556|Drug|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
75583953|NCT04579965|Drug|medical treatment of isthmocele|comparison between different drugs
75583954|NCT04612595|Other|serum urea nitrogen to creatinine ratio|According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.
75583955|NCT00568308|Drug|PI-88|160mg subcutaneous injection
75583956|NCT00568308|Drug|placebo|matched placebo
75583957|NCT04580199|Procedure|thyroidectomy|to excise the thyroid gland
75583958|NCT04612673|Drug|Sintilimab|immune checkpoint inhibitor, 200mg, iv, d1,Q3W
75583959|NCT00572091|Device|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
75583960|NCT04612829|Device|Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic
75583961|NCT04612439|Device|VABB Elite 10G|If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
75583962|NCT04612439|Device|BARD 14G CNB|If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
75583963|NCT04612517|Drug|ZP7570|Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
75583964|NCT04612517|Drug|Placebo|Placebo; corresponding volume
75583965|NCT00568347|Drug|fluticasone 100mcg/ salmeterol 50mcg|inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
75583966|NCT00568347|Drug|fluticasone 250/salmeterol 50|inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
75436013|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Mail-Only Group|Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
76052111|NCT04879862|Combination Product|Epidural stimulation + Bladder Capacity Training|We will initially conduct daily training for capacity in a supervised on-site lab setting. Optimal configurations will be used. The storage phase configuration will be used until the time for voiding/catheterization. The training procedure will be repeated for up to 8 hours daily on-site until three consecutive stable days of maintaining a consistent capacity values are achieved and deemed safe. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation (urodynamics and questionnaires). On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home-based training for bladder capacity.
76052112|NCT04879862|Combination Product|Epidural stimulation + Bladder Voiding Efficiency Training|We will conduct training for voiding efficiency in a supervised on-site lab setting while the participant continues his/her training for capacity. Voiding without catheterization will be attempted. The training procedure will be repeated for up to 8 hours on-site until three stable days of maintaining a consistent voiding efficiency are achieved and deemed safe. The participant will be sent home for one day to perform the stimulation at home. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation and questionnaires. On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home program integrating bladder training for capacity and voiding
76052113|NCT02260388|Drug|Nortriptyline|
76052114|NCT02260388|Drug|Duloxetine|
76052115|NCT02260388|Drug|Pregabalin|
76052116|NCT02260388|Drug|Mexiletine|
76052117|NCT02260154|Drug|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
75436014|NCT01557621|Behavioral|Practice-based Recall|All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
75436015|NCT01557634|Procedure|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
75436016|NCT01557647|Drug|Inhaled treprostinil|0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
75436017|NCT01557647|Drug|Placebo|placebo inhalation solution
76052118|NCT02284178|Other|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
76052119|NCT02284178|Other|Usual Care|Oral suction with suction swab every 4 hours
75436018|NCT01557660|Drug|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
76052120|NCT01643408|Drug|asparaginase Erwinia chrysanthemi|
76052121|NCT02283788|Drug|BIA 2-093|
76052122|NCT02283788|Drug|Moxifloxacin|
75436019|NCT01557673|Dietary Supplement|NG bolus feeding over 5 min|Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
75436020|NCT01557673|Dietary Supplement|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
75583967|NCT00568347|Drug|salmeterol|salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
75583968|NCT00568347|Drug|Salmeterol|salmeterol 50mcg bid X 3months
75583969|NCT00568347|Drug|salmeterol and fluticasone propionate|salmeterol 50mcg/fluticasone 250mcg by DPI bid
75730184|NCT05154448|Device|Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
76052123|NCT02283788|Drug|Placebo|
76052124|NCT01739764|Drug|Vemurafenib|Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).
76052125|NCT01700530|Drug|Statin|Statins (40mg/day)for 12 weeks
76052126|NCT01700530|Other|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
76052127|NCT01700530|Other|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
76052128|NCT01700140|Drug|SyB D-0701|Study drug patches [Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
75583970|NCT04612127|Dietary Supplement|Dietary supplement consumption and physical exercise|"The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week."
75583971|NCT04612361|Other|insommnia severity index questionnaire|insomnia severity index questionnaire and scoring system
75583972|NCT04582071|Behavioral|Psychotherapy|Psychotherapy is a term that we use to describe the use of the psychological method to understand and improve an individual's well-being and mental health. The Principal Investigator of this study, a clinical psychologist will be leading each of the sessions.
75583973|NCT04582110|Diagnostic Test|Optical coherence tomography angiography|Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
75583974|NCT04612205|Device|TECAR followed by pelvic floor exercises|The signal generator was an INDIBA® 448 kHz RF device (vagina/rectum) (INDIBA SA, Barcelona, Spain).
75583975|NCT04612205|Other|pelvic floor exercises|The patients will instructed to contract their pelvic floor muscles without contracting adjacent muscles, such as the abdomen, glutei and hip adductors muscles twenty repletion consisted of contraction and squeezing of the muscle ten seconds followed by relaxation for twenty second then rested for two minutes. The exercises program lasted for lasting 45 min. divided into 5 min. warming up, 35 min. actual treatment and 5 min. cooling down, three times a week for eight consecutive weeks. The patient will teach to contract their pelvic floor muscles before coughing or sneezing thus to prevent leakage. Home exercises through continuing practicing these contractions as frequent as possible according to her ability, at early morning before getting from bed from crock lying position, at afternoon from sitting and standing positions, at evening from sitting and standing positions and finally at night at bed time from crock lying position.
76052129|NCT01700140|Drug|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
75436021|NCT01557686|Behavioral|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
75436022|NCT01557712|Drug|ketamine venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~Intravenous injection on day 0 to 0.5 mg / kg of ketamine~D0 to D4: 75 mg of venlafaxine~D4 to D14: 150 mg per day of venlafaxine~D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
75436023|NCT01557712|Drug|Venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)~D0 to D4: 75 mg of venlafaxine~D4 to D14: 150 mg per day of venlafaxine~D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
75436024|NCT01557738|Dietary Supplement|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
75436025|NCT01557738|Dietary Supplement|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
75436026|NCT01557738|Dietary Supplement|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
75583976|NCT00572130|Genetic|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
75436027|NCT01557738|Dietary Supplement|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
75436028|NCT01557764|Drug|lapatinib ditosylate|Given PO
75436029|NCT01557764|Biological|trastuzumab|Given IV
75583977|NCT00572130|Genetic|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
75730185|NCT05154448|Other|Sham procedure|Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
75730186|NCT05150340|Drug|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
75730187|NCT05150184|Other|Non-interventional|observational study, thus no different arm/groups
75730188|NCT05142787|Device|Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics|placement of Magseed Pro & localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
75730189|NCT05127681|Radiation|HR-pQCT|Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture
75730190|NCT05127681|Biological|Blood sample|Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels
76052130|NCT01717456|Other|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
75583978|NCT04612088|Behavioral|Cognitive Dissonance|"A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study."
75730191|NCT05127681|Radiation|Dual energy X-ray absorptiometry|A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.
76052131|NCT01717456|Dietary Supplement|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
76052132|NCT01717456|Drug|Laxatives or anti-diarrheals|"Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed."
76052133|NCT01717456|Behavioral|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
76052134|NCT01717456|Behavioral|Tips on how to prevent fecal incontinence|"Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze."
76052135|NCT01717456|Behavioral|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
76052136|NCT01717456|Other|Protective pads or garments|In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
76052137|NCT01699750|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
75436030|NCT01557816|Drug|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
75436031|NCT01557816|Drug|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
75436032|NCT01557829|Device|Posterior lumbar interbody fusion with a PEEK cage|PEEK cage suitable for oblique placement in the lumbar spine
75583979|NCT04611737|Behavioral|Interviewing|Self-Determination Theory within motivational interviewing
75583980|NCT04582461|Device|multislice computed tomography|All patients will undergo a preoperative multiphasic multidetector CT scan before surgery.The unenhanced scan will be used to generate a CT reconstruction of the upper abdomen (from the diaphragm to the kidneys) with a 5mm thickness. Two different radiologists (D.F. and D.I.), blinded to patient information, measured total fat volume (TFV), visceral fat volume (VFV), and analyzed pixels with densities in the - 190 hounsfield units (HU) to - 20 HU range. the ratio between the density of the pancreas over the density of the spleen will be calculated and the maximum diameter of the pancreatic duct will be measured using the arterial phase in order to better identify the entire length of the duct.
75730192|NCT05127681|Other|medical data collection|Data of healthy men is already available
75730193|NCT05100095|Drug|Radiation therapy|Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
75436033|NCT01557829|Device|Posterior lumbar interbody fusion with a Valeo OL cage|Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
75436034|NCT01557855|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
75436035|NCT01557907|Device|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
75436036|NCT01557907|Device|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
75436037|NCT01557933|Other|No interventions will be used|No interventions will be used
75730194|NCT05099341|Other|HDRS-17 depression scale|Measuring the severity of depression
75730195|NCT05099341|Biological|Blood sampling|3 tubes of 5 ml
75730196|NCT05098834|Device|ENLIGHT 2100 ventilatory electrical impedance tomograph|The ENLIGHT 2100 system will remain connected to the patient for data acquisition from immediately prior to initiation of the ERT until up to 24 hours following extubation.
76052138|NCT01699750|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
75436038|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
75730197|NCT05098028|Drug|Low Dose Rifaximin ER|Low Dose Rifaximin Extended Release Twice Daily
75730198|NCT05098028|Drug|Low Dose Rifaximin DER|Low Dose Rifaximin Delayed Extended Release Twice Daily
75730199|NCT05098028|Drug|High Dose Rifaximin ER|High Dose Rifaximin Extended Release Twice Daily
75730200|NCT05098028|Drug|High Dose Rifaximin DER|High Dose Rifaximin Delayed Extended Release Twice Daily
75730201|NCT05098028|Drug|Placebo|Placebo Twice Daily
75583981|NCT04611971|Drug|Benlysta|Benlysta injection will be administered subcutaneously.
75583982|NCT04611971|Drug|Candin|Candin will be administered intradermally along with NaCl solution.
75583983|NCT00572208|Drug|Gabapentin group|"Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
75583984|NCT04611386|Drug|computerized tomography|Anti Factor Xa level
75730202|NCT05091918|Device|MotionSense|MotionSense Wearable: Remote patient monitoring
75583985|NCT00572247|Behavioral|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
76052139|NCT01699750|Device|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
76052140|NCT01699750|Device|BIOTRUE®|Contact lens care system, Phase 2
76052141|NCT01699750|Device|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
76052142|NCT01699750|Device|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
76052143|NCT01716754|Drug|QGE031|QGE031 was supplied as 120 mg liquid in vial per 1 mL
76052144|NCT01716754|Drug|Omalizumab|Omalizumab was supplied as 150 mg lyophilisate in vial
76052145|NCT01716754|Drug|Placebo|Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
76052146|NCT01698814|Drug|AL-4943A Ophthalmic Solution|
76052147|NCT01698814|Drug|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
75436039|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
75583986|NCT04611620|Behavioral|Cognitive Dysfunction|To fully characterize factors associated with cognitive dysfunction in BCS and CRC survivors that have cognitive concerns and (2) to fully characterize factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
75583987|NCT04611659|Behavioral|Motivational Interviewing and Educational Training (MIET)|Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
75583988|NCT04581837|Diagnostic Test|2D-speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography (2D-STE) allows for an angle-independent evaluation of myocardial strain, and provides comprehensive information on LV myocardial contractility. Thus, 2DSTE is superior in detecting subtle deteriorations of contractility. we will take 2D speckle tracking views for LV and RV strain (4ch, 2ch, 3ch, RV modified view).
75583989|NCT00563693|Device|ASV|Adaptive servo ventilator
75583990|NCT00563693|Other|without Autoset CS2|without Autoset CS2
75583991|NCT00563732|Drug|Lecozotan|
75730203|NCT05082753|Drug|Ivermectin tablets (3 mg Ivermectin)|Two Ivermectin tablets were administered orally.
75730204|NCT05082753|Drug|Stromectol ® tablets|Two Ivermectin tablets were administered orally.
75730205|NCT05081986|Device|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
76052148|NCT01738984|Behavioral|MomZing Web Program|Online web platform that is accessed via a television connected to internet
76052149|NCT01738984|Behavioral|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
76052150|NCT01738594|Drug|carfilzomib|Given IV
76052151|NCT01738594|Drug|romidepsin|Given IV
75436040|NCT01557985|Drug|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
75436041|NCT01557998|Behavioral|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
75583992|NCT00572364|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
75583993|NCT00563771|Drug|Rasburicase|
75583994|NCT00563810|Drug|MYO-029|
75583995|NCT04582032|Drug|Dexketoprofen (KETAVEL 50 mg/2 ml)|intravenous dexketoprofen (KETAVEL 50 mg/2 ml)
75583996|NCT04582032|Drug|Saline (Isotonic Saline Solution 0.9% )|intravenous 2 ml of saline
75583997|NCT00563849|Drug|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
75730206|NCT05081986|Drug|Cycloserine|Cycloserine 100mg
75730207|NCT05081986|Drug|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
75730208|NCT05079451|Drug|3BNC117-LS|3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
76052152|NCT01738594|Other|laboratory biomarker analysis|Correlative studies
76052153|NCT01738438|Drug|Cabozantinib|
76052154|NCT01716520|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
76052155|NCT01716520|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
76052156|NCT01716520|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
76052157|NCT04548310|Other|Muscles Fatigue|An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.
75583998|NCT04581876|Drug|raltitrexed for injection|Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
76052158|NCT04548232|Procedure|Laparoscopic sleeve gastrectomy|bariatric surgery
75583999|NCT04581876|Drug|nab-paclitaxel|Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
75584000|NCT00563888|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
75584001|NCT04579458|Procedure|Collection of tears and saliva.|Saliva and ocular tears will be collected.
76052159|NCT01698268|Procedure|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
76052160|NCT01698268|Procedure|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
76052161|NCT04555564|Procedure|Technicium 99 MAA infusion|4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
76052162|NCT01697956|Drug|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
76052163|NCT01697956|Drug|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
76052164|NCT01697800|Drug|Tadalafil|
76052165|NCT01697800|Drug|Placebo|
75584002|NCT04611932|Drug|CKD-330 Tab. and D090 Tab.|1T
75584003|NCT04611932|Drug|CKD-333 Tab.|1T
75584004|NCT00563927|Procedure|Conventional RT|
75730209|NCT05079451|Drug|10-1074-LS|10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
75881411|NCT02079818|Device|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
75881412|NCT01358903|Drug|RO5429083|Cohorts receiving multiple escalating doses iv
76052166|NCT01644500|Drug|Dulaglutide|Administered SC
76052167|NCT01644500|Drug|Glimepiride|Administered orally
76052168|NCT01644500|Drug|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
76052169|NCT01644500|Drug|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
76052170|NCT05645120|Other|Education|All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
76052171|NCT01604824|Drug|Alirocumab|SC injection in the abdomen
75584005|NCT00563927|Drug|Cisplatin|
75584006|NCT00563927|Drug|5-fluorouracil|
75584007|NCT00572520|Behavioral|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
75584008|NCT00572520|Behavioral|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
75584009|NCT00572520|Behavioral|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
75730210|NCT05064540|Device|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
75881413|NCT01358903|Drug|RO5429083|Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
76052172|NCT01604824|Drug|Placebo|SC injection in the abdomen
76052173|NCT01716052|Drug|placebo|Lactulose
75584010|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- low dose|
75584011|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- High dose|
75584012|NCT01150123|Biological|Placebo- Saline|
75584013|NCT00572559|Drug|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
75730211|NCT05064540|Device|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
76052174|NCT01716052|Drug|Ibuprofen|
76052175|NCT01641692|Drug|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
75584014|NCT00572559|Drug|Linezolid|600 mg every 12 hours (intravenously [IV] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
75584015|NCT04611464|Drug|Misoprostol|Misoprostol is a PGE1 analog
75584016|NCT04611347|Drug|CBD|Topical CBD application for thumb basal joint osteoarthritis.
75584017|NCT04611347|Drug|Shea Butter|Placebo Shae Butter for comparison
75584018|NCT00572598|Drug|4- [F-18] fluoropaclitaxel|4- [F-18] fluoropaclitaxel, <84 micrograms, <10 mCi, IV followed by PET/CT imaging
75881414|NCT01366261|Device|semirigid thoracoscopy|thoracoscopy with semirigid instrument
75436042|NCT01557998|Drug|HCV+PWID|Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.
75436043|NCT01557998|Behavioral|Control - No intervention|
75436044|NCT01558011|Drug|Capecitabine, Oxaliplatin, Docetaxel|"Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
75436045|NCT01558050|Dietary Supplement|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
75584019|NCT04611776|Drug|Atezolizumab|Atezolizumab will be administered intravenously during the induction phase and the maintenance phase.
75584020|NCT04611776|Drug|Placebo|Placebo will be administered intravenously during the induction phase and the maintenance phase.
75584021|NCT04611776|Drug|Carboplatin|Carboplatin will be administered intravenously during the induction phase.
75584022|NCT04611776|Drug|Cisplatin|Cisplatin will be administered intravenously during the induction phase.
75584023|NCT04611776|Drug|Pemetrexed|Pemetrexed will be administered intravenously during the induction phase.
75584024|NCT04611776|Drug|Gemcitabine|Gemcitabine will be administered intravenously during the induction phase.
75584025|NCT04611776|Drug|Paclitaxel|Paclitaxel will be administered intravenously during the induction phase.
75881415|NCT01366261|Device|rigid thoracoscopy|thoracoscopy with rigid instrument
75584026|NCT00572637|Drug|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
75584027|NCT04611308|Other|C1q tumor necrosis factor-related protein 6 levels|C1q tumor necrosis factor-related protein 6 is a tumor marker
75584028|NCT01149655|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
75584029|NCT01149655|Drug|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
75584030|NCT00575406|Drug|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
75584031|NCT00575406|Drug|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
75584032|NCT00575406|Drug|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
75584033|NCT00575406|Drug|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
75584034|NCT00575406|Drug|Vincristin|i.v., 2mg, d1 of each treatment cycle
75584035|NCT00575406|Drug|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
75584036|NCT00564005|Other|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
75584037|NCT00564005|Other|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
75584038|NCT00564005|Other|Combined therapy (CT)|combined different treatment approaches
75436046|NCT01558141|Other|Aspiration without flushing follicles with culture media|Aspiration without flushing follicles with culture media.
75436047|NCT01558141|Other|Follicular Flushing|Flushing follicles with embryo culture media prior to aspiration.
75584039|NCT00564005|Behavioral|Control intervention|Conventional treatment program
75584040|NCT01149538|Drug|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
75584041|NCT01149538|Dietary Supplement|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
75584042|NCT02884063|Procedure|NGS reading for Media Free DNA|NGS reading for Media Free DNA instead of blstomer biopsy
75584043|NCT04601207|Drug|Cannabis Preparation|Dosed as a single oral dose
75436048|NCT01558154|Drug|Chinese herbs|Chinese herbs special for depression
75436049|NCT01558154|Procedure|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
75436050|NCT01558154|Other|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
75436051|NCT01558154|Device|Transcranial magnetic stimulation|Give magnetic stimulation at head
75436052|NCT01558167|Drug|Bendamustine, Rituximab, Lenalidomide|"Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~Dose level 5: maximal tolerated dose"
75436053|NCT01558180|Behavioral|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
75584044|NCT04601207|Drug|Cannabis Preparation|Dosed as a single oral dose
75584045|NCT01149460|Drug|Valacyclovir|Test 1000 mg Tablet
75584046|NCT01149460|Drug|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
75584047|NCT00575484|Drug|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium </=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
75584048|NCT00575484|Drug|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
75436054|NCT01558180|Behavioral|Usual Care|educational handouts on pediatric insomnia
75436055|NCT01558193|Dietary Supplement|Placebo|"Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance"
75436056|NCT01558193|Dietary Supplement|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
75436057|NCT01558193|Dietary Supplement|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
75436058|NCT01558193|Dietary Supplement|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
75436059|NCT01558206|Other|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
75436060|NCT01558206|Other|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
75436061|NCT01558219|Drug|cabacitaxel|Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
75436062|NCT01558232|Device|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
75436063|NCT01558245|Drug|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
75436064|NCT01558258|Behavioral|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
75436065|NCT01558284|Drug|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
75436066|NCT01558284|Drug|Placebo|Placebo
75436067|NCT01558310|Drug|Ustekinumab|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
75436068|NCT01558310|Drug|Placebo|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
75436069|NCT01558323|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
75436070|NCT01558336|Drug|praziquantel|praziquantel 40 mg/kg oral tablets
75436071|NCT01558362|Drug|123I-CMICE-013|2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections.
75436072|NCT01558375|Drug|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
75436073|NCT01558375|Drug|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
75436074|NCT01558388|Drug|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
75436075|NCT01558388|Drug|Placebo|One vaginal tablet daily for 10 days.
75436076|NCT01558401|Other|Physical activity program|The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
75436077|NCT01558414|Procedure|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
75436078|NCT01558414|Procedure|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
75436079|NCT01558414|Procedure|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
75436080|NCT01558440|Dietary Supplement|Infant Formula|A diet that is being fed to the young infants.
75436081|NCT01558440|Dietary Supplement|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
75436082|NCT01558440|Dietary Supplement|Diluted F-100|300 ml of water is added to 1000 ml of f-100
75436083|NCT01558453|Drug|Oxaliplatin|"Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30)."
75436084|NCT01558466|Drug|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
75584049|NCT00572754|Procedure|Circumcision|Circumcision by tying a ligature around the foreskin.
76052176|NCT01641692|Procedure|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
75584050|NCT04600739|Procedure|TAVI|Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
75584051|NCT04579614|Behavioral|The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers|"A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period."
76052177|NCT01641692|Drug|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
76052178|NCT04859816|Other|Metabolic test|Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
76052179|NCT04859816|Other|DXA-scan|Dual energy X-ray Absorptiometry scan of whole-body fat
76052180|NCT04859816|Other|MRS|Magnetic resonance spectroscopy of liver fat content
76052181|NCT04859816|Other|Feces collection|4-day feces collection
76052182|NCT01682512|Drug|BI 695500|
75584052|NCT04600778|Other|placebo|placebo
76052183|NCT01682512|Drug|BI 695500|
75436085|NCT01558466|Drug|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
75436086|NCT01558505|Device|PEB|paclitaxel-eluting balloon angioplasty
75436087|NCT01558505|Device|POBA|conventional balloon angioplasty
75436088|NCT01558531|Device|DEB|paclitaxel-eluting balloon angioplasty
75584053|NCT04600778|Drug|Cavosonstat 5 mg|Cavosonstat (low dose)
76052184|NCT01682512|Drug|Rituxan®|
76052185|NCT01682512|Drug|Rituxan®|
76052186|NCT01682512|Drug|MabThera®|
76052187|NCT02256488|Biological|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
76052188|NCT02256488|Biological|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
76052189|NCT02256488|Biological|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
76052190|NCT02256488|Biological|TIVf|Single IM administration dose of 0.5 mL of TIVf
76052191|NCT05644886|Behavioral|FP Training and Technical Support|Same as in Intervention arm description
75436089|NCT01558531|Device|POBA|conventional balloon angioplasty
75436090|NCT01558557|Other|Gluten Free Diet|Participants will be given a Gluten Free Diet for 2 weeks
76052192|NCT04863794|Drug|RO7248824|A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
76052193|NCT04863716|Procedure|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered before the surgery.
76052194|NCT04863716|Procedure|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
75436091|NCT01558570|Procedure|Blood Draw|One time blood draw
75436092|NCT01558583|Other|Rating and Ranking Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
75584054|NCT04600778|Drug|Cavosonstat 10 mg|Cavosonstat (medium dose)
75584055|NCT04600778|Drug|Cavosonstat 25 mg|Cavosonstat (high dose)
75584056|NCT00572871|Other|plyometric exercise|single bout of plyometric exercise
75584057|NCT00572871|Other|resistance exercise|single bout of resistance exercise
75584058|NCT00572871|Other|No exercise|Will not do any exercise
76052195|NCT04135352|Drug|200 mg of pembrolizumab|Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
76052196|NCT04135352|Biological|V938|Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
76052197|NCT04862312|Behavioral|VideoDine|Participants will VideoDine with a dining partner at least six times during an eight week period. VideoDining involves sharing a meal with someone not physically present using video chat technology. Dining partners will be recruited, trained and paired with participants. Participants will be provided Amazon Echo Show devices for video chat.
75584059|NCT04600583|Device|Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)|All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
75436093|NCT01558583|Other|Discrete Choice Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
75436094|NCT01558583|Other|Balance Sheet Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
75436095|NCT01558622|Drug|dexketoprofen trometamol|50mg intravenous infusion
75436096|NCT01558622|Drug|tramadol hydrochloride|100mg intravenous infusion
75584060|NCT04600700|Device|Clinical Decision support system (CDSS) for inotrope weaning|A Clinical Decision Support System informed by 6-hour rolling average IDO2, will be utilized during the intervention phase of the study. The CDSS tool will be introduced in a stepped-wedge pattern. Randomization will occur by center, with time of introduction being staggered, with each center ultimately receiving the CDSS intervention. Teams in the CICU make rounds twice per day. During each of the rounds (AM and PM), the team will refer to the CDSS and the 6-hour average IDO2 (as reported on the T3 platform at the bedside computer). The clinical team will consider the CDSS in decision making around inotrope weans. If the decision is made to not utilize IDO2, the bedside clinician will complete a brief survey with rationale.
75584061|NCT00575523|Drug|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
75584062|NCT00575523|Drug|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
75584063|NCT04600661|Other|Traditional exercise therapy|Neuromuscular training
75584064|NCT04600349|Behavioral|Identity Oriented Psychotrauma Therapy|The method will be presented to the group at the beginning of the first group session. Then every person from the experimental group will set an Intention connected to the emotional or physical difficulties they experience in their lives. Then the person will choose for every word in their Intention, a representative from the support group who will resonate with that word. The focus of every Intention should be the current illness and the traumatic or stressful events which happened before the disease onset.
75584065|NCT04600349|Drug|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
75584066|NCT01149421|Drug|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
75584067|NCT01149421|Drug|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
75584068|NCT00575562|Drug|KRN330|Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer
75436097|NCT01558622|Drug|pethidine hydrochloride|50mg intravenous infusion
75584069|NCT04600310|Device|ULTRAPREP|ULTRAPREP device for reducing OR prep times.
76052198|NCT01715896|Biological|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
76052199|NCT01715896|Biological|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
75436098|NCT01558622|Drug|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
75436099|NCT01558622|Drug|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
75436100|NCT01558622|Drug|vitamin c|500mg intravenous infusion
75584070|NCT04600310|Device|No Intervention|Conventional skin preparation technique
75584071|NCT04600232|Diagnostic Test|Alere TB-LAM|Subjects also undergo clinical evaluation including CT, sputum smear, Gene Xpert and mycobacterial culture.
75730212|NCT05058495|Other|Mobile Lymphedema Self-Care Support Program|The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
75730213|NCT05058495|Other|standart lymphedema education|The control group will be received standart lymphedema education. The standart lymphedema education is an oral education that composed of informations about lymphedema and lymphedema self-care.
75730214|NCT05053737|Drug|Atezolizumab|One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
75436101|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
75584072|NCT03453879|Other|no intervention|No intervention - only observation of teams delivering acute obstetric care
75584073|NCT04600193|Other|Diet containing organic phosphate|The patients will be receiving a 5 days diet containing organic phosphate
75584074|NCT04600193|Other|Diet containing inorganic phosphate|The patients will be receiving a 5 days diet containing inorganic phosphate
75584075|NCT00575601|Drug|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
75584076|NCT04600271|Drug|Crystalloid Solutions|exposure
75584077|NCT04600271|Drug|Colloid Blood Volume Expanders|exposure
75730215|NCT05053737|Radiation|Stereotactic Body Radiation Therapy|SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
75730216|NCT05048004|Procedure|QMODE intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For standard ablation, a Thermocool Smarttouch SF (Biosense Webster) catheter will be used (50 W, target ablation index of 550).
75730217|NCT05048004|Procedure|QMODE+ intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For comparison, catheter ablation performed using very high power with a maximum of up tp 90 W (QMODE +) will be used.
75584078|NCT04600271|Other|blood replacement|exposure
75584079|NCT04600271|Drug|Diuretic|exposure
75730218|NCT05047003|Diagnostic Test|EyeBOX Model EBX-4 (Portable version)|The portable EyeBOX takes less than 4 minutes to complete and involves watching a video move around the perimeter of an LCD monitor positioned in front of the patient while a high-speed camera continuously records gaze positions. The Portable EyeBOX software detects subtle changes in eye movements consistent with concussion and calculates a BOX score.
75584080|NCT04600271|Drug|noradrenaline|exposure
75730219|NCT05043987|Drug|CPO102|Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
75730220|NCT05040932|Drug|YH004|IV infusion once every 3 weeks (Q3W).
75730221|NCT05038735|Drug|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
75730222|NCT05038735|Drug|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).
75730223|NCT05038735|Drug|Alpelisib-matching placebo|Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
76052200|NCT02255552|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
75584081|NCT04600271|Drug|Non-Steroidal Anti-Inflammatory Analgesics|exposure
75584082|NCT00575640|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
75584083|NCT00575679|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
75584084|NCT04600388|Device|Nerivio|Nerivio Remote Electrical Neuromodulation (REN) device
75730224|NCT05028933|Drug|EPCAM CAR-T|Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion
76052201|NCT01714726|Drug|MEDI2070|1 iv infusion on Week 0 and Week 4
76052202|NCT01714726|Drug|placebo|1 iv infusion on Week 0 and Week 4
76052203|NCT02255474|Device|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
75584085|NCT04579887|Other|Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations|Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
75584086|NCT04599959|Diagnostic Test|Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol|Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
75584087|NCT04579731|Drug|Lactitol Monohydrate|Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
75584088|NCT00565487|Drug|Capecitabine, Tarceva|Capecitabine is a self-administered (oral) medication & will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine & Tarceva is continued daily until the completeness of the radiation or toxicity.
75584089|NCT03453801|Biological|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
75584090|NCT03453801|Biological|FluMist®|FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
75584091|NCT04600115|Drug|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
75584092|NCT04600115|Drug|Regadenoson|0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
75584093|NCT04600115|Drug|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
75584094|NCT04600115|Device|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
75584095|NCT04600115|Device|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
75584096|NCT03453762|Procedure|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
75730226|NCT05021484|Drug|Felzartamab|Intravenous infusion in regular intervals over 6 months
75584097|NCT03453762|Procedure|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
75584098|NCT04599998|Diagnostic Test|spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire|Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
75584099|NCT04579419|Drug|Sodium Bicarbonate|Botulinum Toxin diluted in Sodium Bicarbonate
75584100|NCT04579419|Drug|Normal Saline|0.9 NaCl
75584101|NCT04600037|Drug|Pregabalin 150mg|"Patients in group I received pregabalin at a dose of 75 mg twice daily during the first week that was increased to 150 mg twice daily thereafter and maintained at that level for 12 weeks.~Patients in two groups received exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months"
75584102|NCT04599842|Procedure|Erector Spinae Plane Block|Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
75584103|NCT04599881|Drug|PTR-01|IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
75584104|NCT00575796|Drug|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
75584105|NCT04599530|Device|Talaris Demonstrator|The Talaris Demonstrator will be evaluated during daily activities and compared to the current prosthesis
75584106|NCT04599452|Biological|Allogeneic NK cell regimen group|"10 patients with recurrent refractory elderly AML were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10^6/kg d13，d15."
76052204|NCT02255474|Device|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
76052205|NCT02255474|Device|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
76052206|NCT05642702|Other|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
75584107|NCT00575835|Dietary Supplement|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
75584108|NCT00575835|Dietary Supplement|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
75584109|NCT04579185|Device|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
75730227|NCT05021484|Drug|Placebo|Intravenous infusion in regular intervals over 6 months
75730228|NCT05019885|Drug|Ketamine Hydrochloride|Three times a week (M, W, F) for 2 consecutive weeks.
76052207|NCT05642702|Other|Peptide complexed HA Age Defying Gel with Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
76052208|NCT05642702|Other|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
75584110|NCT00565565|Drug|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
75584111|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
75584112|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
75436102|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
75436103|NCT01558687|Drug|Drug (including placebo)|"Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide."
75584113|NCT04599413|Other|SURVEY|Pain survey on pianists
75584114|NCT00573222|Drug|Symbicort|
75584115|NCT04599374|Other|no intervention|This study collected data only without any intervention.
75584116|NCT04599179|Device|self-expandable metal stent|self-expandable metal stent endoscopic positioning
75584117|NCT00575874|Drug|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
75584118|NCT00575874|Drug|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
75584119|NCT00575874|Drug|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
75584120|NCT00575874|Drug|pioglitazone HCl|30 mg capsules once daily for 12 weeks
75584121|NCT00575874|Drug|placebo|matching tablets or capsule once daily for 12 weeks
75584122|NCT03454217|Drug|Oxycodone|Postoperative pain treatment with oxycodone
75584123|NCT03454217|Drug|Tramadol|Postoperative pain treatment with tramadol
75584124|NCT00575913|Drug|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
75584125|NCT04598945|Other|Functionel MRI|During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.
76052209|NCT05642702|Other|1% w/v Sodium Lauryl Sulphate (SLS) solution|1g of Sodium Lauryl Sulphate will be dissolved in distilled water and made up to 100 mL solution using distilled water. A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
76052210|NCT05642702|Other|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v|A 0.04 mL of 0.9% w/v solution of Isotonic Saline Solution will be dispensed on the center of an appropriately sized filter paper, which will be further placed in the designated IQ/Finn chambers prefixed to a micropore tape.
76052211|NCT02254772|Biological|Ipilimumab|A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
75881416|NCT05190835|Device|Optical scanner|During the visits (Day 0 before surgery, Day 8, Day 21, Day 45, Month 3 and Month 6 after surgery), a measurement of the volume and the perimeter of the patient's two feet is carried out (operated foot and control foot). The edema is measured by a non-invasive method using an optical scanner (camera + laser scanning). The image processing software accompanying this tool has an automatic calculation of the volumes and the different perimeters of the foot. The measurement time by the scanner is less than 4 seconds.
76052212|NCT02254772|Drug|SD-101|Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
76052213|NCT02254772|Radiation|Radiation therapy|Undergo low-dose radiation therapy to 1 site of disease
76052214|NCT02254460|Dietary Supplement|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
75436104|NCT01558687|Other|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
76052215|NCT02254460|Other|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
76052216|NCT01682044|Biological|pegfilgrastim|Given SC
76052217|NCT01682044|Biological|rituximab|Given IV
76052218|NCT01682044|Other|flow cytometry|Correlative studies
75436105|NCT01558713|Drug|Bupivacaine- Fentanyl - Normal Saline|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
75436106|NCT01558713|Drug|Ropivacaine-Fentanyl-Normal Saline|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
76052219|NCT01682044|Procedure|biopsy|Correlative studies
76052220|NCT01682044|Other|immunohistochemistry staining method|Correlative studies
76052221|NCT01682044|Genetic|western blotting|Correlative studies
76052222|NCT05640986|Behavioral|BART-EEG at V1 + V2|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 + V2 for Parkinsonian patients
76052223|NCT05640986|Behavioral|BART-EEG at V1 only|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 only for healthy volunteers
75584126|NCT04579263|Other|Fecal microbiota|Transplantation of fecal microbiota of healthy donor with normal body mass index
75584127|NCT04598906|Behavioral|Virtual environment rehabilitation|The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.
75584128|NCT04598906|Behavioral|Paper-pencil rehabilitation|The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.
75436107|NCT01558713|Drug|Levobupivacaine- Fentanyl- Normal Saline|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
75584129|NCT04579302|Procedure|Serratus anterior block (SAB)|Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
75584130|NCT04579302|Procedure|Erector spinae block|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
75730229|NCT05019274|Other|Culinary Medicine Intervention|Participants randomized to the Culinary Medicine intervention will complete a series of 6 virtual culinary medicine cooking classes (1 class per month for 6 months). Virtual sessions will be delivered via Zoom using a combination of large group instruction and small group break-out sessions in which participants prepare a recipe in their home kitchen with the virtual assistance from trained group facilitators. After preparing the dish, participants will enjoy the dish they prepared and report-back to the large group about their dish and experience. Classes will be conducted in English and Spanish with language-concordant instructors and facilitators.
75881417|NCT03136367|Other|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
75436108|NCT01558713|Drug|Bupivacaine + Fentanyl|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
75436109|NCT01558713|Drug|Ropivacaine + Fentanyl|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
75436110|NCT01558713|Drug|Levobupivacaine + Fentanyl|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
75584131|NCT04579302|Drug|Saline (as a placebo)|Patients will receive a sham block with 20 ml saline (as a placebo)
75881418|NCT03136367|Other|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
75881419|NCT04419337|Drug|Metformin plus Pioglitazone plus an SGLT2 inhibitor|Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.
75436111|NCT01558726|Behavioral|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
75436112|NCT01558726|Behavioral|Usual Treatment|The usual treatment used for regular patients of CAPSad
75436113|NCT01558765|Other|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
75584132|NCT04579302|Drug|Bupivacaine|bupivacaine
75584133|NCT04598867|Drug|CD-008-0045|CD-008-0045 20 mg capsules
75584134|NCT04598867|Drug|Placebo|Placebo capsules
75584135|NCT04598867|Drug|Afobazol|Afobazol 10 mg tabletes
75584136|NCT00573300|Procedure|Phlebotomy|Single blood draw
75584137|NCT04578795|Device|Single use flexible ureteroscopy (PUSEN-OLIMPUS)|single use flexible ureteroscopy
75584138|NCT00565682|Drug|etoricoxib 120 mg|etoricoxib 120 mg, tablet, orally, OD
75584139|NCT00575952|Drug|Cisplatin|Given IV or IP
75584140|NCT00575952|Drug|Doxorubicin Hydrochloride|Given IV
75584141|NCT00575952|Biological|Filgrastim|Given SC
75584142|NCT00575952|Drug|Paclitaxel|Given IV or IP
75584143|NCT00575952|Biological|Pegfilgrastim|Given SC
75584144|NCT00565799|Procedure|Omentectomy|Removing the omentum
75584145|NCT00565799|Other|No intervention|Only LAGB without Omentectomy
75584146|NCT00573417|Drug|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
75584147|NCT00573417|Drug|Placebo|
75584148|NCT00565838|Procedure|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
76052224|NCT05651204|Diagnostic Test|GABA Blood Level|Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.
76052225|NCT05640596|Drug|Betamethasone|
75730230|NCT05019274|Other|Standard of Care Nutrition Visits|Participants randomized to standard of care nutrition visits will complete a series of 6 nutrition visits (1 session per month for 6 months) led by bilingual (English/Spanish) dieticians. Sessions will consist of a mix of individual and small group sessions per standard of care in the clinic.
75584149|NCT00573456|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
75584150|NCT00565877|Other|Ultrasound inspection|post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
75881420|NCT03124381|Device|Cleanser, Acne Mask|A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
75881421|NCT03124381|Device|Cleanser, Gel-Cream, Acne Mask|A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
76052226|NCT05651126|Drug|Psilocybin 5 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
76052227|NCT05651126|Drug|Psilocybin 2 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
76052228|NCT05651126|Drug|Placebo|Inactive placebo
76052229|NCT01696942|Drug|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
76052230|NCT01696942|Drug|Mesalamine|mesalamine 800 mg orally three times daily
76052231|NCT05494814|Other|Child Care Centers Served Meals Prepared by Central Kitchen|The child care centers who are served by the central kitchen will receive meals that include locally sourced fresh fruits and vegetables to serve their staff and children.
75436114|NCT01558778|Procedure|management of therapy complications|Undergo mechanical stimulation
75436115|NCT01558778|Procedure|musculoskeletal complications management/prevention|Undergo mechanical stimulation
75436116|NCT01558817|Behavioral|Informed Assent|Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
75436117|NCT01558817|Behavioral|Informational Brochure|An informational brochure about CPR will be given without a discussion with a physician.
76052232|NCT05651048|Other|Control Group|Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
76052233|NCT05651048|Other|BEMER Group|BEMER therapy and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
75436118|NCT01558830|Drug|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
75436119|NCT01558830|Drug|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
75584151|NCT00573495|Biological|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
75584152|NCT00565955|Drug|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; > 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
75584153|NCT00565955|Drug|Placebo|The patients will receive placebo tablets.
75584154|NCT04598594|Drug|Patch, Nicotine|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
75584155|NCT04598594|Drug|Patch, Placebo|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
75584156|NCT00575991|Dietary Supplement|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
75584157|NCT04598243|Dietary Supplement|Smart Energy System|A nutritional /herbal combination
75584158|NCT00576030|Other|hab cof with water|habitual coffee drinker provided with water
75584159|NCT00576030|Other|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
75730231|NCT05006443|Diagnostic Test|Cardiac Magnetic Resonance|a non-invasive assessment to determine severity of tricuspid regurgitation
76052234|NCT05651048|Other|Kinesiotape Group|Kinesiotape application and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
76052235|NCT05493020|Other|Questionnaires set|"At baseline, the children's demographics, disease-related data, characteristics of Mukbangwatching behavior, appetite, nutritional status, and quality of life data were collected. From the first day of radiotherapy or chemotherapy, 3 meals a day for 5 consecutive days were followed to track the children's appetite status and the characteristics of Mukbangwatching behavior. Their nutritional status and quality of life were tracked at the end of treatment or when they were discharged from the hospital."
76052236|NCT05485922|Device|Investigational device - intermittent catheter with a micro-hole zone|The investigational device was a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
76052237|NCT05485922|Device|Comparator device -VaPro intermittent catheter|The comparator device is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
75584160|NCT00576030|Other|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
75584161|NCT00576030|Other|non-hab cof with water|non-habitual coffee drinkers given water
75584162|NCT00576030|Other|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
75584163|NCT00576030|Other|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
75436120|NCT01558856|Procedure|Unilateral electrode placement and testing|An electrode is placed near a sacral nerve with an anal motor response under general anesthesia. During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
75584164|NCT04579341|Dietary Supplement|probiotics|probiotics administration
75436121|NCT01558856|Procedure|Bilateral electrode placement and testing|Two electrodes are placed, one near each sacral nerve under general anesthesia. During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters. This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
75436122|NCT01558869|Drug|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
75436123|NCT01558869|Drug|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
76052238|NCT04871204|Drug|Octreotide Injection|10 mg Sandostatin LAR intramuscular injection
76052239|NCT05619770|Drug|101-PGC-005|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
75436124|NCT01558869|Drug|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
75436125|NCT01558882|Device|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
75584165|NCT04598126|Other|Traditional physical therapy|Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
75584166|NCT04598126|Other|patient education manual +traditional physical therapy|"Patient educational Manual~+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/"
75584167|NCT00573573|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
75436126|NCT01558895|Radiation|Infrared ray heat treatment|Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
75436127|NCT01558895|Other|conventional treatment|Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
75436128|NCT01558908|Biological|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
75436129|NCT01558934|Drug|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
75584168|NCT00576108|Drug|KD7040 Topical Gel|KD7040 topical gel
75584169|NCT00576108|Drug|Placebo gel|Placebo gel
75584170|NCT00565994|Procedure|Blood Draw|For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
75584171|NCT00573612|Behavioral|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
75584172|NCT00573612|Behavioral|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
76052240|NCT05612828|Behavioral|Conventional versus simulation manikin training|Two approaches to training Combat Life Savers will be employed and performance of participants will be evaluated.
76052241|NCT04857710|Device|Wide-pulse neuromuscular electrostimulation (WP NMES)|The WP NMES program consists of electrical stimulation trains of 1000 symmetrical biphasic pulses (1 ms, 100 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s. A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé).
75584173|NCT00566033|Behavioral|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
75584174|NCT00573651|Other|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
75584175|NCT00566072|Behavioral|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
75584176|NCT04597970|Drug|cTACE-HAIC|transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
75584177|NCT00573690|Drug|carboplatin|Given IV
75584178|NCT00573690|Drug|cisplatin|Given IV
75584179|NCT00573690|Drug|etoposide|Given IV
75584180|NCT00573690|Drug|pemetrexed disodium|Given IV
75436130|NCT01558947|Drug|Peri-operative chemotherapy of ECX|Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4~6 weeks after surgery.
75584181|NCT00573690|Drug|sorafenib tosylate|Given orally
75584182|NCT04597814|Other|No Intervention|No Intervention
75584183|NCT00576225|Drug|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
75584184|NCT00576225|Drug|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
75584185|NCT04597853|Diagnostic Test|Assessment of lung mechanics and heart-lung interactions|Impedance tomography, right-heart catheterization, oesophageal pressure measurements, indirect calorimetry and classic mechanical ventilation parameters
75436131|NCT01558947|Drug|Peri-operative chemotherapy of XP|Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4~6 weeks after surgery.
75436132|NCT01558960|Drug|IVit Melphalan|IVit injections of Melphalan
75584186|NCT00573807|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
75436133|NCT01558986|Procedure|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
75584187|NCT04597931|Drug|Romosozumab|SC Romosozumab 210 mg/monthly
75584188|NCT04597931|Drug|Zoledronic Acid|IV Zoledronic acid 5 mg
75584189|NCT00576459|Drug|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
75584190|NCT00576459|Drug|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
75584191|NCT00576459|Procedure|standard of care laser photocoagulation|standard of care laser photocoagulation
75592002|NCT06076655|Other|EXERCISE AND MOBILIZATION PROGRAM|"EXERCISE AND MOBILIZATION PROGRAM The Hallux Valgus exercise program determined by the physiotherapist will be applied twice a week in the rehabilitation unit under the supervision of a physiotherapist. Each exercise and mobilization will be planned as 2 sets of 10 repetitions and 15 seconds between sets, and will be carried out throughout the interval for 12 weeks. In addition, home exercises will be given twice a day, and each exercise will be followed in 2 sets of 10 repetitions with a 15-second interval between sets.~The exercise and mobilization program planned to be implemented in this study for children with diplegic cerebral palsy is an exercise and mobilization program that has yielded positive results in various studies in adults. We created a sample protocol with exercise and mobilization practices that were found effective in these studies."
75881422|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
75584192|NCT04597736|Biological|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine|"Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.~For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.~For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology."
75584193|NCT04597775|Drug|hydroxychloroquine|hydroxychloroquine
75730232|NCT05005429|Drug|Bintrafusp alfa|"Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required."
75730233|NCT05002270|Drug|JAB-21822 (KRAS G12C inhibitor)|Administered orally
75730234|NCT05002270|Drug|JAB-21822 (KRAS G12C inhibitor)|Administered orally
75730235|NCT05002270|Drug|JAB-21822 (KRAS G12C inhibitor)|Administered orally
75436134|NCT01558986|Procedure|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
75436135|NCT01559025|Drug|Vildagliptin|Vildagliptin ( Galvus 50mg twice day) during one year
75436136|NCT01559051|Procedure|Lipoaspiration with Local anesthesia|Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
75436137|NCT01559077|Drug|ALN-TTR02|Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
75436138|NCT01559077|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
75436139|NCT01559103|Biological|MEDI5117|Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
75436140|NCT01559103|Biological|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
75436141|NCT01559142|Drug|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
75436142|NCT01559142|Drug|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
75584194|NCT00573885|Drug|defined green tea catechin extract|Given orally
75436143|NCT01559168|Device|UpholdTM LITE placement|Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
75730236|NCT05002270|Drug|Cetuximab (EGFR inhibitor)|Administered IV
75730237|NCT04995588|Other|Blood test|Unique blood draw of 45mL for all the participants
75730238|NCT04990323|Biological|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single UM171-Expanded CB transplant (CD34+: 2.5-50x10^5/kg, CD3+>1x10^6/kg)
75584195|NCT00573885|Other|placebo|Given orally
75584196|NCT00573924|Drug|Proton pump inhibitor (lansoprazole)|"120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~90 mg IV bolus followed 9 mg/hr infusion for 24 hrs"
75584197|NCT04597229|Dietary Supplement|Instant multigrain supplement|A twice daily instant multigrain supplementation for 12 weeks
75584198|NCT04579809|Procedure|4 strand technique|4 strand technique reapir of tendin flexor injury
75584199|NCT04579770|Dietary Supplement|Ketone ester|75g ketone ester in the form of a drink [96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)] will be provided.
75730239|NCT04989647|Radiation|No adjuvant therapy|Patients will not receive any type of adjuvant therapy.
76052242|NCT04857710|Device|Conventional neuromuscular electrostimulation (CONV NMES)|"The CONV NMES program consists of electrical stimulation trains of 500 symmetrical biphasic pulses (0.2 ms, 50 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s (duty cycle: 1/3). A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.~During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé)."
75436144|NCT01559194|Behavioral|Low Fat Diet plus exercise|Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
75584200|NCT04579770|Other|Sodium bicarbonate|Sodium bicarbonate - widely accessible food ingredient will be provided.
75584201|NCT04579770|Other|Placebo|Placebo
75730240|NCT04989647|Radiation|Adjuvant radiotherapy|Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
75730241|NCT04989348|Procedure|Gonadotrophin releasing hormone antagonist protocol|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger or
75730242|NCT04989348|Procedure|Progestin-primed ovarian stimulation protocol|Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
75730243|NCT04965064|Drug|Capecitabine and Neratinib.|Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
75436145|NCT01559194|Behavioral|Low Carbohydrate diet + Exercise|Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
75436146|NCT01559220|Device|Deep Brain Stimulation|Implanted device
75436147|NCT01559233|Device|FPlus RF device for wrinkles and rhytide reduction|Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
75584202|NCT00576498|Other|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
75584203|NCT00576498|Other|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
75584204|NCT04597463|Procedure|Endometrial injury|Endometrial injury was performed hysteroscopically after freeze all cycles and during the cycle before the frozen embryo transfer
75592003|NCT06076421|Other|Fact box|Fact boxes provide a tabular or graphical overview of the benefits and harms of the COVID-19 or influenza vaccination through transparent risk communication. The fact boxes are available for two different age groups each: COVID-19 vaccination for people aged 18 to 59 and over 60, influenza vaccination for people aged 16 to 64 and over 65 in Arabic, German, Russian and Turkish.
75592004|NCT06075784|Other|reiki|placebo reiki
75730244|NCT04952584|Biological|CD30.CAR-EBVST cells|"The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10^8 cells/m2 and we did not reach a MTD.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Day 0 of study, patients will receive their planned single dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL."
76052243|NCT04857710|Device|Control (CONT) modality|Control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations.
76052244|NCT05478746|Device|BioNourish, a component of the Flourish HEC kit|BioNourish is a vaginal moisturizing gel which obtained FDA 510k clearance in 2020. It is one component of the full system being tested. The main intervention is to use this kit to improve the vaginal microbiome.
76052245|NCT05478746|Other|Control - no intervention|No intervention; participants only receive routine care.
76052246|NCT05465798|Drug|MC 3x3|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
76052247|NCT05465798|Drug|Placebo|Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
75436148|NCT01559272|Drug|Paliperidone IR (Period 1)|Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
75436149|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 1)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
75436150|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 2)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
75584205|NCT04578990|Other|Walking intervention|"It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.~Depending on the data obtained in Visit 1, the speed will be determined for each patient and the degree of the initial slope that is comfortable when walking until it induces symptoms of moderate intermittent claudication. The progression of the intensity of the speed and incline of the slope will be increased progressively and individually for each patient."
75584206|NCT04578990|Other|Strength intervention|The training program consists of performing a training program with resistance exercises for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied. The same guidelines will be followed as in the walking exercise, but in this case, applying force stimuli. If symptoms of moderate intermittent claudication occur (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain disappears at the level of the lower limb. This sequence will be repeated until the strength training session is completed. The progression of force stimuli will be increased weekly depending on the subjective perception of the patient's effort and according to the guidelines set by our group of investigation.
75730245|NCT04938024|Dietary Supplement|Vitamin C|Vitamin C is a commercially available over-the-counter food supplement.
75730246|NCT04912895|Device|PneumoniaCheck|Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
75730247|NCT04899778|Drug|Oral Contraceptive Pill, norethindrn a-e estradiol-iron|tablet
75730248|NCT04892706|Drug|IDP-126 Gel|Gel applied to face once daily in the evening.
75730249|NCT04892706|Drug|IDP-126 Vehicle Gel|Gel applied to face once daily in the evening.
75730250|NCT04892706|Drug|Epiduo® Forte Gel|Gel applied to face once daily in the evening.
75730251|NCT04880772|Other|Prehabilitation|exercise & multivitamin (nutritional/dietary advice)
75730252|NCT04872517|Device|Meridian Electroacupuncture Analysis Device (MEAD)|use MEAD to detect energy change in patient with head and neck cancer
75730253|NCT04870762|Other|Best Practice|Receive standard of care
75730254|NCT04870762|Other|Medical Device Usage and Evaluation|Wear 3D printed oral stent
76052248|NCT04860596|Behavioral|collaborative health management model|nursing education program
76052249|NCT05650424|Other|Abdominal massage training|please refer to group description
76052250|NCT05650268|Drug|Vitamin D3|Receiving 576000 international units in single oral dose of liquid vitamin D 3~7 days prior to the surgery.
76052251|NCT05650268|Other|95% MCT|95% MCT supplement 3-7 day before surgery
76052252|NCT05577494|Other|Questionnaire online|"Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual."
75584207|NCT04578990|Other|Concurrent intervention|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli. If claudication symptoms occur moderate intermittent (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain in the lower extremity disappears. This sequence will be repeated until the 20 minutes established to end the session are completed concurrent training. The progression of the strength and resistance stimuli will be increased weekly depending on the perception subjective effort of the patient and according to the guidelines established by our research group.
75881423|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
75881424|NCT01354769|Device|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
75881425|NCT01352273|Drug|MEK162 + RAF265|
75881426|NCT01352351|Behavioral|Breastfeeding promotion intervention|"Breastfeeding counseling during monthly microcredit meetings~Weekly cell phone messages about breastfeeding"
75881427|NCT05189093|Drug|Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection|"In the phase I dose escalation part:it is planned to recruit patients with relapsed/refractory advanced lymphoma, and 4 doses will be explored: 7.5mg/kg, 15mg/kg, 22.5mg/kg and 30mg/kg dose groups. once every two weeks (Q2W), every 14 days is a dosing cycle.~Recommend Phase II dose based on the results of Phase I dose escalation part."
75436151|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 1)|Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
75436152|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 2)|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
75584208|NCT04597385|Other|Long-term Follow-Up|No intervention
75584209|NCT00573963|Drug|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
75584210|NCT00573963|Drug|saline solution|2 injections of 20mL plain saline solution - one on each side.
75584211|NCT04597034|Procedure|AN69-Oxiris|To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.
75584212|NCT04597034|Procedure|AN69-Standard|Standard treatment.
75881428|NCT03620279|Behavioral|Magic camp intervention|Hand-arm bimanual motor skills training
75881429|NCT04006717|Device|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
75881430|NCT04006717|Procedure|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
75584213|NCT00576615|Drug|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
75730255|NCT04862208|Dietary Supplement|Maltodextrin supplement|maltodextrin (25g in 12 oz water) 1 hour pre-exercise
75730256|NCT04862208|Dietary Supplement|Whey supplement|whey (25g in 12 oz water) 1 hour pre-exercise
75730257|NCT04862208|Dietary Supplement|Water|non-caloric control (12 oz flavored water) 1 hour pre-exercise
75730258|NCT04862208|Dietary Supplement|Maltodextrin supplement|maltodextrin (25g in 12 oz water) with no exercise
75584214|NCT00576615|Drug|propofol|"On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.~Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks."
75584215|NCT00576771|Procedure|PSV|Pressure Support Ventilation
75584216|NCT00576771|Procedure|NAVA|Neurally Adjusted Ventilatory Assist
75584217|NCT00576771|Procedure|patient-controlled|assisted controlled MV through a button
75881431|NCT01371097|Other|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
75584218|NCT04596761|Device|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
75584219|NCT04596761|Device|Control placebo with no RF|Placebo control, toothbrush with no RF
75436153|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 3)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
75436154|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 4)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
75730259|NCT04860128|Behavioral|Sports technology application|Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.
75436155|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 5)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
75436156|NCT01559272|Drug|Paliperidone palmitate F016|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
75584220|NCT00574041|Drug|Interferon beta-1a|injected, once a week
75584221|NCT04596956|Drug|sodium bicarbonate Ringer injection|Used in surgery
75584222|NCT04596956|Drug|Lactated Ringer's solution|Used in surgery
75730260|NCT04858789|Behavioral|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This transdiagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase well-being by targeting cognitive and behavioral changes.
75730261|NCT04857658|Procedure|extraction orthodontic treatment plan|patients will be referred for extraction of the upper and lower first premolars then orthodontic treatment will follow.
75730262|NCT04855903|Device|Covirtua Cognition software|Cognitive training with Covirtua Cognition software
75730263|NCT04848740|Device|ReLex-smile|Using VisuMax femtosecond laser we created the stromal pocket with diameter of 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 130 μm from corneal surface and 4 mm superior incision. Hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values We noticed during intervention that implantation of fresh lenticule depends from corneal thickness, for example if c.th.is 300-400 μm we implanted 1/2 stroma, if c.th.is 400 μm or more we implanted 1/3 stroma Example: if corneal thickness is 300 μm we implanted 150 μm (becoming 450 μm) we added more stroma due to more live keratocytes and stromal steam cells, aiming to overcome dead and non-functional keratocytes
75881432|NCT01371175|Biological|DNA.HIVA|0.5mg DNA.HIVA or placebo
75881433|NCT01371175|Biological|MVA.HIVA|5x10^6 pfu MVA or placebo
75730264|NCT04843982|Drug|Esketamine hydrochloride|After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
75436157|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 1)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
75436158|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 2)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
75436159|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 3)|Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
75436160|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 4)|Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
75436161|NCT01559285|Drug|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
75436162|NCT01559285|Drug|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
75436163|NCT01559285|Drug|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
75436164|NCT01559298|Drug|Aspirin (80 mg/d) + clopidogrel (75 mg/d)|Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
75436165|NCT01559298|Drug|Aspirin|Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
75436166|NCT01559324|Device|ECT|Bifrontal ECT, low dosage
75436167|NCT01559324|Device|ECT|Right unilateral electrode position, high dosage
75584223|NCT04597073|Procedure|Initial Periodontal Therapy|Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
75584224|NCT04596722|Dietary Supplement|Pomella|"Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts"
75584225|NCT04596722|Other|Placebo|"White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts"
75730265|NCT04836390|Drug|Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions|Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
75730266|NCT04833699|Other|rubber water bag|bboiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol)
75436168|NCT01559337|Procedure|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
75436169|NCT01559350|Procedure|A right gastroepiploic artery in situ grafting|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
75436170|NCT01559350|Procedure|A saphenous vein grafting|A saphenous vein grafting in the right coronary artery system during OPCAB
75881434|NCT01371175|Biological|MVA.HIVA|5x10^7 pfu MVA or placebo
75436171|NCT01559402|Procedure|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
75584226|NCT00576849|Drug|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
75584227|NCT00576849|Drug|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
75881435|NCT01371175|Biological|MVA.HIVA|2.5x10^8 pfu MVA or placebo
75881436|NCT04208815|Other|Milk Polar Lipids|Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
75881437|NCT04208815|Other|Milk Fat|Effects of the addition of 20 g milk fat.
75584228|NCT00576849|Drug|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
75584229|NCT00566189|Procedure|Roux-en-Y Bypass Gastroplasty|Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
75730267|NCT04827940|Other|Progressive relaxation exercise with music|"The progressive relaxation technique includes exercises for the muscles in the body to consciously contract and relax together with deep breathing exercises while sitting comfortably or lying down accompanied by music.~Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients did the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients were taught to do the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music."
75730268|NCT04824599|Procedure|PECS II|Pectoral nerves block (PECS II) is performed with the help of ultrasound. Two injection are performed in two fascial planes. One between pectoralis major muscle and serratus anterior muscle. Second one between pectoralis major and minor muscles.
75881438|NCT01371253|Other|Nintendo wii balance training|
75881439|NCT01371253|Other|EVA-soles|
75881440|NCT04036045|Other|Cardiac MRI|Patients will have a cardiac MRI at four time points during the study
75584230|NCT00576888|Other|no intervention|no intervention - observational only
75584231|NCT00566267|Drug|simvastatin 20 mg/ezetimibe|see protocol
75730269|NCT04824599|Procedure|Local anesthetic infiltration|Ropivacaine is administered by surgeon prior to scrubbing and following the removal of the tumor.
75881441|NCT04036045|Other|Echocardiogram|Patients will have an echocardiogram at four time points during the study
75436172|NCT01559402|Procedure|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
75436173|NCT01559402|Procedure|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
75436174|NCT01559415|Other|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
75584232|NCT00574314|Other|No Intervention|Participants will be consented.
75584233|NCT00566306|Other|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
75881442|NCT04036045|Other|Blood Draw|Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing.
75881443|NCT01371331|Drug|Tacrolimus granules|oral
75436175|NCT01559415|Other|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
75436176|NCT01559428|Dietary Supplement|Plant sterol-enriched margarine|Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
75730270|NCT04824599|Procedure|Subcutaneus local anesthetic infiltration|Ropivacaine is administered by the surgeon at the end of surgery
75881444|NCT03972865|Other|EmbrunMan race|The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres. Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
75881445|NCT01366339|Drug|Oral methylnaltrexone|
75881446|NCT01366339|Drug|Oral placebo|
75881447|NCT03133793|Drug|CoQ10|Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
75584234|NCT00574353|Radiation|Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission|You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
75730271|NCT04824599|Drug|Ropivacaine|Local anesthetic ropivacaine is administered in both study arms according to the study protocol
75730272|NCT04824599|Device|bk medical Flex Focus 500 Ultrasound Machine|Ultrasound with linear probe is performed. Using in-plane technique a correct placement of the injection needle is secured.
75584235|NCT04596839|Drug|Remdesivir|Remdesivir INN 100 mg lyophilized powder for infusion
75584236|NCT04596839|Other|Standard of Care|Standard of Care Treatment for COVID-19 Infection
75584237|NCT00574392|Device|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
75730273|NCT04817800|Drug|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|It will be nasaly administered
75730274|NCT04807218|Behavioral|Virta Health|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
75730275|NCT04804839|Other|First research arm|Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.
75730276|NCT04804839|Other|Second research arm|Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.
76052253|NCT05092178|Behavioral|calorie restricted diet and exercise|The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.The exercise intervention consists of aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for≥2 d•wk for six months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d•wk, while, resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d•wk, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d•wk. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video.
75584238|NCT04596371|Other|pure pulmonary ground glass nodules in women preparing for pregnancy|pure pulmonary ground glass nodules in women preparing for pregnancy
75584239|NCT00574431|Other|Data Collection|Collection of patient data before implementation of a nutritional management protocol
75584240|NCT00574431|Other|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
75584241|NCT04596683|Procedure|Same-day NSM or SSM|Discharge home same-day after nipple-sparing mastectomy (NSM), or skin-sparing mastectomy (SSM)
75584242|NCT00574470|Drug|daclizumab, infliximab|Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
75584243|NCT04596527|Drug|18F-FMPP|18F-FMPP were injected into the patients at rest (2.5 mCi) and during stress (6.0 mCi) for an individual subject before PET/CT scans.
75584244|NCT00577161|Drug|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
75584245|NCT00577161|Drug|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
75584246|NCT04596332|Other|no intervention measures|Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
75436177|NCT01559428|Dietary Supplement|Plant stanol-enriched margarine|Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake
75436178|NCT01559428|Dietary Supplement|Control margarine|Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
75584247|NCT04579497|Other|38°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 38°C, followed by a ten-minute post-intervention rest period.
75584248|NCT04579497|Other|40°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 40°C, followed by a ten-minute post-intervention rest period.
75881448|NCT03133793|Drug|D-Ribose Oral Powder|Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
76052254|NCT05092178|Behavioral|exercise alone|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
75436179|NCT01559441|Dietary Supplement|Beetroot Juice with oral fat load|140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)
75436180|NCT01559441|Dietary Supplement|Carbohydrate control drink with oral fat load|140 mL (low-nitrate) carbohydrate control drink
75436181|NCT01559467|Other|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
75436182|NCT01559467|Other|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
75584249|NCT04579497|Other|42°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 42°C, followed by a ten-minute post-intervention rest period.
75584250|NCT04579497|Other|38-42°C rising temperature footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water. Water temperature starts at 38°C and is increased by 1°C every 6 minutes, resulting in 42°C after 30 minutes. The footbath is followed by a ten-minute post-intervention rest period.
75584251|NCT04596605|Other|T2309|Food for Special Medical Purpose / 4 capsules daily for 12 weeks
75584252|NCT04596605|Dietary Supplement|Nutrof Total|2 capsules daily for 12 weeks
75584253|NCT04596488|Drug|Efavirenz 400mg|HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
75584254|NCT00574626|Procedure|PBSCT|Peripheral Blood Stem Cell Transplant
75584255|NCT00574626|Procedure|Bone Marrow Transplant|Bone Marrow Transplant
75881449|NCT03133793|Other|Placebo pills|Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
75584256|NCT04596566|Other|Therapeutic diet Intervention|The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
75584257|NCT00574665|Other|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
75584258|NCT04578717|Procedure|Air-abrasion|A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm
75584259|NCT04578717|Procedure|Adhesive application - Etch&rinse|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .
75584260|NCT04578717|Biological|Adhesive application - Self-etch|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
75730277|NCT04804839|Other|Third research arm|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
75584261|NCT04595942|Drug|Midodrine Hydrochloride Tablets|Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).
75584262|NCT04595942|Drug|Fludrocortisone Acetate Tablets|Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.
75730278|NCT04804813|Drug|Cabozantinib|Cabozantinib tablets
75730279|NCT04802408|Combination Product|Shampoo and saline|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
75436183|NCT01559480|Drug|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
75436184|NCT01559480|Drug|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
75436185|NCT01559519|Drug|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
75436186|NCT01559545|Drug|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
75436187|NCT01559545|Drug|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
75436188|NCT01559545|Drug|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
75730280|NCT04802408|Combination Product|Saline and Listerine|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
75730281|NCT04802408|Combination Product|Shampoo and Listerine|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
75730282|NCT04802408|Combination Product|Saline and Saline|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
75730283|NCT04776720|Behavioral|Yoga Practice Program|3 month group yoga classes
75584263|NCT04595942|Behavioral|Lifestyle modification|Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
76052255|NCT01640366|Device|PICO|Single-use Negative Pressure Wound Therapy System
76052256|NCT01640288|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
75730284|NCT04776720|Behavioral|Physical Conditioning Program|3 month group physical conditioning classes
75730285|NCT04749693|Device|DBLG1 System|Use of DBLG1 System in real life condition
75730286|NCT04740593|Other|Orthoptic care with the prescription of glasses from age 12-18 months onwards|Children assigned to the intervention group (group 1) will receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, and glasses, based on accurate determinations of refractive error by retinoscopy in cycloplegia by the study orthoptists at age 12-18 months. The spectacles for the children in this study will be provided by the study via their optician without costs.
75881450|NCT03133793|Other|Placebo powder|Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
75881451|NCT05190601|Device|uroflowmetry|Qmax(ml/s),Qav(ml/s),Volume (ml)
76052257|NCT01640288|Other|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
76052258|NCT04688996|Diagnostic Test|Lateral Flow Assay for Pathogens of the Plague|A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
76052259|NCT04835870|Drug|Zanubrutinib|Zanubrutinib-160mg bid PO d0-d20(1-21d)
76052260|NCT04835870|Drug|Rituximab|Rituximab-375 mg/m2 i.v d0 (/21d)
76052261|NCT04835870|Drug|Cyclophosphamide|Cyclophosphamide-750 mg/m2 i.v d1 (/21d)
76052262|NCT04835870|Drug|Doxorubicin|Doxorubicin-50 mg/m2 i.v d1 (/21d)
76052263|NCT04835870|Drug|Vincristine|Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)
76052264|NCT04835870|Drug|Prednisone|Prednisone-100 mg p.o d1-d5 (/21d)
75436189|NCT01559558|Procedure|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
75584264|NCT00566384|Drug|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
75584265|NCT00566384|Drug|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
75584266|NCT00574743|Drug|Enteric-coated Mycophenolate Sodium|
76052265|NCT01639040|Drug|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
76052266|NCT01639040|Drug|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
76052267|NCT01639040|Other|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
75584267|NCT04596020|Other|Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)|Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
75584268|NCT04578366|Device|Extracorporeal Shockwave Therapy|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
75584269|NCT04578366|Other|Conventional Treatment|hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
75584270|NCT04596059|Other|Frisolac Gold Intensive HA|Regular medical care
75436190|NCT01559584|Radiation|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
75584271|NCT04596176|Other|Program Supportive Housing Services|The existing statewide SH model that included routine access to housing (voucher) and case management
75584272|NCT04596176|Other|Intensive Supportive Housing Services|an intensive treatment SH model with a higher dosage of case management, family teaming, and access to a vocational specialist
75584273|NCT04596137|Behavioral|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
75730287|NCT04740593|Other|Orthoptic care without the prescription of glasses from age 12-18 months onwards|Children with high refractive error in the control group (group 2) will also receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, but they will not receive glasses.
75730288|NCT04740593|Other|First measurement only|Children who have no or mild refractive error (group 3), the majority of all children, will be examined by the study orthoptists only once at the age of 12-18 months, after which youth health care (YHC) physicians and nurses will continue standard vision screening at CHCs, as part of screening for general health disorders and vaccinations. Visual acuity is measured routinely at 42-48 months as part of standard vision screening.
75436191|NCT01559584|Drug|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
75436192|NCT01559597|Biological|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
75436193|NCT01559610|Other|Intervention Group|The patients were instructed by a nurse
75584274|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
75584275|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
75436194|NCT01559623|Procedure|retrospective data analysis|retrospective data analysis
75436195|NCT01559636|Biological|bivalent oral polio vaccine|vaccine given during immunization campaigns
75584276|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
75730289|NCT04725890|Device|The DyaMX Device|The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
75881452|NCT01318421|Drug|ELND002|
75436196|NCT01559662|Dietary Supplement|Sugared Chewing Gum (Juicy Fruit)|One stick of gum, 3 times daily from Postoperative day 1 to 7
75584277|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
75584278|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
75730290|NCT04712318|Procedure|Relex Smile|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
75436197|NCT01559688|Behavioral|Accelerated Resolution Therapy (ART)|ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.
75584279|NCT03453645|Procedure|ventricular tachycardia ablation|The usual organization of hospitalization of the patients addressed for ventricular tachycardia ablation and his follow-up are not modified by the protocol. .
75584280|NCT04595708|Behavioral|Phone Call|Calls were made by volunteers trained to engage with participants. Call structure was unscripted and call length was recommended to be between 5-10 min.
75730291|NCT04712318|Procedure|Relex smile with fresh corneal lenticule implantation|"VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule.~The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.~In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values."
75730292|NCT04695054|Device|Buzzy device plus EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure
75730293|NCT04695054|Drug|Only EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure
76052268|NCT04687904|Behavioral|Mindfulness meditation training|Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
75436198|NCT01559688|Behavioral|Waitlist|Fitness assessment or career counseling
75436199|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
75436200|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
75436201|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
75584281|NCT03453606|Other|Home respiratory rehabilitation|Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.
75730294|NCT04694482|Other|Psychometric scale administration|PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups
75730295|NCT04693663|Procedure|Relex-Smile surgery|surgery using Relex-Smile
75730296|NCT04675151|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
76052269|NCT04687904|Behavioral|Therapeutic education|"Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.~The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.~No specific instructions will be given at the end of this interview."
75436202|NCT01559740|Drug|Bupivacaine|This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
75730297|NCT04675151|Drug|Pilocarpine|Pilocarpine ophthalmic solution
75730298|NCT04675151|Other|Placebo|Topical sterile ophthalmic solution
76052270|NCT05421338|Drug|BI 456906 (C-14)|BI 456906 (C-14)
75584282|NCT03453606|Other|Center respiratory rehabilitation|"In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician"
75584283|NCT04595669|Behavioral|Personalised advise|personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
75584284|NCT04595552|Other|language therapy|auditory training and language therapy for 6 months up to 2 years in 2 session per week the duration of session 30 minuets
75584285|NCT03453411|Other|Non interventional study|Non interventional study
75584286|NCT04595357|Procedure|Iris shelf technique|Removal of posterior segment intraocular foreign bodies through corneal incision combined with phaco-vitrectomy
75584287|NCT04595318|Drug|Standard clinical care and varenicline|Standard clinical care includes methadone clinic-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
75436203|NCT01559753|Drug|Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~Beta-Lactams:~Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~Ceftriaxone : 2 g OD during 3 days, then 1 g OD~Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
75436204|NCT01559753|Drug|compare 8 to15 days of antibiotic treatment|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~Ceftriaxone : 2 g OD during 3 days, then 1 g OD~Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
75436205|NCT01559831|Biological|IXIARO|Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
75436206|NCT01559883|Other|no intervention is being made|This is a Non-Interventional Study (NIS)
75436207|NCT01559896|Dietary Supplement|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
75436208|NCT01559909|Device|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
75584288|NCT04595318|Other|Standard clinical care|Standard clinical care includes methadone clinic-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies
75436209|NCT01559961|Drug|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
75584289|NCT04595396|Procedure|Laparoscopic Gastric Bypass|The LGBP was performed using a classic Roux-en-Y procedure. Briefly, a gastric pouch of 30-50 cc was constructed with an antecolic calibrated gastro-jejunal anastomosis (mechanical anastomosis using a 2.5 mm load). The biliary and alimentary limbs measured ≈70 cm and ≈150 cm, respectively, and the jejuno-jejunal anastomosis was also performed in a latero-lateral fashion (mechanical anastomosis using a 2.5 mm load). Mesenteric defects were closed with running non-absorbable sutures and the omentum was divided in every case
75584290|NCT03453333|Procedure|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
75584291|NCT03453333|Procedure|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
75584292|NCT00566423|Other|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
75436210|NCT01559974|Drug|Placebo|Placebo to 45'000 units of Cholecalciferol per month for 3 months
75436211|NCT01559974|Drug|Cholecalciferol|45'000 units of cholecalciferol per month for 3 months
75436212|NCT01559987|Other|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
75584293|NCT01149343|Biological|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
75584294|NCT04595240|Diagnostic Test|semen analysis|semen analysis
75584295|NCT04578561|Procedure|Prophylactic mesh use|After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
76052271|NCT05400746|Biological|Pfs48/45 in Matrix-M|Three doses of Pfs48/45 in Matrix-M at different doses
75436213|NCT01559987|Other|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
75436214|NCT01559987|Other|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
75436215|NCT01560117|Drug|Rituximab|Rituximab 375 mg/m2 i.v. every 2 months for 24 months
75436216|NCT01560533|Behavioral|Interviews|Interviews will be done with patients
75436217|NCT01560845|Procedure|Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery|Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery
75584296|NCT04595162|Biological|GC019F|GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
75584297|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation~Check head and cannula position~Increase mean arterial pressure~Increase pump flow~Increase systemic oxygenation~Increase PaCO2 > 45~Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~Consider PRBC transfusion for Hct < 21%"
76052272|NCT04834310|Drug|Cefazolin|All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.
75436218|NCT01560845|Procedure|open abdominal portal hypertension surgery|the modified Sugiura procedure was performed for the patients
76052273|NCT04834310|Drug|Cephalexin|The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
76052274|NCT04834310|Other|Placebo|The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
76052275|NCT05397782|Device|BioNourish, a component of Flourish HEC|BioNourish, one of three parts of the Flourish HEC system, is a vaginal moisturizing gel - a Class II medical device with FDA 510k clearance obtained in 2020.
75436219|NCT05570669|Drug|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) full dose|Taking the colonoscopy preparation drug (Clensia) in a single administration
75436220|NCT05570669|Drug|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose|Taking the colonoscopy preparation drug (Clensia) in two stages of administration
75436221|NCT05570643|Drug|LPS|This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.
75436222|NCT05570643|Drug|Placebo|Injection of NaCl 0.9%.
75436223|NCT05570552|Behavioral|mHealth based behavioral change communication intervention|We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.
75436224|NCT05570474|Dietary Supplement|Protein drink supplementation|Daily drink containing 20 grams of whey protein, dissolved in 200mL water.
75436225|NCT05570474|Dietary Supplement|Placebo|Daily placebo drink
75584298|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
75584299|NCT04594967|Other|Patient-centred care home (PCMH)|New model of care defined by care provision by a team of people centered in the community that is both proactive and coordinated to improve the health and wellness of the people in that community.
75584300|NCT00624988|Procedure|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
76052276|NCT05060042|Other|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week
76052277|NCT05060042|Other|Bilateral proprioceptive training|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
76052278|NCT05390606|Combination Product|Flourish HEC and BioGenesis|Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.
76052279|NCT05372198|Drug|Chohort 1: Surufatinib|Surufatinib 300mg, qd, every 3 weeks as a cycle
75436226|NCT05570461|Other|Modified Constraint-Induced Movement Therapy|Experimental group will receive Modified Constraint-Induced Movement Therapyand traditional physical therapy to the impaired upper limb based on the repetitive training of functional activities and behavioral shaping and a task-oriented approach, while the unaffected arm of subjects in the mCIMT group will be constrained by wearing a mitten during the treatment session and for 3 hours/day outside the therapy hours, 6(six) days/week for two weeks by an experienced Physical therapist.The time duration for Group A will be 40 minutes.
75436227|NCT05570448|Procedure|ARAT|For patients randomized to ARAT intervention, the area of cardia, along greater curvature will be cleaned followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC (30W, Effect 2) using the H-APC catheter. Next, the area of cardia, on either side will be injected in sequence using a methylene blue (0.5%) and normal saline (0.9%) using the H-APC catheter jet system (Effect 30-70). Next, the mucosa, starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W till golden-brown discoloration of the ablated tissue in 270-320 degree. For patients randomized to control or sham intervention, upper endoscopy with procedural sedation was performed followed by markings of landmarks followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time. No H-APC or submucosal injection or other intervention will be performed.
75436228|NCT05570448|Procedure|Sham intervention (control)|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
75436229|NCT05570383|Drug|Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).|The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
75730299|NCT04674670|Drug|Bromocriptine Mesylate Capsules|Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
76052280|NCT05372198|Drug|Chohort 2: Immunotherapy|Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
76052281|NCT05372198|Drug|Chohort 2: Surufatinib|Surufatinib 250mg, qd, every 3 weeks as a cycle
76052282|NCT05359406|Combination Product|a combination therapy including tislelizumab|"For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx. Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w, i.v). For patients with RAS or BRAF mutation, chemotherapy adopts FOLFOX+BEV plan. For patients without RAS or BRAF mutation, chemotherapy adopts FOLFIRI+CET plan.~Patients will be followed for safety during the study. The safety follow-up period is defined as 90 days after the last dose of tislelizumab. Safety related data will be collected from the time of signing the informed consent until the end of the safety follow-up period or the start of new therapy."
76052283|NCT01640054|Drug|Fostamatinib|Fostamatinib 100mg once daily
75436230|NCT05570370|Other|This is an observational study|This is an observational study
75436231|NCT05570357|Dietary Supplement|Berberine+Cinnamon|The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract, and trace amounts of vitamins and minerals
75881453|NCT02747238|Device|Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
75436232|NCT05570357|Other|Placebo|Placebo contains Maltodexterin
75436233|NCT05570331|Diagnostic Test|HPV integration test|HPV-positive patients who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT.
75436234|NCT05570318|Drug|Polyethylene Glycols|To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
75881454|NCT02747238|Procedure|No ultrasound|Palpation of anatomical landmarks is used for placement of labor analgesia
75436235|NCT05570318|Device|Low volume trans anal irrigation|To be administered rectally on a daily basis throughout the study period (6 weeks) along with an adjusted dose of polyethylene glycols
75436236|NCT05570201|Other|Control group|No intervention was applied to the women in the control group, only the questionnaires (pre-test, post-test) were filled out. Filling the questionnaires lasted 10-15 minutes on average in all groups
75436237|NCT05570175|Behavioral|Mobile application RA joint protection and activity self-management program|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
75436238|NCT05570110|Drug|Enoxolone|one capsule of active or placebo in the evening
75436239|NCT05570084|Drug|Silodosin|Cap silodosin for medical expulsion therapy
75436240|NCT05570084|Drug|Tamsulosin|Cap tamsulosin
75436241|NCT05570045|Dietary Supplement|Colos Gain|"Dietary Supplement: Colos Gain Colos Gain is a nutrient product made by VITADAIRY Dairy Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~Direction: Mix 5 spoons of Colos Gain (equal to 45 grams) with 180 ml of warm water (50˚C) which provides 210kcal (The energy density reaches 1kal/ml). Consume 2-3 glasses per day or follow the directions from the medical supervisors.~The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
75436242|NCT05570019|Procedure|Revascularization|Open surgery (arterial endarterectomy with or without bypass surgery) and/or angioplasty (with or without stent placement)
75436243|NCT05569993|Drug|Glutamine|.3 mg/kg of glutamine
75436244|NCT05569993|Other|Placcebo|Patients will recieve placcebo
75436245|NCT05569967|Other|Spinal stabilization training through telerehabilitation|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
75436246|NCT05569967|Other|Spinal stabilization training face-to-face|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
75436247|NCT05569850|Other|Brushing|Brushing the teeth 2x a day for 4 weeks.
75881455|NCT02747238|Procedure|Epidural infusion|An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
75881456|NCT03133481|Procedure|Adductor Canal Nerve Block|Adductor Canal never technique
75881457|NCT03133481|Drug|Femoral Nerve Block|Traditional technique
75881458|NCT01366573|Drug|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
75881459|NCT01366573|Other|Placebo|Placebo
76052284|NCT04654208|Drug|palbociclib|patients on palbociclib combination treatment
76052285|NCT05360420|Diagnostic Test|Immediate CEUS|Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
75436248|NCT05569824|Diagnostic Test|Lateral-flow Device|An additional amount of 0.1-0.2 ml (2-4 drops) of bronco-alveolar lavage (BAL) fluid will be collected during the bronchoscopy which is carried out as part of the standard of care. The LFD test will be carried out on the BAL fluid collected.
76052286|NCT04844216|Device|STYLAGE® L Lidocaine|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
76052287|NCT04844216|Device|Active control|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
76052288|NCT05345678|Drug|Durvalumab|Dose: 1500mg Route: IV
75436249|NCT05569785|Other|Resistance Exercise Therapy|"4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only."
75436250|NCT05569720|Drug|ApTOLL|"ApTOLL will be administered as follows:~Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.~Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.~Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection."
75436251|NCT05569707|Device|Magnetic sentinel lymph node biopsy by use of Magtrace®, in combination with SentiMag® and DiffMag|In addition to the standard procedure, SLNs will be detected using two types of magnetometers (SentiMag® & DiffMag) in combination with SPIO particles (Magtrace®).
75436252|NCT05569668|Drug|Paclitaxel- and platinum-based chemotherapy|Neoadjuvant Chemotherapy
75584301|NCT04313101|Other|withdrawl of blood samples for thyroid function testing|"Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~Euthyroid ( Normal TSH, FT3 and FT4)~Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels."
75584302|NCT00577668|Drug|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
75584303|NCT04313179|Other|Music therapy|Mozart lullaby music
75730300|NCT04674670|Drug|Amisulpride 400 MG|Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
75730301|NCT04674670|Drug|Placebo|Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
75730302|NCT04666259|Drug|ABL001|Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
76052289|NCT05345678|Drug|Tremelimumab|Dose: 300mg Route: IV
75584304|NCT04313179|Other|Sucrose|0.5 ml of 24% Sucrose
75881460|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age.
76052290|NCT05345288|Device|BrainHQ cognitive training|"Posit Science's BrainHQ exercises are based on the science of neuroplasticity, also called brain plasticity. Brain plasticity is your brain's natural ability to remodel itself throughout life. The brain is always changing, sometimes for better, and sometimes for worse. What BrainHQ's exercises do is harness that change and direct it in ways that can enhance your overall performance and improve the quality of your life. BrainHQ exercises are grouped into six categories: Attention, Memory, Brain Speed, Intelligence, People Skills, and Navigation."
76052291|NCT05345288|Device|BrainHQ control games|BrainHQ also offers control games for research studies. The control activities will be games similar to candy crush, connect four, gem swap and battleship.
76052292|NCT05335070|Drug|Temporo-masseteric Nerve Block|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
76052293|NCT05327738|Biological|Atezolizumab|Given IV
76052294|NCT05327738|Procedure|Biopsy|Undergo biopsy
76052295|NCT05327738|Drug|Cabozantinib S-malate|Given PO
76052296|NCT05327738|Radiation|Yttrium Y 90 Glass Microspheres|Given intra-arterially
75730303|NCT04639674|Drug|AST-120|If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
75730304|NCT04629547|Drug|Suvorexant 20 mg|Suvorexant 20mg will be taken nightly for 24 months.
75730305|NCT04629547|Drug|Placebo|Placebo will be taken nightly for 24 months.
75730306|NCT04620174|Other|Custom-made zirconia crowns|Ten decayed primary molars will be restored with custom-made zirconia crowns.
75881461|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.
75881462|NCT05190289|Other|Pre-existing degenerative factors of paraspinal muscles and bone mass|Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
75881463|NCT05124509|Biological|Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)|Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
75881464|NCT05124509|Biological|Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)|Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
75881465|NCT02864316|Drug|Nivolumab|
75436253|NCT05569655|Drug|Tolvaptan|Within 12 hours of admission, subjects were randomly assigned to two groups using the central randomization method. For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide:20-40mg/d). The treatment lasts for a total of seven days to assess the efficacy and safety of tolvaptan in the treatment of PAH-induced right heart failure.
75436254|NCT05569655|Drug|Furosemide|Within 12 hours of admission, traditional standard therapy (furosemide:20-40mg/d) is used for all subjects in our clinical trial. The treatment lasts for a total of seven days.
75436255|NCT05569616|Other|Hand massage|Hand massage is a simple comfort intervention that involves touch and conveys care that can easily be incorporated independently into routine nursing care activities. Hand massage is a western technique that includes five basic classical massage manipulations, including eufluorage, petrissage, friction, tapotman and vibration. Kolcaba et al. (2006) hand massage procedure will be applied with baby oil for 20 minutes, three times a week (12 times in total) for 4 weeks.
75730307|NCT04620174|Other|Prefabricated zirconia crowns|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
75730308|NCT04616144|Device|Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser|Fresh Corneal Lenticule Implantation using ReLex-Smile
75730309|NCT04604314|Device|CEREC Tessera|Full ceramic endocrown restorations will be made from the high strength ceramic, CEREC Tessera
75730310|NCT04604301|Device|Celtra Quatro|Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro
75730311|NCT04599907|Device|Roll-In Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for 10 subjects
75730312|NCT04599907|Device|Randomized Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group
75730313|NCT04599907|Device|Randomized Cohort: Single Application of Sham Patch|Single Application of Sham Patch in both axillae for subjects randomized to the control group
75584305|NCT04595084|Behavioral|Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|MBCT-R is designed to foster resilience and prevent new-onset anxiety and depression disorders or exacerbation of existing conditions. MBCT-R follows the MBCT structure of eight classes and one half-day retreat, with home practice and specific daily meditation, but is live-online and focuses on specific stressors (COVID-19, its economic and social consequences). Classes of 40-50 participants are led by 2 co-leaders. Participants have CHA MindWell Monitoring and telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a televisit with a clinician. If monitoring with CAT-MH interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
75584306|NCT04595084|Behavioral|Internet Cognitive Behavioral Therapy plus CHAMindWell|MoodGYM is based on CBT and interpersonal therapy targeting depression, anxiety, stress, and general psychological distress. MoodGYM has 6 sessions with five curriculum modules and a review session that can be completed within an 8-week period. iCBT participants will also be enrolled in CHA MindWell Monitoring and Support (CHA-MW). Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a televisit with a clinician. If there are difficulties with accessing iCBT technology or if monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
75584307|NCT04595084|Behavioral|CHAMindWell|Participants across arms will have CHA MindWell Monitoring and Technician support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a televisit with a clinician. If monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
75584308|NCT00577785|Other|tissue procurement|No intervention. Tissue procurement study.
75584309|NCT01148017|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
76052297|NCT04419662|Drug|Phenylephrine|"Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect."
75584310|NCT04594928|Drug|GLPG3667|GLPG3667 capsules
75584311|NCT04594928|Drug|Placebo|Matching placebo capsules
75584312|NCT00577902|Other|Observation|Head and neck cancer patients receiving chemoradiation
75584313|NCT01147900|Biological|Boostrix™|Intramuscular, single dose
76052298|NCT04419662|Other|Combination of PEEP and positioning|"Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees."
76052299|NCT04614740|Drug|VC004|25 mg capsules,50 mg capsules,100 mg capsules.
75436256|NCT05569616|Other|Play activity|The number of people for the Jenga game was determined as two people in order to strengthen the social relationship among the elderly and to strengthen their psychomotor skills. Each game will be played with two people. For this reason, the elderly will be divided into five separate groups, two people each.These groups will be played the Jenga game for one hour a week on a certain day of the week, accompanied by the researcher, during the activity hours determined by the nursing home. After the game activity (Jenga) application is completed at the end of the fourth week, the post-test scales will be re-administered to the elderly by the researcher.
75730314|NCT04598074|Other|Opioid Package Prototype (OPP)|The Opioid Package Prototype (OPP) is a child-resistant/senior-friendly, calendar-blister packaging of limited pill counts with flat readable billboard space for medication labeling.
75730315|NCT04598074|Other|Usual Care (standard amber vial)|The standard amber vial (orange bottle) is the container that medication is normally dispensed in outside of the study.
75730316|NCT04596293|Drug|BBT-401-1S or Placebo|Administered by 200mg capsules of BBT-401-1S or placebo
75730317|NCT04594512|Other|Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery|A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
75730318|NCT04593186|Procedure|Trans-oral magnifying endoscopy with NBI|"Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure."
75730319|NCT04592887|Radiation|FLASH Radiotherapy|FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
75881466|NCT03941509|Behavioral|Antimicrobial stewardship|Education, guidelines, communication tools and audit and feedback
75881467|NCT01364077|Drug|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
75881468|NCT01364077|Drug|Placebo|Matched placebo
75436257|NCT05569603|Behavioral|Chronobiology-guided lifestyle interventions|1) timed bright light exposure using blue-enriched white light glasses, 2) recommendations for meal timing, and 3) sleep hygiene education
75436258|NCT05569590|Drug|Propolis|Vital tooth bleaching will be performed and Propolis as a desensitizing agent will be applied after bleaching to reduce dentine hypersensitivity.
75730320|NCT04585750|Drug|PC14586|First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.
75730321|NCT04585750|Drug|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
75881469|NCT05190133|Drug|UIC201602 and co-administration of UIC201601 and UIC201602|"UIC201602 4 Cap/day for 14 days~Wash out 21 days~UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
75881470|NCT05190133|Drug|UIC201601 and co-administration of UIC201601 and UIC201602|"UIC201601 4 Tab/day for 7 days~Wash out 14 days~UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
75881471|NCT02862600|Drug|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
75881472|NCT02862600|Device|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
75881473|NCT01359137|Behavioral|Probation as usual|Routine probation with do deferred jail condition.
75584314|NCT01147900|Biological|Boostrix™-US formulation|Intramuscular, single dose
75584315|NCT04594850|Biological|Cellgram-ED|Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
75584316|NCT04594889|Procedure|angioplasty|Balloon releasing a drug inflated in the target vessel
75730322|NCT04580667|Other|Collection of plasma samples|Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
75730323|NCT04580251|Procedure|Targeted axillary dissection|The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
75730324|NCT04574167|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
75730325|NCT04574167|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
75881474|NCT01359137|Behavioral|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
75881475|NCT01359137|Behavioral|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
76052300|NCT05353088|Other|scapular stabilization|Scapular stabilization exercise aims to restore scapular position, orientations, motor control of muscles, and movement pattern, thereby attaining stability of scapula for better kinematics of shoulder.scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II)
75881476|NCT01364155|Drug|LIM-0705|
75881477|NCT01364155|Drug|Placebo capsules|
75881478|NCT05189899|Device|Virtual reality|One hemodialysis session with virtual reality and one other without it
75881479|NCT01354847|Device|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
75881480|NCT03767101|Behavioral|Cognitive behavioral therapy|In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
75881481|NCT01359527|Device|Hip Resurfacing|
75881482|NCT01359527|Device|Total Hip Arthroplasty|
76052301|NCT05353088|Other|Thoracic extension exercises|Thoracic extension involves concurrent posterior rotation (external torsion) and depression of the posterior ribs with elevation of the anterior ribs. Bending to the side is a combination of spinal segments side bending, ribs on the same come together while ribs on the opposite side separate.Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
75436259|NCT05569590|Drug|hydrogen peroxide 35%|hydrogen peroxide 35%
75436260|NCT05569590|Other|fluoride varnish|fluoride varnish
75436261|NCT05569577|Drug|Additional hCG injection|An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
75436262|NCT05569577|Drug|estrogen and dydrogesterone|estrogen and dydrogesterone
75436263|NCT05569564|Procedure|Ridge splitting followed by ossedensificaion|Ridge splitting followed by ossedensificaion with osseodensifying burs.
75584317|NCT01147744|Drug|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
75584318|NCT01147744|Drug|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
75584319|NCT01147744|Drug|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
75584320|NCT01147744|Drug|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
75584321|NCT01147744|Drug|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
75584322|NCT01147744|Drug|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
75584323|NCT01147744|Drug|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
75584324|NCT01147744|Drug|Placebo montelukast|Placebo capsule once daily in the evening
75584325|NCT01147744|Drug|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
75584326|NCT01147744|Drug|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
75730326|NCT04570930|Behavioral|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity [step] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
75730327|NCT04570930|Behavioral|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period.
75584327|NCT04594460|Device|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
75584328|NCT04594460|Device|OLO-1 Medical Molecular Sieve Oxygen Generator|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
75584329|NCT04594655|Procedure|surgery|colectomy
75730328|NCT04570371|Behavioral|Conversation Guide + Clinical Support|The intervention is a bundled intervention (conversation guide + clinician decision support tools) which promotes the solicitation and use of patient preferences for post-surgical, non-pharmacological pain management strategies.
76052302|NCT05351918|Other|acupuncture|Acupuncture points are punctured with needles.
76052303|NCT04589546|Drug|Nicotinamide treatment|Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.
76052304|NCT04589546|Drug|placebo treatment|For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
75730329|NCT04567264|Device|StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).|"Regimen 1 (weeks 0-12): one stimulation every 2 days, for a duration of 30 minutes each.~Regimen 2 (weeks 12-24): Three stimulation treatments per week, for a duration of 30 minutes each."
76052305|NCT01600586|Device|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
75730330|NCT04564703|Drug|Iberdomide|IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
75730331|NCT04562805|Device|DynamX Bioadaptor|DynamX Bioadaptor Treatment
76052306|NCT04411238|Other|interview|interview
76052307|NCT01639742|Device|New texture round breast implants|Breast implant surgery
75730332|NCT04562805|Device|Resolute Onyx|Resolute Onyx Treatment
75730333|NCT04555226|Procedure|Lymph node dissection|Open/minimaly invasive pelvic and para-aortic lymph node dissection
75436264|NCT05569564|Procedure|Osseodensification|Pilot drill is used to make the initial osteotomy to the desired depth, then osseodensifying burs will be used in sequence, gradually wider diameter in a counterclockwise rotation and bouncing motion under profuse saline irrigation
75436265|NCT05569473|Procedure|TEST GROUP: VCMX + OFD, CONTROL GROUP : OFD ONLY|A full-thickness mucoperiosteal flap will be raised, no bone recontouring would be performed, Thorough debridement of the surgical site would be performed. For the test group, VCMX would be placed according to the dimensions of the intrabony defect after open flap debridement (OFD). For the control group, OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
75436266|NCT05569460|Other|No intervention|No intervention
75584330|NCT00625027|Other|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
75584331|NCT04594577|Device|Fluispotter|Fluispotter automated blood sampling system applied for venous blood sampling of 20 10 μL samples in a 20 hours sampling session.
75584332|NCT04313374|Drug|Morphine PCA 1 mg|PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
75584333|NCT04313374|Drug|Morphine PCA 0,5 mg|PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
75584334|NCT04313374|Drug|Placebo|the PCA will contain placebo
75584335|NCT04594148|Behavioral|Weight-shift training|Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
75584336|NCT00577980|Drug|Testosterone|Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
75584337|NCT05219578|Drug|RTX-224|RTX-224 monotherapy
75436267|NCT05569434|Drug|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
75436268|NCT05569369|Procedure|angioplasty and stenting|dilatation of stenotic arteries and insertion of stent
75436269|NCT05569356|Biological|Prospective|-Additional blood samples -Myocarditis biopsy sample (routine care) -Additional pericardial fluid sample (routine care)
75436270|NCT05569356|Other|Retrospective|None (only data collection)
75436271|NCT05569343|Other|No intervention|This is an observational study without any intervention
75436272|NCT05569330|Other|Air purification|Aerosol particles are removed from room air by several methods
75436273|NCT05569304|Procedure|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty
75436274|NCT05569239|Biological|OVX836 480µg|One single administration intramuscularly at Day 1.
75436275|NCT05569239|Biological|Saline Solution|One single administration intramuscularly at Day 1.
75584338|NCT01147471|Device|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
75584339|NCT01147471|Procedure|operative rib fixation surgery|
75584340|NCT04594343|Drug|Disulfiram|The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
75584341|NCT04594343|Drug|Placebo|The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
75584342|NCT00578019|Procedure|IM Nailing|Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith & Nephew supracondylar nail.
76052308|NCT05416736|Procedure|The bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins. Maneuvers will be performed by the researcher. Infants in both groups will be held under the armpit by a parent, male infants will be held in the drooping legs, and female infants will be held in the hip flexion position.
75584343|NCT00578019|Procedure|LISS|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
75584344|NCT04594304|Behavioral|Behavioral: Usual care plus eToolkit|A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
75584345|NCT04578483|Other|PCA group|Patients receiving PCA are allocated in PCA group despite the route of administration. Intravenous PCA is commonly used with morphine or fentanyl while epidural PCA is used with ropivacaine and/or fentanyl frequently.
75584346|NCT04578483|Other|ERDS group|After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
75584347|NCT01147393|Drug|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over ~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
75584348|NCT01147393|Biological|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
75584349|NCT00578058|Other|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
75584350|NCT02884024|Other|no intervention|there is no intervention in this study
75584351|NCT00566774|Other|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
76052309|NCT05416736|Procedure|Steril urine bag|Steril urine bag are attached to the genital area to collect urine samples
76052310|NCT04995380|Procedure|Early Cholecystectomy|Cholecystectomy performed within 10 days from onset of symptoms
76052311|NCT05291468|Radiation|FDG-PET/CT|Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
75584352|NCT00566774|Other|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
75584353|NCT00578097|Biological|Botulinum toxin type A|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
75730334|NCT04555226|Radiation|Standard chemoradiation|"A point/HCR-CTV D90 ≥80Gy（+20%）~Extended-field EBRT: image-positive common iliac lymph nodes with short diameter ≥10mm and/or image-positive para-aortic lymph node~Target doses for the image-positive nodes can range from 55 to 60Gy~Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~CCRT will be completed in 56 days~After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 < 96Gy) will be performed."
76052312|NCT04981496|Other|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs
76052313|NCT05274854|Behavioral|a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing|Pre consultation interventions consist of one of four intervention a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
76052314|NCT05274854|Behavioral|a) consultant-led outpatient clinic or b) a integrated care clinic|Consultation intervention consists of one of two interventions a) consultant-led outpatient clinic or b) a integrated care clinic
75584354|NCT00578097|Drug|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
76052315|NCT05347550|Other|Graduated Compression Stockings - Thromboembolic deterrent stockings|Centres randomised to the intervention arm will consist of participants receiving GCS.
76052316|NCT05415098|Drug|APG-5918|"The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.~The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study."
75584355|NCT04593797|Diagnostic Test|carotid blood flow measurement with ultrasound|carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
75584356|NCT00578370|Drug|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
75584357|NCT00578370|Drug|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
75584358|NCT00578370|Drug|0.1% betamethasone|Solution 200µl once a day (26 days)
75730335|NCT04555226|Radiation|Chemoradiation|"A point/HCR-CTV D90 ≥80Gy（+20%）~Extended-field EBRT: Pathlogical positive para-aortic lymph node~Target doese for pelvic and/or abdomal lymph nodes is usually 45Gy. After operation, the residual lymph node need to be labeled and the target doses for it ranges from 55-60Gy.~Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~CCRT will be completed in 56 days~After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 < 96Gy) will be performed."
75730336|NCT04525183|Behavioral|Enhanced Usual Care (EOC)|Educational materials
75730337|NCT04525183|Behavioral|REVITALIZE ACT Intervention|Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks
75436276|NCT05569213|Diagnostic Test|motor evoked potentials|see previous descriptions
75436277|NCT05569200|Device|Haifu Focused Ultrasound tumor therapeutic System|The device used in this trial will be Haifu Focused Ultrasound tumor therapeutic System. In Uterine benign tumor female, the investigators will observe the possibility of complication and tumor response of treatment.
75436278|NCT05569135|Device|Laser ablation|A diode-laser that has been reported to be safe and effective in several treatments including pilonidal disease, anal fistula, hemorrhoids, and vascular ablation was used to obtain shrinkage of pilonidal cyst
75436279|NCT05569109|Device|doppler ultrasound|doppler ultrasound on arteriovenous fistula in hemodialysis patients
75730338|NCT04523168|Device|The Neovasc Reducer™ System|A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
75730339|NCT04520451|Drug|rilzabrutinib|oral tablet
75730340|NCT04520451|Drug|Glucocorticoids|oral tablet or capsule
75436280|NCT05569096|Diagnostic Test|ELIZA , Flowcytometry|CD25 , CXCL9 by ELISA. T cell population , T regulatory cells by Flow cytometry.
75436281|NCT05569031|Drug|Venlafaxine|patients with tramadol abuse will use venlafaxine for 10 days.
75436282|NCT05569031|Drug|Lofexidine|patients with tramadol abuse will use lofixidine for 10 days.
75436283|NCT05568875|Other|e-self-management intervention (Happy Hands app)|"The 12-week intervention consists of 30 short informational videos addressing the themes prioritized by the patient research partners. These themes are further operationalized into the following categories: Information on hand OA, Hand exercises, Use of assistive devices and orthoses, Medication and surgical alternatives, and Self-management of the disease. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The intervention group will additionally receive treatment as usual."
75436284|NCT05568875|Other|Treatment as usual|Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.
75730341|NCT04519541|Device|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
75584359|NCT00578370|Drug|0.005% calcipotriol|Solution 200µl once a day (26 days)
75584360|NCT00578370|Drug|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
75436285|NCT05568823|Other|Blood sampling|Measurement of markers of disease evolution
75436286|NCT05568771|Other|Core Exercises Assisted Injury Prevention Training Program|After the exercises are fully taught to the athletes, the core training program will be applied on 3 non-consecutive days of the week, accompanied by a physiotherapist or athletic trainer, and the warm-up program will be applied before all trainings of the team, except before the match.The core program will take 20-25 minutes, and the warm-up program will take an average of 20-25 minutes. The exercises consist of an average of 45 minutes. This warm-up program includes running exercises, strengthening exercises, balance and proprioception exercises, and plyometric exercises.
75584361|NCT04593719|Other|Experiment|The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
75730342|NCT04507412|Drug|dexamethasone|perioperatively 9 mg i.v subministration
75881483|NCT01354925|Drug|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
75730343|NCT04503096|Device|High-dose accelerated rTMS|A MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System will be utilized. All participants will receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within an eight-day span. A single session = 600 pulses at 120% resting motor threshold (rMT), intermittent Theta Burst Stimulation (iTBS) triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 s to left dorsolateral prefrontal cortex. Total pulses = 14,400. To enable adherence and retention, the days do not need to be contiguous. Same day sessions will be separated by 10-15 minutes, but more accounting for participant comfort.
75730344|NCT04500795|Procedure|Middle meningeal artery embolization|"MMA embolization will be performed with a liquid embolization agent with local anaesthesia. Selective angiography will be performed before embolization to select MMA branch targets and detect potentially dangerous collateral vessels. If no dangerous collaterals are found, MMA branches supplying to the dura of convexity will be targeted and embolized according to findings of the selective angiography using a liquid embolization agent. If dangerous collaterals are identified, the microcatheter will be advanced more distally or the collaterals will be coiled prior to embolization. Procedure will be concluded once the flow stasis of MMA is confirmed. Embolization is considered successful if all MMA targets are embolized without procedural complications.~Patients with existing use of antiplatelet or anticoagulation medication will not undergo medication reversal for the embolization procedure."
75881484|NCT01354925|Drug|Standard of care|Standard of care during Ramadan according to physicians decision
75436287|NCT05568732|Procedure|Root coverage procedure will be done with VCMX|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.
76052317|NCT02164513|Drug|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
75584362|NCT04593836|Drug|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
76052318|NCT02164513|Drug|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
76052319|NCT02164513|Drug|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
76052320|NCT05369078|Drug|THR-1442 20mg Single dose|THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
76052321|NCT05369078|Drug|THR-1442 20mg Multiple dose group|THR-1442 20mg is administrated QD for 7days, then follow till day 14.
76052322|NCT04540016|Drug|[14C]HSK7653|25 mg of [14C]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
75584363|NCT04593836|Drug|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
75584364|NCT04578405|Procedure|Intracorporeal anastomosis|Anastomosis performed totally laparoscopically
75584365|NCT04578405|Procedure|Extracorporeal anastomosis|Anastomosis performed through a minilaparotomy
75584366|NCT04593368|Other|FMT|oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
75584367|NCT04593524|Dietary Supplement|vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
76052323|NCT04953338|Other|Exposure of mental health condtion of interest|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.
75584368|NCT04593524|Other|nutritional Counseling|control group (C) which only receives nutritional counseling for 28 days
75584369|NCT00578526|Drug|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
75584370|NCT00578526|Drug|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
75584371|NCT04593446|Drug|Oral Sulfate Tablet(ORA·FANGⓇ)|"Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery~Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery"
75584372|NCT04593446|Drug|Sodium Picosulfate Solution(PicosolutionⓇ)|Sodium Picosulfate Solution(PicosolutionⓇ)
75584373|NCT00578604|Device|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
75584374|NCT00566891|Drug|tirofiban|tirofiban high dose bolus 25µ/Kg
75584375|NCT00566891|Drug|Clopidogrel|
75584376|NCT00578682|Biological|MEDI-557|Single IV dose of 3 mg/kg
75584377|NCT00578682|Biological|MEDI-557|Single IV dose of 15 mg/kg
75584378|NCT00578682|Biological|MEDI-557|Single IV dose of 30 mg/kg
75584379|NCT00578682|Biological|MEDI-557|Single IV dose of 0.3 mg/kg
75584380|NCT04593485|Drug|Camrelizumab for injection|Carrelizumab will be administered at a fixed dose
75881485|NCT03812107|Other|Moderate Treatment Approach|The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
75584381|NCT04592900|Other|balance exercising|selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
75584382|NCT00578760|Drug|aspirin|325mg ASA OD for the duration of the cisplatin
75584383|NCT00578760|Drug|placebo|OD for course of cisplatin chemotherapy
75584384|NCT00578799|Dietary Supplement|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
75584385|NCT00578799|Dietary Supplement|placebo|placebo capsules (potato starch
75584386|NCT04592705|Device|Therapeutic plasma exchange|"TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP."
75584387|NCT00578838|Other|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
75584388|NCT00578838|Other|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
75584389|NCT04592822|Drug|WD-1602|dabigatran etexilate mesylate granules for oral suspension
75584390|NCT04592822|Drug|Pradaxa®|dabigatran etexilate capsules
75584391|NCT00578916|Drug|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
75584392|NCT00567047|Drug|vildagliptin|
75584393|NCT00578994|Device|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
75584394|NCT03454178|Diagnostic Test|WatchBP Office (BP measurement machine)|BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
75584395|NCT00579033|Other|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
75584396|NCT00579033|Other|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
75584397|NCT04578171|Drug|Mepolizumab|100 mg subcutaneous injections every four weeks
75584398|NCT03454139|Procedure|Subcostal transversus abdominis plane block|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
75584399|NCT03454100|Behavioral|multisectoral package of activities|A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
75584400|NCT03454061|Other|physical activity|Physical education program (PEP) of 16-week length
75584401|NCT00579267|Other|MINI-KID|Structured Diagnostic Interview for children and adolescent psychiatric disorders.
75881486|NCT03812107|Other|Intensive Treatment Approach|After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
76052324|NCT04524104|Behavioral|Lumen Treatment|the virtual AI agent, Lumen, via an iPad-based application. Each participant will receive a locked, encrypted study iPad installed with Lumen. They will complete 8 problem solving therapy (PST) sessions beginning with 4 weekly and then 4 biweekly intervals over 12 weeks on their assigned iPad.
76052325|NCT05232188|Procedure|Percutaneous nephrolithotomy|percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
76052326|NCT05337020|Other|Survey|Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
76052327|NCT05230706|Other|Cephalic helmet|An acrylic headgear (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm) was placed on the patient's head. The helmet was covered with surgical cloth (green or blue) folded into 50x60cm rectangles, leaving the front part open to maintain adequate airflow.
76052328|NCT05220488|Other|Assessment|Parameters such as physical activity and fear of covid will be evaluated in asthmatic and healthy children and adolescents.
76052329|NCT04513184|Drug|IV Dexamethasone|6 mg from Day 1 to 10 after randomization
76052330|NCT04513184|Drug|Nasal Dexamethasone|0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.
76052331|NCT04756531|Drug|PF-07321332 Dose 1|PF-07321332 Dose 1 or Placebo
75730345|NCT04497064|Other|survey|survey asking questions regarding breakfast habits and composition, sports nutrition knowledge and exercise habits
76052332|NCT04756531|Drug|PF-07321332 Dose 2|PF-07321332 Dose 2 or Placebo
76052333|NCT04756531|Drug|PF-07321332 Dose 3|PF-07321332 Dose 3 or Placebo
76052334|NCT04756531|Drug|PF-07321332 Dose 4|PF-07321332 Dose 4 or Placebo
75584402|NCT03453983|Device|Transcrainial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
75584403|NCT04593017|Dietary Supplement|Active Probiotic|Lactobacillus Reuteri (DSM 17938 and ATCC PTA 4659
75436288|NCT05568732|Procedure|Root coverage procedure will be done with CTG|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
75584404|NCT04593017|Other|Placebo Probiotic|Placebo
75584405|NCT03453294|Device|Apnoeic oxygenation using THRIVE|Apnoeic oxygenation using THRIVE
75584406|NCT03453294|Device|Endotracheal intubation and mechanical ventilation|Endotracheal intubation and mechanical ventilation
75584407|NCT04578054|Other|Flying transport|Patient care who requires flying transport
76052335|NCT04756531|Drug|PF-07321332 Dose 5|PF-07321332 Dose 5 or Placebo
75436289|NCT05568693|Biological|0.3ml of mRNA vaccine|Subjects received 0.3ml of mRNA vaccine intramuscularly
75436290|NCT05568628|Device|ultrasound|screening of breast lesions by ultrasonography
75436291|NCT05568251|Device|transcranial Direct Current Stimulation|Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
75436292|NCT05568251|Procedure|Cognitive training|Participants will be administered Game of Dice Task concurrent with the tDCS session
75436293|NCT05568108|Procedure|masseteric nerve to central branch facial nerve|masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
75436294|NCT05568108|Procedure|Masseteric nerve to free functioning muscle transfer|Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
75584408|NCT04592666|Drug|Almonertinib|the standard therapy of single agent almonertinib
75584409|NCT04592666|Drug|Pemetrexed|standard dose
75584410|NCT04592666|Drug|Carboplatin|AUC=5
75584411|NCT04577937|Diagnostic Test|LAM patients underwent PSG|Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
75584412|NCT04592939|Procedure|immediate weight bearing after surgery|immediate weight bearing
75436295|NCT05567445|Diagnostic Test|Echocardiography, CBC, Liver function, kideny function|Echocardiography, AST, ALT, UREA,CREAT. , CBC,may blood cultures.
75584413|NCT04592939|Procedure|6 weeks of toe-touch weight bearing after surgery|6 weeks of toe-touch weight bearing
75584414|NCT00579462|Other|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
75584415|NCT00579540|Dietary Supplement|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
75584416|NCT00579540|Dietary Supplement|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
75584417|NCT00579540|Dietary Supplement|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
75584418|NCT00579618|Other|Saliva or Blood samples|Extracting sample of saliva or blood only once.
75881487|NCT02864082|Drug|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
75881488|NCT02864082|Drug|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
75436296|NCT05566249|Device|ArtiSential|Articulating laparoscopic instrument
75436297|NCT05564975|Other||
75584419|NCT04592315|Drug|Lipovirtide Injection|Single dosage of Lipovirtide Injection
75584420|NCT00579657|Other|control diet, supported by dietary supplement twice daily|control diet, see above
75584421|NCT00579657|Other|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
75584422|NCT00579657|Other|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
75881489|NCT02864082|Drug|Vehicle for PAT-001 0.1%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
75881490|NCT02864082|Drug|Vehicle for PAT-001 0.2%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
76052336|NCT04756531|Drug|PF-07321332 Dose 4 or Placebo (Fed)|PF-07321332 Dose 5 or Placebo with high fat meal
75584423|NCT00579657|Other|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
75584424|NCT04592198|Drug|Palonosetron Hydrochloride Buccal Film 0.25 Mg|Dose equal to the iv control
75584425|NCT04592198|Drug|Palonosetron Hydrochloride Buccal Film 0.5 Mg|Dose twice that of iv control
75584426|NCT04592198|Drug|Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution|iv control
75584427|NCT04592432|Other|SIGN@L-A|Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).
75584428|NCT04592432|Other|SIGN@L-B|The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.
75584429|NCT00579774|Other|Low AGE Diet|Diet
75730346|NCT04494672|Procedure|Intramedullary nailing with ADAPT system|Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH & Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively
75436298|NCT05564741|Drug|Norepinephrine 1 MG/ML|As proxy for hypotension we record amount of Norepinephrine given during the study time of 30 minutes
75436299|NCT05560880|Behavioral|High Intensity Interval Gait training|Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.
75436300|NCT05560880|Behavioral|Moderate Intensity Interval gait training|subjects will walk for 20 minutes at theri best comfortable pace
75730347|NCT04494672|Procedure|Intramedullary nailing without ADAPT system|Intramedullary nailing without ADAPT system
75881491|NCT05091281|Device|Intubation of the double lumen tube by Macintoch laryngoscope|After induction of anesthesia insertion of the double lumen tube was done by Macintosh laryngoscope
75436301|NCT05556382|Radiation|radiation of brain tissue specimen and dna damage analysis|increasing doses of radiation on brain tissue specimen and analysis of related dna damage.
75584430|NCT00579774|Other|Regular Diet|Diet
75584431|NCT04592354|Dietary Supplement|Oxaloacetate Medical Food/Dietary Supplement|500 mg Anhydrous Enol-Oxaloacetate BID
75584432|NCT04592081|Drug|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
75730348|NCT04488926|Dietary Supplement|micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
75730349|NCT04488926|Other|Placebo microgranules 1800mg|Placebo was prepared to be indistinguishable from color and flavor from the Product
75730350|NCT04488926|Drug|Standard Therapy|(antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
75730351|NCT04488926|Drug|Rescue Drug|Use as needed allowed
75730352|NCT04485858|Device|CorNeat KPro|CorNeat KPro will be implanted into the subject's eye where the optic component snaps into the patient's trephined cornea and is sutured to the eye wall using 3 non-degradable sutures and the skirt component is placed under the conjunctiva
75730353|NCT04483739|Drug|Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
75881492|NCT05091281|Device|Intubation of the double lumen tube by Glidescope videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by GlideScope® videolaryngoscope
75584433|NCT00579852|Procedure|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
75730354|NCT04483739|Drug|Isatuximab Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
75881493|NCT05091281|Device|Intubation of the double lumen tube by C-MAC®(D) videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by C-MAC®(D) videolaryngoscope
76052337|NCT02218489|Drug|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
76052338|NCT02218489|Drug|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
76052339|NCT04419740|Behavioral|Mindfulness based psychological intervention|Women in the intervention group will have to use an application during 1 month. They will do meditation during 15 minutes each day.
75584434|NCT04591964|Combination Product|"mobile application M-Cardio based on android"|"Mobile apllication M-Cardio (android) for remote monitoring of patients with CHF developed on algorithms of clinical indicators, that's give us to evaluate current condition of patient, depends from quantity points of abnormals higher or lower threshold values, with automatically notification for doctor and patient for timely medical service."
75881494|NCT03556345|Drug|RC48-ADC|2.5 mg/kg IV every 2 weeks
76052340|NCT02192905|Behavioral|Diabetes Prevention Program Lifestyle Intervention|
76052341|NCT01713946|Drug|RAD001|Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
75730355|NCT04461535|Drug|Adrenocorticotropic hormone|Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
75730356|NCT04441099|Drug|NBE-002|NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
75730357|NCT04432012|Drug|Dexamethasone Sodium Phosphate 4 mg/ml intravenous|Perioperative intravenous injection of 3 ml of solution (9mg of dexamethasone)
75584435|NCT04592042|Behavioral|Feel-Good- Group|Eight sessions of group intervention focussing on information on emotion regulation, training of emotion regulation techniques and mindfulness.
75730358|NCT04432012|Drug|Dexamethasone Sodium Phosphate 4 mg/ml intra-articular|Perioperative intra-articular injection of 3 ml of solution (9mg of dexamethasone)
75730359|NCT04431479|Procedure|Biospecimen Collection|Undergo collection of blood sample
75730360|NCT04431479|Other|Medical Chart Review|Review of medical chart
75730361|NCT04431479|Other|Quality-of-Life Assessment|Ancillary studies
75730362|NCT04431479|Other|Questionnaire Administration|Complete questionnaire
75730363|NCT04420598|Drug|Trastuzumab deruxtecan|"After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.~In patients with hormone receptor (HR)-positive status (estrogen receptor [ER] and/or progesterone receptor [PgR]) administration of endocrine therapy is not allowed.~In patients allocated in study cohort 5, administration of intrathecal therapy is not allowe"
75436302|NCT05531084|Device|Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)|Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.
75436303|NCT05522582|Drug|Methotrexate tablets|Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
75436304|NCT05522582|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
75584436|NCT04591769|Device|Different tracheal tube cuff design|Comparison of effect between 2 different designs of tracheal tube cuff
75584437|NCT04591847|Drug|Vitamin D 2|Vitamin D2 20000IU 1 tab oral weekly
75584438|NCT04591847|Drug|Placebo drug|Placebo drugs 1 tab oral weekly
75584439|NCT00580086|Other|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
75730364|NCT04406103|Behavioral|Sleepwell|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
75730365|NCT04406103|Behavioral|Empower|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
75730366|NCT04369937|Radiation|IMRT (Intensity Modulated Radiotherapy)|Radiation therapy
75730367|NCT04369937|Drug|Pembrolizumab|A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
75730368|NCT04369937|Drug|Cisplatin|Chemotherapy
75730369|NCT04369937|Biological|ISA101b|ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.
75730370|NCT04364152|Behavioral|Dual-task walking training|Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
75730371|NCT04313738|Other|Assigned Interventions|Home visit, health education
75730372|NCT04312360|Drug|therapeutic endoscopy with metronidazole and fosfomycin disodium|therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
75881495|NCT03610230|Drug|Iron Isomaltoside|Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
75881496|NCT03610230|Drug|Iron sucrose|the currently most widely used intravenous iron preparation with good safety profile
76052342|NCT01713946|Drug|Placebo|Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
75584440|NCT04591535|Drug|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
76052343|NCT01713946|Drug|Antiepileptic drug (1 to 3 only)|no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
76052344|NCT01713946|Drug|open label RAD001 (only used for post-extension phase)|everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
75730373|NCT04290663|Drug|Systematic RAI-treatment|Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
75881497|NCT01359605|Drug|varespladib methyl|500 mg oral suspension
75436305|NCT05522582|Radiation|Radiotherapy|6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
75584441|NCT00580242|Drug|Bortezomib|First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
75881498|NCT01366963|Behavioral|Seated Measurements|"The following measurements will take place in a seated position:~Ruff 1 & 7 (visual search and attention processes) Trails A & B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
75881499|NCT01366963|Behavioral|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
75881500|NCT01366963|Behavioral|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
75881501|NCT03609684|Other|Gymnastic and Core Stabilization|People who regularly do gymnastics and also do 30-45 minutes core stabilization exercises
75881502|NCT03609684|Other|Only Gymnastic Training|People can do gymnastics twice a week but can't do core stabilization exercise
75881503|NCT03609684|Other|Sedentary Group|People who are not interested in any sports and don't do any exercises
75881504|NCT05188859|Drug|Sintilimab+Anlotinib+Pemetrexed+Cisplatin|Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2
75881505|NCT01367041|Procedure|vibration|Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
75881506|NCT02033538|Drug|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
75881507|NCT01364311|Dietary Supplement|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.~Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
76052345|NCT04916444|Device|rTMS|repetitive transcranial magnetic stimulation is a painless, noninvasive form of neurostimulation. This study uses an accelerated protocol in which the neurostimulation pulses are delivered in 4 sessions per day over 4 consecutive days (16 total sessions). Active or sham rTMS will be provided at 9 weeks following botox injections.
75436306|NCT05491304|Drug|Dexamethasone|Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.
75436307|NCT05491304|Drug|Etoposide|Used in severe group combined with etoposide.
75881508|NCT01319513|Other|whey protein bolus|single dose of 25 g whey protein
75436308|NCT05491304|Drug|Ruxolitinib|Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
75436309|NCT05453643|Behavioral|sleep deprivation patterns|Sleep deprivation patterns 1 (SDP1) ; total sleep deprivation for 24 hours followed by early morning sleep and an extended 17 hours wakefulness. Sleep deprivation patterns 2 (SDP2) : Sleep interrupted by two half-hour awakenings
75436310|NCT05435417|Radiation|CBCT radiation|CBCT scanning
75584442|NCT00580242|Drug|Bortezomib|Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
75584443|NCT00580242|Drug|Bortezomib|Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
75584444|NCT00580242|Drug|Lenalidomide|Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
75584445|NCT04591496|Behavioral|Behavioral change intervention;|Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.
75584446|NCT04591496|Behavioral|Health Education|Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
75584447|NCT00580281|Other|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
75584448|NCT04591457|Drug|Insulin Glargine Sansulin|Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose
75584449|NCT04591457|Drug|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
75584450|NCT00580320|Drug|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
75584451|NCT00567086|Drug|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
75584452|NCT00580359|Drug|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
75730374|NCT04290663|Other|Decision of RAI-treatment guided by a post-operative assessment|"The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:~No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy~1.1 GBq after rhTSH if Tg/LT4>1 ng/mL or rhTSH-sTg>10 ng/mL and normal diagnostic RAI-scintigraphy.~3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis~3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition"
75881509|NCT01319513|Other|whey protein pulses|10 2.5 g pulses of whey protein
75881510|NCT02792192|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in respective arm.
75881511|NCT02792192|Biological|Bacille Calmette-Guérin|For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
76052346|NCT04465136|Device|CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)|CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
76052347|NCT05329688|Procedure|novel nutrition program|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
76052348|NCT04464512|Drug|Sufentanil|IV buprenorphine plus IV sufentanil treatment group.
76052349|NCT04897412|Drug|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
75584453|NCT00580437|Procedure|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
75881512|NCT01359683|Device|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
76052350|NCT04897412|Other|Placebo|Sodium Chloride (0.9% NaCl) placebo for injection
76052351|NCT04849130|Procedure|Static reconstruction technique according to Schöttle|In static MPFL reconstruction, a graft (harvested autologous gracilis tendon or allogen transplant) is attached to the femoral and patellar bones using tunnels, screws, and/or anchors.
76052352|NCT04849130|Procedure|Dynamic reconstruction technique according to Becher|Dynamic MPFL procedure by detaching and reinserting only the distal part of a hamstring muscle to the patella and leaving the proximal tendon attached to its muscle. This way the patella position can be adjusted dynamically by hamstring contraction.
75584454|NCT04591340|Dietary Supplement|dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition|All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
75584455|NCT04591418|Device|Rotary handpieces|Dental Caries removal
75584456|NCT04591418|Device|Er:YAG laser|Dental Caries removal
75584457|NCT00580593|Device|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
75584458|NCT00580593|Other|sham-NIPPV|a sham-device
75584459|NCT04591145|Other|Observational group|Patient receive the standard bowel preparation strategy and routine colonoscopy
75881513|NCT05187949|Other|Mixed-method approach|Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
76052353|NCT05179148|Behavioral|Motivational Interviewing|MI is a client-centered counselling style for strengthening a person's own motivation and commitment to change. MI helps evoke the person's own motivation for changes through reflective listening, engaging, evoking, and planning
75584460|NCT00580749|Procedure|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
75584461|NCT00580749|Procedure|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
75584462|NCT04591301|Drug|HEC113995 PA•H2O tablets|Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
75881514|NCT03609996|Device|Panretinal Photocoagulation|Laser treatment for PDR
75881515|NCT03609996|Drug|Lucentis|Intraviteral injection
75584463|NCT04591301|Drug|Placebo tablets|Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
75584464|NCT04577625|Dietary Supplement|Lactobacillus reuteri (L. reuteri)|L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
75584465|NCT00580827|Drug|Placebo|Matched placebo.
75584466|NCT00580827|Drug|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
75584467|NCT00580827|Drug|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
75730375|NCT04289077|Other|Questionnaires|- Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
75730376|NCT04272372|Drug|Ketoprofen|PO and local therapy
75730377|NCT04270760|Drug|Olpasiran|Dose 1 Dose 2 Dose 3 Dose 4
75730378|NCT04270760|Drug|Placebo|Dose 5
75881516|NCT05178199|Behavioral|RPSG|The RPSG program include sharing successful experience, progressive muscle relaxation (PMR), and mindfulness-based stress reduction (MBSR). The duration is at last 8 weeks and includes 1 hour per week of RPSG activities.
75584468|NCT00580827|Drug|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
75584469|NCT00580905|Drug|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
75584470|NCT00580905|Drug|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
75592007|NCT06075329|Behavioral|Contemplative Practice|Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.
75730379|NCT04256473|Drug|mutant pro-urokinase|Intravenous administration
75730380|NCT04256473|Drug|Alteplase|Intravenous administration
75881517|NCT05178199|Behavioral|AVMBM|"The duration is also at last 8 weeks and includes encouraging to use 5 minutes Audio and Video Mindfulness of Breathing Meditation (AVMBM) per week."
75881518|NCT02088008|Drug|cinidipine, valsartan|
76052354|NCT05173766|Other|ergonomic principls|Ergonomic principles for posture correction in office for computer users.
75584471|NCT00580905|Drug|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
75584472|NCT00581022|Procedure|Polysomnography|Overnight Sleep Study
75584473|NCT04577664|Procedure|total thyroidectomy|a total thyroidectomy (TT) in which the entire gland is removed
75584474|NCT04577664|Procedure|subtotal thyroidectomy|subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.
75584475|NCT04591262|Drug|14C-PF-06826647-LR 600 mg PO|14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep
75584476|NCT04591262|Drug|PF-06826647 600 mg PO|Unlabeled PF-06826647 600 mg
75584477|NCT04591262|Drug|14C-PF-06826647 100 ug IV|14C-PF-06826647 100 ug IV
75584478|NCT00567203|Drug|PF-3463275|PF-3463275 10mg
75584479|NCT00567203|Drug|PF-3463275|PF-3463275 25mg
75584480|NCT00567203|Drug|Placebo|Placebo
75584481|NCT04590989|Other|Personalized Nutrition Plan|"Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~Personalized behavioral change program via electronic push notifications by ONMI"
75584482|NCT04590989|Other|Non-Personalized Nutrition Plan|"Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization)."
75584483|NCT04590638|Other|tumescent with adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.
75584484|NCT04590638|Other|tumescent without adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
75584485|NCT04590950|Other|Non interventional study|Non interventional study
75584486|NCT04590677|Other|Samples required from group 1 (procedure within observational study)|"Weekly maternal blood samples to be taken~Daily urine samples to be collected~One rectal swab at the initial visit only~Weekly vaginal swabs~Daily Heart rate monitoring (only applicable to a subset of women in group 1)"
75584487|NCT04590677|Other|Samples required from group 2 (procedure within observational study)|"Weekly maternal blood samples to be taken~Daily urine samples to be collected~One rectal swab at the initial visit only~Weekly vaginal swabs"
75584488|NCT04590755|Behavioral|Interactive father-child sessions and website|The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
75584489|NCT00567281|Device|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
75881519|NCT02033772|Procedure|Thoracoscopic surgery|
76052355|NCT02163499|Drug|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
76052356|NCT02163187|Device|Implantation of the InterStimTM|
75436312|NCT05419570|Other|Fluid Loading|Hemodynamic and ventilatory parameters will be recorded at five time points (T1 - T5). After baseline meausrements (T1), additional 5 cmH2O PEEP will be applied to patients for 30 seconds (short time low peep challenge, SLPC). Prior to PEEP lowering T2 measurement will be performed. T3 measurement will be performed one minute after PEEP is decreased to its initial value and will be recorded as the second baseline. Thereafter, 100 ml isotonic saline will be infused over one minute (MFC). T4 measurement will be performed one minute after MFC is completed,. Lastly, T5 measurement will be performed three minutes after additional 400 ml of isotonic saline is infused within 10 minutes to complete 500 ml of fluid loading.
75436313|NCT05391555|Drug|Remifentanil Hydrochloride|Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes. Pupillary measurements will be taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.
76052357|NCT02163187|Behavioral|MSK BFI questionnaires|
76052358|NCT02163187|Behavioral|The Low Anterior Resection Score (LARS) questionnaires|
76052359|NCT02163187|Behavioral|The EuroQOL5D questionnaires|
76052360|NCT02163187|Behavioral|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
75436314|NCT05391555|Device|Pupillometry measurement|The pupil will be examined with the pupillometer at regular intervals, before during and after the opioid infusion
75436315|NCT05387798|Drug|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
75436316|NCT05384457|Other|High intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
76052361|NCT04419116|Procedure|tibial preservation bone cut|tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
76052362|NCT02191579|Biological|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
75436317|NCT05384457|Other|Moderate intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
75436318|NCT05320471|Other|This is an observational study|This is an observational study
75436319|NCT05306275|Drug|CSL312|Factor XIIa antagonist monoclonal antibody for subcutaneous use
75584490|NCT00567281|Device|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
75584491|NCT00567437|Other|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
75584492|NCT00567515|Device|AtriCure LAA Exclusion System|Placement of clip of LAA.
75584493|NCT04577703|Drug|CT053PTSA|CT053PTSA will be administered daily in fasting state
75584494|NCT04577586|Other|oral contrast|negative oral contrast utilization in PET/CT studies
76052363|NCT02191579|Drug|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
76052364|NCT05125250|Other|Motor Control Group|will received treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day .
76052365|NCT05125250|Other|Vestibular Group|will receive vestibular exercises which comprises of postural awareness training, balance board exercises, Foveal vision exercises .
76052366|NCT05324462|Drug|IDegLira|Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
75436320|NCT05230004|Device|iFIT prosthesis|An adjustable modular prosthesis that can be fit in a single session. Fully adjustable by wearer.
75436321|NCT05219604|Drug|DiphenhydrAMINE Injectable Solution|Intravenous infusion of diphenhydramine 50 mg.
75436322|NCT05197634|Other|Not Applicable (observation)|Questionnaire
75436323|NCT05190744|Drug|PB|500mg BID followed by 1000mg BID. The dose of PB inducing the maximal increase in urine osmolality will be continued for up to three months providing that no side effects are observed including clinical and laboratory surveillance.
75436324|NCT05159765|Device|Single vision contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
75584495|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel|
75584496|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
75584497|NCT00567554|Drug|paclitaxel|
75584498|NCT00567554|Drug|paclitaxel + everolimus (RAD001)|
75881520|NCT01361789|Drug|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
75584499|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
75584500|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + lapatinib|
75584501|NCT04577469|Drug|Maldox tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
75584502|NCT04577469|Drug|G-COSPE® tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
75881521|NCT01361789|Drug|Dexamethasone|8 mg IV
75881522|NCT01361789|Drug|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
75881523|NCT05168761|Procedure|partial nephrectomy|
75881524|NCT02081612|Behavioral|Nutrition Education|12 educational weight management group session each addressing a different weight loss topic
75881525|NCT02081612|Procedure|Acupuncture|12 weight loss acupuncture session using both body and auricular points.
76052367|NCT04838756|Other|AI screening modality|Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.
76052368|NCT04838756|Other|Conventional screening modality|Screen exams will be read by two radiologists without the support of AI.
76052369|NCT01363700|Drug|DE-114 ophthalmic solution|
75436325|NCT05159765|Device|Multifocal contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
76052370|NCT01363700|Drug|Placebo ophthalmic solution|
75436326|NCT05137080|Drug|Dexamethasone|24mg dexamethasone
75436327|NCT05137080|Drug|Isotonic saline|Isotonic saline
75436328|NCT05099835|Drug|Botox|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
75436329|NCT05099835|Drug|triamcinolonacetonide|triamcinolonacetonide stellate ganglion injection
75436330|NCT05094245|Procedure|Stellate Ganglion Block Group|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
75436331|NCT05086094|Drug|BHV3241, verdiperstat|BHV3241/Verdiperstat 600mg BID
75436332|NCT05046899|Device|BIOpH+ Psoriasis Medical Bath|20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
75881526|NCT02964507|Drug|GSK525762|GSK525762 will be administered.
75881527|NCT02964507|Drug|Placebo|Placebo will be administered.
75881528|NCT02964507|Drug|Fulvestrant|Fulvestrant will be administered.
75881529|NCT01359761|Behavioral|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
76052371|NCT01363700|Drug|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
75436333|NCT05046899|Device|Cetaphil Moisturizing Lotion|Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
75881530|NCT02083874|Drug|CBD|
75881531|NCT01367197|Behavioral|exercise training|group based exercise training
75881532|NCT05188781|Drug|Pembrolizumab combined Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
75436334|NCT05043415|Procedure|Immediate endoscopic necrosectomy|In the immediate endoscopic necrosectomy group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent, immediately followed by endoscopic necrosectomy. Endoscopic necrosectomy involves removal of infected necrotic pancreatic tissue via the cystogastrostomy/cystoenterostomy tract using a variety of endoscopic accessories.
75881533|NCT02083952|Other|Swaddle Blanket|Two arms involve varying time spent in blanket
75881534|NCT01367353|Procedure|surgery or debulking surgery|surgery or debulking surgery
76052372|NCT04372706|Drug|RTX-240|Engineered red cells co-expressing 4-1BBL and IL-15TP
75584503|NCT04590911|Behavioral|Cognitive Enrichment Program (CEP)|Multimodal cognitive rehabilitation program for individuals having sustained a traumatic brain injury during older adulthood
75584504|NCT04577508|Behavioral|Functional Remediation|Functional Remediation is a manualized, group-based psychosocial intervention built on a neurocognitive-behavioural approach, involving modeling techniques, role-playing tasks, self-instruction, positive reinforcement and metacognitive cues (Vieta E et al, Cambridge University Press, 2014). It consists of 21 90-min weekly sessions, in which a trained therapist and co-therapist work with 10-12 patients: the first 3 sessions are dedicated to psychoeducation on neurocognitive deficits; then 13 sessions of neurocognitive training sequentially target attention, memory and executive functions domains, comprising exercises carried out individually, in pairs or in small groups; the last 5 sessions focus on skills training (communication, interpersonal relationships, autonomy, stress management). Content of the sessions involves ecological tasks adapted to real-world situations, and to-be-performed in two contexts (clinical and daily). Homework is assigned, collected and discussed each time.
75584505|NCT04577508|Other|Treatment as usual|Standard care for bipolar disorders according to good clinical practice, including drug therapy and individual case management.
75584506|NCT04590716|Other|Data Collection|This is a non-interventional study conducted on the participant's smartphones to record MG related symptoms and conditions.
75584507|NCT04577742|Radiation|106 Ruthenium plaque brachytherapy|All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation
75584508|NCT04590560|Diagnostic Test|screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice|women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
75584509|NCT04590482|Drug|letrozole|Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
75436335|NCT05043415|Procedure|Step-up endoscopic interventions|In the step-up endoscopic interventions group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Endoscopic necrosectomy is not performed during the index drainage session, but is performed at a later time as needed.
75584510|NCT04590482|Drug|placebo|placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
75584511|NCT00581217|Other|Aquacel Ag|Aquacel Ag will be applied to one donor site.
75584512|NCT00581217|Other|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
75881535|NCT01359839|Behavioral|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
75881536|NCT03634735|Drug|Thiamine|Vitamine B1
75881537|NCT03634735|Other|Placebo|Placebo tablets
75881538|NCT03559322|Device|iNAP® Lite Sleep Therapy System|Class II intraoral devices for snoring and/or obstructive sleep apnea
75881539|NCT03634657|Radiation|Plain X-ray protection shield|Coronary angiography with mere X-ray protection shield
75881540|NCT03634657|Radiation|Protection shield & X-ray protective strips|Coronary angiography with X-ray protection shield & X-ray protective strips
75436336|NCT05010018|Behavioral|Web-based application connecting small food store owners and suppliers of healthier foods and beverages|The primary intervention is a web-based app that connects small food store owners in low income Baltimore with suppliers of healthier foods and beverages. To reduce costs associated with small purchasing quantities by corner stores, and high delivery charges, the BUD app uses collective purchasing and shared delivery strategies. BUD will be implemented in four stages, where each stage promotes different food/beverage items and introduces new features. The app will be bundled with a small subsidy in stages 1-2 to encourage initial use, increase familiarity with the app and reduce risk. Trainings in the use of the app will take place at the beginning of each phase. BUD will use collective purchasing at stage 2 of implementation (BuddyUp!). The BuddyLift! feature will start in stage 3, enabling small store owners to deliver BuddyUp! deals to other stores for an additional discount. Participating stores and wholesalers will receive point of purchase materials to promote BUD products.
75881541|NCT03634657|Radiation|Protection shield & protective strips & patient cut-outs|Coronary angiography with X-ray protection shield & X-ray protective strips & X-ray protection patient cut-outs
75881542|NCT04563195|Drug|tibulizumab (LY3090106)|subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
75584513|NCT00581295|Device|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
75730381|NCT04253002|Behavioral|Robinson's Culturally Adapted Coping with Stress Course (A-CWS)|Participants randomized to the experimental condition will take part in the Adapted Coping with Stress Course (A-CWS). The A-CWS is a 15-session, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills to adaptively cope with stress, using standard cognitive-behavioral strategies such as relaxation training and cognitive restructuring. Emphasis is given to the identification of individual and contextual factors associated with suicide risk and the unique day-to-day experiences of the youth, providing options for adaptive coping (e.g., positive thinking) that are culturally consistent. The A-CWS is structured and manualized to allow its transportability to service providers working in similar environments with similar youth.
75730382|NCT04253002|Behavioral|Standard Care Control Condition|Students meeting criteria for study inclusion and randomized into the standard care condition will be referred to the school-based health center (SBHC) mental health provider for case management. Standard care may range from (1) brief intervention by the SBHC mental health provider to (2) outside referral to local community service providers; these determinations will be made by the SBHC mental health team.
75436337|NCT04999891|Other|Neurocognitive tests|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, NuDESC, 3D-CAM.
75436338|NCT04988815|Drug|Ropeginterferon alfa-2b|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
75881543|NCT02084108|Other|intervention|intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
75436339|NCT04980378|Device|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
75436340|NCT04979572|Drug|TS-172|"Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~Multiple dose of TS-172 90 mg before breakfast and dinner"
75436341|NCT04979572|Drug|Placebo|"Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~Multiple dose of TS-172 placebo before breakfast and dinner"
75881544|NCT01371409|Other|continuous theta burst stimulation|80% active motor threshold, 600 pulses
75881545|NCT02084186|Other|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
75881546|NCT02084186|Other|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
75881547|NCT03170869|Device|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
75881548|NCT02084342|Drug|tranexamic acid and sodium chloride injection|10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
75881549|NCT02084342|Drug|normal saline|100ml, IV for 30min,before incision.
75881550|NCT02084342|Drug|desmopressin acetate injection|0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
75436342|NCT04970147|Other|Gastrostomy care bundle|Gastrostomy care bundle
75881551|NCT03558542|Other|cardiopulmonary rehabilitation plus neurorehabilitation|Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
75881552|NCT01371487|Drug|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
75881553|NCT02084420|Drug|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
75436343|NCT04938180|Biological|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
75436344|NCT04927351|Behavioral|Electronic Medical Record Based Discharge Medication Order Set|New medication discharge order set including recommended opioid quantities, adjunct pain medication
75436345|NCT04905615|Other|Data-driven and teacher led school based strategies.|The intervention is individualised to each school, depending on the teacher led strategies which are data-informed
75436346|NCT04889300|Behavioral|Best Possible Self|Participants are asked to think about their Best Possible Self for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
75436347|NCT04889300|Behavioral|Typical Day|Participants are asked to think about their Typical Day for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
75436348|NCT04873323|Drug|TS-142|Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
75436349|NCT04873323|Drug|Moxifloxacin|Single dose of moxifloxacin 400 mg in the morning under fasting in each period
75436350|NCT04873323|Drug|Placebo|Single dose of TS-142 placebo in the morning under fasting in each period
75584514|NCT04589858|Other|Supervised exercise protocol|Strengthening exercises:It included a sets/group of exercises such as a static quad set in knee extension, standing terminal knee extension, seated leg-press, partial squats weight-lessened with arm support as needed, and step-ups Stretching Exercises:A slow, sustained stretching was performed in different positions for different group of muscles with holding time 30-seconds, a gap of 1-minute between two repetitions, and repeated 3-times per session on alternate day for 2-weeks. The stretching performed for the calf muscle, hamstring muscle, and quadriceps femoris muscle in standing, supine, and prone positions respectively.
75436351|NCT04834960|Other|Minimizing Missed Opportunities for Vaccination (MOV)|This bundle of interventions has four components that include: (1) Disseminate (vaccination awareness among healthcare providers and child caregivers); (2) Document (vaccination status); (3) Deploy (vaccines); and (4) Discharge (provide advice/referrals for catch-up and routine vaccinations).
75436352|NCT04814771|Drug|[14C] TS-142|Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq [14C]TS-142 as an oral solution
75584515|NCT04589858|Other|Specified Manual Therapies|"Myofascial Mobilization: Patellar glide performed in all available ROM and direction such as superior-inferior and lateral-medial translation/glides of patella over patellar fossa.~Myofascial manipulation technique: Manipulation of knee joint. An impulse type thrust was delivered, directed in the caudal direction to mobilize the joint in a near-full extension position."
75730383|NCT04217746|Device|High Flow Nasal Cannula|The HFNC group will receive heated and humidified oxygenated gas delivered at high flow.
75730384|NCT04198363|Drug|Vonoprazan|Vonoprazan Tablets
75436353|NCT04792554|Other|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, Brief Psychiatric Rating Scale, NuDESC, 3D-CAM. Blood taking.
75730385|NCT04198363|Drug|Amoxicillin|Amoxicillin Capsules
75730386|NCT04198363|Drug|Clarithromycin|Clarithromycin Tablets
75730387|NCT04198363|Drug|Bismuth Potassium citrate|Bismuth Potassium citrate
75436354|NCT04777344|Behavioral|Tobacco Treatment Specialist (TTS) intervention|A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
75584516|NCT00567671|Procedure|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
75584517|NCT00567671|Procedure|Sham comparator|Sham treatment
75584518|NCT00581451|Drug|bifeprunox|oral tablet once daily
75584519|NCT04589936|Procedure|Prone positioning|Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.
75730388|NCT04198363|Drug|Esomeprazole|Esomeprazole Tablets
75730389|NCT04195828|Drug|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.
75730390|NCT04195828|Drug|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。
75730391|NCT04195828|Drug|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.
75730392|NCT04195828|Drug|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
75730393|NCT04193371|Other|Active acupuncture|The rationale of the active acupuncture protocol is based on Western Medical Acupuncture theories and follows CONSORT and STRICTA protocols. All patients received acupuncture treatment for 30 minutes three times a week, with a maximum of 48 acupuncture treatments.
76052373|NCT04372706|Drug|Pembrolizumab|Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
76052374|NCT04178642|Drug|percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment|Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
75436355|NCT04753580|Genetic|Stool collection|"The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g."
75584520|NCT04577196|Other|Trauma dashboard|A large dashboard available to all, providing a framework for synthesizing and displaying relevant information about the arriving critical patient, to be filled in by the trauma leader.
75584521|NCT04590053|Biological|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
75584522|NCT00567710|Drug|BL - 1020|10 mg/day
75730394|NCT04193371|Other|Sham acupuncture|In the sham acupuncture protocol, 2 needles were inserted superficially to a depth of less than 5 mm, 1 in each shoulder and 1 in each upper arm at nonacupuncture and non-meridian points, and then, 4 needles were attached to electrodes and the stimulator was turned on to mimic the active acupuncture but with zero intensity, no electrical stimulation. They also received the treatment for 30 minutes three times a week and a maximum of 48 treatments.
75730395|NCT04193371|Other|Lifestyle management|"All women will receive lifestyle management before randomization after baseline measurements. The lifestyle management assisted by a PCOS lifestyle management system (Invention patent, ZL 2015 1 0500978.9).~All participants will get a step-counter for daily use and physical exercise diary for daily reporting of exercise: number of steps, type of activity, intensity and time (minutes). Once a week each participant receive a SMS in which they report the activity during the week."
75730396|NCT04192747|Device|Percutaneous Coronary Intervention|Percutaneous coronary intervention of de novo native coronary artery lesions
75584523|NCT00567710|Drug|BL - 1020|BL 1020 20-30 mg/day
75584524|NCT00567710|Drug|Placebo|Capsules
75584525|NCT00567710|Drug|Risperidone|Capsules
75730397|NCT04173247|Device|KeraStat Cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions.
75730398|NCT04173247|Other|Routine Skin Care - Commercially Available Agents|Commercially available skin moisturizers from an approved list that do not interfere with radiation.
75730399|NCT04167891|Diagnostic Test|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
75730400|NCT04149977|Behavioral|Physical Therapy with pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
75881554|NCT02084420|Drug|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
75881555|NCT01367431|Dietary Supplement|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
75881556|NCT01367509|Drug|Methylnaltrexone (MNTX)|
75881557|NCT02084498|Device|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
75584526|NCT04590131|Procedure|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.|Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
75584527|NCT04590131|Procedure|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.|Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
75584528|NCT04589975|Procedure|laparoscopic surgery|
75584529|NCT04589429|Drug|Morphine 10 MG/ML|intrathecal morphine 300 micrograms
75584530|NCT04589429|Drug|Nalbuphine Hydrochloride 10 MG/ML|intrathecal nalbuphine 2mg.
75584531|NCT04577118|Device|iotaSOFT Insertion System|Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
75730401|NCT04149977|Behavioral|Physical Therapy with placebo pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
75730402|NCT04144036|Biological|Neihulizumab, 3 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
75584532|NCT04589390|Drug|Selexipag|treatment with selexipag
75584533|NCT04577040|Drug|Tadalafil 5mg|Drugs
75584534|NCT04577235|Other|severity of lung involvement with COVID-19.|transthoracic lung ultrasound and throcic CT
75730403|NCT04144036|Drug|Neihulizumab, 6 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
75730404|NCT04144036|Drug|Neihulizumab, 9 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
75730405|NCT04144036|Drug|Neihulizumab|This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
75730406|NCT04125355|Other|Reflexology|Foot reflexology massage for 3 consecutive days and 60 minutes per day.
75584535|NCT04589000|Other|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
75584536|NCT04594668|Drug|Senicapoc|The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
75584537|NCT04589234|Drug|Salmonella-IL2|Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
75584538|NCT04589234|Drug|FOLFIRINOX Alone (Historical Controls)|We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
75584539|NCT04589234|Drug|Gemcitabine/Abraxane Alone (Historical Controls)|We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
75584540|NCT03453177|Drug|Standard of Care + Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
75584541|NCT03453177|Procedure|PK|Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
75584542|NCT03453177|Procedure|Analysis of Bacterial Isolates|For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
75730407|NCT04125355|Other|Placebo|Placebo for 3 consecutive days and 60 minutes per day. This intervention only include touch to the foot, it doesn't include deep stimulation.
75730408|NCT04112823|Drug|Dexamethasone 4mg|Dexamethasone 4mg + metoclopramide 10mg, intravenously
75730409|NCT04112823|Drug|Dexamethasone 16mg|Dexamethasone 16mg + metoclopramide 10mg, intravenously
75881558|NCT02084498|Behavioral|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
75584543|NCT04588961|Procedure|Trapeziectomy with suspensionplasty|Surgical removal of trapezium bone and ligamentoplasty of first metacarpal bone using abductor pollicis tendon
75584544|NCT04588961|Procedure|Joint alloplasty|Surgical removal of degenerated joint surfaces nad replacement using modern designed prothesis
75730410|NCT04103879|Biological|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|"Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF"
75730411|NCT04093219|Drug|IV acetaminophen|use of IV tylenol for pain
75730412|NCT04093219|Other|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
75881559|NCT01364545|Dietary Supplement|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
75436356|NCT04753268|Behavioral|Noom Healthy Weight Program|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight, physical activity, and meals daily."
75436357|NCT04748965|Diagnostic Test|Digital Subtraction Angiography|Compare optical coherence tomography lesion sizing and characteristics compared to traditional digital subtraction angiography
75436358|NCT04746105|Drug|TS-142|Subjects received single-dose of 10 mg of TS-142 (oral tablet)
75436359|NCT04746105|Drug|Dose-matched Placebo to TS-142|Subjects received single-dose matched placebo to TS-142 (oral tablet)
75436360|NCT04731675|Biological|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
75730413|NCT04089917|Device|Q Aspiration Catheter|The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
75730414|NCT04087018|Drug|zimberelimab|zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
75881560|NCT01364545|Dietary Supplement|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
75584545|NCT04594629|Drug|Nitroglycerin|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
75584546|NCT04594629|Drug|PGI2|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
75584547|NCT04589078|Device|GI Genius CADe system|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
75584548|NCT04594161|Device|Percutaneous Nephrostomy|A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis
75436361|NCT04715100|Other|Observational group|The study dependent variables will be: pain (vas scale), joint status (Hemophilia Joint Health Score), perception of quality of life (SF-36 questionnaire), list of roles (Oakley questionnaire), performance of basic activities of daily life (Barthel index) and the performance of instrumental activities of daily living (Lawton and Brody scale).
75436362|NCT04713358|Drug|Nalmefene|Immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
75436363|NCT04713358|Drug|normal Saline|Immediately Intravenous injection of normal saline 1ml after surgery
75436364|NCT04705051|Drug|Venglustat GZ402671|Pharmaceutical form: capsule Route of administration: oral
75436365|NCT04696952|Drug|TS-142|TS-142
75584549|NCT04594161|Device|Double J catheter|A Double J catheter will be placed in patients with obstructive urolithiasis
75881561|NCT02088086|Behavioral|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
75436366|NCT04696952|Drug|Zopiclone|Zopiclone
75436367|NCT04696952|Drug|Placebo|Placebo
75436368|NCT04631276|Drug|TS-091|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)
75584550|NCT04588844|Drug|Polyethylene Glycol Recombinant Human Somatropin|Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
75584551|NCT04588532|Drug|BAM8-22|Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
75584552|NCT04588532|Drug|Histamine|histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
75584553|NCT04588532|Drug|Cowhage (Mucuna Pruriens)|cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
75584554|NCT04588532|Drug|Doxepin|Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm
75584555|NCT04594083|Device|Palm Stimulator|The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
75584556|NCT04594083|Device|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
75584557|NCT04588454|Other|18F-PSMA-1007 PET tracer|18F-PSMA-1007 PET/CT
75584558|NCT03453138|Device|LMA Protector|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
75881562|NCT02088086|Behavioral|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
75436369|NCT04627506|Device|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
75436370|NCT04617210|Other|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires: MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, CANTAB, Insomnia Severity Index, Bristol Activities of Daily Living Scale, NuDESC, 3D-CAM. Blood taking.
75436371|NCT04586647|Behavioral|Noom Healthy Weight; mobile behavior change program for weight loss.|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
75436372|NCT04573725|Drug|TS-142|Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)
75730415|NCT04050072|Other|Childhood Cancer Survivors (CCSS)|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
75881563|NCT02088086|Behavioral|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
75881564|NCT01364701|Drug|Sildenafil 100 mg|4 tablets for on demand use
75881565|NCT01364701|Drug|Tadalafil 20 mg|4 tablets on demand
75881566|NCT01364701|Drug|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
75584559|NCT03453138|Device|Tracheal Intubation|tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
75584560|NCT03453099|Other|Preoperative Questionnaires|"The participants will be asked to complete 5 questionnaires:~An abbreviated version of the Caffeine Assessment Tool (CAT)~Sleep Questionnaire (SQ)~Surgical Fear Questionnaire (SFQ)~WHO Alcohol AUDIT Tool~WHO Smoking Questionnaire~They will also be asked to complete a demographics sheet~All participants will undergo standard anaesthetic induction, a research participant will observe the dose of propofol and time taken for loss of consciousness"
75584561|NCT03453099|Other|Postoperative Subjective Pain Scores|After the operation, participants will be provide with a scale from 1-10 in which to rate their pain at rest and whilst coughing. This will be undertaken at 1hr postoperatively.
75584562|NCT04588415|Other|Bereavement Virtual Support Group|"Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased)."
75730416|NCT04050072|Other|SJLIFE|To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
75730417|NCT04050072|Other|Community non-cancer control|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
75730418|NCT04046107|Biological|Cemiplimab|Administered as an intravenous (IV) infusion
75730419|NCT04039243|Behavioral|Being Brave|Up to 12 weekly sessions
75730420|NCT04039243|Other|Parent Education|Parents receive educational materials about helping children overcome shyness and fear
75436373|NCT04573725|Drug|Dose-matched Placebo to TS-142|Participants received single dose-matched placebo to TS-142 (oral capsule)
75436374|NCT04496999|Drug|HDM201|Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)
75436375|NCT04496999|Drug|Midostaurin|Midostaurin 50mg bid d1-28 (morning, evening)
75436376|NCT04469023|Drug|TS-142|Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
75436377|NCT04464421|Behavioral|Contingency Management (CM)|Participants will be able to draw a gift card from a fishbowl when their urine toxicology results are positive for buprenorphine (i.e., they are adherent to Medication-Assisted Treatment). Gift cards in the bowl for drawing will be $25, $50, or $100.
75436378|NCT04464421|Behavioral|Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)|Participants will have one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, and the importance of substance-free activities.
75436379|NCT04423939|Behavioral|Acceptance and Commitment Therapy (ACT)|The ACT sessions will be tailored to the clinical challenges of HCT. Sessions are with a mental health professional and are 45-60 minutes in duration and include both the participant and caregiver.
75584563|NCT04594044|Behavioral|tics training including habit reversal training and exposure response prevention|In an open randomized controlled study, youth were randomized to either individualized, or group treatment. Both therapies included nine sessions, and the parents were offered one group-session.
75592009|NCT06074653|Other|Mulligan Bent Leg Raise technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given.Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
75584564|NCT04588493|Diagnostic Test|Lower extremity Lymphoscintigraphy|Study of lymphoscintigraphy (LCG) abnormalities in a group of patients with history of infiltration of modeling substances in buttocks and hips and complain about lower extremities edema. LCG was performed and evaluated by a single nuclear medicine specialist through injection of the sulfur nanocolloid Technetium 99m, injected intradermal and interdigital in bilateral toes. Dynamic studies were requested for all patients. Standardized acquisition times at 15, 30, 60 and 120 minutes after injection were taken. The following parameters were considered to obtain the transport index in each pelvic limb: transport kinematics, distribution pattern, index time for the appearance of regional lymph nodes, number and collection of colloids in lymph nodes and presence and quality of the colloid uptake by the lymphatic vessels. Summation of these five components resulted in the transport index, which could range from 0 to 45 points
75584565|NCT04577430|Drug|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
75584566|NCT04577430|Drug|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
75584567|NCT04577430|Drug|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
75584568|NCT04577430|Drug|Normal saline|Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
75584569|NCT00567788|Drug|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
75584570|NCT00567788|Drug|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
75436380|NCT04416802|Combination Product|autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy|"The patient who encounters sexual dysfunction and visits our Outpatient Department (OPD) could enter this trial if he meets the inclusion criteria and exclusion criteria.~To fill the questionnaires of International index of erectile function (IIEF) and erectile hardness score (EHS) before starting treatment.~Li-ESWT treatment weekly for three weeks and PRP injection at the same day after the last Li-ESWT treatment.~Coming back at the fourth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~Li-ESWT treatment weekly for three weeks starts on fifth week and PRP injection at the same day after the last Li-ESWT treatment.~Coming back at the eighth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~Coming back at the twelfth week and check is there any side effect and fill the questionnaires of IIEF and EHS."
75436381|NCT04401813|Drug|IBI308 200mg|Received IBI310 combined with sintilizumab 200mg
75436382|NCT04330950|Other|Neurocognitive tests|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
75436383|NCT04314635|Behavioral|Brief family engagement intervention for CHR|The individual sessions, done with the caregiver and the teen separately, include a review of symptoms and a qualitative interview exploring treatment priorities, attitudes, and perceived barriers. The first family session focuses on psychoeducation. The second family session focuses on motivational enhancement, to promote ongoing engagement in services after discharge, including outpatient treatment and case management through the CSC.
75436384|NCT04314635|Behavioral|Treatment as usual (TAU)|The TAU group will receive treatment as usual on the adolescent inpatient unit. This includes individual therapy, psychiatric care, skills groups, and family therapy meetings.
75436385|NCT04298853|Drug|Morphine PRN|Dose given every 3 hours as-needed for severe NAS, defined by a threshold Finnegan score.
75436386|NCT04298853|Drug|Morphine scheduled|Dose given every 3 hours on a scheduled basis and slowly weaned once stabilized.
75436387|NCT04238793|Drug|KLS-2031|KLS-2031 administered by transforaminal epidural injection
75436388|NCT04238793|Other|Placebo|Saline solution administered by transforaminal epidural injection
75730421|NCT04037917|Device|CorNeat EverPatch|Covering Ophthalmic Implants
75881567|NCT02088242|Drug|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
76052375|NCT04178642|Procedure|Percutaneous destruction of the tumor|Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
76052376|NCT04157894|Other|Standard long-lasting insecticidal net|Interceptor® (BASF) contains a pyrethroid insecticide
75436389|NCT04232683|Drug|Tamsulosin 0.4Mg Capsule|Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased
75436390|NCT04232683|Drug|Placebo oral tablet|Placebo pill given preoperatively
75436391|NCT04216810|Other|muscle strengthening exercises|segmental stabilization exercises
75436392|NCT04216810|Other|muscle strengthening exercises and dry cupping|segmental stabilization exercises and dry cupping
75584571|NCT04588766|Other|constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
75584572|NCT04588766|Other|control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
75584573|NCT00581607|Drug|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
75730422|NCT03993509|Device|rTMS to the right dlPFC|A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
75730423|NCT03986736|Diagnostic Test|Laboratory analysis - upon admission|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
75436393|NCT04201028|Behavioral|Video Conferencing Health Coaching with devices|Devices
75436394|NCT04201028|Behavioral|Video Conferencing Health Coaching with no devices|No Devices
75436395|NCT04200547|Other|Immunomonitoring-based follow-up|"Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. 3 months after the surgery, serum levels of adalimumab will be measured:~If the level is below 5ug/mL, adalimumab treatment will be increased to every other week until the end of the study.~If adalimumab level in the serum is above 5ug/mL, the treatment's frequency will be maintained until the end of the study."
75584574|NCT00581607|Drug|Placebo|Placebo twice a day
75584575|NCT00581607|Drug|Bosentan|drug given for 16 weeks
75436396|NCT04200547|Other|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. If clinical relapse (CDAI > 220 together with an increase of 70 points) and biological relapse (CRP > 10mg/mL and fecal calprotectin > 100 ug/g) occur, frequency of adalimumab treatment will be increased to once a week.
75436397|NCT04184661|Other|blood sample|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
75436398|NCT04177576|Biological|2 additional tubes of blood|2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation
75584576|NCT00581607|Drug|Placebo|placebo
75584577|NCT04588571|Procedure|Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent|"Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months."
75730424|NCT03986736|Diagnostic Test|Laboratory analysis - 24 hours after injury|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
75730425|NCT03981263|Device|MEAVANTI prothesis|"The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart."
75436399|NCT04112784|Device|INVSENSOR00039|Noninvasive pulse oximeter sensor
75881568|NCT02088242|Drug|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
75584578|NCT04588571|Procedure|Femoropopliteal proximal bypass|"Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time."
75584579|NCT04594122|Behavioral|Improve hygiene practice of pork sellers|includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
75881569|NCT02440464|Procedure|Allogeneic HSCT|Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
75592010|NCT06074653|Other|PNF Contract Relax technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given. Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
75881570|NCT02440464|Drug|Fludarabine|Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
75881571|NCT02440464|Drug|Melphalan|Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
75881572|NCT02440464|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
75881573|NCT02440464|Drug|Ixazomib|Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
75436400|NCT04108351|Other|Road-tracking test|Driving with simulator program for SDLP measurement
75436401|NCT04108351|Other|Car-following test|Intervention Description: Driving with simulator program for DCV measurement
75881574|NCT02440464|Drug|Placebo|Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
75881575|NCT01367587|Drug|IV Methylnaltrexone|
75881576|NCT02088398|Drug|ACY-1215|
75881577|NCT03103321|Other|Internet-Based Intervention|"Receive Knowing your Options decision aid"
75881578|NCT03103321|Other|Internet-Based Intervention|"Receive Prostate Choice decision aid"
75881579|NCT03103321|Other|Best Practice|Undergo usual care
75436402|NCT04108351|Other|Harsh-braking test|Driving with simulator program for BRT measurement
75436403|NCT04101227|Drug|AD04 (ondansetron)|AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
75436404|NCT04101227|Drug|Matching placebo|Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
75436405|NCT04101227|Device|Companion Diagnostic for Genetic Testing|Companion Diagnostic for Genetic Testing
75436406|NCT04101227|Behavioral|Brief Psychological Counseling|Brief Psychological Counseling
75436407|NCT04096781|Behavioral|SDMT|The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.
75881580|NCT03103321|Other|Quality-of-Life Assessment|Ancillary studies
75436408|NCT04096781|Behavioral|Usual Care|The participants will receive usual care.
75436409|NCT04049617|Drug|Evixapodlin|Tablets administered orally.
75730426|NCT03981263|Device|Standard prothesis|This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.
75730427|NCT03966404|Diagnostic Test|EyeBOX device|The EyeBOX medical device tracks a patient's eye movement and calculates a BOX Score ranging from 0-20. The BOX score is interpreted as a binary classification for eye movement abnormalities, where anything equal to or greater than 10 is a positive result for the initial evaluation of concussion and everything below 10 is negative.
75881581|NCT03103321|Other|Questionnaire Administration|Ancillary studies
75881582|NCT03103321|Other|Survey Administration|Ancillary studies
75881583|NCT03103321|Other|Laboratory Biomarker Analysis|Correlative studies
75584580|NCT00581646|Behavioral|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
75584581|NCT04588376|Behavioral|Peer comparison feedback monthly|Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
75584582|NCT00581685|Drug|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
75584583|NCT04588220|Other|Obstetric ultrasound and fetal-maternal assessment|melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
75584584|NCT00581724|Behavioral|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
75584585|NCT04588181|Behavioral|cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
75584586|NCT00566787|Device|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
75584587|NCT04588064|Diagnostic Test|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging within the specified time.
75730428|NCT03951480|Other|Manual medicine|At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity < 2, manipulations will not be continued. The patient being considered as not very symptomatic.
75730429|NCT03951480|Drug|Corticosteroids infiltration|A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
75436410|NCT04047004|Drug|Doxorubicin|Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
75584588|NCT04587986|Device|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
75436411|NCT04047004|Drug|Cisplatin|Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
75584589|NCT04587401|Procedure|normotensive patients|patients who do not have high blood pressure diagnosis and actual blood pressure is within the normal range
75584590|NCT04587401|Procedure|patients with hypertension diagnosis|Patients who have high blood pressure diagnosis
75584591|NCT04587401|Procedure|patients who do not know they are hypertensive but actual blood pressure is high|patients with preoperative high blood pressure, who do not know they are hypertensive
75730430|NCT03943446|Drug|TAK-018|TAK-018 immediate-release tablets.
75436412|NCT03944798|Other|Frequency: Every 3 Months|every 3 months
75730431|NCT03943446|Drug|TAK-018 Placebo|TAK-018 placebo-matching tablets.
75730432|NCT03940482|Behavioral|Time Restricted Eating As Treatment (TREAT) for Diabetes.|Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
75881584|NCT02084576|Drug|Nepafenac|One drop in the study eye 3 times daily for 30 days
75881585|NCT02084576|Drug|Ketorolac|One drop in the study eye 4 times daily for 30 days
75881586|NCT03131453|Drug|CNP520 50mg|50 mg capsule
75584592|NCT04587557|Behavioral|Storytelling with social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
75584593|NCT04587557|Behavioral|Storytelling without social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
75584594|NCT04587557|Other|Children with ASD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
75584595|NCT04587557|Other|Children with TD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
75881587|NCT03131453|Drug|CNP520 15mg|15 mg capsule
75881588|NCT03131453|Other|Matching placebo|Matching placebo for 15 and 50 mg capsules
75881589|NCT02084654|Drug|Exenatide 5 and 10 mcg 2 times a day|
75436413|NCT03944798|Other|Frequency: Every 6 Months|every 6 months
75436414|NCT03944798|Other|Imaging Modality: Chest Radiograph (CXR)|Chest radiograph (CXR)
75436415|NCT03944798|Other|Imaging Modality: Chest CT|Chest computed tomography (CT)
75436416|NCT03911154|Device|Philips SmartSleep Technology--Continuous Fixed Interval modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~Continuous Fixed Interval~Block~In-Phase Adjustable~Sham: No auditory stimulation while wearing the SmartSleep headband"
75584596|NCT00581841|Other|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
75584597|NCT04587362|Diagnostic Test|Musculoskeletal Ultrasound|High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
75584598|NCT04594317|Device|low level laser therapy|buccal application of diode laser on non-contact mode
75584599|NCT04587596|Other|Pain education|70 minute lecture about chronic pain and one focus group afterwards
75584600|NCT04587713|Drug|TD-1473 [Tablet A]|TD-1473 [Tablet A] (1 Tablet = Dose A) proposed commercial tablet formulation
75584601|NCT04587713|Drug|TD-1473 [Tablet B]|TD-1473 [Tablet B] (2 Tablets = Dose A) current clinical tablet formulation
75584602|NCT04587011|Drug|Tegoprazan dose A or placebo|Tegoprazan A mg or placebo taken orally twice daily for 3 days.
75881590|NCT02084654|Drug|placebo|
75584603|NCT04587011|Drug|Tegoprazan dose B or placebo|Tegoprazan B mg or placebo taken orally twice daily for 3 days.
75881591|NCT01367743|Drug|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
75881592|NCT01367743|Drug|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
75881593|NCT02084732|Drug|Sorafenib|drug
75881594|NCT02084810|Drug|activated recombinant human factor VII|"All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.~Each subject will be allocated to two treatment periods separated by a wash-out period of a week."
75881595|NCT02084810|Drug|eptacog alfa (activated)|All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
75881596|NCT02780401|Other|Laboratory Biomarker Analysis|Correlative studies
75436417|NCT03911154|Device|Philips SmartSleep Technology--Block modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~Continuous Fixed Interval~Block~In-Phase Adjustable~Sham: No auditory stimulation while wearing the SmartSleep headband"
75584604|NCT04587011|Drug|Tegoprazan dose C or placebo|Tegoprazan C mg or placebo taken orally twice daily for 3 days.
75584605|NCT04587011|Drug|Tegoprazan dose D or placebo|Tegoprazan D mg or placebo taken orally twice daily for 3 days.
75584606|NCT04587206|Drug|CKD-348|QD, PO
75584607|NCT04587206|Drug|CKD-828, D097, D337|QD, PO
75881597|NCT02780401|Biological|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
75881598|NCT02780401|Biological|Sargramostim|Given ID
75584608|NCT00581880|Behavioral|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
75584609|NCT00581958|Other|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
75584610|NCT04586816|Combination Product|1% red maple leaf extract in cream base|1% red maple leaf extract is combined in a cream base
75730433|NCT03896763|Other|Either supine or prone positioning and either CMV or HFOV|"Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver."
75730434|NCT03896737|Drug|Daratumumab plus Velcade Cyclophosphamide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
75730435|NCT03896737|Drug|Velcade Thalidomide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
76052377|NCT04157894|Other|Chlorfenapyr insecticide treated net|Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
75436418|NCT03911154|Device|Philips SmartSleep Technology--In-Phase Adjustable modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~Continuous Fixed Interval~Block~In-Phase Adjustable~Sham: No auditory stimulation while wearing the SmartSleep headband"
75436419|NCT03893435|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
75436420|NCT03853837|Diagnostic Test|rest-exercise echocardiography|an echocardiogram performed during rest and exercise
75730436|NCT03896724|Biological|R21 adjuvanted with 25mcg Matrix-M|Vaccine
75730437|NCT03896724|Biological|Rabies Vaccine|Vaccine
76052378|NCT04157894|Other|Piperonyl butoxide long-lasting insecticidal net|PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
76052379|NCT04821752|Behavioral|Avoidance Education|Dietary modification and lifestyle interventions
75436421|NCT03818074|Device|Boston Wavewriter 1000Hz Spinal cord Stimulation|High frequency spinal cord stimulation.
75436422|NCT03813121|Drug|midazolam intravenous infusion|Participants will receive a single drug infusion
75436423|NCT03813121|Drug|placebo intravenous infusion|Participants will receive a single placebo infusion
75436424|NCT03813121|Drug|ketamine intravenous infusion|Participants will receive a single drug infusion
75436425|NCT03784521|Device|In-line filtration|In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.
75436426|NCT03784521|Device|Standard care|Patients are treated with standard intravenous solutions and vascular access management
75584611|NCT04586816|Combination Product|5% red maple leaf extract|5% red maple leaf extract is combined in a cream base
75584612|NCT04586816|Combination Product|vehicle|vehicle cream base only
75730438|NCT03896724|Biological|R21 adjuvanted with 50mcg Matrix-M|vaccine
75730439|NCT03884049|Procedure|Embolization|transcatheter arterial embolization of neovessels around the knee
75730440|NCT03884049|Procedure|Sham embolization|Sham transcatheter arterial embolization of neovessels in the knee
75730441|NCT03880838|Behavioral|Personal testimonial|Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
75881599|NCT02533232|Drug|Minocycline|Minocycline 200mg per day
75584613|NCT04593849|Other|Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)|We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
75584614|NCT04586543|Drug|Selegiline|10 mg selegiline tablet per day
75584615|NCT04586543|Drug|Docetaxel|75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
75584616|NCT00582192|Other|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
75584617|NCT04586777|Device|transvertebral direct current stimulation (tvDCS)|tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
75436427|NCT03781778|Other|Dietary Intervention (resistant starch)|Eat foods with resistant starch
75584618|NCT04593576|Other|Physical activity protocol/out door sports|"Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week."
75584619|NCT04593576|Other|Intensive table teaching speech therapy|Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
75881600|NCT01371799|Drug|Drug|Placebo
75881601|NCT01371799|Drug|Drug|4mg and 8mg Study drug
75436428|NCT03781778|Other|Dietary Intervention (regular starch)|Eat foods with regular corn starch
75436429|NCT03781778|Other|Questionnaire Administration|Ancillary studies
75436430|NCT03778177|Procedure|transcranial electrical brain stimulation|Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
75436431|NCT03744117|Other|Palliative care consultation|A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
75436432|NCT03710590|Other|ECIG Lab Session 15 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
75436433|NCT03710590|Other|ECIG Lab Session 15 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).
75436434|NCT03710590|Other|ECIG Lab Session 15 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
75436435|NCT03710590|Other|ECIG Lab Session 30 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
75436436|NCT03710590|Other|ECIG Lab Session 30 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
75436437|NCT03710590|Other|ECIG Lab Session 30 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
75436438|NCT03676725|Drug|Lidocaine gel|Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
75436439|NCT03624816|Device|Restylane Defyne|hyaluronic acid dermal filler gel
75436440|NCT03607825|Device|Neurapheresis System|CSF filtration system and lumbar catheter
75436441|NCT03572985|Other|Road-tracking test|Driving with simulator program for SDLP measurement
75436442|NCT03572985|Other|Car-following test|Driving with simulator program for DCV measurement
75436443|NCT03572985|Other|Harsh-braking test|Driving with simulator program for BRT measurement
75436444|NCT03566615|Device|CAP-straight|This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
75584620|NCT04586738|Procedure|non-perforating deep sclerectomy surgery|Non-penetrating deep sclerectomy is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma.This surgery is performed to facilitate the outflow of aqueous humour from the anterior chamber to the subconjunctival space through a natural membrane (trabeculo-Descemet's window). This enables a more physiological reduction of intraocular pressure to be achieved.
75584621|NCT04593693|Device|Invia Motion Endure NPWT system|lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
75881602|NCT02686814|Device|17mm MDT-2215 aortic valve bioprosthesis|
75881603|NCT03779828|Device|HOME LINK|Telemonitoring system which include web platform and connected devices.
75584622|NCT04586582|Diagnostic Test|ST-segment resolution <40.15%|Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.
75584623|NCT00581568|Other|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
75584624|NCT04586465|Drug|pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin|"Patients will receive 3 cycles pembrolizumab 200mg, fix dose, 60 minute IV infusion combination with chemotherapy.~Chemotherapy regimen: ① Eligible patients with non-squamous cell lung cancer, Pemetrexed 500mg/m2, IV infusion on day 1 and cisplatin 75mg/m2 or carboplatin area under the curve (AUC=5), on day 1 of a 3-week schedule for 3 cycles. ② Eligible patients with squamous cell lung cancer. Patients will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC=5 on day 1 of a 3-week schedule for 3 cycles"
75584625|NCT04593615|Procedure|ICG near-infrared imaging|Indocyanine green tracer is used to guide laparoscopic D2 lymph node dissection for gastric cancer
75584626|NCT04586309|Behavioral|Transcendental meditation|"Instruction in the TM technique is taught over five sessions.~Introductory session-Review of previous scientific research on the TM program and a vision of possible benefits; Preparation- discussion of the mechanics and origin of the TM technique After the introductory session, a Personal Interview is conducted telephonically-with a teacher of the TM program.~Personal Instruction-individual one-on-one instruction in the TM technique. The student learns the mechanics of the TM technique. At the conclusion of this class the student is able to meditate properly.~First Day of Verification of Correct Practice and Further Instruction.~Second Day of Verification of Correct Practice-understanding the mechanics of the TM technique from personal experiences.~Third Day of Verification of Correct Practice-understanding the mechanics of the development of higher human potential and wellness."
75881604|NCT02673151|Procedure|Computed Tomography (CT) scan|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
75881605|NCT02673151|Drug|68Ga-PSMA-11|68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.
75436445|NCT03566615|Device|CAP-daisy|This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
75436446|NCT03566615|Other|water|using water instead of traditional air insufflation to help insertion
75436447|NCT03548207|Biological|JNJ-68284528|JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
75436448|NCT03532490|Drug|Roflumilast 500 Mcg Oral Tablet|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
75436449|NCT03532490|Drug|Placebo oral capsule|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
75436450|NCT03520517|Drug|BHV-0223|BHV-0223, 40 mg BID
75584627|NCT04586192|Other|Common Elements Toolbox- Adult version (COMET-A)|COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.
75881606|NCT02673151|Procedure|Positron Emission Tomography (PET)|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
75584628|NCT04586192|Other|Self-awareness Control|A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
75584629|NCT00582387|Genetic|specimen samples|blood, urine and tissue
75584630|NCT00582387|Behavioral|questionnaires|
75584631|NCT04586114|Drug|Corticosteroids and Derivatives|Any systemic corticosteroid treatment administrated during ICU stay
75584632|NCT00566865|Drug|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
75584633|NCT00566865|Drug|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
75584634|NCT04585997|Drug|Mepolizumab|Mepolizumab 100mg subcutaneous injection monthly for 6 months
75584635|NCT04585997|Drug|Omalizumab|Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
75584636|NCT04576845|Other|Survey|The children's eating behavior will be evaluated with Turkish validated Children's Eating Behavior Questionnaire - (CEBQ) by interviewing mothers face to face. The CEBQ is a Likert type, parent-report rating scale measuring the variation in eating behavior in children. The CEBQ consists of 35 items comprising eight subscales, each containing 3 to 6 items. Parents will be asked to rate their child's eating behavior on a five-point scale (never, rarely, sometimes, often, always; 1-5, respectively).
75584637|NCT04585880|Other|Virtual Collaborative Care Clinic|The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
75584638|NCT04586036|Other|ankle joint brace 1|The influence of ankle joint brace 1 on gait biomechanics
75584639|NCT04586036|Other|ankle joint brace 2|The influence of ankle joint brace 2 on gait biomechanics
75584640|NCT04586036|Other|ankle joint brace 3|The influence of ankle joint brace 3 on gait biomechanics
75584641|NCT04586036|Other|ankle joint brace 4|The influence of ankle joint brace 4 on gait biomechanics
75584642|NCT04586036|Other|ankle joint brace 5|The influence of ankle joint brace 5 on gait biomechanics
75584643|NCT00582504|Biological|VEE TC-83|Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
75730442|NCT03880838|Behavioral|Forks Over Knives Documentary|Participants will be mailed the documentary Forks Over Knives, which provides scientific arguments promoting a plant-based and whole foods diet. The behavioral effect of this documentary comes from watching the documentary and potentially choosing to order a free cookbook (participants are given this opportunity in the letter accompanying the documentary). The effect of the diet itself is not a central part of the intervention, as people can choose to adopt or not adopt any part of the diet.
75881607|NCT02436655|Procedure|surgical aortic valve replacement|open heart aortic valve replacement
75881608|NCT02082080|Other|Education|
75881609|NCT02082080|Other|Social support|
75881610|NCT02084966|Procedure|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
75584644|NCT04585568|Other|Biosensors|Measures of blood flow and preassures
75584645|NCT04593108|Device|Letrozole misoprostol|Letrozole give pretreatment of abortion by misoprostol
75584646|NCT04593108|Drug|Misoprostol, placebo|Give placebo pretreatment of abortion by misoprostol
75584647|NCT04577391|Other|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).
75584648|NCT04577391|Other|Bimanual Training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
75584649|NCT04585412|Drug|Palonosetron|Pharmacokinetic study under fasting conditions
75584650|NCT04592796|Device|Xiaomi MiBand2|Recording of sleep and activity data to study their association with age.
75584651|NCT04592796|Other|Socio-demographic questionnaire|Self-made questionnaire to be administered at the beginning of the study with the following personal data: age, gender, marital status, residential environment, mobility aids, educational level, occupation, retirement type, socioeconomic status, medical records, treatment.
75584652|NCT04592796|Other|EuroQol-5D-5L|Quality of life questionnaire to be administered at the beginning and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
75584653|NCT04592796|Other|Mini mental State Examination|Questionnaire to be administered at the beginning and completion of the study that measures cognitive impairment.
75584654|NCT04592796|Other|Tinetti Scale|Physical test to be administered at the beginning and completion of the study that measures gait and balance of the participants.
75584655|NCT04592796|Other|Barthel Index|Questionnaire to be administered at the beginning and completion that evaluates the level of independence in basic activities of life.
75584656|NCT04592796|Other|Pittsburgh Sleep Quality Assessment (PSQI)|Questionnaire to be administered whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning and completion of the study.
76052380|NCT04815278|Behavioral|Immediate Chronic Disease Prevention Program (CDPP)|The CDPP is an adaptation of the Diabetes Prevention Program (DPP). It will take place over a 24 week period and involve online instruction and individualized lifestyle coaching sessions. The online classroom curriculum includes 8 modules: Goal setting, self-monitoring and problem solving (M1), Managing stress and negative thoughts (M2), Healthy eating (M3), Taking more steps (M4), Keeping alcohol in check (M5), Lifestyle change (M6), Taking charge of what (and who) is around you (M7), and Staying motivated (M8). The lifestyle coaches will meet in person and over the phone intermittently over the 24 week period (Weeks 2, 4, 6, 10, 12, 16, 24).
76052381|NCT04815278|Behavioral|Workplace Equity, Job and Health Supports Employer Intervention|The employer intervention combines implicit bias awareness training for supervisors of hired DSS-E clients, and regular, structured, interactions between supervisors and DSS-E hires.
76052382|NCT04815278|Behavioral|Delayed, attenuated Chronic Disease Prevention Program (CDPP)|Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
76052383|NCT04821674|Biological|DS-5670a|DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
76052384|NCT04821674|Biological|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
76052385|NCT04327934|Drug|GnRH antagonist|GnRH antagonist up to 16 days.
76052386|NCT04327934|Drug|GnRH antagonist + MethylTESTOSTERone 5 MG|GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
76052387|NCT04791566|Drug|Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
76052388|NCT04791566|Drug|Physiologic saline|100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
75436451|NCT03479606|Behavioral|Online Emotion Regulation Skills-training|Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
75436452|NCT03468335|Drug|Irinotecan Liposomal Injection [Onivyde]|"Cancer treatment for PDAC:~Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~5-FU 2400 mg/m2 as 46 hour infusion~Folinic acid 400 mg/m2 as 0.5 hour infusion~all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
75436453|NCT03465722|Drug|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
75436454|NCT03465722|Drug|regorafenib|Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
75436455|NCT03425591|Drug|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.
75436456|NCT03413592|Other|Road-tracking test|Driving with simulator program for SDLP measurement
75436457|NCT03413592|Other|Car-following test|Driving with simulator program for DCV measurement
75584657|NCT00567866|Drug|Quetiapine|50 or 100 mg of quetiapine orally
75584658|NCT00567905|Dietary Supplement|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
75584659|NCT00582543|Other|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
75584660|NCT00567944|Device|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
75436458|NCT03413592|Other|Harsh-braking test|Driving with simulator program for BRT measurement
76052389|NCT04129736|Drug|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
75436459|NCT03312270|Behavioral|Multimodality information comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
75730443|NCT03880838|Behavioral|Commitment nudge|At the end of the letter promoting a plant-based diet, participants will be asked to write dates and personal signatures committing to watching the documentary. They will be asked to mail back this written commitment. Stating one's intentions to implement certain behavior is meant to increase the likelihood of follow-up behavior. This request might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
75730444|NCT03880838|Behavioral|Prevention nudge|As part of the letter promoting a plant-based diet, one paragraph will describe the risks of not taking action. This phrasing reframes the status quo as contributing to future loss (e.g., costs of medication and operations). In effect, the letter encourages participants to focus on preventing this loss by taking action. This additional text might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
75730445|NCT03828331|Other|Prosthetic/Bicycle Configuration|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
75730446|NCT03815929|Drug|Estradiol 100 Micrograms Patch|Standard
75730447|NCT03815929|Drug|Estradiol Patch|Individualized
75436460|NCT03280511|Drug|PIPAC|PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
75584661|NCT00567983|Drug|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
75584662|NCT00567983|Drug|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
76052390|NCT05301218|Procedure|angioplasty|Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart
76052391|NCT04418960|Diagnostic Test|Magnetic resonance imaging (MRI)|MRI pre- and postoperatively for detailed analysis of the ventricle and the mitral annulus. The first MRI will be performed on the admission day before surgery. The second MRI will be performed during the hospital stay, between 3 and 7 days after the operation. The MRI images are interpreted through a specialized cardiologist and radiologist.
76052392|NCT04769960|Diagnostic Test|MRI Studies|MRI scans will be performed on a 1.5T MRI scanner. Department of Radiology MRI SafetyGuidelines will be followed except regarding breast tissue expanders. Conventional MRIstudies will be performed using the standard of care clinical sequences.
75436461|NCT03267303|Drug|TS-091 5mg|Orally taken once daily for 3 weeks
75436462|NCT03267303|Drug|TS-091 10mg|Orally taken once daily for 3 weeks
75436463|NCT03267303|Drug|Placebo|Orally taken once daily for 3 weeks
75584663|NCT00582582|Drug|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
75584664|NCT00582582|Drug|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
75730448|NCT03810170|Behavioral|safe sex and HIV/STD prevention education via a website|website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
75730449|NCT03810170|Other|written materials on safe sex|2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
75730450|NCT03809988|Drug|Palbociclib|Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
75730451|NCT03809988|Drug|Endocrine therapy|Endocrine therapy alone (letrozole or fulvestrant)
76052393|NCT04769960|Behavioral|Patient Reported Outcomes|Participants will fill out questionnaires before, immediately after, and approximately 3 months following the MRI examination +/- 1 month to evaluate for any pain or perceived changes with the breast tissue expander. The first questionnaire will obtain background participants information as well as establish a baseline pain level, the second questionnaire will evaluate any changes in pain after undergoing the MRI examination, and the last questionnaire will evaluate long term changes in pain. The patient reported outcome questionnaire will be optional at 3 months post-MRI +/-1 month.
75436464|NCT03205423|Drug|Gabapentin|Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
75436465|NCT03149302|Other|Local neck treatment (LNT)|The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
75584665|NCT04585373|Other|kinesio-taping with conventional therapy 24 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
75584666|NCT04585373|Other|kinesio-taping with conventional therapy 48 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
75584667|NCT04585373|Other|kinesio-taping with conventional therapy 72 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
75584668|NCT04592601|Procedure|S.L.I.M.M.S. Procedure|Combined Gastric Bypass with Vertical Sleeve Gastrectomy
75584669|NCT04584944|Radiation|Dual energy X-ray absorptiometry|"Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups."
75584670|NCT04592718|Behavioral|Slow deep breathing plus breath counting|Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
75436466|NCT03149302|Other|LNT plus sensorimotor exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
75436467|NCT03149302|Other|LNT plus balance exercises|The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
75436468|NCT03149302|Other|LNT plus sensorimotor/balance exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
75584671|NCT04592718|Behavioral|Normal-paced breathing plus breath counting|Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
76052394|NCT01637402|Drug|Abiraterone Acetate|"Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration"
76052395|NCT01637402|Drug|Prednisone|5 mg, twice daily, oral administration
75584672|NCT04584905|Dietary Supplement|dietary supplements for CKD patients|follow up and assessment of nutritional status of CKD patients
75881611|NCT02942277|Biological|Pfs25M-EPA|The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
76052396|NCT04419350|Procedure|Microneedling|One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
76052397|NCT04419038|Procedure|conjunctival autografting augmented with topical application of Mitomycin C|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
76052398|NCT04419038|Procedure|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
76052399|NCT04825730|Drug|JOINTSTEM|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
76052400|NCT02217475|Drug|Cenicriviroc|CVC 150 mg, administered orally once daily and taken every morning with food.
76052401|NCT02217475|Drug|Placebo|Placebo administered orally once daily and taken every morning with food.
76052402|NCT05296148|Device|Transcatheter Tricuspid Valve Implantation|Implantation of a tricuspid coaptation valve through a transcatheter approach.
76052403|NCT02191267|Radiation|[F18]-T807|[F18]-T807 PET Scan to measure tau deposition in the brain.
75584673|NCT00566904|Drug|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
75584674|NCT00566904|Drug|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
75584675|NCT00566904|Other|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
75584676|NCT04584983|Drug|usual prescribed intralipid (UL) regimen|Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
75584677|NCT04584983|Drug|restricted prescribed intralipid (RL) regimen|Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
75584678|NCT00568100|Procedure|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
75584679|NCT04576611|Other|face-to-face protocol|The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).
76052404|NCT02191267|Radiation|[F18]-Florbetapir|[F18]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
75584680|NCT04576611|Other|self-managed protocol|Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
75584681|NCT04584515|Drug|IMP4297 40 mg|IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297
76052405|NCT02191267|Device|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
75436469|NCT03122821|Other|Real Transcranial direct stimulation+Mental Imagery|"The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS [2, 19-25]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
76052406|NCT02191267|Genetic|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
75584682|NCT04584515|Drug|IMP4297 100 mg|IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297
75584683|NCT04592679|Device|FES-C|The participants were submitted to 20 sessions of FES-C three/five times per week. Each session lasted about 30'.
75584684|NCT04592679|Other|Standard Treatment|The participants were submitted to 20 sessions of standard rehabilitation for lower limbs with manual mobilization, three/five times per week. Each session lasted about 30'.
75584685|NCT04592757|Device|Virtual mirror therapy via VR headset|Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
75584686|NCT04584476|Procedure|superior capsular reconstuction|these patients underwent arthroscopic superior capsular reconstuction
75584687|NCT04584476|Procedure|partial rotator cuff repair|these patients underwent arthroscopic partial rotator cuff repair
75584688|NCT00582699|Behavioral|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
75584689|NCT04584437|Other|Infrared Energy and Dietary Supplement|Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
75584690|NCT04584593|Biological|Sample|Men will give semen, saliva, nasopharyngeal, urine and blood specimens
75881612|NCT02942277|Biological|Pfs230D1M-EPA|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
75881613|NCT02942277|Other|AS01|AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.
76052407|NCT04418245|Diagnostic Test|Imaging by thoracic scanner|Low-dose computed tomography
75584691|NCT04584710|Drug|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
75584692|NCT04584710|Drug|Placebo|Oral matching placebo once daily for 2 weeks
76052408|NCT04818944|Drug|Tirofiban Hydrochloride|Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV
76052409|NCT04818944|Drug|Placebo|Saline will be dosed for 24 hours post MT via continuous IV
76052410|NCT02189941|Drug|Deferiprone sustained-release|Deferiprone sustained-release tablets
75436470|NCT03122821|Other|Sham Transcranial Direct Stimulation +Mental Imagery|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS [2, 19-25]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
75436471|NCT03073603|Drug|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
75436472|NCT03073603|Drug|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
75584693|NCT00582777|Behavioral|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
75584694|NCT00582777|Behavioral|HS DOSING|Take your usual BP meds at bed time
75584695|NCT00582777|Drug|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
75584696|NCT04584398|Device|Respiratory muscle training with steam inhalation|
75584697|NCT03454113|Device|Ellipsys Vascular Access|The Ellipsys Vascular Access System comprises the Ellipsys Catheter, Ellipsys Crossing Needle and Ellipsys Power Controller. The Ellipsys Crossing Needle is used to facilitate access between the artery and the vein. The Ellipsys Catheter is placed percutaneously into the selected vein in close proximity to the selected artery. The Ellipsys Catheter is actuated at the selected anastomosis site, and the vein and artery are approximated. Once the vessels are in the appropriate relative positions the catheter is connected to the Ellipsys Power Controller to create the anastomosis after which the Ellipsys Catheter is removed, and the access site is closed using standard percutaneous closure techniques.
75881614|NCT02942277|Biological|Engerix-B|ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.
76052411|NCT02189941|Drug|Deferiprone immediate-release|Deferiprone immediate-release tablets
75584698|NCT04584671|Diagnostic Test|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
75584699|NCT04584671|Diagnostic Test|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
75584700|NCT04584671|Diagnostic Test|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
75584701|NCT04584671|Diagnostic Test|Six Minute Walk Test (6MWT)|Participants will perform the six minute walk test as a measure of exercise capacity
75436473|NCT03008369|Other|Laboratory Biomarker Analysis|Correlative studies
75584702|NCT04584671|Diagnostic Test|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
75584703|NCT04584671|Diagnostic Test|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
75584704|NCT04584671|Other|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
75584705|NCT00582855|Drug|AQW051|
75584706|NCT00582855|Drug|Placebo|
75584707|NCT04584359|Other|HVLA|High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.
75584708|NCT04584359|Other|global osteopathic protocol|Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.
75584709|NCT04584359|Other|pelvic floor muscle training|Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
75584710|NCT03454074|Behavioral|Problem-solving|Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
75584711|NCT03454074|Behavioral|Education|Education about healthy brain aging behaviors provided.
75584712|NCT04584047|Procedure|Cell-based non-invasive prenatal testing|Blood sampling.
75584713|NCT04584242|Drug|gluconon tab 15mg|frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST
75584714|NCT04584242|Drug|suganon tab 5mg|frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
75584715|NCT04592835|Drug|DWRX2003|"Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites"
75584716|NCT04583696|Dietary Supplement|The Investigation of effect on Blood Lipid parameters with walnut addition of Diet|Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
75730452|NCT03808987|Behavioral|Child-Parent Psychotherapy (CPP)|Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
75436474|NCT03008369|Drug|Lenvatinib|Given PO
75436475|NCT03008369|Other|Quality-of-Life Assessment|Ancillary studies
75730453|NCT03808987|Behavioral|Community Health Worker (CHW) home visitation|Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
75436476|NCT03002155|Other|EnhanceFitness community exercise program|Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
75436477|NCT02918006|Biological|VXA-A1.1|Enteric coated oral vaccine tablet
75436478|NCT02918006|Biological|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
75436479|NCT02918006|Other|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
75436480|NCT02918006|Other|Saline Solution for Placebo IM Injection|
75584717|NCT04592211|Drug|olaparib+pembrolizumab+paclitaxel|olaparib, 100~200mg, PO, bid, continuous pembrolizumab 200mg, IV, q 3 weeks paclitaxel 175g/m2 IV, q 3 weeks
75584718|NCT04583813|Drug|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
75436481|NCT02917772|Biological|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 8)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)"
75584719|NCT04583813|Other|Placebo|Empagliflozin matching placebo, once daily, for 24 months
75584720|NCT04576143|Drug|Epirubicin|i.v. 90 mg/m2
75584721|NCT04576143|Drug|Cyclophosphamid|i.v. 600 mg/m2
75584722|NCT04576143|Drug|Docetaxel|i.v. 100 mg/m2
75584723|NCT04576143|Drug|Paclitaxel|i.v. 175 mg/m2
75584724|NCT04592367|Procedure|Patient age at time of procedure of reconstruction of ACL|Primary reconstruction of ACL with no other concomitant ligament reconstructions. Treatment of cartilage og meniscal injury may be a part of the procedure
75584725|NCT04576221|Device|stacked breathing exercise|"• Breath stacking was done using a bag which is a simple device used to give artificial breaths..~It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal."
76052412|NCT04194476|Diagnostic Test|StatStrip blood glucose meter and strips|We'll use a drop of heel-stick blood to test blood glucose on the glucose meter. About 200-300 ul of blood from the same stick site will be collected, centrifuged to get plasma for testing of glucose level in a laboratory biochemistry analyzer.
76052413|NCT02216773|Procedure|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
75436482|NCT02909686|Dietary Supplement|Boswellia Serrata|
75436483|NCT02909686|Dietary Supplement|Curcumin|
75436484|NCT02909686|Dietary Supplement|Epimedium|
75436485|NCT02909686|Dietary Supplement|Fisetin|
75436486|NCT02909686|Dietary Supplement|Luteolin|
75584726|NCT04576221|Device|NIV by CPAP mask|provides pressurized air through a mask to help push air into your lungs and help you breathe
75584727|NCT04591899|Device|CAD/CAM splints|"Each of the maxillary and mandibular cast will scanned alone and then both scanned together in the centric relation using FREEDOM HD scanner1.~The CAD/ CAM splint will be designed using Exocad software; the design will be the same as the conventional one. The surveying will be done by the software and the under-cuts blocked.~The splints will be printed using Dent2 3D printer and then cured using Dentcure. The CAD/CAM splints material will be hard resin from PhotoCentric 3D."
75584728|NCT04583657|Other|Eggs|Consumption of two eggs (control or test) per day during three months
75584729|NCT04583267|Drug|tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration|Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
76052414|NCT02216773|Procedure|Portal vein embolization (PVE)|
75436487|NCT02909686|Dietary Supplement|Nettle|
75436488|NCT02909686|Dietary Supplement|Pycnogenol|
75436489|NCT02909686|Dietary Supplement|Reishi Mushroom|
75436490|NCT02909686|Dietary Supplement|Resveratrol|
75436491|NCT02909686|Dietary Supplement|Placebo|
75436492|NCT02885324|Drug|Cabozantinib|Subjects will receive Cabozantinib
75584730|NCT04583111|Drug|Domperidone|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
75584731|NCT04583111|Drug|sulpiride|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
75584732|NCT04583345|Behavioral|Questionnaires|Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.
75584733|NCT04583228|Drug|HLX71|Single-dose, intravenous infusion
75584734|NCT04583228|Other|Placebo|Single-dose, intravenous infusion
75584735|NCT00583245|Other|Gait Training|Gait training with physical therapist 2/week for 3 months
75584736|NCT04583189|Diagnostic Test|Performance of the test antigenic and test RT-PCR|Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
75584737|NCT01146652|Drug|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75584738|NCT04582877|Device|FFR measurement|FFR is measured sequentially with the test article and the predicate device.
76052415|NCT01601132|Drug|theophylline|300mg (80mg/15ml elixir)
75584739|NCT04576026|Behavioral|mental fatiguing task|a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
75584740|NCT04576026|Behavioral|45 - minute simulated soccer game|an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
75584741|NCT04576026|Behavioral|cognitive function|The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
75584742|NCT04582955|Drug|Chidamide in combination with chemotherapy|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
75436493|NCT02879812|Other|Performance Feedback Reports|Medical directors will be provided performance feedback reports that are a summary of clinical performance of transplant and racial disparity performance over a period of time aimed at providing information to allow them to assess and adjust their transplant performance. The report will emphasize tailored facility-specific information on the mean time on dialysis for patients in that facility and transplant access performance measures, such as wait listing and transplantation, including the magnitude of racial disparity, detailing when a facility is performing below the national or regional average.
75584743|NCT04591938|Device|Fantom Encore Bioresorbable scaffold implantation|Fantom Encore Bioresorbable scaffold implantation
75584744|NCT01146613|Drug|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
75584745|NCT01146613|Drug|Placebo|identical matched placebo x 2, 2xday, 13 weeks
75584746|NCT04591704|Other|hospitalisation, necessity of ICU, mortality rate, lung involvement|hospitalisation, necessity of ICU, mortality rate, lung involvement
75584747|NCT04582838|Diagnostic Test|Pulse oximeter|"In both groups, pulse oximeters provide continuous monitoring of oxygen saturation (SpO2).~Also, SpO2 curve can be recorded for off-line analysis."
75584748|NCT04582838|Diagnostic Test|ECG|ECG signal is used to monitor respiratory rate (RR).
75584749|NCT01145755|Drug|AZD2066|18 mg once daily
75584750|NCT01145755|Drug|Placebo|
75584751|NCT01145755|Drug|Duloxetine|60 mg once daily
75584752|NCT02883946|Other|Data collection|
75584753|NCT04591743|Device|Active TCS|TCS active at 1 Hz on the right DLPFC for 6 weeks
75584754|NCT04591743|Device|Placebo TCS|Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
76052416|NCT01601132|Drug|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
75584755|NCT04591743|Drug|nicotine treatment|at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
75584756|NCT04591743|Other|Questionnaires|"EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART"
75584757|NCT00625105|Behavioral|Biofeedback|
75584758|NCT00567060|Drug|Piracetam|
75584759|NCT00568217|Drug|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature > 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still < 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature < 38 degree Celsius
75584760|NCT00568256|Behavioral|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
75584761|NCT00583323|Drug|Lomotil|Orally 10ml of Lomotil
75584762|NCT00583323|Other|Normal saline|10 ml orally
75584763|NCT04575987|Other|Questionnaire|"Questionnaires will be sent by email or by post, in which questions about PFD, obstetrical history or dietetic follow-up will be asked.~Some obstetrical issues will be get from women medical files."
75584764|NCT04582604|Drug|modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine|Day -15 to -14 ： Decitabine 20 mg/m2/day, Ruxolitinib 70mg bid; Day-10： Cytarabine 1.6 g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9： Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 to -7： Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 50mg bid; Day-6: Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid; Day-4： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 20mg bid; Day-3： Carmustine 250mg/m2/day iv, Ruxolitinib 10mg bid; Day-2： Ruxolitinib 5mg bid; Day-1： Ruxolitinib 5mg qd;
75584765|NCT04582760|Other|early mobilization|In patients who require mechanical ventilation for acute respiratory failure or sepsis (non-malignant tumor patients), early mobilization will be performed in addition to conventional bedside physical therapy, for 30 mins per session, two sessions per day, 7 days per week until the patients are discharged from the ICU.
75584766|NCT00583401|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
75584767|NCT04582721|Other|Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)|"the participants with chronic intractable back or back and leg pain will be implanted with the stimulation lead(s). The leads are initially connected to an external trial neurostimulator. Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks trial phase will follow. The first two days after the leads implant will be without stimulation and thereafter alternating stimulation every week will start, randomly ordering the treatments using a Williams design balanced for first-order carryover effects (i.e. incorporating 6 different treatment orders), from:~1) CON-SCS with Subcutaneous stimulation~2) HF-SCS~3) Combination Therapy A patient's favored SCS mode, providing that there is at least 50% reduction in pain intensity on the NRS in the trial phase, will then be implanted and patients will be followed up for 12 months."
75584768|NCT00590928|Drug|esomeprazole|40mg once daily
76052417|NCT04818398|Drug|DS-6016a|DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
75436494|NCT02879812|Other|Educational Video for Staff|Dialysis facility staff will watch a ~10 minute educational video that describes the role of dialysis staff in improving transplant access, the new kidney allocation policy, and how the new policy impacts minority patients and those on dialysis for a substantial period of time.
76052418|NCT04818398|Drug|Placebo|Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
76052419|NCT04824482|Other|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
76052420|NCT04824482|Other|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
76052421|NCT04836962|Drug|normal saline|2cc of normal saline is administered to patient instead of dexamethasone.
75436495|NCT02879812|Other|Educational Video for Patients|Dialysis facilities will receive a ~10 minute educational video targeted to dialysis patients to explain the transplant process and allocation policy.
75584769|NCT00590928|Drug|ranitidine|50mg every h hours
76052422|NCT04836962|Drug|dexamethasone|dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
75436496|NCT02879812|Other|Educational Webinar|Education for medical directors and facility staff about the kidney allocation policy will be discussed in a webinar and information will be hosted on a website for participants to access. The seminar will be roughly 45 minutes, and CME will be offered.
75436497|NCT02879812|Other|Standard Care|Dialysis facilities will conduct standard or usual care and education regarding transplantation.
75584770|NCT00583440|Behavioral|12-step facilitation|12 weekly individual 12-step facilitation sessions
75584771|NCT00583440|Behavioral|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
75584772|NCT04582526|Behavioral|BMS program|A BMS program with three components: relaxation exercises, healthy eating, expressive arts therapy
76052423|NCT04199702|Other|Same day discharge|Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.
76052424|NCT05289440|Drug|Low-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
75436498|NCT02879812|Other|United Network for Organ Sharing (UNOS) Pamphlet|Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
75436499|NCT02829099|Drug|JNJ-64457107|JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
75436500|NCT02815254|Other|High intensity functional exercise|
75436501|NCT02815254|Other|Low intensity functional exercise|
75584773|NCT01145560|Drug|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
75584774|NCT01145560|Drug|Placebo|Placebo
75584775|NCT04582175|Procedure|angioplasty|angioplasty of all non-culprit lesions
75584776|NCT00591045|Drug|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
75584777|NCT01145482|Drug|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
75584778|NCT01145482|Other|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
75584779|NCT00583479|Other|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
75436502|NCT02803853|Behavioral|Intervention|Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
75584780|NCT00583479|Other|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
75881615|NCT02942277|Biological|Menactra|Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age
76052425|NCT05289440|Drug|High-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
75436503|NCT02713373|Biological|Cetuximab|Given IV
75436504|NCT02713373|Other|Laboratory Biomarker Analysis|Correlative studies
75584781|NCT04313413|Other|Yoga|Yoga sessions includes sukshma vyayama (strengthening yoga expertise), stretching and relaxing postures (asana) on chair or standing, breathing and meditation practices.
75584782|NCT00568295|Drug|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
75584783|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
75584784|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
75881616|NCT02942277|Other|Normal Saline|Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
76052426|NCT05289440|Drug|Saline infusion|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
76052427|NCT04709900|Diagnostic Test|CT angiography, FFR-CT and stress CT myocardial perfusion|The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
76052428|NCT04809974|Drug|Niagen|The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
76052429|NCT05226884|Diagnostic Test|Visual Acuity|Measurement of distance and intermediate visual acuity at variety targeted correction.
75436505|NCT02713373|Biological|Pembrolizumab|Given IV
75436506|NCT02686593|Drug|Clofarabine, AraC, mitoxantrone (CLAM)|The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
75584785|NCT00591084|Drug|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
75584786|NCT00591084|Drug|placebo|infusion placebo (group B)once a day and continued for 14 days
75584787|NCT00591084|Drug|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
75584788|NCT00591162|Drug|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
75730454|NCT03782337|Behavioral|multi-discipline disease management program|The multi-discipline disease management program consists of nursing lead education program, dietitian consultation, psychologist consultation and assessment, and cardiac rehabilitation program by physical therapist.The cardiovascular lead nurse will contact the patient by telephone within 3 days after discharge. An appointment at the outpatient clinic will be arranged within 1 to 2 weeks after discharge. The purposes of the telephone call are to reinforce self-management and recognition of HF symptoms and to screen post-discharge health status.
76052430|NCT05226884|Diagnostic Test|Defocus Curve|Measurement of a defocus curve
76052431|NCT03329612|Procedure|Remote Ischemic Preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions.
75436507|NCT02674438|Other|Risk stratification and transitional care intervention|"Intervention consists of 2 components:~Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores (EHMRG30-ST), where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores~Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48-72 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge."
75730455|NCT03773107|Drug|Carfilzomib|Irreversible proteasome inhibitor
75730456|NCT03773107|Drug|Ruxolitinib|Oral JAK inhibitor
75730457|NCT03773107|Drug|Dexamethasone|glucocorticoid
75730458|NCT03755934|Biological|MEDI7352|MEDI7352
75730459|NCT03755934|Other|Placebo|Placebo
76052432|NCT04691960|Other|Ketogenic Diet|Ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis. The diet will begin at an approximately 3:1 fat to carbohydrate + protein ratio for 5 days. If the patient does not show urine ketosis (1.5 mmol/L or 27.0 mg/dL), the ketosis diet will be advanced to approximately 4:1 ratio for 5 days. If the patient still does not attain ketosis a 24 hour fast will be done to promote ketosis. The diet will encourage at least 30 ml per day of Medium Chain Triglycerides (MCT) oil to enhance ketosis.
76052433|NCT04691960|Drug|Metformin|Metformin will be administered as a single 850 mg dose P.O. at Week 8, then titrated up to 850 mg P.O. BID at Week 10, and then 850 mg T.I.D. at Week 12, as tolerated.
75436508|NCT02583282|Other|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
75436509|NCT02583282|Other|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
75436510|NCT02553941|Drug|Azacitidine|Given intravenous or subcutaneous
75436511|NCT02553941|Drug|Ibrutinib|Given by mouth once daily
75584789|NCT00591162|Radiation|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
75584790|NCT00591162|Procedure|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
75584791|NCT00568373|Device|Enterra Gastric Pacemaker|Gastric Pacemaker
75730460|NCT03743766|Drug|Relatlimab|Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.
75730461|NCT03743766|Drug|Nivolumab|Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.
75730462|NCT03743766|Drug|Relatlimab + Nivolumab|Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
75730463|NCT03729817|Device|Submaximal balloon angioplasty|An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.
75584792|NCT00583518|Drug|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
75584793|NCT04582136|Drug|Sirolimus|In the double-blinded phase, sirolimus 1.5mg/day plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate continue on sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
75584794|NCT04582136|Drug|Placebo|In the double-blinded phase, placebo plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate are switched to receive sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
76052434|NCT04796792|Device|Break Wave Lithotripsy and Ultrasonic Propulsion|Novel ultrasound technologies to facilitate passage of stones.This includes Burst Wave Lithotripsy (BWL), a technology to noninvasively fragment urinary calculi within the kidney and ureter, and ultrasonic propulsion, a technology to non-invasively reposition stones within the kidney and ureter. BWL uses short multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. Ultrasonic propulsion uses long multi-cycle bursts of low amplitude ultrasound to move stones within the collecting system.
75584795|NCT04582331|Other|Smartphone-based voice and self-reported symptom collection|Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
75584796|NCT04582253|Diagnostic Test|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterior and posterior surfaces of the cornea to obtain corneal tomographic maps.
75584797|NCT00591201|Drug|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
75730464|NCT03716817|Device|Tetric CAD|Resilient ceramic crowns (Tetric CAD by Ivoclar Vivadent) are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
75730465|NCT03716544|Device|Amplification with hearing aid|Use of hearing aids
75730466|NCT03716544|Device|Customized music|Customized music delivered via an iPod
75730467|NCT03716180|Drug|Paclitaxel|"Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
76052435|NCT05279612|Radiation|Short-term neoadjuvant chemoradiotherapy|Short-term radiotherapy ( 25 Gy, 5f ) + XELOX regimen was performed before operation for two cycles. After the condition was evaluated by enhanced CT, whether the patients belonged to PD, SD, PR and CR was analyzed (reference RECIST 1.1). Surgery was performed four weeks after chemotherapy.
76052436|NCT03948854|Other|Registered dietitian|Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
76052437|NCT03948854|Other|On-line video program|Education on low FODMAP diet is provided by an on-line program via a link sent through email
76052438|NCT03948854|Other|Printed handout|Education on low FODMAP diet is provided through printed handout material at the initial visit.
75436512|NCT02546492|Drug|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
75436513|NCT02527564|Drug|Suvorexant|
76052439|NCT03948854|Other|Dietitian-led group|Education on low FODMAP diet is provided in a dietitian-led group setting
75436514|NCT02527564|Drug|Placebo|
75584798|NCT00591201|Drug|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
75584799|NCT04582058|Behavioral|Mobile Health of lifestyle|Mobile health of lifestyle with an orientation about daily activities and necessary care to patients with CEID, and protocol of exercise training with images and guidelines to execute five days per week, with a duration of 50 minutes, and space for doubts which patients could send message to researcher.
75584800|NCT04575831|Behavioral|Exercise, Nutrition, and Palliative Symptom Management|"Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake."
75584801|NCT04575753|Other|Study group|"Blood samples will be taken from ICU patients on the day of ICU admission, day 2 and day 5 after ICU admission.~Similarly, patients will be subjected to cognitive testing (CAM-ICU) to determine the presence of delirium"
76052440|NCT04816916|Drug|AXA1665|AXA1665 administered TID with food
76052441|NCT04816916|Drug|Placebo|Matching placebo administered TID with food
75436515|NCT02282007|Behavioral|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
75436516|NCT02179749|Drug|Mifepristone 1200 mg daily|Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
75436517|NCT02179749|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 8 week duration.
75436518|NCT02179749|Drug|Placebo|Placebo tablets, Four tablets daily/am for 1-week duration.
75584802|NCT04582097|Drug|Ramipril|angiotensin-converting enzyme inhibitor
75730468|NCT03716180|Drug|Trastuzumab|Trastuzumab works by targeting the HER2/neu receptor on cancer cells
75730469|NCT03716180|Drug|Pertuzumab|Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
76052442|NCT04809038|Other|dry needling|Patient will be placed in a comfortable prone position and encouraged to maintain complete relaxation. The selected active MTrPs was prepared by wiping the area with alcohol pad, and a gauge needle with its plastic guide tube in place will be palced over the active MTrPs .a tapping motion will be used to advance the needle to a depth of 5 to 10 mm for 30 seconds
75436519|NCT02075593|Drug|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
75436520|NCT02065609|Drug|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
75436521|NCT02065609|Drug|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
75584803|NCT04582097|Drug|placebo|same odor, color and size as the drug but without the active ingredient
75730470|NCT03696199|Drug|Long-Acting Local Anesthesia|"The cocktail consists of:~0.5% Ropivicaine, 24.6 mL~Clonidine 100 mcg/mL, 0.4mL~Epinephrine 1mg/mL, 0.5mL~Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded."
75436522|NCT01941108|Behavioral|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
75730471|NCT03696199|Drug|Regional Anesthesia|0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
75436523|NCT01037816|Drug|FS-67 Patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
75436524|NCT01037816|Other|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
75436525|NCT01009138|Behavioral|Diabetes-Specific CBT (DS-CBT)|"5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~Problem Analysis and Definition~Problem Solving Intervention~Cognitive Restructuring~Activation of personal and social Resources~Goal Definition and Agreement"
75584804|NCT04582019|Device|stent extraction|stent extraction using magnetic retriever or flexible cystoscope
75584805|NCT04575714|Other|Data record|Data record
75584806|NCT04581707|Device|Kyphoplasty Single Balloon Catheter Allevo|Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement
75584807|NCT04581707|Device|Quattroplasty Double Balloon Catheter Stop'n GO|Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement
75584808|NCT00591357|Drug|loperamide|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
75584809|NCT00591357|Drug|placebo|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
75584810|NCT04581590|Other|Cognitive training|Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
75584811|NCT00591396|Drug|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
75584812|NCT04581278|Diagnostic Test|KTD Innov-2|"The main objective of the present study (KTD Innov-2) is to validate the feasibility of SDI within a limited time frame to ensure its clinically relevant use, with a high level of evidence to consider its labelling as a medical device by health authorities prior to routine transfer and/or future marketing.~300 kidney transplant patients will be included in the KTD Innov-2 study with data collection, blood, urine and graft biopsies for biomarker analysis and conversion to SDI (decisional algorithms) and interactive multi-dimensional presentation on a web interface for use of the tool by transplant physicians and their patients."
75584813|NCT00591435|Other|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
75584814|NCT04580966|Behavioral|Inquiry Based Stress Reduction (IBSR) workshop|The IBSR intervention workshop included weekly group meetings (3.5 hours/meeting) for 12 weeks. During the workshop, participants were encouraged to identify and inquire their stressful thoughts. Using self-inquiry practices participants were taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants took an active role in investigating their stressful thoughts, and by this regulated their stress and managed symptoms and emotions, thus enabled them to cope better with the psycho-social consequences of the stuttering.
75584815|NCT04580849|Other|telerehabilitation with dance|Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
76052443|NCT04809038|Other|magnesium sulphate iontophoresis|The subjects in the iontophoresis group received MgSO4 iontophoresis using an iontophoretic drug delivery system (Phoresor_IIAuto,ModelPM850,IOMED. MTrPs were examined using pincer palpation and marked by pin. MgSO4 was applied to the active positive electrode using a syringe with a concentration of 100 mg/cm2. The active electrode was placed directly over the marked area where the sensitive MTrPs were located. The dispersive electrode was applied to the skin 6 inches distal from the active electrode.
75436526|NCT01009138|Behavioral|Standard Diabetes Education|"Standard Diabetes Education Lesson including~Health Care and specific Topics (e. g. Blood Pressure)~Social Aspects of Living with Diabetes~Diabetes Complications~Sports, Activities and Exercise~Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy"
75436527|NCT00641186|Drug|sodium oxybate|4.5 to 9.0 grams per night
75436528|NCT01561482|Drug|Metformin|Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
75436529|NCT01561482|Drug|Simvastatin|The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
75436530|NCT01561586|Drug|Weekly cisplatin with RT|"Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
75584816|NCT00591474|Dietary Supplement|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
75584817|NCT00591474|Dietary Supplement|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
75584818|NCT04581239|Other|Active neural mobilization|"Active neural mobilization Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization.~Active oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set"
75881617|NCT02942277|Drug|Coartem|Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
75584819|NCT04581239|Other|passive neural mobilization|"Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization~Passive neural mobilization This oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set. Both groups received total 18 session 3 session per week for consecutive 6 weeks"
75584820|NCT04581083|Diagnostic Test|RT-PCR|RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.
75584821|NCT04581083|Diagnostic Test|LAMP|LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.
75584822|NCT04581083|Diagnostic Test|POOL RT-PCR|POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.
75584823|NCT04581083|Diagnostic Test|POOL LAMP|POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
75584824|NCT03452241|Other|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
75436531|NCT01561586|Drug|Tri-weekly cisplatin with RT|"Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
75436532|NCT01561859|Behavioral|Cognitive Enhancement Therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
75436533|NCT01561859|Behavioral|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
75436534|NCT01562145|Procedure|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
75584825|NCT03452241|Other|Control Group|The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
75584826|NCT04581005|Behavioral|Prehabilitation|Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period
75584827|NCT04575675|Drug|Dapagliflozin|Dapagliflozin 10mg once daily
75584828|NCT04575675|Drug|Sacubitril-Valsartan|Sacubitril-Valsartan, maximal tolerated dosage
75584829|NCT04575675|Drug|Beta blocker|Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
75584830|NCT04575675|Drug|Mineralocorticoid Receptor Antagonist|Mineralocorticoid receptor antagonist, including spironolactone or eplerenone
75730472|NCT03684187|Behavioral|Mindfulness Based Intervention|"Mindfulness - Based Intervention (MBI) Course:~The 8-week MBI program is comprised of an orientation session, 8 separate weekly sessions of 2.5 hours and also a 7.5 hour retreat session on a weekend day. The orientation session will include an introductory session, description of the course and will include completion of stress surveys. During the orientation session, there will be explanation to the patients of objectively the basis of mindfulness teaching. The role of the stress surveys that are conducted are to assess an individual's degree of stress prior to the initiation of any mindfulness practice teaching.~Subjects will also be asked to wear a BodyGuard 2 (BG2) for parts of the study, on average of 7 days at baseline, end of the control phase, end of intervention phase, and end of 48 week follow up period. This will track subjects heart rate (HR), HR variability, VO2, energy expenditure and activity."
75584831|NCT04575675|Device|Cardiac resynchronization therapy and/or implantable cardioverter defibrillator|CRT-P, CRT-D or ICD if clinically indicated
75584832|NCT00568412|Device|Zarzenda|Topical cream, applied twice daily for three weeks
75436535|NCT01562171|Other|Cooked Lentils|Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
75436536|NCT01562171|Other|Potato-Based Foods|Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
75436537|NCT01562184|Device|Sham tDCS device|Sham tDCS
75436538|NCT01562184|Device|Soterix tDCS device|Active tDCS
75436539|NCT01562392|Dietary Supplement|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
75436540|NCT01562392|Dietary Supplement|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
75584833|NCT00568412|Drug|Elidel|1% cream, applied topically twice daily for three weeks
75436541|NCT01562574|Drug|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
75584834|NCT03452163|Device|PMD-200|"the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception."
75584835|NCT03452163|Device|EEG monitor|An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
75584836|NCT00568529|Drug|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
75584837|NCT00568568|Drug|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
75584838|NCT04575558|Drug|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
75730473|NCT03674229|Other|Informational Intervention|Receive information about weight management programs
75730474|NCT03674229|Other|Questionnaire Administration|Ancillary studies
75730475|NCT03674229|Behavioral|Telephone-Based Intervention|Receive phone calls from an assigned patient navigator
75730476|NCT03651349|Drug|HK-001|HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.
75436542|NCT01562574|Drug|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
75436543|NCT01562587|Drug|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
75436544|NCT01562587|Drug|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
75584839|NCT04581161|Device|Life2000® Ventilator|"POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."
75584840|NCT03452124|Device|I quit ordinary smoking (IQOS)|I quit ordinary smoking (IQOS) assisted cessation program
75584841|NCT03452124|Other|Conventional cigarette|Conventional cigarette smoking continuation
75584842|NCT00568607|Drug|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
75584843|NCT03452085|Device|artificial saliva spray (AS)|cross over design
75584844|NCT03452085|Other|maritime throat spray (TT)|cross over design
75584845|NCT00568646|Drug|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
76052444|NCT04809038|Other|stretching exercise|The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
76052445|NCT05652998|Biological|C. albicans antigen|a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.
76052446|NCT05652998|Other|autologous PRP|patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.
76052447|NCT05652998|Other|saline|patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment
75436545|NCT01562704|Drug|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
75436546|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
75436547|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
75436548|NCT01562821|Drug|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
75436549|NCT01563133|Procedure|EUS-FNA|Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
75436550|NCT01563133|Device|nCLE|needle-based Confocal Laser Endomicroscopy
75584846|NCT03452046|Other|IVC diametres|
75584847|NCT00568763|Biological|sargramostim|
75584848|NCT00568763|Other|immunoenzyme technique|
75584849|NCT00568763|Other|immunohistochemistry staining method|
75584850|NCT00568763|Other|immunologic technique|
75584851|NCT00568763|Other|laboratory biomarker analysis|
75584852|NCT00568763|Procedure|biopsy|
75584853|NCT00568763|Procedure|cryosurgery|
75584854|NCT00568763|Procedure|radiofrequency ablation|
75881618|NCT05042947|Device|double-loop clips|a new ligation method using the double-loop clips (D-L clips) technique
75881619|NCT05042947|Device|Titanium Clip|the Titanium Clip
75584855|NCT04575480|Procedure|Shock Wave Lithotripsy for renal stone.|The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with <2 sessions will be excluded from the analysis
75584856|NCT00568841|Drug|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
75584857|NCT00568841|Procedure|FDG-/FLT-PET|
75584858|NCT00583869|Drug|Placebo|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
75584859|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
75436551|NCT01563263|Biological|IC43|100 mcg
75730477|NCT03651349|Drug|Placebo control|In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
75881620|NCT01365013|Behavioral|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
75881621|NCT01365013|Behavioral|Control group|Standard advice for lifestyle change
75436552|NCT01563263|Drug|Placebo|phosphate buffered saline (PBS) solution containing 0,9 % NaCl
75436553|NCT01563445|Drug|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
75436554|NCT01563445|Drug|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
75436555|NCT01563458|Drug|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
75881622|NCT02085044|Dietary Supplement|Ready-to-Used Supplement Food administration|
75881623|NCT02835963|Other|Data collection|Usual data collection
75436556|NCT01563458|Drug|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
75436557|NCT01563458|Drug|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
75584860|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
75730478|NCT03632993|Drug|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
75436558|NCT01563471|Drug|activated recombinant human factor VII|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
75436559|NCT01563471|Drug|placebo|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
75436560|NCT01563497|Drug|PF-05089771|Oral dispersion TS formulation- fasted
75436561|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fasted
75584861|NCT00568880|Drug|bortezomib|bortezomib 1.0-1.3mg/m2 IV
75584862|NCT00568880|Drug|hydroxychloroquine|hydroxychloroquine 200 mg pill
75584863|NCT03451968|Other|amino acid tracer injection for metabolism analysis|"the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc)."
75584864|NCT00569036|Drug|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
75584865|NCT00569075|Other|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
75584866|NCT03453021|Drug|Mepolizumab|
75584867|NCT03453944|Device|VentFree prototype (VF03-K) active stimulation|Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)
75584868|NCT03453944|Device|VentFree prototype (VF03-K) sham stimulation|Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
75584869|NCT03451890|Drug|E2730|oral capsule
75436562|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fed
75584870|NCT03451890|Drug|Placebo|oral capsule
75584871|NCT02277392|Biological|Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells|
75584872|NCT02277392|Biological|SB---485232 (Human recombinant Interleukin---18)|
75584873|NCT00569114|Drug|TG01|Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
75584874|NCT03452904|Device|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
75584875|NCT03452904|Device|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
75584876|NCT00569426|Device|NovoFine® needle 6 mm|
75584877|NCT00569426|Device|NovoFine® needle 8 mm|
75584878|NCT03451695|Drug|Morphine|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
75584879|NCT03451695|Drug|Placebo|Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
75584880|NCT00569465|Drug|Arginine|1200 mg, once a day
75584881|NCT00569465|Drug|Acetylcysteine|600 mg twice a day
75584882|NCT00569465|Drug|Placebo|3 vials a day
75584883|NCT00583986|Drug|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
75584884|NCT00569621|Drug|Moxaverine|intravenous administration
75584885|NCT00569621|Drug|physiological saline|intravenous administration
75584886|NCT03451617|Device|Stent delivery with Xpedition|Use of Xpedition stent delivery system to implant the XIENCE stent
75584887|NCT03451617|Device|Stent delivery with Alpine|Use of Alpine stent delivery system to implant the XIENCE stent
75584888|NCT00569699|Drug|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25 m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
75730479|NCT03626402|Behavioral|Planning for the Care You Want|25-minute culturally specific educational video informing viewers about advance care planning options, palliative care, and hospice care and meeting with a lay health advisor to discuss content of the video.
75584889|NCT00569738|Procedure|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
75584890|NCT00569816|Drug|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
75584891|NCT04580576|Procedure|Hematopoietic stem cell transplantation|Allogeneic or autologous bone marrow transplant
75584892|NCT00569894|Biological|FLuMist|One or two vaccinations with FluMist depending on prior vaccination status.
75584893|NCT00569894|Biological|TIV (Injection)|One or two injections of TIV depending on previous status.
75584894|NCT00569894|Other|Unvaccinated Control|no vaccine
75584895|NCT00584064|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
75584896|NCT00569933|Behavioral|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
75584897|NCT04574661|Other|Static Stretching|In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.
75584898|NCT04574661|Other|Intermittent Occlusion|Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
75584899|NCT00570011|Drug|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
75881624|NCT03559244|Other|Dynamic compression brace|custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
75881625|NCT03559244|Other|Exercises|posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
75584900|NCT00570011|Drug|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
75584901|NCT04574388|Other|open label placebo|open label placebo pill
75584902|NCT04581122|Procedure|Lymphadenectomy|Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
75881626|NCT04548375|Device|SCS|Conventional SCS implants approved through all payors(government and private) for FDA approved indications
75436563|NCT01563510|Procedure|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
75584903|NCT00570050|Drug|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
75584904|NCT00570050|Drug|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
75584905|NCT00584103|Device|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
75584906|NCT00584103|Device|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
75584907|NCT00570167|Procedure|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
75584908|NCT00570167|Procedure|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
75584909|NCT00584142|Behavioral|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
75584910|NCT00570206|Behavioral|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
75584911|NCT00570245|Drug|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
75584912|NCT00570245|Drug|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
75881627|NCT02082236|Drug|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
75881628|NCT02082236|Drug|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
75881629|NCT02082236|Drug|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
75881630|NCT02082236|Drug|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
76052448|NCT05362136|Procedure|perforation of the sinus floor|perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation
76052449|NCT05362136|Procedure|no perforation of the sinus floor|standard procedure for sinus floor elevation
75436564|NCT01563510|Procedure|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
75584913|NCT04574544|Drug|Zinc Supplementation|The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
75584914|NCT04574544|Behavioral|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
75584915|NCT00570284|Drug|LBH589|orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
76052450|NCT05221190|Procedure|Single buccal infiltration|injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.
76052451|NCT05221190|Procedure|Inferior alveolar nerve block|Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
75584916|NCT00570440|Drug|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
75584917|NCT00584259|Other|Coffee|3 cups of coffee over a 24 hour period
75584918|NCT00570479|Drug|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
75584919|NCT04574622|Device|radial Extracorporeal Shockwave Therapy|rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
75584920|NCT00584298|Drug|SMS995|
75584921|NCT00584298|Drug|Placebo|
75584922|NCT00570557|Other|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
75584923|NCT04580264|Behavioral|REINTERVENTION|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
75584924|NCT00584376|Drug|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
76052452|NCT04816682|Drug|Silymarin|Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
76052453|NCT02162719|Drug|Ipatasertib|Participants received ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
75436565|NCT01563523|Drug|activated recombinant human factor VII|Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
75436566|NCT01563523|Drug|placebo|Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
75584925|NCT00584376|Drug|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
75584926|NCT00570830|Device|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
75584927|NCT04574349|Procedure|Decompressive craniectomy|Removing part of the skull (bone flap) to lower intracranial pressure
75584928|NCT00570869|Other|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
76052454|NCT02162719|Drug|Paclitaxel|Participants received paclitaxel 80 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
76052455|NCT02162719|Drug|Placebo|Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
76052456|NCT03939728|Radiation|Chest radiography and lung ultrasound|We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
75584929|NCT04574310|Other|Collect retrospectively data on embryo implantation rate|Collect retrospectively data on embryo implantation rate
75584930|NCT00570947|Other|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
75584931|NCT00584493|Drug|CP-675,206|"This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma~Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206."
75584932|NCT00571025|Behavioral|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
75881631|NCT02085122|Other|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
75881632|NCT02082314|Procedure|RFA Vertebroplasty|
75881633|NCT02085200|Other|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
75436567|NCT01563900|Device|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
75436568|NCT01563900|Device|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
75584933|NCT04573959|Device|SV-3 Capsule Endoscopy|The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
75584934|NCT04574037|Other|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential)|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential) will determine the predictive functional outcome of the upper limb deficit according to the PREP2 algorithm.
75436569|NCT01564095|Drug|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
75584935|NCT04580342|Drug|oral Ivabradine|Ivabradine group will receive ivabradine 5mg PO in the evening and 1 hour before anesthetic induction
75881634|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
75881635|NCT03557996|Drug|Silver Diamine Fluoride|SDF will be applied with a brush
75881636|NCT03557996|Drug|Sodium Fluoride Varnish|NaF will be applied with a brush
75881637|NCT03559166|Drug|BLD-2660|Randomized to active product or placebo
75436570|NCT01564095|Drug|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
75881638|NCT02088710|Behavioral|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
75881639|NCT02085278|Device|Apollo Micro Catheter device|Detachable Tip Micro catheter
75881640|NCT03559088|Other|Migraine App|Smart phone app used to report migraine burden to the EHR.
75881641|NCT02296801|Drug|Letrozole|
75881642|NCT02296801|Drug|palbociclib|
75881643|NCT02082470|Other|follow-up care|Undergo survivorship care planning
75881644|NCT02082470|Other|active surveillance|Undergo cancer surveillance
75881645|NCT02082470|Other|questionnaire administration|Ancillary studies
76052457|NCT05652842|Behavioral|Work-type|Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.
76052458|NCT02161549|Device|Motus Gl CleanUp System|
75584936|NCT04580342|Drug|oral Propranolol|propranolol group will receive propranolol 10 mg PO in the evening and 1 hour before anesthetic induction.
75436571|NCT01564238|Other|Low Na diet (1.3 g/d)|20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.
75436572|NCT01564238|Other|High sodium diet (3.8 g/d)|20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
75436573|NCT01564524|Procedure|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
75436574|NCT01564576|Drug|Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
75436575|NCT01564771|Other|Non Intervention|This Is A Non Interventional Study
75436576|NCT01564823|Drug|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
76052459|NCT05652530|Drug|Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)|This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
76052460|NCT02189863|Device|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
76052461|NCT02189863|Device|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
76052462|NCT02189863|Device|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
75584937|NCT00571142|Procedure|Bevacizumab + Pars plana vitrectomy|2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
75584938|NCT00571142|Procedure|Bevacizumab + pars plana vitrectomy|2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
75436577|NCT01564823|Drug|Metronidazole|Metronidazole 250 mg/8h 3 months
75436578|NCT01564823|Drug|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
75436579|NCT01564823|Drug|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
75584939|NCT03453905|Diagnostic Test|CTFEA|CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.
75584940|NCT03453905|Other|Conventional decision algorithm|Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
76052463|NCT02189863|Device|Comfilcon A MF|Multifocal contact lenses worn in both eyes
76052464|NCT02189863|Device|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
76052465|NCT05274776|Device|EOS calculator|For this study the EOS calculator was developed as a mobile application (by everywhereIM), including CE marking. It is concerned a medical device for health care professionals.
75584941|NCT00584571|Procedure|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
75584942|NCT00584571|Drug|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
75584943|NCT03451500|Drug|carbidopa-levodopa|See previous
75584944|NCT04573998|Procedure|LSG|bariatric surgery
75584945|NCT00571181|Device|Closed-loop system|Automatic delivery of propofol and remifentanil
75584946|NCT00571181|Device|TCI (Infusion Toolbox)|TCI administration of propofol and remifentanil
75584947|NCT00584610|Device|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
75881646|NCT02085434|Behavioral|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
75436580|NCT01565239|Device|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
75730480|NCT03620266|Dietary Supplement|Bilberry|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
75881647|NCT02859324|Drug|CC-122|
75436581|NCT01565265|Drug|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
75436582|NCT01565265|Drug|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
75584948|NCT00584610|Device|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
75584949|NCT00571220|Procedure|gastric bypass surgery|weight loss bariatric surgery
75584950|NCT00571220|Other|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
75584951|NCT00584649|Procedure|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
75584952|NCT00571298|Procedure|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
75584953|NCT00571298|Drug|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
75584954|NCT00571298|Drug|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
75584955|NCT00571298|Drug|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
75584956|NCT00571298|Drug|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
75584957|NCT00571298|Procedure|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
75584958|NCT04574271|Behavioral|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
75584959|NCT04574271|Behavioral|Usual dietary advice and exercise prescription|Generalized dietary advice and excercise prescription in elder patients.
75584960|NCT00571337|Drug|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
75584961|NCT04575519|Drug|Control group|placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
75584962|NCT04575519|Drug|ASA group|Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
75584963|NCT04575519|Drug|IBU group|Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
75584964|NCT04575519|Drug|SoC TB|Standard of Care Tuberculosis treatment
75584965|NCT00571376|Other|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
75584966|NCT04573803|Drug|Phenytoin Sodium|Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
75584967|NCT04573803|Drug|Levetiracetam|Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
75436583|NCT01565863|Behavioral|Progressive Goal Attainment Program|The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
75584968|NCT04575441|Other|Exercise with pilates ball|Pilates ball exercises are used to give various sensory stimulation and increase motor skills. Children usually enjoy these kind of exercises as there is ball in every movement.
75584969|NCT04573374|Procedure|Pulpotomy|Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.
75584970|NCT00571454|Behavioral|telephone depression care management|"1 call per week for first 4 weeks~1 call every other week for next 8 weeks"
75881648|NCT02859324|Drug|Nivolumab|
75436584|NCT01566292|Drug|BOTOX|Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
75584971|NCT01144663|Biological|Nimenrix™|4- or 3-dose intramuscular injection
75584972|NCT01144663|Biological|Menjugate®|3-dose intramuscular injection
75584973|NCT01144663|Biological|NeisVac-CTM|3-dose intramuscular injection
75584974|NCT01144663|Biological|Infanrix™ hexa|4-dose intramuscular injection
75584975|NCT01144663|Biological|Synflorix™|4-dose intramuscular injection
75584976|NCT00571571|Behavioral|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
75584977|NCT00571571|Behavioral|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
75584978|NCT00584688|Drug|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
75584979|NCT00571610|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
75881649|NCT02085512|Procedure|Neurocognitive retraining Web Based Intervention|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
75881650|NCT02085512|Other|Control, web-based tasks|No training modules
75584980|NCT00584766|Procedure|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
75584981|NCT04573686|Drug|Erythropoietin|Erythropoietin will be given subcutenous to all patients
75436585|NCT01566344|Other|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
75584982|NCT05206708|Behavioral|Personalized psychotherapy|Strategy including personalized psychotherapy
75584983|NCT05206708|Behavioral|Standard of care|Strategy based standard intregrative psychodynamic therapy
75730481|NCT03620266|Dietary Supplement|Placebo|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
75730482|NCT03620266|Dietary Supplement|Bioprocessed oat bran|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
75881651|NCT01365247|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
75881652|NCT01365247|Behavioral|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
75436586|NCT01566357|Other|Toothpaste|
75584984|NCT02883634|Other|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
75584985|NCT02883634|Other|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
75436587|NCT01566357|Dietary Supplement|Milk|
75436588|NCT01566357|Dietary Supplement|Fluoridated Milk|
75436589|NCT01566357|Drug|Tooth Mousse|
75436590|NCT01566357|Drug|MI Paste Plus|
75436591|NCT01566357|Drug|Elmex Erosion Protection|
75584986|NCT04573257|Other|Echocardiography and pulse wave velocity measurement|Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
75584987|NCT01143337|Drug|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
75881653|NCT01365247|Behavioral|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
75881654|NCT02085590|Biological|BCG vaccine|
75881655|NCT02085590|Biological|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
75881656|NCT02143063|Behavioral|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
75881657|NCT02143063|Behavioral|prize contingency management on a variable interval schedule for cocaine abstinence|
75881658|NCT02143063|Behavioral|standard care|
75436592|NCT01566422|Drug|Vancomycin powder|patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
75436593|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
75436594|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
75436595|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
75436596|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
75436597|NCT01566760|Drug|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
75436598|NCT01566890|Drug|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
75584988|NCT01143337|Drug|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
75584989|NCT04313023|Drug|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
75881659|NCT02088866|Drug|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
75881660|NCT02859246|Drug|Mucinex®|Mucinex®
75881661|NCT02088944|Drug|Infliximab|
75881662|NCT03609606|Drug|D013, D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
75436599|NCT01566890|Procedure|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
75436600|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
75436601|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
75436602|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
75436603|NCT01566929|Dietary Supplement|Low calorie diet treatment|Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
75436604|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
75436605|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
75436606|NCT01567072|Drug|Placebo|Only placebo treatment instead of NSAID painkillers
75436607|NCT01567098|Procedure|single incision laparoscopic appendectomy|performing appendectomy through a single incision in the abdomen
75436608|NCT01567423|Drug|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
75436609|NCT01567423|Drug|Coartem®, Novartis|"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~tab/dose for children 5 to 14.9 kg (total 6 tabs)~tabs/dose for children 15 to 24.9 kg (total 12 tabs)"
75584990|NCT04313023|Drug|Placebo|Sterile saline for inhalation
75881663|NCT03609606|Drug|D013|Daily oral administration of 1 tablet under fasting conditions for 7 days
75881664|NCT03609606|Drug|D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
75584991|NCT02883595|Drug|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
75584992|NCT02883595|Other|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
75584993|NCT00571766|Drug|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
75584994|NCT00571766|Drug|Placebo|Placebo 2 g twice a day for 14 weeks
75584995|NCT01143259|Drug|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
75584996|NCT01143259|Drug|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
75584997|NCT04573608|Drug|Papacarie|Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
75584998|NCT04573608|Drug|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
75584999|NCT00571805|Drug|varencline|2.0 mg/day varencline (1.0 mg BID)
75585000|NCT00571805|Drug|placebo|matching placebo
75585001|NCT02883556|Drug|Pembrolizumab|200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
75585002|NCT04580069|Procedure|Lymphatic drainage|The interventions follow the validated techniques normally used in international rehabilitation
75585003|NCT00584961|Other|non-interventional|non-interventional
75585004|NCT00571844|Behavioral|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
75730483|NCT03620266|Dietary Supplement|Combination bilberry/oats|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
75730484|NCT03580616|Drug|L-Serine|L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.
75730486|NCT03566667|Drug|Metoprolol|Betablocker
75730487|NCT03566667|Drug|Standard care|Standard care
75730488|NCT03544489|Behavioral|E-ICD Intervention|Home walking 3 days/week x 12 weeks
75730489|NCT03539614|Drug|Prazosin|This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.
75585005|NCT00571844|Behavioral|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
75585006|NCT00585000|Drug|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
75585007|NCT00571883|Other|questionnaire administration|
75585008|NCT00571883|Procedure|psychosocial assessment and care|
75585009|NCT00571883|Procedure|quality-of-life assessment|
75585010|NCT00571883|Procedure|regional lymph node dissection|
75436610|NCT01567631|Procedure|intrahepatic Glisson's approach|Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.
75436611|NCT01567631|Procedure|classical hepatectomy|Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
75436612|NCT01567787|Radiation|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
75436613|NCT01567787|Radiation|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
75585011|NCT00571883|Procedure|therapeutic conventional surgery|
75585012|NCT00585117|Procedure|PET-imaging with CuATSM|imaging with CuATSM
75585013|NCT00585117|Procedure|PET Imaging|Imaging with CuATSM
75585014|NCT00585117|Procedure|PET CuATSM|Imaging with CuATSM
75585015|NCT00585117|Procedure|PET imaging|imaging with CuATSM
75585016|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
75585017|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
75585018|NCT00572000|Biological|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
75585019|NCT00572078|Drug|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
75436614|NCT01568190|Biological|AVANZ MITE|Immunotherapy Dermatophagoides mix
75585020|NCT01142791|Device|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
75585021|NCT04573218|Drug|Placebo|The placebo contains glucose
75585022|NCT04573218|Dietary Supplement|250 mg OPP|250 mg Oil Palm Phenolics
75585023|NCT00572312|Drug|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
75585024|NCT00585156|Drug|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
75585025|NCT00572351|Other|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
75585026|NCT00572351|Other|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
75585027|NCT01142596|Drug|Asenapine|Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
75585028|NCT01142596|Drug|Placebo|Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
75585029|NCT00572390|Drug|oestrogen|Cyclic oestrogen substitution therapy
75585030|NCT01142128|Drug|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
75585031|NCT01142128|Drug|Placebo to Nexium|one capsule per day for one month
75585032|NCT01142128|Drug|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
75585033|NCT01142128|Drug|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
76052466|NCT04808882|Drug|Tinzaparin, Low dose prophylactic anticoagulation|"Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
75585034|NCT04572867|Device|Aquapheresis|The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).
75585035|NCT04572867|Drug|IV Diuretics|Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR< 2.0, or 5mg PO if Cr > 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
75585036|NCT00572429|Dietary Supplement|l-carnitine|3 gram daily dose
75585037|NCT00572507|Device|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
75585038|NCT01142089|Drug|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
75436615|NCT01568515|Procedure|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention & control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
75436616|NCT01568632|Drug|Imetelstat|
75436617|NCT01568645|Drug|Carvedilol|
75436618|NCT01568645|Drug|Imatinib|
75436619|NCT01568684|Other|Citalopram|Treatment
75436620|NCT01568970|Behavioral|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
75436621|NCT01568970|Behavioral|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
75585039|NCT01142089|Drug|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
75436622|NCT01569347|Other|Interviews|Interviews
75436623|NCT01569347|Other|Blood sample|Blood sample
75436624|NCT01569347|Other|Hair sample|Hair sample
75436625|NCT01569685|Drug|Venlafaxine|Tablets, once a day, max 375 mg day (maximal recommended dose)
75436626|NCT01569685|Drug|Sertraline|Tablets, once a day, maximum 200 mg/day (maximum required dose)
75436627|NCT01569997|Other|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
75436628|NCT01570023|Behavioral|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
75436629|NCT01570049|Drug|Bendamustine|for injection
75585040|NCT00585390|Dietary Supplement|Omega-3 Fatty Acids|"Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~Docosahexaenoic acid fish oil concentrate at 1.6 grams"
75585041|NCT00585390|Other|Olive oil placebo|Olive oil capsules, 8 capsules per day
75585042|NCT00585390|Dietary Supplement|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
75585043|NCT00585390|Drug|Placebo|Olive oil capsule
75585044|NCT01141660|Device|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
75585045|NCT01141660|Device|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
75585046|NCT02883790|Dietary Supplement|Somnage|Melatonin 1mg, Zinc, Magnesium
75585047|NCT02883790|Other|Placebo|Placebo
75585048|NCT00572663|Drug|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
75585049|NCT04572672|Other|Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting|"Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study."
75585050|NCT01140880|Drug|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
75436630|NCT01570062|Device|HEPA Filter|"Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration)."
75585051|NCT00572702|Procedure|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
75585052|NCT00572702|Procedure|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
75585053|NCT01140646|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
75730490|NCT03539614|Drug|Placebo|This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
75730491|NCT03514589|Drug|nasal Tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
75730492|NCT03514589|Drug|IV tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
75730493|NCT03497546|Other|Exercise|Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
75730494|NCT03496805|Drug|MGE|The patients will take 4 capsules by mouth BID (twice daily).
75730495|NCT03496805|Other|Placebo|The patients will take 4 capsules by mouth BID (twice daily).
75730496|NCT03496805|Other|ADT|Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
75730497|NCT03495609|Drug|Ovitrelle|Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
75730498|NCT03493282|Drug|Active Treatment- CT1812 100 mg|CT1812
75730499|NCT03493282|Drug|Active Treatment- CT1812 300 mg|CT1812
75730500|NCT03493282|Drug|Placebo|Matching Placebo
75730501|NCT03475810|Device|Virtual Reality|Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.
75436631|NCT01570062|Device|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
75585054|NCT01140646|Other|questionnaire administration|Ancillary studies
75585055|NCT01140646|Procedure|quality-of-life assessment|Ancillary studies
75585056|NCT00572741|Dietary Supplement|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
75585057|NCT00572741|Dietary Supplement|Placebo|cellulose
75585058|NCT00572741|Dietary Supplement|folate|Folinic acid: Dose: 400 µg twice a day (BID)
75585059|NCT00572741|Dietary Supplement|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
75585060|NCT00572741|Dietary Supplement|vitamin C|Vitamin C 500 mg
75585061|NCT00572741|Dietary Supplement|cod liver oil|Cod liver oil 1/2 teaspoon
75730502|NCT03475810|Drug|Midazolam|1-2 mg midazolam will be administered before spinal punction performed.
75585062|NCT00572741|Dietary Supplement|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
75585063|NCT00572741|Dietary Supplement|carnitine|Acetyl L-Carnitine Dose: 250 mg
75730503|NCT03445494|Procedure|Brace|A brace to be weared according to protocol
75730504|NCT03445494|Procedure|Normal sling|A normal sling to be weared according to protocol
75730505|NCT03443856|Drug|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
75436632|NCT01570075|Procedure|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
75585064|NCT01140568|Drug|nilotinib|400mg po (orally) BID (twice daily)
75730506|NCT03443856|Other|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
75881665|NCT02073097|Drug|Carfilzomib|"Given IV, according to dose level. Cohorts begin with dose level (DL)1, escalated in standard 3+3 design to identify a recommended phase 2 dose DL (-2) 11 mg/m2 on day 1 and 2 every 21 days, cycles 1-6~DL (-1) 15 mg/m2 on days 1 and 2 every 21 days, cycles 1-6~DL (1) 20 mg/m2 days 1,2 every 21 days, cycles 1-6~DL (2) 20 mg/m2 days 1,2 of cycle 1 followed by 27 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL (3) 20 mg/m2 days 1,2 of cycle 1 followed by 36 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL(4) 20 mg/m2 days 1,2 of cycle 1 followed by 45 mg/m2 days 1,2 every 21 days for cycles 2-6~DL (5) 20 mg/m2 days 1,2 of cycle 1 followed by 56 mg/m2 days 1,2 every 21 days for cycles 2-6"
75436633|NCT01570075|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
75436634|NCT01570088|Dietary Supplement|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
75436635|NCT01570088|Dietary Supplement|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
75585065|NCT04572945|Diagnostic Test|kidney function test|laboratory and imaging
75585066|NCT00572819|Drug|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
75585067|NCT00572819|Drug|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
75585068|NCT00572858|Procedure|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
75585069|NCT00572858|Genetic|Blood test|Blood test for genetic testing
75436636|NCT01570088|Other|Placebo|Placebo contains no folic acids
75436637|NCT01570101|Device|CE Marked Sapheon Closure System|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
75436638|NCT01570114|Device|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
75436639|NCT01570127|Procedure|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
75585070|NCT00572858|Procedure|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
75585071|NCT00572858|Procedure|Saliva test|Saliva test for cotisol levels
75585072|NCT00572975|Other|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|"Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1"
75730507|NCT03418753|Diagnostic Test|EyeBOX for ICP|non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time
75730508|NCT03418480|Drug|BNT113|Intradermal vaccine
75881666|NCT02073097|Biological|Rituximab|Given IV (375mg/m^2)
75881667|NCT02073097|Drug|Cyclophosphamide|Given IV (750mg/m^2)
75881668|NCT02073097|Drug|Doxorubicin hydrochloride|Given IV (50mg/m^2)
75881669|NCT02073097|Drug|Vincristine sulfate|Given IV (1.4mg/m^2)
75585073|NCT00585624|Dietary Supplement|Impact Advanced Recovery|Nutritional supplement
75881670|NCT02073097|Drug|Prednisone|Given PO (100mg)
75881671|NCT02073097|Drug|Pegfilgrastim|6 mg SC day 4 (every 21 days). Filgrastim 300 or 480 mcg IV/SC daily days 1-10 may be substituted if pegfilgrastim is not available. ONPROTM is also an acceptable method of administration.
75881672|NCT02073097|Drug|Acyclovir|PO (400mg)
75881673|NCT02082548|Other|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
75436640|NCT01570127|Procedure|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
75436641|NCT01570127|Procedure|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
76024984|NCT03995693|Dietary Supplement|Solution ingestion|Two ingestion modalities will be attributed (participant is blinded) in random order: a placebo and a glucose solution. The placebo contains water and a non-caloric sweetener (stevia) in order to reproduce the taste of the glucose solution. The glucose solution contains 6% glucose per volume, labelled with 13C. Both solutions will be administered in 8 doses: a bolus (333 mL) at rest, 30 minutes before the start of exercise, 167 mL immediately before exercise, 167 mL every 15 minutes during arm cranking, 125 mL immediately before concentric or eccentric pedalling and at 15 and 25 minutes of this last exercise period. In total, 1250 mL of solution will be administered during the experimental protocol.
75436642|NCT01570127|Other|Waiting|No interventions were applied to the patients in this group.
75436643|NCT01570140|Behavioral|Web portal|This study investigates the effects of the voluntarily use of a webportal and its educational content.
75585074|NCT00585624|Dietary Supplement|No supplement|No supplement
75585075|NCT04580186|Procedure|bladder exstrophy repair|primary complete bladder exstrophy repair
75585076|NCT04572555|Other|Heat Treatment|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak.
75585077|NCT03451110|Drug|lemborexant|oral tablet
75585078|NCT03451110|Drug|Loestrin|oral tablet
75585079|NCT03451110|Drug|famotidine|oral tablet
75585080|NCT03451110|Drug|fluconazole|oral tablet
75585081|NCT03453827|Other|no intervention|no intervention
75585082|NCT03451032|Other|Non Interventional Study|Non Interventional Study
75585083|NCT03453788|Device|LETSGO app|LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
75436644|NCT01570166|Procedure|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
75585084|NCT03453749|Dietary Supplement|Salovum|Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
75585085|NCT03450993|Other|SMART Program|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology)
75436645|NCT01570166|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
75585086|NCT03450954|Procedure|Amniotic membrane transplant|Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
75585087|NCT03453671|Behavioral|Mindfulness|Participants will use mindfulness techniques while exercising
75585088|NCT03453671|Behavioral|Distraction|Participants will distract themselves while exercising
75585089|NCT03453671|Behavioral|Self-monitoring|Participants will use associative attentional focus while exercising
75585090|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
75436646|NCT01570179|Drug|ideal BW based sugammadex reversal of moderate block|2 mg/kg sugammadex (based og ideal body weight)
75436647|NCT01570179|Drug|real body weight based sugammadex reversal of moderate block|2 mg/kg sugammadex (based on real BW)
75436648|NCT01570179|Drug|real body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on real BW)
75436649|NCT01570179|Drug|ideal body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on ideal BW)
75436650|NCT01570205|Drug|XG-102|single intravenous infusion
75436651|NCT01570218|Behavioral|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
75585091|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
75436652|NCT01570231|Device|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
75436653|NCT01570257|Procedure|lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus|in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
75585092|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
75585093|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
75585094|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
75585095|NCT00573014|Other|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
75585096|NCT00573053|Other|Oxygen saturation range|Maintain functional oxygen saturation range between 91 and 95%
75585097|NCT00573053|Other|Oxygen saturation range|Maintain functional arterial oxygen saturations in the range of 85- 89%
75585098|NCT00585819|Procedure|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
75585099|NCT00585819|Procedure|Freebreathing in Body fix mold|Freebreathing in Body fix mold
75585100|NCT03450876|Other|Non-Interventional|Non-Interventional
75585101|NCT00573209|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
75585102|NCT01140451|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
75730509|NCT03389750|Drug|Intravenous Challenge Drug|Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
75585103|NCT03450837|Diagnostic Test|Coronary Computed Tomography Angiography|To assess coronary artery plaque and calcification, all participants underwent coronary computed tomography angiography according to the guidelines of the Society of Cardiovascular Computed Tomography (SCCT). All CT scans were acquired in a 320-row detector scanner (AquillionOneTM - Toshiba Medical Systems Corporation, Otawara, Japan) with 0.5-mm thick slices. Acquisition protocol included coronary artery calcium scoring (CACS) and coronary CTA. CACS protocol utilized a 370-ms tube rotation, 120-kV tube voltage, 300-mA tube current, and 320x0.5-mm collimation with 3-mm slice thickness reconstructed images, one heart beat acquisition during diastole.
75585104|NCT03450837|Diagnostic Test|Macrophage cholesterol efflux mediated by HDL|Macrophages were incubated with DMEM (Low Glucose, Gibco, Grand Island, New York, USA) containing 1 mg fatty acid free albumin (FAFA) (Sigma-Aldrich, Steinheim, Germany) plus 50 μg acetylated LDL/mL and 0.3 μCi 14C-cholesterol/mL (Amersham Biosciences, UK) for 48h. After washing with PBS/FAFA, cells were incubated in the presence or absence of HDL (50 µg/mL) for 8h. The amount of radioactivity present in the medium at the end of the HDL incubation period will indicate albumin-mediated cholesterol efflux with albumin alone and total efflux with albumin + HDL. Thus, specific HDL-mediated efflux will be calculated, subtracting the albumin-mediated efflux from total efflux
75730510|NCT03385330|Other|LOWER oxygen saturation target group|We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
75730511|NCT03385330|Other|HIGHER oxygen saturation target group|We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
75881674|NCT04523298|Procedure|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
75730512|NCT03328884|Drug|Irinotecan Hydrochloride|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan hydrochloride, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered with a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy."
75436654|NCT01570270|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
75436655|NCT01570374|Behavioral|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
75436656|NCT01570400|Behavioral|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
75436657|NCT01570400|Behavioral|Cognitive bias modification training program variant 1|"Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
75436658|NCT01570400|Behavioral|Cognitive bias modification training program variant 2|"Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
75585105|NCT04579913|Other|Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound|Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
75585106|NCT03450798|Device|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
75585107|NCT03450798|Device|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
75585108|NCT00585897|Behavioral|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
75585109|NCT04579796|Other|ultrasound exam|An abdominal ultrasound exam to assess the placenta implantation site.
75585110|NCT04579796|Procedure|hysteroscopy diagnostic|Diagnostic hysteroscopy to asses the placenta implantation site.
75585111|NCT00573326|Drug|Imatinib|200 mg p.o. once a day for 6 months
75585112|NCT01140061|Drug|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
75585113|NCT01140061|Drug|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
75585114|NCT01140061|Drug|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
75585115|NCT01140061|Drug|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
75585116|NCT01140061|Drug|Plain patch|Plain patch containing no MK-0873 or placebo
75585117|NCT04312750|Drug|Lidocaine topical system 1.8%|
75585118|NCT00573365|Device|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
75730513|NCT03326804|Device|H1 Hip Resurfacing Arthroplasty|A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
75881675|NCT04523298|Other|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
76024985|NCT03995693|Behavioral|Constant load arm cranking|The participants will perform 45 minutes of arm cranking on a specialized ergometer at a power output corresponding to 30% of their concentric cycling VO2max, previously measured.
75585119|NCT00573365|Radiation|Radiation|Weekly radiation treatment
75585120|NCT00573365|Radiation|Radiation|Weekly radiation treatment
75585121|NCT00586014|Procedure|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
75436659|NCT01570413|Procedure|No Pelvic Exam|Will not receive pelvic examination.
75585122|NCT01139164|Drug|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
75585123|NCT01139164|Drug|Regimen B|Other malignancies not addressed in A or C
75436660|NCT01570413|Procedure|Pelvic Examination|Pelvic examination will be performed.
75585124|NCT01139164|Drug|Regimen C|B-Cell Lymphomas
75585125|NCT00573404|Drug|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
75585126|NCT00573404|Drug|sunitinib malate|
75585127|NCT00573404|Other|pharmacological study|
75585128|NCT01139125|Drug|(Cystagon) Cysteamine Bitartrate|Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
75585129|NCT03450759|Drug|AZD9977 Oral suspension (reference)|Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
75585130|NCT03450759|Drug|AZD9977 capsule|Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
75585131|NCT03450759|Drug|AZD9977 ER capsule (fastvrate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
75585132|NCT03450759|Drug|AZD9977 ER capsule (Int. rate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
75585133|NCT01139047|Drug|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
75585134|NCT01139047|Drug|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
75585135|NCT00573482|Behavioral|REDE|"The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~Four group education sessions to introduce the REDE principles of eating;~Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
75585136|NCT00573482|Behavioral|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
75585137|NCT02883829|Behavioral|Peer-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
75881676|NCT02089022|Other|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
75436661|NCT01570452|Procedure|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
75436662|NCT01570478|Drug|Foster® NEXThaler® 100/6 µg/unit dose|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
75881677|NCT03609528|Device|CamPROBE|To be completed
75881678|NCT02082626|Drug|Eribulin mesylate|
75730514|NCT03303547|Diagnostic Test|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
75730515|NCT03301558|Drug|Low dose sodium bicarbonate|1500 mg sodium bicarbonate
75730516|NCT03301558|Drug|High dose sodium bicarbonate|3000 mg sodium bicarbonate
75730517|NCT03301467|Drug|Avacopan|Orally administered
75730518|NCT03301467|Drug|Avacopan Matching Placebo|avacopan matching placebo
75730519|NCT03282981|Drug|Timolol|Topical application of Timolol on non-healing diabetic foot ulcers
75730520|NCT03282981|Drug|Non biologically active gel|Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
75585138|NCT02883829|Behavioral|Provider-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
75585139|NCT03450720|Drug|GLPG2737 single dose|GLPG2737 oral suspension, single dose
75585140|NCT04310878|Other|Survey among perioperative nurses and surgeons|Online survey
75881679|NCT03610152|Behavioral|Hospital Policy change|Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
75585141|NCT01139008|Drug|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
75881680|NCT02921997|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
75436663|NCT01570478|Drug|Seretide® Accuhaler® 250/50 µg/actuation|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
75436664|NCT01570504|Drug|Ivermectin|oral formulation
75436665|NCT01570517|Device|IASD System|Implantation of the DC Devices Inc. IASD System
75436666|NCT01570530|Procedure|Cardiac surgery|Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
75436667|NCT01570530|Procedure|Cardiac surgery|Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
75585142|NCT01139008|Drug|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
75585143|NCT03450681|Procedure|Pulsed radiofrequency of the saphenous nerve before knee replacement surgery|A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.
75585144|NCT03450681|Procedure|Mock incision|A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
75585145|NCT00573560|Device|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
75585146|NCT03450642|Other|Observational|Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
75585147|NCT00573599|Drug|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
75585148|NCT00573599|Drug|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
75585149|NCT04572516|Drug|BTX A Topical|In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
75585150|NCT04572516|Drug|BTX A Injection|In group B (injected group), 20 units of BTX_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
75585151|NCT00573638|Device|Xal-Ease device to be used with Xalatan eye drops|This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
75585152|NCT01138657|Biological|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
75585153|NCT01138657|Drug|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
75585154|NCT01138657|Drug|Placebo|Administered by subcutaneous injection
75585155|NCT04572282|Device|Mentora app|Remote monitoring mobile app
75585156|NCT01138501|Drug|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
75585157|NCT01138501|Drug|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
75436668|NCT01570556|Other|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
75436669|NCT01570569|Drug|Omeprazole|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
76052467|NCT04808882|Drug|Tinzaparin, High dose prophylactic anticoagulation|"Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
75585158|NCT02883361|Behavioral|Motivational enhancement therapy|Counseling meant to enhance motivation and decrease ambivalence about change, including asking open-ended questions, eliciting change-talk, and identifying discrepancies between current behaviour and valued behaviour
75585159|NCT02883361|Behavioral|Attention Control|Having participants come into the lab and fill out questionnaires with a researcher in-person
75585160|NCT04579835|Other|External Cephalic Version|External Cephalic Version Twin A
75436670|NCT01570569|Drug|Losartan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
75436671|NCT01570569|Drug|Dextromethorphan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
75436672|NCT01570569|Drug|Cocktail|"Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days."
75585161|NCT04572360|Other|Cardiorespiratory Exercise|Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
75585162|NCT04572360|Other|Modified Bai He Gu Jin Tang|The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
75585163|NCT01138150|Drug|Treximet|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
75585164|NCT01138150|Drug|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
75585165|NCT00573911|Procedure|Endoscopy and pH study|endoscopy and PH study done one time
75585166|NCT01138111|Drug|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
75585167|NCT00586092|Drug|bevacizumab, ABT-510|"Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days*~Stage 2 (RPTD) ABT-510: X mg SC BID**, bevacizumab: Y mg/kg IV every 14 days**~Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~*Both agents begin on Day 1 of Cycle 1.~**At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
75585168|NCT01137955|Drug|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
75585169|NCT01137955|Drug|Placebo|Placebo orally three times a day for 10 days total
75585170|NCT00573950|Drug|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
75585171|NCT00573950|Drug|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
75585172|NCT03452748|Device|FTIR spectroscopy|FTIR spectroscopy examines collagen fibers in the excised membranes
75585173|NCT03452670|Behavioral|Active Group|Participants will be provided with a contemplative well-being application (CWA) which will facilitate meditation for 10 minutes daily during the 8 week study period.
75585174|NCT03452670|Other|Waitlist Group|The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in CWA at the end of the 8 week study period.
75585175|NCT00574106|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
75585176|NCT03450564|Behavioral|Women Education|This intervention intends to provide health education message for women enhance FP utilization in pastoralist community. It was cognizant that, Ethiopia is the second most populous country in Africa. And there is a great discrepancy between contraceptive use, unmet need for FP and maternal and child morbidity and mortality between the pastoralist and agrarian community. Pastoralist community in the country expressed as low contraceptive users, a high unmet need for FP and highest maternal and child morbidity and mortality. The previous study indicates that only 5.4% of the women use contraceptive. The most common reason mentioned for not using of contraceptive are lack of awareness, demand for a large number of children and male dominance in all decision making power in general and FP in particular. In light of this, the study hypothesized that working with men and educating women towards the use of FP could enhance the use of family planning utilization.
75585177|NCT03450564|Behavioral|Male Involvement|Male involvement was a feature of intervention in this arm. Comprehensive health education about FP was given in addition to the video message about FP. In pastoralist community the most reason mentioned for not using of FP are husband objection and religion influence. And most of the decisions are in the palm of husband to seek care for reproductive, maternal and neonatal health in general and FP in particular. Besides, the pastoralist community manifested by high total fertility rate and maternal and child morbidity and mortality.
75585178|NCT03450564|Other|Control group|The third group in this community based intervention was following the community without provision of male iand married women education. In this group there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
75585179|NCT00574223|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
75585180|NCT00574223|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
75730521|NCT03255954|Other|Interpersonal Counseling for University Counseling Centers|Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
75730522|NCT03253978|Radiation|Stereotatic Radiotherapy|SABR to prostate / seminal nodes
75881681|NCT02921997|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
75436673|NCT01570569|Drug|Midazolam|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
75436674|NCT01570569|Drug|Caffeine|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
75436675|NCT01570582|Drug|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
75585181|NCT03450525|Other|No intervention|No intervention
75730523|NCT03238755|Other|Cardiac MRI/MRS|whole blood, plasma, and serum
75730524|NCT03225222|Diagnostic Test|biopsy|prostate biopsy
75730525|NCT03161379|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
75881682|NCT02921997|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
75585182|NCT00586131|Drug|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
75585183|NCT00586131|Drug|Sodium citrate/citratic acid|dictated by pH
75730526|NCT03161379|Drug|Nivolumab|Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
75881683|NCT02089100|Radiation|stereotactic body radiation therapy|
75585184|NCT00574301|Procedure|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
75585185|NCT00574379|Drug|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
75585186|NCT00574379|Drug|Placebo|Placebo tablets twice daily for 14 days
75730527|NCT03161379|Drug|GVAX Pancreas Vaccine|Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
75730528|NCT03161379|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
75436676|NCT01570595|Behavioral|Web-Based Tailored Smoking Cessation Intervention|"The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
75436677|NCT01570595|Behavioral|Standard of Care|advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
75436678|NCT01570608|Drug|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
75436679|NCT01570608|Drug|Verteporfin|Verteporfin photodynamic therapy standard fluence
75436680|NCT01570621|Procedure|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
75436681|NCT01570660|Drug|Pioglitazone|12 weeks of pioglitazone treatment
75436682|NCT01570673|Behavioral|Group urotherapy|Children in this arm will receive group urotherapy in small groups with other children.
75585187|NCT03450408|Procedure|Method of placement of Foley bulb transcervical dilator|This trial will assess two methods used to place a Foley bulb transcervical dilator.
75585188|NCT00574418|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
75585189|NCT00574457|Other|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
75585190|NCT00586287|Other|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
75730529|NCT03156036|Drug|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
75730530|NCT03023215|Procedure|Meditation|Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
75730531|NCT03023215|Procedure|Electroencephalogram|Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
75730532|NCT03023215|Behavioral|Questionnaires|Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.
75730533|NCT03023215|Procedure|Heart Rate|Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
75881684|NCT02089100|Radiation|Systemic treatment|
76024986|NCT03995693|Procedure|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution.
76024987|NCT03995693|Procedure|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution.
76024988|NCT03995693|Procedure|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain vein open. 10 mL of blood will be collected immediately before ingesting the solution for a total of 80 mL.
76052468|NCT04808882|Drug|Tinzaparin,Therapeutic anticoagulation|"Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
75585191|NCT00586287|Other|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
75585192|NCT00586287|Drug|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
75585193|NCT03450330|Drug|AZD4205|Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
75585194|NCT00574574|Dietary Supplement|anthocyanin|500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
75730534|NCT03005925|Device|Smartphone|Smartphone application coupled with a hand dynamometer
75730535|NCT03005925|Other|physical follow up|regular visits with the specialist
76052469|NCT02189473|Radiation|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
76052470|NCT05652452|Other|Neurodynamics|Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.
75436683|NCT01570673|Behavioral|Individual Urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
75436684|NCT01570699|Genetic|COMT polymorphism|The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
75585195|NCT03450291|Other|Volatility task|Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
75585196|NCT04579562|Other|No intervention|This is observational, non-interventional study
75585197|NCT04575168|Diagnostic Test|Spartan COVID-19 Test|A nasopharyngeal sample analyzed on the Spartan COVID-19 System.
75585198|NCT00574613|Drug|P144|Cream 0,3 ml once a day (3 months)
75730536|NCT03005327|Drug|X4P-001|Mavorixafor will be provided as either 25 mg or 100 mg capsules.
75730537|NCT02998203|Dietary Supplement|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
76052471|NCT05652452|Other|Static stretch|Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
75585199|NCT00574613|Drug|placebo|Cream 0,3 ml once a day (3 months)
75585200|NCT00586365|Drug|Naproxen|500 mg Naproxen twice a day for two weeks
75730543|NCT02972060|Drug|ODM-201|ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
75730544|NCT02972060|Drug|ADT|"ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
75881685|NCT01083433|Behavioral|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
76052472|NCT05164796|Device|IVUS assessment of coronary ostia|"For coronary arteries at high-risk of obstruction during TAVI in native valves or valve-in-valve TAVI:~IVUS analysis before valve implantation (+ coronary angiogram) to detect any leaflet interference with the coronary ostium, existing prior to the transcatheter heart valve (THV) placement~IVUS analysis (+ coronary angiogram) after valve implantation in absence of acute coronary occlusion, to assess the patency of the ostium at-risk, the presence of native or degenerated surgical leaflet adjacent to the ostium, and the interaction of THV-frame with the coronary ostium.~In case of CHIMNEY stenting, re-assessment of the stent expansion and coronary ostia patency with IVUS."
76052473|NCT02188849|Other|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
76052474|NCT02188849|Drug|Creatine|Creatine powder 5 g day
76052475|NCT05164484|Device|Transpulmonary thermodilution|Through the analysis of the thermodilution curve recorded at the tip of an arterial catheter after the injection of a cold bolus in the venous circulation, transpulmonary thermodilution intermittently measures cardiac output.
75436685|NCT01570712|Other|HOUSING FIRST PROGRAM|"Realization of a psychosocial organic evaluation and a citizen;~Support in the development and the maintenance of the housing;~Support in the diverse steps (administrative, judicial, financiers, etc.);~Support around addictions / alcohol;~Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)~to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration."
75436686|NCT01570712|Other|traditional French services|"The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\or the restoring, but this by means of the existing devices"
75436687|NCT01570725|Behavioral|Virtual reality exposure|"The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation."
75436688|NCT01570725|Behavioral|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
75436689|NCT01570764|Drug|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
75585201|NCT00574652|Drug|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
75585202|NCT00574691|Device|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
75585203|NCT03450213|Device|Pentacam|Pentacam will be used to measure the magnitude and axis orientation of anterior and posterior corneal astigmatism.
75585204|NCT03450174|Dietary Supplement|Placebo|In control group, participants will receive only a placebo product
75585205|NCT03450174|Behavioral|Formative messgaes|In this group, participants will only receive daily formative messages
75585206|NCT03450174|Dietary Supplement|Fortified product|In this group, participants will receive fortified product on alternate day up till 8 months
75585207|NCT03450174|Combination Product|Fortified product plus|In this group participants will receive fortified product on alternate day and formative messages up till 8 months
76052476|NCT05652374|Device|Ialuril 50ml Prefill|Bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 1 year
75585208|NCT00574769|Drug|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m^2 every 21 days"
75585209|NCT00586443|Drug|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD* RPTD* RPTD* 3b 10 RPTD** RPTD** RPTD**~Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. **Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
75585210|NCT00574808|Other|Outreach Facilitation implementing elements of the Chronic Care Model|"An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation."
75585211|NCT03450135|Behavioral|Trier Social Stress Test|Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
75585212|NCT03450135|Behavioral|Emotional go/no-go task|Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
75585213|NCT00574925|Drug|Esomeprazole|
75436690|NCT01570764|Drug|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
75436691|NCT01570777|Procedure|renal denervation and optimized medication regimen|Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
75436692|NCT01570777|Procedure|optimized medication regimen|Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
75436693|NCT01570790|Drug|Combretastatin A-4 phosphate|27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
75436694|NCT01570790|Drug|Combretastatin A-4 Phosphate|36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
75436695|NCT01570790|Drug|Combretastatin A-4 Phosphate|45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
75585214|NCT00586560|Drug|Kareniticin and cyclophosphamide|"An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity."
75881686|NCT01083433|Device|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
76052477|NCT05652374|Drug|Nitrofurantoin|100mg daily (1dd100mg or 2dd50mg) for 1 year. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
76052478|NCT01636076|Drug|QMF149|delivered via Concept1 device
76052479|NCT01636076|Drug|Salmeterol|delivered via Accuhaler®
75585215|NCT00574964|Other|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
75585216|NCT00575003|Drug|CYT003-QbG10|6 subcutaneous injections
75585217|NCT00586599|Other|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
75585218|NCT03453593|Other|No intervention|No intervention
75585219|NCT03453554|Other|Digital Notebook app|Training in use of Digital Memory Notebook app
75585220|NCT03453554|Other|Smart Home Prompting|Smart-home sensor based activity-aware prompting to support digital memory notebook app use
75585221|NCT00586638|Behavioral|Video game based training|36 one-hour sessions over 12 weeks
75585222|NCT00586677|Behavioral|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
75585223|NCT00586677|Behavioral|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
75730545|NCT02968654|Procedure|Restrictive Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
75730546|NCT02968654|Procedure|Liberal Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
75730547|NCT02881554|Procedure|Computed Tomography|Undergo SC SPECT/CT
75436696|NCT01570803|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
75730548|NCT02881554|Procedure|Single Photon Emission Computed Tomography|Undergo SC SPECT/CT
75436697|NCT01570803|Device|Complete SE Stent|same to SMART CONTROL Stent
75585224|NCT00586677|Behavioral|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
75585225|NCT03453476|Device|SRP and Fotosan 630|After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
75585226|NCT01137682|Drug|Pasireotide|"Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
75436698|NCT01570816|Device|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
75436699|NCT01570842|Other|Anthropometric measurements|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
75585227|NCT01137682|Drug|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
75585228|NCT01137682|Drug|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
75585229|NCT03453320|Drug|Albumin solution|Infusion rate and effects
75730549|NCT02881554|Drug|Technetium Tc-99m Sulfur Colloid|Given IV
75730550|NCT02873338|Drug|Dociparstat sodium|Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.
75585230|NCT00586755|Procedure|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
75585231|NCT00575120|Other|ischemia reperfusion|reperfusion after a 15 min. lasting cuff induced arm ischemia
75585232|NCT03458442|Other|Simulation-based surgical training|"Those in the intervention group will be introduced to a variety of simulation-based surgical training techniques. Specifically, this will involve breaking down the SICS cataract surgery procedure into stages, and practicing each stage repeatedly using simulation. This sustained deliberate practice will be integrated into the six-week course, as an enhancement to the course, and not as a replacement of any part of the educational content. Within the last three weeks of the course, 'intervention' arm participants will be introduced to the artificial eyes, the Simulation-OSSCAR rubric, and be provided with ongoing feedback.~All participants in both intervention and control arms will undertake the six-week Orbis-COS training course."
75730551|NCT02873338|Drug|Idarubicin|Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
75730552|NCT02873338|Drug|Cytarabine|Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
75730553|NCT02864147|Drug|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
76052480|NCT01635998|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
75730554|NCT02864147|Drug|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
75730555|NCT02863055|Drug|Nintedanib|Nintedanib 200 mg administered twice daily
75730556|NCT02863055|Drug|Placebo|Matching placebo administered twice daily
75881687|NCT02082704|Behavioral|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
76052481|NCT01635920|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
75436700|NCT01570842|Procedure|Tissue samples|Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
75436701|NCT01570894|Drug|Quetiapine Fumarate|25 mg tablet
75436702|NCT01570907|Drug|Quetiapine Fumarate|25 mg tablet
75436703|NCT01570920|Behavioral|physical training|walking many times a week
75436704|NCT01570933|Device|NivNava|Non-invasive Nava ventilation mode on nasal cannula
75436705|NCT01570933|Device|Cpap|nasal Cpap on nasal cannula
75730557|NCT02809690|Device|CAT|Undergo 18F-FMAU PET/CT
75881688|NCT02082704|Behavioral|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
75881689|NCT02791490|Drug|Sitagliptin|Oral tablet, 100 mg, once daily at approximately the same time each day
76052482|NCT01635920|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
76052483|NCT04793984|Device|Carragelose|inhalation 3 times a day
76052484|NCT04793984|Device|NaCl|inhalation 3 times a day
76052485|NCT03029000|Drug|Tbo-filgrastim|solution for subcutaneous injection
76052486|NCT03023150|Other|Ischemic Preconditioning|
76052487|NCT03023150|Other|Sham|
76052488|NCT03783182|Drug|Betamethason Sodium Phosphate|Glucocorticoid
76052489|NCT03783182|Drug|10% glucose solution|Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
76052490|NCT03780920|Procedure|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
75585233|NCT03458442|Other|Standard surgical training|Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
75585234|NCT03457506|Diagnostic Test|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
75585235|NCT00575198|Other|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
76052491|NCT05651984|Device|Comparison between communication board and eye tracking|The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
76052492|NCT05651906|Procedure|Kidney Transplantation|Kidney transplantation as the best option for patients with end-stage kidney disease.
76052493|NCT03760484|Drug|Fidaxomicin 200 mg|Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.
76052494|NCT03760484|Biological|fecal microbiota transplantation (FMT)|Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
76052495|NCT05651750|Drug|Montelukast|receiving 2 months treatment with Montelukast once a day
76052496|NCT05651750|Drug|Fluticasone Furoate|receiving 2 months treatment with Fluticasone Furoate nasal spray once a day
75730558|NCT02809690|Drug|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
76052497|NCT02917460|Genetic|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
75730559|NCT02809690|Other|Laboratory Biomarker Analysis|Correlative studies
75881690|NCT02791490|Drug|Placebo|Oral tablet, once daily at approximately the same time each day
75436706|NCT01570946|Behavioral|Lifestyle Modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
75436707|NCT01570959|Drug|Quetiapine Fumarate|300 mg tablet
75436708|NCT01570972|Behavioral|Group Cognitive Behavioral Therapy|weekly
75436709|NCT01570972|Behavioral|Multifamily Group Psychoeducation|twice monthly
75436710|NCT01570985|Drug|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
76052498|NCT05651672|Drug|Pemigatinib|13.5mg, po, 2 weeks on/1 week off, Q3W
76052499|NCT02160145|Drug|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
76052500|NCT02160145|Drug|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
76052501|NCT04807478|Drug|Omegaven® (fish oil triglycerides) Injectable Emulsion|Dose, frequency and duration is a decision of the Investigator
75436711|NCT01570985|Drug|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
75436712|NCT01571011|Behavioral|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
75436713|NCT01571024|Drug|BKM120|BKM120 40 mg, orally, once daily.
75585236|NCT00575198|Other|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
75585237|NCT00586794|Drug|Sildenafil|3x per day 20 mg TID
75585238|NCT00586794|Drug|Placebo|3x per day, 20 mg TID
75585239|NCT00575237|Procedure|Recruitment manouver|In the intervention group, CO2 was removed by means of Trendelenburg position (> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
75585240|NCT00586833|Procedure|O2 consumption max bike test|Single visit exercise study
75585241|NCT03453255|Drug|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
75585242|NCT00575354|Drug|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
75881691|NCT02791490|Drug|Metformin IR|All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).
75881692|NCT02821143|Other|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
75585243|NCT00575354|Drug|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
75585244|NCT00586911|Drug|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
75585245|NCT00586911|Drug|Identical Placebo|Placebo
75881693|NCT02821143|Other|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
75881694|NCT02660775|Behavioral|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~for emotion perception : Facial emotions recognition task (TREF)~for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~for self assessment : Self - assessment of social cognition (ACSo)"
75585246|NCT00575393|Drug|gold sodium thiomalate|
75730560|NCT02809690|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
75730561|NCT02809690|Device|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
75730562|NCT02809690|Device|Ultrasound|Undergo TRUS-guided biopsy
75585247|NCT00575393|Genetic|gene expression analysis|
75730563|NCT02781935|Procedure|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
75730564|NCT02777385|Drug|Pembrolizumab|In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
76052502|NCT01696396|Drug|Abrilumab|Administered by subcutaneous injection.
75585248|NCT00575393|Other|fluorine F 18 fluorothymidine|
75585249|NCT00575393|Other|mass spectrometry|
75585250|NCT00575393|Other|pharmacological study|
75585251|NCT00575471|Drug|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
75585252|NCT00575471|Drug|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
75585253|NCT00575471|Drug|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
75585254|NCT00575471|Drug|Placebo|Matching placebo tablets once daily for 12 weeks
75730565|NCT02777385|Drug|Cisplatin|Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
75730566|NCT02777385|Radiation|IMRT|IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
75730567|NCT02725567|Drug|IVA|Granules in sachet for oral administration.
75730568|NCT02674217|Procedure|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
75585255|NCT03454308|Behavioral|SMASH|Auditory and visual reminders are active on Pill device will alert subject each time their medication dose is due. Pill device will transmit dose taken time stamps to researchers. Text message the following morning with tailored motivational messages that reflect the medication dose adherence from the preceding day. Subjects will monitor their BP at home at least every third day using Bluetooth monitor linked to smartphone to transmit encrypted readings to researchers.
75730569|NCT02639702|Drug|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
76024989|NCT03995693|Behavioral|Measure of maximal voluntary contraction force production|Maximal voluntary bilateral knee extensions (3 trials of 3-4 seconds each) will be performed on a chair equipped with force sensors to measure peak force production. These measurements will be done before the first ingestion, immediately before exercise, during the transition between arm cranking and concentric or eccentric cycling, and at the end of the exercise protocol.
75436714|NCT01571024|Drug|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
75436715|NCT01571050|Drug|Purified water|Ingestion of 30 mL of purified water
75436716|NCT01571050|Drug|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
75436717|NCT01571050|Drug|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
75436718|NCT01571050|Drug|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
75436719|NCT01571050|Drug|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
75436720|NCT01571063|Drug|Vitamin D3|Vitamin D3, 2.100 IU/d p.o.
75585256|NCT03454308|Behavioral|Enhanced SC|Auditory and visual reminders are inactive on Pill device. Pill device will transmit dose taken times to researchers. Healthy lifestyle test messages as attention control.
75730570|NCT02615275|Procedure|Bioelectric Impedance Analysis|Undergo BIA with seca mBCA
75730571|NCT02615275|Procedure|Computed Tomography|Undergo CT
75730572|NCT02615275|Procedure|Positron Emission Tomography|Undergo PET
75730573|NCT02615275|Other|Quality-of-Life Assessment|Ancillary studies
75436721|NCT01571063|Drug|Placebo|Placebo Tbl. p.o.
75436722|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
75436723|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
75436724|NCT01571076|Other|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
75730574|NCT02615275|Other|Questionnaire Administration|Ancillary studies
75730575|NCT02615275|Radiation|Radiation Therapy|Undergo RT
75436725|NCT01571076|Other|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
75436726|NCT01571089|Behavioral|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
75436727|NCT01571115|Behavioral|Physical Exercise|
75730576|NCT02610673|Device|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
75730577|NCT02592356|Procedure|Computed Tomography|Correlative studies
75730578|NCT02592356|Procedure|Dual X-ray Absorptiometry|Correlative studies
75730579|NCT02592356|Procedure|Physical Examination|Correlative studies
75730580|NCT02592356|Other|Quality-of-Life Assessment|Ancillary studies
75730581|NCT02592356|Other|Questionnaire Administration|Ancillary studies
75585257|NCT04579601|Procedure|ERAS program|We designed our centre's ERAS program through different measures during the preoperative, intraoperative and postoperative period. This program incluided received comprehensive multidisciplinary information, daily goals and expected discharge date, explained the expansión exercises, the video-assisted thoracoscopic surgery (VATS) under general anaesthesia combined with regional techniques, leaving only one chest tube at the end of the surgery, maintain normothermia, extubation after the end of the surgery, and early removal of the urinary catheter. From the time of extubation, the patients began oral tolerance and respiratory physiotherapy exercises. Also, the patients were allowed to walk around early.
75585258|NCT03452397|Drug|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
75585259|NCT03452397|Drug|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
75585260|NCT03452397|Drug|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
75585261|NCT03452397|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
76024990|NCT03995693|Diagnostic Test|Measure of muscle electrical activity (EMG)|Surface electrodes will be placed on the biceps and quadriceps to measure EMG throughout the exercise protocol.
76052503|NCT01696396|Drug|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
75436728|NCT01571141|Device|Monogin|Gynaecological solution with polyhexamethylene biguanide, pH 4.0
75436729|NCT01571167|Drug|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
75436730|NCT01571167|Drug|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
75436731|NCT01571167|Drug|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
75436732|NCT01571206|Biological|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
75436733|NCT01571219|Biological|Infliximab|CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
75436734|NCT01571258|Behavioral|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
75436735|NCT01571271|Procedure|Laser Lithotripsy|Laser Lithotripsy
75585262|NCT03453684|Drug|Administration of Vancomycin|Intravenous Vancomycin Administration
75585263|NCT00575627|Drug|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
75585264|NCT04674878|Other|METs|The isometric contraction of 7 sec will be applied followed by a stretching of 30 sec in painless range. This treatment will be given to the both sides of the neck targeting the three major accessory muscles of respiration.
76052504|NCT02836262|Device|HIT Hip Replacement System|HIT Hip Replacement System
75730582|NCT02592356|Drug|Cabozantinib|
75730583|NCT02592356|Drug|Lenvatinib|
75730584|NCT02555579|Behavioral|Dietary Protein Counting and Free Fruits and Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
75730585|NCT02517684|Drug|Infliximab|
75730586|NCT02517684|Drug|Prednisolone|
75730587|NCT02517684|Other|Exclusive enteral nutrition|
75436736|NCT01571271|Procedure|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
75436737|NCT01571310|Other|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
75436738|NCT01571310|Other|Breakfast|"In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:"
75730588|NCT02517684|Drug|Azathioprine|
75730589|NCT02454790|Radiation|Radiotherapy|
75730590|NCT02431130|Other|low-fidelity instructor driven simulation training|
75730591|NCT02290951|Drug|Odronextamab multiple dose levels|Administered by intravenous (IV) infusion
75585265|NCT04674878|Other|Breathing exercise group|Three exercises will be performed in a circuit, 2 circuits in every session. It will include diaphragmatic breathing exercise in which patient will be in supine position inhaling through nose and expiration through moth with half closed lips. Second exercise pursed lip breathing also in supine position with the hands on abdomen and then inspiration through nose and expiration through mouth with half closing of lips. Third exercise resisted diaphragmatic breathing also in same pattern as second exercise with an addition of 1 kg weight on abdomen.
75585266|NCT00586989|Procedure|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
75585267|NCT04674839|Drug|MS-20|fermented soymilk product
75436739|NCT01571323|Drug|Misoprostol|The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
75436740|NCT01571323|Drug|Oxytocin|The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
75585268|NCT04674839|Other|Placebo|No active ingredient
75585269|NCT03458130|Drug|AG10|TTR stabilizer
75585270|NCT03458130|Drug|Placebo Oral Tablet|Nonactive control
75585271|NCT04674488|Biological|TILs|a single center, single-arm, open label, interventional study
75585272|NCT03459690|Behavioral|Meditation|. IK is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. IK does not incorporate a spiritual or religious focus
75585273|NCT03459690|Device|Enobio 32- EEG machine|The ENOBIO 32 EEG device is an investigational device under US federal law which is a 24-bit EEG data reader which is a wearable wireless device
75436741|NCT01571323|Drug|Oxytocin and Misoprostol|The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
75585274|NCT04674605|Device|biomarkers|biomarkers
75585275|NCT03456219|Other|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
75585276|NCT03456219|Other|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
75585277|NCT02277483|Drug|LAIS®|10 X 1,000 / twice a week
75730592|NCT02290951|Drug|Odronextamab multiple dose levels|Administered by subcutaneous (SC) injection
75730593|NCT02255773|Behavioral|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
75730594|NCT02255773|Behavioral|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
76052505|NCT05269784|Procedure|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol
75585278|NCT00555854|Behavioral|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
75585279|NCT04575129|Other|No intervention will be applied|No intervention will be applied
75585280|NCT00555932|Procedure|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
75585281|NCT04575402|Other|Wearable Activity Monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
75585282|NCT04674332|Drug|Long acting insulin|long acting insulin analogue once daily at bed time
75585283|NCT04674332|Drug|multiple dose regimen|intermediate and short acting insulin
75585284|NCT00587145|Drug|S-1,Docetaxel|"S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
75436742|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
75436743|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
75436744|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
75585285|NCT04674449|Diagnostic Test|Disclosure of IDP results|The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.
75585286|NCT04674449|Other|IDP performed but results not disclosed|The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
75585287|NCT04674176|Drug|Rifaximin|550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
75730595|NCT02209545|Drug|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
75730596|NCT02209545|Drug|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
75730597|NCT02186509|Radiation|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
75585288|NCT00199875|Drug|Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)|Patients received a single infusion of ^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
75881695|NCT02660775|Behavioral|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~for empathy : Empathy quotient (EQ)~for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
76052506|NCT05269784|Procedure|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol
75585289|NCT04674527|Drug|Elemene|Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.
75585290|NCT04674527|Drug|Temozolomide|Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
75585291|NCT00199836|Biological|NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51|
75585292|NCT04674293|Drug|Revelisa|Thrombolytic therapy for patients with ischemic stroke
75585293|NCT00199797|Drug|Oxaliplatin|Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.
76052507|NCT03654638|Combination Product|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
75730598|NCT02186509|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
75730599|NCT02186509|Drug|Alisertib|Given PO
75730600|NCT02186509|Procedure|Quality-of-life assessment|Ancillary studies
75881696|NCT02660775|Behavioral|Healthy controls|only social cognitive measures
76052508|NCT03654638|Combination Product|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
75585294|NCT00199797|Drug|5-Fluorouracil|The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.
75585295|NCT00199797|Drug|Leucovorin|Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
75730601|NCT02108964|Drug|EGF816|EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
75881697|NCT01365325|Other|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
75585296|NCT00199797|Drug|huA33|huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.
76052509|NCT03654638|Other|Questionnaire Administration|Ancillary studies
76052510|NCT02216071|Drug|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
76052511|NCT02216071|Drug|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
76052512|NCT04418570|Behavioral|cognitive remediation|
75585297|NCT04674215|Behavioral|Turning in Bed|Preoperative Turning in Bed Training
75585298|NCT04674215|Behavioral|Mobilization|Preoperative Mobilization Training
75585299|NCT04674215|Other|information|Routine Clinical Care
75585300|NCT04572087|Other|Behavioral training and verum stimulation|Cognitive control training and verum tDCS
75730602|NCT02086045|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System|percutaneous coronary
75730603|NCT02086006|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|
75730604|NCT01976065|Drug|Triple Antibiotic Paste|USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
75730605|NCT01976065|Other|Standard Treatment|Standard Treatment no use of study drug
75730606|NCT01970332|Procedure|Revascularization Surgery|
75585301|NCT04572087|Other|Behavioral training and sham stimulation|Cognitive control training and sham tDCS
75585302|NCT04673903|Other|Copenhagen adduction exercise|The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
75881698|NCT01365325|Other|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
76052513|NCT04418570|Other|attendance to an Early Intervention Service for Psychosis|
76052514|NCT01681576|Drug|Valsartan|Valsartan 320mg tablet once daily
76052515|NCT01681576|Drug|LCZ696|LCZ696 400mg tablet once daily
75585303|NCT04673903|Other|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
75585304|NCT01137604|Drug|Lenvatinib|24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
75585305|NCT01137604|Drug|Bevacizumab|Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
75585306|NCT00637351|Procedure|Blood sample|One blood sample will be collected at the time of screening for subjects
75730607|NCT01970332|Other|Supervised exercise therapy|
76024991|NCT03995693|Diagnostic Test|Measure of central and cutaneous temperatures|Wireless sensors will be placed on the skin of the arm, chest, back, abdomen, thigh and calf using adhesive tape. A wireless thermometric pill will be ingested the morning of the experiment. These will allow the measurement of skin and central temperatures throughout the exercise protocol.
76024992|NCT03995693|Diagnostic Test|Measure of perceived exertion, pain perception and affective response|"100 points scales (CR100) will be used to measure perceived exertion and pain perception immediately before ingesting the gas sampling. At the same time, affective responses will be assessed using the Feeling scale."
76052516|NCT04418726|Other|Intensified Monitoring|Apart from clinical assessment, use non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa, using either indicator dilution techniques or duplex ultrasound every month.
75436745|NCT01571401|Behavioral|Trying Activity for Kidney Cancer Survivors (TRACKS) Trial|Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
75436746|NCT01571414|Drug|PA-824|200-mg tablets once a day
75436747|NCT01571414|Drug|Efavirenz (EFV)|600-mg tablets once a day
75436748|NCT01571414|Drug|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
75730608|NCT01921335|Drug|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
75730609|NCT01921335|Drug|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
75436749|NCT01571414|Drug|Rifampin (RIF)|300-mg capsules once a day
75436750|NCT01571440|Dietary Supplement|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
75585307|NCT00637351|Procedure|Urine sample|One urine sample will be collected at the time of screening for subjects
75585308|NCT03454919|Drug|Palbociclib|"Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance."
75585309|NCT00198822|Dietary Supplement|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
75585310|NCT04674059|Other|patient survey|A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.
76052517|NCT02819960|Drug|Probio-Tec® BG-VCap-6.5|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
75585311|NCT05214976|Drug|Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)|Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
75730610|NCT01921335|Drug|Trastuzumab|6 mg/kg IV every 3 weeks
75730611|NCT01915810|Behavioral|Exercise Intervention|Complete SCwPA intervention
75730612|NCT01915810|Other|Laboratory Biomarker Analysis|Correlative studies
76052518|NCT02819960|Drug|Placebo|Maltodextrin
76052519|NCT04552912|Behavioral|Build Stamina Program|Build StaMINA intervention is a self-management intervention that provides information, motivation, behavioral skills to engage in PA, and ultimately a tailored PA program for adults with AL who are receiving consolidation/maintenance chemotherapy.
75436751|NCT01571440|Dietary Supplement|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
75436752|NCT01571466|Drug|Vaccination|"Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml~3 immunisations at week 0, 4 and 16"
75730613|NCT01915810|Drug|Nicotine Patch|Receive nicotine patch
75730614|NCT01915810|Other|Questionnaire Administration|Ancillary studies
76052520|NCT02188459|Drug|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
75436753|NCT01571466|Drug|Placebo|3 immunisations at week 0, 4 and 16
75730615|NCT01915810|Other|Tobacco Cessation Counseling|Receive smoking cessation counseling
75730616|NCT01909453|Drug|LGX818|LGX818- Orally 100 mg and 50 mg capsules
75730617|NCT01909453|Drug|MEK162|MEK162- Orally 15 mg tablets
75730618|NCT01909453|Drug|vemurafenib|Tablets in bottles or blisters 240 mg
76052521|NCT04793282|Behavioral|Telephone Follow-up|Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
76052522|NCT04759183|Other|Survey Administration|Ancillary studies
76052523|NCT04759183|Procedure|Virtual Reality Game|"Participate in VR Game Angry Birds"
75436754|NCT01571479|Procedure|2- mini-instrument|"The patient was positioned in the supine position with the head and right side up.~Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.~A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups."
75436755|NCT01571492|Procedure|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
75436756|NCT01571492|Procedure|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
75436757|NCT01571505|Biological|IPV vaccination|Randomized IPV or OPV to children aged at 39weeks.
75436758|NCT01571518|Drug|late leukostim|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
75436759|NCT01571518|Drug|early leukostim|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
75436760|NCT01571544|Device|Thermal suit|Thermal suit
75436761|NCT01571544|Other|Conventional clothing|Conventional clothing
75436762|NCT01571570|Drug|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
75436763|NCT01571570|Drug|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
75436764|NCT01571570|Drug|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
75436765|NCT01571570|Drug|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
75585312|NCT05204134|Device|Automated Insulin Delivery Settings Initialization and Adaptation Algorithm|All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
75585313|NCT05187832|Drug|AND019 PO QD|AND019 administrated as oral capsule once per day for 28 days for each cycle
75585314|NCT04673747|Procedure|Total Hip Arthroplasty|Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants
75585315|NCT04673747|Procedure|Manual correction of the sacroiliac joint|Manual correction of the iliosacral displacement of the sacroiliac joint in total hip arthroplasty is performed in the operating room after anesthesia just before total hip arthroplasty. It is carried out according to the methodology developed by us.
75585316|NCT05181436|Diagnostic Test|measuring Total Haemoglobin (SpHb) using Masimo Rad-67.|To determine the prevalence of Malaysian children aged ≥ 6 to ≤ 36 months at risk of anaemia by measuring Total Haemoglobin (SpHb) using Masimo Rad-67.
75585317|NCT04674098|Device|The Beat Analytics System (BAS)|There are three subsystems to the BAS; data aggregation, data analysis and data presentation.
75730619|NCT01882803|Drug|Duvelisib|Phosphoinositide-3-kinase (PI3K) inhibitor
75730620|NCT01855633|Device|Traditional Theta burst stimulation (TBS)|
75730621|NCT01855633|Device|Modified TBS rTMS|
75730622|NCT01855633|Device|Sham rTMS|
75730623|NCT01797523|Drug|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
75730624|NCT01797523|Drug|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
75730625|NCT01797523|Drug|Everolimus|10 mg by mouth once daily in a 28 day cycle.
76052524|NCT04759183|Procedure|Virtual Reality Meditation|"Participate in VR Meditation TRIPP"
76052525|NCT02743364|Other|Laboratory Biomarker Analysis|Correlative studies
76052526|NCT02743364|Other|Placebo Administration|Given PO
76052527|NCT02743364|Other|Quality-of-Life Assessment|Ancillary studies
76052528|NCT02743364|Other|Questionnaire Administration|Ancillary studies
76052529|NCT02743364|Drug|Simvastatin|Given PO
76052530|NCT02214121|Drug|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
75585318|NCT01137292|Drug|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
75585319|NCT00197496|Procedure|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
75585320|NCT04312477|Drug|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
75585321|NCT05367154|Procedure|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (WNY, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
75585322|NCT04673981|Diagnostic Test|diagnostic tes for neuropathic pain|Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
75585323|NCT05176795|Other|Stool sample|Comparaison of the gut microbiota composition
75585324|NCT02883478|Device|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
75585325|NCT02883478|Procedure|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
75585326|NCT02883478|Drug|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
75730626|NCT01787500|Biological|Cetuximab|Given IV
75730627|NCT01787500|Drug|Irinotecan Hydrochloride|Given IV
75585327|NCT00197145|Drug|GW873140|400 mg twice daily
75585328|NCT04674137|Drug|XC8 100 mg|1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
75585329|NCT04674137|Drug|Placebo|1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
75585330|NCT01136785|Device|active CPAP Therapy|7 days of active CPAP therapy
75585331|NCT01136785|Device|sham CPAP therapy|7 days of sham CPAP therapy
75585332|NCT04673864|Drug|CKD-386|QD, PO
75585333|NCT04673864|Drug|D012, D326, D337|QD, PO
75730628|NCT01787500|Other|Laboratory Biomarker Analysis|Correlative studies
75585334|NCT04312321|Device|Mandatory phone call consultation|Use of audio consultation (EMS crew smartphones, doctor smarphone) Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk)
75585335|NCT04312321|Device|Mandatory audiovisual consultation|Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk) with installed Android application (VSee messenger, USA, HIPAA compliant software) for paramedic crews; personal computer (Windows 10) with desktop version of application VSee messenger for Windows and eqipped with webcamera (Logitech C922 PRO) and headset (Jabra Evolve 20) for consulting doctor.
75585336|NCT04312438|Diagnostic Test|oral food challenge with cow's milk proteins|in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
75585337|NCT04673474|Drug|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
75585338|NCT04673474|Drug|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
75730629|NCT01787500|Other|Pharmacological Study|Correlative studies
75730630|NCT01787500|Drug|Vemurafenib|Given PO
75730631|NCT01669824|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
75585339|NCT00197106|Drug|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
75585340|NCT00197106|Drug|fluticasone propionate 2 x 100 mcg|comparator
76052531|NCT02214121|Drug|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
76052532|NCT01681186|Drug|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
75881699|NCT01368367|Other|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
75730632|NCT01472562|Drug|lenalidomide|"Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle."
75585341|NCT01136746|Drug|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
75730633|NCT01472562|Biological|rituximab|"Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
76052533|NCT01681186|Drug|LY2940680 Tablet (Test)|Administered orally as a tablet
75585342|NCT01136746|Drug|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
75585343|NCT01136746|Drug|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
75585344|NCT02883751|Radiation|LED|A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.
76052534|NCT01681186|Drug|Lansoprazole|Administered orally as a capsule
76052535|NCT01681186|Drug|Placebo Capsule(s)|Administered orally as a capsule(s)
75730634|NCT01334021|Procedure|Biopsy|Undergo tumor biopsy
75730635|NCT01334021|Procedure|Conventional Surgery|Undergo surgery
75730636|NCT01334021|Other|Genetic Testing|Undergo genetic testing
75730637|NCT01278225|Behavioral|EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
75730638|NCT01278225|Behavioral|Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
76052536|NCT03597464|Drug|Voclosporin|Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
76052537|NCT03597464|Drug|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
76052538|NCT01695772|Drug|5-FU based doublet chemotherapy|Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.
76052539|NCT01695772|Drug|bevacizumab|5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
76052540|NCT02159521|Device|EkoSonic® Endovascular System|
76052541|NCT02159521|Biological|Alteplase|Recombinant tissue plasminogen activator
76052542|NCT01636934|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
76052543|NCT01636934|Other|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
75585345|NCT02883751|Procedure|Control group|Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
75730639|NCT01278225|Behavioral|Follow UP Questionnaires|After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
75730640|NCT01266044|Procedure|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
75730641|NCT01266044|Procedure|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
75881700|NCT02833935|Behavioral|Physical Activity Intervention|"The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants."
75436766|NCT01571570|Drug|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
75436767|NCT01571583|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.
75436768|NCT01571583|Drug|Pegylated interferon alfa-2a|Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.
75436769|NCT01571583|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day [5 to 6 tablets] based on subject weight), twice daily regimen, for 48 weeks.
75585346|NCT04673435|Device|PermeaDerm for temporary coverage|See above
75585347|NCT04673435|Device|FHCA for temporary coverage|See above
75585348|NCT04673435|Device|PermeaDerm over autograft|See above
75585349|NCT04673435|Device|FHCA over autograft|see above
75730642|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
75730643|NCT01266044|Other|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
75730644|NCT01202851|Other|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
75730645|NCT01202851|Behavioral|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
75881701|NCT02085746|Other|Defining Sexual Activity Questionnaire|
75881702|NCT02085824|Drug|Enoxaparin|
75585350|NCT02883322|Other|Cross cultural adaptation of patient reported outcomes (PRO)|Process used to adapt a questionnaire from one cultural setting to another
75585351|NCT01136356|Drug|buprenorphine|parenteral buprenorphine may be administered at multiple times each day
75585352|NCT01136356|Drug|morphine|parenteral morphine may be administered multiple times each day
75585353|NCT00587379|Drug|Atorvastatin|40 mg atorvastatin pill daily
75585354|NCT00587379|Drug|placebo|40 mg pill per day
75585355|NCT04673396|Drug|Norcantharidin Lipid Microsphere for Injection|"The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen."
76052544|NCT01636934|Behavioral|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
75585356|NCT04673396|Drug|Sodium Demethylcantharidate Injection|Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
75585357|NCT00637390|Drug|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
76052545|NCT01712854|Drug|Budesonide|budesonide 80 mcg
76052546|NCT01712854|Drug|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
76052547|NCT01693120|Device|Medtronic Phased RF Ablation System|Phased RF ablation
76052548|NCT02986594|Drug|Aspirin|
76052549|NCT02986594|Drug|Heparin|
75436770|NCT01571609|Other|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:[9,10-3H]-palmitate 0,3 µCi/min. Duration 60 minutes."
75436771|NCT01571622|Dietary Supplement|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
75436772|NCT01571622|Dietary Supplement|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
75585358|NCT00587418|Dietary Supplement|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
75585359|NCT00587418|Dietary Supplement|Placebo|Placebo powder 9.2g bid for 7 days
75585360|NCT04673669|Diagnostic Test|Posterior tibial tendon strength mesure|Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
75730646|NCT01202851|Other|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
75730647|NCT01196390|Drug|Carboplatin|Given IV
76052550|NCT02159365|Drug|Elotuzumab|
76052551|NCT02159365|Drug|Lenalidomide|
75585361|NCT00196326|Drug|DR-1011|Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
75585362|NCT04673318|Behavioral|heat therapy|leg heated garments with circulating water to conduct heat therapy at home
75881703|NCT02085824|Drug|rivaroxaban|
76052552|NCT02159365|Drug|Dexamethasone|
76052553|NCT01712074|Drug|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
76052554|NCT01712074|Other|Placebo|Placebo QD
76052555|NCT02072200|Drug|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
76052556|NCT04767724|Device|Extracorporeal shock wave|Participants received 3 ESWT sessions once per week for 3 consecutive weeks or a single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
75585363|NCT04673318|Behavioral|exercise training|A velocity based training program will be implemented at home using a mobile app allowing for the quantification the relative intensity.
75585364|NCT00587496|Drug|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
76052557|NCT01692730|Behavioral|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
76052558|NCT01692730|Behavioral|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
76052559|NCT01691794|Drug|Atazanavir|
75585365|NCT00587496|Drug|placebo|lactose placebo capsule, six per day for 30 days
75585366|NCT00587496|Drug|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
75585367|NCT04610606|Behavioral|Multimodal intervention (MM)|"Exercise: Moderate intensity resistance and aerobic exercise, including one weekly supervised session and a home-based program. Participants were asked to 1) accumulate 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2) perform 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps.~Nutrition: Optimize diet with protein-rich foods to meet protein intake of >1.2 g/kg/d and energy of 25-30 kcal/kg/d. The supplement consists of whey protein isolate (with the goal of reaching 1.5 g/kg/d, providing 25 g/meal), 6g of leucine, fruit-flavored fish oil added with vitamin D.~Relaxation strategies: private consultations with psychology-trained personnel whereby techniques aimed at reducing anxiety are practiced. Participants are also provided with a compact disc with relaxation exercises to be used at home 2-3 times per week."
75881704|NCT02085824|Drug|dabigatran|
75881705|NCT01368445|Drug|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM & PM)
75881706|NCT01368445|Drug|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
76052560|NCT01691794|Drug|Ritonavir|
75436773|NCT01571648|Drug|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
75436774|NCT01571661|Drug|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
75585368|NCT00564044|Procedure|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm*5mm*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
75585369|NCT00564083|Procedure|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
75585370|NCT00195663|Biological|Adalimumab|
75436775|NCT01571661|Other|Placebo|Placebo
75436776|NCT01571674|Procedure|Manipulation + Exercise Group|"First 2 sessions~High-velocity, low-amplitude manipulations to the thoracic spine.~Low-velocity mid to end-range mobilizations to the cervical spine.~Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
75436777|NCT01571674|Procedure|Exercise Group|"First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
75436778|NCT01571687|Dietary Supplement|antioxidant supplements|Intake of 6 tablets daily containing: 800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
75436779|NCT01571687|Dietary Supplement|Placebo|Intake of 6 identically appearing tablets daily containing placebo
75585371|NCT00195663|Drug|Methotrexate|
75585372|NCT00195663|Biological|Adalimumab placebo|
75585373|NCT00195663|Drug|Methotrexate placebo|
75585374|NCT00564122|Device|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
75881707|NCT01368445|Drug|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM & PM)
75881708|NCT02085902|Drug|Ropivacaine|
76052561|NCT01710514|Drug|FE 999913 vaginal tablet|
75585375|NCT00564122|Other|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
75585376|NCT01135498|Drug|bevacizumab [Avastin]|Intravenous repeating dose
75730648|NCT01196390|Other|Laboratory Biomarker Analysis|Correlative studies
75730649|NCT01196390|Drug|Paclitaxel|Given IV
75730650|NCT01196390|Other|Quality-of-Life Assessment|Ancillary studies
75730651|NCT01196390|Radiation|Radiation Therapy|Undergo radiation therapy
75881709|NCT02654223|Biological|MG56 Mannosylated 500 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
75881710|NCT02654223|Biological|MG56 Mannosylated 1000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
75436780|NCT01571700|Procedure|Catheterization Pacing|The second part of the study will include patients with pulmonary hypertension >5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
75436781|NCT01571726|Drug|Fluciclatide|7mCi
75730652|NCT01196390|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75436782|NCT01571765|Other|MNCH programming in health district|training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
75436783|NCT01571791|Drug|Placebo|to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
75436784|NCT01571791|Drug|Ketorolac-Lidocaine|receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
75436785|NCT01571804|Drug|Placebo|to receive two identical placebo capsules 1 hr before surgery
75436786|NCT01571804|Drug|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
75730653|NCT01196390|Biological|Trastuzumab|Given IV
75881711|NCT02654223|Biological|MG56 Mannosylated 3000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
75436787|NCT01571804|Drug|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
75436788|NCT01571817|Biological|Isolated Human Pancreatic Islets|
75436789|NCT01571843|Other|Forearm exercise program|Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
75436790|NCT01571843|Other|Walking program|Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
75436791|NCT01571856|Drug|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
75585377|NCT01135498|Drug|eloxatin|Intravenous repeating dose
75585378|NCT01135498|Drug|capecitabine [Xeloda]|Oral repeating dose
75585379|NCT01135498|Drug|erlotinib [Tarceva]|Oral repeating dose
75585380|NCT04610567|Drug|Methotrexate-LDE phase 1|"3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE"
75585381|NCT04610567|Drug|Methotrexate-LDE phase 2|44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
75585382|NCT04610567|Drug|Placebo-LDE phase 2|44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
75585383|NCT02883439|Drug|MP29-02|local nasal application
75585384|NCT02883439|Drug|Fluticasone propionate|local nasal application
75730654|NCT01164995|Drug|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
75730655|NCT01156129|Drug|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
75730656|NCT01156129|Device|Arm B: Acupressure bracelet|Bioband
75436792|NCT01571856|Other|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
75730657|NCT01156129|Dietary Supplement|sugar free gum|Orbit
75730658|NCT00956007|Biological|cetuximab|Given IV
75730659|NCT00956007|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy.
75730660|NCT00905515|Drug|cyclosporine|Maintain on cyclosporine at target trough level of 50-250 ng/mL.
75730661|NCT00905515|Drug|Prograf (Tacrolimus)|Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
75730662|NCT02455791|Procedure|Ultrasound-Guided Biopsy|Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
75881712|NCT02654223|Biological|MG56 Mannosylated 5000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
75881713|NCT02654223|Biological|MG56 Mannosylated 500 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml sublingual
75730663|NCT00898365|Other|Cytology Specimen Collection Procedure|Correlative studies
75881714|NCT02654223|Biological|MG56 Mannosylated 1000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml sublingual
75881715|NCT02654223|Biological|MG56 Mannosylated 3000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml sublingual
75585385|NCT02883283|Procedure|Epidural loading dose|Labor epidural analgesia loading dose
75585386|NCT02883283|Device|Epidural catheter|Epidural loading dose via epidural catheter
75585387|NCT02883283|Device|Epidural needle|Epidural loading dose via epidural needle
75585388|NCT04610255|Other|Assigned Interventions|"Hot pack for 10 minutes~TENS for 10 minutes~Trigger point release if any found.~Myofascial release~Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
75585389|NCT04610255|Other|Dynamic myofascial release|"DMFR involves a manual application of low amplitude, long duration stretch to the fascia and muscle. Participants were instructed to relax as much as possible, and the therapist proceeded to smoothly move the joints in a diagonal or horizontal direction at a slow rate within the ROM. The therapist repeatedly pushed, pulled, or shook the joint area about three to five times for about 3 seconds with slight motion at the end of ROM.~Conventional therapy will includes~Hot pack for 10 minutes~TENS for 10 minutes~Trigger point release if any found.~Myofascial release~Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
75585390|NCT04610333|Behavioral|Modified MBSR programme|1 hour group session once a week in 10 weeks
75585391|NCT00195507|Drug|Etanercept|
75730664|NCT00898365|Other|Laboratory Biomarker Analysis|Correlative studies
75730665|NCT00877500|Other|Best Practice|Receive standard of care
75730666|NCT00877500|Drug|Ixabepilone|Given IV
75730667|NCT00659126|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
75730668|NCT00659126|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
75585392|NCT01134562|Drug|Placebo|Single IV injection.
75585393|NCT01134562|Drug|Etelcalcetide|Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
75585394|NCT04610216|Device|Naida CI M hearing device|speech intelligibility measurement with Naida CI M hearing device
75585395|NCT02883166|Drug|abiraterone|integested with a continental breakfast
75585396|NCT04610489|Diagnostic Test|Quidel Sofia SARS Antigen FIA|Obtained via bilateral mid-turbinate swab.
75730669|NCT00659126|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
75730670|NCT00659126|Drug|Ferumoxytol|Given IV
75730671|NCT00659126|Drug|Gadolinium|Given IV
75730672|NCT00659126|Procedure|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
75730673|NCT00659126|Procedure|Susceptibility Weighted Imaging|Undergo SWI
75730674|NCT00615082|Behavioral|Mindfulness-Based Stress Reduction|An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
75730675|NCT00615082|Behavioral|Caregiver Education & Social Support|An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
75585397|NCT04610021|Biological|i-FactorTM Bone graft|In the i-Factor ™ group it will be placed longitudinally in the intertransverse area. Likewise, in both groups, only autologous and bench bone will be placed in the intersomatic cages. The vertebrae where the i-Factor ™ is placed will be noted on the data collection sheet.
75585398|NCT00195351|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
75585399|NCT00195351|Drug|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
75585400|NCT04609982|Device|ear plugs|giving half of the patients ear plugs
75585401|NCT04609748|Drug|Cannabidiol Oil|Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
75585402|NCT04609748|Drug|Nimesulide|Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
75585403|NCT04574934|Other|aquatic therapy|Aquatic therapy refers to water-based treatments or exercises of therapeutic intent, in particular for relaxation, fitness, and physical rehabilitation. Treatments and exercises are performed while floating, partially submerged, or fully submerged in water. Many aquatic therapy procedures require constant attendance by a trained therapist and are performed in a specialized temperature-controlled pool. Rehabilitation commonly focuses on improving the physical function associated with illness, injury, or disability
75585404|NCT04609631|Behavioral|Tai Chi|24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).
75585405|NCT04609631|Behavioral|CBT|CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.
75585406|NCT00195273|Drug|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
75585407|NCT00195273|Drug|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
75585408|NCT00195273|Drug|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
75585409|NCT00195273|Drug|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
75585410|NCT00195273|Drug|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
75585411|NCT00564200|Drug|Bortezomib|"PREACONDICIONAMIENTO:~2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~- Day -2: Velcade~POSTRANSPLANTATION:~2 cycles of 21 days : Velcade days 1, 8 and 15~5 cycles of 56 days : Velcade days 1, 8 and 15"
76052562|NCT01592344|Device|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:~Stim Settings~Waveform: Symmetric or Asymmetric~Phase Duration: 100-250 µsec~Pulse Rate: 50-100 Hz~Intensity: 0-30mA Time Settings~Constant Stim: On~Total Time: 6 hour"
76052563|NCT01592344|Device|StimRouter - Control|"The stimulation program settings for this arm are as follows:~Stim Settings~Waveform: Symmetric or Asymmetric~Phase Duration: 200 µsec~Pulse Rate: 1 Hz~Intensity: 0 mA Time Settings~Constant Stim: On~Total Time: 6 hour"
75436793|NCT01571869|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
75436794|NCT01571869|Other|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
75436795|NCT01571882|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
75436796|NCT01571882|Other|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
75585412|NCT00564200|Drug|dexamethasone|"PREACONDICIONAMIENTO:~- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
75585413|NCT00564200|Drug|Fludarabine|"ACONDICIONAMIENTO:~- Days -9 al -5: Fludarabine"
75585414|NCT00564200|Drug|Melphalan|"ACONDICIONAMIENTO:~- Days -4 and -3: Melphalan."
75585415|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
75585416|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions
75585417|NCT00193479|Drug|Cyclophosphamide|Cyclophosphamide
75585418|NCT00193479|Drug|Mitoxantrone|Mitoxantrone
75585419|NCT00193479|Drug|Vincristine|Vincristine
75585420|NCT00193479|Drug|Prednisone|Prednisone
75585421|NCT00193479|Drug|Rituximab|Rituximab
75585422|NCT00564317|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
75585423|NCT00564317|Behavioral|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
75585424|NCT04609475|Procedure|Osseodensification technique|Implant bed preparation will be performed according to the manufacturer's guidelines, densifying burs (Densah® Burs) will be used sequentially in densifying mode (counterclockwise drill speed 800-1500 rpm with copious irrigation) to achieve the planned osteotomy diameter and desired ridge expansion. The implant will be then placed in the prepared osteotomy
75585425|NCT04609475|Procedure|Motor driven expanders' technique|The technique consisted of preparing the implant bed by progressively increasing the size of the osteotomes until the desired expansion will be achieved. At the planned implant site, a pilot drill 1000 rpm with irrigation until the desired length, then expansion with the series of ridge spreaders and finally using the final drill. The implant will be then placed in the prepared osteotomy.
75585426|NCT00193206|Drug|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
75585427|NCT00193206|Drug|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
75585428|NCT00193206|Drug|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
75585429|NCT00587691|Biological|Tovaxin Autologous T Cell Vaccine|"Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods."
75585430|NCT04609358|Other|intervention group|When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
76052564|NCT01636778|Drug|SB-497115-GR|TPO receptor agonist to increase platelet count
75436797|NCT01571882|Other|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
75436798|NCT01571921|Dietary Supplement|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
75436799|NCT01571947|Other|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
75436800|NCT01571960|Biological|GEO-D03 DNA vaccine|Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
75436801|NCT01571960|Biological|MVA/HIV62B (MVA62B) vaccine|1 x 10^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
75436802|NCT01571960|Biological|Placebo for GEO-D03 DNA|Administered as a 1-mL IM injection into the deltoid
75585431|NCT00193050|Drug|Gemcitabine|Gemcitabine
75585432|NCT00193050|Drug|Epirubicin|Epirubicin
75585433|NCT00193050|Drug|Docetaxel|Docetaxel
75585434|NCT04609241|Drug|CD79b CAR-T Cells|Each subject receive CD79b CAR-Tcells by intravenous infusion
75585435|NCT00587730|Device|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
75436803|NCT01571960|Biological|Placebo for MVA62B:|Administered as a 1-mL IM injection into the deltoid
75436804|NCT01571973|Procedure|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
75436805|NCT01571999|Drug|Inhaled GSK573719|All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
75436806|NCT01571999|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
75436807|NCT01572012|Drug|Ondansetron|Ondansetron solution 4 mg single administration
75436808|NCT01572012|Drug|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
75436809|NCT01572012|Drug|Zofran ODT|Zofran ODT (8 mg) single administration
75436810|NCT01572012|Drug|Ondansetron solution|Ondansetron solution (4 mg) single administration
75436811|NCT01572025|Drug|Dehydroepiandrosterone|"Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
75585436|NCT04609163|Other|data collection|retrospective data collection
75585437|NCT04608734|Drug|Buccal midazolam|The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
75585438|NCT04608734|Drug|Intranasal midazolam|Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
75585439|NCT00192504|Biological|Motavizumab|Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0
75585440|NCT00192504|Biological|Motavizumab|Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0
75585441|NCT00192504|Biological|Motavizumab|Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0
75585442|NCT00192504|Other|Placebo|Single dose of placebo administered intravenously (in the vein) on Day 0
75585443|NCT00564356|Procedure|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
75585444|NCT00192114|Drug|Enzastaurin HCl|1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.
75585445|NCT04608929|Behavioral|Kegel exercise-focused interventions|After the patients in the intervention group were interviewed on the telephone, the second home visit. During this visit, the patients were trained on Kegel exercises and they were administered the ICIQ-SF. Six weeks after the second visit, the third home visit was paid to determine whether the patients did the Kegel exercises and whether they did them accurately, to assess the perceived impact and to re-administer the ICIQ-SF. After the 2nd and 3rd visit, the patients were called once a week for 6 weeks to monitor if they kept up with doing the Kegel exercises as they were taught. Six weeks later, the 4th home visit were paid to the patients. During this visit, whether the patients did the Kegel exercises and whether they did them accurately was determined, the perceived impact was assessed and the ICIQ-SF was re-administered.
75585446|NCT04608929|Other|Home visit and scale evaluations|After the 1st visit, the patients included in the control group were called by phone and the 2nd home visit was planned. During the second home visit, the ICIQ-SF was administered to them. At the 3rd home visit paid 6 weeks after the 2nd visit, the ICIQ-SF was re-administered to the patients and the perceived impact assessment was performed. During the 4th home visit paid 6 weeks after the 3rd home visit, the ICIQ-SF was re-administered to the patients, assessment of the perceived impact was performed, and finally they were given training on Kegel exercises.
75585447|NCT00192075|Drug|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
75585448|NCT00192075|Drug|avastin|5 milligrams per kilogram (mg/kg)
75585449|NCT00192075|Drug|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
75585450|NCT00192075|Drug|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
75585451|NCT00192036|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
75585452|NCT00192036|Drug|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
75436812|NCT01572025|Drug|Placebo|"Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
75436813|NCT01572051|Behavioral|Educational Course|2 Educational courses
75436814|NCT01572051|Behavioral|Phone Calls|Phone Calls
75436815|NCT01572051|Behavioral|Printed Material|Printed Material
75436816|NCT01572064|Procedure|Blood sample|1 fasted blood sample taken for metabolomics
75585453|NCT00192036|Radiation|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
75585454|NCT04609007|Behavioral|Cognitive behavioral therapy (CBT)|A brief 4 sessions online CBT program with therapist support.
75585455|NCT04609007|Behavioral|Regular help-line telephone counselling|A single session of telephone counselling with a help-line counsellor
75585456|NCT04608461|Drug|Pumpkin seed extract containing cream|Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
75585457|NCT00191724|Drug|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
75436817|NCT01572064|Other|MRI Scan|1 single visit for MRI and MRS
75585458|NCT00191724|Drug|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
75585459|NCT00191724|Drug|Placebo|intravenous (IV), one infusion, over 12 hours
75585460|NCT00191724|Drug|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
75585461|NCT00191724|Drug|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
75730676|NCT00581139|Behavioral|Preoperative Preparation Program (Child Life Specialist)|This group will receive the standard preoperative visit to the hospital with Child Life intervention
75730677|NCT00581139|Drug|Midazolam|0.5 mg/kg oral midazolam
75881716|NCT02654223|Biological|MG56 Mannosylated 5000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml sublingual
75436818|NCT01572077|Radiation|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
75436819|NCT01572090|Behavioral|Lifestyle Changes|"Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian."
75436820|NCT01572090|Other|Adjustment of oral antidiabetics/insulin therapy|Continuation-discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice. In addition to the surgery, patients will have regular follow-up with an endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
76052565|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
75881717|NCT02654223|Biological|Subcutaneous placebo|Comparison between placebo and active group
75881718|NCT02654223|Biological|Sublingual placebo|Comparison between placebo and active group
75881719|NCT01368523|Drug|nilotinib|
76052566|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
75730678|NCT00581139|Behavioral|Parental Presence during Induction of Anesthesia|One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
75730679|NCT00581139|Other|PPIA preparation program PLUS Midazolam premedication|Subjects in this group will receive both interventions 2 and 3.
75436821|NCT01572090|Procedure|Laparoscopic sleeve gastrectomy|The Laparoscopic sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
75436822|NCT01572090|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
75436823|NCT01571908|Drug|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
75436824|NCT01571908|Drug|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
75436825|NCT01571908|Drug|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
75730680|NCT00572013|Drug|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
75881720|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
75881721|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
75881722|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
75881723|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
75881724|NCT01368601|Procedure|CPAP (Continuous airway pressure)|To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
75881725|NCT01368679|Procedure|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
76052567|NCT02159053|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
76052568|NCT02158975|Drug|MLN9708|
76052569|NCT02158663|Device|Repetitive Transcranial Magnetic Stimulation|TMS Device
76052570|NCT04804982|Other|Questionnaire|The participants will have to fill in a questionnaire about their knowledge and their attitude regarding auditory risk.
76052571|NCT04804124|Behavioral|Regularized Sleep Schedule|Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
76052572|NCT02158039|Drug|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
76052573|NCT02158039|Drug|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
75436826|NCT01571908|Drug|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
75585462|NCT00191724|Drug|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
75585463|NCT00564473|Behavioral|questionnaire|"questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
75585464|NCT04608422|Other|Electrical stimulation|A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
75585465|NCT00191646|Drug|Gemcitabine|"1000 mg/m^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
75585466|NCT00191646|Drug|Paclitaxel|"175 mg/m^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
76052574|NCT05261282|Behavioral|Mindful Hand Hygiene|Physicians and nurses randomized to the intervention arm will receive mindfulness education and tools to prompt mindfulness during hand hygiene.
75730681|NCT00572013|Drug|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
75730682|NCT00572013|Procedure|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
75881726|NCT02507973|Other|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
76052575|NCT03563222|Drug|Smoflipid|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
75436827|NCT01572103|Dietary Supplement|Coffee|Administration of 4 cups of coffee per day for 1 month
75436828|NCT01572103|Dietary Supplement|coffee abstinence|total abstinence for both coffee and caffeine containing beverages
75436829|NCT01572116|Drug|Lidocaine with Epinephrine+ Normal saline|PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
75436830|NCT01572116|Drug|Lidocaine with Epinephrine + sufentanil|PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
75436831|NCT01572129|Drug|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
75585467|NCT00191646|Drug|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
75585468|NCT00191451|Drug|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
75585469|NCT00191451|Drug|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
75730683|NCT00515372|Other|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
75730684|NCT00515372|Other|Usual Care|Lists of professional resources and referral recommendations will be provided.
75730685|NCT00498875|Behavioral|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
75730686|NCT00498875|Behavioral|Depression Intervention|"Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques."
75881727|NCT02507973|Other|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
75436832|NCT01572129|Drug|Placebo|Placebo in addition to the chronic daily dose of 75 mg
75436833|NCT01572155|Procedure|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
75585470|NCT00191451|Drug|Herceptin|"Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).~Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion)."
75585471|NCT04608383|Other|Additional and minimal collection of products of the human body carried out during a sample for standard of care|"Swab of the peritoneal fluid for traces of COVID19. The collection of peritoneal fluid is a standard care practice.~Swab from the laparoscopy filter"
75585472|NCT04608071|Procedure|A modified method for blind bedside placement of post-pyloric feeding tube.|Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.
75585473|NCT00191334|Drug|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
75585474|NCT00191334|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
75585475|NCT04608032|Other|[Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder|The first group will have [Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder
75585476|NCT04608032|Other|Recovery-Oriented Therapy|The second group will have [THoR] Recovery-Oriented Therapy
75585477|NCT00191139|Drug|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
75585478|NCT00191139|Drug|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
75436834|NCT01572155|Procedure|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
75436835|NCT01572168|Other|Acupuncture|Eight session of weekly acupuncture
75436836|NCT01572181|Drug|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)|"IV fludarabine (30 mg/m²/day for 5 days)~IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days)."
75436837|NCT01572194|Biological|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
75436838|NCT01572220|Other|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
75585479|NCT00191139|Drug|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
75585480|NCT00191139|Drug|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
75585481|NCT00191139|Radiation|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
75585482|NCT00564512|Biological|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
75585483|NCT00564512|Biological|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
75585484|NCT00564512|Drug|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
75585485|NCT00564512|Drug|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
75730687|NCT00496522|Procedure|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
75881728|NCT03558386|Behavioral|ePRO survey|An electronic patient reported outcomes survey will be completed by the patient.
75585486|NCT04571853|Behavioral|PNE-explained group|There are 9 fact sheets overall. And each fact sheet incorporates two pages relating to one main concept. The first of two pages introduces the concept, and the second one quotes important ideas that emerge from the main concept. The 9 main concepts and consequent ideas presented in the fact sheets are based on current scientific research in pain science and have been selected and structured specifically for PNE education for chronic pain patients. The fact sheets have been fully developed and designed by Pain Revolution, a pain educator network founded by Professor Lorimer Moseley, group leader in Body in Mind Research Group from University of South Australia.
75585487|NCT04571853|Behavioral|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
75436839|NCT01572233|Behavioral|Personalized Physical Activity and Psycho-Education (PPAPE) Program|"Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment."
75436840|NCT01572246|Other|Optimal placement of return pad|The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
75436841|NCT01572259|Drug|Growth Hormone|
75585488|NCT04571853|Behavioral|TAU group|Participants allocated to this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professiona
75881729|NCT02086214|Device|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
75881730|NCT02086214|Device|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
76052576|NCT03563222|Drug|Intralipid, 20%|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
75436842|NCT01572259|Other|interruption of the traitment with growth hormone|
75436843|NCT01572285|Procedure|transforaminal dexamethasone injection|Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
75436844|NCT01572285|Procedure|Sham|Sham procedure using a non-penetrating needle
75436845|NCT01572311|Behavioral|Exercise Intervention|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
75436846|NCT01572311|Behavioral|Exercise Control|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
75436847|NCT01572324|Drug|Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine|HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
75436848|NCT01572350|Other|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
75436849|NCT01572350|Drug|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
76052577|NCT05239364|Procedure|Catheter ablation|Catheter-based ablation of arrhythmias using radiofrequency.
75436850|NCT01572350|Drug|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
75436851|NCT01572363|Drug|Sildenafil|50 mg once
75585489|NCT00564551|Behavioral|High dairy and calcium intake|High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
76052578|NCT04812392|Device|Continuous Glucose Monitoring System|Subjects will wear a continuous glucose monitoring system for 3 days during the 3 day reduced physical activity phase.
76052579|NCT02490800|Drug|Oral daily administration of BAL101553|oral administration
76052580|NCT01635764|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
76052581|NCT05609162|Procedure|neurosurgical resection|neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
76052582|NCT05578430|Drug|Cadonilimab|10mg/kg by intravenous infusions every 3 weeks
75436852|NCT01572376|Procedure|Infusion of autologous bone marrow stem cells after wound debridement.|Cleaning of the wound with heparinized saline, cell infusion and closing with suture.
75436853|NCT01572402|Other|Bagueutte Cheese Gourmet (Crocodille)|180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
75585490|NCT00564551|Behavioral|Usual intake|Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
75585491|NCT00190983|Drug|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
75585492|NCT04607759|Dietary Supplement|nutraceutical|Subjects will consume two capsules for eight weeks
75585493|NCT04607798|Device|Radiofrequency and pulsed electro-magnetic fields treatment|Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
75585494|NCT00190749|Drug|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
75585495|NCT00190749|Drug|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
75585496|NCT04607720|Procedure|artificial-EUS-FNA|The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.
76052583|NCT05578430|Procedure|TACE|TACE will be performed per institutional standard of care.
75436854|NCT01572402|Other|Cous-cous sandwich|235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
75436855|NCT01572402|Other|McCountry sandwich (McDonald's)|150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
75436856|NCT01572454|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
76052584|NCT05578430|Procedure|Surgery|Surgery will be performed per institutional standard of care.
76052585|NCT03432260|Drug|DUR-928 30 mg|Lowest dose of 3 dose escalation arms.
76052586|NCT03432260|Drug|DUR-928 90 mg|Middle dose of 3 dose escalation arms.
76052587|NCT03432260|Drug|DUR-928 150 mg|Highest dose of 3 dose escalation arms.
76052588|NCT04790162|Behavioral|Heartfulness Meditation|Heartfulness meditation with a trainer provided virtually
76052589|NCT03397628|Other|FIFA 11 for health|
76052590|NCT05474456|Other|SNAGs|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
76052591|NCT05474456|Other|Manipulation|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
76052592|NCT03342014|Device|Ultrasound|3DPD and UAD acquisitions (10 min)
75436857|NCT01572454|Drug|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
76052593|NCT03342014|Biological|Blood sample collection|A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
76052594|NCT05228444|Behavioral|CircadianCare|enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
76052595|NCT02407028|Drug|Hyperbaric oxygen (1.5 ATA, no NBH)|HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
75436858|NCT01572467|Genetic|RNA analysis|
76052596|NCT02407028|Drug|Hyperbaric oxygen (2.0 ATA, no NBH)|HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
76052597|NCT02407028|Drug|Hyperbaric oxygen (2.5 ATA, no NBH)|HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
76052598|NCT02407028|Drug|Hyperbaric oxygen (1.5 ATA + NBH)|HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
75436859|NCT01572467|Genetic|gene expression analysis|
75436860|NCT01572467|Genetic|mutation analysis|
75436861|NCT01572467|Genetic|reverse transcriptase-polymerase chain reaction|
75585497|NCT04607720|Procedure|AI-EUS-FNA|In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).
75585498|NCT04607447|Behavioral|low intracranial pressure strategy treatment|"Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.~Abdominal belt compression"
75730688|NCT00493831|Drug|nicotine polacrilex, transdermal system or inhaler|on label use of Nicotine replacement therapy (NRT)
75436862|NCT01572467|Other|laboratory biomarker analysis|
75436863|NCT01572467|Other|medical chart review|
75585499|NCT04607447|Drug|Atorvastatin plus Dexamethasone|Atorvastatin plus Dexamethasone
75730689|NCT00482690|Drug|nicotine polacrilex|
75730690|NCT00482690|Drug|nicotine transdermal system|
75730691|NCT00482690|Drug|nicotine inhaler|
75730692|NCT00177645|Procedure|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
75730693|NCT00152503|Drug|Seletracetam (UCB44212)|"Pharmaceutical form: oral capsules~Concentration: 2, 10 and 50 mg~Route of administration: oral administration"
75730694|NCT00004197|Biological|keyhole limpet hemocyanin|
75730695|NCT00004197|Biological|sargramostim|
75730696|NCT00004197|Biological|tumor cell-based vaccine therapy|
75436864|NCT01572519|Drug|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
75730697|NCT00004197|Drug|cyclophosphamide|
75730698|NCT00004197|Drug|doxorubicin hydrochloride|
75730699|NCT00004197|Drug|mitoxantrone hydrochloride|
75730700|NCT00004197|Drug|prednisone|
75730701|NCT00004197|Drug|vincristine sulfate|
76052599|NCT02407028|Drug|Hyperbaric oxygen (2.0 ATA + NBH)|HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
76052600|NCT02407028|Drug|Hyperbaric oxygen (2.5 ATA + NBH)|HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
76052601|NCT02407028|Drug|Normobaric Hyperoxia (NBH)|100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
76052602|NCT02407028|Other|Usual Care|Will be treated with usual and customary care for severe traumatic brain injury
76052603|NCT01634360|Drug|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
76052604|NCT04810598|Drug|Venetoclax|Oral Tablet
76052605|NCT04570280|Other|Aerobic Exercises|Aerobic exercises with treadmill will be applied 3 times a week for 12 weeks.
76052606|NCT04570280|Other|Resistive Exercises|Resistive exercises with sandbag will be applied 3 times a week for 12 weeks.
76052607|NCT04570280|Other|Range of Motion Exercises|Range of Motion Exercises will be applied 3 times a week for 12 weeks.
75436865|NCT01572519|Drug|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
75436866|NCT01572519|Drug|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
75436867|NCT01572519|Drug|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
75730702|NCT03865407|Drug|Allopurinol|Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
75730703|NCT00487942|Drug|armodafinil|50 mg/day armodafinil
75730704|NCT00487942|Drug|armodafinil|100 mg/day armodafinil
75730705|NCT00487942|Drug|armodafinil|200 mg/day armodafinil
75730706|NCT00487942|Drug|placebo|placebo
75730707|NCT00132301|Drug|Docetaxel|Chemotherapy agent
75730708|NCT00132301|Drug|Prednisone|steroid in combination with chemotherapy agent
75730709|NCT00522873|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
75730710|NCT00522873|Drug|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
75881731|NCT01368757|Drug|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
75436868|NCT01572519|Drug|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
75585500|NCT04607213|Procedure|Advancement-rotation approach based on Millard' for repairing lip defect.|"patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill."
75585501|NCT04607213|Procedure|Straight-line approach|"patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar."
75585502|NCT00190671|Drug|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
76052608|NCT04788758|Other|Educational Intervention|Receive G8 screening tool administration training
75436869|NCT01572545|Drug|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
75436870|NCT01572545|Drug|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
75585503|NCT00190671|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
75585504|NCT00190671|Drug|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
75585505|NCT00199914|Device|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
75585506|NCT04607525|Drug|Dexmedetomidine|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines [5] [6] [7]."
76052609|NCT04788758|Other|Screening Questionnaire Administration|Complete G8 screening tool
76052610|NCT04788758|Other|Referral|Receive referral
76052611|NCT04788758|Other|Questionnaire Administration|Ancillary studies
75881732|NCT02082938|Device|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
76052612|NCT02158052|Drug|Tacrolimus|Tacrolimus starting on Day -1
76052613|NCT02158052|Drug|Equine Anti-thymocyte globulin|20 mg/kg IV on Days -3, -1, +1, +3
76052614|NCT02158052|Procedure|Kidney transplant from a related donor|On Day 0 the renal transplant is performed according to standard surgical techniques.
76052615|NCT02158052|Drug|Bone marrow transplant from a related donor|Donor bone marrow (> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
76052616|NCT02158052|Radiation|Total body irradiation 400 centigray (200 cGy X 2)|On transplant day -1
76052617|NCT01635218|Drug|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
75436871|NCT01572558|Procedure|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
75436872|NCT01572558|Drug|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
75436873|NCT01572597|Drug|10RAC+acetylcystein|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
75436874|NCT01572597|Drug|10RAC+metronidazole|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
75585507|NCT04607525|Drug|normal saline|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D."
75436875|NCT01572610|Drug|RTA 402|once a day, oral administration
75585508|NCT00198276|Combination Product|MedPulser Electroporation with bleomycin|The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
75585509|NCT04607642|Drug|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
75585510|NCT04607642|Radiation|Radiation Therapy|Treatment plan should include a continuous course of treatment delivered as single daily fractions of 2.0 to 2.1 Gy with a cumulative radiation dose between 60 Gy and 70 Gy. Planned radiation treatment volumes must include at least two oral mucosal sub-sites (buccal mucosa, retromolar trigone, floor of mouth, tongue, soft palate, hard palate) with a portion of each site receiving at least 50 Gy.
75585511|NCT04607642|Drug|Cisplatin|Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.
75585512|NCT04607642|Other|Placebo|The placebo to be used in this study is 0.9% Sodium Chloride Injection, USP.
75585513|NCT00587808|Procedure|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
75585514|NCT00587925|Other|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
76052618|NCT01635218|Drug|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
75585515|NCT00588003|Drug|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
75585516|NCT00588003|Other|Placebo|No medication before surgery
76052619|NCT01635218|Drug|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
76052620|NCT05189600|Device|Mechnical Insufflation:Exsufflation|Cough Augmentation device
76052621|NCT05351684|Drug|Dolutegravir 50 MG|already included in arm/group descriptions.
75436876|NCT01572623|Drug|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
75436877|NCT01572623|Drug|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
75436878|NCT01572636|Drug|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
75436879|NCT01572649|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
75436880|NCT01572649|Drug|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
75436881|NCT01572688|Drug|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
75436882|NCT01572701|Drug|99mTc-MIP-1404|20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
75585517|NCT00588042|Device|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
76052622|NCT02049866|Drug|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
76052623|NCT05185856|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
76052624|NCT05185856|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
76052625|NCT04307186|Drug|Gadoquatrane (BAY1747846)|Solution for IV injection, single dose
76052626|NCT04307186|Drug|Gadobutrol (Gadovist/Gadavist)|Solution for IV injection, single dose
76052627|NCT04297826|Behavioral|Harvest for Health|Please see previous description
75436883|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
75730711|NCT03684057|Behavioral|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
76052628|NCT04274894|Drug|AndroGel 1.62%|AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
75881733|NCT04893187|Drug|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
75436884|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
75436885|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
75585518|NCT00588042|Device|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
75585519|NCT00588081|Behavioral|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
75881734|NCT04893187|Drug|Placebo|Matched placebo.
75436886|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
75436887|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
75585520|NCT04607291|Other|Community Health Service|Receive Witness CARES services
75585521|NCT04607291|Other|Survey Administration|Ancillary studies
75585522|NCT00588120|Drug|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
75730712|NCT03864627|Drug|MOR106|MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
75730713|NCT03864627|Drug|Placebo|Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
75730714|NCT00519831|Biological|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
75730715|NCT00519831|Drug|vinflunine|Vinflunine 320 mg/m² every 21 days
75730716|NCT04303845|Drug|Erenumab|140 mg of erenumab via subcutaneous injection
75730717|NCT03964623|Diagnostic Test|OCT-A (Optical Coherence Tomography)|Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
75730718|NCT04269915|Biological|female Schistosoma mansoni cercariae|Viable female Schistosoma mansoni cercariae of the Puerto Rican strain
76052629|NCT04786964|Drug|Cosibelimab|IV infusion
76052630|NCT04786964|Drug|Cisplatin|IV infusion
75730719|NCT04187703|Drug|5-azacytidine|5-azacytidine 50 mg/m^2 Day 1 every week ± G-CSF ~5 µg/kg (300µg vs 480µg)
75730720|NCT04187703|Drug|Decitabine|Decitabine 5 mg/m^2 Day 4 every week ± G-CSF ~5 µg/kg (300µg vs 480µg)
75730721|NCT00131911|Drug|sorafenib tosylate|400 mg given orally
75585523|NCT04574973|Device|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
75585524|NCT04574973|Behavioral|intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
75730722|NCT01077037|Other|Decision Aid|Chest pain choice decision aid
75730723|NCT03968887|Other|plasma oxidized low-density lipoprotein levels|Detection of plasma oxidized low-density lipoprotein levels
76052631|NCT04786964|Drug|Carboplatin|IV infusion
76052632|NCT04786964|Drug|Pemetrexed|IV infusion
75585525|NCT04607057|Drug|Parenteral Nutrition Solutions|"Day0 : fasting(NPO) + crystalloid fluid~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~POD#2 : Semifluid diet (SFD) + crystalloid fluid~POD#3 : Semifluid diet (SFD) + PN~POD#4-7: Soft blended diet (SBD) + PN"
75585526|NCT04575012|Procedure|Deferred invasive strategy|PCI on 7 to 10 days after symptom onset
75585527|NCT04575012|Procedure|Early invasive strategy|Primary PCI
75585528|NCT00564590|Drug|Melatonin|4 mg of Melatonin once a day for 3 months
75585529|NCT00564590|Other|omeprazole|omeprazole 20 mg once a day
75585530|NCT00564590|Drug|Placebo|Placebo once a day
75585531|NCT00564668|Drug|biphasic insulin aspart|
75730724|NCT01582633|Biological|2012 trivalent influenza vaccine|"2012 trivalent influenza vaccine:~influenza A/California/7/2009 (H1N1)~influenza A/Perth/16/2009 (H3N2)~influenza B/Brisbane/60/2008 Single dose."
75585532|NCT04574817|Drug|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
75585533|NCT00564707|Behavioral|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
75585534|NCT00564707|Procedure|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
75730725|NCT03968575|Device|laser treatment|sub-threshold micro-pulse laser treatment
75436888|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
75436889|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
75436890|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
75436891|NCT01572766|Other|FRAX Assessment Tool|FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
75585535|NCT04607018|Device|PMA-zeolite|"subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass)."
75585536|NCT04606862|Device|Morley Medical Sepsis Software Device|The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
75585537|NCT00588276|Radiation|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three *IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
75585538|NCT04606667|Other|Exercise Program|Exercise program
75585539|NCT03452592|Drug|Alflutinib|Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
75585540|NCT04606511|Diagnostic Test|Circumference tape measurements|centimeter and volume criterias
75585541|NCT04606511|Diagnostic Test|Indocyanine green lymphangiography|Presence of dermal backflow
75730726|NCT00184093|Drug|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
75730727|NCT01074619|Drug|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
75730728|NCT01074619|Drug|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
75730729|NCT00183625|Behavioral|Individual Placement and Support (Supported Employment)|
75730730|NCT00183625|Behavioral|Social Skills Training|
75730731|NCT00183625|Drug|Olanzapine|
75730732|NCT00183625|Drug|Risperidone|
75730733|NCT00511875|Drug|doxycycline monohydrate|50mg once daily for 24 months
75730734|NCT00511875|Drug|placebo|placebo taken once daily for 24 months
75730735|NCT02576327|Drug|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
75436892|NCT01572779|Device|BSM device with bio-feedback|A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).
75585542|NCT04606511|Diagnostic Test|bioimpedance spectroscopy|7.5 and 10 L-DEX criterias
75585543|NCT04606511|Diagnostic Test|Symptom score|using lymph-icf, DASH and SF-36 questionnaires
75585544|NCT00564746|Drug|A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323|"[14C] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) [14C] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of [14C]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter [14C] SB-681323 oral solution will be dosed."
75585545|NCT04606277|Other|Smartphone addiction scale, physical activity scale and depression questionnaire|Telephone addiction of the subjects was measured. Then, physical activity levels were questioned, and finally depression scale was applied.
75585546|NCT00588393|Drug|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
75585547|NCT04606043|Procedure|Sandblasting|Sandblasting will be applied onto the vestibular surfaces of the teeth before applying the etchant.
75585548|NCT04606043|Procedure|Acid Etching|Only acid etching will be applied onto the vestibular surfaces of the teeth before rebonding
75730736|NCT02576327|Drug|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
75585549|NCT04606121|Combination Product|enhanced day care of TCM include acupuncture, massage, tai ji quan, TCM herbal medicine|acupuncture twice in enhanced day care of TCM massage twice in enhanced day care of TCM tai ji quan one time in enhanced day care of TCM TCM herbal powder three times a day
75585550|NCT00588510|Other|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
75585551|NCT04606082|Drug|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
75585552|NCT04606082|Drug|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
75585553|NCT04605770|Drug|pemetrexed+cisplatin|"Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.~Vitamin B12 1000 mcg intramuscular (IM) injection will be given within 14 days prior to the first dose of pemetrexed, every 9 weeks (on the same day as study treatment) thereafter, and then 21 days after the last dose of pemetrexed. Folic acid 1 mg will be administered daily starting from 14 days before the first dose of pemetrexed and continued until 21 days after the last dose of pemetrexed. Study treatment will be continued until PD, unacceptable AE, or decision to discontinue by subject or physician."
75585554|NCT00588588|Procedure|Bronchoscopy|Bronchoscopy procedure
75585555|NCT00588588|Procedure|Clinical pulmonary infection score (CPIS)|Calculate CPIS
75585556|NCT04605887|Drug|Angiotensin 1-7|Ang 1-7 subcutaneously 500 mcg/kg /day
75730737|NCT02576327|Drug|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
75730738|NCT00183391|Drug|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
75730739|NCT00183391|Drug|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
75730740|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
75881735|NCT03558308|Behavioral|Computer based cognitive rehabilitation|Computer based cognitive rehabilitation is a supplementary computerized tool for cognitive rehabilitation design to train various cognitive functions. Many programmes are available. The current study investigates the effects on two such programmes on rehabilitation of executive functions in the chronic phase after acquired brain injury.
75585557|NCT00588705|Behavioral|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
75585558|NCT04606004|Other|Stool application|Application of stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time. However, with the stool application no barrier cream will be applied to the skin in order for the stool to achieve penetrance to the skin. Stool application will include removing any barrier creams gently, applying a thin layer of stool with a surface area shown in illustration to ensure consistent coverage, and placing a diaper on the subject. Depending on the type of the participant's ostomy, a medication cup, syringe, and/or tongue blade provided by the researchers, may be used to aid in the application of stool. After 10 minutes of application, the caregiver or inpatient healthcare provider will remove the entire thin layer of stool gently without excessive friction, just enough to remove the stool, a dabbing motion is preferred.
75585559|NCT04606004|Other|Standard of care skincare|"Standard of care for skin care pre-operatively: which is either no application of barrier cream, or an application of an over the counter (OTC) skin barrier such as Aquaphor, Desitin, or Vitamin A&D if the patient is experiencing skin redness from urine incontinence.~Standard of care skin creams post op: 3M no-sting immediately post op, once begin stooling- stoma powder, 3M no-sting, Critic-aid thick barrier paste will be applied to the skin."
75585560|NCT00588783|Device|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
75585561|NCT00588783|Device|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
75585562|NCT04605926|Biological|EQ001|itolizumab [Bmab600]
75585563|NCT04605926|Biological|EQ001 Placebo|EQ001 Placebo
75585564|NCT00588939|Device|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
75585565|NCT04605419|Procedure|Calcium electroporation|Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation
75436893|NCT01572779|Device|BSM device with no bio-feedback|The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
75436894|NCT01572805|Drug|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
76052633|NCT04786964|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
76052634|NCT04786964|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
76052635|NCT04786964|Drug|Dexamethasone 4mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
76052636|NCT05177120|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
76052637|NCT05177120|Other|Short form-36|Standardized questionnaire to investigate the quality of life in patients
75436895|NCT01572805|Drug|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
75436896|NCT01572805|Drug|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
75436897|NCT01572818|Procedure|phlebotomy|7 ml/kg without exceeding 500 mL
75436898|NCT01572818|Behavioral|dietary and lifestyle counseling|dietary and lifestyle counseling
75585566|NCT00588978|Behavioral|diet and/or exercise|Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
75585567|NCT04605536|Other|animation videos|watch animation videos about capsule endoscopy
75585568|NCT04605536|Other|explanation about endoscopy endoscopy|Give general explanations about endoscopy endoscopy
75585569|NCT00589095|Other|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
75881736|NCT03558308|Other|Sham computerized gaming|Sham training with generally stimulating computer-games
75881737|NCT02086292|Procedure|2 ml 1% Lidocaine|
75881738|NCT02086292|Procedure|1 ml 2% Lidocaine|
75881739|NCT03558932|Diagnostic Test|pleural biopsy|diagnostic sampling
76052638|NCT05177120|Other|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
76052639|NCT05177120|Other|Health assessment questionnaire|Standardized questionnaire used to detect the presence of disability
75436899|NCT01572831|Other|PCT and clinical algorithm for stopping abx|In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (<12,000 and >4,000).
75436900|NCT01572857|Biological|urinary excretion of FLC immunoglobulin|"First phase :~Collection of four urine samples daily for 2 days:~Of the 24-hour urine~at 8 AM~at 12 AM~at 4 PM~On each of these urine samples, the following analysis will be performed:~Proteinuria~Albuminuria~Urinary FLC (Freelite ™)~Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row."
75585570|NCT04605575|Drug|Pyrotinib 320mg + Vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
76052640|NCT05177120|Other|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
76052641|NCT05177120|Diagnostic Test|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
75436901|NCT01572896|Behavioral|Taking Charge: Managing JIA Online|"In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French."
75585571|NCT04605575|Drug|Pyrotinib 400mg + Vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
75585572|NCT04605575|Drug|Pyrotinib plus Vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
75585573|NCT00589134|Dietary Supplement|Gatorade Endurance Formula|carbohydrate electrolyte beverage
75585574|NCT00589134|Other|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
76052642|NCT05177120|Other|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
76052643|NCT02213263|Biological|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
76052644|NCT02213263|Biological|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
75585575|NCT00589173|Behavioral|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
75881740|NCT02769273|Device|Percutaneous Transluminal Angioplasty|
75881741|NCT02083016|Device|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
75881742|NCT02083016|Device|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
75881743|NCT02086370|Procedure|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
75881744|NCT02086370|Procedure|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
75881745|NCT02083172|Device|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
75881746|NCT05721105|Other|Quality of life assessment using questionnaires|Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
75881747|NCT02425644|Drug|ponesimod|film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
75881748|NCT02425644|Drug|teriflunomide|film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
75585576|NCT00589173|Behavioral|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
75585577|NCT00589212|Device|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
75585578|NCT04605224|Behavioral|Culinary class|This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
75585579|NCT00589251|Other|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
75585580|NCT00589368|Behavioral|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
75585581|NCT00564785|Drug|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
75881749|NCT02184741|Drug|GB-0998|Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.
76052645|NCT04781036|Drug|4%Chlorhexidine|4%Chlorhexidine was given to participants with foot odor for 1 month.
76052646|NCT05190068|Drug|HMPL-760|HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
76052647|NCT04216784|Drug|Furosemide Injection|Patient will receive furosemide intravenously
76052648|NCT04216784|Drug|Albumin Human|Patient will receive albumin (25%) 12.5 gm intravenously
75436902|NCT01572896|Behavioral|Standard Medical Care and JIA Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments."
76052649|NCT02211313|Device|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
75436903|NCT01572961|Drug|acetylsalicilic acids (Aspirin)|single oral dose of 1g.
75436904|NCT01572961|Drug|Placebo|
75436905|NCT01572987|Device|Radiofrequency Ablation(RFA) by HALO device.|RFA or Surveillance every 2 months for 1 year.
75436906|NCT01572987|Device|Endoscopic mucosal resection(EMR) by mucosectomy kit.|EMR or surveillance every 2 months.
75436907|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
75436908|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
75436909|NCT01573013|Dietary Supplement|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
75436910|NCT01573013|Dietary Supplement|iron fortified biscuits|control biscuit on a daily basis for 8 months
75436911|NCT01573065|Behavioral|Counseling intervention with rapid HIV testing|Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
75585582|NCT00564785|Other|Placebo patch|placebo patch applied 20 minutes prior to epidural
75585583|NCT00564824|Drug|Caffeine|Caffeine 200 mg tablet
75585584|NCT00564824|Drug|Placebo|Placebo pills
75881750|NCT02184741|Drug|Placebo|Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
75881751|NCT02086526|Drug|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
76052650|NCT04801472|Other|Optimisation of dental implant sites protection from irradiation|"Optimal treatment plan validation after two dosimetric computer-tomography scans (with or without radiological guide) and visualisation of virtual dental implants on scanner images.~Evaluation of toxicity, quality of life and dental implant survival rate"
76052651|NCT01975064|Drug|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
76052652|NCT01975064|Drug|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
76052653|NCT05051696|Drug|H101|Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
76052654|NCT04025138|Other|Neuromuscular tests in isometric mode|"Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~Voluntary maximum forces plantar flexors and knee extensors~Electrically evoked forces~ElectroMyoGraphic activity (EMG)~Three-Modality Evoked Potentials (TMEPs)"
75585585|NCT00589446|Device|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
75585586|NCT00564863|Biological|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
75436912|NCT01573078|Behavioral|Questionnaire|Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
75585587|NCT00589485|Device|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
76052655|NCT04025138|Device|Transcranial Magnetic Stimulation (TMS)|Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
76052656|NCT04025138|Other|Neuromuscular fatigue assessment test|Neuromuscular fatigue assessment test in dynamic mode will be assessed by the Force/Velocity Profile (FVP) measure: 2 sprints of 8 seconds on a cycle ergometer.
75436913|NCT01573091|Procedure|Cardiac Resynchronization Therapy|Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
75436914|NCT01573104|Other|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
75585588|NCT00589485|Device|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
75585589|NCT00564941|Drug|deferasirox|
75436915|NCT01573104|Other|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
75436916|NCT01573104|Other|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
75585590|NCT00589524|Device|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
75585591|NCT00589641|Behavioral|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
75585592|NCT00589641|Behavioral|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
76052657|NCT04025138|Other|treadmill|2 sessions of treadmill will be realized: 8 and 10 km.h-1 for level running and 7 km.h-1 with 10% slope for graded running.
76052658|NCT04025138|Biological|Blood sample|Blood sample will be realized to measure hemorrheologic and hematologic parameters.
75585593|NCT04605068|Procedure|Transverse preputial island flap (Duckett's technique)|
75585594|NCT04605068|Procedure|Double-faced preputial flap (DFPF)|
75585595|NCT04605107|Drug|Epifasi: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
75585596|NCT04605107|Drug|Pregnyl: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
75585597|NCT04605341|Device|miniplate|comparison between k wires and miniplate in metacarpal fractures
75881752|NCT04180995|Drug|TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)|TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
75881753|NCT02627690|Other|islet transplanted|islet transplantation
75881754|NCT02627690|Other|non islet transplanted|no islet transplantation (for a non nephrologic reason)
75881755|NCT03558776|Dietary Supplement|linseed oil|linseed oil and defined background diet
76052659|NCT04025138|Biological|Urinary sample|Urinary sample will be realized to measure hemorrheologic and hematologic parameters.
76052660|NCT02210689|Drug|clindamycin phosphate vaginal cream 2%|
76052661|NCT02210689|Other|placebo|vehicle used as placebo
76052662|NCT04780178|Behavioral|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias|A telephone-based acceptance and commitment therapy for caregivers
75585598|NCT04605653|Behavioral|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
75585599|NCT00589758|Diagnostic Test|Echocardiography|2D and 3D echocardiography
75730741|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
76052663|NCT04779710|Other|Staff Survey|A mixed mode survey design comprising of a self-administered electronic survey with a secondary option of a postal survey. The survey population was Speech and Language Therapy (SLT) Clinical Leads for Acute Stroke in Hyper/Acute Hospital Stroke Units in England and Wales. The sample frame was Routinely Admitting, and Non-Routinely Admitting Acute Stroke Hospital Teams registered on the Sentinel Stroke National Audit Programme (SSNAP) register. One hundred and sixty-six hospital teams were included after exclusions. Survey participants were asked to respond about assessment and management of dysphagia and other clinical processes during the first seven days of a person's admission to hospital following a stroke. Respondents were asked to respond about practice on behalf of the Stroke Unit rather than as an individual practitioner.
76052664|NCT02209597|Drug|Bupropion XL 300|"Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
76052665|NCT04418492|Behavioral|Skills for Adaptive Functioning through Executive training (SAFE; tentative title)|An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
75730742|NCT01021150|Drug|ombrabulin (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
75730743|NCT01021150|Drug|cisplatin|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
75730744|NCT03997006|Drug|IV Aminophylline|IV Aminophylline (100 mg/8h)
75881756|NCT02089178|Procedure|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
75436917|NCT01573117|Device|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
75436918|NCT01573117|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
75436919|NCT01573130|Behavioral|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
75436920|NCT01573143|Drug|Rosuvastatin|Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
75436921|NCT01573143|Drug|Placebo|Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
75585600|NCT00589758|Other|Biomarker evaluation|Blood and urine collected
75585601|NCT00564980|Procedure|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
75585602|NCT00564980|Procedure|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
75730745|NCT03997006|Drug|IV Neostigmine Methylsulfate + Atropine Sulphate|IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
75730746|NCT02281955|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
75881757|NCT02089178|Procedure|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
75881758|NCT02089178|Drug|propofol-remifentanil|
75881759|NCT02089178|Drug|sevoflurane-remifentanil|
75585603|NCT00589953|Drug|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
75585604|NCT00589953|Drug|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
75585605|NCT00589992|Drug|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
75585606|NCT00590070|Drug|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
75585607|NCT00590070|Drug|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
75585608|NCT00590070|Drug|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
75730747|NCT02281955|Drug|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
75730748|NCT02281955|Procedure|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
75881760|NCT02089256|Drug|Liraglutide|"Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection)."
75881761|NCT02090816|Procedure|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
75585609|NCT00565019|Drug|Triamcinolone Acetonide|"Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~Doses will range from 60-120 mg depending on extent of the disease.~Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: >10 cm2, dosage 100-120 mg"
75881762|NCT04099329|Behavioral|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
75881763|NCT02086760|Other|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
75881764|NCT02086760|Radiation|Scintigraphy|
76052666|NCT01514552|Other|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
75436922|NCT01573156|Drug|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 & 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
75585610|NCT00565097|Drug|Placebo|
75585611|NCT00565097|Drug|Lanreotide|
75585612|NCT04604756|Drug|Losartan|administration of losartan (50 mg) (oral)
75881765|NCT02861664|Other|Stannous fluoride (SnF2)|Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF
76052667|NCT01514552|Other|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
75881766|NCT02861664|Other|Sodium monofluorophosphate (SMFP)|Dentifrice containing 1400 ppm fluoride as SMFP
75881767|NCT02086838|Drug|Theragran Hematinic|
75881768|NCT02086838|Drug|low molecular weight iron dextran|
75881769|NCT02236962|Drug|Placebo|
75730749|NCT01015144|Drug|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
76052668|NCT01469156|Drug|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
75436923|NCT01573182|Biological|Zostavax|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.
75436924|NCT01573234|Device|MySkin patch|Hydrogel and polyurethane film
75436925|NCT01573234|Device|Gauze and Patch|Traditional Dressing
75436926|NCT01573247|Drug|AKN-028|"Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.~During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit."
75436927|NCT01573286|Drug|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
75436928|NCT01573286|Drug|Glucagon like peptide-2|"Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days."
75436929|NCT01573299|Other|Mobilization of stroke patients|"In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset."
75436930|NCT01573312|Drug|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
75436931|NCT01573312|Biological|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
75436932|NCT01573338|Drug|Roniciclib (BAY1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
75585613|NCT04604756|Drug|Placebo Oral Tablet|administration of placebo (oral)
75585614|NCT00590343|Drug|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
75585615|NCT00590382|Device|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
75585616|NCT04604717|Other|Pulmonary rehabilitation|8 weeks of exercise training (twice weekly) of education and exercise
75730750|NCT00511797|Drug|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
75730751|NCT00511797|Drug|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
75730752|NCT00511797|Drug|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
75730753|NCT00511797|Drug|Placebo|Placebo
75881770|NCT02236962|Drug|Ephedrine, pioglitazone|
76052669|NCT04191434|Drug|Flamboyant 125/12|Flamboyant 125/12 capsule
76052670|NCT04191434|Drug|Budesonide/formoterol 200/6|Budesonid/formoterol 200/6 capsule
76052671|NCT04191434|Other|Flamboyant 125/12 Placebo|Flamboyant 125/12 Placebo capsule
76052672|NCT04191434|Other|Budesonide/formoterol 200/6 placebo|Budesonid/formoterol 200/6 Placebo capsule
75730754|NCT00487552|Device|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
75730755|NCT02272049|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
75730756|NCT03996538|Drug|Metformin Hydrochloride Extended-Release Tablets|Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
75730757|NCT03996538|Biological|Influenza Vaccine|All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
75881771|NCT04431375|Biological|Plasma Exchange|Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .
75881772|NCT04431375|Drug|Tenofovir|Tenofovir [antiviral] 300mg PO once a day .
75881773|NCT04431375|Other|Fecal Mircobiota Transplantation|FMT for 7 days
75881774|NCT02086994|Drug|misoprostol|given after the delivery of the anterior shoulder of the baby.
75881775|NCT02086994|Drug|carbetocin|given after delivery of anterior shoulder
76052673|NCT03849716|Other|Blood sample|Blood samples obtained for biomarker analyses
76052674|NCT03849716|Other|Cheek swab|Cheek swab obtained for genetic analysis
75585617|NCT04574700|Other|knee joint mobilization and traction|"Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks"
75585618|NCT04574700|Other|Post isometric relaxation|"Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks."
75585619|NCT04604600|Drug|amyloid PET|Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
75585620|NCT04604678|Drug|Metformin|Metformin at 1500 mg/day
75436933|NCT01573338|Drug|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
75436934|NCT01573338|Drug|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
75730758|NCT02576015|Procedure|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
75436935|NCT01573338|Drug|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
75436936|NCT01573377|Drug|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
75881776|NCT01307787|Other|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
75436937|NCT01573377|Drug|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
75436938|NCT01573403|Drug|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
75436939|NCT01573403|Drug|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
75881777|NCT01307787|Other|no intervention|waiting list control group with no intervention
75881778|NCT02089412|Drug|E2006|
75436940|NCT01573403|Drug|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
75436941|NCT01573416|Other|ASSIST-linked brief intervention for hazardous and harmful substance use.|ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
75585621|NCT04604678|Drug|Naltrexone|Naltrexone at 4.5 mg/day (LDN)
75585622|NCT04604483|Device|PTNS|Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.
75585623|NCT03452358|Procedure|Partial Ceramic Indirect restoration|Placement of an partial ceramic indirect restoration with the use of immediate dentin sealing as an adjunct to adhesive cementation.
75585624|NCT04604639|Diagnostic Test|NEWS2 score|Patients seen by ambulance crews within the preceeding 48 hrs of their cardiac arrest will have a NEWS2 score performed to assess the level of physiological deterioration at the time of thei intial assessment.
75585625|NCT04604327|Drug|Bemiparin sodium|Prophilactic vs full-dose for 10 days
75585626|NCT00590616|Procedure|transthoracic examination|observational transthoracic examination
75730759|NCT02576015|Procedure|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
75881779|NCT03557606|Procedure|Alar treatment with BMC using anterior approach|Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
75881780|NCT02091050|Other|2D HDR planning|HDR planning using simple radiograph (2D)
75881781|NCT02091050|Other|3D HDR planning|HDR planning using computed tomography (3D)
75436942|NCT01573416|Other|Observation|Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
75436943|NCT01573468|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
75436944|NCT01573468|Drug|Placebo|Placebo orally once on Day 1 of each cycle
75436945|NCT01573468|Drug|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
75436946|NCT01573481|Other|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
75436947|NCT01573481|Other|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min).
75436948|NCT01573494|Other|Sampling of blood|7,5 ml of blood
75585627|NCT00590655|Behavioral|weight loss programme with maintenance programme|After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.
75585628|NCT00590655|Behavioral|weight loss programme|
75730760|NCT02576015|Drug|lidocaine|
75730761|NCT02576015|Device|ultrasound|
75730762|NCT02576015|Device|insulated needle (Contiplex B Braun, Melsungen, Germany)|
75730763|NCT02576015|Drug|ropivacaine|
75730764|NCT02576015|Drug|saline|
75881782|NCT02087228|Device|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
75730765|NCT03998475|Behavioral|Transition preparation intervention|Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
75730766|NCT02577965|Procedure|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
75730767|NCT02577965|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
75730768|NCT00182689|Drug|sorafenib tosylate|Given orally
75730769|NCT01326247|Other|thermal waters nasal irrigation|"The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution."
75730770|NCT03860259|Device|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
75881783|NCT02087228|Device|radiofrequency energy ablation device|
76052675|NCT03835676|Drug|Treprostinil|"After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~CMR will be performed at 6 monthly intervals for 2 years.~Peak power output at 6,12, 18 and 24 month~Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)"
76052676|NCT04192760|Procedure|Stenting|Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
76052677|NCT00909740|Drug|MEGF0444A|Intravenous escalating dose
76052678|NCT04783532|Behavioral|Telehealth Mindfulness Program|Enrolled participants will participate in an individual (one-on-one) Telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight sessions lasting 75 minutes each (except the first session which lasts 90 minutes) over a 3-month period.
76052679|NCT04779008|Other|remote ischemic preconditioning （RIPC）|Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
75436949|NCT01573507|Other|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
75730771|NCT03860259|Device|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
75730772|NCT01078051|Procedure|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
75730773|NCT01078051|Drug|optimal medical therapy|optimal medical therapy
75730774|NCT03915977|Behavioral|Post ICU recovery program|Standardized follow up program
75730775|NCT04071509|Device|Percutaneous Lung Biopsy|Patients will undergo the usual biopsy procedure with a fine needle inserted through a larger guide needle, under CT guidance; at the end of the biopsy, the MIPP-Kit will be introduced through the same guide needle. The guide needle and the MIPP Kit will be retracted together slowly, whilst injecting BioGlue in appropriate amounts along the whole track, from the lesion to the skin.
75730776|NCT00131365|Device|ExAblate 2000|
75730777|NCT02578121|Drug|Ixazomib|4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
75730778|NCT02578121|Drug|Pomalidomide|4.0 mg will be given on days 1-21 of a 28 day cycle
75730779|NCT02578121|Drug|Dexamethasone|20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
75881784|NCT02089490|Device|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
75881785|NCT02089568|Drug|Co-Amoxiclav|Will receive 1.2g co-amoxiclav at induction
75881786|NCT02089568|Drug|Normal Saline|Placebo - 0.9% saline
75881787|NCT03284853|Drug|Netarsudil/Latanoprost 0.02%/0.005%|Topical sterile ophthalmic solution
75881788|NCT03284853|Drug|GANFORT®|Topical sterile ophthalmic solution
76052680|NCT02188303|Drug|LY2944876|Administered SC
76052681|NCT02188303|Drug|Placebo|Administered SC
76052682|NCT03651128|Biological|bb2121|bb2121
76052683|NCT03651128|Drug|Daratumumab|Daratumumab
76052684|NCT03651128|Drug|Pomalidomide|Pomalidomide
76052685|NCT03651128|Drug|Dexamethasone|Dexamethasone
76052686|NCT03651128|Drug|Bortezomib|Bortezomib
75436950|NCT01573520|Other|Monitoring of drug adherence|In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
75585629|NCT04604171|Behavioral|Action Observation Training|Action Observation Training (AOT) is composed, according to Franceschini et al. (2012), by 20 different videos of daily activities (actions) carried out with the upper limbs. Patients underwent only one task per day for 20 sessions, starting from the easiest. Each action (unimanual or bimanual) is observed from a first-person perspective. Actors in the videos are young non-disabled people, either men or women. Patients are asked to carefully observe the videos, in order to prepare themselves to imitate the presented actions, while the therapist consistently holds the patient's attention with verbal feedback. At the end of each sequence, the therapist prompts the patient to perform the same movement with the paretic upper limb over a time period of 2 minutes, providing verbal instructions or help, if needed. Each session lasts about 30 minutes (3 min of sequence observation and 2 min of action performance for 3 motor sequences repeated twice).
75585630|NCT04604171|Behavioral|Task Oriented Training|In Task Oriented Training patients performed functional activities with the upper limbs, using the same objects for AOT, in both unimanual and bimanual modalities, without watching the video beforehand. The therapist just provided for verbal instructions and feedback, avoiding demonstrative or imitative indications. The therapist could passively support the movement if patients were completely unable to perform the actions. When necessary, the therapists could also actively facilitate the upper limb movement if patients were unable to correctly perform the actions. Based on the patient's level of motor ability and progress, the levels of movement and task difficulty could be adjusted accordingly. Patients underwent one task per day for 20 sessions. Each session lasted about 30 minutes.
75585631|NCT04604171|Behavioral|Conventional Treatment|Conventional treatment consists of a range of different patient-tailored interventions, selected by the therapist on the basis of the functional level of the patient. Treatment sessions include training for transfers, mobility, walking up and down steps, balance tasks and tailored functional tasks for the upper limbs (unimanual and bimanual). Moreover, it is also provided for joint and soft tissue mobilization, specific sensory stimulation, exercises to increase strength, both for lower and upper limbs. Each session lasted about 60 minutes.
76052687|NCT03651128|Drug|Ixazomib|Ixazomib
75585632|NCT00590694|Drug|ranibizumab|0.5mg injection monthly according to protocol for one year
75585633|NCT00565175|Drug|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
75730780|NCT00487240|Drug|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
75730781|NCT00487240|Drug|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
75730782|NCT01077115|Procedure|Laparoscopic cholecystectomy|
76052688|NCT03651128|Drug|Lenalidomide|Lenalidomide
76052689|NCT03651128|Drug|Carfilzomib|Carfilzomib
76052690|NCT03651128|Drug|Elotuzumab|Elotuzumab
75436951|NCT01573546|Behavioral|Aerobic Exercise|Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression > 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
75730783|NCT01077115|Procedure|Open Surgery|
75730784|NCT02577809|Drug|Morphine100|100mcg added to the spinal anaesthetic
75881789|NCT02091596|Drug|PluroGel N|Study Drug
75881790|NCT02091596|Drug|PluroGel|PluroGel Vehicle Placebo Comparator
75881791|NCT03557528|Procedure|Laparoscopic colorectal resection|Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
75730785|NCT02577809|Drug|Morphine50|50mcg added to the spinal anaesthetic
75730786|NCT02577809|Drug|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
75881792|NCT03557450|Device|PET/CT Scan|PET/CT scanning with sodium fluoride
75881793|NCT02087384|Biological|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
75881794|NCT02087384|Drug|Placebo|injection of 0.9% saline
76052691|NCT00664898|Drug|bortezomib|Escalating intravenous repeating dose
76052692|NCT00664898|Drug|SGN-40|Escalating intravenous repeating dose
76052693|NCT04867382|Behavioral|Online training|This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.
76052694|NCT04418336|Procedure|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
76052695|NCT04850300|Procedure|Total knee prosthesis with medial condylar stabilization|Surgery will be done of Total knee prosthesis with medial condylar stabilization
76052696|NCT04850300|Procedure|Total knee prosthesis with central pivot stabilization|Surgery will be done of Total knee prosthesis with central pivot stabilization
76052697|NCT04776980|Diagnostic Test|Post Feraheme Infusion MRI|All participants will receive a ferumoxtyol (Feraheme) infusion 20-28 hours prior to a head MRI. In addition, a blood draw for liquid biopsy targeted tissue sampling during surgery and special iron and macrophage staining on the tumor tissue.
76052698|NCT02187055|Drug|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
76052699|NCT02187055|Drug|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
75730787|NCT02577809|Drug|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
75730788|NCT02577809|Drug|Indomethacin|100mg Indomethacin suppository
75730789|NCT03998085|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
75730790|NCT00579579|Behavioral|Questionaires|Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
75730791|NCT02224391|Behavioral|Computer-Assisted Smoking Cessation Intervention|Receive ABM training via a smartphone
75881795|NCT02087462|Other|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
75585634|NCT00565175|Drug|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
75436952|NCT01573546|Behavioral|DASH diet|Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
75730792|NCT02224391|Other|Laboratory Biomarker Analysis|Correlative studies
75436953|NCT01573546|Other|Health education control|The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
75436954|NCT01573585|Behavioral|Usual Care|The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.
75585635|NCT04604249|Diagnostic Test|SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)|Presence of specific SARS-CoV-2 antibodies (IgM or IgG).
75585636|NCT00477165|Drug|Citalopram|20mg/day for 4 weeks, then 40 mg/day for 4 weeks
75730793|NCT02224391|Drug|Nicotine Patch|Given via transdermal patch
75730794|NCT02224391|Other|Questionnaire Administration|Ancillary studies
75730795|NCT02224391|Other|Sham Intervention|Undergo sham training
75881796|NCT02087462|Other|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
76052700|NCT02187055|Biological|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
75585637|NCT00477165|Drug|Placebo|Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
75585638|NCT04604054|Drug|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
75730796|NCT00487162|Procedure|intensive glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
75730797|NCT00487162|Drug|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
76052701|NCT00119366|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
75585639|NCT04604054|Drug|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
75585640|NCT00476229|Drug|Thymoglobulin|1.5 mg/kg by vein on Days -11 to -7.
75585641|NCT00476229|Radiation|Total Lymphoid Irradiation|80 cGy daily on days -11 to -7 and -4 to 0.
75585642|NCT00476229|Procedure|Peripheral Blood Stem Cell Infusion|PBSC infusion administered on day 0.
75730798|NCT03998241|Other|No intervention was provided|No intervention given
75730799|NCT02219711|Drug|MGCD516|MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
75585643|NCT00476229|Drug|Rituximab|375 mg/m^2 by vein on days -13, -6, 1, & 8. Only those patients whose tumors express CD20 will receive Rituximab.
75436955|NCT01573585|Behavioral|FAST protocol|The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
75585644|NCT04603976|Drug|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
75881797|NCT02087462|Drug|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
76052702|NCT00119366|Drug|fludarabine phosphate|Given IV
75881798|NCT02087462|Drug|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
75881799|NCT02087540|Drug|Telmisartan 80mg|
76052703|NCT00119366|Radiation|total-body irradiation|Undergo TBI
75436956|NCT01573598|Drug|Placebo|Matching placebo given orally, once per day
75585645|NCT00476151|Drug|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
75730800|NCT01021384|Behavioral|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
75730801|NCT03871959|Drug|Pembrolizumab|200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
75436957|NCT01573598|Drug|Vilazodone|Vilazodone, 20 mg per day, oral administration
75730802|NCT03871959|Drug|DEBIO1143|3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
75730803|NCT00487084|Drug|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
76052704|NCT00119366|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
76052705|NCT00119366|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
76052706|NCT00119366|Drug|cyclosporine|Given IV or PO
75436958|NCT01573598|Drug|Vilazodone|Vilazodone, 40 mg once per day, oral administration
75730804|NCT00487084|Drug|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
75881800|NCT02087540|Drug|Rosuvastatin 20mg|
75881801|NCT02087540|Drug|Rosuvastatin 10mg|
75881802|NCT02087540|Drug|Placebo(for Telmisartan 80mg)|
75881803|NCT02087540|Drug|Placebo(for Rosuvastatin 20mg)|
75881804|NCT02087540|Drug|Placebo(for Rosuvastatin 10mg)|
75881805|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions of CBT, twice weekly
75881806|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions with goals groups drug testing
75881807|NCT03952923|Biological|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
75881808|NCT05494970|Other|Accompaniment by the dental assistant.|"Inclusion visit (before radiotherapy treatment):~oral hygiene education (prevention of complications related to radiotherapy) will be provided by the dental assistant.~a written information guide on oral hygiene will be given to the patient.~the questionnaire entitled Motivation and oral hygiene behavior will be completed by the patient.~End of study visit (three months post-radiotherapy):~• The Motivation and oral hygiene behavior and the satisfaction questionnaires will be completed by the patient."
76052707|NCT00119366|Drug|mycophenolate mofetil|Given PO
76052708|NCT00119366|Other|laboratory biomarker analysis|Correlative studies
75436959|NCT01573611|Dietary Supplement|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
75436960|NCT01573611|Dietary Supplement|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
75585646|NCT00476151|Drug|placebo cream|inactive placebo cream applied two times daily
75585647|NCT04603703|Other|HVLAT Manipulation|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
75436961|NCT01573637|Drug|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
75585648|NCT04603703|Other|Conventional Physical Therapy|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
75585649|NCT00475644|Drug|Enzastaurin|Administered orally
75585650|NCT04603664|Diagnostic Test|serum NGAL and cystatin c|measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury
75585651|NCT04603235|Behavioral|Manual-based Art Therapy|This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
76052709|NCT02246660|Drug|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
75585652|NCT00474903|Drug|acetylsalicylic acid|Given orally
75730805|NCT00487084|Drug|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
75436962|NCT01573637|Drug|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
75436963|NCT01573663|Drug|Ambroxol and Levodropropizine|Ambroxol HCl 30mg & Levodropropizine 60mg, PO, Single dose
75585653|NCT00474903|Drug|esomeprazole magnesium|Given orally
75585654|NCT00474903|Other|placebo|Given orally
75585655|NCT01134055|Drug|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
75436964|NCT01573663|Drug|Ambroxol|Ambroxol HCl 30mg, PO, single dose
75436965|NCT01573663|Drug|Levodropropizine|Levodropropizine 60mg, PO, single dose
75730806|NCT04770675|Diagnostic Test|Bronchoscopy|All subjects who are scheduled for a bronchoscopy may be eligible.
75730807|NCT00466726|Biological|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
75730808|NCT00466726|Biological|sargramostim|
75730809|NCT03998787|Other|Neurophysiological assessment|Kinematic analysis of movement and transcranial magnetic stimulation
75881809|NCT03206463|Drug|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
75881810|NCT03206463|Drug|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
76052710|NCT02246660|Drug|Placebo|Placebo will be taken orally for 6 months.
75436966|NCT01573689|Behavioral|Group intervention based on mutual aid.|Development of a mutual aid group and his actualization on children between nine and twelve years old who had lost one of their parents.
75436967|NCT01573715|Drug|NIMBEX|
75436968|NCT01573715|Drug|NIMBEX|
75436969|NCT01573715|Other|WITHOUT NIMBEX|
75436970|NCT01573728|Behavioral|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
75436971|NCT01573728|Behavioral|Public Health Exercise|At least 150 minutes at moderate intensity
75730810|NCT01721291|Drug|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
75730811|NCT01021462|Procedure|Comparator: graded infusion of intravenous glucose|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
75730812|NCT01403350|Device|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
75881811|NCT03206463|Drug|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
75881812|NCT02091674|Device|Hyaluronic acid|Injected gel
75881813|NCT02087618|Other|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
76052711|NCT04750447|Device|XEN 63|The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
75436972|NCT01573741|Drug|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
75436973|NCT01573793|Behavioral|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
75436974|NCT01573793|Behavioral|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
75436975|NCT01573806|Drug|Exenatide|Exenatide, dosed subcutaneously every 12 hours for 4 doses
75436976|NCT01573806|Drug|Exenatide vehicle|Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
75436977|NCT01573819|Drug|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
75436978|NCT01573819|Drug|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
75436979|NCT01573832|Other|integrated client care group|receives integrated client care for wound treatment
75436980|NCT01573845|Behavioral|Healthy Eating + Eco-Friendly Campaign|"Participants receive a 6-month school-based campaign that includes:~A 22-lesson classroom curriculum~Homework activities that involve the family~Monthly parent newsletters~A food shopping and packing guide for parents~Food demonstrations~A poster contest~School wide announcements"
75436981|NCT01573845|Behavioral|Healthy Eating Campaign|"Participants receive a 6-month school-based campaign that includes:~A 22-lesson classroom curriculum~Homework activities that involve the family~Monthly parent newsletters~A food shopping and packing guide for parents~Food demonstrations~A poster contest~School wide announcements"
75730813|NCT01021540|Drug|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
75730814|NCT04840511|Drug|lidocaine group|lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)
75730815|NCT04840511|Drug|control group|normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
75881814|NCT02087618|Other|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
75881815|NCT04610827|Drug|Ferrous sulfate|Guideline-recommended 3 mg/kg/day dosing
75881816|NCT01218555|Drug|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
75881817|NCT01218555|Drug|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
75881818|NCT04503733|Drug|Q4W GMA301 IV injections (300 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
76052712|NCT03475550|Other|Standard of Care|The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
75585656|NCT01134055|Drug|placebo|placebo eye drops
75585657|NCT01134055|Biological|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
75585658|NCT00474708|Drug|Effexor|
75585659|NCT00474708|Drug|SSRI|
76052713|NCT02246582|Device|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen & arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
75585660|NCT04603040|Drug|Toripalimab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
75436982|NCT01573858|Other|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
76052714|NCT02246582|Device|Guardian Mobile App|
76052715|NCT02246582|Device|640G Insulin Pump|
75436983|NCT01573858|Other|Acupuncture treatment 2|Needles will be inserted to a depth of <5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
75585661|NCT05366959|Other|Trunk Muscle Endurance test|"Trunk flexors endurance test: Participants will be positioned with trunk flexed to 60º, knees and hips to 90º flexion. The evaluator fixes the feet on the ground by supporting them from the toes. When the 60º trunk flexion is broken, the test will be terminated and the time it maintains this position will be recorded in seconds.~Modified Biering-Sorensen test: With this test, the endurance of trunk extensors is evaluated. The subjects are positioned in the prone position with the pelvis, hips and knees on the bed. The subjects are asked to extend their upper body straight forward from the edge of the table and the time they maintain this position will be recorded in seconds.~Lateral bridge test: During the test, the subjects were asked to lie on their side, raise their bodies on their forearms and toes and maintain this position, and the time they held the position would be recorded in seconds. The test will be done on both sides."
76052716|NCT04741802|Behavioral|TOPS|weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors in the local chapter of a national African American breast cancer support group (Sisters Network Triangle North Carolina, SNTNC).
76052717|NCT02137369|Drug|Selective serotonin re-uptake inhibitor|Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks
75436984|NCT01573858|Other|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
75436985|NCT01573858|Other|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
75436986|NCT01573871|Other|Experimental Hydrolyzed infant formula|Experimental hydrolyzed infant formula to be fed ad libitum
75436987|NCT01573923|Biological|mesenchymal stem cells|Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
75436988|NCT01573923|Biological|Conventional therapy|Conventional therapy without cell therapy
75436989|NCT01573936|Other|Physical therapy, occupational therapy, psycotherapy, medical consultations|The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
75436990|NCT01573975|Drug|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
75436991|NCT01573975|Drug|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
75585662|NCT05366959|Other|Fatigue Severity Scale|"Fatigue Severity Scale was used to evaluate the fatigue level of the participants. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. High scores are associated with increased fatigue. Evaluates the effects of fatigue on physical function, motivation, family and social life. Turkish validity and reliability was established."
75585663|NCT05366959|Other|Roland Moris Scale|"The Roland Moris Scale will be used to evaluate the participants for low back pain assessment. The Roland Morris Inquiry Form was designed to evaluate the functional disability of the patient. The total score ranges from 0 (no disability) to 24 (severe disability). The higher the total score, the lower the patient's functionality. It is a questionnaire filled by the patient, which evaluates the functionality of 24 items questioning the patient's mobility, self-care and sleep status. Each item marked as 'Yes' is given 1 point, and answers marked as 'No' are given 0 points. Turkish validity and reliability was established."
75436992|NCT01573975|Drug|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
75881819|NCT04503733|Drug|Q4W GMA301 IV injections (600 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
76052718|NCT02137369|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
76052719|NCT02137369|Other|Combination treatment (SSRI + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
76052720|NCT02155309|Drug|Scopolamine|
76052721|NCT02155309|Drug|Placebo|
76052722|NCT02186821|Drug|Ceritinib|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
76052723|NCT01710358|Drug|Adalimumab|Administered SC
76052724|NCT01710358|Drug|Baricitinib|Administered orally
75585664|NCT05366959|Other|Physical Activity Levels|The physical activity level of the participants will be measured with the International Physical activity scale: MET values will be calculated according to this scale, which has Turkish validity and reliability.
75585665|NCT04603118|Procedure|Optic ultrasonography|
75585666|NCT04603118|Procedure|Lumbar puncture|
75730816|NCT04072133|Behavioral|Meditative Movement|Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
76052725|NCT01710358|Drug|Methotrexate|Administered orally
76052726|NCT01710358|Drug|Adalimumab Placebo|Adalimumab placebo administered SC.
75436993|NCT01573988|Other|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :~breakfast in one intake at 8:00~breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions."
75585667|NCT02883127|Behavioral|Motivational interviewing|"The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:~Watch portion size - to be conscious about the amount of carbohydrates in each meal.~Eat mainly carbohydrates of low glycaemic index.~Reduce the intake of carbohydrate of high glycaemic index.~Watch daily weight changes - aim for the recommended weekly changes.~In addition to the motivational intervention the women are given unchanged routine care."
75585668|NCT04603586|Radiation|SBRT|SBRT: in 5-6 fractions with CyberKnife
75585669|NCT04603586|Drug|Chemotherapy|1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
75585670|NCT00474240|Drug|Atorvastatin 20 mg|
75585671|NCT00474240|Drug|AEGR-733 5 mg|
75585672|NCT00474240|Drug|AEGR-733 10 mg|
75585673|NCT00474240|Drug|Placebo|
75585674|NCT00474240|Drug|AEGR-733 5 mg + atorvastatin 20 mg|
75585675|NCT00474240|Drug|AEGR-733 10 mg + atorvastatin 20 mg|
75585676|NCT02277561|Procedure|diffusion tensor imaging|Undergo VB-DTI
75585677|NCT02277561|Radiation|whole-brain radiation therapy|Undergo WBRT
75585678|NCT02277561|Radiation|stereotactic radiosurgery|Undergo SRS
75585679|NCT02277561|Procedure|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
75585680|NCT02277561|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
75730817|NCT00486226|Device|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
75585681|NCT00473889|Drug|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
75585682|NCT00473889|Drug|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
75585683|NCT00473889|Drug|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
75585684|NCT00473889|Drug|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
75585685|NCT04602416|Behavioral|Training sessions|
75730818|NCT02199665|Drug|selinexor|Given PO
75730819|NCT02199665|Drug|carfilzomib|Given IV
75730820|NCT02199665|Drug|dexamethasone|Given PO or IV
75730821|NCT01021696|Drug|Paracetamol|Paracetamol Max. dose: 3g/d
75730822|NCT01021696|Drug|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
75730823|NCT01021696|Drug|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
75730824|NCT01021696|Drug|Pregabalin|25mgx1/d; max 300mg/d
75730825|NCT01018498|Behavioral|Restricted FODMAPs diet|Restricted fermentable substrate diet
76052727|NCT01710358|Drug|Baricitinib Placebo|Baricitinib placebo administered orally.
76052728|NCT01633112|Drug|fingolimod|capsule
76052729|NCT01633112|Drug|glatiramer acetate|subcutaneous injection
76052730|NCT03455270|Drug|G1T48|oral SERD
76052731|NCT03455270|Drug|Palbociclib|CDK 4/6 Inhibitor
76052732|NCT01691482|Drug|Albuterol/salbutamol|Albuterol/salbutamol (daily)
75730826|NCT02577575|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
75730827|NCT02577575|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
75881820|NCT04503733|Drug|Q4W GMA301 IV injections (1000 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
76052733|NCT01691482|Drug|Ipratropium|Ipratropium (daily)
76052734|NCT04776044|Drug|ATR-002|150mg tablets for oral intake
76052735|NCT04776044|Drug|Placebo|matching tablets for oral intake
76052736|NCT02246114|Device|piCO+ Smokerlyzer® monitor|
76052737|NCT02246114|Other|Text messages|
76052738|NCT01710046|Drug|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
76052739|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
76052740|NCT01710046|Drug|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
75436994|NCT01574001|Behavioral|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
75436995|NCT01574001|Behavioral|Antismoking intervention with minimal early follow-up|"Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke"
75585686|NCT04602455|Behavioral|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
75585687|NCT00565214|Dietary Supplement|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
75585688|NCT00565214|Dietary Supplement|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
75585689|NCT00565253|Drug|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
75730828|NCT02577653|Other|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
76052741|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
76052742|NCT03267758|Dietary Supplement|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This is followed by 6 weeks of placebo.
76052743|NCT03267758|Dietary Supplement|Placebo first|Consumption of 1 serving of probiotic placebo daily for 6 weeks. of 1 serving of Goodbelly probiotic daily for 6 weeks.
76052744|NCT04633616|Other|Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
75436996|NCT01574001|Behavioral|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
75436997|NCT01574014|Behavioral|CBGT|Cognitive-behavioral group therapy
75436998|NCT01574014|Drug|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
75436999|NCT01574014|Drug|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
75437000|NCT01574027|Drug|Vitamin D3 (cholecalciferol)|One capsule per day for six months
75437001|NCT01574027|Drug|Placebo|One capsule per day for six months
75585690|NCT04602689|Drug|Human fibrinogen concentrate|Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
76052745|NCT04633616|Other|Non-Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
76052746|NCT02154529|Drug|Tesevatinib|
75437002|NCT01574040|Behavioral|Promotion of stair climbing|"Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories."
75585691|NCT02277600|Drug|BMS-663068|BMS-663068
75585692|NCT02277600|Drug|Darunavir|Darunavir
75585693|NCT02277600|Drug|Cobicistat|Cobicistat
75585694|NCT00575250|Behavioral|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
75585695|NCT00575250|Behavioral|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
75585696|NCT04602143|Drug|Testosterone gel|Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
75585697|NCT02277678|Drug|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
76052747|NCT02154529|Drug|Trastuzumab|
76052748|NCT01954017|Biological|STP206|Live Biotherapeutic
76052749|NCT01954017|Other|Control|Sterile Water
75437003|NCT01574040|Behavioral|Promotion of a low-salt soup alternative for the 'soup of the day'|"Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure."
76052750|NCT02154139|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
75437004|NCT01574040|Behavioral|Promotion of a low-fat alternative for the butter croissants|"Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids."
75437005|NCT01574040|Behavioral|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
75585698|NCT02277678|Drug|Opioid administration morphine|
75585699|NCT04601636|Device|Active Prewarming|Active prewarming with Flex Warming Gown (Bair Paws, 3M) for at least 30 minutes before induction of anesthesia, with active warming intraoperatively with Bair Hugger (3M)
75585700|NCT04601636|Other|Standard Care|Standard care with a passive prewarming (warm cotton blankets) before induction of anesthesia, with active warming intraoperatively with (Bair Hugger, 3M)
75585701|NCT04579536|Other|Light curable resin modified glass ionomer varnish|Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
75585702|NCT04579536|Other|Vanish White Varnish|5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
75730829|NCT04827407|Device|Efferon LPS hemoperfusion|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit
75730830|NCT02578979|Device|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
75585703|NCT04601519|Other|Cross-sectional observational study|Online questionnaire on the impact of type 1 diabetes on sleep quality
75585704|NCT04601675|Drug|Ranibizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema
75585705|NCT04601675|Drug|Ranibizumab Ophthalmic only|Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.
75585706|NCT02277756|Device|thermode|thermal stimulation with test thermode
75437006|NCT01574066|Procedure|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
75585707|NCT00565292|Drug|MK0859|
75585708|NCT04601597|Device|Shu Bei Kang (China) Midline Catheters|The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 ~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 ~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.
75437007|NCT01574092|Drug|Combination of two marketed drugs (irinotecan and cisplatin)|Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
75585709|NCT01580865|Drug|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
75585710|NCT04601441|Drug|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
75585711|NCT00473694|Drug|sugammadex|Administered as an intravenous (IV) infusion
76052751|NCT02245568|Drug|LMTM|The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
76052752|NCT02154061|Drug|IIV Flu Vaccine|This is an FDA approved and tested Inactivated Flu Vaccine.
75437008|NCT01574131|Drug|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
75730831|NCT02578979|Device|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
75585712|NCT00473694|Drug|neostigmine|Administered as an IV infusion
75585713|NCT00473694|Drug|vecuronium|Administered as an IV infusion
75585714|NCT00473694|Drug|rocuronium|Administered as an IV infusion
75585715|NCT00473694|Drug|glycopyrrolate|Administered as an IV infusion
75437009|NCT01574131|Drug|Sugar Pill|pill every day for 6 months
76052753|NCT02154061|Drug|Metronidazole|This is a standard antibiotic
75437010|NCT01574196|Other|Autonomic nervous system activity records|The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.
75437011|NCT01574222|Biological|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
75437012|NCT01574235|Biological|Nivestim®|
75437013|NCT01574261|Drug|Placebo|Placebo for four months
75437014|NCT01574261|Drug|Inositol|Inositol 4g/die for four months
75437015|NCT01574300|Other|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
75437016|NCT01574313|Procedure|stellate ganglion block|stellate ganglion block
75437017|NCT01574313|Drug|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
75437018|NCT01574313|Drug|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
75437019|NCT01574313|Drug|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
75585716|NCT04601792|Drug|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
76052754|NCT02154061|Drug|Neomycin|This is a standard antibiotic.
76052755|NCT02154061|Drug|Vancomycin|This is a standard antibiotic.
75881821|NCT04503733|Drug|Q4W GMA301 IV injections (1800 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
75437020|NCT01574339|Device|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative."
75881822|NCT04503733|Other|Q4W placebo IV injections|Placebo is indistinguishable from GMA301.
75881823|NCT03557060|Drug|Nucala|NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
75881824|NCT01368991|Device|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
75881825|NCT01368991|Procedure|Conventional closure|conventional closure, no kryptonite applied
75881826|NCT02091830|Drug|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
75437021|NCT01574365|Drug|RTA 402|
75437022|NCT01574378|Device|conventional closure|non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)
75585717|NCT04601792|Drug|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
75585718|NCT04601792|Drug|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
75585719|NCT04601012|Diagnostic Test|Optical coherence tomography angiography|Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
75585720|NCT00565331|Drug|Rituximab|single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
75585721|NCT00565331|Drug|Placebo|saline solution
75437023|NCT01574378|Device|V-Loc 90|2-layer wound closure using V-Loc 90 barbed suture
75437024|NCT01574391|Device|Epidrum|Epidrum is used
75437025|NCT01574404|Procedure|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
75585722|NCT00473655|Drug|rosuvastatin|10mg or 20mg
75585723|NCT04576481|Behavioral|Text Messaging|Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
75881827|NCT02091830|Other|Physiotherapy|
75881828|NCT02091830|Drug|Cortisone Injection|
75881829|NCT02091830|Other|Others|
75881830|NCT01111305|Drug|Reslizumab|
75881831|NCT01111305|Drug|Diethylcarbamazine|
75881832|NCT01111305|Other|Placebo|
75881833|NCT05191927|Other|male|Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
75881834|NCT02089802|Drug|Pazopanib|
75881835|NCT04497415|Other|Video-Based intervention|Three minutes video of a nurse that shares her personal story
75881836|NCT03752307|Drug|Isoxsuprine Hydrochloride|Compounded Isoxsuprine hydrochloride capsules
75881837|NCT03752307|Drug|Placebo|Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
75881838|NCT03752307|Drug|Corticosteroid|This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
75881839|NCT02087696|Drug|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
75585724|NCT04576481|Behavioral|Coaching|Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.
75585725|NCT04576481|Behavioral|Lottery|Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
76052756|NCT01907217|Device|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
76052757|NCT01907217|Drug|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
75437026|NCT01574417|Dietary Supplement|control margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
75585726|NCT00582920|Radiation|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
75585727|NCT00473382|Drug|Ranibizumab|Sterile solution for intravitreal injection.
75585728|NCT00473382|Drug|Sham injection|
76052758|NCT01907217|Drug|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
76052759|NCT01953783|Drug|IXAZOMIB|"Part A: Ixazomib 4.1 mg containing approximately 500-nCi [14C]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity."
75585729|NCT00582959|Other|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
75585730|NCT02210325|Drug|solithromycin|
76052760|NCT04416009|Device|NİCaS|whole body bioimpedence method
76052761|NCT02134015|Drug|Patritumab|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
76052762|NCT02134015|Drug|Erlotinib|Oral erlotinib 150 mg/day
76052763|NCT02134015|Drug|Placebo|Placebo infusion every 3 weeks
76052764|NCT04411485|Other|Sexual dysfunction|Sexual dysfunction will be determined with separate scales for women and men
76052765|NCT04619979|Procedure|patients undergoing gynecological surgery under general anesthesia|patients undergoing gynecological surgery under general anesthesia
76052766|NCT01924845|Drug|BMN 701|BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
76052767|NCT01630135|Drug|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
76052768|NCT01630135|Drug|Placebo|Placebo, intranasal, 2 weeks
75437027|NCT01574417|Dietary Supplement|plant stanol-enriched margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
75437028|NCT01574430|Procedure|PDT|30% or 50% verteporfin dose PDT was given to patients with CSC
75585731|NCT02210325|Drug|ceftriaxone|
75585732|NCT02210325|Drug|azithromycin|
75585733|NCT00473265|Drug|PTH|
75585734|NCT00583037|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
75585735|NCT04576286|Procedure|Holmium versus Bipolar en bloc transurethral resection|"After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician.~Intervention: all procedures will be done by an expert surgeon who performed over 50 cases of en bloc urinary bladder tumor resection with each energy source. In group A, Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency for Group A and bipolar en bloc resection for Group B. A 550 nm flexible laser fiber will be used in group A and a bipolar resection loop for group B."
75585736|NCT00472641|Drug|Ziprasidone/Geodon|Ziprasidone/Geodon
75585737|NCT04576208|Drug|TAK-788|TAK-788 capsules
75881840|NCT03634423|Behavioral|Sweet Spot: Flexible high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
75585738|NCT04576208|Drug|Antidiarrheal prophylaxis|Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
76052769|NCT01691248|Drug|fidaxomicin|"Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
76052770|NCT01691248|Drug|Placebo|"Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
76052771|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
76052772|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
76052773|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
75437029|NCT01574469|Other|1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)|1 = Intervention 1 (2 test products / day)
75585739|NCT04571151|Drug|LEXETTE 0.05% Topical Foam|Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
75730832|NCT00485758|Drug|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
76052774|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
76052775|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
76052776|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
75730833|NCT00485758|Drug|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
75437030|NCT01574469|Other|2-Low fat fermented dairy product (control)|2 = Intervention 2 (2 control products/day)
75437031|NCT01574482|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
75437032|NCT01574482|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
75437033|NCT01574495|Other|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
75437034|NCT01574508|Drug|Transient Continuous Subcutaneous Insulin Infusion|Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
75437035|NCT01574508|Drug|Transient Multiple Daily Insulin Injections|Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
75437036|NCT01574534|Device|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
75585740|NCT04571151|Drug|Sorilux 0.005 % Topical Foam|Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
75585741|NCT04571151|Other|Vehicle Foam|Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
75730834|NCT04073459|Biological|DTwP-HepB-Sabin IPV-Hib|Intramuscular injection into the anterolateral area of the thigh
75730835|NCT04073459|Biological|Pentavalent vaccine and Salk IPV|Intramuscular injection into anterolateral area of the thigh
75730836|NCT01018576|Other|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
75730837|NCT02577341|Drug|Nimotuzumab|Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.
75881841|NCT03634423|Behavioral|Sweet Spot: Flexible low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
75881842|NCT03634423|Behavioral|Sweet Spot: Rigid high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
76052777|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
76052778|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
76052779|NCT01691092|Drug|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
75881843|NCT03634423|Behavioral|Sweet Spot: Rigid low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
76052780|NCT02133001|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
76052781|NCT02133001|Drug|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
75730838|NCT02577341|Drug|docetaxel and cisplatin|Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
76052782|NCT01709578|Drug|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
75585742|NCT04576169|Procedure|Arthroscopic Debridement|A central or radial TFCC tear found during wrist arthroscopy is debrided with a shaver. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Immediate mobilization of the wrist is allowed after operation. Instructions of home exercise are handed to the patient and patient is instructed to start the exercises two weeks from the operation.
75585743|NCT04576169|Procedure|Placebo surgery|Diagnostic arthroscopy only. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Immediate mobilization of the wrist is allowed after operation. Instructions of home exercise are handed to the patient and patient is instructed to start the exercises two weeks from the operation. The procedure is placebo surgery.
75730839|NCT02577341|Radiation|daily RT to the chest|Patients received daily RT to the chest
75730840|NCT03998800|Dietary Supplement|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
75730841|NCT03998800|Behavioral|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
76052783|NCT01709578|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
75730842|NCT02577497|Drug|beclomethasone|
75730843|NCT02577497|Drug|fluticasone|
76052784|NCT01709578|Drug|hydroxychloroquine|Dispensed according to the local practice.
76052785|NCT01709578|Drug|methotrexate|Dispensed according to the local practice.
75437037|NCT01574534|Device|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
75437038|NCT01574560|Behavioral|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
75437039|NCT01574560|Behavioral|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
75437040|NCT01574573|Behavioral|Self support, group sessions|Self support,group sessions
75437041|NCT01574586|Device|Bifurcation stenting|Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
75437042|NCT01574599|Other|Occupational therapy- Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
75437043|NCT01574638|Drug|Rifapentine (RPT)|Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
75437044|NCT01574664|Device|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
75730844|NCT01021774|Procedure|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
75730845|NCT01602263|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
75730846|NCT02577419|Other|Target Fortification|
75730847|NCT02577419|Other|Higher Initial Concentration|
75881844|NCT03634423|Behavioral|FOTW: High incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
75881845|NCT03634423|Behavioral|FOTW: Low incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
75881846|NCT03634423|Behavioral|FOTW: High incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
76052786|NCT01709578|Drug|sulfasalazine|Dispensed according to the local practice.
76052787|NCT01709578|Drug|leflunomide|Dispensed according to the local practice.
76052788|NCT02132767|Drug|Amiodarone|"Amiodarone Initial Dose~Oral: 400 mg po TID for 3 days is recommended~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~Oral: at least 200 mg/day to be continued until 60 days after randomization~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
76052789|NCT02132767|Procedure|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
76052790|NCT02132767|Drug|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
75585744|NCT04576169|Procedure|Arthroscopic or Open Repair|An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
75585745|NCT04576169|Procedure|Physiotherapy|An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
75585746|NCT01133977|Drug|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
75585747|NCT01133977|Drug|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
75585748|NCT01133977|Drug|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
75585749|NCT04570917|Behavioral|Online educational intervention to reduce ageism|Participants in this group will go over multiple short videos covering the following content:1). Myths about aging, 2). Ageism and its negative effects, 3). Distorted views about aging among young adults, 4). Ageism during the COVID-19 pandemic, and 5). importance of reducing ageism among healthcare professionals. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
75585750|NCT04570917|Behavioral|Online educational intervention to enhance cultural competance|Participants in the control group will go over multiple short videos covering the following content: 1). Myths about cultural competence, 2) Cultural competence for health care professionals including dietitians, 3). Connecting culture and food, and 4). Importance of cultural competence in sports dietitians. At the end of the lesson, they will be asked to briefly write what they learned. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
76052791|NCT02153905|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
75437045|NCT01574690|Device|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
75437046|NCT01574690|Procedure|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
75437047|NCT01574690|Procedure|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
75585751|NCT00583193|Drug|Duloxetine hydrochloride|Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
75585752|NCT01133821|Drug|IPSRT plus placebo (IPSRT-PLA)|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
75585753|NCT01133821|Drug|IPSRT plus quetiapine|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
75585754|NCT00472446|Drug|bilateral superficial cervical block|10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
75730848|NCT02577419|Other|Portagen Formula|
75730849|NCT02576171|Behavioral|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
76052792|NCT02153905|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
76052793|NCT02153905|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
76052794|NCT02153905|Biological|Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)|Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
75437048|NCT01574729|Drug|Surgery combined with rAd-p53 gene therapy|Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
75437049|NCT01574729|Procedure|Surgery|Surgery plus post-surgery chemotherapy
75437050|NCT01574742|Drug|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
75585755|NCT00472446|Drug|placebo bilateral superficial cervical block|"10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side."
75437051|NCT01574768|Procedure|Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle
75585756|NCT00583232|Drug|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
75585757|NCT00583271|Drug|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
75585758|NCT00583271|Drug|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
75730850|NCT04071665|Procedure|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion
75730851|NCT02575937|Behavioral|low glycemic diet|nutrition education-based low glycemic diet intervention
75881847|NCT03634423|Behavioral|FOTW: Low incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
75881848|NCT03634423|Behavioral|Think Twice: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
75881849|NCT03634423|Behavioral|Think Twice: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
75437052|NCT01574781|Procedure|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
75585759|NCT04570995|Dietary Supplement|Fish Oil|Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week
75585760|NCT04570995|Dietary Supplement|Safflower Oil|Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week
75585761|NCT04576013|Device|Peripheral nerve stimulation (PNS)|Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
75730852|NCT02577263|Other|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
75730853|NCT02575859|Drug|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
75730854|NCT02575859|Procedure|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
75730855|NCT04779827|Behavioral|Online Social Network and Collective Intelligence Intervention|The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.
75881850|NCT03634423|Behavioral|WDR: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
75881851|NCT03634423|Behavioral|WDR: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
75585762|NCT04576013|Behavioral|Intensive upper extremity motor training|
75730856|NCT04779827|Behavioral|Independent Control|Independent control aims to test the baseline of population understanding of health behaviors and choices. Participants will respond to health questions independently without getting any feedback from others.
75730857|NCT02576873|Other|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
75730858|NCT00469612|Device|NeuroVision's NVC treatment for Low Myopia|"NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).~The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress."
75730859|NCT00469456|Drug|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
75881852|NCT00792831|Drug|ITF2357|Histone-Deacetylase Inhibitor
75881853|NCT00496431|Drug|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
75881854|NCT03634501|Biological|Activated NK|Cell suspension
75437053|NCT01574781|Procedure|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
75437054|NCT01574794|Other|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
75437055|NCT01574794|Other|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
75437056|NCT01574820|Drug|placebo tablet|placebo tablet for 6 months
75437057|NCT01574820|Drug|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
75437058|NCT01574833|Device|pulsed electromagnetic field|PEMF treatment
75437059|NCT01574833|Device|sham|sham treatment
75437060|NCT01574859|Other|levothyroxine|titration of T4 according to biochemical values
75881855|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
75881856|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
75585763|NCT00472290|Drug|Romiplostim (formerly AMG 531)|"Subjects will begin the study at an initial dose of 750 µg.~Except for:~Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count."
75585764|NCT01133704|Biological|sipuleucel-T|
76052795|NCT02153827|Other|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
75585765|NCT01133704|Biological|APC-Placebo|
75585766|NCT02883088|Procedure|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
75437061|NCT01574872|Device|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
75437062|NCT01574872|Device|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
75437063|NCT01574885|Device|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
75437064|NCT01574885|Device|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
75585767|NCT00583310|Behavioral|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
75437065|NCT01574898|Drug|V0474 - A mg|Single oral administration
75437066|NCT01574898|Drug|V0474 - B mg|Single oral administration
75437067|NCT01574898|Drug|V0474 - C mg|Single oral administration
75585768|NCT05158582|Other|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|"The modified exercise program group will perform following exercises:~Resisted static Squats SLER Banded rows SL Banded Jumps Resisted explosive reverse lunges 5hurdle Jumps Elevated single leg Swiss ball Bosu Banded Stars RLE Barbell lunge Static shoulder Abd.with banded leg Add Ant.Banded static squat with medball press Bosu banded superman Sit ups"
75585769|NCT05158582|Other|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercise program group will perform the same exercises as they doing for their low back pain.
75585770|NCT00583349|Drug|Paclitaxel, nanoparticle albumin-bound|Intravesically administered, dose escalation, 6 weekly instillations
75730860|NCT00469456|Drug|placebo|Placebo oral administration twice daily for 12 weeks
75730861|NCT00581555|Drug|Etanercept|Etanercept 50 mg QW initiated during taper of ciclosporin
75730862|NCT00581555|Other|Placebo|Randomized to placebo during taper of ciclosporin
75437068|NCT01574898|Drug|V0018 - B mg|Single oral administration
75437069|NCT01574898|Drug|Niquitin® Fresh Mint 4 mg|Single oral administration
75437070|NCT01574924|Other|No intervention.|There are no interventions in this observational study.
75437071|NCT01574937|Drug|Cabozantinib|28 day cycle
75437072|NCT01574937|Drug|Abiraterone|28 day cycle
75437073|NCT01574976|Behavioral|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
75585771|NCT04571073|Procedure|Fascial Distortion Model|"Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity."
75585772|NCT00583388|Dietary Supplement|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
75730863|NCT00469144|Drug|Busulfan|"Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
75730864|NCT00469144|Drug|Fludarabine|40 mg/m^2 IV Daily Over 1 Hour x 4 Days
75730865|NCT01025050|Procedure|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
75730866|NCT02576093|Drug|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
75730867|NCT02576093|Drug|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
76052796|NCT02153827|Other|General Shoulder exercise|general exercise consisting of active shoulder movements
76052797|NCT04752631|Drug|Tenecteplase|The participants received TNK-tPA thrombolytic therapy
76052798|NCT02153359|Device|High Efficiency Particulate Air Cleaner|
76052799|NCT02153359|Device|Sham air cleaner|
75585773|NCT00583388|Device|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
75585774|NCT01133665|Drug|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
76052800|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
75730868|NCT02576093|Drug|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
75881857|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
75437074|NCT01574989|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous), (2) active high-frequency rTMS (10Hz, 2 second trains with inter-train interval of 28 seconds) or (3) sham rTMS (using a sham coil). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
75437075|NCT01574989|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will either undergo (1) active anodal tDCS, (2) active cathodal tDCS or (3) sham tDCS. Each session will last 20 minutes and will be conducted using 1mA with 35^2 electrodes.
75437076|NCT01575002|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
75437077|NCT01575015|Device|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
75437078|NCT01575015|Procedure|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
75730869|NCT02576093|Drug|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
75437079|NCT01575041|Dietary Supplement|Sodium|Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
75730870|NCT03987022|Drug|Ketorolac|Use of non-steroidal anti-inflammatory drug for pain control post operatively
75730871|NCT03987022|Drug|Opioids|Use of narcotic for pain control post operatively
75881858|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
75881859|NCT03627897|Drug|Bupivacain|The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).
76052801|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
76052802|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
75881860|NCT03627897|Drug|saline|No drugs or interventions were administered to the control group.
75585775|NCT04571346|Procedure|trans-obturator procedure|TOT procedure will be done using silicon-coated polypropylene tape that will be inserted at the mid-urethral portion. In group 1, a classical vertical vaginal incision will be done proximal to the external urethral meatus with dissection along the axis of the urethra till the mid-urethral zone that is identified by palpating the urethral catheter balloon through the vaginal at the bladder neck, while in group 2, two paramedian incisions will be done 1cm long in the anterior vaginal wall 2 cm apart parallel to the urethra till identification of the mid-urethral portion, communication will be done between the two incisions 1 cm wide in this area creating a tunnel where the tape will be placed, this technique provides healthy tissues proximal and distal to the tape that allows more stabilization and less migration. The rest of the procedure is the same as the standard procedure of Trans-obturator outside-in tension-free technique.
75585776|NCT00583427|Drug|Sulodexide|200 mg per day in an oral gelcap form
75585777|NCT01133626|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
75881861|NCT01372111|Drug|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
75881862|NCT01372111|Radiation|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
75881863|NCT02248532|Biological|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes >1.9 mV, and linear shortening <6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
75881864|NCT05191849|Diagnostic Test|Blood sample collection|Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2~4 cycles of chemotherapy, or at the time of disease progression.
75881865|NCT02250404|Other|cytology specimen collection procedure|Correlative studies
75437080|NCT01575041|Drug|Potassium|Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
75437081|NCT01575041|Drug|Placebo|Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
75437082|NCT01575093|Other|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
75437083|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
75437084|NCT01575119|Behavioral|Control intervention|Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
75437085|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
75437086|NCT01575119|Behavioral|Control|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
75730872|NCT03987022|Other|Ice Packs|Placement of Ice packs on surgical sites post operatively
75437087|NCT01575145|Behavioral|Quitline facilitation intervention|brief quitline facilitation intervention
75730873|NCT03987022|Drug|Tylenol|Use of pain medication post operatively
75730874|NCT03987022|Drug|Motrin|Use of non-steroidal anti-inflammatory drug for pain control post operatively
75730875|NCT03987022|Drug|dilaudid|Use of narcotic for pain control post operatively
75881866|NCT02250404|Other|laboratory biomarker analysis|Correlative studies
75881867|NCT03125941|Drug|Dexamethasone|pre-operative intravenous administration
75881868|NCT02092142|Biological|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
75730876|NCT02575781|Drug|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
75730877|NCT03789838|Other|Sepsis rapid response team|Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
75730878|NCT01025128|Drug|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
75437088|NCT01575145|Behavioral|Brief stop-smoking intervention|brief review of tips to help maintain smoking abstinence, using brochure
75585778|NCT01133626|Drug|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
75585779|NCT01133626|Drug|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
75585780|NCT01133626|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
75585781|NCT04575974|Other|No intervention|No intervention
75585782|NCT01133392|Drug|Insulin lispro A|20 units (U) subcutaneously (SC).
76052803|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
75437089|NCT01575158|Drug|Citalopram|
75437090|NCT01575158|Drug|Clomipramine|
75437091|NCT01575158|Drug|placebo|
75437092|NCT01575171|Behavioral|Nudge|"Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
75437093|NCT01575184|Other|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
75585783|NCT01133392|Drug|Insulin lispro B|20 U subcutaneously (SC).
75585784|NCT04575818|Drug|GLPG4059 oral suspension|GLPG4059 for oral administration
75585785|NCT04575818|Drug|Placebo|Placebo oral suspension
75585786|NCT04575818|Drug|GLPG4059 tablet|GLPG4059 for oral administration
75437094|NCT01575184|Other|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
75437095|NCT01575210|Device|CPAP mask|A new vent CPAP mask system will be used in this trial.
75585787|NCT02882815|Device|IrisFIT PFO Occluder|
75585788|NCT00583505|Device|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
75585789|NCT00471354|Drug|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
75585790|NCT04575701|Other|TNF Alpha therapy|Retrospective analysis of outcome of first TNF Alpha therapy
75585791|NCT02882893|Drug|Clostridium Botulinum A Toxin|
75585792|NCT02882893|Drug|Clostridium Botulinum A Toxin|
75585793|NCT00583544|Drug|TC-2216|Multiple ascending dose groups will be explored.
75585794|NCT02210364|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
76052804|NCT02245412|Biological|ALXN1007 10 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
75585795|NCT02210364|Drug|capecitabine|capecitabine 150 mg tablets
75585796|NCT00583583|Device|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
76052805|NCT02245412|Biological|ALXN1007 20 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
76052806|NCT02245412|Biological|ALXN1007 20 mg/kg twice weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
76052807|NCT02244944|Drug|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
76052808|NCT01689532|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
76052809|NCT01689532|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
75437096|NCT01575210|Device|CPAP mask|A new vent CPAP mask system will be used in this trial
75437097|NCT01575223|Device|NeilMed sinus rinse|High volume saline irrigation
75585797|NCT00471315|Drug|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
75585798|NCT00583739|Behavioral|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
75585799|NCT04575623|Diagnostic Test|Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/|"Central auditory function evaluation including:~Duration Pattern test (DPT) designed to test temporal ordering abilities.~Dichotic Digits Test (DDT) it assesses binaural integration skills.~Auditory fusion test-revised (ART-R) to measure temporal resolution.~speech in test to assess central auditory function."
76052810|NCT01689532|Drug|Placebo|Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
75585800|NCT04575623|Device|Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.|"Cognitive function evaluation including:~-Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing.~Equipment:~Dual band pure tone audiometer (Orbiter 992).~Impedance audiometer (AT 235h).~Sound treated booth (industrial acoustic company IAC model 1602-A-t)~Panasonic stereo CD player SA-AK 240."
75585801|NCT00471237|Drug|Ronacaleret|100mg, 200mg, 300mg, 400mg
75881869|NCT02774889|Behavioral|Stepping Online|"Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~Fall prevention tips~Fall prevention exercise videos with narrations for proper technique and safety precautions~Guest expert videos with online access to the guest expert to ask questions~Tools to set exercise goals, get reminders and track progress~Access to a fall prevention specialist for personal feedback and suggested group homework~Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~Fall prevention resources"
75881870|NCT02095886|Drug|BMS-955176|BMS-955176
75881871|NCT01372579|Drug|eribulin mesylate|Given IV
75437098|NCT01575223|Device|Salinex|Low volume saline irrigation
75437099|NCT01575236|Device|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
75585802|NCT00471237|Drug|Teriparatide|PTH (1-34)
75585803|NCT00471237|Drug|Alendronate|Bisphosphonate
75730879|NCT04073381|Combination Product|Prehabilitation Program|This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
75881872|NCT01372579|Drug|carboplatin|Given IV
75881873|NCT01372579|Procedure|biopsy|Correlative studies
75881874|NCT02089958|Procedure|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
75437100|NCT01575236|Device|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
75881875|NCT02090036|Drug|Primaquine (For artemether-lumefantrine+primaquine arm)|A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.
75881876|NCT02090036|Drug|Placebo (For artemether-lumefantrine arm)|Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
75437101|NCT01575262|Behavioral|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
75437102|NCT01575262|Behavioral|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
75437103|NCT01575288|Drug|Placebo|100g maltose 1/day
75585804|NCT04575545|Diagnostic Test|Serology test for COVID-19|ELISA test
75585805|NCT00583895|Drug|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
75585806|NCT00583895|Drug|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
75881877|NCT03125629|Drug|F-18 FDG|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
75881878|NCT03125629|Drug|Ga-68-DOTA-TATE|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
75881879|NCT03125629|Device|Positron Emission Tomography / Computed Tomography (PET/CT) Scan|Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.
75881880|NCT03125629|Device|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan|Scan using a NOVEL GE PET/MRI scanner.
76052811|NCT01924689|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
76052812|NCT01591330|Drug|LY2140023 Reference form|80-mg tablet administered orally
76052813|NCT01591330|Drug|LY2140023 Test-Low|80-mg tablet administered orally
75585807|NCT04570683|Drug|Nivolumab 10 MG/ML|Se previously
76052814|NCT01591330|Drug|LY2140023 Test-Medium|80-mg tablet administered orally
76052815|NCT01591330|Drug|LY2140023 Test-High|80-mg tablet administered orally
76052816|NCT01591096|Drug|Tissue plasminogen activator (Activase®)|Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
75437104|NCT01575288|Drug|High-dose trehalose|100g 1/day
75437105|NCT01575301|Drug|Exenatide, Liraglutide|Dosage, frequency and duration not specified by protocol
75437106|NCT01575314|Device|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
75437107|NCT01575327|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
75585808|NCT04570683|Device|Ablative fractionated laser|Se previously
75585809|NCT00471081|Biological|Meningococcal vaccine GSK134612|One or 2 intramuscular injections.
75437108|NCT01575327|Device|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
75437109|NCT01575340|Dietary Supplement|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
75730880|NCT00468910|Drug|acetylsalicylic acid|Given orally
75730881|NCT00468910|Drug|placebo|Given orally
76052817|NCT04867174|Behavioral|Financial incentives|Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)
76052818|NCT04867174|Behavioral|Convenient scheduling link|In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).
75437110|NCT01575353|Device|Venturi mask|The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
75730882|NCT00468910|Other|laboratory biomarker analysis|Correlative study
75730883|NCT01025206|Biological|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
75730884|NCT01412333|Drug|Interferon beta-1a|
75730885|NCT01412333|Drug|Ocrelizumab-matching placebo|
75730886|NCT01412333|Drug|Ocrelizumab|
75730887|NCT01412333|Drug|Interferon beta-1a-matching placebo|
75730888|NCT02577185|Drug|Botulinum Toxin Type A|
75730889|NCT02577185|Drug|Sodium chloride 9 mg/ml|
75730890|NCT00519285|Drug|Aflibercept|"25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
75881881|NCT02092376|Drug|Cholecalciferol|
75881882|NCT02092376|Drug|Placebo|
76052819|NCT04867174|Behavioral|Race concordant|Randomized to a messenger who is race concordant with the participant
76052820|NCT04867174|Behavioral|Gender concordant|Randomized to a messenger who is gender concordant with the participant
76052821|NCT01953003|Drug|vinflunine|intravenous administration day 1 once every 3 weeks, 280 mg/m²
76052822|NCT01953003|Drug|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
76052823|NCT01952691|Device|kinesiotaping|correction method was used to align hallux.
76052824|NCT01709500|Drug|LMT (atorvastatin, simvastatin, or rosuvastatin)|
76052825|NCT01709500|Drug|alirocumab|Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
75730891|NCT00519285|Drug|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle"
75730892|NCT00519285|Drug|Docetaxel|"Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
76052826|NCT01709500|Drug|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
75437111|NCT01575353|Device|Nasal high-flow|The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
75437112|NCT01575366|Behavioral|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
75437113|NCT01575405|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
75585810|NCT03453008|Other|elbow extension, electromyography|"Two evaluations before the toxin injection (T0 and T1), to quantify cocontractions and to determine the toxin injection pattern.~The first evaluation (T0) will be carried out within a period of between 1 month and 15 days before the injection. This evaluation makes it possible to pose the indication for the realization of injection of Botulinum Toxin A (TBA).~The second evaluation (T1) will be performed on the day of the injection to specify the muscle targets to be injected.~The first evaluation is a Clinical evaluation and second is Instrumental evaluation"
75585811|NCT03452969|Other|Implantation of multifocal intraocular lens|"Procedure/Surgery:~Bilateral implantation of a segmental refractive multifocal intraocular lens (MIOL) following cataract surgery."
75585812|NCT04570449|Drug|Fluoxetine|20 mg capsule
75585813|NCT04570449|Drug|Placebo|fluoxetine placebo capsule
75585814|NCT00470847|Drug|Lapatinib|Orally twice daily
75585815|NCT00470847|Procedure|Whole Brain Radiation|15 treatments over a period of 3 weeks
75585816|NCT00470847|Drug|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
75585817|NCT00584090|Drug|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
75730893|NCT00519285|Drug|Prednisone or Prednisolone|"Marketed formulation~5 mg twice daily PO from day 1 continuously"
75585818|NCT00584090|Drug|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
75585819|NCT04570527|Procedure|PCI|percutaneous coronary intervention
75585820|NCT00584129|Other|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
75585821|NCT00584129|Other|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
75730894|NCT00464620|Drug|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
75881883|NCT02090192|Procedure|WBV training|
75881884|NCT02090192|Procedure|PRT training|
75881885|NCT05452928|Drug|Acyclovir 50 MG/ML|Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.
75881886|NCT05452928|Drug|Placebo|Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
75881887|NCT03125395|Drug|LUM/IVA|Participants received LUM/IVA every q12h.
75585822|NCT04570566|Procedure|horizontal alveolar ridge augmentation|evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants
75585823|NCT00584168|Drug|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
75585824|NCT00584168|Drug|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
75585825|NCT00470535|Drug|erlotinib hydrochloride|Oral
75585826|NCT00470535|Other|immunohistochemistry staining method|Correlative Study
75585827|NCT00470535|Other|laboratory biomarker analysis|Correlative Study
75585828|NCT00584207|Procedure|radiofrequency ablation|Intraoperative RFA of uterine fibroids
75730895|NCT05212857|Drug|Leuprolide acetate|Given subcutaneously or as an injection
75730896|NCT05212857|Drug|Goserelin acetate|Given subcutaneously or as an injection
75881888|NCT00264602|Drug|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
75585829|NCT00584324|Combination Product|BIS 40|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
75585830|NCT00584324|Combination Product|BIS 60|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
75585831|NCT00470418|Drug|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
75437114|NCT01575405|Drug|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy) propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
75585832|NCT00470418|Drug|Placebo|placebo comparator
75585833|NCT01133275|Drug|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
75585834|NCT01133275|Drug|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
75585835|NCT00470184|Drug|capecitabine|Oral
75585836|NCT00470184|Drug|oxaliplatin|IV
75585837|NCT00470184|Genetic|gene expression analysis|Correlative Study
75585838|NCT00470184|Genetic|microarray analysis|Correlative Study
75585839|NCT00470184|Genetic|reverse transcriptase-polymerase chain reaction|Correlative Study
75585840|NCT00470184|Procedure|adjuvant therapy|Metastatic growth control
75585841|NCT00470184|Procedure|biopsy|Examination of tissue type
75585842|NCT00470184|Procedure|conventional surgery|Tissue removal
75585843|NCT00470184|Procedure|neoadjuvant therapy|Tumor shrinkage
75585844|NCT00470184|Procedure|quality-of-life assessment|Correlative Study
75585845|NCT00470184|Radiation|radiation therapy|Undergoing radiation therapy
75585846|NCT00584519|Other|non-interventional|non-interventional
75585847|NCT04570254|Drug|Vitamin C|Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient. Protect from light at all times, as it is photosensitive.
75585848|NCT04570254|Drug|Vitamin E|Vitamin E. 800 mg tablet. 800 mg dose every 24 hours. Dissolve the capsule in 30 ml of hot water. The administration of vitamin E is recommended during or after meals since its absorption depends on pancreatic enzymes' presence.
75585849|NCT04570254|Drug|Melatonin|"Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast."
75585850|NCT04570254|Drug|N-acetyl cysteine|N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.
75585851|NCT04570254|Drug|Pentoxifylline|Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours. The tablet is dissolved in 30 ml of water and is administered orally or nasogastric tube.
76052827|NCT01599806|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
76052828|NCT01599806|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
75437115|NCT01575405|Drug|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
75437116|NCT01575418|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
75437117|NCT01575418|Drug|Vaginal formulation (VF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy)propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
75585852|NCT00584597|Drug|Saline|Saline Control
75585853|NCT00584597|Drug|Traumeel S|Traumeel S 1 mL
75585854|NCT00584597|Drug|Traumeel S|Traumeel S 2mL
75585855|NCT00584597|Drug|Traumeel S|Traumeel S 3mL
75730897|NCT05212857|Drug|Triptorelin acetate|Given subcutaneously or as an injection
75585856|NCT00470067|Drug|carboplatin|IV
75585857|NCT00470067|Drug|pegylated liposomal doxorubicin hydrochloride|IV
75585858|NCT00584636|Drug|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
75585859|NCT04570137|Dietary Supplement|Dietary fiber supplementation|"16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~16g/day: mix of 50% inulin and 50% oligofructose from chicory"
75585860|NCT00584675|Device|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
75585861|NCT00479817|Drug|AMG 386|10mg/kg
75730898|NCT05212857|Drug|Degarelix acetate|Given subcutaneously or as an injection
75730899|NCT05212857|Drug|Abiraterone acetate|Given orally
75730900|NCT05212857|Drug|Apalutamide|Given orally
75730901|NCT05212857|Drug|Enzalutamide|Given orally
75730902|NCT05212857|Procedure|Local treatment for primary lesion|Radical prostatectomy to remove prostate primary lesion
75730903|NCT05212857|Radiation|Radiotherapy for primary lesion|Radical radiotherapy for primary lesion
75730904|NCT05212857|Radiation|Radiotherapy for metastatic lesion|Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
76052829|NCT01599806|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
76052830|NCT01599806|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
76052831|NCT01599325|Drug|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
76052832|NCT01924299|Drug|Baricitinib|Administered orally
76052833|NCT01924299|Drug|Ketoconazole|Administered orally
76052834|NCT01924299|Drug|Fluconazole|Administered orally
75585862|NCT00479817|Drug|AMG 386|3 mg/kg
76052835|NCT02182999|Device|Wound infiltration catheter|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
75437118|NCT01575418|Drug|Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel|Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
75585863|NCT00479817|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
75585864|NCT00479817|Drug|AMG 386 Placebo|AMG 386 Placebo
75585865|NCT04575506|Other|Multidisciplinary intervention program|The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
75585866|NCT04575194|Drug|Liraglutide 6 MG/ML [Saxenda]|3 mg of sc liraglutide daily plus lifestyle intervention
75585867|NCT04575194|Drug|Naltrexone-Bupropion Combination|32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention
75585868|NCT04570059|Behavioral|Counselling on textured food introduction between 8 and 15 months|"Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months."
75585869|NCT00478179|Drug|Transdermal/Patch (Bupivacaine TTS [Eladur™])|
75585870|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
75585871|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
75585872|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
75585873|NCT04569825|Drug|Ophtamesone|local application intranasally as drops
75585874|NCT00476931|Biological|SB-509|60 mg dose
75585875|NCT00476931|Other|Placebo|Saline
75585876|NCT00585026|Device|D-28 bifocal lenses and frame|
75585877|NCT00585026|Device|Progressive addition computer lenses and frame|
75585878|NCT04569669|Diagnostic Test|FFR and FFRCT|All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
75730905|NCT02099123|Drug|Atorvastatin|Atorvastatin 20 mg tablet
75730906|NCT02099123|Drug|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
75730907|NCT00464542|Drug|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
75730908|NCT00468676|Behavioral|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
75730909|NCT00468676|Behavioral|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
75585879|NCT00479427|Drug|GW842166|100 mg once daily
75730910|NCT02578823|Device|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
75730911|NCT02578823|Device|Arcticgel™|
76052836|NCT02182999|Drug|NaCl 0.9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
75585880|NCT00479427|Drug|Placebo|once daily
75585881|NCT00585143|Drug|ABT-335|45 mg once daily for 10 consecutive days
75585882|NCT00585143|Drug|Rosuvastatin|10 mg once daily for 10 days
75585883|NCT04569981|Other|Climbing|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
75585884|NCT04569981|Other|Unsupervised activity group|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
75585885|NCT00585260|Drug|mannitol|indirect mannitol challenge
75585886|NCT04569474|Device|Transparent dressing|Use of sterile transparente dressing
75585887|NCT00585299|Other|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
75585888|NCT00585299|Other|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
75585889|NCT00585416|Drug|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
75585890|NCT00475020|Drug|Busulfan|Test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days
75585891|NCT00475020|Drug|Fludarabine|40 mg/m^2 by vein daily over 1 hour x 4 days
75730912|NCT02578823|Procedure|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
76052837|NCT02182999|Drug|Ropivacaine 0.2%|The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
75585892|NCT00475020|Drug|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
75730913|NCT01969643|Drug|ladiratuzumab vedotin|LV will be given into the vein (IV; intravenously)
75730914|NCT01969643|Drug|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
75730915|NCT00464308|Drug|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
75730916|NCT00464308|Drug|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
75585893|NCT00585455|Drug|sertraline|open label 25-50 mg daily as tolerated
75585894|NCT02484456|Drug|AV 101 (4-Chlorokynurenine)|L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.
75730917|NCT00464308|Drug|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
75730918|NCT00194285|Procedure|FDG-PET Imaging|
75730919|NCT00468286|Drug|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
75730920|NCT00468286|Drug|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
75730921|NCT00463840|Drug|Oxaliplatin|
75730922|NCT00463840|Drug|5FU|
75730923|NCT00463840|Radiation|Radiation|
75585895|NCT02484456|Other|Placebo Comparator|Placebo
75585896|NCT00585728|Procedure|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
75585897|NCT01132807|Biological|Bleomycin Sulfate|Given IV
75585898|NCT01132807|Drug|Doxorubicin Hydrochloride|Given IV
75585899|NCT01132807|Drug|Procarbazine Hydrochloride|Given PO
75585900|NCT01132807|Drug|Vinblastine Sulfate|Given IV
75585901|NCT01132807|Drug|Dacarbazine|Given IV
75585902|NCT01132807|Drug|Cyclophosphamide|Given IV
75585903|NCT01132807|Drug|Etoposide phosphate|Given IV
75585904|NCT01132807|Drug|prednisone|Given PO
75585905|NCT01132807|Drug|Radiation Therapy|Undergo radiation therapy
75585906|NCT01132807|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
75730924|NCT00463840|Procedure|Surgery|
75730925|NCT00463840|Drug|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
75730926|NCT00129389|Drug|Fluorouracil|Arm A: FAC Arm B: FAC-wP
75730927|NCT00129389|Drug|Doxorubicin|Arm A: FAC Arm B: FAC-wP
75730928|NCT00129389|Drug|Cyclophosphamide|Arm A: FAC Arm B: FAC-wP
75730929|NCT00129389|Drug|Paclitaxel|Arm B: FAC-wP
75730930|NCT01025362|Behavioral|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
75730931|NCT01025362|Behavioral|Standard care|Child Health Services offered standard care
75730932|NCT01025440|Device|Continuous Positive Airway Pressure|"Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:"
75730933|NCT00468052|Drug|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
75730934|NCT00468052|Drug|fentanyl|1 microgram/kilogram as a bolus
75730935|NCT04712981|Other|Behavioral Intervention|Peer leaders/role models will be trained in HOPE intervention fundamentals and assigned to online community groups with participants.
75730936|NCT00453310|Drug|sunitinib malate|
75730937|NCT04071743|Device|gammaCore Sapphire|non-invasive vagus nerve stimulator
75730938|NCT04071743|Device|sham gammaCore Sapphire|sham gammaCore Sapphire
76052838|NCT01598311|Drug|CB-183,315|CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
75585907|NCT01132807|Procedure|computed tomography|Undergo FDG PET/CT
75730939|NCT02578667|Device|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
75730940|NCT00128843|Drug|Exemestane|25mg/day until progression disease
75730941|NCT00128843|Drug|Anastrozole|1mg/day until progression disease
75881889|NCT03557138|Behavioral|alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG)
75585908|NCT01132807|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
75881890|NCT01369303|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
75881891|NCT03556436|Drug|YH25448 240mg|period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
75881892|NCT02092532|Drug|Rescue Intravitreal Aflibercept Injection|Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
75881893|NCT02092532|Procedure|Rescue Therapy with PDT, Laser or Intravitreal Steroids|Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
75881894|NCT02092688|Device|novel kit for the detection of PAMG-1|The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
75585909|NCT04569513|Biological|Thyroid and parathyroid disease|To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.
75585910|NCT00585845|Biological|CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin|2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10^8 cfu to 1x10^10 cfu.
75585911|NCT01132651|Other|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
75881895|NCT02092766|Drug|artesunate|
75881896|NCT02092766|Drug|quinine|
75881897|NCT02090348|Drug|dimethyl fumarate|Administered as specified in the treatment arm
75881898|NCT02721069|Drug|NRL-1|
76052839|NCT01598311|Drug|Vancomycin|Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
76052840|NCT01598311|Drug|Placebo|Placebo size 00 opaque hard gelatin capsules.
75585912|NCT01132651|Other|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
75585913|NCT01089543|Drug|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
75585914|NCT01089543|Drug|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
75585915|NCT01089543|Drug|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
75585916|NCT01089543|Drug|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
75585917|NCT00585962|Radiation|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
75730942|NCT02575703|Drug|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi [¹⁴C]-LY3023414
75730943|NCT04609553|Behavioral|Usual care including ROR|Usual care which includes ROR.
75730944|NCT04609553|Behavioral|Text messages|3 text messages per week and one interactive text per month.
75730945|NCT04609553|Behavioral|Connection to community resources|Referral to a non-profit that connects families with community resources and provides families with case management.
75437119|NCT01575418|Radiation|Radiolabeling of study drugs and semen|"Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing."
75437120|NCT01575457|Behavioral|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
75437121|NCT01575483|Drug|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
75437122|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
75585918|NCT04569396|Diagnostic Test|Biochemistry analysis|Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.
75585919|NCT04569396|Diagnostic Test|NAFLD fibrosis score|NAFLD fibrosis score was determined among the study subjects before and after the surgery.
75585920|NCT04569396|Other|BMI measurement|BMI was measured among the study subjects before and after the surgery.
75585921|NCT04569396|Diagnostic Test|Fibrosis 4 Index|Fibrosis 4 Index was determined among the study subjects before and after the surgery.
75730946|NCT04071431|Other|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
75437123|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
75730947|NCT04073927|Dietary Supplement|Sodium butyrate|"Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane."
75730948|NCT00124657|Drug|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
75730949|NCT00581945|Drug|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
75437124|NCT01575509|Other|Berry product|Sugar infused dried lingonberry
75437125|NCT01575509|Other|Bread product|Brown bread
75437126|NCT01575509|Other|Bread product|Whole grain bread
75585922|NCT04569396|Diagnostic Test|Fatty Liver Index|Fatty Liver Index was determined among the study subjects before and after the surgery.
75730950|NCT00581945|Drug|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
75730951|NCT02578589|Procedure|Plica resection vs conservative treatment|Plica resection vs conservative treatment
75585923|NCT00586040|Procedure|tissue bonding|application of rose bengal and treatment with green light
75585924|NCT00586040|Procedure|sutures|interrupted superficial sutures
75730952|NCT01079845|Behavioral|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
75730953|NCT02578277|Drug|CYP and transporter probe substrates|Cocktail of CYP (cytochrome P450) and transporter probe substrates
75730954|NCT02578277|Drug|BMS-955176|BMS-955176
75730955|NCT02578277|Drug|BMS-955176 plus CYP and transporter probe substrates|BMS-955176 plus the cocktail of CYP and transporter probe substrates
75730956|NCT04071197|Device|Gastostomy-biliary tube|gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
75730957|NCT04071197|Device|External biliary diversion, internal biliary diversion and nasobiliary tube|All biliary diversion modalities other than gastrobiliary tube
75585925|NCT04569630|Other|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.
75585926|NCT00586079|Procedure|Deep brain stimulation surgery.|Deep brain stimulation surgery.
75585927|NCT04569318|Device|Treatment Beam|One of the subject's eyes will be treated with the 415 nm treatment beam (20mW) up to 8 times for 15 minutes.
75585928|NCT03452852|Device|PICO|NPWT with PICO (Smith and Nephew)
75437127|NCT01575509|Other|Glucose control solution|Glucose solution with a corresponding amount of carbohydrates as provided by the bread test products
75437128|NCT01575509|Other|Glucose-fructose control solution|Control solution with a similar carbohydrate content as provided by the dried lingonberry test product
75437129|NCT01575535|Genetic|gene expression analysis|
75437130|NCT01575535|Other|flow cytometry|
75437131|NCT01575535|Other|fluorescence activated cell sorting|
75437132|NCT01575535|Other|laboratory biomarker analysis|
75437133|NCT01575535|Other|medical chart review|
75437134|NCT01575574|Drug|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
75437135|NCT01575587|Drug|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
75437136|NCT01575587|Drug|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
75585929|NCT03452852|Other|Coban 2 lite|Compression bandaging with Coban 2 lite
75585930|NCT03452735|Other|Questionnaire about fertility|Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
75437137|NCT01575587|Drug|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
75585931|NCT01089504|Drug|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
75585932|NCT01089504|Drug|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
75585933|NCT03452696|Dietary Supplement|Calcium supplement|Calcium supplement for low contribution of elemental calcium in the daily diet
75730958|NCT00555906|Drug|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
75437138|NCT01575587|Drug|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
75437139|NCT01575600|Other|Intraoperative lactated Ringer's solution|After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.
75437140|NCT01575613|Drug|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
75437141|NCT01575613|Biological|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
75437142|NCT01575613|Biological|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
75437143|NCT01575613|Biological|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
75585934|NCT01088997|Drug|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
76052841|NCT02182843|Biological|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
75585935|NCT00586118|Drug|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
75585936|NCT00586118|Drug|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
75585937|NCT04569201|Procedure|Endoscope|The use of the neuro endoscope in excision of intraventricular lesions either alone or in assistance of the surgical microscope
75437144|NCT01575626|Drug|Sevoflurane|"All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices."
75437145|NCT01575639|Drug|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
75437146|NCT01575652|Other|Group using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level with use of ACEIs
75585938|NCT01088529|Drug|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
75585939|NCT01088529|Drug|Prednisone|5 mg orally daily.
75585940|NCT01088529|Drug|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
76052842|NCT02208050|Drug|Fampridine|
76052843|NCT02208050|Drug|Placebo|
76052844|NCT04770350|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
75437147|NCT01575652|Other|Group not using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level without usage of ACEIs
75437148|NCT01575665|Device|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
75585941|NCT00586274|Procedure|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
75585942|NCT00586274|Drug|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m^2
75730959|NCT00555906|Drug|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
75730960|NCT00555906|Drug|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
75730961|NCT03817879|Procedure|VivaSight double-lumen tube for single-lung ventilation|Procedure using a tube with a camera
75730962|NCT03817879|Procedure|Conventional double-lument tube for single-lung ventilation|Procedure using a tube without a camera
75730963|NCT04071353|Drug|Interferon|Interferon combined with ribavirin antiviral therapy
75730964|NCT04071353|Drug|ribavirin|Interferon combined with ribavirin antiviral therapy
76052845|NCT02978222|Biological|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
76052846|NCT02978222|Drug|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
76052847|NCT02181673|Drug|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
75881899|NCT02092844|Behavioral|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
75881900|NCT00390741|Behavioral|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
75585943|NCT00586274|Biological|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are > 1000/ul.~Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x 10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg)"
75437149|NCT01575678|Drug|Melatonin|blinded capsule 2-4 mg/day, oral use, for 4 weeks
75585944|NCT00586274|Biological|Campath 1h|10 mg iv over 4 hours day-8 through day-6
75585945|NCT00586274|Biological|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
75585946|NCT00586352|Other|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
75881901|NCT02093000|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
75437150|NCT01575678|Drug|Lactose|blinded capsule 1/day, oral use, for 4 weeks
75585947|NCT01087944|Device|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
75585948|NCT01087944|Device|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
75585949|NCT00586430|Drug|lorazepam|single 2 mg dose of lorazepam
75585950|NCT00586430|Drug|placebo|single dose of placebo
75585951|NCT01132612|Drug|AIN457|AIN457A 150 mg powder for solution
75585952|NCT01132612|Drug|Placebo|Placebo to AIN457A 150 mg powder for solution
75585953|NCT00586547|Biological|T-Cell Infusion Dose Level -1|(1 x 10^3 T cells/Kg)
75437151|NCT01575704|Other|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
75437152|NCT01575704|Other|Mental Training|Memorial/ mental training and relaxation, 5 times per week
75437153|NCT01575717|Drug|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
75585954|NCT00586547|Biological|T-Cell Infusion Dose Level 1|(1 x 10^4 T cells/Kg)
75585955|NCT00586547|Biological|T-Cell Infusion Dose Level 2|(1 x 10^5 T cells/Kg)
75585956|NCT00586547|Biological|T-Cell Infusion Dose Level 3|(1 x 10^6 T cells/Kg)
75585957|NCT00586547|Biological|T-Cell Infusion- Dose Level 4|(5 x 10^6 T cells/Kg)
75585958|NCT04569279|Drug|Rivaroxaban|Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.
75881902|NCT00261807|Drug|Daptomycin 6mg/kg/day|
76052848|NCT02181673|Drug|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
75437154|NCT01575717|Drug|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
75585959|NCT04569279|Drug|Warfarin|Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
75585960|NCT01132495|Other|Stenting plus OMT|FFR guided PCI, plus OMT
76052849|NCT02929004|Device|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
75585961|NCT01132495|Other|OMT|OMT alone
75585962|NCT01132495|Other|Standard of care|FFR > 0.80; treatment according to local practice
75585963|NCT00586586|Behavioral|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
75585964|NCT04312204|Drug|Sintilimab combined with Gemcitabine and Carboplatin|"The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight <40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months."
75585965|NCT04312282|Drug|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
75437155|NCT01575743|Behavioral|aerobic exercising|All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
75585966|NCT04312282|Drug|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
75585967|NCT04312282|Drug|Itraconazole|Itraconazole orally once daily from Day -3 to Day 14 of a 21-day cycle
75585968|NCT04312282|Drug|Rifampin|Rifampin orally once daily from Day -6 to Day 14 of a 21-day cycle
75437156|NCT01575782|Drug|Chloroquine|Daily intake of Chloroquine during radiotherapy
75437157|NCT01575795|Drug|Ticagrelor|Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
75437158|NCT01575795|Drug|Ticagrelor|Ticagrelor 180mg loading dose 180mg loading dose
75585969|NCT04311931|Other|Active Dance Program|All Creative Dance sessions comprised five phases: 1) opening ritual (5 min), in which participants will be welcomed and will be informed about the objectives and structure of the session; 2) warm-up (15 min), in which body muscle groups will be activated through the introduction of basics elements of movement; 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives described above. This phase will end with a choreography composition; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience and they will fill a sheet with attendance, exercise intensity perception (Borg Scale) and satisfaction's (Caregiver Treatment Satisfaction questionnaire).
75730965|NCT04071353|Drug|DAAs|DAAs antiviral treatment
75730966|NCT03968497|Other|Postoperative pain assessment with female investigator|Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
76052850|NCT02131129|Device|rTMS|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
75585970|NCT01087905|Drug|Nicotine patch|"If > 10 cigs/day: one 21 mg nicotine patch per day~If < or = 10 cigs/day: one 14 mg nicotine patch per day"
75730967|NCT03968497|Other|Postoperative pain assessment with male investigator|Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
75730968|NCT01078129|Behavioral|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
75730969|NCT01078129|Behavioral|non-CRT|waiting list
75730970|NCT04071899|Other|Scale vaidation|It's just filling a scale in order to validate it in French
76052851|NCT02131129|Device|Sham Comparator|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
76052852|NCT02152345|Drug|Belatacept|"Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study."
75730971|NCT01078285|Behavioral|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
76052853|NCT02152345|Drug|Tacrolimus|"Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)"
76052854|NCT02152345|Drug|Mycophenolate|"An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)"
76052855|NCT02152345|Drug|rATG|"1.5 mg/kg IV daily on Day 0-3.~(standard of care)"
76052856|NCT02152345|Drug|Methylprednisolone|"500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)"
76052857|NCT02152345|Procedure|Renal transplant|Standard organ transplant of a kidney into a patient with end-stage renal disease.
76052858|NCT02180659|Drug|sublingual buprenorphine tablets|
76052859|NCT02180659|Drug|Buprenorphine implant|
76052860|NCT02180659|Drug|placebo implants|
75437159|NCT01575821|Dietary Supplement|Eucalyptus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
75437160|NCT01575821|Dietary Supplement|Labiatae honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
75585971|NCT01087905|Drug|Nicotine gum|"If < 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
75730972|NCT01078285|Behavioral|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
75730973|NCT02576561|Biological|TVGV-1|Antigen + Adjuvant
76052861|NCT02180659|Drug|sublingual placebo tablets|
76052862|NCT02130427|Diagnostic Test|CT scan|Weekly 3D/4D CT scan
75437161|NCT01575821|Dietary Supplement|Citrus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
75437162|NCT01575821|Dietary Supplement|Silan date extract|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
75437163|NCT01575938|Behavioral|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
75585972|NCT01087905|Behavioral|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
75585973|NCT00586742|Procedure|labral repair|labral repair with suture anchors
75585974|NCT00586742|Procedure|biceps tenodesis|biceps tenodesis with suture anchor
75730974|NCT02576561|Biological|GPI-0100|Adjuvant Alone
75730975|NCT02576561|Biological|Placebo|Placebo
76052863|NCT02207816|Procedure|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
76052864|NCT02207816|Biological|Malaria Vaccine 257049 (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
76052865|NCT02207816|Biological|Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
76052866|NCT02207816|Biological|Cell-culture rabies vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
76052867|NCT02207816|Biological|TritanrixHepB/Hib (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
76052868|NCT02207816|Biological|Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)|Administered orally, during the MALARIA-055 study (NCT00866619).
75730976|NCT04071275|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
76052869|NCT02241512|Drug|Ibuprofen|
76052870|NCT02241512|Drug|placebo|
76052871|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
76052872|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
76052873|NCT01709110|Drug|Teriparatide|Administered SC
76052874|NCT01709110|Drug|Risedronate|Administered orally
76052875|NCT01709110|Drug|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
76052876|NCT01709110|Drug|Calcium|Administered orally
75585975|NCT00586742|Procedure|diagnostic arthroscopy|diagnostic arthroscopy
75585976|NCT04311892|Diagnostic Test|EMG of the hip abductor muscles|EMG will be carried out to examine the (superior gluteal nerve) SGN for all patients. The muscles will be evaluated according to the criteria of the American Academy of Electrophysiological Medicine for needle EMG. In order to exclude patients with polyneuropathy, radiculopathy, or plexopathy, nerve conduction studies of both lower extremities will be performed. Then, gluteus medius muscles will be assessed bilaterally to evaluate the SGN, the vastus medialis muscle for L4 root, tibialis anterior muscle for L5 root, and gastrocnemius muscle for S1 root.
75585977|NCT04311736|Behavioral|Exergame|Cycling on a recumbent cycle ergometer + Virtual Reality Cognitive Training
75585978|NCT04311736|Behavioral|Cycling|Cycling on a recumbent cycle ergometer
75585979|NCT04311736|Behavioral|Stretching|Stretching exercises
75585980|NCT00586781|Device|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
75437164|NCT01575938|Behavioral|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
75437165|NCT01575951|Radiation|MRI-DCE|"The treatment follows the standard practice including radiation dose and treatment volumes.~DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.~Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.~MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.~Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week."
75437166|NCT01576029|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
75437167|NCT01576029|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
75437168|NCT01576068|Other|Spirometry|Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
75585981|NCT00586859|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
75585982|NCT01087788|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
75585983|NCT01087788|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
75585984|NCT01087788|Other|Placebo|Matching Placebo to CZP injection.
75585985|NCT00586937|Behavioral|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
75585986|NCT00586976|Drug|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
75585987|NCT00586976|Drug|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
75437169|NCT01576081|Device|HEPHAISTOS|HEPHAISTOS unloading orthotic
75881903|NCT02093078|Behavioral|CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
75881904|NCT02090504|Drug|Sodium Oxybate (SMO)|
75881905|NCT02090504|Drug|Oxazepam|
75881906|NCT01567059|Drug|tosedostat|Given PO
75881907|NCT01567059|Drug|cytarabine|Given IV
75881908|NCT01567059|Drug|decitabine|Given IV
75881909|NCT02090582|Other|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
75881910|NCT02090582|Other|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
75585988|NCT00587015|Drug|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
75437170|NCT01576094|Drug|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
75585989|NCT01086969|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
75585990|NCT00587093|Other|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
75585991|NCT04568772|Drug|Atovaquone / Proguanil 250/100 mg|Atovaquone / Proguanil 250/100 mg tablet
75585992|NCT04568772|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
75585993|NCT04568772|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg tablet
75585994|NCT04568772|Drug|Vonoprazan 20 mg|Vonoprazan 20 mg tablet
75881911|NCT02093156|Other|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
76052877|NCT01709110|Drug|Vitamin D|Administered orally
75730977|NCT04071275|Other|Mirror therapy|Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
75730978|NCT00709475|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75730979|NCT04071041|Drug|Albumin Human|Administration of albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
75881912|NCT03556982|Biological|CART-123 cells|CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
75881913|NCT02090660|Other|ICG Localization with Spy thoracoscope localization|
75881914|NCT00073671|Behavioral|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
76052878|NCT02240108|Drug|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
76052879|NCT02240108|Drug|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
75881915|NCT00073671|Other|Usual care|Participants receive usual care
76052880|NCT01590628|Drug|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
76052881|NCT02130193|Drug|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
75437171|NCT01576094|Drug|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
75730980|NCT02575625|Device|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
75730981|NCT02575625|Biological|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
75730982|NCT02575625|Device|MRI|Liver MRI
75730983|NCT00555672|Drug|5-fluorouracil|5- fluorouracil is given as 4000 mg/m^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
75881916|NCT02090738|Drug|Acetazolamide group|
75881917|NCT02090738|Drug|Standard regimen group|
75881918|NCT02096510|Drug|Solu-Cortef|administration by pump for minimum 2 weeks
75881919|NCT02096510|Drug|Cortef|tablet treatment 2 ro 3 times per day for 14 days
75881920|NCT05218317|Diagnostic Test|in-vivo Corneal Confocal Microscopy|All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
75881921|NCT03556280|Device|GammaSense Stimulation System (Active Settings)|Proprietary auditory and visual sensory stimulation device.
76052882|NCT02130193|Drug|Placebo|Subjects will receive danirixin matching placebo
76052883|NCT01590082|Drug|Doxycycline|"Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
76052884|NCT01590082|Drug|Ipilimumab|Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
76052885|NCT01590082|Drug|Temozolomide|Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
76052886|NCT02285582|Other|Registry study|No intervention.
76052887|NCT01598636|Procedure|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
76052888|NCT01631474|Drug|CB-03-01|Topical cream, applied once a day
76052889|NCT01631474|Drug|Vehicle|Topical cream, applied once or twice a day
76052890|NCT01631474|Drug|CB-03-01|Topical cream, applied twice a day
76052891|NCT02203916|Drug|Azilsartan medoxomil|Azilsartan medoxomil tablets
75585995|NCT04575272|Procedure|Ultrasound-guided continuous serratus anterior plane block|Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
75585996|NCT04575350|Genetic|reinterpretation of CNV|Reinterpretation of CNV of unknown significance
75585997|NCT01086423|Biological|Infanrix-IPV/Hib™|Intramuscular, three doses
75585998|NCT01086423|Biological|Infanrix Hib™|Intramuscular, three doses
75585999|NCT01086423|Biological|Poliorix™|Intramuscular, three doses
76052892|NCT02203916|Drug|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
75437172|NCT01576107|Other|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
76052893|NCT04774328|Drug|CA-008 (vocacapsaicin)|Single administration of CA-008 (vocacapsaicin) versus placebo
75437173|NCT01576107|Other|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
75586000|NCT04575389|Diagnostic Test|Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level|diagnostic tests
75586001|NCT04575116|Drug|Tafamidis free acid tablet|12.2 mg tafamidis free acid tablet
75586002|NCT04575116|Drug|Tafamidis meglumine capsule|20 mg tafamidis meglumine soft gelatin capsule
75586003|NCT01086150|Procedure|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
75586004|NCT01086150|Drug|Lidocaine 5% patches|Subject will apply patches to affected area QD for 12 hours then remove.
75586005|NCT02278107|Device|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
75730984|NCT00555672|Drug|cisplatin|Cisplatin is given 80 mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
75881922|NCT03556280|Device|GammaSense Stimulation System (Sham Settings)|Proprietary auditory and visual sensory stimulation device.
76052894|NCT04774328|Drug|Placebo|Single administration of CA-008 (vocacapsaicin) versus placebo
76052895|NCT02179177|Drug|Apixaban|Drug is taken by mouth twice a day for 6 months
75437174|NCT01576133|Behavioral|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
75437175|NCT01576133|Behavioral|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
75437176|NCT01576185|Other|laboratory biomarker analysis|Correlative studies
75437177|NCT01576185|Drug|quizartinib|Via gavage
75437178|NCT01576185|Drug|sorafenib tosylate|Via gavage
75437179|NCT01576198|Genetic|DNA analysis|
75437180|NCT01576198|Genetic|nucleic acid amplification|
75437181|NCT01576198|Other|diagnostic laboratory biomarker analysis|
75437182|NCT01576198|Other|medical chart review|
75437183|NCT01576211|Genetic|DNA methylation analysis|
75437184|NCT01576211|Genetic|RNA analysis|
75586006|NCT02278107|Device|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
76052896|NCT02179177|Drug|Placebo|
76052897|NCT02129803|Device|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
75881923|NCT03555656|Behavioral|Repeated intervention|Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
75586007|NCT00587249|Biological|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
75586008|NCT00587249|Biological|Alhydrogel|Aluminum hydroxide gel.
75730985|NCT00555672|Drug|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
75881924|NCT03555656|Behavioral|Single session|Single 2-h group session educating patients at foot hygiene and ulcer prevention
76052898|NCT02129803|Device|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
76052899|NCT02239094|Drug|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
76052900|NCT02129647|Drug|Axitinib|
76052901|NCT02238626|Drug|Placebo (for MN-166)|
76052902|NCT02238626|Drug|MN-166|
75437185|NCT01576211|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
75437186|NCT01576211|Genetic|gene expression analysis|
75437187|NCT01576211|Genetic|nucleic acid sequencing|
75586009|NCT00587327|Drug|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
75586010|NCT00587327|Drug|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
75586011|NCT00587327|Drug|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
75730986|NCT02575547|Drug|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition"
75730987|NCT01037387|Drug|Control|Current treatment according to the ATS/ERS guidelines
75730988|NCT01037387|Device|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
75881925|NCT02093468|Drug|MST-188|
75881926|NCT02093468|Drug|Saline|
75881927|NCT02093546|Procedure|Biospecimen Collection|Undergo collection of blood and tumor
75881928|NCT03441555|Drug|Venetoclax|tablet, oral
75881929|NCT03441555|Drug|Alvocidib|Intravenous
75881930|NCT02098772|Drug|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
75881931|NCT02098772|Drug|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
76052903|NCT02238626|Drug|riluzole|Patient is given 50 mg riluzole twice daily.
75437188|NCT01576211|Genetic|polymorphism analysis|
75437189|NCT01576211|Other|laboratory biomarker analysis|
75437190|NCT01576224|Device|"Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark"|To be removed during training exercises three to five times a day
75437191|NCT01576237|Other|blood donation|blood donation with preparative hemapheresis
75437192|NCT01576250|Other|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
75437193|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
75437194|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
76052904|NCT02151643|Drug|PT20|Modified ferric oxide adipate tablets
76052905|NCT02151643|Drug|Placebo|Placebo tablets matched to each PT20 dose arm
76052906|NCT02203838|Drug|RBP-7000|"120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner."
76052907|NCT02178709|Drug|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
76052908|NCT02238080|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
75437195|NCT01576289|Other|Histological analysis|Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
75586012|NCT00587405|Procedure|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
75730989|NCT02574533|Biological|Vigil|Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
76052909|NCT02150863|Device|Ultrapulse Carbon Dioxide Laser|
75730990|NCT02574533|Drug|Pembrolizumab|Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
75730991|NCT00709553|Drug|midazolam|
75730992|NCT00709553|Drug|ZD4054|ZD4054 10 mg od
75730993|NCT02575391|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
75730994|NCT03958656|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
75730995|NCT03958656|Drug|Fludarabine|30 mg/m^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
75730996|NCT03958656|Drug|Rimiducid|0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
76052910|NCT02150863|Device|Cellutome epidermal harvesting system|
75881932|NCT03357081|Drug|CEUS or Contrast enhanced Ultrasound|Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
75881933|NCT02093780|Behavioral|Alberta Anti-inflammatory diet|Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.
76052911|NCT01445366|Device|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
76052912|NCT01445366|Device|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
76052913|NCT02178553|Drug|Epidural|
76052914|NCT02178553|Drug|Intercostal Bupivicaine (Exparel)|
76052915|NCT01627327|Drug|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
76052916|NCT01627327|Drug|tiotropium bromide 18mcg|inhalation powder
76052917|NCT01627249|Drug|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
75730997|NCT03958656|Biological|Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells|0.3x10^6- 12.0x10^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
75730998|NCT00950274|Drug|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
75730999|NCT00950274|Drug|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
75881934|NCT02093780|Behavioral|Canada's Food Guide Diet|Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
76052918|NCT01627249|Drug|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
76052919|NCT01627249|Drug|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
76052920|NCT01688830|Drug|Dabigatran|
76052921|NCT01688830|Drug|BI 655075|
76052922|NCT01688830|Drug|Placebo|
76052923|NCT01569022|Device|CPAP|CPAP Treatment for 12 weeks
76052924|NCT01569022|Device|MAD|MAD Treatment for 12 weeks
76052925|NCT01629823|Device|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
75437196|NCT01576302|Behavioral|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
75437197|NCT01576302|Behavioral|Muscle relaxation|Progressive passive muscle relaxation
75437198|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
75437199|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
75437200|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
75437201|NCT01576354|Drug|Prolonged-release Fampridine|10mg tablet twice a day (every 12 hours), orally
75586013|NCT00587405|Procedure|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
76052926|NCT01688050|Device|Zenith® TX2® Low Profile Endovascular Graft|Treatment of Blunt thoracic aortic injuries (BTAIs)
75437202|NCT01576354|Drug|Placebo|tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
76052927|NCT01604278|Drug|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
76052928|NCT01604278|Drug|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
75437203|NCT01576380|Drug|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
75437204|NCT01576393|Behavioral|Home-based Family Therapy|12 home-based family therapy sessions
75437205|NCT01576393|Behavioral|office-based family therapy|12 office-based family therapy sessions
75437206|NCT01576393|Behavioral|WHE|12 Women's Health Education Sessions
75586014|NCT01085682|Behavioral|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
75586015|NCT01085682|Behavioral|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
75586016|NCT00587444|Drug|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is < 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is>480 seconds
75586017|NCT00587444|Drug|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is <600 seconds anytime during CPB
75586018|NCT00587444|Drug|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
75881935|NCT03346239|Behavioral|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
75881936|NCT03346239|Drug|Escitalopram|10-20 mg of Escitalopram
75881937|NCT03346239|Behavioral|Waitlist|Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
75881938|NCT05216289|Dietary Supplement|Probiac|Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
76052929|NCT01687270|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
76052930|NCT01687270|Drug|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
76052931|NCT01589770|Other|cardiac Magnetic Resonance imaging|
75437207|NCT01576419|Drug|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
75437208|NCT01576419|Drug|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
75731000|NCT03777306|Other|ARM A EARLY INTERVENTION GROUP|"Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~1 video/picture/worksheet per week covering the topic to be covered.~1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress."
75731001|NCT03777306|Other|ARM B DELAYED INTERVENTION GROUP|The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
76052932|NCT01588990|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 milligrams per square meter (mg/m^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
75437209|NCT01576432|Behavioral|Assess pain with the NIPS score|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
75437210|NCT01576445|Procedure|Mid-vastus approach|Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
76052933|NCT01588990|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
75437211|NCT01576445|Procedure|medial parapatellar approach|medial parapatellar approach
76052934|NCT01588990|Drug|Bevacizumab|Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
75437212|NCT01576458|Drug|ursodeoxycholic acid|450 mg/day for 14 days
75437213|NCT01576458|Drug|Placebo|placebo
76052935|NCT01588990|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m^2 or 50 mg total dose).
75437214|NCT01576497|Procedure|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
75437215|NCT01576497|Device|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
75437216|NCT01576497|Device|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
76052936|NCT01588990|Drug|5-Fluouracil|Participants will receive 5-fluouracil loading dose of 400 mg/m^2 IV on Day 1 followed by 2400 mg/m^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
75437217|NCT01576510|Behavioral|Prolonged Exposure (PE)|Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
75731002|NCT00561912|Drug|Decitabine|15 mg/m^2 IV Daily over one hour for 5 days
75731003|NCT00561912|Drug|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
75731004|NCT00561678|Drug|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
75731005|NCT00561678|Drug|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
76052937|NCT01588990|Drug|Irinotecan|Participants will receive irinotecan 180 mg/m^2 IV on Day 1 every 2 weeks during Phase B treatment.
76052938|NCT02176525|Drug|BI 207127 NA|
76052939|NCT02176525|Drug|Placebo|
76052940|NCT02127931|Device|Groundskeeper for ADHD group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
75586019|NCT00587522|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
76052941|NCT02127931|Device|Groundskeeper for control group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
75731006|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
75731007|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
76052942|NCT02126839|Drug|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
76052943|NCT02126839|Drug|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
76052944|NCT02126839|Drug|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
76052945|NCT02125279|Drug|Calcitriol|
76052946|NCT02124811|Drug|Minocycline|
76052947|NCT02148445|Other|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
76052948|NCT02148445|Other|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
76052949|NCT02148445|Drug|Nicotine replacement therapy|
76052950|NCT02148211|Other|Data collection|Initial and follow-up data was collected using questionnaires.
76052951|NCT02147587|Drug|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
75437218|NCT01576614|Behavioral|Remote physician rounding|Use of Remote physician rounding using Remote Telepresence Robotics
75437219|NCT01576627|Dietary Supplement|zinc citrate|10 mg of zinc as either zinc citrate
75437220|NCT01576627|Dietary Supplement|Zinc Gluconate|10 mg of zinc as either zinc gluconate
75437221|NCT01576627|Dietary Supplement|Zinc oxide|10 mg of zinc as either zinc oxide
75586020|NCT02278302|Drug|Aggrenox®|
75586021|NCT02278302|Drug|Placebo|
75731008|NCT00946608|Drug|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
75731009|NCT00463684|Biological|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.
75731010|NCT00463684|Biological|Live, attenuated measles vaccine|Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
75881939|NCT05216289|Other|Placebo|Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
75437222|NCT01576640|Drug|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
75437223|NCT01576640|Drug|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
75437224|NCT01576640|Other|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
75437225|NCT01576653|Other|Fungitell Assay in BAL|Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
75437226|NCT01576666|Drug|LDE225|
75437227|NCT01576666|Drug|BKM120|
75437228|NCT01576679|Drug|Cathflo (Alteplase)|
75437229|NCT01576679|Drug|Saline|
75586022|NCT02278302|Other|Ethanol|
75586023|NCT00587600|Procedure|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
75731011|NCT00463606|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
75731012|NCT00463606|Drug|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
75731013|NCT00463606|Drug|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
75731014|NCT03996070|Procedure|Laser therapy|Erbium YAG laser
75731015|NCT03961308|Drug|Vedolizumab SC|Vedolizumab SC liquid.
75731016|NCT00956436|Drug|BIIB022|IV Q3W
76052952|NCT02147587|Drug|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
76052953|NCT02147353|Drug|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
76052954|NCT02147353|Drug|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
76052955|NCT02147197|Drug|Ulipristal acetate (UPA)|UPA tablet
76052956|NCT02147197|Drug|Placebo|Matching placebo tablet.
76052957|NCT04751929|Drug|Abemaciclib|Taken orally 2x daily
76052958|NCT04751929|Drug|Atezolizumab|Intravenously Day 1 of 21 day cycle
76052959|NCT02176291|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
76052960|NCT02176291|Drug|Placebo|matched placebo
75586024|NCT00587600|Procedure|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
75586025|NCT01085214|Other|Laboratory Biomarker Analysis|Correlative studies
75586026|NCT01085214|Drug|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
75586027|NCT00587756|Procedure|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
75586028|NCT01085136|Drug|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
75586029|NCT01085136|Drug|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
75586030|NCT00587873|Drug|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
75586031|NCT00587873|Drug|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
75586032|NCT00587873|Drug|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
75586033|NCT04574804|Other|Online training program in weight management for osteoarthritis|"An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~Overweight and obesity and osteoarthritis~Overview of weight regulation, overweight and obesity~Examining weight stigma in physiotherapy and personal beliefs about weight~Communication approach for addressing weight management~Interventions for weight management~Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention."
75586034|NCT01084707|Drug|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
75586035|NCT01084707|Drug|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
75586036|NCT01084707|Drug|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
75586037|NCT00588107|Other|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
75586038|NCT00588107|Behavioral|print materials|tailored print materials designed to aid in smoking reduction and cessation
75586039|NCT02210520|Device|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
75586040|NCT02210520|Device|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
75586041|NCT02210520|Device|laser|1 W/cm², 2 minutes in 6 points around the back spine
75586042|NCT04574726|Other|static balance|30-second right and left unipodal static balance test
75586043|NCT04574726|Other|dynamic balance|"for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~180° elevation of the arms~lowering of the arms on the side of the single-legged support to the horizontal position~180° horizontal translation of the arms~return from the horizontal to the starting point"
75731017|NCT00956436|Drug|Sorafenib|Standard dosing of Sorafenib
75731018|NCT00956514|Device|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
75731019|NCT00950508|Procedure|High volume plasma exchange|3 high volume plasma exchanges over 3 days
75437230|NCT01576692|Biological|Humanized anti-GD2 antibody|"A maximum of 6 courses of therapy may be given on the following schedule:~Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy~Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)~Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m^2)/dose, over 4 hours daily~NK Cell dosage: minimum of 0.1 * 10^6 cells/kg; maximum of 400 * 10^6 CD45+ cells/kg, given once"
75586044|NCT02210598|Device|inpatient Foley balloon induction|The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
75586045|NCT02210598|Device|outpatient Foley balloon induction|The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
75731020|NCT00950508|Procedure|Standard medical treatment|Standard medical treatment
75731021|NCT00950586|Drug|GSK1043702|Oral dose in liquid or tablet formulation
75731022|NCT00950586|Drug|Dextromethorphan|30mg Oral dose
75731023|NCT00950586|Drug|Placebo|To match GSK1034702
75731024|NCT00174187|Drug|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
75731025|NCT01011335|Biological|Monovalent rAT|10, 25, 50 or 100 μg
75731026|NCT01011335|Biological|Monovalent rLukS-PV|10, 25, 50 or 100 μg
75731027|NCT01011335|Biological|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
75731028|NCT01011335|Biological|Placebo with adjuvant|Placebo with adjuvant
75881940|NCT02098928|Behavioral|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
75731029|NCT01011335|Biological|Placebo|Placebo saline
75586046|NCT02210598|Drug|Oxytocin|"When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement."
75586047|NCT00588224|Other|3D ultrasound|measurement of stomach volume by 3D ultrasound
75586048|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
75586049|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
75586050|NCT01084551|Drug|Placebo of SPM 962|once a daily transdermal administration for 13 weeks
75586051|NCT03452657|Drug|Ranibizumab|Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year
75586052|NCT03452657|Procedure|No drug|Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
75586053|NCT02210676|Other|PROMIS Upper Extremity|
75586054|NCT02210676|Other|Likert Pain Scale|
75586055|NCT02210676|Other|Mallet Finger Extensor Lag Measurement|
75586056|NCT03452618|Diagnostic Test|diagnosis variables|"The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~Age of the patient~Sex~Presence of bulbar involvement or not~Time from onset of first symptoms to diagnosis of ALS~Score ALSFRS-R~Presence of another underlying respiratory pathology (COPD, asthma ...)~FVC measurement (Forced vital capacity)~PaCO2 measurement~Measure SNIP (Sniff nasal inspiratory pressure)~Measure of Pimax (Pressure inspiratory maximal)~Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)"
75586057|NCT03452501|Drug|Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
75731030|NCT00467896|Drug|Iloprost PD-6|Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
75586058|NCT00588302|Drug|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
75437231|NCT01576692|Drug|Chemotherapy|"Chemotherapy may include the following at the dosages shown below:~cyclophosphamide: 400 mg/m^2 IV days 1-5~topotecan: 1.2 mg/m^2 IV days 1-5~temozolomide: 150 mg/m^2 PO at least 1 hour before irinotecan~irinotecan: 50 mg/m^2 IV over 1 hour daily for 5 days~carboplatin (AUC 8-dosing based on GFR), IV day 1 only~ifosfamide: 2 g/m2 IV days 1-3~etoposide: 100 mg/m2 days 1-3"
75731031|NCT00467896|Drug|Iloprost PD-15|Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
75437232|NCT01576692|Other|Cytokines|"Cytokines may be given at the following dosages:~interleukin-2: 1 million units/m^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses~GM-CSF: 250 mcg/m^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC >2,000/mm^3"
75731032|NCT00946686|Drug|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
75437233|NCT01576692|Biological|Natural killer cells|NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy & Procedure Manual.
75586059|NCT00588419|Behavioral|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
75586060|NCT04568655|Device|noninvasive ventilation|noninvasive ventilation to support the COVID-19 patients with respiratory failure
75731033|NCT00946686|Drug|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
75731034|NCT00579059|Device|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
75731035|NCT00579059|Device|Regular Maxim® Knee System|Used for total knee replacements
75731036|NCT02531737|Drug|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
75731037|NCT02531737|Drug|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
75731038|NCT00467818|Drug|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
75731039|NCT00467818|Other|Placebo|Same dosage as that of omega 3 fatty acids
75881941|NCT02098928|Device|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
75586061|NCT00588458|Procedure|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
76052961|NCT04769570|Procedure|interscalene brachial plexus block|Single shot ultrasound guided interscalene brachial plexus block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
75437234|NCT01576692|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
75731040|NCT01326559|Drug|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
75437235|NCT01576731|Drug|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
75437236|NCT01576731|Drug|Tenofovir, Emtricitabine, Raltegravir|Combination drug
75881942|NCT02995551|Procedure|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
75437237|NCT01576770|Device|lidocaine/tetracaine transdermal patch (NDC 43469-864-01)|70 mg lidocaine / 70 mg tetracaine
75437238|NCT01576770|Drug|Gebauer's Ethyl Chloride|Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
75437239|NCT01576796|Radiation|Radiotherapy|"No additional dose (patients negative F-miso)~Radiation therapy is conducted under standard conditions of conformal radiotherapy:~The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week~With additional dose (patients positive for F-miso)~The dose in the PTVmiso increased until the maximum tolerable radiation by the lung."
75437240|NCT01576822|Other|This protocol will utilize a sauna as the primary method of detoxification.|"This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna)."
75437241|NCT01576848|Dietary Supplement|Protein|"Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
75586062|NCT01084005|Drug|linagliptin|patients receive linagliptin 5 mg tablets once daily
75586063|NCT01084005|Drug|placebo|patients receive placebo matching linagliptin 5 mg once daily
75731041|NCT02575313|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
75731042|NCT00709709|Procedure|multislice coronary scan|multislice coronary scan
75731043|NCT00709787|Other|Usual Care|Normal care for hypertensive patients with risk factors for CHD
75881943|NCT02995551|Behavioral|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
75881944|NCT03556124|Device|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
75881945|NCT03556124|Device|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
75881946|NCT03556124|Device|Active - Conventional tDCS|Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
75881947|NCT03556124|Device|Sham - Conventional tDCS|Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
76052962|NCT04769570|Procedure|suprascapular nerve block|Single shot ultrasound guided interscalene brachial plexus block and Suprascapular nerve block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
76052963|NCT04769570|Procedure|Group Control|consist of the patient group without any procedure.
76052964|NCT02175745|Drug|18F-fluoro-dihydroxyphenylalanine|Administered intravenously (IV)
76052965|NCT02175745|Procedure|Positron emission tomography (PET)|Component of an 18F-FDOPA PET/CT or PET/MRI scan
76052966|NCT02175745|Procedure|Computed tomography (CT)|Component of an 18F-FDOPA PET/CT
75586064|NCT00588497|Procedure|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
75586065|NCT00588497|Radiation|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
76052967|NCT02175745|Procedure|Magnetic resonance imaging|Component of an 18F-FDOPA PET/MRI
75437242|NCT01576848|Dietary Supplement|Protein + carbohydrate|"subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
75586066|NCT00588497|Procedure|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
75881948|NCT02820753|Behavioral|EHR + (Text or Portal)|"Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey."
75881949|NCT03556046|Diagnostic Test|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
75586067|NCT00588497|Radiation|Hysterosalpingogram|Performed 3 months after micro-inserts placement
75586068|NCT04568577|Other|Tape with tension|The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.
75586069|NCT04568577|Other|Tape without tension|Bandaging applications will be weekly, for five weeks, without tensioning the tape.
75731044|NCT04069949|Drug|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
75731045|NCT00714467|Behavioral|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
75731046|NCT00714467|Behavioral|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
76052968|NCT02175277|Drug|Darbepoetin Alfa|The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
75437243|NCT01576861|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
75586070|NCT00588653|Device|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
76052969|NCT02124265|Drug|CeraLyte 90|"This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5. Patients will be monitored according to standard of care.~a. If gastric residuals are >300cc, ORT will be stopped and only IV fluid resuscitation will be used."
76052970|NCT02146105|Other|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
75586071|NCT00588887|Device|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
75586072|NCT00588887|Device|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
75586073|NCT01083810|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
75586074|NCT00588926|Drug|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
75586075|NCT01083771|Dietary Supplement|Olive Oil|Minimum of 3 tablespoon of olive oil per day
75586076|NCT00589082|Drug|DaunoXome|
75881950|NCT05218161|Drug|Dexmedetomidine alone|All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
75586077|NCT00589082|Drug|Daunorubicine|
75586078|NCT00589199|Procedure|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
75437244|NCT01576900|Behavioral|SyBeMeP (Systemized Behavioural Modification education Program)|"Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.~Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)~During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.~After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education."
75437245|NCT01576913|Other|Music listening|Listening to tempo music while cycling in an exercise test
75586079|NCT00589238|Drug|carboplatin|
75586080|NCT00589238|Drug|cyclophosphamide|
75586081|NCT00589238|Drug|doxorubicin hydrochloride|
75586082|NCT00589238|Drug|paclitaxel|
75586083|NCT04568070|Diagnostic Test|mini-BESTest (Mini-Balance Evaluation Systems Test)|Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.
75586084|NCT04568070|Diagnostic Test|Berg Balance Scale|The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.
75586085|NCT04568070|Diagnostic Test|Timed Up and Go Test|It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
75881951|NCT02861586|Biological|MV-CHIK low dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
75881952|NCT02861586|Biological|MV-CHIK high dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
75586086|NCT04568070|Diagnostic Test|Functional Reach Test|The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
75586087|NCT00589394|Biological|pneumococcal vaccination (Pneumovax)|pneumovax was given
75731047|NCT02574767|Behavioral|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet & Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
75731048|NCT02574767|Dietary Supplement|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
76052971|NCT02175199|Device|Lotrafilcon B contact lenses with color printing|
76052972|NCT02175199|Device|Phemfilcon A contact lenses with color printing|
75437246|NCT01576965|Drug|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
75437247|NCT01576978|Behavioral|hatha yoga|The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
76052973|NCT02175121|Drug|Placebo|Tablet, once daily for 28 days
75437248|NCT01577004|Dietary Supplement|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
75437249|NCT01577017|Drug|Letrozole|Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
75437250|NCT01577030|Dietary Supplement|Non-fat dairy|Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
75437251|NCT01577030|Dietary Supplement|Add 4 servings fruit|Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
75586088|NCT01083576|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
75586089|NCT01083576|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
75586090|NCT04568265|Drug|APG-1387|Weekly intravenous infusion for 30 minutes
75586091|NCT04568265|Drug|Entecavir 0.5 mg|Taken daily by mouth
75586092|NCT00589589|Device|Endo Tool|Computer tool to help achieve glucose control
75586093|NCT04568343|Device|Capsule endoscopy|We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
75586094|NCT00589706|Drug|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
75731049|NCT02574767|Behavioral|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet & PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
75731050|NCT02574767|Dietary Supplement|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
75731051|NCT02575235|Drug|Cetylpyridinium Chloride (CPC)|Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.
76052974|NCT02175121|Drug|PF-06291874|Tablet, 15 mg, once daily for 28 days
76052975|NCT02175121|Drug|PF-06291874|Tablet, 35 mg, once daily for 28 days
76052976|NCT02175121|Drug|PF-06291874|Tablet, 75 mg, once daily for 28 days
76052977|NCT02175121|Drug|PF-06291874|Tablet, 150 mg, once daily for 28 days
76052978|NCT01568866|Drug|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
76052979|NCT01568866|Drug|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
76052980|NCT01568866|Drug|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
75731052|NCT02575235|Drug|placebo|Control group takes the placebo for the same period.
75881953|NCT02861586|Biological|Priorix®|lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
75881954|NCT02861586|Biological|physiological saline solution|sterile physiological saline solution 0.9% used as placebo
75437252|NCT01577043|Drug|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
76052981|NCT01568320|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
76052982|NCT01567852|Drug|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
75437253|NCT01577043|Other|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
75437254|NCT01577056|Dietary Supplement|Fish oil capsule|4g Omega capsule for 12 weeks
75586095|NCT00589745|Other|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
75731053|NCT00467740|Drug|BI 1744 CL|
75731054|NCT02575157|Other|No intervention|No intervention
75731055|NCT04070963|Other|HbA1C|To take additional blood test of HbA1C once patient consented to the study
75731056|NCT00710099|Drug|sildenafil|systemic absorption of sildenafil
75437255|NCT01577056|Drug|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
75586096|NCT04568304|Biological|Toripalimab Injection|Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.
75586097|NCT04568304|Drug|Gemcitabine Hydrochloride for Injection|"Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
75731057|NCT00710099|Drug|nitroprussiate iontophoresis|nitroprussiate iontophoresis
75881955|NCT02096822|Behavioral|Facilitated tucking + non-nutritive sucking|
75881956|NCT02096822|Other|non-nutritive sucking|
75881957|NCT05217771|Other|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
75437256|NCT01577082|Drug|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
75437257|NCT01577082|Drug|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
75437258|NCT01577121|Drug|indomethacin|50 mg / 6 hours during 5 days
75437259|NCT01577121|Drug|placebo|50 mg / 6 hours during 5 days
75881958|NCT02094014|Behavioral|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
75437260|NCT01577134|Behavioral|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
75881959|NCT02094014|Behavioral|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
75881960|NCT02094014|Behavioral|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
76052983|NCT01567852|Drug|Methohexital|Methohexital (1.5mg/kg) will be given for induction
76052984|NCT01588366|Drug|Placebo|Administered orally
76052985|NCT01588366|Drug|LY2409021|Administered orally
75437261|NCT01577134|Behavioral|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
75437262|NCT01577134|Behavioral|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
75731058|NCT02574689|Behavioral|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
76052986|NCT01686958|Device|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
75731059|NCT02574689|Behavioral|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
76052987|NCT01686568|Drug|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
75731060|NCT00714545|Radiation|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
75731061|NCT03944044|Other|Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol|Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
75731062|NCT00714623|Device|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
75731063|NCT00553254|Drug|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
75731064|NCT01022476|Drug|Raltegravir potassium|one pill of raltegravir 400 mg twice a day
75881961|NCT02099162|Device|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
76052988|NCT01686568|Drug|placebo|
76052989|NCT01567462|Device|Monopolar electrocautery loop in Transurethral resection of bladder tumors|Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
75731065|NCT05673239|Drug|Levocarnitine Injection|The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
75731066|NCT01025518|Other|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
75731067|NCT01025518|Dietary Supplement|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
75881962|NCT02099240|Drug|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
75881963|NCT02099240|Procedure|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
75881964|NCT02384421|Device|Adaptive DBS (Activa PC+S Neurostimulator)|
75881965|NCT02384421|Device|Continuous DBS (Activa PC+S Neurostimulator)|
76052990|NCT01567462|Device|PK Button Vaporization Electrode in transurethral resection of bladder tumors|PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
76052991|NCT01587898|Drug|GSK1278863|Tablet
75731068|NCT01025518|Dietary Supplement|Placebo|Maltodextrine
75881966|NCT03610074|Other|Mint Ice Cube|Application in patient's mouth of 3 mint ice cubes
75881967|NCT03610074|Procedure|Blood test|Additional blood test 5 min after mint ice cubes application
75881968|NCT03610074|Other|Patient's questioning|Patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application
75881969|NCT02034084|Procedure|left radial approach|Coronary diagnostic procedures performed through left radial approach
76052992|NCT01587898|Other|Placebo|Tablet
76052993|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
75437263|NCT01577095|Other|EA + Rosiglitazone|electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
75881970|NCT02034084|Procedure|Right radial approach|coronary diagnostic procedures performed through right radial approach
75881971|NCT05215899|Other|MINDFULNESS-BASED YOGA AND MEDITATION|The application was carried out by the researcher who had completed mindfulness-based yoga and meditation training.
76052994|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
76052995|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
76052996|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
76052997|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
76052998|NCT01567306|Biological|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
76052999|NCT01587274|Drug|Naproxen|Naproxen 500mg twice/ day x 10 days
76053000|NCT01587274|Drug|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
75437264|NCT01577095|Drug|TZD|Rosiglitazone 8 mg single dose
75437265|NCT01577147|Other|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
75437266|NCT01577199|Drug|Low-dose Clomiphene|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
76053001|NCT01587274|Drug|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
76053002|NCT01587118|Drug|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
76053003|NCT01905657|Biological|Pembrolizumab|IV infusion
76053004|NCT01905657|Drug|Docetaxel|IV infusion
75881972|NCT03609450|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
75881973|NCT03609450|Behavioral|Low-Dose Comparator|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
76053005|NCT02202980|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
76053006|NCT02202980|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76053007|NCT02202980|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
75881974|NCT05383248|Behavioral|High Reward - High Variance|Computerized reward learning task designed to increase reward responsiveness
75881975|NCT05383248|Behavioral|High Reward - Low Variance|Computerized reward learning task designed to have minimal effect on reward responsiveness
75881976|NCT05215743|Drug|Antioxidant therapy|Active therapy
75437267|NCT01577199|Drug|High dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
75437268|NCT01577212|Radiation|Individualized dose escalation|Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
75437269|NCT01577225|Device|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
75881977|NCT05215743|Drug|NaCl 0.9%|Placebo
75881978|NCT02099396|Drug|Docetaxel+lobaplatin|
75881979|NCT02099396|Drug|Gemcitabine+lobaplatin|
75881980|NCT05215665|Drug|GEMOX Regimen|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
75881981|NCT05215665|Drug|Lenvatinib|8/12mg PO QD continuously
75881982|NCT05215665|Drug|Toripalimab|240mg IV d1 Q3W
75881983|NCT02094092|Other|ProTectis drops (five drops per day) for 21 days|
75881984|NCT02094092|Other|Placebo drops (five drops per day) for 21 days|
75437270|NCT01577225|Device|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
75437271|NCT01577290|Behavioral|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
75437272|NCT01577290|Behavioral|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
75437273|NCT01577303|Behavioral|Cognitive bias modification training program variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
75881985|NCT03627663|Behavioral|Dialectic Behavior Therapy - Skills System|Treatment with Dialectical Behavior therapy adapted for cognitively challenged individuals
75881986|NCT02099474|Other|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
75881987|NCT02250638|Other|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
75881988|NCT02250716|Procedure|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
75881989|NCT03555500|Other|Non fasting|Non fasting group is allowed for clear fluids and food up to the time of the procedure.
75881990|NCT05217069|Drug|5-FU|400 mg/m2 (i.v. bolus) 2400 mg/m2 (i.v. 46h)
75881991|NCT05217069|Drug|Folinic Acid|400mg/m2
75881992|NCT05217069|Drug|Irinotecan|180 mg/m2
75881993|NCT05217069|Drug|Cetuximab|400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w
75881994|NCT05217069|Drug|Avelumab|10mg/kg IV (day 1 q2w)
75881995|NCT02096978|Procedure|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
76053008|NCT02202980|Drug|VOX|100 mg tablet administered orally once daily with food
76053009|NCT01952145|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
76053010|NCT01952145|Drug|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
76053011|NCT04416087|Other|Exercise|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
75586098|NCT04568304|Drug|Cisplatin for Injection / Carboplatin Injection|"Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
75586099|NCT04568304|Drug|Placebo|Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
75586100|NCT01082640|Drug|Febuxostat|Febuxostat capsules
75586101|NCT01082640|Drug|Placebo|Febuxostat placebo-matching capsules
75731069|NCT02575001|Behavioral|Psychological background determinations|"For the psychological background determinations a structured interview and questionnaires will be administered:~Child Attachment Interview (CAI)~General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy~Parenting Stress Index with the 19-item Life Stress Scale (PSI)~Achenbach System of Empirically Based Assessment (CBCL, YSR)~Holmes and Rahe Social readjustment rating scale~Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)~Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)"
75731070|NCT02575001|Genetic|Genetic susceptibility determination|DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.
75731071|NCT02575001|Procedure|Cortisol release test|Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity
75731072|NCT02575001|Procedure|Saliva cortisol measurement|Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
75731073|NCT01021930|Device|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
75731074|NCT00946764|Drug|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
75731075|NCT00946764|Drug|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
75881996|NCT02250170|Drug|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
75881997|NCT02065635|Procedure|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
75586102|NCT00589862|Drug|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
75586103|NCT00589901|Drug|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14"
75586104|NCT04568187|Device|zeltiq|Zeltiq prototype device (Zeltiq Aesthetics, Pleasanton, CA) approved by FDA 2010
75586105|NCT04568187|Device|placebo|radiofrequency with 3000 Hz
75586106|NCT00590174|Drug|Aspirin|stopping clopidogrel at 1 year after DES implantation
75586107|NCT00590174|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
75586108|NCT01082367|Drug|TOBI|TOBI (tobramycin inhaled solution)
75586109|NCT01082367|Drug|Placebo|Placebo
75586110|NCT00590213|Drug|Casodex 150mg|
75586111|NCT00590213|Procedure|Radiotherapy|
75586112|NCT00590213|Procedure|Haematology|
75731076|NCT01022008|Device|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
75731077|NCT00950820|Drug|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
75881998|NCT02065635|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
75881999|NCT02097368|Procedure|tongue strength measurement|tongue strength measurement
75586113|NCT04567797|Device|Laevo 2|The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.
75882000|NCT02097368|Procedure|respiratory function measurement|respiratory function measurement
75882001|NCT02097368|Procedure|swallowing tests|swallowing tests
75882002|NCT02097368|Other|Magnetic resonance imaging|Magnetic resonance imaging
75882003|NCT05425784|Device|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
75731078|NCT00950820|Drug|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
75731079|NCT02574923|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
75586114|NCT04567797|Device|backX|"backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2."
75586115|NCT04567797|Device|FLx ErgoSkeleton|The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.
75586116|NCT04567797|Device|V22 ErgoSkeleton|"Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons."
75586117|NCT01082211|Radiation|3D-Conformal External Beam|Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
75586118|NCT04567758|Other|Telerehabilitation|"The home exercise program includes the following exercises:~Lumbar region and lower extremity stretching exercises;~Exercises to strengthen the abdominal muscles;~Exercises to strengthen the lumbar muscles;~Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises~A web-based telerehabilitation platform (Fizyoweb) will be used to deliver the exercise program. Using the Fizyoweb web application, exercises will be presented to the patients in the form of audio-video and detailed instructions with explanations. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. The exercise protocol will be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each."
75586119|NCT04567758|Other|Conventional Rehabilitation|"The home exercise program, which will be given with conventional rehabilitation, will be educated to the patient in the clinic on the first day. Exercise information form including explanation and picture of the exercises will be given to the patients. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.~The home exercise program includes the following exercises:~Lumbar region and lower extremity stretching exercises;~Exercises to strengthen the abdominal muscles;~Exercises to strengthen the lumbar muscles;~Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises"
75586120|NCT00590408|Dietary Supplement|coenzyme Q10|60mg capsule twice daily for 12 weeks
75731080|NCT00950898|Other|decaff|2 mugs of decaffeinated coffee
75731081|NCT00950898|Other|caffcoff|2 mugs of caffeinated coffee
75731082|NCT00950898|Other|caffeine|2 mugs of hot water containing caffeine
75731083|NCT00950898|Other|placebo|2 mugs of hot water
75731084|NCT00168805|Drug|enoxaparin|40 mg once daily
75731085|NCT00168805|Drug|dabigatran etexilate|150 mg once daily
75731086|NCT00168805|Drug|dabigatran etexilate|220 mg once daily
75731087|NCT00950976|Other|citrulline|TID for 5 days
75731088|NCT00950976|Other|Lemonade|TID for 5 days
75586121|NCT00590408|Dietary Supplement|matching placebo|matching placebo capsule twice daily for 12 weeks
75586122|NCT04574648|Device|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event and non-adherence information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display non-adherence information in their systems."
75882004|NCT05425784|Other|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self-care.
75437274|NCT01577303|Behavioral|Cognitive bias modification training program variant 2|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
75882005|NCT03556748|Other|whole-body electromyostimulation|WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
75882006|NCT02094248|Drug|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
75586123|NCT04567875|Other|No Intervention on patients|No Intervention on patients
75586124|NCT00590447|Drug|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
75586125|NCT00590447|Drug|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
75437275|NCT01577303|Behavioral|CBM training program variant 3|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
75586126|NCT04567953|Other|Saliva collection|Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
75586127|NCT00590525|Procedure|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
75882007|NCT02094248|Drug|control|Normal saline，1ml/day, s.c injection
75882008|NCT02250248|Biological|AttraX Putty|
75882009|NCT02250248|Other|Iliac Crest Bone Graft (ICBG)|
75882010|NCT02099942|Device|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:~as stand-alone intervention~as a bridge to transcatheter aortic valve replacement (TAVR)~as a bridge to surgical aortic valve replacement (SAVR)~as an intraprocedural predilatation prior to TAVR"
75586128|NCT01081626|Drug|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
75586129|NCT03452423|Procedure|ACRFP|Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
75586130|NCT03452384|Other|Acupuncture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
75586131|NCT01080768|Drug|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
75586132|NCT01080768|Drug|Amlodipine|Amlodipine 5 mg/day.
75731089|NCT00467584|Drug|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
75731090|NCT00467584|Drug|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
75731091|NCT00467584|Drug|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
75731092|NCT04521725|Device|Respiratory Function Monitor (RFM)|Use of respiratory function monitor to detect tidal volume and expired CO2 to guide mask ventilation during neonatal resuscitation.
75882011|NCT02100020|Other|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
75437276|NCT01577303|Behavioral|CBM training program variant 4|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
76053012|NCT01923363|Drug|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
75437277|NCT01577303|Behavioral|Control training variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency..
75586133|NCT01080768|Drug|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
75586134|NCT01080768|Drug|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
75586135|NCT03452345|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
75586136|NCT03452345|Drug|Placebo|Placebo (Normal saline)
75586137|NCT03452306|Drug|Metformine|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition"
75882012|NCT02097446|Device|Guardix-FL|
75586138|NCT03452306|Drug|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition"
75882013|NCT02097446|Device|Interceed|
75882014|NCT02097524|Drug|Sarilumab|
75882015|NCT02097524|Drug|Tocilizumab|
75882016|NCT03628053|Biological|Tisagenlecleucel|autologous cellular immunotherapy product
75882017|NCT03628053|Drug|Blinatumomab|bispecific CD19-directed CD3 T-cell engager
75586139|NCT03452306|Drug|Metformin|"Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
75437278|NCT01577303|Behavioral|Control training variant 2|Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
75437279|NCT01577316|Biological|Seasonal influenza vaccination|"2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus;~a B/Wisconsin/1/2010-like virus."
75586140|NCT03452306|Drug|Glucophage® Long|"Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
75586141|NCT04567641|Dietary Supplement|postoperative nutrition|Forty patients (50%) received enteral nutrition 6 hours after surgical procedures and 40 patients (50%) received parenteral nutrition 6 hours after surgical procedures.
75586142|NCT04568109|Behavioral|Cognitive-behavior therapy|The manualized protocol (Gloster et al., 2011) comprise of 12 weekly sessions of CBT focusing on therapist-guided interoceptive and in-situ exposure exercises.
75586143|NCT01080300|Drug|Gabapentin Extended Release|Gabapentin ER 1800mg daily
75586144|NCT01080300|Drug|Placebo|Sugar pill
75586145|NCT00590603|Drug|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I~Loading:~Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
75731093|NCT04521725|Device|Cerebral Near-Infrared Spectroscopy (NIRS)|Use of cerebral NIRS to determine cerebral oxygenation to guide oxygen titration during neonatal resuscitation.
75731094|NCT00956670|Other|Quality-of-Life Assessment|Ancillary studies
75586146|NCT01085097|Drug|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
75586147|NCT01085097|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
75586148|NCT01085097|Drug|Prednisolone/Prednisone|Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
75586149|NCT01085097|Drug|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
75586150|NCT01085097|Drug|Methylprednisolone|Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
75731095|NCT00956670|Other|Questionnaire Administration|Ancillary studies
75731096|NCT00956670|Procedure|Study of High Risk Factors|Undergo lymphedema assessment
75731097|NCT00956670|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75731098|NCT00956670|Procedure|Therapeutic Laparoscopic Surgery|Undergo surgery
75731099|NCT00956670|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
75731100|NCT02574611|Drug|Neostigmine|
75731101|NCT02574611|Drug|Glycopyrrolate|
75731102|NCT02574611|Other|Saline (Placebo)|
75731103|NCT02574611|Device|High Resolution Colonic Manometry|
75731104|NCT01025596|Drug|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
75731105|NCT00710255|Procedure|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
75882018|NCT03628053|Drug|Inotuzumab|CD22-directed antibody-drug conjugate
75586151|NCT00590798|Behavioral|Walking|Patient will walk within 30 minutes of vascular closure system procedure
75882019|NCT02100176|Other|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
75882020|NCT02100176|Drug|Rotigotine|Rotigotine 2-8 mg/24 h
75882021|NCT02250482|Biological|Optivate® (Human Coagulation Factor VIII)|
76053013|NCT01905267|Behavioral|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
76053014|NCT01923285|Device|AXIUM Neurostimulator System|
75437280|NCT01577342|Drug|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
75437281|NCT01577355|Radiation|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
75437282|NCT01577368|Drug|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
75437283|NCT01577368|Drug|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
75437284|NCT01577394|Other|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades"
75437285|NCT01577407|Drug|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
75437286|NCT01577420|Other|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
75437287|NCT01577420|Other|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
75586152|NCT04567446|Other|Stool|collection at diagnosis, before initiating anticancer treatment, during treatment
75586153|NCT04567446|Other|Blood sample|40 mL collection before, 3 and 6 months of treatment cancer
75586154|NCT04567446|Other|Saliva|5 mL collection before initiation of treatment cancer
75586155|NCT00590837|Drug|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
75586156|NCT01086267|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
75586157|NCT01086267|Drug|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
75586158|NCT01086267|Drug|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
75586159|NCT04567563|Device|Remote Ischemic conditioning (RIC)|Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
75586160|NCT04574687|Other|Neurodevelopmental Techniques|)Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
75882022|NCT01377753|Device|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
76053015|NCT01923285|Device|Control Spinal Cord Stimulation Device|
75586161|NCT04574687|Other|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
75586162|NCT02277873|Behavioral|pregnancy|Observational study in order to establish relationship between moon and births
75586163|NCT00590915|Drug|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.~NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
75586164|NCT04574570|Device|High Tibial Osteotomy|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
75586165|NCT04571892|Biological|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
76053016|NCT01904721|Drug|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
76053017|NCT01904721|Drug|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
76053018|NCT01904721|Drug|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
75437288|NCT01577446|Procedure|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
75586166|NCT04567290|Drug|Chewed ticagrelor|Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
75586167|NCT04567290|Drug|Swallowed ticagrelor|Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
76053019|NCT05122533|Diagnostic Test|EOS|EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
76053020|NCT05122533|Diagnostic Test|Clinical limb length measurements|"Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~tape measuring:~Spina iliaca anterior superior - medial malleolus~umbilicus - medial malleolus~greater trochanter - lateral malleolus~in standing, sitting, resupinate and side position"
76053021|NCT01922895|Dietary Supplement|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
76053022|NCT01922895|Drug|Placebo for Probiotic|Capsule manufactured without active ingredients.
76053023|NCT01922739|Drug|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
76053024|NCT01922739|Drug|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
76053025|NCT02236988|Drug|Apremilast Immediate Release|30 mg immediate release tablets
76053026|NCT02236988|Drug|Apremilast Modified Release 1|75 mg oral tablet of prototype modified release (MR) 1
76053027|NCT02236988|Drug|Apremilast Modified Release 2|75 mg oral tablet of prototype MR 2
76053028|NCT02236988|Drug|Apremilast Modified Release 3|75 mg oral capsule of prototype MR 3
76053029|NCT02236988|Drug|Apremilast Modified Release 4|75 mg oral capsule of prototype MR 4
76053030|NCT02236988|Drug|Apremilast Modified Release 5|75 mg oral capsule of prototype MR 5
76053031|NCT02236988|Drug|Apremilast Modified Release 6|75 mg oral capsule of prototype MR 6
76053032|NCT02236988|Drug|Apremilast Modified Release 8|80 mg oral capsule of prototype MR 8
75586168|NCT04567329|Drug|NOV03|100% perfluorohexyloctane
75731106|NCT01025674|Behavioral|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
75586169|NCT04567329|Drug|Saline Solution|0.6% sodium chloride solution
75586170|NCT00591071|Other|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
75586171|NCT00591071|Other|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
75731107|NCT00714779|Drug|Fluoxetine|20-40 mg / day orally
75731108|NCT00714779|Behavioral|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
75731109|NCT03912467|Other|Pressure Ulcer Evaluation|Patient was evaluated according to presence of pressur ulcer or not
75731110|NCT03839212|Behavioral|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
76053033|NCT02236988|Drug|Apremilast Modified Release 9|80 mg oral capsule of prototype MR 9
76053034|NCT02236988|Drug|Apremilast Modified Release 11|80 mg oral capsule of prototype MR 11
76053035|NCT02236988|Drug|Apremilast Modified Release 12|80 mg oral capsule of prototype MR 12
75437289|NCT01577459|Drug|TR-701 FA with PSE|TR-701 FA Oral 200 mg oral with PSE
75437290|NCT01577459|Other|TR-701 FA Placebo with PSE|TR-701 FA Placebo Oral 200 mg with PSE
75586172|NCT01084161|Drug|N1539|5 mg IV once per day
75586173|NCT01084161|Drug|N1539|7.5 mg IV once per day
75731111|NCT03839212|Behavioral|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
76053036|NCT02236988|Drug|Apremilast Modified Release 13|80 mg oral capsule of prototype MR 13
76053037|NCT02236988|Drug|Apremilast Modified Release 14|80 mg oral capsule of prototype MR 14
76053038|NCT02236598|Drug|K+ supplement|
76053039|NCT02236598|Drug|Placebo|
76053040|NCT01922349|Drug|BI 113608|Medium dose (Multiple dosing)
76053041|NCT01922349|Drug|Placebo|Placebo (Multiple dosing)
76053042|NCT01922349|Drug|BI 113608|Low dose (Multiple dosing)
76053043|NCT01922349|Drug|Placebo|Placebo (Single dosing)
76053044|NCT01922349|Drug|BI 113608|High dose (Single dosing)
76053045|NCT01922349|Drug|BI 113608|Medium dose (Single dosing)
76053046|NCT01922349|Drug|BI 113608|Low dose (Single dosing)
76053047|NCT01922349|Drug|BI 113608|High dose (Multiple dosing)
76053048|NCT02236520|Drug|Spironolactone|
76053049|NCT02236520|Drug|Chlorthalidone|
76053050|NCT02236520|Dietary Supplement|Diet|
76053051|NCT02236520|Drug|Placebo|
75586174|NCT01084161|Drug|N1539|15 mg IV once per day
75586175|NCT01084161|Drug|N1539|30 mg IV once per day
75882023|NCT03556670|Behavioral|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
75437291|NCT01577472|Drug|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
75882024|NCT03556670|Other|Control|Usual practice control
75882025|NCT02250560|Biological|Replenine®-VF (High Purity Factor IX)|
75882026|NCT02094482|Device|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
75882027|NCT05194761|Drug|Normal saline|Using normal saline nebulization in neonates postextubation
75882028|NCT02094560|Drug|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
75882029|NCT03627975|Procedure|Conservative treatment|"The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment.~In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima.~In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved."
75882030|NCT05194605|Other|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
75882031|NCT05189145|Drug|estradiol valerate|8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
75437292|NCT01577472|Drug|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
75882032|NCT05189145|Other|Hormonal monitoring progesterone, estradiol, luteinizing hormone|Serum Progesterone, estrogen & LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.
75882033|NCT05189145|Diagnostic Test|transvaginal ultrasound examination|Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
75882034|NCT05189145|Drug|Progesterone 400 Mg Vaginal Suppository|Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
76053052|NCT04769414|Drug|Gemcitabine fluorouracil|"chemotherapy protocol given as:~Gemcitabine 1000mg/m2 IV short infusion~Leucovorin 400 mg/m2 IV short infusion~Flourouracil 400 mg/m2 direct IV shot~Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly"
75437293|NCT01577472|Drug|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
75437294|NCT01577472|Drug|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
75437295|NCT01577485|Dietary Supplement|Probiotics in an pastille|Test group
75437296|NCT01577485|Dietary Supplement|Control pastille|Control group
75437297|NCT01577511|Biological|Samples and follow up|"Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.~Follow-up: disease outcomes assessed at 24 months"
75586176|NCT01084161|Drug|placebo|IV placebo once per day
75586177|NCT01084161|Drug|Morphine|morphine 10-15 mg IV once per day
75586178|NCT01084161|Drug|N1539|60 mg IV once per day
75586179|NCT00591110|Behavioral|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
75586180|NCT00591110|Behavioral|Social-contact control|Participants receive an engaging informational session on a non-health related topic
75586181|NCT01083615|Drug|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
75586182|NCT01083615|Drug|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
75586183|NCT01083615|Drug|docetaxel|
75586184|NCT01083615|Drug|cabazitaxel|
75586185|NCT01083615|Drug|prednisone|
75586186|NCT00591188|Drug|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
76053053|NCT01922271|Drug|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
75437298|NCT01577524|Drug|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
75586187|NCT00591383|Drug|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
75586188|NCT00591383|Drug|erlotinib|erlotinib taken at 150 mg every morning with food.
75586189|NCT01081782|Drug|ONO-4641|0.15 mg once per day for 26 weeks
75586190|NCT01081782|Drug|ONO-4641|0.1 mg once per day for 26 weeks
75586191|NCT01081782|Drug|ONO-4641|0.05 mg once per day for 26 weeks
75586192|NCT01081782|Drug|ONO-4641 placebo|Placebo once per day for 26 weeks
75731112|NCT03839212|Behavioral|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
75882035|NCT05189145|Other|Hormonal monitoring progesterone and estradiol|Measuring the serum Progesterone & Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels < 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels >10ng, continued on 400 mg prontogest suppositories twice daily
75882036|NCT05189145|Drug|Progesterone|group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
76053054|NCT01922271|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
75437299|NCT01577524|Drug|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
75437300|NCT01577550|Drug|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
75437301|NCT01577550|Drug|Placebo, i.v.|Single i.v. administration of placebo
75437302|NCT01577550|Drug|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
75437303|NCT01577550|Drug|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
75437304|NCT01577550|Drug|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
75437305|NCT01577550|Drug|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
75731113|NCT03839212|Behavioral|HOLA Component 4|One booster walking session twice a month for three months post intervention for reinforcement.
75882037|NCT02097836|Device|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
75882038|NCT03555812|Other|Pelvic inclination measurement|Measurement of pelvic inclination per ultrasound
75882039|NCT05423366|Device|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
76053055|NCT01922271|Drug|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
76053056|NCT01922271|Drug|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
75586193|NCT00591422|Drug|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (>36 hours between doses) for 3 weeks with 1 week rest.
75586194|NCT04567212|Genetic|genetic evaluation|A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.
75586195|NCT04567212|Other|MicroRNA evaluation|Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
75586196|NCT01080222|Drug|telaprevir|tablet, 1125-mg, twice daily
75586197|NCT01080222|Drug|VX-222|capsule, 100-mg, twice daily
75586198|NCT01080222|Drug|ribavirin|tablet, 1000-mg for subjects weighing <75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
75586199|NCT01080222|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
75586200|NCT01080222|Drug|VX-222|capsule, 400-mg, twice daily
75586201|NCT03452267|Drug|Metformin|oral, 850 mg twice daily
75586202|NCT03452267|Drug|Pioglitazone|oral, 45 mg daily
75586203|NCT03452267|Drug|Placebo|oral, once daily
75586204|NCT03451994|Other|Breath test|Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
75586205|NCT01088802|Radiation|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
75586206|NCT01088802|Drug|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
75731114|NCT00168103|Biological|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
75731115|NCT00168103|Biological|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
75731116|NCT04011228|Diagnostic Test|Blood sampling|After a fasting period over night blood samples will be taken.
75731117|NCT04011228|Diagnostic Test|Saliva and blood samples|After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.
75586207|NCT01088802|Drug|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
75586208|NCT03451877|Genetic|TGFB1 AND LAMA1 GENE POLYMORPHISMS|we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
75586209|NCT04999683|Dietary Supplement|ITIS diet|anti-inflammatory diet for 14 days
75731118|NCT04011228|Diagnostic Test|Magnet Resonance Spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
75731119|NCT00463060|Drug|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
75882040|NCT05186571|Biological|Pfizer-BioNTech mRNA COVID-19 vaccination|Vaccination in children 5-11 years of age
76053057|NCT01922271|Drug|Salbutamol|Used as resuce medication
75437306|NCT01577550|Drug|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
75437307|NCT01577550|Drug|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
75437308|NCT01577550|Drug|Placebo, s.c.|Single s.c. administration of placebo
75731120|NCT00463060|Procedure|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
75731121|NCT00956748|Drug|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
75731122|NCT00956748|Drug|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
76024993|NCT03995693|Procedure|Measure of sweat and urine production|Sweat production and sampling will be performed by measuring body weight before and after exercise, after voiding the bladder. Mass loss through the urine and gases will be accounted for in order to compute sweat production. A sweat sample will be collected using a cotton gauze placed into a plastic collector affixed in the upper back of the participants. A urine sample will be taken from the urine collected at the end of the exercise period. Urine and sweat volumes along with respective urea concentrations will be used to compute protein oxidation during exercise.
76053058|NCT02236130|Procedure|Regional block|Single shot peripheral nerve block
76053059|NCT02236130|Procedure|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
76053060|NCT02236130|Drug|Local Anesthetic Ropivacaine|0.5% Ropivacaine
76053061|NCT02236130|Drug|Opioids Morphine|Morphine
76053062|NCT02236130|Drug|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
75437309|NCT01577550|Drug|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
75437310|NCT01577589|Drug|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
75437311|NCT01577589|Drug|Placebo in 50 ml infusion volume|IV infusion
75437312|NCT01577589|Drug|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
75437313|NCT01577589|Drug|Placebo in 250 ml infusion volume|IV infusion
75437314|NCT01577589|Drug|600 mg ceftaroline in 100 ml infusion volume|IV infusion
75437315|NCT01577589|Drug|Placebo in 100 ml infusion volume|IV infusion
75437316|NCT01577602|Other|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
75437317|NCT01577602|Other|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
75586210|NCT03451838|Diagnostic Test|Ultrasound|Ultrasound will be done to every pregnant lady
75586211|NCT03451838|Diagnostic Test|HbA1c level in blood|a blood sample will be taken to measure HbA1c level
75586212|NCT03451682|Dietary Supplement|procyanidine|Natural antioxidant
75586213|NCT04566822|Behavioral|High Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
75586214|NCT04566822|Behavioral|Medium Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
75586215|NCT04566822|Behavioral|Low Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
75731123|NCT00710333|Drug|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
75731124|NCT00710333|Drug|placebo|placebo
75882041|NCT05223309|Other|Usinf thick loose sutures in seton techingues|"All patients were informed about doing fistulectomy and thick silk Seton suture placement for three months by excising the extrasphincteric part and putting the Seton suture to the intersphincteric part. Then, the second stage of operation includes the excision of the changing low type tract in which the silk Seton placed. We decrease the time of Seton placement in this study for three months to reduce the annoying symptoms of the patients. Therefore, the patient admitted to the operation theater after obtaining written consent. Most of the patients anesthetized by spinal anesthesia. In the operation theater, the patient assumed a lithotomy position~. After that, the injection of a solution, which is a mixture of methylene blue dye and hydrogen peroxide into the external opening of the fistula, was done to find the internal opening. The exit of color dye or bubbles achieved to localized of inner opening from it after using intraoperative proctoscopy examination."
75882042|NCT02097914|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
76053063|NCT02233946|Behavioral|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
75882043|NCT05150847|Other|Oxygenation|Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
75882044|NCT02094950|Procedure|Acupuncture|
75882045|NCT04967079|Drug|Trametinib|Trametinib 2 mg given orally, once daily
76053064|NCT04768634|Diagnostic Test|Provocative electrophysiology study|Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.
75882046|NCT04967079|Drug|Anlotinib|Anlotinib capsules given orally, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). The initial dose is 8 mg, QD, PO, taken for the first 14 days of each 21-day cycle. If no patients developed DLT in the first treatment cycle, the 10 mg dose was explored. If 1 of 3 patients had a DLT, 3 more patients would need to be included for evaluation at this dose. If >1 out of 3 patients in a given dose group develops DLT, it is suggested that a lower dose group can be explored. If no DLT occurred at the 10 mg dose, the 12 mg dose was explored.
75882047|NCT03555734|Other|Dietary pulses or legumes|Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).
75586216|NCT04566822|Behavioral|Sleep Education Control|Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
75882048|NCT03890601|Biological|blood sample|"A single 15 mL blood draw is planned for this study, as follow:~10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1."
75882049|NCT03556592|Drug|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
75882050|NCT03556592|Drug|Caffeine|1x 100 mg tablet
75437318|NCT01577602|Other|Combined intervention|Combines the printed medication list with the open ended question
75586217|NCT03451643|Procedure|ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT|PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
75586218|NCT03451604|Other|preoperative assessement|All data concerning study, involved in normal care of patient for his anesthesia (non interventional study), where included in anonymous computerized database by anesthesiologist during pre operative clinic.
75882051|NCT03556592|Drug|Warfarin|2x 5 mg tablets
75882052|NCT03556592|Drug|Omeprazole|1x 20 mg capsule
75882053|NCT03556592|Drug|Metoprolol|1x 100 mg tablet
75882054|NCT03556592|Drug|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
75586219|NCT04566744|Other|fRMI|The measurements performed will be the participant's brain activity, as well as behavioral measurements associated with the tasks performed (response time, correctness of the response). Brain activity measurements will be performed on the Siemens 3T system of the MRI department of CERMEP. The subject will perform the task under study while the level of brain activity is recorded. The functional examination will be subdivided into several parts according to its total length in order to spare the subject. The total duration of MRI acquisitions will be approximately 1 hour regardless of the axis.
75586220|NCT04574453|Device|Iracross|Administration of max 2ml of Iracross at first visit
75882055|NCT05070117|Behavioral|Exercise training|Study participants perform resistance/strength exercises 2-3 times per week for one hour, for one year.
76053065|NCT02232698|Device|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
75437319|NCT01577615|Behavioral|Patterned Experience|"The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.~Nonnutritive sucking will be offered to infants.~Blood work will be collected for inflammatory cytokines.~Saliva will be collected for genetic analysis~Saliva will be collected in 10 infant sub study for cortisol pre and post feedings~All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.~Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.~Follow up visits will occur at 2,6and 24 months corrected age."
75731125|NCT01079923|Dietary Supplement|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
75731126|NCT01079923|Dietary Supplement|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
75731127|NCT00951054|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
75437320|NCT01577667|Device|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
75437321|NCT01577680|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
75437322|NCT01577680|Drug|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
75437323|NCT01577693|Drug|dutasteride|novel dutasteride
75437324|NCT01577693|Drug|dutasteride|dutasteride soft gel capsule
75437325|NCT01577719|Behavioral|Multimedia Lifestyle Improvement|"Online Goal setting to improve diet, physical activity or smoking behaviours~regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.~Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks."
75437326|NCT01577719|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
75437327|NCT01577771|Biological|Prevnar13 (manufactured by Pfizer)|Prevnar13 administered IM in the antero-lateral thigh
75731128|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
75731129|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
75882056|NCT02095028|Behavioral|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
75437328|NCT01577784|Drug|Pazopanib|800 mg / day of pazopanib in monotherapy.
75437329|NCT01577797|Behavioral|Text messages|Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
75731130|NCT00462982|Drug|sunitinib malate|
75731131|NCT02573597|Drug|Bupivacaine|Continuous or bolus administration
75731132|NCT02573597|Drug|Sufentanil|Continuous or bolus administration
75731133|NCT05300958|Drug|Deferoxamine Plus Chemotherapy|Deferoxamine：50mg/kg+500ml normal saline (NS)
75731134|NCT00951210|Biological|PLX-PAD|IM injection
75731135|NCT04070729|Other|Placebo gel|Localized subgingival application
75731136|NCT04070729|Drug|Hyaluronic acid gel|Localized subgingival application
75731137|NCT04070729|Biological|Platelet rich fibrin|Localized subgingival application
75731138|NCT00951288|Dietary Supplement|Saffron|Saffron 20 mg/day supplementation
75731139|NCT00951288|Dietary Supplement|Placebo|Placebo
75882057|NCT04964193|Drug|Elzsa film-coated tablet|Administered with 240 mL of water
75731140|NCT00462904|Drug|BPI|BPI will be give IV with an initial bolus given over 30 minutes and then a continuous infusion for the next 47.5 hours
75586221|NCT04574453|Device|Iraline|Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need
75586222|NCT04566471|Other|prevalence/incidence|It is an observational study for prevalence/incidence, no intervention provided.
75586223|NCT03451526|Procedure|Surgeries|Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
75586224|NCT04996602|Drug|2.0 GBq of 177Lu-EB-PSMA|Patients were intravenous administrated with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA every 8 weeks (±1 week) for a maximum of 3 cycles.
75586225|NCT04997694|Procedure|Pre Heating|Before anesthesia was given, the participants were warmed for 20 minutes with prewarming techniques. Presence of postoperative hypothermia, vital signs and temperature comfort level were evaluated.
75586226|NCT04574414|Diagnostic Test|Psychological testing and MRI imaging|"Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI."
75586227|NCT04566549|Combination Product|Test group Probiotic Shampoo|Probiotic Shampoo
75586228|NCT04566549|Combination Product|Placebo group|Shampoo base
75586229|NCT04566705|Other|Risks factors, maternal and neonatal outcomes/complications|Risks factors, maternal and neonatal outcomes/complications
75586230|NCT04566588|Procedure|EAR HoLEP|early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
75586231|NCT04566588|Procedure|Classic HoLEP|classic holmium enucleation of the prostate as a surgical treatment for benign prostatic hyperplasia
75586232|NCT04992858|Drug|CT053PTSA|CT053PTSA will be administered orally once a day
75586233|NCT04997382|Drug|Alectinib|Alectinib Cap 600 mg po bid
75586234|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
75586235|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
75586236|NCT02210754|Other|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
75586237|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
75586238|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
75586239|NCT02210754|Other|Marlboro Cigarette|cigarettes
75437330|NCT01577810|Device|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
75437331|NCT01577823|Device|Foley Catheter|
75437332|NCT01577849|Drug|Vitamin D3|administration of Vitamin D3 24,000 IU
75437333|NCT01577849|Drug|DP-R206|administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
75437334|NCT01577862|Drug|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
75437335|NCT01577862|Drug|Rifampicin|600 mg every 12 hours intravenously
75586240|NCT02210793|Procedure|transepithelial PRK|
75586241|NCT02210793|Procedure|LASIK|
75437336|NCT01577875|Device|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
75437337|NCT01577888|Device|Shockwave System Treatment|Shockwave System Treatment during vascular disease intervention.
75437338|NCT01577901|Other|Clearblue Advanced|Pregnancy test
75437339|NCT01577914|Drug|Carvedilol Tablets USP 12.5 mg|12.5mg tablet once a day
75437340|NCT01577914|Drug|Carvedilol|12.5mg tablet once a day
75586242|NCT03451214|Other|Diet Zinc|4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
75586243|NCT04996056|Drug|TNX-1300|TNX 1300 200 mg Intravenous injection
75586244|NCT04996056|Other|Usual Care|Usual Care per the Emergency Department protocol for Cocaine Intoxication
75586245|NCT04992078|Device|NAVIO/CORI Surgical System|Unicompartmental knee replacement with robotic assistance
75586246|NCT04992078|Procedure|Non-robotic conventional instrumentation|Unicompartmental knee replacement with non-robotic conventional instrumentation
75586247|NCT02210871|Drug|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
75586248|NCT04574141|Dietary Supplement|a prolonged release tablet and a spray containing melatonin|prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.
75586249|NCT04573907|Drug|Drug Levothyroxine 100 mcg|Administration of a 600 mcg levothyroxine dose
75586250|NCT04573907|Drug|Drug Eutirox 100 mcg|Administration of a 600 mcg levothyroxine dose
75586251|NCT02277912|Device|navigated rTMS of motor cortex|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
75586252|NCT02277912|Device|navigated rTMS of somatosensory cortex 2|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
75586253|NCT02277912|Device|SHAM rTMS with SHAM block|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
75586254|NCT02277951|Device|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
75586255|NCT02277951|Device|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
75586256|NCT02277951|Device|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
75586257|NCT02277951|Device|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
75731141|NCT00956826|Device|Agit Vacuum|With an electrode and a regular vacuum device
75437341|NCT01577927|Other|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
75586258|NCT04573790|Procedure|eFONA|Surgical Tracheotomy
75586259|NCT02278068|Device|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
75731142|NCT00709397|Other|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
75731143|NCT00467272|Drug|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
75731144|NCT00956904|Device|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
75437342|NCT01577927|Behavioral|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement."
75437343|NCT01577940|Procedure|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
75731145|NCT00956982|Drug|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing < 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
76053066|NCT02232698|Device|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
75437344|NCT01577940|Procedure|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
75586260|NCT04573595|Device|Blood Pressure Measurement|The purpose of this study is to provide supporting documentation for Noninvasive blood pressure measurement accuracy claims for Fresenius 5008S BPM Module and Cuffs on the intended population(s). The same arm sequential method with dual observer auscultation will be used to collect data.
75882058|NCT04964193|Drug|Diane-35 Sugar-coated tablet|Administered with 240 mL of water
75882059|NCT02095262|Other|reactive auditory training|
75882060|NCT02095262|Other|Interactive auditory training|
76053067|NCT01632800|Device|High pulsed magnetic fields|Magnetic fields will escalate in strength
75437345|NCT01577953|Drug|SB010|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.~Dose levels:~Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL)."
75586261|NCT04566627|Behavioral|"Yo Sé Lo Que Quiero programl"|"Yo Sé Lo Que Quiero program is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
75586262|NCT04573361|Other|Chiropractic care (one visit)|One visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
75586263|NCT04573361|Other|Chiropractic care (more than one visit)|More than one visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
75882061|NCT04814199|Other|Algorithm|Patients will have a printed algorithm to follow while they are in labour with an epidural for pain management.
76053068|NCT01641809|Drug|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
76053069|NCT01641809|Drug|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
76053070|NCT01641809|Drug|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
75437346|NCT01577953|Drug|Placebo|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board."
75437347|NCT01577979|Behavioral|Text Message Reminder/Recall|Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
75437348|NCT01577979|Behavioral|Parent Preference|Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
75437349|NCT01577992|Drug|Levodopa test|Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
75437350|NCT01577992|Procedure|determination of objective and subjective pain threshold|Test without levodopa intake
75437351|NCT01578018|Other|Measure DCAM levels in blood|Measure DCAM levels in blood
75437352|NCT01578018|Other|DCAM levels in blood|DCAM levels in blood
75437353|NCT01578057|Drug|tasimelteon|20mg, once
75586264|NCT04566354|Other|Repeated 30-s sprint exercise|Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
75586265|NCT04573400|Other|HADS|"The HADS is a 14-item self-report questionnaire assessing levels of anxiety (seven items) and depression (seven items) over the past week. Each question is assessed on a 4-point Likert Scale: I feel tense or 'wound up' (0= not at all 3= most of the time). Consistent with recommendations by Bjelland et al cut-off of 8 for each HADS subscale will be used to differentiate normal from mild to severe distress."
75586266|NCT04998981|Drug|K-877 0.1 mg tablet|K-877 0.1 mg tablet x 2 twice daily
76053071|NCT01641809|Drug|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
76053072|NCT01641809|Drug|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
75437354|NCT01578057|Drug|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
75586267|NCT04998981|Drug|Fenofibrate 200 mg capsule|Fenofibrate 200 mg capsule once daily
76024994|NCT02000440|Drug|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
76024995|NCT02781701|Device|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
75437355|NCT01578057|Other|Placebo tasimelteon|once
75586268|NCT04998981|Drug|Placebo tablet|Placebo tablet x 2 twice daily
75586269|NCT04998981|Drug|Placebo capsule|Placebo capsule once daily
75586270|NCT04998981|Drug|K-877 0.1 mg tablet|K-877 0.1 mg tablet twice daily
75586271|NCT04998981|Drug|Placebo tablet|Placebo tablet twice daily
75586272|NCT04573127|Other|descriptive study|Retrospective analysis of existing data collected as a part of the regular follow-up
75586273|NCT04573088|Behavioral|ACCEPTANCE-BASED INTERVENTION|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
75731146|NCT00714857|Drug|Dexmedetomidine|The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
75882062|NCT02100488|Device|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
76053073|NCT01641809|Drug|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
76053074|NCT01641809|Drug|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
75882063|NCT02100488|Other|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
76053075|NCT01632566|Drug|Placebo|Capsules administered orally
75437356|NCT01578057|Drug|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
75437357|NCT01578070|Biological|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
75437358|NCT01578070|Biological|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
75437359|NCT01578070|Biological|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
75437360|NCT01578070|Biological|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
75586274|NCT04566198|Other|Questionnaire|The participants will have to filled out a questionnaire about their working conditions and their lifestyle habits.
75882064|NCT03627819|Dietary Supplement|Plant sterol-enriched margarine|Margarine enriched with plant sterol esters
75437361|NCT01578070|Biological|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
75437362|NCT01578096|Behavioral|stress management|The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
75437363|NCT01578109|Procedure|Bone Marrow Transplantation|Undergo BMT
75437364|NCT01578109|Drug|Sorafenib|Given PO
75882065|NCT03627819|Dietary Supplement|Plant stanol-enriched margarine|Margarine enriched with plant stanol esters
75882066|NCT03627819|Dietary Supplement|Control margarine|Margarine without any addition
75882067|NCT02100566|Behavioral|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
75437365|NCT01578109|Drug|Sorafenib Tosylate|Given PO
75586275|NCT04573049|Drug|Levosimendan|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.
75731147|NCT00957060|Drug|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
75731148|NCT00957060|Drug|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
75882068|NCT02100566|Behavioral|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
75882069|NCT05655819|Drug|Glutamine|5 gram powder, one rounded teaspoon, dissolved in 8 ounces of water or juice prior to drinking) taken orally three times per day
76053076|NCT01632566|Drug|LY3031207|Administered orally
76053077|NCT01632566|Drug|Celecoxib|Administered orally
76053078|NCT01632566|Drug|Simvastatin|Administered orally
75586276|NCT04573049|Other|Placebo|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.
75731149|NCT02573519|Radiation|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) [11C]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
75731150|NCT02573519|Device|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~A wireless electromagnetic capsule to be swallowed by the subject~A portable detector plate comprising four sensors worn in a belt around the waist~Specific software for visualizing and analyzing data"
75731151|NCT02573519|Drug|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
75731152|NCT02573519|Device|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
75731153|NCT00947232|Behavioral|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
76053079|NCT00752804|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
76053080|NCT00752804|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
76053081|NCT00752804|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
75437366|NCT01578122|Device|25mmHg ECS|"Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.~Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg)."
75731154|NCT00947232|Behavioral|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
75437367|NCT01578122|Device|35 mmHg ECS|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
75437368|NCT01578148|Procedure|Noxipoint Therapy|"Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:~Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named Noxipoints).~Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.~Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.~Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age."
75437369|NCT01578148|Procedure|Physical Therapy|"The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:~TENS stimulation (45 minutes):~• Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.~Other modalities of PT per the therapist's choice:~Infrared treatment on the pain areas (about 15 minutes)~Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).~Exercise and training:~Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or~Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes~Hot/cold pack to the pain area for about 15 minutes"
75586277|NCT04572932|Drug|lactobacillus delbruekii|Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
75731155|NCT02572661|Radiation|radiation in Squamous Head and Neck Cancer|
75731156|NCT02572583|Drug|Liugan Shuangjie Heji|
75586278|NCT04572698|Drug|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
75586279|NCT04572698|Drug|Eylea|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
75586280|NCT02210910|Device|InSpace™ system over repair|
75586281|NCT02210910|Procedure|Best Repair of torn Rotator Cuff|
75586282|NCT04572542|Drug|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg
75586283|NCT04572542|Drug|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday
75586284|NCT04572542|Drug|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2
75731157|NCT02572583|Drug|Shufeng Jiedu Capsule|
75731158|NCT02572583|Drug|Oseltamivir Phosphate Capsule|
75731159|NCT04011306|Device|Lumina24 BLU|Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns
76053082|NCT04863521|Other|MHP|MyHealthyPregnancy app (MHP 3.0) is a mHealth app specifically focused on detection and referral for depression and IPV (Intimate Partner Violence) risk, in addition to its other pregnancy risk detection and support features.
76053083|NCT02254304|Drug|Rebif|Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
75731160|NCT00714935|Behavioral|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
75731161|NCT00714935|Behavioral|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
75731162|NCT00951444|Biological|dalotuzumab|Given IV
75437370|NCT01578161|Drug|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
75882070|NCT05655819|Drug|Placebo|Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
75882071|NCT02095418|Drug|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
75437371|NCT01578161|Drug|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
75437372|NCT01578174|Drug|Dexmedetomidine|Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
75437373|NCT01578174|Drug|Normal saline 0.9%|Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
75437374|NCT01578200|Drug|Lanthanum Carbonate|
75437375|NCT01578200|Drug|Calcium Carbonate|
75437376|NCT01578213|Drug|Imatinib mesylate|"Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~Total dosage per day: 800 mg~Oral use"
75437377|NCT01578252|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
75437378|NCT01578252|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
75437379|NCT01578265|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
75437380|NCT01578265|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
75731163|NCT00951444|Drug|carboplatin|Given IV
75731164|NCT00951444|Drug|gemcitabine hydrochloride|Given IV
75437381|NCT01578291|Behavioral|Parental information|An informational brochure indicating the study details
75731165|NCT00462826|Biological|ziv-aflibercept|
75731166|NCT00718601|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
75731167|NCT00951522|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
75731168|NCT00951522|Drug|Placebo|Inhaled placebo in sterile saline
75731169|NCT00718679|Drug|IVN201|Intralymphativ injection of the study drug
75437382|NCT01578291|Behavioral|Play therapy|Play therapy with a child life specialist
75437383|NCT01578304|Drug|Imidafenacin|Tablet, 12 weeks twice daily
75882072|NCT02095418|Drug|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
75882073|NCT03627585|Device|Personalised programming|Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
75882074|NCT04865497|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
75437384|NCT01578304|Drug|Fesoterodine|Tablet, 12 weeks once daily
75586285|NCT04565964|Other|change the health behaviors to clean indoor environment|Sheets and all covers should be wash weekly. Clean indoor environment with a vacuum cleaner twice a week
75586286|NCT04572386|Other|light cure 3m single bond universal bond|light -cure universal bond
75586287|NCT04572386|Other|Self-cure universal bond (Palfique, Tokuyama, Japan)|Self-cure universal bond with no light cure
75586288|NCT04572464|Other|Mindfulness Based Guided Meditation|Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
75731170|NCT00718679|Drug|Placebo|
75586289|NCT04572620|Drug|Rituximab|375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.
75731171|NCT00947388|Drug|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
75731172|NCT00947388|Biological|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
75731173|NCT00710645|Device|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
75731174|NCT00951600|Drug|oxcarbazepine 300 mg/5mL oral suspension|
75731175|NCT00710723|Procedure|vitrification|Vitrification using Hemi-straw carrier system.
75731176|NCT00951678|Other|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
75731177|NCT03910985|Drug|Duovent HFA|bronchodilation
75731178|NCT05300880|Other|Training program|A multi-component intervention based on health coaching. The strategies of this program consisted in five 16-hour sessions using case studies to find out whether nurses were able to empower chronic cardiac patients and debriefing and a 4-hour booster session seven months later.
75731179|NCT00957216|Drug|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
75731180|NCT00957216|Drug|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
75882075|NCT04865497|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
76053084|NCT04863287|Biological|2217LS|Fully Human Monoclonal Antibody
76053085|NCT04863287|Other|0.9% Sodium Chloride (NaCl)|Subcutaneous injection
75437385|NCT01578343|Drug|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|"Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~Consolidation treatment for responders Patients not eligible for transplantation~Vorinostat maintenance up to 6 cycles~200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~Delay of the start of the next cycle by up to 7 days will be acceptable.~If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~High-dose chemotherapy followed by autologous stem cell transplantation"
75731181|NCT00718757|Drug|Dexamethasone|5 doses given on Days 6-10
75731182|NCT00718757|Drug|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
75586290|NCT04572620|Drug|Abatacept|10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.
75586291|NCT04565808|Procedure|primary percutaneous coronary intervention|Primary Percutaneous Coronary Intervention (PPCI), also known as angioplasty or coronary angioplasty, is a procedure used to diagnose and treat the narrowed coronary arteries of the heart.
75731183|NCT00718757|Drug|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~* Patients < 1 year of age or < 10kg in weight: Vincristine 0.05 mg/kg"
75586292|NCT03451097|Radiation|echocardiography|cardiac ultrasound
75586293|NCT04994691|Other|No Message|No messages are sent
75586294|NCT04994691|Other|Standard message|2 MyChart reminders that child is overdue for well child check visit
75586295|NCT04994691|Other|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
75586296|NCT03451019|Drug|Sevelamer Hydrochloride|Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal
75586297|NCT03451019|Drug|Lanthanum Carbonate|Single oral doses of lanthanum (1000 mg)
75731184|NCT00947466|Drug|Buprenorphine|Transdermal patch
75731185|NCT00957606|Procedure|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
75731186|NCT04069013|Procedure|PCNL|Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
75731187|NCT00951756|Other|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
75731188|NCT00718835|Behavioral|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
75731189|NCT00946842|Drug|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
75731190|NCT00946842|Drug|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
75882076|NCT04865497|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
75882077|NCT04865497|Biological|Haemophilus b Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.
75586298|NCT03450902|Combination Product|Chinese herb & acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
75586299|NCT03450902|Combination Product|Chinese herb & sham acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
75586300|NCT03450902|Combination Product|Placebo & acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
75586301|NCT03450902|Other|Placebo & sham acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
75437386|NCT01578369|Other|Exercise classes with pelvic floor muscle training|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
75731191|NCT00946842|Drug|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
75731192|NCT00946842|Drug|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
75882078|NCT05665725|Procedure|Biospecimen Collection|Undergo blood sample collection
75437387|NCT01578395|Radiation|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
75437388|NCT01578395|Radiation|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
75437389|NCT01578395|Other|No radiation exposure|Subjects not undergoing any radiation exposure
75437390|NCT01578408|Procedure|Total Hip Arthroplasty|
75437391|NCT01578408|Device|Cemented Lubinus SPII stem (control arm)|Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
75437392|NCT01578408|Device|Uncemented HA Coated Corail stem|Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
75437393|NCT01578421|Device|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
75437394|NCT01578434|Drug|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
75731193|NCT00946842|Drug|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
75437395|NCT01578434|Drug|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
75437396|NCT01578434|Drug|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
75437397|NCT01578447|Drug|DepoSubQ Provera 104 in Uniject|DepoSubQ Provera 104 in Uniject
75437398|NCT01578447|Drug|Intramuscular DMPA|Intramuscular DMPA
75437399|NCT01578460|Device|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
75437400|NCT01578460|Device|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
75586302|NCT04565652|Device|Device Wearers|The intervention arm will wear the LOIS ICD Smartband during routine ICD defibrillation following elective ICD implant.
75882079|NCT05665725|Procedure|Computed Tomography|Undergo CT scan
75882080|NCT05665725|Procedure|Positron Emission Tomography|Undergo PET scan
75882081|NCT05665725|Biological|Siltuximab|Given IV
75882082|NCT02098148|Drug|Xenon|
75882083|NCT02098148|Drug|Placebo|
75437401|NCT01578473|Drug|Vitamin D2|oral softgel 2000 IU once daily 9 months
75437402|NCT01578473|Drug|Vitamin E|"oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily~1 softgel of 200 IU daily 9 months"
75437403|NCT01578473|Drug|Testosterone Pellets|subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
75437404|NCT01578512|Behavioral|Face-to-Face|Face-to-Face behavioral weight loss
75586303|NCT03450863|Drug|Fast-acting insulin aspart|Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection [MDI]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion [CSII]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
75731194|NCT00946842|Drug|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
75731195|NCT00951834|Drug|Epigallocatechin-Gallate|"Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~Months 1-3: 200 mg EGCG/die (200-0-0 mg)~Months 4-6: 400 mg EGCG/die (200-0-200 mg)~Months 7-9: 600 mg EGCG/die (400-0-200 mg)~Months 10-18: 800 mg EGCG/die (400-0-400 mg)"
75882084|NCT01369381|Procedure|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
75586304|NCT02211027|Biological|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|"Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.~Patients will have vaccinations administered at 4 different sites as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site."
75586305|NCT02211066|Drug|Clopidogrel|
75437405|NCT01578512|Behavioral|Web-based|Web-based behavioral weight loss
75586306|NCT02211066|Drug|Ticagrelor|
75882085|NCT02098382|Device|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
75731196|NCT00951834|Drug|Placebo|Placebo
75731197|NCT00715013|Drug|Patupilone|Patupilone
76053086|NCT04420091|Dietary Supplement|Cartidyss|Oral intake of two tablets of Cartidyss 500 mg, once daily in the morning, preferably during a meal, with water, during 3 months
76053087|NCT04862195|Device|Attune™|Software as a medical device
75731198|NCT00715091|Drug|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
75731199|NCT00715091|Drug|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
75731200|NCT00947622|Device|Transcranial direct current stimulation|Transcranial Direct current stimulation
75882086|NCT05168527|Drug|Fruquintinib,Albumin Paclitaxel,Gemcitabine|The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
76053088|NCT04862195|Device|Cerena™|Software as a medical device
76053089|NCT05650307|Diagnostic Test|MRI|The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.
76053090|NCT04861805|Device|Vienna Aortic Valve SE System|Vienna Aortic Valve SE system for TAVI.
75437406|NCT01578512|Behavioral|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
75437407|NCT01578525|Other|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
75437408|NCT01578538|Procedure|inguinal hernia repair|strangulated hernias will be repaired surgically
75437409|NCT01578564|Drug|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
75437410|NCT01578590|Dietary Supplement|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
75437411|NCT01578603|Dietary Supplement|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
75586307|NCT03450785|Other|ultrasound examination|Doppler ultrasound examinations from the thyroid cartilage level to the supraclavicular region were used after CVC placement and on each of the following days until the catheter was removed.
75731201|NCT00957762|Other|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
75882087|NCT02095496|Device|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
75882088|NCT02095496|Device|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
75882089|NCT01372657|Other|biometry calculation|
75882090|NCT02098460|Drug|Atorvastatin, Probucol, Cilostazol|
76053091|NCT05650151|Dietary Supplement|Vitamin D|576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2
76053092|NCT05650151|Dietary Supplement|Placebo|An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
76053093|NCT02174731|Drug|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
75586308|NCT04572113|Device|Cervical collar|Data will be recorded while patients are not wearing or wearing one of two cervical collars
75586309|NCT04572191|Diagnostic Test|CERAMIDE LEVEL IN BLOOD|BY ELISA ASSAY TO DETECT CERAMIDE LEVEL IN BLOOD IN ANTERIOR STEMI PATIENTS
75731202|NCT00718913|Drug|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
75731203|NCT00718913|Drug|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
76053094|NCT02174731|Drug|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
76053095|NCT01922037|Drug|Omalizumab|Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
75437412|NCT01578603|Dietary Supplement|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
75586310|NCT04998864|Device|Magnetic Resonance guided Focused ultrasound (MRgFUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
75437413|NCT01578629|Other|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
75731204|NCT00718913|Drug|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
75586311|NCT04995042|Drug|SHR7280|Drug: SHR7280 All participants receive SHR7280 alone.
75731205|NCT00718913|Radiation|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
75731206|NCT00718913|Drug|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
75731207|NCT04011930|Drug|cholecalciferol|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
75437414|NCT01578629|Other|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
75437415|NCT01578642|Device|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
75437416|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
75586312|NCT03450551|Device|Twin Block, Herbst, Frog distalising appliance|To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
75586313|NCT03450395|Other|Hot Cereal|Intervention involves consumption of one hot cereal in the beginning of each day
75586314|NCT03450317|Drug|Aspirin 80mg|No treatment
75731208|NCT04011930|Drug|Placebo oral capsule|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
75882091|NCT05166031|Biological|bOPV and nOPV2|Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
76053096|NCT02282813|Drug|CTAP101 Capsules|At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
76053097|NCT02282813|Drug|Calcitriol|At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
75586315|NCT04996563|Other|Video|A brief educational video, approximately 9 minutes in duration, on pelvic organ prolapse is sent electronically to patients to view prior to their initial visit in order to provide early access to information. The video was created to educate patients on the following key components of prolapse: the clinical condition, associated symptoms, common risk factors, evaluation and diagnosis, non-surgical treatment options, and surgical treatment options. Simple drawings and animations are included as visual aids to enhance the ability to conceptualize prolapse and its management options.
75586316|NCT03450278|Procedure|micro-osteoperforation|Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
75586317|NCT04565496|Drug|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
75437417|NCT01578668|Drug|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
75731209|NCT04068857|Device|rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
75731210|NCT00957840|Procedure|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
75437418|NCT01578668|Drug|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
75437419|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
75586318|NCT03450239|Other|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
75586319|NCT04992117|Other|NO INTERVENTION|NO INTERVENTION
75731211|NCT00715169|Drug|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
75731212|NCT00715169|Other|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
75731213|NCT00951990|Behavioral|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
75882092|NCT02095574|Drug|[14C]ABT-199 (GDC-0199)|[14C]ABT-199 will be administered as a single oral administration
75731214|NCT00951990|Behavioral|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
75731215|NCT00718991|Device|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
75731216|NCT00947700|Behavioral|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
75731217|NCT02574377|Drug|A: myDC vaccination|
75731218|NCT02574377|Drug|B: pDC vaccination|
76053098|NCT02282813|Drug|Doxercalciferol|At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
76053099|NCT02282813|Drug|Paricalcitol|At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
76053100|NCT01903863|Biological|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
76053101|NCT02123251|Behavioral|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
76053102|NCT04746469|Behavioral|Delayed automated phone call|Cipher provides automated phone calls to patients; in this case the script for Cipher was modified to provide patients a reminder to return FIT kits, allow patients to request a new kit in case they need a replacement, and to allow patients to provide information if they already completed CRC screening
76053103|NCT05638529|Drug|Pregnyl (1,500) IU|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
75437420|NCT01578681|Procedure|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
75731219|NCT02574377|Drug|C: combined myDC/pDC vaccination|
75437421|NCT01578681|Procedure|Stretching|Patient will be instructed to do muscle stretching of the thorax
75437422|NCT01578694|Diagnostic Test|Magnetic Resonance Imaging (MRI)|T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.
75586320|NCT04572425|Other|Guided imagery|10 minutes of guided imagery experience delivered on tablet
75586321|NCT04572425|Other|Virtual reality|10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
75731220|NCT00551616|Drug|CDB-2914|Single dose
75731221|NCT00551616|Drug|Levonorgestrel|Single dose
75731222|NCT00715325|Device|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
75731223|NCT02574221|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
75731224|NCT02574221|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
75437423|NCT01578720|Drug|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
75586322|NCT04565340|Other|Mode of delivery, maternal and neonatal outcomes/complications|Mode of delivery, maternal and neonatal outcomes/complications
75586323|NCT03450200|Other|exercises for diabetic peripheral neuropathy|Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN
75731225|NCT00719147|Procedure|MRI|Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
75731226|NCT00719147|Other|Functional Status and Symptom Questionnaire|Questionnaire
75731227|NCT02572349|Drug|IW-1701|
75731228|NCT02572349|Drug|Matching Placebo|
75731229|NCT00719303|Behavioral|Behavioral Dietary Intervention|Receive dietary intervention
75882093|NCT03555344|Other|Mantra Chikitsa|Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
75882094|NCT05150119|Diagnostic Test|Evaluation of Synovial IL-6 in diabetic patients with gonarthrosis|To evaluate if there is a linear positive correlation between plasma glycated hemoglobin concentration HbA1c and synovial IL-6 in diabetic patients
75882095|NCT02095730|Drug|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
75882096|NCT02095730|Drug|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
75882097|NCT02095730|Device|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
76053104|NCT05638529|Drug|1.5 mL of normal saline|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
75731230|NCT00719303|Behavioral|Compliance Monitoring|Complete daily fat gram and step diaries
75882098|NCT02095730|Device|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
75882099|NCT04781283|Device|measurement of endothelial cell density by specular microscopy|"During this first appointment (T0), in addition to the usual treatment, measurement of the endothelial cell density by specular microscopy will be carried out on the affected eye (basal cell density). To overcome the variability linked to the machine, three consecutive measurements will be taken; the average of the three measurements will be used.~As part of his post-operative follow-up, the patient will be reviewed at one month, one year, two years, three years, four years and five years after the operation. During these consultations and as part of the research, a new determination of the cell density (3 consecutive measurements) by specular microscopy of the operated eye and an evaluation of the position of the XEN implant will be carried out each time. ® by OCT scan for patients having undergone this surgery."
75437424|NCT01578733|Dietary Supplement|protein intake.|•Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
75437425|NCT01578746|Procedure|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
75437426|NCT01578746|Procedure|Anterior approach|The use of anterior approach in total hip arthroplasty
75437427|NCT01578759|Procedure|Salpingectomy|Removal of the fallopian tubes
75586324|NCT03450200|Other|Health education for diabetic foot care|Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
75586325|NCT03450161|Drug|Fentanyl dosing schemes|We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
75731231|NCT00719303|Other|Counseling|Undergo face-to-face and telephone counseling
75731232|NCT00719303|Other|Educational Intervention|Receive educational materials
75731233|NCT00719303|Behavioral|Exercise Intervention|Undergo physical activity intervention
75731234|NCT00719303|Other|Laboratory Biomarker Analysis|Correlative studies
75731235|NCT00719303|Other|Quality-of-Life Assessment|Ancillary studies
75731236|NCT00719303|Other|Questionnaire Administration|Ancillary studies
75882100|NCT05138731|Other|treatments according guidelines|different group intervened with different treatment following guidelines/consensuses accordingly
76053105|NCT01902303|Drug|Matching Placebo|Sublingual micro dosing of placebo for 7 days
75437428|NCT01578811|Drug|Placebo|Dosage
75437429|NCT01578811|Drug|SK-MS10|Dosage
75731237|NCT00452530|Drug|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
75731238|NCT00452530|Drug|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
75731239|NCT00452530|Drug|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
75731240|NCT00452530|Drug|Apixaban-matching placebo|Oral tablet administered twice daily
75731241|NCT00549198|Drug|Abacavir/lamivudine and efavirenz|
76053106|NCT01902303|Drug|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
76053107|NCT02122783|Device|ADR™ brace resistance|
75586326|NCT04996212|Procedure|Walking APP Group|"The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual."
75586327|NCT04996212|Procedure|Functional APP group|"The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment."
75731242|NCT00549198|Drug|Tenofovir/Emtricitabine and efavirenz|
75731243|NCT00607724|Drug|GDC-0449|
75882101|NCT05406284|Procedure|double kissing nano culotte stenting|patients with true coronary bifurcation lesion treating with double kissing nano culotte stunting technique
76053108|NCT02122783|Device|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
75731244|NCT00506415|Drug|Rivastigmine 5 cm^2|5 cm^2 transdermal patch
76053109|NCT04859933|Procedure|AV-node isolation|Abaltion performed in the right atrium isolating the AV-node from the atrium
76053110|NCT04859933|Procedure|AV-node ablation|Right sided ablation of the AV-node
75437430|NCT01578811|Drug|SK-MS10|Dosage
75437431|NCT01578824|Other|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
75882102|NCT01369459|Behavioral|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
75731245|NCT00506415|Drug|Rivastigmine 10 cm^2|10 cm^2 transdermal patch.
75882103|NCT02102438|Drug|Trastuzumab|"Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
76053111|NCT01921257|Drug|Cat-PAD|
75731246|NCT00506415|Drug|Rivastigmine 15 cm^2|15 cm^2 transdermal patch.
75731247|NCT00506415|Drug|Placebo to 15 cm^2 patch|Placebo of rivastigmine transdermal patch 15 cm^2.
75731248|NCT00506415|Drug|Placebo to 10 cm^2 patch|Placebo of rivastigmine transdermal patch 10 cm^2.
75731249|NCT04036526|Biological|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
76053112|NCT01921257|Drug|Placebo|
76053113|NCT02121847|Drug|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
76053114|NCT02121847|Drug|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
75882104|NCT02102438|Drug|Weekly Paclitaxel|Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
76053115|NCT05637593|Behavioral|Upper-limb movement training with the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
75437432|NCT01578837|Dietary Supplement|Ginseng|2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
75437433|NCT01578837|Dietary Supplement|Wheat Bran|2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
75437434|NCT01578863|Other|Intervention program for obese children|The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
75437435|NCT01578876|Device|cardiac shock wave therapy(CSWT)|CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
75731250|NCT04036526|Other|Placebo|Placebo
75731251|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
75731252|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
75731253|NCT04036604|Other|Exercise|"Pelvic floor exercise programme include repetition of pelvic floor muscle contraction during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.~Pelvic floor education programme include pelvic floor anatomy, information about pelvic floor dysfunction and behavioral changes."
75731254|NCT00947778|Other|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
75882105|NCT02102438|Drug|Carboplatin|Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
75882106|NCT05222217|Device|Gatekeeper|Six polyacrylonitrile prostheses (THD Gatekeeper™ Delivery System, THD SpA, Correggio, Italy) were implanted under 3D-EUS control through a 5mm perianal incision at 1, 3, 5, 7, 9 and 11 o'clock in lithotomy position, and located in the upper-middle intersphincteric space of the anal canal, using a specifically designed system.
75882107|NCT04156789|Diagnostic Test|Home sleep apnea testing|Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
75882108|NCT05222061|Device|Drug coated balloon for the side brunch|Intervention is explained in group description
75882109|NCT05222061|Device|Conventional balloon for the side brunch|Intervention is explained in group description
75882110|NCT02098616|Drug|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
75437436|NCT01578889|Biological|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
75437437|NCT01578889|Biological|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
75437438|NCT01578889|Biological|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10^8 plaque-forming units (PFUs) administered as 5x10^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
75586328|NCT03458039|Behavioral|In-person CETA|The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
75731255|NCT00947778|Other|1 training session|20 sessions of 30 minutes by week during 24 semaines
75731256|NCT02572115|Behavioral|Akutknappen - used|A caller chooses to bypass the telephone waiting line by pressing the emergency access button
75731257|NCT02572115|Behavioral|Akutknappen - not used|A caller chooses NOT to bypass the telephone waiting line.
75731258|NCT00893438|Behavioral|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
75731259|NCT00893438|Other|Usual care|Usual care treatment for adolescents with CFS
75731260|NCT00952146|Procedure|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
75731261|NCT00452452|Biological|13-valent Pneumococcal Conjugate Vaccine|
75882111|NCT02098616|Drug|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
75437439|NCT01578889|Biological|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
75731262|NCT01009437|Drug|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
75882112|NCT05108077|Biological|cytokine-induced killer cells|Autologous cytokine-induced killer cells injected intravenously
75882113|NCT05108077|Other|Standard treatment according to the Clinical protocols|Standard treatment of bladder/renal cancer according to the Clinical protocols
75882114|NCT04952805|Drug|MAD0004J08|MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.
75586329|NCT03458039|Behavioral|Telephone CETA|"For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors."
75586330|NCT03458039|Behavioral|Treatment as Usual (TAU)|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
75586331|NCT04565184|Drug|Artesunate-amodiaquine combination|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
75586332|NCT04565184|Drug|Artemether, Lumefantrine Drug Combination|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
75586333|NCT03455192|Drug|Synbiotic Supplement|
75586334|NCT03455192|Drug|Placebo Oral Tablet|
75586335|NCT04565262|Drug|NAs+IFN-α|NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients<2years old, the drug is LAM）combined with IFN-α（when the CHB patients<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
75586336|NCT04564950|Other|Observation of serum and salivary Galectin-3 levels|Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
75586337|NCT03454022|Behavioral|DART|A one-hour long web-based decision-aid program that explains treatment options for end-stage renal disease, including the benefits and risks of each treatment option.
75586338|NCT03454022|Behavioral|Choosing a Treatment for Kidney Failure|This is an educational pamphlet published by the National Kidney Foundation.
75586339|NCT03452579|Drug|Nivolumab|240mg
75586340|NCT03452579|Drug|Standard Dose Bevacizumab|10mg/kg
75586341|NCT03452579|Drug|Low Dose Bevacizumab|3mg/kg
75731263|NCT01009437|Procedure|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
75437440|NCT01578889|Device|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
75437441|NCT01578928|Drug|SOM230|
75437442|NCT01578941|Other|Diary|"Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM."
75437443|NCT01579019|Drug|RO5024048|1500 mg po bid, 24 or 26 weeks
75437444|NCT01579019|Drug|RO5024048|1000 mg po bid, 24 or 26 weeks
75437445|NCT01579019|Drug|danoprevir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
75437446|NCT01579019|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc qw, 24 or 26 weeks
75437447|NCT01579019|Drug|ribavirin [Copegus]|1000 mg or 1200 mg po daily, 24 or 26 weeks
75731264|NCT04322435|Other|Continuous blood glucose measurement|Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
75731265|NCT04322435|Other|Measurement of capillary blood glucose|"Measurement of capillary blood glucose :~In the morning on an empty stomach, every first week of each month for 12 months.~In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips."
75731266|NCT00947934|Device|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
75586342|NCT04565223|Behavioral|Cognitive behavioral therapy for insomnia|is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed
75586343|NCT04997850|Drug|lenvatinib + sindilimab/carrelizumab|4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
75731267|NCT00719381|Drug|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
75731268|NCT00897416|Other|laboratory biomarker analysis|
75731269|NCT01022086|Procedure|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
75882115|NCT04952805|Other|Placebo|Placebo matching to MAD0004J08, 2.5 mL 2R vial. The pharmaceutical form is solution for intramuscular injection.
75882116|NCT01372267|Behavioral|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
76053116|NCT05637593|Behavioral|Upper-limb movement training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
75437448|NCT01579019|Drug|ritonavir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
75437449|NCT01579058|Drug|bisoprolol|bisoprolol 5mg qd for 4 years
75437450|NCT01579058|Drug|placebo|placebo for 4 years
75437451|NCT01579071|Procedure|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
75437452|NCT01579097|Other|Oliclinomel N4|Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated
75437453|NCT01579097|Other|Compounded ternary parenteral nutrition admixtures|Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days
75437454|NCT01579110|Drug|levamisole|"Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months."
75437455|NCT01579110|Drug|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
75586344|NCT04997850|Procedure|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
75586345|NCT03450629|Drug|Brimonidine Tartrate Ophthalmic Suspension|PDP-716
75586346|NCT03450629|Drug|Brimonidine Tartrate Ophthalmic Solution|Three Times Brimonidine Tartrate Ophthalmic Solution
75586347|NCT04565106|Device|Closed-loop control of oxygen supplementation by O2matic|Closed-loop control of oxygen supplementation to achieve a target SpO2 of 92 - 96 %
75586348|NCT04572347|Other|Observational|It is an observational study, and no intervention will be provided.
75882117|NCT01372267|Behavioral|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
75882118|NCT02098694|Other|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
75882119|NCT04134013|Dietary Supplement|Combination: Nutrition AND Chiropractic Adjustment|LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
75882120|NCT04134013|Other|Chiropractic Adjustment: Spinal Manipulation Therapy|LBP chiropractic adjustment per protocol
75882121|NCT02102516|Drug|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing >=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
75882122|NCT04952467|Drug|14C-XEN1101|Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101
75882123|NCT02106182|Drug|Silodosin|
75731270|NCT01022086|Biological|Biomarker Testing|"In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.~Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay."
75882124|NCT02106182|Other|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
76053117|NCT01921179|Behavioral|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
75586349|NCT04997772|Device|Digital Gaucher Platform|Digital platform specified for Gaucher patients.
75586350|NCT03459014|Other|Stimulus rich VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
75586351|NCT03459014|Other|Stimulus poor VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
75586352|NCT03456947|Drug|Pregabalin|the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
75586353|NCT04999527|Drug|DISC-0974|DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
75731271|NCT05673161|Other|iron|iron treatment
75586354|NCT04999527|Drug|Placebo|Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
75586355|NCT04995861|Procedure|Adductor canal block and IPACK block|Peripheral nerve blocks
75586356|NCT03456791|Diagnostic Test|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
75586357|NCT04564638|Drug|Corticosteroid|
75586358|NCT02277431|Dietary Supplement|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:~Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])~Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
75586359|NCT02277431|Dietary Supplement|placebo|
75731272|NCT00897494|Genetic|protein expression analysis|Venous blood collection
75731273|NCT00897494|Other|laboratory biomarker analysis|Venous blood collection
75731274|NCT00897494|Other|mass spectrometry|Venous blood collection
75437456|NCT01579123|Procedure|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
75731275|NCT00897494|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
75437457|NCT01579123|Procedure|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
75437458|NCT01579136|Behavioral|Home blood pressure monitor|The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
75437459|NCT01579149|Drug|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
75586360|NCT02277509|Behavioral|Chinese DPP|"The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~."
75586361|NCT02277509|Behavioral|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
75586362|NCT01580852|Procedure|Dead Sea water|Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
75731276|NCT00952224|Other|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
75731277|NCT00510783|Drug|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
75731278|NCT00510783|Drug|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
75731279|NCT00510783|Drug|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
75731280|NCT02540252|Other|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
75731281|NCT00952302|Drug|Iron sucrose|Single intravenous infusion of iron 200 mg
75731282|NCT00952302|Drug|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
75731283|NCT00952302|Procedure|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
75437460|NCT01579149|Drug|Placebo|Single subcutaneous (SC) dose of placebo
76053118|NCT01921179|Behavioral|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
76053119|NCT01587040|Drug|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
76053120|NCT01587040|Drug|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
76053121|NCT02144701|Dietary Supplement|Lactobacillus rhamnosus GG|Given PO
76053122|NCT02144701|Other|laboratory biomarker analysis was not performed because of no differences in the clinical outcomes|Correlative studies
75586363|NCT01580852|Procedure|Pool water|Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
75437461|NCT01579175|Other|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
75437462|NCT01579188|Drug|GV1001|Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
75437463|NCT01579188|Drug|normal saline|two injections of normal saline injected in the same manner as the experimental drug, GV1001
75586364|NCT04564326|Procedure|Pericapsular nerve Group block|Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
75586365|NCT04564326|Procedure|Facia Iliaca block|Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.
75586366|NCT04564326|Drug|Fentanyl|Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
75586367|NCT03453164|Radiation|Radiotherapy + Nivolumab|Radiotherapy of 22.5 Gy/5 fractions/5 days will be given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1. Nivolumab will be administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) every 2 weeks to a total of 6 courses of administration.
75437464|NCT01579201|Drug|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
75586368|NCT04571307|Procedure|cryotherapy|comparison between cryotherapy and surgery
75586369|NCT03450434|Drug|XC8 Oral Tablet|1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
75586370|NCT03450434|Drug|Placebo Oral Tablet|Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
75586371|NCT04564716|Biological|Gam-COVID-Vac|vaccine for intramuscular injection
75586372|NCT04564716|Other|Placebo|placebo comparator
75586373|NCT00198029|Device|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
75731284|NCT00952302|Drug|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
76053123|NCT05556161|Behavioral|General Practitioners and Diabetes Specialists Co-management|"Self-monitoring of blood glucose: Participants will monitor blood glucose with a a free intelligent home blood glucose meter. Then, the intelligent blood glucose meter will upload data to the platform.~Glycosylated hemoglobin check: Participants will receive HbA1c test once every three months.~Cooperative General Practitioner-Specialist Management: Based on the remote monitoring of blood glucose and HbA1c tests, general practitioners and specialists will jointly carry out management measures including health education, medication adjustment, outpatient consultation, referral, case discussion, etc. for participants."
76053124|NCT01921101|Behavioral|intensive medical nutrition|provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
75731285|NCT00952302|Drug|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
75731286|NCT00897650|Genetic|DNA/RNA sequencing and expression levels|Lung tumor tissue will be collected.
75731287|NCT00897650|Genetic|Protein expression analysis|Lung tumor tissue will be collected.
75731288|NCT00897650|Procedure|Lung tumor biopsy|Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
75731289|NCT00897650|Procedure|Blood sample|Patients will be asked for a venous blood sample
76053125|NCT01921101|Other|control|participants will receive standard care for nutrition received from hospital admission to discharge
76053126|NCT01586806|Drug|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
75437465|NCT01579227|Device|Topical Tocotrienol (TCT)|Natural Form Vitamin E topical cream(TCT)
75437466|NCT01579227|Dietary Supplement|Oral Tocotrienol Capsules (TCT)|Natural Form Vitamin E Oral capsules (TCT)
75437467|NCT01579227|Device|Tamoxifen Cream|Tamoxifen cream
75437468|NCT01579227|Device|Placebo cream|Placebo cream
75437469|NCT01579227|Dietary Supplement|placebo capsule|placebo capsule
75731290|NCT05300646|Behavioral|Prenatal mindfulness-based stress reduction|An adapted mindfulness-based stress reduction (MBSR) program with a particular focus on pregnancy and early motherhood.
75731291|NCT00897728|Other|laboratory biomarker analysis|
75731292|NCT00518973|Drug|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
75882125|NCT02106182|Other|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
75882126|NCT02106182|Other|12 weeks|
75882127|NCT01369693|Procedure|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
76053127|NCT01586806|Drug|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
75437470|NCT01579240|Other|Internet exercise program|12 voluntary weekly visits to website
76053128|NCT01586806|Drug|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
76053129|NCT02144077|Drug|BF-200 ALA|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
76053130|NCT02144077|Drug|methyl-aminolevulinate|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
76053131|NCT05545553|Device|Piezosurgery|Piezosurgery used as an osteotomy device
76053132|NCT05545553|Device|Conventional burs|Conventional burs used as an osteotomy device
76053133|NCT02985892|Other|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
75586374|NCT00197054|Biological|RTS, S/AS01B|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
75586375|NCT00197054|Biological|RTS, S/AS02A|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
75586376|NCT00197054|Biological|Rabipur (Rabies) Vaccine|1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months
75586377|NCT04564131|Other|Reflexology|"Hands are washed.~The individual is provided to be in a comfortable position to lie down or to be in a semi-sitting position.~The toes of the patient are crossed and the patient's feet are placed at our chest level when we sit.~Depending on the size of the foot, a slightly moisturizing amount of non-allergenic petroleum jelly is taken, and it is spread to provide slipperiness.~Exercises to warm and relax the feet for five minutes.~General massage is applied to the whole foot for five minutes.~Reflexology massage is applied to the application areas for neuropathic pain.~The individual is helped to take a comfortable position.~Hands are washed."
75586378|NCT04564131|Other|Control|No intervention was performed to reduce pain in the control group
75437471|NCT01579279|Drug|ABT-652 6 mg|6 mg capsules
75437472|NCT01579279|Drug|ABT-652 12 mg|12 mg capsules
75437473|NCT01579279|Drug|ABT-652 12 mg - 18 mg|12 mg - 18 mg capsules
75437474|NCT01579279|Drug|Placebo|Placebo capsules
75437475|NCT01579279|Drug|Duloxetine|Duloxetine capsules
75437476|NCT01579292|Behavioral|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
75437477|NCT01579292|Behavioral|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
75586379|NCT04998435|Procedure|Erector Spinae Plain Block|"Using aseptic technique, ultrasound-guided ESPB will be performed with the patient in sitting position. The spinous process of the vertebra and a point 3 cm lateral to it will be marked before performing the block. The needle will be inserted and advanced under sono-visualization to contact the transverse process of the vertebra. After negative aspiration, LA will be deposited into the fascial plane deep to erector spinae muscle.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
75437478|NCT01579331|Device|DCT (PASCAL© Tonometer) IOP and OPA measurement|"Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will undergo a series of 5 Dynamic contour tonometries to evaluate eventual differences among measurements.~Patients will be controlled for 30 days. A diurnal IOP curve performed though GAT, composed of 3 measurements (9am, noon, 4pm) will be taken 1 to 7 days before the DCT. At the end of the DCT measurements a last GAT will be taken to control eventual IOP changes versus previous GAT values obtained through the diurnal curve."
75731293|NCT00518973|Drug|Placebo|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
75437479|NCT01579344|Drug|Radioiodine therapy|Radioiodine therapy with NaI131
75731294|NCT05300334|Diagnostic Test|adenosine deaminase test|adenosine deaminase deficiency test
75731295|NCT00897806|Genetic|Microarray analysis|
75731296|NCT00897806|Other|Laboratory biomarker analysis|
76053134|NCT02985892|Other|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
75731297|NCT00958152|Drug|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
75731298|NCT00958152|Drug|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
75731299|NCT00958152|Drug|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
76053135|NCT02172625|Dietary Supplement|Protandim Dietary Supplement|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
76053136|NCT02172625|Other|Placebo Group|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
75731300|NCT00958152|Drug|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
75731301|NCT00897884|Drug|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
76053137|NCT05618171|Diagnostic Test|Evaluation of the patient's pre- and post-treatment risk profile using the peri-implantitis risk diagram|"By using IDRA, a tool specially developed for patients who have had dental implants in our clinic, patients will be evaluated as low-moderate-high risk in terms of the risk of developing peri-implantitis, according to their initial status. Again, these patients will be re-evaluated 1 year after applying Phase I treatment using the IDRA tool. During this whole process, clinical and radiographic evaluations will be carried out simultaneously."
76053138|NCT04410016|Other|Staff Wellbeing Centres|2 Centres (rooms) accessible to staff for rest and relaxation, work breaks, supports advice and signposting. They are manned by support workers called Wellbeing Buddies.
75437480|NCT01579357|Other|blood samples|"Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).~day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min"
75731302|NCT00958230|Device|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
75731303|NCT01022164|Procedure|fibrin glue|
75882128|NCT03554642|Device|Walkbot|Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
75882129|NCT03554642|Behavioral|Physical Therapy|30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
75586380|NCT04998435|Procedure|Paravertebral Block|"Using sterile technique, ultrasound scanning of thoracic paravertebral space will be done in sitting position. The transverse process will be identified as hyperechoic structure while pleura will be identified as a mobile hypoechoic structure. The needle will be inserted cranio-caudal and advanced under sono-visualization to the identified thoracic paravertebral space. After negative aspiration, LA will be deposited displacing the pleura.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
75586381|NCT00197015|Biological|Havrix®|2 doses administered intramuscularly
75586382|NCT00197015|Biological|M-M-R®II|1 dose administered subcutaneously
75586383|NCT00197015|Biological|VARIVAX®|1 dose administered subcutaneously
75437481|NCT01579370|Other|Quaternary ammonium|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
75437482|NCT01579370|Other|Bleach|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
75731304|NCT01012401|Other|CHESS website for lung cancer patient + internet access if needed|The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
75731305|NCT00897962|Other|Healthy Controls|One blood draw (2 teaspoons)
75731306|NCT00897962|Other|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
75731307|NCT00897962|Other|Non-cancer medical illness|One blood draw (2 teaspoons)
75882130|NCT04663503|Other|Exercise program|Depending on the age, there will be two components of the exercise program completed by the patients. The first component will be strengthening exercises. The second component will be endurance activities. This will be administered by the physical therapist
75882131|NCT02102594|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
76024996|NCT03106363|Drug|delta 9 tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
75437483|NCT01579370|Other|Quaternary ammonium and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
76024997|NCT03106363|Drug|placebo delta 9 tetrahydrocannabinol|A single placebo cannabis cigarette (<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
75586384|NCT04564248|Other|Website access|website access will be provide to families
75586385|NCT02215122|Drug|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
75586386|NCT02215122|Drug|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
75586387|NCT02215122|Drug|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
75882132|NCT03124537|Behavioral|App Experimental condition|This group were given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk. They were also asked to respond to two questions twice a day about their mood and energy levels.
76024998|NCT03106363|Drug|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
76024999|NCT03106363|Drug|Placebo alcohol|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
76025000|NCT04413071|Other|Passed infection of SARS-CoV-2|This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.
76053139|NCT05425433|Other|Tailored serial casting intercention|Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
76053140|NCT02985970|Other|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
76053141|NCT02143843|Drug|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
76053142|NCT02121535|Drug|T80/A5 mg FDC tablet|
76053143|NCT02121535|Drug|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
75437484|NCT01579370|Other|Bleach and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
75437485|NCT01579383|Biological|ALD403|Single Dose IV infusion on Day 1
75437486|NCT01579383|Biological|ALD403|Single Dose subcutaneous injection on Day 1
75437487|NCT01579383|Biological|Sumatriptan|Single Dose subcutaneous injection on Day 1
75437488|NCT01579396|Device|septeX|12 h septeX CVVH treatment after cardiac surgery
75437489|NCT01579396|Other|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
75437490|NCT01579409|Other|PNNS guidelines|Application of PNNS guidelines
75437491|NCT01579422|Behavioral|social cognitive training|social cognitive training, 8-10 sessions
75437492|NCT01579435|Device|transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
75586388|NCT00196976|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
76025001|NCT03106519|Drug|Liposome bupivacaine + bupivacaine|
76053144|NCT02121535|Drug|H12.5 mg tablet|
75586389|NCT00196976|Biological|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
76053145|NCT02121535|Drug|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
76053146|NCT02121535|Drug|H12.5 mf tablet|A HCTZ 12.5 mg tablet
75586390|NCT00196976|Biological|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
75586391|NCT00196976|Biological|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
75586392|NCT00196976|Biological|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
75586393|NCT04563936|Drug|LY01005 3.6 mg|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
75586394|NCT04563936|Drug|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
75586395|NCT04572308|Biological|CD7 CAR-T|"Patients will be treated with CD7 CAR-T cells~Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;"
75586396|NCT04563975|Drug|Toripalimab|Toripalimab，240mg，d1，Intravenous Infusion，q3w
75586397|NCT04563975|Drug|Docetaxel|Docetaxel，60-75mg/m2，d8 and d15，Intravenous Infusion，q3w
75731308|NCT05300178|Procedure|coronary artery bypass grafting surgery|Strategies of Complete Arterial Revascularization THE COMPOSITE TECHNIQUE When the distal RIMA bifurcation cannot loosely reach the LAD, we use the RIMA as a free graft, and a T-shaped , or if more suitable, a Y-shaped anastomosis at the level of the main pulmonary artery, is prepared before connection to cardiopulmonary bypass (CPB) THE CROSS TECHNIQUE The cross arrangement is based on the assumption that patency rates of the right internal mammary artery (RIMA) on the left anterior descending coronary artery (LAD) is similar to that of the left internal mammary artery (LIMA) on the LAD. To improve late survival, every effort should be made to use both IMA grafts for the left system THE IN SITU SEQUENCE When a graft to the posterior wall of the heart is not necessary (the circumflex region), the LIMA is grafted to the left anterior descending and the RIMA to the right coronary artery or its posterior de
75731309|NCT01012479|Drug|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
75731310|NCT04317287|Dietary Supplement|Cardio formulation|Tomato-based formulation with dietary supplement softgels
75586398|NCT04563975|Drug|nab-paclitaxel|nab-paclitaxel，125mg/m2，d1 and d 8，Intravenous Infusion，q3w
75731311|NCT04317287|Dietary Supplement|Placebo|Placebo softgels
75731312|NCT02541734|Drug|Gelofusine|Infusion of gelofusine
75731313|NCT02541734|Radiation|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
75586399|NCT00196313|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
75586400|NCT00196313|Drug|Placebo tablet|1 tablet daily by mouth
75586401|NCT04563858|Diagnostic Test|Validation|Assessment of Polish version of the 4AT
75586402|NCT04563819|Genetic|Genom-wide association study (GWAS) and biological pathway analyses|
75586403|NCT04561440|Diagnostic Test|molecular karyotyping|performed by NGS or CMA chip
75586404|NCT04561479|Other|Pulmonary Rehabilitation|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session. Training group will receive upper extremity aerobic exercise training using arm ergometer at 60-80% of maximal heart rate (dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale). Inspiratory muscle training (Powerbreathe® Wellness-Inspiratory Muscle Trainer) at 50-60% of maximal inspiratory pressure (MIP) and progressive resistance training at 30-60% of 1 RM (using proprioceptive neuromuscular facilitation techniques (flexion, abduction, external rotation/extension, adduction, internal rotation) for upper extremity resistance training; using sandback for knee extensors) will be performed during 24 sessions (3 day/week; 8 weeks)
75586405|NCT04561479|Other|Alternative Exercises|Control group will receive alternative upper extremity exercises combined with breathing exercises. Control group will perform alternative upper extremity exercises combined with breathing exercises during 3 days/week, for 8 weeks
75586406|NCT04563663|Procedure|Posteriorization of the talus.|Three sets of a 30-s grade IV anteroposterior mobilization.
75731314|NCT02541734|Drug|Placebo|
75731315|NCT00952458|Device|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
75731316|NCT00898040|Genetic|polymorphism analysis|
75731317|NCT00462670|Drug|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
75437493|NCT01579448|Biological|Shanchol™, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
75586407|NCT00196196|Device|Codman VPV System|Valve Positioning Verification (VPV) System
75586408|NCT02211885|Drug|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
75586409|NCT00195650|Biological|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
75586410|NCT04563780|Device|99mTC pertechnetate thyroid scan|Thyroid scintigraphy was performed just before RIT. 20 min after intravenous injection 99mTc-pertechnetate, anterior images of the neck were acquired using a scintillation camera equipped with low-energy high resolution collimator. Energy discrimination was provided with a 20% window that was centered on the 140 keV peak of 99mTc .
75731318|NCT01009593|Drug|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
76053147|NCT02121535|Drug|T80/A5/H12.5 mg FDC tablet|
75586411|NCT04560894|Drug|SCT-I10A|Participants receive SCT-I10A intravenously，200mg，d1，Q3w
75586412|NCT04560894|Drug|SCT510|Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
75731319|NCT01009593|Drug|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
75731320|NCT00719459|Drug|Iron Sucrose|Venofer 20 mg/mL
75731321|NCT00719459|Drug|Iron Sucrose|Iron sucrose 20 mg/mL
75731322|NCT00898118|Genetic|polymerase chain reaction|
75731323|NCT00898118|Other|flow cytometry|
75437494|NCT01579448|Biological|Shanchol™, killed, whole cell, bivalent, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
75437495|NCT01579448|Other|no intervention|No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
75586413|NCT04560894|Drug|Sorafenib 200mg|Participants receive sorafenib orally，400mg bid
75731324|NCT00898118|Other|laboratory biomarker analysis|
75586414|NCT04571957|Other|No Intervention|No Intervention
76053148|NCT05535959|Drug|VX-121/TEZ/D-IVA|FDC tablet for oral administration.
76053149|NCT01586338|Drug|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
76053150|NCT02143141|Drug|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
75586415|NCT04560465|Drug|Tranexamic acid|intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
75586416|NCT00195494|Drug|Etanercept|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
75586417|NCT00195494|Drug|Methotrexate|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2"
75731325|NCT00898118|Procedure|allogeneic hematopoietic stem cell transplantation|
75731326|NCT00952536|Dietary Supplement|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule
75731327|NCT00952536|Dietary Supplement|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable & fruit & placebo capsule
75437496|NCT01579461|Drug|mirabegron|oral
75731328|NCT00952536|Dietary Supplement|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
75731329|NCT01022320|Procedure|Lateral Pharyngoplasty|surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
76053151|NCT02143141|Drug|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
76053152|NCT04816708|Behavioral|LIFT Mindfulness|Mindfulness is a type of mind-body therapy that promotes a practice of non-judgmental awareness that can alleviate distress by uncoupling emotional reactions and habitual behavior from unpleasant symptoms, thoughts, and emotions. LIFT is a mobile mindfulness app which can assess levels of emotional distress via survey, and subsequently offer mindfulness content that has previously been used in ICU patients, where it was shown to reduce symptoms of depression, anxiety, and PTSD.
76053153|NCT05500469|Device|Paul glaucoma drainage device (GDD)|Implantation of the GDD
75731330|NCT00711503|Drug|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
75731331|NCT00711503|Drug|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
75731332|NCT00948168|Drug|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
75731333|NCT00888212|Procedure|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
75731334|NCT00958386|Drug|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days."
75731335|NCT00711581|Device|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
75882133|NCT03124537|Behavioral|App Condition Control|This group received the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible. They were also asked to respond to two questions twice a day about their mood and energy levels.
75731336|NCT04035512|Other|Expressive writing|"The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004."
75882134|NCT04946877|Diagnostic Test|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III)|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III): is consists of several subtests, each classified into a verbal or performance scale .
76053154|NCT02171065|Device|sham|
75437497|NCT01579487|Device|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
75437498|NCT01579500|Drug|Botulinum toxin type A|Subcutaneous injection of botulinum toxin type A
75437499|NCT01579500|Drug|normal saline|Subcutaneous injection of normal saline
75437500|NCT01579526|Drug|FP01|comparison of different dosages
75586418|NCT00195494|Drug|Placebo|"Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
75586419|NCT02211144|Drug|BIBR 796 BS|
75882135|NCT02102672|Drug|Trimetazidine|
75882136|NCT01369771|Drug|Tafluprost 0.0015%|Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
75882137|NCT03554564|Behavioral|VOICE/Fitbit|During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)
75437501|NCT01579539|Drug|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
75882138|NCT03554564|Other|Daily self-reported exercise adherence|During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
75882139|NCT02106260|Drug|CLS003|
75437502|NCT01579539|Drug|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
75437503|NCT01579591|Other|VSL#3|1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
75437504|NCT01579591|Other|Placebo|1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
75882140|NCT02106338|Other|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
75882141|NCT02106338|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
75882142|NCT04806217|Other|Theory of Mind|Patients will be submitted to different neuropsychological tests used in routine and the non-verbal false belief task through in the Theory of Mind
75882143|NCT02101346|Dietary Supplement|Mixed High Fat Diet|Healthy, Round 1
76053155|NCT02171065|Device|ABSORB BVS|
75586420|NCT02211144|Drug|Placebo|
75586421|NCT00194987|Drug|IVIG (Intravenous Immunoglobulin)|one gram per kg of IVIG per infusion given either once or twice
75586422|NCT00194987|Drug|prednisone|in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
76053156|NCT05036525|Device|HANBIO BarriGel|an anti-adhesive product
76053157|NCT05033561|Biological|nOPV2|Novel Oral Poliomyelitis Type 2 Vaccine
76053158|NCT01566604|Drug|NVA237|Delivered via a single dose dry powder inhaler
76053159|NCT01566604|Drug|Placebo|Delivered via a single dose dry powder inhaler
75437505|NCT01579604|Procedure|Nerve reconstruction|Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
75586423|NCT04560855|Device|Connected devices measurements|The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
75586424|NCT00194792|Drug|exemestane|Given PO
75586425|NCT00194792|Drug|triptorelin pamoate|Given IM
75586426|NCT00194792|Drug|capecitabine|Given PO
75586427|NCT00194792|Drug|methotrexate|Given IV
75586428|NCT00194792|Drug|vinorelbine tartrate|Given IV
75586429|NCT00194792|Drug|paclitaxel|Given IV
75586430|NCT00194792|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
75586431|NCT00194792|Radiation|radiation therapy|Undergo radiation therapy
75586432|NCT00194792|Other|laboratory biomarker analysis|Correlative studies
75586433|NCT02486367|Drug|Clopidogrel|Standard ADP receptor blockade
75586434|NCT02486367|Drug|Ticagrelor|High potency ADP receptor blockade
75882144|NCT02101346|Dietary Supplement|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
75882145|NCT02101346|Dietary Supplement|Monounsaturated fat diet|Healthy, Round 1
75437506|NCT01579617|Behavioral|BUtiful.|8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.
75437507|NCT01579617|Behavioral|DIVAS.|Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
75882146|NCT02101346|Dietary Supplement|Polyunsaturated fat diet|Healthy, Round 1
75437508|NCT01579630|Drug|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
75437509|NCT01579630|Drug|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
75586435|NCT02211183|Procedure|Best Repair of torn Rotator Cuff|
75586436|NCT02211183|Device|InSpace™ system|
75586437|NCT00194675|Drug|Dutasteride|Dutasteride 0.5 mg orally daily
75586438|NCT00194675|Drug|Testosterone gel|Testosterone gel 7.5 g daily topical
75586439|NCT00194675|Drug|Placebo dutasteride|placebo dutasteride orally daily
75586440|NCT04560387|Behavioral|Physician-lead complex program of weight-reducing interventions|A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.
75586441|NCT04560387|Procedure|Bariatric surgery - sleeve gastrectomy|Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
75586442|NCT04560348|Other|adventure-based cognitive behavioral intervention|The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
75586443|NCT00194012|Drug|Aripiprazole|Addressed in arm description.
75586444|NCT00194012|Drug|Placebo|Addressed in arm description.
75882147|NCT02101346|Dietary Supplement|Triolein 13C|Healthy, Round 2
75586445|NCT04563351|Other|local anaesthetic techniques|The patients were anesthetized with two different local anaesthetic techniques.
75586446|NCT00192647|Drug|PEG-IFN alfa-2a|PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
75586447|NCT00192647|Drug|Ribavirin|Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
75586448|NCT04563312|Procedure|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
75586449|NCT00192296|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
75586450|NCT00192296|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
75586451|NCT00192296|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
75882148|NCT02101346|Dietary Supplement|Low fat|Healthy, Round 1
75586452|NCT00192296|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
75586453|NCT04563429|Dietary Supplement|Oral Vitamin A|Oral administration of 5000 EU of Vitamin A during first 28 days of life
75586454|NCT00192023|Drug|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
75586455|NCT00192023|Drug|placebo|
75586456|NCT00192023|Drug|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
75586457|NCT00192023|Drug|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
75586458|NCT04563624|Drug|composite blocks|cad cam composite blocks
75586459|NCT04563624|Drug|ceramic cad cam blocks|ceramic cad cam blocks
75586460|NCT00191984|Drug|pemetrexed|400 mg/m^2, intravenous (IV), every 14 days x 12 cycles
75586461|NCT00191984|Drug|irinotecan|180 mg/m^2, intravenous (IV), every 14 days x 12 cycles
75586462|NCT04560426|Device|Intraoperative parathyroid gland auxiliary recognition system|The enrolled patients are grouped according to whether or not to use the intraoperative parathyroid auxiliary recognition system.
75586463|NCT04560270|Diagnostic Test|Blood samples|Blood samples to determine ctDNA levels during chemotherapy
75882149|NCT04728139|Diagnostic Test|glypican 3|Assessment of glypican 3 presence in colorectal cancer patients using ELISA
75437510|NCT01579643|Procedure|OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)|"The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.~The host cornea bed will be prepared with an excimer laser.~Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed."
75437511|NCT01579643|Procedure|Penetrating Keratoplasty (KP)|"A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.~The donor cornea is then sutured where the patient's cornea was."
75586464|NCT00191906|Drug|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
75586465|NCT00191906|Drug|placebo|Placebo, every day (QD), by mouth (PO)
76025002|NCT05657587|Device|SPRINT PNS|Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
76053160|NCT05497583|Other|Acetone based HEMA -free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. Bioactive composite ( beautifill II ) will be used.
76053161|NCT05497583|Other|Isopropanol based HEMA- free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. resin composite (Neo Spectra™ ST) will be used.
75586466|NCT04562922|Dietary Supplement|Lifemel|
75586467|NCT00191789|Drug|gemcitabine|1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
75586468|NCT00191789|Drug|doxorubicin|60 mg/m^2, IV, every 21 days x 4 cycles (1-4)
75586469|NCT00191789|Drug|cisplatin|70 mg/m^2, IV, every 21 days x 4 cycles (5-8)
75586470|NCT00191789|Procedure|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
75586471|NCT00191282|Drug|Insulin lispro|Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
75586472|NCT00191282|Drug|Human insulin isophane suspension (NPH)|Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values >8.0%
75586473|NCT00191282|Drug|Insulin glargine|Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
75586474|NCT00191282|Drug|Human insulin isophane suspension|Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
75586475|NCT00191282|Drug|Human insulin 30/70|Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values >8.0%.
76025003|NCT02687815|Drug|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
76025004|NCT02687815|Drug|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
75586476|NCT04563156|Diagnostic Test|Lung Function Test|Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
75586477|NCT04559958|Diagnostic Test|tongue image|capture tongue images by Automatic Tongue Diagnosis System
75586478|NCT04559997|Other|Exercise+FU|6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
75586479|NCT04559997|Other|Active Comparator group Exercise|After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
75586480|NCT00191165|Drug|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
75586481|NCT00191165|Drug|Somatropin|In-label dosage
75586482|NCT04560231|Drug|Remdesivir|200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
75437512|NCT01579656|Dietary Supplement|Salba|25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
75586483|NCT04560153|Other|karate kata|sessions of karate kata every week during 4 months
75586484|NCT00190775|Drug|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
75586485|NCT00190775|Drug|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
76053162|NCT01684930|Drug|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
75586486|NCT02211924|Drug|BI 44847|
75586487|NCT02211924|Drug|Placebo|
75586488|NCT00199901|Biological|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
75586489|NCT00199901|Biological|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
75586490|NCT00198263|Combination Product|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
75586491|NCT04562844|Other|sociale cognition|several social cognition test
75586492|NCT00198107|Drug|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
75586493|NCT00198107|Drug|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
75437513|NCT01579656|Dietary Supplement|Poppy|25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
75437514|NCT01579656|Dietary Supplement|Flaxseed|25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
75586494|NCT00198107|Drug|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
75586495|NCT04563000|Drug|Vitamin C|Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
75586496|NCT04563000|Drug|Placebo|0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
75586497|NCT04562961|Other|Schizophrenia caregivers qualitative interview|"The semi-structured qualitative interview will be carried out in a focus group or individually for a period of 1 hour. Focus groups are a group interview technique, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on a limited number of pre-defined questions. In this study we foresee groups of 4 to 5 subjects. Focus groups will be privileged because they allow a better elaboration of the participants and therefore a better collection of data. If the focus group is not possible, the visit will be done individually. This interview will be framework-guided and recorded in their entirety and anonymously using a dictaphone and then transcribed the objective verbatim on a computer using word processing software. These transcriptions will be called the verbatims. The source data recorded using a dictaphone will be stored in secure, locked cabinets located within the investigation center."
75586498|NCT00179660|Drug|Lenalidomide|Capsules for oral administration.
75586499|NCT00178256|Drug|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
75586500|NCT00178256|Procedure|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
75586501|NCT02211222|Drug|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
75586502|NCT04560192|Behavioral|Mindfulness based Emotion regulation therapy (MBERT) - Treatment as usual (TAU)|"In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.~Waiting period with TAU."
75882150|NCT05221671|Other|information leaflet|Leaflets prepared to inform about anesthesia and endoscopic procedure will be given to both parents and pediatric patients. A standard leaflet has been prepared for parents. Two leaflets have been prepared for children under the age of 12 and for adolescent patients over the age of 12. Unlike routine hospital information forms, all leaflets designed and prepared as a cartoon book. It is narrated using photographs of the materials and toys in the endoscopy room. It was predicted that there would be a difference between the groups who read and did not read this information leaflet in terms of anxiety levels and anesthesia knowledge levels.
75586503|NCT04560192|Other|Treatment as usual (TAU) - Mindfulness based Emotion regulation therapy (MBERT)|"Waiting period with TAU.~In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation."
75731337|NCT05352438|Other|Manual Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day."
76053163|NCT01684930|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
76053164|NCT01566214|Behavioral|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
76053165|NCT02253992|Biological|Urelumab|
76053166|NCT02253992|Biological|Nivolumab|
75586504|NCT00177164|Drug|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
75437515|NCT01579656|Dietary Supplement|Sesame|25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
75437516|NCT01579656|Dietary Supplement|Wheat Bran|Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
75586505|NCT04559841|Other|bone substitute; NanoBone®|surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
76053167|NCT02252588|Drug|Chlorhexidine|Oral Rinse
76053168|NCT02252588|Other|Placebo|Oral Rinse
76053169|NCT05153018|Other|Blood collection|a 4-mL blood sample collected in a dry tube
76053170|NCT01585558|Drug|Ospemifene (Dose 1)|
76053171|NCT01585558|Drug|Ospemifene (Dose 2)|
76053172|NCT01585558|Drug|Placebo|
76053173|NCT01565980|Behavioral|symptom assessment|attention control receives a weekly symptom assessment phone interview for 6 weeks.
75437517|NCT01579682|Behavioral|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
75437518|NCT01579682|Behavioral|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
75437519|NCT01579695|Drug|Tesamorelin for injection|Daily 2 mg subcutaneous injections of Tesamorelin
75437520|NCT01579708|Behavioral|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
75437521|NCT01579721|Procedure|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
76053174|NCT01565980|Behavioral|Mindfulness Intervention|Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
76053175|NCT01585246|Drug|Saw Palmetto|1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
76053176|NCT01585246|Drug|soybean oil soft gel|placebo (soybean oil soft gel)
76053177|NCT01585168|Drug|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
76053178|NCT01585168|Drug|Placebo|Identically appearing sugar pill, given orally
76053179|NCT02232074|Other|Patient navigation enhanced with legal support|
76053180|NCT02142283|Device|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
75437522|NCT01579760|Drug|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
76053181|NCT02142283|Other|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
75586506|NCT02487251|Behavioral|Mealtime Supports|Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.
75586507|NCT02487251|Behavioral|Usual Exposure|Participants receive no supplemental information on family mealtimes beyond what is already currently received
75586508|NCT02489942|Drug|Jardiance|Empagliflozin
76053182|NCT02231918|Drug|MIRAPEX® - low|
76053183|NCT02231918|Drug|MIRAPEX® - medium|
76053184|NCT02231918|Drug|MIRAPEX® - high|
76053185|NCT02199314|Drug|Desflurane|
75437523|NCT01579760|Drug|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
76053186|NCT02251652|Drug|Ingenol Mebutate|Ingenol mebutate 0.05% gel
76053187|NCT02251652|Procedure|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
76053188|NCT02197520|Drug|Insulin Peglispro|Administered subcutaneously (SC), (U-100 formulation)
76053189|NCT02197520|Drug|Insulin Glargine|Administered subcutaneously (SC), (U-100 formulation)
76053190|NCT02197520|Drug|Insulin Lispro|Administered subcutaneously (SC), (U-100 formulation)
75437524|NCT01579786|Procedure|Acetaminophen and acupuncture|All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
75437525|NCT01579799|Drug|L-lysine|Dose finding study for L-lysine
75437526|NCT01579825|Other|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
76053191|NCT04772534|Biological|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
76053192|NCT02230904|Drug|Rotigotine (Test product PR 2.3.1)|"Pharmaceutical form: Transdermal patch~Concentration: 8 mg/24 hours~Route of administration: Transdermal"
76053193|NCT02230904|Drug|Rotigotine (Reference product PR 2.1.1)|"Pharmaceutical form: Transdermal patch~Concentration: 8 mg/24 hours~Route of administration: Transdermal"
76053194|NCT02230670|Drug|IDN-6556|25 mg BID
76053195|NCT02230670|Drug|Placebo|
76053196|NCT02197130|Drug|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
75586509|NCT04562493|Procedure|Transforaminal Epidural injection|Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
75586510|NCT04562571|Other|Charter & patient information leaflets|Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
75731338|NCT05352438|Other|Splint Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month."
75731339|NCT04069871|Device|trans-cutaneous electrical nerve stimulation.|• Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
75731340|NCT04069871|Device|Sham TENS|Patients in the control group will receive sham TENS.
75731341|NCT04035746|Other|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
75731342|NCT00948324|Drug|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
75731343|NCT01012635|Other|Hypnosis|Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
75437527|NCT01579838|Drug|Eculizumab|PNH and or atypical TTP classical protocols
75437528|NCT01579864|Drug|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
75437529|NCT01579864|Drug|rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
75731344|NCT01012635|Other|Meditation|"Meditation: focus on a single word (one) for the entire session."
75731345|NCT01012635|Other|Neurofeedback training|Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
75586511|NCT04559568|Drug|LY3522348|Administered orally.
75586512|NCT04559568|Drug|Placebo|Administered orally.
75586513|NCT04559568|Drug|Midazolam|Administered orally to some participants.
75586514|NCT02211300|Device|The OptiScanner|treatment of blood glucose per standard of care
75731346|NCT01012635|Other|Two different levels of tDCS|Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
75731347|NCT04068701|Other|MaNMT Biofeedback|neuromuscular training intervention that incorporates biofeedback training
75731348|NCT05352360|Diagnostic Test|Pilates Exercises|Exercises with Kinesio Taping
75731349|NCT05352360|Diagnostic Test|Muscle Energy Technique|Exercises with Kinesio Taping
76053197|NCT02197130|Drug|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
75731350|NCT02573285|Procedure|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
75731351|NCT02573285|Procedure|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
75731352|NCT01009671|Drug|ART 44|
75437530|NCT01579877|Dietary Supplement|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
75437531|NCT01579877|Dietary Supplement|Placebo herbal extract granule|The Yukmijihwang-tang_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
75437532|NCT01579890|Drug|Diclofenac|diclofenac topical lotion
75437533|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
75437534|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
75586515|NCT02211300|Device|YSI 2300 STAT Plus™|
75731353|NCT01009671|Drug|ART 50|
75731354|NCT04199988|Diagnostic Test|Posterior Shoulder Endurance Test|"Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded."
75731355|NCT01009749|Behavioral|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
76053198|NCT02197130|Other|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
75437535|NCT01579929|Drug|LDE225, Etoposide and Cisplatin|In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
75437536|NCT01579955|Drug|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
75437537|NCT01579968|Drug|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
75437538|NCT01579981|Procedure|Roux-en-Y Gastric Bypass|On two separate experimental days before, 1 wk, and 3 months after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized. At end of study day an ad libitum meal is served.
75437539|NCT01579994|Drug|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
75437540|NCT01580124|Procedure|PVI alone|PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation
75437541|NCT01580124|Procedure|PVI + Defragmentation + linear lesions|PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
75586516|NCT02211339|Behavioral|Peer facilitator training|Peer facilitation of a project-based activity without staff present
75731356|NCT01009749|Behavioral|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
75437542|NCT01580150|Other|Berries|Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
75437543|NCT01580150|Other|No berries|Meals containing starch (bread) or sucrose are consumed without berries.
75731357|NCT00719693|Drug|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
75731358|NCT00719693|Drug|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
75731359|NCT00952770|Procedure|transradial coronary intervention|percutaneous coronary intervention with transradial approach
76053199|NCT02196506|Drug|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
76053200|NCT02196506|Drug|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
76053201|NCT02228720|Device|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
75437544|NCT01580228|Drug|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m^2 on Day 1, 10 mg/m^2 on Day 8, and 14 mg/m^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
75437545|NCT01580228|Drug|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
75586517|NCT02211339|Other|Usual care|Staff-led social activity
75586518|NCT00176462|Drug|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75586519|NCT00176462|Drug|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75586520|NCT00176462|Drug|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75437546|NCT01580280|Other|Thrust Manipulation|Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
75437547|NCT01580280|Other|Non-thrust Mobilization and Exercise|Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
75586521|NCT00176462|Drug|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75586522|NCT00176462|Drug|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75586523|NCT00176462|Drug|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75586524|NCT00176462|Drug|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75731360|NCT01009827|Other|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
75731361|NCT00719771|Device|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
75731362|NCT00948402|Drug|Metformin|metformin 1250 mg three times daily
75731363|NCT00948402|Drug|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
75731364|NCT04068467|Other|Smartphone App|The application consists of content areas focused on mental health.
75437548|NCT01580475|Other|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
75437549|NCT01580735|Drug|ARQ 197|"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd"
75586525|NCT00176462|Drug|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75586526|NCT00176462|Drug|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75586527|NCT00176462|Drug|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
75586528|NCT00176462|Drug|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
75586529|NCT00176462|Drug|Leucovorin|
75731365|NCT04068467|Other|Waitlist Control|Waitlist control
75437550|NCT01580787|Device|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
75437551|NCT01580787|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
75437552|NCT01581034|Drug|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
75731366|NCT05352126|Other|Biocide|The product being researched, which is a biocide solution in a spray for atmospheric use without a propellant, will be sprayed in the bedroom of each patient at a rate of 2 sprays per day in the evening (half an hour before going to bed).
75437553|NCT01581034|Drug|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
75437554|NCT01581333|Drug|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
75437555|NCT01581333|Drug|Standard empirical antimicrobial treatment discontinuation|"The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3."
75437556|NCT01581359|Drug|Triptorelin acetate|"Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses~Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses"
75586530|NCT04559295|Biological|Bone Marrow Concentrate|The intradiscal delivery of bone marrow concentrate (BMC) into discs, facet , epidural space, and sacroiliac joints
75731367|NCT00719927|Behavioral|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
75731368|NCT00948480|Biological|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
75882151|NCT05221515|Behavioral|Anger can go!|"The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation."
75882152|NCT05221515|Behavioral|Parent psycho-education|Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
75882153|NCT01369927|Biological|Shigella Sonnei O-SPC/rBRU|
75437557|NCT01581476|Drug|Statin|10mg daily for a minimum period of 2 years
75437558|NCT01581476|Drug|ACE inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
75437559|NCT01581476|Drug|Placebo|Participants receive statin placebo and ACEI placebo
75731369|NCT00948480|Drug|GM-CSF|500 mcg
75731370|NCT05351970|Procedure|Barbed|Efficacy of barbed and monofilament closure regarding incisional hernia
75731371|NCT05351814|Other|Exercise|While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
75437560|NCT01581476|Drug|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
75437561|NCT01581502|Other|This is an observational study.|This is an observational, not intervention, study.
75437562|NCT01581749|Radiation|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
75586531|NCT02211378|Other|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
75586532|NCT02211378|Other|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
75731372|NCT03753555|Drug|Atorvastatin Calcium|20mg Qd for 12 months
75731373|NCT03753555|Drug|Atorvastatin Calcium|40-80mg Qd for 6 months
75731374|NCT03753555|Drug|Probucol|0.5g Bid for 6 months
75731375|NCT03753555|Drug|PCSK9 inhibitor|Evolocumab 140mg subcutaneously injected, twice each month
75731376|NCT00606086|Drug|GI-5005|40YU, subcutaneous
75586533|NCT00175019|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
75731377|NCT00606086|Drug|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
75586534|NCT00175019|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
75731378|NCT02573363|Drug|Cytarabine|Given per standard of care
75731379|NCT02573363|Drug|Mitoxantrone Hydrochloride|Given per standard of care
75882154|NCT02101502|Other|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
75882155|NCT02101580|Drug|ADI-PEG 20|
75882156|NCT05648019|Biological|Anti-CD19 CAR T-cells|A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
75882157|NCT02106416|Procedure|PET/MRI|Simultaneous PET/MRI (3T system)
75437563|NCT01581762|Procedure|EUS-guided FNA|EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
75437564|NCT01581892|Procedure|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
75437565|NCT01581905|Procedure|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
75586535|NCT00175019|Drug|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
75882158|NCT05365087|Procedure|Transoral Fundoplication and Sleeve Gastrectomy|Transoral Fundoplication procedure completed prior to Sleeve Gastrectomy
75437566|NCT01581905|Procedure|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
75437567|NCT01581957|Other|Specific Enteral Nutrition|Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
75437568|NCT01581957|Other|Standard Enteral Nutrition|Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
75437569|NCT01582321|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
75437570|NCT01582321|Drug|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
75586536|NCT04559763|Device|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
75586537|NCT04559763|Other|Introduction of Motion conditions: tapping or rubbing|Standard motions include tapping or rubbing at periodic intervals with amplitudes of 1-2 cm and 1-4 Hz with a random variation in frequency will occur at each plateau. Each plateau will have both an interval of tapping and rubbing. Signals are recorded by a validated, computerized data acquisition system (CAS). The device values are sampled once per second and averaged over the time taken to draw the blood sample, taking into account circulation time delays and differences in device response times
75586538|NCT00174941|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
75586539|NCT00174941|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
75882159|NCT05365087|Procedure|Gastric Bypass|Laparoscopic Roux-en-Y gastric bypass
75882160|NCT01372345|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
75882161|NCT04249323|Drug|CORT113176 Lipid Capsule Formulation|CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
75731380|NCT02573363|Drug|Selinexor|Given PO
75731381|NCT03727113|Procedure|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
75731382|NCT03727113|Procedure|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
75731383|NCT00715637|Drug|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
75882162|NCT04249323|Drug|Placebo matching CORT113176 Lipid Capsule Formulation|Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
75882163|NCT04249323|Drug|Prednisone|Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
75586540|NCT00174941|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
75586541|NCT04558944|Device|Extracorporal Shock Wave Therapy|Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
75586542|NCT04562727|Drug|Chemotherapy|perioperative chemotherapy or postoperative chemotherapy
75586543|NCT00171704|Drug|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
75586544|NCT00171704|Drug|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
75586545|NCT04559061|Device|Cardiac ablation procedure|Retrospective data will be collected from cases where successful ablation was completed.
75586546|NCT02211963|Drug|BI 44847|
75586547|NCT02211963|Drug|Placebo|
75586548|NCT00171314|Drug|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
75586549|NCT00171314|Drug|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
75882164|NCT02102750|Drug|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
75882165|NCT01372735|Radiation|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
75586550|NCT04562259|Radiation|Verification of Kimmerle's anomaly by x-ray methods of research|In patients with Kimmerle's anomaly, using computed tomography of the brain with the capture of the upper cervical spine and cervical spine, it is planned to determine at what age this pathology is more common, localization of the anomaly (right, left), complete or incomplete form of the anomaly.
75731384|NCT00715637|Drug|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
75731385|NCT01012791|Other|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
75586551|NCT04571918|Procedure|Biodegradable spacer|Implantation of a biodegradable balloon used as a subacromial spacer.
75882166|NCT01372735|Radiation|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
75882167|NCT04227327|Drug|Abemaciclib|Abemaciclib will be administered orally at 150 mg twice daily
75586552|NCT04571918|Procedure|Debridement and biceps tenotomy|Surgery with arthroscopic debridement and biceps tenotomy
75586553|NCT04562454|Other|Specific diet|use a specific diet in different days with CGM to konw GI of different food in diabetes
75586554|NCT04562337|Drug|SHR1316|Anti-PD-L1 antibody
75586555|NCT04562337|Drug|Chemotherapy|Carboplatin
75586556|NCT04562337|Drug|Chemotherapy|etoposide
75731386|NCT00953004|Dietary Supplement|fiber drink and fiber bread|fiber drink or fiber bread three times daily
75882168|NCT04227327|Drug|Aromatase Inhibitors|Letrozole 2,5 mg daily or Anastrozole 1 mg daily
75882169|NCT02102828|Device|extended compression|Home use of extended compression therapy and aspirin
75882170|NCT02102828|Other|Aspirin|standard therapy of aspirin
75882171|NCT05228119|Biological|Oncolytic Virus Injection(RT-01)|Intravenous injection with or without intratumoral injection of a single dose of RT-01 and intravenous infusion of Nivolumab
75882172|NCT02101658|Other|clinic-based weight measurements|
75882173|NCT01372423|Drug|Lubiprostone|24 mcg capsules
75882174|NCT01372423|Drug|Placebo|24 mcg capsules
75882175|NCT02102906|Procedure|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
75586557|NCT04562337|Radiation|Radiation therapy|thoracic radiation therapy ,TRT
75586558|NCT00171158|Drug|imatinib mesylate|
75586559|NCT04562415|Device|Active Repetitive Transcranial Magnetic Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and inhibitor rTMS was applied with a frequency of 1 Hz consisting of 1200 pulses for 20 minutes. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
75586560|NCT04562415|Device|Active Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
75586561|NCT04562415|Device|Sham Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and sham cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
75586562|NCT00170846|Drug|Everolimus (RAD001)|
75586563|NCT00170846|Drug|Calcineurin Inhibitors (CNI)|
75586564|NCT00170846|Drug|Mycophenolate acid (MPA)/Azathioprine (AZA)|
75586565|NCT00170846|Drug|Steroids|
75882176|NCT02102984|Device|covered biliary stents|endoscopic placement of covered biliary stents
75882177|NCT02102984|Device|uncovered biliary stents|endoscopic placement of uncovered biliary stents
75882178|NCT02101814|Procedure|Roux-en-Y gastric bypass (bariatric surgery)|
75882179|NCT01375933|Biological|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
75882180|NCT02106650|Drug|Folotyn and Leucovorin|
75731387|NCT00953316|Other|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
75731388|NCT00898274|Other|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
75731389|NCT00898274|Other|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
75882181|NCT02106650|Drug|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
75882182|NCT02106650|Drug|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
75882183|NCT05221437|Other|antibiotic prescription|
75882184|NCT01376011|Dietary Supplement|quercetin/placebo|Quercetin 500mg once per day versus placebo
75882185|NCT02106806|Dietary Supplement|Zinc|35 mg of elemental zinc twice daily for 16 weeks
75882186|NCT02106806|Other|Placebo|One capsule, twice daily for 16 weeks
75882187|NCT02966119|Drug|Clopidogrel or Aspirin and/or Dypyridamole|"The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart"
76025005|NCT05742451|Other|kids yoga|"The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.~Kids yoga training included: 5-minute warm-up consisting of jogging, jumping, stretching, relaxation exercises; 20 minutes of asanas (positions) consisting of standing, sitting, prone, supine postures and pranayamas (breathing exercises) consisting of vigorous inspiration and expiration, slow and rhythmic alternating nostril breathing; 10-minute yogic games about balance, reaction time and agility; meditation with focus for 5 minutes with resuscitation techniques."
75437571|NCT01582438|Drug|Access program - sildenafil citrate, Viagra, Revatio|The recommended dose is 20 mg TID for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight. If a subject was receiving a higher dose in study A1481156 and the investigator believes that the subject requires continued treatment on that dose, or if dose reduction is judged to be associated with pulmonary arterial hypertension (PAH) deterioration in a particular subject, the higher dose may be made available, as judged on an individual basis on discussion with the sponsor.
75437572|NCT01582711|Behavioral|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
75437573|NCT01582711|Behavioral|SMS reminders|Short Message Service (SMS) text reminders
75437574|NCT01582711|Drug|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
75586566|NCT04562025|Drug|UC-MSCs|3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).
75586567|NCT04562025|Drug|Placebo|3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
75586568|NCT04562142|Device|CAD-det|CAD-det test will be done on participants with suspected CAD clinically referred for ICA at a participating clinical investigation site.
75586569|NCT00476606|Drug|Zidovudine, Stavudine, Didanosine, Lamivudine|Refer to the Thai guideline for HIV management 2007
75586570|NCT00476606|Drug|Nevirapine, Efavirenz|Refer to the Thai guideline for HIV management 2007
75586571|NCT00476606|Drug|LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir|Refer to the Thai guideline for HIV management 2007
75586572|NCT04562103|Drug|Epinephrine / Ropivacaine|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
75882188|NCT05707299|Procedure|Intradermal acupuncture|"Procedure/Surgery: Bilateral Fengchi（GB20）and Qiuxu（GB40） will be stimulated. According to the position of the acupoints, the needle of φ0.20*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of resting- stimulating-preparing-stimulating-resting to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi（GB20） for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu（GB40） for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level."
75882189|NCT02103296|Procedure|Drawing admission labs from cord blood|
75882190|NCT02103296|Procedure|Drawing admission labs from infant blood|
75437575|NCT01583062|Drug|Amoxicillin/clavulanic acid|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
75437576|NCT01583062|Drug|Amoxicillin plus placebo|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
75437577|NCT01583075|Procedure|Circumferential pulmonary vein ablation|Circumferential pulmonary vein ablation
75437578|NCT01583075|Procedure|single ring pulmonary vein ablation|single ring pulmonary vein ablation
75437579|NCT01583088|Device|phenique nerve stimulation NeurX™ (Synapse Biomedical)|phenique nerve stimulation NeurX™ (Synapse Biomedical)
75437580|NCT01583088|Device|sham phrenic nerve stimulation|sham phenic nerve stimulation
75437581|NCT01583309|Procedure|online pre-dilution hemofiltration|Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one
75437582|NCT01583309|Procedure|online pre-dilution hemodiafiltration|Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
75437583|NCT01583335|Behavioral|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
75437584|NCT01583400|Other|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
75437585|NCT01583400|Other|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
75586573|NCT04562103|Drug|Ropivacaine|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
75437586|NCT01583426|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
75586574|NCT02278380|Other|Low GI Standard Breakfast|Low GI Standard Breakfast
75586575|NCT02278380|Other|Medium GI Standard Breakfast|Medium GI Standard Breakfast
75586576|NCT02278380|Other|Enfamama A+|Nutritional pregnant milk supplement
75586577|NCT02278380|Other|Glucerna Triple Care|Nutritional product for diabetics
75586578|NCT02278380|Other|Dumex Precima|Pregnant and lactation women milk powder
75586579|NCT02278380|Other|Diasip|Nutritional drinks for diabetics
75586580|NCT02278380|Other|Test product|Test product not patented yet
76053202|NCT02228564|Procedure|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
75731390|NCT02541656|Procedure|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
75731391|NCT00898352|Procedure|regional lymph node dissection|
75731392|NCT00898352|Radiation|radiation therapy|
75731393|NCT05300490|Drug|Prednisolone|In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
75731394|NCT00720005|Device|Aspheric Acrysof ReSTOR intraocular lens|Bilateral implantation of Aspheric Acrysof ReSTOR
75882191|NCT02956759|Procedure|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
75731395|NCT00898430|Genetic|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
75731396|NCT00898430|Genetic|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
75731397|NCT00898430|Genetic|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
75731398|NCT00893594|Drug|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
75731399|NCT00893594|Drug|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
75731400|NCT00715715|Drug|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
75731401|NCT00953394|Drug|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
75882192|NCT02101892|Drug|Amitriptyline|per os, daily, evening
75731402|NCT00720161|Drug|Metformin|daily 850 mg
75731403|NCT00720161|Drug|placebo|placebo
75731404|NCT00888368|Procedure|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
75882193|NCT02101892|Drug|placebo|per os, daily, evening
75882194|NCT03634111|Procedure|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
76053203|NCT02228564|Device|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
76053204|NCT01640951|Drug|AIN457 150 mg|(1 injection per dose) and placebo to Secukinumab 150 mg
76053205|NCT01640951|Drug|AIN457 300 mg|Secukinumab 150 mg (2 injections per dose)
76053206|NCT01640951|Drug|Placebo|
76053207|NCT02228096|Biological|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg).
75586581|NCT04561635|Dietary Supplement|Multiple-micronutrients supplement|Multiple-micronutrients supplement with 15 micronutrients
75586582|NCT04561674|Other|Implementation of web-based patient education|Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
75586583|NCT04558671|Other|asthma exacerbations|to collect the number of asthma exacerbations between the 2 latent classes of patients within the year following bronchoscopy
75586584|NCT00479882|Drug|Comparator: simvastatin|
75731405|NCT00888368|Procedure|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
76053208|NCT01640873|Drug|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
75731406|NCT04068077|Device|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
75731407|NCT04010916|Other|Group Preoperatively Adductor Canal Block|The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
75882195|NCT03634111|Drug|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
75882196|NCT03634111|Drug|Ropivacaine|Ropivacaine 0.25% 20 ml each side
75882197|NCT02102048|Drug|Atazanavir|
75882198|NCT02102126|Procedure|Renal denervation|
75882199|NCT03118297|Drug|Ulipristal Acetate|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
75882200|NCT03118297|Drug|Placebo oral capsule|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
75437587|NCT01583426|Drug|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
75437588|NCT01583517|Procedure|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
75437589|NCT01583517|Procedure|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
75437590|NCT01583517|Procedure|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
75437591|NCT01583712|Procedure|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
75437592|NCT01583712|Device|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
75437593|NCT01583972|Dietary Supplement|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
75586585|NCT00479882|Drug|MK-0524A|Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
75586586|NCT00479882|Drug|Placebo|
75586587|NCT00479882|Drug|MK-0524B|
75586588|NCT00479765|Drug|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
75586589|NCT04558242|Device|Genix|Low Level Light (LEDs)
75586590|NCT04558242|Device|Sham|Incandescent Bulbs Colored Red
75586591|NCT00479687|Device|SUPARTZ®|Three Supartz injections over 2 weeks into the glenohumeral joint space.
75586592|NCT00479687|Device|Phosphate Buffered Saline|Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
75586593|NCT02212002|Drug|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
75586594|NCT02212080|Drug|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
75586595|NCT02212080|Drug|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
75586596|NCT00479336|Drug|OPC-41061 7.5mg|7.5mg, 1 tablet a day
75586597|NCT00479336|Drug|OPC-41061 placebo|placebo, 1 tablet a day
75586598|NCT00479336|Drug|OPC-41061 15mg|15mg, 1 tablet a day
75586599|NCT00479336|Drug|OPC-41601 30mg|30mg, 1 tablet a day
75586600|NCT02212158|Behavioral|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
75586601|NCT00478244|Drug|busulfan|Day -9 through Day -6: 1.1 mg/kg if < 12 kg IV every 6 hours; 0.8 mg/kg if > 12 kg.
75586602|NCT00478244|Drug|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
75586603|NCT00478244|Drug|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
75731408|NCT04010916|Other|Group Preoperatively Tourniquet Adductor Canal Block|The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
75731409|NCT04010916|Other|Group Postoperatively Adductor Canal Block|The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
75731410|NCT00948714|Behavioral|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
75731411|NCT00948714|Behavioral|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
75437594|NCT01583972|Dietary Supplement|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
75437595|NCT01584245|Other|Amino Acid formula|
75437596|NCT01584336|Procedure|LATG|"After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy~The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).~The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.~After then, the operator performs the jejunojejunostomy."
75731412|NCT00948714|Other|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
75731413|NCT00898508|Genetic|gene expression analysis|
75437597|NCT01584362|Drug|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
75437598|NCT01584362|Drug|placebo|single oral dose of placebo
75586604|NCT00478244|Procedure|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
75586605|NCT02212236|Other|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
75586606|NCT04558437|Other|Questionnaire|"Questionnaire at M0 M3 M6:~PCL-5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) HAD (Hospital Anxiety and Depression Scale) SDS (Sheehan Disability Scales)"
75586607|NCT00478205|Drug|Aricept (donepezil SR 23 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."
75586608|NCT00478205|Drug|Aricept (donepezil IR 10 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."
75586609|NCT00477971|Biological|filgrastim|No administration information given
75586610|NCT00477971|Drug|dexamethasone|Given orally
75586611|NCT00477971|Drug|melphalan|Given IV or orally
75586612|NCT00477971|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
75586613|NCT04558086|Device|Virtual reality|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
75586614|NCT04558086|Device|Photo book|To develop the intervention strategies of hospitalized school-age children with IV placement, using Photo book to further examine the effectiveness of reducing IV pain and fear.
75731414|NCT00898508|Genetic|mutation analysis|
75731415|NCT00898508|Genetic|proteomic profiling|
75731416|NCT00898508|Genetic|reverse transcriptase-polymerase chain reaction|
75437599|NCT01584362|Drug|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
75437600|NCT01584362|Drug|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
75586615|NCT00477464|Drug|Lapatinib|1250mg once daily
75437601|NCT01584362|Drug|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
75437602|NCT01584362|Drug|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
75437603|NCT01584362|Drug|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
75437604|NCT01579851|Drug|Sugammadex|"sugammadex~4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~2 mg/kg : if there is at least two responses to Train of Four stimulations"
75437605|NCT01584453|Drug|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
75586616|NCT00477464|Drug|capecitabine|2000mg/m^2 twice daily (14 days out of 21 days)
75586617|NCT02212275|Drug|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
75586618|NCT04558008|Behavioral|Online MBSR|Described previously
75731417|NCT00898508|Other|fluorescent antibody technique|
75731418|NCT00898508|Other|immunohistochemistry staining method|
75731419|NCT00898508|Other|laboratory biomarker analysis|
75731420|NCT00898508|Other|liquid chromatography|
75731421|NCT00898508|Other|mass spectrometry|
75731422|NCT00898508|Other|medical chart review|
75731423|NCT00898508|Procedure|quality-of-life assessment|
75731424|NCT00711893|Device|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
75731425|NCT00720239|Other|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
75437606|NCT01584453|Drug|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
75437607|NCT01584713|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
75437608|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
75437609|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|"30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding."
75437610|NCT01584921|Drug|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
75437611|NCT01585493|Other|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
75437612|NCT01585493|Behavioral|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
75731426|NCT00609986|Drug|insulin|"The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140."
75586619|NCT04557774|Other|Cognitive function test|"Laboratory and imaging test~Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.~Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers~Neuropsychological test~-Attention, Language, Visuospatial, Memory, Frontal/executive"
75586620|NCT00477386|Drug|decitabine|"Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."
75586621|NCT02212314|Behavioral|Response Inhibition Training|Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
75882201|NCT02250794|Drug|metformin and sitagliptin|metformin 750 mg PO twice daily
75882202|NCT02250794|Drug|insulin glargine and insulin lispro|insulin glargine given once daily
75882203|NCT02250794|Drug|metformin and sitagliptin|sitagliptin 100 mg PO once daily
75882204|NCT02250794|Drug|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
75882205|NCT02103374|Drug|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
75882206|NCT02103374|Drug|Placebo|1 capsule lactose during 48 weeks
75882207|NCT01374061|Device|Classical intubation|Classical intubation
75882208|NCT01374061|Device|GLIDESCOPE|GLIDESCOPE intubation
75586622|NCT00477269|Drug|Imatinib mesylate|
75586623|NCT00477269|Drug|Placebo|
75586624|NCT04557852|Procedure|ATVM|Tailored anterior transvaginal mesh for pelvic organ prolapse
75586625|NCT00477152|Drug|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
75586626|NCT04557345|Diagnostic Test|Determination of cytokines|Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
75586627|NCT04557345|Diagnostic Test|Two-dimensional transthoracic echocardiogram|With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
75586628|NCT04557657|Drug|Active bio Activa|Cement that release fluoride
75586629|NCT04557657|Drug|Resin Cement|Resin Cement Convinonal
75586630|NCT00476996|Drug|Leflunomide|Oral repeating dose
75586631|NCT00476996|Drug|Methotrexate|Oral or parenteral repeating dose
75586632|NCT00476996|Drug|Ocrelizumab|Intravenous repeating dose (200mg)
75586633|NCT00476996|Drug|Ocrelizumab|Intravenous repeating dose (500mg)
75586634|NCT00476996|Drug|Placebo|Intravenous repeating dose
75586635|NCT04557267|Drug|low-dose|Dosage 1
75882209|NCT05658783|Other|Hot water foot bath|Keeping keep in 42oC (42 Degrees Celsius) hot water for 20 minutes
75882210|NCT02103452|Procedure|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin &amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
75882211|NCT03967587|Device|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
75882212|NCT02250950|Behavioral|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
75882213|NCT02250950|Behavioral|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
75882214|NCT05707221|Other|cleaning removable acrylic appliance with denture brush and chlorhexidine toothpaste|mechanical cleaning of removable appliance by the patient for 7 days before bedtime for one minute
75586636|NCT04557267|Drug|Middle-dose|Dosage 2
75882215|NCT05707221|Other|cleaning removable acrylic appliance with cleansing tablet|chemical cleaning by patient for 7 days with cleansing tablet
75586637|NCT04557267|Drug|Higher-dose|Dosage 3
75586638|NCT04557267|Drug|Placebo|Placebo
75586639|NCT04557579|Procedure|Clear corneal phacoemulsification and IOL implantation|Clear corneal phacoemulsification and IOL implantation were performed by 2 surgeons (Chao-Kai Chang and Hung-Yuan Lin) by using an identical technique to minimize differences in surgically induced aberrations between groups. The surgical process involved topical anesthesia, a 3-step clear corneal incision (2.75 mm) at 180° (temporal in both eyes), a 5.0-mm continuous curvilinear capsulorhexis, phacoemulsification using the stop-and-chop technique, IOL implantation with an injector, IOL centration, and a sutureless incision. The study IOL models include EDOF Symfony IOL (AMO, Santa Ana, CA, USA), bifocal Restor +2.5D IOL (Alcon, Fort Worth, TX, USA), and monofocal Sensar AR40e IOL (AMO, Santa Ana, CA, USA).
75437613|NCT01585493|Behavioral|CHANGE|"Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.~CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change."
75437614|NCT01585662|Procedure|EUS-guided pancreatic pseudocyst drainage|EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.
75586640|NCT02212353|Other|Observational study, not interventional|
75586641|NCT04557306|Biological|CBT101 (2-6 x 10^9 cells), every 2 weeks|CBT101 (2-6 x 10^9 cells), every 4 weeks
75586642|NCT04557306|Biological|CBT101 (2-6 x 10^9 cells), every 4 weeks|CBT101 (2-6 x 10^9 cells), every 4 weeks
75586643|NCT00476957|Device|Stent|Stent implantation
75586644|NCT00476957|Device|Stent|Stent implantation
75586645|NCT04556955|Device|Graston technique|Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.
75586646|NCT04556955|Other|post isometric relaxation|Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier
75586647|NCT00475865|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
75586648|NCT00475865|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
75586649|NCT00475865|Drug|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
75882216|NCT05707221|Other|combination of mechanical and chemical cleaning|cleaning the appliance with denture brush and CHX toothpaste followed by the cleansing tablet
75731427|NCT00609986|Drug|NPH Insulin or glargine insulin and aspartame insulin|"The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL"
75437615|NCT01586013|Drug|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
75437616|NCT01586221|Other|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
75731428|NCT00715871|Drug|Nicotine|"Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study."
75731429|NCT00715871|Device|Smoke-Break nicotine delivery device|"The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive."
76025006|NCT03916133|Diagnostic Test|Intervention group|6s PBV mapping will be conducted
76025007|NCT03915665|Drug|Chlorhexidine|Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
76025008|NCT03915665|Device|Air-powder|Erythritol powder using air-powder device
75586650|NCT04556877|Procedure|Intraabdominal pressure and optic nerve diameters|Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
75586651|NCT00475709|Device|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
75731430|NCT00898664|Genetic|cytogenetic analysis|
75731431|NCT00898664|Genetic|gene expression analysis|
75731432|NCT00898664|Genetic|mutation analysis|
75731433|NCT00898664|Genetic|polymerase chain reaction|
75437617|NCT01586273|Device|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
75437618|NCT01586676|Behavioral|SAU|Supervision-as-usual
75437619|NCT01586676|Behavioral|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
75437620|NCT01586689|Behavioral|Oxford House|community-based recovery home for participants recovering from substance dependency
75437621|NCT01586689|Behavioral|Safe Haven|professionally-staffed treatment facility
75437622|NCT01586689|Behavioral|Usual aftercare|control group - participants may or may not seek treatment on their own
75731434|NCT00898664|Other|immunohistochemistry staining method|
75731435|NCT00898664|Other|laboratory biomarker analysis|
75731436|NCT02572193|Procedure|POEM|To determine the feasibility of same-day discharge following a POEM procedure
75731437|NCT00888446|Biological|tgAAC09|
75731438|NCT00888446|Biological|tgAAC09|
75882217|NCT02103530|Other|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
75882218|NCT05220969|Genetic|Total Genotype Risk Score|A total genotype risk score has been generated based on the results of previously observed genetic association studies
75882219|NCT02251028|Behavioral|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
75731439|NCT00888446|Biological|tgAAC09|
75731440|NCT00888446|Other|Formulation buffer|Sterile isotonic buffered salt solution
75731441|NCT02540174|Procedure|integrated addiction treatment program|"At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program."
75882220|NCT03117361|Drug|plitidepsin|Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
75882221|NCT03117361|Drug|Bortezomib|BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
75731442|NCT02540174|Procedure|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
75437623|NCT01586702|Behavioral|Patient centered structured support program|"Behavioural: Structured support program~Program with up to 8 outpatient appointments focusing on:~Measurement of risk factors~Assessment of medication intake~Monitoring of antithrombotic therapy~Joint agreement of an individual target plan~Target values for risk factors:~Blood pressure < 140/85 mmHg (<130/80 in diabetics), normal circadian profile~HbA1c <7.5%~Nicotine abstinence~LDL < 100mg/dl (< 70mg/dl in high risk patients)~Physical activity ≥ 30min >2 x / week~Targets for pharmaceutical treatment:~Platelet inhibitors for strokes / TIA of arterial etiology~Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis~Cumarins (INR 2-3) or new oral anticoagulants in AF patients~Statin treatment in patients with LDL >100mg/dl~Intervention strategies:~• According to Motivational Interviewing"
75437624|NCT01586715|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
75437625|NCT01586780|Dietary Supplement|Protein drink|Test drink providing 9g protein
75731443|NCT02572271|Procedure|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
75882222|NCT03117361|Drug|Dexamethasone|DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
75437626|NCT01586780|Dietary Supplement|Reference meal|Control meal
75437627|NCT01586793|Device|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
75437628|NCT01586793|Device|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
75731444|NCT02572271|Procedure|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
75731445|NCT04035824|Drug|Gastrodia and Uncaria granule|Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
75882223|NCT01368614|Device|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
75882224|NCT01368614|Device|Respironics OnmiLab BiPAP S mode|Currently cleared Non-Invasive Ventilation (NIV) therapy modality
75437629|NCT01586845|Drug|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
75437630|NCT01586845|Drug|tacrolimus|tacrolimus as per labeled dose
75437631|NCT01586884|Procedure|Pressure/Conductance Catheter|"The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.~The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.~The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point."
75437632|NCT01586949|Behavioral|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
75437633|NCT01586988|Behavioral|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
75437634|NCT01587248|Device|Harmonic|Dissection with harmonic scalpel
75437635|NCT01587248|Procedure|electrocautery|Dissection in modified radical mastectomy
75437636|NCT01587339|Drug|retigabine/ezogabine|oral - all doses
75437637|NCT01587339|Drug|lacosamide|oral - all doses
75437638|NCT01587339|Drug|zonisamide|oral - all doses
75731446|NCT04035824|Drug|Placebo of Gastrodia and Uncaria granule|Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
75731447|NCT00893750|Behavioral|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
75731448|NCT00893750|Behavioral|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
75882225|NCT01368614|Device|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
75882226|NCT05220891|Other|Paracentesis|Paracentesis from ascitic patient
75882227|NCT05219305|Device|Dental Implant Placement|Placement in an edentulous site that was previously bone grafted in the prior study.
75882228|NCT05707065|Other|core strengthening exercises|The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.
75437639|NCT01587339|Drug|pregabalin|oral - all doses
75437640|NCT01587339|Drug|eslicarbazepine|oral - all doses
75437641|NCT01587378|Drug|Metformin|Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
75437642|NCT01587378|Drug|placebo|identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
75437643|NCT01587417|Drug|Placebo to BI 187004 CL|1 single dose per subject as oral solution
75437644|NCT01587417|Drug|BI 187004 CL|1 single dose per subject as oral solution
75437645|NCT01587482|Procedure|PacLitaxel Eluting Balloon Application|Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
75437646|NCT01587625|Drug|Oxytocin|
75882229|NCT05707065|Other|Proprioceptive Neuromuscular Facilitation|lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
75882230|NCT02102360|Device|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
75437647|NCT01587820|Drug|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
75731449|NCT00893750|Behavioral|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
75731450|NCT00712049|Drug|simvastatin|simvastatin 40 mg
75731451|NCT00712049|Drug|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
75731452|NCT00712127|Other|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
75731453|NCT00712127|Other|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
75882231|NCT02102360|Device|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
76025009|NCT01959334|Drug|Nasal Glucagon (NG)|
76025010|NCT01959334|Drug|Glucagon IM|
76053209|NCT01640873|Drug|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
75437648|NCT01587820|Drug|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
75586652|NCT04556994|Other|Phase 1 Cardiac Rehabilitation|"Step 1:Breathing exercises, 3 sets of 10 repetitions. Active upper and lower extremity exercises, 3 sets of 10 repetitions; bed inclined at 45°.~Step 2:Active exercises as in step 1. Stay in the upright position and perform walking on the spot for three series of 1 min.~Step 3:Active exercises as in step 2. Ambulation within the inpatient wards (7 min). Transfer to an allocated chair beside the bed (at least 30 min).~Step 4:Same exercises as in step 3. Ambulation within the inpatient wards (10 min). Transfer to an allocated chair beside the bed (at least 1 h).~Step 5:Same exercises as in step 4. Ambulation within the inpatient wards (15 min). Transfer to an allocated chair beside the bed (at least 2 h).~Step 6:Active exercises from the previous day. Ambulation within the inpatient wards (20 min). Step training (3 times continuously, 20 cm standardized step).~Step 7:Exercises from the previous day. Step training (6 times continuously, 20 cm standardized step)."
75586653|NCT04556994|Other|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Step 1 to step 6 of Phase 1 Cardiac Rehabilitation given to the patients along with Lower limb exercise on Paddler lasting 20 min (5-min warm-up, 10 min of low-intensity exercise, and 5-min recovery), 30 rpm ( rotation per minute)
75731454|NCT00898742|Genetic|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
75731455|NCT00898742|Genetic|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
75882232|NCT03555110|Behavioral|Personality Factor Battery Test (PFB Test)|Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.
75882233|NCT03555110|Behavioral|Eye Movement Desensitization and Reprocessing Therapy (EMDR)|"It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory."
75882234|NCT05083273|Other|Cohorte|Completion of a socio-demographic, professional, medical and personal questionnaire
75882235|NCT02110004|Procedure|Ablation procedure|The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
75882236|NCT02110004|Device|Picasso NAV Catheter|
75586654|NCT04556721|Drug|Sugammadex|On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
75882237|NCT05082337|Device|SAVVY guidewire|The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment
75586655|NCT00475670|Drug|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
75731456|NCT00898742|Other|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
75882238|NCT03053427|Drug|Placebo|Oral administration
75882239|NCT03053427|Drug|Gabapentin enacarbil|Oral administration
76053210|NCT04419623|Drug|TL-895|TL-895, administered by mouth
76053211|NCT04844801|Procedure|Risk control strategy|"Magnesium sulfate 2g intravenous bolus over 20 mn (if creatinine clearance >30 mL/min)~Control of the modifiable NOSVA risk factors: hypovolemia, sepsis, metabolic disorders (e.g., hypokalemia, hyponatremia), acidosis, hypoxia, excess cardiac inotropism of vasopressors, central venous catheter malposition, hyperthermia."
76053212|NCT04844801|Procedure|Rate control strategy:|"Risk-control as described above~Low dose amiodarone:~Intravenous bolus (day-1): 4 mg/kg over 1hr (maximum 300 mg i.e. 2 IVL vials over 1 hour )~Enteral dose maintenance (day-1 to day-7): 200mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)"
75882240|NCT02107118|Biological|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
75437649|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with abdominal pain|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
75882241|NCT02107118|Other|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
75882242|NCT05081089|Drug|Artemether-lumefantrine|Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
75437650|NCT01587846|Dietary Supplement|Administration of placebo in children with abdominal pain|Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
75586656|NCT00475670|Drug|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
75586657|NCT04557072|Drug|Selective alpha-1-antagonist|Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
75586658|NCT04557072|Drug|Non-selective alpha-1-antagonist|Patients treated with non-selective alpha-blockade (phenoxybenzamine)
75586659|NCT04556760|Drug|AZD9567|Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.
75586660|NCT04556760|Drug|Prednisolone|Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.
75586661|NCT04556760|Other|Placebo|Participants will receive placebo for 3 consecutive days of each treatment period in Cohort 3.
75731457|NCT00716027|Behavioral|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
75731458|NCT00716027|Behavioral|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
75586662|NCT00474968|Device|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector [SoftPAP(R)]
75731459|NCT00898820|Genetic|gene expression analysis|
75731460|NCT00898820|Genetic|polymorphism analysis|
75882243|NCT05081089|Drug|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
75731461|NCT00898820|Genetic|protein expression analysis|
75731462|NCT00712205|Drug|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
75731463|NCT00712205|Drug|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
75731464|NCT02574299|Other|E-learning|Management of auditory processing disorders with serious game (E-learning)
75731465|NCT02574299|Device|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
75731466|NCT00720551|Other|alcohol|alcohol 0.05%, 0.08% or 0.11% or placebo
75731467|NCT00451906|Drug|Platinum-based chemotherapy|As prescribed
75882244|NCT05081089|Drug|Sulphadoxine-pyrimethamine with amodiaquine|Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.
75882245|NCT05081089|Drug|Tafenoquine|100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
75882246|NCT03555032|Drug|Talimogene laherparepvec (T-VEC)|One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
75882247|NCT03554408|Drug|10-1074-LS|Subcutaneous injection of 10-1074-LS
75882248|NCT03554408|Drug|10-1074-LS|Intravenous infusion of 10-1074-LS
75882249|NCT03554408|Drug|3BNC117-LS|Subcutaneous injection of 3BNC117-LS
75586663|NCT00474968|Device|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
75586664|NCT04556799|Procedure|computer-assisted surgery|derotation osteotomy with the aid of 3D osteotomy template and computer-assisted simulated surgery
75586665|NCT04556799|Procedure|traditional osteotomy|traditional osteotomy without the aid of 3D osteotomy template
75586666|NCT00474929|Drug|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
75586667|NCT00474929|Drug|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
75586668|NCT04556604|Behavioral|Educational meetings and visual prompts|Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
75586669|NCT04556409|Device|low intensity pulsed ultrasound plus static abdominal and pelvic floor exercises.|Ultrasonic irradiation was employed with parameters of current use in clinical practice, including lower potency (0.16 W/cm2), which is more adequate for stimulation of nerve regeneration, according to results obtained in investigations in which the irradiation was applied at the lesion site 32, 33.
75731468|NCT00451906|Drug|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
75586670|NCT04556409|Device|low level LASER plus static abdominal and pelvic floor exercises.|Application of laser irradiation (Ga-As laser) in the site of the anastomosis inhibits the degeneration process, accelerate remyelination, and nerve function recovery 27, 28
75437651|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with constipation|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
75586671|NCT04556409|Other|static abdominal and pelvic floor exercises only.|static abdominal and pelvic floor exercises., 3 times/week for 4 weeks.
75731469|NCT04162691|Diagnostic Test|Tissue|Four 4-5 mm tissues of the thymoma
75731470|NCT00712283|Drug|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
75731471|NCT04070495|Drug|KW-6356|A single oral dose will be administered at Day 1 and 15
75731472|NCT04070495|Drug|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
75437652|NCT01587846|Dietary Supplement|Administration of placebo in children with constipation|Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
75731473|NCT04070495|Drug|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
75731474|NCT00712361|Device|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
75731475|NCT00720707|Procedure|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
75731476|NCT00720707|Procedure|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
75731477|NCT00716105|Other|Standard infant formula|From 3 to 12 months of age. As per standard requirement
75731478|NCT00716105|Other|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
75731479|NCT02573129|Other|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
75731480|NCT02573129|Other|Red Meat Rich|Mediterranean diet rich in red meat
75731481|NCT00712439|Drug|Gabapentin Extended Release tablets|
75731482|NCT00712439|Drug|Placebo|
75731483|NCT00451282|Behavioral|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
75731484|NCT00716183|Biological|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
75731485|NCT00716183|Biological|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
75731486|NCT00716183|Biological|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
75731487|NCT00716183|Drug|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
75882250|NCT03554408|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS
75437653|NCT01587937|Other|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
75437654|NCT01588132|Drug|Anfibatide|"To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.~To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours."
75437655|NCT01588171|Drug|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
75437656|NCT01588171|Drug|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
75437657|NCT01588210|Other|Sealant application|"A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
75586672|NCT00474812|Drug|dasatinib|
75586673|NCT00474812|Procedure|laboratory biomarker analysis|Correlative study
75586674|NCT00474812|Procedure|physiologic testing|Correlative study
75586675|NCT04556643|Other|Breathing exercises|The main components of breathing exercises during training will be as follows (A) First, fill your stomach and then your lungs with air while breathing in; (B) Feel the expansion in the stomach; (C) Make sure the muscles from your stomach to your knee are relaxed, as if you are urinating while breathing out; (D) When there is pain, perform deep abdominal breathing exercises, and take a deep breath in and hold as much as you can; (E) Try to push the baby downward; (F) You can do it by holding your breath or breathing out quite slowly from your mouth; (G) The most important point in this stage is that you should not fill up the stomach with air, and you should push downward to deliver the baby; (H) You should continue the pushing until the pain is relieved
75731488|NCT03995446|Device|low-level laser|low level laser emission on specific acupuncture points
75731489|NCT03995446|Device|Sham laser|Sham laser
75882251|NCT05220579|Device|"Exposure to TOR device"|"Specific wave spectrum is directed by the TOR device to human tissues affected by the SARS-CoV-2 virus in order to disrupt its activity."
75882252|NCT05220579|Device|"Exposure to switched off TOR device"|"The TOR device has screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators."
76053213|NCT04844801|Procedure|Rhythm control strategy:|"Risk control as described above~High dose amiodarone:~Intravenous bolus (day-1): 7 mg/kg over 1hr 1 hour (maximum 600 mg i.e. 4 IVL vials over 1 hour); followed by continuous intravenous maintenance: for a total of 1200 mg over the first 24 hrs (infusion pump)~Enteral dose maintenance Day-2 and day-3: 400 mg three times a day (720 mg continuous intravenous over 24 hrs if enteral route is unavailable).~Day-4 to day-7: 200 mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)~- Electrical cardioversion (only in patients intubated on mechanical ventilation) if:~NOSVA persists after initial bolus of amiodarone AND norepinephrine base (or epinephrine base) doses > 0.3 µg/kg/min;~NOSVA persists more than 6 hrs after initial amiodarone bolus."
75437658|NCT01588210|Other|sealant application|"A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
75586676|NCT00474383|Drug|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
75437659|NCT01588210|Other|sealant application|"A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
75586677|NCT00474383|Drug|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
75586678|NCT04556448|Other|Aligners|Clear aligners
75586679|NCT04556448|Other|Clear braces|Clear braces
75586680|NCT00474266|Biological|Meningococcal vaccine GSK134612 (Nimenrix)|Single dose intramuscular injection
75731490|NCT04069559|Other|To develop nursing students' attitudes towards refugees program which based on contact hypothesis.|In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
75731491|NCT04070417|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
75731492|NCT03996226|Drug|E7386|E7386 oral tablets.
75731493|NCT00712517|Drug|propofol|propofol anesthesia 3-5mg/kg
75586681|NCT00474266|Biological|Priorix-Tetra|2-dose subcutaneous injection
75586682|NCT00474266|Biological|Meningitec|Single dose intramuscular injection
75586683|NCT02277821|Device|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
75586684|NCT00473564|Procedure|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
75586685|NCT00472199|Drug|Pramipexole|
75586686|NCT00472199|Drug|Placebo|
75586687|NCT04556331|Behavioral|Parenting programme (cognitive behavioural) aimed at reducing generational transmission of anxiety|'Psychoeducation' (psychologically informed information about the topic of transmitting anxiety) and cognitive-behavioural strategies aimed at reducing the transmission of anxiety from parent to young child. These will be shared with a group of maximum 8 remotely delivered, in a didactic format.
75731494|NCT00712517|Drug|sevoflurane|sevoflurane anesthesia
75731495|NCT04070339|Other|transfontanelle ultrasound|cerebral blood flow investigation using transfontanelle ultrasound
75731496|NCT03838198|Behavioral|MI-Enhanced Safety Plan at Hospitalization (1st Component)|"The MI-enhanced safety plan intervention component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy."
75882253|NCT02103686|Drug|Lyrica|
75882254|NCT02103686|Drug|Experimental drug|sustained release formulation of pregabalin
75882255|NCT02103686|Dietary Supplement|High fat meal|
75882256|NCT02103686|Dietary Supplement|fasted|
75882257|NCT01372969|Drug|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
75882258|NCT02110082|Biological|Urelumab|
75882259|NCT02110082|Biological|Cetuximab|
75882260|NCT05706831|Other|Combinatory effect of music stimulation and neurostimulation|music
75437660|NCT01588730|Device|Ankle Dorsiflexion Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
75586688|NCT00472082|Drug|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
75586689|NCT04556136|Device|Standing Phototherapy Kiosk|Benesol is a freestanding booth designed to deliver a small amount of targeted UVB with an interactive user interface and cloud-based software that enables patient self-care. The treatment delivery mechanism uses a metal halide lamp with a series of filters and a lens to optimize full-body exposure to the narrow spectrum (293 - 303nm) of UVB light most efficient at producing vitamin D3. The device uses software to identify patients, establish individual skin types and determine dosage. The system has been designed to manage exposure time and frequency and deliver 60% of a skin-type-adjusted Minimal Erythemal Dose (MED). The expected result for users is a rise in blood levels of 25(OH)D via the endogenous pathway.
75586690|NCT04556136|Dietary Supplement|D3 Oral supplement|Each subject assigned to the comparison group was instructed to take one vitamin D3 pill, dispensed by the research pharmacist, each day with a meal for 70 days. Subjects were instructed not to take any additional vitamin D supplementation during the study period. This dosing frequency is consistent with the RDA recommendation. Subjects were instructed to bring their pill bottle with them when returning for their follow up appointment.
75586691|NCT04556292|Drug|SC10914|SC10914 400mg tid
75586692|NCT00471887|Biological|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
75731497|NCT03838198|Behavioral|MI-Enhanced Text Boosters (2nd Component)|For participants randomized to receive text boosters, booster text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
75731498|NCT03838198|Behavioral|MI-Enhanced Booster Call (3rd Component)|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, will be to to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
75731499|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
75731500|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
75731501|NCT00115765|Drug|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
75731502|NCT00115765|Drug|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
75731503|NCT00115765|Drug|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
75882261|NCT02103764|Drug|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
75882262|NCT02103764|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
75882263|NCT05011201|Device|Dual Joint Visual Feedback without Scoring|Participants will walk on the treadmill while given instantaneous anterior and posterior foot position and immediate scoring information using the DJVF interface. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
75882264|NCT05011201|Device|Dual Joint Visual Feedback with Scoring|Participants will walk on the treadmill using the same DJFB with additional visual cumulative scoring on their performance. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
75882265|NCT02110316|Other|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
75882266|NCT02103842|Drug|Omega-3 fatty acids|
75882267|NCT05220267|Drug|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).
75882268|NCT02110394|Other|bendamustine|Routine practice
75882269|NCT02110394|Other|rituximab|Routine practice
75882270|NCT02373241|Drug|Losartan|Standard dosing
75882271|NCT02373241|Drug|Losartan|Experimental dosing
75437661|NCT01588730|Procedure|Commercially Available Static Night splint|A commericially avilable static night splint will be worn for 4-6 hours during rest.
76025011|NCT04722419|Other|Probe meal|The probe meal will be served in 112 Kcal portions (16 g white bread, 10 g cheese, 10 g jam, 3.25 g butter, and 50 mL orange juice) up to the level of maximal satiation.
75586693|NCT04556058|Drug|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
75586694|NCT04556058|Drug|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
75586695|NCT00471536|Drug|pazopanib hydrochloride|800 mg Given orally
75586696|NCT04556019|Procedure|Hepatobiliopancreatic surgery|Different surgical techniques tailored to each patient´s pathology
75586697|NCT04556253|Drug|AK104|Subjects will receive AK104 by intravenous administration.
75731504|NCT00115765|Drug|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
75731505|NCT00606008|Drug|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
75731506|NCT00721019|Other|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
75731507|NCT00721019|Other|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
75586698|NCT00470834|Drug|dutasteride|0.5mg dutasteride (Investigation Product)
75586699|NCT00470834|Drug|placebo|making placebo
75731508|NCT03837184|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
75731509|NCT00716261|Device|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
76025012|NCT02687581|Device|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
75731510|NCT00898898|Other|diagnostic laboratory biomarker analysis|Correlative studies
75731511|NCT04068233|Other|Pacemaker stimulation mode|Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.
76025013|NCT02687581|Device|patch|6-hour of eye patch on the fellow eye
76053214|NCT01683994|Drug|Cabozantinib|Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
75586700|NCT00470834|Drug|bicalutamide|50 mg Casodex or generic equivalent
75731512|NCT04035122|Other|Robotic Treatment|The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.
75586701|NCT04555746|Behavioral|Physical activity|Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
75586702|NCT04555824|Drug|Recombinant Human Thymosin β4|Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.
76025014|NCT04173754|Procedure|Motion Style Acupuncture Treatment(MSAT)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
76025015|NCT02248805|Drug|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
76025016|NCT02021279|Device|MatriStem Pelvic Floor Matrix|
76025017|NCT02021279|Procedure|native tissue repair|
76053215|NCT01683994|Drug|Docetaxel|75mg/m^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
75586703|NCT04555824|Other|Placebo|Five cohorts, with 10 healthy subjects , were given a single intravenous dose of Placebo. Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1.
75586704|NCT00470366|Biological|pegfilgrastim|
76053216|NCT01683994|Drug|Prednisone|5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
76053217|NCT02247440|Drug|Peg-interferon + ribavirin under HIV physician supervision|Peg-interferon + ribavirin under HIV physician supervision
75437662|NCT01588873|Drug|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
75437663|NCT01589367|Drug|Metformin|Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
75586705|NCT00470366|Drug|cisplatin|
75586706|NCT00470366|Drug|ifosfamide|
75586707|NCT00470366|Drug|paclitaxel|
75586708|NCT02212431|Drug|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
75586709|NCT00470093|Biological|recombinant interferon-α|
75731513|NCT04035122|Other|Conventional Treatment|The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.
75586710|NCT00470093|Biological|recombinant interleukin-6|
75586711|NCT02212548|Device|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
75586712|NCT00470054|Drug|dasatinib|Given PO
75586713|NCT04555668|Other|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks
75586714|NCT04555668|Other|Hamstring Stretch Program|Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
75731514|NCT00461812|Drug|Mometasone|
75731515|NCT00461812|Drug|Advair|
75731516|NCT00721097|Other|spirometry, and blood taken|each month during one year
75731517|NCT02539862|Other|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
75731518|NCT02539862|Other|psychoeducation|the psychoeducation is delivered by a doctor
76025018|NCT05652439|Other|Observational retrospective data collection|Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes
75586715|NCT00478595|Drug|Rimonabant|Tablet, oral administration
75586716|NCT00478595|Drug|Placebo (for Rimonabant)|Tablet, oral administration
75586717|NCT00478595|Drug|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
75586718|NCT04555707|Drug|Apremilast 30mg|30mg PO BID started within 10 days of baseline
75586719|NCT04555707|Drug|calcipotriene and betamethasone dipropionate|1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.
75731519|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
75731520|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
75437664|NCT01589367|Drug|Placebo|Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
75437665|NCT01589432|Drug|ABT-639|two 50 mg oral capsules
75437666|NCT01589432|Drug|Placebo|2 placebo capsules
75437667|NCT01589432|Drug|Lidocaine|3mg/kg infusion over 30 minutes
75731521|NCT00721331|Drug|nortriptyline HCl|Topical
75731522|NCT00721331|Drug|mometasone furoate|Topical
76025019|NCT02392273|Drug|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
76025020|NCT04813705|Radiation|Reduced dose|The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
75437668|NCT01589458|Drug|Toothpaste|1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
75437669|NCT01589614|Drug|PH-797804|Tablet, 6mg, single
75437670|NCT01589614|Drug|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
75437671|NCT01589718|Drug|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
75437672|NCT01589718|Drug|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
75437673|NCT01589757|Other|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
75437674|NCT01589757|Other|Low GI diet|"Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate."
75437675|NCT01589796|Procedure|TAP block|injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
75437676|NCT01589861|Drug|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
75586720|NCT04673279|Diagnostic Test|serology|An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.
75586721|NCT04555980|Device|Warming patch|The warming patch can increase the temp of injection site, result in a blood vessels to dilate, which may have some contribute to decreasing injection pain.
75586722|NCT04555980|Device|Cotton patch|The Cotton patch will cover the injection site as placebo. It dose not have the function of heating comparing to Warming patch.
75586723|NCT04673084|Device|negative pleural suction|by comparing the effect of water seal alone of chest tube in one groups of trauma patients and the effect of both water seal and suction in other group
75586724|NCT02212626|Device|Rotarex S|
75586725|NCT04673201|Procedure|"Viscotrabeculotomy Versus trabeculectomy with MMC"|Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.
75731523|NCT00721331|Drug|Active ingredient free vehicle cream of CRx-197|Topical
75731524|NCT01025908|Behavioral|Psychotherapy|Cognitive Behavioral Therapy
75731525|NCT01025908|Behavioral|Supportative psychotherapy|Supportative psychotherapy
76025021|NCT04813705|Radiation|Conventional dose|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
75586726|NCT04555629|Other|Advanced Cognitive Stimulation Therapy Hong Kong|A modified version of Cognitive Stimulation Therapy for people with moderate to severe dementia translated and culturally adapted for the Hong Kong Chinese population.
75586727|NCT00478088|Device|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
75437677|NCT01589913|Behavioral|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~Introduction to participants and online system~Knowledge regarding ICDs~Strategies for behavior change~Psychological models for anxiety and depression~Strategies to cope with avoidance, anxiety and depression~Resume, evaluation, resolution of open questions, goal setting, good bye"
75731526|NCT02540096|Other|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
75731527|NCT02540096|Other|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
75882272|NCT03052959|Behavioral|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
75882273|NCT03052959|Other|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
75882274|NCT02107430|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
75882275|NCT02107430|Radiation|Standard radiotherapy|radiotherapy
75437678|NCT01589965|Behavioral|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
75586728|NCT00478088|Device|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
75586729|NCT00474188|Drug|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
75586730|NCT00474188|Drug|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
75731528|NCT00123955|Drug|Spironolactone|25mg tablet daily for 9 months
75731529|NCT00123955|Drug|Placebo|Placebo tablet daily for 9 months
75731530|NCT04372121|Drug|75 mg linzagolix tablet|For oral administration once daily
75882276|NCT05706675|Procedure|Non surgical periodontal therapy|Manual root planning+Ultrasonic subgingival debridement
75437679|NCT01589991|Drug|Toothpaste|The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
75437680|NCT01590030|Procedure|Laparoscopic dermoid cystectomy|Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
75882277|NCT03120013|Device|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
75882278|NCT03120013|Device|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
75882279|NCT05656131|Drug|Fluzoparib|Arms A will be treated with fluzoparib alone
75586731|NCT04555473|Procedure|Tumor biopsy|"Both interventions performed at baseline upon study enrolment (pre- and post-NACT for NACT+IDS patients) and at the time of recurrence.~Part of each surgical specimen will be used to obtain organoids, whereas part will be frozen for direct comparative analysis of the original tumor (1-6 organoids from each patient).~Blood samples will be collected to purify extracellular circulating RNA (cRNAs)."
75586732|NCT04555395|Other|survival rates|survival rates
75586733|NCT00475982|Behavioral|Weight Loss|Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
75731531|NCT04372121|Drug|200 mg linzagolix tablet|For oral administration once daily
75882280|NCT05656131|Drug|Fluzoparib+Camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
75437681|NCT01590043|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
75437682|NCT01590056|Other|Electrophysiological recording|"During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~listening to nonverbal affect bursts corresponding to emotions~applying a simple go-no-go auditory test"
75437683|NCT01590108|Drug|(Pyr1)apelin-13|(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
75731532|NCT04372121|Drug|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
75731533|NCT04372121|Drug|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
75731534|NCT04372121|Drug|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
75731535|NCT04372121|Drug|Placebo capsule to match Add-back capsule|For oral administration once daily
75731536|NCT03837028|Other|FSFI|Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
75731537|NCT02539784|Device|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
75731538|NCT04069481|Other|Dance|One-hour class, twice a week. Classes include dance warm up exercises, various dance movements and choreography that include coordinated whole body movements through space synchronized to music.
75731539|NCT04069481|Other|Mindfulness meditation and Exercise|One hour class, twice a week. Classes include upper and lower extremity stretching and resistance exercises and mindfulness meditation, that includes body scan technique and breathing exercises.
75731540|NCT00898976|Other|immunohistochemistry staining method|
75437684|NCT01590108|Drug|Saline|Saline
75437685|NCT01590121|Other|Aeroplane flight in the past- no active intervention for study|Aeroplane flight(s) previously taken by study participants
75731541|NCT00898976|Other|laboratory biomarker analysis|
75437686|NCT01590121|Other|Questionnaire|Flight by aeroplane (previous)
75437687|NCT01590134|Dietary Supplement|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
75437688|NCT01590134|Drug|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
75437689|NCT01590147|Procedure|Yoga therapy|receive YST
75586734|NCT00475982|Other|No Weight Loss Group|These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
75882281|NCT02110472|Device|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
75882282|NCT01373047|Biological|anti-CEA 2nd generation designer T cells|Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
75882283|NCT02103998|Drug|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
75586735|NCT01089647|Drug|budesonide and montelukast|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
75586736|NCT01089647|Drug|Placebo|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
75731542|NCT01027546|Drug|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
75882284|NCT02103998|Drug|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
75437690|NCT01590147|Other|questionnaire administration|Ancillary studies
75437691|NCT01590147|Procedure|quality-of-life assessment|Ancillary studies
75437692|NCT01590147|Other|laboratory biomarker analysis|Correlative studies
75437693|NCT01590147|Other|assessment of therapy complications|Ancillary studies
75437694|NCT01590147|Procedure|management of therapy complications|Receive YST or CE
75437695|NCT01590147|Other|educational intervention|Receive CE
75437696|NCT01590160|Drug|Ganetespib|IV, Using dose from Phase I
75731543|NCT00901082|Behavioral|Relaxation and information session|Relaxation and information session before the medial branch block
75731544|NCT05667545|Drug|Peptide|it is about synthetic protein acting on tooth structure help information apatite crystals
75731545|NCT00115063|Behavioral|group sessions|group sessions lead by a trained primary care clinic employee
75731546|NCT00115063|Drug|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
75731547|NCT00115063|Behavioral|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
75731548|NCT00115063|Other|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
75437697|NCT01590173|Drug|Prednisolone and Heparin during COH for IVF|Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
75731549|NCT00115063|Other|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
75731550|NCT01026064|Other|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
75882285|NCT05220111|Procedure|Cardiac surgical operation (valve, aorta, coronary arteries)|Quality of life assessment using EQ-5D-3L
75882286|NCT01941589|Drug|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
75882287|NCT01941589|Drug|corticosteroids only|IV corticosteroids only
75882288|NCT02110550|Other|IPS.emmax endocrown|
75731551|NCT01026064|Drug|Azithromycin|Zithromax (250 mg oral capsule).
75731552|NCT01026064|Drug|Placebo|Matching placebo
75731553|NCT00899054|Drug|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
75882289|NCT02110628|Procedure|Roux-en-Y anastomosis|Roux-en-Y anastomosis
75882290|NCT02110628|Procedure|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
75586737|NCT04555434|Dietary Supplement|Probiotics|"Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10^9 CFU / day)~Control group Main ingredient: Crystalline cellulose"
75586738|NCT04673240|Drug|Botulinum toxin type A injection|"Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.~As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician."
75586739|NCT04555005|Other|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
75731554|NCT00899054|Radiation|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
75731555|NCT05659745|Other|VM-02|VM-02 is a personal care product for vaginal health.
75882291|NCT02107664|Radiation|Palliative RT for bone cancer pain|
75882292|NCT01845649|Drug|WC3011 Estradiol Vaginal Cream|Daily for 14 days followed by 3 times per week for 10 weeks
75882293|NCT01845649|Drug|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
75882294|NCT03554252|Other|Frequencies|Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)
75882295|NCT03554252|Other|Percentages|Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
75882296|NCT01345929|Drug|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
75882297|NCT01345929|Drug|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
75882298|NCT02107742|Procedure|Normal speed lidocaine injection|30 seconds
75882299|NCT02107742|Procedure|Slow lidocaine injection|speed 45 seconds
75882300|NCT02107742|Procedure|Fast lidocaine injection|speed 15 seconds
75882301|NCT01825291|Procedure|CPAP treatment|
75882302|NCT02250872|Drug|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
75731556|NCT05659745|Dietary Supplement|Commercial Oral Probiotic Competitor|Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
75586740|NCT01089608|Drug|Azithromycin|"Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
76053218|NCT05487989|Other|Clinical examen|MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
75586741|NCT01089608|Drug|Povidone|"Eye drops Single dose unit~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
75586742|NCT04554849|Other|Gender dysphoria psychosocial health|Retrospective analysis of medical records
75586743|NCT04672694|Procedure|Vagus nerve block|Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
75586744|NCT04672694|Procedure|No vagus nerve block|No vagus nerve block will be conducted during the surgery.
75586745|NCT04554654|Diagnostic Test|transvaginal ultrasound,|transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
75586746|NCT04554615|Drug|Insulin|insulin infusion to control postoperative hyperglycemia
75586747|NCT01089413|Drug|bevacizumab [Avastin]|As prescribed by physician
75586748|NCT04554810|Other|Medication Management Service|Medication review was delivered to the Syrian refugees by accredited pharmacists at the baseline visit. This followed by identifying the treatment-related problems (TRP) by the clinical pharmacist, and correction of the approved TRPs by the corresponding physicians and finally convey these changes in medications to the patients. In addition, counselling and education were delivered to the refugees' patients in the base line visit.
75586749|NCT02212665|Behavioral|High intense interval training|
75586750|NCT02212665|Behavioral|Increased daily activity detected by the pedometer|
75586751|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+HIIT|
75586752|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+group intervention|
75437698|NCT01590173|Drug|COH for IVF|Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
75437699|NCT01590199|Drug|RAD001|
75586753|NCT01089023|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
75586754|NCT02212704|Other|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
75586755|NCT02212704|Other|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
75586756|NCT02212704|Other|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
75586757|NCT02212782|Drug|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
75586758|NCT02212782|Drug|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
75586759|NCT01088984|Drug|Bendamustine|
75586760|NCT02212821|Drug|Erythromycin|
75586761|NCT02212821|Drug|Placebo|physiological saline
75586762|NCT01088438|Behavioral|Contextualization workshop|A four-hour course on contextualization.
75586763|NCT04554537|Behavioral|SMART|A treatment program developed to address specific brain functions found to be crucial for the recovery following brain injury.
76053219|NCT04760054|Behavioral|HUBOD|Participants in the intervention group will attend 5 separate training sessions instructing them in Hubod. The Hubod exercise is a partnered coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of the Hubod exercise by the end of their participation in this intervention.
75437700|NCT01590199|Drug|SOM230|
75586764|NCT04554537|Behavioral|Brain Health Workshop|A psychoeducation program designed to provide in depth information to participants about the neuroscience behind their TBI and PTSD and the symptoms and challenges they may experience.
75586765|NCT04554186|Procedure|Serratus anterior plane block|Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound
75586766|NCT04554186|Procedure|Thoracic Paravertebral block|Injection of bupivacaine in the thoracic Paravertebral space using ultrasound
75437701|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
75437702|NCT01590225|Drug|Peginterferon alpha-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 24 weeks.
75586767|NCT04554186|Procedure|Control|Place a fentanyl patch 50 microgram
75586768|NCT01088243|Drug|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
75586769|NCT01088243|Drug|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
75586770|NCT04554342|Other|V01 candy|candy with sweetener (Isomalt) and apple flavour
75586771|NCT04554342|Other|V02 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)
75586772|NCT04554342|Other|V03 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C
75586773|NCT04554342|Other|V04 candy|candy with sweetener (Isomalt) (control group 1)
75731557|NCT05659745|Other|VM-02 Placebo|VM-02 Placebo is a personal care product placebo for vaginal health.
75731558|NCT00899132|Genetic|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
75731559|NCT00899132|Genetic|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
75731560|NCT00899132|Other|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
75731561|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
75731562|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
75731563|NCT00461500|Drug|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
75731564|NCT00461500|Drug|Fluticasone propionate|FP 100
75586774|NCT04554342|Other|V05 candy|candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)
75437703|NCT01590225|Drug|Ribavirin|The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 24 weeks.
75586775|NCT04672499|Drug|Miricorilant 300 mg tablets|Miricorilant 300 mg tablets for oral administration
75586776|NCT04672499|Drug|Miricorilant 150 mg tablets|Miricorilant 150 mg tablets for oral administration
75586777|NCT04672499|Drug|Placebo 150 mg tablets|Placebo to match miricorilant 150 mg tablets for oral administration
75586778|NCT04554108|Other|therapeutic strategy|Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy
75586779|NCT04554303|Drug|S-amlodipine 2.5mg|Oral administration, 1 tablet per day
75586780|NCT04554303|Drug|Amlodipine 5mg|Oral administration, 1 tablet per day
75586781|NCT01088048|Drug|Idelalisib|Idelalisib tablet administered orally
75586782|NCT01088048|Drug|Rituximab|Rituximab administered intravenously
75586783|NCT01088048|Drug|Bendamustine|Bendamustine administered intravenously
75586784|NCT01088048|Drug|Ofatumumab|Ofatumumab administered intravenously
75586785|NCT01088048|Drug|Fludarabine|Fludarabine administered orally
75586786|NCT01088048|Drug|Everolimus|Everolimus administered orally twice daily until disease progression
75586787|NCT01088048|Drug|Bortezomib|Bortezomib administered as a subcutaneous injection
75586788|NCT01088048|Drug|Chlorambucil|Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
75586789|NCT01088048|Drug|Lenalidomide|Lenalidomide administered orally
76053220|NCT04760054|Behavioral|Active Comparator|Participants in the active comparator group will attend 5 separate training sessions. Each session will involve a 5 minute warmup of joint mobilization exercises and mild pedaling on the bicycle before the main effort of continuously using the bicycle for approximately 20 minutes. The session finishes with a 5 minute cooldown period and light stretch. Heartrate will be monitored regularly in order to prevent this exercise exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
76053221|NCT04760054|Behavioral|Control Condition|Participants in this group will attend 5 separate training sessions. Each session will involve watching educational videos on martial arts techniques and training methods from a sedentary position. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
75437704|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
75437705|NCT01590225|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 48 weeks.
75586790|NCT04554498|Device|1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up|"the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands)."
75731565|NCT00893906|Biological|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
75731566|NCT00893906|Biological|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
75731567|NCT00721487|Drug|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
75731568|NCT00167245|Drug|Topiramate|300mg/day for 13 weeks
75731569|NCT00167245|Drug|placebo|placebo pills
75731570|NCT00901160|Procedure|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
75731571|NCT00716339|Behavioral|motivation|
75731572|NCT00894062|Device|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
75437706|NCT01590225|Drug|Ribavirin|"Drug: Ribavirin~The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 48 weeks."
75437707|NCT01590251|Other|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
75437708|NCT01590251|Behavioral|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
75437709|NCT01590290|Other|financial compensation|financial monetary reimbursement
75731573|NCT00894062|Device|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
75731574|NCT00721565|Behavioral|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
75731575|NCT00894140|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
75882303|NCT02250872|Drug|Placebo|100mg in 2 divided doses plus cisplatin
76053222|NCT05421377|Diagnostic Test|clinical assessment|screening of patients at risk for developing unilateral or bilateral lower limb lymphedema
76053223|NCT04857203|Diagnostic Test|Vitamin D|Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer
75882304|NCT02250872|Drug|Cisplatin|All patients will receive intravenous cisplatin
75586791|NCT04554381|Biological|JL1 antigen|we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
75586792|NCT04553952|Other|Measurement of gingival display|"All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all."
76053224|NCT01683838|Drug|Fampridine-SR|25mg bid (twice daily)
75586793|NCT04672577|Other|Observational study|No intervention is planned
75586794|NCT04553796|Device|fibroscan|Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
75586795|NCT01087970|Drug|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
75586796|NCT01087970|Drug|Cetuximab|"Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression."
75437710|NCT01590303|Drug|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
75586797|NCT01087970|Drug|Carboplatin|Administered intravenously, for a maximum of 6 cycles
75586798|NCT01087970|Drug|Cisplatin|Administered intravenously, for a maximum of 6 cycles
76053225|NCT01683838|Drug|Placebo|Placebo
75731576|NCT00443560|Other|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
75731577|NCT04098341|Diagnostic Test|IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection|All eligible pregnant migrants will be offered an opt-out screening IGRA blood test for latent Tuberculosis infection
75731578|NCT00922454|Procedure|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment."
76053226|NCT05474573|Device|Combined ultrasound and fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope and performing sonography
75437711|NCT01590303|Drug|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
76053227|NCT05474573|Device|Fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
75586799|NCT04553874|Other||observational study without intervention
75731579|NCT00922454|Device|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
75731580|NCT00922454|Device|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
75437712|NCT01590316|Device|Cerebral NIRS oximetry|Cerebral NIRS oximetry during the first 72 hours of life.
75586800|NCT01087814|Drug|Efavirenz|Subject will take efavirenz for 5 days.
75586801|NCT01087814|Drug|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
75586802|NCT02212938|Drug|BI 14332 CL|
75586803|NCT02212938|Other|high fat breakfast|
75586804|NCT04672421|Device|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)
75586805|NCT04672421|Device|Placebo|No device after laparoscopic surgery
75586806|NCT04553991|Procedure|Ultrasound guided QL block|20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia
75586807|NCT04553991|Procedure|Ultrasound guided TAP block|20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
75586808|NCT01087775|Behavioral|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
75586809|NCT02213172|Dietary Supplement|Bifidobacterium longum R0175|
75586810|NCT02213172|Dietary Supplement|Lactobacillus paracasei HA-196|
75731581|NCT00721643|Dietary Supplement|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
75731582|NCT00721643|Dietary Supplement|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
75731583|NCT00899210|Other|laboratory biomarker analysis|
75731584|NCT00899210|Procedure|cryosurgery|
76053228|NCT01683604|Other|Observational study|
76053229|NCT05417243|Other|Trauma life support training|Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
76053230|NCT04843709|Drug|MRG004A|Administrated intravenously
75586811|NCT02213172|Other|Placebo|
75586812|NCT04554030|Behavioral|Evaluate sperm count before and after immunotherapy|Evaluate sperm count before and after immunotherapy
75586813|NCT01087502|Drug|Glimepiride|1-4 mg daily after 12 weeks
75586814|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
75586815|NCT01087502|Drug|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
75437713|NCT01590329|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
75586816|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
75586817|NCT01087502|Drug|Linagliptin|5 mg once daily
75586818|NCT02213211|Drug|Artemether lumefantrine|
75586819|NCT02213367|Drug|Bilastine|20mg (8 weeks)
75731585|NCT00899210|Procedure|radiofrequency ablation|
75731586|NCT00899210|Procedure|therapeutic conventional surgery|
75731587|NCT00721721|Behavioral|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
75731588|NCT00721721|Behavioral|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
75437714|NCT01590342|Drug|Diclofenac|Diclofenac 75 mg, two doses
75437715|NCT01590342|Drug|Placebo|Placebo, two doses
75437716|NCT01590368|Device|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
75437717|NCT01590368|Device|"Modified test electrode"|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
75731589|NCT00721721|Dietary Supplement|Potassium Supplementation|60 mmol potassium supplement
75437718|NCT01590407|Drug|ALS-002200|ALS-002200
75437719|NCT01590407|Drug|Placebo|Placebo
75586820|NCT02213367|Drug|Bilastine|40mg
75586821|NCT02213367|Drug|Bilastin|80mg
75586822|NCT01086410|Drug|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
75437720|NCT01590420|Device|CPAP S8- Scape / Resmed|The pressure for treatment is according to PSG titration
75437721|NCT01590446|Drug|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
75437722|NCT01590446|Drug|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
75437723|NCT01590485|Other|starch|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
75437724|NCT01590485|Other|saffron|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
75437725|NCT01590524|Behavioral|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
75437726|NCT01590537|Drug|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
75437727|NCT01590537|Device|Copper IUD|Copper device, inserted intrauterine
75437728|NCT01590615|Drug|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
75731590|NCT01022632|Dietary Supplement|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
75731591|NCT01022632|Drug|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
75731592|NCT01022632|Dietary Supplement|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
75731593|NCT00899288|Procedure|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
75882305|NCT01374139|Drug|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
75586823|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
75586824|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
75586825|NCT01086410|Drug|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
75586826|NCT01086410|Drug|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
75586827|NCT04553679|Behavioral|Mindfulness online intervention|A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
75586828|NCT04553601|Diagnostic Test|18F-FDG PET/CT and PET/CT-guide targeted biopsy in another group of participants|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time
75437729|NCT01590641|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
75731594|NCT03716999|Other|Starlight Therapy|Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
75586829|NCT04553250|Procedure|Doubled-stapled colorectal anastomosis|Anastomosis performed between the colon an the rectal stump, using a double-stapled technique.
75586830|NCT04553328|Device|Us guided nerve blocks|The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
75586831|NCT01085591|Drug|CB-183,315|
75731595|NCT00899366|Genetic|microarray analysis|
75731596|NCT00899366|Genetic|mutation analysis|
75731597|NCT00899366|Other|immunologic technique|
76053231|NCT02196038|Behavioral|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
75731598|NCT01026298|Other|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
75731599|NCT03683381|Behavioral|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
75437730|NCT01590641|Drug|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
75731600|NCT03683381|Other|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
76053232|NCT02196038|Behavioral|Attention Control|Usual care with bi-weekly contact from study staff
75437731|NCT01590654|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
75586832|NCT01085591|Drug|Placebo|
75586833|NCT01085591|Drug|Vancomycin|
75586834|NCT04672265|Other|Mother tongue and Norwegian|The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.
75586835|NCT04553055|Other|online questionnaires|questionnaire (with detailed questions including how/when/which/for how long antibiotics are prescribed)
75586836|NCT02213406|Dietary Supplement|yogurt|Subjects will receive yogurt with varying fat concentrations
75586837|NCT04552977|Drug|fluzoparil|a PARP1 inhibitor
75586838|NCT04552977|Drug|temozolomide|an alkylating chemotherapeutic agent
75586839|NCT04672343|Other|Data collection|from D0 to hospital discharge
75586840|NCT04672343|Other|Querying the INSEE database|Vital status at 3 months and 12 months
76053233|NCT04660643|Drug|Tirzepatide|Administered SC
75731601|NCT00899522|Other|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
75731602|NCT00899522|Procedure|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
75731603|NCT01026376|Drug|decitabine|Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
75731604|NCT01026376|Drug|decitabine|Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
76053234|NCT04660643|Other|Placebo|Administered SC
76053235|NCT04659317|Drug|Oxycodone 5 mg Oral Tablet|Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
76053236|NCT04659317|Drug|Placebo oral tablet|Encapsulated placebo tablets x24, to take po q6 hours as need for pain
75586841|NCT04552860|Behavioral|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
75586842|NCT01085357|Procedure|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
75586843|NCT01085357|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
75437732|NCT01590654|Drug|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
76053237|NCT04855643|Device|home-based active tDCS|Anode and cathode electrodes will be placed over the left and right dorsolateral prefrontal cortexes, respectively, with the use of the Omni-Lateral-Electrode system. Caregivers will set up and administer tDCS for participants with ADRD at home. tDCS will be applied for 30 min at an intensity of 2mA, with 30 s ramping up and down. All sessions will be remotely supervised by trained research staff.
75437733|NCT01590667|Device|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
75437734|NCT01590667|Device|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
75437735|NCT01590693|Drug|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
75437736|NCT01590732|Drug|Carboplatin|Given IV
75437737|NCT01590732|Drug|Etoposide|Given IV
75437738|NCT01590732|Drug|Ifosfamide|Given IV
75586844|NCT04552938|Other|pre-LVA|Venous serum samples were collected from patients before LVA.
75586845|NCT04552938|Other|post-LVA|Venous serum samples were collected from patients one-month after LVA.
75586846|NCT02277860|Behavioral|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
75586847|NCT02213523|Dietary Supplement|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
75586848|NCT02213523|Dietary Supplement|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
75586849|NCT02213523|Dietary Supplement|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
75586850|NCT02213523|Dietary Supplement|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
75586851|NCT01085201|Drug|Lexiscan|Given as an infusion
75437739|NCT01590732|Drug|Romidepsin|Given IV
75586852|NCT02213562|Dietary Supplement|200 mg of chrysanthemum flower oil|
75586853|NCT02213562|Dietary Supplement|300 mg of chrysanthemum flower oil|
75586854|NCT02213562|Dietary Supplement|400 mg of chrysanthemum flower oil|
75586855|NCT04671992|Device|Out of-Plane Technique and In-Plane on|A comparison of out of-plane technique and in-plane
75586856|NCT02213679|Dietary Supplement|Guanidinoacetic acid|Dietary supplement
75586857|NCT02213679|Other|Placebo|Placebo
75586858|NCT02213718|Drug|Desflurane|desflurane (7%-8% end-tidal concentration)
75586859|NCT02213718|Drug|propofol|propofol (TCI:3.5-4.0μg/min)
75586860|NCT02213718|Drug|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
75586861|NCT01085084|Drug|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
75586862|NCT01085084|Drug|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
75586863|NCT01085045|Drug|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
75586864|NCT01085045|Drug|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
75731605|NCT00712829|Drug|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
75731606|NCT00712829|Drug|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
75437740|NCT01590745|Device|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
75437741|NCT01590823|Drug|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
75586865|NCT01085045|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
75586866|NCT01085045|Drug|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
75586867|NCT01085045|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
75586868|NCT01085045|Drug|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
75586869|NCT02213796|Drug|Meropenem|
75586870|NCT04552392|Other|No intervention|No intervention
75586871|NCT04552626|Behavioral|Prolonged sitting (social breaks)|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
75586872|NCT04552626|Behavioral|Prolonged sitting with step-up exercise break|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
75586873|NCT04552626|Behavioral|Prolonged sitting with simple resistance activity breaks|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
75586874|NCT01084772|Other|VISIONAIRE Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.
75586875|NCT01084772|Other|Standard Total Knee Arthroplasty|TKA will be performed with standard instrumentation, depending on randomization assignment.
75731607|NCT00899756|Genetic|molecular diagnostic method|
75731608|NCT00899756|Genetic|mutation analysis|
75731609|NCT00712907|Dietary Supplement|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
75731610|NCT00712907|Dietary Supplement|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
75731611|NCT00712907|Other|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997"
75731612|NCT00901238|Procedure|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
75437742|NCT01590836|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
75437743|NCT01590836|Drug|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
75586876|NCT04552158|Dietary Supplement|Mediterranean diet|The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
75586877|NCT00179673|Drug|Lenalidomide|Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
75586878|NCT01084655|Drug|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
75731613|NCT03734224|Procedure|Adhesix mesh|Adhesix mesh
75731614|NCT03734224|Procedure|Progrip mesh|Progrip mesh
75731615|NCT05003141|Drug|PSB202|PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
75731616|NCT00716495|Biological|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
75731617|NCT00899912|Genetic|microarray analysis|
75586879|NCT01084655|Drug|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
75586880|NCT01084655|Drug|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
75437744|NCT01590849|Drug|Contraceptives, Oral, Combined (Yaz®)|"After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use."
75437745|NCT01590901|Drug|Probucol|250mg (1 tablet) bid. p.o for 14 consecutive days
75731618|NCT00899912|Other|diagnostic laboratory biomarker analysis|
75437746|NCT01590914|Procedure|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
75437747|NCT01590914|Procedure|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
75437748|NCT01590940|Procedure|Open inguinal hernia repair with mesh|
75437749|NCT01590966|Drug|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
75586881|NCT04552431|Drug|Ciprofloxacin|Ciprofloxacin, 500 mg twice daily
75586882|NCT04552431|Drug|Tamsulosin Hydrochloride|Tamsulosin Hydrochloride, 0.4 mg once daily
75731619|NCT00716573|Drug|everolimus|0,75 mg bid, 24 months
75731620|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
75731621|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
75882306|NCT01374139|Drug|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
75882307|NCT03817983|Diagnostic Test|MRE review for axSpA|Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease followed by clinical and MRI assessment
75586883|NCT04552431|Drug|Tamsulosin Hydrochloride Placebo|Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily
75586884|NCT04552431|Drug|Ciprofloxacin placebo|Ciprofloxacin placebo (Placebo-CF) one tablet twice daily
75586885|NCT01084538|Drug|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
75586886|NCT00179517|Drug|Anastrozole 1mg|
75586887|NCT00179517|Drug|Placebo Oral Tablet|
75586888|NCT01083641|Drug|Estradiol|10mg oral three times daily
75586889|NCT00179010|Drug|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
75586890|NCT00179010|Drug|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
75731622|NCT00900068|Other|immunoenzyme technique|
75731623|NCT00900068|Other|laboratory biomarker analysis|
75731624|NCT00900068|Other|medical chart review|
75731625|NCT00451204|Drug|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
75731626|NCT00451204|Drug|Placebo|Placebo capsule, once a day, treatment duration is 2 years
75731627|NCT00451204|Drug|Copaxone|Injection, once a day, all subjects
75731628|NCT04067999|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
76053238|NCT04855643|Device|home-based sham tDCS|For sham stimulation, electric current will be applied only in the first 30s tDCS. All sessions will be remotely supervised by trained research staff.
75586891|NCT04552236|Device|Ultrasound ELastography|"A standardized liver Elastography is critical to obtain reliable and accurate results . The patient is imaged in supine or slight 30 degrees left lateral decubitus position, with the right arm elevated above the head to open the intercostal spaces and improve the acoustic window to the liver . it is recommended to sample measurements in the right lobe , which has shown the most reliable results. Transducer pressure on the skin should be similar to regular anatomical B-mode imaging.~When using SWE techniques, the acoustic radiation force push pulse should be applied perpendicular to the liver capsule, with measurements obtained 4-5 cm deep to the skin and within a minimum 1-2 cm of liver parenchyma to limit refraction of the pulse. The operator should verify that these areas are free of vascular and biliary structures and rib shadows."
75731629|NCT00900302|Genetic|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
75882308|NCT02107820|Behavioral|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
75882309|NCT02107820|Device|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
75437750|NCT01590966|Drug|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
75586892|NCT01083602|Drug|panobinostat|PAN 20 mg PO given TIW, weeks 1&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
75586893|NCT01083602|Drug|bortezomib|
75586894|NCT01083602|Drug|dexamethasone|
75586895|NCT04552002|Dietary Supplement|Synbiotic group|Probiotics and prebiotics
75586896|NCT00178464|Drug|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
75586897|NCT04671914|Drug|Hyaluronic Acid 20 MG/ML Injectable Solution|Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D&C
75731630|NCT00900302|Other|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
75731631|NCT00900302|Other|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
75882310|NCT02110784|Drug|Eurartesim tablets|dosage bands: 24 to <36 kg body weight: 2 tablets a day for three consecutive days 36 to <75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
76053239|NCT03602261|Drug|Calcifediol Oral Capsule|Capsule, weekly
76053240|NCT03602261|Drug|Placebo oral capsule|Capsule, weekly
75586898|NCT04671914|Other|Dilation and curretage|After abortion in II trimester we do D&C.
75586899|NCT01083485|Drug|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
75586900|NCT01083485|Drug|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
75586901|NCT02213835|Other|Specific Carbohydrate diet (SCD)|
75586902|NCT04551924|Drug|HR18034|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
75586903|NCT04551924|Drug|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg [0.5%, 5mg/mL] x 30mL
75586904|NCT04671836|Drug|Lorazepam 1Mg Tablet|"1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI."
75586905|NCT04671836|Drug|Placebo|Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
75586906|NCT04552353|Drug|Vaway|Drug: Voriconazole. Pharmacokinetic study under fasting conditions
75586907|NCT00556088|Drug|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
75437751|NCT01590992|Behavioral|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
75586908|NCT00177294|Drug|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
75586909|NCT00177294|Behavioral|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
75586910|NCT00177294|Behavioral|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
76053241|NCT02141659|Drug|TAK-385|TAK-385 Tablets.
76053242|NCT01640249|Drug|Placebo|Capsules administered orally
75437752|NCT01590992|Behavioral|Relaxation therapy|Progressive muscle relaxation (Jacobson)
75437753|NCT01591031|Drug|Sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
75437754|NCT01591031|Drug|Rocuronium|anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
75437755|NCT01591057|Dietary Supplement|2 portions of fruit and vegetables per day|Consume 2 portions of fruit and vegetables per day
75586911|NCT01082081|Drug|Paracetamol 1000 mg|Paracetamol 1000 mg
75586912|NCT01082081|Drug|Paracetamol 500 mg|Paracetamol 500 mg
75586913|NCT01082081|Drug|Placebo|Placebo
75586914|NCT00177216|Drug|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
75586915|NCT00177216|Drug|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
75586916|NCT00177216|Drug|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
75586917|NCT01081886|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
76053243|NCT01640249|Drug|LY3006072|Capsules administered orally
75586918|NCT01081886|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
75882311|NCT04988425|Drug|TNFα Monoclonal Antibody|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
75882312|NCT04988425|Drug|Methylprednisolone|Injection of 500mg of methylprednisolone immediately after admission before surgery.
75882313|NCT04988425|Drug|Saline|Injection of the same volume of saline immediately after admission before surgery
76053244|NCT02121301|Drug|Low Dose 0.155µg/mL SkQ1 ophthalmic solution|eyedrops
75586919|NCT02213952|Drug|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
75586920|NCT02213952|Other|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
75586921|NCT01081769|Drug|paliperidone palmitate injection|injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
75586922|NCT01081769|Drug|oral antipsychotics|daily treatment according to local label for maximally 24 months
75586923|NCT04551768|Drug|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
75437756|NCT01591057|Dietary Supplement|5 portions of fruit and vegetables per day|Consume 5 portions of fruit and vegetables per day
75586924|NCT04551768|Drug|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
75586925|NCT04671407|Drug|Hypertonic Saline|Hypertonic Saline 3% and 0.9%
75586926|NCT02213991|Device|Intraoperative radiotherapy using Intrabeam®|"Operation day~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~Purse string suture pulles up tissues and wraps up the applicator.~Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~After IORT, applicator was out of the operative field, and usual wound closure will be done.~Postoperative period~Chemotherapy WBRT (46 Gy) for 4~5 weeks~Endocrine therapy or target therapy"
75586927|NCT04671641|Device|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
75731632|NCT00900302|Procedure|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
75731633|NCT00721877|Drug|resveratrol|Given orally
75731634|NCT00721877|Other|pharmacological study|Correlative studies
75731635|NCT00721877|Other|laboratory biomarker analysis|Correlative studies
75437757|NCT01591057|Dietary Supplement|8 portions of fruit and vegetables per day|Consume 8 portions of fruit and vegetables per day
75437758|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
75437759|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
75586928|NCT04551534|Drug|DNL201|Oral dose(s)
75731636|NCT03742570|Behavioral|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
76025022|NCT04813705|Drug|Chemotherapy|The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
75437760|NCT01591083|Drug|esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score >=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score <6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days."
75437761|NCT01591122|Drug|Placebo and prednisone|Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.
75586929|NCT04551534|Drug|Placebo|Oral dose(s)
75731637|NCT00716651|Drug|mepolizumab|750 mg mepolizumab iv q4wk until week 32
75731638|NCT00900380|Other|flow cytometry|
75731639|NCT00900380|Other|immunological diagnostic method|
75731640|NCT00900380|Other|laboratory biomarker analysis|
75731641|NCT01026532|Biological|Segmental Allergen Challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
75731642|NCT01022788|Behavioral|Home-based counselling|
75731643|NCT00900458|Behavioral|Aerobic Exercise training|aerobic exercise training (cycling)
76053245|NCT02121301|Drug|High Dose 1.55µg/mL SkQ1 ophthalmic solution|eyedrops
76053246|NCT02121301|Drug|Placebo (Vehicle) opthalmic solution|eyedrops
76053247|NCT05422703|Device|Kinesio tape|Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).
76053248|NCT05422703|Other|Gauze pack|Place gauze pack over surgical site for one hour after surgery.
76053249|NCT05422703|Device|ice pack|Ice packs will be applied for 6 hours after surgery in all patients
76053250|NCT05422703|Procedure|Manual therapy|passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.
75437762|NCT01591122|Drug|Abiraterone acetate and prednisone|Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
75437763|NCT01591135|Drug|Paclitaxel plus 5-fluorouracil|5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
75437764|NCT01591135|Drug|Cisplatin plus 5-fluorouracil|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
75437765|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
75586930|NCT04551456|Biological|Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS|Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease
75586931|NCT01081301|Behavioral|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
76053251|NCT05422703|Drug|Analgesic|NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
75586932|NCT00174954|Procedure|MRI|Subjects underwent MRI to evaluate tophi.
75586933|NCT04671563|Drug|Tenofovir Disoproxil Fumarate 300 MG|One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
75586934|NCT04551573|Drug|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
75731644|NCT02571803|Behavioral|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
75731645|NCT02571803|Other|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
76053252|NCT05422703|Drug|Proteolytic enzymes|1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
76053253|NCT05422703|Drug|Mouth wash|use 0.12% chlorhexidine or povidone iodine mouthwash daily
76053254|NCT05422703|Dietary Supplement|Soft cold diet|For the day of surgery
76053255|NCT02227862|Drug|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
76053256|NCT02227862|Drug|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
75437766|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
75437767|NCT01591148|Drug|propofol|Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
75437768|NCT01591187|Other|Text messaging|Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.
75586935|NCT04551573|Drug|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
75731646|NCT03537586|Drug|Bivalirudin|After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.
75586936|NCT01081145|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
75586937|NCT01081145|Other|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
75586938|NCT00174915|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
75731647|NCT03537586|Drug|Adenosine|An intravenous infusion of adenosine (140 μg/kg/min) will be administered via a large peripheral or central vein to induce steady-state maximal hyperemia.
75731648|NCT03537586|Drug|Heparin|Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.
75731649|NCT03537586|Device|Pressure-Temperature Sensor Guidewire|Abbott's Pressure Wire X will be used to measure fractional flow reserve (FFR), cardiac magnetic resonance (CMR) and Index of Microcirculatory Resistance (IMR) in the Left Anterior Descending (LAD) Artery and major epicardial coronary vessels associated with myocardial ischemia.
75437769|NCT01591187|Other|Questionnaire|Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.
75586939|NCT00174915|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
75437770|NCT01591187|Other|Interviews|Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
75437771|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
75437772|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
75437773|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
75437774|NCT01591226|Dietary Supplement|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
75437775|NCT01591226|Dietary Supplement|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
75437776|NCT01591226|Dietary Supplement|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
75437777|NCT01591226|Dietary Supplement|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
75437778|NCT01591265|Procedure|Extraction of upper and lower FPM teeth|Extraction of upper and lower FPM teeth
75437779|NCT01591265|Procedure|Extraction of lower FPM tooth|Extraction of lower FPM tooth only
75586940|NCT00174915|Drug|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
75586941|NCT00174915|Drug|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine >1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
75731650|NCT03537586|Device|Guiding Catheter|Medtronic's 6F Launcher Guide Catheter will be used to engage the left main coronary artery.
75731651|NCT00894218|Procedure|Arthroplasty|Hip or knee arthroplasty
75731652|NCT00722033|Drug|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
75731653|NCT00894374|Drug|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
75437780|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
75437781|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
75437782|NCT01591304|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
75437783|NCT01591343|Biological|Depigoid® (500 DPP/ml)|"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"
75437784|NCT01591395|Procedure|laparoscopic total extraperitoneal hernia repair (single port vs. multiport)|comparison of single port laparoscopic TEP and multiport laparoscopic TEP repair for adult inguinal hernia
75437785|NCT01591434|Device|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
75437786|NCT01591434|Device|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
75586942|NCT00174915|Drug|Placebo|Placebo, orally, once daily for up to 28 weeks.
75731654|NCT00894374|Drug|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
75731655|NCT04920149|Drug|Mesalamine|The IMP will be supplied as sachets with slow-releasing granules.
75731656|NCT04920149|Drug|Placebo|The IMP will be supplied as sachets with slow-releasing granules.
75731657|NCT01026610|Drug|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
75731658|NCT01026610|Drug|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
75731659|NCT01026610|Drug|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
75586943|NCT04671368|Diagnostic Test|Artificial Intelligence|The investigators will use the Artificial Intelligence Diagnostic System to review the H＆E stained slide of each patient and then report the classification of the tumor on a 10-type scale.
75586944|NCT04671368|Diagnostic Test|Practicing Pathologists|The ordinary pathologist will review the H＆E stained slide of each patient(without additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale only bases on the slide images
75731660|NCT00900536|Genetic|mutation analysis|
75586945|NCT04671368|Diagnostic Test|Gold Standard|Firstly, the two expert pathologist(>=10 years of experience) will review the H＆E stained slide of each patient on their own (with additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale.If they report the same opinion, that opinion will perform as the ground truth; while if their opinion clash with each other, the expert pathologist(>=15 years of experience) will get involved and the agreement of three experts will perform as the ground truth
75586946|NCT01080716|Biological|Part 1/Arm 1 of Study: WRSS1 vaccine|Single, oral dose of WRSS1
75586947|NCT01080716|Biological|Part 1/Arm 2 of Study: Placebo vaccine|Placebo vaccine
75586948|NCT01080716|Biological|Part 2/Arm 1 of Study: S. sonnei 53G|Subject from Part 1/Arm 1 of Study are given 53G S. sonnei
75586949|NCT01080716|Biological|Part 2/Arm 2 of Study: S. sonnei 53G|10 naïve controls are given S. sonnei 53G
75731661|NCT00900536|Genetic|polymorphism analysis|
75882314|NCT03553784|Other|Group delivered Low Intensity Cognitive Behavioural Therapy|The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
75586950|NCT04551339|Dietary Supplement|PreserVision AREDS formulation soft gels or tablets|Two tabs taken daily for three months
75586951|NCT04551339|Dietary Supplement|Multivitamin with 11mg of zinc|One tab taken daily for three months
75586952|NCT04671446|Diagnostic Test|Autoantibody ELISA|Serum will be tested for novel autoantibodies against eosinophil proteins by ELISA, such as those previously identified as of importance (e.g. eosinophil-peroxidase, EPX) and also novel candidate proteins specific to eosinophils (including ARFIP1, BCL2A1, PPCDC, SLC12A6 etc) as identified by FANTOM5 geneset analysis.
75731662|NCT00900536|Genetic|protein expression analysis|
75731663|NCT00900536|Other|immunohistochemistry staining method|
75731664|NCT00900536|Other|laboratory biomarker analysis|
75731665|NCT00713063|Behavioral|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
75731666|NCT00713063|Behavioral|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
75586953|NCT04671134|Other|Biomimetic remineralizing agent|Self-assempling peptide
75586954|NCT04671134|Other|Resin Modified Glass Ionomer Varnish|Resin Modified Glass Ionomer Varnish
75586955|NCT04571489|Drug|Gimatecan|Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.
75586956|NCT04571489|Drug|tegafur, gimeracil and oteracil potassium|Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.
75586957|NCT04571489|Drug|gemcitabine|Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
75586958|NCT00172185|Drug|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
75586959|NCT00172185|Drug|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
75586960|NCT01080326|Device|Endoscopic Translumenal Omental Patch|The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
75586961|NCT00171951|Drug|Pasireotide|Pasireotide 600 μg or 900 μg was administered as an SC injection.
75586962|NCT01080131|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
75731667|NCT03530254|Diagnostic Test|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
75586963|NCT01080131|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
75586964|NCT01080131|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
75586965|NCT01080131|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
75586966|NCT04551612|Radiation|Multislice computed tomography temporal bone|Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
75586967|NCT00171873|Drug|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
75437787|NCT01591525|Behavioral|Education on risk factors for Type II Diabetes|one-on-one education provided by a nurse practitioner or physician
75437788|NCT01591525|Behavioral|Education on Type II Diabetes|one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
75437789|NCT01591525|Behavioral|Education on regular visits to a Primary Care Provider|one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
75437790|NCT01591551|Drug|Natalizumab (Tysabri)|300 mg IV every 4 weeks
75586968|NCT00171873|Drug|Placebo|Sodium chloride intramuscularly every 28 days
75586969|NCT01087151|Drug|ABT-263|Oral repeating dose
75586970|NCT01087151|Drug|rituximab|Intravenous repeating dose
75731668|NCT03530254|Diagnostic Test|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
75731669|NCT00901550|Drug|Methotrexate|All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
75731670|NCT00901550|Drug|Infliximab|Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
75586971|NCT04551027|Behavioral|compensatory cognitive treatment|a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
75586972|NCT04571528|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
75586973|NCT04571528|Behavioral|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
75437791|NCT01591564|Behavioral|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
75586974|NCT04571528|Behavioral|TAU + Physiotherapy part of VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
75731671|NCT02573051|Drug|Misoprostol|800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
75731672|NCT02573051|Drug|Isosorbide mononitrate|40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
75731673|NCT02573051|Other|placebo|
75731674|NCT02539940|Device|Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV|Angioplasty for revascularization in below-the-knee arteries
75437792|NCT01591590|Other|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
75437793|NCT01591590|Other|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
75437794|NCT01591590|Other|Blood samples (plasma preparation and CTC)|
75731675|NCT01028092|Drug|Anti R-IL2 + Cyclosporine|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
75731676|NCT01028092|Drug|Thymoglobulin + Everolimus|"Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
75882315|NCT03554096|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
75882316|NCT02104154|Device|Samsung LABGEO PT10 Hepatic Panel|
75882317|NCT02110862|Other|Transittime. Defecography|
75882318|NCT01343901|Drug|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
75586975|NCT00171834|Drug|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
75586976|NCT02214030|Device|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
75586977|NCT04571996|Drug|ODM-104|Capsule
75731677|NCT01028092|Drug|Anti R-IL2 + Cyclosporine then Everolimus|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
75731678|NCT00900614|Drug|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
75731679|NCT00900692|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
75731680|NCT02571647|Other|Non interventional study|"Patients agreeing to participate in the study will have a cognitive assessment and geriatric assessment, carried out according to usual practices and grids clinical gerontology cluster.~They will benefit in addition to a noninvasive screening and risk-free ophthalmic (visual acuity, intraocular pressure, examination of the eyelids and fundus)."
75731681|NCT00901706|Other|Comprehensive Geriatric Assessment and APS Usual Care|Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
75882319|NCT02110940|Other|Neurodynamic mobilization exercise|"The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise."
75586978|NCT04571996|Drug|Paracetamol|Rapidly dissolving tablet
75586979|NCT00171249|Drug|STI571 400 mg|STI571 capsules and tablets
75731682|NCT00901706|Other|APS usual care|APS usual care consists of social, medical, and legal assistance.
75731683|NCT00605306|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
75731684|NCT00605306|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
75731685|NCT00905918|Dietary Supplement|vitamin E|Given orally
75731686|NCT00905918|Other|laboratory biomarker analysis|All patients undergo biomarker analyses
75882320|NCT02110940|Other|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
75882321|NCT02104232|Behavioral|THPP-I|
75882322|NCT02104232|Behavioral|EUC|
75586980|NCT00171249|Drug|STI571 600 mg|STI571 capsules and tablets
75586981|NCT04671056|Drug|MGL-3196|MGL-3196 100 mg tablet administered orally in the morning for 13 days
75586982|NCT04671056|Drug|Pioglitazone 15mg|Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state
75586983|NCT01082549|Drug|gemcitabine/carboplatin|i.v.
75586984|NCT01082549|Drug|gemcitabine/carboplatin plus Iniparib|i.v.
75586985|NCT02214069|Device|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
75586986|NCT04550949|Drug|QL1206|The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
75731687|NCT00894608|Drug|letrozole + gonadotropins|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
75731688|NCT00894608|Drug|GnRHa + gonadotropins|patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
75731689|NCT00901784|Drug|Topiramate|25mg Tablets
75731690|NCT00607022|Device|dental implant|Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
75731691|NCT00722345|Behavioral|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
75586987|NCT04550949|Drug|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
75586988|NCT01085630|Drug|pemetrexed disodium|Given IV
75586989|NCT01085630|Other|clinical observation|
75437795|NCT01591603|Procedure|1 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy
75437796|NCT01591603|Procedure|5 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
75437797|NCT01591668|Drug|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
75437798|NCT01591668|Drug|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
75586990|NCT00171210|Drug|Deferasirox|Tablets taken orally once a day.
75586991|NCT04670861|Procedure|Upper extremity Biodex balance training|"The person assumes the prone plank posture with both hands poisoned in the area assigned for foot placement on the tilting balance platform. Using the four keypads, the person's left hand, left wrist, right hand and right wrist positions are entered into the system using the midline of the hand and the platform grid as reference points. The dot that appears on the position patient screen represents the person's segmental center of gravity.~During each trial test, the person should shift his weight to move the cursor from the center along a target path and back as quickly and with a little deviation as possible. The same process is repeated for each of the targets. Target paths activate in a random order."
75731692|NCT00722345|Behavioral|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current & past activities; 2) reviewing the pros & cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
75437799|NCT01591720|Behavioral|Tailored Internet-based CBT for depression and anxiety|"This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
75731693|NCT00905996|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
75437800|NCT01591759|Drug|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
75731694|NCT00905996|Drug|Beta-blocker (propranolol)|
75731695|NCT02574065|Drug|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
75731696|NCT02574065|Other|The placebo consists of an identical formulation without L. reuteri DSM 17938|
75731697|NCT02539628|Drug|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
75731698|NCT00713297|Behavioral|satisfaction questionnaire|Satisfaction questionnaire
75586992|NCT00171054|Drug|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
75586993|NCT00171054|Drug|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
75586994|NCT00171054|Drug|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure < 140 mmHg and Diastolic Blood Pressure < 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
75586995|NCT00174837|Drug|Tirapazamine|in combination with cisplatin and concomitant radiation
75586996|NCT00174837|Drug|Cisplatin|with concomitant radiation
75586997|NCT04670705|Other|patients' characteristics|There was no intervention.
75586998|NCT00179400|Drug|Pioglitazone 45 mg|
75586999|NCT00179400|Drug|Placebo|
75587000|NCT04991090|Radiation|escalation dose of LLNs|The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost of 58Gy.
75587001|NCT04550793|Drug|Botulinum toxin injection|Botulinum toxin injection at affected brachialis and/or biceps brachials.
75587002|NCT04550910|Radiation|Hypofractionation Schedules for Breast Cancer patients after mastecomy|Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
75587003|NCT00479856|Drug|Lapatinib|Small molecule tyrosine kinase inhibitor
75587004|NCT00479856|Drug|Capecitabine|Chemotherapy
75587005|NCT00479856|Drug|Docetaxel|Chemotherapy
75587006|NCT00479856|Drug|nab-Paclitaxel|Chemotherapy
75437801|NCT01591759|Drug|Placebo|Placebo arm of single-blind study
75587007|NCT04997759|Drug|Neostigmine and Sugammadex|Compare both groups efficacy of reverse the neuromuscular blocking agent
75587008|NCT00479466|Drug|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
75587009|NCT00479466|Drug|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
75731699|NCT00901862|Device|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
75437802|NCT01591798|Procedure|Robotic surgery|Robotic assisted rectal resection
75437803|NCT01591798|Procedure|Laparoscopic surgery|Laparoscopic assisted rectal resection
75437804|NCT01591811|Radiation|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
75437805|NCT01591811|Radiation|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
75437806|NCT01591824|Other|Resonant oscillation|"Resonant sustained oscillations are applied in the following areas~general column.~lumbar muscles, and paraspinal muscles,~sacral decompression oscillatory~Opening by lateral vertebral lumbar rhythmic swing.~Balancing and pelvic decompression~Swing-lumbar vertebral rotation."
75437807|NCT01591824|Other|column exercise group|"paraspinal muscle stretching exercises~postural correction~mobilization exercises thoracic and lumbar~Motor control exercises"
75437808|NCT01591850|Drug|RO5093151|Single oral dose
75437809|NCT01591850|Drug|atazanavir|Multiple oral doses
75437810|NCT01591850|Drug|ketoconazole|Multiple oral doses
75437811|NCT01591850|Drug|rifampicin|Multiple oral doses
75437812|NCT01591850|Drug|ritonavir|Multiple oral doses
75587010|NCT00479466|Drug|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
75587011|NCT00479466|Drug|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
75587012|NCT04991948|Drug|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
75587013|NCT04991948|Drug|FOLFOX|5-FU, leucovorin and oxaliplatin
75587014|NCT04991948|Drug|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
75587015|NCT04550286|Behavioral|Smartphone Use Reduction in Academic Context|"Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013)."
75587016|NCT04550286|Behavioral|Control|Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
75731700|NCT00901862|Device|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
75587017|NCT04990778|Drug|Eprenetapopt|Given IV
75882323|NCT02104466|Procedure|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
75882324|NCT05617521|Device|Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device
75437813|NCT01591876|Other|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
75437814|NCT01591876|Other|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
75437815|NCT01591889|Drug|Tinidazole|500 mg tablet
75437816|NCT01591889|Drug|Tinidazole|500 mg tablet
75437817|NCT01591902|Drug|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
75587018|NCT04990778|Drug|Venetoclax|Given PO
75731701|NCT02573987|Drug|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
75731702|NCT02573987|Drug|Lidocaine|standard strategy by local injection anesthesia of lidocaine
75731703|NCT00901940|Biological|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
75731704|NCT00901940|Biological|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
75731705|NCT00906308|Drug|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
75731706|NCT00906308|Drug|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
75882325|NCT05617521|Device|Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.
75731707|NCT00906308|Drug|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
75731708|NCT00906386|Drug|Varenicline|oral, 1 mg twice daily, 12 weeks
75882326|NCT04862858|Other|Educational Intervention|The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
75882327|NCT02104622|Device|ReWalk Rehabilitation 2.0|
75437818|NCT01591902|Drug|Placebo-Control|3.0 mL vials
75587019|NCT04993703|Other|Kinesiotaping|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, kinesiotaping and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.times per day 3sets of ten repetitions) will be applied.
75587020|NCT04993703|Other|Night Splinting|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, night splinting and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
75587021|NCT04993703|Other|Control Group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
75587022|NCT00479388|Drug|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
75587023|NCT00479388|Drug|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
75587024|NCT00479388|Drug|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
75587025|NCT04670939|Procedure|breath exercises|diaphragmatic breathing exercise that used during weaning is the respiratory physiotherapy
75731709|NCT00906386|Drug|placebo|oral, 1 mg twice daily, 12 weeks
75731710|NCT00722501|Drug|ERB-257|
75731711|NCT00722501|Other|placebo|
75587026|NCT04670276|Procedure|injection of emulsified adipose tissue stromal vascular fraction|Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
75587027|NCT00479232|Drug|vorinostat|
75731712|NCT00722579|Device|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
75731713|NCT04067687|Other|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
75731714|NCT04035902|Drug|Ferric carboxymaltose|Ferric carboxymaltose is administered during surgery
75731715|NCT04035902|Drug|control|Ferric carboxymaltose is not administered
75882328|NCT05219643|Device|NAVA|Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
75882329|NCT05219643|Device|PSV|According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
75882330|NCT02108132|Biological|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
75437819|NCT01591915|Other|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
75437820|NCT01591941|Other|Core-PAC|"Core position and control movement strategy (Core-PAC):~Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task."
75437821|NCT01591967|Device|Activator IV Adjusting Instrument|Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
75437822|NCT01591980|Drug|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
75587028|NCT00479232|Drug|decitabine|
75587029|NCT00478881|Drug|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
75587030|NCT00478881|Drug|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
75587031|NCT02214108|Other|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
75587032|NCT04571775|Device|Qi-Shield user group|real device Qi-Shield (treatment)
75587033|NCT04571775|Device|Sham Qi-Shield user group|sham device (placebo)
75731716|NCT00894842|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
75731717|NCT00894842|Drug|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
75731718|NCT02571569|Drug|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
75587034|NCT04670120|Drug|Pyrifazimine (TBI-166)|"The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
75731719|NCT02571569|Drug|BAY1093884|Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
75731720|NCT00906620|Other|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
75731721|NCT02539472|Other|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
75587035|NCT00556127|Drug|Rituximab|375 mg/m2 on day 1
76053257|NCT05422391|Dietary Supplement|3 day caloric restriction/metabolic reset|Participants will consume ~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
75437823|NCT01591980|Drug|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
75437824|NCT01591980|Drug|placebo|Identical placebo capsules will be administered in the same way.
75587036|NCT00556127|Drug|Epirubicin|110 mg/m2 on day 3
75437825|NCT01591993|Procedure|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
75587037|NCT00556127|Drug|Cyclophosphamide|1200 mg/m2 on day 3
75587038|NCT00556127|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
75587039|NCT00556127|Drug|Prednisone|40 mg/m2 from day 1 to 5
75731722|NCT00902252|Device|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
75437826|NCT01591993|Procedure|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
76053258|NCT02120833|Device|EpiCeram® Skin Barrier Emulsion|Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
76053259|NCT02120833|Drug|Colloidal Oatmeal Cream|Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
76053260|NCT04615949|Drug|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
76053261|NCT04615949|Drug|Placebo|Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
76053262|NCT04591379|Drug|Influenza Vaccines|Intratumoral application of an unattenuated influenza vaccine
75437827|NCT01592019|Drug|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
75437828|NCT01592019|Device|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
75437829|NCT01592019|Drug|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
75437830|NCT01592019|Device|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
75587040|NCT00556127|Drug|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
75587041|NCT00556127|Drug|Mitoxantrone|8 mg/m2 for 3-day
75587042|NCT00556127|Drug|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
75587043|NCT00556127|Drug|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
75587044|NCT00556127|Drug|Carmustine BCNU|300 mg/m2 on day -7
75587045|NCT00556127|Drug|Etoposide|100 mg/m2/12 hours
75587046|NCT00556127|Drug|Melphalan|140 mg/m2 on day -2
75587047|NCT00556127|Radiation|Radiotherapy|Involved Field Radiotherapy (IF-RT)
75587048|NCT00556127|Procedure|PBSC reinfusion|ASCT
75731723|NCT00902252|Device|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
75731724|NCT00902252|Device|Vitala™|"After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215)."
75731725|NCT00902408|Dietary Supplement|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
75731726|NCT00713687|Drug|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"Photodynamic therapy (PDT) after successful drainage:~Photosan® 2 mg/kg i.v. 48 hrs before laser activation~9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~iteration every 14 days~afterwards 4 weeks intermission~Iteration of 1. and 2. in case of good compatibility"
76053263|NCT05411627|Device|Shockwave Therapy|Participants will receive shockwave therapy once per week for three weeks.
76053264|NCT02170207|Drug|Lansoprazole|Lansoprazole 30 mg injection
75731727|NCT02539550|Drug|Placebo|Placebo
75731728|NCT02539550|Drug|PF-06266047|PF-06266047
75731729|NCT00717431|Procedure|Hippocampal Electrical Stimulation|Surgical Implantation of electrode and stimulator
75731730|NCT02540876|Drug|Ilorasertib|Given PO
75731731|NCT02540876|Other|Laboratory Biomarker Analysis|Correlative studies
75731732|NCT04353791|Drug|OST-122|Active dose
75437831|NCT01592032|Drug|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
75437832|NCT01592032|Drug|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
75731733|NCT04353791|Drug|Placebo|Placebo
75731734|NCT00894920|Dietary Supplement|biotin|capsule approximately 30 mcg daily 21 days
75731735|NCT00894920|Dietary Supplement|biotin|capsule 300 mcg daily 21 days
75731736|NCT00722735|Drug|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
75731737|NCT00722735|Drug|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
75437833|NCT01592032|Drug|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
75437834|NCT01592032|Drug|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
75437835|NCT01592032|Drug|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
75731738|NCT00902642|Behavioral|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
75731739|NCT00722813|Other|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
75731740|NCT04067531|Drug|treatment of BV with first Deqularum and then direkt after with vaginal clindamycin|All patients will get the same treatment
75731741|NCT00606632|Drug|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
75731742|NCT00606632|Procedure|CT|contrast enhanced CT scan
75731743|NCT00713765|Drug|AZD3480|18 total doses of 40 mg, on days 1-18
75731744|NCT00713765|Drug|Donepezil|One single dose of mg on day 5
75731745|NCT00717587|Drug|motexafin gadolinium|
75731746|NCT00717587|Drug|sunitinib malate|
75731747|NCT00717587|Genetic|comparative genomic hybridization|
75731748|NCT00717587|Genetic|gene expression analysis|
75731749|NCT00717587|Genetic|mutation analysis|
75731750|NCT00717587|Genetic|polymorphism analysis|
75731751|NCT00717587|Other|immunohistochemistry staining method|
75731752|NCT00717587|Other|iodine I-124 girentuximab|
75731753|NCT00717587|Other|laboratory biomarker analysis|
75731754|NCT00717587|Other|pharmacological study|
75731755|NCT00717587|Procedure|adjuvant therapy|
75731756|NCT00717587|Procedure|neoadjuvant therapy|
75731757|NCT00717587|Procedure|therapeutic conventional surgery|
75731758|NCT00713843|Other|Manual Therapy Utrecht|Manual Therapy (6 weeks).
75587049|NCT00478647|Biological|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
75587050|NCT04990934|Behavioral|Semistructured Interview|Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
75587051|NCT04550325|Biological|Kamada Anti-SARS-CoV-2|Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods
75587052|NCT00556205|Drug|Sunitinib|Sunitinib orally once daily
75731759|NCT00713843|Other|Physical Therapy|Physical Therapy (six weeks).
75731760|NCT00894998|Biological|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
75882331|NCT02108132|Biological|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
75882332|NCT05706363|Procedure|Quadriceps graft|Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
76053265|NCT05399927|Other|Music Intervention|The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
75437836|NCT01592123|Procedure|The active anterior rhinomanometry|In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
76053266|NCT04968275|Behavioral|CHAMPS|CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
76053267|NCT04746079|Behavioral|Positive Imagery Therapy|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
75437837|NCT01592123|Behavioral|The Pittsburgh Sleep Quality Index (PSQI)|PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score >5 is considered to be suggestive of significant sleep disturbance.
75587053|NCT00556205|Drug|Bevacizumab|Intravenously every 14 days
75587054|NCT00478608|Drug|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
75587055|NCT00556244|Procedure|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
75587056|NCT04550559|Procedure|Endoscopic ureterolitotripsy|Endoscopic ureterolithotripsy
75587057|NCT00556283|Device|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
75587058|NCT00556283|Behavioral|Biofeedback|electromyographic-based treatment sessions
75587059|NCT00478257|Device|bright white light|Intervention: Bright white light administered for 30 minutes each morning
75587060|NCT00478257|Device|comparator red light treatment|dim red light administered for 30 minutes every morning
75587061|NCT00478140|Biological|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
75587062|NCT00478140|Other|laboratory biomarker analysis|Correlative studies
75731761|NCT00894998|Biological|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
75882333|NCT02108210|Drug|Anakinra|
75882334|NCT02108210|Drug|Placebo|
75882335|NCT03053271|Drug|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
75437838|NCT01592123|Behavioral|The Beck Anxiety Inventory (BAI)|The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
75731762|NCT02572895|Dietary Supplement|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
75731763|NCT00717665|Device|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
75731764|NCT00717665|Other|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
75731765|NCT00713921|Drug|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
75437839|NCT01592123|Behavioral|The Van Dream Anxiety Scale (VDAS)|The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
75437840|NCT01592136|Drug|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
75437841|NCT01592149|Other|No Drug|No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
75731766|NCT04067453|Other|Fatiguing contractions|10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
75731767|NCT02571335|Behavioral|Intensive Training|"Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.~Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.~Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.~Week 3 Same as week 2."
75731768|NCT02571335|Behavioral|Normal Training|The control intervention is the normal rehabilitation program of the Valens clinic.
75731769|NCT04067375|Other|Clinical data collection.|The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.
75731770|NCT02571413|Other|score before teaching|score the check-point of correct INCS usage before teaching
75882336|NCT03053271|Drug|Placebo|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
75882337|NCT02104700|Drug|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
75882338|NCT02104778|Drug|Dexamethasone|In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
75882339|NCT02104778|Drug|Epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
75882340|NCT05205681|Diagnostic Test|Pre-operative imaging|Use of pre-operative imaging or the diagnosis of acute appendicitis
75882341|NCT02104856|Device|Alair System (Bronchial Thermoplasty)|
75437842|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
75437843|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
75437844|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
75437845|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
75731771|NCT02571413|Other|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
75731772|NCT02571413|Other|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
75731773|NCT00713999|Drug|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
75731774|NCT04072601|Drug|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
75731775|NCT04072601|Drug|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
75731776|NCT00717821|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
75731777|NCT00717821|Drug|Epoetin Beta|Participants who are receiving SC or IV epoetin beta will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
75731778|NCT00717821|Drug|Darbepoetin Alfa|Participants who are receiving SC or IV darbepoetin alfa will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
75437846|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
75437847|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
75731779|NCT00722891|Device|Purevision Lenses with ReNu Multiplus|Purevision lenses using ReNu Multiplus lens solution for 28 days
75437848|NCT01592162|Drug|Propofol (B-Braun) and NaCl 0.9%|propofol administered by a closed-loop system and saline
75437849|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
75437850|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
75437851|NCT01592188|Behavioral|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
75731780|NCT00722891|Device|Purevision Lenses with Optifree RepleniSH|Purevision lenses using Optifree RepleniSH lens solution for 28 days
75437852|NCT01592188|Behavioral|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
75437853|NCT01592201|Drug|Paliperdidone ER|Form = osmotic release oral system, route = oral
75437854|NCT01592201|Drug|Aripiprazole, olanzapine and risperidone (Antipsychotics)|Form = tablet, route = oral
75437855|NCT01592214|Other|Placebo|Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
75587063|NCT04990739|Drug|MTB-9655|"MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime."
75587064|NCT00478023|Drug|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
76053268|NCT04855097|Diagnostic Test|BVA-100|The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.
75731781|NCT00717899|Device|Spirometry (Pony spirometer)|Spirometry at rest
75731782|NCT02571257|Drug|Gemcabene|1-300 mg tablet, QD, 56 days
75731783|NCT02571257|Drug|Gemcabene|3-300 mg tablets, QD, 56 days
75731784|NCT02571257|Drug|Placebo|
75731785|NCT00714155|Other|Questionnaires, Physical Examination|Questionnaires, Physical Examination
75437856|NCT01592214|Drug|XF-73 in 2% Klucel gel|XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
75437857|NCT01592214|Drug|XF-73 in 4% Klucel gel|XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
75437858|NCT01592227|Drug|Marketed paracetamol|Marketed paracetamol
75437859|NCT01592227|Drug|Experimental paracetamol formulation|Experimental paracetamol formulation
75437860|NCT01592253|Drug|Sirolimus|Beginning on day, an initial maintenance dose of 2mg/day should be given. A trough level should be obtained between days 3 and 8, and the daily dose of sirolimus should be adjusted thereafter.
75437861|NCT01592279|Drug|liraglutide|
75587065|NCT00478023|Drug|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
75587066|NCT00478023|Drug|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
75731786|NCT02572973|Other|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
75731787|NCT00722969|Drug|sorafenib + erlotinib|sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
75731788|NCT04069325|Drug|simiaowan|pills, 6g twice daily (BID), oral, 12 weeks
75731789|NCT04069325|Drug|placebo|pills, 6g twice daily (BID), oral, 12 weeks
76053269|NCT02227784|Drug|Evacetrapib|Administered orally
76053270|NCT02227784|Drug|Atorvastatin|Administered orally
75437862|NCT01592279|Drug|Insulin injections|
75437863|NCT01592305|Drug|atazanavir|multiple oral doses
75437864|NCT01592305|Drug|danoprevir|multiple oral doses
75587067|NCT00478023|Drug|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
75587068|NCT00478023|Drug|Placebo|4 - 6 hourly; Total 72 hours
75731790|NCT04069325|Drug|febuxostat|tablets, 40 mg once daily (QD), oral, 12 weeks
75731791|NCT00723047|Procedure|Fibrin glue injection in fistula|
75731792|NCT03444779|Device|Tibial Tuberoplasty|Kyphoplasty ballon
75731793|NCT03444779|Device|Open technique|Cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope.
75731794|NCT00726791|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
75731795|NCT05374031|Other|descriptive study|descriptive study
75587069|NCT04993001|Other|Open lung extubation|Before starting emergence from anesthesia, the patient will be transferred to their hospital bed or stretcher and seated at 30 degrees. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be maintained at the same level or increased to 50% (minimum FiO2) with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilation mode will be changed to pressure support. The level of pressure support will be modified by the anesthesiologist to generate the same volumes as with controlled ventilation. The PEEP will be maintained at the same level. The minimum respiratory rate will be reduced by 4 min-1. The inspiratory flow for triggering will be 2 L.min-1.
75587070|NCT04993001|Other|Conventional extubation|Before starting emergence from anesthesia, the patient will be transferred to his hospital bed or stretcher and kept in the supine position. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be increased to 100% with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilator will be stopped with the APL valve open to atmosphere. The patient will be manually ventilated with the reservoir bag until spontaneous ventilation resumes. Then, the patient may be manually assisted if the treating anesthesiologist deems it necessary.
75731796|NCT04069403|Other|Automated Reports on prescription patterns for their patients|de-identified aggregate reports
75882342|NCT05606835|Other|Postural stability assessment|The Biodex Balance System SD (BDS) (Biodex Medical Systems Inc., Shirley, New York, USA) assesses postural stability (PS). Both static PS (SPS) and dynamic PS (DPS) will be assessed. In the DPS assessment, the platform can be tilted 20° in any direction. For static measurement, participants will be asked to stand barefoot on the platform, stand on one leg, keep the knees in 20-30° flexion. Meanwhile the contralateral knee will be asked to keep in 90° flexion, and stabilize their feet until the end of the test. Upon completion of the SPS assessment, the DPS assessment will be performed. The difficulty level of the DPS test will accepted as 4. For both SPS and the DPS assessment, the test consists of 3 trials of 20 seconds each with a 10-second break between trials.
75882343|NCT05606835|Other|Frontal plan prjection angle|Frontal Plan Projection Angle (FPPA) is calculated as the angle between the thigh segment and the trunk segment based on the postural image, considering the position of the thigh and tibia. The FPPA will be evaluated using the Spark motion Pro™ application (2D). Before measurement, markers will be placed bilaterally at the SIAS, at the midpoint of the femoral condyles, and at the midpoint of the ankle bones. Participants will stand on the floor barefoot and arms crossed over the chest. Subjects will be asked to squat in a controlled manner and perform a 60° knee bend without losing balance before returning to the starting position. Test will be performed by using single leg squat test. The one-legged squat will be performed for 5 seconds at a standard pace with the researcher acting as the counter. Degrees smaller than 165 will be accepted as increase in knee valgus.
75731797|NCT05373797|Behavioral|Procedures performed on the experimental and control groups|Intervention Group:26 Control Group (n=26):
75731798|NCT05373251|Diagnostic Test|Whole genomic DNA/RNA tumour sequencing|"All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.~Participants with recurrence will have biopsy and subsequently will undergo rapid sequencing of RNA and DNA followed by bioinformatic analysis to identify somatic mutations or other abnormalities that might be drivers of an individual's cancer or predict response to therapies. These data will be compared to the literature and to a comprehensive database of drugs with the aim of identifying drugs most likely to target individual tumors based on the presence of mutated or abnormally expressed genes in the tumor. Any palliative systemic therapy treatment would be closely monitored for tolerability and response, as part of the general clinical care of someone on systemic therapy. The choice of systemic therapy will be up to the treating medical oncologist and the patient."
75731799|NCT04066985|Behavioral|Growth Mindset Online Single-Session Program|30minute self-administered program for youths
76053271|NCT02227784|Drug|Ezetimibe|Administered orally
75587071|NCT04995107|Device|Electro Press needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
75587072|NCT00477750|Drug|lenalidomide|"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression"
75731800|NCT04066985|Behavioral|Self-Kindness Online Single-Session Program|30minute self-administered program for youths
75731801|NCT04066985|Behavioral|Supportive Therapy Online Single-Session Program (Control)|30minute self-administered active comparator program for youths
75731802|NCT00723359|Drug|BT062|biologic
75437865|NCT01592305|Drug|ritonavir|multiple oral doses
75587073|NCT00477750|Drug|melphalan|"Phase I - dose escalating: 5mg/m^2 dose level -1, 5 mg/m^2 dose level 0, 8 mg/m^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m^2 orally days 1-4 every 28 days until progression"
75587074|NCT00477750|Drug|prednisone|60mg/m^2, orally days 1-4 every 28 days until progression
75587075|NCT04670003|Other|users|Data of users of the web-application
75731803|NCT00450814|Drug|Cyclophosphamide|Given IV
75731804|NCT00450814|Other|Laboratory Biomarker Analysis|Correlative studies
75731805|NCT00450814|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
75731806|NCT00450814|Other|Pharmacological Study|Correlative studies
75731807|NCT02571491|Drug|Ketamine Hydrochloride|50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
75731808|NCT02571491|Other|Placebo|50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
75731809|NCT02571491|Drug|Remifentanil|at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
75731810|NCT02571491|Drug|Morphine hydrochloride|at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
75731811|NCT00723437|Drug|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
75731812|NCT01026688|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
75437866|NCT01592305|Drug|tenofovir disoproxil fumarate|single oral doses
75437867|NCT01592318|Drug|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
75437868|NCT01592318|Drug|danoprevir|Reference tablet, single oral dose
75437869|NCT01592318|Drug|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
75437870|NCT01592318|Drug|ritonavir|Reference tablet, single oral dose
75437871|NCT01592331|Drug|Placebo|Single oral dose
75437872|NCT01592331|Drug|RO5508887|Single oral dose
75587076|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
75587077|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
75731813|NCT01026688|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
75731814|NCT02571023|Procedure|microscope surgery|
75731815|NCT02571023|Procedure|neuroendoscope surgery|
75731816|NCT00723515|Drug|sodium fluoride|sodium fluoride 5%
75731817|NCT00723515|Drug|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
75731818|NCT01022944|Procedure|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
75731819|NCT01022944|Procedure|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
75731820|NCT01028170|Drug|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
75731821|NCT01028170|Drug|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
75731822|NCT00723671|Procedure|MRI|
75731823|NCT00518115|Drug|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
76053272|NCT02227784|Drug|Placebo|Administered orally
75587078|NCT00477672|Drug|Placebo|tablet, once daily by mouth, 6 weeks
75587079|NCT04549935|Drug|Dextenza|Dextenza 0.4mg
75587080|NCT04549935|Drug|Topical Prednisolone|Standard of care topical drop treatment
75587081|NCT00477633|Drug|Norethindrone/ethinyl estradiol|1 tablet per day
75731824|NCT04067219|Procedure|DXA (dual-energy x-ray absorptiometric) measurement|DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
75731825|NCT00723983|Drug|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
75882344|NCT05606835|Other|Foot and Ankle Ability Measure|The Foot and Ankle Ailability Measure (FAAM) is used to assess the self-reported overall functional level of patients with leg, foot, and ankle musculoskeletal injuries and conditions. It consists of 1) activities of daily living [ADL] and 2) sports [S] and can be scored from 0 to 100%. In the FAAM, there are 29 items that are scored from 0 to 4. There are 21 items related to various functional activities under the subtitle activities of daily living, and 8 items related to various activities related to participation in sports under the subtitle sports. Standardized response options are answered on five-point likert scales ranging from 0 (I cannot) to 4 (no difficulty). Point totals between 0 and 84 for the ADL subtitle and between 0 and 32 for the Sports subtitle are converted to percentage points.
75882345|NCT05606835|Other|Navicular Drop Test|The navicular drop test (NDT) is a clinical method for assessing the mobility of the medial longitudinal arch (MLA). The extent of navicular subsidence is assessed to determine the flexibility of the MLA and the position of the navicular with and without transfer of body weight. To assess navicular drop, the subtalar joint will be positioned in neutral position and the height of the navicular will be measured in non-weight bearing position. Then the measurement will be repeated in weightbearing position. The height difference between the two measurements in sitting and standing is recorded as the NDT value. Values more than 10mm is accepted as pathological.
75882346|NCT05606835|Other|Calcaneotibial Angle Measurement|Measurement of the calcaneotibial angle (CTA) is one of the methods used in the evaluation of the foot and ankle. By measuring this angle, it is assessed whether the ankle problems are related to the hindfoot. In the CTA measurement, the angle between the vertical axis of the calcaneus and the longitudinal axis of the achilles tendon is measured in the standing and prone positions, and the differences will be recorded. Values more than 8 degrees is accepted as calcaneal valgus.
75587082|NCT04999787|Drug|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
75587083|NCT04999787|Drug|Placebo|Placebo
75587084|NCT04550091|Device|Detection of ascites using CT|Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
75587085|NCT04992767|Behavioral|Sunnyside|The Sunnyside intervention is an online intervention(an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
75587086|NCT04992767|Behavioral|SunnysideFlex|SunnysideFlex consists of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. SunnysideFlex has adapted the original Sunnyside intervention with revised, trauma-focused content that covers the impact of PTSD symptoms on the perinatal period and daily functioning, more broadly
75587087|NCT04669847|Other|Trunk-oriented exercise program|The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.
75731826|NCT00723983|Drug|NP101 Study Patch|NP101 study patch 4 hour application
75587088|NCT04669847|Other|Conventional exercise program|Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
75587089|NCT04541901|Other|Massage|12 minutes of effleurage and petrissage on the upper limbs
75587090|NCT04541901|Other|Cold water immersion|12 minutes of cold water immersion at the shoulder level with water temperature between 11 to 15°C
75587091|NCT04669730|Other|usual care|Routine care
75587092|NCT04669730|Behavioral|Walk|Walk 30mins
75731827|NCT00450658|Drug|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
75731828|NCT00450658|Drug|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
75731829|NCT02572505|Drug|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
75587093|NCT04669730|Behavioral|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
75731830|NCT03720574|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
75731831|NCT03720574|Drug|Matching Placebo BID|Matching Placebo tablet each morning and evening for a duration of 48 weeks
75587094|NCT04669730|Behavioral|Baduanjin plus walk|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
75882347|NCT05606835|Other|Tibial Torsion Angle|Tibial torsion is a rotational deformity which can be measured between the long axis of the tibia and the transmalleolar axes. This measurement can be used to determine the extent to foot malalignment is due to bone torsion. Measurement will be done by a goniometer. Participants will be asked to lie prone and will be positioned with the knee joint in 90° flexion and the ankle joint in a neutral position. Normal alignment is 20 degrees external rotation. Any increase or decrease accepted as pathological.
75587095|NCT04992338|Device|Mobile app|The CarpeDiem application is a mobile application, designed in collaboration with the Health and Nutrition Technology Unit (UTNS, Eurecat) and the translational research group on respiratory medicine of the Institut de Recerca Biomèdica de Lleida. The application is available for devices with Android as the operative system and its advanced interface allows the user to monitor their physical activity, sleep and diet and motivate them to meet personalized goals through gamification. To do this, the user must answer the questionnaires that they will find on the main page of the application with a predetermined frequency, as well as perform missions that will help them acquire healthier habits. In addition, the user will receive motivational messages and recommendations through notifications that will help and guide them to achieve their missions and achieve their goals, and as a result of changing habits.
75587096|NCT04541823|Drug|Desﬂurane|Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
75587097|NCT04541823|Drug|Propofol|Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
75587098|NCT04996043|Dietary Supplement|Collagen Peptide Drink|Testing product
75731832|NCT00724139|Device|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
75587099|NCT04996043|Dietary Supplement|Placebo drink|Blank
75587100|NCT04541862|Other|Intensive care|intensive care for critically ill patients in the intensive care units
75587101|NCT04549584|Diagnostic Test|Vimentin/pan CK stain|Vimentin/pan CK stain positive/negative
75731833|NCT00718133|Device|Spirometry (Pony spirometer)|Spirometry at rest
75587102|NCT04994093|Other|Collection of blood (PBMC), biopsy (FFPE) and stool samples.|Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).
75587103|NCT04669496|Drug|Neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
75587104|NCT04669769|Other|interview|telephone interview
75587105|NCT04571450|Behavioral|Reintervention|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
75587106|NCT04571411|Other|CBC|The aim of this study is to investigate the relationship between severity of envenomation and hematological parameter by detectig initial mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in pediatric patients presenting with a scorpion sting.
75587107|NCT04541784|Other|WOMAN-PRO III|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III."
75731834|NCT03720418|Drug|OXB-102|Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
75731835|NCT03720418|Other|Imitation Surgical Procedure (ISP)|Participants randomized to the control group in Part B will receive an ISP
75731836|NCT00517881|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
75731837|NCT02572739|Device|PICCO|measurements based on thermodilution
75882348|NCT05606835|Other|Femoral internal and external rotation measurement|Accurate assessment of hip joint range of motion (ROM) is an important component in the overall clinical evaluation of lower extremity injuries, particularly those of the hip and groin. The expected hip rotational range of motion for internal rotation (IR) is 45°, and for external rotation (ER) is 0° to 45°. In this study, a smartphone-based inclinometer will be used to measure femoral IR and ER. The inclinometer will be placed vertically so that the top edge is just below the tibial tuberosity and the bottom edge is pointed at the midpoint of the medial and lateral malleoli.
75587108|NCT04541784|Other|Three counselling sessions with gynaecology-oncology nurses|Standardized care, three counselling sessions with a gynaecology-oncology nurse.
75587109|NCT04669262|Drug|BGB-DXP604|Administered as intravenous (IV) infusion over 30 to 60 minutes
75587110|NCT04669262|Drug|BGB-DXP593|Administered as intravenous (IV) infusion over 30 to 60 minutes
75587111|NCT04669262|Drug|Placebo|Placebo to match BGB-DXP593
75882349|NCT02108366|Drug|Celecoxib|Celecoxib 200mg daily
75882350|NCT02108366|Drug|Oseltamivir|Oseltamivir 75mg bid
75882351|NCT02108366|Drug|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
75882352|NCT05602233|Other|Exercise|The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
75882353|NCT05602233|Other|STARS (Sensory-Targeted Ankle Rehabilitation Strategies)|STARS includes; joint mobilization, plantar massage and triceps surae stretching. The training will be given for 6 weeks, 3 times a week for 5 minutes.
75882354|NCT02104934|Procedure|Adductor Canal Block|
75882355|NCT05706207|Drug|HB0030 injection|0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
75882356|NCT05706207|Drug|HB0030 injection|0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
75437873|NCT01592357|Behavioral|Tai Chi exercise|A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
75882357|NCT05706207|Drug|HB0030 injection|1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
75882358|NCT05706207|Drug|HB0030 injection|3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
75882359|NCT05706207|Drug|HB0030 injection|10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
75437874|NCT01592357|Behavioral|Sham Exercise|"The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks."
75437875|NCT01592422|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
75587112|NCT04669262|Drug|Placebo|Placebo to match BGB-DXP604
75587113|NCT04999319|Procedure|PVB|Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
75587114|NCT04999319|Procedure|ESPB|Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
75587115|NCT04549818|Device|sacral neuromodulation|Sacral neuromodulation group, N=22 will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
75882360|NCT05706207|Drug|HB0030 injection|20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
75587116|NCT04541550|Drug|AMP-001 Low Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
75587117|NCT04541550|Drug|AMP-001 Medium Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
75587118|NCT04541550|Drug|AMP-001 High Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
75587119|NCT00556361|Drug|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
75587120|NCT00556361|Drug|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
75587121|NCT04549350|Other|PSQI|Assessment of sleep quality using Pittsburgh Sleep Quality Index (PSQI): It is a simple tool which assess the sleep quality over one month period. It included seven components with a global PSQI score > 5 is indicative of poor sleep quality
75587122|NCT04671290|Other|Any intervention|No intervention
75587123|NCT04571606|Procedure|Single injection peripheral nerve block with liposomal bupivacaine (Exparel)|10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine
75587124|NCT04571606|Procedure|Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump|20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
75587125|NCT04669613|Other|CUDI|Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
75587126|NCT04541160|Diagnostic Test|CR|Lung imaging evaluation performed with CR
75437876|NCT01592422|Other|Best Supportive Care|Best Supportive Care in the absence of disease progression
75437877|NCT01592448|Behavioral|Active Ingredient Icon|"Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen."
75437878|NCT01592513|Device|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
75437879|NCT01592526|Other|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
75587127|NCT04541160|Diagnostic Test|ULDCT|Lung imaging evaluation performed with ULDCT
75587128|NCT04541277|Drug|Tislelizumab|Tislelizumab combined with DNA demethylation agent +/- CAG regimen
75587129|NCT04541394|Device|MolecuLight|MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
75587130|NCT02210234|Dietary Supplement|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
75437880|NCT01592526|Other|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
75587131|NCT02210234|Dietary Supplement|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
75587132|NCT02214264|Behavioral|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
75587133|NCT02214264|Behavioral|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
75587134|NCT02214264|Behavioral|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
75587135|NCT02214264|Behavioral|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
75587136|NCT04549740|Diagnostic Test|salivary alpha amylase level measurement|Saliva samples will be obtained to estimate salivary alpha amylase
75587137|NCT04571294|Procedure|removal of para-aortic lymphnodes (PALN)|During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
75587138|NCT04541316|Device|ProFlor inguinal hernia device|Inguinal hernia repair
75587139|NCT04541238|Diagnostic Test|MRI|Magnetic resonance imaging
75587140|NCT04997408|Device|Customized exercise app|A Wearable Device-Based Assisted Post-Stroke Rehabilitation system
75587141|NCT04997408|Other|In-person therapist-supervised rehabilitation|In-person therapist-supervised rehabilitation
75587142|NCT04541199|Device|closed loop|RR and VT will be selected according to the respiratory mechanics by closed loop algorithm
75731838|NCT02572739|Device|NICCOMO|measurements based on impedance
75587143|NCT04541199|Device|conventional|RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
75587144|NCT02210351|Device|MRI test|
75587145|NCT02214342|Other|Balance Training|"Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
75587146|NCT04549389|Device|Low intensity shockwave therapy|LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)
75882361|NCT05706207|Drug|HB0030 injection|30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
75587147|NCT04549623|Device|Novel end-tidal CO2 monitoring device|Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.
75587148|NCT04549623|Device|SpO2 and respiratory motion monitoring|Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.
75437881|NCT01592565|Other|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
75437882|NCT01592578|Procedure|Ligation and Cyanoacrylate|Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.
75587149|NCT04570982|Biological|Convalescent Plasma|The objective of this protocol is to provide a coordinated approach for distribution and guidance for safe and effective administration of convalescent serum with antibodies against SAR CoV-2 for treatment of patients with COVID-19 infection who are most likely to benefit from this investigational treatment and monitor them.
75587150|NCT04548843|Procedure|Bone Marrow mobilization|"During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis"
75587151|NCT04548843|Procedure|Apheresis|Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
75587152|NCT04548843|Biological|MNV-BM-PLC infusion|"The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks."
75587153|NCT04993586|Biological|AG0302-COVID19 for Intramuscular Injection|Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
75731839|NCT01009905|Drug|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
75882362|NCT05706207|Drug|HB0030 injection|40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
75882363|NCT02105090|Drug|Anesthetics, Local|
75882364|NCT02105090|Drug|Sodium Chloride 0.9%|
75882365|NCT03627273|Diagnostic Test|6 minutes walking test with walker|to walk during 6 minutes with walker
75882366|NCT03627273|Diagnostic Test|6 minutes walking test|to walk during 6 minutes with walker
75882367|NCT02111330|Drug|PBF-509|
75587154|NCT04993586|Biological|AG0302-COVID19 for Intramuscular Injection|Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
75587155|NCT04993586|Biological|AG0302-COVID19 for Intramuscular Injection|Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
75587156|NCT04993586|Biological|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
75587157|NCT04993586|Biological|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
75587158|NCT04992221|Procedure|arterial line|arterial line inserted for invasice mointroing and sampling
75587159|NCT04548765|Behavioral|Letter|Recipients receive a letter promoting CRC screening.
75731840|NCT05372081|Other|Digital platform|Patients will be randomized (1:1) in the way they will receive or not any assistance from the digital platform.
75731841|NCT01565577|Biological|MenbVac|Blood test
75731842|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
75882368|NCT02111330|Drug|Placebo|
75882369|NCT02105168|Procedure|Blood sample|Optional
75882370|NCT02105168|Procedure|Tumorous biopsy|Optional
75882371|NCT02105168|Procedure|Healthy material sample|Optional
75882372|NCT03553628|Other|Chlorhexidine, Propolis and Clove Oil mouthwash|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash
75882373|NCT03553628|Other|Chlorhexidine mouthwash|Chlorhexidine HCL 0.12% mouthwash
75882374|NCT02111486|Other|breakfast|
75587160|NCT04548765|Behavioral|Loss Frame and Fear Appeals|The letter is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
75587161|NCT04548765|Behavioral|Transparency|The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
75587162|NCT04548765|Behavioral|Default Effect and Presentation of Alternatives|The pros and cons for screening with FIT kits and colonoscopy are presented. By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer). In this situation, inaction is no longer the default option. Changing the default option increases the chance that the FIT kit is used. In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
75587163|NCT04548765|Behavioral|Enhanced Fear Appeals and Decoy Effect|Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed. Inaction is presented as a decoy, which has worse outcomes than either of the screening options. Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
75587164|NCT04540926|Drug|Cyclosporin A|COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
75587165|NCT04540809|Other|Assessment of strength, proprioception, skill and coordination of the hand|Disease Activity Score 28 was used to determine the disease activity of patients with PsA. Grip strength was measured with the help of Baseline Digital Hand Dynamometer®. Pinch strength was measured with Baseline Hydraulic Pinch Gauge®. Wrist proprioception was assessed by measuring the joint position sensation using a goniometer by actively repeating the target angle predetermined by the researcher (30 ° for flexion and extension, 15 ° for ulnar deviation, 10 ° for radial deviation. Finger skills were assessed using a mobile application called Ball Tap©. The application included the fastest contact of the participants to the balls coming from different parts of the screen for 30 seconds. Two hand coordination and skills were evaluated using the Purdue Pegboard test. The Michigan Hand Outcomes Questionnaire was used for functional evaluation of the hand, and the Health Assessment Questionnaire was used to assess the general functional condition and health-related quality of life.
75587166|NCT04540965|Drug|Telaglenastat|Glutaminase inhibitor
75587167|NCT04540965|Drug|Famotidine|Histamine-H2 Receptor Antagonist
75587168|NCT04540965|Drug|Placebo for famotidine|Placebo for Histamine-H2 Receptor Antagonist
75587169|NCT04548687|Procedure|carbon dioxide insufflation|Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass
75731843|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
75731844|NCT01010139|Drug|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
75731845|NCT00724295|Drug|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
75882375|NCT02111720|Behavioral|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
75731846|NCT00724295|Drug|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
75731847|NCT00718289|Other|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
75731848|NCT00718289|Other|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
75731849|NCT02571101|Drug|CDFR0812-15/25mg|Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
75731850|NCT02571101|Drug|CDFR0812-15/50mg|Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
75731851|NCT02571101|Drug|Condencia|Contains chlomipramine HCl 15mg.
75731852|NCT02571101|Drug|CDFR0812-Placebo|Placebo tablet of CDFR0812.
75731853|NCT02571101|Drug|Condencia-Placebo|Placebo tablet of Condencia
75731854|NCT03525886|Drug|NBI-74788|Capsule, administered daily.
75731855|NCT00517413|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
75587170|NCT04548687|Procedure|No carbon dioxide insufflation|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
75587171|NCT02215356|Drug|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
75587172|NCT02215356|Drug|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
75587173|NCT04540653|Biological|Standard vaccination schedule|Administer a standard vaccination schedule (three doses of 20 μg of the hepatitis B vaccine, in months 0, 1, 6) at an age of ≥50 years and evaluate a production kinetics after each dose administered in the period of about 30 to 60 days.
75587174|NCT04540653|Biological|Reinforced vaccination schedule|Administer an enhanced vaccination schedule (three doses of 40 μg of the hepatitis B vaccine, in months 0, 1, 6) in individuals aged ≥50 years and assess the kinetics of antibody production after each dose administered in the period of approximately 30 to 60 days.
75882376|NCT02111720|Behavioral|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
76053273|NCT04419701|Procedure|periarticular infiltration|"The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement."
75882377|NCT02111954|Diagnostic Test|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
75587175|NCT04999514|Behavioral|Mindful Parenting, Tuning in to Kids|The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.
75587176|NCT04548960|Other|cancer patients|Blood sample RNA_seq at time of diagnostic, best response and relapse ; Biopsy Exom_seq and RNA_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse
75587177|NCT04570865|Drug|Dapagliflozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
75587178|NCT04570865|Device|CardioMEMS|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
75587179|NCT04540731|Other|This is an observational study without intervention|This is an observational study without intervention
75587180|NCT04570748|Procedure|Capsule repair|Direct anterior hip arthroplasty with or without capsule repair
76053274|NCT04419701|Procedure|genicular nerve block|The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
75587181|NCT04570748|Procedure|capsulectomy|capsulectomy without repair
76053275|NCT04841213|Procedure|Dental implantation|Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
76053276|NCT01565668|Drug|AC220|oral
76053277|NCT04581551|Procedure|SWE assessor 1|"SWE for 6 shoulder muscles will be performed.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
75882378|NCT03553550|Other|biospecimen collection|Peripheral blood collection Archival tissue collection
76053278|NCT04581551|Procedure|SWE assessor 2|"SWE for 6 shoulder muscles will be performed.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
76053279|NCT04581551|Procedure|Stretch intervention|Transversal stretch of pectoralis major muscle on the hemiplegic side.
76053280|NCT04581551|Procedure|No stretch intervention|Passive mobilisation of the hemiplegic hand.
76053281|NCT04577417|Drug|ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate|Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
75437883|NCT01592578|Procedure|Ligation plus Sclerotherapy and Cyanoacrylate Group|Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
75882379|NCT02112032|Drug|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
76053282|NCT01683058|Drug|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
76053283|NCT04419545|Diagnostic Test|Neural network diagnosis algorithm|we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
76053284|NCT04574921|Other|Light Therapy System (LTS): Active setting|Exposure for 1 hour á day for consecutive days.
76053285|NCT04574921|Other|Light Therapy System (LTS): Sham setting|Exposure for 1 hour á day for consecutive days.
75437884|NCT01592604|Device|Compressive bandage|Compressive below knee bandage for 4 weeks in group A
75437885|NCT01592604|Device|Below knee walking cast|Below knee walking cast for 4 weeks
75437886|NCT01592630|Drug|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
75437887|NCT01592630|Drug|Saline|On-Q pumps containing saline to be attached to TAP catheters
75437888|NCT01592656|Radiation|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
75437889|NCT01592656|Other|Lung compliance measurement|At baseline
75437890|NCT01592656|Device|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 > 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
75437891|NCT01592669|Procedure|passive leg raising|bilateral PLR was achieved by raising the legs of patient
75437892|NCT01592682|Behavioral|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
75587182|NCT04548726|Device|Sapien 3 Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.
75587183|NCT04548726|Device|Myval Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.
75587184|NCT04548492|Other|Survey|to assess and validate how healthcare professionals can trigger or inhibit the use of modern technology applications in home isolation
75587185|NCT04540419|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
75587186|NCT04540419|Biological|Placebo|Intramuscular administration
75587187|NCT04570826|Other|Meditation.|The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.
75587188|NCT04570826|Other|Scientific descriptions about meditation.|The control group received scientific descriptions about meditation.
75587189|NCT04540614|Other|Strengthening exercises programme|Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
75587190|NCT04561427|Other|Study of Sleep architecture in children with narcolepsy|Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children
75587191|NCT04548531|Behavioral|Shared Decision Making|"The decision aid is a paper information sheet presenting the pros and cons of three screening options (colonoscopy, stool-based tests, and postponing cancer screening until next year).~The decision coaching is a structured interview to help patients clarify their preference for screening test and to support them in implementation (whether scheduling colonoscopy, ordering stool test or seeking additional advice from specialist)."
75587192|NCT04570592|Drug|Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg|Comparing PONV incidences in both arms
75587193|NCT04570592|Drug|Granisetron 1 Mg/mL Intravenous Solution|Comparing PONV incidences in both arms
75587194|NCT04540263|Diagnostic Test|Flow Cytometric analysis|Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum
75587195|NCT04570514|Procedure|PCI|percutaneous coronary intervention (PCI)
75587196|NCT04548414|Other|No.|This is an observational study with no intervention.
75587197|NCT04560959|Device|tACS|tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes
75587198|NCT04548336|Behavioral|Motor Imagery|Motor imagery group will have to imagine motor gestures of static and dynamic balance
75882380|NCT02112032|Drug|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
75437893|NCT01592734|Drug|Polyethylene glycol with electrolytes|"Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days."
75437894|NCT01592734|Device|Polyethylene glycol|"Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children > 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.~Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days."
75437895|NCT01592812|Device|electrical muscle stimulation|Duration of the stimulation 20 minutes
75587199|NCT04548336|Behavioral|Action observation|Action observation group will have to observe static and dynamic equilibrium motor gestures
75587200|NCT04548336|Behavioral|Placebo group|This group will watch a video of nature without a human component.
75587201|NCT02211872|Drug|BI 2536 BS, intravenous|
75587202|NCT02214459|Behavioral|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
75587203|NCT04561037|Device|Pulsed Electromagnetic Field therapy (PEMFT)|PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication
75587204|NCT04561037|Other|TMJ physical therapy program|TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
75882381|NCT01343823|Drug|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
75882382|NCT01343823|Drug|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
75587205|NCT04548453|Device|uterine electromyography|Multichannel uterine electromyography will record uterine biosignals during labor.
75587206|NCT02215395|Drug|NES/EE CVR|Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
75587207|NCT04561310|Other|Post facilitation stretch|"Post facilitation stretch with maitland mobilization Grade I & II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
75587208|NCT04561310|Other|Active release technique|"Active release technique with maitland mobilization Grade I & II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
75587209|NCT02215434|Drug|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
75587210|NCT02215434|Drug|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
75587211|NCT04561076|Drug|HLX70|Single-dose, intravenous infusion
76053286|NCT05374421|Device|Erchonia® THL™|The Erchonia® THL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
76053287|NCT05374421|Device|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
76053288|NCT01626859|Drug|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
76053289|NCT01626859|Drug|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
75437896|NCT01592838|Other|Data collection|The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
75437897|NCT01592890|Drug|RO4917523|[14C]-labeled RO4917523, single oral dose
76053290|NCT01626859|Drug|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
76053291|NCT04413682|Behavioral|Structured Supervised Exercise|Structured Exercise Program under the supervision of Physical Therapist
76053292|NCT04413682|Behavioral|Structured telerehabilitation|Structured Exercise Program checked and controlled through telerehabilitation
76053293|NCT02193776|Drug|PA-824|oral
76053294|NCT02193776|Drug|bedaquiline|oral
76053295|NCT02193776|Drug|moxifloxacin|oral
76053296|NCT02193776|Drug|pyrazinamide|oral
76053297|NCT02193776|Drug|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
76053298|NCT05373407|Other|aerobic exercise|participants will perform different dosage of the same intervention, one group will perform moderate intensity and the other will perform low intensity aerobic training
76053299|NCT02170064|Drug|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
76053300|NCT02169830|Drug|nortriptyline|The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
76053301|NCT02169830|Drug|Topiramate|Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
75437898|NCT01592890|Drug|RO4917523|[13C]-labeled RO4917523, single intravenous tracer dose
75587212|NCT04561076|Other|Placebo|Single-dose, intravenous infusion
75587213|NCT02215473|Drug|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
75587214|NCT02215473|Procedure|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
75587215|NCT04560842|Device|A high flow oxygen device.|The HFNC group use high flow oxygen device for 48 hours
75587216|NCT04560842|Device|Conventional oxygen therapy|Conventional oxygen device
75731856|NCT00724529|Biological|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
75587217|NCT04548102|Other|Fetal movement count|Pregnant women in the study group received verbal information regarding normal fetal movements (i.e. description of the changing pattern of movement as the fetus develops, normal sleep/wake cycles, and factors which may modify the mother's perception of movements such as maternal weight and placental position), and its importance to be followed during the third trimester. A chart for fetal movements counting provided and to ensure proper performance of this task, women telephoned once a week. They also asked to show the fetal movements chart to the researcher and the health care providers in each visit. Women followed according to her antenatal visits schedule till delivery.
75587218|NCT04560764|Device|Virtual Reality|"Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty."
75587219|NCT04560764|Device|Action Observation Therapy|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the experimental group will see a video demonstrating the same exercise (according to the level of difficulty selected) he will be later asked to perform for two minutes."
75437899|NCT01592903|Genetic|Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|"Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.~Sample digestion through controlled enzymes.~Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .~Culture of these cells.~Morphological and genetic characterization.~Assessment of pluripotent potential from isolated cells.~Analysis of the degree of functionality."
75437900|NCT01592929|Radiation|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
75882383|NCT01343823|Drug|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
75882384|NCT01343823|Drug|placebo|Administered as two SC 3 mL injections
75882385|NCT01343823|Drug|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
75882386|NCT01343823|Drug|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
75882387|NCT02108678|Behavioral|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
75882388|NCT02108678|Behavioral|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
75437901|NCT01592929|Other|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
75437902|NCT01592929|Radiation|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
75437903|NCT01592929|Radiation|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
75882389|NCT02251184|Drug|Aggrenox|
75882390|NCT02251184|Drug|Dipyridamole|
75882391|NCT02251184|Drug|Aspirin|
75882392|NCT02251184|Drug|Lansoprazole|
75437904|NCT01592929|Other|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
75437905|NCT01592942|Device|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
75437906|NCT01592942|Device|Progrip|self-gripping mesh
75437907|NCT01592942|Device|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
75437908|NCT01592955|Device|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
75437909|NCT01592981|Drug|Bortezomib|1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
75587220|NCT04560764|Device|Landscape video|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the sham comparator group will see a video of a natural landscape for two minutes."
75587221|NCT04560764|Other|Standard treatment|Participants in both groups will receive the standard treatment, one hour a day for three days a week.
75587222|NCT04570241|Behavioral|Malaria toolkit|Knowledge, attitude, and practice on malaria
75587223|NCT02215512|Drug|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
75587224|NCT04548258|Device|electric intraoral weilding|weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally
75587225|NCT04548258|Device|casting|casting metal framework
75587226|NCT02215590|Device|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week."
75587227|NCT04547829|Drug|pegylated recombinant human granulocyte-colony stimulating factor|The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
75587228|NCT02211911|Drug|Bisacodyl|
75587229|NCT02211911|Drug|Sodium picosulfate|
75731857|NCT03714178|Device|FARAPULSE Endocardial Ablation System|Endocardial ablation using the FARAPULSE Endocardial Ablation System.
75731858|NCT01012869|Device|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
75437910|NCT01592981|Drug|Cyclophosphamide|"Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm."
75731859|NCT03690999|Dietary Supplement|Placebo|Placebo product
75731860|NCT03690999|Dietary Supplement|Prebiotic supplement|Prebiotic supplement
75882393|NCT05706051|Other|posturography|posturography will be performed when diagnosis of ARHL, in need of hearing aid fitting, is done and after information and written approval from patient. Posturography is performed later when hearing aid fitting and 3months after hearing aid use
75437911|NCT01592981|Biological|Rituximab|Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
75437912|NCT01592981|Drug|Fludarabine|Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
75587230|NCT04540146|Diagnostic Test|Flow-Cytometric analysis|IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites
75587231|NCT04560491|Diagnostic Test|Intraoperative examination of sentinel node|Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.
75587232|NCT01131676|Drug|BI 10773 low dose|BI 10773 tablets once daily
75587233|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
75587234|NCT01131676|Drug|BI 10773 high dose|BI 10773 tablets once daily
75587235|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
75587236|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
75882394|NCT02108756|Drug|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
75587237|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
75587238|NCT04560569|Drug|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
75587239|NCT04560569|Drug|3BNC117 Antibody|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
75587240|NCT04547322|Other|VR application group|During the transfer from the general surgery clinic to the operating room (3-5 minutes) and in the surgery waiting room, the VR aplication group were asked to wear a virtual reality headset (VR BOX 2) and headphones minimizing sound loss (Earpods with Apple Lightning Connector) that are compatible with mobile phones with IOS operating system. The VR headset and the headphones were controlled by a mobile phone (iPhone 7 Plus). The researchers had the patients watch three-dimensional videos (e.g. underwater world, museum trips, forest and park walks, beach trips, and space travel) for 10 minutes with their preferred background and relaxing music.
75731861|NCT05361785|Biological|FMT|FMT from healthy donor or placebo
75731862|NCT03709342|Drug|CM4620-IE|single IV infusion on Day 1 over 4 hours
75731863|NCT01010295|Drug|doxycycline (tetracycline)|doxycycline 100 mg twice daily for 3 weeks
75731864|NCT03632291|Biological|UB-221|UB-221 (75 mg/ml)
75731865|NCT01010373|Drug|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
75731866|NCT02570945|Procedure|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
75731867|NCT01010451|Procedure|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
75731868|NCT01010451|Procedure|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
75882395|NCT02108756|Drug|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
75587241|NCT04539990|Behavioral|Behavioral treatment for sleep difficulties|"This intervention is mediated by the parents. Parents are educated regarding sleep hygiene and instructed to follow simple rules which create a reliable evening routine and reduce exposure to stimulating factors that delay sleep onset (e.g., caffeine or exercise). In addition, parents are asked to initiate a fading behavioral protocol whereby they teach their child to fall asleep independently, with less parental attention. This requires parents to limit their interaction with their child after the children are put to bed so as not to interfere with sleep onset. This includes limiting conversations and lying in bed with the child. This behavioral approach is applied gradually and is expected to reduce the time it takes children to fall asleep."
75731869|NCT02570789|Drug|patients with sunitinib or pazopanib|The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
75731870|NCT00604214|Drug|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
75882396|NCT05596461|Device|Transcranial magnetic stimulation|Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.
75882397|NCT05596461|Device|Transcranial direct current stimulation|Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
75437913|NCT01592994|Behavioral|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
75437914|NCT01592617|Drug|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
75437915|NCT01593007|Other|Inspiratory muscle training|All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.
75437916|NCT01593007|Other|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
75437917|NCT01593033|Dietary Supplement|Fish oil and Micronutrient Supplementation|"0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months"
75587242|NCT04560530|Radiation|Non-enhanced CT scan of the chest|Non-enhanced CT scan of the chest with multi-slice CT scan machine.
75587243|NCT04540029|Other|Maternal stress|Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.
75587244|NCT04560374|Device|crochet octopus|Delivering crochet octopus to the hands of the neonates
75587245|NCT04539912|Device|angulated screw retained crown|ASC abutment was used in AG;
75587246|NCT04539912|Device|cemented crown|prefabricated Ti abutment was used in CG
75587247|NCT04560257|Device|High flow nasal cannula HFNC|High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
75731871|NCT00604214|Drug|Placebo|0.9% sodium chloride, intravenous, 96 hours
75731872|NCT01010529|Other|occupational therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
75731873|NCT04066439|Other|specimen|Immunohistochemistry analysis
75731874|NCT05325203|Biological|Ongericimab|Administered by subcutaneous injection
75731875|NCT05325203|Drug|Placebo|Administered by subcutaneous injection
75587248|NCT04547361|Drug|E2511|E2511 tablets.
75587249|NCT04547361|Drug|E2511 Matched Placebo|Placebo tablets matching E2511 tablets.
75587250|NCT02882971|Behavioral|Pain Assessment|To create an objective observational pain scoring system and validate.
75587251|NCT02215629|Drug|VS-4718|
75587252|NCT01131520|Behavioral|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
75587253|NCT01131520|Behavioral|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
75587254|NCT01131325|Drug|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
75587255|NCT04547244|Other|echocardiographic optimization of CRTd|the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
75587256|NCT04560062|Other|Spontaneous changes in diabetes-related health care|The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
75587257|NCT01131130|Device|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
75587258|NCT01131130|Device|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
75731876|NCT00450580|Drug|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
75731877|NCT00724685|Drug|Naropeine (Ropivacaine)|
75587259|NCT01131130|Device|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
75587260|NCT04547478|Diagnostic Test|low dose chest CT(LDCT)|cross sectioned muscle area of the 1st vertebrae level obtained by LDCT
75731878|NCT00724685|Drug|Placebo|saline
75731879|NCT00123487|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
75882398|NCT02108834|Procedure|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
75587261|NCT01130974|Device|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
75587262|NCT01130974|Device|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
75587263|NCT04560101|Drug|botulinum toxin A|Intramuscolar injection of botulinum toxin in affected muscles
75587264|NCT02214498|Drug|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
75587265|NCT02214498|Drug|Placebo|
75587266|NCT04311775|Device|larengeal mask insertion with video laryngoscopy|it is a method of inserting a laryngeal mask into the airway with videolaryngoscopy
75587267|NCT04311775|Other|laryngeal mask insertion|laryngeal mask is a method of inserting atube into the upper airway
75587268|NCT04560218|Drug|sublingual Misoprostol|apply drug by Anesthesiologist
75731880|NCT00123487|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
75731881|NCT00509925|Drug|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
75731882|NCT00509925|Drug|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
75731883|NCT00509925|Drug|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
75731884|NCT00724763|Device|acupuncture|to Liv 3 and PE 9.
75731885|NCT00724763|Device|sham needle treatment|needle not in meridian area
75731886|NCT05277974|Drug|inj bupivicain|In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given
75731887|NCT00504777|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
75731888|NCT00504777|Drug|Methotrexate|10-25mg/week po or parenteral
75587269|NCT04560218|Drug|Intrauterine Misoprostol|apply drug by surgeon at uterine cornu
75882399|NCT02108834|Procedure|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
75587270|NCT05135104|Drug|Palbociclib|"Palbociclib, an orally active pyridopyrimidine, is a potent and highly selective reversible inhibitor of CDK 4 and CDK6. The compound prevents cellular DNA synthesis by prohibiting progression of the cell cycle from G1 into the S phase. Specifically, Palbociclib inhibits CDK4/6-catalyzed phosphorylation of the retinoblastoma protein (Rb), which is required for cell division.~Palbociclib has selectivity for CDK4/6, with little or no activity against a large panel of 274 other protein kinases including other CDKs and a wide variety of tyrosine and serine/threonine kinases.~Therapeutic indications:~Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or MBC:~in combination with an aromatase inhibitor;~in combination with fulvestrant in women who have received prior endocrine therapy."
75587271|NCT04547517|Other|Evaluation of Counselling competencies|To complete a set of questionnaires
75587272|NCT04559828|Other|Experimental meal|Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.
75587273|NCT04579718|Other|Zeus Cloud TPS V1.0|Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.
75587274|NCT04579718|Other|Eclipse|Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.
75587275|NCT04540185|Biological|Biological: oral polio vaccine|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
75587276|NCT04540185|Biological|Comparable Placebo|Placebo of a vaccine 0.1 ml administered orally on a sugar lump
75587277|NCT04540185|Drug|NA-831|Drug: NA-831 30 mg of NA-831 in a capsule administered orally
75587278|NCT04540185|Drug|Comparable Placebo of drug|Placebo 30 mg in a capsule administered orally
75882400|NCT05547399|Drug|Zanubrutinib|Administered orally as a tablet or capsule
75587279|NCT04540185|Combination Product|Combination of oral polio vaccine and NA-831|Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally
75587280|NCT04540185|Combination Product|Comparable Placebo of Oral Polio Vaccine and Placebo of drug|Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally
75587281|NCT00575744|Procedure|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
75731889|NCT00902798|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
75731890|NCT00902798|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
75731891|NCT03968263|Device|Hycon device(Routine protocol)|Hycon device will be activated half a turn every 3 days.
75731892|NCT03968263|Device|Hycon device(Modified protocol)|The activation period of the hycon device will be modified.
75587282|NCT02214537|Other|MACS|
75587283|NCT01130272|Drug|Eluxadoline|Tablets, orally, twice daily.
75587284|NCT01130272|Drug|Placebo|Matching placebo oral tablets twice daily.
75587285|NCT04559789|Behavioral|MindMate + Health Coaching|The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.
75731893|NCT03968263|Device|Hycon device(Routine protocol) and Vibration(Acceledent)|Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
75731894|NCT03968263|Device|Hycon device(Modified protocol) and Vibration(Acceledent)|The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
75731895|NCT00895076|Drug|dexamethasone|iontophoretic patch and injection
75731896|NCT01078519|Drug|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
75731897|NCT02539316|Drug|Smoflipid|
75731898|NCT02539316|Drug|Médialipides|
75587286|NCT04559789|Other|Health Education|Health education materials delivered electronically
75587287|NCT04559399|Procedure|smiley face shape rod|For treatment of isthmic spondylolithesis a transpedical screws for the same level and rod revolve around spinal process to stabilization of pars interarticularis of the same segment after removes bone at the margine of defects pars till reach to healthy bleed margine then put bone graft at the defect then stablizing pars and bone graft by rods.
75587288|NCT04539600|Drug|Camrelizumab|Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
75587289|NCT00575822|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
75587290|NCT00575822|Device|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
75587291|NCT04546815|Drug|Daptomycin|According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
75587292|NCT01129960|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
75587293|NCT01129960|Drug|Placebo|Tablets will be used.
75437918|NCT01593033|Dietary Supplement|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
75587294|NCT04539756|Behavioral|positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
75587295|NCT04539756|Behavioral|Active control condition|Participants will be asked to complete the same writing activity each day, which will ask them to list their daily activities. Participants will be encouraged to process their daily activities superficially by the receiving the following instructions: (1) list each activity in brief, incomplete sentences, (2) document only facts about performing the activities, and (3) to not provide any information about emotional responses to performing the activities. By following these instructions, participants are presumably deriving less meaning from their activities, which may minimize gains in positive affect in the active control condition
75587296|NCT01129921|Device|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
75587297|NCT01129921|Device|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
75731899|NCT00724997|Biological|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
75731900|NCT03968185|Other|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
75882401|NCT02109068|Behavioral|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
76053302|NCT02169830|Behavioral|Diet Modification|Emphasis will be given to cessation of known migraine triggers such as caffeine, sodas, chocolates, alcohol (especially red wine) and aged cheeses. Patients who have complete control of their symptoms with diet and behavior modification alone will be followed for a total of 4 months to determine the durability of symptom relief.
76053303|NCT04545905|Diagnostic Test|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits.
75437919|NCT01593033|Drug|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
75437920|NCT01593046|Drug|GSK1265744 Oral|30mg tablet
75437921|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
75437922|NCT01593046|Drug|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
75437923|NCT01593046|Drug|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
75437924|NCT01593046|Drug|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
75437925|NCT01593046|Drug|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
75882402|NCT02109068|Behavioral|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
75437926|NCT01593046|Drug|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
75437927|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
75437928|NCT01593072|Drug|AVI-7537|"Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
75587298|NCT04559672|Procedure|Cervical laminoplasty surgery|The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation
75731901|NCT03968185|Other|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
75437929|NCT01593072|Other|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
75731902|NCT00509769|Drug|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
75731903|NCT02531503|Other|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
75731904|NCT00902876|Device|Mucograft|Collagen Matrix for soft tissue regeneration
75731905|NCT00902876|Procedure|Coronally advanced flap (CAF)|
75731906|NCT02977715|Biological|IMVAMUNE (Liquid Formulation)|Two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL). A subset of participants will receive a booster dose.
75731907|NCT02977715|Biological|IMVAMUNE (Lyophilized Formulation)|Two doses of attenuated live virus smallpox vaccine (IMVAMUNE lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL). A subset of participants will receive a booster dose.
75731908|NCT01074697|Drug|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
75731909|NCT01074697|Drug|Placebo|Saline water
75731910|NCT02539082|Device|Regenseal|Regenseal, collagen, injection in the defect area
75587299|NCT04559672|Procedure|Cervical laminectomy and fusion surgery|The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
75437930|NCT01593085|Behavioral|interview with a doctor for evaluating suicide risk|"patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~--------------------------------------------------------------------------------"
75587300|NCT04312087|Procedure|Lateral neck sentinel lymph node biopsy|Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
75587301|NCT04312087|Procedure|Modified lateral neck lymph node dissection|Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
75731911|NCT02539082|Drug|normal saline|placebo, normal saline, injection in the defect area
75587302|NCT04312087|Procedure|Super selective lateral neck lymph node dissection|Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
75731912|NCT03997695|Other|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
76053304|NCT02169674|Biological|EngerixB, GlaxoSmithKline Vaccines|
75882403|NCT02109146|Drug|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization should be used in the experimental group
75882404|NCT02109146|Other|No intervention No Transcatheter Arterial Chemoembolization|
75437931|NCT01593124|Drug|Imiquimod|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
75587303|NCT04311814|Diagnostic Test|Maximum urethral closure pressure during Valsalva (v-MUCP)|v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
75882405|NCT03553862|Behavioral|collaborative care|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.nurses and dietitians as well as a pharmacist.
75882406|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
75437932|NCT01593124|Other|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
75587304|NCT04559165|Other|sericin and chitosan cream|sericin and chitosan cream
75587305|NCT04312048|Drug|Isosorbide mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
75587306|NCT04312048|Drug|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
75587307|NCT04547127|Biological|Convalescent anti-SARS-CoV-2 MBT Plasma|Intravenous infusion.
75882407|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
75587308|NCT04547127|Drug|Standard Medical Treatment|SMT
75587309|NCT00625222|Procedure|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
75587310|NCT04311697|Drug|Aviptadil by intravenous infusion + standard of care|Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
75882408|NCT01318083|Drug|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
75882409|NCT02109224|Drug|Ibrutinib|Given PO
75882410|NCT02109224|Other|Laboratory Biomarker Analysis|Correlative studies
75882411|NCT02109224|Other|Pharmacological Study|Correlative studies
75882412|NCT03554876|Device|Multi-Im Machined transepithelial component.|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.
76053305|NCT04536467|Drug|Goserelin|chemotherapy+goserelin
76053306|NCT04536467|Drug|Chemotherapy|standard chemotherapy
76053307|NCT04532489|Drug|FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
76053308|NCT04946981|Dietary Supplement|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
76053309|NCT04946981|Dietary Supplement|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
76053310|NCT05341349|Biological|Ipilimumab|Given IV
76053311|NCT05341349|Biological|Nivolumab|Given IV
76053312|NCT05341349|Biological|Pembrolizumab|Given IV
76053313|NCT05341349|Radiation|Stereotactic Radiosurgery|Undergo SRS
75587311|NCT04311697|Drug|Normal Saline Infusion + standard of care|Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
75587312|NCT00575861|Drug|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
75587313|NCT04547088|Drug|Camrelizumab|Anti-PD-1 targeted immunotherapy
75587314|NCT04547088|Drug|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
75587315|NCT04559360|Device|PRESTOapp|The intervention group will be asked to use the app for a period of 2 months.
75587316|NCT01129882|Drug|Aripiprazole|Aripiprazole IM depot - 300 mg or 400 mg
75587317|NCT04546854|Behavioral|Appeals|Written text motivating participants to take up the seasonal influenza vaccination
75437933|NCT01593124|Drug|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
75587318|NCT00575900|Behavioral|dietary intervention|12 weeks of dietary intervention
75587319|NCT02278419|Drug|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
75882413|NCT03554876|Device|Multi-Im Nanogolden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.
75882414|NCT03554876|Device|Multi-Im Ti-Golden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.
75437934|NCT01593137|Drug|Liraglutide + metformin|"Liraglutide 1.8 mg/day + metformin >1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.~Patients will continue on metformin therapy as they were prescribed before enrolment."
75437935|NCT01593137|Drug|Glimepiride + metformin|"Glimepiride 4 mg/day + metformin >1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.~Patients will continue on metformin therapy as they were prescribed before enrolment."
75437936|NCT01593150|Drug|Pradaxa|Pradaxa for 3 weeks prior to DC
75437937|NCT01593150|Procedure|TEE|Transesophageal echo to exclude LAA thrombus, followed by early DC.
75437938|NCT01593150|Other|Compare TEE guided cardioversion to Dabigatran + DC cardioversion|compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
75587320|NCT02278419|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
75587321|NCT04559321|Procedure|Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.|General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization
75587322|NCT02882737|Drug|Glucagon before exercise|
75587323|NCT02882737|Drug|Glucagon after exercise|
75587324|NCT02882737|Drug|Glucagon after resting|
75587325|NCT04539171|Other|Pain Neuroscience Education and Physical Exercise|Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
75587326|NCT02882698|Behavioral|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
75587327|NCT02882698|Behavioral|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
75587328|NCT02882698|Behavioral|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
75587329|NCT02882698|Behavioral|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
75587330|NCT02883010|Device|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
75882415|NCT02109302|Procedure|Blood sample|
75882416|NCT02109302|Procedure|Skin biopsy|
75882417|NCT02109302|Other|Questionnaire|
76053314|NCT05341349|Procedure|Tumor Treating Fields Therapy|Undergo TTFields
76053315|NCT04525547|Drug|Nintedanib|Nintedanib
75731913|NCT03997695|Other|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
75731914|NCT01074775|Biological|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
75731915|NCT01080079|Drug|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
75437939|NCT01593163|Drug|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
75731916|NCT01080079|Other|Purified Water|Purified Water
75731917|NCT02538536|Drug|PBI4050|
75731918|NCT00725231|Biological|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
75731919|NCT00725231|Drug|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
75731920|NCT02539238|Other|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
75731921|NCT03381521|Procedure|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 10cc normal saline between carpal tunnel and median nerve.
75731922|NCT03381521|Procedure|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
75731923|NCT03381521|Device|Ultrasound|The ultrasound was used to measure cross-sectional area and injection guidance
75731924|NCT03381521|Drug|Normal saline|The normal saline was used for injection solution
75731925|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day
76053316|NCT02169284|Drug|Erlotinib Hydrochloride|Given PO
76053317|NCT02169284|Other|Laboratory Biomarker Analysis|Correlative studies
75437940|NCT01593163|Drug|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
75437941|NCT01593176|Procedure|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
75437942|NCT01593189|Behavioral|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
75437943|NCT01593267|Procedure|coil embolization|Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
76053318|NCT02169284|Other|Pharmacological Study|Correlative studies
75437944|NCT01593267|Procedure|clip occlusion|Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
75587331|NCT02883010|Other|Standard Care|Care path normally used by the hospital
76053319|NCT02169284|Other|Placebo|Given PO
76053320|NCT02169284|Other|Quality-of-Life Assessment|Ancillary studies
76053321|NCT02169284|Procedure|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
76053322|NCT02119819|Drug|LY2944876|Administered SC
76053323|NCT02119819|Drug|Exenatide extended-release|Administered SC
76053324|NCT02119819|Drug|Placebo|Administered SC
75587332|NCT02211950|Drug|BI 44847|
75587333|NCT02211950|Drug|Acarbose|
75587334|NCT02211950|Other|Japanese diet|
76053325|NCT02119819|Drug|Metformin|Oral
76053326|NCT04766450|Drug|Acetyl cysteine|NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
75587335|NCT02882776|Dietary Supplement|Ginger drink|Ginger powder dissolved in water
75587336|NCT04539210|Device|Electric Welded Metal Framework|Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework
75587337|NCT02882659|Biological|Dendritic Killer Cell (DKC)|DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
75587338|NCT04579055|Other|1-min STS test: adjusted|Individually adjusted chair seat height of 90° knee joint flexion
75731926|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
75731927|NCT00114127|Drug|Placebo|60mg placebo 1x per day
75731928|NCT05158179|Device|Sensation testing|Sensation testing tactile aesthesiometer.
75731929|NCT00902954|Drug|anastrozole|anastrozole 1 mg qd
75731930|NCT00902954|Drug|letrozole|letrozole 2.5 mg qd
75731931|NCT00902954|Drug|exemestane|exemestane 25 mg qd
75587339|NCT04579055|Other|1-min STS test: standardized|Standardized chair seat height of 46 cm
75587340|NCT04539288|Other||There is no intervention in this study.
75587341|NCT04559087|Procedure|Laparoscopic Surgery|"NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall."
75587342|NCT04546893|Biological|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
75587343|NCT04579289|Other|questionnaire|"A questionnaire was e-mailed to all identified institutions, with 3 reminders in one month. It included 39 questions concerning :~morbidity and mortality linked with COVID-19~structural features of the facility (location, architecture, residents characteristics)~human resources~crisis management (visits and circulation restrictions, personal protective equipment)"
75587344|NCT04579328|Behavioral|Exposure to Growth Mats|see arm/group descriptions for description of intervention
75587345|NCT04546932|Procedure|Lung-protective mechanical ventilation|Patients were provided with a tidal volume of 7 ml/kg IBW and an intraoperative 10 cmH2O in PEEP. Simultaneously, the alveoli were recruited applying a stepwise increase in PEEP (from 4 to 10 cmH2O for 3 breaths, 10 to 15 cmH2O for 3 breaths, and 15 to 20 cmH2O for 10 breaths) with maximum PIP = 50 cmH2O [24]. The recruitment maneuvers were performed right after intubation, 30 minutes after CO2 insufflation, then every hour, and finally before extubation.
75731932|NCT02570009|Behavioral|TEAMS (Talking about Eating, Activity, Mutual Support)|
75437945|NCT01593280|Device|TAP catheter|dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.
75731933|NCT02570009|Behavioral|Need Support Training|
75731934|NCT04034966|Device|Claria telemedicine device|Use of Claria telemedicine module, which stores patient information in the cloud.
75731935|NCT05077553|Dietary Supplement|TCI999 probiotic sachet|Testing product
75731936|NCT05077553|Dietary Supplement|Placebo sachet|Blank
75437946|NCT01593280|Drug|intrathecal morphine|0.3 mg
75437947|NCT01593293|Drug|PemCarbo|Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
75437948|NCT01593293|Drug|Pem only|Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
75437949|NCT01593306|Drug|Paclitaxel, Cisplatin|intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
75587346|NCT04578860|Other|Music therapy with Music Care app|Listening to music with Music Care app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
75587347|NCT04578860|Other|Sound therapy with White Noise|Listening to white noise with an app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
75587348|NCT04578860|Other|Treatment as usual for sleep disorders|No intervention
75587349|NCT04546386|Procedure|Endoscopic endonasal pituitary surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter
75587350|NCT04546503|Procedure|Continuous Regional analgesia|"Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.~Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H~+ General anaesthesia"
75587351|NCT04546503|Procedure|Control Group|General anaesthesia without regional analgesia
75587352|NCT04558853|Drug|autologous NK cells|Autologous ex vivo expanded and activated NK cells
75587353|NCT04546659|Other|Retrowalking|Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed
75587354|NCT04546659|Other|Conventional Therapy|Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
75731937|NCT00572624|Behavioral|Diet|Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
75731938|NCT00572624|Procedure|Gastric bypass surgery|The same surgeon performed all bypass procedures using standard techniques. A small (~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
75437950|NCT01593306|Drug|Cisplatin|intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
75731939|NCT02540720|Drug|Dexamethasone|
75731940|NCT02540720|Drug|Gamma globulin|
75731941|NCT02540720|Procedure|Hemoperfusion|
75731942|NCT02540642|Dietary Supplement|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
75731943|NCT00122317|Drug|eculizumab|
75731944|NCT00895388|Behavioral|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
75882418|NCT05705895|Procedure|CENTRAL VENOUS CATHETER CARE PROTOCOL|"Catheter care is provided in line with the CVC care protocol developed by the researcher:~For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~Vein valve/needleless connector will be used.~Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~Needle-free connectors will be replaced every 96 hours at the latest.~If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~Pulsatile give stop give stop technique will be used in the washing process."
76053327|NCT04852991|Procedure|Modified Purandare cervicopexy|The modified Purandare's cervicopexy will be performed in low lithotomy position . Pfannenstiel incision was utilized and the abdomen was opened in layers maintaining perfect hemostasis. Uterus will be delivered through the incision and held with uterus holding forceps. The bladder was dissected inferiorly. A 25-30 cm long strip of polypropylene mesh was prepared by soaking. The mesh was fixed anteriorly at the level of isthmus by No.1 polypropylene sutures . The ends of the mesh were brought lateral to rectus muscle retroperitoneally on both sides taking care not to injure the inferior epigastric vessels. After confirming the correct fixation and haemostasis the uterovesical fold of peritoneum was approximated. The ends of the mesh were fixed to the rectus muscle by criss crossing using No. 1 polypropylene sutures. After confirming the haemostasis, the abdomen was closed in layers. Per speculum examination was done to note the reduction of prolapse.
75437951|NCT01593319|Drug|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
75437952|NCT01593319|Drug|Natrium chloride|Placebo injection of Natrium chloride solution
75437953|NCT01593332|Drug|Rituximab|two 500 mg rituximab infusions 2 weeks apart
75437954|NCT01593332|Drug|Rituximab|500mg,two times with two weeks interval
75587355|NCT04558814|Diagnostic Test|Serum galectin-9 level|Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group
75731945|NCT00895466|Biological|PEP-223/CoVaccine HT|
75731946|NCT03964675|Device|SenseGuard|A single invitational visit with a respiratory rate measurement duration of 30 minutes.
75731947|NCT03870555|Drug|TAK-954|TAK-954 infusion administered intravenously.
75731948|NCT03870555|Drug|TAK-954 Placebo|TAK-954 placebo-matching infusion intravenous.
75587356|NCT04546464|Behavioral|Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
75587357|NCT01129102|Drug|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
75587358|NCT01129102|Drug|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
75587359|NCT01129102|Drug|Placebo|Placebo for NPC-01
75587360|NCT04539132|Behavioral|ABI Wellness Program|The ABI Wellness program includes a computerized task which will be completed by all participants remotely. The exercise is a sustained visual-spatial processing task of progressively increasing difficulty. Subjects are presented with an analog clock face, initially showing only one hand. The subject uses a keyboard to enter a value for the hour shown. Feedback on the computer screen indicates whether the response is correct or incorrect. If the response was incorrect, the subject continues to respond until the correct response is entered. After this, a new clock face is shown. Once subjects reach a criterion of 90% accuracy over a series of consecutive responses, an additional hand is added to the clock face. Participants will complete the program at home, online, and will be required to be present on a video call during the exercise with the other participants and research assistants. The program is 150 hours over 6 months, through twice weekly 3-hour sessions.
75587361|NCT04538820|Drug|Dexamethasone 4 mg IV-control|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
75587362|NCT04538820|Drug|Dexamethasone 4 mg IV|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
75731949|NCT02569931|Other|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
75731950|NCT02569931|Other|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
75437955|NCT01593345|Other|Mobility self-management with Mentor|will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.
75437956|NCT01593345|Other|Mobility self-management with guidebook|will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
75437957|NCT01593371|Drug|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
75437958|NCT01593371|Drug|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
75437959|NCT01593397|Drug|Propofol and Fentanyl administration|Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
75437960|NCT01593410|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
75587363|NCT04538820|Drug|Dexamethasone 8 mg IV|dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
75587364|NCT00575978|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
75587365|NCT01129024|Drug|Lusutrombopag|tablet
75587366|NCT04546347|Radiation|[14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|Dose of [14C]AZD9833 Solution for Infusion
75587367|NCT04546347|Drug|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet A Dose 1
75587368|NCT04546347|Drug|AZD9833 Oral Solution|AZD9833 Oral Solution
75587369|NCT04546347|Drug|AZD9833 film-coated tablet B Dose 1|AZD9833 film-coated tablet B Dose 1
75731951|NCT02569931|Procedure|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
75587370|NCT04546347|Drug|AZD9833 film-coated tablet A Dose 2|Dose 1 of AZD9833 film-coated tablet A Dose 2
75587371|NCT04546347|Drug|AZD9833 film-coated tablet B Dose 2|Dose 1 of film-coated tablet B Dose 2
75587372|NCT02882932|Procedure|Super Oxidized Solution in group I|Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
75587373|NCT04559477|Other|Static extension endurance exercise|"Static extension endurance exercise were performed, 10 repetitions with 10 sec hold of each of exercises Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
75587374|NCT04559477|Other|Dynamic extension endurance exercise|"Dynamic extension endurance exercise with 10 repetitions of each of exercises which has been performed Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
75587375|NCT04539054|Dietary Supplement|ENGN Shred|ENGN Shred is a multi-ingredient pre-workout supplement.
75731952|NCT00908336|Drug|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
75731953|NCT00908336|Drug|Erlotinib|150 mg/day po daily
75882419|NCT05192187|Other|Cross-sectional self-report (questionnaires)|"participants in this group will be ask to complete questionnaires on one occasion (i.e., cross-sectional investigation). The questionnaires will consist of a self-developed questionnaire and standard questionnaires. The main aspects of the self-developed questionnaires are~perceived harmfulness of activities (selection of PHODA-SeV)~cognitions about lifting and pain~reasons for avoidance behaviour (lifting)~Standardised questionnaires include~NRS for pain~TSK-11~FABQ~RMDQ"
75882420|NCT02105402|Behavioral|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
75437961|NCT01593410|Drug|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
75437962|NCT01593436|Behavioral|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
75437963|NCT01593449|Behavioral|Community-based social networking intervention|Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
75437964|NCT01593462|Procedure|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
75437965|NCT01593462|Procedure|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
75587376|NCT04539054|Dietary Supplement|Nutricost caffeine powder|Caffeine powder.
75587377|NCT04539054|Dietary Supplement|Crystal Light|Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
75587378|NCT00576017|Drug|Fentanyl-TTS|
75587379|NCT04558697|Drug|Shepherd's Purse extractum oleosum vagitories|Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days
75587380|NCT04558697|Drug|Tea tree oil vagitories|Tea tree oil vagitories will be administered once daily for 5 days
75587381|NCT04558697|Drug|Hyperici extractum oleosum vagitories|Hyperici extractum oleosum vagitories will be administered once daily for 5 days
75731954|NCT03964519|Other|Acute changes|In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.
75731955|NCT03964519|Other|Chronic changes|In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.
75731956|NCT03964519|Other|Familiarization|Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
75731957|NCT00908414|Drug|TMC589337 40 mg|Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
75731958|NCT00908414|Drug|TMC589337 100 mg|Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
75882421|NCT02112110|Drug|BMS-791325|
75882422|NCT02112110|Drug|[13C]-BMS-791325|
75587382|NCT04558697|Drug|Vagitories - Probiotic|Vagitories - Probiotic will be administered once daily for 5 days
75587383|NCT04546269|Procedure|Fully-guided vs. conventionally guided implant placement|Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
75587384|NCT04558658|Diagnostic Test|Complete Blood Count|neutrophil to lymphocyte ratio
75587385|NCT02215707|Biological|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
75587386|NCT01128946|Drug|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
75587387|NCT01128946|Drug|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
75587388|NCT01128946|Drug|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
75731959|NCT00908414|Drug|TMC589337 200 mg|Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
75437966|NCT01593462|Behavioral|Study Questionnaires|"The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.~A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete."
75587389|NCT04558580|Drug|Rufinamide|Rufinamide
75587390|NCT04546035|Device|radial Extracorporeal Shockwave Therapy|rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.
75587391|NCT02882620|Behavioral|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
75587392|NCT02882620|Behavioral|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
75587393|NCT02882620|Behavioral|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
75587394|NCT00625261|Other|Heidelberg Parent-based Language Intervention HPLI|The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
75731960|NCT00908414|Drug|TMC589337 400 mg|Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
75882423|NCT02105480|Device|Computer aided auscultation (CAA)|
75587395|NCT00625300|Device|repetitive transcranial stimulation (r-TMS)|Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
75587396|NCT00625300|Device|Repetitive transcranial stimulation|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
75731961|NCT00908414|Drug|TMC589354 40 mg|Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
75731962|NCT00908414|Drug|TMC589354 100 mg|Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
75731963|NCT00908414|Drug|TMC589354 200 mg|Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
75731964|NCT00908414|Drug|TMC589354 400 mg|Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
75731965|NCT00908414|Drug|TMC589337 AA mg|Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
75731966|NCT00908414|Drug|TMC589354 BB mg|Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
75882424|NCT02105714|Procedure|Stool culturing for pathogenic bacteria|
75882425|NCT02105714|Procedure|Kato-Katz technique|
75882426|NCT02105714|Procedure|Baermann technique|
75587397|NCT00576134|Device|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
75587398|NCT02215746|Drug|BI 44370 powder for oral solution|
75587399|NCT02215746|Drug|BI 44370 tablet|
75587400|NCT02215746|Other|high fat breakfast|
75587401|NCT02278458|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
75587402|NCT02278458|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
75437967|NCT01593475|Radiation|Induction chemotherapy followed by CCRT|"Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
75437968|NCT01593501|Dietary Supplement|vitamin D3|pharmaceutical grade D3
75437969|NCT01593514|Biological|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
75437970|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
75437971|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
75587403|NCT02215785|Other|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
75587404|NCT02215824|Drug|BIWH 3|
75587405|NCT02215824|Drug|Placebo|
75587406|NCT01128595|Drug|FF/GW642444M|
75587407|NCT01128595|Drug|GW642444M|
75587408|NCT01128595|Drug|Fluticasone Furoate|
75587409|NCT01128595|Drug|Placebo|
75587410|NCT01129336|Drug|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
75587411|NCT01129336|Drug|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
75587412|NCT02882386|Other|Strength Training|
75587413|NCT02882386|Dietary Supplement|Milk 1%|
75587414|NCT02882386|Dietary Supplement|Whey protein concentrate 80 (WPC-80)|
75587415|NCT02882386|Dietary Supplement|Microparticulated whey|
75587416|NCT02882386|Dietary Supplement|Hydrolyzed whey|
75587417|NCT02882386|Dietary Supplement|Native whey|
75587418|NCT01128361|Behavioral|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
75731967|NCT00908414|Drug|TMC589337 CC mg|Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
75731968|NCT00908414|Drug|TMC589354 DD mg|Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
75731969|NCT00908414|Drug|TMC589337 EE mg|Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
75731970|NCT00908414|Drug|TMC589354 YY mg|Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
75731971|NCT00908414|Drug|TMC310911 300 mg|Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
75437972|NCT01593514|Biological|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
75437973|NCT01593514|Biological|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
75437974|NCT01593527|Drug|ACZ885|Canakinumab 150 mg s.c.
75437975|NCT01593527|Drug|Triamcinelone acetonide|Triamcinelone acetonide 40 mg i.m.
75437976|NCT01593540|Device|metal-free interdental brush|one time per day
75437977|NCT01593540|Device|metal-core interdental brush|one time per day
75437978|NCT01593553|Other|ECG screening for atrial fibrillation using intermittent ECG recorder|ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
75437979|NCT01593566|Drug|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
75437980|NCT01593566|Drug|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
75437981|NCT01593579|Behavioral|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine & standing heart rate & blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
75437982|NCT01593579|Other|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
75437983|NCT01593605|Dietary Supplement|Resveratrol|A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
75587419|NCT01128361|Behavioral|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
75587420|NCT01128244|Dietary Supplement|Vitamin B6|Subjects will receive vitamin B6 supplementation.
75587421|NCT01128244|Procedure|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
75587422|NCT04545996|Other|Suboccipital Inhibition Technique|Suboccipital Inhibition Technique For 2min And Conventional Treatment Hot Pack For 10 To 15 Mints And Muscle Energy Technique(Post Facilitation Stretch) 5 Reps × 1 Set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
75587423|NCT04545996|Other|Cranio Cervical Flexion Exercises.|Cranio cervical flexion exercises10 repetitions for 10 seconds and conventional treatment hot pack for 10 to 15 mints and muscle energy technique(post facilitation stretch) 5 reps × 1 set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
75437984|NCT01593605|Dietary Supplement|resveratrol /HMB|resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
75587424|NCT01127893|Biological|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
75437985|NCT01593605|Other|Placebo treatment|Placebo - one tablet taken twice a day by mouth
75437986|NCT01593618|Behavioral|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
75587425|NCT01127893|Biological|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
75587426|NCT01127893|Biological|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
75587427|NCT00576173|Drug|tramadol hydrochloride; acetaminophen|
75587428|NCT00625339|Drug|Entecavir|entecavir 0.5 mg QD
75587429|NCT00625339|Drug|Lamivudine|lamivudine 100 mg QD
75731972|NCT00908414|Drug|TMC310911 600 mg|Participants will receive TMC310911 600 mg in Panel 7.
75731973|NCT00908414|Drug|Placebo|Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
75882427|NCT02105714|Device|Mini-FLOTAC|
75437987|NCT01593618|Other|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
75437988|NCT01593631|Dietary Supplement|Acid lactase|capsules cotaining 3300 FCC units of acid lactase
75587430|NCT02215863|Biological|Fluad and Prevenar13|
75587431|NCT02215863|Biological|Fluad|
75587432|NCT02215863|Biological|Prevenar13|
75587433|NCT04558463|Drug|Favipiravir|"The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
75437989|NCT01593631|Dietary Supplement|Acid lactase|capsules containing 9000 FCC of acid lactase
75587434|NCT04558463|Drug|Oseltamivir 75mg|"The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
75437990|NCT01593631|Dietary Supplement|Lyoph. yoghurt bacteria|capsules containing 2 billion lyoph. yoghurt bacteria
75437991|NCT01593631|Dietary Supplement|Acid lactase plus yoghurt bacteria|Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria
75437992|NCT01593631|Dietary Supplement|Placebo|Capsules containing di-calcium-phosphate
75437993|NCT01593644|Drug|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
75437994|NCT01593657|Other|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
75587435|NCT04311385|Diagnostic Test|CT imaging|CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
75587436|NCT01126879|Dietary Supplement|genistein|Given orally
75587437|NCT01126879|Other|placebo|Given orally
75587438|NCT01126879|Procedure|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
75587439|NCT00576212|Behavioral|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
75731974|NCT01074853|Drug|propranolol|10mg twice daily escalated to 80mg once daily
75731975|NCT01074853|Drug|placebo|Matched placebo
75731976|NCT03870477|Device|THP Hip Fracture Plating System with telescoping lag screws|The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
75731977|NCT02570633|Other|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
75731978|NCT02570633|Other|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
75882428|NCT02105714|Device|Crypto/Giardia Duo Strip|
75882429|NCT02105714|Procedure|Formalin-ether concentration technique|
75882430|NCT02105714|Device|CCA RDT|
75882431|NCT02105714|Procedure|Koga agar plate culture|
75587440|NCT04311658|Drug|Isosorbide Mononitrate 40 MG|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
75587441|NCT04311658|Drug|Placebo|one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
75437995|NCT01593657|Other|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
75437996|NCT01593657|Procedure|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
75437997|NCT01593657|Procedure|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
75587442|NCT02882308|Drug|Olaparib|50/25 mg BD split x 5 days
75437998|NCT01593683|Behavioral|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
75587443|NCT02882308|Drug|Cisplatin|60 mg/m^2 d1-d5
75587444|NCT02882308|Drug|Olaparib|300 mg BD x 21-28 days.
75587445|NCT02882308|Drug|Durvalumab|1500 mg d1
75587446|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
75587447|NCT02211989|Drug|BI 14332 CL|
75587448|NCT02211989|Drug|Placebo|
75587449|NCT00625456|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10^5 pfu/kg to 3 x 10^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
75587450|NCT04539444|Biological|CD19/22 CART|CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10*107 CART cells per kilogram of body weight.
75587451|NCT04539444|Drug|Tislelizumab|Patients will receive Tislelizumab 200mg/dose every 3 weeks.
75587452|NCT00576329|Drug|Ketorolac|Topical use before surgery
75882432|NCT02105714|Procedure|Kinyoun staining|
75437999|NCT01593735|Drug|MK-2748|MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
75882433|NCT02105714|Device|Multiplex PCR|
75882434|NCT02105714|Procedure|Metagenomics analysis|
75438000|NCT01593735|Drug|Placebo|Placebo tablets, orally, once daily for 7 days
75438001|NCT01593774|Drug|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group
75438002|NCT01593774|Drug|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
75587453|NCT02882464|Device|PC-02 Centrifuge device,2PRF+CAF|In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
75587454|NCT02882464|Device|PC-02 Centrifuge device, 4 PRF+CAF|Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
75587455|NCT02882464|Procedure|CTG+CAF|The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
75587456|NCT02882581|Radiation|11C-metformin|400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
75587457|NCT02882347|Drug|Somatostatin|
75587458|NCT00576368|Drug|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
75587459|NCT00637468|Drug|Intravenous injection of heparin|
75587460|NCT00637468|Drug|Intravenous injection of acetazolamide|
75587461|NCT00637468|Procedure|Local intra-arterial fibrinolysis|
75587462|NCT00637468|Procedure|Globe massage|
75587463|NCT00637468|Drug|Topical use of beta-blocker|
75587464|NCT00637468|Drug|Isovolaemic haemodilution|
75587465|NCT00637468|Drug|Acetylsalicylic acid|
75587466|NCT00637507|Other|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., >10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 >150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
75587467|NCT00637546|Other|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
75587468|NCT02212067|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
75731979|NCT00908492|Behavioral|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
75882435|NCT05540067|Behavioral|Acceptance-Based Behavior Therapy (ABBT)|In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified challenges related to the COVID-19 pandemic, mental health, and social support. Interventionists will help participants identify potential challenges to acceptance. At the second session, participants will practice acceptance-based coping skills and a social support behavioral plan will be developed. These discussions will help the participant clarify how best to align their values with decisions on how to manage their mental health and social support in the context of the COVID-19 pandemic.
75438003|NCT01593800|Dietary Supplement|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
75882436|NCT05540067|Other|Treatment-as-Usual (TAU)|TAU includes brief mental health screening, consultation with providers, and referrals to psychotherapy and/or psychiatric medication.
75882437|NCT02112266|Other|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
75438004|NCT01593826|Drug|Charcoal and Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
75438005|NCT01593826|Drug|Charcoal and Symbicort Turbuhaler|2 inhalations as a single dose
75438006|NCT01593826|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
75587469|NCT02212067|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
75587470|NCT02278575|Drug|Atenativ|intravenous transfusion
75587471|NCT01126060|Drug|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
75882438|NCT02112266|Other|no mail support|follow-up without mail support
75731980|NCT00908492|Behavioral|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
75731981|NCT04880291|Drug|GFB-024|Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody
75731982|NCT04880291|Drug|Placebo|Matched placebo
75731983|NCT00908570|Drug|estriol|4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
75438007|NCT01593826|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
75587472|NCT01126060|Procedure|Thyroidectomy|surgical removal of bilateral thyroid glands
75587473|NCT02882542|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
75731984|NCT00908570|Drug|Placebo|Placebo cream
75882439|NCT05538039|Other|Distract with play dough|Distract with play dough
75882440|NCT05538039|Other|Distract with play kaleidoscope|Distract with play kaleidoscope
75882441|NCT05538039|Other|Control group|Routine nursing care
75882442|NCT02109380|Behavioral|Bed rest|
75882443|NCT02109536|Device|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
75882444|NCT02105792|Drug|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
75882445|NCT03817515|Drug|ABI-009|Sirolimus Albumin-bound Nanoparticles
75438008|NCT01593865|Procedure|BIMA Grafting|Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
75438009|NCT01593865|Procedure|Left-only mammary artery grafting|These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
75438010|NCT01593878|Other|TV|test taken with TV on
75438011|NCT01593930|Other|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
75438012|NCT01593930|Other|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
75438013|NCT01593930|Other|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
75438014|NCT01593930|Other|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
75438015|NCT01593943|Behavioral|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
75438016|NCT01593956|Behavioral|tDCS|
75438017|NCT01593969|Dietary Supplement|RUTF/Flax Oil|Ready to Use Therapeutic Food
75438018|NCT01593969|Dietary Supplement|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
75438019|NCT01593969|Dietary Supplement|Standard RUTF|Standard formulation RUTF given according to National Guidelines
75438020|NCT01593982|Other|repetitive Transcranial Magnetic Stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
75882446|NCT02112344|Radiation|IMRT|
75882447|NCT02105870|Drug|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
75882448|NCT02112422|Drug|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
75882449|NCT02112422|Drug|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
75438021|NCT01593995|Drug|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
75438022|NCT01594008|Other|Breakfast meal with placebo powder|Zero serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and placebo powder.
75438023|NCT01594008|Other|Breakfast meal with 2 serving equivalents of blueberries|Two serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
75882450|NCT02251340|Behavioral|Eczema Care Plan|
75438024|NCT01594008|Other|Breakfast meal with 4 serving equivalents of blueberries|Four serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
75438025|NCT01594021|Drug|Gelatin 500 mL|intravenous administration
75438026|NCT01594021|Drug|Gelatin 50 mL|intravenous administration
75438027|NCT01594034|Procedure|expired air|collection of expired air from ventilator
75882451|NCT05646147|Device|Maximal Systolic Acceleration|Reliability of the maximal systolic acceleration
75882452|NCT02109692|Other|blood sample|dosage of miRNA
75882453|NCT05705583|Other|Other: Blood and Urine Collection|Blood and Urine Collection
75882454|NCT02106026|Other|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
75882455|NCT05159115|Other|Low-FODMAP diet|4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)
75882456|NCT05159115|Other|Starch- and Sucrose Reduced Diet (SSRD)|4 weeks of a diet low in starch and sucrose
75882457|NCT02251418|Device|Extracorporeal shockwave therapy|
75882458|NCT02112500|Biological|Mesenchymal Stem Cell|Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
75587474|NCT02212184|Other|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
75587475|NCT02212184|Other|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
75587476|NCT01125748|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
76053328|NCT04852991|Procedure|Abdominal sacral hysteropexy|After peritoneal entry through pfannenstiel incision was, the bladder is mobilized off the cervix. Windows are made in the broad ligament at the level of the isthmus. Posteriorly, the rectovaginal space is entered at the level of the uterosacral ligaments. Next, a 15x15-cm polypropylene mesh is used to fashion two 4.5- to 5-cm-wide strips of mesh; one is bisected for a distance of 5 cm to produce a Y-configuration for the anterior mesh.The anterior mesh arms are passed through the broad ligament windows and attached to the cervix and pubocervical fascia using interrupted 2-0 PDS. The posterior mesh is attached to the rectovaginal fascia using transverse-interrupted 2-0 PDS sutures. Once the sacral dissection has exposed the anterior longitudinal ligament, the proximal ends of the 2 mesh strips are attached to the sacral promontory using two 2-0 polyester sutures to provide elevation of the uterus without tension. The peritoneum is closed over the mesh using a 3-0 vicryl suture
75731985|NCT01010607|Device|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
75731986|NCT01010607|Device|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
76053329|NCT04765982|Diagnostic Test|Checking diabetes development in follow up at 3 month|An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
75438028|NCT01594060|Drug|Insulin, regular - act rapid|4 shots of regular insulin: 3 before meals and one at bedtime.
75731987|NCT01010607|Device|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
75731988|NCT00725777|Drug|artemether-lumefantrine|Standard artemether-lumefantrine treatment
75731989|NCT00165841|Drug|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
76053330|NCT02168816|Drug|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
75731990|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
75731991|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
75731992|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
75731993|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
75731994|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
75731995|NCT00725855|Drug|MEM 3454|1 mg dose
75731996|NCT00725855|Drug|MEM 3454|5 mg dose
75731997|NCT00725855|Drug|MEM 3454|15 mg dose
75731998|NCT00725855|Drug|MEM 3454|50 mg dose
75731999|NCT00725855|Drug|Placebo for MEM 3454|Placebo dose
75587477|NCT01125748|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
75882459|NCT05644899|Procedure|Interlaminar ultrasound-assisted intrathecal administration of nusinersen|All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
75587478|NCT01125748|Drug|Asthma therapies|Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
75587479|NCT04558268|Drug|Prednisone|"Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders."
75587480|NCT04558268|Drug|Progesterone|"Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy."
75587481|NCT04558268|Dietary Supplement|vit D|Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
75587482|NCT04558268|Dietary Supplement|Iron Supplement|Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
75587483|NCT04558268|Dietary Supplement|Folic Acid|"Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer."
75587484|NCT04545918|Device|Follicle Clarity|Mask Region-based Convolutional Neural Network in Ultrasound Follicle Identification
75587485|NCT01125514|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
75587486|NCT01125514|Drug|Furosemide 60 mg|Furosemide 60 mg commercially-available tablets
76053331|NCT02168816|Drug|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
76053332|NCT05315921|Drug|OsrhAAT 1 mg/kg IV|"Drug: OsrhAAT 1 mg/kg IV A single dose of OsrhAAT 1 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
75587487|NCT01125514|Drug|Placebo for Aliskiren|Matching placebo for aliskiren 150 mg and 300 mg
75587488|NCT01125514|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet
76053333|NCT05315921|Drug|OsrhAAT 3 mg/kg IV|"Drug: OsrhAAT 3 mg/kg IV A single dose of OsrhAAT 3 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
76053334|NCT05315921|Drug|OsrhAAT 10 mg/kg IV|"Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
76053335|NCT05315921|Drug|OsrhAAT 20 mg/kg IV|"Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
76053336|NCT05315921|Drug|OsrhAAT 40 mg/kg IV|"Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
75438029|NCT01594060|Drug|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
75438030|NCT01594086|Dietary Supplement|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
75438031|NCT01594099|Radiation|irradiation|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10)."
75438032|NCT01594099|Drug|Cisplatin|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy."
75587489|NCT04538547|Radiation|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
75438033|NCT01594099|Drug|liposome paclitaxel|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy."
75438034|NCT01594138|Other|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
75587490|NCT04538547|Radiation|Non Accelerated Radiotherapy|Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday
76053337|NCT05315921|Drug|OsrhAAT 60 mg/kg IV|"Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
75438035|NCT01594151|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
75587491|NCT00576446|Biological|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
75732000|NCT01326637|Other|Patient Overview Document|"The Intervention has two components:~Pre-visit care coordination:~5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
75732001|NCT02538458|Drug|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
75732002|NCT02538458|Drug|3 % hypertonic saline up to 24H|"Treatment by inhalation of 3 % hypertonic saline, up to 24H.~followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
75732003|NCT00509223|Device|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
75732004|NCT00509223|Behavioral|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
75438036|NCT01594164|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
75438037|NCT01594164|Radiation|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
75438038|NCT01594177|Drug|Afatinib|20 mg daily for 17 weeks (first two weeks every second day).
75587492|NCT04545879|Dietary Supplement|Raw garlic juice containing allicin|Fresh garlic juice containing around 48mg allicin for 7 days
75587493|NCT04578782|Drug|OnabotulinumtoxinA|BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
75587494|NCT04538703|Behavioral|acne vulgaris|Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease.
75587495|NCT00576485|Procedure|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
75587496|NCT04539015|Device|Prevena Plus|PREVENA Plus is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
75882460|NCT05644899|Procedure|Landmark-based intrathecal administration of nusinersen|All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
75882461|NCT02106104|Drug|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
76053338|NCT05307107|Behavioral|SHINE|Intervention group will use a 8-workweeks the digital Smart Break SHINE program with workplace support (encouragement and time-support) including daily 3 minutes break exercises twice a day; 1) physical exercise - break and 2) body/mind breathing exercise - break earning stars for exercise completed. The program includes weekly self-reflective task of individual well-being during working hours with weekly changing theme (avoiding sitting time, nature benefits, relaxation exercises, increasing physical activity in workplace etc.) earning diamonds for every weekly task completed. Participants self-monitors their weekly individual resources levels asked in every Thursday (1-5, 1= very poor. 5= very good). Program includes e-mail remainders set by participant themselves for suitable time frame These individual well-being actions takes approximately 15 minutes/workday. Control group will receive this program after this study (waitlist protocol).
76053339|NCT01584232|Drug|LY2189265|
76053340|NCT01584232|Drug|Insulin glargine|
76053341|NCT01584232|Drug|Sulfonylureas (SU)|
76053342|NCT01584232|Drug|Biguanide (BG)|
76053343|NCT01639703|Drug|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
76053344|NCT04840121|Diagnostic Test|AdhesioRT|AdhesioRT, a novel diagnostic genetic assay, developed by ovo R&D scientists, helps to predict the endometrial receptivity and embryo implantation.
76053345|NCT04877483|Procedure|Acupuncture|Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
75732005|NCT01582867|Device|ARTIS hemodialysis system|"Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01"
75732006|NCT02538380|Procedure|EUS-B-FNA followed by EUS-FNA for LAG analysis|
75438039|NCT01594177|Drug|Trastuzumab|First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
75438040|NCT01594177|Drug|Paclitaxel|80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
75732007|NCT05277662|Diagnostic Test|cell and molecular diagnostics in accordance with functional test results|"Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1)."
75732008|NCT04067063|Other|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
75732009|NCT00460798|Other|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
75882462|NCT02106104|Drug|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
75882463|NCT02113670|Other|SUI 1|instillation of 50ml of air into the urinary bladder before the urodynamic test
75882464|NCT02109926|Other|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
75882465|NCT02113748|Other|Downhill walking training|Walk on a treadmill with a negative inclination.
75882466|NCT02113748|Other|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
75882467|NCT05703867|Device|Active microcurrent therapy|Non-invasive transpalpebral microcurrent therapy delivery to the upper and lower eyelids
75438041|NCT01594177|Drug|Epirubicin|90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
75587497|NCT00576563|Drug|FDG|contrast medium
75587498|NCT04538391|Drug|local ifiltration Bupivacaine, Meloxican and placebo|no other intervention done
75587499|NCT04558307|Diagnostic Test|Pilot a rapid SARS-CoV-2 testing strategy|Rapid testing strategy at an FQHC using Mayo Clinic Laboratory (MCL) diagnostic processing with a real-time polymerase chain reaction assay for SARS-CoV-2 and a Mayo Clinic drive-through collection protocol.
75587500|NCT04558307|Other|Community-driven messages to promote COVID-19 testing|A one-time communication about the availability of COVID-19 testing at the FQHC to patients randomized to the intervention group using any available means of communication (text and/or mailed letter).
75587501|NCT04545801|Drug|0.25 mg/kg of Ketamine|patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
75587502|NCT04545801|Drug|20ml of normal saline solution|20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
75587503|NCT04558424|Dietary Supplement|zinc gluconate and ascorbic acid|This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
75732010|NCT03965455|Device|Diode laser|In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.
75732011|NCT03965455|Procedure|Conventional|In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
75732012|NCT04034342|Other|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
75882468|NCT02113826|Drug|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
75882469|NCT02118974|Procedure|Hysterectomy|Hysterectomy
75882470|NCT02112656|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
75882471|NCT02112656|Drug|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
75882472|NCT01376323|Drug|GSK256073 1mg|GSK256073 1mg capsule
75882473|NCT01376323|Drug|GSK256073 5mg|GSK256073 5mg capsule
75882474|NCT01376323|Drug|GSK256073 10mg|GSK256073 10mg capsule
75882475|NCT01376323|Drug|GSK256073 25mg|GSK256073 25mg capsule
75882476|NCT01376323|Drug|Placebo|placebo capsule
75438042|NCT01594177|Drug|Cyclophosphamide|600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
75438043|NCT01594190|Behavioral|physical activity 15 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
75438044|NCT01594190|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
75882477|NCT01376323|Drug|Sitagliptin 100mg|Sitagliptin 100mg capsule
75882478|NCT02113904|Drug|Adalimumab|6 injections (one every 15 days during 3 months)
75882479|NCT05703633|Other|uDCD treatment|Thrombolytic treatment/prevention ex-vivo to kidneys procured from patients after circulatory arrest
75882480|NCT02119052|Drug|octeotride|
75882481|NCT02119052|Drug|placebo|
75882482|NCT02119130|Device|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
75882483|NCT05459805|Drug|traditional chinese medicine Xuanfei-Zhike formula|200ml, bid, for 8 weeks
75882484|NCT05459805|Drug|inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)|one suction, q12h, for 8 weeks
75438045|NCT01594203|Other|F18-FGD PET/CT|
75438046|NCT01594229|Drug|ABT-199|ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
75438047|NCT01594229|Drug|Rituximab|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
75438048|NCT01594229|Drug|Bendamustine|Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
75438049|NCT01594242|Drug|Bortezomib|
75438050|NCT01594255|Drug|sotrastaurin|
75587504|NCT02214693|Drug|DA-1229|
75587505|NCT00576602|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
75587506|NCT00576602|Drug|Supportive treatment|As prescribed
75587507|NCT01125358|Drug|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
75587508|NCT01125358|Drug|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
75587509|NCT02214732|Behavioral|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
75587510|NCT02212223|Dietary Supplement|Vitamin D3|
75587511|NCT00637585|Drug|Fexofenadine|
75882485|NCT02119208|Behavioral|Intensity and timing of exercise|
75882486|NCT02113982|Drug|SL-401|
75882487|NCT02112812|Drug|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
76053346|NCT04877483|Diagnostic Test|Oral microbiota|Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
75882488|NCT02112812|Drug|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
75882489|NCT02112812|Drug|Eradication therapy for Helicobacter pylori|
75587512|NCT00576641|Biological|autologous dendritic cells|
75587513|NCT02214810|Drug|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
75587514|NCT04558385|Diagnostic Test|IgG SARS CoV2|IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
75587515|NCT02214849|Behavioral|LATCH Intervention|
75587516|NCT02214888|Drug|BIRB 796 BS, low dose|
75587517|NCT02214888|Drug|BIRB 796 BS, high dose|
75587518|NCT02214888|Drug|Placebo|
75587519|NCT04558034|Other|cryotherapy|cryotherapy will be delivered
75587520|NCT04538508|Device|Diathermy|10 sessions of 12 minutes of radiofrequency diathermy at the anterior surface of the knee, in constant movement
75587521|NCT04538508|Other|Supervised knee exercises|Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.
75587522|NCT04545684|Behavioral|Motor imagery|The person will have to imagine different scenarios of manual gripping
75732013|NCT02570399|Radiation|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
75732014|NCT01075165|Other|silicone spray|application of silicone spray to predefined area qd 12 weeks
75882490|NCT05432115|Drug|Tetracyclin|Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
75882491|NCT02114528|Drug|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
75882492|NCT02114528|Procedure|Catheter ablation|Ventricular tachycardia catheter ablation.
75438051|NCT01594255|Drug|sotrastaurin|
75438052|NCT01594255|Drug|placebo to sotrastaurin|
75438053|NCT01594255|Drug|Avelox|
75882493|NCT04975321|Device|Nu Smile Zirconia crown|Placement of an anterior primary crown restoration
75882494|NCT04975321|Device|Nu Smile Pre Veneered crown|Placement of an anterior primary crown restoration
75882495|NCT04975321|Device|Composite strip crown|Placement of an anterior primary crown restoration
76053347|NCT04877483|Diagnostic Test|Schirmer's test|Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
75438054|NCT01594268|Drug|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
75438055|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
75438056|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
75438057|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
75587523|NCT04545684|Behavioral|Placebo intervention|The placebo group will imagine a place without the presence of humans.
75587524|NCT00576719|Behavioral|Intensive panic control treatment without parent involvement|Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
75587525|NCT00576719|Behavioral|Intensive panic control treatment with parent involvement|Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
75732015|NCT01075165|Other|saline spray|application of saline spray to predefined area qd 12 weeks
75732016|NCT00725933|Drug|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
75732017|NCT00726869|Drug|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8.
75732018|NCT01028248|Drug|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
75732019|NCT00726011|Biological|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
75732020|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
75732021|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
75732022|NCT01028326|Biological|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
75732023|NCT00603980|Drug|Inhaled placebo + oral placebo|Inhaled Staccato placebo + oral placebo
76053348|NCT04877483|Diagnostic Test|Tear breakup time|Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
75587526|NCT00576719|Other|Waitlist control|Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
75587527|NCT01125046|Biological|bevacizumab|Given IV
76053349|NCT04877483|Diagnostic Test|OSDI(Ocular Surface Disease Index)|Group GB20 and Group GB20 plus BL2 will take the OSDI test.
75587528|NCT04538937|Other|no intervention|no intervention
75732024|NCT00603980|Drug|Inhaled alprazolam 0.5 mg|Inhaled Staccato alprazolam 0.5 mg + oral placebo
75732025|NCT00603980|Drug|Inhaled alprazolam 1 mg|Inhaled Staccato alprazolam 1 mg + oral placebo
76053350|NCT04877483|Diagnostic Test|TCM pattern|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
76053351|NCT04877483|Diagnostic Test|Traditional Chinese Medicine (TCM) tongue diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
75438058|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
76053352|NCT04877483|Diagnostic Test|TCM pulse diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
76053353|NCT04877483|Diagnostic Test|TCM heart rate variability|Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
76053354|NCT04877483|Diagnostic Test|ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)|Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
76053355|NCT04877483|Diagnostic Test|Whole-genome genotyping(TWBv2.0)|Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
75438059|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
75438060|NCT01594320|Biological|Saline placebo|Placebo; Intramuscular, deltoid, Day 0 & Day 21
76053356|NCT04877483|Diagnostic Test|Cytokine markers|Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
76053357|NCT04877483|Diagnostic Test|Blood biochemical analysis|Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
76053358|NCT04877483|Diagnostic Test|complete blood count (CBC)|Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.
75438061|NCT01594346|Drug|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
75438062|NCT01594346|Drug|Sugar Pill|
75438063|NCT01594359|Other|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
75438064|NCT01594359|Other|BEAN|Placebo
75438065|NCT01594437|Biological|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
75438066|NCT01594437|Biological|Placebo|One or two doses administered by intravenous infusion.
75438067|NCT01594450|Biological|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
75587529|NCT04311346|Diagnostic Test|Cardiac MR|Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
75587530|NCT04538313|Drug|Tumor infiltrating lymphocyte|Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
76053359|NCT04877483|Diagnostic Test|SF-36(36-Item Short Form Survey )|Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
76053360|NCT02119663|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
76053361|NCT02119663|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
75732026|NCT00603980|Drug|Inhaled alprazolam 2 mg|Inhaled Staccato alprazolam 2 mg + oral placebo
75732027|NCT00603980|Drug|Oral alprazolam 1 mg|Oral alprazolam 1 mg + Inhaled placebo
75732028|NCT00603980|Drug|Oral alprazolam 2 mg|Oral alprazolam 2 mg + Inhaled placebo
75732029|NCT00603980|Drug|Oral alprazolam 4 m|Oral alprazolam 4 mg + Inhaled placebo
75732030|NCT00603980|Drug|Oral alprazolam 2 mg qualifying session|Qualifying session (2 mg oral alprazolam)
75732031|NCT00603980|Drug|Oral placebo qualifying session|Qualifying control session (oral placebo)
75732032|NCT04880603|Device|Restrata Graft|Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.
75732033|NCT04880603|Procedure|Standard of Care Skin Graft|Standard of Care Skin Graft
75732034|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
75732035|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
75732036|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
75732037|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
75438068|NCT01594450|Procedure|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
76053362|NCT02119663|Drug|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
76053363|NCT04481009|Drug|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
76053364|NCT04481009|Drug|Toripalimab|Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
75438069|NCT01594463|Other|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
75438070|NCT01594463|Other|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
75438071|NCT01594489|Drug|Aminophylline|"200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
75438072|NCT01594489|Drug|Hydration plus N-acetylcisteine|"Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
75438073|NCT01594502|Drug|Dutasteride|0.5 mg daily
75732038|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
75732039|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
75732040|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Acute DVT
75732041|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Chronic DVT
75732042|NCT00450190|Device|Saizen® E-Device|Saizen® (recombinant human growth hormone [r-hGH]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.
75732043|NCT00727103|Drug|Varenicline|Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.
75732044|NCT00727103|Drug|Placebo|Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
75732045|NCT01028482|Drug|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months"
75732046|NCT01028482|Drug|placebo|placebo
75732047|NCT01028482|Other|psychotherapy|psychotherapy
75732048|NCT00726167|Device|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
75732049|NCT00907322|Drug|Dimebon|Oral tablet; 20 mg Dimebon, single dose
76053365|NCT04481009|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
75438074|NCT01594502|Drug|Placebo|Placebo Comparator
76053366|NCT04481009|Drug|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
76053367|NCT05327231|Drug|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
75438075|NCT01594567|Other|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
75438076|NCT01594593|Behavioral|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
75732050|NCT00907322|Drug|Dimebon|Oral tablet; 40 mg Dimebon, single dose
75732051|NCT00907322|Drug|Dimebon|Oral tablet; 60 mg Dimebon, single dose
75732052|NCT00907322|Drug|Dimebon|Oral tablet; placebo, single dose
76053368|NCT05327231|Drug|Docetaxel|Docetaxel 75mg/m2 every 21 days a cycle.
76053369|NCT04453085|Drug|JR-171 (lepunafusp alfa)|JR-171 IV infusion
76053370|NCT01639469|Behavioral|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
76053371|NCT01639469|Behavioral|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
76053372|NCT04855721|Drug|AUR101|Oral ROR-gamma inverse agonist
76053373|NCT04855721|Drug|Placebo|Placebo
76053374|NCT02193074|Drug|nusinersen|Administered by intrathecal (IT) injection as specified in the treatment arm.
76053375|NCT02193074|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
75882496|NCT02112890|Other|Data collection|Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
76053376|NCT04852601|Other|ToolboxDetect|The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
75587531|NCT04538469|Other|COVID visitation restrictions|Visitation to patients in hospitals in Scotland was ceased due to the COVID 19 pandemic. Slow reintroduction of visitors has been introduced, however not to the pre COVID 19 levels. This study will examine the effects of these restrictions on patients in the cardiothoracic critical care unit that do not suffer from COVID 19.
75732053|NCT00903188|Drug|cyclosporine|"Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop"
76053377|NCT04418102|Dietary Supplement|Palmitic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period
75732054|NCT00903188|Drug|Everolimus|"Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60."
75438077|NCT01594606|Behavioral|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
75438078|NCT01594619|Drug|Naloxegol|Oral 25mg tablet
75438079|NCT01594619|Drug|Diltiazem XR|Oral 240mg tablet
75732055|NCT00726245|Biological|PRGF|3-6mg IM (to area of muscle tear)
75732056|NCT00726245|Biological|Placebo|3cc IM of physiological saline
75732057|NCT00450112|Device|Gel-200|Single Intra-articular Injection
75732058|NCT00727181|Device|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
75732059|NCT00908726|Drug|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
75882497|NCT05410587|Device|Fracture Monitor (implantable device class III)|Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
75882498|NCT02112968|Procedure|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
75882499|NCT02112968|Procedure|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
75882500|NCT02112968|Procedure|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
75438080|NCT01594632|Drug|Jadelle|LNG containing subdermal contraceptive implant
75438081|NCT01594632|Drug|Sino-implant (II)|LNG containing subdermal contraceptive implant
75438082|NCT01594645|Procedure|Sperm selection by conventional / polarized light microscopy|Selecting spermatozoa for ICSI using conventional and polarized light microscopy
75438083|NCT01594658|Procedure|Foam sclerotherapy|Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.
75438084|NCT01594658|Procedure|conservative|This arm only has medical standard handling (healings performed by the nurse group)
75587532|NCT01124734|Drug|Interleukin-2|Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
75587533|NCT01124734|Drug|Temozolomide|Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
75587534|NCT04538781|Device|VASCADE MVP VVCS|The VASCADE MVP Venous Vascular Closure System (VVCS) is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 - 12F inner diameter (maximum 15F OD) procedural sheaths, with single or multiple access sites in one or both limbs.
75587535|NCT04557839|Other|Traditional physical therapy balance exercise|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward~• Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
75587536|NCT04557839|Other|proprioception based balance training|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward all exercise done under following condition.~eyes open firm surfaces~Eyes open soft surfaces~Eyes closed firm surfaces~Eyes closed soft surfaces (the soft surfaces will be a foam mate with 2.5 cm thick )~These exercise will perform with turning the head side to side ad up and down~Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
75587537|NCT04545450|Drug|dutasteride 5 mg/day|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
75587538|NCT04545450|Drug|Testosterone Undecanoate|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
75438085|NCT01594671|Drug|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
75587539|NCT04579133|Drug|Olaparib|300 mg BID OR 200 mg BID (if glomerular filtration rate [GFR] 31 to 50 mL/min)
75587540|NCT04579133|Drug|Durvalumab|Durvalumab 1500 mg IV
75587541|NCT04545372|Other|aerobic exercise|
75587542|NCT00576914|Drug|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
75587543|NCT04545645|Behavioral|median nerve mobilization|The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
75587544|NCT04545645|Behavioral|Neural stress provocation with cognitive auditory distraction|Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
75587545|NCT04545645|Behavioral|Providing neural stress with a motor distraction|The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
75882501|NCT03627117|Drug|Verum|Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
75882502|NCT03627117|Drug|Placebo|Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
75882503|NCT02113046|Procedure|pancreatico-jejunal anastomosis|
75882504|NCT02113046|Procedure|traditional anastomosis|
75882505|NCT05074641|Other|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
75438086|NCT01594671|Drug|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
75438087|NCT01594671|Other|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
75438088|NCT01594684|Device|balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)|balloon inflation
75438089|NCT01594684|Device|drug coated balloon inflation (Cotavance, Medrad Inc.)|Balloon inflation
75438090|NCT01594684|Device|uncoated balloon (e.g. Admiral, Medtronic)|balloon inflation
75438091|NCT01594684|Device|balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)|ballon inflation
75438092|NCT01594697|Drug|Metformin|
75438093|NCT01594736|Drug|ORSIRO|due randomization ORSIRO will be implanted
75438094|NCT01594736|Device|XIENCE PRIME DES|due randomization XIENCE PRIME DES will be implanted
75438095|NCT01594775|Drug|Syntocinon (Oxytocin) nasal spray|two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
75438096|NCT01594775|Drug|Placebo|two-times daily self-administration of nasal spray containing placebo during five days after wounding.
75438097|NCT01594801|Device|InsuPad|Use of the InsuPad for at least 3 times a day.
75438098|NCT01594814|Procedure|RFA|radiofrequency ablation of slow pathway or accesory pathway
75438099|NCT01594840|Device|Changing chat|Diapers with tips
75438100|NCT01594866|Drug|escitalopram|escitalopram 20mg and 30mg p.o. daily, 6 weeks
75438101|NCT01594866|Drug|escitalopram|escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
75438102|NCT01594879|Device|MIrena(LNG-IUS), oral MPA|"General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate"
75438103|NCT01594892|Radiation|Radiosurgery|Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
75587546|NCT04545645|Behavioral|Neural stress provocation with auditory and motor cognitive distraction.|The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
75587547|NCT02212340|Drug|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
75587548|NCT02212340|Drug|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
75587549|NCT01124617|Drug|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
75438104|NCT01594905|Drug|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
75587550|NCT01124617|Drug|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
75587551|NCT04205890|Drug|Ketamine|The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage varies between 75mg - 1000mg depending on every individual's unique treatment plan.
75587552|NCT00577070|Device|TMS|Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
75587553|NCT00577109|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
75587554|NCT00577109|Drug|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
75587555|NCT00577109|Drug|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
75732060|NCT02948309|Drug|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
75587556|NCT00577109|Drug|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
75438105|NCT01594918|Drug|Cabazitaxel|25 mg/m2 or 20 mg/m2, IV, once every 21 days
75438106|NCT01594918|Drug|Mitoxantrone|4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
75438107|NCT01594918|Drug|Prednisone|5 mg PO BID
75438108|NCT01594918|Drug|Pegfilgrastim|6 mg, SC, once every 21 days
75438109|NCT01594957|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
75587557|NCT00577109|Drug|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
75587558|NCT04538001|Device|Balloon implantation|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and balloon implantation.
75587559|NCT04538001|Procedure|Rotator cuff repair|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and partial repair
75587560|NCT01124422|Drug|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
75732061|NCT02948309|Drug|Placebo|1ml subcutaneous injection 3 times/week
75732062|NCT00726401|Drug|COLD-fX|200mg BID for 4 weeks
75732063|NCT00726401|Drug|Placebo|200mg BID for 4 weeks
75732064|NCT00903266|Behavioral|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
75438110|NCT01595009|Drug|Everolimus (RAD001)|Everolimus was supplied as tablets of 5mg strength.
75438111|NCT01595022|Drug|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
75438112|NCT01595022|Drug|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
75438113|NCT01595022|Drug|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
75438114|NCT01595035|Behavioral|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
75438115|NCT01595074|Other|medical chart review|Correlative studies
75438116|NCT01595074|Other|laboratory biomarker analysis|Correlative studies
75587561|NCT01124422|Drug|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
75587562|NCT04544982|Other|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
75587563|NCT04544982|Other|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
75587564|NCT00577187|Device|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
75587565|NCT04309591|Device|CytoSorb haemoadsorption (HA) device|CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .
75587566|NCT04538196|Other|Resident education on documentation and coding|Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
75732065|NCT00903266|Behavioral|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
75587567|NCT00625495|Drug|Esomeprazole|40mg Intravenous infusion over 3 minutes
75587568|NCT00625495|Drug|Esomeprazole|40mg Oral
75587569|NCT00625534|Procedure|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
75587570|NCT00625534|Procedure|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
75732066|NCT02569775|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
75732067|NCT00449956|Drug|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
75732068|NCT00449956|Drug|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
75732069|NCT00449956|Drug|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
75882506|NCT05074641|Other|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
75438117|NCT01595087|Drug|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
75438118|NCT01595152|Drug|solifenacin succinate|8 mg once daily for 60 days
75438119|NCT01595152|Drug|fesoterodine|8 mg, once daily for 60 dyas
75438120|NCT01595165|Procedure|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
75732070|NCT00908804|Procedure|open appendectomy|
75587571|NCT02882425|Drug|Selexipag for intravenous use|Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
75587572|NCT02882425|Drug|Selexipag for oral use|Tablet containing 200 µg of selexipag
75587573|NCT04538235|Procedure|Thoracic Regional Analgesia|In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
75732071|NCT00908804|Procedure|laparoscopic appendectomy|
75732072|NCT00726479|Drug|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
75732073|NCT00903422|Drug|eltrombopag olamine|thrombopoietin receptor agonist
75732074|NCT00903422|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
75882507|NCT01376401|Drug|Bendamustine|
75882508|NCT01376401|Drug|Velcade|
75438121|NCT01595165|Procedure|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
75438122|NCT01595178|Behavioral|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
75438123|NCT01595191|Other|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
75438124|NCT01595191|Other|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
75587574|NCT00577304|Drug|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
75587575|NCT00577304|Drug|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
75882509|NCT01376401|Drug|Prednisone|
75882510|NCT02119364|Other|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
75882511|NCT05611983|Behavioral|sensory relearning|feasibility of early sensory relearning
75882512|NCT02119520|Drug|Platelet rich fibrin +Atorvastatin|
75882513|NCT02119520|Drug|Platelet rich fibrin|
75882514|NCT02119520|Procedure|open flap debridement|
75587576|NCT01124149|Drug|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
75732075|NCT01323088|Other|Control|Standard care control (no exercise)
75732076|NCT01323088|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
75732077|NCT01323088|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
75732078|NCT03906461|Device|Radiofrequency Ablation|The Tacticath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) is designed to facilitate electrophysiological mapping of the heart chambers and to transmit radiofrequency (RF) current to the catheter tip electrode for intracardiac ablation purposes.
75732079|NCT00907400|Drug|PN400|oral tablet
75732080|NCT00907400|Drug|Naproxen|oral tablet
75732081|NCT00726635|Behavioral|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
75732082|NCT00726635|Other|Control group|A one hour conversation with a nurse
75732083|NCT00726635|Other|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
75732084|NCT04034732|Behavioral|Mindfulness-based Relapses Prevention (MBRP)|"Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement."
75438125|NCT01595204|Procedure|Diagnostic laparoscopy|"Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers."
75438126|NCT01595217|Device|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
75732085|NCT04034732|Behavioral|Usual Care Control|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
75732086|NCT03995602|Dietary Supplement|Dragon fruit juice drink|Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.
75732087|NCT03995602|Dietary Supplement|Placebo|Drink with macro- and micro-nutrient matched against the intervention drink.
75732088|NCT05277506|Device|18 inch slot MBT orthodontic brackets bonded using smile arc protection bonding strategy|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
75882515|NCT02114762|Procedure|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
75882516|NCT00263731|Other|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
75732089|NCT05277506|Device|18 inch slot MBT orthodontic brackets boned using MBT placement guide|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide bonding strategy
75732090|NCT00727493|Drug|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
75882517|NCT05609877|Procedure|NONA-LISA|The staff will perform Less Invasive Surfactant Administration using the standard pre- and post-procedure care including non-pharmacological treatment. The patients will not receive pharmacological analgesic treatment routinely.
75882518|NCT02119754|Drug|Plurogel PN|
75882519|NCT03961789|Other|patients undergoing opioid replacement therapy|patients undergoing opioid replacement therapy
75882520|NCT02119832|Device|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
75882521|NCT01376479|Biological|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
75587577|NCT04538118|Behavioral|Shoulder disability|"Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
75438127|NCT01595230|Procedure|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
75438128|NCT01595243|Behavioral|telephone consultations about psychoeducation program|experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
75732091|NCT00727493|Drug|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
75732092|NCT03878914|Drug|Corticosteroids|Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
75438129|NCT01595256|Behavioral|muscular strength|12-week moderate intensity walking program
75438130|NCT01595269|Other|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
75438131|NCT01595295|Other|non interventional|
75732093|NCT00727727|Drug|Piribedil|
75732094|NCT00907712|Other|cardiac echo examination|cardiac echo examination - before and after the surgery
75438132|NCT01595308|Dietary Supplement|Pomegranate juice|Pomegranate juice
75438133|NCT01595334|Drug|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (>4.5 mIU/ml) in the study arm
75438134|NCT01595334|Drug|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
75438135|NCT01595347|Drug|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
75438136|NCT01595347|Other|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
75438137|NCT01595360|Drug|Placebo|It is applied directly to the bleeding site after tooth extraction
75438138|NCT01595360|Drug|TT-173|It is applied directly to the bleeding site after tooth extraction
75438139|NCT01595373|Drug|Acyl ghrelin|Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
75438140|NCT01595373|Drug|Placebo (Ringer acetate)|Ringer acetate 2 microliter/min for 300 minutes
75438141|NCT01595399|Drug|atropine|Atropine 0.02 mg/kg IV
75438142|NCT01595399|Drug|Placebo|an equivalent volume of normal saline to atropine IV
75438143|NCT01595412|Procedure|Laparoscopic Resection Rectopexy|laparoscopic sigmoidectomy with suture rectopexy
75438144|NCT01595412|Procedure|Laparoscopic Ventral Rectopexy|laparoscopic ventral rectopexy with mesh
75438145|NCT01595425|Drug|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
75438146|NCT01595425|Drug|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
75438147|NCT01595451|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
75438148|NCT01595464|Behavioral|Mind-Body Skills Groups|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
75438149|NCT01595477|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
75587578|NCT04538118|Device|Shoulder Range of Motion|"Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
75587579|NCT04538118|Behavioral|Pain Intensity|"Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
75587580|NCT04545099|Drug|Sugammadex|Administration of Sugammadex for muscle relaxation reversal
75732095|NCT04720079|Procedure|Subcutaneous infiltration of intercostobrachial nerve|Preoperative subcutaneous infiltration of intercostobrachial nerve with 10ml of 0.5% ropivacaine
75732096|NCT04720079|Procedure|T2 paravertebral nerve block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of 0.5% ropivacaine
75732097|NCT00909116|Procedure|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
75732098|NCT00729989|Procedure|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
75732099|NCT00903656|Drug|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
75438150|NCT01595490|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
75587581|NCT04545099|Drug|Neostigmine|Administration of Neostigmine for muscle relaxation reversal
75732100|NCT00730067|Drug|sildenafil|Sildenafil 50 mg three times daily
75732101|NCT00730067|Drug|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
75732102|NCT00909194|Behavioral|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
75732103|NCT00509145|Drug|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
75882522|NCT01376479|Biological|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
75438151|NCT01595542|Behavioral|Modified Vaccine Consent Form|"Packet of written immunization materials for parents and students which includes the following:~Cover letter~Vaccine promotional flyer~Vaccine information sheets (one for adolescent vaccination and one for other vaccination)~Improved consent form~Note advertising a lottery for free movie tickets for returning the consent form~Self-addressed stamped envelope"
75438152|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
75438153|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
75438154|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
75438155|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
75438156|NCT01595594|Drug|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
75438157|NCT01595594|Drug|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
75732104|NCT00509145|Other|Placebo|oral, once daily, capsule
75732105|NCT00907790|Behavioral|Usual Care (Control Group)|
75732106|NCT00907790|Behavioral|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
75732107|NCT02538224|Drug|2.5%ketoprofen gel + 3 % doxycycline|"GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs"
75732108|NCT02538224|Drug|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
75587582|NCT02882269|Drug|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
75587583|NCT02882269|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
75587584|NCT04545294|Device|Theta tACS|See detail in arm/group descriptions regarding the intervention.
75587585|NCT04578899|Device|Transvertebral magnetic stimulation|Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
75732109|NCT04018781|Other|medication reconciliation|"During hospitalization, the hospital pharmacist will carry out a pharmaceutical analysis for all patients included in the study, each time the prescription is changed and within a maximum of 24 hours (working days).~If necessary, in consultation with the doctor in charge of the patient, the pharmacist may also propose a pharmaceutical interview to the patient at any time during his hospitalisation (e.g. proposal for the de-prescription of benzodiazepines, Proton Pump Inhibitors, etc., according to the recommendations in force)."
75732110|NCT02538302|Drug|Minirin|Minirin 5 to 10 mg daily for 6 months
75882523|NCT01376479|Biological|Placebo|Phosphate Buffered Saline (PBS)
75882524|NCT03552614|Device|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
75882525|NCT03552614|Other|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
76053378|NCT04418102|Dietary Supplement|Stearic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period.
76053379|NCT04765592|Device|WeFlow-Arch Modeler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
75438158|NCT01595607|Other|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
75438159|NCT01595633|Drug|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
75438160|NCT01595659|Behavioral|Passenger|Driving with risk accepting or risk averse passenger
75438161|NCT01595672|Device|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
75438162|NCT01595672|Other|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
75438163|NCT01595685|Drug|Telbivudine|Telbivudine 600 mg Daily Oral
75438164|NCT01595685|Drug|Entecavir|Entecavir 0.5 mg Daily Oral
75587586|NCT02882503|Device|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
75587587|NCT04578704|Other|Vacuum formed retainer, fixed bonded retainer, vacuum formed and fixed bonded retainer|"Patients will be instructed to wear the removable vacuum form retainer for 8 to 10 hours per day and only removed the retainers during tooth brushing. (Thickett 2010), (Gill 2007).~The vacuum formed retainer will be constructed using thermoplastic material that will be purchased from manufacturer at 1.0mm thickness.~Meanwhile, bonded retainer will be done using Ormco ® response deadsoft retainer wire size 0.190 round, made in USA by ORMCO Corporation, the fixed bonded wire will be extended distal to the extraction spaces that were previously closed by fixed appliances on both the upper and lower arches. The bonded retainer will be wearing by patients for 24 hours.~Double regime retainer that will be comprised of vacuum formed and bonded retainer will be constructed using the same properties as vacuum formed retainer and bonded retainer. A standard oral and written instruction will be given to patients regarding retainer's uses. (Shawesh M et.al, 2009)."
75587588|NCT01122862|Drug|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
75587589|NCT01122862|Other|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
75587590|NCT01122862|Other|Sterile water|Sterile water
75732111|NCT02538302|Drug|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
75732112|NCT00903734|Drug|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
75587591|NCT04538274|Behavioral|peer-driven intervention|Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
75587592|NCT04578977|Behavioral|Functional assessment of surgical treatment of terrible triade injury of the elbow|Functional assessment of surgical treatment of terrible triade injury of the elbow
75587593|NCT04537767|Drug|Esmolol|The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
75587594|NCT04537767|Drug|Placebo|Placebo
75587595|NCT01122394|Behavioral|TI|Tailored intervention based on the transtheoretical model
75587596|NCT01122394|Behavioral|AP|Attention placebo
75587597|NCT01121926|Drug|Trazodone HCl|"Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
75587598|NCT01121926|Drug|Trazodone HCl|"Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
75587599|NCT04578626|Device|dry needling|The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
75587600|NCT04544826|Drug|JNJ-77474462|JNJ-77474462 will be administered as SC injection.
75587601|NCT04544826|Drug|Placebo|Matching placebo to JNJ-77474462 will be administered as SC injection.
76053380|NCT04764968|Drug|Dasiglucagon|Abdominal s.c. administration using a multi-dose reusable pen injector
76053381|NCT02192606|Device|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
75438165|NCT01595698|Other|Physical Exercise|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
75438166|NCT01595698|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
75438167|NCT01595711|Device|Pain Monitor|Measurement of cutaneous conductance
75438168|NCT01595724|Drug|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
75438169|NCT01595737|Drug|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
75438170|NCT01595737|Drug|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
75438171|NCT01595750|Drug|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
75587602|NCT02216019|Other|Whole blood|preoparatoire whole blood and postoperative whole blood
76053382|NCT02192606|Device|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
75438172|NCT01595750|Drug|Placebo|Placebo 500 mcg , 12 weeks of treatment
75587603|NCT04578587|Device|MicroFET 2|Lumbar Flexor and Extensor Strength Measurement
75587604|NCT00577421|Drug|risedronate|5 mg tablet of risedronate once a day for 2 years
75587605|NCT04537611|Diagnostic Test|dHb contrast and gadolinium contrast imaging|see arm description
75882526|NCT04854343|Diagnostic Test|Secretory leukocyte protease inhibitor (SLPI) in prostate cancer|"7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit. SLPI level will be measured at diagnosis and during the follow-up (3, 9, 15 months and in case of progression).~Immunohistochemistry protocol for SLPI immunostaining to investigate SLPI levels prostate tissue"
75882527|NCT04854343|Diagnostic Test|Determination of molecular alterations|The presence of ETS translocation (or of ETS overexpression) will be tested on bioptic samples in each patient as for routine diagnostic procedures. First, ERG overexpression will be investigated by ERG immunostaining. The samples negative for ERG immunostaining will be studied for TMPRSS2-ERG translocation either by in situ FISH or by a translocation-specific RT-PCR. Next, the biopsies negative for TMPRSS2-ERG will be tested for the overexpression of other ETS proteins (ETV1, ETV4, ETV5 and for others rarely occurring ETS). When possible, it will be determined the status of pTEN gene, the tumor suppressor most frequently lost in prostate patients. The patients negative for the overexpression of the ETS proteins will be tested for SPINK1.
75587606|NCT04537494|Dietary Supplement|L. reuteri|Probiotic
75882528|NCT04854343|Diagnostic Test|Secretory leukocyte protease inhibitor (SLPI) Healthy|"SLPI level will be measured also in the serum and in the urine from controls (patients with BPH and healthy subjects).~7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit."
75587607|NCT04545255|Device|Shockwave treatment|ED 1000 shockwave generator
75587608|NCT00577616|Procedure|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
75587609|NCT04537572|Diagnostic Test|comparison of sample collection methods|Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
75732113|NCT04603079|Behavioral|Intervention for COVID-19 preventive protocols|The intervention will comprise (A) digital communication of written material and (B) monthly online training and discussion through skype and zoom, to allow for physical demonstrations, Q&A and sharing of challenges. The five specific areas covered in the intervention for COVID-19 preventive protocols will include: (1) PPE fitting, (2) PPE removal, (3) hand hygiene, (4) cleaning, disinfection and sterilization, and (5) nurse uniform sterilization.
75732114|NCT00903812|Other|No intervention|No intervention as observational study
75438173|NCT01595763|Other|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
75438174|NCT01595776|Other|Endothelial progenitor cells intramuscular implant|After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
75587610|NCT00577694|Drug|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
75587611|NCT00577694|Drug|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
75587612|NCT04537533|Drug|Tranexamic acid|Intraoperative infusion
75587613|NCT04537533|Other|Normal saline|intravenous infusion
75587614|NCT02214927|Drug|BI 11634 tablet|
75587615|NCT02214927|Drug|BI 11634 drinking solution|
75882529|NCT05695053|Device|Low Level Laser Therapy|Low level laser therapy could provide energy to trigger cell differentiation.
75587616|NCT04544553|Other|SMS reminder|The group receives reminder for the follow-up at 1 week and 2 days prior to their scheduled appointments.
75587617|NCT04544553|Other|No SMS reminder|The group did not receives any SMS regarding scheduled appoinments.
75587618|NCT02216058|Device|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
75587619|NCT00577850|Drug|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
75587620|NCT00577850|Drug|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
75587621|NCT04544631|Other|Virtual reality game as adjunctive pain management tool|A smart phone virtual reality-based pain alleviation tool (VR-PAT).
75587622|NCT04544514|Diagnostic Test|lung ultrasound|LUS was performed within first 20 to 30 minutes and repeated at 1, 2, 4 and 6 hours.
75732115|NCT00907946|Procedure|NT 1 day before PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
75732116|NCT02569619|Behavioral|Activity Intervention|
75732117|NCT02569619|Behavioral|Healthy Diet Intervention|
75732118|NCT00909272|Procedure|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
75732119|NCT00909272|Procedure|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
75732120|NCT00509067|Drug|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
75438175|NCT01595789|Drug|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
75587623|NCT00577967|Drug|Gabapentin|
75587624|NCT04537338|Genetic|1. Characterize the immune response after infection with SARS-CoV-2|1. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens
75587625|NCT00578006|Behavioral|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
75587626|NCT00578006|Behavioral|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
75587627|NCT04537455|Diagnostic Test|Ultra-high frequency electrocardiography|Patients will have an ultra-high frequency electrocardiography performed.
75587628|NCT00578045|Procedure|Transfusion|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
75587629|NCT04544397|Procedure|Catheter Ablation for AF|Pulmonary vein isolation (PVI) is the mainstay goal of atrial fibrillation (AF) ablation procedures, especially in paroxysmal AF (PAF), and is recommended during all AF ablation procedures. PVI can be obtained with different techniques, using 3D-mapping systems guiding point-by-point radiofrequency (RF) ablation procedures or balloon-based ablation systems (cryo- or laser balloon), introduced to simplify catheter ablation for AF. In particular, the 2nd generation of visually guided laser balloon ablation system (LB2) makes use of laser energy to achieve PVI, leading to better PV occlusion and isolation compared to the 1st generation.
75587630|NCT04537221|Biological|Blood transfusion|Transfusion of red blood cells peri-operatively
75882530|NCT05695053|Other|Placebo|Placebo
75587631|NCT00578162|Behavioral|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
75587632|NCT00578201|Drug|radiochemotherapy,combination Cetuximab-FOLFOX|objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
75587633|NCT04537104|Device|Coala Heart Monitor|ECG monitoring
75732121|NCT00509067|Drug|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
75732122|NCT00509067|Drug|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
75438176|NCT01595789|Drug|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
75438177|NCT01595815|Other|Calcium ionophore|Oocytes were activated with calcium ionophore after ICSI
75438178|NCT01595815|Other|Strontium chloride (SrCl2)|Oocytes were activated with strontium chloride after ICSI
75438179|NCT01595828|Drug|Pitavastatin|
75438180|NCT01595867|Drug|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
75587634|NCT00578357|Behavioral|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
75732123|NCT00509067|Drug|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
75732124|NCT04504487|Other|Drain Removal|Abdominal drain placed during surgery removal
75732125|NCT02538146|Dietary Supplement|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
75587635|NCT04544319|Drug|Zemiglo 50mg and Forxiga 10mg|Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD
75587636|NCT04544319|Drug|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
75587637|NCT00578396|Dietary Supplement|grapes|1 pound of seedless red grapes
75732126|NCT00504309|Drug|4/day of 4g P-OM3 capsules|4/day of 4g P-OM3 capsules for 8 weeks
75587638|NCT00578396|Dietary Supplement|grapes|2/3 lb/day fresh red grapes
75587639|NCT00578396|Dietary Supplement|grapes|1/3 lb/day fresh red grapes
75587640|NCT04544085|Behavioral|noise management|The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
75587641|NCT04557410|Drug|PolyMVA|"One-half teaspoon of PolyMVA contains the following:~Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin."
75732127|NCT00504309|Drug|4/day of 1g P-OM3 capsules|4/day of 1g P-OM3 capsules for 8 weeks
75882531|NCT02119910|Behavioral|Technology Supported Manual|
75438181|NCT01595867|Drug|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
75438182|NCT01595867|Drug|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
75438183|NCT01595880|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day
75438184|NCT01595880|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
75438185|NCT01595893|Drug|Oral Vitamin D 3|40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
75438186|NCT01595893|Drug|Miglyol 812 N|Neutral oil of esters extracted from coconut and palm kernel
75587642|NCT04537182|Procedure|Lung volume reduction surgery|Lung volume reduction by surgery
75732128|NCT00504309|Drug|Corn Oil Placebo, 4 capsules/day for 8 weeks|4 capsules per day of corn oil placebo for 8 weeks
75587643|NCT04537182|Procedure|Bronchoscopic lung volume reduction with valves|Lung volume reduction with endobronchial valves.
75732129|NCT04034654|Other|Questionaire|Child behavior checklist is a questionaire, designed to evaluate 1.5-5 years old child's behavior. The checklist is filled out by parents/caregivers.
75732130|NCT00730145|Drug|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
75732131|NCT00908024|Drug|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
75587644|NCT04578470|Drug|Vitamin D|Daily 2000 IU cholecalciferol(two tablets) for 13 weeks,and daily 1000 IUcholecalciferol(1 tablet) foranother 13 weeks.
75882532|NCT05693337|Device|Forward Looking Infrared Radar (FLIR) thermal imaging|The FLIR camera will collect temperature recordings pre-procedure and 5 minutes post-procedure, which will be used to calculate a delta T to assess achievement of a successful sympathetic block.
75882533|NCT02113280|Procedure|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
75882534|NCT02113280|Procedure|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
75587645|NCT04578470|Drug|Placebo|two tablets daily for 13weeks then 1 tablet daily for13 weeks
75587646|NCT00578435|Procedure|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
75732132|NCT00908024|Drug|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
75732133|NCT00730223|Drug|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
75732134|NCT00508755|Device|Gait Robot|gait training with the use of a gait robot
76053383|NCT01628107|Biological|Epoetin Hospira|Intravenous (IV) injection
75438187|NCT01595906|Procedure|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
75438188|NCT01595919|Other|Nutritional Intervention|Ad libitum amounts of beverage at a meal
75587647|NCT04537065|Other|cycloplegic refraction|"Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)."
75587648|NCT04578821|Other|Educational intervention|Educational intervention
75587649|NCT04543929|Behavioral|exercise|partially supervised and home-based exercise activity
75732135|NCT00508755|Device|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
75732136|NCT04065815|Other|Resistance Training|"Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~2 training sessions per week"
75587650|NCT04537260|Behavioral|Educational Video|Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
75587651|NCT04557332|Behavioral|On the Dot Mobile app|On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
75732137|NCT04065815|Other|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
75732138|NCT04065815|Other|High-intensity interval training (HIIT)|"HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~supervised cycle-ergometer training at at 80-95% HRmax~time-effort per session: ~15 min~2 training sessions per week"
76053384|NCT04764734|Device|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
76053385|NCT04740151|Procedure|Best PEEP|In OLV, the investigator will perform a PEEP decremental titration trial, decreasing PEEP from 16 to 4 cmH2O (steps of 2-cmH2O, lasting 1 minute). At the end of every step driving pressure (Pplat-PEEP) will be calculated, and the PEEP corresponding to the lowest driving pressure + 2cmH2O will be set.
76053386|NCT04740151|Procedure|Standard PEEP|In OLV, a PEEP of 5 cm H2O will be set.
76053387|NCT04745377|Diagnostic Test|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
75438189|NCT01595932|Dietary Supplement|α-galactosidase|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children < 20kg: 4 drops;~children > 20kg and < 40kg: 8 drops;~children > 40kg: 1 tablet."
75438190|NCT01595932|Dietary Supplement|Placebo|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children < 20kg: 4 drops;~children > 20kg and < 40kg: 8 drops;~children > 40kg: 1 tablet."
75438191|NCT01595945|Procedure|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
75587652|NCT04544163|Drug|Magnesium sulfate- Fentanyl|drug administration before intubation
75587653|NCT04544163|Drug|Fentanyl 4Mcg/kg|drug administration with induction of anesthesia
75587654|NCT04544163|Drug|Fentanyl 2Mcg/kg|drug administration with induction of anesthesia
75438192|NCT01595945|Behavioral|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
75587655|NCT04544163|Drug|Lidocaine 1.5 mg/kg|drug administaration 90 sec before intubation
75587656|NCT04579016|Other|PAIGE2 lifestyle intervention|Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
75587657|NCT04579016|Other|Standard care|Care routinely provided to all pregnant women diagnosed with GDM
75587658|NCT04543851|Device|CARA - carbon fibre adjustable re-usable accessory for breast positioning|Breast positioning to alleviate infra-mammary fold and lateral breast sag
76053388|NCT04739683|Device|Foley bulb placement|A 16 F Foley catheter with a 30-mL balloon and stylet is inserted into the endocervical canal under direct visualization by sterile speculum exam or by digital palpation. The Foley catheter is advanced to or past the internal os, and the balloon is filled with 30-40 mL of sterile water. The catheter is then placed on genital traction by taping the end of the catheter to the medial portion of the thigh.
75438193|NCT01595958|Drug|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
75438194|NCT01595958|Procedure|cardio-pulmonary resuscitation|usual care of cardiac arrest
75438195|NCT01595971|Behavioral|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
75438196|NCT01595971|Other|usual care|Received the usual care provided
75438197|NCT01595984|Drug|cyclosporin + mycophenolate mofetil|antirejection drug, renal transplantation
75438198|NCT01595984|Drug|everolimus + mycophenolate mofetil|antirejection drug, renal transplantation
75438199|NCT01595997|Drug|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
75438200|NCT01596010|Drug|2 mg estradiol / 1 mg norethisterone acetate (NETA)|A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
75438201|NCT01596023|Device|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
75438202|NCT01596036|Behavioral|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
75438203|NCT01596036|Other|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
75438204|NCT01596049|Device|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
75438205|NCT01596075|Drug|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
75438206|NCT01596114|Other|Stopping treatment with TKI|stopping until loss of MMR
75438207|NCT01596140|Drug|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
75438208|NCT01596140|Drug|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
75438209|NCT01596140|Drug|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
75587659|NCT00578591|Drug|Rituximab|"Rituximab 375 mg/m^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).~Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver."
75587660|NCT04536987|Device|HEXORR|The subject receives robotic assistance from the HEXORR robot during finger and thumb movements. Several different video games are used to provide feedback of performance and motivate the training. The assistance level is adjusted automatically in some games and manually in other games to enable a target success rate of 67% when playing the games.
75587661|NCT04536948|Other|Cooling Gel|Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
75587662|NCT04536948|Other|Cold Pack|Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
76053389|NCT04739683|Device|DILAPAN-S® placement|A bivalve speculum will be used to visualize and prepare the cervix with an antiseptic solution. The DILAPAN-S® (4 x 65 mm) will be inserted in the cervical canal until it traverses the internal os. As many dilators as needed to achieve the desired effect should be inserted. Specific number of pieces always depends on decision and clinical judgement of physician and indications. A gauze pad moistened with sterile water or saline may be inserted into the vagina to help keep the DILAPAN-S® in place, if needed
75587663|NCT04543890|Radiation|Hyperfractionated radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
75587664|NCT04543890|Radiation|Hypofractionated radiotherapy|Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
75438210|NCT01596153|Dietary Supplement|Go Live|Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic
75587665|NCT04543890|Drug|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
75587666|NCT04543890|Drug|Cisplatin|Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
75587667|NCT04536831|Drug|Vitamin D|Vitamin D will be given to group A selected by Lottery method
75587668|NCT04536831|Drug|Normal saline|Vitamin D will be given to group B slected by Lottery method
75587669|NCT02214966|Drug|Telmisartan/Ramipril, fixed dose combination tablet|
75587670|NCT02214966|Other|high fat, high caloric meal|
75438211|NCT01596166|Drug|Ketorolac Tromethamine|Ketorolac 0.5 mg/kg (max 30 mg) IV
75587671|NCT00578630|Other|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
75587672|NCT04536558|Drug|olanzapine plus fosaprepitant-based triple regimen|olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
75587673|NCT04536558|Drug|placebo plus fosaprepitant-based triple regimen|placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
75587674|NCT00578708|Device|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
75587675|NCT04543656|Behavioral|AI-Based Lifestyle Recommendations|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
75438212|NCT01596166|Drug|Metoclopramide|Metoclopramide 0.2 mg/kg (max 10 mg) IV
75438213|NCT01596179|Behavioral|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
75438214|NCT01596179|Behavioral|Internet access|a netbook computer with internet access is provided to participants on the control arm.
75587676|NCT04543656|Other|No Lifestyle Recommendations|The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
76053390|NCT01583530|Biological|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
75438215|NCT01596192|Other|PETCT|"CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec."
75587677|NCT04557605|Other|Progressive cycling exercise test to exhaustion|Progressive step cycling exercise test to exhaustion
75587678|NCT04536753|Procedure|Induction of labour|Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.
75587679|NCT04557137|Drug|Somatostatin analog|120 mg ipstyl every 28 days
75587680|NCT04536675|Drug|Vilanterol and Umeclidinium Bromide|Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
75587681|NCT04536675|Drug|Placebo|Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
75587682|NCT04556942|Diagnostic Test|Flow Mediated Dilation (FMD) measurement|FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or > 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
76053391|NCT01583530|Biological|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
76053392|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
75587683|NCT04556942|Other|Blood pressure, pulse and blood oxygen saturation measurement|"Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient."
75587684|NCT04556942|Other|ST George Respiratory Questionnaire|The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
75587685|NCT04556942|Other|Physical activity level (PAL) measurement|PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
75438216|NCT01596205|Behavioral|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
75587686|NCT04556942|Biological|Withdrawal of a blood sample|5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
75732139|NCT04065815|Other|Combined HIIT and Resistance Training (Combi)|"HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~supervised cycle-ergometer training at at 80-95% HRmax~time-effort per session: ~15 min~1 training session per week~Resistance Training:~five exercises: exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~1 training session per week"
75732140|NCT00908102|Other|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
75732141|NCT00908102|Other|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
76053393|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
75438217|NCT01596205|Behavioral|Conventional cognitive training group|"Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil."
75438218|NCT01596218|Drug|Brentuximab Vedotin|Starting dose is 0.6 mg/kg weekly x 3
75438219|NCT01596244|Behavioral|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
75587687|NCT04556942|Procedure|Immediate Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
75587688|NCT04556942|Procedure|Delayed Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
75587689|NCT04536441|Behavioral|Ultra Brief Online Mindfulness-based Intervention|We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley & Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.
75587690|NCT04536441|Behavioral|Control|The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
75587691|NCT04557293|Device|Continuous Positive Airway Pressure (CPAP) treatment|Treatment of Obstructive sleep apnoea syndrome with CPAP
75587692|NCT04536597|Other|Quince seed jelly group|Quince seed jelly, prepared by the researcher, was given to the mothers belonging to this group. Briefly, 3 g (2-3 pieces) of quince seeds are placed in 100 mL water and heated to boiling for 10 min. The prepared quince kernel was used for 3 days, immediately after cooling.14,15 On the 1st day postpartum, the researcher provided the mothers with practical training at the hospital, regarding the application of quince seed jelly to the nipple and areola and leaving it to dry. This training was repeated on the 3rd, 7th and 10th days, to ensure that the mothers followed it precisely. The training process was completed in 5-10 min, including questions and answers. Every 3-4 days (days 1, 3, 7 and 10), quince seed jelly prepared by the researcher was given to the mothers to continue applying, according to the procedure. The mothers were asked to apply it after every breastfeeding.
75587693|NCT04536597|Other|Breast milk group|Mothers in this group received practical training, conducted by the researcher on the 1st day postpartum at the hospital, on applying a few drops of their breast milk to the nipples and areola after each breastfeeding and leaving it to dry. This training lasted 5-10 min. Breast milk application of mothers in this group was recorded on the 1st, 3rd, 7th and 10th days, by the researcher.
75587694|NCT04536597|Other|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
75587695|NCT04556903|Combination Product|Bilateral Arm Training|First component of mCIMT will comprise one hour activity and a rest period of five minute given between each ten minutes of task practice. These activities will base on activities of daily living (ADL'S) and I
75587696|NCT04556903|Combination Product|modified constrained induce movement therapy|"BAT involves in four sessions, each session involve repetitive practice of bilateral tasks for one hour and a rest period of 5 minutes. The tasks are:~Block placement- 10minutes~Peg targeting- 10 minutes~Peg inversion-10miutes~Transferring objects- 10minutes"
75587697|NCT04536636|Drug|Docohexanoic acid|Patients received 650 mg DHA/3 times/wk/post-HD session
75587698|NCT04536636|Drug|Control-No drug|Patients received usual medical care with no DHA
76053394|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
76053395|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
76053396|NCT01639001|Drug|Crizotinib|250 mg two times daily [BID], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
76053397|NCT01639001|Drug|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
75438220|NCT01596270|Drug|SAR245409|Pharmaceutical form: tablet Route of administration: oral
75438221|NCT01596296|Device|Transcervical foley catheter|16 French foley catheter insertion
75438222|NCT01596296|Drug|Dinoprostone 10mg|Dinoprostone vaginal insertion
75438223|NCT01596309|Dietary Supplement|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
76053398|NCT01639001|Drug|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
76053399|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 5mg QD
76053400|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD
75587699|NCT04556747|Other|VR - Distraction|Participants will be instructed to use any application.
75587700|NCT04556747|Other|VR - Biofeedback|Participants will be instructed to use the Mindful Aurora application.
76053401|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
76053402|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 25 mg QD
76053403|NCT04443959|Behavioral|PUMAS|Treatment consists of 6 weekly telemedicine sessions during pregnancy.
76053404|NCT05263193|Drug|Caplacizumab|as in real world practice
76053405|NCT02167256|Drug|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
75587701|NCT02278653|Other|Questionnaires for the evaluation of Quality of Life|"European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score~Short Form (36) health survey~EORTC CR38~Vaizey score~Low Anterior Resection Syndrome (LARS) score~International Index of Erectile Function for men~International Prostate Symptom Score for men~Female Sexual Function Index for women"
75587702|NCT02278653|Other|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
75732142|NCT00908102|Other|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
75732143|NCT00908102|Other|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
75732144|NCT00730301|Procedure|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
75732145|NCT00908180|Biological|alemtuzumab|
75732146|NCT00908180|Biological|donor lymphocytes|
75882535|NCT05522127|Other|Colonoscopy|Colonoscopy
75882536|NCT05522127|Other|Sedoanalgesia|Ketamine, fentanil, midazolam, propofol
75587703|NCT00578825|Drug|Lopinavir / Ritonavir plus Ribavirin|
75732147|NCT00908180|Drug|carmustine|
75438224|NCT01596387|Drug|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
75438225|NCT01596400|Drug|granisetron transdermal system|patch
75438226|NCT01596400|Drug|Granisetron IV|IV
75438227|NCT01596413|Drug|Sancuso|granisetron transdermal system
75438228|NCT01596413|Drug|IV granisetron|IV
75732148|NCT00908180|Drug|cyclosporine|
75732149|NCT00908180|Drug|cytarabine|
75438229|NCT01596426|Drug|Sancuso|granisetron transdermal system
75438230|NCT01596426|Drug|IV granisetron|IV granisetron
75438231|NCT01596465|Other|Self-Study using MP3 Player|"Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training."
75587704|NCT04536129|Drug|Hydrocortisone (CORTIVIS ®)|Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
75587705|NCT00578981|Behavioral|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
75732150|NCT00908180|Drug|etoposide|
75732151|NCT00908180|Drug|melphalan|
75732152|NCT00908180|Procedure|allogeneic hematopoietic stem cell transplantation|
75732153|NCT02538068|Behavioral|Daily Surveys|Participants complete 28 daily surveys of daily meaning, mood, and physical activities.
75732154|NCT02538068|Behavioral|Random Surveys (8)|Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
75732155|NCT00904124|Dietary Supplement|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
75732156|NCT00504231|Biological|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
75732157|NCT00909506|Drug|Placebo|"Control: Receive placebo pill once every evening on 1~2 weeks.~Receive placebo pill in every morning and evening on 3~24 weeks (twice a day)."
75732158|NCT00909506|Drug|Metformin|"Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3~24 weeks."
75882537|NCT02113358|Drug|Intravenous colloid bolus with Voluven|
75882538|NCT04854187|Device|N95 Mask/Indoor air purifier: Including sham|Participants will be using indoor air purifier and N95 mask (control arm with sham filters). The effect will be studied on blood pressure and blood glucose levels.
75882539|NCT03769142|Procedure|All monitoring|All monitoring (TCD, BIS, NIRS) are collected from the healthy side, contralateral to the interventional side
75882540|NCT02114840|Procedure|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
75882541|NCT02114840|Procedure|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
75882542|NCT02114840|Procedure|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
75882543|NCT04878055|Drug|Reparixin|2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
75587706|NCT04556786|Behavioral|Transitions of care|The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
75587707|NCT04556825|Drug|PRP|After the arthroscopic operation was completed, a local PRP injection was performed
75438232|NCT01596465|Other|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
75438233|NCT01596478|Behavioral|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
75587708|NCT04556825|Drug|normal saline|After the arthroscopic operation was completed, a local normal saline injection was performed
75587709|NCT04536246|Procedure|Bone Quadriceps Tendon (BQT) arthroscopic-assisted ACL reconstruction|New intervention method deployed in Indonesia to gain better clinical outcome for ACL--deficient patients requiring surgical treatment
75732159|NCT00909506|Drug|Metformin|"Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3~24 weeks (metformin 500 mg * twice a day = 1000 mg per day)."
75732160|NCT03997539|Drug|Pyrotinib|Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
75587710|NCT04536246|Procedure|Single-Bundle Hamstring Tendon (SBHT) arthroscopic-assisted ACL reconstruction|Comparator for New Reconstruction Technique
75587711|NCT04556708|Other|salin irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
76053406|NCT02167256|Drug|AZD0530 125mg daily|Patients with plasma drug level <100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
75438234|NCT01596478|Behavioral|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
75438235|NCT01596478|Behavioral|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
75438236|NCT01596491|Procedure|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
75438237|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight <75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
75438238|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
75438239|NCT01596530|Drug|Drug-AZD8931|Active drug for biological activity
75438240|NCT01596530|Drug|Drug-Placebo|Placebo comparator for biological activity comparison
75438241|NCT01596543|Other|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
75438242|NCT01596556|Drug|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
75438243|NCT01596556|Other|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
75438244|NCT01596569|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.
75732161|NCT03997539|Drug|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone [LHRH] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
75732162|NCT03997539|Drug|vinorelbine|vinorelbine
75732163|NCT04422899|Drug|AIV007|intravitreal
75882544|NCT04878055|Other|Placebo|Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).
76053407|NCT02167256|Drug|Placebo|50% of patients will receive placebo treatment for the duration of the study.
76053408|NCT02191046|Device|squeezable bottle|nasal irrigation twice daily for 2 weeks period
76053409|NCT02191046|Device|syringe 20 ml|nasal irrigation twice daily for 2 weeks
75438245|NCT01596569|Behavioral|Cognitive Intervention|"Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.~All participants receive weekly cognitive treatment sessions for 10 weeks."
75438246|NCT01596608|Device|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
75587712|NCT04556708|Other|ozonated water irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
75587713|NCT04556708|Other|chlorhexidine irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
75587714|NCT04535973|Diagnostic Test|unstimulated saliva sample for hormone analysis|hormone levels will be determined in frozen samples of unstimulated saliva
75587715|NCT04535973|Other|quality of life questionnaire|all participants will fill out self-perceived quality of life questionnaire
75587716|NCT04536090|Drug|Isoquercetin (IQC-950AN)|Isoquercetin will be administered by mouth twice daily for 28 days
75587717|NCT04536051|Biological|ChAdOx1 nCoV-19 single dose + paracetamol|Single dose of ChAdOx1nCOV19 vaccine, 5x10^10 vp + paracetamol
75438247|NCT01596634|Other|questionnaire administration|Ancillary studies
75438248|NCT01596634|Procedure|quality-of-life assessment|Ancillary studies
75882545|NCT05305365|Drug|QBS72S|QBS72S 12mg/m2 injection given intravenous once a month.
75438249|NCT01596634|Other|laboratory biomarker analysis|Correlative studies
75438250|NCT01596634|Dietary Supplement|bovine lactoferrin|Given PO
75438251|NCT01596647|Drug|caffeine|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
75587718|NCT04536051|Biological|MenACWY single dose + paracetamol|Single dose of MenACWY + paracetamol
75587719|NCT04536051|Biological|ChAdOx1 nCoV-19 two dose + paracetamol|Two dose of ChAdOx1 nCoV-19 vaccine, 5x10^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10^10 vp), 4-12 weeks apart + paracetamol
75587720|NCT04536051|Biological|MenACWY prime & saline placebo boost + paracetamol|MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
75587721|NCT04543422|Dietary Supplement|Green tea|Green tea extract capsules
75587722|NCT04543422|Other|Placebo|Placebo containing inert material.
75587723|NCT00579215|Behavioral|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
75882546|NCT01376713|Biological|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
75587724|NCT00579215|Behavioral|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
75587725|NCT04536324|Procedure|Subcutaneous parenteral hydration|Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.
75587726|NCT04556669|Biological|Autologous aPD-L1 armored anti-CD22 CAR T cells|Autologous aPD-L1 armored CD22-targeting CAR T cells
75438252|NCT01596647|Drug|diclofenac|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
75587727|NCT02215005|Drug|Telmisartan|
75587728|NCT02215005|Drug|Ramipril|
75587729|NCT04536714|Behavioral|Pythagorean Self-Awareness Intervention program|Stress management program of Pythagorean Self-Awareness Intervention (PSAI), which included eight sessions and lasted for eight weeks. On the first week, a personal session took place for measurements and training in the relaxation technique of diaphragmatic breathing. In the second week, patients attended a group session, in which they were adviced to follow specific directions for a healthy lifestyle, such as organized physical activity, adherence to the Mediterranean diet, creating a daily routine. In the third week, participants were introduced to the cognitive restructuring technique of (PSAI).In the following four group sessions, patients were trained on PSAI and the second relaxation technique, progressive muscular relaxation. In the last week, the final measurements were made. All sessions lasted for 120 minutes, except for the final one, which lasted for 60 minutes.
75587730|NCT02215044|Drug|BI 2536, intravenous|
75587731|NCT02215044|Drug|Gemcitabine, intravenous|
75587732|NCT04556318|Device|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
75438253|NCT01596647|Drug|omeprazole|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
75438254|NCT01596647|Drug|midazolam|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
75438255|NCT01596647|Drug|TKI258|dovitinib, 5 days on / 2 days off dose schedule
75438256|NCT01596660|Drug|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
75438257|NCT01596660|Drug|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
75587733|NCT02215083|Dietary Supplement|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
75587734|NCT04556279|Procedure|adrenalectomy|Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.
75587735|NCT04556279|Drug|Aldosterone Antagonist|Medical treatment of primary hyperaldosteronism.
75587736|NCT04535856|Drug|allogeneic mesenchymal stem cell|"Assignment of Administration Group allogeneic mesenchymal stem cell:~Low-dose group (5 x 10^7cells)~High-dose group (1 x 10^8 cells)"
75587737|NCT04535856|Other|Placebo|Control group (placebo)
75587738|NCT00579332|Dietary Supplement|brassica intervention|diet and phyto-chemical intervention
75882547|NCT01376713|Biological|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
75882548|NCT05286567|Drug|RGRN-305|Heat shock protein 90 inhibitor
75882549|NCT05286567|Drug|Placebo|Placebo (blinded)
76053410|NCT04838795|Biological|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa
75882550|NCT03728179|Combination Product|Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib|"Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a number of metastatic deposits visible by PET/CT, at the PI's discretion.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~Celecoxib: 200mg will be administered orally twice a day from cycle C1 to C4.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; celecoxib will be maintained if the drug is well tolerated"
76053411|NCT04851899|Dietary Supplement|Phaeosol low dose|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
76053412|NCT04851899|Dietary Supplement|Phaeosol high dose|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
76053413|NCT04851899|Dietary Supplement|Placebo|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
76053414|NCT04838171|Other|White blood cell and blood collection|Mononucleocytes will be collected via apheresis
76053415|NCT02166476|Drug|Meropenem-Vaborbactam|Meropenem-vaborbactam
76053416|NCT02166476|Drug|Piperacillin-Tazobactam|Piperacillin-tazobactam
76053417|NCT02166476|Drug|Levofloxacin|Levofloxacin
75732164|NCT04034108|Procedure|Surgical intervention combined with weight-supported ambulation training|"Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months."
75732165|NCT00728117|Other|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
75438258|NCT01596673|Drug|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|"Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet."
75438259|NCT01596673|Drug|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
75438260|NCT01596686|Drug|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
75438261|NCT01596712|Drug|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
75438262|NCT01596712|Drug|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
76053418|NCT02166476|Drug|Saline|Saline
76053419|NCT05318261|Procedure|Spontaneous breathing trial|A spontaneous breathing trial (SBT) is used to identify patients who are likely to fail liberation from mechanical ventilation. The test can be done according to the usual modalities of the participating centre, following the international recommendations, meaning either by disconnecting the endotracheal tube from the ventilator and connecting it to a source of oxygen through the T-tube or by setting pressure support with low positive end-expiratory pressure (PEEP). The choice of the method will not be determined according to the participation in this study but will be done according to the habits of the participating centre.
76053420|NCT05237609|Dietary Supplement|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
75587739|NCT04535622|Behavioral|A structured exercise|Exercise training will be conducted by a physical therapist which will take about 10 to 15 minutes. Patient education will include how to keep face down in various postures, and how to actively exercise the related muscles and joints while maintaining face-down posture through video clip and brochure. Patients will go through three times of self-exercise sessions everyday according to the training provided to the patients. Active exercise for the FDP patients will include exercise in a hands and knees position, limb exercise in an FDP, and exercise in a standing position. The exercises were performed within the range of individual muscle strength and fitness.
75587740|NCT02216253|Drug|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
75587741|NCT02216253|Other|Placebo|Placebo tablet twice a day 7 days before and after surgery
75587742|NCT02216292|Other|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
75587743|NCT02216292|Other|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
75587744|NCT02216331|Drug|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
75587745|NCT02216331|Drug|rifapentine|
75587746|NCT02216331|Drug|rifampicin|
75587747|NCT02212418|Other|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
75587748|NCT04535817|Drug|Omalizumab Injection [Xolair]|300mg via 2 subcutaneous injections every 4 weeks
75882551|NCT02114918|Behavioral|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
75587749|NCT04577924|Other|Interview|"Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital."
75587750|NCT04543149|Diagnostic Test|Flow cytometric immunophenotyping|To evaluate T cell subsets and monocyte
75587751|NCT04555889|Device|lung recruitment maneuver (LRM) with DrageerVN500|interventions involving device that may help to gradually lung development
75587752|NCT04543266|Procedure|Surgery|Resection of tumors
75732166|NCT00728117|Other|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
76053421|NCT05237609|Other|rehabilitation with muscle strengthening|Physical activity with only muscle strengthening
75438263|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
75438264|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
75438265|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
75438266|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
75438267|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
75438268|NCT01596725|Biological|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
75438269|NCT01596738|Drug|Tranexamic Acid|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
75438270|NCT01596738|Drug|Saline|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
75438271|NCT01596764|Drug|Loperamide placebo|200 ml apple juice
75587753|NCT02215239|Behavioral|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
75587754|NCT04578236|Combination Product|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
75587755|NCT04578236|Drug|Drug: Standard treatment Standard treatment|Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
75587756|NCT04555772|Other|factors evaluation|They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
75587757|NCT02215278|Dietary Supplement|10 x 55 g/ bean per arm|
75587758|NCT04578119|Procedure|Sliding Intubating Technique|Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
75587759|NCT04542954|Other|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East
75587760|NCT04542876|Drug|Guduchi Ghan Vati|Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
75882552|NCT02114918|Behavioral|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
75882553|NCT03626961|Other|readmission|Readmission after 48 hours
75438272|NCT01596764|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
75438273|NCT01596764|Device|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
75587761|NCT00579449|Behavioral|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
75587762|NCT00579449|Behavioral|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
75882554|NCT03626961|Other|discharge|Discharge
76053422|NCT02224274|Drug|Clopidogrel|
76053423|NCT02224274|Drug|Ticagrelor|
75438274|NCT01596764|Drug|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
75438275|NCT01596764|Drug|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
75438276|NCT01596764|Drug|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
75438277|NCT01596764|Drug|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
75438278|NCT01596777|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
75438279|NCT01596777|Drug|Loperamide placebo|200 ml apple juice
75438280|NCT01596777|Drug|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
75438281|NCT01596777|Drug|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
75438282|NCT01596777|Drug|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
75438283|NCT01596777|Drug|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
75587763|NCT04542915|Other|No intervention|No intervention.
75587764|NCT04542759|Drug|Besifloxacin Ophthalmic|Prophylaxis for endophthalmitis
75587765|NCT04542759|Drug|Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution|Placebo
75732167|NCT00909584|Drug|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
75732168|NCT00927134|Genetic|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
75732169|NCT02570243|Drug|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
75732170|NCT02570243|Drug|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
75732171|NCT00927212|Drug|AS101 ointment|Twice daily topical application
76053424|NCT04764110|Dietary Supplement|Cyplexinol|partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)
76053425|NCT04764110|Other|Placebo|Maltodextrin
75587766|NCT04556006|Other|Patient education|"The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, FR score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated."
75587767|NCT04542798|Device|Radiofrequency COSMAN|Radiofrequency ablation and neuromodulation
75587768|NCT04555850|Drug|Recombinant Human Thymosin β4|Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
76053426|NCT05219669|Drug|Nalmefene Hydrochloride|3mg nasal spray
75732172|NCT00730379|Drug|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
75732173|NCT00730457|Biological|VAX125|Single intramuscular dose
76053427|NCT04763798|Other|Straight-leg-raise (SLR)|The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the SLR, the knee was kept in full extension and then, hip flexion was performed until a marked resistance. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.The stretch lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes
75438284|NCT01596777|Device|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
75438285|NCT01596777|Drug|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
75438286|NCT01596790|Other|Blood analysis by EPISPOT and Cellsearch|For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
75438287|NCT01596803|Procedure|Taking of blood|Taking venous blood samples to analyse oxidant stress
75732174|NCT00927290|Drug|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
75732175|NCT00927290|Drug|Placebo|Placebo 45 mg QD (30 mg QD the first month)
75732176|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
75732177|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
75732178|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
75732179|NCT00728195|Drug|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
75438288|NCT01596803|Dietary Supplement|needle biopsy of the vastus lateralis muscle|T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
75587769|NCT04555850|Other|Placebo|3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
75732180|NCT00728195|Drug|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
75732181|NCT00927446|Procedure|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
75587770|NCT04542447|Drug|Nuvastatic|Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
75732182|NCT00927524|Drug|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
75732183|NCT00927524|Drug|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
75732184|NCT00728273|Dietary Supplement|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
75438289|NCT01596803|Dietary Supplement|Vit C Vit E Zn Se|T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
75438290|NCT01596803|Dietary Supplement|Placebo Vit E Placebo Vit C Zn Se|venous blood samples and needle biopsy
75438291|NCT01596816|Radiation|First part of treatment : Conformal irradiation|23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
75438292|NCT01596816|Procedure|Fiducials placement|Placement of intra-prostatic markers for the tracking
75438293|NCT01596816|Radiation|Second part : hypofractionated stereotactic boost|3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
75732185|NCT00927602|Drug|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
75732186|NCT04286867|Other|Alcohol Moderation Mobile Application|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. Individuals in this group will define their drinking limits within the application. The application will provide time points to aid the individual in maintaining their predefined drinking limits throughout the course of the drinking occasion. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
75438294|NCT01596829|Dietary Supplement|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
75438295|NCT01596829|Dietary Supplement|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
75438296|NCT01596855|Drug|FG-4592|TIW dosing, capsule
75587771|NCT04542213|Drug|Linagliptin tablet|Linagliptin 5mg once daily plus a basal-bolus insulin scheme
75438297|NCT01596855|Drug|Epoetin Alfa|TIW
75438298|NCT01596868|Drug|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
75587772|NCT04542213|Drug|Insulin|Basal-bolus insulin scheme
75587773|NCT02278406|Other|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
75587774|NCT04542252|Drug|SyB V-1901|SyB V-1901 10 mg via IV infusion for 2 hours
75587775|NCT04542252|Drug|Cyclosporine|200 mg Capsule
75587776|NCT04532775|Drug|magnesium|Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
75587777|NCT04532775|Drug|Methylprednisolone|Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).
75587778|NCT04532775|Drug|Bupivacaine Hydrochloride|local anesthetic drug
75587779|NCT04532775|Drug|saline 0.9%|solution for intravenous and epidural injection
75587780|NCT04532580|Device|Diagnosis of fracture on X-Ray Radiographs|Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
75587781|NCT04578158|Drug|Standard COVID-19 care|Patients will receive standard covid-19 care as per the hospital/physician guidelines
75587782|NCT04578158|Dietary Supplement|Quercetin Phytosome|Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome
75587783|NCT04532736|Drug|Emthexate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
75587784|NCT04532736|Drug|Prednol|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
75438299|NCT01596868|Drug|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
75438300|NCT01596894|Drug|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
75438301|NCT01596894|Drug|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
75438302|NCT01596907|Drug|Ephedrine sulfate with caffeine|Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
75732187|NCT04286867|Behavioral|Alcohol Moderation Drink Tracker|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). Individuals in this group will define their drinking limits, and record their alcohol consumption on the drink tracking card. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
75438303|NCT01596907|Drug|cellulose|sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
75732188|NCT00909662|Procedure|assessment of therapy complications|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~Borg 15-Category Scale"
75732189|NCT00909662|Procedure|cognitive assessment|Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
75732190|NCT00909662|Procedure|fatigue assessment and management|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~Borg 15-Category Scale"
75438304|NCT01596920|Other|Tissue|Allograft Tissue Cellular Repair Matrix
75438305|NCT01596920|Other|Control|Non-adherent Dressing
75438306|NCT01596933|Dietary Supplement|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
75438307|NCT01596933|Dietary Supplement|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
75438308|NCT01596946|Behavioral|Contact tracing mode test at clinic|
75438309|NCT01596946|Behavioral|Self-sampling at home - Sent Test Kit|
75438310|NCT01596959|Procedure|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
75587785|NCT04532736|Drug|Mometasone Furoate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
75587786|NCT00579683|Other|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
75438311|NCT01596959|Procedure|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
75587787|NCT04555733|Drug|Lemborexant|Lemborexant oral tablets.
75587788|NCT02216994|Drug|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
75587789|NCT02216994|Behavioral|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
75587790|NCT02216994|Drug|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
76053428|NCT04763798|Other|Passive Knee extension test (PKE)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the PKE, the hip was kept in 90º flexion and then, knee extension was performed. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
75587791|NCT04555928|Other|No intervention|This is a prospective cohort (survey) study. It has no intervention.
75587792|NCT02217033|Other|'R' (Electro-kinetically altered beverage)|
75732191|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 1 months
75732192|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 3 months
75732193|NCT00730535|Drug|Tolterodine 6|Extended release tolterodine tartrate 4 mg, once daily, for 6 months
76053429|NCT04763798|Other|Maximum hip flexion (MHF)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For MHF, a maximal hip flexion was performed and then, knee extension was applied. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
75438312|NCT01596985|Procedure|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
75587793|NCT02217033|Other|Placebo (water)|
75587794|NCT04555538|Diagnostic Test|Cardiac MRI|These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.
75732194|NCT00909818|Radiation|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
75732195|NCT00909818|Radiation|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
75882555|NCT05108493|Other|Dry needling|Three sessions dry needling of lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).
75587795|NCT02217072|Behavioral|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
75587796|NCT02217072|Behavioral|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
75732196|NCT03743558|Behavioral|smartphone homemade video|value of a video recording of the child sleep on smartphone made by the parents
75732197|NCT00728429|Behavioral|exercise intervention|24 week program of exercise
75732198|NCT04066595|Drug|Cabozantinib|60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
75732199|NCT00927836|Biological|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
75732200|NCT00927836|Drug|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
75587797|NCT02217111|Behavioral|Adventures in Voice: Pediatric Voice Therapy|
75587798|NCT04532697|Other|Uncaria Rhynchophylla (Gou-Teng)|Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
75587799|NCT04532697|Other|Placebo|All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
75587800|NCT02212613|Drug|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
75587801|NCT04532385|Dietary Supplement|Green tea extract|400 mg capsule
75587802|NCT04532385|Dietary Supplement|Placebo|400 mg capsule
75587803|NCT04555460|Procedure|Hemicraniectomy|Large hemicraniectomy and duraplasty
75587804|NCT04555460|Other|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke
75587805|NCT00579800|Procedure|new software sequences, FIESTA and Vibrant-DE and IDEAL|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
75587806|NCT04532268|Drug|Humanized CD19 CAR-T cells|Each subject receive humanized CD19 CAR T-cells by intravenous infusion
75438313|NCT01596985|Procedure|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
75587807|NCT00579839|Procedure|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
75587808|NCT00579839|Procedure|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
75587809|NCT04532112|Device|Biocontainment Device For Aerosol Generating Procedures (Biobox)|The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
75587810|NCT04532112|Device|Control for aerosol generating procedures|There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
75587811|NCT04555499|Other|Standardized neurological examination|
75587812|NCT04532073|Other|Eurythmy Therapy|A mindfulness-oriented movement therapy
75587813|NCT04532073|Other|Tai Chi|A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
75587814|NCT04532073|Other|Standard Care|Treatment process that a clinician should follow for a certain type of patient
75587815|NCT00579917|Behavioral|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
75587816|NCT00579917|Behavioral|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
75587817|NCT02217189|Dietary Supplement|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
75587818|NCT00579956|Drug|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
75587819|NCT00579956|Drug|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
75587820|NCT04555304|Drug|KH903 + Paclitaxel|KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
75587821|NCT04555304|Drug|Placebo + Paclitaxel|Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
75587822|NCT04531800|Procedure|Concentrated growth factor|In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.
75587823|NCT04531800|Procedure|Non-concentrated growth factor|In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
75587824|NCT00579995|Drug|Oral N-Acetylcysteine|600 milligrams (mg)
75882556|NCT05108493|Other|Home exercise program|All participants will start the home exercise program during the study period consisting of range of motion exercises for wrist flexion, extension, ulnar and radial deviation, elbow flexion and extensor; forearm supinator, and pronator muscles; stretching exercises. Eccentric strengthening of the wrist flexor extensors, ulnar and radial deviation, forearm pronation, supination, and strengthening exercise training will be given to the elbow extensors and flexors. Progressive strengthening exercises will be added to the program. The exercise program will be terminated with stretching exercises. The exercises will be performed for 10 repetitions 2 times a day, stay in each position for 10 seconds, and rest for 30 seconds between periods. Both groups will be advised to continue the exercise program for 12 weeks.
75587825|NCT00579995|Drug|Sodium Bicarbonate|3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
75587826|NCT04531683|Other|electroacupuncture|same as described in experimental arm.
75587827|NCT04531683|Other|sham electroacupuncture|same as described in sham comparator.
75882557|NCT03725293|Device|Angiodynamics BioFlo Midline Catheter|Placement of Angiodynamics BioFlo Midline Catheter.
75882558|NCT03725293|Device|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
75438314|NCT01596998|Drug|Levobupivacaine with epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
75587828|NCT04531683|Behavioral|life style counselling|life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
75587829|NCT04555421|Device|Lumen|Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
75587830|NCT04531371|Drug|Dexmedetomidine injection|post surgical agitation prophylaxis
75587831|NCT04531605|Behavioral|YBank program|Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
75587832|NCT04555382|Diagnostic Test|Blood and Urine|Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
75587833|NCT00580112|Drug|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
75587834|NCT00580112|Drug|Trabectedin|Trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
75587835|NCT04531332|Drug|Continuous infusion Linezolid|Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )
75587836|NCT04531332|Drug|intermittent dosing linezolid|Linezolid 600 mg intravenous twice daily
75882559|NCT01368536|Drug|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
75882560|NCT01368536|Drug|Amlodipine|Amlodipine 5 mg and 10 mg capsule
75882561|NCT01368536|Drug|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
75882562|NCT01368536|Drug|Placebo of Valturna Tablet|Matching placebo of valturna tablet
75882563|NCT01368536|Drug|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
75882564|NCT05103735|Drug|Propofol|awake neurosurgery under propofol-remifentanil sedation
75882565|NCT03051165|Device|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
75882566|NCT01319929|Drug|LY2828360|Administered orally
75587837|NCT04555148|Biological|GC5131|COVID19 Hyper-Immunoglobulin
75587838|NCT04555148|Other|Placebo|Placebo
75587839|NCT04530864|Drug|Dextenza 0.4Mg Ophthalmic Insert|All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
75587840|NCT04554875|Diagnostic Test|A scoring system|The scoring system was used to rate score patients.
75732201|NCT02570321|Procedure|Bacterial ulcer cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
75732202|NCT02570321|Procedure|Bacterial ulcer control|For those bacterial ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for bacterial ulcers. This group will have their eyes irrigated with a balanced salt solution.
75732203|NCT02570321|Procedure|Fungal ulcer cross-linking|"Prior to receiving cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.~For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis."
75732204|NCT02570321|Procedure|Fungal ulcer control|"Prior to receiving sham cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.~For those fungal ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for fungal ulcers. This group will have their eyes irrigated with a balanced salt solution."
75732205|NCT00904280|Drug|Oxymorphone ER|Open label
75732206|NCT04015310|Device|Quantitative Multi parametric MRI and enhanced MRCP|Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
75438315|NCT01596998|Drug|Levobupivacaine without epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
75438316|NCT01596998|Other|Monitoring|Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
75438317|NCT01596998|Other|Determining the extent of the block|The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
75438318|NCT01597011|Procedure|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
75438319|NCT01597011|Procedure|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
75882567|NCT01319929|Drug|Placebo|Administered orally
75587841|NCT04531488|Procedure|Powered Mobility Training Simulator|Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.
75587842|NCT04531488|Other|Training with Powered Wheel Chair|Training with Powered Wheel Chair
75587843|NCT00580190|Drug|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
75587844|NCT00580190|Other|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
75587845|NCT00580190|Drug|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
75587846|NCT04531137|Dietary Supplement|CLA-fortified milk powder|3.4 gram of CLA-fortified milk powder one a day for 12 weeks
75587847|NCT04531137|Other|Placebo|Placebo milk powder one a day for 12 weeks
75587848|NCT04531137|Other|Nutrition Counseling|Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
75732207|NCT00924092|Biological|GI-6207 [Recombinant Saccharomyces Cerevisia|
75732208|NCT00924092|Drug|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
75882568|NCT03553316|Drug|PK101-002|-(Single) PK101-002
75882569|NCT03553316|Combination Product|PK101|-(Combination) PK101-001, PK101-002
75587849|NCT04530903|Drug|Clonidine|75 µg (0.5mL) per injection site
75587850|NCT04530903|Drug|Levobupivacaine|0.25% (10 ml) per injection site
75587851|NCT04530903|Drug|NaCl 0.9%|Nacl 0.9% (0.5ml) per injection site
75587852|NCT00580307|Procedure|Septoplasty|Surgical straightening of nasal septum
75587853|NCT00580307|Procedure|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
75438320|NCT01597024|Other|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
75732209|NCT00904358|Diagnostic Test|cross sectional area|
75732210|NCT00730613|Biological|therapeutic autologous lymphocytes|Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
75438321|NCT01597024|Other|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
75438322|NCT01597037|Behavioral|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
75438323|NCT01597063|Device|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
75438324|NCT01597076|Dietary Supplement|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas & Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
75438325|NCT01597102|Other|No interventions|No intervention is planned in this study
75438326|NCT01597115|Procedure|Duplex ultrasonography|
75438327|NCT01597154|Behavioral|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
75438328|NCT01597167|Dietary Supplement|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
75438329|NCT01597206|Device|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
75587854|NCT04530474|Drug|Ivermectin Pill|Ivermecin as a one-time dose
75587855|NCT04530474|Drug|Placebo|Inactive medication as a one time dose
75587856|NCT04554641|Other|Fasted breath samples|Participants will provide fasted breath samples pre and post Bio-Kult Advanced.
75587857|NCT04554641|Other|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis.
75587858|NCT04554641|Other|Stool sample|Participants will provide stool sample pre and post Bio-kult Advanced.
75587859|NCT04530669|Device|High Tone Power Therapy|"High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort."
75587860|NCT04530669|Other|exercise program|physical therapy conventional selected exercise program inform of functional activities of daily living
75732211|NCT00730613|Genetic|gene expression analysis|At the time of excess pathology samples documenting response/relapse
75732212|NCT00730613|Other|laboratory biomarker analysis|CSF generated at the time of each T-cell dose
75732213|NCT00928148|Drug|SPD465|50 or 75 mg once daily for 7 days
75732214|NCT00928148|Drug|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
75732215|NCT00928148|Drug|Placebo|Once daily for 7 days
75732216|NCT02430077|Drug|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
75732217|NCT02430077|Drug|Placebo|Identical to Obeticholic Acid - placebo drug
75732218|NCT00904436|Drug|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
75732219|NCT00728585|Drug|Palifermin|Given IV
75732220|NCT00728585|Other|Placebo|Given IV
76053430|NCT04763252|Other|Spectrum Therapeutics cannabis products|"For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products."
75438330|NCT01597206|Other|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
75438331|NCT01597219|Procedure|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
75587861|NCT04554680|Drug|dabrafenib and trametinib|"Participants will receive systemic therapy in the form of oral tablet dabrafenib 150mg twice a day & oral tablet trametinib 2mg once a day for 1 or 4 weeks.~Pre- & post-systemic therapy assessment of tumor iodine absorption is done using I-124 PET CT scan. Participants are prepared for this scan with intramuscular injection of thyrogen 0.9mg on 2 consequent days, followed by I-124 PET-CT scan over the next 3 days for tumoral lesional dosimetry.~Participants are then started on systemic therapy for 1 week, followed by I-124 PET-CT scan. If at least one tumor site can attain adequate dosimetry, RAI (I-131) treatment under thyrogen stimulation will be considered. Systemic therapy will be stopped 3 days after I-131.~If after 1 week of systemic therapy, tumors do not reach dosimetry criteria, participants will be continued on systemic therapy for a total of 4 weeks duration, followed by I-124 PET-CT scan. If tumor can attain adequate dosimetry, I-131 treatment will be considered."
75587862|NCT00580424|Drug|Norethindrone|Norethindrone 0.35 mg orally daily
75587863|NCT04530396|Biological|Gam-COVID-Vac|vaccine for intramuscular injection
75732221|NCT02422433|Device|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
76053431|NCT05369039|Drug|Roflumilust|A selective phosphodiesterase 4 Inhibitor
75438332|NCT01597219|Procedure|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
76053432|NCT05369039|Drug|Prednisolone|Systemic corticosteroid
75438333|NCT01597232|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
75438334|NCT01597232|Other|Maintenance of hemoglobin level more than 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively
75438335|NCT01597232|Other|Transfusion trigger based on experience|Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
75438336|NCT01597297|Drug|BIIB041 (PR Fampridine)|10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
75438337|NCT01597297|Other|Placebo|Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
75438338|NCT01597310|Drug|Warfarin|single doses at specified time periods
75438339|NCT01597310|Drug|Dexpramipexole|multiple doses
75438340|NCT01597336|Procedure|Tissue plasminogen activator abscess flush|Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
75438341|NCT01597336|Procedure|Saline flush of abscess|Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
75438342|NCT01597362|Procedure|laparoscopy|Trocar access in laparoscopy
75438343|NCT01597362|Procedure|Laparoscopy|"The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume."
75587864|NCT04530396|Other|placebo|placebo comparator
75587865|NCT04554992|Biological|COVID 19 Convalescent Plasma|COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
75587866|NCT04530786|Drug|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~2004-2005: A/Wyoming H3N2; B/Shanghai~2006-2007: A/New Caledonia H1N1~2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia"
75587867|NCT01121575|Drug|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
75732222|NCT00730769|Drug|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
75732223|NCT04200287|Behavioral|Online decision aid tool|The decision aid intervention will be presented via a website
75732224|NCT00728663|Biological|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
75882570|NCT04194099|Device|20 Hz rTMS (Brain)|Higher frequency (>5 Hz) trains increase cortical excitability.
76053433|NCT04373369|Drug|Vorolanib|Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.
76053434|NCT04373369|Drug|Atezolizumab|Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
75882571|NCT04194099|Device|iTBS rTMS (Brain)|Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.
75587868|NCT01121575|Drug|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
75587869|NCT01121575|Drug|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
75882572|NCT04194099|Device|Anode tsDCS (Spinal)|Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.
75732225|NCT00728663|Drug|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
75882573|NCT04194099|Device|20 Hz current square-wave pulses (Spinal)|Higher frequency (>5 Hz) of current increase cortical excitability.
75882574|NCT04194099|Device|iTBS (Spinal)|Intermittent theta-burst stimulation (iTBS) is a newer approach. it may increase corticospinal excitability.
75882575|NCT04194099|Device|sham|with sham stimulation on brain and spinal.
75438344|NCT01597362|Procedure|Laparoscopy|"Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field."
75732226|NCT00728897|Drug|GSK598809 new formulation|GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
75587870|NCT01121575|Drug|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
75732227|NCT00728897|Drug|GSK598809 old formulation|GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
75587871|NCT04554797|Other|Regional Hypothermia|Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
75587872|NCT04530591|Other|Survey|Participants will complete a survey about their opioid use history, its impact on their lives, their current strategies for preventing or reversing opioid overdoses, and their preferences for a device-based intervention.
75587873|NCT04530591|Other|Interview|"Participants will participate in a semi-structured interview, during which they will provide feedback on non-functional, looks-like prototypes of a naloxone delivery device."
75587874|NCT04530708|Radiation|Thoracic radiotherapy|36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
75587875|NCT00625573|Drug|Abraxane|100mg/m2 every week X's 3
75587876|NCT04205851|Drug|KIN-1901|KIN-1901 is a fully human monoclonal antibody (mAb).
75732228|NCT04124705|Drug|Armour® Thyroid|Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
75732229|NCT04124705|Drug|Levothyroxine|Administered orally once a day; the daily dose could range from 25- 200 µg.
75732230|NCT00731003|Drug|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
75732231|NCT00731003|Other|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
75587877|NCT04205851|Drug|Placebo|Saline
75587878|NCT04530240|Procedure|Liver Transplantation|Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
75732232|NCT00731003|Other|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
75882576|NCT03552458|Drug|Lactobacillus Reuteri Oral Solution [BioGaia]|BioGaia Lactobacillus Reuteri drops
75882577|NCT03552458|Drug|Placebos|Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
75882578|NCT03633565|Drug|Sildenafil (Phosphodiesterase inhibitors)|tablet 25mg
75587879|NCT04554758|Procedure|Sleeve gastrectomy|Bariatric operation will be done by laparoscopic sleeve gastrectomy procedure.
75587880|NCT04554758|Procedure|Roux-en-Y gastric bypass|Bariatric operation will be done by laparoscopic Roux-en-Y gastric bypass procedure.
75587881|NCT02882113|Drug|Advagraf|same dose as Tacrolimus bid der day in 24 weeks
75587882|NCT04311190|Other|Family engagement|Physical exercises and simple care tasks
75587883|NCT00580541|Behavioral|variety|variety and nonvariety
75732233|NCT00731003|Drug|Placebo capsule|Placebo for 5-HTP
75732236|NCT00729131|Drug|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
75732237|NCT02569385|Other|Spontaneous breathing trial|
75882579|NCT03633565|Drug|Prednisolone (Steroids)|tablet 20 mg
75882580|NCT03633565|Procedure|Mesenchymal stem cell transplantation|stem cell transplantation intramuscular
75882581|NCT02120066|Procedure|Vitrectomy for submacular hemorrhage|
75882582|NCT02120066|Drug|subretinal injection of tissue-plasminogen activator|
75882583|NCT02120144|Other|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
75882584|NCT02120144|Other|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
75882585|NCT01373359|Drug|Misoprostol|400 µg sublingual misoprostol
75882586|NCT01373359|Drug|Oxytocin|10 IU IM
75882587|NCT02123186|Other|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
75882588|NCT03110185|Device|EEG|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
75587884|NCT04311229|Device|Negative-Pressure Wound Therapy group|The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.
75587885|NCT04311229|Other|contol group|Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
75587886|NCT04530357|Biological|QazCovid-in® - COVID-19 inactivated vaccine|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
75732238|NCT00731159|Biological|sperm capacitation|sperm capacitation measured at Bar Ilan University
75732239|NCT00731159|Other|biologic|sperm synthesis of G-actine to F-actine
75587887|NCT04530357|Other|Placebo|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
75587888|NCT04554563|Other|Core stability training|20 sessions of specific core stability exercise with no external loading.
75587889|NCT04530045|Other|dosage of concentration of piperacillin and cefepim|Dosage of total plasma concentration of piperacillin and cefepim at different timepoints
75438345|NCT01597362|Procedure|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
75587890|NCT01121536|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
75587891|NCT02217423|Other|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
75732240|NCT00731159|Other|sperm capacitation|sperm synthesis of G-actine to F-actine
75882589|NCT03110185|Device|fcDOT|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
75882590|NCT03110185|Device|fcMRI|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
75882591|NCT02123264|Drug|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
76053435|NCT05181761|Other|Gel Polish|One hand of a subject with receive nail polish to compare bacterial growth between hands with gel nail polish to those without.
75438346|NCT01597401|Drug|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
76053436|NCT04310189|Procedure|Biopsy|All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area
75438347|NCT01597401|Drug|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
75732241|NCT04095611|Procedure|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
75732242|NCT04095611|Procedure|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
75732243|NCT00729209|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
75732244|NCT00729209|Drug|Placebo; oral|matching placebo
75732245|NCT04026347|Device|Vesair Balloon|Indwelling, intravesical balloon
75732246|NCT04026347|Other|Sham balloon placement|Sham balloon placement procedure
75732247|NCT00731315|Other|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
75587892|NCT02217423|Other|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
75587893|NCT04311151|Procedure|own seizures visualization|At the hospital discharge, patients
75587894|NCT00580619|Other|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
75587895|NCT00580619|Other|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
75732248|NCT00731315|Other|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
75732249|NCT00729287|Dietary Supplement|selenium|Given orally
75732250|NCT00729287|Other|placebo|Given orally
76053437|NCT04791059|Drug|S-ketamine|S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.
76053438|NCT04791059|Drug|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
75732251|NCT02570087|Procedure|chronic total coronary occlusion percutaneous intervention|Percutaneous intervention of chronic total coronary occlusion with stent implantation
76053439|NCT04791059|Drug|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
76053440|NCT05405855|Behavioral|eLIFEwithIBD|eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.
76053441|NCT02189252|Drug|Epanova|
75438348|NCT01597401|Drug|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
75438349|NCT01597401|Drug|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
75438350|NCT01597401|Drug|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
75438351|NCT01597427|Drug|Clonidine|Administration of 2 μg/kg of intravenous clonidine
75438352|NCT01597427|Drug|Placebo|Injection of placebo solution.
75438353|NCT01597453|Behavioral|Lifestyle counseling|Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
76053442|NCT02189252|Drug|Lovaza|
76053443|NCT05369117|Behavioral|indocyanine green labeled fluorescent laparoscopy|indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
75438354|NCT01597466|Device|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
75438355|NCT01597466|Procedure|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
75438356|NCT01597518|Drug|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
75438357|NCT01597518|Drug|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
75438358|NCT01597531|Drug|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
75438359|NCT01597531|Drug|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
75587896|NCT00580619|Drug|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
76053444|NCT04766099|Other|Childbirth Educational Video|Educational video describing techniques for pushing
75587897|NCT00580619|Drug|methyldopa|Aldomet oral twice a day for 12 weeks
75587898|NCT02217579|Dietary Supplement|Protein|A food containing 5 grams/serving of supplemental protein.
75732252|NCT02569697|Other|HEC Placebo gel|
75732253|NCT02569697|Other|Placebo Intravaginal Ring|
75732254|NCT02569697|Other|Placebo Vaginal Film|
75732255|NCT02569697|Other|Placebo Vaginal Insert|
75732256|NCT03095417|Behavioral|Physical Exercise Intervention|In home exercise intervention.
75732257|NCT03095417|Behavioral|Cognitive Training Intervention|Online cognitive training modules.
75732258|NCT03095417|Behavioral|Stretching Control|In home stretching.
75732259|NCT03095417|Behavioral|Cognitive Control|Online control puzzles and games.
76053445|NCT05399069|Drug|VGR-R01|Gene Replacement Therapy
76053446|NCT05398913|Drug|Rimonabant|Rimonabant
75587899|NCT02217579|Dietary Supplement|Prebiotic fiber|A food containing 8 grams/serving of supplemental prebiotic fiber.
75587900|NCT02217579|Dietary Supplement|Protein plus prebiotic fiber|A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
75587901|NCT02217579|Dietary Supplement|Control|An isocaloric food not containing the test protein and fiber.
75438360|NCT01597531|Drug|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
75438361|NCT01597544|Procedure|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
75438362|NCT01597570|Device|Vascular Closure Device|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
75438363|NCT01597609|Drug|sibutramine|10 mg, taken orally once per day for 12 weeks
75438364|NCT01597609|Other|sibutramine placebo|taken orally once per day for 12 weeks
75438365|NCT01597648|Drug|Maraviroc|300 mg
75438366|NCT01597648|Drug|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
75587902|NCT04554524|Drug|Chemotherapy+Pembrolizumab.|Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). After 4 cycles treatment, complete response subjects continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, some of partial disease and stable disease subjects can receive surgical treatment. And then continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, other partial disease and stable disease subjects cannot be removed by surgery will continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab for 4 cycles and then pembrolizumab or Normal Saline up to disease progression.
75587903|NCT04530084|Device|OMNI Surgical System|Scheduled for canaloplasty and trabeculotomy with or without cataract extraction
75587904|NCT02212652|Dietary Supplement|Vitamin D|10,000 IU of VitD3 daily (one gel daily)
75587905|NCT02212652|Other|Placebo|Gummy button placebo, which will appear very similar to the vitamin D supplement.
75438367|NCT01597648|Drug|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
75587906|NCT02212652|Other|Standard of Care|Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
75587907|NCT02217657|Device|Thermocool Smart Touch Catheter|Physician informed to contact force
75587908|NCT02212769|Drug|Losartan 50mg|Losartan 50mg once daily for 7 days
75587909|NCT02212769|Drug|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
75587910|NCT02217696|Other|Computerized reading training|
75587911|NCT00580658|Device|Medtronic Activa Gpi|Activa Therapy, Gpi
75587912|NCT02212808|Other|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
75732260|NCT00731393|Biological|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
75732261|NCT00731393|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
75732262|NCT00731471|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
75732263|NCT04390217|Drug|LB1148|LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
75732264|NCT04390217|Drug|Placebo|Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
75587913|NCT02212808|Other|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
75732265|NCT02569463|Drug|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
75732266|NCT00729443|Drug|AZD3241|single oral dose
75732267|NCT00729443|Drug|Placebo|
75732268|NCT00731627|Drug|placebo|one tablet a day for up to 21 days
75732269|NCT00731627|Drug|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
75732270|NCT00731705|Procedure|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
75882592|NCT04132869|Behavioral|Sports Readiness Intervention|Sixth graders will participate in a 6 month after-school program in which each daily session will last 90 minutes, 60 minutes of which will be moderate to vigorous physical activity. Two sports tracks will be offered during each 8-week season, and children will choose which they prefer. Coaches will be trained through a one day capacity building session and will receive online training throughout the program. Coaches will integrate sports readiness/physical activity programming, nutrition and healthy eating, and social emotional learning into the program with a focus on habit formation. A text-based platform will be utilized to encourage habits learned in the active portion of the program during June and July as well as on weekends during the intervention. Parents will be sent fliers weekly summarizing concepts addressed, and will be invited to cooking classes to watch students compete.
75438368|NCT01597661|Drug|Exposure to any bupropion during the first trimester|"The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
75438369|NCT01597661|Drug|Exposure to bupropion alone during the first trimester|"The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
75438370|NCT01597661|Other|Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy|"The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
75438371|NCT01597674|Drug|YF476|"There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.~Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments."
75438372|NCT01597700|Drug|10mg Ezetimibe|1 tablet taken by mouth
75438373|NCT01597700|Drug|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
75587914|NCT02217774|Device|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
75587915|NCT02217852|Drug|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
75587916|NCT02217852|Drug|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
75587917|NCT02217852|Drug|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
75732271|NCT03050489|Procedure|On-Pump CABG.|Standard On-Pump CABG.
75732272|NCT03050489|Procedure|Off-Pump CABG.|Standard Off-Pump CABG.
75732273|NCT03050489|Procedure|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
75587918|NCT02217852|Drug|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
75587919|NCT02217930|Drug|WCK 2349|
75587920|NCT02217930|Drug|Placebo|
75732274|NCT00568178|Drug|Losartan Potassium|"Losartan Use During the Double-Blind Treatment Phase:~Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed <50 kg)~or 100 mg/day (if the patient weighed ≥50 kg).~Losartan Use During the Treatment Extension Phase:~Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance."
75732275|NCT00568178|Other|Comparator: Placebo (Losartan)|Placebo (losartan suspension), administered orally, once daily for 12 weeks
75732276|NCT00568178|Drug|Comparator: amlodipine besylate|Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
75732277|NCT00568178|Other|Comparator: Placebo (amlodipine besylate)|Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
75732278|NCT00568178|Other|Placebo (Losartan)|Normotensive patients randomized to losartan placebo for 12 weeks.
75732279|NCT00568178|Drug|Enalapril Maleate|Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
75732280|NCT00924248|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
75438374|NCT01597713|Drug|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
75438375|NCT01597713|Drug|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
75438376|NCT01597713|Drug|placebo|Subjects will receive a single dose of oral placebo within each dose group
75438377|NCT01597713|Drug|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
75438378|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
75438379|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
75732281|NCT00904514|Genetic|gene expression analysis|
75732282|NCT00904514|Genetic|microarray analysis|
75732283|NCT00904514|Genetic|mutation analysis|
75732284|NCT00904514|Genetic|polymerase chain reaction|
75732285|NCT00904514|Other|flow cytometry|
75732286|NCT00904514|Other|immunoenzyme technique|
75882593|NCT02251964|Drug|Rituximab|2 times 1000mg dose at 14 days interval treatment
75438380|NCT01597726|Drug|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D&E, repeated once 3 hours after the first dose if needed
75438381|NCT01597726|Device|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D&E
75438382|NCT01597739|Drug|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
75438383|NCT01597739|Drug|Placebo|Form=capsule; route=oral use; twice daily.
75587921|NCT02217930|Drug|Moxifloxacin|
75587922|NCT01121185|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
75587923|NCT01121185|Other|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
75587924|NCT01121146|Device|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
75587925|NCT04529733|Device|IB10 sphingotest PCT+|Whole blood in EDTA for procalcitonin POC testing on IB10 sphingotest PCT+ device
75732287|NCT00904514|Other|laboratory biomarker analysis|
75732288|NCT00928460|Procedure|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
75732289|NCT00577889|Drug|gemcitabine hydrochloride|750 mg/m2 Given IV
75732290|NCT00577889|Drug|tanespimycin|154 mg/m2 Given IV
75882594|NCT02251964|Radiation|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
75882595|NCT04739995|Drug|Low-dose naltrexone|4.5 mg LDN/day for 1 year
75587926|NCT01120756|Behavioral|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
75587927|NCT01120756|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
75587928|NCT01120717|Drug|QVA149|capsules for inhalation, delivered by an SDDPI
75587929|NCT01120717|Drug|Placebo|capsules for inhalation, delivered by an SDDPI
75438384|NCT01597752|Biological|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
75438385|NCT01597765|Drug|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
75438386|NCT01597765|Drug|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
75438387|NCT01597804|Procedure|Infection Prophylaxis and Management|"Undergo preoperative preparation with the Bathing Bundle"
75587930|NCT04577846|Drug|Cephalexin 500 MG|Cefalexin 500 mg PO q8 hours will be continued for the duration of the indwelling drains which usually is about 14 days.
75587931|NCT04577846|Drug|Placebo|A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
75587932|NCT04529811|Drug|Rifaximin Novel Formulation|Rifaximin Novel Formulation
75587933|NCT04529811|Drug|Placebo|Placebo
75587934|NCT04554407|Device|SOMAVAC® 100 Sustained Vacuum System|The SOMAVAC® 100 is a battery operated device that delivers 100mm/Hg of continuous suction.
75587935|NCT02217969|Behavioral|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
75438388|NCT01597817|Other|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
75438389|NCT01597817|Other|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
75587936|NCT02218047|Drug|Pegylated-Proline-interferon alpha-2b|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
75438390|NCT01597830|Other|Mobility shoe|flat, specialized shoe
75587937|NCT02218047|Drug|Best available therapy (BAT)|Best available therapy as selected by the investigator
75587938|NCT00580814|Drug|Methylphenidate|Methylphenidate
75587939|NCT01120600|Drug|Odanacatib|One 50 mg tablet once weekly
75587940|NCT01120600|Drug|Placebo for Odanacatib|One 50 mg tablet once weekly
75587941|NCT01120600|Dietary Supplement|Vitamin D3|5600 IU of open-label Vitamin D3 once weekly
75587942|NCT01120600|Dietary Supplement|Calcium carbonate|Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
75587943|NCT04529694|Other|Psychotherapy|
75587944|NCT04577885|Drug|SHR2554 and Rifampin|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
75587945|NCT02218086|Device|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
75587946|NCT02218086|Device|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
75587947|NCT02218086|Device|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
75732291|NCT00928538|Other|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
75732292|NCT00928616|Dietary Supplement|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
75587948|NCT02218086|Device|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
75587949|NCT02218086|Device|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
75732293|NCT00928616|Dietary Supplement|margarine (placebo)|non-sterol ester supplemented margarine
75732294|NCT00460564|Drug|GSK1358820|botulinum toxin type A
75732295|NCT00460564|Drug|Placebo|Placebo
75587950|NCT02218086|Device|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
75587951|NCT02218086|Device|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times ~15minutes within y few weeks.
75732296|NCT00729599|Drug|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
75882596|NCT02120612|Other|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
75882597|NCT01374295|Other|video|watch a 3 minute video
75438391|NCT01597830|Other|control shoe|control shoe
75438392|NCT01597869|Device|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
75438393|NCT01597895|Drug|Maraviroc|Maraviroc 150 mg BID x 5 days with food
75438394|NCT01597895|Drug|Maraviroc + Boceprevir|Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
75438395|NCT01597895|Drug|Maraviroc + Telaprevir|Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
75587952|NCT04554251|Other|Survey|invited questionnaire
75732297|NCT04015076|Drug|Inzomelid|Active Drug
75732298|NCT04015076|Drug|Placebo|Placebo to Match
75732299|NCT03743480|Other|early palliative care|experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
75732300|NCT02538926|Drug|Asparaginase|Given IM or IV
75732301|NCT02538926|Drug|Cyclophosphamide|Given IV
75438396|NCT01597934|Drug|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
75438397|NCT01597934|Drug|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
75732302|NCT02538926|Drug|Doxorubicin Hydrochloride|Given IV
75882598|NCT01374295|Other|standard education|Receives standard verbal education from healthcare provider
75438398|NCT01597947|Drug|ACHN-975|Intravenous single dose
75438399|NCT01597947|Drug|placebo|Intravenous single dose
75438400|NCT01597960|Other|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
75587953|NCT01120210|Drug|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
75587954|NCT01120210|Drug|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
75587955|NCT01120210|Drug|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
75587956|NCT01120210|Drug|Placebo|1-hour infusion of matching placebo on Day 1
75732303|NCT02538926|Drug|Etoposide|Given IV
75732304|NCT02538926|Drug|Imatinib Mesylate|Given PO
75732305|NCT02538926|Other|Laboratory Biomarker Analysis|Correlative studies
75732306|NCT02538926|Drug|Prednisone|Given PO
75732307|NCT02538926|Biological|Rituximab|Given IV
75732308|NCT02538926|Drug|Vincristine Sulfate|Given IV
75732309|NCT01323400|Drug|Pazopanib|Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
75882599|NCT02115152|Drug|fluorouracil|
75882600|NCT02115152|Drug|capecitabine|
75882601|NCT02115152|Drug|cyclophosphamide|
75438401|NCT01597986|Drug|isavuconazole|oral
75732310|NCT01323400|Other|Best supportive care|"Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency."
75732311|NCT00904592|Drug|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
75882602|NCT02115152|Drug|Epirubicin|
75882603|NCT04680871|Device|In-Ear Sensor|The device will passively monitor participants' biometrics
75438402|NCT01597986|Drug|Oral Contraceptive (ethinyl estradiol / norethindrone)|contraceptive pill consisting of ethinyl estradiol and norethindrone
75732312|NCT00904592|Drug|Placebo Comparator|"Control group: Basic therapy ＆ placebo~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~placebo,Usage: 4.5g，po，tid"
75882604|NCT02115230|Procedure|Renal denervation + medical therapy|Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
75732313|NCT00928850|Procedure|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|"Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
75882605|NCT04657861|Drug|APRIL CAR-T cells|Each subject receive APRIL CAR T-cells by intravenous infusion
75882606|NCT02115464|Drug|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
75438403|NCT01597999|Radiation|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
75438404|NCT01598012|Drug|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
75438405|NCT01598012|Drug|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
75587957|NCT01120210|Drug|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
75587958|NCT04554329|Procedure|bandage contact lens|bandage contact lens
75587959|NCT02218125|Biological|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
75882607|NCT02115464|Radiation|Chemo-radiotherapy|Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
75882608|NCT02858076|Drug|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
75882609|NCT02858076|Procedure|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
75438406|NCT01598038|Other|Blood sample|Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
75438407|NCT01598051|Drug|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
75587960|NCT02218125|Biological|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
75587961|NCT00580931|Drug|Nicotinamide|1500 mg twice a day for 6 months
75587962|NCT00580931|Drug|Enduramide placebo|1 tab twice a day
75587963|NCT02218281|Behavioral|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
75587964|NCT02218281|Behavioral|NCI's QuitSTART app|NCI's smoking cessation app
75732314|NCT00928850|Procedure|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|"Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
75732315|NCT00928850|Procedure|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
75438408|NCT01598077|Drug|LJM716|
75438409|NCT01598142|Procedure|Team 1|experienced endoscopist with a experienced assistant
75732316|NCT00928850|Procedure|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
75882610|NCT02115620|Other|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
75438410|NCT01598142|Procedure|Team 2|same experienced endoscopist with a new trained assistant
75438411|NCT01598155|Procedure|Group 1 - Supragingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~Scaling, planning and polishing coronary surface;~Education and motivation for oral hygiene and daily supragingival biofilm control by the patient."
75438412|NCT01598155|Procedure|Group 2 - Supra- and subgingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~Scaling, planning and polishing of coronary surface;~Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;~Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged."
75732317|NCT03745313|Device|Edwards PASCAL Transcatheter Valve Repair System|Repair of the tricuspid valve through a transcatheter approach
75732318|NCT00904904|Drug|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
75732319|NCT00904904|Drug|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
75732320|NCT00731861|Drug|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
75732321|NCT00928928|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
75882611|NCT01319695|Drug|corifollitropin alfa|100 microg for a group of women weighing <or=60 kg and 150 microg for a group of women weighing >60 kg
75438413|NCT01598168|Drug|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
75438414|NCT01598181|Device|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
75438415|NCT01598181|Device|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
75438416|NCT01598220|Behavioral|Computer-assisted cognitive remediation therapy|"Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient."
75438417|NCT01598220|Other|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
75438418|NCT01598233|Device|Silimed Intragastric balloon|Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
75438419|NCT01598259|Drug|Melatonin|po 1 hour before bedtime
75732322|NCT00928928|Procedure|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
75732323|NCT00729755|Dietary Supplement|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
75732324|NCT00729755|Dietary Supplement|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
75438420|NCT01598259|Other|placebo|po, 1 hour before bed
75587965|NCT02218281|Behavioral|Written smoking cessation materials only|Receipt of written smoking cessation materials
75587966|NCT01120093|Drug|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
75732325|NCT03903263|Diagnostic Test|survey on sleep disorders|self-administered patient questionnaire regarding the different aspects of sleep disorders in patients with dermatologic diseases
75882612|NCT01319695|Drug|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are >18mm
75587967|NCT01120093|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
75438421|NCT01598272|Dietary Supplement|Vitality product AM + Vitality product PM|Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
75438422|NCT01598272|Dietary Supplement|Placebo|Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
75438423|NCT01598337|Drug|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
75587968|NCT01120093|Drug|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
75587969|NCT01120093|Drug|Placebo|Placebo via inhalation in the morning and evening for 7 days
75732326|NCT00567476|Drug|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
75732327|NCT00567476|Drug|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device > 500 mcg of fluticasone or equivalent
75882613|NCT01373437|Device|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
75882614|NCT02123342|Behavioral|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
75438424|NCT01598337|Drug|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
75438425|NCT01598337|Drug|Clopidogrel|75 mg orally started 6-8hours before surgery
75438426|NCT01598337|Drug|Prasugrel|10 mg daily as per instructions of investigators
75882615|NCT04594759|Drug|Isotretinoin|Participants will be getting isotretinoin (1-1.5 mg/kg/week)
75438427|NCT01598376|Procedure|7/0 vicryl suture|7/0 vicryl test suture placed as one of 3 everting sutures
75438428|NCT01598376|Procedure|5/0 vicryl test suture|5/0 vicryl test suture placed as one of 3 everting sutures
75587970|NCT01120093|Drug|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
75587971|NCT00581009|Other|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
75587972|NCT00581009|Drug|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
75732328|NCT00567476|Drug|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
75732329|NCT00567476|Drug|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
75732330|NCT04065737|Drug|Sintilimab|"Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308"
75732331|NCT00516321|Drug|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
75732332|NCT00516321|Drug|placebo|matched placebo taken once daily orally
75587973|NCT00581009|Radiation|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
75587974|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
75732333|NCT00729911|Procedure|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
75732334|NCT00729911|Drug|Amiodarone|Taken orally on a daily basis.
75732335|NCT04018703|Drug|Dexmedetomidine|loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
75882616|NCT02123420|Device|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, St-Stevens-Woluwe, Belgium)."
75882617|NCT02123498|Drug|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
75438429|NCT01598389|Other|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
75438430|NCT01598402|Drug|amoxicillin/clavulanic acid suspension|625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
75438431|NCT01598415|Drug|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
75438432|NCT01598415|Drug|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
75438433|NCT01598441|Drug|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
75438434|NCT01598441|Drug|distilled water|1-2 ml aerosolized distilled water inhalation per session
75732336|NCT04018703|Drug|Midazolam|loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
75732337|NCT04629872|Drug|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.
75882618|NCT02123498|Drug|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
75882619|NCT02123498|Drug|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
76053447|NCT04256837|Device|Transcutaneous electrical auricular vagus nerve stimulation (VNS)|Electrical auricular stimulation is accomplished using a Roscoe Medical TENS 7000 that delivers a programmable electrical current density, frequency, and pulse width. The TENS 7000 will be connected to ear clip (or hand held) electrodes to transcutaneously stimulate the cymba conchae of the ear to activate the auricular branch of the vagus nerve (diagram above), also known as Arnold's nerve, which provides sensory innervation to the skin surrounding the ear canal. Through a neural reflex arc, activation of this sensory nerve sends a neural signal to the brainstem that then activates the efferent vagus nerve through the nucleus of the solitary tract (NTS). This is a well-described and clinically accepted neuromodulatory pathway, as transcutaneous electrical auricular stimulation has been studied to treat seizures, similarly to how invasive electrical vagus nerve stimulation has been approved by the FDA for the past two decades for the same indication.
76053448|NCT05396729|Device|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
75732338|NCT04065581|Drug|Acarbose/Metformin FDC(BAY81-9783)|Single dose: 50 mg acarbose/500 mg metformin tablet, oral
75732339|NCT04065581|Drug|Glucobay|Single dose: 50 mg tablet, oral
75732340|NCT04065581|Drug|Glucophage|Single dose: 500 mg tablet, oral
76053449|NCT01583374|Drug|Apremilast tablet 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
76053450|NCT01583374|Drug|Apremilast tablet 30 mg BID|Apremilast 30 mg was taken orally twice a day
76053451|NCT01583374|Drug|Placebo|Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
75438435|NCT01598454|Drug|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
75587975|NCT02218359|Drug|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
75587976|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
75587977|NCT02882191|Drug|LevoCept|placement of LevoCept IUD
75587978|NCT02882035|Other|OFA|
75587979|NCT02212847|Other|vestibular stimulation|
75587980|NCT02218398|Drug|Albuterol|
75587981|NCT02218437|Drug|MSC+ATG|MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
75587982|NCT04577768|Device|HD-tDCS 2 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA
75587983|NCT04577768|Device|HD-tDCS 1.5 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
75587984|NCT04577768|Device|HD-tDCS sham|sham stimulation of the right primary motor cortex
75587985|NCT02218515|Procedure|Open Flap Debridement|Open Flap Debridement (Control Group)
75587986|NCT02218515|Biological|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
75587987|NCT02218515|Biological|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
75587988|NCT02218554|Genetic|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
76053452|NCT01583296|Behavioral|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
76053453|NCT01583296|Behavioral|CBT and HRVB|cognitive behavioral therapy and heart rate variability biofeedback
76053454|NCT04189835|Diagnostic Test|EBV DNA in whole blood and plasma|Consecutive measurements of EBV DNA in whole blood and plasma
76053455|NCT04823585|Drug|Mepolizumab|Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
76053456|NCT04823585|Drug|Placebo|Solution. Subcutaneous.
76053457|NCT04165577|Device|rTMS|1-Hz rTMS targeting frontal pole
75587989|NCT02218593|Device|WREX orthosis|Upper extremity exoskleton used to assist movement
75587990|NCT04577612|Drug|CHI-554|hemp-derived CBD in MCT oil
75587991|NCT02218671|Drug|WE 941 OD tablets|
75587992|NCT01119937|Drug|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
75587993|NCT01119937|Drug|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
75587994|NCT02278731|Other|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
75587995|NCT01119898|Drug|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
75587996|NCT01119898|Drug|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
75587997|NCT04577534|Drug|iv Tocillizumab (TCZ)|Participants are randomized (2:1) to receive TCZ or Standard of Care
75587998|NCT02278809|Behavioral|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring…"
75587999|NCT04553900|Diagnostic Test|Transesophageal Echocardiography|Placement of a transesophageal probe and performance of a diagnostic Transesophageal echocardiography examination.
75588000|NCT01119859|Drug|Tocilizumab|The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
75588001|NCT01119859|Drug|Adalimumab|
75588002|NCT01119859|Drug|Placebo to tocilizumab|
76053458|NCT04165577|Device|sham rTMS|sham rTMS targeting frontal pole
75588003|NCT01119859|Drug|Placebo to adalimumab|
75588004|NCT02278926|Other|Ultrasound|Ultrasound measurements
75588005|NCT02278926|Other|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
75588006|NCT01119703|Biological|Tetanus & Diphtheria booster vaccine (Td)|Tetanus & Diphtheria booster vaccine (Td), single intramuscular dose
75588007|NCT01119703|Biological|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine], intramuscular, two doses of standard three dose regimen (opposite arms)
75588008|NCT01119703|Biological|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
75588009|NCT04554446|Procedure|T-MSAT(Motion style acupuncture treatment using traction)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
75588010|NCT04554446|Procedure|Korean medicine treatment|acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
75588011|NCT02882074|Drug|Human albumin|human albumin 5% during surgery
75438436|NCT01598467|Procedure|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
75588012|NCT02882074|Drug|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
75588013|NCT02218749|Other|Initially triaged to physiotherapist|
75732341|NCT00929084|Other|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
75732342|NCT05585645|Biological|Stimus (NNG-DEPO)|Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
75732343|NCT04572854|Drug|Pegcetacoplan|Complement (C3) Inhibitor
75732344|NCT00732017|Device|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
75732345|NCT00732017|Device|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
75438437|NCT01598480|Drug|Flamazine|Silver sulfadiazine cream
75438438|NCT01598480|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
75438439|NCT01598493|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
75438440|NCT01598493|Drug|Flamazine|Silver sulfadiazine cream
75588014|NCT02218749|Other|Initially triaged to physician|
75588015|NCT02882230|Drug|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|chemical dosage ARV
75588016|NCT00581087|Drug|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
75588017|NCT00581087|Drug|Placebo|Treatment : 200 mg/day hard gelatine capsule
75588018|NCT01119625|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
75588019|NCT01119625|Biological|Infanrix-IPV/Hib|Intramuscular injection, one dose
75588020|NCT02218827|Drug|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
75588021|NCT00581126|Drug|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
75588022|NCT04553978|Drug|WD-1603|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
75588023|NCT02881918|Other|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
75588024|NCT02881762|Drug|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
75588025|NCT02218905|Behavioral|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
75588026|NCT04554017|Other|Education/Training|It consisted of a brief overview of hypertension, risk factors, complications and much emphasis placed on the preventive measures (what they include and why it is necessary to practice them).
75588027|NCT04307017|Other|StimaWell®EMS|The StimaWell®EMS device is a 12-channel medium-frequency device with modulated low frequency using a high-tech stimulation suit for the trunk and strap electrodes for the arms and legs allowing whole-body stimulation. The device has 70 preprogramed training programs based on goals (e.g., strengthening, endurance training, aerobic training).
76053459|NCT02222714|Biological|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
76053460|NCT02222714|Drug|Placebo|Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
75588028|NCT04561947|Procedure|Tunnel technique|After local anesthesia, the exposed root surfaces were mechanically treated with curettes. A tunnelling knives were used to prepare a split-thickness flap and create a continuous tunnel in the buccal soft tissues, following the intrasulcular incision with a #69 microblade. Split-thickness flap preparation was performed to beyond the mucogingival junction with supraperiosteal dissection by placing the tunneling knives to the soft tissue. This process was repeated by entering through the sulcus of each tooth. After the elevation of the flap, a papilla elevator placed under the flap was entered through the sulcus to mobilize the papilla, the periosteum at the base of the papilla was cut, and the full-thickness flap was elevated.
76053461|NCT04836689|Device|nasal intermittent positive pressure ventilation (NIPPV).|"NIPPV will be administered using Leoni (Heinen&Löwenstein, Bad Ems, Germany) and RAM cannula (Neotech, Valencia, CA).~After initial setting and before routine blood gas testing, tcCO2 will be connected and calibrated. We will use SenTec digital monitor (SenTec AG, Therwil, Switzerland). Correlation/agreement between the tcCO2 and PCO2 will be assessed and documented in each infant.~For Each infant we will get 2 set of data: Change in measurements when changing from 30 bpm to 10 bpm, and change in measurements when changing from 10 bpm to 30 bpm At the end of each hour, before rate change, we will document the following measurements:TcCO2, FiO2, saturation, the infant's respiratory rate (as measured in the monitor), number of apneas, bradycardia (heart rate<100 bpm), saturation<90% and>94% episodes (as measured in the monitor), 1-hour saturation histogram clasification."
75588029|NCT04561947|Procedure|Connective tissue graft|CTG was harvested using the de-epithelialized connective tissue graft technique. The epithelial tissue on the outer surface of the graft was removed with a 15 blade and a 1-mm-thick graft was obtained.
75588030|NCT04561947|Other|Concentrated growth factor membrane|Intravenous blood samples were collected in without anticoagulant 10-mL tubes and immediately centrifuged in a CGF centrifuge machine using a program with the following features: 30 ̋ acceleration, 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, 3 min at 3000 rpm, and 36 ̋ deceleration and stop. After centrifugation, four layers were formed in the tube: the serum layer at the top, the second buffy coat layer, the third CGF layer containing GF and unipotent stem cells, and the red blood cell layer at the bottom. The resulting CGF was removed from the tube and separated from the red blood cell layer using microsurgical scissors.
75588031|NCT01119118|Drug|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
76053462|NCT04821401|Dietary Supplement|Rejuvant|"Rejuvant tablets are sustained release tablets that release the active ingredients over 8-12 hours. Both product tablets are 0.500 round and 0.290 thick.~AKG and AKG salts are grandfathered as GRAS compounds because these compounds were supplements prior to the Dietary Supplement Health and Education Act of 1994 (DSHEA). AKG and AKG salts are currently sold in the United States as supplements.~The other components of the tablets are Vitamin A for the men's product and Vitamin D3 for the women's product. Vitamin A and Vitamin D are GRAS compounds per the FDA"
76053463|NCT04821401|Dietary Supplement|Placebo|Matching placebo tablets are composed of Cellulose, Carnauba wax and/or rice bran wax (to match the specs), stearic acid, magnesium stearate and silica.
76053464|NCT05226143|Other|Gel Cream|Gel Cream
75588032|NCT04577339|Procedure|Laparotomy or laparoscopy|"Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause."
75588033|NCT01119001|Device|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
75882620|NCT02123498|Procedure|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
75588034|NCT02212925|Drug|BI 14332 CL|
75882621|NCT02123498|Procedure|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
76053465|NCT03291743|Device|Capsule endoscopy|PillCam(TM) CROHN'S CAPSULE
75588035|NCT02212925|Drug|Placebo|
75588036|NCT01118962|Drug|Lacosamide|Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
75588037|NCT04561830|Procedure|laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision|"We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides."
76053466|NCT04145219|Biological|Sublingual allergy immunotherapy tablet|For daily administration (1 tablet per day)
76053467|NCT04145219|Other|Placebo|For daily administration (1 tablet per day)
75438441|NCT01598519|Behavioral|suicide intervention|"universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net."
75438442|NCT01598558|Drug|Cu-64 Rituximab|Up to 14 mCi, iv
75438443|NCT01598571|Drug|Fostamatinib|Fostamatinib 50 mg tablet
75438444|NCT01598571|Drug|Fostamatinib|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose
75438445|NCT01598584|Drug|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
75438446|NCT01598584|Drug|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
75732346|NCT00732017|Other|standard physical therapy treatment|"Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
76053468|NCT04808921|Diagnostic Test|Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
76053469|NCT05652959|Device|Cerviron®|Cerviron® is a medical device manufactured by PFC Pharma Manufacturing SL formulated following the provisions of the European Regulation 2017/745 on Medical Devices. Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21. Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
75588038|NCT00581165|Drug|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
75588039|NCT05362006|Device|Exopulse Mollii Suit|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
75588040|NCT05362006|Device|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
75588041|NCT05092984|Drug|Spironolactone|"77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
75588042|NCT05092984|Drug|Placebo|"77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
75588043|NCT02218944|Behavioral|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
76053470|NCT05652881|Procedure|Joint Lavage|An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
76053471|NCT04102865|Device|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
75438447|NCT01598623|Drug|Oxytocin|24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
75438448|NCT01598623|Behavioral|Social Skills Training|three times a week for three weeks.
75438449|NCT01598623|Behavioral|Placebo + Non Specific Counselling|
75438450|NCT01598649|Dietary Supplement|Fabricated foods with lupin protein|- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)
75588044|NCT01118728|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75588045|NCT02218983|Device|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
75588046|NCT02218983|Other|Usual care|
75588047|NCT02219022|Other|Control group|
75588048|NCT02219022|Other|Experimental group|
75438451|NCT01598649|Dietary Supplement|Mannitol|- Placebo capsules containing mannitol (four capsules per day)
75438452|NCT01598649|Dietary Supplement|Arginine|- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)
75438453|NCT01598649|Dietary Supplement|Fabricated foods with milk protein|Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
75438454|NCT01598675|Other|Same Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait
75588049|NCT02213159|Drug|Dexmedetomidine|
75588050|NCT02213159|Drug|Morphine|
75732347|NCT00924794|Procedure|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
75438455|NCT01598675|Other|Different Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
75588051|NCT00581282|Radiation|PET scan|positron emission tomography PET scan
75588052|NCT00581282|Other|fMRI|functional magnetic resonance imaging fMRI
76053472|NCT03132155|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
76053473|NCT03107195|Drug|Imaging Time|Participants will be asked to be imaged at an additional time point.
75882622|NCT02237040|Procedure|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
75882623|NCT02115776|Drug|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
75882624|NCT02115776|Drug|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
75438456|NCT01598688|Other|Blood collection immediately after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
75732348|NCT00733889|Drug|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
75732349|NCT03903731|Device|Total knee arthroplasty with Journey II BCS Total Knee System|Journey II BCS Total Knee System
75882625|NCT02115776|Drug|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
75882626|NCT02856282|Drug|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
75882627|NCT05231421|Behavioral|Focus Group|Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
75882628|NCT02115854|Other|labial biopsy|
75588053|NCT01118455|Device|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
75882629|NCT02115932|Other|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
75588054|NCT01118455|Drug|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
75588055|NCT02219100|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
75588056|NCT04553861|Device|Ambulatory blood pressure monitoring|Every 30 minutes from 7 AM to 10 PM and every 1 hour from 10 PM to 7 AM
75588057|NCT04553861|Device|Galaxy Watch Active2|Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
75732350|NCT01010685|Procedure|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
75882630|NCT03959319|Other|Movement Pattern Training|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
76053474|NCT02164916|Biological|cetuximab|Given IV
76053475|NCT02164916|Drug|irinotecan hydrochloride|Given IV
76053476|NCT02164916|Drug|vemurafenib|Given PO
75438457|NCT01598688|Other|Blood collection five minutes after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
75588058|NCT02219139|Device|ESTA abutment Roxolid|Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
75588059|NCT04561752|Drug|ZN-c5|ZN-c5 is the study drug.
75438458|NCT01598714|Device|Darco shoe|Darco shoe
75732351|NCT05153655|Procedure|Local ischemic post-conditioning|"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min."
75732352|NCT00929318|Procedure|blood sampling|
76053477|NCT05652569|Other|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions
75438459|NCT01598714|Device|Podalux shoe|Podalux shoe
75438460|NCT01598714|Device|Standard dressing shoe|Standard dressing shoe
75438461|NCT01598727|Device|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
75438462|NCT01598766|Device|16 Channel SPEEDER Flex Coil|This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
75438463|NCT01598792|Biological|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
75438464|NCT01598805|Behavioral|electronic alerts|An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
75438465|NCT01598844|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via a transapical access
75438466|NCT01598857|Drug|Blisibimod|
75438467|NCT01598857|Drug|Placebo|
75438468|NCT01598870|Other|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
75438469|NCT01598883|Drug|Heparin|150 U/kg
75732353|NCT00929318|Procedure|blood sampling|
75732354|NCT00733967|Drug|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
75732355|NCT00733967|Drug|Placebo|Matching oral placebo capsules as control.
75438470|NCT01598883|Drug|ATryn|1000 IU
75438471|NCT01598909|Drug|Arnica|Application of Arnica ointment periorbitally
75588060|NCT01118377|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
75588061|NCT01118377|Radiation|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
75588062|NCT04561323|Diagnostic Test|Dual-energy CT|"Patients suspected of acute bowel ischemia will be scanned in the dual-energy CT scanner.~The abdominal imaging protocols are predetermined by the Department of Diagnostic Radiology, Righospitalet, Denmark."
75588063|NCT04577222|Procedure|Technical modification during radical prostatectomy|Covering the NVB with fat
75588064|NCT02219178|Drug|lenalidomide|25mg days 1 - 14 of 21 day schedule
75588065|NCT02219178|Drug|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
75588066|NCT02219178|Drug|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
75588067|NCT02213315|Drug|100mg Mavrilimumab|100mg Mavrilimumab
75588068|NCT02213315|Drug|150mg mavrilimumab|150mg mavrilmumab
75588069|NCT02213315|Other|Placebo|Placebo
75588070|NCT02219217|Drug|Dolutegravir, Elvitegravir and Cobicistat|
75588071|NCT02213393|Dietary Supplement|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
75732356|NCT01010841|Dietary Supplement|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
75732357|NCT01010841|Other|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
75732358|NCT00732095|Behavioral|Promoting Self-Change with Ads|Use of Ads immediate or delayed or no ad
75588072|NCT02213393|Dietary Supplement|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
75588073|NCT04577378|Drug|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
75588074|NCT04577378|Drug|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)|Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
75588075|NCT02211573|Other|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
75588076|NCT04553627|Device|ZELTIQ thermoelectric device|This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
75588077|NCT02219412|Drug|ticagrelor|90 mg bid for 2 weeks
75588078|NCT02219412|Drug|Aspirin|100mg Qd for 2 weeks.
75588079|NCT04577027|Drug|Topical travoprost 0.004% solution|30 Patches treated with Topical Travoprost 0.004% solution: Topical travoprost 0.004% solution once daily (1 drop for each 2.5 x 2.5 cm2) for 3 months.
75438472|NCT01598909|Drug|Placebo ointment|Application of Arnica ointment, twice a day, for the period of one week.
75588080|NCT04577027|Device|Fractional CO2 laser|30 Patches treated with Fractional CO2 laser: Fractional CO2 laser sessions twice monthly for 3 months, parameters settings as follows: Energy\ dot 100mj, pulse duration 5ms, density level 17, pattern: array, depth level 1, 2 passes used
75588081|NCT04577027|Device|Excimer laser|30 Patches treated with Excimer laser: Excimer laser sessions will be repeated twice weekly on the selected patch only, The starting dose will be 200 mj /cm2, an increase of 100 mJ/cm2 in the following session if no erythema appears, an increase of 50 mJ/cm2 every session till the appearance of erythema that lasts 24 hours or more.
75882631|NCT03959319|Other|Manual Therapy|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
75438473|NCT01598948|Drug|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
75438474|NCT01598961|Other|TOF count-guided partial NMB|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
75588082|NCT04577027|Other|Combination therapy|30 Patches treated with Combination therapy: Fractional CO2 laser twice per month followed by application of topical travoprost 0,004% daily and excimer laser twice weekly .
75732359|NCT00732173|Behavioral|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
75732360|NCT00732173|Behavioral|exercise intervention|Undergo SUCCEED lifestyle intervention
75732361|NCT00732173|Other|counseling intervention|Undergo SUCCEED lifestyle intervention
75438475|NCT01598961|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
75438476|NCT01598961|Other|No NMB|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
75732362|NCT00732173|Other|educational intervention|Receive information
75732363|NCT00732173|Other|survey administration|Undergo SUCCEED lifestyle intervention
75438477|NCT01598974|Procedure|Traditional Acupuncture|
75438478|NCT01598974|Procedure|Laser Acupuncture|
75438479|NCT01599000|Drug|Artemether-lumefantrine combination|fixed-dose tablet, six doses over three days, according to weight group
75438480|NCT01599013|Drug|Vinflunine, Gemcitabine|"Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
75732364|NCT04650243|Drug|ursodeoxycholic acid|The two experimental groups will receive reduced dosage of UDCA at 250mg bid and 250mg qd respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be five years.
75882632|NCT02123654|Drug|Daclatasvir|
75882633|NCT02123654|Drug|Asunaprevir|
75882634|NCT02123654|Drug|DCV 3DAA|
75882635|NCT02123654|Other|Placebo for DCV 3DAA|
75882636|NCT02123654|Other|Placebo for Daclatasvir|
75882637|NCT02123654|Other|Placebo for Asunaprevir|
75882638|NCT03609138|Device|Spinal Hardware|Pedicle screws and patient specific rods
75588083|NCT04577027|Other|Excimer laser and travoprost|30 Patches treated with Excimer laser twice weekly and topical travoprost once daily for 3 months
75588084|NCT04577027|Other|fractional CO2 laser and topical travoprost|30 Patches treated with fractional CO2 laser twice monthly and topical travoprost once daily for 3 months
75588085|NCT04553354|Procedure|cortical resections|is the removal of the epileptic focus either temporal or extra temporal area
75588086|NCT02211612|Dietary Supplement|PUFA-group|
75588087|NCT02211612|Dietary Supplement|SFA-group|
75588088|NCT04553315|Procedure|chest expansion exercises|Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.
75588089|NCT02211690|Drug|dolutegravir 50 mg (one tablet daily)|
75588090|NCT02211690|Drug|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
75588091|NCT04553393|Drug|Chidamide|Chidamide will be added 1 month after responding to CART cells infusion
75588092|NCT04553393|Drug|Decitabine|Decitabine will be added 1 month after responding to CART cells infusion
75588093|NCT04553393|Drug|Chidamide and Decitabine|Both chidamide and decitabine will be added 1 month after responding to CART cells infusion
75588094|NCT04553393|Biological|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem CAR19/20 engineered T cells
75588095|NCT02219451|Other|exercise training|exercise training
75588096|NCT04553588|Other|Disposal pouch|Medication Disposal Pouch
75588097|NCT02211846|Drug|Mirabegron|oral
75732365|NCT00738569|Drug|Raltegravir|Raltegravir 400 mg PO BID for 12 months
75438481|NCT01599013|Drug|Vinflunine, Carboplatin|"Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
75438482|NCT01599065|Other|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
75438483|NCT01599078|Drug|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
75438484|NCT01599078|Drug|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
75438485|NCT01599091|Other|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
75438486|NCT01599117|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
75588098|NCT02219568|Procedure|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
75588099|NCT02219568|Device|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
75588100|NCT02219646|Drug|Vardenafil|Vardenafil 10 mg twice daily for six months
75588101|NCT02219646|Drug|Placebo|Placebo two tablets daily for 6 months
75588102|NCT04553510|Drug|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
75588103|NCT04553510|Drug|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
75588104|NCT02219724|Drug|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
75732366|NCT04646811|Procedure|Tricuspid valve|Clip for the tricuspid valve implantation on top of best medical therapy
75588105|NCT01642017|Drug|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
75588106|NCT00581594|Procedure|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
75588107|NCT00581594|Procedure|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
75732367|NCT04646811|Other|Best medical treatment|Best medical therapy alone
75438487|NCT01599117|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
75438488|NCT01599130|Drug|Entecavir|entecavir 0.5mg per day
75588108|NCT01642095|Other|Laboratory Biomarker Analysis|Correlative studies
75588109|NCT03453281|Drug|Aflibercept Injection [Eylea]|Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
75588110|NCT02219841|Procedure|radiofrequency catheter ablation|
75732368|NCT00732329|Behavioral|Occupational Therapy|"optimized home Based Occupational Therapy including:~diagnostic assessment~patient-centered definition of targets involving the care giver~occupational therapy"
75732369|NCT04644627|Drug|Gentamicin Sulfate|Topical gentamicin ointment on wounds once daily for 6 weeks
75732370|NCT02568761|Procedure|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
75732371|NCT02568761|Other|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
75732372|NCT00460408|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
75732373|NCT02569151|Device|HBP & CBP measurement using systo 130 mmHg|
75732374|NCT00732407|Drug|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
75732375|NCT00732407|Drug|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
75438489|NCT01599130|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
75438490|NCT01599143|Behavioral|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
75438491|NCT01599156|Procedure|Reflexology|Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
75438492|NCT01599169|Dietary Supplement|Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)|2 tablets/day after breakfast during 12 weeks
75438493|NCT01599169|Dietary Supplement|B-Back® placebo (without active compounds)|2 tablets/day after breakfast during 12 weeks
75438494|NCT01599195|Device|AudioDoc|AudioDoc will be used to identify the carotid and femoral bruit
75438495|NCT01599208|Device|TMS|TRANSCRANIAL MAGNETIC STIMULATION
75438496|NCT01599221|Device|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
76053478|NCT04091867|Drug|sEphB4-HSA with chemotherapy|sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
76053479|NCT04091867|Drug|Cetuximab|Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
75438497|NCT01599260|Other|Resistance Exercise|Two 30-minute individually supervised exercise sessions per week for 16-weeks
75438498|NCT01599273|Drug|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
75438499|NCT01599312|Device|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
75588111|NCT04553159|Biological|Autologous adipose derived stem cells|Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
75588112|NCT01642134|Drug|aspirin+clopidogrel (Duoplavin)|100 mg aspirin ;75 mg clopidogrel 3º months
75588113|NCT04552964|Other|Single arm|Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire
75588114|NCT03453086|Procedure|Thoracic paravertebral block(TPVB) group|"Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior"
75732376|NCT00507819|Drug|Sildenafil|One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
75732377|NCT00507819|Drug|Placebo|One placebo capsule will be taken by mouth three times-a-day.
75732378|NCT00738647|Procedure|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
75732379|NCT01566058|Device|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
75732380|NCT01566058|Other|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
75732381|NCT02569307|Drug|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
75732382|NCT02569307|Drug|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
75732383|NCT02569307|Drug|Placebo|Placebo added to TAU
75732384|NCT02569307|Drug|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
75882639|NCT02116010|Drug|E. coli Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
75882640|NCT02116010|Drug|Standard of care : Silver Sulfadiazine|Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
76053480|NCT04091867|Radiation|Radiation Therapy|6930 cGy IMRT starting D15-D18
76053481|NCT05652179|Drug|Stellate ganglion block|Before anesthesia induction, ultrasound-guided stellate ganglion block is performed, injecting 7 ml of 0.375% ropivacaine.
75732385|NCT01013103|Drug|Atorvastatin, high vs low dose|In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
75882641|NCT02116010|Drug|P. Aeruginosa, Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
76053482|NCT05652101|Other|collection of medical data|"The data collected concerns:~Sex~Age~Socio-professional category of patients or parents / level of education of the parents~Family history~Neonatal patient data (pregnancy, childbirth)~Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation)~Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years)~Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG))~Genetic data if available"
76053483|NCT05652101|Other|Vineland Adaptive Behaviour Scales (VABS2) questionnaire|"This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.~Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose."
76053484|NCT05290259|Other|Ballroom Dance|The Ballroom Basics for Balance Program is a dance focused exercise program developed by a Physical Therapist in the Madison area.
75438500|NCT01599338|Drug|Liraglutide|3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
75438501|NCT01599351|Radiation|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
75438502|NCT01599364|Drug|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
75732386|NCT01013103|Drug|Atorvastatin vs Placebo|In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
75732387|NCT00732485|Drug|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
75438503|NCT01599377|Drug|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
75732388|NCT00732485|Drug|placebo|Placebo, sugar pill, from admission to 6 months post burn
75732389|NCT01010919|Dietary Supplement|Chicory root extract|
75732390|NCT01566136|Behavioral|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
75438504|NCT01599377|Drug|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
75438505|NCT01599390|Other|Data collection|"The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.~Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted."
75732391|NCT02569073|Drug|Dronabinol|Dronabinol 5 mg, every other night, orally
75732392|NCT02569073|Drug|Placebo|Placebo--no drug
75732393|NCT03490084|Other|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
75732394|NCT03490084|Other|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
75732395|NCT00732563|Drug|chemotherapy|Given IV and Orally
75732396|NCT00732563|Procedure|lymphadenectomy|Removal of lymph nodes
75882642|NCT03609294|Drug|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
75882643|NCT03609294|Drug|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
75882644|NCT05214495|Drug|topical oral Omega-3 hydrogel|Topical oral Omega-3 hydrogel prepared from fish oil
75882645|NCT05214495|Drug|conventional preventive treatment|"topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)"
75882646|NCT03608904|Other|Music listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
75438506|NCT01599403|Procedure|Paravertebral Block|The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
75882647|NCT03608904|Other|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
75882648|NCT03551990|Procedure|whole-body electromyostimulation WB-EMS|Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
75882649|NCT03907917|Device|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
75882650|NCT01917552|Drug|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
75882651|NCT02120690|Device|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
75588115|NCT03453047|Diagnostic Test|S100β and Neuron specific enolase (NSE)|S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.
75588116|NCT02219880|Dietary Supplement|Kava (240mg of kavalactones per day)|Kava 60 milligrams per tablet = 240mg of kavalactones per day
75438507|NCT01599403|Procedure|Intercostal Nerve Block|The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
75732397|NCT00732563|Procedure|neoadjuvant therapy|Tumor reduction
75732398|NCT00732563|Procedure|quality-of-life assessment|Correlative Study
75732399|NCT00732563|Procedure|therapeutic conventional surgery|Treatment for cancer
75732400|NCT00732563|Procedure|thoracic surgical procedure|removal of tissue
75732401|NCT00732563|Radiation|fludeoxyglucose F 18|given IV
75732402|NCT00732563|Radiation|radiation therapy|undergoing radiotherapy
75732403|NCT03449667|Device|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
75732404|NCT03449667|Device|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
75732405|NCT00734123|Drug|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
75732406|NCT00734123|Drug|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
75882652|NCT02120768|Procedure|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
75882653|NCT02120846|Other|Flywheel leg-press resistance exercise|
75882654|NCT03833817|Behavioral|Talking about Cancer (TAC)|The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
75882655|NCT02116088|Behavioral|Teacher Coaching|
75882656|NCT05022771|Drug|PMG1015 Dose 1|Dose level 1 of PMG1015
75882657|NCT05022771|Drug|PMG1015 Dose 2|Dose level 2 of PMG1015
75588117|NCT02219880|Dietary Supplement|Placebo|Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
75588118|NCT04553042|Drug|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
75732407|NCT00734123|Drug|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
75588119|NCT01642173|Device|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
75732408|NCT00734123|Drug|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care"
75732409|NCT00734201|Drug|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
75438508|NCT01599403|Procedure|Epidural Block|The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
75438509|NCT01599416|Dietary Supplement|U-relax|Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
75438510|NCT05691153|Drug|ThisCART19A with Dose Level 1|ThisCART19A，2×10^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
75438511|NCT05691153|Drug|ThisCART19A with Dose Level 2|ThisCART19A，3×10^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
75732410|NCT00734279|Drug|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
75732411|NCT00734279|Drug|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
75732412|NCT00734279|Drug|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
75732413|NCT00734279|Drug|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
75732414|NCT00442936|Drug|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
75732415|NCT00442936|Drug|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
75732416|NCT00442936|Drug|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
75732417|NCT00442936|Drug|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
75732418|NCT00442936|Drug|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
75882658|NCT05022771|Drug|PMG1015 Dose 3|Dose level 3 of PMG1015
75438512|NCT05691088|Device|Paracetamol injection|"Patients were randomized to receive either paracetamol during mechanical ventilation. When patients were randomized to receive paracetamol (40 mg/kg per day in 4 doses), a placebo infusion of normal saline was administered continuously at the same rate as an equivalent infusion. Placebos could not be distinguished from the active study drug in color, odor, or viscosity.~In both study groups, IMV was maintained with sufentanil (0-0.2 mcg/kg/h), propofol (0-4 mg/kg/h), and dexmedetomidine (0-1 mcg/kg/h). Assessment of sedation levels by the bedside nurse using the FLACC pain scale to determine if the child is adequately comfortable or in need of more or less medication to maintain adequate ventilation. Assessment of sedation levels by the bedside nurse using the FLACC pain scale (every 6 hours as a minimum time interval)."
75588120|NCT02213432|Biological|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
75588121|NCT02219919|Other|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
75588122|NCT02219919|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
75588123|NCT01118299|Device|AMPLATZER Cardiac Plug|AMPLATZER Cardiac Plug is a percutaneous transcatheter device
75882659|NCT05022771|Drug|PMG1015 Dose 4|Dose level 4 of PMG1015
75882660|NCT05022771|Drug|PMG1015 Dose 5|Dose level 5 of PMG1015
75588124|NCT04552574|Dietary Supplement|HMR(Home meal replacement)-type omega-3-balanced diet|A diet of which omega-3 to omega-6 ratio is below 1:4 was developed by Agricultural entity Green Grass Co., Ltd.. A committee of experts that is composed of several university professors in authorities of IPET(Institute of Planning and Evaluation for Technology in food, agriculture and forestry) also participated in the development of this diet.
75588125|NCT01118143|Behavioral|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
75732419|NCT00442936|Drug|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
75732420|NCT00442936|Drug|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
75882661|NCT05022771|Drug|PMG1015 Dose 6|Dose level 6 of PMG1015
75882662|NCT05022771|Drug|Placebo|Placebo to match
76053485|NCT04818125|Other|Patients with breast cancer (stage I, II III or IV)|"Blood samples will be collected at different times:~at Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients);~at the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV)~For each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study."
75588126|NCT00581711|Other|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
75882663|NCT05022771|Drug|PMG1015 Dose 7|Dose level 7 of PMG1015
75732421|NCT00734357|Procedure|Blood work|Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
75882664|NCT02116400|Other|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
75732422|NCT04065503|Biological|Probiotic Strains|A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
76053486|NCT05651789|Drug|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure <90 mmHg.
75732423|NCT00732719|Device|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
75438513|NCT05691049|Device|Profhilo® Structura|"Dosage form: Profhilo® Structura (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2 ml non-pyrogenic pre-filled syringe, containing 2 ml of 4.5% hyaluronic acid for intradermal use (45 mg H-HA + 45 mg L-HA) dissolved in 1.5 ml of saline buffered sodium chloride.~The principal component of the medical device is Hyaluronic Acid of non-animal origin, produced by bacterial fermentation."
76053487|NCT05651789|Drug|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
76053488|NCT05651477|Device|Wearable Device (Smart Watch)|A smart watch refers to an embedded system portable watch equipped with improved functions than a general watch, and is almost always in the form of a wrist watch. The device we are using is the Samsung Galaxy 4 (SM-R860/870).
76053489|NCT05651477|Device|Edge-Box|Edge-Box collects data such as air. The device we are using is the TDS Mfepc-4C2R.
75732424|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
76053490|NCT02999477|Drug|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
75438514|NCT05691023|Device|Vivistim System|Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
75438515|NCT05690945|Drug|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
75732425|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
75732426|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
75732427|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
75732428|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
75732429|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
75882665|NCT02116400|Other|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
75438516|NCT05690945|Drug|Tilesizumab|Tilesizumab will be administered by IV infusion at 200mg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
75882666|NCT02116400|Biological|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
75882667|NCT02732184|Drug|Co-ArgI-PEG modified human arginase I|
75882668|NCT02121080|Drug|REGN2222(SAR438584)|
75882669|NCT02121080|Drug|placebo|
75882670|NCT03608592|Biological|umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
75732430|NCT01010997|Device|Foresee Home|using the Foresee home device
75438517|NCT05690867|Other|Starting with volume controlled ventilation and changing the ventilation mode every 20 minutes|group 1 starts with volume controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to pressure controlled ventilation after letting washout we take three consecutive measurements at pressure controlled ventilation and we will repeat this protocol during surgery
75438518|NCT05690867|Other|Starting with pressure controlled ventilation and changing the ventilation mode every 20 minutes|group 2 starts with pressure controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to volume controlled ventilation after letting washout we take three consecutive measurements at volume controlled ventilation and we will repeat this protocol during surgery
75438519|NCT05690802|Drug|Palonosetron hydrochloride capsules|"This protocol only stipulates Palonosetron capsule containing hydrochloric acid protocol, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage."
75438520|NCT05690711|Drug|HRS8179|HRS8179 injection
75438521|NCT05690711|Drug|Placebo|physiological saline
75438522|NCT05690620|Behavioral|laughter yoga|Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
75438523|NCT05690620|Other|Control|"The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied."
75438524|NCT05690607|Other|Doctors Laboratory TINIES small volume blood testing kit|Doctors Laboratory TINIES small volume blood testing kits comprise microcontainers manufactured by BD Diagnostics designed for sample collection from skin puncture, along with home testing pack with lancets, instructions and Royal Mail postal packs.
75438525|NCT05690568|Other|multimodal chiropractic care|functional movement score followed by intervention of multimodal chiropractic care including spinal/extremity manipulation and exercise recommendation
75438526|NCT05690542|Other|blood tests|evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;
75438527|NCT05690529|Procedure|Ablation|Radiofrequency AF ablatoon
75438528|NCT05690490|Procedure|Endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion with an offset of 2-5 mm. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
75438529|NCT05690490|Procedure|Endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision is made around the lesion. Then dissection will be performed in the submucosal layer.
75438530|NCT05690399|Radiation|Radiotherapy|Effect of radiotherapy on patients
75438531|NCT05690347|Behavioral|Back At work After Surgery (BAAS)|see protocol
75438532|NCT05690321|Drug|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
75438533|NCT05690321|Drug|Placebo|Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
75732431|NCT01011231|Procedure|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
76053491|NCT02999477|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
76053492|NCT02999477|Procedure|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
76053493|NCT02222558|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
75438534|NCT05690191|Drug|Chidamide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
75438535|NCT05690191|Drug|Lenalidomide|Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
75438536|NCT05690191|Drug|Rituximab|Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
75438537|NCT05690152|Device|EyeSimplify web-browser-based visual field test|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
75438538|NCT05690139|Procedure|Pre-operative LSG patients|Baseline
75438539|NCT05690139|Procedure|Post-operative patients 1st month|1 month after surgery
75588127|NCT00581711|Other|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
75588128|NCT00581711|Other|1-part intervention|Provision of feedback on otitis media quality indicators
75588129|NCT00581750|Other|Tissue specimen|Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
75588130|NCT00581789|Drug|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
75588131|NCT01642368|Other|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
75588132|NCT02213549|Dietary Supplement|Placebo|
75588133|NCT02213549|Dietary Supplement|Ume paste and ginger powder|
75588134|NCT01642446|Procedure|Precise hepatectomy|Precise hepatectomy
75588135|NCT01642446|Other|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
75882671|NCT03608592|Biological|normal saline|A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
75588136|NCT02213588|Dietary Supplement|AOX blend|Antioxidant supplement
75588137|NCT02213588|Dietary Supplement|Placebo|
76053494|NCT02975999|Drug|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
75588138|NCT01642524|Biological|hypertonic saline mixed Dextran|single dose administered intravenously
75588139|NCT01642524|Biological|Saline solution|placebo - saline solution
75588140|NCT02213705|Biological|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
75732432|NCT00738803|Procedure|Total hip replacement|Total hip replacement typically preformed for hip arthritis
75732433|NCT01013259|Drug|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
76053495|NCT02975999|Drug|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
75438540|NCT05690139|Procedure|Post-operative patients 3rd month|3 months after surgery
75438541|NCT05690139|Procedure|Post-operative patients 6th month|6 months after surgery
75588141|NCT02217228|Device|Sebacia microparticles and laser|
75732434|NCT01013259|Drug|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
75732435|NCT00732953|Device|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
75732436|NCT00732953|Device|Genous stent implantation|Genous stent implantation
75588142|NCT02217228|Device|Vehicle suspension and laser|
75588143|NCT02217228|Device|Sebacia microparticles without laser|
75588144|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
75588145|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
75588146|NCT01642563|Procedure|Platelet transfusion|One dose of pathogen reduced platelets
75732437|NCT00577655|Drug|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
75732438|NCT00577655|Drug|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
75732439|NCT00577655|Drug|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
75732440|NCT01013337|Procedure|acupuncture therapy|
75882672|NCT03552302|Behavioral|Yoga|"Yoga stretch warm-up exercise for 15 minutes.~Five kinds of yoga correction method for 30 minutes (abdominal breathing, throat breathing, wind box breathing, nasal alternating breathing, buzzing breathing).~Great rest for 15 minutes"
76053496|NCT05287529|Behavioral|Yoga Via Telehealth - Immediately|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
75438542|NCT05690022|Procedure|sleeve gastrectomy|Patients will be recruited for a sleeve gastrectomy according to the guidelines of the National Institute of Health.
75438543|NCT05689996|Drug|Ozone-Based Agent|Ozone-based eye drops as adjuvant therapy in microbial keratitis
75438544|NCT05689983|Drug|Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA|In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
75588147|NCT01642563|Procedure|Platelet transfusion|One dose of standard platelets
75588148|NCT01642680|Other|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
75588149|NCT01642680|Other|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
75588150|NCT00582101|Behavioral|Family-Based HIV Prevention for Latinos|7-hour one-day workshop with adolescents and parents in separate and joint sessions
75588151|NCT00582101|Behavioral|General Health Promotion|7 hour one-day workshop on general health promotion topics
75588152|NCT01642719|Behavioral|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
75588153|NCT01642719|Behavioral|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
75588154|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
75588155|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
75882673|NCT03827265|Device|repetitive transcranial magnetic stimulation (rTMS)|A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
76053497|NCT05287529|Behavioral|Yoga Via Telehealth - Waitlisted|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
76053498|NCT02188784|Drug|Polysaccharide Iron Complex 150 mg|Oral Iron
76053499|NCT02188784|Drug|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
75438545|NCT05689970|Diagnostic Test|AI platform to detect ST elevation in ECG|A clinical decision support software as a medical device that detects whether a patient has ST elevation due to acute myocardial ischemia or due to another etiology based upon the input of one or more ECGs and other clinical data obtained at the point-of-care.
75438546|NCT05689957|Drug|Deep neuromuscular block using intravenous rocuronium induction at 1.2mg/kg and maintainance of 8-12mcg/kg/min for deep neuromuscular block|both arm are using low pressure pneumoperitoneum in laparoscopic surgery, moderate and deep neuromuscular block are monitor with neuromuscular monitoring. if surgical condition is inadequate, surgeon are allowed to increase intraabdominal pressure as per standard care
75438547|NCT05689931|Biological|Mepolizumab|"Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.~Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)"
75438548|NCT05689931|Drug|Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)|Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
75438549|NCT05689918|Other|No intervention|No intervention
75438550|NCT05689905|Diagnostic Test|HLA typing of the children|The HLA typing is made on a mouth swab of the children, that is a painless non-invasive procedure.
75438551|NCT05689801|Other|"Questionnaire recovery time after a dialysis session."|A very short questionnaire just after the dialysis session
75438552|NCT05689801|Other|SF-12 questionnaire|Questionnaire about quality of life of the patient
75438553|NCT05689801|Other|EQ-5D-5L Questionnaire|Questionnaire about quality of life of the patient
75438554|NCT05689801|Other|Pittman, John et McIntyre questionnaire|Questionnaire about quality of life of the patient under dialysis
75588156|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
75588157|NCT01642758|Drug|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
75588158|NCT00582179|Procedure|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
75588159|NCT00582179|Device|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
75588160|NCT01642797|Device|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
75588161|NCT01642797|Device|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
75732441|NCT01013337|Procedure|sham intervention|Placebo acupuncture
75732442|NCT04514679|Behavioral|Healthy Lifestyles Program|Regular group visits with a health coach in addition to routine dietician and clinician visits, reviewing successes and challenges from the previous session as well as data collected through self-monitoring
75882674|NCT02720718|Device|Stratafix|
75882675|NCT02720718|Device|Vicryl|
75882676|NCT02123732|Dietary Supplement|DbXell|
75438555|NCT05689801|Procedure|Conventional hemodialysis|patient on polyethersulfone membrane dialysis (Revaclear®, Baxter) with HemoControl™ for 12 weeks
75882677|NCT02123732|Dietary Supplement|Placebo|
75882678|NCT04059588|Drug|2141 V-11|intratumoral injection of 2141-V11
75882679|NCT02123810|Other|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
75882680|NCT03119701|Drug|Interferon Beta-1A|Lyophilisate for solution for injection.
75882681|NCT03119701|Drug|Placebo|Lyophilisate for solution for injection as placebo.
75882682|NCT03717129|Drug|Genvoya Oral dose|Single Genvoya oral dose directly observed
76053500|NCT02900339|Device|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
76053501|NCT02848781|Device|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
76053502|NCT02848781|Procedure|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
76053503|NCT02222246|Drug|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
75438556|NCT05689801|Procedure|Optimized hemodialysis|patient on Medium Cut-Off membrane dialysis (Theranova®, Baxter) with HemoControl™ for 12 weeks.
75438557|NCT05689775|Procedure|Reconstruction with robot-assisted rectus abdominis muscle flap|Reconstruction of perineum and/or vagina with robot-assisted rectus abdominis muscle flap.
75438558|NCT05689723|Procedure|Lumbar manipulation|Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
75438559|NCT05689723|Procedure|Sham Manipulation|The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
75438560|NCT05689697|Dietary Supplement|PanTrek|administration of exogenouse keton body
75438561|NCT05689645|Drug|F573 for injection|"The first stage: DILI patients were given doses of 0.5, 1.0, 2.0mg/kg. The dose for CHB patients was determined based on the efficacy and safety test results of DILI patients. The dosages of the second and third stages were determined according to the results of the first stage. The dosage volume was 2mL for intramuscular injection.~Medication course: The first and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 consecutive days"
75882683|NCT03717129|Drug|Genvoya Crushed Dose|Single Genvoya crushed tablet in water directly observed
75882684|NCT03551912|Procedure|Surgery|All patients coming for elective surgery
75882685|NCT02116478|Procedure|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
75882686|NCT02123888|Radiation|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
75882687|NCT03627039|Drug|SGLT2|All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)
75882688|NCT03627039|Drug|Metformin|Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
75882689|NCT01374373|Biological|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
75882690|NCT02116556|Drug|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
75882691|NCT02116556|Drug|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
75882692|NCT03634345|Drug|Period 1 - Day 1: PF-04965842 administered|Period 1: Single administration of 100 mg PF 04965842.
75882693|NCT03634345|Drug|Period 2: Cohort 1: Fluvoxamine & PF-04965842|Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
75882694|NCT03634345|Drug|Period 2: Cohort 2: Fluconazole & PF-04965842|Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
75882695|NCT02116634|Biological|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
75882696|NCT02906137|Other|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
75882697|NCT02121314|Drug|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
75882698|NCT04987359|Behavioral|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling.
75882699|NCT05760859|Other|Initial cue|"Symptom volunteered by the patient"
75882700|NCT03553238|Drug|Chidamide|Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
75882701|NCT03553238|Drug|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
75882702|NCT03553238|Drug|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
75438562|NCT05689645|Drug|Sterilizing water for injection|"The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days."
75588162|NCT04552379|Biological|Peginterferon beta-1a|"Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at ~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use."
75588163|NCT02215668|Procedure|Physical exercise|Exercise muscle stretching and body warming.
75588164|NCT01642836|Behavioral|MMM|"a theory-based community team sports program designed specifically for overweight and obese children,~a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~a primary care provider behavioral counseling intervention linked to the community and home interventions."
76053504|NCT02222246|Drug|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
76053505|NCT02222246|Drug|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
75588165|NCT01642836|Behavioral|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~notification of primary care providers about metabolic measures and blood pressure~state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
75588166|NCT01117987|Drug|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
76053506|NCT02222246|Drug|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
76053507|NCT04793555|Other|Monitoring by unobtrusive sensors|During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
76053508|NCT02188160|Drug|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
75438563|NCT05689632|Dietary Supplement|Vitamin D3 + K2-MK7|Combined supplementation
75438564|NCT05689632|Dietary Supplement|Placebo|MCT
75438565|NCT05689632|Dietary Supplement|Vitamin D3|Vitamin D3 - 7000 IU
75438566|NCT05689606|Behavioral|Exercise|Exercise includes acute high-intensity interval training.
75438567|NCT05689580|Dietary Supplement|Ketogenic diet|The course of the trial to medium-chain triglyceride lipid intervening 50-70% of dietary intake
75438568|NCT05689580|Dietary Supplement|Balanced diet|Balanced diet
75588167|NCT01117987|Drug|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
75588168|NCT02215902|Device|Affinity plasmapheresis|Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
76053509|NCT02188160|Drug|Placebo|Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
75588169|NCT02213822|Other|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
75588170|NCT01117870|Other|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
75438569|NCT05689554|Behavioral|STOP Falls Educational Intervention|This is a pragmatic, cluster-randomized, parallel-group, controlled clinical trial. The unit of randomization is the clinic, to avoid the risk of contamination if healthcare providers within a clinic were randomized (i.e., reducing the potential for intervention providers to communicate with control providers about the intervention and share materials). Eighteen clinics were identified for the trial, of which 9 were randomized to the intervention and 9 to usual care.
75438570|NCT05689515|Behavioral|Mobile health app|A mobile app provided to participants to assess effectiveness in managing HIV
75882703|NCT03553238|Drug|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
75882704|NCT03553238|Drug|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
76053510|NCT04190030|Behavioral|mindfulness training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
76053511|NCT04190030|Behavioral|cognitive reappraisal training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
75588171|NCT01117870|Other|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
75588172|NCT01642875|Other|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
75588173|NCT01642875|Other|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
75588174|NCT01117792|Device|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
76053512|NCT03991949|Other|Experimental Infant Formula|Formula fed Ad libitum
76053513|NCT02220998|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
75588175|NCT04552184|Other|GPOEM|gastric per oral endoscopic pyloromyotomy
75588176|NCT04552184|Other|SHAM Procedure|intrapyloric injection of saline solution
75588177|NCT02219490|Drug|ABT-450/r/ABT-267|Tablet for oral use
75588178|NCT02219490|Drug|ABT-333|Tablet for oral use
75588179|NCT02219490|Drug|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing < 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
75588180|NCT04310722|Other|None intervention. This is an observational study.|None intervention. This is an observational study.
75882705|NCT03553238|Drug|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
75882706|NCT03553238|Drug|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
75882707|NCT03553238|Drug|Methotrexate|Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
75882708|NCT03553238|Drug|6-Mercaptopurine|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
75882709|NCT03553238|Drug|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
75882710|NCT03553238|Drug|Cytarabine|AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
75882711|NCT03553238|Procedure|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
76053514|NCT02220998|Drug|SOF|SOF 400 mg tablet administered orally once daily
75588181|NCT04310605|Behavioral|CBT 1|CBT for tinnitus (Step 1) comprised: individual audiometric assessment, and counselling about hearing and tinnitus (1hr) with an audiologist; a one-off educational group session (a max 10 participants and partners) (2hrs); an assessment session with a psychologists (1 hr).
75588182|NCT04310605|Behavioral|CBT 2|Step 2 group sessions were 2 hrs long over a 12-week period. Two therapists (a psychologist and physiotherapist) were present at any one time for Step 2 sessions. Step 2 included: psycho-education; exposure therapy; mindfulness exercises; cognitive restructuring; attention redirecting techniques; stress reduction; and, relaxation techniques. Evening sessions were also provided for participants to attend with family or partners.
75438571|NCT05689489|Other|Puzzle Method|While preparing the puzzle to be used in the study, the puzzle preparation program will be used (Crossword Puzzle Maker). Students in the initiative group will be asked to solve a total of 6 puzzles, one puzzle each week. The answers to the prepared puzzles will cover the theoretical course topics of psychiatric nursing. In the puzzles, students will be expected to place their answers in the specified rows and columns. Students will be asked to solve puzzles individually. In addition, the answer to each puzzle will be found on the reverse on the back page. Students will be reminded that there is no time limit for solving the puzzles. Researchers will guide students while students solve puzzles.
75588183|NCT01117051|Drug|placebo|placebo
75588184|NCT01117051|Drug|prucalopride|1 or 2 mg prucalopride once daily before breakfast
75588185|NCT01642953|Dietary Supplement|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
75732443|NCT04514679|Behavioral|Obesity Medicine Program|A tailored approach to obesity care for patients including individual dietician and health coach visits as appropriate.
75882712|NCT03553238|Procedure|Intrathecal injection|Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
75882713|NCT03553238|Radiation|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
76053515|NCT02220998|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75438572|NCT05689489|Other|Ongoing Education|Students in the control group will only take the theoretical course of psychiatric nursing.
75882714|NCT03553238|Genetic|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
75732444|NCT00733031|Drug|AZD6918|liquid suspension, daily, oral dose
76053516|NCT02220920|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 16 weeks
76053517|NCT02220920|Drug|Placebo|The patients will receive Placebo orally for 16 weeks
75438573|NCT05689437|Other|Application of ILD prediction machine learning model to planning imaging|The ILD prediction machine learning model will be applied to the treatment planning imaging of lung cancer patients receiving radiation therapy (RT). The model will score the risk as high risk or low risk for having underlying ILD.
75732445|NCT00733031|Drug|gemcitabine|intravenous, doses are on an intermittent schedule
75732446|NCT00733031|Drug|pemetrexed|intravenous, dose administered every 21-days
75732447|NCT00734669|Drug|Glibenclamide|Taking a single dose of 3.5 mg glibenclamide
75732448|NCT00738959|Drug|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
76053518|NCT02220920|Drug|Insulin|
75732449|NCT00113269|Drug|basiliximab|IV
75732450|NCT00113269|Drug|rabbit anti-thymocyte globulin|IV
75882715|NCT03553238|Procedure|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
75882716|NCT03553238|Diagnostic Test|Flow-MRD|Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
75882717|NCT03553238|Diagnostic Test|FISH|FISH will be performed in PDT-ETP-ALL for bone marrow samples.
75882718|NCT03553238|Diagnostic Test|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.
75882719|NCT03553238|Diagnostic Test|Karyotyping|Karyotyping will be performed in PDT-ETP-ALL protocol.
76053519|NCT03966053|Drug|Trifluoperazine|Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
76053520|NCT05204693|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
76053521|NCT05204693|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
76053522|NCT03949829|Diagnostic Test|Cardiovascular CT|Cardiac and cardiovascular non-contrast and contrast CT
76053523|NCT03946631|Diagnostic Test|2 hour glucose tolerance test using 75g glucose drink|intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
75588186|NCT05360173|Behavioral|acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating on the patient's arm and leg.
75588187|NCT05360173|Behavioral|sham acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating at about 3 cm next to the acupoint on the patient's arm and leg.
75588188|NCT04577105|Diagnostic Test|Simple chest tomography|The images were acquired with a Siemens 256-slice multidetector tomograph (SOMATOM DEFINITION FLASH 128x2) following the recommended parameters for low-dose simple chest tomography. The chest topogram was acquired using 35 mA, 100 Kv, and 6 mm slices, then the chest tomographic slices holding inspiration in a cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, a pitch of 1, and slices 1 mm with a total of 110 DLP, which is calculated with the conversion factor for thorax a total of 1.5 mSv. Multiplanar reconstructions with Kernel filters B26f, B50f, and B70 for mediastinum and lung, respectively, at 1 mm slices.
75588189|NCT02211417|Drug|Oral DS107|
75732451|NCT00113269|Drug|tacrolimus|oral
75732452|NCT00113269|Drug|alemtuzumab|Intravenous (IV)
76053524|NCT05203133|Dietary Supplement|Energy Balance|Energy balance phase to elicit weight-maintenance
75588190|NCT02211417|Drug|Placebo|
75588191|NCT00582413|Behavioral|questionnaires|Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
75588192|NCT00582452|Other|Telephone survey|Telephone survey
75732453|NCT00113269|Drug|mycophenolate mofetil|oral
75732454|NCT00113269|Drug|steroids|IV and/or oral
75732455|NCT04065269|Drug|AZD6738|ATR inhibitor
75438574|NCT05689437|Other|Routine, automatic presentation of ILD risk level for evaluation by the clinician.|Participating clinicians will be provided with an ILD risk estimate for all lung cancer patients receiving RT who are deemed potentially high-risk based on the model. In these cases, the clinician will receive an email identifying the patient medical record number (MRN) and 'potential high-risk for ILD' flag. Clinicians will then be able to decide whether, based on the information, they want to reassess the patient for ILD prior to starting treatment. Clinicians will also be presented with a short survey each time they are sent an email for a potential high-risk for ILD case so the study team can better understand how that information was used, if at all.
75588193|NCT02279121|Device|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
75588194|NCT02279121|Drug|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
75732456|NCT04065269|Drug|Olaparib|PARP inhibitor
75732457|NCT00515619|Drug|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
75732458|NCT00733109|Procedure|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
75732459|NCT00733109|Other|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
75732460|NCT00733187|Drug|ABT-869|0.25 mg/kg
76053525|NCT05203133|Dietary Supplement|Energy Deficit|Energy deficit phase to elicit weight-loss
75732461|NCT00449644|Drug|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
75732462|NCT00449644|Drug|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
75732463|NCT00449644|Drug|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
76053526|NCT05203133|Dietary Supplement|Baseline Assessment|Free-living assessment of energy status
76053527|NCT04791293|Other|MELD-Na score|MELD-Na scores will be compared between the groups
76053528|NCT02710721|Other|Fasting|Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.
76053529|NCT02710721|Other|Control|Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
76053530|NCT02673905|Other|Tissue Engineered Product|Implantation of tissue engineered products
76053531|NCT04790279|Drug|Amlodipine|Initiation of amlodipine 2.5 mg
76053532|NCT04790279|Drug|NIFEdipine ER|Initiation of nifedipine ER 30 mg
76053533|NCT02610023|Other|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
76053534|NCT02610023|Other|Laboratory Biomarker Analysis|Correlative studies
76053535|NCT02610023|Device|Spectroscopy|Undergo resonance Raman spectroscopy
75732464|NCT00515541|Drug|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
75732465|NCT00733265|Drug|AZD6140|single oral dose
75732466|NCT03462628|Procedure|CPVI plus low-voltage substrate modification|CPVI plus low-voltage substrate modification in the left atrium during SR
75732467|NCT03462628|Procedure|CPVI alone|circumferential pulmonary vein isolation
75882720|NCT04980027|Drug|Insulin glargine (U300)|Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
75882721|NCT01373593|Drug|lidocaine|
75882722|NCT01373593|Drug|Placebo|
75438575|NCT05689437|Other|Application of SGR machine learning model to diagnostic and planning imaging|The SGR machine learning model will be applied to the imaging of lung cancer patients with node negative lung cancer receiving stereotactic RT. The automatic calculation will compare target lesions on the patient's diagnostic images with those same lesions on treatment planning images.
75588195|NCT04576520|Procedure|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
75588196|NCT04576520|Procedure|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
75438576|NCT05689437|Other|Routine estimation of tumor specific growth rate (SGR) for lesions being considered for radiation therapy presented to clinician.|Participating clinicians will be provided with an SGR calculation for each lung cancer patient with node negative lung cancer receiving stereotactic RT. This SGR calculation will be presented to clinicians, who will then be able to decide, based on the information, how they want to address and track a patient's overall survival and failure free survival. Clinicians will also be presented with a short survey each time they are provided with a patient's SGR calculation so the study team can better understand how that information was used, if at all.
75588197|NCT02218164|Drug|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
75588198|NCT02218164|Drug|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
75732468|NCT00112489|Drug|carboplatin|
75732469|NCT00112489|Drug|paclitaxel|
75732470|NCT03666598|Device|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
75732471|NCT01023100|Drug|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
75732472|NCT00711971|Drug|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
75732473|NCT00711971|Drug|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
75732474|NCT00711971|Drug|placebo|control arm
75732475|NCT01078831|Other|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
75882723|NCT04611477|Other|Rice Hulk|Placebo
75882724|NCT04611477|Other|Synbiotic365 Ver 5|Active Comparator
75882725|NCT04611477|Other|Synbiotic365 Ver 7|Active Comparator
75882726|NCT02116712|Drug|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
75882727|NCT02116790|Drug|Naproxen|Subjects will take one 250mg Naproxen capsule
75882728|NCT02116790|Drug|Sinemet|Subjects will take one 12.5mg/50mg Sinemet.
75882729|NCT02116790|Drug|Sinemet|Subjects will take one 25mg/100mg Sinemet.
75882730|NCT02116790|Drug|Placebo|Subjects will take two placebos.
75588199|NCT02218164|Drug|5-FU|If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
75588200|NCT01643109|Other|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
75438577|NCT05689437|Other|Application of CBCT machine learning model to on-treatment imaging|The CBCT machine learning model will be applied to on-treatment imaging as part of routine care for patients with node positive lung cancer receiving standard RT. An indicator of lung density changes will be calculated automatically by comparing cone beam CTs (CBCTs) completed prior to each treatment.
75588201|NCT04552106|Dietary Supplement|3 caps x3/day|3 capsules 3 times daily for 28 days
75732476|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
75732477|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
75732478|NCT00739037|Drug|Placebo|
75732479|NCT00739037|Drug|PAZ-417|
75732480|NCT01080157|Device|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
75882731|NCT04675489|Other|Procedure: Vivity Toric IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
75882732|NCT04935021|Drug|ATTR-CM|Current treatment
75882733|NCT02859961|Drug|PRO 140 (350 mg)|PRO 140 350 mg (175 mg/mL) SC injection per week
75882734|NCT02859961|Drug|PRO 140 (525 mg)|PRO 140 525 mg (175 mg/mL) SC injection per week
75882735|NCT02859961|Drug|PRO 140 (700 mg)|PRO 140 700 mg (175 mg/mL) SC injection per week
75882736|NCT02124200|Device|EGO/CE4, 9mg nicotine|
75882737|NCT02124278|Drug|PUL-042 Inhalation Solution|
75588202|NCT04552106|Dietary Supplement|3 caps x2/day|3 capsules 2 times daily for 28 days
75588203|NCT04552106|Dietary Supplement|2 caps x3/day|2 capsules 3 times daily for 28 days
75588204|NCT04552106|Dietary Supplement|2 caps x2/day|2 capsules 2 times daily for 28 days
75588205|NCT04552106|Dietary Supplement|3 caps x1/day|3 capsules 1 times daily for 28 days
75588206|NCT04552067|Drug|Lovenox|patients given curative dose of Lovenox
75588207|NCT04552067|Drug|Enoxaparin|patients given curative dose of Enoxa
75732481|NCT03902483|Device|renal doppler ultrasound|renal doppler ultrasound measuring renal resistive index
75732482|NCT01080235|Other|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
75732483|NCT01080235|Other|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
75732484|NCT00734825|Other|Omnipaque|oral contrast for CT scan
75732485|NCT01080313|Other|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
75732486|NCT00739115|Other|Heliox gas|Heliox gas used in conjunction with nasal CPAP
75732487|NCT01082731|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
75732488|NCT01082731|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
75732489|NCT00739193|Drug|amiodarone|
75882738|NCT04503993|Other|Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody|The hepatitis B tests are released into the electronic medical charts of at-risk patients who have never been screened for chronic hepatitis B using population health tools.
75588208|NCT01643187|Dietary Supplement|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
75588209|NCT01643187|Dietary Supplement|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
75588210|NCT01643265|Dietary Supplement|Whey Milk Protein|20 grams of Whey Milk Protein
75732490|NCT01011543|Procedure|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
75732491|NCT00733577|Drug|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
75732492|NCT03997461|Device|BPro|BPro and Oscar 2 comparison for 24 hours
75882739|NCT02116868|Device|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
75438578|NCT05689437|Other|Routine monitoring of lung density changes during the course of treatment presented to clinician.|Participating clinicians will be provided with a daily indicator of lung density changes for each patient with node positive lung cancer receiving standard RT. This measurement will be presented to the clinical team, who will then be able to decide, based on the information, how they want to address and track relevant outcomes such as pneumonitis. Additionally, this information may provide the clinical team with feedback about the lung reaction occurring as a result of treatment. Density changes will be documented and monitored for future validation studies, which are outside of the scope of this application.
75882740|NCT02116868|Drug|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
75882741|NCT02116868|Drug|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
75882742|NCT02679781|Drug|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
75882743|NCT02679781|Drug|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
75438579|NCT05689372|Drug|Semaglutide|Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.
75882744|NCT03551834|Other|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
75588211|NCT01643265|Dietary Supplement|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
75588212|NCT04551833|Drug|Levobupivacaine|Tramadol versus Dexamethasone as adjuvant to Levobupvacain
75588213|NCT01643304|Behavioral|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
75732493|NCT00739271|Other|Early feeding|
75732494|NCT00739271|Other|late feeding after bowel sounds return|Traditional method
75732495|NCT04513977|Other|Geriatric Oncology Supportive Clinic|Patients will undergo Comprehensive Geriatric Assessment with subsequent tailored intervention based on deficits identified. Comprehensive palliative assessment for any symptom burden and symptommatic treatment will be done as well.
75732496|NCT00735059|Device|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, > 3 hours
75732497|NCT00735059|Device|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, > 3 hours
75882745|NCT03551834|Other|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
75882746|NCT03633877|Device|DuraporeTM and Hy-Tape®|Medical tapes
75882747|NCT02124356|Other|Evaluation of functional performance|
75732498|NCT00735137|Device|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
75732499|NCT04064255|Other|Practical Body Image (session 1 - 7)|Practical body image therapy
75732500|NCT04064255|Other|Practical Body Image (session 8 - 14)|Twice weekly mirror exposure plus ending session
75732501|NCT00733733|Drug|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
75732502|NCT00733811|Drug|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
75588214|NCT00582686|Procedure|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
75588215|NCT00582686|Procedure|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
75588216|NCT04551755|Drug|Ivermectin and Doxycycline|"Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes"
75588217|NCT04551755|Other|Placebo|Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
75588218|NCT01640106|Dietary Supplement|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
75588219|NCT01640106|Dietary Supplement|Placebo|Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
75588220|NCT01643421|Other|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
75588221|NCT04552028|Other|Non invasive oxygenation|To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.
75588222|NCT01643499|Drug|oxaliplatin|Given IV
75588223|NCT01643499|Drug|irinotecan hydrochloride|Given IV
75588224|NCT01643499|Drug|leucovorin calcium|Given IV
75588225|NCT01643499|Drug|fluorouracil|Given IV
75588226|NCT01643499|Other|laboratory biomarker analysis|Correlative studies
75588227|NCT00582725|Drug|R-CHOP+GM-CSF|addition of GM-CSF
75588228|NCT01643538|Behavioral|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
75588229|NCT01643538|Behavioral|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
75732503|NCT00733811|Drug|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
75732504|NCT00739505|Biological|Asfotase Alfa|"The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC."
75732505|NCT00739505|Biological|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
75732506|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 16 weeks
75588230|NCT01643538|Behavioral|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
75588231|NCT01643538|Behavioral|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
75588232|NCT00582764|Other|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
75588233|NCT01640145|Dietary Supplement|Protein|Whey protein intake
75438580|NCT05689320|Other|Behavioral: EMA-based intervention|This study will compare the effect of fixed and incremental incentive strategies on compliance rates. All participants will be promised a basic incentive. An additional gift voucher will be given to intervention group participants who comply with the intervention at least 85% of the time, whereas a basic incentive will only be given to control group participants.
75438581|NCT05689242|Drug|Dexmedetomidine Injection [Precedex]|intravenous dexmedetomidine for group I and nalubphine for group II in colposcopy
75588234|NCT01640145|Other|Exercise|Unilateral low intensity exercise
75882748|NCT04475133|Other|Ultrasound guided percutaneous neuromodulation|It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
75588235|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
75588236|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
75588237|NCT04551794|Behavioral|Selfapy with therapeutic guidance|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.
75732507|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 8 weeks
75732508|NCT00920777|Behavioral|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
75732509|NCT00507507|Drug|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
75732510|NCT00507507|Drug|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
75732511|NCT00507507|Drug|Placebo|Placebo to match FTC taken once daily
75882749|NCT02251730|Behavioral|Smoking cessation|Refer for smoking cessation
75882750|NCT02121548|Behavioral|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
75882751|NCT02121548|Behavioral|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
75882752|NCT02121704|Device|Magnetic Endoscope Imaging (Scope Guide)|
75732512|NCT00540761|Device|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
75732513|NCT00459706|Device|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
75732514|NCT00459706|Device|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
75732515|NCT00735293|Device|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
75732516|NCT02568527|Device|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
75732517|NCT00735527|Drug|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
75732518|NCT00735527|Drug|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
75882753|NCT04373031|Drug|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
75438582|NCT05689229|Drug|Colistin|COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
75438583|NCT05689216|Behavioral|Awake timed prone and repositioning|"Patients were instructed to adopt a timed prone and repositioning strategy with 4 sessions for four consecutive days.~Session 1, lying on the belly; Session 2, lying on the right side; Session 3, sitting up; Session 4, lying on the left side; then back to session 1 (30 minutes to two hours for each session). The daily duration of timed prone and repositioning is strongly recommended for 8-10 hours."
75438584|NCT05689203|Drug|QLS1128|dose 1
75588238|NCT04551794|Behavioral|Selfapy with additional peer support|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
75588239|NCT01643577|Procedure|Acupuncture for gastroparesis|A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
75588240|NCT01643577|Procedure|Acupuncture for musculoskeletal pain|Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
75588241|NCT01117012|Drug|Ivacaftor|
75588242|NCT01640262|Other|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
75588243|NCT04551209|Procedure|Maintaining apical patency|In apical patency group, a size 10 K file will be passed beyond the apical foramen between each instrument change to maintain apical patency while in Non apical patency group, K file will be carried up to the working length only. A final peri-apical radiograph will be taken in the group A with the 10 K patency file 01mm beyond the apical foramen to confirm patency.
75588244|NCT01640418|Device|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
75732519|NCT00735605|Other|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
75588245|NCT01116739|Device|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
75588246|NCT01116739|Behavioral|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
76053536|NCT03877289|Drug|Oxybutynin|Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
75438585|NCT05689203|Drug|QLS1128|dose 2
75438586|NCT05689203|Drug|Placebo|Placebo
75588247|NCT01116739|Other|Dental services delivered by the Indian Health Service.|
75438588|NCT05688046|Drug|Immune checkpoint inhibitors plus angiogenesis inhibitors|PD-(L)1-based therapy plus Bevacizumab or Anlotinib
75438589|NCT05688046|Drug|Immune checkpoint inhibitors without angiogenesis inhibitors|PD-(L)1-based therapy
75438590|NCT05687812|Dietary Supplement|Cephalaria Syriaca flour-added bread|100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH).
75438591|NCT05686252|Other|Held Position|Change in angle of held position during kangaroo mother care to alternative angle
75438592|NCT05684471|Procedure|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients in this group will be administered SFIB with 50 mL of local anesthetic solution (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
75588248|NCT01116544|Device|AMES Therapy (assisted movement and enhanced sensation)|Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
75588249|NCT01640496|Drug|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
75588250|NCT01640496|Other|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
75588251|NCT04551443|Biological|Intravenous infusion placebo|Intravenous infusion placebo or WJMSCs in patients with AMI
75588252|NCT04551443|Biological|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with AMI
75882754|NCT04373031|Drug|IRX 2|IRX-2, is a cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.
75882755|NCT02116946|Biological|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
75438593|NCT05684471|Procedure|Ultrasound Guided Anterior Quadratus Lumborum Block|Patients in this group will be administered anterior QLB with 40 mL of local anesthetic (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
75588253|NCT01643655|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
75588254|NCT04551248|Biological|10 or 13-valent pneumococcal conjugate vaccine|a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
75882756|NCT02116946|Other|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
75438594|NCT05680246|Device|DHOPE-PRO|Prolonged DHOPE preservation >4 hours
75588255|NCT04551248|Biological|23-valent pneumococcal polysaccharide vaccine|Single 0.5-mL dose administered intramuscularly or subcutaneously only.
75588256|NCT04551248|Biological|Influenza vaccine|One dose of trivalent influenza vaccine in flu seasons.
75882757|NCT02624869|Biological|Evolocumab|Administered by subcutaneous injection
76053537|NCT03877289|Other|"Orasweet Liquid Placebo"|A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
75438595|NCT05678140|Device|soft tissue mobilization|soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
75588257|NCT01643733|Device|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
75588258|NCT02214056|Other|Patient recruitment|Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.
75588259|NCT02214056|Procedure|Mobile team exam|"Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:~questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).~At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations."
75588260|NCT04529382|Diagnostic Test|Cognitive testing (Bayley III, WPPSI III and WISC V)|Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
75732520|NCT00735605|Procedure|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
75882758|NCT03553160|Other|Frequent Self-Weighing|Were given scales to weigh themselves daily. Change in weight was measured at the beginning and end of the two year observation period.
75438596|NCT05678140|Other|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
75588261|NCT04550819|Procedure|intraintestinal extended biliary stents|The test group will be placed intraintestinal extended biliary stents in intrahepatic bile duct in ERCP
75588262|NCT04550819|Procedure|ordinary plastic biliary stents|The test group will be placed ordinary plastic biliary stents in intrahepatic bile duct in ERCP
75732521|NCT00735605|Other|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
75438597|NCT05674552|Drug|Exogenous ketone ester|500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
75732522|NCT05741255|Behavioral|Acceptance and Commitment Therapy|type of mindful psychotherapy that helps you stay focused on the present moment and accept thoughts and feelings without judgment. It aims to help you move forward through difficult emotions so you can put your energy into healing instead of dwelling on the negative.
75732523|NCT05741177|Diagnostic Test|lung ultrasound|lung ultrasound score
75882759|NCT02121782|Biological|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
75882760|NCT02121782|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
75882761|NCT02117102|Other|Bladder and lumbar stimulation technic|
75588263|NCT01640535|Drug|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
75588264|NCT01640535|Drug|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
75588265|NCT01640535|Drug|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
75588266|NCT04550936|Drug|Isavuconazole|antifungal agent
75588267|NCT04550858|Drug|Rebamipide|rebamipide use for ttt of h.pylori infection
75588268|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
75588269|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
75588270|NCT01640574|Drug|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
75588271|NCT01640574|Drug|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
75732524|NCT05741099|Biological|Umbilical cord mesenchymal stem cells implantation|Patient in Mscs group will receive MSCs implantation by intravenous injection.
76053538|NCT03877289|Drug|Antibiotics|"All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin."
76053539|NCT03877055|Drug|Copanlisib|Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
75588272|NCT04550975|Other|Advanced Cognitive Stimulation Therapy|An adapted version of Cognitive Stimulation Therapy for people with moderate to severe dementia.
76053540|NCT03877055|Drug|Ibrutinib|Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
75732525|NCT05741099|Other|Comparator|Patients in comparator group will receive placebo treatment
75588273|NCT01643811|Procedure|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
75588274|NCT01643811|Procedure|Endoscopic submucosal dissection|endoscopic submucosal dissection
75588275|NCT01116427|Biological|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
75588276|NCT01116427|Drug|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
75588277|NCT04550897|Drug|BM7PE|BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.
76053541|NCT04194047|Other|Transfusion|RBC transfusion (1 unit)
76053542|NCT04194047|Other|Crystalloids infusion|Infusion of 500 ml of balanced crystalloids
75588278|NCT04529226|Drug|Clozapine|Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
75732526|NCT04063475|Drug|cyanoacrylate tissue adhesive beside sutures|using cyanoacrylate tissue adhesive for FGG fixation
75588279|NCT04529226|Drug|haloperidol, pimozide, olanzapine, risperidone, amisulpride|Treatment as usual using first-generation or second-generation antipsychotics
75588280|NCT04310683|Other|natural cycle for endometrium preparation|patients will not use oral contraceptive drugs
75588281|NCT04310683|Other|hormone replaced cycle for endometrium preparation|patients will receive oral contraceptive drugs for menstruation before embryo transfer
75588282|NCT04550702|Drug|Mirabegron 25mg|Mirabegron 25 mg per day
76053543|NCT04792151|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
75588283|NCT01116232|Biological|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
75588284|NCT01116232|Biological|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
75588285|NCT01116232|Drug|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
75588286|NCT01116232|Drug|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
75588287|NCT01116232|Other|laboratory biomarker analysis|laboratory biomarker analysis
75588288|NCT01116232|Procedure|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
75588289|NCT01116232|Procedure|management of therapy complications|management of therapy complications
75588290|NCT01116232|Procedure|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
75588291|NCT04310527|Drug|Enasidenib|Enasidenib
75732527|NCT00735683|Drug|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
75732528|NCT00735683|Drug|Placebo|includes diet, physical activity, and lifestyle modification
75438598|NCT05673473|Radiation|scoliosis radiographs|Low dose fluoroscopic imaging technique for scoliosis x-rays
75438599|NCT05670847|Drug|Exogenous ketone ester|500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
75588292|NCT04550663|Drug|KD-025 CAR-T cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
75588293|NCT01115998|Other|Power wheelchair|Children used power wheelchairs for one year. They continued to receive their usual early intervention services.
75588294|NCT01115998|Other|No power wheelchairs|Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
75588295|NCT04528914|Other|Low-FODMAP diet|The low-FODMAP diet will contain the amount of FODMAPs that will not exceed the cut-offs for each FODMAP sugar per serving of food per sitting. Diets will be individually tailored by dietitian and delivered by a catering company (five meals each day).
75588296|NCT02214095|Drug|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
75588297|NCT02214095|Drug|lactose capsules|
75588298|NCT04550351|Biological|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
75732529|NCT03663322|Procedure|OMT Protocol|Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions
75732530|NCT03663322|Procedure|OMT-Sham Protocol|Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
75732531|NCT00735761|Drug|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
75732532|NCT00735761|Drug|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
75732533|NCT03454438|Procedure|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
75588299|NCT04550351|Biological|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
75588300|NCT04550351|Biological|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
75588301|NCT02214173|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
75588302|NCT02214173|Dietary Supplement|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
75588303|NCT01640691|Biological|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine~Administration route: Intramuscular Injection~Dosing schedule: 2 injections - at Day 1 and Day 22 separately~Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
75588304|NCT01205230|Drug|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
75588305|NCT04550390|Diagnostic Test|Saliva collection|2 saliva samples are self-collected by participants
75588306|NCT04549961|Other|Nutrition|type and amount of food eaten or type and amount of oral nutritional supplements as well as enteral or parenteral nutrition
75588307|NCT01643889|Drug|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
75438600|NCT05641519|Behavioral|SERVE OC Intervention|"SERVE OC intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment and discussing prevention/risk reduction 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations such as local churches, parks, community centers, or grocery stores (for field trips) They will also receive messages from them throughout the duration of the study using their preferred method of contact (text, email, webportal/app, phone call) for reinforcement and scheduling meetings"
75438601|NCT05641519|Behavioral|Enhanced Standard Intervention|Enhanced Standard Intervention will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care
75588308|NCT01643889|Drug|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
75588309|NCT01643889|Drug|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
75588310|NCT01643889|Drug|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
75438602|NCT05634109|Biological|Transfusion of blood products|The intervention will be either a) administration of 6 units of whole blood or b) administration of blood component therapy in the proportion of 6:6:6 units of red blood cells, plasma, and platelets.
75588311|NCT04550078|Dietary Supplement|Calcium Carbonate|Subjects receive a single-dose of 800 mg calcium as calcium carbonate provided in 6 capsules with a standardized breakfast served in the morning.
75588312|NCT04550078|Dietary Supplement|Calcium Permeate|Subjects receive a single-dose of 800 mg milk calcium as calcium permeate provided in 6 capsules with a standardized breakfast served in the morning.
75588313|NCT04550078|Dietary Supplement|Placebo|Subjects receive a single-dose of 0 mg calcium as placebo with maltodextrin provided in 6 capsules with a standardized breakfast served in the morning.
75588314|NCT01640730|Drug|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
75588315|NCT02214251|Device|PK-16CH EXG system|
75732534|NCT00740285|Drug|Lidocaine 2% without vessel constrictor|"first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days"
75882762|NCT04656847|Drug|in daily everyday routine practice|patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.
75588316|NCT01643967|Other|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
75588317|NCT01643967|Other|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
75732535|NCT00740285|Other|Placebo - physiological solution 0,9%|first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
75882763|NCT03553082|Drug|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
75882764|NCT03553082|Drug|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
75882765|NCT03318393|Drug|Bivalirudin|Continuous infusion
75438603|NCT05632237|Behavioral|Family strengthening program|"Phase I: 2-day Family Strengthening Workshop. The specific topics included in the workshop include: emotions, Body Progressive Muscle Relaxation, body stretch, self care, apologizing, routines to promote attachment, teamwork, saving, delayed gratification, anticipating unexpected expenses, identifying family strengths and values.~Phase II: Case management with family strengthening curriculum. Curriculum is delivered over the course of four visits (about 3 months), some of which involve both caregiver and child while others are just for the caregiver. Topics included are using appropriate discipline, effective communication for family problem-solving, and home budgeting."
75588318|NCT04549805|Diagnostic Test|Computed Tomography Coronary Angiography|In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
75732536|NCT00507429|Drug|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
75588319|NCT01640769|Procedure|Image guided delivery of cardiac pacing leads.|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm).
75588320|NCT01640769|Procedure|Standard delivery of cardiac pacing leads.|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
75588321|NCT04550273|Behavioral|aerobic treadmill exercise|The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
75732537|NCT00507429|Drug|paclitaxel|200mg/m squared on Day 1
75882766|NCT03318393|Drug|Unfractionated heparin|Continuous infusion
75588322|NCT01644006|Procedure|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
75588323|NCT01205152|Biological|asfotase alfa|
75732538|NCT00507429|Drug|carboplatin|6 AUC on Day 1 following paclitaxel
75732539|NCT01011621|Drug|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
75732540|NCT01011621|Drug|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
75732541|NCT00449176|Drug|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
75732542|NCT00449176|Drug|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
75732543|NCT00449176|Drug|placebo|matching placebo twice daily for 15 weeks
75882767|NCT02117180|Other|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
75882768|NCT02117258|Drug|Z-360|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
75882769|NCT02117258|Drug|Placebo|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
75588324|NCT01640847|Drug|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
75588325|NCT04549727|Other|Organoids creation|Organoids are created from discarded tissue
75732544|NCT00515073|Drug|Paclitaxel|50 mg/m^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
76053544|NCT05554679|Drug|Metformin|Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.
76053545|NCT05494619|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and <100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
76053546|NCT05494619|Drug|Placebo|Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to < 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
76053547|NCT05494619|Drug|Intravenous immunoglobulin therapy|All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
75588326|NCT01205035|Drug|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
75588327|NCT01644045|Device|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
75588328|NCT04549844|Drug|Bupivacaine|"After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery."
75732545|NCT00515073|Radiation|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
75732546|NCT00515073|Drug|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
75732547|NCT00515073|Drug|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
76053548|NCT03826043|Diagnostic Test|Blood sample analysis|Thrombophilia, blood count and coagulation count
76053549|NCT05474495|Other|Pelvic floor muscle training|Pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
76053550|NCT05474495|Other|Transverse abdominas strength training|Transverse abdominas strength training will be given 5 days a week and continued for 6 weeks.
76053551|NCT01634555|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
76053552|NCT01634555|Drug|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
76053553|NCT01634555|Drug|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
76053554|NCT01634555|Drug|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
76053555|NCT05355155|Drug|Bevacizumab Biosimilar IBI305|Patients received bevacizumab and FOLFOX4 every two weeks
75588329|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
75588330|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
75588331|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
76053556|NCT01634243|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
76053557|NCT02402309|Drug|Active topical NS2 1% dermatologic cream|
76053558|NCT02402309|Drug|Vehicle placebo 0.0% NS2 dermatologic cream|
75588332|NCT04549883|Other|Theoretical practical educational session|1 Theoretical practical educational session of 15 Min about the importance of low back control during hip extension. Includes anatomical issues and one practical exercise in quadruped position
75588333|NCT01204918|Drug|Riluzole|Riluzole 100mg PO
75588334|NCT01204918|Drug|placebo|placebo
75588335|NCT04528797|Drug|Levothyroxine|
75588336|NCT04528797|Drug|Methylprednisolone|
75588337|NCT00624481|Drug|Teriparatide|20ug subcutaneous injection daily for 24 weeks
75588338|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
75588339|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
75588340|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
75588341|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
75732548|NCT00515073|Drug|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
75588342|NCT04549766|Other|calculate PRECISE DAPT score using clinical data|calculate PRECISE DAPT score using clinical data in STEMI patients after PPCI
75588343|NCT04318054|Other|Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
75588344|NCT01644162|Device|iVAPS ventilation|3 months of ventilation on iVAPS mode
75588345|NCT04549649|Other|Dual triggering|Adding GnRH agonist (0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) to routine oocyte triggering (two ampoules of Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) is defined as dual triggering.
75588346|NCT01644201|Dietary Supplement|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
75588347|NCT01644201|Dietary Supplement|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
75588348|NCT02214329|Device|Sensor-based exercise training|Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.
75588349|NCT02214329|Other|In-home balance training|The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
75588350|NCT04529187|Drug|Midazolam|To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
75588351|NCT04529187|Drug|Dexmedetomidine|To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
76053559|NCT04815317|Other|Auditive stimulation|"The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes."
75588352|NCT04549415|Drug|Metformin Hydrochloride|"patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months"
75882770|NCT03110029|Drug|Efinaconazole 10% Topical Application Solution [JUBLIA]|Topical efinaconazole 10% solution (Jublia)
75588353|NCT04549415|Other|lifestyle modification|Lifestyle modification Standard Principles
75588354|NCT04549064|Diagnostic Test|diagnosis of pancreatic cancer|Diagnosis of pancreatic cancer based on the concentration of serum biomarkers
75588355|NCT02214368|Other|Early application of NIV|"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
75588356|NCT02214368|Device|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
75588357|NCT02214368|Drug|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."
75732549|NCT00710021|Drug|Vitamin D3|8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
75732550|NCT00710021|Drug|Vitamin D3 placebo|86% microcrystalline cellulose, 14% fumed silica by weight
75732551|NCT00504153|Drug|dasatinib|
75732552|NCT00504153|Other|laboratory biomarker analysis|Correlative studies
75732553|NCT05740787|Other|No intervention|Observation only
75732554|NCT00739895|Procedure|Cardiac magnetic Resonance study|follow-up studies
75732555|NCT00739895|Procedure|Blood testing|Blood sample tested for myocardial biomarkers
75882771|NCT03110029|Other|Application of Nail Polish|Application of Nail Polish
75882772|NCT04051749|Procedure|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
76053560|NCT04815317|Other|Sensitive stimulation|Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes.
75732556|NCT00735995|Behavioral|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
76053561|NCT04815317|Other|Auditory control|"The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise."
76053562|NCT04815317|Other|Sensitive control|The sensitive control condition will be achieved by administering fresh air on the calf.
76053563|NCT01542034|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
75438604|NCT05618132|Diagnostic Test|Acetylcholine rechallenge|"STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.~In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.~ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm)."
75438605|NCT05595291|Other|investigation of the factors affecting walking characteristics|In order to investigate the factors affecting walking characteristics, 2-minute walking test, 10-point VAS (overall prosthesis satisfaction level, socket comfort and satisfaction level, knee joint satisfaction level, prosthetic foot satisfaction level, pain level in amputated extremity) and locomotor capacity index will be applied.
75438606|NCT05585606|Drug|Placebo|Volume Matched Placebo
75438607|NCT05585606|Drug|scp776 (1.9 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 1.9 mg/kg"
75438608|NCT05585606|Drug|scp776 (3.8 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 3.8 mg/kg"
75438609|NCT05567848|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with functional MRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses per session. Sessions will be separated by an interval of 50 minutes (up to a total of 8 per day)."
75438610|NCT05553808|Drug|Docetaxel|Docetaxel was administered as IV infusion.
75438611|NCT05553808|Drug|Feladilimab|Feladilimab was administered as IV infusion.
75732557|NCT00735995|Behavioral|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
75732558|NCT04064177|Device|NICAS cardiac output monitor|Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
76053564|NCT01542034|Drug|Placebo|Phosphate buffered saline placebo for injection
76053565|NCT01564732|Device|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
76053566|NCT01564732|Device|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body & greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
75732559|NCT05740631|Drug|Ocaliva|Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
75732560|NCT05740631|Drug|Placebo|Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
75732561|NCT00740363|Drug|sitagliptin|Once daily sitagliptin. If GFR>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
75732562|NCT00740363|Drug|placebo|No active sitagliptin treatment for 4 weeks
75732563|NCT04065035|Other|Topical Body Firming Moisturizer|Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
75732564|NCT04065035|Other|Body Cleanser|Body cleanser to be used by study participants
75732565|NCT04065035|Other|Sunscreen|Sunscreen to be applied after application of moisturizer
75732566|NCT04065035|Other|Placebo Moisturizer|Placebo moisturizer is the vehicle control of the topical body firming moisturizer
75732567|NCT00442702|Drug|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
76053567|NCT05271929|Biological|Current standard of care and COVID-19 convalescent and vaccinated plasma|ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
75438612|NCT05549388|Other|Front-of-pack labeling|The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.
75588358|NCT02214368|Other|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2> 0.5 or breathing at least 10 L/min oxygen.
75588359|NCT04529148|Drug|Ginkgo biloba dropping pills，best western medicine treatment|oral
75588360|NCT04529148|Drug|Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment|oral
75732568|NCT00442702|Drug|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
75732569|NCT04065191|Other|High-intensity interval training|Heart rate based high-intensity interval training
75732570|NCT03444844|Drug|Ga-68 P16-093 PET/CT scan|IV injection followed by PET/CT scanning
75732571|NCT00740441|Drug|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
75732572|NCT00740519|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
75732573|NCT00740675|Other|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:~Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
75732574|NCT03385486|Biological|TBX-3400|Autologous transfusion
75732575|NCT00736151|Drug|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
75732576|NCT00514917|Drug|Docetaxel|75 mg/m^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
75732577|NCT00514917|Drug|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
75732578|NCT00514917|Drug|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
75732579|NCT00711425|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
75438613|NCT05544890|Procedure|Exercise|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~- Therapeutic exercise"
75438614|NCT05544890|Procedure|Manual Therapy|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~- Manipulation"
75438615|NCT05544890|Procedure|Kinesiotape|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~- Kinesiotaping"
75438616|NCT05540184|Drug|Trimetazidine 35 mg|Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
75438617|NCT05540184|Drug|Allopurinol 300 MG|allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
75438618|NCT05540184|Drug|Normal saline|rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
75438619|NCT05533268|Other|Mental training|Mental training (guided mindfulness meditation by Jon Kabat-Zinn for 20 minutes, 3 times per week.
75882773|NCT02122016|Device|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
75882774|NCT02122016|Other|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
75438620|NCT05533268|Other|Physical training|Physical training (continuous moderate-intensity training at 40-60% of participants' heart rate reserve for 20 minutes excluding warm-up/cool-down, 3 times per week.
75438621|NCT05533268|Other|Mental & physical training|Mental and physical training (combination of mindfulness mediation for 20-minutes, 3 times per week and continuous moderate-intensity training for 20 minutes, 3 times per week.
75438622|NCT05533268|Other|DASH diet|DASH diet ( (more vegetables, fruits and low-fat dairy foods and moderate amounts of whole grains, fish, poultry and nuts; and less than 3 grams of sodium daily) for 6-weeks.
75438623|NCT05523271|Diagnostic Test|CAD EYE (Computer Aided Diagnosis ----?|CADEYE is a CAD-e system (FUJIFILM) that enables real-time video processing at the same rate as the standard procedure and and allows a real time computer aided detection of polyps with high accuracy.
75438624|NCT05522777|Other|Drink one bottle of Yakult a day|Yakult is a branded probiotic drink with 8x10^9 CFU Lacticaseibacillus paracasei strain Shirota
75438625|NCT05512884|Behavioral|Speeded anomia therapy|The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.
75882775|NCT04858815|Behavioral|yogic breathing|participation in yogic breathing
75438626|NCT05506852|Behavioral|Web-based training strategy|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game using specific strategies, in order to optimize the performance."
75438627|NCT05506852|Behavioral|Web-based regular training (no strategy)|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game under regular game instructions."
76053568|NCT05271929|Other|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~Casirivimab~Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~Imdevimab~Sotrovimab (Xevudy)~Tixagevimab / Cilgavimab (Evusheld)~Molnupiravir (MK-4482)~Nirmatrevlir / Ritonavir (Paxlovid)~Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
75588361|NCT04548908|Diagnostic Test|Serelogy testing, RT PCR|Serology testing for all the participants and RT PCR for participants with symptoms
75732580|NCT05740397|Other|Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm|"The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect"
76053569|NCT01541644|Device|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
76053570|NCT05428397|Diagnostic Test|Iopromide (Ultravist, BAY86-4877)|X-Ray/CT Diagnostic Imaging
76053571|NCT04853056|Device|virtual reality|wearing virtual reality glasses
76053572|NCT04853056|Device|Cold vibration|Buzzy
75438628|NCT05488769|Device|Clareon Vivity extended depth of focus (EDOF) intraocular lens|Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
75438629|NCT05473195|Drug|BVL-GSK098 9mg|BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
75438630|NCT05473195|Drug|Ethionamide 250mg|Ethionamide 250 mg po OD (Eto250)
75438631|NCT05473195|Drug|Ethionamide 250 mg|Ethionamide 750 mg po given in a single or divided dose (Eto750)
75438632|NCT05473195|Drug|Isoniazid 300 MG|Isoniazid 300 mg po OD (INH)
75438633|NCT05463406|Other|The PLUS algorithm|Combination of a clinical prediction score and LUS, and if needed PCT measurement
75438634|NCT05463406|Other|Usual care|Management as usual
75438635|NCT05458817|Other|digital platform|Patients in the digital group complete the tests in the patient's mobile application and/or in the Internet-based research environment of the Institute of Psychology of the University of Tartu kaemus.psych.ut.ee. Patients and specialists of the control group fill in the tests and the satisfaction questionnaire in the kaemus.psych.ut.ee environment.
75438636|NCT05450952|Dietary Supplement|Theanine Formulation|Theanine Formulation Tablet
75438637|NCT05450952|Dietary Supplement|Placebo|Placebo Tablet
75438638|NCT05449418|Behavioral|Full Intervention|A small group of employees who work at facilities randomized to this arm will be invited to develop tailored COVID-19 vaccination promotion materials in teams with other long-term care staff sharing the same or similar language and/or cultural affinity. These employees will also help promote these materials to all of the employees who work at their facilities.
75438639|NCT05449418|Other|Enhanced Usual Care|Employees who work at facilities randomized to this arm will see COVID-19 vaccine promotion materials from the Centers for Disease Control and Prevention [CDC] or other national organization.
75588362|NCT04548635|Device|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
75588363|NCT01204294|Drug|Linagliptin|Linagliptin once daily
75588364|NCT01204294|Drug|Linagliptin|Linagliptin once daily
76053573|NCT04814615|Drug|89Zr-daratumumab PET/CT|CD38-targeting imaging
76053574|NCT04814537|Drug|Bupivacaine Hydrochloride|Local Anesthetic Agent
76053575|NCT01582282|Dietary Supplement|placebo|fiber-free placebo
76053576|NCT01582282|Dietary Supplement|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
76053577|NCT01582282|Dietary Supplement|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
76053578|NCT01599650|Drug|Ranibizumab|
76053579|NCT01599650|Procedure|Laser|laser photocoagulation
76053580|NCT01541254|Device|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
76053581|NCT02163902|Drug|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
75588365|NCT01204294|Drug|Metformin|Metformin twice or three time per day
75588366|NCT01204294|Drug|Metformin|Metformin twice or three time per day
75588367|NCT01204294|Drug|Linagliptin|Linagliptin once daily
75588368|NCT01204294|Drug|Linagliptin|Linagliptin once daily
75588369|NCT01204294|Drug|Linagliptin|Linagliptin once daily
76053582|NCT02163902|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
76053583|NCT01630616|Drug|Odanacatib|single oral dose, tablets, 10 or 50 mg
76053584|NCT01630616|Drug|Placebo|single oral dose, tablets
76053585|NCT03774875|Drug|Apremilast|Apremilast 30 mg tablets taken orally twice a day.
76053586|NCT03774875|Drug|Placebo|Placebo tablets taken orally twice a day
76053587|NCT02220764|Device|Teeth abutment|
76053588|NCT02220764|Device|Implant abutments|
76053589|NCT05264324|Procedure|Maximal Exercise Capacity|Maximal Exercise Capacity in incremental ramp exercise tests.
76053590|NCT04755920|Drug|SGM-101|Fluorescence-guided surgery
75588370|NCT01641276|Device|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
75438640|NCT05433103|Other|Low-Load Exercise with Blood Flow Restriction|Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
75588371|NCT01182181|Drug|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
75588372|NCT01182181|Drug|Anastrozole (Arimidex®)|1 mg Tablets
75588373|NCT04548674|Other|Whiteness HP 35%|Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
75588374|NCT04548674|Device|Whiteness HP 35% + LASER|A dose of LASER (60 J / cm2, for 16 seconds) was applied at two points, one point in the cervical region and another in the center of the buccal surface of the third molars, using visible infrared LASER therapy (Photon III / DMC, São Carlos, SP, Brazil), with a wavelength of 808 nm, and AsGaAl, as an active medium.
75588375|NCT04548674|Other|Whiteness HP 35% + CPP|Topical application of casein phosphopeptide amorphous calcium phosphate fluoride CPP-ACPF (My Paste Plus, Recaldent, GC, USA) with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes.
75588376|NCT04548674|Other|Whiteness HP 35% + NANO|A topical application of nanohydroxyapatite (Nano P FGM, SC, Brazil) was performed with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes after teeth whitening.
75588377|NCT01181986|Drug|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
75588378|NCT01181986|Drug|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
75588379|NCT01181986|Drug|Placebo SC|Placebo sc BID/10days
76053591|NCT04758806|Biological|Fecal microbial transplantation|Procured faeces procured from unrelated donor
76053592|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
76053593|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
75438641|NCT05433103|Other|Low-Load Exercise Control Group|Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
75438642|NCT05422053|Device|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.
75438643|NCT05418127|Dietary Supplement|Active|Traditionally-fermented coconut milk kefir
75438644|NCT05418127|Other|Placebo|Solution of Calcium Carbonate and coconut extract
75588380|NCT01181986|Drug|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
75588381|NCT01181986|Drug|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
75438646|NCT05360056|Device|DexCom G6|Wearable continuous glucose monitor
75438647|NCT05349760|Biological|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
75438648|NCT05349760|Drug|Placebo|Saline/D5W
75438649|NCT05344911|Drug|Propofol combined with alfentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, alfentanil 20 μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with alfentanil(0.5-2ug/kg/min)
75588382|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
75588383|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
75588384|NCT04315909|Drug|PRP-Fibrin Glue|Platelet-Rich Plasma-Fibrin Glue
75588385|NCT04315909|Dietary Supplement|Vitamin E and C|Vitamin E and vitamin C
75588386|NCT04315909|Other|Placebo|Placebo
76053594|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
76053595|NCT01563172|Other|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
75588387|NCT04548362|Other|Meat arm|Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
76053596|NCT04755764|Drug|Labetalol|Beta blocker
76053597|NCT04755764|Drug|Atenolol|Beta blocker
76053598|NCT04755764|Drug|Nifedipine|Calcium channel blocker
76053599|NCT02161718|Drug|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
76053600|NCT02161718|Drug|Placebo + olanzapine|Oral tablet, taken once daily
76053601|NCT05292989|Other|Frailty Assessment|Personalised (tailored) approach that includes assessment of frailty and structured information provided to the consumer
76053602|NCT05292989|Other|Standard Care|Standard care practice
76053603|NCT03697343|Radiation|Radiosurgery|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm)
76053604|NCT03697343|Radiation|Fractionated stereotactic radiotherapy|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm
75732581|NCT01011699|Drug|nicotinamide|"Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
75732582|NCT01011699|Drug|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
76053605|NCT05186987|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
75438650|NCT05344911|Drug|Propofol combined with remifentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, remifentanil 1μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with remifentanil(0.1-0.3ug/kg/min)
75438651|NCT05339438|Radiation|functional MRI|Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)
75588388|NCT04548362|Other|Starchy foods arm|Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
75732583|NCT01011699|Drug|cinacalcet|"After 6 months of treatment, patient screening on PTH level:~For patients with PTH > 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH < 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be < 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia < 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l."
75732584|NCT00740909|Behavioral|Cognitive Behavioral Therapy|A therapy designed to help patients with response prevention skills.
75732585|NCT05740319|Other|FMT|FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
75882776|NCT02122094|Behavioral|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
76053606|NCT05186987|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
75438652|NCT05338021|Procedure|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
75438653|NCT05338008|Procedure|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
75588389|NCT01181167|Drug|edoxaban|
76053607|NCT02100449|Other|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
75588390|NCT01181167|Drug|enoxaparin sodium|
75588391|NCT04550507|Behavioral|Mindful sensory awareness intervention|The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
75588392|NCT04550507|Behavioral|Mindful sensory awareness + mindful body awareness check-ins intervention|During the intervention period for Group B: Mindful Sensory & Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
75588393|NCT01644630|Procedure|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
75588394|NCT01644630|Procedure|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
76053608|NCT02100449|Other|Lung ultrasound and Doppler (Day 0 and Day 3 to 5)|In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
76053609|NCT02219048|Drug|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
76053610|NCT02219048|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
75438654|NCT05334680|Device|ANNE Sensor|The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
76053611|NCT03635645|Device|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
76053612|NCT03635645|Device|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
75438655|NCT05325112|Diagnostic Test|FFRCT|FFRCT is a diagnostic test following a CCTA to help diagnose and treat coronary artery disease.
75438656|NCT05323097|Other|Drowning-related OHCA|Drowning-related out-of-hospital cardiac arrest (OHCA): YES
75438657|NCT05322590|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.
75438658|NCT05322590|Other|Placebo|Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible (Stage 2 only)
75438659|NCT05314023|Biological|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
75438660|NCT05308797|Procedure|ESP block|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
75438661|NCT05308797|Procedure|CASP block|Preoperative, awake, bilateral, ultrasound-guided combine serratus anterior plane block with 30 mL 0.25 % bupivacaine
75588395|NCT04548557|Biological|intravenous immunoglobulin therapy|It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
76053613|NCT04786145|Procedure|Cryoneurolysis|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.
75588396|NCT04548323|Behavioral|Motor imagery|Subjects will perform motor imagery tasks on the motor gestures of running and walking.
75588397|NCT01181128|Drug|Factor VIII (rFVIIIFc)|
75588398|NCT01181128|Drug|Advate®|
75588399|NCT04548401|Drug|Antiplatelet Drug|aspirin and/or clopidogrel or ticagrelor
75588400|NCT04548284|Drug|Glucocorticoids|Periorbital injection of glucocorticoid. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
76053614|NCT04786145|Procedure|Radiofrequency ablation|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.
76053615|NCT04786145|Procedure|Placebo|No active treatment is given.
76053616|NCT04813991|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg for breakthrough pain.
76053617|NCT04813991|Drug|OxyCODONE 5 Mg Oral Capsule|OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
76053618|NCT04801901|Procedure|dTRA|Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)
76053619|NCT04801901|Procedure|fTRA|Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
76053620|NCT02218736|Drug|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
76053621|NCT02218736|Drug|placebo|oral dosing of 10 mg placebo daily for 8 weeks
76053622|NCT04418687|Device|Orthoglide|Knee rehabilitation device.
76053623|NCT04418687|Other|Physiotherapy only|Physiotherapy only.
76053624|NCT05268965|Behavioral|Experimental: group comparison|"Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~State-Trait-Anxiety Inventory (Spielberger, 1993)~Beck Depression Inventory (BDI-II, 1998)~Cognitive Emotional Regulation Questionnaire (Jermann & al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~Step 2: experience of the same scenarios in virtual reality"
76053625|NCT05266781|Procedure|Surgical repair|Patients affected by a thoracoabdominal aortic aneurysm who received an open surgical repair (aneurysmectomy and aortic reconstruction with a surgical graft
75438662|NCT05305638|Other|Exercise|Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.
75438663|NCT05303545|Other|standard of care for patients with poliomyelitis sequelae|clinical examination, radiological, biological and physiological examinations.
75588401|NCT04547894|Drug|ASC09F|ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
75588402|NCT01641315|Biological|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
75438664|NCT05282992|Dietary Supplement|Native type II collagen|1 capsule/day
75588403|NCT04548011|Other|Acupuncture|The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
75438665|NCT05282992|Dietary Supplement|Placebo|1 capsule/day
75588404|NCT01641393|Drug|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
75588405|NCT01641393|Drug|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
75438666|NCT05281328|Drug|CAM2029|SC injection using a pre-filled pen
75438667|NCT05281328|Drug|Placebo|SC injection using a pre-filled pen
75438668|NCT05251376|Drug|Levomethadone HCl|One dose given orally on Day 8 of the study.
75438669|NCT05251376|Drug|Methadone|Daily usual oral dose given on Day 1 and Day 2 of the study.
75588406|NCT04547933|Diagnostic Test|Bladder diary|A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
75588407|NCT01641432|Behavioral|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
75588408|NCT01641432|Behavioral|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
75588409|NCT04547972|Other|Higher-load resistance training|This intervention will have one arm and one leg of each participant training with ~80% of their one repetition maximum
75438670|NCT05251376|Drug|Morphine Sulfate|Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.
76053626|NCT05266781|Procedure|Endovascular repair|Patients affected by a thoracoabdominal aortic aneurysm who received endovascular repair (with off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR)
75588410|NCT04547972|Other|Lower-load resistance training|This intervention will have one arm and one leg of each participant training with ~30% of their one repetition maximum
75588411|NCT01644825|Drug|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
75438671|NCT05251376|Diagnostic Test|x-ray|Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.
75588412|NCT01644825|Drug|pazopanib|orally, 800 mg orally daily
75588413|NCT04547660|Biological|Convalescent Plasma|Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.
75588414|NCT04547660|Other|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
75588415|NCT01644864|Drug|0.375% ROPIVACAINE|
75588416|NCT01644864|Drug|placebo|
75588417|NCT04547855|Drug|anlotinib combined with dose-dense temozolomide|Temozolomide Capsule 150mg, p.o., qd, d1-7,15-21,4 weeks one cycle; Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
75588418|NCT01641510|Drug|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
75588419|NCT01641510|Drug|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
75438672|NCT05251376|Diagnostic Test|blood tests|Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.
75732586|NCT01011777|Drug|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
75732587|NCT00740987|Device|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
76053627|NCT05084261|Drug|BT051 200 mg|Oral BT051 200 mg once daily for 28 days.
75438673|NCT05248555|Diagnostic Test|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
75438674|NCT05219097|Diagnostic Test|CBA Assay|Comparsion of specificity, sensitivity and clinical correlation of CBA, ELISA and RIPA assay in autoantibodies detection of myasthenia gravis
75438675|NCT05196906|Procedure|Modified Broström operation and anatomic reconstruction operation|Patients with CLAI and GJL will accept the Modified Broström operation or anatomic reconstruction operation.
75438676|NCT05188820|Procedure|PRP - platelet rich plasma injection|Facet block using PRP
75438677|NCT05188820|Procedure|Cortisone injection|Facet block using cortisone
75588420|NCT01644942|Other|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
75588421|NCT04547621|Device|Radiation|Intensity-modulated radiotherapy 20Gy/10fx
75588422|NCT04547621|Device|Radiation|Hypofractionated Stereotactic Radiotherapy 30Gy/5fx
75588423|NCT04547621|Drug|Temozolomide|Temozolomide 75 mg/m2 concurrently administered with RT.
75588424|NCT01644981|Other|blood sampling|blood sampling
75588425|NCT01641549|Procedure|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
75588426|NCT01641549|Drug|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
75588427|NCT04547348|Drug|Denosumab Injection|Injections made subcutaneously per standard description
75588428|NCT04547426|Other|Wine with or without alcohol and snuff with or without nicotine|Two by two factorial of wine and snuff with meals
75732588|NCT04064645|Device|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
75732589|NCT00736307|Procedure|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
75588429|NCT01641588|Behavioral|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
75588430|NCT04547387|Device|Trans-carotid access revascularization with MicroNET covered stent implantation|Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
75588431|NCT01641627|Procedure|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
75732590|NCT00504075|Biological|Gammaplex, intravenous immunoglobulin|"Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX."
75732591|NCT00741065|Procedure|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
76053628|NCT05084261|Drug|BT051 800 mg|Oral BT051 800 mg once daily for 28 days.
75732592|NCT00503997|Drug|oxaliplatin|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
75732593|NCT00503997|Drug|pemetrexed disodium|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
76053629|NCT05084261|Drug|BT051 3200 mg|Oral BT051 3200 mg once daily for 28 days.
76053630|NCT05084261|Drug|Matching Placebo|Placebo Matching BT051
76053631|NCT05037149|Drug|STP707|Investigational Product
75438678|NCT05164354|Other|Aromatherapy|Aromatherapy: It will be applied to each child three times, three days in a row. Each application will be 20 minutes. The application time will be decided together with the patient. At the end of the three-day practice.
75438679|NCT05164354|Other|music concert|Music Concert: In this study, a music (lullaby, classical music) to be preferred by the patient or family Children are played for 20 minutes once a day. (morning or afternoon) for three days to help the child sleep. The volume of the music being played will be preserved. Aromatherapy: To be applied each child three times for three consecutive days. Each one The application will take 20 minutes. It will be time to implement The decision is made with the patient. Finally The patient's sleep quality will increase in three days of application. measured by actigraphy.
76053632|NCT05037149|Drug|STP707|Investigational Product
76053633|NCT05037149|Drug|STP707|Investigational Product
76053634|NCT05037149|Drug|STP707|Investigational Product
76053635|NCT05037149|Drug|STP707|Investigational Product
75882777|NCT02117336|Drug|P1446A-05|"The study have dose escalation phase, followed by a dose extension phase.~Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death."
75732594|NCT00741143|Other|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
76053636|NCT03580421|Procedure|ambulatory surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
75588432|NCT04547231|Diagnostic Test|Fractional flow reserve, Coronary CT angiography|"Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge.~Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).~Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan)."
75588433|NCT01641666|Drug|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
75882778|NCT05551533|Other|Kampung Care App|Please refer to the previous session
75588434|NCT01641666|Drug|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
76053637|NCT03580421|Procedure|standard surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
76053638|NCT01540474|Biological|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
76053639|NCT01540474|Biological|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
75588435|NCT01641666|Drug|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
75588436|NCT02214485|Behavioral|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
75588437|NCT02214485|Behavioral|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
75588438|NCT01645215|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
75732595|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
75732596|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
75732597|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
76053640|NCT01540474|Biological|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
76053641|NCT01540474|Other|Controlled group-Challenged Only: no vaccination|The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
76053642|NCT01580488|Drug|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
76053643|NCT01580488|Drug|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
76053644|NCT01580488|Drug|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
75588439|NCT04547270|Other|Ultrasound scan|Volunteers will have an ultrasound scanning of both sides of their neck lying in supine position. Sequentially the scanning will start from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. Images will be recorded as video loops.
75588440|NCT01203787|Drug|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
75588441|NCT01203787|Drug|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
75438680|NCT05163613|Other|magnetostimulation|Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.
75588442|NCT01641744|Behavioral|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
75588443|NCT01641744|Behavioral|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
75588444|NCT02887768|Device|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
75438681|NCT05163613|Other|standard therapy|Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.
75438682|NCT05147246|Behavioral|ParentCorps-Professional Development (PD)|PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
75438683|NCT05145036|Behavioral|Tai-Chi|Tai Chi exercise could improve muscle performance, balance and have the benefit for fall down prevention in the elders and patients with frailty.
75438684|NCT05145036|Behavioral|Comprehensive training|There are 3 exercises. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down.
75438685|NCT05127954|Drug|Ubrogepant|Oral Tablet
75588445|NCT02887768|Procedure|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
75588446|NCT04547504|Drug|Pembrolizumab|Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
75732598|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
75732599|NCT01011855|Device|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
75732600|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
75588447|NCT04547504|Drug|Pembrolizumab and Chemotherapy drugs|"An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop."
75588448|NCT01645254|Drug|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
75732601|NCT04063319|Other|High-fidelity simulation|The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
75588449|NCT01181011|Drug|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
75588450|NCT04528602|Procedure|Control (Extended leg position) Group|"Common procedure steps -Legal representatives of the infants will sign an informed consent form. Materials (soap, napkin, non-sterile gloves, diaper, wet cotton towels for newborns, waste container, diaper change mat) will be prepared.~Hands will be washed and gloves will be worn. Tapes of the infant's dirty diaper will be opened.~For the Control Group~-The infant will be grasped on the legs, the legs will be given extension position and lifted up.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed. The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed.~The infant's legs will be given in extension position and a clean diaper will be placed under them.~Tapes of the clean diaper will be fastened. Hands will be washed after the procedure Data will be collected before, during, after and 3 minutes after application."
75588451|NCT04528602|Procedure|Experimental (Legs are flexed toward abdomen) Group|"Procedure steps for the Experimental Group~Common procedure steps~The infant will be grasped on the legs; the legs will be kept in the flexion position and approached toward the abdomen.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed.~The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed and thrown into the medical waste bin.~The infant's legs will be kept in the flexion position and a clean diaper will be placed under them. A bottom care plan will be applied in line with the treatment plan, if necessary.~Tapes of the clean diaper will be fastened.~Hands will be washed after the procedure.~Data will be collected immediately before, during, immediately after and 3 minutes after the end of application."
75588452|NCT04546997|Diagnostic Test|Optical Coherence Tomography Angiography|Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
75588453|NCT01180777|Device|etafilcon A (A)|Daily wear contact lens
75588454|NCT01180777|Device|etafilcon A (B)|Daily wear contact lens
75438686|NCT05111964|Device|High Intensity Focused Ultrasound Ablation|"The focused ultrasound exposure will be performed using the Haifu® Model-JC200 Focused Ultrasound Tumour Therapeutic System at the Churchill Hospital site, CE-approved for tumour therapy (or subsequent CE-approved device upgrades by Haifu®). The participant will be positioned over the therapeutic device and water bath used to transmit the focused ultrasound to the target tumour. No anaesthesia or any combination of local anaesthesia, nerve block, epidural, conscious sedation or general anaesthetic may be used, depending on anatomical location, size of tumour, preference of HIFU team, patient and anaesthetist and other patient factors.~In therapy mode, the tumour volume is treated with focused ultrasound to ablate the tumour tissues to high temperatures (in excess of 60ºC) using focused ultrasound targeted from outside the body.~Patients are typically discharged with 24 hours."
75588455|NCT01180777|Device|etafilcon A (C)|Daily wear contact lens
75588456|NCT01641783|Drug|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
75588457|NCT02214524|Device|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
75732602|NCT00736463|Drug|Simvastatin|One arm of randomized crossover
76053645|NCT01580488|Drug|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
76053646|NCT01580488|Drug|Daivonex® ointment|once daily application, 3 weeks
75732603|NCT00736463|Drug|Atorvastatin 80 mg|Second arm of randomized crossover
75882779|NCT03552146|Drug|Propofol|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
76053647|NCT01580488|Drug|Daivonex® ointment vehicle|once daily application, 3 weeks
75732604|NCT00736541|Drug|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
75438687|NCT05111964|Diagnostic Test|Tumour Biopsy and Venous Blood Tests|"Where appropriate, participants are also encouraged to undergo a pre-HIFU (and in the case of unresectable STS, post-HIFU) ultrasound biopsy of the target tumour and additional blood tests to inform the immunological aspects of the study. Having the biopsy does not mandate enrolment on the trial, and patients will be free to leave the trial at any stage. The pre-HIFU (and post-HIFU) biopsies are altruistically encouraged but not absolutely essential to enrolment on the trial.~Biopsies will be performed under ultrasound guidance by an experienced radiologist using local anaesthetic."
75732605|NCT00096265|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
75732606|NCT00096265|Drug|Erlotinib Hydrochloride|Given orally
75732607|NCT00096265|Radiation|Stereotactic Radiosurgery|Patients undergo surgery after radiation therapy
75732608|NCT00096265|Drug|Temozolomide|Given orally
75732609|NCT01082809|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
75732610|NCT01078987|Procedure|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
75732611|NCT01080469|Drug|Tacrolimus 1 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
75882780|NCT03552146|Drug|Dexmedetomidine|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
76053648|NCT01580020|Biological|RFB002|0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
75588458|NCT02214602|Drug|Epirubicin|"Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"
75588459|NCT01646580|Drug|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
75732612|NCT01079065|Drug|Famotidine|Tablets
75588460|NCT04546802|Drug|Elbasvir / Grazoprevir Oral Tablet|Elbasvir / Grazoprevir
75732613|NCT01079221|Behavioral|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at < 90 % of peak power, 3 days/week for 6 weeks
75732614|NCT00711191|Biological|monoclonal antibody|CP-870,893 intravenous administration [IV] on day 3 of 4-week cycles
75438688|NCT05082831|Biological|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery. The primary purpose of the study is to compare the two groups: microfracture surgery + HST003 as compared to the microfracture surgery only group.
75438689|NCT05071820|Other|Health U mobile application|Health U mobile application delivers daily microlearning modules and the health coach interactions within the Health U application
75588461|NCT04528875|Device|Ultrasound imaging|Imaging of low back with ultrasound
75588462|NCT04546880|Other|Breathing exercises|"Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing."
75588463|NCT04546880|Other|Stabilization exercises|"Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability."
75588464|NCT01645293|Genetic|Genetically modified T cells # 1138|
75438690|NCT05071820|Other|National Diabetes Prevention Program|CDC recognized National DPP that follows a set curriculum with modules delivered over 12 months
75732615|NCT00711191|Drug|chemotherapy|gemcitabine 1000 mg/m^2 intravenous administration [IV] q week [wk]x3 of 4-week cycles
75882781|NCT01374763|Drug|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
75882782|NCT01374763|Drug|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
75732616|NCT00741221|Drug|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
75438691|NCT05062265|Device|Tight rope fixation|a traditional tight rope fixation is performed on one randomized set of subjects
75732617|NCT00741221|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
75882783|NCT02117492|Procedure|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
75882784|NCT02340403|Procedure|NMR Spectroscopy|
75882785|NCT02122250|Behavioral|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
75882786|NCT02122250|Behavioral|Static web-based materials|Static web-based materials
75882787|NCT03608514|Drug|Experimental|Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
75438692|NCT05062265|Device|Tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace|A tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace set of subjects to compare syndesmotic volume
75438693|NCT05012904|Behavioral|parent involvement application|A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
75438694|NCT05011565|Other|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function
75438695|NCT04997395|Drug|MediCabilis Cannabis sativa 50|Already described
75732618|NCT00736619|Other|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored."
75882788|NCT03551756|Other|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
75882789|NCT04207749|Device|LID015385 contact lenses|Investigational soft contact lenses
75882790|NCT04207749|Device|Comfilcon A contact lenses|Commercially available soft contact lenses
75882791|NCT04207749|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
75882792|NCT02237274|Other|High altitude exposition|High altitude exposition
75882793|NCT02117726|Drug|Dexmedetomidine,midazolam|
75882794|NCT02117726|Drug|Propofol,midazolam|
75588465|NCT04546919|Other|sepsis|Body temperature higher than 38°C or lower than 36°C; Heart rate higher than 90/min; Hyperventilation evidenced by respiratory rate higher than 20/min or PaCO2 lower than 32 mmHg; White blood cell count higher than 12,000 cells/ µl or lower than 4,000/ µl.
75732619|NCT04557761|Device|microMend®|microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.
75882795|NCT04125342|Device|Preventive Conditioned NIV Therapy after planned extubation|Conditioned NIV during 48 hours following extubation.
75882796|NCT04125342|Device|Preventive HFOT after planned extubation|HFOT set according to patients tolerance during 48 hours following extubation
75882797|NCT03551678|Device|Active feedback gait retraining|The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
75882798|NCT02733432|Drug|CD101 Vaginal Gel (3%)|CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
76053649|NCT01580020|Drug|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
76053650|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
76053651|NCT01579474|Drug|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
76053652|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
76053653|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
76053654|NCT01579318|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
75438696|NCT04997161|Drug|Sodium Zirconium Cyclosilicate (SZC)|Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
76053655|NCT01579318|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
76053656|NCT01562782|Other|Fructose + Glucose Beverage|Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
76053657|NCT01579006|Drug|Tocilizumab|
75438697|NCT04997161|Other|Enhanced dietary advice|Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.
75438698|NCT04997161|Other|Standard dietary advice including K+ restriction.|Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.
75438699|NCT04969250|Biological|Moderna mRNA-1273 COVID-19 vaccine|100 µg intramuscular injection
75588466|NCT01648023|Device|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
75588467|NCT01648023|Drug|Gem-Cis or Gem-Carbo|
75732620|NCT04557761|Device|Closure with Sutures|The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
75732621|NCT00741377|Drug|BHQ880|
76053658|NCT01578850|Drug|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
76053659|NCT01578850|Drug|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
75438700|NCT04969250|Biological|Pfizer BNT162b2 COVID-19 vaccine|30 µg intramuscular injection
75438701|NCT04956016|Device|classic rTMS using the 8-shaped coil|20 rTMS sessions are planned (5 sessions per week)
75438702|NCT04956016|Device|deep rTMS using the H1-shaped coil|20 rTMS sessions are planned (5 sessions per week)
75438703|NCT04952922|Other|Treatment for recurrent oropharyngeal cancer (curative/ palliative)|Open salvage surgery, transoral robotic surgery, palliative chemotherapy, immunotherapy.
75438704|NCT04938609|Drug|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
75588468|NCT04547114|Diagnostic Test|Multicapillary column coupled ion mobility spectrometry|sampling of nasal air via a foam cuffed oxygen catheter
75588469|NCT01580033|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
75732622|NCT00741377|Drug|Zoledronic acid|
76053660|NCT01539538|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
76053661|NCT01539538|Drug|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
76053662|NCT01562548|Drug|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
76053663|NCT01562548|Drug|Placebo|no active ingredient
76053664|NCT03027934|Drug|Ticagrelor|Ticagrelor, 90mg twice daily
76053665|NCT03027934|Drug|Prasugrel|Prasurgrel, 10mg once daily
75732623|NCT02567903|Device|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
75882799|NCT02733432|Drug|CD101 External gel (1%)|CD101 external gel (1%) applied topically twice daily over 72 hours as needed
75882800|NCT02733432|Drug|CD101 Vaginal Ointment (6%)|CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
75882801|NCT02733432|Drug|CD101 External ointment (1%)|CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
75882802|NCT02733432|Drug|Fluconazole|oral fluconazole (150mg) on Day 1
75882803|NCT03634189|Drug|Cannabidiol|Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
75588470|NCT01580033|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
76053666|NCT01562314|Drug|GWP42003|1 to 5 50 mg capsules taken BID
76053667|NCT01562314|Drug|Placebo|1 to 5 matching capsules taken BID
76053668|NCT01539226|Combination Product|Placebo Vaginal Ring|Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
75588471|NCT01580033|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
75588472|NCT01580033|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
75588473|NCT04547036|Device|XEN45|Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
75588474|NCT01645332|Drug|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
75732624|NCT02567903|Procedure|Knee arthroscopy|Knee arthroscopy
76053669|NCT01539226|Combination Product|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
76053670|NCT01577758|Drug|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
76053671|NCT04769674|Other|Sensory Integration Intervention through the STAR Frame of Reference|The individualized therapy program will be based on the results of the comprehensive evaluation. Intervention aligns with the STAR Frame of Reference fidelity measure and Ayres Fidelity Measure.
75438705|NCT04938609|Radiation|Stereotactic Body Radiation Therapy (5 days)|8Gy x 3 (Mon-Fri) GTV+3mm
75438706|NCT04938609|Procedure|Surgical Resection|Surgical Resection of Tumor
75438707|NCT04935411|Other|nAMD|patients diagnosed with Neovascular Age-Related Macular Degeneration
75438708|NCT04934007|Device|rTMS Treatment|1 Hz rTMS
75438709|NCT04917419|Other|Luminotherapy and /or Psychoeducation Program|TO complete
76053672|NCT01537432|Drug|secukinumab|secukinumab
76053673|NCT01537432|Drug|placebo|placebo comparator
76053674|NCT04409938|Other|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
75732625|NCT00706511|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
75438710|NCT04898062|Device|CRP-apheresis|The major advantages of depleting C-reactive protein by therapeutic apheresis are the selective removal of the damaging agent by the highly specific ligand and the good controllability of the procedure, since the plasma can be passed over the column as often as necessary to achieve the desired reduction. In addition, treatment can be interrupted or discontinued at any time.
75438711|NCT04891354|Drug|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
75588475|NCT01645332|Drug|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
75732626|NCT00448864|Drug|Ecallantide|
75732627|NCT00448864|Drug|Placebo|
75732628|NCT00567398|Drug|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
75732629|NCT00567398|Drug|Physioneal|Physioneal 40 or Physioneal 35
75732630|NCT00567398|Drug|Extraneal|Extraneal - 7.5% Icodextrin
75732631|NCT00567398|Drug|Nutrineal|Nutrineal - 1.1% Amino Acids
75732632|NCT02538848|Drug|HTD4010|injectable solution
75732633|NCT00448708|Device|Vascular Wrap Paclitaxel-Eluting Mesh|0.9 µg/mm^2 paclitaxel
75732634|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
76053675|NCT04409938|Other|Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
75588476|NCT01645332|Other|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
75732635|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
75732636|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
76053676|NCT01537120|Drug|Vildagliptin|
75438712|NCT04891354|Drug|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
76053677|NCT01537120|Drug|Placebo|
75438713|NCT04885491|Drug|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
75438714|NCT04885491|Drug|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
76053678|NCT01537042|Drug|Rotigotine|"Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal."
75438715|NCT04873557|Other|Copper-based surfaces plus copper-enriched linen|We will assess the efficacy of our intervention to decrease the acquisition of nasal and intestinal colonization with MDROs and the development of HAIs in the ICU setting.
75438716|NCT04866511|Other|Narrative Exposure Therapy|"NET is a trauma-focused psychological treatment for people who experienced multiple traumas (Schaeur et al., 2011).~An adaptation named KIDNET was developed for use with children and young people (Neuner et al., 2008; Schauer et al., 2011, 2017).~Participants will be offered 6-10 weekly sessions of NET lasting approximately 90 minutes each. The sessions will be delivered by a Trainee Clinical Psychologist via videoconferencing, in line with the UK's Government guidelines around reducing face-to-face contacts during the Covid-19 pandemic."
75438717|NCT04858126|Device|ECOM cardiac output|Measure cardiac output during perioperative period and compare to pulmonary artery catheter thermal dilution cardiac output measurement.
75438718|NCT04830995|Dietary Supplement|moderate restricted diet (1800-2000 kcal/day) for four weeks|high intensity interval training 3 sessions for four weeks
75438719|NCT04812457|Drug|Hialucic|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
75438720|NCT04812457|Drug|Betadine gel|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
75438721|NCT04810871|Procedure|Brain Surgery|Undergo surgery
75438722|NCT04789616|Drug|Maraviroc|Half of the participants will take maraviroc for a period of 8 weeks.
75588477|NCT04546763|Device|Study Watch|The Study Watch is a miniaturized wearable device made with biocompatible contact materials containing various sensors capable of measuring physiological and environmental metrics.
75588478|NCT04546763|Device|Zio XT|The Zio XT Patch, the reference device, is a FDA-cleared single-patient use, continuously recording ECG monitor that can be worn up to 14 days.
75588479|NCT02757222|Radiation|Escalated Dose|"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
75732637|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
75732638|NCT00929552|Dietary Supplement|Dietary oils (fish, vegetable oil)|6g pr day.
75732639|NCT00924872|Other|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
75732640|NCT00925028|Drug|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
76053679|NCT01537042|Drug|Placebo|"Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period."
76053680|NCT04111666|Biological|AL101|Active dose of AL101
76053681|NCT04111666|Other|Placebo|Saline solution administered as a single and multiple infusion as placebo.
76053682|NCT03897712|Device|Custom Samfilcon B Contact Lenses|Contact lens
76053683|NCT03897712|Device|Alden Optical HP Sphere Contact Lens|Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
76053684|NCT03897712|Device|ReNu MultiPlus Lubricating and Rewetting Drops|For use as needed during the study.
76053685|NCT03897712|Device|Biotrue Multi-Purpose Solution|For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
75438723|NCT04789616|Behavioral|Exercise Program|"All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for PT & OT) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program."
75438724|NCT04789616|Other|Placebo|Half of the participants will take a placebo for a period of 8 weeks.
75588480|NCT02757222|Radiation|Standard Dose|"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
75588481|NCT04546490|Other|Pressure Release technique|Manual therapy technique used by the treatment of Myofsacial Trigger points. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point and increasing the pressure as he perceives a reduction in the resistance offered by the soft tissue under the finger
75732641|NCT00925028|Drug|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
75732642|NCT00905138|Drug|GLPG0259|single ascending doses, oral solution
75732643|NCT00905138|Drug|placebo|single dose, oral solution
76053686|NCT01536574|Drug|Requip PR|Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
76053687|NCT01536418|Drug|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
76053688|NCT01536418|Drug|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
76053689|NCT04410094|Drug|Lazertinib|Lazertinib tablets will be administered orally.
76053690|NCT04410094|Drug|Itraconazole|Itraconazole capsules will be administered orally.
76053691|NCT04410094|Drug|Rifampin|Rifampin capsules will be administered orally.
76053692|NCT01576042|Drug|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
75732644|NCT00905138|Drug|GLPG0259|multiple dose, oral solution, 5 days
76053693|NCT01576042|Drug|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
75732645|NCT00905138|Drug|placebo|oral solution, 5 days
75732646|NCT00905216|Drug|heparin sodium - Bergamo|5.000 UI/mL
75732647|NCT00905216|Drug|heparin sodium - APP|5.000 USP
75732648|NCT00929630|Procedure|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
75732649|NCT00929630|Procedure|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
75732650|NCT00929630|Procedure|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
75438725|NCT04789616|Device|Activity Sensor|"Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study."
76053694|NCT01576042|Device|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
76053695|NCT01561300|Other|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
76053696|NCT01561300|Other|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
76053697|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
76053698|NCT01536262|Device|Respimat|Respimat inhaler
76053699|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
76053700|NCT01536262|Drug|Olodaterol|Olodaterol once daily inhalation
76053701|NCT01536262|Device|Respimat|Respimat inhaler
76053702|NCT01536262|Device|Respimat|Respimat inhaler
75588482|NCT04546490|Other|Ischemic pressure technique|Manual therapy technique by making pressure in Myofascial Trigger Point. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point. This is performed until the patient's tolerance, when he refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier.
75588483|NCT04546685|Other|Usual Care|Participants who are randomized in the waitlist or usual care do not receive the study intervention and will be instructed to continue with the care they would normally receive as part of their ongoing clinical care. Upon completion of the 3-month study, participants in the waitlist will be invited to enroll in the Empowered Relief class.
75588484|NCT04546685|Behavioral|Empowered Relief|The participants will attend the Empowered Relief class offered online via Zoom. The class is designed to treat pain catastrophizing in people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
75588485|NCT04546373|Drug|Niraparib|Patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria. The study comprises a single study visit, in which the patient will give her informed consent to participate (when the patient is alive) and the physician will extract the study data from the patient's medical charts. All eligible deceased and consenting living patients at the participating centers will be included. Data will be directly retrieved from hospital medical records and reported in the electronic Case Report Form (eCRF).
75588486|NCT01645410|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
75438726|NCT04789616|Behavioral|Motor Learning|Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 24 hours of the initial assessment (initial test and 24-hour retention test).
75438727|NCT04785300|Drug|Dasatinib|100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles
75588487|NCT04546334|Drug|Medical treatment|routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)
75732651|NCT00929630|Procedure|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
75732652|NCT00905294|Other|Blood draws|Observational: blood draws only
75438728|NCT04785300|Drug|Quercetin|Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles
75438729|NCT04765280|Diagnostic Test|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
75438730|NCT04765280|Other|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
75438731|NCT04765280|Other|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability in patients with low back pain. The score of the scale is between 0-90. It is accepted that the higher the score, the higher the disability.
75588488|NCT04546334|Procedure|Real Erector Spinae block|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose)
75588489|NCT04546334|Procedure|Real Erector Spinae block with magnesium sulphate|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg))
75588490|NCT04546334|Procedure|Sham Erector Spinae block|Ultrasound guided Erector spinae plane block with injection ofnormal saline
75588491|NCT04546256|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
75588492|NCT04546256|Drug|ADVAIR DISKUS® 500/50|2 inhalations of Test and Reference product in each study period
75438732|NCT04765280|Other|Disabilities of the Arm, Shoulder and Hand (DASH)|Standardized questionnaire to investigate the disability in patients with upper extremity musculoskeletal disorders. The score of the scale is between 0-100 It is accepted that the higher the score, the higher the disability.
75438733|NCT04765280|Other|Neck Pain and Disability scale|Standardized questionnaire to investigate the disability in patients with neck pain. The score of the scale is between 0-100. It is accepted that the higher the score, the higher the disability.
75438734|NCT04765280|Other|Knee Injury and Osteoarthritis Outcome Score|Standardized questionnaire to investigate the disability in patients with knee pain. The score of the scale is between 0-100It is accepted that the higher the score, the higher the disability.
75438735|NCT04765280|Other|Western Ontario and McMaster Universities Arthritis Index|Standardized questionnaire to investigate the disability in patients with hip osteoarthritis. The score of the scale is between 0-240. It is accepted that the higher the score, the higher the disability.
75732653|NCT00925106|Drug|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
75732654|NCT00925106|Drug|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
75882804|NCT02117804|Other|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
75438736|NCT04765280|Other|Visual analogue scale|global pain score on a 0 to 10
75732655|NCT00925106|Drug|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
75732656|NCT00925106|Drug|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
75732657|NCT02538692|Drug|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
75882805|NCT03043365|Drug|control fish oil|4 capsules, 3 times a day after meals
75882806|NCT03043365|Drug|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
75882807|NCT03608046|Drug|Avelumab|Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
76053703|NCT01560988|Drug|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
76053704|NCT01560988|Dietary Supplement|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
75438737|NCT04753216|Biological|Bevacizumab|Given IV
75438738|NCT04753216|Drug|Irinotecan Sucrosofate|Given IV
76053705|NCT03897556|Dietary Supplement|Guarana herb|The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.
75438739|NCT04717466|Biological|Secukinumab|300mg subcutaneous injection
75732658|NCT02538692|Drug|Placebo|The placebo is the same as Tong-Xie-Yao-Fang in appearance.
75732659|NCT00706355|Drug|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
75732660|NCT00905528|Drug|Telmisartan 80 mg/d|
76053706|NCT03897556|Other|Usual Care|Participant will receive 'usual-care' for cancer survivors. At the end of the study, after completing the Final Visit, they will receive 21 guarana energy bars to thank them for being in the study.
75732661|NCT00905528|Drug|Ramipril 10 mg/d|
76053707|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
76053708|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
76053709|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
75732662|NCT00925262|Behavioral|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
75732663|NCT00925262|Behavioral|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
75732664|NCT00925262|Behavioral|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
75882808|NCT03608046|Drug|Cetuximab Injection|Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
76053710|NCT03889132|Procedure|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
75438740|NCT04714619|Drug|CB-103|"Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily, and based on a 28-day treatment cycle.~A run-in phase for safety and tolerability of CB-103 in combination with anastrozole or letrozole will be conducted as an initial step of the phase II trial to confirm the safe dose of CB-103 in combination with NSAI given at standard dose.~Patients will receive treatment until disease progression (as defined by RECIST v.1.1), symptomatic deterioration, unacceptable toxicity, death, consent withdrawal or study termination, whichever occurs first."
75438741|NCT04689945|Drug|Morphine|"PREOPERATIVE ANALGESIA: None~INTRAOPERATİVE ANALGESIA:~Paracetamol 1000 mg IV~Morphine 0,1 mg/kg IV~POSTOPERATIVE ANALGESIA IV Morphine Patient-Controlled Analgesia (PCA) Rescue analgesic: IV paracetamol"
75882809|NCT03608046|Drug|Irinotecan|Irinotecan will be administered every 2 weeks (180 mg/m2)
76053711|NCT01535560|Drug|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
76053712|NCT01535560|Drug|AL-60371 Vehicle|Inactive ingredients used as placebo
76053713|NCT04102618|Biological|Pelareorep|4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 & 9
76053714|NCT04102618|Drug|Letrozole|Oral dose of 2.5 mg/day starting on Day 3 for 13 days
76053715|NCT04102618|Drug|Atezolizumab|1200 mg administered intravenously on Day 3
76053716|NCT04102618|Drug|Trastuzumab|8mg/kg administered intravenously or 600mg subcutaneously on Day 3
75588493|NCT01645449|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
75588494|NCT04546100|Other|Maternal-Infant Exercise Program|"Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
75588495|NCT01645761|Drug|Endonase|PPI- based triple therapy with endonase
75588496|NCT04546646|Other|Elastic Band Exercises|Resistance exercise will be performed using theraband. The color of the band denotes the degree of elasticity and resistance level(yellow , red ,green ,blue, black or silver).Exercise load in terms of individual yielding elasticity (band color) in resistance training will set at a level that a patient perceived as somewhat hard, which is equivalent to a 13-grade rating (moderate intensity exercise) on the RPE, According to American College of Sports Medicine. For each exercise movement 3 sets of 10 repetitions of gentle concentric and eccentric contractions through the full range of motion will be slowly performed using a yellow Thera band initially. The exercise intensity will be increased when the patient is able to achieve a perceived yield strength corresponding to a 13- grade rating on the RPE scale.
75588497|NCT02759640|Drug|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
75438742|NCT04689945|Procedure|Erector Spinae Block|"PREOPERATIVE ANALGESIA:~Ultrasonography (USG) guided ESP block:T4 spinal level, %0,25 concentration 20 ml, single injection~INTRAOPERATİVE ANALGESIA:~Paracetamol 1000 mg IV~dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
75438743|NCT04689945|Drug|Control|"PREOPERATIVE ANALGESIA: none~INTRAOPERATİVE ANALGESIA:~Paracetamol 1000 mg IV~Dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
75438744|NCT04682483|Drug|Vasopressor|The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
75438745|NCT04682483|Drug|Inotrope|Inotropes include dobutamine and milrinone.
75438746|NCT04682483|Device|Acute Mechanical Circulatory Support Devices|Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
75588498|NCT04546529|Device|Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing real TsMS with coil
75588499|NCT04546529|Device|Sham Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing placebo TsMS with coil
75588500|NCT04546022|Drug|Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.|
75588501|NCT01645800|Drug|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
75588502|NCT01645800|Drug|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
75588503|NCT01645878|Behavioral|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
75588504|NCT01645878|Behavioral|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
75732665|NCT04063553|Other|Volunteers Service|"Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.~All volunteers are recruited from TTSH volunteers pool managed by Center of Health Activation (CHA). TKR volunteers are trained by the study team, including a formal classroom session and a practical and role play session. After the training, volunteers need to pass 3 assessment by the physiotherapists in order to attend to patients independently by themselves. Volunteers who are bilingual will attend to the subject alone, or else those who can only converse in Chinese/ English will pair up with another volunteer who knows another language to make sure there is no communication barrier between volunteers and patients."
75732666|NCT04063553|Other|Exercise brochure|. The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given. The exercises in the brochure and exercises taught by the volunteers are the same. The video and brochure are available in both English and Chinese version.
75438747|NCT04643366|Drug|Chemotherapy|Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)
75588505|NCT01645878|Behavioral|routin breast feeding education|
75588506|NCT04546607|Other|Nuvastatic TM (C5OSEW5050ESA) 1000 mg|Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
75588507|NCT01645917|Device|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
75588508|NCT02278445|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
75588509|NCT02278445|Device|Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)|
75588510|NCT02278523|Device|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
75588511|NCT02214680|Drug|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
75588512|NCT02214680|Drug|Timolol|0.5% eye drop
75588513|NCT02214875|Other|CQI/BTS|Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.
76053717|NCT01575028|Drug|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
76053718|NCT01575028|Drug|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
75438748|NCT04643366|Radiation|Radiation Therapy|Pelvic Intensity-modulated radiation therapy (IMRT)
75438749|NCT04642625|Other|Visual Analog Score|"The VAS is a widely used tool in research and clinical practice, and its reliability and validity in pain assessment has been clearly demonstrated. It consists of a 100 mm line. 0 cm no pain, 10 cm is associated with 'worst possible pain'. The patient is asked to mark the line to 'score' the pain. VAS values of 1cm - 3cm weak, 4cm - 6cm moderate, and >7cm are the indicators of severe pain."
75438750|NCT04642625|Other|patient satisfaction|The patient's satisfaction with postoperative pain treatment will be recorded. 4 options; excellent, good, medium and bad.
75438751|NCT04600154|Drug|MS-20|Specific fraction from fermented soy milk
75438752|NCT04600154|Other|Placebo|Fermented soy milk without active component
75588514|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
75588515|NCT02756208|Biological|300 ug FLSC vaccine|FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
75588516|NCT02756208|Biological|150 ug FLSC vaccine|FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
75588517|NCT02756208|Biological|75 ug FLSC vaccine|FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
75588518|NCT02756208|Biological|Placebo|Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
75588519|NCT04545788|Drug|Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.|AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
75588520|NCT02756013|Drug|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
75588521|NCT02756013|Drug|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
75588522|NCT01680003|Drug|Hepar-P|
75588523|NCT01680003|Drug|Placebo for Hepar-P|
75588524|NCT01680042|Drug|Phenytoin paste|
75882810|NCT02122484|Drug|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
76053719|NCT04783961|Procedure|Cold snare endoscopic resection|Cold snare endoscopic resection
76053720|NCT04443569|Drug|Lidocaine patch|Lidocaine patch to be placed in post-operative recovery area and used in addition to routine post-cesarean delivery pain management
76053721|NCT04443335|Behavioral|continous feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. Patients in the CF group received continuous feeding with constant velocity by enteral feeding pump over one day.
76053722|NCT04443335|Behavioral|sequential feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. In the SF group, continuous feeding was changed into time-restricted feeding. The total daily dosage of enteral nutrition was equally distributed during three time periods at 7-9:00, 11-13:00 and 17-19:00. Other times of the day were fasting times. Enteral nutritional suspension in each time period was administered at a uniform rate within two hours by an enteral feeding pump.
75438753|NCT04584827|Other|lactate level|Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.
75438754|NCT04584827|Other|Glasgow Outcome Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
76053723|NCT04801355|Procedure|full-thickness laparo-endoscopic colon adenomas excision|Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
75438755|NCT04582045|Device|silver impregnated dressing|comparison of Mepilex versus our standard techniques
75588525|NCT01680042|Drug|Placebo|
75732667|NCT00925340|Behavioral|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
75732668|NCT00925340|Behavioral|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
75732669|NCT00736697|Drug|moxidectin|
76053724|NCT04801355|Procedure|laparoscopic colon resection|Standard laparoscopic colon resection
75882811|NCT04051515|Other|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
75588526|NCT01646229|Other|Polymyxin-B hemoperfusion|
75438756|NCT04563494|Drug|dexamethasone|Prevention of post op nausea and vomiting
75438757|NCT04542343|Behavioral|Change in knowledge, motivation, skills, resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges.
75438758|NCT04541173|Other|Y-90 TARE|"This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres."
75438759|NCT04541173|Drug|Atezolizumab|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks). The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 minutes.
75588527|NCT01646229|Other|Control|
75588528|NCT01680081|Other|Adenosine stress dynamic CT perfusion|
75588529|NCT04545203|Other|Slow-stroke back massage|Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
75588530|NCT04545086|Behavioral|Video Based Education, Music Therapy|Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
75732670|NCT00929942|Device|SX-ELLA Stent Degradable DV Bronchial (DV Stent)|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
75588531|NCT01646307|Drug|Atorvastatin|
75588532|NCT01646307|Drug|Rosuvastatin|
75732671|NCT00711113|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
75732672|NCT02568995|Drug|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
75732673|NCT03784898|Other|Blood draw for future biomarker analysis|Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
75732674|NCT00930020|Drug|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
75732675|NCT00930020|Drug|Matched placebo|matched placebo (cornstarch) once a day for 5 days
75882812|NCT04051515|Other|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
75882813|NCT02251574|Other|Low Calorie Diet|Weight management program designed around a low calorie diet.
75882814|NCT02251574|Other|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
75882815|NCT02251574|Other|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
75732676|NCT00710879|Device|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
75732677|NCT00930098|Drug|clofarabine|
75882816|NCT03108157|Procedure|Endometrial scratch|Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
75882817|NCT03608124|Behavioral|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
75882818|NCT04051437|Procedure|Plasma exchange|During each plasma exchange session 3-4lt (1.2-1.3 times of plasma volume) of plasma will be exchanged with fresh frozen plasma and 5% albumin. Plasma exchange session will be done on an alternate day to a maximum of 5 procedures. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session No improvement in clinical condition Intolerant to PLEX procedure
76053725|NCT01823549|Other|questionnaire administration|Ancillary studies
76053726|NCT03511157|Other|Ischemic Preconditioning|See Ischemic Preconditioning Experimental group description
76053727|NCT03511157|Other|Control Group|See Control group description
76053728|NCT04800965|Behavioral|Patient MyChart Scheduling Link|Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.
76053729|NCT04800965|Behavioral|Patient Educational Video|Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.
75588533|NCT04548089|Behavioral|Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)|Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
75588534|NCT04545359|Behavioral|Alpha-based neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
75588535|NCT04545359|Behavioral|Sham neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
75732678|NCT00905684|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
75732679|NCT00905684|Drug|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
75438760|NCT04541173|Drug|Bevacizumab|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle.The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 minutes
75882819|NCT04051437|Drug|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections,tablet entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
75438761|NCT04539795|Drug|Alvelestat|oral tablet
75882820|NCT02122874|Device|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
75882821|NCT02122874|Other|1200 Kcal diet|
75882822|NCT03619993|Device|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
75438762|NCT04539795|Drug|Placebo|oral tablet
75438763|NCT04530747|Drug|Metformin + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
75588536|NCT01680276|Behavioral|PBS based staff training|"Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219"
75588537|NCT01680276|Other|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
75588538|NCT02214914|Drug|BI 11634 drinking solution|
75588539|NCT02214914|Drug|BI 11634 tablet|
75588540|NCT02214914|Drug|Placebo|
75732680|NCT00736775|Drug|anti-Abeta|Intravenous single and multiple doses
75732681|NCT00736775|Drug|placebo|Intravenous single and multiple doses
75732682|NCT00925418|Procedure|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
75732683|NCT05742191|Other|Daylight Savings time transitions|Daylight Savings time transitions.
75732684|NCT03979274|Drug|Reference Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
75732685|NCT03979274|Drug|Test Eutirox®|Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
75732686|NCT00930254|Procedure|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
75732687|NCT00905762|Drug|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
75732688|NCT00905762|Drug|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
75732689|NCT00905762|Drug|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
75732690|NCT02568137|Behavioral|Smart-phone based technology|
75732691|NCT02568059|Drug|Sahastara remedy alcoholic extract|comparison of different dose of drug
75882823|NCT03619993|Device|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
75882824|NCT02124590|Other|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
75882825|NCT02124590|Other|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
75882826|NCT02124668|Drug|Enzalutamide|oral
75588541|NCT04544969|Drug|cisplatin-based chemotherapy|"GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge."
75438764|NCT04530747|Drug|Placebo oral capsule + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
75732692|NCT00459316|Biological|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
75438765|NCT04493242|Biological|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
75438766|NCT04493242|Other|Intravenous normal saline|Placebo
75438767|NCT04483440|Biological|4D-110|4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
75438768|NCT04456296|Drug|Aveed Injectable Product|Testosterone undecanoate administered by intramuscular injections.
75438769|NCT04456296|Drug|Fortesta|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
75438770|NCT04456296|Drug|Testim|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
75438771|NCT04429165|Other|collection of Patient Reported Outcome (PRO) data|collection of Patient Reported Outcome (PRO) data by questionnaires
75438772|NCT04429165|Other|collection of anthropometric and clinical functional data|collection of anthropometric and clinical functional data including range of motion (ROM), isokinetic muscle strength, joint position sense, single leg balance ability, and muscle activity
75438773|NCT04429165|Other|gait analysis|gait analysis in a motion capture volume on a walkway including force plates and on a treadmill with pressure plates, while 3D kinematics and kinetics, pressure and electromyographic (EMG) data will be recorded
75438774|NCT04412837|Drug|Topical CBD Patch|35 mg CBD patch
75438775|NCT04412837|Other|Placebo Patch|Identical patch without active ingredient.
75438776|NCT04403321|Drug|Tacrolimus|Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.
75438777|NCT04403321|Drug|Placebo (for Tacrolimus)|placebo will be given at 1mg bid.
75438778|NCT04300400|Other|Delphi questionnaire|Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
75438779|NCT04265755|Drug|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
75438780|NCT04260984|Procedure|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
75732693|NCT00925574|Drug|CNTO 1959; Placebo|
75732694|NCT02568839|Drug|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
75588542|NCT01646463|Behavioral|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
75588543|NCT01646463|Behavioral|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
75732695|NCT02568839|Drug|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
75438781|NCT04260984|Procedure|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
75732696|NCT00930410|Procedure|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
75438782|NCT04246320|Other|Goal directed therapy (GDT)|Goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
75438783|NCT04231981|Drug|INCMGA0012|INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
75438784|NCT04230512|Other|Pump prototype|Effects of pump function on gait
75438785|NCT04229771|Drug|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
75438786|NCT04229771|Drug|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
75438787|NCT04192409|Behavioral|Smartphone Application|Patients will use a smartphone application contain the following functions: providing health education information about DM and CAD, reminding patients to take medicine on time by alarm, recording patients' recent fast plasma glucose value.
75438788|NCT04182334|Other|Slow Tempo Music|For up to seven days, enrolled subjects will receive one-hour slow tempo music listening sessions twice daily through noise-cancelling headphones.
75588544|NCT01680354|Procedure|ReLEx|
75588545|NCT01680354|Procedure|LASIK|
75588546|NCT04544657|Other|no intervention|No intervention for enrolled patients
75588547|NCT01646502|Biological|Esp protein|
75732697|NCT02538770|Other|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
75438789|NCT04182334|Other|Attention Control|Subjects will receive a noise cancellation headphone-applied condition identical to the music intervention experimental treatment in twice daily one hour-sessions for up to seven days.
75732698|NCT02538770|Other|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
75732699|NCT05742035|Procedure|Venipuncture|Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
75732700|NCT06140875|Device|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
75732701|NCT06140862|Other|calf muscle strengthening and streching|lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
75882827|NCT02117960|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
75438790|NCT04180904|Other|Diet 1|Diet 1 will focus on which foods are eaten and the impact on disease outcomes.
75732702|NCT06140849|Diagnostic Test|artificial intelligence model|artificial intelligence model of anterior open bite diagnosis
75882828|NCT02117960|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
75882829|NCT03606018|Drug|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
75588548|NCT01646502|Other|Standard wound care|
75588549|NCT01680393|Device|Sequential compression device|a sequential compression device will be applied to the legs
75588550|NCT01680393|Other|TED stockings|TED stockings will be applied to the patients legs during surgery
75588551|NCT04544579|Device|Stent grafts anchored in different areas|Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
75588552|NCT04541732|Other|Thoracic epidural block|Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.
75588553|NCT04541732|Other|Ultrasound-guided bilateral quadratus lumborum block|Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia
75588554|NCT04541732|Drug|Induction of general anaesthesia with propofol|propofol: 1.5-2.5mg/Kg
75588555|NCT04541732|Drug|Muscle Relaxant|Atracurium : 0.5mg/Kg.
75588556|NCT04541732|Drug|Maintenance of general anaesthesia|Sevoflurane 0.7-1.5 MAC in 40% oxygen
75588557|NCT04544774|Drug|AIT|AIT for airborn allergens (SCIT/SLIT)
75588558|NCT04544774|Diagnostic Test|NAPT|NAPT test with airborn allergens ( HDM, Threes, Grasses)
75732703|NCT06140797|Combination Product|Pre-operative risk assessment combined with targeted intervention|Preoperative risk assessment and targeted intervention provided by multidisciplinary team
75732704|NCT06140784|Drug|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
75732705|NCT06140784|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
76053730|NCT04800965|Behavioral|Enhanced Follow through Message|Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
76053731|NCT01340261|Behavioral|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
75588559|NCT01680432|Dietary Supplement|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
75588560|NCT01680432|Dietary Supplement|Regular Cheese|
75732706|NCT06140784|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
75732707|NCT06140784|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
75732708|NCT06140771|Drug|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
75732709|NCT06140771|Drug|1.15% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
75882830|NCT03606018|Drug|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
76053732|NCT04676633|Drug|STP705|Investigational Product
76053733|NCT03508895|Other|Whole hemp seed protein|The intervention was provided in the form of a smoothie.
76053734|NCT03508895|Other|Whole hemp seed protein plus bioactive peptides|The intervention was provided in the form of a smoothie.
76053735|NCT03508895|Other|Casein protein|The intervention was provided in the form of a smoothie.
76053736|NCT01313351|Device|RPS InflammaDry Detector™|A noninvasive immunoassay for detecting MMP-9 levels in tears
76053737|NCT03418259|Device|KCS Medical Device|Patient treated 6 times with the Active KCS Medical Device during 2 weeks.
76053738|NCT03418259|Device|KCS Medical Device|Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
76053739|NCT01574716|Drug|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
76053740|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
76053741|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
76053742|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
76053743|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
75588561|NCT04541927|Genetic|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
76053744|NCT01574716|Drug|Placebo|
76053745|NCT02161562|Drug|omalizumab|150mg omalizumab via sub-cutaneous injection once every 4 weeks
75882831|NCT01373749|Drug|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
75882832|NCT01373749|Drug|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
75882833|NCT02035254|Other|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
75882834|NCT03551600|Procedure|Near-infrared spectroscopy (NIRS)|NIRS analyzes regional oxygen saturations (rSO2)
75882835|NCT04505605|Other|Blood samples|A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.
76053746|NCT02161562|Drug|omalizumab|300mg omalizumab via sub-cutaneous injection once every 4 weeks
75438791|NCT04180904|Other|Diet 2|This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject's demographics (age, sex, weight, height).
76053747|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
76053748|NCT01559116|Drug|tiotropium|low dose
76053749|NCT01559116|Drug|olodaterol|one dose only
76053750|NCT01559116|Drug|tiotropium|high dose
75588562|NCT04542044|Other|management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia|Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis
75588563|NCT02279277|Behavioral|Supervised physical therapy program prior to total knee replacement surgery|
75588564|NCT04544423|Other|Block group|Patients received lumbar erector spinae plane Block before operation
75588565|NCT01680471|Drug|Midazolam 0.03mg/kg|"This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
75882836|NCT02118116|Other|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
75882837|NCT03607968|Procedure|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
75882838|NCT05760625|Diagnostic Test|analysis BDNF|We analysed consentration of BDNF in venous blood of patient with primary headache
76053751|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
76053752|NCT01559116|Drug|Placebo|placebo matching tiotropium+olodaterol FDC
76053753|NCT01559116|Device|Respimat|Respimat inhaler
76053754|NCT01574326|Drug|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
76053755|NCT01574326|Drug|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
76053756|NCT01574248|Drug|icatibant|Subcutaneous at time 0 and 6 hours
76053757|NCT01574248|Other|Placebo|Subcutaneous at time 0 and 6 hours
76053758|NCT04761094|Device|Insulin pump|Treatment with continuous subcutaneous insulin infusion
76053759|NCT01573624|Drug|FF/GSK573719|100/15.6
76053760|NCT01573624|Drug|FF/GSK573719|100/31.25
75588566|NCT01680471|Drug|Midazolam 0.05mg/kg|"This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
75588567|NCT01680471|Drug|Placebo|"This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
75588568|NCT02215304|Dietary Supplement|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
75588569|NCT02215304|Dietary Supplement|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
75588570|NCT02215304|Dietary Supplement|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
75588571|NCT02215304|Dietary Supplement|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
75588572|NCT02279316|Drug|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
75588573|NCT02279316|Other|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
75732710|NCT06140771|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
75732711|NCT06140771|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
75588574|NCT02279316|Other|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
75588575|NCT04544306|Other|Partial oral antimicrobial therapy|Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
75882839|NCT02034786|Procedure|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
75588576|NCT01680588|Drug|[18F]NAV4694|
75732712|NCT06140758|Drug|Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
75732713|NCT06140758|Drug|Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
75732714|NCT06140758|Drug|Toms of Maine 0 ppm Fluoride Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
75732715|NCT06140758|Drug|Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
75732716|NCT06140758|Drug|1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
75732717|NCT06140758|Drug|1100 ppm (0.454% Stannous fluoride) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
75882840|NCT02034786|Biological|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
75882841|NCT02034786|Procedure|Transdermal injection|Transdermal injection of hyaluronic acid only.
75882842|NCT04045795|Drug|isatuximab SAR650984 IV|"Pharmaceutical form: solution~Route of administration: intravenous"
75882843|NCT04045795|Drug|pomalidomide|"Pharmaceutical form: tablet~Route of administration: oral"
75882844|NCT04045795|Drug|dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
75882845|NCT04045795|Drug|isatuximab SAR650984 SC|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75882846|NCT04045795|Device|Investigational injector device|Subcutaneous administration
75882847|NCT03605940|Combination Product|Methoxsalen + ECP device|2 sessions per week during 4 weeks and 1 session per week during 8 weeks
75882848|NCT03605940|Drug|Corticosteroids|2 mg/kg/day
76053761|NCT01573624|Drug|FF/GSK573719|100/62.5
75882849|NCT02124980|Behavioral|Recovery Line|
75882850|NCT03605472|Other|cervical ultrasound|cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
75882851|NCT02125058|Procedure|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
75882852|NCT02125058|Procedure|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
75882853|NCT04421131|Device|Pocket colposcope/Mobile phone camera|The Pocket colposcope or mobile phone camera will be used to capture magnified digital images of the cervix
75438792|NCT04169295|Other|Gynecologists' feedback on ART-Birth rates|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
75588577|NCT04544228|Procedure|Serratus Anterior Plane Block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
75588578|NCT04544228|Procedure|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes."
75588579|NCT04544228|Drug|bupivacaine +ketamine|30 ml bupivacaine 0.25% + 1 ml ketamine (50mg) in Serratus Anterior Plane Block.
75588580|NCT04544228|Drug|bupivacaine + neostigmine|30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.
75588581|NCT04544228|Drug|bupivacaine +saline|30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
75588582|NCT04544540|Other|Units of transfusion|Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions
75588583|NCT02279433|Drug|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
75588584|NCT04544345|Device|His bundle pacing, AV optimized|A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.
75588585|NCT04544345|Device|Backup VVI pacing|Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
75588586|NCT01680627|Behavioral|CASI|
75732718|NCT06140745|Drug|0 ppm Fluoride Dentifrice 1|Each subject will use this product during one of the five treatment periods in the crossover study design.
75732719|NCT06140745|Drug|1100 ppm NaF Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
75732720|NCT06140745|Drug|1500 ppm NaMFP Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
75732721|NCT06140745|Drug|0 ppm Fluoride Dentifrice 2|Each subject will use this product during one of the five treatment periods in the crossover study design.
75732722|NCT06140745|Drug|0 ppm Fluoride Dentifrice 3|Each subject will use this product during one of the five treatment periods in the crossover study design.
75732723|NCT06140732|Drug|camrelizumab and apatinib|camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
75882854|NCT04421131|Other|mIVAA|A mobile-phone-based telemedicine platform that enables remote consultation with an expert colposcopist
75882855|NCT03607734|Drug|Amoxicillin|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~50mg amoxicillin (10% total dose)~250mg amoxicillin (50% total dose)~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
75438793|NCT04169295|Other|Control group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
75438794|NCT04167540|Biological|AAV2-GDNF|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
75588587|NCT01680744|Other|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
75588588|NCT01646697|Other|cytology specimen collection procedure|Undergo cytopathologic sample collection
75588589|NCT04541771|Drug|Lactobacillus Reuteri DSM 17938|The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
75588590|NCT04541771|Drug|Placebo|expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
75588591|NCT01646736|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
75882856|NCT02118272|Device|Physica KR|
75882857|NCT04167345|Drug|VX-814|Tablet for oral administration.
75438795|NCT04146441|Combination Product|SonoVue|1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only
75882858|NCT04167345|Drug|Placebo|Placebo matched to VX-814 for oral administration.
75438796|NCT04146441|Drug|Chemotherapy|FOLFIRINOX Regime according to Norwegian national guidelines
75882859|NCT03605316|Procedure|Deep brain stimulation (DBS)|Neurosurgical treatment by stereotactic implantation of electrodes in the brain that affects the functioning of subcortical neuronal circuits
75438797|NCT04142788|Drug|Patiromer|Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
75438798|NCT04124380|Behavioral|Imaginal Exposure|Six 50 min, twice weekly video telehealth sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).
75438799|NCT04124380|Behavioral|Alcohol Skills Training|Six 50 min, twice weekly video telehealth sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.
75438800|NCT04124380|Behavioral|Supportive Telehealth|The supportive counseling intervention, modeled after Litz et al. (2007), will ask participants to self-monitor their experience of weekly symptoms and complete weekly online writing about daily non-trauma related concerns and hassles. Participants will talk with a therapist on the telephone twice per week.
75438801|NCT04123444|Drug|Iloprost|Continuously infusion for 72 hours. treatment dose 1 ng/kg/min
75438802|NCT04123444|Drug|Isotonic saline|Continuously infusion for 72 hours.
75438803|NCT04120025|Behavioral|Diaphragm Training|training on isolated abdominal breathing with proper effort and hold time to promote strengthening
75438804|NCT04072926|Drug|BioRoot|Influence of biomaterial BioRoot on periapical healing
75438805|NCT04041375|Behavioral|iNSPiRED|The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.
75438806|NCT04041375|Other|Usual Care|Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
75588592|NCT01646736|Drug|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
75588593|NCT01646736|Drug|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
75882860|NCT01375153|Drug|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
75882861|NCT01375153|Drug|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
75882862|NCT02035488|Drug|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
75588594|NCT04542005|Behavioral|q3h albuterol|Using q3h albuterol as discharge criteria from hospital
75588595|NCT01646775|Drug|epidural fentanyl|withold epidural fentanyl
75588596|NCT01680978|Drug|aleglitazar|150 mcg orally daily, 6 weeks
75588597|NCT01680978|Drug|placebo|orally daily, 6 weeks
75588598|NCT04541576|Device|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
75588599|NCT01646853|Radiation|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
75588600|NCT01646853|Drug|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
75882863|NCT05196997|Other|Mobility and Functional Assessments|"The first evaluation was made on the day the patient was discharged from the intensive care unit. DEMMI, Bartel Index, Katz Activities of Daily Living Rating Scale and MRC Muscle Strength Test were performed to the patient, respectively.~De-Morton Mobility assessment for test-retest reliability was performed again on the 1st day of the patient's service."
75882864|NCT03602430|Drug|Cholecalciferol|Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
75882865|NCT03602430|Drug|Placebo|A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
75588601|NCT04541459|Device|new device against ambient electromagnetic radiation|New device provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
75588602|NCT04541459|Device|sham device against ambient electromagnetic radiation|Sham device as as a control for new device, which provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
75588603|NCT01647165|Drug|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
75588604|NCT01647165|Drug|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
75588605|NCT01647165|Drug|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
75438807|NCT04040751|Behavioral|CARE-CITE|The primary CARE-CITE components will be education via web platform. Carepartners complete 6 online CARE-CITE modules (15-30-minute sessions each). The modules include demonstration videos and instructive content covering following areas: principles of functional task practice (i.e., activities of daily living such as eating, grooming, or leisure/vocational activities), adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity (i.e., increasing numbers of practice repetitions or weight of objects lifted). Underpinning the content is the concept of autonomy support, with examples of fostering empathy, problem solving, instruction in the use of non-controlling language with role playing situations and the importance of creating choice in activities.
75438808|NCT04040751|Behavioral|Standard of care|The carepartner will receive a support brochure with general caregiving information including website resources to mimic web interaction of intervention group (e.g., stroke caregiver resource site).
75588606|NCT01681056|Behavioral|Autosuggestion for 30 days|
75588607|NCT01681134|Drug|Advagraf®|oral
75588608|NCT01681134|Drug|Prograf®|oral
75588609|NCT04543916|Drug|Venetoclax 50 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
75882866|NCT02126852|Device|Acceleromyography (AMG, one-dimensionally)|Neuromuscular monitoring
75882867|NCT02126852|Device|Acceleromyography (AMG, three-dimensionally)|Neuromuscular monitoring
75882868|NCT02126852|Device|Electromyography (EMG)|Neuromuscular monitoring
76053762|NCT01573624|Drug|FF/GSK573719|100/125
76053763|NCT01573624|Drug|FF/GSK573719|100/250
75588610|NCT04543916|Drug|Venetoclax 100 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
75588611|NCT04543916|Drug|Venetoclax 200 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
75588612|NCT04543916|Drug|Venetoclax 400|Escalating doses to determine recommended phase 2 dose (RP2D)
75588613|NCT04543916|Drug|Venetoclax 600|Escalating doses to determine recommended phase 2 dose (RP2D)
75588614|NCT04543916|Drug|Irinotecan 60 mg/m2|Intravenously (IV), days 1, 8, and 15
75588615|NCT04543916|Drug|Venetoclax (RP2D)|orally, once per day
75588616|NCT04541147|Drug|Dexamethasone|dexamethasone solution or tablet (depending on age of patient) at 0.5mg/kg/day max of 8mg/day, administered on post-operative days 1,3,5,7.
76053764|NCT01573624|Drug|FF|100
75588617|NCT04541147|Drug|Analgesics|"standardization of post-operative analgesics (narcotics and non-narcotic medication).~Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)"
75588618|NCT01681173|Dietary Supplement|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
75588619|NCT01681173|Dietary Supplement|Placebo|200ml Placebo, BID, over 24 months
76053765|NCT01573624|Drug|FF/VI|100/25
75438809|NCT04010344|Behavioral|Enhanced Usual Care Group|"Medtronic® Labs' Akoma pa app, a culturally-tested and locally attuned mobile health platform, will be used in the intervention arm of the study to improve communication between the Community Health Officer (CHO) and the participant. This platform will be used to enhance shared decision making, clinical decision support, participatory communication, knowledge, treatment adherence (medication and lifestyle modification), and self-monitoring of hypertension. We will test the feasibility of the Akoma pa app in addressing patient-level and provider-level barriers to hypertension control.~The app will consist of the following components:~Reminders~Participant to CHO messaging~Home BP tracking~Educational materials on cardiovascular disease (CVD) and Stroke- Participants will have access to education modules on reducing the risk of CVD and stroke tailored to their knowledge level.~CHO provider portal- The provider portal will include decision support tools."
76053766|NCT01557946|Drug|citalopram|citalopram 20-40 mg daily
75438810|NCT04010344|Other|Usual Care Group|Regular/usual appointments or visits to patients' healthcare provider for management of study outcomes
75438811|NCT03998748|Other|Sham Genetic Feedback|Participants will be told either that they have or do not have a genetic predisposition to developing depression.
75438812|NCT03997916|Device|Belun Ring|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
75438813|NCT03997916|Diagnostic Test|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
75588620|NCT02214953|Drug|BI 11634 ER formulation A|
75588621|NCT02214953|Drug|BI 11634 ER formulation B|
75588622|NCT02214953|Drug|BI 11634 ER formulation M|
75588623|NCT02214953|Drug|BI 11634 ER formulation C|
75588624|NCT02214953|Drug|BI 11634 IR tablet|
75588625|NCT01647204|Other|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
75588626|NCT04541303|Drug|Tranexamic acid|tranexamic acid diluted to concentration of 25ml/mg
75588627|NCT04541303|Drug|normal saline|0.9% sodium chloride
76053767|NCT01534078|Drug|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
75588628|NCT01647243|Other|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
75588629|NCT02214992|Drug|Telmisartan/Ramipril|Fixed dose combination tablet
75588630|NCT02214992|Drug|Telmisartan|
75882869|NCT03605238|Biological|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
75882870|NCT02252120|Device|Supreme|
75882871|NCT02252120|Device|Laryngeal Tube|
76053768|NCT01534078|Drug|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
76053769|NCT03919942|Other|OxyFlower gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
75588631|NCT02214992|Drug|Ramipril capsule|
75588632|NCT02214992|Drug|Ramipril tablet|
75588633|NCT01647321|Behavioral|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
75588634|NCT01647321|Behavioral|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
75438814|NCT03987503|Drug|Epclusa (SOF/VEL)|a trained physician will provide research participants with two-week supply of SOF/VEL. Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks. The initial 2-week supply is provided by Gilead Sciences and will be dispensed to participants upon enrollment. Prescriptions and insurance prior authorizations for SOF/VEL will be submitted by the study pharmacist though the UCSF Specialty Pharmacy. The study team will be notified once insurance-authorized drug is available and will bring participants' medication in 2 supplies to the study site prior to study visits.
75438815|NCT03987503|Drug|Standard of care|Standard of HCV care provided by medical care provider
75438816|NCT03987503|Device|Fibroscan® 430 Mini Plus|"Trained research staff will measure participants liver stiffness using liver ultrasonographic elastography. Research staff place ultrasound gel directly on participant's skin on the area of the torso. Research staff will position the participant's body on the exam table to assure the liver can be located, placing the small probe on the body's surface (skin with gel) and begin recording images of the participant's liver.~The procedure will take 15-30 minutes, depending on the ease with which the research staff is able to accurately locate the participant's liver.~Results from the FibroScan will be discussed with a trained provider."
75438817|NCT03977181|Behavioral|Group-based Community Health Club|GBHCs will be facilitated by trained Lay Health Counsellors (LHC). GBHCs will consist of a maximum 20 participants. GBHC sessions will held multiple times a month in each study area, allowing for flexibility for study participants. Sessions will be held at a safe and secure, centrally located area within the study community, and will be regularly monitored and assessed by the study coordinator. Participants will be invited to join a club-specific WhatsApp group to facilitate group communication and adherence support throughout the month. They will also be invited to partner up with another participant to provide mutual peer support. Permission will be sought from group-based adherence support participants before they are added to WhatsApp groups. Group adherence counsellors assigned will be members of WhatsApp groups, and will monitor all shared content to ensure that no inappropriate content or private information is shared in the group.
75438818|NCT03977181|Behavioral|Individual-based Adherence Support|IAS participants will be matched to a LHC and will schedule IAS sessions once-a-month for the duration of the study. These sessions will be held at a centralized location within the study community. The sessions will be semi-structured to allow for participant-driven discussion of any adherence challenges and key-messages. The adherence curriculum will also explore motivations for PrEP and adherence and focus on practical adherence tips, environmental cues, integration of PrEP within daily routines, short-term goal-setting, problem-solving, safe PrEP disclosure and social support, risk reduction counselling, partner communication, and HIV risk perception. A subset of IAS sessions will be audio-recorded for quality assurance by investigators and the study coordinator. These recordings are for training purposes only and will not form part of the dataset. Consent for recording IAS sessions will be sought from participants during the pre-enrolment consent process.
75438819|NCT03967197|Drug|Saline spray|Physiologic saline spray
75438820|NCT03967197|Drug|Lidocaine Hydrochloride|Lidocaine hydrochloride 10% spray
75438821|NCT03935646|Drug|Adderall IR 10mg|At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
75438822|NCT03935646|Drug|Placebo|Placebo
75438823|NCT03831009|Procedure|Open reduction internal fixation (ORIF)|Open fracture reduction followed by internal fixation using a plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
75588635|NCT04544150|Other||
76053770|NCT03919942|Other|Chlorhexidine gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.
76053771|NCT03919942|Other|Placebo gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
76053772|NCT02185040|Drug|CC-220|0.3 mg oral capsules once every other day with or without food
75438824|NCT03831009|Other|Conservative treatment|Conservative treatment involves ankle protection with a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
75438825|NCT03788616|Drug|Fuji IX EXTRA|High-viscosity glass ionomer (Fuji IX EXTRA)
75588636|NCT01681290|Drug|CBX129801|
76053773|NCT02185040|Drug|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
76053774|NCT02185040|Drug|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
75588637|NCT04543721|Device|24-h-ABPM|24-h- blood pressure measurement and pulse wave analysis
75588638|NCT04528095|Drug|Clozapine|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d
75588639|NCT04528095|Device|MECT|MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total
75588640|NCT04528095|Device|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
75438826|NCT03788616|Drug|ACTIVA KIDS bioactive restorative material|Modified composite (ACTIVA KIDS)
75732724|NCT06140706|Behavioral|transcutaneous Spinal Cord Stimulation (tSCS)|Neurostimulation for upper extremity training, delivered through video telehealth, 8 weeks of home use for (i) feasibility and (ii) potential functional improvement.
75882872|NCT03605160|Procedure|traditional polish|After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.
75438827|NCT03769493|Behavioral|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
75438828|NCT03769441|Drug|Ferric carboxymaltose|Four intravenous dosages of ferric(III) carboxymaltose
75438829|NCT03769441|Drug|Sodium chloride|Four intravenous dosages of sodiumchloride
75438830|NCT03732768|Drug|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
75438831|NCT03713619|Drug|secukinumab|Secukinumab 300mg every 2 or every 4 weeks
75438832|NCT03713619|Drug|Placebo|Placebo 300mg every 2 or every 4 weeks
75438833|NCT03690336|Drug|Nonacog beta pegol|Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.
75438834|NCT03670693|Diagnostic Test|Muscle strength and fatigue assessment|Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
75588641|NCT04541264|Diagnostic Test|radiomic of chest CT|radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
75732725|NCT06140680|Behavioral|LifelongU|"The LifelongU intervention is an abbreviation name from LifelongU: Cultivating Physical Literacy for University & Beyond. LifelongU is a unique and coined term that symbolizes the program's commitment to promoting physical literacy as a lifelong journey. It combines the words Lifelong and University to represent an intervention that focuses on physical literacy development not only during the university years but also throughout a person's entire life. The name is designed to convey the idea that physical literacy is an asset that will benefit individuals in all aspects of life, even after they leave the university."
75732726|NCT06140680|Behavioral|Physical education|The control group received 12-week traditional physical education lesson as usual.
75882873|NCT03605160|Procedure|fluid-jet|After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
76053775|NCT02185040|Drug|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
76053776|NCT02185040|Drug|Placebo|Matching oral placebo daily
76053777|NCT02161406|Drug|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
75438835|NCT03670693|Diagnostic Test|Dual-energy X-ray absorptiometry (DEXA scan)|Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
75438836|NCT03670693|Diagnostic Test|Supine cardiorespiratory fitness assessment|VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)
75438837|NCT03670693|Diagnostic Test|fMRI Exercise assessment|Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
76053778|NCT02161406|Drug|Placebo|125 mg of Placebo
75588642|NCT04543604|Behavioral|Leatlet + visual aid (pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
76053779|NCT02161016|Device|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
75438838|NCT03670693|Diagnostic Test|Muscle deconditioning assessment|Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
75438839|NCT03666416|Behavioral|Sprint Interval Training|Participants will attend two experimental appointments, during which they will complete two identical executive functioning tasks (i.e., sustained attention, working memory). During one appointment, participants will receive the sprint interval training manipulation prior to completing the tasks.
75438840|NCT03615937|Behavioral|Child interactive intervention|The Child Interactive Intervention will be delivered through a Dialogic Reading Program, which is an individual/group level intervention component for both families and kindergartens. The original Dialogic Reading Program aims to enhance children's literacy and oral language skills by using the specific technique of shared book reading developed by Whitehurst and colleagues (1988). However, this project will expand from the original Dialogic Reading Program template to include alignment with local kindergarten curriculum and themed interactive activities that help build social competence and emotional maturity in children, in addition to cognitive skills.
75588643|NCT04543604|Behavioral|Leaflet + no visual aid (no pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
75588644|NCT04528056|Drug|Sulfasalazine|Sulfasalazine is an anti-inflammatory and immunosuppressive drug
75588645|NCT04528056|Drug|Ambrisentan|Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
75588646|NCT04528056|Drug|Sulfasalazine's placebo|Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
76053780|NCT01573000|Biological|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
75438841|NCT03615937|Behavioral|Family Empowerment|Family empowerment in this project can be conceptualized across three main pillars: 1) adaptive parenting; 2) adaptive extended family environment; and 3) familial resources. Typically, adaptive parenting is translated into positive parenting programs for primary caregivers, and the rest of the family environment involves extended caregivers. However, families from disadvantaged environments encounter many hurdles that hinder effective parenting and relationship nurturing, and parents' mental wellbeing are also consistently impacted by competing demands.
75588647|NCT04528056|Drug|Ambrisentan's placebo|Ambrisentan's placebo is similar to Ambrisentan in form and dosage
75588648|NCT04541342|Procedure|initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal|It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.
75588649|NCT04543565|Drug|Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet|Once daily
75588650|NCT04543565|Drug|Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate|Once daily
75588651|NCT01681329|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
75588652|NCT01681329|Other|Interpretation training|Computerized interpretation training using Word-Sentence Association Paradigm
75588653|NCT02215343|Dietary Supplement|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R&D Centre Europe).
75588654|NCT02215343|Dietary Supplement|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
75588655|NCT01647477|Behavioral|interview|25 minutes of semi directive interview
75588656|NCT01647477|Behavioral|questionnaires|questionnaires to answer at baseline 45 minutes
75438842|NCT03615937|Behavioral|Access to Community Hub and its services|A new model of Community Hub will be implemented and there will be two hubs established in two respective districts. The Community Hubs act as an alternative venue to implement service delivery of intervention packages, such as activity sessions in the Child Interactive Intervention, Parenting Program, and mentor-mentee experience exchange, which provide families institutional flexibility and extended support while internalizing new practices. There will also be health education, consultation support and developmental assessments. The Hubs will play the roles of promoting and interweaving play-based learning into the lives of families frequently faced with competing demands and a lack of resources, and enable a protracted network for parents.
75438843|NCT03615937|Other|Enhancement to the kindergartens|This intervention package aims at providing a better physical and social kindergarten environment to maximize developmental reach and expedite timely interception and feedback without adding burden to teachers and frontline service professionals.
75588657|NCT04540991|Procedure|implant placement|The implants are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
75588658|NCT04540991|Procedure|gingiva former placement|Gingiva former are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures of oppeninf implant cower and gingiva former placement on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
75588659|NCT04540991|Diagnostic Test|Collecting gingival epithelial cellsusing the swab technique|Samples of gingival epithelial cells are collected from each participant's implementation site using the swab technique at three different time points: a control swab is taken just before the placement of the dental implant (T0); the second swab is taken 90 days after implantation meaning immediately before placement of the gingiva former (T1); and the third swab is taken 21 days after placement of the gingiva former (T2).
75438844|NCT03615937|Other|Health education, screening, and support|Health seminars and interactive workshop will be provided to the families. Screen for common child health problems (e.g. dental and visual) will also be conducted. A support hotline and website will be established for the participants.
75438845|NCT03596177|Drug|MEDI0382|MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
76053781|NCT01572922|Device|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
76053782|NCT01572922|Device|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
76053783|NCT01572922|Procedure|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
75438846|NCT03596177|Drug|Placebo|Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
75438847|NCT03585517|Drug|IM23|T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
75438848|NCT03579459|Biological|Clostridium difficile vaccine|Toxoid based Clostridium difficile vaccine
75438849|NCT03579459|Biological|placebo|Normal saline solution
75438850|NCT03547999|Drug|mFOLFOX6|The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.
75438851|NCT03547999|Biological|MVA-BN-CV301|The experimental arm (Arm B) will receive MVA-BN-CV301 in 4 injections of 4 x 10(8) infectious units/0.5 mL given subcutaneously prior to the start of chemotherapy on days -28 and -14.
75438852|NCT03547999|Biological|FPV-CV301|The experimental arm (Arm B) will receive FPV-CV301 in 1 dose of 1 x 10(9) infectious units/0.5 mL given subcutaneously concurrently with chemotherapy (at least an hour prior to chemotherapy) on days 0, 14, 28 and 42 pre-operatively, and FVP-CV301 boosters on day 0 and 14 and then every 4 weeks (day 42, 70, 98). After day 98, FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
75438853|NCT03547999|Drug|Nivolumab|Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.
75438854|NCT03536728|Drug|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
75438855|NCT03536728|Drug|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
75438856|NCT03517423|Drug|Brivaracetam|An antiepileptic drug whose putative mechanism of action is as a result of direct inhibition of SV2A receptors, responsible for the successful release of excitatory neurotransmitters from the the neuronal presynaptic membrane.
75438857|NCT03477305|Behavioral|Blackberry Consumption|Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
75438858|NCT03477019|Drug|SonoVue|"consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol."
75438859|NCT03477019|Procedure|Focused Ultrasound|ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
75438860|NCT03462251|Combination Product|Ribociclib and aromatase inhibitor or fulvestrant|Combination of ribociclib and aromatase inhibitor or fulvestrant
75438861|NCT03462251|Combination Product|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab|Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
75438862|NCT03434132|Procedure|Open or robotic radical cystectomy|"ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed."
75438863|NCT03430479|Drug|Cohort A|Radiation + Nivolumab + hormone therapy
75438864|NCT03405779|Procedure|Lung ultrasonography|Mechanically ventilated patients suffering from pulmonary diseases will undergo a lung ultrasonography during their stay in the intensive care unit (ICU)
75438865|NCT03404089|Device|pharmacokinetic device|MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement
75588660|NCT01647555|Drug|Cetuximab|First cycle: 400 mg/m2 Next cycles: 250 mg/m2
75588661|NCT01647555|Radiation|Radiotherapy|Curative dose: 66 to 70 Gy
75588662|NCT04541615|Procedure|Online course with proficiency test|Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
75588663|NCT04541615|Procedure|Online course|Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
75588664|NCT04541615|Procedure|Standard training group|After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
75588665|NCT04541615|Procedure|Apprenticeship group|Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
75588666|NCT01647594|Behavioral|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
76053784|NCT01572844|Device|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
76053785|NCT01572844|Drug|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
75438866|NCT03404089|Device|pharmacokinetic device|High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using
76053786|NCT01557400|Drug|Ataluren|Oral powder for suspension
76053787|NCT04122118|Other|Medical Chart Review|Review of medical chart
76053788|NCT04122118|Other|Educational Intervention|Receive pharmacist-led education
76053789|NCT04122118|Other|Survey Administration|Ancillary studies
76053790|NCT04121806|Other|UC intervention diet|The treatment diet has been designed based on the literature with the goal of influencing the biodiversity and density of the microbiome. All food through the duration of the 8 week dietary intervention period of the study will be provided to the treatment arm study participants.
76053791|NCT01533922|Drug|Placebo|placebo matching tiotropium + olodaterol FDC
76053792|NCT01533922|Drug|Tiotropium|Tiotropium 5 mcg once daily
76053793|NCT01533922|Drug|Olodaterol|Olodaterol 5 mcg once daily
75882874|NCT02260544|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
75438867|NCT03370393|Behavioral|Pathways for African-Americans' Success (PAAS)|PAAS is a 6-week, technology-delivered, family-based youth risk intervention program. PAAS includes 6 sessions for parents and youth, and joint sessions in which they both engage on the same computer to integrate and practice the skills they have just learned in their separate sessions. Each session includes a review, a virtual discussion, and observing and interacting with four parent and four youth Avatars that reflect phenotypes of African Americans (AA), with voice-overs by AA parents and youth. Videos portraying family interactions and intrapersonal processes are integrated into each session to convey key points of the intervention along with interactive activities to promote skill-building and to reinforce learning. PAAS also includes a technology tutorial and an introductory session.
75438868|NCT03327857|Biological|Neihulizumab (ALTB-168)|"Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.~Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks."
75438869|NCT03324308|Diagnostic Test|Computed Tomography Angiography|This will be a prospective study comparing the low-dose dynamic vs. static CTP combined with the CTA for detecting hemodynamically significant coronary artery stenosis. Patients will have two 18-20 gauge intravenous lines placed for contrast administration. The following image sequences will be completed: coronary calcium scan (non-contrast), rest coronary arterial imaging (with 4-5 mL/sec intravenous ISOVUE-370 infusion), stress myocardial perfusion imaging 20 minutes after rest acquisition imaging (blood pressure will be checked then an infusion of adenosine will be started for a total of 5 minutes; after 5 minutes of adenosine infusion, CT perfusion imaging will be performed during a 4-5 mL/sec ISOVUE-370 infusion). Total estimated radiation dose: 10.551 mSv.
75438870|NCT03272685|Drug|Very Low Nicotine Content Cigarettes|0.4 mg/g nicotine; 9 mg tar
75438871|NCT03272685|Drug|Normal Nicotine Content Cigarettes|15.8 mg/g nicotine; 9 mg tar
75438872|NCT03272334|Drug|HER2 BATs with Pembrolizumab|8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
75588667|NCT01647594|Behavioral|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
75588668|NCT04543448|Other|Traditional Rehabilitation for multiple sclerosis|Traditional rehabilitation program include strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs.
75588669|NCT04543448|Other|Cervical mobilization for multiple sclerosis|Cervical mobilization program include myofascial relaxation techniques and mobilization to cervical spine in addition to traditional program.
75588670|NCT04543370|Drug|Edasalonexent 2000 mg TID|CAT-1004 capsules
75588671|NCT04543370|Drug|Midazolam 2 MG/ML|2 mg/ml syrup
75588672|NCT04543370|Drug|Deflazacort 36Mg Tab|36 mg tablets
75588673|NCT01681524|Drug|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
75732727|NCT06140654|Diagnostic Test|Clinical oral examination|Clinical oral examinations are conducted by a dental practitioner. They point out the number of teeth (ranging from 0 to 32), the number of occlusal functional units (OFU, ranging from 0 to 10, with one unit considered as a pair of antagonist premolars and molars that had at least one contact area during maximum intercuspal relationships, evaluated by asking the participants to clench on a 200 µm thick articulating paper, the presence of dental prostheses (fixed prosthesis and removable denture), the number of denture worn during meals (removable partial or complete denture, either maxillary or mandibular, or both, with number ranging from 0 to 2), the number of decayed, missing, filled teeth (DMFT index, based on 28 teeth), and the Russel's periodontal index which is presently preferred to the Community (namely CPITN) because it takes tooth mobility into account.
75882875|NCT05470647|Biological|Interleukin-4 receptor responders 1|Interleukin-4 receptor was injected subcutaneously.
76053794|NCT01533922|Drug|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
75438873|NCT03258281|Drug|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
75438874|NCT03258281|Drug|Placebo|Patients will receive placebo administered subcutaneously
75438875|NCT03231787|Diagnostic Test|Platelet function assay|"Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours."
75438876|NCT03230981|Device|Optical imaging of the cornea in healthy subjects|OCT vibrography and Brillouin microscopy
75438877|NCT05705466|Drug|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
75588674|NCT04528485|Other|Sea swimming|8 sessions of swimming activities in the sea
75588675|NCT04543487|Other|Therapeutic touch|Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the active phase of the first stage of labour, and the second was done in the second stage of labour.
75588676|NCT01681563|Drug|Pentostatin|Lyophilized powder for intravenous administration.
75882876|NCT05470647|Biological|Interleukin-4 receptor responders 2|Interleukin-4 receptor was injected subcutaneously.
75882877|NCT05470647|Biological|Placebo|Placebo was injected subcutaneously.
75882878|NCT03552848|Biological|MSC|MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
76053795|NCT01533922|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
76053796|NCT01533922|Device|Respimat|Respimat inhaler
76053797|NCT01533688|Drug|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
76053798|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
75732728|NCT06140654|Diagnostic Test|Food behavior|"Food selective behavior is assessed using a food selectivity questionnaire previously developed for French adults 34. Participants will be interviewed and asked to check each food item they do not eat among a list of 71 familiar products which includes raw foods and dishes from the following categories: starters, meat, fish, egg, garnish, dairy products, desserts, bread, and beverages. A food selectivity score corresponding to the total number of avoided foods will be assessed for each participant. For each avoided food, participants explain why they do not eat it among reasons including I don't know it, I dislike it, I suffer from chewing or swallowing it (oral discomfort), I experience difficulties digesting the food, This food is forbidden for medical reason, and This food is forbidden for ethical or religious reasons."
75438878|NCT05705466|Drug|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.
75438879|NCT05705466|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
75588677|NCT01681563|Drug|Cyclophosphamide|IV
75588678|NCT01681563|Drug|Ofatumumab|Liquid concentrate for solution for infusion.
75588679|NCT04543292|Device|MATFILL (PTFE)|Filling of the prosthetic chimney with the compressed material
75588680|NCT01681641|Other|A psycho-social intervention|
75732729|NCT06140641|Dietary Supplement|Probiotics|Bifidobacterium Longum BL21 or placebo for 8 weeks.
75732730|NCT06140589|Drug|Cadonilimab|The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment
75588681|NCT04543214|Other|Enhanced recovery after surgery|Enhanced recovery after surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response after surgery. It benefits patient by reducing complications and enhancing recovery and saves resources for the health care system. In this concept, surgeons work collaboratively with anesthesiologist, nurses, nutritionists and physical therapists to develop and manage the perioperative care.
75588682|NCT01681680|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
75588683|NCT04543175|Other|Taste disorder´s test|Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.
75588684|NCT01647633|Other|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
75588685|NCT04541069|Behavioral|Social Communication and Emotional Skill Development (SCESD) module|The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
75588686|NCT01647672|Drug|Abraxane|Abraxane for neoadjuvant chemotherapy
75588687|NCT04540562|Other|COPD app|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
75588688|NCT01681719|Device|WBV and Resistance|"use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
75438880|NCT05705388|Device|POSE2.0 Endoscopic Gastric Remodeling|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
75438881|NCT05705388|Drug|Liraglutide injection|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
75732731|NCT06140576|Drug|Sindilimab|Sindilimab, 200mg, Intravenous，every three weeks
75732732|NCT06140576|Drug|Nab-paclitaxel|Nab-paclitaxel，125mg/m^2, d1,8, every three weeks
75732733|NCT06140576|Drug|Lenvatinib|Lenvatinib 8mg, 12mg, 16mg everyday
75732734|NCT06140550|Device|Drug balloon dilated|Through the expansion after the balloon is in place,Release drugs on the surface of the balloon and improve the blood perfusion of nerve vessels to treat stenosis
75732735|NCT06140550|Device|balloon dilated|Through the expansion after the balloon is in place, improve the blood perfusion of nerve vessels to treat stenosis.
75732736|NCT06140524|Drug|Linvoseltamab|Administration by intravenous (IV) infusion
75732737|NCT06140498|Behavioral|Self-Efficacy Training and Ecological Momentary Assessment|Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week
75732738|NCT06140498|Behavioral|Control intervention: Ecological Momentary Assessment only|Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
75732739|NCT06140472|Behavioral|Phoenix|Specific individualized nurse follow-up using the PHOENIX application.
75732740|NCT06140472|Behavioral|Journal de bord|Regular nursing follow-up, with the use of an electronic journal.
75438882|NCT05705362|Procedure|Simple Crossover|Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
75438883|NCT05705362|Procedure|Side branch opening|According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
75438884|NCT05705336|Drug|Tranexamic Acid Oral Product|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
75438885|NCT05705336|Drug|Placebo pills|Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
75588689|NCT01681719|Device|resistance & sham WBV|"used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off."
75588690|NCT01681719|Device|WBV & resistance sham|"used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
75588691|NCT04543058|Device|BeatPark Application|"The participant walks for 30 minutes a day, 5 day a week for 4 weeks. During the walking session, BeatPark Application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
75588692|NCT04543058|Other|BeatPark Application without synchronized music|"The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
75732741|NCT06140433|Device|VSC-MEDlib|VSC-MEDlib will be used for post-processing
75588693|NCT04543058|Other|BeatPark Application without music|The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
75588694|NCT01647789|Drug|CFG920|
75588695|NCT02215031|Drug|BI 44370|
75732742|NCT06140407|Drug|Cisplatin|Receive Cisplatin
75588696|NCT02215031|Drug|Placebo|
75588697|NCT01681758|Other|IV fluid according to PPV|intravenous fluids
75588698|NCT01681758|Other|fluids according to standard care|
75588699|NCT04540679|Other|VIP4SCI|Technology-enabled self-management & rehabilitation solution
76053799|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
76053800|NCT01532986|Other|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
75588700|NCT01647867|Other|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
75732743|NCT06140407|Drug|Carboplatin|Receive Carboplatin
75732744|NCT06140407|Drug|Etoposide|Receive Etoposide
75732745|NCT06140407|Biological|Pembrolizumab|Receive Pembrolizumab by IV
75732746|NCT06140407|Procedure|Computed Tomography|Undergo Computed Tomography
75732747|NCT06140407|Procedure|Positron Emission Tomography|Undergo Positron Emission Tomography
75732748|NCT06140407|Procedure|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
75732749|NCT06140407|Procedure|Biospecimen Collection|Undergo blood sample collection
75732750|NCT06140407|Radiation|Radiation Therapy|Undergo Radiation Therapy
75732751|NCT06140381|Procedure|Eccentric training|The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase
75732752|NCT06140381|Procedure|Conventional therapy|3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation
76053801|NCT01532986|Other|Educational handout|"To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise."
76053802|NCT01532908|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
76053803|NCT01532908|Drug|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
76053804|NCT01532908|Drug|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
76053805|NCT02160782|Drug|LUM001 (Maralixibat)|LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
75588701|NCT04540367|Device|Blood flow restriction therapy|The study group underwent the same exercises as the control group modified by the use of a tourniquet for blood flow restriction during those exercises.
75732753|NCT06140368|Behavioral|virtual reality|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
76053806|NCT02160782|Drug|Placebo|Placebo will be administered orally once daily during randomized withdrawal period
76053807|NCT02160626|Drug|A-101 Vehicle|Placebo control
76053808|NCT02160626|Drug|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
75732754|NCT06140355|Behavioral|Qigong|a Qigong introduction class and a 12-week remote Qigong intervention, with a 6-month follow-up
75732755|NCT06140355|Behavioral|"HIPAA-compliant app: Manage My Pain app"|"Completing one short survey (2-3min) daily with a HIPAA-compliant app, called 'Manage My Pain (Pro version) group, with a 6-month follow-up."
75732756|NCT06138093|Device|Sealing device|Intratracheal tracheostomy sealing
75732757|NCT06138093|Device|No device|Open tracheostomy wound
75732758|NCT06138080|Diagnostic Test|Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography|We have no specific intervention. We investigate different diagnostic modalities of VUR.
75732759|NCT06138041|Drug|intravenous lidocaine infusion|Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
75732760|NCT06138041|Drug|Saline|Same volume of normal saline in bolus and continuous infusion as lidocaine group.
75588702|NCT01682070|Biological|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
75588703|NCT01682070|Biological|Placebo|
75588704|NCT04542941|Biological|COVID Convalescent Plasma|Plasma collected from recovered COVID 19 individuals
75588705|NCT01647984|Dietary Supplement|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
75882879|NCT04409665|Drug|Ketamine|Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
76053809|NCT02160626|Drug|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
76053810|NCT02160314|Device|pessary|disposable, single-use pessary
76053811|NCT02160314|Device|Absorbent pad|
76053812|NCT02160002|Procedure|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
76053813|NCT02160002|Procedure|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
76053814|NCT02218268|Drug|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
76053815|NCT02218268|Drug|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
76053816|NCT02217878|Drug|Morphine|IV bolus injection
76053817|NCT02217878|Drug|Placebo|IV bolus injection
76053818|NCT02217878|Drug|Ticagrelor|180 mg loading dose
75732761|NCT06138028|Drug|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.
75588706|NCT01647984|Dietary Supplement|placebo|
75588707|NCT04540328|Other|Non-surgical periodontal treatment|
75732762|NCT06138015|Behavioral|Exercise and Time-Restricted Eating|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks and a time-restricted eating following 16:8 protocol for 12 weeks.
75732763|NCT06138015|Behavioral|Exercise only|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks only.
75732764|NCT06137989|Procedure|Fill-Up Class ӀӀ restoration|Bulk-fill technique
76053819|NCT04189640|Drug|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
76053820|NCT02217566|Drug|Abiraterone acetate|Participants will receive abiraterone acetate 1000 mg (4*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
75588708|NCT01648062|Behavioral|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
75588709|NCT04540640|Device|Kidney perfusion pump|The pulsatile perfusion device will circulate room temperature oxygenated perfusion solution through the donor kidney ex vivo.
75732765|NCT06137989|Procedure|QuiXfil Class ӀӀ restoration|Bulk-fill technique
75732766|NCT06137989|Procedure|Tetric N-Ceram Bulk Fill Class ӀӀ restoration|Bulk-fill technique
75732767|NCT06137950|Drug|gel Interferon arm|0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.
75732768|NCT06137950|Drug|gel Interferon and interferon suppository arm|"0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.~3MIU suppository will be given to patients and will be trained how to use. Each patient in the arm will use the suppository twice a day for 10 days with vaginal therapy."
75732769|NCT06137937|Behavioral|Aerobic Exercise|Intradialytic aerobic exercise for eight weeks
75732770|NCT06137924|Drug|Local anesthetic injection Bupivacaine plus dexamethasone|The autonomic neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. Infiltration of 20 mL of non-diluted 0.5% bupivacaine plus dexamethasone 8 mg is performed at the celiac plexus and vagus nerve trajectory.
75732771|NCT06137924|Drug|Local anesthetic injection bupivacainde plus dexamethasone plus a colloid|bupivacaine plus dexamethasone 8 mg plus a colloid 10 cc (Gelofucin, B. Braun Medical S.A., Crissier, Suiza.) is performed at the celiac plexus and vagus nerve trajectory.
75732772|NCT06137924|Drug|Local anesthetic injection bupivacaine plus clonidine|bupivacaine 5% plus clonidine (0,150mgs) is performed at the celiac plexus and vagus nerve trajectory
75438886|NCT05705310|Behavioral|Self Management Strategies|During their maintenance stage cardiac rehabilitation programme, participants will be given a pedometer and asked to wear it during waking hours to record their daily step counts and/or time in physical activity each week. Participants will be encouraged to gradually achieve 150 minutes of moderate-intensity exercise per week and self-monitor their progress using the pedometer. At the end of every week, participants will review progress and set goals with an exercise professional. Group discussions will also take place, focusing on the benefits of regular physical activity, demonstrating lifestyle activities that can help accumulate activity and identifying various means of social support, and identifying local opportunities (groups or places) for physical activity after the cardiac rehabilitation programme has ended. Following this, they will receive a monthly phone call from the exercise professional to check progress and encourage them to continue with the programme.
75588710|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
75588711|NCT01648179|Drug|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
75588712|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
75588713|NCT01648179|Drug|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
75588714|NCT02215382|Drug|sugammadex|sugammadex 2 mg/kg
75588715|NCT02215382|Drug|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
75732773|NCT06137898|Biological|biological check-up|Blood sampling
75732774|NCT06137885|Behavioral|Cardiac rehabilitation|Cardiac rehabilitation is a comprehensive model of care involving prescribed exercise, medication management, lifestyle modification, and psychosocial counseling to help people with heart diseases resume and enhance their psychosocial and vocational status.
75732775|NCT06137885|Other|Active post-market surveillance of devices|Active post-market surveillance of devices is an essential and ongoing process that involves systematic monitoring and assessment of medical devices once they are available on the market. It involves continuous data collection and analysis, early detection of issues, risk assessment, compliance with regulatory requirements, adaptive decision-making, and transparent communication with healthcare professionals and patients.
75732776|NCT06137885|Other|Multi-omics approach to precision medicine|Multi-omics analysis refers to the collective analysis of extensive biological data from multiple omics sources to gain a holistic understanding of an individual's health status, disease susceptibility, and response to therapies. By considering a broad spectrum of genetic and molecular information, multi-omics precision medicine aims to deliver more accurate diagnoses, predict disease risks, select optimal treatment options, and monitor therapeutic responses with a high degree of specificity, ultimately improving patient outcomes and minimizing adverse effects.
75732777|NCT06137885|Other|The prescription pattern analysis|The prescription pattern analysis refers to the systematic examination and evaluation of the types, dosages, frequencies, and trends in medications prescribed to patients with cardiovascular conditions. By scrutinizing prescription patterns, researchers and healthcare professionals can identify prevalent medications, assess adherence to treatment guidelines, uncover potential gaps or areas for improvement in patient care, and gain insights into the evolving landscape of cardiovascular therapies.
75732778|NCT06137859|Behavioral|Weekly-based functional fitness training|Participants will receive a 12-week duration of functional fitness training in daycare centers, which will be implemented twice a week. The 60-minute per session training series will be delivered and guided by qualified elderly health and fitness instructors, who will be provided with a workshop before this intervention. The workshop will be designed and delivered by the research team. The first session will focus on the physical literacy of older adults and the second session will focus on how to lead functional fitness training under the FITT principle for older adults. The main goal of functional training is to improve the range of joint motion, increase muscle strength and flexibility, and boost blood circulation safely. Therefore, symmetry training together with cardiovascular training is the core of the training program. Examples of the main training activities include cardio-full-body exercises, upper-body exercises, lower-body exercises and sensory integrative training.
75732779|NCT06137859|Behavioral|Mastering Physical Literacy Class|"A 30-minute MPLC program will be conducted by experienced elderly health and fitness instructors after WBFFT. This MPLC program aims to enhance the knowledge and understanding of physical literacy. Referring to the newly developed consensus statement, the MPLC includes the following five domains related to the relationship with movement and physical activity throughout life:~i) Why physical literacy matters - improves health, well-being and quality of life.~ii) Understanding physical literacy - value, enjoy and engage in physical activity for life.~iii) Everyone's physical literacy is different - their individual needs and experiences of movement and physical activity.~iv) Building physical literacy - think, feel, move and connect with others. v) How experience affects physical literacy - people, places and spaces around us."
75438887|NCT05705284|Other|Structured multidisciplinary medication review|Multidisciplinary process for medication review/deprescribing: The intervention will be a structured process for performing a shared-decision, person-centred medication review among those living with frailty involving GPs, PCN-pharmacist and ANPs.
76053821|NCT02217566|Drug|Prednisone|Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
76053822|NCT02217566|Drug|Androgen deprivation therapy (ADT)|Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
76053823|NCT02217410|Biological|CFZ533|
75588716|NCT04540601|Other|Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)|"We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday."
75588717|NCT01682109|Drug|Valacyclovir|
76053824|NCT02217410|Drug|Tacrolimus (Tac)|
76053825|NCT02217410|Drug|Mycophenolate mofetil (MMF)|
76053826|NCT02217410|Drug|Corticosteroids (CS)|
76053827|NCT02217410|Biological|anti-IL2 Induction|
76053828|NCT02217332|Drug|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
75588718|NCT02215148|Drug|Tolvaptan|
75588719|NCT01682265|Other|Stretta procedure|
75588720|NCT01682265|Other|Sham procedure|No radiofrequency delivered
75438888|NCT05705245|Other|recruitment|Automated alveolar recruitment menouever applied during mechanical ventilation in the intraoperative period
75438889|NCT05705180|Biological|recombinant adjuvanted zoster vaccine|vaccination with recombinant adjuvantes zoster vaccine
75438890|NCT05705076|Drug|catheter induced thromboprophylaxis|Direct oral anticoagulation for catheter induced thromboprophylaxis
75438891|NCT05705063|Other|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 6 weeks
75588721|NCT01682343|Dietary Supplement|Calcium|Milk-calcium supplement
75588722|NCT04542746|Procedure|Minimally invasive surgical technique|After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
75732780|NCT06137859|Behavioral|Daily based reflective writing|At the end of the baseline stage of this study, each participant of the intervention group will receive a template notebook for daily-based reflective writing. The required columns consist of the daily diet, physical activity, mood and sleep quality. Participants will be required to write down their behavior in this notebook daily. In each week's functional training course, there will be a life-sharing session, where the participants will be reminded to bring their notebooks and share their daily activities with others. They will receive feedback, advice and encouragement from the instructor and each other. The notebook will be collected during the last week of the intervention.
75732781|NCT06137859|Behavioral|Buddy Peers Support Group|Peer-support groups with buddy members will be arranged in each daycare center. Three pairs of buddies and hence about 6 participants will be formed per group. A total of 6 buddy pairs and 2 groups will be formed per daycare center. Buddy peers will encourage each other to do functional exercises regularly or to perform functional exercises together. The time and place for the practice will be decided among buddy members. A member in each group will be nominated as the leader to assist in the liaison and coordination of group activities. The group will perform weekly group-based functional exercises, and the time and place for the practice will be decided among group members. The group will be encouraged to hold monthly gatherings with their fitness instructor in order to strengthen social support.
76053829|NCT02184572|Biological|Priorix|1 dose administered subcutaneously in the triceps region of left arm at Day 0
76053830|NCT02184572|Biological|M-M-R II|1 dose administered subcutaneously in the triceps region of left arm at Day 0
75588723|NCT01648257|Drug|GSK1265744 Na Salt Tablets|Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
75882880|NCT04409665|Drug|Glucose|Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
76053831|NCT02184572|Biological|Varivax|1 dose administered subcutaneously in the triceps region of right arm at Day 0
76053832|NCT02184572|Biological|Havrix|1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
76053833|NCT02184572|Biological|Prevnar 13|1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
76053834|NCT02181842|Drug|Pioglitazone|Pioglitazone tablets
76053835|NCT01632020|Drug|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
76053836|NCT01632020|Drug|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
76053837|NCT02181296|Drug|ropivacaine|
76053838|NCT04761692|Behavioral|Full VEPMP Intervention|Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
75588724|NCT01648257|Drug|GSK1265744 Free Acid Nanomilled Capsules|Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
75588725|NCT01648257|Drug|GSK1265744 Free Acid Micronized Capsules|Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
75588726|NCT04540250|Other|questionnaire|conventional intra-oral examination and questionnaire
76053839|NCT04761692|Behavioral|Partial VEPMP Intervention|Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
75438892|NCT05705037|Other|CPP-ACPF|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
75438893|NCT05705037|Other|PBMT|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
75438894|NCT05705037|Other|CPP-ACPF+PBMT|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2.
75438895|NCT05704998|Other|Physiotherapy|Posture exercises, myofascial release techniques, sternocleidomastoideus and upper trapezius kinesio taping, trigger point ischemic compression, suboccipital release technique, cervical traction, deep neck flexors endurance exercises, massage
75438896|NCT05704972|Other|the operating room environment risk|in determining the risks they face in the operating room environment.
75438897|NCT05704959|Diagnostic Test|povidone iodine|Reference measurements were made simultaneously with two separate calibrated pulse oximeter devices from the index, middle and ring fingers of both hands of the participants. One layer of 10% povidone iodine was applied to the index finger, two layers to the middle finger, and three layers to the ring finger of one hand of the participant's choice. Two pulse oximetry measurements were made with the fingers of the other hand, immediately after the application of povidone-iodine and three minutes later, and it was noted on the data collection form.
75438898|NCT05704894|Biological|Erythropoietin|Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between <12g/dL
75588727|NCT01648335|Device|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
75588728|NCT01648335|Device|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
75588729|NCT02215460|Procedure|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
75588730|NCT02215460|Procedure|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
75588731|NCT02215460|Drug|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
75588732|NCT02215460|Drug|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
75882881|NCT02854800|Drug|varenicline|Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
75882882|NCT03552770|Drug|Bevacizumab|pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
76053840|NCT04761692|Behavioral|Delayed VEPMP Intervention|Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start
76053841|NCT02215616|Drug|Laquinimod|Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
76053842|NCT02215616|Drug|Placebo|Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
76053843|NCT02213666|Device|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
76053844|NCT02213510|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
75732782|NCT06137833|Dietary Supplement|APPOPRTAL®|1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg
75438899|NCT05704881|Diagnostic Test|End-Tidal CO2 measurement during COPD exacerbation|The EtCO2 will be measured at the emergency reception during assessment of vital signs by the nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. The outcome will be the initiation of invasive or non-invasive ventilation (NIV) within the first 24 hours of admission to the emergency department, as indicated by the physician in charge of the patient.
76053845|NCT02213510|Device|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
76053846|NCT02158442|Procedure|Percutaneous Isolated Limb Perfusion (PILP) delivery|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
75438900|NCT05704842|Behavioral|Exercise|Home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises.
75438901|NCT05704816|Other|Spinal anesthesia application|The success of the needles with different tip designs and thicknesses used in spinal anesthesia application
75438902|NCT05704790|Other|Cognitive Compensatory Training|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
75438903|NCT05704777|Behavioral|Exercise|A 24-weeks concurrent exercise training program
75438904|NCT05704777|Other|Control|Usual care
75438905|NCT05704699|Behavioral|eTRE|eating between 0800h and 1600h daily
75588733|NCT02215460|Drug|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
75588734|NCT02215460|Drug|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
75588735|NCT02215460|Drug|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
76053847|NCT02158442|Drug|Timentin|The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
76053848|NCT02158364|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
76053849|NCT02180672|Drug|Nasal Fluticasone|One spray per nostril, per day.
76053850|NCT02180672|Drug|Placebo|One spray per nostril, per day.
75438906|NCT05704699|Behavioral|eTRE with BISC|eating between 0800h and 1600h daily and completing 3 sessions of BISC per week of study duration
75438907|NCT05704686|Device|Isopure 1.2.3 intraocular EDOF lens implantation|Bilateral Isopure 1.2.3 intraocular EDOF IOL implantation during a routine cataract surgery.
75438908|NCT05704660|Behavioral|Adjusted Cognitive-biased modification task|The intervention of the proposed project is based on a go/no-go task in which older adults need to quickly decide whether or not they should react to the stimulus. A rectangle containing an image, or a word will be presented on a screen. In the intervention group, older adults will be instructed to restrain their actions when the rectangle is tilted to the right and to react by pressing a key on the keyboard when the rectangle is tilted to the left, irrespective of the content of the rectangle (because the training is meant to be implicit). In order to train inhibitory processes counteracting the automatic attraction to sedentary behavior, 90% of the rectangles tilted to the right (counterbalanced across participants) will contain a picture or a word related to sedentary behavior. To foster the automatic attraction toward physical activity, 90% of the rectangles tilted to the left will contain a picture or a word related to physical activity.
75732783|NCT06137833|Other|Placebo|Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene
75732784|NCT06137820|Device|Cetilar® (topical cream)|Topical cream twice daily for 30 days. An average amount of 5 g per day.
75438909|NCT05704660|Behavioral|Cognitive-biased modification task|In the comparison group, instructions will be identical, but the percentage of physical activity and sedentary stimuli will be equal in each tilt condition (i.e., 50% sedentary stimuli and 50% physical activity stimuli in both right- and left-tilted rectangles)
75732785|NCT06137820|Device|Cetilar Placebo|Cetilar placebo cream matching to Cetilar®. Topical cream twice daily for 30 days. An average amount of 5 g per day
75438910|NCT05704608|Other|Aerobic training|Exercises on a treadmill at different speeds and inclination were performed.
75438911|NCT05704348|Procedure|Sleeve gastrectomy with gastropexy|Gastropexy in this project means suturing the gastric remnant to the gastrocolic ligament.
75732786|NCT06137807|Device|TricValve® Transcatheter Bicaval Valve System|The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve implantation system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The system is a single use, sterile device compatible with all the valve sizes. The valves are premounted in the TricValve® Delivery System. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system available in sizes 25 and 29 for superior vena cava and 31 and 35 for inferior vena cava. The valve is implanted percutaneously by the transfemoral approach. The valves are supplied already premounted into the TricValve® Delivery System.
75732787|NCT06137807|Procedure|Medical Therapy Arm|"Subjects will be randomized and managed on standard of care therapy, per physician discretion.~*Ability to cross-over after 18-Month Follow-Up completed"
75588736|NCT02215460|Drug|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
75732788|NCT06137794|Other|"Use of I-Anticoagulation to make the decision and manage patients"|I-Anticoagulation will offer a flexible and efficient communication platform for healthcare professionals and AF patients. The tool is composed of two modules: an anticoagulation decision support system and a full-process patient management system.
75732789|NCT06137781|Behavioral|Six weeks of digital prehabilitation|All participants will be allocated to receive six weeks of digital prehabilitation via PreActiv's website, plus usual care.
75588737|NCT02215460|Drug|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
75588738|NCT02215460|Drug|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
75732790|NCT06137768|Drug|HRS-5965|HRS-5965
75732791|NCT06137768|Drug|Placebo|Placebo.
75732792|NCT06137729|Drug|PF-07899895|Participants will receive oral ascending doses.
75438912|NCT05704348|Procedure|Sleeve gastrectomy without gastropexy|Sleeve gastrectomy without suturing the gastric remnant to the gastrocolic ligament.
75588739|NCT02215499|Drug|Placebo|
75588740|NCT02215499|Drug|Sodium Oxybate|
75588741|NCT02215499|Drug|JZP-386|
75732793|NCT06137729|Drug|Placebo|Participants will receive matching placebo.
75732794|NCT06137716|Device|Training with a Robotic Hand Exoskeleton|The rehabilitation program extended over six consecutive weeks. Each therapy session, lasting 45 minutes, occurred four times per week, resulting in a total of 24 sessions. Within each session, a total of six exercises, consisting of three passive exercises and three bilateral exercises, were performed in an alternating manner. The exercises were executed in the following sequence: 1) Bilateral hand opening and closing; 2) Passive independent finger opening and closing; 3) Bilateral pinch; 4) Passive hand opening and closing; 5) Bilateral hand opening and closing based on a VR-based game involving squeezing an orange; 6) Passive pinch.
75732795|NCT06137703|Drug|Zavegepant 100mg non-enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule
75438913|NCT05704270|Behavioral|Multi-domain adaptive cognitive training|The multi-domain adaptive cognitive training covers seven aspects of fundamental cognitive function, including sensory perception, cognitive flexibility, attention, memory, language, logic calculation, and emotion recognition and management. A self-adaptive algorithm is embedded in the tablet-based cognitive training platform, which will help deliver suitable tasks at the right difficulty level for each participant according to their personal profile and real-time performance. The intervention dosage is 30 minutes per time, 5 times a week.
75438914|NCT05704270|Behavioral|Basic cognitive training with no difficulty change|The basic cognitive training for the control arm will also be delivered via a tablet. The training tasks will be fixed at a primary difficulty level without adaptive algorithm. The intervention dosage is also 30 minutes per time, 5 times a week.
75438915|NCT05704231|Behavioral|Behavioral: Motivational Interviewing with WhatsApp video call|The intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interviews will be applied every two weeks, 6 times in total.
75438916|NCT05704218|Biological|blood sample|the patient will have a blood sample in order to perform serology tests
75732796|NCT06137703|Drug|Zavegepant 100mg immediate release tablet|Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet
76053851|NCT02213198|Behavioral|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
75588742|NCT01648608|Drug|Exemestane|Exemestane for neoadjuvant chemotherapy
75588743|NCT02215538|Drug|OROS methylphenidate|
75588744|NCT02215538|Drug|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
75588745|NCT01682421|Drug|Weak steroid (Flurolon, Allergan)|
75588746|NCT01682421|Drug|Potent steroid (Maxidex, Alcon)|
75588747|NCT04540172|Behavioral|Music Therapy|"Mahur tune, one of the nonverbal instruments of the Traditional Turkish Music Authorities, was selected for the study with the opinion of a music therapy specialist."
75588748|NCT04540172|Behavioral|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercise were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association."
75588749|NCT01682499|Drug|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
75732797|NCT06137703|Drug|Zavegepant 2 x 100mg immediate release tablets|2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg
75588750|NCT04540055|Procedure|Paravertebral block|The subjects in this group received general anesthesia and USG-guided paravertebral block
75588751|NCT04540055|Procedure|General Anesthesia|The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
75588752|NCT02215655|Behavioral|Motivational interviewing|Motivational interviewing counselling sessions will be administered to the subjects.
75438917|NCT05704179|Other|Obstetric Quality of recovery score|Patients' quality of recovery will be evaluated with Obstetric Quality of recovery score (ObsQoR-11) on postpartum day 1 and day 2.
75438918|NCT05704153|Device|Parasym 1Hz|Transcutaneous auricular vagus nerve stimulation of 1Hz
75438919|NCT05704153|Device|Parasym 30Hz|Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz
75732798|NCT06137703|Drug|Zavegepant 4 x 25mg enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg
75438920|NCT05704153|Device|Sham Intervention|Sham stimulation
75438921|NCT05704140|Other|Catheter based Dialysis|We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.
75438922|NCT05704127|Other|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
75438923|NCT05704127|Other|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
75438924|NCT05704114|Drug|Tazarotene 0.045% Lotion|Daily topical use of tazarotene for 16 weeks.
75438925|NCT05704088|Drug|Dapagliflozin tablet|randomized control trial, study group will receive dapagliflozin tablets
75588753|NCT01202773|Drug|LY2127399|Administered Subcutaneously (SC)
75588754|NCT01202773|Drug|Placebo Q4W|Administered SC
75588755|NCT01202773|Drug|Placebo Q2W|Administered SC
75588756|NCT01648686|Procedure|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
75588757|NCT02215694|Dietary Supplement|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
75588758|NCT02215694|Dietary Supplement|placebo|2g of powder daily without probiotics
75588759|NCT01648725|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
75588760|NCT01648725|Procedure|usual care|Standard care before induction of anesthesia
75732799|NCT06137677|Other|Sweet Snack|A sweet food will be served for the snack
75732800|NCT06137677|Other|Savory Snack|A savory food will be served for the snack
75732801|NCT06137664|Biological|Novel oral poliomyelitis vaccine type 1 (nOPV1)|Live attenuated novel poliomyelitis virus type 1 at two different dosages, containing middle-dose (MD) 10^6.0, or high-dose (HD) 10^6.5 CCID₅₀/dose
75588761|NCT04539782|Other|Physiotherapy intervention|Compare the effect of structured pelvic floor muscle training supported by physiotherapist post operation on POP on recurrence of symptoms or symptoms in a new compartment, quality of life and pelvic floor muscle function.
76053852|NCT02213198|Behavioral|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
76053853|NCT02157506|Drug|CXL-1427|
76053854|NCT02157506|Drug|Placebo|
76053855|NCT01920711|Drug|LCZ696|LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
75438926|NCT05704088|Drug|placebo|randomized control trial, control group will receive placebo tablets
75438927|NCT05704075|Procedure|Transverse Tibial Transport (TTT)|Transverse tibial transport is a novel adaptation of concepts used in distraction histogenesis. The most common use of this surgical principle is in bone lengthening surgery, which is a well-established surgical procedure by applying an external fixator to the bone, creating a corticotomy, and gradually lengthening the bone at the optimal rate of 0.5mm/12hrs. The biological mechanisms of distraction histogenesis involve activating signalling pathways such as cytokines Interleukin 1 and Interleukin 6, pro-inflammatory markers TNF alpha, pro-osteogenic TGF-beta, BMPs and pro-angiogenic factors VEGF and angiopoietin . TTT utilises the concept of distraction histiogenesis, but distraction is performed in the transverse plane instead of a longitudinal distraction. In addition, the period of distraction is coupled with a corresponding compression period and ultimately results in no net change in limb length.
75438928|NCT05704075|Procedure|Conventional|Dressing + Negative Pressure Wound Therapy
75438929|NCT05704023|Behavioral|Reminder to exercise|Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
75588762|NCT01180660|Drug|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
75588763|NCT01180660|Drug|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
75588764|NCT04539860|Device|Transdermal Optical Imaging|Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
76053856|NCT01920711|Drug|Valsartan|Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
76053857|NCT02180438|Drug|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
75438930|NCT05703997|Dietary Supplement|Cyclic, 5-day calorie restriction|Cyclic, 5-day, calorie-restricted (about 600 Kcal on day 1; about 300 Kcal on days 2 to 5), plant-based, low-protein, low-carbohydrate diet.
75438931|NCT05703997|Drug|Atezolizumab|Atezolizumab 1200 mg administered intravenously.
75438932|NCT05703984|Drug|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
75588765|NCT01648881|Radiation|TEP-18FDG for every patient after aortic dissection|"Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.~Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
75588766|NCT01202227|Drug|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
75588767|NCT04539821|Other|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials.
75588768|NCT01682694|Dietary Supplement|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
75588769|NCT01682694|Dietary Supplement|placebo|
75588770|NCT04539587|Other|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22"
75588771|NCT01682733|Drug|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
75588772|NCT01682733|Device|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
75588773|NCT01682772|Drug|Olaparib|Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
75588774|NCT01682850|Behavioral|Mindfulness Based Pulmonary Rehabilitation|Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
75882883|NCT01373827|Device|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
75588775|NCT01682850|Other|Usual Care|
75588776|NCT01649037|Drug|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.[ No response defined as MAP < 10, or 4 hr Urine output < 200 ml] with maximum dose upto 3 mg/h."
75588777|NCT01649037|Drug|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response [< 25% decrease in s.creatinine] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
75438933|NCT05703984|Drug|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
75438934|NCT05703984|Drug|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
75438935|NCT05703984|Drug|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
75588778|NCT04539119|Drug|Tenofovir|Participants will be given tenofovir 300mg (1 capsule) qd po two weeks before the first cycle of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Tenofovir will be given until the copy count of HBV DNA drops below 1*10^3/L.
75588779|NCT04539119|Drug|Entecavir|Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
75588780|NCT02279511|Drug|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
75588781|NCT02279511|Drug|PLACEBO|Infusion of 500 mL of saline solution. (IV)
75588782|NCT04538885|Biological|The pleiotropic factor derived from mesenchymal stem cells|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
75588783|NCT01682889|Dietary Supplement|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
75588784|NCT01682889|Dietary Supplement|Placebo|NaCl 0.9% intravenously for 24h
75588785|NCT04538963|Device|Orthodontic Band affixed with Glass Ionomer Cement|Glass ionomer cement utilized to affix a blank orthodontic band to the tooth; the mechanical retention of the band will also help retain cement in contact with the tooth- the hypothesis is that the fluoride release from the cement will aid in remineralization of tooth structure.
75882884|NCT02118350|Behavioral|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
75882885|NCT05196139|Other|retrospective study|vitrectomy performed in case of submacular bleeding
75882886|NCT02125214|Device|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
75882887|NCT01375231|Procedure|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
75588786|NCT04538807|Diagnostic Test|electromyography|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
75588787|NCT04542902|Biological|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
75588788|NCT04542902|Procedure|Blood sampling|An amount of a person's blood taken from their body for use in medical.
75588789|NCT04542902|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
75588790|NCT02279628|Drug|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
75588791|NCT02279628|Drug|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
75588792|NCT04538924|Other|extended clinical, laboratory and instrumental examination; treatment options comparison|Multimodality investigation and different treatment comparison
75588793|NCT02279706|Other|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
75882888|NCT01375231|Procedure|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
75588794|NCT04538612|Device|measure capillary refill time|"Each time, capillary refill time will be evaluated three times consecutively by clinical method applying a firm pressure with the finger during 15s, then brutally releasing it, and estimating time of skin recoloration with a chronometer and by DiCART TM device~Three vascular occlusion tests will be successively performed with a cuff during less than 10 minutes:~Arterial vascular occlusion test (50mmHg above systolic arterial pressure of the healthy volunteers),~Veinous vascular occlusion test (30mmHg),~Control test without vascular occlusion test. Capillary refill time measurements will be repeated just before, during and just after vascular occlusion tests.~Randomization determine the order of the vascular occlusion tests. Investigators performing capillary refill time evaluation will be blinded from it. Vascular occlusion tests will be alternatively performed by one and the other limb. The whole protocol will be performed at the upper and then at the lower limb."
75588795|NCT04528524|Other|Questionnaire|QoR-15Dt
75588796|NCT04542629|Drug|RiTUXimab Injection [Rituxan]|375 MG/M2 /WEEK INFUSION
75588797|NCT01683006|Drug|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
75588798|NCT01683006|Drug|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
75588799|NCT04542668|Other|Cycling then running|Ergometer cycling Treadmill running
75588800|NCT04542668|Other|Running then cycling|Treadmill running Ergometer cycling
75588801|NCT04542668|Other|Inotropy|Adrenaline induced inotropy
75588802|NCT04542668|Other|Resting|Subjects must be minimally physically active
75732802|NCT06137664|Biological|Novel oral poliomyelitis vaccine type 2 (nOPV2)|Live attenuated novel poliomyelitis virus type 2 administered at low-dose (LD) 10^5.3 and HD 10^5.6 CCID₅₀/dose.
75588803|NCT01683045|Device|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
75588804|NCT01683162|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
75588805|NCT01683162|Drug|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
75588806|NCT01683162|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
75588807|NCT02215733|Drug|ARB|other than telmisartan
75588808|NCT02215733|Drug|ACEI|
75588809|NCT02215733|Drug|Beta-blockers|
75588810|NCT02215733|Drug|Diuretics|
75588811|NCT02215733|Drug|Telmisartan|
75588812|NCT01683201|Procedure|Functional exercise class|Functional exercise class running twice weekly for six weeks from week 12 to week 18
75588813|NCT01683201|Procedure|usual care group|Usual care group adhere to post operative instructions given on discharge from hospital
76053858|NCT02179190|Device|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
75588814|NCT02215772|Drug|BI 44370 BS|
75588815|NCT01202188|Drug|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
75732803|NCT06137664|Biological|Novel oral poliomyelitis vaccine type 3 (nOPV3)|Live attenuated novel poliomyelitis virus type 3 at two different dosages, containing MD 10^6.0, or HD 10^6.5 CCID₅₀/dose.
75438938|NCT05703932|Other|home-based exercises|Joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises will be applied. Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
75588816|NCT01202188|Drug|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
75588817|NCT01202188|Drug|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
75588818|NCT01202188|Drug|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
75732804|NCT06137664|Biological|Bivalent Oral Poliomyelitis Vaccine (bOPV)|Live attenuated poliomyelitis viruses types 1 and 3 (Sabin strains). Each dose (2 drops = 0.1 mL) contains not less than 10^6.0 infective units of type 1 and 10^5.8 of type 3.
75732805|NCT06137651|Procedure|Biospecimen Collection|Undergo collection of blood samples
75732806|NCT06137651|Procedure|Computed Tomography|Undergo CT scan
75732807|NCT06137651|Procedure|Magnetic Resonance Imaging|Undergo MRI
76053859|NCT02157116|Drug|cisplatin|
76053860|NCT02157116|Drug|Docetaxel|
75438939|NCT05703906|Behavioral|Telerehabilitation - VRRS Khymeia|Participants will receive an individualized, multidomain exercise program set up by the therapist, based on their needs. The intervention applied will consist of 20 sessions of motor, language and/or cognitive training distributed in five sessions for week, each lasting 1 hour. Remotely, the therapist will supervise the participant's exercise program.
75438940|NCT05703893|Diagnostic Test|Supine resting (REST) and active standing (STAND)|Analysis of baroreflex sensitivity
75588819|NCT01202188|Drug|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
75588820|NCT01649115|Other|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
75588821|NCT02215811|Biological|Mesenchymal stromal cells|
75588822|NCT01580046|Drug|iodixanol|"coronary angiography, 32gI/100ml, 40～60 ml once injection~left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
75588823|NCT01580046|Drug|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
75588824|NCT02215850|Drug|SLC-0111|
75588825|NCT01683318|Procedure|Thermal Pulsation therapy|
75588826|NCT01201915|Drug|Vismodegib|Vismodegib was supplied in gelatin capsules.
75588827|NCT01649154|Procedure|Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus|
76053861|NCT02157116|Drug|Pegfilgrastim|
76053862|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
76053863|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
76053864|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
76053865|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
75882889|NCT02035098|Other|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
76053866|NCT01920555|Drug|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
75438941|NCT05703802|Diagnostic Test|Procalcitonin-variants ELISA-Assay|Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.
75438942|NCT05703789|Procedure|Dental rehabilitation with either composite resin of crown therapy|Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
75438943|NCT05703789|Other|Waiting list|Waiting list. Patients randomized to this group will not receive any intervention but answer questionnaires after 4 months on waiting list
75438944|NCT05703776|Behavioral|Nordic Walking|Nordic Walking (NW) is an aerobic physical activity where regular walking is enhanced by the addition of the active use of specifically designed NW poles. The physical strain is distributed in a balanced way to various muscle groups of the whole body.
75438945|NCT05703698|Behavioral|Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
75438946|NCT05703620|Device|Renal Denervation|All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels
75588828|NCT04542122|Behavioral|Choices and judgements|In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
75588829|NCT04124770|Other|Movement|Re-positioning of neck
75588830|NCT04532879|Device|HygiPrep (HyGIeaCare System)|Controlled gravity-based high-volume colon irrigation
75588831|NCT01649193|Other|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
75588832|NCT04318288|Other|Observational|Observational
75732808|NCT06137651|Radiation|Radiation Therapy|Undergo radiation therapy
75588833|NCT01179919|Drug|Oseltamivir|Capsule, 75 mg by mouth for 9 doses
75732809|NCT06137651|Procedure|Resection|Undergo surgery
75732810|NCT06137651|Drug|Trotabresib|Given PO
75732811|NCT06137651|Drug|Vinorelbine|Given IV
76053867|NCT02156804|Drug|Nivolumab (BMS-936558)|
75732812|NCT06137625|Behavioral|With regular rhythm|All children learn one dance choreographie with regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
75732813|NCT06137625|Behavioral|Without regular rhythm|All children learn one dance choreographie without regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
75732814|NCT06137612|Diagnostic Test|MRI|axial 2D rAMIRA (radially sampled averaged magnetization inversion recovery acquisitions) imaging at selected levels of cervical and thoracic spinal cord at the intervertebral disc levels perpendicular to the spinal cord.
75732815|NCT06137599|Other|Capillary analysis|Samples taken between 2 and 6 months after the presumed events. A pre-analytical treatment of the hair (washing, fragmentation), followed by detection by high-resolution mass spectrometry is carried out by an expert laboratory to search for both GHB and psychoactive drugs.
75882890|NCT04394923|Procedure|Modification of the pulmonary vein ablation line|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.
75882891|NCT04394923|Procedure|Regular PVI ablation|Blinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF
75882892|NCT02125370|Other|Qualitative and survey|
75882893|NCT03605082|Drug|UCB0107|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
75882894|NCT03605082|Other|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
76053868|NCT02156492|Drug|Evacetrapib|Administered orally.
76053869|NCT02156492|Drug|Simvastatin|Administered orally.
76053870|NCT02156492|Drug|Atorvastatin|Administered orally.
76053871|NCT04753892|Other|3SM2-G-CRM197 with squalene adjuvant|Immune challenge agent
76053872|NCT04187690|Drug|Jin-shui Huan-xian granule|Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
75882895|NCT02126930|Other|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
75438947|NCT05703594|Diagnostic Test|performance based balance test|Performance based balance test; 360° Turn Test, Alternative Step Test, Pen Pickup Test,5 Repetitive Stand Up and Sit Test, 10 Meter Walk Test Lower extremity strengthening exercises; Quadriceps femoris strengthening exercise Hamstring strengthening exercise Gluteus medius muscle strengthening exercise Strengthening exercise for hip adductor muscles Balance exercises; Standing tandem walk Standing side walks Standing cross walks Standing back walking
75438948|NCT05703581|Procedure|TRIANGLE operation|dissection the region composed of common hepatic artery (CHA), superior mesenteric artery (SMA) and superior mesenteric vein (SMV)
75438949|NCT05703555|Drug|Tusamitamab ravtansine|Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Subjects without evidence of disease progression or drug related toxicity can continue treatment with Tusamitamab ravtansine (100 mg/m2 IV Q2W) until disease progression, unacceptable toxicity occurs, or the participant's or Investigator's decision to stop the treatment.
75588834|NCT01649310|Other|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
75438950|NCT05703529|Behavioral|Positive Psychotherapy|A 6-week group-based positive psychotherapy was conducted in this group. The themes of each week include positive introduction, three good things and positive reactions, gratitude, positive memory, identifying personal strengths and utilizing strengths.
75588835|NCT01201798|Drug|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
75438951|NCT05703529|Other|Usual Care|Usual Care means treating as usual, including a regular home visit.
75438952|NCT05703451|Other|laparoscopic surgery|"during laparoscopy Any adhesions will be noticed, the prevalence of adhesions will be calculated regarding the age, parity, previous history of miscarriage and past medical history.~The prevalence of adhesions will be calculated according to the indication of laparoscopy.~The prevalence of adhesions will be compared according to different items. Comparison between patients with no past surgical history and those who have past surgical history.~Comparison between patients who have history of ectopic pregnancy and those who have no history of ectopic pregnancy.~Comparison between patients with previous caesarean section and patients with previous other abdominopelvic surgery."
75438953|NCT05703373|Dietary Supplement|Multiple Micronutrient Supplement|Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,
75588836|NCT01201798|Drug|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
75588837|NCT04539353|Other|Heart Rate Variability|Heart Rate Variability will be measured with a Polar device.
75588838|NCT04539353|Other|Pain intensity|Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
75588839|NCT02887456|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
75588840|NCT02887456|Drug|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
75588841|NCT01201759|Drug|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
75588842|NCT01201759|Drug|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
75732816|NCT06137573|Drug|[14C]TNP-2198|600mg suspension containing 150μCi of [14C] TNP-2198
76053873|NCT04187690|Drug|Jin-shui Huan-xian granule placebo|Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
76053874|NCT01920477|Biological|Ofatumumab|Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product
75438954|NCT05703321|Behavioral|preoperative fasting|Fasting for 6 hours is required for the patients regarding the preparation of the operation and preparation for anesthesia
75588843|NCT04315597|Drug|Laif® 900, BAY98-7108|1 x daily, 1 tablet, 900 mg
75588844|NCT04315597|Drug|Placebo|1 x daily, 1 tablet, 900 mg
75732817|NCT06137560|Device|Single vision spectacle lens|Standard single vision spectacle lens
75732818|NCT06137560|Device|Single vision spectacle lens + S.T.O.P.® Kit 1|Standard single vision spectacle lens + S.T.O.P.® Kit 1
75732819|NCT06137560|Device|Single vision spectacle lens + S.T.O.P.® Kit 2|Standard single vision spectacle lens + S.T.O.P.® Kit 2
75732820|NCT06137560|Device|Single vision spectacle lens + S.T.O.P.® Film|Standard single vision spectacle lens + S.T.O.P.® Film
75732821|NCT06137560|Device|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
75882896|NCT02126930|Other|Routine care|Patients randomized to this arm will receive care in the habitual manner.
75882897|NCT03602274|Diagnostic Test|Hepatic function monitoring|AST, ALT, GGT, AP, Bilirubin
75588845|NCT01683396|Drug|Placebo|Solution for subcutaneous injection
75882898|NCT03602274|Diagnostic Test|Nutritional status assesment|PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements
75882899|NCT03602274|Other|Biomarker research sampling|Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
75588846|NCT01683396|Drug|gevokizumab|Solution for subcutaneous injection
75882900|NCT02118506|Other|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
75438955|NCT05703308|Biological|Autologous Menstrual Blood Stem Cells|The menstrual blood of patients in the MenSCs treatment group was collected in sterile menstrual cups on the second day of menstruation, and directly transferred to a class B clean room for MSC isolation and culture. All cell quality control studies were performed prior to the International Conference of Harmonization Q2 (ICH Q2) guidelines. The density of the final product was 20×106 cells/ml. 150 μl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia
75882901|NCT02118506|Other|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
75882902|NCT05376384|Diagnostic Test|ultrasound parameters|Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.
76053875|NCT01920477|Biological|Placebo|Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
75588847|NCT04532840|Device|cryotherapy (Gymna Cryoflow ICE-CT)|Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
75732822|NCT06137547|Device|Hypotension prediction index (HPI)|The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.
75732823|NCT06137534|Other|Proprioceptive Neuromuscular Facilitation Upper Extremity Pattern|"Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.~PNF upper extremity patterns to be applied to the participants:~Bilateral symmetrical flexion-adduction-external rotation.~Bilateral symmetrical flexion-abduction-external rotation.~Bilateral asymmetric right: flexion-abduction-external rotation, left: flexion-adduction-external rotation.~Bilateral reciprocal (same diagonal) right: extension-adduction-internal rotation, left: flexion-abduction-external rotation.~Bilateral reciprocal (same diagonal) right: flexion-adduction-external rotation, left: extension-abduction-internal rotation.~Bilateral reciprocal (opposite diagonal) right: extension-adduction-internal rotation, left: flexion, adduction, external rotation."
75732824|NCT06137521|Procedure|Coronary angiography|
75882903|NCT05376384|Procedure|intraoperative parameters|Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use
75882904|NCT02127008|Procedure|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
75882905|NCT02127008|Procedure|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
76053876|NCT04641195|Dietary Supplement|Vitamin D3 (cholecalciferol)|180,000 international units (IU) of vitamin D3 at enrollment, followed by 2000 IU once per day from enrollment to 8 weeks
75438956|NCT05703295|Procedure|Biopsy|Sentinel lymph node biopsy
75588848|NCT04532840|Other|Exercising, Positioning and splinting, Pressure Therapy and Massage|Exercising, Positioning and splinting, Pressure Therapy and Massage
75588849|NCT01649349|Device|two-piece nasogastric tube|one week period
76053877|NCT04641195|Dietary Supplement|Zinc (zinc gluconate)|40mg of zinc gluconate taken once per day from enrollment to 8 weeks
75438957|NCT05702320|Other|the heating procedure|The patients will undergo a heating procedure.
75438958|NCT05702190|Drug|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
75438959|NCT05702190|Drug|Placebo|Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
75588850|NCT04538846|Other|Culinary art therapy|Culinary art therapy is a novel approach which broadly perceives food and cooking as enabling participants to explore needs, patterns and relationships and facilitate therapeutic processes.
75588851|NCT01683435|Other|HBA binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
75588852|NCT04532684|Drug|Duloxetine|
75588853|NCT04532684|Drug|Pregabalin|
75882907|NCT02931539|Drug|Maribavir|Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
75438960|NCT05701124|Drug|Ranibizumab (0.25 mg/0.025 mL)|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
75438961|NCT05700071|Diagnostic Test|MRI|MRI without contrast agent
75438962|NCT05699889|Other|Data collection|acute kidney injury and tubular dysfunction
75438963|NCT05696015|Behavioral|Standard education|Without telehealth education, this group has only postdischarge education.
75438964|NCT05696015|Behavioral|Ampiled Education|With telehealth education, in addition of discharge education.
75438965|NCT05692037|Combination Product|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres|Yttrium-90 carbon microspheres SIRT
75438966|NCT05673291|Other|No intervention|Volunteers who will be included in the research will be informed about the research and an informed consent form will be signed. Questionnaire evaluating sociodemographic characteristics and working positions; The Extended Nordic Musculoskeletal Questionnaire (7) and measurements made with the Spinal Mouse device for posture analysis will be applied when individuals feel comfortable. Questionnaires and device and posture analysis will be carried out after the purpose of the research is explained to the individuals and their consent is obtained. The data will be analyzed in the SSPS program. Number, percentage, standard deviation and mean from descriptive statistics will be used in the evaluation of the data. The relationship between posture and musculoskeletal pain will be evaluated by correlation analysis. The confidence interval of the research will be 95% and the significance level will be considered as p<0.05.
75588854|NCT01683474|Device|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
75438967|NCT05627453|Other|Arm-in-arm gait training|An older adult walk side-by-side, arm-in-arm with a younger adult while synchronizing steps.
75438968|NCT05627453|Other|Normal gait training|An older adult walk side-by-side, without contact, with a younger adult without step synchronization.
75588855|NCT04538768|Procedure|Mesh augmentation|P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure
75732825|NCT06137456|Device|Exoskeletal robotic therapy for walking.|Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.
75732826|NCT06137456|Other|Conventional exercise therapy|Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
75732827|NCT06137443|Device|Balance Training|Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
75882908|NCT02931539|Drug|Ganciclovir|Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
75882909|NCT02931539|Drug|Valganciclovir|Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
75438969|NCT05612529|Device|US , Echocardiography|"Carotid ultrasonography: Parameters will be measured by single blinded independent examiner using an ultrasound device. Baseline carotid FTc, ΔVpeak, will be measured.~Echocardiography: Stroke Volume will be measured by transthoracic echocardiography.~Renal and splenic Doppler resistivity index.~Inferior vena cava collapsibility and distensibility indices.~Central venous pressure estimation by central venous catheter, and central - Lung ultrasound for detection of lung congestion~Lung ultrasound for detection of lung congestion."
75588856|NCT04538768|Procedure|Direct suture|direct fascia suture
75882910|NCT02931539|Drug|Foscarnet|Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
75438970|NCT05610254|Drug|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
75438971|NCT05593107|Drug|[68Ga]N188|68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
75438972|NCT05584709|Biological|STI-6129|Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).
75438973|NCT05576441|Procedure|volume stable collagen matrix|Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.
75588857|NCT01683513|Drug|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
75588858|NCT01649466|Drug|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
75588859|NCT01649466|Drug|Protaphane|Protaphane will be used as commercially available injection pens
75588860|NCT01200589|Biological|Ofatumumab|liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.
75588861|NCT01200589|Biological|Rituximab|sourced locally from commercial stock
75588862|NCT01200589|Biological|Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
75732828|NCT06137430|Drug|Sodium-glucose cotransporter 2 inhibitor|Sodium glucose cotransporter 2 inhibitiors
75732829|NCT06137417|Device|PET/CT|• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.
75732830|NCT06137404|Other|Splint|Comparison of splints for trigger finger
75882911|NCT02931539|Drug|Cidofovir|Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
75588863|NCT01200589|Biological|Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
75588864|NCT04532762|Device|nasal spray|Application of a nasal spray
75588865|NCT01683552|Drug|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
75882912|NCT03602196|Other|Perineal ultrasound assessment|"women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study."
76053878|NCT04641195|Dietary Supplement|Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|180,000 IU of vitamin D3 at enrollment, followed by 2000 IU of vitamin D3 and 40mg of zinc gluconate once per day from enrollment to 8 weeks
75588866|NCT01683552|Drug|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
75732831|NCT06137352|Other|Follow up|Each subject was recruited in 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and followed up at 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, with a total of two follow-up visits. At enrollment and both follow-up visits, subjects were required to collect 2 tubes of peripheral venous blood each.
76053879|NCT04641195|Other|Placebo|Placebo vitamin D bolus at enrollment followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
75438974|NCT05576441|Procedure|subepithelial connective tissue graft|SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
75438975|NCT05568030|Behavioral|Mindfulness|One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.
75438976|NCT05568030|Behavioral|Psycho-education|One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
75438977|NCT05558904|Drug|Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|Given IV
75438978|NCT05558904|Procedure|Computed Tomography|Undergo PET/CT
75438979|NCT05558904|Other|Laboratory Biomarker Analysis|Correlative studies
75438980|NCT05558904|Procedure|Positron Emission Tomography|Undergo PET/CT
75438981|NCT05506098|Other|no intervention|no intervention
75588867|NCT01683552|Drug|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
75438982|NCT05504486|Drug|Brexpiprazole|Oral tablet; take once daily; target daily dose of 2 mg
75438983|NCT05502835|Device|pulse pressure variation|Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
75438984|NCT05502835|Other|conventional fluid management|Infusion of 6 ml/kg/hr. Ringer's solution.
75438985|NCT05480995|Drug|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
75438986|NCT05479630|Other|Transition With a Heart (TWAH)|TWAH is a transition program, especially developed for adolescents with CHD and their parents. TWAH is starting at the age of 12 years and continuing after transfer. The most vital core components include a general and individualized flowchart, adolescent-centred communication, a joined transfer consultation and an appointed transition coordinator. TWAH focuses on promoting disease knowledge, autonomy and skills development of adolescents with CHD. Interventions encompass the use of a communication-paper, autonomously talking to professionals, individualized education and skills development plan. Details can be found in De Hosson et al, 2020 (1).
75438987|NCT05476939|Drug|Everolimus|Tablets of 2.5 mg or 10mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10mg once daily.
75588868|NCT04532723|Device|ExoAtlet II|ExoAtlet II is the second version of an exoskeleton that ExoAtlet has manufactured
75588869|NCT01200511|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
75732832|NCT06137339|Other|Avocado Group|Participants will consume provided avocados daily and track consumption for the duration of the study. Participants will be adding avocados to their diet and will receive education on maintaining usual diet.
75732833|NCT06137326|Device|Pulsed Electromagnetic Field Therapy|Participants in this arm will receive pulsed electromagnetic field (PEMF) therapy to the pelvic floor area along with pelvic floor muscle training. The PEMF device generates a pulsed magnetic field with the following parameters: frequency 10 Hz, intensity 200 μT, pulse duration 250 μs. It will be applied over the pelvic floor for 20 minutes per session, 5 days per week for 8 weeks.
75588870|NCT04532567|Drug|GLPG1205|GLPG1205 film-coated tablets
75588871|NCT04532567|Drug|Placebo|placebo film-coated tablets
75588872|NCT04528368|Biological|Convalescent plasma|The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.
75588873|NCT01683591|Procedure|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
75588874|NCT02216981|Behavioral|Cognitive Behavioural Therapy (CBT)|
75438988|NCT05476939|Drug|ONC201|Capsules of 125mg. 375mg/m2 per dose, day 1 and day 2 of each week. Dose will be capped at 625mg per dose.
75588875|NCT01683708|Dietary Supplement|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
75588876|NCT01649544|Device|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
75588877|NCT01649544|Drug|Amiodarone|
75438989|NCT05476939|Radiation|Radiotherapy|"All patients will be treated with 30 conventional single daily fraction of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start ideally within three weeks (MAXIMUM four weeks) after the biopsy or last surgery. Radiotherapy should be planned as soon as the biopsy date is known (between 10 and 21/28 days after the planned date of biopsy).~Treatments will start on the first day of irradiation (+3 days max). Reirradiation is permitted according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within three weeks (4 weeks maximum) after the biopsy while targeted treatment will start at the end of the irradiation."
75438990|NCT05470621|Behavioral|PlayOn! playground curriculum|A staff and student training to implement a playground curriculum in after-school and recess settings
75588878|NCT04538729|Behavioral|Acne Vulgaris|Alternative medicine and complementary therapies that acne vulgaris patients apply without informing the doctor, how they learn these techniques, what make them use these techniques for their illness
75588879|NCT04528290|Drug|Ozanimod|Ozanimod capsule formulation of 0.92mg
75438991|NCT05465057|Behavioral|High intensity interval training (HIIT) + lifestyle intervention (TCOCT)|"The participants randomized for HIIT will perform supervised training sessions three times a week for 3 months. All HIIT programs consist of activities that involve 4 x 4 min. intervals at 90-95% of HRmax.~The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks."
75588880|NCT04528290|Drug|Ozanimod|Ozanimod, granule formulation of 0.92mg
75588881|NCT04538690|Other|Shoulder Exercises|Exercises consist of shoulder range of motion, releasing exercises, strength training, stretching.
75588882|NCT04538690|Other|Electrotherapy|TENS, US
75588883|NCT01179334|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
75588884|NCT01179334|Drug|Placebo|Placebo for 12 weeks
75588885|NCT01179334|Drug|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
75588886|NCT01649583|Device|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
75588887|NCT04532450|Device|Branched / fenestrated aortic stent graft|Endovascular repair of an aortic aneurysm with a branched/fenestrated stent graft to revascularise all visceral arteries together with exclusion of the aortic aneurysm.
75588888|NCT02886481|Device|perioperative monitoring|
75588889|NCT02886520|Device|PVDF transobturator tape|
75588890|NCT02886520|Device|Polypropylene transobturator tape|
75588891|NCT01649622|Drug|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
75732834|NCT06137326|Device|Laser Acupuncture|Participants in this arm will receive low-level laser acupuncture to pelvic floor trigger points along with pelvic floor muscle training. A continuous wave 810 nm diode laser will be used at 100 mW power and 0.5 J/point, delivered to 6 pelvic floor acupoints bilaterally (12 points total) for 15 seconds per point. Acupuncture will be performed 3 days per week for 8 weeks.
75732835|NCT06137300|Drug|Urinary kallidinogenase for injection|Urinary kallidinogenase 0.15PNA once daily for 7 days.
75732836|NCT06137300|Other|Guideline-prescribed medical therapy|Guideline-prescribed medical therapy
75732837|NCT06137274|Radiation|Intensity-modulated radiotherapy|All patients will be treated with intensity-modulated radiotherapy (IMRT) plans.
75732838|NCT06137274|Other|Magnetic Resonance Guidance|All patients will undergo combined CT and/or MR simulation and will be treated with a sequential-boost technique.
76053880|NCT02213042|Drug|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
75438992|NCT05465057|Behavioral|Lifestyle intervention (TCOCT)|The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks.
75438993|NCT05458232|Drug|Tadalafil 5mg|Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.
75588892|NCT04538300|Diagnostic Test|Abramowitz Emesis Score|Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.
75732839|NCT06137235|Other|cows milk infant formula and follow-on formula with bioactive ingredients|infant formula and follow-on formula with bioactive ingredients
75732840|NCT06137235|Other|standard cows milk infant formula and follow-on formula|standard cows milk infant formula and follow-on formula
75732841|NCT06137222|Device|Tenex TXB MicroTip Ultrasound system plus SOC|Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).
75732842|NCT06137222|Other|Standard of Care for diabetic foot ulcer|Use of standard of care for the treatment of a diabetic foot ulcer
75732843|NCT06137209|Other|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e7 cfu/ dose (Active)
75882913|NCT03602196|Other|Peripheral muscles assessment|"The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study."
75882914|NCT03602196|Other|Clinical pelvic floor assessment|"Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination"
75882915|NCT02125448|Device|MRI and PET-CT|
75882916|NCT05195671|Other|Review|Reviewing all protocols
75588893|NCT04538300|Diagnostic Test|Degree of nausea|Degree of postoperative nausea was evaluated.
75588894|NCT04538300|Diagnostic Test|Observer's Assessment of Alertness/Sedation Scale|Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
75588895|NCT04538300|Diagnostic Test|Patient Satisfaction|Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
75588896|NCT04538300|Diagnostic Test|Surgeon Satisfaction|Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
75732844|NCT06137209|Other|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group B: Blis Q24 Serum at 1e6 cfu/ dose (Active)
75732845|NCT06137157|Drug|ATR12-351|Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
75732846|NCT06137144|Drug|AZD3470|AZD3470 is a novel, potent and selective, secondgeneration, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
75732847|NCT06137092|Drug|Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)|rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
75882917|NCT02125526|Device|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
75732848|NCT06137040|Drug|Magnesium Sulfate within the first hour|"The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~>40 kg: 2000 mg"
75732849|NCT06137040|Other|No Magnesium sulfate within the first hour|The control group will not receive IV magnesium sulfate within the first hour of treatment.
75732850|NCT06137027|Drug|Cannabidiol Oil|Cannabidiol oil will be administered sublingually 2-3 hours preoperatively
75732851|NCT06137027|Drug|Placebo|Placebo will be administered sublingually 2-3 hours preoperatively
75438994|NCT05447598|Other|Nurse-led remote monitoring program|Symptoms of disease progression, clinical parameters, medication adherence and follow-up needs will be reported by patients or with support from relatives or homecare nurses 2-4 times/months over a three months period using a digital platform. Telephone monitoring is planned for patients who are not able to comply with the digital platform. In addition, an individualized self-treatment plan for diuretics and lifestyle advice will be prepared, preferably together with relatives at the outpatient clinic. Participants will also have access to a website with written information and videos about HF and self-management. Finally, a pillbox will be delivered to facilitate drug adherence.
75438995|NCT05447598|Other|Usual care treatment|Usual care treatment and follow-up care at the outpatient clinic and in primary care
75438996|NCT05412693|Device|Functional orthosis|See arm descriptions
75588897|NCT04538300|Other|Chewing Peppermint gum|Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
75588898|NCT02886676|Drug|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
75588899|NCT04315753|Other|LDCT (Low Dose CT)|validate the role of non-invasive molecular and cellular biomarkers and combined radiomic signature, as complementary tools to assist early detection of lung cancer by LDCT using bioinformatic techniques for the integration of the results
75732852|NCT06137014|Drug|Fortified Oral Rehydration Therapy|Oral rehydration solution with reduced glucose and added amino acids.
75438997|NCT05412693|Device|Cast immobilization|See arm descriptions
75438998|NCT05404594|Behavioral|Maternal vocal contact|"Two consecutive venipuncture (order randomly balanced) within a short period of time will be realized with and without the presence of the mother talking/singing to her VPI infant.~In this intervention group, the mother will be supported to talk or to sing to her infants during before and during the venipuncture."
75438999|NCT05389124|Behavioral|Partial abstinence from oral hygiene|One quadrant of the dentition will be protected from oral hygiene for 3 weeks.
75588900|NCT02886598|Drug|degarelix|
75588901|NCT01683747|Drug|Tranexamic Acid|
75588902|NCT01683747|Drug|Control Intervention (Carrier fluid only)|
75588903|NCT04538027|Procedure|Lumbar Microdiscectomy at 6 weeks of symptoms|Microscope assisted lumbar discectomy done at 6 weeks of starting symptoms
75588904|NCT04538027|Procedure|Lumbar Microdiscectomy at 3 months of symptoms|Microscope assisted lumbar discectomy done at 3 months of starting symptoms
75732853|NCT06137014|Dietary Supplement|Standard of Care Oral Rehydration Therapy|Glucose-based oral rehydration therapy according to World Health Organization guidelines.
75732854|NCT06136988|Drug|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m^2, Intravenous infusion, Q3W
75882918|NCT05195593|Device|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
75588905|NCT04538027|Procedure|Lumbar Microdiscectomy at 6 months of symptoms|Microscope assisted lumbar discectomy done at 6 months of starting symptoms
75588906|NCT01178671|Drug|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
75588907|NCT01178671|Drug|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
75588908|NCT01178671|Other|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
75588909|NCT02886637|Other|None intervention|
75588910|NCT04532216|Procedure|Arthroscopic-Assisted Acromioclavicular Joint Reconstruction Using the TightRope Device|Arthroscopic-assisted AC joint reconstruction with the TightRope device with allograft augmentation and with the patient in the lateral decubitus position is a method of restoring joint stability
75732855|NCT06136988|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
75588911|NCT04532216|Procedure|Traditional surgery|Tendon transfer
75588912|NCT01649700|Biological|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10^7 cells of autologous adipose-derived mesenchymal stem cells.
75588913|NCT04532060|Drug|Nystatin|
75439000|NCT05383274|Combination Product|Optilume Urethral DCB|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
75439001|NCT05382702|Other|Test meal description changed|Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.
75732856|NCT06136988|Drug|Cisplatin for injection|Cisplatin for injection, 25 mg/m^2, Intravenous infusion, D1-D3, Q3W
75732857|NCT06136988|Drug|Paclitaxel|Paclitaxel 135 mg/m^2, Intravenous infusion, Q3W
75439002|NCT05364840|Drug|STI-1558|Orally available protease inhibitor capsule
75732858|NCT06136988|Radiation|Simultaneous Radiotherapy|Radiotherapy (28×1.8Gy)
75732859|NCT06136975|Device|Low-level laser therapy|The treatment was once a week for eight weeks. The patient was in a supine position. The gain medium of the laser was Gallium-Aluminum-Arsenide. The laser was introduced into vagina via a silicon vaginal probe inserted by a doctor for 30 minutes (wavelength 660nm, power density 18.17mW/cm2, energy density 0.018J/cm2s, total energy density 32.4J/cm2).
75732860|NCT06136936|Device|CT-156-C-001|CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
75732861|NCT06136910|Drug|Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy|"Recombinant human adenovirus type 5 injection : 21 days is one treatment cycle, in principle, 4 cycles of administration, 1 injection on day 1 (d1) of each cycle; the number of injections is determined according to the patient's tolerance and the ease of operation of the injection site, no less than 2 times.~tirelizumab: 200mg intravenous, d1, Q21d, administered until disease progression or intolerable side effects occur~platinum-containing two-drug chemotherapy: adenocarcinoma, pemetrexed combined with carboplatin, 4-6 cycles, d2, Q21d; non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin, 4-6 cycles, d2, Q21d."
76053881|NCT02213042|Biological|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
75439003|NCT05364840|Drug|Placebo|Placebo product capsule
75439004|NCT05341622|Behavioral|Differentiated Box|Patients will receive mailed FIT kits in a box with differentiated packaging
75439005|NCT05341622|Behavioral|Standard Mail|Patients will receive mailed FIT in a standard mailing envelope
75588914|NCT04532060|Procedure|Antimicrobial Photodynamic Therapy|
75588915|NCT01649739|Drug|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
75588916|NCT04532138|Device|VS-CMAC Rigid Fiberoptic Stylet|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
75588917|NCT04532138|Device|C-MAC Video laryngoscope awake intubation|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using C-MAC Video Laryngoscope intubation.
75588918|NCT04527822|Other|Nurse led discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
75588919|NCT01178125|Drug|DR-102|
75732862|NCT06136897|Procedure|Biopsy|Undergo biopsy
75732863|NCT06136897|Procedure|Biospecimen Collection|Undergo collection of blood samples
75732864|NCT06136897|Procedure|Echocardiography|Undergo ECHO
75732865|NCT06136897|Biological|Pertuzumab|Given IV
75588920|NCT01649778|Drug|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
75588921|NCT04532333|Drug|Bivalirudin 250 MG Injection|Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
75439006|NCT05341622|Behavioral|Text|Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.
75439007|NCT05341622|Behavioral|No Text|Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.
75588922|NCT04532333|Drug|Heparin|Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
75588923|NCT04538183|Other|WO 5000|WO 5000
75588924|NCT04538183|Other|WO 5001|WO 5001
75588925|NCT04538105|Other|Control|Saline Articular Nerve Branch Block
75588926|NCT04538105|Other|Articular Branch Block (ABB)|0.5% Bupivacaine with epinephrine 1:200,000 (Articular Branch Block)
75588927|NCT01649895|Drug|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
75588928|NCT01649895|Drug|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
75732866|NCT06136897|Procedure|Radiologic Examination|Undergo radiologic evaluation
75732867|NCT06136897|Biological|Trastuzumab|Given IV
75882919|NCT03602118|Drug|Phenobarbital Sodium Injection|Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
75882920|NCT02131142|Device|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
75882921|NCT01375309|Dietary Supplement|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5*10to9th bacteria per day
75439008|NCT05341622|Behavioral|Reminder|Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.
75439009|NCT05341622|Behavioral|No Reminder|Patients will not receive any mailed letter reminder to complete their FIT kit.
75439010|NCT05324709|Behavioral|Yoga Based Stress Management Program|Yoga-based stress management program is applied to the intervention group.
75588929|NCT04527939|Procedure|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
75588930|NCT04527783|Other|experimental group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
75588931|NCT04527783|Other|control group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
75588932|NCT04537754|Device|bleaching device|activated bleaching
75588933|NCT02217215|Device|CNDS Advanced Cervical Scan|"Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated."
75588934|NCT04537676|Other|No intervention, this is an observational study|No intervention
75588935|NCT01649505|Drug|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
75588936|NCT01649505|Procedure|breast reconstruction|Undergo sharp dissection technique
75588937|NCT01649505|Procedure|breast reconstruction|Undergo electrocoagulation dissection technique
75588938|NCT02279784|Device|Freeway PTA|angioplasty with Freeway drug-eluting balloon
75588939|NCT02279784|Device|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
75588940|NCT02217254|Procedure|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
75588941|NCT01178086|Drug|Rituximab|Rituximab IV
75588942|NCT04531865|Drug|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 7
75588943|NCT04531865|Drug|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20~30mg/kg/day，BID. Total duration : 8 months.
75882922|NCT01375309|Dietary Supplement|Placebo contains dextrin|0.5 of dextrin
75882923|NCT03604848|Drug|WHO-approved MDR-TB regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
75588944|NCT04531865|Drug|Placebo tablets matching Mycophenolate Mofetil|Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20~30mg/kg/day，BID. Total duration : 8 months.
75588945|NCT01683981|Drug|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
75588946|NCT01177969|Behavioral|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
75588947|NCT01177969|Behavioral|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
75588948|NCT01643070|Drug|Capecitabine, Oxaliplatin|Induction chemotherapy - Capecitabine (1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.
75588949|NCT01643070|Radiation|Radiotherapy|Preoperative radiotherapy, 5040 cGy with 28 fractions
75588950|NCT02216006|Procedure|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
75882924|NCT03604848|Drug|NGS-guided regimen: Regimen A|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
75882925|NCT03604848|Drug|NGS-guided regimen: Regimen B|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
75439011|NCT05319964|Behavioral|Anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~Participants were provided 30 minutes 30% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
75439012|NCT05319964|Behavioral|Conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
75439013|NCT05319964|Behavioral|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.
75588951|NCT02216006|Procedure|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
75439014|NCT05288413|Device|3-compression Ultrasound scan with AutoDVT software integrated Ultrasound probe|The study coordinator, Miss Kerstin Saupe will perform a three-point compression ultrasound scan (USS) of the upper leg with the AutoDVT software. The AutoDVT software will store the results of the scan for retroperspective analysis and review. Effectiveness of AutoDVT as diagnostic tool will be evaluated in perspective to different patient groups, eg. patients with adipositas or maligner disease,
75439015|NCT05274243|Drug|2-HOBA|2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
75588952|NCT04532021|Diagnostic Test|matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements|These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
75588953|NCT04531787|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
75588954|NCT05140707|Other|Virtual Reality Distraction|The patients were administered to use the virtual reality device and they were free to choose the theme and video in the library to watch. Patients used the device during the port catheter implantation and untill the 4 hour after the implantation when they felt pain.
75588955|NCT01684059|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
75588956|NCT04531748|Drug|Toremifene|Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
75732870|NCT06136858|Device|Cuirass ventilation|We will fit the Cuirass Shell and start Biphasic Cuirass Ventilation on all participants.
75882926|NCT03604848|Drug|NGS-guided regimen: Regimen C|"Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, >70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, >70kg 1200 mg daily;"
75882927|NCT02125682|Drug|atovastatin 10 mg/day|patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
75439016|NCT05274243|Other|Placebo|Placebo (provided as three capsules) three times a day for 4 weeks
75439017|NCT05273879|Procedure|decompression|laminotomy of the corresponding adjacent vertebrae, partial flavectomy and medial facetectomy are planned to be performed unilaterally. Depending on the surgeon's personal preferences, the following two options are available: 1) equivalent decompression procedure contralaterally and 2) crossover contralateral decompression. Irrespective of the selected option, the spinous process, the interspinous and supraspinous ligaments, part of the facet joints, and the corresponding part of the vertebral arch must be preserved intact in all participants.
75439018|NCT05273879|Procedure|fusion|First, decompression is performed according to one of the above methods. Next, trans-foraminal interbody fusion with a cage (TLIF) and fixation with pedicle screws are performed.
75439019|NCT05271799|Drug|Gepotidacin|Gepotidacin will be administered
75439020|NCT05270733|Drug|Ustekinumab|Subjects will receive ustekinumab for 8 weeks followed by guselkumab or risankizumab for 8 weeks.
75439021|NCT05261841|Other|Standard care for T2D patients, Smartwatch|No intervention, observational study
75439022|NCT05253417|Drug|50 mg Cannabidiol (CBD)|For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
75439023|NCT05253417|Drug|Placebo|Participants take four (4) placebo capsules.
75588957|NCT04531748|Drug|Melatonin|Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
75588958|NCT04531748|Other|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions.
75439024|NCT05253417|Drug|100 mg Cannabidiol (CBD)|For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
75439025|NCT05250570|Behavioral|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) to assist individuals in tolerating benzodiazepine withdrawal symptoms and teaching skills to prevent relapse to benzodiazepine use. It will also provide psychoeducation about benzodiazepine use in OAT. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
75439026|NCT05250570|Behavioral|Relaxation Therapy|The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
75588959|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
75588960|NCT01177813|Drug|BI 10773|BI 10773 low dose tablet once daily
75588961|NCT01177813|Drug|BI 10773 open label|Patients receive BI 10773 high dose tablets open label once daily
75588962|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
75588963|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
75732871|NCT06136806|Diagnostic Test|Ferumoxytol Enhanced Magnetic Resonance Angiography（ FE-MRA）；Coronary/Renal /Lower artery Arteriography|When the patient is suspected with multisite artery disease, FE-MRA and angiography will be performed according to the patient's clinical manifestation. For example, when the patient is suspected with coronary artery disease, coronary FE-MRA and angiography will be performed; when the patient is suspected with renal artery stenosis, renal artery FE-MRA and angiography will be performed; and when the patient is suspected with the lower extremity artery occlusion, the lower extremity artery FE-MRA and angiography will be performed.
75439027|NCT05213195|Drug|NKG2D CAR-NK|NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.
75439028|NCT05204030|Other|HPV Twitter Education Program - Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine narrative messages (i.e., stories). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
75588964|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
75588965|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
75588966|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
75588967|NCT01177813|Drug|BI10773|BI 10773 high dose tablets once daily
75588968|NCT01177813|Drug|Sitagliptin|Sitagliptin tablets 100 mg once daily
75588969|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
75588970|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
75588971|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
75588972|NCT04537481|Other|Lipid extraction|The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.
75588973|NCT04531826|Other|5-strand hamstring graft preparation|Five-strand hamstring graft preparation
75588974|NCT01684137|Dietary Supplement|Joalis Bambi Analerg|
75588975|NCT01684137|Dietary Supplement|Joalis Bambi Bronchi|
75588976|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
75588977|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
75588978|NCT04315831|Drug|Transdermal Buprenorphine|Intervention will be applied for patients with moderate to severe cancer pain
75588979|NCT04531436|Other|Brief mindful eating intervention|Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
75588980|NCT01684176|Behavioral|Complex tailored intervention|
75588981|NCT01684176|Behavioral|Usual care|
75588982|NCT02216045|Drug|Peginterferon, Ribavirin, camel milk|"Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks."
75588983|NCT02216045|Drug|Peginterferon, Ribavirin|"Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks."
75588984|NCT04531358|Device|nasal spray|application of nasal spray
75588985|NCT04531358|Other|no treatment|no treatment
75588986|NCT01684293|Behavioral|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
75588987|NCT01684293|Behavioral|Psychoeducation/games|Psychoeducation/games
75882928|NCT02125682|Drug|Atorvastatin 80 mg/day|patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
75588988|NCT02216084|Drug|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
75588989|NCT01684332|Other|Strawberry Jam|
75439029|NCT05204030|Other|HPV Twitter Education Program - Non-Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine non-narrative messages (i.e., scientific information - numbers and facts). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
75588990|NCT01684371|Other|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
75732872|NCT06136806|Diagnostic Test|Ferumoxytol Enhanced Magnetic Resonance Venography（ FE-MRV）, Computed Tomography Pulmonary Angiography, Ultrasound for Lower Extremity Deep Vein.|When the patient is suspected with venous thromboembolism, the lower extremity vein FE-MRV, pulmonary FE-MRA and ultrasound for lower extremity deep vein as well as computed tomography pulmonary angiography will be taken to ensure whether the patient with thrombus or not.
75439030|NCT05200416|Device|Heylo|Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
76053882|NCT02213042|Drug|Aromatase Inhibitors (AIs)|Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
76053883|NCT04721314|Device|Adjustment of lower rate limit|Patients with preserved ejection fraction (EF >50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.
75439031|NCT05200416|Device|Standard of Care|Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
75439032|NCT05184803|Drug|Docetaxel injection, oxaliplatin, S-1|As a prior chemotherapy, intravenous administration is performed every 3 weeks for docetaxel 50 mg/m2 D1, intravenous administration for oxaliplatin 100 mg/m2 D1, and oral administration twice a day for S-140 mg/m2 D1 to 14.
75439033|NCT05184582|Behavioral|Physical training|Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
75439034|NCT05143671|Procedure|Coronary artery bypass grafting|Coronary artery bypass grafting in coronary revascularization.
75588991|NCT04531397|Drug|ACEI treatment|ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
75588992|NCT04531397|Drug|Dapagliflozin+ACEI treatment|Dapagliflozin will be given 10 mg/day (weight>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.
76053884|NCT04721314|Device|Maintenance of lower rate limit|Lower rate limit will be maintained at 60 beats-per-minute
76053885|NCT04418180|Drug|Fenofibrate|Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
75588993|NCT04531475|Drug|X842|X842 capsules
75588994|NCT04531475|Drug|X842 Placebo|X842 placebo-matching capsules
75439035|NCT05143671|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention in coronary revascularization.
75439036|NCT05143671|Procedure|Surgical valve replacement|Surgical mitral and / or aortic valve replacement.
75732873|NCT06136780|Other|Free reading glasses immediately following surgery|Free reading glasses will be given immediately after cataract surgery in the intervention arm and four months after cataract surgery in the control arm.
76053886|NCT04418180|Drug|Placebo|oral distilled water
76053887|NCT02212730|Drug|Pembrolizumab Pre-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
76053888|NCT02212730|Procedure|Surgical Resection|Standard of care surgical resection of RCC tumor
76053889|NCT02212730|Drug|Pembrolizumab Post-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
75439037|NCT05143671|Procedure|Carotid artery stenting|Carotid artery stenting.
75439038|NCT05085470|Biological|Schistosoma mansoni infection|20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
75439039|NCT05085470|Biological|Placebo mock infection|Placebo mock infection with water
75588995|NCT04531475|Drug|Lansoprazole|Lansoprazole capsules
75588996|NCT04531475|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
76053890|NCT02178956|Drug|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
76053891|NCT02178956|Drug|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
76053892|NCT02178956|Other|Placebo|Orally two times daily
76053893|NCT02211638|Drug|Candesartan Cilexetil|Candesartan Cilexetil tablet
76053894|NCT02178566|Drug|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
76053895|NCT02211014|Drug|acalabrutinib|
76053896|NCT01631864|Drug|LCZ696|LCZ696 was provided as 400 mg tablets.
75588997|NCT01684449|Drug|Gemcitabine + Rapamycin|"Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination."
75588998|NCT01684527|Other|Respiratory secretions obtained|
75439040|NCT05071846|Other|MVX-ONCO-2|"One administration of MVX-ONCO-2 (or vaccination) consists of the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10^6 lethally irradiated autologous tumor cells. Tumor cells will have prealably been harvested from the participant through a surgical procedure.~A full treatment course with MVX-ONCO-2 consists of a total of 6 vaccinations: 4 vaccinations 1 week apart, followed by 2 boosters 2 weeks apart. Capsules are removed 1 week after implantation."
75439041|NCT05060133|Procedure|Orthognathic Surgery|Surgical corrections of dentofacial deformities and malocclusions.
75588999|NCT01684605|Drug|NESP 60μg|Administrated NESP 60μg once intravenously
75589000|NCT01684605|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
75589001|NCT04531319|Diagnostic Test|Flow cytometric analysis|Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
75589002|NCT01580085|Other|polysomnography|full night supervised laboratory polysomnography
75589003|NCT04537442|Drug|IM21 CAR-T cells|"IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide"
75589004|NCT01684683|Drug|Theophylline|Theophylline 0.1 bid
75589005|NCT01684683|Drug|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
75589006|NCT04537325|Device|RenalGuard system|Periprocedural intravenous hydration matched to urinary output.
75589007|NCT01684761|Biological|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
75732874|NCT06136702|Behavioral|Educational session|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.
75882929|NCT03602040|Behavioral|PISICC|"PISICC consists of:~Standard disease-specific information leaflet~Personalised lifestyle consideration form~1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c)."
76053897|NCT01631864|Drug|amlodipine|amlodipine was provided as 5 mg tablets.
75589008|NCT01684761|Biological|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
75589009|NCT04537091|Procedure|rESWT|rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
75589010|NCT04537091|Procedure|PRP injection|PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
75589011|NCT01684800|Drug|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
76053898|NCT01631864|Drug|Placebo|Matching placebo to LCZ696 and amlodipine.
76053899|NCT02210780|Drug|Dupilumab|Administered via subcutaneous injection.
76053900|NCT02210780|Drug|Placebo|An inactive substance containing no medicine administered via subcutaneous injection.
76053901|NCT01557244|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
76053902|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
76053903|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
75439042|NCT05037188|Biological|Low dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
76053904|NCT01557244|Drug|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
76053905|NCT01557244|Drug|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
75439043|NCT05037188|Biological|High dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
76053906|NCT01557244|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
76053907|NCT01557244|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
76053908|NCT02177942|Other|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
75439044|NCT05037188|Biological|Low dose or high dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
75439045|NCT05037188|Other|Placebo injection|Placebo injection
75589012|NCT01684800|Drug|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
75589013|NCT01684800|Drug|C: Placebo|1 orally disintegrating tablet every night during study period
75589014|NCT04531163|Drug|N Acetylcysteine|(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
75589015|NCT04537169|Procedure|Levator resection|Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation
75589016|NCT01684995|Behavioral|Brief physician advice|Brief physician advice to quit smoking
75589017|NCT01684995|Drug|nicotine patch|nicotine patch
75589018|NCT01684995|Behavioral|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
75589019|NCT04530851|Procedure|ERAS|"Counseling~H2- antagonist and metroclopramide for prevent aspiration~Drink clear liquid until 2 hour before surgery~First generation cephalosporin in 60 minute before surgery~Clorhexidine for skin cleansing and Povidine for vaginal cleansing~Regional anesthesia~Keep warming~Blunt expansion of uterine incision~Do not peritoneal suture and subcuticular suture if less than 2 cm~Local wound anesthesia.~Paracetamol and NSAIDs for for pain control~Early remove catheter and ambulation~5-HT3 antagonist for prevent nausea"
75589020|NCT04536896|Other|Smartphone breastfeeding application|This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.
75589021|NCT04536896|Other|Traditional face-to-face breastfeeding lecture|This intervention consists of the impartition of a face-to-face breastfeeding course
75589022|NCT01685190|Radiation|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
75439046|NCT05032365|Device|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
75439047|NCT05032365|Device|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values
75439048|NCT05030506|Drug|Belzutifan|40 mg tablet administered orally at a dose of 120 mg
75439049|NCT05030506|Biological|Pembrolizumab|25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
75439050|NCT05030506|Drug|Lenvatinib|10 mg capsule administered orally at a dose of 20 mg
75439051|NCT05029102|Drug|TAS 102|35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle
75439052|NCT05029102|Drug|Anlotinib|10mg，per oral，once daily，days 1-14 of each 21-day cycle
75589023|NCT01685190|Radiation|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
75589024|NCT01685346|Behavioral|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
76053909|NCT02177942|Other|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
76053910|NCT02155322|Biological|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
76053911|NCT02155322|Biological|Pegylated Interferon Alfa-2b|3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
76053912|NCT02210000|Drug|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
76053913|NCT02210000|Drug|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
75732875|NCT06136702|Behavioral|Self-sampling|Women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site, to measure the uptake of the self-sampling test (% of women who take the self-sample). Furthermore, two self-administrated questionnaires are applied to 1) assess attitudes regarding self-sampling (pre-intervention), and 2) assess users' experience regarding self-sampling (post-intervention). The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time. All women will be contacted 1-2 weeks after the self-sample taking to inform them on their test result.
75732876|NCT06136702|Behavioral|Follow-up assessment|To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.
75882930|NCT03551444|Drug|Administration of DAA-based treatment|"Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~Virological failures and early discontinuations of therapy due to adverse events will be also registered."
75882931|NCT03604770|Other|Survey & Food Diary|Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
75882932|NCT02125760|Other|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
76053914|NCT01531894|Drug|GSK2110183 (afuresertib)|Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
76053915|NCT02209766|Drug|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
76053916|NCT02209766|Drug|Placebo|"st cohort: Dose 1(2g) D5884(n=3) in Japanese~nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
76053917|NCT02209454|Drug|Enantyum® oral solution|One dose of 25 mg DKP oral solution
76053918|NCT02209454|Drug|Keral® tablet|One dose of 25 mg DKP tablet
75439053|NCT05008328|Other|Music therapy plus standard care during an SBT|If the participant is randomly assigned to standard care plus music therapy, a music therapist will enter the room five minutes prior to the start of the breathing trial and begin to play quiet music on a guitar. The nurse will reduce medicine to bring the participant to an alert state. The music therapist will introduce themselves and the music intervention, and will continue to play quiet guitar music and sing softly while the respiratory therapist begins the breathing trial. The music therapist will continue playing and singing for 20 minutes into the breathing trial.
75589025|NCT04531124|Other|integrated management|establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients
75589026|NCT01685385|Other|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
75589027|NCT04530968|Other|No intervention|No intervention
75589028|NCT01200394|Drug|PF-00489791|Tablet, 20 mg once daily for 12 weeks
76053919|NCT01571596|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
75439054|NCT05008328|Procedure|Standard care during an SBT|The patient's nurse will reduce sedatives so the patient is alert and awake. The respiratory therapist will introduce themselves to the patient and inform them of the SBT, stating they will turn off the ventilator machine and allow the patient to breathe independently. The respiratory therapist will switch off the ventilator and leave the room. The respiratory therapist and nurse will both be available throughout the SBT, and the ventilator will automatically turn on if the patient stops breathing. The SBT will last for 30-60 minutes.
75439055|NCT04989517|Drug|AT193|Topical
75439056|NCT04955379|Device|EQ103|Ophthalmic Refractometer with a measurement and background channel
75589029|NCT01200394|Drug|Placebo|Tablet, placebo once daily for 12 weeks
75589030|NCT04527354|Drug|Treamid|Participants will receive Treamid 50 mg once a day during 4 weeks
75589031|NCT04527354|Drug|Placebo|Participants will receive Placebo once a day during 4 weeks
75882933|NCT02125760|Other|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
75589032|NCT04531280|Other|Home hospital care|Patients receive hospital-level care in their home.
75589033|NCT01685502|Drug|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
75882934|NCT05760391|Radiation|Radiotherapy|IMRT or SABR for patients with ESCC.
76053920|NCT01557166|Drug|liraglutide|3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
76053921|NCT01557166|Drug|placebo|Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
76053922|NCT01556932|Drug|ABH gel|Given topically
76053923|NCT01556932|Other|placebo|Given topically
76053924|NCT02985736|Drug|Topicort Topical Spray|
75589034|NCT04537130|Biological|IN01 vaccine|"INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis."
75732877|NCT06136676|Behavioral|Arm 1 - Heart-Centred Spiritual Meditation: Christian contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks focused on Christian contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Christian tradition and prayer recitation with breathing to focus their attention on and connection to God.
75589035|NCT04527276|Other|Oral care with 0,12% Chlorhexidine|0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
75589036|NCT04537052|Procedure|Ven Restoration Therapy|This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
75882935|NCT03604614|Drug|Hyperthermic Intraperitoneal Chemotherapy|The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area <1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
75882936|NCT03604614|Drug|Without Hyperthermic Intraperitoneal Chemotherapy|The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area <1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
76053925|NCT02985658|Drug|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit"
76053926|NCT02985658|Drug|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
75589037|NCT01200355|Drug|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
75589038|NCT01200355|Drug|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
75732878|NCT06136676|Behavioral|Arm 1 - Heart-Centred Spiritual Meditation: Islamic contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks, focused on Islamic contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Islamic tradition and prayer recitation with breathing to focus attention on and connection to God.
76053927|NCT02985658|Drug|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
75439057|NCT04911621|Biological|Dendritic cell vaccination + temozolomide-based chemoradiation|"Leukocyte apheresis (before chemoradiation): for dendritic cell (DC) vaccine production.~Chemoradiation (1st part standard treatment, initiated as soon as the patient's hematological blood values are adequate after apheresis, but no later than 6 weeks after surgery or confirmed diagnosis): 1.8 Gy once daily 5 days/week for 6 weeks with 90 mg/m² temozolomide daily from the first until the last day of radiotherapy.~Induction immunotherapy: intradermal vaccination with autologous Wilms' tumor-1 (WT1) mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 1 week after radiotherapy.~Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 3 days (max. 6 months, 2nd part standart treatment) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle."
75439058|NCT04911621|Biological|Dendritic cell vaccination +- conventional next-line treatment|"Leukocyte apheresis (upon recovery of hematological blood values following previous anti-glioma treatments and ≥ 4 weeks after the last dose of any investigational agent): for DC vaccine production.~Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 4 weeks after apheresis.~Booster immunotherapy: 6 DC booster vaccinations administered at regular intervals (+- 4 weeks), starting ≥ 3 weeks after the last induction vaccine.~(Optional) Concomitant conventional anti-glioma treatment: The decision to continue or re-initiate conventional anti-glioma treatment, and, if applicable, its dose and scheme, are at the Investigator's discretion and will depend on the patient's previous treatment scheme and condition."
75732879|NCT06136676|Behavioral|Arm 2 - Action Control: Mindfulness Meditation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 week, focused on mindfulness meditation delivered through a mobile app. The intervention will consist of the mindfulness-based stress reduction program which emphasizes focused attention on breathing and sensations as well as the practice of non-judgemental acceptance of the present experience.
75589039|NCT04527705|Procedure|Non-surgical root canal retreatment|Non-surgical root canal retreatment
76053928|NCT02177786|Drug|Selonsertib|Tablets administered orally once daily
76053929|NCT02177786|Drug|Placebo to match selonsertib|Tablets administered orally once daily
75589040|NCT04530929|Dietary Supplement|SANPROBI BARRIER|Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
75589041|NCT04530929|Dietary Supplement|PLACEBO|Competitors used placebo for three months at a dose of 2x2 capsules daily.
75589042|NCT04536818|Procedure|Laparotomy|Exploratory laparotomy.
75589043|NCT04527666|Drug|Anticoagulation Agents|Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
75589044|NCT04530500|Genetic|COVID-19 Androgen Sensitivity Test (CoVAST)|The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
75589045|NCT01685580|Device|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
75882937|NCT01361945|Drug|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
75439059|NCT04900428|Biological|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
75439060|NCT04900428|Drug|Placebo|Diluent solution
75439061|NCT04873492|Other|Biological sample collection|Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.
75589046|NCT01685658|Drug|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
75589047|NCT01685658|Drug|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
75589048|NCT04530578|Drug|Heparin sodium|Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours
75589049|NCT04530578|Drug|Enoxaparin|Subcutaneous Enoxaparine every 24 hours
75589050|NCT01200238|Drug|STA-9090|
75732880|NCT06136611|Device|TTFields|TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
75882938|NCT03601962|Dietary Supplement|Aqualief|400mg oral mucoadesive tablets
75882939|NCT03601962|Other|Placebo|400mg Placebo oral mucoadesive tablets
75882940|NCT02127242|Procedure|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
75589051|NCT01685853|Drug|Bisacodyl plus PEG-CS|"the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam"
75589052|NCT01685853|Drug|PEG 4 litres split|"the day before colonoscopy: 2 litres of PEG~the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination"
75882941|NCT02237430|Device|MynxGrip|Closure device for femoral artery access closure
75882942|NCT02237430|Other|Manual compression|Conventional manual compression
75882943|NCT02546999|Drug|botox|The agent will be given only once at point zero in the time scheme for the project.
75439062|NCT04852172|Drug|L-citrulline|L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.
75439063|NCT04852172|Other|D5 1/2NS|Saline
75882944|NCT02546999|Drug|placebo|The agent will be given only once at point zero in the time scheme for the project.
75882945|NCT02131220|Drug|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
75439064|NCT04818580|Procedure|Progressive Tension Sutures|In each patient, one side of the chest will receive progressive tension sutures inside the mastectomy pocket, from pectoral fascia to underside of mastectomy flap. 2-0 Vicryl about 15-20 sutures per chest. Both sides will receive bilateral drains (standard of care)
75589053|NCT04317976|Other|paralaryngeal pressure|cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance
75589054|NCT04317976|Other|cricoid pressure|cricoid pressure by fingertips applied under ultrasound guidance
75589055|NCT04530422|Drug|Sofosbuvir plus Ledipasvir|"Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~Oseltamivir 150 mg q 12 hours for 10 days ;~HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days."
75589056|NCT02887573|Drug|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
75589057|NCT02887573|Drug|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
75589058|NCT02887573|Procedure|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
75589059|NCT02887573|Drug|2L PEG|2L PEG are laxatives for experiment group.
75589060|NCT02887573|Drug|4L PEG|4L PEG are laxatives in the control group.
75589061|NCT02887573|Drug|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
75589062|NCT02887573|Drug|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
75589063|NCT01685892|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
75589064|NCT01685892|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
76053930|NCT02153918|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
76053931|NCT02153918|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
76053932|NCT03028090|Device|SHERLOCK 3CG™ Tip Confirmation System with MODUS Software|The SHERLOCK 3CG™ Tip Confirmation System (TCS) is a fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology. It was cleared by the FDA on March 19, 2012 and is indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients. In order to further develop the SHERLOCK 3CG™ platform and simplify the PICC placement for the clinician, Bard Access Systems, Inc. is developing MODUS, a software package.
75439065|NCT04804215|Procedure|Intraductal transanastomotic stent group|When bile duct anastomosis is performed, a intraductal transanastomotic stent is inserted into the bile duct.
75589065|NCT02887534|Drug|SPARC1401-low dose|SPARC1401- low dose
75589066|NCT02887534|Drug|SPARC1401-mid dose|SPARC1401- mid dose
75589067|NCT02887534|Drug|SPARC1401-high dose|SPARC1401-high dose
75589068|NCT02887534|Drug|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
75589069|NCT02887534|Drug|Placebo1401|Placebo
75589070|NCT01685931|Drug|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
75732881|NCT06136533|Other|Assessment-OHS|Demographic information of individuals diagnosed with OHS without sarcopenia risk is recorded.Bioelectrical Impedance Analysis is used to analyze body composition.The comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index',sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index' and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'.The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'.Patients' physical activity levels are monitored with a pedometer.Quadriceps muscle strength is measured with Hand-held dynamometer and grip strength is measured with Jamar hand dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with 'Nottingham Health Profile' and 'Functional Outcomes of Sleep Questionnaire'.
75589071|NCT04530461|Diagnostic Test|Serological test|Positive serological test of SARS Cov2
75589072|NCT01685970|Drug|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
75589073|NCT01685970|Drug|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
75882946|NCT02131220|Drug|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
75882947|NCT02131220|Drug|normal saline|intracoronary bolus infusion using selective catheter during PCI
75439066|NCT04804215|Procedure|No stent group|Do not insert a stent into the bile duct during anastomosis of the bile duct.
75589074|NCT04530617|Drug|Camostat Mesilate|Tablets
75589075|NCT04530617|Drug|Artemisia Annua Leaf|Tea bags
75589076|NCT01686009|Drug|Intra-nasal ketamine|
75589077|NCT01686243|Other|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
75589078|NCT01686243|Other|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
75589079|NCT04530695|Other|Scaling and Root Planing|Periodontal treatment by scaling and root planing (SRP), deep cleaning
75882948|NCT03601884|Behavioral|Optimal Health Program|The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication & Metabolic Monitoring, Collaborative & Strategies, Change enhancement, Visioning & Goal Setting and Maintain Well-being.
75439067|NCT04802707|Combination Product|deoxycytidine and deoxythymidine|The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over 3 taking/day for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 730. Doses was chosen according to the safety and efficacy doses used in the literature.
75439068|NCT04781127|Device|Soterix Medical mini-CT tDCS stimulator|Stimulation will last 30 minutes per day, 5 days per week, for 5 weeks, then 3 days per week for 1 week and then 1 day per week for 4 weeks.
75439069|NCT04764643|Drug|N-acetylcysteine solution|use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
75439070|NCT04764643|Drug|sodium thiosulfate solution|use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
75439071|NCT04657705|Procedure|High power ablation|High power ablation parameters (50-55 W)
75589080|NCT01686282|Dietary Supplement|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
75589081|NCT01686282|Dietary Supplement|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
75589082|NCT04536389|Procedure|Office Hysteroscopy|"The hysteroscope with its light source and flowing fluid was gently introduced into the vagina allowing for gradual distention. Once this was accomplished, the anatomy was followed with delicate movements. The hysteroscope was advanced under vision to the level of the ectocervix, and guided into the endocervical canal. Once the endocervical canal was completely explored, the endoscope was advanced across the internal cervical os to allow evaluation of the panoramic view of the uterine cavity.~hysteroscopic correction of any detected lesion will be scheduled to the endoscopic operative list or the patient will receive the appropriate medical treatment."
75589083|NCT04536662|Drug|Hydrocortisone|The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.
75589084|NCT04536662|Drug|Prednisone|The initial dose of prednisone (5mg/tablet) was 3mg/m2/day to the maximum dose of 15mg. The dosage ratio was 1:2 and the administration time was 8:00 and 21:00.
75882949|NCT03601884|Other|Treatment as Usual|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
75439072|NCT04657705|Procedure|Standard ablation power|Standard ablation power parameters (40-45 W)
75439073|NCT04610047|Drug|Norketotifen|Oral capsule
75439074|NCT04610047|Drug|Placebo|Oral capsule
75439075|NCT04585191|Behavioral|Conversation Aid|"Intervention is a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? that patients receive prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
75439076|NCT04585191|Other|Attention Control Educational Handout|Attention control is an existing health education handout that provides some general health advice geared towards older patients.
75439077|NCT04563234|Behavioral|COFLEX neurocognitive training|The COFLEX training group will then be provided with the cognitive training module and participants will be required to complete a targeted 30-minute daily training until the day of surgery, and then after the surgery, for a total of 6 weeks.
75439078|NCT04563234|Behavioral|Crossword puzzles|The control (crossword puzzles) group will be given a training module, where they can access crossword puzzles on the same platform, and can do puzzles whenever they desire over the 6-week time period.
75439079|NCT04558892|Drug|Enoxaparin|
75439080|NCT04558476|Biological|Convalescent Plasma|2 units of convalescent plasma
75439081|NCT04558476|Other|Standard of Care|Gold Standards
75439082|NCT04506359|Other|Experimental Group|The Ex group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1).
75589085|NCT04536662|Drug|Dexamethasone|The initial dose of dexamethasone (0.75mg/tablet) was 0.3mg/m2/day to the maximum dose of 0.75mg and the administration time was 21:00.
75589086|NCT01686321|Drug|Bendamustine and subcutaneous rituximab|
75589087|NCT01199731|Drug|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
75589088|NCT01199731|Drug|GSK2248761 200 mg once daily|2 100mg capsules OAD
75589089|NCT01199731|Drug|Etravirine|2 100mg tablets twice daily
75589090|NCT01686360|Behavioral|Decision Aid|
75589091|NCT04530266|Diagnostic Test|Six minute walk test|Assessment of walking related performance fatigability using six minute walk test
75439083|NCT04449276|Biological|CVnCoV Vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
75439084|NCT04449276|Drug|Placebo|Participants will receive an intramuscular injection by needle in the deltoid area.
75439085|NCT04391894|Drug|ECF843|Topical ocular eye drop
75439086|NCT04391894|Other|ECF843 vehicle|Topical ocular eye drop
75439087|NCT04288830|Behavioral|Tai Chi Moving Mindfulness Meditation and Resilience Training|Low-impact mind-body exercise adapted from traditional tai chi.
75439088|NCT04288830|Behavioral|Aerobic Exercise|Low-impact aerobic exercise, led by instructor
75439089|NCT04288271|Behavioral|Adherence Intervention|"Intervention:~Adherence Support Team (patient, parent or a significant other, Coach)~Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~Identification of adherence barriers, self-efficacy for medication-taking, and allocation of treatment responsibility~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~Device:~Electronic pillbox monitoring with text message and/or audio/visual dose reminders and access to e-pillbox website~Feedback of electronic monitoring data at increasing intervals between initiation of the intervention at 4-week and exit at 14-week."
75882950|NCT03550664|Device|Monitoring of neuromuscular transmission|Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
75882951|NCT04042077|Drug|Delafloxacin|Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
76053933|NCT02176928|Device|AutoPAP|"PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.~AutoPAP treatment 7 nights a week for four months (16 weeks)."
75439090|NCT04288271|Other|Healthy living education intervention|"Intervention:~Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~Healthy living topic discussion at increasing intervals between 4-wk and 14-wk visits~'Action-Focused Problem-Solving' to address barriers on healthy living topic selected by the patient~Device:~• Electronic adherence monitoring without dose reminders or feedback (enrollment to 14w)"
75439091|NCT04260282|Diagnostic Test|Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab|PCR for viruses and bacteria in nasal swab
75439092|NCT04260282|Diagnostic Test|Induced sputum microbiome|Microbiome in induced sputum
75589092|NCT01686399|Behavioral|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
75589093|NCT01686555|Drug|ABT-199|Tablet
75589094|NCT01686555|Other|Placebo|Tablet
75589095|NCT01686672|Behavioral|Web Intervention|Behavioral
75589096|NCT02217371|Other|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
75589097|NCT05393596|Behavioral|Virtual Reality Software Intervention|Virtual Reality Software Intervention
75589098|NCT02217488|Drug|DG3173|
75732882|NCT06136533|Other|Assessment-Sarcopenic Obesity With OHS|The sarcopenia diagnostic algorithm is used as a reference in the assessment of the presence of sarcopenic obesity. Demographic information of patients diagnosed with sarcopenic obesity is recorded. Then, the comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index', sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index', and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'. The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'. Patients' physical activity levels are monitored with a pedometer. Quadriceps muscle strength is measured with Hand-held dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with the 'Nottingham Health Profile' and the 'Functional Outcomes of Sleep Questionnaire'.
76053934|NCT02176928|Device|Sham PAP|"Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.~Sham PAP treatment 7 nights a week for four months (16 weeks)./"
76053935|NCT04752566|Biological|Eculizumab|Eculizumab will be administered via IV infusion once a week for 4 weeks.
76053936|NCT04752566|Drug|Placebo|Placebo will be administered via IV infusion once a week for 4 weeks.
75439095|NCT04233788|Device|MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)|The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
75439096|NCT04225533|Drug|SP16|All patients will receive a single dose of SP16
75439097|NCT04204538|Other|Dietary habits|Data collected using food frequency questionnaire
75589099|NCT02217488|Drug|Placebo|
76053937|NCT01628510|Device|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
75589100|NCT04536740|Device|PDT treatment device|All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
75589101|NCT01686789|Drug|Pegylated interferon alpha-2a|
76053938|NCT01628510|Other|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
75439098|NCT04204538|Other|Risk factors associated with metabolic syndrome|Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome
76053939|NCT01571362|Drug|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
75439099|NCT04202705|Drug|SYD1875|SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
75439100|NCT04077515|Drug|Sirolimus(0.8mg/m2)|The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
75439101|NCT04077515|Drug|Sirolimus(0.7mg/m2)|The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
75589102|NCT02217605|Dietary Supplement|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
75732883|NCT06136520|Behavioral|Baby massage|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
76053940|NCT01571362|Drug|Placebo|oral placebo, divided into symmetric doses and administered twice daily
75439102|NCT04026711|Drug|Mitoquinol|Mitoquinol (MitoQ) 40 mg per day for 12 weeks
75439103|NCT04026711|Drug|Placebo oral tablet|Placebo daily for 12 weeks
75439104|NCT04022616|Other|Specimen collection|Specimens are obtained from patients who are being treated for breast malignancies.
75439105|NCT04021589|Drug|Weileshu|a probiotics products which help to rebuild homeostasis of gut microbiome
75439106|NCT04021589|Drug|Chemotherapy|chemotherapy
75439107|NCT03975907|Biological|CAR-BCMA T Cells|The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
75439108|NCT03959982|Device|HHHFA Device|Participants will be instructed to use the HHHFA for at least 4 hours during their sleep but will be allowed to use it as long as they want during sleep.
75439109|NCT03959982|Diagnostic Test|Spirometry|Pre and post spirometry using albuterol.
75439110|NCT03959982|Diagnostic Test|6-minute walk|6-minute walk
75439111|NCT03959982|Diagnostic Test|CT scan|CT scan
75439112|NCT03959982|Other|Medical Research Council dyspnea scale (MRC)|MRC questionnaire
75439113|NCT03959982|Other|St. George's Respiratory Questionnaire (SGRQ)|SGRQ questionnaire
75439114|NCT03959982|Other|COPD Assessment Test (CAT)|CAT questionnaire
75439115|NCT03959982|Other|Pittsburgh Sleep Quality Index (PSQI)|PSQI questionnaire
75439116|NCT03959982|Other|CASA-Q|CASA-Q questionnaire
76053941|NCT01571284|Drug|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
76053942|NCT01571284|Drug|FOLFIRI|irinotecan, 5-FU and leucovorin
75439117|NCT03959982|Other|Spirehealth Tag Device|Subjects will wear the Spirehealth Tag Device to measure heart rate, respiratory rate, sleep time, physical activity (movement), and calories burned with activity.
75439118|NCT03958461|Procedure|Anti-infective treatment of periodontal pockets|Removing calculi from teeths' periodontal pockets
75439119|NCT03928808|Biological|Fecal Microbiota Transplantation (FMT)|Nasogastric administration of OpenBiome 25 g/mL solution administered nasogastrically once weekly for 4 consecutive weeks
75589103|NCT01686867|Device|Improved, ventilated cookstove|"An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial."
75589104|NCT02217644|Drug|BI 653048 H3PO4 solution|
75589105|NCT02217644|Drug|BI 653048 H3PO4 low dose capsule|
75589106|NCT02217644|Drug|BI 653048 H3PO4 high dose capsule|
75439120|NCT03926637|Other|Multiple Sclerosis Performance Test (MSPT)|Administered as specified in the treatment arm.
75439121|NCT03922217|Device|Mindful My Way|Mindful My Way (MMW) is a mobile application created for iOS, designed to delivered a form of mindfulness-based therapy to depressed older adults
75589107|NCT02217644|Drug|Placebo|
75439122|NCT03879161|Device|Vu-Path™|Femoral arterial access in eligible participants will be performed using the Vu-Path™.
75439123|NCT03863145|Drug|CB-03-10|CB-03-10, 100 mg capsule for oral use
75439124|NCT03851705|Drug|Inclisiran Sodium for injection|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
75439125|NCT03851705|Drug|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection)
75589108|NCT04536311|Procedure|internal fixation of mulitiple rib fracture|The dislocated rib fracture was anatomically reduced, and then fixed with appropriate equipment to prevent the fracture from being displaced again
75589109|NCT02217683|Drug|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
75439126|NCT03851705|Drug|Placebos|Sterile normal saline (0.9% sodium chloride in water for injection)
75439127|NCT03841110|Drug|FT500|FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
75439128|NCT03841110|Drug|Nivolumab|Immune Checkpoint Inhibitor
75589110|NCT04536233|Biological|MSCs Derived Pleiotropic Factors|The pleiotropic factor derived from mesenchymal stem cells was injected on the wound
75589111|NCT04536233|Other|physiological saline|The physiological saline was injected on the wound
75589112|NCT02217722|Other|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
75589113|NCT02217722|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
75589114|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
75589115|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
75589116|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
75589117|NCT01686945|Drug|placebo|Placebo semaglutide. For oral administration.
75589118|NCT01686945|Drug|placebo|Placebo semaglutide with carrier. For oral administration.
75589119|NCT04536506|Other|Bobath Therapy|Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns
75589120|NCT04536506|Other|Vojta technique|Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
75439129|NCT03841110|Drug|Pembrolizumab|Immune Checkpoint Inhibitor
75589121|NCT01686984|Other|Altered breath|
75589122|NCT02217839|Drug|DG3173|
75589123|NCT02217839|Drug|DG3173+Octreotide|
75589124|NCT02217839|Drug|Octreotide|
75439130|NCT03841110|Drug|Atezolizumab|Immune Checkpoint Inhibitor
75439131|NCT03841110|Drug|Cyclophosphamide|Lympho-conditioning agent
75439132|NCT03841110|Drug|Fludarabine|Lympho-conditioning agent
75439133|NCT03841110|Drug|IL-2|Biologic response modifier
75439134|NCT03824366|Device|Volumetric MR imaging|This will most frequently be supine with arms positioned so not in the way of treatment beams.
75439135|NCT03824366|Radiation|Radiation therapy|-Standard of care
75439136|NCT03810313|Drug|Brolucizumab 6 mg|Solution for injection (intravitreal use)
75439137|NCT03810313|Drug|Aflibercept 2 mg|Solution for injection (Intravitreal use)
75589125|NCT02217839|Drug|DG3173 Placebo|
75732884|NCT06136468|Behavioral|Virtual coach|The virtual coch will be displayed to the participants using an optical see-through head-mounted display
75439138|NCT03810313|Other|Sham injection|Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
75439139|NCT03808389|Other|Donor FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.
75439140|NCT03808389|Other|Autologous FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
75589126|NCT02217839|Drug|DG3173 Placebo+Octreotide Placebo|
75589127|NCT02217839|Drug|Octreotide+DG3173 Placebo|
75589128|NCT02217917|Drug|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
75732885|NCT06136429|Procedure|Transcatheter aortic valve replacement|Device: Transcatheter Heart Valve System (Silara SR)
75732886|NCT06136416|Other|Questionnaire for Non-dystrophic myotonias|Patients will have to complete the questionnaire created specifically for their pathology, as well as an evaluation grid of the same questionnaire to assess its relevance and good understanding
75589129|NCT02217917|Drug|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
75589130|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
75589131|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
75732887|NCT06136390|Other|Oxytocin|Oxytocin nasal spray in combination with mindfulness based group therapy (MBGT).
75589132|NCT02217917|Drug|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
75732888|NCT06136390|Other|Placebo|Placebo nasal spray in combination with mindfulness based group therapy (MBGT).
76053943|NCT04825756|Behavioral|Manualized equine assisted therapy|This equine assisted therapy (EAT), which is delivered in a group setting, combines therapeutic horseback riding with cognitive behavioral strategies for anxiety. Each 45 minute session is delivered in a group format with up to four children between 6 and 17 years of age. Each session follows the same structure: (1) weekly review; (2) groom and connect; (3) warm-up period; (4) session activity; (5) cool down; (6) parent/caregiver psychoeducation, during which the instructor facilitates psychoeducation; and (7) homework instruction.
75439141|NCT03802630|Drug|Brolucizumab 6 mg|Solution for injection (intravitreal use)
75439142|NCT03802630|Drug|Aflibercept 2 mg|Solution for injection (Intravitreal use)
75439143|NCT03802630|Other|Sham injection|"Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator."
75439144|NCT03785691|Drug|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
75439145|NCT03785691|Drug|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
75439146|NCT03785691|Drug|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
75439147|NCT03775213|Behavioral|Decision Support Tool with Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including active monitoring and surgery options.
75439148|NCT03775213|Behavioral|Decision Support Tool without Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including surgery options only.
75439149|NCT03739450|Behavioral|Problem Solving Training (PST)|The PST intervention consists of six sessions that will follow a structured format based on the PST manual. In these sessions, the interventionist will first provide the TBI-specific education, introduce the participant to the PST steps, then help the care partner generate and select a problem to address first. Interventionist will facilitate the care partner's use of the ABCDEF steps of PST to develop a specific action plan to solve the problem. As problems are attempted or solved, the care partner will learn how to perform the steps on his/her own, thus acquiring self-management problem solving skills that will be applicable to future problems. The final session will include a review and generalization of the PST steps and progress made.
75589133|NCT01687062|Other|FeSO4|
75589134|NCT01687062|Other|reduction of phytate|
75589135|NCT01687062|Other|NaFeEDTA|
75589136|NCT02217956|Drug|Cisplatin|
75589137|NCT02217956|Drug|Bevacizumab|
75589138|NCT01687140|Drug|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
75589139|NCT01687140|Drug|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
75589140|NCT04535960|Drug|Empagliflozin 25 MG + Liraglutide 1.8 MG|Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.
75589141|NCT04535960|Drug|Liraglutide 1.8 MG + Empagliflozin 25 MG|Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.
75732889|NCT06136377|Radiation|177Lu-PSMA-617 PET scan|Patients then begin their first course of treatment an average of 2 months after the 68Ga-PSMA-11 PET scan, with IVR usually divided into a total of 6 courses. During the first course of treatment, patients undergo an initial SPECT scan 5h (±1h) post-injection, and return to the nuclear medicine department for three further SPECT scans, at 24h, 4 days and 8 days post-injection.
76053944|NCT02137772|Drug|Letermovir|Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
76053945|NCT02137772|Drug|Placebo|Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
76053946|NCT04410250|Behavioral|oral hygiene|Mothers will be instructed on the oral hygiene of the newborn
75589142|NCT02270463|Drug|SL-401|
75732890|NCT06136364|Biological|CAR-T|CAR-T immunotherapy targeting CD7+
75732891|NCT06136338|Behavioral|Mindfulness training|Women in the experimental group underwent four sessions of mindfulness training. The mindfulness training started at the 28th week of pregnancy for the women, the second training was at the 30th week of pregnancy, the third was at the 32nd week of pregnancy, and the last was at the 34th week of pregnancy, with each session lasting 45 minutes.
75732892|NCT06136325|Procedure|Obsidian RFP anal fistula surgery|Anal fistula closure with instillation in the fistula tract and the inner ostium of Obsidian RTF®
75439150|NCT03739450|Behavioral|Education|Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
75732893|NCT06136312|Device|Multi4|TURBT procedure performed with the Multi4 instrument in local anesthesia
76053947|NCT04418024|Drug|AG10|TTR stabilizer administered orally twice daily (BID)
75732894|NCT06136299|Other|Neuromuscular Training|This intervention uses the FIFA 11+ Kids program as a warm-up during soccer practice sessions.
76053948|NCT04418024|Drug|Placebo|Non-active control
76053949|NCT03027856|Device|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
75439151|NCT03736863|Drug|Apatinib+ SHR-1210（Camrelizumab）|Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W continuous medication，A course of treatment need 28 days.
75439152|NCT03710564|Biological|Brolucizumab|6 mg/0.05mL solution for intravitreal injection
75439153|NCT03710564|Biological|Aflibercept|2 mg/0.05mL solution for intravitreal injection
75732895|NCT06136286|Device|Blood Flow Restriction (BFR) Cuff|The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
75732896|NCT06136273|Behavioral|Treatment measures and intervention strategies|To conduct observational process improvement and hypothesis-deriving studies related to penetrating traumatic injuries using data from the Methodist trauma registry and open source data repositories.
75732897|NCT06136260|Other|CommunityRx-Bereavement|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For CRx-B, a Grief Navigator from Missing Pieces will call the parent; share information about grief and support resources; learn what resources the parent needs for themselves and their family; send the parent a personalized list of grief and social support community resources called a HealtheRx via text, email, or mail; and plan future text message communications with bidirectional functionality and, if requested, calls from the Grief Navigator to occur at least 3, 6, and 12 months after the child's death."
75732898|NCT06136260|Other|General Bereavement Support Information|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For GBSI, Missing Pieces sends parents a unidirectional text message providing a general list of grief resources (e.g., support groups) and information about grief and bereavement within two weeks of the child's death and again 3, 6, and 12 months after the child's death."
75732899|NCT06136208|Drug|s.c 25 mg estradiol pellet|Subcutaneous insertion of 25 mg estradiol pellet.
75732900|NCT06136195|Drug|Mavoglurant|Participants randomized to the Mavoglurant arm will take 100mg of Mavoglurant each day during the first medication period for 6-8 days. During the second medication period, participants will take 200mg of Mavoglurant each day for 6-8 days.
75732901|NCT06136195|Other|Placebo|Participants randomized to the placebo arm will take matching placebo tablets during both the first and second medication period.
76053950|NCT01555138|Drug|Indacaterol|Indacaterol is delivered via a SDDPI.
76053951|NCT01555138|Drug|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
76053952|NCT02137226|Drug|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
76053953|NCT02137226|Drug|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
76053954|NCT01530334|Drug|Gefitinib 250mg|Gefitinib 250mg once daily
76053955|NCT01570192|Drug|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
75882952|NCT04042077|Drug|Vancomycin|Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
75732902|NCT06136182|Procedure|Pericardial Closure Using Gentrix Following Cardiac Surgery|To determine feasibility and effectiveness of Gentrix for cardiac use, and if this product is patient population specific.
76053956|NCT01570192|Drug|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
76053957|NCT01570192|Drug|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
76053958|NCT01570192|Drug|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
76053959|NCT01570192|Device|tobramycin nebulization|tobramycin nebulization 600mg/day
76053960|NCT02136914|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
75732903|NCT06136169|Behavioral|Reminder-cue scanning training|Auditory reminders to scan when scanning to the side of the field loss is inadequate
75439154|NCT03624127|Drug|BMS-986165|Specified dose on specified days
75439155|NCT03624127|Other|Placebo|Specified dose on specified days
75439156|NCT03624127|Drug|Apremilast|Specified dose on specified days
75732904|NCT06136143|Procedure|Group 1: Autogenous bone graft|The maxillary sinus will be grafted with the autogenous bone graft.
75732905|NCT06136143|Procedure|Group 2: Plenum® Osshp|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device.
75732906|NCT06136143|Procedure|Group 3: Plenum® Osshp; + i-PRF|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with i-PRF.
75439157|NCT03616912|Drug|Baricitinib|Administered orally.
75732907|NCT06136143|Procedure|Group 4: Plenum® Osshp + autogenous bone graft|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with autogenous bone graft.
75732908|NCT06136130|Device|Tortoise Positioning Material Group|Preterm infants were placed in the nest with positioning material and placed in lateral and prone positions The positioning material and hand-face maneuver were applied together to the preterm infants in the Positioning Material Group 2, and they were given lateral and prone positions in this way
75732909|NCT06136104|Dietary Supplement|Mixhers HERTIME|A daily self-administered powder supplement packet mixed into water.
75732910|NCT06136104|Dietary Supplement|Placebo|A daily self-administered powder placebo supplement packet mixed into water.
75732911|NCT06136078|Other|rate of appropriate and inappropriate transfers from Methodist interfacility transfers|Evaluating rate for patients experiencing traumatic intracranial subarachnoid hemorrhage or spontaneous bleeds
75732912|NCT06136065|Diagnostic Test|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography scan
75732913|NCT06136052|Other|Forms|All participants filled out a case evaluation form including demographic information, information about headache complaints, and scores of the questionnaire results. Participants completed the Tampa Kinesiophobia Scale (TKS) for kinesiophobia assessment. The International Fall Efficacy Scale (IFES) used in our study is a questionnaire consisting of 16 questions that provide information about the level of fear of falling during daily life activities. In our study, the visual analog scale (VAS), one of the most commonly used, oldest, and best validated scales, was used to measure pain intensity. The short form of the International Physical Activity Questionnaire (IPAQ)- consisting of seven questions- was used in our study. The Quality of Life Scale for Children (QoLSC) is a general quality of life scale that is widely used in research and evaluates the physical and psychosocial experiences of children between the ages of 2 and 18.
75882953|NCT04042077|Drug|Linezolid|Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
75882954|NCT04042077|Drug|Piperacillin/Tazobactam|Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
75882955|NCT04042077|Drug|Tigecycline|Powder for solution for infusion 50 mg, TID, for 5 to 14 days
76053961|NCT02136914|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
75439158|NCT03616912|Drug|Placebo|Administered orally.
75439159|NCT03594253|Behavioral|Regulation Focused Psychotherapy for Children|RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
75439160|NCT03499899|Drug|LAG525|LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first
75439161|NCT03499899|Drug|PDR001|Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525
75439162|NCT03499899|Drug|Carboplatin|Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed
75439163|NCT03481634|Drug|Brolucizumab|Intravitreal injection
75439164|NCT03481634|Drug|Aflibercept|Intravitreal injection
75439165|NCT03432182|Diagnostic Test|electroencephalography|Sleep states definition by electroencephalograpy
75439166|NCT03430700|Drug|Pembrolizumab|Intravenous infusion
75439167|NCT03373461|Drug|LNP023|LNP023 5, 25, 100 mg capsles
75439168|NCT03373461|Other|Placebo|Matching placebo to LNP023
75882956|NCT03557359|Drug|Nivolumab|Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
76053962|NCT01530256|Biological|ALD518|160 mg IV q 4 weeks for 4 doses
75439169|NCT03364751|Other|IQOS|Patients will switch from cigarette smoking to ad libitum IQOS use.
75732914|NCT06136039|Procedure|Arm I (Sarcopenia)|Same as standard treatment
76053963|NCT01530256|Biological|ALD518|320 mg IV q 4 weeks for 4 doses
76053964|NCT01530256|Biological|ALD518|640 mg IV q 4 weeks for 2 doses
75589143|NCT04536428|Device|Endoscopic hemostasis with clip|"This intervention is performed as the following orders.~The tip of endoscope is accessed to a bleeding site.~The accurate visualization of bleeding site is done.~A sheath of delivery system of clip is inserted through a working channel of endoscope.~The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.~The both ends of clip are placed on both sides of a bleeding site.~If bleeding is still continued, additional placements of clip are tried until bleeding stops."
76053965|NCT01554904|Device|Facial-Flex|Oral exercise device
75589144|NCT01687374|Drug|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
75589145|NCT01687374|Drug|Placebo|Saline injection daily for 8 weeks.
75589146|NCT04530188|Drug|Sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
75732915|NCT06136039|Procedure|Arm II(Normal)|Same as standard treatment
75732916|NCT06136013|Behavioral|HIIT|1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.
75589147|NCT04530188|Drug|Propofol|Intravenous sedation with propofol, as already used in our ICU
75589148|NCT01687452|Biological|Blood samples|
75732917|NCT06135987|Device|TLC-NOSF dressings (D'URGOSTART PLUS® BORDER, URGOSTART PLUS® PAD and URGOSTART INTERFACE®)|Clinical evaluation of the dressing in the local treatment of chronic wounds (DFU and VLU)
75732918|NCT06135974|Drug|LC106|Tablet containing at least 2 x 10^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus
75732919|NCT06135974|Drug|LC115|Tablet containing at least 2 x 10^6 CFU/tablet, and comprised of 15 strains of Lactobacillus crispatus
75732920|NCT06135974|Drug|Placebo|Vaginal tablets containing primarily microcrystalline cellulose and no live bacteria
75732921|NCT06135974|Drug|Metronidazole Oral|Metronidazole tablet orally twice daily for 7 days
76053966|NCT01529632|Drug|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
75439170|NCT03364751|Other|Cigarette|Patients will continue to smoke cigarettes ad libitum.
75439171|NCT03364127|Other|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
75439172|NCT03364127|Other|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
75439173|NCT03251508|Drug|Peanut OIT|Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
75439174|NCT03106454|Drug|Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate|Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
75439175|NCT03106454|Drug|Norethindrone|Norethindrone 1.05mg
76053967|NCT01529632|Drug|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
75439176|NCT03074617|Other|LTE field|electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
75439177|NCT03074617|Other|sham field|no electromagnetic field
75439178|NCT03045913|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
75439179|NCT02990806|Drug|NI-071|IV infusion.
75439180|NCT02990806|Drug|Remicade|IV infusion.
76053968|NCT01529632|Drug|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
76053969|NCT01529632|Drug|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
76053970|NCT01554514|Biological|rituximab|rituximab intravenously 100 mg every week for four doses
76053971|NCT01553188|Drug|AMG 386|AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
75732922|NCT06135935|Other|No-added-sugar ice cream|The initial focus of this clinical trial will be the impact on postprandial glycaemia of 300g of ice cream, since, from a nutrition perspective, the flavored milks and ice creams are very similar in composition.
75732923|NCT06135935|Other|Conventional products|The overconsumption of sugar-added conventional products leads to an increased risk of poor control of glycaemic levels.
75882957|NCT03550586|Other|Questionaires|Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS)translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire . Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire .
75882958|NCT03626025|Other|Spaced learning|Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
75439181|NCT02979587|Device|Harmony TPV System|"The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame.~The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 Model HTPV254952 is not applicable for Continued Clinical Experience).~The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter."
75589149|NCT02216162|Other|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
75589150|NCT02216162|Other|No intervention|Usual clinical follow-up
75589151|NCT01687491|Drug|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
75589152|NCT01687491|Drug|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
75439182|NCT02947048|Drug|L1-79|
75439183|NCT02947048|Drug|Placebo|
75589153|NCT01687530|Procedure|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
75589154|NCT04530227|Drug|Biological: Camrelizumab|PD-1
75589155|NCT04530227|Drug|Pemetrexed|chemotherapy
75732924|NCT06135922|Biological|EBV-TCR-T cells|The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10^6/kg to 1×10^8/kg EBV-TCR-T cells per dose.
75732925|NCT06135896|Drug|Tripegfilgrastim|Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers
75732926|NCT06135857|Device|Protocol ECOEMS|Use electo estimulation therapy. The 4-channel stimulator will be used. The 6 electrodes will be located on the biceps, triceps and deltoids. Two daily sessions will be distributed, five days a week, lasting 20 minutes, the vascular program designed by the electro stimulation team itself will be applied.
75732927|NCT06135844|Drug|Purell Hand Sanitizer|Active ingredient. Ethyl alcohol 70%
75589156|NCT04530227|Drug|Nab-paclitaxel|chemotherapy
75589157|NCT01687569|Other|Control Cracker Snack|Base cracker snack
75589158|NCT01687569|Other|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
75589159|NCT01687569|Other|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
75589160|NCT01199263|Other|Laboratory Biomarker Analysis|Correlative studies
75589161|NCT01199263|Drug|Paclitaxel|Given IV
75589162|NCT01199263|Biological|Pelareorep|Given IV
75589163|NCT01687647|Other|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
75882959|NCT02127320|Drug|Rosuvastatin 20mg|
75882960|NCT02127320|Drug|Ezetimibe 10mg|
75882961|NCT02127320|Drug|Rosuvastatin 20mg + Ezetimibe 10mg|
75882962|NCT03604380|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
75882963|NCT03604380|Other|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
75439184|NCT02866721|Biological|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10^6, 3 x 10^6 or 5 x 10^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation."
75439185|NCT02814227|Device|Zansors® sleep screening device|Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
75439186|NCT02557438|Procedure|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
75439187|NCT02557438|Procedure|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
75439188|NCT02503254|Other|CHTP 1.0|CHTP 1.0 ad libitum for 5 days in confinement
75589164|NCT02217995|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual (automatic) dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams & Teasdale, 2002)."
75589165|NCT01687725|Device|Renal denervation using Symplicity Catheter system|percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
75589166|NCT02218034|Drug|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
75732928|NCT06135844|Drug|Medical Grade Mineral Oil|Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.
75732929|NCT06135818|Diagnostic Test|IRISA-TB|ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.
75732930|NCT06135805|Drug|Fluocinonide 0,05% oral gel|Application of Fluocinonide oral gel on oral syntomatic lesions
75732931|NCT06135805|Drug|Placebo|Application of placebo oral gel on oral lesions
75732932|NCT06135792|Other|Arginine|See arm description
75732933|NCT06135792|Other|Placebo|See arm description
75732934|NCT06135753|Other|psychosomatic intervention based on cognitive restructuring.|Participants will receive information on psychosomatic phenomena and over-listening of somatic manifestations (Session 1), interpretation and possible catastrophization of somatic manifestations even when they might be well-known health problems or potential physiological or para-physiological manifestations (Session 2), pain-proneness (Session 3) and mental pain and psychological distress in somatizers (Session 4). The second part of each session will be devoted to group cognitive restructuring, thus participants will be stimulated in verifying how the phenomena illustrated are in their lives and how they can be differently conceptualized in order to be less intrusive and less able to reduce their own functioning.
75882964|NCT02125916|Other|oxygen therapy|
75882965|NCT03522415|Drug|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
75882966|NCT03522415|Drug|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
75882967|NCT02125994|Procedure|Interscalene nerve block|
75882968|NCT04226833|Drug|entrectinib|1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal
75439189|NCT02503254|Other|Conventional Cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
75439190|NCT02489539|Device|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
75439191|NCT02438436|Dietary Supplement|simo decoction|
75439192|NCT02438436|Other|gum chewing|
75882969|NCT02131298|Drug|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
75439193|NCT02420821|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle.
75589167|NCT02218034|Drug|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
75732935|NCT06135753|Behavioral|Control condition|The control condition will include 4 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health.
75732936|NCT06135753|Other|Experimental and control condition: Museum therapy|"Session 5-6-7: preselected painting works from the Uffizi Galleries (Florence) will be presented to the participants in order to trigger reflections and emotional responses on specific pain related topics. Session 8: visit the Galleria di Arte Moderna at Palazzo Pitti, in person. Each session will be aimed at facilitating emotional expressions and partecipants' behavioral activation and identifying thoughts associated with those emotions and, if appropriate, remodulating them in a functional way (cognitive restructuring).~Session 9: share the experience of the previous meetings and to recap strategies and skills which could be implemented in FM participants' daily life to cope with their illness."
75882970|NCT02131298|Drug|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
75882971|NCT01375387|Drug|Lacosamide|100 mg oral tablet, single dose
75882972|NCT01375387|Drug|Lacosamide|Lacosamide 2 X 100 mg tablet
75439194|NCT02420821|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle.
75439195|NCT02420821|Drug|Sunitinib|Sunitinib will be administered at a dose of 50 mg once daily, orally via capsule, on Day 1 through Day 28 of each 42-day cycle.
75439196|NCT02811263|Drug|Normal saline placebo|Equal volume of normal saline to be used as placebo
75439197|NCT02811263|Drug|Erythropoietin|Epogen drawn from commercially available single dose 4000U/mL vials
75439198|NCT02188121|Drug|Simvastatin|3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
75439199|NCT02188121|Drug|Losartan|Angiotensin II receptor antagonist
75439200|NCT02177162|Other|Education to physiotherapists|
75439201|NCT02085486|Device|Ultrasound-assisted puncture|Portable ultrasound device
75589168|NCT02218034|Drug|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
75589169|NCT02218034|Drug|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
75882973|NCT01375387|Drug|Lacosamide|Lacosamide 4 X 100mg tablet
75589170|NCT01687764|Other|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
75589171|NCT01687764|Other|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
75589172|NCT01687764|Behavioral|Cognitive Behavioral Group Therapy|"FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children"
75589173|NCT01687764|Behavioral|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
75589174|NCT04529759|Other|Control Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with an oligosaccharide
75589175|NCT04529759|Other|Experimental Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with oligosaccharides blend
75882974|NCT01375387|Other|Placebo 3|Placebo - 3 tablets
75589176|NCT01687803|Behavioral|Physical Activity|Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
75589177|NCT01687803|Behavioral|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
75439202|NCT02085486|Other|Standard|Standard inspection, palpation.
75439203|NCT02039063|Drug|E6011 2 mg/kg|
75439204|NCT02039063|Drug|E6011 5 mg/kg|
75589179|NCT01687842|Other|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
75589180|NCT01687959|Other|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
75589181|NCT02216240|Other|Paramedic|
75589182|NCT02216240|Other|Standard care|
75589183|NCT01688115|Procedure|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
75589184|NCT01688115|Other|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
75882975|NCT01375387|Other|Placebo 4|Placebo - 4 tablets
75882976|NCT01375387|Other|Placebo 2|Placebo - 2 tablets
75732937|NCT06135727|Device|Maestro2 OCT|3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
75732938|NCT06135675|Drug|TNP-2092 placebo capsules|TNP-2092 placebo capsules will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.
75732939|NCT06135675|Drug|TNP-2092 capsules|TNP-2092 capsules will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.
75882977|NCT03936699|Device|Transcutaneous Nerve Stimulator (TENS)|"The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet & Exercise Subjects to be instructed on a healthy 1200 calorie diet."
75439205|NCT02039063|Drug|E6011 10 mg/kg|
75439206|NCT02039063|Drug|E6011 15 mg/kg|
75439207|NCT01970410|Drug|teriflunomide|14 mg oral teriflunomide daily
75439208|NCT01746173|Drug|Cyclophosphamide|
75439209|NCT01746173|Drug|Doxorubicin|
75439210|NCT01746173|Drug|Vincristine|
75439211|NCT01746173|Drug|Etoposide|
75439212|NCT01746173|Drug|Prednisone|
75439213|NCT01746173|Drug|Filgrastim|
75439214|NCT01746173|Drug|Plerixafor|
75439215|NCT01746173|Procedure|Stem Cell Collection|
75439216|NCT01746173|Drug|Palifermin|
75439217|NCT01746173|Drug|Gemcitabine|
75439218|NCT01746173|Drug|Busulfan|
75439219|NCT01746173|Drug|Melphalan|
75439220|NCT01746173|Procedure|Stem Cell Transplant|
75439221|NCT01694004|Drug|Benzocaine Infusion into Duodenum|
75439222|NCT01679275|Other|measuring cerebral oxygenation|
75439223|NCT01545843|Behavioral|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
75589185|NCT04529486|Other|Kinesio taping|Before applying the tape, it was checked whether the children were allergic. Tape was first started from the distal part of the fingers and taped with 0% tension with Kinesio Taping Functional Correction Technique. Another I tape was applied from palmar area of the hand to spina scapula for supination of the forearm and external rotation of the shoulder with %0 tension to make functional correction (Figure 2). Kinesio Taping Functional Correction method is suggested to be done with 75% of tension but for children, we applied it with 0% tension to minimize the shear effects to the skin4. Kinesio Tex Light Touch Plus tape was used for taping application (Kinesio Co., USA).
75589186|NCT01688154|Dietary Supplement|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
75589187|NCT01688154|Other|2 empty capsules|
75589188|NCT02216279|Drug|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
75589189|NCT04529681|Device|Stroke Riskometer Application|Mobile phone application uses to measure, monitor and manage, it mainly calculates the stroke risk probability within 5 year and 10 years by providing the absolute risk and relative risk which is compared to the normal healthy people with the same age and gender. Not only that, the application purposes to increase general awareness about stroke and its risk factors, and to improve stroke and heart attack prevention on an individual level.
75589190|NCT04529681|Other|Informational Leaflets|Informational leaflets consist of the stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors including; disease introduction, what are the risk factors, early symptoms and also the preventive measures. These materials were developed and published by health education and promotion division Ministry of Health, Malaysia in 2013 - 2016. Usually it will be distributed to public during health screening program and also can be found at all healthcare facilities. All materials were in Malay language only.
75439224|NCT01545843|Drug|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
75589191|NCT04529642|Diagnostic Test|Inertial Measurement Unit evaluation|An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.
75589192|NCT01688349|Other|analyze the role of glucocorticoid in AT distribution.|"The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance."
75439225|NCT00843791|Drug|placebo|treatment with placebo for 3 months
75732940|NCT06135649|Procedure|Systematic lymphadenectomy|The nodal dissection protocol included the ISGPS lymphadenectomy stations (5, 6, 8a, 12b-c, 13, 14a-b, and 17) extended to stations contiguous to the regional basin (8p, 12a-p, and jejunal mesentery nodes). Stations embedded in the PD specimen (13, 14a-b, 17 and jejunal mesentery LN) were defined as first nodal echelon, while stations sampled as distinct specimens (5, 6, 8a-p, 12a-b-p-c) were defined as second nodal echelon.
75732941|NCT06135636|Behavioral|Education|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
75732942|NCT06135636|Biological|Vaccine administration|Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
76053972|NCT01553188|Drug|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
75439226|NCT00843791|Drug|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
75439227|NCT03187769|Drug|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
75439228|NCT03187769|Drug|Olanzapine|Daily oral dosing
75439229|NCT03187535|Device|TEAS via ES-130|Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.
75732943|NCT06135610|Diagnostic Test|Postive SAR-CoV-2 PCR nasopharyngeal swab|Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
75732944|NCT06135597|Other|This is a blood test without regarding to intervention nor diagnostic tests|This is a blood test without regarding to intervention nor diagnostic tests
75732945|NCT06135584|Drug|Pioglitazone metformin tablets|Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
76053973|NCT01553188|Drug|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
76053974|NCT02175758|Drug|SOF|SOF administered orally once daily
76053975|NCT02175758|Drug|RBV|RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
76053976|NCT01529008|Drug|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
76053977|NCT01529008|Drug|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
75732946|NCT06135584|Drug|Other drugs|Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
75732947|NCT06135584|Other|Drug-free|Drug-free
75732948|NCT06135571|Procedure|Laparoscopic colorectal surgery|Patients underwent laparoscopic left colectomy, sigmoid resection or rectal surgery according to the location of tumor.
75732949|NCT06135558|Diagnostic Test|MAI detection|to detect the presence of marginal acute inflammation
75732950|NCT06135545|Combination Product|Bupivacaine Liposome SAPB|Dilute 266mg of bupivacaine liposome with saline solution to 30ml.The patients are placed in the lateral position and the probe is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The investigators count the ribs inferiorly and laterally, until The investigators identify the fifth rib in the midaxillary line. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) are then easily identifiable by ultrasound overlying the fifth rib.
75732951|NCT06135545|Combination Product|Traditional TPVB|The TPVB was recommended by the American Society of Anesthesiologists.The transducer is placed sagitally over a transverse process(TP), placing it at the center of the ultrasound image. Alternatively, the space in-between two adjacent transverse processes may be positioned at the center. The needle is inserted using an out-of-plane technique and advanced until the central TP is contacted, or else the cranial of the two, with no or minimal angulation in the sagittal plane or the transversal plane. Subsequently, the needle is walked off the TP into the TPV space and advanced 1 to 1.5 cm beyond the TP without further visualizing the needle tip on ultrasound. Entering of the needle tip into the TPV space can result in a loss of resistance to normal saline and by visualizing anterior displacement of the pleura upon injection. Select the fifth TP as the insertion point, and inject 20ml of 0.5% ropivacaine (Hengrui, Jiangsu) into the TPV space.
75732952|NCT06135532|Procedure|Non-Surgical Periodontal Treatment|Nonsurgical periodontal therapy primarily aims to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and improve active disease's clinical signs and symptoms.
75439230|NCT03187535|Other|No TEAS|No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
75439231|NCT03158402|Other|Prehabilitation with inspiratory muscle training|3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
75439232|NCT03146156|Behavioral|Lifestyle Intervention|The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
75439233|NCT03136731|Diagnostic Test|Celiac disease antibody screening|Observational parameters
75439234|NCT03092245|Drug|OctaplasLG|OctaplasLG is given as an infusion when resuscitation fluids are required.
75439235|NCT03092245|Drug|Ringer-Acetate|Ringer-acetate is given as an infusion when resuscitation fluids are required.
75439236|NCT03008642|Other|CO-Rebreathing technique at diagnosis of polycythemia|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
75439237|NCT02995733|Drug|PARTICS using QVAR|Patient takes inhaled corticosteroid at the time of rescue inhaler use
75732953|NCT06135480|Other|subcision ,PRP or saline and microneedling|minimally invasive procedures
75732954|NCT06135415|Drug|Tirbanibulin|Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
75732955|NCT06135415|Other|Vehicle ointment|Participants will apply vehicle ointment topically on the face or balding scalp with AK.
75439238|NCT02994043|Behavioral|Mindfulness-Based Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
75439239|NCT02994043|Behavioral|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
75439240|NCT02956382|Drug|Ibrutinib|Ibrutinib is dispensed as a capsule.
75439241|NCT02956382|Drug|Venetoclax|Venetoclax is dispensed as a tablet.
75439242|NCT02855229|Drug|Methylphenidate|cross-over, single-dose intervention
75439243|NCT02833883|Drug|Enzalutamide|
75439244|NCT02833883|Drug|CC-115|
75439245|NCT02829931|Radiation|Hypofractionated Stereotactic Irradiation|Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
75439246|NCT02829931|Drug|Nivolumab|Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
75589193|NCT02216318|Other|blue light|
75589194|NCT04822389|Device|Telerehablitation using heart rate monitor|Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
75732956|NCT06135402|Device|Treatment with Monalisa Glide Laser|3 fractional laser treatment-sessions with Monalisa Glide
75732957|NCT06135402|Drug|Treatment with Clobetasol|Application of Clobetasol twice per week
75732958|NCT06135376|Behavioral|comprehensive multi-component interventions|It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.
75732959|NCT06135363|Drug|SC1011|SC1011 tablet
75732960|NCT06135363|Drug|Placebo tablet|SC1011-matching placebo tablet
75589195|NCT02218073|Drug|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
75589196|NCT02218073|Drug|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
75882978|NCT03936699|Behavioral|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
75439247|NCT02829931|Drug|Bevacizumab|Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
75732961|NCT06135350|Drug|Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day|"Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:~2400 mg/day (4 tablets twice a day) for the first 2 days and;~1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
75589197|NCT02218073|Drug|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
75589198|NCT05138523|Combination Product|Sofosdac®|Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
75439248|NCT02829931|Drug|Ipilimumab|Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
75439249|NCT02815566|Drug|tenofovir-alafenamide-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
75439250|NCT02815566|Drug|tenofovir-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
75439251|NCT02769845|Drug|Hydroxyurea|drug to be administered
75732962|NCT06135350|Other|Placebo|"Placebo arm patients will receive placebo:~4 tablets twice a day for the first 2 days and;~3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
75732963|NCT06135337|Device|Thioderm Elate|Test Device
75732964|NCT06135337|Device|Juvéderm Ultra 3|Active Comparator Device
75732965|NCT06135285|Device|Control subjects|The subject will be repositioned from the prone to recovery position
75732966|NCT06135272|Drug|Resin infiltration|Icon Resin Infiltration as minimally invasive technique
75732967|NCT06135272|Drug|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish as minimally invasive technique
75732968|NCT06135272|Drug|Light cured giomer varnish|Light cured giomer varnish as minimally invasive technique
75882979|NCT02126072|Dietary Supplement|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
75882980|NCT02126072|Dietary Supplement|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
75882981|NCT05194813|Other|Aqua alvim CM, neodent implant (Test)|Acqua, Hydrophilic sandblasted, and acid-etched dental implants
75882982|NCT05194813|Other|Neoporous alvim CM, neodent implant (Control)|Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
75882983|NCT02853318|Biological|Bevacizumab|Given IV
75882984|NCT02853318|Drug|Cyclophosphamide|Given PO
75882985|NCT02853318|Other|Laboratory Biomarker Analysis|Correlative studies
75882986|NCT02853318|Biological|Pembrolizumab|Given IV
75882987|NCT02127476|Drug|KHK6640|Single ascending dose and multiple ascending doses administration
75882988|NCT02127476|Drug|Matching Placebo|Single ascending dose and multiple ascending doses administration
75882989|NCT03918213|Diagnostic Test|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
76053978|NCT01599104|Drug|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
75589199|NCT02218112|Procedure|bariatric surgery (gastric bypass)|
75589200|NCT04535570|Other|Indirect Calorimetry|In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
75589201|NCT05138484|Drug|experimental group 10% mouthwash of M. sylvestris extract|To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
75589202|NCT04535804|Drug|Aspirin/placebo|By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
75732969|NCT06135246|Device|High Intensity Laser Therapy|Participants will receive high-intensity laser therapy using an 810nm continuous wave diode laser (Multiwave locked System (MlS) provided by aSa). The laser applicator has a flat top hat beam profile with a spot size of 1cm2. The laser will be delivered in direct contact mode perpendicularly to the ulcer surface. Each 1cm2 area of the venous ulcer and a 1cm margin of periwound skin will be treated sequentially using a overlapping grid pattern to cover the entire ulcer area, with a 1 second exposure time per point. This results in a laser energy density of 4J/cm2 delivered to each point.
75732970|NCT06135246|Other|Standard Care|Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).
76053979|NCT01599104|Drug|Olmesartan|Olmesartan 20 mg capsule one daily
75439252|NCT02769845|Procedure|TCD examination|TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
75589203|NCT04535765|Other|early warm water sitz bath|The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.
75589204|NCT04535765|Other|Regular time warm water sitz bath|According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
75439253|NCT02702492|Drug|KPT-9274|
75439254|NCT02702492|Drug|Niacin ER|
75439255|NCT02702492|Drug|Nivolumab|
75589205|NCT05138445|Behavioral|FAME-W self-management intervention|FAME-W is an occupational therapy led, four-week group based self-management intervention. It focuses on providing people with IA skills and confidence to manage demands of their employment and daily life through education on IA, self-management techniques, managing symptoms of fatigue, pain and stress and managing physical and mental health.
75589206|NCT05138445|Behavioral|FAME-W Handbook|Individuals in this arm receive a self-guided FAME-W handbook containing the same information as that covered in the four week FAME-W program
75589207|NCT04529603|Device|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
75589208|NCT04535739|Radiation|prophylactic cranial irradiation|25Gy/2.5Gy/10f were given for PCI patients
75589209|NCT04529525|Drug|Ivermectin|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
75732971|NCT06135233|Other|No intervention|all patients undergoing minimally invasive pancreatic surgery, no intervention, no randomization
75732972|NCT06135194|Drug|T-DXd|Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
75732973|NCT06135181|Drug|Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg|0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)
75732974|NCT06135181|Drug|Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg|0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)
75732975|NCT06135181|Drug|Matching placebo|0.9% sodium chloride by intravenous injection (at 2 mL/s)
76053980|NCT01599104|Drug|Placebo|Placebo to LCZ696 or Olmesartan
76053981|NCT01569568|Other|MRI scanning|1H MRS, DTI, FMRI
76053982|NCT01569568|Behavioral|Cognitive testing|Behavioral testing
76053983|NCT05255432|Other|nil intervention|Users observation using medical device on manakin, different scenarios per group
76053984|NCT02136680|Other|CASA Education|Basic palliative care competencies for outpatient use.
76053985|NCT01552954|Behavioral|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
76053986|NCT02175368|Device|Adhese One F Upgrade|
76053987|NCT01518244|Drug|Brinzolamide/timolol maleate fixed combination|
75589210|NCT04529525|Drug|Placebo|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
75732976|NCT06135168|Drug|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
75732977|NCT06135168|Drug|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
76053988|NCT01552408|Drug|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
75732978|NCT06135155|Drug|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
75589211|NCT02218346|Drug|AG221|AG221 in fed and fasted conditions
76053989|NCT01552408|Procedure|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
76053990|NCT01528696|Device|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
75732979|NCT06135155|Drug|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
75732980|NCT06135129|Device|Sonoelastography|Sonoelastography (SE) is a new ultrasound-based method measure the stiffness or elasticity of tissues, has no hazards on poatients.
75732981|NCT06135090|Behavioral|Trauma Recovery Program (official title TBD)|See arm description
75732982|NCT06135077|Other|T-PRF alone|T-PRF is the material to be tested in this study as an alternative to classical bone graft
75732983|NCT06135077|Other|T-PRF/Xenograft|One part of T-PRF will be divided into minute pieces to be mixed with xenograft
75732984|NCT06135064|Device|Diadem|The device delivers low-intensity ultrasonic waves into specified brain targets.
75589212|NCT04535427|Drug|L-arginine|Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
75589213|NCT04535427|Drug|Placebo|Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
75589214|NCT05138367|Procedure|transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients|After vaginal sterilization, TVUS-guided transplantation was performed by the senior-level medical physician B Wang), using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcae Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The solution (a total number of 2×10^7cells, 1×10^7 /400 μL for unilateral ovarian injection) was injected into the ovary by using 21G PTC needles (Hakko Medical Co, Japan) under TVUS guiance. Each patent received up to three transplantations.
75589215|NCT02218385|Device|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
75589216|NCT02216409|Drug|Hu5F9-G4|
75589217|NCT02218580|Other|Massage therapy|
75589218|NCT02218580|Other|Standard care|
75732985|NCT06135051|Device|Diadem prototype|The device delivers low-intensity ultrasonic waves into specific brain targets.
75732986|NCT06135038|Other|Suprascapular nerve block with physical therapy|"Suprascapular nerve block was applied to the relevant shoulder area of all patients before treatment. Afterwards, a physical therapy program (5 days a week for 3 weeks, a total of 15 sessions) was applied, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
75732987|NCT06135038|Other|Group 2 Physical therapy|"A physical therapy program (5 days a week for 3 weeks, a total of 15 sessions), including a hot pack at 60 ° C for 20 minutes, conventional TENS at 80 Hz for 20 minutes and US at 3 MHz frequency and an intensity of 1.5 watts / cm2, was applied to the relevant shoulder area of all patients.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
75732988|NCT06135025|Other|Telemonitoring|the patients included receive a weekly phone call from the participating physician to to support self-management improvement, use of inhalation devices, rehabilitation, monitoring of signs/symptoms by treatment management, counseling, motivation, and prevention of exacerbations, early recognition of exacerbation signs and planify access to health care facility. at 1 month a Face to Face visit is planned to collect data.
75732989|NCT06135012|Device|Cavitron ultrasonic surgical aspirator (CUSA)|Transection of pancreatic tissue with cavitron ultrasonic surgical aspirator (CUSA).
75732990|NCT06135012|Other|Scalpel|Transection of pancreatic tissue with scalpel.
75732991|NCT06134999|Device|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
76053991|NCT01528696|Device|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
76053992|NCT02174276|Drug|Tenofovir disoproxil fumarate|TDF 300 mg tablet administered orally once daily
75439256|NCT02652455|Drug|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
75439257|NCT02652455|Procedure|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
75439258|NCT02652455|Drug|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
75439259|NCT02652455|Drug|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
75589219|NCT05126121|Drug|three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol|Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
75589220|NCT02218658|Drug|WE941 OD tablets|
75589221|NCT02218658|Drug|Brotizolam|
75589222|NCT05125653|Procedure|Indocyanine Green Fluorescent Laparoscopic Cholangiography|Indocyanine Green Fluorescent Cholangiography
75589223|NCT05125653|Procedure|White Light|Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
75589224|NCT02278679|Procedure|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
75589225|NCT01199068|Drug|CS-7017|CS-7017 from 0.25 mg to 0.50 mg twice daily
75589226|NCT01199068|Drug|Erlotinib|Erlotinib 150 mg once daily
75589227|NCT05103891|Drug|Binimetinib Oral Tablet|two-period, crossover study
75589228|NCT04535375|Diagnostic Test|Doppler Ultrasound of venous cerebral circulation|No additional ultrasound examinations, specifically for the purpose of this study, will be performed. Instead, with each routine ultrasound examination, additional images on top of the routine frames will be collected. Those images will document the velocity and flow in the internal cerebral veins bilaterally using the standard Color Doppler tech-nique. Taking these additional images will prolong the time of ultrasound examination only minimally (with a few minutes).
75589229|NCT01198873|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
75589230|NCT01198873|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
75439260|NCT02652455|Drug|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
75439261|NCT02652455|Biological|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
75589231|NCT04535297|Other|exposure|Exposure to social distancing due to COVID-19
75589232|NCT04535388|Device|LK scleral lens|LK scleral lens fitting and application were done for 12 weeks.
75589233|NCT01198795|Drug|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
75589234|NCT04535024|Radiation|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED > 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
75589235|NCT04535024|Drug|Sintilimab|Starts within one week upon SABR completion: 200mg, d1, q3w; Continued until disease progression, unacceptable toxicity or patient withdrawal.
75589236|NCT04535336|Other|Vitality acupunch (VA) exercise program|The VA had 3 phases and took 40 minutes to complete.
75732992|NCT06134999|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
75732993|NCT06134960|Biological|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
76053993|NCT02174276|Biological|GS-4774|GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
76053994|NCT01528072|Device|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
76053995|NCT01527682|Drug|Latanoprost, Dorzolamide|"Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
76053996|NCT01527370|Biological|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
75439262|NCT02652455|Drug|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
75439263|NCT02590289|Drug|BBI-5000|BBI-5000 low dose, middle dose, or high doses
76053997|NCT01527292|Radiation|Stereotactic Radiation Therapy|SRT only
76053998|NCT01527292|Radiation|SRT with Vertebral Augmentation Procedure|SRT with VAP
75589237|NCT04535336|Other|Control|Participants maintained their daily activities.
75589238|NCT04535154|Other|No interventions|No interventions
75589239|NCT04535180|Diagnostic Test|Dual-energy X-ray absorptiometry (DXA)|"Body composition will be measured using whole-body DXA (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.). Extremity skeletal muscle mass will be calculated using the values measured via the DXA; ASM will be calculated as the sum of skeletal muscle mass in the arms and legs, assuming that the mass of lean soft tissue is a skeletal muscle. Appendicular skeletal mass index (ASM/Ht2 ) will be determined as the sum of the arm and leg lean mass (kg)/height2 (m2~). BMD will be measured in lumbar spine and bilateral hip by the same DXA device (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.)"
75882990|NCT03431545|Behavioral|PALS and|"Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call."
76053999|NCT04748692|Procedure|Local exercise therapy|The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.
76054000|NCT04748692|Procedure|Spinal manual therapy|The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
76054001|NCT01516216|Drug|FOLFOX + bevacizumab|
75589240|NCT02216448|Other|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
75589241|NCT02216448|Other|OR Training|Training on diagnostic knee arthroscopy in the OR
75589242|NCT02278757|Other|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
75589243|NCT02278757|Other|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
75589244|NCT04534946|Other|This is not an intervention study|This is not an intervention study
75589245|NCT02278913|Drug|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
75589246|NCT02278913|Drug|Human Insulin|NPH twice a day + Regular insulin before meals
75589247|NCT04846530|Device|RHA® 1, RHA® 2, RHA® 3, and RHA® 4|For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
75589248|NCT02278991|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
75589249|NCT02216474|Other|Transcranial direct current stimulation|
75589250|NCT02216513|Drug|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
75589251|NCT02216513|Drug|placebo|normal saline IV for 4 hours for 5 consecutive days
75589252|NCT04534998|Procedure|Partial nephrectomy|Partial nephrectomy for localized kidney cancer as curative treatment.
76054002|NCT01516216|Dietary Supplement|Vitamin D|
76054003|NCT01950819|Biological|Induction therapy|All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
76054004|NCT01950819|Drug|Corticosteroids|All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
75439264|NCT02572284|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first group of patients to enter the study will receive 5 Gy of SBRT per day for 5 days, the second group will receive 6 Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
76054005|NCT01950819|Drug|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
76054006|NCT01950819|Drug|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
76054007|NCT04742608|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
76054008|NCT04742608|Other|Electronic Health Record Review|Medical charts are reviewed
76054009|NCT04767490|Procedure|Standard Duodenal Switch|
75439265|NCT02572284|Procedure|Prostatectomy|About 4-6 weeks after SBRT, participants will have a prostatectomy.
75439266|NCT02572284|Other|Quality of Life Questionnaires|Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
75439267|NCT02525783|Device|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty
75439268|NCT02491983|Drug|Palbociclib|
76054010|NCT04767490|Procedure|Single Anastomosis Duodenal Switch|
76054011|NCT01514422|Drug|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
75439269|NCT02491983|Drug|Fulvestrant|
75439270|NCT02491983|Drug|Letrozole|
75439271|NCT02467478|Drug|Linagliptin|5 mg tablet once daily for 12 weeks
75439272|NCT02467478|Drug|Placebo|1 tablet daily for 12 weeks
75732994|NCT06134947|Other|Echocardiographic examination|"Standard 2D echocardiographic evaluation of right ventricle systolic function will be performed as follows:~Tricuspid annular peak systolic excursion (TAPSE) will be measured by placing M- mode cursor through tricuspid annulus and measuring the amount of longitudinal motion of the annulus at the peak systole in the longitudinal apical 4chamber view, TAPSE <-2 Z Score is considered abnormal .~Tricuspid annular peak systolic velocity (TAPSV) by tissue Doppler <-2 Z Score is considered abnormal.~Through Tissue Doppler Imaging values of right ventricle will be obtained from the apical four -chamber view using a sample volume placed at the lateral corner of the tricuspid annulus. Peak systolic annular velocity (Ś)."
76054012|NCT03027700|Device|MRI|MRI scan performed on 1.5T Philips Ingenia MRI scanner.
76054013|NCT01513330|Device|SenSura Mio|Ostomy product - 1 piece closed bag
76054014|NCT01513330|Device|Standard Care|Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
76054015|NCT04415775|Other|Game based treadmill Program|Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.
75439273|NCT02466243|Drug|JBT-101|"Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
75439274|NCT02466243|Drug|Placebo|"Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
75439275|NCT02333825|Procedure|Medial patellofemoral ligament reconstruction surgery|Medial patellofemoral ligament reconstruction surgery using hamstring autograft
75439276|NCT02333825|Other|Physical therapy and rehabilitation|A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
75439277|NCT02321098|Drug|Loceryl NL + Cosmetic varnish|Loceryl NL + Cosmetic varnish once/week for 12 weeks
75439278|NCT02321098|Drug|Loceryl NL 12 weeks|Loceryl NL once/week for 12 weeks
75439279|NCT02321098|Drug|Loceryl NL 15 months|Loceryl once/week for additional 15 months
75439280|NCT02250339|Other|LAKU family program|Multi-systemic and multicomponent family-based intervention program
75439281|NCT02250339|Other|Etä-LAKU family program|Ecosystem-based intervention for families living in rural parts of Finland
75439282|NCT02250339|Other|Family therapy|Treatment as usual (TAU)
75439283|NCT02211794|Other|data collection|
75439284|NCT02185417|Drug|Hydrochlorothiazide (HCTZ)|Thiazide-type diuretic. Daily dose of 50 or 25 mg for duration of the study.
75439285|NCT02185417|Drug|Chlorthalidone|Thiazide-type diuretic. Daily dose of 25 or 12.5 mg for duration of the study.
75439286|NCT02158234|Drug|Cisplatin|Cisplatin 15 mg/m^2 prior to each fraction
75439287|NCT02158234|Radiation|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
75589253|NCT02218775|Drug|LY2456302|Mood and Anxiety Disorders
75732995|NCT06134934|Other|Telemonitoring 1|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.
75732996|NCT06134934|Other|Telemonitoring 2|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.
75732997|NCT06134921|Device|transcranial direct current stimulation (Active)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Active-tDCS group, participants will receive real tDCS with intensity 2.0 mA for 30 minutes, with a 30-second ramp-up and ramp-down."
75882991|NCT03431545|Behavioral|BEECH|"Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration."
75732998|NCT06134921|Device|transcranial alternating current stimulation (active)|Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.
75882992|NCT03431545|Behavioral|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
75882993|NCT05194657|Device|enhanced depth of focus IOL|Acrysof IQ Vivity, enhanced depth of focus IOL
75439288|NCT01953926|Drug|Neratinib|240 mg administered orally, once daily with food, continuously in 28 day cycles
75439289|NCT01953926|Drug|Fulvestrant|500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
75439290|NCT01953926|Drug|Trastuzumab|Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
75439291|NCT01859026|Drug|MEK162|Treatment as outlined in study arms.
75439292|NCT01859026|Drug|Erlotinib|Treatment as outlined in study arms.
75439293|NCT01753089|Biological|WDVAX|
75439294|NCT01705067|Device|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
75439295|NCT01657591|Drug|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
75439296|NCT01657591|Drug|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
75439297|NCT01558544|Procedure|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
75439298|NCT01028144|Behavioral|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
75439299|NCT01028144|Behavioral|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
75439300|NCT01025726|Behavioral|Police Patrolled Walking plus Social Marketing|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route
75589254|NCT02216552|Dietary Supplement|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
75882994|NCT05194657|Device|monofocal IOL|Acrysof IQ, monofocal IOL
75882995|NCT02131376|Procedure|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
75882996|NCT02131376|Procedure|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
75882997|NCT05375370|Other|circulating tumor DNA dosage|blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
75882998|NCT05194501|Other|Nine Hole Peg Test, Jamar dynamometer, pinchmeter|"Hand grip and pinch strengths: Hand grip strengths and tip pinch strengths were measured using a Jamar type hand dynamometer and pinchmeter available in our clinic.~The Nine Hole Peg Test (NHPT): Hand dexerities were evaluated with the NHPT available in our clinic."
75439301|NCT01025726|Behavioral|Police Patrolled Walking Program Only|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs
75439302|NCT01025726|Behavioral|General Health Education|Host community events for chronic disease education
75439303|NCT01599468|Drug|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
75439304|NCT01599468|Drug|saline serum|The Placebo group received normal saline with the same volumes
75439305|NCT01599481|Behavioral|Individual Career Management (ICM)|The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.
75439306|NCT01599481|Behavioral|Standard Care|A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
75439307|NCT01599507|Drug|FG-4592|TIW dosing, capsule
75439308|NCT01599507|Drug|Placebo|TIW dosing, capsule
75439309|NCT01599533|Other|blood samples|
75439310|NCT01599572|Other|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
75439311|NCT01599598|Behavioral|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
75589255|NCT02216552|Dietary Supplement|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
75439312|NCT01599598|Behavioral|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
76054016|NCT04415775|Other|Conventional Gait Rehabilitation|Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
75439313|NCT01599611|Procedure|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
75589256|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
76054017|NCT05110911|Biological|Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad|Influenza vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
75882999|NCT03626727|Drug|Sodium Oxybate Oral Solution [Xyrem]|Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
75883000|NCT02237742|Drug|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
75439314|NCT01599624|Behavioral|Stress Resilience Training System (SRTS)|SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
75589257|NCT01198756|Biological|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
75883001|NCT02131454|Other|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
76054018|NCT05110911|Biological|SARS-CoV-2 vaccination: Comirnaty or Vaxzevria|SARS-CoV-2 vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
76054019|NCT01524796|Other|No intervention. Non-interventional study|No intervention. Non-interventional study
75732999|NCT06134921|Device|transcranial electrical stimulation (sham)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for applied the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Sham group, participants will receive sham stimulation with intensity 2.0 mA for 1 minute, with a 30-second ramp-up and ramp-down, and no stimulation until the end of 30 minutes of stimulation. Electrodes will remain for 30 minutes."
75733000|NCT06134921|Other|Conventional physical therapy program|A conventional physical therapy program will be provided after 30 minutes of stimulation immediately. The program will be provided for both upper and lower limbs which consist of stretching exercise, active exercise, and functional exercise.
75733001|NCT06134908|Behavioral|Multifaceted Intervention|The multicomponent intervention elements include education for clinicians and patients as well as a shared decision-making program among clinicians and patients. A shared decision-making booklet and a mobile application will be used to promote osteoporosis management and fracture practice.
75883002|NCT03604224|Drug|Canagliflozin 300 mg|Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
75883003|NCT01373905|Procedure|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
76054020|NCT01547728|Drug|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
76054021|NCT01523392|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
75439315|NCT01599624|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad & Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
75733002|NCT06134895|Drug|Tramadol with Ketamine|Tramadol with Ketamine is being provided randomly using prospective, double-blind
75733003|NCT06134895|Drug|Tramadol|Tramadol alone is being provided randomly using prospective, double-blind
75589258|NCT01198756|Biological|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
75589259|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
75589260|NCT04534647|Diagnostic Test|different serum and urine biomarkers|urine exosomes and serum biomarkers
76054022|NCT01523392|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
76054023|NCT01512160|Drug|PF-04531083|2000 mg oral solution
76054024|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
76054025|NCT01512160|Drug|PF-04531083|1000 mg oral solution
76054026|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
75439316|NCT01599663|Other|Pain management algorithm|The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
75439317|NCT01599676|Dietary Supplement|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
75439318|NCT01599676|Dietary Supplement|Non essential amino acid|Non essential amino acid supplementation
75439319|NCT01599689|Other|Mirrors Intervention|"Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams."
75439320|NCT01599702|Drug|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
75439321|NCT01599715|Behavioral|Instructional DVD|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
75589261|NCT04534868|Other|taking macroscopic and dermoscopic pictures of suspicious skin lesions|"If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~A table containing the useful information about the patient for the lesion's analysis will be completed.~The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~The photo is anonymized via a serial number assigned by the Handyscope application.~Sending photos and information via a secure email address to the dermatologists.~Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox"
75883004|NCT01373905|Procedure|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
75883005|NCT04159753|Device|Spinal Cord Stimulator|We will record patient's experience on the 30-Day FDA approved Burst Spinal Cord Stimulator Trial (BurstDR™, Abbott Saint Jude Medical).
75439322|NCT01599715|Behavioral|Bladder Health Class|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
75589262|NCT02216487|Drug|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
75589263|NCT01198600|Device|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
75589264|NCT01198600|Device|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
75883006|NCT02126384|Drug|pneumovax vaccination|vaccination
75883007|NCT02035410|Procedure|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
75883008|NCT02404155|Drug|Clozapine|
76054027|NCT01512160|Drug|Ibuprofen|2 x 200 mg tablets
76054028|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
75439323|NCT01599728|Drug|Urocortin 2, Urocortin 3 and Substance P|"After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min [15, 50 and 150 ng/min] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) [to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release [2, 4 and 8 pmol/min]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones."
75439324|NCT01599767|Device|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
75439325|NCT01599819|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
76054029|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
76054030|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
75439326|NCT01599819|Biological|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
75439327|NCT01599858|Drug|YF476|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
75439328|NCT01599858|Drug|Omeprazole|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
75589265|NCT01198600|Device|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
75589266|NCT02218814|Procedure|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
75733004|NCT06134882|Behavioral|Contingency management|Monetary incentives are delivered via reloadable debit card based on verified engagement in target behaviors, including drug abstinence, appointment attendance, and completion of self-paced cognitive behavior therapy modules.
76054031|NCT01546168|Device|esophageal deviation with IDE device|esophageal deviation during AF ablation
76054032|NCT01901289|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
76054033|NCT01950741|Drug|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
76054034|NCT01950273|Drug|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
75439329|NCT01599871|Drug|theophylline|theophylline 100 mg, twice at day
75439330|NCT01599871|Other|placebo|Placebo
76054035|NCT01950273|Drug|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
76054036|NCT01919307|Other|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
76054037|NCT01919229|Drug|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
76054038|NCT01919229|Drug|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
75439331|NCT01599884|Drug|N-acetylcysteine|1800 mg twice daily for 8 weeks
75439332|NCT01599884|Drug|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
75439333|NCT01599897|Biological|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
75439334|NCT01599897|Biological|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
75439335|NCT01599910|Other|Scribes|Scribe
75439336|NCT01599923|Biological|Antivenin Centruroides (scorpion) equine immune F(ab')2|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
75439337|NCT01599936|Biological|Anascorp|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
75733005|NCT06134882|Behavioral|Cognitive-Behavior Therapy Modules|Self-paced cognitive-behavior therapy modules delivered via smartphone.
75733006|NCT06134882|Behavioral|Peer Contingency Management (CM) Guide|Peer supports delivered via telehealth. Support is informed by the community reinforcement approach and includes motivational interviewing
75733007|NCT06134882|Behavioral|Drug testing|Self-performed salivary drug testing with incentives contingent upon proper completion of test procedures as confirmed by video.
75589267|NCT02218814|Procedure|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
75589268|NCT04317898|Procedure|serratus plane block by ultra-sound|To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.
75589269|NCT04317898|Procedure|paravertebral block by ultra-sound|TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
75589270|NCT02216565|Other|Hospitalization in specialized neuro-vascular unit|
75589271|NCT02216565|Drug|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
75733008|NCT06134882|Behavioral|Wellness modules|Basic health and wellness information delivered via self-paced learning modules.
75733009|NCT06134882|Behavioral|Peer technical support|Peer support for promoting engagement and addressing technical issues delivered via a mobile digital platform.
75733010|NCT06134869|Procedure|Bone augmentation|Dense PTFE membranes covering an allograft biomaterial were used without any attempt to passivate the flap
75733011|NCT06134856|Procedure|Ankle mobilization|Ankle joint mobilization as described in treatment arm description
76054039|NCT04626375|Drug|Bioarginine|In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
75883009|NCT05760235|Procedure|Endoscopic sleeve gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free15. The procedure will be performed with the patient in supine position. Carbon dioxide will be blown to stretch the gastric lumen. An initial endoscopic evaluation will be performed immediately to confirm the absence of any contraindication to ESG before suturing. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch.
75883010|NCT02127788|Drug|Micafungin|intravenous
76054040|NCT04626375|Drug|Placebo oral tablet|In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
76054041|NCT01901055|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
76054042|NCT01901055|Device|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
76054043|NCT01901055|Behavioral|Diabetes Education|Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
76054044|NCT04615377|Behavioral|Kaia hip and knee pain application|The Kaia Knee and Hip pain app software, when loaded onto a smartphone, recommends to the participant specific exercises for the lower extremity. Using the camera on a smartphone, the software then tracks the participant's movements as the participant performs the exercises, analyzes those movements using machine learning, and provides audio-visual feedback to the participant. The exercise therapy is augmented by educational content and cognitive behavioral therapy to provide a multidisciplinary approach to self-management of osteoarthritis. Behavioral Health Coaches ensure participant motivation throughout the program based on a predefined curriculum.
75439338|NCT01599949|Drug|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
75439339|NCT01599962|Drug|Cinacalcet|single administration, 90mg
75439340|NCT01599962|Drug|Placebo|single administration
75439341|NCT01599975|Drug|Long acting methylphenidate|Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
75439342|NCT01599975|Drug|Long acting methylphenidate|18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
75439343|NCT01599975|Drug|Matched placebo|2 tablets of matched placebo daily by mouth
75439344|NCT01599988|Dietary Supplement|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate
75733012|NCT06134856|Procedure|Sham treatment|Light passive movement of the foot and ankle, avoiding the end-ranges which may actually elicit a mechanical change
75733013|NCT06134843|Combination Product|DERMASEAL|plasma film containing metallic silver microparticles and fibrin
75733014|NCT06134830|Drug|RAI|Radioactive iodine
75733015|NCT06134817|Device|Embozene Color-Advanced Microspheres.|"Embozene Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer. The microspheres are intended to occlude vasculature for the purpose of blocking blood flow to a target tissue.~In the study, the abnormal vessels will be embolized with 100 μm Embozene Microspheres solution under direct fluoroscopic visualization to prevent reflux and non-target embolization. Multiple geniculate arteries may be embolized until neovascularity is no longer seen."
75439345|NCT01599988|Dietary Supplement|Milk Protein Isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
75439346|NCT01600157|Procedure|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
75733016|NCT06134791|Other|No intervention|No intervention
75439347|NCT01600391|Behavioral|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
75733017|NCT06134778|Other|Inspiratory Muscle Training|Inspiratory muscle training was performed for six weeks. Athletes performed two daily sessions of 30 forced inspirations followed by long but not maximal expirations, with load adjusted between 50% and 60% of maximum inspiratory pressure, five times a week. A specific device was used for this purpose (Classic, Powerbreathe, United Kingdom), with light or medium resistance adjustment, depending on the subject's maximum inspiratory pressure.
75733018|NCT06134765|Drug|Bemalenograstim alfa|Bemalenograstim alfa,20mg, once every treatment
75733019|NCT06134739|Other|No intervention.|Observational study, no intervention.
76054045|NCT04615377|Other|Treatment as usual|Participants allocated to the control arm will be advised to continue receiving treatment as usual ( standard care) without restrictions, except participation in other investigational trials, and will likewise be followed up for 90 days. Apart from that, they are encouraged to seek care, as they would do normally.
75589272|NCT02216565|Other|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
75589273|NCT02216565|Procedure|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
75589274|NCT02218931|Behavioral|Targeted ESTEEM diet|"The key components of the diet are:~High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
75589275|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
75589276|NCT04534790|Radiation|Low Dose Radiotherapy|anti-inflammatory effect with low-dose radiation to the lungs
75589277|NCT02216630|Drug|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
75589278|NCT02218970|Behavioral|strength training|
75883011|NCT03601650|Behavioral|Mindful eating|Attending to the sensory properties of food as it is eaten
75883012|NCT03601650|Behavioral|Eating without distractions|Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
75883013|NCT05194423|Device|Tricuspid Valve Replacement System via jugular vein|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.
76054046|NCT01511536|Drug|Cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: injection
76054047|NCT01511536|Drug|Abiraterone acetate|Pharmaceutical form:tablets Route of administration: oral
76054048|NCT01511536|Drug|Prednisone 5 mg|Route of administration: oral
76054049|NCT01890759|Biological|Meningococcal Diphtheria Toxoid Vaccine|0.5 mL, Intramuscular
76054050|NCT01900899|Procedure|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
75589279|NCT02218970|Behavioral|no training (control)|
75589280|NCT04534803|Drug|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
75589281|NCT04534803|Other|Placebo|.1 nL of diluent (saline) given intradermally at baseline
75589282|NCT02219126|Other|Dietary intervention|
75589283|NCT04534569|Other|Experts consensus|Consensus opinion using Delphi Methodology
75589284|NCT04534634|Combination Product|IFN-α combined with CAR-T cell therapy|"Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.~Children: 14 daily intramuscular injections 200mg/m^2 of Interferon-α for a 28-day cycle.~CAR T cell: (1-2)×10^7/kg, intravenously infusion."
76054051|NCT01510912|Drug|Diclofenac|35 mg bid or tid Capsules
76054052|NCT04615221|Other|Specimens|Specimens (blood, biopsy, cervical smear, vaginal swab)
76054053|NCT01510756|Drug|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
75733020|NCT06134713|Drug|cryotherapy with sterile saline at 2.5ºC|In the cryotherapy (experimental group), final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept refrigerated at 2.5ºC and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
75589285|NCT01198132|Dietary Supplement|Cholecalciferol (Vitamin D3)|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
75589286|NCT01198132|Dietary Supplement|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
75589287|NCT01198132|Drug|Rebif|Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
75439348|NCT01600391|Behavioral|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
75589288|NCT02219165|Drug|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
75589289|NCT02219165|Drug|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
75733021|NCT06134713|Drug|control with sterile saline at room temperature|In the control group, final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept at room temperature and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
75439349|NCT01600391|Behavioral|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
75589290|NCT02887690|Device|Modular Prosthetic Limb|
75589291|NCT02216604|Behavioral|Multimodal Exercise Intervention|During their inpatient hospitalization the participants perform 3-5x weekly guided training sessions about 15-30min. The intervention includes: game console-based training using Nintendo Wii® (endurance, strength endurance and balance), age-specific resistance training and sessions of body awareness. During the outpatient phases the participants perform a home-based exercise training 3-5x weekly using a training manual. In addition, the patients obtain a movement diary and a pedometer for documenting their activity level.
75589292|NCT04534439|Drug|APX-115|oral administration of APX-115 400mg capsule once daily for 12 weeks
75589293|NCT04534439|Drug|Placebo|oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
75733022|NCT06134700|Procedure|Laparoscopic Surgery|"Surgery will then proceed at either 8 - 10 or 12 - 15 mmHg pneumoperitoneum pressure depending on study group the patient falls into~Port Placement~Reflection of colon~Isolation of ureterogonadal packet~Upper pole dissection~Hilar dissection~Vessel clipping and division~Dissection of kidney~Delivery through either Pfannenstiel or iliac fossa incision"
76054054|NCT01522456|Drug|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
76054055|NCT01522456|Drug|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
75589294|NCT04534478|Drug|Prednisone|Patients will be randomized 1: 1 between the two arms of the study
75589295|NCT02216669|Drug|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
75589296|NCT03881748|Other|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
75883014|NCT03626649|Device|DiamondTemp Cardiac Ablation System|"The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:~DiamondTemp Ablation Catheter~o Unidirectional and Bidirectional models~DiamondTemp Catheter-to RFG Cable~DiamondTemp GenConnect Cable~DiamondTemp FASTR Generator with Footswitch~DiamondTemp Irrigation Pump~DiamondTemp Irrigation Tubing Set"
75439350|NCT01600430|Dietary Supplement|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
75733023|NCT06134687|Procedure|Endoscopic Submucosal Dissection|Removal of study eligible lesions per endoscopic submucosal dissection
75439351|NCT01600430|Dietary Supplement|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
75439352|NCT01600430|Dietary Supplement|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
75439353|NCT01600508|Other|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
75733024|NCT06134687|Device|Novel Rigidizing Overtube|Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection
75733025|NCT06134661|Device|cTBS (continuous Theta Burst Stimulation)|"Continuous Theta Burst Stimulation (cTBS) is an inhibitory stimulation protocol of the Transcranial Magnetic Stimulation (TMS) device that temporarily inhibits brain activation in a small targeted brain area.~The investigators apply the cTBS protocol 3 times daily at 100% of the resting motor threshold (RMT) for 500 pulses per session (total 1500 pulses per day)."
75733026|NCT06134648|Biological|RSV/hMPV vaccine candidate Dose L|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
76054056|NCT04409626|Other|Plasma sodium level (continuous variables)|Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
76054057|NCT01545934|Behavioral|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
76054058|NCT03027544|Radiation|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles."
75883015|NCT02131688|Drug|Mitoxantrone Hydrochloride Liposome|
75883016|NCT03604146|Behavioral|Medical quality control intervention strategy|Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
75439354|NCT01600599|Drug|Tranexamic Acid|intravenous 1g and topical 1g
75439355|NCT01600599|Drug|saline|100mls of topical saline
75439356|NCT01600937|Behavioral|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
75439357|NCT01600976|Drug|telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
75439358|NCT01601028|Drug|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
75439359|NCT01601028|Drug|Placebo|2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
75439360|NCT01601301|Device|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
75439361|NCT01601457|Drug|activated recombinant human factor VII|90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
75733027|NCT06134648|Biological|RSV/hMPV vaccine candidate Dose A|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
75733028|NCT06134648|Biological|RSV/hMPV vaccine candidate Dose B|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
75733029|NCT06134648|Biological|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
75733030|NCT06134635|Drug|Statins|Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
75733031|NCT06134635|Drug|Evolocumab|Evolocumab 140mg twice a month, subcutaneous injection
75733032|NCT06134622|Drug|Intravenous thrombolysis plus tirofiban|Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.
75589297|NCT03881748|Other|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
75589298|NCT02219204|Procedure|Acupuncture|
75589299|NCT02219204|Other|Herbal treatment|
75589300|NCT03772158|Drug|Cetirizine 10mg|Chewable tablet
75589301|NCT03772158|Drug|Cetirizine 10 mg|Immediate Release Tablet
76054059|NCT01521364|Drug|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
75589302|NCT03772158|Drug|Cetirizine 10 mg|Immediate Release Tablet
75733033|NCT06134622|Drug|Intravenous thrombolysis plus placebo|placebo (saline)
75733034|NCT06134583|Procedure|Superior cervical sympathetic block group|5 ml bupivacaine 0.5% will be injected around the internal carotid artery at the level of carotid bifurcation
75733035|NCT06134583|Procedure|Stellate ganglion block group|5 ml bupivacaine 0.5% will be injected between the common carotid artery and longus capitis muscle at the level of C7 vertebra
75733036|NCT06134557|Procedure|conventional stents|performed the study to compare the safety and efficacy between flow diverters and conventional stents in IVADA patients undergoing endovascular therapy. Stent-assisted coiling is the preferred option for most surgeons. In addition,It is believed that dense packing is not necessary as long as the aneurysm neck is covered to isolate the dissection. How ever,whether it is really necessary to adjunct coil,and if it is necesary, what is the ideal packing density of coils, there is no clear conclusion at present.This study aimed to compare the safety and efficacy between flow diverter and conventional stents in patients with IVADA, determine the ideal packing density of coils after FD stent placement,and to observe the hemodynamic changes before and after the treatment of FD stent.
75439362|NCT01601457|Drug|placebo|Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
75589303|NCT03653988|Procedure|PEC I/II blocks by anesthesiologist - pre-operative|PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
75883017|NCT01375465|Device|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
75883018|NCT03604068|Device|RecoveryRx|A pulsed shortwave therapy medical device
75589304|NCT03653988|Procedure|PEC I/II blocks by surgeon - intra-operative|PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
75589305|NCT01197508|Drug|TC-5214|Twice daily for 8 weeks.
75589306|NCT01197508|Drug|Placebo|Twice daily for 8 weeks.
75589307|NCT02219243|Behavioral|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
76054060|NCT01545388|Drug|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
76054061|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
76054062|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
75589308|NCT02219243|Behavioral|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
75589309|NCT04534764|Device|etafilcon A with cosmetic pattern|TEST
75589310|NCT04534764|Device|1-Day Acuvue DEFINE Vivid Style|CONTROL
75883019|NCT03604068|Device|Sham RecoveryRx|A sham pulsed shortwave therapy medical device
75883020|NCT02126462|Biological|Na-APR-1 (M74)/Alhydrogel®|
75883021|NCT02126462|Biological|Na-GST-1/Alhydrogel®|
75589311|NCT04534062|Other|PNF D2 technique|PNF D2 technique of bilateral upper limb will be performed
75589312|NCT02219399|Dietary Supplement|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
75589313|NCT02219399|Dietary Supplement|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
75589314|NCT02219399|Dietary Supplement|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
75589315|NCT02887378|Device|hot clamps|reusable hot biopsy forceps
76054063|NCT01545388|Drug|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
76054064|NCT03027232|Other|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
75589316|NCT02887378|Device|normal clamps|
75589317|NCT04534244|Device|VBox Hybrid|Medical device intended to treat permanent venous insufficiency of saphenous veins and tributary veins in patients with superficial venous reflux
75589318|NCT04534140|Dietary Supplement|HBKB Capsule|The botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB) taken daily orally.
75589319|NCT04534140|Other|HBKB Supplement Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
76054065|NCT01545076|Biological|IgPro20 (low dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)"
76054066|NCT01545076|Biological|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
75439363|NCT01601587|Other|A psychoeducational group intervention.|"The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:~What is mental health?~Treatment options: orientation about individual and group based treatment modalities.~Former patients experience with their own treatment, self-help and participation.~How to influence and participate actively in the treatment and patient rights.~What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?"
76054067|NCT01545076|Biological|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
75439364|NCT01601639|Device|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
75439365|NCT01601639|Device|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
75439366|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
76054068|NCT01545076|Biological|IgPro20 (high dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)"
75439367|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
75439368|NCT01602029|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
75589320|NCT03596697|Drug|CRV431|Single or multiple dose(s) of CRV431
75589321|NCT03596697|Drug|Placebo|Single Placebo dose
75589322|NCT03596697|Drug|TDF|Single or multiple dose(s) of TDF
75589323|NCT01196416|Drug|Cisplatin|Given IV
75589324|NCT01196416|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
75589325|NCT01196416|Other|Laboratory Biomarker Analysis|Correlative studies
75589326|NCT01196416|Other|Pharmacological Study|Correlative studies
75589327|NCT01196416|Drug|Temozolomide|Given PO
75589328|NCT01196416|Drug|Vinblastine Sulfate|Given IV
75589329|NCT02219555|Drug|Steroid Injection|volume and specific steroid drug will be based on the recommendation of the treating clinician
75589330|NCT02219555|Procedure|Carpel Tunnel surgery|Standard of care carpel tunnel surgery
75589331|NCT03272178|Device|Depuy total knee implant|patients from Dr Nunley's clinic will get a Depuy implant
75589332|NCT03272178|Device|Triathlon total knee implant|patients from Dr Barrack's clinic will get a Triathlon implant
75589333|NCT04534166|Other|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis
75589334|NCT04534088|Behavioral|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|Standard Behavioral Weight Loss Program
75589335|NCT04534088|Behavioral|Standard Behavioral Weight Loss plus Weight-Related VR app|Standard Behavioral Weight Loss plus Weight-Related VR app
75589336|NCT01196104|Drug|Technosphere® Insulin Inhalation Powder|
75883022|NCT02126462|Biological|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
75439369|NCT01602029|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
75439370|NCT01602029|Drug|Placebo|Placebo added to TAU
75439371|NCT01602029|Drug|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
75439372|NCT01602705|Other|Usual care|Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
75439373|NCT01602705|Other|Feedback of Performance|Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
75589337|NCT01196104|Drug|Insulin Aspart|Usual Care
75589338|NCT01196104|Drug|Insulin Glargine|
75883023|NCT03113071|Drug|Decitabine|Decitabine will be administered in combination with Digoxin
75883024|NCT03113071|Drug|Digoxin|Decitabine will be administered in combination with Digoxin
75883025|NCT03601572|Other|No intervention|No intervention
75439374|NCT01602705|Other|Feedback of Performance + Health Psychology Informed Intervention|Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
75439375|NCT01602718|Other|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
75439376|NCT01602796|Behavioral|School intervention|The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
75439377|NCT01602848|Other|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
75439378|NCT01602874|Drug|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
75589339|NCT04534322|Drug|Melphalan Flufenamide|Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
75589340|NCT04534322|Drug|Dexamethasone|Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
75589341|NCT04534179|Procedure|Vacuum myofascial therapy and physical activity program.|"This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program"
75589342|NCT04534179|Other|Physical activity program.|Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
75589343|NCT02219594|Device|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
75589344|NCT02219633|Drug|LEO 39652 cream|Applied for 21 days
75589345|NCT02219672|Drug|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
76054069|NCT01544920|Biological|peg-Interferon alfa-2a|peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
76054070|NCT01544920|Drug|Ribavirin|RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight <75 kilograms [kg]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
76054071|NCT01544920|Drug|Boceprevir|Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
75589346|NCT02219672|Drug|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
75589347|NCT03113955|Device|Tandem Microsphere loaded with Epirubicin|The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
75733037|NCT06134531|Drug|MR001|"Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle"
75733038|NCT06134518|Other|The education program|The intervention group will receive the competency-based education program for 1 month at each PHC, after baseline data collection. The education program will be conducted weekly. This education session will be conducted for 4 hours per session, with 20 health cadres in a group per PHC. The competency level is measured by the researcher developing a competency questionnaire which consists of a knowledge test, skill, and attitude checklist score at the 2nd post-assessment (2 months after being given the education program).
75733039|NCT06134518|Other|the initial orientation from the PHCs|the initial orientation from the PHCs
75439379|NCT01602874|Drug|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
75733040|NCT06134492|Drug|Acyclovir|"Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information.~Mode of administration: intravenous (i.v.)"
75733041|NCT06134479|Drug|150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5|On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
75439380|NCT01602874|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
75589348|NCT04533971|Other|Whole body cryotherapy|The WBC procedure consisted of 2-3 min walk in the cryogenic chamber at -110℃. Immediately before the WBC procedures, the patients were provided with a special treatment suit, they were instructed as to how to protect the parts of the body that are particularly vulnerable to frostbite, on the proper way of moving and breathing during the treatment. Excluding Saturdays and Sundays, the WBC treatments were performed daily for the next four weeks. Each time after the WBC the subjects participated in 15-minute kinesitherapy exercises conducted in groups of 5-6 people. The exercises were of general improvement nature and took into account the mobility of the subjects.
75589349|NCT02219750|Drug|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
75589350|NCT04534374|Behavioral|Resistance exercise|Barbell back squat, press, and deadlift for three sets of five repetitions with the weight closest to 75% of their estimated 1 repetition max. The participants were instructed to execute the movement with moderate speed (2s eccentric, 2s concentric, no pause in between). The rest period between sets and exercise movements was two to three minutes.
75883026|NCT02131844|Other|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
75589351|NCT04534374|Behavioral|Stretching exercise (sham exercise)|Participants completed a passive stretching exercise session for a similar duration of time as the resistance exercise (≈ 30 min) as sham intervention, which included 15-20 stretching movements twice, holding each for 30 seconds as recommended by ACSM.
75589352|NCT04534452|Drug|Phenylephrine HCl (Sinus Comfort, BAY112476)|30 mg Extended Release Tablets, single oral dose
75589353|NCT04533789|Other|selected physical therapy program|strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
75439381|NCT01602874|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
75439382|NCT01602887|Drug|PD-0332991|isethionate hard capsule, 125 mg, single dose
75883027|NCT02131844|Other|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
75439383|NCT01602887|Drug|PD-0332991|"freebase hard capsule with a small particle size, 125 mg, single dose"
75439384|NCT01602887|Drug|PD-0332991|"freebase hard capsule with a large particle size, 125 mg, single dose"
75439385|NCT01602887|Drug|PD-0332991|oral solution, 50 mg, single dose
75439386|NCT01602926|Procedure|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
75439387|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
75589354|NCT04533776|Behavioral|Celiac Disease Definition, Symptoms and Treatment|"Adolescents share their knowledge about the disease~Emphasizing the definition and symptoms of celiac disease~Discussion of the treatment of celıac disease Expression Question-Answer Discussion Summarizing"
75589355|NCT04533776|Behavioral|Difficulties Due to Celiac Disease|"Determining what experience living with celiac is fot the patient (What do I think about the disease, how do I feel about the disease,how do I perceive the disease, how does the disease affect me)~Determining the difficulties encountered in Daily life due to illness (How do I deal with difficulties)~Determining how the disease affects life Expression Question-Answer Discussion Summarizing"
75589356|NCT04533776|Behavioral|Gluten Free Diet in Celiac Disease|"Evaluating dietary information~Identifying the difficulties in diet therapy Expression Question-Answer Discussion Summarizing Case Study Presentation (Transfer of life experience of an individual who is 22 years old with celiac disease)"
75589357|NCT04533776|Behavioral|Difficulties Related to Disease in School and Social Life|"Assessment of difficulties encountered in school and social life~Evaluation of the solution suggestions fort he difficulties encountered Expression Question-Answer Discussion Summarizing Örnek Olay Sunumu (Transfer of life of experience of a 23 years old dietician with celiac disease)"
75883028|NCT03050307|Drug|TAK-438|TAK-438 tablets
75883029|NCT03050307|Drug|Lansoprazole|Lansoprazole capsules
75883030|NCT03050307|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
75883031|NCT03050307|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
75883032|NCT03050307|Drug|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
76054072|NCT04105036|Other|Data Collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
76054073|NCT01509664|Behavioral|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
75733042|NCT06134479|Drug|150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger|On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
75733043|NCT06134466|Dietary Supplement|Liquid Extensively hydrolyzed cow's milk protein infant formula|Liquid Investigational Formula (Extensively hydrolyzed cow's milk protein infant formula) 2.8 g protein/100 kcal
75733044|NCT06134453|Other|Reiki/Sham Reiki|Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.
75733045|NCT06134427|Other|basic combat training (investigator did not design the intervention)|12 weeks basic combat training is 12 weeks is a compulsory program for all cadets accepted in republic indonesia defense university
75439388|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
75439389|NCT01603147|Biological|normal saline|saline 225 ml
75589358|NCT04533776|Behavioral|Celiac Disease and Its Effects on Acamdemic Success Peer Relations|"Evaluation of the effects of the disease on academic success~Evaluation of the effects of the disease on peer relationships in the school enviroment~Difficulties experienced in peer relations and evaluation of relationships (exclusion) Expression Question-Answer Discussion Summarizing"
75589359|NCT04533776|Behavioral|Celiac Diseae anf Future Goals|"General summary of all sessions so far~Summarizing the topics discussed in the previous session~Evaluating the future goals of the participants Expression Question-Answer Discussion Summarizing"
75589360|NCT04533776|Other|No Intervention: routine health care- control group|Peer interactive group support was not provided to the control group. After all the sessions of the peer interactive group support of the study were completed, a separate training meeting was held for the control group.
75589361|NCT04533828|Drug|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
75589362|NCT02219789|Drug|Alisertib|Given PO
75589363|NCT02219789|Drug|Fulvestrant|Given IM
75589364|NCT02219789|Other|Laboratory Biomarker Analysis|Correlative studies
75439390|NCT01603147|Biological|ch-mAb7f9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
75439391|NCT01603264|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
75439392|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
75439393|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
75439394|NCT01603485|Drug|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
75589365|NCT04533633|Procedure|Retrograde Percutaneous Coronary Intervention of Chronic Total Occlusion|Retrograde CTO-PCI using epicardial collateral connections
75589366|NCT04533932|Diagnostic Test|Elastography|Endosonographic shear wave elastography
75589367|NCT02219828|Drug|Anakinra|2mg/Kg daily sc up to 100mgday as maximum dose
75589368|NCT02219828|Drug|Placebo|Placebo
75589369|NCT04533867|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape
75589370|NCT04533867|Drug|Palonosetron 1mcg/kg|Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
75589371|NCT04533867|Drug|Ondansetron 1 mg/kg, max dose 8 mg|Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
75589372|NCT01196026|Biological|Fluarix™|One or two intramuscular injections
75733046|NCT06134401|Device|saline|nebulised
75733047|NCT06134388|Drug|Sulfasalazine|Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.
75733048|NCT06134349|Device|lithium MRSI|lithium magnetic resonance spectroscopy imaging
75733049|NCT06134336|Other|Interview|No interventional or behavioral intervention will be applied. Only interviews will be conducted through a questionnaire.
75589373|NCT01196026|Biological|Havrix™ Junior|Two intramuscular injections
75589374|NCT02216708|Other|Rapid dehydration|
75733050|NCT06134310|Procedure|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
75883033|NCT03601494|Other|perineural injection of platelet-rich plasma|Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
75439395|NCT01603485|Drug|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
75439396|NCT01603485|Drug|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
75439397|NCT01603485|Drug|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
75439398|NCT01603485|Drug|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
75589375|NCT02216708|Other|Slow rehydration|
75589376|NCT02219867|Drug|Ketamine|Drug (including placebo)
75589377|NCT04533906|Device|Coldamaris lozenges|sucking carageenan containing lozenge
75589378|NCT02219906|Dietary Supplement|Resveratrol|1000mg tid
75589379|NCT02219906|Dietary Supplement|Placebo|1000mg tid placebo
75589380|NCT04533893|Other|Medical simulator (3B Scientific Lilly Pro) and Platform combining simulator sensor data with OSCE scores|Hands-on training app combining OSCE scoring criteria with sensor data retrieved from the simulator's sensors was used for hands-on performance evaluation.
75589381|NCT02219945|Other|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
75589382|NCT01620918|Procedure|normal healing abutment|Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
75589383|NCT01620918|Procedure|nano-structured healing abutment|Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
75589384|NCT04533516|Other|Manual therapy technics|Manual therapy technics
75589385|NCT04533516|Other|Inspiratory Muscle Training|Inspiratory Muscle Training
75589386|NCT04533243|Drug|2.5ug/h transdermal fentanyl|2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
75589387|NCT04533243|Drug|Oral immediate-released morphine|5mg immediate-released morphine every 4 hours, double dose before sleep.
75883034|NCT03601494|Drug|medical|vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
76054074|NCT04409704|Device|Repetitive Transcranial Magnetic Stimulation|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week, 20-30 sessions.
76054075|NCT01543828|Drug|indacaterol|delivered via single-dose dry-powder inhaler
75439399|NCT01603524|Other|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
75439400|NCT01603524|Behavioral|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
75439401|NCT01603589|Procedure|Coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation|We use a prototype AHEPA (modular type IV) circuit comprised of the standard and a standby accessory. Components of the standard circuit include: aortic cannula, three-stage venous cannula, coated tubing, a centrifugal pump, a new-generation membrane oxygenator with integrated arterial filter, a venous air removal device, a soft coated bag and pulmonary artery as well as aortic root vent. In addition, there is a standby hard-shell reservoir in parallel to the venous line, so as to convert the closed system to an open one. The standby component is bridged to the main circuit with an afferent line which is connected just before the VARD sending blood to the hard-shell reservoir and an efferent that re-directs it back to the VARD. A cell-saver device is added to the circuit for collecting shed blood and washing red blood cells for autotransfusion.
75589388|NCT04533620|Radiation|Standardized CIRT|CIRT with a dose of 63 GyE/21 fx
75589389|NCT04533620|Radiation|Individualized CIRT|A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
75589390|NCT02210585|Other|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
75589391|NCT04533321|Drug|Afatinib|Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
75589392|NCT04533191|Procedure|Bilateral implantation of light adjustable intraocular lens and subsequent adjustment to binocular custom vision|Subjects will receive bilateral implantation of a commercially available Light Adjustable Intraocular lens at the time of cataract surgery. Subsequently, they will undergo light adjustment of the lens to target binocular custom vision.
75589393|NCT01004367|Other|Experimental|Environmental- and individual based components carried out in the school.
75883035|NCT05760157|Other|Possible risk factors of heart failure|Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.
75883036|NCT02126540|Device|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
75883037|NCT03603990|Procedure|Vitrectomy|"During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
75883038|NCT03603990|Procedure|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
76054076|NCT01543828|Drug|placebo|delivered via single-dose dry-powder inhaler
76054077|NCT03027622|Behavioral|quality of life in the patients with mild pericoronitis|active surviallence by OHIP-14 TR after treatment
76054078|NCT01520506|Device|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
76054079|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
75589394|NCT02211599|Other|15% protein|Meal to provide 15%en from protein.
75589395|NCT02211599|Other|30% protein|Meal to provide 30%en from protein.
75733051|NCT06134310|Procedure|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
75589396|NCT02211599|Other|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
75733052|NCT06134310|Procedure|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
75733053|NCT06134310|Behavioral|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
75883039|NCT02127866|Drug|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
75589397|NCT00734019|Device|P.F.C. Sigma Knee|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
75589398|NCT01195948|Drug|B27PD|
75589399|NCT01195948|Drug|Placebo|Capsule with no active ingredients to mimic B27PD
75589400|NCT02213354|Drug|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
75589401|NCT02213354|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
75589402|NCT04533048|Combination Product|MW33 injection|a recombinant fully human antibody to coronavirus
75733054|NCT06134297|Device|Cycle ergometer|The Aerobic Exercise Group will perform a cycle ergometer for 15 consecutive minutes with a load adjusted to maintain heart rate (HR) between 65-75% of the maximum HR predicted for age (HRmax = 200-age). Peripheral oxygen saturation will be controlled and, upon a sustained drop (> 2 minutes after load reduction) below 90%, the session will be interrupted. The subjective feeling of tiredness in the legs and shortness of breath will be constantly monitored and if values equal to or greater than 8 (0-10) occur, the exercise will be stopped.
75733055|NCT06134297|Device|Strength Training - elastic band and shin guards|The Anaerobic Exercise Group will perform muscular strength training using maximum strength, where the contraction time should not exceed 20 seconds. For the upper limbs, the overload used will be through the use of an elastic band, with guidance for the patient to perform the shoulder external rotation exercise, elbow flexion exercises and open row rowing exercise. For the lower limbs, bridge movements, lunges and sit-up exercises will be performed with a maximum of 15 repetitions, and overload with ankle weights or dumbbells can be used in addition to body weight. The muscle contraction should lead the patient to a state of muscular fatigue and if the objective is not achieved, the exercise will be adapted to require greater strength from the patient so that he or she can reach maximum strength.
75589403|NCT04533048|Combination Product|MW33 injection placebo|Placebo
75589404|NCT01195831|Drug|Xamiol® gel|Once daily application
75883040|NCT02127866|Drug|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
75883041|NCT03601416|Drug|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
75883042|NCT03601416|Drug|No Transplantation of Mesenchymal Stem Cell|Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
75589405|NCT01195831|Drug|Calcipotriol scalp solution|Twice daily application
75589406|NCT02210273|Device|Solace Bladder Control (Vesair) Balloon|Subjects may undergo treatment every 12 months until study completion.
75589407|NCT02210273|Device|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
75589408|NCT01195675|Drug|BI 10773 (low)|single oral dose
75589409|NCT01195675|Drug|Moxifloxacin|single oral dose
75589410|NCT01195675|Drug|BI 10773 Placebo|2 times single dose
75589411|NCT01195675|Drug|BI 10773 (high)|single oral dose
75589412|NCT04532931|Other|Standard of care (Paracetamol)|SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed
75589413|NCT04532931|Drug|Artesunate-amodiaquine|SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days
75589414|NCT04532931|Drug|Pyronaridine-artesunate|SOC plus pyronaridine-artesunate (PA) Weight 45 to <65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days
75733056|NCT06134297|Device|Cycle ergometer, elastic band and shin guards|Mixed Exercise Group will perform the exercises by alternating between aerobic and anaerobic overload, in a 1:1 ratio until the end of the physical rehabilitation program, following exactly the same protocols described previously (alternating one session of the aerobic protocol and in the following session the anaerobic protocol).
75733057|NCT06134271|Drug|Rezvilutamide|Rezvilutamide 240mg qd
75733058|NCT06134271|Drug|Rezvilutamide plus abiraterone|Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
75733059|NCT06134271|Drug|Continue previous treatment|Continue using the previous treatment regimen for treatment.
75733060|NCT06134245|Device|Entia Liberty|Home monitoring
75733061|NCT06134232|Drug|Sipuleucel-T Injection|Single Infusion
75589415|NCT04532931|Drug|Favipiravir plus Nitazoxanide|SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days
75589416|NCT04532931|Drug|Sofosbuvir/daclatasvir|"SOC plus sofosbuvir/daclatasvir (SOF/DCV)~1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days"
75589417|NCT02210975|Device|LES-Stimulation Device|
75589418|NCT01195636|Drug|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
75589419|NCT01195636|Drug|Placebo|Twice daily application of Placebo ointment
75589420|NCT04533113|Procedure|Carious tissue selective removal|Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration
75589421|NCT01195363|Drug|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
75439402|NCT01603589|Procedure|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
75439403|NCT01603680|Procedure|Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow|Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
75589422|NCT01195363|Drug|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
75589423|NCT04317625|Diagnostic Test|mpMRI scanning|The patients whose PSA levels are between 2.5 and 4.0ng/ml will be recommended to mpMRI scanning at first but not biopsy or active surveillance.
75883043|NCT04071379|Biological|Recombinant Hepatitis B + DTP-HB-Hib|1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib
75883044|NCT04071379|Biological|Hep B + Pentabio (registered)|1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
76054080|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
76054081|NCT01543204|Drug|Etanercept|Administered by subcutaneous injection
76054082|NCT01488994|Biological|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
75589424|NCT04315870|Other|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
75589425|NCT04533269|Other|Arnica montana, Ledum palustre|Homeopathic
75589426|NCT01195090|Drug|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
75589427|NCT01195090|Drug|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
75883045|NCT03869697|Drug|SCB-313|5 mg or 20 mg lyophilized powder in a single-use glass vial
75883046|NCT03550508|Biological|Anti-RANKL Monoclonal Antibody|JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
75883047|NCT03607578|Behavioral|Other: Control Group - Minimal Intervention|Basic Campaign Folder
76054083|NCT01508650|Behavioral|Usual care|Usual care control group
76054084|NCT01508650|Behavioral|Rehabilitation intervention|Multi-domain rehabilitation intervention
76054085|NCT03027154|Biological|ESAT6-CFP10 in left arm and TB-PPD in right arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
76054086|NCT03027154|Biological|ESAT6-CFP10 in right arm and TB-PPD in left arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
76054087|NCT01488448|Drug|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
76054088|NCT01488448|Drug|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
76054089|NCT01518946|Drug|Midodrine HCl|dose at the subject's current dose level
76054090|NCT01518946|Drug|Placebo|single dose of matching placebo
76054091|NCT01488370|Device|Endotracheal intubation|Endotracheal intubation
75589428|NCT04533282|Diagnostic Test|Blood samples.|Peripheral blood samples (TEMPUS(TM) whole blood samples, EDTA plasma and heparin plasma, total volume 40ml) taken during (1) initial hospitalisation and (2) three month follow-up visit after hospital stay (follow-up samples are not taken from coronary CT healthy control patients).
75589429|NCT04533282|Diagnostic Test|Collection of right atrial appendage tissue sample.|Collection of the clinically insignificant small piece of heart's right atrial appendage tissue during either standard cannulation of the right atrium for the installation of the heart-lung machine in the beginning of the operation or additionally for routine surgical protocol.
75589430|NCT04533282|Diagnostic Test|Health Survey, Clinical symptom scaling|Patients in the study CABG and AVR cohorts are invited to both pre- and postoperative (3-month time-point), and in the case of PCI cohort only to postoperative, appointments led by experienced clinical cardiologists. The appointments will include clinical anamnesis, status and assessment of morbidity level with combined use of Canadian Cardiovascular Society grading of Angina Pectoris (CCS), New York Heart Association Classification for Heart Failure (NYHA) classification systems and Short Form 36 (SF36) Health Survey. The CT imaging control cohort is not invited to these appointments.
75589431|NCT04533282|Diagnostic Test|Transthoracic echocardiography (TTE)|In order to acquire comprehensive insight into the patients' functional heart status, all appointments are supplemented with echocardiographic evaluation for both functional as well as structural parameters. Detailed echocardiographic analysis criteria for the IHD-EPITRAN study are prespecified in the research plan.
75589432|NCT02211287|Other|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q&A form and can help answer frequent family questions.
75589433|NCT02211287|Other|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
75439404|NCT01603680|Procedure|Non circumferential spread in ultrasound-guided median and ulnar nerves block|Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
75589434|NCT04524546|Diagnostic Test|Sterno-mental displacement test|While the patient is in sitting position, (SMD neutral) will be is measured using tape as the distance between upper borders of the manubrium sterni to the mentum with the head in a neutral position. The (SMD extension) will be then measured in the same way with the head extended on the neck. The difference between SMD extension and SMD neutral will be then calculated as sternomental displacement (SMDD).
75589435|NCT02213081|Drug|Ulipristal|Patients will take 15mg every other day, or every 4 days per week.
75589436|NCT02216760|Device|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
76054092|NCT01518322|Device|NIOX MINO®|Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
76054093|NCT03026998|Procedure|MRI|MRI will be performed each year during 10 years.
76054094|NCT01507246|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
76054095|NCT01507246|Drug|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
75589437|NCT02216760|Device|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
75589438|NCT02213627|Drug|Corifollitropin alfa|
75589439|NCT02213627|Drug|Recombinant FSH|
75589440|NCT02213627|Drug|HP-hMG|
75589441|NCT02216799|Drug|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
75589442|NCT02216799|Drug|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
76054096|NCT01507090|Device|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
76054097|NCT03870022|Device|Pivot Breath Sensor System|Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
75439405|NCT01603706|Procedure|Echo guided implantation group|Lead placement according echo strain imaging result
75589443|NCT04532996|Behavioral|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
75589444|NCT02216877|Drug|Mablet 360 mg|
75589445|NCT02216877|Drug|Placebo|
75589446|NCT02214563|Dietary Supplement|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
75589447|NCT02214563|Dietary Supplement|Olive oil|
75589448|NCT01194973|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
75733062|NCT06134206|Diagnostic Test|Trans-burr hole ultrasound|All ultrasound examinations were conducted alongside the routine postoperative CT scan between 3-7 days postoperatively. To minimize potential influences of the patient's head position on the distribution and thickness of the subdural fluid, we first carried out the CT scan with the patient and their head in a supine position. Immediately after the CT scan, the patient remained on the same examination bed, and burr hole ultrasound was performed in the identical supine position. The burr hole was centered in the image, with the outer table surrounding the burr hole displayed as a horizontal line. The content of the burr hole could be differentiated by its higher echogenicity from the subdural residual hematoma or residual fluid. The brain's surface and overlying leptomeninges, however, displayed higher echogenicity compared to the subdural fluid. The subdural hematoma's thickness was measured at its maximum extent.
75733063|NCT06134193|Drug|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
76054098|NCT03870022|Device|Similar Carbon Monoxide breath sensor system|Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
75589449|NCT02218619|Drug|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
75589450|NCT02218619|Drug|Sugar Pill (placebo)|Placebo
75733064|NCT06134193|Drug|Surufatinib|250mg PO d1, Q3W
75733065|NCT06134193|Drug|Tislelizumab|200mg IV d1, Q3W
75733066|NCT06134180|Behavioral|CONFIDENCE-AI|Multicomponent psychoeducational intervention focused on financial wellbeing
75733067|NCT06134128|Behavioral|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|8-week manualized group-based behavioral intervention delivered via telehealth
75589451|NCT04524234|Diagnostic Test|Echocardiography|Echocardiography for assessment of cardiac function
75589452|NCT02218697|Biological|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
75589453|NCT02218697|Biological|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
75589454|NCT02218697|Biological|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
75589455|NCT02216916|Drug|HM781-36B|
75589456|NCT02279069|Device|4-roll canne|
75589457|NCT02216747|Drug|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
75589458|NCT02216747|Drug|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
75589459|NCT02216747|Drug|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
76054099|NCT01464346|Device|Enlite Sensor|This is the Enlite sensor (all subjects)
76054100|NCT02073448|Drug|GK530G|
76054101|NCT02073448|Drug|CD0271|
76054102|NCT02073448|Drug|CD1579|
76054103|NCT01487200|Drug|FX006 10 mg|single 3 mL IA injection
76054104|NCT01487200|Drug|FX006 40 mg|single 3 mL IA injection
76054105|NCT01487200|Drug|FX006 60 mg|single 3 mL IA injection
76054106|NCT01487200|Drug|TCA IR 40|single 1 mL IA injection
76054107|NCT01463878|Dietary Supplement|Glycerna|Diabetes specific formula
75589460|NCT04521933|Other|Survey|"Each participant completes a questionnaire. In the questionnaire, he performs a subjective qualitative evaluation of Point-of-Care ultrasound records of the heart.~Each participant will complete a questionnaire in which they perform a subjective qualitative evaluation of ultrasonographic recordings of the heart."
75589461|NCT02216786|Drug|AZD2014|Oral tablet
76054108|NCT01463878|Dietary Supplement|Jevity - Control Diet|Control Diet
76054109|NCT01486966|Drug|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
76054110|NCT01486966|Drug|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
75589462|NCT02216786|Drug|Everolimus|Oral tablet
76054111|NCT01486966|Drug|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
76054112|NCT01486966|Drug|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
76054113|NCT01486966|Drug|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
75439406|NCT01603914|Device|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|"Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site."
75589463|NCT02216786|Drug|Fulvestrant|Im injection
75589464|NCT02279147|Drug|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
75733068|NCT06134115|Dietary Supplement|Lipocet® (food supplement)|1 sachet, 10 ml corresponding to 1500 mg of Cetylated fatty acids
75733069|NCT06134115|Dietary Supplement|Lipocet Placebo|Lipocet Placebo matching to Lipocet
75733070|NCT06134076|Other|Unfermented chickpea|Frozen meals containing 100 g unfermented chickpeas
75733071|NCT06134076|Other|Fermented chickpea|Frozen meals containing 100 g fermented chickpeas
76054114|NCT04080076|Drug|Acthar 80 UNT/ML Injectable Solution|ACTHar 80 Units SQ 1042 x Week
75589465|NCT02216825|Dietary Supplement|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
75589466|NCT02216825|Dietary Supplement|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
75589467|NCT04518384|Procedure|colon or rectum resection|surgical procedure to resect the colon or rectum
75589468|NCT02279186|Drug|Tranexamic Acid|Intravenous Injection
75589469|NCT04471350|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in spine surgery.
75589470|NCT04532957|Drug|KBP-7072|QD oral capsules
75589471|NCT04532957|Drug|Placebo|matching placebo capsules
75589472|NCT01177540|Drug|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
75733072|NCT06134063|Drug|Xuanfei Baidu granule|Xuanfei Baidu granule will be administered twice daily for 7 days on the basis of basic treatment
75733073|NCT06134063|Drug|Xuanfei Baidu granule Placebo|Xuanfei Baidu granule Placebo will be administered twice daily for 7 days on the basis of basic treatment
76054115|NCT04080076|Drug|Oral Tab Tacrolimus|Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
75883048|NCT03607578|Behavioral|Experimental: Protection Routine 1|New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
75883049|NCT03607578|Behavioral|Experimental: Protection Routine 2|The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
75589473|NCT01177540|Drug|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
75883050|NCT05760079|Dietary Supplement|Lactoferrin|750mg of Jarrow formulas taken three times daily for 30 days
76054116|NCT01900665|Drug|Solanezumab|Administered Intravenously (IV)
76054117|NCT01900665|Drug|Placebo|Administered IV
75589474|NCT04516707|Other|clinical database|"The various clinicam database will be collected solely to meet the objectives of the study.~All data collected to create the database for this project will be anonymized"
75589475|NCT04317469|Diagnostic Test|VWF measurement|Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
75733074|NCT06134050|Procedure|Procedure: HTO using PSI aiming at 55% correction|HTO using PSI designed to achieve correction to 55% tibial width.
75733075|NCT06134050|Procedure|Procedure: HTO using PSI aiming at 62% correction|HTO using PSI designed to achieve correction to 62% tibial width.
75883051|NCT03603834|Drug|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours~Leucovorin, 400 mg/m2, IV over 2 hours~Irinotecan, 150 mg/m2, IV over 90 minutes~5 FU, 400 mg/m2, IV bolus~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
75883052|NCT03551132|Other|Exercise test|Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
75883053|NCT02400723|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
75883054|NCT02400723|Behavioral|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
75883055|NCT02400723|Other|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
75883056|NCT03601338|Drug|Bemiparin|second generation low molecular weight Heparin
75883057|NCT03601338|Other|multivitamins and routine antenatal follow up|multivitamins and routine antenatal follow up
75883058|NCT02128022|Drug|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
76054118|NCT01900431|Drug|Sarilumab|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
76054119|NCT01900431|Drug|Prednisone|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
75589476|NCT04468737|Behavioral|Bowel preparation|Observe patients who undergo bowel preparation by enema or irrigation
75589477|NCT01177384|Drug|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
75733076|NCT06134024|Procedure|Introduction of double pigtail plastic stents through the LAMS during endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections|During endoscopic procedure of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces double pigtail plastic stents through the LAMS.
75883059|NCT02128022|Drug|Glibenclamide|Oral Glibenclamide 5mg
75883060|NCT03256045|Drug|Carfilzomib|Given IV
75883061|NCT03256045|Other|Chemosensitivity Assay|Undergo in vitro chemosensitivity testing
75883062|NCT03256045|Drug|Dexamethasone|Given PO
75883063|NCT03256045|Other|Laboratory Biomarker Analysis|Correlative studies
75883064|NCT03256045|Drug|Panobinostat|Given PO
75883065|NCT03551054|Behavioral|Healthy for Two, Healthy for You|Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
75883066|NCT03551054|Behavioral|Health Education|
75883067|NCT03603756|Drug|SHR-1210|a novel anti-PD-1 antibody
75883068|NCT03603756|Drug|Apatinib|a VEGFR-2 tyrosine kinase inhibitor
75883069|NCT03603756|Drug|Irinotecan Injection|cytotoxic agent that binds to topoisomerase I
76054120|NCT01900431|Drug|Methotrexate|Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
76054121|NCT01900431|Drug|Folic/folinic acid|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
76054122|NCT01900431|Other|Placebo (for Sarilumab)|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
76054123|NCT01948791|Drug|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
76054124|NCT01899729|Drug|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
75589478|NCT01177384|Drug|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
75589479|NCT01177384|Drug|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
75733077|NCT06134024|Procedure|Endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of LAMS only|During endoscopic procedure of transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces transmurally the LAMS only, without the double pigtail plastic stents.
75883070|NCT03603756|Drug|Paclitaxel liposome|cytotoxic agent that prevent depolymerization of cellular microtubules
75883071|NCT03603756|Drug|Nedaplatin|cytotoxic agent that cross-links and denatures strands of DNA
75883072|NCT02372409|Device|MRI-guided laser ablation|
75883073|NCT02372409|Drug|Doxorubicin|
75883074|NCT02372409|Drug|Etoposide|
75883075|NCT02372409|Device|Dynamic contrast-enhanced (DCE) MRI|
75883076|NCT02372409|Device|Dynamic susceptibility contrast (DSC) MRI|
75883077|NCT03603678|Drug|BAY2253651|100 µg (500 µg/ml * 200 µl) BAY2253651 intranasally
75883078|NCT03603678|Drug|Placebo|Matching Placebo dosing
75439407|NCT01603927|Device|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
75883079|NCT03626259|Drug|Losartan and Amlodipine|Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
75733078|NCT06134011|Other|Without any intervention|There were no special interventions for the two groups.
75883080|NCT03626259|Drug|Losartan|Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
75883081|NCT03551366|Behavioral|Linear|The linear pedagogy arms consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives aligned to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. Linear curriculum lessons will be focused on the functioning of the body and children learning movement patterns. These lessons will be far more prescriptive and have clearly stated outcomes/goals for each lesson, with a typical lesson structure following the structure of warm up, isolated practice of technique or skill, simulated game and warm down.
75883082|NCT03551366|Behavioral|Nonlinear|The non-linear pedagogy arm consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives align to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. The nonlinear curriculum lessons will look to make sure that children are both engaged and empowered throughout the learning process. In adherence to representative learning design, we will look to contextualise lessons and guide learning through the use of books/stories, lived experiences and the sharing of ideas.
75883083|NCT03601260|Drug|Allopurinol|Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
75883084|NCT03168373|Procedure|language rehabilitation therapy|language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
75439408|NCT01604213|Drug|Metformin plus vildagliptin|Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
75439409|NCT01604213|Drug|Metformin only|Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
75439410|NCT01604798|Other|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
75439411|NCT01605240|Drug|Acetaminophen and Ibuprofen|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
75589480|NCT01177384|Drug|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
75589481|NCT04315714|Other|Yoga Program|Six-week, twice weekly, 60-minute private yoga program (delivered online/virtually via Zoom).
75589482|NCT01640015|Other|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
75589483|NCT04315519|Other|Exercise|Aerobic Exercise
75439412|NCT01605240|Drug|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
76054125|NCT01899729|Drug|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
75439413|NCT01605279|Drug|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.
75439414|NCT01605279|Drug|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
75439415|NCT01605565|Procedure|A nasal brushing|A nasal brushing in every nostril
75439416|NCT01606072|Drug|Desmopressin|20 patients in 5 groups 4 each, advancing progressively to each dose level.
75439417|NCT01606657|Procedure|Irrigation|The patient will receive irrigation as a part of their wound care
75439418|NCT01606657|Other|No Irrigation|The patient will not receive irrigation as part of their wound care
75439419|NCT01606722|Drug|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
75439420|NCT01606904|Behavioral|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
75439421|NCT01607060|Drug|Lactulone|Patients will receive lactulone to daily laxation
75439422|NCT01607242|Other|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
75439423|NCT01607242|Other|Voice Handicap Index|Subjective Evaluation of Voice disorders
75589484|NCT01641887|Other|Decision Aid|Patients will use a decision aid administered on a computer.
75589485|NCT01640093|Drug|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
75589486|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
76054126|NCT01899729|Drug|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
76054127|NCT01899729|Drug|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
75439424|NCT01607242|Other|Swallowing Assesment|Swallowing function questionnaire
75439425|NCT01607489|Radiation|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
75589487|NCT01640093|Drug|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
75589488|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
75589489|NCT04512807|Diagnostic Test|AMH|AMH & PREGNANCY
75589490|NCT01641965|Device|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 < 45 mmHg and improve symptoms.
75589491|NCT04466124|Radiation|Liver Cancer Patients Treated With Proton Beam Therapy|Proton Beam Therapy
75589492|NCT01642121|Other|laboratory biomarker analysis|Correlative studies
76054128|NCT01899729|Drug|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
76054129|NCT01898091|Drug|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
75589493|NCT01194154|Drug|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
75589494|NCT01194154|Drug|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
75589495|NCT01640210|Device|JewelPUMP (insulin patch pump)|"The study will be proposed during the visit of selection.~Visit of inclusion:~This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.~Patients treated with insulin pump will be instructed to reproduce the same programming between their usual pump and the JewelPUMP, they will use in parallel.~Volume infused will be evaluated during a period of basal and bolus with a precision scale.~Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:~Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.~Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump"
75589496|NCT01642160|Behavioral|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
75589497|NCT01642160|Behavioral|Standard of care|participants will receive education from staff nurses as needed.
75589498|NCT01640405|Drug|modified FOLFOX6 + bevacizumab|"Bevacizumab 5 mg/kg iv, day 1, followed by~Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by~5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:~LV 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
76054130|NCT01898091|Drug|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
75439426|NCT01607749|Behavioral|Educational Program|"Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.~Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days."
75439427|NCT01607749|Other|Usual Asthma Information for teachers|Common asthma information for teachers
75589499|NCT01640405|Drug|FOLFOXIRI + Bevacizumab|"Bevacizumab 5 mg/kg iv, followed by~Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by~Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by~LV 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
75439428|NCT01607983|Drug|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
75439429|NCT01608217|Drug|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
75589500|NCT04465929|Biological|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
75883085|NCT03717597|Behavioral|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
75439430|NCT01608217|Drug|Placebo|placebo (tablet) three times daily for a period of three weeks.
75439431|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
75883086|NCT03603522|Dietary Supplement|BioGaia-DSM17938|2mL per day (1x10^9 CFU) per day taken orally for 28 days
76054131|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
75589501|NCT02279225|Radiation|Group Phototherapy|
76054132|NCT01947855|Drug|Empagliflozin|Empagliflozin low dose
76054133|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
76054134|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
76054135|NCT01947855|Drug|Empagliflozin|Empagliflozin high dose tablet once daily
75439432|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
75589502|NCT02279225|Radiation|Phototherapy + Physical activity|
75589503|NCT02279225|Other|Physical activity|
75589504|NCT02279225|Other|Placebo|
75589505|NCT01640444|Drug|FOLFIRI + bevacizumab|"Bevacizumab 5 mg/kg iv, followed by~Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
75589506|NCT01640444|Drug|FOLFIRI + cetuximab|"Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~FOLFIRI:~Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
75589507|NCT04464096|Other|non|non
75589508|NCT04509804|Other|non-interventional|non-interventional
75589509|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
75589510|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
75589511|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
76054136|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
76054137|NCT01888965|Drug|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
75883087|NCT03603522|Other|Placebo Comparator: Placebo Control|2mL per day of placebo formulation taken orally for 28 days
75589512|NCT01642316|Other|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
75589513|NCT01642316|Other|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
75883088|NCT05193253|Procedure|Radiofrequency ablation|Treatment-naive patients with solitary HCC <= 3 cm who received ablation as the first-line treatment
76054138|NCT01888497|Drug|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
75589514|NCT01642355|Behavioral|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
75589515|NCT01642355|Behavioral|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
75589516|NCT04529330|Procedure|fasciotomy|if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
75589517|NCT04508556|Device|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
75589518|NCT04508556|Diagnostic Test|Nasopharyngeal swab|Is a method for collecting a clinical test sample of nasal secretions from the back of the nose and throat.
75883089|NCT05193253|Procedure|Liver resection|Treatment-naive patients with solitary HCC <= 3 cm who underwent liver resection as the first-line treatment
75883090|NCT05193253|Procedure|Liver transplantation|Treatment-naive patients with solitary HCC <= 3 cm who were listed for liver transplantation as the first-line treatment
75883091|NCT05265182|Procedure|virtual reality|Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.
75883092|NCT03601104|Other|High intensity eccentric training|High intensity eccentric training group with 80% of isometric peak torque.
76054139|NCT01888497|Drug|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
76054140|NCT01888497|Drug|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
76054141|NCT01888497|Drug|Placebo|Oral, prior to bedtime on the night before performance testing
76054142|NCT01505530|Drug|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
76054143|NCT01505530|Drug|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
76054144|NCT01505530|Drug|Standard of Care Chemotherapy|Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
75589519|NCT04508556|Diagnostic Test|oropharyngeal swabs|Is a method for collecting a clinical test sample from the back of the throat.
75589520|NCT01642433|Drug|Placebo|Placebo capsules, 3x daily
75589521|NCT01642433|Drug|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
75589522|NCT04529213|Procedure|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
75589523|NCT01642472|Drug|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
75439433|NCT01608425|Procedure|telemedicine consultations|Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
75589524|NCT04507191|Diagnostic Test|immunohistochemical staining|immunohistochemical staining of programmed death-ligand 1 (PDL1) marker
75589525|NCT04460196|Other|survey|Each admitted patient will complete a questionnaire
75589526|NCT01640639|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
75589527|NCT01640639|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
76054145|NCT01485796|Biological|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
75589528|NCT01640678|Procedure|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
75589529|NCT01640678|Procedure|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
75733079|NCT06133998|Device|incentive spirometer with aerobic exercises|"Group A: Aerobic exercise (running, jugging, cycling, walking) will be given to the group A for the checking the effect of incentive spirometer~In sitting position, for the relaxation of body, patient will take a deep breath.~In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung. This schedule will be following supervised exercise training for a minimum 60 minutes 3 days a week in moderate patient,75 minutes in moderate to vigorous patients and 150 minutes in healthy patients~We will check the dyspnea of the patient by the borage scale~We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~We will check the quality of life by the questionnaire."
75883093|NCT03601104|Other|High intensity eccentric training with BFR|Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
75883094|NCT03601104|Other|Low intensity eccentric training with BFR|Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
75883095|NCT03601104|Other|Low intensity eccentric training|Low intensity eccentric training group with 40% of isometric peak torque
75883096|NCT02131922|Procedure|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
76054146|NCT01485796|Biological|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
75439434|NCT01608594|Drug|administration of ipilimumab10mg/kg|"Ipilimumab IV infusion:~Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
75589530|NCT01642628|Other|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
75589531|NCT04459143|Behavioral|Advance directives|A workshop will take place during the third week of patient care to inform them about COPD, exacerbations, prognostic and advance directives. Then, a personal interview with patients who have participated to this workshop will take place at the end of their hospital stay, to collect their advance directives and their degree of satisfaction about this process.
75883097|NCT02131922|Procedure|Dental Hygienization Treatment|
75883098|NCT02131922|Drug|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
75883099|NCT03600948|Device|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
75883100|NCT03551288|Drug|SUVN-911|Tablet
75589532|NCT01642667|Drug|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
75589533|NCT01642667|Drug|Placebo|
75589534|NCT04458012|Diagnostic Test|Oculus Keratograph. Schirmer test. Tear fluid sample.|Objective measurements of the ocular surface using Oculus 5 keratograph. Slit lamp examination and tear fluid sample using Schirmer strips.
75589535|NCT04456179|Device|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
75589536|NCT04456179|Device|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
76054147|NCT01505374|Procedure|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
75439435|NCT01608594|Drug|administration of ipilimumab 3mg/kg + HDI|"Ipilimumab IV infusion:~Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
75589537|NCT01640912|Drug|RXI-109|Single intradermal injection of RXI-109 at incision sites
75589538|NCT01640912|Drug|Placebo|Single intradermal injection of placebo at incision sites
75589539|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
75733080|NCT06133998|Device|incentive spirometry without aerobic exercises|"Group B: In group B we will check the effects of incentive spirometer without the aerobic exercise.~In aerobic exercise following treatment protocol will be involve~In sitting position, for the relaxation of body, patient will take a deep breath.~In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~We will check the dyspnea of the patient by the borage scale~We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~We will check the quality of life by the questionnaire.~We will check the chest expansion by measuring tap."
75733081|NCT06133985|Other|Costovertebral mobilizations + Conventional PT|"Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 10 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness."
75589540|NCT01642745|Drug|Mannitol (Aridol)|single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
75589541|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
75589542|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
75589543|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
75883101|NCT03607344|Procedure|Cohort|Patients undergoing ambulatory laparoscopic sacrocolpopexy
75883102|NCT02132000|Drug|toremifene or tamoxifen|
75883103|NCT03118765|Drug|GSP304 (tiotropium bromide) Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
75589544|NCT04502238|Other|Fluid restriction|Study participants will refrain from drinking fluids overnight to facilitate 1-2% fluid loss from baseline
75589545|NCT01640990|Drug|Saline|30mins run-in period
75589546|NCT01640990|Drug|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
75589547|NCT01640990|Drug|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
75589548|NCT01641029|Other|No intervention|There is no intervention
75589549|NCT01641068|Other|Cognitive Intervention|Participate in memory and thinking skills workshop
75589550|NCT01641068|Other|Educational Intervention|Participate in workshops focusing on increasing knowledge and education on the brain and cognition
75733082|NCT06133985|Other|Conventional treatment|diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
75733083|NCT06133972|Drug|Placebo|Placebo s.c. monthly
75439436|NCT01608607|Other|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
75439437|NCT01608854|Other|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
75439438|NCT01608880|Drug|nitroglycerin ointment|Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
75439439|NCT01608880|Drug|Polysporin ointment|Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
75439440|NCT01608958|Drug|Oxytocin|10 IU oxytocin in 500 ml infusion
75733084|NCT06133972|Drug|Ianalumab|Ianalumab s.c. monthly Ianalumab s.c. quarterly
75733085|NCT06133946|Genetic|Genetic screening test (Deafness gene variant detection array kit)|Infant participants were screened for fifteen variants in four genes (i.e., GJB2, SLC26A4, MT-RNR1 and GJB3).
75589551|NCT01641068|Procedure|Functional Magnetic Resonance Imaging|Undergo functional neuroimaging
75733086|NCT06133933|Device|Pain Threshold using algometer/dolorimeter|These patients who consent to participation in the study will receive a preoperative pain threshold measured using a pain algometer/dolorimeter. We will rely on the completion of the questionnaires, opioid consumption journal, and surveys to establish a correlation between pre-operative pain threshold and post-operative outcomes.
75733087|NCT06133920|Other|Early Range of Motion|The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist
75883104|NCT03118765|Drug|GSP304 Placebo Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
75883105|NCT03118765|Drug|Spiriva® Respimat® inhalation spray|Once daily (QD) oral inhalation
75589552|NCT01641068|Other|Memory Intervention|Participate in memory and thinking skills workshop
75589553|NCT01641068|Other|Quality-of-Life Assessment|Ancillary studies
75589554|NCT01641068|Other|Questionnaire Administration|Ancillary studies
75589555|NCT04454385|Diagnostic Test|Patients with well controlled asthma|"Patients with well controlled asthma~The following parameters are to be evaluated:~Blood eosinophils FeNO Findings on lung function test"
75439441|NCT01608958|Drug|Oxytocin|10 IU oxytocin IM injection
75439442|NCT01609140|Drug|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
75439443|NCT01609140|Drug|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
75439444|NCT01609140|Drug|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
75439445|NCT01609140|Drug|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
75439446|NCT01609140|Drug|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
75439447|NCT01609140|Drug|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
75439448|NCT01609153|Drug|Olanzapine|Coated tablet 5-20 mg milligram(s) per day for 16 weeks
75589556|NCT04529057|Procedure|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
75439449|NCT01609153|Drug|Amisulpride|200-800 mg milligram(s)per day for 16 weeks
75439450|NCT01609153|Drug|Olanzapine and Amisulpride|"Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks"
75439451|NCT01609309|Procedure|Laparoscopic gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
75733088|NCT06133920|Other|Immobilization|"The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery."
75733089|NCT06133907|Genetic|Serum|Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
75439452|NCT01609309|Procedure|Open gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience."
75589557|NCT01642862|Drug|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
75589558|NCT04501263|Behavioral|DEMCoN Educational Intervention|Educational programme on constipation for Health care professionals in this clinical specialist palliative care
75733090|NCT06133894|Behavioral|Exercise program PERMANENTO inspired by developmental kinesiology|"The intervention is based on activation of reflexive movement patterns which ensures the original reflexive control of strength, mobility and stability. After birth, we cannot control our body movements - they are reflexes hard-wired into our brains and vitally important for proper development of our body (muscular system, vestibular system, sensory system, cardiovascular system or digestive system) as well as our brain and nervous systems. During early childhood, everything becomes integrated and works perfectly according to the original design. But this design is slowly abandoned due to for example sedentary lifestyle and replaced by compensatory movement patterns that are making us weaker and defective with all the consequences that are becoming more severe as we age. The aim is restore the original design and improve posture and other crucial components of functional fitness and move better and more."
75439453|NCT01609530|Procedure|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
75733091|NCT06133881|Drug|prilocaine|intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
75733092|NCT06133881|Drug|bupivacaine|intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
75733093|NCT06133868|Drug|Lavender and Chamomile Essential Oils|essential oils
75733094|NCT06133842|Diagnostic Test|Intra-op EEG and CO data collection|Intra-op EEG and CO data will be collected non-invasively. This will not guide or affect patient care of procedure in any way.
75733095|NCT06133803|Drug|Lovenox|A low-molecular-weight heparin, 40mg daily injection.
75589559|NCT04529369|Procedure|Middle lobe only Photoselective vaporization of the prostate (PVP)|Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
75589560|NCT04529369|Procedure|Complete PVP|Traditional Photoselective vaporization of the prostate PVP
75733096|NCT06133803|Drug|Aspirin|Aspirin 81mg daily tablet.
75733097|NCT06133803|Procedure|Embryo transfer|Embryo transfer
75733098|NCT06133712|Drug|Dexmedetomidine|Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.
75733099|NCT06133712|Drug|Ozone|Participants will receive a single local injection of 4 ml ozone (10 micrograms/dl) plus to 1 ml lidocaine (1%) using a 25 G needle.
75439454|NCT01609530|Procedure|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
75589561|NCT01641146|Behavioral|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
75589562|NCT01641146|Behavioral|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
75589563|NCT01642940|Drug|Prasugrel|Prasugrel 10mg/day
75589564|NCT01642940|Drug|Ticagrelor|Ticagrelor 90mg twice a day
75589565|NCT01643018|Procedure|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
75589566|NCT01643018|Procedure|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
75589567|NCT01641185|Procedure|radiation|radiation with protons or carbon ions
76054148|NCT01505374|Procedure|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
75439455|NCT01609608|Procedure|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
75439456|NCT01609725|Device|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
75439457|NCT01609725|Device|Oral prophylaxis|One session of supraginigval calculus removal
75589568|NCT04497519|Drug|inhaled hydroxychloroquine|ascending dose of iHCQ
75733100|NCT06133712|Drug|Dexamethasone|Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL [8 mg] dexamethasone) via the same technique.
75733101|NCT06133504|Procedure|Early Multimodal Therapy|Early multimodal therapy is defined as the collection of therapeutic maneuvers performed by the physiotherapy, speech therapy, respiratory therapy, and occupational therapy team at the time of study inclusion.
75733102|NCT06133504|Procedure|Late Multimodal Therapy|Late multimodal therapy is characterized by the same set of maneuvers carried out by the same disciplinary team, but it is initiated once indicated by the attending physician.
75733103|NCT06133465|Procedure|Surgical wide local excision|Surgical excision of breast carcinoma
75733104|NCT06133465|Procedure|Cavity shaving|Cavity shaving of resection margins to guarantee oncological safety
75733105|NCT06133465|Procedure|Excision margin surgical clearance|Surgical clearance of involved and/or closed excision margins
75733106|NCT06133465|Radiation|Adjuvant Radiotherapy|Adjuvant radiotherapy
75733107|NCT06133465|Biological|Adjuvant Hormone Therapy|Adjuvant hormone therapy
75439458|NCT01609751|Dietary Supplement|Yakult|62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
75733108|NCT06133309|Behavioral|Experiential Phenomenological Interview|"Consciousness fluidity of patients suffering from depressive disorder and treated with Esketamine will be evaluated thanks to Experiential Phenomenological Interview and EQFC Trait questionnaire"
75733109|NCT06133075|Drug|Mirabegron 50 MG|10 patients will receive drug for 8 weeks
75733110|NCT06133075|Drug|Mirabegron 25 MG|10 patients will receive drug for 8 weeks
75733111|NCT06132828|Drug|DR30206|Subjects receive DR30206 intravenously
75733112|NCT06132737|Drug|[90Y]Y-PentixaTher|[90Y]Y-PTT i.v. injection
75733113|NCT06132178|Drug|Psilocybin|A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).
76054149|NCT04613674|Drug|Camrelizumab Plus Chemotherapy|camrelizumab+chemotherapy
76054150|NCT04613674|Drug|placebo+chemotherapy|placebo+chemotherapy
76054151|NCT01897233|Drug|Lumacaftor|
75589569|NCT01641224|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
75589570|NCT01641224|Device|Atractylodes|Atractylodes (~10-15g)
75589571|NCT01641224|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
75589572|NCT01641224|Device|Tangerine Peel|Tangerine Peel (~10g)
75439459|NCT01609894|Dietary Supplement|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
75589573|NCT01641224|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
75589574|NCT01641224|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
75589575|NCT01641224|Drug|Radix curcumae|Radix curcumae (~10g)
75589576|NCT01641224|Drug|Fingered citron|Fingered citron (~10g)
75883106|NCT02252198|Other|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
75589577|NCT01641224|Drug|Tuckahoe|Tuckahoe (15g)
75589578|NCT01641224|Drug|Placebo|Placebo is blindly given to patients.
75589579|NCT01641263|Behavioral|Sleep Education Therapy|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
75589580|NCT01641263|Behavioral|Cognitve Behavioral Therapy for Insomnia|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
75589581|NCT04451733|Procedure|Endotracheal intubation|Perform the endotracheal intubation during CPR
75589582|NCT01643057|Device|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
75589583|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
75589584|NCT01643096|Other|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
75589585|NCT01643135|Drug|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
75589586|NCT01643135|Drug|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
75589587|NCT01641419|Drug|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
75883107|NCT03603444|Other|No intervention are provided|
75439460|NCT01609894|Dietary Supplement|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
75439461|NCT01610024|Dietary Supplement|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
75439462|NCT01610050|Drug|LFA102|
75589588|NCT01641419|Drug|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
75883108|NCT02128100|Drug|Folfirinox|"Oxaliplatin 85 mg/m² for over 2 hours,~Leucovorin 400n mg/m² for over 2 hours,~Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
76054152|NCT01897233|Drug|Ivacaftor|
75439463|NCT01610089|Other|stable isotope infusion|"Control subjects: [15N2-ureido] arginine (0.69 mg/kg); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of [15N2-ureido] arginine (0.69 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr).~Citrullinemia type 1 subjects,[15N2-ureido] arginine (4.14 mg/kg); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of [15N2-ureido] arginine (4.14 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr)."
75589589|NCT01641419|Drug|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
75439464|NCT01610141|Other|Genotype-guided warfarin dosing|Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
75589590|NCT04449081|Behavioral|Knowledge, Attitude, Practice, Awareness, Preference|KAP, Awareness level and Preference were assessed using questionnaires
75439465|NCT01610141|Other|Non-genotype guided warfarin dosing|A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
75589591|NCT01643252|Drug|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
75589592|NCT01643252|Drug|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
75733114|NCT06132178|Device|Accelerated intermittent theta burst (aiTBS) rTMS treatment|A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.
75733115|NCT06132178|Drug|Low-dose psilocybin|A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).
75733116|NCT06132178|Device|Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment|The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.
75883109|NCT02128100|Radiation|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
75883110|NCT03603366|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
75883111|NCT02128178|Drug|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
75883112|NCT02128178|Drug|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
75883113|NCT03606954|Combination Product|Combination topical corticosteroid|Comparison of a vasoconstriction index between the 2 study arms
75883114|NCT03600870|Drug|Midodrine|Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
75883115|NCT02128256|Device|Cerament G|
75883116|NCT03600792|Genetic|whole exome sequencing (WES)|"WES analysis will be performed in the UF de Génomique du Développement (APHP, Pitié-Salpêtrière hospital), using DNA extracted from amniotic fluid for the foetus (also used for chromosomal studies) and DNA extracted from peripheral blood for both parents. There will be no supplemental invasive sampling for this study. The result of WES will be returned during a consultation with the geneticist and the associated prognosis will be explained in case of molecular diagnosis"
75883117|NCT02128334|Drug|Eligard 45 mg Exposure|Subcutaneous injections
76054153|NCT01887717|Device|TheraSphere®|Intrahepatic treatment of advanced hepatocellular carcinoma
76054154|NCT01887717|Drug|Sorafenib|Standard of care therapy for treatment of advanced hepatocellular carcinoma
75439466|NCT01610180|Drug|Eltrombopag Olamine|"Initial dose : 50 mg/day for 14 days.~Next doses:~If platelet count <60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~If platelet count >60000/µL and ≤200000/µL same dose for the next 14 days.~If platelet count >200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~If platelet count >400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is <150000/µL, reinitiate therapy at a daily dose reduced by 25 mg."
75439467|NCT01610193|Procedure|Appendicectomy|Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
75439468|NCT01610219|Behavioral|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
75439469|NCT01610219|Other|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
75439470|NCT01610232|Device|Photon stimulation by light-emitting diodes (LEDs)|Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
75439471|NCT01610232|Other|Treadmill training|Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
75439472|NCT01610258|Other|Blood and placenta samples|"The placenta sample is realised, specially for the study, in surgical unit after the delivery.~The blood samples are taken, specially for the study, the day of admission and at time of delivery or seven days after the admission."
75439473|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
75439474|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Autoinjector|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
75439475|NCT01610323|Other|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
75589593|NCT01641458|Other|5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G>A, c.1679T>G, HapB3/c.1129-5923C>G and c.2846A>T).
75439476|NCT01610323|Other|Standard Care|
75439477|NCT01610362|Biological|Human Rabies Immune Globulin|HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
75883118|NCT01375699|Drug|Doxorubicin|As prescribed by treating provider.
75883119|NCT01375699|Drug|Sildenafil|Given PO, by mouth
76054155|NCT01886781|Drug|Lactobacillus plantarum 299v|two capsules of 5 X 10 ^9 c.f.u each
76054156|NCT01886781|Drug|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
76054157|NCT01886781|Other|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
76054158|NCT01886781|Other|Wash - out period|Wash - out period following treatment phase of eight weeks
76054159|NCT01463098|Drug|E2006 1.0 mg|E2006 1.0 mg capsule.
76054160|NCT01463098|Drug|E2006 2.5 mg|E2006 2.5 mg capsule.
76054161|NCT01463098|Drug|E2006 5.0 mg|E2006 5.0 mg (2 capsules of 2.5 mg each).
76054162|NCT01463098|Drug|E2006 10.0 mg|E2006 10.0 mg capsule.
76054163|NCT01463098|Drug|E2006 25.0 mg|E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
76054164|NCT01463098|Drug|E2006 50.0 mg|E2006 50.0 mg capsule.
76054165|NCT01463098|Drug|E2006 100 mg|E2006 100 mg (2 capsules of 50 mg each).
76054166|NCT01463098|Drug|E2006 200 mg|E2006 200 mg (4 capsules of 50 mg each).
76054167|NCT01463098|Drug|Zolpidem 10 mg|Zolpidem 10 mg immediate release tablet.
75589594|NCT01641458|Other|Therapeutic drug monitoring of 5FU|Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
75589595|NCT01641497|Radiation|3D conformational radiation|25 * 1.8 Gy in 5 weeks (=45 Gy)
75589596|NCT01641497|Radiation|IMRT|25 * 1.8 Gy in 5 weeks (=45 Gy)
76054168|NCT01463098|Drug|E2006 Matched Placebo or Zolpidem Matched Placebo|E2006-matched placebo capsules or zolpidem-matched placebo tablets.
76054169|NCT01463098|Drug|E2006 Matched Placebo|E2006-matched placebo capsule.
75439478|NCT01610375|Other|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
75439479|NCT01610388|Drug|500mg IV GSK1322322/placebo|500mg IV
75439480|NCT01610388|Drug|1000mg oral GSK1322322/placebo|1000mg oral
75589597|NCT01641536|Genetic|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
75589598|NCT01641575|Drug|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
75589599|NCT01643369|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
75589600|NCT01643369|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
75733117|NCT06131944|Behavioral|Rested & Ready to Learn|The intervention arm targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
75733118|NCT06131892|Other|Defibrillation|Defibrillation
76054170|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
75733120|NCT06131723|Behavioral|Behaviorally informed tickler email|The email notification from patients' PCP office will inform patients that a new review of their records shows they are due for an important medical exam. This intervention harnesses behavioral principles related to importance (medical exam described as important), personalization (records described as belonging to participants), urgency (participants are asked to sign in and make the recommended appointment as soon as possible), timeliness (participants are told that there has been a new review of their records), source effects and accountability (participants are told that a message from their PCP's office is waiting for their response). To make it easier for patients to find and review the MAP letter, the email also contains a link that directs patients to the MAP letter on their patient portal.
75733121|NCT06131619|Other|assesment of cognitive parameters with DLOTCA-G|All three groups were evaluated once with the DLOTCA-G, a cognitive assessment battery.
75883120|NCT02252276|Procedure|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
76054171|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
76054172|NCT01462942|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
75439481|NCT01610388|Drug|1000mg IV GSK1322322/placebo|1000mg IV
75439482|NCT01610388|Drug|1500mg oral GSK1322322/placebo dose|1500mg oral
75439483|NCT01610388|Drug|1500mg IV GSK1322322/placebo|1500mg IV
75439484|NCT01610388|Drug|2000mg IV GSK1322322J/placebo|2000mg IV
75439485|NCT01610388|Drug|3000mg IV GSK1322322J/placebo|3000mg IV
75439486|NCT01610388|Drug|1000mg IV GSK1322322J/placebo|1000mg IV
75439487|NCT01610401|Drug|Metformin|metformin 500 mg three times a day, for 3 days
75439488|NCT01610401|Drug|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
75589601|NCT01643369|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
76054173|NCT01462942|Drug|Placebo|Inhaled dose-matched placebo, twice per day
76054174|NCT01462942|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
75439489|NCT01610401|Drug|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
75589602|NCT01641731|Other|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
75589603|NCT01643447|Drug|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
75589604|NCT01643447|Drug|Diammonium glycyrrhizinate|
75589605|NCT01643486|Other|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
75589606|NCT01643486|Other|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
75589607|NCT04491669|Diagnostic Test|GFR - Glomerular Filtration Rate|"Chronic Renal Failure staging according to GFR by Chronic Renal Failure EPI is:~Stage1 in which GFR>90 mil/min but evidence of kidney damage.~Stage 2 GFR 60-89 mil/min.~Stage 3 GFR 30-95 mil/min.~Stage 4 GFR 15-29 mil/min.~Stage 5 GFR<15 mil/min."
75589608|NCT01641770|Other|Nutritional beverage 10003RF|2 sachets per day
75439490|NCT01610440|Biological|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
75589609|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
75589610|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
75589611|NCT01600911|Other|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
75589612|NCT01643603|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
75589613|NCT01643603|Other|laboratory biomarker analysis|Correlative studies
75589614|NCT02279238|Procedure|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest [Washout time] in between the two test.~6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.~3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.~The data of [HR, SPO2, PSG RPE scale, Distance walked, BP] the participants are collected before, during and after the completion of each lap [according to American Thoracic Society [ATS] protocol]."
75589615|NCT02488863|Other|MRI Neuroimaging|MRI scans utilized to measure the structural and functional integrity of the brain.
75589616|NCT02488863|Other|Quantitative Sensory Testing|Vibratory Detection Thresholds; Tactile Detection Thresholds; Thermal Detection Thresholds, Pain Thresholds, and Temporal Summation; Allodynia and Temporal Summation; Punctate Pain Testing and Temporal Summation; and Pressure Pain Thresholds.
75589617|NCT02488863|Other|Questionnaires|The Modified Mini-Mental State Examination (3MS), the Montreal Cognitive Assessment (MoCA), the Center for Epidemiologic Studies Depression Scale (CES-D), the Geriatric Depression Scale (GDS), the Edinburg Handedness Inventory, the Ten-Item Personality Inventory (TIPI), the Pittsburgh Sleep Quality Index (PSQI), the state and trait versions of the State-Trait Anxiety Inventory (STAI), the state and trait versions of the Positive and Negative Affect Schedule (PANAS), pain questionnaires (the Graded Chronic Pain Scale (GCPS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Pain-Detect, the short-form McGill Pain Questionnaire (SF-MPQ-2), and the Coping Strategies Questionnaire-Revised (CSQ-R)), a standardized paper and pencil cognitive battery (Hopkins Verbal Learning Test (HVLT), Trail Making A&B, Boston Naming Test, Controlled Oral Word Association Test (COWAT), Stroop Interference Test, Ruff Figural Fluency Test, and Raven's Progressive Matrices Test).
75589618|NCT02488863|Other|Physical and Cognitive Function Testing|Upper Limb Isometric Strength, Short Physical Performance Battery (SPPB), GAITRite Instrumented Walking, Galvanic Skin Response, Knee Extension Isokinetic Strength, the Pepper Assessment Tool for Disability (PAT-D), and an electronic NIH Toolbox Cognitive Battery.
75589619|NCT02755844|Drug|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).~One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
75589620|NCT02755844|Drug|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
75883121|NCT02252276|Procedure|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
75883122|NCT03606720|Other|low level laser therapy|low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
76054175|NCT01462630|Drug|pazopanib hydrochloride|Given PO
76054176|NCT01462630|Other|laboratory biomarker analysis|Correlative studies
75733122|NCT06131528|Other|Relaxation Breathing Exercises Group|This group will preform Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing
75733123|NCT06131528|Other|Usual Care Group|The control group received lifestyle modifications that are an important part of hypertension management
75733124|NCT06131502|Device|ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy|The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.
75733125|NCT06131463|Device|Electrocardiogram (ECG) feature in smart watches|A study participant that is randomly assigned to the experimental group should enable the ECG function on his or her smart watch and make sure that there is synchronization with a corresponding application on his or her mobile phone. The ECG function must stay enabled, and the participant should wear the smartwatch every day for 30 days.
75733126|NCT06131450|Drug|BL-M07D1|Administration by intravenous infusion
75733127|NCT06131242|Other|It is an observational study|It is an observational study
75733128|NCT06131164|Other|Diaphragmatic Breathing Exercise Group|The subjects in this group will perform Diaphragmatic Breathing Exercise Group
75733129|NCT06131164|Other|Thoracic Extension Exercise Group|The subjects in this group will perform Thoracic Extension Exercise Group
75733130|NCT06131112|Diagnostic Test|64Cu-DOTATATE PET/CT scan|Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.
75883123|NCT03606720|Other|pelvic stabilization exercises|special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
75883124|NCT01373983|Drug|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
75883125|NCT03550430|Behavioral|alpha/delta neurofeedback|neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.
75883126|NCT03550430|Behavioral|beta/theta neurofeedback|neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.
75439491|NCT01610466|Procedure|Laparoscopic bariatric surgery ex-vivo training curriculum|The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
75883127|NCT03550430|Other|Diary completion|completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
75883128|NCT03603132|Drug|Hetrombopag Olamine|7.5mg in each cycle
75883129|NCT03600636|Procedure|Diffusion tensor imaging MRI|"axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~Fluid-attenuated inversion recovery~three-dimensional axial image weighted in T1~axial echo-planar image sequence~three-dimensional pulse sequence axial flight time"
76054177|NCT01462630|Procedure|positron emission tomography|Correlative studies
75439492|NCT01610479|Drug|TAS-114 + S-1|
75439493|NCT01610518|Dietary Supplement|oat beta-glucan|4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
75439494|NCT01610518|Dietary Supplement|Placebo|Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
75439495|NCT01610531|Other|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
75439496|NCT01610544|Drug|3'-deoxy-3'-18F fluorothymidine (FLT)|
75439497|NCT01610544|Other|PET/CT scan|
75439498|NCT01610609|Behavioral|Population Health Management Intervention|"This intervention includes:~Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention"
75589621|NCT02755844|Drug|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
75589622|NCT01643642|Other|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
75589623|NCT01643642|Other|Treatment As Usual|Other: Treatment As Usual
75733131|NCT06130813|Other|increased perioperative communication program|Thanks to this communication program, informative content (8 times) will be shared with patients.
75733132|NCT06130579|Drug|IFN-Α|Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
75883130|NCT05812638|Other|Mental imagery technique|Warm up Period Mental Imagery (Sit-stand task Static stance (30 seconds) Indoor walk on a leveled surface Walk indoor towards target Forward / Side Stepping) Walk outdoors
75883131|NCT05812638|Other|Virtual Reality technique|Virtual reality training (River rush, 20000 water leaks, reflex ridge.)
75883132|NCT05812625|Other|Myokinetic stretching technique|Myokinetic stretching technique (MST) is a form of myofascial release, which involves active or passive stretching and movement as well as muscle energy techniques until a desirable release from the taut band is achieved.
76054178|NCT01462630|Procedure|computed tomography|Correlative studies
76054179|NCT01462630|Radiation|fludeoxyglucose F 18|Correlative studies
75439499|NCT01610622|Device|COstatus cardiac output measurement with isotonic saline|"Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.~No other interventions are made for the purpose of the study."
75439500|NCT01610635|Other|Reduced versus standard intervals between blood donations|Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
75439501|NCT01610661|Other|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
75439502|NCT01610674|Other|Tailored improvement strategy|"A step-wise implementation model is applied:~1) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients."
75589624|NCT04490070|Behavioral|Cognitive Stimulation|The caregiver training program consisted of applying the cognitive stimulation model of the CUIDA-2 program. This application included theoretical training made up of three modules: 1) person-centered care, 2) communication strategies, and 3) mediated cognitive stimulation strategies. The training was given in two group sessions of two hours each, plus 50 hours of individual practice, either on the job (in the case of professional caregivers) or in the home (in the case of family caregivers), in both cases supervised by psychologists who were experts in the program. In these individual practice hours, the caregivers were required to keep a weekly log. Here they had to plan in advance the activities that they were going to carry out with the older adult, and once they had taken place, they had to record how they were done and how the older adult had responded.
75589625|NCT01600989|Other|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
75589626|NCT01600989|Other|blood sampling|Blood samples will be taken twice at a 7 day interval
75589627|NCT01643681|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
75589628|NCT04489914|Device|High-Flow Oxygen Therapy|high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement
76054180|NCT01504204|Drug|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
75589630|NCT06032195|Drug|Custodiol-N|heart will preserved in and will be treated with Custodiol-N solution
75589631|NCT06032195|Drug|Custodiol|heart will preserved in and will be treated with Custodiol solution
75589632|NCT06032078|Device|Cutera laser machine|1064nm Nd: YAG laser
75733133|NCT06130501|Device|Sparrow Ascent tAN|The Sparrow Ascent device from Spark Biomedical (Dallas, TX), applies stimulation frequencies of 15 Hz at the cymba concha (vagal innervation) and 100 Hz anterior to the tragus (trigeminal innervation). Both tAN and active sham conditions have square biphasic waveforms with identical pulse widths of 250 µs separated by a 125 µs interval between pulses. Stimulation is applied using a duty cycle of 5-minutes ON and 10 seconds OFF. The stimulation intensities (mA) will be programmed for each individual based on the highest amplitude for each channel that is both comfortable and perceptible. Patients using the device may alter the intensity of stimulation at these sites using the Patient Controller to achieve the desired effect.
75883133|NCT05812625|Other|Post Isometric Relaxation|Post Isometric Relaxation (PIR) is the effect of the decrease in muscle tone in a single or group of muscles, after a brief period of submaximal isometric contraction of the same muscle.
75883134|NCT05812612|Drug|ursodeoxycholic acid|To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
75883135|NCT05812599|Other|Educational Module|The COVID Test Learning Module will present four multi-part character scenarios that someone might experience when considering testing for COVID-19. Participants will answer questions about the character's behavior. Accurate guidelines will be provided in response to each scenario to educate participants about what to do in nuanced COVID testing decision-making situations.
75883136|NCT05812586|Biological|SCB-2019/Clover|SCB-2019/Clover Vaccine
75883137|NCT05812586|Biological|AstraZeneca/Fiocruz|AstraZeneca/Fiocruz Vaccine
75589633|NCT06032065|Behavioral|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
75589634|NCT06032065|Behavioral|Home-Based Exercise|This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.
75589635|NCT06032065|Dietary Supplement|Nitrate-rich beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
75589636|NCT06032039|Drug|Triamcinolone|Standard treatment for osteoarthritis knee pain
75589637|NCT06032039|Other|Platelet Rich Plasma|Alternative treatment for osteoarthritis knee pain
75589638|NCT06031987|Device|CareSens N (iSENS)|Control group is asked to perform SMBG (4 times or more per day).
75589639|NCT06031987|Device|Freestyle Libre (Abbott)|CGM group is asked to scan CGM (4 times or more per day).
75589640|NCT06031961|Drug|melatonin|We will premedicate the children whom involved in the 1st group with 0.5 mg/kg oral melatonin in the midnight before surgery and the dose will be repeated at morning before getting in the catheterization room
75589641|NCT06031948|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
75589642|NCT06031948|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
75589643|NCT06031948|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
75589644|NCT06031948|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
75589645|NCT06031935|Behavioral|Yoga|The patients will receive links to two yoga videos. They will do each of these videos at home for 4 weeks.
75589646|NCT06031922|Device|Microprocessor controlled knee|Microprocessor controlled knee
75589647|NCT06031909|Diagnostic Test|Multimodal frailty assessment|"Different domains are assessed during hospital stay, these include:~Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI)~Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging~Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers~Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS)~Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle."
75589648|NCT06031896|Other|No interventions|No interventions
75883138|NCT05812586|Biological|Pfizer/Wyeth|Pfizer/Wyeth Vaccine
75439503|NCT01610726|Procedure|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
75439504|NCT01610739|Drug|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
75589649|NCT06031883|Drug|Ketamine|Total intravenous anesthesia in craniotomy
75733134|NCT06130501|Device|Sparrow Ascent Active Sham|The Sparrow Ascent Active Sham is a modified version of the Sparrow Ascent tAN System that has been designed to provide sub-therapeutic stimulation to the trigeminal nerve only and no stimulation to the vagus nerve. The trigeminal nerve will receive 1 Hz stimulation at the temporomandibular region at an amplitude that is comfortable and perceptual. The pulse duration will be set to a value that does not exceed 250 μs in a square biphasic waveform. The patient controller device for the active sham will give the appearance that stimulation is being applied at both vagal and trigeminal electrode sites.
75733135|NCT06130358|Other|Experimental: Well-being intervention followed by classic intervention|2 x 6 weeks of weekly museum visits
75883139|NCT05812573|Other|no intervention|No intervention, only observation
75883140|NCT05812547|Device|Lumen|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.
75883141|NCT05812547|Other|Glucose monitoring mobile app|The control group will use a designated glucose monitoring mobile app to record their glucose levels
76054181|NCT01504204|Drug|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
76054182|NCT01485640|Drug|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
75439505|NCT01610765|Drug|Novel Antiviral Drug|4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
75439506|NCT01610765|Drug|Placebo|4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
75439507|NCT01610778|Dietary Supplement|Placebo|
75439508|NCT01610778|Dietary Supplement|5-aminolevulinic acid phosphate|
75439509|NCT01610817|Other|InPAct : Information for Participating Actively in cardiovascular treatment|Educational guide presented by general practitioners to the patients. A first part of the guide contains some information on cardiovascular risk and on the benefits and risks of antihypertensive drugs. A second part of the guide consists of encouraging the patient to take an active part in monitoring of its treatment.
75589650|NCT06031870|Device|Vaginal pessary|In the pessary group, all patients received a cube pessary, which was individually adapted to each patient. These pessaries exist in sizes 0 (25 mm edge length) to 9 (75 mm edge length). Patients were instructed by a physician or a trained nurse on how to autonomously manage the pessary, including daily changing and cleaning. After one week of treatment, all patients had an office visit to check if fitting was correct and if autonomous handling of the pessary was feasible. Treatment duration was 12 weeks.
75589651|NCT06031870|Behavioral|Standard care|Standard care consisted of a pelvic floor group exercise course led by a midwife, a physiotherapist, or an osteopath. Courses were in general once a week for a minimum of seven to a maximum of twelve weeks. The course was chosen by the patient, and the study team had no influence on the choice.
75589652|NCT06031870|Procedure|Pelvic floor muscle training|Twelve pelvic floor physiotherapy sessions were prescribed by the study physician. Pelvic floor physiotherapy was performed in individual courses by trained physiotherapists. The patient was free to choose the physiotherapist and the study team had no influence on the choice.
75589653|NCT06031857|Other|kinesio tape|kinesio tape was applied over the specific muscle of rotator cuff
75589654|NCT06031857|Other|Dry needling|dry needling was applied over the affected muscles
75589655|NCT06031831|Other|airway anomalies|with or without airway anomalies
75589656|NCT06031792|Procedure|Endodontic Microsurgery|Osteotomy will be done with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
76054183|NCT04745065|Behavioral|Connect2BWell|Please see the description provided for arm 1.
76054184|NCT04744207|Drug|GS-248|120 mg, capsule, once daily for 4 weeks
76054185|NCT04744207|Drug|Placebo|capsule, once daily for 4 weeks
76054186|NCT02118961|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
75439510|NCT01610856|Drug|Polyethylene Glycol|4 Litres of polyethylene glycol bowel preparation solution
75439511|NCT01610856|Drug|polyethylene glycol|Polyethylene glycol 4L given in two split doses of 2L each
75589657|NCT06031766|Dietary Supplement|Dietary supplement|The participation of the patients in the study will consist of performing the screening for malnutrition that is usually used in the hospital (CIPA) to which the GLIM test will be added, considered as the gold standard for this work. Subsequently, the sample of patients with a positive CIPA (as it is currently considered the screening test used in the hospital) will be implemented the therapeutic measures according to the usual protocol, while the subjects with a negative CIPA test but a positive GLIM will be studied. and constant monitoring taking the appropriate measures according to optional criteria. The patients will be followed up for the study of prognostic factors based on the variables obtained.
75589658|NCT06031753|Behavioral|Time restricted eating|Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.
75589659|NCT06031714|Other|Saliva sampling|HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
75733136|NCT06130358|Other|Experimental: Classic intervention followed by well-being intervention|2 x 6 weeks of weekly museum visits
75733137|NCT06130280|Radiation|MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)|40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance.
75733138|NCT06130254|Drug|Adagrasib|Given by PO BID
75733139|NCT06130254|Drug|Olaparib|Given by PO BID
75733140|NCT06129695|Procedure|Zygomatic implants|the ideal way to support implant-based restorative procedures for full and partially edentulous patients who are missing bone in the upper posterior maxilla.
75883142|NCT05812521|Procedure|Paravertebral block with methylene blue|The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
76054187|NCT02118961|Biological|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
76054188|NCT02140645|Drug|linagliptin|non-randomized
76054189|NCT02140411|Drug|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
76054190|NCT02139943|Drug|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
76054191|NCT02139943|Drug|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
76054192|NCT02139943|Drug|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
76054193|NCT01485172|Drug|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
76054194|NCT01485172|Drug|placebo monotherapy|placebo as monotherapy in Parkinson's disease
76054195|NCT02105701|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
75439512|NCT01610869|Drug|BIBF 1120|Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
75439513|NCT01610882|Device|Panda first followed by manual pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Panda will be used first, manual method 5 mins later.
75439514|NCT01610882|Device|Manual first followed by Panda pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Manual method will be used first, Panda 5 mins later.
75589660|NCT06031714|Other|Blood sampling|"Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out."
75589661|NCT06031714|Other|Interviews|V2 and/or V3
75589662|NCT06031714|Other|Clinical examination|V2 and/or V3
75589663|NCT06031688|Procedure|Biospecimen Collection|Undergo blood sample collection
75589664|NCT06031688|Procedure|Computed Tomography|Undergo CT scan
75589665|NCT06031688|Procedure|Lymphoscintigraphy|Undergo lymphoscintigraphy scan
75589666|NCT06031688|Procedure|Magnetic Resonance Imaging|Undergo MRI
75589667|NCT06031688|Biological|Ramucirumab|Given IV
75589668|NCT06031688|Drug|Tepotinib|Given PO
75589669|NCT06031675|Other|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
75439515|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed."
75589670|NCT06031649|Device|MyotonPRO device|It is a valid and reliable device for measuring the muscular mechanical properties
75589671|NCT06049147|Drug|MBF-015 4 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
75733141|NCT06129149|Behavioral|Trauma-Informed Care-adapted and Checklist-guided ACP intervention|The intervention will consist of a single one- to two-hour visit wherein the PI (Kimpel) will facilitate a flexible conversational approach with the resident (and, optionally, a healthcare decision-maker) in a quiet, private location in the resiliency hub. Using a conversation checklist adapted from a narrative synthesis of advance care planning (ACP) guides (Fahner et al., 2019), the PI will explore ACP with participants and use each visit to continually adapt the checklist and approach with trauma-informed care (TIC) principles: safety, trustworthiness and transparency, peer support, collaboration and mutuality, empowerment, and choice, and cultural, historical, and gender issues. Adverse Childhood Experiences and previous death-related experiences assessed during baseline data collection will be used to tailor the discussion to carefully explore relevant history to assess resident ACP values, preferences, and goals.
75589672|NCT06049147|Drug|MBF-015 16 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
75589673|NCT06049147|Drug|Placebo|Hard gelatin capsules filled with cellulose microcrystalline
75589674|NCT06049121|Other|moderately rough surface|treated surface
75733142|NCT06128616|Device|ESWT|Extracorporeal Shock Wave Therapy
75733143|NCT06128616|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
75589675|NCT06049121|Other|implantoplasty|threads removal and polishing
75589676|NCT06049069|Diagnostic Test|physical activity in stroke|physical activity in stroke
75589677|NCT06049030|Drug|HS-10516|Oral HIF-2α inhibitor
75589678|NCT06048939|Other|moderate intensity aerobic training and body weight resistance training|"Bodyweight Resistance exercises Frequency: twice a week Intensity: moderate Time: 40 Minutes Warm up: 10mins Rotations and Dynamic stretches Body weight resistance Exercises: 20mins Calf raises (1 x 10-15 Reps) Squats (1 x 10-15 Reps) Lunges (1 x 10-15 Reps on each side) Modified push-ups (1 x 10-15 Reps) Bridging (1 x 10-15 Reps) Plank hold (10 Seconds) Side planks (10 Seconds each side) Cool down: 10 mins Slow marching and static stretches for next 6 weeks progression will be made by adding one more set of same exercises Aerobic training: Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Exercise Protocol Warm up: 10mins Rotations and Dynamic stretches~Aerobic exercises will be same as given to control group"
75733144|NCT06128616|Other|Serial Casting|Serial Casting
75733145|NCT06128616|Behavioral|Physical Therapy|Physical Therapy
76054196|NCT02105701|Drug|Ribavirin|200 mg capsule
75733146|NCT06128616|Behavioral|Occupational Therapy|Occupational Therapy
75733147|NCT06127771|Other|Programming DBS using Percept PC neurostimulator's full potential|This study aims to enroll patients who previously had Activa PC neurostimulator and underwent a battery change to Medtronic PerceptTM PC as standard-of-care. However, in this study, the investigators intent to fully utilize the programming potential of Medtronic PerceptTM PC to optimize treatment outcome.
76054197|NCT04411225|Drug|Cannabidiol oral solution|Both the active drug (cannabidiol) and placebo will be in oral solution.
76054198|NCT04743349|Procedure|Steam inhalations|Exposure of airway mucosae to humidified steam through steam inhalation for at least 20 min (4 cycles of 5 min) daily, for 10 days.
75733148|NCT06127069|Device|chitosan brush|debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
75589679|NCT06048939|Other|moderate intensity aerobic training|"Aerobic Exercises Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Warm up: 10mins Rotations and Dynamic stretches Aerobic exercises: 25 mins~(1 minute of each exercise with 60 seconds rest and repeating the same sequence for 1 minute.) Exercises will be performed at slow pace Marching, Single step touch, Step touches front and back, Double step touch, V step, knee lift, leg curl , forward walk, reach outs, lunge side and back, L Step, jumping jacks Cool down: 10 mins Slow marching and static stretches for next 6weeks progression will be made by increasing speed of same exercises"
75589680|NCT06048926|Drug|Carrelizumab|200 mg/time, iv, Q3W
75733149|NCT06127069|Device|ultrasonic scaler|debridement of periodontal pockets only with ultrasonic scaler
75733150|NCT06126770|Behavioral|The social norm intervention|"The intervention will target Married adolescent girls, their spouses, and elderly/influential community members. Thirty-six 2-hour weekly sessions will be conducted with MAGs. The session topics will be categorized into two broad headings: i) Health and life skills sessions covering, for example topics such as sex and gender, rights, marriages, SRHR, and ii) Business and entrepreneurship sessions.~Spouses of the MAGs will receive 20 2-hour bi-weekly sessions. A total of three 2-hour couples sessions will be held. Elderly women and influential community members will have three 2-hour bi-monthly sessions. In addition, MAGs with leadership qualities will be identified and trained to conduct campaigns and activism. They will also receive training on income generating."
75883143|NCT05812521|Procedure|Thoracic Epidural Anesthesia|The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
76054199|NCT01502956|Device|InterStim® device|Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
76054200|NCT01502956|Drug|Botox® injection|Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
76054201|NCT01502644|Drug|Oxycodone|Daily dosage up to 120 mg
76054202|NCT01502644|Drug|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
75439516|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM.~Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed."
75439517|NCT01610921|Other|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
75439518|NCT01610934|Drug|liraglutide|The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
75883144|NCT05812508|Device|corneal topography|corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft
75589681|NCT06048926|Drug|Paclitaxel injection|50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
75589682|NCT06048926|Drug|Cisplatin|25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
75883145|NCT05812495|Procedure|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
76054203|NCT01502644|Drug|Placebo|Placebo-matching oxycodone, placebo-matching morphine
76054204|NCT04408378|Other|observation of covid 19 pneumonia|We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
76054205|NCT01462318|Drug|Midazolam|5 mg
76054206|NCT01462318|Other|Caffeine|200 mg
75883146|NCT05812495|Procedure|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
75439519|NCT01610934|Drug|Glimepiride|At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
75589683|NCT06048926|Radiation|Concurrent chemoradiotherapy|Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
75439520|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
75439521|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
75439522|NCT01610960|Device|Non invasive ventilation HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
75439523|NCT01610960|Device|Non invasive ventilation facemask (Respironics)|The facemask Respironics (Herrsching, Germany) will be used by each patient.
75439524|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
75589684|NCT06048913|Drug|Nimotuzumab|Nimotuzumab 400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses. The use of Taixinsen is not interrupted due to interruption of radiotherapy during the administration until the end of radiotherapy.
75589685|NCT06048913|Drug|Tigio|Oral chemotherapy with the tigio regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral tigio course from Monday to Friday is synchronized with radiation therapy.
75589686|NCT06048913|Radiation|Concurrent radiation therapy|Outline the target area layer by layer on the enhanced CT image, PGTV, PTV. The endangered organs are delineated layer by layer on the cross-section, and extended 0.3cm to form a corresponding plan to endanger the organs. The reverse intensity modulated radiotherapy plan was designed on the Monaco treatment plan system, with a prescribing dose of 56Gy/30F for PTV and 60Gy/30F for pGTV, and the target dose distribution and organ exposure dose were evaluated layer by layer on a cross-sectional surface, and combined with dose-to-volume histogram (DVH) evaluation and optimal treatment plan, the maximum dose of radiation in the spinal cord < 40 Gy and lung V20<30%. After the treatment plan is confirmed, the dose is verified on the treatment machine, and the treatment plan is executed after it is accurate. govern
75589687|NCT06048900|Device|ultrasound guided optic nerve sheath diameter measurement|First, both eyes were measured in a neutral position while awake and after intubation. Measurements were made at regular intervals until the end of the operation after the head-down position and in the neutral position after the operation.
75589688|NCT06048887|Drug|CRN04894 Oral Solution|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
75589689|NCT06048887|Drug|Placebo Oral Solution|Placebo
75589690|NCT06048861|Device|KForce Sens|The device was attached to the middle of the wrist joint with the help of Velcro for all movements. Starting position of the extremity was determined and this position was introduced to the device as the reference position. Then, the participant was asked to perform the movement.
75439525|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
75439526|NCT01610986|Dietary Supplement|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
75733151|NCT06126614|Drug|Chlorhexidine Gluconate|0.05% chlorhexidine gluconate solution for irrigation
75883147|NCT05812482|Procedure|Drug balloon dilatation|The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated
75439527|NCT01610986|Dietary Supplement|Water|Only water intake during training
75733152|NCT06126614|Drug|Vancomycin Hydrochloride|2 grams of topical vancomycin hydrochloride added to the wound
75733153|NCT06126614|Other|Povidone-Iodine|0.35% povidone-iodine solution for irrigation
75733154|NCT06126614|Other|Saline|saline for irrigation
75733155|NCT06125548|Other|Lactation Management Model|The mother provides skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes by hand milking, 2 minutes by breast massage). Head stimulation, stroking for 3 minutes) were asked.
75883148|NCT05812482|Procedure|Direct vision internal urethrotomy (DVIU)|A control subject will choose DVIU surgery until the desired effect is achieved
75883149|NCT05812469|Behavioral|Brain Awareness Intervention|effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders
76054207|NCT01462318|Drug|S-warfarin|10 mg
76054208|NCT01462318|Other|Vitamin K|10 mg
75589691|NCT06048861|Device|Baseline Electrıgoniometer|The pivot point of the goniometer was placed next to the ulnar styloid for 30° and 60° wrist flexion and extension, and also it was placed in the middle carpometacarpal joint for radial and ulnar deviation. A passive movement was made to the extremity in a predetermined amount and direction. The participant was asked to remember this position. Then, the participant was asked to return the extremity to this position when their eyes were closed.
75589692|NCT06048835|Device|Blood sample|For each patient, a 15 ml EDTA blood sample will be collected at different time-points
75589693|NCT06048822|Behavioral|Pickleball|Participants will be encouraged to attend ≥2 pickleball sessions per week, with the YMCA offering 5 sessions per week. Sessions will last 2 hours, with participants encouraged to attend ≥1 hour. New players will receive instruction from a YMCA exercise trainer with a USA Pickleball Association Instructor Certification during sessions. At the end of each session, the YMCA trainer will note on attendance sheets whether participants engaged in training/skill development, open play, or both. Participants will be encouraged to engage in 5-10 minutes of structured warm-up exercise (i.e., walking laps around the courts and dynamic and static muscle stretches) prior to playing in each session, and they will be encouraged to perform cool-down stretches after they complete each session.
75589694|NCT06048796|Other|Early cessation of sedation and TTM|Early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate
75589695|NCT06048770|Biological|RBI-4000|RBI-4000 intramuscular injection.
75589696|NCT06048770|Biological|RabAvert|RabAvert intramuscular injection.
75589697|NCT06048757|Device|Diactive-1 application|Participants will engage in 24 weeks resistance exercise program with goal of maintaining at least 3 sessions per week with 4-5 exercises per session (13-33 minutes). The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper and lower body and the core, utilizing the participants' body weight as the primary resistance or auxiliary materials such as elastic bands and a water-fillable kettlebell. The load and intensity of the exercise will be based on the number of repetitions, the resistance of the elastic bands and/or the weight of the aquaball, as well as the difficulty of the exercises. A mobile application known as Diactive-1 will be utilized.
75589698|NCT06048705|Drug|GSK3901961|GSK3901961 was administered.
75733156|NCT06125132|Procedure|Restoration with-tooth colored material|Restoration of abrasions with different composite resin materials
75733157|NCT06124794|Biological|PROTOXIN|Clostridium botulinum toxin type A
75733158|NCT06124534|Device|Neurostimulation of the Occipital Nerve Field|BliStim Neurostimulation system
75733159|NCT06123689|Device|AMT-Regenera activa|"Patient's preparation: is an ambulatory procedure, the sterility of the Micrograft and the method should be guaranteed during the whole procedure.~Punch biopsy extraction:~The punch should be obtained by the posterior auricular shell area. The zone cleaned with antiseptic solution. Anesthesia is applied in the posterior zone in the base area of the auricular shell. It should be applied superficially to separate the skin from the cartilage . Should be obtained by 3 dermic punches of 2,5mm diameter. The skin is separated from the perichondrium and cartilage.~Once the samples are obtained, they must be put on the metallic grid of the Rigeneracon~Afterwards, 4 ml of Saline solution are added in the inferior part of the Rigeneracon, then close the lid and then put it in the machine with the needed adaptors.~The samples are processed for 6 minutes~The Rigeneracon is extracted from the machine."
75733160|NCT06123689|Device|Hyalubrix|"Patients randomized in Group 2 Sodim Hyaluronate (Hyalubrix 60 -1,5%-2ml vial). NOTE: For the infiltration in the medial knee compartment treatment, the use of intramuscular needle is recommended.~The care post-treatment The homeostasis of the donor's area is achieved by mechanical compression. Usually, there is no need of stitches.~Often it can be seen a bit of inflammation during the first 24-72 hours. The use of analgesic drugs is recommended, avoiding the NSAID, they can interfere in the function of micrografts. Apply intermittently cold on the area or a compressive bandage, if needed"
75733161|NCT06123208|Other|Whole cooked pinto bean|Meal comprised of whole cooked pinto beans
76054209|NCT01462318|Drug|Omeprazole|40 mg
76054210|NCT01462318|Drug|Dextromethorphan|30 mg
76054211|NCT01462318|Biological|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
75589699|NCT06048705|Drug|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
75589700|NCT06048705|Drug|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
75589701|NCT06048692|Drug|Cefepime 1000 MG|Cefepime is a fourth-generation cephalosporin antibiotic
75589702|NCT06048692|Drug|Ampicillin-sulbactam|Broad-Spectrum Antibiotic
75733162|NCT06123208|Other|Pinto bean flour|Meal comprised of pinto bean flour
75733163|NCT06123208|Other|Control|Control meal
75733164|NCT06121843|Drug|BMS-986393|Specified dose on specified days
75733165|NCT06121843|Drug|Alnuctamab|Specified dose on specified days
75733166|NCT06121843|Drug|Mezigdomide|Specified dose on specified days
75733167|NCT06121843|Drug|Iberdomide|Specified dose on specified days
76054212|NCT01485094|Drug|GRT6010|Oral solution given once daily.
76054213|NCT01485094|Drug|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
76054214|NCT01485094|Drug|Matching Placebo|"Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily."
76054215|NCT04079686|Drug|Cephazolin|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
76054216|NCT04079686|Other|Sterile saline|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
76054217|NCT01484938|Device|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
76054218|NCT01502410|Drug|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
76054219|NCT01502410|Other|pharmacological study|Optional correlative studies
76054220|NCT01502410|Other|laboratory biomarker analysis|Optional correlative studies
75439528|NCT01610999|Drug|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
75439529|NCT01611038|Dietary Supplement|Methylselenocysteine|Methylselenocysteine capsule given daily
75439530|NCT01611038|Dietary Supplement|Placebo|Placebo capsule given daily
75589703|NCT06048679|Device|Endovascular pulmonary artery flow-limiting covered stent implantation|selective reduction of flow in the pulmonary arteries affected by anomalous pulmonary venous drainage using a modified flow-limiting covered stent
75589704|NCT06048666|Biological|Intra ovarian by platelet rich plasma|On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide.
75589705|NCT06048653|Other|A computer based cognitive rehabilitation program (Rehacom system)|"Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction~Patients will receive training for four weeks, two sessions per week.~Each patient will assume a comfortable sitting position on a chair in front of the screen.~A report will be generated at the end of the session. It will be used for follow up.~Session duration will range from 45 to 60 min. including rest period."
75589706|NCT06048653|Device|Vagus nerve stimulation|stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.
76054221|NCT01462162|Drug|Tocilizumab|
76054222|NCT01483924|Drug|Apo805K1|Sequential parallel dose escalation.
76054223|NCT01462084|Device|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
75589707|NCT06048601|Diagnostic Test|18F-florbetaben PET/CT|18F-florbetaben positron emission tomography/computed tomography
75439531|NCT01611051|Drug|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
75439532|NCT01611051|Drug|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
75439533|NCT01611051|Drug|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
75439534|NCT01611064|Drug|Oxygen|Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
75589708|NCT06048575|Procedure|Cholecystectomy|Early or late surgery, ambulatory, emergency, or differed.
76054224|NCT01462084|Device|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
76054225|NCT02134028|Drug|Dupilumab|Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
76054226|NCT04752488|Other|Telerehabilitation (TR)|The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
76054227|NCT04752488|Other|Conventional Rehabilitation (CR)|The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
75589709|NCT06048562|Diagnostic Test|echocardiography|evaluation idm for cardiomyopathy by echo
75589710|NCT06048536|Drug|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
75589711|NCT06048536|Drug|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
75589712|NCT06048536|Drug|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period
75589713|NCT06048536|Drug|MR-130A-01 Transdermal patch|MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.
75589714|NCT06048523|Procedure|Patient cohort|"For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation~Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations~Biological samples offered to patients in the context of research:~Annual blood sample~Annual urine sample~Collection of 1 skin biopsy at the inclusion visit (for 30 patients)~Cerebrospinal fluid sample at the inclusion visit (for 15 patients"
75589715|NCT06048523|Procedure|Control cohort|"controls without LP: 1 visit for blood, urine and optional skin biopsy~controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up"
75439535|NCT01611064|Drug|Medical air|Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
75589716|NCT06048484|Radiation|Stereotactic body radiotherapy (SBRT)|SBRT 40 gray (Gy) over 5 fractions
75589717|NCT06048484|Drug|Zimberelimab|240 mg intravenously (IV)
75589718|NCT06048484|Drug|Quemliclustat|100 mg IV
75589719|NCT06048484|Drug|Etrumadenant|150 mg orally
75589720|NCT06048484|Drug|Modified FOLFIRINOX|"Oxaliplatin 85 mg per square meter IV~Irinotecan 150 mg per square meter IV~Leucovorin 400 mg per square meter IV~Fluorouracil 2400 mg per square meter IV~Pegfilgrastim injector kit (6mg subcutaneous)"
75589721|NCT06048458|Diagnostic Test|Cardiovascular magnetic resonance with stress perfusion|Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
75589722|NCT06048458|Diagnostic Test|CT coronary angiography|CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease
75589723|NCT06048458|Diagnostic Test|Retinal OCT angiography|Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
75589724|NCT06048458|Diagnostic Test|Sublingual microscopy (GlycoCheck)|To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
75589725|NCT06048458|Diagnostic Test|Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)|Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
75589726|NCT06048445|Device|intraoperative plancement of Biliary Drainage Stent|plancement of Biliary Drainage Stent in liver transplantation of pediatric patients
75589727|NCT06048432|Other|Conventional Physiotherapy + telephysiotherapty|Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
75589728|NCT06048393|Drug|SA55 nasal spray|"The novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray (SA55 nasal spray) is provided by Beijing Kexing Zhongwei Biotechnology Co., Ltd. The main component of this product is the novel coronavirus broad-spectrum neutralizing antibody, which is a colorless to pale yellow solution. Each milliliter contains 5mg of broad-spectrum neutralizing antibody against novel coronavirus. Excipients include histidine hydrochloride, arginine hydrochloride, histidine, sucrose, polysorbate 80 (II), hydroxypropyl cellulose, glycerol, and benzalkonium chloride (concentration 0.005%).~20 sprays per bottle, approximately 100 sprays per bottle μ L. Containing 0.5 mg of broad-spectrum neutralizing antibody against novel coronavirus."
75883150|NCT05812469|Behavioral|Being Healthy Education|This training included trainings on Healthy Nutrition, Sexually Transmitted Diseases, Importance of Physical Activity and Personal Hygiene prepared by the researcher in the form of presentations for the patients in the control group.
76054228|NCT02172950|Biological|rVIII-SingleChain|Recombinant single-chain coagulation factor VIII
76054229|NCT02151266|Behavioral|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
75439536|NCT01611077|Drug|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
75439537|NCT01611077|Drug|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
75439538|NCT01611077|Drug|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
75439539|NCT01611103|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
76054230|NCT02151266|Behavioral|Exercise Only|
76054231|NCT02151266|Behavioral|Stretching and Flexibility|
76054232|NCT02151110|Biological|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
75439540|NCT01611129|Behavioral|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI & CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
75439541|NCT01611142|Biological|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
75439542|NCT01611181|Drug|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
75589729|NCT06048380|Drug|Ripasudil|"Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil."
75589730|NCT06048380|Other|Placebo|Saline eye drops
75733168|NCT06121479|Drug|Branched-chain amino acid|Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
76054233|NCT02151110|Biological|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
76054234|NCT02151110|Biological|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
76054235|NCT02151110|Biological|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
75439543|NCT01611181|Drug|Kräuterblut|40 mg iron, 20 ml twice daily.
75439544|NCT01611181|Drug|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
75439545|NCT01611207|Device|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
75439546|NCT01611207|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
75439547|NCT01611220|Behavioral|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
76054236|NCT02151110|Biological|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
76054237|NCT02151110|Biological|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
76054238|NCT02151110|Biological|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
75439548|NCT01611246|Device|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
75439549|NCT01611311|Drug|BI 409306 BS|Medium dose film-coated tablet
75439550|NCT01611311|Drug|BI 409306 BS|High dose film-coated tablet
75439551|NCT01611311|Drug|Placebo|Film-coated tablet
76054239|NCT02151110|Other|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
75589731|NCT06048367|Drug|CNSI-Fe(II) 30 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
75733169|NCT06121440|Other|Listening to audiobook|Audiobook by children will be chosen by child psychologists. The books will be played to children via tablet computers. The researcher has a fairy tale therapy certificate. The audiobook listening will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. Audiobook will be listen to children only one day.
75733170|NCT06121440|Other|Playing musical-moving toy|Musical-moving toy by children will be chosen by child psychologists. The toy will be played to children by the researcher. Playing musical-moving toy will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. The toy will be played to children only one day.
75733171|NCT06121089|Procedure|ileocecal resection with extended D3 lymphadenectomy.|Laparoscopy ileocecal resectionith extended D3 lymphadenectomy including 201, 202, 203 and 213 groups of lymph nodes. Manual double-row ileo-ascendo-anastomosis.
75733172|NCT06121089|Procedure|Right hemicolectomy with D3 lymphadenectomy.|Laparoscopy right hemicolectomy with D3 lymphadenectomy including 201, 202, 203, 213, 211, 212, 221, 222-rt groups of lymph nodes. Manual double-row ileo-transverse-anastomosis.
76054240|NCT04749680|Device|PD cycler Silencia|Treatment for 2 weeks either with PD-Night or Homechoice PD cycler (Comparators) depending on the previous Treatment ((clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
76054241|NCT02132312|Drug|OMS302|
75883151|NCT05812456|Other|Estimation of Shear Bond Strength|"Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure."
76054242|NCT02132312|Drug|Phenylephrine HCl|
76054243|NCT02131766|Device|DiAs|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
76054244|NCT02131766|Other|Sensor Augmented Pump Therapy|Insulin pump plus CGM.
76054245|NCT02150954|Drug|pitocin|
76054246|NCT04757012|Device|calinange|calinange
76054247|NCT02131532|Behavioral|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
76054248|NCT04188392|Drug|Pimavanserin|pimavanserin tablet
76054249|NCT02170688|Drug|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
76054250|NCT02170688|Other|Weight calculation|
75589732|NCT06048367|Drug|CNSI-Fe(II) 60 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
75589733|NCT06048367|Drug|CNSI-Fe(II) 90 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
75589734|NCT06048354|Dietary Supplement|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
75589735|NCT06048354|Dietary Supplement|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
75589736|NCT06048354|Dietary Supplement|Placebo|The study foresees the intake of 2 capsules per day during 84 days
75883152|NCT05812430|Drug|anlotinib+TQB2450+nab-paclitaxel+cisplatin|"Anlotinib: 10mg, po, d1~14, q3w, until disease progression or unacceptable toxicity.~TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity.~nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles."
76054251|NCT02170298|Drug|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
75883153|NCT05812404|Drug|DWP14012|Potassium-competitive acid blocker
75883154|NCT05812404|Drug|DWC202201|Atorvastatin Calcium Trihydrate
75439552|NCT01611324|Drug|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
75439553|NCT01611324|Drug|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
75439554|NCT01611337|Other|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
75439555|NCT01611350|Other|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
75439556|NCT01611350|Other|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
75439557|NCT01611350|Other|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
75439558|NCT01611363|Drug|ASP1941|Oral
75439559|NCT01611363|Drug|Placebo|Oral
75439560|NCT01611376|Device|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
75439561|NCT01611389|Device|Prolonging atrioventricular (AV) delay.|Prolonging atrioventricular (AV) delay to maximum 350 ms.
75439562|NCT01611389|Device|Standard atrioventricular (AV) delay.|Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
75439563|NCT01611415|Drug|Ipragliflozin|Oral
75439564|NCT01611415|Drug|Furosemide|Oral
75589737|NCT06048315|Drug|Anlotinib|Every 3 weeks is a treatment cycle, starting from the first day of each treatment cycle with oral administration of 12mg of arotinib once a day, stopping for one week after taking it for two weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
75589738|NCT06048315|Drug|Penpulimab|On the first day, Pianzumab (200mg intravenous infusion) was administered every 3 weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
75589739|NCT06048224|Drug|HS628+MTX|Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week
75589740|NCT06048224|Drug|Actemra +MTX|Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week
75439565|NCT01611428|Drug|Ipragliflozin|Oral and Intravenous (i.v.)
75439566|NCT01611467|Drug|CC-223|20 mg oral CC-223 capsule containing a microtracer of [14C]-CC-223 solution
75733173|NCT06120998|Procedure|Arthroscopic rotator cuff repair|All patients were placed in a semi-sitting position. Initially, a posterior portal was established to explore the inside of the joint, a lateral portal was created for the removal of subacromial bursa, and an additional anterior portal was created for repairing the tendons. Measurements were taken to determine the extent of rotator cuff damage, including its anterior-posterior and medial-lateral dimensions. In cases where complete repair was possible, a single-row or double-row repair technique was used depending on the degree of tendon damage. For situations where complete repair was not feasible, partial repair was performed. If the tendon could be stretched after relaxation, it was repaired to an anatomical position near the bone bed with the assistance of acellular dermal reinforcement. However, if the tendon lacked elasticity and was fully retracted upon relaxation, acellular dermis was used to bridge the tendon back to the anatomical position.
75733174|NCT06120205|Device|Teal Wand Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of vaginal cells and material using the Teal Wand Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A healthcare provider collected sample will be performed by a clinician after self-collection. The patient will serve as their own comparator/control.
75733175|NCT06118385|Drug|BEN8744|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
75589741|NCT06048211|Other|Stool color scale|observationnal trial about the use of the stool color scale by the health professionnals
75589742|NCT06048198|Other|No intervention|No intervention
75589743|NCT06048172|Behavioral|Prolonged Exposure|In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
75589744|NCT06048081|Drug|zolbetuximab|"intravenous infusion~mFOLFOX6 or CAPOX (used at physician discretion) will be used in combination with zolbetuximab"
75589745|NCT06048068|Behavioral|Educational Informational Platform|This intervention contains many informational articles for surrogates about cardiac arrest, the subsequent hospitalization, and the emotional journey following cardiac arrest. All articles are available in both English and Spanish.
75733176|NCT06118385|Drug|Matching Placebo|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
75733177|NCT06116266|Other|Education and support for primary care providers (PCPS)|All PCPs in the EUC and Co-Care arms receive brief education on SUD treatment, including medications for OUD and AUD and contingency management for StUD, and recognizing and counteracting stigma while caring for patients with SUD.
75733178|NCT06116266|Other|Nurse Care Manager (NCM) visits|A full-time clinic-embedded nurse care manager who works with patients and their PCPs to facilitate and support patient engagement in evidence-based treatment for polysubstance use and management of associated health conditions
75733179|NCT06116266|Other|Addiction specialist consultant|An addiction specialist consultant who supports the nurse care manager and PCP in formulating and adjusting treatment plans
76054252|NCT02131064|Drug|Carboplatin|Carboplatin IV infusion at a dose to achieve an AUC of 6 mg*min/mL q3w
76054253|NCT02131064|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infusion q3w
75439567|NCT01611467|Drug|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
75439568|NCT01611480|Drug|Imiquimod (topical use)|
75439569|NCT01611493|Device|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
75439570|NCT01611493|Device|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
75439571|NCT01611506|Biological|Cetuximab|"Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1"
75439572|NCT01611506|Drug|Capecitabine|"Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle"
75589746|NCT06048055|Other|Transcutaneous auricular vagus nerve stimulation|Patients in this group will be treated with 12 sessions of transcutaneous auricular nerve stimulation, three sessions per week for four weeks. The stimulation of the left auricular branch of the vagus nerve will be performed by conventional transcutaneous electrical nerve stimulation (TENS) through a Gamna Duo 200 electrotherapy device with one channel and two electrodes (5mm diameter disposable adhesive stimulation electrodes). The TENS parameters will be used: 30 30-minute treatment time, a pulse width of 200 milliseconds, and a pulse frequency of 20 hertz. The intensity of stimulation will be individually adjusted according to the patient's perceptual threshold. The perceptual threshold (PT) is defined as the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. The stimulation intensity will be set at super-threshold levels, such as 200% of the patient's perceptual threshold.
75589747|NCT06048055|Other|selected physical therapy program|The selected physical therapy program session will be from 25 to 30 minutes, three sessions per week for four weeks. The program will be selected mainly for stretching for shortened upper limb muscles, strengthening for weak upper limb muscles, occupational therapy for hand, trunk, and pelvic control exercises, and gait training.
75733180|NCT06116266|Other|Health coaching sessions|Health coaches who use motivational interviewing and cognitive behavioral therapy to motivate and support patients in behavior change to reduce polysubstance use-related harms. Patients may receive up to 12 health coaching sessions in total. The sessions will occur via phone and/or HIPAA compliant video chat software.
75733181|NCT06116266|Other|Patient educational materials|Patient participants receive an educational pamphlet addressing overdose prevention, information about accessing naloxone, and local SUD treatment options.
75733182|NCT06113263|Procedure|Anterior cervical decompression surgery|The aim of the surgery is to reduce the compression of the affected nerve. With anterior cervical decompression surgery this is achieved by removing the disc and osteophytes.
75733183|NCT06113263|Procedure|Posterior cervical foraminotomy with or without laminectomy|The aim of the surgery is to reduce the compression of the affected nerve. With posterior cervical decompression surgery more space is created for the nerve by widening the foramina where the nerve exits
75733184|NCT06111794|Other|REACH TBI|Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
75733185|NCT06110572|Drug|Carboplatin|Given by IV
75733186|NCT06110572|Biological|Atezolizumab|Given by IV
75733187|NCT06110572|Drug|Etoposide|Given by IV
75733188|NCT06110572|Radiation|Total Body Irradiation|Undergo Total Body Irradiation
75733189|NCT06110572|Radiation|Hypofractionated Radiation Therapy|Undergo Hypofractionated Radiation Therapy
75733190|NCT06110572|Procedure|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
75883155|NCT05812326|Drug|AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells|AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
75733191|NCT06110156|Behavioral|Patient-tailored deprescribing assessment and intervention|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
75733192|NCT06109480|Device|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
75733193|NCT06109480|Device|Sham High definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
75733194|NCT06109480|Device|electroconvulsive therapy device|ECT induces brief generalized epileptic seizures by electric current to stimulate the forehead under general anesthesia
75883156|NCT03607110|Drug|Ketamine|sedation drugs
75883157|NCT03607110|Drug|fentanyl|sedation drugs
75883158|NCT03607110|Device|patient control analgesia|patient control analgesia
76054254|NCT02131064|Drug|Pertuzumab|Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
76054255|NCT02131064|Drug|Trastuzumab|Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
76054256|NCT02131064|Drug|Trastuzumab Emtansine|Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
76054257|NCT02130986|Other|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
76054258|NCT02130986|Other|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (<1 hour goal) provide clinicians the procalcitonin result.
75439573|NCT01611506|Drug|Cisplatin|"Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle"
75439574|NCT01611545|Genetic|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
75439575|NCT01611584|Drug|ALA-induced Fluorescence|ALA Dose- 20 mg/kg
75439576|NCT01611597|Other|Different standardized tasks with an accelerometer device|Patients will perform tests like hand grip (MyoGrip), pinch (MyoPinch), Moviplate, box and block test of hand function, Minnesota Manual Dexterity Test. The tests will be performed with the accelerometer device worn on the wrist.
75439577|NCT01611610|Other|Functional tests|"The ambulant patients will perform~MFM (20 items)~Hammersmith modified module - MHMFS~Timed tests (time to rise from the floor,...)~6 minute walk test~PedsQL - neuromuscular module"
75439578|NCT01611610|Other|Functional tests|"The non-ambulant patients will perform:~MFM (20 items)~Hammersmith modified module - MHMFS~Upper Limb Functional Items~Egen Klassifikation 2 questionnaire - EK2~PedsQL questionnaire - neuromuscular module"
75439579|NCT01611623|Drug|SNX-5422|Tablets dose every other day; dose escalation based on safety
75439580|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils|4 months consumption
75439581|NCT01611649|Dietary Supplement|Formula containing plant oils|4 months consumption
75439582|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
75439583|NCT01611675|Drug|Vemurafenib|take orally, twice daily
75439584|NCT01611675|Drug|Leflunomide|take orally, once daily
75439585|NCT01611688|Drug|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
75439586|NCT01611688|Drug|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
75589748|NCT06048042|Biological|Autogenous Demineralized Dentin Graft|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high- speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill. Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid5 for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the intra-bony defect after modified minimally invasive surgical technique.
75733195|NCT06108037|Behavioral|Generative AI for electronic communication and disclosure|We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.
75439587|NCT01611688|Drug|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
75733196|NCT06107907|Device|Non-invasive ventilation (NIV) or high-flow oxygen therapy (HFOT) using electrical impedance tomography (EIT)|Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase. NIV will be administered in continuous positive airway pressure (CPAP) mode. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities.
75733197|NCT06107725|Drug|Minocycline|Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
76054259|NCT02130986|Other|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~For outpatients, antibiotic duration based on level (> 0.25-0.5 ug/L:3 days; > 0.5-1.0 ug/L:5 days; >1.0 ug/L:7 days). Physician follow-up is recommended."
76054260|NCT02130986|Other|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
76054261|NCT02130284|Device|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
76054262|NCT04749212|Diagnostic Test|serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)|Both biomarkers will be determined in each patient preoperatively and at postoperative day 1 and day 2.Measurements will not necessarily be taken independently of other measurements, meaning that the addition of the biomarker could be included in routine pre or postoperative day-1 and day 2 blood tests.
75589749|NCT06048042|Biological|Autogenous Bone Graft|Modified minimally invasive surgical technique (M-MIST) will be performed in the intra-bony defects, with autogenous bone graft placement. The graft will be harvested from the retromolar area using automatic chip maker (ACM) bur and a hand bone mill will be used to grind the chips into particles, then it will be placed in the defect.
75733198|NCT06107218|Other|Bioactive Glass Air Abrasion Particles.|Finishing of cavity walls by AquaCare Air Abrasion Device using Bioactive Glass Air Abrasion Particles.
75733199|NCT06107218|Other|Diamond Stone.|Finishing of cavity walls using Diamond Stone.
76054263|NCT04748822|Other|questionnaires|The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
76054264|NCT02147288|Device|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
75439588|NCT01611701|Procedure|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
75589750|NCT06048029|Procedure|laparscopic Cholecystectomy in children|Evaluate preoperative and operative risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy
75589751|NCT06048016|Diagnostic Test|Scaling and Root Planning|Scaling and Root Planning by using ultrasonic scaler ,and Gracy currettes.
76054265|NCT05209178|Diagnostic Test|Collection of nasal and oropharyngeal specimen for COVID19 antigen test|Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.
76054266|NCT04739150|Drug|nintedanib|nintedanib
76054267|NCT04737356|Behavioral|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
75439589|NCT01611701|Procedure|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.
76054268|NCT04751708|Procedure|endovascular treatment|For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
75439590|NCT01611714|Other|Audit-feedback|Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
75439591|NCT01611714|Other|Clinical Decision Support|"Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template."
75733200|NCT06107075|Dietary Supplement|Active|40g bio-active whey protein concentrate powder containing phospholipids
75589752|NCT06047990|Device|Cryobiopsy catheter|Comparison of endobiliary forceps biopsy and cryobiopsy of biliary stenosis during percutaneous transhepatic drainage.
75439592|NCT01611727|Drug|Cisplatin|Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
75589753|NCT06047964|Device|DCB|Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
75733201|NCT06107075|Dietary Supplement|Placebo|around 40g pea protein powder not containing phospholipids
75589754|NCT06047964|Device|POBA|Intracranial PTA balloon catheter
75589755|NCT06047925|Procedure|3D printed crown|Reduction will be performed on the occlusal surface using a flame stone or a wheel stone, to perform occlusal clearance by 1 mm. Reduction will be performed by 1 mm on the mesial, distal, buccal and lingual surfaces of the tooth. Impression for the preparation will be taken using putty and light poly vinyl siloxane material. Temporary crown will be placed above the preparation as temporisation.The impression will be sent to the lab .The preparation will be optically scanned in the lab and the restoration will be digitally designed using computer designing software.The crown will be printed using 3D printer using hybrid resin(micro-filled hybrid composite) material.The 3d printed crown is cemented with resin cement.
75733202|NCT06104930|Other|Explorative biomarker study|Analysis of blood biomarker
75733203|NCT06100575|Behavioral|Website (www.mee-leven.be)|"The tool is a website aimed siblings and children of someone who has suicidal thoughts and/or behaviors. The intended objectives of the tool are 1) to contribute to knowledge about suicide and health care options, 2) to increase perceived competences in dealing with suicidality of a family member, 3) to reduce perceived pressure and negative feelings such as hopelessness and 4) to be accessible and user-friendly.~These objectives are achieved by providing the following content: 1) concerning the sibling/child themselves (primary objective) : information about the potential impact of having a suicidal family member, own needs, informal and formal (self) care, dealing with the suicidal family member, dealing with other family members 2) concerning the suicidal family member (Secondary objective): information about the suicidal process, signal recognition, how to provide support/create a safe environment for suicidal loved ones , help available for suicidal relatives"
75733204|NCT06096922|Other|No intervention|No intervention
75733205|NCT06095492|Drug|Empagliflozin 25 MG|Patient will get Empagliflozin 25
75589756|NCT06047925|Procedure|stanless steel crown|The occlusal surface of the tooth should be reduced by about 1.5 mm, maintaining its occlusal contour or until the tooth is out of occlusion with adequate room to fit a crown.Proximally, tooth reduction will be made through the mesial and distal contact areas, then roundation of line angles to avoid the creation of ledges or steps.The crown selection will be done by trial and error or by measuring the mesiodistal dimension of the tooth space with dividers. It can also be helpful to measure the dimension of the contralateral tooth. A correctly fitting crown should snap or click at try in.
75733206|NCT06095492|Drug|Linagliptin|linagliptin 5 mg once a day
76054269|NCT04751708|Other|best medical management|best medical management
75733207|NCT06092749|Other|Transgrade technique (TG)|Transgrade (TG) Epidural Steroid Injection technique
75733208|NCT06092749|Other|Interlaminar technique (IL)|Interlaminar (IL) Epidural Steroid Injection technique
75589757|NCT06047873|Device|Endoscopy|clinical and endoscopic pattern in patients with upper and lower gastrointestinal bleeding
75589758|NCT06047860|Radiation|Radiotherapy|hypofractionated radiotherapy/SBRT
75589759|NCT06047860|Drug|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor within one week of radiotherapy
75589760|NCT06047860|Drug|Granulocyte-macrophage colony-stimulating factor subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
75589761|NCT06047860|Drug|Interleukin 2 subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
76054270|NCT02147132|Drug|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
75733209|NCT06091995|Behavioral|impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)|Evaluate the clinical impact of administering one dose of belatacept on eGFR at one-year post-transplant, patient and graft survival outcomes, graft rejection, and incidences of BK virus, EBV and CMV infections.
75439593|NCT01611740|Procedure|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :~the variability of the cardiac cycle duration ;~the variability of respiratory cycle amplitude and duration ;~and their relationships."
75589762|NCT06047860|Drug|Endostatin|Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
75589763|NCT06047808|Behavioral|Storytelling Through Music|"Storytelling Through Music is a six-week expressive arts intervention."
75589764|NCT06047795|Other|Experimental|"Cycling 2 days per week with Borg dyspnea 4-6 level for 15-20 minutes/ day with 5 minutes warm-up and cool-down.~Strengthening exercises for upper limb muscles (pull-ups and biceps curls) and for lower limb muscles (sit-to-stand and step-up exercises) with 3 sets of 8-12 repetitions * 2 days per week.~Pursed Lip breathing exercise 3 sets of 5-10 repetitions for 6 weeks"
75589765|NCT06047795|Other|Control|"Usual care: frontal chest radiographs, verbal advice to quit smoking, and reduce exposure to biomass smoke.~Spirometry to screen for airway diseases. Antibiotic and systemic glucocorticoid therapy."
75733210|NCT06091124|Drug|Adebrelimab|Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
75733211|NCT06091124|Drug|Etoposide|Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
75733212|NCT06091124|Drug|Cisplatin|Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
75733213|NCT06091124|Procedure|Radical Cystectomy|Radical cystectomy should be performed within 4-6 weeks after completion of last dose
75733214|NCT06089915|Behavioral|Standard occupational therapy|Standard occupational therapy as part of inpatient rehabilitation
75733215|NCT06089915|Device|Robot-assisted exercise using Amadeo device and Armeo Spring exoskeleton|Exercise for fingers and hand using Amadeo device plus gross-motor exercise using Armeo Spring exoskeleton
75733216|NCT06088641|Diagnostic Test|preoperative BNP value|preoperative BNP value
75733217|NCT06088329|Behavioral|Mindful Walking for Adults with Chronic Pain|Participants identified with chronic pain will complete 6 sessions of mindfulness based walking exercises.
75733218|NCT06087432|Other|Rocabado's 6x6 Exercises|Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique.
75589766|NCT06047782|Other|Cardiac MRI (with contrast agent)|Cardiac MRI with contrast agent
75589767|NCT06047769|Other|Board Games|Participants will receive cognitive training in board games including Ludo, Chutes & Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
75589768|NCT06047730|Procedure|operation ways|nothing
75733219|NCT06087432|Other|PNF Exercises|Proprioceptive neuromuscular facilitation (PNF) exercises will be applied to the neck and jaw with rhythmic stabilization (RS) and combined isotonic contraction (CIC) techniques. The RS protocol consists of alternating isometric contractions for 10 seconds and does not involve movement. The KIK technique involves combined concentric, isometric and eccentric contraction of the agonist muscle without rest, with each contraction lasting 5 seconds. KIK exercises consist of 5-15 repetitions per set, depending on the individual's tolerance. Between sets, a 30-second rest will be included. First, the RS protocol will be applied and after a 2-minute rest interval, the exercise will continue with the KIK protocol applications. The expected duration of exercise exercises is 30 minutes. Maximum performance will be requested from the individual in all repetitions and the necessary verbal commands will be given for appropriate movement.
75589769|NCT06047691|Behavioral|Abbreviated, Intensive, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy for PTSD|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format. Couples are provided with psychoeducation about PTSD and relationship functioning and are taught cognitive and behavioral skills to address the manifestation of PTSD in the couple relationship. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and once 1-2 weeks after the retreat.
75439594|NCT01611753|Other|packed red blood cell transfusion|Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
75439595|NCT01611766|Procedure|Secondary Cytoreductive Surgery|Complete Cytoreduction
75439596|NCT01611766|Drug|Salvage Chemotherapy|6 cycles of postoperative chemotherapy
75439597|NCT01611805|Drug|GSK1605786|Opaque Swedish orange body and cap.
75733220|NCT06086912|Drug|HR17031|Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
75733221|NCT06086912|Drug|HR17031|Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
75733222|NCT06086912|Drug|HR17031|Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
76054271|NCT02147132|Drug|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
76054272|NCT02147132|Drug|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
76054273|NCT02147132|Drug|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
76054274|NCT02146430|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
76054275|NCT02146430|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
76054276|NCT02146430|Drug|Placebo tablet|Placebo tablet (matching DS-5565) for oral administration
75733223|NCT06086184|Behavioral|ACT group therapy|"Participation in four sessions of the inpatient Compass Group and eight sessions of the inpatient Here-and-Now Group. This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan."
75439598|NCT01611805|Drug|GSK1605786 Placebo|Opaque Swedish orange body and cap.
75589770|NCT06047691|Behavioral|Prevention and Relationship Education Program|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format.The content of PREP and workshop experiences focuses on helping couples communicate effectively, manage conflict without harming their relationship, preserve and act on commitment, improve relationship decision-making, increase understanding of differences between partners, and protect positive connections between partners. Approximately 12 hours of PREP content will be delivered over 2 consecutive days in a multi-couple group retreat format. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and will check in with a member of the study staff 1-2 weeks after the retreat.
75733224|NCT06085755|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.
75733225|NCT06085755|Drug|Afatinib|Afatinib will be administered orally 20mg ~40mg once a day or three times a week(Monday, Wednesday, Friday [MWF]) or twice weekly (Monday, Thursday [MT]) for 3weeks as one cycle.
75733226|NCT06085209|Device|The truFreeze Spray Cryotherapy|A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
75733227|NCT06085209|Device|Ballon dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.
75733228|NCT06085209|Device|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
76054277|NCT02146430|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
76054278|NCT02129192|Drug|Amlodipine 5mg capsule|Amlodipine 5mg capsule
76054279|NCT02129192|Drug|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
75439599|NCT01611818|Other|Low Intensity Internet-delivered psychotherapy|Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
75439600|NCT01611818|Other|Self-guided Internet delivered psychotherapy|No contact with the therapists over the treatment period will be done.
75439601|NCT01611818|Other|Improved treatment as usual|Any kind of treatment administered by the GP to the patient with depression
75439602|NCT01611831|Behavioral|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
76054280|NCT02129192|Drug|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
76054281|NCT02105948|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
76054282|NCT02105948|Drug|Placebo|Sterile 0.9% sodium chloride solution
76054283|NCT02128724|Drug|BKM120|Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
76054284|NCT02128490|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
76054285|NCT02128490|Drug|Febuxostat XR|Febuxostat over-encapsulated capsules
75883159|NCT05812274|Other|Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation|"The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:~ApricityCare™ Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.~ApricityOncology™ Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.~ApricityManage™ Dashboard - a dashboard intended for administrators, sponsors or funders to track program status."
76054286|NCT02128490|Drug|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
75883160|NCT05812209|Procedure|Stellate Ganglion Block|Ultrasound guided block of the Stellate Ganglion with local anesthetics.
76054287|NCT02128490|Drug|Colchicine|Colchicine tablets
75439603|NCT01611831|Behavioral|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
75439604|NCT01611844|Device|Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~1 intradermal injection of Tuberculin (5UI)~1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
75883161|NCT05812092|Device|CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System|CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
75883162|NCT05812066|Procedure|all ceramic single-retainer resin bonded fixed partial denture|The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.
75439605|NCT01611844|Device|medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~1 intradermal injection of Tuberculin (5UI)~1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
75883163|NCT05812053|Procedure|pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline was performed by sterile #330 high speed bur using water spray. Caries was removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber removed by low speed round bur. Haemostasis was obtained by applying pressure with moist cotton pellet with saline. Then the test materials was applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material then the tooth will be restored with a preformed stainless steel crown
75883164|NCT05812053|Radiation|cone beam computed tomography (CBCT) assessment|a post-operative CBCT image will be taken immediately after completing the procedure with fixed exposure parameters (120 Kv, 5mA, and 0.125mm voxel size) using the smallest field of view (8D, 8Hcm) also, after 6 and 12 months follow-up periods.
75883165|NCT05811975|Drug|KSX01-TCRT injection|individualization TCR-T cell injection
76054288|NCT02128490|Drug|Naproxen|Naproxen tablets
76054289|NCT02128490|Drug|Lansoprazole|Lansoprazole capsules
76054290|NCT02146352|Device|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
76054291|NCT02105636|Drug|Nivolumab|
76054292|NCT02105636|Drug|Cetuximab|
76054293|NCT02105636|Drug|Methotrexate|
76054294|NCT02105636|Drug|Docetaxel|
76054295|NCT01626872|Drug|MP-214 3mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
76054296|NCT01626872|Drug|MP-214 6mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
75883166|NCT05811962|Other|No intervention|No intervention, only comparison
76054297|NCT01626872|Drug|MP-214 9mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
76054298|NCT01626872|Drug|Risperidone 4mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
76054299|NCT01598090|Biological|Peginterferon Lambda-1a|Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
76054300|NCT01598090|Biological|Peginterferon Alfa-2a|Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
75439606|NCT01611896|Dietary Supplement|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
75439607|NCT01611896|Other|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
75439608|NCT01611909|Drug|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
75439609|NCT01611922|Other|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
75439610|NCT01611922|Device|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
75439611|NCT01611961|Drug|DT-LM|Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
75589771|NCT06047652|Device|e-CPD user testing|nurses who meet the criteria will carry out user testing on the e-CPD application via a mobile device. after accessing the e-CPD system the nurse will fill in the System Usability Scale instrument.
75883167|NCT05811923|Other|Venous Blood Collection|Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent. Blood will be collected via a forearm vein using standard phlebotomy techniques using either an indwelling catheter or single venipunctures. All blood samples will be collected into ethylenediaminetetraacetic acid EDTA-coated Vacutainer™ tubes and gently inverted ten times before being centrifuged at 3000 revolutions per minute (rpm) (MegaFuge XFR, Thermo Fisher Scientific, Waltham, MA, USA) at 4oC for 20 minutes. After centrifugation, 400 μl aliquots of plasma will be removed and frozen at -80oC within four hours of collection.
76054301|NCT01598090|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
76054302|NCT01598090|Drug|Telaprevir|Tablets, Oral, 750 mg, three times a day, 12 weeks only
76054303|NCT02105012|Drug|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
76054304|NCT02105012|Drug|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
76054305|NCT02105012|Drug|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
76054306|NCT02105012|Drug|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
76054307|NCT02105012|Drug|Placebo MDI|Placebo MDI administered as 2 inhalations BID
76054308|NCT02145182|Drug|Eculizumab|Eculizumab is a complement component 5 inhibitor.
75439612|NCT01611961|Drug|docetaxel|Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
75589772|NCT06047600|Other|Uroconnect Follow Up Group|Inplementation of UroConnect remote monitoring Medical Device (DM) to optimize patient support and nursing coordination.
75589773|NCT06047587|Behavioral|VR-TrAC|Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each.
75589774|NCT06047587|Other|Care as Usual|Care as usual as provided in prison.
75589775|NCT06047574|Other|This study does not involve any interventions|This study does not involve any interventions
75589776|NCT06047561|Radiation|PET-CT|PET combined with CT or MRI
76054309|NCT02145182|Drug|Placebo|0.9% sodium chloride
76054310|NCT02145026|Drug|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
75589777|NCT06047535|Drug|Naxitamab|"Naxitamab + GM-CSF:~Cycles 1-5: Patients will receive naxitamab IV at 3 mg/kg/infusion on Day 1, 3 and 5 and GM-CSF sc at 5 µg/kg/day on Days -4 to 0 and at 10 µg/kg/day on Days 1-5 for 5 cycles.~Isotretinoin:~Cycles 3-8: Patients will receive isotretinoin PO at 160 mg/m2/day divided into two daily doses on Days 15-28 for 6 cycles."
75589778|NCT06047522|Device|Casque Lumeen|Participants will take part in virtual reality sessions via headset. They will benefit from a before/after evaluation, and a 3-week intervention where they will have 1 virtual reality session per week.
75589779|NCT06047483|Drug|HRF2105 patch|HRF2105 patch ，external use，once a day
75589780|NCT06047483|Drug|Loxoprofen patch|Loxoprofen patch ，external use，once a day
75733229|NCT06085092|Behavioral|Open weighing|The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.
75589781|NCT06047483|Drug|placebo|placebo ，external use，once a day
75589782|NCT06047431|Drug|QL1706H|QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
75589783|NCT06047418|Procedure|Blepharoplasty|This is an cross-sectional, retrospective observational study, to evaluate the clinical characteristics and surgical outcome of blepharoptosis patients who undergone the surgery
76054311|NCT02144012|Drug|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
75589784|NCT06047340|Device|G:DATA, dementia screen videogame|A videogame for screening
75589785|NCT06047327|Diagnostic Test|EUS guided liver biopsy|Procedure will be performed by 19G Franseen needle.
75589786|NCT06047327|Diagnostic Test|Percutaneous Liver Biopsy|procedure will be done by 18G BioPince Needle
75589787|NCT06047249|Behavioral|KAP Popular Science Research|By conducting a survey questionnaire, investigate the knowledge, attitude, and practice tendencies of patients and their caregivers towards a certain disease, and conduct relevant science popularization；Pre discharge satisfaction survey questionnaire
75589788|NCT06047249|Behavioral|No KAP Popular Science Research|Pre discharge satisfaction survey questionnaire
75589789|NCT06047210|Other|Blood Draws Data Collection|
76054312|NCT02144012|Drug|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
76054313|NCT02144012|Drug|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m^2) or 100 mg/m^2 Q3W.
75589790|NCT06047197|Biological|RC19D2 cell injection|The functional component of RC19D2 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
75733230|NCT06085092|Behavioral|Blind weighing|The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or self-esteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
76054314|NCT02103062|Drug|ABI-007|
76054315|NCT02141672|Drug|Voclosporin High Dose|
76054316|NCT02141672|Drug|Voclosporin Low Dose|
76054317|NCT02141672|Drug|Placebo|
76054318|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
76054319|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
76054320|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
75439613|NCT01611987|Other|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
75439614|NCT01611987|Other|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
75439615|NCT01612013|Drug|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
75439616|NCT01612013|Drug|Intravenous NAC plus saline|Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
75733231|NCT06084793|Other|Music|In the pre-transfer room, the personalized playlist will be played through earphones or speakers, according to the patient´s preference. In the transfer room, the personalized playlist will be played through speakers at a volume that is loud enough for the participant to hear but soft enough to ensure clear communication between the patient and doctor, without causing any disturbance to the doctor.
75733232|NCT06081920|Biological|IBI363|RP2D of IBI363
75733233|NCT06080451|Other|Integrated Diabetes and Hypertension Primary Care Model|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~Training health workers on diabetes and hypertension treatment protocols~Team-based care and task sharing~Strengthening access to medications and diagnostics~Electronic medical record system and registry~Systems monitoring and feedback of key indicators"
76054321|NCT02141360|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
76054322|NCT01628198|Device|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter|"Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions.~There are 2 devices that can be used---this is optional, based on physician preference:~Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California~or~Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California"
75589791|NCT06047184|Drug|BEBT-209 capsules|BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
75439617|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
75589792|NCT06047184|Drug|Letrozole tablets|Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.
75589793|NCT06047184|Drug|Fulvestrant|Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
75589794|NCT06047158|Drug|Omega-3 fish oil fat emulsion|Use omega-3 fish oil fat emulsion
75883168|NCT05811923|Other|Resting Metabolic Rate Determination|During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment.
76054323|NCT01628120|Biological|Epoetin Hospira|Subcutaneous(SC) injection
76054324|NCT01627340|Biological|Engerix™-B vaccine|3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
75589795|NCT06047106|Radiation|multiparametric MRI|"For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.~For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment."
75589796|NCT06047106|Procedure|kidney graft biopsy|Biopsy of the graft itself prior to transplantation in the recipient.
76054325|NCT02125838|Device|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
75439618|NCT01612013|Drug|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
75439619|NCT01612013|Drug|NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
75589797|NCT06047106|Biological|blood samples|"For donors who are not selected to donate their kidney, a total of 2 mL of blood will be collected at inclusion.~For donors eligible to donate, a total of 4 mL of blood will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 26 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant)."
75589798|NCT06047106|Biological|urine specimens|"For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.~For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant)."
75589799|NCT06047093|Procedure|Investigation of the intrahepatic compartment using the fine needle aspiration (FNA) technique|"The FNA will be performed at the Croix Rousse digestive pathology day hospital of the Hospices Civils de Lyon by a doctor from the hepatology department who has been trained to perform FNA.~After echography, a subcutaneous anesthesia with LIDOCAÏNE is administered. Two FNA passages will be performed for virological and immunological analyses. The patient will be monitored in the supine position for 1 hour after the procedure.~A single FNA will be performed during the study."
75589800|NCT06047093|Biological|Creation of a serum biobank|42ml blood sample for study of circulating peripheral blood mononuclear cells (PBMC) and new circulating hepatitis B markers. These samples will enable us to gain a better understanding of peripheral immune responses and to correlate intrahepatic virological data with new serum markers of HBV.
75589801|NCT06047093|Other|FNA feasibility and acceptability questionnaire|An FNA feasibility and acceptability questionnaire carried out at inclusion (V1) and at V2 after the FNA has been performed.
76054326|NCT02125838|Device|Endotracheal Tube|ETT
76054327|NCT02125604|Drug|dimethyl fumarate|capsules administered according to the prevailing product label
76054328|NCT02124746|Drug|Momelotinib|Momelotinib tablets administered orally once daily
75589802|NCT06047015|Combination Product|IRE plus checkpoint inhibitor|Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.
75589803|NCT06047015|Combination Product|IRE plus Checkpoint Inhibitor plus CpG-ODN|"Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug.~IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
76054329|NCT02123966|Drug|Sirolimus|
76054330|NCT02123576|Drug|Pentoxyfylline|
76054331|NCT02123576|Drug|Placebo|
76054332|NCT02123576|Drug|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
76054333|NCT01177397|Drug|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
76054334|NCT01160861|Drug|MEMP1972A|Repeating ascending dose
76054335|NCT01160861|Drug|placebo|Repeating ascending dose
76054336|NCT01158677|Procedure|Meniscectomy|patients undergoing meniscectomy will be asked to complete the KOOS-scale,Vas-scale, Tegner questionnaire, SF-36 questionnaire pre-operatively and at 3, 6 and 12 months post-operatively
76054337|NCT05235347|Biological|Sotrovimab|500mg IV
76054338|NCT00864227|Biological|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~Fludarabine: 40 mg/m^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~Cyclophosphamide: 50 mg/kg IV on Day -6~Total body irradiation: 200 centigray (cGy) on Day -1"
76054339|NCT00864227|Biological|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:~Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm^3 for three consecutive measurements, each on different days."
75589804|NCT06046989|Behavioral|Building Emotion Awareness and Mental Health (BEAM)|BEAM is based on best-practices in telehealth and science-based program design principles aimed at promoting parental mental health and supportive parenting. The BEAM Program mobile application is designed and managed by MindSea. The weekly one-on-one check-ins with peer coaches (parents who previously participated in another research group-based mental health intervention) will use the secure videoconferencing platform Zoom (Healthcare license) and direct messaging through the BEAM app. Peer coaches will also engage with participants on the community peer support forum. Monthly drop-in group peer support sessions will be facilitated by peer coaches and/or mental health professionals on the BEAM research team. The BEAM program's content emphasizes self-compassion, effective communication practices, and building social support networks.
76054340|NCT05230511|Drug|Lactobacillus RhamnosusGG|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
76054341|NCT05230511|Drug|Saline bladder wash|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
76054342|NCT04810715|Other|Patients with Ankylosing Spondylitis|Observational study, not applicable
75439620|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
75439621|NCT01612026|Procedure|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
75439622|NCT01612052|Drug|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
75589805|NCT06046963|Drug|Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion|Sintilimab: 200 mg, intravenous infusion, d1, q3w; Nab-paclitaxel: 100 mg/m2 intraperitoneal infusion, d1, q3w; S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w; Oxaliplatin: 130 mg/m2, intravenous infusion, d1, q3w; The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects wil continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of informed Consent Form, or termination in the investigator's judgment.
75733234|NCT06080451|Other|Integrated Diabetes and Hypertension Primary Care Model - Providers|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~Training health workers on diabetes and hypertension treatment protocols~Team-based care and task sharing~Strengthening access to medications and diagnostics~Electronic medical record system and registry~Systems monitoring and feedback of key indicators~Health care providers will administer this intervention to patient participants and will report on their experience."
75733235|NCT06079697|Other|Electronic Health Record Review|Ancillary studies
75733236|NCT06079697|Other|Exercise Intervention|Receive prehabilitation exercise intervention
75733237|NCT06079697|Other|Medical Device Usage and Evaluation|Wear Fitbits
75733238|NCT06079697|Other|Survey Administration|Ancillary studies
76054343|NCT02102204|Drug|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
76054344|NCT02141204|Biological|HRV Liquid|Two doses administered orally according to a 0, 1-month schedule.
76054345|NCT02141204|Biological|HRV Lyophilized|Two doses administered orally according to a 0, 1-month schedule.
76054346|NCT02140970|Drug|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
76054347|NCT02140970|Drug|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
76054348|NCT04736342|Other|PALI questionaire|Survey comprised of a series of multiple choice questions
75589806|NCT06046963|Other|Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected|"Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected at diferent time points (if feasible, according to the samples taken in the standard practice):~at Baseline; After 1-2 cycles of treatment; at the time of the progression or recurrence, if applicable."
75589807|NCT06046924|Other|Fruits and vegetables (F+V)|Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups/day for each participant randomized to this group, depending on the type of F+Vs used, provided in weekly allotments. Participants will receive standard care for their medical concerns.
75589808|NCT06046924|Drug|NaHCO3 Tablets|Participants will receive 0.4 mEq/kg bw NaHCO3 /day, an amount designed to match the alkali provided by the added F+V. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in 2 divided doses for each participant randomized to this group. Participants will receive standard care for their medical concerns.
75589809|NCT06046924|Other|Usual Care|Participants will receive standard care for their medical concerns and no additional alkali (F+V or NaHCO3).
75589810|NCT06046911|Other|Tai Chi|In this study, Tai Chi has a total of 24 movements, which are connected step by step according to the principles of sports training.
75589811|NCT06046911|Other|Daily activity group|The daily activity group does not receive special intervention, and the subjects must maintain their daily habits and complete the 12-week test.
75589812|NCT06046885|Device|Neuromuscular electrical stimulation|"As regards the electrodes position, one proximal electrode on the gastrocnemius, which will be located below the popliteal fossa (at least 5cm below it) for a better position on the muscle belly; and one distal electrode, located at least 10 cm from the calcaneus.~This protocol will last 20 minutes per session. The placement of the electrodes is as mentioned above, and the parameters to be used will be the following: a stimulation frequency between 35 and 80Hz, a pulse width between 150 and 200 µs, the intensity will be established individually using an intensity that generate a visible contraction of maximum intensity without generating pain. The duration of the contraction will be of 6 seconds with 30 seconds of rest."
75589813|NCT06046872|Behavioral|Report-back training|Researchers participate in a report-back training program to evaluate potential impacts on knowledge and future behaviors with respect to sharing personal exposure results with study participants.
75589814|NCT06046859|Drug|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
75589815|NCT06046859|Drug|Placebo|When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
75589816|NCT06046846|Device|Asensei app|The study will compare the delivery of a prehabilitation programme via a mHealth application against standard preoperative care for patients undergoing surgery for oesophago-gastric cancer
75589817|NCT06046807|Other|Phone call|This follow-up will be conducted over the phone and by mail (some questionnaire may be sent by patient, as per his/her preference)
75733239|NCT06079229|Other|Phone call|The only follow-up visit provided for in the protocol was a telephone contact 3 to 30 months after the patient's surgery. The rest of the data required for the study were obtained from the patient's medical records, collected in the course of routine practice.
76054349|NCT02101112|Drug|Apixaban|
76054350|NCT02139644|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
75733240|NCT06078241|Drug|Intravenous lidocaine infusion|Intravenous lidocaine infusion
75733241|NCT06078241|Other|Erector spinae plane block (ESPB)|Unilateral erector spinae plane block
76054351|NCT02139644|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
76054352|NCT02139644|Drug|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
75589818|NCT06046781|Other|physical exercise|The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.
75589819|NCT06046768|Other|Psychological care|Psychological consultations (interviews, scales), participation in a discussion group for parents in Visio via Zoom, a speech therapy assessment and possible complementary multidisciplinary consultations)
75733242|NCT06078241|Other|Intravenous infusion of normal saline|Intravenous infusion of normal saline
75589820|NCT06046755|Other|Very low calorie ketogenic diet (VLCKD)|Weight loss therapies in patients with excess body weight based on a ketogenic diet
75589821|NCT06046755|Behavioral|Group educational intervention program (IGOBE)|Balanced hypocaloric diet plus structured groupal program of habits change and exercise
76054353|NCT02139644|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
76054354|NCT02139644|Drug|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
76054355|NCT02100644|Drug|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
75589822|NCT06046716|Behavioral|Mindful compassion based on behavioural change taxonomy experimental group|Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
75589823|NCT06046677|Other|No intervention|No intervention
75589824|NCT06046664|Diagnostic Test|ONCOTYPE DX DCIS test|"The Oncotype DX DCIS score, comprised of 12 of the 21 genes of the Oncotype DX Recurrence score, has been developed by Genomic Health Inc.~Two clinical utility studies have now been performed in USA, assessing the value of the Oncotype DX DCIS to clinical decision making (18,19) The first study by Alvarado et al. evaluated the influence of the test in 10 centres and in 115 patients (18). The DCIS score led to a change in the treatment recommendation in 36 patients (31.3%; 26 patients had a change to no radiation and 10 patients had a change to recommend radiation). The second study similarly showed change in recommendations following the Oncotype DX DCIS test in 26.4% of cases. It is unclear what the impact of the DCIS score test would be in the UK."
75589825|NCT06046638|Drug|Cyclopofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
75733243|NCT06078241|Other|ESPB with normal saline|Unilateral ESPB with normal saline
75733244|NCT06077656|Biological|IVT PCV-25 Formulation A|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant
75733245|NCT06077656|Biological|IVT PCV-25 Formulation B|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant
75733246|NCT06077656|Biological|IVT PCV-25 Formulation C|25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant
75733247|NCT06077656|Biological|PCV 20|20 valent pneumococcal conjugate vaccine
75439623|NCT01612065|Drug|Misoprostol|200 ug
75439624|NCT01612065|Drug|Misoprostol|Misoprostol vaginally, 400 ug
75439625|NCT01612078|Drug|Droxidopa|200mg/tab 2tablets, po, three times a week
75439626|NCT01612078|Drug|Placebo|200mg/tab, po, three times a week.
75439627|NCT01612091|Device|Monitoring Messenger|Monitoring Messenger prototype device
75439628|NCT01612091|Device|Traditional tools|Paper based records, screenshots of monitors and therapy devices
75439629|NCT01612104|Behavioral|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
75589826|NCT06046638|Drug|Propofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
75589827|NCT06046612|Drug|Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment|The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
75589828|NCT06046560|Drug|SGLT2 inhibitor, GLP-1 RA|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
75589829|NCT06046560|Behavioral|Education-First|For the first 2-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 2 months, be invited to participate in the remote clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for therapy.
76054356|NCT04782323|Drug|aQII-1|Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
76054357|NCT04782323|Drug|aQII-3 Investigational|Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
75589832|NCT06046508|Other|blood samples collection|patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention
75589833|NCT06046469|Diagnostic Test|CT with contrast|CT abdomen and pelvis with IV contrast
75589834|NCT06046469|Diagnostic Test|MRI pelvis|MRI pelvis with contrast
75589835|NCT06046469|Procedure|TURBT|transurethral resection of bladder tumor
76054358|NCT04782323|Drug|aQII-6 Investigational|Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
76054359|NCT04782323|Other|aQII-7 Investigational|Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
75439630|NCT01612130|Drug|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
75439631|NCT01612130|Drug|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
75439632|NCT01612143|Drug|setrobuvir|200 mg capsule formulation, single oral dose
75439633|NCT01612143|Drug|setrobuvir|200 mg tablet formulation, single oral dose
75733248|NCT06075849|Drug|PB101|"Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator."
75733249|NCT06074614|Diagnostic Test|Hypercapnic ventilatory response|Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.
75733250|NCT06074614|Diagnostic Test|Respiratory related evoked potential|The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.
75733251|NCT06074614|Diagnostic Test|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.
75733252|NCT06069934|Drug|Pridopidine|Pridopidine 45 mg once daily p.o. (or via feeding tube) over a 2-week up-titration period; followed by pridopidine 45 mg twice daily p.o. (or via feeding tube) for the remainder of the treatment period (through Week 104)
75733253|NCT06069180|Drug|Busulfan|Conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
75733254|NCT06069180|Drug|Flu/Cy/ATG or Cy/ATG|Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
75733255|NCT06067711|Device|resistance band|The program will consist of six exercises: triceps press, biceps curl, lat pull down, leg press, leg extension and sit-ups using resistance band.
75439634|NCT01612169|Behavioral|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
75589836|NCT06046404|Procedure|closed reduction|the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.
75589837|NCT06046404|Procedure|no closed reduction|no reduction will be performed
75589838|NCT06046391|Biological|LP-003 dose 1|Liquid in vial
75733256|NCT06067217|Drug|Tranexamic acid 250 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
75733257|NCT06067217|Drug|Progynova 1 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
75439635|NCT01612169|Behavioral|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
75439636|NCT01612182|Other|renal replacement therapy|renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
75589839|NCT06046391|Biological|LP-003 dose 2|Liquid in vial
75589840|NCT06046391|Biological|Placebo|Liquid in vial
75589841|NCT06046378|Other|Digital Story Group Prepared With Digital Audio File (Podcast)|"The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to. At the end of the subject on the date planned according to the academic calendar, the students will be interviewed again and a questionnaire will be applied to evaluate the effectiveness of the digital stories prepared with the post-test and digital audio file (podcast). The retention test will be applied 21 days after the last test application."
75733258|NCT06067009|Behavioral|ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease|ImPart-Multi is a psychoeducational, decision support training program, designed to impact Black chronic kidney disease patients with concurrent metabolic disease and their care partners' ability to 1. contemplate the decision needed, 2. request resources/support, and 3. make an informed patient-centered decision. Participants will participate in either communication training, social support effectiveness training, or a combination of both.
75733259|NCT06066723|Combination Product|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.
76054360|NCT04782323|Drug|aQII-9 Investigational|Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
75439637|NCT01612195|Procedure|Anal fistula plug|All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
75589842|NCT06046378|Other|Control Group|After the students in the control group are determined, a pre-test will be conducted before the subject receives education. The same knowledge test will be repeated as a post-test after the students receive the classical course education and after the end of the subject. Students will be given a retention test 21 days after the last test. After the retention test application, digital stories prepared with a digital audio file (podcast) will be sent to the students in the control group. In this way, all students participating in the study will have access to the training material used in addition.
75733260|NCT06062108|Other|Pain evaluation|All included patients will have an evaluation of their pain, if they have no pain, the assessment stop with one date (pain or no pain), if they have pain, an assessment is done (localization of the pain, pain intensity), if they have a pain duration over 3 months, a DN4 questionnaire, HAD scale, ISI scale and SF-1 questionnaire is evaluated.
75439638|NCT01612208|Device|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
75733261|NCT06062043|Behavioral|Brief ACT with CPP Education Treatment|The Brief ACT with CPP Education treatment provides women veterans with new ways of responding to difficult thoughts and emotions related to pain while also encouraging them to engage in meaningful life activities. The CPP educational component includes information about pathology, risk factors, health outcomes, and treatment that are specific to women's biological and reproductive functioning. Treatment content has been further tailored to reflect the cultural experiences of women veterans (including discussions on the interplay between military culture, perceived social norms, and gender role expectations).
75589843|NCT06046365|Diagnostic Test|lymphoscintigraphy|lymphoscintigraphy
75733262|NCT06061523|Drug|Sotorasib|Oral Tablet
75733263|NCT06060392|Drug|Semaglutide Pill|Patient will receive oral semaglutide
75733264|NCT06059872|Other|High Intensity Interval Training (HIIT)|HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
76054361|NCT04782323|Drug|aQII-10 Investigational|Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
75589844|NCT06046365|Diagnostic Test|circumference measurement|circumference measurement
75589845|NCT06046365|Diagnostic Test|sonography|B-mode sono and elastography
75589846|NCT06046365|Diagnostic Test|DXA body composition analysis|DXA body composition analysis
75589847|NCT06046352|Procedure|Electrophysiological study (and ablation when appropriate)|Electrophysiological study (and ablation when appropriate)
75589848|NCT06046339|Other|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
75589849|NCT06046326|Behavioral|virtual community of practice|The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
75589850|NCT06046313|Drug|Decitabine for Injection|6mg/m2, ivgtt qd d1-10
75589851|NCT06046313|Drug|VENCLYXTO|100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration
75589852|NCT06046222|Drug|NS-229|Experimental
75589853|NCT06046222|Drug|Placebo|Placebo comparator
75589854|NCT06046196|Drug|Sarpogrelate SR|Sarpogrelate SR 300mg, once a daily, for 24weeks
76054362|NCT04782323|Drug|aQII-11 Investigational|Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
76054363|NCT04782323|Drug|QII Active Comparator|Biological/Vaccine: Investigational QII Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
76054364|NCT04239521|Other|Exposure of interest (studies 2 & 3).|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
75733265|NCT06057597|Procedure|Laparoscopic OAGB|It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
76054365|NCT04219007|Drug|Vosoritide|After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
75589855|NCT06046196|Drug|Sarpogrelate|Sarpogrelate 100mg, 3 times a day, for 24weeks
75589856|NCT06046183|Behavioral|Process group|The medical student process group serves as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
75589857|NCT06046157|Other|Breast milk-scented PIOMI|"During PIOMI, the scent of breast milk will be provided through cotton soaked in breast milk placed 1.5 cm away from the babies.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
75733266|NCT06057597|Procedure|Laparoscopic RYGB|A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
75733267|NCT06056804|Drug|capecitabine|825-1000mg/m2,po,bid
75733268|NCT06056804|Drug|tislelizumab|200mg,iv.gtt,q3w
76054366|NCT04168073|Other|High-sodium diet 300 mmol sodium/day|Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
76054367|NCT04168073|Other|Low-sodium diet 10 mmol sodium/day|Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
76054368|NCT02074982|Drug|AIN457 300 mg|
76054369|NCT02074982|Drug|ustekinumab 45/90 mg|
76054370|NCT02074982|Drug|placebo secukinumab|Placebo
75439639|NCT01612208|Device|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
75439640|NCT01612234|Dietary Supplement|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
75589858|NCT06046157|Other|Breast milk-tasting PIOMI|"The finger used during PIOMI application will be performed by dipping it into breast milk. This will ensure that babies taste breast milk.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
75589859|NCT06046144|Diagnostic Test|Fluorescence-Advanced videodermatoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
75589860|NCT06046144|Diagnostic Test|Reflectance confocal microscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
75883169|NCT05811923|Other|Mood State|Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire to evaluate perceptual responses. The Profile of Mood States (POMS) is a 65-item validated scale that uses a 5-point Likert scale with each individual area being scored and summed into profiles for tension, anger, vigor, fatigue, depression, and confusion. Finally, a total mood disturbance score will be calculated by summing all categories and subtracting the vigor score.
75733269|NCT06056804|Drug|thymalfasin|4.8mg,sc,biw
76054371|NCT04150913|Drug|Anakinra|Subcutaneous, dosage per protocol. Day 0 through Day 6.
76054372|NCT04150913|Drug|Axicabtagene Ciloleucel|Once, intravenous infusion, dosage per protocol
75733270|NCT06056804|Radiation|long-term radiotherapy|50 Gy/25 f, 2 Gy/day
75439641|NCT01612247|Drug|Cyclophosphamide and Methotrexate and Aspirin|Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
75439642|NCT01612260|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
75733271|NCT06050889|Other|Positive Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention known to be effective for some people with shoulder pain. We expect this will make you less sensitive to the pressure applied to your shoulder and thigh and you will require more pressure than what was previously necessary to experience pain."
75733272|NCT06050889|Other|Negative Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention which is not effective for some people with shoulder pain. We expect this will make you more sensitive to the pressure applied to your shoulder and thigh and you will require less pressure than what was previously necessary to experience pain."
75733273|NCT06050265|Device|DEXCOM Continuous Glucose Monitor (CGM)|Dexcom CGMs are placed every 10 days and provide a continuous assessment of blood glucose.
75733274|NCT06049732|Device|PainChek®|Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profession caregivers assess pain in people who cannot self-report their pain
75883170|NCT05811923|Other|Visual Analog Scales|"Participants will complete electronic versions of the visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by Lowest Possible and Highest Possible to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. The validity and reliability of VAS to assess fatigue and energy have been previously established (Lee, Hicks, et al. 1991) and our methods have been published elsewhere (Ziegenfuss, Habowski, et al. 2017, Ziegenfuss, Lopez, et al. 2017, Ziegenfuss, Kedia, et al. 2018, Zabriskie, Blumkaitis, et al. 2020)."
76054373|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
76054374|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
76054375|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
76054376|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops
75439643|NCT01612260|Drug|placebo Capsule|4 granules t.i.d. po for 12 weeks
76054377|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray|Single intranasal dose on Day 1, by intranasal spray
75439644|NCT01612273|Drug|Triflusal|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
75439645|NCT01612273|Drug|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
75439646|NCT01612286|Drug|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle *4cycles
76054378|NCT02074514|Drug|Sofosbuvir|400 mg tablet administered orally once daily
75589861|NCT06046144|Diagnostic Test|Super-high magnification dermoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
75589862|NCT06046131|Other|Standard care|"Extra blood collection for dosages Urine collection for the dosage of non-persistent pollutants, isolation of extracellular vesicles released in urine, analysis of the microbiome, metagenomics to obtain a complete description of the bacterial functions represented as well as other microorganisms present, metabolome profiling and identification and/or assays of any other biological compound of interest strictly related to the specific objectives of the research.~Saliva collection for the extraction of the constitutional DNA. An interview using a structured questionnaire A quality of live auto-questionnaire"
75589863|NCT06046118|Device|Yellow and red light emitting diode photobiomodulation (Eye Light, Espansione Group, Bologna, Italy)|"Each session consists of:~1st phase: 300 seconds of continuous Yellow light (eyes closed) + 60 seconds of pulsed Yellow light (eyes opened)~2nd phase: 300 seconds of continuous Red light(eyes closed) + 60 seconds of pulsed Red light (eyes opened).~Cycle 1: 8 sessions (two PBM per week for 4 weeks); Cycle 2: 6 sessions (two PBM per week for 3 weeks)."
75589864|NCT06046118|Device|Sham Mask|Low light emission mask (Sham Mask, Espansione group, Bologna, Italy)
75439647|NCT01612299|Drug|Zortress® /Everolimus|"Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml >6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 &2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml >6 mo post transplant 4-7 ng/ml."
75589865|NCT06046105|Drug|Administering intraperitoneal bupivacaine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
75589866|NCT06046105|Drug|Administering intraperitoneal bupivacaine plus Dexmedetomidine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Dexmedetomidine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
76054379|NCT02074514|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76054380|NCT04191161|Device|Wearing the rigid brace|Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
76054381|NCT02099708|Drug|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
76054382|NCT02073656|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
76054383|NCT02073656|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76054384|NCT02242643|Biological|FluLaval™ Quadrivalent|1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
76054385|NCT02242643|Biological|Fluzone® Quadrivalent|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
76054386|NCT02097290|Device|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
76054387|NCT04061213|Diagnostic Test|Tc-99m-DPD scintigraphy|Myocardial scintigraphy
76054388|NCT02072174|Drug|Anaferon for Children|Anaferon for children: For oral use.
76054389|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
75589867|NCT06046105|Drug|Administering intraperitoneal bupivacaine plus Ibuprofen for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Ibuprofen injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
75439648|NCT01612312|Procedure|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
75883171|NCT05811897|Behavioral|Self-Managed Online Treatment|"Self-help online cognitive-behavioural therapy focusing on post-traumatic stress, sleep and mood. The content is divided into three modules :~Coping with my trauma: psychoeducation about PTSD, cognitive restructuring prolonged exposure to avoided situations and memories (14 sessions)~Sleeping better: psychoeducation about, sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education), Imagery Rehearsal Therapy (10 sessions)~Improving my mood: psychoeducation about depression, behavioural activation; relaxation and mindfulness exercises; problem-solving strategies (6 sessions)~A small portion of material is unlocked each week, and access to one module will be accessible after the completion of a previous one. Access to the online material will be unlimited in time. Participants complete self-report questionnaires after each module, the platform then provides feedback and suggests corresponding modules."
75883172|NCT05811897|Behavioral|Therapist-Assisted Online Treatment|Same online intervention. Supervised graduate psychology students will provide brief regular weekly contacts for up to 30 weeks by video chat or phone, according to the participant's preference.
76054390|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
76054391|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
76054392|NCT02209181|Drug|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
75589868|NCT06046066|Drug|NM6603|NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
75733275|NCT06049238|Other|Maitland Mobilization|"Hot Pack for 10 mints~Active and active-assisted exercises (10 reps x 3 sets) for the~Elbow flexion and extension~Wrist flexion and extension~Forearm supination and pronation"
75733276|NCT06049238|Other|Post facilitation stretch|"Hot Pack for 10 mints~Active and active-assisted exercises (10 reps x 3 sets) for the~Elbow flexion and extension~Wrist flexion and extension~Forearm supination and pronation"
75439649|NCT01612312|Procedure|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
75439650|NCT01612325|Device|Holmium-166 polylactic microspheres|Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
75439651|NCT01612338|Behavioral|Targeted|Targeted letter and booklet
75733277|NCT06047756|Other|Hippotherapy|Patient will perform different movement of the trunk while sitting on a horse.
75733278|NCT06047756|Other|Swiss Ball therapy|Patient will perform movements of trunk on swiss ball
75733279|NCT06047223|Diagnostic Test|Magnetic resonanace imaging|Magnetic resonance imaging for measurement of diffustion tensor imaging
75733280|NCT06046053|Drug|Placebo Vaginal Film with Square Corners|"2 x 2 placebo vaginal film with square corners"
75733281|NCT06046053|Drug|Placebo Vaginal Film with Rounded Corners|"2 x 2 placebo vaginal film with rounded corners"
75733282|NCT06045273|Behavioral|Elders' Resilience Curriculum|The Elders' Resilience Curriculum (ERC) is a culturally grounded, school-based program taught by White Mountain Apache Tribe (WMAT) Elders to youth. It is designed to prevent suicide ideation and behaviors for American Indian youth
75439652|NCT01612338|Behavioral|Enhanced Tailored|Tailored letter and booklet, enhanced family communication and support brochure
75589869|NCT06046027|Device|Accupressure band|The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery
75589870|NCT06046014|Other|BI Focused writing|BI Focused writing program
75589871|NCT06046014|Other|Control|Attention Control Writing
75589872|NCT06045975|Drug|Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting|"Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by IRE procedure at Day 30+/-7 days~11 monthly Durvalumab 1500 mg infusions."
75589873|NCT06045936|Drug|Lidocaine|2 teaspoons of 2% lidocaine injection
75589874|NCT06045936|Drug|Placebo|Saline injection
75589875|NCT06045897|Device|EEG 64 channels|64-channel EEG in wake and resting conditions for 1h30, with oculogram, electromyogram and electromyogram and electrocardiogram. Five minutes of eyes closed will be used for microstate analysis. 1h30 will be used for the sensorimotor task.
75589876|NCT06045897|Device|Polysomnography 19 electrodes|Overnight polysomnography with 19 EEG channels and ventilatory polygraphy.
75589877|NCT06045897|Behavioral|Light hypnosis|Healthy controls will undergo a 5 min light hypnosis exercise that will be focused on proprioception.
75589878|NCT06045897|Biological|Biological sampling|Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.
76054393|NCT02208089|Procedure|Transepithelial Photorefractive Keratectomy (TransPRK)|Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
75883173|NCT05811884|Device|Rehabilitation|"The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements."
75883174|NCT05811832|Other|Evaluation|Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
76054394|NCT02208089|Procedure|Corneal Collagen Cross-Linking (CXL)|"Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)"
76054395|NCT02242487|Drug|CVT-301|
75439653|NCT01612364|Procedure|thoracic sympathetic block|Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
75439654|NCT01612377|Drug|Prednisolone-Dipyridamole|Oral, QD
75439655|NCT01612377|Drug|Prednisone|Oral QD Prednisone 5mg
75439656|NCT01612377|Drug|prednisone|Oral, QD prednisone 7.5mg
75439657|NCT01612403|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
75589879|NCT06045897|Behavioral|Virtual reality|Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.
75589880|NCT06045897|Device|Voice recording|A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.
75589881|NCT06045871|Procedure|Corticotomy followed by compression osteogenesis|Surgical corticotomy supra apical in anterior maxilla then application of the compression osteogenesis concept via traction on miniscrews implanted above the corticotomy line
75589882|NCT06045858|Drug|Anticoagulation Agents|anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
75589883|NCT06045832|Device|MAXPOWER Biological Antibacterial Liquid|MAXPOWER Biological Antibacterial Liquid is a mouthwash product self-developed in China, which contains betaine, antibacterial peptide and other antimicrobial substances, which have been proved by experiments to have a good biological safety and at the same time have a killing effect on bacteria. Mouthwash belongs to the category of medical devices, not drugs.
75589884|NCT06045832|Device|Water|Water
75589885|NCT06045780|Other|nothing|disease
75733283|NCT06042920|Drug|Deucravacitinib|Specified dose on specified days
75733284|NCT06042920|Drug|Placebo|Specified dose on specified days
75733285|NCT06042647|Drug|0.01% Halobetasol|Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.
75733286|NCT06042647|Drug|0.045% Tazarotene|Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.
75733287|NCT06042647|Drug|0.05% Clobetasol Propionate|Drug to be applied to designated psoriatic plaque at bedtime.
76054396|NCT02241785|Drug|natalizumab|Administered as specified in the treatment arm
76054397|NCT02241551|Drug|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
76054398|NCT02241551|Drug|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
75733288|NCT06042062|Device|Novel spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a United Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either a Cellbrick spacer or an articulating spacer will be placed. As for the United Cellbrick spacer, antibiotic loaded bone cement (ALBC) will be molded into the designed holes (fenestrations). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
75883175|NCT05811819|Device|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
75883176|NCT05811806|Device|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
75883177|NCT05811793|Drug|Tislelizumab and Bevacizumab|Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
75883178|NCT05811767|Other|Health Examination|The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
75883179|NCT05811754|Other|Data collection|"This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum."
76054399|NCT04769687|Biological|probiotic Vivomixx®|Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
76054400|NCT04769687|Biological|prebiotic Orafti®Synergy1|Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
76054401|NCT04769687|Other|Placebo|Placebo
76054402|NCT02207621|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
76054403|NCT02207621|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
76054404|NCT02207621|Other|Placebo|1 drop QD, AM, OU
76054405|NCT02207621|Drug|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
76054406|NCT02240693|Drug|BI 409306|
76054407|NCT02240693|Drug|Placebo|
76054408|NCT02240693|Drug|BI 409306|
75439658|NCT01612416|Device|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
76054409|NCT02240693|Drug|Placebo|
76054410|NCT02240693|Drug|Placebo|
76054411|NCT02240693|Drug|BI 409306|
75439659|NCT01612429|Dietary Supplement|Amino acid supplementation|Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)
75589886|NCT06045728|Other|Pilates exercises|Pilates is a group of low impact muscle exercises that strengthen abdominal muscles, back, hips and pelvic floor muscles. the exercise consists of 10 min warm up, 40 min exercise and 10 min cooling down. the exercises that will be included: spine twist, double leg stretch, double leg circles, side leg circle, curl up, shoulder bridges and pelvic curl.
75589887|NCT06045728|Behavioral|Mediterranean diet|it is a type of diet used for obesity management based on high vegetable intake, olive oil as a source of fat, the consumption of grains, legumes, and nuts with high amounts of pulp, low-medium consumption of fish, low consumption of red meat.
75589888|NCT06045715|Other|follow-up with different time intervals|After radical surgery, patients are followed up with different time intervals
75589889|NCT06045624|Drug|OR-101 (Single ascending dose)|SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
75589890|NCT06045624|Drug|OR-101 (Food effect)|Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
76054412|NCT02240693|Drug|BI 409306|
76054413|NCT02240693|Drug|Placebo|
76054414|NCT02240693|Drug|Placebo|
76054415|NCT02239679|Drug|Aminolevulinic Acid|20% ALA applied to face for one hour prior to 10 J/cm2 blue light
76054416|NCT02239679|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
76054417|NCT02239679|Device|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
75589891|NCT06045624|Drug|OR-101 (Multiple ascending dose)|MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
75733289|NCT06042062|Device|Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an United Cellbrick spacer or an Articulating Spacer will be placed. The Articulating Spacer will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic loaded bone cement (ALBC). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
75883180|NCT05811715|Other|whole body stretching excercise|For the WBS group, each 30 minutes exercise class was run by a one trained physiotherapist to serve a maximum of 10 participants (10 x 3 = 30 participants) working in the hospital. Participants invited to attend the exercise class 3 times a week for 6 weeks in their hospital during lunch-break. During each session, participants asked to perform WBS exercise (Franco et al., 2008).
75883181|NCT05811715|Other|educational program|Participants received an education program which includes ergonomic principles, WRMSDs and their risk factors, as well as manual handling techniques(Bolbol et al., 2017).
76054418|NCT02239679|Procedure|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
75439660|NCT01612442|Behavioral|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
75733290|NCT06042049|Drug|Nirsevimab|Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is <5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is <5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.
75439661|NCT01612442|Behavioral|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
76054419|NCT02072096|Drug|Glimepiride|Administered orally
76054420|NCT02072096|Drug|Metformin|Administered orally
75733291|NCT06042036|Other|Spontaneous mode of mechanical ventilation|any mode of mechanical ventilation classified as spontaneous or proportional, mainly pressure support ventilation, but also CPAP, APRV, NAVA, PAV+
75439662|NCT01612455|Behavioral|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
75589892|NCT06045624|Drug|Placebo|Participants will receive matching placebo across Part A and C of the study
75733292|NCT06041009|Diagnostic Test|Pancreatic elastase-1 in blood serum|Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.
75733293|NCT06037889|Drug|Tirofiban|Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.
75733294|NCT06037889|Drug|Aspirin tablet|Aspirin. Oral administration.
75733295|NCT06037889|Drug|Clopidogrel tablet|Clopidogrel. Oral administration.
75589893|NCT06045585|Biological|infusion of JY231 injection|Infusion of JY231 Injection by dose of 1-10 x10^6 TU/kg、 1-5 x10^7 TU/kg、 5-10 x10^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.
76054421|NCT02072096|Drug|Pioglitazone|Administered orally
76054422|NCT02072096|Drug|Acarbose|Administered orally
76054423|NCT02072096|Drug|Linagliptin|Administered orally
76054424|NCT02072096|Drug|Sitagliptin|Administered orally
76054425|NCT02072096|Drug|Liraglutide|Administered subcutaneously (SC)
76054426|NCT02072096|Drug|Insulin Glargine|Administered SC
76054427|NCT02072096|Drug|Exenatide once weekly (QW)|Administered SC
76054428|NCT02072096|Drug|Exenatide twice daily (BID)|Administered SC
76054429|NCT02071706|Device|PET/MRI system|Enrolled subject undergoes PET/MR scan
75589894|NCT06045572|Device|VTM examination and breast biopsy|VTM examination performed by a radiologist, at the MART (Metabolic Activity in Real-Time) station, using the SaMD Mart 2.0, according to the inspection protocol to identify breast alterations and/or suspicious images to be biopsied for validation by genetic tests and histology / immunohistochemistry.
75733296|NCT06034340|Device|LET Gel after STAR Particle Application (Right Arm)|STAR particles are made of titanium dioxide, a widely used and safe ceramic material found in sunscreens, cosmetics, and paint. The particles will vary in concentration and length in order to find the optimal concentration and length. Topical lidocaine (0.5 grams of Lidocaine in LET gel) will be applied immediately after applying a STAR particle preparation to the volar surface of the mid-forearm at two locations (right antecubital fossa and wrist). Immediately after application of the STAR particles, the topical lidocaine (LET gel) will be applied. Immediately after the topical lidocaine (LET gel) is applied, the pain will be assessed every minute using the Pin-Prick Pain test. The time that the subject reports no pain (complete local anesthesia) will be recorded as the time to achieve anesthesia for the topical lidocaine after STAR particle application (TSP) at both sites.
75589895|NCT06045546|Procedure|5-5-5-8 technique|the new technique of 5-5-5-8 for laparoscopic cholecystectomy
76054430|NCT05107700|Procedure|Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
75589896|NCT06045546|Procedure|10-10-10-5 technique|the standard technique of 10-10-10-5 for laparoscopic cholecystectomy
75589897|NCT06045520|Behavioral|Information-Motivation-Behavioral Skills Model|1.-2.Meeting:Regarding the information component of the IMB model; Answers given by the adolescents to the epilepsy knowledge test, the topics on which the adolescent wants to get information will be agreed with the adolescent and an education training will be created.3.,4.,5.-6. Meeting:Personal motivation, which is the first step of the motivation component; A meeting will be held regarding the obstacles to the disease, attitudes and behaviors towards the disease. In order to strengthen social support systems, a one-session seizure management training will be planned with a person chosen by the adolescent from his parent or friend group.7-8. Meeting:Seizure self-efficacy and treatment compliance will be evaluated in the behavioral skills component. During training, achievable goals will be set to ask the adolescent to provide personal feedback, ask open-ended questions, engage in reflective listening, and increase personal and social motivation to comply with medical recommendations
75589898|NCT06045429|Drug|Oroxid®|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash."
75883182|NCT05811689|Diagnostic Test|sm tbs group|"After collecting anthropometric data, information on environmental factors and lifestyle (smoking, alcohol intake, physical activity, sun exposure, vitamin D supplementation, fish consumption) will be acquired through a questionnaire.~The genetic and environmental aspects related to multiple sclerosis will also be studied. Disability status will be assessed through the Kurtzke Extended Disability Status Scale (EDSS). [10] All recruited patients will be administered the questionnaire (Multiple Sclerosis Quality of Life-54 (MSQOL-54) composed of 14 scales and 54 items. The scales investigate physical functions, limitations with respect to physical and emotional role, pain, emotional well-being, degree of energy, perceptions of one's health, social, cognitive and sexual functioning, distress, changes in health, satisfaction with sexual functioning and quality of life in general."
76054431|NCT05107700|Procedure|Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
76054432|NCT01631825|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
75439663|NCT01612468|Drug|Liraglutide|1.8 mg/day subcutaneous
75439664|NCT01612468|Drug|Placebo|1.8 mg/day subcutaneous
75439665|NCT01612481|Procedure|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
75439666|NCT01612481|Procedure|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
75439667|NCT01612507|Drug|600 mg Ceftaroline fosamil|1 h infusion
75439668|NCT01612507|Drug|Placebo|1 h infusion
75439669|NCT01612507|Drug|600 mg Ceftaroline fosamil|2 h infusion
75439670|NCT01612507|Drug|Placebo|2 h infusion
75733297|NCT06034340|Other|LET Gel Application without STAR Particle Application (Left Arm)|Topical lidocaine (0.5 grams of Lidocaine in LET gel) will be applied immediately after applying aloe gel (CONTROL) to the volar surface of the mid-forearm at two locations (right antecubital fossa and right wrist). Immediately after application of the aloe gel, the topical lidocaine (LET gel) will be applied. Immediately after the topical lidocaine (LET gel) is applied, the pain will be assessed by the investigator every minute using the Pin-Prick Pain test. The time that the subject reports no pain (complete local anesthesia) will be recorded as the time to achieve anesthesia for the topical lidocaine without STAR particle application (TLET) at both sites.
75733298|NCT06033781|Behavioral|Cognitive Behavioral Therapy for Nightmares in Children|The Cognitive Behavioral Therapy for Nightmares in Children (CBT-NC) is a brief, five-session manualized therapy designed to treat children ages 6-17. The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
75733299|NCT06023368|Drug|Num Vapocoolant Spray|Spray applied around port prior to access
75439671|NCT01612520|Behavioral|telecoaching|"The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.~The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).~The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy."
75733300|NCT06023368|Drug|EMLA Cream|cream applied around the port prior to access
75883183|NCT05811650|Behavioral|Oral Health Counseling and promotion|The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
75589899|NCT06045429|Drug|Chlorhexidine mouthwash|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine"
75883184|NCT05811637|Other|Pilates Exercise|The program will be applied with the Pilates exercises every week. All patients were evaluated before and after the treatment (6 weeks).
75883185|NCT05811637|Other|Supervised Rehabilitation|The program will be applied with the progression of the supervised rehabilitation in the 4th week
75883186|NCT05811611|Behavioral|WeChat Mini Program plus tailored online health promotion videos|Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
75883187|NCT05811611|Behavioral|WeChat Mini Program Only|Participants only have access to a WeChat Mini Program.
75439672|NCT01612598|Other|counseling intervention|Undergo PCI
75589900|NCT06045403|Behavioral|The electrocardiography(ECG) and blood pressure monitoring|The electrocardiography (ECG) and blood pressure indicators will be monitored every day during the study period in the monitoring group.
75589901|NCT06045390|Other|App|"App features (App will be used during the office visit):~Pictorial representation of drops (color-coded) and schedule.~Quiz to assess understanding of the regimen.~Narrated instructions (language-concordant) on how and when (frequency and eye laterality) to take each drop.~Graphical print-out of the regimen."
75439673|NCT01612598|Procedure|quality-of-life assessment|Ancillary studies
75589902|NCT06045377|Dietary Supplement|Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia|A prospective single center cohort study
75589903|NCT06045364|Drug|Glycopyrrolate|During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
75589904|NCT06045364|Drug|Anisodamine|During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
75439674|NCT01612598|Other|questionnaire administration|Ancillary studies
75439675|NCT01612598|Other|educational intervention|Undergo PCI
75733301|NCT06020703|Behavioral|Fermented Food Diet|Subjects will incorporate 1 serving of fermented food a day and increase to 6 more each day as tolerated for 4 weeks. After the initial 4 weeks, subjects will eat 6 or more servings of fermented foods each day for 8 weeks.
75733302|NCT06019546|Other|PEQUOD|During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
75733303|NCT06018974|Device|Yetitablet gaming|Playing digital games like bowling, memory games, coordination games ect. with the Yetitablet.
75733304|NCT06018428|Drug|ADX-914|Subcutaneous administration of ADX-914
75733305|NCT06018428|Drug|Placebo|Subcutaneous administration of placebo
75733306|NCT06016686|Other|VNS stimulation and intraneural recordings|A minimum of three stimulation frequencies (1, 10 and 30 Hz), each up to 60s in duration, will be delivered via the VNS device. Intraneural recordings proximal or distal to the VNS electrodes during delivery of VNS will be performed. Approximately two to five fascicles will be explored in each nerve.
75733307|NCT06016686|Other|Record multi-unit activity from intraneural sites|Perform a more detailed vagal nerve mapping study by recording from single nerve fibers, including those fibers supplying the heart, lungs, airways and other end-organs. The investigators shall perform functional mapping of the left and right vagus nerves, such as those with cardiac-related and/or respiratory-related neural activity. The research team will also record activity from other nearby fibers to map the differences in neurological behavior in fascicles that control the heart, lungs, airways and other systems.
75439676|NCT01612637|Behavioral|Pelvic floor muscle training and lifestyle advice|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
75589905|NCT06045338|Behavioral|Mind Body Intervention #1|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
76054433|NCT02071082|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
76054434|NCT02123108|Drug|Basiliximab|Peri-operative 40 mg IV dose within 4 hours of OLT Postoperative 20mg IV dose Day 4
75589906|NCT06045325|Diagnostic Test|Orbscan II|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
76054435|NCT02123108|Drug|Tacrolimus|Day #7 post-transplant or when serum creatinine (SCr) < 1.8 mg/dl 6 months to 1 year: 0.03-0.1 mg.kg q12h po to maintain whole blood trough concentration of 3-5ng/mL
75589907|NCT06045325|Diagnostic Test|IOL Master 700|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
75589908|NCT06045325|Diagnostic Test|IOL Master 500|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
75589909|NCT06045325|Diagnostic Test|Atlas 9000|Diagnostic assessment to measure white-to-white.
76054436|NCT02123108|Drug|Tacrolimus|Day #1 post-transplant to 6 months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL + 6 months to 1 year: maintain whole blood trough concentration of 5-8ng/mL
75733311|NCT06010953|Drug|SS109|on-demand treatment with SS109 at the time of a new hemorrhage event
75589910|NCT06045325|Diagnostic Test|Lenstar 900|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
75589911|NCT06045325|Diagnostic Test|Pentacam|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
75589912|NCT06045325|Diagnostic Test|iTrace|Diagnostic assessment to measure white-to-white and corneal thickness.
75589913|NCT06045325|Diagnostic Test|Argos|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
75733312|NCT06010160|Behavioral|Game Changers for Cervical Cancer Prevention|The peer advocacy training sessions focus on reduction of internalized stigma, disclosure decision making, education on cervical cancer facts and myths, and building skills for cervical cancer prevention advocacy.
76054437|NCT02123108|Drug|Mycophenolic Acid|Enteric coated mycophenolic acid 360-720 mg po bid
76054438|NCT02121392|Device|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
76054439|NCT02121392|Device|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
75589914|NCT06045325|Diagnostic Test|Manual caliper measurement|Manual diagnostic assessment to measure white-to-white.
75733313|NCT06008028|Drug|BR1015|One tablet administered alone
75589915|NCT06045312|Other|education|Comparison of the effectiveness of peer or adult education to adolescents with asthma
75733314|NCT06008028|Drug|BR1015-1|One tablet administered alone
75733315|NCT06008028|Drug|BR1015-2|One tablet administered alone
75733316|NCT06007911|Drug|Navitoclax Dose Level -1|25 mg by mouth on days 1-7.
75733317|NCT06007911|Drug|Navitoclax Dose Level 0|50 mg by mouth on days 1-10.
75883188|NCT05811572|Device|measurement of pelvic floor muscle with perinometer|Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
76054440|NCT02121392|Drug|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
75883189|NCT05811559|Other|No intervention|No intervention
76054441|NCT02097056|Drug|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
76054442|NCT02121002|Drug|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
76054443|NCT02121002|Drug|Voltaren Topical Gel, 1%|Opaque, white gel
76054444|NCT02121002|Drug|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
76054445|NCT02096900|Drug|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
75439677|NCT01612637|Behavioral|Lifestyle advice|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
75439678|NCT01612650|Device|tomosynthesis|2 incidences 3D numeric mammography
75439679|NCT01612650|Device|2D mammography|2 incidences 2D analogic mammography
75589916|NCT06045286|Radiation|Radiation: High- and Low-dose radiotherapy|High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.
76054446|NCT02096900|Drug|Midazolam|
76054447|NCT02120924|Drug|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
76054448|NCT02120924|Drug|Vehicle|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
75439680|NCT01612689|Device|Accelerometer Device|A sensor platform that enables physiological monitoring in routine, home or office environments.
75439681|NCT01612715|Other|Segmental Allergen Challenge|segmental allergen challenge
75589917|NCT06045286|Drug|PD-1 Inhibitors|Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
75589918|NCT06045260|Drug|177Lu-DOTATOC|Administration of 4 cycles of therapy with a 2 months interval between each cycle of therapy
75589919|NCT06045208|Other|Foot exercise|This group will engage in an 8-week foot intrinsic strengthening training
75589920|NCT06045208|Other|Lower Extremity Exercise|This group will engage in an 8-week lower extremity strengthening training
75733318|NCT06007911|Drug|Navitoclax Dose Level 1|75 mg by mouth on days 1-10.
75733319|NCT06007911|Drug|Navitoclax Dose Level 2|100 mg by mouth on days 1-10.
75733320|NCT06007911|Drug|Venetoclax Dose Level -1|400 mg by mouth on days 1-7.
75733321|NCT06007911|Drug|Venetoclax Dose Levels 0 to 2|400 mg by mouth on days 1-14.
75733322|NCT06007911|Drug|Cladribine|5 mg/m^2 intravenously days 1-5.
75733323|NCT06007911|Drug|Cytarabine (Cladribine Low Dose Cytarabine Backbone)|20 mg/m^2 subcutaneous days 1-10.
75733324|NCT06007911|Drug|Cytarabine (CLAG-M Backbone)|2 g/m^2 intravenously days 1-5.
75733325|NCT06007911|Drug|Mitoxantrone|10 mg/m^2 intravenously days 1-3.
75733326|NCT06007911|Drug|Granulocyte Colony-Stimulating Factor|300 mcg subcutaneously days 1-5.
75733327|NCT06007235|Device|CACIPLIQ20|CACIPLIQ20 contains RGTA heparan sulphate mimetics
75733328|NCT06007235|Drug|Placebo|Saline solution in identical spray bottles
75733329|NCT06005441|Drug|CBL-514 injection|Provided as a ready for use injectable CBL-514 solution
75733330|NCT06005441|Drug|CBL-A1 Injection|Provided as a ready for use injectable CBL-A1 solution
75733331|NCT06005441|Drug|CBL-A2 Injection|Provided as a ready for use injectable CBL-A2 solution
75733332|NCT06005441|Drug|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
75733333|NCT06004570|Dietary Supplement|Complex product|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica, rutin, vitamin B6, vitamin B12, folic acid Single oral dose - 2 capsules
75883190|NCT05811546|Diagnostic Test|Immunohistochemical staining for DNMT1 and EZH2|Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.
76054449|NCT02120924|Drug|Finacea|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
76054450|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Oppanol
76054451|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
76054452|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
76054453|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
76054454|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Vistanex
76054455|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
76054456|NCT02120456|Drug|LEO 43204|
76054457|NCT02120456|Drug|Placebo|
76054458|NCT02120300|Drug|LDV/SOF|90/400 mg FDC tablet administered orally
76054459|NCT02120300|Drug|SOF|400 mg tablet administered orally once daily
75883191|NCT05811507|Diagnostic Test|serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate|Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
75439682|NCT01612728|Other|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine & Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
75883192|NCT05811507|Diagnostic Test|The Childhood Autism Rating Scale (CARS)|It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
75883193|NCT05811507|Diagnostic Test|DSM-5 Diagnostic Criteria for ASD|Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
75883194|NCT05811507|Diagnostic Test|Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):|"IQ Score ranges for the Stanford-Binet:~Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+"
75883195|NCT05811494|Device|Lexo|Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.
75439683|NCT01612728|Drug|Women with Arthralgia|
75439684|NCT01612741|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
75439685|NCT01612754|Behavioral|Noise reduction work place rules|"Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones."
75439686|NCT01612754|Behavioral|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
75733334|NCT06004570|Dietary Supplement|Polyphenol-rich extracts|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica Single oral dose - 2 capsules
75733335|NCT06004570|Other|Placebo|Single oral dose - 2 capsules
75733336|NCT06003790|Device|MR-001|Use of device 3 times per week for 8 weeks - for a total of 24 sessions.
75733337|NCT06002178|Diagnostic Test|Neck ultrasound|A neck ultrasound will be performed in order to map superficial arteries and veins of the neck
75883196|NCT05811494|Device|Lokomat|Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.
75883197|NCT05811494|Device|C-Mill|C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.
75883198|NCT05811494|Device|Body-weight support treadmill|Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
75883199|NCT05811481|Procedure|TACE|Transcatheter Arterial Chemoembolization
75883200|NCT05811481|Drug|Regorafenib|Regorafenib alone
75883201|NCT05811455|Other|Aerobic exercises|To compare the effects of aerobic exercise and progressive muscle relaxation exercises on pain and quality of life in premenstrual syndrome
75883202|NCT05811455|Other|Progressive muscle relaxation|progressive muscle relaxation exercises.
75883203|NCT05811338|Behavioral|Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement|The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
76054460|NCT02120300|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76054461|NCT02070380|Drug|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
75439687|NCT01612806|Device|PriMatrix|fetal bovine dermal scaffold
75439688|NCT01612806|Device|PriMatrix Ag|fetal bovine dermal scaffold with Ag
75439689|NCT01612806|Procedure|moist wound therapy|standard of care moist wound therapy
75733338|NCT05994976|Procedure|Blood samples collection|biomarkers and optional genetic analysis
75733339|NCT05994976|Procedure|Oral samples collection|biomarkers analysis
75733340|NCT05994976|Procedure|Hair samples collection|biomarkers analysis
75733341|NCT05994976|Procedure|Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping)|biomarkers analysis
75733342|NCT05994976|Procedure|Skin surface material samples|biomarkers analysis
75733343|NCT05994976|Procedure|Drainage fluid samples collection|biomarkers analysis
75733344|NCT05994976|Procedure|Stool samples collection|biomarkers analysis
75883204|NCT05811338|Behavioral|Project 2, Phase 2: Intelligent Adaptive System|An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
76054462|NCT02070380|Drug|Dotarem|Dotarem administered at 0.1 mmol/kg
75589921|NCT06045195|Drug|Pembrolizumab|"As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and an eBEACOPP variant without bleomycin (P-EACOPP). Response to induction therapy will be measured after P-mono (PET-1; only for scientific purposes) and after completion of 1x P and 2x P-EACOPP (PET-3).~Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two cycles of P-EACOPP while participants with a positive PET-3 will receive four cycles of P-EACOPP. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care."
75733345|NCT05993845|Other|Recording of total hip arthroplasty|"We record total hip arthroplasties (THA) of hip surgeons at Balgrist University Hospital (BUH), Kantonsspital Baden (KSB), Kantonsspital Winterthur (KSW). Video & audio data are stored locally at Balgrist-managed servers (patient-sensitive information removed).~Data includes:~Demographics (year of birth, sex, smoking status, body mass index) Diagnosis Surgery-specific data & other surgical procedures during recording Standard preoperative Computed tomography of the hip/pelvis Standard pelvis x-rays pre- & postoperative Standard axial hip x-rays pre- & postoperative Western Ontario & McMaster Universities Osteoarthritis Index & Harris-Hip-Score To ensure the generated Surgical process model(SPM), evaluated using the recordings obtained from surgeries performed at BUH, generally describes the surgical process of THA, we apply our model to surgeries from the KSB and the KSW. There, 3 THAs are recorded and analyzed regarding commonalities and discrepancies in the SPM."
76054463|NCT02070380|Drug|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
75439690|NCT01612832|Drug|Pregabalin|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
75439691|NCT01612832|Other|Control|pain treatment as customary in the department
75439692|NCT01612845|Procedure|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
75439693|NCT01612845|Biological|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
75439694|NCT01612871|Drug|Tamoxifen, Letrozole , Anastrozole, Exemestane|"Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day"
75439695|NCT01612897|Other|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
75589922|NCT06045182|Procedure|Maitland mobilization|Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.
75589923|NCT06045182|Procedure|Piriformis stretch|Piriformis stretch will be given to this group. In first session piriformis stretch will be given for 10 sec with 10-second resting time in between with, 7 rep total of 1 set. For the 2nd and 3rd session repetitions will be increase to 8 and 10 respectively.
75589924|NCT06045182|Procedure|Electrotherapy|Hot pack and TENS for 10 min
75883205|NCT05811338|Behavioral|Project 3, Phase 3: Intelligent Decision Support Tool|An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
75883206|NCT05811325|Other|kinesiotaping without craniosacral therapy|The first treatment group will receive kinesio taping for 6 weeks atleast 4 times per week
75883207|NCT05811325|Other|kinesiotaping with craniosacral therapy|The second treatment group will receive kinesio taping with craniosacral therapy for 6 weeks atleast 4 times per week with each session lasting for 60 minutes
76054464|NCT02069366|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive dronabinol.
76054465|NCT02069366|Drug|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive placebo.
76054466|NCT04732208|Diagnostic Test|Colour fundus photography|Fundus images will be captured before and after administration of mydriatic agent
76054467|NCT02068508|Drug|Pioglitazone|Pioglitazone Tablets
76054468|NCT02068352|Drug|OPA-15406|OPA-15406 topical ointment
76054469|NCT02068352|Drug|Vehicle ointment|OPA-15406 1%-matching placebo topical ointment
76054470|NCT02207231|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
76054471|NCT02207231|Drug|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
76054472|NCT02207231|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
75439696|NCT01612910|Drug|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
75439697|NCT01612910|Other|laboratory biomarker analysis|Correlative studies
75439698|NCT01612923|Other|Midwife|gynecological exam and ultrasound and contraceptive advice provided by midwife
76054473|NCT02207231|Drug|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
76054474|NCT02239601|Other|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
75441745|NCT01637909|Dietary Supplement|Treatment group 1(Dietary intervention)|The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
75883208|NCT05811273|Other|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
76054475|NCT02236559|Device|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
75883209|NCT05811273|Other|Control group|general exercises
76054476|NCT02236559|Device|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%.
75589925|NCT06045169|Procedure|Post Isometric Relaxation|Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
75589926|NCT06045156|Drug|Tirofiban|Tirofiban is a selective glycoproteinⅡb/Ⅲa receptor inhibitor, which inhibits platelet aggregation and thrombi formation
75589927|NCT06045156|Drug|Tirofiban simulant|Tirofiban simulant is placebo packed the same style as tirofiban
75589928|NCT06045091|Drug|Human BCMA targeted CAR-NK cells injection|Allogenic genetically modified anti-BCMA CAR transduced NK cells
75589929|NCT06045065|Other|Fresh tumor sampling|Patient samples will be collected during neurosurgical resection. .
75589930|NCT06045052|Drug|Eltrombopag|Eltrombopag tablets by mouth once daily for 24 weeks (6 months) with the dose depending on race, age and weight.
75883210|NCT05811221|Drug|Esketamine of single injection|Single group: give esketamine 0.75 mg/kg at the time of induction
75883211|NCT05811221|Drug|Esketamine of Intermittent injection|Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
75883212|NCT05811208|Device|automated pupillometry|Automated pupillometry every 6 hours
75883213|NCT05811208|Diagnostic Test|questionnaire|"CAM ICU questionnaire will be used for delirium screening the incidence of pain will be assessed using 3 valid scales. The Visual Analogue Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Observational Tool (CPOT) will be used.~questionnaires will be done the same time as pupillometry"
76054477|NCT02206685|Drug|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
76054478|NCT02206685|Drug|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
76054479|NCT02206607|Drug|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
76054480|NCT02206607|Drug|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
76054481|NCT02206607|Drug|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
75589931|NCT06045039|Other|Stent-balloon-stent (SBS) technique|Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique. The procedure of this technique is to implant the stent into the side branch at the 1~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel. The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
75589932|NCT06045013|Drug|5% dextrose injection|Single ultrasound-guided injection of 4 ml 5% dextrose in carpal tunnel via ulnar approach.
76054482|NCT02206607|Drug|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
75439699|NCT01612936|Biological|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|"On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent."
75589933|NCT06045013|Drug|5% dextrose injections with methylprednisolone acetate 40 mg/ml|Single ultrasound-guided injection of 3 ml 5% dextrose with 1 ml 40 mg/ml methylprednisolone acetate in carpal tunnel via ulnar approach.
75733346|NCT05993754|Other|Non-pharmacological intervention|"The intervention consists of six main elements:~Correction of sensory deficits: Before surgery, the use of glasses, hearing aids and/or removable dental prostheses will be allowed, which will be removed before starting anesthesia in the emergency room. After surgery, they will be delivered back to the user.~Reorientation: In the postoperative period, the person will be informed where they are and the visit of the companion will be coordinated.~Early mobilization: A protocolized mobilization routine will be applied according to pain, state of consciousness, risk of thromboembolic disease and risk of falls.~Environmental management: You will be shown the time on a clock, it will reinforce the idea of the place where you are and that you can count on the team in case you need assistance.~Sleep protocol: The elderly person who does not want or cannot perform the mobilization routine, non-pharmacological sleep will be privileged.~Reduction of anticholinergic drugs"
75589934|NCT06045000|Drug|DC-806|Oral tablets
75733347|NCT05991570|Procedure|Video Assisted Thoracoscopic Surgery (VATS)|VATS is minimally invasive procedure for exploration to diagnose and treat thoracic injuries alternative to exploratory thoracotomy.
76054483|NCT02119676|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
75589935|NCT06045000|Drug|[14C]-DC-806|Oral capsules
75589936|NCT06044987|Procedure|Trans Obturator Tape Procedure (TOT)|Done under Spinal anesthesia in the dorsal lithotomy position.
75589937|NCT06044987|Procedure|Cystocele Repair|Done under Spinal anesthesia in the dorsal lithotomy position..
75589938|NCT06044974|Device|Nd-YAG Fotona|four combined therapy sessions using 1064 nm Nd-YAG laser (once/week)
75589939|NCT06044974|Drug|Epidermal Growth Factor|"Epidermal growth factor EGF-genesis by Dermaquel Paris n into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle"
75589940|NCT06044961|Radiation|CT scan|All pre-operative CT scan collected
75589941|NCT06044922|Device|24-hour Holter monitoring|Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
75589942|NCT06044883|Procedure|Injection of Botulinum neurotoxin (BoNT)|"Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum, an anaerobic ,gram-positive bacterium. Poisoning with BoNT can cause botulism, resulting in generalized paralysis, respiratory failure, and death .There are seven serotypes of BoNT: A, B, C1, D, E, F, and G. BoNT-A is the most commonly used serotype for medical purposes.~Since its first use in 1977 for the treatment of strabismus in children, BoNT-A has since been used in aesthetic medicine and for the treatment of a number of disorders associated with overactive striated muscles, such as strabismus, esotropia, exotropia , focal dystonia, spasticity, and movement disorders.~BoNT-A has also been used in the management of some smooth-muscle disorders, such as achalasia, oesophageal spasm , ptyalism, hyperhidrosis, and intrinsic rhinitis, blepharospasm, muscle spasms and spasticity, axillary hyperhidrosis, and neurogenic detrusor muscle overactivity of the urinary bladder."
75589943|NCT06044883|Diagnostic Test|Penile duplex and shear wave elastosonography (SWE).|Penile duplex study using intracavernosal injection of prostaglandin E1 (PGE1) before and after Botox injection (in the follow-up visit in the 6th week after Botox injection). Penile cavernosal arteries diameters and colored waves will be assessed. Shear wave elastosonography will be conducted comparing the stiffness of penile tissues before and after Botox injection
76054484|NCT02119676|Drug|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
76054485|NCT02119676|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
76054486|NCT02206061|Behavioral|School-Based Asthma Care for Teens (SB-ACT)|
76054487|NCT02206061|Behavioral|Directly Observed Therapy|
76054488|NCT02206061|Behavioral|Asthma Education|
76054489|NCT02095106|Device|Waterproof Cast|
76054490|NCT02095106|Device|Traditional cast|
76054491|NCT01631747|Behavioral|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
75733348|NCT05990764|Dietary Supplement|Probiotic, Prebiotic, Polyphenol-rich Extracts|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry extract~Once a day"
75733349|NCT05990764|Dietary Supplement|Probiotic, Prebiotic|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum)~Once a day"
75733350|NCT05990764|Other|Placebo|"placebo~Once a day"
75733351|NCT05989919|Other|CT scan for nose and paranasal sinuses|CT scan for nose and paranasal sinuses
75733352|NCT05989555|Other|Blood drawing|Blood is drawn twice in all subjects. Once before treatment with radioacitve iodine and once after.
75733353|NCT05989204|Biological|TMhuCART19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
75733354|NCT05985044|Other|Care cO-ORDInatioN And sympTom managEment (CO-ORDINATE) Intervention|The intervention consists of the following four components: i) needs assessment; ii) question prompt list; iii) goals discussion and; iv) symptom assessment and tracking. The intervention will start with the enrolment of a patient living with multimorbidity. The intervention consists of one in-person pre-discharge visit by the study team and four follow-up telephone calls (at 48 hours, 1 week, 4 weeks, and 6 weeks post-discharge).
75733355|NCT05984459|Dietary Supplement|VLCKD|The analysis will focus on the observation of the evolution of anthropometric and clinical parameters,such as the improvement or normalization of HbA1c, as well as on the evolution of the hypoglycemic medication between patients who accept VLCKD method
75883214|NCT05811195|Device|Diode Semiconductor, Duo|Intraoral photobiomodulation therapy (660nm, 3s/point, 10J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
76054492|NCT01631747|Behavioral|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
76054493|NCT02068118|Device|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
76054494|NCT01623830|Behavioral|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
75589944|NCT06044870|Procedure|Modified laterally stretched technique with a connective tissue graft.|Modified laterally stretched technique with a connective tissue graft.
75733356|NCT05984056|Behavioral|Multidisciplinary lifestyle interventions|Multidisciplinary lifestyle interventions (Brain health training, Yoga, Music therapy, and the MINDS diet education)
76054495|NCT04731896|Procedure|Amniotomy|artificial rupture of the amniotic sac
76054496|NCT01634165|Drug|LY2963016|Administered subcutaneously
75439700|NCT01612936|Procedure|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
75589945|NCT06044844|Drug|Tofacitinib|tofacitinib efficacy
75733357|NCT05981547|Device|Libre 3 continuous glucose monitoring sensor|Libre 3 CGM sensor applied to women prior to their Oral Glucose Tolerance test.
75733358|NCT05981209|Procedure|Biospecimen Collection|Undergo blood sample collection
75733359|NCT05981209|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
75883215|NCT05811195|Device|Gemini laser|Extraoral photobiomodulation therapy (810 + 980 nm, 20s/point, 4.07J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
76054497|NCT01634165|Drug|Lantus|Administered subcutaneously
76054498|NCT02235311|Drug|Pantoprazole|Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
75589946|NCT06044818|Device|Accexible|Speech Analysis
75589947|NCT06044792|Other|differences in CD4 reconstruction|Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.
75589948|NCT06044766|Procedure|Surgical exatrction of impacted lower third molars|Surgical exatrction of impacted lower third molars to verify the form of the root
75589949|NCT06044753|Device|Virtual Reality Headset|"Non immersive VR experience basically means providing a near reality environment for viewers, however, viewers won't be able to make any changes to it as they can only watch.~This Non-immersive Virtual reality experience will be applied unto the child by using a headset that incorporates a computerized dimensional environment which will be simulated to make the child feel near reality .The VR headset consist of a cover for handphone slot, screen display, two lenses with adjustable eye pieces to focus, foam padding and adjustable elastic head mount strap."
76054499|NCT04777955|Other|core stabilization exercises|"Core is at the center of almost all kinetic chains in the body. Core force, balance, and motion control maximize all kinetic chains of upper and lower limb function. A stable and strong core can contribute to more efficient use of the lower extremities. Core stability is defined as the ability of the lumbo-pelvic hip complex to prevent bending of the vertebral column and return to balance after perturbation.~Neuromuscular electrical stimulation (NMES) is a technique in which muscle contraction is electrically stimulated in the area where the surface electrodes are connected. It improves secondary muscle atrophy and weakness in immobilization by preventing a decrease in muscle protein synthesis.~Kinesiological banding (CT) is a treatment method used in the treatment of various musculoskeletal and neuromuscular deficits. The mechanism of action of CT is to facilitate muscle activation, increase blood and lymph circulation and reduce pain due to neurological suppression."
75589950|NCT06044714|Procedure|Manual Standardized Stress Acupuncture (MSSA)|Participants in the experimental group will receive 4 weekly sessions of MSSA, which consists of 8 acupuncture points: bilateral auricular (ear) shen men, GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. Needles are left in situ for 30 minutes per session.
76054500|NCT02204579|Drug|NPSP795|
76054501|NCT02235077|Drug|Spironolactone|"Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
75733360|NCT05981209|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
75733361|NCT05981209|Procedure|Computed Tomography|Undergo CT
75733362|NCT05981209|Drug|Dexamethasone|Given IV or PO
75733363|NCT05981209|Procedure|Echocardiography|Undergo ECHO
75439701|NCT01612975|Drug|Naproxen|Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
75439702|NCT01612975|Drug|Placebo|Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
75733364|NCT05981209|Biological|Elotuzumab|Given IV
76054502|NCT02235077|Drug|Placebo|"Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
76054503|NCT02234141|Drug|Placebo|Tablet administered orally once daily
75589951|NCT06044714|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants will receive four sessions of MBSR group psychotherapy (no more than 10 participants per group session) via Microsoft Teams. The first session will be 90 minutes followed by three 60-minute weekly sessions.
75589952|NCT06044701|Other|Hologram Distraction Technique|Hologram fan application during blood collection process
75589953|NCT06044701|Other|Bubble Machine Distraction Technique|Bubble machine application during blood collection
75589954|NCT06044688|Device|EyeQue VisionCheck|Automated subjective refraction system provides estimates of sphere, cylinder, and axis measurements of the eye.
75733365|NCT05981209|Procedure|Magnetic Resonance Imaging|Undergo MRI
75733366|NCT05981209|Biological|Mezigdomide|Given PO
76054504|NCT02234141|Drug|Selonsertib|Tablets administered orally once daily
75589955|NCT06044688|Device|Phoropter|Standard of care, ophthalmic testing device, used by eye care professionals to measure the refractive error of the eye and determine prescription.
76054505|NCT02234063|Other|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
75589956|NCT06044675|Drug|MDMA assisted psychotherapy|This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.
75733367|NCT05981209|Procedure|X-Ray Imaging|Undergo x-ray imaging
75733368|NCT05978414|Other|Visceral therapy|Visceral therapy will be performed manually by a physiotherapist, a detailed description of the techniques is above. Therapy will be in 2 subgroups with prolapse of the usual genitals and endometriosis.
75733369|NCT05978414|Other|Placebo|Placebo will be in 2 subgroups that will not have visceral therapy. The placebo will consist of the physiotherapist holding hands on the patient's pelvis.
76054506|NCT02232893|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
76054507|NCT02232893|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
76054508|NCT02203721|Device|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|
75439703|NCT01612988|Drug|BOMP|"Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
76054509|NCT02203721|Device|TECNIS Monofocal IOL, Model ZCB00|
75439704|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 1
75439705|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 11
75439706|NCT01613040|Drug|RO4917838|Multiple daily low doses of RO4917838 for 10 days
75439707|NCT01613040|Drug|RO4917838|Multiple daily oral high doses of RO4917838 for 10 days
75439708|NCT01613040|Drug|RO4917838 placebo|Oral daily doses of placebo to RO4917838 for 10 days
75439709|NCT01613053|Drug|Glivec|800 mg per day
75439710|NCT01613066|Procedure|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
75439711|NCT01613079|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
75439712|NCT01613079|Drug|Methotrexate|Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
75439713|NCT01613092|Drug|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
75439714|NCT01613092|Drug|Cefazolin|Preoperative antibiotic
75439715|NCT01613105|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
75439716|NCT01613170|Drug|Toviaz|Toviaz 4mg daily
75589957|NCT06044675|Behavioral|Psychotherapy|A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.
75589958|NCT06044597|Device|SyncAV function on|CRT-D with SyncAV plus activated
75589959|NCT06044584|Other|No intervention|Observational study with no intervention - Monitoring
75589960|NCT06044545|Diagnostic Test|Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors|"With this research, according to the health promotion model for the care that should be taken during the preconceptional period (pre-pregnancy) of women who are not yet pregnant, who will marry soon and who are considering pregnancy.~It is thought that they will gain knowledge, increase their awareness and develop positive health behaviors with the web-based pregnancy preparation training. In data collection; Introductory Characteristics Form, Preconceptional Knowledge and Attitudes Scale, Preconception Health Behaviours Scale will be used."
75883216|NCT05811169|Genetic|Next generation sequencing|Next generation sequencing
75589961|NCT06044532|Other|Experimental|At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
75883217|NCT05811156|Behavioral|Hybrid Multimodal digital intervention|Multimodal digital intervention, including an internet-delivered CBT treatment based on a biopsychosocial exposure treatment, tailored explicitly for Exhaustion due to persistent non-traumatic stress.
76054510|NCT01618695|Drug|Perampanel|"Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.~Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day."
76054511|NCT01618695|Drug|Placebo|"Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day."
75439717|NCT01613170|Drug|Premarin|Premarin cream 1 g per vagina twice weekly
75589962|NCT06044519|Biological|different types of dressings|different types of dressings were compared ti see the effectiveness for for STSG donor site wound
75589963|NCT06044506|Drug|Autologous Natural Killer Cell Therapy|The therapy will be administered intravenously
75733370|NCT05977348|Behavioral|Healthy Eating Curriculum|The Healthy Eating (HE) curriculum is designed to provide children with skills needed to develop healthy eating habits. Each lesson builds upon the overall goal of creating a healthy restaurant. Children are taught to identify differences between GO and WHOA foods, recognize the five food groups, and learn to make healthy food choices.
75733371|NCT05977348|Behavioral|Improving the Classroom Food and Mealtime Environment|"HBP+ Classrooms will receive additional sensory activities for each lesson (e.g., posters, food models, games) designed to improve the classroom food environment and provide repeated exposure to activities and messages about fruits and vegetables. Teachers in HBP+ classrooms will be provided with additional training on strategies shown to increase food acceptance in preschool children (e.g., modeling, encouraging children to try foods without coercion). In addition, HBP+ classrooms will include tasting charts that children will stamp to indicate their liking for each food each week."
75883218|NCT05811104|Device|Sequential bilateral theta burst stimulation|Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
75439718|NCT01613170|Drug|Placebo cream|Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
75439719|NCT01613183|Drug|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
75439720|NCT01613183|Other|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
75589964|NCT06044506|Device|Clinimacs Plus|The CliniMACS Plus device is an automated cell separation tool that uses MACS Technology. It incorporates a flexible system designed for isolating clinically labeled cells using MicroBeads.
75589965|NCT06044480|Drug|Dexamethasone|Administration of a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
75589966|NCT06044480|Other|Placebo|Administration of the same amount of saline solution instead of dexamethasone
75589967|NCT06044467|Drug|Anti-human CCL24 monoclonal antibody (CM-101) - Part One|Anti-human CCL24 monoclonal antibody (CM-101) - Part One
75589968|NCT06044467|Drug|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
75589969|NCT06044467|Drug|Placebo - Study Part One|Placebo Comparator
75589970|NCT06044467|Drug|Placebo - Study Part Two|Placebo Comparator
76054512|NCT01896531|Drug|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
75589971|NCT06044428|Device|Steadytemp®|Steadytemp® is a clinical thermometer intended to continuously measure axillary temperature and to display relative changes in axillary temperature to the user. The system consists of a sensor patch and a smartphone application, the body temperature measured by the sensor is transmitted via Near-Field-Communication (NFC) and subsequently displayed in the App.
75589972|NCT06044415|Drug|JWH018|A vaporized dose of 7.5 mg of JWH-018 will be inhaled by the participants
75589973|NCT06044415|Other|non-active control (no substance)|Participants will inhale from a vaporizer with an empty chamber.
75589974|NCT06044402|Other|group L (Vt 6 ml/kg)|low tidal volume ventilation (tidal volume was set to 6 ml/kg)
75733372|NCT05977348|Behavioral|Parent Education|Parents in intervention classrooms will be given access to 8 web-based lessons on food parenting and responsive parenting. Topics include: establishing mealtime routines, shopping healthy on a budget; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; the division of responsibility in feeding, and portion control.
75733373|NCT05977348|Behavioral|ECE Food Acceptance Training|HBP+ early childhood educators (ECEs) will be asked to complete an online, self-paced course on increasing food acceptance in preschool children. Topics will include: repeated exposure to foods; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; and the division of responsibility in feeding.
75733374|NCT05977127|Biological|Comirnaty|Administration of Comirnaty vaccine
75733375|NCT05977088|Device|Repetetive Transcranial Magnetic Stimulation|".Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken immediately after (max. 2 minutes later) in the Faraday cage. The same procedures will be done with the sham coil in the control group."
75733376|NCT05974969|Drug|BCD-264|a single intravenous infusion of BCD-264
75733377|NCT05974969|Drug|Darzalex|a single intravenous infusion of Darzalex
75733378|NCT05974293|Drug|Nabiximols|Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.
75733379|NCT05974293|Drug|Placebo|The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.
76054513|NCT01896531|Drug|Ipatasertib|Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
75439721|NCT01613196|Other|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|"2 or 3 FDG-PET scans will be performed in all patients : at inclusion*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~*except if already done in the last 15 days."
75439722|NCT01613209|Drug|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
75439723|NCT01613209|Drug|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
75439724|NCT01613235|Other|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
75589975|NCT06044402|Other|group I (Vt 8 ml/kg)|intermediate tidal volume ventilation (tidal volume was set to 8 ml/kg)
75589976|NCT06044389|Device|Fructosin|"Fructosin® is a CE marked medical device. The capsules with 30.23 mg xylose isomerase are taken as recommended. This means that, depending on the total intake, 1-2 capsules are to be taken with water 15 minutes before meals containing fructose, a maximum of 3 times a day.~Use as needed during the 4-week intake phase."
75589977|NCT06044376|Combination Product|Formula milk with triple Bifidobacterium probiotic strain|Formula milk with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10^7 CFU/serving), Bifidobacterium longum subsp. infantis M-63 (6.9 x 10^7 CFU/serving).
76054514|NCT01896531|Drug|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
75589978|NCT06044376|Other|Formula milk|Formula milk without any addition of probiotic strain
76054515|NCT01896531|Drug|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
75439725|NCT01613261|Drug|TAK-733 and alisertib|"TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle."
75589979|NCT06044350|Drug|BAT4406F Injection|Intravenous infusion; Dosage:500mg/time
75589980|NCT06044350|Drug|BAT4406F Placebos|Intravenous infusion; Dosage:500mg/time
75589981|NCT06044272|Other|Factors associated|Factors associated with the type of resistance by microorganisms.
75733380|NCT05972109|Other|Workplace SSB sales ban|Environmental Intervention. The hospital food services will replace sugary drinks with non-sugar added alternative beverages throughout the campus.
75733381|NCT05972109|Behavioral|Brief Intervention|Participants receive single-session brief intervention, which is an intervention that uses motivational interviewing, and helps participants understand amount and effect of their baseline SSB intake, identify realistic goals for reduction and overcoming obstacles.
75589982|NCT06044259|Procedure|AMDS; Artivion, Atlanta, Georgia, US|Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, US) hybrid prosthesis which comprises a proximal sewing collar and a distal self-expanding nitinol un-covered stent.
75589983|NCT06044259|Procedure|Conventional hemiarch replacement|Coventional open hemiarch replacement
76054516|NCT01896531|Drug|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
76054517|NCT01618305|Drug|Lamivudine/zidovudine|"Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery*.~* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
76054518|NCT01618305|Drug|Efavirenz|Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
75439726|NCT01613274|Other|gum chewing|gum chewing three times a day for up to 20 minutes
75439727|NCT01613274|Other|no gum chewing|no gum chewing
75439728|NCT01613287|Device|TheraSorb® - Ig flex|"TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.~5 treatments performed over 5 to 8 consecutive days."
75439729|NCT01613300|Drug|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
75439730|NCT01613352|Other|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
75589984|NCT06044207|Diagnostic Test|Pittsburgh sleep quality index|The scale is suitable for evaluating sleep quality in patients with sleep disorders and psychiatric disorders, as well as for assessing sleep quality in the general population.
75589985|NCT06044207|Diagnostic Test|Self-rating depression scale|The scale is easy to use, can fairly intuitively reflect whether the patient has depression and the degree of depression, has been widely used in outpatient gross screening, mood state assessment.
75733382|NCT05971381|Device|RECELL® Autologous Cell Harvesting Device|The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.
75883219|NCT05811078|Behavioral|training sessions with peer interactive group|"Data were collected with data collection forms consisting of  Diabetes Adolescent Diagnosis Form, Diabetes Information Evaluation Form, Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes and Child's Attitude towards Own Disease Scale ."
75589986|NCT06044207|Diagnostic Test|Montreal Cognitive Assessment|The scale is a tool used for rapid screening of mild cognitive dysfunction to identify patients with preoperative cognitive dysfunction
75589987|NCT06044194|Drug|L-arginine and liposomal vitamin C|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group) or an oral supplement of Placebo once a day for 3 months (control group)
75589988|NCT06044181|Procedure|Diode laser photocoagulation.|If there is evidence of active leakage by FFA The confluent laser burns will be applied to the entire avascular retina from the ridge to the ora serrata for 360 through the transpupillary route. The laser settings used are: power 250-400 mW and duration of 200-400 ms for 810 nm DLPC.
75439731|NCT01613365|Drug|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
75733383|NCT05968261|Procedure|Real time 'near remote' guidance of regional blocks|Trainees who are to perform regional blocks will do so under expert guidance via tele-mentoring. This will be done using a novel technology consisting of a wirelessly linked iPad which will display the ultrasound image to the block operator/trainee. This image will be concurrently visualized by an expert mentor through their smartphone, who will then provide feedback/guidance in real-time to the operator/trainee.
75883220|NCT05811052|Other|Suboccipital Release Technique|The suboccipital release technique was applied to the participants in the experimental group by an experienced practitioner who had received osteopathy training. The individual lay in the supine position, and the practitioner applied the relaxation technique by placing his hands on the patient's nape-atlantooccipital joint. The application was continued until the relaxation of the muscles under the hand of the practitioner.
75733384|NCT05967962|Behavioral|The Trauma Film Paradigm|"Trauma film paradigm is a well-known, validated and established procedure that produces reactions similar to those generated by trauma, and that is often used in research to predict susceptibility for peritraumatic and posttraumatic reactions. In this study the trauma film paradigm will be utilized to simulate combat exposure. The two groups of participants will undergo the trauma film paradigm by watching 16 min traumatic combat scenes vs. non-traumatic movie scenes, respectively. Participants will be given standardized instructions (i.e., ''Imagine you are present at the scene; Do not close your eyes)."
75733385|NCT05967962|Behavioral|non-traumatic (neutral) film|non-traumatic (neutral) film
75439732|NCT01613365|Drug|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
75733386|NCT05966727|Drug|Cholestyramine Powder|Bile salt chelating resin, used as a lipid-lowering treatment.
75733387|NCT05966155|Other|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
75439733|NCT01613404|Other|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
75439734|NCT01613430|Behavioral|Coach Training (COACH)|"Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening."
75439735|NCT01613430|Behavioral|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
75733388|NCT05966155|Other|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
75733389|NCT05966142|Other|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
75733390|NCT05966142|Other|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
75733391|NCT05966129|Other|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
75883221|NCT05811052|Other|Sham Suboccipital Release|The participants in the control group were given a sham application by touching the hands of the therapist on the nape of the neck and waiting for a while.
75733392|NCT05966129|Other|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
75883222|NCT05811026|Device|Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)|"Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment~Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment~Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed"
76054519|NCT01618305|Drug|Raltegravir|Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
75439736|NCT01613456|Dietary Supplement|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
75439737|NCT01613456|Dietary Supplement|Placebo|"Capsule with comparable organoleptic properties and weight than the experimental product.~2 capsules/day during 12 weeks"
75439738|NCT01613469|Drug|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
75439739|NCT01613482|Radiation|cerebral prophylactic radiation|24Gy, 12 fractions of 2 Gy
76054520|NCT01886313|Drug|Civamide Nasal Spray|
76054521|NCT01886313|Drug|Placebo|
75733393|NCT05961527|Drug|MDMA|Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose
75439740|NCT01613482|Drug|Trastuzumab|Weekly, 2mg/kg of corporal weight
75883223|NCT05811026|Device|Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)|"Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment~Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment~Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed"
76054522|NCT01896297|Drug|Pradaxa, dabigatran etexilate|75mg BID by oral
75733394|NCT05961527|Behavioral|Group Therapy|Standardized group psychotherapy performed by therapist team in combination with non-directive MDMA therapy
76054523|NCT04618263|Drug|GATE-101|GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
75733395|NCT05960955|Drug|Cadonilimab|IV infusion,Specified dose on specified days
75883224|NCT05811000|Drug|PM012|PM012 650 mg tablet drug
76054524|NCT01884675|Drug|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
76054525|NCT01884675|Drug|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
75733396|NCT05960955|Drug|AK117|IV infusion,Specified dose on specified days
75733397|NCT05960955|Drug|Oxaliplatin|IV infusion,Specified dose on specified days
75883225|NCT05811000|Drug|PM012 Placebo|PM012 tablet placebo
75883226|NCT05811000|Drug|Donepezil|Aricept 5 mg (donepezil hydrochloride) drug
75883227|NCT05811000|Drug|Donepezil placebo|Aricept 5 mg (donepezil hydrochloride) placebo
75883228|NCT05810922|Other|arbutus berry|consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
75439741|NCT01613482|Drug|Other chemotherapy in association with Trastuzumab|other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
75439742|NCT01613508|Procedure|Direct Anterior Approach|
75439743|NCT01613508|Procedure|Mini-Posterior Approach|
75733398|NCT05960955|Drug|Tegafur-gimeracil-oteracil potassium|Oral,Specified dose on specified days
75733399|NCT05960955|Drug|Docetaxel|IV infusion,Specified dose on specified days
75733400|NCT05960955|Drug|5-Fluorouracil|IV infusion,Specified dose on specified days
75733401|NCT05960682|Other|Questionnaire|Patients will complete the French version of the Brief Index of Sexual Functioning for Men (BISFM) paper questionnaire. The BISFM is a self-administered questionnaire. It has 22 questions, grouped into 7 domains allowing a qualitative and quantitative evaluation of the sexual experience: D1 (desire), D2 (excitement), D3 (frequency of activity), D4 (receptivity), D5 (pleasure, orgasm ), D6 (relationship satisfaction), D7 (problems affecting sexuality).
75883229|NCT05810909|Dietary Supplement|amorphous calcium carbonate/ Placebo|The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
75883230|NCT05810350|Drug|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed|Patients receive Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
75883231|NCT05810064|Other|Falls-Risk Clinical Decision Support (CDS) Tool|CDS in the Electronic Health Record (EHR) to screen patients at high-risk for future falls enabling referrals to the UW Health Mobility and Falls clinic.
76054526|NCT01884597|Drug|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
76054527|NCT01884597|Drug|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
76054528|NCT01895361|Drug|SelG1|
76054529|NCT01895361|Drug|Placebo|
75439744|NCT01613521|Other|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
75439745|NCT01613534|Drug|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
75883232|NCT05807360|Device|Hyaluronic acid eye drops|Hyaluronic acid (HA)-based eyedrops
75439746|NCT01613534|Drug|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
75439747|NCT01613547|Drug|Amoxicillin|80 mg/kg/day for 7 days
75589989|NCT06044129|Device|Mri scan of fetal head and pelvis|The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.
75589990|NCT06044103|Drug|PDB + PCS|Pudendal nerve block (PNB) with ropivacaine AND Patient-controlled sedation with propofol by the participant
75589991|NCT06044090|Drug|Minocycline|Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
75589992|NCT06044090|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
75589993|NCT06044077|Biological|23-valent pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
75883233|NCT05801224|Drug|Nitric Oxide|20ppm for 15 minutes
75439748|NCT01613547|Drug|Placebo|7 days
75883234|NCT05801211|Procedure|primary tumor resection|"primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)"
75883235|NCT05799391|Drug|SJC|Soothing cream jel
75439749|NCT01613573|Drug|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
75439750|NCT01613573|Drug|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
75439751|NCT01613586|Drug|ASP3652|Oral
75439752|NCT01613586|Drug|Placebo|Oral
75439753|NCT01613612|Procedure|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
75439754|NCT01613612|Procedure|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
75439755|NCT01613625|Procedure|Elastography|
75439756|NCT01613651|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
75439757|NCT01613651|Other|questionnaire administration|Ancillary studies
75439758|NCT01613651|Other|intraoperative complication management/prevention|Undergo placement of pelvic drain
75439759|NCT01613664|Drug|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
75589994|NCT06044077|Biological|control pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Merck Sharp & Dohme Corp
75589995|NCT06044051|Other|Blood sample|An additionnal volume of blood will be collected at inclusion and at each follow-up visit
75589996|NCT06044051|Other|Expectoration|Expectoration will be collected at inclusion and at each follow-up visit
75589997|NCT06044051|Other|Nasopharyngeal swab|A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum
75589998|NCT06044038|Behavioral|Physical activity|Bi-weekly supervised physical activity intervention
75589999|NCT06044038|Behavioral|Cognitive rehabilitation program|weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.
75883236|NCT05799391|Other|Placebo|Placebo cream jel
75590000|NCT06044012|Procedure|Double layer of buccal myomucosal Flap and buccal pad of fat|The buccal myomucosal flap will be harvested from cheek below stenson papilla and will be sutured over buccal pad of fat which will be sutured at palatal mucosa after complete curettage of infected fistulous tract.
75439760|NCT01613664|Other|no tisseel|the surgeon does not applied tissucol during the surgery
75883237|NCT05793489|Other|Silibinin|"WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions."
76054530|NCT01883895|Device|Forgionei-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
76054531|NCT01883895|Other|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
76054532|NCT01883895|Other|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
75590001|NCT06043999|Procedure|Radical total mesorectal excision|Standard TME surgery was performed 3-4 weeks after local resection. The operation is roughly divided into the following steps:After abdominal exploration, gradually ligation and from the inferior mesenteric vessels, pay attention to protect the left ureter, reproductive blood vessels and upper abdominal nerve; The descending colon was fully mobilized and the splenic flexure was mobilized if necessary. Follow the principle of TME, perform sharp resection of the total mesorectum, and pay attention to the protection of the prostate, vagina, pelvic nerve, etc.For can be removed through double stapling technique in low former (LAR) need not inline sphincter resection (excluding cases), to must be inline sphincter resection can be turned to the anus operation (ditto), consistent way can choose according to the intraoperative situation drag anastomosis or manual suture or stapling anastomosis. Prophylactic loop colostomy of transverse colon or ileostomy is recommended.
76054533|NCT01864005|Drug|Ticagrelor|90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
76054534|NCT01864005|Drug|Clopidogrel|75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
75439761|NCT01613677|Drug|BKM120|
75883238|NCT05791110|Diagnostic Test|Fecal pancreatic elastase 1 test|Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
75883239|NCT05780060|Behavioral|Standard of care, RPM and digital feedback|Standard stroke follow up, RPM and a patient facing smartphone application containing real time BP feedback, educational models, treatment adherence push notification reminders, digital education and digital incentives (n=30). Outcomes will include recruitment, retention and follow up metrics, self-reported adherence to medication regimens and life-style recommendations, patient engagement with RPM data and patient-facing application, cost-effectiveness of the interventions and changes in blood pressure as well as biomarkers like LDL and Hemoglobin A1C.
75883240|NCT05780060|Behavioral|Standard of care and RPM only|Standard stroke clinic follow up and remote blood pressure monitoring (n=30). Outcomes will include qualitative patient and provider experiences with the TBIs including barriers and facilitators to the use of RPM and patient-facing application in the study population
75439762|NCT01613690|Drug|NVA237|NVA237 is administered via a BREEZHALER device
75439763|NCT01613703|Drug|ONO-2952|1 mg to 200 mg QD at a single descending dose
75439764|NCT01613755|Drug|Metformin, dipyridamole|Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
75439765|NCT01613755|Drug|Metformin|Metformin 500 mg twice daily for four days
75439766|NCT01613781|Other|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
76054535|NCT01863849|Biological|Vaccination with Fluval AB suspension for injection|Single intramuscular injection with Fluval AB suspension for injection in both age groups
76054536|NCT01863771|Drug|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
76054537|NCT01863771|Other|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
76054538|NCT01894581|Dietary Supplement|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
75439767|NCT01613781|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
75439768|NCT01613794|Drug|Rosuvastatin|20 mg od
75439769|NCT01613807|Drug|Insulin LISPRO|Humalog® Mix50/50™ [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)], three times daily at mealtime. Dose determined by blood glucose history.
75590002|NCT06043999|Other|Salavge Adjuvant Chemoradiotherapy|Concurrent adjuvant chemotherapy:5-Fu or 5-Fu analogues based chemotherapy regimens were selected. CapeOx or capecitabine monotherapy or FOLFOX is recommended, and no more than 3 months.Adjuvant radiotherapy protocol:long-course radiotherapy protocol.a. Target definition: areas at high risk for recurrence of the primary tumor and regional lymphatic drainage.b. Radiotherapy technology: conventional radiotherapy, three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy, etc.c. Radiation dose:DT of 45Gy,1.8Gy per fraction in 25 fractions, was recommended for the high-risk recurrence area of the primary tumor and the regional lymphatic drainage area.
76054539|NCT01894581|Drug|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
76054540|NCT04776629|Drug|Orticumab|A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
76054541|NCT04776629|Drug|Placebo|Placebo for orticumab, containing all components of formulation except the active ingredient
75439770|NCT01613807|Drug|Insulin, Long-Acting and Insulin|Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
75439771|NCT01613820|Drug|Ketamine|ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.
75439772|NCT01613820|Drug|Scopolamine|Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
75439773|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
75439774|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
75439775|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
75439776|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
75439777|NCT01613846|Drug|Sorafenib+Pazopanib|Sorafenib (first-line) followed by Pazopanib (second-line)
75439778|NCT01613846|Drug|Pazopanib+Sorafenib|Pazopanib (first-line) followed by Sorafenib (second-line)
75439779|NCT01613872|Other|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
75733402|NCT05960630|Procedure|MIRRORS Protocol|Diagnostic laparoscopic assessment proceeding to either robotic (if considered appropriate following laparoscopic assessment) or open Interval cytoreductive surgery with conversion to open at any point should this be required to remove all visible disease.
75733403|NCT05960630|Procedure|Standard Open Cytoreductive Surgery|Extended midline incision. Open surgical approach to interval cytoreductive surgery with the aim of removing all visible disease.
75883241|NCT05778136|Other|Resistance training|Supervised resistance training. 2 sessions/week for 12 weeks. The exercises are one-legged leg-press and one-leg knee extension. Resistance training start-up phase comprises 3 sets of 10 repetitions in each of the two exercises with 50% of 1RM. Resistance training progressive phase comprises 3 sets (leg-press) of 5-8 repetitions (70-90% 1 RM) and 6 sets (knee extension) of 8 repetition (75% 1RM). Rest between sets: 3 minutes
76054542|NCT01893411|Drug|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
76054543|NCT01893411|Drug|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
76054544|NCT01893411|Drug|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
75590003|NCT06043973|Drug|almonertinib|The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
76054545|NCT02232425|Drug|IX-01|
76054546|NCT02232425|Drug|Placebo|
76054547|NCT01631435|Other|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
75439780|NCT01613885|Other|No Intervention|This study does not involve any intervention other than obtaining blood, nasal/cheek/throat/skin swabs, saliva, sputum, urine, and stool samples, breathing and skin tests.
75439781|NCT01613898|Biological|Blood tests|Blood tests
75590004|NCT06043960|Other|Humac Norm İsokinetic Machine|Tecno Body Prokin Isokinetic Balance System CSMI (CYBEX) Humac Norm Isokinetic Testing and Exercise System Romberg Test Mini Mental Test (MMSE) Fugl-Meyer Assessment of the lower limb
75590005|NCT06043934|Other|Neural Mobilization with Intermittent Cervical Traction|This group will receive Neural Mobilization with Intermittent Cervical Traction along with routine physical therapy. The patient will be positioned in a supine position with 10 to 15 degrees of flexion on a comfortable treatment table. A suitable pillow will be arranged to support their head. The cervical traction device's integrity and readiness will be confirmed by the therapist. The starting weight will be about 10% of the patient's body weight, and this will slowly increase up to an appropriate level. The on-and-off times will be decided based on the patient's comfort and specific condition. Generally, a ratio of 3:1 or 4:1 (hold: rest) is used. For instance, 60 seconds of traction followed by 20 seconds of rest. The total treatment time will generally range between 15-20 minutes for 3 to 4 times per week. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).
75733404|NCT05959499|Drug|BR6002A|One tablet administered alone
75733405|NCT05959499|Drug|BR6002B|One tablet administered alone
75733406|NCT05959499|Drug|BR6002|One capsule administered alone
75733407|NCT05956223|Device|Virtual Reality measurement of essential tremor and dystonia|"The virtual reality (VR) platform, which detects whole-of-body movements. The VR environment is a series of sensors in a room that detect whole body motion and a series of sensors worn by the participant. As well the participant dons VR goggles that allows them to see a virtual environment in which they can perform the TETRAS.~Within the VR platform, an avatar (an electronic image that represents the participant) is produced in the VR environment, and this will be used to review the participant.~Sensors for the detection of wrist, head and voice tremor. The sensors are small devices worn on the wrists and head of the participant and are similar to those used in the VR system. A microphone is attached to the participants to detect voice tremor."
75733408|NCT05953038|Drug|Lysergic Acid Diethylamide Tartrate|D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
75733409|NCT05952089|Drug|Danicamtiv|Specified dose on specified days
75733410|NCT05952089|Drug|Midazolam|Specified dose on specified days
75883242|NCT05773391|Drug|Take probiotics|Take medication for 21 days (Yihuo 0.2g bid+ Jin Bifid2g tid)
75883243|NCT05766982|Other|Platelet Rich Plasma|Platelet rich plasma will be applied to assess rate of wound healing.
76054548|NCT01631435|Device|Ileocolonoscopy|"Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum"
76054549|NCT02230085|Other|Administration of the questionnaire and monitoring of CPAP adherence|
76054550|NCT02202785|Drug|MLN0264|MLN0264 IV infusion
76054551|NCT01882647|Drug|000-0551 Lotion|
76054552|NCT01882647|Drug|Vehicle Lotion|
75439782|NCT01613924|Device|Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
75883244|NCT05766254|Device|Active 10-Hz TMS to the DLPFC|The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
76054553|NCT01882257|Device|BiPAP|BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
76054554|NCT01882257|Device|BiPAP/AVAPS (Phillips Respironics)|BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
76054555|NCT01862991|Other|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
75590006|NCT06043934|Other|Neural Mobilization|"This Group will receive Neural Mobilization with routine physical therapy. Each nerve glide exercise will be performed ideally around 2-3 times, depending on the patient's comfort and tolerance levels. The intensity of the exercise is governed by the degree of stretch applied to the nerve. This should be within the patient's comfort level, causing a mild stretching sensation rather than pain. Each nerve glide will be performed in a set of 10-15 repetitions. Rest periods should be provided between each repetition and set, ensuring the patient's comfort.~In median nerve glide the patient will be seated comfortably. Their arm will be guided into shoulder depression, elbow extension, forearm supination, and wrist and finger extension. The patient will then be instructed to slowly flex and extend their wrist while maintaining the other positions. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session)."
75883245|NCT05766254|Device|Sham TMS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
75439783|NCT01613924|Device|Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
75883246|NCT05754853|Drug|MRG002|Administrated intravenously
75883247|NCT05754853|Drug|Docetaxel Injection|Administrated intravenously
75439784|NCT01613937|Behavioral|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
75439785|NCT01613950|Drug|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
75883248|NCT05754853|Drug|Paclitaxel Injection|Administrated intravenously
75883249|NCT05754853|Drug|Gemcitabine Hydrochloride for Injection|Administrated intravenously
76054556|NCT01862991|Drug|Misoprostol|400 mcg buccal misoprostol 90 pre-op
76054557|NCT01862991|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
76054558|NCT01862991|Drug|Mifepristone|200 mcg Mifepristone orally
76054559|NCT04415697|Diagnostic Test|Gene expression test using nanostring technology.|Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology
75439786|NCT01613950|Drug|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
76054560|NCT02202551|Drug|ADS-5102|
75439787|NCT01613963|Drug|Immunosuppressive Agents|Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
75590007|NCT06043921|Other|No intervention|There is no intervention associated with this observational study.
76054561|NCT02202317|Device|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
76054562|NCT02118337|Biological|MEDI0680|Participants will receive IV infusion of MEDI0680 0.1 or 0.5 or 2.5 or 10 or 20 mg/kg Q2W in dose-escalation phase and 20 mg/kg Q2W in dose-expansion phase.
75590008|NCT06043908|Drug|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
76054563|NCT02118337|Biological|Durvalumab|Participants will receive IV infusion of durvalumab 3 and 10 mg Q2W in dose-escalation phase and 750 mg Q2W in dose-expansion phase.
76054564|NCT02118337|Biological|Nivolumab|Participants will receive IV infusion of nivolumab 240 mg Q2W in dose-expansion phase.
76054565|NCT02117713|Drug|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
76054566|NCT02105467|Drug|Grazoprevir 100mg / Elbasvir 50 mg FDC|
76054567|NCT02105467|Drug|Placebo to Grazoprevir / Elbasvir 50 mg FDC|
76054568|NCT02202161|Drug|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
75439788|NCT01613976|Drug|Panobinostat|
75439789|NCT01614015|Behavioral|Supervision|SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
75439790|NCT01614015|Behavioral|Observational Supervision|One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
75439791|NCT01614028|Procedure|Total Hip Arthoplasty|
75439792|NCT01614041|Drug|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
75439793|NCT01614041|Drug|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
75439794|NCT01614054|Other|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
75590009|NCT06043908|Drug|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
75733411|NCT05949983|Other|APA Program|Patients treated and monitored for their breast cancer following the 6-month APA program.
75733412|NCT05949983|Other|Recommendations for physical activity|Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
76054569|NCT02202161|Drug|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
76054570|NCT02202161|Drug|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
76054571|NCT02202161|Drug|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
76054572|NCT03267563|Behavioral|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
76054573|NCT03267563|Behavioral|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
76054574|NCT03267563|Behavioral|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
76054575|NCT03109847|Drug|Metformin Hydrochloride|Given Orally
76054576|NCT03109847|Other|Radioactive Iodine|Undergo radioactive iodine treatment
76054577|NCT03109847|Other|Placebo|Given orally
76054578|NCT01461928|Drug|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
76054579|NCT01461928|Drug|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
76054580|NCT03097991|Behavioral|Focused Coparenting Consultation|Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
76054581|NCT02892305|Procedure|Hepatic Resection or Ablation with Pancreaticoduodenectomy|"Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care."
76054582|NCT02623205|Drug|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
75439795|NCT01614119|Other|Hypoxic exposure|Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture
75590010|NCT06043843|Combination Product|Focused diabetes tele-education and medication adjustment based on guidelines with remote monitoring from trial of fasting from before to throughout Ram|"Ramadan-focused online education by physician, specialist nurse, and dietitian via video conferencing~Fasting and exemptions~Self-monitoring of blood glucose~Acute diabetes complications and treatment~Ramadan nutritional plan~Safe physical activity You will be taught to record~Meal plans~Physical activities~Blood glucose monitoring, and~Monitoring for diabetes complications Perform a trial fasting day prior to Ramadan.~Medication adjustments will be made according to the Diabetes and Ramadan Alliance guideline as well as individualized modifications based on their HbA1c as follows Baseline HbA1c Recommended dose reduction < 8% 30% 8 to 10% 15% > 10% None~2) Glucose monitoring~up to 4 times daily Before Ramadan for 1 week During Ramadan After Ramadan for 1 week~uploaded into an online portal for data collection, without remote monitoring."
75590011|NCT06043804|Other|Doppler ultrasound measurement of changes in uterine artery blood flow|Doppler ultrasound measurement of changes in uterine artery blood flow
75733413|NCT05949281|Drug|Colchicine 0.5 MG Oral Tablet|Colchicine 0.5 mg once-daily
75733414|NCT05949281|Drug|Placebo|Placebo tablet once-daily
75733415|NCT05949021|Drug|Combination of liposomal doxorubicin|Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.
75439796|NCT01614132|Drug|maintenance chemotherapy (vincristin, cisplatin and CCNU)|maintenance chemotherapy of maximum of 8 cycles á 42 days
75439797|NCT01614132|Radiation|Radiotherapy|Radiotherapy of the partial brain
75439798|NCT01614158|Device|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) [Schiefer 2008] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
75439799|NCT01614158|Other|D-BCVA|D-BCVA using EDTRS chart
75439800|NCT01614158|Other|RAPD|RAPD using swinging flashlight test
75439801|NCT01614158|Device|IOP|IOP using applanation tonometer
75439802|NCT01614158|Device|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
75439803|NCT01614158|Other|Fundus photography|Optic disk morphology will be documented by fundus photography
75439804|NCT01614184|Drug|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
75439805|NCT01614223|Procedure|ACP|Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
75733418|NCT05948566|Biological|TS23|Monoclonal antibody
75439806|NCT01614223|Drug|Corticosteroid (celestone) injection|Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
75883250|NCT05754853|Drug|Pemetrexed Disodium Injection|Administrated intravenously
75883251|NCT05750420|Other|There was no intervention, the study was a cross-sectional observational study|Questionnaires for measuring self-care, anxiety, depression, emotinal distress and quality of live were administered to patients with chronic cardiovascular disease
75439807|NCT01614236|Drug|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
75590012|NCT06043778|Behavioral|Community care for People with Schizophrenia in India (COPSI)|This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).
75439808|NCT01614236|Drug|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
75439809|NCT01614262|Other|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
75590013|NCT06043778|Behavioral|mindLAMP Mobile Application|Participants in COPSI plus mindLAMP arm will have access to COPSI and the mindLAMP mobile application. mindLAMP has already been co-developed and culturally adapted by patients, family members, and clinicians at both Indian sites. Materials (articles, videos, web links, audio files, etc.) will be available on-demand and can be accessed by patients at any time. Community Health Officers will also schedule content to specific participants to promote engagement.
75590014|NCT06043765|Device|repetitive transcranial magnetic stimulation (rTMS)|real rTMS versus sham rTMS
75590015|NCT06043765|Behavioral|cognitive strategy training|7 weekly sessions with a trained neuropsychologist.
75590016|NCT06043752|Drug|Remsima|The patient will be given one Injection of REMSIMA 120 mg subcutaneously at week 0, 1, 2, 3, 4 and then every 2 weeks i.e., at 6, 8, 10 and 14 weeks. If the weight of the patient is >80 kg, 2 injections will be given.
75590017|NCT06043726|Diagnostic Test|Laboratory testing: D-dimeer and astrup|Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated
75590018|NCT06043687|Drug|Dentifrice Paste|Scaling and Root planing followed by dentifrice usage
75439810|NCT01614275|Behavioral|Technology-Enhanced Parent Training|"The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a Power Point presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
75733419|NCT05947656|Device|NaviFUS System|NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
75733420|NCT05946655|Drug|Ofloxacin + Metronidazole|Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
75883252|NCT05747625|Biological|Panitumumab|Given IV
75883253|NCT05747625|Drug|Zirconium Zr 89 Panitumumab|Given IV
75883254|NCT05747625|Procedure|Positron Emission Tomography|Undergo PET/CT
75883255|NCT05747625|Procedure|Computed Tomography|Undergo PET/CT
75883256|NCT05747625|Other|Electronic Health Record Review|Ancillary studies
75439811|NCT01614275|Behavioral|Technology-Enhanced Tutor Training|"The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
75590019|NCT06043648|Device|Endotracheal tube cuff pressure monitoring|The endotracheal tube cuff pressure was continuously monitored using a transducer from a standard invasive pressure monitoring device that is routinely used to measure arterial or central venous pressure.
75590020|NCT06043622|Other|Optical coherence tomography angiography|Optical coherence tomography angiography
75590021|NCT06043622|Other|ophthalmological exam|ophthalmological exam
75590022|NCT06043583|Procedure|Intrauterine device|The vagina is visually inspected to check the size and position of the uterus. The speculum is inserted into the vagina. The IUD is placed inside the uterus and then the strings are cut.
75590023|NCT06043583|Procedure|Uterine artery embolization|The right common femoral artery is punctured under ultrasound guidance and a 5F vascular sheath is inserted into the Rt common femoral artery. A 5F catheter was inserted into the internal iliac artery, and a 2.0F microcatheter is advanced into the uterine artery. Embolization is performed using polyvinyl alcohol (PVA). One third (20 mL) of a 60-mL mixture comprising 150-250-µm PVA particles was injected at the beginning of embolization into each uterine artery, followed by injection of at least two thirds (40 mL) to all (60 mL) of a mixture comprising 250-355- µm PVA particles and finally completion with 355-500- µm PVA particles. Embolization was performed until complete cessation of blood flow in the ascending uterine artery for 10 heart beats.
75590024|NCT06043570|Device|Remote Monitoring arm|Patients will be follow-up using remote monitoring. In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification.
75590025|NCT06043544|Device|Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe|Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other
75590026|NCT06043544|Drug|Corticosteroid injection|Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
75590027|NCT06043518|Diagnostic Test|MRI|We will examine patients with congenital upper-limb amputations using functional and structural MRI in both the brain and the spinal cord as well as questionnaires and clinical measures of motor function
75590028|NCT06043518|Diagnostic Test|MRI|We will examine healthy patients using functional and structural MRI in both the brain and the spinal cord and questionnaires.
75590029|NCT06043505|Other|Echographic hemodynamic algorithm guiding fluid resuscitation|"Ultrasound Hemodynamic Algorithm (UHA):~st step: 1/ Assessment of left ventricular filling pressures by Mitral Doppler echocardiography (2) 2/ Pulmonary ultrasound on 4 anterior dials (3)~E/Ea >14 and/or E/A >2~YES => No filling test => Bilateral anterior B lines on lung ultrasound => YES => Consider administration of diuretics~NO => Step 2~nd step: Assessment of filling response by dynamic maneuvers VTI (Velocity Time Integral) increase >15% after passive leg raising (4) or Mini-fluid challenge (5,6) Or decision of a 250ml filling test~YES => consider 250ml bolus filling~NO => stop vascular filling~rd step if dynamic maneuvers in favor of a response to filling: 1/ Assessment of response to 250ml filling 2/ If no response to vascular filling: Pulmonary ultrasound on 4 anterior dials (3) Change from a pulmonary profile A to a pulmonary profile B~YES => depletion~NO => stop vascular filling"
75590030|NCT06043479|Other|Fever Management Education|The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.
75590031|NCT06043466|Biological|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
75590032|NCT06043453|Other|revitalization|The main idea behind revitalization is to firstly disinfect the root canal and subsequently attract or transplant mesenchymal stem cells from the (remaining) dental pulp and apical papilla (in case of immature permanent teeth) into the root canal. More specifically, this therapy is not based on mechanical and (aggressive) chemical debridement as in conventional root canal treatment but is supported by the pillars of tissue engineering: stem cells, growth factors and a scaffold .
75590033|NCT06043440|Drug|Oxygen|Active nocturnal oxygen concentrator
75590034|NCT06043427|Drug|Paclitaxel|80 mg/m²
75590035|NCT06043427|Drug|Ramucirumab|8 mg/kg
75590036|NCT06043427|Drug|Zanidatamab|Dose and schedule to be assigned at enrollment
75590037|NCT06043401|Other|Neuroimaging with Magnetic Resonance Imaging (MRI)|MRI will be used to observe brain states over time.
75590038|NCT06043375|Dietary Supplement|Licorice Root Powder Capsule|Fresh licorice root will be obtained from local market of Lahore. The root will be washed and dried at room temperature. Then it will be converted into powder using grinder. After sieving the ground powder, it will be filled in capsules. One capsule will contain 1000mg of powder. Participants in experimental group will be instructed to consume one capsule per day.
75590039|NCT06043349|Combination Product|Platelet-Rich Plasma and Topical 5% Minoxidil|The intervention group will receive three PRP injections during three months in addition to the topical 5% minoxidil.
75590040|NCT06043349|Drug|Topical 5% Minoxidil|The intervention group will receive topical 5% minoxidil as standard therapy for male androgenetic alopecia.
75590041|NCT06043336|Drug|Dexamethasone, granisetron & palonosetron|. Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
75590042|NCT06043310|Drug|Nω-nitro-L-arginine methyl ester (L-NAME)|L-NAME will be infused locally through microdialysis catheters.
75590043|NCT06043310|Drug|Acetylcholine|ACh will be infused locally through microdialysis catheters.
75590044|NCT06043310|Drug|Sodium Nitroprusside|SNP will be infused locally through microdialysis catheters.
75590045|NCT06043284|Device|Hyperbaric Oxygen Therapy|Subjects received 100% medical grade oxygen for 60 minutes at 2.0 ATA for 40 sessions in a hard-sided monoplace hyperbaric chamber
75733421|NCT05941013|Device|Ultrasound detectable cuffed endotracheal tube (USD-ETT)|Intubation with a novel ultrasound-detectable endotracheal tube
75733422|NCT05939726|Other|Moisturising cream with vitamin E concentrate|The vitamin E moisturising cream contains 3% w/w of palm-oil-derived vitamin E concentrate, consisting of the following isomers: alpha-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. This formula provides a total of 1.2g tocotrienols per 100g product.
75733423|NCT05939726|Other|Moisturising cream without vitamin E concentrate|This moisturising cream is a similar moisturising cream but without the addition of the vitamin E concentrate
75439812|NCT01614275|Behavioral|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
75590046|NCT06043271|Behavioral|The EMPOWER Program|The EMPOWER Program is a web-based, self-administered SSI for parents that takes about 30 minutes to complete.
75590047|NCT06043258|Other|Bond Apatite|composite graft formed of biphasic calcium sulphate and hydroxyapatite at a ratio of 2:1
75733424|NCT05939726|Other|Urea cream|Urea cream (10%w/w) is used as the standard of care for PPE.
75590048|NCT06043258|Other|Bio-Oss|xenograft bone substitute
75590049|NCT06043245|Procedure|Duodenal Switch|Classic Duodenal Switch
75590050|NCT06043245|Procedure|SADI-S|SADI-S with a 300cm common channel
75590051|NCT06043245|Procedure|Minigastric Bypass|Classic minigastric bypass
75733425|NCT05939713|Device|Cera™ VSD occluder implantation|To collect data from patients who have implanted with the device before 2022.
75733426|NCT05939193|Procedure|Urine-guided hydration|The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of surgery, with a cumulative dose not exceeding 250 mg. Intravenous rehydration is performed to balance urine output and to maintain the SVV ≤10%.
75733427|NCT05939193|Procedure|Routine hydration|The target is to maintain urine output at 0.5 ml/kg/h or higher according to routine practice. That is, furosemide is only administered when clinically necessary or at discretion of responsible anesthesiologists; intravenous rehydration is performed to maintain the SVV ≤10%.
75733428|NCT05939193|Drug|Forced administration of furosemide|Forced administration of furosemide
75883257|NCT05744349|Procedure|K-wires Fixation of Pediatric Shaft Both Bone Forearm Fractures|After administration of anesthesia, surgery will be performed with the patient supine on the operating table and fracture will be analyzed with an image intensifier. In radius, the wire will be inserted by surgical drilling through Lister's tubercle or the radial styloid while in ulna, the wire will be inserted through the tip of the olecranon.
75883258|NCT05742347|Device|DriGo Skin Protectant Textile|All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
75590052|NCT06043232|Biological|DC vaccine|DC vaccine produced by the Team
75590053|NCT06043219|Other|Action Observation|"Action observation is defined as watching human movement either via a pre-recorded video or a live demonstration (Eaves et al, 2022). In the current study action observation will be via a pre-recorded video.~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
75590054|NCT06043219|Other|Motor Imagery|"Motor imagery practice is defined as the structured engagement in motor imagery over time for the purpose of acquiring and enhancing motor skills (Eaves et al, 2022).~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
75590055|NCT06043219|Other|Traditional Teaching|Traditional anatomical teaching via a powerpoint slide deck
75590056|NCT06043206|Procedure|Bariatric Surgery|Bariatric Surgery
75590057|NCT06043180|Procedure|Transcatheter aortic valve implantation|Intervention on aortic valve for severe aortic stenosis
75733429|NCT05939193|Drug|Routine administration of furosemide|Routine administration of furosemide
75733430|NCT05938933|Behavioral|PHP|personalized health planning (PHP)
75733431|NCT05938933|Behavioral|SMA|shared medical appointments (SMAs)
75883259|NCT05714267|Device|Active noise cancelling|During the operation, active noise canceling device (Sony wh100xm3) will be applied to the patients in Group-1 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
75733432|NCT05938439|Device|MAGUS placement|"An upper endoscopy will be performed with the use of fluoroscopy under general anaesthesia with orotracheal intubation. The delivery system will be placed over a guidewire, under fluoroscopy. The main steps are the following:~Placement through the endoscope of a soft guidewire through the upper GI tract;~Insertion of the MAGUS system on the guidewire;~Advancement of the MAGUS system until proximal magnet reach the top of the septum;~Release and placement of the proximal magnet at the bottom of the septum, pouch side;~Meeting of the distal and proximal magnet on both sides of the septum, by pulling on the delivery system;~Release of the distal magnet and activate the retractable wire;~Insure that wire is not blocked and unblocked it if applicable.~Endoscopy and contrast injection will be performed before and after placement to ensure the correct positioning of the magnets."
75733433|NCT05933772|Device|Lens A (comfilcon A toric lens)|One month wear
75733434|NCT05933772|Device|Lens B (lehfilcon A toric lens)|One month wear
75733435|NCT05929729|Drug|Ferric derisomaltose|Refer to arm/group descriptions
75733436|NCT05929729|Drug|NovaFerrum|Refer to arm/group descriptions
75439813|NCT01614275|Behavioral|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
75733437|NCT05926466|Drug|BTZ-043|BTZ-043 belongs to the chemical class of benzothiazinones, and is a promising antibiotic for the treatment of Tuberculosis. Its mechanism of action is based on the covalent inhibition of the enzyme decaprenylphosphoryl-ß-D-ribose-2'-epimerase (DprE1), which is essential for the cell wall assembly of mycobacteria. . Formation of the covalent adduct between BTZ-043 and DprE1 results in inhibition of cell wall biosynthesis and loss of viability of Mycobacteria Tuberculosis. BTZ-043 has been evaluated in three clinical studies: a phase Ia, First Time in Human study (FTIH), a two-stage phase Ib multiple ascending dose (MAD) and phase IIa monotherapy early bactericidal activity (EBA) study, and a human ADME (Absorption/Distribution/Metabolism/Excretion) study.
75733438|NCT05926466|Drug|Bedaquiline|Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.
75733439|NCT05926466|Drug|Delamanid|Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.
75439814|NCT01614288|Procedure|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
75439815|NCT01614288|Other|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
75883260|NCT05714267|Device|Passive noice cancelling|During the operation, passive noise canceling device (3M Peltor X5a) will be applied to the patients in Group-2 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
75883261|NCT05714267|Device|Active noise cancelling with music therapy|The patients in Group-3 will be given music therapy with an active noise canceling tool (Sony wh100xm3) during the surgery. The music that the patient will listen to will be left to the patient's preference. Music therapy with an active noise canceling device will be applied after spinal anesthesia is applied and will not be removed until the surgery is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
75883262|NCT05703100|Other|Incremental exercise test|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W)
75883263|NCT05703100|Other|Incremental exercise test under hyperthermia|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) performed at a room temperature of 35-38ºC (degrees Celsius).
75439816|NCT01614301|Drug|dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus|"Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity"
75439817|NCT01614314|Other|Preceptorship|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
75439818|NCT01614314|Other|Auto-instructional guide|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
75590058|NCT06043167|Diagnostic Test|The predictive value russian rendition the FOUR score.|"It is planned to include at least 200 adult OAR patients and all those transferred to the rehabilitation department for evaluation.~To maintain accounting documentation, an individual registration card is offered for registration. The paper version of the IRC records the age of the patient, the diagnosis according to the International Classification of diseases of the tenth revision (ICD-10), the day of hospital stay and ICU. The level of consciousness is assessed according to the unified interdisciplinary scale of disorders of consciousness, Glasgow Coma Scale (GCS), Full Outline of Unresponsiveness (FOUR) and Richmond Agitation-Sedation Scale (RASS). After each inspection, the data is entered into the electronic version of the IRC."
75590059|NCT06043115|Other|covid-19 survival cohort|consists of surviving patients
75590060|NCT06043115|Other|covid-19 mortality cohort|consists of deceased patients
75590061|NCT06043102|Device|TheraClearX|TheraClear®X combines vacuum pressure with a broadband light source (500 nm to 1,200 nm) to treat facial acne.
75590062|NCT06043089|Dietary Supplement|Beetroot juice supplementation or placebo|Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
75439819|NCT01614340|Behavioral|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
75439820|NCT01614353|Other|Electronic Diaries|Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
75439821|NCT01614353|Other|Hermeneutic Interviews|Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
75439822|NCT01614366|Drug|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
75439823|NCT01614366|Drug|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
75439824|NCT01614366|Drug|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
75590063|NCT06043076|Device|TMS|Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
75590064|NCT06043076|Device|Sham|Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head
75590065|NCT06043024|Device|Stabilization occlusal splint|Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance. OS will be made by the same dental technician in the dental laboratory.
75590066|NCT06042998|Procedure|Robotic radical gastrectomy|Laparoscopic gastrectomy
75590067|NCT06042985|Drug|The absorption effect between calcium citrate and calcium carbonate|Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.
75590068|NCT06042959|Other|Laughter therapy|We used laughter yoga to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
75590069|NCT06042868|Other|Nursing protocol|Emergency nursing protocol
75590070|NCT06042829|Device|Intubation using aerosol box|Intubation time and ease of intubation using aerosol box
75733440|NCT05926466|Drug|Moxifloxacin|Moxifloxacin belongs to the group of fluoroquinolones (FQ). FQs are a mainstay of MDR-TB treatment, and Moxifloxacin is considered the most potent drug in second line MDR-TB therapy, recently reviewed by WHO, with only moderate pre-existing resistance in the community.
75439825|NCT01614366|Drug|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
75733441|NCT05925127|Biological|NVX-CoV2373 (5μg)|Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg/mL and 100 μg adjuvant per mL, respectively
75733442|NCT05925127|Biological|NVX-CoV2601 (5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 50 µg Matrix-M adjuvant.
75733443|NCT05925127|Biological|NVX-CoV2601(5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 75 µg Matrix-M adjuvant.
75590071|NCT06042829|Device|Intubation without aerosol box|Intubation time and ease of intubation without aerosol box
75590072|NCT06042816|Procedure|Free-opioid anesthesia|Free opioid anesthesia (FOA) has been used in many countries around the world, making use of multimodal analgesia therapy which includes hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics and anti-inflammatory agents and sympathetic block in surgery. This method was demonstrated to contribute to enhanced recovery after surgery (ERAS). The use of long-acting local anesthetics also enhances postoperative pain relief. As a result, the concept of balanced anesthesia now has a change in three basic components: hypnotics, muscle relaxants and sympathomimetic inhibitors
75590073|NCT06042816|Procedure|opioid anesthesia|Opioids have been used as one of three basic components of balanced anesthesia, including anesthetic drugs, pain relievers, and neuromuscular blockade agents (opioid anesthesia). Opioids not only facilitate deep anesthesia but also create the most favorable conditions for surgeries. Fentanyl is a potent opioid used to control pain, reduce the dose of sympathomimetic inhibitors and maintain hemodynamic stability. However, several common side effects of fentanyl are well known: nausea and vomiting, constipation, urinary retention, headache, pruritus, rash, histamine release, biliary spasm and respiratory depression, the most severe adverse effect
75590074|NCT06042803|Other|Human milk collection|Every time the mother would normally feed the child, we ask to collect the total milk volume for the feed from both breasts by an electric pump. For each collection, the volume and time will be noted, the container will be inverted and 5 to 10ml of that volume will be transferred in a polypropylene test tube or other tube type depending on the type of compounds (=sample to determine drug concentration in milk) for analysis (max 10% of the collected volume of each feed). The participant decides how the remainder of the collected milk is used. The milk samples will immediately be stored in the refrigerator (4°C) after being labeled. The samples will be collected by one of the investigators within 24 hours, will be transported on ice and frozen at -80°C until analysis.
75590075|NCT06042803|Other|Optionally: maternal blood sample|Blood collection to determine the drug concentration in plasma (6 to 10mL EDTA or other tube type, depending on the type of compound) will be performed at least within 1 hour interval with the first feeding (pumping) after medication intake, and 24 hours after medication intake (with preferable milk collection within 1 hour of blood sampling). The sample label, date and time of sampling will be noted.
75590076|NCT06042803|Other|Optionally: child blood sample|Blood collection of the infant to determine systemic exposure of child(1-5% of the total blood volume, according to the FDA guidelines, in an EDTA or other tube type, depending on the type of compound,) will be performed at the same day as the maternal sampling, if parental consent is obtained. The sample label, date and time of sampling will be noted.
75590077|NCT06042777|Behavioral|Acupuncture and TCM-based lifestyle management|Non-pharmacological treatment based on traditional Chinese medicine.
75590078|NCT06042764|Drug|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
75439826|NCT01614405|Drug|Truvada and Kaletra|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
75439827|NCT01614418|Device|Endoscopic radiofrequency ablation catheter|Endoscopic radiofrequency ablation
75439828|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
75439829|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine for cystinosis patients CKD stages 1 to 4
75439830|NCT01614444|Other|Active Acupressure Treatment|Participant will receive 8 active acupressure treatments.
75439831|NCT01614444|Other|Placebo Acupressure Treatment|Participants will receive 8 placebo acupressure treatments.
75439832|NCT01614496|Other|Algorithm for insulin administration|
75439833|NCT01614522|Drug|ASLAN001|ASLAN001 500mg BID
75733444|NCT05925127|Biological|NVX-CoV2601 (35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 50 µg Matrix-M adjuvant.
75733445|NCT05925127|Biological|NVX-CoV2601(35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 75 µg Matrix-M adjuvant.
75733446|NCT05925127|Biological|NVX-CoV2601(50μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 50 µg of antigen with 100 µg Matrix-M adjuvant
76054583|NCT02623205|Drug|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
76054584|NCT01500694|Drug|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
75590079|NCT06042738|Combination Product|proxeed plus|Group 1 was recommended to receive a food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg selenium, 3750 µg vitamin B12 and 500 µg folic acid as one sachet in the morning and evening
76054585|NCT04188977|Other|Usual Practice|OTP Directors are able to ask their state health officials permission to use interim methadone treatment. The state officials are in turn able to ask officials from the Center of Substance Abuse Treatment for permission to provide interim methadone treatment.
76054586|NCT04188977|Other|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
75439834|NCT01614535|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence|Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
75590080|NCT06042634|Behavioral|Online psychoeducation|Online psychoeducation aimed to enhance the knowledge and skill of family caregivers of people with dementia, who could not physically attend in-person class. Knowledge covering dementia caregiving including disease nature, communication skill, stress and coping, daily care, management of behavioral and psychological symptoms of dementia, and future planning. The intervention provided opportunities to practice through simulation and weekly home assignment. There was a total of 6 sessions and provided weekly. Each session lasted for 2 hours. Participants had discussion with peers and coached by a facilitator. Online psychoeducation wad delivered via Zoom videoconferencing.
75590081|NCT06042634|Behavioral|Face-to-face psychoeducation|Face-to-face psychoeducation has the same content and flow of presentation as online psychoeducation.
76054587|NCT01500382|Drug|Vibegron|Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
76054588|NCT01500382|Drug|Tolterodine ER|Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
76054589|NCT01500382|Other|Placebo (vibegron)|Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
76054590|NCT01500382|Other|Placebo (tolterodine ER)|Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
76054591|NCT01500382|Drug|Prophylactic Antibiotic|A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
76054592|NCT02137837|Drug|Fulvestrant|
76054593|NCT02137837|Drug|Anastrozole|
76054594|NCT02137837|Drug|Everolimus|
76054595|NCT02137837|Drug|Placebo - Anastrozole|
76054596|NCT02137837|Drug|Placebo - Everolimus|
76054597|NCT01483690|Drug|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
76054598|NCT01483690|Drug|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
76054599|NCT01483690|Drug|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
76054600|NCT01483690|Drug|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
76054601|NCT01483690|Drug|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
75439835|NCT01614639|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
75439836|NCT01614652|Device|CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)|CardioKinetix Parachute implant and all appropriate medical therapy
75439837|NCT01614678|Device|Lotrafilcon B contact lens with color, automated|Silicone hydrogel contact lens with color manufactured via an automated process
75439838|NCT01614678|Device|Lotrafilcon B contact lens with color, semi-automated|Silicone hydrogel contact lens with color manufactured via a semi-automated process
75439839|NCT01614691|Drug|SPARC1203|Active
75439840|NCT01614691|Drug|Placebo|Placebo
75439841|NCT01614717|Device|CRT-P Implant|All patients will be implanted with a CRT-P device, then randomized to Treatment or Control Group
75439842|NCT01614730|Device|Modified Neurotech Vital Device|verify no contraction is stimulated in the Modified Neurotech Vital.
75590082|NCT06042530|Diagnostic Test|Neuropsychological investigation|Comprehensive neuropsychological test battery covering logical reasoning, different attention functions, executive functions, visuospatial functions, different memory functions, psychomotor speed, motor functions, and smell identification
75590083|NCT06042530|Diagnostic Test|Optometric investigation|Extended vision examination including symptom assessment, visual acuity, visual field (confrontation), eye movements, eye teaming and clinical assessment of hypersensitivity to visual stimuli.
75883264|NCT05703100|Other|Incremental exercise test under glycogen depletion|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) under glycogen depletion by performing an exercise protocol to deplete glycogen stores plus a low-carbohydrate diet 24 h before incremental testing
75883265|NCT05695300|Dietary Supplement|BLM ORGANIC GOLD+|Participants in this arm need to be fed the assigned infant formula daily for three months, no other formula or breast milk
75883266|NCT05695300|Dietary Supplement|BLM ORGANIC|Participants in this arm need to be fed the assigned infant formula daily for three months,no other formula or breast milk
75883267|NCT05695300|Dietary Supplement|Breast milk|Participants in this arm need to be fed with breast milk daily for three months, no infant formula
75883268|NCT05692869|Drug|Propranolol|Administered orally.
76054602|NCT01483690|Drug|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
75590084|NCT06042530|Diagnostic Test|Magnetic Resonance Imaging|The MRI sequence protocol includes resting state fMRI before and after the participants do an established 20 min long reaction time measurement paradigm (E-prime). During the paradigm a pseudo-continious arterial spin labeling sequence (pCASL) is acquired for continuous measurement of brain perfusion. Following the functional sequences the imaging protocol also includes a high resolution 3D T1weighted sequence Magnetization Prepared Rapid Gradient Echo (MPRAGE) for brain structure, a high resolution 3D T2-weighted sequence Fluid-Attenuated Inversion Recovery (FLAIR) for pathology and a 3D susceptibility weighted image (SWI) for microvascular abnormalities.
75883269|NCT05692869|Drug|Pseudoephedrine|Administered orally.
75439843|NCT01614730|Device|Neurotech Vital Device|Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
75439844|NCT01614756|Biological|BMS-981164|
75439845|NCT01614756|Biological|Placebo matching with BMS-981164|
75439846|NCT01614782|Drug|MK-5823|"MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo."
75439847|NCT01614782|Other|Placebo|Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
76054603|NCT01483690|Drug|Methotrexate|"Given intrathecally to all patients the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
76054604|NCT02104765|Drug|LY2951742|Administered subcutaneously.
75883270|NCT05692869|Device|ABPM and Wearable Novel Devices|ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.
75883271|NCT05692869|Other|No Intervention|No intervention during this period (Control Period)
76054605|NCT02104765|Drug|Placebo|Administered subcutaneously.
76054606|NCT01483144|Drug|Eflornithine|Eflornithine [250 mg tablet, three tablets (750 mg) orally once a day]
76054607|NCT01483144|Drug|Eflornithine Placebo|Eflornithine placebo [three tablets orally once a day]
76054608|NCT01483144|Drug|Sulindac 150 MG|Sulindac [one tablet orally once a day]
76054609|NCT01483144|Drug|Sulindac placebo|Sulindac placebo [one tablet orally once a day]
76054610|NCT01881789|Drug|Oprozomib|Extended release (ER) tablets administered orally
76054611|NCT01881789|Drug|Lenalidomide|Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.
75439848|NCT01614808|Other|laboratory biomarker analysis|Correlative studies
76054612|NCT01881789|Drug|Dexamethasone|Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants > 75 years of age, at the discretion of the investigator.
76054613|NCT01881789|Drug|Cyclophosphamide|Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
76054614|NCT02075203|Biological|AERAS-404|The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK & a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 & saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
75883272|NCT05691439|Behavioral|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
75590085|NCT06042530|Diagnostic Test|Immunological biomarkers|Venous blood samples (10-20 ml) are taken from the elbow crease. They are drawn in the morning, and the participants are asked to fast for 12 hours prior to sampling. They are also asked to avoid physical activity prior to blood sampling. The samples are drawn into citrated tubes.
75883273|NCT05691439|Behavioral|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
76054615|NCT02075203|Drug|Placebo|Saline
76054616|NCT02075203|Biological|Bacillus Calmette-Guérin (BCG)|BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
76054617|NCT01892163|Device|Ozurdex|Dexamethasone implant (Ozurdex)
76054618|NCT01881009|Device|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
76054619|NCT01881009|Device|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
76054620|NCT01500226|Drug|Rolapitant|(4 X 50 mg capsule) 200 mg PO
75439849|NCT01614873|Device|Servo-i® ventilator, MAQUET,Critical Care, Sweden|Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
75439850|NCT01614938|Drug|Cetuximab|400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
75439851|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
75590086|NCT06042439|Behavioral|6 weeks of exercise training (Pre-training)|handgrip and treadmill walking 4 days per week
75590087|NCT06042439|Behavioral|6 weeks of exercise training (Post-training)|handgrip and treadmill walking 4 days per week
75439852|NCT01614938|Drug|Docetaxel|2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
76054621|NCT01500226|Drug|Granisetron|2 mg PO
76054622|NCT01500226|Drug|Dexamethasone|20 mg PO
76054623|NCT01500226|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
75590088|NCT06042283|Behavioral|Metacognitive Training-Silver|"The Metacognitive Training-Silver program includes the following topics: Thinking and Reasoning 1 (module 1), Memory (module 2), Thinking and Reasoning 2 (module 3), Self-Esteem (module 4), Thinking and Reasoning 3 (module 5), Behaviors and Strategies (module 6), Thinking and Reasoning 4 (module 7) and Perception of Feelings (module 8).~Each session is planned to last 45-60 minutes. Materials will be used in the Metacognitive Training-Silver program are PPT (Power Point Presentations) slides, videos, homework exercises, and yellow-red cards.~Metacognitive Training-Silver is planned to be applied face-to-face in 3 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group. In order to increase compliance with the Metacognitive Training-Silver program, the sessions will be applied during the routine treatment period."
75590089|NCT06041958|Device|Extracorporeal shock wave therapy|2 times/week for 12 weeks
75590090|NCT06041958|Device|Pulse electromagnetic field therapy|2 times/week for 12 weeks
75590091|NCT06041958|Other|Rehabilitation|2 times/week for 12 weeks
75590092|NCT06041854|Procedure|Freeze-dried bone allograft combined with Enamel Matrix derivative|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft mixed with enamel matrix derivative.~Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle.The major components of EMD are amelogenins, a family of hydrophobic porcine tooth-derived proteins. They account for more than 95% of the total EMD protein content. Other proteins found in the enamel matrix include enamelin, ameloblastin, amelotin, apin and various proteinases, which have found in trace amounts in EMD. EMD adsorbs on decontamined root surfaces and alveolar bony defects and forms an insoluble scaffold complex."
75590093|NCT06041854|Procedure|Freeze-dried bone allograft|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft .~Allogeneic bone graft refers to bony tissue that is harvested from one individual and transplanted to a genetically different individual of the same species, principally osteoconductive, although it may have some osteoinductive capability, depending on how it is processed."
75590094|NCT06041737|Other|consultation|nephrology consultation during 2020
75590095|NCT06041685|Procedure|local warming|local warming on the site for arterial catheterization using forced air warmer
75590096|NCT06041555|Other|3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed|Generate 3D maps of intra-tumoral hypoxia and characterize their evolution during treatment thanks to the establishment of a prospective database of MRI sequences
75590097|NCT06040749|Other|Virtual group-based handcycling|Virtual group-based handcycling
75733447|NCT05925127|Biological|Bivalent BA.4/5|The bivalent BA.4/5 (or recommended mRNA vaccine at the time of the conduct of this study) Omicron subvariant/prototype licensed mRNA vaccine will be procured and stored per the manufacturer's instructions. For this vaccine group, treatment will be administered open label as a single IM injection
75733448|NCT05922124|Drug|Cefiderocol|Test drug regimen
75439853|NCT01614938|Radiation|Intensity-modulated radiotherapy|a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
75439854|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
75439855|NCT01614951|Procedure|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
75439856|NCT01614951|Drug|HTK Custodiol|Pulmoplegia before ECC.
76054624|NCT02075047|Drug|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
76054625|NCT02075047|Drug|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
76054626|NCT01859949|Drug|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
76054627|NCT01859793|Drug|sitagliptin|100 mg pill, administered once/day orally
76054628|NCT01859793|Drug|Placebo|Matching placebo in appearance given once/day orally
75439857|NCT01614951|Other|Standard ECC|ECC after standard procedure
76054629|NCT01859715|Drug|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
75883274|NCT05679284|Radiation|Low-dose X-ray of subcutaneous tissues|To identify needle fragment retentions, the radiologic imaging of all volunteers will be performed with X-ray using radiation doses as low as reasonably achievable (ALARA) and one projection per anatomic site.
75883275|NCT05663476|Other|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
75883276|NCT05660226|Other|Home blood pressure monitoring (telemonitoring)|Using a digital mobile phone based telemonitoring platform to A: monitor patients and adjust their treatment accordingly based on the remote monitoring outcomes and B: provide E-Coaching/self learning modules (lifestyle)
76054630|NCT01859715|Drug|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
75883277|NCT05660226|Other|Standard care|Standard outpatient blood pressure management
75883278|NCT05655468|Drug|Dronedarone|oral administration fed conditions
76054631|NCT01859715|Drug|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
76054632|NCT01890915|Other|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
76054633|NCT04616235|Drug|Tocilizumab Injectable Product|The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
76054634|NCT04616235|Other|Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour|The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
76054635|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
76054636|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
75590098|NCT06040645|Other|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
76054637|NCT04590495|Drug|300 mg Cannabidiol (CBD) oil|Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
75733449|NCT05922124|Drug|Ampicillin-sulbactam|Synergistic combination
75733450|NCT05922124|Drug|Colistin|Historical comparator
75733451|NCT05922124|Drug|Meropenem|Historical comparator synergistic combination
75733452|NCT05919888|Drug|Povidone-Iodine|Applied to skin incision.
75733453|NCT05919888|Device|SURGX Wound Gel|Applied to skin incision.
75733454|NCT05919160|Device|DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task|Devices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab)
75733455|NCT05917119|Other|BLT|Bright light therapy delivered via glasses
75733456|NCT05917119|Other|s-BLT|sham delivered with bright light therapy glasses to which a neutral density filter has been applied
75733457|NCT05915533|Other|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the disabled adults housed in the establishments of UNIVI group.
75733458|NCT05914779|Other|No use of antibiotics|Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
75733459|NCT05914779|Other|with antibiotics treatment|with antibiotics treatment
75733460|NCT05908630|Other|Hypothermia|"Accidental hypothermia is defined as: an involuntary drop in core body temperature <35C"
75883279|NCT05655468|Drug|Placebo|strictly identical in appearance with dronedarone,oral administration fed conditions
75883280|NCT05650242|Drug|BA1106|"In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W)."
75883281|NCT05649488|Device|Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus|"Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle.~Therapeutic apparatus specification: IVL-HVG-C01； Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015"
75883282|NCT05649488|Device|Dragonfly Opstar Imaging Catheter|OCT (optical coherence tomography) measurement using Dragonfly Opstar Imaging Catheter was performed in the OCT subgroup before or after the treatment of intracoronary lithotripsy balloon catheter and intracoronary lithotripsy therapeutic instrument, or after stent placement.
75883283|NCT05645627|Drug|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
75883284|NCT05645627|Drug|placebo /IBI112|placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
75883285|NCT05645627|Drug|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
75733461|NCT05907720|Behavioral|Human-centered design prototype solutions for vulnerable pregnant women|The intervention package will include various social and behavior change programs derived from a human-centered design approach. The intervention will be tailored to vulnerable pregnant women's needs and contexts. It may include but is not limited to health communication campaigns, including radio and print media.
75883286|NCT05644353|Drug|Mirikizumab|Administered SC.
75883287|NCT05628155|Other|Oral diet including n-3 PUFA intake|menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
75733462|NCT05906875|Other|Lateral Stepping Exercise 1|1. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.
75733463|NCT05906875|Other|Active Control Group Exercise 1|1. Seated ankle movements (dorsi-/plantarflexion)hree sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
75439858|NCT01614964|Drug|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
75439859|NCT01614964|Drug|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
75733464|NCT05906875|Other|Active Control Group Exercise 2|2. Knee extension Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
75733465|NCT05906875|Other|Active Control Group Exercise 3|3. Hip flexion Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
75733466|NCT05906875|Other|Active Control Group Exercise 4|4. Hip abduction Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
75590099|NCT06040645|Other|E-consult|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
75439860|NCT01613729|Drug|Rosuvastatin 5 mg|Rosuvastatin 5 mg
76054638|NCT04590495|Drug|Placebo|Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
75590100|NCT06040242|Other|Exercise|Participants will perform 3 min of the different activities, followed by a 10-min recovery window.
75590101|NCT06040203|Biological|Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)|Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.
75590102|NCT06040203|Biological|Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)|Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.
75590103|NCT06040203|Drug|Placebo (saline solution)|Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
75590104|NCT06038903|Other|caffeine consumption expectation|The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption.
75590105|NCT06038799|Behavioral|Caregiver Skills Training (CST)|The investigators are comparing the relative efficacy of CST between a CST group led by clinicians trained and supervised remotely versus a group led by clinicians trained an supervised face-to-face.
75590106|NCT06038682|Drug|Argatroban Injection|Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
76054639|NCT01859403|Genetic|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
75590107|NCT06038682|Drug|Heparin|Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
76054640|NCT01859403|Genetic|Usual Care|Patients receive the same dietary recommendation regardless of their genetic information
75590108|NCT06038669|Device|Dried blood spot device|Patients will be asked to provide a dried blood spot sample
75883288|NCT05620966|Device|CGX Systems Quick-20m|The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
75883289|NCT05617287|Dietary Supplement|Semaine Menopause Supplement|Synergistic Dietary Supplement
75439861|NCT01613729|Drug|Rosuvastatin 10 mg|
75439862|NCT01614977|Drug|Methylprednisoline|Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
75439863|NCT01615003|Drug|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
75439864|NCT01615003|Drug|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
75590109|NCT06038669|Other|Healthcare professional interviews|Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
75733467|NCT05906875|Other|Lateral Stepping Exercise 2|2. Lateral stepping: Performed without and with resistance bands. The participant will perform a series of steps to the side. If using a resistance band, the band will be placed around both ankles in a 'loop' and the participant will perform the lateral stepping. Three sets of 8-12 repetitions will be performed per side per subject.
75733468|NCT05906875|Other|Lateral Stepping Exercise 3|3. Single leg stance: The participant will stand on one leg with support as needed. The contralateral knee will be held at 45 degrees throughout the exercise. The instructor will observe to ensure the bent leg does not contact the ground. Three repetitions of static stance per side will be performed with a goal of 30 seconds, and a maximum time of 60 seconds, per repetition.
75590110|NCT06038656|Dietary Supplement|Galactooligosaccharides (GOS)|"10 g of GOS provided as 14 g of powder will be consumed after mixing it in water or yoghurt.~The absorption study test drinks administered during the 3 test conditions will be comprised as follows:~Post rest period - 50 mg of iron as ferrous fumarate (Fefum) supplement, 6 mg 54Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout - 50 mg of iron as Fefum, 6 mg 58Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout co-administered with GOS - 50 mg of iron as Fefum, 6 mg 57Fe as Fefum and 300 ml of water with 10 g GOS."
75590111|NCT06038500|Other|Multicomponent intervention of resistance exercises, dancing sessions and nutritional education|The intervention consisted of two sets of ten repetitions of resistance exercises, the second month four sets of eight repetitions, and the third month four sets of fifteen repetitions. It was estimated that each session (dance + resistance exercise) generated a caloric expenditure of 270.85 calories corresponding to 4.5 and 3.5 METs per activity. The resistance exercises and the dance sessions began and with a warm-up and stretching session 10 min, followed by the resistance exercises 30 min and dancing practice 30 min. The session ended with a cooling down session 10 min. The nutritional education offered included weekly topics lasting 20 min, on basic concepts of nutrition and recommended diet for the maintenance of skeletal muscle mass. Reinforcement of the topics was carried out through triptychs that were provided throughout the 12 sessions.
75590112|NCT06038448|Procedure|Urinary catheter balloon size|The investigators will collect 120 participants divided into two groups ,in different procedure(stone procedure, herniarraphy, nephrectomy), and the investigators used different urinary catheter balloon size(10ml and 5ml), tp investigate the patient with the severity of catheter-related bladder discomfort.
75590113|NCT06037993|Dietary Supplement|Ultra-micronized Palmitoylethanolamide (PEA)|"Palmitoylethanolamide (PEA) is an N-acylethanolamine (AE), produced on demand by different cell types as a response to actual or potential damage, proven to down-regulate central and peripheral activity of mast cells and non-neuronal cells (e.g., astrocytes, microglia) and to exert protective functions against glutamate neuro-toxicity, accounting for its naturally-occurring anti-inflammatory, analgesic, and anticonvulsant properties. Due to the shared pharmacodynamic properties, PEA is considered as the endogenous equivalent of Cannabidiol (CBD). A growing body of literature has confirmed the role of PEA in most neurobiological mechanisms underpinning several neuropsychiatric conditions both in clinical and preclinical settings. The effect of PEA over neuroinflammation and glutamate signaling may represent a promising biobehavioral mechanism underlying the clinical utility of its oral supplementation in CHR state."
76054641|NCT01858701|Device|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
75590114|NCT06037408|Drug|20mM sodium pyruvate nasal spray|The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with 0.02% benzalkonium chloride preservative, pH 7.2 (N115). Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
75590115|NCT06037408|Other|Saline Placebo control nasal spray|The placebo is 0.9% sodium chloride with 0.02% benzalkonium chloride preservative, pH 7.2. Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
75733469|NCT05906875|Other|Lateral Stepping Exercise 4|4. Staggered stance mini-squat: Participants will stand with the feet hip-width apart and one leg placed a short step forward. The participant will squat straight down keeping the trunk upright and return to an upright position.
75733470|NCT05906875|Other|Lateral Stepping Exercise 5|5. Lateral Reactive Postural Control: The participant will lean into the researcher's hand to shift their center of mass outside of their base of support. Hand placement will be at the glenohumeral joint and the pelvis. The researcher will withdraw support and guard the participant as the participant regains their balance. This is item 6 on the Mini-BESTest assessment that will be incorporated as an intervention. To be performed 3x per side.
75590116|NCT06037369|Behavioral|customized standardized educational program sent by LINE software.|At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object.
75590117|NCT06037317|Drug|SY-3505|LTK tyrosine kinase inhibitor
76054642|NCT01858701|Device|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
76054643|NCT01461538|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
76054644|NCT01461538|Drug|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
76054645|NCT01461538|Drug|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
76054646|NCT02117479|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
75590118|NCT06036459|Other|uterine peristalsis|Transabdominal us followed by Transvaginal ultrasonography scans (Sono Ace R5 ) of uterine peristalsis will performed on the day of embryo transfer while the patient lying relaxed in lithotomy position. The probe will be introduced into the vagina as gently as possible to avoid stimulating the cervix. After scanning the mid-sagittal plane of the uterus, the probe will be fixed as steady as possible while a 3 min video of uterine peristalsis will be recorded simultaneously. The records will be analyzed at 4X regular speed using a Video player application by two independent experienced observers. The uterine peristaltic wave frequency will be the mean of the results from each observer.
75733471|NCT05905276|Other|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
75439865|NCT01615016|Other|Minimally invasive endotracheal surfactant application|"What are the planned trial interventions?~MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26"
75590119|NCT06036303|Device|Nasr fascial closure device|Nasr fascial closure device is a novel device for fascial closure
75590120|NCT06036303|Device|Berci Fascial Closure Device|Berci Fascial Closure Device is a known device for fascial closure
75590121|NCT06035302|Procedure|Madany Closure|Madany Closure is a new technique for the porte site closure
75590122|NCT06035302|Procedure|Standard closure|Standard closure technique of the port site from ecternal
75590123|NCT06034899|Drug|BMS-986196|Specified dose on specified days
75590124|NCT06034873|Drug|Propofol injection and fentanyl|The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
75590125|NCT06034873|Drug|Bupivacain|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
75590126|NCT06034535|Biological|CD62L depleted donor lymphocyte infusion|Intravenous infusion of CD62L depleted donor lymphocytes
75733472|NCT05905276|Other|Standard of Care|Patients in the usual care arm of the EMBRACE trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
76054647|NCT02117479|Drug|Placebo|5 mg tablets to be administered by mouth twice daily (BID)
76054648|NCT02117479|Drug|Capecitabine|150 and 500 mg tablets to be administered by mouth twice daily (BID)
76054649|NCT02229851|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
76054650|NCT02229851|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
75439866|NCT01615042|Drug|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
75439867|NCT01615055|Drug|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
75439868|NCT01615055|Other|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
75590127|NCT06034379|Device|eSpectacle Clinical prototype (CP1) device|The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
75590128|NCT06034379|Drug|0.01% atropine|Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
76054651|NCT02229851|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
75883290|NCT05615480|Other|Controlled hypotension guided by cerebral oxygen saturation monitoring|In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% ~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% ~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 ~ 100 μg or ephedrine 5 ~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
75883291|NCT05604924|Other|virtual reality training for cesarean section|Participants who received virtual reality training for cesarean section can learn the surgical procedures as if they were in a real field.
75439869|NCT01615081|Other|The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake|2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
75439870|NCT01615107|Device|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
75439871|NCT01615107|Drug|PITOCIN|: Oxytocin infusion alone (Standard Protocol
75439872|NCT01615107|Other|double balloonand oxytocin|balloonand oxytocin
75590129|NCT06034249|Behavioral|Mindfulness-Based VR|Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
75590130|NCT06034249|Behavioral|Audio|The mindfulness-based audio files for six weeks.
75590131|NCT06034158|Drug|single-dose madopar, single-dose propranolol, and single-dose placebo by order|Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
75590132|NCT06034158|Drug|single-dose madopar, single-dose placebo, and single-dose propranolol by order|Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
75590133|NCT06034158|Drug|single-dose propranolol, single-dose madopar, and single-dose placebo by order|Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
75590134|NCT06034158|Drug|single-dose propranolol, single-dose placebo, and single-dose madopar by order|Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
75590135|NCT06034158|Drug|single-dose placebo, single-dose propranolol, and single-dose madopar by order|Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
75590136|NCT06034158|Drug|single-dose placebo, single-dose madopar, and single-dose propranolol by order|Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
75733473|NCT05904717|Drug|PXS-4728 (A)|Participants will receive once daily (QD) for period of 12 weeks
75439873|NCT01615107|Other|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
75439874|NCT01615107|Procedure|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
75439875|NCT01615146|Other|Platelet Transfusion|"Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is < 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded."
75439876|NCT01615172|Procedure|cannulation|The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
75439877|NCT01615185|Drug|full-dose amisulpride|amisulpride 800mg/d
75439878|NCT01615211|Drug|Letrozole|Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
75439879|NCT01615211|Drug|Trilostane|Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
75439880|NCT01615224|Drug|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
75590137|NCT06033950|Drug|Finerenone|Oral finerenone.
75590138|NCT06033950|Drug|Placebo|Matching oral placebo.
75733474|NCT05904717|Drug|Matching Placebo (B)|Participants will receive once daily (QD) for period of 12 weeks
75883292|NCT05600400|Radiation|Stereotactic Ablative Body Radiation|2 Fraction
75883293|NCT05581953|Other|Omnivorous|Pork-added plant-forward diet
75883294|NCT05581953|Other|Vegetarian|Plant-forward lacto-ovo-vegetarian diet
75883295|NCT05576051|Other|patterns of use of combination therapy and monotherapy|
75883296|NCT05575687|Other|Water (reference)|Ingestion of 500 ml mineral water
75883297|NCT05575687|Other|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
75883298|NCT05575687|Other|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
75883299|NCT05575687|Other|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
75883300|NCT05575687|Other|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
76054652|NCT01482910|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
76054653|NCT01482910|Drug|Visudyne|Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
75439881|NCT01615237|Behavioral|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
75439882|NCT01615237|Behavioral|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
76054654|NCT04077190|Device|Adipose-derived stem cells|5cc adipose derived stem cells.
76054655|NCT04077190|Device|cortisone injection|cortisone injection
75439883|NCT01615237|Behavioral|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
75439884|NCT01615250|Biological|Intramyocardial implantation of stem cells|Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
75439885|NCT01615276|Device|Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)|One our of one-legged neuromuscular electrical stimulation (NMES)
75590139|NCT06033885|Device|PONDUS®|"PONDUS® is a CE-marked medical device to support the positioning of the user in a R82 standing frame.~PONDUS® is designed as a pair of instrumented foot plates and an app as an external display.~PONDUS® gives individual readings from the right and the left plate telling how much force is applied to each plate by combining high frequency data from three pressure sensors in each plate. The data is displayed in the app as a time series graph and can also be exported."
75590140|NCT06033625|Procedure|CEMENTLESS TOTAL KNEE REPLACEMENT|CEMENTLESS CRUCIATE RETAINING BICOMPARTMENTAL TOTAL KNEE REPLACEMENT
75590141|NCT06033495|Device|Coronary sinus reduction stent|Percutaneous stent implantation to reduce the dimension of the coronary sinus
75733475|NCT05898100|Device|Virtual Reality Distraction|The experimental group will receive the VR video game Dream designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. Dream aims at reducing anxiety in children aged 6 to 17 years old by mean of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded.
75883301|NCT05575687|Other|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
76054656|NCT01626391|Drug|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
76054657|NCT01626391|Drug|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
76054658|NCT02103439|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
76054659|NCT02103439|Drug|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
76054660|NCT02229539|Drug|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
76054661|NCT02229539|Drug|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
76054662|NCT02229539|Other|Placebo|2.5 mL placebo and 2.5 mL water administered orally
76054663|NCT01835223|Drug|Tivozanib (1mg)|Given PO
76054664|NCT01835223|Drug|Tivozanib (1.5mg)|Given PO
76054665|NCT01482598|Device|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
76054666|NCT01460446|Device|Aviva Expert blood glucose meter|
75883302|NCT05568277|Behavioral|Education on preventive health behaviors based on Pender's Health Promotion Model|Pregnant women included in the study will be given education on preventive health behaviors based on Pender's Health Promotion Model on the prevention of gestational diabetes over the web (ZOOM/Teams etc.) every two weeks. Pregnant women's questions will be answered. At the end of each training, data will be collected from pregnant women and follow-up charts will be filled. The education booklet prepared by the researcher will be given to the pregnant women after the first education and will be sent to their e-mail addresses.
75883303|NCT05563389|Drug|Atorvastatin 20mg|active arm
75883304|NCT05563389|Drug|Placebo|placebo arm
75883305|NCT05557214|Behavioral|Audit and Feedback Letter|Physicians in the Audit and Feedback Letter Arm will receive an initial letter indicating their high prescriber status with guidance on reducing unnecessary antimicrobial use. They will also receive a follow-up letter at the 6 month mark indicating any change in prescribing habits. There will be a study closure letter mailed at the 12 month mark.
75883306|NCT05548660|Other|Pharmacogenetic testing|Genetic testing of CYP2B6, CYP2C19, CYP2C9, CYP2C cluster CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-A, HLA-B, IFNL4, NUDT15, SLCO1B1, TPMT, UGT1A1, and VKORC1.
76054667|NCT01460446|Device|Aviva Nano blood glucose meter|
75439886|NCT01615276|Device|No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES|No neuromuscular electrical stimulation (NMES) will be applied in the control leg
75439887|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml green tea extract|Intragastric instillation by feeding tube
75439888|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml green tea extract|Intragastric instillation by feeding tube
75439889|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml control solution|Intragastric instillation by feeding tube
75439890|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml control solution|Intragastric instillation by feeding tube
75439891|NCT01615302|Procedure|Mucosa advancement flap|Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
75439892|NCT01615302|Other|Platelet rich plasma (PRP)|"The PRP will be injected into the fistula, after the mucosa advancement flap was created.~For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP."
75439893|NCT01615354|Drug|Aleglitazar|Multiple oral doses
75439894|NCT01615354|Drug|Microgynon®|Multiple oral doses
75883307|NCT05548660|Other|Pharmacist note with genotype-guided analgesic recommendations|"CYP2C9 normal metabolizers will be recommended to receive ibuprofen and intermediate and poor metabolizers will be recommended to receive naproxen.~CYP2D6 normal metabolizers will be recommended to receive tramadol and ultrarapid, intermediate and poor metabolizers will be recommended to receive oxycodone."
75439895|NCT01615354|Drug|Placebo|Multiple oral doses
75439896|NCT01615380|Behavioral|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
75439897|NCT01615380|Behavioral|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
76054668|NCT02229383|Drug|Exenatide|2 mg weekly suspension injection
76054669|NCT02229383|Drug|Exenatide matching placebo|Once weekly Placebo injection
76054670|NCT01499368|Drug|Lafutidine|Lafutidine 20mg/day
75733476|NCT05898100|Behavioral|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes a television mounted on the wall showing cartoons and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose so.
76054671|NCT01499368|Drug|Famotidine|Famotidine 40mg/day
75439898|NCT01615393|Drug|ribavirin [Copegus]|Single oral dose of 400 mg tablets
76054672|NCT01499368|Drug|Omeprazole|Omeprazole 20mg/day
76054673|NCT01835145|Drug|Cabozantinib S-malate|Given PO
75439899|NCT01615393|Drug|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
75439900|NCT01615406|Drug|99mTc MIP 1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
75439901|NCT01615432|Device|V-PAP III ventilator|
76054674|NCT01835145|Drug|Dacarbazine|Given IV
75439902|NCT01615432|Device|Stellar 150 ventilator|
75439903|NCT01615432|Device|BiPAP vision ventilator|
75439904|NCT01615432|Device|V60 ventilator|
76054675|NCT01835145|Other|Laboratory Biomarker Analysis|Correlative studies
76054676|NCT01835145|Drug|Temozolomide|Given PO
76054677|NCT02229227|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
75590142|NCT06032650|Other|Calisthenics exercise and High intensity interval training|"The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax"
75590143|NCT06032455|Behavioral|Multisystemic therapy|Multisystemic Therapy (MST) is an intensive, evidence-based treatment aimed at preventing out-of-home placement of adolescents with severe behavioural problems. The intervention is home-based and focuses not only on the adolescent, but also on the various systems surrounding the adolescent, such as the family, neighbourhood, school, and friends. MST helps parents increase their parenting competencies such as parental monitoring and find (more) social support in their environment. MST also helps adolescents improve their relationship with their parents, school participation, and social activities, and promotes contact with pro-social peers. These goals are achieved by working together with key figures in the family's environment. MST treatment duration is three to five months. In MST, a family can contact a therapist 24/7.
75590144|NCT06032455|Behavioral|Multisystemic therapy - intellectual disabilities|Multisystemic therapy - intellectual disabilities (MST-ID) is a specialisation of standard MST (see above), tailored to the needs and skill deficits of families in which the adolescent and/or parent(s) has/have a known or suspected ID. In MST-ID, among others, simplified language and visual support are used, and extra attention is paid to the generalisation of what has been learned in the treatment sessions.
75733477|NCT05897775|Device|Deep brain stimulation|"Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week."
75733478|NCT05893381|Drug|[177Lu]Lu-PSMA I&T|The radiopharmaceutical 177Lu-PSMA-I&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
75883308|NCT05548660|Other|Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines|Genotype-guided recommendations for all actionable phenotypes resulted from the 16-gene PGx panel per CPIC guidelines and FDA labeling
76054678|NCT02229227|Drug|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
75733479|NCT05893381|Radiation|Stereotactic Radiotherapy|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
75439905|NCT01615445|Drug|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
75439906|NCT01615445|Drug|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
75439907|NCT01615458|Behavioral|Chronic Care Model for Mood Disorders|CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
75439908|NCT01615471|Behavioral|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
75439909|NCT01615497|Behavioral|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
75883309|NCT05539963|Drug|Stimulan-VG|Participants will receive Stimulan-VG via implantation during debridement surgery on Day 1.
76054679|NCT01499290|Drug|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
75439910|NCT01615497|Behavioral|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
76054680|NCT01499290|Drug|Metronidazole|500 mg of Metronidazole
75590145|NCT06031558|Drug|SY-5007|a RET selective Inhibitor
75590146|NCT06031337|Diagnostic Test|ELISA|quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.
75590147|NCT06030466|Other|With virtual standardized patients|The virtual standardized patient is a software system that presents on a computer screen like a video conference, allowing medical students to interact with it for medical consultation. The virtual character modeling adopts 3D model, the expression of the character is delicate, and the voice feedback is clear. After the students' questions are asked by voice recognition and key words are extracted, appropriate responses are given.
75590148|NCT06030466|Other|With physical standardized patients|The physical standardized patient is a real person who has received professional training courses in the department of medical education of National Taiwan University Hospital, and can help medical students practice consultations.
75590149|NCT06027788|Device|CardioGard Embolic Protection Cannula|The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.
75590150|NCT06027788|Device|Standard Aortic Cannula|An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.
75590151|NCT06027411|Device|qER (qER EU 2.0)|Qure.ai's emergency room software solution qER (qER EU 2.0) is an AI medical device, developed by training a deep-learning algorithm using over 300,000 scans labelled by expert radiologists. qER has been shown to be accurate in identifying a range of abnormalities in NCCT head scans as well as prioritising them for urgent review and radiologist reporting. It is designated as a clinical support tool and, when used with original scans, can assist the clinician to improve efficiency, accuracy, and turnaround time in reading head CTs.
75733480|NCT05893277|Behavioral|Motivational Interviewing (MI) and Behavioral Couples Therapy (BCT)|Four Motivational Interviewing sessions with the husband (wife joins for last MI session) to reduce alcohol use dependency, followed by six Behavioral Couples Therapy session with the husband and wife together to improve their relation and communication and reduce intimate partner violence. Session 1: couple establishes daily trust contract and discusses strategies to cope with reduced alcohol use. Session 2: couple revisits these coping skills and builds on additional strategies, as necessary. Session 3: they shift to improving the relationship and communication. Session 4: activity to promote caring behavior between partners. Session 5: couple reviews communication strategies learned previously, learn active listening and address any ongoing communication challenges. Session 6: review session and plans to address challenges to create long-term change.
75439911|NCT01615497|Behavioral|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
75439912|NCT01615523|Other|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
75439913|NCT01615536|Procedure|Canine fossa trephine technique|Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.
75733481|NCT05888597|Drug|L-menthol|(Sigma-Aldrich, St. Louis, US)
75733482|NCT05888597|Other|Placebo|Strawberry scent (Sigma-Aldrich, St. Louis, US)
75733483|NCT05885542|Drug|Cannabidiol oral solution|Double-blind cannabidiol oral solution 800 mg administered once
75439914|NCT01615536|Procedure|Standard Endoscopic Sinus Surgery|Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
75439915|NCT01615549|Procedure|Laparsocopic cholecystectomy|Perform laparsocopic cholecystectomy on a virtual reality devise
75439916|NCT01615575|Procedure|Transanal haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
75733484|NCT05885542|Drug|Placebo|Double-blind placebo oral solution administered once
75883310|NCT05539963|Drug|Systemic Antibiotics|Participants will receive Antibiotics per site-specific requirements via oral or intravenous route during Pre and post operatively.
75590152|NCT06027190|Device|Repetitive transcranial magnetic stimulation|"Intervention Name and Specification~Transcranial magnetic stimulator (M-100 Ultimate, Yingzhi Technology Co., Ltd., China) .~70-mm-diameter figure-of-eight coil (BY90A, Yingzhi Technology Co., Ltd., China). 3) Placebo coil (Magstim Company, Whitland, UK): the appearance and sound were consistent with the true coil, but no current stimulation was produced."
75590153|NCT06027190|Device|Sham|Placebo coil (Magstim Company, Whitland, UK):
75590154|NCT06025513|Device|Embrace Patch|Tension offloading skin patch
75590155|NCT06021444|Device|DKM420|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
75590156|NCT06021444|Device|Conjuran|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
75590157|NCT06018688|Drug|Osimertinib|Osimertinib is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
75590158|NCT06018688|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a verysafe medication used to treat pain,fever, or inflammation.
75590159|NCT06018480|Other|Creatine Monohydrate|The supplementation is the intervention.
75590160|NCT06018480|Other|Maltodextrin (Placebo)|Placebo to Creatine Monohydrate
75590161|NCT06017505|Diagnostic Test|electronic self administered gerocognitive examination (eSAGE)|A self-administered digital assessment that evaluates multiple cognitive domains: orientation, language, memory, executive function, calculations, abstraction, and visuospatial abilities, through multiple questions. Additionally, it includes the collection of six clinical variables: education, gender, race, family history of dementia, stroke, and emotion.
75590162|NCT06016322|Dietary Supplement|Dried Chicory Root|"Subjects will receive 1 sachet of 10g WholeFiberTM for the first 2 weeks (equals 8.5 g fiber), and 2 sachets of 10g WholeFiberTM per day for the last two weeks (equals 17 g fiber).~WholeFiberTM is a fiber-rich dried vegetable made from the chicory root that contains four types of prebiotic fibers (inulin, pectin, cellulose, hemi-cellulose)."
75733485|NCT05884424|Behavioral|PARO Therapy Robot|"Participants allocated to the PARO Therapy Robot group will receive three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.~Robot therapy session will last 20 minutes. The sessions will be partially guided, intending to allow participants to interact with the robot seal freely for as long as possible, but redirecting the activity if necessary. The sessions will be conducted in group format, in groups of 4 users, with participants sitting in a circle around a table. The professional conducting the sessions will be a therapist with experience in NPT for people living with dementia, and who has attended the training session on the study intervention protocol.~The sessions will be structured as follows:~Welcome and presentation.~Main activity with PARO.~PARO cleaning.~End of session. A total of 13 different sessions are proposed, to be conducted in a cyclical manner (each session 3 times, except sessions 1 and 2)."
75733486|NCT05884320|Drug|Sacituzumab Govitecan|Given by IV (vein)
75733487|NCT05882721|Device|Sofwave|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB"
76054681|NCT01499290|Drug|Meropenem|1 gram of Meropenem
75439917|NCT01615575|Procedure|Stapler haemorrhoidopexy|Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
75439918|NCT01615588|Dietary Supplement|Manuka Honey|honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
75439919|NCT01615601|Drug|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
75439920|NCT01615601|Drug|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
75439921|NCT01615601|Drug|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
75439922|NCT01615601|Drug|Other antiretroviral medications|Given as per Canadian Product Monograph
75439923|NCT01615614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
75439924|NCT01615614|Drug|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
75439925|NCT01615627|Drug|HypotonicTreprostinil Solution|Hypotonic Treprostinil Solution
75439926|NCT01615627|Drug|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
75439927|NCT01615653|Procedure|EUS|EUS Guided Therapy
75590163|NCT06012058|Diagnostic Test|ROTA assessment by AI|The RNFL is imaged with OCT for ROTA and the data are analyzed with a deep learning model.
75439928|NCT01615718|Procedure|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
75883311|NCT05532917|Other|Gupta score|The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (>130 mmol/L or >1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
75883312|NCT05530434|Other|transpulmonary pressure guided positive end expiratory pressure|Positive end expiratory pressure will be titrated to achieve a transpulmonary pressure of 0-2 cm H2O
75883313|NCT05530434|Other|standard positive end expiratory pressure|Positive end expiratory pressure will be set to a standard 5-8 cm H2O by the clinician for spontaneous breathing trials
75883314|NCT05530265|Device|the smart watch and Samsung Health app|Use the smart watch (Galaxy Watch 4, Samsung Electronics Co., Ltd., Korea) and the Samsung Health app (Samsung Electronics Co., Ltd., Korea) for 90 days of positive airway pressure treatment
75883315|NCT05525273|Drug|Oral dabrafenib and trametinib|Neoadjuvant or postoperative treatment of patients with verified BRAF mutated papillary craniopharyngioma
75883316|NCT05511766|Drug|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
75883317|NCT05511766|Drug|Atorvastatin 20mg|is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties
75883318|NCT05511766|Drug|Placebo|not containing drugs
76054682|NCT01833897|Drug|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
75439929|NCT01615718|Procedure|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
75439930|NCT01615744|Procedure|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
75590164|NCT06012058|Diagnostic Test|Optic disc assessment by AI|The optic disc is imaged with color fundus camera and the data are analyzed with a deep learning model.
75883319|NCT05505422|Device|Routine ECMO|Routine ECMO during lung tansplant
75883320|NCT05505422|Device|On demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~Prolonged high dose pressor required to maintain adequate perfusion~A sustained drop in cerebral saturation > 25% of baseline despite initial attempts at optimization~Inability to tolerate pulmonary artery clamping~Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~Inadequate exposure to the surgical field"
75883321|NCT05501444|Other|Topical antiperspirant|The participants will be instructed to use topical antiperspirant (aluminum chloride, 15 percent every evening for four weeks. The PI will contact the participants every week. If the participant experiences that antiperspirant have an effect, the use of antiperspirant will be reduced from daily use to 3 times a week.
75883322|NCT05495711|Biological|human umbilical cord mesenchymal stem cell complex collagen|1 * 10^7 cells (2ml)
75439931|NCT01615744|Procedure|Non-surgical management|Early active exercises and elevation to decrease swelling
75439932|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
75439933|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
75590165|NCT06011226|Other|focus groups|A dozen patients with Chiari malformation and syringomyelia (n = 4) or isolated Chiari malformation (n = 4) or isolated syringomyelia (n = 4) will be brought together in at least two focus groups. Each focus group will include 5 to 8 patients and will last approximately 1 to 2 hours. The focus groups will be recorded (audio only, no personal data will be collected during these sessions) and will be conducted in the presence of a neurosurgeon and a psychologist, who will moderate the session.
75590166|NCT06011226|Other|questionnaire|developed questionnaire will be proposed to the patients in phase 2 and 3
75590167|NCT06010810|Drug|3 % Topical Tranexamic Acid|Patient will be given 3% Topical Tranexamic Acid, on half of the face, twice a day for 2 months
75590168|NCT06010810|Drug|4% Topical Hidroquinone|Patient will be given 4% Topical Hidroquinone, on half of the face, twice a day for 2 months
75590169|NCT06009653|Behavioral|Standard Care|Participants will meet with community health workers to receive general health information through individual check-ins.
76054683|NCT01833897|Drug|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
76054684|NCT01833897|Drug|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
76054685|NCT01481896|Device|Metal-on-metal primary total hip arthroplasty (DePuy )|Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
76054686|NCT02226653|Drug|Evacetrapib|Administered orally
75439934|NCT01615770|Behavioral|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
75590170|NCT06009653|Behavioral|Culturally-tailored dietary and behavioral intensive lifestyle intervention|Participants will meet with community health workers to receive information focused on healthy eating while still adhering to a culturally-tailored plant-forward diet.
75590171|NCT06009653|Drug|Placebo|Participants will receive placebo subcutaneous injections.
75590172|NCT06009653|Drug|Tirzepatide|Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.
75590173|NCT06009302|Procedure|US guided block of mandibular nerve|Extraoral ultrasound-guided block of the mandibular nerve will be performed in the examined group using an ultrasound device, using ropivacaine (0.75%, 2.5 mL).
75590174|NCT06009302|Procedure|Intraoral block of lower alveolar nerve|Block of lower alveolar nerve will be applied intraoraly using articaine+adrenaline
75590175|NCT06009107|Biological|HY004|A single infusion of Autologous 2nd generation CD19/CD22-directed CAR-T cells administered intravenously.
75590176|NCT06009107|Drug|Cyclophosphamide|Administered intravenously.
75590177|NCT06009107|Drug|Fludarabine Phosphate|Administered intravenously.
76054687|NCT02201771|Drug|Aspirin|
76054688|NCT02201771|Drug|Ticagrelor|
76054689|NCT01460368|Drug|LY2409021|Administered orally
76054690|NCT01460368|Drug|Placebo|Administered orally
76054691|NCT01460368|Drug|Moxifloxacin|Administered orally
75590178|NCT06007846|Drug|Namenda|Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily
75590179|NCT06006611|Drug|Azvudine|Received antiviral treatment with azvudine
75590180|NCT06006338|Other|3D Printed Model for preoperative planning|Besides conventional preoperative planning based on contrast-enhanced CT/MRI, the investigator refers to a 3D printed model to determine the optimal surgical approach via a trial-and-error method. Specifically, a personalized 3D printed model is fabricated. By referring to the printed model and CT/MRI images, a preliminary surgical trace is determined. Then, a simulation surgery is performed on the model, and surgical margin and the potential injury of vital vascular structures are evaluated. This assessment leads to the adjustment of the surgical path as necessary. The refined surgical route is then validated through a second simulation surgery performed on the healed 3D model. This iterative process is repeated multiple times, allowing for a comprehensive exploration of various approaches until the optimal surgical strategy crystallizes. Next, the investigator proceeds to execute the real surgery on the participant, meticulously adhering to the determined optimal surgical approach.
75590181|NCT06005649|Biological|HY004|"Autologous 2nd generation bispecific CAR-T cells targeting both CD22 and CD19, single infusion intravenously.~Start Dose level: 2.00 x 10^6/kg CAR+T-cells"
75883323|NCT05495711|Procedure|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
76054692|NCT02135705|Drug|Lomitapide|As prescribed by Physician.
76054693|NCT01460290|Drug|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
76054694|NCT01911533|Procedure|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
76054695|NCT01911533|Procedure|No extracorporeal CO2-removal|Patients are their own control group.
76054696|NCT04408456|Drug|HCQ|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
75590182|NCT06005129|Behavioral|Personality-Based Therapy|Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, [low] conscientiousness, [low] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed
75590183|NCT06003205|Device|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
75590184|NCT06001333|Procedure|fecal microbiota transplantation|Fecal microbiota transplantation will be conducted on patients using donor stool (frozen or capsulized stool) from a stool bank.
75590185|NCT05998759|Biological|Telitacicept|subcutaneous telitacicept 160 mg weekly for 24 weeks.
75590186|NCT05998759|Drug|Placebo|subcutaneous placebo weekly for 24 weeks.
75883324|NCT05495581|Drug|pudexacianinium chloride|Intravenous
75439935|NCT01615783|Other|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
75439936|NCT01615783|Other|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
75439937|NCT01615796|Drug|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
75439938|NCT01615796|Drug|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
75439939|NCT01615835|Other|EnSite NavX System|EnSite NavX system is a 3D Mapping system
75439940|NCT01615848|Other|mediterranean diet restricted calorie|1500 k/cal 30% fat
75439941|NCT01615848|Other|high protein diet|50 pcos diagnosed women will be assigned to high protein diet for 18 month
75439942|NCT01615848|Other|mediterranean diet restricted calorie|50 pcos women will be assigned to 1500 k/cal diet for 18 month
75883325|NCT05479604|Device|SinuSonic|Handheld device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion. The device is held over the nose and creates vibrations similar to humming.
76054697|NCT04408456|Other|Standard therapy|Home quarantine for 2 weeks plus social distancing plus personal hygiene
76054698|NCT03026608|Behavioral|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
75439943|NCT01615861|Procedure|IOL implantation|Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.
76054699|NCT02200211|Device|iPad®|Binocular therapy on iPad®
76054700|NCT02200211|Other|Patching 2 hours per day, 7 days per week|
75439944|NCT01615861|Device|IOL Implantation|Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
76054701|NCT01459666|Drug|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
76054702|NCT01459666|Drug|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
76054703|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
76054704|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
75439945|NCT01615900|Other|Teleconsultation / Standard consultation|"Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)"
75439946|NCT01615913|Drug|3 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
75590187|NCT05992844|Other|KB Exercises Program|"Kinesthetic Brain Exercises will carried out for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
75590188|NCT05992844|Other|Conventional Rehabilitation program|Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
75590189|NCT05992688|Other|Sucrose sweetened beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
75590190|NCT05992688|Other|Stevia sweetened beverages|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
75590191|NCT05992688|Other|Calorie free flavored water beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
75590192|NCT05992597|Drug|ZR2 RDHAP|ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.
75590193|NCT05992038|Procedure|Osteotomy with putty|Synthetic ceramic putty
75590194|NCT05992038|Procedure|Conventional osteotomy|conventional osteotomy
75590195|NCT05991310|Other|Telemedicine Assessment by Remote Neurologist|Use of a telemedicine platform for a neurologist, remotely located, to assess a MSU patient, review imaging, and decide on the required treatments.
75883326|NCT05479604|Device|Sham Device|Device looks exactly like study device but does not emit the same pressure or make the same noise as the study device
75590196|NCT05991310|Other|In-Person Assessment by an Onboard Neurologist|Traditional in-person assessment of a patient by a neurologist located onboard the MSU
75590197|NCT05986331|Drug|BCD-201|up to 8 treatment cycles
75590198|NCT05986331|Drug|Keytruda|up to 8 treatment cycles
76054705|NCT01645475|Drug|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
76054706|NCT04767113|Drug|Heparin sodium|"For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol."
75590201|NCT05984446|Device|real-rTMS|Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
75883327|NCT05468346|Drug|[14C]-HEC585|Single Dose = Solution containing 200 mg/100 µCi [14C]-HEC585
75883328|NCT05466734|Drug|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
76054707|NCT04767113|Drug|Normal saline|For infants enrolled, normal saline was infused at the corresponding speed.
76054708|NCT02199509|Drug|Levetiracetam|Anticonvulsant
76054709|NCT01458574|Drug|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
76054710|NCT01458574|Drug|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
76054711|NCT01458574|Drug|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
76054712|NCT02224703|Drug|GWP42003-P|
76054713|NCT02224703|Drug|Placebo Control|
76054714|NCT02198963|Drug|Hypochlorous acid solution 106 mg/L|test product
76054715|NCT02198963|Drug|0.1% (w/v) Sodium Lauryl Sulfate|positive control
75439947|NCT01615913|Drug|6 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
75590202|NCT05984446|Device|sham-rTMS|The sham condition will match the real-rTMS protocol, but a sham coil will be used.
75439948|NCT01615913|Drug|8 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
76054716|NCT02198963|Drug|0.9% Physiological Saline, USP|negative control
76054717|NCT02074384|Device|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
76054718|NCT02074384|Device|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
75439949|NCT01615965|Other|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
75439950|NCT01615978|Drug|liraglutide|5 mcg/kg daily for 14 days. Injected subcutaneously once daily
75439951|NCT01615978|Drug|liraglutide|Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
75439952|NCT01615978|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
75439953|NCT01615991|Drug|Radiosynoviorthesis|Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
75439954|NCT01616004|Drug|N2O|
75439955|NCT01616004|Drug|Air|sham comparator
75439956|NCT01616030|Other|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
75439957|NCT01616043|Procedure|Glyaderm|acellular dermis
75439958|NCT01616043|Procedure|STSG|autologous split skin only
76054719|NCT02074384|Other|Clinician|Survey of clinicians after study visits
76054720|NCT01458106|Drug|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
76054721|NCT01458106|Drug|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
76054722|NCT01457950|Drug|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
75439959|NCT01616069|Drug|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
75439960|NCT01616108|Drug|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
75439961|NCT01616121|Other|Usual treatment of patients with developing acute heart failure|
75439962|NCT01616121|Device|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
75439963|NCT01616134|Other|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
75590203|NCT05984238|Device|ReCET|Investigational product.
75590204|NCT05984238|Drug|Semaglutide, 1.0 mg/mL|Already registered medicine for type 2 diabetes
75590205|NCT05984238|Other|Sham procedure|The sham control for the ReCET procedure.
76054723|NCT01457950|Drug|placebo|double-blind phase: placebo subcutaneous injection, single dose
76054724|NCT01457950|Drug|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
75439964|NCT01616134|Other|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
75590206|NCT05983705|Behavioral|AFFEKT - a manual based brief parent program for parents of children (aged 6-12 years) with externalizing behaviors.|The AFFEKT program includes five group sessions, two hours each, provided on a weekly basis. The program is delivered by therapist trained in Cognitive and Behavioral Therapy (CBT) and AFFEKT. The participants also receive a participation material, covering the same themes that are addressed in the program and working sheets for the home-assignments that are provided in-between sessions.
75590207|NCT05982600|Diagnostic Test|Single Assessor Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.
75590208|NCT05982600|Diagnostic Test|2 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
75590209|NCT05982600|Diagnostic Test|3 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
75590210|NCT05982600|Diagnostic Test|5 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
75883329|NCT05466734|Drug|PMR Tablet 135 mg|Single oral dose (total daily dose of 270 mg)
75733488|NCT05881850|Other|Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49. The research is carry out as a randomized controlled experimental in a pretest-posttest design.|The education program consisting of three sessions was held once a week and each session lasted approximately 40-50 minutes. In the realization of the education program, a power point presentation consisting of the contents of the education booklet prepared for Osteoporosis awareness, a three-dimensional bone model with Osteoporosis and normal bone tissue, some food samples containing calcium during nutrition education, and measuring cups to show portions and amounts were used. During the training, a question and answer activity was also held. The education booklet was also given to the intervention group at the end of the first session.
75733489|NCT05881759|Behavioral|Revised ESBA|Four intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols. Two of the four intervention sites will also participate in the Food Rx program. The control group sites will receive the existing ESBA curriculum. All program materials will be available in English and Spanish. Study participation will be maintained via weekly phone calls/text messaging by the Extension staff. For the online feeding practices content, participants will receive messages to visit the project website and watch the videos, participate in online activities, and engage in facilitated online discussions. For the Food Rx arm, participants will receive a 'Food Rx' card for bi-weekly redemption of ~30 lbs of fresh produce, plus whole grains, lean protein and low-fat dairy at a co-located Houston Food Bank food pantry. The prescription will be eligible for redemption every two weeks for 3 months, for a total of 6 redemptions.
75883330|NCT05452317|Other|Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
75883331|NCT05452317|Other|Non-Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
75883332|NCT05439395|Device|Sternum Closure after Cardiac Surgery|Sternal closure using Steelex® Sternum Set after CABG or cardiac valve replacement / reconstruction.
75439965|NCT01616147|Behavioral|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
75439966|NCT01616147|Behavioral|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
75590211|NCT05979064|Procedure|Laparoscopically harvested omental tissue autograft|"Standard neurosurgical removal of recurrent GBM,~removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically),~the omental fat will be transferred and implanted into brain tumor cavity,~standard closure of surgical resection cavity."
75590212|NCT05978895|Other|Targeted canteen menus|"The nutritional intervention consisted in the development of targeted menus aiming at the needs of individuals with ASD and in assessing their acceptance of the targeted menus.~The revision of the standard menus was carried 1) balancing energy and macronutrient content, according to LARN 2014; 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus according to CREA 2018; 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population was evaluated through meal evaluation forms. These results were compared with the ones collected during the first observational phase (WP1). In fact, referring to the results of WP1, new canteen menus were drafted according to the nutritional and sensory needs of the population."
75590213|NCT05976685|Procedure|Left atrial appendage Occlusion|Left atrial appendage Occlusion and therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
75590214|NCT05976685|Drug|DOAC|Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
75590215|NCT05976464|Drug|Magnesium sulfate in erector spinae plane block|"Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery."
75590216|NCT05975684|Drug|Baclofen|0.5 mg/kg/day up to 15 mg/day divided three times a day for 4 weeks
75590217|NCT05975684|Drug|Placebo|Placebo three times a day for 4 weeks
75590218|NCT05975151|Drug|Pseudomonas aeruginosa|A total of 63 subjects with intermediate and high risk NMIBC who were scheduled for transurethral resection of bladder tumor (TURBT) from March 2023 in three centers were enrolled in this study. The enrolled patients received submucosal injection of 1U of Pseudomonas aeruginosa injection and bladder irrigation with chemotherapy drugs (gemcitabine, mitomycin C, epirubicin or pirarubicin) immediately after TURBT. After urine was cleared, a sterile urinary catheter was placed, and 10U of Pseudomonas aeruginosa injection and 40ml of normal saline were injected. The perfusion solution was kept for 1 hour, and the position was changed every 20 minutes. The treatment was given once within 24 hours after operation, then once a week for 12 weeks, and then once a month for 12 months in total. Patients were followed up every 3 months after surgery. The last follow-up was completed in February 2025
75590219|NCT05971784|Other|Telerehabilitation Group|The group that will receive upper extremity training via telerehabilitation in addition to an exercise program consisting of balance and walking activities
75590220|NCT05971784|Other|Control Group|The group that will receive an exercise program consisting of balance and walking activities
75590221|NCT05968469|Device|Aerobic exercises with cycling ergometry|"A total of 20 sessions of high-intensity interval (HIIT) aerobic exercise program will be applied to the patients using a bicycle ergometer, five days a week and once a day for four weeks. And then, it was planned to perform stretching exercises for the cervical, thoracic and lumbar regions and posture exercises accompanied by a specialist physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
76054725|NCT01499134|Drug|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
76054726|NCT01499134|Drug|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
76054727|NCT02198651|Biological|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
76054728|NCT02198651|Other|Placebo|Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
76054729|NCT03026920|Procedure|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
76054730|NCT03026842|Drug|Decitabine|20 mg/m2/day for 5 days
76054731|NCT03026842|Drug|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
76054732|NCT03026842|Drug|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
76054733|NCT03026842|Drug|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
75439967|NCT01616186|Drug|Everolimus and sorafenib|"Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
75439968|NCT01616186|Drug|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
75439969|NCT01616212|Other|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
75439970|NCT01616212|Other|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
75439971|NCT01616212|Other|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
75733490|NCT05880992|Behavioral|Exercise|Aerobic and Strength exercises (equipment free, simple, modifiable)
75733491|NCT05880992|Dietary Supplement|Nutrition|Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)
75733492|NCT05880992|Behavioral|Mindfulness|Deep (box) breathing completing in the morning, evening and as needed.
75733493|NCT05876689|Device|DREAM OCT|Swept Source OCT (similar to Zeiss Plex Elite)
75733494|NCT05876312|Drug|ADX-038|siRNA duplex oligonucleotide
75733495|NCT05876312|Drug|Placebo|Saline
75733496|NCT05872945|Diagnostic Test|Electrocardiogram|Study by Artificial Intelligence the biosignal or biodata from profesional football players
76054734|NCT01498822|Drug|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
76054735|NCT01498822|Drug|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
75439972|NCT01616212|Other|Drug Education for adolescents|Drug Education for adolescents
75733497|NCT05872256|Drug|0.045% Tazarotene/0.01% Halobetasol Lotion|FDA approved drug for psoriasis treatment
75883333|NCT05432921|Behavioral|Lifestyle modification|50min of endurance combined with 50min of strength training; 1-2 sessions/week for 6 month, follow up after 3-6month
76054736|NCT04774211|Diagnostic Test|SOS-PD|Validation of SOS-PD bedside assessments comparing the Danish SOS-PD scale with a Child Psychiatrist using DSM-V as the reference standard
75439973|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
75733498|NCT05871905|Drug|TY-9591|C14 TY-9591
76054737|NCT01421849|Procedure|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months."
76054738|NCT01498120|Drug|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)~1 patch /day"
76054739|NCT01381211|Drug|TACE-DEB|Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
76054740|NCT01381211|Drug|90Y-RE|Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
75733499|NCT05871541|Biological|JCXH-105|As IM injection
75590222|NCT05968469|Other|Stretching exercises|"Stretching exercises for the cervical, thoracic and lumbar regions and posture exercises were planned to be performed with the expert physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
75883334|NCT05421988|Behavioral|Emotional Freedom Techniques (EFT)|EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.
75590223|NCT05966935|Combination Product|Fenugreek Cumin Powder|Fenugreek and Cumin seeds will be procured from the market. They will be cleaned of debris, winnowed, and grinded to fine powder passed through a mesh size of 30 for metal cleaning. 5g of fenugreek powder and 5g of cumin powder will be packed in packets. Participants in the intervention group will be instructed to consume the powder before breakfast and dinner with a glass of water.
75590224|NCT05966376|Device|Hemostatic device for distal radial approach.|Hemostasis after distal radial approach is done with one of two devices, one of them is designed specifically for the distal radial approach; the other is not but a modified technique with the last one could be helpful.
75590225|NCT05964452|Drug|Methimazole Tablets|Testing dosing algorithm for efficacy.
75590226|NCT05961748|Other|Multi-disciplinary assessment|Multi-disciplinary assessment
75590227|NCT05960305|Other|P1213416|Tobacco Flavor
75590228|NCT05960305|Other|P1213422|Tobacco Flavor
75590229|NCT05960305|Other|P1213716|Tobacco Flavor
75883335|NCT05420402|Drug|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at 3 minutes before the end of the surgery.
75590230|NCT05960305|Other|P1213722|Tobacco Flavor
76054741|NCT01497262|Drug|Fingolimod|Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
75590231|NCT05960305|Other|P1211216|Menthol Flavor
75590232|NCT05960305|Other|P1211222|Menthol Flavor
75590233|NCT05960305|Other|P1213616|Menthol Flavor
75590234|NCT05960305|Other|P1213622|Menthol Flavor
76054742|NCT02224625|Drug|2% CHG Cloth solution|Investigational CHG
75590235|NCT05960305|Other|P1213816|NTNM Flavor
75590236|NCT05960305|Other|P1213822|NTNM Flavor
75590237|NCT05960305|Other|P1211916|NTNM Flavor
75590238|NCT05960305|Other|P1211922|NTNM Flavor
75590239|NCT05959915|Device|device e-patch Implantation|"The ePatch device (Phillips) was used. This device is attached to the sternum, using a specific dressing adapted for the device itself. Manufacturer's recommendations for skin preparation and placement will be followed.~The device will remain in place for 4-5 days, at which time the patient will be readmitted for data extraction and reading.~The team of research nurses will analyze the data through the ePatch platform and later, the electrophysiologists will review the results and make a diagnosis."
75590240|NCT05959707|Biological|VRC01.23LS|VRC01.23LS will be administered IV over approximately 30 to 60 minutes.
75590241|NCT05959707|Biological|PGT121.414.LS|PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.
75590242|NCT05959707|Biological|PGDM1400LS|PGDM1400LS will be administered IV over approximately 30 to 60 minutes.
75733500|NCT05871541|Biological|Active Control (Shingrix)|As IM injection
75733501|NCT05870995|Drug|CALGE-VEN- RIC-conditioning|Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
75733502|NCT05869708|Device|Active RS-EFP|15 (+/- 3) active NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 8 consecutive weeks. Subjects will also receive two single booster sessions, one month and two months after their last training session.
75883336|NCT05420402|Drug|Propofol continuous infusion|1 mg/kg propofol was started by continuous infusion 3 minutes before the end of surgery, and the infusion time was 3 minutes.
75883337|NCT05420402|Drug|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at the end of the surgery.
75883338|NCT05417087|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
75733503|NCT05869708|Device|Sham RS-EFP|15 (+/- 3) sham NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 8 consecutive weeks. Subjects will also receive two single sham booster sessions, one month and two months after their last training session.
75733504|NCT05869643|Drug|Low-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
75733505|NCT05869643|Drug|Medium-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
75733506|NCT05869643|Drug|High-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
75733507|NCT05869643|Drug|Placebo|Matching placebo capsule, taken orally once daily after breakfast
75733508|NCT05868226|Drug|ALX148|CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
75733509|NCT05868226|Drug|Fam-Trastuzumab Deruxtecan-Nxki|Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
75883339|NCT05417087|Drug|Vortioxetine Hydrobromide Tablets|Vortioxetine Hydrobromide Tablets 20mg
75883340|NCT05416957|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg administration under fasting condition
75883341|NCT05416762|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
75883342|NCT05416762|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
75883343|NCT05416762|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
75733510|NCT05868226|Drug|Zanidatamab|Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
75883344|NCT05408949|Behavioral|Single exercise into pain (SEP) program|"Baseline assessment & commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~Initial follow-up & progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~Second follow-up & progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~Functional rehabilitation program"
75883345|NCT05408949|Behavioral|Shoulder Symptom Modification Procedure (SSMP)|[1] Finger on the sternum,[2A] Scapula modification [3] 'Humeral head' modification [4] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free
75733511|NCT05868226|Drug|Tucatinib|Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
75733512|NCT05867615|Drug|[177Lu]Lu-PSMA I&T|177Lu activity to be administered to single patient (range 5.5-7.4 GBq), every 8 weeks (±2 weeks) will be measured in a dose calibrator, properly calibrated for the radionuclide. The radiopharmaceutical will be slowly infused intravenously over 15-30' in a dedicated room using a dedicated pump system.
75733513|NCT05864456|Device|Prizvalve Pro™ transcatheter aortic valve system|Transcatheter Aortic Valve Replacement
75733514|NCT05859555|Other|Thematic quality circles - Deprescription|Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)
75733515|NCT05858801|Device|PRIMUS|Peripheral Nerve Stimulator System
75733516|NCT05855083|Drug|Biological: narsoplimab|Treatment with narsoplimab 4 mg/kg will be administered
75883346|NCT05408949|Behavioral|Functional Rehabilitation Program|Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability[18] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units [18]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
75883347|NCT05408949|Behavioral|EPTL|In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .
76054743|NCT02224625|Device|Vehicle Cloth|Excipients from CHG cloth only
76054744|NCT02224625|Drug|Active Comparator|Active comparator
76054745|NCT02224625|Other|Saline|Negative control
76054746|NCT02224625|Other|SLS|Provides a slight irritation for a positive control
75590243|NCT05958615|Behavioral|Reimagining Us in the Context of Bariatric Surgery (ReConnect)|ReConnect is an intervention for bariatric surgery patients approximately 2 years after surgery and their romantic partners to participate in together with the goal of improving mental health and enhancing resilience. The intervention is entirely remotely-delivered via handouts sent by PDF and mail to participants instructing them through the 8 weekly modules, as well as associated videos. Each module features psychoeducational materials, instructions and guidance on positive psychology activities, choices of activities to complete both individually and as a couple, and additional resources relevant to that week's theme. The themes are: channeling strengths and focusing on the positive, clarifying values and finding meaning, goal setting, intimacy and fostering the relationship, open communication and gratitude, self-care and savoring the moment, fostering relationships and acts of kindness, and maintaining progress long-term.
75590244|NCT05957445|Device|active continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, and subsequently a 600-pulse cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
75439974|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
75439975|NCT01616225|Drug|No Saizen Control (Standard IVF Protocol)|All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
75439976|NCT01616238|Drug|Chemotherapy|Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
75439977|NCT01616251|Other|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
75439978|NCT01616290|Drug|PRT-201|0.03, 1, or 3 mg single adventitial administration
75439979|NCT01616316|Procedure|subfascial flap|subfacial dissection to thyroid
75883348|NCT05408949|Behavioral|HSR|In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
75883349|NCT05404113|Other|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 minutes/session Type: Mobilization with movement SNAG Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
75439980|NCT01616316|Procedure|subplatysmal flap|subplatysmal approach to thyroid
75439981|NCT01616342|Device|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
76054747|NCT01195493|Other|Essential Oils solution|(Essential oils solution, Listerine®, Johnson & Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
75439982|NCT01616355|Other|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
76054748|NCT01195493|Other|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
75439983|NCT01616368|Behavioral|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
75590245|NCT05957445|Device|sham continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences，including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, and subsequently a 600-pulse sham cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
75590246|NCT05956340|Behavioral|Research interview|Research interview to capture speech data with high quality cardioid headset microphone
75733517|NCT05853406|Diagnostic Test|Functional Reach test|"The determination by statistical research is carried out during a usual physiotherapy assessment of the volunteers. Data patient demographics and standard tests (FRT, Tinetti test, Timed Up and Go test, unipodal station) will be noted.~A satisfaction questionnaire inspired by Patient rating of change will be sent to participants for the determination of the MCID by ANCHOR method.~Concerning the Delphi method, a questionnaire will be sent to physiotherapists with proven geriatric activity."
75733518|NCT05851976|Drug|Naproxen|Naproxen 500mg twice daily for 16 days
75733519|NCT05851976|Drug|Duloxetine|Duloxetine 60mg daily for 14 days
75733520|NCT05848674|Other|CArdiac Brief INtervention (CABIN)|CABIN is designed as a brief intervention with a facilitated discussion between a patient and a nurse, with the provision of a short leaflet that summarises information and acts as an aide memoir. The discussion takes place in a quiet area and is intended to last 15-20 minutes. CABIN involves a nurse listening to the patient and recognising any concerns he / she may have and / or identifying erroneous beliefs. It also provides the patient with personalised education on coronary artery disease and cardiac rehabilitation (i.e., information about stenting, stent placement, medication, and purpose / potential benefits of cardiac rehabilitation), along with facilitating psychological and emotional support discussions with a nurse (i.e., explaining causes of a STEMI, discussing support / treatment options, and exploring methods of improving health).
76054749|NCT04094038|Drug|Olimel N12|A mixture of glucose, lipids, amino acids.
76054750|NCT04094038|Drug|Glucose IV|Glucose 5%
76054751|NCT00913679|Procedure|Surgical approach (ReCap Hip Resurfacing System)|two different surgical approaches in hip resurfacing arthroplasty
76054752|NCT00752453|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
75733521|NCT05848674|Other|Refined version of CABIN|Participants of the control group will receive a refined version of CABIN, which excludes psychological and emotional support discussions with a nurse and details some standard discharge information (information about coronary artery disease and stenting / stent placement).
75733522|NCT05848232|Device|coraFlex Catheter|The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
75733523|NCT05848232|Device|coraForce Catheter|The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
75733524|NCT05848232|Device|coraCross Catheter|The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
75733525|NCT05846893|Device|SeQuent® Please NEO drug-coated balloon catheter|Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries
75439984|NCT01616381|Drug|Sildenafil|PDE-5 Inhibitor
75733526|NCT05846893|Device|Current-generation drug-eluting stent|Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
75439985|NCT01616381|Drug|Placebo|Placebo for sildenafil 40mg x 3 daily
75439986|NCT01616407|Drug|3,4-Methylenedioxymethamphetamine|75 mg per os, single dose
75439987|NCT01616407|Drug|Methylphenidate|40 mg per os, single dose
75439988|NCT01616407|Drug|Placebo|capsules identical to MDMA or methylphenidate but containing no active drug
75439989|NCT01616420|Other|Assisted-partner notification services|Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
75439990|NCT01616433|Behavioral|AFEP|Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
75439991|NCT01616433|Behavioral|"10 Keys to Healthy Aging"|"10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session."
76054753|NCT00752453|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
76054754|NCT00752453|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
76054755|NCT02197247|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
76054756|NCT02197247|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
76054757|NCT02197247|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
76054758|NCT02197247|Procedure|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
76054759|NCT02197247|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
76054760|NCT02224157|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
76054761|NCT02224157|Drug|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
76054762|NCT02196701|Drug|Adalimumab|Administered by subcutaneous injection every other week.
76054763|NCT02196701|Drug|Methotrexate|Methotrexate was provided as 2.5 mg tablets for oral administration.
76054764|NCT04763291|Dietary Supplement|Juice Plus+ Fruit, Vegetable and Berry blends|Encapsulated juice powder concentrate derived from 36 dried fruits, vegetables and berries.
76054765|NCT04763291|Dietary Supplement|Juice Plus+ Omega blend|Encapsulated plant-based fatty acid supplement.
76054766|NCT04773119|Procedure|PVI only|Patients in this group receive PVI only
76054767|NCT04773119|Procedure|PVI with substrate ablation|Patients in this group receive PVI as well as substrate ablation
76054768|NCT01481116|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
76054769|NCT01481116|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
76054770|NCT01481116|Drug|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
76054771|NCT02222207|Drug|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
75590247|NCT05953597|Behavioral|Nutrition Education|The intervention will consist of 12 monthly nutrition education sessions catered to people with spinal cord injuries. The curriculum is based on the 2020-2025 Dietary Guidelines for Americans such as consuming recommended amounts of fruits/vegetables, whole grains, etc. The sessions will be approximately 30-60 minutes and will be available in-person.
75883350|NCT05404113|Other|deep friction massage|Cyriax deep friction massage+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 20 minutes/session Type: Deep soft tissue massage Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
76054772|NCT02222207|Procedure|Sham IVT|Sham injections
76054773|NCT02222207|Drug|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
76054774|NCT02222207|Drug|Placebo|Placebo eye drops
76054775|NCT01457014|Device|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
76054776|NCT01457014|Device|Continuous positive airway pressure|continuous positive airway pressure
76054777|NCT01457014|Device|servo ventilation manual|servo ventilation titrated in manual mode
76054778|NCT02254421|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
75439992|NCT01616472|Drug|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
75439993|NCT01616485|Drug|TA-1790|2 TA-1790 100 mg capsules
75439994|NCT01616485|Drug|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
75590248|NCT05953415|Device|active iTBS|Participants in this group will receive two sessions of 1800-pulse active stimulation per day, with an intersession interval of 50 minutes. The stimulation will be administered on workdays over a period of 3 weeks, totaling 15 days.
76054779|NCT02254421|Drug|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
76054780|NCT02252939|Radiation|X-Ray|X-ray as part of standard care
76054781|NCT02196077|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
76054782|NCT02196077|Drug|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
76054783|NCT02196077|Drug|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
76054784|NCT02196077|Drug|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
76054785|NCT02196077|Drug|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
76054786|NCT02195687|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
76054787|NCT02195687|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
76054788|NCT02195531|Behavioral|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
75883351|NCT05402540|Other|STRAIN COUNTER STRAIN GROUP|"Strain Counterstrain Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~Therapist palpate surrounding and opposing tissues to locate trigger point by using one or two finger pads to monitor fasciculation and MTrP.~Hold the POC (position of comfort) until fasciculation decreases significantly or ceases. Average positions hold time while pressure is 90 s to 3 min.~Release tissue or joint slowly and reassess. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
76054789|NCT02252081|Drug|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
75439995|NCT01616485|Drug|Placebo|2 placebo capsules for TA-1790 100 mg capsules
76054790|NCT02252081|Drug|Placebo|placebo pill(s) orally per day for 16 weeks
75439996|NCT01616485|Drug|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
75439997|NCT01616537|Other|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
75439998|NCT01616550|Other|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
75439999|NCT01616550|Other|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
75440000|NCT01616550|Other|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
75440001|NCT01616550|Other|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
75590249|NCT05953415|Device|sham iTBS|Participants in this group will receive two sessions of 1800-pulse sham stimulation per day, with an intersession interval of 50 minutes. The stimulation will be comprehensively mimic the active condition, and also administered on workdays over a period of 3 weeks, totaling 15 days.
75590250|NCT05950581|Device|Modified Twin-Block Appliance with Clear Plates.|Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily
75590251|NCT05950581|Device|Traditional Twin-Block appliance|Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
75590252|NCT05947890|Biological|MTBVAC|The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.
75590253|NCT05947890|Biological|BCG|The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.
75590254|NCT05944510|Drug|Dextromethorphan|Dextromethorphan 30mg will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
75590255|NCT05944510|Drug|Placebo|Matched placebo will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
75590256|NCT05940675|Behavioral|Food and Nutrition|A key element is that children receive a free of charge healthy do-it-yourself school lunch 4 days per week. The meals adhere to the Nordic Nutrition Recommendations and the Danish Food-Based Dietary Guidelines with focus on fish, wholegrains, fruits and vegetables and drinking water as well as stimulation of children's food literacy. Other intervention components involve the after school clubs, local retail stores and the parents.
75733527|NCT05846815|Device|ARVO 2.0 WEB|"Medical device software where the subject navigates in a virtual apartment, with the goal of performing the tasks given by a cartoon dragon character. The child is asked to perform the subtasks in the given order, except for the subtasks to be completed at a certain time or after a certain sound cue, but the completion order does not influence the scoring. One task scenario lasts until all subtasks are correctly performed or until the time limit of 60 s is reached.~The classification whether the subject belong to typically developed population is based on quantitative neurological performance indicators produced during the game. However, even if the activity performed is differential diagnostics, ARVO does not create any medical diagnosis. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed."
76054791|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
76054792|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
76054793|NCT01623596|Drug|Fingolimod|
76054794|NCT01623596|Drug|Disease Modifying therapy|
76054795|NCT02219477|Drug|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
75440002|NCT01616602|Other|Prone Position|Patients were asked to lay on their abdomen for their elective colonoscopy.
75440003|NCT01616602|Other|Standard Position|The traditional left-lateral decubitus position
75590257|NCT05940675|Behavioral|Physical Activity (FitFirst)|To ensure that all children reach the recommended 3x30 minutes of vigorous activity per week, we will implement three weekly 40-minute sessions in the school curriculum. These sessions will be carried out throughout the study period and will encompass modified and varied sporting activities and games, which promote motivation, physical literacy, active involvement of all children, and high training intensity.
75590258|NCT05940675|Behavioral|Sleep and screen media|The aim of this component is to promote healthy sleep and screen media behaviours. Sleep and screen media recommendations will be presented for parents at three parent workshops and in electronic infographics. Teachers/pedagogues will facilitate small assignments on screen media and sleep practices with children during school time. Children will talk about and reflect upon screen media and sleep practices in their family, based on assignments and material from e.g., Medierådet (The Danish Media Council). The results of the children's assignments will be presented to their parents at later workshops. This is done to integrate the children's perspective in the parent workshops, especially in relation to screen media habits.
75590259|NCT05940675|Behavioral|Community capacity building|Community capacity building in selected local communities. To promote healthier eating, children and families need to be supported within their local community by food environments that make the healthy choice the easy choice and not a challenge in their everyday life. To promote physical activity, the children will be invited to participate in activities in the local sports clubs including camps in the holidays.
75590260|NCT05940493|Drug|Abemaciclib|Tablet
75883352|NCT05402540|Other|ACTIVE RELESAE TECHNIQUE GROUP|"Active Release Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~The targeted muscle will be palpated while the therapist will looks for localized tenderness or trigger points with referred pain elicitation.~With the thumb therapist will relieve the trigger point. In ART the particular muscle is taken from shortened to lengthened position or from lengthened to shortened position.~Duration of treatment will be 8-15 minutes. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
75590261|NCT05940493|Drug|Placebo|Tablet
75590262|NCT05938907|Other|concentrated growth factor|Implanting concentrated growth factor into the area of root apical bone defect
75590263|NCT05938907|Other|bone substitute|Implanting bone substitute into the area of root apical bone defect
75733528|NCT05846815|Other|Conners Continuous Performance Test 3rd Edition™ (CPT 3)|"Subjects are required to respond by pressing the spacebar or the appropriate key on the mouse when any letter other than the letter X appears on the monitor. The Conners CPT 3 presents 14-minute, 360 scored stimuli trials (i.e., individual letters) on the screen, with 1, 2, or 4 sec. between the presentation of letters (i.e., the interstimulus interval; ISI). The 360 trials are divided into 6 blocks, with 3 sub-blocks each consisting of 20 trials. Each block lasts approximately 2 min and 20 sec. Scores and Score Dimensions of Attention Measured: Inattentiveness, Impulsivity, Sustained Attention and Vigilance. The Conners CPT 3 produces computer-generated reports that describe the respondent's performance.~It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed"
75733529|NCT05842096|Diagnostic Test|Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in both arms of the study
76054796|NCT02219477|Drug|dasabuvir|tablet
75883353|NCT05398588|Other|Cyriax Deep Friction Massage|Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week Cyriax DFM on targeted muscles (Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis) 3 minutes each muscle (15 mins in total ) x 1 set , 3 days / week
75883354|NCT05398588|Other|Spencer Muscle energy technique|"Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week The Spencer technique will be applied in Abduction, External rotation and Internal rotation for targeting muscles Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis.~10 repetitions x 3set , 3 days/week."
76054797|NCT02219477|Drug|ribavirin|tablet
76054798|NCT02119286|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
76054799|NCT02119286|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
76054800|NCT02119286|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
76054801|NCT02119286|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
76054802|NCT02250443|Drug|BYM338 (Bimagrumab)|
75440004|NCT01616615|Drug|Aspirin|150 mg/day oral use
75440005|NCT01616615|Drug|placebo|1 capsule / day oral use
76054803|NCT02093390|Drug|TAK-385|TAK-385 tablets
76054804|NCT02093390|Drug|Fluconazole|Fluconazole tablets
75440006|NCT01616277|Biological|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
75440007|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
75440008|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
75440009|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
75440010|NCT01616277|Biological|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
75440011|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
75440012|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
75440013|NCT01616277|Drug|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
75440014|NCT01616277|Biological|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
75440015|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
75590264|NCT05938907|Combination Product|concentrated growth factor + bone substitute|Implanting concentrated growth factor + bone substitute into the area of root apical bone defect
75590265|NCT05935982|Behavioral|Virtual reality exercise|During school special physical education, participants will be asked to exercise using a virtual reality exercise headset, that will be adapted for arm use. Participants will asked to be seated during gameplay. Heart rate will be monitored and recorded during exercise.
75590266|NCT05934253|Drug|Chloroprocaine ophthalmic gel 3%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
75590267|NCT05932888|Drug|QLM3003|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）
75590268|NCT05932888|Drug|QLM3003 Placebo|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）(matching corresponding study medication)
75590269|NCT05925959|Other|Preoperative Weight Management Program|The medical obesity intervention is comprised of monthly visits with an obesity medicine (OM) provider +/- a registered dietitian (in person or virtual). Lifestyle modifications (nutrition, physical activity, stress, sleep), appetite control, and medication side effects will be addressed in all visits. At initial visit, patients will evaluated in person by an OM provider +/- registered dietitian. An individualized intense lifestyle intervention will be implemented with the addition of an anti-obesity medication (phentermine, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, etc). Medication use will be based on disease risk, patient preference, severity of obesity, contraindications, potential drug interactions and insurance coverage. A diet recommendation will be tailored to the patient's medical and food allergy history. Weight and vital signs will be monitored at each visit. Participants will have a total of 5 follow-up monthly encounters, every 30 +/- 7 days.
75590270|NCT05925400|Device|Virtual Reality during Embryo Transfer|Patients randomized to the study group, will be provided with the VR headset. The VR exposure will take place 30 minutes before the Embryo Transfer (ET) and a 10 min immersion after the ET
75590271|NCT05924854|Other|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints). Equipment used in the trial included:~Huatuo brand copper filiform needle (diameter: 0.35×50mm), Suzhou Medical Supplies Factory, Food and Drug Administration firearms production: Suzhou Food and Drug Administration firearms production No. 20010020.~Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675"
75590272|NCT05921916|Drug|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
75590273|NCT05921916|Drug|Placebo oral capsule|Placebo oral capsule solid microcrystalline cellulose
75590274|NCT05918822|Drug|Maribavir Commercial Tablet Formulation|Maribavir commercial tablet.
76054805|NCT02093390|Drug|Atorvastatin|Atorvastatin tablets
76054806|NCT02194985|Drug|migalastat HCl 150 mg|Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
76054807|NCT02219087|Drug|Liposomal bupivacaine|
75440016|NCT01616277|Biological|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
75440017|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
75440018|NCT01616277|Biological|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
75440019|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
75440020|NCT01616628|Behavioral|Fruit and vegetable rewards|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
75440021|NCT01616667|Procedure|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
75590275|NCT05918822|Drug|Maribavir Pediatric Powder-for-oral Suspension Formulation|Maribavir pediatric powder-for-oral suspension.
75590276|NCT05918822|Drug|Rabeprazole|Rabeprazole tablet.
75590277|NCT05916300|Other|Diagnostic ultrasonography-guided physiotherapy group|"All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination."
75590278|NCT05906394|Procedure|Posterolateral Fusion|Posterolateral spinal fusion is a neurosurgical or orthopaedic surgical technique that joins two or more vertebrae. This procedure can be performed at any level in the spine (cervical, thoracic, lumbar, or sacral) and prevents any movement between the fused vertebrae.
76054808|NCT02219087|Drug|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
75440022|NCT01616680|Drug|brentuximab vedotin|Given IV
75440023|NCT01616680|Other|laboratory biomarker analysis|Correlative studies
75440024|NCT01616680|Other|pharmacological study|Correlative studies
75440025|NCT01616719|Device|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
75440026|NCT01616732|Drug|Testosterone|TU im
75440027|NCT01616732|Drug|placebo|placebo im
75440028|NCT01616758|Drug|GTx-024 9mg|
75440029|NCT01616784|Other|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
75440030|NCT01616784|Other|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
76054809|NCT02248961|Drug|Fimasartan|"Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning."
75733530|NCT05842096|Diagnostic Test|Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha depending on the blood concentrations of TSH, a-TPO and a-TG in women in both study arms
76054810|NCT02248961|Drug|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg
76054811|NCT02219009|Device|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
76054812|NCT02248649|Behavioral|Structured physical activity|Walking instruction and encouragement
76054813|NCT02248649|Behavioral|Health education|Provision of general information about a variety of health topics
76054814|NCT02218541|Device|abutment margin 0.5 mm subgingival|
76054815|NCT02218541|Device|abutment margin 1.5 mm subgingival|
76054816|NCT02217527|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
75590279|NCT05900856|Other|low caloric diet regimen|lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
75590280|NCT05900856|Device|ultrasound cavitation|patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks
76054817|NCT02217527|Drug|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
76054818|NCT01456936|Drug|Placebo|Triple dummy placebo for each treatment arm
76054819|NCT01456936|Drug|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
76054820|NCT01456936|Drug|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
75590281|NCT05899582|Procedure|Extracranial-Intracranial Bypass Surgery|Extracranial-intracranial bypass surgery plus medical treatment
75590282|NCT05899582|Other|Medical treatment alone|Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.
75590283|NCT05898464|Biological|Recombinant zoster vaccination|Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart
75590284|NCT05895838|Drug|Dexamethasone|Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.
75733531|NCT05842096|Diagnostic Test|Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha and AMH, FSH in women in both study arms
76054821|NCT01456936|Drug|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
76054822|NCT01456780|Drug|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
76054823|NCT01456780|Drug|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
76054824|NCT01456780|Drug|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
76054825|NCT01480258|Biological|PR5I|DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis [acellular, component], hepatitis B [recombinant DNA], polio virus [inactivated], and Haemophilus influenza type b conjugate vaccine [adsorbed]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
75733533|NCT05839574|Drug|MTX monotherapy|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)
76054826|NCT01480258|Biological|Rotavirus vaccine|Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
76054827|NCT01480258|Biological|Prevenar 13™|Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
75590285|NCT05895838|Procedure|Backrest elevation|Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).
75733534|NCT05839574|Drug|MTX + letrozole add-on|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)
75733535|NCT05839561|Drug|Letrozole as monotherapy|Letrozole 5 mg daily orally for 10 days from day 0
75733536|NCT05839561|Drug|MTX as monotherapy|MTX in a single dose of 100 mg intravenously on day 0
75883355|NCT05396612|Other|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
75883356|NCT05391607|Drug|Hyperoncotic Albumin 20%|Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
76054828|NCT01480258|Biological|INFANRIX™ hexa|Combined Diphtheria-Tetanus-acellular Pertussis [DTaP], Hepatitis B [HepB], Poliovirus [IPV] and Haemophilus influenzae type b [Hib] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
76054829|NCT01479868|Drug|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
76054830|NCT01479868|Drug|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
76054831|NCT01479868|Drug|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
75440031|NCT01616797|Behavioral|Computerized neurobehavioral intervention|Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
75590286|NCT05895838|Procedure|Early wakeup call|Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.
75590287|NCT05895838|Drug|Olanzapine|Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
75590288|NCT05894291|Other|Swimmer Prone Position|"Patients will be positioned with the head rotated. This rotation is followed by shoulder elevation/abduction, then 90° elbow flexion for the arm opposite to the head rotation. The hand is placed flat on the bed.~A 60° to 90° flexion is performed on the hip homolateral to head rotation, combined with knee flexion.~The position is changed to the mirror position every 4 hours."
75590289|NCT05894291|Other|Prone position with arms alongside the body|"The head will be positioned either straight or rotated to one side, depending on ICU habits. The arms are positioned symmetrically along the body, palms up. The lower limbs are positioned symmetrically and parallel, knees extended or slightly flexed if a cushion is used on the front of the feet.~Head rotation, if applicable, is performed every 4 hours."
75883357|NCT05391607|Drug|Isooncotic Albumin 5%|Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
75883358|NCT05391607|Drug|Ringer's Lactate Crystalloid Solutions (control group)|Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
75883359|NCT05388097|Other|Managed Services|coordination of care and assistance with community resources (food, transportation)
76054832|NCT01478620|Drug|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
75440032|NCT01616836|Other|continuous FNB|femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration
75440033|NCT01616836|Other|single femoral nerve block|single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration
75440034|NCT01616836|Other|local infiltration analgesia|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
75440035|NCT01616849|Drug|cisplatin and 5-Fu combined with nimotuzumab|"DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week"
75440036|NCT01616875|Drug|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
75440037|NCT01616888|Device|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
75733537|NCT05839444|Other|BioPB-01|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
75733538|NCT05839444|Other|Placebo|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
75733539|NCT05834959|Other|An Educational and Training Program|Education and practical training program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury
75733540|NCT05833204|Procedure|Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
76054833|NCT01455220|Drug|Tysabri ® (Natalizumab)|IV, monthly
75733541|NCT05833204|Procedure|Laparoscopic colporrhaphy with standard 0-caliber absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
75733542|NCT05832424|Behavioral|UPLIFT program|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
75733543|NCT05829317|Drug|Magnesium sulfate|Intravenous Magnesium sulfate
75733544|NCT05829317|Drug|Placebo|0.9% NaCl
75733545|NCT05828108|Drug|Bitopertin|Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
75883360|NCT05386563|Procedure|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|"taVNS will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (cymba concha, earlobe, and ulnar side of the wrist). Stimulation is delivered by a 3000ms pulse train (100us pulse width and 25Hz stimulation frequency). The current applied will be between 0.01uA to 9uA. The intervention will be delivered over the course of four sessions approximately one week apart."
76054834|NCT01454830|Behavioral|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
76054835|NCT01454830|Other|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
76054836|NCT01454596|Biological|Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.
76054837|NCT01454596|Drug|Aldesleukin|Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
76054838|NCT01454596|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
76054839|NCT01454596|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
75440038|NCT01616901|Procedure|Spontaneous breathing trial|"5 spontaneous breathing trial will be tested by the patients in the same order :~7 cm H2O continuous positive airway pressure~T piece~7 cmH2O of pressure support~0 cmH20 of pressure support~7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure."
75440039|NCT01616927|Drug|Lanreotide|Lanreotide will be administered once every 4 weeks as a subcutaneous injection
75590290|NCT05888896|Other|methyldopa tablets 250mg|patients will be taken methyldopa tablets 250mg in the morning orally with a lot of water after breakfast daily and this medication continues for 8 weeks
75590291|NCT05888896|Other|methyldopa tablets 250mg + foot reflexology|patients will receive methyldopa tablets 250mg in oral way once daily per 8 weeks and patients will receive foot reflexology two sessions per week, every session will last for 30 minutes and sessions will last for 8 weeks.
75440040|NCT01616940|Behavioral|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~Introduction and Assessment~HIV Transmission & Viral Life Cycle~Effective Communication and Self-Advocacy~Understanding Lab Values~HIV Medications~Drug Resistance & Adherence, and Understanding & Managing Side Effects~Disclosure and Stigma~Harm & Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~Are any services needed?~Have referrals or appointments been made?~Does patient need accompaniment to a visit?~Connect patient with services as needed.~Appointment reminders.~Overall well-being?~Schedule next peer contact."
75440041|NCT01616966|Drug|Sevoflurane|Maintenance of anesthesia with sevoflurane 1.0 Vol%
75440042|NCT01616966|Drug|propofol|Maintenance of anesthesia with propofol
75590292|NCT05886582|Drug|Rotigotine Transdermal System [Neupro]|Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.
75733546|NCT05826886|Behavioral|Emotional Writing|Participants complete four 20-minute sessions of emotional writing (at home) on four consecutive days. Instructions are provided online before each writing session.
75733547|NCT05825391|Drug|Adjustment of Antiplatelet Drugs|The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
75590293|NCT05886582|Drug|Placebo|Placebo drug
75733548|NCT05824819|Diagnostic Test|Next Generation Sequencing (NGS)|Biological materials (stool, peritoneal/ovarian cyst fluid, endometrial aspirate) will be secured and then subjected to molecular analysis using the Next Generation Sequencing (NGS) method. The stages will include: i) isolation of bacterial DNA from biological materials, ii) preparation of libraries for sequencing, including the performance of the PCR and nested-PCR methods on bacterial DNA isolates from the tested samples of biological materials, iii) purification of amplification products, indexing, validation of the concentration of amplicons, pooling and denaturation of libraries, iv) standardization and optimization of the procedure for the isolation of bacterial metagenomic DNA from biological materials from intestines, peritoneal cavity, uterine cavity and endometrial tissues, v) standardization of the nested-PCR method on bacterial DNA isolates from the tested biological materials, vi) submission of samples for sequencing.
75733549|NCT05824507|Diagnostic Test|Endometrial aspiration biopsies for CE diagnosis|1 ml of aspirate will be taken from the uterine cavity for histopathological examination and immunohistochemistry for CE during general anesthesia for scheduled surgery
75883361|NCT05386563|Procedure|Sham Stimulation|"Sham stimulation will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (either earlobe or forearm)."
75883362|NCT05377190|Other|Continuum HFC-IN|Combination of a mobile application (with remote monitoring) and digital therapeutics
75440043|NCT01616979|Procedure|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
75883363|NCT05377190|Other|Standard of care for the follow-up|No mobile application or digital therapeutics are used
76054840|NCT04542850|Dietary Supplement|5-ALA-Phosphate + SFC (5-ALA + SFC)|"Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days"
76054841|NCT02247479|Drug|Lampalizumab|Participants will receive 10 mg dose of lampalizumab administered intravitreally.
76054842|NCT02247479|Other|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
75590294|NCT05885932|Procedure|Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor|All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
75590295|NCT05885932|Drug|Aspirin and clopidogrel or ticagrelor|All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
75590296|NCT05885932|Procedure|mono anti-platelet therapy|mono anti-platelet therapy
75440044|NCT01616992|Drug|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
75590297|NCT05885763|Drug|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
75590298|NCT05884684|Other|Reviewing Imaging with Participant|Post-operatively, the images taken during the procedure will be reviewed with the participant.
75440045|NCT01617044|Dietary Supplement|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
76054843|NCT01454284|Drug|Glargine|
75440046|NCT01617044|Dietary Supplement|Placebo|Placebo
75590299|NCT05884671|Drug|Sulpiride 400 MG|All participants will receive one single dose of 400mg sulpiride. None of the participants will receive repeated doses. In order for the fMRI data acquisition to coincide with the time-window of maximal drug effects represented by a combination of plasma kinetics and physiological effects we will administer the drug 90 minutes prior to fMRI data acquisition.
75440047|NCT01617057|Drug|tiludronic acid|400 mg / day for 3 months
75440048|NCT01617057|Drug|Placebo|400 mg / day for 3 month
75440049|NCT01617109|Dietary Supplement|Ca/Vit D|800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars
75440050|NCT01617109|Other|Placebo|administered as 5 pills daily or as 2 snack bars
75440051|NCT01617122|Biological|Bacteriophage OX174|Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.
75883364|NCT05377190|Other|Continuum HFC-OUT|Combination of a mobile application (without remote monitoring) and digital therapeutics
75590300|NCT05884671|Drug|Placebo|All participants will receive placebo during one of the sessions.
75590301|NCT05881863|Other|No intervention|This is an observational study
75883365|NCT05365802|Drug|68Ga-FAPi-46|Radiopharmaceutical will be administered via IV
75883366|NCT05365802|Procedure|Computed Tomography|As part of PET/CT scan
76054844|NCT01454284|Drug|LY2605541|
76054845|NCT01454284|Drug|Insulin Lispro|
76054846|NCT04541290|Drug|Protopic 0.1 % Topical Ointment|Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
76054847|NCT02247401|Drug|2 DAA|ABT-450/r/ABT-267 tablets
76054848|NCT02247401|Drug|RBV|Ribavirin tablets
75440052|NCT01617135|Drug|CVT-301|
75440053|NCT01617135|Drug|Placebo|
75440054|NCT01617135|Drug|Sinemet (carbidopa/levodopa)|
75440055|NCT01617135|Drug|CVT-301|
75733550|NCT05823311|Drug|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.
75733551|NCT05823311|Drug|Gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
75440056|NCT01617174|Behavioral|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
76054849|NCT02247011|Other|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
75883367|NCT05365802|Procedure|Positron Emission Tomography|As part of PET/CT scan
76054850|NCT02247011|Radiation|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
76054851|NCT02247011|Radiation|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
76054852|NCT02247011|Other|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
75733552|NCT05821205|Behavioral|Narrative Persuasion|Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.
76054853|NCT02246777|Device|Ex-PRESS® Glaucoma Filtration Device, Model P50PL|
76054854|NCT01495702|Drug|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
76054855|NCT01495702|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
75733553|NCT05821205|Behavioral|Reciprocity|Researchers will track clicking on the gift card as a measure of engagement
75733554|NCT05821205|Behavioral|Personalized Feedback|Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.
75733555|NCT05821205|Behavioral|Commitment|Providers will receive a commitment message and be asked to reply as a measure of engagement.
75733556|NCT05819099|Diagnostic Test|An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning|This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
75883368|NCT05365802|Procedure|High Resolution Computed Tomography|Will be conducted immediately after FAPI PET/CT
76054856|NCT01495702|Drug|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
75733557|NCT05816122|Device|MSCopilot® Detect mobile application|MSCopilot® Detect includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life
75733558|NCT05814055|Drug|AB-free kava|Participants on this arm will take one kava capsule (each capsule contains 37.5 mg of kavalactones) orally three times daily for 4 weeks.
75733559|NCT05814055|Drug|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.
75883369|NCT05363826|Combination Product|photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)|"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"
75883370|NCT05358639|Drug|Olaparib tablet|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
76054857|NCT01630889|Drug|Roxadustat|Oral capsule
75590302|NCT05880667|Radiation|Adaptive Stereotactic Body Radiation|"Radiation therapy is given following generation of planning imaging at the time of simulation. A recent development has been diagnostic quality onboard imaging incorporated within radiation treatment machines. The incorporation of onboard imaging into standard practice has allowed the use Stereotactic Body Radiation (SBRT), which is a precise radiation technique that allows safe delivery of ablative radiation doses.~More recently, the development of improved technologies and software have allowed radiation plans to be generated and delivered that are specific to the anatomy of the very moment the patient is being treated. This novel ability to adjust the radiation treatment plan based upon real time imaging is termed adaptive radiation therapy. This study will utilize the novel adaptive radiation therapy technology in a patient population with technically challenging disease to deliver ablative radiation with an appropriately low toxicity rate."
75590303|NCT05876286|Other|Neurological examinations|Neurological, neuropsychological, polysomnography examinations and multiple sleep latency test. The protocol is divided into three visits.
75440057|NCT01617200|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
75733560|NCT05814055|Drug|AB-free kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.
75733561|NCT05813535|Drug|Sodium bicarb lock|8.4% sodium bicarb locks when off venous nutrition
75733562|NCT05812287|Other|Detection of biological samples based on multi-omics analysis|In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.
75733563|NCT05810961|Biological|efgartigimod IV|infusion of efgartigimod
76054858|NCT01495000|Drug|denosumab|60mg subcutaneous injection, single dose
75440058|NCT01617200|Drug|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
75590304|NCT05873179|Other|role-playing for learning the clinical interview|role-playing for learning the clinical interview
75440059|NCT01617200|Drug|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
75440060|NCT01617200|Drug|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
75440061|NCT01617213|Drug|Melphalan|200 mg/m2/IV
75440062|NCT01617213|Drug|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
75440063|NCT01617226|Drug|Azacitidine|Azacitidine both arms; 75mg/m^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
75733564|NCT05810961|Other|placebo|infusion of placebo
75733565|NCT05810948|Biological|efgartigimod IV|infusion of efgartigimod
75733566|NCT05810948|Other|Placebo|infusion of placebo
75733567|NCT05810116|Drug|Levagen+|Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
75733568|NCT05810116|Drug|Microcrystalline cellulose|Daily dose of 1-2 capsules (1 capsule containing 350mg)
76054859|NCT01495000|Drug|placebo|placebo subcutaneous injection, single dose
76054860|NCT01494922|Drug|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
75590305|NCT05872581|Behavioral|Hand scanner instant feedback|Participants will be informed about their hand scanner results of the first hand washing attempt to get individualized feedback about their hand wash performance.
75440064|NCT01617226|Drug|Vorinostat|Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
75440065|NCT01617239|Biological|Virosomal influenza vaccine|"Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)"
75440066|NCT01617252|Device|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
75440067|NCT01617265|Procedure|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
75590306|NCT05872581|Behavioral|Video training|Participants will watch a training video about the 7 steps of hand washing after the first hand washing attempt.
75733569|NCT05807932|Drug|Venetoclax|Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.
75733570|NCT05807932|Drug|Amsacrine|Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
75733571|NCT05807932|Drug|Ara-C|Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
75733572|NCT05807932|Drug|Tacrolimus|Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
75733573|NCT05807932|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
76054861|NCT02192099|Drug|Rapastinel (225 mg/450 mg IV administration)|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
75590307|NCT05871151|Device|taVNS|Trans-auricular Vagus Nerve Stimulation is a non-invasive method of stimulating the auricular branch of the vagus nerve through the inner ear. Trans-auricular Vagus Nerve Stimulation will be provided using a commercially available device. The investigators will use custom earbuds that will make the experience significantly more comfortable than traditional transauricular Vagus Nerve Stimulation.
75733574|NCT05806944|Device|TMS followed by Sham TMS|double blinded crossover schedule in which participants will undergo TMS and assessment in one visit, followed by sham-TMS and assessment the next visit.
75733575|NCT05806944|Device|Sham TMS followed by TMS|double blinded crossover schedule in which participants will undergo sham TMS and assessment in one visit, followed by TMS and assessment the next visit.
76054862|NCT01494610|Drug|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
75440068|NCT01617265|Procedure|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
75733576|NCT05803941|Drug|AAA617|Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent clinical interventional Novartis sponsored clinical trials.
75883371|NCT05358639|Drug|Navitoclax|For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
75733577|NCT05800210|Device|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
75733578|NCT05798078|Behavioral|Cognitive Bias Modification for Interpretation (CBM-I)|The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.
75733579|NCT05798078|Behavioral|Sham Training Control Condition|The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
75733580|NCT05797376|Drug|Rivaroxaban 2.5mg|patients are prescribed aspirin at a daily dose of 100mg and Rivaroxaban (2.5 mg twice a day)
75733581|NCT05797116|Other|Survey|29-item Dutch survey about the implementation and practice variation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients in the Netherlands.
75883372|NCT05355090|Dietary Supplement|PP|Protein Pacing three times per day
76054863|NCT01494610|Drug|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
76054864|NCT02116777|Other|Laboratory Biomarker Analysis|Correlative studies
75440069|NCT01617278|Device|I-Scan 1|I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
75440070|NCT01617278|Device|HD Colon|High definition white light
75590308|NCT05871151|Behavioral|Exercise|All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations; 3) a home program, which consists of exercises and tasks that the patient can do on their own and performed nightly; and 4) group exercise sessions. The exercise intervention proposed involves the supervision of a trained exercise specialist at all times during the treatment session. Exercise will be provided in a clinical setting, 60 minutes per session, up to 3 sessions/week, for 4 weeks total.
75733582|NCT05796557|Biological|Platelet Transfusion|Participants will be transfused according to the assigned threshold for each group, with a transfusion dose of 10 mL/kg, up to one adult unit.
75733583|NCT05794321|Drug|Intravenous TXA|Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.
75733584|NCT05789407|Diagnostic Test|Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry|1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
75733585|NCT05789056|Drug|QRX003, 4% Lotion|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
75733586|NCT05782582|Diagnostic Test|Package investigation|Investigations performed on a single visit, according to arm description
75733587|NCT05782582|Device|Sound registration with Cadscore® and added risk calculation|Recording of cardiac diastolic sounds enabling the calculation of a risk score.
75733588|NCT05782582|Diagnostic Test|Standard investigation|Sequential investigations according to arm description
75883373|NCT05347225|Drug|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD.
75883374|NCT05330871|Biological|1 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
75883375|NCT05330871|Biological|2 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
75883376|NCT05330871|Biological|3 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
75883377|NCT05330871|Biological|4 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
76054865|NCT02116777|Other|Pharmacological Study|Correlative studies
75883378|NCT05330871|Biological|5 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
75883379|NCT05330871|Biological|6 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
76054866|NCT02116777|Drug|Talazoparib|Given PO
76054867|NCT02116777|Drug|Temozolomide|Given PO
75440071|NCT01617278|Device|I-Scan 2|I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
75440072|NCT01617304|Other|Dietary intervention|Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
75883380|NCT05330871|Biological|7 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
75883381|NCT05330871|Biological|8 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
76054868|NCT01494532|Drug|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
76054869|NCT01494532|Drug|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
76054870|NCT02191397|Drug|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
75440073|NCT01617317|Drug|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
75590309|NCT05868876|Drug|AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion|AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
75590310|NCT05867316|Behavioral|Unified Protocol|Unified Protocol based treatment, modified for use in brief treatment on inpatient units
75590311|NCT05866341|Dietary Supplement|nitrate-rich lettuce juice|Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice
75590312|NCT05866341|Dietary Supplement|nitrate-depleted lettuce juice|Daily consumption of 300 ml of a nitrate-depleted lettuce juice
75733589|NCT05780125|Drug|FIBRICLOTTE|30 mg/kg of FIBRICLOTTE (rounded up to the nearest 2 or 3 grams) after protamine administration
75733590|NCT05780125|Drug|RiaSTAP|30 mg/kg of RIASTAP (rounded up to the nearest 2 or 3 grams) after protamine administration
75733591|NCT05776758|Drug|cisplatin based neoadjuvant chemotherapy|cisplatin based neoadjuvant chemotherapy
75440074|NCT01617317|Drug|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG
75440075|NCT01617330|Procedure|Bronchoscopy|Bronchoscopy with endobronchial biopsy sampling and bronchoalveolar lavage (BAL) 18 hours post exposure. Airway inflammation was assessed.
75590313|NCT05863702|Behavioral|Penny|The chatbot will assist patients who have not been see for cancer follow-up care, with scheduling follow-up appointments, labs, scans, specialty appointments, and monitor compliance with the appointments made.
75590314|NCT05862324|Biological|TAC01-CLDN18.2|TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
75590315|NCT05855161|Other|Rebound therapy|Participants will receive exercise-based training on a trampoline
75590316|NCT05855161|Other|Exercises on a stable surface|Participants will receive exercise-based training on a stable surface
75733592|NCT05776758|Procedure|Radical cystectomy alone|RC alone
75733593|NCT05766514|Drug|Cladribine|Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
75733594|NCT05766514|Drug|Cytarabine|Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
75883382|NCT05330871|Biological|9 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
75883383|NCT05330871|Biological|10 Intramuscular injection for booster groups|1 dose 0.5ml
75883384|NCT05330871|Biological|11 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
76054871|NCT02191397|Drug|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
76054872|NCT02191397|Drug|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
76054873|NCT02191397|Drug|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
75590317|NCT05848739|Drug|ST316|IV
75440076|NCT01617343|Behavioral|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
75590318|NCT05846568|Biological|GR1801|The injection solution GR1801 does not contain preservatives. The excipients include histidine/histidine hydrochloride (20mM), trehalose (90 mg/mL), disodium EDTA (0.372mg/mL) and polysorbate 80 (0.5 mg/mL). The pH value is 5.8 and each bottle contains 2mg of GR1801 protein. The packaging material is a borosilicate glass tube injection bottle (2mL) with a halogenated butyl rubber stopper for injection and an aluminum-plastic composite cap for antibiotic bottles.
75883385|NCT05330871|Biological|12 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
75883386|NCT05330871|Biological|13 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
75883387|NCT05330871|Biological|14 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
75883388|NCT05330871|Biological|15 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
75883389|NCT05330871|Biological|16 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
75440077|NCT01617356|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
75883390|NCT05330871|Biological|17 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
75440078|NCT01617356|Other|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
75590319|NCT05846568|Biological|Human Rabies Immunoglobulin(HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin produced by BOYA-BIO, which are derived from human plasma, and then purified and filled in the injectable vial form.
75883391|NCT05330871|Biological|18 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
75883392|NCT05330871|Biological|19 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
76054874|NCT01630811|Drug|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
75590320|NCT05846568|Biological|Rabies Vaccine|The Chinese licensed freeze-dried rabies vaccine produced by CHENGDA PHARMACEUTICALS for human use (Vero Cells) which is indicated for the rabies Post-exposure Prophylaxis (PEP) .
75733595|NCT05766514|Drug|Decitabine|Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
75733596|NCT05766514|Drug|azacitadine or decitabine|Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitadine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
75883393|NCT05330871|Biological|20 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
75883394|NCT05330871|Biological|21 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
75883395|NCT05330871|Biological|22 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
75883396|NCT05330871|Biological|23 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
75883397|NCT05330871|Biological|24 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
75883398|NCT05327595|Drug|LY3549492|Administered orally.
76054875|NCT01630811|Other|Placebo|Placebo will be given once daily for 7 days.
76054876|NCT03027076|Procedure|Genitourinary Specimen Collection|Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)
76054877|NCT03027076|Procedure|Collect midstream urine samples|Collect midstream urine samples
75590321|NCT05845450|Drug|Trastuzumab deruxtecan|trastuzumab deruxtecan 5.4 mg/kg IV on day 1
75590322|NCT05845450|Drug|Durvalumab|durvalumab 1500 mg IV on day 1
75883399|NCT05327595|Drug|Placebo|Administered orally.
75590323|NCT05845450|Drug|Panitumumab|panitumumab 6 mg/kg IV on days 1 and 15
75590324|NCT05845450|Drug|Botensilimab|botensilimab 1 mg/kg on day 1
75590325|NCT05845450|Drug|Balstilimab|balstilimab 3 mg/Kg on days 1 and 15
75733597|NCT05766514|Drug|Venetoclax|Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
75733598|NCT05763160|Drug|RZL-012|Ready to use drug product for injection into the subcutaneous fat
75733599|NCT05760482|Diagnostic Test|Metobolites serum level measurement|Blood samples will be taken from all volunteer participants in 1 yellow cap tube of 10 cc. After the blood has cooled and the clot development process (approximately 15 minutes), the serum will be separated by centrifugation at 2000 g for 5 minutes. Separated sera will be aliquoted and stored at -40°C until analysis. The tryptophan and tryptophane metabolite levels of the participants will be measured by Liquid Chromatography-Tandem Mass Spectrometer API 3200 device. The kynurenine, kynurenic acid, 3-HK, 3-HAA, 3-HOA, and QA values obtained as a result of this test will be recorded.
75733600|NCT05760482|Behavioral|Anxiety and stress level measurement|Anxiety and stress levels will be evaluated by applying State-Trait Anxiety Inventory and Perceived Stress Scale Tests by all volunteer participants. Scores from these tests will be recorded.
75733601|NCT05760365|Other|3D printed educational model|3D printed cardiac catheterization model
75733602|NCT05760365|Other|Slide-based presention|Slide-based presention
75733603|NCT05757310|Biological|Anti-Thymocyte Globulin|Given IV
75733604|NCT05757310|Procedure|Biospecimen Collection|Undergo blood sample collection
75733605|NCT05757310|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspirate
75733606|NCT05757310|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75733607|NCT05757310|Drug|Cyclophosphamide|Given PO and IV
75590326|NCT05845450|Drug|Sotorasib|sotorasib 960 mg orally once daily from day 1 to 28
75733608|NCT05757310|Procedure|Haploidentical Hematopoietic Cell Transplantation|Undergo CD4+ T-cell depleted haploHCT
75733609|NCT05757310|Drug|Pentostatin|Given IV
75883400|NCT05327595|Drug|Atorvastatin|Administered orally.
75883401|NCT05327595|Drug|Midazolam|Administered orally.
75590327|NCT05842213|Biological|AVT05 (proposed biosimilar to golimumab)|AVT05 is a recombinant human IgG1қ mAb developed as a subcutaneous injection
75590328|NCT05842213|Biological|Simponi (Golimumab)|Simponi (Golimumab) is a recombinant human IgG1қ mAb developed as a subcutaneous injection
75440079|NCT01617473|Procedure|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
75440080|NCT01617486|Behavioral|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
75733610|NCT05757310|Other|Questionnaire Administration|Ancillary studies
75733611|NCT05754034|Device|High flow oxygen|humidified and heated oxygen delivered at high flow rates via nasal cannula, with protocol to target SpO2 90-94%
75733612|NCT05754034|Other|Standard flow oxygen|oxygen delivered at standard flow rates via nasal cannula, facemask, or nonrebreather mask, with protocol to target SpO2 90-94%
75733613|NCT05752539|Device|CEREC System by Dentsply Sirona|CEREC Tessera blocks achieve exceptional three-way performance through a unique chemistry that incorporates two complementary crystal structures within a glassy zirconia matrix. These two crystals work together to create an unprecedented fusion of strength and beauty in one block while significantly improving overall processing time.
75733614|NCT05748626|Device|Anti-snoring device|For group 1, the study team will aid the subject in molding and preparing the device in the pre-operative area. They will wear the device throughout the entirety of the case.
75733615|NCT05748626|Procedure|No anti -snoring device during their procedure.|For group 2 there will be no anti snoring device used during the case.
75883402|NCT05314153|Drug|Brexanolone|Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
76054878|NCT02169791|Drug|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
76054879|NCT02216591|Device|Active Cognitive Training (ACT)|
76054880|NCT02216591|Device|Control (CON)|
75733619|NCT05745727|Drug|PRX-115|Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 7
75733620|NCT05745727|Drug|Placebo|Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 7
75883403|NCT05313035|Biological|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
75883404|NCT05313035|Biological|placebo|the placebo is NaCl injection manufactured by PT. Bio Farma
75883405|NCT05308940|Drug|TB001|once-daily subcutaneous injection, on Day 1 in SAD stage
75883406|NCT05308940|Drug|TB001|once-daily subcutaneous injection, on Days 1-7 in MAD stage
75883407|NCT05308940|Drug|Placebo|once-daily subcutaneous injection, on Day 1 in SAD stage
75883408|NCT05308940|Drug|Placebo|once-daily subcutaneous injection, on Days 1-7 in MAD stage
76054881|NCT02216357|Drug|Ifetroban, Oral Capsule|
75440081|NCT01617499|Behavioral|Physical activity|The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
75440082|NCT01617512|Device|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
75440083|NCT01617525|Other|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
75440084|NCT01617538|Drug|atorvastatin|40mg per day,duration for 24 weeks
75590329|NCT05839912|Procedure|Excision of clinically detected lymph node metastasis before any systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted
75590330|NCT05839912|Procedure|Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery
75590331|NCT05833854|Other|Virtual reality glasses group|It is suggested that the use of virtual reality glasses during the injection will positively affect the pain and fear levels in children who received penicillin injection in the pediatric emergency department where the study was conducted.
75733621|NCT05745064|Drug|TL-925|TL-925 is an eye drop.
75733622|NCT05745064|Drug|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
76054882|NCT02216357|Drug|Placebo, Oral Capsule|
76054883|NCT01492426|Drug|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
76054884|NCT01492426|Drug|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
76054885|NCT01492426|Drug|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
76054886|NCT01492426|Drug|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
76054887|NCT01453348|Biological|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.
76054888|NCT01453348|Biological|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 & 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
75733623|NCT05741489|Device|Continuous glucose monitoring (CGM)|The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
75733624|NCT05739331|Device|machine learning algorithm|Machine learning algorithm run on EBUS images for real-time labelling of mediastinal lymph nodes and lymph node level
75883409|NCT05306626|Behavioral|Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design principles aimed at promoting maternal mental health and supportive parenting. The BEAM Program mobile application is designed and managed by Tactica Interactive and hosted on the University of Manitoba secure servers. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or trainee) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in another research group-based mental health intervention. Parent coaches will engage with participants on the community peer support forum and attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve anxiety and depression symptoms and parenting skills using content that draws from the Unified Protocol, and emphasizes self-compassion, effective communication practices, and social support networks.
75883410|NCT05302830|Behavioral|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
75883411|NCT05302830|Behavioral|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
76025023|NCT01958476|Drug|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
75440085|NCT01617551|Drug|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
75440086|NCT01617564|Drug|bipuvacain|PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
75440087|NCT01617564|Other|NaCl|PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
75590332|NCT05833854|Other|Manual pressure group|In the pediatric emergency department where the study was conducted, pressure will be applied to the area to be injected for 10 seconds before the injection procedure in children who received penicillin injection. Pressing with the thumb of the hand, which will be passive in the pressing application, will be understood by the whitening of the nail, and thus pressure will be applied to the skin. It is suggested that it can positively affect pain and fear levels.
75590333|NCT05830942|Behavioral|Walking Exercise|aerobic walking exercise using complex (cognitively engaging) walking tasks
75590334|NCT05830942|Device|Prefrontal Active tDCS|20 minutes of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
75590335|NCT05830942|Device|Prefrontal Sham tDCS|30 seconds of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
75590336|NCT05827861|Behavioral|HeartAge|HeartAge is a phenotypic age-based risk presentation which is a modified tool for CVD risk communication based on the Framingham risk Score. The Heart-Age risk presentation is the age at which an individual of the same sex would be expected to experience the same absolute risk as the individual, had their risk factors been 'normal' based on the clinical guidelines.
75590337|NCT05827861|Behavioral|HOPE-CVD Mobile App|The HOPE-CVD mobile app is an evidence-based behaviour change platform that runs for 24 weeks. The programme supports behavioural modification through seven self-care behaviours (active living, exercise, weight management, blood pressure-friendly diet, cholesterol-friendly diet, medication adherence and smoke-free lifestyle). To adopt a digital delivery of Motivational Interviewing and Cognitive Behavioural Therapy, the HOPE-CVD platform incorporates interactive decision aids, dramatic vignettes, expert content, peer videos and behaviour tracking.
75733625|NCT05735639|Drug|Dalteparin Sodium|Low molecular weight heparin
75733626|NCT05735639|Drug|Tinzaparin Sodium|Low molecular weight heparin
75733627|NCT05735639|Drug|Enoxaparin Sodium|Low molecular weight heparin
75733628|NCT05735639|Drug|Rivaroxaban|Direct oral anticoagulant
75733629|NCT05735639|Drug|Apixaban|Direct oral anticoagulant
75733630|NCT05735639|Drug|Dabigatran Etexilate|Direct oral anticoagulant
75733631|NCT05733611|Biological|RP2|Genetically modified herpes simplex type 1 virus
75440088|NCT01617590|Drug|leflunomide|"Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once 200-400mg per 3 weeks."
75590338|NCT05827861|Behavioral|Genetic Risk Score|Participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. they will receive a genetic risk communication which indicates which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future.
75590339|NCT05826418|Dietary Supplement|MEND diet|Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
75883412|NCT05293756|Behavioral|OPTIMA-BP Intervention|"Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~Six weekly web-based education sessions on hypertension management.~Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: < 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor."
75590340|NCT05826418|Dietary Supplement|mNICE diet|Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
75590341|NCT05821842|Device|Sonu|Acoustic energy delivery
75590342|NCT05816083|Behavioral|Virtual Reality Tool|Virtual Reality Tool for At-Risk Trauma-Exposed Young People
75590343|NCT05811377|Drug|Ferumoxytol|After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.
75590344|NCT05811377|Drug|Gadobutrol|After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
75590345|NCT05809427|Device|Periodontal probing|"Imaging/Scanning and recording : Ultrasonic periodontal probing per operator (10 teeth X 6 sites/teeth = 60 probing sites per operator). In addition, 2 teeth per patient will be probed with the ultrasonic probe a second time (2 teeth x 6 sites per tooth = 12 sites per patient) for intra-operator reproducibility purpose.~Manual probing per operator with the OMS probe (part of the routine of care)"
75590346|NCT05802225|Drug|BCD-178|at an initial dose of 840 mg (1 cycle), then 420 mg
75590347|NCT05802225|Drug|Perjeta|at an initial dose of 840 mg (1 cycle), then 420 mg
75590348|NCT05801835|Drug|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m^2 on days 1 and day3 of the first cycle of induction.
75590349|NCT05801835|Drug|Vyxeos|Be given intravenously at 65U/m^2 on days 1 and day3 of the first cycle of induction.
75733632|NCT05733611|Biological|RP3|Genetically modified herpes simplex type 1 virus
75733633|NCT05733611|Biological|atezolizumab|anti-PD-L1 monoclonal antibody
75733634|NCT05733611|Biological|bevacizumab|anti-VEGF therapy
75733635|NCT05733598|Biological|RP3|Genetically modified herpes simplex type 1 virus
75733636|NCT05733598|Biological|atezolizumab|anti-PD-L1 monoclonal antibody
75733637|NCT05733598|Biological|bevacizumab|anti-VEGF therapy
75883413|NCT05289310|Other|Normobaric hypoxia (NH)|Low oxygen exposure to mimic ~8500 feet elevation (experimental).
75883414|NCT05289310|Other|Normobaric normoxia (NN)|Normal oxygen exposure to mimic sea level conditions (sham comparator).
75590350|NCT05801835|Drug|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m^2 on days 1 and day3 of the second cycle of induction.
75440089|NCT01617590|Drug|methotrexate|"MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once"
75440090|NCT01617694|Drug|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
75440091|NCT01617694|Drug|Normal Saline|
75590351|NCT05801835|Drug|Vyxeos|Be given intravenously at 65U/m^2 on days 1 and day3 of the second cycle of induction.
75590352|NCT05799482|Other|Qualitative Interview|Qualitative, semi-structured interview
75590353|NCT05797545|Diagnostic Test|Breast MRI for Breast Cancer Detection|Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance
75590354|NCT05796141|Behavioral|Core Behavioral Weight Loss (BWL) intervention|Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)
75590355|NCT05796141|Behavioral|Dyadic Action Planning|Participants will develop dyadic action plans together.
75590356|NCT05796141|Behavioral|Joint Feedback|Participants will see data on their partner's progress, in addition to their own weight and behavioral data.
75590357|NCT05796141|Behavioral|Autonomy Support Training|Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.
75733638|NCT05730309|Behavioral|Customized discharge and expedited referral instructions|The intervention for subjects with LVH on research POCUS will consist of three elements: 1) disclosure of presence of LVH to subject, ED team and primary care physician (PCP) (if applicable); 2) educational discharge instructions describing high BP, HTN, LVH, implications for development of cardiovascular disease (such as development of heart failure, stroke), options for treatment (lifestyle, medications) and importance of follow-up; A preliminary version will be refined prior to the start of the trial by feedback from ED physicians and patients. Refinement will target content, phrasing, and literacy level. 3) referral to outpatient care, consisting of one of two options, based on whether the subject has an established PCP. For subjects with existing PCP, the study team will call the office, inform about study participation, LVH findings, and secure a follow-up appointment. For those with no PCP, study team will arrange for follow-up to special clinic.
75733639|NCT05727800|Drug|VX-668|Suspension for oral administration.
75590358|NCT05796141|Behavioral|Home Environment Modifications|Participants will be trained in how to structure their home environment to support health behavior.
75590359|NCT05790681|Drug|Insulin icodec|Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.
75590360|NCT05784662|Behavioral|Social Workers Addressing Firearm Risk|Educational intervention for social workers.
75590361|NCT05781386|Drug|SIM1811-03 or in combination with Sintilimab injectiont|"SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)"
75590362|NCT05780216|Drug|DMT + harmine|The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.
75590363|NCT05780216|Drug|Placebo|The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
75590364|NCT05778162|Diagnostic Test|Synovasure® RISC™ Panel|The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments [CLIA] Registration No.: 21D0216863) intended to provide indications for diagnosing different types of arthritis that may correspond to higher risk levels for postoperative complications in patients experiencing knee pain and/or inflammation prior to primary knee arthroplasty.
75590365|NCT05777291|Device|Activity watch monitoring|Patients will be using activity devices during the study period
75590366|NCT05777291|Device|Sleep mattress monitoring|Patients will be using sleep mattress during the study period
75590367|NCT05777291|Behavioral|Physical activity counseling|Physical activity counseling in accordance to the Swedish model
75733640|NCT05727800|Drug|Placebo|Suspension for oral administration.
75733641|NCT05723445|Behavioral|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence to a low glycemic load diet with close nutritionist follow up
75733642|NCT05719714|Drug|Dapagliflozin 10 MG [Farxiga]|10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
75883415|NCT05283408|Drug|Dexmedetomidine infusion|Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
75590368|NCT05775627|Behavioral|Sleep Restriction|Participants are randomized into either a group (n=10) that is sleep restricted first or control first (n=10) group; the groups will crossover halfway through the protocol. Both arms are fed 3 meals and have access to ad libitum food between meals. Both groups will also undergo up to 3 mixed-meal tolerance tests to measure glucose tolerance.
75440092|NCT01617707|Drug|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
75590369|NCT05770570|Behavioral|Counseling|In-person individual diet and physical activity (PA) counseling
75590370|NCT05770570|Behavioral|Text Messages|Thrice-weekly diet/physical activity(PA) text messages
75590371|NCT05770570|Behavioral|Phone calls|Weekly telephone support
75590372|NCT05770570|Behavioral|Self-monitoring tools|Self-monitoring tools
75590373|NCT05768529|Drug|U16|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
75440093|NCT01617707|Drug|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
75440094|NCT01617733|Drug|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
75440095|NCT01617746|Drug|Ambrisentan|5mg od two weeks
75440096|NCT01617746|Drug|Bosentan|62.5mg bd two weeks
75440097|NCT01617746|Drug|Placebo|bd for two weeks
75440098|NCT01617772|Drug|Atorvastatin|Atorvastatin 20 mg
75440099|NCT01617772|Drug|L-Carnitine|1000mg L-carnitine
75590374|NCT05766631|Behavioral|DynamiCare Health|"Participants earn incentives for:~CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment."
75590375|NCT05766631|Drug|Methadone Treatment-As-Usual|Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
75590376|NCT05761847|Other|Pediatric Medication Therapy Management (pMTM)|The pMTM intervention is comprised of 3 activities: comprehensive review of the medication regimen; optimization of the medication regimen; and creation of the medication action plan.
75733643|NCT05719077|Behavioral|EDITH-HC|This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
75440100|NCT01617772|Drug|Placebo|Identically looking placebo
75440101|NCT01617798|Drug|Supplemental metolazone diuresis|Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
75590377|NCT05759078|Drug|Ferinject|The first dose of FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4 and 8 months (visits V2, V3) for: haemoglobin, serum ferritin and TSAT. They will receive an additional dose of 1000 mg of FCM during these visits if ferritin <100 ng/mL or/and TSAT <20% (ferritin cannot exceed 400 ng/dL, TSAT cannot exceed 40%, haemoglobin cannot exceed 15 g/dL). If these criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
75883416|NCT05283408|Drug|Co-administration dexmedetomidine and low-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
75883417|NCT05283408|Drug|Co-administration dexmedetomidine and high-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
75590378|NCT05759078|Drug|Sodium Chloride 0.9% Inj|The first dose of placebo will be administered during the first visit on the day of randomisation (V1). During visits V2 i V3 (at 4 and 8 months) they will receive next dose of placebo.
75590379|NCT05757882|Other|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water.
75733644|NCT05718258|Drug|Venglustat (GZ402671)|"Pharmaceutical form: tablet~Route of administration: oral"
75733645|NCT05714566|Diagnostic Test|Clostridioides difficile toxin detection|Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.
75733646|NCT05714501|Device|Millipede System|Mechanical thrombectomy
75440102|NCT01617798|Drug|Placebo Comparator: Control-- furosemide (lasix) only|Control arm will receive furosemide as monotherapy for diuresis
75733647|NCT05707858|Other|Development of the NAPFA score|In subjects with suspected food allergy we will evaluate main anamnestic, and clinical features to develop the NAPFA score
75733648|NCT05706402|Drug|N-acetylcysteine|Patients will be randomized to receive oral N-acetylcysteine at 600 mg twice daily for 1 week. The randomization will be done via computer software with half of the patients randomized to receive NAC. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
75883418|NCT05275400|Drug|Insulin Efsitora Alfa|Administered SC
75440103|NCT01617811|Procedure|epidural anesthesia and analgesia|"A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.~Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).~Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed."
75440104|NCT01617824|Drug|Linagliptin|Linagliptin 5 mg tablets for 4 days
75440105|NCT01617824|Drug|Placebo|Placebo tablets for 4 days
75440106|NCT01617837|Device|P6 acupressure band|Comparison between groups 0-48 hours postoperatively.
75883419|NCT05275400|Drug|Insulin Degludec|Administered SC
75883420|NCT05264103|Device|Exoskeleton for gait rehabilitation (Atalante)|Subjects will walk with different levels of assistance given by the robot.
75883421|NCT05255172|Other|Supervised Exercise|12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
75590380|NCT05757882|Other|2 hours of fasting time|Oral intake is not allowed for 2 hours before sedation including water.
75590381|NCT05755776|Drug|TMF|switch ETV to TMF
75590382|NCT05753306|Procedure|Biospecimen Collection|Undergo stool and blood sample collection
75590383|NCT05753306|Drug|Cisplatin|Given via HIPEC
75590384|NCT05753306|Procedure|Computed Tomography|Undergo CT scan or PET/CT
75590385|NCT05753306|Drug|Docetaxel|Given via HIPEC
75590386|NCT05753306|Procedure|Gastrectomy|Undergo robotic gastrectomy
75590387|NCT05753306|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
75883422|NCT05254535|Other|I-SITE|I-SITE includes coaching facilitation, technical assistance, and an online toolkit to allow primary care clinics to tailor the integration of teleophthalmology into their daily workflows based on each clinic's unique needs and resources. The program includes a series of coaching sessions between a skilled practice facilitator and clinical personnel at each health system.
75883423|NCT05240755|Drug|Cannabidiol Oil|Subjects will self-administer CBD sublingually.
75440107|NCT01617837|Other|Placebo band|Comparison between groups 0-48 hours postoperatively
75440108|NCT01617850|Other|Supervised physical exercise training x3 weekly for 12 weeks|Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
75440109|NCT01617850|Other|Supervised physical exercise training x2 weekly for 8 weeks|Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
75590388|NCT05753306|Procedure|Magnetic Resonance Imaging|Undergo MRI
75590389|NCT05753306|Procedure|Positron Emission Tomography|Undergo PE/CT
75590390|NCT05753306|Other|Questionnaire Administration|Complete questionnaire
75590391|NCT05752734|Drug|Group D|"Patients who received 8 mg dexamethasone before bariatric surgery will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
75590392|NCT05752734|Drug|Group C|"Patients not administered dexamethasone will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
75590393|NCT05748522|Other|Shoulder Mobility|t is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands.
75733649|NCT05706402|Drug|Placebo|Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
75733650|NCT05704725|Drug|ABP 938|IVT injection
75733651|NCT05704725|Drug|Aflibercept|IVT injection
75733652|NCT05700903|Drug|Gonadotropin-Releasing Hormone Agonist|8 weeks of GnRH agonist
75733653|NCT05700903|Drug|Androgen receptor inhibitor|2 weeks of AR Inhibitor
75733654|NCT05700903|Drug|Placebo|Placebo tablet and injection
75733655|NCT05698901|Drug|Agalsidase beta|The treatment is following local reimbursement criteria and judge by physician
75733656|NCT05697029|Drug|Tetrandrine|tetrandrine TID for 28 days
75590394|NCT05748522|Procedure|Diaphragmatic Breathing|"The participant will lie on his back in a comfortable position, diaphragmatic breathing will be taught first in the application group and he will be asked to do diaphragmatic breathing for 90 seconds. At the end of this period, the participant will be referred back to the evaluator physiotherapist, and the physiotherapist will evaluate the shoulder mobility again without knowing which group the participant is in.~In the participant control group, shoulder mobility will be evaluated and the practitioner will be asked to stay in a comfortable position on his back for 90 seconds next to the physiotherapist. At the end of the period, shoulder mobility will be evaluated again by the assessing physiotherapist."
75590395|NCT05746520|Other|Antibiotic|Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.
75590396|NCT05744661|Other|Mechanical Method|Use of Rotary Master Apical file for the removal of Calcium Hydroxide Medicament from Root Canal System
75590397|NCT05744661|Other|Chemomechanical Method|Sonic Activation of Endodontic irrigants for the removal of Calcium Hydroxide from Root Canal System
75590398|NCT05744310|Device|Long term mechanical ventilation support|Patients that choose life prolonging treatment with long term mechanical ventilation support
75440110|NCT01617889|Other|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
75733657|NCT05696197|Behavioral|Targeted touchscreen training|Participants will practice the Swipe Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants form different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 minutes per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14 seconds. Instruction and answers are also included. Feedback will be provided by means of knowledge of performance. On each training day, participants will receive a reminder on the training tablet.
75733658|NCT05695105|Device|Electric Toothbrush-Generated Vibration|Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth
75733659|NCT05695105|Device|Mini-Implant-Assisted Orthodontic Treatment|Testing mini-implant-assisted heavy force application to treat ankylosis of teeth
75733660|NCT05693805|Behavioral|Tai Chi|The remote delivery Tai Chi protocol that will be developed in this study for Veterans with PTSD and pain will be adapted from a protocol that has been well-tested in previous trials All components of the program derive from the classical Yang-style Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Sessions will last 60 minutes, twice a week for 12 weeks. Experienced instructors will follow the Tai Chi protocol with rigorous quality control procedures. We will provide the patients with printed materials on the Tai Chi program, including Tai Chi principles, practice techniques, and safety precautions. Every session will include: warm up and a review of Tai Chi principles; breathing techniques; meditation with Tai Chi movement; and relaxation.
75883424|NCT05229315|Drug|Toripalimab|PD-1 Immune Checkpoint Inhibitor Combined With IMRT,used at 2 weeks before radiotherapy, once every 2 weeks, 10 cycles in total
75440111|NCT01617889|Other|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
75440112|NCT01617928|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
75440113|NCT01617928|Drug|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
75440114|NCT01617928|Drug|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
75590399|NCT05744310|Device|No long term mechanical ventilation support|Patients that decline life prolonging treatment with long term mechanical ventilation support
75883425|NCT05229315|Procedure|Intensity modulated radiotherapy|Intensity modulated radiotherapy
75883426|NCT05222880|Device|JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3|TEST Lens
75440115|NCT01617941|Drug|BGG492|
75590400|NCT05741905|Drug|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
75590401|NCT05741905|Drug|Levofloxacin simulant|Levofloxacin simulant is placebo. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
75590402|NCT05739149|Diagnostic Test|Microvessel Ultrasound Examination|Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
75590403|NCT05739149|Procedure|Skin Biopsy|Dermatology will remove a small piece of skin from the affected ulcer area and control skin
76054889|NCT01453348|Biological|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
76054890|NCT01453348|Biological|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
76054891|NCT04076410|Device|Z1 lens|CE marked device
76054892|NCT04076410|Device|Experimental Lens 1|CE marked device
76054893|NCT04076410|Device|Experimental Lens 2|CE marked device
75440116|NCT01617941|Drug|Placebo|In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
75440117|NCT01617954|Device|MammaPrint|All subjects
75590404|NCT05737966|Other|evaluation of professional practices|Evaluation of professional practices : evaluation of the case management carried out in a program for early psychosis in France using a checklist according good practices guidelines
75590405|NCT05736445|Behavioral|Wellness coaching plus app use|Participants will participate in wellness coaching and interact with apps on their smartphones
75590406|NCT05733832|Other|Transitional Liver Clinic (TLC)|Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs
75590407|NCT05733585|Device|Purabond|hemostatic efficacy of PuraBond
75590408|NCT05732974|Other|Resected non small cell lung cancer|plasma sample, tissue sample and computed tomography scan images
75590409|NCT05728866|Procedure|VR immersive therapy|Participants will be asked to participate in 5 consecutive, 1-hour, 1:1 therapy sessions focused on rehabilitation of their weakened arm. Each session will involve use of a Virtual Reality (VR) system to deliver an immersive environment to encourage movement of the arm. The system also relies on 6 body-worn sensors that will detect movements of participant's arms and trunk. VR use will encompass 30-minutes of the therapy session, the remainder of the session will involve working with the therapist in addressing the functional tasks that are most meaningful for the participant and that involve the upper extremities.
75440118|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
75590410|NCT05728658|Drug|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
75590411|NCT05728034|Behavioral|Injectable PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about injectable PrEP), visit those pages, and return to the main results page.
75733661|NCT05693805|Behavioral|Wellness program|The Wellness intervention that will be developed for this study will consist of 60-minute sessions that meet twice a week for 12 weeks, and will be facilitated by doctoral level psychology staff and/or psychology trainees who will be supervised by staff. The Wellness intervention will be based on the VA Whole Health Program which helps individuals identify and achieve their personal health goals. The Whole Health Program include modules that address physical activity, personal development, healthy eating and drinking, stress management, relationships, personal surroundings, and spirituality. Using the SMART goals model, participants will set health and wellness goals each week. Discussions about ways to address potential barriers will be included in this condition.
75733662|NCT05689710|Dietary Supplement|Inositol and alpha-lactalbumin|The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
75733663|NCT05687084|Device|Uterine manipulator use|After peritoneal washing, the uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.
75440119|NCT01618006|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
75440120|NCT01618006|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
75590412|NCT05728034|Behavioral|Oral PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about oral PrEP), visit those pages, and return to the main results page.
75590413|NCT05726656|Other|traditional physical therapy session|manual lymph drainage-pneumatic compression and skin care
75590414|NCT05726656|Other|wii console based exercise|execise session using the wii console video games
75733664|NCT05684549|Other|No intervention|Observational study, no intervention
75733665|NCT05683990|Drug|Diamyd|4 μg (0.1 mL) of Diamyd administered 1 month apart.
75440121|NCT01618006|Drug|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
75440122|NCT01618032|Other|HVLA|High velocity and low amplitude manipulation in traction of subtalar jonit
75440123|NCT01618032|Other|MWM|Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing
75440124|NCT01618032|Other|placebo|Manual contact during a period of time similar of teh other interventions
75590415|NCT05725018|Biological|EB-101 Surgical application of RDEB wounds|"EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets [LEAES]"
75590416|NCT05724160|Other|Using sitting ellipticals|Patients will receive routine physiotherapy protocols as well as Non-weightbearing stationary elliptical
75590417|NCT05724160|Other|Physiotherapy Protocol|Routine physiotherapy protocol
75590418|NCT05723471|Other|Adaptative Physical Activity|12 weeks of a collaborative program of customized, adaptative and supervised physical activity by sports instructor
75590419|NCT05722496|Other|Aerobic pedaling exercise|aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities
75590420|NCT05719883|Device|Maurora® Sirolimus Eluting Stent System|The Maurora® for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
75590421|NCT05719883|Device|APOLLO™ Intracranial Stent System|The Apollo stent system comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
75590422|NCT05717491|Other|Biological analysis, Physical examination and Questionnaires|Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
75440125|NCT01618045|Dietary Supplement|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
75590423|NCT05717491|Other|Physical examination and Questionnaires|In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.
75590424|NCT05717049|Drug|Theophylline Tablets|12 week oral treatment
75883427|NCT05216016|Other|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN intervention group participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
76054894|NCT04076410|Device|Experimental Lens 3|CE marked device
75440126|NCT01618058|Drug|No Investigational Product|"This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants"
75440127|NCT01618071|Dietary Supplement|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
75590425|NCT05714280|Behavioral|PA4Health Open Pilot|"The goal of this aim is to collect data that guide the refinement of intervention components and structure to increase appeal to AA women. Fifteen physically inactive AA women will participate in a 12-week study examining the feasibility, acceptability, and usage of the PA4Health app.~They will receive a Fitbit tracker to be worn during the trial. Following the trial, participants will complete self-report measures as well as a semi-structured interview to learn about their experience in using the app, any experienced difficulties, and recommendations for improving the acceptance and usage of the app."
75590426|NCT05714033|Procedure|Ventilatory Strategy To Prevent Atelectasis|Given
75590427|NCT05714033|Procedure|Lateral Decubitus Strategy (LADS)|Given
75590428|NCT05711888|Behavioral|Semantic Recognition Procedure|A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.
75440128|NCT01618084|Device|Tritanium acetabular component|Total hip arthroplasty using a tritanium uncemented acetabular component
75440129|NCT01618097|Behavioral|DVD Decision Aid|Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
75590429|NCT05711056|Behavioral|Sociobehavioral Intervention|"Utilizes two primary evidence-based strategies:~Delivering OUD consultation via telemedicine, which has been demonstrated to be a safe and effective means for initiating MOUD with buprenorphine; and,~Incorporating psychosocial support in the form of PRC, whose involvement in patient care is associated with increased treatment retention and MOUD initiation."
75733666|NCT05682859|Drug|Roflumilast 500 Mcg Oral Tablet|Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.
75733667|NCT05682859|Drug|Placebo|Placebo tablets
75440130|NCT01618097|Behavioral|Internet Based Decision Aid|Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
75733668|NCT05680272|Behavioral|empathic communication-based education|The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
75733669|NCT05679245|Diagnostic Test|Assessment for exposure to psychological trauma and related symptoms|To be assessed for exposure to traumatic life events, post-traumatic stress disorder, trauma-related symptoms, dissociative symptoms, affective symptoms, and psychosocial functioning.
76054895|NCT04076410|Device|Experimental Lens 4|CE marked device
75440131|NCT01618110|Device|Transcranial Magnetic Stimulation (Magstim, Rapid)|Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
75440132|NCT01618110|Other|Placebo Treatment|Sham coil (minimal magnetic field, same noise and feeling)
75440133|NCT01618149|Radiation|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
75590430|NCT05708105|Diagnostic Test|Cerebral near-infrared spectroscopy|Continuous cerebral NIRS will be monitored using the INVOS 5100C Cerebral Oximeter (Medtronic, Minneapolis, MN, USA), initiated as early as feasible after birth or postnatal consent and continued until 48 hours of age. Neonatal sensors applied over a light-permeable barrier will be placed on the right or left side of forehead, like the methods used in our pilot study and in line with our clinical protocol. The continuous parameters recorded for this study using cerebral NIRS will include CrSO2 and COIx.
75590431|NCT05708105|Diagnostic Test|Functional echocardiography|"The first echocardiogram will be completed as soon as possible after consent and < 24 hours of age in all cases. This will be to capture markers of early low systemic blood flow and document patent ductus arteriosus and its size, as known to be associated with IVH.~The second scan will be performed at the end of the monitoring period, between 48-60 hours of age. This scan is planned to record the change in LVO from baseline (re-perfusion), which has been postulated to relate to development of IVH."
75590432|NCT05708105|Diagnostic Test|Head Ultrasound|HUS will be paired with both echocardiograms. The first HUS will document baseline IVH status (paired with the first ECHO). The final HUS will be performed between days 4-7 of age, as per the standard clinical practice by site radiology service and will be used to confirm the final IVH status.
75590433|NCT05704387|Procedure|individualized GDFT|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommandation of the AFM software in order to optimize patient's SV
75590434|NCT05704387|Procedure|Restrictive fluid therapy strategy|from anesthesia induction until end of the liver resection, patient will have a restrictive fluid therapy strategy
75590435|NCT05703568|Other|virtual reality|14 elderly participants receive intervention protocol of group- based virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
75590436|NCT05703568|Other|Virtual reality|14 elderly participants receive intervention protocol of individual virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
75733671|NCT05674318|Dietary Supplement|Alpha-lactalbumin|Oral assumption of two tabs/day containing Alpha-lactalbumin for 30 days
75883428|NCT05213143|Drug|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.
75883429|NCT05208931|Procedure|Anti-vascular endothelial growth factor therapy|0.05 ml anti-VEGF, intravitreal, monthly
75883430|NCT05208593|Behavioral|Negative Event + Counterfactual Task|Participants will complete a counterfactual based intervention where they come up with three if only..then statements about how a past drinking behavior could have been altered to be better and to think about protective behavioral strategies that they could use in a future similar situation to make the outcome better.
75440134|NCT01618175|Device|Home oxygen therapy|"Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.~During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration."
75590437|NCT05700708|Diagnostic Test|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin, midodrine, diuretics and domiciliary albumin
75590438|NCT05698888|Drug|VP301|VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
75590439|NCT05698368|Behavioral|Mindset intervention|Participants receive a digital mindset intervention to improve mindsets about osteoarthritis and exercise.
75590440|NCT05698368|Other|Active comparator|Participants receive a series of osteoarthritis education videos and reflective questions that matches the digital mindset intervention in duration and attention.
75590441|NCT05698147|Drug|Selinexor|"Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death."
75590442|NCT05698147|Drug|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
75590443|NCT05698147|Drug|Methotrexate|high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
75590444|NCT05696236|Device|Transepidermal water loss (TEWL) monitor and stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will also be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers. If they numbers match the stopping rules, they will tell the doctor and the oral food challenge will be over.
75440135|NCT01618253|Drug|Sorafenib|Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
75733672|NCT05669365|Behavioral|Care Ecosystem|"Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).~The CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols."
75733673|NCT05669352|Drug|CA-4948|Subjects on both the phase I and phase II portions will take 200 mg CA-4948 orally two times daily.
75733674|NCT05669352|Drug|Pembrolizumab|Subjects on both the phase I and phase II portions will receive 400 mg pembrolizumab intravenously once every six weeks.
75733675|NCT05663541|Diagnostic Test|Lower extremity position test|Assessing proprioception of the lower extremity of individuals multiple sclerosis
75590445|NCT05696236|Device|Monitor (TEWL) without stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers, but the stopping rules will not be used to end the oral food challenge.
75733676|NCT05659563|Drug|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
75733677|NCT05659563|Drug|Tamoxifen|Tamoxifen is a selective estrogen receptor (ER) modulator
75733678|NCT05655949|Drug|Gemcitabine|Intravenous infusion
75733679|NCT05655949|Drug|Cisplatin|Intravenous infusion
75733680|NCT05655949|Drug|Durvalumab|Intravenous infusion
75733681|NCT05655949|Radiation|Yttrium-90|Injection of radiation microsphere beads
75733682|NCT05654103|Device|endoAVF|The device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.
75733683|NCT05654103|Procedure|surgAVF|The surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
75440136|NCT01618253|Radiation|Conventional fractionation (2 Gy per day) external beam radiation therapy|"Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or >10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If >1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.~The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions >10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced."
75440137|NCT01618292|Procedure|Robotic sacral colpopexy|Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
75733684|NCT05652062|Device|Prizvalve® system|Transcatheter valve-in-valve replacement
75883431|NCT05208593|Behavioral|Personalized Normative Feedback|Participants will be asked to rate the frequency and quantity of students who use protective behavioral strategies while drinking. They will be given feedback on how close their estimate is from the national averages.
75883432|NCT05208593|Behavioral|Negative Event + Factual Thinking Task|Active Control condition where participants write about a negative event and list three facts about it
75883433|NCT05208593|Behavioral|Negative Event Only|Participants are asked to write about a negative event related to alcohol and write about it
75883434|NCT05205772|Device|transcranial magnetic stimulation|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes."
76054896|NCT01453036|Procedure|23S rRNA point mutation test of Helicobacter pylori|mutation test group>> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group >> no intervention
75440138|NCT01618331|Behavioral|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
75440139|NCT01618331|Dietary Supplement|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
75440140|NCT01618370|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
75733685|NCT05647512|Drug|LM-305|Administered intravenously
75733686|NCT05647512|Drug|Dexamethasone|Administered orally
76054897|NCT01453036|Procedure|UBT test & Gastroenterology with biopsy c silver stain|UBT test & Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group >> intervention
76054898|NCT01475734|Biological|albiglutide|subcutaneous injection
75590446|NCT05693818|Other|Clinical Limping Evalution|"Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp).~If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided."
75733687|NCT05645042|Behavioral|Transcendental Meditation (TM)|During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.
75733688|NCT05645042|Behavioral|Present Centered Therapy (PCT)|PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.
75883435|NCT05191862|Drug|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
75883436|NCT05191862|Drug|PMR 135 mg|Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
76054899|NCT01475734|Biological|placebo|subcutaneous injection
75733689|NCT05644561|Drug|Ravulizumab|Ravulizumab will be administered by intravenous (IV) infusion.
76054900|NCT01452412|Drug|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
76054901|NCT01452412|Drug|Placebo|To be taken on the same schedule as the active arm
75440141|NCT01618383|Other|colonoscopy or rectosigmoidoscopy|Usual procedure
75440142|NCT01618396|Drug|Sedation drug (Propofol and Midazolam)|Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
75440143|NCT01618409|Behavioral|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
75440144|NCT01618188|Drug|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
75440145|NCT01618188|Drug|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
75883437|NCT05189704|Drug|NSAID|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
76054902|NCT04409392|Other|Prothestic joint infection due to Staphylococcus lugdunensis|description of prosthetic joint infection with Staphylococcus lugdunensis
75440146|NCT01618435|Biological|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
75440147|NCT01618448|Drug|Tolvaptan|Tolvaptan 15mg once daily
75440148|NCT01618448|Drug|Placebo|Placebo
75440149|NCT01618461|Behavioral|Drug indication icons|Icons illustrate the purpose of each medication
75440150|NCT01618461|Behavioral|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
75883438|NCT05189704|Drug|Opioid|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
75440151|NCT01618474|Drug|DX|Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
75440152|NCT01618474|Drug|XELOX|oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
76054903|NCT01491802|Drug|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
76054904|NCT01491802|Drug|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
75883439|NCT05181722|Other|Patient navigator support|Support of a patient navigator for patients who have experienced an abnormal screening mammogram
75883440|NCT05179421|Drug|saline (placebo) then oxytocin 1.3 micrograms|10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
75883441|NCT05179421|Drug|Experimental: oxytocin 0.3 micrograms then oxytocin 7 micrograms|10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
76054905|NCT02168777|Drug|Refametinib (BAY86-9766)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
76054906|NCT02168777|Drug|Regorafenib (Stivarga, BAY73-4506)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
76054907|NCT01491178|Drug|Prazaxa|Dabigatran etexilate
76054908|NCT02189837|Biological|Evolocumab|Administered by subcutaneous injection
76054909|NCT02189837|Drug|Atorvastatin|Administered by mouth
76054910|NCT02189837|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
76054911|NCT02189837|Drug|Placebo to Atorvastatin|Administered by mouth
76054912|NCT02216123|Drug|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
76054913|NCT02216123|Drug|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
75590447|NCT05690841|Drug|Focal Mass Drug Administration (fMDA)|"Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by 9-11 month intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for >= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for <16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals >=6mo and <16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for >= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for <16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals >=6mo and <16y ((CQ: Day1 600 mg, PQ age-based dosing)."
75590448|NCT05689333|Device|Vista Vitrectomy Probe|Vitrectomy will be performed through 27 GA Vista Ophthalmics vitrector
75733690|NCT05644002|Behavioral|Puff Topography Biofeedback Training|"Visit 1: Participants will be asked to smoke their usual brand cigarette using the CReSS smoking topography device. Participants will be instructed on how to follow visual and auditory puffing prompts provided to them by a computer program in order to control puffing behavior for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
75733691|NCT05644002|Behavioral|Control|"Visit 1: Participants will be instructed to smoke their usual brand cigarette using the CReSS smoking topography device while passively viewing time-matched control stimulus presented to them on a computer monitor for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
75733692|NCT05640245|Drug|Sonelokimab|randomized treatment; parallel group
75883442|NCT05137366|Diagnostic Test|Transthoracic ultrasound scan|"An ultrasound scan of the thoracic aorta will be performed using an ultrasound machine with 2 MHz phased array transducer. The patient will lay supine on an ultrasound scan couch.The measurements will be taken in B-mode but colour Doppler imaging may be used to identify the thoracic aorta if it is obscured by artefacts. The measurement will be taken inner wall to inner wall and several images will be taken to check reliability.~Three different acoustic windows will be used to image the thoracic aorta:~Suprasternal window~Parasternal long axis window~Apical two chamber views~Ultrasound assessment will be considered satisfactory when at least two of the three regions of the descending thoracic aorta were visualised, partially satisfactory when a single view was obtained and inconclusive when none of the three windows could be obtained."
75440153|NCT01618487|Procedure|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
75440154|NCT01618487|Procedure|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
75440155|NCT01618487|Procedure|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
76054914|NCT02216123|Drug|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:~tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
76054915|NCT02216123|Drug|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
76054916|NCT02216123|Drug|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
75440156|NCT01618513|Drug|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
75440157|NCT01618526|Dietary Supplement|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
75440158|NCT01618526|Dietary Supplement|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
75440159|NCT01618539|Drug|propofol|varying intravenous dosages
75440160|NCT01618552|Behavioral|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
75440161|NCT01618552|Other|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
75440162|NCT01618578|Procedure|rubber hand illusion|"There were three consecutive trials of the RHI:~one control trial: asynchronous condition (3 Min.)~two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)"
75733693|NCT05640245|Drug|Placebo|randomized treatment; parallel-group
75733694|NCT05640245|Drug|Adalimumab|randomized treatment; parallel-group
75733695|NCT05638568|Diagnostic Test|LS test|If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 > 0.30)
75590449|NCT05689268|Diagnostic Test|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
75440163|NCT01618591|Drug|Single dose rifaximin 1650 mg|Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
75440164|NCT01618591|Drug|Single dose azithromycin 500 mg|Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
75440165|NCT01618591|Drug|Single dose levofloxacin 500 mg|Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
75440166|NCT01618591|Drug|Single dose azithromycin 1000 mg plus loperamide|Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
75440167|NCT01618591|Drug|Single dose azithromycin 1000 mg plus placebo|Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
76054917|NCT02189759|Other|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
75440168|NCT01618604|Procedure|Quantitative Sensory Testing|following the standardized protocol of DFNS
75440169|NCT01618604|Procedure|Conditioned Pain Modulation|test stimulus by hot thermode conditioned stimulus by cold water bath
75440170|NCT01618604|Procedure|Repetition of four QST parameters|"warm detection threshold (WDT)~cold detection threshold (CDT)~mechanical detection threshold (MDT)~mechanical pain threshold (MPT)"
75590450|NCT05685251|Other|Health Coaching|Participants will receive a health coach telehealth/video visit or phone call every 2 weeks for 4 months, for a total of 8 calls. After these initial 8 calls, at approximately 6 months postpartum, the health coach will schedule maintenance calls 1 per month until approximately 12 months postpartum, for a total of 6 additional calls.
75590451|NCT05685251|Other|Home Blood Pressure Monitoring|Participants will be provided an A&D UA-651 (BT) home blood pressure monitor with an appropriate cuff size, they will be asked to take their blood pressure at least three days a week, 2 measurements each time
75590452|NCT05684653|Drug|Orelabrutinib Tablets|50 mg, single oral dose
75733696|NCT05638412|Behavioral|JASPER|JASPER is a therapist and caregiver-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes caregivers as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
75440171|NCT01618617|Dietary Supplement|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
75440172|NCT01618617|Dietary Supplement|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
75440173|NCT01618630|Dietary Supplement|EAA Supplementation + Exercise Training|Amino acids in drinks between meals for exercise training period.
75440174|NCT01618630|Dietary Supplement|Placebo + Exercise Training|Placebo supplementation as drinks in between meals for exercise training period.
75590453|NCT05684510|Device|clear aligners|clear aligners will be applied to the upper and lower arch, then a class II elastics 1\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
75590454|NCT05684510|Device|traditional treatment Fixed appliances with class II elastics.|Agroup of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
75883443|NCT05132816|Diagnostic Test|high-resolution manometry|"High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed."
75883444|NCT05123690|Device|Neurofeedback|A device that assists in training patients in relaxing.
76054918|NCT02189759|Other|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
75590455|NCT05682677|Device|iTBS|iTBS over the left dorsolateral prefrontal cortex
75883445|NCT05110014|Other|Primary Care Office Visits|mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence
75883446|NCT05100160|Drug|Gabapentin|Given by PO
75883447|NCT05100160|Other|Placebo|Given by PO
75883448|NCT05098093|Dietary Supplement|SBE|Hard-shell capsule
75883449|NCT05098093|Dietary Supplement|DBE|Hard-shell capsule
75883450|NCT05098093|Dietary Supplement|BP|Hard-shell capsule
75883451|NCT05097521|Other|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings
75590456|NCT05682677|Device|sham iTBS|sham iTBS over the left dorsolateral prefrontal cortex
75590457|NCT05682677|Behavioral|Personalized, Augmented Cognitive Training (PACT)|6 sessions of PACT
75590458|NCT05676736|Other|No intervention|No intervention to be done for the group
75590459|NCT05672550|Drug|Bayesian based dose adjustment of enoxaparin|"A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7."
75733697|NCT05638412|Behavioral|Psychoeducational Curriculum|The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The material provided will be similar to what a pediatrician or developmental specialist may review as a part of routine care.
75733698|NCT05637112|Other|None (Observational study)|Not Applicable since Observational Study
75733699|NCT05633550|Diagnostic Test|Flexion-extension radiographs|Participants will undergo (regular) flexion-extension radiographs.
75733700|NCT05633108|Other|No Intervention|No intervention will be administered.
75733701|NCT05631093|Drug|ART|Standard of care ART, per approved product list, taken orally
75733702|NCT05631093|Drug|DOR/ISL|Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
75733703|NCT05630937|Drug|NMS-01940153E|Route of administration: intravenous (IV) solution
75883452|NCT05097521|Other|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
75883453|NCT05097521|Other|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
75883454|NCT05090332|Other|Facial Gun|Vibration massage applied for five Minutes directly on the trigger point
75883455|NCT05090332|Other|Dry Needling|For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain
76054919|NCT02189759|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
75590460|NCT05672550|Drug|Usual dose adjustment of enoxaparin|A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
75590461|NCT05672407|Drug|Tranexamic acid|100 mg/mL Tranexamic acid with lidocaine with 1:100,000 epinephrine in 1:1 manner administered subcutaneously
75590462|NCT05672407|Drug|Placebo|Lidocaine with 1:100,000 epinephrine mixed with 1:1 Basal Saline Solution (BSS) administered subcutaneously
75883456|NCT05088525|Procedure|MRI|MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
75590463|NCT05667246|Other|Caffeinated Coffee|"Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee."
75590464|NCT05667246|Other|Decaffeinated Coffee|"Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee."
75883457|NCT05082857|Behavioral|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others.
75883458|NCT05082857|Behavioral|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking.
75883463|NCT05073276|Other|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
75883464|NCT05073263|Other|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
75883465|NCT05052931|Drug|Nab-paclitaxel combined with oxaliplatin and S-1|Nab-paclitaxel 100mg/m^2, D1, Q3W; oxaliplatin 85 mg/m^2, D1, Q3W; S-1 60 mg/m^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
75883466|NCT05052229|Drug|Nitric Oxide|Nitric oxide gas for inhalation
75883467|NCT05052229|Drug|Medical air|Medical grade air for inhalation (placebo)
75883468|NCT05040802|Other|Not applicable / dataset analysis|Not applicable / dataset analysis
75590465|NCT05663515|Drug|Exenatide|All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.
75590466|NCT05663515|Drug|Non-GLP-1 RA based glucose lowering drugs|Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
75590467|NCT05659394|Other|Standard Wound Care Alone|gold standard compression therapy
75440175|NCT01618643|Procedure|Acetic acid chromoendoscopy|"Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray."
75440176|NCT01618760|Drug|Risperidone Tablet 1 mg|1 mg tablet once a day
75590468|NCT05659394|Device|Stand Wound Care plus IPC|gold standard compression therapy plus IPC (WoundExpress)
75590469|NCT05654805|Dietary Supplement|Drinking powder supplement|Drinking powder supplement, to be taken twice daily over 12 weeks
75590470|NCT05654623|Drug|ARV-471|orally, once daily on a 28-day continuous dosing schedule
75590471|NCT05654623|Drug|Fulvestrant|intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
75590472|NCT05654363|Procedure|Administration of morphine by intrathecal route|Lumbar puncture was performed before the induction of general anesthesia, in the operating room. Spinal anesthesia was performed in sitting position using a midline approach into the L3-L4 or L4-L5 interspaces with a 25ga pencil-point spinal needle administering 75-100 mcg morphine, with or without local anesthetic (levobupivacaine 0,5% 10-15 mg or bupivacaine 0,5% 10-15 mg or ropivacaine 0,5% 10-15 mg), depending on the anesthesiologist's preference. General anesthesia was then conducted according to clinical practice. All patients were transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery. Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
75590473|NCT05654363|Procedure|Administration of morphine by intravenous route|General anesthesia was conducted according to clinical practice and a morphine bolus was administered before emergence from anesthesia according to clinical needs. All patients were then transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery and received Patient-Controlled Analgesia (PCA) with morphine 1mg/mL (CADD®-Solis 2110 Infusion System, Smiths Medical ASD, Inc., USA, 1 mL bolus on demand, no background infusion, 7 minute lockout, max 8 mg/h). Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
75590474|NCT05653401|Drug|Magnesium sulfate and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
75590475|NCT05653401|Drug|Lidocain and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
75440177|NCT01618760|Drug|Risperidone|1 mg tablet once a day
75440178|NCT01618773|Drug|0.1% adapalene / 2.5% benzoyl peroxide|topical application
75440179|NCT01618799|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
75440180|NCT01618799|Drug|Lamotrigine|2 x 25 mg tablet once a day
75440181|NCT01618812|Procedure|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
75440182|NCT01618825|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
75440183|NCT01618825|Drug|Lamotrigine|2 x 25 mg tablet once a day
75440184|NCT01618877|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
75440185|NCT01618877|Other|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
75440186|NCT01618890|Procedure|Hepatic venous pressure gradient measurement|"Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.~In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.~In hemodynamic responders (HVPG second measurement< 12 mmHg or >20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up."
75733704|NCT05629910|Device|O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
76054920|NCT02189759|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
76054921|NCT01490866|Drug|Axitinib|5-mg tablets PO BID
76054922|NCT01490866|Drug|Bevacizumab|5 mg/kg Days 1 and 15; IV
76054923|NCT01490866|Drug|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
76054924|NCT01490866|Drug|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
76054925|NCT01490866|Drug|Leucovorin|400 mg/m2 Days 1 and 15; IV
76054926|NCT01490866|Drug|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
76054927|NCT02215967|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
76054928|NCT02215967|Drug|Fludarabine|30 mg/m^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
75440187|NCT01618903|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
75440188|NCT01618903|Drug|Levetiracetam|Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
75440189|NCT01618929|Drug|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
75440190|NCT01618981|Procedure|pace make active/inactive cross over|
76054929|NCT02215967|Biological|Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells|0.3x10^6- 15.0x10^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
76054930|NCT02168387|Device|continuous high frequency oscillator (CHFO)|
76054931|NCT02168387|Drug|Acetylcysteine|
76054932|NCT02168387|Drug|dornase alfa|
76054933|NCT04418219|Drug|Cyclophosphamide|alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
75440191|NCT01618994|Procedure|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
75440192|NCT01619007|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
75440193|NCT01619007|Drug|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
75440194|NCT01619020|Dietary Supplement|Flaxseed Lignans|We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
75440195|NCT01619033|Drug|BF2.649|single dose 20 mg
75733705|NCT05629026|Procedure|Micro-biopsies|Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
75733706|NCT05628116|Drug|XC243 50 mg single|The volunteers will receive a single dose of the ID (1 tablet once, 50 mg)
76054934|NCT04418219|Biological|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
76054935|NCT04418219|Biological|Pembrolizumab|1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
76054936|NCT04418219|Biological|Recombinant Interferon Alpha 2b-like Protein|Novaferon, Recombinant IFN Alfa-2b-like Protein
76054937|NCT04418219|Other|Questionnaire Administration|Ancillary studies
76054938|NCT04418219|Other|Quality of Life Assessment|Ancillary studies
76054939|NCT02188589|Device|INEX nasal implant|Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
76054940|NCT02167451|Drug|Maraviroc|
76054941|NCT02167139|Drug|Humira (adalimumab)|
76054942|NCT02167139|Drug|SB5 (proposed biosimilar to adalimumab)|
76054943|NCT02116621|Behavioral|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
76054944|NCT02116621|Device|smartphone|
76054945|NCT02116309|Drug|Rectal Indomethacin|
75590476|NCT05653401|Drug|Placebo and diclofenac|Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
75590477|NCT05648162|Device|Electrical acupuncture|Electrical acupuncture (2Hz, 150 μs) once daily
76054946|NCT02116309|Drug|Epinephrine|
75590478|NCT05648162|Device|Acupuncture|Electrical acupuncture (no electricity) once daily
75590479|NCT05648162|Device|tDCS|tDCS (1mA) once daily
75590480|NCT05648162|Device|sham tDCS|tDCS (no electricity) once daily
75590481|NCT05645276|Drug|AK129 IV infusion|AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
75590482|NCT05636020|Behavioral|ICARE Treatment|The treatment is 12 teletherapy sessions lasting approximately 60-90 minutes. Of the 12 treatment sessions, 7 of them will focus on training skills to help the participant with TBI better recognize emotions from facial expressions. The remaining 5 sessions will teach skills important for empathizing with others' thoughts and feelings, and how to be emotionally supportive. Role-playing will be a big part of these last 5 sessions. The care-partner will be expected to attend as many of these 5 empathy sessions with the participant with TBI as possible.
75590483|NCT05634538|Device|Robotic-assisted PCI with Corpath GRX® System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).
75590484|NCT05634538|Procedure|Standard PCI|Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.
75590485|NCT05630404|Drug|Surgical ESPB|"In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
75590486|NCT05630404|Drug|US guided ESPB|"US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
76054947|NCT02115607|Drug|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
76054948|NCT01490632|Drug|Placebo|Administered orally
75440196|NCT01619046|Biological|GreenGene™ F and an approved recombinant Factor VIII product|one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate < 10 mL/min
75440197|NCT01619046|Biological|GreenGene™ F|intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
75440198|NCT01619046|Biological|GreenGene™ F|"intra-venous infusion,~On-demand safety and efficacy substudy:~minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg"
76054949|NCT01490632|Drug|Baricitinib|Administered orally
76054950|NCT04726111|Other|Specimens specific for the study|Specimens (blood, umbilical cord, umbilical cord blood, placenta)
76054951|NCT01451554|Behavioral|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
75440199|NCT01619046|Biological|GreenGene™ F|"intra venous infusion,~Surgical substudy:~Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.~Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level."
75590487|NCT05624996|Drug|Carboplatin|Given IV
75590488|NCT05624996|Drug|Cisplatin|Given IV
75590489|NCT05624996|Procedure|Computed Tomography|Undergo CT and/or PET/CT
75590490|NCT05624996|Biological|Durvalumab|Given IV
76054952|NCT01451554|Behavioral|Usual Care|self-help booklets
75440200|NCT01619072|Other|Misoprostol + referral|800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
75440201|NCT01619072|Other|Placebo + referral|Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
75590491|NCT05624996|Drug|Etoposide|Given IV
75590492|NCT05624996|Radiation|Image Guided Radiation Therapy|Undergo IGRT
75590493|NCT05624996|Drug|Paclitaxel|Given IV
75590494|NCT05624996|Drug|Pemetrexed|Given IV
75733707|NCT05628116|Drug|XC243 100 mg single|The volunteers will receive a single dose of the ID (2 tablets once, 100 mg)
75733708|NCT05628116|Drug|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 tablets once)
75733709|NCT05628116|Drug|XC243 200 mg single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets, 200 mg)
75440202|NCT01617291|Other|Induced therapeutic hypothermia|induced therapeutic hypothermia
75440203|NCT01619098|Other|Patient Navigator|In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
75440204|NCT01619098|Other|Usual care|Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
75440205|NCT01619137|Drug|water and soap|water and soap for 6-8 hours per day.
75440206|NCT01619137|Drug|Povidone-iodine And normal salin treatment|use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
75590495|NCT05624996|Procedure|Positron Emission Tomography|Undergo PET/CT
75590496|NCT05624996|Other|Quality-of-Life Assessment|Ancillary studies
75590497|NCT05624996|Other|Questionnaire Administration|Ancillary studies
75590498|NCT05624996|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75590499|NCT05621161|Drug|Postoperative analgesia management|Intravenous paracetamol 1 gr and a dose of 0,5 mg/kg-1 tramadol intravenously will be performed on all patients 30 min before the end of the surgery for postoperative analgesia. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol including 10 mg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine IV will be administered.
75590500|NCT05620849|Behavioral|Online program|The online program is 4 weeks and focused on topics such as alcohol and sexual health
75590501|NCT05619653|Drug|Prednisolone|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
75590502|NCT05619653|Drug|Losartan|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
75590503|NCT05615701|Diagnostic Test|EOSedge imaging|Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery
75733710|NCT05628116|Drug|Placebo single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets)
75733711|NCT05628116|Drug|XC243 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily, 200 mg each)
75733712|NCT05628116|Drug|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily)
75733713|NCT05619354|Other|Survey study|Participants will be asked to complete and evaluate the Dutch version of the Headache Disability Index. Validity (face validity, content validity, convergent validity with the RAND-36 and HIT-6) will be determined. Second, internal consistency and test-retest reliability will be evaluated.
75733714|NCT05619211|Behavioral|Sprint-Intensity Interval Training with Telecoaching|Maximal intensity exercises that use the arms.
75733715|NCT05615974|Drug|LM101|Administered intravenously
75733716|NCT05615974|Drug|Toripalimab|Administered intravenously
75733717|NCT05615974|Drug|Rituximab|Administered intravenously
75883469|NCT05020769|Drug|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).
75733718|NCT05615974|Drug|Envafolimab|Administered intravenously
75590504|NCT05614882|Behavioral|Written Stroke Education|The written education will be provided in the stroke folder currently in use by the Yale New Haven Health system. This written information is presented in a stroke folder and includes how to respond to the signs of stroke, dialing 9-1-1, following up with a health care provider after hospitalization due to a stroke and the importance of medication management as well as stroke risk factors, healthy eating habits, exercise habits, common changes following a stroke, stroke recurrence and stroke types. After being given two days to review the materials, patients will be asked to complete the stroke knowledge test (SKT). All participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
75733719|NCT05615818|Drug|Futibatinib|Dose 20 mg once a day (QD)
75733720|NCT05615818|Drug|Ivosidenib|Dose 500 mg QD
75883470|NCT05020769|Drug|Osimertinib|Osimertinib is administered at the recommended dose of 80mg daily.
75883471|NCT05008614|Procedure|Erector spinae plane block group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)"
75883472|NCT05008614|Procedure|Thoracic epidural analgesia group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)"
75883473|NCT05002738|Drug|Desogestrel and Ethinyl Estradiol Tablets|Combined oral contraceptive pill
76054953|NCT01474486|Drug|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
76054954|NCT04075552|Behavioral|Pre Meal Presentation|Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
75440207|NCT01619150|Drug|Etoricoxib, followed by placebo (matching tablet, without active ingredient)|Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
75733721|NCT05615818|Drug|Zanidatamab|Dose: Patients < 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
75883474|NCT04993443|Drug|LQ036|"For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D."
75883475|NCT04993443|Other|Matching Placebo|Matching Placebo for LQ036: Matching Placebo
75883476|NCT04990284|Drug|Opicapone|50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).
75440208|NCT01619150|Drug|Placebo (matching tablet, without active ingredient), followed by etoricoxib|Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
75440209|NCT01619163|Drug|Placebo|
75440210|NCT01619163|Drug|Prednisolone|low dose, 7.5 mg/day
75440211|NCT01619189|Biological|epithelial stem cells cultured|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
75733722|NCT05615818|Drug|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
75733723|NCT05615818|Drug|Neratinib|Dose: 240 mg QD (combination with trastuzumab)
75733724|NCT05615818|Drug|Encorafenib|Dose: 450 mg QD (Combination with binimetinib)
75733725|NCT05615818|Drug|Binimetinib|Dose: 45 mg twice a day (BID) (Combination with encorafenib)
75733726|NCT05615818|Drug|Niraparib|Dose: 200 mg QD or 300 mg QD
75733727|NCT05615818|Drug|Cisplatin|Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
75733728|NCT05615818|Drug|Gemcitabine|Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
75733729|NCT05612880|Drug|androgen receptor signaling inhibitors|Prior to or within 8 weeks of ARSI initiation, men with advanced prostate cancer will perform baseline testing, with follow ups at 12 and 24 weeks
75733730|NCT05609682|Drug|Gabapentin|Scheduled gabapentin given for two weeks after surgery
75733731|NCT05609682|Drug|Placebo|Placebo given for two weeks after surgery
75883477|NCT04990284|Drug|L-DOPA/DDCI|L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
75440212|NCT01619189|Procedure|transplantation of cultured cells|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
76054955|NCT04075552|Behavioral|Pre Meal Presentation + Modeling|"Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model."
76054956|NCT04075552|Behavioral|Pre Meal Presentation + Token Economy|Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
75590505|NCT05614882|Behavioral|Verbal Stroke Education|Participants in the verbal education group will be provided with education over two days from therapists including occupational therapy, physical therapy, speech therapy as well as a physician or nurse. The disciplines will present general stroke information including causes, risk factors, prevention, nutrition and exercise recommendations, importance of managing chronic conditions and the significance of medication compliance. After the verbal education topics are presented, the participants will be tested with the stroke knowledge test (SKT) to measure learning. All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
75733732|NCT05600322|Drug|Hexaminolevulinate Hydrochloride|Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
75733733|NCT05600322|Device|Richard Wolf Photodynamic Diagnostic Equipment (PDD) system|Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
75733734|NCT05600062|Drug|Racecadotril 100 milligram (MG) Oral Capsule|Licensed NEP inhibitor
75733735|NCT05600062|Drug|Placebo|Placebo capsule
75733736|NCT05599932|Drug|Siremadlin|HDM201 capsule
76054957|NCT01451398|Drug|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
76054958|NCT01451398|Drug|Technosphere Powder|Placebo Comparator
75733737|NCT05597657|Other|Fluid administration (Fresenius Kabi Sodium Chloride 0.9%)|All participants in substudy 2 will be administered 2 liters of isotonic saline infusion (Fresenius Kabi Sodium Chloride 0.9%) intravenously. CMR and echocardiography will be performed before and after infusion.
75733738|NCT05597475|Diagnostic Test|GLP-1R PET|Beta cell function (tests) and measure for beta cell mass (PET)
75440213|NCT01619202|Behavioral|Risk Anticipation -Perception Training|Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
75733739|NCT05596630|Radiation|Stereotactic body radiation therapy|Stereotactic body radiotherapy for small intrahepatic recurrent HCC. Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
75733740|NCT05596318|Device|Digital CBT-I|The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.
75440214|NCT01619241|Other|PET/CT|F-18 FLT PET/CT
75440215|NCT01619254|Behavioral|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
75590506|NCT05611073|Diagnostic Test|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
75590507|NCT05611073|Diagnostic Test|Biometric Data Collection|Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
75590508|NCT05611073|Other|Patient Questionnaire|Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
75590509|NCT05610657|Drug|Mitapivat|Mitapivat tablets
75733741|NCT05596318|Device|Digital SHE|The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
75733742|NCT05594069|Other|triple pre-rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
75883478|NCT04979247|Drug|Oliceridine|Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.
75883479|NCT04973631|Genetic|Sex, Age|Evaluate the effect of sex and age on the incidence and survival of GC.
76054959|NCT02073565|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
75883480|NCT04969835|Drug|AVA6000|AVA6000 is a FAP-activated prodrug of doxorubicin. AVA6000 will be administered via IV infusion every 3 weeks. Dosing will occur based on the calculated patient's BSA on the day of dosing.
75590510|NCT05607537|Drug|E7386 Tablet|E7386 40 mg tablet.
75590511|NCT05607537|Drug|(14C)E7386 Capsule|(14C)E7386 40 mg capsule.
75590512|NCT05607537|Drug|(14C)E7386|(14C)E7386 administered intravenously.
75883481|NCT04965350|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)|sterile solution for intramuscular injection
75883482|NCT04955158|Drug|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
75883483|NCT04955158|Drug|Ketamine|50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
75883484|NCT04955158|Other|saline 0.9%|20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
75590513|NCT05602506|Drug|Biktarvy 50 mg/200 mg/25 mg film-coated tablets|The duration of the study treatment will be 48 weeks.
75590514|NCT05600114|Drug|Cannabidiol oral solution|CBD 150 mg BID
75590515|NCT05600114|Drug|Cannabidiol oral solution|CBD 300 mg BID
75590516|NCT05600114|Drug|Placebo|Placebo BID
75590517|NCT05599841|Procedure|PI solution|3,000 cc of <2% concentrated povidone iodine solution will be used as irrigation solution at primary hip/knee arthroplasty. The PI solution was left in the joint for 3 minutes.
75883485|NCT04952077|Device|MRI|Magnetic Resonance Imaging (MRI)
76054960|NCT02073565|Device|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
75590518|NCT05599841|Procedure|Saline Solution|3,000 cc of 0.9% saline solution will be used as irrigation solution at primary hip/knee arthroplasty. The saline solution was left in the joint for 3
75590519|NCT05599139|Behavioral|Low iodine diet|Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake < 50 mcg per day and thereby depleting the overall iodine store in the body.
75590520|NCT05595434|Procedure|Acute Maastricht Stress Test (MAST), active condition.|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the active condition, participants have to switch between immersion of the hand into cold water and complex mental arithmetic operations.
75590521|NCT05595434|Procedure|Acute Maastricht Stress Test (MAST), placebo condition|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the placebo condition, participants have to switch between immersion of the hand into tempered water and simple mental arithmetic counts.
75590522|NCT05593276|Behavioral|Empower@Home|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
75590523|NCT05589220|Other|Music Intervention|Music therapy carried out with MUSIC CARE©
75590524|NCT05589220|Drug|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
75733743|NCT05594069|Other|triple rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
75733744|NCT05593055|Drug|Eplerenone|After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
75733745|NCT05593055|Drug|Chlorthalidone|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
75883486|NCT04938973|Procedure|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
75883487|NCT04938973|Procedure|Open Transthoracic Esophagectomy (OTE)|Open Transthoracic Esophagectomy (OTE) is the current standard of care.
75590525|NCT05588960|Device|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch."
75883488|NCT04938973|Device|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
75733746|NCT05593055|Drug|Potassium|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
75883489|NCT04936958|Other|patients having had an osteomyelitis since 2017|description of osteomyelitis and their management
75883490|NCT04935554|Other|Person centred care|physical activity, nutrition, motivation, health competence, psychosocial.
75883491|NCT04931160|Other|Blood, fluid, sells and urine samples|Blood, fluid, sells and urine samples will be collected.
75590526|NCT05588960|Device|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age."
75590527|NCT05581186|Other|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 25 Hz frequency, 30 Gauss, %35 intensity and for 25 minutes. The treatment period was 5 days a week for 3 weeks, in total. It was applied as 15 sessions.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
75733747|NCT05592054|Procedure|Balloon guide catheters (BGCs)|MT procedure with Balloon guide catheters (BGCs)
75733748|NCT05592054|Procedure|Standard guide catheter|MT procedure with standard guide catheter
75733749|NCT05589688|Drug|Acyclovir|Subjects will receive a single dose of 5 mg/kg infused over 1 hour. Then, 13 blood samples after placement of a catheter, and 4 urine samples will be taken over the 12 hours following the start of administration
75733750|NCT05584735|Biological|Influenza vaccine|Observe effects of flu vaccine on microbiome
75733751|NCT05584735|Biological|COVID-19 vaccine|Observe effects of COVID-19 vaccine on microbiome
75733752|NCT05584514|Other|Sentence Stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
75733753|NCT05584514|Other|Auditory Noise|The sentences will be presented either A) in quiet, or B) with speech- shaped stationary background noise presented 3dB below the speech.
75883492|NCT04930289|Device|LungGuard|The LUNGguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs. The intended organ storage time for the LUNGguard is up to 8 hours.
75883493|NCT04928391|Drug|Dexmedetomidine|A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
75883494|NCT04928391|Drug|Nalbuphine|A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery
75883495|NCT04928391|Other|0.9% saline|Same volume of saline placebo IV at the end of surgery
75883496|NCT04928352|Drug|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
75883497|NCT04928352|Drug|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
75883498|NCT04928352|Other|0.9% saline|Preoperative nebulized same volume of saline placebo
75883499|NCT04928300|Drug|Dexmedetomidine|low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.
75883500|NCT04928300|Drug|Ketamine|low dose ketamine infusion 2.5 µ/kg/min for 5 days.
75590528|NCT05581186|Other|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 15 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
75440216|NCT01619280|Drug|Sodium Nitroprusside|Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
75440217|NCT01619345|Drug|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
75440218|NCT01619371|Device|Simplisse Double Electric Breast Pump|Use of breast pump for 10 minutes.
75440219|NCT01619384|Behavioral|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
75440220|NCT01619397|Device|Test condom with new Xanthan gum condom coating|
75440221|NCT01619436|Drug|Clonidine|bolus, clonidine 2 mg/kg IV
75440222|NCT01619436|Drug|Ringer lactato|1 ML ringer lactato IV, as placebo
75590529|NCT05581186|Other|Therapeutic Exercise|Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
75590530|NCT05580679|Other|Abdominal massage|"Application time of the massage: 30 minutes after meals, twice a day, at 10:00 in the morning and at 16:00 in the evening.~Application time of the massage: 15 minutes each Materials needed: Gloves, Liquid Vaseline, Paper Towel Massage methods used: Efflorage, Petrissage, Vibration"
75440223|NCT01619449|Procedure|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
75440224|NCT01619462|Biological|Prevenar 13 and Synflorix|260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
75883501|NCT04928300|Other|0.9% saline|the same dose and duration of normal saline will be given for 5 days.
75883502|NCT04924140|Drug|Aducanumab|Administered as specified in the treatment arm
75883503|NCT04920864|Device|rTMS|Repetitive transcranial magnetic stimulation
75440225|NCT01619527|Drug|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
75440226|NCT01619527|Drug|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
75440227|NCT01619540|Other|Valsalva maneuver|
75883504|NCT04913948|Other|No intervention|No intervention
75590531|NCT05579704|Behavioral|My Viva Plan (www.myvivaplan.com)|A web-based platform is based on preventive self-care and contains tools to monitor nutrition, physical activity, and mental wellbeing.
75590532|NCT05579704|Behavioral|Online support group with health professionals|Participants will take part in weekly group video conferencing sessions with various health professionals (registered dietitian, psychologist, and exercise specialist). The sessions will occur once per week for 1 hour each. The group sessions will contain cohorts of approximately 10 individuals.
75590533|NCT05573464|Drug|BGF MDI HFO 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
75590534|NCT05573464|Drug|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
75590535|NCT05569811|Drug|Patritumab deruxtecan|HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
75590536|NCT05569811|Drug|Chemotherapy|Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
75440228|NCT01619566|Drug|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
75440229|NCT01619592|Device|webbased education (telemonitoring)|"Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon."
75440230|NCT01619605|Procedure|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
75440231|NCT01619618|Genetic|mutation analysis|
75590537|NCT05569811|Drug|Letrozole|Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
75590538|NCT05566899|Procedure|esophagogastroduodenoscopy (EGD)|"After colonoscopy, the patient will undergo the EGD at which time biopsy specimens will be obtained.~Participants will also be provided with a home stool collection kit which they can bring to the endoscopy visit or mail back. Satisfaction questions will be administered 3-7 days after EGD-SC"
75440232|NCT01619618|Genetic|polymerase chain reaction|
75440233|NCT01619618|Genetic|polymorphism analysis|
75440234|NCT01619618|Other|laboratory biomarker analysis|
75440235|NCT01619631|Behavioral|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
75590539|NCT05560789|Behavioral|Physical activity (cycling on a stationary bicycle ergometer or walking on a treadmill)|At time 0, exercise will be initiated and intensity will be increased at 2 minute intervals to achieve low intensity for 30 minutes (as defined by heart rate target 50-55% of maximum heart rate determined as 220-age). Next, intensity will be increased at 2 minute intervals until the heart rate target for moderate intensity exercise is achieved (55-65% of max heart rate), or the total duration of exercise of up to 60 minutes is achieved.
75590540|NCT05556876|Dietary Supplement|Protein omega-3|An oral supplement with a high content of protein and with essential fatty acids
75590541|NCT05546528|Device|Photobiomodulation|G1 will receive the photobiomodulation application with the Laser Therapy XT device, (DMC, São Paulo, Brazil). The laser will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
75883505|NCT04910464|Drug|Tranexamic acid|administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.
75590542|NCT05546528|Device|Photobiomodulation- Sham|G2 will receive the photobiomodulation application with the Laser Therapy XT device off. The laser off will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
75590543|NCT05539326|Other|Performance Clinical Outcome Test|Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
75590544|NCT05538962|Diagnostic Test|Sensor skin|Skin sensor to detect inflammatory molecules in sweat
75590545|NCT05538806|Device|TTFields|all patients will receive routine clinical care and TTFields
75590546|NCT05525546|Biological|Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation|One dose of the full-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The full-strength conjugate vaccine consists of 25 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
75590547|NCT05525546|Biological|Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation|One dose of the half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The half-strength conjugate vaccine consists of 12.5 mcg of Salmonella Enteritidis, 12.5 mg of Salmonella Typhimurium, and 25 mcg of Salmonella Typhi Vi.
75733754|NCT05582512|Other|sequelae tracking|"An integrated outpatient clinic for Long COVID-19 Syndrome in Children will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection"
75883506|NCT04910464|Other|0.9% saline|administer the same volume (100ml normal saline) and same duration (first three days).
75883507|NCT04905901|Drug|Tranexamic acid|Tranexamic acid nebulization 15 minutes before sinus surgery
75883508|NCT04905901|Other|Saline placebo|Normal saline placebo nebulization 15 minutes before sinus surgery
75440236|NCT01619631|Behavioral|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
75440237|NCT01619644|Drug|sodium valproate|sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
75440238|NCT01619644|Drug|Placebo|Placebo with an oral dosage of 30 mg/kg/jour
75440239|NCT01619657|Drug|6% Hypertonic Saline (HS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
75440240|NCT01619657|Drug|0.9% Isotonic Saline (IS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
75440241|NCT01619670|Device|Apligraf|non adhesive layer
75590548|NCT05525546|Biological|Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation|One dose of the dilutional half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The dilutional half-strength conjugate vaccine consists of 12.5 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
75590549|NCT05525546|Other|Placebo|One dose of placebo is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The placebo consists of sterile phosphate-buffered saline (PBS) solution containing polysorbate 80, and 2-phenoxyethanol preservative.
75590550|NCT05525247|Drug|SLC-3010|Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
75733755|NCT05578326|Drug|Trilaciclib|240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
75733756|NCT05578326|Drug|Lurbinectedin|3.2 mg/m2, over 60 minutes at day 1 of each cycle
75883509|NCT04901988|Drug|Nivolumab 10 MG/ML|Eligible patients randomised to Arm B will receive 480 mg nivolumab monotherapy 4 weekly via IV infusion for up to 2 years.
75883510|NCT04901546|Other|Patient's own saliva|Infants with esophageal atresia will be given their own saliva
75883511|NCT04900974|Drug|Doravirine|100mg
75590551|NCT05525247|Combination Product|Gemcitabine|1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle
75590552|NCT05521321|Behavioral|Stanford Cannabis Awareness and Prevention curriculum|Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session course administered in a school classroom setting.
75590553|NCT05520814|Drug|PD-1 inhibitors|treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg * q21d (until the disease progresses, intolerable toxicity or the investigator / subject decides to withdraw from the study, and the duration of PD-1 inhibitor is not more than 96 weeks)
76054961|NCT02072941|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
76054962|NCT02100631|Biological|PXVX0200|
75440242|NCT01619683|Drug|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
75440243|NCT01619683|Drug|Placebo|1 placebo capsule per day, oral
75440244|NCT01619696|Procedure|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
75440245|NCT01619709|Other|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
75440246|NCT01619761|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic umbilical cord blood transplant
75440247|NCT01619761|Drug|Cyclophosphamide|Given IV
75440248|NCT01619761|Drug|Fludarabine Phosphate|Given IV
75440249|NCT01619761|Other|Laboratory Biomarker Analysis|Correlative studies
75440250|NCT01619761|Drug|Lenalidomide|Given PO
75590554|NCT05520814|Radiation|chemoradiotherapy|"Chemotherapy：~GP: gemcitabine 1g/m2 D1, 8 Cisplatin 80 mg/m2 d1~* Treatment courses every 3 weeks~Cisplatin 80mg/m2 d1 or carboplatin area under the curve 5mg/ml/min * Treatment courses every 3 weeks~Radiotherapy： All the metastatic lesions received radiation dose from 30 to 60Gy according to different metastatic sites."
75590555|NCT05518045|Drug|LM-108|Administered intravenously
75590556|NCT05518045|Drug|Toripalimab|Administered intravenously
75590559|NCT05516329|Drug|A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide|The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60~120 min after the injection.
76054963|NCT02100631|Biological|Placebo|
75440251|NCT01619761|Drug|Melphalan|Given IV
75440252|NCT01619761|Drug|Mycophenolate Mofetil|Given IV or PO
75440253|NCT01619761|Biological|Natural Killer Cell Therapy|Given IV
75440254|NCT01619761|Biological|Rituximab|Given IV
75440255|NCT01619761|Drug|Tacrolimus|Given IV or PO
75440256|NCT01619761|Radiation|Total-Body Irradiation|Undergo TBI
76054964|NCT01451164|Drug|OPC-34712|orally administered once daily
75440257|NCT01619761|Procedure|Umbilical Cord Blood Transplantation|Undergo allogeneic umbilical cord blood transplant
75440258|NCT01619891|Dietary Supplement|Vitamin D|100mcg per day
75440259|NCT01619904|Procedure|Goal-Directed Therapy|Peri-operative optimisation of fluid status, based on Oxygen Delivery
75440260|NCT01619904|Procedure|Standard Therapy|Following standard protocol during peri-operative period
75590560|NCT05515796|Drug|Terelizumab (aka Tislelizumab)|q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
75590561|NCT05515796|Drug|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
75590562|NCT05515796|Drug|Trastuzumab|q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
76054965|NCT01451164|Drug|OPC-34712|orally administered once daily
76054966|NCT01451164|Drug|OPC-34712|orally administered once daily
76054967|NCT01451164|Drug|Placebo|orally administered once daily
76054968|NCT02071849|Device|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
76054969|NCT02071771|Device|Nelfilcon A toric contact lenses|
76054970|NCT02071771|Device|Etafilcon A toric contact lenses|
75440261|NCT01619930|Behavioral|Physical activity without motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback.
75440262|NCT01619930|Behavioral|Physical exercise with motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback. An initial motivational interview (MI) per telephone is also conducted, to explore the intrinsic motivation to change in participants.
75440263|NCT01619930|Behavioral|Behavioral activation with rationale|A behavioral activation program, based on the TRAP-TRAC model according to which suffering individuals are trapped in a vicious circle of avoidance and ever fewer reinforcers, leading to increasing discomfort. To break free of this vicious circle, patients have to replace avoidance patterns with alternative coping strategies. Unlike previous applications of this program done in the U.S., this study will feature an internet-based administration. Approximately 15 minutes of electronic therapist support will be included per week.
75590563|NCT05515796|Radiation|Radiotherapy|25 Gy/5 fractions
75590564|NCT05515783|Drug|68Ga-FAP-RGD|The dose will be 4-7mCi given intravenously.
75590565|NCT05515783|Drug|68Ga-FAP-RGD|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
75590566|NCT05514366|Procedure|Modifying EIP under a tOLA before pneumoperitoneum|"Phase 1:~Moment (M) 1) Standard PPV and an initial EIP of 10%~M 2) ARM with titration of optimal PEEP (PEEPop) on a decremental PEEP trial, followed by a new ARM and setting a tailored open-lung PEEP (tOL-PEEP), that 2 cm H2O higher than PEEPop~M 3) Incremental modification of the EIP in steps of 10% (from 10 to 40%)"
76054971|NCT02071225|Drug|bendamustine|70 milligrams per square meter (mg/m^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
75440264|NCT01619930|Behavioral|Behavioral activation without rationale|"A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week."
75590567|NCT05514366|Procedure|Modifying EIP under a tOLA with pneumoperitoneum|"Phase 2:~M 4) The investigators will apply the EIP that guarantees the lowest Pdriv~M 5) After applying pneumoperitoneum and trendelenburg~M 6) Atelectasis test (see below)~M 7) M 7a) In case of atelectasis test = negative: the investigators will modify the EIP in incremental or decremental steps of 10% M 7b) In case of atelectasis test=positive: ARM~M 8) In those cases recruited (M 7b), modify the EIP (as in M 7a)~Once the EIP that guarantees the best ventilation conditions has been stablished based on the lowest Pdriv (and higher Crs), the investigators will maintain these conditions until the end of surgery, with periodic evaluation of the pulmonary collapse by means of the atelectasis test (see below) performed every 40 minutes or regardless of time if an oxygen saturation by pulse oximetry (SpO2) < 97% is detected."
75440265|NCT01619943|Other|no intervention|clinical follow up
75590568|NCT05514366|Procedure|Atelectasis test|It is performed during mechanical ventilation, due to suspicion of alveolar collapse. Alveolar collapse will be suspected on observation of a reduction in Crs > 10% over post-recruitment values. In these cases the atelectasis test will be performed, consisting of a reduction in FiO2 to 0.21, maintaining this FiO2 for 5 minutes. If lung collapse is >10%, a fall in SpO2 below 97% will be expected (positive atelectasis test), in which case, an ARM and a PEEPop titration test will be performed.
76054972|NCT02071225|Drug|obinutuzumab|1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
76054973|NCT01450696|Drug|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
75440266|NCT01619943|Other|no intervention|no intervention
76054974|NCT01450696|Drug|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
75440267|NCT01619956|Device|SLA dental implants|Dental implant with surface modification.
75590569|NCT05513846|Device|DREEM EEG Device|The DREEM EEG device will be used to measure brain age.
76054975|NCT01450696|Drug|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
76054976|NCT02070991|Drug|Macitentan|oral tablet, 10 mg once daily
76054977|NCT02070991|Drug|Placebo|matching placebo
76054978|NCT02114515|Behavioral|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
76054979|NCT02114515|Behavioral|Navigator intervention|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
76054980|NCT02114515|Behavioral|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
76054981|NCT01490086|Drug|RP5063|daily
76054982|NCT01490086|Drug|placebo|daily
76054983|NCT01490086|Drug|RP5063|daily
76054984|NCT01490086|Drug|RP5063|daily
76054985|NCT01490086|Drug|aripiprazole|daily
76054986|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
76054987|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
76054988|NCT02114203|Drug|placebo for PDE9i|oral dose, every 12 hours for 28 days
76054989|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
76054990|NCT02113579|Device|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
75590570|NCT05513846|Device|SleepImage Ring|The SleepImage ring uses plethysmography to analyze sleep architecture and cardiopulmonary coupling.
75733757|NCT05574868|Device|Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis|Treatment: Erectile dysfunction
75733758|NCT05566366|Other|Qualitative research interview|Qualitative research interview Administration of quantitative scales
75733759|NCT05565729|Drug|LY3471851|Administered SC.
76054991|NCT02113579|Other|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
76054992|NCT01474018|Drug|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
76054993|NCT02100475|Drug|insulin degludec/liraglutide|"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted."
76054994|NCT02100475|Drug|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
76054995|NCT04741087|Drug|AMT-101 (oral)-Dose A|AMT-101 is an orally administered biologic therapeutic, taken once daily.
75440268|NCT01619956|Procedure|Osteotome sinus floor elevation|"After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre."
76054996|NCT04741087|Drug|AMT-101 (oral)-Dose B|AMT-101 is an orally administered biologic therapeutic, taken once daily.
76054997|NCT02113189|Other|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
76054998|NCT02113189|Other|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
76054999|NCT02113189|Other|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
75590571|NCT05513209|Procedure|opioid based multimodal anesthesia|elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
75590572|NCT05513209|Procedure|pterygopalatine ganglion block based multimodal anesthesia)|elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
75733760|NCT05565729|Drug|Placebo|Administered SC.
75733761|NCT05565729|Drug|Levocetirizine|Administered orally.
75733762|NCT05564416|Biological|Atezolizumab|Given IV
75733763|NCT05564416|Procedure|Biospecimen Collection|Undergo collection of blood
75733764|NCT05564416|Procedure|Biospecimen Collection|Correlative studies
75733765|NCT05564416|Procedure|Computed Tomography|Undergo CT
75733766|NCT05564416|Procedure|Cystoscopy|Undergo cystoscopy
75733767|NCT05564416|Drug|Erdafitinib|Given PO
75733768|NCT05564416|Procedure|Magnetic Resonance Imaging|Undergo MRI
76055000|NCT01440946|Drug|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
75733769|NCT05562960|Procedure|Plasmapheresis|Regular plasmapheresis to remove anti-NRIP autoantibody
75733770|NCT05561257|Drug|Vitamin C|Vitamin C
75883512|NCT04899687|Drug|Fluoxetine|Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
75883513|NCT04899687|Drug|Dextromethorphan|Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
75440269|NCT01619956|Procedure|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
76055001|NCT01440946|Drug|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
75440270|NCT01619969|Drug|celgosivir|100 mg capsules, 400 mg loading dose 200 mg bid
75590573|NCT05511610|Procedure|Sevoflurane uptake and supply|"Phase sevo 1)~Moment 1 (M1): from OTI until end-tidal sevoflurane (etSEVO%) exceeds ettSEVO% by 10%. Deliver of sevoflurane to the system (SEVOdel) carried out by completely opening sevoflurane vaporizer (8%).~M2) once etSEVO% surpass ettSEVO% by 10%: turn off sevoflurane vaporizer and observe the progressive fall etSEVO%. When etSEVO% approaches ettSEVO% (0.1-0.2 points above ettSEVO%), the investigators will turn on the sevoflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of sevoflurane.~Phase sevo 2) Objective: to maintain etSEVO% = ettSEVO% ±5% When the etSEVO% increases above the mentioned levels >> reduce SEVOdel by 0.25-0.5%.~When the etSEVO% decreases below the mentioned levels>> increase SEVOdel by 0.25-0.5%."
75590574|NCT05511610|Procedure|Washout phase|The investigators will close the sevoflurane vaporizer and will start the administration of Propofol in intravenous perfusion; the investigators will then open the FGF sequentially at 2>5>10 liters per minute (LPM), until the etSEVO% is <0.2 MAC.
75590575|NCT05511610|Procedure|Desflurane uptake and supply|"Phase desflu 1)~Moment 1 (M1): from the end of Washout phase until end-tidal desflurane (etDESFLU%) exceeds ettDESFLU% by 10%. Deliver of desflurane to the system (DESFLUdel) carried out by completely opening the desflurane vaporizer (18%).~M2) once etDESFLU% surpass ettDESFLU% by 20%: turn off the desflurane vaporizer and observe the progressive fall etDESFLU%. When etDESFLU% approaches ettDESFLU% (0.8-1.2 points above ettDESFLU%), the investigators will turn on the desflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of desflurane.~Phase desflu 2) Objective: to maintain etDESFLU% = ettDESFLU% ±5% When the etDESFLU% increases above the mentioned levels >> reduce DESFLUdel by 0.25-0.5%.~When the etDESFLU% decreases below the mentioned levels>> increase DESFLUdel by 0.25-0.5%."
75440271|NCT01619969|Drug|placebo|Capsules of identical appearance containing starch
75590576|NCT05511610|Procedure|Final phase|"From the end of Phase desflu 2 until the end of the intervention. Maintenance of anesthesia with desflurane following the principles of MAAS Method.~Between 15-20 minutes before the end of the intervention, the investigators will stop the administration of desflurane, registering the time until the reaching etDESFLU% < 0.2 MAC."
75590577|NCT05511584|Procedure|VO2 estimation|"st) VO2 (ml/min) will be estimated based on the formula: Inspired fraction of O2 (FiO2) - Expired fraction of O2 (FeO2) * minute volume (Volmin)~nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the VO2 corresponding to effective alveolar ventilation (VO2.alv), which will be the result of subtracting VDphys from Volmin.~rd) The investigators will calculate the O2 delivered fraction (DO2) (ml/min) corresponding to the estimated VO2.alv, and will supply it to the system while working in a closed-circuit mode."
76055002|NCT01450540|Device|REMstar Auto A-Flex|Standard CPAP
76055003|NCT01450540|Device|modified REMstar Auto A-Flex with AGPAP|Modified device -Software upgrade to GP 12
75440272|NCT01620008|Procedure|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
75440273|NCT01620034|Radiation|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
75440274|NCT01620073|Other|HIV counseling and testing|Male partner HIV counseling and testing
75440275|NCT01620099|Drug|Extrafine treatment (Clenilexx(R) or Foster(R))|Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
75440276|NCT01620112|Drug|high Clonidine concentration|Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
76055004|NCT04075240|Drug|Rivaroxaban 10 MG and acetylsalicylic acid 81 mg|Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
75440277|NCT01620112|Drug|low clonidine concentration|Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
75440278|NCT01620112|Drug|Lidocaine|Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
75883514|NCT04866823|Behavioral|Medically Tailored Meals|Participants will receive weekly meals (20 per week) prepared by a local community kitchen and catering group. Each week, 10 dinners and 10 lunches will be delivered to the participant's home with instructions for storage, re-heating, recipes, and nutritional information.
76055005|NCT04075240|Drug|acetylsalicylic acid 81 mg|Starting post op, aspirin for 9 days for TKA and 30 days for THA
76055006|NCT02070757|Drug|Ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
76055007|NCT02070757|Drug|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
75590578|NCT05511584|Procedure|SEVOup estimation|"st) SEVOup (ml/min) will be estimated based on the formula: Inspired fraction of sevoflurane (Fi.sevo) - Expired fraction of sevoflurane (Fe.sevo) * Volmin~nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the SEVOup corresponding to effective alveolar ventilation (SEVOup.alv), which will be the result of subtracting VDphys from Volmin.~rd) The investigators will calculate the sevoflurane delivered fraction (SEVOsuppl) (ml/min) corresponding to the estimated SEVOup.alv, and will supply it to the system while working in a closed-circuit mode."
75590579|NCT05510531|Behavioral|Diabetes Survival Skills Training|During the course of the DSS sessions, participants receive blood glucose logs, glucose meters; lancets, testing strips and demonstration insulin pens with injecting pillow will only be used in class. In summary, the DSS is focused on increasing knowledge, motivation, and self-efficacy and decreasing diabetes related distress, IMB components relevant to incarcerated persons and proximal to behavior change, through engagement, return demonstrations, skill practice, and positive reinforcement.
75590580|NCT05509894|Drug|Ngenla|As provided in real world practice
75590581|NCT05509569|Drug|Icatibant|Icatibant, 10 to 30 mg, Subcutaneous injection
75590582|NCT05506605|Drug|Doravirine 100Mg Tab|Switch from Etravirine to Doravirine
75440279|NCT01620112|Drug|Lidocaine 40 ml|Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
76055008|NCT04417933|Device|Tumor Electric Fields Treatment System|Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.
76055009|NCT04417855|Diagnostic Test|G-Walk|"Every individual will be examined with a non-invasive G-Walk device which is a sensor mounted on a belt and fasten on individuals' lumbar spine region during two test activities: Timed up and go and 6-meter walk tests. Data collection will include kinematic parameters. Oswestry Disability Index (ODI) score will also be collected."
76055010|NCT02100319|Drug|Azilsartan|Azilsartan tablets
75440280|NCT01620125|Dietary Supplement|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
76055011|NCT01625845|Drug|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
76055012|NCT01625845|Other|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
75590583|NCT05506566|Drug|68Ga-FAP-CHX|The dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging
75590584|NCT05506566|Drug|68Ga-FAP-CHX|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging； 68Ga-FAPI-04, the dose will be 1.8 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging； 18F-FDG, the dose will be 3.7 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging；
76055013|NCT01625845|Behavioral|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
76055014|NCT01473940|Biological|ipilimumab|Given IV
76055015|NCT01473940|Drug|gemcitabine hydrochloride|Given IV
75440281|NCT01620151|Procedure|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
75440282|NCT01620164|Other|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
75440283|NCT01620229|Drug|brentuximab vedotin|Given IV
75440284|NCT01620229|Other|laboratory biomarker analysis|Correlative studies
75883515|NCT04854785|Other|[18F]FEPPA PET scan|One [18F]FEPPA PET for TSPO VT, and one MRI scan
75883516|NCT04854785|Other|[11C]SL25.1188 PET scan|One [11C]SL25.1188 PET scan for MAO-B VT, and one MRI scan
75883517|NCT04852809|Other|No intervention|This is an observational study
76055016|NCT01473940|Other|laboratory biomarker analysis|Correlative studies
76055017|NCT04408846|Device|Lumbar fusion|Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
75440285|NCT01620229|Other|pharmacological study|Correlative studies
75440286|NCT01620242|Drug|Cabazitaxel|25 mg/m2 every 3 weeks by IV administration
75440287|NCT01620268|Drug|Leflunomide and orotic acid|Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
75440288|NCT01620281|Device|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
75883518|NCT04843124|Device|Remote HA adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
75883519|NCT04843124|Other|Traditional hearing aid|Traditional hearing aid
75883520|NCT04838574|Other|15 years Follow-up group|Phone recruitment, screening interview and eligibility questionnaire. Patient inclusion during rheumatologic evaluation : questionnaire, examination and data collection in one of the 4 study hospital centers.
75883521|NCT04829877|Behavioral|Web-based mind-body intervention with HRVB|The web-based mind-body intervention with HRVB contains the following components: 1) Breathing training with HRV biofeedback; 2) 5 different topics will be included ; 3) Home exercise of slow breathing and mindfulness exercise.
75883522|NCT04829877|Behavioral|Web-based mind-body intervention|The web-based mind-body intervention will receive 5 different topics courses.
75440289|NCT01620294|Procedure|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
75883523|NCT04823845|Drug|Topical Adapalene Gel 0.1%|applying Adapalene Gel 0.1% to plantar warts topically
75440290|NCT01620294|Procedure|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
75440291|NCT01620307|Drug|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
75883524|NCT04810962|Drug|APP13007, 0.05%|APP13007 eye drop, 0.05%
75883525|NCT04810962|Drug|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
75883526|NCT04806776|Other|24hrs dressings change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
75883527|NCT04806776|Other|7days dressings change|The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
75883528|NCT04806451|Drug|Crinecerfont|CRF1-receptor antagonist
75883529|NCT04806451|Drug|Placebo|Non-active dosage form
75883530|NCT04806269|Device|Fitbit and Glandy|Data collection from wearable devices (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) Fitbit collects user's heart rate, activity, and sleep data. Glandy collects user's subjective symptom scores.
75440292|NCT01620320|Other|Stress echocardiography|Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
75440293|NCT01620333|Drug|biphasic insulin aspart 50|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
75883531|NCT04805983|Drug|BMS-984923|Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
75883532|NCT04798378|Device|Neurosleeve|Myoelectric devices for restoration of independent arm function
75440294|NCT01620333|Drug|biphasic insulin aspart 70|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
75590585|NCT05505825|Drug|AK104 IV infusion；Chiauranib oral|AK104 IV infusion once every 3 weeks；Chiauranib once a day oral
75590586|NCT05503732|Other|Energy Drink|Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
75590587|NCT05503732|Other|Placebo Drink|Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
75590588|NCT05500482|Biological|Typhoid conjugate Vaccine|TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
75883533|NCT04792749|Drug|Metformin|Patients are given 750, 1500, and 2000 mgs of metformin per os daily (dose increases weekly, then maintain at 2000 mgs) in addition to 500 mgs of medroxyprogesterone acetate per os daily and levonorgestrel-releasing intrauterine device for the treatment of early stage endometrial cancer.
75590589|NCT05500170|Dietary Supplement|Nicotinamide riboside|Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.
75590590|NCT05500170|Dietary Supplement|Placebo|The placebo pill will contain micro cellulose powder.
76055018|NCT03026374|Behavioral|Be Resilient to Breast Cancer|This is a supportive-expressive group therapy.
76055019|NCT01832727|Drug|Oprozomib|Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.
76055020|NCT01832727|Drug|Dexamethasone|Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
75590591|NCT05499390|Drug|AK112|Subjects receive AK112 intravenously.
76055021|NCT03026296|Behavioral|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
75440295|NCT01620346|Procedure|Intracytoplasmic sperm injection (ICSI)|ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
75590592|NCT05499390|Drug|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
75733771|NCT05558995|Other|ketogenic diet|All the subjects will be instructed by a nutrition professional to have at least 3 meals per day consisting of 20 g to 30 g of carbohydrate in the form of green vegetables and salad, and 80 g to 100 g of protein in the form of meat, fish, fowl, eggs, shellfish and cheese for 12 weeks. Polyunsaturated and monounsaturated fats will also be included in the diet. Micronutrients (vitamins and minerals) will be given to each subject in the form of one capsule per day. The adherence to diet will be confirmed weekly through a food log and urinary ketones assessment using dipstick to ensure that all individuals remain in a ketotic state.
75733772|NCT05558280|Drug|Dinutuximab beta|The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.The treatment phase foresees 5 cycles of Dinutuximab Beta.
75733773|NCT05557955|Other|Breathing test|Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
75733774|NCT05551377|Other|Head-up tilt sleeping|Whole-body head-up tilt sleeping (HUTS) will be carried out in three different angles, each for the duration of two weeks. Prior to the first angle the participant will sleep in a horizontal position for 1 week. The different angles will be installed using a wedge between the mattress and bed frame.
75733775|NCT05547464|Biological|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
75733776|NCT05547464|Biological|BNT164b1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
75733777|NCT05547464|Other|Placebo|Placebo
76055022|NCT04647058|Procedure|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
76055023|NCT04647058|Procedure|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
76055024|NCT01473394|Drug|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
76055025|NCT01473394|Drug|Vilazodone|Vilazodone was supplied as tablets.
76055026|NCT04408144|Drug|Dydrogesterone 10mg Oral Tablet|oral 10mg dydrogesterone (Duphaston) 2 times daily
75590593|NCT05497908|Procedure|TAP block via lateral approach|TAP block via lateral approach
75590594|NCT05497908|Procedure|TAP block via posterior approach|TAP block via posterior approach
75590595|NCT05492773|Device|Micro-osteoperforations Technique|Micro-Osteoperforations Technique (MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
76055027|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
75590596|NCT05492773|Device|Active comparater|Active Comparator: Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
75590597|NCT05492162|Other|well-being promotion intervention|"The intervention will be organized on both conferences and workshops.~Four themes will be covered :~Well-being (Workshops)~Smoking prevention (Conference)~Balanced diet (Workshop)~Optimal organization for daily healthy living (Conference)"
75733778|NCT05542355|Drug|EXL01|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
75590598|NCT05490615|Behavioral|Virtual Mindfulness|Investigators have previously developed and tested a virtual mindfulness program. Six 1-hour weekly group sessions will be led on WebEx. Focus will be on skill building through the teaching of formal and informal mindfulness practices. The intervention, based on the MBSR curriculum, has been modified to make it more accessible for autistic adults. The curriculum developed for this program was designed with autistic advisors guiding the team on the length of meditations, the language used when giving instructions, and the range of techniques that would be most helpful for autistic adults. Each activity is presented as optional, recognizing that some people may find certain silent sensory experiences too distressing. Autistic advisors will participate in sessions as co-facilitators and multiple communication options will be available to group participants (text and audio, camera on or off).
75733779|NCT05542355|Drug|Placebo|Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
75733780|NCT05542355|Other|SoC corticosteroid - Induction Period|Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
75440296|NCT01620346|Procedure|Intracytoplasmic morphologically selected sperm injection|IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
75440297|NCT01620359|Device|ExAblate MRgFUS|100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
75440298|NCT01620385|Device|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
75440299|NCT01620398|Behavioral|BALANCE|
75440300|NCT01620398|Behavioral|Control diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
75440301|NCT01620411|Other|Comprehensive Medical Management|Standard of care for failed back surgery syndrome sustained while on active duty, primarily focused on physical therapy, medication including: opioid analgesics, muscle relaxants, non-opioid analgesics, etc.
75440302|NCT01620411|Procedure|Spinal Cord Stimulator|This arm combines comprehensive medical management (as above) with the trial and possible eventual permenant placement of a spinal cord stimulator, a common pain management procedure.
76055028|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
76055029|NCT01449526|Device|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
76055030|NCT01449526|Device|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
75440303|NCT01620424|Drug|biphasic insulin aspart 30|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
75440304|NCT01620424|Drug|biphasic insulin aspart 50|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
76055031|NCT01440322|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
75440305|NCT01620437|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
75440306|NCT01620450|Drug|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
75440307|NCT01620463|Drug|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
75440308|NCT01620463|Drug|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
75440309|NCT01620476|Drug|liraglutide|5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
75590599|NCT05486559|Other|ECMO-free protocol|"All patients randomized to the ECMO-Free Protocol Group will receive a protocolized daily assessment of readiness for liberation from VV-ECMO, which will be initiated between 6:00 AM local time and 10:00 AM local time. If the patient is enrolled after 10:00 AM local time the ECMO-free protocol will begin the following calendar day.~The ECMO-Free Protocol is a 3-step process of assessing readiness for liberation from VV-ECMO: a safety screen (Phase 1: ECMO-Free Safety Screen), titration of the non-ECMO fraction of inspired oxygen (Phase 2: Non-ECMO respiratory support titration), and a trial of cessation of sweep gas flow (Phase 3: ECMO-Free Trial)."
75590600|NCT05486559|Other|Usual Care|All patients randomized to the Usual Care Group will undergo assessments of readiness for liberation, weaning, and decannulation at the discretion of the treatment team.
75590601|NCT05486520|Device|Magnetic Resonance Imaging (MRI)|MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time
75590602|NCT05484999|Other|Meals|12 weeks of medically tailored meals
75440310|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
75440311|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily
75590603|NCT05484999|Other|Meals + Social Support|12 weeks of medically tailored meals and12 weeks of social media based support
75590604|NCT05484999|Other|Control|Waitlist Control Group (no intervention for first 4 months and then receive MamaMeals between 16-20 weeks postpartum)
75590605|NCT05477186|Biological|CV0501 (3 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75733781|NCT05542355|Other|SoC corticosteroid - Tapering|"Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop."
75733782|NCT05540314|Procedure|robotic bariatric surgery|robotic bariatric surgery
76055032|NCT01440322|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
75440312|NCT01620476|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
75440313|NCT01620502|Dietary Supplement|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
75440314|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
75440315|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
75440316|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
75440317|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
75440318|NCT01620554|Drug|Placebo|1 capsule per week during 2 weeks
75590606|NCT05477186|Biological|CV0501 (6 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75590607|NCT05477186|Biological|CV0501 (12 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75590608|NCT05477186|Biological|CV0501 (25 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75590609|NCT05477186|Biological|CV0501 (50 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75590610|NCT05477186|Biological|CV0501 (75 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75590611|NCT05477186|Biological|CV0501 (100 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75590612|NCT05477186|Biological|CV0501 (150 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75590613|NCT05477186|Biological|CV0501 (200 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
76055033|NCT02985580|Dietary Supplement|Blueberry|
76055034|NCT02985580|Dietary Supplement|Placebo|
76055035|NCT01832493|Device|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
75590614|NCT05464147|Device|DynamX Drug-Eluting Coronary Bioadaptor System|DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
75590615|NCT05463263|Drug|STP938|Small molecule
75590616|NCT05462951|Radiation|Standard|Radiation then brachytherapy
75590617|NCT05454891|Drug|Extended bolus of insulin then standard bolus of insulin|For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.
75733783|NCT05539560|Other|Olfactory training with essential oils|Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
75733784|NCT05539560|Other|Olfactory training with fragrance-free oils|Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
75733785|NCT05539014|Other|Data collection|Prospectif data collection
75590618|NCT05454891|Drug|Standard bolus of insulin then extended bolus of insulin|For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
76055036|NCT01831791|Drug|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
76055037|NCT01857531|Drug|Ganaxolone|"Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."
76055038|NCT01857531|Drug|Nicotine Patch|"Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."
76055039|NCT02166047|Drug|Vesatolimod|Vesatolimod tablet administered orally
76055040|NCT02166047|Drug|Placebo|Placebo to match vesatolimod tablet administered orally
76055041|NCT01493284|Device|Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a transfemoral delivery system
75440319|NCT01620580|Behavioral|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3"
75440320|NCT01620580|Behavioral|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills & adherence to renal diet and fluid restriction without discussing any intervention with the group.
75440321|NCT01620606|Behavioral|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy & Social Learning
75440322|NCT01620606|Behavioral|Education and Support|Education about the GI system, nutrition and food safety
75440323|NCT01620619|Other|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
75440324|NCT01620619|Procedure|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
75440325|NCT01620632|Procedure|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
75440326|NCT01620645|Radiation|CT scan and PA chest X-ray|"All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.~The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK."
75440327|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
75590619|NCT05452564|Drug|Baricitinib 2 MG Oral Tablet|Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
75590620|NCT05452564|Drug|Placebo|Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
75590621|NCT05448274|Biological|Placebo|The placebo will consist of solely glycerol-phosphate-buffered isotonic saline.
75590622|NCT05448274|Biological|Ruminococcus torques|10^11 live bacterial cells in glycerol-phosphate-buffered isotonic saline
75733786|NCT05538897|Procedure|Biospecimen Collection|Undergo blood sample collection
75733787|NCT05538897|Procedure|Computed Tomography|Undergo CT scan
75440328|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
75590623|NCT05447091|Behavioral|LOH game- high dose|Participants will be asked to complete 15 half-hour training sessions, over 3 weeks, ie about 5 training sessions a week, and a total of 7.5 hours of training for 3 weeks.
75590624|NCT05447091|Behavioral|LOH game- low dose|Participants will be asked to complete 6 half-hour training sessions, over 3 weeks, ie about 2 training sessions a week, and a total of 3 hours of training for 3 weeks.
75440329|NCT01620684|Drug|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
75440330|NCT01620684|Drug|placebo|placebo capsules
75440331|NCT01620697|Procedure|Colorectal surgery|Colorectal surgery
75590625|NCT05447091|Behavioral|LOH sham game|Participants will be asked to complete 15 half-hour training sessions, over three weeks, using sham version of the game. the sham version does not include components of cognitive training.
76055042|NCT02165735|Behavioral|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
76055043|NCT02165735|Other|Usual care|Usual HIV care
75440332|NCT01620710|Radiation|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
75440333|NCT01620710|Radiation|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
75440334|NCT01620723|Other|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
75590626|NCT05445167|Drug|KLH-2109|Oral administration
75590627|NCT05445167|Drug|Placebo|Oral administration
75590628|NCT05443945|Device|Nasal Spray|3 sprays in each nostril 3 times per day
75590629|NCT05440383|Drug|KLH-2109|Oral administration
75440335|NCT01620723|Other|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
75440336|NCT01620736|Drug|Raltegravir|Raltegravir 400 mg po bid
75440337|NCT01620749|Radiation|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
75440338|NCT01620775|Other|MRIs|Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.
75440339|NCT01620775|Other|Pain testing|There will be a 1-1.5 hour session including pain tolerance testing.
75590630|NCT05440383|Drug|Leuprorelin|Subcutaneous administration
75590631|NCT05434689|Drug|Iberdomide|Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
75590632|NCT05434689|Drug|Daratumumab|Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
75440340|NCT01620801|Biological|AAV8-hFIX19|One-time IV vector administration.
75440341|NCT01620814|Drug|Dinoprostone|
75440342|NCT01620814|Drug|misoprostol|
75440343|NCT01620814|Drug|control|
75440344|NCT01619319|Other|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
75440345|NCT01619319|Other|computer games|computer games that that consist of word puzzles
75440346|NCT01619826|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
75590633|NCT05434689|Drug|Dexamethasone|Corticosteroid active against multiple myeloma in combination with other agents
75590634|NCT05434689|Drug|Carfilzomib|Second generation proteasome inhibitor with activity in multiple myeloma
75590635|NCT05432297|Behavioral|Preventive physical exercise|Daily physical activity depending on daily condition
75590636|NCT05431920|Dietary Supplement|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
75590637|NCT05431920|Dietary Supplement|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
75590638|NCT05431478|Device|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
75590639|NCT05431478|Device|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
75733788|NCT05538897|Drug|Ipatasertib|Given PO
75733789|NCT05538897|Procedure|Magnetic Resonance Imaging|Undergo MRI
75590640|NCT05431478|Device|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
75590641|NCT05428618|Other|e-BariS app group|"During the discharge process, informed consent will be obtained from the patients and the measurement tools will be filled and the mobile application will be downloaded to their phones. The intervention group will have access to all the content of the mobile application, which includes the Self-Monitoring Module and the Patient Education Module. Passwords will be defined so that patients in the intervention group can access the Patient Education Module. Information on the introduction and use of the application will be presented to the patient by the researcher.~The patients will be followed for six months within the scope of the project. In addition, reminder notifications will be sent to patients via the mobile application in line with the areas that patients can access. At one, three, and six months after surgery, he will complete other assessment scales during outpatient follow-up. For patients providing remote control, the scale will be sent online."
75733790|NCT05538897|Drug|Megestrol Acetate|Given PO
75733791|NCT05537259|Other|Observation Group|No intervention; this is an observational study.
75733792|NCT05536414|Drug|Centanafadine|capsule
76055044|NCT02069899|Drug|Emapalumab|Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
76055045|NCT01831089|Drug|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
76055046|NCT02112877|Device|Veniti Vici™ Venous Stent System|
75733793|NCT05536414|Drug|Escitalopram|capsule
75733794|NCT05536414|Drug|Placebo|capsule
75733795|NCT05536349|Drug|Pirtobrutinib|Given by PO
75733796|NCT05536349|Drug|Obinutuzumab|Given by (IV) vein
75733797|NCT05536349|Drug|Venetoclax|Given by PO
75440347|NCT01619826|Behavioral|Physical Activity|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
75440348|NCT01620827|Other|Hospital Landline Phone Calls|Follow-up phone calls are made from the hospital landline phones in a research office
75440349|NCT01620827|Other|Private Cell Phone Calls|Follow-up phone calls are made from the private cell phones of research assistants
75440350|NCT01620840|Drug|Lacosamide 10mg/ml|intravenous administration up to 10 days
75440351|NCT01620866|Other|Eye Movement Desensitization Reprocessing (EMDR)|EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
75733798|NCT05536349|Drug|Valacyclovir|Given by PO
75733799|NCT05536349|Drug|Allopurinol|Given by PO
75883534|NCT04789070|Drug|Sirolimus|Sirolimus is a currently licensed drug primarily used for immunosuppression post-kidney transplantation to prevent organ rejection. Sirolimus was initially considered as a treatment in IBM for its immunosuppressive action and beneficial effects in an experimental myositis mouse model.(11) Transfer of effector T cells from affected to healthy animals resulted in myositis, but the presence of Treg cells were protective against development of myositis. As Sirolimus, which acts to deplete effector T cells but preserving the Treg cells, was effective in this mouse model of myositis, it was therefore postulated that it may also be effective in IBM, not only for its effects on effector T cells and Treg cells, but also for its additional effects on protein degradation.
75883535|NCT04789070|Drug|Placebo|Placebo
75883536|NCT04756427|Drug|Sodium Citrate 4% Inj Syringe 3Ml|3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
75590642|NCT05428618|Other|Self-Monitoring Group|"Patients in the control group will only have access to the Self-Monitoring Module in the application. Other fields will be encrypted. Patients in the control group will also be informed about the area they can access. Patients in the control group will only have access to the self-monitoring section. One, three, and six months after surgery, she will complete other assessment scales during her outpatient follow-up. Scales will be sent online for patients providing remote control. After the project is completed, all content will be opened to the control group patients."
75590643|NCT05427890|Behavioral|T2D Risk Communication Tool: Relative Risk|Risk of T2D is presented in comparison to the rest of the Singapore population in a scale 1-10. Suggestions on different lifestyle changes and its potential to reduce the individual's relative risk is presented for user to observe impact of preventative behaviours.
75590644|NCT05427890|Behavioral|T2D Risk Communication Tool: Metabolic Age|Risk of T2D is presented as an age, compared to their chronological age as a proxy for their current health status. Suggestions on different lifestyle changes and its potential to reduce the individual's metabolic age is presented for user to observe impact of preventative behaviours.
75590645|NCT05427890|Behavioral|T2D Risk Communication Tool: Traffic Light|Risk of T2D is presented as either High (Red) or Low (Green). Generic tips on how to reduce risk of diabetes are included. This imitates the tool that is currently available for residents of Singapore to use to assess their risk of T2D.
75590646|NCT05427760|Drug|Oxygen|After changing the diaper, free flow oxygen will be provided to the diaper area for 1 hour with an oxygen cannula placed inside the diaper (oxygen flow is %21 Fio2, 5 L/min)
75590647|NCT05421793|Other|Fermented product of carrot derived rhamnogalacturonan I|Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I
75590648|NCT05420233|Diagnostic Test|MRE|Magnetic Resonance Enterography at year 1 (in some patients)
75883537|NCT04753359|Other|Med|Mediterranean diet
75883538|NCT04753359|Other|WL|Measuring change in weight
75883539|NCT04733417|Drug|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
75440352|NCT01620905|Procedure|Manipulation|Single level cervical spine joint manipulation
75440353|NCT01620931|Drug|RO5469754|Single ascending doses, iv or sc
75440354|NCT01620931|Drug|Placebo|Single doses, iv or sc
75440355|NCT01620970|Drug|PF03446962|PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
75440356|NCT01621022|Drug|bupropion + nicotine gum|150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
75440357|NCT01621022|Drug|Active bupropion-Placebo gum|150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)
75733800|NCT05535309|Drug|cefoperazone sulbactam sodium|Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
75440358|NCT01621022|Drug|Placebo bupropion-Placebo gum|Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
75440359|NCT01621074|Dietary Supplement|Sodium bicarbonate|Ergogenic effect
75440360|NCT01621074|Dietary Supplement|Placebo|Placebo effect
75440361|NCT01621087|Other|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
75590649|NCT05418244|Other|Inhaled Isopropyl Alcohol|Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares
75590650|NCT05418244|Drug|Oral Ondansetron|4 mg oral disintegrating ondansetron tablet once
75440362|NCT01621100|Drug|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
75590651|NCT05418244|Other|Inhaled Placebo|Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares
75590652|NCT05415670|Diagnostic Test|Whole-genome Methylation Sequencing(GM-seq)|A Whole-genome Methylation detection method, which can analyze the genome-wide, single base resolution methylation of tissue / blood samples, and is used to develop a benign and malignant classification model for Pulmonary Nodule.
75590653|NCT05411991|Diagnostic Test|UNa measurement after intravenous loop diuretic bolus|Sodium concentration is measured on a urine spot sample, collected 30-120 min after administration of every protocol-specified intravenous bumetanide dose.
75590654|NCT05411991|Drug|Intravenous acetazolamide 500 mg OD|Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (>145 mmol/L) or metabolic acidosis (bicarbonate <22 mmol/L) is present at the moment of the scheduled administration.
75590655|NCT05411991|Drug|Intravenous bumetanide TID|An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR >45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR <30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa <80 mmol/L), a dose of 4 mg TID is used.
75733801|NCT05533944|Other|Simulation training in Boškoski-Costamagna ERCP Trainer|Coached simulation training in Boškoski-Costamagna ERCP Trainer, by participating in three intensive courses during the first three months of training, with a monthly basis
75733802|NCT05533619|Drug|Proton pump inhibitor|Inpatients using proton pump inhibitor
75733803|NCT05533606|Drug|Beta-Lactam Drugs|During hospitalization，patients used Beta-Lactam drugs.
75733804|NCT05533593|Drug|Aminoglycoside|Inpatients using aminoglycoside
75440363|NCT01621113|Drug|Dalfampridine|Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
75440364|NCT01621113|Drug|Placebo|Placebo tablet, twice daily, for 10 weeks.
75440365|NCT01621139|Procedure|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
75590656|NCT05411991|Drug|Oral chlorthalidone OD|In case of hypernatremia (>145 mmol/L) or low eGFR (<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa <80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration <135 mmol/L.
75590657|NCT05411991|Drug|Intravenous canrenoate 200 mg OD|At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa <80 mmol/L), intravenous canrenoate 200 mg OD is provided. Canrenoate is never administered in case of hypotonic hyponatremia with serum sodium concentration <135 mmol/L or if serum potassium levels are >5.5 mmol/L. If canrenoate is administered, oral mineralocorticoid receptor drugs are temporarily withhold until switch to oral diuretic treatment.
75733805|NCT05532059|Drug|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Lenvatinib, tislelizumab, gemcitabine and cisplatin
75733806|NCT05532059|Drug|gemcitabine and cisplatin|gemcitabine and cisplatin
75733807|NCT05531149|Drug|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
75733808|NCT05531149|Drug|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
75733809|NCT05530460|Device|retinal imaging with low-cost OCT device|Retinal imaging with low-cost OCT device
75883540|NCT04733417|Drug|famitinib|Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.
75883541|NCT04731441|Behavioral|Home-based Exercise Program Prior to CRS-HIPEC|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
75883542|NCT04731441|Behavioral|Exercise Education|Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
75883543|NCT04724603|Other|patients having had avderse event after phagotherapy for bone or joint or implant infection|to determine the accountability of adverse effects in having had avderse event after phagotherapy for bone or joint or implant infection
76055047|NCT02098369|Behavioral|Written education material (basic)|Education material on COPD distributed to all participants.
75440366|NCT01621165|Drug|Addition of prazosin to usual care (add-on study)|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
75440367|NCT01621165|Drug|Placebo|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
75590658|NCT05411991|Other|Maintenance infusion|A maintenance infusion with 500 mL dextrose 5% and 3 g MgSO4 is started at an infusion rate of 20 mL/h upon the moment of first protocol-specified administration of intravenous diuretics and continued until switch to oral diuretic therapy. 40 mmol KCl is added if serum potassium levels are <4 mmol/L. In case of hypotonic hyponatremia with serum sodium concentration <130 mmol/L, dextrose 5% will not be provided and MgSO4 will be administered in 50 mL of normal saline (NaCl 0.9%).
75590659|NCT05411991|Drug|Oral potassium supplements|If serum potassium levels are <3.5 mmol/L at any time during the administration of intravenous diuretics, oral potassium supplements are provided as needed to keep serum potassium levels >4 mmol/L
75590660|NCT05411991|Other|Intravenous hypertonic saline|In case of hypotonic hyponatremia with serum sodium concentration <125 mmol/L, a bolus of 150 mL hypertonic saline 3% is administered and repeated OD if necessary, until sodium levels are ≥135 mmol/L.
75590661|NCT05411991|Other|Switch to oral diuretic therapy|"Upon complete resolution of clinical signs of fluid overload with UNa <80 mmol/L, intravenous diuretics are switched to an oral schedule including:~Loop diuretics with dose & frequency at the discretion of the treating physician~Chlorthalidone 50 mg if added for diuretic resistance at any time during the intravenous diuretic phase~Spironolactone 25 mg or another equivalent mineralocorticoid receptor antagonist"
75590662|NCT05411991|Other|Usual AHF care|It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines.
75733810|NCT05530460|Device|retinal imaging with commercial OCT device|retinal imaging with commercial OCT device
75733811|NCT05529927|Drug|Sustained-release Dexamphetamine|"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."
76055048|NCT02098369|Behavioral|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
76055049|NCT02098369|Behavioral|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
76055050|NCT02098369|Behavioral|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
75733812|NCT05529927|Drug|Placebo|"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."
75733813|NCT05527444|Drug|Secukinumab 150 mg/ml|Secukinumab 150 mg will be administered at Baseline, Week 1, 2, 3, 4, 6, 8 followed by dosing every 4 weeks until Week 24
75733814|NCT05527444|Drug|Adalimumab Ab|adalimumab biosimilar 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 24
75733815|NCT05527444|Drug|NSAID|stable dose
75733816|NCT05527444|Drug|Thalidomide Pill|If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.
75733817|NCT05527054|Other|Diuretics|Inpatients using diuretics
75883544|NCT04723420|Other|Steamroller technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
75883545|NCT04723420|Other|Direct technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
75883546|NCT04722601|Drug|Venetoclax|A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
75883547|NCT04722601|Drug|Obinutuzumab|Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.
75883548|NCT04722601|Drug|CC-486|An oral form of azacitidine (a standard chemotherapy drug).
75883549|NCT04702243|Diagnostic Test|Genetic Testing for PCD or PID|Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.
75883550|NCT04702243|Other|Unaffected Family Member Genetic Testing|Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.
75733818|NCT05525468|Drug|TDM-180935|TDM-180935 topical ointment
75733819|NCT05525468|Drug|Placebo|Placebo for TDM-180935 topical ointment
75440368|NCT01621204|Drug|Eltrombopag|Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
75440369|NCT01621204|Drug|IVIG infusion|IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
75440370|NCT01621217|Drug|Cetuximab|Will be given weekly intravenously during study treatment.
75440371|NCT01621217|Drug|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
75733820|NCT05524870|Other|Mobilization|Movement with mobilization plus exercise
75883551|NCT04692844|Drug|Propranolol|Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
75883552|NCT04692844|Drug|Primidone|Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
75883553|NCT04657003|Drug|Tirzepatide|Administered SC
75883554|NCT04657003|Other|Placebo|Administered SC
75883555|NCT04650607|Other|Adverse event after injection of phages|rate and description of adverse event after injection of phages
75883556|NCT04648852|Other|Heart failure risk estimation|Evaluation by heart failure risk score
75883557|NCT04643067|Drug|KPG-818 low dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
75883558|NCT04643067|Drug|KPG-818 mid dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
75883559|NCT04643067|Drug|KPG-818 high dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
75883560|NCT04643067|Drug|Placebo|This is the comparative arm.
75883561|NCT04625361|Drug|HEC122505MsOH|Part2：Mulltiple doses once daily, up to 8 days
75883562|NCT04624906|Drug|Acalabrutinib|100 mg oral capsules twice daily for 1 year
75883563|NCT04624906|Drug|Bendamustine|90 mg/m2 on days 1 and 2 of each cycle.
75883564|NCT04624906|Drug|Rituximab|day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
75883565|NCT04610320|Drug|Daratumumab-SC|>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
75883566|NCT04606134|Device|Hybrid fractional laser|two treatments given one month apart
75440372|NCT01621217|Drug|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
75440373|NCT01621217|Radiation|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
75440374|NCT01621256|Drug|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
75440375|NCT01621256|Drug|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
75440376|NCT01621269|Drug|Fingolimod|
75440377|NCT01621282|Other|Education|A 6-month interactive course on critical appraisal
75590663|NCT05411263|Diagnostic Test|Comprehensive transthoracic echocardiography, Doppler echography & Kino-cardiograph (Kino)|As per inclusion criteria, all patients undergo right heart catheterisation to obtain a full profile of invasive hemodynamic measurements, including pulmonary arterial wedge pressure (PAWP), pulmonary artery pressure, right ventricular pressure, right atrial pressure (RAP), superior and/or inferior vena cava pressure, hepatic vein pressure with/without balloon occlusion. Immediately after the invasive hemodynamic exam, a comprehensive 2D, Color Doppler and Doppler echocardiography exam, including a Doppler study of the Vv. hepaticae, V. portae and V. renalis is performed. Based upon logistic feasibility, ballistocardiography and seismocardiography with the completely non-invasive Kino device (HeartKinetics, Waterloo, Belgium) is performed in a subpopulation of patients envisioned to be at least 50 patients.
75883567|NCT04606134|Other|Alastin Regenerating Skin Nectar with TriHex Technology|applied twice daily
75440378|NCT01621282|Other|Conventional|Conventional method/no intervention
75440379|NCT01621308|Other|Mode of insulin administration|There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
76055051|NCT02111785|Drug|Dexamethasone|Treatment with a short course of oral dexamethasone
75440380|NCT01621321|Drug|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
75590664|NCT05410951|Diagnostic Test|Illumina panel|"Determination of germline mutations using a recent panel including 113 genes from the Illumina protocol"
75883568|NCT04606134|Other|Cetaphil face cream|applied twice daily
76055052|NCT02111785|Procedure|Burr Hole Craniostomy|Treatment with surgical burr hole craniostomy and evacuation of SDH
76055053|NCT02068885|Behavioral|Feeding study|Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
76055054|NCT02068495|Drug|Candesartan cilexetil/Amlodipine besilate|Candesartan cilexetil/Amlodipine besilate tablets
76055055|NCT02097823|Drug|Olanzapine|
76055056|NCT02097823|Drug|Aprepitant|
75440381|NCT01621321|Drug|Voriconazole|Voriconazole 200 mg BD for 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
75440382|NCT01621334|Behavioral|Motivational Enhancement Therapy|Two personal feedback sessions with counselor using motivational interviewing strategies.
75590665|NCT05410860|Drug|Etripamil NS 70 mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
75590666|NCT05410860|Drug|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
76055057|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
75440383|NCT01621334|Behavioral|Educational information|Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
75590667|NCT05409612|Biological|Supemtek®|"Quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
75590668|NCT05409612|Biological|Vaxigriptetra®|Quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
75590669|NCT05408845|Drug|Docetaxel|Given IV
75590670|NCT05408845|Other|Questionnaire Administration|Ancillary studies
75590671|NCT05408845|Biological|Trastuzumab|Given IV
75590672|NCT05408845|Biological|Trastuzumab Emtansine|Given IV
75590673|NCT05408507|Behavioral|ABC123 Framework|This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced cancer and to test the delivery of goal-concordant care. This patient-centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation, and a guided goals of care discussion.
75590674|NCT05407662|Other|sMRA therapies|No drug will be provided to participants. Patients follow routine clinical practice/administration.
75590675|NCT05403385|Drug|inupadenant|Adenosine 2a receptor antagonist
75590676|NCT05403385|Drug|Placebo|matched placebo capsule to inupadenant
75590677|NCT05403385|Drug|Carboplatin|standard of care chemotherapeutic, alkylating agent
75883569|NCT04568759|Other|Global postural re-education|GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
75883570|NCT04556188|Procedure|Cardiac surgery|
76055058|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
76055059|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
76055060|NCT01830855|Biological|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
76055061|NCT01830855|Biological|Saline|0.5 mL dose of sterile normal saline for injection.
76055062|NCT01857063|Drug|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
76055063|NCT01857063|Drug|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
76055064|NCT01856907|Drug|Sitagliptin-Metformin|Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
76055065|NCT01856907|Drug|Metformin|Biguanide- insulin sensitizer
76055066|NCT01856907|Drug|Placebo pill|Will evaluate effect of lifestyle and diet only
76055067|NCT02212457|Biological|Bexsero|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.
75590678|NCT05403385|Drug|Pemetrexed|standard of care chemotherapeutic, anti-metabolite
75590679|NCT05402280|Behavioral|Sleep protocol|To investigate the effect of a multicomponent sleep protocol on the quality of sleep hospitalized patients assessed both subjectively and objectively.
75590680|NCT05401084|Other|Diet|Macronutrient diet changes.
75590681|NCT05400863|Behavioral|avoid sugary and NNS drinks plus start Metformin|Subjects will receive education and counseling to avoid all sweetened drinks (drink water only). Participants will be asked to consume minimum of 3 drinks/day
75590682|NCT05400863|Behavioral|avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin|Subjects will avoid drinks sweetened with sugar (can have diet drinks sweetened with NNS). Participants will be asked to consume minimum of 3 drinks/day
75590683|NCT05400720|Behavioral|Mentoring|At least one meeting between the mentor and mentee will occur to share experiences and see if the mentee would like to continue meeting with a mentor
75733821|NCT05524415|Device|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
75733822|NCT05521997|Drug|Telaglenastat|-800 mg twice per day by mouth
75733823|NCT05521997|Radiation|Radiation treatment|"Standard of care~External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy."
75733824|NCT05521997|Drug|Cisplatin|"Standard of care~Weekly administration of cisplain"
75733825|NCT05521438|Drug|QRX003-2% Lotion|QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
75883571|NCT04550598|Device|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 5 times a week, lasting for 2 weeks.
75440384|NCT01621360|Procedure|Arthroscopic hip surgery|Hip arthroscopy
75440385|NCT01621360|Other|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
75440386|NCT01621373|Drug|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
75440387|NCT01621386|Drug|Montelukast|Administered orally as a single daily 10 mg dose for 2 weeks
75440388|NCT01621386|Drug|Prednisone|Administered orally as a single daily 20 mg dose for 2 weeks
75440389|NCT01621399|Drug|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
75590684|NCT05398198|Drug|GSK3923868|GSK3923868 dose and administration as per study intervention.
75590685|NCT05398198|Drug|Placebo|Placebo matching GSK3923868 will be administered.
75590686|NCT05396833|Drug|M1774|M1774 will be administered orally once daily over a defined period of time in Part A1 and Part B1 until disease progression, death, discontinuation, or end of study.
75590687|NCT05396833|Drug|M4076|M4076 will be administered orally once daily over a defined period of time in Part A1 until disease progression, death, discontinuation, or end of study.
75590688|NCT05396833|Drug|Avelumab|Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
75590689|NCT05395052|Drug|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy
75590690|NCT05395052|Drug|Cyclophosphamide|Lympho-conditioning agent
75590691|NCT05395052|Drug|Fludarabine|Lympho-conditioning agent
75590692|NCT05395052|Drug|IL-2|For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD
75733826|NCT05521438|Drug|QRX003-4% Lotion|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
75733827|NCT05521438|Drug|Vehicle|Vehicle Lotion
75733828|NCT05521191|Drug|RGLS8429|Solution for subcutaneous injection
75733829|NCT05521191|Drug|Placebo|Solution for subcutaneous injection
75733830|NCT05520775|Drug|Semaglutide|Semaglutide (subcutaneous)
75733831|NCT05520775|Drug|Sham/placebo|Sham subcutaneous injection
75733832|NCT05520619|Drug|Paclitaxel, Cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.
75883572|NCT04550598|Device|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
75590693|NCT05395052|Combination Product|Avelumab|Monoclonal antibody
75590694|NCT05395052|Combination Product|Pembrolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
75590695|NCT05395052|Combination Product|Nivolumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
75440390|NCT01621399|Drug|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
75440391|NCT01621425|Other|Lean body mass|Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
75590696|NCT05395052|Combination Product|Atezolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
75590697|NCT05395052|Combination Product|Trastuzumab|Monoclonal antibody
75733833|NCT05520619|Drug|tislelizumab|Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
75440392|NCT01621425|Other|Total body weight|Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
75440393|NCT01621425|Other|bloodsampling|Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
75590698|NCT05395052|Combination Product|Cetuximab|Monoclonal antibody
75590699|NCT05395052|Combination Product|Amivantamab|Monoclonal antibody
75440394|NCT01621451|Drug|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
75590700|NCT05395052|Drug|IL-2|For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD
75590701|NCT05389657|Behavioral|Web-based training|Web-based training will be divided into training modules that will be completed by participants over the course of 6-8 weeks. Training will include didactic training videos, knowledge checks, example sessions, and a library of resources.
75590702|NCT05389657|Behavioral|Live training|The live training will be delivered by two trainers over the course of two days via Zoom.
75590703|NCT05389527|Drug|Pembrolizumab+Lenvatinib|"After enrollment, subjects receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 9 weeks: Lenvatinib 8 mg (body weight <60 kg) or 12 mg (body weight ≥60 kg) orally once daily for 9 weeks.~Subjects conduct surgery 1 week after the last dose of Lenvatinib. 4 weeks after surgery, Pembrolizumab and Lenvatinib will restart as adjuvant treatment for up to 1 year."
75590704|NCT05389423|Drug|Vincristine|0.4 mg/m2/day administered by CIVI on days 1 to 4
75590705|NCT05389423|Drug|Prednisone|60 mg/m2/day administered orally on days 1 to 5
75590706|NCT05389423|Drug|Doxorubicin|10 mg/m2/day administered by CIVI on days 1 to 4
75590707|NCT05389423|Drug|Etoposide|50 mg/m2/day administered by CIVI on days 1 to 4
75590708|NCT05389423|Drug|Pomalidomide|An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
75733834|NCT05520619|Radiation|Radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
75733835|NCT05520008|Other|Game-based exercise|Patients in the active group will put on a sensor connected to a tablet to play a game-based foot/ankle exercise twice a day for 5 minutes for four weeks.
75590709|NCT05389423|Drug|Cyclophosphamide|750 mg/m2 administered IV on day 5
75590710|NCT05389423|Drug|Rituximab|375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
75590711|NCT05388435|Drug|SKL27969|SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
75733836|NCT05514990|Drug|Bortezomib|Given SC or IV
75733837|NCT05514990|Drug|Dexamethasone|Given PO, IV, or IM
75733838|NCT05514990|Biological|Pelareorep|Given IV
75733839|NCT05514990|Biological|Pembrolizumab|Given IV
75590712|NCT05384704|Behavioral|Empower@Home|The intervention is a 9-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive weekly support from a trained research staff.
75440395|NCT01621451|Drug|aspirin and/or clopidogrel|"Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.~In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer."
75590713|NCT05384145|Other|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
76055068|NCT02212457|Other|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.
76055069|NCT02212457|Biological|Havrix|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
75590714|NCT05383092|Other|Adapted Physical Activity Strong|Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.
75590715|NCT05376488|Other|One meal|One meal given to assess impact on ammonia levels serially
75590716|NCT05376176|Drug|STN1010904 ophthalmic suspension 0.03% BID|0.03% STN1010904 ophthalmic suspension BID
75590717|NCT05376176|Drug|STN1010904 ophthalmic suspension 0.1% BID|0.1% STN1010904 ophthalmic suspension BID
75590718|NCT05376176|Drug|Placebo (Vehicle) BID|Placebo (vehicle) BID
75590719|NCT05370235|Drug|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
75590720|NCT05364541|Device|MyoVista wavECG|A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
75590721|NCT05362071|Other|Remote Exercise Group|The intervention will have a weekly frequency of two sessions on non-consecutive days during the first six weeks and three sessions on non-consecutive days for the remaining six weeks. The exercise intervention will consist of four 3-week mesocycles. The session's structure will consist of a warm-up, the main part, in which a combined training program will be carried out, consisting of three distinct blocks, and at the end, stretching. Blocks 1 and 2 will consist of three strength exercises with bodyweight and alternative materials and aerobic training. Between blocks 1 and 2, and later in block 3, participants will take a free walk with displacement in the space they have available in their own home. The session will end with stretching exercises for the main muscle groups. The sessions will last 37 to 57 minutes over 12 weeks, with approximately 5 min of warm-up and stretching, and the main part ranging from 27 min to 47 min throughout the intervention.
75590722|NCT05362071|Other|Group control|"Participants allocated to the GC will receive recommendations for the practice of physical activity based on information from three specific chapters of the Physical Activity Guide for the Brazilian Population (2021). The GC will receive through Whatsapp the information that is available in chapters 1, 4, and 5, which address the following topics: Understanding Physical Activity, Physical Activity for Adults, and Physical Activity for the Elderly. If sending via Whatsapp is not possible, the booklet will be printed and delivered to the participant. At the end of the 12 weeks, the same booklet will be made available to IG participants."
75590723|NCT05361720|Drug|Cabozantinib|Given PO
75590724|NCT05361720|Biological|Ipilimumab|Given IV
76055070|NCT02212457|Biological|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
76055071|NCT02097745|Drug|methotrexate|a 10-25 mg stable dose given orally or parenterally throughout study
76055072|NCT02097745|Drug|rituximab [MabThera/Rituxan]|1 g given by intravenous infusion on Days 1 and 15 of each treatment course
76055073|NCT02111083|Biological|Insulin Lispro|LY275585 administered SC.
75440396|NCT01621464|Device|Pacemaker with Closed Loop Stimulation (CLS sensor)|Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
76055074|NCT01629563|Drug|PGL4001 5 mg|PGL4001 5 mg daily administration
76055075|NCT01629563|Drug|PGL4001 10 mg|PGL4001 10mg daily administration
76055076|NCT02097277|Biological|BMS-986036|
76055077|NCT02097277|Biological|Placebo (Matching with BMS-986036)|
76055078|NCT02212379|Drug|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
75440397|NCT01621503|Device|NT-530P|intraocular pressure and central corneal thickness measurement
75440398|NCT01621620|Drug|Yohimbine|
75883573|NCT04546399|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
75440399|NCT01621646|Other|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
75883574|NCT04546399|Biological|Blinatumomab|Given IV
75733840|NCT05512793|Diagnostic Test|Standard technique First colonoscopy without PolyDeep|Standard technique First colonoscopy without PolyDeep
75733841|NCT05512793|Diagnostic Test|Combination technique First colonoscopy with PolyDeep|Combination technique First colonoscopy with PolyDeep
75440400|NCT01621685|Biological|biological/vaccine|Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
75883575|NCT04546399|Drug|Cyclophosphamide|Given IV
75440401|NCT01621698|Procedure|Early paravertebral block|In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
75590725|NCT05361720|Biological|Nivolumab|Given IV
75590726|NCT05361590|Device|Lumoral device|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
75590727|NCT05359653|Drug|Clemastine Fumarate|8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
75883576|NCT04546399|Drug|Cytarabine|Given IT
75883577|NCT04546399|Drug|Dexamethasone|Given PO or IV
75883578|NCT04546399|Drug|Etoposide|Given IV
76055079|NCT02110693|Other|Interviewer and tablet administration of the TAPS Tool|All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
75440402|NCT01621698|Procedure|Late Paravertebral block.|In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
75440403|NCT01621724|Genetic|WT1 TCR-transduced T cells|"Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"
75590728|NCT05359653|Drug|Placebo|Matched sugar tablet
75883579|NCT04546399|Drug|Hydrocortisone Sodium Succinate|Given IT
75883580|NCT04546399|Drug|Leucovorin Calcium|Given PO and IV
75883581|NCT04546399|Drug|Mercaptopurine|Given PO
75883582|NCT04546399|Drug|Methotrexate|Given IT, PO, and IV
75883583|NCT04546399|Biological|Nivolumab|Given IV
75733842|NCT05512520|Combination Product|Intensity-modulated radiotherapy concurrent with capecitabine|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks.
75733843|NCT05509023|Drug|ADX-914|Subcutaneous administration of ADX-914
75733844|NCT05509023|Drug|Placebo|Subcutaneous administration of Placebo
75733845|NCT05505474|Device|IVF with the Neria™ Guard Subcutaneous Catheter|Use of the Neria™ Guard subcutaneous catheter for administration of subcutaneous medication in an IVF cycle.
75733846|NCT05505396|Other|Sampling of blood and cerebrospinal fluid|Blood HbA1c, insulin, C-peptide and IL-6 measured at admission. Glucose and lactate measured every 4 hours during intensive care stay. Daily sampling of CSV analysed for glucose and lactate in patients with EVD.
75733847|NCT05505279|Device|THRIVE (High Flow Nasal Cannula)|2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen
75883584|NCT04546399|Drug|Pegaspargase|Given IM or IV
75883585|NCT04546399|Drug|Thioguanine|Given PO
75883586|NCT04546399|Drug|Vincristine Sulfate|Given IV push or via infusion
75883587|NCT04540120|Drug|dapansutrile capsules|Hard opaque capsules containing 250 mg of API.
75883588|NCT04540120|Drug|placebo capsules|Hard opaque capsules containing 0 mg of API.
75883589|NCT04522791|Behavioral|RFB|The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).
75883590|NCT04522791|Behavioral|VSOP|The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.
76055080|NCT02212301|Device|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
76055081|NCT02212301|Device|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
76055082|NCT02211209|Drug|Volanesorsen|
76055083|NCT02211209|Drug|Placebo|
76055084|NCT02187809|Drug|Clobazam|
76055085|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
76055086|NCT02187029|Other|Placebo|Daily dosing (tablet) for 14 days
75590729|NCT05358704|Drug|combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)|To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
75590730|NCT05358249|Drug|JDQ443|KRAS G12C inhibitor, oral
75733848|NCT05498220|Drug|Polatuzumab vedotin (PV)|1.8 mg/kg, intravenous, at day 1, in every 21 days
75733849|NCT05498220|Drug|Rituximab|375 mg/m2 intravenous, at day 1 or day 2, in every 21 days
75883591|NCT04522791|Behavioral|IR|Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.
75883592|NCT04518059|Procedure|punch skin biopsy|An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.
75883593|NCT04517383|Procedure|post-operative sedation|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. After the ET surgery is done, patients in POS group will be sedated for 6hrs before extubation.
75883594|NCT04517383|Procedure|routine recovery|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. Patients in Con group will be routinely recovered and extubated after the ET surgery is done.
75883595|NCT04513665|Drug|ZW25|ZW25 at 20mg/kg intravenously (IV) every two weeks.
75883596|NCT04505930|Behavioral|Interventional HPV vaccination video modules|The study team provide participants in the intervention group with interventional education, using interactive video watch and dynamic discussion. The educational videos were aiming to reinforcement and improvement the awareness, knowledge, attitude, intention and actual uptake of HPV vaccination shots among Chinese parents.
75440404|NCT01621750|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
75440405|NCT01621763|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
75440406|NCT01621789|Other|dye of lutein, zeaxanthin, trypan blue|dye composed of lutein, zeaxanthin, trypan blue
75590731|NCT05358249|Drug|trametinib|MEK inhibitor, oral
75733850|NCT05498220|Drug|Hyaluronidase|1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days
75883597|NCT04505930|Behavioral|General Vaccination Education|Education session conducted using only handouts of vaccinations including HPV
75883598|NCT04489524|Behavioral|individualized counselor-led MI sessions|Intervention consisted of four 60-min in-person sessions of AMI counseling and a packet of self help smoking cessation materials.
75883599|NCT04489524|Behavioral|general health education session|four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco.
75883600|NCT04489524|Behavioral|NRT|nicotine replacement therapy
75733851|NCT05498220|Drug|Gemcitabine|1,000 mg/m2 intravenous at day 1 and 8, in every 21 days
75883601|NCT04480086|Drug|Mivebresib|Tablet: Oral
75883602|NCT04480086|Drug|Navitoclax|Tablet; Oral
75440407|NCT01621815|Behavioral|Video Game|Playing various video games: RPG, Race, FPS, Strategy
75440408|NCT01621854|Drug|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
75590732|NCT05358249|Drug|Ribociclib|CDK4/6 inhibitor, oral
75590733|NCT05358249|Biological|cetuximab|EGFR inhibitor, intravenous
75733852|NCT05498220|Drug|Cisplatin|75 mg/m2, intravenous, at day 1, in every 21 days
75733853|NCT05498220|Drug|Dexamethasone|40 mg intravenous at day 1, Per oral days at days 2-4
75733854|NCT05498220|Drug|GCSF|granulocyte-colony stimulating factor (GCSF )
75733855|NCT05494502|Procedure|Erector spinae plane block|Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
75733856|NCT05494502|Procedure|Control group|General anesthesia alone.
75733857|NCT05492370|Dietary Supplement|EpiCor|2 gummies daily
75733858|NCT05492370|Dietary Supplement|Placebo|2 gummies daily
75733859|NCT05489341|Diagnostic Test|Histopathology and Magnetic Resonance Imaging with Follow-Up|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.
75590734|NCT05350826|Other|Ambulatory medical assistance|Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
75590735|NCT05349968|Drug|Lipovirtide for injection|Multiple dosing of Lipovirtide
75883603|NCT04480086|Drug|Ruxolitinib|Tablet; Oral
75883604|NCT04476212|Other|Topical antibiotic prophylaxis|The surgical wound will be irrigated with an antibiotic solution, and then we will apply the same solution using gauze for two minutes on the wound
75883605|NCT04432688|Drug|Lurasidone HCl|This is a non-interventional, observational study
75440409|NCT01621867|Drug|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
75440410|NCT01621867|Drug|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
75440411|NCT01621893|Procedure|Subchondroplasty|
75440412|NCT01621932|Procedure|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
75440413|NCT01621932|Procedure|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
75883606|NCT04426825|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
75883607|NCT04426825|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
75883608|NCT04424030|Diagnostic Test|Echocardiography|Standard echocardiography exam performed as part of clinical management.
75440414|NCT01621945|Biological|MenBvac|Blood test
75440415|NCT01621958|Behavioral|Repeated perturbation training|One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
75440416|NCT01621958|Behavioral|Minimal perturbation training|One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
75883609|NCT04424030|Diagnostic Test|Magnetic resonance imaging (MRI)|Standard comprehensive cardiac MRI exam of the heart performed as part of clinical management.
75440417|NCT01621971|Drug|inhaled milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
75440418|NCT01621971|Drug|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
75440419|NCT01621984|Other|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
75440420|NCT01621997|Behavioral|operation inspection|"Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months"
75440421|NCT01622023|Procedure|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
75590736|NCT05347238|Drug|Dopamine|Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
75590737|NCT05347238|Drug|Norepinephrine|Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
75590738|NCT05339776|Behavioral|Hand Lateralization Test|Before hand lateralization test, participants will be evaluated. Both groups (Amputees and Control) will complete hand lateralization test for at least 10 days. The test will be sent each day on an online system. Participants' performances will be recorded via online system. After hand lateralization test, participants will be evaluated.
75590739|NCT05336760|Diagnostic Test|Iowa Oral Performance Instrument (IOPI)|IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.
75590740|NCT05336760|Diagnostic Test|Mann Assessment of Swallowing Ability (MASA)|MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.
75883610|NCT04424030|Diagnostic Test|Computed tomography (CT)|ECG-triggered, contrast-enhanced CT scan of the heart performed for research purposes in eligible study participants.
75883611|NCT04419233|Drug|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
75883612|NCT04418479|Drug|Aspirin|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients being treated with dual antiplatelet therapy (DAPT) at high risk for recurrent ischemic events who have been over 12 months after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period."
76055087|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
76055088|NCT02187029|Other|Placebo|Daily dosing (tablets) for 14 days
75590741|NCT05336760|Diagnostic Test|Fiberoptic Endoscopic Evaluation of Swallowing|The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).
75590742|NCT05336760|Diagnostic Test|Respiratory function measurements|Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
75590743|NCT05331755|Drug|Dupilumab|start medication in cohort
75590744|NCT05327946|Drug|BI 770371|BI 770371
75590745|NCT05327946|Drug|ezabenlimab|ezabenlimab
76055089|NCT04750655|Drug|Moxifloxacin (Topical)|We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
75733860|NCT05489341|Diagnostic Test|Histopathology and Magnetic Resonance Imaging|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.
75733861|NCT05486416|Drug|HSK3486|HSK3486 for induction of general anesthesia
75733862|NCT05486416|Drug|Propofol|Propofol for induction of general anesthesia
76055090|NCT02162771|Biological|Rituxan|
76055091|NCT02162771|Biological|CT-P10|
75440422|NCT01622049|Device|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
75440423|NCT01622075|Device|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
75733868|NCT05484544|Diagnostic Test|High sensitivity troponin T|Collection of hs-cTnT samples
75733869|NCT05484115|Device|endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|treatment of AAA's with wide proximal neck diameters with Endurant II/IIs endograft system
76055092|NCT02162771|Drug|Cyclophosphamide|
76055093|NCT02162771|Drug|Vincristine|
76055094|NCT02162771|Drug|Prednisone|
76055095|NCT02161757|Biological|Tralokinumab|Subcutaneous injection
76055096|NCT02161757|Other|Placebo|Subcutaneous injection
75440424|NCT01622075|Device|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
76055097|NCT02160977|Procedure|total knee arthroplasty|
76055098|NCT02160899|Drug|ISIS-APO(a)Rx|ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
76055099|NCT02160899|Drug|Placebo|Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
76055100|NCT02160041|Drug|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
76055101|NCT02186873|Drug|Placebo|Participants will receive matching placebo.
76055102|NCT02186873|Drug|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
76055103|NCT02096263|Biological|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
75883613|NCT04418479|Drug|Clopidogrel|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients being treated with dual antiplatelet therapy (DAPT) at high risk for recurrent ischemic events who have been over 12 months after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period."
75733870|NCT05484115|Device|endosuture aneurysm repair (ESAR) using Heli-FX EndoAnchor system|treatment of AAA's with wide proximal neck diameters with the Endurant II/IIs in conjunction with the Heli-FX EndoAnchor system
75883614|NCT04417998|Drug|18F-FDG|A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.
75883615|NCT04417998|Drug|18F-AV1451|A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.
76055104|NCT02096263|Biological|Pediarix|3 doses administered intramuscularly in the right thigh
76055105|NCT02096263|Biological|ActHIB|4 doses administered intramuscularly in the upper left thigh
76055106|NCT02096263|Biological|Pentacel|4 doses administered intramuscularly in the right thigh
75440425|NCT01622101|Dietary Supplement|Thermogenic properties of Zantrex-3®|The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by >7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
75440426|NCT01622114|Other|Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
75440427|NCT01622153|Procedure|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
75440428|NCT01622153|Procedure|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
75440429|NCT01622166|Behavioral|psychodynamic art therapy|2 sessions à 1.5 hrs /week, intervention duration 6 weeks
75440430|NCT01622179|Procedure|sewed indirectly|The epitenon was repaired and sewed indirectly.
75440431|NCT01622179|Procedure|sewed directly|The epitenon was unrepaired and sewed directly.
75440432|NCT01622205|Other|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
75733871|NCT05478512|Drug|VenObi+Ven or VenObi+VenZan|"Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~if uMRD = Venetoclax 400 mg/d orally until cycle 13.~if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~if uMRD = stop treatment~if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression"
75883616|NCT04417998|Device|Siemens E7 Reconstruction Tool|Software to correct for motion
75883617|NCT04414384|Other|Abdominal Binder|Abdominal Binder placement
75883618|NCT04414384|Other|Step Counter|step counter to track steps
76055107|NCT02096263|Biological|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
76055108|NCT02096263|Biological|Infanrix|1 dose administered intramuscularly in the right thigh
76055109|NCT02096263|Biological|Hiberix|1 dose administered intramuscularly in the left thigh
76055110|NCT02096263|Biological|Prevnar13|3 doses administered intramuscularly in the lower left thigh
76055111|NCT02096263|Biological|Rotarix|2 doses administered orally
76055112|NCT01830543|Drug|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
76055113|NCT01830543|Drug|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
76055114|NCT01830543|Drug|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
76055115|NCT01830543|Drug|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
76055116|NCT01830543|Drug|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
76055117|NCT01830543|Drug|clopidogrel|One 75 mg tablet once daily for up to twelve months
76055118|NCT01830543|Drug|prasugrel|One 10 mg tablet once daily for up to twelve months
75590746|NCT05319184|Other|Myofascial Release Technique and Kinesiology Taping|"Myofascial release is a manual release technique that increases the elasticity and glide between soft tissue layers, reduces this increased muscle activity and pain intensity. Myofascial release is usually characterized by prolonged mechanical forces exerted directly or indirectly on the limited fascial layers with low load. Following the direction of the fascial restraint, the therapist's hands slowly maintain the stretch and allow the fascia to relax on its own.~Kinesio Taping is a non-invasive, painless and less time consuming method with fewer side effects. It is an elastic-cotton adhesive tape that is latex-free and can be used on any joint or muscle. It can stretch significantly (130-140% of its original length), which reduces mechanical movement limitations and mimics skin in thickness and elasticity. It is used in the treatment of LBP to reduce muscle tone and stiffness as a rehabilitative taping technique designed to support the body's natural healing process."
75590747|NCT05318417|Device|The Cochlear™ Nucleus® Cochlear Implant (CI) System|"The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components.~Implanted component:~The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear.~External components:~The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®."
75590748|NCT05316168|Drug|Bupivacaine HCl 0.5% Injectable Solution|During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%
75590749|NCT05316168|Drug|Dexamethasone|During adductor canal block participants will receive 2mg Dexamethasone
75590750|NCT05316168|Procedure|Infiltration between Popliteal Artery and Capsule of the knee (iPACK)|Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone
75590751|NCT05316168|Drug|Percocet 5Mg-325Mg Tablet|Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control
75590752|NCT05306964|Procedure|Restrictive UFnet Rate Strategy|In the restrictive group, the UFnet rate will be titrated between 0.5-1.5 mL/kg/h and maintained throughout fluid removal.
76055119|NCT01830543|Drug|ticagrelor|One 90 mg tablet twice daily for up to twelve months
76055120|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
75590753|NCT05306964|Procedure|Liberal UFnet Rate Strategy|In the liberal group, the UFnet rate will be titrated between 2.0-5.0 mL/kg/h and maintained throughout fluid removal.
75590754|NCT05300191|Diagnostic Test|Effluent dialysate|Effluent dialysate samples evaluated for evidence of peritonitis
76055121|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
76055122|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
76055123|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
75440433|NCT01622205|Other|Ordinary rehabilitation|Ordinary rehabilitation
75440434|NCT01622218|Behavioral|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
75440435|NCT01622244|Other|Co-ordinated Access to Care from Hospital Emergency Departments|brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
75590755|NCT05298904|Diagnostic Test|Genetic Health Screen Panel|This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).
75590756|NCT05297487|Device|early use of intermittent positive pressure breathing|standard care associated with daily and early use of intermittent positive pressure breathing
75590757|NCT05295732|Drug|TMB-001|Topical TMB-001 0.05% QD/BID
75590758|NCT05295732|Drug|Matching Vehicle|Topical Vehicle
75590759|NCT05293509|Drug|Fludarabine|40 mg/m2/day i.v.- by vein
75590760|NCT05293509|Drug|Dexamethasone|25 mg/m2/day i.v.-by vein
75590761|NCT05293509|Drug|Cyclophosphamide|100 mg/m2 IV-by vein
75590762|NCT05293509|Drug|Bortezomib|Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
75590763|NCT05293509|Drug|Rituximab|Four doses of rituximab at a dose of 375 mg/m2- by vein
75590764|NCT05293509|Drug|Busulfan|110 mg/m2 i.v-by vein
75590765|NCT05293509|Drug|Cyclophosphamide (Cy)|by vein
75883619|NCT04408508|Drug|Amoxicillin 250 MG|Low dose oral amoxicillin will be administered to patients enrolled in the study meeting the inclusion and exclusion criteria.
75883620|NCT04399538|Drug|PF-06865571|Tablet
75883621|NCT04399538|Drug|PF-05221304|Tablet
75440436|NCT01622244|Other|Coordinated Access to Care from Hospital Emergency Departments|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
75440437|NCT01622244|Behavioral|Counseling and Resource Education|Participants will receive usual care as well as an educational session and resource guide outlining community-based services
75883622|NCT04399538|Drug|Placebo|Tablet
76055124|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
76055125|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
76055126|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
76055127|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
76055128|NCT02109133|Procedure|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
75440438|NCT01622270|Other|Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index|Indirect calorimetry test by a indirect calorimeter (OHMEDA) body composition by a DEXA machine blood tests, 3 days food records, Crohns disease activity index
75590766|NCT05293509|Drug|Tacrolimus (or cyclosporine)|by vein
75440439|NCT01622283|Drug|Levocetirizine|Levocetirizine
75440440|NCT01622283|Drug|Cetirizine|Cetirizine
75440441|NCT01622309|Dietary Supplement|eggplant meal|13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
75440442|NCT01622309|Other|cassava meal|13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
75590767|NCT05293509|Drug|Mycophenolate mofetil (MMF)|given by PO
75590768|NCT05293509|Drug|Rabbit ATG|by vein
75883623|NCT04359433|Behavioral|Exercise programme|"Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~8 anerobic movements in 20 seconds is a set~Rest for 10 seconds before another set~Finish 4 sets every time, it shall take you 4 minutes~Do 4 sets 2 to 3 times a week"
76055129|NCT02109133|Procedure|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
75440443|NCT01622361|Drug|Adriamycin+Cyclophosphamide>Docetaxel|"Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~Route: by slow intravenous bolus~Schedule: every 3weeks for 4 cycle~Docetaxel 75mg/m2~Route: intravenous as per local practice~Schedule: every 3weeks for 4 cycle"
75590769|NCT05292443|Other|Observation|observe the association of ctDNA with efficacy of treatment
76055130|NCT02109133|Drug|Rocuronium|
76055131|NCT02109133|Drug|Sugammadex|
76055132|NCT02109133|Drug|Atracurium|
76055133|NCT02109133|Drug|Neostigmine|
76055134|NCT01623271|Drug|Gabapentin|
75440444|NCT01622361|Drug|GnRHa with Tamoxifen|"Goserelin(GnRHa) 3.6mg~Route: subcutaneously under the abdominal skin~Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~Tamoxifen 20mg/day~Route: Oral~Schedule: everyday"
75590770|NCT05288790|Dietary Supplement|Probiotic|Dietary supplement
75590771|NCT05288790|Dietary Supplement|Placebo|Placebo sachet
75590772|NCT05286892|Other|Diabetes LIVE JustICE|Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
75440445|NCT01622374|Behavioral|Music|Ten minutes of music or silence were applied prior to dental procedures
75440446|NCT01622387|Procedure|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
75440447|NCT01622387|Procedure|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
75590773|NCT05286892|Other|Enhanced Education|See control group description above
75590774|NCT05284643|Radiation|Intensity Modulated Proton Therapy (IMPT)|Participants will receive radiation therapy delivered via intensity modulated proton therapy (IMPT) simultaneous integrated boost technique over a period of 10 days, 5 days per week for approximately 2 weeks.
75590775|NCT05284643|Drug|Bevacizumab|Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.
75590776|NCT05273736|Behavioral|5 Behavioral Change Techniques|"Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
75733872|NCT05478031|Drug|REM0046127 High Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days"
75883624|NCT04356261|Behavioral|Gamified Personalized Normative Feedback|Each week, all players will answer 3 questions of interest about first-year students' attitudes and behaviors (e.g., drinking, partying, exercising, studying, dorm life, etc.) generated by the student players. They will also guess how the typical same-sex student at their University answered the same questions and wager points on how close to the correct answer (group norm) each of their guesses is. Further, they will rate (e.g., thumbs up/thumbs down) the reported behaviors of other players and, then, submit and vote on questions for subsequent rounds. At the end of each week, players will receive enhanced personalized normative feedback feedback on two of the three questions, and receive feedback on how other students rated the answer they reported (preferred-sex injunctive norms).
75440448|NCT01622400|Other|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
75440449|NCT01622413|Procedure|joimax TESSYS|Transforaminal Endoscopic Surgery System
75440450|NCT01622413|Procedure|Microdiscectomy|Standard procedure for disc surgery
75440451|NCT01622426|Dietary Supplement|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
75440452|NCT01622426|Dietary Supplement|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
75440453|NCT01622439|Drug|Valproate|Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
75440454|NCT01622439|Drug|Rituximab|Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
75440455|NCT01622439|Drug|Cyclophosphamide|Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
75733873|NCT05478031|Drug|REM0046127 Low Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days"
75733874|NCT05478031|Drug|Placebo|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~Placebo: placebo oral suspension bid for 28 days and during the 14-days run-in phase"
75733875|NCT05476770|Drug|Tagraxofusp|Dose will be assigned at study entry. Give IV over 15 minutes.
75440456|NCT01622439|Drug|Doxorubicin|Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
75440457|NCT01622439|Drug|Vincristine|Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
75733876|NCT05476770|Drug|Fludarabine|"30 mg/m^2 will be given IV over 30 minutes on days 1-5.~Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5."
75733877|NCT05476770|Drug|Cytarabine|2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine.
75883625|NCT04342091|Device|SOL Nova Device|A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
75883626|NCT04333342|Device|heart rate monitoring using wearable devices|Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
75883627|NCT04332731|Device|Symplicity Spyral™ multi electrode renal denervation system|Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity Spyral catheter, Medtronic) and associated Symplicity G3™ renal denervation radiofrequency generator (Symplicity G3 generator, Medtronic) will be used in this study. The Symplicity Spyral™ multi-electrode renal denervation catheter is intended to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.
76055135|NCT01856673|Behavioral|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
76055136|NCT01856673|Behavioral|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
75590777|NCT05270369|Behavioral|digital CBTI|The app-based intervention will consists of 6 weekly sessions and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
75733878|NCT05476770|Drug|Dexamethasone|"20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.~Any oral formulation of dexamethasone is acceptable.~IV may be given if oral formulation is not tolerated"
75733879|NCT05476770|Drug|Vincristine|"1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.~Infusion will start 30 minutes after start of tagraxofusp on day 8."
75440458|NCT01622439|Drug|Prednisone|Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
75440459|NCT01622465|Behavioral|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
75440460|NCT01622465|Behavioral|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
75440461|NCT01622478|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
75440462|NCT01622478|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
75590778|NCT05270369|Behavioral|group CBTI|The group-based CBT-I intervention will consist of 6 weekly sessions (90-min, 5-8 adolescents in each group) and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
75440463|NCT01622478|Procedure|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
75590779|NCT05266911|Behavioral|high-intensity functional strength training|HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.
75590780|NCT05266911|Behavioral|Lower extremity stretching|Lower extremity stretching program to be completed by participants at home 3 days per week.
75590781|NCT05265000|Device|tSpinalStim|Patients will undergo 12-21 sessions of spinal cord stimulation therapy (30 minutes per session, 3 times a week). Up to five round stimulating electrodes will be placed on the skin midline between spinous processes in cervical, thoracic and/or lumbar region, as cathodes and rectangular pads will be placed symmetrically on the skin over the iliac crests as anodes. The stimulator generates pain-free biphasic rectangular waveform with 1 ms width pulses filled with 5-10 kHz (kilohertz) carrier frequency. A range of stimulation intensities from 0-250 mA (milliamps) may be used. We expect that the stimulation intensities needed for therapeutic effect may differ based on individual's body mass index and/or the amount of subcutaneous fat present at the stimulation site.
75590782|NCT05263362|Other|no intervention|At one timepoint patients will get physical examination of the breasts, medical photographs will be taken, and they will fill in five questionnaires about satisfaction of the breasts, quality of life and general health.
75590783|NCT05263206|Drug|Dupilumab|Injection solution subcutaneous
76055137|NCT01856673|Other|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
76055138|NCT02095951|Drug|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
76055139|NCT02095873|Dietary Supplement|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
75590784|NCT05263206|Drug|Placebo|Injection solution SC
75590785|NCT05263206|Drug|Fexofenadine (loratadine if not available)|Tablet or capsule Oral
75590786|NCT05263206|Drug|Moisturizer|Topical
76055140|NCT02095873|Dietary Supplement|Placebo|Mannitol, 108 mg
75440464|NCT01622478|Procedure|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
75590787|NCT05256472|Drug|AK104|anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
75590788|NCT05256472|Drug|axitinib|an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally
76055141|NCT02094937|Drug|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
75733880|NCT05476770|Drug|Azacitidine|"75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.~Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion."
75440465|NCT01622504|Drug|MVP005|2 mg single dose administered intranasally
75440466|NCT01622504|Drug|MVP005|4 mg single dose administered intranasally
75440467|NCT01622504|Drug|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
75440468|NCT01622556|Drug|Fludarabine|35 mg/m2 IV/day x 5 days
75440469|NCT01622556|Drug|Busulfan|.8 mg/kg IV Q6h x 8 doses
75440470|NCT01622556|Drug|Thymoglobulin|1.5 mg/kg/day x 3 days
75440471|NCT01622556|Radiation|Total Body Irradiation|150 cGy for 2 days
75440472|NCT01622556|Biological|Umbilical Cord Blood|Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
75440473|NCT01622608|Behavioral|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
76055142|NCT02094937|Drug|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
75440474|NCT01622621|Procedure|Sublobar Resection|Undergo surgery which removes a sublobar resection of the lung
75440475|NCT01622621|Radiation|Stereotactic Body Radiotherapy (SBRT)|54 Gy in 3 fractions
75440476|NCT01622634|Behavioral|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
75440477|NCT01622634|Other|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
75440478|NCT01622634|Other|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
75440479|NCT01622647|Other|Nasal Continuous Positive Airway Pressure (NCPAP)|Subjects will receive NCPAP
75440480|NCT01622686|Behavioral|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
75590791|NCT05240014|Device|Modular powered orthosis|This study will investigate modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. The central hypothesis is that high-torque, low-inertia motor systems controlled with energetic objectives will enable modular powered orthoses to partially assist the joints. High-torque electric motors combined with minimal transmissions can be freely rotated (i.e., backdriven) by human joints, allowing the use of an emerging torque control method called energy shaping to reduce the perceived weight/inertia of the body during any motion. By mounting these modular actuators to commercial orthoses, this technology will be easily prescribed/configured by clinicians.
75590792|NCT05238558|Biological|FMPV-1|Intradermal administration
75590793|NCT05238558|Biological|GM-CSF (as adjuvant)|Intradermal administration
75590794|NCT05237128|Behavioral|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
75590795|NCT05237128|Behavioral|Moderate-carbohydrate plate-method diet|"Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
76055143|NCT02094937|Drug|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
76055144|NCT02094937|Drug|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
76055145|NCT02094937|Drug|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
76055146|NCT02094937|Drug|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
76055147|NCT04724629|Biological|Ixekizumab|80 mg of IL-17 inhibitor
76055148|NCT04724629|Biological|Aldesleukin|1.5 million IU (low-dose) of IL-2
76055149|NCT04724629|Drug|Colchicine|0.5 mg of indirect IL-6 inhibitor
76055150|NCT04724629|Drug|Standard of care (SOC)|Active comparator (Corticoids and antiretrovirals)
75590796|NCT05236192|Behavioral|Take Root Home Visitation (TRHV)|TRHV is a home-visiting, standardized program that home visitors can use to structure their time spent with families during home visits.
75590797|NCT05236192|Behavioral|Services as Usual (SAU)|SAU includes an installation's current NPSP home visiting practice, which may vary across the installations participating in this study.
75733881|NCT05476770|Drug|Methotrexate|"Give intrathecally:~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients ≥9 years of age"
75733882|NCT05476770|Drug|Cytarabine IT|"Give intrathecally:~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients ≥3 years of age~If given as part of Triple IT Therapy:~AML Patients:~Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg"
75733883|NCT05476770|Drug|Hydrocortisone|"Given intrathecally.~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg~AML Patients:~Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg"
75733884|NCT05472337|Drug|Colchicine|Oral colchicine (1 mg loading dose followed by 0.5 mg 1 hour later, administered 6 to 24 hours before angioplasty, followed by 0.5 mg (1 comp.) per day for 6 weeks.
75733885|NCT05467046|Device|Smartwatch system|The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
75733886|NCT05463133|Drug|Sirolimus|Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
75733887|NCT05463133|Drug|Cyclophosphamide|Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
75733888|NCT05463133|Drug|Alemtuzumab|Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
75733889|NCT05463133|Drug|Busulfan|Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
75733890|NCT05463133|Biological|Pheripheral blood stem cells|Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
75883628|NCT04332731|Diagnostic Test|Renal angiogram|Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
75590798|NCT05235880|Other|Virtual reality based games|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes virtual reality based games aiming improvement on upper extremities, trunk and cognitive functions.
75590799|NCT05235880|Other|Conventional exercises|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes conventional physiotherapy approaches aiming improvement on upper extremities, trunk and cognitive functions.
75733891|NCT05463133|Drug|Emapalumab-Izsg|Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
75733892|NCT05463133|Drug|Tociluzumab|Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
75733893|NCT05463133|Drug|Total Body Irradiation|Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
75733894|NCT05462496|Procedure|Biopsy|Pre-treatment tumor biopsy
75733895|NCT05462496|Drug|FOLFIRINOX|"Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows*:~Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~Leucovorin**: 400 mg/m2 IV over 2 hours on Day 1, followed by,~5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3"
75733896|NCT05462496|Drug|Ciprofloxacin|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
75883629|NCT04327141|Behavioral|P-IF|Protein pacing and intermittent fasting
75883630|NCT04327141|Behavioral|HH|Heart Healthy
76055151|NCT04724395|Other|Hospitalization|Hospitalization in intensive care and non-intensive care units for COVID-19 followed by usual care
75733897|NCT05462496|Drug|Metronidazole|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
75883631|NCT04316026|Device|shock wave therapy|Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium
76055152|NCT04723537|Drug|Part A: Upamostat 200 mg|1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
75733898|NCT05462496|Drug|Pembrolizumab|Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
75883632|NCT04309864|Device|Use of CMAP app for education (in-hospital)|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
76055153|NCT04723537|Drug|Part A: Upamostat 400 mg|2 capsules, each capsule comprising 200 mg of upamostat
75440481|NCT01622764|Radiation|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
75440482|NCT01622777|Drug|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
75440483|NCT01622777|Drug|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
75590800|NCT05227937|Drug|Amikacin|patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients >120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
75590801|NCT05227144|Drug|ORIC-533|ORIC-533 once daily in consecutive 28-day cycles
75590802|NCT05225298|Behavioral|Offering SARS-CoV-2 test|A pragmatic cluster (facility-level) randomized clinical trial, comparing test-based screening performed at a static (every two weeks) frequency versus a dynamic frequency (ranging from once a week to once every four weeks) anchored to county COVID-19 case rates
75590803|NCT05219968|Drug|LYR-210|LYR-210 drug matrix (mometasone furoate)
75590804|NCT05219968|Drug|Sham procedure control|Sham procedure control
75590805|NCT05219968|Other|Background Therapy|Daily Saline Irrigation
75883633|NCT04309864|Device|Use of CMAP app (in-home)|The Veteran will use the CMAP system at home for two weeks during their daily routines.
75883634|NCT04290611|Drug|Enzalutamide|Enzalutamide for the treatment of prostate cancer or other solid tumors
76055154|NCT04723537|Drug|Part A and B: Placebo|1 or 2 capsules, each capsule a matching placebo
76055155|NCT04723537|Drug|Part B: Upamostat 200 or 400 mg|"Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days."
76055156|NCT04183465|Other|Health Education|Current gold standard in older patients admitted to hospital for MI. The group will receive a 20-minute session with one of the study physicians. Both the patient and relatives will attend these sessions. The study physician will stress the major issues related to a heart-healthy lifestyle and will explain the importance of PA as a powerful and independent factor to improve cardiovascular health and minimize cardiovascular risk. A detailed brochure explaining the benefits of physical activity will be provided to all patients
75440484|NCT01622790|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
76055157|NCT04183465|Other|Multi-domain lifestyle intervention|The intervention includes diet counselling, smoke cessation program, aggressive CV risk control and PA intervention. The PA intervention consisted of supervised sessions combined with an individualized home-based PA program. Centre-based sessions will be supervised by a sports physician and a nurse, and will take approximately 30 to 40 minutes, including a moderate standardized treadmill-walk, and strength and balance exercises. Based on the practice sessions, patients will receive a walking program to perform at home, unsupervised. The PA programs will be individualized, and consistent with current international recommendations. A selection of calisthenic exercises will be prescribed. Participants will be encouraged to perform the exercises three times per week (approximately 20 minutes). Adjustment of the type and intensity of the home-based PA regimen will be made at each visit. The PA program will be extensively described to the patient and family members.
75733899|NCT05462496|Procedure|Surgical Resection|Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
75733900|NCT05460741|Other|integrated exercise approach|Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.
75733901|NCT05460741|Other|educational program|educational program related to menstrual cycle will be given to females.
75733902|NCT05460676|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
75590806|NCT05219331|Procedure|Ventriculoperitoneal shunt|Treatment oh hydrocephalus
75590807|NCT05212181|Device|H-Man|H-Man device will be deployed to patients for onboarding and home-based training.
75590808|NCT05209750|Diagnostic Test|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (shortly called FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated tumour-associated fibroblasts as a marker of tumour stroma and indirectly as a marker of CRC.
75733903|NCT05460676|Other|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
75733904|NCT05460676|Other|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
75883635|NCT04283188|Behavioral|Dialectical behavioral therapy|Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
75733905|NCT05459818|Device|Viabahn implanted|An individual patient data analysis obtained from databases used in prospective studies that published results of patients treated with the latest generation heparin-bonded Viabahn in the femoropopliteal artery.
75733906|NCT05458284|Procedure|Real Acupuncture|Real Acupuncture weekly till taxane completion
75883636|NCT04279470|Drug|CAR T-cell and Cellular Therapies|Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy
75883637|NCT04261010|Procedure|Global/single cell gene expression profiles obtained from Synovial biopsies|Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.
75883638|NCT04217473|Biological|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
75440485|NCT01622790|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
75440486|NCT01622790|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
75440487|NCT01622803|Procedure|parallel stent|bilateral parallel stent insertion (right and left side)
75440488|NCT01622803|Device|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
75440489|NCT01622829|Procedure|"Prescription for Activity and individual instructions"|"Structured education. Prescription for Activity. This contains an exercise programme which consists of a 30 minutes muscle strengthening exercises to be performed at home at least three times per week and an endurance sports, chosen by the patient, to be performed at least 2 times per week. Additional the physiotherapists advise them in being more active during their individual daily life ( e.g. using a bike for short distances, regular walking, abandon the lift/escalator)."
75733907|NCT05458284|Other|Sham Acupuncture|Sham Acupuncture weekly till taxane completion
75883639|NCT04204668|Procedure|TMR|Surgical procedure to connect injured proximal nerve stumps to motor nerve branches directly innervating a muscle
75883640|NCT04204668|Procedure|RPNI|Surgical procedure to wrap the ends of injured nerves in small muscle grafts
75883641|NCT04204668|Procedure|VDMT|Surgical procedure that creates a small muscle graft that is both denervated and vascularized, which will then receive the damaged nerve ending
75733908|NCT05457010|Biological|SPRX002|"SPRX002 is a soluble protein with a TAG region to which ARC-T cells bind and a binding region targeting CD123"
76055158|NCT02093923|Drug|DX-2930|Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary [CHO] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
76055159|NCT02093923|Drug|Placebo|Participants will receive matching placebo subcutaneously.
76055160|NCT02186561|Device|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
76055161|NCT02066467|Device|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
76055162|NCT02186171|Biological|Romosozumab|Administered by subcutaneous injection once a month.
75440490|NCT01622829|Other|"Prescription for Activity, without instructions"|"Prescription with exercise programme. Prescription for activity. This contains an exercise program consisting of 30 minutes of muscle strengthening exercises to be performed at home at least three times per week, the patient also needs to perform in an endurance sport at least two times per week."
75440491|NCT01622829|Other|usual physiotherapy|physiotherapy, treatment as usual
75440492|NCT01622855|Behavioral|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
75590809|NCT05208879|Biological|Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only)|"Carotenoid status will be determined by measuring plasma and erythrocyte concentrations of lutein and zeaxanthin obtained during an annual blood draw. These molecules will be analyzed by high performance liquid chromatography.~The oxidative stress markers will be measured, in the blood sample already collected, thanks to specific assay kits: Erythrocyte reduced glutathione, Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Plasma and erythrocyte malondialdehyde, Plasma vitamin C, Plasma oxidized cholesterol, F2-isoprostanes.~This study does not result in any change in patient management, but requires the collection of an additional volume of blood (14 ml of study-specific blood) during the annual blood draw performed as part of routine patient follow-up."
75590810|NCT05208879|Other|Characterization, evaluation and comparison of macular pigment density|The macular pigment optical density (OD) will be determined by an additional photograph during the fundus usually performed for annual follow-up through two-wavelength autofluorescence imaging. Indeed, the measurement of the optical density consists of an additional post-examination analysis of additional retinal images obtained during the fundus performed for the patients' ophthalmologic follow-up.
75590811|NCT05201313|Drug|Lidocaine Hydrochloride|nebulization of 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
76055163|NCT02186171|Drug|Placebo|Administered by subcutaneous injection once a month.
76055164|NCT02186015|Drug|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
76055165|NCT02066389|Drug|Placebo|Tablets for oral administration
76055166|NCT02066389|Drug|Upadacitinib|Tablets for oral administration
75440493|NCT01622881|Drug|Normal saline|Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
75440494|NCT01622881|Drug|Nefopam|Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
76055167|NCT02106403|Other|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
76055168|NCT02106403|Other|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
76055169|NCT02106403|Other|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
76055170|NCT02133131|Drug|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
75440495|NCT01622920|Other|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
75440496|NCT01622933|Biological|DC Vaccine + IFN|"Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks."
76055171|NCT02133131|Drug|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
76055172|NCT02106325|Drug|Ketamine|IV of Ketamine (.25mg/kg)
76055173|NCT02106325|Drug|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
76055174|NCT01625689|Biological|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
76055175|NCT01625689|Biological|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
75733909|NCT05457010|Biological|ARC-T Cells|"ARC-T Cells is a genetically modified autologous T-cell product. The T cell has a binding domain chimeric antigen receptor (CAR), which specifically binds to the TAG protein of the soluble protein antigen-receptor x-linker (sparX; specifically, SPRX002). When ARC-T cells bind to a TAG and the SPRX protein is bound to its target (in this case CD123), ARC-T cells are capable of activation, expansion, and killing (based on preclinical experiments)."
75733910|NCT05455138|Procedure|Arterial bypass grafting|Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease
75883642|NCT04435340|Diagnostic Test|Selective Sonography of the ventral abdominal hernia level|The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
75733911|NCT05453630|Behavioral|Patient Navigation|Patients will receive navigation from a trained lay navigator at a community-based nonprofit organization that supports access to high quality healthcare. The patient navigator will work with patients to schedule their colonoscopy and identify, explore, and overcome barriers. They will educate patients about the colonoscopy procedure and preparation, provide resources, and coach and motivate patients.
75733912|NCT05453630|Behavioral|Usual Care Control|Educational brochure about colonoscopy
75733913|NCT05447910|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
75733914|NCT05447910|Drug|Letrozole|Given PO
75440497|NCT01622933|Biological|AdVTMM2/DC Vaccination|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
75440498|NCT01622946|Drug|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
75440499|NCT01622946|Drug|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
75440500|NCT01622959|Procedure|Acupuncture|"-Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%. Treatment failure is defined as VAPS>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion."
75590812|NCT05201313|Drug|Mepivacaine Injection|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
75590813|NCT05200988|Drug|Ipilimumab + nivolumab|"Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy"
75590814|NCT05199766|Drug|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease|This is an open-label, single-arm, single-stage phase II trial of voxelotor in patients with sickle-cell disease. Voxelotor 500mg tablets. Voxelotor will be administered as 500mg tablets orally once daily. The participant should always take all 3 tablets in a row at the same time each day, unless the study doctor has instructed them to adjust the dose.
75590815|NCT05199753|Drug|LM-108|Administered intravenously
75590816|NCT05199753|Drug|An Anti-PD-1 Antibody|Administered intravenously
75590817|NCT05198934|Drug|Sotorasib|Sotorasib will be administered orally
75883643|NCT04181515|Drug|Placebo oral tablet|placebo stressor
75883644|NCT04181515|Drug|Yohimbine + Hydrocortisone|Yohimbine 54mg + Hydrocortisone 20mg
75733915|NCT05445830|Procedure|High-Intensity-Interval-Exercise|Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
75733916|NCT05445830|Procedure|Moderate-Intensity-Continuous-Exercise|Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
75733917|NCT05445830|Procedure|Strength training|Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
75883645|NCT04181515|Device|sham rTMS|sham rTMS (inactive coil)
75440501|NCT01622972|Drug|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
75440502|NCT01623011|Procedure|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
75590818|NCT05198934|Drug|Panitumumab|Panitumumab will be administered as intravenous (IV) infusion
75883646|NCT04181515|Device|active rTMS|active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)
75590819|NCT05198934|Drug|Trifluridine and Tipiracil|Trifluridine and Tipiracil will be administered orally
75590820|NCT05198934|Drug|Regorafenib|Regorafenib will be administered orally
75590821|NCT05195918|Combination Product|EGCG 300 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
75590822|NCT05195918|Combination Product|EGCG 300 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
75883647|NCT04180969|Drug|yohimbine + hydrocortisone|yohimbine 54mg + hydrocortisone 20mg oral
75883648|NCT04180969|Device|medial prefrontal cortex rTMS|1 Hz mPFC rTMS
75883649|NCT04180969|Drug|Placebo oral tablet|placebo stressor
75883650|NCT04180969|Device|sham rTMS|sham mPFC rTMS
75590823|NCT05195918|Combination Product|Placebo 2 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
75590824|NCT05195918|Combination Product|EGCG 600 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
75590825|NCT05195918|Combination Product|EGCG 600 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
75590826|NCT05195918|Combination Product|Placebo 4 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
75590827|NCT05192382|Drug|Paltusotine|Paltusotine, tablets, once daily by mouth
75590828|NCT05192382|Drug|Placebo|Placebo, tablets, once daily by mouth
75590829|NCT05188872|Diagnostic Test|68Ga-Pentixafor|Each patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
75590830|NCT05184348|Radiation|Narrow band Ultraviolet B phototherapy group|3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
75590831|NCT05184348|Drug|Acitretin group|dose of 0.5-1 mg per kg per day orally for 3 month.
75590832|NCT05184348|Combination Product|Acitretin plus Narrow band Ultraviolet B phototherapy group|Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
75733918|NCT05445830|Procedure|Baseline assessment|Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
75883651|NCT04172649|Other|Acupuncture|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack needles (diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
75883652|NCT04172649|Other|Acupressure|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack placebos (knob without needle, diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
76055176|NCT02184611|Drug|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
76055177|NCT02184611|Drug|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
76055178|NCT02066311|Drug|Nelfinavir|
75733919|NCT05445830|Procedure|1 year follow-up|Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
75733920|NCT05445557|Drug|RZL-012|small synthetic molecule for submental fat reduction
75733921|NCT05445557|Drug|Placebo|Placebo
75883653|NCT04131725|Device|Cardiac Performance System (NSR)|Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
75733924|NCT05439161|Device|surgery|2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study
75440503|NCT01623011|Procedure|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
75590833|NCT05184270|Device|Acoustic stimulation|"In this project, the intervention is a presentation of low-volume non-arousing auditory stimuli during deep NREM sleep via attached headphones. Stimuli will be applied targeting the up-phase of slow waves to enhance sleep slow-wave activity.~Previous studies showed that this procedure does not lead to reduced sleep quality nor result in changed sleep architecture. Therefore, no negative consequences as a result of our intervention are to be expected. In fact, it is currently applied in several other studies including children, adults, and the elderly. Importantly, stimulation is not arousing, as the sounds presented during deep sleep are brief (50 ms) and at low volume (around 50 dB). In case of arousal during sleep (detected using the surface EEG signal), the volume will be adjusted."
75733925|NCT05436106|Behavioral|Adaptive Intervention Approach|"This is an adaptive intervention approach with 7 module-based sessions selected on the basis of post-session assessments of acceptability and satisfaction;~weekly group sessions will be co-led by a community member with expertise in working with transgender women and a public health nurse,~supplemental educational content will be available for individual consumption via an online portal or application (and tracked via participant click counts), and~additional social resources will be available through the online portal or app."
75733926|NCT05429645|Procedure|setting up of the pace maker|Setting up of a pace maker using a 3-dimensional (3D) guidance technique
75733927|NCT05428982|Procedure|Postoperative Modified Trendelenburg position|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours at ward.
75733928|NCT05428956|Procedure|Single Inhalation technique|Single maximal inhalation with breath hold technique
75733929|NCT05428956|Procedure|Tidal inhalation technique|5 tidal breaths technique
75883654|NCT04128969|Dietary Supplement|CS+|Oral carnitine supplementation
75883655|NCT04128969|Dietary Supplement|CS-|Placebo
75883656|NCT04123470|Genetic|delolimogene mupadenorepvec|LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL
75883657|NCT04123470|Biological|atezolizumab|Atezolizumab is an anti-PD-L1 antibody
75883658|NCT04099810|Diagnostic Test|three-dimensional echocardiography|"A focused echocardiographic exam will be performed. In details will be acquired:~high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition."
75883659|NCT04097314|Drug|Zibotentan|10mg OD Zibotentan
75883660|NCT04097314|Drug|Placebo oral tablet|Placebo
75883661|NCT04080518|Drug|Dapagliflozin 10 MG [Forxiga]|24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
75883662|NCT04074811|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will use the Figure of 8 coil, which affects ~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on >50% of trials.
75883663|NCT04060108|Drug|MDMA|80mg, 120mg, Placebo
76055179|NCT02184455|Biological|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
75733930|NCT05428384|Device|MRI/ CardioMEMS comparison|Each subject will have CardioMEMS readings paired with MRI scans
75440504|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
75440505|NCT01623024|Drug|Vitamin D|20.000 UI/week for 96 weeks
75440506|NCT01623024|Behavioral|Lifestyle counseling|Lifestyle counseling for 96 weeks
75440507|NCT01623063|Procedure|Hysteroscopy|hysteroscopy with guided biopsies
75440508|NCT01623102|Drug|cisplatin and gemcitabine combination with Bevacizumab|Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
75440509|NCT01623102|Drug|Gemcitabine combined with cisplatin chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
75883664|NCT04043936|Behavioral|Cognitive Bias Modification Intervention for Help-Seeking Stigma|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
75590834|NCT05183412|Device|The Sedakit Oncomfort VR glasses (30-minutes Aqua program)|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone. The patients watch a VR underwater view of the ocean while listening to speeches to induce relaxation and meditation.
75590835|NCT05183412|Procedure|Ultrasound-guided regional nerve block and hand surgery without VR glasses|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are NOT subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone.
75590836|NCT05183412|Procedure|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Ultrasound-guided regional nerve block and hand surgery with VR glasses
75440510|NCT01623128|Behavioral|Prenatal video|Participants are randomized to view either the intervention video or a sham video.
75440511|NCT01623141|Procedure|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
76055180|NCT02184143|Behavioral|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
76055181|NCT02184143|Other|Education|Patient education
75440512|NCT01623180|Device|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
75590837|NCT05182125|Biological|AdC6-HIVgp140|"The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS [tris(hydroxymethyl)aminomethane], pH 8.0 formulation buffer to a concentration of 1.2 x 10^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB)."
75590838|NCT05182125|Biological|AdC7-HIVgp140|"The products is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS [tris(hydroxymethyl)aminomethane], pH 8.0 formulation buffer to a concentration of 1.2 x 10^11 vp/mL and filled at 0.6 mL for AdC7-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC7-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the IB."
75590839|NCT05182125|Biological|CH505TF gp120|"CH505TF gp120 is formulated in 20 mM sodium phosphate, 150 mM NaCl, 0.02% polysorbate 80 (PS80), pH 6.5, supplied as a frozen liquid in 2 mL glass vials. Each 2 mL vial contains 0.75 mL of formulated gp120 at a concentration of 0.8 mg/mL and is stored at ≤ -65°C.~The study product is described in further detail in the IB."
75440513|NCT01623180|Device|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
75440514|NCT01623206|Drug|Desmopressin|"Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion."
75590840|NCT05182125|Biological|GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])|The GLA-SE adjuvant will be provided as vials containing 20 mcg/mL GLA in a 4% oil-in-water emulsion. Each sterile, single use vial contains 0.4 mL of product. Product appears as a milky-white liquid. GLA-SE must be stored at 2° to 8°C and must not be frozen. The study product is described in further detail within the IB.
76055182|NCT01625611|Drug|Naltrexone|Naltrexone 100 mg titrated over one week
75590841|NCT05182125|Biological|Placebo|Placebo will be Sodium Chloride for Injection, 0.9%, will be used as the placebo. It must be stored as recommended by the manufacturer.
75733931|NCT05425823|Other|Health Belief Model Based Intervention|In intervention group-1, Information Form and PAVS-HBM will be applied as a pre-test to pregnant women who have completed their 28th gestational week. Childhood Vaccination Training Based on the Health Belief Model will be given in the prenatal period by organizing 2 face-to-face and individual sessions for the researcher's pregnant women. Each session will take approximately 30-45 minutes, with each session being in a different week. In addition, at the end of each session, HBM-based short messages will be sent to the pregnant woman's husband and recorded with the Short Message Tracking Form. Intervention group-2 will receive the same training, but no text messages will be sent.
75733932|NCT05425537|Other|Drowning accident|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
75733933|NCT05422690|Drug|Induction Chemotherapy Triplet Therapy|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2, Nab-paclitaxel 125 mg/m2 given on days 1 and 8 of a 21-day cycle for two cycles.
75883665|NCT04043936|Behavioral|Placebo Cognitive Bias Modification (CBM-Placebo)|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
75733934|NCT05422690|Radiation|Concurrent Y-90 treatment|One or two cycles (depending on whether or not one or two sessions of yttrium-90 are indicated as per the treating interventional radiologist) of gemcitabine 300 mg/m2 and cisplatin, 25 mg/m2 given on day 1 and 8 of a 21-day cycle. Y-90 will be administered on day 3-7 or day 10-21 of the cycle.
75733935|NCT05422690|Drug|Consolidation Doublet Therapy:|Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle for 4-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
75883666|NCT04043936|Behavioral|Self-Directed Psychoeducation|Material presented with information on mental health literacy, mental health stigma, & treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
75733936|NCT05415709|Drug|Carboplatin|Given IV
75733937|NCT05415709|Drug|Cisplatin|Given IV
75883667|NCT04042766|Procedure|laser vaginal treatment|Er:YAG laser
75883668|NCT04036123|Other|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
75883669|NCT04023773|Device|Liver Machine Perfusion (MP) device|Donor livers will have ex vivo continuous perfusion on the institutional-developed Liver MP device. The temperature of liver grafts will be controlled during perfusion.
75883670|NCT04017598|Dietary Supplement|Ferrous sulfate|60 mg elemental iron as ferrous sulfate
75883671|NCT04017598|Dietary Supplement|Ferrous Bisglycinate|18 mg elemental iron as ferrous bisglycinate
75883672|NCT04017598|Dietary Supplement|Placebo of microcrystalline cellulose|placebo
75883673|NCT04014803|Drug|Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin|"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~Prasugrel plus Aspirin arm~Clopidogrel plus Aspirin arm"
75883674|NCT04011371|Procedure|Cyanoacrylate closure|Cyanoacrylate glue embolization targeting venous insufficiency
75590842|NCT05181371|Procedure|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB) for VATS|Programmed Intermittent Bolus (PIB) of Levobupivacaine
75590843|NCT05181371|Procedure|Ultrasound Guided ESP Block with Continuous Infusion (CI) for VATS|Continuous Infusion (CI) of Levobupivacaine
75590844|NCT05179122|Procedure|Surgical drain|In this arm a surgical drain will be inserted prior to surgical wound closure
75590845|NCT05174988|Procedure|Angle stitch|Surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) vaginal cuff apexes.
75733938|NCT05415709|Procedure|Cytoreductive Surgery|Undergo CRS
75733939|NCT05415709|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
75733940|NCT05415709|Drug|Paclitaxel|Given IV
75733941|NCT05415709|Other|Quality-of-Life Assessment|Ancillary studies
75733942|NCT05415709|Other|Questionnaire Administration|Ancillary studies
75590846|NCT05172648|Other|oral spry|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength.
75590847|NCT05172648|Other|Cotton swab|Moisten the mouth with sterile distilled water with an oral cotton swab.
75590848|NCT05166629|Behavioral|Eatable Alphabet|Eatable Alphabet is a set of kitchen activity cards developed by ChopChop Family, in collaboration with the American Academy of Pediatrics, with funding from the CDC (https://www.chopchopfamily.org/eatable-alphabet/). It includes a series of alphabet cards with family-friendly recipes.
75590849|NCT05166629|Behavioral|Usual Care|Please see above description of usual care.
75733943|NCT05413616|Behavioral|FITFOOD lifestyle intervention|Lifestyle intervention with a nutritional and exercise component.
75733944|NCT05409872|Dietary Supplement|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
75733945|NCT05409872|Other|Placebo|The subject takes the placebo twice a day for three months.
75733946|NCT05404425|Procedure|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
75733947|NCT05404425|Procedure|Control|For patients randomized in the control group, the evaluation is performed by the Emergency Medical Call Center physician only by pone call
75733948|NCT05404100|Procedure|Aortic valve replacement|SAVR or TAVR
75590850|NCT05165238|Behavioral|Impact of four week coaching program on dietary habits|A registered dietitian will provide dietary coaching via online groups to participants.
75590851|NCT05159908|Drug|NBI-921352|Tablets for oral administration
75733949|NCT05401903|Other|Chiropractic Maintenance Care|"Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study."
75590852|NCT05159908|Drug|Placebo|Matching placebo tablets for oral administration
75883675|NCT04007471|Other|Anonymous survey|Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
75883676|NCT03994302|Drug|Drug inducing antiphospholipid syndrome|Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
76055183|NCT02159807|Drug|Bupivacaine|The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.
75440515|NCT01623219|Behavioral|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
75590853|NCT05156957|Other|physiotherapeutic intervention|The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.
75590854|NCT05156944|Other|physiotherapeutic intervention|"The intervention consists of a brief physiotherapeutic assessment, the short physical performance battery, a brief information on the expected course of the condition, a check of fall hazards at home using the Bundesamt für Unfallverhütung (bfu) checklist, and instructions on self-management (eg. staying active, adaptation of behavior and surrounding at home). Additionally, two exercises for daily self-guided therapy will be instructed, namely, sit-to-stand and balance performance exercises."
75590855|NCT05147675|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75590856|NCT05147376|Drug|Curcumin mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
75590857|NCT05147376|Drug|Placebo mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
75590858|NCT05140083|Drug|68Ga-NOTA Evans Blue|Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.
75590859|NCT05139264|Other|Observational|Observation of diet, physical activity, sleep and interstitial glucose
75590860|NCT05135169|Drug|Definity Suspension for Injection|Administration of Definity
75590861|NCT05131100|Drug|Somavert|As provided in real world practice
75590862|NCT05127174|Drug|Fedratinib Pill|Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
75590863|NCT05126563|Biological|HB-adMSCs (allogeneic)|HB-adMSCs allogenic
75440516|NCT01623232|Biological|MAS-1 adjuvant and influenza HA antigen|"Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.~Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).~Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.~Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS."
75590864|NCT05126563|Other|Placebo|Placebo comarator
75590865|NCT05126472|Drug|2141-V11|All subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks, at weeks 1 (±3 days), 2 (±3 days), and 3 (±3 days) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points. Dose escalation of 2141-V11 will proceed incrementally from the initial dose of 0.7 mg to doses of 2 mg, 7 mg, 21 mg, and 70 mg using an MCRM design to assess AEs/DLTs (according to CTCAE version 5.0) and to determine the MTD and/or a RP2D. There will be no intra-patient dose escalations or dose reductions of 2141-V11. Subjects with evidence of HG disease at the week 25 evaluation will not continue on treatment, but be followed on study for survival data.
75733950|NCT05390775|Behavioral|Written Exposure Therapy (WISE)|WISE consists of five weekly sessions. At session one, the therapist will provide psychoeducation about PTSD, rationale for the proposed intervention, and then instructions for writing about their traumatic experience during each session. Psychoeducation and treatment rationale are scripted to ensure consistency. The participant will be instructed to write about the same trauma memory (their recent MVC) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report SUDs levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
75883677|NCT03985189|Drug|ME-401|"[Phase 1 study (DLT evaluation)] ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.~[Roll over study] 60 mg ME-401 will be administrated on intermittent schedule (1 week on and 3 week off in every 4-week cycle)and will continue until the prescribed mediation in ME-401-004 study is completed or discontinuation criteria are met."
75590866|NCT05122247|Other|Machine learning algorithm|machine learning directed identification of chemotherapy patients at high-risk for emergency department acute care and/or hospitalization
75590867|NCT05118854|Drug|AMG 510|Given by IV
75883678|NCT03978481|Combination Product|Helicobacter pylori eradication (combination therapy)|Antibiotic eradication therapy (triple or quadriple regimen)
75883679|NCT03959410|Diagnostic Test|Cervical biopsy|in office Cervical biopsy
75883680|NCT03945903|Drug|Golimumab|Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
75883681|NCT03943589|Drug|Imlifidase|All subjects will receive imlifidase (Day 1) prior to standard care IVIg
75883682|NCT03937219|Drug|Cabozantinib|Specified dose on specified days.
75883683|NCT03937219|Biological|Nivolumab|Specified dose on specified days.
75590868|NCT05118854|Drug|Cisplatin|Given by IV
75590869|NCT05118854|Drug|Carboplatin|Given by IV
75590870|NCT05118854|Drug|Pemetrexed|Given by IV
75590871|NCT05116007|Drug|AK112|IV infusion
75883684|NCT03937219|Biological|Ipilimumab|Specified dose on specified days.
75883685|NCT03937219|Drug|Cabozantinib-matched placebo|Specified dose on specified days.
75883686|NCT03918460|Device|ANEUFIX|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
75883687|NCT03905148|Drug|Lifirafenib|RAF Dimer Inhibitor
75883688|NCT03905148|Drug|mirdametinib|MEK Inhibitor
75883689|NCT03869268|Drug|Aspirin|Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
76055184|NCT02159807|Drug|Fentanyl|20 micrograms routinely administered in combination in the spinal anesthetic
76055185|NCT02066233|Device|EG Scan II (transnasal endoscopy)|
75440517|NCT01623232|Biological|standard dose, inactivated trivalent influenza vaccine (TIV)|"Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.~4. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains."
75440518|NCT01623284|Drug|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of [N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
75440519|NCT01623284|Drug|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of [18-F]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
75590872|NCT05116007|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
75440520|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
75733951|NCT05390775|Behavioral|Non-emotional Writing|Following randomization, the first session for the control writing condition will be conducted as follows, which is detailed in a structured manual for therapists. The therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did yesterday from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. As discussed, the participant will self-report Subjective Unites of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
76055186|NCT02066233|Procedure|Standard Endoscopy|
76055187|NCT04755491|Device|Continuous veno-venous hemofiltration|Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
76055188|NCT04755491|Device|Continuous veno-venous hemodialysis|Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
75440521|NCT01623336|Drug|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
75440522|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
75590873|NCT05116007|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
75590874|NCT05114161|Other|Novel Care Pathway|The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP > 60mg/L will be deemed 'appreciable risk' while patients with CRP < 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of <95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.
76055189|NCT04755491|Device|Continuous veno-venous hemodiafiltration|Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
75590875|NCT05114005|Behavioral|Rhythmic Auditory Stimulation|Rhythmically-entrained sensorimotor activity.
75590876|NCT05114005|Behavioral|Evidence-Based Exercise|This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hr training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
75733952|NCT05387655|Biological|BCG|BCG vaccination
76055190|NCT02159729|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
76055191|NCT02159729|Drug|ATX-101 (1 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
75440523|NCT01623349|Drug|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
76055192|NCT02159729|Drug|ATX-101 (2 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
76055193|NCT02159729|Drug|ATX-101 (4 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
76055194|NCT04749563|Drug|IGC AD1|IGC AD1 oral Solution
76055195|NCT04749563|Drug|Placebo|Placebo of IGC AD1 oral Solution
76055196|NCT02159183|Device|Standard Plus ESTA STL Roxolid implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
75440524|NCT01623349|Drug|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
75440525|NCT01623362|Other|Low-fluoride acidic dentifrice|550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.
75440526|NCT01623362|Other|conventional dentifrice|1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months
75440527|NCT01623362|Other|neutral pH and low-fluoride dentifrice|500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
75733953|NCT05387655|Biological|Placebo vaccine|Placebo vaccination
75883690|NCT03869268|Drug|Ticagrelor|Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
75883691|NCT03868397|Diagnostic Test|Liver MRI|"Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique."
75883692|NCT03845465|Behavioral|Positive Affect + Education|Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
75883693|NCT03845465|Behavioral|Education|Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
76055197|NCT02159183|Device|Standard Plus STL implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
76055198|NCT02183675|Drug|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
75440528|NCT01623375|Drug|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
75883694|NCT03843463|Drug|Escitalopram 10mg|Escitalopram tablet
75883695|NCT03843463|Drug|Placebo|Sugar pill manufactured to mimic escitalopram 10 mg tablet
76055199|NCT02183675|Drug|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
75440529|NCT01623375|Drug|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
75590877|NCT05112289|Diagnostic Test|Brain Neuroimaging|Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
75590878|NCT05107726|Behavioral|TRE Group|This group will practice time-restricted eating
75590879|NCT05104476|Drug|Lu AF82422|Solution for infusion
75590880|NCT05104476|Drug|Placebo|Solution for infusion
76055200|NCT02183675|Drug|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
76055201|NCT02183519|Drug|Capsaicin|For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.
76055202|NCT02183519|Other|Voluntary cough test|Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.
76055203|NCT02132195|Drug|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
76055204|NCT02182973|Dietary Supplement|donor human milk|"Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.~GI-subscores from the Finnegan NAS Scoring system will be computed."
76055205|NCT02182895|Drug|Saxagliptin|2.5-5 mg daily
76055206|NCT01625377|Drug|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
75883696|NCT03843463|Behavioral|Computer-delivered naming treatment|15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
75883697|NCT03828942|Drug|drug inducing hematological toxicity|Drugs susceptible to induce hematological toxicities
75883698|NCT03826433|Biological|Peripheral iv|6*10^7 cells
75883699|NCT03816852|Biological|hucMSCs|Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
76055207|NCT01625377|Drug|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
75440530|NCT01623388|Procedure|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
75440531|NCT01623401|Drug|TR-701 FA|TR-701 FA 200 mg once daily
75440532|NCT01623427|Procedure|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
75440533|NCT01623427|Procedure|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
75590881|NCT05095376|Drug|Lomustine|Given PO
75590882|NCT05095376|Radiation|Photon Beam Radiation Therapy|Undergo radiation therapy
75590883|NCT05095376|Other|Quality-of-Life Assessment|Ancillary studies
75590884|NCT05095376|Other|Questionnaire Administration|Ancillary studies
75590885|NCT05095376|Drug|Temozolomide|Given PO
75733954|NCT05385653|Behavioral|"experimentation of the virtual reality RevBED"|"ReVBED is a VR-based exposure scenario for CBT for the induction of food craving in patients with bulimia nervosa and binge eating disorder.~The use of ReVBED requires no VR experience and only generic and commonly used virtual reality tools (a computer with VR software, a wireless virtual reality headset, two controllers and headphones), all with a CE mark, allowing its users to move in and interact with a specially designed virtual environment.~This exhibit scenario takes place in a VR environment built to represent a standard apartment consisting of four exhibit rooms (a bedroom, a teenager's bedroom, a living room and a kitchen) in which the ReVBED user moves sequentially through the scenario. In each room, specific cues of craving are displayed. These cues are not only visual, but also audio, emotional and socio-environmental. A central hall connects the other rooms and serves as a safe place for debriefing, where measures such as craving are assessed."
75733955|NCT05383456|Diagnostic Test|Diagnostic Test|Standard diagnostic tests.
75733956|NCT05383456|Drug|HIV Anti-retroviral Background Therapy|"All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study."
75733957|NCT05378893|Drug|DR10624 for injection|administered via subcutaneous injection
75440534|NCT01623440|Combination Product|Placebo and fMRI|Pill form, participant dosed one time an hour before fMRI.
75590886|NCT05090696|Device|Mechanical In-Exsufflator (MI-E)|The feasibility will be estimated by quantifying relief and discomfort of four MI-E sessions (2 days x 2 sessions = 4 sessions). Vital signs will be also noted before and after such MI-E session.
75590887|NCT05090358|Dietary Supplement|Ketogenic Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
75590888|NCT05090358|Dietary Supplement|Low Carbohydrate Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
75590889|NCT05090358|Drug|Alpelisib|The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
75590890|NCT05090358|Drug|Fulvestrant|"The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter."
75733958|NCT05378893|Drug|Placebo|administered via subcutaneous injection
75733959|NCT05374590|Biological|Efgartigimod IV or Efgartigimod PH20 SC|Intravenous infusion of Efgartigimod or Subcutaneous injection of Efgartigimod PH20 SC
75733960|NCT05367024|Other|Broccoli soup|Participants will consume one broccoli soup three times a week for one 12-week intervention period as part of their normal diet.
75733961|NCT05367024|Other|Courgette soup|Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
75733962|NCT05365490|Procedure|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
75733963|NCT05364580|Biological|PROTOXIN|Botulinum toxin Type A
75733964|NCT05364580|Biological|Botox®|Botulinum toxin Type A
75733965|NCT05361343|Other|1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement|"Nutrition: intermittent fasting;~Physical activity: medium-intensity or high-intensity physical activity;~Hypoxic training (at least three per visit to the center);~correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~Individual motivational counseling."
76055208|NCT01625377|Drug|Basiliximab|Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
76055209|NCT01625377|Drug|Mycophenolic Acid|Dose of 1440 mg/day from transplantation to month 6 post- transplantation
76055210|NCT01625377|Drug|Corticosteroids|Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
75440535|NCT01623440|Combination Product|Naltrexone and fMRI|50 mg pill given one time, one hour before fMRI
75440536|NCT01623453|Biological|Autologous adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
75440537|NCT01623453|Biological|Autologous adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
75440538|NCT01623492|Other|Subjects with diagnosis of Eisenmenger Syndrome|"Antibiotic recommendation for SBE prophylaxis and influenza vaccine~Contraception counseling, and recommendations regarding avoidance of pregnancy~Documentation and prescription of the specific medications:~Oxygen~Diuretic~ASA, Anticoagulant~CCB, BB, ACEI, ARB~Iron Supplementation~Allopurinol~PAH specific therapy"
75440539|NCT01623505|Drug|Champix|"Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
75590891|NCT05090358|Drug|Canagliflozin|Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
75590892|NCT05087888|Procedure|Biospecimen Collection|Undergo collection of blood samples
75590893|NCT05087888|Procedure|Magnetic Resonance Imaging|Undergo functional MRI
75733966|NCT05359081|Drug|SEP-363856|SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
75883700|NCT03808467|Behavioral|Cognitive Remediation Therapy|Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
75590894|NCT05087888|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
75733967|NCT05358860|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
75733968|NCT05358847|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
75590895|NCT05087888|Other|Questionnaire Administration|Complete questionnaires
75590896|NCT05084560|Drug|AWZ1066S|Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
75590897|NCT05084560|Drug|Placebo|Placebo
75590898|NCT05083546|Drug|Gly-low|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
75590899|NCT05083546|Other|Placebo|sugar pill
75733969|NCT05358327|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
75733970|NCT05358145|Behavioral|Tinkering Activities|Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
76055211|NCT02158949|Behavioral|mROAD|
76055212|NCT02132117|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
76055213|NCT02132117|Drug|Vehicle to Oxymetazoline HCL Cream|Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
75590900|NCT05083312|Drug|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
76055214|NCT02093689|Drug|Part 1 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
75590901|NCT05083312|Drug|Placebo oral tablet|Placebo orally disintegrating tablet
75590902|NCT05080946|Drug|Aspirin 325mg|"Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
75590903|NCT05080946|Drug|Placebo|"Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
75590904|NCT05080920|Dietary Supplement|Rosmalip®|Nutritional Supplement+Usual Care
75590905|NCT05080920|Other|Placebo|Placebo+Usual Care
75440540|NCT01623505|Drug|Transdermal Nicoderm patch combined with gum or inhaler|"Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~*Off-label dosage approved by Health Canada via No Objection letter."
75590906|NCT05079698|Drug|177Lu-PSMA-617|Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
75590907|NCT05079698|Procedure|Stereotactic Body Radiotherapy (SBRT)|No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
75733971|NCT05358145|Behavioral|Control Tinkering Activities|Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
75440541|NCT01623505|Drug|Transdermal Nicoderm patch|"Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
75733972|NCT05358145|Behavioral|Board Games Activities|Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
75440542|NCT01623518|Biological|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;~5 x10^8 vp, 5 x10^9 vp, 2.5 x10^10 vp, 5 x10^10 vp"
75733973|NCT05353569|Diagnostic Test|OCT Device(s)|Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).
75440543|NCT01623557|Biological|ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
75733974|NCT05352698|Diagnostic Test|NT ProBNP (Roche)|This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
75733975|NCT05351229|Drug|Morphine Sulfate|5 mcg/kg intrathecal preservative free morphine sulfate
75733976|NCT05351229|Other|Placebo|Sterile saline
75440544|NCT01623557|Biological|ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
75440545|NCT01623557|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately 3 weeks post MVA dosing
75440546|NCT01623570|Drug|Pergoveris: 150IU r-hFSH + 75IU r-hLH|Fixed formulation of two recombinant gonadotropins
75440547|NCT01623570|Drug|Menopur: HMG-HP (150 IU)|Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
75440548|NCT01623583|Other|Enhanced Needle Phobia Intervention|"The enhanced intervention will include the standard intervention, with two enhancements:~The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch~Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity."
75590908|NCT05078138|Drug|Epoetin Alfa|Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
75883701|NCT03808467|Other|Treatment as usual|According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
75883702|NCT03796104|Other|Delta-haemolysin|comparison of groups having infection with S. aureus with and without delta-haemolysin Production
75883703|NCT03705156|Drug|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
75883704|NCT03705156|Drug|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
75440549|NCT01623583|Other|Standard Needle Phobia Intervention|"The standard intervention will include the following components:~Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.~Basic training on relaxation breathing~Brief video of a patient overcoming needle phobia~Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle"
75883705|NCT03686371|Procedure|posterior surgery for spinal arthrodesis|posterior surgery for spinal arthrodesis
75883706|NCT03667339|Procedure|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
75883707|NCT03660930|Drug|Sirolimus Albumin-bound Nanoparticles|Given IV
75440550|NCT01623609|Drug|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
75440551|NCT01623609|Drug|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
75440552|NCT01623622|Drug|HC-58|once or more / week
75590909|NCT05073874|Other|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
75590910|NCT05072210|Other|Mobile Intervention|Active mobile data will be used to provide automated, personalized notifications to frontline healthcare workers. Key information on mental health and links to access additional health resources will be available on the mobile platform.
75883708|NCT03660930|Drug|Pazopanib hydrochloride|Given PO
75883709|NCT03648372|Drug|TAK-981|Intravenous infusion.
75440553|NCT01623622|Drug|Placebo|once or more / week
75590911|NCT05069935|Drug|FT538|FT538 is an allogeneic natural killer (NK)-cell immunotherapy
75590912|NCT05069935|Drug|Cyclophosphamide|Lympho-conditioning agent
75590913|NCT05069935|Drug|Fludarabine|Lympho-conditioning agent
75590914|NCT05069935|Combination Product|Monoclonal antibody - Dose Escalation|either avelumab, trastuzumab or cetuximab
75590915|NCT05069935|Combination Product|Monoclonal antibody - Dose Expansion|either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab
75590916|NCT05067478|Drug|Vibegron|Vibegron to be administered.
75590917|NCT05064696|Other|Non-stick gauze dressing|Group 1 (Control group): surgical site will be dressed with a standard non-stick gauze dressing
75590918|NCT05064696|Device|PICO dressing|Group 2 (Treatment group): surgical site will be dressed with PICO dressing
75883710|NCT03643796|Drug|Remifentanil|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
75883711|NCT03643796|Drug|Ketamine|Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
75440554|NCT01623635|Drug|Ropivacaine|"ADMINISTRATION OF STUDY DRUG All surgical port sites will be injected with 2 ml/each study drug prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~each subdiaphragmatic area 3.5 ml + 3.5ml~surgical dissection site 3 ml~diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining medication with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining drug (no repeat port site injections)."
75590919|NCT05062902|Device|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.
76055215|NCT02093689|Drug|Part 2 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
75590920|NCT05062902|Drug|Botulinum Neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
75590921|NCT05059678|Other|Best Practice|Receive standard of care
75590922|NCT05059678|Other|Educational Intervention|Receive educational materials and attend videoconference sessions
75590923|NCT05059678|Other|Questionnaire Administration|Ancillary studies
75590924|NCT05058859|Drug|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes
75590925|NCT05056818|Other|Electronic Health Record Review|Review of medical records and past imaging examinations
75590926|NCT05056779|Drug|Nemolizumab|Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.
75590927|NCT05056779|Drug|CD14152 placebo|Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
75590928|NCT05053152|Drug|Placebo Administration|Given PO
75590929|NCT05053152|Other|Quality-of-Life Assessment|Ancillary studies
75590930|NCT05053152|Drug|Relugolix|Given PO
75590931|NCT05053152|Radiation|Stereotactic Body Radiation Therapy|Undergo SABR
75590932|NCT05050500|Drug|Dapagliflozin 10mg/Tab|patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months
75590933|NCT05050500|Drug|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
75590934|NCT05050162|Drug|Cisplatin|Given high-dose cisplatin IV
75590935|NCT05050162|Drug|Cisplatin|Given low-dose cisplatin IV
75590936|NCT05050162|Other|Quality-of-Life Assessment|Ancillary studies
76055216|NCT02093689|Drug|Part 2 Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
75590937|NCT05050162|Other|Questionnaire Administration|Ancillary studies
75590938|NCT05050162|Radiation|Radiation Therapy|Undergo radiation therapy
75590939|NCT05050084|Drug|Bicalutamide|Anti-androgen
75590940|NCT05050084|Drug|Buserelin|GnRH agonist
75590941|NCT05050084|Drug|Darolutamide|Anti-androgen
75590942|NCT05050084|Drug|Degarelix|GnRH antagonist
75883712|NCT03643796|Drug|Dexmedetomidine|dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
75590943|NCT05050084|Drug|Flutamide|Anti-androgen
75440555|NCT01623635|Drug|placebo (normal saline)|"ADMINSTRATION OF PLACEBO All surgical port sites will be injected with 2 ml/each placebo prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the placebo will be delivered as an atomized spray in the following volumes:~each subdiaphragmatic area 3.5 ml + 3.5ml~surgical dissection site 3 ml~diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining placebo with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining placebo (no repeat port site injections)."
75440556|NCT01623648|Other|Arm 1 Whey Breakfast|The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
75883713|NCT03623854|Biological|Nivolumab|Given IV
75883714|NCT03623854|Biological|Relatlimab|Given via infusion
75883715|NCT03592264|Drug|OBI-3424|liquid formulation for Intravenous infusion
75883716|NCT03584334|Radiation|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
75883717|NCT03575884|Behavioral|Screen Time Reduction Curriculum|"Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year."
75883718|NCT03560167|Device|AccuCinch® Ventricular Restoration System|AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
75440557|NCT01623648|Other|Arm 2 No Whey Breakfast|The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
75440558|NCT01623648|Other|Arm 3 Low Protein Breakfast|The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
75440559|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0 % (7 ml/kg)
75440560|NCT01623687|Device|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
75440561|NCT01623687|Device|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
75440562|NCT01623687|Device|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
75440563|NCT01623687|Device|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson & Johnsson, USA).
75440564|NCT01623713|Drug|iloperidone|Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
75440565|NCT01623713|Drug|Risperidone|Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
75590944|NCT05050084|Drug|Goserelin|GnRH agonist
75590945|NCT05050084|Drug|Histrelin|GnRH agonist
75590946|NCT05050084|Drug|Leuprolide|GnRH agonist
75590947|NCT05050084|Radiation|Radiation Therapy|Undergo RT
75590948|NCT05050084|Drug|Relugolix|GnRH antagonist
75590949|NCT05050084|Drug|Triptorelin|GnRH agonist
75590950|NCT05049590|Biological|Acute normovolemic hemodilution (ANH)|A blood conservation technique that removes whole blood (~8-10cc/kg) from a patient in the operating room prior to incision.
75590951|NCT05044026|Other|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
75590952|NCT05043870|Drug|Infliximab and immunosuppressives|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
75590953|NCT05043870|Drug|Infliximab|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
75590954|NCT05036083|Procedure|Contrast-Enhanced Mammography|Undergo CEM
75733977|NCT05351164|Drug|Metreleptin|Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
75733978|NCT05350072|Biological|VAY736|ianalumab s.c.
75733979|NCT05350072|Other|Placebo|placebo s.c.
75733980|NCT05349851|Other|Follow-up with blood and urine analysis|The patients will receive the preparation standards according to the usual clinical practice of each center. On the day of the colonoscopy, patient will be informed about this study and the informed consent will be requested to record the study information. Then, an analysis will be carried out. A second visit will be carried out, follow-up at 3-7 days, which will include a clinical interview and an analysis, being the unique intervention that patients receive.
75733981|NCT05346484|Biological|CF33-hNIS|CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)
75733982|NCT05346484|Biological|Pembrolizumab|Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
75883719|NCT03531892|Drug|AJM300|AJM300 film-coated tablets.
75733983|NCT05346081|Device|Electrical impedance tomography|Electrical impedance tomography (EIT) is a potential alternative non-invasive diagnostic screening measure to spirometry.
75590955|NCT05036083|Procedure|Digital Tomosynthesis Mammography|Undergo DBT
75440566|NCT01623726|Procedure|Transcranial Direct Current Stimulation (tDCS)|"Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by Chattanooga Iontophoresis Dual Channel Delivery Device, that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA."
75590956|NCT05036083|Other|Electronic Health Record Review|Medical records reviewed
75733984|NCT05344508|Drug|Brensocatib|Brensocatib tablets
75590957|NCT05036083|Drug|Iodinated Contrast Agent|Given IV
75590958|NCT05035654|Drug|LYR-220 Design 1|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
75590959|NCT05035654|Drug|LYR-220 Design 2|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
76055217|NCT02047045|Procedure|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
76055218|NCT02047045|Drug|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 32 weeks.
76055219|NCT02131259|Drug|Afatinib dimaleate|20mg - 50mg
76055220|NCT01856595|Drug|PF-06291874|The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
76055221|NCT01856595|Drug|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
75590960|NCT05035654|Drug|Bilateral sham procedure control|Bilateral sham procedure control
75440567|NCT01623778|Drug|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
75590961|NCT05034731|Device|Remote Fitting|Processors will be programmed using remote fitting application.
75590962|NCT05034731|Device|In-Office Fitting|Processors will be programmed using standard Target CI application.
75590963|NCT05033288|Other|Electronic Health Record Review|Medical records are reviewed
75590964|NCT05033288|Other|Quality-of-Life Assessment|Complete quality of life questionnaires
75590965|NCT05030350|Drug|PH94B|Nasal spray
75733985|NCT05343793|Other|Enhanced Monitoring and Feedback (EMF)|Enhanced Monitoring and Feedback consists of performance data (reach, adoption, effectiveness, implementation) gathered and reported by the program on a quarterly basis. Data summaries for each program and in comparison to the entire sample, will be reflected back to participants, via dashboards, within one-month of data submission.
75733986|NCT05343793|Other|NIATx/MAT Academy|This two-day workshop will provide participating clinics with rationale, clinical practice and program integration with MOUD (Day 1), and an overview of NIATx principles and tools (Day 2).
75590966|NCT05029596|Drug|Normal Saline Group|A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
75590967|NCT05029596|Drug|Heparin Group|All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
75733987|NCT05343793|Other|NIATx-Internal Facilitation (NIATx-IF)|Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications.
75883720|NCT03531892|Drug|Placebo|Placebo matched to AJM300 tablets.
75883721|NCT03531502|Procedure|Ventricular Tachycardia Ablation|Ventricular Tachycardia Ablation
75440568|NCT01623804|Device|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
75440569|NCT01623804|Device|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
75883722|NCT03531502|Other|Standard Medical Therapy|For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.
75883723|NCT03531502|Procedure|Non-Invasive Programmed Stimulation (NIPS)|All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
75883724|NCT03530215|Drug|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
75440570|NCT01623817|Drug|Vancomycin HCL|"Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.~Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day."
75883725|NCT03520075|Drug|ASTX029|Described above
75590968|NCT05027386|Drug|Apatinib, Irinotecan, Temozolomide|The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.
75590969|NCT05018767|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75440571|NCT01623843|Procedure|Arthroscopic Lavage|Lavage: inflammation debris caused from continual friction in the hip is washed out.
75440572|NCT01623843|Procedure|Arthroscopic Osteochondroplasty|"Osteochondroplasty: reshaping the hip ball and socket (osteoplasty or rim trimming)."
75440573|NCT01623856|Other|laboratory biomarker analysis|Correlative studies
75440574|NCT01623908|Drug|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
75440575|NCT01623921|Drug|standard care treatment|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
75440576|NCT01623921|Drug|Celecoxib|Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
75440577|NCT01623921|Drug|Rosuvastatin|Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
75590970|NCT05016622|Biological|BNT162b2 vaccine|administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
75440578|NCT01623921|Drug|Combined therapy|Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
75733988|NCT05343793|Other|NIATx-External Facilitation (NIATx-EF)|For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.
75883726|NCT03487926|Radiation|[18F]FEPPA|up to 3 PET Scans ([18F]FEPPA PET scans done 3 to 6 months apart, and one [11C]SL2511.88 PET scan) and 1 MRI
75883727|NCT03475277|Drug|Ketamine|Acute administration
75883728|NCT03472274|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks x 3 cycles
75883729|NCT03472274|Drug|Tremelimumab|Tremelimumab 75 mg every 4 weeks x 3 cycles
75883730|NCT03472274|Drug|Cisplatin-based neoadjuvant chemotherapy|"Regimen 1: 21-day treatment cycle x 3 cycles.~Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~Methotrexate 30mg/m2 intravenously on day 1~Vinblastine 3mg/m2 intravenously on day 2~Doxorubicin 30mg/m2 intravenously on day 2~Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~Paclitaxel 80 mg/m2 intravenously on day 1 and 8~Cisplatin 70mg/m2 intravenously on day 1"
75883731|NCT03456284|Device|Normothermic Liver perfusion|The liver grafts will be preserved and evaluated at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase
75883732|NCT03437928|Device|Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
75883733|NCT03436433|Drug|Lacosamide|LCM 100mg twice a day.
75883734|NCT03436433|Drug|Levetiracetam|LEV 1000mg twice a day.
75590971|NCT05015803|Combination Product|CBTi with Application|Participants randomized to this study arm will experience an attempted enhancement of standard video conferencing CBTi, that is facilitated with electronic device-based data and resources to the clinician. Noninvasive ambulatory worn and nearable devices deliver feedback of data to the clinician on an application interface. This information will be used to inform the therapeutic approach and to facilitate a living-space environment that is conducive to effective therapy.
75733989|NCT05343585|Device|PortionSize AI|For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods provided in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided in the laboratory. Meals will be simulated, and participants will not consume the foods provided.
75440579|NCT01623947|Dietary Supplement|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
75440580|NCT01623947|Dietary Supplement|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
75440581|NCT01623947|Dietary Supplement|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
75590972|NCT05015803|Behavioral|CBTi|Participants randomized to this study arm will experience standard CBTi that is delivered via video conferencing by a clinician, with some application interface use.
75590973|NCT05015803|Behavioral|Sleep Hygiene Education|Participants randomized to this study arm will experience sleep hygiene education and training, with some application interface use.
75590974|NCT05013073|Other|ASTHMAXcel ED Application|A mobile application designed to assist patients in asthma symptom recognition, treatment best practices, and trigger identification.
75440582|NCT01623973|Other|specific training of paretic upper limb|nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
75590975|NCT05010824|Behavioral|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem. The second and third session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. Follow-up phone calls provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
75590976|NCT05010434|Drug|Sintilimab and Bevacizumab Combined with Radiotherapy|Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.
75590977|NCT05009381|Device|Stylage XXL at enrollment|Injection in the chin at enrollment
75733990|NCT05339711|Other|Robotic Pet Therapy/Robot Cat Group|"İn this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher."
75733991|NCT05339711|Other|Pet Therapy/Betta Fish Group|İn this study, two fish and the necessary materials (aquarium, fish food, plastic plant, aquarium stone, etc.) were given to the patients by the researcher to keep pets for eight weeks.
75883735|NCT03432832|Behavioral|EASE|Weekly behavioral sessions with therapist to work on emotional control through measures such as mindfulness.
75440583|NCT01623986|Device|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
75590978|NCT05009381|Device|Stylage XXL at Month 6|Injection in the chin 6 months after randomization
75883736|NCT03432832|Behavioral|Supportive Therapy|Weekly behavioral sessions with a therapist to work on emotional control
75883737|NCT03425318|Device|CNAP|Application of CNAP in patients with ARDS
75883738|NCT03405090|Drug|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer
75883739|NCT03405090|Drug|Combivent|0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
75883740|NCT03383081|Biological|Low dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 * 10^7 cells (5ml);
75883741|NCT03383081|Biological|High dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 * 10^7 cells (5ml)
75590979|NCT05008315|Other|Myofascial abdominal diaphragm release|Myofascial abdominal diaphragm release
75440584|NCT01623986|Device|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
75733992|NCT05331443|Diagnostic Test|Reactive hyperemia-peripheral arterial tonometry Index (RHI )|RHI was assessed by RH-PAT using the EndoPAT2000 system .
75733993|NCT05324098|Other|STAND-T platform|Internet-based intervention comprised of evidence-based, patient materials and resources
75733994|NCT05324098|Other|Survey Administration|Satisfaction and follow-up surveys will be administered to participants
75733995|NCT05324098|Other|Text Messages|Participants will receive periodic text messages
75733996|NCT05319587|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
75733997|NCT05319587|Drug|Cytarabine|Administered during cycle 1 at a dose of 2.0 g/m2/day by 4 hours IV infusion for 5 consecutive days and this dose will remain constant for all cohorts, including the expansion phase.
75883742|NCT03383081|Procedure|Intraarticular injection|Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
76055222|NCT04589559|Behavioral|Heart Rate Variability Biofeedback Training|First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
76055223|NCT01829295|Drug|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg BID orally. After two weeks, the dose will be increased to 1.5 g BID.
75590980|NCT05008315|Other|Direct focused scar release technique|Direct focused scar release technique
75590981|NCT05008315|Other|Direct manipulations to visceral structures|Direct manipulations to visceral structures
75590982|NCT05008315|Other|pelvic anatomy education|pelvic anatomy education
75590983|NCT05008315|Other|sham|sham
75590984|NCT05006807|Device|Mechanomyograph Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
75733998|NCT05318755|Drug|GAHT for transgender men|Testosterone undecanoate
75883743|NCT03378414|Procedure|Intravenous infusion|Intravenous infusion of mesenchymal stem cells: 2 * 10^7 cells (30ml)
76055224|NCT01829295|Drug|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
76055225|NCT01829295|Drug|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
75590985|NCT05006807|Device|Stimpod Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
75733999|NCT05318755|Drug|GAHT for transgender women|Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
75734000|NCT05317429|Other|A meal delivering 75 g of carbohydrate|"The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity."
75734001|NCT05315258|Drug|Tebentafusp|Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
76055226|NCT02157935|Drug|Symbicort|Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
76055227|NCT02157935|Drug|Formoterol turbohaler|Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
75440585|NCT01624012|Device|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
75440586|NCT01624012|Device|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
75440587|NCT01624025|Other|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
75590986|NCT05006807|Device|TetraGraph Twitch Monitor|Measurement of train-of-four count and ratio and post titanic count
75590987|NCT05006807|Device|TwitchView Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
75590988|NCT05006807|Device|Nihon Kohden Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
75590989|NCT05006807|Other|Palpation of twitch count|The train-of-four count is determined by manual palpation of the evoked twitch response
75590990|NCT04997265|Other|Low intensity anticoagulation|Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.
75883744|NCT03378414|Procedure|Intrathecal injection|Intrathecal injection of mesenchymal stem cells: 2 * 10^7 cells (1ml)
75883745|NCT03378414|Biological|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
75734002|NCT05308472|Drug|DISC-1459|Oral dose level 1, once a day for 120 days
75440588|NCT01624038|Drug|Hydroxyurea ,Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
75734003|NCT05308472|Drug|DISC-1459|Oral dose level 2, once a day for 120 days
75734004|NCT05308472|Drug|Placebo|Oral dose, once a day for 120 days
76055228|NCT02157935|Other|Placebo for Symbicort pMDI|pMDI, aerosol for oral inhalation, placebo, 120 doses
75734005|NCT05308472|Drug|DISC-1459|Oral dose level 1, once a day for up to 8 months
75734006|NCT05308186|Behavioral|Auditory stimulation|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.
75440589|NCT01624038|Drug|hydroxyurea, blood transfusion|Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
75440590|NCT01624051|Other|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
75440591|NCT01624051|Other|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
75440592|NCT01624064|Drug|Enalapril|2.5-20 mg/day
75440593|NCT01624064|Drug|Calcium Supplement|Calcium 2.5-20 mg/day
75440594|NCT01624077|Biological|Regulatory T cells|Tregs will inject after liver transplantation
75440595|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 20 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
75734007|NCT05308186|Behavioral|Auditory and tactile stimulations|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
75734008|NCT05306561|Procedure|Systane iLux thermal pulsation treatment|Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
75734009|NCT05305053|Other|preoperative MDT discussion|high-risk patients are subjected to an MDT discussion among care providers
75734010|NCT05301933|Behavioral|Behavioral Parent Training (BPT)|BPT is an evidence-based psychosocial intervention that is directed exclusively to parent of children with ADHD and related disorders. BPT focuses on instructing parents to use approaches to enhance the parent-child relationship (e.g., quality time, praise) and proactive discipline strategies (e.g., time out, reward systems) to reduce challenging child behavior.
75734011|NCT05298995|Biological|GD2-CART01 (iC9-GD2-CAR T-cells)|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
75440596|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 32 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
76055229|NCT02157935|Other|Placebo for Formoterol Turbohaler|PLacebo powder for oral inhalation, 60 doses
76055230|NCT04589403|Drug|OPT101|15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40
76055231|NCT02157779|Behavioral|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
76055232|NCT02157779|Behavioral|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
75440597|NCT01624116|Drug|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
75440598|NCT01624116|Other|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
75440599|NCT01624116|Drug|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
75440600|NCT01624116|Drug|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
75440601|NCT01624116|Drug|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
75440602|NCT01624129|Drug|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
75734012|NCT05297045|Drug|RGT001-075|Oral GLP1 Receptor Agonist
76055233|NCT02093221|Biological|180 mg/kg Alpha1-PI|
76055234|NCT02093221|Biological|90 mg/kg Alpha1-PI|
76055235|NCT02093221|Biological|Placebo|
76055236|NCT02092909|Drug|IMO-8400|IMO-8400 at escalating dose levels by subcutaneous injection
76055237|NCT01623115|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
75440603|NCT01624155|Behavioral|Education|EMR referral to teratogen and contraception counseling
75440604|NCT01624207|Drug|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
75440605|NCT01624207|Drug|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
75440606|NCT01624246|Drug|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil [600 mg] plus avibactam [600 mg]) infused over 60 (± 5) minutes.
75440607|NCT01624272|Device|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
75440608|NCT01624272|Other|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
75440609|NCT01624298|Behavioral|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
75440610|NCT01624311|Other|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
75440611|NCT01624311|Other|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
75734013|NCT05297045|Other|Placebo|Placebo comparator
75734014|NCT05291403|Other|Medical thoracoscopic cryotherapy combined with standard first-line therapy for advanced non-cell lung cancer|"Medical thoracoscopic cryotherapy: medical thoracoscopy biopsy hole insert bendable freezing probes, place the frozen probe placed in the center of the tumor at the top will be frozen carbon dioxide gas source pressure adjustment to the bar of 50-60 bar, tread down switch, foot pedal to start the probe, after about 30 s at the top of the probe to form a ice hockey, local tissue after frozen white, sometimes a small amount of bleeding; Fix the probe, loosen the pedal, and wait 30 seconds for automatic melting and rewarming (bleeding probability is low after full rewarming). Freeze 5 to 10 at a time.~In addition, all patients were treated with standard first-line regimens according to guidelines of non small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) scores."
75734015|NCT05291403|Other|Sequential intrathoracic injection of cisplatin/erythromycin combined with standard first-line therapy for advanced non-cell lung cancer|"The pleural effusion was fully drained and cisplatin 40mg/m2 was given, dissolved in 100mL 0.9% sodium chloride (NaCl) solution 100 mL, then injected into the pleural cavity and retained for 24 hours. Erythromycin was sequentially injected into the thorax to seal the pleural cavity.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
75440612|NCT01624337|Drug|DHA-piperaquine|"Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)"
76055238|NCT01623115|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
76055239|NCT01623115|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
75440613|NCT01624337|Drug|placebo|
75440614|NCT01624376|Drug|DLX105|10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
75440615|NCT01624376|Drug|Placebo|Placebo injections are administered over the treatment period of 4 weeks.
76055240|NCT02092285|Drug|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
76055241|NCT02091739|Drug|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
76055242|NCT02091739|Drug|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
76055243|NCT02091739|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
76055244|NCT02045875|Drug|Dulera|Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
76055245|NCT01597635|Drug|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
76055246|NCT01597635|Drug|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
75883746|NCT03350243|Other|CCENT Intervention|"Acceptance and Commitment Therapy approach: engaging families through structured individual or group sessions within the NICU and continue this support once discharged.~Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support."
75883747|NCT03324360|Drug|Hyperpolarized 13C-Pyruvate|MRI with Hyperpolarized 13C-Pyruvate Injection
75883748|NCT03284307|Drug|Dexmedetomidine|20 participants will be administered Dexmedetomidine.
76055247|NCT01597635|Drug|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
76055248|NCT01597635|Drug|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
75440616|NCT01624389|Drug|F18-AV45|"This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
75440617|NCT01624402|Behavioral|Education on Stroke and Depression (ESD)|"Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.~Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.~Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.~ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy)."
75734016|NCT05291403|Other|Standard first-line therapy for advanced non-cell lung cancer without intrathoracic treatment|"Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
75734017|NCT05288088|Diagnostic Test|No intervention|This is an observational study
75734018|NCT05283239|Other|Follow up|Participants will be followed up at 6th，12th, 18th and 24th months with HPV viral integration/genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopy and biopsy will be conducted for participants if necessary.
75734019|NCT05283135|Drug|risankizumab|Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
75734020|NCT05282745|Other|Follow-up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
75734021|NCT05282641|Dietary Supplement|10 g of collagen hydrolysate|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 10-gram collagen protein hydrolysates + 5-gram erythritol and it has to be dissolved in 250 ml of water.
75734022|NCT05282641|Dietary Supplement|Placebo|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 5-gram erythritol (placebo) and has to be dissolved in 250 ml of water.
75883749|NCT03284307|Drug|Ketamine|20 participants will be administered Ketamine.
75883750|NCT03284307|Drug|Propofol|20 participants will be administered Propofol.
75883751|NCT03284307|Drug|Midazolam|20 participants will be administered Midazolam.
75883752|NCT03279289|Drug|Aflibercept|4 mg/kg administered intravenous infusion on day 1
75883753|NCT03279289|Drug|Irinotecan|180 mg/m2 intravenous infusion
75883754|NCT03279289|Drug|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
75883755|NCT03279289|Drug|5Fluorouracil|400 mg/m2 intravenous bolus
75883756|NCT03279289|Drug|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
75883757|NCT03265535|Diagnostic Test|Single-Scan Two-Injection Protocol|Single-Scan Two-Injection Protocol
75883758|NCT03225989|Drug|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
75883759|NCT03207867|Drug|NIR178|NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.
75883760|NCT03207867|Drug|PDR001|PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
76055249|NCT01597635|Drug|Placebo (saline)|Administered intravenously to match intervention
76055250|NCT01828281|Device|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
76055251|NCT01827267|Drug|neratinib|
76055252|NCT01827267|Drug|temsirolimus|
76055253|NCT01855425|Radiation|Radiation|Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
76055254|NCT01854879|Device|Nucleus 6 sound processor|
76055255|NCT01827111|Drug|ABI-007|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
76055256|NCT01827111|Drug|Ipilimumab|3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
75590991|NCT04997265|Other|Moderate Intensity Anticoagulation|"Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers."
75590992|NCT04994639|Device|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
75734023|NCT05281939|Diagnostic Test|Artificial intelligence diagnosis|Participants were divided into the intervention group and the control group using a random number table. The intervention group participants' cervical colposcopic image data and non-image data as follow：age, the infection of high-risk human papillomavirus (HR-HPV),the type of HR-HPV infection,the duration of HR-HPV infection, cervical cytology (TCT) results, HIV/sexually transmitted infection history, marriage and childbearing history,first sexual life history, sexual partner history, smoking history,oral contraceptives history,the use of immune drug and possible clinical symptoms of cervical lesions such as postcoital bleeding, abnormal vaginal secretions, vaginal bleeding symptoms, etc.
75734024|NCT05280756|Device|Home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
75883761|NCT03186456|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 *10^6/kg. once a month, total 3 times.
75883762|NCT03186456|Drug|Aspirin Tablet|Drug: Aspirin Tablet, 100 mg/d
75883763|NCT03184935|Biological|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
75883764|NCT03184935|Drug|Decitabine|Decitabine，20mg/m^2/d
76055257|NCT01827111|Behavioral|Phone Call|Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
75440618|NCT01624402|Behavioral|Ecosystem Focused Therapy (EFT)|"EFT offers an action-oriented, new perspective about the subject's recovery;~It provides an adherence enhancement structure;~It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;~It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;~It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities."
75883765|NCT03180463|Drug|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2*10^7 cells,
76055258|NCT02045095|Drug|MLN7243|"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
76055259|NCT04183309|Other|Measure the transpulmonary pressure in pediatric patients|Esophageal pressure will be measured by an esophageal ballon to assess transpulmonary pressure during laparoscopy surgery. Lung collapse will detected when transpulmonary pressure became negative and using lung ultrasound images. Lung ultrasound examinations will be performed at different times-points: after anesthesia induction, 10 minutes after pneumoperitoneum insufflation, and at the end of surgery. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery.
75440619|NCT01624428|Drug|Varenicline|1 mg bid varenicline titrated over a 2 week period
75883766|NCT03180463|Procedure|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
76055260|NCT02181803|Drug|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg
76055261|NCT02181803|Drug|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
75883767|NCT03180450|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
75883768|NCT03180450|Drug|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
75883769|NCT03176498|Biological|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
75440620|NCT01624428|Drug|Placebo|1 mg bid placebo titrated over a 2 week period
75440621|NCT01624441|Drug|Dinaciclib|Given IV
75440622|NCT01624441|Drug|Epirubicin Hydrochloride|Given IV
75440623|NCT01624441|Other|Laboratory Biomarker Analysis|Correlative studies
75883770|NCT03176498|Drug|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
75590993|NCT04986696|Device|FLASH therapy|Dose escalation of high dose rate radiotherapy (FLASH therapy) as single dose treatment for skin melanoma metastases that progress locally despite systemic treatments.
75734025|NCT05280756|Device|Sham home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
75883771|NCT03126591|Drug|Olaratumab|Administered IV
75440624|NCT01624454|Other|Laxabon|4 l PEG solution split dose cleansing
75883772|NCT03126591|Drug|Pembrolizumab|Administered IV
75883773|NCT03107000|Procedure|Trabeculectomy|Incisional surgery for glaucoma
75883774|NCT03107000|Procedure|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
75440625|NCT01624454|Other|CitraFleet|Small volume osmotic bowelcleansing
76055262|NCT02181803|Drug|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone [not to exceed daily dose of 6 mg], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
76055263|NCT01826487|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
76055264|NCT01826487|Drug|Placebo|Placebo will be administered as per the schedule specified in the arm.
75440626|NCT01624493|Drug|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
75440627|NCT01624493|Drug|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
75590994|NCT04985214|Other|Questionnaire|Questionnaire on the quality of life
75590995|NCT04984993|Device|MED3000 (Male)|Gel formulation
75590996|NCT04984993|Drug|Tadalafil 5mg (Male)|Tablets
75590997|NCT04984993|Device|MED3000 (Female)|Gel formulation
75590998|NCT04984993|Drug|Tadalafil 5mg (Female)|Tablets
75590999|NCT04982848|Drug|Talzenna|Talzenna treatment under Korea regulatory approval indication/dosage
75591000|NCT04979611|Drug|68Ga-NOTA-exendin-4|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously
75734026|NCT05280379|Other|no intervention will take place|no intervention will take place
75883775|NCT03094832|Drug|Miransertib|Miransertib capsules administered orally at an initial dose of 15 mg/m^2 or 25 mg/m^2 QD and then titrated up to 25 mg/m^2 or 35 mg/m^2 QD at the investigator's discretion.
75883776|NCT03085004|Drug|Ethanol|The cyst will be lavaged for 3 to 5 minutes using >/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
75883777|NCT03085004|Drug|Normal saline|The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
75883778|NCT03085004|Drug|Paclitaxel + Gemcitabine admixture|Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
75883779|NCT03082716|Drug|Custodiol Solution|After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
75883780|NCT03082716|Drug|Blood cardioplegia|After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
76055265|NCT02064439|Drug|BAY 59-7939|10 mg tablet once daily for 12 months
76055266|NCT02064439|Drug|BAY 59-7939|20 mg tablet once daily for 12 months
76055267|NCT02064439|Drug|ASA|100 mg tablet once daily for 12 months
75883781|NCT03069287|Behavioral|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
75883782|NCT03059862|Dietary Supplement|L-tryptophan|3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
75883783|NCT03059862|Dietary Supplement|Placebo|A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
75440628|NCT01624493|Drug|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
75440629|NCT01624493|Drug|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
75440630|NCT01624493|Drug|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
75591001|NCT04975646|Behavioral|Prescribed exercise program|Active or passive exercises for the spastic upper limb, including functional electrical stimulation (FES), performed regularly for two weeks.
75591002|NCT04971577|Drug|Simvastatin 40mg|participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
75591003|NCT04970225|Other|1 blood sample|4 tubes of 7 ml per sample (a single sample)
75591004|NCT04970225|Other|2 blood samples|4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment
75591005|NCT04967248|Other|Alpelisib|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
76055268|NCT02130557|Drug|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.[1] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
75883784|NCT03037723|Other|CT simulation|
75883785|NCT03036579|Device|Celtra Duo|Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
75883786|NCT03034811|Device|Persona Partial Knee system|Fixed bearing partial knee
76055269|NCT02130557|Drug|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
76055270|NCT01854645|Drug|GFF MDI|GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
75591006|NCT04967248|Other|Fulvestrant|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
75591007|NCT04966520|Other|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)|"Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients.~Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be ~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days."
75440631|NCT01624519|Procedure|Blood Lactate Analysis|When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
75440632|NCT01624545|Other|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
75440633|NCT01624558|Device|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
75440634|NCT01624571|Drug|LD02GIFRO|comparison of different dosages of drug
75440635|NCT01624584|Behavioral|Experimental treatment|six sessions of child anxiety treatment
75440636|NCT01624584|Behavioral|Traditional Treatment|six sessions of treatment consistent with current practice
75440637|NCT01624597|Behavioral|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
75734027|NCT05279651|Drug|Ivabradine|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
75883787|NCT03015844|Drug|131-I-meta-iodobenzylguanidine|
75883788|NCT02916862|Dietary Supplement|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
75440638|NCT01624597|Behavioral|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
75883789|NCT02916862|Combination Product|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
75883790|NCT02916862|Dietary Supplement|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
75883791|NCT02916862|Combination Product|Placebo + calcium|Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
75883792|NCT02891447|Drug|Cisplatin|Given intraperitoneally
75883793|NCT02891447|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
75883794|NCT02891447|Drug|Mitomycin|Given intraperitoneally
75883795|NCT02867761|Drug|Indacaterol/Glycopyrrolate|27.5/15.6 mcg active indacaterol/glycopyrrolate
75883796|NCT02867761|Drug|Placebo|27.5/15.6 mcg placebo
75883797|NCT02858050|Device|Portal-724 MEMs Cap|
75883798|NCT02740790|Biological|HPV vaccine|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
75883799|NCT02740790|Biological|Placebo|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
75591008|NCT04957901|Drug|modified BFM-95 protocol|Clinical stage system, risk stratification and treatment for pediatric mature B-NHL were according to the modified BFM-95 protocol. The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
75883800|NCT02740777|Biological|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
75440639|NCT01624610|Other|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
75591009|NCT04952792|Drug|Apixaban 2.5 milligram Oral Tablet|Apixaban 2.5mg/12h, oral, 28 days
75591010|NCT04952389|Device|Acupuncture Therapy|Consists of two treatments per week for five weeks
75591011|NCT04952389|Drug|Budesonide|Twice daily nasal rinses with steroid medication (budesonide)
75591012|NCT04952389|Other|Olfactory Training|involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
75883801|NCT02719990|Drug|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
75883802|NCT02680626|Drug|Magnesium Sulfate|Given via transversus abdominis plane block
75440640|NCT01624649|Drug|Methylphenidate hydrochloride|Form = tablet, route = oral, administered as a flexible dosage
75883803|NCT02680626|Drug|Ropivacaine|Given via transversus abdominis plane block
75591013|NCT04950582|Diagnostic Test|Spectral characteristics assessment|Urine sample analysis for evidence of urinary tract infection
75591014|NCT04948450|Behavioral|Physical activity intervention|"Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home for 45 minutes twice a week. The sessions will be organized in groups (10 patients/ group) and supervised by 2 physiotherapists. Within each small group (maximum 10), participants will follow the program tailored to their individual functioning level, with constant oversight by trainers.~People with dementia and care staff will be instructed to follow the prescribed PRT exercises for the rest of the week. Subjects will be encouraged to exercise daily."
75591015|NCT04948450|Behavioral|Cognitive stimulation intervention|"The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts. The intervention involves 14 sessions of themed activities, which typically run twice weekly. The sessions will be organized in groups (10 patients/ group).~People with dementia and their care staff will be instructed on how to practice the various activities at their nursing home for the rest of the week."
75591016|NCT04948450|Behavioral|Social intervention|Social intervention will be combined with physical and cognitive interventions through doing these in a group, playing games during exercises (dancing, throwing ball to each other) or doing cognitive stimulation therapy in a group.
75883804|NCT02576483|Behavioral|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
76055271|NCT01854645|Drug|GP MDI|GP MDI administered as two puffs BID
75440641|NCT01624649|Drug|Atomoxetine|Form = tablet, route = oral;
75591017|NCT04948450|Other|Management of metabolic and vascular risk factors|"Study physicians will assess the risk of developing new chronic diseases, change in blood pressure, weight and BMI, and hip and waist circumference, blood test (glucose, lipid parameters, fasting glucose, and HbA1C if the person with dementia has diabetes) at 3 and 6 months.~Participants in the intervention group will be provided with information on the importance of reducing risk factors, guidance on lifestyle changes and prescribing treatment if necessary by cardiologists and endocrinologists. The target for blood pressure is less than 120/90 mmHg and the target for HbA1c is less than 7.5 %."
75591018|NCT04947631|Drug|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
75591019|NCT04947631|Drug|Dutasteride|Dutasteride 0.5 mg once daily for 48 weeks
75591020|NCT04947631|Drug|Tadalafil|Tadalafil 5 mg once daily for 48 weeks
75883805|NCT02573415|Procedure|Uterus Transplant|transplant of a deceased donor uterus.
75883806|NCT02494583|Biological|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
75883807|NCT02494583|Drug|Cisplatin|Cisplatin 80 mg/m^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
75883808|NCT02494583|Drug|5-FU|5-FU 800 mg/m^2/day IV continuous from Day 1-5 of each 3-week cycle.
75883809|NCT02494583|Drug|Capecitabine|Capecitabine 1000 mg/m^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
76055272|NCT01854645|Drug|FF MDI|FF MDI administered as two puffs BID
76055273|NCT01854645|Drug|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
76055274|NCT01854645|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID
75440642|NCT01624675|Drug|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
75591021|NCT04947631|Drug|DKF-313 placebo|Once daily for 48 weeks
75591022|NCT04947631|Drug|Dutasteride placebo|Once daily for 48 weeks
76055275|NCT04418089|Drug|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
75440643|NCT01624675|Drug|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
75591023|NCT04947631|Drug|Tadalafil placebo|Once daily for 48 weeks
75440644|NCT01624688|Procedure|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
75591024|NCT04936321|Behavioral|Internet-delivered CBT for Insomnia|The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
75591025|NCT04936321|Behavioral|Internet-delivered CBT for Pain Management|The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
75591026|NCT04936321|Behavioral|Internet-delivered Sleep Education|The program delivers publicly available information about sleep.
75734028|NCT05279651|Drug|Placebo|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
75734029|NCT05276024|Device|iFuse Bedrock technique|Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
75734030|NCT05275088|Device|Prizvalve® system|Transcatheter atrioventricular valve replacement
75734031|NCT05273749|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
75734032|NCT05273749|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
75440645|NCT01624701|Other|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
75734033|NCT05272579|Other|Fecal Filtrate Transfer|Treatment with donated fecal samples filtered to contain practically no bacteria and mainly viruses, including bacteriophages
75734034|NCT05272579|Other|Placebo|Saline solution
75734035|NCT05269459|Drug|Cannabidiol (CBD) as Nantheia ATL5|Gel caps containing 100mg of Nantheia ATL5. Subjects will take 4 capsules twice daily.
75734036|NCT05269459|Drug|Placebo|Matching gel caps containing no active drug. Subjects will take 4 capsules twice daily.
75734037|NCT05268250|Behavioral|R2D2 mHealth intervention|R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
76055276|NCT04418089|Drug|Placebo oral capsule|The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
76055277|NCT01825941|Drug|metoclopramide|10 milligrams, administered intravenously over 15 minutes
76055278|NCT01825941|Drug|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
76055279|NCT01825941|Drug|placebo|
76055280|NCT02064205|Dietary Supplement|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
75440646|NCT01624714|Drug|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
75440647|NCT01624714|Drug|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
75440648|NCT01624727|Dietary Supplement|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
75591027|NCT04931069|Other|Microbiota analysis|Microbiota analysis will be carried out on different samples: blood, stool and saliva samples will be collected during the surgery, between 5 and 10 days after surgery and at 3 and 6 months after the surgery. Bile, pancreatic and intestinal mucosa samples will only be collected during the surgery.
75591028|NCT04930822|Other|Table Top Visual Intervention|Table top visual interventions and exercises.
76055281|NCT02064205|Dietary Supplement|glucose syrup|Glucose syrup is used a control product for the polydextrose
76055282|NCT02090959|Drug|Ataluren|Ataluren will be administered per the dose and schedule specified in the arm.
76055283|NCT02044159|Drug|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
76055284|NCT02044159|Other|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
76055285|NCT02090725|Drug|3-4 Diaminopyridine|
76055286|NCT02180165|Drug|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
76055287|NCT02180165|Drug|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
76055288|NCT04748705|Drug|IMC-1|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
75440649|NCT01624753|Device|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
76055289|NCT04748705|Drug|Placebo BID Tablet|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
76055290|NCT02155985|Drug|Aspirin|Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
75440650|NCT01624766|Biological|Anakinra|Given SC
75440651|NCT01624766|Biological|Denosumab|Given SC
75440652|NCT01624766|Drug|Everolimus|Given PO
75440653|NCT01624779|Drug|autologous adipose tissue derived mesenchymal stem cells|autologous adipose tissue derived mesenchymal stem cells 9x107cells / 3mL Day 1 and Month 1&2
75440654|NCT01624792|Dietary Supplement|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
75440655|NCT01624792|Dietary Supplement|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
76055291|NCT02155985|Drug|Placebo|Placebo for aspirin
76055292|NCT02155829|Drug|Riluzole|
75591029|NCT04930822|Device|Bioness Integrated Therapy System Visual Intervention|Digital visual interventions and exercises.
75591030|NCT04929951|Biological|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
75591031|NCT04929951|Biological|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
75591032|NCT04915495|Diagnostic Test|LuViva Advanced Cervical Scan|Multimodal hyperspectral device
76055293|NCT02155829|Drug|Placebo (for Riluzole)|
76055294|NCT02129777|Drug|Namilumab|Namilumab subcutaneous injection
76055295|NCT02129777|Drug|Placebo|Placebo subcutaneous injection
75734038|NCT05267184|Procedure|Endovascular treatment of the middle meningeal artery|The middle meningeal artery on the same side(s) as the chronic subdural hematoma is embolized with liquid embolic agents.
76055296|NCT02178995|Drug|Methylphenidate|"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."
76055297|NCT02128997|Device|Closed incision wound vacuum (Prevena)|wound vacuum to be placed on a closed incision
76055298|NCT02155283|Device|Continuous Passive Motion|Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
76055299|NCT02154581|Device|SLActive implant|
76055300|NCT02154425|Procedure|Breast milk sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
75440656|NCT01624792|Dietary Supplement|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
75440657|NCT01624818|Behavioral|Cardiac habilitation program|physical activity three weeks
75591033|NCT04914910|Device|Minimed 780G insulin pump|This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
75734039|NCT05267184|Procedure|Standard neurosurgical hematoma evacuation|Standard neurosurgical evacuation of chronic subdural hematoma through burr-hole or mini craniotomy and postoperative subdural or subgaleal drainage.
75734040|NCT05261672|Drug|Midazolam/ bupivaciane|20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
75734041|NCT05261672|Drug|Bupivacain|20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
75734042|NCT05259527|Drug|Ergocalciferol Capsules|Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
75734043|NCT05259527|Dietary Supplement|Cholecalciferol Capsules|Vitamin D3 5,000IU by mouth daily
75734044|NCT05257551|Other|Observation|No intervention
75734045|NCT05257187|Device|Transcervical foley catheter|The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
75734046|NCT05255588|Device|EarlyTect® CRC test|A highly accurate and sensitive real time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE/qMSP) for measuring SDC2 methylation in stool DNA to detect CRC.
75440658|NCT01624844|Other|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
75440659|NCT01624857|Drug|Rosuvastatin|Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
75440660|NCT01624857|Drug|Placebo|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
75440661|NCT01624935|Behavioral|interpersonal psychotherapy|interpersonal psychotherapy
75440662|NCT01624961|Biological|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
75440663|NCT01624987|Behavioral|NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
75440664|NCT01624987|Other|Control group|The control group receives no intervention.
75440665|NCT01625026|Drug|Obeticholic acid|Obeticholic acid 25 mg/day in three weeks
75440666|NCT01625026|Drug|Placebo|Placebo to obeticholic acid
75440667|NCT01625039|Behavioral|Employee wellness programme|The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.
75591034|NCT04913610|Drug|ABBV-4083|Oral Capsule
75734047|NCT05251207|Dietary Supplement|L-carnitine|L-carnitine-L-tartrate
75734048|NCT05251207|Dietary Supplement|L-leucine|L-leucine
75734049|NCT05251207|Behavioral|Change of the circadian cycle|Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)
75734050|NCT05240716|Other|FES program|8 weeks intervention. 3 sessions per week. Previous to the intervention, volunteers will familiarize with the electrical stimulation by receiving three trials of the stimuli. Electrical current intensity will be set for each volunteers, with the capacity of generating a muscle contraction without inducing discomfort in the volunteer. During the FES program, patient in standing position will perform a step, while electrical current stimulation will be applied to the skin over the tibial nerve on the contralateral of the stimulation side. The FES will be delivered during the paretic plantarflexor activation according to the gait cycle. The FES session will consist of 5-minutes stimulation blocks with breaks between blocks (total session time: 30 minutes). For safety reasons, a physical therapist will supervise all the FES intervention sessions.
75440668|NCT01625039|Behavioral|Comparator (Once off educational session and educational materials)|Once off educational session and educational materials
75591035|NCT04913610|Drug|Placebo for ABBV-4083|Oral Capsule
75591036|NCT04913610|Drug|Albendazole|Oral encapsulated tablets
75591037|NCT04913610|Drug|Placebo for Albendazole|Oral Capsule
75591038|NCT04913610|Drug|Placebo for Ivermectin|Oral Capsule
75591039|NCT04913610|Drug|Ivermectin|Encapsulated Oral Tablet
75591040|NCT04910217|Procedure|Conventional rehabilitation|Patients will undergo conventional rehabilitation
75591041|NCT04910217|Procedure|Leg/lower body exerciser device intervention.|Patients will undergo leg/lower body exerciser device therapy.
75440669|NCT01625052|Device|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
75440670|NCT01625078|Device|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
75440671|NCT01625117|Behavioral|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
75440672|NCT01625130|Dietary Supplement|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
75440673|NCT01625130|Dietary Supplement|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
75440674|NCT01625143|Other|laboratory biomarker analysis|Correlative studies
75440675|NCT01625195|Dietary Supplement|omega-3 fatty acid supplementation|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
75734051|NCT05240547|Other|Spinal Manipulation|Spinal manipulative therapy delivered to the cervical spine by a chiropractor
76055301|NCT02154425|Biological|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
76055302|NCT02154347|Drug|KAD-1229|
75591042|NCT04910217|Procedure|Lokomat intervention|Patients will undergo therapy with Lokomat Pro FreeD device intervention.
75591043|NCT04904835|Diagnostic Test|Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|All samples will be tested with both CE-marked HBV serological predicate assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) and Access HBV serological assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) according to respective Instructions For Use to determine non-reactive (NR), initially reactive (IR), repeatedly reactive (RR), or confirmed or not confirmed Positive.
75591044|NCT04903197|Drug|VAY736|VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.
75734052|NCT05240547|Other|Placebo|Sham manipulative treatment delivered to the cervical spine by a chiropractor
76055303|NCT02154347|Drug|Placebo|
76055304|NCT02154347|Drug|Insulin|
76055305|NCT01627067|Drug|Everolimus|10 mg by mouth once daily.
76055306|NCT01627067|Drug|Exemestane|25 mg by mouth once daily.
76055307|NCT01627067|Drug|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
76055308|NCT02178059|Drug|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate (delivered dose) per inhalation
76055309|NCT02178059|Drug|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate (metered dose) per inhalation
76055310|NCT01626989|Device|BiPAP auto Advanced|Auto Servo Ventilation Device
76055311|NCT01626989|Device|BiPAP auto SV4|Auto Servo Ventilation Device
76055312|NCT04748237|Diagnostic Test|Coronary computed tomopraphic angiography|CCTA as soon as possible, preferably within 24 hours, but not later than within 7 days.
75591045|NCT04903197|Drug|lenalidomide|Immune-modulatory agent that enhances activation of NK cells.
76055313|NCT02128217|Drug|Sofosbuvir|Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
75591046|NCT04903197|Drug|CC-99282|Cereblon (CRBN) E3 Ligase Modulator that induces the recruitment, ubiquitination and destruction of key target substrates (e.g. Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3)
75440676|NCT01625195|Dietary Supplement|corn/soybean oil placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4x 1285 mg capsules/d, two capsulesat breackfast and two capsules at dinner. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials.
75440677|NCT01625208|Procedure|Combined nerve block|Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
75440678|NCT01625208|Procedure|Supraclavicular block|Standard supraclavicular brachial plexus block
75440679|NCT01625247|Procedure|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
75440680|NCT01625260|Biological|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
75591047|NCT04898010|Device|Selective Cytopheretic Device|The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
75591048|NCT04893161|Drug|Belimumab|All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
75591049|NCT04891757|Drug|FHD-286|FHD-286 administered orally
75591050|NCT04891757|Drug|Low Dose Cytarabine|LDAC administered subcutaneously (SC)
75591051|NCT04891757|Drug|Decitabine|Decitabine administered intravenously
75591052|NCT04890470|Drug|Oxytocin|intranasal administration of oxytocin (24 IU)
75591053|NCT04890470|Drug|Vasopressin|intranasal administration of vasopressin (20 IU)
75591054|NCT04890470|Drug|Placebo|intranasal administration of placebo
75591055|NCT04888338|Other|Data Capture|Treatment related data is collected
75591056|NCT04888338|Other|Electronic Medical Record|Medical records are reviewed
75591057|NCT04882137|Behavioral|Education plus Coaching|Providers in Intervention group will receive standard education (1.5 hr CME), a tip sheet on how to manage side effects for quick reference and a number to directly reach a provider experienced with managing etonogestrel side effects with questions regarding how to manage side effects.
75591058|NCT04881201|Procedure|blood sample|blood sample
75440681|NCT01625260|Drug|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
75440682|NCT01625273|Other|Lactobacillus paracasei paracasei strain F19|Provided in an infant formula, 10^8 CFU per day from 28 days to 6 months of infant age
75440683|NCT01625299|Dietary Supplement|Gluten and dry milk|0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
75440684|NCT01625299|Dietary Supplement|Placebo|Rice flour 1.0 g/kg/day
75440685|NCT01625351|Drug|alemtuzumab|Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
75440686|NCT01625351|Drug|fludarabine|Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
75591059|NCT04880161|Biological|Ampion|Inhaled Ampion
75591060|NCT04880161|Other|Placebo|Inhaled Placebo
75591061|NCT04875221|Combination Product|Connectivity-based neurofeedback|Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.
75591062|NCT04873778|Device|Kinesio taping|Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints
75591063|NCT04873778|Device|Dynamic taping|Dynamic taping: Invented by Kendrick,elasticised with multi-directional rebound and with strong elastic resistance and recoil than KT
75591064|NCT04870788|Behavioral|Mindfulness Relaxation|Participate in mindfulness program
75591065|NCT04870788|Other|Quality-of-Life Assessment|Ancillary studies
75591066|NCT04870788|Other|Questionnaire Administration|Ancillary studies
75591067|NCT04865159|Drug|Tipifarnib|Cardiac Safety of Tipifarnib
76055314|NCT02128217|Drug|Ribavirin|Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
76055315|NCT02128217|Drug|Ledipasvir/Sofosbuvir|Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
76055316|NCT01629953|Other|Group vocational intervention|Group based manualized vocational rehabilitation
75734053|NCT05238896|Drug|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg/d oral route for 42 days
75734054|NCT05238896|Drug|Placebo|Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
75734055|NCT05234879|Other|Frame Running|Frame Running (FR) provides an opportunity for people with walking and balance problems to walk or run safely without the risk of falling. The frame consists of three wheels and has a saddle and handlebars like a trike without pedals.
75734056|NCT05232851|Biological|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
75440687|NCT01625351|Drug|sirolimus|"Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy."
75734057|NCT05232851|Biological|Pembrolizumab|Given IV
75734058|NCT05232851|Procedure|Computed Tomography|Undergo CT, FDG-PET/CT
75734059|NCT05232851|Procedure|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
76055317|NCT01629953|Other|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
76055318|NCT02127281|Device|Prevena|Device will be applied at end of procedure over closed incision.
76055319|NCT01628549|Drug|50 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
76055320|NCT01628549|Drug|Placebo|Dose-matched Placebo capsule administered as an oral capsule(s) once daily
75440688|NCT01625351|Drug|Busulfan|Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
75440689|NCT01625351|Drug|melphalan|Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
75440690|NCT01625351|Biological|stem cells|Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
75591068|NCT04864210|Drug|Liposomal bupivacaine|Surgeons will perform an intercostal nerve block in the operating room under thoracoscopic guidance while the patient is asleep under anesthesia. This intervention (block) is one of the standards of care but the medication (liposomal bupivacaine) currently is not FDA approved for this type of block.
75440691|NCT01625351|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
75440692|NCT01625364|Behavioral|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
75440693|NCT01625364|Behavioral|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
75440694|NCT01625403|Drug|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
75440695|NCT01625403|Drug|standard of care|standard of care for heart failure
75591069|NCT04864210|Drug|Bupivacaine|An anesthesiologist trained in regional anesthesia will perform a paravertebral block in the hospital's pain service unit. This intervention is standard of care and will use plain bupivacaine with epinephrine as the medication
75591070|NCT04853966|Behavioral|Physical activity counseling|Physical activity counseling will be performed using physical activity behavior steps of the transtheoretical model.
75734060|NCT05232851|Procedure|Biospecimen Collection|Undergo blood sample collection
75734061|NCT05232851|Procedure|Biopsy|Undergo biopsy
75734062|NCT05231070|Other|TeleSPC|Multidisciplinary video consultations with the SPC team. The team is multiprofessional and composed by physician, nurse, psychologist, social worker, physiotherapist and a chaplain, which is in line with the staffing of most SPC teams in Denmark and abroad. Video consultations will follow the same approach already used in physical consultations at the Section of Palliative Medicine, considering patients' changing needs and providing differentiated treatment and support, with the addition of a psychological intervention for dyadic coping between patient and closest informal caregiver
75734063|NCT05230745|Device|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
75734064|NCT05227326|Drug|PCNA Inhibitor AOH1996|Given PO
75734065|NCT05226871|Drug|Palbociclib|oral
75734066|NCT05226871|Drug|Cetuximab|Intravenous (IV) infusion
75734067|NCT05226871|Drug|Fulvestrant|Intramuscular (IM)
75734068|NCT05226871|Drug|Letrozole|oral
75883810|NCT02494583|Drug|Placebo|Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
76055321|NCT01628549|Drug|100 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
76055322|NCT02127125|Drug|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
76055323|NCT02127125|Drug|Synbiotic|Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
76055324|NCT02127125|Drug|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
75734069|NCT05225428|Behavioral|Video Education|Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
75734070|NCT05225428|Behavioral|Genetic Counseling|Standard genetic counseling
75734071|NCT05222451|Other|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~A variety of vegetables and fruits~Grains, at least half of which are whole grains~Fat-free or low-fat dairy~A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
75734072|NCT05222451|Other|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
75734073|NCT05222451|Other|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
75734074|NCT05218980|Dietary Supplement|Olives|Organic olives (provided by Sakellaropoulos Organic Farms; Sparta, Greece)
75734075|NCT05217849|Behavioral|Tai Chi|Tai Chi is an ancient Chinese form of exercise/martial art that involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
75734076|NCT05217849|Behavioral|Preventing Loss of Independence through Exercise (PLIE)|PLIE is a gentle, mindful movement exercise program that integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection.
75883811|NCT02466841|Procedure|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
75883812|NCT02371447|Drug|VPM1002BC|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"
75883813|NCT02359799|Device|IntelliStretch|The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
75883814|NCT02359331|Procedure|H. pylori culture and antimicrobial susceptibility testing|"This intervention will be performed in 7 days tailored therapy group.~All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method"
75883815|NCT02359331|Drug|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|"Giving the 14 days PBMT regimen as 2nd rescue therapy~Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d."
75440696|NCT01625429|Drug|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
75883816|NCT02359331|Drug|Metronidazole|
75883817|NCT02359331|Drug|Tetracycline|
75883818|NCT02359331|Drug|tripotassium dicitrate bismuthate|
75883819|NCT02359331|Drug|7 days tailored therapy Proton Pump Inhibitor|
75883820|NCT02359331|Drug|Moxifloxacin|
75883821|NCT02359331|Drug|Amoxicillin|
75883822|NCT02322814|Drug|Cobimetinib|Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
75440697|NCT01625442|Drug|Saffron tablet|Saffron tablets 100 mg
75734077|NCT05217849|Behavioral|Health and Wellness Education|This on-line class will consist of hour-long lectures/talks about various topics related to healthy aging and wellness.
75734078|NCT05215509|Behavioral|Exercise|Supervised high-intensity interval training for 12 weeks three times per week. The supervision may be physical or online supervision
75883823|NCT02322814|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
75883824|NCT02322814|Drug|Placebo|Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
75883825|NCT02322814|Drug|Atezolizumab|Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
76055325|NCT04417751|Behavioral|Cognitive Stimulation|The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation [CS] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
75440698|NCT01625442|Drug|Barberry tablet|Barberry tablets 200 mg
75440699|NCT01625442|Drug|Placebo|Placebo tablets received daily for 45 days
75440700|NCT01625468|Behavioral|Educational print materials and a coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
75440701|NCT01625481|Device|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
75591071|NCT04843488|Procedure|Guided bone regeneration with a PTFE membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws.
75591072|NCT04843488|Procedure|Guided bone regeneration with a PTFE+collagen membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws and covered with a Collagen membrane subsequently.
75440702|NCT01625494|Drug|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
75734079|NCT05215509|Behavioral|No exercise|Control group, therefore no supervised exercise regime
76055326|NCT02090413|Drug|dimethyl fumarate|
75591073|NCT04837625|Other|no interventions|no interventions
76055327|NCT02090413|Drug|acetylsalicylic acid|enteric-coated capsule
75440703|NCT01625494|Drug|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
75440704|NCT01625494|Drug|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
75440705|NCT01625494|Drug|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
75440706|NCT01625520|Drug|SOM230 alone or in combination with RAD001.|SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
75440707|NCT01625533|Procedure|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
75440708|NCT01625533|Procedure|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
75591074|NCT04837040|Drug|Paltusotine|Paltusotine, tablets, once daily by mouth
75591075|NCT04837040|Drug|Placebo|Placebo, tablets, once daily by mouth
75591076|NCT04835857|Device|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
75591077|NCT04835857|Device|Oscillometric BP Device|Oscillometric blood pressure measurement is the standard of care for measuring blood pressure in outpatient / home settings.
75591078|NCT04835857|Device|Auscultatory cuff|The auscultatory method is the gold standard for clinical blood pressure measurement. A brachial cuff is mounted and a trained healthcare provider uses a sphygmomanometer and listens for the Korotkoff sounds using a stethoscope to measure blood pressure.
75591079|NCT04831541|Drug|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
75591080|NCT04831034|Drug|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
75591081|NCT04829760|Dietary Supplement|Psyllium|Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks
75591082|NCT04829760|Dietary Supplement|Coarse wheat bran|Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks
75734080|NCT05215132|Radiation|MRI|1.5T or 3T MRI scanner (Siemens Medical Systems)
75734081|NCT05215132|Drug|Gadavist 2Ml Solution for Injection|Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
75734082|NCT05207813|Device|Intracept Procedure|Intraosseous Basivertebral Nerve (BVN) Ablation
75734083|NCT05206617|Other|No intervention - pure observational study|No intervention
75883826|NCT02322814|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
75883827|NCT02234947|Procedure|MRI, US, and blood samples|All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
75883828|NCT02170168|Other|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
75883829|NCT02161263|Other|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
76055328|NCT02090413|Drug|ASA-Placebo|matched placebo
75591083|NCT04829760|Dietary Supplement|Maltodextrin|Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (~2 tablespoons) in two doses each day for 8 weeks
75734084|NCT05205486|Drug|Cefazolin 3gm for Injection USP and Dextrose Injection USP|Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing >/= 120 kg
75734085|NCT05203159|Other|Ocean sound|The experimental group will listen to ocean sound, starting at the 1st minute before the ROP examination and ending at the 5th minute after the ROP examination.
76055329|NCT04702165|Device|lung resection with Lung Resection Marker Locator Kit|Nodules eligible for surgical resection using the Lung Resection Marker Locator Kit
76055330|NCT02063737|Behavioral|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
76055331|NCT02063737|Behavioral|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
76055332|NCT02125877|Drug|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
75734086|NCT05203159|Other|Routine|No sound will be played before, during and after the ROP examination.
75734087|NCT05200403|Drug|Crisaborole 2%|The adult caregiver will apply a thin layer of Crisaborole 2% topically on their child participant twice a day for 2 weeks.
75734088|NCT05200403|Drug|Vehicle treatment|The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).
75734089|NCT05200403|Device|Accelerometry device for children|Children participants will wear two wrist worn (or wrist worn AND ankle worn for 3 months up to <2 years) accelerometry devices. Devices will be optional for child participants who have active AD on location of device placement, with a minimum of at least one wrist device needed for enrollment.
75883830|NCT01922791|Dietary Supplement|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
75883831|NCT01904188|Device|Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z regularly)|The Gene Z device or other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
76055333|NCT02125877|Drug|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
76055334|NCT01598987|Drug|Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.|Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m^2/dose in combination wit Cyclosporine A or 2.0 mg/m^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
76055335|NCT02063659|Drug|Telotristat etiprate|Telotristat etiprate tablets
75591084|NCT04828863|Behavioral|Neurocognitive testing|Participants will undergo a battery of neurocognitive tests that examine intellectual, executive, and adaptive function. The tests will be given remotely via internet-based surveys.
75883832|NCT01837862|Drug|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
75883833|NCT01837862|Drug|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients < 12kg: 0.05 mg/kg; for patient > 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
76055336|NCT02063659|Drug|Placebo|Placebo-matching telotristat etiprate tablets
76055337|NCT02062879|Drug|Ketamine|Ketamine administered as patient-controlled analgesia.
75734090|NCT05200403|Device|Accelerometry device for adult caregivers|Adult caregiver participants will wear two accelerometry devices (one on each wrist) and complete daily assessments related to scratching, sleeping habits, pain, AD severity, quality of life, and device comfort questionnaires.
75734091|NCT05200117|Device|Pregnolia System|The cervical stiffness is measured with the Pregnolia System three times over a two-day period.
75883834|NCT01837862|Drug|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
75591085|NCT04828031|Drug|Vitamin D|Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
75734092|NCT05195138|Behavioral|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education described in study arm.
75734093|NCT05195138|Behavioral|Standard Diabetes Self-Management Education (DSME)|Standard DSME described in study arm.
75734094|NCT05193500|Behavioral|Addressed Speech|New words are introduced directly to the child by an experimenter.
75734095|NCT05193500|Behavioral|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
75734096|NCT05193149|Behavioral|Inspiratory muscle training|Training of respiratory muscles
75734097|NCT05193149|Behavioral|Exercise training|Supervised aerobic exercise intervention
76055338|NCT02062879|Drug|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
75440709|NCT01625546|Device|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
75440710|NCT01625559|Biological|MA09-hRPE|MA09-hRPE: 50,000 cells
75440711|NCT01625572|Procedure|Transversus abdominis plane blockade|Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.
75440712|NCT01625572|Procedure|Morphine-patient-controlled-analgesia-device|Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
75734098|NCT05192603|Dietary Supplement|low FODMAP or SSRD|The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
75883835|NCT01837862|Drug|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
76055339|NCT02062645|Drug|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
75591086|NCT04826861|Behavioral|SLIM intervention|Core components: 1) goal setting, 2) motivational interviewing, 3) feedback, 4) health technology
75440713|NCT01625598|Procedure|Photography of the retina|Every subject will undergo photography of the retina in both eyes
75440714|NCT01625598|Procedure|Retinal photography|"Device~Subjects will have photography of both eyes"
75440715|NCT01625624|Other|Carbohydrate Food Bar|Control Food Bar containing carbohydrate
75591087|NCT04825496|Genetic|ssCART-19 Cells|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
75591088|NCT04825496|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
75591089|NCT04825496|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
75591090|NCT04815239|Behavioral|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.
75734099|NCT05188807|Diagnostic Test|Airway ultrasonography|we will measure hyomental distance, skin-epiglottis distance, skin-hyoid distance, epiglottis-vocalcords distance
75734100|NCT05188508|Drug|Pembrolizumab|Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.
75734101|NCT05188508|Combination Product|Olaparib and Temozolomide|Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.
75734102|NCT05185115|Drug|Oxygen|administration of oxygen at a flow rate of 3 liters per minute, via nasal cannula throughout the hospitalization.
75734103|NCT05185115|Other|no oxygen therapy|No oxygen therapy during hospitalization
75591091|NCT04815239|Behavioral|The Healthy Lifestyle Behavior Intervention (HL)|HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
75591092|NCT04809220|Drug|Dulaglutide|Administered SC
75591093|NCT04809220|Drug|Oral antihyperglycemics|Administered orally
75883836|NCT01837862|Drug|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
75440716|NCT01625624|Other|Modified Carbohydrate Food Bar|Test Food Bar containing modified carbohydrate
75883837|NCT01837862|Drug|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
75883838|NCT01675219|Procedure|white light TUR-BT|traditional transurethral bladder tumor resection
75883839|NCT01675219|Procedure|blue light TUR-BT|photodynamic transurethral bladder tumor resection
75883840|NCT01675219|Drug|optimized MMC|six weekly optimized mitomycin-C instillations
75883841|NCT01675219|Drug|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
75883842|NCT01436227|Other|Laboratory Biomarker Analysis|Correlative studies
75883843|NCT01436227|Drug|Pazopanib Hydrochloride|Given PO
75440717|NCT01625637|Behavioral|AAT-experiment|This AAT condition trains kids to avoid cigarettes
75440718|NCT01625637|Behavioral|AAT-placebo|This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
75440719|NCT01625676|Other|Investigate efficacy of modified ciat schedule|2 hours of training over 15 days
75440720|NCT01625676|Other|examine the efficacy of standard treatment versus modified ciat schedule|2 hours of training over 15 days
75440721|NCT01625702|Device|CellSearch® CTC kit|"Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
75440722|NCT01625715|Drug|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
75440723|NCT01625741|Drug|Rituximab|2000 mg, IV, monthly, for 4 months (= 4 doses)
75440724|NCT01625754|Behavioral|Exercise|All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
75440725|NCT01625767|Behavioral|AAT experiment|Smokers and nonsmokers complete AAT experiment
75440726|NCT01625780|Procedure|3-layer block|"0.3 mL/kg of 0.25% bupivacaine (one injection in each layer) will be delivered by the 3-layer method using a standard 20-gauge block needle."
75440727|NCT01625780|Procedure|Single-shot block|0.3 mL/kg of 0.25% bupivacaine will be delivered by the standard, single-shot method using a 20-gauge block needle.
75883844|NCT01333033|Drug|Oxaliplatin|Given IV
75883845|NCT01333033|Drug|Leucovorin Calcium|Given IV
75883846|NCT01333033|Drug|Fluorouracil|Given IV
75591094|NCT04804969|Device|MyoVista wavECG Test|The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.
75591095|NCT04800471|Device|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
75591096|NCT04800471|Other|Point of Care Glucose Group|Participants in this group will be monitored by POC glucose values.
75591097|NCT04798755|Drug|Methotrexate|Inicial dose 15mg/week increasing up to 25 mg/week
75591098|NCT04798755|Drug|Adalimumab|At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.
75883847|NCT01333033|Drug|Carboplatin|Given IV
75883848|NCT01333033|Drug|Paclitaxel|Given IV
75883849|NCT01333033|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75440728|NCT01625793|Drug|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
75734104|NCT05184816|Drug|Deferoxamine (DFO)|The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
75734105|NCT05184621|Other|Eyesing Redlight Instrument|Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.
75734106|NCT05183776|Device|Fractional administration device|The novel fractional administration device enable the administration of the microspheres in fractions determined by the user. For this study, 5 fractions of 20% will be administered and validated using MRI.
75883850|NCT01333033|Procedure|Computed Tomography|Undergo PET/CT scan
75440729|NCT01625806|Drug|RO4602522|Single oral dose
75440730|NCT01625806|Drug|ketoconazole|Multiple oral doses
75440731|NCT01625819|Behavioral|Tai Chi|32 1-hour bi-weekly group sessions of Tai Chi instruction
75591099|NCT04798755|Drug|Adalimumab+Methotrexate|"Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.~Methotrexate:Inicial dose 15mg/week increasing up to 25 mg/week"
75591100|NCT04797897|Device|CORI|unicondylar knee arthroplasty (UKA) treated with CORI
75440732|NCT01625819|Behavioral|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
75440733|NCT01625819|Behavioral|Health Education|32 1-hour bi-weekly group sessions of health education
75440734|NCT01625832|Procedure|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
75440735|NCT01625871|Drug|tablets artemether/lumefantrine|six doses of oral tablets of artemether/lumefantrine
75440736|NCT01625936|Drug|CRLX101 (Cerulean)|CRLX101 is an innovative tumor-targeting nanopharmaceutical.
75440737|NCT01625936|Drug|Bevacizumab|
75440738|NCT01625949|Procedure|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
75440739|NCT01625949|Procedure|coronary dilatation and stenting|coronary dilatation and stenting
75440740|NCT01626001|Procedure|4D CT scans|4 (or 5 for Cohort 2) 4DCT scans performed. 1 scan performed while breath held for less than 20 seconds. CT scans take about 5 minutes each to complete.
75440741|NCT01626014|Behavioral|Usual Care Educational Website|Using the control website: Participants access a website with standard ovarian cancer informational handouts.
75591101|NCT04797897|Device|Conventional|unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation
75440742|NCT01626014|Behavioral|Prototype System|An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
75440743|NCT01626040|Drug|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
75440744|NCT01626053|Behavioral|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
75440745|NCT01626053|Other|Control Group|no intervention
75440746|NCT01626066|Drug|LUM015|LUM015 assigned dose given once by IV push
75591102|NCT04794816|Other|Questionnaire Administration|Complete questionnaire
75591103|NCT04787783|Other|Web based preoperative assessment|Preoperative assessment conducted through a web based application
75734107|NCT05178862|Drug|SCY-078|Oral ibrexafungerp (SCY-078) as step-down therapy.
75734108|NCT05178862|Drug|Fluconazole|Oral fluconazole (SCY-078) as step-down therapy.
75883851|NCT01333033|Radiation|Radiation Therapy|Undergo RT
75734109|NCT05178862|Drug|Echinocandin|Intravenous echinocandin
75883852|NCT01327690|Behavioral|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
75883853|NCT01327690|Behavioral|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
75883854|NCT01192776|Procedure|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
75440747|NCT01626131|Behavioral|exercise training|"Participants will engage in 3 aerobic and resistance exercise sessions (~60-75 min total per session) weekly for 8 consecutive weeks.~Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.~Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form."
75440748|NCT01626131|Behavioral|Stretching training|Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
75591104|NCT04783779|Device|Implant of STARgraft-2 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
75591105|NCT04778371|Other|Almonds|64 g total dry roasted, unsalted almonds per day for a total of 12 weeks
75591106|NCT04778371|Other|Placebo|200 g total calorie matched granola bar per day for total of 12 weeks
75591107|NCT04775550|Drug|Daratumumab|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
75734110|NCT05171153|Other|Densitometry with Trabecular Bone Score|"Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine."
76055340|NCT04700839|Drug|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
75591108|NCT04775550|Drug|Bortezomib|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
75591109|NCT04775550|Drug|Lenalidomide|Oral, dosage per protocol, days 1-21 per cycle
76055341|NCT04700839|Drug|Metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
76055342|NCT02088697|Drug|Placebo|
75440749|NCT01625156|Other|Laboratory Biomarker Analysis|Correlative studies
75440750|NCT01625156|Other|Pharmacological Study|Correlative studies
75591110|NCT04775550|Drug|Dexamethasone|Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
75591111|NCT04775082|Drug|Liraglutide|"The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.~The dose will increase each week over 4 or 5 weeks until the final dose is reached."
76055343|NCT02088697|Drug|ASC-01|
76055344|NCT01825785|Drug|Romosozumab|Administered by subcutaneous injection
75591112|NCT04775082|Drug|Placebo|The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
75591113|NCT04774991|Drug|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children as follows:~Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~For children 1 to <12 months of age, weight-based dosing will be used~For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
75591114|NCT04773600|Drug|Roflumilast (ARQ-151) cream|Roflumilast (ARQ-151) cream 0.15% - Active
75591115|NCT04773600|Drug|Vehicle cream|Vehicle cream
75734111|NCT05171153|Other|Quantitative Ultrasound of Calcaneus|Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).
75734112|NCT05171153|Other|Laboratory test|Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
75734113|NCT05168423|Drug|CART-EGFR-IL13Ra2 Cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
76055345|NCT01825785|Drug|Placebo|Administered by subcutaneous injection
76055346|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
76055347|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
76055348|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
76055349|NCT01598753|Drug|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
75591116|NCT04769024|Device|LUMEEN Virtual Reality sessions|"It will consist in carrying out 12 virtual reality sessions in groups of 6 participants, at a rate of 2 per week for approximately 6 weeks, using the LUMEEN EVASION module. Each session lasts approximately 45 minutes. This module allows the simultaneous broadcasting in virtual reality headsets of 360° videos accompanied by music about different themes: nature, animals, travel, art and live performance.~The course of an EVASION session is as follows:~The participants are seated in armchairs in an open environment and sufficiently spaced so that they can move their arms without bumping into each other.~The facilitator announces the immersion theme of the session~Participants are equipped with virtual reality head-mounted displays.~Participants watch the content.~The head-mounted displays are removed.~A group discussion encouraging participants to share their feelings and what they have learned from the immersion is conducted by the facilitator."
75440751|NCT01625156|Drug|Temsirolimus|Given IV
75440752|NCT01625156|Drug|Tivantinib|Given PO
75440753|NCT01626170|Other|laboratory biomarker analysis|Correlative studies
76055350|NCT01598753|Drug|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
75440754|NCT01626183|Genetic|RNA analysis|
75440755|NCT01626183|Genetic|proteomic profiling|
75440756|NCT01626183|Other|laboratory biomarker analysis|
75440757|NCT01626196|Other|No intervention|This was an observational study
75440758|NCT01626209|Drug|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
75734114|NCT05165888|Behavioral|Communication and Bias Mitigation Training|Training to improve communication skills and reduce the effect of racial bias on clinician communication behavior
75734115|NCT05165888|Behavioral|Communication skills training|Training to improve communication skills between physicians and caregivers.
75734116|NCT05163353|Device|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
75734117|NCT05162664|Other|Pressure pain thresholds|PPT will be performed firstly at the anterior tibial muscle halfway between the most superior attachment to the tibia and its tendon in the upper one third of the muscle belly (13) and secondly at the middle of the temporalis muscle (12), using a digital algometer (Wagner FPX 50) with a 1 cm2 rubber tip. The pressure algometer will apply a perpendicular increasing pressure (1kg/s) at the different test locations until the participant reports the first feeling of pain. The PPT of 4 series of ascending stimulus intensities, with an inter-stimulus interval (ISI) of 20sec between the different stimuli and an ISI of 60sec between the 2 locations, will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated.
75883855|NCT01169831|Other|Exercise Training|2 weeks of daily aerobic exercise training
76055351|NCT01598753|Behavioral|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
76055352|NCT01598753|Behavioral|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
76055353|NCT02177123|Device|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
76055354|NCT01824693|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
75440759|NCT01626222|Drug|Exemestane|Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
75440760|NCT01626222|Drug|Everolimus (RAD001)|Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
75883856|NCT01169831|Other|Exercise Cessation|Stopping all exercise for 2 weeks
76055355|NCT01824693|Drug|Busulfan|Given IV
76055356|NCT01824693|Drug|Cyclophosphamide|Given IV
76055357|NCT01824693|Drug|Fludarabine Phosphate|Given IV
76055358|NCT01824693|Other|Laboratory Biomarker Analysis|Correlative studies
76055359|NCT01824693|Drug|Melphalan|Given IV
76055360|NCT01824693|Drug|Mycophenolate Mofetil|Given IV or PO
76055361|NCT01824693|Other|Pharmacological Study|Correlative studies
76055362|NCT01824693|Drug|Tacrolimus|Given IV or PO
75591117|NCT04769024|Behavioral|Control/non-digital stimulation sessions|It will consist in non-digital stimulation (sensory, social, cognitive, creative) group sessions offering various typical pen-and-paper activities for this public which mainly stimulate language, immediate memory, semantic memory, and visual recognition (e.g., definitions, games of 7 differences, reconstruction of proverbs, quizzes…). A set of activities with instructions will be provided to the investigating centres but the choice of activities in each session will be left to the facilitator's decision in order to adapt the sessions to the participants' desires and abilities, as is usually done in such stimulation groups. The sessions will last 45 minutes and will be offered twice a week for 6 weeks by a facilitator or a caregiver with group care training. The sessions will be organized in groups of 6 participants to match the group size of the intervention groups.
75591118|NCT04768621|Other|Questionary|Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
75734118|NCT05162664|Other|Thermal detection and pain thresholds|The thermal tests will be performed unilateral at tibial anterior, thenar and the forehead, using a TSA-2 (Neuro Sensory Analyzer, MEDOC). At first cold and heat detection thresholds will be measured. The patient will be asked to indicate when they feel a change in temperature. Afterwards the patient will be asked to indicate when the stimulus becomes painful to determine the cold and heat pain thresholds. The thresholds of 4 series of stimuli will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated for every location. The subject will push a button when the thresholds are reached. The baseline temperature will be 32°C and the stimuli will increase with 1°C/s (14).
75883857|NCT00904241|Other|Cytology Specimen Collection Procedure|Correlative studies
76055363|NCT02176655|Drug|VVD-101|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
76055364|NCT02176655|Drug|Placebo|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
76055365|NCT02125331|Procedure|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
75440761|NCT01626261|Device|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
76055366|NCT01622569|Drug|Fluticasone Propionate|Delivered via Optinose Exhalation Delivery System
75591119|NCT04764162|Dietary Supplement|Choline capsule|Participants will consume 1000 mg (2 x 500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. They will continue to consume 1000 mg of choline bitartrate during the post-testing period.
75440762|NCT01626274|Device|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
75591120|NCT04764162|Dietary Supplement|Placebo capsule|Participants will consume 1000 mg (2 x 500 mg) of placebo (maltodextrin) for 28 consecutive days. They will continue to consume 1000 mg of placebo during the post-testing period.
76055367|NCT01824303|Drug|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
76055368|NCT01824303|Other|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
75440763|NCT01626287|Other|Frozen perineal pad|Frozen ice pads will be provided as per participants' request
75591121|NCT04762290|Other|Dance|The intervention is a series of expressive dance movements.
75591122|NCT04761120|Device|Abbott SJM Rigid Saddle Ring|The Abbott SJM Rigid Saddle Ring is a rigid, polyester-velour-covered, titanium alloy mitral annuloplasty ring with a saddle shape intended to mimic the shape of a healthy mitral annulus during systole.
75591123|NCT04761120|Device|Abbott SJM Séguin Ring|The Abbott SJM Séguin Ring is a semi-rigid, polyester-velour-covered, polyethylene mitral annuloplasty ring that varies in thickness and flexibility over its circumference, with the posterior portion of the ring having greater flexibility than the anterior portion.
75883858|NCT00904241|Other|Laboratory Biomarker Analysis|Correlative studies
75883859|NCT00778063|Drug|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
76055369|NCT01853397|Device|Liposonix System (Model 2)|
75440764|NCT01626287|Other|Warm water soaked Black Tea Bags|warm water soaked black tea bags will be provided to participants' as per their request
75440765|NCT01626326|Behavioral|San Francisco Stop Smoking iPhone app|iPhone app designed to help people quit smoking
75440766|NCT01626339|Drug|Intravitreal Ranibizumab|
75440767|NCT01626339|Drug|Intravitreal bevacizumab|
75883860|NCT00778063|Drug|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
76055370|NCT02088073|Drug|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
76055371|NCT02088073|Drug|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
76055372|NCT01823991|Drug|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
75440768|NCT01626365|Procedure|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
75440769|NCT01626365|Procedure|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
76055373|NCT01823991|Other|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
75440770|NCT01626417|Device|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
76055374|NCT01823991|Drug|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
75440771|NCT01626430|Dietary Supplement|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
75440772|NCT01626430|Dietary Supplement|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
75440773|NCT01626443|Dietary Supplement|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
75440774|NCT01626443|Dietary Supplement|Folic acid|Folic acid (200 mcg); 2 x die
75440775|NCT01626469|Drug|Captopril|25mg Captopril
75591124|NCT04761120|Device|Abbott SJM Tailor Ring|The Abbott SJM Tailor Ring is a flexible, polyester-velour-covered, silicone annuloplasty ring indicated for use in surgical repair of the mitral or tricuspid valve. The Tailor Ring can be implanted as a full annuloplasty ring, or the surgeon can remove the ring's cut zone with a scalpel and use the partial Tailor Ring as a posterior annuloplasty band.
75591125|NCT04761120|Device|Abbott SJM Tailor Band|The Abbott SJM Tailor Band is a flexible, polyester-velour-covered, silicone band for posterior annuloplasty indicated for use in surgical repair of mitral or tricuspid valve. The Tailor Band is identical to the Tailor Ring with the cut zone removed, save that the polyester covering is sewn closed at the ends of the band during manufacturing.
75591126|NCT04760652|Behavioral|Cognitive Behavioral Therapy CBT|CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT
75591127|NCT04760613|Drug|Cannabidiol|600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)
75591128|NCT04760613|Drug|Placebo|identical capsules containing placebo (taken daily by mouth)
75440776|NCT01626469|Drug|placebo|placebo
75440777|NCT01626482|Other|Kinesio Taping|"The taping consisted of two strips of material in the form of I on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12."
75883861|NCT00737399|Behavioral|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
75883862|NCT00547196|Biological|filgrastim|
76055375|NCT04729855|Diagnostic Test|serum HOTTIP ,EIF4EBP1 and serum SNP HOTTIP rs1859168|5 ml fresh blood sample
75440778|NCT01626482|Other|Placebo|The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
75440779|NCT01626521|Other|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
75440780|NCT01626534|Drug|Clopidogrel|600mg loading dose then 75mg/day
75440781|NCT01626534|Drug|trigagrelor|180 mg loading dose then 90 mg Twice a day
75440782|NCT01626560|Drug|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
75440783|NCT01626560|Drug|Vancomycin|Vancomycin 1g q12h 10 - 14 days
75440784|NCT01626586|Behavioral|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
75440785|NCT01626612|Procedure|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
75440786|NCT01626612|Procedure|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
75440787|NCT01626625|Drug|stem cells + hydroxy apatite|patient will be transplanted with stem cells and hydroxyapatite
75440788|NCT01626625|Other|autograft taken from iliac crest|patient will be transplanted with autograft
75440789|NCT01626638|Procedure|Confocal Micro Endoscopy|
75440790|NCT01626651|Drug|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
75440791|NCT01626651|Drug|Ketoconazole|Ketoconazole (400 mg [2 x 200 mg] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
75591129|NCT04759911|Other|Quality-of-Life Assessment|Ancillary studies
75591130|NCT04759911|Other|Questionnaire Administration|Ancillary studies
75591131|NCT04759911|Drug|Selpercatinib|Given PO
75591132|NCT04759911|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
75883863|NCT00547196|Drug|Busulfan|
75883864|NCT00547196|Drug|Cyclophosphamide|
75883865|NCT00547196|Drug|Cyclosporine|
75883866|NCT00547196|Drug|Fludarabine phosphate|
75883867|NCT00547196|Drug|Melphalan|
75883868|NCT00547196|Drug|Mycophenolate Mofetil|
75883869|NCT00547196|Procedure|allogeneic hematopoietic stem cell transplantation|
75883870|NCT00547196|Procedure|umbilical cord blood transplantation|
76055376|NCT02087059|Drug|Ruxolitinib|
75591133|NCT04751292|Other|Exposure to high altitude|permanence at high (>2500 m) altitude; permanence is defined as being born and living at high altitude with the total time spent at lower altitudes not exceeding 2 years in the past 10 years
75591134|NCT04744883|Other|Spinal Manipulation Therapy (SMT)|2 SMT techniques are administered each session, both of which are scripted interactions between the physical therapist (PT) providing the SMT and the subjects: 1) Participants will lie on the SMT table for 20 mins, while the PT sits approximately 6 ft away. As part of the script, the PT will review with subjects the inclusion/exclusion criteria ostensibly to ensure that nothing has changed. 2) The PT will perform the 2 SMT techniques during the next 20 mins. 3) Subjects will sit upright in a chair for the remaining 20 mins, while the PT sits approximately 6 feet away. The PT will review home exercises with participant.
75591135|NCT04744883|Drug|Naloxone|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
75591136|NCT04744883|Drug|Placebo|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
75591137|NCT04744883|Behavioral|Mindfulness Based Stress Reduction Therapy (MT)|Each MT session consists of (a) body scan meditation accompanied by awareness of breathing and other bodily sensations while in a lying position, (b) sitting meditation, focusing on awareness of breathing, bodily sensations, thoughts, and emotions (c) gentle movement exercises intended to develop awareness (mindfulness) during movement. In-session activities include suggestions for application of mindfulness as a method for responding positively to stress; dealing with the challenges of pain; and exercises focusing on the challenges and achievements patients experience in integrating mindfulness into their lives and the stressful situations they encounter. Additional discussion will focus on stress reactivity and they will be taught problem-solving skills to develop solutions to meet MT goals. Finally, patients will develop a written maintenance plan that includes a list of short- and long-term goals for applying mindfulness methods and a plan for dealing with possible setbacks.
75591138|NCT04740827|Drug|Atogepant 60 mg|Atogepant tablets.
75440792|NCT01626677|Biological|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
75440793|NCT01626677|Procedure|Microfracture|Active control
75440794|NCT01626703|Other|Reminding call|
75440795|NCT01626716|Other|care management|patients who assigned to the intervention group will take 7 times phone calls from case manager
75440796|NCT01626729|Behavioral|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
75591139|NCT04740827|Drug|Placebo|Atogepant matching placebo tablets.
75883871|NCT00547196|Radiation|total-body irradiation|
75440797|NCT01626729|Behavioral|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
75440798|NCT01626729|Behavioral|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
75883872|NCT00547196|Radiation|Fractionated total body irradiation|
75883873|NCT00330941|Drug|lidocaine|
75734119|NCT05162664|Other|Temporal summation|The temporal summation will be assessed at the thenar eminence (19,20) using a ramp and hold protocol with the TSA-2 (Neuro Sensory Analyzer, MEDOC). Heat stimuli will be applied for a duration of 15sec. The stimulus temperature will increase from a baseline temperature of 35°C for 9sec at a sensitivity-adjusted rate of about 1,5°C/s until the HTP 5/10 of the thenar is reached. Afterwards the temperature will remain steady for the next 6 seconds. The maximal pain rating should be 50 ± 10 NRS. Subjects rate the pain intensity at the end of the ramp (9sec) and at the end of the hold procedure (15sec) using the NRS. Afterwards the ramp and hold aftersensations are measured. The subjects have to rate the pain intensity every 5sec for 30sec after the termination of the heat stimulus.
75591140|NCT04740697|Other|Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.|"Each included patient will be referred to the health care staff for a blood sample:~for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...)."
75734120|NCT05162664|Other|Conditioned pain modulation|CPM will be assessed by comparing heat pain thresholds and pressure pain thresholds before and after giving a conditioning stimulus at a pain free distant zone by using a second thermode of the TSA-2 (17). The conditioning stimulus (HPT 4/10 (18) at the TA) will be applied for 120 seconds. The first test stimulus will be applied at the forehead 30 seconds after the start of the conditioning stimulus (17). The HPT will be measured twice with an ISI of 20 seconds. Immediately after the end of the application of the conditioning stimulus (120 seconds), the HPT at the forehead will be measured again twice, with an ISI of 20 seconds. Afterwards, there will be 10 minutes of rest to avoid bias.
75734121|NCT05162508|Other|Nasopharyngeal swab|Nasopharyngeal swab available in Standard Of Care (SOC) will be analysed (Full-length SARS-CoV-2 RNA sequencing and Transcriptomic analyses)
75883874|NCT02135978|Other|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
75883875|NCT03603054|Other|Active neck mobilization|The subjects, receive an active neck mobilization intervention.
75883876|NCT03603054|Other|Active Mobilization of the sciatic nerve|The subjects, receive an active sciatic nerve mobilization intervention.
75883877|NCT05759923|Drug|OATD-02|Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
75440799|NCT01626729|Behavioral|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
75440800|NCT01626729|Behavioral|No label control group|No label control group
75440801|NCT01626742|Other|Ready to Drink Flavored Beverage|2 servings a day
75883878|NCT02136056|Behavioral|Self-management program (SMP)|A self-management course
75883879|NCT03149107|Drug|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
75883880|NCT03149107|Drug|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
75440802|NCT01626742|Other|Ready to drink flavored beverage w/ AN 777|2 servings a day
75440803|NCT01626755|Procedure|Sciatic name block|Ultrasound-guided sciatic nerve block.
75440804|NCT01626781|Device|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
75591141|NCT04739696|Behavioral|PEPRR|Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)
75883881|NCT03149107|Behavioral|IPPI (Integrated Preventive Psychological Intervention)|IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater)
75883882|NCT03149107|Behavioral|PSM (Psychological stress management)|PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).
75883883|NCT03606564|Other|study of fasting time among pediatric patients undergoing day care surgery|parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
75440805|NCT01626781|Other|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
75440806|NCT01626794|Biological|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
76055377|NCT04747301|Device|Double-balloon catheter (UTAH CVX-RIPE) for cervical ripening|"Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA). The catheter will be inserted manually until the proximal balloon is in the cervical canal, the distal balloon should be intrauterine and in the extra-amniotic space. The intrauterine balloon is inflated with 40mL saline and retracted so that it rests against the internal oz. The proximal balloon should now be outside the external oz and is inflated with 20mL saline. If the balloons are correctly situated on both ends of the cervix, they can be inflated with up to 80mL saline each.~Cardiotocograph will be performed 30min, 2 hours after insertion and every 6 hours. The balloon is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another balloon is placed for a maximum of another 24 hours.~The patients will be examined in case of extremely painful or membranes ruptured."
76055378|NCT04747301|Drug|Dinoprostone 10mg (Propess)|"Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured."
75883884|NCT03550976|Behavioral|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
76055379|NCT02152163|Drug|IV Ibuprofen|
76055380|NCT02152163|Drug|placebo|
76055381|NCT02152007|Drug|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
76055382|NCT02151851|Biological|Certolizumab Pegol|"Active substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringes~Concentration: 200 mg/ml~Route of administration: Subcutaneous injection"
75591142|NCT04739696|Behavioral|Pep-Pal|Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
75591143|NCT04739124|Other|Follow-up questionnaires|"The patient normally follows the education program as usual but research specific data is collected:~Biological sampling at the start and end of the education program (glycated hemoglobin).~Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)"
75440807|NCT01626794|Biological|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
75440808|NCT01626794|Biological|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
75440809|NCT01626807|Behavioral|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
75440810|NCT01626833|Drug|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
75591144|NCT04739124|Other|Interviews|Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.
75883885|NCT03135301|Drug|letrozole plus metformin|letrozole 5 milligram tablets plus metformin 850 milligram tablets
75883886|NCT03135301|Drug|letrozole|letrozole 5 milligram tablets
76055383|NCT02151851|Drug|Methotrexate|"Active substance: Methotrexate~Pharmaceutical form: Tablet~Concentration: Maximum dose 10 mg per week~Route of administration: Oral"
76055384|NCT02151851|Other|Placebo|"Active substance: Placebo~Pharmaceutical form: Prefilled syringes~Concentration: 0.9 % saline~Route of Administration: Subcutaneous injection"
76055385|NCT02176421|Device|VOLBELLA® with lidocaine|VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
75440811|NCT01626833|Biological|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
75883887|NCT03550274|Device|App-based exercise rehabilitation|"App-based exercise rehabilitation available on any mobile device and/or tablet using Android or iOS operating systems. The app Injurymap© is hosting the exercise program. The app requires user-registrations and a monthly paid subscription fee to access the exercise program. The participants in this study will not be charged for using the app.~The exercise program consists of three phases with increasing difficulty. Each phase consists of several categories of exercise types. The categories are 1) mobility, 2) stability/balance, 3) strength and 4) stretching. Within each phase, there can be more than one exercise for each category. This makes it possible to adjust the difficulty of the exercises depending on user-feedback."
75440812|NCT01626898|Behavioral|HOLA en Grupos|HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
75591145|NCT04732494|Drug|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
75591146|NCT04732494|Drug|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
75440813|NCT01626898|Behavioral|General Health intervention (comparison intervention )|The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
75591147|NCT04732494|Drug|Placebo|Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
75883888|NCT03602898|Biological|Anti-Thymocyte Globulin|Given IV
75883889|NCT03602898|Drug|Busulfan|Given IV or PO
75883890|NCT03602898|Drug|Cyclophosphamide|Given IV
75883891|NCT03602898|Drug|Cyclosporine|Given IV or PO
75883892|NCT03602898|Drug|Fludarabine Phosphate|Given IV
75734122|NCT05157438|Behavioral|virtual reality device|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, it has been used to manage cases of phobia and extreme fear through the use of exposure-based treatment programs. The virtual reality system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment into which the child can be entirely immersed. It works to distract the brain from the painful procedure and reduce the perception of pain stimuli
75440814|NCT01626911|Procedure|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
75883893|NCT03602898|Drug|Methotrexate|Given IV
75440815|NCT01626911|Other|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
75883894|NCT03602898|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplantation
75591148|NCT04732273|Other|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests depending on examined organ system (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels).
75883895|NCT03602898|Other|Quality-of-Life Assessment|Ancillary studies
75883896|NCT03602898|Other|Questionnaire Administration|Ancillary studies
75883897|NCT03602898|Drug|Tacrolimus|Given IV or PO
75883898|NCT03602898|Radiation|Total-Body Irradiation|Undergo TBI
76055386|NCT02042443|Drug|Capecitabine|Given PO
75591149|NCT04732273|Other|Personal history, questionnaire|Personal history and focused questionnaires per organ system including symptoms, medication use, physical activity, and general wellbeing.
75734123|NCT05157438|Behavioral|screen programs|the screens are used for distraction during dental treatments. they could be on tablets, iPads or televisions.
75734124|NCT05155449|Dietary Supplement|Probiotics|Capsule
75734125|NCT05155449|Dietary Supplement|Placebo|Capsule
75734126|NCT05152147|Drug|Zanidatamab|Administered IV
76055387|NCT02042443|Drug|Fluorouracil|Given IV
75734127|NCT05152147|Drug|Tislelizumab|Administered IV
75591150|NCT04725240|Drug|Setmelanotide|Setmelanotide for SC injection
75591151|NCT04721132|Biological|Atezolizumab|Given IV
75734128|NCT05152147|Drug|Trastuzumab|Administered intravenously (IV)
75591152|NCT04721132|Biological|Bevacizumab|Given IV
75591153|NCT04721132|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75734129|NCT05152147|Drug|Capecitabine|Administered orally (PO bid)
75734130|NCT05152147|Drug|Oxaliplatin|Administered IV
75734131|NCT05152147|Drug|Cisplatin|Administered IV
75734132|NCT05152147|Drug|5-Fluorouracil|Administered IV
75734133|NCT05143567|Other|standard of care anticoagulation in absence of thrombotic complications|Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
75734134|NCT05143567|Other|standard of care anticoagulation in presence of thrombotic complications|Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
76055388|NCT02042443|Other|Laboratory Biomarker Analysis|Correlative studies
75591154|NCT04721106|Drug|Vizimpro|treatment group
75591155|NCT04721067|Device|SHUTi|SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.
75734135|NCT05143567|Other|standard of care anticoagulation in combination with elastic compression|Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
75734136|NCT05139979|Behavioral|Breathing and Wellness Webinar|"Simha Kriya : a 3-minute energizing breathing practice to expand lung capacity and improve immunity, to be practiced twice daily.~Nadi Shuddhi - a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.~Isha Kriya - a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily."
75734137|NCT05139979|Other|Routine Daily Activity|Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.
75734138|NCT05139563|Other|Placebo injection: Intralipid 20% fat emulsion|placebo intralipid 20% intramuscular (IM) injection
75734139|NCT05139563|Other|Placebo implant|placebo subdermal implant rod
75734140|NCT05139121|Drug|MR-100A-01|Transdermal contraceptive delivery system
76055389|NCT02042443|Drug|Leucovorin Calcium|Given IV
76055390|NCT02042443|Drug|Trametinib|Given PO
76055391|NCT02118896|Drug|FK506E|oral
76055392|NCT02124707|Drug|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
75734141|NCT05138549|Drug|Astaxanthin|12 mg oral astaxanthin supplement
75734142|NCT05138549|Other|Placebo|Oral placebo identical to astaxanthin supplement
75734143|NCT05137743|Behavioral|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
75734144|NCT05137743|Behavioral|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
75734145|NCT05135377|Other|Observational|Not applicable - observational study
75734146|NCT05130593|Dietary Supplement|Nutrasorb bar|250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
75883899|NCT02983747|Other|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
76055393|NCT02124707|Drug|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
76055394|NCT02124707|Drug|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
76055395|NCT02067728|Behavioral|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
76055396|NCT02067728|Behavioral|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
76055397|NCT02118428|Device|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
76055398|NCT02118428|Biological|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
76055399|NCT02067104|Drug|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
76055400|NCT02067104|Drug|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
75734147|NCT05127603|Behavioral|Cognitive behavioral intervention|Individually tailored physiotherapy that fits within the guideline non-specific neck pain (KNGF, 2016) with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior, by means of communication, body awareness exercises, functional movements and exposure techniques. Tools are supplied to create an appropriate explanatory model for the pain, for functional movement behavior and active coping in a patient's daily lives.
75591156|NCT04721067|Behavioral|Sleep Education/Hygiene|A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
75591157|NCT04717843|Other|4D Flow MRI|Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.
75591158|NCT04717843|Other|Medical consultation with 12 leads ECG|Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.
75440816|NCT01626924|Drug|2-Iminobiotin|2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
75440817|NCT01626937|Other|Non invasive ventilation|After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
75440818|NCT01626937|Other|conventional medical treatment|Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
75440819|NCT01626963|Procedure|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
75440820|NCT01626963|Procedure|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
75440821|NCT01626976|Drug|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
75440822|NCT01626976|Drug|Placebo|Solution, single dose
75591159|NCT04717843|Other|Holter ECG|48 hours ECG recording
75591160|NCT04717843|Other|Trans thoracic echocardiography|Trans thoracic echocardiography with standard measures performes in the core lab.
76055401|NCT02092220|Device|Bionic Pancreas|
75591161|NCT04717843|Biological|Blood sample|Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.
75591162|NCT04717843|Other|Standard MRI|Acquisitions of MR imagining
75591163|NCT04715035|Other|Physical therapy interventions|mobilization, stretch, education, eccentric exercises
75591164|NCT04713150|Other|No Intervention|No Intervention
75591165|NCT04713124|Behavioral|R2C-M|R2C-M comprises 12 modules addressing core practice elements and skills from evidence-based cognitive and behavioural interventions. Modules include: (i) self-monitoring, goal setting and behaviour change skills; (ii) identification of strengths and motivational enhancement; (iii) relapse prevention; (iv) psychoeducation and harm reduction; (v) emotion regulation skills; (vi) anger management skills; (vii) urges and cravings management skills; (viii) sleep hygiene skills; (ix) mindfulness skills; (x) interpersonal skills; (xi) anxiety management skills; (xii) depressed mood management skills. The R2C-M workbooks contain psychoeducation and intervention exercises, to facilitate counsellor-delivered exercises within sessions, and between-session practice.
75440823|NCT01626976|Drug|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
75440824|NCT01626976|Drug|Placebo|suspension, single dose
75440825|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
75440826|NCT01626976|Drug|Placebo|suspension, single dose
75440827|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
75440828|NCT01626976|Drug|Placebo|suspension, single dose
75734148|NCT05122078|Device|ANI|Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
75883900|NCT02983747|Drug|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
75734149|NCT05122078|Other|Control|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.
76055402|NCT02092220|Device|Insulin pump with or without CGM|
75734150|NCT05106595|Device|Bimanual Arm Trainer|tabletop/desktop device that couples bilateral simultaneous upper extremity movement with virtual reality games or activities via computer monitor
75734151|NCT05106387|Other|Noninterventional|No investigational treatment will be given in this noninterventional extension study
75734152|NCT05091190|Other|Blood draws|"Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration."
75883901|NCT02128412|Device|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
75883902|NCT02128412|Device|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
75883903|NCT05759845|Drug|Topiramate 25Mg Tab|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
75440829|NCT01626976|Drug|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
75440830|NCT01626976|Drug|Placebo|suspension, single dose
75440831|NCT01627015|Other|Modified infant follow-on formula|The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
75883904|NCT05759845|Drug|Amitriptyline 25 Mg Oral Tablet|Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
76055403|NCT02066402|Drug|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
76055404|NCT02066402|Drug|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
75440832|NCT01627015|Other|Standard infant follow-on formula|Infants are fed a commercial follow-on formula
75440833|NCT01627028|Procedure|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
75440834|NCT01627041|Drug|Cytarabine|Given IV
75440835|NCT01627041|Drug|Daunorubicin Hydrochloride|Given IV
75440836|NCT01627041|Drug|Decitabine|Given IV
75440837|NCT01627041|Other|Laboratory Biomarker Analysis|Correlative studies
75440838|NCT01627041|Other|Pharmacological Study|Correlative studies
76055405|NCT02066402|Drug|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
76055406|NCT02066402|Drug|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
75440839|NCT01627080|Other|Cardiac Biomarker Blood Draws|Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
75591166|NCT04713124|Other|Self-help booklet|A booklet of information and self-help strategies for methamphetamine use problems.
75591167|NCT04701476|Drug|TATE and pembrolizumab|All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
75591168|NCT04701476|Drug|TAS-102 pill|The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
75591169|NCT04701476|Drug|Regorafenib Pill|As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
75734153|NCT05084378|Drug|Povidone-Iodine Lavage Solution|0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.
75883905|NCT05759845|Drug|topiramate 25mg plus amitriptyline 25mg|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
75883906|NCT03550196|Other|Provisional stenting with rePOT technique|"All revascularizations have to be performed with complete rePOT technique: initial POT + side branch inflation + final POT. Compliant or semi compliant balloon have to be preferred to inflations. The POT balloon positioning have to be precise as obtain the loose of the parallelism just at the carina cut plan. The rest of the medication or procedure characteristics stay at the discretion of the operator.~The follow-up will be clinic every years."
76055407|NCT02060383|Drug|Pasireotide s.c.|Administered to Cushing's disease participants.
75440840|NCT01627106|Drug|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
75440841|NCT01627106|Drug|Amiodarone|Administered IV as per product label
75440842|NCT01627132|Drug|Dasatinib|100mg QD
76055408|NCT02060383|Drug|Sitagliptin|Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
76055409|NCT02060383|Drug|Liraglutide|Participant switched to liraglutide if sitagliptin was found not to be effective.
75440843|NCT01627145|Drug|Solifenacin|Solifenacin 5 mg qd,
75440844|NCT01627158|Drug|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
76055410|NCT02060383|Drug|Insulin|"Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin."
76055411|NCT02060383|Drug|Pasireotide LAR|Administered to Acromegaly participants.
75440845|NCT01627158|Drug|Symbicort Turbuhaler|Symbicort Turbuhaler
75440846|NCT01627158|Drug|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
75591170|NCT04678427|Other|6 Minute Walk Functional Test|Complete 6-minute walk test
75591171|NCT04678427|Behavioral|Behavioral Intervention|Participate in walking and other activities
75734154|NCT05084378|Drug|Chlorhexidine Lavage Solution|0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.
75734155|NCT05084378|Drug|Topical Antibiotic|2 grams Vancomycin powder
75734156|NCT05084378|Drug|Saline Lavage Solution|1 litre of sterile isotonic saline
75883907|NCT03931291|Drug|APR-246|APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
75440847|NCT01627158|Drug|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
75591172|NCT04678427|Other|Survey Administration|Complete survey
75591173|NCT04678427|Behavioral|Timed Get Up and Go Test|Complete timed get up and go test
75734157|NCT05077072|Other|Best Practice|Receive SOC
75734158|NCT05077072|Other|Counseling|Participate in CHAT counseling intervention
75883908|NCT02136212|Behavioral|Approach-positive AAT|
75883909|NCT02136212|Behavioral|Control AAT|
75883910|NCT02136290|Behavioral|Prepackaged meals|Portion-controlled prepackaged meals
75883911|NCT02136290|Behavioral|Usual Care|Usual care dietary counseling
75883912|NCT01375855|Procedure|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
75883913|NCT00799110|Drug|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
75734159|NCT05077072|Procedure|Electroencephalography|Undergo EEG
75734160|NCT05077072|Behavioral|Neurofeedback|Undergo NFB intervention
75734161|NCT05077072|Other|Questionnaire Administration|Ancillary studies
75734162|NCT05076630|Other|Air pollutants|Particulate matter and gaseous pollutants
75734163|NCT05074498|Drug|TB006|intravenous infusion
75734164|NCT05074498|Drug|Placebo|intravenous infusion
75734165|NCT05073926|Other|No intervention is part of the study protocol|No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
75883914|NCT00799110|Biological|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
75883915|NCT00799110|Drug|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
75883916|NCT05199727|Device|LI-ESWT|Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
75883917|NCT05199727|Drug|Tadalafil 20Mg Oral Tablet|Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
75883918|NCT03600402|Other|Experimental|6 sessions of ankle manual therapy
75591174|NCT04678271|Behavioral|AFIX-OB Quality Improvement Package|Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
75591175|NCT04675424|Device|ANSwatch|"ANSwatch wrist sphygmomanometer and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients. Two measurements will be obtained:~Pulse diagnosis: Pulse diagnosis done on radial artery is recorded by traditional Chinese medicine physician and ANSwatch wrist sphygmomanometer at the same time.~Heart rate variability: Heart Rate Variability represents significant information on autonomic nervous system (ANS)'s regulating function and balance status."
75734166|NCT05072821|Drug|Botulinum Toxin Type A Injection [Botox]|After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
75734167|NCT05072821|Drug|0.9% Sodium Chloride Injection|After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
75734168|NCT05067582|Drug|L1-79|tyrosine hydroxylase inhibitor
75734169|NCT05067166|Drug|Ansuvimab|single infusion 50 mg/kg IV
75734170|NCT05059535|Drug|standard pain relievers|Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice
75591176|NCT04672811|Device|Study App and Apple Watch|Study App and Apple Watch
75734171|NCT05053867|Drug|tranexamic acid|Inhaled
75734172|NCT05053867|Other|Usual Care|Standard of Care
75734173|NCT05052268|Drug|XTX202|XTX202 Monotherapy
75734174|NCT05051852|Other|Follow up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
75734175|NCT05048407|Device|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
75734176|NCT05045963|Other|Electronic Health Record Review|Medical record reviewed
75734177|NCT05035420|Device|Fitbit|Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.
75734178|NCT05035420|Device|Douglas Bag|The Douglas Bag will be used for inducing hypercapnia.
76055412|NCT02060383|Drug|Metformin|"If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin."
76055413|NCT02086591|Drug|Doxycycline|
76055414|NCT02065622|Drug|Adalimumab|
76055415|NCT02065622|Other|Placebo|
75440848|NCT01627171|Drug|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
75440849|NCT01627171|Drug|Polyethelene Glycol|280g reconstituted in 4 liters of water
75440850|NCT01627171|Drug|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
75440851|NCT01627184|Device|Dexcom G4 CGM System|
75440852|NCT01627197|Procedure|Surgery of percutaneous catheter system|Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
75883919|NCT03600402|Other|Control|6 sessions of placebo intervention
76055416|NCT02117648|Drug|Abemaciclib|Administered orally
76055417|NCT02117648|Drug|Clarithromycin|Administered orally
75591177|NCT04663074|Diagnostic Test|IVUS control|Intravascular Control of the bridging stentgrafts during branched EVAR
75734179|NCT05035420|Device|Periflux 6000 EPOS|Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.
75734180|NCT05035420|Device|BIOPAC|The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
75440853|NCT01627223|Drug|Lamivudine|"Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
75734181|NCT05035420|Device|Flowmet|Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.
75883920|NCT02132234|Drug|Etanercept|biological treatment according to rheumatologic indication
75883921|NCT02132234|Drug|Adalimumab|biological treatment according to rheumatologic indication
75883922|NCT02132234|Drug|Certolizumab|biological treatment according to rheumatologic indication
75883923|NCT02132234|Drug|Infliximab|biological treatment according to rheumatologic indication
76055418|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
76055419|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
76055420|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
75591178|NCT04651192|Other|Combat Exposure|Soldiers will be exposed to combat as part of their routine military service. The ROTC students will not be exposed to combat.
75591179|NCT04646434|Procedure|Electroencephalography|Undergo EEG
75883924|NCT05415241|Drug|FB2001|"Stage 1 (Exploring the dose): Twenty participants will be enrolled for aerosol inhalation of FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, another twenty participants will be enrolled for aerosol inhalation of FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): Another twenty participants will be enrolled for aerosol inhalation of FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1."
75440854|NCT01627223|Drug|Entecavir|"•Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
75883925|NCT03602742|Device|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
75591180|NCT04646434|Procedure|Electromyography|Undergo EMG
75591181|NCT04646434|Other|Questionnaire Administration|Complete questionnaire
75591182|NCT04645420|Procedure|Global gene expression profiles obtained from synovial biopsies.|Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
76055421|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
75591183|NCT04638088|Other|assessment of urinary function and erectil function before and after prostatectomy|assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete
75883926|NCT02136368|Behavioral|Multi-modal exercise|Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)
75883927|NCT02136368|Behavioral|Mind-Motor Exercise|Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).
75591184|NCT04636177|Behavioral|Pain Rehabilitation Virtual Reality (PRVR)|Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
75591185|NCT04633551|Dietary Supplement|Anti-inflammatory supplement|commercially available combination of curcumin, quercitin, resveratrol, and green tea
76055422|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
76055423|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
76055424|NCT02175641|Behavioral|Peer-Led Group Lifestyle Balance|The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
75440855|NCT01627236|Drug|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
75440856|NCT01627262|Drug|Mesalamine|3x1000mg mesalamine granules per day
75440857|NCT01627262|Drug|Placebo|3x1000mg placebo granules per day
75440858|NCT01627275|Biological|Naive T Cell Depleted Donor Lymphocyte Infusion|A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
75440859|NCT01627353|Procedure|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
75440860|NCT01627353|Procedure|Pre-emptive wound infiltration|"The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.~The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case."
75440861|NCT01627366|Other|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
75591186|NCT04633096|Behavioral|tailored feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
75591187|NCT04633096|Behavioral|standardized feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
75591188|NCT04632498|Behavioral|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
75591189|NCT04620746|Drug|Penicillin Major Determinant (PrePen) Skin Testing|Skin testing followed by oral challenge with amoxicillin 250 mg single dose
75591190|NCT04620746|Drug|Direct Oral challenge|Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose
75883928|NCT02136368|Behavioral|Balance and range of motion exercises|Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
75440862|NCT01627379|Drug|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
75591191|NCT04614909|Drug|Pamiparib|60mg administered orally BID for 4 days prior to surgical resection
75591192|NCT04614909|Drug|Olaparib|200mg administered orally BID for 4 days prior to surgical resection
75591193|NCT04614909|Radiation|Radiation therapy|Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care
75591194|NCT04614909|Drug|Temozolomide|Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
75591195|NCT04614636|Drug|FT538|Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
75591196|NCT04614636|Drug|Cyclophosphamide|Lympho-conditioning Agent
75440863|NCT01627379|Drug|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
75591197|NCT04614636|Drug|Fludarabine|Lympho-conditioning Agent
75591198|NCT04614636|Drug|Daratumumab|Monoclonal Antibody, CD38, Anti-CD38
75734182|NCT05035420|Device|NIRS|a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
75734183|NCT05031130|Other|Empowered program integrated with family support|The empowered program integrated with family support is an intervention consisted of five steps that will be given when pregnant adolescents on gestational age 32 or 33 weeks the second meeting will be when the pregnant adolescents on gestational age 34 or 35 weeks.
75734184|NCT05029193|Behavioral|Langerian mindfulness|A 3-week Langerian mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
75734185|NCT05026723|Behavioral|MTM + ILI|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program
75883929|NCT05199649|Drug|SintilimabCombined With Chemotherapy|Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
75591199|NCT04614636|Drug|Elotuzumab|Monoclonal Antibody
75591200|NCT04609943|Drug|BAY1211163|Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
75591201|NCT04609280|Radiation|Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)|Delivered over 6 weeks in 30 daily fractions in the adjuvant setting and over 6.5 weeks in 33 daily fractions in the definitive setting. In the adjuvant setting, areas with positive surgical margins or nodal stations with pathologic extranodal extension will receive 63 Gy. Margin negative resection bed and involved nodal stations without extranodal extension will receive 54 Gy. Low-risk elective nodal volumes (i.e. ceCTV) will receive 51 Gy. In the definitive setting, gross disease will receive 69.96 Gy, areas at high-risk for subclinical disease will receive 60 Gy, and areas at low-risk for harboring subclinical disease (i.e. ceCTV) will receive 52.8 Gy.
76055425|NCT02175641|Behavioral|Usual Care Services|The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
75440864|NCT01627392|Behavioral|Smoking abstinence|6 hour smoking abstinence
75591202|NCT04596995|Drug|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion during the Treatment Period.
76055426|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
75440865|NCT01627418|Behavioral|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
75591203|NCT04593927|Drug|Mayzent|There is no treatment allocation. Patients administered Mayzent by prescription that have started before inclusion of the patient into the study will be enrolled.
75440866|NCT01627418|Behavioral|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
75440867|NCT01627431|Drug|Acetylsalicylic acid|100 mg once per day
75591204|NCT04588246|Drug|Memantine|Given PO
75591205|NCT04588246|Other|Quality-of-Life Assessment|Ancillary studies
75591206|NCT04588246|Other|Questionnaire Administration|Ancillary studies
75440868|NCT01627431|Drug|Clopidogrel|75 mg once per day
75591207|NCT04588246|Radiation|Stereotactic Radiosurgery|Undergo salvage SRS
75734186|NCT05026723|Behavioral|Standard MTM|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian
75591208|NCT04588246|Radiation|Whole-Brain Radiotherapy|Undergo HA-WBRT
75591209|NCT04578912|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is a manualized treatment program focused on tic management skills
75591210|NCT04578912|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|During repetitive transcranial magnetic stimulation (rTMS), a electromagnetic coil is placed against the scalp while an electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the target brain region
75591211|NCT04578912|Device|Continuous Theta Burst Stimulation (cTBS)|During continuous theta burst stimulation (cTBS), a electromagnetic coil is placed against the while an electromagnet painlessly delivers magnetic bursts that stimulate nerve cells in the target brain region
75591212|NCT04571736|Other|access to the internet information platform|This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.
75734187|NCT05026541|Behavioral|Nap Practitioners|Regular nappers will be given a 30 minute nap opportunity to nap for as long as they please.
76055427|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
76055428|NCT02117570|Biological|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
76055429|NCT02123459|Drug|Cephalexin|Administered orally
76055430|NCT01853475|Drug|PQP tablets 960mg|Piperaquine phosphate tablets 960mg
75591213|NCT04568824|Other|GraphoLearn reading intervention|This is an Edtech reading intervention
75734188|NCT05026541|Behavioral|Shoonya Meditation|This is a 15 minute meditation, described as a process of conscious non-doing.
75734189|NCT05022511|Behavioral|Screening status|Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
75734190|NCT05021614|Device|Valveclip® Transcatheter mitral valve repair|Transcatheter mitral valve repair system
75883930|NCT05373576|Behavioral|TACHIDINO|"TACHIDINO is based on two principles a) selective stimulation of a cerebral hemisphere and specific reading strategies, and b) the training of selective visuospatial attention, as well as the perception of rapid movement and the visual characteristics of words even in the presence of so-called visual crowding or crowding, an automatic effect of our perceptual system that leads to obfuscation of the visual areas surrounding the object to be analyzed, to make its vision clearer (as suggested by the Magnocellular theory of dyslexia; Stein et al., 2019)."
75591214|NCT04568824|Other|Vektor math control intervention|This is an Edtech math/cognition intervention
75591215|NCT04564755|Drug|abrocitinib|Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
75734191|NCT05020574|Drug|Cephalexin|Given orally (PO)
76055431|NCT01853475|Drug|PQP tablets 1440mg|Piperaquine phosphate tablets 1440mg
76055432|NCT01853475|Drug|OZ439+TPGS 800mg|OZ439+TPGS prototype formulation 800mg
76055433|NCT01853475|Drug|OZ439 PIB 800mg|OZ439 Powder in Bottle Aqueous Solution 800mg
76055434|NCT04411160|Drug|Vitamin C|4 gram of vitamin c slowly intravenous once daily for 4 days duration.
76055435|NCT04411160|Drug|Nitric Oxide|nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose
76055436|NCT04411160|Device|ventilators|All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90%
76055437|NCT02151773|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
76055438|NCT02151461|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
76055439|NCT02151461|Drug|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
76055440|NCT02151461|Drug|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
75591216|NCT04557787|Device|SpeediCath® Standard female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
75591217|NCT04557787|Device|New intermittent Variant 1 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
75591218|NCT04557787|Device|New intermittent Variant 2 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
75591219|NCT04553666|Drug|Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)|800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
75591220|NCT04551885|Drug|FT516|Experimental Interventional Therapy
75591221|NCT04551885|Drug|Avelumab|Monoclonal antibody
75591222|NCT04551885|Drug|Cyclophosphamide|Lympho-conditioning agent
75591223|NCT04551885|Drug|Fludarabine|Lympho-conditioning agent
75591224|NCT04551885|Drug|IL-2|Biologic response modifier
75591225|NCT04547998|Device|Control Intervention (UVB)|Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.
75591226|NCT04547998|Device|Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)|Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.
75883931|NCT02128568|Behavioral|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
76055441|NCT02151461|Drug|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
76055442|NCT02117414|Device|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
76055443|NCT02117414|Other|Waiting Period Visit|Waiting period time will equate to 1 hour
75591227|NCT04545502|Device|Gelsoft Plus Vascular Graft|Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.
75591228|NCT04545502|Device|Vascular Bypass Graft|Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.
75591229|NCT04545502|Device|Cardiovascular Patch|Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.
75591230|NCT04545502|Device|Gelweave Vascular Graft|The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.
75591231|NCT04545502|Device|Gelweave Valsalva Vascular Graft|This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.
75591232|NCT04545242|Drug|Dexamethasone|Intravenous dexamethasone (low vs. moderate doses) during 10 days
75734192|NCT05018169|Behavioral|BA-A|Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.
75734193|NCT05017974|Behavioral|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement|MBSR+PS
75734194|NCT05017974|Other|Treatment as Usual|TAU
75734195|NCT05013710|Other|Complete Clinical Interaction|The intervention consists of a completed interaction with the mobile health clinic during the study periods, on which adequate evaluative data was collected on the patient visit (e.g. staff was able to note their visit and reason for visit, the patient met with an healthcare professional, etc)
75734196|NCT05013632|Drug|Antiviral Agents|Antiviral medications indicated for the treatment of mild to severe COVID-19
75734197|NCT05013632|Drug|Monoclonal antibody|Monoclonal antibodies indicated for the treatment of mild to severe COVID-19
76055444|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
75440869|NCT01627444|Procedure|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
75440870|NCT01627457|Device|Guided Exercise (GEx) system|30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
75440871|NCT01627470|Device|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
75591233|NCT04540536|Other|Continuous Glucose Monitoring|Participants will be provided with a Dexcom G6 continuous glucose monitor for the duration of the study.
75591234|NCT04540536|Other|Secure texting|A secure platform (TigerConnect) will be used for three-way communication between parents, participants, and clinical personnel
76055445|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
76055446|NCT02091986|Other|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
75591235|NCT04538482|Behavioral|DASH Diet|Participant will receive foods following the DASH dietary pattern for 28 days.
75591236|NCT04538482|Behavioral|standard American diet|Participants will receive foods following the standard American diet for 28 days.
75591237|NCT04532970|Behavioral|Cessation Counseling|Two different types of smoking cessation counseling
75591238|NCT04532047|Drug|Aldurazyme (laronidase)|Enzyme replacement therapy for lysosomal storage diseases
75591239|NCT04531670|Behavioral|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
75591240|NCT04531670|Other|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
75591241|NCT04524858|Drug|ATI-450|Oral, small molecule MK2 inhibitor
75591242|NCT04521179|Drug|KN026 combination|30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046
75591243|NCT04516447|Drug|ZN-c3|Investigational drug
75591244|NCT04516447|Drug|Carboplatin|Carboplatin is an approved drug
75591245|NCT04516447|Drug|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin (PLD) is an approved drug
75591246|NCT04516447|Drug|Paclitaxel|Paclitaxel is an approved drug
75591247|NCT04516447|Drug|Gemcitabine|Gemcitabine is an approved drug
75591248|NCT04515459|Other|Surgical prehabilitation program.|"This programme will include the practice of general physical activity and the implementation of nutritional and psychological support.~Each patient will have 8 Oncorehabilitation Transdisciplinary Evaluations (OTE):~2 OTE will be performed before the surgery,~6 OTE will be performed after the surgery.~During the program (at each OTE), patients will also be asked to complete the QLQ-C30 questionnaire."
75591249|NCT04515186|Drug|Meglumine Antimoniate|Vials of a 5mL solution. Each vial contains 405 mg of Sb5+ corresponding to 8.1% Sb5+ (81 mg/mL).
75591250|NCT04515186|Drug|Miltefosine|50 mg capsule
75591251|NCT04515186|Device|Thermotherapy machine|Localized Current Field radio-frequency generating device
75591252|NCT04513717|Drug|Apalutamide|Nonsteroidal Antiandrogen
75591253|NCT04513717|Drug|Bicalutamide|Antiandrogen
75591254|NCT04513717|Drug|Buserelin|Luteinizing hormone-releasing hormone (LHRH) agonist
75591255|NCT04513717|Drug|Degarelix|Gonadotropin-releasing hormone (GnRH) antagonist
75591256|NCT04513717|Drug|Flutamide|Antiandrogen
75591257|NCT04513717|Drug|Goserelin|Gonadotropin-releasing hormone (GnRH) agonist
75591258|NCT04513717|Drug|Histrelin|Gonadotropin-releasing hormone (GnRH) agonist
75591259|NCT04513717|Drug|Leuprolide|Gonadotropin-releasing hormone (GnRH) agonist
75591260|NCT04513717|Other|Quality-of-Life Assessment|Ancillary studies
75591261|NCT04513717|Other|Questionnaire Administration|Ancillary studies
75734198|NCT05009823|Dietary Supplement|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml.
75591262|NCT04513717|Radiation|Radiation Therapy|Undergo radiation therapy
75591263|NCT04513717|Drug|Triptorelin|Gonadotropin-releasing hormone (GnRH) agonist
75591264|NCT04505254|Drug|Acalabrutinib|Given PO
75591265|NCT04505254|Biological|Obinutuzumab|Given IV
75591266|NCT04502693|Combination Product|rMenB+OMV NZ vaccine|rMenB+OMV NZ vaccine is administered intramuscularly to the non-dominant arm as 3 doses in a 0,2,6-M schedule or as 2 doses in a 0,6-M schedule to participants in the MenB_0_2_6 Group, as 2 doses in a 0,6-M schedule to participants in the MenB_0_6 Group and as 2 doses at Day 181 and Day 211 to participants in the ACWY Group.
75591267|NCT04502693|Biological|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|MenACWY vaccine is administered intramuscularly to the non-dominant arm as 1 dose at Day 211 to participants in the MenB_0_2_6 Group, as 1 dose at Day 61 to participants in the MenB_0_6 Group and as 1 dose at Day 1 to participants in the ACWY Group.
75591268|NCT04502693|Combination Product|Placebo|Placebo is administered intramuscularly to the non-dominant arm as 1 dose at Day 211 to participants in the MenB_0_6 Group, 2 doses at Day 61 and Day 211 to participants in the ABCWY groups and as 1 dose at Day 61 to participants in the ACWY Group.
75591269|NCT04502693|Combination Product|MenABCWY-1|Lot 1 of the MenABCWY vaccine is administered intramuscularly to the non-dominant arm as 2 doses at Day 1 and Day 181 to participants in the ABCWY-1 Group.
75591270|NCT04502693|Combination Product|MenABCWY-2|Lot 2 of the MenABCWY vaccine is administered intramuscularly to the non-dominant arm as 2 doses at Day 1 and Day 181 to participants in the ABCWY-2 Group.
75591271|NCT04502693|Combination Product|MenABCWY-3|Lot 3 of the MenABCWY vaccine is administered intramuscularly to the non-dominant arm as 2 doses at Day 1 and Day 181 to participants in the ABCWY-3 Group.
75734199|NCT05009823|Dietary Supplement|Alternative F75 With CMV|Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.
75734200|NCT05009823|Dietary Supplement|Alternative F75 Without CMV|Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.
75734201|NCT05009823|Dietary Supplement|F100|100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
75591272|NCT04502121|Behavioral|EXPECT: Preoperative optimization of cardiac valve patient's expectations|The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
75591273|NCT04496479|Biological|LYG-LIV0001|Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.
75591274|NCT04496323|Other|EE Golf|Exercise in Golf and Playing 9 holes
75440872|NCT01627483|Other|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
75591275|NCT04485559|Drug|Everolimus|Given PO
75591276|NCT04485559|Drug|Trametinib|Given PO
75591277|NCT04474834|Genetic|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 300 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (>40 %).
75591278|NCT04466345|Biological|Semaglutide|3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
75591279|NCT04466345|Biological|Placebo|Semaglutide placebo capsules
75591280|NCT04466150|Drug|Ocrelizumab|open label biomarker study
75591281|NCT04465721|Behavioral|TRE|The TRE intervention will be administered and monitored via the study app. It combines self-monitoring behavior, daily eating window reminders, positive reinforcement based on number of log entries or based on meeting eating widow target, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring, and to reducing the eating window.
75734202|NCT05009823|Dietary Supplement|Standard F75 + RUTF|Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive
75591282|NCT04465721|Behavioral|HABIT|The HABIT intervention will be administered and monitored via the study app. It combines self-monitoring behavior, positive reinforcement based on number of log entries, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring.
75734203|NCT05009823|Dietary Supplement|Alternative F75 with CMV + RUTF|Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase
75734204|NCT05009823|Dietary Supplement|Alternative F75 without CMV + RUTF|Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
75734205|NCT05008718|Other|38% SDF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
75734206|NCT05008718|Other|5% NaF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
75883932|NCT03600246|Device|WATCH-PAT|WatchPAT is an FDA-approved portable diagnostic device that uniquely uses finger based physiology and innovative technology to enable simple and accurate Obstructive Sleep Apnea (OSA) testing while avoiding the complexity and discomfort associated with traditional air-flow based systems.
75440873|NCT01627522|Procedure|TURP|Transurthral resection of prostate
75440874|NCT01627535|Other|Interoperative Optical Imaging and Spectroscopy|Real time processing and display of i2DOS maps in the operating arena
75440875|NCT01627561|Biological|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.
75440876|NCT01627561|Biological|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.
75440877|NCT01627561|Biological|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.
75440878|NCT01627587|Drug|GSK221149 750 mg|Treatment A: 750 mg GSK221149 single dose
75734207|NCT05005845|Drug|NFX-179 gel|NFX-179 topical gel is the active investigational product being studied
75734208|NCT05005845|Drug|Vehicle gel|NFX-179 vehicle gel is the placebo comparator for this study
75734209|NCT05004181|Biological|BNT162b2|Intramuscular (IM)
75734210|NCT05004181|Biological|BNT162b2 (B.1.1.7 + B.1.617.2)|Intramuscular (IM)
75734211|NCT05004181|Biological|BNT162b2 (B.1.1.7)|Intramuscular (IM)
75734212|NCT05004181|Biological|BNT162b2 (B.1.617.2)|Intramuscular (IM)
75734213|NCT05004181|Biological|BNT162b2 (B.1.1.529.1)|Intramuscular (IM)
75440879|NCT01627587|Drug|Ketoconazole|Treatment B: 400 mg of Ketoconazole single dose
75440880|NCT01627587|Drug|GSK221149 100 mg|Treatment C: 100mg of GSK221149 single dose
75734214|NCT05004181|Other|Observational|No vaccination within 3 months after Visit 1.
75734215|NCT05004077|Drug|AMIODARONE|Assess the effectiveness of different dosing strategies of amiodarone.
75734216|NCT05003505|Other|Follow up|Participants will be followed up at 6, 12 and 24 months with the test of enous blood, vaginal secretions, faeces, and cervical exfoliated cells.
75734217|NCT05003453|Drug|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
76055447|NCT02091752|Drug|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to <200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
75440881|NCT01627587|Drug|GSK221149 750 mg Fasted|Treatment D: 750 mg of GSK221149 administered fasted
75440882|NCT01627587|Drug|GSK221149 750 mg + Food|Treatment E: 750 mg of GSK221149 administered with a high fat meal
75734218|NCT05003453|Drug|Placebo Comparator|A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
75440883|NCT01627613|Drug|AP301|"AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."
75440884|NCT01627613|Drug|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
75440885|NCT01627626|Drug|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute."
75440886|NCT01627626|Drug|saline|0.9% saline solution
75440887|NCT01627639|Drug|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
75440888|NCT01627639|Drug|Placebo|Placebo
75440889|NCT01627652|Other|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
75734219|NCT05001854|Drug|Fludrocortisone|100 μg every 6 hours of fludrocortisone per os
75734220|NCT05001854|Drug|Placebo|100 μg every 6 hours of placebo per os
75734221|NCT04998487|Drug|LY3471851|Administered SC.
75734222|NCT04997486|Behavioral|Time restricted eating|Participants will be asked consume all meals/snacks during a ~9-h daily eating period (~15-h fasting).
75734223|NCT04991493|Drug|Tramadol hydrochloride|"pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured."
75734224|NCT04991493|Other|Normal Saline|"pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia."
75734225|NCT04989712|Other|Exposure|Participants randomised to one of the three exposures
76055448|NCT02117024|Drug|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
75440890|NCT01627665|Drug|D->R->C+R|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
75440891|NCT01627665|Drug|D->R->C+D|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
75591283|NCT04464265|Other|Functional Magnetic Resonance Imaging (fMRI)|"Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations which will be maintained for 4 minutes each.~Four types of music, including Jazz, Rock, Pop and Country, will be presented in a pseudo-randomized order. During the behavioral test period, participants will be asked to squeeze an Magnetic Resonance Imaging (MRI) compatible grip dynamometer (a rubber ball) for every 10-second periods (96 cycles in total). The beginning of each cycle will be cued with the spoken word squeeze."
75734226|NCT04988516|Device|Virtual reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
75734227|NCT04988516|Other|Standard protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. The research nurse will be able to complete any information should they find it incomplete or substandard.
75734228|NCT04986852|Drug|Olinvacimab|Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
75734229|NCT04982406|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
75734230|NCT04980612|Behavioral|Mindfulness Based Pain Reduction|40 participants will participate in a MBPR program. It will be an optimized mindfulness program specifically designed for treating cLBP that we will develop and test in this project. The format is the same as MBSR: 8 weeks of weekly 2½-hour group sessions and a daylong retreat.
76055449|NCT02117024|Drug|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
76055450|NCT02117024|Drug|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~Vinorelbine~Erlotinib~Gemcitabine~Paclitaxel~Docetaxel~Pemetrexed"
76055451|NCT02091440|Device|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
76055452|NCT02064920|Drug|Placebo|Placebo for donepezil hydrochloride capsule
76055453|NCT02064920|Drug|Donepezil|5 mg donepezil hydrochloride capsule.
76055454|NCT02064920|Drug|Donepezil|10 mg donepezil hydrochloride capsule.
76055455|NCT02151149|Drug|nab-paclitaxel|
75440892|NCT01627665|Drug|R->D->C+D|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
75440893|NCT01627665|Drug|R->D->C+R|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
75440894|NCT01627678|Drug|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
75440895|NCT01627678|Drug|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
75440896|NCT01627704|Drug|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
75440897|NCT01627717|Drug|Maraviroc (5 days)|Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
75440898|NCT01627717|Drug|Maraviroc and boceprevir (14 days)|From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
75440899|NCT01627730|Other|pretest and posttest scores|pretest and post-test scores are calculated for relative growth scores
76055456|NCT02151149|Drug|Carboplatin|
76055457|NCT04746131|Drug|IMM0306|IMM0306 is an bi-specific antibody
76055458|NCT02150213|Procedure|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
76055459|NCT02150213|Procedure|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
76055460|NCT02150213|Procedure|Sonogram|Sonogram of the uterus (females only)
76055461|NCT02150213|Procedure|Biopsy|Uterine endometrial biopsy (females only)
76055462|NCT02150213|Drug|BGG492|No study-drug was administered in this study
76055463|NCT02091362|Drug|LY2409021|Administered orally
75591284|NCT04462419|Radiation|Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography|Undergo PET-MRI imaging
75440900|NCT01627756|Other|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
75440901|NCT01627756|Other|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
76055464|NCT02091362|Drug|Placebo|Administered orally
76055465|NCT02091362|Drug|Metformin|Administered as background therapy.
76055466|NCT02150057|Device|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
75440902|NCT01627795|Drug|Oshadi D and Oshadi R|anti cancer agents
75440903|NCT01627834|Drug|Ropinirole|
76055467|NCT02064296|Device|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device (AS Super 4 digital needle stimulator).
76055468|NCT02064296|Device|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device (Vita Laser 650, Lhasa OMS) will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
76055469|NCT02063984|Behavioral|Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
76055470|NCT02063984|Behavioral|Working Memory Training|25 computer-delivered sessions of neurocognitive training
75440904|NCT01627847|Drug|Ropinirole|
75591285|NCT04462419|Other|Fluciclovine F18|Given IV
75591286|NCT04461808|Diagnostic Test|tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
75591287|NCT04461808|Diagnostic Test|digital mammography|"Women will be screened for one round digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
75591288|NCT04448184|Drug|Tranexamic Acid|"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
75591289|NCT04437888|Drug|Ketamine|Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
75591290|NCT04432506|Biological|Anakinra|Given SC
75591291|NCT04432506|Biological|Axicabtagene Ciloleucel|Given IV
75591292|NCT04432506|Drug|Cyclophosphamide|Given IV
76055471|NCT02091284|Device|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
75591293|NCT04432506|Drug|Fludarabine|Given IV
75591294|NCT04428554|Radiation|Experimental arm|Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
75591295|NCT04423302|Dietary Supplement|TOTUM-63 3 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
75591296|NCT04423302|Dietary Supplement|Placebo 3 intakes per day|Placebo. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
76055472|NCT02115386|Drug|Nilotinib|supplied in 150 mg capsules to be taken orally
75591297|NCT04423302|Dietary Supplement|TOTUM-63 2 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes (4 in the morning and 4 at dinner)
75591298|NCT04417062|Drug|Olaparib|Olaparib is taken by mouth, twice daily through out the 28 day study cycle.
75591299|NCT04417062|Drug|Ceralasertib|Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.
75591300|NCT04406389|Drug|Enoxaparin sodium|"Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours"
75591301|NCT04406389|Drug|Unfractionated heparin|"Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol"
75591302|NCT04406389|Drug|Fondapariniux|"Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~If greater than or equal to 100 kg: 10 mg daily~If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~If less than 50 kg: 5 mg daily"
75591303|NCT04406389|Drug|Argatroban|"Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol"
75591304|NCT04401462|Procedure|Tension band wiring or plate fixation|Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name
75591305|NCT04401462|Behavioral|Sling or a long-arm plaster|Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
75591306|NCT04379544|Other|Observation only|There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.
75591307|NCT04378751|Behavioral|Decision aid video|Decision aid video
75591308|NCT04378751|Behavioral|Genetic counseling informational brochure|Genetic counseling informational brochure
75591309|NCT04358458|Biological|GEN3009|GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
75591310|NCT04358458|Biological|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
75591311|NCT04356924|Behavioral|Psychological treatment|The treatment is an adjusted (to the cognitively impaired individual) combination of CBT, ACT, validation strategies, and psychoeducation. One focus is to increase motivation to lifestyle changes, and to a larger degree live life in correspondence with internal goals.
75591312|NCT04356924|Behavioral|Cognitive training|Computer based training tasks implemented with adaptive intensity. The cognitive training method that will be used is mainly related to executive control (i.e., ability to coordinate thoughts and actions in accordance with internal goals).
75591313|NCT04356729|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.
75591314|NCT04356729|Drug|Bevacizumab|Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
75734231|NCT04980612|Behavioral|Mindfulness Based Stress Reduction|10 participants will participate in MBSR program. MBSR is a standardized and manualized 8-week program, delivered once a week in 2½-hour group sessions and a daylong retreat. It trains individuals in several mindfulness practices, e.g. focus on breath, varying degrees and directions of object orientation, open monitoring of awareness of intero- and exteroceptive stimuli and thoughts, de-reification (i.e. the notion that thoughts and perceptions are not always true to reality), and meta-awareness (i.e., awareness of thinking) in addition to focused attention.The program typically includes audio-recordings and a workbook for home practice and has shown benefits in patients with cLBP.
75734232|NCT04978779|Drug|VIP152|Weekly IV infusion for 28 day cycles.
76055473|NCT02091206|Drug|GWP42003-P 5 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
75440905|NCT01627873|Drug|Remifentanil|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
75591315|NCT04345393|Behavioral|Digital Transformation Network (DTN) Program|Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.
75591316|NCT04343716|Behavioral|Low-carbohydrate diet|A diet low in daily carbohydrates (<40 grams/day) provided as prepared meals.
75591317|NCT04339894|Other|Duplex ultrasonography (data collection by extra-corporeal non-invasive sensors)|Search for venous thrombosis and description of thrombosis
75591318|NCT04336826|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
75591319|NCT04335721|Drug|Voxelotor|Voxelotor 1500mg once a day
75591320|NCT04333810|Device|Whoop strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).
75591321|NCT04329650|Drug|Siltuximab|A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
75591322|NCT04329650|Drug|Dexamethasone|A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
75591323|NCT04327310|Drug|Meplazumab for Injection|humanized mAb against CD147
75591324|NCT04327310|Drug|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
75591325|NCT04326231|Device|Usability assessment of Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
75591326|NCT04308499|Behavioral|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions accessed using either a computer or a smartphone
75591327|NCT04308499|Behavioral|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions comprised of comprise a website and a downloadable booklet
75591328|NCT04308135|Diagnostic Test|Neuro-radiological tools:|"MRI brain: to measure white matter~c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected."
75591329|NCT04308135|Diagnostic Test|cognitive tests|"All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset~, and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale"
75734233|NCT04978779|Drug|BTKi|Taken per local prescribing information
75734234|NCT04976140|Biological|PN-101|"PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose."
76055474|NCT02091206|Drug|Placebo control|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
76055475|NCT02091206|Drug|GWP42003-P 10 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
75591330|NCT04308135|Diagnostic Test|lab investigations|Each patient will undergo full lab investigations:[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes]
75734235|NCT04971993|Device|Wearable Cardiac Monitor|Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
75734236|NCT04970485|Behavioral|Talking Matters|Group-level, facilitator-led behavioral intervention for 14-19 year old Black and African American adolescents with an intergenerational component to reduce teen pregnancy, strengthen protective factors to improve optimal health, and increase access to trusted adults.
75734237|NCT04969094|Other|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
75734238|NCT04969094|Other|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
75734239|NCT04964076|Other|No intervention|No intervention
75734240|NCT04959175|Drug|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
75734241|NCT04959175|Procedure|Allogeneic HSCT|Stem cell transplant
75734242|NCT04959175|Drug|Fludarabine|30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
75734243|NCT04959175|Drug|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
75734244|NCT04959175|Drug|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is > 1,000/mm3 over the course of three days or > 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
75440906|NCT01627873|Drug|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
75440907|NCT01627886|Drug|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
75440908|NCT01627912|Other|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink [white wine or red wine or 12.5% ethanol or water]/kg of individual, parallel with a standardized meal.
75440909|NCT01627925|Device|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
75440910|NCT01627938|Drug|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
75734245|NCT04959175|Drug|Cyclophosphamide|Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
75734246|NCT04959175|Drug|Mesna|25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
75734247|NCT04959175|Procedure|Total Body Irradiation (TBI)|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice daily. Pre-Transplant Day -1 (or Day 0 prior to graft administration)
75734248|NCT04957329|Drug|Xalatan|Eye drop
75734249|NCT04957329|Drug|Monoprost|Eye drop
75734250|NCT04953949|Device|NU-MAX®|Topical Hemostat
75734251|NCT04946279|Other|Best Practice|Receive usual/standard of care
75734252|NCT04946279|Other|Informational Intervention|Receive conversation tool
75734253|NCT04946279|Other|Questionnaire Administration|Ancillary studies - Baseline and follow-up questionnaires
75440911|NCT01627938|Drug|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
75440912|NCT01627951|Other|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
75440913|NCT01627951|Other|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
75591331|NCT04308135|Diagnostic Test|Beck depression inventory (BDI)(Arabic version)|Clinical Tool for depression
75591332|NCT04308135|Diagnostic Test|Clinical Tools for Urinary symptoms:|the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
75591333|NCT04308135|Diagnostic Test|Freezing of gait questionnaire|"Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~.Freezing of gait questionnaire~Berg balance scale.~10 meter walk test .~Timed up and go test."
75591334|NCT04308135|Diagnostic Test|non-motor symptoms scales (NMSS).|Clinical Tool for assessment of non-motor symptoms of PD
75591335|NCT04308135|Diagnostic Test|Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):|"Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS"
75591336|NCT04308135|Diagnostic Test|ELIZA for alpha-synuclein|measuring serum of alpha-synuclein, tau and their autoantibodoies
75591337|NCT04308135|Other|transcranial color-coded duplex(TCCD)|TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
75591338|NCT04308135|Other|extracranial carotid duplex|to assess atherosclerosis, stenosis of carotids
75591339|NCT04308135|Other|The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)|Clinical tool for quality of life of PD patients
75591340|NCT04300764|Behavioral|Gamification Intervention|Intervention participants will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Each participant will be given a Fitbit watch that will transmit data to the Way to Health study platform. Data will be passively collected during the inpatient stay and for 30 days after hospital discharge.
75440914|NCT01627951|Other|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
75440915|NCT01627977|Other|Dye of Lutein, Zeaxanthin and Brilliant Blue|dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
75591341|NCT04296071|Other|Research study|Blood and tracheal aspirates will be collected
75591342|NCT04289415|Behavioral|Individual Placement and Support|Employment specialist will work together with the participants in accordance to the method IPS in order to help the participant obtain competitive employment
75591343|NCT04283370|Other|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
75591344|NCT04283370|Other|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
75591345|NCT04282187|Drug|Decitabine|Given IV
75591346|NCT04282187|Drug|Ruxolitinib|Given PO
75591347|NCT04282187|Drug|Fedratinib|Given PO
76055476|NCT02091206|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
75440916|NCT01628003|Device|Brain MRI|Brain MRI
76055477|NCT04417790|Diagnostic Test|Lung ultrasound and EVLW measurement by transpulmonary thermodilution.|Lung ultrasonography by 8 Quadrant protocol of Volpicelli et al. Transpulmonary thermodilution for extravascular lung water measurement
76055478|NCT02090426|Other|Link2Care|
76055479|NCT02063828|Device|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 12 weeks.
76055480|NCT02063828|Device|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 12 weeks.
76055481|NCT02063828|Device|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 12 weeks.
76055482|NCT02063672|Device|Lutonix DCB|
76055483|NCT02063672|Device|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
76055484|NCT02062658|Drug|Ketamine|0.5mg/kg IV
76055485|NCT02062658|Behavioral|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
75440917|NCT01628003|Device|MRI|Physical examination Neuropsychological testing Questionnaires
75440918|NCT01628055|Biological|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (~3-4 hours depending on weight).
75440919|NCT01628055|Other|Normal Saline|"Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours."
75591348|NCT04282187|Other|Questionnaire Administration|Ancillary studies
75734254|NCT04938596|Combination Product|Respiratory bundle|"Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks~Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks~Promotion of strategies to improve house ventilation during 2 weeks~Provision of a TB leaflet and nurse education about TB transmission."
76055486|NCT02115308|Drug|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
76055487|NCT02114684|Drug|moxifloxacin|[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)]
76055488|NCT02090114|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
75440920|NCT01628068|Device|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
75440921|NCT01628081|Dietary Supplement|Alga Dunaliella Bardawil placebo|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
75440922|NCT01628081|Dietary Supplement|Dunaliella Bardawil|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
75440923|NCT01628133|Procedure|ultrasound|sonographic evaluation of intestinal blood flow
75440924|NCT01628146|Device|SUPRACOR LASIK treatment|The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
75591349|NCT04282187|Drug|Pacritinib|Given PO
75591350|NCT04275336|Drug|EMLA application|A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse perform IV cannulation for them.
75591351|NCT04275336|Behavioral|Distraction techniques|Multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They will also be taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
75734255|NCT04934826|Dietary Supplement|Hydrolyzed Proteins|Patients in experimental arm will receive a test meal based on marked hydrolyzed proteins
75734256|NCT04934826|Dietary Supplement|Intact proteins|Patients in active comparator arm will receive a meal based on intact marked proteins.
75440925|NCT01628172|Device|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
76055489|NCT02090114|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
76055490|NCT02090114|Drug|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
75591352|NCT04275336|Other|EMLA cream and distraction techniques|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
75734257|NCT04932096|Drug|melatonin|melatonin supplementation
75440926|NCT01628185|Procedure|Repositioning|pain assessment at baseline then following routine care repositioning in bed
75440927|NCT01628237|Device|comparison of spinal cord stimulation|
75440928|NCT01628263|Other|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
75440929|NCT01628276|Behavioral|Cog Rehab|Cognitive rehab for MS patients
75734258|NCT04932096|Other|placebo|microcrystalline cellulose filled capsule
75734259|NCT04931082|Dietary Supplement|Probiotics|Capsule
75734260|NCT04931082|Dietary Supplement|Placebo|Capsule
75591353|NCT04269005|Other|Implementation of the SCCM|Implementation of the SCCM includes a baseline survey, assessment of screening questions stage 1 (with consequence), screening questions stage 2 (with consequence) and if necessary psychosomatic-psychiatric consultation and liaison service including if applicable post hospital intervention and a follow-up survey in a distressed focus sample.
76055491|NCT02090114|Drug|Enzalutamide|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
75591354|NCT04266886|Other|Best Practice|Receive usual care
75734261|NCT04928586|Drug|Pirfenidone|CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose
75734262|NCT04928586|Drug|DMARDs|CTD-ILD patients treated with DMARDs according to the condition of the disease
76055492|NCT01623050|Device|SinuSys Dilation System|Sinuplasty
76055493|NCT02089334|Drug|RX-0201|"RX-0201 will be administered in a dose up to 250mg/m^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles."
76055494|NCT04742036|Drug|Capivasertib|Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
76055495|NCT04742036|Drug|Paclitaxel|"Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression."
75440930|NCT01628289|Other|charging a co-payment for Diabetic Retinopathy screening|The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
75440931|NCT01628289|Other|free screening without charging a co-payment|The intervention is to provide free screening without charging a co-payment
75440932|NCT01628302|Behavioral|Lowering salt in diet|Low salt diet (50mmol)for three weeks.
75440933|NCT01628315|Device|MRI|Annual MRIs as part of participation in the ASA study.
75440934|NCT01628341|Drug|insulin|Patients will be asked to complete 2 self-assessment questionnaires
75591355|NCT04266886|Procedure|Hypnotherapy|Receive self-hypnosis guided relaxation
75734263|NCT04928066|Drug|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
75734264|NCT04928066|Drug|Tofacitinib|Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
75734265|NCT04928066|Drug|Pred|Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
75734266|NCT04926376|Device|Eye90 Microspheres|Y90 glass microspheres
75734267|NCT04925700|Dietary Supplement|ProDentis Lozenge|1-2 ProDentis Lozenges per day
75734268|NCT04925700|Other|Placebo Lozenge|1-2 Placebo Lozenges per day
76055496|NCT02114606|Device|Cytosponge™ Cell Collection Device|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
76055497|NCT04729634|Other|Mobilization|Mobilization and breathing exercises according to clinical care
76055498|NCT02113436|Drug|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
76055499|NCT02113436|Drug|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
76055500|NCT02087774|Behavioral|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
75591356|NCT04266886|Other|Quality-of-Life Assessment|Ancillary studies
75591357|NCT04266886|Other|Questionnaire Administration|Ancillary studies
75591358|NCT04266717|Behavioral|Baby Play Intervention|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
75734269|NCT04918524|Drug|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
75734270|NCT04918524|Drug|Hydroxychloroquine|100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
75591359|NCT04266717|Behavioral|Milestone Education|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
75734271|NCT04918524|Drug|Aspirin|100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
75591360|NCT04265625|Device|endoscopic guidance|Percutaneous tracheotomy performed by endoscopic guidance
75734272|NCT04918524|Drug|low molecular weight heparin Enoxaparin|40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
76055501|NCT02111564|Drug|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
75440935|NCT01628354|Drug|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of >5 letters or increase in retinal thickness of >100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
75440936|NCT01628380|Procedure|Cytoreductive Surgery and HIPEC|"CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).~HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C."
75440937|NCT01628380|Procedure|CRS alone|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
75591361|NCT04264208|Drug|68-Ga RM2.|PET radiopharmaceutical
75440938|NCT01628419|Behavioral|Health intervention|"physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.~Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects."
75440939|NCT01628432|Procedure|conservative hysterectomy I|conservative hysterectomy for benign disease
75591362|NCT04264208|Drug|68-Ga PSMA11|PET radiopharmaceutical
76055502|NCT02111564|Drug|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from >=30 to less than (<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
76055503|NCT02111564|Drug|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
75440940|NCT01628432|Procedure|Conservative hysterectomy II|bilateral salpingectomy during hysterectomy without conservation of the ovaries
75591363|NCT04264208|Device|PET/MRI|PET/MR scanner by GE healthcare
75734273|NCT04912115|Drug|Ketamine|Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).
75734274|NCT04912115|Drug|Midazolam|Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.
75734275|NCT04908631|Device|Transcranial Direct Stimulation|Brain stimulation using low-intensity current via electrodes on scalp to modify neuronal excitability in the underlying cortex. The tDCS system has customizable head gear with disposable, snap-in electrodes wihich can be applied at home without assistance.
75734276|NCT04908631|Other|Auditory Training Program|Web-based program uses consonant and vowel recognition and understanding sentences/conversations in quiet and in noise using different talkers, and other types of listening exercises.
75734277|NCT04906044|Drug|Sintilimab|Sintilimab combined withTotal Neoadjuvant Treatment
76055504|NCT02087150|Device|Acclarent Eustachian Tube Balloon Catheter (ETBC)|
76055505|NCT02111174|Device|Scrambler Therapy|
76055506|NCT02111174|Device|Sham Therapy|
76055507|NCT02111096|Drug|LY2409021|Administered orally
76055508|NCT02111096|Drug|Sitagliptin|Administered orally
76055509|NCT02111096|Drug|Placebo|Administered orally
76055510|NCT02111096|Drug|Metformin|Administered orally
76055511|NCT02111096|Drug|Sulfonylurea|Administered orally
76055512|NCT02110706|Drug|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
76055513|NCT02110706|Drug|Placebo|The placebo group will receive a vehicle control infusion
76055514|NCT02110238|Device|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
75591364|NCT04256915|Behavioral|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Bright Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes. Participants will receive constant blue-green light (500 nm, 506 lux)."
75734278|NCT04896645|Device|Digihaler Albuterol Device by TEVA|Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home
75591365|NCT04256915|Behavioral|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Placebo Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes.Participants will receive red-filtered dim light (<50 lux)."
75591366|NCT04255745|Behavioral|progressive resistance training|Individual, tailored, progressive muscle strength and function intervention
75591367|NCT04254575|Other|None, observational study only (no interventions)|None, observational study only (no interventions)
75591368|NCT04251910|Drug|Sublingual film containing Dexmedetomidine|Sublingual film containing Dexmedetomidine
75591369|NCT04251910|Drug|Sublingual Placebo Film|Sublingual placebo film that matches BXCL501
75734279|NCT04894266|Drug|Apabetalone|Apabetalone 100mg BID
75734280|NCT04894266|Other|Standard of care|Standard of Care
76055515|NCT02110238|Device|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
75440941|NCT01628445|Drug|liraglutide|liraglutide titrated to 1.8 mg sc daily
75440942|NCT01628445|Drug|placebo injection|placebo injected sc daily volume equal to active comparator
75440943|NCT01628458|Procedure|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
75440944|NCT01628471|Drug|decitabine in combination with genistein|decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
75440945|NCT01628484|Other|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
75440946|NCT01628484|Other|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
75440947|NCT01628484|Other|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
76055516|NCT02108912|Other|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
76055517|NCT02108912|Other|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
76055518|NCT02108600|Drug|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
76055519|NCT02107898|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
76055520|NCT02107898|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
76055521|NCT02107898|Drug|Lipid-Modifying Therapy (LMT)|Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
75440948|NCT01628562|Drug|Esmolol|Esmolol 50 mcg/kg/min
75591370|NCT04248582|Device|Cryotherapy|LNSC will be performed with low-pressure liquid nitrogen (<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
75591371|NCT04248491|Device|BTL Emsella chair|Subjects will sit on the device. The Research Nurse Coordinator (RNC) will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.
75734281|NCT04877236|Device|Green Sun Medical Brace|"All patients in the study will receive the Green Sun Medical Whisper Brace. Each GSM brace will be custom-fabricated via computer-assisted design using the 3D torso scans and a treatment plan (e.g. placement of corrective forces) devised by the treating orthotist as inputs. The brace components are then assembled. Once fabricated, the GSM brace will be fit to the subject by representatives of the manufacturer and in consultation with the treating orthotist.~The GSM brace will be prescribed for the same number of hours per day as was the TLSO (generally 18-22 hours per day, individualized based on patient characteristics). Subjects and the family will be shown how to don and doff the brace, how to clean the brace cover, how to remove the temperature monitor, and how to remove the iButton and how to replace batteries in the GSM sensor board."
75734282|NCT04873752|Biological|UDI-001|2.5 x 10^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.
75734283|NCT04871113|Biological|GSK3810109A|GSK3810109A will be available as sterile aqueous solution.
75440949|NCT01628562|Drug|Remifentanil|Remifentanil 0.5 mcg/kg/min
75734284|NCT04871074|Drug|UCB-J|PET imaging with UCB-J
75734285|NCT04870580|Diagnostic Test|Fluorodopa PET tracer|PET/CT scan using fluorodopa tracer
75734286|NCT04856163|Behavioral|Telelactation support|Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
76055522|NCT02059148|Drug|LY2835219|Administered orally.
76055523|NCT04721600|Device|Evoke Radiofrequency Device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
76055524|NCT04720820|Other|Early Supported discharge with home based Rehabilitation|Treatment by Physiotherapist and occupational therapist at least 30 minutes each, per week provided at home.
76055525|NCT04720820|Other|Conventional rehabilitation|Treatment will be provided according to current hospital's stroke rehabilitation program.
75440950|NCT01628575|Procedure|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
75440951|NCT01628627|Device|Frequency Modulated Neural Stimulation (FREMS) (Aptiva)|FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly ~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
76055526|NCT04720742|Drug|Analytical Treatment Interruption + bNAbs infusion|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
75734287|NCT04854395|Drug|Marcain 5 mg/ml|Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
76055527|NCT02058992|Drug|Ramelteon|Ramelteon 8 mg tablets
75440952|NCT01628627|Device|sham treatment (Aptiva)|The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
76055528|NCT04719416|Behavioral|Guided Meditation|Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
75440953|NCT01628653|Device|U-SMART|4-weeks' training
75440954|NCT01628666|Drug|Incremental|Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
75440955|NCT01628666|Drug|Conventional|Cefazolin preoperative
75591372|NCT04248192|Biological|DD HST-NEETs|HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
75440956|NCT01628679|Behavioral|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
75591373|NCT04246151|Drug|Vancomycin|Vancomycin capsules
75591374|NCT04246151|Dietary Supplement|Culturelle|Culturelle capsules
75591375|NCT04246151|Drug|Vancomycin Placebo|sugar pill manufactured to mimic the vancomycin 125 mg capsule
75591376|NCT04246151|Drug|Probiotic Placebo|sugar pill manufactured to mimic 10 billion unit probiotic capsules.
75591377|NCT04236882|Other|Focus Group|Attend focus group
75591378|NCT04236882|Behavioral|Health Education|Receive educational material on healthy homes
75591379|NCT04236882|Other|Internet-Based Intervention|Receive web-based sleep intervention
75591380|NCT04236882|Other|Internet-Based Intervention|Receive web-based health coaching sessions
75591381|NCT04236882|Other|Internet-Based Intervention|Receive web-based counseling sessions
75591382|NCT04236882|Other|Interview|Complete interview
75591383|NCT04236882|Other|Questionnaire Administration|Ancillary studies
75591384|NCT04236791|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75591385|NCT04236791|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75591386|NCT04236479|Biological|BM-MSC|Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
75591387|NCT04235140|Drug|LUM/IVA|LUM/IVA granules for oral administration
75591388|NCT04220684|Drug|Cytarabine Hydrochloride|Given IV
75591389|NCT04220684|Drug|Fludarabine|Given IV
75591390|NCT04220684|Biological|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given via infusion
75591391|NCT04216589|Drug|Semaglutide|Administered subcutaneously
75591392|NCT04204915|Procedure|Aortic valve replacement|Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.
75440957|NCT01628705|Other|Nutritional intervention|"The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat <7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber)."
75591393|NCT04204798|Drug|Dexmedetomidine|"Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events."
75591394|NCT04204798|Drug|Placebo|"Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~Propofol sedation is administered when considered necessary."
75591395|NCT04197869|Drug|Polyethylene Glycol Powder|Polyethylene Glycol 3350 17g should be mixed in 8 ounces of fluid for administration. Polyethylene glycol is a high molecular weight, water soluble polymer which can form hydrogen bonds with water molecules. It is an osmotic laxative solution which stimulates bowel movements by increasing the amount of water absorbed in the GI tract. It decreases feces consistency and increases their volume by promoting peristalsis and evacuation. The side effects of polyethylene glycol are bloating, gas or diarrhea. The half-life of polyethylene glycol is 4-6 hours and after 18 hours the concentration declines to non-quantifiable levels.
75591396|NCT04193293|Drug|Duvelisib|Phosphoinositide 3-kinase (PI3K) Inhibitor
75734288|NCT04852016|Behavioral|Consent process with the addition of Digital educational platform (DEP)|In-patients being consented for laparoscopic cholecystectomy will be provided with a Digital Educational Platform (DEP), in the form of modules on an iPad. These participants will still undergo the usual standard verbal consent (SVC). Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using DEP.
75883933|NCT05199181|Procedure|Full pulpotomy|After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
75883934|NCT02132390|Drug|Goserelin|
75440958|NCT01628705|Dietary Supplement|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
75591397|NCT04193293|Biological|Pembrolizumab|Immunotherapy (programmed cell death protein 1 [PD-1] inhibitor)
75734289|NCT04852016|Behavioral|Consent process using the standard verbal consent (SVC)|In-patients being consented for laparoscopic cholecystectomy will go through the SVC. Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using SVC.
75440959|NCT01628731|Drug|furosemide|furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
75440960|NCT01628731|Drug|ethacrynic acid|ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
75440961|NCT01628770|Drug|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
75440962|NCT01628770|Drug|Ferrous sulphate|200mg twice daily
75883935|NCT02132390|Drug|Toremifene|
75734292|NCT04844294|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|BCBT is divided into three phrases. In phase I (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills such as relaxation and mindfulness. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
75734293|NCT04844294|Behavioral|Present-Centered Therapy (PCT)|PCT includes (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions. PCT differs from BCBT in several key ways including less structure (i.e., patients are allowed to have more input into PCT session agendas) and no systematic training in behavioral or cognitive strategies for managing emotions and changing suicide-focused thoughts. PCT will be used as an active comparator because it is an empirically supported treatment for depression and PTSD that also reduces suicidal ideation (Bryan et al., 2016; Resick et al., 2017), but contains unique elements that distinguish the treatment from BCBT.
75883936|NCT03875443|Other|Instructional video|Video (produced by AO Trauma and Prof. Daniel Rikli) includes a stepwise and structured explanation of the different fluoroscopic views necessary to evaluate intraoperatively with the fluoroscope different aspects of the proximal femur. The video is publically available under: (https://www.aointeract.org/#/watch/video/L3YxL3ZpZGVvcy8xOTc=/intraoperative-imaging-of-femur).
75591398|NCT04191876|Other|Wellth - Financial Incentives|Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.
75734294|NCT04841811|Drug|Almonertinib|ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
75591399|NCT04188990|Dietary Supplement|Nutritional dietary intervention|The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
75591400|NCT04188990|Dietary Supplement|By demand|"In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now"
75734295|NCT04839991|Drug|CB307|Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
75591401|NCT04188990|Dietary Supplement|Usual current care|"In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide"
75591402|NCT04188457|Other|Usual follow-up|2 medical consultations (nurse and doctor) over 24 months
75591403|NCT04188457|Other|Intensive follow-up|10 medical visits (nurse, doctor, pharmacist) over 24 months
75591404|NCT04187118|Other|Quality of life|Quality of life one year post chemo-therapy
75591405|NCT04171843|Genetic|PBCAR269A|Allogeneic anti-BCMA CAR T-cell
75591406|NCT04171843|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
75591407|NCT04171843|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
75591408|NCT04171843|Drug|Nirogacestat|Allogeneic anti-BCMA CAR T-cell
75591409|NCT04166552|Drug|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken once a day
75591410|NCT04166552|Drug|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken twice a day
75591411|NCT04165993|Drug|Concurrent chemotherapy and KN026|30 mg/kg Q3W KN026 75 mg/m2 docetaxol
75734296|NCT04839900|Other|Proactive iCCM|CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children < 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
75734297|NCT04827537|Drug|20-hydroxyecdysone Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
75734298|NCT04827537|Drug|Metronidazole Oral|500 mg (one pill) x two times a day orally, 10 consecutive days
75591412|NCT04165993|Drug|KN026 monotherapy|30 mg/kg Q3W KN026
75591413|NCT04165993|Drug|KN026 combination|30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
75591414|NCT04141501|Drug|Psilocybin|single dose of psilocybin (25mg). orally in form of a capsule
75591415|NCT04141501|Drug|Placebo oral capsule|single dose of mannitol (100%)
75440963|NCT01628783|Drug|escitalopram 10 mg|orally once daily
75440964|NCT01628783|Drug|Placebo|once daily
75440965|NCT01628796|Other|contrast material injection|using ultrasound to locate ac joint and injecting contrast material to ensure that the dye is actually in the joint
75440966|NCT01628809|Behavioral|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
75440967|NCT01628822|Behavioral|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
75440968|NCT01628822|Behavioral|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
75440969|NCT01628835|Behavioral|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
75591416|NCT04134260|Drug|Apalutamide|Given PO
75440970|NCT01628835|Behavioral|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
75591417|NCT04134260|Drug|Hormone Therapy|Receive hormone therapy
75591418|NCT04134260|Other|Quality-of-Life Assessment|Ancillary studies
75591419|NCT04134260|Other|Questionnaire Administration|Ancillary studies
75591420|NCT04134260|Radiation|Radiation Therapy|Undergo pelvis and prostate bed radiation therapy
75591421|NCT04127604|Behavioral|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
75591422|NCT04127604|Behavioral|Safety Assessment and Follow-up Evaluation (SAFE)|Measurement-based care assessment and evaluation.
75591423|NCT04126187|Device|Panoptix|Panoptix trifocal intraocular lens (IOL)
75591424|NCT04111133|Drug|Betablocker + ivabradine|Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute
75591425|NCT04111133|Drug|Betablocker|Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.
75591426|NCT04106167|Genetic|Allogeneic natural killer (NK) cell|No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
75591427|NCT04101318|Device|Non-Conformité Européene marked product|New Baseplate is not named at this point
75591428|NCT04101318|Device|Conformité Européene marked competitor products|The Conformité Européene marked competitor products are considered Standard of Care or products considered to be part of Standard of Care in coming years.
75591429|NCT04091672|Procedure|Control Intervention (Conventional Autograft)|Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)
75591430|NCT04091672|Device|Investigational Intervention (RECELL + more widely meshed autograft)|More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
75591431|NCT04091490|Drug|Nivolumab|Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab
75734299|NCT04827537|Drug|Placebo Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
75591432|NCT04090125|Behavioral|PAS Intervention|The PAS program will be initiated during the final usual care PT visits. The PAS content will be included within the last two routine PT visits (Sessions 1 and 2). Session 1 will emphasize the importance of PA in TKA recovery, work with participants to establish SMART goals regarding overall PA and provide community-based and other resources to support overall PA. Session 2 will include balance exercise content to improve joint loading symmetry and home exercises will be assigned. Then, PAS participants will receive a follow-up phone call after 4 weeks (to assist with activity progression and problem-solving) and an additional in-person visit after 8 weeks (to visually monitor exercise performance and re-assess proportional weight-bearing ability).
75591433|NCT04090125|Behavioral|Attention Control|This will include usual in-person post TKA PT followed by 2 additional contacts (Session 1 and 2) with the physical therapist. Session 1 (phone) will review recovery benchmarks, assessment of participants' daily activities and reminders about symptoms that should trigger contacting a medical professional. Session 2 (in-person) will involve physical performance tests and comparison to appropriate normative values.
75591434|NCT04088318|Drug|OQL011|OQL011 is an ointment containing active ingredient.
75591435|NCT04088318|Drug|Vehicle Ointment|Vehicle ointment is an ointment containing no active ingredient.
75591436|NCT04087057|Other|Interview|Participate in interview
75591437|NCT04087057|Other|Medical Chart Review|Patients' medical records are reviewed
75591438|NCT04087057|Behavioral|Questionnaire|Complete questionnaires
75591439|NCT04084704|Device|Cingal|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
75591440|NCT04082780|Drug|Rifamycin SV MMX|Intervention arm
75591441|NCT04082780|Other|Placebo|Placebo arm
75591442|NCT04082117|Behavioral|Educational video|Educational genetic counseling video
75591443|NCT04080284|Drug|Niraparib|Study treatment will be administered orally Q day continuously. Up to three capsules of 100mg strength will be taken at each dose administration. Initiation dose will be defined per current FDA guidelines for Niraparib treatment in ovarian cancer. Dose interruption (no longer than 28 days) will be allowed. Dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200mg) and subsequently to 1 capsule daily (100mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.
75591444|NCT04078373|Behavioral|Immediate urination|Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.
75591445|NCT04078373|Behavioral|Bladder diary|Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
75591446|NCT04067115|Drug|Trabectedin 1 MG [Yondelis]|Patients with Ewing sarcoma will be administered trabectedin intravenously. Cycles are 21 days.
75591447|NCT04067115|Drug|Irinotecan|Patients with Ewing sarcoma will be administered inirotecan intravenously. Cycles are 21 days.
75591448|NCT04067115|Diagnostic Test|tumor biopsy|Tumor tissue samples will be collected collected at two timepoints. The first biopsy will be prior to treatment. If a biopsy is not possible archival tissue may be submitted. A second tumor biopsy will be taken fro consenting patients when possible after the first administration of Trabectedin to evaluate the effect on the tumor cells.
75591449|NCT04067115|Other|3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging|Some patients will receive PET scans with the use of 18F-FLT, a radioactive tracer, performed at the National Institute of Health.
75591450|NCT04065347|Device|Digital Pill|Digital Pill over encapsulating tenofovir alafenamide ART
75591451|NCT04054375|Drug|Prednisone|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
75591452|NCT04051593|Other|Cervical stabilization exercise|The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
75734300|NCT04825288|Biological|XB2001 or Placebo|XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
75591453|NCT04048668|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
75591454|NCT04039386|Device|Cell Phone Based Cognitive Based Therapy (Pacifica App)|Cell phone application that provides support for individuals with psychosocial conditions.
75591455|NCT04039386|Other|Control|Subjects in the control group will receive standard care.
75591456|NCT04037254|Biological|Gonadotrophin Releasing Hormone|Receive standard of care GnRH agonist androgen suppression therapy
75591457|NCT04037254|Radiation|Intensity-Modulated Radiation Therapy|Undergo standard of care IMRT
75591458|NCT04037254|Drug|Niraparib|Given PO
75591459|NCT04034433|Procedure|Handgrip exercise program|Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
75734301|NCT04822740|Device|Control Glucose Monitoring System|"With a sensor, transmitter and display device (receiver and/or compatible smart device).~The CGMS sends glucose readings to a compatible smart device every 5 minutes. In this study the CGMS for all patients with use of the results of the device in real time by the health care team for the Experimental arm and without the use of the results by the health care team for Active Comparator (Conventional strategy ."
75440971|NCT01628861|Device|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
75440972|NCT01628861|Behavioral|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
75734302|NCT04820179|Drug|Cabozantinib + Atezolizumab|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
75440973|NCT01628887|Other|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
75734303|NCT04820036|Diagnostic Test|Insulin Resistance|Insulin resistance: Fasting glucose and insulin will also be measured to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), as a surrogate of IR
75734304|NCT04820036|Behavioral|Quality of Life Assessment|Quality of life will be assessed using the Chronic Liver Disease Questionnaire.
75591460|NCT04028830|Other|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
75591461|NCT04028830|Other|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
75591462|NCT04023708|Drug|CYD-TDV Dengue Vaccine|Pharmaceutical form:Solution Route of administration: Intramuscular
75734305|NCT04820036|Diagnostic Test|Liver Function Test|EUS-guided liver biopsy and portal pressure gradient measurement
75883937|NCT03875443|Other|Reduction algorithm|Intraoperative reduction algorithm (developed by PD Henrik Eckardt); each step in the algorithm will be checked and documented with the fluoroscope and archived using the store function of the fluoroscope.
75440974|NCT01628900|Other|care management arm N°1 vs arm N°2|7 days for mono-antibiotherapy at hospital
75440975|NCT01628900|Other|Care management|Hospital vs home
75591463|NCT04023422|Behavioral|Clinical intervention|The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
75591464|NCT04023422|Behavioral|Feedback|The community health navigator will give the clinician real-time feedback on guideline-related health.
75591465|NCT04021641|Diagnostic Test|Speech recognition in noise|Measurement of speech recognition performance in noise
75591466|NCT04017442|Drug|Preservative Free Morphine|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
75591467|NCT04017442|Drug|Saline|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
75591468|NCT04015622|Drug|Enzalutamide|Enzalutamide 160 mg PO OD
75591469|NCT04015622|Drug|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks
75734306|NCT04820036|Diagnostic Test|Radiologic features of NASH|Controlled attenuation parameter (CAP) and liver stiffness scores assessed by transient elastography (TE)
75734307|NCT04820036|Diagnostic Test|Serologic features of NASH|Laboratory value assessment of alanine aminotransferase (ALT), liver chemistries, platelet counts, albumin and calculated NAFLD Fibrosis Score (NFS).
75734308|NCT04817865|Diagnostic Test|Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)|M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.
75734309|NCT04817865|Diagnostic Test|Urine Culture|A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
75883938|NCT02128646|Drug|EXPAREL|
75591470|NCT04010578|Dietary Supplement|MK-7 and vitamin D3|Patients will receive 400 micro-grams of Menaquinone-7 and 80 micro-grams of vitamin D3 per day.
75591471|NCT04010578|Other|Placebo|Patients will receive a placebo each day.
75883939|NCT02128646|Drug|Ketorolac|
75591472|NCT04005521|Behavioral|Preventive intervention|Preventive, structured exercise protocol
75591473|NCT04003389|Drug|fezolinetant|administered orally
75591474|NCT04003389|Drug|placebo|administered orally
75591475|NCT04000282|Drug|SAR442085|Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
75591476|NCT03996018|Other|T-cell lymphocyte responses|T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
75591477|NCT03994055|Other|Omega-3 fatty acids|Diet will include foods rich in omega-3 fatty acids.
75734310|NCT04817124|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 6 sessions with 20 minutes stimulation each (1,5 mA).
76055529|NCT02058836|Drug|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
76055530|NCT02058836|Procedure|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
75591478|NCT03994055|Other|Antioxidants|Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.
75591479|NCT03994055|Other|Soluble fiber|Diet will include foods rich in soluble fiber.
75591480|NCT03994055|Other|Probiotics|Diet will include foods rich in probiotics.
75734311|NCT04817124|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 6 sessions for approximately 20 min
75734312|NCT04817124|Device|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 6 sessions with 30 sec stimulation each (1,5 mA) to ensure blinding of participants.
75734313|NCT04816773|Device|EVOLUTION® NitrX™|EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
75734314|NCT04815564|Device|Invisalign|Invisalign clear aligner system
75883940|NCT02128646|Procedure|laparoscopic abdominal hernia repair|
76055531|NCT02107274|Drug|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
76055532|NCT02107274|Drug|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
76055533|NCT02174627|Drug|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
76055534|NCT02174627|Drug|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
76055535|NCT02173769|Drug|Spiriva® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
75591481|NCT03994055|Other|Lactose restriction|Diet will be restricted to 5g lactose/day
75591482|NCT03994055|Other|Fiber restriction|Diet will be restricted to 20g fiber/day
75591483|NCT03994055|Other|Fat restriction|Diet will be restricted to 20% total energy intake
75591484|NCT03991104|Drug|Oxaliplatin|Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
75883941|NCT02128646|Procedure|an open surgery for abdominal hernia repair|
75591485|NCT03991104|Drug|S-1 capsule|Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
75591486|NCT03991104|Radiation|Intensity modulated radiotherapy (IMRT)|The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
75591487|NCT03989349|Drug|Placebo|Placebo
75591488|NCT03989349|Drug|Nemolizumab|Nemolizumab
75591489|NCT03988595|Other|Exercise Treatment|Exercise sessions will consist of individualized, walking delivered following a non-linear (i.e.,exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
75734315|NCT04808986|Diagnostic Test|Serological test for the detection of IgG anti-SARS-CoV-2|Self-sampling dried-blood spot (DBS) kits will be send to each participant including material (a DBS card, lancets, pad), detailed printed instructionson how to perform thetest, and a self-addressed stamped padded envelope to be returned with the card to the centralized biobank (CEPH Biobank, Paris, France). Tubes will be sent sent to the virology laboratory (Unité des virus Émergents, Marseille, France) for serological analysis.
75734316|NCT04805918|Behavioral|VIPP-SD|Parenting program
75734317|NCT04800692|Drug|Tetrahydrobiopterin 10 mg/kg|10mg/kg of Tetrahydrobiopterin daily.
75734318|NCT04800692|Drug|Tetrahydrobiopterin 20 mg/kg|20mg/kg of Tetrahydrobiopterin daily.
75591490|NCT03985943|Drug|Placebo|Placebo
75591491|NCT03985943|Drug|Nemolizumab|Nemolizumab
75591492|NCT03983473|Other|Microbiota Sequencing|virome, bacteriome, fungome NGS sequencing
75734319|NCT04800692|Drug|L-Ascorbate|3300 mg of l-ascorbate once daily
75734320|NCT04800692|Drug|L-Arginine|3400mg of l-arginine once daily
75734321|NCT04800055|Other|Attractive Targeted Sugar Bait|ATSBs will be installed on all structures of consenting households in intervention areas for six months according to instructions from the manufacturer. Monitoring assistants will be responsible for providing individual level household orientation for the ATSB and seeking informed consent. Prior to ATSB deployment, community sensitization activities will be conducted to prepare communities for the intervention and research activities. Where appropriate, local media may be used to disseminate messages to sensitize the community to the intervention and the research.
75734322|NCT04791709|Behavioral|Happy Older Latinos are Active (HOLA)|HOLA is a multicomponent health promotion intervention. First component is a one-on-one social and physical activation with the participant and the community health worker (CHW). Each session will last approximately 30 minutes at day 1 and week 8. The second component is a group walk led by a CHW for 45 minutes, 3 times a week, for 16 weeks. The third component consists of scheduling pleasant events at the end of each group walk session.
75883942|NCT02136446|Device|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
75883943|NCT02136446|Device|Pajunk® Nerve Block Catheter|Nerve Block Catheter
75883944|NCT03785665|Device|MDI|Capsule MD1 (Motility dummy 1)
75883945|NCT02136524|Drug|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
75440976|NCT01628939|Other|MRI of the lumbar spine|standard protocol, approximately 30 minutes
75440977|NCT01628939|Other|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
75440978|NCT01628952|Drug|Transversus Abdominis Plane|PIA coelioscopic
75440979|NCT01628952|Drug|Curare|IAP coelioscopic
75440980|NCT01628978|Other|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
75440981|NCT01628978|Other|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
75440982|NCT01628991|Behavioral|behavioural program|interventional behavioural program
75440983|NCT01628991|Device|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
75440984|NCT01629004|Other|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
75440985|NCT01629004|Other|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
75440986|NCT01629056|Procedure|ablation|RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
75440987|NCT01629056|Procedure|RF ablation|RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
75440988|NCT01629069|Behavioral|Mindfulness based Resilience Training|6 weekly group sessions
75440989|NCT01629082|Drug|Clofarabine|
75591493|NCT03968913|Drug|Anakinra injection|anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
75440990|NCT01629082|Drug|Lenalidomide|
75440991|NCT01629121|Behavioral|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated."
75591494|NCT03968913|Procedure|sterile saline injection|5 milliliters of sterile saline will be injected into the knee joint
75591495|NCT03968315|Procedure|Diaphragm Fluoroscopy|Undergo diaphragm fluoroscopy
75591496|NCT03968315|Procedure|Magnetic Resonance Imaging|Undergo MRI
75591497|NCT03962712|Other|Increase Minimum Wage to $15-an-hour|Increase in minimum wage to $15-an-hour
75591498|NCT03962712|Other|No Increase in Minimum Wage|No increase in minimum wage
75591499|NCT03960437|Drug|Etelcalcetide|Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
75591500|NCT03959488|Drug|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
75591501|NCT03959488|Drug|Palivizumab|Approved anti-RSV monoclonal antibody
75591502|NCT03950817|Drug|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg|Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
75591503|NCT03950817|Drug|Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
75591504|NCT03950817|Drug|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
75591505|NCT03948984|Behavioral|Therapeutic Music Session|The 20 minute therapeutic music session will consist of classical music performed by a pianist with or without flute accompaniment with an individual patient's ICU room.
75591506|NCT03948100|Other|Educational Intervention|Undergo dyadic education program
75591507|NCT03948100|Other|Quality-of-Life Assessment|Ancillary studies
75591508|NCT03948100|Other|Questionnaire Administration|Ancillary studies
75591509|NCT03948100|Procedure|Yoga|Undergo dyadic yoga
75591510|NCT03942250|Biological|REGE pro dressing|REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
75591511|NCT03936894|Drug|Canakinumab Injection [Ilaris]|Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg
75591512|NCT03934268|Genetic|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
75591513|NCT03931707|Genetic|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
75591514|NCT03926507|Procedure|Computed Tomography|Undergo PET/CT scan
75591515|NCT03926507|Other|Fluciclovine F18|Given IV
75591516|NCT03926507|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75591517|NCT03913195|Drug|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
75591518|NCT03912038|Other|No intervention.|No intervention
75591519|NCT03907124|Drug|Genetically-guided treatment with FDA-approved psychotropic drugs|Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
75440992|NCT01629147|Dietary Supplement|Biogaia|5 drops containing Lactobacillus reuteri Protectis
75591520|NCT03907124|Drug|Treatment as usual (TAU)|All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
75591521|NCT03894059|Other|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
75591522|NCT03889119|Radiation|Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.|SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer.
75591523|NCT03888040|Other|Exercise|The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
75591524|NCT03885622|Device|ANTHEM™ CR Total Knee System|The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.
75591525|NCT03884790|Device|surgical repair of long bone defects|"Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects."
75591526|NCT03884374|Behavioral|Focused Breathing and Attention Training (BAT)|Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.
75591527|NCT03884374|Behavioral|Standard Breathing and Attention Training (BAT)|Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.
76055536|NCT02173769|Drug|Striverdi® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
75440993|NCT01629147|Other|Placebo|5 drops
75440994|NCT01629173|Procedure|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
75591528|NCT03884374|Device|Transcranial Direct Current Stimulation (tDCS)|A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges
75734323|NCT04791306|Other|supervised exercise training|Participates perform once a week for 4 months an in-house supervised endurance and strength training.
75734324|NCT04791306|Other|home-based exercise training|Participants are provided with an application for planning and documentation of their physical activity, together with an expert participants plan their physical activities for their home-based training to reach at least 150 min physical activity per week.
76055537|NCT02121509|Drug|Linagliptin|1 x Linagliptin tablet
76055538|NCT02121509|Drug|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
75591529|NCT03884374|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
75591530|NCT03873818|Biological|Ipilimumab|Given IV
75591531|NCT03873818|Biological|Pembrolizumab|Given IV
76055539|NCT02121509|Drug|Metformin ER|3 x Metformin ER tablets
76055540|NCT02149199|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
75591532|NCT03848676|Diagnostic Test|Evaluation of patients resistance to immunotherapies in Multiple Myeloma|There are only collections of the samples.
76055541|NCT02149199|Drug|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
75734325|NCT04786600|Device|Signatera ctDNA assay|Subjects will be tested with the Signatera ctDNA assay every 2 weeks.
75734326|NCT04786600|Drug|pre-specified sequence of FDA-approved drugs and drug combinations|Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
75734327|NCT04783454|Other|Exercise program|educational video on training program design and healthy lifestyle 24 training sessions (12 on cardiovascular endurance training, 12 on mobility and strength)
75734328|NCT04783415|Drug|Acalabrutinib|Given PO
75734329|NCT04783415|Biological|Ublituximab|Given IV
75734330|NCT04783415|Drug|Umbralisib|Given PO
75734331|NCT04781140|Drug|100mg SPN-812|100mg SPN-812 will be administered once daily and compared to Placebo
75734332|NCT04781140|Drug|Placebo|Placebo will be administered once daily
75734333|NCT04779736|Behavioral|A set of implementation strategies to reduce sexual stigma|The intervention will be finalized based on formative interviews and consultation with an advisory board. It is likely to include an educational mHealth component followed by an in-person workshop for skills development, then supportive coaching components (i.e., coaching calls and an optional email listserve) to encourage and respond to the implementation of recommended practices.
75883946|NCT02136524|Drug|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
75883947|NCT05199103|Drug|rabbit anti-thymocyte globulin|0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
75883948|NCT02132546|Drug|Chlorhexidine|
75883949|NCT05198947|Drug|Permethrin Lotion 5%|Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.
75883950|NCT05198947|Drug|Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg|Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
75883951|NCT05256212|Other|exposure to environmental contaminants|to measure levels of contaminants in different matrixes
75883952|NCT05239520|Other|3D movement analysis with surface electromyography and ultrasound|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles
75883953|NCT05198869|Device|Spectral scan|Consenting participants will have a SpotLight-19 scan
75883954|NCT01367834|Drug|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
75883955|NCT03106753|Drug|Bupivacaine|intrathecal bupivacaine 7.5 mg
76055542|NCT02149199|Drug|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
75440995|NCT01629173|Procedure|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
75440996|NCT01629173|Procedure|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
75440997|NCT01629173|Procedure|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
75440998|NCT01629186|Other|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) <5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) <80 beats/min or oxygen saturation (SpO2) <85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
75440999|NCT01629199|Drug|rhEGF(recombinant human Epidermal Growth Factor)|
75441000|NCT01629199|Drug|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
75441001|NCT01629212|Drug|Tiropramide HCl 100mg|
75441002|NCT01629212|Drug|Octylonium bromide 20mg|
75441003|NCT01629225|Drug|Candesartan|To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
75441004|NCT01629251|Device|Closed-loop insulin delivery|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
75591533|NCT03847194|Behavioral|Promoting Resilience in Stress Management (PRISM)|PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
75591534|NCT03843294|Biological|TAA-T cells|The patient will receive two TAA-T cell infusions given 2 weeks apart. TAA-T cell dose: 2 x 107 cells/m2.per infusion.
75591535|NCT03843294|Drug|Nivolumab|Nivolumab: For patients <18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks
75591536|NCT03836443|Other|"western diet meal"|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."
75883956|NCT03106753|Drug|Terbutaline|0.25 mg Terbutaline subcutaneously
75883957|NCT02132624|Biological|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
75883958|NCT02128880|Behavioral|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
76055543|NCT02120417|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
76055544|NCT02120417|Drug|Capecitabine|Capecitabine 2000 mg/m^2 daily given as 1000 mg/m^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
75883959|NCT02128880|Behavioral|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
75883960|NCT02136758|Behavioral|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
75883961|NCT05385679|Procedure|Surgical Extraction of lower third molar|The surgical removal of mandibular third molar is one of the most common procedures done in oral and maxillofacial surgery. Patients often experience pain, swelling, trismus, dehiscence, alveolar osteitis, infection, nerve injury and periodontal tissue damage after third molar surgery. Flap design is an important step in third molar surgery. Envelope flap and modifications of triangular flap are the two most commonly used flaps in surgical removal of lower third molar.
75441005|NCT01629264|Device|Ocular Response Analyzer|To measure corneal biomechanics, specifically corneal hysteresis (CH) and the Corneal Resistance Factor (CRF). The devise measures in a non-contact manner, by analyzing the deformation of the cornea upon a defined pulse of air.
75441006|NCT01629264|Device|Scheimpflug measurement|A Scheimpflug camera will be used in a non-contact manner to assess topographical data from the anterior and posterior corneal surface as well as detailed data on corneal thickness.
75441007|NCT01629264|Other|Blood sample|A blood sample will be taken at 6 months after surgery to determine the levels of several hormones. The blood needed to détermine hormone levels during pregnancy will be acquired during the routine examinations that are performed during pregnancy. Here, blood is taken routinely and an additional volume is taken for the purpose of this study.
75441008|NCT01629277|Device|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
75883962|NCT02132702|Device|Ekso|
75883963|NCT05198401|Other|covid-19|viral infection
76055545|NCT02120417|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
75883964|NCT05198323|Drug|LT3001 Drug Product|Administered by intravenous infusion
76055546|NCT02148263|Device|senofilcon A|
75883965|NCT05198323|Drug|Placebo|Administered by intravenous infusion
75883966|NCT03550898|Diagnostic Test|Dynamic Ultrasonography|Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
75883967|NCT05704621|Procedure|secondary cytoreductive surgery|Maximum effort cytoreductive surgery
75883968|NCT05704621|Drug|chemotherapy|six cycles of bevacizumab [10 mg/kg, days 1 and 15] plus carboplatin [AUC 5, day 1] plus pegylated liposomal doxorubicin [30 mg/m2, day 1] every 4 weeks, followed by maintenance bevacizumab [15 mg/kg every 3 weeks]
76055547|NCT05135585|Other|Blood sample collection|Blood sample collection at 1 month and 6 months after vaccination
76055548|NCT05135585|Other|Questionnaires|data collection (health data, vaccination data, etc.)
76055549|NCT02147561|Biological|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
76055550|NCT02058368|Drug|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
76055551|NCT02058368|Drug|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
75734334|NCT04779437|Behavioral|Imagery Cognitive Bias Modification|"The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell & Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. The training aims to train a bias to automatically imagine positive resolutions for ambiguous situations encountered in daily life.~Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website."
75734335|NCT04779437|Behavioral|Cognitive Control Training|The cognitive control training is an adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015; Blackwell et al., 2018). Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website.
76055552|NCT02058368|Drug|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
75441009|NCT01629277|Device|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
75734336|NCT04777357|Drug|Cariprazine|Oral Capsule
75734337|NCT04777357|Drug|Placebo|Oral Capsule
75734338|NCT04772196|Drug|Vitamin D3|50,000 IU Vitamin D3 weekly for 8 weeks
76055553|NCT02058368|Drug|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
76055554|NCT02107196|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
76055555|NCT02107196|Drug|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
76055556|NCT04185428|Behavioral|Integrative Therapy|still meditation, meditative movement, relaxation techniques, and massage therapy
75441010|NCT01629303|Procedure|sacral nerve modulation|"After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks"
75441011|NCT01629316|Behavioral|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
75441012|NCT01629316|Behavioral|Standard of care - control arm|The control arm is standard of care for each subject.
75441013|NCT01629342|Behavioral|Standardized activities|"All patients do each of the following standardized activities over a course of 2 days:~treadmill walking (5 minutes, 1 and 2km/h)~staircase walking (1 floor, normal pace)~cycling with fixed load (5 minutes)~standing up from sitting position and sitting down again (x5)~standing up from supine position~turning from left to right and back while lying in bed~raising outstretched arm 90° (x5, standing position)~eating (5 minutes, sitting position)~drinking a glass of water~sleeping (6 hours)"
76055557|NCT02058290|Drug|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
76055558|NCT02058290|Drug|EXPAREL|"Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
76055559|NCT02082158|Other|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
76055560|NCT04417322|Other|observation of serum A.actinomycetemcomitans levels|Analysis of serum A.actinomycetemcomitans levels
76055561|NCT04718480|Drug|Placebo|po placebo tablets
76055562|NCT04718480|Drug|Fluvoxamine|po fluvoxamine tablets
76055563|NCT02106884|Drug|Nab-paclitaxel|
76055564|NCT02106884|Drug|Gemcitabine|
75591537|NCT03828747|Drug|Semorinemab|Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
75591538|NCT03828747|Drug|Placebo|Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
75591539|NCT03828747|Drug|[18F]GTP1|[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
75441014|NCT01629368|Drug|Carbamazepine|Multiple doses of carbamazepine
75441015|NCT01629368|Drug|RO4917523|Single dose of RO4917523
75441016|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
75441017|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
76055565|NCT02081846|Other|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
75441018|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
75441019|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
75441020|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)]
75441021|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
75441022|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
75441023|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
75441024|NCT01629407|Other|Standard of Care|Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
75441025|NCT01629420|Drug|KLH-2109|
75441026|NCT01629420|Drug|KLH-2109|
75591540|NCT03825315|Biological|DAXI 80 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)
75591541|NCT03825315|Biological|DAXI 120 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
76055566|NCT02081846|Other|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
75734339|NCT04761770|Other|Geriatric assessment (GA) pre-transplant|Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
75734340|NCT04761770|Drug|conditioning regimen|"Based on the Geriatric assessment.~HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -> Myeloablative (MA) regimen~HCT-CI/Age >4 AND/OR any IADL impairment (more vulnerable) -> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen"
75734341|NCT04761770|Procedure|Allogeneic CD34+ selected stem cells|Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
76055567|NCT02081690|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
76055568|NCT02057666|Drug|Tasquinimod|A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
76055569|NCT02057666|Drug|Placebo|Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
75734342|NCT04758338|Other|VUMC telehealth services|Participants will access the CTS link (sent to them via email), which will connect them directly to a videoconference and enable them to see and hear the facilitators and other patients in the group.
75734343|NCT04758338|Other|Interview|25-30 participants will be interviewed
75441027|NCT01629446|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
75441028|NCT01629459|Behavioral|Resistance exercise and protein supplementation|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
75441029|NCT01629472|Behavioral|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
75441030|NCT01629485|Behavioral|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
75591542|NCT03825315|Other|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
75591543|NCT03821402|Biological|DAXI for injection 250 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
75591544|NCT03821402|Biological|DAXI for injection 375 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
75734344|NCT04758338|Other|Educational materials|Participants will be provided educational materials
75734345|NCT04752618|Behavioral|P-STAIR|PCIT+ STAIR
75734346|NCT04752618|Behavioral|Supportive Counseling|Non-trauma focused psychotherapy
75734347|NCT04751773|Behavioral|Exercise training|Perioperative exercise training
75734348|NCT04751279|Other|Blood sample|Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml
75734349|NCT04749043|Device|Oculus Quest 2 Virtual Reality Device|30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects
75734350|NCT04749043|Drug|Nitrous oxide|30 min exposure for labor analgesia
76055570|NCT04417400|Behavioral|medicines use review|The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).
76055571|NCT01625000|Drug|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
76055572|NCT01625000|Drug|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
76055573|NCT01625000|Drug|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
76055574|NCT01625000|Drug|Risperidone 4mg|Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
76055575|NCT01625000|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
76055576|NCT02081534|Drug|AZD1722|AZD1722, oral tablet
75734351|NCT04747626|Device|B-SAFER|Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
76055577|NCT02081534|Drug|Placebo|Placebo bid, double dummy technique
76055578|NCT02057198|Drug|Fidaxomicin|
76055579|NCT02057198|Drug|Metronidazole|
75441031|NCT01629485|Behavioral|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
75441032|NCT01629485|Behavioral|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
75441033|NCT01629511|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
75441034|NCT01629511|Biological|Anti-Thymocyte Globulin|Given IV
75441035|NCT01629511|Drug|Busulfan|Given IV
75441036|NCT01629511|Drug|Clofarabine|Given IV
75441037|NCT01629511|Biological|Filgrastim|Given SC
75441038|NCT01629511|Drug|Gemcitabine|Given IV
76055580|NCT02057198|Drug|Vancomycin|
75441039|NCT01629511|Drug|Methotrexate|Given IV
75734352|NCT04745403|Drug|mRNA HBV/TCR T-cells|"Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW."
76055581|NCT04417478|Other|Scaling and root planning|Periodontal debridement was performed in all patients.
76055582|NCT02056652|Device|Bioteque cup pessary|
76055583|NCT02056340|Drug|Atorvastatin|
76055584|NCT02056340|Drug|Placebo|
76055585|NCT04727060|Device|patient with knee arthroplasty|
76055586|NCT02046122|Drug|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
76055587|NCT02046122|Drug|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
76055588|NCT02046122|Biological|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
76055589|NCT04704362|Behavioral|Ensuring Quality in Psychological Support|Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.
76055590|NCT04704362|Behavioral|Standard Training and Supervision|Trainees are trained using a manual for non-specialist-delivered psychological interventions.
76055591|NCT02080832|Drug|Citalopram|20 mg or 40 mg daily for 8 weeks
75441040|NCT01629511|Drug|Tacrolimus|Given PO
75441041|NCT01629537|Procedure|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
75591545|NCT03821402|Biological|DAXI for injection 500 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
76055592|NCT02080832|Drug|Placebo|Placebo daily for 8 weeks
76055593|NCT02080364|Drug|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
75591546|NCT03821402|Other|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
75591547|NCT03816176|Drug|Isavuconazonium sulfate|Intravenous (IV) infusion
75591548|NCT03816176|Drug|Isavuconazonium sulfate|Oral capsule
75591549|NCT03815045|Procedure|Landmark-based lumbar puncture|Traditional landmark based lumbar puncture involves palpating spinous processes on the back and finding the inter-spinous space which is the site of needle entry to gain access to the thecal sac. Finding this space may be difficult by palpation, especially when subjects undergoing the procedure are obese, elderly, have had prior back surgery, or if the patient is positioned incorrectly.
75734353|NCT04728334|Drug|AK117|An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal
75591550|NCT03815045|Procedure|Ultrasound-guided lumbar puncture|Ultrasound guided lumbar puncture is a novel technique being increasingly utilized by emergency physicians, pediatricians and anesthesiologists. In this technique, an ultrasound probe is used to visualize the inter-spinous space. This space can be marked on the skin as the potential point of entry. This could potentially make it easier when patient factors make it difficult to palpate and find the site of entry.
75591551|NCT03804606|Other|Referral to MTM Pharmacist|Patients will be referred for an encounter with a medication therapy management pharmacist.
75591552|NCT03801876|Drug|Carboplatin|Given IV
75441042|NCT01629537|Procedure|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
75441043|NCT01629550|Procedure|skin disinfection prior catheter insertion|
75441044|NCT01629576|Other|economic incentive|economic incentive for weight loss
75441045|NCT01629576|Other|economic incentive|economic incentive for weight loss
75591553|NCT03801876|Procedure|Esophagectomy|Undergo esophagectomy
75734354|NCT04726566|Procedure|Tendon graft|Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft
75734355|NCT04726566|Procedure|Suture with biological reinforcement|Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
75883969|NCT02133014|Procedure|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
76055594|NCT02080364|Drug|Placebo|Placebo administered orally, once daily for 18 months
76055595|NCT02079038|Device|Totalis|
76055596|NCT02079038|Procedure|Comparator Surgical Procedure|
75591554|NCT03801876|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75591555|NCT03801876|Drug|Paclitaxel|Given IV
75441046|NCT01629602|Procedure|the Boomerang Nerve Flap|The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
75591556|NCT03801876|Radiation|Proton Beam Radiation Therapy|Undergo PBT
75591557|NCT03801876|Other|Quality-of-Life Assessment|Ancillary studies
75591558|NCT03801876|Other|Questionnaire Administration|Ancillary studies
75883970|NCT02133014|Drug|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
75883971|NCT05759455|Dietary Supplement|vitamin d|Assessment of Vitamin D level in Children with Autism in assiut university children hospital
75883972|NCT02129114|Device|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
76055597|NCT02045732|Biological|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
75441047|NCT01629628|Drug|Adalimumab|Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
75441048|NCT01629628|Drug|6 Mercaptopurine|"6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~--------------------------------------------------------------------------------"
75441049|NCT01629654|Behavioral|Health promotion program|"A 13 weeks organized program:~One group session about poststroke fatigue involving both patient and relatives~Two personal meetings, involving both patient and relatives~Three telephone meetings, involving only patient"
75441050|NCT01629680|Drug|Moxaverine|Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
75441051|NCT01629680|Drug|Placebo|coated tablets identical in number and appearance as the study drug
75441052|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
75441053|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
75441054|NCT01629732|Drug|BMS-986094|Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
75441055|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
75441056|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 24 Weeks
75441057|NCT01629732|Drug|Ribavirin|Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
75591559|NCT03801876|Drug|FOLFOX regimen|Folinic acid, flurouracil and oxaliplatin
75591560|NCT03801876|Drug|CAPOX regimen|Capecitabine combined with oxaliplatin
75591561|NCT03801876|Drug|Docetaxel|Chemotherapy
75591562|NCT03801876|Drug|5FU|Chemotherapy
75591563|NCT03774758|Diagnostic Test|Guardant Health ct-DNA LUNAR assay|Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
75734356|NCT04719663|Behavioral|Biological illness and treatment rationale|Depression is described as a brain disorder and the role of monoamine, brain structures, and brain functions are reported as central mechanisms of relevance for its etiology and treatment. Biological processes are illustrated using typical charts and visualizations. Psychological influences are mentioned, but only as a byproduct of the disorder.
75734357|NCT04719663|Behavioral|Psychological illness and treatment rationale|Depression is described as a psychological disorder resulting from emotion regulation deficits. The suppression of emotions receives a special role in explaining depression. The psychological processes are illustrated using charts and visualizations. Biological aspects are mentioned, but only as a byproduct of the disorder.
75734358|NCT04719663|Drug|Active pharmacological placebo|"The active placebo pill does not have direct effects on the brain. Buscopan (butylscopolamine, 10 mg daily, 1 pill in the morning) does not cross the blood-brain barrier, yet induces some smaller side effects that resemble those of antidepressants (e.g., mouth dryness, fatigue, nausea). Treatment duration is 4 weeks. The rationale is briefly explained to participants as stimulating the biological balance in humans with depression, using a well-tolerated drug similar to Buscopan, which is well-known from pain treatments."
75734359|NCT04719663|Behavioral|Active psychological placebo|"Emotional writing consists of writing about emotional experiences (4 sessions, one per week, 30 minutes each). The study instructor will be present displaying standard psychotherapeutic attitudes but will not read the participant's notes. The rationale for this treatment is briefly explained as improving the dealing with emotions to achieve a psychological balance in humans with depression."
75734360|NCT04716933|Biological|Pembrolizumab|IV infusion Q3W
75734361|NCT04716933|Drug|Carboplatin|IV infusion Q3W
75734362|NCT04716933|Drug|Cisplatin|IV infusion Q3W
75734363|NCT04716933|Drug|Pemetrexed|IV infusion Q3W
75734364|NCT04716933|Drug|Lenvatinib|Oral capsule once daily
75734365|NCT04716933|Drug|Placebo matching lenvatinib|Oral capsule once daily
75734366|NCT04715230|Biological|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
75734367|NCT04715230|Drug|Lorazepam|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting.
75734368|NCT04715230|Drug|Haloperidol|Haloperidol is commonly used to treat agitation due to psychosis.
75883973|NCT02129114|Device|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
75883974|NCT03653143|Behavioral|JASPER|JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
75883975|NCT02136992|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
75883976|NCT02136992|Drug|placebo|placebo will be taken two tablets 3 times a day during the whole study process
76055598|NCT02045732|Biological|Placebo|Bi-Weekly Subcutaneous Injections X 6
75441058|NCT01629732|Drug|Placebo for BMS-986094|Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
75441059|NCT01629745|Genetic|gene expression analysis|
75734369|NCT04710368|Drug|Evolocumab Injections|Administered on day 1 (the day of the first treatment) and through week 26 with a personal injector or prefilled auto injector/pens.
75734370|NCT04709939|Other|OPAT|Observation of patients who are discharged from the hospital on OPAT.
75734371|NCT04709939|Other|Focus Group|Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
75734372|NCT04708834|Drug|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
75734373|NCT04708730|Device|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
75441060|NCT01629745|Other|flow cytometry|
75441061|NCT01629745|Other|laboratory biomarker analysis|
75441062|NCT01629758|Biological|Denenicokin|
75734374|NCT04707872|Diagnostic Test|MMDx diagnostic test|Microarray test of gene expression in heart biopsies
75734375|NCT04707872|Diagnostic Test|Prospera|Donor derived cell-free DNA in patient blood
75734376|NCT04707872|Diagnostic Test|HLA antibody|Centralized measurement of HLA antibodies in patient blood
75734377|NCT04705116|Biological|COVID-19 vaccine|At least one dose of a COVID-19 vaccine.
76055599|NCT02045732|Biological|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
76055600|NCT02045732|Biological|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
76055601|NCT02044874|Drug|APD356-lorcaserin hydrochloride|
76055602|NCT02044874|Drug|Placebo|
75441063|NCT01629758|Biological|Nivolumab|
75441064|NCT01629810|Device|Whole body periodic acceleration (Exer-Rest)|Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.
75441065|NCT01629849|Drug|Placebo to BI 1021958 qd|tablet
75441066|NCT01629849|Drug|BI 1021958 bid|tablets
75441067|NCT01629849|Drug|Placebo to BI 1021958 bid|tablets
75441068|NCT01629849|Drug|BI 1021958 qd|tablet
75591564|NCT03765541|Drug|Dexamethasone|"In combination with intensive chemotherapy amsacrine-cytarabine:~Induction (1 cycle): 10 mg/12h from Day 1 to Day 3 of cycle (2 infusions/24h, slow IV [10 minutes])~Consolidation (3 cycles): 10 mg/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV [10 minutes])~In combination with azacitidine:~Cycle 1: 20 mg/24h from Day 1 to Day 3 of cycle (1 infusion/24h, slow IV [10 minutes]).~Subsequent cycles: 20 mg/24h on Day 1 of each cycle (1 infusion/24h, slow IV [10minutes])."
75591565|NCT03765541|Drug|Amsacrine|"Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV [3 hours])~Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV [3 hours])"
75591566|NCT03765541|Drug|Cytarabine|"Patients < 60 years of age:~Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV [2 hours])~Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV [2 hours]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h"
75591567|NCT03765541|Drug|Azacitidine|75 mg/m2/24h from Day 1 to Day 7 of each cycle [or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle] (SC)
75734378|NCT04704375|Device|Bio Electro-Magnetic Regulation (BEMER) Therapy|BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.
75441069|NCT01629875|Drug|Generic equivalent of Clostridium Botulinum A Toxin|
75734379|NCT04704375|Procedure|OMT (osteopathic manipulative treatment)|i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.
75883977|NCT03629119|Dietary Supplement|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
75883978|NCT02133092|Other|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
75883979|NCT03045081|Behavioral|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
75883980|NCT03621397|Device|brainHQ by Posit Science|This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
75591568|NCT03753334|Combination Product|MAG-EPA|5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months
75591569|NCT03753334|Dietary Supplement|Placebo group|5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months
75591570|NCT03752242|Drug|BMX-010 0.3%|Safety and efficacy of BMX-010 in topical treatment of acne.
75591571|NCT03748667|Diagnostic Test|White light endoscopy (WLE)|Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.
75883981|NCT02137148|Device|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
75883982|NCT02252978|Drug|ciprofloxacin|Given PO
75883983|NCT02252978|Other|placebo|Given PO
75883984|NCT02252978|Other|quality-of-life assessment|Ancillary studies
75441070|NCT01629875|Drug|Botox (Clostridium Botulinum A Toxin)|
75441071|NCT01629888|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
75441072|NCT01629888|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
75441073|NCT01629901|Device|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
75441074|NCT01629914|Behavioral|Mindfulness Meditation|8-week, group-based mindfulness meditation intervention
75591572|NCT03748667|Diagnostic Test|NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)|Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
76055603|NCT04716920|Other|Tai Chi|Attend Tai Chi exercise classes
76055604|NCT04716920|Device|FitBit|Wear FitBit
75591573|NCT03747887|Behavioral|Daily Report Card|Students assigned to the DRC group will have a consultant assigned to the student for the duration of the school year. The consultant will work with the child's primary special education teacher (or regular education teacher if the child spends the majority of his or her day mainstreamed) to establish a DRC over the course of three consultation visits. The How to Establish a Daily Report Card manual contains a standard DRC instruction packet that is provided to teachers to explain the rationale of the DRC, procedures for creating, modifying, and evaluating the DRC, procedures for parents to create home-based rewards for DRC performance, and information on trouble-shooting.
75591574|NCT03747887|Other|School as Usual|The Individualized Education Program will be implemented as usual, with no additional study-related supports.
75591575|NCT03738748|Other|Ultrasound- guided Percutaneous Neuromulation|The experimental group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L-3, once a week for 4 weeks.
75591576|NCT03738748|Other|TENS Therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region, once a week for 4 weeks.
75734380|NCT04704375|Procedure|Light touch|Treaters will place their hands lightly on the subject's lumbar paraspinal muscles in the supine and prone positions in the same area as where one would place your hands for lumbar MFR technique for the same amount of time as it would take to perform MFR in this area (approximately 5 minutes). However, no lifting or action will be done. In addition, the subject will lie down on the BEMER mat (as they would do during a BEMER session), but the device will not be activated.
75883985|NCT02252978|Other|laboratory biomarker analysis|Correlative studies
75883986|NCT05507385|Behavioral|IMAGINE-POSITIVE|The intervention will combine aspects of Memory Specificity Training (MeST), which includes information about the links between memories and emotions, with Positive Prospective Mental Imagery (PPMI), to increase vividness and savouring of positive future images, in order to harness positive affect. IMAGINE-PA will follow a treatment manual and delivery will be accompanied by a therapy workbook.
75883987|NCT05507385|Behavioral|Control|Non-directive supportive therapy (NDST) consists of individual sessions, with an empathetic, emotionally supportive practitioner and provides non-directive problem solving and monitoring. Using NDST will control for factors that may contribute to change, which are not active components e.g. speaking to an empathetic therapist. NDST will follow treatment guidelines.
75591577|NCT03736590|Behavioral|Financial coaching and services|The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.
75591578|NCT03712956|Drug|Caelyx®|Caelyx® every two weeks for 8 courses
75734381|NCT04702880|Biological|BMS-986012|Specified dose on specified days
75734382|NCT04702880|Drug|Carboplatin|Specified dose on specified days
75734383|NCT04702880|Drug|Etoposide|Specified dose on specified days
75734384|NCT04702880|Biological|Nivolumab|Specified dose on specified days
75883988|NCT02133170|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
76055605|NCT04716920|Other|Support Group Therapy|Join Tai4Chijoint group
76055606|NCT04716920|Other|Questionnaire Administration|Ancillary studies
76055607|NCT04716920|Other|Quality-of-Life Assessment|Ancillary studies
76055608|NCT04716608|Other|physiotherapy program|"physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program."
76055609|NCT04716608|Other|usual care treatment|stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
76055610|NCT02078960|Drug|Omacetaxine mepesuccinate|3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
76055611|NCT02078102|Drug|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
76055612|NCT02078102|Drug|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
75883989|NCT02133170|Behavioral|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
76055613|NCT02054702|Drug|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
75883990|NCT02133170|Behavioral|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
76055614|NCT02054702|Drug|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
76055615|NCT02044094|Drug|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
75883991|NCT03107377|Drug|EVO100|5 g dose applied up to 1 hour prior to coitus
75883992|NCT03107377|Drug|Placebo|5 g dose applied up to 1 hour prior to coitus
75883993|NCT02253056|Other|Fasting / Caloric Restriction|
75883994|NCT02253056|Other|Healthy Diet|
75883995|NCT02129270|Drug|Lidocaine HCl 2% .|comparison of different dosages of drug
76055616|NCT02044094|Drug|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
76055617|NCT02044094|Drug|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
76055618|NCT02044094|Drug|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
76055619|NCT02043938|Device|SedLine EEG sensor|Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
76055620|NCT04702646|Drug|Bowel preparation before colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
76055621|NCT04702646|Procedure|Colonoscopy|colonoscopy will be performed to every patient included in the study
76055622|NCT02053610|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
76055623|NCT02053610|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
76055624|NCT02053610|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
76055625|NCT02075606|Drug|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
75883996|NCT02129270|Drug|Lidocaine HCl 1%|comparison of different dosages of drug
75883997|NCT03550742|Other|Fuco-N-Tetraose|Daily bolus of Fuco-N-Tetraose
75883998|NCT03549884|Procedure|Delayed cord clamping|Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section
75883999|NCT03549884|Procedure|Early cord clamping|Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
75884000|NCT05370547|Drug|Chidamide|"Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.~Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc."
75884001|NCT05370547|Drug|Fludarabine and cyclophosphamide|Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m^2) and cyclophosphamide (250-500 mg/m^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
76055626|NCT02043782|Device|Coloplast Test|Newly developed 1-piece convex ostomy product
76055627|NCT02043782|Device|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
76055628|NCT02043782|Device|Competitor soft convex|A commercially available soft convex product
75734385|NCT04695340|Dietary Supplement|Psyllium|Psyllium is given to patients
75591579|NCT03712098|Drug|Liraglutide|Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
75591580|NCT03712098|Drug|Placebo|The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
75734386|NCT04693351|Drug|Troriluzole|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
75591581|NCT03712098|Behavioral|Smoking Cessation Counseling|All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
75591582|NCT03710772|Drug|Cyclophosphamide|Given IV
75591583|NCT03710772|Drug|Cytarabine|Given IV
75591584|NCT03710772|Drug|Dexamethasone|Given PO or IV
75734387|NCT04693351|Drug|Placebo|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
75734388|NCT04692324|Procedure|Biospecimen Collection|Undergo collection of CSF samples
76055629|NCT04701008|Drug|Ketamine|IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
75591585|NCT03710772|Drug|Doxorubicin Hydrochloride|Given IV
75591586|NCT03710772|Drug|Ibrutinib|Given PO
75884002|NCT05370547|Biological|Anti-CD19 CAR-T cells|A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10^6 for Relma-cel or 2 × 10^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
75884003|NCT02133326|Drug|Caldolor|Subject will be given Caldolor by IV prior to surgery.
75884004|NCT02133326|Drug|Ofirmev|Subject will be given Ofirmev prior to surgery.
76055630|NCT02052596|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
76055631|NCT02052596|Biological|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
75591587|NCT03710772|Drug|Methotrexate|Given IV
75591588|NCT03710772|Biological|Rituximab|Given IV
75591589|NCT03710772|Drug|Venetoclax|Given PO
75591590|NCT03710772|Drug|Vincristine Sulfate|Given IV
75591591|NCT03706014|Behavioral|SIBS Program|Universal prevention program promoting positive sibling and family relationships conducted in an afterschool setting
75591592|NCT03706014|Behavioral|Control|Contact-equivalent attention control program in which students play educational games
75591593|NCT03704688|Drug|Trametinib 0.5 mg|0.5mg PO q daily
75591594|NCT03704688|Drug|Trametinib 1 MG|1.0 mg PO q daily
75591595|NCT03704688|Drug|Trametinib 1.5 MG|1.5mg PO q daily
75591596|NCT03704688|Drug|Trametinib 2 mg|2 mg PO q daily
75591597|NCT03704688|Drug|Ponatinib 15 MG|15mg PO q daily
75591598|NCT03704688|Drug|Ponatinib 30 MG|30mg PO q daily
75591599|NCT03686332|Drug|Arm A: Atezolizumab and Radiotherapy|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.
75591600|NCT03686332|Drug|Arm B: Atezolizumab|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
75591601|NCT03684486|Behavioral|rehabilitation by effort|
75734389|NCT04692324|Other|Electronic Health Record Review|Review of medical records
75734390|NCT04692324|Other|Survey Administration|Ancillary studies
75734391|NCT04684641|Drug|Standard Dose YPT-01|Participants will be randomized to receive the standard dose of phage therapy YPT-01.
75734392|NCT04684641|Other|Placebo|Participants will be randomized to receive the placebo.
75734393|NCT04681066|Drug|CM-4620 Injectable Emulsion or CM-4620-IE|Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
75734394|NCT04681066|Other|Placebo|Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
75734395|NCT04679844|Device|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
75884005|NCT02137304|Device|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
75884006|NCT02133482|Drug|Placebo|placebo solution
75884007|NCT02133482|Drug|BI 639667|oral solution BI 639667, single rising doses
75884008|NCT05341141|Device|Frozen glove and sock|Preparation of frozen glove and sock: 4℃ for 3 hours.
75884009|NCT05341141|Drug|ddEC-ddT|Epirubicin (E) 90~100mg/m^2, i.v., d1 + cyclophosphamide (C) 600 mg/m^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m^2, i.v., d1, q2w, for 4 cycles.
75884010|NCT02137616|Drug|risperidone|Risperdal tablets
75591602|NCT03683394|Behavioral|SMARRT Intervention|Interventionists will follow a standard protocol for delivering the SMARRT intervention that allows for personalization of the specific risk reduction action plan; these plans will evolve over time according to participant progress, motivation and preferences or newly identified risk factors. Staff will use a tracking database to record information for each participant, including session dates, identified risk factors, motivational barriers and important values, and the outcome of discussions around developing goals. For each participant, the exact number and mode (phone or in-person) of contacts will differ, but we will aim to have at least 1 contact per month with each participant. Best practice will include in-person meetings twice a year during the 2-year intervention period.
75591603|NCT03683394|Behavioral|Health Education Intervention|Participants randomized to the Health Education (HE) group will receive mailed materials (typically 1-2 pages) every 3 months. This will include general information on Alzheimer's and dementia risk reduction using materials from sources such as the Alzheimer's Association and educational materials commonly provided as part of routine care at Kaiser Permanente Washington (KPWA).
75591604|NCT03677102|Other|higher chloride crystalloid|Normal saline (chloride concentration 154 mmol/L)
75591605|NCT03677102|Other|lower chloride crystalloid|Ringer's Lactate (chloride concentration 110 mmol/L)
75591606|NCT03671746|Drug|Ketorolac|Participants will receive Ketorolac at 30 mg IV every 6 hours for their first 5 days of hospitalization
75734396|NCT04679844|Device|Demineralized Bone Matrix mixed with Autograft Bone|Demineralized Bone Matrix mixed with Autologous bone graft used in instrumented posterolateral fusion, 7cc-10cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
75441075|NCT01629979|Procedure|Grafting with epidermal cells|"A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
75441076|NCT01629979|Radiation|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
75441077|NCT01629992|Other|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
75441078|NCT01630005|Behavioral|talk therapy|Psychotherapy
75441079|NCT01630018|Drug|Topotecan|1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
75441080|NCT01630018|Drug|Belotecan|0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
75441081|NCT01630044|Device|TNM device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
75591607|NCT03671746|Drug|Saline Solution|Participants will receive 10 ml of saline solution IV every 6 hours for their first 5 days of hospitalization
75591608|NCT03667092|Biological|non-drug intervention type|8 peripheral blood samples (8x5ml) will be obtained at different times ; before, during and after treatment
75591609|NCT03658278|Dietary Supplement|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations
75591610|NCT03656510|Drug|JNJ-53718678|Participants will receive JNJ-53718678 (high dose or low dose) orally twice daily for 7 days.
75591611|NCT03656510|Drug|Placebo|Participants will receive matching placebo (high volume or low volume) orally twice daily for 7 days.
75734397|NCT04676529|Drug|PXS-5505|PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
75734398|NCT04676490|Other|RECORD-ED Card|Low-cost and low-tech recordable audio card containing language-concordant discharge instructions for families of children under age 10 presenting to the ED for asthma exacerbations with no or public insurance and a preference for English or Spanish. Recordable cards allow for multiple audio reviews of the instructions by multiple caregivers without dependence on access to the internet or smartphone technologies.
75441082|NCT01630057|Drug|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
75734399|NCT04676490|Other|RECORD-ED Patient Portal|Audio recorded, language concordant discharge instructions via patient portal
75734400|NCT04672005|Drug|Folfirinox alternating with Gemcitabine-nab-Paclitaxel|modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
75734401|NCT04668651|Other|antral ultrasound|Preoperative evaluation of gastric contents by antral ultrasound
75734402|NCT04658537|Radiation|Radiation Therapy|Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours
75734403|NCT04652375|Other|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
75734404|NCT04652375|Other|Lactated Ringer's Solution|Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
75734405|NCT04649125|Radiation|dose escalation|single fraction dose escalation to the tumour
75734406|NCT04643379|Drug|Olaparib|Supplied by Merck & Co.
75734407|NCT04643379|Drug|Pembrolizumab|Supplied by Merck & Co.
75734408|NCT04643379|Drug|Carboplatin|Commercially available
75734409|NCT04643379|Procedure|Peripheral blood draw|Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression
75734410|NCT04642066|Other|Cold water immersion|Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.
75734411|NCT04642066|Other|No cold water immersion|People without cold water immersion
75734412|NCT04641143|Drug|Troriluzole|Troriluzole - 2 100mg capsules QD for the first two weeks.
75441083|NCT01630057|Drug|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
75441084|NCT01630070|Device|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
75441085|NCT01630083|Drug|epirubicin|Epirubicin will be administered at a dose of 50 mg/m^2 as a 15-minute intravenous infusion on day 1 of each cycle.
75441086|NCT01630083|Drug|oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m^2 as a 2-hour intravenous infusion on day 1 of each cycle.
75734413|NCT04641143|Drug|Placebo|Matching placebo - 2 140mg capsules QD from week two through week ten.
75441087|NCT01630083|Drug|capecitabine|The daily dose of capecitabine will be 1250 mg/m^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
75734414|NCT04638751|Drug|Immunotherapy|Checkpoint inhibitor
75734415|NCT04638751|Drug|Chemotherapy|Any form of chemotherapy
75734416|NCT04638751|Procedure|CRC surgical resection|Surgical resection to remove colorectal cancer
75734417|NCT04638751|Procedure|Colonoscopy|Standard-of-care colonoscopy for CRC screening
75734418|NCT04634916|Device|EndoAVF Creation|Subjects will have an endoAVF created using the WavelinQ EndoAVF System
75734419|NCT04628507|Other|Spent media collection|Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
76055632|NCT04681118|Biological|NurOwn (MSC-NTF cells)|Intrathecal administration
76055633|NCT02052440|Drug|Baclofen|Treatment arm: baclofen 10mg tid
75734422|NCT04616209|Biological|donor-derived NK cell infusion|PB103 administrations will be separated by 4-week interval
75734423|NCT04614870|Diagnostic Test|DETEC® Esterase|DETEC® Esterase is a disposable diagnostic device that is used to indicate the presence or absence of infection based on the presence or absence of the evaluated level of leukocyte esterase by testing the freshly recovered wound dressing which are soaked with wound exudate.
76055634|NCT02052440|Drug|Placebo|Sugar pill by mouth three times daily
75734424|NCT04614519|Procedure|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
75884011|NCT02137616|Drug|olanzapine|olanzapine tablets
75884012|NCT02137616|Drug|Quetiapine|quetiapine tablets
75884013|NCT02137616|Drug|Aripiprazole|Aripiprazole tablets
75441088|NCT01630083|Drug|zolbetuximab|Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
75591612|NCT03652545|Biological|TAA-T|Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
75734425|NCT04614519|Procedure|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
75734426|NCT04614038|Diagnostic Test|DETEC® pH|DETEC® pH is a disposable diagnostic device that is used to indicate the alkalinity of the wound by testing wound exudate adsorbed onto wound dressing.
75734427|NCT04608305|Biological|IIBR-100, low dose (prime)|Single administration of IIBR-100 1*10E5 pfu/ml
75734428|NCT04608305|Biological|IIBR-100 medium dose (prime)|Single administration of IIBR-100 1*10E6 pfu/ml
75734429|NCT04608305|Biological|IIBR-100 high-dose (prime)|Single administration of IIBR-100 1*10E7 pfu/ml
75734430|NCT04608305|Biological|IIBR-100 low-dose (prime-boost)|Two administrations of IIBR-100 1*10E5 pfu/ml, 28 days apart
75734431|NCT04608305|Other|Saline Placebo (single)|Single administration of saline placebo
76055635|NCT02049944|Drug|Cefazolin|Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
76055636|NCT02043548|Drug|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
75734432|NCT04608305|Other|Saline Placebo (double)|Two administrations of saline placebo, 28 days apart
75734433|NCT04608305|Biological|IIBR-100 medium-dose (prime-boost)|Two administrations of IIBR-100 1*10E6 pfu/ml, 28 days apart
75734434|NCT04608305|Biological|IIBR-100 high-dose (prime-boost)|Two administrations of IIBR-100 1*10E7 pfu/ml, 28 days apart
75734435|NCT04608305|Biological|IIBR-100 top-dose (prime-boost)|Two administrations of IIBR-100 1*10E8 pfu/ml, 28 days apart
75884014|NCT02129504|Device|root coverage comparing two techniques|The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
75884015|NCT02133560|Behavioral|Video recording|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
76055637|NCT02043548|Drug|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
76055638|NCT01622348|Drug|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
75441089|NCT01630096|Drug|Nu-Lytely|Bowl prep solution.
75441090|NCT01630148|Drug|Bemiparin|Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
75591613|NCT03646175|Dietary Supplement|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
75734436|NCT04606446|Drug|PF-07248144|KAT6 Inhibitor
75734437|NCT04606446|Drug|Fulvestrant|Endocrine Therapy
75734438|NCT04606446|Drug|Letrozole|Endocrine Therapy
75734439|NCT04606446|Drug|Palbociclib|CDK4/6 Inhibitor
75734440|NCT04606446|Drug|PF-07220060|CDK4 inhibitor
75884016|NCT02133560|Behavioral|Medication Administration Log|Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
75884017|NCT02133560|Behavioral|Education|"During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.~Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation."
76055639|NCT01622348|Drug|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
76055640|NCT01622348|Drug|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
76055641|NCT01621880|Drug|bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
75734441|NCT04602117|Drug|Vic-trastuzumab duocarmazine (SYD985) + paclitaxel|"SYD985 ([vic-]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly."
75884018|NCT05198011|Procedure|3D customized Titanium Mesh (Study)|approach for planning and augmenting atrophic posterior mandibular ridge using a pre-customized TiMe on a 3D model. The 3D surgical model will be virtually created from a cone-beam computed tomography (CBCT) and printed using Fused deposition modeling (FDM) machine. The 3D model will be then used to contour the TiMe in accordance with the needed amount of augmentation then will be used to help pack and contour the graft material.
75884019|NCT05198011|Procedure|Conventional ridge augmentation (Control)|the conventional technique of ridge augmentation using Titanium Mesh
75884020|NCT02133638|Drug|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
75884021|NCT02133638|Drug|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
75884022|NCT05197933|Procedure|Laparoscopic resection|Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
75734442|NCT04599764|Other|HD-tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.The respective excitability alterations-enhancement by anodal and reduction by cathodal tDCS-can last for over an hour after the end of stimulation.
75734443|NCT04599764|Other|computer-based cognitive training|Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. Cognitive training in healthy older adults and those at risk of dementia has been linked to benefits in cognitive functioning.
75734444|NCT04596865|Procedure|Pancreaticoduodenectomy|Date of surgery 01/06/2010 - 31/05/2015
75734445|NCT04592289|Procedure|Full bowel preparation|MBP+OA
75734446|NCT04592289|Procedure|Mechanical bowel preparation only|MBP
75734447|NCT04590963|Drug|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
75734448|NCT04590963|Drug|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
75734449|NCT04590963|Other|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
75734450|NCT04583488|Drug|Intraperitoneal docetaxel|Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).
75734451|NCT04581382|Biological|Nivolumab|Given IV
75734452|NCT04581382|Biological|Pembrolizumab|Given IV
75734453|NCT04581382|Radiation|Radiation Therapy|Undergo radiation therapy
75734454|NCT04581382|Biological|Therapeutic Exchange Plasma|Undergo therapeutic plasma exchange
75734455|NCT04580160|Device|Duo Venous Stent System|Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.
75734456|NCT04579107|Combination Product|Contrast Enhanced Mammography|A modality for examining breast conditions which is already approved and used but the evaluation of its role in a recalled screening population is limited. Intravenous iodine contrast is given prior to the mammogram.
75734457|NCT04575051|Other|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
75734458|NCT04575051|Other|Engage Model|The Engage Model is a chronic care approach to supportive hearing loss self-management of ARHL. Engage includes (a) hearing screening for all residents, (b) an individualized communication plan for those with an identified hearing loss (e.g., one-to-one, group, telephone, television plans, hearing aid trouble shooting, communication strategies, etc.), (c) provision of simple, non-custom amplifiers, (d) referral to audiology if needed, and (e) ongoing support provided by trained personnel (Communication Facilitator) under the supervision of the audiologist.
75734459|NCT04573985|Behavioral|Serious game Eurekoi intervention|1 session in group using the serious game eurekoi
75884023|NCT02545283|Drug|Cytarabine|Participants will receive cytarabine 1 gram per square meter (g/m^2) intravenous (IV) infusion for 5 days of every treatment cycle.
75884024|NCT02545283|Drug|Idasanutlin|Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
75591614|NCT03646175|Dietary Supplement|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
75591615|NCT03642795|Other|Questionnaire|Patients are asked to complete several questionnaires
75734460|NCT04573712|Other|Follow up and Assessment|each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
75734461|NCT04565665|Other|Best Practice|Receive standard of care
75591616|NCT03637816|Drug|Anamorelin Hydrochloride|Given PO
75734462|NCT04565665|Biological|Mesenchymal Stem Cell|Given IV
75734463|NCT04563598|Behavioral|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
75734464|NCT04563598|Behavioral|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
75734465|NCT04562935|Other|admission to pediatric intensive care with mechanical ventilation|admission to pediatric intensive care with mechanical ventilation
75734466|NCT04561778|Device|HOT-CRT|Subjects enrolled in the study will receive a permanent cardiac implantable electronic device (CIED) (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to HOT-CRT will have His bundle pacing lead placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and left ventricular timing may be optimized to achieve maximal resynchronization.
75441091|NCT01630161|Behavioral|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
75441092|NCT01630161|Behavioral|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
75441093|NCT01630187|Drug|Carbetocin|Administration of carbetocin 50 mcg , after clamping the umbilical cord
75591617|NCT03637816|Other|Placebo|Given PO
75591618|NCT03637816|Other|Questionnaire Administration|Ancillary studies
75591619|NCT03630991|Drug|Edetate Calcium Disodium|Given IV
75734467|NCT04561778|Device|Biventricular Pacing|Subjects enrolled in the study will receive a permanent CIED (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to Biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.
75734468|NCT04559646|Procedure|Pacemaker implantation|Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.
75734469|NCT04559646|Drug|"Haemostatic solution Haemoblock application"|"Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
75734470|NCT04559646|Drug|Saline solution application|Saline solution will be used after pocket formation during pacemaker implantation.
75734471|NCT04559646|Diagnostic Test|Ultrasound of pacemaker pocket|Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.
75734472|NCT04559646|Diagnostic Test|Blood sampling|Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.
75734473|NCT04559646|Diagnostic Test|Echocardiography|Heart ultrasound examination for left ventricular ejection fraction measurement.
75734474|NCT04558528|Diagnostic Test|Novel in vitro diagnostics and medical applications|Novel in vitro diagnostics and medical applications
75591620|NCT03630991|Dietary Supplement|Multivitamin|Given PO
75591621|NCT03630991|Drug|Succimer|Given PO
75591622|NCT03622528|Radiation|Chest CT scan|Standard dose chest CT scan
75591623|NCT03620188|Other|Standard of care|Standard of care in PsA is outline in treatment guidelines as adjustment of therapy every 3 months until goals of treatment are being met. Goals of treatment are defined as remission or low disease activity.
75591624|NCT03616886|Drug|Paclitaxel|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
75734475|NCT04558515|Diagnostic Test|Novel malaria diagnostics & tools|Next generation microscopy tools for malaria diagnosis and medical applications
75734476|NCT04556890|Device|Active rTMS/Active iTBS DFPLC/Sham Pain M1|Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
76055642|NCT01621880|Drug|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
75591625|NCT03616886|Drug|Carboplatin|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
75591626|NCT03616886|Drug|MEDI4736|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
76055643|NCT01621802|Biological|Priorix|One dose administered subcutaneously in the triceps region of the right arm.
75591627|NCT03616886|Drug|MEDI9447|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
75591628|NCT03609840|Drug|Thiotepa|Given IV
75734477|NCT04556890|Device|Sham rTMS/ Active iTBS Pain|Sham rTMS for depression and active iTBS for pain (600 pulses of iTBS followed by 1500 pulses of 10 Hz rTMS, both at 120% MT
75734478|NCT04556890|Device|Active rTMS/Active iTBS|Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
75591629|NCT03601897|Drug|rebastinib|25 mg tablets or 75 mg tablets
75591630|NCT03601897|Drug|Paclitaxel|Paclitaxel administered by IV infusion at 80 mg/m2
75734479|NCT04556656|Drug|Pridopidine|Pridopidine hard gelatin capsule
75734480|NCT04556656|Drug|Placebo|Pridopidine-matching placebo hard gelatin capsule
75734481|NCT04550143|Other|Diaphragm ultrasound (DUS)|"DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.~A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = thickness at end inspiration - thickness at end-expiration / thickness at end-expiration, %).~SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa)."
76055644|NCT01621802|Biological|M-M-R II|One dose administered subcutaneously in the triceps region of the right arm.
76055645|NCT01621802|Biological|Kinrix|One dose administered by deep intramuscular injection in the upper left deltoid.
76055646|NCT01621802|Biological|ProQuad|One dose administered subcutaneously in the triceps region of the left arm.
75591631|NCT03594981|Biological|CMV/AdV /EBV/BKV specific T cells|Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
75591632|NCT03586583|Device|FBP|Old processing
75591633|NCT03586583|Device|ISR|New processing
75884025|NCT02545283|Other|Placebo|Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
75884026|NCT02137694|Other|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
75884027|NCT02260700|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
76055647|NCT02059291|Drug|Canakinumab|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
76055648|NCT02059291|Drug|Placebo|Matching placebo to canakinumab solution for subcutaneous injection
76055649|NCT02042924|Radiation|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
76055650|NCT02042924|Device|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
76055651|NCT02041520|Drug|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
76055652|NCT02041520|Other|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
76055653|NCT04699994|Drug|FLOT therapy|Preoperative FLOT therapy
75591634|NCT03581461|Behavioral|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
75591635|NCT03573349|Drug|Ketamine|We will enroll 20 adults (aged 18-65 years) with treatment-resistant depression and will provide two i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), and following ketamine treatment (change biomarkers). This will be an open-label feasibility trial.
75591636|NCT03562507|Drug|ESK981|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
75591637|NCT03562507|Drug|Nivolumab|480 mg/dose IV, Day 1 of each 28-day cycle
75591638|NCT03552705|Drug|Tranexamic Acid|5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
75591639|NCT03552705|Drug|Placebos|5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
75591640|NCT03550092|Behavioral|Abstract Semantic Association Network Training (AbSANT)|In each session, the participant will be asked to categorize words, choose/discuss semantic features for each word that accurately describe the word, and generate as many words as possible within a category.
75734482|NCT04550143|Other|Peripheral Muscle Ultrasound (PMUS)|"PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.~Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:~(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.~CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.~For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.~All assessments will be performed with minimal compression and a copious amount of water-gel."
75734483|NCT04550143|Other|Airway occlusion pressure (P0.1)|"P0.1 is the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration. Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.~For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen."
75734484|NCT04550143|Other|Medical Research Council (MRC) sum score|"This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, no visible/palpable contraction; 1, visible/palpable contraction without movement of the limb; 2, movement of the limb, but not against gravity; 3, movement against gravity; 4, movement against gravity and some resistance; 5, normal.~The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score <48 indicating the presence of weakness."
75734485|NCT04546009|Drug|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
75734486|NCT04546009|Drug|Giredestrant-matched Placebo|Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
75734487|NCT04546009|Drug|Letrozole|Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
76055654|NCT04711226|Drug|AT-1501|AT-1501 IV infusion
75441094|NCT01630187|Drug|Carbetocin|Administration of carbetocin 100 mcg , after clamping the umbilical cord
75441095|NCT01630226|Drug|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
75441096|NCT01630239|Procedure|Laser ablation|Laser ablation of hepatic tumors
75441097|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
75734488|NCT04546009|Drug|Letrozole-matched Placebo|Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
75734489|NCT04546009|Drug|Palbociclib|Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
75734490|NCT04546009|Drug|LHRH Agonist|Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
75734491|NCT04545151|Drug|Verapamil SR 120 mg|"For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~from Day 0 to Week 4: 120 mg once daily~from Week 4 to Week 8: 240 mg once daily~from Week 8 to Month 12: 360 mg once daily"
76055655|NCT04699292|Procedure|Surgery|Surgery
76055656|NCT04699292|Radiation|Preoperative RT 36Gy|Preoperative radiotherapy to 36Gy (equivalent)
76055657|NCT04699292|Radiation|Preoperative RT 50Gy|Preoperative radiotherapy to 50Gy (equivalent)
76055658|NCT04699292|Radiation|Postoperative RT 50-66Gy|Postoperative radiotherapy to 50-66Gy (equivalent)
76055659|NCT04699292|Radiation|RT 36Gy|Definitive radiotherapy to 36Gy (equivalent)
76055660|NCT02041429|Drug|Ruxolitinib|
76055661|NCT02041429|Drug|Paclitaxel|
76055662|NCT02083783|Drug|TRI102|formulation containing active moiety (amphetamine)
76055663|NCT02083783|Other|Placebo|formulation without active moiety
76055664|NCT04698109|Other|Biological sample collection|Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
76055665|NCT04698109|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
75441098|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
75441099|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
75441100|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
76055666|NCT04698109|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
76055667|NCT02083081|Behavioral|Community level intervention|Community intervention plus individual counseling
75734492|NCT04545151|Drug|Placebo|"The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~from Day 0 to Week 4: 120 mg once daily~from Week 4 to Week 8: 240 mg once daily~from Week 8 to Month 12: 360 mg once daily"
75734493|NCT04544592|Drug|CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells|The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
75734494|NCT04540822|Other|peripheral venous catheter with compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. Under the catheter-extension tube junction will be inserted a sterile non-woven compress, cut sterilely (3.5x1.5 cm). The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
75734495|NCT04540822|Other|peripheral venous catheter without compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. No compresses will be inserted under the catheter-extension tube junction.The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
75734496|NCT04538573|Device|Virtual Reality Distraction|Patients in this group will be offered to use Oculus Rift goggles while undergoing the burn treatments, dressing changes and hydrotherapy to reduce pain and anxiety during treatment. The goggles will display Dreamland, a virtual reality videogame created by our team to maximize fun, diminish difficulty, and motion sickness. The system will be available 5 minutes before treatment to the patient in order to ease acclimatation to the goggles until the end of the treatment session.
75884028|NCT02260700|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
75884029|NCT02260700|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
75441101|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
75441102|NCT01630265|Other|Standard written discharge instructions|Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire
75441103|NCT01630265|Other|Video Discharge Instructions|Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
75441104|NCT01630278|Drug|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
75441105|NCT01630278|Drug|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
75441106|NCT01630291|Device|Electrode device|Lacrimal gland stimulation
75441107|NCT01630304|Behavioral|WelTel SMS service|"Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician."
75441108|NCT01630317|Procedure|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
75441109|NCT01630317|Procedure|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
75884030|NCT05682391|Other|Bed rest|Strict bed rest ordered after surgery that does not allow the participant to elevate the head of bed over 30 degrees
75441110|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
75441111|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
75441112|NCT01630343|Drug|Paracetamol tablet and Tramadol capsule|Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
75441113|NCT01630343|Drug|Panadol 500mg tablet, tramadol 50mg capsule|Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
75591641|NCT03543371|Diagnostic Test|Neuropsychological assessment|Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A & B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
75591642|NCT03539081|Diagnostic Test|Dual-energy X-ray absorptiometry Scan|Body composition analysis will be obtained by DEXA scan.
75734497|NCT04538573|Drug|Standard Treatment|"Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented."
75734498|NCT04538092|Other|Enhanced Recovery After Surgery Protocol|The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
75734499|NCT04524689|Drug|SAR408701 (Tusamitamab ravtansine)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
75734500|NCT04524689|Drug|Pembrolizumab|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
75591643|NCT03539081|Other|Laboratory Measurements|The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
75734501|NCT04524689|Drug|Cisplatin|Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
76055668|NCT02040805|Behavioral|Group Cognitive Behavioral Therapy|"Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF."
76055669|NCT02040805|Behavioral|Peer Facilitated Support Group|Fifteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
76055670|NCT02059135|Biological|Recombinant human antithrombin (ATryn)|Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
76055671|NCT02059135|Other|Normal Saline 0.9%|Placebo Comparator: Normal Saline 0.9%
76055672|NCT02081677|Device|ACUVUE 2|worn in a daily wear modality; lenses will be replaced after 2 weeks
75591644|NCT03539081|Other|Blood Flow Measurement|The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
75591645|NCT03539081|Other|Continuous Blood Pressure|Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
75591646|NCT03539081|Other|Partial pressure of oxygen|Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
75734502|NCT04524689|Drug|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
75734503|NCT04524689|Drug|Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
75734504|NCT04518670|Device|Comaneci Embolization Assist Device|assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm.
75734505|NCT04516135|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
75734506|NCT04516135|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75734507|NCT04516135|Other|Quality-of-Life Assessment|Ancillary studies
75734508|NCT04516135|Other|Questionnaire Administration|Ancillary studies
75734509|NCT04516135|Radiation|Volume Modulated Arc Therapy|Undergo VMAT
75591647|NCT03539081|Other|Microneurography|The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
75591648|NCT03539081|Other|Anthropometric Measurements|Height and weight will be obtained.
75591649|NCT03539081|Behavioral|John Hopkins Restless Legs Severity Scale|Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.
75591650|NCT03539081|Behavioral|Continuous Blood Pressure Diary|Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.
75591651|NCT03538626|Biological|VRC-HIVMAB091-00-AB|N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.
75734514|NCT04502849|Procedure|Bypass surgery|Creating a bypass with graft or vein.
75734515|NCT04502849|Procedure|Endovascular angioplasty/stenting|Performing an angioplasty with or without stenting in stenosis.
75591652|NCT03538626|Biological|rHuPH20|Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP). EDP is a purified preparation of rHuPH20.
75591653|NCT03534713|Drug|Carboplatin|carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
75591654|NCT03534713|Drug|Paclitaxel|paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
75441114|NCT01630356|Behavioral|in-person counseling|The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
75591655|NCT03534713|Drug|Cisplatin|Cisplatin 40mg/m² given once a week during 5 weeks
75591656|NCT03534713|Radiation|Radiotherapy|45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
75591657|NCT03534076|Other|Cohort Observational study|Cohort Observational study - there is no intervention
75591658|NCT03533543|Device|CEM|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
75591659|NCT03518203|Drug|Eculizumab|Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
75734516|NCT04502849|Procedure|Hybrid surgery|Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.
75734517|NCT04502849|Drug|Vitamin E|100 mg Vitamin E per os 1 per day (1 month).
76055673|NCT02081677|Device|Prototype E1|worn in a daily wear modality; lenses will be replaced after 2 weeks
75591660|NCT03507062|Other|0.9% saline administration|Each patient will receive 0.9%saline based on attending physician decision
75591661|NCT03507062|Other|Ringer's lactate administration|Each patient will receive Ringer's lactate based on attending physician decision
75591662|NCT03507062|Other|Plasmalyte-like solution administration|Each patient will receive Plasmalyte-like solution based on attending physician decision
75591663|NCT03501693|Device|DBT plus S-View|DBT plus S-View images
75591664|NCT03501693|Device|FFDM Alone|FFDM alone images
75591665|NCT03500172|Behavioral|DTP|Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
75591666|NCT03500172|Behavioral|ICM|Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
75591667|NCT03493932|Drug|Nivolumab|OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
75591668|NCT03493932|Drug|BMS-986016|Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
75591669|NCT03487809|Drug|Budesonide/Cisclesonide|One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older
75734518|NCT04502849|Diagnostic Test|Duplex ultrasound|Duplex ultrasound of lower limbs arteries.
75734519|NCT04502849|Diagnostic Test|Blood sampling|Blood sampling for apoptosis and endothelial dysfunction markers.
75734520|NCT04502849|Diagnostic Test|Arterial wall sampling|Arterial wall sampling for apoptosis markers.
75734521|NCT04502602|Drug|Neratinib 160 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
75734522|NCT04502602|Drug|Neratinib 200 mg|Determined RP2D dose
75734523|NCT04502602|Drug|Neratinib 240 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
76055674|NCT02081677|Device|Prototype E2|worn in a daily wear modality; lenses will be replaced after 2 weeks
76055675|NCT02081677|Device|Prototype E3|worn in a daily wear modality; lenses will be replaced after 2 weeks
75591670|NCT03485963|Biological|HST-NEETs|The primary objective of this study is to evaluate the safety and tolerability of expanded HIV-specific T cell therapy (HST-NEETs) in HIV-infected individuals suppressed on cART. Patients with a partial response or stable disease 8 weeks after T-cell infusion were eligible to receive additional T-cells, consisting of the same number of cells as their second injection.
75591671|NCT03470922|Biological|Relatlimab|Specified dose on specified day
75591672|NCT03470922|Biological|Nivolumab|Specified dose on specified days
76055676|NCT04720027|Diagnostic Test|Duplex imaging|Completion of AVVQ and EQ5D questionnairs
75734524|NCT04502602|Drug|Niraparib 100 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
75734525|NCT04502602|Drug|Niraparib 200 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
76055677|NCT04695769|Drug|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.
75441115|NCT01630356|Device|Demonstration of PM2.5 Pollution|The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
75441116|NCT01630356|Behavioral|Follow-up Counseling Calls|Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
75441117|NCT01630356|Behavioral|Printed material|"The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency."
75441118|NCT01630369|Drug|insulin human (HR1799)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
75441119|NCT01630395|Procedure|protective ventilation|low tidal volume and PEEP
75441120|NCT01630395|Procedure|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
75591673|NCT03469024|Other|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
75734526|NCT04502602|Drug|Niraparib 300 mg|Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)
75734527|NCT04502602|Drug|Niraparib at RP2D|Phase 1b: Determined dose
75734528|NCT04502602|Drug|Neratinib at RP2D|Phase 1b: Determined dose
75734529|NCT04499612|Procedure|Cardiac implantable electronic device implantation.|Patients who have indications will receive cardiac implantable electronic device implantation.
75734530|NCT04499612|Procedure|Cardiac implantable electronic device replace.|Patients who have indications will receive cardiac implantable electronic device replace.
75734531|NCT04499612|Diagnostic Test|Duplex ultrasound.|Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.
75734532|NCT04499612|Diagnostic Test|Echocardiography.|Patients will undergo an ultrasound examination of the heart.
75734533|NCT04499612|Diagnostic Test|Blood sampling.|Patients will be taken venous blood to determine the studied markers of hemostasis system.
75734534|NCT04494386|Biological|Umbilical Cord Lining Stem Cells (ULSC)|IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection
75734535|NCT04494386|Other|Placebo (carrier control)|IV infusion of carrier control consisting of sterile saline for injection
76055678|NCT04695769|Drug|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.
76055679|NCT04417309|Behavioral|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
76055680|NCT04417309|Behavioral|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at ~50% of MHR) for 30 minutes.
75591674|NCT03469024|Other|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
75591675|NCT03465774|Drug|Doxycycline|Receive via IPC
75884031|NCT02133716|Other|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
75441121|NCT01630408|Drug|Paricalcitol|Paricalcitol oral capsules 1 mcg/day for 48 weeks
75441122|NCT01630473|Procedure|Corticotomy|After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
75591676|NCT03465774|Device|Indwelling Catheter|Receive IPC
75734536|NCT04493216|Drug|GSK3640254|GSK3640254 will be available as a 25 mg and 100 mg tablets to be administered via oral route.
75734537|NCT04493216|Drug|ABC/3TC|ABC/3TC will be available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.
75734538|NCT04493216|Drug|FTC/TAF|FTC/TAF will be available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
75734539|NCT04493216|Drug|Dolutegravir|Dolutegravir will be available as a 50 mg tablet to be administered via oral route.
75884032|NCT02133716|Behavioral|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
76055681|NCT04694911|Behavioral|Focus Group|Participate in focus group
76055682|NCT04694911|Other|Interview|Complete cognitive interview
76055683|NCT04694911|Other|Research or Clinical Assessment Tool|Receive OOCAT
76055684|NCT04694521|Procedure|openSide to end colorectal anastomosis .|open Side to end colorectal anastomosis
75441123|NCT01630473|Procedure|Conventional orthodontics|Conventional orthodontic treatment
75441124|NCT01630499|Behavioral|Tailored Lifestyle Intervention (TLI)|The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
75591677|NCT03465774|Procedure|Quality-of-Life Assessment|Ancillary studies
75734540|NCT04493216|Drug|Placebo|Placebo matching GSK3640254 will be administered in the form of tablets via oral route.
75441125|NCT01630499|Behavioral|Commercial Weight Loss Program (CWLP)|This intervention is a generic, widely-available weight management program.
75591678|NCT03465774|Other|Questionnaire Administration|Ancillary studies
75591679|NCT03465774|Other|Survey Administration|Ancillary studies
75734541|NCT04489212|Other|Medical Chart Review|Review of medical chart
75734542|NCT04489212|Other|Patient Observation|Undergo observation
75734543|NCT04489212|Other|Quality-of-Life Assessment|Ancillary studies
75734544|NCT04489212|Other|Questionnaire Administration|Ancillary studies
75734545|NCT04488523|Behavioral|Family-based Telehealth Intervention|"The Family Telehealth intervention focuses on improving parent-child relationships and communication.~For the dyadic version, the intervention involves eleven hours of intervention material; it includes motivational interviews, individual and joint sessions co-led by two separate clinicians. The sessions will be delivered on a weekly basis.~For the caregiver-only version, the intervention involves six hours of intervention material; it includes a motivational interview and individual sessions led by a single clinician. The sessions will be delivered on a weekly basis."
75734546|NCT04486261|Other|High-intensity strength training|The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
76055685|NCT04694521|Procedure|open end end to end stapler anastomosis|open end to end stapler anastomosis
76055686|NCT02038933|Drug|Nivolumab|
76055687|NCT02081599|Drug|Teneli (Teneligliptin)|
76055688|NCT02081599|Drug|Placebo|
76055689|NCT02081599|Drug|Insulin|
76055690|NCT02038543|Drug|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
76055691|NCT02038153|Other|Laboratory Biomarker Analysis|Correlative studies
75734547|NCT04481399|Behavioral|Family Strengthening Intervention for Early Childhood Development|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
76055692|NCT02038153|Drug|Lenalidomide|Given PO
76055693|NCT02058589|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
75591680|NCT03451292|Drug|Albutein 20% Injectable Solution|Within 96 hours after discharge and following randomization, subjects will receive the first Albutein 20% infusion at the dose of 1.5 g/kg body weight (maximum 100 grams per subject). Thereafter, subjects will receive Albutein 20% infusions at the dose of 1.5 g/kg body weight (maximum 100 grams per subject) every 10 ± 2 days for the rest of the study (up to a maximum of 12 months). Subjects in this treatment group will also receive SMT.
75884033|NCT02137928|Drug|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
75591681|NCT03451292|Other|Standard medical treatment|Subjects will receive SMT according to published guidelines for the management of decompensated cirrhosis.
75591682|NCT03440814|Drug|DCCR|Once daily oral administration
76055694|NCT02058589|Drug|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
76055695|NCT02079805|Drug|Azilsartan|Azilsartan tablets
76055696|NCT02079805|Drug|Telmisartan|Telmisartan tablets
75884034|NCT02137928|Drug|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
75884035|NCT02138084|Drug|BMS-663068|BMS-663068
76055697|NCT02037295|Drug|Vancomycin|Vancomycin 125mg orally four times per day for 12 days
76055698|NCT02037295|Drug|Placebo oral tablet|Placebo pills orally four times per day for 12 days
76055699|NCT02037295|Other|Overfeeding diet (OF)|Diet in which the calories are 150% of their weight maintaining energy requirements
75441126|NCT01630512|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
75441127|NCT01630512|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
75591683|NCT03440814|Drug|Placebo for DCCR|Once daily oral administration
75591684|NCT03439228|Device|Lumbar brace|3 months of lumbar brace wear
75591685|NCT03427814|Drug|Pamiparib|60 mg orally twice daily
75591686|NCT03427814|Drug|Placebo|60 mg orally twice daily
75591687|NCT03420651|Other|Peak Expiratory Flow Rate (PEFR)|PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
75591688|NCT03420651|Other|Standard Clinical Judgement|Providers will use physical exam and standard clinical judgement to guide management.
75884036|NCT02138084|Drug|Rifabutin|Rifabutin
75884037|NCT02138084|Drug|Ritonavir|Ritonavir
76055700|NCT02037295|Other|Underfeeding diet (UF)|Diet in which the calories are 50% of their weight maintaining energy requirements
76055701|NCT02079649|Drug|AL-53817 Ophthalmic Solution, 0.1%|
76055702|NCT02079649|Drug|AL-78843 Ophthalmic Solution, 0.03%|
76055703|NCT02079649|Drug|Dexamethasone Ophthalmic Suspension, 0.1%|
76055704|NCT02079649|Drug|AL-53817 Vehicle|Inactive ingredients used for masking purposes
75591689|NCT03418493|Drug|LY3316531 - IV|Administered IV.
75734548|NCT04481399|Other|Community Health Worker Routine|Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
76055705|NCT02036515|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
76055706|NCT02036515|Drug|Ertugliflozin 15 mg|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
76055707|NCT02036515|Drug|Placebo for ertugliflozin 5 mg|Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
76055708|NCT02036515|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
75441128|NCT01630525|Other|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
75441129|NCT01630525|Other|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
75441130|NCT01630525|Other|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
75441131|NCT01630538|Drug|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
75441132|NCT01630551|Dietary Supplement|Fishoil supplement|1 capsule per day
75591690|NCT03418493|Drug|LY3316531 - SC|Administered SC.
75591691|NCT03418493|Drug|Placebo - IV|Administered IV.
75591692|NCT03396731|Device|geko™ medical device|The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.
75591693|NCT03383016|Other|Lifestyle questionnaires|
75591694|NCT03383016|Diagnostic Test|Prostate Biopsy|Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
75734549|NCT04476901|Biological|allogeneic human mesenchymal stem cells (hMSCs)|allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).
75734550|NCT04476901|Other|Placebo|Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
75734551|NCT04472338|Procedure|Biospecimen Collection|Undergo collection of blood, urine, and/or tissue samples
75734552|NCT04472338|Other|Laboratory Biomarker Analysis|Correlative studies
75734553|NCT04472338|Other|Quality-of-Life Assessment|Ancillary studies
76055709|NCT02036515|Drug|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
76055710|NCT02036515|Drug|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
76055711|NCT02036515|Biological|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
76055712|NCT02036515|Drug|Placebo for ertugliflozin 10 mg|Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
75734554|NCT04472338|Other|Questionnaire Administration|Ancillary studies
75734555|NCT04469790|Behavioral|SIT+WALK|Participants will interrupt their sitting for one week
76055713|NCT04417075|Behavioral|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.
75441133|NCT01630551|Dietary Supplement|Olive Oil|1 capsule per day
75441134|NCT01630564|Biological|Aldesleukin|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
75441135|NCT01630564|Procedure|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
75441136|NCT01630564|Biological|Umbilical Cord Blood-Derived Lymphocyte Therapy|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
75734556|NCT04469790|Behavioral|EX|Participants will perform a single bout of exercise and then sit for the remaining time for one week
75441137|NCT01630577|Other|volume expansion using modified gelatin|Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
75734557|NCT04462328|Drug|Durvalumab|Durvalumab will be administered over 60 minutes
75884038|NCT05677087|Behavioral|PREPARE Nutrition Education Module|The Perinatal Remote Education for Pandemic Resilience (PREARE) program is a 6-week intensive program aimed at increasing maternal and infant dietary diversity as well as maternal health literacy. Modules that will be completed in the program include education on early initiation of breastfeeding, food groups and the benefits of a balanced diet, appropriate meal frequency for mother and infant, and appropriate sources of health information. Information on personal hygiene and COVID-19 hygiene protocols as well as danger signs during pregnancy are included in the module to improve maternal knowledge on safety protocols and pregnancy complications.
75884039|NCT02129582|Radiation|total marrow irradiation|Undergo TMI
75884040|NCT02129582|Drug|fludarabine phosphate|Given IV
75884041|NCT02129582|Drug|busulfan|Given IV or PO
75441138|NCT01630642|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
75591695|NCT03382249|Combination Product|Sonodynamic therapy (SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
75591696|NCT03382249|Combination Product|pseudo-SDT|Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
75591697|NCT03380559|Drug|Injection, botulinum toxin + corticoid|"Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
75591698|NCT03380559|Drug|Injection, placebo of toxin + corticoid|"Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
75591699|NCT03380559|Drug|Injection, botulinum toxin + placebo corticoid|"Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)"
75591700|NCT03379909|Drug|Metformin|Metformin orally at doses up to 1500 mg twice daily for 3 months.
75734558|NCT04462328|Drug|Acalabrutinib|Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
75734559|NCT04458961|Procedure|One-stage|A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
76055714|NCT04417075|Behavioral|Dejar de Fumar Asistente (Mobile App)|Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
75441139|NCT01630655|Drug|Torrent's Felodipine Extended-Release Tablets|
75441140|NCT01630668|Dietary Supplement|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
75884042|NCT02129582|Procedure|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
75441141|NCT01630668|Dietary Supplement|One-a-Day placebo capsule|Once per day, 12 weeks
75441142|NCT01630681|Behavioral|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
75441143|NCT01630720|Dietary Supplement|vitamin C or vitamin D|vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
75591701|NCT03376984|Combination Product|ND and AMOX modified Gutta Percha|Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin
75734560|NCT04458961|Procedure|Two-stage|A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
75734561|NCT04458506|Procedure|Maxillary expansion|Correction of the unilateral posterior cross bite in children
75884043|NCT02129582|Biological|anti-thymocyte globulin|Given IV
75884044|NCT02129582|Drug|tacrolimus|Given IV or PO
75884045|NCT02129582|Drug|methotrexate|Given IV
75884046|NCT02129582|Other|laboratory biomarker analysis|Correlative studies
75884047|NCT03282565|Other|Functional Resistance Training with Brace|A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
75734562|NCT04449432|Behavioral|GROWell (Interactive Obesity Treatment Approach)|Personalized messaging via cell phone to support healthy eating behaviors during pregnancy and through 6 months postpartum
75734563|NCT04449432|Behavioral|Attention Support Control|Personalized messaging via cell phone to support healthy behaviors during pregnancy and through 6 months postpartum
75734564|NCT04445844|Biological|Pelareorep|Given IV
75884048|NCT03282565|Other|Control|A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
75734565|NCT04445844|Other|Quality-of-Life Assessment|Ancillary studies
75884049|NCT03282565|Other|Functional Resistance Training with Elastic Band|An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
75734566|NCT04445844|Other|Questionnaire Administration|Ancillary studies
75734567|NCT04445844|Biological|Retifanlimab|Given IV
75884050|NCT01355549|Biological|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
75884051|NCT02129738|Device|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
75441144|NCT01630733|Drug|Custirsen|Custirsen: Three loading doses of custirsen 640 mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle
75441145|NCT01630733|Drug|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
75441146|NCT01630746|Drug|TAK-438|
75441147|NCT01630746|Drug|TAK-438|
76055715|NCT02078713|Behavioral|Contraceptive Decision Support Tool|"The decision support tool:~Provides an educational session about different aspects of contraception~Elicits patient preferences about different aspects of contraception~Identifies potential contraindications to certain contraceptive methods~Allows the patient to view details about and compare available contraceptive methods~Suggests methods most appropriate based on the patient's preferences~Collects questions the patient may have for her provider~Generates a printout the patient can bring to her contraceptive counseling visit"
76055716|NCT02035267|Drug|Deoxycholic Acid|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
75441148|NCT01630759|Device|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
75441149|NCT01630759|Other|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
75441150|NCT01630772|Other|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
75441151|NCT01630772|Other|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
75734568|NCT04445792|Other|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
75734569|NCT04445792|Other|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
75734570|NCT04434092|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.
75734571|NCT04434092|Drug|Eculizumab|Eculizumab will be administered at a dose of 600 mg for the first 4 weeks, followed by maintenance doses of 900 mg starting on Week 5, as per the dosing schedule described above.
75734572|NCT04433585|Drug|LY3471851|Administered SC
75734573|NCT04433585|Drug|Placebo|Administered SC
75884052|NCT01362023|Behavioral|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~Classroom practice by HPA to highlight healthy lifestyle habits~Teaching practice by HPA using books designed to include the nutritional objectives~Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~Experimental development of activities regarding each healthy lifestyle habit~Assessment of activity performed in classroom~An activity developed for use at home"
76055717|NCT02035267|Drug|Placebo|Phosphate buffered saline placebo for injection.
75734574|NCT04433338|Other|14-day Low Calorie Diet|"Participants will be asked to:~Use 4 (women) or 5 (men) Modifast meal replacements per day.~Daily consume a minimum of 250 grams of (raw) vegetables without dressing.~Daily consume 100 grams of lean meat/fish/meat analogues.~Daily consume two spoons of liquid oil~Daily drink at least 2.0 litres of water, coffee or tea without added sugar or milk, bouillon or sugar-free drinks."
75734575|NCT04431726|Drug|Emicizumab|"Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first."
75734576|NCT04429919|Drug|AP-325|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
75734577|NCT04429919|Drug|Placebo|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
75734578|NCT04423783|Behavioral|7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)|Confrontation with spiders via gamified app
75734579|NCT04423783|Behavioral|Therapist-guided one-session online exposure therapy according to (Öst, 1989)|Massed exposure therapy over the course of one single session, applied in a remote-online context
75734580|NCT04413994|Dietary Supplement|Humavant|"Premature infants are randomized to either:~An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR~Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.~After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included."
75441152|NCT01630798|Drug|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
75441153|NCT01630824|Other|Structured education program|structured education program after kidney transplantation
75591702|NCT03376984|Device|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
75734581|NCT04410042|Drug|Tranexamic Acid|Given IV
75441154|NCT01630837|Other|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
75591703|NCT03368664|Drug|Alemtuzumab GZ402673|Pharmaceutical form: solution, Route of administration: IV
75591704|NCT03368664|Drug|Glatiramer acetate|Pharmaceutical form: solution, Route of administration: subcutaneous (SC)
75734582|NCT04410042|Other|0.9% sodium chloride|Given IV
75734583|NCT04409873|Drug|Oral-B Mouth Sore mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
75734584|NCT04409873|Drug|Crest Pro-Health Multi-Protection mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
75591705|NCT03368664|Drug|Beta-Interferon|Pharmaceutical form: solution, Route of administration: SC / intramuscular (IM)
75591706|NCT03368664|Drug|Methylprednisolone|Pharmaceutical form: solution, Route of administration: IV
75591707|NCT03368664|Drug|Ranitidine|Pharmaceutical form: tablet, Route of administration: oral
75591708|NCT03368664|Drug|Ceterizine|Pharmaceutical form: tablet, Route of administration: oral
75734585|NCT04409873|Drug|CloSYS Ultra Sensitive Rinse mouthwash|Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
75734586|NCT04409873|Drug|Distilled water|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
75734587|NCT04409873|Drug|Listerine Zero Mouthwash Product|Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
75734588|NCT04409821|Behavioral|Tele-delivered psychological intervention|The intervention consists of two (or one, if preferred by caregivers) weekly tele-sessions during the ICU stay, lasting up to 30 minutes, and two sessions in the month after discharge from or death in the ICU. Sessions will be conducted via phone-calls or video-conferencing. Therapists will 1) validate caregivers' subjective experience, 2) normalize and psychoeducate about emotional reactions, and 3) offer emotion regulation drawing on contemporary cognitive treatment packages of decentering, acceptance and emotion tolerance. Sessions for bereaved caregivers will include psycho-education about grief, assessment of risk for adverse outcomes and information about available support, if needed. The intervention will be performed based on an intervention manual. The content of the intervention will be continually adapted and tailored to the needs of the participating caregivers by involving all caregivers in co-creating the intervention trough brief post-session interviews.
75884053|NCT02133794|Device|Tomosynthesis|
76055718|NCT05887596|Other|Patient education|The education given to the intervention group included preoperative preparation, operating room environment, breathing exercises, cough exercises, etc. to be performed after surgery, non-pharmacological methods related to pain management (cold application, positioning, distraction), and pharmacological methods related to pain management.
76055719|NCT05887466|Drug|A9-DPC|"IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~Main ingredients and quantities: A9-DPC~7.0X10^6 cells (Use 3.15X10^6 cells of this)~1.4X10^7 cells (Use 6.30X10^6 cells of this)~Formulation: milky white cell suspension~Storage method: Refrigerated storage (5±3℃)~Expiration date: within 24 hours of manufacture~Dosage:~1st Stage Dosage: 3.15X10^6 cells/body (6 tracks in total, 52.5X10^4 cells per track)~2nd Stage Dosage: 6.30X10^6 cells/body (6 tracks in total, 105X10^4 cells per track)~Frequency: single dosing~Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
76055720|NCT05887453|Device|Magnetocardiography|Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases
76055721|NCT05887427|Other|Neural Mobilisation|Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)
76055722|NCT05887427|Other|Conservative physiotherapy|Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
76055723|NCT05887375|Drug|Sugammadex|Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
75441155|NCT01630863|Procedure|Photodynamic therapy|Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
75441156|NCT01630876|Procedure|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
75441157|NCT01630876|Procedure|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
75884054|NCT05188625|Other|Telesupport - Telehealth|Online self-paced dietary education videos; Dietary counselling via video consultation; Blood glucose monitoring via a specially-designed health app
76055724|NCT05887375|Drug|Neostigmine|Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
75591709|NCT03368664|Drug|Dexchlorpheniramine|Pharmaceutical form: tablet, Route of administration: oral
75591710|NCT03368664|Drug|Paracetamol|Pharmaceutical form: tablet, Route of administration: oral
75884055|NCT02129816|Drug|Bryophyllum|
76055725|NCT05887375|Drug|Glycopyrrolate|Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
76055726|NCT05887375|Drug|Rocuronium|To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
76055727|NCT05887362|Behavioral|Hand Reflexology|Reflexology is a well-known, safe, and noninvasive alternative medicine technique. It alludes to a treatment that is applied to particular areas of the hands and feet. The compression on the hands or feet serves as a sensor linked to particular body areas. These sensors are activated by the reflexology technique to improve blood flow, energize, relax, and maintain homeostasis.
75441158|NCT01630902|Drug|Torrent's Felodipine Extended-Release Tablets|
75441159|NCT01630915|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
75591711|NCT03368664|Drug|Acyclovir|Pharmaceutical form: tablet, Route of administration: oral
75591712|NCT03368664|Drug|Prednisolone|Pharmaceutical form: tablet, Route of administration: oral
75591713|NCT03368664|Drug|Diphenydramine|Pharmaceutical form: solution, Route of administration: IV
75591714|NCT03368664|Drug|Other H1 antagonist|Pharmaceutical form: solution, Route of administration: IV
75591715|NCT03368664|Drug|Other H1 antagonist|Pharmaceutical form: tablet/pill, Route of administration: oral
75591716|NCT03367702|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
75591717|NCT03367702|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
76055728|NCT05887349|Other|Neck Stabilization Exercise|"1. Control Group exercise program (Cervical Stabilization exercises group)~The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects."
75441160|NCT01630928|Procedure|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
75441161|NCT01630941|Drug|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
76055729|NCT05887349|Other|Neck Stabilization Exercise + Rocabado Exercises|"2. Intervention group exercise program (the group to which Robacado exercises will be added in addition to cervical stabilization exercises) The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. In addition, individuals in this group will be given Robacado exercises.~Robacado exercises:~Resting position for the tongue: The tip of the tongue is placed on the upper palate, just behind the front teeth (resting position for the tongue).~When the body is in an upright position, scapular retraction and depression movements are performed without disturbing the position of the cervical region.~When the body is in an upright position, at C2-C7 levels, hands are clamped on the neck and cranio-cervical flexion is studied."
75591718|NCT03360422|Other|Survey|Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
75591719|NCT03360422|Other|Focus Group|After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
76055730|NCT05887336|Device|Walther System|Walther System providing INMEST treatment
76055731|NCT05887336|Device|Sham Walther System|Walther System not providing INMEST treatment, but otherwise behave as the active comparator.
76055732|NCT05887336|Drug|Non preserved ocular lubricants|"Hyaluronic acid (HyloGel)~Hyaluronic acid and Ectoin (Hylo Dual Intense)~Hyaluronic acid and Trehalos (Theloz Duo)"
75591720|NCT03360422|Other|Usability study|After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
75591721|NCT03345485|Drug|Tinostamustine (EDO-S101)|The study is designed as an open label, Phase 1/2 trial of single agent EDO-S101. The Phase 1 portion of the study is designed to define the MTD by evaluating toxicities during dose escalation until MAD. The Phase 2 portion of the study is designed to evaluate ORR and SD that persists for at least 4 months of the RP2D.
75734589|NCT04392297|Diagnostic Test|Bood leukocyte subsets|Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells
75591722|NCT03343054|Drug|talazoparib|Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
75591723|NCT03339596|Drug|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
75591724|NCT03339596|Drug|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
75591725|NCT03322358|Other|Naps|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
75734590|NCT04392297|Diagnostic Test|CMV specific T-cells|CMV specific T-cells detected by flow cytometry
75734591|NCT04392297|Diagnostic Test|serum CMV IgM / IgG antibodies|serum CMV IgM / IgG antibodies detected by ELISA
75591726|NCT03322358|Device|Home sleep aids|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
75591727|NCT03322358|Other|Sleep incentives|After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
75734592|NCT04391348|Radiation|PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine|Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine
75884056|NCT05106205|Drug|DA-5213 10mg|single dose administration (one tablet once a day)
75441162|NCT01630954|Procedure|Suction and evacuation|In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
75441163|NCT01630954|Procedure|Suction and evacuation|In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
75441164|NCT01630967|Drug|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
75441165|NCT01630980|Other|Tree nuts|Almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts in whole, meal, or flour form
75441166|NCT01630993|Other|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
75441167|NCT01631006|Device|CPAP|A low or high CPAP pressure is delivered for 20 minutes
75591728|NCT03315975|Biological|Inactivated influenza vaccine|One dose of quadrivalent inactivated influenza vaccine
75591729|NCT03309878|Biological|Mogamulizumab|Given IV
75884057|NCT05106205|Drug|DA-5213-R 10mg|single dose administration (one tablet once a day)
75591730|NCT03309878|Biological|Pembrolizumab|Given IV
75591731|NCT03303248|Behavioral|Web-based Educational Intervention|A web-based educational tool, created for patients with congenital heart disease, will be given to patients using an ipad. This additional educational tool will be used with the standard of care visit with provider.
75734593|NCT04387734|Drug|Ocrelizumab|Ocrevus will be administered following the FDA's regulations.
75734594|NCT04387734|Drug|Platform|The applications of the platform DMTs will follow the FDA-approved regulations.
75734595|NCT04380324|Drug|LY3471851|LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
75734596|NCT04380324|Drug|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
75734597|NCT04380077|Procedure|vitrectomy with sulfur hexafluoride gas|vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy
75734598|NCT04380077|Procedure|vitrectomy with balanced salt solution|vitreous substitution with balances salt solution during vitrectomy
75734599|NCT04380064|Procedure|ILM Peeling|ILM peeling performed during primary PPV for PDR
75734600|NCT04380064|Procedure|No ILM Peeling|ILM peeling not performed during primary PPV for PDR
75734601|NCT04371510|Other|blood sample|a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
76055733|NCT05887336|Procedure|Eye lid procedure|Lid hygiene, warm eye bag, lid massage and Omega 3
75734602|NCT04369053|Diagnostic Test|Freenome test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled. Participants will undergo blood collection and will then complete a standard-of-care screening colonoscopy.
75734603|NCT04355533|Biological|serology test|volume according to child weight
75734604|NCT04355533|Biological|nasopharyngeal swab|nasopharyngeal swab for PCR
75734605|NCT04355533|Biological|rectal swab|rectal swab for PCR
75734606|NCT04355533|Biological|saliva sample|for biocollection
76055734|NCT05887297|Behavioral|Cognitive behavioural therapy for insomnia|CBT-I is a multi-component, evidence-based intervention which incorporates both cognitive and behavioural techniques to address symptoms of insomnia, aiming to improve satisfaction with the duration and quality of sleep by reducing trouble falling and/or staying asleep. CBT-I will be delivered over 4 weekly 1-hour sessions, via videoconferencing. Session 1 will include psychoeducation about sleep (the relationship between sleep and mental health, the '3P' model of insomnia), and begin to explain components of CBT-I (sleep restriction and relaxation). Session 2 will reinforce previous learning about these components and introduce stimulus control. Session 3 will introduce sleep hygiene and its importance in preventing poor sleep. Session will 4 discuss cognitive therapy techniques and relapse prevention.
75441168|NCT01631019|Behavioral|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
75441169|NCT01631019|Behavioral|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
75441170|NCT01631032|Drug|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
75591732|NCT03298295|Device|Continous Subcutaneous Insulin Infusion Catheter|Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
75734607|NCT04345341|Drug|TAP block with liposomal bupivacaine and bupivacaine|injecting the mixture of bupivacaine with liposomal bupivacaine in transversus abdominis plane to block the somatic nerves
75734608|NCT04332705|Diagnostic Test|Detection of Cryptosporidium infection|A biopsy or a surgical sample will be collected from every participant
76055735|NCT05887284|Radiation|low dose radiotherapy (0.5 Gy)|12 times 0.5 Gy
76055736|NCT05887284|Radiation|mock radiation treatment|6 times 0.0 Gy
76055737|NCT05887284|Radiation|low dose radiotherapy (1.0 Gy)|6 times 1.0 Gy
76055738|NCT05887271|Drug|Low calorie meal replacement plan|Meal replacement diet containing ~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
75734609|NCT04329949|Drug|Relacorilant, 100 mg and 25 mg|Relacorilant is supplied as capsules for oral dosing.
75734610|NCT04329949|Drug|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
75734611|NCT04329065|Biological|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
75734612|NCT04329065|Drug|Paclitaxel|Given via infusion
75734613|NCT04329065|Biological|Trastuzumab|Given IV
75734614|NCT04329065|Biological|Pertuzumab|Given IV
75734615|NCT04310891|Radiation|Markerless Tumour Tracking|Intrafraction Kolovoltage X-ray Imaging using Fiducials
75441171|NCT01631058|Drug|Everolimus|"This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.~Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
75734616|NCT04304495|Other|Fall Prevention|The intervention arm participants will receive a physical therapy and pharmacy consults as well as Apple Watch training and an Apple Watch device to test memory and mobility during the ED visit and during our home visits.
75591733|NCT03293264|Behavioral|Exercise training group|"Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome."
75591734|NCT03291158|Drug|Minocycline|Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
75591735|NCT03282890|Other|CHRP-BB|The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
75734617|NCT04300647|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
75734618|NCT04300647|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
75734619|NCT04300504|Other|observational study|observational study
75734620|NCT04296617|Other|Medical Chart Review|Review of medical chart
75734621|NCT04290624|Other|Experimental Dentifrice: Stannous Fluoride|Participants will be instructed to dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion containing 0.454% w/w Stannous fluoride for 2 minutes twice daily (morning and evening) for 12 weeks.
75734622|NCT04290624|Device|COREGA Denture Foaming Cleanser|Participant will clean their denture using 2 pumps of the denture cleansing foam and a denture cleaning brush for 90 timed seconds outside of the mouth twice daily (morning and evening) for 12 weeks.
75734623|NCT04290624|Other|Mouth rinse: Sodium Fluoride|Participants will take 10 ml of the mouth rinse containing 90 ppm sodium fluoride and swished around the mouth for 1 minute twice daily (morning and evening) for 12 weeks.
75441172|NCT01631097|Drug|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
75441173|NCT01631123|Other|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
75591736|NCT03264989|Drug|crizanlizumab|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion
75591737|NCT03264196|Procedure|Open Reduction and Internal Fixation|Surgical treatment of fracture
75734624|NCT04288115|Drug|Levothyroxine|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
75591738|NCT03259867|Drug|Nivolumab Injectable Product|a PD-1 immune check inhibitor
75591739|NCT03259867|Combination Product|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
75591740|NCT03256539|Behavioral|Sleep intervention|Behavioral sleep intervention program
75591741|NCT03256539|Behavioral|Placebo intervention|Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
75734625|NCT04288115|Other|Placebo|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
75734626|NCT04287868|Biological|PDS0101|PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.
75734627|NCT04287868|Biological|M7824|M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.
75734628|NCT04287868|Biological|NHS-IL12|NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.
75734629|NCT04287738|Behavioral|Navigated Care|Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
75441174|NCT01631123|Other|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
75734630|NCT04279028|Behavioral|Adapted CBT|"ACBT is derived from traditional CBT principles, but eliminates the text-heavy requirements. Traditional CBT incorporates the use of complex worksheets and a lengthy workbook, whereas ACBT replaces these skill learning activities with simpler, straightforward exercises that are practiced in session along with the therapist. This real world practice eliminates the need for reading and writing as part of CBT while simultaneously recapitulating how the patient would actually implement CBT procedures. In session exercises will mirror that of standard CBT practices. For example, they could include lessons in goal setting, distinguishing situations, moods, and thoughts, and experiments to test underlying assumptions. Participants will be assigned paper-free homework assignments."
75591742|NCT03226691|Drug|Plerixafor|Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
75734631|NCT04279028|Behavioral|Standard CBT|CBT involves the therapist and client working to identify and change negative beliefs and thoughts, replacing them with more accurate and balanced thoughts. CBT for Depression will be conducted according to standard manuals and incorporate the use of a common workbook used within CBT sessions. As per standard practice, participants will be assigned worksheets from their workbook used both in session and as homework assignments.
75734632|NCT04276935|Other|Interview|Participate in cognitive interview
75734633|NCT04276935|Other|Quality-of-Life Assessment|Ancillary studies
75734634|NCT04276935|Other|Questionnaire Administration|Ancillary studies
75734635|NCT04271813|Drug|Anlotinib plus Sintilimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
75884058|NCT01362101|Behavioral|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
75441175|NCT01631136|Drug|Cisplatin|75 mg/m²
75441176|NCT01631136|Drug|Pemetrexed|500 mg/m²
75441177|NCT01631136|Drug|Cisplatin|80 mg/m²
75441178|NCT01631136|Drug|Gemcitabine|1250 mg/m²
75591743|NCT03219502|Other|Best Practice|Receive standard of care
75591744|NCT03219502|Other|Quality-of-Life Assessment|Ancillary studies
75591745|NCT03219502|Other|Questionnaire Administration|Ancillary studies
75591746|NCT03219502|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
75591747|NCT03219502|Procedure|Sham Intervention|Undergo sham rTMS
75591748|NCT03218761|Diagnostic Test|NET mRNA level|quantification of mRNA to the Norepinephrine Transporter (NET)
75884059|NCT02129894|Device|abdominal Binder|placement of abdominal binder
75884060|NCT04756739|Device|Clearblue Connected Ovulation Test System|Clearblue Connected Ovulation Test System which is a CE marked device used for tracking the menstrual cycle
75441179|NCT01631162|Other|Breath sample in all patients|Breath sample will be collected by a special nylon bag
75441180|NCT01631175|Behavioral|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
75441181|NCT01631201|Drug|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
75441182|NCT01631201|Drug|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
75441183|NCT01631253|Procedure|Laparoscopic ovarian cyst enucleation|
75441184|NCT01631266|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
75441185|NCT01631266|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
75591749|NCT03218761|Diagnostic Test|Plasma catechols|plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
75591750|NCT03218761|Diagnostic Test|Urine Catechols|urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
75591751|NCT03202628|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
76055739|NCT05887271|Diagnostic Test|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
76055740|NCT05887271|Diagnostic Test|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function
75591752|NCT03202628|Drug|Dexamethasone|Given PO
75591753|NCT03202628|Drug|Ixazomib Citrate|Given PO
75591754|NCT03202628|Other|Laboratory Biomarker Analysis|Correlative studies
75441186|NCT01631279|Drug|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
75591755|NCT03202628|Drug|Pomalidomide|Given PO
75591756|NCT03200704|Combination Product|IC2000 and SPY-PHI|Investigational treatment to assess the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
75734636|NCT04269577|Behavioral|SSP training|Participants will practice the Swipe Slide Pattern (SSP) task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
75441187|NCT01631305|Drug|Levothyroxine|3 mcg/kg/day
75441188|NCT01631305|Other|Calcium magnesia|Placebo.
75441189|NCT01631344|Other|"Daily physical activity consultation, Using the Stage of change model"|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
75441190|NCT01631357|Biological|CIK cell|CIK cell injection
75591757|NCT03200704|Combination Product|Tc-99m radioactive colloid and Gamma Probe|Comparator; standard of care for sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
75591758|NCT03180216|Biological|Virus Specific T cells (VSTs)|"This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.~In this trial, we will utilize a rapid generation protocol for broad spectrum multivirus-specific T cells for infusion to recipients of allogeneic hematopoietic stem cell transplant (HSCT), who are at risk of developing EBV, CMV, adenovirus, HHV6, BKV, JCV and/or HPIV3, or with PCR/culture confirmed active infection(s) of EBV, CMV, adenovirus, HHV6, BKV, JCV, and/or HPIV3 that has failed to resolve with at least 14 days of standard antiviral therapy (if available and tolerated). These cells will be derived from HSCT donors, and the study agent will be assessed at each dose for evidence of dose-limiting toxicities (DLT)."
75591759|NCT03176472|Drug|ricolinostat|120 mg per dose in 12 mL liquid formulation
75591760|NCT03176472|Drug|Placebo|12 mL liquid formulation placebo
75591761|NCT03164057|Drug|Azacitidine|Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
75734637|NCT04263714|Behavioral|Exercise|Aerobic exercise and resistance exercise
75441191|NCT01631357|Drug|Gemcitabine Injection|Gemcitabine injection
75441192|NCT01631357|Drug|Cisplatin injection|Cisplatin injection
75884061|NCT02129972|Device|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
75591762|NCT03164057|Drug|Decitabine|Administered intravenously (IV) over approximately one hour.
75591763|NCT03164057|Drug|Cytarabine|Given IV or intrathecally (IT).
76055741|NCT05887271|Diagnostic Test|Blood test|Collection of blood samples from each participant to characterise the participant's health status and fibroinflammatory markers.
76055742|NCT05887271|Diagnostic Test|Electrocardiogram|An ECG will be obtained to assess for baseline rhythm.
75591764|NCT03164057|Drug|Daunorubicin|Given IV.
75591765|NCT03164057|Drug|Etoposide|Given IV.
75884062|NCT04715243|Device|High flow nasal cannula (HFNC)|High flow nasal cannula as a form of non-invasive oxygen delivery
75884063|NCT04715243|Device|Helmet NIV|NIV interface
75884064|NCT04715243|Device|Face-mask NIV|NIV interface
75884065|NCT02138162|Drug|enzalutamide|oral
75591766|NCT03164057|Combination Product|ITMHA|Given IT.
75591767|NCT03164057|Drug|Idarubicin|Given IV.
75591768|NCT03164057|Drug|Fludarabine|Given IV over approximately 30 minutes.
75734638|NCT04262193|Drug|Suvorexant|In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.
75734639|NCT04262193|Drug|Suvorexant Placebo|Suvorexant Placebo
75591769|NCT03164057|Drug|Mitoxantrone|Given IV.
75734640|NCT04261478|Device|Carotid artery stenting|The type of stent should be one commonly used for ICA stenting. Balloon angioplasty before and/or after stent placement will be allowed as required. Stenting should be performed after intracranial thrombectomy unless specific technical circumstances suggest that access to the intracranial circulation requires anterograde stenting. Embolic protection devices should not be used routinely during ICA stent placement.
75884066|NCT02138318|Other|High definition (HD) endoscopy|
76055743|NCT05887271|Diagnostic Test|Accelerometery|Accelerometer (GeneActiv) measured daily activity levels continuously for 7 consecutive days.
76055744|NCT05887271|Diagnostic Test|6 minute walk test (6MWT)|Supervised 6MWT will be performed with symptom assessment using dyspnoea scale (Borg's).
76055745|NCT05887271|Diagnostic Test|Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)|Skeletal muscle strength will be measured using a cybex dynamometer.
75591770|NCT03164057|Drug|Erwinia asparaginase|Given IV or intramuscularly (IM).
75591771|NCT03164057|Drug|Sorafenib|Given PO.
75591772|NCT03164057|Drug|G-CSF|Given IV.
75734641|NCT04261478|Drug|Antiplatelet Agents|The following antiplatelet regimen should be used: For patients having received IV thrombolysis, immediate post-procedural oral or intrarectal single antiplatelet agents, (Aspirin 325mg PO or 650mg PR). A second agent (usually Clopidogrel 300mg PO) is added after follow-up brain imaging at 12-24 hours confirms absence of significant ICH. For patients having not been treated with IV thrombolysis, dual antiplatelet therapy (Aspirin 325mg PO or 650mg PR and Clopidogrel 300-600mg PO) is given immediately post-procedure. Routine use of GPIIb/IIIa inhibitors, periprocedural IV Heparin is discouraged.
75734642|NCT04251026|Drug|tividenofusp alfa|Intravenous repeating dose
75734643|NCT04248452|Drug|Capecitabine|Given PO
75734644|NCT04248452|Drug|Fluorouracil|Given IV
75734645|NCT04248452|Drug|Leucovorin|Given IV
75734646|NCT04248452|Drug|Leucovorin Calcium|Given IV
75591773|NCT03164057|Drug|Dexrazoxane|Given IV immediately before idarubicin administration.
75591774|NCT03164057|Biological|Stem Cell Transplant|The transplant protocol will depend on the patient's donor and transplant physician's preference.
75734647|NCT04248452|Drug|Oxaliplatin|Given IV
75884067|NCT02138318|Other|chromoendoscopy|
76055746|NCT05887271|Other|Assessment of quality of life and heart failure symptoms|Quality of life and HF symptoms will be assessed using the Minnesota Living with Heart Failure (MLWHF) questionnaire, which is used as a standardised measure of self-reported health status, and HF symptoms and is considered to have a good discriminatory power and validity
76055747|NCT05887271|Other|Assessment of sarcopenia|Participants will be assessed for presence of sarcopenia using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire. It is a robust tool for diagnosis of sarcopenia and prediction poor physical function, with excellent specificity in multimorbid individuals.
76055748|NCT05887271|Other|Assessment of frailty|Frailty will be assessed using the Edmonton Frail Scale (EFS). The EFS is a multidimensional frailty assessment which assesses multiple domains of frailty including functional independence, social support, cognition, medication use, and mood.
76055749|NCT05887271|Other|Qualitative interview|Participants in the MRP and control groups will be invited to attend a focused semi-structured, 1-2-1 interview aimed to elicit barriers and enablers to the MRP and describe their perspective on the relationship between healthy eating and health interview during the 12-week visit. Participants who complete or drop out will be eligible. Inclusion of participants in the control arm will allow us to compare the experiences of MRP versus health coaching and detect any specific issues people face when trying to introduce lifestyle changes themselves.
76055750|NCT05887271|Diagnostic Test|Skeletal muscle magnetic resonance spectroscopy|Assessment of skeletal muscle volume (quadriceps and calf muscle) using MRI, and 31P-magnetic resonance spectroscopy (31P-MRS) of the skeletal muscle using fysiometer and during isometric exercise at rest and after 5 minutes of exercise to assess changes in muscle energetics at rest and on exercise.
76055751|NCT05887258|Drug|Opioid free anesthesia|Administer a combination of drugs in substitution for morphine
76055752|NCT05887232|Procedure|Fractional CO2 laser|Patient in group A received FCL treatments four sessions with four weeks apart
76055753|NCT05887232|Procedure|Fractional CO2 with Platelet Rich Plasma|Group B received four PRP and FCL sessions 4 weeks apart
76055754|NCT05887219|Drug|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months
75441193|NCT01631370|Procedure|Renal denervation|The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
76055755|NCT05887219|Drug|Group B Azelaic Acid 20 % Cream for 6 months|Group B was managed with topical 20% azelaic acid (daily at night) for six months.
76055756|NCT05887206|Other|Collection of datas|The collected data are : sex, age, date of first immunotherapy cycle, dose, date of first consultation, objective refraction in spheric equivalent, keratometry, visual acuity, microcyst-like epithelial changes (MECs), location and density, corneal toxicity grade and complementary exams (topography, in vivo confocal microscopy).
75441194|NCT01631383|Drug|l-THP (l-tetrahydropalmatine)|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
76055757|NCT05887193|Device|Biothesiometry|Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
75591775|NCT03164057|Drug|Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn|May be used in the event of an Erwinia asparaginase shortage. Given intramuscularly (IM).
75591776|NCT03141060|Drug|Delamanid|Administered orally; dosing will be based on participants' age and weight.
75591777|NCT03141060|Drug|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
75734648|NCT04248452|Radiation|Radiation Therapy|Undergo radiation therapy
75734649|NCT04244942|Device|CERAMENT BVF|CERAMENT BONE VOID FILLER is a synthetic biphasic bone graft substitute.
75734650|NCT04238637|Drug|Durvalumab|Durvalumab IV (intravenous Infusion)
75734651|NCT04238637|Drug|Tremelimumab|Tremelimumab IV (intravenous Infusion)
75734652|NCT04232670|Procedure|EUS + SHAM|Endoscopic Ultrasound
75591778|NCT03136146|Drug|Bortezomib|Given SC
75591779|NCT03136146|Drug|Clofarabine|Given IV
75591780|NCT03136146|Drug|Cyclophosphamide|Given IV
75734653|NCT04232670|Procedure|EUS + Pancreatic Endotherapy|Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement.
75884068|NCT03549572|Behavioral|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
75591781|NCT03136146|Drug|Dexamethasone|Given IV or PO
75591782|NCT03136146|Drug|Etoposide|Given IV
76055758|NCT05887193|Device|Near Infrared Spectroscopy|Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.
75441195|NCT01631383|Drug|Placebo|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
76055759|NCT05887193|Device|Cycling on a home trainer|Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
76055760|NCT05887193|Device|Bike Fitting|Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
75441196|NCT01631396|Drug|Sugammadex vs. Neostigmine|"Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body."
75441197|NCT01631409|Other|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
75441198|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
75441199|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
75884069|NCT02133950|Procedure|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
75884070|NCT02133950|Procedure|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
76055761|NCT05887180|Other|PräVaNet-Intervention|interdisciplinary and digitally supported prevention concept
76055762|NCT05887154|Device|Microwave ablation|microwave ablation
75884071|NCT04566029|Biological|Blood test|The patients' blood will be collected in four 5mL heparinized tubes
75884072|NCT04566029|Biological|Stool sample|The patients' stools will be collected at home
75884073|NCT04566029|Other|Questionnaires|At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE
75884074|NCT02138396|Drug|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
75884075|NCT02138396|Drug|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
75441200|NCT01631409|Procedure|PCA|Percutaneous coronary angioplasty
75441201|NCT01631409|Procedure|CABG|Coronary artery bypass grafting
75441202|NCT01631409|Device|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
75591783|NCT03136146|Biological|Ofatumumab|Given IV
75591784|NCT03136146|Biological|Pegfilgrastim|Given SC
75591785|NCT03136146|Biological|Rituximab|Given IV
75591786|NCT03136146|Drug|Vincristine Sulfate Liposome|Given IV
75591787|NCT03129828|Drug|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
75591788|NCT03128866|Procedure|Hemipelvectomy|Undergo hemipelvectomy
75591789|NCT03128866|Drug|Tranexamic Acid|Given IV
75734654|NCT04230278|Behavioral|START-Play Physical Therapy|Physical Therapy focused on movement and cognitive skills at the same time
75734655|NCT04230278|Behavioral|Usual Care Physical Therapy|Physical Therapy focused on movement and reducing impairments
75734656|NCT04225182|Device|traditional rehabilitation protocol|muscular strengthening protocol with traditional rehabilitation protocol without orthosis
75734657|NCT04225182|Device|with instrumented Orthosis|8 weeks of muscular strengthening with the orthosis connected to the phone app associated
75734658|NCT04221893|Radiation|Radiation Therapy (RT)|Undergo radiation therapy
75591790|NCT03127631|Behavioral|Nutrition|Standardized advice on healthy diet practices.
75734659|NCT04217551|Device|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
75734660|NCT04204473|Drug|TY-9591(10mg,40mg) qd. po|Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
75734661|NCT04198623|Drug|Montelukast 10 Mg Oral Tablet|Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
75734662|NCT04197934|Procedure|Biospecimen Collection|Undergo collection of blood samples
75734663|NCT04197934|Procedure|Biospecimen Collection|Undergo collection of CSF samples
75884076|NCT02138396|Drug|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
75441203|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
75441204|NCT01631422|Drug|RO4602522|Single radiolabeled dose
75441205|NCT01631448|Biological|Fibrin Glue|The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
75734664|NCT04197934|Procedure|Computed Tomography|Undergo CT
75734665|NCT04197934|Drug|EGFR/EGFRvIII Inhibitor WSD0922-FU|Given PO
75734666|NCT04197934|Procedure|Magnetic Resonance Imaging|Undergo MRI
75734667|NCT04197934|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
75734668|NCT04191096|Biological|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
75734669|NCT04191096|Drug|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
75734670|NCT04191096|Drug|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
75884077|NCT02138474|Other|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
75734671|NCT04191096|Other|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
75884078|NCT02138474|Other|Placebo|Unmedicated sucrose pillules
75441206|NCT01631487|Drug|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
75441207|NCT01631487|Drug|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
75441208|NCT01631487|Drug|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
75591791|NCT03127631|Behavioral|Exercise|Standardized advice on exercise including strength training and resistance training exercises.
75591792|NCT03127631|Behavioral|Smoking cessation|Advice to quit smoking, if applicable, and on available aids to quit smoking,
75591793|NCT03127631|Drug|Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
75591794|NCT03127631|Drug|ACE inhibitor|Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater >130mmHg, or other blood pressure lowering medication as applicable.
75734672|NCT04188652|Other|Detailed symptomregistration|Information on symptoms, specialized ultrasound in accordance to IOTA, and HE4 is registered in women with ovarian cysts. Participation in the study including symptom registration, description of the cyst using IOTA terminology, and HE4 determination will not affect further diagnostics or treatment. HE4 will not be informed to the patient or clinician.
75884079|NCT04560881|Biological|Inactivated SARS-CoV-2 vaccine (Vero cell)|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
75884080|NCT04560881|Biological|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
75734673|NCT04187833|Drug|Nivolumab|480mg intravenously every 4 weeks (28 days)
75734674|NCT04187833|Drug|Talazoparib|1mg orally daily
75734675|NCT04183426|Diagnostic Test|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
75734676|NCT04183426|Diagnostic Test|Arterial Stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~Peripheral pressure parameters~Central and abdominal aneurysm pressure parameters (derived using a transfer function)~Cardiac output parameters (sub-endocardial viability ratio (SEVR), Ejection Duration (ED))~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
75884081|NCT02911675|Device|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
75884082|NCT02252510|Other|HALOSPERM|
75884083|NCT05223842|Behavioral|Family Promoting Positive Emotions (F-PPE)|F-PPE is an 8-session dyadic intervention designed to enhance positive emotionality and buffer against the effects of stress on anhedonia in children. The intervention will be administered online through videoconferencing sessions with a clinician to mothers and their children.
75884084|NCT05223842|Behavioral|Written Information|Mothers assigned to the Written Information condition will receive email newsletters providing resources relevant to depression.
75884085|NCT02875613|Drug|Avelumab|Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
75884086|NCT02823457|Behavioral|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
75441209|NCT01631487|Drug|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
75441210|NCT01631500|Behavioral|Conventional treatment|Conventional treatment
75441211|NCT01631500|Other|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
75441212|NCT01631500|Other|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
75441213|NCT01631513|Drug|Nucynta ER|100 to 250 mg every 12 hours
75734677|NCT04178915|Diagnostic Test|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)
75884087|NCT02130128|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
75884088|NCT02130206|Other|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
75884089|NCT02130206|Other|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
75441214|NCT01631526|Dietary Supplement|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
75884090|NCT02130206|Other|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
75884091|NCT02130206|Other|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
75884092|NCT02815267|Drug|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
75884093|NCT02815267|Drug|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
75884094|NCT02130440|Drug|Resveratrol nasal spray|
75441215|NCT01631539|Device|DC Bead™|chemoembolization with DC Bead™ loaded with Irinotecan
75734678|NCT04178915|Diagnostic Test|The cholesterol content of the cell membrane of T-cells and monocytes|The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
75734679|NCT04174963|Behavioral|eToke + TPsy|Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
75734680|NCT04167748|Procedure|Preimplantation genetic testing for aneuploidy (PGT-A)|24-chromosome screening for aneuploidy in the preimplantation embryo (blastocyst stage)
75884095|NCT02138552|Drug|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
75884096|NCT02138552|Drug|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
75884097|NCT02930837|Drug|alteplase|
75884098|NCT02138708|Other|Pharmacological test of pulmonary endothelial|
76055763|NCT05887115|Behavioral|Nurse Family Partnership|During NFP visits, the nurse: 1) engages in a therapeutic nurse-client relationship focused on promoting client abilities and behavior change to protect and promote her own health and child's health; 2) provides service coordination based on client's identified needs, referring to available community services; 3) follows NFP Visit Guidelines tailoring them to the strengths and challenges of each family; 4) works with client to support a healthy pregnancy by recognizing and reducing risk factors and promoting prenatal health care, healthy diet, exercise, and stress management; and 5) gathers data on program implementation and maternal and child health. The visits include content from six domains: personal health, environmental health, life-course, maternal role, family and friends, and health and human services. Nurses use educational materials to address the content from the six domains with their clients.
75441216|NCT01631539|Drug|Cetuximab|400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly
76055764|NCT05887089|Other|drone transport|additional transport of samples at room temperature by drone (departure from the CHU Amiens-Picardie, 1 hour flight in the CHU Amiens-Picardie air perimeter, return to the CHU Amiens-Picardie)
76055765|NCT05887063|Other|Dementia Awareness Course UK|An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
76055766|NCT05887024|Device|Radial Extracorporeal Shock wave Therapy|Shock wave therapy: (BECO) S/N 16B011375
76055767|NCT05887024|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|EME (Therapic 9400) TENS
76055768|NCT05887024|Procedure|McKenzie Back exercises|Graduated Progressive back exercise program.
76055769|NCT05887024|Device|electric heating pads|electrical conducting heat pack.
76055770|NCT05886998|Drug|Heparin|Heparin sodium (Generic, 5000 IU/ml ampoules)
75441217|NCT01631539|Drug|5 FU|every 2 weeks IV
75441218|NCT01631539|Drug|Irinotecan|every 4 weeks chemoembolization
75441219|NCT01631565|Behavioral|Early allocation to palliative care|Symptoms management (e.g. Pain, nausea, dehydration management).
75441220|NCT01631565|Behavioral|Nutritional counseling|Nutritional status evaluation and dietary supplementation according to the patient requirements.
75441221|NCT01631565|Behavioral|Psychoeducation.|Patient and care-taker psychoeducation, depression and anxiety evaluation.
75734681|NCT04162418|Device|Temporary Spur Stent System|Treatment of qualifying infrapopliteal lesions with Temporary Spur Stent System and a commercially available, limus-base drug-coated balloon
75734682|NCT04160013|Behavioral|Discipline education|Discipline education using the Play Nicely program.
75734683|NCT04160013|Behavioral|Cavity Prevention|Cavity prevention using a 2 page handout.
75884099|NCT03633175|Drug|Vaginal progesterone|400 mg vaginal progesterone [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
75441222|NCT01631578|Procedure|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
75884100|NCT02138864|Radiation|18F-FP-(+)-DTBZ|no available
75884101|NCT01362647|Procedure|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
75441223|NCT01631604|Device|Walking aids and devices|Walking aids, e.g. braces, canes,orthoses, prosthetics, etc.
75884102|NCT01362647|Procedure|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
75441224|NCT01631604|Drug|Muscle/nerve injection|Injection to muscle or nerve
75884103|NCT02539693|Drug|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
76055771|NCT05886998|Other|Normal Saline|0.9% sodium chloride solution (normal saline)
76055772|NCT05886959|Other|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
75441225|NCT01631604|Procedure|Corrective surgery|correction of spinal and bony deformities, muscle transfer, tendon elongation etc.
75441226|NCT01631604|Other|Physical therapy treatment|
75441227|NCT01631643|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
75441228|NCT01631669|Drug|Celecoxib|200 mg Q 12 hours orally
75441229|NCT01631708|Procedure|Erythrocytapheresis|"To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.~An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to ~100 ug/L in accordance with current guidelines."
75441230|NCT01631708|Procedure|Plasmapheresis|An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
75441231|NCT01631760|Genetic|no intervention|We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
75591795|NCT03112200|Procedure|Subchondroplasty with Arthroscopy|The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
75734684|NCT04157335|Biological|Benralizumab 30 mg|"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
75734685|NCT04157335|Biological|Matched placebo|"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
75441232|NCT01631773|Genetic|microRNA|Biological samples will be taken from subjects w/ Nasal polyps & AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
75884104|NCT02539693|Drug|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
76055773|NCT05886959|Other|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
75441233|NCT01631799|Device|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
75591796|NCT03112200|Procedure|Arthroscopy Alone|An endoscopic examination, therapy and surgery of the knee joint.
75734686|NCT04157127|Biological|Autologous DC vaccine|Autologous DC vaccine given as 3 doses every 14 days. Dosage is cohort-dependent.
75591797|NCT03103139|Procedure|Transpapillary Stent|ERCP with placement of short stent
75734687|NCT04146493|Diagnostic Test|Blood samples for Heparin-binding protein measurement|Blood samples before and after given heparin
75734688|NCT04145531|Drug|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 & 2
75884105|NCT02539693|Drug|Lidocaine|3 ml lidocaine 1% is injected at each block site
75884106|NCT02539693|Procedure|Pilonidal sinus|Removal of pilonidal sinus
75734689|NCT04145531|Drug|IV JZP-458|IV JZP-458 will be administered in Part B
75734690|NCT04143295|Drug|Diiodothyropropionic acid|Drug Administration
75591798|NCT03103139|Procedure|Stent across bile leak|ERCP with long stent
75734691|NCT04133116|Drug|LY3471851|Administered SC
76055774|NCT05886959|Other|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
76055775|NCT05886959|Other|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
75591799|NCT03100487|Device|Apple iPod Shuffle|One session at least 5 days a week for a total of 8 weeks
75591800|NCT03067571|Biological|Daratumumab|Given IV
75591801|NCT03061201|Biological|SB-525 (PF-07055480)|Single dose of investigational product SB-525 (PF-07055480)
75734692|NCT04133116|Drug|Placebo|Administered SC
75884107|NCT02138942|Device|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
75884108|NCT01362725|Device|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
75884109|NCT05062135|Drug|Progesterone 400 Mg Vaginal Suppository on PCOS|The same drug will be used in control group
75591802|NCT03060096|Other|Severe Anxiety/depression: High Intensity Stepped Care|The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.
75591803|NCT03060096|Other|Moderate Anxiety/depression: Low Intensity Stepped care|The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.
75734693|NCT04124692|Device|Sculptra Aesthetic new dilution|Treatment of cheek wrinkles
75884110|NCT02130518|Drug|Auriclosene Irrigation Solution, 0.2%|
75734694|NCT04123795|Drug|Certolizumab pegol|"Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Other Names:~Cimzia~CDP870~CZP"
75734695|NCT04123795|Drug|Placebo|"Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Other Names:~-PBO"
75734696|NCT04119986|Device|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds.
75734697|NCT04119986|Device|drug eluted stent|with regular techniques
75884111|NCT02130518|Drug|Auriclosene Vehicle Solution|
75884112|NCT01355783|Drug|E7777|Treatment in both arms is for 6 cycles at 21 days/cycle.
75734698|NCT04119687|Biological|FX201|FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
76055776|NCT05886959|Other|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
75884113|NCT05061667|Procedure|Thoracic Paravertebral Block|Paravertebral block for postoperative analgesia in thoracic surgery
75884114|NCT05061667|Procedure|Rhomboid Block|Rhomboid block for postoperative analgesia in thoracic surgery
76055777|NCT05886959|Other|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
76055778|NCT05886959|Other|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
76055779|NCT05886959|Other|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
75441234|NCT01631799|Device|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
75441235|NCT01631838|Dietary Supplement|Tocotrienol-rich fraction 400mg|Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
75441236|NCT01631838|Dietary Supplement|Placebo|Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
75441237|NCT01631877|Drug|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
75441238|NCT01631877|Other|placebo|injection placebo will be given for 5 days along with placebo tablets
76055780|NCT05886946|Other|ABG|ABG
76055781|NCT05886933|Drug|Fexuprazan Hydrochloride|Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet)
76055782|NCT05886829|Combination Product|Chlorpheniramine Maleate 0.4% Nasal Spray|Chlorpheniramine Maleate 0.4% Nasal Spray
75591804|NCT03060096|Other|Enhanced Usual Care Control|"Participants with moderate to severe anxiety/depression that are randomized to Enhanced Usual Care Control (EUC) will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study."
75591805|NCT03052985|Procedure|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
75591806|NCT06081101|Drug|Methylprednisolone Injection|Medication will be injected into SI joint under ultrasound guidance
75591807|NCT06081101|Drug|Ketorolac Injection|Medication will be injected into SI joint under ultrasound guidance
75591808|NCT06081075|Other|Genetic testing|Rapid whole genome sequencing
75591809|NCT06081062|Biological|Fabagal® (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
75591810|NCT06081062|Drug|Active comparator (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
75591811|NCT06081036|Other|Questionnaire|Questionnaire about children development
75591812|NCT06081023|Behavioral|Psycho-educational weight reduction program|This program provides behavioral technique in order to minimize level of emotional eating and level of obesity
75734699|NCT04106128|Diagnostic Test|ultrasound examination|Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
75734700|NCT04104854|Device|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds
75884115|NCT02134106|Drug|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
75591813|NCT06081010|Behavioral|Community Health Worker Intervention|After receiving the training, Community Health Workers (CHW) will conduct home visits using a locally adapted CHW's manual for hypertension management. They will visit households in their catchment area and measure BP. Each CHW will take the high BP clients (>=140/90) to the nearest health center. They will enlist the individuals with preHTN and HTN and conduct three follow-up visits to these participants, every four months. In the first visit (tentative 90 minutes), CHWs will explain the purpose of the home visit and discuss HTN and its consequences. CHWs will apply inductive questioning techniques to initiate dialogue and reflection regarding lifestyle modifications and choose lifestyle goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent visits (approximately 60 minutes), the CHWs will measure BP and address ongoing problems.
75884116|NCT02134106|Drug|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
75884117|NCT01354301|Drug|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
75884118|NCT01354301|Drug|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
75884119|NCT01354301|Drug|Basiliximabe|days 0 and 4, according to the package insert instructions.
75884120|NCT01354301|Drug|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
75884121|NCT01354301|Drug|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
76055783|NCT05886829|Combination Product|Placebo|Placebo nasal spray
75884122|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
75884123|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
76055784|NCT05886803|Other|Spontaneous ventilation test|The purpose is to mimic ventilation conditions after extubation and thus to help the clinician predict the outcome of an extubation decision.
76055785|NCT05886790|Biological|Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation|Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively
76055786|NCT05886790|Biological|Bivalent COVID-19 mRNA Vaccine|Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively
75591814|NCT06080984|Drug|Oncolytic Virus SDJ001|"Patients in the study receive intratumoral treatment with SDJ001 at two dose levels: 5x10^11 and 1x10^12 pfu per person. At the current dose levels, intratumoral injection is administered on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects.~Ultrasound-guided injection may be used when necessary (2.0 mL for tumors with a diameter >2.5 cm, 1.0 mL for diameters of 1.5-2.5 cm, 0.5 mL for diameters of 0.5-1.5 cm, and 0.1 mL for diameters <0.5 cm, with a maximum of 4 mL)."
75591815|NCT06080984|Drug|Oncolytic Virus YD06-1|Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10^6 pfu/mL to 10^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
75884124|NCT02134262|Drug|Cyclophosphamide or Bendamustine|Cyclophosphamide [1.5 g/m^2 x 1 day Intravenous (IV)] or Bendamustine [120 mg/m^2 x 2 days Intravenous (IV)] is administered as Pre-treatment medication of CD19-CAR-T.
75591816|NCT06080945|Other|pharmacist-led patient-centered medication therapy management|The intervention group will receive a pharmacist-driven discharge counseling on budesonide, an inhaled glucocorticoid, from recruitment, until 12 months.
75591817|NCT06080932|Other|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
75884125|NCT02134262|Genetic|Dose Level -1|CD19-CAR-T [1 x 10^5 cells/kg x 1 day and 2 x 10^5 cells/kg x 1 day Intravenous (IV)] are administered.
76055787|NCT05886790|Biological|Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation|Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type
75591818|NCT06080932|Other|NIH Toolbox|IPAD-based assessments that examines cognitive function
75591819|NCT06080932|Other|gradCPT|The gradCPT contains grayscale photographs of mountain scenes and city scenes. Scene images gradually transition from one image to the next
75591820|NCT06080932|Other|Resting-state fMRI|Whole brain echo-planar imaging (EPI) volumes sensitive to the BOLD signal will be acquired. Images will be re-aligned, un-warped, and normalized. Confounding effects of white matter, CSF signal, and head motion will be regressed from the functional time series, followed by bandpass filtering, linear detrending and smoothing, and whole brain resting state networks will be identified (e.g., default mode network, salience network, etc).
76055788|NCT05886751|Other|Black Doctor Screening Video|Participants will view an online video with a Black doctor speaking about prostate cancer screening.
76055789|NCT05886751|Other|White Doctor Screening Video|Participants will view an online video with a White doctor speaking about prostate cancer screening.
76055790|NCT05886751|Other|Black Patient Screening Video|Participants will view an online video with a Black patient speaking about prostate cancer screening.
76055791|NCT05886751|Other|White Patient Screening Video|Participants will view an online video with a White patient speaking about prostate cancer screening.
76055792|NCT05886751|Other|Black Doctor Clinical Trials Video|Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.
76055793|NCT05886751|Other|White Doctor Clinical Trials Video|Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.
76055794|NCT05886751|Other|Black Patient Clinical Trials Video|Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.
75591821|NCT06080932|Other|Task-fMRI|During whole brain EPI data acquisition, participants will be presented with words and pictures and asked to make judgements about the stimuli, such as indicating whether a particular stimulus (e.g., face-name association, word, number, or letter) has been previously presented, if a presented stimulus is a city or mountain scene, the direction an arrow is pointing (left or right), if a pair of stimuli match (e.g., faces with neutral or emotional expressions; word with a face). Behavioral responses will be recorded with an MRI compatible button box.
75884126|NCT02134262|Genetic|Dose Level 1|CD19-CAR-T [1/3 x 10^6 cells/kg x 1 day and 2/3 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
75884127|NCT02134262|Genetic|Dose Level 2|CD19-CAR-T [1 x 10^6 cells/kg x 1 day and 2 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
75884128|NCT02134262|Genetic|Dose Level 3|CD19-CAR-T [1/3 x 10^7 cells/kg x 1 day and 2/3 x 10^7 cells/kg x 1 day Intravenous (IV)] are administered.
75884129|NCT01355861|Behavioral|Negative work exercise|Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
76055795|NCT05886751|Other|White Patient Clinical Trials Video|Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
76055796|NCT05886738|Other|Fasting|Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.
76055797|NCT05886725|Other|Patients using Step Test Application and Accelerometer|Patients who are scheduled to have surgery at University of Chicago Medical Center (UCMC) who agree to use the step test application and study accelerometer before and after their surgery.
76055798|NCT05886699|Other|PRP combined with DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
75591822|NCT06080932|Other|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at ~2- week intervals during the study. The sensor will be removed at the end of the final test day.
75591823|NCT06080932|Biological|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
75884130|NCT01343277|Drug|Trabectedin|Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
75884131|NCT01343277|Drug|Dacarbazine|Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
75884132|NCT02130596|Behavioral|Acceptance-Based Behavioral Intervention|
76055799|NCT05886699|Other|DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
76055800|NCT05886660|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel.
75884133|NCT02130596|Other|Nutritional Counselling|
76055801|NCT05886660|Drug|Placebo Nasal Gel|Subjects will self-administer Placebo Nasal Gel.
76055802|NCT05886660|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
75591824|NCT06080932|Other|Sleep Monitoring|Sleep will be assessed by ring-based acceleration with cloud technology (Oura Ring). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands. Worn daily throughout intervention
75591825|NCT06080932|Biological|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
75591826|NCT06080932|Other|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
75591827|NCT06080932|Behavioral|PHQ-9|It is a self-assessment tool used to screen and assess the severity of depression in individuals. The PHQ-9 consists of nine questions based on the nine criteria for diagnosing major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
75591828|NCT06080932|Behavioral|WHO-5|The WHO-5, also known as the World Health Organization-Five Well-Being Index, is a self-assessment tool used to measure subjective well-being and mental health. It was developed by the World Health Organization (WHO) as a brief and reliable instrument to evaluate well-being in clinical and research settings.
75734701|NCT04103970|Behavioral|Graded Activity and Pain Education (GAPE)|"GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement."
75884134|NCT02130674|Drug|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
75884135|NCT04856293|Drug|Crizotinib|A single 250 mg crizotinib dose of the FC formulation
75884136|NCT04856293|Drug|Crizotinib|A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
75884137|NCT04856293|Drug|Crizotinib|A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
75884138|NCT03135899|Drug|BI 443651|Three doses, each 12 hours apart
75884139|NCT03135899|Drug|Placebo|Three doses, each 12 hours apart
75884140|NCT02253212|Device|SonoCloud|SonoCloud : dose escalation
76055803|NCT05886660|Drug|Placebo Nasal Gel|"Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject."
76055804|NCT05886647|Other|Active non-invasive stimulation and inspiratory muscle training|Simultaneously with the current application, the patient will perform inspiratory muscle training (IMT) by KH2; PowerBreathe International Ltd. UK along with a feedback Breathelink, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI.
76055805|NCT05886647|Other|Sham compatorator and inspiratory muscle training|As for the patients allocated in the control group, they will receive the HD-tDCS sham for 20 minutes associated with IMT, following for the same training, duration and load increment used in the experimental group.
75884141|NCT02253212|Drug|Carboplatin|Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
75884142|NCT01355939|Procedure|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
75884143|NCT01356017|Drug|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
75884144|NCT01356017|Drug|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
75591829|NCT06080932|Behavioral|SKID|The SKID refers to the Structured Clinical Interview for DSM Disorders (SCID). It is a widely used diagnostic tool in the field of psychiatry and clinical psychology. The SCID is a semi-structured interview designed to assess and diagnose various mental disorders according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), which is published by the American Psychiatric Association.
75734702|NCT04096664|Device|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
75734703|NCT04092894|Drug|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
75734704|NCT04092894|Drug|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
75734705|NCT04088292|Drug|Alteplase 20 Mg Powder for Solution for Injection Vial|Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
75734706|NCT04088292|Device|Ultrasound assisted Thrombolysis|Ultrasound assisted thrombolysis (USAT)
75734707|NCT04083495|Biological|ATLCAR.CD30 T cells|Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10^8 CAR-T/m^2 with a maximum dose of 5 × 10^8 CAR-T cells
75734708|NCT04083495|Drug|Bendamustine|70 mg/m^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
75884145|NCT05220332|Behavioral|Heart to Heart|The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.
75884146|NCT05220332|Behavioral|Money Smart|The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
75441239|NCT01631890|Procedure|Endoscopic Ultrasound assisted endoscopic glue injection|N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
75441240|NCT01631890|Procedure|Standard Endotherapy|Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
75591830|NCT06080880|Drug|Ondansetron every 3 weeks|Ondansetron, Po, 24mg/d, 3 days' application every 3 weeks
75734709|NCT04083495|Drug|Fludarabine|30 mg/m^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
75734710|NCT04083495|Drug|Cyclophosphamide|300 mg/m^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
75734711|NCT04080063|Other|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
75734712|NCT04074642|Procedure|Neurosurgery|adenoma removal
76055806|NCT05886608|Device|AI 500™ SINGLE-DOSE GEL|AI500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, intended to provide relief in cases of pain due to tension in muscles and adjacent tissues, to improve movement and function.
76055807|NCT05886569|Device|DIGIPREDICT Physiopatech|Application of the DIGIPREDICT Physiopatch investigational device
75591831|NCT06080880|Drug|Aprepitant|aprepitant, Po, 125mg/d, 1day' application every 3 weeks
75591832|NCT06080880|Drug|Dexamethasone|dexamethasone, iv, 10mg/d, 1day' application every 3 weeks
75591833|NCT06080880|Drug|Ondansetron weekly|Ondansetron, Po, 24mg/d, 3 days' application weekly
75591834|NCT06080854|Drug|Toripalimab|Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks
75591835|NCT06080854|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered intravenously on Days 1 & 8 of every 3 weeks
75591836|NCT06080854|Drug|Nab paclitaxel|Nab paclitaxel 125 mg/m^2 administered intravenously on Days 1 & 8 of every 3 weeks.
75734713|NCT04066946|Device|Microcurrent therapy|Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.
76055808|NCT05886543|Behavioral|Conventional chest physical therapy|Conventional chest physical therapy: The patients performed four series of five breath with 3 seconds of sustained breathing interspersed with periods of quite breathing followed by two or three coughs or huffs (with wound support by a pillow or his/her hands), twice a day in the first two postburned days and once a day from the third to the tenth days.
75591837|NCT06080854|Other|SBRT|SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy*10 fractions, Planning target volume (PTV) 3Gy*10 fractions
75734714|NCT04066946|Other|Standard of care|"Standard of Care consists of:~During the first two weeks:~Histoacryl glue to close the surgical incisions.~Suture strips to keep the wound closed.~Isobetadine Dermicum as anti-septic treatment~Dry wound dressings during the first 2 weeks.~Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet."
75884149|NCT02134340|Drug|[I-124]-CPD-1028 Injection|A single intravenous dose of [I-124]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
75884150|NCT02134340|Biological|CPD-1061|[Optional] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of [I-124]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
75884151|NCT04723615|Other|Orebro Musculoskeletal Screening Questionnaire-12|It is a 12-item self-report questionnaire that aims to estimate the severity of the problem, functional impairment, reporting status, cost and recovery time in musculoskeletal problems.
76055809|NCT05886543|Behavioral|Pilates exercise|The Pilates technique, which stretched laterally and to the back, stressed costal breathing, in which the ribs climb and drop throughout the ventilatory stream. The transverse muscle had to work harder to avoid abdominal distension, provide more support to the diaphragm to promote lower rib movement, and provide more diaphragmatic excursion, During the expiratory phase, the transversus abdominis, the multifidus and the pelvic floor musculature were contracted.
75591838|NCT06080841|Dietary Supplement|Curcumin|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.
75591839|NCT06080841|Dietary Supplement|Curcumin + Piperine|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.
76055810|NCT05886530|Other|No intervention|Observational data collection only.
75734715|NCT04066777|Procedure|alcohol septal ablation|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
75441241|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
75441242|NCT01631903|Drug|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
75441243|NCT01631903|Drug|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
75441244|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
75441245|NCT01631903|Drug|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
75441246|NCT01631916|Drug|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
75441247|NCT01631942|Drug|NNC172-2021|"Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation."
75441248|NCT01631955|Drug|Ciprobay|Ciprobay (250mg, bid, oral)
75591840|NCT06080815|Device|CAD/CAM Complete denture|four implant-supported CAD/CAM complete overdenture
75734716|NCT04059393|Other|Internet-Based Intervention|Complete web-based legacy intervention
75591841|NCT06080802|Drug|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily 1 gm daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner) during the rest of the follow-up. Patients will be followed up by telephone call 2 weeks intervals during the study period 5 SGL-2 will be prescribed to group 1 after diagnosis with HFpEF while group 2 will have SGL-2 and Metformin
75734717|NCT04059393|Other|Best Practice|Receive standard of care
75734718|NCT04059393|Other|Quality-of-Life Assessment|Ancillary studies
75734719|NCT04059393|Other|Questionnaire Administration|Ancillary studies
75884152|NCT04723615|Other|Visual Analog Scale|A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
75884153|NCT04723615|Other|The Tampa Scale of Kinesiophobia|The Tampa Scale of Kinesiophobia that was developed in 1990 is a 17 item scale originally developed to measure the fear of movement related to chronic lower back pain.
75884154|NCT04723615|Other|Short Form-12 (SF-12)|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
75884155|NCT01356095|Other|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
75441249|NCT01631968|Procedure|Cement without antibiotic.|
75591842|NCT06080789|Drug|RABI-767|125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
75591843|NCT06080776|Drug|SH-1028 tablets|The initial dose of SH-1028 tablets is 200 mg once daily.
75884156|NCT01356095|Other|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
75884157|NCT02134418|Behavioral|CBT of irony comprehension|Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
75441250|NCT01631968|Procedure|Cement with erytromycin and colistin.|
75591844|NCT06080776|Drug|Placebo SH-1028 tablets|Placebo SH-1028 tablets.
75441251|NCT01631981|Drug|PGL2001 + Primolut-Nor 5|"PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up."
75591845|NCT06080763|Procedure|Physical Therapy Management|Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.
75591846|NCT06080750|Genetic|Quantitative Real Time Polymerase chain reaction (qRT-PCR)|to study gene expression of NLRP3 inflammasome and IL-1B in blood
75591847|NCT06080750|Diagnostic Test|ELISA and colorimeter|IL-6 and total LDH
75734720|NCT04040530|Procedure|CT-guided cryoablation|Percutaneous computed tomography guided cryoablation with the patient in sedation or general anaesthesia.
75734721|NCT04040530|Procedure|Partial nephrectomy|Surgical removal of the renal cancer, leaving the healthy renal tissue. Surgery is either done laparoscopically, robot-assisted laparoscopically or as an open surgery. The patient is under general anaesthesia.
75734722|NCT04039750|Drug|antibiotic rinse with suction|antibiotic rinse with suction
75734723|NCT04039750|Procedure|suction only|no irrigation, suction only
75734724|NCT04038840|Drug|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
75734725|NCT04038840|Device|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
75734726|NCT04035486|Drug|Osimertinib|"Drug: Osimertinib (Oral)~Other Names:~AZD9291"
75734727|NCT04035486|Drug|Pemetrexed/Carboplatin|Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
75441252|NCT01631981|Drug|Placebo + Primolut-Nor 5|"Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up."
75441253|NCT01631994|Drug|metoclopramide|1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
75441254|NCT01632046|Drug|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
75734728|NCT04035486|Drug|Pemetrexed/Cisplatin|Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
75734729|NCT04029883|Behavioral|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
75734730|NCT04029883|Behavioral|Behavior Economic Incentive|In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.
75734731|NCT04029883|Behavioral|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
75734732|NCT04028596|Drug|Paracetamol|once, 1000mg, 2 h before ECT session
75884158|NCT04712305|Other|No intervention required|No intervention required
75441255|NCT01632072|Dietary Supplement|Nutritional support|Nutritional support and counseling
75441256|NCT01632085|Device|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|"Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.~Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R."
75591848|NCT06080724|Drug|Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone|already described
75591849|NCT06080711|Other|AI assistance|Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
75591850|NCT06080685|Behavioral|Character Strengths Intervention|Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Gratitude Letter + Fresh Look Meditation Session 4. Open Your Character Strength Doors Each session will consist of 30-40 minutes, which will be delivered once a week for 4 weeks. Moreover, participants will be given homework which they will practice the rest of the week.
75591851|NCT06080620|Procedure|Modified radical mastectomy for breast cancer|Modified radical mastectomy for breast cancer
75591852|NCT06080620|Procedure|neoadjuvant therapy|"neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）"
75591853|NCT06080620|Procedure|Systematic treatment|"chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）"
75591854|NCT06080490|Drug|TAC C/D ratio|Pharmacokinetics of TAC according to possible influencing factors
75591855|NCT06080438|Drug|Botulinum toxin|15 units of botulinum toxin administered one time to the eye via eye drops
75591856|NCT06080438|Other|Saline solution|1 cc of saline solution eye drops administered one time to the eye via eye drops
75591857|NCT06080386|Diagnostic Test|UDFF|quantification of liver fat: UDFF (lipid fraction derived from ultrasound) from one of the probes of an ultrasound system
75591858|NCT06080373|Behavioral|PROBECO|"Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.~German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention."
75591859|NCT06080373|Behavioral|Formulation-based cognitive behavioral therapy|"The CBT program includes these core modules:~A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.~B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.~C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.~D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges."
75591860|NCT06080334|Device|Dry needling|Dry needling using the Hong technique on the most hyperalgesic trigger point in the gastrocnemius muscle.
75591861|NCT06080334|Device|Electrolysis|Electrolysis on the Achilles tendon using ultrasound-guided technique.
75734733|NCT04028596|Drug|Nimotop|once, 60mg, 2 h before ECT session
75734734|NCT04018066|Dietary Supplement|GP-SPI|grape polyphenol-soy protein isolate complex (GP-SPI)
75734735|NCT04012645|Procedure|application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used to evaluate the anastomotic flood perfusion during the operation; The operator may decide whether to change the surgical programme based on the outcome of the evaluation.
75441257|NCT01632111|Other|Lung function measurement|Spirometry
75441258|NCT01632124|Other|Lung function measurement|Spirometry and measurement of diffusing capacity for carbon monoxide
75441259|NCT01632163|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
75441260|NCT01632163|Drug|Placebo|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
75591862|NCT06080321|Other|WhatsApp reminders|"Patients will receive active oral hygiene reminders in the form of WhatsApp messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
75734736|NCT04012645|Procedure|Non-application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
75734737|NCT04009330|Diagnostic Test|POC Assay|"Interventions:~Blood Baseline - up to 40ml Day 3 - up to 40ml~Urine Baseline - 10ml Day 3 - 10ml~Study population:~Adults (18 plus) in ICU units diagnosed with ARDS."
75441261|NCT01632176|Behavioral|Brief, motivational interview and one booster session|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
75884159|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
76055811|NCT05886517|Device|Transfemoral transcatheter aortic valve implementation|ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide. The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve. Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
75441262|NCT01632189|Drug|Varenicline|Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
75441263|NCT01632293|Behavioral|progressive resistance training|The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
75441264|NCT01632319|Behavioral|Combined Motivational Interviewing and Cognitive Behavioral Therapy|"8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.~In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms"
75441265|NCT01632319|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
75441266|NCT01632332|Biological|HER-2/neu peptide vaccine|Given ID
75441267|NCT01632332|Other|laboratory biomarker analysis|Correlative studies
75591863|NCT06080321|Other|Instagram reminders|"Patients will receive active oral hygiene reminders in the form of Instagram messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
75734738|NCT04008485|Device|Magnetic Electric Impedance Spectroscopy Device to predict PTB|During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
75734739|NCT04006483|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
75441268|NCT01632358|Drug|TAP311 capsules|
75734740|NCT04006483|Drug|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
75734741|NCT04006483|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
75734742|NCT04003649|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given ITV/ITC
75884160|NCT02139098|Drug|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
75884161|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
75884162|NCT02139098|Drug|Placebo|Placebo
75441269|NCT01632358|Drug|Placebo|
75441270|NCT01632371|Device|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
75884163|NCT04498715|Procedure|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.
75591864|NCT06080321|Other|Phone calls|"Patients will receive active oral hygiene reminders in the form of phone calls one weekday each week. The structured phone call will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
75884164|NCT04498715|Drug|Zoledronic Acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
75884165|NCT04498715|Device|CERAMENT BONE VOID FILLER (BVF)|"CERAMENT™|BONE VOID FILLER is a synthetic, injectable, osteoconductive bone void filler. CERAMENT™I is biphasic, consisting of 60% calcium sulfate and 40% hydroxyapatite mixed with the radio-opacity enhancing component CERAMENT™|C-TRU (iohexol 300 mg iodine/ml), which allows bone in-growth after curing. The high injectability of CERAMENT™ allows transcortical administration and ensures good intraosseous spread. In this trial, CERAMENT BVF paste will be injected by a sterilized metal needle (2-3 mm diameter and 15 cm length) through the hollow dynamic hip screw."
75884166|NCT02130752|Device|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
75884167|NCT02130752|Device|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
75884168|NCT01362257|Drug|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
75884169|NCT01362257|Drug|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
75884170|NCT02487979|Drug|Glembatumumab Vedotin|Given IV
75591865|NCT06080321|Other|Application alerts|"Patients will download an app on their mobile phones which has cleaning tips, demonstrations and alerts. The structured message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
75884171|NCT02487979|Other|Laboratory Biomarker Analysis|Correlative studies
75591866|NCT06080308|Other|No intervention|No intervention
75734743|NCT04003649|Biological|Ipilimumab|Given IV
75734744|NCT04003649|Biological|Nivolumab|Given IV
75734745|NCT04003649|Other|Quality-of-Life Assessment|Ancillary studies
75884172|NCT02487979|Other|Pharmacological Study|Correlative studies
75884173|NCT02134496|Procedure|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
75884174|NCT01356173|Drug|GDC-0349|Oral escalating dose
75884175|NCT02130830|Drug|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
75884176|NCT02130830|Drug|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
75884177|NCT02279771|Procedure|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
75441271|NCT01632371|Device|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
75441272|NCT01632384|Behavioral|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
75441273|NCT01632397|Behavioral|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
75441274|NCT01632397|Behavioral|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
75734746|NCT04003649|Other|Questionnaire Administration|Ancillary studies
75734747|NCT04002141|Drug|Placebo oral tablet|1 tablet oral daily
75734748|NCT04002141|Drug|Letrozole|5mg oral daily
75734749|NCT03999710|Radiation|Radiation Therapy|Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
75734750|NCT03999710|Drug|Durvalumab|A dose of 1500mg (for patients >30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
75734751|NCT03991416|Behavioral|Understanding Your Baby|Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.
76055812|NCT05886504|Other|Community-based psychiatric intervention|intervention will take place in CBO offices instead of mental health department, medication will be given freely and psychiatric consultations will be free. Trained CBO members will provide individual and collective support including recall of appointments and tracing of those lost to follow-up, information on mental health, main psychiatric disorders, psychiatric medication, their potential side effects and expected benefits, contact with families and continuous support
76055813|NCT05886465|Drug|Atezolizumab|1200 mg, iv.drip, Q3W
75441275|NCT01632449|Drug|Test product|Dimethyl Fumarate (BG00012)
75441276|NCT01632449|Drug|Reference product|Dimethyl Fumarate (BG00012)
75591867|NCT06080269|Device|technology based intervention along with conventional therapy|Technology based intervention are training session given to the participants through devices which has software installed to train cognitive functions for patients with cognitive deficit.
75591868|NCT06080269|Other|conventional therapy alone|Participants in the control group will receive only conventional therapy
75591869|NCT06080256|Drug|Alirocumab|alirocumab (75 mg every 2 weeks)
75884178|NCT02279771|Procedure|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
76055814|NCT05886465|Drug|Bevacizumab|15mg/kg, iv.drip, Q3W
76055815|NCT05886465|Procedure|HAIC with FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries, Q3W
76055816|NCT05886439|Drug|LK101 injection (personlized neoantigen pulsed DC vaccine )|LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.
75591870|NCT06080256|Drug|Atorvastatin|Atorvastatin 20-40mg
75591871|NCT06080243|Biological|R21/Matrix-M1|10 µg of R21 and 50 µg of Matrix-M1
75591872|NCT06080243|Biological|Saline and R21/Matrix-M1|Saline and 10 µg of R21 and 50 µg of Matrix-M1
76055817|NCT05886439|Drug|Pembrolizumab|Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.
75441277|NCT01632462|Drug|VSL#3|"This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks."
75591873|NCT06080243|Other|Sterile isotonic (0.9%) normal saline|Saline
75591874|NCT06080230|Behavioral|Participants in the 8-week program|Psychological resilience program based on positive psychotherapy was applied to nurses
75591875|NCT06080152|Device|Mobility Tool|An A-Linker device will be given to 12 patients 3 months before their total knee arthroplasty
75591876|NCT06080100|Drug|Xenon|inhalation of xenon in a sub-narcotic dosage
75734752|NCT03991416|Behavioral|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
75884179|NCT02279771|Device|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
76055818|NCT05886439|Drug|Durvalumab|Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
76055819|NCT05886426|Diagnostic Test|4DCT wrist and standard CT wrist|Dynamic CT aquistion of wrist during movement and standard static wrist CT
75441278|NCT01632475|Biological|Pneumostem®|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10^7 cells/kg, High Dose Group (6 patients): 2 x 10^7 cells/kg~* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
75441279|NCT01632501|Device|Coronary stent - Tsunami|A coronary angioplasty was done
75591877|NCT06080100|Other|premedication hydroxyzine 25 mg|taking anxiolytic 30 minutes before surgery
75591878|NCT06080087|Behavioral|I-TEAM|I-TEAM is a web-based implementation toolkit that supports to enhance cultural responsiveness of EI providers in their EBP delivery with minoritized families of young autistic children
75591879|NCT06080074|Device|Cardiohelp device (VA-ECMO)|In children receiving the Cardiohelp device for severe heart failure, participants will be consented to a systematic data collection to describe the safety and effectiveness of the device in children.
75591880|NCT06080035|Other|Topical Cetyl Tranexamate Mesylate|Topical product will be applied onto clean skin morning and night.
75591881|NCT06079996|Other|CAFFEINE GUM|Observing the effect of chewing gum on the performance of female softball players.
75591882|NCT06079983|Drug|JSKN003|Administered intravenously according to protocol.
75591883|NCT06079983|Drug|Capecitabine tablets|Administered according to protocol, as one option for investigator's choice (determined before randomization).
75591884|NCT06079983|Drug|Gemcitabine hydrochloride for injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
75591885|NCT06079983|Drug|Vinorelbine tartrate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
75884180|NCT02139332|Behavioral|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
75734753|NCT03975660|Device|Pain Measurement Device|When participants request labor analgesia, the sensors of the pain measurement device (ROPA System [CereVu Medical, Inc. San Francisco, CA] and Edwards Foresight device) will be applied to the forehead and connected to the device. Data recording is then started.
75441280|NCT01632514|Drug|Cholecalciferol|100,000 U of cholecalciferol weekly for 4 weeks
75441281|NCT01632527|Drug|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
75441282|NCT01632540|Drug|Beclomethasone Dipropionate (BDP) Nasal Aerosol|BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
75591886|NCT06079983|Drug|Paclitaxel for injection (albumin-bound type)|Administered according to protocol, as one option for investigator's choice (determined before randomization).
75591887|NCT06079983|Drug|Docetaxel injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
75591888|NCT06079983|Drug|Eribulin mesylate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
75591889|NCT06079957|Procedure|Ergonomic training|"1. Individuals will be given a copy of ergonomic guidelines to follow which includes:~Organize workstation according to the primary , secondary and tertiary zones.~Place frequently used items within the reach of an arm.~Don't move head while reading documents instead raise or lower the eyes to read.~Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~Keep reference material upright at desk.~Avoid slouched postural habits, sit upright.~Adjust chair height in such a way that it shouldn't compress the thigh.~Arm rest should be at elbow flexion of 90 degrees.~Phone must be cradled between neck and shoulder to avoid forward head posture."
75591890|NCT06079957|Procedure|Neck Exercises|"Neck Exercises Strengthening exercises of Deep cervical flexors,rhomboids,lower Trapezius, Middle Trapezius, serratus anterior.~Neck Stretching of Suboccipitals,Sternocleidomastoid ,Scalenes,Upper trapezius, Levator scapulae,Pectoralis major and minor."
75591891|NCT06079944|Procedure|Progressive resistance training|"6RM Load will be determined after which multipulley system will be used for treatment and treatment will be divided in to two series of 8 repetition:~25%, 30%,35%,40%, 50% of 6RM over the period of 6 weeks~Speed of movement will be 2 seconds for both the eccentric and concentric phases.~To strengthen the shoulder muscles patients will perform flexion, extension, medial and lateral rotation using multipulley system."
75734754|NCT03970096|Radiation|Total-Body Irradiation|Undergo TBI
75734755|NCT03970096|Drug|Thiotepa|Given IV
75734756|NCT03970096|Drug|Fludarabine|Given IV
75734757|NCT03970096|Drug|Tacrolimus|Given IV
75734758|NCT03970096|Biological|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
75734759|NCT03970096|Drug|Methotrexate|Given IV
75591892|NCT06079944|Procedure|Traditional physical therapy|"TENS+ Hot pack~Pendulum exercises and stretching exercises"
75591893|NCT06079918|Dietary Supplement|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily from the time of randomization until delivery.
75591894|NCT06079918|Dietary Supplement|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
75734760|NCT03970096|Drug|Cyclophosphamide|Given IV
75591895|NCT06079918|Dietary Supplement|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
75591896|NCT06079905|Other|Nonoperative treatment|Nonoperative treatment
75884181|NCT02139332|Behavioral|Resource & Referral Group|The Resource & Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc…), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
75884182|NCT01360151|Drug|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
75441283|NCT01632592|Drug|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
75441284|NCT01632592|Drug|Placebo|placebo given by injection 2mg subcutaneously daily
75441285|NCT01632605|Drug|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
75441286|NCT01632618|Behavioral|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
75441287|NCT01632618|Behavioral|Passive control intervention|Passive physical therapy approach to low back pain
75441288|NCT01632670|Other|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
75441289|NCT01632696|Drug|I-124 PGN650 for PET/CT|I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
75441290|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|"ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2"
75591897|NCT06079905|Other|Operative treatment|Operative treatment
75591898|NCT06079892|Procedure|radiofrequency|haemorrhoidal removal using radiofrequency
75591899|NCT06079866|Device|Mask A (Oran Park Mask) then Mask B (Evora Mask)|Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days
75734761|NCT03970096|Biological|Peripheral Blood Stem Cell|Given IV
75734762|NCT03970096|Drug|Cyclosporine|Given IV
75734763|NCT03970096|Drug|Sirolimus|Given IV
75734764|NCT03970096|Drug|Busulfan|Given IV
75734765|NCT03970096|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
75734766|NCT03970096|Procedure|Echocardiography|Undergo ECHO
75734767|NCT03970096|Procedure|Multigated Acquisition Scan|Undergo MUGA
75734768|NCT03970096|Procedure|Biospecimen Collection|Undergo blood sample collection
75734769|NCT03964454|Behavioral|WIC support + home-based individual support + Breastfeeding Incentives (SC+BFI)|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives (Breastfeeding Incentives, BFI) contingent on observed breastfeeding.
75734770|NCT03964454|Behavioral|WIC support + home-based individual support (SC)|Participants randomized into SC will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
75884183|NCT02134652|Other|diagnostic bedside ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck."
75591900|NCT06079866|Device|Mask B (Evora Mask) then Mask A (Oran Park Mask)|Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.
75884184|NCT03633097|Other|Acupuncture and Usual care|patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
75884185|NCT03633097|Drug|Usual care|patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
75884186|NCT02139410|Procedure|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
75441291|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|"ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)"
75591901|NCT06079853|Behavioral|PureSomni Sleep Health Product Kit|PureSomni sleep health products offered: blue light blocking glasses, eye mask, nasal strips, white noise machine, lavender spray, herbal tea, ear plugs
75591902|NCT06079814|Other|virtual reality intervention|Patients will be shown content through the patient's virtual reality glasses throughout the cystoscopy procedure.
75591903|NCT06079788|Drug|Adrenocorticotrophic Hormone|"For patients in complete remission, ACTH is given at a prednisone dose of 1.5-2mg/kg qod or 0.75-1mg/kg qd. ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks.If stable, taper to 5mg qod (body surface area > 1.0m2) and 2.5mg qod (body surface area < 1.0m2) and maintain the dose until study completion."
75591904|NCT06079788|Drug|Steroid|For patients in complete remission, Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks. If stable, taper to 5mg qod (body surface area > 1.0m2) and 2.5mg qod (body surface area < 1.0m2) and maintain the dose until study completion.
75734771|NCT03957161|Other|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
75884187|NCT02139488|Other|Fiducial markers|
75441292|NCT01632748|Device|Neurotech Vital Device|5 minute treatment
75734772|NCT03944954|Drug|Marinol|Individuals will receive 0, 10, 30mg of Marinol.
75734773|NCT03944954|Device|Transcranial Magnetic Stimulation|Individuals will receive excitatory or inhibitory TMS
75734774|NCT03940313|Procedure|Prolotherapy|Musculoskeletal injection of lidocaine + 15% dextrose into damaged tissue
75884188|NCT02139488|Other|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
75884189|NCT03765320|Procedure|Peritoneal closure|Peritoneal closure after pelvic lymph node dissection for early gynecologic cancer
75441293|NCT01632748|Device|Modified Neurotech Vital Device|5 minute stimulation
75441294|NCT01632761|Dietary Supplement|Vitamin D3 .|
75441295|NCT01632761|Drug|omega-3 fatty acids (fish oil)|
75441296|NCT01632761|Dietary Supplement|Vitamin D3 placebo|
75441297|NCT01632761|Dietary Supplement|Fish oil placebo|
75884190|NCT03765320|Procedure|Retroperitoneal drainage|Retroperitoneal drainage after pelvic lymph node dissection for early gynecologic cancer
75441298|NCT01632787|Other|Questionnaires and Optometrist Prism Challenge/Treatment|A Vertical Heterophoria Symptom Questionnaire (VHSQ) as well as Headache Disability Index (HDI) survey is used on all Emergency Department (ED) headache patients to assess medical history and symptom burden. Prism testing (or Prism Challenge) is performed by the study optometrist to identify those who have Vertical Heterophoria (VH). Prism Challenge is similar to prescription eyeglass testing, but with unique lenses that are meant to reduce strain on eyes that are misaligned. Follow-up questionnaires are then administered to assess any improvement in symptom burden.
75441299|NCT01632826|Drug|Pomalidomide|4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation
75734775|NCT03932656|Behavioral|Combined schema-therapy and cognitive behavioral therapy|A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
75734776|NCT03932656|Drug|Psychopharmaceuticals|Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
75884191|NCT01363037|Drug|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
75884192|NCT01363037|Drug|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
75884193|NCT01363037|Other|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
75884194|NCT01363037|Drug|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
75884195|NCT02130908|Other|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
75591905|NCT06079762|Behavioral|AGE SELF CARE group visit program|"AGE SELF CARE: Adaptation, Growth, and Engagement; Socialization, Empowerment, Learning, and Function; and Community Activation for Resilience in Elderhood, is a virtual group visit program. It includes education and behavioral change elements in the broad areas of self/health, home environment, and community. There are 8 weekly 90-minute virtual sessions facilitated by an aging expert (e.g., geriatrician). Examples of topics include Aging Well: The Power of Movement, People Can Change, Homes Can Too, and Social World."
75884196|NCT02130908|Other|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
75441300|NCT01632852|Biological|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
75441301|NCT01632865|Device|stenting|Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
75591906|NCT06079749|Procedure|Simultaneous BTKA|Simultaneous BTKA
75591907|NCT06079749|Procedure|Staged BTKA|Staged BTKA
75884197|NCT02130908|Other|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
75884198|NCT01363115|Dietary Supplement|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
75884199|NCT01363115|Dietary Supplement|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
75884200|NCT01363115|Behavioral|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
75884201|NCT02134730|Behavioral|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
75734777|NCT03930199|Other|Needs-based intervention (physical, psychological, or both)|Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
76055820|NCT05886413|Other|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO application we will compare the recommended settings (for mechanical ventilation) vs the real clinician settings done by clinician after patient admission in ICU after cardiac surgery.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
76055821|NCT05886361|Other|No intervention involved|No intervention involved
76055822|NCT05886322|Diagnostic Test|patient reported outcome measures|MIAH, mHI, Manotiba IBD Index, p-HBI/SCCAI, IBD-control
76055823|NCT05886322|Diagnostic Test|fecal calprotectin|fecal calprotectin point-of-care test and laboratory test
75734778|NCT03927989|Behavioral|Text messaging plus nicotine replacement therapy|Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
75734779|NCT03927989|Other|Standard Care at Lung Cancer Screening|Brief advice to quit smoking prior to lung cancer screening
75734780|NCT03924219|Other|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
76055824|NCT05886322|Diagnostic Test|colonoscopy|endoscopic activity scores (SES-CD, UCEIS, MES)
75591908|NCT06079684|Device|Intermittent vacuum therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, level of education, occupation, environment, degree of functional deficit, body mass index and Kellgren-Lawrence classification.~Also, scores for the Knee Injury and Osteoarthritis Outcome Score, the Western Ontario and McMaster Universities Osteoarthritis Index, the Functional Independence measurement, the Fall Risk Score, and the Visual Analogue Scale were recorded at baseline and after 10 days.~A blinded expert used a 7-15 MHz linear probe to take ultrasonographic measurements of Baker Cyst at baseline and after 10 days."
75441302|NCT01632917|Drug|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
75441303|NCT01632917|Drug|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
75591909|NCT06079658|Behavioral|Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss|This intervention seeks to investigate two different caloric restriction protocol on fat mass.
75591910|NCT06079619|Other|Analysis of photos of pigmented tumours by the three groups|Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.
75441304|NCT01632943|Device|Symplicity renal denervation system|"Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.~A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator."
75734781|NCT03899805|Drug|Eribulin|The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
75884202|NCT01356329|Drug|Enoxaparin, Heparin|"Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician."
75591911|NCT06079606|Other|Antibiotic treatment|Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
75591912|NCT06079528|Device|Electromagnetic device|"Health wave's generator (Manufactured with Simeds S.r.l. by Machiavelli, Italy, with serial number 11492.) with two separate emission channels and asynchronous operation was employed, along with 100 saved and storable programs that could be altered by the user (intensity, frequency and phase time). The different associated applicators are recognized automatically. Magnetic field strength up to 100 Gauss and output frequency from (1 - 100) Hertz are programmable."
75591913|NCT06079528|Other|visceral manipulation therapy|for the pelvic reproductive organs and their related structures (ligaments and fasciae) was applied one session/week for 12 weeks. Each patient was was advised to evacuate her bladder before starting the treatment session, mobility and motility testing of pelvic organs, together with the assessment of fascial tension, was then performed, with detecting restrictions, treatment was applied according to Hebgen
75591914|NCT06079528|Other|General advice|were directed for both groups in term of the following: Perform pelvic floor exercises regularly ; avoid constipation and straining; treat the cause of any chronic cough and infection of urethra or bladder; stop smoking; maintain a healthy weight; drinking sufficient amounts of healthy fluids (water); decrease the caffeine intake; and decrease the amount of acidic and spicy foods.
75591915|NCT06079528|Other|pelvic floor muscle training|consisted of 24 sessions of 45-60 min each, twice a week, for 12 weeks. The PFMT was divided into four phases. Proprioceptive (3 weeks): where the woman has gained adequate perception of PFM and performed fast and slow contractions; Simple (3 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (3 week): where the exercise evolved into functional exercises of greater amplitude; and Power (3 week): where the maximum voluntary contraction of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and fast fibers
75591916|NCT06079515|Procedure|Suprascapular Nerve Block|SSNB group: The patients were asked to sit comfortably in the chair, and the transducer was placed on the spine of the scapula in the coronal plane and moved laterally to observe the supraspinatus notch and the suprascapular nerve. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle on the suprascapular nerve, under the fascia of the supraspinatus muscle.
75734782|NCT03899805|Drug|Pembrolizumab|The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
75734783|NCT03897491|Drug|5-aminolevulinic acid|5-aminolevulinic acid powder for oral solution
75884203|NCT05579522|Procedure|Fat graft injection|Fat graft injection in the interdental papilla.
75884204|NCT05579522|Procedure|Hyaluronic acid injection|Hyaluronic acid injection in the interdental papilla
75884205|NCT04579939|Diagnostic Test|Candy Glucose Tolerance Test|Participants will use a popular dextrose candy alternative to help assess glycemic response.
75884206|NCT02139566|Behavioral|Video consent (high-tech)|Consent provided by an animated video with captions
75884207|NCT02139566|Behavioral|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
75884208|NCT02139566|Behavioral|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
75884209|NCT02139566|Behavioral|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
75441305|NCT01632969|Behavioral|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
75591917|NCT06079515|Procedure|Intraarticular Shoulder Injection|IAI group: The patients were asked to sit on the chair with their hands facing the opposite shoulder, and the transducer was placed slightly below the spina scapula. The humeral head was observed by moving laterally. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle entering the skin at a 45-degree angle and applied to the joint space
75591918|NCT06079489|Other|Brochure-Based Exercise Program|Simple posture exercises
75591919|NCT06079489|Other|Telerehabilitation-Based Structured Exercise Program|Progressive physical fitness and posture exercises
75591920|NCT06079463|Other|progressive relaxation exercise|"Step 1: Take a comfortable position (sitting or lying down) and wear comfortable, non-tightening clothes.~Step 2: Try to relax with eyes closed, without focusing on thoughts, by focusing on your own body muscles.~Step 3: Right and left, respectively, hands, arms (triceps muscle), chest, abdomen, hips, legs (thigh muscles), feet and toes, neck, shoulder (scapula muscles) and muscle groups on the face (around the eyes, chin) and eyebrow muscles) by concentrating on contracting and relaxing these muscles.~Step 4: Focusing on the muscle groups of the whole body, contracting and relaxing.~Step 5: Opening the eyes slowly, trying to feel the feeling of comfort in the body (Turkish Psychologists Association Progressive Relaxation Exercises)."
75591921|NCT06079450|Other|artificial intelligence based mobile application|Artificial intelligence-based mobile application developed by me that includes diabetes education for individuals with diabetes.
75884210|NCT02139566|Behavioral|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
75441306|NCT01632982|Behavioral|standard treatment|the standard drug counseling offered to patients at the study site's methadone maintenance program
75441307|NCT01632982|Behavioral|MTS (Mobile Therapeutic System)|a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
75441308|NCT01632982|Behavioral|mobile control|a mobile phone-based application that directs participants to the NIDA website's homepage
75734784|NCT03897127|Drug|Cytarabine|"Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~Patients age 18-60 years~o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~Patients age >60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3"
75734785|NCT03897127|Drug|Daunorubicin|Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3
75734786|NCT03897127|Drug|CPX-351|"Induction 1:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3,5~Induction 2:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine [65 U/m²] i.v. (90 min) d1,3"
75884211|NCT05188079|Dietary Supplement|Beetroot juice|high nitrate supplement
75884212|NCT05188079|Dietary Supplement|Placebo drink|placebo
75884213|NCT04579549|Device|Saliva Assay|saliva assay test for high concentrations of SARS-CoV-2
75884214|NCT05188001|Other|Not an Interventional Study|Not an interventional Study
75441309|NCT01633008|Behavioral|ACT Workshop|The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
75441310|NCT01633047|Other|electrical stimulation|Intervention group that will be submitted to physical therapy exercises plus electrical stimulation (low frequency device with a current of 47 Hz with symmetrical, biphasic and pyramidal waveforms, with pulse duration of 1.5 s and interval of 1.8 s)
75591922|NCT06079437|Procedure|Cheer|Maximum isometric contraction was performed with cheering.
75591923|NCT06079437|Procedure|The cold pressure test|Maximum isometric contraction was performed with the cold pressure test.
75591924|NCT06079424|Other|high-precision carotid echo-tracking|evaluation of vascular aging parameters and baroreflex sensitivity
75734787|NCT03896425|Device|Transcranial direct current stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
75734788|NCT03895203|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
75734789|NCT03895203|Drug|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
75734790|NCT03895203|Other|Placebo|Subjects will receive placebo at pre-specified time-points.
75734791|NCT03892915|Combination Product|evidence-based depression treatment|We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
75734792|NCT03892200|Behavioral|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.
75734793|NCT03888404|Other|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
75734794|NCT03888404|Other|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
75734795|NCT03888404|Other|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
75734796|NCT03888404|Other|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
75734797|NCT03878628|Drug|Adipose tissue-derived mesenchymal stem cells|CSCC_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
75734798|NCT03871309|Device|Tigertriever|Mechanical Thrombectomy
75734799|NCT03868514|Device|TiLOOP® Bra Pocket|Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket
75734800|NCT03860142|Behavioral|Archet scale|Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
75734801|NCT03855007|Drug|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
75441311|NCT01633047|Other|physical therapy exercises|Control group that will be submitted only to physical therapy exercises
75591925|NCT06079411|Device|virtual reality non-embodied|the non-embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with passive navigation of 8 sessions of 30/40 minutes 3 times a week.
75441312|NCT01633073|Device|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
75734802|NCT03855007|Drug|MTX|MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
75734803|NCT03855007|Drug|HCQ|HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
75734804|NCT03855007|Drug|Pred|Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
75734805|NCT03854474|Procedure|Biospecimen Collection|Undergo collection of blood samples
75734806|NCT03854474|Procedure|Computed Tomography|Undergo CT
75734807|NCT03854474|Procedure|Magnetic Resonance Imaging|Undergo MRI
75734808|NCT03854474|Biological|Pembrolizumab|Given IV
75734809|NCT03854474|Drug|Tazemetostat|Given PO
75734810|NCT03847636|Device|CryoBalloon ablation|Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.
75734811|NCT03836287|Drug|Sofpironium Bromide Gel, 15%|Active
75734812|NCT03836287|Drug|Vehicle|Vehicle gel
75591926|NCT06079411|Device|virtual reality embodied|the embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with active navigation of 8 sessions of 30/40 minutes 3 times a week.
75591927|NCT06079411|Other|treatment as usual|"the treatment as usual (TAU; i.e., visuospatial paper and pencil stimulation) will consist of paper and pencil exercises"
75734813|NCT03828019|Biological|Adalimumab (ADA)|Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
75734814|NCT03828019|Drug|Conventional immunosuppression (CON)|The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
75734815|NCT03825458|Other|Blood sampling|Blood sampling at each clinical follow-up visit.
75734816|NCT03819322|Drug|sofosbuvir/velpatasvir|12 week, oral, fixed dose
75734817|NCT03817970|Drug|Granisetron|An antiemetic regimen containing granisetron 2 mg oral or IV.
75734818|NCT03817970|Drug|Ondansetron|An antiemetic regimen containing ondansetron 8 mg oral or IV.
75734819|NCT03817970|Drug|Palonosetron|An antiemetic regimen containing palonosetron 0.25 mg IV.
75734820|NCT03815812|Drug|IBI306|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
75734821|NCT03815812|Drug|placebo|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
75441313|NCT01633073|Device|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
75441314|NCT01633086|Drug|nitric oxide gel|"st gel: sodium nitrites,BID local use X 28 days~nd gel: maleic/ascorbic acids ,BID local use X 28 days"
75734822|NCT03815058|Biological|Autogene cevumeran|Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
75734823|NCT03815058|Drug|Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
75734824|NCT03814395|Other|No intervention|This is an observational study without any intervention
75734825|NCT03811249|Device|VisAbility™ Micro Insert|No (new) intervention will be administered during the course of this long term follow-up study. Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively.
75734826|NCT03810742|Drug|Nanoliposomal Irinotecan|Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
75734827|NCT03807531|Device|Temporary Spur Stent System|Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
75734828|NCT03790670|Drug|sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
75734829|NCT03786536|Device|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream.
75734830|NCT03783494|Drug|Target control infusion with propofol|Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
75591928|NCT06079346|Drug|OT-101|OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene
75591929|NCT06079346|Drug|FOLFIRINOX|Folinic acid, 5-FU, Irinotecan, Oxaliplatin
75591930|NCT06079333|Drug|dabrafenib/trametinib|braf/mek-inhibition
75441315|NCT01633086|Drug|placebo gel|placebo gel,BID local use X 28 days
75591931|NCT06079255|Device|IscAlert sensor(s) in patient with risk of acute compartment syndrome|of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)
75591932|NCT06079203|Behavioral|Emergency Care Redesign (ECR)|"Care Process Redesign: Care process redesign with a shared structured worksheet for data gathering, standardized assessment and referral. Education of all providers (Physician, Nurse, and Social Work Champion) on new processes at huddles and via on-line training, smart phone-compatible animated videos, faculty meetings, e-mail and from ED champions on shift~CDS System: Alerts and new workflow to refer the dyad to social work or care manager. Continued use throughout study period and beyond~Follow up: Within 72 hours of ED visit if discharged home Social Work Champion will have a single phone call. Triadic telephone encounter to ensure understanding of discharge plan, medication management and connection to community services"
75734831|NCT03774472|Drug|Hydroxychloroquine|Given PO
75734832|NCT03774472|Drug|Letrozole|Given PO
75734833|NCT03774472|Drug|Palbociclib|Given PO
75734834|NCT03764592|Other|radiofrequency ablation|Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
75734835|NCT03762291|Biological|CVD908ssb-TXSVN|"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."
75734836|NCT03753659|Drug|Pembrolizumab|IV infusion
75734837|NCT03753659|Procedure|Radio Frequency Ablation (RFA)|Local ablation via RFA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
75591933|NCT06079203|Behavioral|Nurse-led Telephonic Care (NLTC)|Telephonic support for dyad for safe ED to home care transition, and to enhance knowledge and management of AD/ADRD and co-morbid conditions. First call to dyad within 72 hours of index ED visit from Registered nurses. Each call ~30 minutes depending on needs and willingness of dyad. Calls also occur at 14 days, and at least monthly thereafter for 6 months. Dyad or nurse can initiate additional as-needed calls and coordinate care and care needs with other providers
75734838|NCT03753659|Procedure|Microwave Ablation (MWA)|Local ablation via MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
75734839|NCT03753659|Radiation|Brachytherapy|Local ablation via brachythwerapy will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
75734840|NCT03753659|Drug|Transarterial Chemoembolisation (TACE)|According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
75734841|NCT03720782|Device|LEGION Porous HA Tibial Baseplate and/or the LEGION Porous HA CR Femoral Component|LEGION Porous HA Tibial Baseplate (with and without holes) and/or the LEGION Porous HA CR Femoral Component
75734842|NCT03706417|Diagnostic Test|Telemedicine consult|Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.
75734843|NCT03705416|Procedure|Endoscopy|endoscopic suturing of stomach
75734844|NCT03705416|Procedure|Surgery|Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
75734845|NCT03700034|Other|mHealth Integrated Model of Antenatal Care|"In the intervention facilities, antenatal care (ANC) will be provided to all pregnant women using the mIRA electronic decision support system (EDSS) by ANMs (Auxiliary Nurse Midwife), Staff nurses, or Medical Officers (MOs). These frontline healthcare workers (FHWs) will be trained to use the EDSS and will also be provided refresher training on the guideline-recommended processes of ANC. This training will enable them to use the mIRA EDSS in the provision of ANC. Non-physician FHWs (ANMs and staff nurses) will screen, detect, and refer PIH, GDM, and severe anemia cases. They will not prescribe treatments, but will carry out all other duties including diagnosis, referral to the MO to prescribe drugs, provide lifestyle advice, follow-up, and subsequently support adherence to management plans."
75734846|NCT03679676|Drug|Omalizumab|Omalizumab is injected every 2 to 4 weeks
75734847|NCT03679676|Drug|Dupilumab|"Dupilumab is injected every 2 weeks~combination, or placebo."
75441316|NCT01633099|Drug|Decitabine|"Number of Cycles: 4 cycles.~Dose and drug delivery(decitabine):~The 1st cycle: 20 mg/m2, (iv,>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.~If bone marrow blast cells<5%, the following cycle:decitabine 20 mg/m2, (iv,>1h) on d1-5 of each 28 day cycle.~If Grade 4 neutropenia（<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,>1h, on d1-3 of each 28day cycle)."
75591934|NCT06079203|Behavioral|Community Paramedic-led Transitions Intervention (CPTI)|Community paramedics to provide coaching with dyad to improve medication management, outpatient follow up, understanding of red flags necessitating medical care. Home visit within ~5 days of index ED visit. One home visit and three telephone encounters over 30 days
75591935|NCT06079190|Drug|GSK4527226|GSK4527226 will be administered.
75591936|NCT06079190|Other|Placebo|Placebo will be administered.
75591937|NCT06079151|Device|Nasal high-flow|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary
75591938|NCT06079138|Device|Transcranial direct current stimulation (Active)|"Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application.~In the experimental group, participants will receive real tDCS at 2.0 mA for 20 minutes, with a 30-second ramp-up and ramp-down period."
75734848|NCT03679676|Other|Placebo|Placebo is injected every 2 to 4 weeks
75734849|NCT03678688|Drug|10 mg OPC-167832|Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
75734850|NCT03678688|Drug|30 mg OPC-167832|Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
75734851|NCT03678688|Drug|90 mg OPC-167832|Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
75734852|NCT03678688|Drug|3 mg OPC-167832|Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
75884215|NCT03549806|Diagnostic Test|No Intervention. Test is computer algorithm.|Diagnostic algorithms (test) will be run on already acquired clinical data. No study intervention in operator-prescribed clinical ablation. Predictive accuracy of test for study outcome will then be determined in follow-up
75884216|NCT01356485|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
75734853|NCT03678688|Drug|RHEZ|"RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight:~Participants weighing 30 to 37 kg received 2 tablets per day~Participants weighing 38 to 54 kg received 3 tablets per day~Participants weighing 55 to 70 kg received 4 tablets per day~Participants weighing > 70 kg received 5 tablets per day"
75441317|NCT01633125|Other|Group music therapy|The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
75591939|NCT06079138|Device|Transcranial direct current stimulation (Sham)|Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application. The sham group will receive sham tDCS, where the current will only be delivered for the first 30 seconds and automatically stopped, while the electrodes remain in place for 20 minutes.
75734854|NCT03678688|Drug|30 mg OPC-167832 + 300 mg delamanid|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.
75734855|NCT03678688|Drug|30 mg OPC-167832 + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
75734856|NCT03678688|Drug|30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
75734857|NCT03667196|Procedure|antegrade and retrograde approach|This study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO
75734858|NCT03666780|Device|LAmbre occluder|All patients are implanted with a LAmbre occluder device
75734859|NCT03666000|Genetic|PBCAR0191|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
75884217|NCT01356485|Drug|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
75884218|NCT01363193|Drug|Lean Body Weight-based heparin dose|"For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.~Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = [9270 x weight (kg)] / [6680+216 x BMI] Female = [9270 x weight (kg)] / [8780+244 x BMI]"
75884219|NCT03764930|Other|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
75884220|NCT02134808|Drug|Creatine|Creatine is a nutritional supplement.
75884221|NCT02134808|Drug|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
75884222|NCT01319279|Drug|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
76055825|NCT05886309|Diagnostic Test|Collection of Blood samples|"The following samples will be drawn from each study participant immediately after the venipuncture performed for the whole blood donation:~1 sample with no anticoagulant (5 ml) for SF measurement with the CDMS method~1 EDTA (Ethylendiamintetraazetat) sample (7,5 ml) for a complete blood count with red blood cell indices and reticulocytes~1 EDTA sample (2,7 ml) for the measurement of hepcidin~1 Li-Heparin-Gel sample (4.7 ml) for the measurement of SF with the ECLIA (Electrochemiluminescence-enzymeimmunoassay) and of the complete set of iron biomarkers (Transferrin Saturation, serum iron, Soluble Transferrin Receptor)~1 Li-Heparin-Gel sample (4.7 ml) for the measurement of CRP (C-reactive Protein)~1 sample with no anticoagulant (5 ml) for the measurement of SF with the CMIA (Chemiluminescence Immunoassay)~1 sample with no anticoagulant (5 ml) for storage"
75441318|NCT01633138|Behavioral|Cognitive Remediation Therapy - Standard|Computerized cognitive remediation therapy provided three times per week for four weeks
75441319|NCT01633138|Behavioral|Cognitive Remediation Therapy plus Contingency Management|Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
75441320|NCT01633164|Behavioral|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
75734860|NCT03666000|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
75734861|NCT03666000|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
75734862|NCT03665493|Drug|PD patients H&Y=1.5-2 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
75734863|NCT03665493|Drug|PD patients H&Y=1.5-2 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
75441321|NCT01633164|Other|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
75734864|NCT03665493|Behavioral|Healthy age-matched controls|Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
75734865|NCT03665493|Drug|PD patients H&Y=3 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
75734866|NCT03665493|Drug|PD patients H&Y=3 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
75441322|NCT01633203|Drug|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea."
75734867|NCT03660280|Dietary Supplement|Probiotics|Specific probiotic lactobacilli (added to stabilized ongoing treatment)
76055826|NCT05886257|Drug|Candonilimab|10mg/kg, iv.drip, every 3 week
75441323|NCT01633216|Biological|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
75441324|NCT01633216|Biological|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
76055827|NCT05886257|Drug|Bevacizumab|15mg/kg, iv.drip, every 3 week
76055828|NCT05886231|Other|music sound therapy|investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
75734868|NCT03660280|Other|Placebo|Placebo
75734869|NCT03648385|Drug|DHEA tablet|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.
75734870|NCT03648385|Other|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
75734871|NCT03641209|Drug|Paracetamol 10mg/mL infusion solution|Intravenous paracetamol solution for infusion
75734872|NCT03641209|Other|Placebo|Half physiological saline solution as the non-active placebo solution
75734873|NCT03637062|Drug|Progesterone|progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
75734874|NCT03637062|Device|pessary|pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.
76055829|NCT05886218|Device|Quantitative Neuromuscular Function Monitoring|Quantitative electromyographic (EMG) monitoring
76055830|NCT05886205|Drug|iPSC-Exos|iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
76055831|NCT05886192|Drug|norepinephrine+vasopressin|Norepinephrine combined with vasopressin to maintain blood pressure
76055832|NCT05886192|Drug|Norepinephrine|norepinephrine
76055833|NCT05886179|Other|cross-sectional study|analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.
75441325|NCT01633216|Biological|Monovalent OPV 2 week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
76055834|NCT05886166|Other|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
75441326|NCT01633216|Biological|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
75441327|NCT01633216|Biological|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
75441328|NCT01633229|Procedure|Bone Marrow Stromal Cell Infusion|
75441329|NCT01633255|Drug|18F-Fluciclatide|
75441330|NCT01633281|Procedure|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
75441331|NCT01633294|Drug|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
75441332|NCT01633307|Other|Education|Teaching program
75441333|NCT01633333|Other|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
75441334|NCT01633333|Other|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
75441335|NCT01633359|Drug|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
75441336|NCT01633359|Drug|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
75441337|NCT01633437|Drug|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
75441338|NCT01633437|Other|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
75441339|NCT01633450|Other|Zinc biofortified rice|1.12 mg zinc per meal
75441340|NCT01633450|Other|Rice extrinsically fortified with zinc|1.12 mg zinc per meal
75441341|NCT01633476|Drug|Valaciclovir|2g q.d.s. orally for 6 months (dose adjusted according to renal function)
75441342|NCT01633515|Procedure|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
75441343|NCT01633528|Drug|Asprin|100 mg
75734879|NCT03624036|Biological|brexucabtagene autoleucel|CAR-transduced autologous T cells administered intravenously
75734880|NCT03624036|Drug|Fludarabine|Administered intravenously
75734881|NCT03624036|Drug|Cyclophosphamide|Administered intravenously
75441344|NCT01633528|Drug|placebo|100mg
75441345|NCT01633567|Behavioral|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
75591940|NCT06079138|Other|Telerehabilitation exercise|Telerehabilitation exercise will be provided via tele-conference meeting program. The program will consist of 3 parts. First part, there will be a limb exercise program for 20 minutes to prepare the joint range of motion and muscles. Second part, participants will receive functional balance training for 15 minutes to promote their postural balance during changing positions and static positions. Each exercise will perform 10 repetitions for each set and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. Final part, participants will receive 20 minutes of functional training of wheelchair/bed transferring exercise. Each wheelchair and bed transfer exercise will perform 10 repetitions for each completely transfer and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. After finishing all the programs, they will be asked to cool down by doing breathing exercises with torso stretching for 5 minutes.
75591941|NCT06079125|Procedure|Posterior fossa decompression with duraplasty|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
75591942|NCT06079125|Procedure|PFDD with tonsillar resection/reduction|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. Then herniated tonsil will be manipulated and adhesion was released. After microsurgical manipulated, the dura is sewn closed with a dural graft.
75591943|NCT06079112|Drug|9MW2821|1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
75591944|NCT06079112|Drug|Toripalimab|240mg intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
76055835|NCT05886153|Device|Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
75591945|NCT06079086|Device|Breast Implants Lifesil|The surgery is performed through an incision (4 cm) in the inframammary fold and displacement in the supra-muscular plane, creation of a pocket for the inclusion of the prosthesis, followed by strict hemostasis and washing with an antibiotic solution. Placement of the prosthesis by digital maneuver and closure in layers using absorbable synthetic 4-0 polycaprolactone suture. Afterwards, an occlusive dressing is applied to the surgical wound. IV antibiotics (cephalosporin) 1g are administered at the beginning of surgery, followed by repeat/booster doses every 6 hours in the first 24 hours. Analgesic and anti-inflammatory medications are administered, varying according to each patient's restrictions.
75734882|NCT03621306|Device|DXA and pQCT precision testing|The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
75734883|NCT03618134|Biological|Durvalumab|Given IV
76055836|NCT05886127|Device|A novel hemostatic agent (Purastat®)|A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater
76055837|NCT05886101|Behavioral|Health Education|Health education will be provided to the intervention group on health literacy, self care, productivity improvement
76055838|NCT05886088|Drug|LID104|Experimental
76055839|NCT05886088|Drug|Dapagliflozin|Active comparator
76055840|NCT05886088|Drug|Linagliptin|Active comparator
75441346|NCT01633567|Behavioral|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
75441347|NCT01633580|Drug|corifollitropin alfa|long acting FSH
75441348|NCT01633593|Drug|Donepezil|5 mg PO a day, during 2 weeks
75441349|NCT01633632|Behavioral|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
75734884|NCT03618134|Procedure|Modified Radical Neck Dissection|Undergo modified radical neck dissection
75734885|NCT03618134|Other|Quality-of-Life Assessment|Ancillary studies
76055841|NCT05886075|Drug|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
75441350|NCT01633632|Behavioral|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
75441351|NCT01633645|Drug|Bortezomib|Velcade
75441352|NCT01633645|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
75441353|NCT01633645|Drug|Cisplatin|Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
75734886|NCT03618134|Other|Questionnaire Administration|Ancillary studies
75734887|NCT03618134|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75734888|NCT03618134|Procedure|Transoral Robotic Surgery|Undergo TORS
75734889|NCT03618134|Biological|Tremelimumab|Given IV
75734890|NCT03609944|Procedure|ERCP with miES|Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy
75884223|NCT02139722|Behavioral|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
75884224|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
75884225|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
75734891|NCT03609944|Procedure|EUS|Endoscopic ultrasound
75884226|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
76055842|NCT05886062|Other|Motor Imagery to Facilitate Sensorimotor Re-Learning Training|In order to motor imagery to facilitate sensorimotor re-learning training will be given for 20 minutes a day, 3 days a week, for a total of 8 weeks. Basketball-specific movement patterns will be used (squat, single leg jump, side stepping, standing on one leg, squat on one leg, etc.). Exercises will be started from easy and progressed to more advanced levels. During the exercise, the person will not only be physically active, but will be asked to dynamically visualize the determined scenario. Thus, a holistic exercise program will be applied both physically and psychologically.
76055843|NCT05886062|Other|Control Group|They will only continue their routine basketball technical-tactical training.
75591946|NCT06079073|Behavioral|Orofacial myofunctional therapy with autofeedback|Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.
75884227|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
76055844|NCT05886010|Device|prototypes 1 everyday|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75441354|NCT01633658|Dietary Supplement|cholecalciferol|a single dose of 2500 micrograms of cholecalciferol
75591947|NCT06079047|Procedure|group Dexamethasone|Adductor canal block with dexamethasone
75884228|NCT02134886|Drug|Erlotinib Hydrochloride|Given PO
75441355|NCT01633658|Dietary Supplement|25(OH)D|a single dose of 625 micrograms of 25(OH)D
75591948|NCT06079047|Procedure|group Controle|Adductor canal block with saline solution
75591949|NCT06079034|Procedure|Venovenous ECMO|Initial support type of venovenous ECMO via a dual-lumen on two-site VV ECMO cannulation strategy
75591950|NCT06079034|Procedure|Venoarterial ECMO|Initial support type of venoarterial ECMO
75591951|NCT06079008|Other|calcified cardiac valve|patients have cardiac cardiac valve before surgery
75441356|NCT01633697|Behavioral|Pranayama|Specific yoga-related breathing method.
75441357|NCT01633697|Behavioral|Education alone|No special attention to breathing
75441358|NCT01633723|Drug|DA-6886|"single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)~multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)"
75441359|NCT01633723|Drug|Placebo of DA-6886|DA-6886 placebo
75591952|NCT06078995|Drug|Tenecteplase|Thrombolysis wtih rhTNK-tPA
75591953|NCT06078995|Drug|Alteplase|Thrombolysis wtih rt-PA
75591954|NCT06078982|Drug|Disitamab Vedotin|2.0mg/kg, intravenously D1, once every 14 days (Q2W)
75591955|NCT06078982|Drug|Toripalimab|3.0 mg/kg, once every 14 days (Q2W)
75734892|NCT03607032|Device|Respin Pad|RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
75734893|NCT03607032|Other|usual treatment|medical aerosol session followed by aspiration or not, as required
75734894|NCT03602612|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
75734895|NCT03602612|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
75884229|NCT02134886|Other|Laboratory Biomarker Analysis|Correlative studies
75734896|NCT03602612|Biological|Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells|0.75x10^6 - 12.0X10^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
75734897|NCT03598244|Procedure|Biospecimen Collection|Undergo blood sample collection
75734898|NCT03598244|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
75884230|NCT02134886|Other|Pharmacological Study|Correlative studies
75884231|NCT02134886|Other|Quality-of-Life Assessment|Ancillary studies
75884232|NCT01360463|Behavioral|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
75884233|NCT01360463|Behavioral|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
75591956|NCT06078956|Device|Measuring of analytes|Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.
75884234|NCT02139956|Device|ultrasonography|open
75884235|NCT01360541|Procedure|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
75884236|NCT01360541|Other|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
75884237|NCT02253368|Other|sleep|
75884238|NCT03548870|Other|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
75884239|NCT03548870|Other|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
75884240|NCT01356563|Behavioral|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
75441360|NCT01633736|Other|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
75441361|NCT01633749|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
75591957|NCT06078943|Device|method comparison|to quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for all ctBil and FHbF in heparinized arterial and venous neonatal whole blood in syringe measuring mode (S65, SP65) and heparinized mixed venous/arterial whole blood samples in capillary measuring mode (C65)
75591958|NCT06078930|Diagnostic Test|Tongue imaging, tougue coating, saliva, and feces|Tongue images, coating, saliva, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.
75591959|NCT06078891|Biological|BCG vaccine|Three intra-dermal vaccinations over a period of one year.
75734899|NCT03598244|Drug|Savolitinib|Given PO
75734900|NCT03598244|Procedure|X-Ray Imaging|Undergo X-ray imaging
75734901|NCT03585010|Behavioral|Supportive Parenting for Anxious Childhood Emotions|12 sessions with parents
75734902|NCT03585010|Behavioral|Parent Educational Support|12 sessions with parents
75734903|NCT03585010|Behavioral|Cognitive-Behavioral Therapy|12 sessions with child
75884241|NCT01356641|Drug|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
75884242|NCT01356641|Procedure|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
75884243|NCT03103087|Drug|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
75884244|NCT03103087|Drug|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
75734904|NCT03584113|Other|Video assisted thorascopic decortication|Video assisted thorascopic decortication surgery as primary intervention for empyema
76055845|NCT05886010|Device|prototypes 1 every week|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75884245|NCT03103087|Drug|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
75591960|NCT06078878|Device|HF-OCT Imaging System with Vis-M Micro-Imaging Catheter|Subjects undergo HF-OCT imaging of the desired intravascular segement
75591961|NCT06078865|Device|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System,Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
76055846|NCT05886010|Device|prototypes 1 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75441362|NCT01633762|Drug|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
75591962|NCT06078852|Diagnostic Test|Diaphragmatic ultrasound|Each patient will undergo a diaphragmatic ultrasound using a MyLab TM 50 Gold Cardiovascular ultrasound machine (Esaote Spa, Rome, Italy), both in a semi-recumbent position (45° inclined bed) and in sitting position. If the patient is unable to maintain the supine position, the examination will be assessed only in the sitting position. Diaphragmatic thickness (DT) and diaphragmatic contractility will be assessed bilaterally with a 10 MHz linear probe. The amplitude of the diaphragm excursion will also be calculated with a 5 MHz convex probe in order to evaluate the cranio-caudal excursion of the diaphragm.
75591963|NCT06078839|Drug|Nafamostat mesilate|Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)
75591964|NCT06078839|Drug|5% glucose|Add 50ml of 5% glucose into a 50ml syringe
75734905|NCT03584113|Other|Interventional radiology guided chest tube insertion with MIST2 trial fibrinolytics|Image guided chest tube insertion by IVR with intrapleural fibrinolytics (six doses of dornase [5mg] and alteplase [10mg] Q12hours).
75441363|NCT01633775|Procedure|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
75734906|NCT03583190|Other|Cervical-cranial dry needling|Segmental needling of the neck and needling in the patient's headache distribution. Peripherally sensitized areas of the neck may also be dry needled based on the findings of the clinical evaluation.
75884246|NCT03103087|Drug|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
75884247|NCT05579288|Drug|Nitrous oxide (N2O/O2)|Nitrous oxide (N2O/O2) for pain alleviation
75441364|NCT01633801|Device|Use of high flows versus oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
75441365|NCT01633801|Device|oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
75591965|NCT06078826|Other|passive music therapy|30 minutes before tracheal aspiration to intubated patients connected to mechanical ventilator treated in the 3rd step intensive care unit. and music between 60-74 dB will be played via headphones and MP3 player during aspiration (Şahin, 2018). This music is a 30-minute Hüseyni makam mp3 music recording . Hüseyni makam is effective in the morning and at dawn, and its effect is high between morning and noon. For this reason, passive music therapy practice in the research will be done by the researcher in the morning and afternoon. This maqam has beauty, benevolence, silence, comfort, a sense of peace and a refreshing feature. It has positive effects on the liver, heart, internal organs and spirit and unites with nature.
75734907|NCT03583190|Other|Orthopedic manual therapy|Orthopedic Manual Therapy (OMT) that includes either mobilization or manipulation to the cervical spine applied pragmatically to the most symptomatic level.
75884248|NCT05579288|Drug|Oxygen (O2)|Oxygen (O2) as placebo for control group
75884249|NCT02081105|Other|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
75441746|NCT01637909|Other|Treatment group 2(dietary and exercise intervention)|The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
75909496|NCT03475784|Drug|Liberal fluid therapy|This group will receive crystalloid preload of 5 mL/Kg, then will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
75441747|NCT01637948|Drug|Listerine mouthrinse|For six months
75441748|NCT01637948|Drug|Chinese Medicine mouthrinse|six months
76071833|NCT03944577|Drug|Evolocumab|Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.
75441749|NCT01637974|Drug|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
75441750|NCT01638026|Drug|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
75441751|NCT01638039|Other|Laboratory Tests|Stool, blood, urine and saliva samples
75441752|NCT01638078|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
75441753|NCT01638078|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
75441754|NCT01638091|Behavioral|Ex vivo module|Pre-test, ex vivo computerized training module, post-test
75909497|NCT03368066|Drug|Cosyntropin|Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
75909498|NCT02481986|Behavioral|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
75909499|NCT02481986|Behavioral|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
75735016|NCT03187080|Procedure|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
75909500|NCT03475628|Drug|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
75769119|NCT03908008|Drug|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
75769120|NCT01253512|Drug|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
75769121|NCT01253512|Drug|Placebo|Intravenous
75441755|NCT01638091|Behavioral|In vivo practice-base learning phase|Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
75441756|NCT01638104|Drug|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
75441757|NCT01638104|Drug|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
75769462|NCT03899506|Drug|Olanzapine|Patients receiving Olanzapine per the ED protocol
75441758|NCT01638117|Other|PAC14028-Vehicle|PAC-14028 Cream Vehicle, Daily for up to 21 days
75441759|NCT01638117|Drug|PAC14028-0.1|PAC-14028 Cream, 0.1%, Daily for up to 21 days
75441760|NCT01638117|Drug|PAC14028-0.3|PAC-14028 Cream, 0.3%, Daily for up to 21 days
75441761|NCT01638117|Drug|PAC14028-1.0|PAC-14028 Cream, 1%, Daily for up to 21 days
75441762|NCT01638117|Other|Saline|Saline, Daily for up to 21 days
75909501|NCT03477734|Device|CS1 & heart monitor|Daily activities while wearing the investigational device as well as the control device
75909502|NCT05234294|Other|Survey|We will investigate symptoms through monthly surveys.
76071834|NCT03941236|Drug|dasiglucagon|Glucagon analog
75769463|NCT03899506|Drug|Midazolam|Patients receiving Midazolam per the ED protocol
75769464|NCT03897166|Device|Trimodality|Positron Emission Tomography coupled with Computed tomography and immediately followed by Magnetic Resonance Imaging
75441763|NCT01638117|Other|Positive|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
75462810|NCT01868568|Drug|placebo|A single dose administered subcutaneously (s.c., under the skin).
75616194|NCT01698658|Procedure|magnetic resonance imaging|Undergo MRI of the breast
75616195|NCT02847676|Procedure|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
75616196|NCT04218292|Device|Micro Plug Set|The Micro Plug Set is indicated for arterial embolization in the peripheral vasculature.
75616197|NCT04710706|Other|Colonoscopy insertion technique used during procedure|Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
75616462|NCT04201678|Procedure|CLIA Group (conventional local anesthesia infiltration)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
75909503|NCT05231564|Other|hybrid training|The experimental group trained two to three sessions of 45 to 50 minutes a week with a recovery of 24 to 48 hours between each session to burn 500 kcal. The first three weeks held hybrid training with a metabolic program and the other three weeks held a strength training program.
75909504|NCT02738138|Drug|ABT-493 coformulated with ABT-530|Tablet
76071835|NCT03935724|Biological|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
75441764|NCT01638143|Dietary Supplement|MenaQ7 M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~MenaQ7 M-1500 capsule~Gnosis P-1000 capsule~Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
75441765|NCT01638143|Dietary Supplement|Gnosis P-1000 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~MenaQ7 M-1500 capsule~Gnosis P-1000 capsule~Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
75441766|NCT01638143|Dietary Supplement|Gnosis M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~MenaQ7 M-1500 capsule~Gnosis P-1000 capsule~Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
75441767|NCT01638169|Device|adding a heel|walking with and without heels on the gaitrite system
75441768|NCT01638182|Dietary Supplement|Placebo|27 participants received for three months 1 placebo capsule per day
75441769|NCT01638182|Dietary Supplement|Vitamin K1-capsules|27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
75909505|NCT03018860|Procedure|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
76055865|NCT05885659|Behavioral|Cognitive Behavioral Treatment (CBT) for smoking cessation|CBT for smoking cessation will be implemented in group-based sessions of four to six patients, once a week over an eight-week period (Becoña, 2007), and includes three different components: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards. This modality of treatment also includes the following components, among others: Therapeutic contract, self-monitoring and graphical representation of tobacco consumption, psychoeducation about tobacco and specific characteristics of smoking behavior, stimulus control, strategies for coping with nicotine withdrawal symptoms, physiological feedback of consumption (using CO and cotinine in urine levels), social reinforcement when meeting nicotine reduction and abstinence goals, training in alternative behaviors to consumption and strategies for the prevention of relapses.
76055866|NCT05885659|Behavioral|CBT for smoking cessation + DiMeSALUD2 protocol|In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation). CBT plus DiMe-SALUD2 protocol will be developed as in the precedent group, but with the addition of a psychoeducational protocol for monitoring nicotine fading and abstinence specifically designed to address the particular needs of T2DM smokers. The main components of this protocol will be focused on strengthening healthy lifestyle habits as well as structured around the following core elements: dietary control and healthy nutrition, physical exercise, and glycemic control through daily self-registration of both glycemic variability and nicotine fading or abstinence. If necessary, the therapist will adapt these guidelines according to the established medical advice that the smokers receive from their own endocrinologist, so that this program is developed in accordance with their usual medical care.
75441770|NCT01638182|Dietary Supplement|Vitamin K2-capsules|27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
75441771|NCT01638195|Device|Focused Ultrasound|Focused Ultrasound
75441772|NCT01638208|Drug|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
75441773|NCT01638234|Dietary Supplement|Melatonin|melatonin 3 mg tab 1 tab po hs for 4 weeks
75441774|NCT01638234|Dietary Supplement|Placebo|starch pill
75441775|NCT01638247|Drug|Tamoxifen|25 mg daily.
75441776|NCT01638247|Drug|Tamoxifen and GnRH analogue|"25 mg Tamoxifen daily and GnRH analogue:~Goserelin (10.8 mg s.c. after randomisation and after three months) or~Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
75441777|NCT01638247|Drug|Exemestane and GnRH analogue|"25 mg Exemestane daily and GnRH analogue:~Goserelin (10.8 mg s.c. after randomisation and after three months) or~Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
75441778|NCT01638260|Drug|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
75441779|NCT01638260|Behavioral|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
75441780|NCT01638273|Drug|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
75441781|NCT01638273|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
75441782|NCT01638299|Device|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
75441783|NCT01638325|Drug|Insulin Lispro|Administered SC
75441784|NCT01638325|Drug|BC106 insulin lispro|Administered SC
75441785|NCT01638338|Behavioral|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
75441786|NCT01638338|Behavioral|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
75441787|NCT01638351|Behavioral|Resistance exercise|Progressive resistance exercise training, 3 times a week for 12 weeks.
75441788|NCT01638351|Behavioral|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
75441789|NCT01638364|Drug|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
75441790|NCT01638364|Drug|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
75441791|NCT01638377|Drug|Naltrexone|50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
75441792|NCT01638377|Drug|Control|Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
75884273|NCT01360697|Other|JADE|"The nurse will complete the CA using standardized protocol including blood & urine tests, eye & feet examination.~Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications & healthy lifestyles, perform self blood glucose monitoring as appropriate.~At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight & blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~After the FU visit, the patients will see the nurse or HCA again to clarify any issues & concerns, reinforce compliance & record any changes in medications.~After each FU visit, the HCA will generate summary reports to be given to patients & doctors to promote sharing of information."
75592011|NCT06074640|Other|MET PIR with Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) MTrPs will be identified and located using flat or pincer palpation method in the Triceps Surae complex of the affected leg. The identified trigger points will be marked with a marker. Piston technique of dry needling is performed on the identified MTrPs in calf muscles. The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
75592012|NCT06074640|Other|MET PIR without Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
75884274|NCT01360697|Other|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
75884275|NCT02135510|Drug|metoclopramide|
75884276|NCT02135510|Drug|dexamethason|
75884277|NCT02135510|Drug|palonosetron|
75884278|NCT02140112|Biological|Trichuris suis ova|
75884279|NCT02140112|Other|Placebo|
75884280|NCT02263885|Device|ExAblate Transcranial System|Transcranial MRgFUS
75317880|NCT03595670|Other|interview|Semi-directive interviews will be conducted. The purpose of this approach is to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inscription in the socio-cultural condition of the patients.
75317881|NCT00466661|Drug|Acamprosate|666 mg po TID
75317882|NCT00466661|Drug|Placebo|2 tabs po TID
75317883|NCT05360576|Drug|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|To prevent pregnancy
75317884|NCT05360576|Drug|NuvaRing Vaginal Ring|To prevent pregnancy
75317885|NCT00535925|Drug|SoC therapy|the patients have to be treated according the standard good medical practice by any center
75317886|NCT00535925|Drug|irbesartan|"Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
75317887|NCT00535925|Drug|ramipril|"Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
75317888|NCT00535925|Drug|hydrochlorothiazide|"Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine <2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
75317889|NCT00535925|Drug|furosemide|"Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine <2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
75317890|NCT00535925|Drug|amlodipine|"Therapy for hypertension~- Step 3: amlodipine up to 10 mg/die"
75317891|NCT00535925|Drug|atenolol|"Therapy for hypertension~- Step 4: atenolol up to 100 mg/die"
75317892|NCT00535925|Drug|doxazosin|"Therapy for hypertension~- Step 5: doxazosin up to 4 mg/die"
75317893|NCT00535925|Drug|clonidine|"Therapy for hypertension~- Step 6: clonidine"
75317894|NCT00535925|Drug|insulin|"Therapy for Hyperglycaemia (to achieve HbA1c <7):~- insulin"
75317895|NCT00535925|Drug|simvastatin|"Therapy for hypercholesterolemia:~- for reducing LDL cholesterol < 100 mg/dl: simvastatin up to 80 mg/die"
75441793|NCT01638403|Drug|BF2.649|"BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
75592013|NCT06074393|Behavioral|Tailored Support Group|Participants engage in a secure, confidential environment, sharing caregiving insights and knowledge. Expert-led sessions, lasting 90 minutes, occur biweekly for 16 weeks, held via Zoom and at the University of Calgary's Cumming School of Medicine. These sessions take place twice annually, emphasizing the structured nature of the support group. Weekly themes include self-care, adaptation, coping skills, emotions, anticipatory grief, forgiveness, mindfulness, boundaries, and closure. Care partners actively participate by sharing experiences and asking questions in each session.
75592014|NCT06074289|Behavioral|Family connections program|Caregivers meet weekly for 90 minute sessions led by two trained psychologists. The program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills.
75441794|NCT01638403|Drug|Vigil|"Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
75592015|NCT06073704|Procedure|antimicrobial photodynamic therapy (aPDT)|Scaling and root planing followed by antimicrobial photodynamic therapy
75592016|NCT06073704|Procedure|Control|Treatment of scaling and root planing
75592017|NCT06073405|Device|Colonic Polyp Measurement Assessment Via Artificial Intelligence|In this study, we collect colonoscopy video clips of polyps and, among the related clinical information, their estimated size using the gold standard technique, and we use them offline to evaluate the measurement performances of the novel virtual polyp sizing tool
75592018|NCT06073002|Other|home-based concurrent exercise|3 weekly sessions of home-based concurrent exercise on non-consecutive days. Resistance exercise is comprised of lunges, hip thrusts, pushups, resistance band rows, core and performed for 3 sets with 15-20 repetitions at an RPE of 14-18 (6-20 BORG scale). Endurance exercise can be done by the mode of choice and is monitored by heartrate zones. Sessions are of low to moderate intensity (below VT2) and the duration will be slowly increased for 20-40min.
75592019|NCT06072456|Procedure|laparoscopic lateral suspension|Lateral suspension involves the lateral attachment or suspension of vaginal tissue to a stable structure, often using mesh or sutures, to provide support and stability to the pelvic organs. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
75592020|NCT06072456|Procedure|laparoscopic pectopexy|Pectopexy involves attaching or suspending the vaginal vault to the pectineal ligament, which is a strong ligament in the pelvis. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
75592021|NCT06072456|Procedure|Sacrospinous ligament fixation|Sacrospinous ligament fixation entails the attachment or fixation of the vaginal vault to the sacrospinous ligament, which is a strong fibrous band located in the pelvis
75592022|NCT06072287|Diagnostic Test|Living with LTC Questionnaire|A questionnaire that will ask about demographic information, mental wellbeing and distress related to chronic illness.
75592023|NCT06072209|Behavioral|Behavioral Activation|- instruction to create a list of individual positive activities. - instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity.
75592024|NCT06072209|Behavioral|Mindfulness and Gratitude|- instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with
75592025|NCT06072209|Behavioral|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
75884281|NCT02192671|Procedure|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
75441795|NCT01638403|Drug|palcebo|"placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
75441796|NCT01638455|Device|Noninvasive device|Noninvasive device
75884282|NCT02192671|Procedure|Radiofrequency Ablation|
75884283|NCT03548714|Drug|PT150|Intervention 1 includes PT150 with alcohol consumption
75884284|NCT03548714|Other|Beverage|Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
75884285|NCT02160691|Device|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
75884286|NCT02135588|Drug|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
75884287|NCT03633019|Drug|rhTPO|high dose rhTPO ih
75441797|NCT01638520|Drug|Pascolizumab|0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
75441798|NCT01638520|Drug|Placebo|Saline (volume determined based on weight of patient, and cohort of enrollment)
75592026|NCT06070961|Diagnostic Test|Cellular immunity vs SARS-CoV-2|Evaluation of cellular immunity vs SARS-CoV-2 by ELISpot assay
75592027|NCT06070961|Diagnostic Test|Humoral immunity vs SARS-CoV-2|Evaluation of Humoral immunity vs SARS-CoV-2 by ELISA assay (IgG anti-RBD and anti-N)
75884288|NCT05755243|Device|glucose sensor|skin biopsy (punch)
75592028|NCT06070961|Diagnostic Test|Cellular immunity vs Varicella Zoster Virus|Evaluation of cellular immunity vs VZV by Enzyme-Linked immunoSPOT (ELISPOT) assay
75884289|NCT05578508|Drug|Mesenchymal Stem Cells (MSCs)|Endoscopic injection of allogeneic bone marrow derived mesenchymal stem cells (MSCs) to the ileal pouch.
75592029|NCT06070961|Diagnostic Test|Humoral immunity vs Varicella Zoster Virus|Evaluation of humoral immunity vs VZV by ELISA (VZV gE-binding IgG)
75592030|NCT06070961|Diagnostic Test|Diphtheria toxin-binding IgG|Evaluation of diphtheria toxin-binding IgG by ELISA assay
75592031|NCT06070961|Diagnostic Test|Tetanus toxoid-binding IgG|Evaluation of tetanus toxoid-binding IgG by ELISA assay
75592032|NCT06070961|Diagnostic Test|T-cell populations and markers characterization|Characterization of T-cell populations and markers by flow cytometry
75592033|NCT06070350|Biological|Low Titer Group O Whole Blood (LTOWB)|LTOWB is whole blood from group O donors with low titer (<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.
75592034|NCT06070350|Drug|Placebo|Placebo will be made by the research pharmacy at each of the clinical sites
75592035|NCT06070350|Drug|Tranexamic Acid (TXA)|TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure.
75592036|NCT06070350|Biological|Component Therapy (CT)|Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo
75592037|NCT06069817|Device|High flow nasal cannula|home treatment with HFNC after airway stent placement both for malignant and benignant central airway obstruction
75592038|NCT06069817|Device|nebulized normal saline|home treatment with nebulized normal saline after airway stent placement both for malignant and benignant central airway obstruction
75592039|NCT06069596|Combination Product|Natalis Obstetric Lubrican Gel|The obstetric lubricant gel was applied to the vaginal canal with a special applicator at the beginning of the active phase of the labor. The gel used in the study was highly viscose and isotonic with a slight acid pH of 6.0 - 6.7 and contained hydroxyethylcellulose, propylene glycol, glycerin. The gel box contained a sterile syringe (15 ml) and a flexible applicator.
75592040|NCT06068660|Behavioral|The Goal-Oriented Care program|The Goal-Oriented Care Interventions The GOC intervention included the following steps: respecting the participant's values in setting goals, considering direct and indirect factors influencing the goals, communicating and setting goals, implementing goal-oriented strategies, and evaluating goals while adjusting the content of the strategies.
75592041|NCT06068660|Behavioral|The routine health education|The control group received routine education, which consisted of oral education and provision of educational pamphlets by nurses during hospitalization.
75592042|NCT06068582|Behavioral|Strenghtening the brain|Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.
75884290|NCT01491763|Drug|Imatinib|600 mg p.o. from day 1 until consolidation
75884291|NCT03597750|Device|Repose®|"Repose® Mattress~Repose® Cushion~Repose® Wedge or Foot Protectors"
75317896|NCT00535925|Drug|fibrate|"Therapy for hypertriglyceridemia~- for reducing triglycerides < 150 mg/dl and/or increasing HDL cholesterol > 40-50 mg/dl: a fibrate"
75884292|NCT03549260|Biological|LIB003|LIB003 or placebo
75884293|NCT01563302|Drug|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
75317897|NCT00535925|Drug|erythropoietin|"Treatment of anaemia:~- erythropoietin"
75317898|NCT00535925|Drug|aspirin|"Antiplatelet therapy (in all patients without contraindications):~- aspirin up to 160 mg/die"
75317899|NCT00211172|Behavioral|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
75317900|NCT01796093|Drug|Digoxin and ivabradine|No more details
75317901|NCT00537511|Drug|Pomalidomide|
75317902|NCT00537511|Drug|Cisplatin|
75317903|NCT00537511|Drug|Etoposide|
75317904|NCT00435929|Drug|Ritonavir|100mg po bid
75317905|NCT00435929|Drug|saquinavir [Invirase]|1000mg po bid
75317906|NCT00436475|Drug|Vitamin D3 2,000 IU orally once daily|Vitamin D3 2,000 IU orally once daily
75317907|NCT00436475|Drug|Calcium Carbonate 400 mg orally twice daily|Calcium Carbonate 400 mg orally twice daily
75317908|NCT00436475|Drug|Vitamin D3-Placebo|Vitamin D3-Placebo
75317909|NCT00436475|Drug|Calcium-Placebo|Calcium-Placebo
75317910|NCT00210626|Drug|PROCRIT|40,000 IU/mL/week for max of 12 weeks
75317911|NCT00210626|Drug|Placebo|40,000 IU/mL/week for max of 12 weeks
75317912|NCT00538213|Biological|Fluarix™|Single dose, Intramuscular injection
75317913|NCT00538213|Biological|GSK Bio's Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
75884294|NCT04254341|Other|patients with OSA|Sleep study
75884295|NCT02237586|Biological|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
75441799|NCT01638585|Drug|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
75441800|NCT01638598|Drug|matching placebo|matching placebo in each dose level
75441801|NCT01638598|Drug|Test drug|BI 1021958
75441802|NCT01638598|Drug|matching placebo|matching placebo in each dose level
75441803|NCT01638598|Drug|Test drug|BI 1021958
75441804|NCT01638598|Drug|Test drug|BI 1021958
75441805|NCT01638598|Drug|Test drug|BI 1021958
75441806|NCT01638598|Drug|Test drug|BI 1021958
75441807|NCT01638598|Drug|matching placebo|matching placebo in each dose level
75441808|NCT01638598|Drug|matching placebo|matching placebo in each dose level
75441809|NCT01638598|Drug|matching placebo|matching placebo in each dose level
75441810|NCT01638611|Drug|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
75592043|NCT06068582|Behavioral|Strengthening the mind|Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
75884296|NCT02252822|Behavioral|Overcoming Bulimia Online Programme|
75884297|NCT01363817|Drug|BMS-906024|
76055867|NCT05885633|Procedure|endometrial sampling with pipelle|Following oocyte retrieval while the patient was under anesthesia, endometrial tissue sampling was performed with the help of pipelle cannula. A portion of the endometrial tissue was put into RNA stabilization buffer (RNAlater) to be used in qPCR and stored at -20°C until the analysis. The remaining endometrial tissue was first fixed with 10% formalin, followed by paraffin blocking and prepared for immunohistochemical analysis.
75884298|NCT01363817|Drug|Dexamethasone|
75884299|NCT03597048|Behavioral|Curriculum|The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
76055868|NCT05885620|Device|drinking reminder and cognitive task (smartwatch-based application)|task A: prompt to drink some water task B: prompt to circle bells on a sheet
75441811|NCT01638611|Drug|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
75441812|NCT01638624|Drug|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
75441813|NCT01638624|Drug|Placebo|
75441814|NCT01638637|Device|APTIMA Assays; PANTHER System|APTIMA Assays; PANTHER System
75441815|NCT01638650|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
75441816|NCT01638650|Drug|ritonavir|100 mg bid orally, Days 1-14
75441817|NCT01638650|Drug|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
75441818|NCT01638663|Drug|Tolvaptan|15 mg pr day for 1 day
75441819|NCT01638663|Drug|Placebo|1 tablet Unikalk 1 pr day for 1 day
75441820|NCT01638676|Drug|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
75441821|NCT01638676|Drug|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
75441822|NCT01638689|Drug|Escitalopram|20 mg p.o.
75441823|NCT01638702|Other|Follow up of complications|Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
75441824|NCT01638715|Drug|Remicade|- Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
76055869|NCT05885568|Biological|blood sampling|Blood sampling from healthy volunteers
75462811|NCT01868581|Drug|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
76055870|NCT05885568|Other|drone transportation|drone transportation
76055871|NCT05885568|Other|car transportation|car transportation
76055872|NCT05885529|Other|UCH-L1 GFAP|measurment of UCH-L1 GFAP within 12 hours in adult patients after a mild traumatic brain injury
76055873|NCT05885451|Drug|AMG 592|Administered as SC injection
76055874|NCT05885451|Other|Placebo|Administered as SC injection
75317914|NCT03595514|Other|Single injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
75317915|NCT03595514|Other|Double injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
75317916|NCT03595514|Drug|lidocaine, bupivacaine, epinephrine, dexamethasone|lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
75317917|NCT05368220|Other|Whole genome sequencing|Each participant will have WGS performed in order to report on clinically actionable genetic variation in diabetes.
75317918|NCT03595436|Dietary Supplement|Pea Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 20 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
75317919|NCT03595436|Dietary Supplement|Pea Protein-30g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 30 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 32 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
75317920|NCT03595436|Dietary Supplement|Pea Protein-40g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 40 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 24 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
75317921|NCT03595436|Dietary Supplement|Whey Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 20 g whey protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
75317922|NCT03595436|Dietary Supplement|Carbohydrate Control|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 5 g mixed protein (from yogurt and peanut-butter), 59 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
75317923|NCT00215852|Drug|Alferon LDO|500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
75317924|NCT03595046|Procedure|erector spinae plane block (20 mL of 0.25% ropivacaine with dexamethasone 5mg)|In group E, The patient was placed in a sitting position and a high-frequency linear ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the thoracic spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle was inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between transverse process and erector spinae muscles, as evidenced by visible linear spread of fluid between erector spinae muscles and the bony acoustic shadows of the transverse process. A total of 20 mL of 0.25% ropivacaine with dexamethasone 5mg was injected here.
76055875|NCT05885425|Behavioral|Telemedicine correction of medical treatment|On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine
76055876|NCT05885425|Behavioral|Education for proper lifestyle|Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle
76055877|NCT05885399|Drug|Penpulimab|Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
76055878|NCT05884372|Drug|Eldecalcitol|the same as arm descriptions.
76055879|NCT05884372|Drug|Native Vitamin D|the same as arm descriptions.
75441825|NCT01638715|Drug|Orencia|- Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.
75441826|NCT01638715|Drug|Ro-Actemra|- Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
75441827|NCT01638715|Drug|Mabthera|"- Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.~Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©)."
75441828|NCT01638741|Behavioral|Rehabilitation goals of patients with gynaecological cancer.|Conversations with the nurse and supportive phone calls. Conversation are structured and placed 1 and 3 months after surgery. Phone calls are carried out at two and three months after surgery.
75441829|NCT01638754|Procedure|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
75441830|NCT01638754|Procedure|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
75441831|NCT01638767|Drug|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
75441832|NCT01638767|Drug|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
75441833|NCT01638780|Dietary Supplement|placebo|A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
75441834|NCT01638780|Dietary Supplement|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
75441835|NCT01638793|Device|Microcap (Oridion, Needham, MA, USA)|
75441836|NCT01638793|Device|Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)|
75441837|NCT01638806|Procedure|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
76055880|NCT05884372|Drug|Denosumab|the same as arm descriptions.
75441838|NCT01638832|Device|Transient Elastography (FibroScan), Echosens, Paris, France|
75441839|NCT01638832|Device|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
75441840|NCT01638845|Procedure|continuous perineural catheter|continuous perineural catheter
75441841|NCT01638858|Drug|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
75441842|NCT01638871|Behavioral|PainCOACH|The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
76055881|NCT05884372|Drug|Calcium|the same as arm descriptions.
75592047|NCT06066190|Other|Web-Based Training on ERAS Protocols Applied in Gynecological and Obstetric Surgery|Web-Based Training will be given to Midwives and Nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
75592048|NCT06065007|Other|No intervention|This is a cross-sectional observational study, no intervention will be implemented or exposure studied. Data for outcomes of interest will be collected via questionnaires
75592049|NCT06064526|Other|No intervention|Non-interventional study based on secondary use of hospital medical records
75592050|NCT06064448|Drug|Sildenafil|Subjects were given sildenafil citrate, 25mg/capsule, once a night, one capsule each time, for 4 weeks.
75441843|NCT01638884|Behavioral|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
75441844|NCT01638884|Other|Structural MRI|to compare differences between each populations
75592051|NCT06064448|Drug|Ningmitai capsule|The subjects took Ningmitai capsule, 0.38 g/capsule, 3 times a day, 4 capsules each time, after meals, and continued to treat for 4 weeks.
75735017|NCT03187080|Other|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to our current standard of care, we will utilize the following perioperative strategies [Arsalani]:~Standardized written information given preoperatively.~Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~Use paravertebral block to augment postoperative pain control.~Standardized multimodal analgesic regimen~Antiemetics~Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~PVB is less commonly used in elective surgery.~Patients do not eat or drink after midnight.~There is no standardized preoperative information packet.~Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
76055882|NCT05884346|Other|Ultrahigh-frequency ultrasound|Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease
76055883|NCT05884307|Other|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
76071836|NCT03932799|Other|Prospective prior authorization (PA) with hard stops in Washington|"Under Washington regulatory procedures, payment for any opioid prescription billed beyond six weeks after the injury is denied unless the prescriber has submitted a checklist attesting to completion of all best practices from the regulations/guidelines.Thus, the Washington intervention is prospective and includes a hard stop subject to an insurer's decision based on regulatory authority."
75441845|NCT01638884|Other|Functional MRI|to compare differences between each populations
75441846|NCT01638884|Other|Virtual reality / Memory assessment|to compare differences between each populations
75441847|NCT01638910|Drug|EV/DNG (Qlaira, BAY86-5027)|Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
75592052|NCT06064448|Drug|Ningbitai capsule + sildenafil|The subjects took Ningmitai capsule orally, 0.38 g/capsule, 3 times a day, 4 capsules each time, and took it after meals. Sildenafil citrate, 25mg/capsule, once a night, one capsule each time, was taken orally for 4 weeks.
75592053|NCT06064032|Behavioral|cognitive behavioral therapy|In control group there is 10 min session of PMR, 2 min deep breathing exercises,3 min training for life style modification which include use of planner, setting alarms breaking a task into parts positive reinforcement and communication.
75592054|NCT06064032|Behavioral|Motor Learning Techniques|In experimental group, participants will be given a 10 min PMR ,2 min deep breathing exercises, 3 min training for life style modification which include the use of planners setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with 3 min session of drawing a specific pattern with installing pegs on pegboard, 2 min session of balance board training, 3 min session of jigsaw puzzle training, 1 min session of squeezing a ball with maximum repetition and 1 min session of finding beads in puttey.
75592055|NCT06061250|Dietary Supplement|Chewing a piece of gum (Xylitol gum, LOTTE WELLFOOD, Korea) before induction of anesthesia|To replicate Xylitol chewing gum, which has been shown to reduce postoperative sore throat in previous studies of single-lumen endotracheal tubes and supraglottic airways, the investigators will use a commercially available gum from South Korea.
75592056|NCT06054893|Drug|Omaveloxolone|One dose of omaveloxolone will be taken orally. Dosage to be determined based on age and PK data from prior Parts.
75592057|NCT06041269|Drug|Rosnilimab|PD-1 agonist antibody
75592058|NCT06041269|Drug|Placebo|Placebo
75592059|NCT06040697|Device|Thermal Anisotropy|Usability assessment observation.
76071837|NCT03932799|Other|Retrospective review (RR) with prescriber notification in Ohio|In Ohio an automated report identifies new opioid prescriptions beyond the acute phase. Ohio Workers' Compensation pharmacy and clinical staff review the medical record at 12 weeks to determine whether best practices were met. If not, the prescriber is notified via letter, and cases are reviewed again at 16 weeks. If best practices have still not been met, the prescriber and worker are notified via letter that opioid coverage will end in 4 weeks. The Ohio program relies on retrospective chart review and communication of best practices to prescribers.
75592060|NCT06036147|Behavioral|Concussion-focused cognitive behavioral therapy|Youth randomized to receive this component will participate in six 30-minute sessions of cf-CBT. The intervention includes modular CBT targeting post-concussive, anxiety and depressive symptoms. In this CBT treatment, the adolescent can be taught coping skills, relaxation strategies, and cognitive strategies to manage their symptoms, while they are encouraged to increase appropriate activation, including pacing of activities. Six sessions from the CHIP Study Cognitive and Behavioral Skills for Concussion Recovery will be chosen by the interventionist based on the youth's goals in the Introduction Session.
75735018|NCT03187080|Procedure|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
75441848|NCT01638923|Drug|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
75735019|NCT03187080|Drug|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is *NOT* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
75441849|NCT01638923|Drug|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
75441850|NCT01638936|Drug|BT062 , intravenous administration|Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
75441851|NCT01638962|Drug|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
75735020|NCT03179384|Drug|Ceftriaxone|ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
75735021|NCT03176693|Drug|Phenoxybenzamine|Non-selective alpha blocker
75884300|NCT03597048|Behavioral|Contact|The contact intervention involves two college students-a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder-who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
76071838|NCT03930576|Other|Receipt of termination services outside of legal setting|This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
75441852|NCT01638962|Other|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
75441853|NCT01638975|Behavioral|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
75735022|NCT03176693|Drug|Doxazosin|Selective alpha blocker
75735023|NCT03175874|Procedure|Hip bone sampling|Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
75735024|NCT03148418|Drug|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
75735025|NCT03148418|Drug|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
75735026|NCT03143075|Dietary Supplement|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
75735027|NCT03142919|Biological|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
75884301|NCT03597048|Behavioral|Materials|"The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill."
75735028|NCT03142919|Biological|Placebo|Saline solution
76071839|NCT03930459|Procedure|Static cold storage (SCS)|The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
75592061|NCT06036147|Behavioral|Parent skills training|The focus of the PST component is on the use of positive parenting skills as well as helping parents manage their own emotional distress. Parents are taught to set positive recovery expectations, and to use praise or attention to increase their teen's positive coping behaviors and decrease unhelpful coping behaviors. They are also taught positive communication skills to use with their teen, and guided to schedule pleasant events together in order to strengthen the relationship. In-vivo skills practice and feedback are provided to help parents generalize and use PST techniques. Parents randomized to receive this component will participate in six 30-minute sessions of PST, chosen from the CHIP Study Parent Support Skills Training for Concussion recovery based on the parent's goals in the Introduction Session.
75735029|NCT03141034|Drug|Irinotecan|-Irinotecan is commercially available and will be billed to insurance.
75735030|NCT03141034|Drug|Ramucirumab|-Ramucirumab will be provided free of charge by Eli Lilly and Company.
75735031|NCT03141034|Genetic|Blood for angiome profiling|-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment
75735032|NCT03141034|Genetic|Blood for cfDNA|-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
75735033|NCT03094052|Drug|Neratinib|Given orally (PO)
75735034|NCT03094052|Biological|Trastuzumab|Given Intravenously (IV)
75884302|NCT02140268|Drug|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
75441854|NCT01638988|Drug|Metformin|"cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy"
75441855|NCT01638988|Drug|Clomiphene citrate|Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
75441856|NCT01639014|Drug|F2695|75 mg OD in 2 capsules
75441857|NCT01639014|Drug|placebo|2 capsules
75735035|NCT03094052|Drug|Loperamide|Given PO
75735036|NCT03094052|Drug|Diphenoxylate Hydrochloride/Atropine Sulfate|Given PO
75735037|NCT03092323|Drug|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
75735038|NCT03083821|Drug|Baraclude|Specified dose on specified day
75884303|NCT02140268|Drug|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
75884304|NCT02140268|Drug|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
75884305|NCT05187689|Behavioral|VR + MHL intervention|The intervention will include: 1) a Virtual Reality (VR) interactive and immersive 30-minute session viewed using a low cost VR headset; and 2) an 8-week program of weekly WelTel SMS check-ins managed by Peer Navigators (PNs), weekly WelTel SMS blasts informed by Psychological First Aid (PFA) with mental health literacy (MHL) messages developed with PN, and weekly WelTel web-based secure platform social group discussions on MHL, stress coping, and stigma moderated by PN alongside a trained Coordinator. Weekly MHL WelTel platform moderated discussion foci will address MHL, stigma and stress coping strategies, including self-compassion and other strategies that emerge from the urban refugee youth interviews and focus groups, through diverse methods, including: 'scenarios' mimicking real life situations; a 'question box'; sharing photos demonstrating stress coping strategies; memes; songs; and ways participants interrupted stigma in their daily lives.
75735039|NCT03073278|Radiation|Stereotactic Body Radiotherapy|Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
75735040|NCT03071393|Device|Hypoxia via Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
75441858|NCT01639027|Drug|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
75735041|NCT03071393|Device|Sham via Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
76071840|NCT03930459|Device|Normothermic machine perfusion (NMP)|During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
76071841|NCT03928041|Device|Device: EVOS Lumbar Interbody System (EVOS-HA)|All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
75441859|NCT01639027|Drug|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
76071842|NCT03925025|Drug|Magnesium Sulfate|Treatment in addition to standard therapy
75441860|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
75441861|NCT01639066|Drug|Entecavir|Entecavir 1 mg daily Oral
75441862|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
75735042|NCT03056001|Drug|Pembrolizumab|IV infusion on day 1 of each 3 week cycle, at dose of 200 mg
75735043|NCT03056001|Drug|Doxorubicin|IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1)
75735044|NCT03043599|Radiation|Thoracic Radiation Therapy|All participants will receive radiation therapy (3Gy x 10 fractions) to the chest for 10 days (Monday through Friday for 2 weeks).
75735045|NCT03043599|Drug|Ipilimumab|Ipilimumab 3 mg/kg (90 minute IV infusion) will be administered every 3 weeks for 4 doses.
75735046|NCT03043599|Drug|Nivolumab|Nivolumab 1 mg/kg (30 minute IV infusion) will be administered every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks.
75735047|NCT03041987|Other|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
75884306|NCT05187689|Behavioral|Group PM+|"Participants will attend small groups (5-6 participants with a PN and a coordinator supporting) outdoors with physically distancing, for Group PM+ sessions following the adapted WHO Group-PM+ manual (adaptations made in Phase 1 explain above) 5 weekly 3-hour sessions delivered by PN who will co-facilitate sessions with the Coordinator. Each session has a mechanism of action:~Managing stress: mechanism of action-identify goals, learn deep breathing and techniques for stress management~Managing problems: mechanism of action-identify 1 solvable practical problem, brainstorm possible solutions together~Get going, keep doing: mechanism of action-learn about depression and inactivity, identify and plan small enjoyable activities~Strengthen social support: mechanism of action-discuss a range of social support resources, make plan to increase social support~Staying well: mechanism of action- this session reviews all of the mechanisms of action in the prior 4 sessions"
75884307|NCT03548636|Behavioral|Single-Arm Feasibility Study|Groups of 8 to 12 participants, consisting of >50% breast cancer survivors, were invited to apply for up to $2000 to enable access to equipment, resources, facilities, instruction and/or transportation to implement a physical activity intervention. Applicants were assessed by a Grant Review Panel. Successful applicants were informed that they would receive an additional $500 incentive if they increased their group's mean physical activity at six month follow-up (assessed via accelerometry).
75884308|NCT01360775|Behavioral|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
75735048|NCT03039309|Procedure|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection is an endoscopic resection technique that utilises an endoscopic knife to remove lesions within the gastrointestinal tract in an en bloc fashion.
76071843|NCT03925025|Drug|Nimodipine|Treatment in addition to standard therapy
75884309|NCT03600168|Device|PuraStat®|Synthetic haemostatic material
75884310|NCT02252900|Other|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
75884311|NCT01363895|Procedure|Percutaneous closure of LAA|Percutaneous closure of LAA
75884312|NCT01363895|Procedure|Catheter ablation of AF|Catheter ablation of AF
75884313|NCT02237664|Procedure|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
75884314|NCT02237664|Procedure|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
75884315|NCT05750095|Behavioral|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
76071844|NCT03924947|Drug|Pancrelipase|Delayed release capsules
76071845|NCT03924947|Drug|Pancrelipase|Delayed release capsules
75441863|NCT01639079|Behavioral|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
76071846|NCT03919292|Drug|Neratinib|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
75441864|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
75441865|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
75441866|NCT01639092|Drug|Entecavir|Entecavir 1 mg daily Oral
75462812|NCT01868581|Drug|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
75462813|NCT01868620|Device|Iontophoretic CXL|
75462814|NCT01868620|Device|Standard CXL|
75462815|NCT01868659|Behavioral|Diagnostic checklist|Diagnostic checklist used before patient discharged
75462816|NCT01868659|Behavioral|Usual care with no diagnostic checklist|Patient receives usual care with no research intervention
75462817|NCT01868672|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
75735055|NCT03023449|Drug|Nitric Oxide|Inhaled Nitric Oxide gas
75884316|NCT05750095|Behavioral|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
75735056|NCT03016130|Other|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
75441867|NCT01639170|Radiation|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
75441868|NCT01639183|Device|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
75735057|NCT03009331|Procedure|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
75735058|NCT03009331|Procedure|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
75884317|NCT05578352|Other|Add oral hyppoglycemia drug|Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
75884318|NCT05578352|Other|Add GLP-1 receptor agonist|Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
75735059|NCT02998918|Dietary Supplement|PolyResveratrol Supplementation|Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
75735060|NCT02998918|Dietary Supplement|Curcumin Supplementation|Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
75735061|NCT02990338|Drug|Isatuximab|Pharmaceutical form: solution for infusion Route of administration: intravenous
75884319|NCT05578352|Other|Change insulin|Change premix insulin to long-acting insulin
75441869|NCT01639183|Other|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
75441870|NCT01639209|Procedure|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
75462818|NCT01868685|Drug|BYM338|BYM338
75735062|NCT02990338|Drug|Pomalidomide|Pharmaceutical form: capsule Route of administration: oral
75884320|NCT04090229|Drug|ASLAN004|Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
75735063|NCT02990338|Drug|Dexamethasone|Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
75884321|NCT04090229|Drug|ASLAN004 Placebo|Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
75884322|NCT03602508|Drug|mirabegron|oral
76071847|NCT03919292|Drug|Divalproex Sodium|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
75735064|NCT02964182|Drug|Cigarette|Smoke usual brand of cigarettes
75735065|NCT02964182|Drug|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
75735066|NCT02964182|Drug|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
75735067|NCT02964182|Other|Questionnaire Administration|Ancillary studies
75441871|NCT01639209|Procedure|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
75441872|NCT01639248|Drug|ENMD-2076|250 mg per day in oral capsules in 28 day continuous cycles
75884323|NCT03602508|Drug|solifenacin|oral
75884324|NCT03602508|Drug|darifenacin|oral
75884325|NCT03602508|Drug|imidafenacin|oral
75884326|NCT03602508|Drug|tolterodine|oral
75884327|NCT03602508|Drug|oxybutynin|oral
75441873|NCT01639261|Drug|Interferon gamma 1b|Initial dose: 50µg s.c. three times/week, without fever >38,5 dose increase: 50µg/m² BSA three times/week
75441874|NCT01639274|Other|COPD prevalence|Determine prevalence of COPD
75441875|NCT01639300|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
75441876|NCT01639300|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
75441877|NCT01639326|Drug|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
75462819|NCT01868685|Drug|Placebo|Placebo
75462820|NCT01868698|Other|high-voltage electrical stimulation|
75462821|NCT01868698|Other|Kinesiotherapy|
75462822|NCT01868698|Other|shortwave diathermy|
75462823|NCT01868737|Dietary Supplement|Probiotic|Lactobacillus rhamnosus GG and Bifidobacterium infantis'
75462824|NCT01868737|Dietary Supplement|Placebo|MCT oil
75462825|NCT01868750|Dietary Supplement|Calcitriol|1.0ug twice daily for 7 days before surgery
75462826|NCT01868750|Dietary Supplement|Control Pill|placebo pill taken twice daily for 7 days before surgery
75462827|NCT01868763|Device|telemedical devices (weighing machine and step counter)|
75462828|NCT01868763|Behavioral|care calls once per week for 12 weeks|
75462829|NCT01868802|Drug|Ketamine|A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
75462830|NCT01868802|Drug|Placebo|Saline at 0.9% intravenous infusion will be administered over 40 minutes.
75462831|NCT01868828|Drug|PAD|Induction Therapy of PAD for 4 cycles.
75462832|NCT01868828|Drug|VCD|Induction Therapy of VCD for 4 cycles.
75462833|NCT01868828|Other|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
75462834|NCT01868841|Drug|AdreView|10 millicurie of AdreView (123I-mIBG)
75462835|NCT01868841|Other|Single Photon Emission Computed Tomography|
75462836|NCT01868867|Behavioral|Intervention|On line tutorial followed by text messaging during treatment and iPad for patient education
75462837|NCT01868906|Drug|18F-FMISO|18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
75462838|NCT01868906|Procedure|PET without SCS|PET-scanning using 18F-fluoromisonidazole without SCS
75462839|NCT01868906|Device|SCS|Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.
76071848|NCT03918577|Other|Caloric Vestibular Stimulation|Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.
76071849|NCT03914118|Drug|Preoperative modafinil + postoperative placebo|200 mg modafinil pre-operatively and placebo immediately post-operatively.
75735068|NCT02964182|Other|Survey Administration|Ancillary studies
75441878|NCT01639326|Drug|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
75441879|NCT01639378|Procedure|Renal Denervation|Symplicity Catheter System
75441880|NCT01639391|Procedure|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
76071850|NCT03914118|Drug|Preoperative modafinil + postoperative modafinil|200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
75441881|NCT01639404|Procedure|Umbilical Cord Blood Administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
75441882|NCT01639404|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
76071851|NCT03914118|Drug|Preoperative placebo + postoperative placebo|Placebo pre-operatively and placebo immediately post-operatively.
76071852|NCT03911973|Drug|Gedatolisib|Gedatolisib, 150-180MG IV
75441883|NCT01639430|Other|rectal, tympanal and temporal artery thermometry|"Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well."
75441884|NCT01639456|Biological|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
75441885|NCT01639456|Biological|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
75462840|NCT01868906|Procedure|PET without/with SCS|Second PET-scanning using 18F-fluoromisonidazole: without/with SCS
76071853|NCT03911973|Drug|Talazoparib|.75-1.00mg
76071854|NCT03903653|Drug|Botulinum toxin type A|"Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
75462841|NCT01868906|Radiation|Radiotherapy|Standard radiation therapy
75462842|NCT01868906|Drug|Temozolomide|Standard treatment with concurrent and adjuvant Temozolomide.
75462843|NCT01868919|Behavioral|Positive Parenting Program|Level 3 or 4 of Triple P
75462844|NCT01868932|Other|hypertonic saline|inhaled nebulized 3%NaCl
75462845|NCT01868932|Other|saline|inhaled nebulized 0.9% NaCl
75462846|NCT01868945|Dietary Supplement|5 µg/day Hy.D Calcifediol|5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
75462847|NCT01868945|Dietary Supplement|10 µg/day Hy.D Calcifediol|10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
75462848|NCT01868945|Dietary Supplement|15 µg/day Hy.D Calcifediol|15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
75441886|NCT01639456|Device|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
75441887|NCT01639456|Device|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
75592062|NCT06036147|Behavioral|Care management|In the CM component, parents are provided support regarding advocating for their child's needs across different contexts in the healthcare system, school and athletic departments (including guidance regarding medication referrals), using applied problem-solving together with the skills coach to address emergent needs. Adolescents can also be involved in CM, if developmentally appropriate based on their age, independence, and interest. Of note, while the CM component engages youth and parents, treatment effects are hypothesized to result from facilitating access to supportive services including medication referrals at the organizational level. Families randomized to receive this component will participate in six 30-minute sessions of CM, following the guidelines in the CHIP Care Management Manual.
75884328|NCT03602508|Drug|trospium|oral
75441888|NCT01639456|Drug|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
75592063|NCT06034210|Device|Customised 3D-printed insoles|Based on measurements from the 3D scanning procedure, and factoring in individual data such as age, weight, and activity preferences, custom insoles are designed using the ZOLA software. The insoles are then 3D-printed by Zoles ApS in Espergærde (Denmark), using BCN3D printers (Barcelona, Spain) and a TPU (Thermoplastic Polyurethane) filament material from Recreus (Alicante, Spain). The printed insoles are tailored for optimal support, performance, and comfort, with varying densities for areas like the arch and heel. They are finished with an OnSteam® microfiber cover for added durability and comfort. The insoles are intended for regular insertion into participants' shoes to align with their unique biomechanical needs. (Information translated and adapted from: https://www.zoles.eu/da/processen-bag-saalerne/)
75592064|NCT06028035|Dietary Supplement|BB01|20 grams minimally processed form of Hemp hulls in the form of a bar/wafer.
75592065|NCT06026254|Drug|IMSA101|Intra-tumoral administration on Days 1 and 15 of every 28-day cycle
75592066|NCT06026254|Drug|Immune Checkpoint Inhibitor|Administered according to product label
75592067|NCT06018818|Device|Amvia/Solvia pacemaker family|Implantation of a pacemaker or CRT-P devices
75735069|NCT02964182|Drug|Very Low Nicotine Content Cigarette|Smoke very low nicotine content cigarette
75735070|NCT02964182|Device|ECIG-Hi|Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.
75735071|NCT02964182|Device|ECIG-Lo|Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks
75735072|NCT02950766|Drug|NeoVax|combination of Neoantigen peptides and poly-ICLC
75735073|NCT02950766|Drug|Ipilimumab|local administration of ipilimumab
75735074|NCT02933918|Other|Probiotics|Safety of nasal irrigation with probiotics in healthy volunteers
75884329|NCT03602508|Drug|fesoterodine|oral
75884330|NCT03602508|Drug|propiverine|oral
75884331|NCT05546671|Diagnostic Test|Hand grip strength measurement|"Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI >28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI >29: hand grip strength ≤21 kg"
75884332|NCT03549728|Drug|Granulocyte Colony-Stimulating Factor|In group A, at the day of oocyte retrieval, after oocytes collection, 30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion with IUI catheter (AINSEGREY, RIMOS, Italy). In controls, normal saline was used for intrauterine infusion instead of G-CSF.
75884333|NCT03549728|Procedure|Intrauterine infusion of normal saline|In group B (controls), normal saline will be used for intrauterine infusion instead of granulocyte colony-stimulating factor on the day of oocyte retrieval.
75884334|NCT01356797|Drug|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
75884335|NCT01356797|Drug|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
75909506|NCT03018860|Procedure|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
75441889|NCT01639456|Drug|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
75735075|NCT02907983|Drug|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
75735076|NCT02907983|Drug|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
75735077|NCT02892487|Other|Swallowing therapy|Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
75884336|NCT05200585|Behavioral|Healthy Liver/Hígado Sano program|The program will last 4-6 months and include 16 sessions, each 30-60 minutes long, that focus on self-management strategies for dietary changes and physical activity and is meant to be delivered in 4-6 months. The 16 sessions are as follows: 1) Introduction to the program, 2) Get Active, 3) Track Your Activity, 4) Eat Well, 5) Track Your Food, 6) Get More Active, 7) Burn More Calories Than You Take In, 8) Shop and Cook, 9) Manage Stress, 10) Find Time for Fitness, 11) Cope with Triggers, 12) Keep Your Heart Healthy, 13) Take Charge of Your Thoughts, 14) Get Support, 15) Eat Well Away from Home, and 16) Staying Motivated
75441890|NCT01639456|Drug|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
75441891|NCT01639521|Drug|cisplatin|Given IV
75592068|NCT06016478|Dietary Supplement|L-citrulline|4 weeks of L-citrulline (6 g/day) in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
75592069|NCT06016478|Dietary Supplement|Placebo|4 weeks of microcrystalline cellulose in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
75735078|NCT02886533|Other|Antithrombotic|Collection of clinical, biological data
75735079|NCT02877303|Biological|Blinatumomab|Given IV
75884337|NCT05200585|Behavioral|Usual standard of care|Participants will receive ongoing monitoring of condition at the clinic per standard of care and a short informational pamphlet
75441892|NCT01639521|Drug|gemcitabine hydrochloride|Given IV
75592070|NCT06006741|Biological|MM-specific universal CAR T cells|Infusion of MM-specific universal CAR T cells
75592071|NCT06000774|Other|Therapeutic Ketogenic Diet|therapeutic ketogenic diet
75884338|NCT03600012|Other|Cycling Functional Electrical Stimulation|
76071855|NCT03903653|Device|Serial Casting|"Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
75441893|NCT01639521|Drug|methotrexate|Given IV
75441894|NCT01639521|Drug|vinblastine|Given IV
75441895|NCT01639521|Drug|doxorubicin hydrochloride|Given IV
75735080|NCT02877303|Drug|Cyclophosphamide|Given IV
75735081|NCT02877303|Drug|Cytarabine|Given IT and IV
75735082|NCT02877303|Drug|Dexamethasone|Given PO
75441896|NCT01639521|Biological|pegfilgrastim|Given SC
75441897|NCT01639521|Other|laboratory biomarker analysis|Correlative studies
75441898|NCT01639547|Drug|Peginterferon alfa-2a plus Ribavirin|Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
75441899|NCT01639612|Biological|ALD-451|ALD-451 iv
75441900|NCT01639625|Drug|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
75884339|NCT03600012|Other|Physiotherapy|
75884340|NCT05747443|Other|Stepped Reminders|Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.
75884341|NCT05747443|Other|Patient Education|The Patient Voices Video is an educational video about lung cancer screening.
75884342|NCT02140346|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
75735083|NCT02877303|Drug|Doxorubicin Hydrochloride|Given IV
75884343|NCT02140346|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
75884344|NCT02238132|Drug|ATROVENT® inhalets|
75441901|NCT01639638|Drug|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
75735084|NCT02877303|Biological|Inotuzumab Ozogamicin|Given IV
75441902|NCT01639651|Other|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
75441903|NCT01639651|Other|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
75441904|NCT01639677|Procedure|Laparoscopic gastric bypass|Laparoscopic gastric bypass surgery
75441905|NCT01639677|Procedure|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
75441906|NCT01638494|Dietary Supplement|Colecalcium supplement|Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
75441907|NCT01639768|Drug|SUBLIVAC FIX Birch|Comparison of different dosages to placebo
75441908|NCT01639781|Dietary Supplement|Flavanol rich intervention|Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
75441909|NCT01639781|Dietary Supplement|Flavanol free control|Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
75441910|NCT01639794|Drug|Vesitirim™ (Solifenacin)|Oral
75441911|NCT01639807|Drug|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
75441912|NCT01639807|Procedure|SLT|Selective Laser Trabeculoplasty
75735085|NCT02877303|Other|Laboratory Biomarker Analysis|Correlative studies
75735086|NCT02877303|Drug|Mercaptopurine|Given PO
75735087|NCT02877303|Drug|Methotrexate|Given IT, IV, and PO
75735088|NCT02877303|Biological|Ofatumumab|Given IV
75735089|NCT02877303|Drug|Prednisone|Given PO
75735090|NCT02877303|Biological|Rituximab|Given IV
75735091|NCT02877303|Drug|Vincristine Sulfate|Given IV
75735092|NCT02875561|Device|Sonopet Ultrasonic Aspirator|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
75735093|NCT02875561|Device|CO2 Laser Ablation|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
75884345|NCT05200507|Device|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to the ventilatory assistance
75884346|NCT03595722|Device|High Intensity Focused Ultrasound|High intensity focused ultrasound to rectal/pelvic cancer
75884347|NCT05200429|Drug|Trikafta|Highly Effective CFTR Modulator Therapy
75884348|NCT02000219|Biological|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
75441913|NCT01639820|Procedure|identification of sentinel nodes + full pelvic lymph-node dissection|identification of sentinel nodes + full pelvic lymph-node dissection
75592072|NCT05997329|Other|App for diet record (MyFood)|Patients in the intervention group will record their food intake, tube feeding, nutrition-related symptoms and body weight in the MyFood app in at least three consecutive days in advance of follow-up.The patients will thus be able to keep track of their nutrition status. They will also have access to nutrition tips for how to reach requirements if they struggle to eat sufficiently or relief symptoms that can affect food intake.Healthcare staff at the hospital and outpatient clinics will use MyFood to monitor the patient's nutrition and document this information in the electronic patient record. They will also receive decision support tailored to each individual patient, e.g. recommendations for how to use oral nutrition supplements if the patient's intake of energy or protein is too low. Patients who struggle to fulfill their requirements will receive an additional referral to a registered dietitian for nutrition treatment between week 5 and 11.
75592073|NCT05988697|Drug|Combind asprin with Trametinib and Dabrafenib|Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD
75441914|NCT01639820|Procedure|only identification of sentinel nodes (without pelvic lymph-node dissection)|only identification of sentinel nodes (without pelvic lymph-node dissection)
75735094|NCT02850146|Drug|18F-AV-1451|
75735095|NCT02846571|Biological|Human Pancreatic Islet Transplantation|Human Pancreatic Islet Transplantation in the Eye Anterior Chamber of legally blind Type 1 Diabetic Patients with or without a Stable Prior Kidney Transplant
75735096|NCT02837939|Drug|Human derived Transfer factor|"One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~3 x TF in first week: day 1,3,5~2 x TF in week 2: day 8 , 11~1 xTF in week 3 and 4 : day 15, 22~1 x TF once a month up to 6 month"
75735097|NCT02837939|Drug|Aqua pro injectione 4ml ampules for subcutaneous injection|"12 doses in total:~3 doses in first week: day 1,3,5~2 doses in week 2: day 8 , 11~1 dose in week 3 and 4 : day 15, 22~1 dose once a month up to 6 month"
75735098|NCT02822378|Dietary Supplement|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
75735099|NCT02822378|Dietary Supplement|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
75735100|NCT02822378|Dietary Supplement|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
75735101|NCT02813655|Drug|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
75441915|NCT01639846|Drug|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
75441916|NCT01639846|Drug|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
75441917|NCT01639859|Other|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
75441918|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
75735102|NCT02813655|Drug|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
75735103|NCT02742246|Behavioral|Individual clinician-provided CBT|Individual clinician-provided CBT
75735104|NCT02742246|Behavioral|CBT4CBT|CBT computer program assisted therapy
75735105|NCT02733042|Drug|Durvalumab|Administered as an IV infusion (250 mL) over approximately 1 hour in duration
75735106|NCT02733042|Drug|Lenalidomide|Administered orally
76071856|NCT03898388|Procedure|Bone Marrow Concentrate treatment|Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
75441919|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
75735107|NCT02733042|Drug|Rituximab|Administered by intravenous infusion
75441920|NCT01639885|Biological|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
75735108|NCT02733042|Drug|Ibrutinib|Administered orally
75735109|NCT02733042|Drug|Bendamustine|Administered as a 30-minute intravenous infusion
75735110|NCT02725619|Behavioral|CBT|
75735111|NCT02725619|Behavioral|PST|
75441921|NCT01639898|Drug|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
75735112|NCT02723721|Drug|Picato gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
75441922|NCT01639898|Drug|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
75441923|NCT01639911|Drug|Alisertib|Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
76071857|NCT03892928|Drug|Dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
75441924|NCT01639911|Drug|Pazopanib|Pazopanib at the assigned dose once a day continuously for the duration of treatment.
75441925|NCT01640119|Dietary Supplement|Bicarbonate|bicarbonate administration
75441926|NCT01640158|Other|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
75441927|NCT01640158|Other|Commercially available computerized training|Commercially available computerized training, up to 65 hours
75441928|NCT01640431|Other|Lumbar stabilization exercises|The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
75441929|NCT01640457|Drug|NOVOCART® Disc plus|Autologous Disc Chondrocyte Transplantation System (ADCT)
75441930|NCT01640457|Device|NOVOCART® Disc basic|ADCT (Media with no active cell component)
75441931|NCT01640561|Behavioral|MISC|The Mediational Interventions for Sensitizing Caregivers
75735113|NCT02719574|Drug|FT-2102 (olutasidenib)|FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
75441932|NCT01640561|Behavioral|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
75441933|NCT01640743|Drug|Tacrolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
75441934|NCT01640743|Drug|Tacrolimus + Everolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
75441935|NCT01641016|Drug|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
75441936|NCT01641354|Procedure|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
75441937|NCT01641614|Procedure|Mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
75735114|NCT02719574|Drug|Azacitidine|azacitidine will be administered per site's standard of care
75735115|NCT02719574|Drug|Cytarabine|low-dose cytarabine will be administered per site's standard of care
75735116|NCT02709278|Biological|BCG|BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)
75735117|NCT02709278|Other|Saline placebo|Saline placebo
75884349|NCT02135666|Procedure|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
75441938|NCT01641614|Procedure|mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
75735118|NCT02709278|Biological|BCG|BCG Bulgaria (InterVax)
76055884|NCT05884216|Device|Entarik Feeding Tube System|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System is designed to aid qualified operators in the placement of the Entarik Feeding Tube (Entarik FT) into the stomach of patients requiring enteral feeding. The Entarik FT is equipped with sensors designed to provide information about the location of the tube tip relative to the stomach, thus assisting in reducing the incidence of misplacement during first positioning. The Entarik Monitor also monitors the feeding tube position continuously during the course of feeding and automatically and in real-time alerts of tube migration."
75441939|NCT01641757|Procedure|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
75462849|NCT01868945|Dietary Supplement|20 µg/day vitamin D3|20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
75462850|NCT01868971|Device|EndoRings|Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician's evaluation
75462851|NCT01868984|Drug|Paclitaxel|Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
75735119|NCT02704416|Procedure|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
75735120|NCT02690558|Drug|pembrolizumab, gemcitabine and cisplatin|neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
75735121|NCT02690402|Behavioral|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
75735122|NCT02689427|Procedure|Axillary Lymph Node Dissection|Undergo axillary lymph node dissection
75735123|NCT02689427|Drug|Enzalutamide|Given PO
75735124|NCT02689427|Other|Laboratory Biomarker Analysis|Correlative studies
75735125|NCT02689427|Procedure|Lymph Node Biopsy|Undergo lymph node biopsy
75735126|NCT02689427|Drug|Paclitaxel|Given IV
75735127|NCT02689427|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of primary tumor
75735128|NCT02686528|Other|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
75884350|NCT03595488|Drug|Dupilumab|dupilumab 300 mg subcutaneous injection every 2 weeks
75884351|NCT01356875|Drug|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
75884352|NCT01356875|Drug|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
75462852|NCT01868984|Procedure|Standard Therapy|Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
75441940|NCT01642394|Behavioral|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
75592074|NCT05978791|Procedure|collection of venous blood or arterial blood|"Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots).~Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP).~Healthy volunteer (group 1) collected 40 mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP).~Healthy volunteer (group 2) collected 9 mL venous blood samples (for platelet aggregation assay)."
75441941|NCT01642511|Radiation|99mTc-labeled Sulfur Colloid|Control Group: Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5~1.0 mCi/0.5mL) in the tumor quadrant. Study Group: Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
75592075|NCT05977192|Behavioral|Standard MI|One phone-based MI session
75592076|NCT05977192|Behavioral|Intensive MI|Four phone-based MI sessions
75592077|NCT05977192|Behavioral|MOTIVACC|mHealth-based MI
75592078|NCT05977192|Behavioral|Ecological momentary assessment (EMA) messages|EMA messages focused on vaccinations and health
76055885|NCT05884216|Device|Entarik Feeding Tube System without monitoring|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System will collect data from the Entarik Feeding Tube. There will be no monitoring or dislodgement alerts, and no placement guidance."
75441942|NCT01642511|Procedure|Axillary Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy
75441943|NCT01642511|Drug|Methylthioninium|Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
75441944|NCT01642511|Device|Lymphoscintigraphy|Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
75441945|NCT01642511|Procedure|Axillary Lymph Node Dissection|ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
75441946|NCT01642511|Procedure|Internal Mammary Sentinel Lymph Node Biopsy|Internal mammary sentinel lymph node biopsy
75441947|NCT01642771|Drug|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
75592079|NCT05976750|Device|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
75592080|NCT05976750|Device|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
75592081|NCT05975450|Drug|Abatacept 125Mg/Ml Syringe|"Participants on qualifying belatacept regimen (with low dose tacrolimus, mmf and prednisone) will have their maintenance regimen changed from i.v. belatacept to s.c. abatacept, which will continue through week 52 (month 12) post-transplant:~Costimulation blockade:~- Abatacept 125 mg subcutaneous weekly"
75592082|NCT05974592|Other|Education|Diabetic Foot Self-Management Training Program will be implemented.
75592083|NCT05967468|Behavioral|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
75592084|NCT05967468|Behavioral|Bibliotherapy, low therapist contact SPACE|Parent-based bibliotherapy for treating anxiety disorders in youth
75592085|NCT05967468|Other|Relaxation and Mentorship|Relaxation based treatment
75592086|NCT05956535|Device|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
75592087|NCT05956535|Device|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
75884353|NCT03594708|Dietary Supplement|Nutrition supplement|Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc
75592088|NCT05949619|Drug|BL-M02D1|Administration by intravenous infusion
75592089|NCT05945966|Other|Unilateral training group (UTG)|stroke patients will be undergone task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) for the hemi-paretic side
75884354|NCT03594708|Dietary Supplement|Placebo supplement|rice starch, light olive oil, vegetable oil
76055886|NCT05884060|Other|No intervention|No interventions
76055887|NCT05881993|Drug|CBP-4888|siRNA therapeutic
76055888|NCT05881993|Other|Placebo|Normal Saline
75735129|NCT02686528|Other|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
76055889|NCT05876260|Behavioral|Greek yogurt|Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise
75441948|NCT01642771|Drug|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
75592090|NCT05945966|Other|Bilateral training group (BTG).|stroke patients will be undergone strength training using frequency, intensity, type, time (FITT) principle to non-hemi-paretic side and task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) to hemi-paretic side
75441949|NCT01642979|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
75441950|NCT01642979|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
75441951|NCT01642979|Drug|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
75592091|NCT05945225|Device|Sonicare DiamondClean 9000 Philips®|Brush teeth with the electric toothbrush daily during 3 months
75592092|NCT05945225|Device|HydroSonic Easy Curaden®|Brush teeth with the hydrosonic toothbrush daily during 3 months
75592093|NCT05945225|Device|Manual toothbrush Oral-B 123|Brush teeth with the manual toothbrush daily during 3 months
75592094|NCT05945225|Device|Manual toothbrush Curaprox CS 5460|Brush teeth with the manual toothbrush daily during 3 months
75592095|NCT05944471|Other|Providing breastfeeding support with Telehealth|After discharge, training videos on the importance of breast milk and breastfeeding prepared in line with the literature and explained by experts, and written documents (e-brochure, plain text version of breastfeeding trainings) were sent to individual mothers once a week between 10.00-14.00 hours via telehealth application. At the same time intervals, visualised messages explaining breastfeeding and that breast milk is sufficient for the baby were sent via telehealth application five days a week. In addition, if the mothers requested at 10.00-17.00 on weekdays, they were given live support by the researcher for the issues they were curious about breastfeeding by calling the researcher via telehealth application.
75592096|NCT05943821|Drug|Allopurinol 200 mg|The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
75592097|NCT05943821|Drug|Optional intervention|"Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels >5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up."
75592098|NCT05940610|Biological|MSC-EVs|10 E10 MSC-EV particles per 100ml for a single dose. Once a week for 4 weeks.
75735130|NCT02673931|Drug|Byetta (Lilly, Exenatide)|See description of arms
75735131|NCT02673931|Drug|Conoxia (AGA, oxygen)|See description arms
75735132|NCT02673931|Drug|20% Human Albumin|
75909507|NCT05195450|Drug|Tenofovir alafenamide fumarate|• TAF 25 mg OD vs no treatment x 5 years and beyond
75909508|NCT03477656|Procedure|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption using GLYCOSORB®-ABO column
75909509|NCT03477656|Procedure|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis
75909510|NCT03477578|Other|freezers|neuropsychological evaluation
75441952|NCT01643031|Drug|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
75441953|NCT01643031|Drug|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
75592099|NCT05939362|Other|MRI follow-up|MRI follow-up for patient with early onset Alzheimer's disease
76055890|NCT05876260|Behavioral|Carbohydrate-based study supplement|Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise
75592100|NCT05938543|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces an electrical current in neurons and allows for modulation of neural circuitry.~Other Name: iTBS"
75592101|NCT05934708|Behavioral|Downhill Running|Participants will complete a 20 minute downhill running protocol on a -12% grade, at ~6 mph. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump and maximal voluntary isometric contraction. After the running protocol, the same tests will be performed again. The metrics will be collected a third and fourth time at 24 hours and 48 hours post exercise, respectively.
75441954|NCT01643291|Procedure|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
75441955|NCT01640067|Biological|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
75441956|NCT01643434|Drug|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
75592102|NCT05911074|Diagnostic Test|The Abbott Panbio™ COVID-19 Ag Rapid Test|This is the intervention or medical device(s) intended to be used with a study participant according to the study protocol.
75592103|NCT05900947|Other|analysis of carotid atherosclerotic plaque|To assess the presence of air pollutants (benzene, toluene, xylene, and ethylbenzene) or of microplastics within tissues from atherosclerotic plaques by Chromatographic analyses.
75592104|NCT05898412|Drug|Andexanet alfa|Patients treated with andexanet alfa
75884355|NCT05578196|Drug|fecal bacteria solution|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
75884356|NCT05578196|Drug|physiological saline solution|physiological saline solution 20ml
76055891|NCT05876260|Behavioral|Exercise|Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
76071858|NCT03889197|Drug|Sodium supplementation guided by urine sodium concentration algorithm|4 mEq/kg/d sodium added the first time urine [Na] below threshold; for each subsequent time urine [Na] below threshold, add additional 2 mEq/kg/d.
76071859|NCT03888651|Other|Quality-of-Life Assessment|Complete quality of life assessment
75441957|NCT01643434|Drug|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
75441958|NCT01643694|Behavioral|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
75441959|NCT01643941|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
75441960|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
75441961|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
75441962|NCT01643941|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
75592105|NCT05895552|Drug|RTA 901|RTA 901 capsules will be administered once daily during a fasted state in either Dose 1 or Dose 2.
75592106|NCT05895552|Drug|Placebo|Matching placebo capsules will be administered once daily during a fasted state.
75592107|NCT05891327|Dietary Supplement|Maca|2.25 g Lepidium meyenii (Maca) extract twice per day for 12 weeks
75592108|NCT05891327|Dietary Supplement|Placebo|Placebo
75592109|NCT05888311|Device|Liquid bandage|Two areas measuring 3.0 cm x 3.0 cm will be randomly demarcated on one of your forearms, with activated carbon applied to both areas. An area to be treated with the experimental product will be determined by randomization.
75592110|NCT05888311|Other|Activated carbon|Two areas measuring 3.0 cm x 3.0 cm will be randomly demarcated on one of your forearms, with activated carbon applied to both areas. An untreated area (control area) will be determined by randomization.
75592111|NCT05887934|Device|X-Ray Fluorescence Analyzer|The XRF analyzer (the ThermoFisher Niton XL3t GOLDD+) is a portable x-ray fluorescent analyzer specifically configured to measure low levels of metals, lead in particular, in bone. The device is designed to rapidly assess cumulative lead exposure, not to support or sustain human life.
75592112|NCT05881668|Biological|MSC-EV|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
75592113|NCT05878951|Drug|OnabotulinumtoxinA|Intra-detrusor OnabotulinumtoxinA is commonly known as botox
75884357|NCT05200273|Drug|AK114|AK114 administered by subcutaneous injection
75884358|NCT01363973|Device|VITALSTIM transcutaneous electrical stimulation|
76071860|NCT03888651|Other|Questionnaire Administration|Complete questionnaire
75592114|NCT05878080|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
75735133|NCT02663297|Drug|ATLCAR.CD30 cells|"Three dose levels will be evaluated:~Group One, 2x10^7 cells/m^2 (maximum dose 5x10^7 cells)~Group Two, 1x10^8 cells/m^2 (maximum dose 2.5x10^8 cells)~Group Three, 2x10^8 cells/m^2 (maximum dose 5x10^8 cells)"
75735134|NCT02654561|Drug|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
75735135|NCT02654561|Drug|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
75735136|NCT02614066|Biological|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
75735137|NCT02614066|Drug|Cyclophosphamide|Administered intravenously.
75735138|NCT02614066|Drug|Fludarabine|Administered intravenously.
75592115|NCT05877027|Other|Exercise|The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.
75735139|NCT02600949|Drug|Imiquimod|Applied topically
75592116|NCT05877027|Other|Topical Diclofenac|They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.
75441963|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
75441964|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
75592117|NCT05877027|Other|Platelet-Rich-Plasma (PRP)|8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
75735140|NCT02600949|Biological|Pembrolizumab|Given IV
75735141|NCT02600949|Biological|Sotigalimab|Given IV
75735142|NCT02600949|Biological|Synthetic Tumor-Associated Peptide Vaccine Therapy|Given SC
75735143|NCT02600949|Procedure|Computed Tomography|Undergo CT
75735144|NCT02600949|Procedure|Magnetic Resonance Imaging|Undergo MRI
75735145|NCT02599324|Drug|ibrutinib|Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
75735146|NCT02599324|Drug|everolimus|Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
75884359|NCT02135822|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
75441965|NCT01643941|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
75441966|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
75441967|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
75592118|NCT05870748|Drug|Luveltamab tazevibulin|antibody-drug conjugate
75592119|NCT05870748|Drug|Pegfilgrastim|pegylated G-CSF
75735147|NCT02599324|Drug|paclitaxel|Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m^2, once weekly, in continual 3 weekly cycles.
75735148|NCT02599324|Drug|docetaxel|Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m^2 (according to local institutional standard of care), given continually in 21-day cycles.
75735149|NCT02599324|Drug|cetuximab|Cetuximab 400 mg/m^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m^2 infused over 60 minutes.
75735150|NCT02599324|Drug|pembrolizumab|Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
75735151|NCT02586831|Drug|Anti-Thymocyte Globulin (ATG)|2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
75735152|NCT02586831|Drug|Interleukin 2|1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
75735153|NCT02586831|Drug|Exenatide|2 mg administered subcutaneously weekly for up to 52 weeks.
75735154|NCT02586831|Drug|Adalimumab|50 mg administered subcutaneously once a month for 1 year.
75884360|NCT02135822|Drug|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
76055892|NCT05875870|Behavioral|Daylight exposure combine walking|"Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks.~Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes.~Weekly exercise consultation via communication software (LINE App).~Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage."
75441968|NCT01643941|Biological|SA3Ag vaccine|Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
75592120|NCT05861115|Device|"Chang Gung Ventricular Systolic Dysfunction Screening Software"|This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
75592121|NCT05857592|Diagnostic Test|Adaptive functioning self-report questionnaire|A self-report questionnaire for assessing level of adaptive functioning
75441969|NCT01643941|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
75592122|NCT05857592|Diagnostic Test|Adaptive functioning self-report questionnaire - adapted|A self-report questionnaire for assessing level of adaptive functioning, adapted to the communication level of the participant
75592123|NCT05855369|Device|Trigeminal Nerve Stimulation (TNS)|Non-invasive, pain-free, low-level electrical stimulation to the forehead to modulate the trigeminal nerve and enhance smell function through activation of the highly connected olfactory-intranasal trigeminal brain circuits.
75592124|NCT05855369|Other|Active Smell Training (ST)|Sniffing various higher intensity odorant chemicals while performing odor-related cognitive tasks. 16 odorant chemicals will be used for training including: 2 phenyl ethanol, eugenol, lemon, eucalyptus, cinnamon, peppermint, coffee, mandarin, lavender, vanilla, lilac, ginger, chocolate, thyme, banana, and bacon.
75441970|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
75441971|NCT01643941|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
75592125|NCT05855369|Other|Placebo Smell Training (PBO)|Sniffing the same lower intensity odorant chemicals (i.e. N-butanol and 2-phenyl ethanol) over the course of the trial and performing no odor-related cognitive tasks.
75592126|NCT05850533|Behavioral|Virtual Tai Chi Easy|Unique to other mind-body therapies, Tai Chi Easy (TCE) is multi-component mind-body therapy including: 1) Gentle movement, 2) Breath practice, 3) Self-massage, and 4) Meditation.
75592127|NCT05850312|Device|Gamified Digital Intervention - Feasibility Analysis on MoM|In first round we aim to clinically analyze the game Militant of the Maze (MoM) as a vehicle for Exposure Theory, including, play, observation, and feedback from five clinicians.
75735155|NCT02586831|Other|ATG Placebo|ATG placebo mimicking Thymoglobulin administered intravenously.
75884361|NCT05534893|Dietary Supplement|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
75884362|NCT05534893|Dietary Supplement|Placebo powder group|Participants in the placebo powder group will receive an isocaloric placebo powder
75884363|NCT02238210|Drug|Atrovent®|
75884364|NCT05739955|Other|Sani24|24-hour continuously acting quaternary ammonium salt disinfectant
75441972|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
75441973|NCT01643941|Procedure|Colonization swab samples|Colonization swabs will be collected from all subjects at various timepoints.
75441974|NCT01643980|Drug|Vaginal micronized progesterone|200 mg vaginal route per day
75441975|NCT01643980|Device|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
75441976|NCT01644214|Other|6 month follow up for pessary check in the clinic setting|The standard of care is considered to be pessary checks every 3 months, therefore those that are checked every 6 months will be considered to be in the intervention group.
75592128|NCT05850312|Device|Gamified Digital Intervention|In the first phase of round 2 of the study, 5 clinicians will play the game to evaluate the revised game MoMG. In the next phase, 5 carefully-selected non-clinician participants will play the game. under real-time observation of clinicians, to ensure that subjects experience no harm, and that the gameplay is interesting and enjoyable.
75441977|NCT01644708|Behavioral|Self empowerment|"1. Group meeting, introducing the method and the assessment tools~Self-empowerment,~Handing over the journal,~Questionnaire about emotional states and motivations for losing weight and for change.~The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant weighs himself and he notes his weight down in his journal."
75441978|NCT01644721|Biological|Early measles vaccine|Standard Edmonston-Zagreb measles vaccine
75441979|NCT01644916|Procedure|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
75441980|NCT01644916|Procedure|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
75441981|NCT01644929|Procedure|transcranial direct current stimulation (tDCS)|Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
75592129|NCT05848180|Other|Ankle proprioceptive training (APT)|"APT comprise of exercises including towel curls, uni-leg stance on foam with activity, writing alphabets on gym ball with toes, picking marbles with toes.~BT includes tendem walk, side leg raises, sit to stand, side walk, back leg raise"
75592130|NCT05848180|Other|Balance training (BT)|Balance training exercises comprising of side walk, tandem walk, standing on one leg, walking with alternating arm raise up to 90 degrees
75592131|NCT05838742|Drug|GSK3858279|GSK3858279 will be administered.
75592132|NCT05838742|Drug|Placebo|Placebo will be administered.
75592133|NCT05837806|Drug|tislelizumab+disitamab-vedotin|patients in group will receive 3 cycles of tislelizumab 200 mg in combination with disitamab-vedotin 120 mg intravenously.
76055893|NCT05875870|Behavioral|Stretching exercise|"The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks.~The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen.~A video is shown to the participants (the content same as hardcopy of education manual)."
75592134|NCT05828654|Behavioral|Focus Group Discussions and Semi-structured Interviews|Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials
75592135|NCT05828654|Behavioral|Training community lay navigators|Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
75592136|NCT05827874|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
75592137|NCT05827874|Biological|Tdap|Tdap will be administered as an IM injection.
75592138|NCT05827874|Biological|PPSV23|PPSV23 will be administered as an IM injection.
75592139|NCT05824728|Drug|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
76055894|NCT05868772|Device|Active Sentry Handpiece|With low IOP settings
75592140|NCT05821959|Combination Product|AAVAnc80-hOTOF via Akouos Delivery Device|AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
75592141|NCT05821582|Other|Stool Collection and Survey Completion|Participants will have 2 scheduled at-home stool self-collections at the time points specified in section 4.0 and complete a questionnaire by telephone contact. The biospecimens collected from participants on this study are stool samples.
75592142|NCT05818137|Biological|Sotatercept|SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
76055895|NCT05868772|Device|Ozil Handpiece|With high IOP settings.
76071861|NCT03886818|Device|Standard dressings|Standard dressings will be used from surgery to wound healing
75592143|NCT05818085|Drug|ABP-671|Low, medium or high dose (Part 1); Selected dose(s) (Part 2)
75592144|NCT05818085|Drug|Allopurinol|Standard of care according to American College of Rheumatology (ACR) guideline for the management of gout
75592145|NCT05818085|Other|Placebo|ABP-671 matching placebo
75592146|NCT05816343|Drug|Orlistat|Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
75592147|NCT05816343|Drug|Placebo|Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
75592148|NCT05813314|Combination Product|BMN 111 administration via Injector Pen|BMN 111 Injection will be given using an injector pen
75884365|NCT05739955|Other|Standard EPA-registered disinfectant|Standard EPA-registered disinfectant
75884366|NCT05739955|Other|Routine Disinfection|Routine disinfection at the study hospital
75884367|NCT02978456|Device|quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro/Orsiro mission stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus ~10% of distal reference vessel diameter).
76055896|NCT05867719|Other|Hypoxic breathing conditions|Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.
75441982|NCT01644929|Procedure|Sham stimulation, then tDCS|Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks
75884368|NCT02978456|Device|intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is selected by intravascular ultrasound measurements.
75592149|NCT05813314|Drug|BMN 111 administration via vial and syringe|BMN 111 Injection will be given using vial and syringe
75592150|NCT05799963|Device|BioMatrix Alpha|Patient will be treated with BioMatrix Alpha
75592151|NCT05789173|Drug|Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)
75441983|NCT01644929|Procedure|Sham stimulation|Sham stimulation for 30 seconds on 15 days during 6 weeks
75441984|NCT01645137|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
75592152|NCT05789173|Drug|Efavirenz, Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
75592154|NCT05773755|Device|Medtronic Percept PC DBS system|Open label active Deep Brain Stimulation (DBS)
75735156|NCT02586831|Other|IL-2 Placebo|IL-2 placebo mimicking Aldesleukin administered subcutaneously.
75735157|NCT02586831|Other|Adalimumab Placebo|Placebo mimicking Adalimumab administered subcutaneously.
75735158|NCT02586831|Other|Exenatide Placebo|Placebo mimicking Exenatide administered subcutaneously.
75735159|NCT02504866|Other|Vigorous exercise|Exercise training of vigorous intensity
75735160|NCT02504866|Other|Light to moderate exercise|Exercise training of light to moderate intensity
75735161|NCT02502162|Drug|LDN|
75909511|NCT03477578|Other|non freezers|neuropsychological evaluation
76055897|NCT05863741|Device|Implantation of GMK Sphere with conventional instrumentation|Implantation of GMK Sphere with conventional instrumentation (control group)
76055898|NCT05863741|Device|Implantation of GMK Sphere using the NextAR guidance system|Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
75441985|NCT01645137|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
75441986|NCT01645228|Radiation|coronary calcium score measurement|
75441987|NCT01645228|Biological|high sensitivity C reactive protein measurement|
75441988|NCT01645228|Procedure|ankle brachial index measurement|
75441989|NCT01645566|Behavioral|instruction|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
75592155|NCT05773170|Drug|Refralon|1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
75592156|NCT05764785|Behavioral|MentorPRO|MentorPRO is a novel application and web platform for mentoring programs that allows students to set goals, track their challenges, and find just-in time resources, while connecting to a mentor for personalized support and progress monitoring.
75592157|NCT05763199|Drug|AHCC|AHCC is the cultured mycelia of Lentinula edodes mushrooms from the Basidiomycetes family.
75592158|NCT05763199|Drug|Chemotherapy|Chemotherapy will be administered per standard of care.
75592159|NCT05763199|Other|Placebo|Dextrin
75592160|NCT05762276|Drug|VXX-401|A synthetic PCSK9 peptide-based immunotherapy
75592161|NCT05762276|Biological|Placebo|Normal saline
75592162|NCT05753774|Biological|FMT|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut. FMT was given 1-3courses, 3-6 times per courses
75592163|NCT05749835|Other|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland.
75592164|NCT05749835|Other|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\her head is cradled between your body and your right forearm (when you stand at his\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
75735162|NCT02502162|Drug|Placebo|Sugar pill
75735163|NCT02500316|Drug|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
76055899|NCT05861232|Behavioral|Behavioral|fear and anxiety during inhalation therapy
75592165|NCT05743517|Behavioral|Fit4Treatment|This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.
76055900|NCT05860257|Behavioral|PeerLearning.net|PeerLearning.net provides an easy-to-use, scalable, and widely accessible means to support teachers in effectively designing and delivering high-fidelity Cooperative Learning (CL) lessons and, in turn, it has the potential to amplify the positive effects of CL found in previous research. Using PeerLearning.net, teachers design their lesson by selecting from among a set of typical CL lesson templates (e.g., jigsaw, peer tutoring, group projects) which they can customize and populate with their own curriculum and materials. These design templates represent the optimal, high-fidelity design that is required in order for CL to be successful. During lesson delivery, PeerLearning.net manages membership in learning groups, distributes instructional materials, directs student activities according to a pre-specified timetable, supports teacher observations of student behavior, and delivers post-lesson group activities and reviews.
76071862|NCT03886818|Device|PICO strategy|The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.
75735164|NCT02497677|Behavioral|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration
75735165|NCT02497677|Behavioral|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
75735166|NCT02494115|Procedure|subcutaneous drainage|
75735167|NCT02459769|Behavioral|Exercise for Cancer Patients|a standardized, daily, 6 week, home-based, progressive exercise program
75441990|NCT01645722|Procedure|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
75441991|NCT01645839|Drug|Liposomal Cytarabine|50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
75592166|NCT05743387|Other|T2D care package|T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.
75592167|NCT05743387|Other|Referral to the responsible health facility|CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
75735168|NCT02434744|Drug|KD026|Dosed in combination
75735169|NCT02434744|Drug|Placebo|Dosed in combination
75735170|NCT02434744|Drug|Metformin|Drug prescribed by each subject's prescribing physician
75735171|NCT02432417|Drug|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
75735172|NCT02390895|Procedure|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
75735173|NCT02390635|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
75735174|NCT02390635|Procedure|Diffusion Weighted Imaging|Undergo whole body PET/MRI
75735175|NCT02390635|Radiation|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
75735176|NCT02390635|Drug|Gadolinium|Given IV
75735177|NCT02390635|Procedure|Magnetic Resonance Imaging|Undergo whole body PET/MRI
75735178|NCT02390635|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT and whole body PET/MRI
75735179|NCT02390635|Procedure|Three-Dimensional Spoiled Gradient MRI|Undergo whole body PET/MRI
75735180|NCT02369016|Drug|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
75441992|NCT01645995|Dietary Supplement|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
75441993|NCT01645995|Dietary Supplement|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
75441994|NCT01646190|Dietary Supplement|Preoperative Carbohydrate load|oral intake in the evening before surgery and 2-3h before intubation
75441995|NCT01646190|Procedure|individualized i.v fluids therapy|by Transoesophageal aortic US-Doppler done intraoperatively
75441996|NCT01646190|Behavioral|Fasting state after midnight|No preoperative glucose load
75441997|NCT01646190|Behavioral|No Nasogastric tube postoperatively|Withdrawal after complete awakening in operating room
75441998|NCT01646190|Behavioral|urinary catheter removal|at POD 1
75441999|NCT01646190|Behavioral|Oral liquids|0.3-0.5L oral liquids at 6h postoperatively on POD 0
75442000|NCT01646190|Behavioral|Stimulation of inspirex utilization|using 6-8 times/day to prevent pulmonary atelectasis
75442001|NCT01646190|Behavioral|Mobilization|First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), >4h out of bed on POD1, >6h on POD2, complete at POD3
75442002|NCT01646190|Other|Preanesthetic medication|Preanesthetic oral medication before surgery
75442003|NCT01646437|Drug|Polycap|Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
75442004|NCT01646437|Drug|Aspirin|75 mg daily
75442005|NCT01646437|Drug|Vitamin D|60,000 IU monthly
75442006|NCT01646437|Drug|Matching Placebo|Matching Placebo
75442007|NCT01646619|Drug|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%."
75442008|NCT01646619|Drug|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
75442009|NCT01646749|Dietary Supplement|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
75442010|NCT01646840|Drug|PF-04958242 capsule|Single dose of PF-04958242 0.35 mg oral capsule
75442011|NCT01646840|Drug|PF-04958242 oral solution|Single dose of PF-04958242 0.35 mg oral solution
75442012|NCT01647490|Procedure|Permanent Cardiac Pacemaker Implantation|
75442013|NCT01647750|Drug|Levothyroxine|Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
75442014|NCT01647750|Drug|Levothyroxine|Participants in the standard dose of treatment will receive their usual dose of levothyroxine
75442015|NCT01647880|Drug|Verum arm receiving Gilenya®|
75442016|NCT01647880|Drug|Active Comparator receiving Extavia®|
75442017|NCT01647997|Other|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
75442018|NCT01648218|Drug|Neutral protamine hagedorn (NPH) insulin|
75442019|NCT01648218|Drug|Regular human insulin or Insulin Aspart|
75442020|NCT01648218|Drug|Insulin glargine|
75442021|NCT01648465|Drug|Everolimus|Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
75442022|NCT01648621|Behavioral|40 minute standardized education session|40 minute standardized education session based on the Living Well with COPD Patient's Education Tool on study enrolment to assess and improve understanding of disease and ability to monitor symptoms and recognize exacerbation
75442023|NCT01648621|Behavioral|Individualized action plan|Individualized action plan using the Living Well with COPD template with patient individualized modification to address management strategies for exacerbation of comorbidity developed during the initial 40 minute session with case manager.
75442024|NCT01648621|Behavioral|Individualized care plan|Individualized care plan for management of COPD and comorbidities developed by the case manager in consultation with family physician and specialists.
75442025|NCT01648621|Behavioral|Standardized reinforcement/motivational interviewing and action plan teach-back sessions|Standardized reinforcement/motivational interviewing and action plan teach-back sessions based on Living Well with COPD modules as well as assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions) (telephone script; NOTE: case managers will make up to 3 attempts to contact participants during each week of the 12 weeks of weekly phone calls before determining inability to contact the participant for that week.
75592168|NCT05737160|Biological|Telitacicept|Administered as an SC infusion
75592169|NCT05737160|Drug|Placebo|Administered as an SC infusion
75592170|NCT05736497|Other|Digital Care Plans|Investigators will develop digital care plans for 10 common Cancer Predisposition Syndromes for patients diagnosed within 3 years.
75442026|NCT01648621|Behavioral|Tele-home monitoring|"Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.~Inclusion criteria for tele-home monitoring:~a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness [MRC] Class 4 & 5 or modified MRC [mMRC] 3 & 4) f. frequent ED visits (> 2) in last 12 months~5. 12 weeks of clinical stability with no ED visits."
75735181|NCT02363959|Drug|Hyperbaric Oxygen Therapy|2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
75735182|NCT02363959|Procedure|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
76055901|NCT05858151|Behavioral|Food system and demand generation|The Global Alliance for Improved Nutrition (GAIN) will implement the Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable program, which will use a market-based approach to improving diets through food systems. The set of interventions proposed is based on characteristics and challenges of the food environments of bottom of pyramid consumers in Mozambique. GAIN will focus on elements of the food environment related to accessibility, affordability, and desirability of animal source foods (ASFs) in Mozambique.
76055902|NCT05855122|Drug|Tocilizumab|Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
75442027|NCT01648621|Behavioral|Coordinated and improved communication|Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
75442028|NCT01648621|Behavioral|Priority access|Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
75442029|NCT01648621|Behavioral|Dictated patient summary|Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
75442030|NCT01648621|Behavioral|in-hospital rehabilitation/self-management program|"Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:~have had a recent exacerbation, but are now clinically stable;~symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;~have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and~have sufficient motivation to participate."
75442031|NCT01648621|Behavioral|Smoking cessation|Referral to a smoking cessation program (as applicable)
75442032|NCT01648621|Behavioral|Action plan Respirologist|Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
75442033|NCT01648621|Behavioral|Web based self management materials|Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
75442034|NCT01648777|Device|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
75442035|NCT01648777|Drug|placebo|"Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
75735183|NCT02345265|Procedure|Biopsy|Undergo biopsy of tumor
75592171|NCT05725733|Other|Physical Therapy|The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
75592172|NCT05724953|Behavioral|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
75592173|NCT05721755|Drug|Carboplatin|Given IV
75592174|NCT05721755|Drug|Cisplatin|Given IV
75592175|NCT05721755|Procedure|Computed Tomography|Undergo CT and/or PET/CT
75592176|NCT05721755|Drug|Fluorouracil|Given IV
75735184|NCT02345265|Procedure|Biospecimen Collection|Undergo blood sample collection
75735185|NCT02345265|Drug|Cediranib Maleate|Given PO
75735186|NCT02345265|Procedure|Computed Tomography|Undergo CT scan
75735187|NCT02345265|Procedure|Echocardiography|Undergo echocardiogram
75735188|NCT02345265|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
75735189|NCT02345265|Procedure|Multigated Acquisition Scan|Undergo MUGA
76055903|NCT05837117|Behavioral|Patient's Perspective|"Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic.~Participants/Researchers will learn about your attitudes, beliefs, and feelings about sexual well-being"
75735190|NCT02345265|Drug|Olaparib|Given PO
75735191|NCT02345265|Other|Questionnaire Administration|Ancillary studies
75735192|NCT02337829|Drug|Acalabrutinib (Arm A)|"A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"
76055904|NCT05824858|Drug|LY3537982|Administered orally.
75442036|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
75442037|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
75442038|NCT01648998|Drug|Fludrocortisone|single dose 500 mg, capsule
75735193|NCT02337829|Drug|Acalabrutinib (Arm B)|"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."
75442039|NCT01648998|Drug|Placebo|
75442040|NCT01649024|Drug|Tremelimumab|Given IV
75442041|NCT01649843|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
75442042|NCT01649934|Behavioral|Implementation Intention|Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
75592177|NCT05721755|Procedure|Magnetic Resonance Imaging|Undergo MRI
75592178|NCT05721755|Drug|Paclitaxel|Given IV
75592179|NCT05721755|Biological|Pembrolizumab|Given IV
75735194|NCT02317887|Biological|RS1 AAV Vector|Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
75735195|NCT02316886|Device|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) + Optimal Medical Treatment
75735196|NCT02316886|Drug|Optimal Medical treatment|
75735197|NCT02316314|Procedure|Cardiac magnetic resonance imaging (CMR)|"CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart."
75735198|NCT02316314|Procedure|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
75735199|NCT02316314|Procedure|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
75735200|NCT02316314|Procedure|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
75735201|NCT02288221|Other|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~aromatherapy~music therapy~cognitive training in multimedia application offering cognitive games"
75735202|NCT02288221|Other|Patient's answer without non pharmacological therapeutic|No installation at patient's home
75735203|NCT02276573|Biological|buccal cavity sample|
76055905|NCT05804201|Procedure|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob|(2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
76055906|NCT05794984|Other|Focus group discussions and survey questionnaire|Questions regarding internet and social media usage, as well as telemedicine concept and knowledge. Assessment of the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare. Perceptions for high-quality healthcare access, confidentiality, privacy, and security, will also be explored.
76055907|NCT05794477|Biological|Adebrelimab|Specified dose on specified days
75592180|NCT05721755|Procedure|Positron Emission Tomography|Undergo PET/CT
75592181|NCT05721755|Other|Quality-of-Life Assessment|Ancillary studies
75592182|NCT05721755|Radiation|Radiation Therapy|Undergo radiation therapy
75592183|NCT05719805|Drug|Mavacamten|Specified dose on specified days
75592184|NCT05719623|Other|CUEVAS MEDEK EXERCISES|stretchings/strengthening
75592185|NCT05719623|Other|BALANCE AND POSTURAL|BALANCE AND POSTURAL
76055908|NCT05794477|Biological|SHR-1802|Specified dose on specified days
76055909|NCT05794477|Drug|Carboplatin/Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
76055910|NCT05794477|Drug|Paclitaxel/Nab-Paclitaxel/Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
75735204|NCT02274155|Drug|Anti-OX40 antibody administration|Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
75442043|NCT01649934|Behavioral|Contact Clinic|Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
75442044|NCT01649960|Drug|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
75442045|NCT01650012|Drug|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
75735205|NCT02274155|Procedure|Surgical Resection|Surgical Resection of Tumor
75735206|NCT02252237|Biological|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at following visits. Buccal cell collection swab
75735207|NCT02250352|Other|cytology specimen collection procedure|Correlative studies
76055911|NCT05789381|Procedure|Magnesium sulfate|This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
75442046|NCT01650012|Drug|Placebo|Placebo
75735208|NCT02239783|Device|total hip arthroplasty implant|
75735209|NCT02238301|Other|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
75735210|NCT02238301|Other|Bold + ASL sequence|"A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
75735211|NCT02231723|Drug|BBI608|Administered continuously twice daily with doses separated by 12 hours
75735212|NCT02231723|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
75735213|NCT02231723|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
75735214|NCT02231723|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
75442047|NCT01650025|Dietary Supplement|VSL#3 active probiotic|
75442048|NCT01650025|Other|VSL#3 placebo|
75442049|NCT01650038|Other|treatment with faecal transplantation (donor faeces)|faecal transplantation
75442050|NCT01650038|Other|treatment with faecal transplantation (own faeces)|faecal transplantation
75442051|NCT01650090|Drug|Inhaled Lipid Cisplatin (ILC)|ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
75735215|NCT02231723|Drug|Leucovorin|Arm C, D: Leucovorin 400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
75884369|NCT03598686|Diagnostic Test|OraQuick|Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
75442052|NCT01650129|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
75442053|NCT01650129|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
75735216|NCT02231723|Drug|Irinotecan|Arm B: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
75735217|NCT02231723|Drug|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m^2 I.V. bolus followed by 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
75735218|NCT02231723|Drug|MM-398|MM-398 70 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
75735219|NCT02199145|Procedure|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
75735220|NCT02198404|Drug|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
75735221|NCT02150889|Behavioral|Running Program|16 week supervised running program
75735222|NCT02150889|Behavioral|Yoga Program|once weekly supervised yoga
75735223|NCT02131597|Drug|Guadecitabine|Given SC
75735224|NCT02108054|Device|7T MRI|Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
75735225|NCT02104349|Behavioral|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
75442054|NCT01650142|Other|No intervention|No intervention
75442055|NCT01650155|Drug|BI 1005273 s.c.|injection
75442056|NCT01650155|Drug|BI 105273 i.v. Placebo|infusion
75442057|NCT01650155|Drug|BI 1005273 s.c. Placebo|injection
75442058|NCT01650155|Drug|BI 1005273 i.v.|infusion
75442059|NCT01650181|Drug|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
75442060|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
75735226|NCT01969968|Other|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
75735227|NCT01965184|Behavioral|Cognitive-Behavioral Therapy for Anger and Aggression|
75735228|NCT01965184|Behavioral|Supportive Psychotherapy (SPT)|
75735229|NCT01931709|Radiation|fludeoxyglucose F 18|Undergo FDG PET
75884370|NCT05736913|Biological|ID BNT162b2 vaccine|intradermal BNT162b2 vaccine
75884371|NCT05736913|Biological|IM BNT162b2 vaccine|intramuscular BNT162b2 vaccine
75442061|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
75442062|NCT01650181|Drug|Metformin|Patients with fatty liver treated with diet, exercise and metformin
75442063|NCT01650207|Procedure|acupuncture|"All participants were received regular rehabilitation program, and received different interventions.~treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks"
75735230|NCT01931709|Device|positron emission tomography|Undergo FDG PET
75735231|NCT01931709|Device|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
75735232|NCT01931709|Other|laboratory biomarker analysis|Correlative studies
75769465|NCT03896932|Other|minipooled- Intravenous immunoglobulin(MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
75592186|NCT05717166|Radiation|Palliative Radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
75442064|NCT01650207|Procedure|TENS|
75735233|NCT01834755|Other|Evaluation of psychological phenotype|
75735234|NCT01824875|Drug|temozolomide|Given PO
75735235|NCT01824875|Drug|capecitabine|Given PO
75735236|NCT01812694|Behavioral|Enhanced standard care|Standard prenatal care plus education
75735237|NCT01812694|Behavioral|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
75735238|NCT01806129|Other|Standard practice related to reproductive heath|Patients undergo usual standard practice related to reproductive health.
75735239|NCT01806129|Other|Training modules, algorithm, referral development|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
75735240|NCT01774240|Other|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
75735241|NCT01765218|Drug|Topiramate|Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
75735242|NCT01765218|Drug|Placebo|A placebo identical in appearance to the active agent (topiramate)
75442065|NCT01650207|Procedure|sham acupuncture|
75442066|NCT01650233|Behavioral|Mindfulness-based stress reduction|
75442067|NCT01650272|Drug|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
75735243|NCT01756040|Drug|Lactulose -rhamnose solution|Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
75735244|NCT01701284|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
75735245|NCT01698892|Drug|I.V Sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
75884372|NCT03598452|Drug|Ganciclovir|Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
75442068|NCT01650272|Drug|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
75442069|NCT01650337|Other|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
75442070|NCT01650363|Other|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
75442071|NCT01650363|Drug|Homeopathic placebo medication|2-3 mm small spheric suger pils
75442072|NCT01650376|Drug|Olaparib|Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
75442073|NCT01650376|Drug|Carboplatin|AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
75592187|NCT05717166|Drug|Chemotherapy|Pre-specified based on the standard of care approach for that patient.
75592188|NCT05717166|Drug|Hormone therapy|Pre-specified based on the standard of care approach for that patient.
75592189|NCT05717166|Drug|Immunotherapy|Pre-specified based on the standard of care approach for that patient.
75735246|NCT01698892|Drug|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
75735247|NCT01685541|Other|Maximum After Visit Summary Content|
75735248|NCT01685541|Other|Intermediate After Visit Summary Content|
75735249|NCT01685541|Other|Minimum After Visit Summary Content|
75735250|NCT01685541|Other|Usual AVS|
75735251|NCT01631851|Behavioral|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
75735252|NCT01550861|Procedure|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
75735253|NCT01550861|Procedure|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
75735254|NCT01500473|Drug|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
75735255|NCT01459510|Behavioral|Play Nicely Program|Multi media educational intervention
75735256|NCT01326182|Behavioral|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
75592190|NCT05717166|Drug|Targeted Systemic Therapy|Pre-specified based on the standard of care approach for that patient.
75735257|NCT01326182|Behavioral|MAAS|Group-based intervention including asthma education and education regarding general child health
75592191|NCT05717166|Other|Observation|Pre-specified based on the standard of care approach for that patient.
75735258|NCT01306357|Drug|Somatropin|4 mg or 10 mg delivered by needle-free device
75735259|NCT01294020|Drug|Tacrolimus|Oral capsule
75735260|NCT01294020|Drug|Tacrolimus prolonged release|Oral capsule
75735261|NCT01219075|Dietary Supplement|soy isoflavones|Given orally
75442074|NCT01650376|Drug|Paclitaxel|60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
75592192|NCT05717166|Radiation|Stereotactic Ablative Radiotherapy|"The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board.~Preferred doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every second day), and 35 Gy in 5 fractions (daily)."
75442075|NCT01650389|Biological|MVA85A|
75592193|NCT05717166|Procedure|Surgery|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board. Because of the convenience in using SABR for all lesions, non-SABR modalities should only be used if they are likely to provide a benefit over SABR."
75735262|NCT01219075|Other|placebo|Given orally
75735263|NCT01219075|Other|questionnaire administration|Ancillary studies
75735264|NCT01219075|Procedure|magnetic resonance imaging|Correlative studies
75884373|NCT03549182|Drug|ATD treatment|oral administration of ATD (100g)(Acute Tryptophan Depletion)
75884374|NCT03549182|Drug|placebo treatment|oral administration of placebo (102.3g)
75884375|NCT05736055|Diagnostic Test|Cambodia Version Five Minutes Hearing Test|The FMHT was developed by American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). The FMHT is composed of 15 questions. Each answer is scored as 0, 1, 2 or 3 according to the frequency of experience. If they answered 'never', the score was 0. The answer 'occasionally' scored 1, the answer 'half the time' scored 2, and the answer 'almost always' scored 3. Furthermore, it has shown more aspects, more reliability, and more assessments of the hearing impairment of the patients. is a standard hearing questionnaire. So, we plan to translate the FMHT into Cambodian language and validate by comparing its result with those of audiometry.
75884376|NCT03598296|Other|Large size tube|Patients in Group A are inserted the large size tube (28F).
75442076|NCT01650389|Biological|Candin|
75442077|NCT01650389|Biological|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."
75592194|NCT05717166|Other|Radiofrequency Therapy (RFA)|Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.
76071863|NCT03885232|Behavioral|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
75442078|NCT01650415|Drug|Erythropoietin|twice a week for 1 month
75592195|NCT05717166|Radiation|Fractionated Radiation|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~Tumors in the esophagus, stomach, small intestine or colon should be treated with either fractionated radiation or a lower SABR dose (e.g. 25 Gy in 5 fractions) to minimize the risk of perforation."
75442079|NCT01650415|Drug|Placebo erythropoietin|twice a week for 1 month
75735265|NCT01219075|Procedure|biopsy|Correlative studies
75735266|NCT01219075|Other|immunohistochemistry staining method|Correlative studies
75735267|NCT01219075|Other|laboratory biomarker analysis|Correlative studies
75735268|NCT01219075|Procedure|mammography|Correlative studies
75735269|NCT00929214|Drug|Standard Therapy|"Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist."
75735270|NCT00929214|Procedure|Local Therapy|"Surgery and/or Radiation Therapy~With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks."
75735271|NCT00871936|Drug|SLx-4090|SLx-4090
75735272|NCT00871936|Other|Placebo|matching tablets
75735273|NCT00871936|Drug|Metformin|
75735274|NCT00810979|Drug|SLx-4090|tablet
75735275|NCT00810979|Drug|SLx-4090|tablet
75735276|NCT00810979|Other|Placebo|matching tablet
75735277|NCT00810979|Drug|Statin|Subjects were dosed with the statin prescribed specifically by their prescribing physician.
76071864|NCT03885232|Other|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
75735278|NCT00741910|Drug|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
76071865|NCT03871556|Diagnostic Test|LOGIQ P6 Diagnostic Ultrasound|Ultrasound measurements of subcutaneous fat thickness
75592198|NCT05689099|Drug|Semaglutide B, 1.34 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
75442080|NCT01650428|Biological|Bevacizumab|5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).
75442081|NCT01650428|Drug|Irinotecan|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
75442082|NCT01650428|Drug|Oxaliplatin|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
75442083|NCT01650428|Drug|5-Fluorouracil|3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
75442084|NCT01650441|Drug|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
75442085|NCT01650441|Radiation|CT thorax|"CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose."
75442086|NCT01650454|Other|2 night polysomnography|Polysomnography
75442087|NCT01650454|Other|battery of neuropsychological tests|
75592199|NCT05689099|Drug|Semaglutide B, 0.68 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
75592200|NCT05687539|Dietary Supplement|Mastiha water|10ml of mastiha water before every meal for one month
75592201|NCT05687539|Dietary Supplement|Mastiha capsules|2x350mg mastiha capsules before every meal for one month
75735279|NCT00567684|Device|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
75735280|NCT00567684|Other|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
75592202|NCT05687266|Drug|Datopotamab deruxtecan|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
75735281|NCT00562614|Drug|SLx-2101|
76071866|NCT03864094|Drug|Ephedrine|0,1 mg/kg
75592203|NCT05687266|Drug|Durvalumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
75592204|NCT05687266|Drug|Carboplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
75592205|NCT05687266|Drug|Pembrolizumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
75592206|NCT05687266|Drug|Cisplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
75735282|NCT00562575|Drug|SLx-4090|
75735283|NCT00562575|Drug|Placebo|
76071867|NCT03864094|Drug|Phenylephrine|1 microg/kg
75442088|NCT01650454|Other|virtual reality test|
75442089|NCT01650454|Other|subjective evaluation of sleep and somnolence|
75592207|NCT05687266|Drug|Pemetrexed|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
75592208|NCT05687266|Drug|Paclitaxel|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
75735284|NCT00528242|Drug|SLx-2101|
75735285|NCT00528242|Drug|Placebo|
75735286|NCT00483249|Device|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
75735287|NCT00001160|Drug|68-Gallium Dotatate|For evaluation risk/benefit evaluation
75735288|NCT00931424|Procedure|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
75735289|NCT05701319|Procedure|PCI|percutaneous coronary intervention
75735290|NCT00930488|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
75735291|NCT04063943|Device|Sidus Stem-Free Shoulder|Device: Sidus Stem-Free Total Shoulder Arthroplasty System
75735292|NCT00736931|Drug|Brivaracetam|Brivaracetam 10 mg tablets
76071868|NCT03864094|Drug|Norepinephrine|0,1 microg/kg
76071869|NCT03864094|Drug|Sodium chloride|0,1 ml/kg
76071870|NCT03864094|Drug|Propofol|2 mg/kg
76071871|NCT03864094|Drug|Remifentanil|1,7 microg/kg
75592209|NCT05684055|Drug|First-line antihypertensive single-pill combination (SPC)|In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
75592210|NCT05684055|Other|Standardized counselling and referral to the closest health facility|In control villages, participants diagnosed with aHT receive a standardized counselling by the CC-VHW and are referred to the closest health facility for initiation or continuation of antihypertensive treatment.
75592211|NCT05682612|Other|outcome|hospital survivors and nonsurvivors
75592212|NCT05682612|Other|Subtype of COVID-19|Different subtype of COVID-19
75442090|NCT01650480|Other|HELP-COPD action plan|The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
75442091|NCT01650493|Device|Clinpro 5000|Dentrifice containing 950ppm fluoride
75442092|NCT01650493|Device|MI Paste Plus|Dentrifice containing 950ppm fluoride
75592213|NCT05681559|Behavioral|Medi for All|Please see description of Medi for All arm
75592214|NCT05681559|Dietary Supplement|Standard Fiber Supplementation|Please see description of Fiber Supplementation arm
75592215|NCT05680480|Biological|Telitacicept 240 mg|Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
75592216|NCT05680480|Biological|Telitacicept 160 mg|Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
75592217|NCT05680480|Drug|Placebo|Participants will receive placebo weekly in addition to SOC for 48 weeks.
75592218|NCT05675891|Other|Supplemental Feeding System Group|The body weight is measured in the morning fasting on the day when oral feeding is decided, 3 feeding between 08-16:00 are carried out with the supplemental feeding system, The amount of food prepared is recorded, Heart rate, oxygen saturation, respiratory rate and early feeding skill score are recorded before, during and after feeding, When the feeding is finished, the total amount of food taken by the baby and the feeding time are recorded, The rate of food intake (%) and the amount of food received per minute are calculated and recorded, Infants who can take 80% of the amount of food given at each meal by being fed orally for 8 meals two days in a row are considered to have switched to full oral feeding.
75592219|NCT05675085|Diagnostic Test|Personalized screening protocol|"At the first screening round (recruitment) all participating women had the same tests;~Two-view tomosynthesis of both breasts~Calculation of volumetric breast density (VBD)~Calculation of lifetime risk (LTR) using the Tyrer-Cuzick model~At subsequent rounds:~Women with non-dense breasts and low breast cancer risk are re-screened only with DBT every 2 years;~Women with dense breasts and low breast cancer risk are re-screened with DBT+US every 2 years;~Women with non-dense breasts and intermediate breast cancer risk are re-screened only with DBT every year;~Women with dense breasts and intermediate breast cancer risk are re-screened with DBT+US every year;~Women at high risk of breast cancer associated with a family history of breast cancer (w/wo hereditary factors) undergo DBT and MRI every year."
75735293|NCT00736931|Drug|levetiracetam|500mg tablets
75442093|NCT01650493|Device|Tom's of Maine|Dentrifice that is fluoride free
75442094|NCT01650506|Drug|Metformin|Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
75735294|NCT00736931|Drug|lorazepam|lorazepam 2 mg over encapsulated tablets
75735295|NCT00736931|Other|placebo|placebo capsules
75735296|NCT00737087|Device|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
75884377|NCT03598296|Other|Drainage ball|Patients in Group B are inserted the small-bore tube connects with a negative pressure ball(drainage ball).
75442095|NCT01650506|Drug|Erlotinib|Erlotinib dosing will start and remain at 150 mg daily.
75442096|NCT01650532|Behavioral|Yoga Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
75442097|NCT01650532|Behavioral|Stretching Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
75442098|NCT01650597|Drug|JNJ-42165279 2.5 - 500 mg oral|Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
75442099|NCT01650597|Drug|Placebo|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
75442100|NCT01650597|Drug|JNJ-42165279 100 mg oral|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
75592220|NCT05668897|Drug|GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
76071872|NCT03863184|Drug|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
76055912|NCT05778396|Procedure|Active spinal manual therapy protocol|The chiropractor will start by (1) placing one hand over L4-L5 or L5-S1 and then will apply a high-velocity, low-amplitude (HVLA) thrust with a therapeutic line of drive. Side-lying lumbar manipulation will be performed bilaterally, with the treating clinician choosing any suitable technique and with or without occurrence of the characteristic audible joint cavitation associated with spine manipulation. The chiropractor will then perform (2) prone lumbar mobilisation by placing the contact hand and applying downward pressure over L4-L5 or L5-S1 with the other hand guiding a manual flexion-distraction piece to apply therapeutic mobilization of the lumbar spine. The chiropractor will deliver (3) a prone thoracic manipulation by placing two hands over the transverse processes of T5-T6 or T6-T7 and applying a HVLA thrust in a posterior-to-anterior direction.
75442101|NCT01650610|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
75592221|NCT05668897|Drug|placebo of GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
76071873|NCT03863184|Drug|Lenalidomide|Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
75592222|NCT05665166|Genetic|Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII|Autologous CD34+ haematopoietic stem cells from MPS II patients will be genetically modified ex vivo using CD11b.IDS-ApoEII Lentiviral Vector (LV), a self-inactivating (SIN) LV expressing the human codon-optimized IDS gene tagged with ApoEII and regulated by a human CD11b myeloid-specific promoter. These transduced CD34+ HSCs will then be cryopreserved until the time of infusion back to the patients
75592223|NCT05664815|Biological|Human Amniotic Membrane|"After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges.~With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone.~For closure after hAM grafting : 2 options are possible:~Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa."
75592224|NCT05664815|Other|Conventional/Standard treatment|"Surgical procedure: Endo-oral approach:~Trimming of the mucous edges if they are necrotic or inflamed (granulation tissue)~For the bone: either simple sequestrectomy (the mobile sequestered bone is grabbed using forceps); either reaming until bleeding is obtained; either resection with the rongeur; either monobloc resection of the entire necrotic fragment with a saw or with a piezzotome (ultrasound); or a combination of different techniques. Rq: the resection of the necrotic bone (according to the practices of the center) will operate until the appearance of an apparently healthy bone (bone bleeding, clean appearance of the bone site)~Closure of the mucosa with possible incision of the periosteum to provide laxity: Suture points by points separated in one plane with non-absorbable braided thread of the 3.0 silk thread type and round needle."
75592225|NCT05657184|Drug|REGEND001 Autologous Therapy Product|Transplantation of REGEND001 Autologous Therapy Product for dosage re-escalation.
75442102|NCT01650623|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
75592226|NCT05656560|Behavioral|Clinical decision support (CDS)-Commitment nudge|EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
75592227|NCT05656560|Other|Clinician education|Brief, online education module for primary care clinicians
75592228|NCT05656560|Behavioral|Clinical decision support (CDS)-Justification nudge|EHR clinical decision support alerts-clinician rational for high risk polypharmacy
75592229|NCT05656443|Drug|GST-HG171/Ritonavir|dose of 150 mg GST-HG171 with 100 mg ritonavir
75592230|NCT05656443|Drug|Placebo|Placebo
75592231|NCT05653323|Drug|VX-993|Suspension for oral administration.
75592232|NCT05653323|Drug|Placebo|Suspension for oral administration.
75592233|NCT05650918|Biological|MesoPher|autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)
75592234|NCT05650918|Biological|Mitazalimab|agonistic human monoclonal (IgG1) antibody targeting CD40
75592235|NCT05649410|Other|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
75592236|NCT05649410|Other|sleeper stretch along with conventional therapy|it will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
76071874|NCT03863184|Drug|Rituximab|Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
75592237|NCT05643755|Other|Preoperative image-based education|Intervention group: education handout containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
75769466|NCT03908866|Other|PICC(Peripherally inserted central catheter)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
75769467|NCT03908866|Other|CVC(Central venous catheter )|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
75769468|NCT03908554|Other|WORKPLACE HEALTH PROMOTION PROGRAM|WHPP was PMR training, posture and breath exercises, and ergonomic suggestions.
76071875|NCT03860792|Behavioral|Ketogenic Diet|Three-month 1:1 ketogenic diet intervention (approximately 70% fat, <10% carbohydrate, and 20% protein).
76071876|NCT03860792|Behavioral|Therapeutic Lifestyles Changes Diet|Three-month diet intervention that is low in fat and cholesterol, high in fruits, vegetables, and whole grains, and moderate in protein.
75442103|NCT01650623|Behavioral|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
75442104|NCT01650649|Drug|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
75442105|NCT01650649|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
75442106|NCT01650662|Drug|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
75442107|NCT01650675|Behavioral|WIDUS computer-delivered, indirect brief intervention|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
75442108|NCT01650675|Behavioral|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
75442109|NCT01650714|Other|Full thickness gastric biopsy|
75442110|NCT01650714|Procedure|Full thickness gastric biopsy|
75442111|NCT01650727|Drug|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m^2 up to a maximum dose of 14 mg/m^2.
75442112|NCT01650727|Biological|Rituximab|Rituximab 375 mg/m^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
75442113|NCT01650740|Drug|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
75442114|NCT01650740|Drug|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
75442115|NCT01650740|Other|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
75442116|NCT01650753|Dietary Supplement|Probiotic Powder|Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10^10 cells/sachet)
75442117|NCT01650753|Dietary Supplement|Placebo powder|powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
75442118|NCT01650818|Other|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
75442119|NCT01650818|Other|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
75442120|NCT01650870|Drug|Crystalline Lactulose|
75442121|NCT01650883|Dietary Supplement|Cholecalciferol|Cholecalciferol 50,000 IU PO every 10 days for 40 days
75442122|NCT01650883|Dietary Supplement|Cholecalciferol 5,000 IU|Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
75442123|NCT01650896|Other|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
75442124|NCT01650922|Procedure|phlebotomy|
75442125|NCT01650922|Procedure|biopsy|
75442126|NCT01650935|Behavioral|diet|When the first set of urine samples confirmed hyperoxaluria (urine oxalate>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
75442127|NCT01650948|Device|RetnaGene AMD LDT|
75442128|NCT01650961|Drug|Palonosetron|0.075 mg IV as bolus before induction of general anesthesia
75442129|NCT01650961|Drug|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
75442130|NCT01650974|Device|HFNOT|high flow nasal oxygen therapy
75442131|NCT01651091|Other|Meditation Awareness Training|Psychotherapy Intervention
75442132|NCT01651091|Other|Treatment as usual|
75442133|NCT01651130|Drug|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
75735297|NCT04064099|Device|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
75735298|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
75442134|NCT01651156|Drug|Tolvaptan|oral taken
75442135|NCT01651156|Drug|Placebo|
76055913|NCT05778396|Procedure|Control spinal manual therapy protocol|(1) Control side-lying lumbar manipulation will be operationalised as the application of a low-velocity broad push manoeuvre to the gluteal region following a non-therapeutic line of drive. The chiropractor will then perform (2) control prone lumbar mobilisation, consisting of a non-therapeutic manual manoeuvre involving minimal oscillations (0 to ±2°) of the flexion-distraction piece with light touch over the lumbar spine region, and (3) control prone thoracic mobilisation consisting of two-handed left and right scapula pushes with a nontherapeutic line of drive.
75442136|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity"
75442137|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity."
75735299|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
76071877|NCT03855813|Other|Intra rater reliability|Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
75735300|NCT00567164|Drug|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
75735301|NCT00920933|Biological|AIN457|
75735302|NCT00920933|Other|Placebo|
75735303|NCT00920933|Drug|prednisolone|
75442138|NCT01651182|Drug|No tranexamic acid|Control
75442139|NCT01651182|Drug|Tranexamic Acid|
75442140|NCT01651221|Other|Habituation|Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
75769469|NCT01257334|Drug|BI 10773|patients with type 2 diabetes mellitus with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea
75769470|NCT01150084|Other|16-week lunchtime walking intervention|10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking
75769471|NCT01150084|Other|delayed treatment|to start at week 10
75769472|NCT01151176|Drug|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
75442141|NCT01651234|Drug|GCC-4401|"Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~single dose~dosage~Cohort 1: 2.5-mg GCC-4401C~Cohort 2: 5.0-mg GCC-4401C~Cohort 3: 10-mg GCC-4401C~Cohort 4: 20-mg GCC-4401C~Cohort 5: 40-mg GCC-4401C~Cohort 6: 80-mg GCC-4401C"
75442142|NCT01651234|Drug|GCC-4401C|"Capsule, identical in appearance to GCC-4401C, for oral use~single dose~dosage~Cohort 1: 2.5-mg matching placebo~Cohort 2: 5.0-mg matching placebo~Cohort 3: 10-mg matching placebo~Cohort 4: 20-mg matching placebo~Cohort 5: 40-mg matching placebo~Cohort 6: 80-mg matching placebo"
75442143|NCT01651247|Procedure|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
75735304|NCT00930566|Drug|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
75442144|NCT01651273|Drug|BMS-852927|Capsules, Oral, 0.25 mg, Once daily, 28 days
75442145|NCT01651273|Drug|BMS-852927|Capsules, Oral, 1.0 mg, Once daily, 28 days
75442146|NCT01651273|Drug|BMS-852927|Capsules, Oral, 2.5 mg, Once daily, 28 days
75442147|NCT01651273|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 28 days
75442148|NCT01651286|Procedure|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
75442149|NCT01651286|Procedure|full face mask|using a standard full face mask during the induction of general anesthesia.
75442150|NCT01651312|Drug|14C-labeled YM178|oral solution (1.85 MBq)
75442151|NCT01651325|Drug|Isavuconazole|oral
75442152|NCT01651325|Drug|dextromethorphan|oral
75442153|NCT01651338|Procedure|acupuncture|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
75442154|NCT01651364|Drug|Placebo|Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
75442155|NCT01651364|Drug|Cabergoline|Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
75442156|NCT01651377|Drug|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
75442157|NCT01651377|Drug|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
75442158|NCT01651390|Device|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
75442159|NCT01651390|Device|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
75442160|NCT01651416|Drug|Artemether-lumefantrine combination|
75442161|NCT01651416|Drug|Dihydroartemisinin Piperaquine combination|
75442162|NCT01651416|Drug|Amodiaquine plus sulphadoxine-pyrimethamine combination|
75442163|NCT01651429|Behavioral|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
75592238|NCT05643430|Device|BioFreedom Ultra|The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
75442164|NCT01651468|Dietary Supplement|HEMOFIX|unique complex herbal mixture
75442165|NCT01651481|Drug|HCP1102|
75442166|NCT01651481|Drug|Singulair and Xyzal|
75592239|NCT05643365|Radiation|Radioactive Iodine therapy|All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.
75592240|NCT05641701|Device|System On|The DBS system will be turned on, and the individual's stutter will be assessed.
75592241|NCT05641701|Device|System off|The DBS system will be turned off, and the individual's stutter will be assessed.
75442167|NCT01651494|Drug|DAS181|DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
75442168|NCT01651494|Other|Placebo|Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
75442169|NCT01651520|Drug|PET with 11C-Flumazenil|PET with 11C-Flumazenil.
75592242|NCT05630755|Drug|DOR/ISL|DOR/ISL 100 mg/0.25 mg oral tablets once daily
75442170|NCT01651546|Behavioral|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
75442171|NCT01651572|Drug|Cisatracurium|"Cisatracurium (Nimbex):~initial dose: 0.2 mg/kg~maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
75442172|NCT01651572|Drug|Rocuronium|"Rocuronium (Esmeron):~initial dose: 0.6 mg/kg~maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
75442173|NCT01651585|Drug|Valacyclovir arrow|dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
75442174|NCT01651598|Drug|Placebo to BI 144807|multiple dose (bid)
75442175|NCT01651598|Drug|BI 144807|multiple dose (bid, low to high dose)
75442176|NCT01651611|Behavioral|Motivational interviewing|The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
75442177|NCT01651611|Behavioral|Smoking cessation counseling|The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
75442178|NCT01651611|Behavioral|Navigation to smoking cessation resources|The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
75592243|NCT05630755|Drug|BIC/FTC/TAF|BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
75592244|NCT05630755|Drug|Placebo to BIC/FTC/TAF|0 mg oral tablets once daily
75442179|NCT01651611|Behavioral|Social support|Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
75442180|NCT01651624|Other|Invitation to screening|
75442181|NCT01651637|Drug|synthetic surfactant (CHF5633)|CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
75442182|NCT01651650|Device|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
75442183|NCT01651663|Drug|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
75442184|NCT01651663|Other|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
75442185|NCT01651663|Drug|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
75592245|NCT05630755|Drug|Placebo to DOR/ISL|0 mg oral tablets once daily
75592246|NCT05621486|Biological|B4T2-001 Autologous CAR T cells|Each subject will receive infusion with B4T2-001 autologous CAR T Cells
75592247|NCT05621174|Drug|Dexamfetamine|Magisterial Dexamfetamine
75592248|NCT05621174|Drug|Dexamfetamine|Tentin
75592249|NCT05617911|Device|Blood Flow Restriction Cuff|Blood Flow Restriction (BFR) involves the application of an external device to reduce arterial blood flow to the exercising area, while largely occluding venous return from that same area.
75592250|NCT05617911|Procedure|Sham and standard of Care Therapy|SoC PT + non-inflated BFR cuff
75442186|NCT01651663|Other|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
75442187|NCT01651676|Other|VQ11 validation|"Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug."
75442188|NCT01651702|Device|Carto|Group of patients where Carto Express system will be used for electroanatomical mapping.
75442189|NCT01651702|Device|Ensite|Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
75442190|NCT01651715|Drug|TAO1, oral homeopathic antibodies|"TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime)."
75592251|NCT05610189|Drug|Tavapadon|Oral tablets
75592252|NCT05606887|Other|Wearable Device and Ecological Momentary Assessments|"The intervention will consist of three components:~Completion of brief text-message based surveys 2-3 times per week~Wearing a wrist-based wearable device to generate individual data insights on physiological data related to stress and well-being, including heart rate variability, stress scores, and sleep quality~Individual biweekly reports of survey response trends and curated resources intended to support participant well-being"
75592253|NCT05579977|Drug|PF-07081532|Oral glucagon-like peptide-1 receptor agonist
75592254|NCT05579977|Other|Placebo|No drug
75592255|NCT05579977|Drug|Rybelsus|Oral Semaglutide
75592256|NCT05576584|Drug|GST-HG121 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
75592257|NCT05576584|Drug|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
75592258|NCT05553145|Diagnostic Test|Autoimmune Antibody Assays|GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
75592259|NCT05549648|Other|Home oral excrise|The current study aimed to evaluate the efficacy and user experience of mobile phone APP, a mobile application with AI component in facial movement tracking, in improving oral functions of elderly people
75592260|NCT05544565|Drug|IV Antibacterial Agents|Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .
75735305|NCT00930566|Procedure|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
75442191|NCT01651728|Drug|Simvastatin|Tablet 20 mg once daily for 30 days
75442192|NCT01651728|Drug|Placebo|daily for 30 days
75592261|NCT05544565|Drug|Orally antibacterial agents|Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days
75592262|NCT05544565|Procedure|Fecal/Rectal Swab|Collected by the nurse or the physician (D0,D3,D14) (and parents for D45), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools < 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.
75592263|NCT05544565|Procedure|PCT assay|Dosage of procalcitonin (if not performed in standard care) at D0
75592264|NCT05544565|Procedure|Renal scintigraphy|A DMSA scintigraphy (99mTc-DMSA) will be performed at 6 months (± 15 days) for evaluation of the kidney growth and renal scars
75592265|NCT05543044|Behavioral|Peer mentor intervention|Peer mentor delivered intervention for transitions to adult-oriented treatment for eating disorders
75592266|NCT05538624|Drug|AVB-001 (Dose Escalation Phase)|One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).
75592267|NCT05538624|Drug|AVB-001 (Dose Expansion Phase)|The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.
75592268|NCT05537064|Behavioral|Non-visit Based Intervention|At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
75735306|NCT00737165|Behavioral|Multimodal suicide prevention program|"A community intervention of multimodal suicide prevention program includes following components:~Building support networks for suicide prevention and mental health promotion in public health system~Primary prevention of suicide and suicide related behaviors~Secondary prevention of suicide and suicide related behaviors~Tertiary prevention; after care for suicide survivors~Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~Suicide prevention targeting for people with work-related problems"
75735307|NCT00737165|Behavioral|Suicide prevention program as usual|Usual suicide prevention program
75735308|NCT00925730|Drug|Pimecrolimus|
75735309|NCT00925808|Behavioral|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
75735310|NCT00925886|Procedure|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
75735311|NCT00713219|Radiation|IMRT, cetuximab, docetaxel|IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
75735312|NCT03699644|Device|Spectral-Domain Optical Coherence Tomography (SD-OCT)|Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.
75735313|NCT03699644|Device|Magnetic Resonance Imaging (MRI)|Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.
75735314|NCT03699644|Device|Positron Emission Tomography (PET)|Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.
75442193|NCT01651741|Dietary Supplement|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~Form: brown granule~Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~Duration: 4 weeks of treatment period~Duolac7S:~The probiotics, Duolac7S, consist of 7 bacteria.~Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (30 min after morning and evening meal)~Duration: 4 weeks of treatment period"
76071878|NCT03855813|Other|Inter rater reliability|Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
75442194|NCT01651741|Dietary Supplement|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~Form: brown granule~Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
75442195|NCT01651754|Biological|Seasonal influenza vaccination|single dose of influenza vaccination
75442196|NCT01651767|Drug|Placebo|Form=suspension, route=oral.
75442197|NCT01651767|Drug|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
75592269|NCT05537064|Behavioral|Visit-Based Intervention|"The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated."
75592270|NCT05531604|Behavioral|appetitive conditioning|The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
75592271|NCT05524649|Dietary Supplement|Food Supplement 1|Probiotic single strain formulation containing Bifidobacterium longum CECT7894 for 3 months 5 drops/day
75735315|NCT03699644|Diagnostic Test|Comprehensive Ophthalmic Examination|Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.
75442198|NCT01651819|Procedure|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
75442199|NCT01651832|Behavioral|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
75442200|NCT01651858|Drug|Nurigra Chewable tablet|1 tablet of 100mg, once a day
75592272|NCT05524649|Dietary Supplement|Food Supplement 2|Probiotic single strain formulation containing Pediococcus pentosaceus CECT8330 for 3 months 5 drops/day
75735316|NCT03699644|Device|Fundus Photography|Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.
75735317|NCT00931580|Dietary Supplement|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
75735318|NCT00930800|Other|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
75735319|NCT00930878|Device|Cardiac Stenting|Drug Eluting stent
75735320|NCT00931736|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
75735321|NCT00931736|Drug|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
75735322|NCT00930956|Dietary Supplement|Resistant Starch|30 g of carbohydrate per Arm
75735323|NCT00931034|Behavioral|South Beach Diet with South Beach Diet Products|
75735324|NCT00931034|Behavioral|American Diabetes Association Diabetes Meal Plan|
75735325|NCT02567981|Dietary Supplement|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
75735326|NCT02567981|Dietary Supplement|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%."
75735327|NCT02567981|Dietary Supplement|Ferrous sulphate|"Ferrous sulfate drops children <12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months."
75735328|NCT02567981|Dietary Supplement|Vitamin A|Vitamin A Capsules: children <12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
75735329|NCT00931814|Other|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
75735330|NCT05741567|Procedure|correction of anterior prolapse|percentage of failed prolapse correction
75735331|NCT00931112|Other|individualized exercise training|Lower extremities resistance exercise and bicycle training
75592273|NCT05524649|Dietary Supplement|Placebo|5 drops/day for 3 months of sunflower oil
75592274|NCT05521074|Device|Active tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.
75442201|NCT01651884|Device|HD-tDCS (Soterix)|Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
75735332|NCT00926120|Dietary Supplement|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
75735333|NCT00737555|Drug|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
75735334|NCT00932048|Drug|Atorvastatin|Atorvastatin 10mg once daily for 12 weeks
75592275|NCT05521074|Device|Sham tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid. tDCS will not be active in this condition.
75592276|NCT05519475|Drug|ALN-HSD|Administered by subcutaneous injection (SC)
75592277|NCT05519475|Drug|Placebo|Administered by SC injection
75884378|NCT05501834|Other|Supracondylar Pin Removal Before Imaging|Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider. The order of these steps differs from our current standard of care, during which patients' pins are removed following cast removal and x-ray imaging.
76055914|NCT05762133|Behavioral|African-American Social Support Effectiveness Treatment-Partners alleviating Perinatal Depression (ASSET-PPD)|This proposed novel intervention has four prenatal modules and two postpartum review sessions addressing key correlates of PND with the largest effect sizes by targeting fathers': 1) prenatal and postpartum family involvement; 2) mental health psychoeducation; 3) interparental communication and relationship skills; and 4) balanced division of family tasks. The intervention is based on the stress-generation and cognitive-behavior theories to frame skill-based individual sessions of didactics, interactive training, and trackable objectives.
75442202|NCT01651884|Device|Transcranial Direct Current Stimulation (Neuroconn)|
75592278|NCT05509257|Drug|Naltrexone|Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
75592279|NCT05509257|Drug|Placebo|Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
75592280|NCT05507541|Procedure|Biospecimen Collection|Undergo correlative studies
75592281|NCT05507541|Procedure|Computed Tomography|Undergo PET/CT or CT scans of the chest, abdomen, and pelvis
75592282|NCT05507541|Drug|Ontorpacept|Given IV
75592283|NCT05507541|Biological|Pembrolizumab|Given IV
75735335|NCT04015778|Biological|Nivolumab|240mg Q2W or 360mg Q3W
75735336|NCT04015778|Drug|carboplatin|AUC 5, d1 every three weeks
75735337|NCT04015778|Drug|nab-paclitaxel|135 mg/m2, d1, 8
75735338|NCT02568293|Other|SBCV|SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
75735339|NCT02568293|Other|Saline|Saline is used as a control.
75735340|NCT00926276|Procedure|Fundoplication|Fundoplication
75735341|NCT05540873|Drug|YYB-103|Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
75442203|NCT01651923|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
75442204|NCT01651962|Drug|Terbutaline|
75442205|NCT01651962|Drug|Fentanyl|
75442206|NCT01651962|Drug|0.9% NaCl|
75592284|NCT05507541|Procedure|Positron Emission Tomography|Undergo PET/CT scans
75592285|NCT05507541|Drug|Maplirpacept|Given IV
75592286|NCT05501054|Drug|Ipilimumab|Given by IV (vein)
75884379|NCT03549026|Drug|Duloxetine|The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption
75592287|NCT05501054|Drug|Nivolumab|Given by IV (vein)
75592288|NCT05501054|Drug|Ciforadenant|Given by PO
75592289|NCT05489562|Device|Intraoral Suction|stabilization of the tongue using intraoral suctioning and its effects on sleep parameters in patients with obstructive sleep apnea (OSA).
75592290|NCT05473507|Diagnostic Test|Digital Dermoscopy|Digital Dermoscopy will be performed every 3 months.
75592291|NCT05473507|Diagnostic Test|Reflectance confocal microscopy (RCM)|Reflectance confocal microscopy (RCM) will be performed every 3 months.
75592292|NCT05473507|Diagnostic Test|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) will be performed every 3 months.
75592293|NCT05473507|Diagnostic Test|Dermtech tape-stripping|Dermtech tape-stripping for genetic analysiswill be performed every 6 months.
75592294|NCT05473507|Diagnostic Test|Total Skin Examinations|Total Skin Examinations will be performed every 12 months.
75592295|NCT05463965|Biological|QM1114-DP|Intramuscular injection
75592296|NCT05463965|Biological|OnabotulinumtoxinA|Intramuscular injection
75592297|NCT05463965|Biological|Placebo|Intramuscular injection
76071879|NCT03851640|Drug|HC-1119|oral
75735342|NCT00926354|Drug|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
75735343|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
76071880|NCT03851640|Drug|placebo|oral
75592299|NCT05438680|Dietary Supplement|The bovine colostrum ( trade name : baby steps sachets, 300mg )|"The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally."
75735344|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
75735345|NCT00712985|Drug|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
75735346|NCT00926510|Behavioral|Language toolkit|Simple toolkit of interactive things to stimulate language.
75735347|NCT00926510|Behavioral|Safety counseling|Smoke detector and general safety counseling
75735348|NCT00737789|Drug|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
75735349|NCT00737789|Drug|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
75735350|NCT05612789|Behavioral|Exercise Program (Cohort A Prehab)|Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
75735351|NCT05612789|Behavioral|Exercise Program (Cohort B Rehab)|All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
76055915|NCT05752825|Radiation|HR-pQCT|HR-pQCT is a 3-dimensional imaging modality that can be applied to bone and joints in vivo, in order to non-invasively assess the quantity and quality of trabecular and cortical bone compartments separately. HR-pQCT will be applied to peripheral skeletal sites, namely the distal radius and tibia, where image slices equivalent to 9 mm of bone will be acquired. From this, parameters such as volumetric bone mineral density (vBMD), cortical density, cortical porosity, trabecular density, trabecular thickness, trabecular spacing and others will be calculated using specialized software. In the same scanning session, images of the wrist and ankle joints will be produced and analyzed for features of arthrosis, such as erosions, osteophytosis and others.
75735352|NCT00700115|Drug|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
75442207|NCT01651975|Dietary Supplement|Thickenup|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
75592300|NCT05438680|Dietary Supplement|Placebo|distilled water with no bovine colostrum
75735353|NCT00700115|Drug|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
75735354|NCT04062929|Behavioral|4-day physical activity program with behavioral intervention|Each program included 8-12 patients. During the four days, the participants had 4 collective sessions of educational information on PA and heart disease and 2 one-to-one sessions for promoting personal advice and experience on PA behavior. The participants had 6 sessions of PA and 2 food-counseling sessions.
75735355|NCT05556473|Drug|1-(2-[18F]FLUOROETHYL)-L-Tryptophan|Radioactive tracer 1-(2-[18F]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
75735356|NCT04062773|Behavioral|TRF|time restricted feeding group
75735357|NCT04062773|Behavioral|Normal timing of food intake|no time restricted feeding
75735358|NCT02568917|Procedure|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
75592301|NCT05436041|Behavioral|Collaborative Diet Goal Setting Clinical Decision Support|Receives Nutri
75592302|NCT05434078|Device|Orthofeet Shoes|Participants will wear a pair of Orthofeet shoes to wear for 6 weeks
75592303|NCT05417854|Device|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
75592304|NCT05414565|Device|Vivity IOL|Commercially available extended vision IOL
75735359|NCT02568917|Procedure|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
75592305|NCT05414565|Device|Aspheric monofocal IOL|Commercially available aspheric IOL
75735360|NCT00566852|Drug|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
75735361|NCT00566852|Other|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
75735362|NCT00566852|Radiation|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
75735363|NCT00931346|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
75735364|NCT00931346|Drug|Placebo|Placebo
75735365|NCT00936650|Drug|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
75735366|NCT00936650|Drug|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
75735367|NCT00442546|Drug|pregabalin|150 milligram (mg)/ day (double blind)
75735368|NCT00442546|Drug|pregabalin|300 mg/day (double blind)
75735369|NCT00442546|Drug|Placebo|Placebo
75735370|NCT03545594|Other|Patient-centered in home rehabilitation|Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts before the Corona pandemic and eight sessions with up to six of them video delivered if necessary during the Corona pandemic ) delivered over a 4-month period in three phases
75442208|NCT01651975|Dietary Supplement|Thickenup Advance|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
75592306|NCT05407012|Other|Application of the barrier enhancing preparation.|Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
75592307|NCT05400707|Diagnostic Test|Assessment of vital signs|heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
75735371|NCT03545594|Other|Control|Usual follow-up in the municipality
75735372|NCT00936962|Biological|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
75592308|NCT05400707|Diagnostic Test|Assessment of impaired mobility on presentation (IMOP)|Assessment of IMOP: defined as being unable to stand unaided or walk without help
75592309|NCT05400707|Diagnostic Test|Assessment of level of consciousness by AVPUC scale|Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)
75735373|NCT00514683|Drug|low dose BIBF1120 once daily|low dose BIBF1120 once daily
75735374|NCT00514683|Drug|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
75735375|NCT00514683|Drug|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
75735376|NCT00514683|Drug|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
75735377|NCT00514683|Drug|placebo|placebo
75735378|NCT00566696|Device|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
75735379|NCT00566696|Procedure|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
75592310|NCT05400707|Diagnostic Test|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 37 symptoms
75735380|NCT00566696|Drug|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
75735381|NCT00566696|Drug|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
75735382|NCT00566696|Drug|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
75884380|NCT03549026|Drug|placebo|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
75442209|NCT01651988|Drug|Ketamina-Propofol Combination|"After randomization to the study group, the patients were given:~Procedures < 10 minutes~Ketamine-Propofol Combination KETOFOL 1:1~Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Ketamine-Propofol Combination KETOFOL 1:2~Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures > 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min"
75592311|NCT05400707|Diagnostic Test|Assessment of current living situation in patients of 65 years and older|Questionnaire to assess living situation (living at home independently, living at home with help by family members or professional services, and living in a retirement or nursing home)
75735383|NCT00566696|Drug|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
75735384|NCT00566696|Drug|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
75735385|NCT00566696|Drug|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
75442210|NCT01652014|Drug|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
76055916|NCT05752825|Radiation|DXA scan|Through DXA scans, we will obtain information regarding body composition, hip and spine bone mineral density, as well as examine any previous vertebral fractures using vertebral fracture assessment (VFA). VFA is a function of DXA scanners which allows for visualization of thoracic and lumbar vertebrae (usually T4-L4) in order to detect vertebral fractures34. Vertebral fractures can then be classified as either mild, moderate or severe using the method described by Genant et al35.
75442211|NCT01652014|Drug|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
75442212|NCT01652014|Drug|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
75442213|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
75442214|NCT01652014|Procedure|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
75442215|NCT01652014|Procedure|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
75442216|NCT01652014|Radiation|total-body irradiation|Undergo TBI
75592312|NCT05400707|Diagnostic Test|Assessment of elder abuse (EA)|The ED Senior AID tool is a questionnaire with 15 questions to identify elder abuse
75592313|NCT05400707|Diagnostic Test|Assessment of caregiver burden:|"The caregiver will be asked 4 questions about caregiver burden: do you feel emotionally burdened by caring for your relative?, is caring for your relative a physical strain for you?, has the care of the relative negatively affected the relationship with someone close (family, care recipient)?, is caring for your relative a financial burden for you?."
75735386|NCT00566696|Drug|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
75735387|NCT00566696|Drug|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
75735388|NCT00566696|Drug|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
75735389|NCT00566696|Drug|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
75735390|NCT00937196|Drug|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
75735391|NCT00937196|Drug|Histaminum hydrochloricum globuli|
75735392|NCT00937274|Other|T4 phage cocktail test|T4 phages 106 PFU/ ml up to 5 days
75735393|NCT00937274|Other|Commercial T4 phage cocktail|Treatment as recommended by the manufacturer (Microgen phages)
75735394|NCT00937274|Other|standard oral rehydration solution (ORS)|Standard hospital treatment with ORS
75884381|NCT03101371|Drug|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
75884382|NCT03101371|Procedure|Standard of care catheter insertion|Catheter inserted right out of package.
75592314|NCT05398640|Biological|Lifileucel|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
75592315|NCT05395091|Biological|denosumab|AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL developed as a subcutaneous injection.
75592316|NCT05388864|Behavioral|Three-Tier Model|Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
75442217|NCT01652014|Drug|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
75592317|NCT05387759|Drug|Aticaprant Supratherapeutic Dose|Aticaprant supratherapeutic dose capsule will be administered orally.
75592318|NCT05387759|Drug|Aticaprant Therapeutic Dose|Aticaprant therapeutic dose capsule will be administered orally.
75592319|NCT05387759|Drug|Placebo|Placebo will be administered orally.
75592320|NCT05387759|Drug|Moxifloxacin|Moxifloxacin capsule will be administered orally.
75592321|NCT05380921|Device|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
75592322|NCT05380921|Device|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
75592323|NCT05380180|Other|OneClick Social Engagement Intervention|Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8. Participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform. During each session participants will watch a short slideshow around a series of topics (e.g., nature, technology, hobbies) and get to engage in conversations surround the topics presented, which will be held in breakout rooms. Breakout room discussions will be set for 30 minutes, and participants will be provided with questions surrounding the topics to help stimulate conversation.
75592324|NCT05380180|Other|OneClick Social Engagement Intervention Extension|Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension. Waitlist participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform over the span of 8 weeks. Intervention effects will be measured at week 4 and week 8 of the intervention extension.
75735395|NCT00926666|Drug|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
75735396|NCT00926744|Behavioral|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
75442218|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
75442219|NCT01652014|Procedure|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
75442220|NCT01652027|Drug|FVIII concentrate|usual treatment as directed by treating physician
75442221|NCT01652053|Device|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
75769473|NCT01151176|Drug|Regular Insulin|"Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose >141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; > 400=16U"
75769474|NCT01257412|Drug|Dapagliflozin|5mg Oral dose od
75769475|NCT01257412|Drug|Dapagliflozin|10 mg Oral dose od
75884383|NCT03588078|Drug|APR-246|Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
75442222|NCT01652066|Dietary Supplement|Mixture of probiotics|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
75769476|NCT01257412|Drug|placebo|5/10 mg Oral dose od
75884384|NCT03588078|Drug|Azacitidine|azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
75884385|NCT02238366|Drug|triptorelin|This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
75884386|NCT05494190|Drug|Docetaxel|60 mg/m2 i.v. day 1
75884387|NCT05494190|Drug|Cisplatin|60 mg/m2 i.v. day 1-3
75884388|NCT05494190|Drug|Capecitabine|750 mg/m2 po bid day 1-14
75884389|NCT05494190|Radiation|Concomitant chemoradiotherapy|"Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65~70 Gy in total, 1.7~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50~60 Gy in total, 1.7~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks."
75884390|NCT05494190|Procedure|Surgery|Neck dissection and primary tumor resection
75884391|NCT03582540|Procedure|Double-guidewire cannulation technique|With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
76055917|NCT05752825|Diagnostic Test|Bone microindentation|Using the OsteoProbe®, we will by microindentation measure the bone material strength index (BMSi), an in vivo surrogate measure of the fracture resistance of the cortical bone in the tibia. The participant is placed in a supine position with the examined leg rotated slightly outward. After identifying the site of interest, located midway between the medial tibial plateau and the medial malleolus, disinfectant is applied to the skin of the tibia being examined. Finally, under local anesthesia and fully sterile conditions, a test probe is inserted through the skin and onto the midshaft of the tibia, and the fracture resistance of the bone tissue is measured.
76055918|NCT05752825|Diagnostic Test|Hand grip and leg extension strength|Hand grip strength will be assessed using a digital hand dynamometer as a measure of peripheral muscle strength. Leg extensor strength will be examined using the peak torque measured by an isometric dynamometer mounted on a fixed chair. 3 attempts will be given for each method, and the maximum value recorded.
76055919|NCT05752825|Diagnostic Test|Timed up-and-go test|The TUG test is a functional test frequently used to assess balance in older individuals and is performed by measuring the time it takes for an individual to go from sitting to standing position, walk 3 meters, turn around and return to sitting position. A TUG score of >13,5 seconds is associated with an increased risk of falls.
75616198|NCT02847208|Other|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
75735397|NCT00932204|Device|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area."
75735398|NCT04014686|Other|No exercise intervention group|no exercise intervention
75735399|NCT04014686|Behavioral|Resistance band exercise intervention group|Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
75735400|NCT00926900|Drug|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
75735401|NCT00926900|Drug|Placebo|Placebo
75884392|NCT05360095|Behavioral|Meaning of Screening|The Meaning of Screening game is a decision making tool that is accessible through the most common web platforms. Users have the ability to explore learn about prenatal screening through multiple approaches, including presentation of facts, personal stories, and values clarification. Users will access the game from their personal phone or computer prior to completing prenatal screening.
75884393|NCT05360095|Behavioral|Genetic Counseling|This intervention consists of a 45-minute prenatal screening genetic counseling session (in person or online) completed after confirmation of pregnancy and before actual screening.
75884394|NCT05360095|Behavioral|Usual Care|Participants in the Usual Care group will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format so they can read it before they complete prenatal screening.
75735402|NCT00937430|Other|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
75735403|NCT00503841|Drug|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
75735404|NCT00503841|Other|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
75735405|NCT00503841|Other|laboratory biomarker analysis|Correlative studies
75442223|NCT01652066|Dietary Supplement|Mixture of probitiocs|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
75442224|NCT01652079|Drug|CRLX101|q 14 days
75442225|NCT01652105|Dietary Supplement|Standard diet versus standard VLCD (Prodimed)|
75735406|NCT00503841|Procedure|biopsy|14 days prior to surgery
75442226|NCT01652118|Drug|clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia|
75735407|NCT00503841|Procedure|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
75735408|NCT00503841|Procedure|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
75592325|NCT05379556|Diagnostic Test|Assessment of andrological profile of LO-COCO-ANDRO male patients|"Assessment of serum prolactin (PRL), luteininzing hormone (LH), follicle stimulating hormone (FSH), 17β-estradiol, testosterone. Physical examination with measurement of body weight, height, body mass index, waist and hip circumference. Andrological physical examination with evaluation of testis volume with Prader orchidometer, testicular consistency and lesions, varicocele. Scrotal ultrasound performed in longitudinal, transverse and oblique scans using a high frequency linear probe with grayscale and color-doppler; transrectal prostate ultrasound performed with transverse, longitudinal and oblique scans using an end fire probe; basal penile ultrasound will be performed in longitudinal and transverse scans using a high frequency linear probe with grayscale and color-doppler; dynamic penile ultrasound performed as described for basal penile ultrasound after intra-cavernous infiltration of 10 mcg of prostaglandin-E1 (PGE1)."
75592326|NCT05379556|Diagnostic Test|Assessment of reproductive function of LO-COCO-ANDRO male patients|Semen samples will be collected on site by masturbation directly into a sterile plastic container after 3-5 days of sexual abstinence. The sample will be analyzed according to World Health Organization (WHO) 2010 guidelines. Semen samples will be stored for biochemical and molecular evaluations.
75592327|NCT05379556|Diagnostic Test|Assessment of sexual function of LO-COCO-ANDRO male patients|Validated questionnaires to assess the prevalence of male sexual disorders, namely erectile dysfunction with International Index of Erectile function 15 (IIEF-15), premature ejaculation with premature ejaculation diagnostic tool (PEDT), hypoactive sexual desire disorder with andrological structured interview on erectile dysfunction (ANDRO-SIEDY). Patients will be also interviewed to evaluate lifestyle habits.
75735409|NCT00937508|Behavioral|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
76055920|NCT05752825|Diagnostic Test|Stabilometry|Postural control will be assessed by means of a force platform that registers Center of Pressure (CoP) as a measure of postural stability. Measurements are performed under a variety of conditions, including eyes open/closed and on different surfaces. From the CoP measurements, parameters such as CoP range and CoP velocity in both antero-posterior and medial-lateral directions will be calculated using specialized software.
76055921|NCT05752825|Diagnostic Test|Nerve conduction test|To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.
75735410|NCT00937508|Drug|varenicline|varenicline (an approved medication for smoking cessation)
75735411|NCT00937508|Drug|placebo|sugar pill without any active medication
75735412|NCT00937664|Drug|AZD7762|solution, intravenous, weekly
75735413|NCT00937664|Drug|gemcitabine|intravenous, weekly
75735414|NCT03743324|Procedure|Immediate Breast reconstruction|Immediate Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
75735415|NCT03743324|Procedure|Delayed Breast Reconstruction|Delayed Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
75735416|NCT03743324|Radiation|Radiation|Radiation is performed to the surgical site and complies with the ASCO guidelines on post-mastectomy radiotherapy
75735417|NCT00937820|Drug|YM150|oral
75735418|NCT00932516|Behavioral|South Beach Diet™ with South Beach Diet™ Products|
75884395|NCT03548480|Dietary Supplement|Placebo|Intervention with a daily dose of placebo
75884396|NCT03548480|Dietary Supplement|Probiotic|Intervention with a daily dose of probiotic
75442227|NCT01652118|Drug|Saline|
75442228|NCT01652131|Other|Tetrastarch (130/0.4)|
75442229|NCT01652157|Biological|ULTRESA|pancreatic enzyme replacement therapy
75442230|NCT01652157|Biological|PANCREAZE|pancreatic enzyme replacement therapy
75442231|NCT01652157|Biological|CREON|pancreatic enzyme replacement therapy
75442232|NCT01652157|Biological|ZENPEP|pancreatic enzyme replacement therapy
75442233|NCT01652157|Biological|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
75442234|NCT01652157|Biological|PERTZYE|pancreatic enzyme replacement therapy
75442235|NCT01652157|Other|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
75442236|NCT01652183|Drug|intravenous paracetamol|
75442237|NCT01652183|Drug|Placebo|
75442238|NCT01652196|Biological|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
75442239|NCT01652196|Drug|oxaliplatin|85 mg/m2 IV infused over 2 hours
75442240|NCT01652196|Drug|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
75442241|NCT01652196|Drug|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
75735419|NCT00932516|Behavioral|South Beach Diet™|
75735420|NCT00932516|Behavioral|Calorie restricted diet with South Beach Diet™ Products|
75735421|NCT00932516|Behavioral|Calorie Restricted Diet|
75884397|NCT03587766|Drug|Fexinidazole|Drug: fexinidazole (FEXI)
75884398|NCT03587766|Drug|Placebo Oral Tablet|Drug: fexinidazole
75442242|NCT01652196|Other|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
75442243|NCT01652196|Procedure|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
75884399|NCT03734185|Other|Learning and Coping|'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
75442244|NCT01652196|Radiation|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
76055922|NCT05752825|Diagnostic Test|Visual acuity test|Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
76055923|NCT05745701|Drug|PF-07081532|Oral Tablet
76055924|NCT05745701|Device|Cyclosporine|Oral Solution
75442245|NCT01652196|Procedure|PET (positron emission tomography)|Correlative studies
75592328|NCT05379556|Diagnostic Test|Assessment of olfactory function of LO-COCO-ANDRO male and female patients|"Brief interview to collect patient's anamnesis relative to olfactory function, with particular reference to hypo / anosmia and hypo/ageusia onset timeline, duration and regression.~Interview for the self-assessment of chemosensory skills and for the evaluation of quality of life in relation to olfactory dysfunction.~Sniffin 'Sticks test for the evaluation of odor threshold (T), odor discrimination (D) and odor identification (I) (TDI score)."
75592329|NCT05377827|Biological|WU-CART-007|Provided by Miltenyi Biotec
75592330|NCT05373186|Drug|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
75592331|NCT05373186|Drug|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
75592332|NCT05373186|Drug|Euglycemic clamp with Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
75442246|NCT01652209|Biological|Hearticellgram-AMI|
75442247|NCT01652222|Other|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
75442248|NCT01652222|Other|Socio-educational training only|4 socio-educative training sessions during 8 weeks
75442249|NCT01652248|Procedure|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
75442250|NCT01652261|Drug|ABVD + FDG-PET/CT Scan treatment adaptation|
75592333|NCT05366010|Device|Oscillation and Lung Expansion (OLE) therapy|Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
75592334|NCT05361746|Device|Scotchbond Universal Plus Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU+ treatment group will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive using total-etch mode and Filtek Universal Restorative material.
75735422|NCT00442468|Other|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
75735423|NCT00937976|Procedure|Periodontal Scaling and Root Planing|Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
75769477|NCT01257490|Behavioral|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
75884400|NCT03548402|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of anxiety and self-injury.
76055925|NCT05745701|Drug|Itraconazole|Oral Capsule
75592335|NCT05361746|Device|Scotchbond Universal Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU Control group will undergo restoration(s) using Scotchbond Universal Plus (SBU) Adhesive using total-etch mode and Filtek Universal Restorative material.
75592336|NCT05349227|Behavioral|Digital Health Coaching Program|Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
75769478|NCT03896542|Device|Commercial video game.|Stroke patient had played with commercial video game, along 12 sessions.
75884401|NCT05485610|Dietary Supplement|NMN intervention|NMN capsules (total of 600mg/day) for 3 months
75884402|NCT05485610|Other|Placebo|NMN-free placebo capsules for 3 months
75884403|NCT02850276|Drug|Pyridostigmine|
76055926|NCT05742594|Drug|Lazertinib|Lazertinib will be administered orally.
75442251|NCT01652261|Drug|BEACOPPesc|
75442252|NCT01652300|Behavioral|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
75442253|NCT01652300|Behavioral|no education|women in the control group received no education
75442254|NCT01652313|Drug|Rasagiline|1 mg/day, tablets for 7 days, orally
75442255|NCT01652326|Drug|Diazepam|
75442256|NCT01652339|Drug|Exforge tab. 10/160mg|
75442257|NCT01652339|Drug|Lodivixx tab. 5/160mg|
75592337|NCT05349227|Device|Fitbit|Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
75769479|NCT03896542|Device|rehabilitation video game|Stroke patient had played with an specific video game for rehabilitation, along 12 sessions
75769480|NCT03896698|Device|Transcranial Ultrasound Stimulation|TUS activate the brain cells
75592338|NCT05337007|Other|high protein diet|48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
75884404|NCT05418517|Procedure|Tracheostomy|temporary tracheostomy insertion
75442258|NCT01652365|Behavioral|RDT Training and Subsidy Offered|
75442259|NCT01652365|Behavioral|Information/Education Campaign|
75442260|NCT01652378|Drug|ondansetron, lidocaine|"Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion)."
75442261|NCT01652391|Device|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
75442262|NCT01652404|Behavioral|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
75592339|NCT05337007|Other|moderate protein diet|48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
75592340|NCT05326386|Behavioral|HTN and Medication Adherence|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
75592341|NCT05321758|Biological|Fecal Microbiota Transplantation|In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
75442263|NCT01652404|Behavioral|Conventional treatment|The antibiotics duration will be determined by treating physician.
75592342|NCT05321758|Drug|Immunosuppressive Agents|hormones, azathioprine, thalidomide
75592343|NCT05321745|Other|Standardized FMT|Fecal microbiota transplantation of fresh bacteria from healthy donor to the whole colon
75592344|NCT05314933|Drug|2-Deoxyglucose|Intranasal administration
75735424|NCT00926978|Radiation|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
75735425|NCT00506883|Drug|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
75735426|NCT00506883|Drug|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
75735427|NCT00506883|Other|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
75735428|NCT00932594|Procedure|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
75735429|NCT00932594|Other|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
75884405|NCT05418517|Procedure|Overnight intubation|Patient who had overnight intubation
75884406|NCT03592134|Other|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
76055927|NCT05742334|Procedure|Robot-Assisted Radical Prostatectomy with MLG-COMPLETE Allograft Implantation|The intervention will be administered on an inpatient basis. Participants receiving MLG-Complete™ will have it placed around the neurovascular bundle. Placement of the graft should not take more than 5 minutes, therefore, there should be minimal impact to overall surgical time.
75442264|NCT01652417|Drug|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
75592345|NCT05314933|Other|Placebo|Intranasal administration
75592346|NCT05309187|Biological|IO-202|IO-202 given as monotherapy
75592347|NCT05309187|Biological|IO-202 + pembrolizumab combination therapy|IO-202 and fixed dose pembrolizumab combination therapy
76055928|NCT05742334|Device|MLG-COMPLETE Allograft Implantation|The MLG-Complete™ allograft will be placed on each neurovascular bundle (NVB) bilaterally as shown on the above picture after excision of the prostate prior to completing the urethrovesical anastomosis.
76055929|NCT05741086|Drug|Evolocumab|evolocumab (140 mg every 2 weeks)
76055930|NCT05741086|Drug|Atorvastatin|Atorvastatin 20-40mg
75442265|NCT01652456|Other|Addiction support|one consultation with an addiction specialist
75592348|NCT05309187|Biological|RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types|Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.
76055931|NCT05731388|Diagnostic Test|Push enteroscopy|A push enteroscopy using a pediatric colonoscope will be performed along with capsule endoscopy. These are part of the standard of care.
75442266|NCT01652508|Other|Control|Participants in the control group are provided a self-help leaflet on smoking cessation only
75442267|NCT01652508|Behavioral|Acceptance and Commitment Therapy|All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
75442268|NCT01652534|Drug|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
75592349|NCT05306743|Other|CONQUEST Quality Improvement Program|"CONQUEST supports primary healthcare professionals to diagnose, assess, and optimize the management of their patients with modifiable high-risk COPD, through the promotion of guideline-based care. CONQUEST will promote management according to four Quality Standards for the care of modifiable high-risk COPD patients. The Quality Standards can be summarized as the timely and appropriate: Identification of high-risk patient groups for assessment; Assessment of disease and quantification of future risk; Non-pharmacological and pharmacological intervention; Follow-up. CONQUEST program will promote adherence to these standards through the use of electronic medical record -based algorithms for the identification of high-risk patients and clinical decision support resources. All decisions regarding patient management are made entirely at the discretion of the clinicians and patients who together negotiate the preferred course of action during consultations."
75592350|NCT05300425|Other|Blood sample collection|Blood sample collection (at baseline and approximately two years after baseline). Enzyme-linked immunosorbent assays will be used to screen for IgG and IgM antibodies directed against the three pathogens (Leptospirosis, Tularemia, Hepatitis E).
75592351|NCT05300425|Other|Data collection|Data collection on sociodemographic questions e.g. profession, leisure activities, animal contact
75592352|NCT05289544|Behavioral|Phone-Based Walk With Ease|6 week phone-delivered Walk With Ease Program
75735430|NCT01028638|Other|89Zr-bevacizumab PET scan|"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43."
75735431|NCT00938132|Drug|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
75735432|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
75735433|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
76055932|NCT05722262|Drug|K-001|K-877-ER and CSG452 combination tablet
76055933|NCT05722262|Drug|K-877-ER|K-877-ER tablet
75442269|NCT01652534|Drug|Placebo|Sugar Pill
76055934|NCT05722262|Drug|CSG452|CSG452 tablet
75592354|NCT05276622|Other|Comprehensive Geriatric Assessment|"A modified Cancer and Aging Research Group (CARG) Geriatric Assessment that includes validated measures of 7 geriatric domains: functional status, comorbidity, cognition, psychological state, social activity, and support, nutritional status, and medications will be performed at baseline (pre-treatment), every 3 months for a total of 3 assessments. The modified comprehensive Geriatric Assessment includes patient-reported surveys and research staff assessments.~Cognitive Testing: The National Institutes of Health Toolbox Cognition Battery (objective) and PROMIS Short Form v2.0 - Cognitive function 8a (subjective)"
75735434|NCT04015388|Device|iPro Continuous Glucose Monitoring|iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
75735435|NCT00932672|Behavioral|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
75735436|NCT00927056|Procedure|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
75735437|NCT00938210|Procedure|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
75735438|NCT00932750|Dietary Supplement|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
76055935|NCT05711446|Other|Double Voiding|Participant will be instructed to void twice.
76055936|NCT05711446|Other|Regular Voiding|Participant will void as usual
75442270|NCT01652547|Drug|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
75442271|NCT01652547|Drug|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
75442272|NCT01652560|Drug|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
75735439|NCT00932750|Dietary Supplement|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
75442273|NCT01652586|Drug|dexmedetomidine-remifentanil|
75442274|NCT01652586|Drug|midazolam-remifentanil|
75442275|NCT01652599|Drug|Eltrombopag and dexamethasone|Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
75442276|NCT01652612|Other|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
75442277|NCT01652625|Drug|Yunnan Baiyao toothpaste|The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
75442278|NCT01652625|Drug|Placebo toothpaste|One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
75442279|NCT01652638|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
75442280|NCT01652651|Behavioral|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
75442281|NCT01652677|Procedure|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
75442282|NCT01652742|Drug|BI 135585 XX|one single dose
75442283|NCT01652768|Other|Research Questionnaires|Hospital Anxiety and Depression Scale Pearlin & Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
75442284|NCT01652768|Other|Palliative Care Team|"Week 1: Early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse).~Introduce the palliative care team concept.~Provide contact information for the palliative care team given~Administer Initial Patient and Caregiver Psychosocial Assessments (Appendix A)~Offer community resources to patient and caregiver (Appendix B)~Provide additional resources/referrals for any needs that are identified by patient or care partner during initial psychosocial assessment~Provide supportive care"
75442285|NCT01652768|Other|Educational Information Session for Patients and Caregivers|"Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver Week 5 through 7: The PRESENCE Project Social Worker and oncology RN will provide an educational class.~Intervention (Length of time for class = 2 hours):~Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver.~Provide additional resources/referrals for any needs that are identified by patient or care partner during the educational class.~Provide supportive care."
76055937|NCT05710887|Drug|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
75592355|NCT05276622|Other|Qualitative patient-care partner interviews|Semi-structured Interviews: Baseline and again at 3 months.
75735440|NCT00938288|Drug|KW-3357|50IU/mL, IV single dose
75442286|NCT01652768|Other|Contact every 2 weeks|"The PRESENCE Project APN and/or Presence Project Social Worker will contact the patient and caregiver via telephone or office visit every two weeks and as needed until the second medical oncology visit.~(Anticipated length of time for phone intervention or visit is 20 minutes; however, length of time for intervention is tailored to the patient and caregiver's needs):~Administer Patient and Caregiver Follow-up Assessment~Provide pain and/or symptom management intervention for any issues identified during the follow-up assessment~Provide resources/referrals for any needs identified during the social work follow-up assessment~Provide supportive care"
75592356|NCT05276622|Other|Surveys on well-being and function|Care partner's Surveys on well-being and function: Baseline and again at 3 months
75592357|NCT05262595|Drug|NNC0471-0119 A|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
75592358|NCT05262595|Drug|NNC0471-0119 B|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
75592359|NCT05262595|Drug|NNC0471-0119 D|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
75735441|NCT00932906|Other|Different self-training methods|Self training with MiniAnne Training Kit
75442287|NCT01652768|Other|Follow-up Surgical Visit Session|"The PRESENCE Project APN will meet with patient and caregiver at the surgical follow-up visit, approximately two weeks after surgery.~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~Administer Patient and Caregiver Follow-up Assessment~Administer Symptom Assessment Tool~Provide pain and/or symptom management intervention~Provide supportive care"
75592360|NCT05262595|Drug|Faster aspart|"Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
75592361|NCT05260424|Other|non-invasive ventilation|Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.
75592362|NCT05260047|Behavioral|IMANI|For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.
75592363|NCT05260047|Behavioral|Telehealth MAT|Describe what is the Telehealth MAT briefly
75592364|NCT05260047|Behavioral|Traditional MAT plus Referral and Linkage|Describe what he traditional MAT plus referral and linkage briefly
75592365|NCT05250258|Other|Telephone peer support by telephone|"Peer support by telephone from experienced father to new father with depressive symtoms.~4 times or more if requested during 4 months"
75592366|NCT05248659|Drug|Sibeprenlimab 400 mg s.c. Q4weeks|Sibeprenlimab 400 mg s.c. q 4 weeks
75592367|NCT05248646|Drug|Sibeprenlimab 400 mg|Sibeprenlimab 400 mg s.c. q 4 weeks
75592368|NCT05248646|Drug|Placebo|Placebo s.c. q 4 weeks
75592369|NCT05248204|Device|Scotchbond™ Universal Plus Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU+ treatment group will undergo restoration with Scotchbond™ Universal Plus Adhesive using self-etch mode and Filtek Universal Restorative
75592370|NCT05248204|Device|Scotchbond™ Universal Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU control group will undergo restoration with Scotchbond™ Universal Adhesive using self-etch mode and Filtek Universal Restorative
75592371|NCT05223010|Drug|Melatonin 5 MG/15 ML Oral Solution 0.05 mg/kg|will be administered 1 hour before arrival to operating room
75592372|NCT05223010|Drug|Melatonin 5 MG/15 ML Oral Solution 0.2mg/kg|will be administered 1 hour before arrival to operating room
75592373|NCT05223010|Drug|Melatonin 5 MG/15 ML Oral Solution 0.4mg/kg|will be administered 1 hour before arrival to operating room
75592374|NCT05223010|Drug|Sevoflurane|for anaesthesia induction 3-8 MAC
75735442|NCT00932906|Other|Standard training|Instructor-based training meeting ERC directions
75735443|NCT00938522|Drug|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
75769481|NCT03894280|Drug|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals|2 inhalations in one study period
75769482|NCT03894280|Drug|SERETIDE DISKUS® 250/50 inhalation powder/GSK|2 inhalations in one study period
75884407|NCT05577962|Drug|T group|OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
75735444|NCT00938522|Drug|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
75442288|NCT01652768|Other|Medical and/or Radiation Oncology Appointment Session|"The PRESENCE Project APN and/or Presence Project Social Worker will meet with patient and caregiver at the first medical and/or radiation oncology appointment (weeks 3 and 4).~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~Administer Patient and Caregiver Follow-up Assessment~Re-assess pain and/or symptom management issues and /or intervention~Provide resources/referrals for any needs identified during the social work follow-up assessment~Provide supportive care."
75442289|NCT01652781|Drug|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
75442290|NCT01652794|Radiation|stereotactic body radiation therapy|Undergo SBRT
75442291|NCT01652794|Drug|carboplatin|Given IV
75442292|NCT01652794|Drug|gemcitabine hydrochloride|Given IV
75442293|NCT01652794|Other|laboratory biomarker analysis|Optional correlative studies
75442294|NCT01652794|Other|pharmacogenomic studies|Optional correlative studies
75592375|NCT05222802|Drug|ERAS-801|Administered orally
75592376|NCT05208112|Drug|M6229|Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
75592377|NCT05203471|Other|integrated care model|The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.
75735445|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
75735446|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
75735447|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
75735448|NCT00932984|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
75735449|NCT00938678|Drug|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
75735450|NCT00938678|Drug|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
75735451|NCT03743168|Other|Intermittent stretching protocol|Intermittent stretching protocol of five sets of 1 minute and15 second rest
75735452|NCT03743168|Other|Continuous stretch|2 minutes continuous stretch
75735453|NCT00933062|Drug|SRT2104|2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
75735454|NCT00933062|Drug|Placebo|Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
75735455|NCT00938756|Other|diagnostic laboratory biomarker analysis|
75735456|NCT00938756|Other|immunoenzyme technique|
75735457|NCT00938756|Procedure|magnetic resonance imaging|
75735458|NCT00503685|Biological|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
75735459|NCT00503685|Biological|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
75735460|NCT00712673|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
75884408|NCT05577884|Diagnostic Test|noncontrast-enhanced whole-body CT|"noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation).~conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction~ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software."
76055938|NCT05710887|Drug|Placebo|Administration of the placebo (oxygen-air mixture [FiO2 ≈0.3]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
75442295|NCT01652807|Behavioral|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
75442296|NCT01652820|Drug|Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|
75442297|NCT01652820|Drug|Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d|
75592378|NCT05181592|Drug|Luspatercept|Once 1.75 mg/kg on Day 1 of each 21-day cycle for 24 weeks (9 cycles)
75592379|NCT05180032|Drug|Romoszumab|Monthly SQ injections
75592380|NCT05180032|Drug|Denosumab|2 injections 6 months apart SQ
75735461|NCT00712673|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
75735462|NCT00712673|Device|Pen auto-injector|
75442298|NCT01652859|Drug|Liposomal Amphotericin B|
75592381|NCT05180032|Drug|Placebo|Monthly Placebo Injections
75735463|NCT00712673|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
75442299|NCT01652859|Drug|AmBisome|
75442300|NCT01652898|Drug|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
75592382|NCT05178706|Other|upper extremity rehabilitation program|Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.
75735464|NCT01562990|Drug|Rituximab, CMC544, Gemcitabine and Oxaliplatine|"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."
75735465|NCT00939380|Behavioral|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
75735466|NCT00939380|Other|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
75735467|NCT00939380|Other|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
75735468|NCT00939380|Other|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
75735469|NCT00933218|Dietary Supplement|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
75884409|NCT03862170|Drug|Ciprofloxacin|Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
75884410|NCT03862170|Drug|Cefazolin|
76055939|NCT05699044|Diagnostic Test|Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)|"Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.~DPD-scintigraphy. (Echocardiography)"
75442301|NCT01652898|Drug|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
75442302|NCT01652898|Drug|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
75884411|NCT02140580|Device|Minimally invasive surfactant therapy|Active Comparator
75884412|NCT02140580|Other|Continuation on CPAP|Sham Comparator
75884413|NCT04955431|Behavioral|Sleep Restriction|Participants will be allowed ~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
75735470|NCT00933218|Dietary Supplement|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
75442303|NCT01652924|Device|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
75442304|NCT01652924|Device|Manual ventilation with facial mask|"This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist."
75442305|NCT01652937|Drug|BIIB057|Oral
76055940|NCT05693272|Biological|COVAC-1|Intramuscular vaccine against SARS-CoV-2
75592383|NCT05178706|Diagnostic Test|Results of assessment|The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.
75735471|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
75442306|NCT01652937|Drug|Placebo|Oral
75592384|NCT05178589|Device|One Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Single unit TENS was administered via 2 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
75592385|NCT05178589|Device|Two Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Double unit TENS was administered via 4 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
75592386|NCT05169554|Drug|Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.|Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.
75616199|NCT01551550|Procedure|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
75616200|NCT01551550|Procedure|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
75735472|NCT00737867|Drug|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
75735473|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
75884414|NCT04955431|Behavioral|Normal Sleep|Participants will be allowed ~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
75884415|NCT05577806|Drug|Dydrogesterone|progestin primed ovarian stimulation
75735474|NCT00737867|Drug|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)
75884416|NCT03591432|Device|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
76055941|NCT05693272|Biological|Saline Placebo|Intramuscular injection of saline placebo
76055942|NCT05657041|Drug|Clopidogrel|Body weight adjusted clopidogrel dosing
76055943|NCT05653362|Device|Coconut Oil|Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.
75616201|NCT01551550|Procedure|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
75616202|NCT01478698|Drug|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
75735475|NCT03976466|Device|Antibiotic local prophylaxis with medicated calcium sulfate beads|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
75769483|NCT03894280|Other|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
75442307|NCT01652950|Behavioral|Financial incentives|"The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: <150 fitness points per month - equivalent to < 1 gym visit per month - no reward, up to Level 5, which was >3000 fitness points/month - equivalent to >20 gym visits/month."
75442308|NCT01652963|Other|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
75442309|NCT01652989|Behavioral|Weight loss maintenance intervention face-to-face|
75735476|NCT03976466|Procedure|Classical parenteral antibiotic prophylaxis|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
75735477|NCT02536755|Drug|Eliglustat, GZ385660|"Pharmaceutical form: capsule~Route of administration: oral"
75735478|NCT02567279|Drug|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
75735479|NCT02567279|Drug|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
75735480|NCT00938834|Other|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
75735481|NCT05460689|Other|M-HEALTH APP|The intervention group will have in use a mHealth App for education and support of caregivers of children undergoing tonsillectomy and/or adenoidectomy in the perioperative process. An out-patient nurse will be in charge of instructing intervention group participants to mHealth App use and content options. The mHealth App will be available for intervention group families from the day of pre-admission visits to the 7th day post surgery or follow up visit.
75735482|NCT05460689|Other|Standard Care|The control group will receive information and education provided by nurses and physician in the preoperative visits and during hospitalization. Information and education will be provided orally or through printed booklets.
75735483|NCT04013594|Dietary Supplement|carbohydrate group|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery.
75735484|NCT00933374|Drug|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
75735485|NCT00933374|Drug|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
75735486|NCT03303105|Drug|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks.
75735487|NCT03303105|Drug|TEV-48125|TEV-48125 will be administered subcutaneously once every 12 weeks.
75735488|NCT00933452|Drug|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
75735489|NCT00933452|Drug|duloxetine|15mg, oral administer
75735490|NCT00933452|Drug|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
75735491|NCT03263325|Other|Discarded urine sample|Collection of discarded urine during surgery and following surgery
75735492|NCT00933530|Drug|SRT2104|SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
75769484|NCT03893968|Behavioral|Information by an assistant nurse|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by an assistent nurse.
75769485|NCT03893968|Behavioral|Information by a doctor|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by a doctor.
75769486|NCT01255462|Biological|LFG316|
75769487|NCT01255462|Biological|LFG316|
76055944|NCT05653362|Device|Commercial Ultrasound Gel|Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
75442310|NCT01652989|Behavioral|Weight loss maintenance intervention delivered via DVD|
75442311|NCT01653002|Other|No intervention|
75442312|NCT01653015|Biological|Trivalent Inactivated Vaccine|Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
75442313|NCT01653015|Biological|Live Attenuated Influenza Vaccine|Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
75442314|NCT01653041|Drug|Everolimus|
75592387|NCT05169554|Drug|Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.|"On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.~Dosages for amoxicillin/clavulanate are calculated according to manufacturer indications:~Dose of amoxicillin/clavulanate 1000/125 mg twice daily, which makes a total of 2000/250 mg/day, for patients over 40 kg, and 22.5/5.6 mg/kg twice daily, which makes a total of 45/11.25 mg/kg/day, for those equal and below 40 kg. For children, posology will be adapted to the age of the patient according to drug manufacturer indications. Frequency of AMX/CLV administration will match that of CLA, twice daily."
75592388|NCT05161390|Drug|LM-302 Injection|LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
75616203|NCT01478698|Drug|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
75592389|NCT05156320|Drug|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
75592390|NCT05156320|Drug|Placebo|Placebo will be administered every 4 weeks by intravenous (IV) infusion.
75735493|NCT00933530|Drug|Placebo|Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
75592391|NCT05154994|Drug|Belinostat|Given IV
75592392|NCT05154994|Biological|Durvalumab|Given IV
75592393|NCT05152342|Behavioral|Stigma Awareness Training for Legal System Staff|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
75735494|NCT00447694|Drug|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
75442315|NCT01653054|Procedure|Anal Pap Smear, HPV DNA Testing|Anal Pap Smears and HPV DNA testing will be performed on all subjects.
75592394|NCT05152342|Behavioral|Acceptance and Commitment Therapy for self-stigma|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
75592395|NCT05138003|Diagnostic Test|cardiac MRI|"T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified."
75735495|NCT00564278|Drug|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
75735496|NCT00564278|Behavioral|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
75735497|NCT04013906|Diagnostic Test|Rotational atherectomy|Rotational atherectomy
75442316|NCT01653067|Drug|Rituximab, Temsirolimus, DHAP, intravenous|Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
75442317|NCT01653106|Procedure|cryotherapy|Receive shaved ice
75442318|NCT01653106|Other|questionnaire administration|Participate in PROMS
75442319|NCT01653106|Other|pharmacological study|Correlative studies
75442320|NCT01653119|Drug|Rosuvastatin|Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
75442321|NCT01653145|Other|Diet A|Dietary
75442322|NCT01653145|Other|Diet B|Dietary
75442323|NCT01653145|Other|Diet C|Dietary
75442324|NCT01653171|Drug|Water (Placebo)|Water 100 mL
75442325|NCT01653171|Drug|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
75442326|NCT01653171|Drug|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
75442327|NCT01653171|Drug|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
75442328|NCT01653184|Dietary Supplement|Omega-3 fatty acid|The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
75442329|NCT01653197|Behavioral|Control|No scratch off element
75442330|NCT01653197|Behavioral|Curiosity|The recipient will be prompted to scratch off for answer to question.
75442331|NCT01653197|Behavioral|Curiosity linked to Action|The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
75442332|NCT01653236|Drug|Boceprevir|
75735498|NCT00933842|Drug|LACTIC ACID(ND)|Treatment duration: 5 weeks
75735499|NCT00565604|Device|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
75735500|NCT00933920|Drug|Aliskiren|
75735501|NCT00933920|Drug|Aliskiren|
75735502|NCT00938990|Drug|Etomidate|
75735503|NCT00938990|Drug|Midazolam|
75735504|NCT00933998|Other|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
75769488|NCT01255462|Biological|LFG316|
75769489|NCT01255462|Biological|LFG316|
75592396|NCT05138003|Diagnostic Test|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
75884417|NCT03591432|Device|Facemask ventilation|Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
75592397|NCT05138003|Diagnostic Test|RootiRx for the ECG monitoring during the cycling ride|The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate > 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
75592398|NCT05138003|Diagnostic Test|Blood sample|Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
75592399|NCT05130047|Drug|Aldafermin|1 mg solution
75592400|NCT05130047|Drug|Placebo|Aldafermin placebo solution
75884418|NCT03547388|Device|Moderate whole body hyperthermia using water-filtered IR-A-radiation|four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
75442333|NCT01653236|Drug|Peginterferon alfa-2b|
75442334|NCT01653236|Drug|ribavirin|
75442335|NCT01653249|Biological|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
75442336|NCT01653275|Other|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
75592401|NCT05128162|Drug|Psilocybin|Two oral doses of psilocybin in a capsule formulation taken approximately 2 weeks apart.
75592402|NCT05128162|Behavioral|Psychotherapy|1. Pre-dose preparatory sessions; 2. Dosing day monitoring; and, 3. Post-dose integration sessions.
75592403|NCT05127616|Behavioral|Minimal Contact-Cognitive Behavior Therapy|This 4 session largely home-based version of CBT with minimal therapist contact treatment is aimed at improving UCPPS symptoms by teaching symptom self-management skills that modify illness beliefs, information processing strategies, and reactions that aggravate pelvic pain and urinary symptoms.
75592404|NCT05127616|Behavioral|Patient Education/Support|This 4 session largely home-based treatment is aimed at improving UCPPS symptoms through the provision of support and science-based information about UCPPS symptoms, how it is diagnosed, its causes, impacts, and triggers, treatment options and a collaborative relationship between the patient and clinician.
75592405|NCT05121558|Other|Yoga|Participants will have instructional yoga classes twice each week over the course of 8 weeks. Each yoga class will be 60 minutes, and it will be taught by an experienced yoga instructor. Participants in the yoga group will also have the option to participate in a recorded final check-in session after they have completed their 16 yoga classes. The discussion facilitator will follow the Semi-Structured Interview Guide to further understand participants' experiences in the yoga group.
75592406|NCT05121558|Other|Education control|Participants will have educational sessions over 8 weeks. The sessions will be on the causes and impact of Chemotherapy-Induced Peripheral Neuropathy (CIPN) , how yoga may help with CIPN, and how different therapies may help with CIPN.
75592407|NCT05121558|Other|Usual care|Participants in the usual care control group will complete the same assessments as the other two arms. To encourage participation and adherence, patients in the UC group will receive a voucher for sixteen free yoga sessions after completing the study. Patients in the UC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
75592408|NCT05117554|Drug|AB521|Capsule
75592409|NCT05117554|Drug|Placebo|Capsule
75592410|NCT05117554|Drug|Midazolam|Syrup solution
75592411|NCT05113563|Device|Transcranial Electric Stimulation Therapy|TEST is a form of brain stimulation.
75884419|NCT03591276|Drug|Chemotherapy Drugs, Cancer|IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
75592412|NCT05112952|Drug|Lazertinib|Lazertinib tablet will be administered orally.
75592413|NCT05106426|Behavioral|Healthy Caregivers- Healthy children|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom or in-person.
75592414|NCT05106426|Behavioral|Jump Start|The Jump Start intervention is a behavioral health and safety program that provides behavior management and safety programs administered weekly via Zoom or in-person.
75592415|NCT05101356|Biological|Antineoplastic Vaccine|Given LabVax 3(22)-23 ID
75769490|NCT03899584|Drug|4-Aminopyridine|Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
75592416|NCT05101356|Biological|Sargramostim|Given SC
75592417|NCT05101356|Biological|Pembrolizumab|Given IV per standard of care
75592418|NCT05101018|Drug|Romosozumab|Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month
75592419|NCT05101018|Drug|Denosumab|Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months
75592420|NCT05088876|Drug|Placebo|Blinded withdrawal of regular co-medication with paracetamol
75592421|NCT05088876|Drug|Paracetamol|Paracetamol in the dose already used
75592422|NCT05074186|Device|neurological thrombectomy device is an investigational device.|Revascularization device is an investigational device.
75592423|NCT05070767|Device|Neurolens spectacle lens|spectacle lens
75592424|NCT05070767|Device|Placebo spectacle lens|spectacle lens for refractive error correction
75592425|NCT05059158|Radiation|positron emission tomography (PET)|18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.
75592426|NCT05054348|Biological|IO-108|IO-108 given as monotherapy
75592427|NCT05054348|Biological|IO-108 + pembrolizumab combination therapy|IO-108 and fixed dose pembrolizumab combination therapy
75592428|NCT05054348|Biological|IO-108 + cemiplimab combination therapy|IO-108 and fixed dose cemiplimab combination therapy
75592429|NCT05046431|Drug|BAT2506|50mg/0.5mL
75592430|NCT05046431|Drug|EU Simponi|50mg/0.5mL
75592431|NCT05046171|Other|Pharmacist-led deprescribing|A pharmacist recruited onto the study will review the patient's current medication list and develop a list of targeted recommendations for deprescribing using the 3-step potentially inappropriate medications identification method.
75592432|NCT05046171|Other|Patient education|Subjects receive a written pamphlet about deprescribing.
75592433|NCT05039671|Behavioral|Measurement-based care (MBC)|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
75592434|NCT05039164|Behavioral|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
75592435|NCT05039164|Behavioral|CBT for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
75592436|NCT05039164|Behavioral|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
75592437|NCT05039164|Behavioral|Initial Training (CC)|School personnel will participate in an initial live remote training.
75592438|NCT05039164|Behavioral|Initial Training plus Video (RV)|School personnel will participate in an initial live remote training and receive access to asynchronous video training modules.
75769491|NCT03899584|Drug|Placebo oral capsule|The placebo arm will include a placebo of microcrystalline cellulose.
75769492|NCT03893890|Biological|Previously Treated with EN3835|No treatment to be administered - Observational only
75769493|NCT01258270|Procedure|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
75769494|NCT01258270|Procedure|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
75884420|NCT03582384|Drug|Tocofersolan|After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
75884421|NCT03783468|Other|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
75884422|NCT03854526|Other|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
75884423|NCT04928287|Biological|HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
75884424|NCT04928287|Other|Placebo|Placebo will be administered intravenously to study participants who qualify.
75884425|NCT03590964|Procedure|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
75884426|NCT03590964|Procedure|Sinus lift using bone ring containing the implant.|Patients with atrophied posterior maxilla will undergo sinus lift with chin bone ring containing the implant.
75592439|NCT05039164|Behavioral|Initial Training plus Video plus Coaching (RV+)|School personnel will participate in an initial live remote training, receive access to asynchronous video training modules, and receive coaching support from study staff.
75592440|NCT05032040|Biological|vudalimab|Monoclonal bispecific antibody
75442337|NCT01653301|Drug|XELAC RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
75592441|NCT05022134|Behavioral|CHOICE-AYA|Adapted contraceptive counseling specific to AYA experiencing homelessness
75592442|NCT05001347|Drug|TJ004309|Antibody to CD73
75592443|NCT04996654|Behavioral|Exergame|According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).
75592444|NCT04996654|Behavioral|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
75592445|NCT04996433|Behavioral|inpatient CBASP individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual CBASP therapy sessions (duration: 50 min per session).
75616204|NCT04968340|Procedure|conventional cs|opening the lower uterine segment with introduction of the surgeon hand below the fetal head during its extraction
75884427|NCT03548948|Other|High heme iron diet|"A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
75884428|NCT03548948|Other|Low iron diet|"A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
75884429|NCT03548948|Other|Plant-based high non-heme iron diet|"A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
75884430|NCT04926337|Device|Tight Fitting Facemask|Preoxygenation with tight facemask, 10 L/min, 100% oxygen.
75884431|NCT04926337|Device|High Flow Nasal Oxygen (HFNO)|Preoxygenation with high flow nasal oxygen, 40-70 L/min, 100% oxygen.
75884432|NCT02238444|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
75884433|NCT02238444|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
75884434|NCT02238444|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
75884435|NCT02238444|Drug|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
75442338|NCT01653301|Drug|XELOX RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
75442339|NCT01653314|Drug|Megavec|
75442340|NCT01653314|Drug|Glivec|
75442341|NCT01653340|Device|Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine|http://nevro.com/corporate/system-us
75592446|NCT04996433|Behavioral|inpatient CBASP group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 CBASP group therapy sessions (duration: 100 min per session).
75735505|NCT00447226|Drug|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
75592447|NCT04996433|Behavioral|inpatient CBASP nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP nurse contact (duration: 30 min per session).
75592448|NCT04996433|Behavioral|inpatient CBASP exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP exercise therapy (duration: 75 min per session).
75592449|NCT04996433|Behavioral|outpatient CBASP group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 CBASP group therapy session (duration: 100 min per session).
75592450|NCT04996433|Behavioral|inpatient BA individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual BA therapy sessions (duration: 50 min per session).
75592451|NCT04996433|Behavioral|inpatient BA group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 BA group therapy sessions (duration: 100 min per session).
75735506|NCT00446992|Drug|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
75735507|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
76055945|NCT05635097|Behavioral|Motivational Interviewing counseling on the Mediterranean diet and weight checks at regular intervals|Each participant will meet virtually on Zoom with the DNP project leader and receive 1:1 counseling on pairing the Repnho smart scale and tape measure with the Renpho application. The expectations of the weight management program will be explained in detail during the first session, which will last one hour (session one= week zero). The weight loss goal will be at least 1-2 pounds per week as recommended by the Centers for Disease Control and Prevention (CDC) (2022).
76055946|NCT05632484|Biological|Cord blood sampling|Collection of 2 milliliters (mL) of cord blood on an Ethylenediaminetetraacetic acid (EDTA) tube, on the day of delivery and after cutting the umbilical cord, for genetic testing
75442342|NCT01653353|Behavioral|peer physician-applied recommendation to the physicians|The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
75442343|NCT01653366|Behavioral|Physical Activity Goal Setting|"Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them."
75442344|NCT01653392|Biological|Observational Intervention|This is an observational study, therefore no interventions are specified.
75442345|NCT01653431|Device|Transcranial direct current stimulation|
75442346|NCT01653444|Drug|GC1119|biweekly, IV infusion
75592452|NCT04996433|Behavioral|inpatient BA nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA nurse contact (duration: 30 min per session)
75592453|NCT04996433|Behavioral|inpatient BA exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA exercise therapy (duration: 75 min per session).
75592454|NCT04996433|Behavioral|outpatient BA group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 BA group therapy session (duration: 100 min per session).
75592455|NCT04996433|Drug|algorithm-based study medication|"All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~1st line dose escalation (if appropriate)~2nd line lithium augmentation~3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~4th line change of antidepressant."
75735508|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
75735509|NCT00503139|Drug|Enbrel (etanercept)|Enbrel 10 to 25 mg twice a week subcutaneous injection
75735510|NCT00577031|Drug|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
75735511|NCT00577031|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
75735512|NCT00577031|Drug|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
75735513|NCT00565448|Drug|docetaxel|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
76055947|NCT05632484|Biological|Cord blood sampling|Collection of 50 to 100 mL of cord blood from the cord blood collection bag
76055948|NCT05632484|Biological|Cord sampling|Collection of 20 centimeters (cm) of umbilical cord
75735514|NCT00565448|Drug|cisplatin|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
75735515|NCT00565448|Drug|5-fluorouracil|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
75884436|NCT03638479|Other|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
76055949|NCT05622461|Behavioral|Road-to-recovery|R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
75442347|NCT01653457|Drug|Memantine|"Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:~1st week: 5 mg daily~2nd week: 10 mg daily~3rd week: 15 mg daily~From 4th week up to 24th week: 20 mg daily"
75442348|NCT01653457|Drug|Placebo|Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
75442349|NCT01653470|Drug|Paclitaxel|
75442350|NCT01653470|Drug|5-Fluorouracil (5FU)|
75442351|NCT01653470|Drug|Carboplatin|
75442352|NCT01653470|Drug|Leucovorin|
76055950|NCT05621889|Procedure|virtual group speech therapy intervention guided by a patient partner|virtual group speech therapy intervention guided by a patient partner
76055951|NCT05607420|Biological|UCART20x22|Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
75442353|NCT01653470|Drug|Irinotecan|
75442354|NCT01653470|Drug|Paclitaxel|
75442355|NCT01653470|Drug|BMS-906024|
75735516|NCT01012011|Drug|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
75735517|NCT00934076|Drug|Tarceva plus AT-101|"150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
75769495|NCT01150162|Drug|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
75442356|NCT01653483|Drug|GSK573719|Novel Dry-Powder Inhaler
75442357|NCT01653483|Drug|GSK573719matched-placebo|Novel Dry-Powder Inhaler
76055952|NCT05607420|Biological|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
76055953|NCT05607316|Drug|Metformin Hydrochloride|"Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily at bedtime for the remainder of the study."
76055954|NCT05607238|Procedure|Ultrasound Guided Vascular Access - Midline catheter|Ultrasound guided vascular access with a midline IV catheter
76055955|NCT05607238|Procedure|Ultrasound Guided Vascular Access - peripheral IV|Ultrasound guided vascular access with a peripheral IV catheter
75442358|NCT01653496|Procedure|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
75442359|NCT01653522|Drug|Triptan|
75592456|NCT04995497|Drug|Intravenous Administration of Lidocaine Post Cardiac Surgery|Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
75592457|NCT04995497|Drug|Administration of Lidocaine Post Cardiac Surgery via ESP Catheter|Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
75592458|NCT04966169|Device|GentleWave System|The GentleWave hydrodynamic cavitation system is a 510k FDA-approved multisonic energy system that is used in complex root canal procedures.
75592459|NCT04957082|Behavioral|Culturally Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans.
75592460|NCT04957082|Behavioral|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information
75592461|NCT04949958|Other|Exercise Based Manual (Supervised)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise, Exercise and Education. The exercise will be supervised while other component will be home based.
75735518|NCT04495803|Other|Cognitive Behavioural Group Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population. Additional strategies for COVID-19 specific worry content have been included.
75735519|NCT00934154|Drug|Thalidomide|100 mg/day continuously for 12 months
75735520|NCT00934154|Drug|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
75735521|NCT00446446|Drug|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
75735522|NCT05078255|Drug|Semaglutide 1.34 MG/ML [Ozempic]|Semaglutide 1.34 mg/ml
75592462|NCT04949958|Other|Exercise Based Manual (Home Based)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise and Education. All two components will be home based.
75442360|NCT01653522|Drug|Doxycycline|
75884437|NCT02783768|Device|E-cigarette|The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.
76055956|NCT05605587|Drug|Leflunomide 20 mg|once daily for 6 months
75442361|NCT01653548|Behavioral|Habituation Reminder Training|Participants will hear a unique sound after habituating to a personal stressor.
75442362|NCT01653548|Behavioral|Habituation Reminder|Participants will hear the habituation reminder outside of the lab via a cellular phone.
75735523|NCT05078255|Drug|Glucose-dependent insulinotropic polypeptide (GIP)|GIP
75442363|NCT01653548|Behavioral|Habituation|Participants will habituate to personally-relevant stressor.
75442364|NCT01653561|Drug|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
75442365|NCT01653574|Drug|Famitinib Malate|The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
75442366|NCT01653600|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
75442367|NCT01653600|Device|LifeStent|same to SMART STENT
75592463|NCT04949958|Other|Control|General advice to be active
75616205|NCT04968340|Procedure|external pop out teqnique|support of lower uterine segment without introduction of the surgeon hand below the fetal head during its extraction
75735524|NCT05078255|Other|Semaglutide 1.34 mg/ml placebo|Saline
75735525|NCT05078255|Other|GIP placebo|Saline
75735526|NCT00939458|Drug|Lamotrigine|
75769496|NCT01150162|Drug|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
75769497|NCT03893734|Drug|methadone|Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia
76055957|NCT05596682|Device|supplementary intraocular lenses|Implantation of supplementary intraocular lenses into the ciliary sulcus in previously pseudophakic eyes.
75442368|NCT01653613|Genetic|DNA analysis|
75884438|NCT02783768|Other|Sham|"The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off."
75884439|NCT02783768|Drug|Hyperpolarized 3-Helium|Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.
75884440|NCT02783768|Drug|Gadolinium|Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
75884441|NCT02238522|Drug|ZEN003365|
75884442|NCT03131687|Drug|tirzepatide|Administered SC
75884443|NCT03131687|Drug|Dulaglutide|Administered SC
75884444|NCT03131687|Drug|Placebo|Administered SC
75884445|NCT03579888|Biological|Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|Given IV
75884446|NCT03579888|Drug|Cyclophosphamide|Given IV
75884447|NCT03579888|Drug|Fludarabine|Given IV
76055958|NCT05588700|Behavioral|Physical activity recommendations|At the baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population.
75442369|NCT01653613|Genetic|fluorescence in situ hybridization|
75442370|NCT01653613|Genetic|gene expression analysis|
75442371|NCT01653613|Genetic|microarray analysis|
75884448|NCT05344027|Drug|Mitotane|Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
75884449|NCT05435144|Dietary Supplement|Elderberry|European black elderberry extract
75442372|NCT01653613|Genetic|mutation analysis|
75884450|NCT05435144|Other|Placebo|Inactive placebo
75884451|NCT05343247|Diagnostic Test|Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
75884452|NCT05343247|Diagnostic Test|Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
75884453|NCT05343247|Diagnostic Test|London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
75884454|NCT03586986|Diagnostic Test|Brain MRI|Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
75884455|NCT05430698|Drug|PD-1antibody plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1，intravenous infusion.~Three weeks is a course of treatment,a total of 6-8 courses."
75442373|NCT01653613|Genetic|polymorphism analysis|
75442374|NCT01653613|Genetic|reverse transcriptase-polymerase chain reaction|
75442375|NCT01653613|Other|laboratory biomarker analysis|
75442376|NCT01653626|Other|package of 3 interventions|Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
75442377|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)
75442378|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)
75884456|NCT03585972|Behavioral|Frailty Prevention Program|4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.
75884457|NCT05577416|Procedure|Biopsy|Patients will undergo stereotactic biopsy by craniotomy or burr hole.
75884458|NCT05577416|Drug|Part A: AB-218|Part A: AB-218 orally 250 mg BID for 28 days.
75884459|NCT05577416|Procedure|Surgery (maximal resection)|Surgery: Maximal safe resection, within 24 hours of last dose of AB-218.
75884460|NCT05577416|Drug|Part B: AB-218|Part B: AB-218 orally 250 mg BID for 28 days for up to 12 cycles.
75884461|NCT03585894|Other|Sumatriptan|Receive intravenous infusion of sumatriptan
75884462|NCT03585894|Other|Ketorolac|Receive intravenous infusion of ketorolac
75884463|NCT04912921|Dietary Supplement|palmitoylethanolamide|4 tablets taken daily (2 in the am and 2 in the pm)
75884464|NCT04912921|Dietary Supplement|Placebo|4 tablets taken daily (2 in am and 2 in pm)
75884465|NCT04912921|Dietary Supplement|Curcumin|500 mg HydroCurc® twice a day
76055959|NCT05588700|Behavioral|Connected activity tracker|At baseline, all participants will receive a connected activity tracker to wear 24 hours a day during one year. Patients will be asked to download an application, dedicated to the study so that the physical activity data (ie. number of steps per day) will be synchronized in the application.
76071881|NCT03845985|Behavioral|Seeking Safety + Signs of Safety toolkit|"Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters."
75442379|NCT01653652|Dietary Supplement|Probiotic|
75442380|NCT01653652|Dietary Supplement|Maltodextrin|
75592464|NCT04940650|Diagnostic Test|exercise testing|To define the strenuous physical exercise in this study, each participant will be asked to perform two hours of high intensity (HIT)-effort during the endurance exercise of at least 6 to 7 hours. Therefore all participants will have exercise testing approximately 1 week before the physical exercise to set aerobic and anaerobic gas exchange thresholds, as well as VO2max.
75592465|NCT04940650|Diagnostic Test|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles at rest enabling comparisons with cardiac MRI and traditional echo measures.
75735527|NCT05077943|Behavioral|Breathing and chest mobilization exercises|Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.
75735528|NCT05077943|Behavioral|Second phase cardiac rehabilitation|Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.
75735529|NCT04014608|Other|Standard Practice to Prevent Hospital Onset CDI|Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
75884466|NCT04912921|Dietary Supplement|Control (microcrystalline cellulose)|2 tablets taken daily
75442381|NCT01653665|Drug|Leukine|Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
75442382|NCT01653665|Drug|Normal Saline|Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
75884467|NCT03590808|Biological|Influenza vaccination|Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
75884468|NCT05420324|Drug|YH003|YH003 will be administered intravenously over 30 minutes every 21-day cycle.
75884469|NCT05420324|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
75884470|NCT05420324|Drug|albumin paclitaxel|Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
75884471|NCT02238288|Drug|Aminocaproic acid|Crushed tablet in the dental socket
75442383|NCT01653691|Procedure|Pulse-Dye Laser|Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
75442384|NCT01653691|Procedure|Sham|No treatment to one side of subject's scar.
75442385|NCT01653717|Procedure|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
75442386|NCT01653717|Drug|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
75442387|NCT01653717|Drug|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
75442388|NCT01653717|Procedure|T-cell Infusion|Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
75442389|NCT01653730|Device|Eclipse 3 portable oxygen concentrator|
75442390|NCT01653730|Device|EverGo portable oxygen concentrator|
75442391|NCT01653730|Device|iGo portable oxygen concentrator|
75442392|NCT01653756|Drug|IPI-145, a PI3K Inhibitor|Active drug
75884472|NCT02238288|Other|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
75884473|NCT02238288|Drug|lidocaine and epinephrine|2%
75884474|NCT02238288|Drug|Paracetamol|750 mg
75884475|NCT04901455|Biological|LAIV|Standard dose of LAIV administered by a licensed health care providers.
75884476|NCT01364129|Procedure|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
75884477|NCT01561040|Dietary Supplement|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
75884478|NCT03590496|Dietary Supplement|Calcium-Propionate 500mg|Calcium-Propionate capsules
75884479|NCT03590496|Other|Placebo|Placebo capsules without any active ingredient
75884480|NCT03914651|Drug|300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
75884481|NCT03914651|Drug|150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
75884482|NCT03101293|Drug|TAK-831|TAK-831 film-coated tablet.
75884483|NCT01356953|Other|Aerobic exercise|Intensity of aerobic exercise
76071882|NCT03842007|Diagnostic Test|Rectal Barostat Study|Contractions will be recorded with a balloon inserted into the rectum and inflated
75884484|NCT05577260|Drug|magnesuim sulphate|magnesuim sulphate
75884485|NCT05577260|Drug|Dexmedetomidine|Dexmedetomidine
75884486|NCT05577260|Drug|isobaric bupivacaine|20ml isobaric bupivacaine 0.25%
75884487|NCT01361087|Other|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
75442393|NCT01653756|Drug|Placebo to match IPI-145|Comparator
76071883|NCT03842007|Diagnostic Test|Fecoflowmetry|Rectum will be filled with a small amount of paste.Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Subjects will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.
76071884|NCT03832790|Other|observation|observation
75442394|NCT01653795|Device|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
75442395|NCT01653795|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
75616206|NCT00902746|Drug|NPC-01|"This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point."
75884488|NCT03590340|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
75884489|NCT03590340|Other|Normal saline|Normal saline is 0.9% sodium chloride
75884490|NCT03590340|Biological|PfSPZ Challenge (for CHMI)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
75884491|NCT03760562|Drug|Glucocorticoids|Oral Glucocorticoids.
75884492|NCT01357031|Drug|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
75884493|NCT01357031|Drug|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
75884494|NCT01357031|Drug|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
75884495|NCT05577104|Procedure|Negative pressure wound therapy (NPWT)|For patients in the NPWT group, the wound bed preparation was facilitated by vacuum-assisted closure (VAC).
75884496|NCT05577104|Procedure|conventional moist dressings|For patients in the control group, the wound bed preparation was facilitated by conventional dressing change method (with alginates ).
75884497|NCT01357109|Drug|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
75884498|NCT01357109|Drug|Placebo|Matched placebo bid
75884499|NCT04808492|Device|CureWave High Intensity Laser|"The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include:~Power (44 Watts)~Mode (continues wave)~Time on (60000 ms)~Time off (1 ms)~Repeats (9)~Distance of electrode from skin will begin 10 from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2 intervals until it is comfortable. The entire process will take approximately 10 minutes.~The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted."
75884500|NCT04808492|Other|Placebo|"The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE.~o Distance of electrode from skin will begin 10 from skin surface. The entire process will take approximately 10 minutes."
75884501|NCT03896399|Procedure|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
75884502|NCT02850978|Drug|Spiolto|
75442396|NCT01653808|Device|Elisio-210H|comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
75442397|NCT01653808|Procedure|conventional hemodialysis|comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
75616207|NCT00632710|Other|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
75884503|NCT02253446|Drug|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
75884504|NCT02253446|Drug|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
75884505|NCT03589170|Diagnostic Test|Opportunistic atrial fibrillation screening|Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
75884506|NCT05417893|Device|MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)|The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
75884507|NCT03135431|Procedure|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
75442398|NCT01653808|Procedure|on line hemodiafiltration|comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
75442399|NCT01653821|Procedure|Carotid body excision|
75442400|NCT01653834|Procedure|Lymphocyte harvesting & reinfusion|Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
75442401|NCT01653860|Behavioral|The Brøset anger management model|manualised structured cognitive treatment program 15 weeks (30 hours)
75442402|NCT01653860|Behavioral|Ordinary group treatment|group treatment 8 weeks (16 hours)
75616208|NCT00632710|Other|phototherapy placebo|disconnected laser (same device - experimental group)
75735530|NCT02566967|Drug|tofacitinib|oral tofacitinib will be taken 2 times daily
75735531|NCT00939068|Drug|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
75735532|NCT00939068|Biological|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
75735533|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
75769498|NCT03893734|Drug|Hydromorphone|Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
75442403|NCT01653886|Other|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
75884508|NCT03135431|Procedure|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
75884509|NCT03546452|Diagnostic Test|in vitro NGS-panel|cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel
75884510|NCT03585348|Other|Neuromuscular blocking agents|Neuromuscular blocking agent ED95 equivalent dose by provider
75884511|NCT03579810|Other|Investigational|"The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity"
75884512|NCT03579810|Other|Control|The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
75884513|NCT03556085|Device|Venous sinus stenting (Serenity River)|Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
75884514|NCT03767634|Other|Parenteral nutrition|Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
75884515|NCT01563224|Drug|Baclofen 10mg|Baclofen 10mg single dose po
75884516|NCT01563224|Drug|Baclofen 60mg|Baclofen 60mg single dose po
76071885|NCT03827174|Other|Return To Work Coordination|External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.
76071886|NCT03827174|Behavioral|Behaviour Change Ability Program|"Return to work coordination~Education for employers and employees in pain neuroscience, validation and problem-solving.~Patient-specific goal setting for return to work~Exercise and behavioural skills training related to return to work"
75884517|NCT01563224|Drug|placebo|placebo
76071887|NCT03826693|Drug|Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
75442404|NCT01653886|Other|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
75735534|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
75735535|NCT00934232|Drug|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
75735536|NCT01013571|Drug|insulin glargine|pre-filled disposable pen, in package of 5.
75735537|NCT01013571|Drug|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
75735538|NCT04061837|Device|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
75884518|NCT01361243|Behavioral|NOURISH+|6 week face-to-face parent intervention.
75884519|NCT01361243|Behavioral|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
75884520|NCT03632629|Other|interactive cognitive training|Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
75884521|NCT05576870|Other|Plant based toddler nutrition|Plant based toddler nutrition fed daily ad libitum
75884522|NCT05576870|Dietary Supplement|Dairy based toddler nutrition|Commercially available toddler nutrition fed daily ad libitum
75884523|NCT01369979|Procedure|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
75735539|NCT03128385|Other|Intensive CIT Model Program|"Day Camp Model:~The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~constraint of the unaffected hand to encourage the use of the affected hand~massed and repetitive practice of the affected hand during the period of constraint~use of behavioral techniques termed shaping to train the affected hand"
75442405|NCT01653886|Other|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
75442406|NCT01653938|Behavioral|video decision aid|
75442407|NCT01653951|Other|nurse-led care management or peer-led self management|
75442408|NCT01653977|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
75884524|NCT03577860|Drug|Bupivacaine 4 mL|The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000
75884525|NCT03577860|Drug|Bupivacaine 15 mL|The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
75884526|NCT03547661|Other|P-Dragees rosa Lichtenstein|Placebo dragées
75884527|NCT03577782|Biological|Entyvio (Vedolizumab)|"Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48."
75884528|NCT03548090|Other|Skateboard exercise at an incline angle of 0 degrees and 50% body weight|Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
75884529|NCT03548090|Other|Skateboard exercise at an incline angle of 5 degrees and 50% body weight|Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
75442409|NCT01653977|Other|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
75442410|NCT01653990|Drug|moxifloxacin|oral dose of 400mg moxifloxacin
75442411|NCT01653990|Drug|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
75442412|NCT01654003|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
75442413|NCT01654003|Other|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
75442414|NCT01654016|Drug|Detralex|Detralex 500 mg twice daily for three month prior to surgery
75884530|NCT03548090|Other|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
75442415|NCT01654029|Behavioral|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
75769499|NCT03899194|Dietary Supplement|fish oil capsules|fish oil capsules(1000mg，EPA 180mg；DHA 120mg)
75769500|NCT03899194|Drug|escitalopram|escitalopram 10-20 mg/d
75769501|NCT01151800|Other|Using IVR to maintain ACS patients on best practice guidelines|
75769502|NCT03893578|Device|Mitral valve-in-valve|The Synecor Conveyor System shall be used to position the Edwards SAPIEN 3 valve at the mitral location.
75769503|NCT01257646|Other|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
75769504|NCT03896074|Drug|Atezolizumab|Atezolizumab administered intravenously at 1200 mg every 3 weeks
75769505|NCT03896074|Drug|Bevacizumab|Bevacizumab intravenously at 15 mg/kg every 3 weeks
75769506|NCT03899116|Other|deflation of pneumatic tourniquet|gradual deflation with variable degrees
75884531|NCT03548090|Other|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
75735540|NCT03128385|Other|Distributed CIT Model Program|"Home-Based Model:~The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~constraint of the unaffected hand to encourage the use of the affected hand~massed and repetitive practice of the affected hand during the period of constraint~use of behavioral techniques termed shaping to train the affected hand"
76055960|NCT05588700|Behavioral|Physical Activity (PA) Intervention|"The intervention will last 1 year and will have 2 phases. Phase 1: At each cycle of chemotherapy, patients will be proposed to perform 2-4 sessions per week. This program will be individual, supervised, performed at a moderate intensity. Between cycles, patients will be asked to perform 1-2 supervised collective live online physical activity sessions per week, proposed by a partner specialized in online PA.~Phase 2: After chemotherapy, patients will be asked to perform 2-3 PA sessions per week at a moderate intensity. Patients will be offered 2 options of PA practice: in the supervised collective live online PA session (as already performed in the phase 1), and/or in a fitness center (this practice will take place in a classic environment with a 9-month free access for patients thanks to a partnership).~In addition, patients will benefit from 4 individual motivational interviews, conducted by videoconference and/or by phone call with a professional."
76055961|NCT05585515|Behavioral|Sleep deprivation|Total sleep deficit of consecutive 8 hours
76055962|NCT05585515|Behavioral|Sleep restriction|Total sleep deficit of cumulative 8 hours
75442416|NCT01654042|Other|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
75442417|NCT01654081|Drug|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
75442418|NCT01654094|Device|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
75735541|NCT04062071|Other|no intervention|no intervention
75735542|NCT00514449|Drug|Valacyclovir|1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
75735543|NCT00514449|Drug|Placebo|2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
76055963|NCT05584163|Device|Extracorporeal shock waves|3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
76055964|NCT05582993|Biological|Recombinant von Willebrand Factor (rVWF)|rVWF administered by intravenous injection.
76055965|NCT05582993|Biological|ADVATE|ADVATE administered by intravenous injection.
76055966|NCT05582642|Device|Inspiratory Muscle Training (IMT)|"The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above)."
76055967|NCT05582369|Behavioral|Affective Rewards Messages|Messages about the affective rewards of exercise
76055968|NCT05581758|Drug|AMG 510|Oral Tablet
76055969|NCT05564364|Device|Recumbent Bike|The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.
75442419|NCT01654094|Other|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
75442420|NCT01654120|Drug|Liraglutide|SC, 1.8mg,QD, six months to one year
75442421|NCT01654120|Drug|Insulin|SC, will be titrated during the study, 4 times a day, 1 year
75769507|NCT03899038|Procedure|spinal anesthesia|Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
75769508|NCT01151878|Dietary Supplement|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
75769509|NCT01151878|Dietary Supplement|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
75769510|NCT03893422|Other|WB-010|Medical food formulation
75442422|NCT01654146|Drug|Carboplatin|AUC5 by intravenous infusion over 30-60 minutes
75769511|NCT03893422|Other|WB-011|WB-011 medical food product
75769512|NCT03893422|Other|Placebo|Placebo Capsules identical to those containing WB-010 and WB-011.
75769513|NCT03898882|Drug|oxytocin|PK measurements of oxytocin
75884532|NCT03548090|Other|Control 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
75616209|NCT01199380|Behavioral|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
75735544|NCT04061759|Other|Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.|Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
75884533|NCT03548090|Other|Experimental 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
76055970|NCT05564364|Device|Upright Bike|The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
76055971|NCT05554146|Other|Receipt of Coupon for Placebo Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
76055972|NCT05554146|Other|Receipt of Coupon for High THC Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
75735545|NCT00565136|Device|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
75735546|NCT00738179|Device|Continuous Positive Airway Pressure (CPAP)|CPAP worn nightly
75735547|NCT00738179|Other|Standard care|Standard care of cardiovascular risk factors
75735548|NCT00492921|Drug|Cyclophosphamide|
76055973|NCT05554146|Other|Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
75442423|NCT01654146|Drug|Carboplatin|AUC2 by intravenous infusion over 30-60 minutes
75442424|NCT01654146|Drug|Paclitaxel|175mg/m2 by intravenous infusion over 3 hours
75442425|NCT01654146|Drug|Paclitaxel|80mg/m2 by intravenous infusion over 1 hour
75442426|NCT01654172|Dietary Supplement|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is ~900mg
75442427|NCT01654172|Dietary Supplement|Low Flavanol Cocoa|
75735549|NCT00738257|Drug|Pamidronate|
75735550|NCT00738335|Drug|erlotinib hydrochloride|
75735551|NCT00738335|Other|immunoenzyme technique|
75735552|NCT00738335|Other|laboratory biomarker analysis|
75735553|NCT00738335|Other|liquid chromatography|
75884534|NCT03548090|Other|Over-ground multi-directional gait training|In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
76055974|NCT05554146|Other|Receipt of Coupon for High CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
76055975|NCT05553301|Biological|Quadrivalent Influenza mRNA Vaccine MRT5407|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
75735554|NCT00738335|Other|mass spectrometry|
75735555|NCT00738335|Other|pharmacological study|
75735556|NCT00738335|Radiation|stereotactic radiosurgery|
75735557|NCT00502671|Drug|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
75884535|NCT03548090|Other|Home exercise|Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
75884536|NCT01364441|Drug|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
75884537|NCT01364441|Drug|Placebo|Placebo dosed in the same manner as ONO-2952
75884538|NCT02238756|Biological|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
75884539|NCT02238756|Biological|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
76055976|NCT05553301|Biological|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
76055977|NCT05553301|Biological|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
76055978|NCT05553301|Biological|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
75735558|NCT00738413|Drug|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
75735559|NCT00738413|Drug|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
75735560|NCT00697463|Drug|Teriparatide (PTH 1-34)|20 micrograms subcutaneous injection daily
75884540|NCT02238756|Biological|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
75884541|NCT03432065|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
76055979|NCT05548127|Drug|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until the recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
76055980|NCT05548127|Drug|Abemaciclib|Daily oral dosages of Abemaciclib continuously, cycles lasting 28 days
76055981|NCT05541315|Drug|JNJ-88260237|JNJ-88260237 will be administered orally.
75442428|NCT01654185|Drug|AI plus Dimethyldiguanide|AI 1 tablet per day Dimethyldiguanide 0.5 bid
75884542|NCT03577626|Drug|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
75884543|NCT03577626|Drug|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
75884544|NCT03412799|Drug|SBP-101|Administered as subcutaneous (SC) injection, escalating dose cohorts
75884545|NCT03412799|Drug|nab-paclitaxel|Administered as intravenous (IV) infusion
76055982|NCT05541315|Drug|Placebo|Matching placebo will be administered orally.
76055983|NCT05538741|Drug|Bolus of remimazolam|0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for >80 years old
76055984|NCT05538741|Drug|Continuous infusion of remimazolam|12 mg/kg/hr until loss of consciousness
76055985|NCT05536323|Drug|Remimazolam bolus|Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, <40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, >80 years
76055986|NCT05536323|Drug|Remimazolam continuous|Remimazolam 12 mg/kg/hr
75442429|NCT01654185|Drug|Aromatase Inhibitor|1 tablet per day
75442430|NCT01654198|Radiation|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
75442431|NCT01654211|Drug|danoprevir|single iv infusion
75442432|NCT01654211|Drug|danoprevir|single oral dose
75442433|NCT01654211|Drug|placebo|single iv infusion
75442434|NCT01654211|Drug|ritonavir|oral doses
75735561|NCT04409795|Drug|Metformin Extended Release Oral Tablet|Initial oral hypoglycemic agent added to existing insulin treatment
75735562|NCT04409795|Drug|Sitagliptin|Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
75735563|NCT00492531|Drug|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
75735564|NCT00492531|Drug|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
75735565|NCT04334603|Other|Exercise Training Program|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
75735566|NCT04334655|Other|Physical Therapy|Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
75735567|NCT00111475|Drug|Romiplostim|Administered by subcutaneous injection
75735568|NCT00111475|Drug|Placebo|Administered by subcutaneous injection
75884546|NCT03412799|Drug|Gemcitabine Injection|Administered as intravenous (IV) infusion
75884547|NCT03375359|Diagnostic Test|cfDNA screening|cfDNA screening test for aneuploidy risk assessment
75884548|NCT03579732|Drug|Aspirin (Acetylsalicylic Acid, BAYE4465)|Low dose of aspirin, i.e. < 150 mg daily
75884549|NCT03579732|Other|No drug|Non-consumers
75884550|NCT01365533|Drug|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
75884551|NCT01365533|Drug|Placebo|Placebo, one tablet once daily, orally
75735569|NCT02566655|Biological|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
75884552|NCT03583788|Behavioral|Hypnotherapy|The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
75884553|NCT03583788|Other|Motivational Interviewing|The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
75884554|NCT03548012|Behavioral|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
75735570|NCT01015209|Device|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
75735571|NCT04948463|Drug|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.
76055987|NCT05535738|Drug|Squaric Acid Dibutyl Ester|Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
76055988|NCT05535738|Other|Known patch test allergens|Positive patch test allergens during the course of clinical patch testing will be re-applied on the back followed by skin sampling
75735572|NCT04948463|Drug|Cefepime Injection|Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.
75735573|NCT04948463|Drug|Ceftazidime Injection|If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly
75884555|NCT05272345|Procedure|sexual therapy|In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month.
76055989|NCT05535738|Drug|Dupilumab|300mg
76055990|NCT05535738|Drug|Adalimumab|40mg
76055991|NCT05535738|Drug|Ustekinumab|45mg
76055992|NCT05535738|Drug|Guselkumab|100mg
76055993|NCT05535738|Drug|Canakinumab|150mg
75735574|NCT04948463|Drug|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly
76055994|NCT05535738|Drug|Sarilumab|200mg
76055995|NCT05535738|Drug|Triamcinolone Acetonide|0.1% ointment
76055996|NCT05535738|Drug|Betamethasone Valerate|0.1% ointment
76055997|NCT05535738|Drug|Fluticasone Propionate|0.005% ointment
76055998|NCT05535738|Device|Microneedle|Painless and non-scarring skin sampling with a 7mm x 7mm patch of hydrogel-coated poly-l-lactide microneedles (<2mm length) will be used to collect interstitial fluid
75442435|NCT01654237|Other|questionnaires|185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
75735575|NCT04948463|Drug|Amikacin Injection|Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.
75735576|NCT04948463|Drug|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly
75735577|NCT04948463|Drug|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.
75735578|NCT04948463|Drug|Cefepime Injection|If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
75735579|NCT04948463|Drug|Ceftazidime Injection|If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
75735580|NCT04948463|Drug|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution
75735581|NCT04948463|Drug|Amikacin Injection|At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution
76055999|NCT05535738|Device|Suction blistering|Suction blistering is a technique to induce and collect blister fluid using a negative pressure instrument (Electronic Diversities Finksburg, MD). It does not require local anesthetic, stitches or pain medication following the procedure. The blisters will be no greater than 1cm in diameter and no deeper than the epidermis (<1mm deep). This process of inducing blisters is typically less than 1 hour. After the formation of blisters, the blister fluid will be extracted using a syringe. The blister roofs will be left attached to the skin and covered with petrolatum and a bandage.
76056000|NCT05535738|Procedure|Skin punch biopsy|A skin biopsy is the removal of a small piece of tissue, under local anesthetic.
75735582|NCT04948463|Drug|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
75592466|NCT04932421|Behavioral|Emotion Detectives: Unified protocol for transdiagnostic treatment of emotional disorders in children (UP-C)|"UP-C is a transdiagnostic and emotion-focused cognitive-behavioral group intervention for children aged 6-13 years old with emotions disorders (i.e., anxious and/or mood disorders) and their parents. UP-C unifies cognitive-behavioral, contextual (eg. mindfulness) and parental training techniques aiming to reduce the intensity and frequency of children's clinical symptomatology.~The intervention consists of 15 weekly group sessions (90 minutes per session; 5-8 children and parents per group) conducted by at least two clinical psychologists trained in the UP-C. The sessions start with the parents and children together (15 minutes); then, one psychologist conduct the session with the group of children while the other psychologist conduct the session with the group of parents, simultaneously (60 minutes); finally, the session ends with the group together (15 minutes). This is a structured and manualized intervention with a manual for the therapist and a workbook for the child and parents."
75735583|NCT04945421|Drug|Sintilimab|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
75884556|NCT05191589|Other|Haptic|Trainees are randomized in this group to use the haptic device.
75884557|NCT05477095|Biological|UB-313|A synthetic peptide-based immunotherapy
75884558|NCT05477095|Biological|Placebo|Normal saline
75884559|NCT03547934|Device|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
75884560|NCT02259816|Drug|Telmisartan|
75884561|NCT02259816|Drug|Amlodipine|
75884562|NCT04639505|Diagnostic Test|ELISA|ELISA kit detecting the serum AMH level
75884563|NCT04639505|Diagnostic Test|Chemiluminescence|CLIA method detecting the serum AMH level
75884564|NCT03547310|Behavioral|MyoBeatz|Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
75884565|NCT03577548|Other|Auto- questionnaires|10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).
75735584|NCT04945421|Drug|IBI310|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
75735585|NCT01080547|Procedure|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
75735586|NCT01080547|Drug|XELOX Chemotherapy|XELOX chemotherapy
75735587|NCT01080547|Drug|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
75735588|NCT01080547|Other|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
75735589|NCT01080547|Other|Conventional Perioperative Treatment|Conventional treatment during perioperation period
75735590|NCT01080547|Procedure|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
75735591|NCT02566811|Procedure|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
75735592|NCT02566811|Procedure|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
75735593|NCT00111241|Drug|aromatase inhibitors (letrozole, anastrozole)|Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
75884566|NCT01567735|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
75884567|NCT04631471|Drug|Ibudilast|Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
75884568|NCT04631471|Procedure|Cervical decompressive surgery|Surgical decompression of degenerate cervical myelopathy
75884569|NCT04631471|Drug|Matching placebo|Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
75884570|NCT03577470|Drug|D/C/F/TAF Fixed-Dose Combination (FDC)|Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
75884571|NCT05269771|Drug|Ruxolitinib|Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.
75884572|NCT03577392|Drug|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
75884573|NCT03577392|Drug|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
75884574|NCT05575778|Diagnostic Test|computed tomographic perfusion|The recruited patients would complete both pre- and post-operative computed tomographic perfusion
75884575|NCT03577314|Other|miscarriage|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
75884576|NCT04534517|Device|JJV Investigational Multifocal Contact Lens|TEST Lens
76056001|NCT05518110|Drug|Trametinib|2mg of Trametinib (orally) daily.
76056002|NCT05518110|Drug|Hydroxychloroquine|1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
75735594|NCT02567747|Other|Data collection|Data will be collected retrospectively for cases identified through RIPS*/ DANE** from 2008 until 2014 and through PAI*** from 2009 until 2014. *Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. **Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. ***Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
75735595|NCT00492297|Drug|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
75735596|NCT02567513|Behavioral|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
75735597|NCT02567513|Behavioral|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
75735598|NCT04608435|Other|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
75735599|NCT03997227|Procedure|Erector spinae Block|After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
75735600|NCT00565058|Biological|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
75735601|NCT04061681|Behavioral|Behavioral Intervention (BIPAMS)|This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
75735602|NCT00934388|Procedure|Pre peritoneal mesh placement|
75735603|NCT00934388|Procedure|Laparoscopy|
75735604|NCT00939224|Device|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
75735605|NCT00564902|Drug|3R 3'R Zeaxanthin|8 mg per day during 12 months
75735606|NCT00564902|Dietary Supplement|Lutein|9 mg of Lutein during 12 months
75735607|NCT00564902|Dietary Supplement|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
75735608|NCT04013516|Behavioral|Cash Incentive|During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
75735609|NCT04013516|Behavioral|Call|A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
75735610|NCT04014452|Procedure|Microwave ablation|Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
75735611|NCT04014452|Procedure|Radiofrequency ablation|Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
75884577|NCT04534517|Device|ACUVUE OASYS® with HYDRACLEAR® PLUS|The spherical test lens was used in the troubleshooting steps only for low ADD subjects who have reported a distance vision complaint.
75442436|NCT01654328|Drug|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
75884578|NCT03577236|Device|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
76071888|NCT03826693|Drug|Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
75884579|NCT03579654|Biological|Proscavax|Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
76071889|NCT03809598|Behavioral|Mindfulness Based Cognitive Therapy|"See Mindfulness Based Cognitive Therapy (MBCT) Arm description"
75442437|NCT01654328|Drug|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
75442438|NCT01654341|Behavioral|Exercise, dietary and educational program|
75442439|NCT01654354|Drug|NEOVIST 370 INJ.(Iopromide 768.86mg)|
75442440|NCT01654354|Drug|Ultravist 370 INJ.(Iopromide 768.86mg)|
75442441|NCT01654367|Drug|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
75442442|NCT01654393|Other|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
75442443|NCT01654406|Device|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
75442444|NCT01654406|Device|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
75442445|NCT01654419|Device|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
76071890|NCT03806842|Device|Easytech group|total shoulder replacement
76071891|NCT03801213|Device|urinary catheterization|Urinary catheterization with pain controlled
75616210|NCT01199380|Behavioral|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
75616211|NCT01199380|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
75735612|NCT04013750|Other|Modified Constraint Induced Movement Therapy|constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
75735613|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
75735614|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
75735615|NCT00446134|Drug|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
75735616|NCT00446134|Drug|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
75735617|NCT00934466|Drug|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
75735618|NCT00934466|Drug|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
75735619|NCT00934466|Drug|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
75735620|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
75735621|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
75735622|NCT00921245|Drug|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
75442446|NCT01654419|Device|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
75442447|NCT01654432|Other|Paravertebral Blocks (PVB)|
75616212|NCT02847286|Drug|Dapivirine Ring-004|Treatment A: Dapivirine Ring-004 for 28 days
75616213|NCT02847286|Drug|Dapivirine Ring-004 for 28 days along with clotrimazole|Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
75616214|NCT02847286|Drug|Clotrimazole|Treatment C: Clotrimazole, 5 g per day for 7 days
75616215|NCT00902668|Drug|lovastatin|
75616216|NCT00902668|Other|questionnaire administration|
75442448|NCT01654458|Behavioral|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
75442449|NCT01654484|Drug|DE-117|Ophthalmic Solution, QD, 28 Days
75442450|NCT01654484|Drug|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
75442451|NCT01654484|Drug|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
75442452|NCT01654484|Drug|Placebo|Ophthalmic Solution, QD, 28 days
75442453|NCT01654497|Drug|Dexanabinol|"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg"
75616217|NCT00902668|Procedure|adjuvant therapy|
75616218|NCT00902668|Radiation|accelerated partial breast irradiation|
75616219|NCT00902668|Radiation|external beam radiation therapy|
75616220|NCT02846662|Behavioral|CONEMO|The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
75616221|NCT00433420|Biological|pegfilgrastim|
75616222|NCT00433420|Drug|cyclophosphamide|
75616223|NCT00433420|Drug|epirubicin hydrochloride|
75616224|NCT00433420|Drug|fluorouracil|
75616225|NCT00433420|Drug|paclitaxel|
75442454|NCT01654510|Behavioral|Cognitive Behavioral Therapy Group|This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
75442455|NCT01654510|Other|Vocational Services as Usual|
75442456|NCT01654562|Drug|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
75442457|NCT01654575|Drug|Methotrexate|Methotrexate 25mg/week for 16 weeks
75442458|NCT01654575|Drug|Placebo|Placebo tablets once a week for 16 weeks
75442459|NCT01654627|Device|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
75592467|NCT04932421|Other|ABC of Emotions|"ABC of Emotions is a psychoeducational group intervention for children with anxiety and/or mood disorders, aged between 6 to 13 years. ABC of Emotions consists of 5 group psychoeducation sessions (about 90 minutes per session; 5-8 children per group). This is a structured and manualized intervention, with a manual for the therapist and a workbook for the child.~The contents of the sessions were developed by the researchers of this study and are based on classic psychoeducational cognitive-behavioral therapies (CBT) strategies. Since anxiety disorders are more frequent in childhood than mood disorders (e.g., Merikangas et al., 2009), this program is essentially based on psychoeducation materials focused on emotions such as anxiety and fear. However, the same materials are available in an attachment, adapted for use with children to whom the main emotion is not fear/anxiety, but sadness (as in mood disorders)."
75592468|NCT04929236|Drug|Panzyga|PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.
75616226|NCT00433420|Procedure|adjuvant therapy|
75735623|NCT00563186|Other|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
75735624|NCT00699413|Drug|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
75735625|NCT00699413|Drug|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
75735626|NCT01028872|Device|Intraocular lens|
75735627|NCT01028872|Device|Intraocular lens|
75735628|NCT01028872|Device|Intraocular lens|
75735629|NCT04061525|Procedure|Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration|Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
75442460|NCT01654627|Device|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
75442461|NCT01654640|Drug|Metformin|metformin 500mg p.o. bid for 24 weeks
75442462|NCT01654640|Drug|Placebo (for metformin)|placebo 1T bid
75442463|NCT01654653|Drug|Hypertonic sodium lactate|Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
75442464|NCT01654653|Drug|6% Hydroxy Ethyl Starch|Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
75735630|NCT04808609|Device|Lumme mobile phone application|Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
75735631|NCT04808609|Behavioral|Standard of Care|Smoking cessation counseling and nicotine replacement therapy
75735632|NCT00940160|Drug|QAX576|
75735633|NCT00940160|Drug|QAX576|
75735634|NCT00940160|Drug|QAX576|
75884580|NCT04508075|Biological|SARS-CoV-2 vaccine (inactivated)|SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac
75442465|NCT01654679|Device|wIRA irradiation|wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.
75442466|NCT01654679|Other|visible light only|visible light application at a distance of 27cm from the skin surface with for 20 min.
75442467|NCT01654692|Drug|Ipilimumab and Fotemustine|Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
75442468|NCT01654705|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
75735635|NCT00940160|Drug|Placebo|
75735636|NCT00940238|Drug|Citalopram Hydrobromide|
75735637|NCT02565875|Behavioral|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
75735638|NCT02565875|Behavioral|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
75735639|NCT02565875|Other|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
75884581|NCT04508075|Biological|Placebo|Placebo manufactured by PT. Bio Farma
75884582|NCT05259397|Drug|PF-07225570|PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.
75884583|NCT05259397|Drug|sasanlimab|Sasanlimab will be administered SQ on day 1 of each 28 day cycle.
76071892|NCT03801213|Procedure|manual bladder stimulation technique|manual gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
76071893|NCT03785600|Device|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
75442469|NCT01654705|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
75442470|NCT01654718|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
75442471|NCT01654718|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
75442472|NCT01654770|Device|video capsule endoscopy|
75442473|NCT01654770|Device|double balloon enteroscopy|
75442474|NCT01654809|Biological|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
75592469|NCT04921631|Behavioral|Early Integration of Specialty Palliative Care with Critical Care|The PC team will visit the patient within 24 hours of randomization and the consultation will address the following domains of PC: illness understanding and goals of care conversations with patients/surrogates; symptom assessment and management; spiritual needs; patient and family coping and support; and care coordination and transitions. The initial family meeting will be scheduled to occur within two days of randomization. Follow-up visits will be conducted by the PC MD/APP every weekday. During this time, the ICU and PC team will be in daily communication. The PC team will continue to follow the patient in the hospital once discharged from ICU. Prior to discharge, the PC team will document patient goals and preferences for future treatment, coordinate appropriate PC services in the home and/or outpatient clinic settings and contact the patient's primary physician to provide an update on the patient's hospital stay.
75884584|NCT03579576|Drug|sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.|Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
75884585|NCT01364519|Drug|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
75884586|NCT01364519|Drug|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
75884587|NCT03579420|Behavioral|Brief lifestyle program|3-session program for modification of lifestyle habits (exercise and diet)
75884588|NCT03579420|Behavioral|Conventional lifestyle program|6-session program for modification of lifestyle habits (exercise and diet)
75442475|NCT01654809|Biological|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
75442476|NCT01654809|Biological|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
75442477|NCT01654822|Drug|topical application cervical spray|one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
75442478|NCT01654822|Drug|topical spray on the cervix|one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
75442479|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
75442480|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
75442481|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
75442482|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
75592470|NCT04914429|Drug|Guselkumab|Guselkumab 100 mg will be administered as a SC injection.
75592471|NCT04914429|Drug|Placebo|Matching placebo will be administered as a SC injection.
75884589|NCT01370057|Device|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
75884590|NCT02239146|Drug|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
75884591|NCT02239146|Drug|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
75884592|NCT03225365|Biological|Blood and biopsy sampling|"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."
75442483|NCT01654835|Other|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
75884593|NCT02831257|Drug|AZD2014|
75884594|NCT03577158|Device|Closed-loop controller with exercise mitigation module|"Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
75884595|NCT03577158|Device|Closed-loop controller without exercise mitigation module|"On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
75884596|NCT03577158|Device|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.
75884597|NCT03092609|Behavioral|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
75442484|NCT01654835|Other|standard of care|A Low Blood Pressure condition as specified (SAP <80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
75442485|NCT01654874|Drug|99mTc-MIP-1404|
75442486|NCT01654900|Other|No intervention in this study|
75442487|NCT01654913|Device|hemoglobin measurement|"Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin)."
75442488|NCT01654926|Procedure|blood ultrafiltration|
75442489|NCT01654939|Drug|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
75592472|NCT04910139|Device|Soniflow System|Treatment using acoustic vibrational headband worn circumferentially at the level of the forehead paired with a Smartphone App.
75442490|NCT01654965|Other|Laboratory Biomarker Analysis|Correlative studies
75442491|NCT01654965|Biological|Pegfilgrastim|Given SC
75442492|NCT01654965|Other|Pharmacological Study|Correlative studies
75442493|NCT01654965|Drug|Tivantinib|Given PO
75442494|NCT01654965|Drug|Topotecan Hydrochloride|Given IV
75592473|NCT04902443|Drug|Pomalidomide|Pomalidomide will be administered as an oral planned starting dose of 3 mg daily. Pomalidomide will be given from day 1 to day 21 of each cycle
75592474|NCT04902443|Drug|Nivolumab|Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days
75884598|NCT03092609|Behavioral|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
75884599|NCT02253914|Drug|BILR 355 BS, solution|
75442495|NCT01654991|Behavioral|Home Screening|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
75442496|NCT01654991|Behavioral|Clinic Screening|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
75884600|NCT02253914|Drug|BILR 355 BS, tablet|
75884601|NCT02253914|Drug|Ritonavir|
75884602|NCT02253914|Drug|Placebo|
75884603|NCT01364675|Drug|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
75884604|NCT01364675|Drug|Placebo tablet|Identical Placebo Tablet
75884605|NCT03577080|Other|ET+RT+ NMES|Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
75884606|NCT02253758|Drug|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
75884607|NCT05191511|Radiation|Far- infrared|safety of far- infrared
75884608|NCT03100825|Drug|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
75442497|NCT01655004|Drug|Exemestane|Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
75442498|NCT01655017|Procedure|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
75442499|NCT01655056|Drug|YM150|oral
75442500|NCT01655056|Drug|Placebo|oral
75884609|NCT03547232|Drug|Indomethacin SR|Indomethacin SR 50mg given q12h from admission day 1 to day 7
75884610|NCT03547232|Drug|Placebos|Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
75884611|NCT02250534|Other|Very low nicotine content cigarettes|
75884612|NCT01370135|Drug|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
75442501|NCT01655082|Drug|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
75442502|NCT01655082|Drug|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
75442503|NCT01655095|Drug|PEG|PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
75592475|NCT04897945|Behavioral|Shared decision-making for diabetes prevention|Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
75592476|NCT04886856|Behavioral|Mindful Moms|Twelve 75 minutes weekly group sessions involving gentle yoga practices designed for pregnant women, led by experienced yoga teachers.
75592477|NCT04886856|Behavioral|Prenatal Education|Twelve 75 minutes weekly group sessions involving prenatal education (for example, what to expect during your pregnancy, during labor and delivery, and after the delivery of your child).
75592478|NCT04879368|Drug|Regorafenib|Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
75592479|NCT04879368|Biological|Nivolumab|human IgG4 monoclonal antibody inhibitor of PD-1
75592480|NCT04879368|Drug|Docetaxel|"Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them"
75592481|NCT04879368|Drug|Paclitaxel|Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
75592482|NCT04879368|Drug|Irinotecan|Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
75592483|NCT04879368|Drug|Trifluridine/Tipracil|The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
75592484|NCT04878757|Behavioral|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
75592485|NCT04876599|Behavioral|IN FOCUS|Adapted Resiliency Group Intervention
76056003|NCT05451589|Behavioral|RESET|RESET consists of 7 weekly group phone sessions led by Community Health Workers, along with an accompanying podcast series.Topics will include positive psychology, physical activity, social connection, eating well, relaxation, and more. There will be one individual session with the Community Health Worker to screen for unmet social needs and to offer connections to resources as needed. In the group sessions, participants will set goals incorporating positive activities and strategies to improve daily functioning. Up-to-date information related to COVID-19 prevention and treatment will be provided.
75442504|NCT01655095|Drug|Prucalopride|Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
75442505|NCT01655095|Drug|Picosalax|One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
75442506|NCT01655095|Drug|Bisacodyl|Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
75442507|NCT01655095|Procedure|Colon capsule|The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
75442508|NCT01655095|Procedure|Colonoscopy|At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
75442509|NCT01655108|Drug|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
75735640|NCT04013438|Drug|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
75735641|NCT04013438|Drug|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
75442510|NCT01655108|Drug|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
75592486|NCT04876599|Behavioral|Usual Care|Referral to Virtual Group Support
75735642|NCT02565719|Drug|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
75735643|NCT02565719|Drug|Pegasys|immunotherapy
75735644|NCT02565719|Drug|Viread|HBV RT polymerase inhibitor
75735645|NCT02565719|Drug|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
75735646|NCT00934778|Procedure|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
75735647|NCT00111007|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
75442511|NCT01655121|Dietary Supplement|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months."
75442512|NCT01655134|Other|Blood simples|
75442513|NCT01655134|Other|Capillary punction|
75442514|NCT01655134|Other|Urine simples|
75442515|NCT01655147|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
75442516|NCT01655147|Drug|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
75592487|NCT04868604|Drug|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
75592488|NCT04868604|Drug|67Cu-SAR-bisPSMA|67Cu-SAR-bisPSMA
75616227|NCT02846818|Procedure|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
75616228|NCT02846584|Biological|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
75735648|NCT00111007|Drug|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
75442517|NCT01655160|Behavioral|MT with low-intensity group (MT-LI)|The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
75442518|NCT01655160|Behavioral|MT with moderate-intensity group|The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
75442519|NCT01655160|Behavioral|Mirror therapy with high intensity group|The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
75735649|NCT00111007|Drug|Placebo|Placebo, 2 tablets bid Study Days 2-19
76056004|NCT05451589|Behavioral|Wellness Check Control|"After completing the baseline survey, control group participants will be mailed an educational packet consisting of information about COVID-19 prevention and treatment, as well as essential community resources. Control group participants will also be invited to take part in a wellness check telephone session with a Community Health Worker, about a half-hour long, at which a social needs screener will be administered, and any needed referrals will be made. After completing the 8-month follow up, they will have the opportunity to participate in the full intervention."
76056005|NCT05429164|Other|Self Myofascial Release|In the self-myofascial release technique, a tennis ball will be placed on the 4th rib on the shoulder side to be applied on the wall, and the participants will be asked to move the ball using their body along the pectoralis minor.
76056006|NCT05429164|Other|Myofascial Release|A slight caudal force will be applied by the physiotherapist until the pectoralis minor muscle meets the comfortable elastic limit of the soft tissue.
75735650|NCT03975920|Device|The Restful Jaw Device|The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
75735651|NCT00699335|Drug|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
75735652|NCT01082887|Other|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
76056007|NCT05429164|Other|Instrument Assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization will be performed with the specified instruments for the pectoralis minor muscle.
75735653|NCT00939614|Drug|Lamotrigine|
76056008|NCT05372003|Drug|Dupilumab|dupilumab injections will be prescribed and managed by dermatology as standard of care
75735654|NCT03963037|Other|Blood draw|Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
75735655|NCT00935168|Drug|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
75735656|NCT00935168|Drug|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
75735657|NCT03962881|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
75735658|NCT03962881|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
75735659|NCT03962881|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
75735660|NCT00940394|Behavioral|mutual support group|bi-weekly, 12-session, family-led mutual support group
75735661|NCT00940394|Behavioral|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
75735662|NCT00940394|Other|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
75735663|NCT00935246|Drug|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
76056009|NCT05372003|Other|Photo therapy|light therapy will be prescribed and managed by dermatology as standard of care
76056010|NCT05351489|Drug|Dexmedetomidine|Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .
76056011|NCT05345717|Drug|Belatacept Injection|Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy
76056012|NCT05332613|Behavioral|TRE plus SOC|Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
76056013|NCT05332613|Behavioral|SOC|Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
76056014|NCT05332613|Behavioral|TRE|Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
76056015|NCT05332054|Biological|Allogeneic CAR-T therapy|N/A this is an observational study
76056016|NCT05327127|Drug|K-877-ER|K-877-ER tablet
76056017|NCT05327127|Drug|CSG452|CSG452 tablet
76056018|NCT05327127|Drug|Placebo|Placebo tablet
75442520|NCT01655160|Behavioral|Control intervention group|The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
76056019|NCT05319717|Dietary Supplement|Ready-to-use therapeutic food with heat stabilized rice bran|Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
76056020|NCT05319717|Dietary Supplement|Ready-to-use therapeutic food (no rice bran)|Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
75442521|NCT01655173|Behavioral|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
75442522|NCT01655173|Behavioral|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
75442523|NCT01655199|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
75442524|NCT01655212|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
75442525|NCT01655238|Other|BMI|Screening guideline to assess body mass index.
75442526|NCT01655251|Behavioral|Intervention|
75592489|NCT04867798|Drug|Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet|PrEP eligible participants will be asked to follow up monthly for 12 months. PrEP will be prescribed for once-daily use and discontinued if HIV tests are positive. At quarterly visits, participants will receive Integrated Next Steps Counseling (iNSC) for PrEP adherence with point-of-care drug level feedback. Participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine tenofovir levels <1500 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing. Medication refills will consist of 3-month supplies.
75735664|NCT04013360|Other|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
75735665|NCT04013360|Other|Expiratory Positive Airway Pressure|Patients will perform exhalation of air through a facial mask containing an extrinsic positive expiratory pressure valve with a defined load of 10 cmH2O for 5 min. During the application of the technique the patients will have a trunk inclined 30º and will be stimulated to breathe normally, without effort or deep and fast breaths.
75735666|NCT02793284|Radiation|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
75735667|NCT00935402|Behavioral|Sleep|Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
75735668|NCT02667002|Procedure|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
75735669|NCT02667002|Procedure|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
75735670|NCT02667002|Other|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
75735671|NCT00935480|Drug|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
75735672|NCT00935480|Drug|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
75735673|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
75735674|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
75735675|NCT00939848|Drug|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
75735676|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
75735677|NCT00939848|Drug|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
76056021|NCT05297201|Drug|CPL500036 - low dose|CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
76056022|NCT05297201|Drug|CPL500036 - high dose|CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
76056023|NCT05297201|Drug|Placebo|Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
76056024|NCT05278156|Drug|CPL500036 - low dose|CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
75442527|NCT01655264|Behavioral|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
75442528|NCT01655264|Behavioral|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
75442529|NCT01655277|Procedure|Ultrasound Guided Adductor Canal Block|
75592490|NCT04867122|Behavioral|Problem-Solving Therapy|Over an approximately 3-week period, family caregivers randomized to the intervention study arm will learn and apply a problem-solving approach based on the ADAPT model, which encourages participants to follow five steps when solving caregiving problems: 1) focus on adopting a positive attitude to problem solving, 2) define the problem and set goals, 3) generate a list of alternative solutions to the problem, 4) predict consequences of the alternative solutions, and 5) try implementing the most promising solution from among the list of alternatives. The intervention will be delivered by a trained interventionist over the course of three structured sessions via telephone or videoconferencing technology, depending on the FCG's preference. Session content will be summarized in an intervention manual, which we will provide to all intervention participants. Sessions will last approximately 45-60 minutes.
75884613|NCT05252221|Other|ATC Intervention|The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
75735678|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
75884614|NCT03634787|Diagnostic Test|CT Scan Day 5-7|Computed Tomography on Day 5-7 according to a clinical protocol.
75884615|NCT05266586|Drug|Obicetrapib|tablets
75884616|NCT05266586|Drug|Ezetimibe 10mg|capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
75592491|NCT04867122|Other|Attention-matched Control|"Over an approximately 3-week period, family caregivers randomized to the attention control study arm will participate in informal conversations (friendly visits) with a trained member of the research team."
75616229|NCT04835038|Drug|Sodium Bicarbonate Ringer's Injection|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
75735679|NCT04013048|Drug|[14C]-Fluzoparib|Patients will receive single dose of orally [14C]- Fluzoparib on Day 1.
75735680|NCT04014218|Drug|Inhalation Sedation|Inhalation Sedation by Administration of Sevoflurane
75735681|NCT04014218|Drug|Intravenous Sedation|Intravenous Sedation by Administration of Propofol
75735682|NCT00935558|Biological|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
75884617|NCT05266586|Other|Obicetrapib placebo|tablets; no active ingredient
75884618|NCT05266586|Other|Ezetimibe placebo|capsules; no active ingredient
75884619|NCT01370291|Other|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
75442530|NCT01655277|Procedure|Ultrasound Guided Femoral Nerve Block|
75884620|NCT01370291|Other|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
75884621|NCT01370291|Other|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
75884622|NCT05575544|Procedure|Acupuncture plus morphine|The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure
75884623|NCT01364831|Behavioral|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
75442531|NCT01655290|Other|Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)|Other (Diagnostic)
75442532|NCT01655303|Drug|Propranolol|
75442533|NCT01655303|Drug|Metoprolol|
75592492|NCT04867122|Other|In-depth interviews|The 30 key stakeholders interviews will discuss how the PST intervention fits into existing clinical practice and institutional values, what might incentivize adoption of the PST intervention, and how the intervention compares to alternative existing or proposed programs.
75442534|NCT01655303|Drug|Verapamil|
75442535|NCT01655303|Drug|Diltiazem|
75592493|NCT04858230|Device|LymphoPilot|"LymphoPilot is an investigational medical device composed of an implanted part (pump, drainage catheter and output catheter), implanted in the subcutaneous tissue of the arm or of the leg and draining excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The implanted part is activated and controlled via a wearable device.~The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure.~Patients will wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. The implanted device will be removed with a surgical procedure in local anesthesia 8 weeks after device implantation."
75616230|NCT04835038|Drug|Sodium Lactated Ringer's Injection|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
75442536|NCT01655316|Drug|Verapamil|
75442537|NCT01655368|Behavioral|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
75442538|NCT01655368|Behavioral|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
75884624|NCT01364909|Other|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
75884625|NCT01364909|Other|Usual practice|These patients will not receive exercise early in their intensive care admission
75884626|NCT05179772|Drug|Olanzapine|Olanzapine (2.5 mg to 20 mg)
75884627|NCT05191199|Diagnostic Test|Penile Duplex Study|A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
76056025|NCT05278156|Drug|CPL500036 - high dose|CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
75442539|NCT01655407|Drug|Autologous Engineered Skin Substitute|"The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place."
75442540|NCT01655407|Drug|Split-Thickness Autograft (AG)|"The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin."
75442541|NCT01655420|Procedure|LASIK|Laser eye surgery
75442542|NCT01655433|Device|Velomedix APLS device|Velomedix, Automated Peritoneal Lavage System
75442543|NCT01655433|Other|No Hypothermia Treatment|
75735683|NCT00935558|Drug|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
75735684|NCT05280236|Drug|Propofol TIVA|Patients will receive propofol-based TIVA with propofol and remifentanil TCI (target controlled infusion)
75884628|NCT05417503|Other|Non-invasive ventilation bi-level|For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).
75884629|NCT05417503|Other|Non-invasive ventilation placebo|The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
75442544|NCT01655446|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
75442545|NCT01655446|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
75442546|NCT01655446|Behavioral|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
75442547|NCT01655446|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
75442548|NCT01655446|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
75442549|NCT01655459|Procedure|Ultrasound exam of upper airway|LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
75616231|NCT03856918|Procedure|PEEP 3 cm of water|PEEP of 3 cm of water will be applied during one-lung ventilation.
75616232|NCT03856918|Procedure|PEEP 6 cm of water|PEEP of 6 cm of water will be applied during one-lung ventilation.
75616233|NCT03856918|Procedure|PEEP 9 cm of water|PEEP of 9 cm of water will be applied during one-lung ventilation.
75735685|NCT05280236|Drug|Remimazolam TIVA|Patients will receive remimazolam-based TIVA with remimazolam infusion and remifentanil TCI
75735686|NCT00940472|Drug|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
76056026|NCT05278156|Drug|Placebo|Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
75616234|NCT03825094|Device|DyeVert™ Contrast Reduction Systems|Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.
75616235|NCT04201912|Diagnostic Test|saliva analysis for Toll like receptor activity|Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
76056027|NCT05276362|Device|Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
75884630|NCT05575232|Behavioral|Application Group (GA)|The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.
75884631|NCT01370681|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001|
75442550|NCT01655472|Device|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
75442551|NCT01655472|Device|imaging follow up: Ultrasonographic examination|
75442552|NCT01655485|Other|Patient teaching|The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
75592494|NCT04852224|Drug|Androgen deprivation therapy|Prostate cancer survivors in the ADT+ group will have been prescribed androgen deprivation therapy for a period of 6-months or more by their treating oncologist prior to consent for this study.
75735687|NCT00940472|Drug|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
75735688|NCT04013204|Other|Endothelial function guided therapy|To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
75735689|NCT00939926|Drug|Risperidone|
75884632|NCT01370681|Drug|Period I : CJ30001, Period II : HKB0701 and SLM0807|
75884633|NCT02848326|Drug|Atogepant|Atogepant capsule.
75884634|NCT02848326|Drug|Placebo-matching Atogepant|Placebo-matching atogepant capsule.
75884635|NCT05190965|Device|OCTAngiography .FFangiography|octa.ffa findings in pts with diapetic retinopathy
75884636|NCT02477657|Procedure|Paracentesis|Paracentesis
75884637|NCT02477657|Device|Tunneled Intraperitoneal Drain (IPD)|Tunneled Intraperitoneal Drain (IPD)
75442553|NCT01655511|Drug|Tafamidis|240 mg, solution, single dose
75442554|NCT01655511|Drug|Tafamidis|480 mg, solution, single dose
75442555|NCT01655511|Drug|Tafamidis|TBD dose will be a single dose if < 720 mg or a loading dose followed by additional dose if > 720 mg.
75735690|NCT00940550|Drug|Prolonged-release melatonin|2 mg tablet, once.
75735691|NCT00940550|Drug|Temazepam|20 mg capsule, once
75735692|NCT00940550|Drug|Zolpidem|10 mg capsule, once
75735693|NCT00940550|Drug|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
75592495|NCT04833114|Drug|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
75592496|NCT04833114|Drug|Mabthera|Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
75592497|NCT04833114|Drug|Ifosfamide|Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
75592498|NCT04833114|Drug|Carboplatin|Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
75592499|NCT04833114|Drug|Etoposide|Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
75592500|NCT04829045|Device|SEIRIN PYONEX Acupuncture Needles|10 press needles (PYONEX ø0.20×1.5mm made by Seirin Corporation) will be placed on abdomen area; 10 sessions over 6 weeks.
75884638|NCT02477657|Device|Peritoneal-Venous shunts (PVS)|Peritoneal-Venous shunts (PVS)
75884639|NCT04450043|Behavioral|Run-In Sessions 1-5|Session 1 explores patient goals and wishes for life after cancer treatment with a study interventionist. Sessions 2-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
75884640|NCT04450043|Behavioral|RCT Transitions Program Sessions 1-5|Sessions 1-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
75884641|NCT04450043|Behavioral|RCT Control Session|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
75884642|NCT01567514|Procedure|Glass ionomer cement lining|Resin-modified glass ionomer lining
75884643|NCT01364987|Drug|ASP015K|oral
75884644|NCT01364987|Drug|Mycophenolate Mofetil|oral
75884645|NCT01365923|Drug|remifentanil|remifentanil effect site-TCI 2-4ng/ml
75884646|NCT01365923|Drug|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
76071894|NCT03785600|Device|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
76071895|NCT03771469|Other|Sleep study|Sleep study
75884647|NCT03579342|Behavioral|App-technology and active coaching to improve lifestyles behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
75884648|NCT03579342|Behavioral|App-technology to improve lifestyle behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
75884649|NCT03128723|Device|Acne Mask|The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
75884650|NCT05575154|Device|optical coherence tomography (OCT)|measuring retinal nerve fiber layer and neuroretinal rim thickness
75442556|NCT01655524|Drug|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
75884651|NCT03579264|Behavioral|My Viva Plan|Use of the online platform, My Viva Plan, to support health and wellness.
76056028|NCT05276362|Device|Actiwatch|The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.
76056029|NCT05245968|Drug|Pimitespib|Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
76056030|NCT05245968|Drug|Imatinib|Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
75735694|NCT00935714|Other|Exercise|
76056031|NCT05245968|Drug|Sunitinib|Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
75442557|NCT01655550|Other|Withhold oral contrast|The intervention is to withhold oral contrast
75442558|NCT01655576|Procedure|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
75592501|NCT04829045|Other|PYONEX Placebo|Subjects are given placebo on abdomen area; 10 sessions over 6 weeks.
75592502|NCT04821440|Device|Water displacement volumetry|The examination will take place in several stages and by two operators. Initially, the patient will strip the limb concerned (leg or arm). Once the member is in the water column of the volumeter, a delimitation of the submerged area of the member will be carried out using a marking (black dermographic marker). Indeed, the level of acquisition in 3D is determined relative to the height of the water line marked on the skin with a black felt, this felt is usually used for venous mapping and is well tolerated The first operator will carry out two measurements one after the other with a change of water previously stabilized at room temperature.
75616236|NCT02850952|Other|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
75735695|NCT00935714|Other|Exercise|
76056032|NCT05232682|Dietary Supplement|Seed DS-01 Daily Synbiotic|Daily administration of Seed DS-01 Daily Synbiotic (dietary supplement)
75735696|NCT00935870|Device|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
75735697|NCT00935948|Drug|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
75735698|NCT00935948|Drug|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
75735699|NCT00936026|Drug|Neramexane|Drug-Drug Interaction Study
75735700|NCT00940628|Behavioral|Diet and Exercise|mildly hypocaloric diet and physical exercise
75735701|NCT00940628|Drug|orlistat [Xenical]|120mg po tid
75442559|NCT01655602|Procedure|Trichophytic closure upper edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
75884652|NCT05261906|Behavioral|LIBERATE|"Five bi-weekly, followed by three monthly, one-hour videoconferencing group education classes via Microsoft Teams video platform will be offered. Participants will be given the choice to communicate with the LIBERATE clinical team (exercise specialist, MD, and/or RN) weekly between the group classes using their preferred method of communication i.e., email.~Classes will offer FreeStyle® Libre-assisted behavioural coaching (i.e., nutrition and exercise). FreeStyle® Libres will be used during the first three months of the program and optionally in the last three months of the intervention. The FitBit Inspire 2™ monitors will be worn for six months. Participants are provided the option to receive individualized aerobic and resistance training prescriptions."
75735702|NCT00921323|Behavioral|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
75884653|NCT03579108|Other|Retrospective Chart Review|Chart review
76056033|NCT05225337|Other|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
75442560|NCT01655602|Procedure|Trichophytic closure lower edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
75442561|NCT01655602|Procedure|Trichophytic closure both edge trimming|'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
75592503|NCT04821440|Device|Three dimension volumetry|The 3D volumetric acquisition is done with the sensor (CE marking) attached to the touch pad and does not require invasive or cutaneous contact with the patient (minimum acquisition distance of 40 cm). The operator triggers the acquisition via a button in an application installed on the tablet and physically turns around the patient to carry out the acquisition of the affected member. At the end of the acquisition, the operator presses a stop button and chooses whether or not to calculate the volume using another button depending on the quality of the acquisition.
75884654|NCT01370759|Other|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
76056034|NCT05225337|Other|Daily calorie restriction|25% energy restriction every day Diet counseling provided
75735703|NCT00921323|Behavioral|Control|The control group will be advised to continue to be physically active and record daily steps
75735704|NCT00940004|Biological|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
75592504|NCT04812535|Drug|IFX-1|IFX-1 Monotherapy
75592505|NCT04812535|Drug|IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
75735705|NCT02565797|Device|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
75735706|NCT00936182|Drug|Fluconazole|Fluconazole daily for 30 days
75735707|NCT00936260|Drug|alendronate|several duration of treatment
75735708|NCT00445978|Drug|Sapropterin Dihydrochloride|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
75735709|NCT02566733|Drug|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
75735710|NCT02566733|Drug|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
75735711|NCT00936338|Behavioral|splint and joint mobilization self exercise|
76056035|NCT05220514|Drug|(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
76056036|NCT05220514|Drug|2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
75735712|NCT05281991|Device|Doppler ultrasonography|color flow Doppler ultrasonography
75735713|NCT05281991|Device|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
75884655|NCT05154110|Other|stretching on whole body vibration|"SSubjects will be refrained from maximum-effort or new routines for exercise the day before each treatment.Static stretching of hamstring on whole body vibration will include Pre- and post-test active and passive ROM for the both legs, with subjects first undergoing a 5-minute warm-up on a stationary bicycle. The traditional static stretch consisted of a supine active knee extension on whole body vibration (WBV) at 30 Hz at the high amplitude setting will be performed. The stretch will be held at the point of the onset of discomfort 3 times each for 30 seconds, with a 20-second rest period between each stretch. Participants will stretch for 4 days per week for 4 weeks. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assist ted knee extension with the leg in 90° of hip flexion."
76056037|NCT05194969|Device|Wet-to-Dry Dressings|This dressing technique involves moistening a piece of gauze with normal saline or other cleansing solution, placing the moistened gauze on the wound, allowing the gauze to dry, and then removing and replacing the bandage regularly over a period of days to weeks
76056038|NCT05194969|Device|Petrolatum with Non-Stick Gauze|This dressing approach involves applying a thick layer of petrolatum to the wound once or twice daily to maintain a moist wound base. After placement of petrolatum, the wound is covered with nonadherent gauze and tape or another bordered dressing.
75442562|NCT01655615|Behavioral|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
75442563|NCT01655628|Drug|GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
75592506|NCT04806516|Device|Summit RC+S System with ECoG Paddles|"Summit RC+S System with ECoG Paddles consists of:~Olympus RC+S implantable pulse generator (IPG), Model B35300R: 2 per subject x 5 subjects = 10 units~Extension Leads, Model 37087: 2 per subject X 5 subjects = 10 units~DBS Leads, Model 3387: 2 per subject X 5 subjects = 10 units~Patient Therapy Manager (PTM), Model 4NR009: 1 per subject x 5 subjects = 5 units~Recharge Therapy Manager (RTM), Model 97755: 1 per subject x 5 subjects = 5 units~Clinician Telemetry Module (CTM), Model 4NR011: 1 per subject x 5 subjects = 5 units~Research Lab Programmer (RLP), Model 4NR010: 1 unit~Research Software Development Kit (RDK), Model 4NR013: 2 units~Subdural Quadripolar Paddle Lead, Model 09130: 2 per subject x 5 subjects = 10 units"
75735714|NCT00936416|Procedure|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
75735715|NCT02566421|Other|Laboratory Biomarker Analysis|Correlative studies
75735716|NCT02566421|Other|Quality-of-Life Assessment|Ancillary studies
75735717|NCT02566421|Other|Targeted Therapy|Receive treatment based on genomic sequencing
75909512|NCT03477422|Drug|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
76056039|NCT05185440|Behavioral|GIFTSS Training|training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)
75442564|NCT01655628|Drug|GC chemotherapy (Gemcitabine, Cisplatin)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
75442565|NCT01655641|Drug|Tranexamic acid|"Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
75442566|NCT01655641|Other|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
75442567|NCT01655654|Behavioral|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
75592507|NCT04806516|Other|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
75592508|NCT04805320|Procedure|Dental Extraction|Extraction
75735718|NCT00940706|Device|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
75735719|NCT00940706|Other|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
75735720|NCT00940706|Behavioral|Monitoring physical activity|Activity monitoring with accelerometers
75592509|NCT04739254|Diagnostic Test|CardioFlux|Magnetocardiography
75592510|NCT04730947|Drug|Dapagliflozin|10 mg orally once a day
75735721|NCT01023412|Dietary Supplement|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
75735722|NCT02566499|Device|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
75735723|NCT00936494|Procedure|Cold ablation inferior turbinate reduction|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
75735724|NCT01028950|Drug|YM150|oral
75735725|NCT00940784|Drug|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
75735726|NCT00940784|Drug|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
75735727|NCT00940784|Drug|Aspirin|81-100 mg qd
75735728|NCT01023490|Drug|Vitamin D|34,5000 IU vitamin D per week
75735729|NCT01023490|Drug|Placebo|Placebo
75442568|NCT01655654|Behavioral|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
75442569|NCT01655654|Other|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
75442570|NCT01655706|Drug|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
75442571|NCT01655706|Drug|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
75442572|NCT01655732|Procedure|Atraumatic Restorative Treatment|ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
75442573|NCT01655745|Procedure|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
75442574|NCT01655758|Drug|0.5% timolol|
75442575|NCT01655758|Drug|timolol-dorzolamide fixed combination|
75442576|NCT01655758|Drug|Latanoprost|
75442577|NCT01655758|Drug|Travoprost|
76056040|NCT05185440|Behavioral|Learning Collaborative|learning collaborative (anticipated meeting monthly) with college health center staff and clinicians to address common barriers to implementation of GIFTSS intervention, reinforce GIFTSS training
76056041|NCT05185440|Behavioral|Provider Scripts|scripts and prompts for college health center staff and clinicians to encourage implementation of GIFTSS intervention
75442578|NCT01655758|Drug|Bimatoprost|
75442579|NCT01655771|Drug|TD-1211 Dose 1|
75442580|NCT01655771|Drug|TD-1211 Dose 2|
75442581|NCT01655797|Behavioral|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
75442582|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
75592511|NCT04730947|Drug|Placebo|Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
75592512|NCT04725331|Biological|BT-001|Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose [Phase I, Part A]; one dose lower and at Recommended Dose for Part B [Phase I, Part B] by intra-tumoral (IT) route.
75592513|NCT04725331|Drug|Pembrolizumab [Keytruda]|Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
75592514|NCT04716725|Drug|68Ga-PSMA-11|Given IV
75592515|NCT04716725|Procedure|Positron Emission Tomography (PET)|Undergo PET
75592516|NCT04715191|Genetic|CARE T cells|"Three different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL1: 1x10^8/m2 DL2: 3x10^8/m2 DL3: 1x10^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
75735730|NCT00566228|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
75735731|NCT00566228|Procedure|leukapheresis|Stem cells collected
75735732|NCT00698009|Drug|Fludarabine|25 mg/m^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
75735733|NCT00698009|Drug|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
75735734|NCT00698009|Biological|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
75735735|NCT00698009|Drug|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
75735736|NCT00698009|Drug|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
75735737|NCT01027156|Behavioral|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
75735738|NCT01029106|Procedure|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
76056042|NCT05178082|Behavioral|Educational Video-based Pain Program|Educational videos with 10 modules with information about pain.
76056043|NCT05178082|Behavioral|Empowered Relief Program|Educational online session for skills acquisition to manage pain. Empowered Relief TM by Beth Darnall ©2013-2022 Stanford University
75442583|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
75735739|NCT05264831|Procedure|Pulmonary Vein Isolation (PVI) alone|PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.
75735740|NCT05264831|Procedure|PVI procedure associated with substrate modulation|PVI procedure associated with substrate modulation
75735741|NCT00936572|Procedure|Probiotics (La1, BB536)|
75735742|NCT00936572|Biological|probiotics (La1, BB536)|
75735743|NCT00936572|Biological|placebo|Maltodoxtrin
75735744|NCT04012658|Other|No intervention|No intervention
75735745|NCT03894605|Device|thalassemia|thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion
75735746|NCT00944606|Dietary Supplement|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
75735747|NCT00944606|Other|Placebo candy|candy gum drops
75735748|NCT00941018|Drug|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
76056044|NCT05168826|Device|SAPIEN 3 Transcatheter Heart Valve|Implantation of the SAPIEN 3 valve
76056045|NCT05166239|Procedure|HAIC|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
76056046|NCT05166239|Drug|Lenvatinib 1|12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily after HAIC.
76056047|NCT05166239|Drug|PD-1 Inhibitors|PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
76056048|NCT05166239|Drug|Lenvatinib 2|12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily.
76056049|NCT05166239|Drug|PD-1 inhibitors 2|PD-1 inhibitors injection intravenously or percutaneously every 4 week.
75442584|NCT01655810|Dietary Supplement|Calcium carbonate|500 mg orally twice daily
75442585|NCT01655849|Drug|z160|
75442586|NCT01655849|Drug|Placebo|
75442587|NCT01655862|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
76071896|NCT03769415|Device|Intrinsic Subtyping of Primary Breast Cancer|Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
75884656|NCT05154110|Other|strength training|In second group, strength training will be done for 4 days per week for 4 days. Subjects will have 5 minutes warm up. In 1st week, the protocol will be Nordic hamstring curl (NHC) with bend (3 sets of 8 reps), Prone hamstrings curl (4 sets of 12 reps/leg), Physio-ball leg curl (3 sets of 8 reps), Glute bridge (2 sets of 50 s/leg). In 2nd to 4th week, the protocol will be NHC with bend (3 sets of 12 reps) Prone hamstrings curl (3 sets of 14 reps/leg) Physio-ball leg curl (3 sets of 10 reps) Glute bridge (2 sets of 50 s/leg). There will be 30 seconds rest between each set and 1 minute rest between each exercise . Pre and post AROM and PROM will be measured. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assisted knee extension with the leg in 90° of hip flexion.
75592517|NCT04715191|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
75592518|NCT04715191|Drug|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
75592519|NCT04706624|Behavioral|High intensity contingency management|Participants receive 12 weeks of contingency management.
75884657|NCT01370915|Drug|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
75884658|NCT01370915|Drug|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
75442588|NCT01655875|Drug|AMD3100|AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
75884659|NCT03577002|Other|Serious Illness Care Program (SICP)|SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
75884660|NCT05574998|Drug|Recombinant human endostatin (Endostar)|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
76071897|NCT03768349|Drug|Ga-68 PSMA11|Ga-68 PSMA11 PET/CT for detection of tumor location
76071898|NCT03768349|Drug|F-18 PSMA 1007|F-18 PSMA 1007 PET/CT for detection of tumor location
76071899|NCT03765983|Drug|Trastuzumab|"Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system"
75442589|NCT01655888|Drug|Tremelimumab|Tremelimumab is administered as endovenous infusion
75442590|NCT01655914|Drug|Flumazenil|
75442591|NCT01655927|Drug|Tranexamic Acid|
75442592|NCT01655927|Drug|Placebo: Saline|
75442593|NCT01655940|Device|Somanetics cerebral oximeter|Somanetics cerebral oximeter
75592520|NCT04706624|Behavioral|Low intensity contingency management|Participants receive 6 weeks of contingency management and 6 weeks of group education.
75592521|NCT04706624|Behavioral|SMS reminders|Participants receive two daily SMS reminders plus one weekly self-monitoring assessment.
75592522|NCT04706624|Behavioral|Matrix only|Participants attend 12 weekly Matrix group counseling sessions.
75592523|NCT04706624|Behavioral|Matrix + Contingency management|Participants attend 12 weekly Matrix group counseling sessions plus 12 weeks of contingency management.
75592524|NCT04700488|Diagnostic Test|6D-MRI|Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI
75592525|NCT04688255|Behavioral|MSTEP|Aerobic exercise that is advanced weekly
75592526|NCT04688255|Behavioral|Stretching|Stretching exercises that are advanced weekly
75442594|NCT01655940|Device|CASMED cerebral oximeter|CASMED cerebral oximeter
75442595|NCT01655953|Dietary Supplement|High NaCl + KHCO3|7.7 mmol Na/kgBW/d + 90 mmol KHCO3
75442596|NCT01655953|Other|Control: high NaCl|7.7 mmol Na/kgBW/d
75592527|NCT04680468|Drug|Belantamab mafodotin|2.5 mg/kg IV
75592528|NCT04673409|Diagnostic Test|Novel Cardiac MRI sequences|Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.
75592529|NCT04660799|Drug|Rituximab IV|Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m^2 (milligram per square meter).
75592530|NCT04660799|Drug|Rituximab SC|Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).
75592531|NCT04660799|Drug|Rituximab IV|Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m^2.
75592532|NCT04660799|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at a dose of 750 mg/m^2
75592533|NCT04660799|Drug|Doxorubicin|Doxorubicin will be administered IV at a dose of 50 mg/m^2
75592534|NCT04660799|Drug|Vincristine|Vincristine will be administered IV at a dose of 1.4 mg/m^2
75592535|NCT04660799|Drug|Prednisone|Prednisone will be administered orally at a dose of 100 mg/day
75592536|NCT04660799|Drug|Paracetamol|All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab
75884661|NCT03576846|Other|Stretching and Spinal manipulative therapy|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy
75884662|NCT03576846|Other|Stretching|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
75592537|NCT04660799|Drug|Diphenhydramine hydrochloride or alternative antihistamine|All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab
75884663|NCT03547778|Drug|Misoprostol 50 mcg pesssary|Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.
75884664|NCT03547778|Drug|Placebos|The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
76056050|NCT05145296|Combination Product|Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab|"Four consecutive cohorts each comprising 3 patients are planned. STEP I: Patients receive Belatacept 10mg/kg, administered on days 1, 5, end of week 2, 4 and 8 .~Patients without a significant decrease in the global cPRA (cPRA or TGI ≥99%) or significant reduction of anti-HLA Ab MF will continue to the second step.~STEP II: (15 weeks) One week after the last injection of belatacept, patients will undergo 4 sessions of apheresis (plasmapheresis (PF) or Immunoadsorption (IA)) which will be given every 48h. At week 11, patients will receive 4 doses of daratumumab (8mg/kg) every two weeks until week 17. Daratumumab will be alternated with 4 additional doses of belatacept 5 mg/kg FOLLOW-UP (24 weeks) All patients exiting the study, either having completed all treatment courses or exiting prematurely (transplanted or not), will be proposed monthly follow-up visits"
75592538|NCT04648033|Drug|Atovaquone Oral Suspension|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will be allocated one of four doses of atovaquone: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).
75884665|NCT02238912|Drug|kandhaga rasayanam|KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
75884666|NCT03547700|Drug|Romidepsin|Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
75884667|NCT03547700|Drug|Ixazomib|Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
75442597|NCT01655966|Drug|vitamin D +pegylated interferon + ribavirin|Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
75442598|NCT01655966|Drug|pegylated interferon + ribavirin|pegylated interferon 160ug once weekly Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
75442599|NCT01655979|Dietary Supplement|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
75442600|NCT01655979|Other|Control|Bed rest without dietary supplement
75442601|NCT01655992|Drug|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
75442602|NCT01655992|Drug|S1 generic|40mg／m2 bid four weeks on two weeks off
75442603|NCT01656005|Drug|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
75442604|NCT01656005|Drug|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
75442605|NCT01656005|Drug|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
75442606|NCT01656005|Drug|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
75442607|NCT01656005|Drug|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
75884668|NCT02239458|Drug|Saxagliptin|
75884669|NCT03546218|Device|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
75884670|NCT03546218|Device|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
75884671|NCT03574740|Other|Tobacco Smoking|Influence of Tobacco Smoking on the development of OSA
75884672|NCT04606550|Device|Microablative Fractional CO2 Laser Therapy|Microablative Fractional CO2 Vaginal Laser Therapy
75884673|NCT03574662|Other|Frailty assessment|This assessment consists of a combination of gait speed measurement via infrared sensors as well as a grip strength assessment. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
76056051|NCT05133180|Drug|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
76056052|NCT05133180|Other|Vehicle|Vehicle will be instilled with the same scheme of the test product
75442608|NCT01656018|Drug|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
75442609|NCT01656044|Procedure|wound care management|Receive SSD
75884674|NCT03574662|Other|Quality of life assessment|This assessment consists of two questionnaires, Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure questionnaire. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
75884675|NCT03578952|Device|TAVR with Evolut R valve|TAVR with Evolut R valve
75442610|NCT01656044|Procedure|wound care management|Receive NPT
75442611|NCT01656057|Drug|Acetaminophen|Acetaminophen dissolved in 50 ml of water
75442612|NCT01656057|Drug|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
75442613|NCT01656057|Drug|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
75442614|NCT01656057|Other|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
75442615|NCT01656057|Other|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
75442616|NCT01656070|Drug|oral cholecalciferol 1000000 UI (vitamin D3)|
75442617|NCT01656070|Drug|Placebo|
75884678|NCT03128411|Drug|Bosutinib|All patients will receive bosutinib at a starting dose of 400 mg QD.
75884679|NCT03578874|Drug|Sorafenib|PO
75884680|NCT03578874|Drug|Capecitabine|PO
75884681|NCT03578874|Drug|Oxaliplatin|IV
75884682|NCT02847858|Behavioral|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
75884683|NCT05168306|Device|FreeStyle Libre 2 Flash Glucose Monitoring System|The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.
75884684|NCT01366001|Drug|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
75442618|NCT01656096|Device|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
75442619|NCT01656096|Other|Sham procedure|
75442620|NCT01656109|Drug|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
75884685|NCT01366001|Drug|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
76071900|NCT03765983|Drug|GDC-0084|GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
76071901|NCT03761225|Drug|Masitinib|
76071902|NCT03761225|Drug|Docetaxel|
76071903|NCT03761225|Drug|Prednisone|
76071904|NCT03761225|Drug|Placebo|
76071905|NCT03755804|Drug|bendamustine|Given intravenously (IV)
76071906|NCT03755804|Drug|Etoposide|Given intravenously (IV)
76071907|NCT03755804|Drug|Doxorubicin|Given intravenously (IV)
76071908|NCT03755804|Drug|Bleomycin|Given intravenously (IV)
76071909|NCT03755804|Drug|Vincristine|Given intravenously (IV)
75884686|NCT01366001|Drug|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
76056053|NCT05122767|Drug|Dolutegravir|"Groups 1a/1b: Participants will take the FDA-approved weight-based DTG once daily + either TDF/FTC, TDF/3TC, ABC/3TC or AZT/3TC x 4 weeks. During HP treatment and for two weeks afterward, DTG dose will be increased to twice daily.~Participants will continue with the NRTI regimen they have previously tolerated, except where their age and weight allow them to transition from either AZT or ABC to TDF, as per South African National ART Guidelines. HLA-B*5701 screening will therefore not be performed, as children will be currently taking and tolerating an ABC-containing regimen at enrolment. If any clinically suspected hypersensitivity reaction to ABC is suspected by history, ABC will not be continued.~Groups 2a/2b: Participants will take weight-based DTG dosing twice or once daily, depending on the results of the modelled data for the Group 1a (for Group 2a) and/or Group 1b (for Group 2b) participants in the interim analysis."
76056054|NCT05122767|Drug|3HP|3HP Dosing is by Age and Weight Children 2-15 years of age: 10-15kg (P 300mg, H 300mg); 16-23kg (P 450mg, H 500mg); 24-30kg (P 600mg, H 600mg); 31-34kg (P 750mg, H 700mg). Children 15-17 years, >=30kg (P 900mg, H 900mg)
76056055|NCT05105958|Drug|Tideglusib|1000 mg/day per os
75769514|NCT03898882|Device|Shore durometer|The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
75884687|NCT03574584|Drug|NNC0165-1562|Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
75884688|NCT03574584|Drug|Semaglutide|Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
75884689|NCT03574584|Drug|Placebo (NNC0165-1562)|Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
76056056|NCT05100654|Drug|Doxycycline|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
76056057|NCT05100654|Drug|Ciprofloxacin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
76056058|NCT05100654|Drug|Augmentin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
75442621|NCT01656122|Drug|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
75592539|NCT04648033|Drug|Standard of care chemotherapy|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will receive two 21-day cycles of cisplatin and vinorelbine chemotherapy, comprising 80 mg/m2 cisplatin on days 1 & 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 & 29.
75592540|NCT04648033|Radiation|Standard of care radiotherapy|Thoracic radiotherapy will commence on day one of chemotherapy and be delivered in 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday) for 6.5 weeks.
75592541|NCT04640779|Drug|Choline Salicylate|Given PO
75592542|NCT04640779|Drug|Selinexor|Given PO
75884690|NCT03546998|Diagnostic Test|Clinical instrumental examinations|Achalasia patients were periodically submitted to clinical assessment, barium swallow (esophageal diameter and residual barium column were measured), endoscopy. Mucosal esophageal biopsies were taken in order to diagnose dysplasia or epidermoid carcinoma.
75884691|NCT01365065|Drug|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
75884692|NCT03576456|Drug|Alprazolam 0.5 mg|receive alprazolam prior to angio
75442622|NCT01656122|Drug|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
75442623|NCT01656135|Other|Blood drawing for immune monitoring and questionnaires|
75442624|NCT01656148|Drug|Fampridine-SR|Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
75442625|NCT01656174|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
75735749|NCT04060901|Behavioral|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
75884693|NCT03576456|Drug|Placebo Oral Tablet|receive placebo prior to angio
75884694|NCT04537988|Other|Behavioral: eCHANGE|eCHANGE is an eHealth intervention aiming to support long-term weight maintenance after initial weight loss
75735750|NCT00944684|Drug|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
75884695|NCT03576378|Drug|BrentuximabVedotin (BV)|All patients will be treated with 6 cycles of BV-EPEM
75884696|NCT04380701|Biological|BNT162a1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
75884697|NCT04380701|Biological|BNT162b1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
75735751|NCT00944684|Drug|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight <65kg) or 1,200mg (body weight equal or >65kg)
75884698|NCT04380701|Biological|BNT162b2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
75884699|NCT04380701|Biological|BNT162c2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
75442626|NCT01656213|Device|Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).|Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
75442627|NCT01656226|Device|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
75442628|NCT01656226|Other|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
75442629|NCT01656265|Drug|ARQ 197|Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
75442630|NCT01656278|Procedure|Magnetic resonance imaging (MRI)|"Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28>3.2 AND/OR MRI-detected bone marrow oedema score > 0 (RAMRIS-score)"
75442631|NCT01656278|Other|Conventional biochemical and clinical examinations|"Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28>3.2"
75442632|NCT01656317|Other|Early multidisciplinary rehabilitation|"Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist."
75442633|NCT01656330|Drug|Rivaroxaban 20 mg twice daily|One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
75442634|NCT01656330|Drug|Rivaroxaban 20 mg once daily|One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
75442635|NCT01656330|Drug|Profilnine SD|Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
75884700|NCT05572190|Drug|ETR028, ETR029, [ETR028 + ETR029] or HCBT|Hydrocodone prodrugs
75884701|NCT01365143|Procedure|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
75884702|NCT01365143|Procedure|Open Radical Prostatectomy|Open radical prostatectomy
75884703|NCT02035722|Behavioral|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
75884704|NCT02035722|Behavioral|Video|AMD-related information is presented as in the form of a video
75884705|NCT01365221|Drug|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
76071910|NCT03755804|Drug|Vinblastine|Given intravenously (IV)
75592543|NCT04625517|Procedure|Digital Mammography|Digital Mammography enhanced with an iodinated contrast agent
76056059|NCT05100654|Drug|Bactrim|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
76056060|NCT05095922|Drug|Heart-Protecting Musk Pill|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
76056061|NCT05095922|Drug|Valsartan Capsules|Valsartan Capsules(capsule, 80mg, once a day, 3 months）
76056062|NCT05095922|Drug|Calcium Dobesilate Capsules|Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
75442636|NCT01656330|Drug|Beriplex P/N|Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
75735752|NCT04061057|Drug|Lidocaine|"Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
75442637|NCT01656330|Other|Saline|Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
75592544|NCT04625517|Drug|Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml|Injection of low osmolar contrast material during the digital mammography exam
75592545|NCT04601987|Behavioral|Breastfeeding|Counseling about the maternal health benefits of lactation.
75592546|NCT04601987|Behavioral|Smokefree Homes|Counseling about the importance of smoke-free homes.
75592547|NCT04599192|Other|No study intervention|The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.
75592548|NCT04598321|Drug|Talazoparib Oral Capsule|An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
75592549|NCT04594616|Device|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
75592550|NCT04592523|Other|No Intervention|This is a non-interventional study.
75442638|NCT01656356|Biological|Avian Flu Vaccine|
75442639|NCT01656356|Biological|Placebo|
75442640|NCT01656369|Procedure|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
75592551|NCT04577352|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
75592552|NCT04577352|Drug|Placebo|Placebo will be administered per schedule specified in the arm.
75735753|NCT04061057|Drug|Normal saline|"Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
76056063|NCT05062980|Biological|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, re-establishing pathways that promote cancer cell death and modulating the immune system response against cancer cells.
76056064|NCT05062980|Drug|pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.
76056065|NCT05062980|Drug|docetaxel|Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.
76071911|NCT03755804|Drug|Prednisone|Given orally (PO)
76071912|NCT03755804|Drug|Filgrastim|Given subcutaneously (SQ) or IV
76071913|NCT03755804|Drug|Brentuximab Vedotin|Given intravenously (IV)
75884706|NCT01365221|Drug|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
75884707|NCT03576222|Device|PICO DRESSING|USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
75884708|NCT03576222|Device|MEPORE dressing|MEPORE dressing
76056066|NCT05062980|Drug|ramucirumab|Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.
76056067|NCT05062980|Drug|Investigator's Treatment of Choice|Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
76056068|NCT05046574|Other|Stroke rehabilitative therapy sessions with therapy dog present|Therapy dog will be present during stroke rehabilitative therapy sessions. This is expected to be at least three times a week per 7-day period.
75442641|NCT01656369|Procedure|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
75442642|NCT01656382|Drug|ABLC|
75442643|NCT01656473|Other|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
75442644|NCT01656473|Other|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
75592553|NCT04571684|Other|HITSystem 2.1|HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
75592554|NCT04564898|Drug|Capecitabine|"Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days"
75735754|NCT04635059|Drug|Pacritinib|Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).
75735755|NCT00921167|Drug|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs [EIAEDs] or 340mg/m2 for patients on EIAEDs) every 2 weeks
75735756|NCT04061447|Drug|susceptibility-guided therapy|rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
75769122|NCT01253590|Behavioral|questionnaire about the use of ECG device|Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
75884709|NCT01366079|Procedure|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
75884710|NCT01366079|Procedure|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
75884711|NCT05567588|Combination Product|Drug: Pembrolizumab|200mg(body weight >75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
75884712|NCT03124199|Drug|Rifaximin|Rifaximin 400 mg/8 h added to the standard triple therapy
75909513|NCT03477422|Drug|Meropenem|Meropenem was the Comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg.Patients were given either Meropenem or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Drug) was given at 8th hour from first dose, third dose (Placebo) at 12th hour from first dose and the fourth dose (Drug) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
75909514|NCT03920384|Behavioral|Experimental intervention arm|Psychological therapy for psychosis with new therapy components
75909515|NCT03920384|Behavioral|Active control arm|Standard psychological therapy for psychosis without new therapy components
76056069|NCT05044598|Other|RAFT-OS|RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) is an artificial tissue, populated with limbal epithelial cells and stromal cells.
75442645|NCT01656499|Dietary Supplement|Arabinoxylanoligosaccharides|
75442646|NCT01656499|Dietary Supplement|Maltodextrine|
76056070|NCT05030961|Behavioral|Virtual team-based clinic|Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.
75884713|NCT03546920|Behavioral|ALIGN Intervention Phase|"Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives."
75884714|NCT03574428|Drug|GNbAC1|Monoclonal Antibody infused i.v.
75884715|NCT03574428|Other|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
75884716|NCT01366157|Genetic|microarray analysis|
75592555|NCT04564898|Drug|Bevacizumab|"Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days"
75592556|NCT04564898|Drug|Trifluridine/Tipiracil|"Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days"
75884717|NCT01366157|Genetic|protein expression analysis|
75735757|NCT04061447|Drug|empirical clarithromycin-based triple therapy|The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
75884718|NCT01366157|Other|immunohistochemistry staining method|
75884719|NCT01366157|Other|laboratory biomarker analysis|
75884720|NCT03574350|Behavioral|KS in Kangaroo Position|KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
75884721|NCT03574350|Behavioral|KS in incubator|The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
75592557|NCT04561661|Procedure|Percutaneous pinning|Closed reduction, percutaneous pinning and plaster
75592558|NCT04561661|Procedure|Conservative treatment|Closed reduction, custom made orthosis and early mobilization
75592559|NCT04553471|Radiation|Stereotactic body radiotherapy|Treatment will take approximately 2 weeks.
76056071|NCT05030961|Behavioral|Remote cochlear implant programming|Remote cochlear implant programming will be provided via Zoom on a study-provided encrypted laptop.
76056072|NCT05014360|Drug|JNJ-64251330|JNJ-64251330 tablets will be administered orally.
75592560|NCT04553471|Procedure|Research blood draw|-Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up
75884722|NCT01365377|Other|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
75909516|NCT01355289|Drug|Avatrombopag|
75909517|NCT01355289|Drug|Placebo|
75909518|NCT01355289|Drug|Pegylated interferon (PEG-IFN)|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
75909519|NCT01355289|Drug|Telaprevir|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
75592561|NCT04542616|Device|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
75592562|NCT04540068|Drug|Transforaminal Epidural Injection|Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
75592563|NCT04523701|Drug|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"
75442647|NCT01656512|Drug|zolendronic acid|"patients will receive calcium & vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~Initial dose: (0.025) mg /kg~Subsequent doses ( 0.05) mg /kg.~Maximum dose of 4 mg."
75735758|NCT03968978|Biological|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
75735759|NCT03968978|Biological|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
75735760|NCT02567591|Other|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
75735761|NCT02565953|Device|Paclitaxel-releasing PTA balloon catheter|
75735762|NCT02565953|Device|PTA balloon catheter|
75735763|NCT00562718|Drug|capecitabine|
75735764|NCT00562718|Procedure|adjuvant therapy|
75735765|NCT00562718|Radiation|radiation therapy|
75592564|NCT04491422|Combination Product|Integrated Next Steps Counseling with Real-Time Drug Level Feedback|Integrated next steps counseling with real-time drug level feedback using point-of-care urine tenofovir testing at quarterly visits
75735766|NCT05222165|Drug|Infigratinib|Hard gelatin capsules for oral use
75884723|NCT03578640|Drug|Elbasvir, Grazoprevir 50-100Mg Oral Tablet|Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
75884724|NCT02035644|Drug|Jinlida granules|
75884725|NCT02035644|Drug|placebo granules|
75884726|NCT03578562|Other|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
75884727|NCT04465916|Drug|EYP001a|Oral tablets
76056073|NCT04954300|Other|no intervention|No intervention
75442648|NCT01656512|Drug|calcium & vitamin D|patients will receive calcium & vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
75592565|NCT04490356|Behavioral|Legacy Intervention|The Legacy intervention is a nutrition and exercise protocol delivered using video conference technology. The Legacy protocol incorporates behavioral strategies along with nutrition and exercise to maintain and extend functional benefits of obesity treatment.
75592566|NCT04484831|Behavioral|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
75592567|NCT04484831|Other|Enhanced Care|This includes 15 handouts on elements of a healthy lifestyle and a midpoint one-on-one nutrition consultation with a registered dietitian.
75735767|NCT02567357|Behavioral|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
75735768|NCT02567357|Behavioral|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
75735769|NCT04555811|Drug|FT596|FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
75735770|NCT04555811|Drug|Rituximab|Rituximab 375 mg/m^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
75884728|NCT04465916|Drug|Placebo|Oral tablets
75884729|NCT04465916|Drug|Nucleotide analogue (Entecavir or Tenofovir Disoproxil)|Oral tablets
75884730|NCT03575988|Other|Diabetes|The patients have diabetes without diabetic retinopathy from the diabetic outpatient
75884731|NCT01366235|Drug|chloroquine phosphate 1000 mg|1000 mg, 1day
75442649|NCT01656525|Drug|Gantenerumab|75 mg subcutaneous doses every 4 weeks for 24 weeks
75442650|NCT01656525|Drug|Gantenerumab|105 mg subcutaneous doses every 4 weeks for 24 weeks
75884732|NCT03578484|Diagnostic Test|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
75884733|NCT04871165|Diagnostic Test|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.
75884734|NCT04871165|Diagnostic Test|Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)|Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)
75884735|NCT04871165|Diagnostic Test|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
75442651|NCT01656525|Drug|Gantenerumab|225 mg subcutaneous doses every 4 weeks for 24 weeks
75442652|NCT01656525|Drug|Placebo|subcutaneous doses every 4 weeks for 24 weeks
75442653|NCT01656577|Drug|Pexacerfont|
75592568|NCT04477850|Drug|Luspatercept|Specified dose on specified days
75769123|NCT01251172|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
75769124|NCT01251172|Drug|Gamma-Secretase Inhibitor RO4929097|Given orally
75769125|NCT01251172|Procedure|Hematopoietic Stem Cell Mobilization|Undergo standard mobilization
75884736|NCT05090852|Device|Hi-VNI|Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
75884737|NCT03578406|Drug|HPV E6-specific TCR-T cells|Patients were infused with HPV E6-specific TCR-T cells
76071914|NCT03755804|Drug|Cyclophosphamide|Given intravenously (IV)
75884738|NCT03575676|Drug|SOM3355 100mg BID|Oral
75884739|NCT03575676|Drug|SOM3355 200mg BID|Oral
75884740|NCT03575676|Drug|Placebo BID|Oral
75884741|NCT04249739|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
75884742|NCT03574272|Other|Patient Transfer Monitoring System|The subjects will be provided with portable oximeter and smart-phone which application for monitoring is installed, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward.
75884743|NCT01366313|Drug|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
75442654|NCT01656590|Other|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|"High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age & gender~500 cc Formula - Nutren Replete with Fiber overnight [8 hours] via gastrostomy tube~Conditioning Exercise once daily"
75884744|NCT01366313|Drug|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
75884745|NCT01366313|Drug|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
75884746|NCT05190809|Procedure|Goldilocks mastectomy and fat transfer|Skin sparing mastectomy (Goldilocks mastectomy), then autologous fat grafting in the medial and lateral breast pillars as well as the inferior dermal flap
75442655|NCT01656616|Drug|Cyanide antidote administration|
75442656|NCT01656642|Drug|Atezolizumab|Atezolizumab will be administered q3w or q2w.
75442657|NCT01656642|Drug|Cobimetinib|Oral repeating dose
75442658|NCT01656642|Drug|Vemurafenib|Oral repeating dose, depending on arm/cohort
75442659|NCT01656668|Drug|BC1036|
75442660|NCT01656681|Dietary Supplement|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
75442661|NCT01656681|Dietary Supplement|Placebo|Placebo tablet
75442662|NCT01656694|Device|DePuy Sigma HP Partial Knee|
75442663|NCT01656707|Behavioral|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
75884747|NCT01371149|Other|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
75884748|NCT02253524|Drug|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
75884749|NCT02253524|Drug|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
75884750|NCT01371227|Drug|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
75884751|NCT02253602|Drug|Ferumoxytol|maximum rate of administration 1 ml/sec
75884752|NCT05190497|Device|Exercise group|Maximal respiratory pressure and reflecting muscles strength were measured by a mouth pressure meter
75442664|NCT01656707|Behavioral|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
75442665|NCT01656720|Drug|1R, 2S-methoxamine hydrochloride|
75884753|NCT03575520|Drug|Pegfilgrastim|A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
75884754|NCT03575520|Drug|Doxorubicin/Cyclophosphamide(AC) treatment|"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."
75884755|NCT01366391|Drug|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
75884756|NCT04589195|Behavioral|Mindfulness Training|The intervention includes four weeks of MT application use, accessed via phone or computer, consisting of 15-minute daily mindfulness practices 5 days a week.
75884757|NCT03546764|Device|Percutaneous catheter|tube inserted to drain hemothorax
75884758|NCT04408586|Drug|Phentermine-Topiramate Extended Release|Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
75442666|NCT01656720|Drug|Placebo|
75442667|NCT01656746|Procedure|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
75442668|NCT01656785|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
75442669|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
75442670|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
75442671|NCT01656811|Drug|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
75442672|NCT01656811|Drug|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
75884759|NCT04408586|Drug|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient
75884760|NCT04408586|Other|Online support system|VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
75884761|NCT00075816|Biological|Allogeneic bone marrow transplantation|Bone marrow transplant from HLA compatible unrelated donors.
75884762|NCT00075816|Biological|Peripheral blood stem cell transplantation|Peripheral blood transplant from HLA compatible unrelated donors.
75735771|NCT04546217|Combination Product|Treadmill training + transfer package (TT+TP)|Participants will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. In combination with the gait training, participants will also receive a group of behavioral strategies (Transfer Package). Participants will sign the behavioral contract to achieve safety while engaging in activities, increase use of the paretic leg in daily activities, and increase coordination of both legs. A list of activities to be performed outside the clinical setting, the Home Skill Assignment, will be developed for each day of the week during the treatment period and given to the participants at the end of the session. The Home Practice after treatment aims to assure continued progress with LE use after the intervention program is completed. The LE-MAL Log will be administered in all sessions to assess quality of movement of the affected leg, level of assistance needed to perform daily activities, and level of confidence.
75884763|NCT04479917|Drug|TPN171H|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
75884764|NCT04479917|Drug|placebo|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
75442673|NCT01656811|Drug|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
75442674|NCT01656811|Drug|Placebo|Placebo 2 actuations QID
75442675|NCT01656837|Behavioral|Comprehensive Community Treatment|
75442676|NCT01656837|Behavioral|MST-BSF|
75442677|NCT01656863|Other|Questionnaire|
75442678|NCT01656876|Behavioral|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
75442679|NCT01656876|Other|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
75442680|NCT01656876|Behavioral|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
75592569|NCT04471233|Other|Multimodal analgesia including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal. Patient will be provided with an preoperative pregabalin dose and will continue medication two weeks postoperatively.
75884765|NCT05159726|Other|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
75884766|NCT03578328|Procedure|targeted temperature management|Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
75884767|NCT05542862|Biological|SpikoGen vaccine|Recombinant spike protein based Covid-19 vaccine
75884768|NCT03575442|Behavioral|"3 session program of art therapy"|With this program, we expect to offer socio-emotional well-being in the psychiatric context, and creative self-expression through painting. In addition, we hope to provide contributions towards the creation of quality standards of the professional practice of nurses, within the context of implementing psychosocial programs in mental health.
75884769|NCT03578250|Other|Robotic Training|Upper extremity training on a robotic device with or without error augmentation force field.
75884770|NCT03575286|Diagnostic Test|Pregnancy test|Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy
75909520|NCT01355289|Drug|Ribavirin|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
76056074|NCT04944147|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA)
76056075|NCT04944147|Device|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants
76071915|NCT03755804|Drug|DTIC|Given intravenously (IV)
75592570|NCT04471233|Other|Multimodal analgesia not including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal.
75735772|NCT04546217|Device|Treadmill training (TT)|Participants in this group will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. The treadmill training will be identical to the experimental group, but no element of the TP will be delivered.
75735773|NCT00697619|Drug|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
75884771|NCT03578016|Other|Circle of Security-Parenting|COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.
75735774|NCT02566187|Drug|Fimasartan/Atorvastatin Combination Tablet|
75735775|NCT02566187|Drug|Fimasartan|
75884772|NCT03578016|Other|Treatment as Usual|TAU consists of clinical assessment and treatment.
75884773|NCT02239614|Biological|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
75442681|NCT01656928|Behavioral|preschool-based nutritional intervention|6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
75884774|NCT02239614|Biological|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
75442682|NCT01656954|Procedure|Passive Leg Raise (PLR)|From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
76056076|NCT04944147|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions
75442683|NCT01656980|Drug|Carmustine|As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
75884775|NCT05031572|Other|dietary intervention|Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
75884776|NCT02253680|Procedure|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
75884777|NCT03572400|Drug|Gemcitabine|Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles
75884778|NCT03572400|Drug|Durvalumab|Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year
75884779|NCT02253836|Drug|Tipranavir|TPV
75442684|NCT01656980|Procedure|tumor resection surgery|For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
75442685|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
75442686|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
75442687|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
75884780|NCT02253836|Drug|Ritonavir|RTV
75592571|NCT04449510|Other|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
75884781|NCT02253836|Drug|Atazanavir|TAZ
75884782|NCT03575130|Drug|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
75884783|NCT03575130|Drug|Optive eye drops|Artificial tears (placebo)
75442688|NCT01657058|Dietary Supplement|Soluble viscous fibre blend powder in hydrophobic matrix|5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
75592572|NCT04445571|Procedure|Thin catheter technique or standard ET-tube for surfactant administration|Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.
75735776|NCT02566187|Drug|Atorvastatin|
75735777|NCT05324891|Drug|Dexmedetomidine|Infants received dexmedetomidine IV loading dose: 0.5 mcg/kg given over 20 minutes followed by maintenance dose 0.3 µg/kg/hour by infusion over 24 hours.Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
75735778|NCT05324891|Drug|Fentanyl|Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
75884784|NCT03575130|Procedure|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
75884785|NCT02241018|Drug|CD25 monoclonal antibody|
75884786|NCT02241018|Drug|calcineurin inhibitors|
75884787|NCT02241018|Biological|MSCs|
75884788|NCT04039022|Drug|AXS-05 (dextromethorphan and bupropion) oral tablets|Oral tablets, taken twice daily for up to 12 months.
75909521|NCT04680741|Behavioral|Addiction Pilot App behavior tracking|a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.
75909522|NCT03473288|Behavioral|Exercise|Participants will undergo supervised exercise 3 times a week for 10-12 weeks.
75909523|NCT03473288|Behavioral|Sedentary|Participants will be asked to maintain the sedentary lifestyle that they already have for 10-12 weeks.
75909524|NCT03473210|Drug|Antibiotics|ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
75909525|NCT03473210|Drug|Corticosteroid|dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
75592573|NCT04426019|Behavioral|CLS Intervention|Community health workers (or promotoras) will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening
76056077|NCT04944147|Behavioral|Progressive muscle relaxation (PMR)|Standardized instructed PMR training, 9 sessions
76056078|NCT04939558|Device|N-Tidal C handset|Participants are to use the 'N-Tidal C' handset every day for 14 days. This will ideally be two times a day (once in the morning and once in the evening, before using any regular inhalers). Each breath record requires the participant to breathe through the mouthpiece for 75 seconds in a relaxed manner.
75442689|NCT01657058|Dietary Supplement|Soluble viscous fibre blend in pre hydrated form|0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
75442690|NCT01657058|Dietary Supplement|No soluble viscous fibre blend|0g soluble viscous fibre blend margarine + white bread + jello
75442691|NCT01657058|Dietary Supplement|Soluble viscous fibre blend premixed with ½ carbohydrate gel|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
75442692|NCT01657058|Dietary Supplement|No soluble viscous fibre blend, ½ carbohydrate jello|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
75442693|NCT01657071|Drug|YH14659|YH14659 capsule by oral
75592574|NCT04426019|Behavioral|No CLS intervention|This control arm will receive only usual practice care (print education) and will not receive the CLS intervention. They may receive the intervention after the study has been completed
75442694|NCT01657071|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
75735779|NCT00445432|Biological|adalimumab|Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
75735780|NCT00445432|Other|Placebo|Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
75442695|NCT01657084|Device|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
75735781|NCT00696137|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
75442696|NCT01657084|Device|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
75442697|NCT01657097|Drug|INCS|
75735782|NCT02565641|Drug|Capecitabine|Capecitabine will be administered orally at 830 mg/m^2 BID (equivalent to a total daily dose of 1660 mg/m^2) as intermittent treatment (given days 1 to 21 q4w).
75442698|NCT01657097|Drug|Placebo|
75442699|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
75442700|NCT01657123|Other|ergometry|ergometry measurements
75442701|NCT01657123|Other|ergometry|Ergometry measurements
76056079|NCT04921449|Other|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
75442702|NCT01657136|Drug|Ivabradine|comparison of different drugs
75442703|NCT01657136|Drug|Beta blocker|comparison of different drugs
75442704|NCT01657149|Procedure|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
75442705|NCT01657149|Procedure|individual physiotherapy only|individual physiotherapy only
75735783|NCT02565641|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
75884789|NCT03570684|Device|Cable Tie|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
75884790|NCT02244450|Biological|SCID screening|
75884791|NCT04000178|Device|polyurethane stent|patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
75884792|NCT04000178|Device|silicone stent|silicone stent
75884793|NCT03573726|Other|Closed diurnal indwelling catheter (CDIC)|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
75884794|NCT03573570|Other|Fortified rice kernels|The proposed project will leverage the existing state-run public distribution system (PDS) to provide fortified rice through Fair Price Shops (FPS) using a domestically manufactured rice grain (Fortified Rice Kernels: FRK). FRKs are grains made from rice flour, enriched with iron, zinc, Vitamin A, Vitamins B1, B3, B6, B9 and B12, and shaped like a conventional grain of rice. It is mixed into conventional rice in specified ratio of 1:100. The proposed study will be conducted as a cluster-randomized controlled trial, with baseline and follow-up surveys conducted 12-15 months apart. In the interim, 110 Treatment FPS, and all households receiving rice from them, will be randomly assigned to receive fortified rice, and another 110 randomly assigned Control FPS, and the households receiving rice from them, will continue receiving conventional rice and represents the status quo. This study will be conducted in one sub-district of Tamil Nadu with a population of about 1/2 million people.
75884795|NCT00109772|Drug|lenalidomide|Two 5 mg capsules taken one time per day
75884796|NCT00109772|Drug|Placebo|Two placebo capsules taken one time per day
75735784|NCT04036721|Drug|Prolonged glucocorticosteroid (prednisone) regimen|Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
75884797|NCT03573492|Other|Education|Type of teaching being assigned to student arms
75884798|NCT03572010|Dietary Supplement|FeFum fortified maize test meal|Maize porridge extrinsically labeled with 2 mg ferrous fumarate (58FeFum); only for iron deficient children (defined by plasma ferritin <40 mikrogramm/L and/or sTfR >8.3 mg/L); cereal staple foods, like maize, depending on milling, may be high in phytic acid, a potent iron absorption inhibitor
75884799|NCT03572010|Dietary Supplement|FeSO4 fortified LNS|self-made Lipid-based nutritional supplement (LNS) extrinsically fortified and labeled with 6 mg ferrous sulfate (57FeSO4); only for iron deficient children (defined by plasma ferritin <40 mikrogramm/L and/or sTfR >8.3 mg/L); LNS may be a better food matrix for iron supplementation compared to maize-based porridge; contains canola oil, peanut paste, milk powder, sugar, maltodextrin and palm stearin
75884800|NCT03572010|Dietary Supplement|FeSO4 supplement|170 mg iron tablets as FeSO4 (containing 55 mg of elemental iron) with 6 mg extrinsically labeled 57Fe; will be given together with a glass of water; only for iron deficient children (defined by plasma ferritin <40 mikrogramm/L and/or sTfR >8.3 mg/L);
75884801|NCT03572010|Dietary Supplement|FeSO4 fortified fruit juice|Fruit juice labeled with 12 mg 57Fe as FeSO4; in the group for iron sufficient children
75884802|NCT03571932|Behavioral|Family planning and immunization service integration|The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
75884803|NCT02245152|Dietary Supplement|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
75909526|NCT03473210|Procedure|Amniopatch|a total of around 60-80 mL of platelets, 100-150 mL of FFP and 100-150 mL of amnioinfusion fluid was used throughout the procedure
75735785|NCT04036721|Drug|Short glucocorticosteroid (prednisone) regimen|Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
75735786|NCT00441142|Drug|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
75769126|NCT01251172|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
75769127|NCT01251172|Other|Laboratory Biomarker Analysis|Correlative studies
75769128|NCT01251172|Drug|Melphalan|Given IV
75769515|NCT03893344|Diagnostic Test|detection of STAT4 gene|Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
75884804|NCT02245152|Behavioral|Child's health and nutrition topics|"After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children."
75616237|NCT03678766|Behavioral|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
75735787|NCT00441142|Drug|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
75735788|NCT00441142|Radiation|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
75735789|NCT05208281|Drug|GNR-055 1.0-2.0-3.0 mg/kg|Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
75884805|NCT02245152|Behavioral|National policy well-baby visits|
75884806|NCT03908450|Device|PTCA of coronary de novo lesion PCB|PTCA of coronary de novo lesion with drug coated balloon
75884807|NCT03908450|Device|PTCA of coronary de novo lesion SCB|PTCA of coronary de novo lesion with drug coated balloon
75884808|NCT03571854|Device|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
75884809|NCT03571854|Device|Group VCV|Volume controlled ventilation
75884810|NCT01560104|Drug|Veliparib|
75735790|NCT05208281|Drug|GNR-055 2.0 mg/kg|Weekly IV infusion (lyophilized powder) 2.0 mg/kg
75735791|NCT05208281|Drug|GNR-055 3.0 mg/kg|Weekly IV infusion (lyophilized powder) 3.0 mg/kg
75735792|NCT00921401|Behavioral|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
75735793|NCT01029184|Other|commercialized complete cereals|complete cereals suitable for the weaning period
75884811|NCT01560104|Drug|Carboplatin|
75884812|NCT01560104|Drug|paclitaxel|
75884813|NCT01560104|Drug|placebo|
75884814|NCT03573258|Dietary Supplement|Fiber or Placebo (depending on the randomization)|ingestion of dietary fibers prior to meal intake
75884815|NCT00101972|Biological|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
75884816|NCT02245854|Device|Exacto™|Cold snare polypectomy
75884817|NCT00100256|Drug|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
75884818|NCT03571698|Device|Neuromuscular Electrical Stimulator|The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
75884819|NCT02245932|Dietary Supplement|Resveratrol|4 weeks of 150 mg resveratrol (2 times 75mg/day)
75884820|NCT02245932|Dietary Supplement|Placebo|4 weeks of placebo supplementation (two doses per day)
75884821|NCT03573102|Drug|SGLT2 inhibitor|SGLT2 inhibitor 10 mg/day
75884822|NCT03573102|Drug|ACE inhibitor|ACE inhibitor once daily
75884823|NCT02246088|Procedure|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
75884824|NCT02246088|Procedure|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
75884825|NCT02254070|Drug|BIBT 986 BS|
75884826|NCT04944368|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
75884827|NCT04944368|Biological|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
75884828|NCT03720704|Device|GORE VIABAHN VBX Balloon Expandable Endoprosthesis|GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.
75884829|NCT03545672|Diagnostic Test|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
75884830|NCT02783066|Device|Offloading boot: PulseFlow|A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
75884831|NCT03754868|Diagnostic Test|Detailed coagulation monitoring|Monitoring of coagulation using activity of coagulation factors, rotational thrombelastometry and multiple electrode aggregometry
75442706|NCT01657175|Other|Supportive care|"The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~Discharge information about surgery and life after surgery together with their relatives.~Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery"
75442707|NCT01657188|Device|Cheyne-Stokes respiration by adaptive servoventilation|
75884832|NCT03546530|Drug|Interferon|Interferon
75884833|NCT03546530|Drug|Interferon+resveratrol|Interferon+resveratrol
75884834|NCT03568526|Other|Educational Intervention|Attend a therapy session
75884835|NCT03568526|Behavioral|Exercise Intervention|Complete exercise
75592575|NCT04421235|Behavioral|Childbirth support|"There are 5 program components that women may receive as a part of childbirth support:~Prenatal education - consists of up to 8 sessions of education on pregnancy, childbirth, and postpartum health and wellness.~Support group - semi-structured group which provides time for women to process their pregnancy and postpartum-related experiences with other women facing similar challenges. Integrates mindfulness exercises, cognitive-behavioral skills, and special topics as requested by group members.~Lactation program - program for women who wish to provide breastmilk for infants from which they are separated.~Doula support program - 2 prenatal and 2 postnatal individual visits with a doula who will also provide continuous childbirth support and support during separation from infants.~Parenting classes - group classes focused on helping women learn parenting skills and (if applicable) meet state requirements for reunification with children"
75884836|NCT03568526|Other|Quality-of-Life Assessment|Ancillary studies
75884837|NCT03568526|Other|Questionnaire Administration|Ancillary studies
75884838|NCT03568526|Other|Survey Administration|Ancillary studies
75884839|NCT03545828|Diagnostic Test|Multi-channel aEEG monitoring|18 channel aEEG monitoring in comatose TTM-treated patients
75884840|NCT03480386|Behavioral|Home Based Pulmonary Rehabilitation|The intervention consists of doing 12 weeks of exercises at home, with a weekly call from a health coach.
75884841|NCT04178252|Other|mask|investigators will add eye mask to standard treatment
75884842|NCT04178252|Other|headset|investigators will add headset to standard treatment
75442708|NCT01657201|Drug|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
75884843|NCT04178252|Other|standard drug|investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
75884844|NCT04872140|Dietary Supplement|Low phytate pea powder|Exercise performance with low phytate pea powder
75884845|NCT04872140|Dietary Supplement|Regular pea powder|Exercise performance with regular pea powder
75884846|NCT04872140|Dietary Supplement|Placebo (maltodextrin)|Exercise performance with placebo (maltodextrin)
75884847|NCT01371305|Drug|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
75592576|NCT04415281|Device|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
75735794|NCT01029184|Other|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
75592577|NCT04415281|Device|sham THOR® laser system|sham THOR® laser system
75592578|NCT04401267|Drug|Intensive Antihypertensive Therapy|Receives intensive antihypertensive therapy
75442709|NCT01657201|Drug|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
75735795|NCT03896555|Device|ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring
75735796|NCT04025021|Dietary Supplement|Targeted Fortification|The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
75884848|NCT01371305|Drug|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
75884849|NCT03397550|Other|salt restriction education|Salt intake target：<5g/d Method：the standard salt restriction education will be lasting for 10-15 minutes by oral explanation at baseline.
75884850|NCT03545204|Other|Kangaroo Mother Care Package|"The KMC package will include creation of KMC Champions from within the community, social mobilization to create awareness and its acceptance with families using powerful IEC tools such as docudrama, flip charts, pictorials in local languages; engagement of community and community leaders, capacity building of health care providers on Kangaroo mother care, essential newborn care ENC, policy dialogues with stake holders in the public and private sectors and delivery of a KMC kit  to the pregnant female by the Implementation team"
75884851|NCT03545204|Other|Routine Standard Care|Routine Standard Care ( essential Newborn care )ENC
75884852|NCT01366547|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
75884853|NCT01366547|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
76056080|NCT04921449|Other|Usual Care|Includes any diagnostic imaging, patient education and reassurance, and administration or prescribing of analgesic medications, as per the treating physician's usual and customary practice.
76056081|NCT04907253|Drug|Quercetin|500 mg twice daily
75442710|NCT01657214|Drug|SAR125844|"Pharmaceutical form:Concentrate for solution~Route of administration: intravenous"
75442711|NCT01657227|Behavioral|Intervention to patients|"Multifaceted intervention consisting of:~Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.~Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.~Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change."
75735797|NCT04025021|Device|The Miris Human Milk Analyzer|The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
75735798|NCT03848416|Biological|Ixekizumab|Administered SC
75735799|NCT01029418|Drug|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
75735800|NCT04060979|Drug|Nitric Oxide|Nitric Oxide given intermittently via inhalation
75735801|NCT04060979|Other|Standard Supportive treatment|Standard Supportive treatment (including oxygen)
75884854|NCT01366547|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
75884855|NCT01319669|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
75884856|NCT04032041|Device|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
75884857|NCT05190341|Drug|Ibuprofen 800 mg oral|1 hour before HSG
76056082|NCT04907253|Drug|Placebo|twice daily
76056083|NCT04898400|Procedure|endoscopy sleeve gastroplasty|endoscopic procedure for weight loss
75442712|NCT01657227|Behavioral|Intervention to professionals|"Multifaceted intervention consisting of:~Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.~Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.~Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional."
75442713|NCT01657227|Other|Usual care|Usual care for T2DM received in primary health care
75442714|NCT01657240|Drug|PRO-118|instill one drop in each eye once a day for 21 days
75442715|NCT01657240|Drug|Olopatadine Hydrochloride|instill one drop in each eye once a day for 21 days
75442716|NCT01657279|Other|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome [i.e. from low (<10%) to high (>50%) expected risk death at 30 days].
75442717|NCT01657318|Other|Olivamine containing wound care products|Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
75442718|NCT01657331|Drug|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
75442719|NCT01657331|Drug|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
75442720|NCT01657331|Drug|Neulasta|(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
75442721|NCT01657357|Other|Routine followup|questionnaires
75442722|NCT01657409|Drug|BoNT-A (10 injection)|BoNT-A 100 U 10 injections
75442723|NCT01657409|Drug|BoNT-A (20 injection)|BoNT-A 100 U 20 injections
75442724|NCT01657409|Drug|BoNT-A (40 injection)|BoNT-A 100 U 40 injections
75735802|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
75735803|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
75735804|NCT03851146|Biological|LeY CAR T cells|Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
75735805|NCT01023646|Other|Carbohydrate + Protein|Light Tuna Packed in water.
75735806|NCT01023646|Other|Carbohydrate + Fat|Butter
75735807|NCT01023646|Other|Fiber|Unrefined Carbohydrate
75735808|NCT01023646|Other|Carbohydrate load|Carbohydrate
75735809|NCT00444106|Drug|Artesunate-mefloquine|
75735810|NCT00444106|Drug|Atovaquone-proguanil|
75735811|NCT00444106|Drug|Artemether-lumefantrine|
75735812|NCT00561470|Drug|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
75735813|NCT00561470|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
75735814|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~5-FU 2400 mg/m² continuous IV infusion over 46-hours"
75735815|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~5-FU 2400 mg/m² continuous IV infusion over 46-hours"
75735816|NCT00443872|Drug|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
75735817|NCT01323166|Procedure|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
75769516|NCT01589692|Procedure|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
75592579|NCT04401267|Drug|Conventional Antihypertensive Therapy|Receives conventional antihypertensive therapy
75592580|NCT04401267|Other|Symptom Survey|The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
75442725|NCT01657422|Behavioral|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
75442726|NCT01657435|Device|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
75592581|NCT04401267|Other|Semi-structured interview|Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
75592582|NCT04398966|Device|Prostatic Artery Embolization (HydroPearl® compressible microspheres)|Embolic material
75592583|NCT04394676|Procedure|Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 12 mmHg (experimental) or 15mm Hg (standard technique).
75592584|NCT04391049|Drug|Carboplatin|Given IV
75592585|NCT04391049|Drug|Paclitaxel|Given IV
75592586|NCT04391049|Radiation|Radiation Therapy|Undergo radiation therapy
75592587|NCT04391049|Biological|Telomerase-specific Type 5 Adenovirus OBP-301|Given by intratumoral injection
75592588|NCT04370509|Drug|Axitinib (VEGF-TKI)|Given PO
75592589|NCT04370509|Procedure|Cytoreductive Nephrectomy (CN)|Undergo CN
75442727|NCT01657448|Drug|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
75884858|NCT05190341|Drug|Ketorolac 30mg oral|1 hour before HSG
75442728|NCT01657448|Drug|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
75442729|NCT01657474|Other|Weekly application of EpiFix plus standard of care|
75442730|NCT01657474|Other|Biweekly application of EpiFix plus standard of care|
75592590|NCT04370509|Procedure|Metastasectomy (MET)|Undergo MET
75592591|NCT04370509|Biological|Pembrolizumab|Given IV
75592592|NCT04355572|Drug|Vitamin D 4000IU daily|Randomized to receive vitamin D 4000IU daily
75592593|NCT04355572|Drug|Placebo|Randomized to placebo daily
75592594|NCT04331444|Device|CGM|Using the CGM during the entire study period of 12 months.
75592595|NCT04331444|Behavioral|training course|The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.
75592596|NCT04331444|Behavioral|Peer-support|The peer-support will be facilitator-led by the primary investigator with peer exchange in group sessions (3 sessions over the study period, 3 hours per session) with 6-8 participants in every group.
75592597|NCT04312659|Drug|Infliximab|Participants will be observed who were treated with Infliximab.
75592598|NCT04308590|Drug|relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
75592599|NCT04308590|Other|Placebo|Placebo is supplied as 100 mg capsules for oral dosing.
75592600|NCT04308512|Device|Care4AD system|Eligible subjects will be randomized to intervention, IG, and control groups, CG, with ratio of 1:1 and will be assessed at baseline and six months. All reminders will be activated in the intervention group and de-activated in the control group. Essential ADL tasks will be preprogrammed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
75592601|NCT04300894|Device|Mamma Mia|"Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs."
75884859|NCT04347239|Drug|Placebos|Placebos
75884860|NCT04347239|Drug|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
75884861|NCT00109928|Drug|cisplatin|
75884862|NCT00109928|Drug|etoposide|
75884863|NCT00109928|Drug|gemcitabine|
75884864|NCT00109928|Drug|methylprednisolone|
75884865|NCT02104310|Drug|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
75442731|NCT01657487|Drug|Fluticasone/Salmeterol high dose|
75735818|NCT01323244|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
75884866|NCT00109850|Biological|cetuximab|400mg/m^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m^2 maintenance dose, IV over 60 min, Days 8 & 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
75884867|NCT00109850|Drug|cisplatin|30mg/m^2, bolus intravenous (IV), on Days 1 & 8 of each cycle.
75884868|NCT00109850|Drug|irinotecan hydrochloride|65mg/m^2, intravenous (IV) over 30 min, on Days 1 & 8 of each cycle.
75884869|NCT00109850|Radiation|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
75884870|NCT02143232|Device|remote patient monitoring (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
75884871|NCT03318770|Drug|Dasatinib and blinatumomab|Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
75884872|NCT05499273|Procedure|scalpel-bougie tracheostomy|"The assistant places themselves with two preparation clamps at the head end of the table and assists with each hand placed lateral to the neck, so that the operating field is freely accessible. After the trachea or cricoid is palpated, a long median longitudinal skin incision of 2-3 cm is made from the cricoid caudally~The assistant uses straight clamps to pull the two edges of the skin incision apart dorso-laterally. In the event of major bleeding this maneuver should allow the blood to drain off dorsally and the view of the anatomical structures should be less impaired.~Layer by layer of the anatomical structures are cut through with the scalpel and tightened with the clamps accordingly.~Using a longitudinal incision, two to three tracheal rings are cut through distally to the cricoid~An 8 FR Frova catheter is inserted through the orifice into trachea.~A tracheal tube (ID 3.0 mm) is inserted over the Frova catheter to secure the airway permanently."
75884873|NCT05499273|Procedure|rapid sequence tracheotomy|"Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~Perform a vertical puncture with a tip scissors between the cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~A tracheal tube (inner diameter 3.0 mm, cuffed) is inserted to secure the airway permanently."
75884874|NCT01065519|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
75884875|NCT01065519|Device|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
75884876|NCT01342926|Drug|GSK933776|GSK933776
75884877|NCT01342926|Drug|Placebo|Placebo
75909527|NCT05177432|Device|QPOP|QPOP will be used as a clinical decision support platform to identity suitable patient-specific drug combinations across a range of breast cancer patients, which are derived from drug sensitivity tests using patient-derived materials.
75909528|NCT05161520|Procedure|phacoemulsification combined with IOL and CTR implantation|Device: CTR (276001G； OPHTEC BV, Netherlands) Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL is implanted.
75442732|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
75442733|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
75442734|NCT01657526|Biological|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
75442735|NCT01657539|Dietary Supplement|Yogurt containing probiotics|patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.
75442736|NCT01657539|Dietary Supplement|Placebo yogurt|Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
75592602|NCT04300894|Other|Mamma Mia Plus|Participants will use the Mamma Mia program, plus receive contact (phone calls or emails or texts) from study staff every few months.
75592603|NCT04287647|Device|Transpyloric stent|See arm/group descriptions
75592604|NCT04287647|Other|Sham|Sham
75592605|NCT04276701|Biological|blood sample|35 ml whole blood for Peripheral blood mononuclear cell (PBMC), serum and plasma
75735819|NCT01027234|Drug|AZD8418|Single oral dose
75735820|NCT01027234|Drug|Placebo|single oral dose
75769129|NCT00413777|Drug|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
75769130|NCT03912922|Other|Activity regime|Activity regime of 4 days followed by a test day.
76056084|NCT04875715|Other|Almond Oil|Almond oil
75442737|NCT01657552|Drug|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
75442738|NCT01657552|Drug|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
75442739|NCT01657552|Drug|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
75442740|NCT01657578|Drug|Omeprazole|administration of Omeprazole
75442741|NCT01657630|Device|Accu-Chek Combo System|12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
75735821|NCT01029496|Procedure|different time of umbilical cord clamping|"for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.~control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.~for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):~experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.~control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table."
75442742|NCT01657643|Dietary Supplement|Probiotics|
75592606|NCT04276701|Other|Ultrasonography assessment|assessment of atherosclerotic plaques and measurement of carotid intima-media thickness (cIMT)
75592607|NCT04276701|Behavioral|questionnaires|Food and exercise questionnaires validated by the American heart Association
75592608|NCT04274465|Diagnostic Test|digital PCR (dPCR) assay|It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA
75592609|NCT04270188|Other|evolution of patient symptoms|evolution of symptoms on the PGI-I scale (score 1, 2, or 3) 2 months after surgery
75592610|NCT04258462|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
75592611|NCT04258462|Procedure|Magnetic Resonance Imaging|Undergo MRI
75592612|NCT04258462|Drug|Hyperpolarized 13C,15N2-urea|Given IV
75735822|NCT01027390|Behavioral|physical training exercise|physical exercise training at the work site during work time
76056085|NCT04875715|Drug|Hydroquinone Topical|Hydroquinone 2% cream
75442743|NCT01657643|Dietary Supplement|placebo|
75442744|NCT01657656|Dietary Supplement|Vitamin D|
75442745|NCT01657669|Drug|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
75442746|NCT01657708|Other|Shared Decision Making|
75442747|NCT01657721|Behavioral|Cogmed Working Memory Training Program|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
75442748|NCT01657734|Other|MR imaging|MR imaging
75592613|NCT04253977|Behavioral|HEALTH-P2|The HEALTH-P2 curriculum includes evidence based lifestyle change strategies to prevent excess gestational weight gain and postpartum weight retention embedded within and delivered as part of home visits.
75592614|NCT04253977|Behavioral|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
75592615|NCT04247100|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Active Transcutaneous Auricular Microstimulation delivered by TENS device
75735823|NCT03034642|Procedure|Bronchoscopy with bilateral bronchoalveolar lavages|Bronchoscopy with bilateral bronchoalveolar lavages
75735824|NCT04839562|Drug|Solriamfetol 75 MG|Daily oral consumption
75884878|NCT03626181|Device|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
75884879|NCT02524002|Dietary Supplement|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
75884880|NCT02524002|Dietary Supplement|Usual clear diet|Usual clear liquids
75884881|NCT01810016|Biological|Ipilimumab|Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
75884882|NCT01810016|Biological|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
75884883|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
75884884|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine with Poly-ICLC|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
75884885|NCT02843178|Behavioral|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
75884886|NCT03571620|Drug|Q301 Cream|1.0% or 1.4% Q301 Cream
75884887|NCT03571620|Drug|Vehicle|Vehicle Control
75884888|NCT03571542|Other|pulmonary function|The aim of this study is to assess the respiratory function thanks to pulmonary function tests in renal transplanted children in France.
75884889|NCT03571464|Device|GGRO Mobile App|"GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards)."
75592616|NCT04247100|Device|Sham Transcutaneous Electrical Nerve Stimulation|Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered
75592617|NCT04245397|Drug|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
75884890|NCT03123185|Drug|Placebo|Tablet and solution formulation
75884891|NCT03123185|Drug|BI 705564 (Test)|Fed state
75884892|NCT03123185|Drug|BI 705564 (Reference)|Fasting state
75884893|NCT03123068|Drug|CocoaVia®|CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
75884894|NCT03123068|Other|Placebo|The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
75884895|NCT01372631|Device|miniature spectral imaging system|Use of miniature spectral imaging system
75592618|NCT04245397|Drug|Decitabine|Decitabine is a hypomethylating agent.
75592619|NCT04228991|Radiation|Locoregional radiation treatment - Conventional fractionation|40 Gray in 15 daily fractions over 3 weeks
75592620|NCT04228991|Radiation|Locoregional radiation treatment - Hypofractionation|26 Gray in 5 daily fractions over 1 week
75592621|NCT04218539|Drug|Psilocybin|10mg Psilocybin
75592622|NCT04218539|Drug|Placebo|25mg Diphenhydramine
75592623|NCT04211675|Biological|Natural Killer Cells|NK cells dose 1x 108 cells/ kg on day 8 of each cycle
75884896|NCT01372631|Device|Bench-top optical spectrometer|Use of bench-top optical spectrometer
75884897|NCT01372631|Device|High resolution microendoscope|Use of high resolution microendoscope
75884898|NCT02254148|Drug|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
75884899|NCT02254148|Drug|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
75884900|NCT02254148|Drug|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
75884901|NCT02254148|Drug|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
75884902|NCT02254148|Drug|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
75884903|NCT02254148|Drug|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
75884904|NCT02254148|Drug|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
75884905|NCT01366625|Device|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
75884906|NCT02842866|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
75442749|NCT01657747|Other|Whole body diffusion-weighted MRI|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for this reason not eligible for the study.~During the whole body MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.~During the whole body MRI examinations, a bowel relaxing injection (Buscopan) is also needed to reduce movement of the intestines."
75884907|NCT02842866|Biological|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined|0.5 mL, Subcutaneous (SC), single dose on Day 0.
75884908|NCT03078296|Other|survey respondents|all survey participants will be asked to complete a questionnaire
75884909|NCT01316913|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
75884910|NCT01316913|Drug|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
75592624|NCT04211675|Drug|Temozolomide|Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is <0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.
75592625|NCT04211675|Drug|Irinotecan|Irinotecan 50mg/m2/dose IV daily on Days 1-5
75592626|NCT04211675|Drug|Dinutuximab|Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5
75592627|NCT04211675|Drug|Sargramostim|Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12
75735825|NCT04839562|Drug|Solriamfetol 150 MG|Daily oral consumption
75884911|NCT01316913|Drug|GSK573719|125 mcg once-daily
75592628|NCT04195347|Drug|CM4620|IV
75592629|NCT04169529|Device|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
75592630|NCT04166851|Behavioral|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
75735826|NCT04839562|Other|Placebo|Placebo
75735827|NCT04888624|Device|DrySee® dressing with moisture detection|DrySee® is a waterproof bandage designed to protect surgical incisions. It contains an indicator at the perimeter of the dressing, and at the wound site that turns blue when it comes into contact with liquid (figure 1). The indicator identifies a break in the integrity of the postoperative dressing. Changing the dressing at this point prevents bacteria from reaching the incision reducing the risk of infection. In addition, the waterproof dressing allows patients to shower or bath following surgery.
75884912|NCT01316913|Drug|tiotropium bromide|18 mcg once-daily
75442750|NCT01657773|Other|Ultrasound examination and Colonoscopy examination|
75592631|NCT04166851|Behavioral|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
75592632|NCT04165018|Procedure|Fine-Needle Biopsy (FNB)|Fine-needle biopsy may be used to take samples of a pancreatic neoplasm.
75592633|NCT04153890|Behavioral|FamPALcare|"Intervention participants will receive standard care plus five weekly coaching sessions with telephone follow-up to reinforce HF palliative home care. FamPALcare intervention will be delivered by community-based nurses. FamPALcare intervention involves coaching patients and family caregivers in advanced HF home care and supporting EOLPC discussions.~The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines."
75735828|NCT04888624|Device|Tegaderm® + Pad transparent film dressing|Tegaderm® is a transparent adhesive dressing commonly used as a postoperative dressing. The dressing has been shown to be superior to gauze in reducing SSIs. Tegaderm®, like DrySee,® is waterproof; however, it lacks technology that identifies a breach in dressing integrity.
75884913|NCT02875067|Biological|Pembrolizumab|
75884914|NCT02875067|Drug|Lenalidomide|
75884915|NCT03544580|Procedure|immediate implant with dentine chips|Using dentin chips
75884916|NCT03544580|Procedure|conventional immediate implant|using xenograft
75884917|NCT02254538|Drug|BILR 355 BS|
75884918|NCT02254538|Drug|PEG 400|
75884919|NCT03572946|Procedure|Targeted prostate biopsy|MRI-guided targeted prostate biopsy
75884920|NCT03572946|Procedure|Standard biopsy|Transperineal ultrasound guided prostate biopsy(SB).
75884921|NCT01366703|Device|implantable loop recorder Medtronic reveal XT Full view|Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
75884922|NCT02143544|Device|Intra-aortic balloon pump.|Preoperative placement of the intra-aortic balloon pump.
75909529|NCT05161520|Procedure|phacoemulsification combined with IOL implantation|Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag.
75592634|NCT04151342|Drug|Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.|Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
75735829|NCT01030978|Behavioral|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
75884923|NCT03570294|Drug|Atosiban|The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
75884924|NCT02143622|Biological|LJM716|antibody
75884925|NCT02143622|Biological|cetuximab|antibody
75884926|NCT03142659|Other|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
75884927|NCT02781506|Drug|Nivolumab|Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist
75735830|NCT01030978|Behavioral|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
75884928|NCT02781506|Radiation|SAbR|SAbR (1-3 lesions)
75884929|NCT03780179|Biological|MMRvaxpro|MMRvaxpro vaccine
75884930|NCT03780179|Biological|Placebo|Placebo
75884931|NCT03570216|Other|Cardiopulmonary exercise test|Participants will perform a graded cardiopulmonary exercise test to asses their cardiorespiratory fitness. It will also provide a peak exercise stimulus to examine acute changes in arterial stiffness, and to prescribe both moderate intensity continuous exercise and high intensity interval exercise.
76056086|NCT04874584|Behavioral|CTNSM|The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .
75735831|NCT01029574|Other|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
75592635|NCT04151342|Other|Patient-reported outcomes (PROs)|Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
75616238|NCT03678766|Behavioral|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
75735832|NCT03316222|Drug|GNS561|Escalating doses to be administered 3 times a week.
75735833|NCT01031056|Procedure|Blood Draw|
75735834|NCT01031056|Procedure|Frozen Tumor Specimens|
75735835|NCT03742492|Dietary Supplement|Meal containing canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
75735836|NCT03742492|Dietary Supplement|Meal containing canned tuna + soybean oil|Meal containing canned tuna + soybean oil
75735837|NCT04773652|Diagnostic Test|speckle tracking echo|Two-dimensional and 3D Speckle tracking echocardiography and feature tracking CMR will be performed twice: within 48 hours of admission and 3 months following the index event.
75884932|NCT03570216|Other|Moderate-intensity continuous exercise|Participants will perform a 30-minute session of moderate-intensity continuous exercise.
75884933|NCT03570216|Other|High-intensity interval exercise|1 week later, participants will perform a 19-minute session of high-intensity interval exercise.
75909530|NCT03473132|Drug|four factor prothrombin complex concentrate|After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
75909531|NCT02899754|Behavioral|Lung Cancer Screening Decision Tool|This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
76056087|NCT04874584|Behavioral|Standard of Care Chemotherapy Education|Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
76056088|NCT04861597|Behavioral|Internet based cognitive behavioral therapy|Participants with elevated psychological distress will receive 8 weeks of internet-based cognitive behavioral therapy
76056089|NCT04861597|Behavioral|Digital mood tracking|Participants with elevated psychological distress will receive 8 weeks of digital mood tracking
75592636|NCT04136652|Procedure|CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch|women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
75592637|NCT04136626|Device|Perspectives OCD|The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work) and behavioral skills (e.g., exposure and response prevention).
75735838|NCT00441064|Drug|Aliskiren|
75735839|NCT03962738|Drug|Lasmiditan|Administered orally
75884934|NCT03132753|Behavioral|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with up to $700 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
75884935|NCT03572868|Other|Evaluation of the long term neurodevelopmental outcome|Evaluation of the long-term neurodevelopmental outcome of newborns who have an isolated transverse cerebellar diameter < 5th centile during the second or the third trimester of pregnancy.
75735840|NCT03962738|Drug|Placebo|Administered orally
75884936|NCT05190185|Biological|TAA06 injection|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106~1×108 CAR-T/kg. And the subjects will be administered once.
75735841|NCT05280002|Biological|Adipose Tissue derived Total-Stromal-Cells (TOST)|Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
75735842|NCT00561392|Drug|Rivastigmine 5 and 10 cm^2 patch|
76056090|NCT04847050|Biological|mRNA-1273|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered IM on Day 1 and 29 for vaccine naive cohorts or on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study
76056091|NCT04836429|Drug|Porfimer Sodium|Given IV
75442751|NCT01657786|Dietary Supplement|administration of ondanstron and screening of genomic DNA|Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).
75592638|NCT04136626|Device|The Health and Well-Being Program|The website includes 12 modules related to general health and well-being (e.g., sleep and nutrition). Each module contains educational information and questions about an indvidual's experience with the given topic.
75592639|NCT04116112|Drug|Nicardipine|In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.
76056092|NCT04836429|Procedure|Video-Assisted Thoracic Surgery|Undergo VATS
76056093|NCT04836429|Drug|Photodynamic Therapy|Undergo photodynamic therapy
76056094|NCT04836429|Device|Intraoperative PDT|Subjects will receive one course of light therapy at the time of surgery
75735843|NCT00694109|Drug|Mipomersen Sodium|Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
75735844|NCT03137693|Other|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
75735845|NCT03137693|Procedure|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
75769131|NCT01250080|Dietary Supplement|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
75769132|NCT01250080|Other|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
76056095|NCT04832152|Other|OT4ASD|Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
76056096|NCT04828954|Other|Immobilization for 2-weeks postoperative|Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks
76056097|NCT04828954|Other|Immobilization for 6-weeks postoperative|Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
76056098|NCT04822467|Device|SQ53 Wipe|SQ53-based wipe to be used by the participant daily or upon dressing change
76056099|NCT04822467|Device|Ethanol Wipe|Ethanol-based wipe to be used by the participant daily or upon dressing change
76056100|NCT04817566|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
76056101|NCT04817566|Device|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
75592640|NCT04116112|Drug|Labetalol|If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.
76056102|NCT04817566|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
75442752|NCT01657812|Drug|dexmedetomidine|"Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery."
75592641|NCT04116112|Drug|Hydralazine|If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.
75592642|NCT04077684|Drug|Interleukin-2|IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
75592643|NCT04072458|Drug|L-Bcl-2 antisense oligonucleotide|There will be 2 planned dose levels, 20, and 40 mg/m^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.
75592644|NCT04063787|Device|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
75735846|NCT03078491|Other|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
75735847|NCT00562484|Biological|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
75735848|NCT00562484|Biological|Placebo|Placebo
75592645|NCT04051346|Dietary Supplement|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
75769133|NCT03908320|Other|Menstrual Cycle Timing|Quit date is set to menstrual phase.
75442753|NCT01657825|Drug|Isavuconazole|oral
75442754|NCT01657825|Drug|Warfarin|oral
75442755|NCT01657838|Drug|Isavuconazole|oral
75442756|NCT01657838|Drug|Ketoconazole|oral
75442757|NCT01657851|Drug|dutasteride/tamsulosin|Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
75442758|NCT01657851|Drug|dutasteride|Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
75769134|NCT03908320|Other|Menstrual Cycle Timing|Menstrual cycle timing of quit date is monitored
75769135|NCT03908320|Drug|NRT Patch|NRT patch is provided
75769136|NCT03908320|Behavioral|Cessation Counseling|Cessation counseling is provided
76071916|NCT03755804|Other|Quality of Life Measurements|Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.
75616239|NCT02850796|Behavioral|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
76056103|NCT04777266|Behavioral|Music therapy and treatment as usual|The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy [37], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence [38]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
75442759|NCT01657851|Drug|tamsulosin|Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
76056104|NCT04769713|Procedure|Hepatic Hilar Nerve Block Needle placement|Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.
76056105|NCT04769713|Drug|Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block|Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
76056106|NCT04769713|Drug|Injection of normal saline in the hepatic hilum for the sham procedure|15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
76056107|NCT04756674|Other|No intervetion will be used|No intervention will be used
76056108|NCT04728581|Drug|Mirtazapine|Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.
75442760|NCT01657864|Drug|Lamotrigine|Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
75442761|NCT01657890|Drug|isavuconazole|oral
75442762|NCT01657929|Biological|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
75442763|NCT01657929|Biological|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
75442764|NCT01657929|Biological|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
75442765|NCT01657929|Biological|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
75442766|NCT01657942|Device|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
75442767|NCT01657955|Drug|Bendamustine Hydrochloride Injection|
75442768|NCT01657955|Drug|Chlorambucil|
75442769|NCT01657513|Drug|subjects will receive either infliximab, adalimumab or etanercept|"The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~infliximab or~adalimumab or~etanercept~The consulting dermatologist decides which drug to use according to official guidelines"
75442770|NCT01657981|Drug|YM150|14C-labeled YM150, oral solution
75442771|NCT01657994|Other|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
75442772|NCT01658007|Drug|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
75442773|NCT01658033|Drug|Avastin + mFOLFOX6|"mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w"
75442774|NCT01658046|Other|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
75442775|NCT01658046|Other|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
75442776|NCT01658046|Other|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
75442777|NCT01658085|Device|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
75442778|NCT01658085|Device|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
75442779|NCT01658098|Behavioral|edinburgh postpartum depression scale questionary|the investigators will apply the qusetionary one time only in the period of time described previously
75442780|NCT01658124|Drug|Tranexamic Acid|
75442781|NCT01658124|Drug|Placebo|
75442782|NCT01658137|Other|Prudent Diet|This intervention lasts 2 weeks (14 days).
75442783|NCT01658137|Other|Typical Western Diet|This intervention lasts 2 weeks (14 days).
75884937|NCT03571230|Drug|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
76056109|NCT04728581|Drug|Quetiapine|Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.
76056110|NCT04728581|Drug|Placebo|a gelatinous capsule without an active ingredient
76056111|NCT04720703|Behavioral|Newsletters|Similar to prior empirical pediatric obesity interventions (Elder et al., 2009), the active attention waitlist control group will receive monthly newsletters that focus on physical activity, healthy eating, and screen time. These newsletters will be based on standard materials from the We Can program of the National Heart, Lung, and Blood Institute (NHLBI).
75592646|NCT04051346|Dietary Supplement|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
76071917|NCT03755804|Radiation|Radiotherapy|Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
75735849|NCT00944762|Behavioral|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
76071918|NCT03754660|Drug|BAY1237592|Oral inhalation with dry powder inhaler, single dose.
75442784|NCT01658176|Drug|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
75442785|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
75592647|NCT04040400|Radiation|intraoperative radiotherapy (IORT)|intraoperative radiotherapy (IORT) during brain tumor resection to establish a maximum tolerated dose (MTD) through a dose-escalation trial using intraoperative radiotherapy (IORT)
75735850|NCT00944762|Behavioral|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
75592648|NCT04027972|Drug|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
75592649|NCT04027972|Device|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
75735851|NCT04012892|Combination Product|CD19 CART|CD19 CART
75735852|NCT03070301|Drug|LEE011|LEE011 200 mg daily
75735853|NCT03070301|Drug|everolimus|everolimus 5 mg daily or 2.5mg daily
75442786|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
75442787|NCT01658202|Drug|V0116 transdermal patch (Test treatment )|
75442788|NCT01658202|Drug|Nicotine transdermal patch (Reference Treatment )|
75442789|NCT01658215|Drug|V0116 transdermal patch (Test treatment )|
75442790|NCT01658215|Drug|Nicotine transdermal patch (Reference treatment )|
75442791|NCT01658254|Other|survey by email|"The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention."
75442792|NCT01658267|Other|nutritional supplement|2 servings per day
75616240|NCT02850796|Other|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
75769137|NCT03908086|Other|Risk factors in RA cohort|
75884938|NCT03571230|Drug|two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)|Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
75884939|NCT03571230|Drug|one proton pump inhibitor(PPI)|All the patients need this drug.
75442793|NCT01658280|Device|EBUS-TBNA|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
75442794|NCT01658306|Procedure|remote ischemic preconditioning|RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
75442795|NCT01658306|Procedure|sham remote ischemic preconditioning|Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
75442796|NCT01657396|Procedure|Standard Oral Hygiene|Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
75735854|NCT00940862|Biological|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
75735855|NCT00940862|Device|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
75735856|NCT00940862|Other|Topical treatment|"This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids."
75735857|NCT03068741|Drug|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
75735858|NCT03068741|Drug|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
75735859|NCT03068741|Drug|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
76056112|NCT04720703|Behavioral|Family-based Telehealth Intervention|All communications related to the intervention will occur through weekly small group video conferencing calls via Zoom and emails or text messages. The intervention will include diverse topics proven effective in prior interventions (Davis et al., 2019; McLean et al., 2003), including reading food labels, eating out, eating at social gatherings, sticker charts, praising/rewarding healthy choices, healthy foods available at home, portion sizes, healthy/easy/low-cost cooking ideas, goal setting, monitoring screen time, exercise opportunities available in neighborhood, family exercise ideas, and healthy sleep. The research team will also send relevant video/audio clips, brochures, reminders (text messages and emails) every week.
76056113|NCT04677543|Drug|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes.
76056114|NCT04677543|Drug|Azithromycin|Oral tablet
75592650|NCT04026009|Biological|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
75592651|NCT04026009|Biological|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
75592652|NCT04026009|Drug|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
75884940|NCT03571230|Drug|Colloidal Bismuth Pectin|All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
75735860|NCT03068741|Drug|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is <90mmHg and continued until systolic blood pressure is >=100mmHg.
75442797|NCT01657396|Procedure|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
75735861|NCT04012580|Behavioral|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
75442798|NCT01657396|Procedure|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
75442799|NCT01658319|Drug|fludarabine phosphate|Given IV
75884941|NCT03571230|Drug|two antibiotics for failed eradication(tetracyclin,furazolidone)|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
75884942|NCT03644615|Other|Mindfluness and usual care|Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
75884943|NCT03644615|Other|Usual care|No intervention on the patients
75884944|NCT01468454|Drug|18 F-DOPA|1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
75884945|NCT01366781|Other|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
75884946|NCT02143700|Other|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
75884947|NCT04151225|Drug|GSK2330811|GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
75884948|NCT04151225|Drug|Placebo|Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
75735862|NCT03937661|Biological|PRP|Autologous PRP intra ovarian infusion
75884949|NCT03067077|Procedure|SMILE|SMILE surgery
75442800|NCT01658319|Drug|methoxyamine|Given IV
75735863|NCT03937661|Biological|Placebo|Autologous PFP intra ovarian infusion
75735864|NCT04012502|Other|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
75442801|NCT01658319|Other|laboratory biomarker analysis|Correlative studies
75442802|NCT01658319|Other|pharmacological study|Correlative studies
75442803|NCT01658319|Genetic|western blotting|Correlative studies
75442804|NCT01658319|Other|mass spectrometry|Correlative studies
75442805|NCT01658319|Genetic|DNA analysis|Correlative studies
75442806|NCT01658332|Other|blood samples|3 tubes (15 ml)
75442807|NCT01658358|Drug|Lapatinib|"dose level I, II 1000mg po daily~dose level III, IV 1250mg po daily"
75735865|NCT04012502|Other|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
75769138|NCT03908086|Other|Risk factors in general population|
75769139|NCT01148290|Procedure|Tension free vaginal tape|Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
75769140|NCT01148290|Procedure|Bulking agent injection|Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
75769141|NCT00197028|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
75769142|NCT00197028|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
75769143|NCT00197028|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
75884950|NCT03067077|Procedure|LASIK|LASIK surgery
75884951|NCT02143856|Drug|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
75884952|NCT03545438|Biological|LIB003|LIB003 or placebo
75884953|NCT01372709|Device|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
75884954|NCT02939612|Behavioral|App for stress management|An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
75884955|NCT02254226|Drug|Salmeterol Diskus low|
75884956|NCT02254226|Drug|Salmeterol Diskus high|
75884957|NCT02254226|Drug|Salmeterol MDI low|
75884958|NCT02254226|Drug|Salmeterol MDI high|
75884959|NCT02143934|Drug|Primaquine|
75884960|NCT02143934|Drug|Placebo|Sugar pills, appearance identical to Primaquine tablets
76056115|NCT04677543|Drug|Ethambutol|Oral tablet
75735866|NCT04062149|Other|single leg stance treatment|SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
75592653|NCT04013854|Drug|nivolumab|All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.
76056116|NCT04677543|Drug|ELC|Inhalation via nebulization over approximately 6 to 15 minutes.
75442808|NCT01658358|Drug|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
75442809|NCT01658397|Behavioral|Fasting|Ten day fast
75592654|NCT04013854|Drug|Ipilimumab|Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )
75442810|NCT01658410|Drug|BQ-123|BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
75592655|NCT03995316|Behavioral|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
75592656|NCT03995316|Behavioral|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
75592657|NCT03951012|Procedure|Blood draw|Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).
75735867|NCT04062149|Other|Usual physiotherapy|Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
75442811|NCT01658410|Drug|NaCl|NaCl, Route: intracoronary
75592658|NCT03927690|Drug|LKA651|LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
75592659|NCT03927690|Drug|Lucentis|Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
75592660|NCT03864068|Other|Placebo|Placebo
75442812|NCT01658449|Other|Inhalable Hypertonic saline 7% + Hyaluronan 0.1%|Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
75442813|NCT01658449|Other|Inhalable Hypertonic saline 7%|Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
75442814|NCT01658462|Drug|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
75442815|NCT01658462|Drug|Nintedanib|"200 mg x 2 per os daily from D2*~*No Nintedanib on days when docetaxel is administered"
75592661|NCT03864068|Drug|Inositol|1gm/bid, 2gm/bid or 3gm/bid of Inositol powder
75592662|NCT03833921|Drug|Abiraterone Acetate|1000 mg orally daily until disease progression
75769517|NCT01589692|Procedure|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
75884961|NCT02143934|Drug|Chloroquine|
76056117|NCT04671511|Procedure|Targeted Axillary Dissection|Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)
76056118|NCT04671511|Diagnostic Test|Ultrasound of the axilla|Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.
76071919|NCT03752827|Device|Adipose Derived Regenerative Cells|Adipose-derived regenerative cells isolated with the Transpose Ultra system
75592663|NCT03833921|Drug|Prednisone|5 mg oral low dose prednisone, twice daily
75735868|NCT02565563|Other|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
75884962|NCT02143934|Drug|Artemether Lumefantrine|
75884963|NCT01366859|Dietary Supplement|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
75442816|NCT01658462|Drug|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
75884964|NCT01366859|Dietary Supplement|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
75884965|NCT03096847|Drug|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
75909532|NCT02899754|Behavioral|Control Intervention|This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
75442817|NCT01658488|Other|Non-fortified rice|Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
76071920|NCT03752827|Drug|Corticosteroid|Corticosteroid injection into subacrominal space
75442818|NCT01658488|Other|Iron-fortified Rice|Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
75592664|NCT03821246|Drug|Atezolizumab|Given IV
75592665|NCT03821246|Drug|Tocilizumab|Given IV
75442819|NCT01658527|Drug|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy"
75442820|NCT01658527|Drug|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
75442821|NCT01658553|Drug|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
75442822|NCT01658592|Other|Deep brain stimulation|Stimulator setting is ON
75442823|NCT01658592|Other|Placebo|Stimulator setting is OFF
75442824|NCT01658605|Drug|GSK1605786|500 mg twice daily administered orally
75442825|NCT01658605|Other|Placebo|500 mg twice daily administered orally
75442826|NCT01658618|Biological|HP802-247|
75592666|NCT03821246|Drug|Etrumadenant|Given Orally
75592667|NCT03806985|Drug|Placebo oral capsule|microcrystalline cellulose capsule
75592668|NCT03806985|Drug|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
75592669|NCT03806985|Drug|High Dose Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
75592670|NCT03793842|Other|Usual care|Intervention is the standard basic lung protective ventilation strategy used at the University Hospital Respiratory Care at Michigan Medicine.
75592671|NCT03793842|Device|PEEP titration by EIT|PEEP Titration procedure involves two phases: a recruitment phase followed by a gradual reduction in the end-expiratory pressure phase (Decremental PEEP).
75592672|NCT03763604|Drug|Abemaciclib|Administered orally.
75735869|NCT02565563|Device|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
75735870|NCT00561080|Biological|Zostavax|
75735871|NCT01307306|Drug|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
75735872|NCT01307306|Drug|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
75735873|NCT00941096|Drug|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
75769518|NCT01589692|Procedure|Percutaneous Pinning|Pinning with any number of Kirschner wires
75884966|NCT03096847|Drug|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
75884967|NCT03096847|Drug|goserelin|Premenopausal patients additionally received goserelin 3.6mg as monthly implant
75884968|NCT01365182|Behavioral|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
75884969|NCT01365182|Behavioral|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
75884970|NCT05190107|Diagnostic Test|DASS-21 scale|"Each construct consists of 7 questions. The participants must select the answer that better represents their feelings over the last week in each scenario. Each question has a Likert scale of 4 options where 0 represents did not apply to me to 3 applied to me very much."
75884971|NCT02144090|Device|Fractional flow reserve measurement|Fractional flow reserve measurement
75592673|NCT03739411|Radiation|Hyperpolarized Carbon C 13 Pyruvate|Given IV
75442827|NCT01658631|Device|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
75884972|NCT03019575|Drug|Corifollitropin alfa|CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight >60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
75884973|NCT03019575|Drug|hCG|hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
75442828|NCT01658644|Other|Provision of Clinical Care Handout|Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.
75592674|NCT03739411|Procedure|Magnetic Resonance Imaging|Undergo MRI
76056119|NCT04662840|Procedure|Geniculate artery embolization|Under fluoroscopic guidance and angiographic imaging, a microcatheter is used to select all the arteries feeding the affected knee and Embosphere (100-300um) particles are injected to obtaining pruning of the hypervascular tissues arteries.
75592675|NCT03739411|Radiation|Radiation Therapy|Undergo radiation therapy
75735874|NCT04012424|Drug|curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf|"effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric"
75735875|NCT04012424|Dietary Supplement|400mg starch|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
75909533|NCT03475238|Procedure|Nursing care|The nursing care will be defined as a lateral mobibization and a length of care superior or equal to 10 min
75909534|NCT02737592|Device|"Trojan Simply Pleasure Personal Lubricant"|silicone base without sensate
75909535|NCT02720432|Other|CIMT|Constraint-induced movement therapy
76056120|NCT04662840|Procedure|Geniculate nerve ablation|Under fluoroscopic guidance, a Cool-tip RFA ablation needle is advanced such that it touches the femur at the condylar convexity on each side and the tibia at the tibial plateau convexity on the medial side. The ablation is performed to obtain an approximate zone of ablation of 2cm.
76071921|NCT03745651|Drug|Ruxolitinib cream|Ruxolitinib 0.75% or 1.5% cream.
76071922|NCT03745651|Drug|Vehicle cream|Ruxolitinib matching vehicle cream.
75442829|NCT01658696|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu heterologous prime-boost immunisation
75442830|NCT01658696|Biological|Rabies vaccine|2 x 2.5IU Verorab
75442831|NCT01658722|Drug|Bapineuzumab|
75592676|NCT03739411|Drug|Temozolomide|
75592677|NCT03721653|Drug|Bevacizumab|5 mg/kg iv over 30 minutes day 1
75592678|NCT03721653|Drug|Irinotecan|165 mg/sqm iv over 60 minutes day 1
75592679|NCT03721653|Drug|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
75592680|NCT03721653|Drug|L-Leucovorin|200 mg/sqm iv over 2 hours day 1
75592681|NCT03721653|Drug|5-fluorouracil|3200 mg/sqm 48 h-continuous infusion
75592682|NCT03721653|Drug|Atezolizumab|840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
75592683|NCT03709992|Drug|Trospium Chloride|30 mg of Trospium chloride tablet twice daily
75592684|NCT03709992|Drug|Tamsulosin|0.4 mg of Tamsulosin tablet once daily
75592685|NCT03699345|Device|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards CENTERA THV System and accessories
75616241|NCT04802200|Other|Data collect|Data collect following a vascular closure by MANTA
75616242|NCT03630562|Procedure|Aqueous humor samples collection|In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
75442832|NCT01658748|Device|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.
75592686|NCT03696225|Behavioral|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
75592687|NCT03696225|Behavioral|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
75592688|NCT03658694|Procedure|Conventional rTMS - study 1|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
75592689|NCT03658694|Procedure|Sham rTMS - study 1|Patients will be undergoing to sham transcranial magnetic stimulation session
75592690|NCT03658694|Procedure|Conventional rTMS - study 2|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
75592691|NCT03658694|Procedure|Patterned rTMS - stage 2|Patients will be undergoing to theta-burst transcranial magnetic stimulation session
75735876|NCT00562094|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
75735877|NCT03817853|Drug|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
75735878|NCT03817853|Drug|Bendamustine|Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
75735879|NCT03817853|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
75735880|NCT03817853|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
75735881|NCT03817853|Drug|Prednisone/Prednisolone/Methylprednisolone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
75735882|NCT03817853|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
75735883|NCT02565251|Device|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
75735884|NCT02565251|Device|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
75735885|NCT02565251|Device|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
75735886|NCT02565095|Procedure|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
75909536|NCT02720432|Other|HABIT|hand-arm bimanual intensive training
75909537|NCT02720432|Other|baby-massage|instructions for baby-massage
75909538|NCT03475160|Drug|Sildenafil Citrate vaginal suppositories|Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
75735887|NCT02567045|Procedure|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
75884974|NCT03634709|Behavioral|Memory Flexibility training (MemFlex)|MemFlex is a primarily self-guided, paper workbook-based program which aims to reduce overgeneral memory bias and improve recall of positive, specific event memories. Prior to completing one month of self-guided, workbook-based intervention, the participant will attend one 45 minute face-to-face session in which the facilitator outlines the importance of autobiographical memory in everyday life, discusses the impact of trauma on autobiographical memory, and provides information on the different types of autobiographical memories (e.g., specific, general) and their potential everyday functions. The session also introduces the cued-recall tasks which were used to train the memory skills throughout the workbook, and provides facilitator-assisted practice with the tasks. Once participants are comfortable with the training exercises, they set a schedule for completion of the eight-session workbook over the following four weeks.
75884975|NCT02144168|Dietary Supplement|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
75884976|NCT02144168|Dietary Supplement|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
75909539|NCT03475160|Drug|Placebo vaginal suppositories|Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
75592692|NCT03606499|Drug|Ustekinumab|No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
75735888|NCT02567045|Procedure|colonoscopy with sedation|One-time Colonoscopy with sedation.
75735889|NCT00944840|Drug|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
75735890|NCT00944840|Drug|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
75884977|NCT03128099|Behavioral|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
75884978|NCT03545516|Drug|Bupivacaine|Injection of bupivacaine into the surgical incision prior to its closure.
75884979|NCT03545516|Drug|Dexmedetomidine|Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
75884980|NCT03545516|Drug|Placebo|Injection of a placebo into the surgical wound
75884981|NCT04756453|Device|clip-traction|A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
76056121|NCT04662840|Procedure|Skin infiltration of local anesthetic at groin and knee|Freezing of the skin will be performed at the groin (as prior to an arterial access for embolization procedure) and at three areas around the knee (as prior to insertion of the ablation needles for nerve ablation procedure).
75442833|NCT01658748|Device|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
75442834|NCT01658761|Procedure|vitrectomy|Surgery
75592693|NCT03601286|Drug|Lentiviral vector transduced CD34+ cells|Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
75884982|NCT04545333|Diagnostic Test|clonoSEQ Assay|minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells
75884983|NCT01372787|Procedure|Assessment of Therapy Complications|Ancillary studies
75442835|NCT01658774|Drug|Albendazole|Single 400mg dose
75592694|NCT03597100|Device|Cala TWO|Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
75592695|NCT03587688|Procedure|mitral valve surgery|pre-, intra- and postoperative data on patients undergoing mitral valve surgery at the Department for Cardiac Surgery of Universitätsspital Basel/ Switzerland since 2009
75592696|NCT03570632|Drug|Metformin|Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
75884984|NCT01372787|Other|Medical Chart Review|Ancillary studies
75884985|NCT01372787|Other|Quality-of-Life Assessment|Ancillary studies
76056122|NCT04633317|Device|A pneumatic nebulizer|Inhaled colistimethate sodium generated by a pneumatic nebulizer
76056123|NCT04633317|Device|A vibrating mesh nebulizer|Inhaled colistimethate sodium generated by a vibrating mesh nebulizer
76056124|NCT04630951|Other|Blood Flow Restriction Strength training with low load|Low Load (20-50% 1RM), 4 set of 30/15/15/15 repetitions, 30 seconds resting between sets.
75592697|NCT03555695|Behavioral|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief.
75735891|NCT00439270|Drug|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
75592698|NCT03555695|Behavioral|Pre-Intervention Focus Group|At the pre-intervention focus group, the study logistics will be reviewed, informed consent process will occur, the subject will complete a brief, individual pre-intervention assessment focused on overall mobility, gait, balance, mood, neurological status, and quality of life, and the subjects will be prompted to share aloud their thoughts on exercise, balance, and mindfulness practices in general and in PD specifically, and any expectations or preconceptions that they have regarding karate classes for PD.
75735892|NCT00439270|Drug|Docetaxel|Infusion, 60 or 75 mg/m^2, administered every 3 weeks.
75735893|NCT00944918|Drug|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
75735894|NCT00944918|Drug|anastrozole|Tablet, oral, once daily until disease progression.
75735895|NCT00944918|Drug|exemestane|Tablet, oral, once daily until disease progression.
75735896|NCT04012268|Device|RIC|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
75735897|NCT04012268|Drug|Aspirin|patients will accept medication guided by neurologists
75735898|NCT03995134|Combination Product|Propofol and Remifentanil administered by TCI pump|Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
75735899|NCT00553280|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
75735900|NCT01024192|Drug|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
75735901|NCT01024270|Drug|Misoprostol|
75735902|NCT00944996|Drug|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
75735903|NCT03266536|Behavioral|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with < 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
75735904|NCT00950066|Drug|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
75884986|NCT01372787|Other|Questionnaire Administration|Ancillary studies
75884987|NCT02886494|Drug|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
75884988|NCT02886494|Drug|Matched vehicle|BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
75884989|NCT04660903|Procedure|Autologous fat cell transplantation|Up to 75 ml of fatty tissue mixture fluid
75884990|NCT04519749|Biological|4D-310|4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).
75735905|NCT00950066|Drug|Amlodipine|Oral administration of Amlodipine 5mg once a day
75884991|NCT00204477|Dietary Supplement|soy milk|Each drink contained soy protein, fat, and carbohydrates calcium and phosphorous to give a total energy of 177.8 kcal. Subjects took two drinks per day.
76056125|NCT04630951|Other|High Load Strength Training|High Load (60-80% 1RM) 4 sets of 8 repetitions, 2 minutes resting between sets
75442836|NCT01658774|Dietary Supplement|Vitamin C|500 mg Vitamin C
75442837|NCT01658800|Biological|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
75442838|NCT01658852|Drug|metronidazole|
75442839|NCT01658852|Drug|Placebo|
75442840|NCT01658891|Drug|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
75442841|NCT01658891|Drug|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
75442842|NCT01658956|Drug|GCSF administration on days 8 and 12 after chemotherapy|
75442843|NCT01658982|Other|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
75592699|NCT03555695|Behavioral|Post-Intervention Focus Group|At the post-intervention focus group, the pre-intervention assessments will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
75592700|NCT03538691|Drug|Brexpiprazole|Administered as tablets.
75592701|NCT03538691|Drug|Antidepressant therapy|"Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules."
75735906|NCT00950066|Drug|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
75735907|NCT00950066|Drug|Placebo|Oral administration of a placebo once a day
75735908|NCT01031212|Drug|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
75735909|NCT01031212|Drug|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
75735910|NCT01031212|Drug|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
75735911|NCT01031212|Drug|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
75884992|NCT00204477|Dietary Supplement|cow's milk|Each drink contained casein, fat, carbohydrates, calcium and phosphorous to give a total energy of 178.6 kcal. Subjects took two drinks per day.
75884993|NCT02835326|Behavioral|Exercise and Dietary Weight Loss|The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.
75884994|NCT02835326|Behavioral|Walk with Ease|The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
75735912|NCT00950144|Other|medical chart review|
75735913|NCT00950144|Other|questionnaire administration|
75735914|NCT00950144|Other|study of socioeconomic and demographic variables|
75884995|NCT04514367|Drug|ANX005|Intravenous Infusion
75884996|NCT03545048|Other|Internet based exercises|Exercises for knee OA (online- digital health)
75909540|NCT03475160|Procedure|Uterine artery Doppler before treatment|Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
75442844|NCT01659008|Drug|Estradiol|
75442845|NCT01659008|Drug|Lysteda|
75442846|NCT01659034|Drug|Thienopyridine for 3 months|
75442847|NCT01659047|Drug|GS-1101|150 mg taken twice daily by mouth
75442848|NCT01659060|Other|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
75735915|NCT00950144|Procedure|quality-of-life assessment|
75735916|NCT01024348|Drug|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
75735917|NCT01024348|Drug|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
75735918|NCT00945074|Other|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
75735919|NCT00945074|Other|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
75735920|NCT00945074|Other|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
75735921|NCT03994744|Drug|PD-1 inhibitor|Intravenous administration of Sintilimab (1200mg/3weeks)
75769519|NCT01589692|Procedure|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
75769520|NCT01151254|Drug|Isoflurane/sevoflurane|Volatile for sedation in the CVICU while intubated
76056126|NCT04580459|Behavioral|CARE Parenting Group Treatment|The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.
75735922|NCT03994744|Drug|Metformin|"Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week."
75735923|NCT00950222|Drug|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
75735924|NCT01031290|Device|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
75735925|NCT05301530|Drug|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
75735926|NCT05301530|Drug|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
75735927|NCT05301530|Drug|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
75735928|NCT03228160|Other|Linearly Polarized Near-Infrared light Irradiation|The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
75735929|NCT00941174|Drug|13C5-Calcium-L-Leucovorin|This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
75769521|NCT01151254|Other|Propofol|Propofol for sedation in the CVICU
76056127|NCT04580459|Behavioral|Treatment as Usual (TAU)|Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
76056128|NCT04546568|Device|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC|"FiO2 adjustments will be made by the Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical, Germany).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
76056129|NCT04546568|Device|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
75442849|NCT01659060|Other|Placebo Chocolate|Placebo intervention
75442850|NCT01659073|Procedure|Caloric Vestibular Stimulation|
75442851|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
75592702|NCT03511664|Drug|177Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
75442852|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
75442853|NCT01659086|Biological|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
75735930|NCT00950456|Biological|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
75735931|NCT00440518|Drug|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
75735932|NCT00440518|Other|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
75884997|NCT02846532|Drug|Rivaroxaban|Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to <8 kilogram (kg) will receive 2.2 milligram (mg); 8 to <10 kg will receive 3.2 mg; 10 to<12 kg will receive 3.4 mg; 12 to <20 will receive 4.0 mg and 20 to <30 will receive 5.0 mg.
75884998|NCT02846532|Drug|Acetylsalicylic Acid|Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
75884999|NCT02809521|Other|Activity Liking|
75885000|NCT02744001|Other|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
75442854|NCT01659099|Drug|GA101|in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
75442855|NCT01659099|Drug|Rituximab|in R-ACBVP or in R-CHOP 375 mg/m² on D1
75885001|NCT03634631|Other|Focused Ultrasound|Test ultrasound in 7T MRI scanner
75442856|NCT01659099|Drug|Doxorubicin|in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
75442857|NCT01659099|Drug|Cyclophosphamide|in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
75735933|NCT00440518|Drug|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
75735934|NCT00945230|Procedure|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
75885002|NCT01371461|Drug|Paroxetine|
75885003|NCT02731521|Device|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
76056130|NCT04544293|Drug|Molgramostim|Molgramostim 300 µg nebulizer solution
76056131|NCT04544293|Drug|Placebo|Matching placebo
76056132|NCT04513548|Drug|Ligelizumab|One injection every four weeks
75442858|NCT01659099|Drug|Prednisone|in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
75442859|NCT01659099|Drug|Bleomycin|in ACBVP 10 mg from D1 to D5
75442860|NCT01659099|Drug|Vindesin|in ACBVP 2 mg/m² from D1 to D5
75442861|NCT01659099|Drug|Vincristine|in CHOP 1,4 mg/m² on D1
75442862|NCT01659112|Other|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
75442863|NCT01659112|Other|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
75442864|NCT01659164|Behavioral|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
75442865|NCT01659177|Drug|LY2140023|Administered orally
75442866|NCT01659190|Other|Oiled-limestone liniment|
75442867|NCT01659203|Radiation|IG-IMPT|Daily, Monday-Friday for about 6 weeks
75442868|NCT01659203|Radiation|IG IMRT|Daily, Monday-Friday for about 6 weeks
75592703|NCT03511664|Other|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator
75592704|NCT03490760|Drug|Durvalumab|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks
75592705|NCT03490760|Radiation|Radiation Therapy|24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
75592706|NCT03407417|Other|virtual technology - highly tailored|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Highly tailored patient reminders will be customized using all 12 constructs.
75885004|NCT02731521|Device|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
75885005|NCT02728557|Behavioral|Supportive-Expressive Therapy|Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
75885006|NCT02728557|Behavioral|Supportive Therapy|Supportive psychotherapy for depressive disorder for 16 weeks.
75885007|NCT03571152|Other|Educational videos|The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
75885008|NCT05337527|Dietary Supplement|beetroot juice|Acute effects of beetroot juice or placebo juice ingestion
75885009|NCT05324423|Drug|Colchicine|Colchicine0.5 mg Oral Tablet Day-7~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
75885010|NCT03570138|Device|FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System|Specific therapeutic education for diabetes self management
75885011|NCT03570138|Device|Usual self monitoring Blood Glucose device|Standard therapeutic education for diabetes self management
75442869|NCT01659242|Drug|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
75442870|NCT01659242|Drug|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
75442871|NCT01659281|Drug|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
75442872|NCT01659281|Drug|Artesunate|4 mg/kg/day for 3 days
75442873|NCT01659281|Drug|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
75442874|NCT01659281|Drug|Mefloquine|8 mg/kg daily for 3 days
75592707|NCT03407417|Other|virtual technology - tailored minimally|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Minimally tailored patient reminders will be customized using 4 randomly selected constructs.
75592708|NCT03398135|Drug|risankizumab|subcutaneous (SC) injection
75592709|NCT03398135|Drug|placebo for risankizumab|subcutaneous (SC) injection
75592710|NCT03383874|Combination Product|Probio-Tec BG-VCap-6.5|"The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally."
75735935|NCT00950534|Drug|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
75442875|NCT01659294|Behavioral|Nurse Case Management|
75442876|NCT01659294|Behavioral|standard diabetologist care|routine care by diabetologist & team
75735936|NCT00950534|Drug|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
75735937|NCT01029964|Behavioral|Individually and in groups|During three year in a clinical setting.
75735938|NCT00941252|Drug|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
75735939|NCT01031368|Drug|cytarabine|Given IV
75735940|NCT01031368|Drug|clofarabine|Given IV
75735941|NCT01031368|Drug|filgrastim|Given SC
75735942|NCT01031368|Biological|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
75442877|NCT01659346|Procedure|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication.
75442878|NCT01659346|Drug|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
75442879|NCT01659359|Device|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
75442880|NCT01659359|Drug|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
75442881|NCT01659372|Radiation|low level laser therapy|
75442882|NCT01659372|Drug|Naproxen|
75442883|NCT01659398|Device|External Counterpulsation (EECP)|A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
75442884|NCT01659411|Other|Observational|Yearly clinical visits
76056133|NCT04513548|Drug|Placebo|One injection every four weeks
76056134|NCT04502082|Biological|ET140203 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
75592711|NCT03383874|Other|Placebo|This placebo is made almost identically to the Probio-Tec but without active microorganisms.
75442885|NCT01659424|Radiation|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
75442886|NCT01659437|Drug|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
75592712|NCT03370016|Procedure|Amount of Pneumoperitoneum Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
75592713|NCT03364803|Other|Cushing's QoL (Quality of Life Questionnaire)|Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
75592714|NCT03364803|Other|Nottingham Health Profile (NHP)|NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
75592715|NCT03364803|Other|Hospital Anxiety and Depression Scale (HADS)|HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
75735943|NCT01031368|Other|laboratory biomarker analysis|Correlative studies
75735944|NCT00945308|Drug|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
75735945|NCT00945308|Drug|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
75735946|NCT00950768|Procedure|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
75735947|NCT03172936|Drug|MIW815|MIW 815 (ADU-S100) is a STING agonist
75735948|NCT03172936|Biological|PDR001|PDR001 is an anti-PD-1 antibody
75735949|NCT00950924|Device|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
75735950|NCT00950924|Device|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
75735951|NCT01024426|Procedure|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
76056135|NCT04495998|Diagnostic Test|Brief Motor Scale_portuguese version (BMS_pt)|translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
76056136|NCT04485494|Diagnostic Test|Biochemical Analysis of Blood Biomarkers|Using established biochemical techniques, the bloods will be probed for specific biomarkers s100B, UCH-L1, GFAP, and BDNF. The techniques include individual ELISA kits for each biomarker mentioned and Luminex multiplate assay which will probe for all biomarkers in one plate. Ultimately, these techniques will be able to measure the level of these biomarkers in the blood relative to the participants baseline reading.
75442887|NCT01659437|Drug|Streptomycin intramuscular injection|daily intramuscular drug injection
75442888|NCT01659450|Other|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
76071923|NCT03745638|Drug|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
75442889|NCT01659450|Other|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
75442890|NCT01659450|Other|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
75442891|NCT01659463|Other|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
75442892|NCT01659463|Behavioral|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
75885012|NCT02659605|Procedure|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
75885013|NCT02659605|Procedure|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
75885014|NCT03570060|Biological|Blood sample|2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
75885015|NCT03570060|Procedure|Long term ECG monitor|Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
75442893|NCT01659476|Other|Methacholine(MCh) Challenge Testing|"Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine."
75442894|NCT01659476|Other|Methacholine(MCh) Challenge Testing|"Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.~Visit 2: Subjects will perform the opposite protocol, based on their first visit:"
75442895|NCT01659502|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
75735952|NCT01024426|Other|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
75885016|NCT03570060|Procedure|Monitoring ECG|Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
75885017|NCT05232539|Device|Intraoperative Optical Coherence Tomography (iOCT)|The use of iOCT during surgery offers the advantage of a new view of the operating field, theoretically allows more precise performance and can also change decision-making mechanisms during surgery with more precise visual control of some surgical steps.
75885018|NCT02242188|Drug|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
75442896|NCT01659515|Drug|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
75735953|NCT00951002|Procedure|acellular dermal matrix plug|anal fistula treated with human acellular dermal matrix plug
75735954|NCT01030042|Drug|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
75885019|NCT02242188|Dietary Supplement|Placebo|Maltodextrin (packed in identical sachets as active products)
75885020|NCT04704843|Drug|Guselkumab|Guselkumab will be administered as IV infusion (induction dose) and SC injection.
75885021|NCT04704843|Drug|Placebo|Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
75885022|NCT03572712|Other|No Interventional study|every patient will be monitored with a blood gase, a nocturnal oximetry and a transcutaneous capnography
75885023|NCT05189873|Drug|Long GnRH agonist + HRT|Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
75885024|NCT05189873|Drug|HRT|In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
75885025|NCT02524080|Procedure|Triage to optimal healthcare level|Triage to optimal healthcare level
75885026|NCT01367015|Other|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
75885027|NCT01367015|Other|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
75885028|NCT01371617|Drug|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
75885029|NCT04051671|Device|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy. Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 2 weeks. The two experiments will be performed in random order for each subject.
75885030|NCT02243982|Other|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
75885031|NCT02552277|Biological|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
75885032|NCT02552277|Drug|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
75885033|NCT05185817|Biological|Pasocovac vaccine|All enrolled post-Allo-SCT participants who meet the inclusion criteria are recruited to study from 3 to 12 months after Allo-HSCT and vaccinated with 2 doses of Pastucovac, with a 4-week (±7 days) interval and a booster dose at an 8-week (±7 days) interval from the second dose.
75885034|NCT03571074|Other|Oxygenation|Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
75442897|NCT01659580|Drug|T89 high dose|225mg bid
75442898|NCT01659580|Drug|T89 Low dose|150mg bid
75442899|NCT01659580|Drug|Sanqi+Bingpian|225 mg bid
75592716|NCT03364803|Other|Perceived Stress Scale (PSS)|The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
75592717|NCT03364803|Other|Barratt's Impulsivity Scale (BIS)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
75885035|NCT00842348|Drug|lanreotide (Autogel formulation)|Autogel 120 mg
75885036|NCT03095599|Biological|IVACFLU-S|"IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA"
75885037|NCT03095599|Other|Placebo|Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
75885038|NCT03569826|Other|Observational; no intervention|Observational; no intervention
75885039|NCT02144246|Other|Non-hormonal period|
75885040|NCT02144246|Drug|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
76071924|NCT03745638|Drug|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
76071925|NCT03742050|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
75442900|NCT01659580|Drug|Placebo|225mg bid
75442901|NCT01659593|Other|procog|3 to 5 people group program
75442902|NCT01659593|Other|Placebo|
75442903|NCT01659619|Drug|Erythromycin|125mg in normal saline single use infusion for 5 min.
75442904|NCT01659645|Drug|FACBC|Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
75442905|NCT01659671|Procedure|Uvulopalatopharyngoplasty|Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
75442906|NCT01659684|Biological|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
75592718|NCT03364803|Other|Beck Depression Inventory (BDI)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
75592719|NCT03364803|Other|State-Trait Anxiety Inventory (STAI)|The STAI provides data to help distinguish between anxiety and depression.
76056137|NCT04484948|Other|scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT|"Participants will perform the SHAQ.~BHT and 6MWT will be performed in the randomized way for each participant.~For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~6MWT will be performed according to the ATS guidelines.~Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT."
75735955|NCT01030042|Drug|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
76056138|NCT04480255|Other|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~a welcome packet from the nursing staff~access to their infant's medical team including doctors and nurse~opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
75885041|NCT03569670|Device|Posterior stabilized all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
75885042|NCT03569670|Device|Cruciate retaining all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
75885043|NCT03544502|Device|CD player|CD player opened during anesthesia induction and continued until postoperative 15 minute
76056139|NCT04480255|Other|Group 2: NICU2HOME+ app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
75442907|NCT01659697|Behavioral|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
75442908|NCT01659723|Drug|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
75442909|NCT01659762|Biological|autologous mesenchymal stromal cell|
75735956|NCT00941408|Procedure|Diagnostic tumor core biopsy|
75735957|NCT01024504|Drug|Oxaliplatin|Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
75735958|NCT01024504|Drug|Capecitabine|Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
75735959|NCT01024504|Drug|Bevacizumab|Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
75735960|NCT00945464|Other|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
75592720|NCT03364803|Other|State Food Craving Questionnaire-State (FCQ-S)|The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
75735961|NCT01030120|Drug|etanercept|etanercept 50mg BIW S.Q.
75735962|NCT01030120|Drug|placebo|placebo
75735963|NCT04012112|Device|thoracolumbar brace (Flexpine brace)|Patient's would wear the FLEXpine brace over 18 hours a day for the 6 month
75735964|NCT01024582|Procedure|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
75735965|NCT01024582|Procedure|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
75735966|NCT01024582|Radiation|accelerated partial breast irradiation|
75735967|NCT01024582|Radiation|image-guided radiation therapy|
75735968|NCT00941564|Other|Infant Formula milk based|Consume ad lib
75735969|NCT00941564|Other|Infant formula milk based|consume ad lib
75885044|NCT03544502|Device|CEL-480 Sound Level Meter Sonometre|Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.
75885045|NCT03544502|Device|Earplug|the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.
75735970|NCT00951158|Dietary Supplement|Conjugated Linoleic Acid|"This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression."
75885046|NCT03544502|Procedure|Ambient operating room noise|patients were exposed to the ambient operating room noise.
76056140|NCT04469231|Device|Anterior Cervical Discectomy & Fusion|ACDF
76056141|NCT04448951|Other|transcriptomics|transcriptomics
75442910|NCT01659788|Dietary Supplement|Coenzyme Q10 concomitant treatment|
75592721|NCT03364803|Other|Trait Food Craving Questionnaire-Trait (FCQ-T)|Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
75735971|NCT00951158|Drug|Conjugated Linoleic Acid|Phase I Dose Escalation Study
75735972|NCT00951236|Drug|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
75442911|NCT01659788|Dietary Supplement|Placebo|
75592722|NCT03364803|Other|Visual Analogue Scale (VAS)|"A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark."
75735973|NCT00951236|Drug|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
75885047|NCT03572556|Biological|Blood samples|"5 mL dry tube to separate serum~Two 6 mL EDTA tubes for plasma separation~Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers."
75885048|NCT03572556|Other|Epistaxis charts|Three monthly epistaxis charts to be completed
75885049|NCT03095521|Drug|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
75885050|NCT03095521|Drug|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
75885051|NCT01372865|Drug|Mometasone furoate|
76056142|NCT04448951|Other|flow-cytometry|peripheral blood myeloid cells and lymphocytes flow-cytometry
76056143|NCT04448951|Other|cytokines|peripheral blood cytokine analysis
76056144|NCT04448080|Device|Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)|Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
75442912|NCT01659801|Device|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
75442913|NCT01659827|Other|Marcaine|Injection of 2cc of Marcaine
75442914|NCT01659827|Other|0.5cc AmnioFix|Injection of 0.5cc of AmnioFix Injectable
75442915|NCT01659827|Other|1.25cc AmnioFix|Injection of 1.25cc of AmnioFix Injectable
75442916|NCT01659827|Other|Saline|Injection of 1.25cc of Saline
75885052|NCT01372865|Drug|Mometasone furoate|
75885053|NCT05368116|Other|Video Assisted Self Management Program|"The main aim of this intervention is to educate the cancer patients receiving chemotherapy regarding the management of chemotherapy related side effects.~It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including nausea vomiting , Diarrhea , Fever , Mucositis , Skin changes , and Alopecia related distress.~The participants were given video when they comes to the Oncology day care and researcher instructs the participants to watch the video and at the same time the doubts asked by the participants were cleared by the researcher."
75442917|NCT01659840|Radiation|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
75442918|NCT01659840|Radiation|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
75442919|NCT01659892|Drug|Montelukast|5 mg Chewable Tablet
75592723|NCT03364803|Other|Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant|A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
75592724|NCT03341689|Drug|High Dose Psilocybin|0.143 mg/kg psilocybin capsule
75592725|NCT03341689|Drug|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule
76056145|NCT04421040|Device|Biotronic 3 implant of device|The Biotronic 3 device will be implanted by the research team physician.
75592726|NCT03341689|Drug|Placebo|microcrystalline cellulose capsule
75592727|NCT03307746|Drug|Varlilumab|"Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27."
75735974|NCT00945542|Other|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
76056146|NCT04421040|Device|Biotonic 3 explant of device|The Biotronic 3 device will be removed from the patient by the research team physician.
76056147|NCT04413201|Drug|Afatinib|Afatinib followed by osimertinib or ICT
76056148|NCT04413201|Drug|Osimertinib|Osimertinib followed by ICT
75442920|NCT01659892|Drug|Singulair|5 mg Chewable Tablet
75442921|NCT01659905|Drug|Montelukast|Chewable Tablet
75442922|NCT01659905|Drug|Singulair|5 mg Chewable Tablet
75442923|NCT01659918|Drug|Montelukast|
75442924|NCT01659918|Drug|Singulair|
75442925|NCT01659931|Drug|Montelukast|10 mg Tablet
75442926|NCT01659931|Drug|Singulair|10 mg Tablet
75442927|NCT01659944|Drug|Eliglustat|Capsules for oral administration
75442928|NCT01659944|Drug|Metoprolol|Tablets for oral administration
75442929|NCT01659957|Behavioral|Group Couples Counseling|
75442930|NCT01659957|Behavioral|One-on-One Couples Counseling|
75442931|NCT01659983|Procedure|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
75592728|NCT03294954|Genetic|GINAKIT Cells|"Six dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~Dose Level 1 = 3 x 10^6~Dose Level 2 = 1 x 10^7~Dose Level 3 = 3 x 10^7~Dose Level 4 = 1 x 10^8~Dose Level 5 = 3 x 10^8~Dose Level 6 = 1 x 10^9"
75592729|NCT03287908|Drug|AMG 701|Subjects will receive IV infusions of AMG 701.
75592730|NCT03287908|Drug|Pomalidomide|Subjects will receive oral capsules of pomalidomide.
75592731|NCT03287908|Drug|Dexamethasone|Subjects will receive IV injections or oral dexamethasone.
75592732|NCT03286257|Behavioral|Exercise Intervention|A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
75592733|NCT03266991|Drug|Rifapentine|Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
75442932|NCT01660009|Other|Glycemic clamping|During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
75885054|NCT05368116|Other|Standard of care|Standard of care
75885055|NCT05708898|Device|Pharyngeal exerciser|
75885056|NCT05708898|Device|sham pharyngeal exerciser|
75885057|NCT02144324|Device|Tandem Appliance|We are going to use a modified version of the Tandem Appliance
75442933|NCT01660048|Procedure|SILS TEP repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
75442934|NCT01660048|Procedure|Total extraperitoneal inguinal hernia repair|Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
75735975|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
75735976|NCT00438256|Procedure|Proton Beam Radiation|Given over different schedules and duration
75885058|NCT01372943|Biological|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
75885059|NCT02254382|Device|Adaptive servo ventilation (ASV)|Non-invasive Ventilation used to control central and obstructive sleep apnea.
75885060|NCT03569592|Behavioral|Overdose Prevention Intervention|Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
75885061|NCT01371773|Procedure|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
75885062|NCT00475280|Procedure|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
75442935|NCT01660074|Other|test food|All food, include reference food was tested in 50g available carbohydrate portion size.
75442936|NCT01660087|Device|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
75885063|NCT00475280|Procedure|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
76056149|NCT04411251|Behavioral|Nature-near integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
76056150|NCT04411251|Behavioral|Conventional integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
75442937|NCT01659775|Drug|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy."
75442938|NCT01659775|Drug|Zofran inj.+Zofran tab.|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5."
75592734|NCT03266991|Drug|Isoniazid|Treatment with daily isoniazid in 6 months
75735977|NCT00438256|Drug|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
75885064|NCT03569358|Device|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
76056151|NCT04373460|Biological|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
75592735|NCT03191266|Device|Active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
75592736|NCT03191266|Device|Sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
75592737|NCT03180398|Device|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
75592738|NCT03120949|Drug|Olokizumab 64 mg SC q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
75592739|NCT03120949|Drug|Olokizumab 64 mg SC q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
75885065|NCT03569358|Device|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
76056152|NCT04373460|Biological|Plasma from a volunteer donor|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
75735978|NCT00951392|Drug|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests"
75885066|NCT03033875|Behavioral|Tele-Savvy|The Tele-Savvy program engages groups of six dementia family caregivers in a program that extends over 43 days. The program begins with a scheduled 75-minute group videoconference led by facilitators; similar group videoconferences then take place weekly for six weeks. In between the video-conferences, caregivers will receive daily emails with links to 5-15 minute on-line video lessons that can be watched on their own schedule as often as they wish. The videoconferences allow caregivers to report enactment of learned and self-developed management strategy behaviors into their own caregiving and allow them to raise questions. Each daily video presents a teaching point linked to the overall curriculum. The lesson is carried forward by brief, scripted talks by experts or is enacted in vignettes in which a fictional family caring for a father living with Alzheimer's demonstrates effective caregiving techniques linked to the day's teaching points.
75885067|NCT03033875|Behavioral|Healthy Living Education Program|The Healthy Living Education Program contains video and text materials on exercise, diet, and healthy living. Participants will be asked to log into the Canvas site daily over the course of six weeks to view the videos. Each participant will also receive 7 weekly brief scripted phone or video calls from a project facilitator to inquire about participants' use of the materials. Additionally, all participants will convene weekly for a video conference centered on the application of healthy living strategies. Facilitators will greet and check in with each of the caregivers, coach and debrief caregivers on the homework, answer questions and/or respond to feedback about the week's material, review key points and concepts from the week's video sessions and introduce new material, report on any activities that caregivers may have implemented based on the materials, and provide homework assignments.
75885068|NCT05241457|Device|Ekso gait training|Ekso sessions will be 60 minutes each. Patients will be measured to optimize Ekso fit during their initial training session. Ekso settings will be progressed as deemed appropriate by the trained clinician. The progression of Ekso settings allows the patient to use their maximum effort while the Ekso assists only as much as the patient requires to complete stepping. Patients may also spend time working on pre-gait activities and balance activities including weight shifting, stepping in place, side-stepping and backwards ambulation based on the patient's needs as determined by the clinician.
76056153|NCT04302272|Device|Spiration Valve System (SVS)|Spiration Valves are one-way endobronchial valves indicated for adult patients with shortness of breath and hyperinflation associated with severe emphysema in regions of the lung that have evidence of low collateral ventilation. The Spiration Valve is loaded in the deployment catheter, then passed through the channel of a flexible bronchoscope and deployed at the intended target location. The SVS device is designed to relieve the symptoms of shortness of breath and hyperinflation associated with severe emphysema without surgery.
76056154|NCT04298658|Diagnostic Test|Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised|Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
75442939|NCT01660100|Procedure|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
75735979|NCT00951392|Procedure|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :~Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~Global transcriptome analysis by DNA Chip"
75735980|NCT00951392|Device|indirect calorimetry|energy expenditure measurement
75735981|NCT00941642|Drug|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
75909541|NCT03475160|Procedure|Uterine artery Doppler after treatment|Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
75592740|NCT03120949|Drug|Concomitant treatment|"Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent"
75592741|NCT03104855|Drug|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
75592742|NCT03089905|Drug|Sevoflurane|Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
75885069|NCT05241457|Procedure|Standard physical therapy|Standard physical therapy sessions will be 60 to 90 minutes a day. Clinicians typically focus on gait, balance, and strengthening activities that address goals related to functional mobility. Other devices that would normally be used during PT sessions, including the Lite Gait and Rifton tram body weight support devices and electrical stimulation devices including the XCITE and RT300 (from Restorative Therapies).
75885070|NCT02144402|Other|infant formula with DHASCO|
75885071|NCT02144402|Other|infant formula with DHASCO-B|
75885072|NCT03569046|Drug|local anaesthetic injection|ear block by 0.25% bupivacaine
75735982|NCT00941642|Drug|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
75885073|NCT03569046|Drug|Normal Saline Flush, 0.9% Injectable Solution|ear block by Normal Saline Flush, 0.9% Injectable Solution
75442940|NCT01660100|Procedure|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
75592743|NCT03089905|Drug|Remifentanil|Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
75592744|NCT03089905|Drug|Dexmedetomidine|Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
75592745|NCT03077347|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
75592746|NCT03035448|Behavioral|Questionnaires|"Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete."
75735983|NCT01031524|Biological|PfCS102|Antigen of the sporozoite protein
75735984|NCT01031524|Biological|Montanide ISA 720|adjuvant alone
75735985|NCT00945620|Drug|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
75735986|NCT00945620|Drug|placebo|Placebo
75735987|NCT01030276|Other|Bright light therapy|Bright light therapy
75735988|NCT01030276|Other|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
75885074|NCT03569046|Drug|general anesthetic|general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
75885075|NCT03569046|Drug|Hypotensives|hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
75885076|NCT02935595|Drug|Ketamine|Ketamine Hydrochloride Injection
75885077|NCT02140658|Behavioral|multiple health education interventions|
75885078|NCT02140658|Behavioral|conventional health education|
75885079|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
75885080|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
75885081|NCT02817347|Drug|piperacillin 2% + tazobactam 0.25%|
75885082|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5%|
75885083|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0%|
75885084|NCT02503111|Device|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
75885085|NCT02503111|Other|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
75442941|NCT01660126|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
75442942|NCT01660126|Drug|Placebo|
75442943|NCT01660152|Other|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
75442944|NCT01660152|Procedure|management of therapy complications|Receive VED
75885086|NCT01367327|Behavioral|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
75885087|NCT01367327|Behavioral|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
76056155|NCT04298658|Diagnostic Test|Resmed ApneaLink Air device (Resmed, San Diego, CA).|Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
75442945|NCT01660152|Procedure|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
75735989|NCT03814252|Device|MRI-TULSA|"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"
75442946|NCT01660204|Other|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
75442947|NCT01660217|Other|A written Eczema Action Plan (EAP)|A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
75592747|NCT03035448|Other|Video Presentation|Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
75735990|NCT02037620|Device|5-6-5 Specify electrode|
75592748|NCT02981329|Drug|Metformin|Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.
75592749|NCT02981329|Behavioral|Questionnaires|Questionnaires will be completed to assess the impact quality of life
75592750|NCT02921256|Drug|Capecitabine|Given PO
75735991|NCT02037620|Device|Restore Advance Pulse Generator|
75592751|NCT02921256|Drug|Fluorouracil|Given IV
75592752|NCT02921256|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
75592753|NCT02921256|Drug|Leucovorin|Given IV
75592754|NCT02921256|Drug|Oxaliplatin|Given IV
75735992|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
75735993|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
75885088|NCT05708820|Behavioral|Online education programme|Online group will follow the education programme through videos that they can view at any time and a live session to answer questions.
75885089|NCT05708820|Behavioral|Standard education programme|Face-to-face educacion programme in a group session
76056156|NCT04298658|Other|Quantitative Sensory testing (QST)|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
76056157|NCT04298658|Diagnostic Test|OraQuick Advance Rapid HIV 1/2 Swab test|Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.
75885090|NCT05417191|Behavioral|Conventional fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
75592755|NCT02921256|Biological|Pembrolizumab|Given IV
75592756|NCT02921256|Drug|Veliparib|Given PO
75885091|NCT05417191|Behavioral|Enriched fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
75885092|NCT02742311|Procedure|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
75885093|NCT03570762|Procedure|hybrid percutaneous intervention|
75885094|NCT02464553|Other|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
75885095|NCT05708508|Drug|ROVALCYTE|"Immuno-guided strategy arm"
75592757|NCT02757885|Procedure|Bone Marrow Transplant (BMT)|Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) mismatched donor through a central venous catheter.
75885096|NCT01373021|Drug|Fentanyl|Fentanyl 2500mcg+NS50ml
75885097|NCT01373021|Drug|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
75885098|NCT03568812|Drug|Rillus®|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
75885099|NCT03568812|Other|Placebo|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
75885100|NCT01367405|Procedure|Surgical decompression|Surgical decompression within 24 hour postinjury
75442948|NCT01660295|Drug|Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU subcutaneous injection once daily
75442949|NCT01660295|Drug|Certoparin 3,000 IU Twice a Day|Certoparin 3,000 IU subcutaneous injection twice a day
75442950|NCT01660295|Drug|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU subcutaneous injection once daily
75442951|NCT01660295|Drug|Certoparin 8,000 IU Twice a Day|Certoparin 8,000 IU subcutaneous injection twice a day
75442952|NCT01660347|Biological|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
75442953|NCT01660347|Biological|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
75442954|NCT01660347|Procedure|Management of therapy complications|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
75442955|NCT01660360|Biological|Tanibirumab|
75442956|NCT01660373|Drug|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
75442957|NCT01660373|Drug|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
75442958|NCT01660386|Drug|Sitagliptin|100mg po once
76056158|NCT04298658|Diagnostic Test|Cluster of Differentiation 4 (CD4) and Viral load|Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
76056159|NCT04280081|Drug|Selpercatinib|Administered orally
76056160|NCT04254627|Drug|Etanercept|Etanercept 50 mg weekly injection
76056161|NCT04254627|Drug|Mifepristone|Mifepristone 300 mg pill
76056162|NCT04213014|Behavioral|Guys/Girls Opt for Activities for Life (GOAL)|The 4 month (16-wk) GOAL intervention has 3 components: (1) After-school GOAL Club: 26 events (2 days/week; 120 min/event/day; 13 weeks due to no club during 3 school break weeks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school for parents and adolescents [Zoom option if needed]; 2nd and 3rd meetings delivered virtually for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality during a prior week.
76056163|NCT04210583|Device|Vulvovaginal Treatment|"Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment)."
76056164|NCT04200690|Other|Interdisciplinary management|"The intervention in this trial consists of the combined efforts of the interdisciplinary team in the combined clinic arm.~The interdisciplinary team consists of dermatologists, gastroenterologists, rheumatologists, nurses, psychologists, dieticians, social workers, physiotherapists, and secretaries. Treatment will be individualized based on clinical, biomarker, phenotypic, and psychosocial characteristics. The medical treatment will follow local, national and international guidelines."
75592758|NCT02757885|Drug|Hydroxyurea|Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing >125% ideal body weight.
75592759|NCT02757885|Drug|Thiotepa|Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing >125% ideal body weight.
75735994|NCT00951470|Other|Follow -Up Visits|If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
75442959|NCT01660386|Drug|Saxagliptin|5mg po once
75442960|NCT01660386|Drug|Glimepiride|2mg po once
75442961|NCT01660386|Drug|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
75442962|NCT01660399|Drug|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
75592760|NCT02757885|Drug|Fludarabine monophosphate|Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing > 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.
75885101|NCT01367405|Procedure|Conservative treatment|Usual conservative treatment without surgery
76056165|NCT04200690|Other|Usual-care management|Usual care will be carried out by HCPs that are not otherwise involved in the trial. In usual care the patients will not be offered an interdisciplinary patient-centered care as described, but only attend their usual disease-specific departments at the usual appointments.Treatment will be prescribed as felt appropriate according to local, national and international guidelines by the treating physicians with no set protocol and no restrictions.
76056166|NCT04193904|Drug|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
76056167|NCT04193904|Radiation|Hypofractionated Preoperative Radiation|Radiation will be delivered as 30Gy/10 fractions over two weeks.
76056168|NCT04159805|Drug|TAK-079|TAK-079 subcutaneous injection
76056169|NCT04159805|Drug|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection
75442963|NCT01660399|Drug|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
75442964|NCT01660425|Behavioral|Enhancement with psychosocial intervention|
75442965|NCT01660464|Behavioral|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
75442966|NCT01660477|Drug|Isavuconazole|oral
75442967|NCT01660477|Drug|Lopinavir/ritonavir|oral
75442968|NCT01660490|Procedure|ORIF|Open reduction internal fixation of the proximal femur
75442969|NCT01660503|Dietary Supplement|0 grams SCF|Given in snack foods (muffins and flavored beverage)
75442970|NCT01660503|Dietary Supplement|10 grams SCF|Given in snack foods (muffins and flavored beverage)
75442971|NCT01660503|Dietary Supplement|20 grams SCF|Given in snack foods (muffins and flavored beverage)
75442972|NCT01660529|Biological|hTERT|
75442973|NCT01660542|Drug|Neoadjuvant Chemotherapy with Docetaxel|Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
75442974|NCT01660581|Biological|intramyocardial injection (electromechanical mapping based)|Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
75592761|NCT02757885|Drug|Cyclophosphamide|"Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight."
75885102|NCT03568734|Other|Fecal transplant|At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
75885103|NCT02144480|Behavioral|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
75592762|NCT02757885|Other|Rabbit Anti-thymocyte Globulin|Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).
75885104|NCT02144480|Behavioral|traditional training|usual care: conventional rehabilitation
75592763|NCT02757885|Radiation|Total Body Irradiation|Participants will receive 200 cGy of TBI in a single fraction.
75592764|NCT02729480|Device|Halo Craniofacial Nerve Stimulator System|The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
75885105|NCT03568578|Drug|Entecavir 0.5 mg|Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
75442975|NCT01660581|Biological|Placebo|Patients in the placebo group receive 0.9% NaCl solution with 0.5% solution of the patient's own serum.
75592765|NCT02703623|Drug|Abiraterone Acetate|Given PO
75592766|NCT02703623|Drug|Apalutamide|Given PO
75592767|NCT02703623|Drug|Cabazitaxel|Given IV
75442976|NCT01660594|Other|CT calcium scoring|CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
75735995|NCT00951470|Other|Full CDT|"Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.~During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months."
75735996|NCT00951470|Other|Modified CDT Program|The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
75885106|NCT03568578|Drug|Anluohuaxian Pill 12g|Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
75885107|NCT04700371|Device|Interwoven stent|Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
75885108|NCT04700371|Device|Laser-cut stent|Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
75885109|NCT01367483|Drug|IV methylnaltrexone (MNTX)|
75885110|NCT02140736|Drug|Epoetin biosimilar|
75885111|NCT05417035|Drug|Nebido|To evaluate if traditional treatment induces puberty similary to newer treatment
75442977|NCT01660620|Drug|Betaxolol|
75442978|NCT01660620|Drug|topical betaxolol|given topically
75592768|NCT02703623|Drug|Carboplatin|Given IV
75592769|NCT02703623|Biological|Ipilimumab|Given IV
75735997|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
75735998|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
75735999|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
75885112|NCT01968785|Radiation|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
75885113|NCT01968785|Radiation|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
75442979|NCT01660646|Behavioral|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
75885114|NCT01373099|Procedure|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
76056170|NCT04139902|Drug|Dostarlimab (TSR-042) (singly)|"If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks."
75442980|NCT01660659|Device|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
75442981|NCT01660685|Behavioral|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
75442982|NCT01660685|Behavioral|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
75442983|NCT01660685|Behavioral|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
75592770|NCT02703623|Other|Laboratory Biomarker Analysis|Correlative studies
75592771|NCT02703623|Drug|Prednisone|Given PO
75592772|NCT02670811|Dietary Supplement|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
75592773|NCT02670811|Dietary Supplement|Acidified milk|150 mL daily of artificially acidified milk
75592774|NCT02654119|Drug|Cyclophosphamide|Given IV
75592775|NCT02654119|Other|Laboratory Biomarker Analysis|Correlative studies
75592776|NCT02654119|Drug|Paclitaxel|Given IV
75592777|NCT02654119|Biological|Trastuzumab|Given IV
75736000|NCT00951548|Dietary Supplement|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
75736001|NCT00951548|Dietary Supplement|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
75736002|NCT01031602|Behavioral|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
75442984|NCT01660685|Behavioral|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
75442985|NCT01660750|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
75442986|NCT01660750|Drug|Cyclophosphamide|PO on days 1, 8, and 15 every 28 days
75592778|NCT02635867|Procedure|Indirect Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
75592779|NCT02635867|Procedure|Indirect Pulp capping-Calcium hydroxide - Dycal|Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
75592780|NCT02635867|Procedure|Indirect Pulp capping-Resin-based dentin bonding agent|Use of a dental restorative protocol using resin-based dentin bonding system only
75592781|NCT02635867|Procedure|Direct Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
75592782|NCT02635867|Procedure|Direct Pulp capping-Calcium hydroxide - Dycal|\Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
75592783|NCT02565446|Procedure|Magnetic Resolution Elastography (MRE)|Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.
75736003|NCT00951626|Behavioral|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
75736004|NCT00951626|Behavioral|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.~For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
75592784|NCT02433054|Device|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
75592785|NCT02426658|Other|Laboratory Biomarker Analysis|Correlative studies
75736005|NCT00951626|Dietary Supplement|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
75736006|NCT00951626|Other|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
75736007|NCT00951626|Other|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
75592786|NCT02426658|Drug|Pemetrexed Disodium|Given IV
75592787|NCT02426658|Other|Quality-of-Life Assessment|QOL studies
75592788|NCT02400242|Drug|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
75592789|NCT02400242|Drug|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
75592790|NCT02400242|Drug|Dexamethasone|40 mg qd on days 1, 8, 15, 22
75592791|NCT02397720|Drug|Azacitidine|Given SC or IV
75592792|NCT02397720|Biological|Ipilimumab|
75592793|NCT02397720|Other|Laboratory Biomarker Analysis|Correlative studies
75736008|NCT00951626|Procedure|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
76056171|NCT04139902|Drug|Dostarlimab (TSR-042) and TSR-022 (combination)|"If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
75442987|NCT01660750|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
75442988|NCT01660789|Behavioral|Physical activity, dietary counseling, coaching|Physical activity, dietary counseling, coaching
75442989|NCT01660828|Other|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
75442990|NCT01660841|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
75442991|NCT01660854|Biological|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
75442992|NCT01660854|Drug|Malarone treatment|Three days: 4 tablets 250/100mg per day
75442993|NCT01660867|Drug|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
75592794|NCT02397720|Biological|Nivolumab|Given IV
75592795|NCT02369575|Other|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
75592796|NCT02338687|Dietary Supplement|calcium|one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)
75592797|NCT02338687|Behavioral|Educational sessions|Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
75592798|NCT02318472|Device|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
75592799|NCT02318472|Device|Plaster cast|Lower limb plaster cast
75736009|NCT00951626|Procedure|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
75736010|NCT00951626|Procedure|assessment of therapy complications|Collected throughout the 12 month study period
75736011|NCT00951626|Procedure|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
75736012|NCT00951626|Procedure|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
75736013|NCT00951626|Procedure|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
75736014|NCT00951626|Procedure|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
75885115|NCT01373099|Procedure|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
75885116|NCT05354388|Procedure|Resection surgery of gastrointestinal stromal tumor|oral administration of Ripretinib 150 mg QD. Resection of gastrointestinal stromal tumors was performed in patients who achieved PR or SD
76056172|NCT04136509|Procedure|sinus floor elevation|sinus floor elevation with the lateral technique
76056173|NCT04136509|Procedure|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
75736015|NCT03994666|Biological|allogeneic umbilical cord-derived mesenchymal stem cells|Injection of mesenchymal stem cells
75736016|NCT03994666|Biological|Placebo (NaCl)|Placebo injection
75736017|NCT03994588|Procedure|Intraperitoneal Mesh hernia repair|The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.
75442994|NCT01660867|Drug|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
75442995|NCT01660919|Drug|placebo|
75442996|NCT01660919|Drug|rosuvastatin|
75442997|NCT01660932|Drug|placebo|
75736018|NCT00951782|Device|High frequency TMS|deep TMS HADD coil
75736019|NCT00951782|Device|Sham TMS|sham deep TMS HADD coil
75736020|NCT00951782|Device|Low frequency TMS|Deep TMS - HADD coil
75736021|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
75885117|NCT03095287|Biological|Alphanate|Bolus IV injection.
75442998|NCT01660932|Drug|omega|
75442999|NCT01660945|Drug|placebo|
75443000|NCT01660945|Drug|vytorin|
75443001|NCT01660958|Dietary Supplement|MNP|The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.
75443002|NCT01660958|Behavioral|Early Learning|• Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
75443003|NCT01660997|Drug|MLN9708|
75443004|NCT01660997|Drug|Dexamethasone|
76056174|NCT04136509|Device|dental implant placement|During reentry after bone biopsy dental implants were placed.
76056175|NCT04136509|Diagnostic Test|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
76056176|NCT04136366|Drug|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
76056177|NCT04136366|Other|Standard surgical care procedure|Standard surgical care performed upon completion of pars plana vitrectomy
76056178|NCT04103450|Drug|Vibegron|oral administration
76056179|NCT04098835|Behavioral|ASCEND|ASCEND is a behavioral intervention that combines computer-based cognitive exercise, strategy coaching with a neuropsychologist, and homework exercises in order to improve attention, working memory, and cognitive control after stroke.
76056180|NCT04049591|Drug|Higher Dose UFH|Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
75885118|NCT01335581|Device|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
75885119|NCT01335581|Drug|Retin-A and microdermabrasion|Microdermabrasion and topical lightening agent regimen
75885120|NCT05354310|Combination Product|VOILA|Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.
75885121|NCT05204563|Drug|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
75885122|NCT05204563|Drug|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25 g for Injection
75885123|NCT02144558|Other|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
75885124|NCT03566940|Biological|sIPV|Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
75885125|NCT03566940|Biological|cIPV|Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
75885126|NCT02144636|Dietary Supplement|herbalife protein shake|
75885127|NCT03566862|Diagnostic Test|Leicester Cough Monitor (LCM)|The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
75736022|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
75736023|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
75736024|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
75443005|NCT01661101|Drug|Dabigatran|Dabigatran 110 mg taken twice daily
75443006|NCT01661101|Drug|Placebo (for Dabigatran)|Dabigatran placebo taken twice daily
75443007|NCT01661101|Drug|Omeprazole|Omeprazole 20 mg capsule taken once daily
75443008|NCT01661101|Drug|Placebo (for Omeprazole)|Omeprazole placebo taken once daily
75443009|NCT01661192|Drug|AAT( Alpha 1 Antitrypsin)|
75443010|NCT01661231|Device|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
75443011|NCT01661244|Drug|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
76056181|NCT04049591|Drug|Lower Dose UFH|Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
75592804|NCT02158091|Drug|IPI-145|oral PI3K delta/gamma inhibitor
75592805|NCT02158091|Drug|Fludarabine|intravenous chemotherapy
75592806|NCT02158091|Drug|Cyclophosphamide|intravenous chemotherapy
75592807|NCT02158091|Drug|Rituximab|intravenous immunotherapy
75885128|NCT03545360|Device|BTL-703 (Treatment group)|Treatment with BTL-703 device
75885129|NCT03566784|Procedure|Inguinal hernia repair|Standard procedure for inguinal hernia repair
75885130|NCT01209923|Device|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
75885131|NCT02140814|Dietary Supplement|Niacinamide|
75592808|NCT02057133|Drug|LY2835219|Administered orally.
75592809|NCT02057133|Drug|Letrozole|Administered orally.
75592810|NCT02057133|Drug|Anastrozole|Administered orally.
75592811|NCT02057133|Drug|Tamoxifen|Administered orally.
75592812|NCT02057133|Drug|Exemestane|Administered orally.
75592813|NCT02057133|Drug|Everolimus|Administered orally.
75592814|NCT02057133|Drug|Trastuzumab|Administered IV infusion.
75592815|NCT02057133|Drug|LY3023414|Administered orally.
75592816|NCT02057133|Drug|Fulvestrant|Administered IM.
75885132|NCT03015090|Drug|Theophylline|After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
75885133|NCT02140892|Procedure|respiratory physical therapy manual technique- Autogenic Drainage|
75885134|NCT02140892|Device|respiratory physical therapy technique- IPV|
75885135|NCT00139139|Biological|Hepatitis A vaccine|
76056182|NCT04024293|Device|Goldfish (GF)|The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
76056183|NCT03993171|Drug|gold nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
76056184|NCT03910907|Drug|Comparison of two standard of care regimens|Treatment according to results of laboratory detection of resistance markers
75885136|NCT02141048|Behavioral|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
76056185|NCT03909139|Biological|BMAC|A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone marrow is aspirated then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers) is removed. The buffy coat layer contains mesenchymal stromal cells. This is called BMAC or Bone Marrow Aspirate Concentrate. The BMAC will be injected into the intra-articular space.
75736025|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
75443012|NCT01661244|Drug|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
75443013|NCT01661244|Drug|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
75592817|NCT02057133|Drug|Pertuzumab|Administered IV infusion.
75592818|NCT02057133|Drug|Loperamide|Administered orally.
75592819|NCT02057133|Drug|Endocrine therapy|Endocrine therapy administered orally.
75736026|NCT00945698|Dietary Supplement|Maize-soy flour|"No food supplement during the primary trial period (6 to 18 months of age)~1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
75736027|NCT01565824|Other|web-based support|
75736028|NCT01030510|Drug|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
75736029|NCT00941876|Behavioral|Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
75736030|NCT04813822|Drug|Miconazole Nitrate 2% + Domiphen Bromide Low Dose|Dosage 1
75736031|NCT04813822|Drug|Miconazole Nitrate 2% + Domiphen Bromide High Dose|Dosage 2
75736032|NCT04813822|Drug|Miconazole Nitrate 2%|Active Comparator
75736033|NCT00951860|Other|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
75592820|NCT02054429|Drug|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
75592821|NCT01940757|Biological|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
75592822|NCT01460654|Drug|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
75592823|NCT01460654|Drug|Alendronate|Alendronate (Fosamax) 70mg every week.
75443014|NCT01661244|Drug|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
75443015|NCT01661257|Drug|Infliximab|
75443016|NCT01661296|Other|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
75443017|NCT01661296|Drug|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
75592824|NCT01460654|Drug|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
75592825|NCT01460654|Drug|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
75592826|NCT01408225|Procedure|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
75592827|NCT01224275|Other|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
75592828|NCT01093326|Drug|Ponesimod 10 mg|Ponesimod 10 mg oral use
75592829|NCT01093326|Drug|Ponesimod 20 mg|Ponesimod 20 mg oral use
75592830|NCT01093326|Drug|Ponesimod 40 mg|Ponesimod 40 mg oral use
75736034|NCT00945776|Behavioral|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
75736035|NCT00945776|Behavioral|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
75443018|NCT01661309|Dietary Supplement|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
75885137|NCT01367639|Behavioral|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
75443019|NCT01661309|Dietary Supplement|Methylcobalamin|Aimed at reducing plasma tHcy.
75885138|NCT01373177|Diagnostic Test|Bayley Scales of Infant Development-II|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
75592831|NCT01091038|Other|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
75592832|NCT01091038|Other|Routine Care|Routine Care
75885139|NCT01373177|Diagnostic Test|Bayley Scales of Infant Development-III|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
75736036|NCT00945776|Behavioral|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
75736037|NCT02917564|Drug|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.
75736038|NCT02917564|Other|Sham - Participants will not recieve the Triamcinolone Acetonide|Patients will be given a sham.
75443020|NCT01661322|Drug|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
75443021|NCT01661335|Drug|Ondansetron, dexamethasone, aprepitant|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
75736039|NCT00941954|Behavioral|Structured Education|The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.
75736040|NCT00941954|Behavioral|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
75885140|NCT02620748|Drug|Tranexamic Acid|
75885141|NCT02620748|Other|Saline Solution|
75885142|NCT01373255|Procedure|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
75885143|NCT03566706|Behavioral|Discussion Tool: Unhealthy Eating|Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.
75885144|NCT03566706|Behavioral|Discussion Tool: Marijuana Use|Parent Discussion Tools
75443022|NCT01661335|Drug|Ondansetron, Dexamethasone, placebo|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
75443023|NCT01661361|Procedure|blood levels|
75443024|NCT01661439|Drug|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
75443025|NCT01661452|Other|Referral to counseling services if desired|
75443026|NCT01661478|Other|Training on motivational interviewing|
75592833|NCT00752531|Behavioral|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
75592834|NCT00497952|Biological|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
75592835|NCT03039439|Procedure|Biospecimen Collection|Previously collected tumor tissue and blood samples
75736041|NCT03079414|Procedure|Invasive Electrophysiology Study|Invasive electrophysiology studies will be performed using four catheters placed in the right ventricular apex, the coronary sinus, the His bundle region, and the high right atrium. Standard induction protocols for supraventricular and ventricular arrhythmias will be utilized in the absence and presence of isoproterenol. Long-short ventricular extra-stimuli will also be delivered to screen for bundle branch reentrant ventricular tachycardia. The study is considered observational as the participating sites perform electrophysiology studies in this patient population as part of standard clinical care.
75736042|NCT00945932|Drug|GW870086X|Investigational product
75885145|NCT03566706|Behavioral|Discussion Tool: Sedentary Behavior|Parent Discussion Tools
75736043|NCT00945932|Drug|Placebo|Placebo control
75736044|NCT01031758|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
75885146|NCT03566628|Other|Warmed Isotonic Saline|Isotonic saline warmed to 39ºC.
75885147|NCT03566628|Other|Room-Temperature Isotonic Saline|Isotonic saline at room temperature
75885148|NCT02141126|Other|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
75443027|NCT01661504|Behavioral|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
75443028|NCT01661517|Behavioral|Motivational interviewing and referral to treatment|
75443029|NCT01661530|Dietary Supplement|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
75443030|NCT01661530|Dietary Supplement|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
75443031|NCT01661543|Dietary Supplement|Beans|90g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
75443032|NCT01661543|Dietary Supplement|Control (rice)|90g of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group.
75443033|NCT01661543|Dietary Supplement|Peas|90 grams of peas will be consumed 5 out of 7 days per week
75443034|NCT01661556|Drug|Miconazole|Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
75592836|NCT03039439|Other|Laboratory Biomarker Analysis|Correlative studies
75736045|NCT05300828|Drug|Genexl PM|Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
75885149|NCT02141126|Other|Usual care|Standard inpatient 'usual care' physiotherapy
75885150|NCT03566472|Diagnostic Test|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
75885151|NCT02144792|Drug|[11C] -verapamil PET|While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
75885152|NCT03564990|Other|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
75885153|NCT03564990|Other|conventional approach|conventional follow-up
75885154|NCT02144870|Behavioral|Habit Reversal Training|awareness training, competing response training
75443035|NCT01661556|Drug|Hydroquinone|Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
75592837|NCT03035552|Behavioral|Pacifier activated music player|Therefore the immediate goal of the current proposal is to demonstrate that intensive NNS-training using reinforcement with mother's voice can improve the oral feeding outcomes of infants with CCHD using a randomized controlled trial (RCT) design, with wait-list controls to ensure that infants in the trial all benefit from a treatment with only demonstrated positive effects. Establishment of optimal NNS patterns in the first 6 months after birth in these infants will improve downstream feeding skills and may promote better motor and language outcomes by one year of age.
75592838|NCT03021460|Drug|Ibrutinib|Given PO
75592839|NCT03021460|Other|Laboratory Biomarker Analysis|Correlative studies
75592840|NCT03021460|Biological|Pembrolizumab|Given IV
75592841|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL.
75592842|NCT03020199|Radiation|nbUVB|Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application will be performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face is recommended
75592843|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
75736046|NCT05300750|Other|Oral fluids|Starting amount of oral fluid after 2 hours post C/s should be 5cm and then increase gradually to be 45-50 cm of oral fluid at 4 hours post C/s and 100 cm each hours later.
75736047|NCT05300750|Other|Chewing gum|Chewed free sugar gum for 15 minutes
75443036|NCT01661569|Other|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
75736048|NCT00952016|Drug|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
75736049|NCT00952094|Drug|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
75736050|NCT00942110|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
75736051|NCT00942344|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
75736052|NCT00942344|Drug|Amlodipine|amlodipine 5mg, 10mg
75736053|NCT00942344|Drug|Losartan|Losartan 50mg, 100mg
75736054|NCT00952172|Behavioral|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
75736055|NCT00952250|Behavioral|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
75736056|NCT00952250|Behavioral|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
75736057|NCT00952328|Dietary Supplement|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
75736058|NCT00952406|Other|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
75885155|NCT02144870|Behavioral|Resources activation|
75885156|NCT03566394|Drug|Gabapentin 300mg|Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
75885157|NCT03544424|Other|No intervention|No intervention
75885158|NCT00033293|Other|Clinical Observation|Undergo observation
75885159|NCT00033293|Drug|Cyclophosphamide|Given IV
75885160|NCT00033293|Other|Laboratory Biomarker Analysis|Correlative studies
75885161|NCT00033293|Procedure|Magnetic Resonance Imaging|Correlative studies
75443037|NCT01661582|Other|CT/PET Myocardial Perfusion Imaging using O-15 water|
75443038|NCT01661582|Other|Coronary blood flow measured by doppler echocardiography|
75443039|NCT01661608|Device|Using the EOS for gastric restriction|
75885162|NCT00033293|Drug|Prednisone|Given orally
75885163|NCT00033293|Biological|Therapeutic Immune Globulin|Given IV
75443040|NCT01661673|Drug|EVP-0962|Arms: 1,2,3,4
75443041|NCT01661673|Drug|Placebo|Arm 5
75443042|NCT01661725|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
75443043|NCT01661738|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|360 subjects were divided into three groups (120 subjects in each group), children (2~6 years of age), early youth (7~15 years of age) and adult (16~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
75736059|NCT00946010|Biological|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
75736060|NCT00436852|Drug|ABT-751|Given orally
75736061|NCT00436852|Procedure|quality-of-life assessment|Ancillary studies
75736062|NCT00946166|Drug|simvastatin|40 mg daily in the evening for a maximum of 14 days
75736063|NCT00946166|Drug|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
75736064|NCT00952562|Dietary Supplement|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
75443044|NCT01661751|Biological|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
75443045|NCT01661751|Biological|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
75443046|NCT01661777|Drug|Nasal steroid|
75443047|NCT01661777|Procedure|Myringotomy tube placement|
75443048|NCT01661777|Drug|Diuretic|
75736065|NCT00952562|Dietary Supplement|placebo|Empty capsules, 3 capsules per day for 16 weeks
75736066|NCT00952640|Dietary Supplement|vitamin A|high dose vitamin A, 200.000 IU
75736067|NCT00942500|Procedure|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade <2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
75736068|NCT00952796|Drug|moxifloxacin|moxifloxacin 400mg once daily (IV form, 60minutes)
75736069|NCT00952796|Drug|ampicillin/sulbactam|ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
75736070|NCT00952952|Drug|Mesalamine|
75885164|NCT03566316|Drug|Telmisartan/Amlodipine|
75885165|NCT03566316|Drug|Rosuvastatin|
75885166|NCT03566316|Drug|Telmisartan|
75885167|NCT02144948|Drug|e.-coli-nissle|1 ml qd for 24 weeks
75885168|NCT03566004|Diagnostic Test|Stool specimen collection|The stool specimen collection was performed at the hospital or at home using a disposable device to be placed on the toilet seat and an E-nat Tube sent by postal to the lab.
75443049|NCT01661777|Drug|Antihistamine|
75443050|NCT01661777|Behavioral|Low salt diet|
75443051|NCT01661816|Behavioral|interview|psychological, emotional, family and social parameters
75443052|NCT01661842|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
75443053|NCT01661842|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
75736071|NCT00953030|Behavioral|COACH|
75736072|NCT00953030|Behavioral|RealAge|
75736073|NCT00953108|Drug|quetiapine|300 mg per day
75736074|NCT00953108|Drug|escitalopram|escitalopram 10 mg per day
75736075|NCT00953186|Device|hyperbaric air|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
75736076|NCT00953186|Device|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
75736077|NCT00953264|Behavioral|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
75885169|NCT03565926|Other|Manual Therapy|"Articulation technique L4-S1~Lumbar neuromuscular technique~Fascial technique of crossed hands~Posteroanterior mobilizations of the lumbar vertebrae"
75885170|NCT03565926|Other|Hypopressive exercises|Protocol 5 Hypopressive exercises
75885171|NCT02145104|Drug|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
75443054|NCT01661855|Drug|Riluzole|50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
75592844|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
75885172|NCT03565848|Procedure|Mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection|Laparoscopic segmental colorectal resection performed by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved.
75443055|NCT01661855|Drug|Placebo|Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
75885173|NCT02145338|Drug|Nitrofurantoin or Trimethoprim or Cefalexin|Antibiotic prophylaxis
75885174|NCT02145338|Other|No prophylaxis|Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
76056186|NCT03901456|Behavioral|Care to Plan|Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.
75443056|NCT01661868|Drug|Olaparib|Tablet formulation will be used.
75443057|NCT01661894|Device|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
75443058|NCT01661907|Procedure|Combined Epi-GA/PCEA|An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.375%-0.5% ropivacaine during surgery. Patient-controlled epidural analgesia will be provided after surgery.
75592845|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
75592846|NCT03020199|Drug|Calcipotriol|Its a topical treatment for Psoriasis. the concentration it is used is 50mcg/g
75736078|NCT00953342|Behavioral|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
75736079|NCT00953342|Behavioral|Usual care|Standard medical care
75736080|NCT00953498|Drug|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
75885175|NCT03565770|Other|individual coaching|coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.
75885176|NCT03565770|Other|Standard care|completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
75885177|NCT03565692|Biological|the lung mycobiota and microbiota profile|"All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~Separation of the pellet and supernatant, stored at -20 ° C until testing~Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~Pseudomonas aeruginosa load measured by qPCR"
75443059|NCT01661907|Procedure|GA/PCIA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
75443060|NCT01661920|Other|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
75443061|NCT01661920|Other|Control group|Those antibiotic duration treatments which are not modified by their doctors.
75443062|NCT01662011|Device|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
75443063|NCT01662011|Device|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
75592847|NCT03020199|Drug|Betamethasone|this is topical cream which is used in 0.5mg/g concentration
75592848|NCT02996266|Device|Targeted Temperature Management|Prophylactic normothermia
75592849|NCT02996266|Other|Standard Care|No intervention to control temperature unless fever occurs
75592850|NCT02954497|Device|Surgical placement of the Jarvik 2015 VAD|The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
75736081|NCT00953498|Drug|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
75736082|NCT00942656|Other|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
75736083|NCT00942656|Other|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
75736084|NCT00942656|Other|VA|base diet plus 3.0% energy added from vaccenic acid
75736085|NCT00942656|Other|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
75885178|NCT03565692|Biological|the gut mycobiota and microbiota profile|All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
75736086|NCT00942812|Other|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
75736087|NCT00942812|Other|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
75736088|NCT00943046|Device|Pacemaker therapy|Implantation of the SIELLO pacemaker leads
75736089|NCT04012034|Device|Radiofrequency A|Application of radiofrequency for 30 minutes per week during 8 weeks
75736090|NCT04012034|Device|Radiofrequency B|Application of radiofrequency without energy for 30 minutes per week during 8 weeks
75885179|NCT02254616|Behavioral|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
75885180|NCT02254616|Behavioral|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
75885181|NCT02254616|Behavioral|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
75885182|NCT02254616|Behavioral|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
75443064|NCT01662037|Drug|Bosentan|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
75443065|NCT01662076|Other|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
75592851|NCT02954497|Procedure|Surgical Placement of Jarvik 2015 VAD|Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
75592852|NCT02952248|Drug|BI 754091|
75592853|NCT02939755|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
75736091|NCT00946400|Other|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
75592854|NCT02939755|Behavioral|Enhanced Usual Care|usual care from health providers
75592855|NCT02933736|Drug|Ribociclib|
75592856|NCT02926859|Drug|Cannabidiol as add-on|Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
75736092|NCT00946400|Other|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
75885183|NCT02254694|Other|high heeled shoes|see detailed study description
75885184|NCT03565614|Behavioral|Reablement|Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
76056187|NCT03901456|Behavioral|Usual Care|"Receive care as usual.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
76056188|NCT03866148|Device|Reveal LINQ|Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
76056189|NCT03811847|Drug|Methylphenidate Extended Release Oral Capsule|"Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg"
75736093|NCT05301296|Diagnostic Test|Clinical examination of the breast for early detection of Cancer|Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
75736094|NCT00943358|Biological|MF59 H1N1 vaccine|3.75-7.5ug dose
75736095|NCT00943358|Biological|Plain H1N1 vaccine|7.5-15ug
75443066|NCT01660724|Procedure|Ultrasound guided arterial puncture|Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
75736096|NCT00120289|Drug|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
75736097|NCT00120289|Drug|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
75736098|NCT00946556|Drug|Valacyclovir|1g po od for 2 months
75736099|NCT00946556|Drug|Placebo|Placebo po od for 2 months
75736100|NCT00946634|Drug|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
75736101|NCT00946634|Drug|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
75443067|NCT01660724|Procedure|Conventional arterial puncture technique|Arterial puncture is performed using the conventional technique
75443068|NCT01662089|Drug|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
75443069|NCT01662089|Drug|Placebo drug supplement|Placebo drug instead of Zinc supplement
75443070|NCT01662128|Drug|Xeloda|Xeloda as Adjuvant Therapy
75443071|NCT01662154|Device|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
75443072|NCT01662154|Device|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
75443073|NCT01662167|Drug|Single|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
75443074|NCT01662167|Drug|Multipe|In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
75443075|NCT01662180|Drug|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
75443076|NCT01662193|Dietary Supplement|vitamin D3 supplement|
75443077|NCT01662193|Dietary Supplement|calcium supplement|
75443078|NCT01662193|Dietary Supplement|vitamin D3 and calcium supplement|
75443079|NCT01662193|Dietary Supplement|placebo|
75443080|NCT01662206|Dietary Supplement|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
75443081|NCT01662206|Dietary Supplement|Placebo|2 capsules daily containing 348.25 mg of potato starch
75443082|NCT01662219|Other|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
75443083|NCT01662232|Dietary Supplement|Green tea beverage|
75443084|NCT01662232|Dietary Supplement|Green tea extract|
75443085|NCT01662232|Dietary Supplement|EGCG|
75443086|NCT01662232|Other|Placebo|
75443087|NCT01662258|Device|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
75443088|NCT01662284|Drug|124I-NM404|124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
75443089|NCT01662323|Behavioral|GP's treating HF according the dutch guidelines|
75443090|NCT01662349|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
75443091|NCT01662375|Other|Surveillance and interview|The interventional nature of the study is justified by the need for particular monitoring of patients in whom life support is withdrawn following the clinical team's decision. The questions posed to the patient's family and/or relatives, do not modify the care provided to the patient.
76056190|NCT03811847|Other|Placebo|Placebo comparator MPH Matched Placebo Tablet
76056191|NCT03809000|Radiation|Radiation Therapy|Radiation Therapy
76056192|NCT03809000|Drug|Enzalutamide|Anti-androgen
76056193|NCT03809000|Drug|Bicalutamide|Anti-androgen
76056194|NCT03809000|Drug|GnRH analog|Anti-androgen
75443092|NCT01662388|Device|Separation ring|Separation ring placed along with automatrix band
75443093|NCT01662388|Device|automatrix band|band placed with a tightening device
75592857|NCT02926859|Drug|Placebo as add-on|Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
75736102|NCT00946634|Drug|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
75443094|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
76056195|NCT03795454|Behavioral|Singing|Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
76056196|NCT03743844|Behavioral|Compassion-focused psychoeducation group|Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
76056197|NCT03732794|Device|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
75443095|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
75443096|NCT01662414|Dietary Supplement|Whey protein|1 sachect (10 g) 2times/ day
75443097|NCT01662414|Dietary Supplement|Soy protein|1 sachect (10g) 2times/day
75443098|NCT01662427|Other|Questionaire to assess Noctural Parkinson's Disease Symptoms|Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
75443099|NCT01662466|Drug|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
75443100|NCT01662466|Dietary Supplement|DHEA|DHEA 25mg tid
75443101|NCT01662466|Drug|Placebo|Carrier cream without added testosterone in the identical type of pump
75592858|NCT02912312|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RNI
75592859|NCT02912312|Other|Laboratory Biomarker Analysis|Correlative studies
75592860|NCT02912312|Other|Quality-of-Life Assessment|Ancillary studies
75592861|NCT02912312|Other|Questionnaire Administration|Ancillary studies
75592862|NCT02912312|Radiation|Radiation Therapy|Undergo standard RNI
75592863|NCT02903420|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
75592864|NCT02876107|Drug|Carboplatin|Given IV
75592865|NCT02876107|Other|Laboratory Biomarker Analysis|Correlative studies
75592866|NCT02876107|Drug|Paclitaxel|Given IV
75736103|NCT00953732|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
75443102|NCT01662518|Device|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
75443103|NCT01662544|Procedure|Oxygen delivery|
75443104|NCT01662557|Behavioral|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
75443105|NCT01662557|Other|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
75443106|NCT01662570|Behavioral|Beverage Choice and Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
75592867|NCT02876107|Biological|Panitumumab|Given IV
75592868|NCT02874885|Procedure|Biospecimen Collection|Undergo collection of blood sample
75592869|NCT02872259|Drug|BGB324+pembrolizumab|Combination
75592870|NCT02872259|Drug|BGB324+dabrafenib and trametinib|Combination
76056198|NCT03725410|Device|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
75885185|NCT03565614|Behavioral|Traditional home care|Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
75885186|NCT03565536|Drug|Nexavar|for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
75885187|NCT03565536|Procedure|operation|If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
75443107|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
75443108|NCT01662622|Drug|Sevoflurane|"The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted."
75443109|NCT01662661|Drug|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
75443110|NCT01662661|Drug|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
75885188|NCT03565536|Radiation|External radiation therapy|As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
75885189|NCT05128253|Other|High fat meal in a subset of patients with NAFL or NASH|In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
75885190|NCT05360862|Procedure|Prone positioning session|To perform respiratory measurements before, during and after a prone positioning session.
75885191|NCT05193383|Behavioral|Imaginal exposure|Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
75592871|NCT02872259|Drug|pembrolizumab|Monotherapy
75443111|NCT01662674|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
75592872|NCT02872259|Drug|dabrafenib and trametinib|Combination
75592873|NCT02859467|Other|Kinesio Taping and Inhibitory Treatment Techniques|"Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~Release Technique of the trapezius muscle.~Release Technique for scalene muscles.~Technique suboccipital inhibition.~Technique hands crossed for induction dorsal superficial fascia."
75592874|NCT02859467|Other|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
75592875|NCT02831933|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
75592876|NCT02831933|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
75885192|NCT05193383|Behavioral|Exposure|Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
75885193|NCT05193383|Behavioral|Approach-avoidance conflict|Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).
75885194|NCT05193383|Behavioral|In vivo exposure|Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
75885195|NCT03565458|Drug|Gemigliptin|zemiglo 50mg,LG Chem
75592877|NCT02831933|Radiation|SBRT|Low-dose SBRT
75885196|NCT03565458|Drug|Dapagliflozin|forxiga, dapagliflozin 10mg
75443112|NCT01662674|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
75592878|NCT02831933|Drug|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
75443113|NCT01662687|Drug|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy."
75443114|NCT01662687|Drug|Kytril inj.+Kytril tab.|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~Kytril tab. 1mg: administered twice a day by orally at Day 2~4."
75443115|NCT01662700|Drug|Artesunate|
75592879|NCT02821741|Device|The Twin Stim Plus, 3rd Edition|Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.
75592880|NCT02821741|Device|Medoc Pathway System|Device used to apply Thermal stimulation to both arms.
75736104|NCT04011488|Other|Shared Decision Making Tool|"We've used the framework from this model and adapted it to the patient perspective to create a Patient Shared Decision Making Tool. The model is interactive so it can be customized to a specific patient. It has adjustments built in for gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).~The strongest, underlying message is that any treatment choice is better than not seeking treatment. To illustrate this, a Do Nothing pathway is included for comparison purposes."
75736105|NCT01083277|Device|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
75736106|NCT01083277|Other|Conventional ventilation|tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
75736107|NCT00943748|Drug|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
75736108|NCT00943748|Drug|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
75736109|NCT01326793|Other|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
75736110|NCT00953810|Other|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
75736111|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
75736112|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
75736113|NCT00953888|Drug|AZD5069|Single dose of oral solution.
75736114|NCT00953888|Drug|Placebo|Single dose of oral solution.
75736115|NCT00953966|Other|Genetically modified potatoes|Starch from genetically modified potatoes
75736116|NCT00954044|Behavioral|Randomized Exercise Intervention|"The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months."
75736117|NCT00954044|Behavioral|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
75736118|NCT00954200|Drug|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
75736119|NCT00954200|Drug|ibuprofen|10mg/kg syrup - single dose
75736120|NCT00954278|Drug|sorafenib|sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
75736121|NCT00550446|Drug|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
75736122|NCT00550446|Drug|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
75736123|NCT00550446|Drug|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
75736124|NCT00550446|Drug|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
75736125|NCT00550446|Drug|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
75736126|NCT00550446|Drug|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
75736127|NCT00550446|Drug|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
75736128|NCT00953472|Drug|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
75736129|NCT00953472|Other|no-added salt diet|instruction to reduce salt for one week prior to study
75443116|NCT01662700|Drug|Chloroquine|
75885197|NCT03565458|Drug|Empagliflozin|jardiance 25mg, empagliflozin
75885198|NCT01367717|Dietary Supplement|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
75885199|NCT01367717|Dietary Supplement|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
75885200|NCT03565302|Drug|Formoterol|Subjects are treated with daily inhalation of formoterol
75885201|NCT03565302|Drug|Terbutaline|Subjects are treated with daily inhalation of terbutaline
75885202|NCT03565302|Other|Placebo|Subjects are treated with placebo
75885203|NCT03568032|Diagnostic Test|Measurement of intima media thickness of carotid artery|IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.
75885204|NCT03568032|Diagnostic Test|Detection and measurement of carotid plaques|Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound
75885205|NCT03568032|Diagnostic Test|Carotid Color Flow Duplex Testing|Velocity measurement of carotid artery to determine carotid stenosis
75885206|NCT03568032|Diagnostic Test|Montreal Cognitive Assessment|Cognitive assessment
75885207|NCT03568032|Other|Medical history of cardiovascular risk factors and cardiovascular diseases|Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
76056199|NCT03725410|Device|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
76056200|NCT03709472|Behavioral|Computer Assisted CIFFTA|This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
75736130|NCT05279820|Procedure|Partial pulpotomy|Partial pulp tissue amputation
75736131|NCT05279820|Procedure|Full Pulpotomy|Full Pulpotomy
75736132|NCT00953550|Drug|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
75885208|NCT03567798|Dietary Supplement|UPLAT|Carica papaya leaf Extract + Tinospora cardifolia Extract
75736133|NCT00953550|Drug|Succinylcholine|1 mg/kg
75736134|NCT00948870|Drug|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
75736135|NCT05351034|Device|Anorectal manometry|Anorectal manometry in diagnosis of Functional anorectal disorders
75736136|NCT05350956|Drug|TPO-RA (Herombopag)|During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
75736137|NCT05350956|Drug|TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)|During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
75885209|NCT03567798|Other|Placebo|Placebo
75885210|NCT01372007|Drug|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
75885211|NCT01372007|Drug|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
76056201|NCT03709472|Behavioral|Behavioral: Traditional face-to-face treatment-no technology|Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
76056202|NCT03675477|Drug|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
76056203|NCT03675477|Drug|Placebo|Placebo Oral Tablet
76056204|NCT03674736|Dietary Supplement|Dietary Intakes|Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
75736138|NCT00948948|Device|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~Gel-filled device which is available in smooth surface and textured surface (Siltex®)~Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
75443117|NCT01662726|Drug|Irosustat|Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
75443118|NCT01662739|Behavioral|Questionnaire|
75885212|NCT03037164|Device|INTERCEPT Blood System for Red Blood Cells|The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5 or SAG-M for non-US sites. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
75885213|NCT03037164|Device|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
76056205|NCT03647358|Device|PET/CT Scan|Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
75443119|NCT01662804|Drug|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
75443120|NCT01662817|Behavioral|Intervention|PCP receives one day training in depression screening guidelines and uses guidelines for six months
75736139|NCT00953628|Drug|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
75736140|NCT00953628|Drug|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
75592881|NCT02813668|Behavioral|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
75592882|NCT02805803|Other|Quality of life questionary|Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.
75736141|NCT00949026|Drug|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
75736142|NCT00953784|Procedure|standard operating management|As previously described
75736143|NCT00949104|Drug|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
75736144|NCT00949104|Drug|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
75885214|NCT01373411|Drug|ticagrelor|ticagrelor 90 mg BID for 90 days
75885215|NCT01373411|Drug|Placebo|Placebo 1 pill BID for 90 days
75443121|NCT01662817|Behavioral|Control|PCP manages depression in the usual way for six months
75443122|NCT01662869|Drug|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m^2) IV bolus and then 2400 mg/m^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
75443123|NCT01662869|Drug|Folinic acid|Participants will receive folinic acid 400 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
75443124|NCT01662869|Drug|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
75592883|NCT02792881|Procedure|Laparoscopic completion total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic completion total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and the anastomotic procedure will be performed extracorporeally through an auxiliary incision.
75736145|NCT00953940|Drug|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
75885216|NCT03567564|Diagnostic Test|Abdominal muscles ultrasound|Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
75885217|NCT03567408|Procedure|Selective PCI|Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
76056206|NCT03647358|Drug|Iodine-124|Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose.
75443125|NCT01662869|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
75885218|NCT03567408|Drug|Bivalirudin|Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
75736146|NCT00436618|Drug|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
75736147|NCT03995836|Device|CPAP|Decision of CPAP treatment is according to clinical guidelines
75885219|NCT05354154|Procedure|endotracheal intubation|Consenting healthy patients of either sex will be endotracheally intubated under controlled environment
75885220|NCT05354076|Drug|doxorubicin hydrochloride liposome injection|According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
75885221|NCT05192993|Other|visual motor integration group|Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises
75885222|NCT05192993|Other|Handwriting intervention programs|(1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping
75885223|NCT05192993|Other|visual motor integration program and Handwriting intervention programs|"Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises 6)Eye motor coordination (7)position in space(8)coping-figure ground(9)spatial relationship(10)visual closure(11)constancy of shapes(12)far and near coping~Hand writing intervention as follow (1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping"
75885224|NCT05065697|Other|Brain MRI|Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
75885225|NCT01367951|Procedure|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws~Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
75885226|NCT05708664|Procedure|precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction|Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
75885227|NCT05192759|Device|Transcranial Magnetic Stimulation|The stimulations were performed by MagStim Rapid2.
75885228|NCT05192681|Drug|Tislelizumab|Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
75885229|NCT01368029|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
75885230|NCT01368029|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
76056207|NCT03596606|Procedure|Manual Treatment|"The manual treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~Soft tissue techniques.~Articulatory techniques applied at cervical level~Osteopathic manipulation techniques applied at the affected jaw/s.~Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis."
75443126|NCT01662869|Drug|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
75443127|NCT01662921|Drug|NPH|Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
75443128|NCT01662921|Drug|Insulin LISPRO|Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
75443129|NCT01662921|Drug|Insulin glulisine|Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
75736148|NCT03995836|Procedure|Bariatric Surgery|All patients.
75736149|NCT01024660|Drug|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
75736150|NCT01024660|Drug|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
75736151|NCT01024660|Drug|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
75736152|NCT01751126|Drug|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
75736153|NCT01751126|Drug|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
75736154|NCT00943982|Drug|Interferon Gamma 1-b|
75885233|NCT03634553|Other|Training with e-health product|The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
75736155|NCT01570010|Other|Norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
75736156|NCT00944060|Other|lifestyle intervention|
75736157|NCT00548808|Drug|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
75736158|NCT00548808|Drug|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
75736159|NCT00548808|Drug|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
75885234|NCT03634553|Other|Usual care|usual care, i.e. participates in regular training regime at the physiotherapy department
75885235|NCT01368107|Drug|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
75885236|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
75885237|NCT01368107|Drug|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
75443130|NCT01662934|Device|I RUNE|
75443131|NCT01662934|Device|sham|
75443132|NCT01662947|Device|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
75592884|NCT02789228|Biological|Tumor associated antigen lymphocytes (TAA-CTL)|"This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2"
75592885|NCT02763566|Drug|Abemaciclib|Administered orally
75592886|NCT02763566|Drug|Anastrozole|Administered orally
75736160|NCT00944138|Behavioral|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
75885238|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
75885239|NCT02039674|Biological|Pembrolizumab|IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
75885240|NCT02039674|Drug|Paclitaxel|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
75885241|NCT02039674|Drug|Carboplatin|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
75885242|NCT02039674|Biological|Bevacizumab|IV on Day 1 of each 3-week cycle
75885243|NCT02039674|Drug|Pemetrexed|IV on Day 1 of each 3-week cycle
75885244|NCT02039674|Biological|Ipilimumab|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
75885245|NCT02039674|Drug|Erlotinib|Orally tablet once daily
75885246|NCT02039674|Drug|Gefitinib|Oral tablet once daily
75443133|NCT01662947|Device|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
75885247|NCT03126227|Biological|AR101|AR101 powder provided in capsules
75885248|NCT03126227|Biological|Placebo|Placebo powder provided in capsules
75885249|NCT01373567|Drug|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
75885250|NCT01373645|Device|Yinyi stent|subjects with Yinyi stent implantation
75885251|NCT03099187|Drug|Pirfenidone|Pirfenidone 267 mg capsules three times in a day.
75443134|NCT01662973|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1*10E6 UC-MSC/kg body weight for 12 weeks.
75443135|NCT01662973|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
75443136|NCT01663025|Behavioral|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
75592887|NCT02763566|Drug|Letrozole|Administered orally
75592888|NCT02763566|Drug|Placebo|Administered orally
75592889|NCT02763566|Drug|Fulvestrant|Administered intramuscularly
75592890|NCT02760849|Other|Laboratory Biomarker Analysis|Correlative studies
75592891|NCT02760849|Procedure|Oophorectomy|Undergo ISDO
75885252|NCT03099187|Drug|Placebo|Matching placebo capsules three times in a day.
75885253|NCT04192474|Device|Flexible cystoscopy|Treatment with the investigational device: Ambu® aScope™ 4 Cysto
75885254|NCT03634475|Drug|PP-001|Drug - no placebo
75885255|NCT04162756|Biological|Brexucabtagene Autoleucel (KTE-X19)|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
75885256|NCT04162756|Drug|Fludarabine|Administered per package insert
75885257|NCT04162756|Drug|Cyclophosphamide|Administered per package insert
75885258|NCT04544267|Biological|Quadrivalent influenza vaccine, high-dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
75736161|NCT00954434|Dietary Supplement|red wine|intake of red wine on a daily basis
75736162|NCT04011878|Procedure|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
75736163|NCT00954096|Drug|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
75736164|NCT00949338|Procedure|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
75736165|NCT00954252|Drug|CHF 5074|1x, oral capsule, single dose
75443137|NCT01663038|Drug|Clopidogrel|Clopidogrel and Aspirin separate combination, single dose
75736166|NCT00954252|Drug|placebo|placebo, oral capsule, single dose
75736167|NCT00954252|Drug|CHF 5074|2x, oral capsule, single dose
75736168|NCT00954252|Drug|CHF 5074|4x, oral capsule, single dose
75736169|NCT00954252|Drug|CHF 5074|8x, oral capsule, single dose
75736170|NCT00954252|Drug|CHF 5074|16x, oral capsule, single dose
75736171|NCT00954252|Drug|CHF 5074|24x, oral capsule, single dose
75885259|NCT04544267|Biological|Quadrivalent influenza vaccine, standard dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
75885260|NCT05036746|Other|No intervention|No intervention
75885261|NCT04535453|Biological|Ad26.COV2.S|All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.
75736172|NCT01563042|Drug|Intravenous (IV) single dose|GSK2434735 administered as a single intervenous dose at the beginning of the study
75736173|NCT01563042|Drug|Subcutaneous (SC) single dose|GSK2434735 administered as a single subcutaneous dose at the beginning of the study
75736174|NCT00110617|Drug|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
75736175|NCT00110617|Drug|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
75736176|NCT00954330|Procedure|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
75736177|NCT00954330|Device|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
75885262|NCT04535453|Other|Placebo|Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.
75443138|NCT01663038|Drug|Fixed dose combination of clopidogrel/Aspirin|Fixed dose combination of clopidogrel/aspirin
75443139|NCT01663038|Drug|Aspirin|
75443140|NCT01663051|Device|Zilver Vena Venous Stent|Stenting iliofemoral venous outflow obstruction
75443141|NCT01663064|Device|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
75443142|NCT01663077|Drug|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
75443143|NCT01663090|Drug|Ferumoxytol|
75592892|NCT02760849|Other|Quality-of-Life Assessment|Ancillary studies
75592893|NCT02760849|Procedure|Salpingectomy|Undergo ISDO
75592894|NCT02760849|Procedure|Salpingo-Oophorectomy|Undergo RRSO
75592895|NCT02760433|Drug|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
75592896|NCT02760433|Drug|Placebo|sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
75592897|NCT02760407|Drug|Olokizumab 64mg q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
75736178|NCT00949494|Device|Synvisc|intra-articular, 3 weekly injections
75736179|NCT04011462|Device|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
75736180|NCT04011462|Device|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
75885263|NCT04926220|Device|Trans-esophageal Doppler monitoring|Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
75885264|NCT04926220|Device|MostCareUP Haemodynamic Monitor|MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
75885265|NCT04926220|Device|Argos Cardiac Output (CO) Monitor|Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
75885266|NCT04895488|Drug|Vortioxetine|"First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks"
75443144|NCT01663116|Genetic|Stem cells|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
75443145|NCT01663116|Genetic|Placebo|"first cohort: 20 ml administered at days 1, 8 and 15~second cohort: 40 ml administered at days 1, 8 and 15~third cohort: 80 ml administered at days 1, 8 and 15"
75592898|NCT02760407|Drug|Olokizumab 64mg q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
75443146|NCT01663155|Device|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
75443147|NCT01663168|Drug|Rifabutin|
75885267|NCT04895488|Drug|Usual Antipsychotic Treatment|Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
75885268|NCT04463069|Other|Adapted physical activity|This PA program was modified from an adapted physical activity (APA) program that designed for obesity management among adolescents with intellectual disability (ID). The aim of the APA program was to promote PA and health for people in special needs. In this study, the APA program was carefully designed based on a comprehensive pre-intervention assessment of each adolescent with ID, so that can be able to address their individual needs in learning and adaption. The APA program comprised three stages of APA training at school and each stage consisted of simple and fun endurance and strength-building exercise, at a frequency of two sessions per week, and lasting for about three months.
75885269|NCT04397029|Device|SureTouch|"The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch."
75885270|NCT04893460|Behavioral|CoQuit App|The CoQuit App is a cognitive dissonance based app for smoking cessation.
75443148|NCT01663194|Procedure|primary percutaneous coronary intervention, each groups|All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
75443149|NCT01663246|Procedure|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
75443150|NCT01663298|Procedure|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
75443151|NCT01663311|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
75592899|NCT02760407|Drug|Adalimumab 40mg q2w|0.4 or 0.8 mL prefilled, single-dose syringe
75885271|NCT04835272|Procedure|the Decannulation Protocol With Suctioning|In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
75885272|NCT04811248|Other|telephone call for parents of patients|telephone call for parents of patients aged 6 years old
75592900|NCT02760407|Drug|Placebo q2w|sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
75592901|NCT02760368|Drug|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
75592902|NCT02760368|Drug|Placebo|sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules
75592903|NCT02754752|Procedure|Electroacupuncture Therapy|Undergo electroacupuncture therapy
75592904|NCT02754752|Procedure|Electroacupuncture Therapy|Undergo modified electroacupuncture therapy
75592905|NCT02754752|Other|Laboratory Biomarker Analysis|Correlative studies
75592906|NCT02754752|Other|Quality-of-Life Assessment|Ancillary studies
75592907|NCT02754752|Other|Questionnaire Administration|Ancillary studies
75592908|NCT02752750|Other|MRI|MR imaging (MRI) at 3 Tesla
75592909|NCT02747004|Drug|Abemaciclib|Administered orally
75592910|NCT02747004|Drug|Tamoxifen|Administered orally
75592911|NCT02747004|Drug|Prophylactic Loperamide|Administered orally
75592912|NCT02741570|Biological|Nivolumab|
75592913|NCT02741570|Biological|Ipilimumab|
75592914|NCT02741570|Drug|Cetuximab/Erbitux|
75736181|NCT00954486|Drug|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
75736182|NCT03956862|Drug|GB001|film-coated oral tablet
75736183|NCT03956862|Drug|Placebo|film-coated oral tablet
75736184|NCT00550238|Drug|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
75736185|NCT00946946|Drug|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
75443152|NCT01663311|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
75736186|NCT00946946|Drug|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
75736187|NCT00946946|Drug|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
75592915|NCT02741570|Drug|Cisplatin/Platinol|
75736188|NCT00946946|Drug|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
75736189|NCT03956550|Drug|REGN5069|Intravenous (IV) Dose every 4 weeks (Q4W)
75736190|NCT03956550|Drug|Matching Placebo|Intravenous (IV) Dose every 4 weeks (QW4)
75736191|NCT00954668|Procedure|immediate angiography and revascularization|immediate angiography < 2 hours after randomization
75736192|NCT00954668|Procedure|early invasive angiography|early invasive angiography 12-72 h after randomization
75443153|NCT01663324|Device|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS"
75736193|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
75592916|NCT02741570|Drug|Carboplatin/Paraplatin|
75592917|NCT02741570|Drug|Fluorouracil/Adrucil|
75592918|NCT02741180|Other|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
75592919|NCT02741180|Other|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
75592920|NCT02738359|Procedure|optical colonoscopy|optical colonoscopy
75592921|NCT02738359|Procedure|colon capsule endoscopy|colon capsule endoscopy
75592922|NCT02738359|Diagnostic Test|fecal immunological test (FIT)|fecal immunological test (FIT)
75736194|NCT00947024|Drug|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
75736195|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
75736196|NCT01033708|Behavioral|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
75736197|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
75736198|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
75736199|NCT01031992|Drug|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
75736200|NCT01031992|Drug|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
75736201|NCT00954564|Other|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
75736202|NCT00954564|Other|medical chart review|Observational only
75736203|NCT00954564|Other|questionnaire administration|Observational only
75443154|NCT01663324|Device|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS"
75443155|NCT01663337|Behavioral|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
75592923|NCT02730416|Drug|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
75736204|NCT00954564|Procedure|assessment of therapy complications|Observational only
75885273|NCT01373333|Drug|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
75736205|NCT04012346|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.
75736206|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
75885274|NCT01368341|Drug|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
75443156|NCT01663337|Behavioral|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
75443157|NCT01663376|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 ~3x10e8 cells
75443158|NCT01663389|Drug|GSK1322322 1000 mg containing radioactive 14C-GSK1322322|GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
75443159|NCT01663389|Drug|GSK1322322 1200 mg containing radioactive 14C-GSK1322322|GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
75443160|NCT01663415|Drug|Enzalutamide|oral
75443161|NCT01663428|Other|Sup-ER Splint|
75885275|NCT01368341|Drug|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
75885276|NCT01368341|Drug|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
75885277|NCT01368419|Drug|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
75885278|NCT01368419|Radiation|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
75443162|NCT01663428|Other|Currently accepted treatment|
75443163|NCT01663441|Drug|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
75443164|NCT01663441|Drug|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
75443165|NCT01663441|Drug|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
75443166|NCT01663441|Drug|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
75443167|NCT01663454|Behavioral|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
75885279|NCT03139864|Procedure|controlled physical activity|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
75885280|NCT05171933|Behavioral|Survey|This study is based on a survey made on COVID-19
75885281|NCT04639219|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
75443168|NCT01661985|Drug|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
75443169|NCT01661985|Drug|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
75443170|NCT01661985|Drug|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
75443171|NCT01663467|Drug|Ginkgo biloba|Ginexin-F 80mg tablet will be given twice a day for 6 months.
75885282|NCT01373723|Other|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
75885283|NCT04516564|Drug|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects
75885284|NCT04516564|Drug|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects
75885285|NCT05166317|Other|This is an observational study|This is an observational study
75885286|NCT04455100|Drug|SHR1459/Itraconazole|SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
75885287|NCT04332523|Drug|JNJ-53718678|Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.
75885288|NCT04439578|Drug|SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin|600 mg rifampicin was administered in the morning.
75885289|NCT04082585|Behavioral|Total Health Improvement Program|The Total Health Improvement program is a 13 week community based nutrition program designed to assist participants in improving their physical and emotional well being. The program focuses on a plant based diet and increased physical activity.
75885290|NCT03110848|Drug|Atorvastatin|Atorvastatin 20 mg daily
75443172|NCT01663467|Behavioral|modified TRT|"modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
75443173|NCT01663493|Procedure|FNB|
75443174|NCT01663519|Other|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
75443175|NCT01663519|Other|Prefabricated insoles|Prefabricated insoles
75736207|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
75736208|NCT00949728|Procedure|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
75736209|NCT00947102|Other|Observation|
75736210|NCT00954902|Dietary Supplement|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
75885291|NCT03110848|Drug|Methylprednisolone|500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
75885292|NCT03992417|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
75885293|NCT03139474|Drug|Gonadotropin-Releasing Hormone Analogue|Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
75885294|NCT03139474|Drug|Gonadotropin releasing hormone antagonist|antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach > 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
75885295|NCT05166148|Other|Session (a)|Eccentric cycling
76056208|NCT03596606|Procedure|Myofunctional Motor control exercises|"The protocol is a set of 8 exercises to improve the execution of the function in the stomatognathic and cervical area.~The therapist explains the objectives of the exercises and the patient performs it after each session and at home three times a day.~The first day before performing the myofunctional exercises, will be an explanatory talk prior to the exercises in order to educate the patient. The second day, before doing the exercises, will review the concept of memory of pain and the benefits of doing the exercises"
75443176|NCT01663519|Other|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
75592924|NCT02723760|Drug|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
75443177|NCT01663558|Drug|imiquimod|
75736211|NCT00954902|Behavioral|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
75443178|NCT01663558|Procedure|ablative|
75592925|NCT02706197|Device|OxyChip|The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
75736212|NCT00954902|Other|Placebo antioxidant concentrate|Placebo capsules
75736213|NCT01034020|Drug|Nicotine|
75736214|NCT00944372|Drug|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
75885296|NCT05166148|Other|Session (b)|High intensity concentric cycling realized at the same mechanical power output than eccentric cycling
75885297|NCT05166148|Other|Session (c)|Low intensity concentric cycling realized at the same metabolic demand than eccentric cycling
76056209|NCT03590054|Drug|Abexinostat|Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
75443179|NCT01663584|Procedure|Blood draw|
75736215|NCT01032148|Drug|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
75885298|NCT01368575|Procedure|CABG|CABG
75885299|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
75885300|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
75885301|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
75885302|NCT01368575|Procedure|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
75885303|NCT04029142|Diagnostic Test|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
75885304|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
75443180|NCT01663610|Behavioral|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
75443181|NCT01663649|Behavioral|Deprexis|web-based treatment program for depression
75443182|NCT01663649|Behavioral|Wait-list|the wait-list group receives Deprexis after 6 month
75443183|NCT01663662|Drug|Tolvaptan|
75443184|NCT01663662|Drug|placebo|
75443185|NCT01663675|Genetic|karyotype|
75443186|NCT01663701|Other|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
75443187|NCT01663701|Other|Usual care|Patients are managed according to admitting doctors' orders
75443188|NCT01663753|Device|18F-FDG-PET|
75736216|NCT00949806|Drug|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
75736217|NCT00947180|Behavioral|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
75885305|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
75885306|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
75885307|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
75443189|NCT01663766|Drug|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
75443190|NCT01663792|Other|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
75885308|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
75443191|NCT01663792|Other|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
75885309|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
75443192|NCT01663792|Other|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
75885310|NCT01372163|Drug|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
75885311|NCT04170478|Device|Echolaser X4 system|Transperineal laser ablation
75592926|NCT02703610|Drug|Oxycodone/acetaminophen|Patients will be discharged home with a 3 day supply of oxycodone/acetaminophen
75592927|NCT02703610|Drug|Ibuprofen/acetaminophen|Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
75592928|NCT02685566|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
75592929|NCT02685566|Device|FFDM|FujiFilm Aspire Cristalle System
75885312|NCT05142553|Biological|COVID-19 Vaccine HIPRA|Subjects will receive one injection of COVID-19 Vaccine HIPRA
75443193|NCT01663805|Drug|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
75443194|NCT01663818|Device|Tack-It Endovascular Stapler|
75443195|NCT01663831|Other|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
75592930|NCT02683824|Diagnostic Test|Computed Tomography|Undergo CT scan
75443196|NCT01663870|Behavioral|Audio Recorded Interviews|Audio recorded interview at beginning of visit and after using HealthATM website.
75443197|NCT01663870|Behavioral|Focus Group Session|Focus group session taking 60-90 minutes.
75592931|NCT02683824|Other|Laboratory Biomarker Analysis|Correlative studies
75592932|NCT02683824|Diagnostic Test|PET/MRI scan|Undergo PET/MRI scan
75592933|NCT02683824|Drug|[18F]FP-R01-MG-F2|radioactive tracer
75592934|NCT02681185|Other|Virtual Care|"Virtual Care consists of the following services and resources:~Have a virtual consult through online methods or telephone with one of the study endocrinologists~Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods~Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic~Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support."
75592935|NCT02681185|Other|Standard of Care|Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
75592936|NCT02675231|Drug|Abemaciclib|Administered Orally
75592937|NCT02675231|Drug|Trastuzumab|Administered IV
75885313|NCT05142553|Biological|Cominarty (Pfizer-BioNtech)|Subjects will receive one injection of Cominarty Vaccine
75885314|NCT03943966|Diagnostic Test|18F-GP1 PET CT|PET CT scan using platelet radiotracer 18F-GP1
75885315|NCT01373801|Device|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
75885316|NCT01373801|Device|Control|Standard packing gauze roll bandage.
76056210|NCT03590054|Biological|Pembrolizumab|Given IV on day 1 of every 21 day cycle
75443198|NCT01663870|Other|Website Session|10-15 minute session with the HealthATM website.
75885317|NCT01372241|Behavioral|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
75736218|NCT00947180|Other|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
75736219|NCT00947180|Behavioral|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
75736220|NCT01032304|Drug|Erdosteine|One 300 mg capsule twice a day
75736221|NCT01032304|Drug|Placebo|One capsule twice a day
75736222|NCT05190510|Other|Data collection|Collection of data from preoperative imaging examinations (routine examination prescribed before the operation)
75443199|NCT01663870|Behavioral|Questionnaire|Questionnaire completion at end of audio recorded interview taking about 5 minutes.
75736223|NCT05190510|Procedure|collection of the carotid plaque (surgical specimen)|collection of the carotid plaque
75736224|NCT05190510|Other|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens
75443200|NCT01663883|Other|Isometric exercise|use of a handgrip for 3x2 minutes
75443201|NCT01663909|Behavioral|Guided imagery intervention|A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
75443202|NCT01663961|Drug|YM178 OCAS|oral
75736225|NCT00954642|Drug|bevacizumab|Intravenous repeating dose
75885318|NCT03442504|Diagnostic Test|FES PET/CT|"There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service."
75885319|NCT03140566|Diagnostic Test|Ultrasound evaluation of the inferior vena cava diameter|Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index >50% in addition to relief of symptoms and signs of congestion before discharge.
76056211|NCT03581123|Behavioral|Supported-Self Management (SSM)|Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
75443203|NCT01663961|Drug|Digoxin|oral
75443204|NCT01664000|Drug|thioureidobutyronitrile|Kevetrin (thioureidobutyronitrile)
75443205|NCT01664013|Drug|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
75443206|NCT01664026|Behavioral|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
75443207|NCT01664026|Behavioral|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
75592938|NCT02675231|Drug|Fulvestrant|Administered IM
75592939|NCT02675231|Drug|Standard of Care Single Agent Chemotherapy|Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
75592940|NCT02661035|Drug|Allopurinol|300 mg/day (for peds -150 mg/m^2/day), day -6 and continue through day 0 or longer if clinically indicated
75592941|NCT02661035|Drug|Fludarabine|30 mg/m^2 IV over 1 hour, day -6, -5, -4, -3 and -2
75592942|NCT02661035|Drug|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
75592943|NCT02661035|Drug|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
75592944|NCT02661035|Radiation|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
75736226|NCT00954642|Drug|MNRP1685A|Escalating intravenous dose
75736227|NCT00954642|Drug|paclitaxel|Intravenous repeating dose
75736228|NCT00955058|Drug|OCP|Daily For 3 months
76056212|NCT03581123|Other|Spinal Manipulation Therapy (SMT)|SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
75443208|NCT01664065|Drug|200 mg Ceftaroline fosamil|1 h infusion
75443209|NCT01664065|Drug|600 mg Ceftaroline fosamil|1 h infusion
75443210|NCT01664143|Drug|Placebo|Multiple doses of placebo
75443211|NCT01664143|Drug|RO5508887|Multiple doses of RO5508887
75736229|NCT01024816|Behavioral|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
75443212|NCT01664156|Drug|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
75592945|NCT02661035|Drug|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
75443213|NCT01664156|Drug|Placebo|
75443214|NCT01664169|Other|laboratory biomarker analysis|
75443215|NCT01664195|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
75592946|NCT02661035|Drug|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, MMF will continue as long as clinically indicated."
75592947|NCT02661035|Biological|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
75592948|NCT02661035|Biological|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
75592949|NCT02641483|Other|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
75769144|NCT01250158|Device|Liver-PILP kit|"Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.~The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.~The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.~The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen."
76056213|NCT03581123|Combination Product|SMT + SSM|Combination Treatment
76056214|NCT03581123|Drug|Standard Medical Care (SMC)|Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
76056215|NCT03568097|Drug|Avelumab|10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
75443216|NCT01664221|Drug|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
75443217|NCT01664260|Drug|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
75443218|NCT01664260|Drug|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
75443219|NCT01664273|Drug|Plasmid AMEP|"Cohorts of 3 patients will received increasing doses of plasmid AMEP:~50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.~Injection volume will remain constant at 200 μL.~Once-only treatment and intra-individual dose escalation will therefore not occur."
75736230|NCT01024816|Behavioral|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
76056216|NCT03546582|Drug|Pembrolizumab|Anti-PD-1 targeted immunotherapy
76056217|NCT03546582|Radiation|Stereotactic Body Radiation Therapy (SBRT)|High-precision radiotherapy
76056218|NCT03536585|Device|Vulvovaginal treatment|"Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes."
76056219|NCT03536585|Device|Baseline|Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
76056220|NCT03511352|Behavioral|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
76056221|NCT03511352|Behavioral|Stand More|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
75885320|NCT03140566|Diagnostic Test|Sham ultrasound evaluation of the inferior vena cava diameter|Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
75885321|NCT01319747|Procedure|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
75885322|NCT01319747|Procedure|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
76056222|NCT03382860|Diagnostic Test|Fundus videos|Recordings of fundus videos
76056223|NCT03381326|Procedure|blood and FFPE sample collection|blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection
75592950|NCT02627846|Device|EVLA|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
75592951|NCT02627846|Device|ClariVein®|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
75736231|NCT00954720|Other|No Intervention|There is no intervention on this trial
75736232|NCT01024894|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
75769145|NCT01251250|Other|laboratory biomarker analysis|Correlative studies
75885323|NCT02038972|Genetic|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
75885324|NCT03895684|Drug|SP-2577 Seclidemstat|Dose escalation and dose expansion of SP-2577.
75885325|NCT01368887|Drug|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
75885326|NCT01368887|Other|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
75885327|NCT01368887|Drug|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
75885328|NCT01368887|Drug|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
75885329|NCT03859258|Device|Transvaginal sonography|Niche is assessed using TVS, SIS (cases only) and office hysteroscopy
76056224|NCT03354377|Behavioral|Dietary Intervention Meetings|Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.
75885330|NCT05049083|Drug|New Process SHR2554 tablet、Former Process SHR2554 tablet|New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
75885331|NCT05049083|Drug|Former Process SHR2554 tablet、New Process SHR2554 tablet|Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
75736233|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
75443220|NCT01664520|Drug|Dexmedetomidine infusion|"Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.~Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments"
75443221|NCT01664546|Procedure|Trophectoderm biopsy|
75885332|NCT01369043|Dietary Supplement|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
75885333|NCT04477096|Drug|HS-10234|HS-10234
75885334|NCT04477096|Drug|Emtricitabine|Emtricitabine
75592952|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
75592953|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
75736234|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
75885335|NCT01369121|Drug|XERECEPT|BID dosing, subcutaneous for 1 year
75885336|NCT03868150|Drug|Amiodarone Injection|Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
75885337|NCT03868150|Device|Intraoperative Rapid Atrial Pacing|Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
75736235|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
75736236|NCT00110305|Drug|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
75736237|NCT00110305|Drug|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
75736238|NCT00110305|Drug|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
75769146|NCT01251250|Genetic|western blotting|Correlative studies
75443222|NCT01664585|Behavioral|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
75736239|NCT00110305|Drug|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
75885338|NCT03606239|Radiation|isotoxic hypofractionated group|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
75736240|NCT00110305|Drug|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
75736241|NCT00954954|Device|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
75885339|NCT03551795|Biological|Infusion of iNKT cells|The eligible patients receive twice infusions of iNKT cells(1E8~1E10) in one course of treatment.
75885340|NCT03141892|Device|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
75885341|NCT05084794|Procedure|Internal fixation|Fixation of posterior malleolus with either plate or screws.
75885342|NCT03521687|Drug|Apremilast|30 mg BID
75885343|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
75443223|NCT01664585|Behavioral|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
75443224|NCT01664611|Procedure|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
75736242|NCT00954954|Device|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
75736243|NCT00428116|Drug|HAART|Combination first line antiretrovirals as previously described.
75736244|NCT00560066|Biological|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
75736245|NCT00560066|Biological|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
75885344|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
75885345|NCT03141658|Drug|Placebo|Multiple doses of placebo once daily for 6 days
75885346|NCT03141658|Other|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
75443225|NCT01664611|Procedure|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
75443226|NCT01664637|Drug|10 mg TZP-102|One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
75736246|NCT00549900|Biological|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
75736247|NCT00435994|Drug|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
75736248|NCT00435994|Other|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
75736249|NCT00947258|Other|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
75736250|NCT01563120|Drug|metformin|metformin up to 2550mg per day.
75736251|NCT01563120|Drug|glybenclamide|glybenclamide up to 20mg per day.
75736252|NCT00435370|Drug|Tropisetron|10 mg/day
75736253|NCT00435370|Drug|Placebo|placebo
75736254|NCT00435370|Drug|Risperidone|6mg/day
75736255|NCT05098548|Procedure|angioplasty|using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
75736256|NCT00096031|Biological|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
75769147|NCT01251250|Genetic|gene expression analysis|Correlative studies
75769148|NCT01251250|Other|pharmacological study|Correlative studies
75885347|NCT03139396|Procedure|tub shaped inlay bridge design|inlay retained bridge with tub shaped retainer on both abutments
75885348|NCT03498911|Procedure|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
76056225|NCT03354377|Behavioral|Physical Activity|Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.
76056226|NCT03354377|Behavioral|Podcasts/Mailings|Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
75736257|NCT04010526|Combination Product|local co-administration of autologous ADIpose|local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging.
75736258|NCT04010526|Other|placebo|local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV
75736259|NCT05043324|Drug|AntiCov-220 (1)|The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.
75736260|NCT05043324|Drug|AntiCov-220 (2)|The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
75736261|NCT04303728|Diagnostic Test|Muscle ultrasound|The muscle thickness and muscle quality will be assessed on ultrasound
75736262|NCT00118417|Drug|Clonazepam|Participants will receive clonazepam.
75736263|NCT00118417|Drug|Sertraline|Participants will receive sertraline.
75885349|NCT03142048|Other|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
75885350|NCT05411419|Procedure|Spinal cord stimulation|Two leads for spinal cord stimulation would be implanted.
75885351|NCT03498131|Drug|3 mg Melatonin|3 mg melatonin once each day
75885352|NCT03498131|Drug|5 mg Melatonin|5 mg Melatonin once each day
75736264|NCT00118417|Behavioral|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
75443227|NCT01664637|Drug|Placebo|One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
75443228|NCT01664650|Dietary Supplement|Genistein|
75443229|NCT01664650|Dietary Supplement|Placebo|
75736265|NCT04293744|Device|Colloid priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
75736266|NCT04293744|Device|Standard priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
75736267|NCT00955188|Other|computer-assisted intervention|
75736268|NCT00955188|Other|educational intervention|
75885353|NCT03141580|Diagnostic Test|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
75885354|NCT05013827|Behavioral|Filling in an online survey|Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
75885355|NCT03287752|Device|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
75885356|NCT03287752|Device|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
75885357|NCT04566289|Device|PiCSO|Percutaneous coronary intervention
75885358|NCT01319825|Drug|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
75736269|NCT00955188|Other|medical chart review|
75885359|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
75443230|NCT01664663|Radiation|Standard radiochemotherapy to 68 Gy|
75443231|NCT01664663|Radiation|Dose escalated radiochemotherapy up to 84 Gy|
75885360|NCT01369277|Drug|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
75885361|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
75443232|NCT01664676|Drug|Liraglutide|
75443233|NCT01664676|Drug|Placebo-liraglutide|
75443234|NCT01664689|Procedure|Microcoaxial Phacoemulsification|
75443235|NCT01664702|Dietary Supplement|Dairy Products|See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
75736270|NCT01080703|Other|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
75736271|NCT01079455|Drug|Corticosterone|Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
75736272|NCT00549848|Drug|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
75736273|NCT00549848|Drug|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
75736274|NCT01083589|Drug|Imatinib Mesylate|Oral 400 mg daily
75736275|NCT01083589|Drug|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
75885362|NCT02983006|Biological|DS-8273a|"Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
75885363|NCT02983006|Biological|Nivolumab|5 mg/kg IV Q 3 weeks
75885364|NCT05409859|Other|Manual therapies|Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
75736276|NCT01080859|Device|OCT|Optical coherence tomography
75885365|NCT04983953|Device|cHS|Clinical decision support system for diagnosing intracranial haemorrhage
75736277|NCT01080859|Device|OCT|Optical coherence tomography
75885366|NCT03811756|Dietary Supplement|Test syrup containing CoQ10 and collagen|Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
75885367|NCT03811756|Dietary Supplement|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
75885368|NCT03125915|Behavioral|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
75885369|NCT03125915|Behavioral|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
75736278|NCT01079533|Behavioral|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
75885370|NCT03125915|Behavioral|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
75885371|NCT05397067|Behavioral|Peer specialist (PS) and vouchers|this participants will receive vouchers from PS
75736279|NCT01079533|Behavioral|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
75736280|NCT05299788|Other|Active external warming|In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .
75769149|NCT01251250|Other|flow cytometry|Correlative studies
75769150|NCT01251250|Genetic|fluorescence in situ hybridization|Correlative studies
75769151|NCT01251250|Biological|azadirachta indica|Given orally
75885372|NCT03141268|Diagnostic Test|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
75885373|NCT03139006|Device|Dual-layer spectral detector CT|A dual energy CT approach
75885374|NCT03122171|Other|Occupational Therapy Treatment|Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
75885375|NCT03138850|Device|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
75885376|NCT03138850|Device|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
75885377|NCT03138850|Device|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
75885378|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
75885379|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
75443236|NCT01664702|Dietary Supplement|Dairy Servings|Continue baseline consumption of one or fewer servings of dairy per day
75443237|NCT01664728|Drug|Abiraterone acetate|Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
75885380|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
75885381|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
75443238|NCT01664728|Drug|Glucocorticoid|prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
75443239|NCT01664754|Drug|exemestane|Given PO
75443240|NCT01664754|Drug|pemetrexed disodium|Given IV
75443241|NCT01664754|Drug|carboplatin|Given IV
75443242|NCT01664754|Other|laboratory biomarker analysis|Correlative studies
75885382|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
75885383|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
75443243|NCT01664754|Other|pharmacological study|Correlative studies
75592954|NCT02627846|Drug|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
75443244|NCT01664754|Other|questionnaire administration|Ancillary studies
75592955|NCT02627846|Drug|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
75592956|NCT02603887|Other|Laboratory Biomarker Analysis|Correlative studies
75592957|NCT02603887|Biological|Pembrolizumab|Given IV
75592958|NCT02581787|Biological|Fresolimumab|Given IV
75592959|NCT02581787|Radiation|Stereotactic Body Radiation Therapy|Undergo SABR
75592960|NCT02576496|Drug|Tinostamustine|
75592961|NCT02573766|Procedure|Neurofeedback Training|Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
75592962|NCT02573766|Procedure|Electroencephalogram|"Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month."
75592963|NCT02573766|Behavioral|Pain Scale|Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
75592964|NCT02573766|Behavioral|Questionnaires|Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
75592965|NCT02554279|Drug|menotropin|
75592966|NCT02554279|Drug|recombinant FSH|
75592967|NCT02542293|Biological|Durvalumab +Tremelimumab|
75592968|NCT02542293|Drug|Paclitaxel + carboplatin|Chemotherapy Agents
75592969|NCT02542293|Drug|Gemcitabine + cisplatin|Chemotherapy Agents
75592970|NCT02542293|Drug|Gemcitabine + carboplatin|Chemotherapy Agents
75592971|NCT02542293|Drug|Pemetrexed + cisplatin|Chemotherapy Agent
75592972|NCT02542293|Drug|Pemetrexed + carboplatin|Chemotherapy Agent
75736281|NCT05299788|Other|Ice application|In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
75885384|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
75443245|NCT01664754|Procedure|quality-of-life assessment|Ancillary studies
75443246|NCT01664767|Other|Sulfur Thermal water|
75736282|NCT00949182|Drug|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
75736283|NCT00949182|Other|laboratory biomarker analysis|
75736284|NCT00955344|Behavioral|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
75736285|NCT00955344|Behavioral|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
75885385|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
75443247|NCT01664767|Other|Placebo|
75443248|NCT01664780|Device|ARFI imaging|
75443249|NCT01664819|Dietary Supplement|Antioxidant|
75443250|NCT01664819|Dietary Supplement|Placebo|
75443251|NCT01664832|Device|S-nIMV|Synchronization of nasal breaths to infant's own respiratory effort
75443252|NCT01664845|Drug|metformin|metformin 500mg tid
75443253|NCT01664845|Drug|pegylated-IFN|pegasys 180 mcg qw
75592973|NCT02535988|Radiation|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
75592974|NCT02535988|Drug|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
75592975|NCT02515773|Drug|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
75592976|NCT02515773|Behavioral|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
75592977|NCT02511730|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
75592978|NCT02511730|Device|FFDM|FujiFilm Aspire Cristalle System
75592979|NCT02510417|Biological|VSTs|most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus
75592980|NCT02484248|Drug|Ketotifen|Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
75592981|NCT02484248|Drug|Placebo|The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
75885386|NCT03663088|Other|GPR-A|Standard Global postural re-education physiotherapy scoliosis specific exercises
75885387|NCT03663088|Other|GPR-B|Experimental Global postural re-education physiotherapy scoliosis specific exercises combining individual and class exercises
75885388|NCT03138928|Device|XEN45 gel stent implantation in glaucoma surgery|The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space
75885389|NCT03634696|Other|mPCL|Smart phone application to support palliative care among late-stage cancer patients
75885390|NCT03634696|Other|Usual Care|Usual care through OCRI palliative care clinic
75885391|NCT03634163|Behavioral|Neighbourhood exchange|Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
75885392|NCT03634163|Behavioral|Quality of Life Assessment|Completion of baseline measures
75885393|NCT05084170|Procedure|Bilateral anterior cingulotomy|Stereotactic bilateral anterior cingulotomy is a brain operation with demonstrated efficacy in the treatment of intractable pain from a variety of causes, including a few cases of spinal cord injury related neuropathic pain.
75885394|NCT03316781|Drug|HLX03|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
75885395|NCT03316781|Drug|adalimumab|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
75885396|NCT03138772|Other|This is an observational study, no intervention used.|No intervention is being used in this study.
75885397|NCT01427725|Drug|Lipacreon|This study was an observational study and no intervention was specified
75885398|NCT01319903|Biological|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
75885399|NCT05084014|Other|Deep Stripping|The deep longitudinal stripping can be applied on adhesions and knots in muscles. The lengthening stokes are parallel to muscle fiber and applied in an oblique direction with the help of the thumbs of hands/ elbow/ knuckles
75885400|NCT05084014|Other|Kneading|kneading lifts the muscle in circular movements with the help of the hands. It lifted, rolled, and squeezed muscle
75885401|NCT03138694|Other|BHCG monitoring|Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
75885402|NCT02839200|Drug|ACT-541468 5 mg|Capsule for oral administration containing ACT-541468 at a strength of 5 mg
75885403|NCT02839200|Drug|ACT-541468 10 mg|Capsule for oral administration containing ACT-541468 at a strength of 10 mg
75443254|NCT01664845|Drug|ribavirin|ribavirin 800-1200 mg qd according to BW
75885404|NCT02839200|Drug|ACT-541468 25 mg|Capsule for oral administration containing ACT-541468 at a strength of 25 mg
75885405|NCT02839200|Drug|Zolpidem|Over-encapsulated zolpidem tablet at a strength of 10 mg
75885406|NCT02839200|Drug|Placebo 1|Placebo capsules matching ACT-541468 capsules
75592982|NCT02478788|Drug|mixed amphetamine salts-extended release (MAS-XR)|MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
75592983|NCT02478788|Drug|Placebo|Pills with no medication in it
75592984|NCT02456194|Device|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
75885407|NCT02839200|Drug|Placebo 2|Placebo capsules matching over-encapsulated zolpidem
75736286|NCT01083823|Other|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
75592985|NCT02439450|Biological|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
75736287|NCT00549770|Drug|LCZ696|
75736288|NCT00549770|Drug|Valsartan|
75736289|NCT00549770|Drug|AHU377|
75885408|NCT04846907|Other|Web-based survey|Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
75592986|NCT02439450|Drug|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
75736290|NCT00549770|Drug|Placebo|
75736291|NCT00548184|Drug|Lapatinib|Monoclonal Antibody
75736292|NCT00548184|Drug|Trastuzumab|Monoclonal Antibody
75443255|NCT01664871|Device|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
75736293|NCT00548184|Drug|Endocrine|Hormonal Therapy
75736294|NCT00955500|Dietary Supplement|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
75736295|NCT00955500|Dietary Supplement|Maltodextrin|30 grams of oral maltodextrin daily
75736296|NCT00955578|Procedure|Punch Biopsy|5-6 punch biopsies of affected areas
75736297|NCT00955734|Other|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
75736298|NCT00955734|Other|Immobilization|This set of patients will be casted for 6 weeks after surgery.
75736299|NCT00955812|Drug|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
75736300|NCT04010994|Procedure|Transorbital electrical stimulation|Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
75885409|NCT05083936|Drug|[18F]FET|Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
75885410|NCT01375907|Drug|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
75592987|NCT02439450|Drug|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
75592988|NCT02439450|Drug|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
75592989|NCT02437136|Drug|entinostat|An orally available histone deacetylases inhibitor (HDACs)
75592990|NCT02437136|Drug|pembrolizumab|A selective humanized monoclonal antibody (mAb)
75592991|NCT02435758|Procedure|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
75592992|NCT02403778|Drug|VESANOID|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
75592993|NCT02403778|Drug|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
75592994|NCT02386826|Drug|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
75592995|NCT02386826|Biological|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
75592996|NCT02378272|Other|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
75592997|NCT02365454|Device|Stent Graft Placement (Nexus)|"The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.~This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system."
75592998|NCT02326402|Device|TandemHeart or LifeSPARC System|Percutaneous insertion of TandemHeart or LifeSPARC System
75592999|NCT02312258|Drug|Placebo|Ixazomib placebo-matching capsules.
75593000|NCT02312258|Drug|Ixazomib|Ixazomib capsules.
75593001|NCT02276274|Drug|SYR-322-MET|Oral administration of SYR-322-MET
75593002|NCT02221700|Procedure|Massage Therapy|Undergo massage therapy
75769152|NCT01251250|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
75769153|NCT01073982|Dietary Supplement|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
75769154|NCT01250236|Drug|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
75769155|NCT01250236|Drug|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
75769156|NCT01074060|Drug|plerixafor|Given IV
75769157|NCT01074060|Biological|filgrastim|Given SC
75769158|NCT01074060|Drug|cyclophosphamide|Given IV
75769159|NCT01074060|Procedure|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
75769160|NCT01074060|Other|laboratory biomarker analysis|Correlative studies
75443256|NCT01664936|Radiation|Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I|We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
75593003|NCT02221700|Other|Quality-of-Life Assessment|Ancillary studies
75593004|NCT02221700|Other|Questionnaire Administration|Ancillary studies
75885411|NCT05083858|Other|Classical Physiotherapy Program + Cervical Stabilization Exercises|First of all, patients will be taught correct craniocervical flexion movement without activation of superficial muscles in different positions (supine, prone, crawling, sitting, standing). The program will be continued by asking to maintain the cranio-cervical flexion position during all movements. In order to gain dynamic stabilization, unilateral, bilateral, contralateral, ipsilateral and reciprocal extremity movements will be added to the program together with craniocervical flexion movement. Resistance will be added to the exercises as control of the movement is achieved. The exercises will progress from static to dynamic, from stationary floors to moving floors, from simple movements to complex movements.
75443257|NCT01665001|Other|Treatment strategy: induction, consolidation, HSCT, maintenance|"Patients <55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD <0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.~Patients >55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.~Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT."
75443258|NCT01665014|Radiation|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
75593005|NCT02203903|Biological|Tumor associated antigen lymphocytes (TAA-T)|TAA-T may be generated from donors or recipients and will be tested for specificity to 3 tumor antigens commonly found in hematological malignancies (WT1, PRAME, and SURVIVIN,). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
75736301|NCT05299710|Procedure|Laparoscopic surgery|Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
75736302|NCT00454636|Drug|Cisplatin|80 mg/m2/day, intravenous (IV), every 3 weeks
75736303|NCT00454636|Drug|Capecitabine|1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
75885412|NCT05083858|Other|Classical Physiotherapy Program + Oculomotor Exercises|Oculomotor Exercises is a program consisting of exercises that support proprioception in the cervical region. It consists of 4 main contents; Sacadic Eye movements, Gaze stability, Head/eye coordination, Head repositioning exercise.
75593006|NCT02203240|Other|Cocoa|
75593007|NCT02203240|Other|Placebo|
75593008|NCT02199184|Drug|Cyclophosphamide|Given IV
75593009|NCT02199184|Drug|Doxorubicin Hydrochloride|Given IV
75593010|NCT02199184|Drug|Etoposide|Given IV
75593011|NCT02199184|Biological|Ofatumumab|Given IV
75593012|NCT02199184|Drug|Prednisone|Given PO
75593013|NCT02199184|Biological|Rituximab|Given IV
75593014|NCT02199184|Drug|Vincristine Sulfate|Given IV
75593015|NCT02196376|Other|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
75593016|NCT02196376|Other|Physical|"the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis"
75736304|NCT00454636|Drug|Epirubicin|50 mg/m2/day, IV, every 3 weeks
75736305|NCT00454636|Drug|Cisplatin|60 mg/m2/day, IV, every 3 weeks
75736306|NCT00454636|Drug|Capecitabine|625 mg/m2, oral, twice daily per 3-week cycle
75736307|NCT00454636|Drug|Oxaliplatin|130 mg/m2/day, IV, every 3 weeks
75736308|NCT00454636|Drug|Docetaxel|60 mg/m2/day, IV, every 3 weeks
75736309|NCT00454636|Drug|Capecitabine|825 mg/m2, oral, twice daily for 2 weeks
76056227|NCT03338374|Device|Biventricular pacemaker|All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
75443259|NCT01665027|Procedure|vacuum|"Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).~Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections."
75443260|NCT01665027|Procedure|routine manual maneuvers for fetal head extraction|fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
75443261|NCT01665066|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
75593017|NCT02196376|Other|blood draw|"blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn."
75593018|NCT02196376|Behavioral|Questionnaires|"The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31"
75593019|NCT02185755|Other|Internet-Based Glucose Monitoring System|
75593020|NCT02185755|Drug|Normal Medication Positive Control|
75736310|NCT04850196|Device|TEAS|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
75736311|NCT04850196|Other|control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
75443262|NCT01665066|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
75443263|NCT01665066|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
75443264|NCT01665066|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
76056228|NCT03251495|Drug|Vaxchora|Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
75443265|NCT01665066|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
75593021|NCT02165007|Drug|peripheral blood stem cell graft that are CD34+ selected|The preparatory regimen will consist of Hydroxyurea from Days -50 to -22, Alemtuzumab from days -21 to -19 (test dose Alemtuzumab on day -22), Fludarabine days -8 to -4, Thiotepa Day -4, Melphalan day -3 to -2 (Table 4a). In patients with intolerance to or have received alemtuzumab in the prior 6 months, alemtuzumab will be replaced with rabbit ATG on days -10 through -7, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year.
75593022|NCT02164734|Device|Endotracheal intubation|
75593023|NCT02164734|Device|Laryngeal mask airway|
75593024|NCT02164734|Drug|remifentanil|additional premedication in the endotracheal intubation/INSURE arm
75593025|NCT02135133|Drug|Idelalisib|150 mg BID Oral Daily
75736312|NCT00427960|Behavioral|Dietary advice|
75736313|NCT00427960|Drug|rosuvastatin|rosuvastatin 5 mg
76056229|NCT03239132|Behavioral|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
76056230|NCT03239132|Behavioral|Meditation educational materials|Meditation educational materials
76056231|NCT03234478|Other|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
76056232|NCT03226249|Procedure|Computed Tomography|Undergo FDG-PET/CT
76056233|NCT03226249|Drug|Dacarbazine|Given IV
75885413|NCT05083858|Other|Classical Physiotherapy Program|"Conventional TENS will be applied to apply analgesic current. TENS application will be made to the cervical paravertebral region, using four 5 x 5 cm adhesive surface electrodes, at 80 Hz frequency for 20 minutes, 100 msec.~All participants will be asked to lie in a prone position. The neck will be in a neutral position. The hot pack will be applied to the cervical region for 20 minutes.~Classical massage will be applied for 20 minutes using the Swedish technique. The technique will be performed on the upper and neck region of the back with 3 strokes, 3 kneading and 3 strokes. The patient will be massaged while lying in the prone position.~Stretching/Posture Exercises Exercises will be applied as a 5-10 minute warm-up-cool-down program at the beginning and end of the study. Cervical flexor, lateral flexor, rotator muscles, pectorals, inferior shoulder joint capsule will be stretched. In addition to this, posture exercises will also be done."
75736314|NCT00427960|Drug|atorvastatin|atorvastatin 10 mg
75736315|NCT00548340|Drug|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
75885414|NCT01369667|Dietary Supplement|Vitamin D3|
75885415|NCT01369667|Other|Placebo|
76056234|NCT03226249|Drug|Doxorubicin Hydrochloride|Given IV
76056235|NCT03226249|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
76056236|NCT03226249|Other|Laboratory Biomarker Analysis|Correlative studies
76056237|NCT03226249|Biological|Pembrolizumab|Given IV
76056238|NCT03226249|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
76056239|NCT03226249|Drug|Vinblastine Sulfate|Given IV
76056240|NCT03184155|Drug|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
76056241|NCT03184155|Drug|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
75593026|NCT02135133|Drug|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
75593027|NCT02131805|Radiation|Electronic Skin Surface Brachytherapy|
75593028|NCT02131805|Behavioral|Quality of life assessment|
75593029|NCT02110069|Drug|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
75593030|NCT02110069|Drug|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
75593031|NCT02049515|Drug|IPI-145|PI3K Inhibitor
75593032|NCT02049515|Drug|Ofatumumab|Monoclonal antibody
75736316|NCT00548340|Drug|Placebo|Placebo capsules, PO daily for five weeks
75736317|NCT00548340|Drug|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
75736318|NCT04839588|Other|Usability study|"Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center."
76056242|NCT03172624|Drug|Nivolumab|nivolumab 3 mg/kg every 2 weeks
76056243|NCT03172624|Drug|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
76056244|NCT03100331|Other|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
76056245|NCT03063944|Drug|STAT Inhibitor OPB-111077|Given PO
76056246|NCT03063944|Drug|Decitabine|Given IV
76056247|NCT03063944|Drug|Venetoclax|Given PO
76056248|NCT03063944|Other|Laboratory Biomarker Analysis|Correlative studies
76056249|NCT03062631|Drug|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
76056250|NCT03013309|Behavioral|Family Check-Up 4 Health|A parent-training intervention to improve child health and prevent/manage obesity
76056251|NCT03013309|Other|Treatment as usual|Treatment as usual
76056252|NCT02971046|Other|varying protein intakes|"In healthy school-aged children: Four randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are 0.95, 1.3,1.55, and 2.0 grams per kilogram of bodyweight per day.~In healthy young and old adults: Up to six randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are : 0.66, 0.8, 1, 1.2, and 1.5 grams per kilogram of bodyweight per day."
75593033|NCT02046460|Drug|Acetylsalicylic acid|Acetylsalicylic acid, 300mg o.p.d.
76056253|NCT02901860|Other|Sleep, Dietary and Cardio-metabolic Measurements|"At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken."
76056254|NCT02849548|Drug|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
76056255|NCT02849548|Other|placebo|Pill with inactive ingredients
75736319|NCT03994198|Dietary Supplement|Alpha-lactalbumin|A protein fraction of whey protein, higher in tryptophan
75885416|NCT05083702|Procedure|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|Patient lies prone, L5-S1 interspace identified under fluoroscopy, the skin is prepared and sterile drapes are placed after local anesthetic infiltration of the skin the subcutaneous tissue with 2% lidocaine a 20 guage, 15 cm needle with short bevel is inserted at the center of L5- S1 interlaminar space under anteroposterior fluoroscopic vision. The needle is then advanced toward the intervertebral disc. After confirmation, the needle is advanced through the intervertebral disc until it exists at its anterior surface confirmed by administration of 4 ml of soluble contrast media in both lateral and anteroposterior fluoroscopic view. Neurolysis is performed with 8 ml 8 % phenol solution. After neurolysis, 0.5 ml of saline is given to avoid the deposition of phenol within the intervertebral disc material. While withdrawing, the needle cephazoline 50 mg in 1 ml is injected into the disc.
75885417|NCT05083702|Procedure|ultrasound-guided superior hypogastric plexus block|Patients are placed in the supine position and after sterilization, the low-frequency curved probe is used in the longitudinal axis to visualize the aortic bifurcation and is identified using a longitudinal Ultra-Sound (Phillips Healthcare, Andover, Massachusetts, US). Next, the probe is placed deeply transverse till aorta end and bifurcation seen of iliac vessels once seen we enter out of plane and inject.as it lies in front the vertebral body of the L5 vertebra. Local infiltration with 1% lidocaine is obtained at port of entry 1-1.5 inches below the umbilicus. A 15-cm, 22-G Chiba needle is inserted (out-of-plane) and advanced by avoiding vascular structures until contact with the L5-body. The needle will be withdrawan the 1-2 mm and inject 8 ml 8% phenol in saline. Finally, 0.5 ml of lidocaine is injected during Chiba needle removal
75885418|NCT03564912|Drug|Capecitabine Oral Tablet [Xeloda]|2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
75885419|NCT05083624|Behavioral|rehabilation therapy|After comprehensive assessment by doctors, nurses and rehabilitation therapists, patients gradually begin rehabilitation treatment.IMS 0: no mobilisation or passively exercised by staff. IMS 1: sitting in bed and actively exercising .IMS 2: passively moved to chair without standing.IMS 3: sitting over edge of bed.IMS 4: standing in front of bed.IMS 5: transferring bed to chair.IMS 6: marching on spot.IMS 7: walking with assistance of more than one person.IMS 8: walking with assistance of one person.IMS 9: walking independently with a gait aid.IMS 10: walking independently without a gait aid.
75885420|NCT01369901|Behavioral|A functional exercise program|
75593034|NCT02046460|Drug|Vitamin K antagonist|Vitamin K-antagonists, target INR 2.0-3.0
75736320|NCT03994198|Dietary Supplement|Collagen peptides|Collagen peptides from bovine sources
75736321|NCT04142814|Procedure|T-PEP|"First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist."
75736322|NCT04142814|Procedure|IPV|IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
75885421|NCT01369901|Behavioral|A stretching exercise program|
75443266|NCT01665079|Drug|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 > 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS > 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
75443267|NCT01665105|Device|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
75593035|NCT02039401|Biological|VM202|
75593036|NCT02004522|Drug|Duvelisib|PI3K Inhibitor
75593037|NCT02004522|Drug|Ofatumumab|monoclonal antibody
75593038|NCT01959139|Drug|PEGPH20|3 ug/kg on Day 1, IV over 15 minutes
75593039|NCT01959139|Drug|Oxaliplatin|85 mg/m^2, on Day 2, IV over 2 hours
75593040|NCT01959139|Drug|Leucovorin|400 mg/m^2, on Day 2, IV over 2 hours
75593041|NCT01959139|Drug|Irinotecan|180 mg/m^2, on Day 2, IV over 1.5 hours
75593042|NCT01959139|Drug|5-fluorouracil|2,400 mg/m^2, Days 2-4, IV over 46 hours
75885422|NCT01567969|Behavioral|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
75885423|NCT01567969|Behavioral|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
75885424|NCT03551626|Drug|Dabrafenib|Supplied as dabrafenib 50 mg, 75 mg Capsules for oral use
76056256|NCT02791685|Behavioral|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
75885425|NCT03551626|Drug|Trametinib|supplied as trametinib 0.5mg, 2.0mg tablets for oral use
76056257|NCT02791685|Behavioral|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
76056258|NCT02791685|Behavioral|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
75736323|NCT04010760|Diagnostic Test|Test of biomarkers for PE in EBC|"New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient."
76056259|NCT02780310|Drug|Lenvatinib|
75593043|NCT01956084|Drug|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
75736324|NCT00955890|Drug|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
75736325|NCT00955890|Drug|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
75885426|NCT03565146|Device|PiQo4 Laser System|PiQo4 Laser System for treatment of pigmented lesions
75885427|NCT05353686|Drug|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
75885428|NCT05353686|Drug|XEN-D0501|Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
75885429|NCT05760053|Drug|EP/EC+PD-1|Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
75885430|NCT03509116|Other|Observations|Consultation observations
75885431|NCT03509116|Other|Interviews, key stakeholders, documents|Qualitative interviews, key stakeholders, documentary analysis
75885432|NCT03121157|Behavioral|Multi-Component Technology Based Intervention|The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
75443268|NCT01665131|Device|Cameron Health S-ICD SQ-RX|
75885433|NCT03505060|Biological|DNA CON-S env|Administered by intramuscular injection in the deltoid.
76056260|NCT02772367|Procedure|skin punch biopsy|
76056261|NCT02763072|Device|Enlighten Laser|
76056262|NCT02763072|Device|Excel V Laser|
75443269|NCT01665183|Drug|ADI-PEG 20|
75593044|NCT01956084|Drug|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
75593045|NCT01953640|Other|Laboratory Biomarker Analysis|Correlative studies
75736326|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
75736327|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
75736328|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
75736329|NCT00454246|Drug|methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
75736330|NCT00454246|Drug|epoetin alfa|Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
75736331|NCT00454246|Drug|darbepoetin alfa|Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
75736332|NCT04717284|Other|Self-compassion intervention (SCI)|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the SCI group will then be instructed to reflect on their recalled parenting event and prompted to think about and write about the event in a self-compassionate manner. The prompt is designed to induce on all of the three key elements of self-compassion described by Neff (2003a): self-kindness; common humanity; and mindfulness. The same instructions will be provided for follow-up period.
75736333|NCT04717284|Other|Control condition|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the control group will then be instructed to make notes about factual information of the event (e.g. time of day, who was there, the weather, etc.). During the two-week follow-up period, participants in the control group will not take part in any intervention as part of the trial.
75736334|NCT00434590|Drug|Enteric coated mycophenolate sodium (Myfortic®)|
75736335|NCT04711512|Behavioral|Encouragement/Support|Messages that focus on improving self-efficacy and motivation for physical activity
76056263|NCT02758431|Drug|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
75736336|NCT04711512|Behavioral|Social Comparison|Messages that provide exposure to another person's physical activity engagement data (for comparison)
75736337|NCT04010838|Procedure|spinal cord stimulation|The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
75736338|NCT04012164|Biological|blood sampling|5ml blood sampling
75885434|NCT03505060|Biological|IHV01|Administered by intramuscular injection in the deltoid.
76056264|NCT02758431|Drug|Placebo Gel|Placebo gel packet applied daily for 28 days.
75443270|NCT01665196|Drug|18F-FDG|Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
75443271|NCT01665209|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
75443272|NCT01665222|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
75885435|NCT03505060|Biological|Placebo|Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
75885436|NCT03500614|Behavioral|Air cleaner use method 1|All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.
75885437|NCT03500614|Behavioral|Air cleaner use method 2|All interventions in the second cohort will start from the beginning to the end of smog episodes.
76056265|NCT02758431|Drug|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
76056266|NCT02758431|Drug|Testosterone Gel|Testosterone Gel applied daily for 28 days
76056267|NCT02758431|Drug|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
76056268|NCT02756000|Procedure|PCI|percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
76056269|NCT02756000|Procedure|dobutamine stress echocardiography|Echocardiographic stress test of provoked myocardial ischemia using dobutamine
76056270|NCT02601365|Drug|Sargramostim 0.04 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
75443273|NCT01665235|Drug|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
75443274|NCT01665235|Drug|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
75443275|NCT01665235|Drug|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
75443276|NCT01665235|Drug|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
75443277|NCT01665248|Other|18-F Sodium Fluoride Uptake in Positron emission tomography|
75443278|NCT01665339|Other|preload diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
75593046|NCT01953640|Other|Quality-of-Life Assessment|Ancillary studies
75593047|NCT01945814|Drug|CTL for CMV seropositive donors|CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
75593048|NCT01945814|Drug|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
75736339|NCT04012164|Biological|stool collection|self stool collection (2g)
75885438|NCT03495700|Procedure|L-PRF block|The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
75885439|NCT03495700|Procedure|DBBM|The use of bovine xenograft will be analysed
75885440|NCT04811170|Other|Counselling|Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.
75885441|NCT03118739|Drug|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
75885442|NCT03118739|Drug|Placebo|Capsule administered orally, once daily for 24 weeks
75885443|NCT03181126|Drug|Navitoclax|tablet
75885444|NCT03181126|Drug|Chemotherapy|peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)
75885445|NCT03181126|Drug|Venetoclax|tablet
75736340|NCT04012164|Other|Participatory activity and contact investigation|30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.
75885446|NCT03157492|Behavioral|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
75885447|NCT03157492|Behavioral|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
75443279|NCT01665339|Other|control diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
75736341|NCT04012164|Other|Anthropological and historical interviews|Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
75885448|NCT03146338|Other|Magnesium-rich mineral water (Rozana)|intakes of 1.5 L by day
75885449|NCT02995889|Device|FLT-PET|
75885450|NCT03141502|Device|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
75885451|NCT03141502|Procedure|Skin grafting|the standard technique of skin grafting after wound preparation.
75736342|NCT04674618|Device|US-assisted nusinersen administration|Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
75736343|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
75885452|NCT04477252|Device|App-core|"Farmalarm App of the Inmovens group - Vall d´Hebrón Hospital will be used, adapted and updated by the main researcher. The App will have the rehabilitation option where the user can consult the description of the exercise and view a demonstration video so that it can be carried out correctly at home, independently or with help. The administrator therapist of the App has the permission to create users, contact them directly through chat or video-call and personalize the exercise program.~The exercises that will be carried out in this study phase, are described in previous studies by the author Rosa Cabanas et al. All possible exercises will be included in the administration platform, and according to of each user, the prescription of some exercises or others will be made."
75885453|NCT04477252|Other|Conventional physiotherapy|Conventional physiotherapy is considered neuromotor development therapy as the most frequently used therapy in the management of stroke patients and in the center where the study is performed.
75885454|NCT03094195|Drug|EMA401|EMA401
75885455|NCT03094195|Drug|Placebo|Placebo
75443280|NCT01665365|Procedure|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
75593049|NCT01932697|Drug|Docetaxel|Given IV
75593050|NCT01932697|Radiation|Hyperfractionation|Undergo hyperfractionated IMRT
75593051|NCT01932697|Radiation|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
75593052|NCT01932697|Other|Laboratory Biomarker Analysis|Correlative studies
75593053|NCT01932697|Other|Quality-of-Life Assessment|Ancillary studies
75885456|NCT03140410|Other|Antibiotic resistance|"Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated"
75885457|NCT05759975|Device|Photobiomodulation therapy (intraoral)|Intraoral photobiomodulation therapy (660nm, 100mW, 10 J/cm 2 , 3 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
75593054|NCT01820182|Device|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
75736344|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
75885458|NCT05759975|Device|Photobiomodulation therapy (extraoral)|Extraoral photobiomodulation therapy (810 + 980 nm, 1 W, 6.11 J/cm2 , 30 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
75885459|NCT04799548|Drug|Transcatheter Arterial Chemoembolization|"Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid."
75885460|NCT04799548|Drug|Tislelizumab|PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
75593055|NCT01752049|Drug|Topical timolol maleate|"Topical timolol maleate 0.5% drops~Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~Study drops will be applied to 3 cutaneous telangiectasias per patient"
75736345|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
75885461|NCT05083234|Other|Moisturizing with SSO|Vital signs of newborns in the sunflower seed oil group were measured. The skin of newborns in the sunflower seed oil group was wiped without rubbing. The skin of newborns in the sunflower seed oil group was evaluated with the NSCS scale.
75885462|NCT05083234|Other|Moisturizing with LV|Vital signs of newborns in the liquid vaseline group were measured. The skin of newborns in the liquid vaseline group was wiped without rubbing. The skin of newborns in the liquid vaseline group was evaluated with the NSCS scale.
75736346|NCT02891837|Drug|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
75769161|NCT03907930|Procedure|percutaneous nephrolithotripsy|removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast
75885463|NCT05083234|Other|The control group was not moisturized.|Vital signs of newborns in the control group were measured. The skin of newborns in the control group was wiped without rubbing. The skin of newborns in the control group was evaluated with the NSCS scale.
75443281|NCT01665378|Dietary Supplement|Multiple Micronutrient|"There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
75443282|NCT01665378|Dietary Supplement|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
75593056|NCT01752049|Drug|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
75593057|NCT01747447|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
75593058|NCT01747447|Dietary Supplement|Fish oil placebo|Fish oil placebo
75593059|NCT01747447|Dietary Supplement|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
75593060|NCT01747447|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
75593061|NCT01739309|Drug|Abemaciclib|Administered orally
75736347|NCT02891837|Other|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
75885464|NCT01375985|Drug|AVI-7100|Single intravenous administration
75443283|NCT01665378|Dietary Supplement|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
75885465|NCT01375985|Drug|Placebo|Single intravenous administration
75885466|NCT05391295|Other|Short daily questionnaire|This study includes 1 survey that needs to be filled out by the patient on his/her phone daily during the course of corticosteroid treatment. The investigators will start the survey few days before the corticosteroid treatment and it will continue till the end of the treatment regime. The treatment regime is regular care and patient specific, but will approximately have a duration of 40 days. In case of prolonged treatment with steroids it is decided to have a limit for our study: either until 7 days after the end of corticosteroid treatment or a maximum of 60 days.
75885467|NCT01376063|Drug|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
75885468|NCT02893150|Behavioral|TAU|"TAU (Treatment as Usual), individuals presenting with overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, teams of primary care (PC) organized care plans to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²).~For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities, evaluates the need for individual dietary prescription by the nutritionist. This decision is discussed among the team of PC and Matrix support team"
75885469|NCT02893150|Behavioral|TAU+MBHP|"TAU (Treatment as Usual) + MBHP. We used a general (general vulnerability, not specific) mindfulness-based intervention (MBI) developed by our research group, an 8-week-group-based MBI called Mindfulness-Based Health Promotion (MBHP) program . It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems, which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice; more feasible to be implement in health services and facilities"
76056271|NCT02601365|Drug|Sargramostim 0.2mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
76056272|NCT02601365|Drug|Sargramostim 1 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
76056273|NCT02583893|Drug|Sirolimus|Given PO
75443284|NCT01665404|Drug|Fluvoxamine|Multiple doses of fluvoxamine
75736348|NCT03682458|Genetic|Study of Neurodegenerative Diseases Induced Stem Cells|The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
75736349|NCT04009590|Other|Educational Intervention|Read educational booklet
75736350|NCT04009590|Other|Questionnaire Administration|Ancillary studies
75736351|NCT04009590|Behavioral|Smoking Cessation Intervention|Utilize Quit4Health
75443285|NCT01665404|Drug|RO4917523|Single dose of RO4917523
75443286|NCT01665417|Drug|Experimental|Icotinib: 125mg, oral administration, three times per day.
75443287|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
75443288|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
75443289|NCT01665469|Dietary Supplement|Tomato extracted lycopene|
75443290|NCT01665469|Dietary Supplement|Placebo|
75443291|NCT01665482|Other|A 2000 kcal test meal|
75443292|NCT01665482|Other|A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate|
75443293|NCT01664988|Behavioral|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
75443294|NCT01664988|Behavioral|breath control|breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
75736352|NCT00961974|Behavioral|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
76056274|NCT02583893|Drug|Mitoxantrone|Given IV
76056275|NCT02583893|Drug|Etoposide|Given IV
76056276|NCT02583893|Drug|Cytarabine|Given IV
76056277|NCT02538315|Drug|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by [18F]FDOPA PET/CT imaging
76056278|NCT02411448|Drug|Ramucirumab|Administered IV.
76056279|NCT02411448|Drug|Placebo|Administered IV.
75443295|NCT01664988|Other|control (routine care)|received routine care of clinic or health center and use drugs if necessary
75593062|NCT01724346|Drug|Post-Chlorambucil Therapy Follow-up|Patients remain in this Arm for continued follow-up until PD, unacceptable toxicity, or other reason for treatment discontinuation. All patients in this Arm have completed Chlorambucil therapy. Patients who have progression will exit the study.
75593063|NCT01724346|Drug|Ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily.
75593064|NCT01724346|Drug|Second-line Ibrutinib|Patients in this arm who were previously eligible to receive Second-line Ibrutinib will exit the study with option to roll-over to another long-term Ibrutinib study, if eligible.
75593065|NCT01724346|Drug|Alternative Anticancer Treatment|Specific therapy and treatment regimen are at the Investigator's discretion.
75736353|NCT00961974|Behavioral|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
75736354|NCT00962130|Device|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
75736355|NCT00695903|Drug|daptomycin|daptomycin 10 mg/kg IV every 24 hours
75736356|NCT00695903|Drug|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
75736357|NCT02793167|Device|AKI alert|
75736358|NCT00548262|Drug|Anidulafungin|All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
75885470|NCT02893150|Behavioral|TAU+MB-EAT|TAU (Treatment as Usual) + MB-EAT (mindfulness-based eating awareness training). Adapted from the MBSR, Mindfulness-based Eating Awareness Training (MB-EAT) or awareness training. This program was specially developed for the compulsive eating disorders and related problems[47]. In addition the four main techniques of meditation mentioned in the MBHP program includes modifications to these basic techniques, and include experimentation with different flavors, sweet and savory foods, etc. Has 10 weekly sessions of 2,5h
75885471|NCT05759897|Drug|HRS-7535|HRS-7535
75593066|NCT01724346|Drug|Alternative Anti-cancer Treatment|Specific therapy and treatment regimen are at the Investigator's discretion. Patients originally randomized to Chlorambucil will exit the study. Patients originally randomized to Ibrutinib will continue on study.
75593067|NCT01659658|Drug|IXAZOMIB|Ixazomib capsules
75885472|NCT05759897|Drug|Placebo|Placebo
75885473|NCT03981497|Procedure|Microwave ablation (MWA)|Thermal ablation
75885474|NCT04754074|Behavioral|Education|Weekly education related to behavior change
75443296|NCT01665495|Procedure|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return<30 ml.
75443297|NCT01665534|Behavioral|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
75443298|NCT01664507|Drug|conventional dose epinephrine|conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
75443299|NCT01664507|Drug|low dose epinephrine|low dose epineprhine : 0.1mg/kg + 0.9% normal saline
75443300|NCT01665547|Drug|l-carnitine|3gm l-carnitine from day 1 to day 12 of the menstrual cycle
75593068|NCT01659658|Drug|Dexamethasone|Dexamethasone tablets
75593069|NCT01659658|Drug|Melphalan|Melphalan tablets
76056280|NCT02411448|Drug|Erlotinib|Administered orally.
76056281|NCT02411448|Drug|Gefitinib|Administered orally.
76056282|NCT02411448|Drug|Osimertinib|Administered orally.
76056283|NCT02368041|Device|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
76056284|NCT02350465|Behavioral|Eccentric Exercise|Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
76056285|NCT02350465|Behavioral|Concentric Exercise|Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
76056286|NCT02321514|Device|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
75736359|NCT00548262|Drug|Voriconazole|Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if <40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if <40 kg body weight).
75885475|NCT04754074|Behavioral|Personalized coaching|Weekly calls with personalized coaches in behavior modification, nutrition, and physical activity/exercise.
75885476|NCT04754074|Behavioral|Weekly behavior modification challenges|Weekly challenges to address behavior change
76056287|NCT02266134|Behavioral|Tailored Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
76056288|NCT02266134|Behavioral|Standard Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
76056289|NCT02197845|Behavioral|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
76056290|NCT02197845|Behavioral|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
75443301|NCT01665586|Drug|dexmedetomidine|"Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration"
76056291|NCT02107144|Drug|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
76056292|NCT01943643|Procedure|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
75593070|NCT01659658|Drug|Cyclophosphamide|Cyclophosphamide tablets
75593071|NCT01659658|Drug|Thalidomide|Thalidomide capsules
76056293|NCT01860170|Drug|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
75443302|NCT01665612|Device|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
75593072|NCT01659658|Drug|Lenalidomide|Lenalidomide capsules
75593073|NCT01591356|Drug|EphA2-targeting DOPC-encapsulated siRNA|Given IV
75593074|NCT01591356|Other|Laboratory Biomarker Analysis|Correlative studies
75593075|NCT01591356|Other|Pharmacological Study|Correlative studies
75593076|NCT01586767|Radiation|Proton radiation therapy|Daily proton radiation therapy
75593077|NCT01586767|Radiation|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
75593078|NCT01523977|Drug|Everolimus|Orally, daily days 1-32 per assigned dose level
75593079|NCT01523977|Drug|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
75593080|NCT01523977|Drug|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
75593081|NCT01523977|Drug|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
75593082|NCT01523977|Drug|Doxorubicin|30 mg/m2 IV on days 4 and 5
75593083|NCT01523977|Drug|Dexrazoxane|300 mg/m2 IV on days 4 and 5
75593084|NCT01517243|Drug|Sunitinib|Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
75593085|NCT01517243|Drug|Temsirolimus|Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
75593086|NCT01512589|Radiation|Proton Beam Therapy (PBT)|1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
75593087|NCT01512589|Radiation|Intensity Modulated Radiation Therapy (IMRT)|1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
75736360|NCT00742547|Other|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
75736361|NCT02757989|Other|transplantation|allogeneic hematopoietic stem cell transplantation in patients with donor
75736362|NCT02565173|Drug|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
75736363|NCT02565173|Drug|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
75443303|NCT01665625|Procedure|regional interventional chemotherapy group|The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
75443304|NCT01665638|Drug|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
75443305|NCT01665638|Drug|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
75443306|NCT01665638|Drug|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
75593088|NCT01512589|Behavioral|Questionnaires|Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
75593089|NCT01407510|Drug|Mapracorat|Application of the investigational product on the affected skin areas
75593090|NCT01357161|Drug|adavosertib|Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
75593091|NCT01357161|Drug|Placebo|placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
75593092|NCT01357161|Drug|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
75593093|NCT01357161|Drug|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
75593094|NCT01321073|Device|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
75593095|NCT01308203|Drug|Extended release niacin/laropiprant|Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
75593096|NCT01308203|Drug|placebo|Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
75593097|NCT01289171|Drug|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
75593098|NCT01276704|Drug|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
75593099|NCT01276704|Drug|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
75736364|NCT02565173|Drug|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
75593100|NCT01190930|Drug|Cyclophosphamide|Given IV
75593101|NCT01190930|Drug|Cytarabine|Given IT, IV, or SC
75593102|NCT01190930|Drug|Dexamethasone|Given orally (PO) or IV
75593103|NCT01190930|Drug|Doxorubicin Hydrochloride|Given IV
75593104|NCT01190930|Other|Laboratory Biomarker Analysis|Correlative studies
75593105|NCT01190930|Drug|Leucovorin Calcium|Given PO
75593106|NCT01190930|Drug|Mercaptopurine|Given PO
75593107|NCT01190930|Drug|Methotrexate|Given IT, PO, or IV
75593108|NCT01190930|Drug|Pegaspargase|Given IV
75593109|NCT01190930|Other|Quality-of-Life Assessment|Ancillary studies
75593110|NCT01190930|Other|Questionnaire Administration|Ancillary studies
75593111|NCT01190930|Drug|Thioguanine|Given PO
75593112|NCT01190930|Drug|Vincristine Sulfate|Given IV
75593113|NCT01169259|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
75593114|NCT01169259|Drug|omega-3 fatty acids (fish oil)|Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
75593115|NCT01169259|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
75593116|NCT01169259|Dietary Supplement|Fish oil placebo|Fish oil placebo
75736365|NCT02565173|Drug|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
75736366|NCT02565173|Drug|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
75736367|NCT04619082|Drug|Tenofovir alafenamide|Tenofovir alafenamide 25 mg once per day for one year
75736368|NCT02724683|Device|Ascites drainage with vascular catheter.|In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
76056294|NCT01860170|Drug|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
76056295|NCT01860170|Drug|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
76056296|NCT01847274|Drug|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
76056297|NCT01847274|Drug|placebo|
75593117|NCT01163682|Device|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
76056298|NCT01802788|Device|St Jude Medical Portico replacement aortic valve|
76056299|NCT01802788|Procedure|Transcatheter Aortic Valve Implant|
75593118|NCT01163682|Device|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The electro-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
75736369|NCT02724683|Behavioral|Interview.|Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
76056300|NCT01611168|Other|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
75736370|NCT02724683|Behavioral|Quality of life.|Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
75736371|NCT02724683|Device|Quality of procedure.|Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
75736372|NCT02724683|Other|Nutritional status|Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
75736373|NCT04593342|Device|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
75736374|NCT04593342|Device|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
75736375|NCT02717897|Other|No intervention|This study is not interventional
75769162|NCT03915340|Drug|Propafenone|Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
76056301|NCT01603316|Behavioral|surveys|Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
75443307|NCT01665638|Drug|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
75593119|NCT01047007|Drug|adavosertib 20 mg|Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
75443308|NCT01665651|Drug|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
75443309|NCT01665651|Drug|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
75443310|NCT01665651|Drug|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
75736376|NCT04060667|Combination Product|Wireless physiologic monitoring|The intervention in this study is the use of a wireless monitor to perform physiologic monitoring of women undergoing emergency cesarean delivery for the first 24 hours after completion of the cesarean and send alerts to responding clinicians should vital signs fall out of a pre-specified range.
75443311|NCT01665651|Drug|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
75443312|NCT01665664|Other|Hypocaloric feeding|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
75593120|NCT01047007|Drug|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
75593121|NCT01047007|Drug|CDDP|CDDP 60 mg/m^2 to 100 mg/m^2 administered as an IV infusion on Day 1.
75736377|NCT03717623|Drug|Posaconazole pharmacokinetics|Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
75736378|NCT00742703|Other|Mineralized water|
75736379|NCT00742703|Other|Low mineralized water|
75736380|NCT00095173|Drug|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
75736381|NCT00095173|Drug|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
75736382|NCT00095173|Drug|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing < 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing > 100 kg, monthly
75736383|NCT03704753|Drug|Ropivacaine|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients
75736384|NCT03704753|Drug|Sodium chloride 0.9%|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
75736385|NCT02565017|Behavioral|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
75736386|NCT01079689|Other|needle stimulation|stimulation with acupuncture needles
75736387|NCT00690443|Drug|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
75736388|NCT00690443|Drug|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
75736389|NCT03954834|Drug|Tirzepatide|Administered SC
75885477|NCT05039047|Other|Standard stroke acute care and rehabilitation|According to Swiss national guidelines and local protocols
76056302|NCT01603316|Behavioral|Focus groups|Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
75593122|NCT01047007|Drug|adavosertib 65 mg|Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
75593123|NCT01007578|Device|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
76056303|NCT01560819|Drug|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
75443313|NCT01665690|Other|Patient delivered partner therapy|The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
76056304|NCT01497184|Procedure|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
76056305|NCT01497184|Genetic|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
75443314|NCT01665690|Behavioral|Targeted public health partner services|During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
75443315|NCT01665703|Procedure|FDG PET/MR|Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
75443316|NCT01665742|Dietary Supplement|Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene|"1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks~AND~4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks~in conjunction with a weight management programme"
75443317|NCT01665742|Dietary Supplement|Placebo supplement|"1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks~AND~4 x film-coated placebo tablets daily for 8 weeks~in conjunction with a weight management programme"
75443318|NCT01665755|Device|Upstroke Compression Defibrillation|
75443319|NCT01665755|Device|Precompression Defibrillation|
75443320|NCT01665781|Drug|Erythropoietin|
75443321|NCT01665820|Device|Auscultate with electronic or mechanical stethoscope (3M Littmann)|
75443322|NCT01665846|Drug|Ferumoxytol|A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
75736390|NCT03954834|Drug|Placebo|Administered SC
75736391|NCT00693017|Drug|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
75736392|NCT00693017|Drug|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
75736393|NCT03965065|Device|Sutureless aortic bioprosthesis|Patients will receive a sutureless aortic bioprosthesis
75736394|NCT03965065|Device|Conventional stented sutured aortic prosthesis|Patients will receive a stented sutured aortic prosthesis
76056306|NCT01425528|Drug|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
76056307|NCT01330446|Drug|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
76056308|NCT01330446|Other|Placebo|1 by mouth every morning for a 28 day cycle.
75736395|NCT00692237|Drug|Sildenafil|100 mg daily (3 capsules/day)
75736396|NCT00692237|Drug|Placebo|Placebo 100 mg (3 capsules/day)
75736397|NCT00110149|Biological|rituximab|
75736398|NCT00110149|Radiation|yttrium Y 90 ibritumomab tiuxetan|
76056309|NCT01330446|Behavioral|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
76056310|NCT01300832|Procedure|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
75736399|NCT03890081|Other|Questionnaire|Translate and culturally adapt the original English version of the Coping Strategies Questionnaire into Turkish
75736400|NCT03964285|Other|rumination induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.
76056311|NCT01150487|Procedure|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
76056312|NCT00866554|Drug|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
75443323|NCT01665885|Device|ZOLL Thermogard XP|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.
75443324|NCT01665885|Device|BARD/Medivance Arctic Sun 5000|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.
75443325|NCT01665898|Procedure|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
75593124|NCT01002872|Drug|Lanthanum Carbonate (Fosrenol)|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill three times a day (TID) Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus <3.5mg/dL Reduce to 1 pill twice a day (BID). If Phosphorus >5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is <3.5mg/dL Reduce to 1 pill daily. If phosphorus >5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus <3.5mg/dL stop the drug If phosphorus is >5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
75443326|NCT01665898|Procedure|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
75593125|NCT01002872|Drug|placebo|Initial dose of placebo will be 1 pill three times a day
75593126|NCT01000350|Drug|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
75593127|NCT01000350|Other|Placebo|Placebo x1 lactose tablet
75593128|NCT00815815|Behavioral|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
75593129|NCT00707473|Drug|Carboplatin|Given IV
75593130|NCT00707473|Other|Chemoradiotherapy|Undergo chemoradiotherapy
75443327|NCT01665924|Drug|GLPG0634 100mg capsule once a day for 10 days|
75443328|NCT01665937|Drug|STA-9090|"IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen."
75593131|NCT00707473|Drug|Cisplatin|Given IV
75593132|NCT00707473|Procedure|Definitive Surgical Resection|Undergo surgery
75593133|NCT00707473|Drug|Docetaxel|Given IV
75443329|NCT01665963|Device|TopClosure(c) System|
75443330|NCT01665963|Device|Pressure Bandage|
75443331|NCT01665976|Drug|RO4917838|film coated tablet, single dose
75593134|NCT00707473|Drug|Fluorouracil|Given IV
75593135|NCT00707473|Procedure|Quality-of-Life Assessment|Correlative studies
76056313|NCT00866554|Drug|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
76056314|NCT00648635|Behavioral|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
75593136|NCT00707473|Radiation|Radiation Therapy|Undergo radiation therapy
75736401|NCT03964285|Other|distraction induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
76056315|NCT00645931|Behavioral|protein and calorie controlled diet and self-hypnotic relaxation|daily
76056316|NCT00452023|Drug|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
75443332|NCT01665976|Drug|RO4917838|oral suspension, single dose
75443333|NCT01665976|Drug|RO4927838|hard gelatin capsule, single dose
75443334|NCT01665989|Behavioral|Group Lifestyle Program|
75443335|NCT01665989|Behavioral|Usual Care|Visits with a dietitian at nutrition services at MGH
75593137|NCT00692471|Device|Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter|Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
75593138|NCT00648648|Drug|adavosertib|adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
75593139|NCT00648648|Drug|gemcitabine|Gemcitabine administered at 1000 mg/m^2 by IV infusion in a 28-day cycle.
75593140|NCT00648648|Drug|cisplatin|Cisplatin administered at 75 mg/m^2 by IV infusion in a 21-day cycle.
75593141|NCT00648648|Drug|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
75593142|NCT00625638|Behavioral|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
75593143|NCT00625638|Other|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
75593144|NCT00614172|Radiation|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
75593145|NCT00608725|Radiation|DAXOR|131-I-Human Serum Albumin Blood Volume Assessment Kit
75593146|NCT00608725|Procedure|QSweat|Quantitative Sweat Testing
75593147|NCT00608725|Drug|Intrinsic Heart Rate|Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
75593148|NCT00581633|Other|normal saline (0.9%)|liter normal saline over 30 minutes x 1 dose
75593149|NCT00581373|Other|water 16 fl oz|water 16 fl oz in AM and repeat in late afternoon
75593150|NCT00581321|Dietary Supplement|water|water 500 ml x 1
75593151|NCT00580996|Other|water high dose|water 16 oz PO x 1
75593152|NCT00580996|Other|water tiny dose|water 1 oz PO x 1
75736402|NCT02530957|Device|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
75736403|NCT02530957|Device|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
75885478|NCT04741594|Device|Densah|Alveolar bone remodeling after tooth extraction may result in significant ridge resorption and inadequate bone volume for implant placement. Several methods have been designed for ridge augmentation, among which is the new technique of osseodensification, using the Densah® burs by Versah® (Versah®, LLC, Jackson, MI, USA). This method compresses the trabecular bone to periphery of the osteotomy site and has shown up to 80% ridge expansion in animal histological studies , , , , , . Apart from being an animal model with a short follow-up, another limitation of these studies is the lack of three-dimensional evaluation of the change in morphology of the ridge. Human clinical studies , , , , have reported similar results, but they do not evaluate if this bone volume is retained during osseointegration and loading periods. No standardization method or long-term evaluation of peri-implant health was reported.
75885479|NCT02654080|Biological|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
75885480|NCT02654080|Biological|rVSV HIV envC vaccine|1 × 10^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
75593153|NCT00546351|Drug|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
75885481|NCT02654080|Biological|Placebo|"Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
75885482|NCT03140332|Other|Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib|To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
75885483|NCT05082532|Other|Interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) .|we here conduct a prospective study to evaluate the efficacy and safety of self- expandable nitinol stent especially interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) in femoropoliteal complex occlusive lesions.
75443336|NCT01666015|Other|EXERCISE (EX)|"This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games)."
75593154|NCT00542373|Other|Cytology Specimen Collection Procedure|Undergo oral tissue collection
75736404|NCT01084057|Drug|vorinostat|Given orally
75736405|NCT01084057|Drug|ixabepilone|Given IV
75736406|NCT01084057|Other|laboratory biomarker analysis|Correlative studies
75736407|NCT01084057|Other|pharmacological study|Correlative studies
75736408|NCT03954444|Drug|Oxymetazoline Hydrochloride|Test Comparator
75736409|NCT03954444|Drug|Rhofade Cream, 1%|Reference Comparator
75736410|NCT03954444|Drug|Placebo|Placebo Comparator
75736411|NCT03953820|Drug|Diazepam Buccal Film|Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.
75885484|NCT05079724|Procedure|Cardiac Surgery|About 3.5-31.0% of Patients undergoing cardiac surgery Complains from Postoperative Acute renal injury (AKI) that is a severe complication increasing the risk factor for mortality about 8-folds, The occurrence of AKI in patients undergoing cardiac surgery raises the mortality rate from 0.4-4.4% to 1.3-22.3%; when those same patients require dialysis.
75443337|NCT01666015|Other|Standard Care|This group will be under standard care without any EX intervention.
75593155|NCT00542373|Procedure|Diagnostic Microscopy|Mouth tissue examined microscopically for cytologic features
75593156|NCT00542373|Procedure|Diagnostic Procedure|Undergo standard white light headlamp oral examination
75593157|NCT00542373|Procedure|Fluorescence Imaging|Undergo widefield fluorescent and reflectance imaging
75593158|NCT00542373|Procedure|Fluorescence Spectroscopy|Undergo point fluorescent spectroscopy
75593159|NCT00536172|Drug|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
75593160|NCT00536172|Drug|Placebo|Placebo distribution matches the active medication.
75593161|NCT00477100|Procedure|Biospecimen Collection|Undergo collection of blood, tissue, and stool
75593162|NCT00477100|Other|Interview|Participate in interview
75593163|NCT00477100|Other|Medical Chart Review|Undergo collection of medical data
75593164|NCT00477100|Other|Questionnaire Administration|Ancillary Studies
75593165|NCT00386906|Procedure|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
75593166|NCT00003838|Procedure|T-cell replete PBPC allograft|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver >5x10^6 CD34+ cells/kg.
76056317|NCT00442104|Drug|Ganaxolone|
75443338|NCT01666028|Device|FlorenceD or similar closed loop glucose control system|Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
75443339|NCT01666028|Device|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
75443340|NCT01666041|Drug|placebo|
75443341|NCT01666041|Drug|fenofibrate/omega|
75443342|NCT01666041|Drug|fenofibrate|
75443343|NCT01666054|Other|PSV|Pressure Support Ventilation will be used until patient is extubated
75593167|NCT00003838|Drug|Methotrexate|IV MTX on days +1, +3, and +6 will be given
75593168|NCT00003838|Drug|Cyclosporine|CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade > II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade > II GVHD will have CSA discontinued regardless of chimerism results.
75593169|NCT00003838|Drug|G-CSF|G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
75593170|NCT06031636|Drug|Oncolytic Adenovirus H101|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
75593171|NCT06031636|Drug|Programmed death receptor-1 inhibitor|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
75593172|NCT06031610|Procedure|carotid artery stenting|Patients were monitored for at least 24 h after surgery, with control for hyperperfusion syndrome, dual antiplatelet therapy was continued for 4-6 weeks, and the postoperative patients have the final residual stenosis of less than 30%, thrombolysis in Myocardial Infarction (TIMI) grade 3, and no dissection or thrombosis. Any surgery-related complications were recorded.
75593173|NCT06031584|Drug|BL-M07D1|BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.
75593174|NCT06031545|Other|Long peripheral venous catheters for use|Long peripheral venous catheters for use during the perioperative period in obese patients
75593175|NCT06031545|Other|Midline catheter|Midline catheters for use during the perioperative period in obese patients
75593176|NCT06031519|Procedure|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller; Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts up to 12 min, and the ablation power gradually increases from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
75593177|NCT06031506|Device|Implant supported hybrid maxillary prosthesis|All patients will receive immediately loaded hybrid prosthesis supported by 4 zygomatic implants.
75443344|NCT01666054|Other|PAV|Proportional Assist Ventilation will be used until patient is extubated.
75443345|NCT01666067|Drug|placebo|
75443346|NCT01666067|Drug|vytorin|
75593178|NCT06031493|Combination Product|Multimodal intervention on sexual dysfunction and quality-of-life|Multimodal intervention includes education on healthy habits, the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens, and a systematic evaluation of the need of hormone replacement therapy.
75443347|NCT01666067|Drug|simvastatin|
75443348|NCT01666093|Procedure|Angioplasty of the lower limbs vessels|Standard revascularization techniques will be used in the study
75443349|NCT01666132|Other|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
75443350|NCT01666132|Other|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
75443351|NCT01666132|Other|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
75736412|NCT03953820|Drug|Diastat® Rectal Gel (Valeant Pharmaceuticals USA)|Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
75736413|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
76056318|NCT00441896|Drug|Ganaxolone|
76056319|NCT00441896|Other|Placebo|
75593179|NCT06031480|Drug|Anlotinib and TQB2450|"Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent."
75885485|NCT02835690|Biological|Pembrolizumab|IV infusion
76056320|NCT00202800|Drug|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
75593180|NCT06031389|Drug|Henagliflozin|On the basis of hypoglycemic therapy, the patients in the intervention group were given the drug treatment of hengglinide, once a day, 10mg or 5mg each time, taken in the morning, for 12 months.
75593181|NCT06031389|Drug|Placebo|On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
75593182|NCT06031376|Drug|Fruquintinib|5mg once daily for 14 days on/7 days off, over a 21-day cycle
75593183|NCT06031376|Drug|PD-1 inhibitors|The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
75593184|NCT06031376|Drug|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
75593185|NCT06031376|Drug|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
75885486|NCT04629820|Device|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
75443352|NCT01666158|Behavioral|Exercise|The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
75443353|NCT01666171|Drug|metformin hydrochloride|
75443354|NCT01666171|Other|clinical observation|
75443355|NCT01666171|Other|diagnostic laboratory biomarker analysis|
75885487|NCT02486224|Dietary Supplement|Kona Deep|Subjects will receive Kona Deep post exercise
75443356|NCT01666171|Other|imaging biomarker analysis|
75443357|NCT01666171|Other|medical chart review|
75885488|NCT02486224|Dietary Supplement|Spring Water|Subjects will receive Spring Water post exercise
75885489|NCT02486224|Dietary Supplement|Sports Drink|Subjects will receive Sports Drink post exercise
75443358|NCT01666171|Procedure|digital mammography|
75885490|NCT03564834|Procedure|Laparoscopic gastrectomy|Patients will receive laparoscopic gastrectomy within one week after randomization.
75443359|NCT01666223|Drug|Colesevelam|Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
75443360|NCT01666223|Drug|Chenodeoxycholic Acid|1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
75593186|NCT06031363|Drug|Indomethacin Suppository|Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
75593187|NCT06031350|Diagnostic Test|Optical Coherence Tomography Angiography|Optovue, Inc., Fremont, CA, USA
75885491|NCT03564834|Procedure|Open gastrectomy|Patients will receive open gastrectomy within one week after randomization.
76056321|NCT00194714|Biological|HER-2/neu Peptide Vaccine|Given ID
76056322|NCT00194714|Other|Laboratory Biomarker Analysis|Correlative studies
75885492|NCT03564288|Drug|SKI-G-801|SKI-G-801 is administered as an IV infusion over 10 minutes
76056323|NCT02034877|Biological|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
75443361|NCT01666223|Other|saline|100 ml saline
75593188|NCT06031298|Biological|Dentin Graft|Dentin graft is a grafting technique of autogenous origin that uses the teeth extracted from the patient for the graft material preparation.
75736414|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
75736415|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
75736416|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
75736417|NCT03678636|Device|Silver antimicrobial dressing|Silver dressing suitable for exudate level
75736418|NCT03678636|Device|Standard care|Usual care for wound type and condition
75736419|NCT04517994|Behavioral|Active Treatment|See arm description.
75736420|NCT04517994|Behavioral|Supportive Treatment|See arm description.
75736421|NCT04492956|Drug|Ecopipam|Oral tablet
75736422|NCT04492956|Drug|Placebo|Oral tablet
75736423|NCT04478136|Diagnostic Test|Blood test of factor levels|Blood draw from central line to check coagulation factors
75736424|NCT00117793|Device|Total Surface Bearing Suction Socket|Current clinical practice
76056324|NCT02034877|Procedure|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
75593189|NCT06031285|Drug|Sintilimab|Perioperative Sinitilimab, bevacizumab biosimilar and TACE-HAIC
75593190|NCT06031246|Procedure|Selective Lymph Node Dissection|For patients with NSCLC with CTR>0.5 located in the apical segment, the inferior mediastinal lymph node was not need to dissected
75593191|NCT06031233|Drug|Nivolumab|Gradual shortening of infusion times
75736425|NCT00117793|Device|Vacuum assisted socket system|Novel socket system
75736426|NCT01084213|Drug|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
75736427|NCT01084213|Drug|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
75736428|NCT00695669|Biological|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
75736429|NCT03671369|Other|Safety data collection (following routine vaccination) by a continuous surveillance method.|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS."
75769163|NCT03915340|Drug|Rytmonorm|Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
75443362|NCT01666223|Drug|Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg|Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
76056325|NCT02034799|Biological|Bioseal Fibrin Sealant|
76056326|NCT02034799|Other|Standard of Care (SoC)|
75593192|NCT06031233|Drug|Pembrolizumab|Gradual shortening of infusion times
76056327|NCT02057575|Drug|PG324 Ophthalmic Solution 0.01%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
76056328|NCT02057575|Drug|PG324 Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
75443363|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
75593193|NCT06031233|Drug|Ipilimumab|Gradual shortening of infusion times
75593194|NCT06031233|Drug|Durvalumab|Gradual shortening of infusion times
75593195|NCT06031233|Drug|Atezolizumab|Gradual shortening of infusion times
75593196|NCT06031233|Drug|Bevacizumab|Gradual shortening of infusion times
75593197|NCT06031233|Drug|Trastuzumab|Gradual shortening of infusion times
75593198|NCT06031168|Other|Metformin gel coated implants|Patients will be treated with 1% concentrated metformin gel coated hydrophilic dental implant.
75593199|NCT06031168|Other|uncoated hydrophilic dental implants|Patients treated by uncoated implants
75769164|NCT03907618|Diagnostic Test|ovarian reserve|To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.
75769165|NCT01250314|Other|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
75885493|NCT02033980|Device|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
75885494|NCT05352906|Diagnostic Test|Intraocular pressure|Measurements of intraocular pressure in millimeter mercury (mmHg).
76056329|NCT02057575|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
76056330|NCT02057575|Drug|Latanoprost Ophthalmic Solution 0.005%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
76056331|NCT02077465|Drug|Andecaliximab|400 mg andecaliximab administered intravenously
75443364|NCT01666249|Biological|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
75443365|NCT01666262|Biological|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
75443366|NCT01666262|Other|Placebo:Stabilizer|5% sucrose
75443367|NCT01666301|Drug|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
75736430|NCT04060745|Other|cooling using a water-perfused vest|"BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed"
75736431|NCT04060745|Other|thermoneutrality|In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
75736432|NCT00742937|Dietary Supplement|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
75736433|NCT00742937|Dietary Supplement|Placebo|second capsule with vitamin E, eight days after delivery.
75736434|NCT00692003|Drug|Zonisamide|"25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg; >= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
75885495|NCT03564210|Behavioral|Screen time permitted|Cohort will not be directed to abstain from screen time
75885496|NCT03564210|Behavioral|Screen Time Abstain|Cohort will be directed to abstain from screen time
75885497|NCT04496986|Diagnostic Test|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
75885498|NCT04496986|Diagnostic Test|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like moving x-ray of the participant swallowing foods and liquids (barium).
75885499|NCT04496986|Other|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
76056332|NCT02077465|Drug|Placebo to match Andecaliximab|Placebo to match andecaliximab administered intravenously
75885500|NCT04496986|Other|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
75885501|NCT04496986|Other|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
75885502|NCT04496986|Diagnostic Test|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
75885503|NCT02837952|Drug|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
75885504|NCT02837952|Drug|Placebo|Placebo
75885505|NCT02832167|Biological|Nivolumab|Specified dose on specified days
76056333|NCT02034565|Drug|Apixaban|
76056334|NCT02075515|Biological|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
76056335|NCT02034409|Device|Pulsed Low Intensity Ultrasound|20 minutes daily for 48 weeks
76056336|NCT02034409|Device|Sham Comparator|20 minutes daily for 48 weeks
76056337|NCT04682587|Drug|Axitinib|Inlyta, axitinib
75443368|NCT01666327|Drug|MT-1303|
75443369|NCT01666353|Radiation|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
75443370|NCT01666366|Procedure|Coronary artery bypass grafting|
75443371|NCT01666379|Drug|Fentanyl|
75443372|NCT01666392|Dietary Supplement|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
75443373|NCT01666392|Dietary Supplement|Placebo|Placebo
75443374|NCT01666405|Device|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
75443375|NCT01666418|Drug|Pazopanib/Paclitaxel|
75443376|NCT01666431|Drug|Lapatinib|
75885506|NCT04941040|Drug|Opioid free anesthetics|"Patients will receive over the 10 minutes prior to induction:~Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~Lidocaine loading dose 1.5 mg/kg i.v. infusion.~Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~Dexmedetomidine 0.25-0.5 μg/kg/h~Lidocaine 0.375-0.75 mg/kg/h~Ketamine 0.0625- 0.125 mg/kg/h"
75443377|NCT01666457|Other|SOFFI|NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
75885507|NCT04941040|Drug|Opioid Anesthetics|Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
76056338|NCT04682587|Drug|Avelumab|Avelumab, Bavencio
75885508|NCT03632395|Diagnostic Test|computed tomography|computed tomography
76056339|NCT04682587|Drug|Pembrolizumab|Pembrolizumab, Keytruda
75885509|NCT04937374|Other|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast.
75443378|NCT01666470|Other|Questionnaires|DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
75885510|NCT04937374|Other|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast.
75885511|NCT05708430|Drug|SVF injection into wrist|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
75885512|NCT04936516|Device|Endotracheal intubation|Endotracheal intubation using either McGrath or C-MAC video laryngoscopy
75885513|NCT00913705|Drug|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
75443379|NCT01664715|Behavioral|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
75443380|NCT01664715|Behavioral|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
75443381|NCT01664715|Behavioral|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
75443382|NCT01666483|Procedure|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
75885514|NCT00913705|Drug|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
76056340|NCT04417543|Drug|Memantine Hydrochloride|Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
76056341|NCT04417543|Drug|Placebo|Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
76056342|NCT02021318|Drug|Roxadustat|Oral tablet.
76056343|NCT02021318|Drug|Darbepoetin alfa|Subcutaneous or intravenous injection.
75593200|NCT06031142|Device|use wearable devices to monitoring fetal health conditions.|We used wearable devices and clinical cardiotocography (CTG) equipment to monitor pregnant women for 30 minutes to demonstrate the reliability of wearable devices.
75593201|NCT06031129|Drug|Butorphanol|The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery
75593202|NCT06031129|Drug|normal saline|normal saline contain 0.9% NaCl sodium.
75593203|NCT06031116|Procedure|depigmentation|gingival depigmentation
75593204|NCT06031103|Procedure|mini-PCNL procedure|"Mini-PCNL~. A 12 Fr rigid nephroscope and a Holmium:YAG laser as energy source was used for surgery Percutaneous renal puncture was achieved with an 18 Ga needle after displaying renal collecting system with contrast material. and tract dilatation was achieved using Amplatz dilators up to 16-18 Fr according to patient age"
76056344|NCT02041286|Device|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
76056345|NCT02020616|Drug|LY3053102|Administered SC
76056346|NCT02020616|Drug|Exenatide ER|Administered SC
76056347|NCT02020616|Drug|Placebo|Administered SC
75736435|NCT00692003|Drug|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg Zonisamide Placebo; >= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
75593205|NCT06031103|Procedure|RIRS procedure|RIRS Technique the 9.5 Fr ureteral access sheath (UAS). UAS was inserted over the guide wire under fluoroscopy control. A flexible ureteroscope was passed through the UAS. If the UAS did not pass over the guide wire, the investigator moved the flexible ureteroscopy over the guide wire without access sheat
75443383|NCT01666483|Procedure|Laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
75736436|NCT02564315|Drug|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
75736437|NCT02564315|Behavioral|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
75736438|NCT02564315|Behavioral|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
75593206|NCT06031090|Drug|Clonidine Injection|intravenous Clonidine 0.5 µg/kg diluted in 10ml normal saline 20 minutes before spinal anesthesia
75885515|NCT00913705|Procedure|Surgery|Surgery
75885516|NCT04934410|Drug|Etomidate|Use of etomidate during induction as decided by attending anesthesiologist
76056348|NCT02020616|Drug|Metformin|Administered orally (PO)
76056349|NCT02048072|Drug|Gilenya|Autonomic testing during first dose administration of Gilenya.
76056350|NCT02047604|Drug|SAN-300 0.5 mg/kg QW|
75593207|NCT06031090|Drug|Granisetron Injection|intravenous 1mg of granisetron diluted in 10ml normal saline 20 minutes before spinal anesthesia.
75885517|NCT04934410|Drug|Midazolam|Use of midazolam during induction as decided by attending anesthesiologist
76056351|NCT02047604|Drug|SAN-300 1.0 mg/kg QW|
75593208|NCT06031090|Drug|Normal Saline 10 mL Injection|intravenous 10 ml normal saline 20 minutes before spinal anesthesia
75593209|NCT06031051|Device|Pillcam Crohn's Capsule Endoscopy|Patients with scheduled colonoscopy are invited to a previous exploration with capsule endoscopy
75593210|NCT06031038|Other|TECCU Software|patient monitoring by software application
75593211|NCT06031025|Other|Questionnaire, clinical examination|At each follow up visit, a clinical examination and anthropometric evaluation will be performed. Parents will fill a structured questionnaire to describe the occurrence and characteristics of functional gastrointestinal disorders.
76056352|NCT02047604|Drug|SAN-300 2.0 mg/kg QOW|
76056353|NCT02047604|Drug|SAN-300 4.0 mg/kg QOW|
76056354|NCT02047604|Drug|SAN-300 4.0 mg/kg QW|
76056355|NCT02047604|Drug|Placebo|
76056356|NCT01622660|Drug|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
76056357|NCT01622660|Drug|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
75885518|NCT04934410|Drug|Sevoflurane|Use of sevoflurane during induction as decided by attending anesthesiologist
75736439|NCT02564315|Behavioral|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
75885519|NCT02787239|Drug|HLX01|
75443384|NCT01666496|Behavioral|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
75443385|NCT01666496|Behavioral|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
75443386|NCT01666509|Device|Rossoseq™|
75443387|NCT01666509|Device|Placebo|
75443388|NCT01666522|Drug|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
75443389|NCT01666522|Other|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
75443390|NCT01666535|Biological|Influenza vaccination|
75443391|NCT01666561|Other|Breakfast Test Cereal 1, Oat based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
75443392|NCT01666561|Other|Breakfast Test Cereal 2, Oat-based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
75593212|NCT06031012|Drug|glutamine combined with thalidomide|Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
75736440|NCT02564315|Behavioral|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
75885520|NCT02787239|Drug|Rituximab|
75885521|NCT02787239|Drug|CHOP|
75443393|NCT01666561|Other|Ready-to-eat cereal|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
75443394|NCT01666574|Other|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
75885522|NCT03140956|Drug|Levodopa, carbidopa, ODM-104|Crossover design. Study treatments will be administered in randomized order 4 times a day.
75885523|NCT02681237|Drug|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
75885524|NCT02681237|Drug|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
75885525|NCT03141112|Procedure|renal replacement therapy|
75593213|NCT06031012|Drug|glutamine alone|Patients received glutamine alone from the beginning of radiotherapy to one week after radiotherapy.
75593214|NCT06030986|Diagnostic Test|ILCOR Utstein OHCA Core Outcome|ILCOR Utstein OHCA Core Outcome
75593215|NCT06030973|Behavioral|Filling in an online survey|Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.
75593216|NCT06030960|Device|Virtual Reality (VR)|Virtual Reality (VR) Stabilization Exercises
75885526|NCT04362007|Drug|ASTX660|Treatment of ASTX660 for r/r PTCL and r/r CTCL
75885527|NCT04362007|Drug|ASTX660|Treatment of ASTX660 for r/r ATLL
75885528|NCT04362007|Drug|ASTX660|Treatment of ASTX660 for r/r PTCL
75885529|NCT02674529|Drug|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
75885530|NCT02674529|Drug|Placebo|Placebo
75885531|NCT02674529|Behavioral|Real-time Neurofeedback fMRI task pre- and post-RCT|Placebo experiment during an fMRI scanning session
75885532|NCT05082064|Diagnostic Test|arterial blood gases and serum electrolytes|arterial bloog gases parameters serum potassium serum sodium serum calcium
75736441|NCT02564315|Behavioral|Cessation Phase Skill Training Counseling|"Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution."
75885533|NCT05000437|Other|HIIT|3x/week high intensity interval training for 12 weeks
76056358|NCT04697498|Procedure|Bilateral bi-level Erector spine plane block|After intubation of the trachea and rotation on the abdomen before the skin incision will be performed bilateral bi-level Erector spine plane block. Before surgery, the level of screw placement will be discussed with the surgeon, and the blockade will be performed at two levels of the spine bilaterally as close as possible to the screw placement site. For blockade a solution for prolonged blockade of peripheral nerve plexuses with bupivacaine 0.375%, dexamethasone 0.02% and epinephrine 0.00018% will be used.
76056359|NCT04697498|Procedure|General anaesthesia|The control group - will include patients who will undergo surgery under general anaesthesia
75885534|NCT05250427|Other|No treatment given|No treatment given
76056360|NCT04680182|Procedure|Suction drain|Suction drain either kept for three weeks or gradually pulled out.
76056361|NCT02019602|Procedure|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
76056362|NCT02019602|Procedure|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
76056363|NCT02019602|Procedure|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
75593217|NCT06030960|Other|Regular Exercises|Regular Stabilization Exercises
75593218|NCT06030960|Other|patient instructions and education|a unified form of patient instructions and education in regards of LBP
75885535|NCT05081908|Procedure|Radiosurgery|Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife
75885536|NCT01374035|Other|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
75885537|NCT02626949|Behavioral|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
76056364|NCT02019602|Biological|Certolizumab Pegol|"Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection~Concentration: 200 mg/ml~Route of Administration: Subcutaneous Use"
76056365|NCT01994876|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
76056366|NCT01994876|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
76056367|NCT04696718|Dietary Supplement|daily supplementation|the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days
76056368|NCT02040428|Biological|EVARREST™ Fibrin Sealant Patch|
75443395|NCT01666574|Other|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
75443396|NCT01666587|Dietary Supplement|Antioxidant|
75443397|NCT01666587|Drug|Prostaglandin inhibitor (Ibuprophen)|
76056369|NCT02040428|Biological|Topical hemostat|
76056370|NCT02018822|Device|urethane dimethacrylate|Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent
75443398|NCT01666600|Drug|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
75443399|NCT01666600|Radiation|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
75443400|NCT01666613|Drug|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
75443401|NCT01666613|Drug|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
75443402|NCT01666613|Drug|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
75593219|NCT06030934|Drug|envafolimab and lenvatinib combined with paclitaxel-albumin|envafolimab: 200mg d1,15 s.c. Q4W; lenvatinib: 8mg (<60kg) or 12mg (≥60kg) p.o. Q.d.; paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
75593220|NCT06030921|Other|Osteopathic Structural Exam, State - Trait Anxiety Questionnaire|During a single patient encounter they will fill out the State-Trait Anxiety Questionnaire , and undergo a Osteopathic Structural Exam
75593221|NCT06030895|Drug|Sorafenib Tablets|Sorafenib Tablets (200 -400 mg) twice daily
76056371|NCT02018822|Device|TPH3|light-cured resin composite for teeth
75593222|NCT06030856|Device|STI test kits (NG, CT and TV) for home use|The adolescent randomized to the at-home STI testing arm will be provided with in-person instruction at enrollment and flyers (in English and isiZulu) with printed step-by-step instructions for kit use. Information will include details on how to store the kits, criteria for adequate specimen collection and preparation, how to run the test, and how to interpret the test results. Video-based instructions with accompanying text subtitles and audio options may also be provided for home use.
76056372|NCT02018822|Device|Esthet-X HD|light cured resin composite for teeth made by Dentsply Caulk
76056373|NCT02055157|Drug|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
76056374|NCT02022007|Drug|Metformin XR|"Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks~Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study"
76056375|NCT02022007|Drug|Saxagliptin|"Start 1 pill (5 mg)) for 3 weeks~Remain at 1 pill (5mg dose) for remainder of study"
76056376|NCT02022007|Drug|Saxagliptin-Metformin XR|"Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks~Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study"
76056377|NCT04716595|Drug|K-877 ER 0.2 mg/day morning administration (once daily)|K-877 ER 0.2 mg tablet
75443403|NCT01666613|Drug|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
75443404|NCT01666626|Procedure|Ultrasound stiffness imaging|Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
75443405|NCT01666639|Behavioral|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
75443406|NCT01666639|Behavioral|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
76056378|NCT04716595|Drug|K-877 ER 0.2 mg/day evening administration (once daily)|K-877 ER 0.2 mg tablet
75443407|NCT01666665|Drug|Metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
75593223|NCT06030856|Behavioral|Self Administered Behavioural Risk Assessment|Self Administered assessment to determine risk of HIV, STIs and pregnancy
75736442|NCT02564315|Behavioral|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
75736443|NCT02564315|Drug|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke >10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke <=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
75736444|NCT00743015|Drug|BI 44370 TA tablet|
75736445|NCT02564237|Biological|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
75736446|NCT02564237|Biological|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
76056379|NCT04689919|Drug|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
75736447|NCT02564237|Biological|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
75736448|NCT02564237|Biological|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
75736449|NCT00434512|Biological|HIV vaccine 732461|
75736450|NCT02564939|Drug|ramelteon|double-blind RCT
75736451|NCT02564939|Drug|Placebo|double-blind RCT
75736452|NCT02564783|Other|No intervention|No intervention
75885538|NCT02626949|Behavioral|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
75885539|NCT03140878|Dietary Supplement|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
75885540|NCT03140878|Dietary Supplement|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
75885541|NCT01374113|Drug|50mg safinamide|50 mg safinamide on Day 1
75885542|NCT02666599|Radiation|18F-FDG PET/CT|"A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically."
75593224|NCT06030830|Behavioral|SMaRT Mom|"SMaRT Mom intervention that we have developed is based on several approaches to digital addiction detection, prevention, and intervention aimed to help breastfeeding mothers to manage and reduce smartphone use during breastfeeding. The SMaRT Mom intervention results will be measured in changes in two main outcomes: 1) reduced maternal reports of their infants' negative emotionality, and 2) increased maternal self-efficacy as distal outcomes as well as two proximal outcomes: 1) breastfeeding as a rewarding experience, and 2) maternal attention towards their infant during breastfeeding. We will then assess changes in breastfeeding mothers' neural activity, physiology and behavior before and after the implementation of the SMaRT Mom intervention, as potential mechanisms underlying changes in the main outcomes of the intervention."
75885543|NCT04459936|Other|URICORI|Treatment for cardiovascular risk factors according to national guideline administered at the department of Rheumatology
75885544|NCT04459936|Other|CONTROL|Treatment for cardiovascular risk factors according to national guideline administered at the General Practitioner
75885545|NCT02616887|Radiation|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
75885546|NCT03632317|Drug|Panobinostat|30 mg/m^2
75443408|NCT01666665|Drug|Sugar pill|Sugar pill up to 3 times per day for 12 months
75443409|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
75443410|NCT01666678|Drug|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
75593225|NCT06030817|Diagnostic Test|99mTc-CNDG SPECT/CT|Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
75593226|NCT06030791|Diagnostic Test|MRI|MRI of operated knee
75885547|NCT03632317|Drug|Everolimus|3.0 mg/m^2
75885548|NCT04394494|Other|Motor Imagery. Imaging doing Extension exercises without actually doing them.|This study will compare imagining doing specific extension based exercises for LBP vs. actually performing the exercises. This intervention will be just imaging doing the exercises.
75885549|NCT04394494|Other|Control: Physically performing extension based exercises.|This study will compare imagining doing specific extension based exercises for LBP vs. actually doing them. This intervention will be actually, physically performing the exercises.
75885550|NCT02591784|Drug|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
76056380|NCT04689685|Other|Wearing smartwatch and continous glucose sensor|Patients will be wearing a smartwatch and a continuous glucose meter (CGM) over a maximum duration of 3 months in an outpatient setting.
75443411|NCT01666678|Drug|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
75443412|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
75443413|NCT01666691|Drug|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
75885551|NCT02591784|Radiation|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
75885552|NCT05203003|Other|Assessment of MRD|"Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration."
76056381|NCT04681963|Other|Clinical Assessment within 4 hours of admission|Demographics, Symptoms, Severity scores (Triage at admission, confusion, urea, respiration, blood pressure, age (CURB 65) and pneumonia severity score (PSI), clinical parameters, blood testing, chest x-rays, comorbidities, electro-cardiogram
76056382|NCT04680949|Drug|Anakinra|Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
75443414|NCT01666691|Drug|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
75443415|NCT01666704|Drug|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
75443416|NCT01666704|Drug|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
75443417|NCT01666704|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
75885553|NCT03116399|Behavioral|PRISM 2.0 Condition|Access to the PRISM 2.0 program
75885554|NCT03116399|Behavioral|Tablet Condition|Access to the tablet
75593227|NCT06030752|Drug|Washed Microbiota Transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
75593228|NCT06030674|Other|Secondhand cannabis emissions/smoke exposure|This is an environmental exposure performed in public places where people are consuming cannabis.
75885555|NCT02653963|Drug|Adjunctival Triamcinolone|Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
76056383|NCT04680949|Drug|Placebo|Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
76056384|NCT02031679|Drug|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
75593229|NCT06030648|Biological|Mesenchymal stem cells (IV-MSC)|Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.
75736453|NCT03605771|Other|Daily Clinical Practice|The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
75736454|NCT02470468|Biological|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
75736455|NCT02470468|Biological|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
75736456|NCT02470468|Other|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
75885556|NCT02623933|Radiation|MRI assisted focal boost with HDR monotherapy|Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
75885557|NCT05092997|Diagnostic Test|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL >200 c/ml will receive additional adherence counseling, following the STREAM protocol, [26] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
76056385|NCT02031679|Drug|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
75443418|NCT01666743|Drug|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
75443419|NCT01666756|Dietary Supplement|Chinese herbal formulation PHY906|Given PO
76056386|NCT04689139|Diagnostic Test|blood sample tests for determination of biomarkers levels|Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
76056387|NCT02053753|Drug|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
75443420|NCT01666756|Drug|sorafenib tosylate|Given PO
75443421|NCT01666756|Other|laboratory biomarker analysis|Correlative studies
75443422|NCT01666756|Other|pharmacological study|Correlative studies
75443423|NCT01666769|Drug|Micafungin|4 mg/kg/day
75443424|NCT01666769|Drug|Micafungin|8 mg/kg/day
75593230|NCT06030609|Drug|Ringer's Lactate Crystalloid Solutions|The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
75593231|NCT06030609|Drug|Normal saline|The patient will receive NSS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
75593232|NCT06030570|Other|Rehabilitation program (Revita)|Multidisciplinary programs in an outpatient hospital setting are coordinated by specialists in Physical and Rehabilitation Medicine. These programs combine a physical part (e.g., specific exercises, manual techniques) with at least one other element (psychological, social, educational or occupational intervention). In a multidisciplinary spine rehabilitation program, a maximum of 36 sessions over a maximum time period of 6 months is offered. Afterwards, a (monodisciplinary) follow-up trajectory (K15) is possible, consisting of maximum 104 sessions a year.
75593233|NCT06030557|Drug|Truvada|Participants will receive either Truvada or Descovy (based on prescription guidelines).
76056388|NCT02053753|Drug|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
76056389|NCT02019979|Drug|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
76056390|NCT02019979|Behavioral|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
75443425|NCT01666769|Drug|Micafungin|Standard of care Dosing
75736457|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
75593234|NCT06030544|Dietary Supplement|OA-enriched functional olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a functional olive oil enriched in Oleanolic acid (equivalent dose 30 mg/day OA) Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494).
75443426|NCT01666821|Other|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
75443427|NCT01666847|Procedure|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
75736458|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
75736459|NCT00427648|Drug|alkalinized xylocaine|30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
75736460|NCT00427648|Drug|placebo|normal saline
75443428|NCT01666860|Procedure|Anterior Lumbar Interbody Fusion procedure|
75443429|NCT01666886|Device|Mandibular Advancement Device (MAD)|
75443430|NCT01666899|Procedure|Skin and blood vessel procedures|Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
75443431|NCT01666925|Biological|ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu
75736461|NCT02153177|Procedure|Rotator cuff repair|Arthroscopic procedure
75443432|NCT01666925|Biological|Rabies vaccine|2 x 2.5IU Verorab
75443433|NCT01666938|Other|Diabetes Education Group|Diabetes Education Group: Diabetes Education for four month, one time per week.
75443434|NCT01666938|Other|Telephone Counseling|Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
75443435|NCT01666964|Other|Blast Traumatic Brain Injury|Exposure during combat to blast-wave mediated Traumatic Brain Injury
75443436|NCT01666990|Drug|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
75443437|NCT01666990|Drug|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
75443438|NCT01667068|Other|Comprehensive non invasive cardiovascular examination|"Anamnesis with the participian~File recherche,Physical examination~Documentation of the carciovascular and antiretroviral medical therapy~Electrocardiogram~Transthoracic echocardiography~Exercise electrocardiogram~Measuring of the arterial media thickness~Exercise Montreal Cognitive Assesment test~Exercise the Grooved Pegboard test~Blood collection~Questionnaire to quality of life and health economics"
75443439|NCT01667094|Drug|Intermittent, short infusion Ceftazidime|Ceftazidime 1g q8/24
75443440|NCT01667094|Drug|Continuous infusion Ceftazidime|Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
75443441|NCT01667094|Drug|Intermittent, short infusion Meropenem|Meropenem 1g q8/24, infusion over 30 minutes
75443442|NCT01667094|Drug|Continuous infusion Meropenem|Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
75443443|NCT01667094|Drug|Intermittent, short infusion Ticarcillin-clavulanate|Ticarcillin/clavulanate 3.1g q6/24
75593235|NCT06030544|Dietary Supplement|commercial olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
75593236|NCT06030531|Other|Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation|We will test for presence of biological markers in blood that may correlate with levels of spasticity or neurological recovery and functional improvement, including the presence or absence of neuroplastic genetic polymorphisms (e.g. BDNF Val66Met polymorphism), as well as circulating levels of neuroplastic(e.g. BDNF) or inflammatory factors (e.g. interleukins, TNF) that may affect neuronal growth and functional restoration.
75736462|NCT02153177|Drug|Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole|In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
75885558|NCT05092997|Other|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
75885559|NCT03939364|Drug|SBS-101|Isotretinoin Oral-Adhesive Film
75885560|NCT03939364|Drug|Placebo|Placebo
75593237|NCT06030531|Other|Analysis of biomarkers|We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.
75593238|NCT06030518|Diagnostic Test|Magnet Assisted Capsule Endoscopy|Procedures will be performed in the morning after an overnight fast. Patients wear a belt containing sensors and a data recorder. The patient will be asked to drink 500-1000ml (containing 80mg simethicone; volume depending on tolerance) immediately before swallowing the capsule. Gastric examination will proceed as previously described for a robot-controlled magnetic assisted capsule endoscopy. The whole procedure is anticipated to take 30-60 minutes. The patient will be discharged from hospital on completion of gastric examination but if clinically indicated will wear the belt for small bowel capsule study for eight hours to allow small bowel examination before detaching the equipment and returning it the following day. On completion of examination, the patient will be asked to complete a questionnaire about their capsule endoscopy experience. The full study (upper GI tract and small bowel) will then be downloaded onto the computer for formal reading and reporting.
75443444|NCT01667094|Drug|Continuous infusion Ticarcillin-clavulanate|Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
75593239|NCT06030492|Drug|packing placental site with hydrogen peroxide soaked towels|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics & a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution"
75593240|NCT06030492|Drug|normal Saline|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics & a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution"
75593241|NCT06030479|Drug|Topical adrenaline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the pelvic surgical field with towels fully saturated with adrenaline 1:10000 solution."
75736463|NCT02153177|Drug|Hydrocodone/Acetaminophen|Hydrocodone/Acetaminophen is given for pain control after the surgery.
75736464|NCT00743327|Drug|Pioglitazone|45mg capsule, once daily for 1 year
75736465|NCT01032460|Device|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
75736466|NCT01032460|Device|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
75736467|NCT01032460|Device|intubate with the Airtraq device|intubate with the Airtraq device
75736468|NCT03888599|Behavioral|knowledge questioannaire|", all enrolled undergraduate student received directly on your email the online questionnaire based on the Fluid Survey tool, which was an on line survey tool (https://fluidsurveys.com/)"
75736469|NCT02564861|Drug|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
75736470|NCT02564861|Drug|Placebo|Placebo matching DS-1971a suspension
75736471|NCT00416884|Drug|Campath|30 mg on day -8 over 5-6 hours
75736472|NCT00416884|Drug|Fludarabine|Fludarabine 30 mg/m^2 on day -4 through day -2
75736473|NCT00416884|Radiation|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
75736474|NCT00416884|Other|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
75736475|NCT02564627|Procedure|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
75736476|NCT02564627|Procedure|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
75736477|NCT02564627|Dietary Supplement|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
75736478|NCT00743405|Drug|GSK1034702|Oral or liquid
75736479|NCT00743405|Drug|Placebo|To match GSK1034702
75736480|NCT01032616|Other|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
75736481|NCT01032616|Other|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
75736482|NCT02564081|Other|Static Stretching lower limb|
75736483|NCT02564081|Other|Static stretching Cervical|
75443445|NCT01667094|Drug|Intermittent, short infusion Cefepime|Cefepime 1g q8/24
75443446|NCT01667094|Drug|Continuous infusion Cefepime|Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
75443447|NCT01667094|Drug|Continuous infusion Piperacillin tazobactam|Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
75443448|NCT01667094|Drug|Intermittent, short infusion Piperacillin tazobactam|Piperacillin tazobactam 4.5g q6/24
75736484|NCT01032772|Behavioral|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
75885561|NCT05418829|Drug|AT-007|AT-007 20 mg/kg once daily
76056391|NCT04687501|Device|Virtual Reality|Virtual reality in gynaecological surgery in the pre- and postoperative setting
76056392|NCT02019667|Drug|SGS-742|
75443449|NCT01667146|Other|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH > 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
75443450|NCT01667146|Other|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
75593242|NCT06030479|Drug|Warm saline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the surgical field with towels fully saturated with warm saline solution ( 50 degrees)."
75593243|NCT06030453|Combination Product|SMART HOME strategy|Sleep hygiene: quiet and dim environment for 6 hours to facilitate sleep (Score: 0-100%).Multidisciplinary collaboration: pharmacists, respiratory therapists, rehabilitation therapists, and physical therapists (Score: ≥20%).Assessment : Evaluating and assessing the levels of pain, anxiety, and agitation (Score: 0-100%).Release of tracheal tubes and restraints: relieving pressure from tracheal tubes and restraints (Score: 0-100%).Time and schedule: Orienting the patient to time and a schedule (Score: 0-100%).Home-like environment and Hearing: A comfortable environment similar to home and music (Score: 0-100%).Orientation support: assisting with a sense of person, time, and place (Score: 0-100%).Medication review : Reviewing and adjusting medications (Score: ≥20%).Early mobilization and nutrition(Score: 0-100%).
75593244|NCT06030453|Combination Product|PADIS nursing intervention|pharmacological treatments for pain, agitation, delirium, immobility, and sleep disruption as well as nursing interventions
75593245|NCT06030401|Device|Transthoracic Ultrasound|Sonar of The Chest
75736485|NCT01032772|Behavioral|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
75736486|NCT00434122|Drug|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
75593246|NCT06030375|Drug|KAND567|Continuous intravenous infusion for 6 hours
75736487|NCT00434122|Drug|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
75736488|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
75736489|NCT00555620|Drug|oxaliplatin|Oxaliplatin is given 110mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
75736490|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
75885562|NCT04288960|Device|Gwalk accelerometer walking trials|No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
75885563|NCT03097861|Drug|Lubiprostone|24 mcg administered orally BID
76056393|NCT02019667|Drug|Placebo|
76056394|NCT02030821|Drug|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
75885564|NCT03097861|Drug|Placebo|24 mcg administered orally BID
76056395|NCT02030821|Drug|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
75885565|NCT04215562|Combination Product|rehabilitation|electro-therapy, heat therapy, massage and exercise therapy
75885566|NCT03137914|Biological|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
76056396|NCT02052739|Drug|SAGE-547|Solution for injection for IV infusion
75443451|NCT01667159|Behavioral|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
76056397|NCT02019277|Drug|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
76056398|NCT02019277|Drug|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
76056399|NCT02019277|Drug|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
76056400|NCT02019277|Drug|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
76056401|NCT02019277|Drug|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
76056402|NCT04712773|Device|PMD-200 monitor|Patient is connected to non-invasive PMD-200 monitor, measuring Nociception Level
76056403|NCT04712773|Device|Surgical Pleth Index monitor|Patient is connected to non-invasive monitor measuring Surgical Pleth Index
75885567|NCT03137914|Procedure|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
75593247|NCT06030375|Other|Placebo|Continuous intravenous infusion for 6 hours
75885568|NCT03137758|Drug|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
75443452|NCT01667159|Behavioral|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
75443453|NCT01667172|Device|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
75443454|NCT01667198|Procedure|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
75593248|NCT06030349|Device|Non-invasive ventilation|Non-invasive ventilation
75593249|NCT06030323|Other|No intervention|This is not an interventional study. The study is classified as 'pre-clinical device development or performance testing'. The purpose of the study is to develop and validate the AI models using data collected from people affected by stroke in a hospital environment, to test the accuracy of the optimised models, and to ascertain patient preference for sensor location.
75593250|NCT06030310|Other|The developmental Exercise Programme of INPP|"The INPP school motor program consists of a series of developmental movements based on the normal movements of a child in their first year of life. Exercises must be performed as slow as possible and must be repeated for at least six weeks.~Once the children have performed a set of movements, a new set will be presented for practice in a more complex position.~The exercises are done on the floor and aid in developing:~Proper alignment of the head with the body, trunk stability. Balance and coordination. The ability to use both sides of the body and upper and lower parts independently.~Muscle tone in prone and supine position. Hand-eye coordination and visual skills"
75593251|NCT06029647|Other|Mango|The participants will consume the treatment for 16 weeks, followed by a 4-week washout period.
75593252|NCT06029647|Other|vanilla wafers|vanilla wafers
75593253|NCT06029179|Drug|sodium zirconium cyclosilicate (SZC)|30 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 4 weeks.
75593254|NCT06029179|Drug|sodium polystyrene sulfonate|30 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 4 weeks.
75593255|NCT06028490|Biological|GR1802 injection-1|subcutaneous，dose*1
75593256|NCT06028490|Biological|GR1802 injection-2|subcutaneous，dose*2
75593257|NCT06028490|Biological|Placebo|subcutaneous，dose*2
75736491|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
75736492|NCT00555620|Drug|cisplatin|Cisplatin is given 80mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
75736493|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
75736494|NCT00433966|Drug|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
75885569|NCT05087927|Behavioral|Gain framing plus demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
75885570|NCT05087927|Behavioral|Loss framing plus demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
75885571|NCT05087927|Behavioral|Gain framing plus not demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
75885572|NCT05087927|Behavioral|Loss framing plus not demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
75885573|NCT01376141|Drug|Sumatriptan|
75885574|NCT04180852|Other|Functional tests without clinical consequence for the patients therapy|Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
75885575|NCT03861689|Diagnostic Test|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
76056404|NCT02030119|Behavioral|Financial Incentives|
75593258|NCT06028386|Device|AC5® Advanced Wound System|This group will receive AC5® Advanced Wound system, a synthetic self-assembling peptide matrix to the wound and covered with non-adherent dressing followed with appropriate outer dressing to maintain moisture balance. AC5 is applied weekly and outer dressing will be redressed as necessary.
75593259|NCT06028386|Device|Fibracol Plus Collagen Dressing|This group will receive Fibracol Plus collagen dressing to the wound and covered with appropriate out dressing. Treatment will be done 3x a week.
75593260|NCT06028100|Procedure|sacral erector spinae plane block|espb from bilateral sacral level 2 with 20 ml %0,25 bupivacaine
75593261|NCT06028074|Drug|GIM122|GIM-122 administered IV once every 3 weeks
75593262|NCT06027892|Radiation|Two-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a dose biologically comparable to 40 Gy in 5 treatments, but in only 2 treatments
75593263|NCT06027892|Radiation|Five-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a standard stereotactic dose of 40 Gy in 5 treatments
75593264|NCT06027567|Drug|Semaglutide|Subcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg
75593265|NCT06027567|Dietary Supplement|Very Low Calorie Diet|Very Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products
76056405|NCT02030119|Behavioral|Daily feedback|
75593266|NCT06027567|Behavioral|Dietician counselling|Counselling by a dietician on weight loss through behavioural changes and life style intervention
75885576|NCT03137680|Behavioral|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
75736495|NCT00433966|Drug|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
75885577|NCT03215914|Device|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
75885578|NCT03691402|Behavioral|MCT-Silver|Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
75885579|NCT03691402|Behavioral|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
75593267|NCT06027528|Procedure|dentin graft mixed with autologous fibrin glue|extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket using centrifuge
75885580|NCT03636100|Device|Cryoballoon ablation|Cryoballoon ablation using standard equipment and techniques
75885581|NCT01816139|Drug|Vehicle|Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
75885582|NCT01816139|Drug|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
75885583|NCT03443674|Drug|SCB-313|Lyophilized powder in a single-use vial
75885584|NCT01100879|Drug|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
76056406|NCT04686331|Diagnostic Test|Biomarkers for pneumonia|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of surfactant protein D, Krebs von den Lungen (KL-6), and YKL-40. Laboratory staff will be blinded to participant diagnosis and outcome. None of the biomarkers will be available to the treating physician.~Diagnostic test of surfactant protein D - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~Diagnostic test of KL-6: will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~Diagnostic test of YKL-40 - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis"
76056407|NCT01823835|Drug|GDC-0810|GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
75593268|NCT06027528|Procedure|dentin graft|extracted tooth will be grafted in the socket
75593269|NCT06027099|Drug|Tizanidine|Tizanidine 2mg three times a day for 5 weeks after surgery
75593270|NCT06027099|Behavioral|MI-Opioid Taper|Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.
75593271|NCT06027099|Drug|Placebo|1 tablet three times a day for 5 weeks after surgery
75736496|NCT00433966|Device|Bare metal stent|Uncoated bare metal stent
75736497|NCT00433966|Device|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
75736498|NCT00743561|Device|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
75736499|NCT00743561|Device|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
75885585|NCT05070689|Procedure|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
76056408|NCT01823835|Drug|LHRH Agonist|LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
75443455|NCT01667198|Behavioral|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
75443456|NCT01667211|Drug|albumin-bound paclitaxel plus nedaplatin|intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
75736500|NCT00743639|Procedure|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10[7] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
75736501|NCT00947336|Drug|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
75736502|NCT00947336|Drug|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
75736503|NCT00956384|Procedure|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
75736504|NCT00956384|Procedure|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
75736505|NCT00955214|Device|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
75736506|NCT00947414|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
75736507|NCT00947414|Device|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
75736508|NCT00955292|Drug|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
75736509|NCT00956462|Drug|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
75736510|NCT00947492|Biological|Venous blood sample|Venous blood sample twice a year during 3 years
75736511|NCT05300360|Diagnostic Test|adenosine deaminase test|adenosine deaminase enzyme deficiency test
75885586|NCT00904553|Radiation|Novalis Shaped Beam Surgery|Treatment using Novalis SRS
75885587|NCT05392660|Other|assumed upright position during first stage of labor|The study group assumed one of upright positions during first stage of labor, defined as walking , sitting, standing, kneeling & squatting positions )
75736512|NCT00956696|Drug|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
75736513|NCT00955448|Device|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
75736514|NCT00955448|Procedure|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
75885588|NCT01374191|Drug|onabotulinum toxin type-A|1 injection of Btx-A
75885589|NCT01374191|Other|placebo|1 injection of saline solution
75885590|NCT01374191|Drug|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
75885591|NCT04021810|Device|Continuous Positive Airway Pressure (CPAP) and patient education|Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
75885592|NCT04021810|Device|Mandibular Advancement Device|Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
75885593|NCT03140098|Device|cardiac surgery requiring a collagen membrane COVA™+|At the end of the cardiac surgery, the collagen membrane is implanted on the dissection area in order to prevent the formation of postoperative adhesions.
75885594|NCT03140020|Procedure|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
75885595|NCT03140020|Procedure|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
75885596|NCT03764735|Drug|Low Dose - SkQ1|SkQ1 Low dose ophthalmic solution
75885597|NCT03764735|Drug|High dose - SkQ1|SkQ1 High Dose ophthalmic solution
75885598|NCT03764735|Drug|SkQ1 (Vehicle)|Vehicle for SkQ1 ophthalmic solution
76056409|NCT01823835|Drug|Palbociclib|Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
75443457|NCT01667237|Behavioral|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
76056410|NCT01823679|Drug|Capecitabine|Given orally
75443458|NCT01667263|Drug|All-trans retinoic acid|
76056411|NCT04414293|Radiation|Lung Low Dose Radiation|The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
76056412|NCT01823289|Drug|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
75443459|NCT01667263|Drug|Danazol|
76056413|NCT01822899|Drug|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
75885599|NCT03957694|Drug|Romiplostim|Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
75885600|NCT05759507|Procedure|abdominal surgery|
75885601|NCT05041673|Drug|Metformin|Antidiabetic drugs
75769522|NCT01255618|Device|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
75885602|NCT03907540|Drug|Belumosudil 200 mg tablet|Belumosudil 200 mg tablet, development candidate
76056414|NCT01822899|Drug|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
76056415|NCT01822899|Drug|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
76056416|NCT01822899|Drug|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
76056417|NCT01822821|Drug|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
76056418|NCT01822821|Drug|Placebo|Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
76056419|NCT01822665|Drug|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
76056420|NCT01822665|Drug|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
76056421|NCT01822665|Other|Placebo|Placebo tablets
76056422|NCT02173301|Drug|XP23829 400 mg QD|active dose 1
76056423|NCT02173301|Drug|XP 23829 800 mg QD|active dose 2
76056424|NCT02173301|Drug|XP23829 400 mg BID|active dose 3
76056425|NCT02173301|Drug|Placebo|control
76056426|NCT01822587|Drug|Propranolol, 40 mg|
75443460|NCT01667289|Radiation|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
75443461|NCT01667289|Drug|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
76056427|NCT01822587|Drug|Propranolol, 80 mg|
76056428|NCT01822587|Drug|Placebo|
76056429|NCT04588077|Biological|Heplisav-B Injectable Product, 2-dose regimen|Investigators will randomly assign patients into a 2-dose regimen.
76056430|NCT04588077|Biological|Heplisav-B Injectable Product, 3-dose regimen|Investigators will randomly assign patients into a 3-dose regimen.
75885603|NCT03907540|Drug|[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose|test investigational medicinal product
75885604|NCT03907540|Drug|[14C]-KD025 200 mg capsule|test investigational medicinal product
75885605|NCT05759429|Other|BWRP|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education
75885606|NCT05759429|Other|BWRP + melatonin|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
76056431|NCT04595331|Device|Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection|Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
75885607|NCT04005209|Drug|Ketamine|The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
75885608|NCT04005209|Other|Pain management|Pain management
75885609|NCT05088304|Other|no intervention|
75885610|NCT05088226|Drug|Ruxolitinib combined with Chidamide.|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
75885611|NCT01376219|Other|asthma control test|results of asthma control testing collected
75443462|NCT01667302|Drug|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
75443463|NCT01667315|Drug|Bupivacaine 0,375%|Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
75885612|NCT03751553|Drug|obsteric gel(k-Y jelly)|A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
75885613|NCT03904108|Drug|Ramucirumab|platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
75443464|NCT01667328|Procedure|Massage therapy|Presurgical 15 minute massage performed by a licensed massage therapist
75885614|NCT03636581|Behavioral|Lifestyle counseling|This group will receive online education modules to educate them on exercise prescription, nutrition and behavioral changes.
75885615|NCT04976309|Drug|Lu AG09222|Single dose
75885616|NCT04976309|Drug|Placebo|Single dose
75885617|NCT05392348|Dietary Supplement|stachyose|Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1->6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.
75885618|NCT05392348|Dietary Supplement|Maltodextrin|Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.
75885619|NCT03137524|Device|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
75443465|NCT01667328|Procedure|Standard of care|Control group will receive standard of care with no massage therapy
75443466|NCT01667354|Behavioral|Academic Detailing|"The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations."
75443467|NCT01667367|Drug|RG1662|Single oral dose
75443468|NCT01667367|Drug|placebo|Single oral dose
75443469|NCT01667393|Device|IDEV SUPERA Stent|
75443470|NCT01667393|Device|Percutaneous Transluminal Angioplasty|
75885620|NCT02833350|Drug|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
75885621|NCT02833350|Drug|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
75885622|NCT02833350|Drug|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
75885623|NCT02833350|Drug|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
75885624|NCT02833350|Drug|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
75885625|NCT03137602|Device|ATOMIC mobile app|(a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
76056432|NCT04587999|Other|bladder stimulation|"The bladder stimulation technique requires the presence of 2 people:~The child must be held by an adult (caregiver or parent) under the armpits, legs dangling.~the first person (the investigator), performs the stimulation technique consisting of: rapid tapping (frequency of about 100 / min), over the pubic area, at the level of the bladder, alternated with external rotational movements of the pits lumbar, in the kidneys. Alternate these 2 maneuvers every 30 seconds.~The second person starts the stopwatch at the start of the stimulation, and is about to collect the urine, 2nd jet in a sterile pot~The maneuver ends as soon as urine is obtained, and will be stopped after 5 minutes in case of failure."
76056433|NCT04587999|Other|Quick wee|"The Quick wee technique requires the presence of only one person:~Stimulation of the suprapubic area by circular movements, with a cold and wet compress held by sterile forceps.~Collection of urine in a sterile container."
75736515|NCT03952650|Drug|Chloroquine Phosphate|Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
76056434|NCT01822353|Dietary Supplement|Dietary supplement|Milk, egg or nut oral immunotherapy
75443471|NCT01667445|Drug|Epimorph|Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
75443472|NCT01667445|Drug|Spinal analgesia|Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
75736516|NCT03952650|Biological|PfSPZ Challenge|PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
76056435|NCT01821963|Drug|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
75443473|NCT01667484|Drug|Adderall XR 5mg|
75443474|NCT01667484|Drug|Adderall XR 10 mg|
75443475|NCT01667484|Drug|Placebo|
75443476|NCT01667497|Drug|Fampridine SR|
75443477|NCT01667497|Drug|Placebo|
75443478|NCT01667510|Dietary Supplement|Cardio Mato|Soft gel capsule for oral use
76056436|NCT01821963|Drug|Ribavirin|Starting dose: 1,000 mg by mouth daily.
76056437|NCT01821963|Drug|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
76056438|NCT01821729|Drug|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
76056439|NCT01821729|Drug|Losartan|Taken orally every day during Phase I for all 8 cycles
75443479|NCT01667510|Dietary Supplement|Placebo|Soft gel capsule without test material
75443480|NCT01667523|Dietary Supplement|Capsaicin|1.5 mg capsaicin administered intraduodenally
75443481|NCT01667523|Dietary Supplement|Cinnamaldehyde|70 mg per intervention administered intraduodenally
76056440|NCT01821729|Radiation|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
75443482|NCT01667523|Dietary Supplement|Placebo|Physiological saline
75593272|NCT06027099|Behavioral|Enhanced Usual Care|Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide & Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
75736517|NCT03952650|Drug|Pyrimethamine|"Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses."
75593273|NCT06027021|Diagnostic Test|18F-Fluoromisonidazole PET|Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.
75736518|NCT03952650|Drug|Coartem|Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
75736519|NCT03952650|Drug|ibuprofen|Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
75593274|NCT06026800|Biological|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
75736520|NCT00955526|Drug|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
75736521|NCT00955526|Drug|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
75736522|NCT00955526|Drug|Placebo|Two placebo tablets once daily for 12 weeks
75736523|NCT00955604|Drug|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
75736524|NCT00955604|Drug|Group R Rasagiline|At least 2 months of rasagiline
75736525|NCT00955604|Drug|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
75736526|NCT00947570|Behavioral|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
75736527|NCT03623646|Drug|Chemoradiotherapy arm|Radiation Therapy in combination with Chemotherapy (Cisplatin)
75736528|NCT03623646|Drug|Immunotherapy + Radiotherapy arm|Radiation Therapy in combination with Immunotherapy drug (Durvalumab)
75885626|NCT03137212|Combination Product|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
75443483|NCT01667575|Drug|Esomeprazole|antisecretary drug of the quadruple therapy
75443484|NCT01667575|Drug|Amoxicillin|antibiotic of the quadruple therapy
75443485|NCT01667575|Drug|Clarithromycin|antibiotic of the quadruple therapy
75593275|NCT06026774|Biological|iNeo-Vac-R01 in combination with standard adjuvant therapy|Personalized mRNA vaccine encoding neoantigen, IH injection
75736529|NCT00947648|Other|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
75736530|NCT00947648|Other|Cooked Foods|Diet containing only cooked foods.
75885627|NCT03137212|Combination Product|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
75443486|NCT01667575|Drug|Bismuth Potassium Citrate|one of a component of a quadruple therapy
75443487|NCT01667575|Other|long duration (14 day)|
75443488|NCT01667601|Other|Routine Care|Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
75443489|NCT01667601|Behavioral|Mindfulness-based program|The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
75443490|NCT01667601|Behavioral|Psychoeducation group|A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
75443491|NCT01667614|Drug|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
75885628|NCT03137134|Drug|Crizotinib|Crizotinib in a coated microsphere formulation
75885629|NCT03137134|Drug|Esomeprazole|Proton pump inhibitor, esomeprazole
75885630|NCT03137368|Drug|Exemestane Tablets|drug therapy
76056441|NCT01820637|Device|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
76056442|NCT02172911|Biological|INO-3112|1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.
75885631|NCT03137368|Other|ovarian function suppression/ablation|Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
75885632|NCT03137368|Genetic|CYP2D6*10 gene test|CYP2D6*10 gene test
75885633|NCT03137368|Drug|Tamoxifen|drug therapy
76056443|NCT02172911|Device|CELLECTRA™-5P|CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.
76056444|NCT02120027|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
75593276|NCT06026683|Device|Pacemaker implant|Implantation of pacemaker with conduction system pacing or right ventricular apical pacing
75593277|NCT06026358|Drug|Tirbanibulin|subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
75593278|NCT06021275|Other|Microneedling with topical application of regular insulin|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
75593279|NCT06021275|Other|Microneedling with topical application of saline|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
75736531|NCT00962286|Drug|Furosemide|"Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid."
75736532|NCT00691301|Drug|cisplatin|Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
75736533|NCT00691301|Drug|pemetrexed disodium|
75736534|NCT00955760|Drug|Neramexane|Drug-Drug Interaction Study
75736535|NCT04010448|Biological|TV P2-VP8|90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
75736536|NCT04010448|Biological|Rotarix|Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
75736537|NCT00955838|Other|Rehabilitation technique|12 therapy session
75736538|NCT03554382|Other|system to support self-management of hypertension|The patients are provided with a home BP monitor. Thereafter they will be asked to use the self-management support system and self-report, once daily in the evening, via their own mobile phone during eight weeks. At each occasion, the patients first answer the questions on wellbeing, symptoms, lifestyle, medication intake and side effects and then measure their BP and pulse, and when these data (mean of three readings) are input into the mobile phone, they automatically register in the database. During intervention the paient has regular access to self-reported data via graphs
75885634|NCT05391958|Behavioral|base on Lean Body Mass Pattern|PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC > 2.
76056445|NCT02120027|Drug|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
76056446|NCT01850823|Drug|placebo|
76056447|NCT01850823|Drug|Mometasone Nasal Spray|
76056448|NCT01850823|Drug|Mometasone nasal spray|
76056449|NCT01820559|Drug|Placebo|Tablets
76056450|NCT01820559|Drug|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
76056451|NCT01820559|Drug|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
76056452|NCT01818765|Procedure|Trans-ventricular-septal placement of LV pacing lead|
76056453|NCT01818765|Other|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
76056454|NCT01818765|Other|Acute response assessment|Cardiac output monitoring
75885635|NCT05391958|Behavioral|base on Actual Body Weight|PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC > 2.
75736539|NCT00947726|Drug|CeraVe|Using OTC cream on foot twice daily for two weeks.
75885636|NCT05391958|Genetic|obese patients|obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ ~ Ⅲ.
75885637|NCT05391958|Genetic|normal patients|normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ ~ Ⅲ.
76056455|NCT01850589|Other|Aggressive Therapy|"Pharmacotherapy adjuncts offered at no cost are as follows:~Chantix (varenicline) GlaxoSmithKline,~Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
76056456|NCT01818531|Drug|Adductor canal block|
75443492|NCT01667627|Dietary Supplement|Bio-25|"Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria.~Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus."
75443493|NCT01667627|Other|Placebo|Identical placebo
75443494|NCT01667640|Radiation|sector irradiation|"Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.~A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.~Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.~Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.~Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported."
75593280|NCT06020001|Dietary Supplement|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
75736540|NCT03887819|Diagnostic Test|Hystological evaluation|The original tissues samples will be fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Sections (4 μm thick) will be stained with hematoxylin and eosin stain (H&E) for diagnosis. The immunohistochemistry for anti-LCA, anti-CD68, and anti-CD3 will be performed to identify the inflammatory infiltrate.
75736541|NCT00955994|Drug|asimadoline|
75885638|NCT05391802|Device|Transcatheter mitral valve repair|Transcatheter mitral valve repair (TMVr) is a minimally invasive procedure. Doctors place a thin tube (calleda catheter) into a large vein to reach your heart. A clip is then placed onto the center of your mitral valve. The valve continues to open and close, allowing blood to flow through while reducing MR.
75885639|NCT03138616|Drug|vitamin D|take 1600 units of vitamin D daily for nine months
75593281|NCT06020001|Dietary Supplement|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
75593282|NCT06020001|Other|Placebo|Twice a day
75593283|NCT06019702|Biological|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
75736542|NCT05277480|Drug|Apatinib+IE|apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
76056457|NCT01818531|Drug|Lumbar plexus block|
75593284|NCT06016010|Drug|USL|500mg of Achyranthis Radix Extract
75593285|NCT06016010|Drug|USL Placebo|USL Placebo
76056458|NCT02171429|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
76056459|NCT02171429|Other|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
76056460|NCT02171429|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
75593286|NCT06014073|Biological|TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)|"Phase 1 dose escalation (3+3) : dose 1 (1 × 10^6 cells/kg) , dose 2 (3 × 10^6 cells/kg), dose 3 (1 × 10^7 cells/kg); Phase 2 : dose of RP2D.~No more than 2 × 10^5 per kilogram of allogenic residual CD3+T cells harbouring in grafts can only be released for recipient infusion."
75593287|NCT06014073|Drug|Fludarabine|Intravenous fludarabine 30~50 mg/m^2/day on days -5, -4, and -3.
75593288|NCT06014073|Drug|Cyclophosphamide|Intravenous cyclophosphamide 500~1000 mg/m^2/day on days -5, -4, and -3.
75736543|NCT05277480|Drug|IE|ifosfamide ivgtt ; etoposide ivgtt .
75736544|NCT03429335|Behavioral|Teaching session|The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.
76056461|NCT02171429|Other|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
76056462|NCT01818297|Device|PrimeAdvanced® neurostimulator system|Neurostimulator and associated components
76056463|NCT01818141|Drug|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
76056464|NCT01818141|Drug|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
76056465|NCT01849497|Biological|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
75885640|NCT03137290|Drug|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
75885641|NCT03137290|Drug|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
75885642|NCT03782818|Drug|Olaparib|Olaparib up to 300 mg BID for 24 weeks
75593289|NCT06013319|Drug|Esmolol|The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
75885643|NCT05391724|Drug|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
75885644|NCT03137446|Other|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
75885645|NCT03641248|Drug|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
75885646|NCT03641248|Drug|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
75885647|NCT03138460|Other|standard medications crossed over to cannabis|
76056466|NCT01849497|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
76056467|NCT02147093|Device|Test (multi-focal)|contact lens was to be worn a daily wear.
76056468|NCT02147093|Device|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
76056469|NCT04170465|Drug|Metformin Hydrochloride 850 mg Tablets|Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
75885648|NCT05391490|Genetic|KCAT19 T cells|Allogeneic, cord unit derived KCAT19 T cells
75885649|NCT03355534|Drug|Intravenous dexmedetomidine|drug is intravenously infused to patients
75885650|NCT03355534|Drug|nasal dexmedetomidine|drug is nasally given to patients
76056470|NCT04170465|Drug|AC-T chemotherapy regimen|AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
76056471|NCT02119325|Dietary Supplement|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
75593290|NCT06012110|Device|Transcutaneous electrical stimulation|While participants are supine with a pillow placed below the knees for comfort, one 30-minute transcutaneous electrical stimulation session will be performed at a frequency of 50 Hz, pulse width of 400 microseconds and individualized amplitude will be completed.
75593291|NCT06007417|Drug|GenSci004|GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)
75593292|NCT06007417|Drug|Genotropin|Genotropin
75593293|NCT05990231|Drug|Cadonilimab combined Anlotinib|Cadonilimab: intravenous administration at a dose of 10mg/kg on day 1 of each cycle, every 3 weeks (Q3W) Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle
75593294|NCT05989906|Behavioral|Sprint Interval Training (SIT)|Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.
75593295|NCT05989906|Behavioral|Usual Care|Participants will have the opportunity to participate in optional group endurance exercise classes two to three times a week.
75885651|NCT03355534|Drug|intravenous saline|saline is given to patients intravenously
75885652|NCT03355534|Drug|nasal saline|normal saline is given to patients nasally
75885653|NCT05341284|Other|Questionnaire Survey and Cervical Cancer Screening|"A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36."
75885654|NCT05385640|Other|NO intervention|NO intervention
75885655|NCT05385562|Drug|Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate|formulated with sodium hyaluronate and chondroitin sulfate
75885656|NCT05385562|Drug|Triamcinolone Acetonide alone|Triamcinolone Acetonide alone
76056472|NCT02119325|Dietary Supplement|0% fibre|Placebo is an energy matched powdered beverage
76056473|NCT01816893|Other|Hypoglycemic hyperinsulinemic clamp|
75885657|NCT01343043|Drug|NY-ESO-1(c259)T Cells|Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
75885658|NCT01343043|Drug|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy.
75885659|NCT01343043|Drug|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy.
75885660|NCT03139708|Drug|Alphagan|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one."
75885661|NCT03139708|Drug|Phenylephrine|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
75885662|NCT03139708|Drug|Tropicamide|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
75885663|NCT03548987|Drug|Semaglutide|Subcutaneous (under the skin) injection of semaglutide once-weekly.
75885664|NCT03548987|Drug|Placebo|Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
75593296|NCT05989906|Behavioral|Home Ergometer (ERGO)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery.
75736545|NCT03429335|Behavioral|Just TRAC It!|Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.
75736546|NCT03429335|Behavioral|MyHealth Passport|"MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!"
75736547|NCT00956072|Drug|imatinib mesylate|Patients receive imatinib mesylate
75736548|NCT00956072|Procedure|therapeutic conventional surgery|Patients undergo surgery
75736549|NCT03518190|Device|Infrared spectroscopy (ODP)|Infrared spectroscopy device will be used to detect non-visible pressure injuries
75885665|NCT01358760|Drug|Placebo|Placebo vaginal suppository
75885666|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
75885667|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
75885668|NCT03139942|Device|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
75885669|NCT05692557|Device|Virtual reality|"The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there."
76056474|NCT01816893|Other|Euglycemic hyperinsulinemic clamp|
76056475|NCT01848483|Behavioral|AIDS EPC Package plus MI|"Motivational Interviewing: In MI session #1, the nurse will set the agenda & ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 & 4, the nurse will also introduce advance care planning.~EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic & conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation & coordination of care."
75443495|NCT01667640|Radiation|whole brain irradiation|"For whole brain radiation the entire brain, the base of the skull and the meninges are included.~Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.~The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented."
75443496|NCT01667653|Dietary Supplement|Probiotic|Probiotic capsule once daily
75736550|NCT02565407|Behavioral|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
75443497|NCT01667653|Dietary Supplement|Placebo|Placebo capsule once daily
75443498|NCT01667666|Drug|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
75593297|NCT05989906|Behavioral|Motivational Interviewing (MI)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery. These participants will also receive weekly Motivational Interviewing (MI) counseling sessions during IPR plus six post-discharge MI sessions delivered via telehealth to be held over six months.
75736551|NCT02565407|Behavioral|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
75736552|NCT00962364|Biological|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
75736553|NCT02564003|Drug|Oxycodone|oxycodone 0,1 mg/kg iv
75736554|NCT00956150|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
75736555|NCT00956150|Drug|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
75736556|NCT00956150|Drug|Placebo|Placebo TID PO x 10 days
75736557|NCT00967824|Other|informational intervention|
75736558|NCT00967824|Other|questionnaire administration|
75736559|NCT00967824|Other|survey administration|
75736560|NCT00947960|Drug|Triheptanoin|1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
75736561|NCT00947960|Other|Vegetable Oil|1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
75736562|NCT00923663|Drug|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
75736563|NCT00956228|Radiation|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
75736564|NCT00743873|Biological|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
75443499|NCT01667692|Drug|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.[1] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
75443500|NCT01667692|Drug|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
75593298|NCT05985005|Other|online simulation of high alert medication safety training|online simulation of high alert medication safety training
75593299|NCT05980247|Device|Thimble Application|Use of of thimble application to practice mindfulness before needle procedure.
75593300|NCT05977933|Device|Shape II CPET|Submaximal Cardiopulmonary exercise test equipment
75736565|NCT00743873|Drug|placebo|injection of 6 cc of saline into injured area
75593301|NCT05975060|Biological|XBB.1.5 Vaccine (Booster)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent [5 μg/50 μg] NVX-CoV2601) XBB.1.5 Vaccine (Booster)
75736566|NCT04011098|Drug|Epidural Fentanyl Bolus|Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
75736567|NCT04011098|Drug|Standard Epidural Group|The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
75736568|NCT00927563|Drug|Tolcapone|pill, 100-300mg/day for 8 weeks
75885670|NCT05692557|Procedure|Progressive muscle relaxation|The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
75443501|NCT01667718|Drug|Bismuth|Bismuth 220mg b.i.d for 2 weeks
75443502|NCT01667718|Drug|Lansoprazole|Lansoprazole 30 mg b.i.d.for 2 weeks
75443503|NCT01667718|Drug|Levoﬂoxacin|Levoﬂoxacin 0.5 q.d. for 2 weeks
75736569|NCT00967902|Device|coronary stenting|Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
75443504|NCT01667718|Drug|Amoxicillin|Amoxicillin 1 g b.i.d. for 2 weeks
75443505|NCT01667770|Procedure|decompression of Chiari malformation|Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
75593302|NCT05975060|Biological|XBB.1.5 Vaccine (single dose)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent [5 μg/50 μg] NVX-CoV2601) XBB.1.5 Vaccine ( single dose)
75593303|NCT05961306|Diagnostic Test|SCID 5|"SCID 5 is a semi-structured standard clinical interview. We will focus on current depressive episode, (hypo)manic episode, anxiety disorders, OCD and PTSD.~The interview will be conducted by phone."
75736570|NCT00956306|Drug|Udenafil|100mg Single Oral Dose of Udenafil
75593304|NCT05951985|Behavioral|HIFT|Exercise sessions will be 60 to 75 minutes in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on functional movements performed at a high intensity. Exercises will be tailored/modified to meet the needs of each participant.
75593305|NCT05943249|Procedure|magnetic resonance|
75593306|NCT05931965|Dietary Supplement|L-methylfolate|Participants receive L-methylfolate 400µg orally twice daily for 4 weeks
75593307|NCT05931965|Dietary Supplement|Vitamin B12|Participants receive mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
75736571|NCT00957164|Behavioral|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
75736572|NCT00957164|Behavioral|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
75736573|NCT00957164|Behavioral|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
75736574|NCT05228340|Procedure|Flexor tenotomy|Minimally-invasive percutaneous needle flexor tenotomy of the long digital flexor tendon
75736575|NCT00775229|Drug|Naltrexone|pill, by mouth, 50mg-150mg/day for the duration of the study
75736576|NCT00775229|Drug|Placebo|pill, by mouth, daily
75443506|NCT01667783|Procedure|Gastric Banding|Laparoscopic Adjustable Gastric Banding using the LapBand
75443507|NCT01667783|Behavioral|Medical Weight Loss|Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
75443508|NCT01667783|Procedure|Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
75443509|NCT01667809|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
75593308|NCT05931965|Dietary Supplement|magnesium|Participants receive magnesium glycinate 400mg twice daily orally for 4 weeks (elemental 120mg approx.)
75593309|NCT05921578|Diagnostic Test|Pre-operative planning based on CBCT|Pre-operative planning based on CBCT
75736577|NCT00962442|Drug|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
75736578|NCT00962442|Drug|placebo|Glucosé 5% perfusion for 14 days, intravenously
75736579|NCT00948038|Dietary Supplement|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
75736580|NCT00948038|Dietary Supplement|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
76056476|NCT01848483|Other|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
75593310|NCT05921084|Behavioral|MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
75443510|NCT01667809|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
75443511|NCT01667822|Behavioral|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
75443512|NCT01667822|Behavioral|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
75443513|NCT01667835|Behavioral|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
75736581|NCT00967980|Procedure|Femoral Nerve Block vs. Psoas Compartment Nerve Block|Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
76056477|NCT05133479|Behavioral|Let's Know! small-group or TierL 2 Intervention|Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
75736582|NCT00743951|Behavioral|1 Patient decision aid|"Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
75736583|NCT00743951|Behavioral|2 Usual care|"Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings."
75736584|NCT00957320|Drug|Sirolimus|Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
75736585|NCT00957320|Drug|PEG-asparaginase|Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
75443514|NCT01667874|Drug|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
75443515|NCT01667913|Other|6 minutes walking test|
75593311|NCT05921084|Behavioral|General dietary advice|General dietary advice
75593312|NCT05917964|Drug|LP-168 tablet|LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
75736586|NCT00968058|Procedure|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
75443516|NCT01667939|Behavioral|Healthy Eating Index (HEI) in supervised pregnancies|Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
75736587|NCT00957476|Dietary Supplement|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
75736588|NCT04316078|Other|patient engagement platform|"Allows patients to receive the action plan as educational videos on demand.~Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan."
75885671|NCT03137056|Device|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
75885672|NCT03137056|Device|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
75885673|NCT03137056|Device|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
75885674|NCT04432701|Behavioral|proactive extubation|when children is breathing spontaneously and adequately in PACU,endotracheal tube was removed directly
75443517|NCT01667965|Behavioral|questionnaires|Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
75593313|NCT05915806|Dietary Supplement|High-dose DHA|Direct enteral DHA supplementation at a dose of at least 40 mg/kg/day or DHA supplementation of breast milk or formula aiming for at least 0.4% of total fatty acids.
75443518|NCT01668043|Drug|Antibody UB-421|UB-421 is administered by intravenous infusion
75593314|NCT05915806|Dietary Supplement|Control|Control with no or low-dose DHA.
75593315|NCT05911763|Drug|Efanesoctocog Alfa BIVV001|Given per investigator's discretion
75593316|NCT05908955|Procedure|PVI|pulmonary vein isolation
75885675|NCT05330364|Drug|Chidamide|Chidamide 30mg/d p.o. begin at day 1, twice per week, during a 28-days cycle.
75885676|NCT05330364|Drug|Cladribine|Cladribine 5mg/m2/d i.v. d1-5, once per day, during a 28-days cycle.
76056478|NCT01610271|Device|Air Barrier System|ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
75593317|NCT05908955|Procedure|PVI+ quantitative SVCI|pulmonary vein isolation and superior vena cava isolation guided by quantitative ablation index
75593318|NCT05908487|Behavioral|AA Communities Speak to Healthcare Professionals|The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.
75593319|NCT05907707|Device|Gamma transcranial alternating current stimulation|tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
75736589|NCT05277324|Other|Protective facial mask|Participants, students of health related professions, who wear protective facial mask daily during their internship/practice in health institutions.
75736590|NCT00653159|Device|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
75736591|NCT00653159|Device|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
75736592|NCT03047070|Drug|Lidocaine|IV Lidocaine infusion
75736593|NCT03047070|Drug|Normal saline|IV normal saline infusion
75736594|NCT00948272|Biological|Purified Vero Rabies Vaccine - Serum Free|0.5 mL, Intramuscular
75736595|NCT00948272|Biological|Purified inactivated rabies vaccine|0.5 mL, Intramuscular
75736596|NCT00968214|Genetic|polymorphism analysis|
75736597|NCT00968214|Other|laboratory biomarker analysis|
76056479|NCT02170727|Drug|DCV/ASV/BMS-791325|
76056480|NCT01847313|Drug|Liraglutide|Daily administration of liraglutide for 6 months
75736598|NCT00957554|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
75736599|NCT00957554|Drug|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
75885677|NCT05087602|Drug|Toripalimab and Anlotinib|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
75885678|NCT05087368|Biological|ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
75885679|NCT05087368|Biological|CoronaVac (Sinovac Biotech)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
76056481|NCT02144285|Drug|LY3113593|Administered IV
76056482|NCT02144285|Drug|LY3113593|Administered SC
75443519|NCT01668056|Drug|Ovulation induction with choriogonadotropin alfa|Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
75443520|NCT01668056|Procedure|Aspiration of the dominant follicle|Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
75443521|NCT01668056|Other|Control|Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
75443522|NCT01668069|Drug|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
75443523|NCT01668095|Other|Laboratory Biomarker Analysis|Correlative studies
75593320|NCT05907707|Device|Control transcranial alternating current stimulation|tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).
75593321|NCT05907707|Device|EEG headband|At-home, ambulatory, single-channel EEG headband which records brain activity during sleep
75885680|NCT05087368|Biological|Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
75885681|NCT01341990|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
75885682|NCT01341990|Device|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
76056483|NCT02144285|Drug|Placebo|Administered IV
76056484|NCT02144285|Drug|Placebo|Administered SC
76056485|NCT02117687|Drug|carboxymethylcellulose 0.5%/glycerin 0.9%|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
76056486|NCT02117687|Drug|sodium hyaluronate 0.18%|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
76056487|NCT04742153|Drug|MRG002|Administrated intravenously
76056488|NCT02105987|Drug|ABC/DTG/3TC FDC|Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
76056489|NCT02105987|Drug|Ongoing cART regimen|Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
76056490|NCT04185623|Procedure|denudation time lag|The time between ovum pickup and denudation of oocyte
76056491|NCT02141633|Procedure|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
75443524|NCT01668121|Drug|Symbicort Turbohaler|
75443525|NCT01668121|Drug|Budesonide/formoterol Easyhaler|
75443526|NCT01668134|Radiation|Stereotactic radiation|
75593322|NCT05907707|Device|Actigraphy wristband|At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day
75593323|NCT05903339|Drug|V3G CH848 Pr-NP1 60mcg|(60 mcg)
75443527|NCT01668160|Procedure|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
75443528|NCT01668199|Drug|TZP-101|
75593324|NCT05903339|Drug|3M-052-AF 5mcg|(5 mcg)
75593325|NCT05903339|Drug|Alum 500 mcg|(500 mcg)
75593326|NCT05903339|Drug|V3G CH848 mRNA-Tr2 50mcg|(50 mcg)
75593327|NCT05903339|Drug|ACU-026-001-1 2.0mg|(2.0 mg)
75593328|NCT05903339|Drug|V3G CH848 Pr-NP1 100mcg|(100 mcg)
75593329|NCT05898672|Drug|Rosuvastatin|Single oral dose of rosuvastatin tablets
75593330|NCT05898672|Drug|Nirmatrelvir/ritonavir|Twice daily oral doses of nirmatrelvir/ritonavir tablets
75736600|NCT00921713|Other|Oncology Nurse Care Management|
75736601|NCT00921713|Other|Patient-centered materials|
75736602|NCT00744029|Behavioral|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
75736603|NCT03024684|Drug|Atorvastatin|Atorvastatin 10mg daily
75736604|NCT03024684|Drug|Placebo Oral Tablet|Placebo one tablet daily
75885683|NCT01341990|Device|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
75885684|NCT05087134|Drug|11C-Choline|11C-Choline were injected into the patients before the PET/CT scans
75443529|NCT01668212|Procedure|Doppler ultrasound|Doppler Ultrasound
75443530|NCT01668264|Procedure|Echocardiograph|
75443531|NCT01668264|Procedure|Magnetic Resonance Imaging (MRI)|
75443532|NCT01668277|Drug|7.2% NaCl|
75443533|NCT01668277|Drug|0.9% NaCl|
75593331|NCT05897554|Drug|intra-arterial alteplase|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
75593332|NCT05883566|Behavioral|experimental|During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
75593333|NCT05864482|Other|Psychosocial nursing intervention|The sessions were planned to be at least 45 minutes in a time suitable for the groups, with the bed curtains drawn if possible. Session 1: The purpose of this session; Brief CIS information will be provided. Session 2: The session starts with mood control of individuals. It is discussed whether they have experienced an event that occupies their minds and is likely to affect their illness. Session 3: It starts with mood control of individuals. They are asked if there is anything from the places where the guests are. Cognitive reviews are reviewed. It aims to describe recent stressful observations, negative automatic outcome descriptions, and evaluation of such experiences. 4.Session: The session starts with the mood control of the patient. It is discussed whether the patient has experienced an event that occupies his mind. Continuous analysis of negative thoughts and review of cognitive techniques and coping mechanisms are provided.
75736605|NCT00746057|Biological|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
75736606|NCT00948350|Procedure|awake intubation|two anesthesia techniques
75885685|NCT05086900|Other|Non-interventional Cross-sectional Patient Reported Outcome Measure Development|Development of Patient Reported Outcome Measure
75885686|NCT03048747|Drug|Tolvaptan Oral Tablet|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
75885687|NCT05086822|Drug|Irinotecan liposome|Irinotecan liposome
75443534|NCT01668303|Behavioral|Miami Juvenile Drug Court-MDFT|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
75443535|NCT01668303|Behavioral|Miami Juvenile Drug Court -TAU|Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
75443536|NCT01668316|Behavioral|Weight loss|"Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
75443537|NCT01668342|Behavioral|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
75885688|NCT05354128|Drug|Thrombolytic|Standard intravenous thrombolysis.
75885689|NCT05354128|Procedure|percutaneous coronary stenting|Percutaneous coronary stenting
75885690|NCT03670277|Device|etafilcon A|Test Soft Contact Lens
75885691|NCT03670277|Device|Habitual Orthokeratology Lenses|CONTROL
75443538|NCT01668368|Other|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
75769523|NCT01257724|Other|SHARE (Synthesized HIV/AIDS Research Evidence)|"SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~an online searchable database of HIV-relevant systematic reviews;~monthly email updates highlighting new reviews;~access to user-friendly summaries produced by us or by others (when available);~links to scientific abstracts;~peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~an interface for participants to leave comments in the records of systematic reviews in the database;~links to full-text articles (when publicly available); and~access to worksheets that help CBOs find and use research evidence"
75736607|NCT00968292|Device|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
76056492|NCT02141633|Procedure|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
75593334|NCT05856994|Drug|Tacrolimus ointment|For the active comparator group, the wound(s) will be cleaned and bacitracin ointment will be applied to the wound. External dressings on all treated wounds will be placed based on the current standard of care. For the control group, the wound(s) will be cleaned and a hydrocolloid Dressing will be affixed to the burn and treated area. For the treatment group, the wound(s) will be cleaned and tacrolimus (0.03%) ointment will be applied over the burn. Hydrocolloid Dressing will be affixed to the burn and treated area. External dressings on all treated wounds will be placed based on the current standard of care.
76056493|NCT02141633|Drug|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
75593335|NCT05846399|Drug|Amoxicillin/clavulanate|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 1 day or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 1 day
76056494|NCT02141633|Drug|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
76056495|NCT01846611|Drug|Trabectedin|1.1 mg/m^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
76056496|NCT01846611|Drug|DOXIL|30 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
76056497|NCT01846611|Drug|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
76056498|NCT01846611|Drug|DOXIL|50 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
75443539|NCT01668381|Procedure|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
75443540|NCT01668394|Behavioral|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
75736608|NCT00957710|Behavioral|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
76056499|NCT02141399|Drug|ALKS 5461|Sublingual tablet, taken daily
76056500|NCT04586673|Biological|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10^9 vp
75443541|NCT01668394|Other|Control arm|Usual care. Teaching style: deductive.
75443542|NCT01668420|Other|thermal stimulation|hot and cold/warm and cool pads applying.
75443543|NCT01668433|Drug|Regimens (Primaquine, Methylene blue)|Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
75736609|NCT00962910|Other|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
75736610|NCT00744107|Device|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
75736611|NCT00117637|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
75736612|NCT00117637|Drug|Interferon|Interferon
75443544|NCT01668446|Drug|Sildenafil|sildenafil tablets(50 mg) daily
75443545|NCT01668446|Drug|estradiol valerat|
75443546|NCT01668459|Drug|Cabazitaxel|25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
75443547|NCT01668459|Other|Best Supportive Care|Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
75593336|NCT05846399|Drug|Ciprofloxacin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
75593337|NCT05846399|Drug|Clindamycin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
75593338|NCT05846399|Other|Placebo (microcrystalline cellulose)|Placebo (microcrystalline cellulose) by mouth twice daily by mouth for 5 days
75736613|NCT00746135|Device|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
75736614|NCT00744185|Drug|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
75736615|NCT00744185|Drug|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
75736616|NCT02897778|Drug|Entinostat|Single, supratherapeutic dose of entinostat given orally.
75736617|NCT02897778|Drug|Placebo|Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).
76056501|NCT04586673|Biological|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10^10 vp
76056502|NCT04586673|Biological|MVA.tHIVconsv3 (M3)|MVA.tHIVconsv3 1 x 10^8 pfu
76056503|NCT04586673|Biological|MVA.tHIVconsv4 (M4)|MVA.tHIVconsv4 09. x 10^8 pfu
76056504|NCT01846299|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
76056505|NCT01846299|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
76056506|NCT01628393|Drug|Ozanimod|Oral capsule taken once a day
76056507|NCT01628393|Drug|Placebo|Oral capsule taken once a day
75736618|NCT00746291|Other|6 min walk test, Step climbing|walking for 6 minute and climbing steps
75443548|NCT01668485|Procedure|Hypoglycemic and euglycemic glucose clamp|Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
76056508|NCT01846221|Drug|Clonidine|Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
76056509|NCT01846221|Drug|Fentanyl|Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
75736619|NCT01084291|Biological|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
75736620|NCT01084291|Other|Placebo injection|Subcutaneous injection of placebo
75736621|NCT00741689|Drug|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
76056510|NCT01815099|Device|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
75443549|NCT01668498|Drug|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
75443550|NCT01668498|Drug|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
75443551|NCT01668511|Biological|ABT-981|Injection
75443552|NCT01668511|Biological|Placebo|Placebo Injection
75443553|NCT01668524|Drug|ATS907|Single dose of each of three increasing concentrations
75443554|NCT01668550|Drug|AZD0424|"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."
75443555|NCT01668615|Drug|all-trans-retinoid acid|10 mg three times a day oral administration for 4 months
75443556|NCT01668641|Drug|GLPG0634|
75443557|NCT01668641|Drug|Placebo|
75736622|NCT00963066|Device|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
75736623|NCT00963066|Device|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
75443558|NCT01668680|Drug|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
75736624|NCT00963066|Device|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
75736625|NCT01081093|Procedure|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
75736626|NCT00744341|Drug|SLV320|1.25mg i.v. bid
75736627|NCT00744341|Drug|SLV320|3.75mg i.v. bid
75736628|NCT00744341|Drug|SLV320|7.5mg i.v. bid
75736629|NCT00744341|Drug|SLV320|15.0mg i.v. bid
75736630|NCT00744341|Drug|Placebo|
75885692|NCT05230186|Procedure|Tumor Biopsy|Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
75885693|NCT04954469|Biological|CoVAC-1|Peptide vaccination should be started as soon as possible after the screening visit.
75885694|NCT04051827|Drug|Midazolam|Midazolam Oral Solution and Midazolam Intravenous Infusion.
76056511|NCT01845831|Drug|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
75443559|NCT01668693|Other|ERA (Endometrial Receptivity Array)|"The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction."
75443560|NCT01668693|Other|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
76056512|NCT01845831|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
75443561|NCT01668693|Other|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
75736631|NCT00968370|Other|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
76056513|NCT01845831|Drug|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
76056514|NCT01845831|Drug|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
76056515|NCT01845831|Drug|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
75443562|NCT01668745|Biological|Early measles vaccine|
75593339|NCT05846399|Procedure|Wound management|Wound management includes hemostasis, copious irrigation, removal of foreign bodies, and excisional debridement of devitalized tissue. If only punctures are present, lancing of the punctures is not typically required unless infection has already developed. Local anesthesia (1% lidocaine hydrogen chloride (HCl) with epinephrine 1:100,000; 200mg/20mL vial) will be used prior to irrigation (30mL of povidone-iodine in 1L of 0.9% sodium chloride (NaCl) solution and/or 118mL of 3% hydrogen peroxide) and debridement. Open wounds will be irrigated and debrided at bedside. Wounds will be covered with soft dressings in place until first follow-up at day 2.
75736632|NCT00968370|Other|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
76056516|NCT01845831|Drug|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
76056517|NCT01627691|Device|Lotus Valve System|"bioprosthetic bovine pericardial aortic valve~delivery system"
75443563|NCT01668823|Drug|HPPH|Given IV
76056518|NCT01844895|Drug|Abatacept|
76056519|NCT02116361|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
75736633|NCT02685384|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
75885695|NCT04051827|Drug|TAK-788|TAK-788 Oral Capsules.
75885696|NCT05346874|Drug|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
76056520|NCT02116361|Drug|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
76056521|NCT02140775|Behavioral|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
76056522|NCT01844817|Drug|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
75443564|NCT01668823|Drug|photodynamic therapy|Undergo photodynamic therapy with HPPH
75443565|NCT01668823|Procedure|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
75443566|NCT01668862|Biological|Autologous Human Platelet Lysate|Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space
75443567|NCT01668862|Drug|Corticosteroid|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
75443568|NCT01668875|Other|Head down 30 degree postural drainage position|supine head down 30 degree on tilt table (intervention period in the treatment condition)
75443569|NCT01668875|Other|Horizontal supine lying|horizontal supine lying on tilt table (intervention period in the sham condition)
75443570|NCT01668901|Drug|warfarin|anticoagulation
75443571|NCT01668901|Drug|Aspirin|antiplatelet
75443572|NCT01668914|Procedure|IM-SLNB|IM-SLNB is performed according to the pre-operative lymphoscintigraphy
75443573|NCT01668914|Radiation|99mTc-SC|Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
75593340|NCT05842759|Procedure|Monitoring|Continuous blood pressure monitoring
75443574|NCT01668914|Device|Histologic Examination|All IMSLNs were analyzed by histologic examination for future therapy planning.
75443575|NCT01668914|Device|LSG|lymphoscintigraphy was performed 0.5~1.0 hour before surgery
75443576|NCT01668914|Drug|Methylthioninium|Four milliliters of methylthioninium was injected intraparenchymally around the primary tumor 10 min before surgery
75443577|NCT01668927|Drug|Proton Pump Inhibitor|
75443578|NCT01668927|Drug|Bismuth|
75736634|NCT00968448|Behavioral|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
75736635|NCT00968448|Behavioral|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
75736636|NCT00741767|Drug|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
75736637|NCT00741845|Drug|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
75736638|NCT02564549|Procedure|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
75736639|NCT02564549|Procedure|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
75736640|NCT00741923|Other|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
75885697|NCT05346874|Drug|Teysuno|Oral S-1, 40mg-60mg, day 1-14 for four 21-day cycles.
75736641|NCT00746369|Behavioral|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
75443579|NCT01668927|Drug|Metronidazole|
75885698|NCT05346874|Procedure|Transarterial chemoembolization (TACE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1.
76056523|NCT01844817|Drug|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
76056524|NCT04594239|Device|Belotero Balance (+) Lidocaine, needle|Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles
75736642|NCT00746447|Drug|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
75443580|NCT01668927|Drug|Tetracycline|
75443581|NCT01668927|Drug|Furazolidone|
75736643|NCT00746447|Drug|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
75736644|NCT00746447|Drug|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
75736645|NCT00744419|Drug|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose [0.4 mg/kg (< 44 wks PMA) or 0.8 mg/kg (44 wks to < 1 yr)] and the last 6 subjects in each age group will receive high dose [0.8 mg/kg(< 44 wks PMA) or 1.6 mg/kg(44 wks to < 1 yr)]
75885699|NCT03730636|Procedure|PCT dosage|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
76056525|NCT04594239|Device|Belotero Balance (+) Lidocaine, cannula|Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas
76056526|NCT04594239|Device|Untreated-control / delayed-treatment, needle|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)
75443582|NCT01668927|Drug|Amoxicillin|
75443583|NCT01668979|Device|new system to detect Near Falls|We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
75443584|NCT01668992|Behavioral|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
75443585|NCT01669018|Procedure|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
75443586|NCT01669018|Procedure|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
75443587|NCT01669031|Other|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
75443588|NCT01669044|Drug|dexmedetomidine|dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
75443589|NCT01669044|Drug|propofol|propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
75443590|NCT01669070|Drug|FF, 50 mcg|Novel dry powder inhaler
75736646|NCT00549302|Drug|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
75736647|NCT00549302|Drug|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
75736648|NCT00957788|Drug|NST-001|Comparison of different dosages of drug.
75736649|NCT05299424|Drug|CM336_group 1|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75769524|NCT01255774|Drug|ranibizumab|An open-label, study of intravitreally administered ranibizumab
75885700|NCT03136588|Device|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
75885701|NCT02123823|Drug|Everolimus|10mg dose
75885702|NCT02123823|Drug|Everolimus|at recommended dose as per Phase I data
75443591|NCT01669070|Drug|FF, 100 mcg|Novel dry powder inhaler
75443592|NCT01669070|Drug|FF, 200 mcg|Novel dry powder inhaler
75443593|NCT01669070|Drug|FF, 250 mcg|Intravenous
75443594|NCT01669083|Drug|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
75443595|NCT01669083|Drug|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
75443596|NCT01669083|Drug|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
75736650|NCT05299424|Drug|CM336_group 2a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75736651|NCT05299424|Drug|CM336_group 2b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75736652|NCT05299424|Drug|CM336_group 3a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75736653|NCT05299424|Drug|CM336_group 3b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75885703|NCT02123823|Drug|Everolimus|Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg
75885704|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
75443597|NCT01669083|Drug|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
75443598|NCT01669109|Behavioral|Hatha yoga|
75443599|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|
75443600|NCT01669161|Device|Vivistim System|The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
75769525|NCT03895918|Other|Educational Activity|Undergo parenting skills intervention
75769526|NCT03895918|Procedure|Patient Monitoring|Undergo medication adherence monitoring
75769527|NCT03895918|Other|Questionnaire Administration|Ancillary studies
75885705|NCT02123823|Drug|BI 836845|Human monoclonal antibody at recommended dose as per Phase I data
75885706|NCT02123823|Drug|BI 836845|Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored
75885707|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
75885708|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
75885709|NCT03380273|Behavioral|Implementation of the AO Trauma SSI Prevention Bundle|"AOT SSI Prevention Bundle~Preventive measure~Antibiotic prophylaxis~Perioperative antibiotics~Oxygen administration~Patient temperature~Surgeon protective wear~Patient operative skin preparation~Suction drains~Blood glucose level~Red cell transfusion~Dressing changes"
75443601|NCT01669161|Other|Rehab Only|Rehabilitation without device implant and VNS
75443602|NCT01669213|Drug|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
75443603|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
75885710|NCT05086666|Drug|AZD4547|"In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor."
75593341|NCT05842759|Procedure|Norepinephrine preparation|Norepinephrine infusion will be prepared and connected to peripheral or central venous catheter (infusion will not be started)
75443604|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
75443605|NCT01669213|Drug|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
75443606|NCT01669226|Drug|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
75736654|NCT05299424|Drug|CM336_group 4a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75736655|NCT05299424|Drug|CM336_group 4b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75736656|NCT05299424|Drug|CM336_group 5|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75736657|NCT05299424|Drug|CM336_group 6a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75736658|NCT05299424|Drug|CM336_group 6b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75769528|NCT01255852|Drug|atorvastatin|Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
75885711|NCT05086042|Diagnostic Test|Ultrasonography, Magnetic resonance imaging|The cross-sectional area of the median nerve was measured with US and MRI.
75885712|NCT03138304|Behavioral|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
75885713|NCT03138304|Behavioral|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
75885714|NCT03287687|Drug|Carbon dioxide (CO2) gas insufflation|CO2 gas use for insufflation during endoscopy instead of air insufflation
75443607|NCT01669226|Drug|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
75593342|NCT05842759|Procedure|Propofol administration|Propofol infusion will be started only when clinical effects of opioid are noticeable: 1.5 mg/kg propofol in patients less than 55 years old and 1.0 mg/kg propofol in patients 55 years or older over 90 seconds
75593343|NCT05842759|Procedure|Alarm adjustment|Lower mean arterial pressure alarm threshold will be set to 75 mmHg
75593344|NCT05842759|Procedure|Intervention threshold|Lower mean arterial pressure intervention threshold will be 75 mmHg: continuous norepinephrine infusion will be started when mean arterial blood decreases below 75 mmHg
75593345|NCT05794165|Drug|Thrombate infusion|Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
75593346|NCT05794165|Drug|Placebo|Normal Saline will be given as one time IV after the 3rd dose of Enoxaparin. The dose will be based on patient weight.
75736659|NCT05299424|Drug|CM336_group 7|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75885715|NCT03287687|Drug|Air insufflation|Air insufflation is the standard of practice (used in the control arm)
75885716|NCT01991067|Biological|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
75885717|NCT03138148|Other|Routine mechanical ventilation|Routine mechanical ventilation in PICU amid children with acute respiratory failure
75885718|NCT03285269|Diagnostic Test|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
75885719|NCT03285269|Device|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
75593347|NCT05784545|Dietary Supplement|Blueberry powder supplement|The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.
75885720|NCT03285269|Procedure|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
75885721|NCT05085652|Procedure|spinal anesthesia induced hypotension in SARS-CoV-2 patients.|SARS-CoV-2 infection prognosis remains unclear during pregnancy. according to ESA, ASRA and WHO regional anesthesia was recommended to use for caesarian section procedures. But at the beginning of the pandemic Chen et al shared their retrospective analyses about regional anesthesia for caesarian section and they showed high spinal anesthesia induced hypotension in 14 patients of the 17 and also again Chen and Zahng et al made another study and this time they found 57,4% hypotension incidence. In our study we aimed to find if the spinal anesthesia safe procedure in the 249 patients and one center hospital.
75885722|NCT01940835|Procedure|Upper endoscopy with small bowel biopsies and brushings.|
75885723|NCT01940835|Other|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
75885724|NCT01940835|Other|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
75885725|NCT03089398|Procedure|Hybrid Coronary Revascularization (isolated LIMA-LAD)|sternal-sparing, off-pump, isolated LIMA-LAD revascularization
75885726|NCT03089398|Device|Hybrid Coronary Revascularization (PCI)|percutaneous revascularization of at least one non-LAD target
76056527|NCT04594239|Device|Untreated-control / delayed-treatment, cannulas|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
75443608|NCT01669239|Drug|Liposomal Doxorubicin|"Six cycles of:~Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
75885727|NCT03089398|Device|Percutaneous Coronary Intervention|Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
75885728|NCT01872273|Other|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
75443609|NCT01669252|Drug|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
75443610|NCT01669278|Device|Endosheath|Flexible sheathed nasopharyngolaryngoscopy
75443611|NCT01669291|Drug|Bravelle and Menopur|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
75443612|NCT01669291|Drug|Agonist|Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
75443613|NCT01669291|Drug|Antagonist|Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
75443614|NCT01669304|Drug|Verapamil|
75885729|NCT02886845|Genetic|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
75885730|NCT01787643|Other|Height-Adjustable Desk Intallation in Office|
75885731|NCT01374503|Biological|ALX-0651|single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
75443615|NCT01669304|Drug|Sertraline|
75443616|NCT01669317|Other|8-ounce glass of cherry juice|You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
75443617|NCT01669317|Other|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice
75443618|NCT01669330|Procedure|Nissen fundoplication|Laparoscopic Nissen fundoplication
75443619|NCT01669330|Procedure|Laparoscopic antireflux surgery ad modum Watson|Laparoscopic anterior fundoplication
75443620|NCT01669356|Other|Parenteral supplement with enteral nutrition for patients after esophagectomy|
75443621|NCT01669356|Other|Enteral Nutrition alone for patients after esophagectomy|
75593348|NCT05784545|Dietary Supplement|Maltodextrin supplementation|The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
75593349|NCT05781178|Dietary Supplement|Oral nutritional supplement rich in omega-3 and olive oil polyphenols|Nutritional intervention with an oral nutrition supplement with anti-inflammatory effect and a programme of physical exercise
75593350|NCT05779007|Drug|Pirfenidone|Pirfenidone
75736660|NCT05299424|Drug|CM336_group 8a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
76056528|NCT01814553|Drug|afatinib|Daily treatment starting 40 mg per day
76056529|NCT01814553|Drug|loperamide|Follow cohort assignment and diarrhea management guidelines
76056530|NCT02116205|Biological|HTNV/PUUV DNA vaccine|HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
75443622|NCT01669369|Drug|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
75443623|NCT01669369|Drug|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
75443624|NCT01669382|Device|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
75443625|NCT01669395|Other|Early homebased rehabilitation after hospital admission|Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
75593351|NCT05779007|Drug|Nintedanib|Nintedanib
75443626|NCT01669395|Other|Usual care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
75443627|NCT01669408|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
75593352|NCT05764252|Device|BioEP|All patient's EEG will have the BioEP score conducted on it
75593353|NCT05761600|Other|Ethnographically-informed group observation|The chief investigator will visit each art therapy group 3-6 times; there will be up to 5 groups recruited. They will record observational data and insights; making use of visual reflective journaling where appropriate. These will later be written up as full field notes.
75593354|NCT05761600|Other|Semi-structured Interviews|Individual interviews will take place with all three key stakeholders in group art therapy at different stages of the study. Each interview will have a topic guide to structure the discussion and will combine arts-based methods with conversation to maximise accessibility. Interview location, timing and format (online or in-person) are flexible, and the chief investigator will adapt to the needs of the participants.
75593355|NCT05761600|Other|Focus Group|After data collection and initial analysis (likely 3-5 months after final observation and/or interview) a focus group will be held with the art therapist participants. This session will use arts-based engagement to support member checking of the initial results and triangulation of the findings, which is likely to include potential active ingredients in group art therapy and principles of practice with this client group.
75593356|NCT05744856|Behavioral|Self-care with informal support|"The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
75593357|NCT05743153|Behavioral|Multimodal intervention program|"Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.~Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.~Psychological intervention: screening for psychological risk factors and if present, patients are referred to a psychologist for psychological support."
75885732|NCT01374503|Biological|Placebo|single or multiple i.v. administration
76056531|NCT02116205|Biological|Placebo|0.9% sodium chloride
76056532|NCT02116205|Device|TriGrid Delivery System (TDS)|The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses
76056533|NCT01844583|Drug|Alisertib|Alisertib tablets
76056534|NCT01844583|Drug|Esomeprazole|Esomeprazole capsules
76056535|NCT01844583|Drug|Rifampin|Rifampin capsules
76056536|NCT02115815|Biological|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
76056537|NCT02115815|Biological|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
75885733|NCT05085418|Biological|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
75885734|NCT05759195|Diagnostic Test|Biomolecular tumor analysis|NGS analysis, other molecular analyses on FFPE tumor tissue
75885735|NCT03466996|Behavioral|Intervention group|More frequent follow up with face to face interaction.
75443628|NCT01669447|Biological|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
75885736|NCT03466996|Behavioral|Standard of care group|Transition goal setting during annual follow up.
75885737|NCT01709331|Drug|Corifollitropin alfa|Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
75885738|NCT01709331|Drug|hCG|hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
75443629|NCT01669460|Other|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
75443630|NCT01669473|Other|EHR Based Strategy to promote Safe and Appropriate Drug Use|"The printed tools presented in the intervention include:~Medication Review: a consolidated list of the medications a patient is currently taking.~Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen"
76056538|NCT02115815|Biological|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
75616243|NCT04801030|Behavioral|YourCoViDVaxFacts|The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks. Participants receive culturally-tailored message on COVID-19 and the vaccine. The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone. On the website, participants will be prompted to select their top concerns from a list. Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
75885739|NCT04883099|Device|APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism|Contact Lenses for Presbyopia
76056539|NCT02115815|Biological|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
75885740|NCT03136510|Drug|Apixaban 5 mg|"Bood collection for biological analyses at:~inclusion visit~follow-up visit at 1 month~end of research at 3 month"
75885741|NCT05693259|Device|Electrolyzed Alkaline Reduced Water (EARW) generated from electrolyzed ionizer|Patient will be allocated randomly to two groups: EARW and PW groups. For 6 weeks, patients drink water (10mL/kg body weight/day ) generated from the device installed in the house before starting intervention. Patients will be instructed to drink in empty stomach, and to drink immediately after generation of water. The total amount that the patient drank the day before will be monitored by a researcher using survey form of mobile phone everyday.
75885742|NCT03451474|Procedure|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
75885743|NCT05693181|Biological|Multiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells|Each HUCBCs sample contain 500 +/- 50 x 10*6 allogenic non-related group- and rhesus-compatible mononuclear cord blood cells
75885744|NCT05693181|Other|Control vehicle (sterile saline)|Sterile saline infusion in control patients
76056540|NCT02115815|Biological|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
76056541|NCT02115815|Biological|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
76056542|NCT02115815|Biological|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
76056543|NCT02115113|Drug|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
75443631|NCT01669486|Other|CPOT, BPS|Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
75885745|NCT03136354|Procedure|Endoscopic Submucosal Dissection|
75885746|NCT03136354|Procedure|Laparoscopic assisted Gastrectomy|
76056544|NCT02115113|Drug|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
76056545|NCT02114879|Behavioral|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
75593358|NCT05732935|Behavioral|Time Restricted Eating intervention|"In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
75616244|NCT04202068|Drug|Ceftriaxone sodium and Sulbactam Sodium for injection|Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
75736661|NCT05299424|Drug|CM336_group 8b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75736662|NCT05299424|Drug|CM336_group 9|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75885747|NCT05692245|Drug|Ondansetron|Administered Medication
75885748|NCT05692245|Drug|Dexamethasone|Administered Medication
75885749|NCT03136276|Other|IPS Empress CAD|standard etchable glass ceramics
76056546|NCT02114879|Behavioral|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
76056547|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
76056548|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
75443632|NCT01669499|Drug|Dexamethasone acetate|
75443633|NCT01669499|Drug|Placebo|
75443634|NCT01669512|Biological|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
75443635|NCT01669512|Biological|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
75443636|NCT01669512|Biological|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
75736663|NCT05299424|Drug|CM336_RP2D|CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
75736664|NCT03969914|Procedure|PEEP changes|All patients will be ventilated with a tidal volume of 6 ml/kg before the RRI assessment. Further, three level of PEEP (5, 10 and 15 cmH2O) will be randomly set. For each levels of PEEP, the RRI will be evaluated
75736665|NCT03961724|Device|magnetic resonance image (MRI)|serum metabolomics
75736666|NCT00957866|Drug|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
75736667|NCT00117325|Drug|GW685698X|Aqueous Nasal Spray 100mcg
75885750|NCT03136276|Other|polished Celtra Duo|new glass ceramic material
75885751|NCT05693103|Device|High-Intensity Focused Electromagnetic therapy|"The HPM-6000UF is a non-invasive therapeutic device. The device produces electromagnetic field that interacts with the tissues of the human body.~The electromagnetic field delivered in the muscular or neuronal tissue area is triggering the stimulation and tonisation."
75885752|NCT05085106|Drug|Felbinac trometamol eye drop|Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
75885753|NCT05085106|Drug|Placebo eye drop|Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
76056549|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
76056550|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
76056551|NCT02138825|Drug|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
76056552|NCT02138825|Drug|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
75443637|NCT01669564|Other|Will use HIT patient feedback to activate patients.|"After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.~Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL."
75443638|NCT01669564|Other|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
75593359|NCT05732935|Behavioral|Successful Aging Comparison Group (LEARN)|"In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
75593360|NCT05731323|Drug|D-cycloserine|Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).
75736668|NCT00958022|Drug|LBH589 and carboplatin with etoposide|"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin & mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."
75736669|NCT00958100|Drug|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
75736670|NCT00958100|Drug|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
75885754|NCT03079336|Behavioral|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
76056553|NCT02138747|Drug|Mirabegron|Oral
75593361|NCT05731323|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
76056554|NCT02138747|Drug|Tolterodine ER|Oral
76056555|NCT02105285|Drug|OPC-1085EL ophthalmic solution|
76056556|NCT02105285|Drug|Carteolol long-acting ophthalmic solution|
76056557|NCT02104895|Radiation|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
76056558|NCT02104895|Radiation|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
75443639|NCT01669668|Procedure|radiofrequency ablation|Undergo RFA
75443640|NCT01669668|Procedure|laparoscopy|Undergo laparoscopic ultrasound
75443641|NCT01669694|Other|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
75593363|NCT05700981|Diagnostic Test|colon capsule endoscopy|Patient allocated for the intervention arm will have a CCE using the PillCam Colon 2 (Medtronic, Minneapolis, Minnesota, USA). Upon inclusion and allocation to the intervention arm patients are contacted by a dedicated CCE nurse. The course of the CCE procedure and preparations are explained thoroughly. In case of additional questions patients can contact the nurses by telephone during office hours (Monday-Friday, 8am-3pm). Before the CCE participants will have to undergo a bowel preparation procedure. The bowel preparation kit will be distributed by mail and is to be completed at home, beginning 72 hours before the CCE. The kit contains polyethylene glycol (PEG) sachets (Movicol, Norgine Danmark A/S, Herlev, Denmark), PEG solutions (MoviPrep, Norgine Danmark A/S, Herlev Denmark) and instructions on how to properly perform the preparation procedures.
75736671|NCT00958100|Drug|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
75736672|NCT00948584|Other|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
76056559|NCT01621490|Biological|Nivolumab|
76056560|NCT01621490|Drug|Ipilimumab|
76056561|NCT02018887|Drug|LY2969822|Capsules administered orally
75443642|NCT01669707|Drug|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
75443643|NCT01669707|Drug|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
75593364|NCT05684159|Drug|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.
75593365|NCT05677048|Behavioral|Free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing
75736673|NCT00958178|Drug|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
75736674|NCT00948662|Drug|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
75736675|NCT00948662|Drug|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
75736676|NCT00948662|Drug|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
75736677|NCT03748472|Procedure|Continuous gavage feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
75736678|NCT03748472|Procedure|Bolus feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
75736679|NCT04010084|Radiation|Low level laser therapy|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
76056562|NCT02018887|Drug|Placebo|Capsules administered orally
76056563|NCT02030041|Drug|Vitamin D|Vitamin D will be given to achieve normal serum levels
76056564|NCT02030041|Drug|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
76056565|NCT02030041|Drug|Placebo|Placebo will be provided to the study participants
76056566|NCT01994720|Drug|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
75593366|NCT05677048|Behavioral|IGNITE-TX Group|Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator
75593367|NCT05677048|Behavioral|IGNITE-TX and free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
75593368|NCT05674422|Drug|total neoadjuvant therapy|All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
75593369|NCT05658705|Procedure|15-min supine time|The length of preoperative supine time before AVS was 15 minutes.
75593370|NCT05658705|Procedure|2-hour supine time|The length of preoperative supine time before AVS was 2 hours.
75593371|NCT05647811|Drug|NM8074|NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
75736680|NCT04010084|Procedure|Placebo group|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
75885755|NCT03079336|Behavioral|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
76056567|NCT01994720|Drug|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
76056568|NCT01814397|Drug|Anastrozole|1 mg orally daily
76056569|NCT01814397|Drug|exemestane|25 mg orally daily
76056570|NCT01814397|Drug|letrozole|2.5 mg orally daily
75593372|NCT05646563|Drug|NM8074|NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
75593373|NCT05646563|Drug|Soliris|Complement C5 blocker administered intravenously
76056571|NCT01814007|Device|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
76056572|NCT01844115|Drug|Placebo|
76056573|NCT01844115|Drug|Vilazodone|Viibryd
76056574|NCT02018042|Drug|Abatacept|"After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug."
76056575|NCT04667390|Other|total knee arthroplasty|total knee arthroplasty
76056576|NCT01813305|Drug|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
76056577|NCT01813305|Drug|CSTC1 Matched vehicle|
76056578|NCT01993940|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
76056579|NCT01993940|Drug|Placebo|Placebo tablet taken orally once a day
76056580|NCT01843803|Other|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
75593374|NCT05646524|Drug|NM8074|NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
75593375|NCT05639933|Drug|HT-001 2% Topical Gel|Topical gel, 2% active
76056581|NCT01843803|Other|attention control|Patients will view a brief healthy living video on an iPad
76056582|NCT02017171|Drug|Allopurinol|
75593376|NCT05639933|Drug|HT-001 1% Topical Gel|Topical gel, 1% active
75593377|NCT05639933|Drug|HT-001 0.5% Topical Gel|Topical gel, 0.5% active
75593378|NCT05639933|Drug|HT-001 Placebo|Topical gel, vehicle gel
75593379|NCT05636306|Drug|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
75593380|NCT05636306|Drug|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
75593381|NCT05629260|Drug|ATG|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
75593382|NCT05629260|Drug|Post-transplantation cyclophosphamide|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
75593383|NCT05621694|Behavioral|Tai Chi Easy|A meditative movement practice that includes simple qigong movement/breath practices and single, repeated tai chi movements taught to generate a meditative state and flow
75593384|NCT05616208|Biological|Bioengineered Internal Anal Sphincter|Autologous Bioengineered Internal Anal Sphincter
75593385|NCT05615012|Drug|BMS-986322|Specified dose on specified days
75593386|NCT05615012|Drug|Rosuvastatin|Specified dose on specified days
76056583|NCT02017171|Drug|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
75593387|NCT05615012|Drug|Metformin|Specified dose on specified days
75593388|NCT05615012|Dietary Supplement|Glucose|Specified dose on specified days
76056584|NCT04686097|Procedure|treatment: puncture of coagulation|ultrasound-guided puncture of coagulation
76056585|NCT04686097|Procedure|treatment: sclerosing agent injected|ultrasound-guided sclerosing agent injected
76056586|NCT02029417|Drug|cytarabine|Given SC
76056587|NCT02029417|Drug|omacetaxine mepesuccinate|Given SC
76056588|NCT02029417|Drug|decitabine|Given IV
76056589|NCT02029417|Other|laboratory biomarker analysis|Correlative studies
76056590|NCT02016716|Drug|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
76056591|NCT02016716|Drug|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
76056592|NCT02016716|Drug|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
76056593|NCT02016716|Drug|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
76056594|NCT02050321|Drug|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
76056595|NCT02050321|Drug|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
76056596|NCT02017015|Drug|nab-paclitaxel|nab-paclitaxel at 125 mg/m^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
76056597|NCT02017015|Drug|Gemcitabine|Gemcitabine at 1000 mg/m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
76056598|NCT02016625|Drug|Faldaprevir|
75593389|NCT05615012|Drug|Methotrexate|Specified dose on specified days
76056599|NCT02016625|Drug|Faldaprevir|
75443644|NCT01669733|Other|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
75443645|NCT01669733|Other|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
75443646|NCT01669746|Biological|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
75443647|NCT01669772|Drug|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
75443648|NCT01669772|Drug|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
75443649|NCT01669837|Device|Mesh fixation with surgical tissue glue|Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
75443650|NCT01669850|Device|Clipped anastomosis|The vascular clip devise will be used to complete the anastomosis during fistula creation.
75443651|NCT01669850|Procedure|Handsewn anastomosis|a handsewn anastomosis technique will be used during fistula creation.
75443652|NCT01669876|Dietary Supplement|Anatabloc(R)|Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
75443653|NCT01669876|Dietary Supplement|Placebo|Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
75443654|NCT01669941|Drug|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
75443655|NCT01669941|Drug|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
75593390|NCT05615012|Drug|Leucovorin|Specified dose on specified days
75593391|NCT05609240|Drug|Cefuroxime|See arm/group description
75593392|NCT05606198|Other|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
75593393|NCT05597033|Behavioral|Exercise|walking and handgrip exercise
75593394|NCT05597033|Behavioral|Control|seated rest
75593395|NCT05588141|Drug|Zotiraciclib|Zotiraciclib will be given orally at the DL1, DL-1, or DL 2 once a day on days 1, 4, 8, 11, 15, 18 of every 28-days cycle (18 cycles total).
75593396|NCT05566964|Device|ME&MGopen smartphone application|Smartphone application includes digital tests and e-questionnaires
75593397|NCT05544526|Biological|GD2 CAR T cells|Infusion with: GD2 CAR T-cells
75593398|NCT05535439|Procedure|EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle|Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle
76056600|NCT02016625|Drug|Cyclosporine|
76056601|NCT02016625|Drug|Tacrolimus|
76056602|NCT02016482|Biological|Adalimumab|
75593399|NCT05534763|Behavioral|IERGD|A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.
75593400|NCT05534763|Other|IER SUPPORT|A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.
75593401|NCT05531643|Device|Active Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A biphasic rectangular wave will be delivered for a maximum of 20 minutes at a maximum amplitude of 16mA. Participant may halt amplitude before it reaches maximum amplitude. The device has previously been cleared by the FDA for use in migraine patients.
75593402|NCT05531643|Device|Sham Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A 1Hz wave will be delivered for 20 minutes at 1mA.
75593403|NCT05529628|Diagnostic Test|Cytokine levels|Preoperative cytokine levels of the patients
75593404|NCT05523973|Other|Lingual Endurance Exercise|Participants will participate in 3 training sessions per day for 8 weeks. Group 1 will complete 3 sessions of lingual endurance exercise. For example, if the participant completed 100 repetitions during the baseline measurement, they would complete 75 repetitions during their exercise session.
75616245|NCT02850250|Drug|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
76056603|NCT02016482|Other|Placebo|
76056604|NCT02028871|Drug|Intranasal Insulin|
76056605|NCT02028871|Drug|Placebo|
76056606|NCT04679467|Dietary Supplement|PKU sphere|"TYR sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); Docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
75885756|NCT03079336|Behavioral|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
75885757|NCT05084872|Drug|Hydroxychloroquine|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
75885758|NCT00159796|Drug|Asenapine|Asenapine, 3 weeks
75885759|NCT00159796|Drug|Olanzapine|Olanzapine, 3 weeks
75885760|NCT00159796|Drug|Placebo|placebo, 3 weeks
75443656|NCT01669941|Drug|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
75443657|NCT01669967|Drug|Lidocaine|Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
75443658|NCT01669967|Drug|Diphenhydramine|Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
75443659|NCT01670149|Drug|Rifaximin|Tablets
75443660|NCT01670149|Drug|Placebo|Tablets
75885761|NCT03626571|Other|18F-FDG|Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
75443661|NCT01670370|Drug|R-GemOx|Rituximab Gemcitabine Oxaliplatin
75443662|NCT01670552|Drug|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
75593405|NCT05523973|Other|Lingual Endurance + Transference Exercise|"Group 2 will complete lingual endurance exercise for 2 sessions, and for the 3rd training session participants will complete 30 swallows where they are instructed to press their tongue hard on the bulb and swallow their saliva. The TongueometerTM will provide biofeedback on performance and will be instructed to generate more pressure during this effortful swallow than during a natural, saliva swallow."
75885762|NCT03368014|Behavioral|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
75885763|NCT03361462|Behavioral|Joyful Adventure Day|"Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session."
75443663|NCT01670552|Drug|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
75443664|NCT01670578|Biological|PRP|
75443665|NCT01670578|Device|Hyaluronic acid|
75443666|NCT01670604|Drug|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
75593406|NCT05519397|Diagnostic Test|Immune checkpoint measurement|Measurement of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9
75593407|NCT05517382|Other|supportED|suicide prevention videogame
75885764|NCT03327844|Drug|RET using antibiotics (Ciprofloxacin and Metronidazole)|RET using antibiotics Ciprofloxacin and Metronidazole. First Treatment Visit: Local analgesic, tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal drying using paper points. Delivery of mixture of Bi antibiotic paste (Ciprofloxacin and Metronidazole with sterile water). Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstriction, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
76056607|NCT02028715|Drug|Placebo|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
76056608|NCT02028715|Drug|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
75443667|NCT01670604|Drug|Tetraspan, B. Braun, Melsungen, Germany|
75443668|NCT01670617|Other|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
75443669|NCT01670812|Drug|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
75443670|NCT01670916|Dietary Supplement|probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
75443671|NCT01671241|Device|Polyethylene wrap|
75443672|NCT01671241|Device|Polyethylene wrap|
75443673|NCT01671267|Behavioral|Strength training|
75443674|NCT01671267|Behavioral|Ergonomic|
75443675|NCT01671371|Other|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
75443676|NCT01671449|Drug|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
75885765|NCT03327844|Drug|RET using non-setting Calcium Hydroxide|First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
75885766|NCT03288766|Procedure|PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software|The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
75885767|NCT03230032|Device|pacifier-activated device|The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
75443677|NCT01671449|Drug|Cisplatin|60 mg/m2/day Day 1
75769529|NCT02527720|Behavioral|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at ~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
75769530|NCT01153360|Drug|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
75885768|NCT05691855|Drug|89Zr-NY009|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
75885769|NCT03123640|Other|Medication reconciliation and medication review|Pharmacist performed medication reconciliation and medication review
75443678|NCT01671449|Drug|Oxaliplatin|130 mg/m2/day Day 1
75885770|NCT03068416|Biological|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
75443679|NCT01671462|Device|BD HPV assay on Viper LT|
75443680|NCT01671475|Device|microEEG (Bio-Signal microEEG)|"At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1."
75443681|NCT01671501|Behavioral|Motivational Interviewing|
75443682|NCT01671501|Behavioral|Email Feedback|
75593408|NCT05517382|Other|Control|non-health related videogame
75593409|NCT05511623|Drug|tislelizumab|standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
75593410|NCT05511623|Other|concurrent chemoradiotherapy|standard radiotherapy with concomitant cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
75593411|NCT05508503|Diagnostic Test|Test of methylated NTMT1 and MAP3K14-AS1|A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.
75443683|NCT01671501|Other|Usual Care|
75443684|NCT01669187|Other|Education brochure|
75443685|NCT01669187|Other|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
75443686|NCT01671800|Drug|Botulinum Type B|
75443687|NCT01671800|Drug|Placebo|
75593412|NCT05508503|Diagnostic Test|FIT|Fecal immunochemical test（optional）
75616246|NCT05012644|Drug|Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
75616247|NCT05012644|Drug|Aromatase inhibitor|Aromatase inhibitor
75443688|NCT01671917|Other|Educational and exercise program|"4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement~4 (twice a week) sessions of an exercise programme lasting 1 hour"
75443689|NCT01671917|Other|Usual care|Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
75443690|NCT01671995|Procedure|Nurse monitored heart failure program|Standard program for a heart failure clinic with information, education, drug titration
75443691|NCT01671995|Procedure|Standard primary health care|Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
75443692|NCT01672359|Dietary Supplement|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
75443693|NCT01672359|Dietary Supplement|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
75616248|NCT04202302|Procedure|IVF/ICSI|ovarian stimulation ，vaginal disinfection of flushing
75736681|NCT03571022|Behavioral|USE-MI System|"Pilot Phase: 10 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for 1 month and receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s).~Second Phase: Up to 50 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for up to 6 months. During their first month, subjects will receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s). Subjects will then have monthly follow-up visits to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s)."
75769531|NCT01153360|Drug|placebo|vitamin B12
76056609|NCT02016170|Drug|Ticagrelor 180mg|"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"
76056610|NCT02016170|Drug|Prasugrel 10mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
75443694|NCT01672359|Dietary Supplement|Placebo|
75443695|NCT01672437|Other|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
75885771|NCT03109912|Behavioral|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
75443696|NCT01672541|Behavioral|Dating Matters Comprehensive Approach|"The Dating Matters Comprehensive Approach includes:~6th, 7th, and 8th grade Student Curricula; Parent Programs for parents of 6th, 7th, and 8th graders; A communications campaign involving brand ambassadors, a text message campaign, and social media campaign; An online training about teen dating violence for educators; Developmental component: A guidance document for sites on assessing and informing local policies relevant to teen dating violence for comprehensive schools (likely to be substantial cross and within site variation on this component)"
75443697|NCT01672541|Behavioral|Standard of Care Safe Dates Approach|Safe Dates curriculum for 8th grade students
75443698|NCT01672645|Biological|NIC7-001|Intramuscular, multiple dose
75443699|NCT01672645|Biological|NIC7-003|Intramuscular, multiple dose
75593413|NCT05499650|Behavioral|Supervised Exercise Regiment|Subjects will undergo supervised aerobic exercise. There will be a set goal mean energy expenditure of at least 1000 kcal/wk after a two-week ramp-up period. The protocol will include 30 minutes of moderate-intensity exercise with a treadmill and cycle ergometry, two times weekly. Strenuous resistance training and swimming will be withheld from this protocol due to the potential concerns for safety in exacerbating dissections. Heart rate and ratings of perceived exertion will be quantified during the therapy with a standard set heart rate ad pulse pressure threshold for discontinuing exercise protocols.
75443700|NCT01672645|Biological|Saline|Saline (0.9% sodium chloride)
75443701|NCT01673035|Behavioral|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
75593414|NCT05465538|Drug|[11C]UCB-J PET|Single PET scan using the radioligand [11C]UCB-J
75593415|NCT05465317|Drug|Empagliflozin|Empagliflozin
75593416|NCT05465317|Drug|Dipeptidyl Peptidate-4 inhibitors|Dipeptidyl Peptidate-4 inhibitors
75443702|NCT01673035|Behavioral|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
75443703|NCT01673165|Other|Skimmed mother's milk|Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
75443704|NCT01673165|Other|Specialized Formula|Infants will receive our standard of care - specialized formula
75443705|NCT01673308|Drug|Lenalidomide|Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
75443706|NCT01673503|Device|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
75593417|NCT05465317|Drug|Sodium glucose co-transporter-2 inhibitors|Sodium glucose co-transporter-2 inhibitors
75593418|NCT05465317|Drug|Glucagon-like Peptide-1 Receptor Agonists|Glucagon-like Peptide-1 Receptor Agonists
75593419|NCT05457322|Behavioral|Behavioral intervention one|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
75593420|NCT05457322|Behavioral|Behavioral intervention two|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
75736682|NCT05300126|Behavioral|Hypnosis|Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
75736683|NCT00948740|Drug|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
75443707|NCT01673516|Procedure|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
75443708|NCT01673516|Device|The HOTMAN® System|"Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co"
75443709|NCT01673737|Drug|SAR260301|Pharmaceutical form: film-coated tablets Route of administration: oral
75593421|NCT05451823|Device|Post auriclar-frontal|"Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline."
75593422|NCT05446597|Procedure|Symptom-specific Headache Treatment|Greater Occipital Nerve Block
75593423|NCT05446597|Other|Symptom-specific Dizziness &/or Neck Pain Treatment|Cervicovestibular Physiotherapy Treatment
75593424|NCT05446597|Behavioral|Multimodal Concussion Treatment|Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
75736684|NCT00108433|Drug|Cefazolin IV|
76056611|NCT02016170|Drug|Ticagrelor 90mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
75443710|NCT01673737|Drug|Vemurafenib|Pharmaceutical form: film-coated tablets Route of administration: oral
75443711|NCT01673815|Other|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
75443712|NCT01674114|Procedure|TAP block|
75593425|NCT05445869|Device|ProSomnus® EVO Sleep and Snore Device|The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
75593426|NCT05443633|Behavioral|individualized speech-language training|Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
75736685|NCT00108433|Drug|Linezolid IV|
75736686|NCT00108433|Drug|Vancomycin (IV)|
75736687|NCT00949052|Genetic|DNA analysis|
75443713|NCT01674114|Procedure|control|
75443714|NCT01674153|Procedure|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
75443715|NCT01674335|Behavioral|Operant Learning|"The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
75736688|NCT00949052|Genetic|polymorphism analysis|
75736689|NCT00949052|Other|laboratory biomarker analysis|
75736690|NCT00949052|Other|medical chart review|
75736691|NCT00949052|Other|questionnaire administration|
75736692|NCT00949052|Procedure|assessment of therapy complications|
75736693|NCT00949052|Procedure|evaluation of cancer risk factors|
75736694|NCT01084369|Drug|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
75736695|NCT05352308|Behavioral|Common Sense Model Guided Narrative Video|The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
75885772|NCT03109912|Behavioral|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
75885773|NCT03109912|Behavioral|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
75885774|NCT03109912|Behavioral|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
75885775|NCT05691621|Drug|Standard Reagents, Whole Blood|All patients receive standard treatment, only their blood and urine samples are needed
75885776|NCT05058820|Other|Post Facilitation stretch|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Post facilitation stretch 15 secs isometric hold/ 15 secs stretch/ 30 secs relax/ 5 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
75885777|NCT05058820|Other|Active Isolated Stretching|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Active Isolated Stretching 2 secs hold/ 10 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
75885778|NCT05691543|Procedure|sacrospinous fixation Using Posterior Vaginal wall flap|"Identification of the sacro spinous ligament.~Insertion of the sacrospinous stitch. Using a long - handled needle holder, a J - shaped Ethibond suture is placed 2 - 3 cm medial to the right ischial spine. Using posterior vaginal wall flap (rectangular flap )will be incised and retracted Superior to the right , the stitch of sacro spinous ligament will be attached to the flap not the vault after adjusting its size , then the sit . The stitch should be placed through and not around the ligament. The application of firm traction to the suture length will test the correctness of its placement. A second suture is inserted for additional support. We may do it directly or by using an alternative surgical instruments for placement of the suture include the knee scorpion. Per rectum examination should be undertaken to check for misplaced sutures.~Attachment of the sutures to the vaginal flap . The two sutures are then secured to the upper posterior aspect of the vaginal flap ,"
75593427|NCT05443633|Behavioral|standard language intervention|Participants will undergo standard speech-language naming therapy
75736696|NCT03416738|Behavioral|Semantically focused treatment|"Tasks are as follows:~Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation."
75736697|NCT03416738|Behavioral|Phonologically focused treatment|"Tasks are as follows:~Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation."
75736698|NCT04010006|Procedure|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
75736699|NCT04010006|Procedure|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
75736700|NCT04010162|Other|Mesh debate awareness survey|"A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute"
75736701|NCT03084224|Genetic|neurological and neurodegenerative diseases|NGS on a large scale of Patients with complexes phenotypes
75885779|NCT05042206|Biological|Cellgram-CKD|Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
75885780|NCT05008510|Drug|Sabizabulin|Sabizabulin (Veru-111)
75593428|NCT05428891|Procedure|Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.|We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.
75593429|NCT05405270|Drug|Imiquimod|Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
75593430|NCT05405270|Diagnostic Test|3x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
75593431|NCT05405270|Other|Expectative management|Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
75593432|NCT05405270|Diagnostic Test|2x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
75736702|NCT02994446|Device|Saline-Enhanced Radiofrequency Catheter and Ablation System|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
75736703|NCT00116779|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
75736704|NCT00949130|Drug|NXL103|BID for 7-14 days
75736705|NCT00949130|Drug|Linezolid|BID for 7-14 days
75736706|NCT03943290|Drug|ACE-083|Recombinant fusion protein
75736707|NCT04010318|Procedure|Spinal Anesthesia|The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
75736708|NCT00108355|Drug|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
75736709|NCT00108355|Drug|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
76056612|NCT02015546|Drug|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
75736710|NCT00108355|Drug|Midodrine|Midodrine oral tablet at 10 mg three times a day.
76056613|NCT02027701|Biological|IgPro20|
76056614|NCT02038790|Drug|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
76056615|NCT02038790|Drug|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
76056616|NCT04693286|Biological|novel oral polio type 2 vaccine (nOPV2)|• nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
75443716|NCT01674335|Behavioral|Energy Conservation|"The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
75443717|NCT01674426|Behavioral|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
75443718|NCT01674439|Procedure|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
75593433|NCT05394376|Other|Level of noise and environment (public vs private) while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.
75593434|NCT05372328|Other|Position of arm while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
75593435|NCT05343650|Device|NOVAPAK nasal packing applied to forearm|Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm.
75593436|NCT05343650|Device|NOVAPAK nasal packing applied to nasal cavity|A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes
75736711|NCT00108355|Drug|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
75736712|NCT00108355|Drug|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
75736713|NCT00108355|Drug|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
75736714|NCT00108355|Procedure|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
76056617|NCT04693286|Other|Placebo|Placebo contains no active ingradients, only sucrose in buffer
75443719|NCT01674439|Procedure|Without supplementation of ADRC|Standard fat graft preparation
75443720|NCT01674556|Drug|Gemzar|Gemcitabine in combination with ultrasound (US) contrast agent under sonication
75736715|NCT05351996|Device|Kinesiotape|The participants received kinesiotape application three times with one-week intervals. Y strip tape was used. The interventionist applied the band to the rectus femoris muscle with facilitation technique.
75769532|NCT03895606|Other|Data collection|This study is an observational study collecting perioperative data. There is no intervention regarding this study.
75769533|NCT03895528|Drug|Lonafarnib|Farnesyl transferase inhibitor
75885781|NCT05008510|Drug|Sacituzumab Govitecan-hziy|Sacituzumab govitecan-hziy
75885782|NCT05008510|Drug|Sabizabulin/Sacituzumab govitecan-hziy Combo|Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
75769534|NCT03895138|Other|Standard Glucommander Protocol (SGP)|Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.
75885783|NCT05001256|Other|questionnaire study|Participants will be surveyed through face-to-face interviews.
76056618|NCT02027623|Behavioral|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
76056619|NCT02027623|Behavioral|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
76056620|NCT04684381|Drug|L-glutamine|Pharmacokinetic study
76056621|NCT02015221|Device|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
76056622|NCT02015221|Device|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
76056623|NCT04678843|Behavioral|Virtual Family-Based Treatment|Treatment involving the youth/adolescent who has been diagnosed with anorexia nervosa and their family, delivered virtually via videoconferencing.
76056624|NCT02027311|Drug|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
76056625|NCT02027311|Drug|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
76056626|NCT02027311|Drug|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders > 80 years old were administered 25mg iv bolus.
75443721|NCT01674595|Biological|AVANZ olea|Immunotherapy Olea europaea
75443722|NCT01675115|Drug|BNG-1|BNG-1 3 grams TID for 4 weeks
75443723|NCT01675115|Drug|Aspirin|Aspirin 100 mg QD for 4 weeks
76056627|NCT02047903|Drug|Afatinib|50, 40, 30 or 20 mg
76056628|NCT02015065|Drug|Vandetanib|Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
76056629|NCT02026141|Drug|Dexmedetomidine|
75443724|NCT01675271|Other|individual exercise|individual exercise and dietary prescription
75443725|NCT01675271|Other|general exercise|general exercise counselling
75443726|NCT01675310|Drug|medical nutrition therapy + metformin|
75443727|NCT01675310|Behavioral|Medical nutrition therapy|medical nutrition therapy
75443728|NCT01675401|Other|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
75443729|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
75443730|NCT01675674|Other|Dried blood spot test for MPS|The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
75443731|NCT01675713|Behavioral|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
75443732|NCT01676103|Dietary Supplement|Tyrosine|Tyrosine supplementation (500 mg 2 x daily) for 7 days
75443733|NCT01676103|Other|Placebo Comparator:Sugar Pill|Placebo sugar pills (2x daily
75443734|NCT01676649|Biological|Ipilimumab|3 mg/kg
75443735|NCT01676649|Drug|Carboplatin|AUC = 6
75616249|NCT02846506|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
75885784|NCT03019510|Behavioral|No exercise|No exercise will be done on the day of the study night to be tested
75443736|NCT01676649|Drug|Paclitaxel|175 mg/m2
75443737|NCT01676883|Device|Bioelectric impedance|removal of calluses and corns by pedicure
75443738|NCT01676883|Device|Air displacement plethysmography|
75443739|NCT01676987|Drug|Fixed combination of budesonide and formoterol|Delivered dry powder inhaler for 12 weeks.
75443740|NCT01676987|Drug|Budesonide|Delivered dry powder inhaler for 12 weeks.
75885785|NCT03019510|Behavioral|Morning exercise|Early morning exercise will be done on the day of the study night to be tested
75885786|NCT03019510|Behavioral|Evening exercise|Evening exercise will be done on the day of the study night to be tested
75885787|NCT04402996|Other|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
75885788|NCT04402996|Other|gingival crevicular fluid|"GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
75885789|NCT05194995|Drug|JAB-21822|JAB-21822 administered orally as a tablet.
76056630|NCT02026141|Drug|Normal Saline Placebo|
76056631|NCT02026063|Drug|Telotristat etiprate|Telotristat etiprate tablet (250 mg)
76056632|NCT02025907|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
76056633|NCT02025907|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
75885790|NCT05194995|Drug|Cetuximab|Cetuximab administered as an intravenous (IV) infusion.
76056634|NCT02025907|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily.
75443741|NCT01677039|Drug|Test formulation administered with water|single dose of 20 mg of test formulation with 240 mL of water
75885791|NCT02972944|Procedure|Laparoscopic cholecystectomy|
75885792|NCT02972944|Procedure|Non-operative treatment|
76056635|NCT01813071|Biological|WRSS1|
75593437|NCT05338346|Drug|ATG-018|"Dose Escalation Phase:~For both dose escalation groups, subjects will receive a single dose of ATG-018 monotherapy on Cycle 1 Day 1 (C1D1) for single dose PK samples' collection. From the morning dose on Cycle 1 Day 2, twice daily dosing (except Dose Level 1: 5 mg QD) will be initiated. Subject(s) will receive intermittent dosing in a 3 days on/4 days off schedule in 21-day cycles until disease progression or unacceptable toxicity.~Dose Expansion Phase :~Dose Expansion Phase will begin at the defined MTD/RP2D for solid tumors and hematological malignancies groups, to further evaluate the safety, tolerability, and PDx profile of ATG-018. Subjects with solid tumors and hematological malignancies will be enrolled."
75885793|NCT03136978|Diagnostic Test|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
76056636|NCT02025751|Drug|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
76056637|NCT02025751|Drug|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
76056638|NCT02025205|Device|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
75443742|NCT01677039|Drug|Test formulation administered with 20% ethanol|single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
75443743|NCT01677039|Drug|Test formulation administered with 40% ethanol|single dose of 20 mg of test formulation with 240 mL of 40% ethanol
75443744|NCT01677065|Drug|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
75443745|NCT01677065|Drug|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
75443746|NCT01677247|Drug|Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
75443747|NCT01677247|Drug|Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
75443748|NCT01677260|Drug|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
75736716|NCT05351996|Device|Sham-kinesiotape|"The participants received sham-kinesiotape application three times with one-week intervals.~In the sham group, the interventionist adhered KT to the rectus femoris transversely, without stretching."
75736717|NCT05351996|Other|Home-based exercise program|Participants were taught exercise program training. The exercise intervention was based on quadriceps and knee flexor muscle group strengthening, and knee joint range of motion exercises, in their home.
76056639|NCT01812837|Device|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
76056640|NCT01812837|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
76056641|NCT01812837|Radiation|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
76056642|NCT02024971|Drug|Pioglitazone/metformin hydrochloride|Pioglitazone/metformin hydrochloride combination tablets
75443749|NCT01677260|Drug|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
75736718|NCT02755220|Device|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
75736719|NCT00963222|Drug|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
75736720|NCT00963222|Drug|placebo|1 cap placebo/day for 3 month
76056643|NCT01843023|Drug|Extended Release Naltrexone|naltrexone for extended release injectable suspension
76056644|NCT01843023|Behavioral|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
76056645|NCT01843023|Drug|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
76056646|NCT01812759|Drug|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
76056647|NCT01812759|Drug|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
76056648|NCT01812759|Other|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
76056649|NCT01812057|Drug|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
75885794|NCT05187039|Other|Electrical impedance tomography during anesthesia|Thoracic electrical impedance tomography measurements ( min each) will be performed at the following time points: before induction of the anaesthesia; before the surgical procedure when the induction is terminated and recruitment manoeuvers have been performed; after the termination of the surgical procedure; before transport to the Post anaesthesia Care Unit (PACU); before the discharge from the PACU after 2 hours of monitoring. An additional thoracic EIT-measurement will be performed before discharge at home. For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated. Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity will be calculated using customised code (Matlab R2021a, The MathWorks, Nattick, Massachusetts, USA).
75885795|NCT04401280|Drug|BiominF|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
75885796|NCT04401280|Drug|Novamin|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
75885797|NCT04401280|Drug|CPP-ACP|applied in accordance with the manufacturer's specifications
75885798|NCT02963272|Other|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines.
75885799|NCT02963272|Other|ST2-guided strategy|patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
75885800|NCT03137836|Behavioral|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
75885801|NCT05181891|Behavioral|Contingency Management|Incentives for submitting negative-alcohol urine samples
75885802|NCT05181891|Behavioral|Non-contingent control|Incentives for submitting urine samples
75885803|NCT05180487|Behavioral|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
75885804|NCT04896970|Other|Concert|A musical show in a closed hall, lasting for about 2 hours, in respects of safety measure (masks, hydroalcoholic gel, etc…) with approximately 200 participants.
75885805|NCT03136666|Drug|Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil|Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
75885806|NCT03255083|Drug|DS-1205c|DS-1205c 200 mg capsule
76056650|NCT01812057|Drug|Placebo|Sodium Chloride 0.9% -5 ml
76056651|NCT01842633|Drug|Paracetamol and Caffeine|Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
75443750|NCT01677572|Drug|Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
75593438|NCT05338190|Drug|Combination of Rituximab with subcutaneous belimumab|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
75593439|NCT05338190|Drug|Combination of Rituximab with subcutaneous placebo|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
75736721|NCT00963300|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
75736722|NCT00963300|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
75736723|NCT00963300|Procedure|magnetic resonance spectroscopic imaging|
76056652|NCT01842633|Drug|Ibuprofen|Caplets containing 200 mg of ibuprofen
75736724|NCT00963300|Procedure|tissue-oxygen-level-dependent functional magnetic resonance imaging|
75736725|NCT05297474|Other|MRI|No intervention was performed in this study.
75593440|NCT05330637|Other|Climate and environment in Sanya|Sanya have unique island climate and environment campared with the north of China, with a feature of warm, moist and long-sunshine.
75593441|NCT05325840|Other|music terapy|The aim of this study was to examine the effects of the music concert applied during the nonstress test procedure on the health of the fetus, the anxiety level of the pregnant woman and blood pressure.
75736726|NCT00968604|Genetic|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
75736727|NCT02703584|Drug|Buseralin|
75736728|NCT02703584|Other|Placebo|
75885807|NCT03255083|Drug|Osimertinib|Osimertinib 80 mg tablet
75885808|NCT02514148|Behavioral|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
76056653|NCT01842633|Other|Placebo|Matching placebo caplets
76056654|NCT01810263|Dietary Supplement|high protein supplement|Dietary Supplement: high protein supplement
76056655|NCT01841697|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
76056656|NCT01841697|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
76056657|NCT01841697|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
75736729|NCT02703584|Drug|pregnyl|
75736730|NCT00968682|Biological|trastuzumab|
75736731|NCT00968682|Other|laboratory biomarker analysis|
76056658|NCT01841697|Drug|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
75593442|NCT05319691|Behavioral|Yoga|The trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment Phase during which, yoga participants will receive a reproducible standardized weekly yoga intervention delivered virtually with additional resources for home practice, followed by a 12-week Follow-up Phase.
75736732|NCT00968682|Procedure|assessment of therapy complications|
76056659|NCT01841697|Drug|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
76056660|NCT01841697|Drug|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
76056661|NCT01841073|Dietary Supplement|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
76056662|NCT01841073|Dietary Supplement|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
76056663|NCT01841073|Dietary Supplement|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
75593443|NCT05314855|Device|functional MRI|Subjects will undergo functional MRI at 4 time points in 24 hours.
75443751|NCT01677572|Drug|Placebo|Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
75443752|NCT01677650|Drug|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
75443753|NCT01678053|Drug|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
75593444|NCT05305586|Device|Splint retained by Bulk-fill flowable|Luxated teeth were splinted with bulk-fill flowable composite
75443754|NCT01678053|Drug|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
75443755|NCT01678326|Procedure|EUS-Rendezvous or direct intervention|
75593445|NCT05305586|Device|Splint retained by Packable Composite|Luxated teeth were splinted with packable composite
75443756|NCT01678326|Procedure|Advanced ERCP Biliary Access Techniques|
75593446|NCT05296109|Diagnostic Test|Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)|The MRI examination will consist of both conventional sequences for diagnosis of salivary gland neoplasms (including DWI and DCE-MRI), together with additional neurogram sequences. (please refer to attached protocol for list of sequences)
75593447|NCT05287503|Drug|Ambroxol Hydrochloride|Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.
75736733|NCT04010292|Behavioral|Patient education card|Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
75736734|NCT02575976|Behavioral|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
75736735|NCT02575976|Other|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
75736736|NCT02575976|Other|wait list control|No cardiac rehabilitation.
75736737|NCT04009980|Other|OMK2 group|topical administration of OMk2 ophthalmic solution for 36 months three times/day
75736738|NCT04009980|Other|Placebo group|topical administration of ophthalmic placebo solution for 36 months three times/day
75593448|NCT05287503|Drug|Placebo|Excipients
75593449|NCT05271617|Diagnostic Test|VIDAS® NEPHROCLEAR™ CCL14|Measurement of CCL14 in sample aliquots after being subjected to different testing conditions
75593450|NCT05271344|Dietary Supplement|Nutritional Products|Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d
75593451|NCT05263908|Drug|nirmatrelvir / ritonavir|The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.
75593452|NCT05259371|Drug|Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
75736739|NCT02465138|Drug|Ketorolac|Intravenous ketorolac
75736740|NCT02465138|Drug|Placebo|Intravenous saline
76056664|NCT01841073|Dietary Supplement|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
76056665|NCT01841073|Dietary Supplement|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
76056666|NCT01841073|Dietary Supplement|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
76056667|NCT01809327|Drug|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
75736741|NCT00968916|Drug|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
76056668|NCT01809327|Drug|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
76056669|NCT01809327|Drug|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
76056670|NCT03272139|Drug|Bupivacaine|Anesthetic that will help treat pain and sensation after shoulder arthroscopy
76056671|NCT03272139|Device|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
75593453|NCT05245513|Behavioral|Recovery Community Center Linkage (RCCL)|A certified recovery coach will meet with participants to educate them on recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (e.g., calling a standby peer, scheduling a meet-up at the center). The coach will also provide the participant with a brochure of recovery support resources.
75443757|NCT01678391|Procedure|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
75593454|NCT05245513|Behavioral|Control Condition (CC)|A certified recovery coach will meet with participants to educate them on recovery support services more broadly, including recovery community centers, and will provide them with a brochure of recovery support resources.
75593455|NCT05227001|Biological|PF-07852352 Influenza saRNA 1|Intramuscular injection
76056672|NCT01808313|Drug|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
76056673|NCT01840605|Drug|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
76056674|NCT01840605|Drug|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
76056675|NCT04593381|Radiation|Stereotactic body radiotherapy|All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.
76056676|NCT02023879|Drug|Alirocumab|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
76056677|NCT02023879|Drug|Placebo (for Alirocumab)|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
75593456|NCT05227001|Biological|PF-07836391 Influenza saRNA|Intramuscular injection
75593457|NCT05227001|Biological|PF-07836394 Influenza saRNA|Intramuscular injection
75593458|NCT05227001|Biological|PF-07836395 Influenza saRNA|Intramuscular injection
75593459|NCT05227001|Biological|PF-07836396 Influenza saRNA|Intramuscular injection
75593460|NCT05227001|Biological|PF-07867246 Influenza saRNA|Intramuscular injection
75593461|NCT05227001|Biological|Placebo|Intramuscular injection
75593462|NCT05227001|Biological|Quadrivalent influenza vaccine (QIV)|Intramuscular injection
75593463|NCT05227001|Biological|PF-07871987 Influenza saRNA|Intramuscular injection
75593464|NCT05227001|Biological|PF-07914705 Influenza saRNA|Intramuscular injection
75593465|NCT05227001|Biological|PF-07915048 Influenza saRNA|Intramuscular injection
75593466|NCT05212571|Drug|S-ketamine infusion inpatient setting|S-ketamine is administered intravenously for six consecutive days. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
75593467|NCT05212571|Drug|S-ketamine infusion outpatient setting|S-ketamine is administered intravenously for six hours. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
75736742|NCT05351528|Other|Questionnaire|Caregiver burden and healthy lifestyle behaviors were evaluated.
75736743|NCT00968994|Device|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
75736744|NCT00968994|Device|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
75736745|NCT00969072|Drug|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
75736746|NCT00969072|Drug|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
75736747|NCT00969072|Drug|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
75736748|NCT00094861|Drug|Palifermin|
75885809|NCT02514148|Other|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
75736749|NCT00094861|Drug|Placebo|
75885810|NCT02514148|Other|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
75885811|NCT02514148|Other|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
76056678|NCT02023879|Drug|Non-statin LMT|Ezetimibe or Fenofibrate at stable dose as background therapy.
76056679|NCT02023879|Other|Diet Alone|Stable cholesterol-lowering diet as background therapy.
76056680|NCT04417153|Behavioral|Mindfulness Based Intervention|The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.
76056681|NCT02014441|Drug|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
76056682|NCT02013817|Drug|rituximab [MabThera/Rituxan]|Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
76056683|NCT02013817|Drug|fludarabine|Every 4 weeks, 6 cycles
75593468|NCT05209763|Procedure|More intensive rehabilitation|Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
75736750|NCT00094861|Radiation|Radiotherapy|
76056684|NCT02013817|Drug|cyclophosphamide|Every 4 weeks, 3 cycles
76056685|NCT01994863|Device|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
75593469|NCT05209763|Dietary Supplement|More intensive nutrition|"in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~inclusion of probiotics in standard doses"
75736751|NCT00094861|Drug|Paclitaxel|
75736752|NCT00094861|Drug|Carboplatin|
75736753|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."
75736754|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
75736755|NCT00963612|Procedure|BOLD MRI test|Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
75736756|NCT00963690|Device|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
75736757|NCT00963690|Procedure|Standard compression|Use standard compression to achieve hemostasis
75736758|NCT01079767|Drug|temsirolimus|
75736759|NCT01151124|Biological|CTX0E03 neural stem cells|Single administration by surgical delivery to the damaged area of the brain
75736760|NCT01084447|Device|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
75736761|NCT01084447|Device|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
75736762|NCT00969306|Drug|Chloroquine, A-CQ 100|"Administration:~Orally~Timing: Once daily~Tablets of 100 mg~During or after meals~In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~Patients should always note date and time of intake on the chloroquine monitoring form."
75736763|NCT05260710|Behavioral|Telemedicine Intervention|"Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~+~Continuing education activities: video classes and discussions of complex cases."
75736764|NCT00958464|Procedure|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- [Gd-DTPA2-] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
75885812|NCT05244915|Other|Experimental (Delphi Surveys)|The Delphi method, a process used to arrive at a group opinion or decision by surveying a panel of experts, will be used with experts in geriatric oncology to develop a supportive care management intervention for older caregivers of older adults with cancer.
75885813|NCT05244915|Other|Experimental (Focus Groups)|Focus group qualitative interviews will be conducted with key stakeholders consisting of older adults with cancer and their caregivers.
76056686|NCT01994863|Device|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
76056687|NCT02023099|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
76056688|NCT02023099|Drug|Placebo|Tablet
76056689|NCT02013037|Drug|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
76056690|NCT01967719|Other|mTHS 2.2|Single use of mTHS 2.2
75443758|NCT01678937|Procedure|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
75736765|NCT00963768|Drug|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
75736766|NCT00963768|Drug|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
75736767|NCT00969384|Behavioral|Active awareness/Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
75736768|NCT00958542|Procedure|Surgical fusion|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
75736769|NCT00969462|Drug|Doxorubicin|measurements of serum Doxorubicin levels
75736770|NCT00963846|Drug|placebo|matching pill placebo
75736771|NCT00963846|Drug|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
75736772|NCT00963846|Drug|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
75736773|NCT00963846|Drug|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
75885814|NCT05244915|Other|Qualitative interviews|Qualitative interviews will be conducted with older caregivers of older adults with cancer to inquire about their experience with caregiving and unmet supportive care needs.
75885815|NCT05234853|Drug|PUR001|Monoclonal antibody
75885816|NCT03240419|Dietary Supplement|Probiotics|Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
75885817|NCT03240419|Dietary Supplement|Placebo|capsule manufactured to mimic probiotic capsules.
75885818|NCT03745053|Device|Xlimus DES Implantation during coronary angioplasty|Xlimus DES Implantation during coronary angioplasty
75885819|NCT03745053|Device|Synergy DES Implantation during coronary angioplasty|Synergy DES Implantation during coronary angioplasty
75885820|NCT01665118|Device|Trusculpt (Radio Frequency) Device|
76056691|NCT01967719|Other|mCC|Single use of subject's own mCC
76056692|NCT01967719|Other|NNS|Single administration of 1 mg of nicotine
75593470|NCT05209269|Other|Work of breathing observation|We will place soft elastic bands around the infant's chest and abdomen to assess their work of breathing.
75736774|NCT00958620|Procedure|Shock Wave Therapy|Extracorporal shock-wave therapy
75736775|NCT00958698|Other|Communication Intervention|Ancillary studies
75885821|NCT03735537|Drug|Teriparatide Pen Injector|
75593471|NCT05201495|Device|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
75736776|NCT00958698|Other|Educational Intervention|Ancillary studies
75736777|NCT00958698|Other|Internet-Based Intervention|Ancillary studies
75885822|NCT03735537|Drug|Zoledronic Acid|Any brand or preparation may be used to deliver the required dose of 5mg
75593472|NCT05201001|Drug|APX005M|adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
75593473|NCT05198050|Drug|Letrozole tablets|Letrozole is a third-generation non-steroidal aromatase inhibitor
76056693|NCT04416607|Drug|Corifollitropin Alfa|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
76056694|NCT04416607|Drug|Menotropins|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
76056695|NCT01967173|Drug|Flovent Diskus® 100 mcg|Flovent is an ICS
76056696|NCT01967173|Drug|Flovent Diskus® 250 mcg|Flovent is an ICS
75736778|NCT00958698|Procedure|Psychosocial Assessment and Care|Ancillary studies
75736779|NCT00958698|Other|Quality-of-Life Assessment|Ancillary studies
75736780|NCT00958698|Other|Questionnaire Administration|Ancillary studies
75736781|NCT00969696|Drug|Placebo|8Mg a day of a sugar pill
75736782|NCT00969696|Drug|Galantamine|8mg of Galantamine
75885823|NCT04552587|Behavioral|Heart APP|The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
76056697|NCT01967173|Drug|Flovent Diskus® 500 mcg|Flovent is an ICS
76056698|NCT01967173|Drug|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
76056699|NCT01967173|Drug|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
76056700|NCT01994629|Biological|MenACWY-CRM|MenACWY-CRM
76056701|NCT01994629|Biological|MenACWY-TT|MenACWY-TT
76056702|NCT01994395|Device|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
76056703|NCT01994395|Other|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
75593474|NCT05198050|Drug|Misoprostol Tabets|a synthetic prostaglandin medication
75593475|NCT05198050|Drug|Placebo tablets|Placebo tables with a similar appearance to letrozole
75593476|NCT05189223|Behavioral|Brief, values based intervention for early buprenorphine treatment|The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.
75736783|NCT00958854|Drug|cyclophosphamide|
75736784|NCT00958854|Drug|fludarabine phosphate|
75736785|NCT00958854|Drug|thalidomide|
75736786|NCT00958854|Other|laboratory biomarker analysis|
75736787|NCT04009278|Other|Self compression arm|The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
76056704|NCT01992536|Biological|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
76056705|NCT01992536|Biological|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
76056706|NCT01992536|Biological|Placebo|Saline solution for injection (0.5mL)
76056707|NCT01993927|Drug|Voglibose|Voglibose Tablets / Voglibose OD Tablets
76056708|NCT02015390|Procedure|Autogenous RIA bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.
76056709|NCT02015390|Procedure|Allogeneic bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).
76056710|NCT02012959|Drug|Tolvaptan|
76056711|NCT01990742|Behavioral|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
76056712|NCT02012491|Drug|Misoprostol|
76056713|NCT02012491|Drug|Mifepristone|
76056714|NCT01990664|Device|senofilcon A|
76056715|NCT01990664|Device|senofilcon A for Astigmatism|
76056716|NCT04416139|Biological|Infusion IV of Mesenchymal Stem cells|Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
76056717|NCT02038010|Drug|PI3K inhibitor BYL719|Given PO
76056718|NCT02038010|Biological|ado-trastuzumab emtansine|Given IV
75736788|NCT00964080|Drug|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
75885824|NCT04809922|Device|cardiac wearable devices|"five cardiac wearable devices~Apple Watch, Apple Inc., Model Number: A1977 / A1978~Kardia Mobile, AliveCor Inc., AC-009/Kardia Mobile 6L, AliveCor Inc., AC-019~Fitbit Sense, Fitbit, Inc, Model Number: FB512~Samsung Galaxy Watch 3 Samsung Inc., Model Number: SM-R855F~Withings Scanwatch, Withings SA, Model Number: HWA09 Used for recording of one single-lead ECG. The results will be 274 compared to a simultaneous 12-lead ECG, which is considered the gold standard for detecting AF. There is no comparator in this trial."
75885825|NCT04531059|Drug|Esomeprazole|Proton pump inhibitor
76056719|NCT02038010|Other|pharmacological study|Correlative studies
76056720|NCT02038010|Other|laboratory biomarker analysis|Optional correlative studies
76056721|NCT04416698|Behavioral|Individual qualitative interview|Individual interviews will be conducted to understanding the needs and concerns of youth smokers of e-cigarette or other new tobacco products, including their risk perceptions, and the behaviour, attitudes, and experiences related to these tobacco products.
76056722|NCT04416698|Behavioral|cross-sectional survey study|structured questionnaire will be constructed for a cross-sectional survey to further explore the behaviour, attitudes, and experiences related to electronic cigarettes or other new tobacco products among youth.
76056723|NCT04178798|Drug|Acalabrutinib 100 MG Oral Capsule|Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
75593477|NCT05189223|Behavioral|Treatment as Usual|Veterans will be recruited from an intensive treatment phase where all Veterans receive case management and regular group therapy in addition to appointments with their buprenorphine prescriber. After the first two weeks, they have the option to continue with a less intensive group schedule and case management support through an Aftercare program.
75593478|NCT05176418|Drug|low dose Nicotine|IV nicotine infused over different delivery rates
75885826|NCT04531059|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
75885827|NCT04531059|Drug|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
76056724|NCT01989572|Other|Laboratory Biomarker Analysis|Correlative studies
76056725|NCT01989572|Other|Placebo|Given GM-CSF placebo SC
76056726|NCT01989572|Other|Placebo|Given peptide placebo SC
76056727|NCT01989572|Biological|Sargramostim|Given SC
76056728|NCT01989572|Biological|Tyrosinase Peptide|Given SC
76056729|NCT04416776|Drug|Strabismus diagnostic system.|An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
75443759|NCT01678937|Procedure|Blood Draw from Control Subjects|"Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
76056730|NCT02036294|Other|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
75443760|NCT01678937|Procedure|Blood Draw - CyA|"Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
75593479|NCT05176418|Drug|high dose Nicotine|IV Nicotine infused over different delivery rates
75593480|NCT05171894|Drug|Hemopfin+PDT|All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
75885828|NCT04531059|Drug|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
76056731|NCT02036294|Other|Usual Care|Standard Healthcare Services
76056732|NCT02035748|Drug|Ocriplasmin|0.5 mg/0.2 mL solution for injection
76056733|NCT02014376|Drug|SD-101 dermal cream (3%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
75593481|NCT05171894|Drug|Vehicle+PDT|All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
75593482|NCT05166642|Device|Bandgrip Micro-Anchor Wound Closure|This treatment group will utilize a suture closure technique for the deep dermal layers with Bandgrip being applied to the most superficial layer of the surgical incision
75593483|NCT05166642|Device|Suture closure|This treatment gourd will utilize suture closure technique for all layers of the surgical incision.
75885829|NCT03136744|Behavioral|Sit Less with MS|The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
75885830|NCT05171127|Procedure|Diffuse Reflectance Spectroscopy|Measurements of DRS patterns in extirpated tumor and cerebral tissue
75736789|NCT00958932|Behavioral|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
75885831|NCT05090176|Other|povidone-soaked suture|suture soak with povidone solution for 3 mins
75885832|NCT05090176|Other|ordinary suture|suture no need to soak with povidone solution
76056734|NCT02014376|Drug|SD-101 Dermal Cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
76056735|NCT02014376|Drug|Vehicle (SD-101 0%)|A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
76056736|NCT02035202|Behavioral|CBT2go|CBT administered using mobile intervention.
76056737|NCT02035202|Device|Smartphone|A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
75593484|NCT05161780|Drug|Lactated Ringer's Irrigation|Lactated Ringers at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
75593485|NCT05161780|Drug|Normal Saline|Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
75593486|NCT05159414|Device|Pulse Electrical Stimulation|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
75593487|NCT05134740|Biological|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:~2 x 10^7/m2"
75593488|NCT05133076|Biological|Lactobacillus gasseri BGP345A|Active and placebo capsules for oral use
75885833|NCT05090020|Procedure|Treatment|Surgery and PAIR
75885834|NCT05158335|Drug|MBX 2109 (Part A)|Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
75885835|NCT05158335|Drug|MBX 2109 (Part B)|Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
75885836|NCT05158335|Drug|Placebo|Single SC dose or repeated SC doses of placebo.
75885837|NCT04716166|Other|Volume-oriented incentive spirometry|3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
75885838|NCT04716166|Other|Flow-oriented incentive spirometry|3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
75885839|NCT04701502|Dietary Supplement|Viusid|"Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days"
75885840|NCT04701502|Dietary Supplement|Asbrip|"Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days"
75885841|NCT04701502|Drug|Standard Care|Standard care for COVID-19
75593489|NCT05133076|Biological|Placebo|Placebo
75593490|NCT05130567|Drug|LP-128 capsules|Oral dosing with LP-128 capsules
75593491|NCT05130567|Other|Matching Placebo|Oral dosing with placebo capsules to match LP-128 capsules.
75593492|NCT05130060|Biological|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Given SC
75736790|NCT00958932|Behavioral|Speech recognition|Automated, speech recognition telephone calls
75736791|NCT00969852|Drug|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
75736792|NCT00959010|Dietary Supplement|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
75736793|NCT00959010|Dietary Supplement|Placebo|capsules containing middle chain triglycerides
75736794|NCT04009434|Device|Mitral Valve Clipping|Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
75885842|NCT01316055|Drug|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
75885843|NCT04685668|Behavioral|The PartoMa guidelines and training|"All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics in five study sites during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.~The intervention includes the following two components:~Implementation of a pocket booklet with simple and locally achievable clinical guidance for safe and respectful care at birth developed by the research team and birth attendants at the five hospital study sites;~Quarterly, the birth attendants will be offered training in the use of the booklet in 3-hour case-based seminars."
75885844|NCT05349357|Other|Sliding Neural mobilization|Sliding neural mobilization to femoral, sciatic and tibial nerve
75885845|NCT05349357|Other|Tensioner Neural mobilization|Tensioner neural mobilization to femoral, sciatic and tibial nerve
75885846|NCT05349357|Other|Stretching exercises|Stretching exercises
75885847|NCT05349357|Device|TENS|TENS
76056738|NCT01988402|Drug|allopurinol|
76056739|NCT01988402|Drug|Placebo (sugar pill)|
75443761|NCT01678937|Procedure|Blood Draw - Tacrolimus|"Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
75593493|NCT05130060|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
75593494|NCT05121493|Other|Platelet Poor Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.
75593495|NCT05121493|Other|Platelet Rich Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.
75593496|NCT05120973|Procedure|multispectral imaging|Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
75593497|NCT05120973|Procedure|fluorescence for lymphatic mapping|Indocyanine green injected in abdominal wall
75593498|NCT05114486|Combination Product|Pilocarpine Ophthalmic administered with the Optejet dispenser|Pilocarpine 2% ophthalmic spray administered with the Optejet dispenser
75593499|NCT05114486|Combination Product|Placebo administered with the Optejet dispenser|Vehicle ophthalmic solution administered with the Optejet dispenser
75593500|NCT05108506|Behavioral|No Strict need to void following surgery|Certain patient will be randomized without a strict need to void prior to discharge following surgery.
75593501|NCT05108506|Behavioral|Strict need to void following surgery|Certain patient will be randomized with a strict need to void prior to discharge following surgery.
75593502|NCT05105048|Biological|mRNA-1647|Lyophilized product that is reconstituted with saline
75593503|NCT05105048|Biological|Placebo|0.9% sodium chloride (normal saline) injection
75593504|NCT05103384|Other|Virtual Reality Environment|Participants complete various tasks in a virtual home and grocery store environment.
75736795|NCT04009434|Device|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
75736796|NCT00426556|Drug|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
75736797|NCT00426556|Drug|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel & Trastuzumab
76056740|NCT01988090|Drug|800 IU Vitamin D Supplement|Standard Dose
76056741|NCT01988090|Drug|50,000 IU Vitamin D supplement|High Dose
76056742|NCT01988012|Biological|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
75443762|NCT01678937|Procedure|Blood Draw - MMF|"Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
75736798|NCT00426556|Drug|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
76056743|NCT02011945|Drug|Dasatinib|
75593505|NCT05082675|Procedure|HLA Matched allogeneic transplant|
75593506|NCT05074953|Other|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
75593507|NCT05073419|Other|Standard of Care|Routine monitoring of post AMI patient with clinic visits
76056744|NCT02011945|Drug|Nivolumab|
76056745|NCT04666909|Diagnostic Test|blood pressure|"The Welch Allyn ABPM 7100 is an easy-to-use 24-hour ambulatory blood pressure monitor that is designed to help avoid the effects of white coat hypertension, provide accurate sleep blood pressure readings, and tailor drug therapy regimes to your individual patient's needs.~This device is programmed to take three BP readings a minute apart. To be eligible, participants must have an average SBP > 135 mm Hg or DBP > 85 mmHg (based on the average of 3 BP readings); or average SBP > 130 mm Hg or DBP > 80 mm hg (for those with diabetes or kidney disease) based on JNC-7 criteria for uncontrolled HTN."
76056746|NCT02013830|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
76056747|NCT02013830|Drug|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
75593508|NCT05073419|Device|ICM Implantation|Implantation of ICM through small incision (2 mm) under the skin
75593509|NCT05064839|Procedure|Bony scintigraphy|Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
75593510|NCT05058976|Drug|Romosozumab|Monthly dose: 210 mg subcutaneous injection
75593511|NCT05058976|Drug|Placebo|Monthly saline injection
75736799|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
75736800|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
75736801|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
75736802|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
75443763|NCT01678937|Procedure|Blood Draw - Rapamycin|"Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
75736803|NCT03994354|Procedure|J-P drainage and cutaneous penrose drainage insertion|Lots of the stoma wound closure technique have been developed, including subcutaneous antibiotic material implantation, wound irrigation with iodine, closure wound with a drain tube, secondary closure, delayed primary closure and pursestring closure. But there still is in debate about best skin closure test. In Division of Colorectal Surgery Shuang Ho Hospital, two current stoma wound closure methods were subcutaneous Jackson-Pratt drainage and cutaneous penrose drainage insertion.
75736804|NCT03950856|Drug|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
75736805|NCT03950856|Drug|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
75736806|NCT00970008|Other|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
75736807|NCT00970008|Other|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
76056748|NCT02010775|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
75443764|NCT01679041|Drug|Alemtuzumab|Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen
75736808|NCT00970008|Other|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
76056749|NCT02010775|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
75443765|NCT01679041|Drug|Fludarabine|Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen
75443766|NCT01679041|Drug|Cyclophosphamide|Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
75443767|NCT01679093|Drug|ondansetron|ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
75443768|NCT01679093|Drug|Droperidol|droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
75593512|NCT05058976|Drug|Zoledronic acid|5 mg IV infusion at Month 12 Visit
75593513|NCT05058976|Dietary Supplement|Calcium and Vitamin D|Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
75593514|NCT05041647|Drug|25:1 CBD/THC|"1 dose (1 mL) of HIGH CBD~50 mg/ml CBD and 2 mg/ ml THC"
75593515|NCT05041647|Drug|5:1 CBD/THC|"1 dose (1 mL) of LOW CBD~10 mg/ml CBD and 2 mg/ ml THC"
75593516|NCT05041647|Other|Placebo|"1 dose (1 mL) of PLACEBO~No active ingredients"
75736809|NCT00970008|Other|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
75885848|NCT04674124|Behavioral|Brief Online Mindfulness Intervention|A nine-week mindfulness course compromising of 9x weekly 15 minute group sessions which will be on an online platform and daily micro meditations for participants to undertake.
75885849|NCT01340976|Drug|LY2787106|Administered IV.
75885850|NCT01340976|Dietary Supplement|Iron Supplementation|Administered orally.
75885851|NCT05089240|Device|Ophthalmic lens with extra power|
76056750|NCT01993615|Procedure|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
75443769|NCT01679093|Drug|Dexamethasone|dexametasone: 4 mg intravenous administration after the induction of anesthesia.
75443770|NCT01679210|Behavioral|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
75443771|NCT01679418|Device|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
75593517|NCT05021237|Radiation|Ultra-fractionated radiation therapy|Patients enrolled in this study are planned to receive systemic therapy. Imaging based Ultra-fractionated radiation therapy using a PULSAR technique, which is 5 pulses to gross tumor in pelvis.
75593518|NCT05014815|Drug|Ociperlimab|Ociperlimab intravenous injection
75593519|NCT05014815|Drug|Tislelizumab|Tislelizumab intravenous injection
75593520|NCT05014815|Drug|histology-based chemotherapy|Administered intravenously
75593521|NCT05014815|Drug|Placebo|Administered as an intravenous injection
75593522|NCT05012384|Other|Vergence exercises (Orthoptic exercises)|Vergence exercises as described by the Convergence Insufficiency Treatment Trials Group (CITT)
75593523|NCT05012384|Genetic|Placebo|Generic management plan with non-visual elements
75593524|NCT05003674|Device|Focused stimulation strategy|Investigational focused stimulation strategy
75593525|NCT05003674|Device|ACE stimulation strategy|Standard of care stimulation strategy
75593526|NCT05002465|Drug|68Ga-PSMA-11|Injection of 68Ga PSMA-11
75593527|NCT05002465|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
75593528|NCT04983264|Drug|GBT021601|Tablets and capsules which contain GBT021601 drug substance
75593529|NCT04970992|Drug|DZ-002|DZ-002 Injection
75736810|NCT05281146|Dietary Supplement|Chickpeas and crushed peanuts fortified biscuit|This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
76056751|NCT01993615|Procedure|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
75443772|NCT01679418|Other|No-drain after surgery|After surgery, no drain was put
75443773|NCT01679431|Diagnostic Test|Doppler-echocardiography|
75593530|NCT04966299|Dietary Supplement|Eryhtritol|"Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks~EryClot-Pilot:~Erythritol 50g dissolved in 300mL water administered once per visit"
75593531|NCT04966299|Dietary Supplement|Sucrose|Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
75593532|NCT04966299|Dietary Supplement|Glucose|Glucose 75g dissolved in 300mL water administered once per visit
75593533|NCT04966299|Dietary Supplement|Fructose|Fructose 25g dissolved in 300mL water administered once per visit
75443774|NCT01679431|Radiation|Computed tomography|
75593534|NCT04953858|Other|Social network strategy (SNS)|SNS utilizes peers to reach and recruit their network members into HIV services, therefore having the advantage that recruiters with different behavioral risks and HIV statuses are likely to have access to a wide variety of HIV at risk populations
75593535|NCT04943848|Biological|rHSC-DIPGVax|Off-the-shelf, neoantigen heat shock protein vaccine
75593536|NCT04943848|Drug|Balstilimab|BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)
75593537|NCT04943848|Drug|Zalifrelimab|ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
75593538|NCT04942860|Drug|1% Methotrexate gel|1% methotrexate gel applied onto a predefined limb
75736811|NCT05281146|Other|Cognitive stimulation for the mothers|"I. Sessions for mothers~Informing mothers about the most common causes of poor school achievement~Clarification of mother's and family roles in improving student's cognitive abilities~Defining cognitive functions needed for learning and school achievement~o Attention, perceptive reasoning, memory, problem solving, proper use of language~Identifying sensory functions necessary for the growth of cognitive functions~Explaining factors that assist in academic excellence"
75736812|NCT05281146|Other|Cognitive stimulation for students|"Activities to improve focus and visual attention~Activities to improve visual memory~Activities to improve vigilance and auditory attention~Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~Training on skills of problem-solving"
75736813|NCT00433654|Device|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
75736814|NCT00433654|Other|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
75736815|NCT00970086|Drug|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
75736816|NCT00689351|Biological|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
75736817|NCT00689351|Biological|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
75736818|NCT05448287|Behavioral|Health and family planning|Promotion of health and family planning behaviors
76056752|NCT01619059|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
75443775|NCT01679431|Other|Magnetic resonance imaging|
75443776|NCT01679431|Biological|Fasting blood sample|
75443777|NCT01679496|Other|Food items|Food items with different fatty acid composition
75443778|NCT01679587|Drug|Molidustat (BAY85-3934)|20 mg molidustat as a single tablet
75443779|NCT01679587|Drug|Placebo|Single oral dose of matching placebo will be given in each treatment arm
75443780|NCT01679743|Drug|Trastuzumab|Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
75443781|NCT01679743|Drug|GRN 1005|GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
75593539|NCT04942860|Drug|0.5% Methotrexate gel|0.5% methotrexate gel applied onto a predefined limb
75616250|NCT02846506|Drug|Canagliflozin 50 mg|Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
75736819|NCT05448287|Behavioral|Nutrition|Promotion of maternal, infant, and young child feeding behaviors and nutrition
75736820|NCT05448287|Behavioral|Agriculture and homestead food production|Promotion of knowledge and practices about homestead food production
75736821|NCT05448287|Behavioral|Water, sanitation, and hygiene|Promotion of behaviors to improve water, sanitation, and hygiene
75736822|NCT02563301|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
75885852|NCT05089006|Procedure|Partial nephrectomy with robot-assisted and open surgery|Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.
76056753|NCT01619059|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
75736823|NCT03950622|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
75593540|NCT04942535|Behavioral|Social Incentive Gamification|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Each participant signs a pre-commitment contract. Participants are entered into a game with their family members. Each family receives 70 points weekly. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family keeps its points; if not, they lose 10 points. The participant is notified the following day if they were the family rep.~At the end of the week, if the family has 40 points or more, they advance 1 level. If they have less than 40 points, the family drops down 1 level. Each family team starts in the middle of 5 levels.~At the end of the intervention, families in the top 2 levels receive a small gift.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
75593541|NCT04942535|Behavioral|Social Goals through Incentives to Charity|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Families select a charity at the beginning of the intervention. They are informed that $20 is available each week to be donated to a charity of their choice. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family gets credit for meeting their goal; if not, the entire family does not get credit. The participant is notified the following day if they were the family rep.~If the family achieves their goal on at least 4 of 7 days in a week, $20 is donated to charity.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
75736824|NCT03950622|Biological|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
75736825|NCT00746525|Other|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
75736826|NCT00746525|Other|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
75736827|NCT00746525|Other|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
75736828|NCT02563847|Dietary Supplement|0.52 g L-Tryptophan|
75736829|NCT02563847|Dietary Supplement|1.56 g L-Tryptophan|
75736830|NCT02563847|Dietary Supplement|1.56 g L-Leucine|
76056754|NCT01619059|Drug|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
76056755|NCT01619059|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
76056756|NCT04691804|Drug|Fuzuloparib , Abiraterone acetate and Prednisone|"Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po~Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po~Prednisone tablets (strength: 5 mg) 5mg, Bid po"
75443782|NCT01679977|Device|Vibrational-proprioceptive Resistance Exercise Training|
75443783|NCT01679977|Device|Neuromuscular Electrical Stimulation Training|
75443784|NCT01680094|Drug|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
75593542|NCT04942535|Behavioral|Daily Performance Feedback|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
75736831|NCT02563847|Dietary Supplement|50 g Xylitol|
75736832|NCT02563847|Dietary Supplement|75 g Erythritol|
75736833|NCT02563847|Dietary Supplement|75 g Glucose|
75736834|NCT02563847|Dietary Supplement|300 mL tap water|
75736835|NCT02563847|Other|50 mg 13C-sodium acetate|
75736836|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
75885853|NCT05088915|Behavioral|Primary Care Intervention for PTSD (PCIP)|"This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb."
75885854|NCT05088915|Behavioral|Treatment As Usual|Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
75885855|NCT05088850|Other|no intervention|no intervention
75593543|NCT04930328|Drug|Oxbryta® (voxelotor) 500-mg Tablets|Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
75885856|NCT05665959|Other|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing.
76056757|NCT04691804|Drug|Fuzuloparib Placebo， Abiraterone acetate and Prednisone|"Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po~Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po~Prednisone tablets (strength: 5 mg)5mg, Bid po"
76056758|NCT04416997|Procedure|Blood and serum samples|The blood and serum samples will taken from RA patients
76056759|NCT04176757|Drug|ZN-c5|ZN-c5 study drug to be administered orally daily
76056760|NCT02013206|Drug|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
76056761|NCT04690634|Procedure|laparoscopic sleeve gastrectomy (LSG)|Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
75593544|NCT04902820|Other|PrEPTECH website|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine [200 mg]/tenofovir disoproxil fumarate [300 mg]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
75736837|NCT00746681|Drug|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
75736838|NCT00746681|Drug|Placebo|Placebo, Oral, twice daily for 4 weeks
75736839|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
75736840|NCT00746681|Drug|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
75736841|NCT00746759|Device|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
75736842|NCT00746837|Drug|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
75736843|NCT00746837|Drug|AZD5672|50 mg od, 12 days
75736844|NCT00746837|Drug|AZD5672|150mg od, 12 days
75885858|NCT04592692|Drug|PEGylated Liposome (PEGLip)|Intravenous co-administration of PEGLip with Simoctocog alfa
75885859|NCT04558294|Drug|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
75885860|NCT04558294|Drug|Ketanserin Placebo|Mannitol capsules instead of capsules containing Ketanserin.
75885861|NCT04558294|Drug|Ketanserin|A dose of 40 mg Ketanserin will be administered.
75885862|NCT05088538|Other|Patient Education|After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
76056762|NCT04416854|Procedure|resection of primary tumor|resection of primary lesion with unresectablely metastatic colon cancer
75885863|NCT04409301|Other|My Special Aflac Duck (MSAD)|The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.
75885864|NCT04409301|Behavioral|Standard of care control|Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
75885865|NCT01680016|Biological|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
75885866|NCT01680016|Biological|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
75885867|NCT04530994|Drug|maralixibat|Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
75885868|NCT03378466|Drug|Unfractionated heparin|UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.
75885869|NCT03378466|Other|Venous thromboprophylaxis (VTE)|May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
75885870|NCT05080270|Biological|Tolerogenic Fibroblasts|administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
75593545|NCT04902820|Other|Online PrEP resource list|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
75593546|NCT04900740|Device|Catheter fixation with surgical stitch|The catheter will be fixed using the standard procedure - surgical stitch.
75593547|NCT04900740|Device|Catheter fixation with glue (cyanoacrylate tissue glue Secure PortIV)|The catheter will be fixed using the experimental procedure - novel surgical glue.
75736845|NCT00964236|Drug|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
75736846|NCT00749099|Drug|pancrelipase|"The test drug (PANCRECARB® [pancrelipase] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
75736847|NCT00749099|Drug|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
75736848|NCT00959322|Device|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
75736849|NCT00749177|Other|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
75736850|NCT00964314|Other|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done."
75885871|NCT05077540|Drug|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
75885872|NCT05077540|Drug|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
76056763|NCT04416854|Drug|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
76056764|NCT04416854|Drug|mFOLFOX6|Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
75443785|NCT01680120|Procedure|Continuous spinal anaesthesia|"Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.~Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.~Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12)."
75736851|NCT04059419|Behavioral|PARQVE Program|Two days of lectures about knee OA, come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved, participate in a group therapy session with the psychologists and sessions with the physical educators.
76056765|NCT01807923|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
76056766|NCT01807923|Drug|Ivacaftor|Film-coated tablet
75443786|NCT01680198|Drug|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
75443787|NCT01680198|Drug|placebo|
75593548|NCT04880473|Device|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
75885873|NCT03619473|Behavioral|Standard motorcycle child safety helmet|"Educational session followed by demonstration on~proper helmet wearing~how to differentiate non-standard and standard helmets~how to keep motorcycle safe using ABCD concept~importance of wearing bright clothes~police summon for not wearing helmets~live demo on poor performance of non-standard helmet~giving away standard motorcycle child safety helmets~oath taking by parents and children~distribution and placement of VEM on parents' motorcycles"
75885874|NCT05412225|Diagnostic Test|Pre-neoadjuvant radiotherapy (NART) biopsy|Participants will undergo pre-NART core biopsy guided by post-NAC MRI to the area of residual enhancement or to the previously biopsied cancer if no residual enhancement remains
75885875|NCT05412225|Radiation|Neoadjuvant radiotherapy|After biopsy, participants will undergo neoadjuvant radiotherapy/NART
75885876|NCT05412225|Procedure|Unilateral total mastectomy with axillary lymph node dissection|At 2-6 weeks after completion of NART, participants will undergo unilateral MRM (total mastectomy with axillary lymph node dissection), with resection of all involved breast skin. Skin-sparing mastectomy will not be permitted. All patients will also undergo simultaneous unilateral autologous-based breast reconstruction with DIEP, ms-TRAM, or latissimus dorsi flap.
75885877|NCT03625791|Biological|blood sample|1 tube with 4 ml of blood per patient
75885878|NCT05407545|Device|Current prosthesis|A unilateral transfemoral amputee will conduct experiments with the current prosthesis
75885879|NCT05407545|Device|Active Prosthesis (PowerKnee)|A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
76056767|NCT01807923|Drug|Placebo|Matching placebo tablet
75443788|NCT01680224|Behavioral|Healthy Weight|
75443789|NCT01680224|Behavioral|Project Health|
75443790|NCT01680224|Behavioral|Placebo Control|Participants will view a video on overweight and obesity
75443791|NCT01680289|Procedure|Three adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
75443792|NCT01680289|Procedure|Two adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
75616251|NCT02846506|Drug|Canagliflozin 100 mg|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
75443793|NCT01680315|Behavioral|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
75616252|NCT02846506|Drug|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
75885880|NCT01340898|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
75885881|NCT01340898|Biological|SynflorixTM|Intramuscular injection
75885882|NCT01340898|Biological|Infanrix-IPV/HiberixTM|Intramuscular injection
75443794|NCT01680315|Behavioral|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
76056768|NCT01966003|Drug|Carboplatin|Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
76056769|NCT01966003|Drug|Paclitaxel|Administered 200 mg/m² IV Q3W
76056770|NCT01966003|Drug|ABP 215|Administered 15 mg/kg Q3W by IV infusion
76056771|NCT01966003|Drug|Bevacizumab|Administered 15 mg/kg Q3W by IV infusion
76056772|NCT01839279|Drug|Tizanidine|
76056773|NCT01839279|Drug|Placebo|
76056774|NCT01839279|Drug|Moxifloxacin|
76056775|NCT01807299|Dietary Supplement|Omega 3|Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
76056776|NCT01807299|Other|Physical Training|
76056777|NCT01965535|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
75593549|NCT04852055|Behavioral|Advance Care Planning Video|Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
75736852|NCT04059419|Behavioral|Geriatric Care|Remain under geriatric care as usual
75736853|NCT00959400|Drug|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
75885883|NCT02426749|Device|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
75443795|NCT05597215|Radiation|Tc-99m MDP and gamma camera|Injection of radioactive element (Tc-99m MDP) then imaging with gamma camera and low dose CT (SPECT/CT)
75443796|NCT05597111|Diagnostic Test|DHA levels of blood and cervical mucus|DHA levels of blood and cervical mucus of the control and the study groups will be measure
76056778|NCT01965535|Drug|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing < 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
76056779|NCT01965535|Drug|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
76056780|NCT01965535|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
76071926|NCT03713515|Behavioral|ALTA|The study will involve each site starting with the usual care phase, followed by a period of 6 months during which practice facilitators will conduct the pre-implementation evaluation (e.g., workflow analysis, environmental scan), refine the practice facilitation strategies that will be used in the implementation phase, and train staff in the Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach (ALTA) intervention model. ALTA is an efficacious systems-level intervention designed to help patients improve their ability to take their high blood pressure medications and control their blood pressure. Practices and the Project ALTA team will work together to implement the ALTA model into routine care to improve blood pressure control and medication adherence in Latinx patients.
75443797|NCT05597072|Behavioral|Intervention|Less people within the OR but longer waiting time.
75443798|NCT05597072|Behavioral|Control|More people in the OR but shorter waiting time
75736854|NCT00970398|Other|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
75736855|NCT00970398|Other|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
75736856|NCT00959478|Behavioral|Educational Tool & Carbon Monoxide Alarm|Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
75885884|NCT02426749|Device|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
75885885|NCT03563820|Behavioral|Resilience and Well-Being Program|"The Resilience and Well-Being Program is offered through VA Puget Sound Rehabilitation Care Services as part of standard clinical care offerings. The program includes five (5) positive psychology group sessions once a week for five weeks. Participants will use strengths-based strategies, narrative strategies, and prospective strategies to learn ways to deal with stressful life challenges and improve their mental health and well-being.~Each participant will be given a brief rating sheet at the end of each session to fill out. The rating sheet will ask participants to rate different aspects of the session (e.g., how helpful or interesting the session was to the participant), if home practice activities were assigned, whether the participant completed the home practice assignment, as well as feedback to improve that session."
75443799|NCT05596981|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
75443800|NCT05596968|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
75593550|NCT04836182|Drug|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
75593551|NCT04836182|Drug|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
75736857|NCT03937908|Drug|2g Centella asiatica water extract product|2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
75736858|NCT03937908|Drug|4g Centella asiatica water extract product|4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
75885886|NCT05328492|Device|iVAPS-AE|Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
75443801|NCT05596942|Dietary Supplement|Albumin Channa Striata Extract|This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.
75885887|NCT05328492|Device|ST-mode|Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
75885888|NCT03097315|Drug|4 mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints
75593552|NCT04788511|Drug|Semaglutide|"Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks."
75736859|NCT00964470|Device|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
75885889|NCT05530707|Other|Moisturizer containing saccharide isomerate and niacinamide|Moisturizer containing saccharide isomerate and niacinamide
76056781|NCT04659577|Behavioral|ICBT for panic and depression|The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks. As for depression, the most known type of CBT for treating depression consists of two major strategies: cognitive restructuring, the relationship between thoughts and feelings, behavioural activation, sleep hygiene and relaxation. Each ICBT program includes six modules, containing psychoeducation, cognitive restructuring exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress
76056782|NCT01964755|Drug|Doxorubicin|Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
75443802|NCT05596890|Drug|Paclitaxel-albumin|260mg/m2, ivdrip, d1
75593553|NCT04788511|Drug|Placebo (semaglutide)|"Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks."
75593554|NCT04781673|Drug|Ketamine|Will receive titratable infusion.
75593555|NCT04781673|Drug|Lidocaine|Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
75593556|NCT04750642|Device|CI632D|CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells (CI632D)
75593557|NCT04750642|Device|CI632|CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
75443803|NCT05596890|Drug|Cisplatin|60mg/m2, ivdrip, d1
75443804|NCT05596890|Drug|Carboplatin|AUC=4-6, ivdrip, d1
75443805|NCT05596890|Drug|Tislelizumab|200mg, ivdrip, d1
75593558|NCT04749667|Other|MSCs|Autologous bone-marrow derived mesenchymal stem cells
75593559|NCT04749667|Drug|Saline|Isotonic saline
75736860|NCT00689273|Drug|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
75593560|NCT04724291|Device|MAGNET|This study will test the accuracy of a single-use ingestible video capsule (NaviCamTM, AnX Robotica) which is remotely controlled to record images of the inside of your stomach. Participants in this research study will have symptoms for which an evaluation by a traditional tube-based endoscopy (EGD) is indicated.
75593561|NCT04715386|Drug|StrataXRT|Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.
75736861|NCT00689273|Drug|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
75736862|NCT00959556|Other|laboratory biomarker analysis|
75736863|NCT00959634|Drug|ABT-126|Dose administered twice daily on Study Days 1-10
75736864|NCT00959634|Drug|Placebo|Dose administered twice daily on Study Days 1-10
75736865|NCT00970554|Other|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
75736866|NCT00970554|Other|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
75736867|NCT00959790|Dietary Supplement|Vegetables|200 or 50 grams of vegetables daily for four weeks
75885890|NCT05376475|Device|Infrared video-audio camera|Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA
75885891|NCT05376475|Device|Level III home sleep apnea test|NightOwl® by Ectosense, Leuven, Belgium
75885892|NCT05376475|Device|Maternal-fetal transabdominal electrocardiographic heart rate monitor|The Monica AN24 Antenatal Fetal Holter by Monica Healthcare, Nottingham, UK
75885893|NCT05376475|Device|Pressure sensing mat|Tactilus® V Series Mattress Pressure Monitoring System by Sensor Products Inc., Madison, USA
76056783|NCT01964755|Drug|Methotrexate|Methotrexate administered starting on Day 2, per study protocol.
76056784|NCT01964755|Drug|Leucovorin|Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
75885894|NCT05372731|Other|Recruitment Maneuver|RM after BAL
75885895|NCT03518671|Behavioral|cognitive behavioral therapy, face to face|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method
75885896|NCT03518671|Behavioral|cognitive behavioral therapy, telemedicine|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
75885897|NCT03039699|Drug|Ergoferon|
75885898|NCT03039699|Drug|Placebo|
75736868|NCT00959790|Dietary Supplement|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
75885899|NCT02003443|Behavioral|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
75885900|NCT02833974|Drug|GSK2245035 Nasal Spray Solution|GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
75443806|NCT05596890|Radiation|VMAT or IMRT|15Gy/5F (d43-d50, d57-d64), 5 times a week
75443807|NCT05596890|Procedure|Esophagectomy|Minimally-invasive or open McKeown and Ivor-Lewis esophagectomy
75593562|NCT04713683|Device|Percutaneous Patent Foramen Ovale Closure|Patients with well-documented embolic stroke of unknown source (ESUS) and a patent foramen ovale (PFO) are indicated for percutaneous closure of PFO. The intervention is performed through the right femoral vein. The interventional cardiologist introduces the sheath and advances the device via inferior vena cava to right atrium. Then, the catheter is passed through the PFO, the device is deployed and the occlusion is achieved. The procedure is performed under fluoroscopy guidance with or without transesophageal echocardiography guidance.
75736869|NCT04059575|Other|Kinesio Taping (Performance Plus)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
75736870|NCT04059575|Other|Kinesio taping (Gold Tex)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
75736871|NCT00964626|Drug|cisplatin|
75885901|NCT02833974|Drug|Placebo Nasal Spray Solution|Nasal Spray Solution as for GSK2245035 without active ingredient.
75885902|NCT03632005|Device|Vacuum Assisted Closure|Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.
75885903|NCT03632005|Other|Sterile dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
75593563|NCT04701203|Combination Product|TransCon PTH|TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
75593564|NCT04701203|Combination Product|Placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
75593565|NCT04691323|Other|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
75593566|NCT04688411|Behavioral|MED-Go App|A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
75736872|NCT00964626|Drug|paclitaxel|
75443808|NCT05596864|Diagnostic Test|gastric contrast ultrasound|"Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.~In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed."
75443809|NCT05596812|Other|New Care Pathway|The New Care Pathway will include continuation of lifestyle and dietary modification, self-blood glucose monitoring, and routine prenatal care.
75443810|NCT05596669|Drug|Ketamine|to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
75443811|NCT05596643|Diagnostic Test|Composite Autonomic Symptom Score-31|Standardized questionnaire to determine the level of autonomic dysfunction
75885904|NCT05303493|Biological|Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI|Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma
75885905|NCT03093415|Drug|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
75736873|NCT02562209|Dietary Supplement|PACER Diet|Pacer diet to be followed for 8 weeks
75736874|NCT02562209|Other|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
75736875|NCT00749333|Drug|AZD8566|solution. Specific dose will be selected by the safety review committee
75736876|NCT00749333|Drug|Placebo|Single 10ml oral solution.
75736877|NCT02562287|Drug|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
75736878|NCT02562287|Drug|Risperidone|Risperidone, in a flexible dosage
75885906|NCT04145817|Genetic|BRIDGES gene panel testing|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
75885907|NCT04145817|Genetic|Breast cancer risk polygenic risk score (PRS)|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
75443812|NCT05596643|Diagnostic Test|r-r interval variability with normal breathing|electrophysiological test to detect parasympathetic dysfunction
75443813|NCT05596643|Diagnostic Test|r-r interval variability with deep breathing|electrophysiological test to detect parasympathetic dysfunction
75443814|NCT05596643|Diagnostic Test|Valsalva ratio|electrophysiological test to detect parasympathetic dysfunction
75593567|NCT04670471|Drug|Remimazolam|Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.
75443815|NCT05596643|Diagnostic Test|30:15 ratio|electrophysiological test to detect parasympathetic dysfunction
75443816|NCT05596643|Diagnostic Test|sympathetic skin response|electrophysiological test to detect sympathetic dysfunction
75443817|NCT05596643|Diagnostic Test|blood pressure response to standing|clinical test to detect sympathetic dysfunction
75443818|NCT05596643|Diagnostic Test|blood pressure response to sustained handgrip test|clinical test to detect sympathetic dysfunction
75443819|NCT05596643|Other|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
75593568|NCT04670471|Drug|Remifentanil|Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.
75443820|NCT05596643|Diagnostic Test|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
75443821|NCT05596643|Other|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
75593569|NCT04652804|Behavioral|Low intensity HCV treatment adherence support|A 28-day supply of medication will be dispensed to participants at entry, 4 weeks, and 8 weeks. Participants will receive standard adherence counseling at entry and every refill pickup/home or field delivery. Participants will have access to all of the services available at the ICC including facilitated linkage to referrals as needed. Site staff will routinely track clients who miss refill appointments in real-time using standard tracking measurements
75616253|NCT02846428|Drug|5-Fluorouracil|5-FU will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
75616254|NCT02846428|Drug|Capecitabine|Capecitabine will be administered at 900 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
75736879|NCT02562287|Drug|Olanzapine|Olanzapine, flexible dosage
75736880|NCT02562287|Drug|Quetiapine|Quetiapine, flexible dosage
75736881|NCT02562053|Drug|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
75736882|NCT02562053|Drug|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
75736883|NCT02562053|Drug|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
75736884|NCT02562053|Drug|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
75443822|NCT05596643|Other|Jenkins Sleep Evaluation Scale|Standardized questionnaire to investigate the sleep quality and disturbance
75443823|NCT05596643|Other|The Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue severity
75736885|NCT00746915|Device|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
75736886|NCT02563223|Other|Parabolic flight|
75736887|NCT02563223|Device|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
75736888|NCT00746993|Other|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
75736889|NCT04060433|Behavioral|Family Therapy|Swedish version of the evidence based manualized Family Therapy
75443824|NCT05596617|Drug|Oral bedtime melatonin|Different doses of oral bedtime melatonin
75885908|NCT04145817|Behavioral|Questionnaires|Self-administered questionnaires for counselees to evaluate Psychosocial Aspects of Hereditary Cancer (PAHC), Breast Cancer risk perception adequacy, risk communication within the family and cancer risk management choice,
75885909|NCT05470257|Other|Cast|Application of fiberglass long arm cast.
75885910|NCT01358526|Drug|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
75885911|NCT01358526|Drug|Placebo|Placebo tablets to match OXN taken orally every 12 hours
75885912|NCT03564054|Procedure|Photodynamic Therapy|Participants on this arm will be treated with photodynamic therapy. PDT is a two-stage process. The first stage of PDT is the intravenous injection of porfimer sodium (Photofrin) administered as a single slow intravenous injection over 3 to 5 minutes. The second stage involves the application of laser light to the tumor by bronchoscopy.
75885913|NCT03564054|Procedure|Argon Plasma Coagulation|"Participants on this arm will be treated with argon plasma coagulation. A flexible probe housing a wire delivers high-frequency, high-voltage electric current to a monopolar tungsten electrode present at the tip of the probe. Argon gas flows through the probe, and is charged or ionized to produce plasma as it flows around the tungsten electrode. Electric current flows through the plasma to the nearest tissue, and heat is produced as it passes through the tissue. Increased resistance created by coagulated tissue impairs the flow of electric current, and keeps the ablation depth to 1 to 2 mm."
75885914|NCT02156232|Procedure|TIPS|TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
75885915|NCT02156232|Procedure|SPSS embolization|Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
76056785|NCT01964755|Biological|Hydroxyurea|Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
76056786|NCT01964755|Drug|Zidovudine|Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
76056787|NCT01964755|Drug|Rituximab|Rituximab is optional and will be administered to study participants, per study protocol.
76056788|NCT01964521|Device|Mepilex Transfer Ag|A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
76056789|NCT04416295|Device|LifePod|LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.
76056790|NCT01991743|Drug|Group 2.5|Administration of bupivacaine 2.5 mg.
76056791|NCT01991743|Drug|Group 5|Administration of 5 mg bupivacaine
76056792|NCT01991743|Drug|Group 7.5|Administration of 7.5 mg bupivacaine
75443825|NCT05596604|Other|survey- no intervention|survey- no intervention
75443826|NCT05596565|Other|Supervised Exercise by a physiotherapist via face to face|"Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference"
76056793|NCT01991743|Drug|Group 10|Administration of 10mg bupivacaine.
75443827|NCT05596552|Drug|hyperbaric bupivacaine and dexmedetomidine|In a 3 ml syringe, 5 µg dexmedetomidine was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
75443828|NCT05596552|Drug|Bupivacaine-Fentanyl group|In a 3 ml syringe, 25 μg fentanyl was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
76056794|NCT01991197|Drug|Sitagliptin|"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
76056795|NCT01991197|Drug|Gliclazide|"Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
76056796|NCT01991197|Drug|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
75736890|NCT04060043|Drug|Goserelin Acetate|The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
76056797|NCT01991197|Drug|Gliclazide matched placebo capsule|"Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
76056798|NCT01990573|Drug|0.3mg/kg IV methadone HCl|Group I will receive 0.3mg/kg IV methadone HCl
76056799|NCT01990573|Drug|0.4mg/kg IV methadon HCl|Group II will receive 0.4mg/kg IV methadone HCl.
76056800|NCT01990573|Other|control no methadone|The control group will not receive methadone.
76056801|NCT01990495|Other|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
76056802|NCT01990495|Other|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
76056803|NCT01990339|Drug|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
76056804|NCT02007577|Drug|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
76056805|NCT02007577|Drug|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
76056806|NCT01990261|Drug|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
76056807|NCT04658095|Device|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System
76056808|NCT04658095|Device|iStent inject|Ab-interno implantation of iStent inject (2 microstents)
75443829|NCT05596539|Other|Data collection|Collection data from diagnostic Data collected following to medical exam as part of care
75443830|NCT05596526|Biological|recombinant zoster vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
75736891|NCT00553358|Drug|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
75736892|NCT00553358|Biological|Trastuzumab|Therapeutic Monoclonal Antibody
76056809|NCT04658095|Device|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System
76056810|NCT01963117|Radiation|Combined hyperthermia and radiation therapy|
76056811|NCT02006719|Biological|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
75443831|NCT05596500|Dietary Supplement|Blueberry-protein gel|Sport gel with blueberry extract and plant protein.
75443832|NCT05596500|Dietary Supplement|Blueberry gel|Sport gel with blueberry extract only.
75443833|NCT05596500|Dietary Supplement|Placebo|Sport gel without the blueberry extract polyphenols and without protein.
75443834|NCT05596487|Other|repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.
75443835|NCT05596448|Procedure|Coccygeal nerve radiofrequency ablation|During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
75443836|NCT05596435|Other|No intervention|No intervention
75443837|NCT05596396|Behavioral|LifeHack|Participants assigned to LifeHack will follow a six week-guided online intervention with a fixed structure where the themes are delivered in a predefined order, and the contents get unlocked sequentially. The first mandatory module is the introduction module which also functions as a goal-setting module. Following this, students complete one mandatory module per week (and the optional modules if they choose to do so) delivered sequentially, starting with the theme of mood, studies, social life and finally, self-esteem. Students complete the themes one by one and the consecutive themes (and modules) are unlocked only after completing the main module of the assigned theme.
75616255|NCT02846428|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
75616256|NCT02846428|Drug|Docetaxel|Docetaxel will be administered at 100 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
75616257|NCT02846428|Drug|Epirubicin|Epirubicin will be administered at 100 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
75736893|NCT00553358|Drug|Paclitaxel|antimicrotubule agent
75736894|NCT00744809|Drug|TMC278; Moxifloxacin; Efavirenz|
75736895|NCT00688259|Behavioral|Supportive Therapy (ST)|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
75736896|NCT00688259|Behavioral|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
76056812|NCT02006719|Other|Placebo|Placebo injection
76056813|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
76056814|NCT01962493|Other|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
76056815|NCT01962493|Drug|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
76056816|NCT01989169|Drug|Midazolam|
75736897|NCT00749489|Procedure|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
75443838|NCT05596396|Behavioral|LifeHack-C|Participants assigned to LifeHack-C will receive the same guided online intervention, but they can choose what theme they would like to start with, when to work on it and how many modules they wish to complete. After completing the introduction module, the participants will be advised to complete two modules per week and at least four in total. Therefore, the program's duration will be approximately two and six weeks. However, participants can follow the program at their own pace.
75736898|NCT00744887|Drug|Darunavir|
75736899|NCT04059029|Procedure|Bariatric surgery|During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance.
75593570|NCT04652804|Behavioral|Medium intensity HCV treatment adherence support|The medium intensity intervention will include standard of care dispensation of a 28-day supply of medication at entry, 4 weeks and 8 weeks. Participants will be assigned to a patient navigator (PN) and receive tailored patient navigation support for medication reminders, picking up medication refills (or home or field delivery of study medications), overcoming barriers as well as service linkage. Participant will be contacted by the PN at least once every two weeks.
75593571|NCT04652804|Behavioral|High intensity HCV treatment adherence support|The high intensity intervention will involve patient-centered DOT with flexibility in terms of the frequency of pickup and the site of DOT (ICC, field-based) with a minimum of at least 1 observed dose per week. Participants in this arm will also receive PN support for overcoming barriers and service linkage similar to participants in Arm 2. The main differences between Arms 2 and 3 are: (i) medications will not be dispensed for more than one week at a time (to coincide with opioid agonist therapy (OAT) dosing, where applicable); and (ii) ≥1 dose/week will be observed.
75593572|NCT04620213|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
75593573|NCT04620213|Other|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
75736900|NCT02286830|Drug|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
75736901|NCT00688181|Device|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
75443839|NCT05596305|Behavioral|educational psychiatry intervention|educational anti-stigma intervention related to psychiatric illness composed of a lecture, video, role models play, and open discussion
75443840|NCT05596279|Diagnostic Test|Intravascular ultrasound|Hybrid IVUS-OCT and control IVUS were performed after stenting
75443841|NCT05596279|Diagnostic Test|Optical coherence tomography|Hybrid IVUS-OCT and control OCT were performed after stenting
75443842|NCT05596266|Biological|CD5 CAR-T|CD5 CAR-T will be administered by I.V. infusion.
75443843|NCT05596227|Drug|Propofol|Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
75443844|NCT05596227|Drug|Fentanyl|Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)
75443845|NCT05596227|Drug|Rocuronium|Rocuronium will be injected during induction of anesthesia (0.6 mg/ kg)
75736902|NCT02563535|Device|DEB|angioplasty with Litos drug eluting balloon
75736903|NCT02563535|Device|PTA|angioplasty with conventional balloon
76056817|NCT01989169|Drug|SSP-004184SS|
75443846|NCT05596227|Drug|Sevoflurane|Sevoflurane inhalationa anesthesia will be used for maintainance of anesthesia
75736904|NCT00749567|Drug|Erlotinib|Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
76056818|NCT01988779|Drug|oral levofloxacin|
76056819|NCT01988779|Drug|nebulized levofloxacin|
76056820|NCT01988233|Behavioral|BAILAMOS© Dance Program|
75593574|NCT04615273|Drug|Lonapegsomatropin|Due to the different hGH dose requirements, depending on subject's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
75736905|NCT00749567|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
75736906|NCT04010942|Drug|Vit D|Injection
75736907|NCT04010942|Drug|Metformin|tablets
75736908|NCT04010942|Drug|Clomiphene|Tablet
75736909|NCT00749645|Drug|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
75593575|NCT04615273|Other|Placebo|The placebo for lonapegsomatropin drug product will contain the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution will be administered by SC injection via syringe and needle. Due to the different hGH dose requirements, depending on subject's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo will receive the same dose volume as if they would have been randomized to once-weekly lonapegsomatropin.
75593576|NCT04615273|Drug|Somatropin|Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on subject's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
75593577|NCT04608955|Drug|WX-081|WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
75593578|NCT04608955|Drug|Bedaquiline|This licensed drug will be used in arm F as positive comparator.
75593579|NCT04608955|Drug|Standard treatment|Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
75736910|NCT00749645|Drug|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
75736911|NCT00949364|Drug|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
75736912|NCT01634048|Dietary Supplement|High Protein, low calorie meal replacement|The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
75736913|NCT00689117|Drug|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
75736914|NCT00689117|Drug|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
75736915|NCT00689117|Drug|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
75736916|NCT00689117|Drug|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
75885916|NCT03563898|Other|Sweating with Portable Sauna Bath|Patients will be subjected daily for 30 minutes to the Portable Sauna Care steam bath (45 degree C temperature). The patient will decide if the time and / or temperature of the Sauna Bath is reduced to Tolerance. Before being subjected to the sauna bath, blood pressure will be taken 10 minutes prior. Weigh the patient with a Scale. You will be informed of the symptoms that may occur during the bath, and if present, you will let the health staff know that you will be present at all times during the bathing period, which will have a SURVEILLANCE TABLE which It will be filled during the intervention where they are monitored and comply with the stipulated norms as well as notes for adverse effects. After the completion of the bath, there will be a space of 15 minutes for the patient to dry the skin and the bathing suit with a towel. After 15 minutes, the patient will be weighed and the blood pressure will be taken again.
75593580|NCT04608955|Drug|Multi-drug background treatment (MBT)|MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
75593581|NCT04607421|Drug|Encorafenib|75 mg capsules
75736917|NCT00949442|Drug|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
75736918|NCT00949442|Drug|Glimepiride|tablets of 1 and 2 mg
75736919|NCT00949442|Drug|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
75736920|NCT00749723|Drug|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
75736921|NCT00749723|Drug|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
75736922|NCT00749723|Drug|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
75736923|NCT00749723|Drug|thiotepa, carboplatin, etoposide|high dose chemotherapy followed by to autologous stem cell transplantation
75736924|NCT00749723|Drug|temozolomide, thiotepa|high dose chemotherapy followed by autologous stem cell transplantation
75736925|NCT00749723|Procedure|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
75736926|NCT00749723|Drug|intraventricular etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (>3m to <3y 0.7 mg; >3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
75443847|NCT05596227|Other|Erector spinae plane block|In the ESPB group, the probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe will move 3 cm laterally from the midline. The erector spinae muscle will be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution was injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered.
75443848|NCT05596227|Other|Thoracolumbar interfascial plane block|In the mTLIP group, the probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probe will move laterally to identify the longissimus and iliocostalis muscles. The needle will be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered.
75443849|NCT05596149|Other|Toothpaste without fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste without fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
75593582|NCT04607421|Drug|Cetuximab|Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
75593583|NCT04607421|Drug|Oxaliplatin|Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
75593584|NCT04607421|Drug|Irinotecan|Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
75593585|NCT04607421|Drug|Leucovorin|Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
75593586|NCT04607421|Drug|5-FU|Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
75593587|NCT04607421|Drug|Capecitabine|150 mg or 500 mg Tablet
75736927|NCT00749723|Drug|trofosfamide, etoposide|maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
75736928|NCT00958490|Other|Walking program|4 week physical activity walking program
75736929|NCT00949520|Other|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
75736930|NCT00949520|Other|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
75736931|NCT00749801|Drug|Nattokinase|2 capsules in the morning and before bed-time daily
75736932|NCT00958646|Other|Osteopathic Manipulation|Standardized rib raising protocol
75736933|NCT00958646|Other|Placebo|Light touch control procedure
75736934|NCT02561975|Other|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~Alveolar volume (VA)~Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
75736935|NCT00958802|Other|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
75736936|NCT00958802|Other|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
75736937|NCT00547248|Biological|Synflorix|Intramuscular injection, 1 dose
75593588|NCT04607421|Drug|Bevacizumab|Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
75593589|NCT04595682|Drug|Placebo|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
75616258|NCT03568084|Other|MEFAP|multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
75885917|NCT01310010|Drug|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
75885918|NCT02830776|Drug|bimatoprost 0.03% ophthalmic solution|Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
75885919|NCT03039621|Drug|Ergoferon|For oral use.
75885920|NCT03039621|Drug|Placebo|For oral use.
75885921|NCT01235130|Drug|OMEGA-3|600mg, 2 caps, twice a day
75885922|NCT01235130|Drug|Placebo soybean oil|600mg, 2caps twice a day
75885923|NCT05708118|Diagnostic Test|Echocardiographic assessment.|Patients will be contacted to carry out an echocardiography at least 90 days after surgery. Measurements will be taken for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta. Aortic valve will be assessed as well.
75443850|NCT05596149|Other|Toothpaste with sodium fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
75443851|NCT05596149|Other|Toothpaste with sodium monofluorophosphate|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium monofluorophosphate and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
75593590|NCT04595682|Drug|Alcohol|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
75593591|NCT04593277|Other|Internet Mobile Technology|Use INSPIRE mobile application
75593592|NCT04593277|Other|Internet-Based Intervention|Access to a study-specific control website
75593593|NCT04593277|Other|Questionnaire Administration|Ancillary studies
75593594|NCT04593277|Procedure|Supportive Care|Receive telehealth stepped care
75593595|NCT04593277|Other|Informational Intervention|Receive printed SCP materials
75593596|NCT04588116|Behavioral|Strategies Empowering activities in Everyday life (SEE 1.0)|"The patients are provided a person-centered activity-based intervention on the web aiming at facilitating the level of engagement in a variety of activities, at different places in society, together with other people to support an active life. In the long-term, the change to an active life will be reflected in a healthy and balanced pattern of activities.~The program provide the patients with tools to see their activities in everyday life in a new light and, also, tools to identify activity-based strategies that can empower them to take an active role to prevent and overcome challenging situations in everyday life."
75593597|NCT04587024|Other|mHealth intervention|Subjects will receive mHealth direct observation of therapy for 12 weeks
75593598|NCT04587024|Other|standard of care|Subjects will receive standard of care observation for 12 weeks
75593599|NCT04559893|Behavioral|Collaborative Care|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In our model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care.
75593600|NCT04546633|Drug|KAF156|Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
75593601|NCT04546633|Drug|LUM-SDF|Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
75736938|NCT00547248|Biological|Tritanrix-HepB|Intramuscular injection, 1 dose
75736939|NCT00547248|Biological|Hiberix|Reconstituted with Tritanrix-Hep B before injection
75736940|NCT00547248|Biological|Polio Sabin|Oral, 1 dose
75736941|NCT00547248|Biological|Poliorix|Intramuscular injection, 1 dose
76056821|NCT01988233|Behavioral|Health Education Control Group|
75593602|NCT04546633|Drug|Coartem|Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
75736942|NCT00547248|Biological|Prevenar (Wyeth)|Intramuscular injection, 1 dose
75593603|NCT04512144|Behavioral|Headspace Smartphone Application|Headspace is a smartphone application used for mindfulness, meditation, and stress reduction. It has been utilized in other behavioral and quality of life studies.
75736943|NCT02562833|Device|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
75736944|NCT02562833|Device|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
76056822|NCT01987765|Drug|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
76056823|NCT01987609|Drug|Hylenex|
75736945|NCT05351060|Other|Custom Fabricated Splint|Participants will wear a customized splint on their affected hand(s)during the hours of sleep for the duration of the study.
75736946|NCT05350982|Device|SalivaBio +/- SaliPac|Sterile collection swab (SalivaBio), Modified dummy (SaliPac)
75736947|NCT00688103|Drug|ETN Alone|etanercept (25 mg, twice/week, s.c.)
76056824|NCT01987609|Drug|Normal Saline|
75736948|NCT00688103|Drug|ETN+MTX|etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
75443852|NCT05596149|Other|Toothpaste with amine fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with amine fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
75593604|NCT04476173|Drug|Methoxyflurane - Penthrox|ACS patients who received inhaled methoxyflurane as analgesic treatment
75593605|NCT04476173|Drug|Morphine|ACS patients who received intravenous morphine as analgesic treatment
75593606|NCT04475328|Drug|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
75736949|NCT00949598|Drug|letrozole|Given orally
75736950|NCT00949598|Drug|tamoxifen citrate|Given orally
75736951|NCT02562911|Procedure|Data collection|"Clinical examination~Complete pelvic ultrasound abdominal ultrasound~Bone age: X-ray~biological examination~Lung function assessed by the Maximum Volume Expired~Brasfield radiological score (if available)"
75736952|NCT00964704|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
75736953|NCT00964704|Drug|capecitabine [Xeloda]|added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
75736954|NCT00964704|Drug|docetaxel|background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
75736955|NCT00964704|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
75736956|NCT00747071|Drug|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
75736957|NCT05350670|Behavioral|Perineal massage and cold compress|Using perineal massage and cold compress during the second stage of labor to observe the effect
75736958|NCT00970710|Behavioral|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
75736959|NCT00958958|Other|multifaceted strategy|"There are multifaceted Interventions Including~Distribution of educational materials: distribution of published or printed recommendations for clinical care.~Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used~Reminders~Practical training"
75736960|NCT00959868|Drug|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
75736961|NCT00686855|Drug|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
75736962|NCT00686855|Drug|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
75736963|NCT00949754|Drug|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
75736964|NCT00960024|Behavioral|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
75736965|NCT00960024|Behavioral|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
75885924|NCT05708118|Diagnostic Test|Computed-tomography assessment|All enrolled patients will undergo a multislice CT scan (retrospectively ECG-gated, whenever possible) with standard contrast medium injection protocol of nonionic contrast agent. All post-surgery controls will be performed at least 90 days after surgery. All CT datasets will be analysed on a dedicated workstation for the qualitative and quantitative assessment of the aortic root including measurements for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta.
75885925|NCT05708196|Other|Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).|After tooth extraction, the tooth socket will begrafted with Alloplast grafting material
75443853|NCT05596136|Diagnostic Test|Artery Alert|A device for the measurement of the protein of interest that can be administered in a physician's office without requiring any capital equipment
75443854|NCT05596097|Drug|Zanubrutinib|Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days
75443855|NCT05596071|Drug|Sufentanil Citrate|Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
75593607|NCT04475328|Drug|Placebo of AngongNiuhuang pill|This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
75593608|NCT04475328|Other|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke
75593609|NCT04467723|Drug|Atezolizumab|Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30
75593610|NCT04466579|Other|BIS monitor|BIS monitor is used to control and monitor the depth of general anesthesia.
75593611|NCT04466579|Other|Standard care|Standard anesthesiology care according to the protocol of the study
75885926|NCT05708196|Other|Allograft bone grafting material.|After tooth extraction, the tooth socket will be grafted with allograft grafting material
76056825|NCT04657159|Other|Pain rehabilitation program|Effect on health related quality of life och health-care consumption after rehabilitation
75736966|NCT00745043|Drug|bronchodilator response|
75736967|NCT00949832|Dietary Supplement|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
75736968|NCT00949832|Dietary Supplement|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
75736969|NCT00949832|Dietary Supplement|Vitamin D2|50,000 IU given orally once
75885927|NCT03563664|Procedure|Pre-treatment endometrial biopsy|Timed suction endometrial biopsy was obtained from participants via Wallach Endocell® 908014A endometrial cell sampler timed during the implantation window of the pretreatment cycle; followed by immunohistochemical staining using immunoperoxidase staining incorporating avidin-biotin complex (ABC) method.
75736970|NCT00949832|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 IU given orally once
75736971|NCT00970788|Behavioral|Video intervention|Video of goals of care
75885928|NCT03563664|Drug|Danazol|Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks.
75736972|NCT00745199|Drug|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
75885929|NCT03563664|Procedure|Post-treatment endometrial biopsy|Post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment, timed, processed and stained as described previously.
75885930|NCT03041181|Drug|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
75885931|NCT03041181|Drug|Nivolumab|Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)
75885932|NCT03041181|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
75443856|NCT05596071|Drug|Ropivacaine 0.75% Injectable Solution|Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
75593612|NCT04464070|Dietary Supplement|niacin|induce biosynthesis of PGD2
75736973|NCT00745199|Drug|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
75443857|NCT05596071|Procedure|Epidural catheter|Intraoperative and postoperative analgesia
75593613|NCT04464070|Drug|aspirin|inhibition of cyclooxygenase
75593614|NCT04464070|Other|PGD2|labeled precursor
75736974|NCT00961844|Biological|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
75736975|NCT00961844|Drug|Temozolomide|
75736976|NCT00959426|Drug|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
76071927|NCT03704948|Behavioral|RCT Treatment -Listening Visits delivered by NICU nurse in person|6 sessions, approximately one hour in length, delivered by a nurse who uses empathic listening and problem solving.
75443858|NCT05595928|Other|position|To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.
75443859|NCT05595824|Drug|Molnupiravir (Esperavir)|Capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days
75443860|NCT05595824|Drug|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines'(Version 14 of 27.12.2021), or inforce at the time of the study
75593615|NCT04462536|Drug|Placebo|Vehicle only
75593616|NCT04462536|Drug|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
75736977|NCT00959426|Drug|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
75885933|NCT03041181|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
75593617|NCT04459234|Drug|Ketamine use in CLCC sites (indication and administration protocol)|"Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription):~Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain~Administration protocol: route, posology, duration, administration sequence, premedication~Antalgic efficacy~Tolerance profile~Quality of life, anxiety and depression evaluations"
75593618|NCT04444479|Other|ECG verification|The correct positioning of the PICC catheter tip will be verified using ECG.
75593619|NCT04444479|Other|X-ray verification|The correct positioning of the PICC catheter tip will be verified using X-ray imaging.
75736978|NCT05328050|Other|Registry|observational, data collection
75885934|NCT02828436|Device|Precision Spectra System|Spinal Cord Stimulation
75885935|NCT02828436|Behavioral|Exercise Intervention|Standard Exercise
75885936|NCT05278221|Device|Software EstimLT|Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested
75885937|NCT05369247|Other|High intensity Interval Training|HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., > 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).
75885938|NCT05369247|Other|Moderate Intensity Continuous Training|The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).
75885939|NCT04059159|Device|Connected Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
75885940|NCT05342103|Procedure|high flow oxygenation|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
75736979|NCT05297162|Diagnostic Test|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"The prostate profile and ROIs will be drawn on PSMA PET and mpMRI and fused in real time with the TRUS image stack during biopsy. Biopsies, transrectal or transperineal according to lesion site, will be performed with patients in the dorsal lithotomy position, under antibiotic prophylaxis and local anesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz).~Biopsy cores will be numbered according to ROI number and topography. Specimens will be processed and evaluated by a genitourinary pathologist. Tumor foci will be quantified and graded according to the ISUP consensus conference on Gleason grading."
75885941|NCT05323071|Other|Sucrose 24%|"According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, >37 weeks : 1 mL"
75736980|NCT00686777|Biological|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
75443861|NCT05595759|Other|Violence against women education supported by creative drama|Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.
75443862|NCT05595759|Other|Routine service operation|No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.
75443863|NCT05595733|Device|Ventilator mode|Neurally Adjusted Ventilatory Assist (NAVA) mode is a new mode of ventilator, using electronic potential of diaphragm to adjust tidal volume. At the same time, this mode can trigger and cycle-off inspiratory time by high sensitivity of electronic potential of diaphragm, increase patient-ventilator synchrony, reduce sedative drug, improve oxygenation, shorten mechanical ventilation day and reduce the rate of diaphragm atrophy. It can improve survival rate and hospital day of patients. Both the animal and human experiment have the effect of lung and diaphragm protection.
75736981|NCT00686777|Drug|Ribavirin|Ribavirin 400 mg/day orally
75736982|NCT04009772|Drug|Cefepime|Antibiotic prophylaxis
75443864|NCT05595590|Drug|Tislelizumab|Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W)
75593620|NCT04441138|Drug|Durvalumab|Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
75593621|NCT04440189|Device|GID SVF-2 Device System|The GID SVF-2 Device System is used for harvesting, filtering, separating and concentrating autologous stromal vascular fraction from adipose tissue.
75736983|NCT04009772|Drug|Cefuroxime plus Metronidazole|Antibiotic prophylaxis
75736984|NCT00961922|Other|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
75736985|NCT00961922|Other|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
75736986|NCT00959582|Procedure|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
75736987|NCT00962156|Drug|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
75736988|NCT00962156|Drug|Ringers acetate|Infusion for volume expansion in the ICU
75736989|NCT00959738|Procedure|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
75736990|NCT00959738|Procedure|diverting loop ileostomy without rod|diverting loop ileostomy without rod
75736991|NCT00686699|Drug|Preladenant|capsules
75736992|NCT00686699|Drug|Placebo|capsules
75736993|NCT00959816|Drug|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
75736994|NCT01563068|Drug|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
75736995|NCT00747305|Drug|sunitinib malate|
75443865|NCT05595590|Radiation|Pulse radiation|66-70Gy/33-35Fx, 2Gy/Fx.
75593622|NCT04428177|Device|Intravascular lithotripsy|Intravascular lithotripsy uses sonic pressure waves to disrupt calcium with minimal impact to soft tissue of coronary vessel
75593623|NCT04428177|Device|Standart therapy|conventional preparation of calcified lesion: non-compliant, cutting or scoring ballons predilatation or rotational atherectomy
75736996|NCT00747305|Genetic|gene expression analysis|
75736997|NCT00747305|Genetic|reverse transcriptase-polymerase chain reaction|
75736998|NCT00747305|Genetic|western blotting|
75736999|NCT00747305|Other|immunohistochemistry staining method|
75737000|NCT00747305|Other|laboratory biomarker analysis|
75737001|NCT00747305|Procedure|adjuvant therapy|
75737002|NCT00747305|Procedure|neoadjuvant therapy|
75885942|NCT05263713|Other|Suture Closure of Linear Wounds|Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
75593624|NCT04311502|Drug|Clofazimine (CFZ)|Administered orally once daily
75593625|NCT04311502|Drug|Rifapentine (RPT)|Administered orally once daily
75737003|NCT00747305|Procedure|therapeutic conventional surgery|
75737004|NCT05254106|Device|Lower limb artery revascularization with paclitaxel-eluting device|Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon
75737005|NCT00747383|Drug|Glimepiride|3mg oral tablet.
75737006|NCT00747383|Drug|Sitagliptin|100mg oral tablet.
75737007|NCT00106639|Drug|CP-690,550|15 mg twice daily
75737008|NCT00106639|Drug|CP-690,550|30 mg twice daily
75737009|NCT00106639|Drug|tacrolimus|dose adjusted according to level
75737010|NCT00747539|Drug|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
75737011|NCT00962234|Other|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
75737012|NCT00962234|Biological|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
75885943|NCT02828124|Biological|BMS-986183|specified dose on specified days
75443866|NCT05595564|Device|Photobiomodulation therapy|A previous application of photobiomodulation therapy was offered or not, for possible performance enhancement.
75737013|NCT00962234|Procedure|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
75593626|NCT04311502|Drug|Isoniazid (INH)|Administered orally once daily
75443867|NCT05595538|Biological|Multiple doses of anti-SARS-CoV-2 Convalescent Plasma|SARS-CoV-2 Convalescent Plasma(1-2 units; ~300-600 mL with the presence of IgG anti-SARS-CoV-2.
75737014|NCT00747695|Drug|Rabeprazole sodium|
75737015|NCT00959972|Drug|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
75737016|NCT00959972|Drug|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
75737017|NCT00747773|Device|CryoSpray Ablation System|"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"
75593627|NCT04311502|Drug|Pyrazinamide (PZA)|Administered based on weight orally once daily
75737018|NCT04059653|Device|Electrical stimulation|Electrical stimulation device
75737019|NCT04059653|Other|Treatment as usual|GP treatment as usual
75737020|NCT04009616|Drug|Aloe Vera mouthwash|rinsing with aloe vera mouthwash for 5 days.
75737021|NCT04009616|Drug|Chlorhexidine mouthwash|rinsing with chlorhexidine mouthwash for 5 days.
75737022|NCT04009616|Drug|Placebo mouthwash|rinsing with placebo mouthwash for 5 days.
75737023|NCT00750035|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
75737024|NCT00750035|Procedure|Subtotal abdominal hysterectomy|
75737025|NCT00106249|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
75737026|NCT00106249|Device|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
75737027|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
75737028|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
75737029|NCT01086943|Device|LT2420|
75737030|NCT00960284|Drug|capecitabine|Given orally
75737031|NCT00960284|Drug|cisplatin|Given IV
75737032|NCT00960284|Drug|epirubicin hydrochloride|Given IV
75737033|NCT00960284|Drug|fluorouracil|Given IV
75737034|NCT00960284|Drug|gemcitabine hydrochloride|Given IV
75737035|NCT00105469|Drug|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
75737036|NCT00105469|Drug|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
75885944|NCT02828124|Biological|Nivolumab|specified dose on specified days
75885945|NCT03619629|Other|Kinesio-tape|"Kinesiotape will be applied both ankles as Correction technique."
75593628|NCT04311502|Drug|Ethambutol (EMB)|Administered based on weight orally once daily
75593629|NCT04311502|Drug|Rifampicin (RIF)|Administered orally once daily
75593630|NCT04311502|Dietary Supplement|Pyridoxine (vitamin B6)|All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.
75593631|NCT04311073|Drug|Tranexamic Acid|IV Tranexamic acid in 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
75593632|NCT04311073|Drug|Placebos|IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
75593633|NCT04298827|Other|Unimodal|Patients will receive physical therapy alone.
75593634|NCT04298827|Other|Trimodal|Patients will receive physical therapy, nutrition counseling, and cognitive behavioral therapy in the form of group counseling.
75593635|NCT04283669|Drug|Crizotinib|Oral
75593636|NCT04276883|Drug|Sublingual film containing Dexmedetomidine (BXCL501)|Sublingual film containing Dexmedetomidine (BXCL501)
75885946|NCT03619629|Other|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.
75885947|NCT03619629|Other|Sham Kinesio-taping|Sham Kinesio-taping technique will be applied both ankles.
75885948|NCT03619629|Other|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement technique will be applied both ankles.
75885949|NCT02259894|Drug|BIRT 2584 XX|
75885950|NCT02259894|Drug|Placebo|
75593637|NCT04276883|Drug|Placebo Film|Placebo Film for BXCL501
75885951|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
75885952|NCT02829996|Drug|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
75885953|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
75885954|NCT02829996|Drug|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
75443868|NCT05595525|Device|1064NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
75443869|NCT05595525|Device|755NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
75443870|NCT05595512|Behavioral|Naser Al-Husban|depressive symptoms within 6 months of delivery
75443871|NCT05595473|Drug|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV
75443872|NCT05595473|Drug|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV
75443873|NCT05595473|Drug|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV
75769535|NCT03895138|Other|Optimized Glucommander (OGM)|The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
75885955|NCT02829996|Drug|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
75885956|NCT05306457|Biological|CNS10-NPC-GDNF|Unilateral injections of CNS10-NPC-GDNF into the motor cortex
75593638|NCT04271930|Behavioral|Mindfulness Awareness Practices for Insomnia|MAP-I is a curriculum-based intervention that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
75593639|NCT04271930|Behavioral|Sleep Health Information|A video SHE seminar will serve as active comparator for nonspecific treatment elements that pose rival explanations for the effectiveness of MAP-I.
75593640|NCT04271085|Other|Observational study|No intervention involved
75885957|NCT02827500|Drug|ivabradine|Active Comparator: ivabradine
75885958|NCT02827500|Other|Usual Care|Placebo Comparator: usual care
75443874|NCT05595473|Drug|RZ-001 Dose 4|RZ-001 Dose 4 and VGCV
75443875|NCT05595447|Drug|Brentuximab Vedotin 50 MG [Adcetris]|Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1
75443876|NCT05595408|Drug|Adjuvant chemotherapy|cisplatin/carboplatin-gemcitabine 4-6 cycles
75443877|NCT05595408|Drug|adjuvant immunotherapy|immunotherapy for one year
75616259|NCT03568084|Other|control usual practice|Individuals allocated to this arm, will be look after as usual in their health Centers.
75769536|NCT01257958|Drug|19 nor vitamin d|
75769537|NCT03893032|Drug|Modafinil 200mg|single 200 mg dose
75769538|NCT03893032|Drug|mixed amphetamine salts|single 10 mg dose
75769539|NCT03893032|Drug|Placebo|single oral-administration placebo tablet
75769540|NCT03893110|Procedure|surgical stabilization of the spine due to primary and secondary spinal tumors|Posterior instrumentation with pedicle screw system
75769541|NCT01258036|Radiation|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
75769542|NCT01258036|Biological|Sampling|Urine and blood samples
75769543|NCT01258036|Radiation|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
75769544|NCT01259986|Procedure|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
75885959|NCT05385549|Drug|Imatinib Mesylate|Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)
75885960|NCT05238285|Behavioral|Production of vocal sounds|"Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.~For example, they can read a script containing vowels ('a', 'e', 'i', 'o', 'u'), short sentences ('hello, how are you'), longer passages of standardised reading texts, and can also be asked to speak freely about any topic ('freedom of speech'). They can be asked to play a role or to imitate a particular emotional state. For example, imagine that you have just been told that you have won a million euros in the lottery. Produce a vocalisation to express your excitement or talk to your dog your dog by imagining that he has done a negative action and then do the same thing by imagining that this time imagining that the action was positive."
75885961|NCT03563586|Other|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
75443878|NCT05593822|Procedure|primary percutaneous intervention|percutaneous catheterization through peripheral arteries to coronary arteries
75885962|NCT03563586|Other|Bowel Preparation|Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
75769545|NCT01258114|Other|SPA treatment (ST)|"Drug: spa treatment soon after randomization :~Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;~nutritional counseling (french nutritional recommendations booklet) ;~caloric restriction and physical training on demand (non mandatory)."
75885963|NCT03929679|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
75885964|NCT02826798|Drug|VBI-1501A 0.5 μg|VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
76056826|NCT04174651|Behavioral|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
76056827|NCT04174651|Behavioral|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
75443879|NCT05577455|Drug|Medical prescription before ovulation|Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
75593641|NCT04267107|Other|Individual Managing Fatigue Program|The Individual Managing Fatigue Program includes six weekly sessions that focus on sleep, communication and body mechanics, activity stations, priorities and standards, and balancing daily schedule. Each session includes three parts: 1) a pre-session activity 2) in-session activities/information and 3) homework. Prior to coming to each session, participants will be asked to complete activities that will help them prepare for the in-session discussions. During each session participants will discuss and practice the topics most important to them. Based on their discussions, participants and therapists will decide on activities to complete during each session and as homework. The therapist will help the participant begin the homework at the end of each session, and the participant will finish it outside of the session at home. At the beginning of the following session, the therapist and participant will review the homework.
75593642|NCT04262609|Radiation|hypofractionated radiotherapy|volumetric modulated moderately fractionated arc therapy
75593643|NCT04261790|Drug|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
75593644|NCT04238546|Device|sirolimus-coated balloon catheter|angioplasty with sirolimus-coated balloon catheter
75769546|NCT01258114|Other|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
75769547|NCT03889366|Drug|Aprepitant 125 mg|Single dose in the fasted state during treatment period 1,2 or 3
75769548|NCT01151488|Other|Resistance Training|RT 3x/wk for 4 months
75885965|NCT02826798|Drug|VBI-1501A 1.0 μg|VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
75885966|NCT02826798|Drug|VBI-1501A 2.0 μg|VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
75885967|NCT02826798|Drug|VBI-1501 1.0 μg|VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
75885968|NCT02826798|Drug|Placebo|buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
75885969|NCT02829138|Genetic|Genetic information and Omega-3 fat intake|Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
75885970|NCT02829138|Behavioral|General Nutrition related to Omega-3 fats|Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
75885971|NCT03832842|Diagnostic Test|Blood sample|Blood sample
75885972|NCT03563430|Other|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate as a recovery method following a single bout high-intensity interval exercise program
75885973|NCT03563430|Other|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session as a recovery method following a single bout high-intensity interval exercise program.
76056828|NCT02013674|Biological|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
76056829|NCT01987232|Drug|Carfilzomib|Administered by intravenous infusion.
75737037|NCT05192408|Behavioral|Multi-component intervention|"Individual intervention will comprise:~Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone."
75885974|NCT03563430|Other|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position as a recovery method following a single bout high-intensity interval exercise program.
76056830|NCT01987232|Drug|Carboplatin|Administered by intravenous infusion.
76056831|NCT01987232|Drug|Etoposide|Administered by intravenous infusion.
76056832|NCT04676204|Drug|Cladribine|Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults.
76056833|NCT04676204|Drug|Dimethyl fumarate|Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
76056834|NCT04676204|Drug|Fingolimod|Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
75443880|NCT05577455|Drug|Medical prescription after ovulation|Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
75443881|NCT05571683|Other|oxygen support|40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.
75885975|NCT05218590|Device|Video rigid stylet|Nasal intubation was performed using the video rigid stylet.
76056835|NCT04676204|Drug|Teriflunomide|Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
76056836|NCT04676204|Drug|Ozanimod|Ozanimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.
76056837|NCT04676204|Drug|Diroximel fumarate|Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
76056838|NCT01986920|Drug|A-101 25%|Low Dose Concentration of A-101 applied to one of 4 Target Lesions
76056839|NCT01986920|Drug|A-101 32.5%|Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
75443882|NCT05567822|Drug|Esmolol Hydrochloride|In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively
75885976|NCT02825550|Device|Taiwan ACE Beads|Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
75885977|NCT03563352|Other|Interview|Attend an interview
75885978|NCT03563352|Other|Survey Administration|Ancillary studies
76056840|NCT01986920|Drug|A-101 40%|High Dose Concentration A-101 applied to one of 4 Target Lesions
76056841|NCT01986920|Drug|A-101 Vehicle|Placebo applied to one of 4 Target Lesions
76056842|NCT02010632|Drug|Generic clopidogrel product Apolets®|"Clopidogrel 75 mg once daily for 7 days~Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
76056843|NCT02010632|Drug|Original clopidogrel product Plavix®|"Clopidogrel 75 mg once daily for 7 days~Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
75443883|NCT05567822|Drug|normal saline|In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
75443884|NCT05557253|Drug|Remimazolam|Anesthesia induction: remimazolam 6-12 mg/kg/h Anesthesia maintenance: remimazolam 1-2 mg/kg/h
75443885|NCT05557253|Drug|Balanced Anesthesia|Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
75885979|NCT05197062|Drug|14C-aticaprant|14C-aticaprant will be administered orally as capsule on Day 1.
75885980|NCT03563196|Radiation|Chest Radiograph|Chest radiogram will be obtained on day 1
76056844|NCT01986140|Device|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
76056845|NCT01986140|Other|Control No treatment|No treatment to prevent hair loss
76056846|NCT01986062|Drug|AR11|
76056847|NCT01986062|Drug|Placebo|
76056848|NCT01985360|Procedure|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
75737038|NCT05192408|Other|Usual Care|Patient Education Materials
75885981|NCT03563196|Diagnostic Test|Lung Ultrasound|Lung ultrasound will be done on day 1
75737039|NCT04009694|Other|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
75737040|NCT00960362|Drug|AGS-009|Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
75443886|NCT05546372|Device|Endobiliary radiofrequency ablation (eRFA)|Intraductal radiofrequency ablation of tumor prior to stent placement
75593645|NCT04238546|Device|uncoated balloon catheter|angioplasty with uncoated balloon catheter
75593646|NCT04212416|Drug|Leflunomide|Given PO
75737041|NCT00960362|Drug|placebo|Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
75737042|NCT00962312|Drug|capecitabine|
75737043|NCT00962312|Drug|lapatinib ditosylate|
75737044|NCT00962468|Other|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
75737045|NCT00960518|Drug|adefovir|adefovir at 10 mg daily for 48 weeks
75885982|NCT05004870|Device|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
75885983|NCT05122260|Drug|Q-Griffithsin|intranasal spray administered as a single dose
75885984|NCT05122260|Other|Placebo|intranasal spray administered as a single dose
76056849|NCT01985360|Procedure|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
75443887|NCT05546372|Device|uncovered self-expanding metal stent (uSEMS)|Intraductal placement of uncovered metal stent
75885985|NCT05000736|Drug|palbociclib + aromatase inhibitor|palbociclib + aromatase inhibitor therapy
75443888|NCT05539924|Drug|Pregabalin 150mg gabapentin 400mg|oral administration
75885986|NCT05000736|Drug|fulvestrant|fulvestrant monotherapy
75443889|NCT05536050|Other|Migraine diary and Questionnaires|Patients who already have a prescription for low-dose naltrexone will be administered questionnaires twice during the trial. Additionally, patients will maintain migraine diary for the duration of the trial.
75443890|NCT05530096|Diagnostic Test|Standard of care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy
75593647|NCT04187105|Device|Arm1|Experimental: Total marrow irradiation 1.5 Gray (Gy) twice a daily on days -3 and -2
75593648|NCT04187105|Drug|Arm1|"All patients will receive the following standard conditioning regimen:~Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2"
75593649|NCT04187105|Drug|Arm1|IV cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5.
75593650|NCT04187105|Device|Arm 1|Total body irradiation 2Gy on day -1.
75593651|NCT04187105|Other|Arm1|Stem cell infusion on day 0.
75593652|NCT04187105|Drug|Arm1|Tacrolimus IV initially in doses of 0.15 mg/kg/day for 3 days, followed by conversion to oral therapy (0.15 mg/kg twice daily)
75593653|NCT04187105|Drug|Arm1|Cyclophosphamide on days 3 and 4 after transplant at a dose of 50mg/kg per day
75593654|NCT04172246|Drug|Zanubrutinib|Zanubrutinib at 160 mg orally twice daily
75593655|NCT04108117|Procedure|Robotic nipple sparing mastectomy|Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
75616260|NCT04368130|Behavioral|SIGNAL|"SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
75616261|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
75616262|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
75737046|NCT00960518|Procedure|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
75737047|NCT00960596|Behavioral|Health promotion and health education for smoking habits|We provide the education to intervention group.
75737048|NCT00960674|Procedure|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
75737049|NCT00960674|Behavioral|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
75737050|NCT04010864|Other|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
75737051|NCT01563146|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
75885987|NCT02744040|Drug|ART initiation at time of HIV diagnosis|Immediate ART initiation
75885988|NCT02744040|Drug|ART at 24 weeks|ART initiation 24 weeks after enrollment
75885989|NCT03833856|Procedure|colonoscopy perforation|The development of perforation after colonoscopy
76056850|NCT01985360|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
76056851|NCT01985360|Behavioral|Lifestyle|Diet, physical activity, smoking cessation
76056852|NCT01985360|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
76056853|NCT02032706|Device|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
76056854|NCT02032238|Device|laser photocoagulation|Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
76056855|NCT04689074|Other|Biological sample collection|Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
75443891|NCT05528250|Other|Survey|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale.
75593656|NCT04099992|Behavioral|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction (MBSR) is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session. MBSR teaches to become more aware of thoughts, feelings, and sensations, and to skillfully respond to stressors. Each of the sessions includes education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. Participants learn formal mindfulness practices (e.g., meditation, yoga, body scan, body scan) as well as informal such as awareness of breath, thoughts, or emotions, and mindfulness of daily activities. Participants will receive digital audio (MP3) downloads with guided MM practices, a home practice manual, and handouts with each week's assignments. Daily home practice will consist of 40-45 minutes of recorded practice. Participants will log their daily practice. If a participant misses a class, it is possible to make up the class on a different day.
76056856|NCT04689074|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
75593657|NCT04099992|Behavioral|Health enhancement program (HEP)|"8-week health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP matches MBSR in structure and content, and in parallel to MBSR, consists of music therapy, nutritional education, posture and balance movements, walking and stretching. Work with all practices with group discussion and exercises during an all-day spa day will match the all-day retreat in MBSR. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions. Participants will receive MP3 downloads on an MP3 player with recordings of health education topics, a home listening manual, and weekly handouts with each week's listening assignments. Participants will listen to these MP3 recordings daily for 40-45 minutes and log their daily adherence."
75593658|NCT04099992|Device|Transcutaneous Vagus Nerve Stimulation (tVNS)|Transcutaneous Vagus Nerve Stimulation (tVNS) is delivered using gammaCore (Electrocore), a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and a button for operator control of the stimulation intensity. Conductive gel is applied to the stainless steel round discs on the device and placed vertically on the skin overlying the vagus nerve under the angle of the mandible, between the trachea and sternocleidomastoid muscle. A low-voltage electrical signal is delivered consisting of 5-kilohertz (kHz) sine wave series for 1 ms and repeated every 40 ms, with a maximum delivery of 24 V and 60 milliampere (mA) output. Stimulation amplitude is adjusted by the user and is increased until there is a vibration and slight muscle contraction in the lower face or neck. Stimulation is delivered for 2 minutes on the left side of the neck, and 2 minutes on the right side of the neck, for a total 4 minutes per one dose.
76056857|NCT04689074|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
76056858|NCT04688450|Device|VIGORIS Blood Pressure Management Clinical Decision Support System|Software system to optimize tight blood pressure management during vasopressor infusion
75593659|NCT04099992|Device|Sham-transcutaneous Vagus Nerve Stimulation (tVNS)|Sham stimulation will be delivered using a sham device that is identical in appearance and function, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve.
75593660|NCT04099888|Drug|Fimaporfin and Gemcitabine|PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
75593661|NCT04099888|Drug|Gemcitabine/Cisplatin chemotherapy|Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
75593662|NCT04081389|Drug|Celecoxib|Given PO
75593663|NCT04081389|Drug|Cyclophosphamide|Given IV
75593664|NCT04081389|Drug|Doxorubicin|Given IV
76056859|NCT01985126|Drug|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
76056860|NCT01985126|Drug|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
76056861|NCT01985126|Drug|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
76056862|NCT01985126|Drug|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
76056863|NCT01985126|Drug|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
76056864|NCT01985126|Drug|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
75885990|NCT02743962|Device|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
75885991|NCT02743962|Other|Routine physiotherapy control|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
75885992|NCT05314920|Behavioral|Transdiagnostic cognitive-behavioral therapy (TD-CBT)|Transdiagnostic cognitive-behavioral therapy (TD-CBT)
75885993|NCT05314920|Behavioral|Bernstein and Borkovec progressive muscle relaxation (PMR)|Bernstein and Borkovec progressive muscle relaxation (PMR)
75443892|NCT05528250|Device|Treadmill|Participants will sign a consent form approved by the ethics committee.Before data collection, height, weight, circumference measurements, leg length, thigh area subcutaneous fat measurement, heart rate, blood pressure and saturation values will be recorded. Before the muscle fatigue protocol, the muscle strength, balance assessment and fatigue of the participants will be evaluated. The muscle fatigue protocol will be done with a treadmill. At the end of the muscle fatigue protocol, the necessary evaluations will be made again and the participants will be rested.
75885994|NCT03834792|Other|No intervention but exposure|Different sleep disorders will be considered as an exposure. The data elements included in the database: demographics, date of the sleep study, study type, all available polysomnography indices, symptoms, sleep schedule, comorbidities, medications, social history, electrocardiography, positive airway pressure treatment related variables.
75885995|NCT03563274|Device|Selective Internal Radiation Therapy with QuiremSpheres®|The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.
75885996|NCT03828162|Drug|Anticoagulants|
75885997|NCT03563040|Drug|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
75885998|NCT03563040|Device|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
75443893|NCT05523882|Diagnostic Test|point-of-care ultrasound|"All participants will receive the same ultrasound education through attendance of the ultrasound course arranged by PLO-e. The educations intervention consists of three teaching seminars delivered over three months, a curriculum of 10 POCUS applications, an online learning platform providing educational support before, during, and after the teaching sessions (see Figure 2).~The online platform includes videos demonstrating the performance of POCUS, suggestions for additional literature, assignments to support the development of skills, self-quizzes to focus attention of learning outcomes and specific actioncards for each of the 10 POCUS applications framing the examinations in the clinical context. In addition, the online platform provides participants access to webinars and communication with other participants and teachers"
75443894|NCT05514782|Other|Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
75593665|NCT04081389|Drug|Doxorubicin Hydrochloride|Given IV
75593666|NCT04081389|Drug|Paclitaxel|Given IV
75593667|NCT04081389|Biological|Recombinant Interferon Alfa-2b|Given IV
75593668|NCT04081389|Drug|Rintatolimod|Given IV
75593669|NCT04079218|Drug|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
75593670|NCT04078854|Behavioral|Diabetes education|Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.
76071928|NCT03704948|Behavioral|RCT Control Usual mental health care delivered by NICU social workers|RCT Control Usual mental health care delivered by NICU social workers
75593671|NCT04075396|Drug|Lazertinib|Participants will receive Lazertinib tablets once daily.
75593672|NCT04033081|Device|CivaSheet|Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
75616263|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
75616264|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
75616265|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
75443895|NCT05514782|Other|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.
75443896|NCT05514782|Other|Sunscreen SPF 40+|"Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter"
75593673|NCT04032080|Combination Product|Drug 1: LY3023414; Drug 2: Prexasertib|"Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses."
75885999|NCT03828552|Other|Questionnaire|"Parents will be recruited in a Pediatric Resuscitation Department of the Mother and Child Hospital for 3 months. The doctor taking care of a child and his parents meeting the eligibility criteria will distribute, during the stay, a questionnaire accompanied by a pre-stamped envelope to the two parents not opposing the study.~A phone call and / or an email reminder by the intern in the month of the exit will invite each parent to return the questionnaire.~The completed questionnaire will be mailed back by the parents using the pre-stamped envelope."
75886000|NCT04777734|Biological|efgartigimod|an intravenous infusion of efgartigimod
75886001|NCT03094416|Drug|levothyroxine sodium capsule|after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
75886002|NCT03094416|Drug|Proton pump inhibitor (PPI)|for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
75593674|NCT04022005|Drug|Chidamide, Rituximab, Gemcitabine,Oxaliplatin|"All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy."
75737052|NCT05069948|Other|HeadOn|HeadOn is a web application which takes the participant through a 5-stage CBT programme including: (i) understanding post-concussion symptoms; (ii) sleep after a concussion; (iii) lifestyle habits and exercise; (iv) managing negative thought patterns and (v) returning to baseline. The programme is delivered through a combination of weekly tasks (such as completing symptom diary, setting exercise goals and setting up a sleep time routine), audio/video media and reading material.
75737053|NCT00960830|Drug|mirtazapine|mirtazapine 15 mg daily tablets
75737054|NCT00960830|Drug|mirtazapine|15 mg daily
75737055|NCT00960908|Device|Endeavor Resolute stents|2nd generation ZES
75737056|NCT00960908|Device|Endeavor Sprint stent|1st generation ZES
75886003|NCT03094416|Drug|Levothyroxine Sodium (LT4) Tablets|during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
75886004|NCT03106038|Drug|Nerindocianine for Injection|Procedure: routine minimally invasive pelvic surgery.
75886005|NCT03041025|Drug|GSK2330811|GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
75886006|NCT03041025|Drug|Placebo|Normal saline (0.9 percent weight per volume sodium chloride).
75886007|NCT04765566|Device|Endovascular revascularization of peripheral arteries|Endovascular revascularization of peripheral arteries involves placement of a self-expanding Nitinol Stent encapsulated with ePTFE in diseased vessel segments
76071929|NCT03704948|Behavioral|Open trial: Listening Visits delivered by a NICU nurse via zoom|Open trial: Listening Visits delivered by a NICU nurse via zoom
75443897|NCT05512065|Device|Ultrasound|Ultrasound scan of the right and left uterine arteries and umbilical artery.
75443898|NCT05501925|Device|GlideSheath Slender® and conventional arterial sheath|Using the GlideSheath Slender® with the outside diameter 2.46mm
75886008|NCT01338870|Drug|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
75886009|NCT01338870|Drug|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
75886010|NCT01338870|Drug|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
75886011|NCT01338870|Drug|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
75886012|NCT01338870|Drug|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
75886013|NCT01338870|Drug|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
75886014|NCT02824224|Drug|Tamoxifen|10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
75443899|NCT05501925|Device|Conventional arterial sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II )
75616266|NCT00947349|Drug|BI 201335 NA low placebo|Placebo
75593675|NCT04020276|Radiation|SBRT|Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
75886015|NCT02824224|Drug|Placebo (for Tamoxifen)|Sugar pill manufactured to mimic the tamoxifen 10mg tablet
75886016|NCT03824964|Biological|Anti-CD19/CD22 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19/CD22 CAR NK cells will be administered at day0
75886017|NCT01338792|Drug|oxaliplatin|Given IV
75886018|NCT01338792|Drug|pemetrexed disodium|Given IV
75886019|NCT01338792|Other|questionnaire administration|Ancillary studies
75886020|NCT01338792|Other|laboratory biomarker analysis|Correlative studies
76056865|NCT01984892|Drug|Poly-ICLC|"Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments."
75443900|NCT05490277|Device|Active Vibrotactile coordinated reset|Participants will receive active vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
75737057|NCT00962624|Drug|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
75737058|NCT00962702|Device|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
75737059|NCT00105235|Drug|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
75737060|NCT00105235|Drug|Cyclosporine|Oral immunosuppressant
75886021|NCT01338792|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
76071930|NCT03701737|Other|questionnaires|"VAS on the feeling of hunger~Evaluation of food wanting by the Finlayson test~PREFQUEST Questionnaire~24-hour food recall~Stunkard Questionnaire~Measurement of daytime sleepiness by Epworth score"
75443901|NCT05490277|Device|Sham vibrotactile coordinated reset|Participants will receive sham vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
75443902|NCT05479370|Biological|Flublok Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75443903|NCT05479370|Biological|Fluarix Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75443904|NCT05479370|Biological|Flucelvax Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75593676|NCT04016142|Drug|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)"
75737061|NCT00105235|Drug|Mycophenolate mofetil|Oral immunosuppressant
75737062|NCT00105235|Drug|Tacrolimus|Oral immunosuppressant
75737063|NCT00105235|Procedure|Liver transplant|Occurs at study entry
75737064|NCT00105235|Procedure|Immunosuppression withdrawal|Beginning no earlier than Year 1
75737065|NCT03962803|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
75737066|NCT03962803|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
75886022|NCT01338792|Genetic|polymorphism analysis|Correlative studies
75886023|NCT04752072|Behavioral|Enhanced Skills Training in Affective and Interpersonal Regulation|"The first (formulation) session enables linking present difficulties and traumatic events, identifying current issues/concerns, and collaboratively agreeing on the order of modules based on symptom severity and client readiness.~The PTSD module provides narrative exposure to the traumatic memories and targets re-experiencing, avoidance and hyperarousal symptoms. The AD module focuses on identifying and labelling feelings, emotion management, distress tolerance, acceptance of feelings and experiencing positive emotions. The NSC module focuses on staying in the present moment and combating dissociation; self-compassion and mindfulness skills; challenging thinking patterns and developing a balanced view of self. The DR module focuses on exploring and revising maladaptive schemas; effective assertiveness; awareness of social context; and flexibility in interpersonal expectations and behaviours displayed in social interactions."
75886024|NCT04752072|Behavioral|Treatment as usual|The first session will involve a mental health assessment by either a psychiatrist or psychologist. A treatment package will be developed based on the information collected during the assessment. Details of the interventions delivered to each participant receiving TAU, which will include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, will be recorded.
76071931|NCT03701737|Device|wrist actimeter|Actimeter delivery: it is worn on the wrist for 7 days, 24 hours a day.
75443905|NCT05479136|Drug|PET imaging with 18F fluciclovine|PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
75443906|NCT05478369|Behavioral|storybook|anxiety and fear during operative
75737067|NCT03962803|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
75593677|NCT04004936|Other|EQUIPPED with Active Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
75886025|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
75886026|NCT01314105|Drug|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
75886027|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
75886028|NCT03562884|Drug|BLI800|Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
76071932|NCT03701737|Biological|Blood samples|2 dry tubes of 7 ml of blood collected at each visit for plasma assays (ghrelin, leptin, FGF 21, amino acids including tryptophan, insulin resistance)
76071933|NCT03699475|Biological|rivogenlecleucel|Biological: T cells transduced with caspase 9 safety switch
76071934|NCT03699475|Drug|rimiducid|administered to inactivate rivogenlecleucel in the event of GVHD
75443907|NCT05475821|Drug|ABBV-990|Oral Tablet
75443908|NCT05475821|Drug|Placebo for ABBV-990|Oral Tablet
75737068|NCT00547118|Drug|Rimonabant|One 20 mg tablet given 1 time per day for 112 days.
75737069|NCT00547118|Drug|Placebo|One placebo tablet given 1 time per day for 112 days.
75737070|NCT01087021|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
75737071|NCT01084525|Drug|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
75737072|NCT01084525|Drug|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
75737073|NCT01084525|Drug|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
75737074|NCT00962936|Drug|CT-011|CT-011
75443909|NCT05454098|Drug|Clifutinib with fed state|40 mg Clifutinib with food
75443910|NCT05454098|Drug|Clifutinib with fasted state|40 mg Clifutinib without food
75616267|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
75616268|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
75616269|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
75616270|NCT00947349|Drug|BI 201335 NA low|BI 201335 NA
75616271|NCT00947349|Drug|BI 201335 NA high placebo|placebo
75616272|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
75737075|NCT00502593|Biological|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
75737076|NCT00502593|Biological|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
75737077|NCT01087099|Drug|Albendazole|Treatment with albendazole
75737078|NCT00686543|Drug|Posaconazole|Posaconazole will be used for prophylaxis
75737079|NCT04009538|Other|Rehabilitation program|exercise program twice a week
75737080|NCT02561741|Drug|COV155|COV155 tablets
75737081|NCT00750113|Drug|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
75737082|NCT00750113|Drug|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
75737083|NCT00750113|Drug|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
75443911|NCT05451901|Procedure|Immediate necrosectomy|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the immediate necrosectomy group, endoscopic necrosectomy (EN) will be performed in the same session of EUS-guided drainage using a gastroscope. The endoscope is inserted into the WON cavity through the LAMS, and necrotic tissue is removed using biopsy forceps, snare, or basket catheter. The EN procedures will be repeated until clinical improvement."
75593678|NCT04004936|Other|EQUIPPED with Passive Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
75593679|NCT03985800|Other|TEAM|TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.
75593680|NCT03985800|Other|TECH|TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
75593681|NCT03970720|Drug|Metoclopramide|10 mg metoclopramide four times a day
75593682|NCT03970720|Drug|Placebo|10 mg matching placebo capsules four times a day
75593683|NCT03957382|Device|Accero® (heal) Stent|The Accero® (heal) Stent will only be used in line with the Instructions For Use (IFU). Patients participating in this PMCF (Post- Market Clinical Follow-up) will not be exposed to any additional risk. There are no additional treatments or investigations other than done in the clinical routine.
75593684|NCT03943498|Drug|Fingolimod|Given PO daily for 4 weeks
75593685|NCT03943498|Drug|Fingolimod Hydrochloride|Given PO
75593686|NCT03943498|Other|Questionnaire Administration|Ancillary studies
75593687|NCT03912818|Drug|Carboplatin|Given IV
75593688|NCT03912818|Drug|Cisplatin|Given IV
75593689|NCT03912818|Procedure|Cystectomy|Undergo cystectomy
75593690|NCT03912818|Drug|Doxorubicin|Given IV
75737084|NCT04971590|Other|Participant completed survey|Participants will be required to complete the participant survey.
75737085|NCT04971590|Other|Medical chart review|Data will be collected from medical charts of participants.
75737086|NCT00963092|Genetic|DNA analysis|
75737087|NCT00963092|Genetic|RNA analysis|
75593691|NCT03912818|Biological|Durvalumab|Given IV
75593692|NCT03912818|Drug|Gemcitabine|Given IV
75593693|NCT03912818|Drug|Methotrexate|Given IV
75593694|NCT03912818|Drug|Vinblastine|Given IV
75616273|NCT00947349|Drug|Placebo|
75616274|NCT02846194|Behavioral|brief guided imagery|
75737088|NCT00963092|Genetic|microarray analysis|
75737089|NCT00963092|Genetic|protein analysis|
75737090|NCT00963092|Other|cytology specimen collection procedure|
75737091|NCT00963092|Other|laboratory biomarker analysis|
75737092|NCT00963092|Other|questionnaire administration|
75737093|NCT00745511|Drug|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
75737094|NCT00745511|Drug|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
75737095|NCT00961376|Biological|PBMC re-infusion|Autologous PBMC re-infusion
75737096|NCT00961376|Biological|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
76071935|NCT03699475|Drug|Cyclophosphamide|GVHD prophylaxis
76071936|NCT03699475|Procedure|haplo-HSCT|treatment for disease
76071937|NCT03696160|Drug|Biktarvy|Integrase inhibitor used to treat HIV-1 infection
76071938|NCT03696160|Drug|Symtuza|Protease inhibitor used to treat HIV-1 infection
76071939|NCT03680586|Drug|Radiation Therapy|Undergo ultra low-dose radiation
75737097|NCT00961454|Device|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
75886029|NCT03562884|Drug|Fortrans®|Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
75886030|NCT05339724|Other|platelet count and mean platelet volume are obtained from whole blood count|The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
75593700|NCT03865277|Radiation|dose-escalated radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases > 2 cm.~Radiotherapy is always applied with 5 fractions per week."
75443912|NCT05451901|Procedure|Step-up approach|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the step-up approach group, an additional interventional procedure will be withheld for 72-96 hours after initial EUS-guided drainage. In cases without clinical improvement after 72-96 hours, additional drainage will be permitted, which includes increasing the number of stents, additional EUS-guided drainage, and performing percutaneous drainage (step-up treatment). Insufficient improvement even after two times of step-up treatment allows subsequent endoscopic necrosectomy (EN)."
75443913|NCT05451602|Drug|HEC169096|Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2.
75443914|NCT05433402|Drug|ChlorproMAZINE 50 MG|The experimentall group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours) plus choloropromazine 50 mg daily for 6 months
75443915|NCT05433402|Drug|Control|The control group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours)
75443916|NCT05418153|Device|Tecnis Synergy IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
75443917|NCT05406596|Device|LiquID GCE Use|Use of the LiquID GCE to aid in percutaneous coronary intervention (PCI)
75593701|NCT03865277|Radiation|dose-escalated radiochemotherapy with carbon ion boost|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases > 2 cm using a carbon ion boost.~Radiotherapy is always applied with 5 fractions per week."
75593702|NCT03865277|Radiation|standard radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.~Radiotherapy is always applied with 5 fractions per week."
75593703|NCT03853733|Radiation|rectal cancer radiotherapy|Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
75593704|NCT03852498|Genetic|Lenti-D|Participants received a single IV infusion of Lenti-D Drug Product.
75593705|NCT03781934|Drug|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|MIV-818 - oral capsules; pembrolizumab - IV
75593706|NCT03781934|Drug|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|MIV-818 - oral capsules; lenvatinib - oral capsules
75737098|NCT00545688|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
75737099|NCT00545688|Drug|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
75737100|NCT00545688|Drug|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
75886031|NCT05297799|Device|Ameda Pearl breast pump|The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
75886032|NCT05265156|Other|Plant based formula for children aged between 12 and 36 months|Daily intake of plant based formula for 3 weeks (400ml-600ml per day).
75886033|NCT03562962|Behavioral|Functional Analytic Psychotherapy|FAP is a therapeutic procedure based on behavior analytic principles. This approach seeks to implement procedures to manipulate the contingencies of reinforcement involved in clients' problem and alternative behaviors within the context of a meaningful therapeutic relationship that is functionally equivalent to other interpersonal contexts outside (Follette, Naugle & Linnerooth, 2000; Kohlenberg & Tsai, 1991). FAP therapists modify CRBs by implementing contingent responding (TCRB) within the therapeutic setting. That is, FAP aims to administer differential reinforcement (TCRB1) to reduce CRB1s and to provide positive reinforcement to enhance CRB2s. Based on the changes within the therapeutic setting, clients are prompted to discriminate contexts where those repertoires are likely reinforced and to generalize those responses to such environments (Kohlenberg & Tsai, 1991).
75443918|NCT05406076|Behavioral|oral motor therapy|Rigorous Chinese language oral motor therapy, including treatment of oral perceptual disorders and treatment of oral motor disorders. The treatment follows three basic principles: a combination of basic training and specific treatment; a combination of self-help and assisted treatment; and a combination of exercises, cues, and stimulation techniques. 30-40 min/session, 1 session/day, 5 sessions/week.
75443919|NCT05406076|Behavioral|ABA|The mainstream ASD intervention approach with evidence-based support is currently recognized worldwide. Treatment follows the operational core principles of ABA, which are to establish learning goals based on the child's ability level, design teaching situations and select reinforcers for them, change the child's behavior problems with operational constraints, and to eliminate or improve problem behaviors through appropriate interventions to shape new adaptive behaviors. The training time is at least 20 hours per week.
75593707|NCT03781323|Drug|FOLFOX|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
75737101|NCT01563380|Biological|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
75737102|NCT00961610|Behavioral|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
75886034|NCT03040713|Drug|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie [mCi]) injection, single dose
75593708|NCT03779854|Radiation|Total-Body Irradiation|Undergo TBI
75886035|NCT03040713|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain
75886036|NCT04726176|Biological|Exposure to COVID-19|To study the exposure of COVID-19 on the brain and executive functioning
75443920|NCT05405621|Drug|BAT8009 for Injection|BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30~120 minutes.
75443921|NCT05400395|Drug|GNX80|GNX80 oral intake(BID) for 24 weeks
75443922|NCT05400395|Drug|Placebo|Placebo oral intake(BID) for 24 weeks
75593709|NCT03779854|Drug|Thiotepa|Given IV
75593710|NCT03779854|Drug|Fludarabine|Given IV
75593711|NCT03779854|Drug|Cyclophosphamide|Given IV
75593712|NCT03779854|Drug|Busulfan|Given IV
75886037|NCT01966471|Drug|Trastuzumab Emtansine|Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
75886038|NCT01966471|Drug|Trastuzumab|Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
75886039|NCT01966471|Drug|Pertuzumab|Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
75886040|NCT01966471|Drug|Paclitaxel|IV infusion of paclitaxel 80 mg/m^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
75886041|NCT01966471|Drug|Epirubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
75593713|NCT03779854|Procedure|Allogeneic Bone Marrow Transplantation|Receive unmanipulated T cell replete BM
75593714|NCT03779854|Drug|Tacrolimus|Given IV
75593715|NCT03779854|Drug|Methotrexate|Given IV
75593716|NCT03779854|Procedure|Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation|Receive naive T-cell depleted PBSCs
75886042|NCT01966471|Drug|Doxorubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
75886043|NCT01966471|Drug|Docetaxel|IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter [mg/m^2] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m^2 in the first cycle and escalate to 100 mg/m^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
75886044|NCT01966471|Drug|Cyclophosphamide|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
75886045|NCT01966471|Drug|5-Fluorouracil|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
75886046|NCT01568437|Procedure|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
75886047|NCT01568437|Other|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
75886048|NCT04188847|Drug|Chemotherapy plus apatinib|"A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6."
75886049|NCT05255107|Combination Product|Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the experimental arm, riboflavin will be administered (1 drop every 2 min for 40 min with PESCHKE-L solution [0.23%], or longer as needed to assure adequate corneal penetration). Then the eye will be aligned under the PXL Platinum 330 light (the treatment plane will be at the correct working distance from the PXL Platinum 330 beam aperture when the border of the projected beam is in sharp focus). The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).
75737103|NCT00961766|Drug|BG00010 (Neublastin)|Single dose, weight-based IV administration
75593719|NCT03771261|Behavioral|Weight Loss|Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
75593720|NCT03771261|Dietary Supplement|Egg Protein|Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.
75593721|NCT03742687|Radiation|Heterogeneously Hypofractionated Radiotherapy|A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
75737104|NCT00961766|Drug|Placebo|Single dose IV matched placebo
75737105|NCT00502203|Drug|Carboplatin|AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
75737106|NCT00502203|Drug|Paclitaxel|175 mg/m^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
75737107|NCT03049371|Other|No Intervention for both groups|No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
75737108|NCT00546078|Biological|Cervarix™|Intramuscular injection, one or three doses
75737109|NCT04819256|Other|PACE-It mobile application|Care co-ordination platform
75737110|NCT03035565|Behavioral|Computerized Cognitive Training with Brain HQ|Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
75737111|NCT03035565|Behavioral|Computerized Crossword Puzzles|Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
75737112|NCT00963326|Other|laboratory biomarker analysis|
75737113|NCT00967772|Drug|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
75737114|NCT00967850|Drug|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
75737115|NCT00967850|Drug|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
75737116|NCT00964938|Device|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
75886050|NCT05255107|Other|Standard of Care Therapy + Sham CXL + Artificial Tears|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the Sham comparator group, artificial tears (1 drop every 2 min for 40 min) will be administered. After instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min, during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
75886051|NCT04788589|Other|Sedation and ventilator weaning protocol|Subjects randomized to this group will underwent sedation and ventilator weaning protocol as mentioned before.
75737117|NCT00965016|Procedure|hypothermia|Core temperature --> 34.9℃ within 30 min --> 33.5℃ within 120min --> 33℃for 24 H Decrease temperature in 0.9℃/hour
75737118|NCT00967928|Drug|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
75737119|NCT00967928|Drug|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
75737120|NCT00967928|Radiation|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
75886052|NCT04298047|Other|participatory art-based activity|The intervention is a 3-month cycle of weekly guided tours carried out at the MMFA. Each visit will be performed with a group of 8 participants and a trained guide. They will meet at the museum once per week for a 45 min museum guided tour during a 3-month period. Each visit will be different and supervised by a museum guide. Regardless the topic of the visits, each visit will be standardized and separated in two consecutive phases: (1) Presentation of the objectives of the activity and (2) tour with a guide. Guided tours will target visual art (i.e., painting). They will be tailor-made and based on emotions and interactions in front of painting. The levels of information given to participants will regularly (i.e., each month) increase during the 3-month cycle of museum guided tours. The participants will be separated in 8 groups of 8 individuals per week. The same guide will manage each group of 8 participants during the 12 planned visits.
75886053|NCT04774081|Device|24h Continuous glucose monitoring and urinary C-peptide collection|Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).
75886054|NCT05224843|Behavioral|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
75593722|NCT03729362|Biological|Cipaglucosidase Alfa|Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).
75737121|NCT00546000|Drug|Fluticasone propionate 0.05% lotion|Daily applications
75737122|NCT00963404|Radiation|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
75593723|NCT03729362|Drug|Miglustat|Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
75593724|NCT03729362|Biological|Alglucosidase Alfa|Participants received an IV infusion dose over a 4-hour duration Q2W.
75593725|NCT03729362|Drug|Placebo|Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
75593727|NCT03725202|Drug|Upadacitinib|It will be administered orally.
75593728|NCT03725202|Drug|Corticosteroid (CS)|It will be administered orally.
75593729|NCT03725202|Other|Placebo|It will be administered orally.
75737123|NCT00968006|Drug|Sitagliptin|100 mg once daily for 4 weeks
75886055|NCT04692493|Drug|targeted synthetic DMARD class|Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
75886056|NCT04692493|Drug|non-TNFi-biologic class|Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
75737124|NCT00971022|Behavioral|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
75886057|NCT05200741|Biological|DelNS1-2019-nCoV-RBD-OPT1|Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
75886058|NCT05200741|Biological|Matching placebo|Solution for Intranasal Spray
75886059|NCT03227471|Drug|IVA|IVA tablet for oral administration
75886060|NCT03227471|Drug|TEZ/IVA|TEZ/IVA fixed-dose combination for oral administration.
75886061|NCT03227471|Drug|VX-445|VX-445 tablet for oral administration.
75886062|NCT03227471|Drug|Matched Placebo|Matched placebo.
75886063|NCT03227471|Drug|TEZ|Tablet for oral administration.
75886064|NCT03227471|Drug|VX-561|Tablet for oral administration.
75886065|NCT03227471|Drug|VX-445|VX-445 IV injection
75886066|NCT01354314|Drug|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
75886067|NCT01354314|Drug|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
75737125|NCT00971022|Behavioral|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
75737126|NCT00963716|Device|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
75737127|NCT00963716|Device|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
75737128|NCT00971100|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
75886068|NCT01354314|Drug|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
75886069|NCT01354314|Drug|Placebo|One capsule in the morning, three capsules in the evening
75886070|NCT04567836|Other|Investigation of the prevalence of test positivity|"The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses ."
75886071|NCT04561908|Device|Transseptal puncture with Brockenbrough-needle|Conventional transseptal puncture with Brockenbrough-needle
75886072|NCT04561908|Device|Microguidewire-assisted transseptal puncture|Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
75443923|NCT05374941|Device|Injectable and wearable neurostimulator for the hypoglossal nerve|Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve
75886073|NCT04509336|Drug|Orphenadrine|100 mg twice daily
75443925|NCT05351333|Other|placebo|Sugar pill, with an essential-oil smell and of blue color used for conditioning.
75593730|NCT03677440|Behavioral|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
75593731|NCT03677440|Behavioral|Stretching-and-Toning Exercise Training|12-weeks of supervised, progressive stretching-and-toning exercise training
75593732|NCT03653884|Diagnostic Test|Ultrasound monitoring|Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.
75593733|NCT03630211|Drug|Cyclophosphamide|Stem Cell Mobilization
75593734|NCT03630211|Drug|Mesna|Stem Cell Mobilization
75593735|NCT03630211|Drug|Rituximab|Transplantation Conditioning
75593736|NCT03630211|Drug|Alemtuzumab|Transplantation Conditioning
75593737|NCT03630211|Drug|Thiotepa|Transplantation Conditioning
75593738|NCT03630211|Drug|GM-CSF|Transplantation Conditioning
75593739|NCT03630211|Drug|Intravenous immunoglobulin|Transplantation Conditioning
75886074|NCT04509336|Drug|Baclofen|initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
75886075|NCT03194321|Drug|Tacrolimus Extended-Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
75886076|NCT04684602|Biological|PrimePro™/ PrimeMSK™|Injection via condition specific route of administration.
75886077|NCT04367142|Diagnostic Test|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
75886078|NCT04367142|Diagnostic Test|Biosensor|Portable and Connected Biosensor viral
75886079|NCT02259972|Drug|BI 113823 solution|
75886080|NCT02259972|Drug|BI 113823 tablet|
75886081|NCT02259972|Drug|Placebo|
75886082|NCT02259972|Other|High fat, high calorie breakfast|only for dose group 5
75886083|NCT01374581|Drug|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~Weight in kg Number of tablet per dose Age 5 to < 15 kg 1 tablet per dose 15 to < 25 kg 2 tablets per dose 25 to < 35 kg 3 tablets per dose"
75886084|NCT01374581|Drug|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to < 9kg):1 tablet (25 mg/675mg) for 3 days~1 to 5 years (= 9 kg to < 18 kg)1 tablet(25mg/67,5mg)for 3 days"
75886085|NCT01374581|Drug|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to < 11 kg: ½ tablets 12 to < 19 kg: 1 tablets per dose 20 to < 27 kg: 1½ tablets per dose 28 to < 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily"
75886086|NCT02585921|Behavioral|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
75886087|NCT02585921|Behavioral|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
75886088|NCT04501536|Behavioral|Word Learning Intervention|The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).
75886089|NCT03562650|Behavioral|Safety Behavior Fading|Participants are asked to fade their three most common safety behaviors associated with their social anxiety
75886090|NCT03562650|Behavioral|Present Centered|Participants are asked to try to increase their focus on the present.
75886091|NCT01354938|Drug|Clarithromycin modified release 500 mg|Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
75886092|NCT02516969|Radiation|Stereotactic Body Radiotherapy|Radiation
75443926|NCT05339828|Procedure|unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing. Hemostasis was achieved using diathermy with no drainage needed.
75443927|NCT05339672|Other|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)
75443928|NCT05322200|Radiation|A computerized tomography (CT) coronary angiogram|Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
75443929|NCT05322200|Procedure|Vicorder (Skidmore medical, UK)|Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
75593740|NCT03630211|Radiation|Total Body Irradiation|Transplantation Conditioning
75593741|NCT03630211|Drug|Anti Thymocyte Globulin|Transplantation Conditioning
75593742|NCT03629106|Behavioral|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
75593743|NCT03623984|Drug|Gallium Dotatate|Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
75737129|NCT00968162|Drug|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
75737130|NCT00968240|Drug|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
75737131|NCT00501969|Drug|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
75737132|NCT03942042|Drug|Ixekizumab|Administered SC
75737133|NCT00968318|Procedure|Excision of strip of deep fascia|operative technique to excise deep fascia.
75886093|NCT04364256|Device|RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)|Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
75886094|NCT03092791|Biological|Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)|sIPV intramuscular injection
75443930|NCT05322200|Other|Blood tests for inflammation and oxidative stress markers|All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
75886095|NCT03092791|Biological|Reference IPV|Reference IPV intramuscular injection
75886096|NCT03092791|Biological|sIPV Placebo|sIPV placebo-matching intramuscular injection
75886097|NCT03065556|Drug|188-0551 Solution|Topical solution containing active drug
75737134|NCT00968396|Procedure|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
75737135|NCT00968396|Procedure|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
75443931|NCT05303974|Other|Ultrasound guided joint injection|The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.
75737136|NCT00968396|Drug|Melphalan|100 mg/m^2 IV over 30 minutes daily on Days -2 and -1
75737137|NCT04008732|Drug|MED2005|(Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
75737138|NCT04008732|Drug|Nitrostat 0.6Mg Sublingual Tablet|Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
75737139|NCT04008732|Drug|Nitro Pohl|to be dosed intravenously in Part 2 of the study
75737140|NCT01013727|Radiation|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
75737141|NCT00960180|Drug|MR1817|
75737142|NCT00960180|Drug|Placebo|
75886098|NCT03065556|Drug|Vehicle Solution|Topical solution containing no active drug
75886099|NCT01374737|Drug|Dexmedetomidine|dexmedetomidine, 0.1ug/kg up or down
75886100|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
75886101|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
75886102|NCT02350595|Other|Lean fish|
75886103|NCT02350595|Other|Fatty fish|
75886104|NCT02203409|Procedure|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
75886105|NCT05172505|Device|prefrontal tDCS|2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
75886106|NCT01374893|Behavioral|Exercise|The intervention group will perform the multi-session per day training program
75886107|NCT01374893|Behavioral|Control|Usual care
75886108|NCT04638127|Behavioral|PREEMIE PROGRESS|PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).
75886109|NCT04638127|Behavioral|Attention Control|usual care and welcome videos
75886110|NCT05197283|Other|Glucose as reference food|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75886111|NCT05197283|Other|White bread|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from white bread, along with 300ml water, tested two times, in different visits, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75886112|NCT05197283|Other|Regular spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from regular spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75886113|NCT05197283|Other|Whole wheat spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from whole wheat spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75886114|NCT05197283|Other|High fibre - low carbohydrates spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from high fibre - low carbohydrate spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75886115|NCT03631615|Drug|Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)|"Patients will be given the perioperative treatment as below once recruited:~induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery."
75886116|NCT05197205|Procedure|nasopharyngeal swabbing|A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study
75886117|NCT03631537|Other|NST group|Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
75886118|NCT05197127|Device|exoskeleton-based gait training|Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
75886119|NCT04275817|Other|Data collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
75886120|NCT01376375|Procedure|Acupuncture|
75886121|NCT04632667|Behavioral|Comparison School Group|All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.
75886122|NCT04632667|Behavioral|Intervention School Group|"This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media."
75886123|NCT01376453|Drug|Sorafenib|In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
75443932|NCT05299346|Other|Follow up|Comprehensive follow up in dedicated follow up unit
75443933|NCT05261477|Behavioral|Bilingual Brain Injury Education and outpatient Navigation for Hispanic families|1st BIEN was informed by Hispanic parents and clinical providers working with them. It considers their specific needs including lack of familiarity with shared decision models and of knowledge about patient rights and eligibility for community and school services. Based on principles of Social Cognitive Theory, 1st BIEN provides TBI education, teaches problem-solving skills to promote self-efficacy and advocacy; and provides outpatient navigation that allows for observational and experiential learning while supporting access to services in a timely manner. Central to the development of our intervention is the recognition of heterogeneity in individuals' level of readiness to adopt a health behavior according to their level of self-efficacy, expectations, and environment. The 1stBIEN intervention flexibly reduces barriers to access care, and simultaneously improves parental knowledge, health literacy, and self-efficacy to optimize outcomes.
75886124|NCT01376453|Drug|5-Fluorouracil (5-FU)|5-FU will be delivered at a dose of 225 mg/m^2 daily through a catheter in a large vein continuously until the last day of radiation.
75886125|NCT01376453|Radiation|Radiation|Radiation sessions will be daily, Monday through Friday, except for holidays.
75443934|NCT05256355|Other|musculoskeletal ultrasound|The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.
75443935|NCT05226923|Drug|KSP-1007|Single and multiple doses, intravenous administration
75443936|NCT05226923|Other|Placebo:0.9% sodium chloride|Single and multiple doses, intravenous administration
75443937|NCT05226923|Drug|Meropenem|Multiple doses, intravenous administration
75443938|NCT05209464|Device|Tele-Tai Chi|Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via an application installed on a tablet. The intervention emphasizes essential TC movements that are easily comprehensible and can be performed repetitively in a flowing manner. The protocol includes up to six core TC movements based on the traditional Cheng Man-Ch'ing's Yang-style short form. Additionally, a set of traditional TC warm-up exercises that focus on loosening the physical body, incorporating mindfulness and imagery into movement, promoting overall relaxation, and coordinating breathing awareness are included. Chairs are used in the protocol for a subset of seated warm-up exercises, as well as for stability and rest as needed. Participants will be asked to practice the protocol (45-60 min) at home for at least 3 days a week for 12 weeks. The TC program will also include 2 or more live instructional sessions via Zoom with a TC instructor.
75737143|NCT00963794|Other|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
76056866|NCT04416620|Other|The PCOS pharmaceutical care service|"The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects."
75593744|NCT03587961|Drug|Symdeko|explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
75593745|NCT03580772|Device|Persona TKR|Persona® TKR (Zimmer Biomet)
75443939|NCT05209165|Drug|Semaglutide|weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program
76056867|NCT01807221|Drug|Finerenone (BAY94-8862)|
76056868|NCT01807221|Drug|Placebo|
75443940|NCT05209165|Drug|Placebo|Matching placebo and intake visit for VA MOVE
75443941|NCT05202769|Other|Video filming|Video clips taken using RGB and thermal imaging cameras under varying conditions of lighting, movement and procedures taking place.
75443942|NCT05172297|Behavioral|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
75593746|NCT03580772|Device|Attune TKR|Attune® TKR (Depuy synthes)
75593747|NCT03551665|Behavioral|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
75443943|NCT05169983|Diagnostic Test|iPad-Based Visual Field Test|In this study, the investigators aim to teach the participants to use the the visualFields easy App . The investigators will be using the app in the clinic with the patients watching, demonstrating its use and discussing and explaining its functions. Having observed how to use the application, the participant will then complete the visual field assessment.
76056869|NCT01807221|Drug|Inspra (eplerenone)|
76056870|NCT01838499|Biological|MEDI8968|SC injection at baseline, Week 4 and Week 8
76056871|NCT01838499|Biological|Saline|SC injection at baseline, Week 4 and Week 8
75443944|NCT05158933|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75443945|NCT05158114|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75443946|NCT05158101|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75443947|NCT05152368|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75593748|NCT03534453|Drug|Olaparib 300mg tablets|300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
75593749|NCT03453385|Behavioral|Electronic Cigarette|An e-cigarette and four weeks of e-liquid provided to participants.
75593750|NCT03426293|Other|Measuring the ACT to determine effect of heparin|Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures
75593751|NCT03396718|Radiation|De-escalation radio(chemo)therapy - Level 1|54/ 59,4 Gy
76056872|NCT01807065|Biological|sipuleucel-T|Given IV
76056873|NCT01807065|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
76056874|NCT01807065|Other|laboratory biomarker analysis|Correlative studies
76056875|NCT04583709|Device|ECG Belt|"ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording"
75737144|NCT04593290|Device|Oticon Opn S 1 miniRITE hearing aid|Everyone who participates in Part 1 (listening effort testing and cognitive testing) will be invited to participate in Part 2 (hearing aids). It is not a requirement to participate in the administration, 6-week use, and re-testing procedures involved in Part 2 of the study. All cognitively healthy participants will be invited to participate, only MCI patients with a live-in informant will be given this opportunity. After ear measurement and dome and wire length selection, Oticon Opn S 1 miniRITE hearing aid fitting will occur wirelessly using Genie software, followed by hearing aid use instructions. The fitting will use Open domes, the standard NAL-NL2 protocol, and will increase gain seven steps on top of Real Ear Unaided Gain (REUG) from 750 Hz to 6 kHz.
75737145|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
75443948|NCT05147701|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75886126|NCT05196893|Behavioral|Link Intervention|Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
75886127|NCT04569253|Device|TempSure|Non-invasive radiofrequency treatments
76056876|NCT02031458|Drug|Atezolizumab|1200 mg IV every 3 weeks
75737146|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
75737147|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
76056877|NCT02009696|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
75443949|NCT05137275|Biological|Anti-5T4 CAR-raNK Cells|In the 3+3 dose escalation study, the minimum initial dose is 3.0×10^9 cells and then escalate to 6.0× 10^9 and 9.0× 10^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 3\8 of each cycle. In dose extension study, the initial dose will be determined by RP2D determined by the results of dose escalation study, and the other intervention methods are consistent.
75737148|NCT01015365|Procedure|Cementless one-stage surgical revision|A Cementless one-stage surgical revision is to be performed for all included in the cohort.
75737149|NCT01013805|Radiation|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
75737150|NCT01013805|Drug|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
75886128|NCT05420779|Drug|TSL-1502 capsules(low dose)|350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
75886129|NCT05420779|Drug|TSL-1502 capsules(high dose)|500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
76056878|NCT02009696|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
76056879|NCT01806597|Biological|secukinumab 150 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
75593752|NCT03396718|Radiation|De-escalation radio(chemo)therapy - Level 2|48,8/ 55 Gy
75593753|NCT03396718|Radiation|Standard radio(chemotherapy)|60/ 66 Gy
75593754|NCT03387423|Drug|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
75593755|NCT03378739|Procedure|Cardiogenic Shock team activation|Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.
75593756|NCT03340766|Drug|Blinatumomab|Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.
75593757|NCT03340766|Drug|Pembrolizumab|One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
75593758|NCT03302949|Dietary Supplement|Lacprodan® DI-8090|Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
75593759|NCT03290534|Device|CivaSheet|implanting CivaSheet for localized radiation dose delivery
75593760|NCT03267589|Drug|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
75443950|NCT05126316|Drug|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
75443951|NCT05126316|Drug|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
75593761|NCT03226106|Behavioral|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
75593762|NCT03226106|Other|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
75886130|NCT05420779|Drug|Investigator's choice of chemotherapy|Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 ~ 30 mg/m2 each time, intravenous drip (15 ~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 ~ 5 min)
75593763|NCT03208452|Drug|Magnesium Sulfate|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
75886131|NCT02547311|Behavioral|Team Clinic|
75886132|NCT01376531|Procedure|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
75886133|NCT01568125|Drug|Incretin-related drugs|DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
75593764|NCT03208452|Drug|Normal saline|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
75593765|NCT03190265|Drug|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
75593766|NCT03190265|Drug|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
75737151|NCT01013805|Drug|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
75737152|NCT01013805|Drug|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
75737153|NCT01013805|Procedure|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
75886134|NCT05598931|Device|Transcranial Magnetic Stimulation|Subjects will participate in an on-line neuro-navigation session in which 6 TMS coil positions will be recorded.
75886135|NCT02505425|Behavioral|Behavioral Support|"ENABLE CHF-PC includes:~In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
75886136|NCT02505425|Behavioral|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
75886137|NCT05196425|Genetic|Blood sampling|Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
75443952|NCT05094713|Other|Flossing experimental group|Flossing of the tight muscles with medium wrapping pressure, which is individualized in based on the tight circumference of the participant.
75443953|NCT05094713|Other|Low wrapping pressure|Control group where flossing wrapping pressure is between 20 and 30 mmHg
75443954|NCT05071729|Drug|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant on Day 1.
75443955|NCT05059886|Other|completion of a questionnaire on the practice of sports and possible injuries|completion of a questionnaire on the practice of sports and possible injuries
75443956|NCT05057949|Drug|Larotinib|Larotinib Capsules
75443957|NCT05057949|Drug|Rifampin|Rifampin Capsules
75443958|NCT05057949|Drug|Itraconazole|Itraconazole Capsules
75443959|NCT05048368|Drug|Larotinib|Capsules, Oral, 350 mg, single dose, one day
75443960|NCT05047159|Device|rTMS|"Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex."
75443961|NCT05047159|Device|light therapy|Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.
75886138|NCT03089047|Biological|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
75886139|NCT03089047|Biological|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
75886140|NCT01371006|Drug|low dose|efavirenz single dosing once daily
76056880|NCT01806597|Biological|secukinumab 300 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
76056881|NCT01806597|Biological|Placebo|Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
75737154|NCT04491045|Other|Workshop Training on Multicomponent Collaborative Care for Depression|Hybrid Workshop Trainings on Stepped collaborative care model for depression that involves using a team-based approach to integrating depression care components (screening, psychoeducation, Behavior Activation therapy, and antidepressant medications) into primary care settings. This integration involves task-shifting mental health tasks from mental health specialist to community providers at the commune health stations.
75737155|NCT04491045|Other|Supervision|Ongoing supervision and coaching is provided to community health providers by local mental health specialist from the provincial psychiatric hospital for 6-9 months
75443962|NCT05047159|Device|ECT|The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.
75443963|NCT05047159|Device|MST|A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram [EEG] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.
75443964|NCT05047159|Drug|drug therapy|There is no restriction on the choice of therapeutic drugs.
75443965|NCT05033431|Drug|Brazikumab|Participants will receive IV or SC injection of brazikumab as per the group they are assigned.
75593767|NCT03190265|Drug|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
75593768|NCT03190265|Drug|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
75737156|NCT04491045|Other|Community-Engaged Learning Collaborative|The CELC group will receive support for continuous quality improvement using a province-wide learning collaborative that will meet monthly for 3 months, followed by bi-monthly meetings for 12 months.
75737157|NCT00104299|Drug|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m^2 infusions once weekly for 4 week
75737158|NCT00104299|Drug|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
75737159|NCT00104299|Drug|Azathioprine|2 mg/kg/day orally for months 4-6
75886141|NCT01371006|Drug|normal dose|efavirenz once daily
75443966|NCT05023616|Other|Real-time home CPR training|The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.
75593769|NCT03190265|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
75886142|NCT01371006|Drug|low dose|Efavirenz single dosing once daily
75886143|NCT05195957|Procedure|Robotic tranversus abdominis release operation|Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
75737160|NCT00104299|Drug|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
75886144|NCT05195957|Procedure|Open transversus abdominis release operation|Original open TAR using midline incision.
75886145|NCT05009173|Procedure|Lumbar puncture using the stylet-in technique|This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.
75593770|NCT03190265|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
75886146|NCT05009173|Procedure|Lumbar puncture using the stylet-out technique|This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
75593771|NCT03160612|Behavioral|Transfer Training|Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
75737161|NCT00104299|Drug|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
75737162|NCT03939312|Drug|Atogepant|Atogepant Tablets
75737163|NCT00968552|Procedure|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
75737164|NCT00968630|Other|Laboratory Biomarker Analysis|Correlative studies
75737165|NCT00968630|Procedure|Leukapheresis|Undergo leukapheresis
75737166|NCT00963950|Procedure|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
75593772|NCT03150329|Other|Laboratory Biomarker Analysis|Correlative studies
75593773|NCT03150329|Biological|Pembrolizumab|Given IV
75593774|NCT03150329|Drug|Vorinostat|Given PO
75593775|NCT03124186|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
75593776|NCT03109041|Device|CivaSheet|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
75616275|NCT02844556|Procedure|SMILE surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
75737167|NCT00963950|Procedure|laparoscopic cholecystectomy|laparoscopic cholecystectomy
75737168|NCT01563432|Drug|Feburic®|80 mg*1 tablet
75737169|NCT01563432|Drug|TMX-67|40 mg*2 tablets
75886147|NCT04864925|Drug|Colgate Total Clean Mint|2 minutes of whole mouth toothbrushing
75737170|NCT00968786|Device|Home monitoring|automated measuring devices for patients using at home
75737171|NCT00960258|Drug|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
75737172|NCT04566926|Drug|JNJ-64140284|Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.
75737173|NCT04566926|Drug|Placebo|Participant will receive matching placebo.
75737174|NCT00082381|Drug|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
75737175|NCT00082381|Drug|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
75737176|NCT00964106|Drug|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
75737177|NCT00964106|Drug|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
75737178|NCT00964106|Drug|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
75737179|NCT00964106|Drug|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
75737180|NCT00964106|Drug|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
75737181|NCT00964106|Drug|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
75737182|NCT00964106|Drug|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
75737183|NCT00964106|Drug|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
75886148|NCT04864925|Drug|Tom's Botanically Bright Peppermint|2 minutes of whole mouth toothbrushing
75886149|NCT04111068|Device|anodal tDCS Active Stimulation|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
75886150|NCT04111068|Device|anodal tDCS Sham/Placebo Stimulation|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
75886151|NCT03820050|Device|Freestyle LIbre Flash Glucose Monitoring System|System Performance will be characterized with respect to YSI reference venous plasma measurements
75737184|NCT00964106|Drug|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
75737185|NCT00964106|Drug|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
75886152|NCT04180098|Behavioral|C-mill intervention|A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
75886153|NCT04180098|Other|No intervention|Participants in the control group are placed on a waiting list.
75737186|NCT00964106|Drug|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
75593777|NCT03103880|Device|BreatheSmart|BreatheSmart is a comprehensive asthma monitoring system that combines a medical device, mobile application, and mobile spirometry designed for use with iOS and Android operating systems. Using Bluetooth to connect, the devices sync with the mobile application to facilitate the collection of controlled medication adherence, rescue medication usage, lung function data, and asthma control.
76056882|NCT02031302|Device|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
75737187|NCT00960336|Drug|pegylated liposomal doxorubicin hydrochloride|
75737188|NCT00971646|Other|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
75737189|NCT00971646|Other|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
75737190|NCT00971646|Other|EuroQol-5D|This questionnaire grades the health condition of the subject.
75737191|NCT00971646|Other|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
75593778|NCT03057119|Behavioral|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
75737192|NCT00965172|Other|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
75737193|NCT00965172|Other|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
75737194|NCT01084681|Device|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
75737195|NCT01084681|Device|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
75737196|NCT04505852|Device|Embrace|Patients wear Embrace2 to help in seizure reporting and patient care.
75737197|NCT00960414|Behavioral|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detained nutritional education.
75737198|NCT00969020|Procedure|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
75886154|NCT02288897|Drug|PV-10 (10% rose bengal disodium)|
75886155|NCT02288897|Drug|Dacarbazine, temozolomide or talimogene laherparepvec|
75886156|NCT01371552|Device|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
75886157|NCT01371552|Device|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
76056883|NCT01610037|Drug|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
76056884|NCT01610037|Drug|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
76056885|NCT01610037|Drug|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
75593779|NCT03057119|Behavioral|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
75593780|NCT03057119|Behavioral|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
75737199|NCT01084837|Drug|velcade|"INDUCTIoN (Cycles 1-4)~Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)~For patients wich is not planned autotransplantation, add:~Cycles 5-8~Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)~EXTENSION TREATMENT(Cycles 9-12)~Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22~Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)"
76056886|NCT04687514|Drug|Dulaglutide|Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.
75737200|NCT03962413|Procedure|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
75737201|NCT00545844|Drug|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
75737202|NCT01084993|Drug|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
75737203|NCT01084993|Drug|Heparin|70 U/kg
75737204|NCT00492063|Biological|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
75737205|NCT00492063|Biological|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
75737206|NCT04008654|Behavioral|ERAS Protocol|"Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
75737207|NCT04008654|Behavioral|Conventional care|This group of patients will not receive the specific ERAS protocol but will receive conventional care.
76056887|NCT04687514|Drug|Placebo|Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
76056888|NCT01806051|Drug|Kuvan|Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
75737208|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
75737209|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
75737210|NCT00960492|Drug|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
75737211|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
76056889|NCT01837797|Drug|Placebo|Once daily, tablets, orally
76056890|NCT01837797|Drug|Brexpiprazole 1 mg|once daily dose, tablets, orally
76056891|NCT01837797|Drug|Brexpiprazole 3 mg|once daily dose, tablets, orally
76056892|NCT01984424|Drug|Atorvastatin|Atorvastatin was supplied as over-encapsulated 20 mg tablets
76056893|NCT01984424|Drug|Placebo to Atorvastatin|Placebo matching to atorvastatin supplied as over-encapsulated tablets
76056894|NCT01984424|Other|Placebo to Ezetimibe|Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
75593781|NCT03057119|Behavioral|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
75737212|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
75737213|NCT00960492|Radiation|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
75737214|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
75737215|NCT00971724|Drug|Placebo|Oral administration, once daily, for 15 days
75737216|NCT00971724|Drug|Prednisolone|Oral administration
76056895|NCT01984424|Drug|Ezetimibe|Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
76056896|NCT01984424|Other|Placebo to Evolocumab|Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
76056897|NCT01984424|Drug|Evolocumab|Evolocumab supplied as single-use prefilled autoinjector/pen(s)
76056898|NCT01837719|Drug|Atazanavir|300-mg capsule
76056899|NCT01837719|Drug|Cobicistat|150-mg tablet
75593782|NCT03057119|Behavioral|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
75593783|NCT02998983|Drug|Racotumomab|
76056900|NCT01837719|Drug|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
76056901|NCT01984268|Drug|ACTHAR|
75737217|NCT04331301|Procedure|Bipolar Vapo-Enucleation of the prostate|group A: Patient will be subjected to bipolar endoscopic enucleation of the prostate by vaporization electrode (vapoenucleation).
75737218|NCT04331301|Procedure|Bipolar Needlescopic Enucleation of the prostate|group B: Patient will be subjected to bipolar endoscopic enucleation of the prostate by hot knife electrode (Needlescopic Enucleation ).
75737219|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
76056902|NCT04675580|Behavioral|Toy Talk|Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.
76056903|NCT04675190|Procedure|Major abdominal Surgery|Any surgery performed under general or regional anesthesia and procedures involving abdominal cavity is considered major abdominal surgery and those who have undergone any major abdominal surgery before 6 months from the date of ultrasound findings confirming the presence or absence of gall stone will be considered exposed.
76056904|NCT04674800|Biological|MYL-1701P, a proposed biosimilar to Eylea|Open label and single arm
76056905|NCT02031146|Procedure|Lumbar puncture|
75593784|NCT02974647|Drug|Ruxolitinib|
76056906|NCT02009384|Drug|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
76056907|NCT01805037|Drug|brentuximab vedotin|Given IV
76056908|NCT01805037|Biological|rituximab|Given IV
75593785|NCT02943746|Dietary Supplement|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
75737220|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
75737221|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
76056909|NCT01805037|Other|laboratory biomarker analysis|Correlative studies
75737222|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
75737223|NCT05181813|Procedure|Ginge-Cal|Fill the infected root canal of of primary teeth with Gingerols extract and Calcium Hydroxide (Ginge-Cal)
75737224|NCT05181813|Procedure|Metapex|Fill the infected root canal of of primary teeth with Metapex
75737225|NCT00971880|Other|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
75737226|NCT02976909|Drug|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
75737227|NCT00960648|Device|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
75737228|NCT00960648|Device|Cypher|Retrospective historical controls that received sirolimus-eluting stent
76056910|NCT01803711|Drug|Desvenlafaxine|
76056911|NCT01803711|Dietary Supplement|Omega 3 Fatty acids|
75593786|NCT02943746|Dietary Supplement|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
75737229|NCT02878083|Drug|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
76056912|NCT01803711|Drug|Placebo (for Omega 3 fatty acid supplement)|
76056913|NCT01836549|Drug|imetelstat sodium|Given IV
76056914|NCT01836471|Drug|QAW039|QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
76056915|NCT01836471|Drug|Placebo QAW039|Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
75593787|NCT02882282|Other|Laboratory Biomarker Analysis|Correlative studies
75593788|NCT02882282|Other|Patient Observation|Undergo observation
75593789|NCT02882282|Biological|Pembrolizumab|Given IV
75616276|NCT02844556|Other|FS-LASIK surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
75616277|NCT02846116|Other|Prosthetic crown|
75616278|NCT00947193|Drug|Ataluren|Oral powder
75737230|NCT02878083|Drug|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
75737231|NCT00971958|Procedure|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
75737232|NCT00971958|Device|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
75737233|NCT00971958|Device|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
75737234|NCT00971958|Device|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
75737235|NCT00093145|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
75886158|NCT01371552|Device|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
76056916|NCT01836471|Drug|Fluticasone 250 mcg|Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
76056917|NCT01836471|Drug|Fluticasone 100 mcg|Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
76056918|NCT02030600|Drug|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
76056919|NCT02030600|Drug|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
76056920|NCT01802775|Drug|edoxaban|
76056921|NCT01802775|Drug|Clopidogrel|75mg tablet
76056922|NCT01802775|Drug|Aspirin|
75737236|NCT00093145|Drug|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
75886159|NCT02207075|Drug|[C11]PK-1195 PET scan|PET scan with tracer [C11]PK-1195
75886160|NCT05707572|Drug|methylprednisolone|a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine
76056923|NCT04591041|Device|HoloSIM Software via Hololens 2|Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
75443967|NCT05023616|Other|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance."
75443968|NCT05018858|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75443969|NCT05018845|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75443970|NCT05018819|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75443971|NCT05016817|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75593790|NCT02875158|Procedure|Cyclophotocoagulation protocol|"Intravenous route is installed~Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~Pars plana measurement using transillumination (if needed)~Laser treatment applied approximately 1mm post to limbus~Dexamethasone 0,5 mg subconjunctival injection~Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h"
75443972|NCT05016804|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75443973|NCT05010993|Diagnostic Test|Nine Hole Peg Test|Each person will be tested by the Nine Hole Peg Test (3 attempts per subtest)
75443974|NCT05010993|Diagnostic Test|Purdue Pegboard Test|Each person will be tested by the Purdue Pegboard Test (3 attempts per subtest)
75443975|NCT05010993|Diagnostic Test|Box and Block Test|Each person will be tested by the Box and Block Test (3 attempts per subtest)
75737237|NCT00093145|Drug|Herceptin®|Administered by IV infusion
75737238|NCT02808195|Other|Constraint-induced therapy|
75737239|NCT02808195|Other|kinect-based constraint-induced therapy|
75593791|NCT02875158|Procedure|Conventional cyclophotocoagulation|1250 mW for 4 seconds.
75737240|NCT00965328|Procedure|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
75737241|NCT00965328|Procedure|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
75737242|NCT01014039|Procedure|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
76056924|NCT04591041|Other|Training by Mannequin Based Simulation|Medical students will train a via traditional mannequin based medical crisis scenario
76056925|NCT01802385|Drug|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
75443976|NCT05009277|Device|Device|LINDA thermal device
75443977|NCT05003947|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75443978|NCT05003934|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75593792|NCT02875158|Procedure|Modified cyclophotocoagulation|2000 mW for 2 seconds.
75616279|NCT03425812|Drug|To withdraw NSAIDs therapy|NSAIDs therapy will be withdrew after washout period.
75737243|NCT00965406|Drug|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
75886161|NCT05707572|Procedure|manual manipulation|The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
76056926|NCT01773993|Drug|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
75593793|NCT02843945|Device|Directional Brachytherapy Source Implant|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
75593794|NCT02816099|Biological|Prise de sang|
76056927|NCT01802073|Drug|Oral Vancomycin|
75737244|NCT00960726|Drug|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
75737245|NCT00972036|Device|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
76056928|NCT01607073|Drug|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
76056929|NCT01773291|Other|acupuncture|acupuncture on GV26 and 12 Well points
76056930|NCT01773291|Other|laser acupuncture|laser acupuncture on GV26 and 12 Well points
76056931|NCT01773291|Other|control|sham laser acupuncture
75443979|NCT05001581|Procedure|Arthroscopic partial repair of massive rotator cuff tear|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons
75443980|NCT05001581|Procedure|Arthroscopic partial repair of rotator cuff with biceps augmentation|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons and because of good quality of the long head of the biceps tendon, its uses as biological reinforcement of the reconstruction to achieve better clinical and radiological outcome
75593795|NCT02755610|Other|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
75737246|NCT00513357|Drug|Melatonin|20 mg by mouth daily for 4 Weeks
75737247|NCT00513357|Drug|Placebo|Capsule by mouth daily for 4 Weeks
75737248|NCT00960882|Drug|DMMET-01|1050.6 mg daily for 30 days
75593796|NCT02711852|Drug|Duvelisib|Administered as oral capsules
75593797|NCT02703597|Behavioral|Surveys|Surveys include questions related to tobacco use behavior and attitude toward tobacco, as well as demographic and personality questions. Psychosocial surveys and social network surveys are also completed to capture adolescents' network of friends and opinion leaders.
75737249|NCT05163678|Other|monitoring naturalistic of cohort|"Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6)."
75737250|NCT00972114|Procedure|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
75737251|NCT00972114|Procedure|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
75737252|NCT00972114|Procedure|CABG alone|Coronary artery bypass graft surgery alone
75737253|NCT01014117|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
75737254|NCT01014117|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
75886162|NCT04854629|Other|Spinomed active|Wearing of the orthosis 2-3 h/twice a day for 16 weeks Supplementation of a maximum of 1000 mg/d calcium and 800 IE/d vitamin D
76056932|NCT01801917|Drug|Placebo|Matching placebo tablet for oral administration
76056933|NCT01801917|Drug|BAF312|BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
76056934|NCT04170075|Behavioral|Whole Body Vibration|Undergo WBV
76056935|NCT02008916|Drug|Secukinumab|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).
76056936|NCT02008916|Drug|Placebo secukinumab|Placebo to AIN457 (Secukinumab)
75737255|NCT00960960|Drug|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
75886163|NCT04068636|Procedure|Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.|Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
75737256|NCT00960960|Drug|Pictilisib|Pictilisib will be administered PO QD on escalating doses.
75737257|NCT00960960|Drug|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
75886164|NCT03633071|Other|Web-knee brace|Web -Knee Brace
75886165|NCT02035800|Drug|Adalimumab|Patient will received medication as standard of care
75886166|NCT04807361|Behavioral|Auditory biofeedback traing|Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
76056937|NCT01772823|Behavioral|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
75443981|NCT04980365|Behavioral|Mindfulness|Participants will be asked to use the app Mindfulness Coach daily for 10 minutes. Participants will follow app instructions for brief guided meditation sessions for 14 days.
75443982|NCT04980365|Behavioral|Gratitude|Participants will be asked to use the app Grateful daily for 10 minutes. Participants will follow app instructions and will be answering to prompts related to gratitude provided by the app daily, for 10 minutes for 14 days.
75443983|NCT04980365|Behavioral|Food Journal|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
75443984|NCT04976959|Drug|High Fiber supplement|The supplement consists of a mixture of soluble fibers (from inulin and fibersol-2) and insoluble fibers (from oat bran, corn bran, wheat bran and sorghum bran) and it will be consumed as a drink.
75616280|NCT03425812|Drug|To continue NSAIDs therapy|NSAIDs therapy will be continued.
75737258|NCT00960960|Drug|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
75616281|NCT00947115|Procedure|Blood sampling|Blood samples were collected at Years 5, 6, 7, 8, 9 and 10.
75616282|NCT00947115|Procedure|Cervico-vaginal secretion (CVS) samples|CVS samples were collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteered for this procedure.
75616283|NCT02845804|Device|Alpine|
75616284|NCT02845960|Behavioral|rapid recovery|rapid recovery
75616285|NCT02844634|Drug|Doxycycline 100mg PO daily x 12 months|Immediate use of daily doxycycline (12 months duration, to start immediately)
75737259|NCT00960960|Drug|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
75616286|NCT02844634|Drug|Tenofovir/emtricitabine 200/300mg PO daily|Daily use of tenofovir/emtricitabine
75616287|NCT02844634|Drug|Doxycycline 100mg PO daily x 6 months|Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
75737260|NCT00972192|Behavioral|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
75886167|NCT05195021|Device|EDDY|EDDY (VDW) sonic irrigation activation system
75886168|NCT05195021|Device|Diode Laser device|980-nm diode laser device
75886169|NCT05195021|Device|Conventional irrigation|Conventional root canal irrigation with 31-guage side port needle
75886170|NCT05707650|Procedure|reverse breech extraction technique or push technique|using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix
75886171|NCT03993912|Drug|Daratumumab SC in combination with Lenalidomide|"Daratumumab SC 1800 mg~once every week for 8 weeks~then once every other week for 16 weeks~thereafter once every 4 weeks, until progression"
75443985|NCT04959162|Device|E-learning|Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound
75443986|NCT04959162|Device|Conventional preparation|Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
75443987|NCT04936620|Procedure|Duroplasty|Expansion Duroplasty
75737261|NCT00972192|Behavioral|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
75886172|NCT03993912|Drug|Lenalidomide PO (25mg)|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
75886173|NCT03993912|Drug|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
75886174|NCT05194943|Procedure|revisional bariatric surgical procedures|Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
75886175|NCT05598697|Behavioral|Life Skills Building (LSB) curriculum for males|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All male study participants attending LSB curriculum classes are married to BISP-CT clients.~For men, the MEWE intervention provides access to the LSB curriculum only."
76056938|NCT01772823|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
76056939|NCT01772823|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
76056940|NCT04177082|Combination Product|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
75737262|NCT04315857|Other|interstitial glycaemia|Continuous measurement of interstitial blood glucose during the first 15 days of the first two chemotherapy courses.
75737263|NCT01014195|Other|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
75886176|NCT05598697|Behavioral|Life Skills Building (LSB) curriculum for females|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs."
75886177|NCT05598697|Other|Cash transfer to adult females|The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
75886178|NCT01568749|Drug|Paracetamol|Paracetamol
75886179|NCT01568749|Drug|Paracetamol formulation 1|Paracetamol
75886180|NCT01568749|Drug|Paracetamol Formulation 2|Paracetamol
75886181|NCT01568749|Drug|Paracetamol formulation 3|Paracetamol
75886182|NCT01568749|Drug|Paracetamol formulation 4|paracetamol
75886183|NCT03920358|Device|FRED, FRED Jr and FRED X|Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm
75443988|NCT04936620|Procedure|Spinal surgery|Spinal surgery including laminectomy
75443989|NCT04904432|Genetic|PLIN1 gene sequencing|One supplementary blood sample will be taken (compare to classical ACS treatment and follow up) to realize genetic analyse of PLIN1 gene, looking for mutations
75593798|NCT02703597|Behavioral|ASPIRE|Participants engage in four to five 70-minute sessions of ASPIRE spread over a period of 4 weeks. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco.
75593799|NCT02703597|Behavioral|GSA-ASPIRE-Network|In groups, participants engage in four to five 70-minute sessions of ASPIRE conducted over a period of 4 weeks. However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
75886184|NCT03633851|Device|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
75886185|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
76056941|NCT02029976|Behavioral|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
76056942|NCT02029976|Behavioral|Mailed monthly newsletters|Newsletters
75737264|NCT00972270|Device|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
76056943|NCT01983254|Behavioral|coping skills training|6-session coping skills training program delivered by telephone w/ web augmentation
76056944|NCT01983254|Other|education program|web-based, ICU-specific education program
76056945|NCT01771809|Drug|75mg SHP647 (PF-00547659)|75 mg sterile liquid injected subcutaneously every 4 weeks.
76056946|NCT01771809|Drug|225mg SHP647 (PF-00547659)|225 mg sterile liquid injected subcutaneously every 4 weeks.
76056947|NCT01771731|Drug|Cannabis|
75443990|NCT04901312|Behavioral|Adolescent Community Reinforcement Approach|The Adolescent Community Reinforcement Approach (A-CRA) is a developmentally-appropriate behavioral treatment for youth and young adults ages 12 to 24 years old with substance use disorders. A-CRA seeks to increase the family, social, and educational/vocational reinforces to support recovery. This intervention has been implemented in outpatient, intensive outpatient, and residential treatment settings. A-CRA includes guidelines for three types of sessions: individuals alone, parents/caregivers alone, and individuals and parents/caregivers together. According to the individual's needs and self-assessment of happiness in multiple life areas, clinicians choose from a variety of A-CRA procedures that address, for example, problem-solving skills to cope with day-to-day stressors, communication skills, and active participation in positive social and recreational activities with the goal of improving life satisfaction and eliminating alcohol and substance use problems.
75443991|NCT04901312|Behavioral|Assertive Continuing Care|Assertive Continuing Care (ACC) uses Community Reinforcement Approach (CRA) procedures, home visits, and case management for individuals following an initial substance use treatment episode. It stresses rapid initiation of services after discharge from residential, intensive outpatient, or regular outpatient treatment in order to promote recovery and prevent relapse.
75593800|NCT02688114|Procedure|Baseline surveillance endoscopy|All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
75593801|NCT02688114|Procedure|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
75593802|NCT02688114|Procedure|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
75593803|NCT02688114|Procedure|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
75737265|NCT00972270|Device|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
76056948|NCT01982942|Drug|ibudilast|Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
76056949|NCT01982942|Drug|Placebo oral capsule|Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
76056950|NCT01769469|Drug|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
76056951|NCT02008526|Behavioral|Text Messages Transmitted by Peer Health Educators (TXT-PHE)|"Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
76056952|NCT02008526|Behavioral|Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
76056953|NCT04581915|Drug|Triazavirin (Riamilovir)|Capsule - 250mg 8 hourly po
75737266|NCT01015521|Drug|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
75737267|NCT00965640|Drug|Botulinum Toxin - A injections|
75737268|NCT04307277|Drug|Standard of care + chemotherapy|Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
75737269|NCT04307277|Other|Standard of care|Surgical excision with external radiotherapy (if applicable)
75886186|NCT04443829|Biological|CD19CAR T-cells|Infusion with: CD19CAR T-cells
76056954|NCT04581915|Other|Placebo|Placebo capsule
76056955|NCT01769391|Drug|Necitumumab|Administered IV
75737270|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
75886187|NCT02819310|Drug|BLI400 Laxative|oral laxative
75886188|NCT03633773|Biological|MUC-1 CART cell immunotherapy|After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
76056956|NCT01769391|Drug|Paclitaxel|Administered IV
76056957|NCT01769391|Drug|Carboplatin|Administered IV
76056958|NCT01800903|Device|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
76056959|NCT01800903|Device|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
76056960|NCT01800903|Device|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
75886189|NCT01375361|Drug|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
75886190|NCT01375361|Drug|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
75443992|NCT04901312|Behavioral|Trauma Affect Regulation Guide for Education and Therapy|Trauma Affect Regulation: Guide for Education and Therapy is a psychosocial intervention for traumatized adolescents, adults, and families, and for workforce and organizational responses to secondary/vicarious traumatization. T4, the 4-session version, provides education about the impact of complex traumatic stress on the brain's stress response system, and strengths-based practical skills for re-setting the trauma-related alarm/survival reactions that occur in complex PTSD.
76056961|NCT04413747|Behavioral|morning Yoga-based breathing support|Low and deep inspiration and phonetic syllable OM laryngeal vibration ( OM technique) as expiratory exercises, sitting in easy pose. The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Bhramari pranayama n° of 5 RAc.
76056962|NCT04413747|Behavioral|pre_lunch Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Surya Bheda pranayama n° of 5 RAc.
75443993|NCT04901312|Behavioral|Motivational Interviewing|Motivational interviewing is a collaborative, person-centered form of guiding to elicit and strengthen motivation for change.
75443994|NCT04901312|Other|Opioid Education Workbook|A digital workbook designed to be completed on a computer in about 2 hours. Topics include opioid use, opioid use disorder, and prevention and treatment of opioid overdose.
75443995|NCT04886297|Drug|Mega Resveratrol® capsules|Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.
75443996|NCT04886297|Drug|Mega Resveratrol® Placebo capsules|Mega Resveratrol® Placebo capsules
75593804|NCT02688114|Procedure|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
75737271|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
75737272|NCT00961038|Drug|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
75737273|NCT00972348|Other|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
75886191|NCT03087643|Other|Passive mobilization - PM|
75886192|NCT05194865|Device|cardiac MRI|assessment of the viability using CMR
75443997|NCT04810793|Drug|Amoxicillin , Levofloxacin and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
75443998|NCT04810793|Drug|Amoxicillin , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
75443999|NCT04810793|Drug|Tetracycline , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
75444000|NCT04810793|Drug|Amoxicillin,Levofloxacin and Vonoprazan fumarate|Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
75444001|NCT04810793|Drug|Amoxicillin,Furazolidone and Vonoprazan fumarate|Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
75444002|NCT04810793|Drug|Tetracycline,Furazolidone and Vonoprazan fumarate|Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
75593805|NCT02615691|Biological|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII).
75593806|NCT02615691|Biological|ITI|Immune tolerance induction therapy
75593807|NCT02579460|Other|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
75593808|NCT02573779|Other|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
75593809|NCT02530463|Drug|Azacitidine|Given IV
75593810|NCT02530463|Biological|Ipilimumab|Given IV
75593811|NCT02530463|Other|Laboratory Biomarker Analysis|Correlative studies
75593812|NCT02530463|Biological|Nivolumab|Given IV
75737274|NCT00972348|Other|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
75737275|NCT00961194|Drug|Ketamine|"Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~0.35 mg/kg~0.7 mg/kg~1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
75737276|NCT02665923|Other|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
75886193|NCT05194865|Procedure|Percutaneous coronary intervention|direct revascularization using PCI
75886194|NCT02821962|Behavioral|Sedentary prompts from a VTAP device|
75886195|NCT05598541|Procedure|Surgical or non-surgical treatment|Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
75886196|NCT01376765|Drug|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
75444003|NCT04797832|Drug|IV Sodium Ferric Gluconate Complex|125 mg of IV Iron per day to 3 to 5 days according to hospitalisation length.
75886197|NCT01376765|Other|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
75886198|NCT01376765|Biological|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
75593813|NCT02475434|Dietary Supplement|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
75593814|NCT02429570|Drug|Meclofenamate|
75444004|NCT04742647|Procedure|Double cerclage|Two cervical cerlages will be placed
75593815|NCT02342613|Biological|Activated PTCy-MILs|The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
75593816|NCT02221934|Device|Altius|Electrical signal
75593817|NCT02204072|Drug|BI 836845|
75593818|NCT02204072|Drug|Enzalutamide|
75593819|NCT02204072|Drug|Enzalutamide|
75593820|NCT02163525|Procedure|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
75593821|NCT02163525|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
75593822|NCT02163525|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
75737277|NCT03933462|Device|InnoSpire Go|Participants will use for 30 days.
75737278|NCT03933462|Device|Jet Nebulizer|Participants will use for 30 days.
75737279|NCT03929562|Behavioral|Brief advice|One 10-minute brief advice session
75444005|NCT04742647|Procedure|Single cerclage|One cerclage will be placed
75444006|NCT04709575|Drug|REGN5713|Administered subcutaneously
75444007|NCT04709575|Drug|REGN5714|Administered subcutaneously
75444008|NCT04709575|Drug|REGN5715|Administered subcutaneously
75444009|NCT04709575|Drug|Placebo|Placebo that replaces REGN5713-5714-5715
75444010|NCT04684511|Drug|TRM-201 (Rofecoxib)|Eligible patients will be randomized to receive TRM-201 or placebo
75444011|NCT04684511|Drug|Placebo|Matching Placebo
75444012|NCT04679311|Biological|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with fresh frozen plasma that has been preselected for ACE activity content of ≥ 50 U/L
75593828|NCT02143128|Other|Efficacy Safety Score|Evaluation using the score for postoperative patients
75593829|NCT02143128|Other|Verbal Numeric Rating Scale|Patients assessed for postoperative pain using VNRS (0-10)
75593830|NCT01977417|Drug|Salsalate|
75593831|NCT01977417|Drug|Placebo|
75593832|NCT01969578|Drug|bicalutamide + triptorelin|
75593833|NCT01969578|Drug|Cisplatin + Doxorubicin|
75593834|NCT01969578|Drug|Carboplatin + Paclitaxel|
75737280|NCT03929562|Behavioral|Health coaching|Two 45-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
75737281|NCT05279586|Drug|lactulose|all interventions are used in secondary prophylaxis in cirrhotic patients
75737282|NCT05279586|Drug|colistin|all interventions are used in secondary prophylaxis in cirrhotic patients
76056963|NCT04413747|Behavioral|pre_dinner Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Nadi Shodhana pranayama n° of 5 RAc.
76056964|NCT01767987|Drug|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
76056965|NCT01767987|Drug|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
76056966|NCT01800201|Behavioral|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
76056967|NCT01767909|Drug|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
76056968|NCT01767909|Drug|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
75737283|NCT00965796|Drug|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
76056969|NCT02029274|Drug|BAF312|BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
76056970|NCT02029274|Drug|Placebo|Matching placebo to BAF312 as tablets for oral administration.
75737284|NCT00415636|Drug|IC83/LY2603618|40 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m^2.
76056971|NCT02008370|Drug|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
76056972|NCT01981616|Drug|Vedolizumab|Vedolizumab for intravenous infusion
76056973|NCT01981616|Drug|Placebo|Placebo intravenous infusion
76056974|NCT01981616|Biological|Hepatitis B vaccine|
76056975|NCT01981616|Biological|Oral cholera vaccine|
75737285|NCT00415636|Drug|IC83/LY2603618|70 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
75737286|NCT00415636|Drug|IC83/LY2603618|105 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
75737287|NCT00415636|Drug|IC83/LY2603618|150 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
75737288|NCT00415636|Drug|IC83/LY2603618|195 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
75444013|NCT04679311|Other|Normal Saline|Subjects will be treated with normal saline 500 cc
75444014|NCT04673149|Biological|GLS-5310|GLS-5310 DNA plasmid vaccine
75444015|NCT04673149|Biological|Placebo|Placebo
75444016|NCT04669652|Device|Piezo-ICSI|During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjection of a sperm with less psychical stress applied on the oocytes than by the conventional technique.
75444017|NCT04644978|Other|anonymous online survey|An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.
76056976|NCT02104817|Drug|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
76056977|NCT02104817|Drug|corn oil control|corn oil control arm
75444018|NCT04637438|Other|Fecal Microbiota Transplantation|FMT via colonoscopy
76056978|NCT01962103|Drug|nab-paclitaxel|nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
76056979|NCT01962103|Drug|nab-paclitaxel|IV infusion
75444019|NCT04637438|Other|Placebo|Water infusion via colonoscopy
75444020|NCT04624854|Drug|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
75593835|NCT01951885|Drug|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
75444021|NCT04624854|Drug|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
75593836|NCT01951885|Drug|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient < 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
75737289|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
75737290|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
75737291|NCT00965874|Drug|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
75737292|NCT00965874|Drug|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
75737293|NCT00965874|Drug|Placebos|serum salin
75444022|NCT04912648|Other|Longitudinal follow up|Repeat follow up at 3,5 and 10 years
75444023|NCT04636164|Diagnostic Test|Model Dermatology (deep neural networks; Build 2020)|Physicians in the DNN group take pictures of the skin lesion and use the algorithm by uploading pictures.
75444024|NCT04565171|Drug|Yimitasvir Phosphate Capsule|DAG181 100 mg (100 mg Capsule) administered orally
75886199|NCT04404205|Diagnostic Test|Postural stability measurements by Biodex Balance System|Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
75886200|NCT04788563|Other|Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
75886201|NCT04788563|Drug|Original antihypertensive treatment (compulsively randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
75886202|NCT04788563|Other|Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
75593837|NCT01951885|Drug|Mycophenolate mofetil|Patients will receive Mycophenolate beginning on day +1. Patients >40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients < 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol
76056980|NCT01961323|Drug|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP<140 and DBP <90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
75444025|NCT04528238|Other|Relaxing Visual Immersion|During the intravenous treatment for cancer, a nature movie will be projected on the ceiling of the room, along with natural sounds or a relaxing music. The patient will choose the movie or movies he wants to watch and can decide to stop the Relaxing Visual Immersion (RVI) at any time. The RVI is a system that does not isolate the patient from his familiar or medical entourage and which integrates virtual scenarios in the environment of care.
75593838|NCT01951885|Drug|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
75593839|NCT01810588|Device|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
75886203|NCT04788563|Drug|Original antihypertensive treatment (voluntarily randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
76056981|NCT04186403|Drug|Brexpiprazole|Administered as tablets.
76056982|NCT01960855|Drug|ABT-494|ABT-494 capsule administered orally twice daily (BID).
76056983|NCT01960855|Drug|Placebo|Placebo for ABT-494 capsule administered orally twice daily (BID).
76056984|NCT02007434|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
76056985|NCT02007434|Drug|Placebo|Phosphate buffered saline placebo for injection
76056986|NCT02007434|Other|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
75444026|NCT04505449|Diagnostic Test|Left heart catheterization|Patients who underwent left heart catheterization
75444027|NCT04463719|Behavioral|Counseling using the electronic conversation aid|Patients receive counseling about thyroid biopsy with the use of the conversation aid.
75444028|NCT04463719|Behavioral|counseling by routine care|Patients receive counseling by routine care without the use of the conversation aid
75444029|NCT04450407|Drug|LY3209590|Administered SC
75444030|NCT04450407|Drug|Insulin Degludec|Administered SC
75444031|NCT04396886|Drug|Bintrafusp Alfa|Bintrafusp alfa will be administered intravenously every 2 weeks
75444032|NCT04388826|Drug|Veru-111|Respiratory Distress Syndrome, Adult
75444033|NCT04336202|Radiation|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
75444034|NCT04334681|Procedure|Un-roofing curettage method|In this method, the roof of the pilonidal cyst is opened, and the inside is cleaned, and curettage is performed. The wound is closed with a dressing after hemostasis.
75444035|NCT04334681|Procedure|Modified Limberg Flap Group|In this method, the pilonidal cyst is excised with a rhomboid incision and closed with the modified Limberg flap method.
75593840|NCT01810588|Drug|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
75593841|NCT01810588|Drug|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
76056987|NCT02007434|Drug|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
76056988|NCT02007434|Drug|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
76056989|NCT02007434|Drug|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
76056990|NCT02007434|Other|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
76056991|NCT01987453|Drug|LDV/SOF|Tablet(s) administered orally once daily
76056992|NCT01987453|Drug|RBV|"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."
75593842|NCT01810588|Drug|anti-thymocyte globulin (rabbit)|Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
75593843|NCT01810588|Drug|Rituximab|Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
75593844|NCT01810588|Radiation|Total Body Irradiation|Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
75593845|NCT01810588|Drug|Mycophenolate Mofetil|Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
75616288|NCT02844478|Behavioral|SBP English|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.
75737294|NCT00972426|Drug|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
75737295|NCT00972582|Dietary Supplement|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
75737296|NCT00972660|Biological|Mesenchymal stem cell (MSC)|"Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).~Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally)."
76056993|NCT02006641|Drug|Placebo|Once daily, matching placebo capsules, orally
76056994|NCT02006641|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
76056995|NCT04416919|Other|Assembled mask|Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
76056996|NCT04652167|Diagnostic Test|PCT|"Serum PCT concentration is quantified with an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas e801. Calibration (BRAHMS PCT LIA assay) is performed once per reagent lot and no later than 24 h after Cobas e pack has been registered in the instrument. Quality control is performed after each calibration."
76056997|NCT04652167|Diagnostic Test|suPAR|Serum suPAR was measured using suPARnostic© Turbilatex assay reagents (validated on Cobas© c111) protocol for Cobas© c702 and c502 applying the Multi-Pack cassettes (Roche Diagnostics, Mannheim, Germany). Calibration is performed at least once a month or in connection to a new batch of TurbiLatex reagents, after calibration a quality control is performed.
75737297|NCT00972660|Drug|Prednisone and cyclosporine or primary therapies|"Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus~Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)"
75886204|NCT04788563|Other|Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
75886205|NCT04788563|Drug|Original antihypertensive treatment (preference selection arm)|In this group, patients will maintain their original antihypertensive treatment.
75886206|NCT05196347|Drug|Dapagliflozin|In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip <20%.
75886207|NCT03092479|Behavioral|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
75886208|NCT01358201|Drug|vINCRISTINE|
75886209|NCT01358201|Drug|Dexamethasone|
75886210|NCT01358201|Drug|Methotrexate|
75593846|NCT01810588|Drug|Tacrolimus|Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
75593847|NCT01698840|Dietary Supplement|Vitamin D|
75593848|NCT01698840|Dietary Supplement|Placebo|
75737298|NCT00961506|Procedure|LESS cholecystectomy|LESS cholecystectomy
75886211|NCT01358201|Drug|Cytosine arabinoside|
75886212|NCT00732797|Behavioral|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
75886213|NCT00732797|Behavioral|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
75886214|NCT03086551|Device|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
75886215|NCT03086551|Device|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
75886216|NCT03086551|Behavioral|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
75593849|NCT01627301|Device|Device-Guided Breathing (DGB)|The RESPeRATE device will be used for 15 minutes of device-guided breathing daily for 8 weeks. The participant places the elastic belt with a respiration sensor around the upper abdomen, and wears earbuds for audio feedback. The device monitors the breathing rate, calculates inspiration and expiration times, and generates a personalized melody of two distinct ascending and descending tones for inhalation versus exhalation. Users effortlessly entrain their breathing pattern with the tones, and the device gradually guides the user to a prolonged expiration time and slower respiratory rate (to < 10 breaths/minute). The device automatically stores usage data, allowing for quantification of adherence and performance.
75737299|NCT00961506|Procedure|Laparoscopic cholecystectomy|laparoscopic cholecystectomy
75737300|NCT04008966|Drug|combined oral contaraceptive pills|1 tablet daily between days 5 and 25 of the cycle before stimulation
75737301|NCT04008966|Drug|recombinant FSH|300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
75886217|NCT01375439|Other|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
75886218|NCT05193773|Other|multifactorial interventions|The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
75886219|NCT05193617|Drug|GP+Peramprizumab+Anlotinib|GP combine with peramprizumab and anlotinib neoadjuvant therapy+CCRT+peramprizumab adjuvant therapy
75886220|NCT05193617|Drug|GP+Peramprizumab|GP combine with peramprizumab neoadjuvant therapy+CCRT+peramprizumab adjuvant therapy
76056998|NCT04652167|Diagnostic Test|Standard care|Standard care is the measurement of CRP (C-reactive protein) will be measured with C - reactive protein (CRP4) immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi cobas© systems c701/702. Calibration is performed (Tina-quant® C - reactive protein IV) once per reagent lot and after 6 months using the same reagent lot. Quality control is required after calibration and according manufacturing instructions.
76056999|NCT01959919|Device|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
75444036|NCT04317911|Other|Catheter Ablation|Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.
75737302|NCT04008966|Drug|Urinaru gonadotropin|150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
75444037|NCT04309292|Dietary Supplement|Prebiotic food supplement|Darmocare Pre = trade name Gut microbiome modulator
75886221|NCT03265249|Device|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
75444038|NCT04309292|Dietary Supplement|Protein supplement|commercially available protein supplementation with high leucine content
75444039|NCT04309292|Dietary Supplement|Maltrodextrin (placebo)|Starchy substance
75444040|NCT04306601|Device|Low-Intensity Focused Ultrasound|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
75444041|NCT04301544|Behavioral|INDAK (Improving Neurocognition through Dance and Kinesthetics)|INDAK (Improving Neurocognition through DAnce and Kinesthetics) is a structured modular dance consisting of 8 types of ballroom dances (Reggae, Cha-cha, Samba, Merengue, Bachata, Swing, Tango and Salsa) with increasing complexity. The intervention group will receive dance intervention from a dance teacher two times a week, one hour each time, for 12 months. Each 60-minute session has 3 parts: 10 minutes warm-up/ stretching, 40 minutes dance proper and 10 minutes cool down. This dance intervention will last for 12 months.
75593850|NCT01627301|Device|Sham DGB|The sham device is identical to the DGB device, except it does not guide respiratory rates to slow down and instead maintains a rate of 14 breaths per minute. The sham device is used for 15 minutes per day for 8 weeks.
75593851|NCT01627301|Device|Transcutaneous Vagal Nerve Stimulation (tVNS)|tVNS is a noninvasive method that involves placing a device over the skin overlying the vagus nerve on the neck. The device delivers mild electrical stimulation, using transcutaneous electrical nerve stimulation (TENS) unit. The stimulation is increased until there is a vibration and slight muscle contraction in the lower face or neck. Then the stimulation is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes. The tVNS device is used twice daily for 8 weeks.
75593852|NCT01627301|Device|Sham tVNS|Sham stimulation is delivered using a device that is identical to the gammaCore device but is programed to deliver a lower frequency that can be felt by the participant but does not actually stimulate the vagus nerve. The sham device is used twice daily for 8 weeks.
75737303|NCT04008966|Drug|GnRH antagonist|0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
75737304|NCT04008966|Drug|Human chorionic gonadotropin|10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
75737305|NCT04008966|Drug|GnRH agonist|0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
75737306|NCT04008966|Procedure|Ovum pick up|34 hours after triggering under the guidance of transvaginal ultrasound
75886222|NCT04778111|Other|Measurement of the actual and perceived maximum reachable distance|A device (a table) will present luminous targets (green circles) to the subjects. Subjects will be asked to determine whether or not they are able to reach this target with their upper limb.
75886223|NCT04772261|Diagnostic Test|13C-Spirulina GEBT|Various lots of 13C-Spirulina GEBT test meals
75886224|NCT05193461|Procedure|Pulsed mood radiofrequency on dorsal root ganglion|3) Pulsed radio frequency (PRF): PRF of the dorsal root ganglion (DRG) will be performed to all participants in this study. The procedures will be performed in the operating room under fluoroscopic guidance following radiation safety standards. The dorsal root ganglion of lumbosacral roots will be targeted. The patients will be positioned prone .Lidocaine 1% will be infiltrated at the skin entry site. A 10 cm, 22-gauge radiofrequency needle with a 5 mm curved active tip will be used. A radiculogram will be done to confirm appropriate placement and DRG will be stimulated for confirmation of the appropriate nerve root involved. Proximity of the needle to the DRG will be determined by appropriate sensory stimulation with 50 Hz (0.4-0.6 V), and motor stimulation at 2 Hz will be used to determine a threshold 1.5-2.0 times greater than the sensory threshold to avoid placement near the anterior nerve root. A pulsed lesion will be generated by applying 45 V to the DRG for 6 minutes at 42°C.
75886225|NCT04726475|Behavioral|Interoceptive Aversive Memory Reactivation|In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
75886226|NCT04726475|Dietary Supplement|Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil|300mg CBD-rich hemp-derived formulation in MCT coconut oil.
75737307|NCT04008966|Procedure|Embryo transfer|Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
75737308|NCT04008966|Drug|natural Progesterone|400 mg twice daily per vagina
75737309|NCT00425854|Drug|BIBW 2992|high dose once daily
75737310|NCT00961740|Behavioral|Cognitive Behavioural Therapy|See summary
75737311|NCT00961740|Other|Waitlist condition|See Summary
75737312|NCT02771938|Other|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
75737313|NCT00972972|Dietary Supplement|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
75737314|NCT00972972|Dietary Supplement|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
75737315|NCT00425698|Drug|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
75737316|NCT00425698|Drug|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
75737317|NCT00966030|Drug|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
75737318|NCT00966030|Drug|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
75737319|NCT01037530|Drug|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
75737320|NCT00973050|Drug|Bicalutamide|50 mg Tablet
75886227|NCT04726475|Dietary Supplement|Placebo Oil|3ml oral dose of MCT coconut oil.
76057000|NCT04176601|Behavioral|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
76057001|NCT01986985|Device|PET/MRI system|Compared to PET CT
75593853|NCT01499888|Procedure|Allogeneic Non-Myeloablative Stem Cell Transplantation|"Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion"
75593854|NCT01499888|Drug|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
75593855|NCT01499888|Drug|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
75593856|NCT01487928|Dietary Supplement|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
75593857|NCT00745316|Drug|Tonapofylline|Oral Tonapofylline - 2 capsules bid
75593858|NCT00745316|Drug|Placebo|Oral placebo - 2 capsules bid
75593859|NCT00709865|Drug|tonapofylline|IV
75593860|NCT00709865|Drug|Placebo|IV
75593861|NCT00682318|Drug|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
75737321|NCT00973050|Drug|Casodex®|50 mg Tabelt
75737322|NCT00973128|Drug|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
75886228|NCT05747495|Other|Online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link [https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/]."
75593862|NCT00682318|Dietary Supplement|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
75737323|NCT00973128|Drug|Meglumine antimoniate|20mg/daily for 20 days
75737324|NCT00966108|Device|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
75737325|NCT00973908|Drug|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
75737326|NCT00973908|Drug|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
75737327|NCT00966342|Drug|Fluviral 2009/10|single dose given IM .05 mL
75737328|NCT00966420|Device|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
75737329|NCT00966498|Procedure|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
75737330|NCT00973986|Drug|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
75886229|NCT05183945|Device|Localization needle|A localization needle which is used for preoperative localization of lung nodules.
75886230|NCT05183945|Device|Coil|A coil which is used for preoperative localization of lung nodules.
75444042|NCT04301544|Behavioral|Nutrition Counseling|The dietary advice will follow Filipino Nutrition Research Institute (FNRI) recommendation called Pinggang Pinoy or Filipino Plate, which is a picture of a nine-inch plate with foods proportionally distributed among the food groups to provide approximately 1,200 to 1,500 calories per day. It is advised that half of the plate is composed of green leafy vegetables and one serving of fruit per meal. For fruits, 4 to 6 servings are encouraged per day. In general, affordable nutritious food is recommended: high consumption of local fruits and vegetables, brown/purple rice instead of white rice, coconut oil and other vegetable oils, and fish. Participants will be asked to use structured 3-day meal diary for diet monitoring. Individual counseling sessions depending on identified vascular risks based on FNRI recommendations will also be conducted. This is followed-up by study nutritionists every 3-month of intervention period.
75886231|NCT02951767|Drug|Atezolizumab|Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
75886232|NCT05182541|Other|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
75886233|NCT05182541|Other|Problem solving therapy|Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks
75886234|NCT05182541|Other|Face to face PST course|Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.
75886235|NCT05182541|Other|Professional psychological intervention|The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
75444043|NCT04301544|Behavioral|Standardized Vascular Care|The management advice for hypertension, diabetes, and dyslipidemia will be based on Filipino standard clinical practice guidelines. This is followed-up by study physicians every 3-month of intervention period
75737331|NCT00979524|Behavioral|Comprehensive Mental Health Services and Supports|"This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group."
75886236|NCT05181839|Drug|Burosumab|To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.
76057002|NCT01986907|Drug|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
76057003|NCT01959841|Drug|ASP2151|200 mg once daily or 400 mg once daily
75444044|NCT04284319|Procedure|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
76057004|NCT01959841|Drug|valaciclovir|1000 mg three times daily
76057005|NCT02005627|Drug|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
75444045|NCT04231838|Other|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
75593863|NCT00682318|Dietary Supplement|Ethanol|"Part 1 & Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
75593864|NCT00682318|Dietary Supplement|Omega-3 polyunsaturated fatty acids|"Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
75593865|NCT00682318|Dietary Supplement|Omega-6 polyunsaturated fatty acid|"Part 2b:~Control omega-6 fatty acid alimentary diet (<130 mg/day EPA/DHA)"
75593866|NCT00626990|Drug|temozolomide|Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
75593867|NCT00626990|Genetic|DNA methylation analysis|O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.
75593868|NCT00626990|Other|laboratory biomarker analysis|Prognostic factor analyses
75593869|NCT00626990|Procedure|adjuvant therapy|Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
75593870|NCT00626990|Procedure|quality-of-life assessment|Quality of Life analysis will also be used to assess neurological deterioration free progression
75737332|NCT00966576|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
75737333|NCT00425308|Drug|Everolimus + Cyclosporine|
75737334|NCT00425308|Drug|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
75737335|NCT00425308|Drug|Steroids|
75737336|NCT04008888|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Stem Cell Transplant: Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients.
75886237|NCT05760833|Procedure|Ablation|Ablation of either the pulmonary veins or the atrioventricular node
75444046|NCT04231838|Other|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with their allocated products to select the C-F NDS of their preference. They will be trained and counselled on the chosen C-F NDS; participants will also have the option to try and choose among a selection of either 3 e-liquids or 3 tobacco sticks (depending on the C-F NDS they have chosen). Participants wishing to use a heated tobacco device (HTD) will receive one kit and a full 1 week supply of tobacco sticks of their choice (they will receive a number of tobacco sticks/day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 1 week supply of e-liquids of their choice (they will receive 4 x 10 ml refill containers).
75444047|NCT04218266|Drug|BAY2433334|Tablet, taken orally once a day.
75593871|NCT00626990|Radiation|radiation therapy|Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
75593872|NCT00107198|Procedure|Conventional Surgery|Undergo surgery
75593873|NCT00107198|Drug|Cyclophosphamide|Given IV
75593874|NCT00107198|Drug|Doxorubicin Hydrochloride|Given IV
75593875|NCT00107198|Drug|Prednisone|Given IV or PO
75593876|NCT00107198|Radiation|Radiation Therapy|Undergo IFRT
75593877|NCT00107198|Drug|Vincristine Sulfate|Given IV
75593878|NCT01601106|Drug|liposomal prednisolone|Two weekly dosages with 150 mg.
75593879|NCT01601106|Drug|Placebo|
75737337|NCT04008888|Procedure|Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2|Autologous hematopoietic stem cell transplantation :Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day followed collecting CD34+ peripheral blood stem cells . Day 0 Infusion of autologous stem cells. Patients during 3-6 months after the 1st SCT will undergo a 2nd SCT. Patients who had not enough PBSC will undergo a 1st SCT.
75737338|NCT04008888|Drug|Melphalan Given IV|conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes
75737339|NCT04008888|Drug|Fludarabine Injection|conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
75737340|NCT04008888|Drug|PI and dexamethasone as maintenance therapy|Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
75737341|NCT04008888|Drug|PI+IMids+Dexamethasone as Consolidated Chemotherapy|Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11&12 of each 21-day.
75737342|NCT01563588|Behavioral|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
76057006|NCT02005627|Drug|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
75444048|NCT04218266|Drug|Apixaban|Capsule, taken orally twice a day.
75444049|NCT04218266|Other|BAY2433334 matching placebo|Tablet, taken orally once a day.
75593880|NCT04529018|Combination Product|[18F]CETO|[18F]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
75444050|NCT04218266|Other|Apixaban matching placebo|Capsule, taken orally twice a day.
75593881|NCT01601145|Dietary Supplement|consumption of lozenges|Each subject two lozenges a day for 6 weeks
75593882|NCT02750540|Drug|Tenofovir enema|
75593883|NCT02750540|Other|Saline enema|
75444051|NCT04172363|Drug|Octenisept and Serasept|Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings
75444052|NCT04087304|Behavioral|Risk Status Optimization|Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
75444053|NCT04074603|Device|The needle-free jet injector|Continuous insulin therapy for 2 weeks
75444054|NCT04074603|Device|Conventional insulin pen|Continuous insulin therapy for 2 weeks
75444055|NCT04068246|Drug|Metformin|1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly
75444056|NCT04068246|Drug|Placebo|Placebo tablet plus plus Methotrexate 7.5 mg weekly
75593884|NCT04488588|Other|Kaplan Meier analysis|Kaplan Meier survival analysis was conducted to calculate the cumulative overall survival rates using Log Rank test for comparison between age groups
75593885|NCT01601184|Drug|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
75593886|NCT01601184|Drug|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
75593887|NCT01643759|Drug|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
75737343|NCT00966732|Behavioral|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
75737344|NCT01033006|Procedure|Active Comparator: Arm 1: catheter injection|
75737345|NCT01033006|Procedure|Active Comparator: Arm 2: transarterial injection|
75737346|NCT01033006|Procedure|Active Comparator: Arm 3: catheter and transarterial injection|
76057007|NCT02104583|Drug|Eleclazine|Eleclazine tablets administered orally
75737347|NCT00974298|Procedure|Total elbow replacement arthroplasty|Total elbow arthroplasty using pressfit technique in which no cement is used.
75886238|NCT05170763|Drug|PA9159 nasal spray solution, 10 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.
76057008|NCT02104583|Drug|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
75737348|NCT01033084|Device|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
75444057|NCT04063033|Drug|IV iron - Sodium Ferric Gluconate Complex|IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
75737349|NCT01033084|Drug|Sertraline|Patient will receive sertraline 50mg/day.
75593888|NCT04488237|Drug|Vitamin D|oral administration of Vitamin D in patients with acute leukemia treated with methotrexate
75737350|NCT01033084|Other|double placebo|double placebo arm (sham stimulation/placebo pill)
75886239|NCT05170763|Drug|PA9159 nasal spray solution, 20 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
75886240|NCT05170763|Drug|PA9159 nasal spray solution, 40 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
76057009|NCT02073929|Drug|Liraglutide for 26 weeks|GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
76057010|NCT02073929|Drug|placebo|Placebo s.c. daily for 26 weeks
75444058|NCT04061915|Behavioral|Infographic Intervention|The intervention consists of participants viewing an HIV self-testing infographic.
75593889|NCT02754557|Other|Breath-Focused Meditation|"Participants will attend two breath-focused meditation sessions per week for three weeks. During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
75444059|NCT04061915|Behavioral|Paper-based HIV self-testing information|The control arm will read paper-based HIV self-testing instructions.
75737351|NCT00979758|Drug|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
75737352|NCT01672060|Behavioral|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
75737353|NCT01672060|Behavioral|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
75737354|NCT00545064|Drug|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
75737355|NCT01034332|Procedure|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
75737356|NCT00979836|Drug|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
75737357|NCT01588912|Drug|Telbivudine|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
75737358|NCT01588912|Drug|Tenofovir|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
75737359|NCT01588912|Drug|Entecavir|Maintain the entecavir through the study period
75886241|NCT05170763|Drug|PA9159 nasal spray solution, 80 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, four sprays each in the left and right nostril.
75444060|NCT04012333|Drug|OLIMEL 7,6%E / PeriOLIMEL 2,5%E|OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
75444061|NCT04002258|Drug|Antipsychotic|any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
75444062|NCT03993184|Behavioral|Hot Yoga|Bikram or hot yoga is a standardized series of 26 postures with two breathing exercises. Classes will be performed at local yoga studios in Austin, Texas and participants will be required to sign in for each session. All participants will receive 12 weeks of free classes for their participation.
75444063|NCT03926819|Drug|HBI-002|Oral liquid carbon monoxide drug product.
75444064|NCT03910959|Other|Animal-assisted therapy|Therapy in the presence and with interaction with an animal. Involved animals can be all species that live at REHAB Basel and are part of the AAT program. All animals are trained for the specific service with vulnerable patients.
75886242|NCT05170763|Drug|PA9159 nasal spray solution, 20 μg 7-day treatment|Repeated doses of PA9159 (5 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
76057011|NCT02113007|Drug|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
75737360|NCT00966810|Procedure|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect > 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
75737361|NCT00966888|Procedure|standard follow-up care|No intervention
75737362|NCT00966888|Radiation|radiation therapy|Chest wall radiotherapy
75886243|NCT05170763|Drug|PA9159 nasal spray solution, 40 μg 7-day treatment|Repeated doses of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
75593890|NCT02754557|Device|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
75886244|NCT05170763|Drug|Placebo, the same intranasal spray solution without PA9159 active ingredient|Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
75886245|NCT05734391|Diagnostic Test|Routine Infection control|routine part of hospital IPC activities
75886246|NCT03093181|Other|Washout / Standard Cleanser|Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
75593891|NCT04528979|Other|BioRoot RCS® root canal sealer|Root canal obturation with guttapercha and BioRoot RCS® root canal sealer
75886247|NCT03093181|Other|Test product|Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
75886248|NCT03093181|Other|Positive control cleanser|Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
76057012|NCT02104505|Drug|Gamma Tocopherol 700 mg capsules,|2 capsules daily
76057013|NCT02104505|Drug|Placebo|Safflower oil capsules
76057014|NCT02111993|Device|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
76057015|NCT02111993|Device|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
75737363|NCT00974454|Drug|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
75737364|NCT00974454|Drug|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
75737365|NCT00432562|Drug|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
75737366|NCT00966966|Drug|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
75737367|NCT00979914|Other|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
75737368|NCT00974532|Dietary Supplement|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
75886249|NCT03093181|Other|Positive control moisturiser|Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
75593892|NCT04528979|Other|AH Plus® root canal sealer|Root canal obturation with guttapercha and AH Plus® root canal sealer
75737369|NCT00974532|Dietary Supplement|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
75737370|NCT00980070|Device|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
75737371|NCT00980070|Device|Lumbar Puncture Device|Lumbar Puncture positioner
75737372|NCT00980070|Other|Standard of Care|Lumbar Puncture positioner
75886250|NCT05200091|Other|Combined explosive strength and specific balance training group|"Training will consist to perform one hour of combined ankle explosive strength training and specific balance training using randomized perturbations.~Explosive strength training: Participants will perform only 2 sets of 3 min (12 contractions for each set) for both lower limbs and both ankle plantar- and dorsiflexion movements.~Balance specific training: Participants will be standing, secured by an adjusted harness, which do not support the weight but is strictly there to prevent a fall. They will have online visual feedback of their CoP via an avatar on the screen in front of them. Each training session will consist of 10 sequences of 3 min, including the 5 different conditions:~Forward tilt of base of support;~Backward tilt of base of support;~Translation forward;~Translation backward;~Without moving their feet, participants will have to move their avatar to reach different targets placed around them on the screen, at different distance from the center."
75886251|NCT04666181|Behavioral|Dual-task training|See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
75886252|NCT02922439|Behavioral|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
75444065|NCT03910959|Other|Conventional therapy|Parallelled conventional therapy sessions (treatment as usual)
75444066|NCT03909204|Procedure|LAPEC|Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy: Initially, one to tree-laparoscopy port technique will be used, with hand placement of seroperitoneal sutures for cecal fixation. After than during colonoscopy a cecal position will be visualized and colonic lumen will be insuflated. After than the PEC tube will be introduced into the cecum using the dilators and sheath. Intravenous antibiotics will be given prior to the procedure and will continued parental temporary and later orally after catheter insertion. One weeks later, antegrade colonic enema will start during an out-patient visit including an educational training of the patient to the catheter manipulation. Antegrade enema solution will start at dose of 2ml/kg and will be increased up to 20ml/kg or a maximum dose of 2000 mL daily. Adjuvant of colonic motility stimulants are allowed during follow-up.
75444067|NCT03907800|Drug|Nab-paclitaxel|125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
75444068|NCT03907800|Drug|Carboplatin|AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles
75444069|NCT03907800|Drug|Herceptin|In case of HER2-positive, patients receive Herceptin weekly during all cycles.
75593893|NCT01601262|Device|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
75593894|NCT02279849|Other|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
75593895|NCT02279849|Other|Pricing|The pricing incentives were used to help promote sales of healthier food items.
75593896|NCT02279849|Other|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
75593897|NCT04488549|Other|Survey|International E-survey
75593898|NCT01680029|Device|PBASE-system 2.0|
75737373|NCT00432172|Drug|Epirubicin|
75737374|NCT00432172|Drug|Cyclophosphamide|
75737375|NCT00432172|Drug|Docetaxel|
75886253|NCT02922439|Behavioral|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
75886254|NCT05199623|Drug|tailored Guizhi decoction|Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
76057016|NCT01959607|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
75593899|NCT04528628|Drug|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
75737376|NCT00432172|Drug|Exemestane|
75593900|NCT04528628|Drug|Treatment as Usual|The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
75737377|NCT00432172|Drug|Goserelin|
75737378|NCT00432172|Drug|Carboplatin|
75737379|NCT01034410|Drug|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
75737380|NCT01034410|Drug|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
75737381|NCT01034488|Biological|Suine|5000UI /mL
75737382|NCT01034488|Biological|Suine|5000UI/mL
75737383|NCT00415168|Drug|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
75737384|NCT00415168|Drug|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
75737385|NCT01034566|Radiation|Proton Beam Radiation Therapy|
75737386|NCT00424762|Drug|rosiglitazone|6 months of treatment of blinded study drug
75737387|NCT00424762|Drug|placebo|blinded treatment with matching placebo
75737388|NCT00967122|Procedure|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
75737389|NCT00967200|Other|laboratory biomarker analysis|laboratory biomarker analysis
75444070|NCT03900117|Radiation|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.
75737390|NCT00967200|Other|pharmacogenomic studies|pharmacogenomic studies
75737391|NCT00974688|Behavioral|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
75737392|NCT00974688|Behavioral|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
75737393|NCT00967356|Drug|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
75737394|NCT00967356|Drug|Placebo|Oral suspension
75737395|NCT00980304|Drug|Rituximab|
75737396|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
75737397|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
75444071|NCT03900117|Drug|concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
75444072|NCT03894904|Drug|Papaverine|0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose
75444073|NCT03894904|Drug|Heparin|2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
75737398|NCT00980382|Drug|S-1, Docetaxel|"Phase I study~S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~Phase II study~S-1 (80mg/m2/day) q 12 hours po Days 1-14~Docetaxel (35 mg/m2) iv : Days 1, 8"
75444074|NCT03894904|Drug|Rescue papaverine, as needed|If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
75737399|NCT00967434|Drug|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
75593901|NCT04528628|Combination Product|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations|Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.
75593902|NCT04528940|Diagnostic Test|PD-1/PDL-1 staining|Every endometrial or ovarian carcinoma will be stained for PD-1/PDL-1. The stage and grade of the tumor will be determined and correlation between tumor grade and stage and PD-1/PDL-1 staining will be made.
75593903|NCT01601340|Drug|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
75593904|NCT01601340|Drug|Placebo|Placebo tablets, twice daily for 48 weeks
75737400|NCT00967434|Drug|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
75737401|NCT00967434|Drug|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
75737402|NCT00967512|Drug|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
75737403|NCT00967512|Drug|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
75593905|NCT04528862|Behavioral|Nature slides|participants will view a presentation of nature slides
75737404|NCT00967512|Drug|idarubicin, cytarabine|idarubicin, cytarabine
75737405|NCT00414544|Device|CosmetaLife|Dermal filler
75737406|NCT00414544|Device|Restylane|Dermal filler
75737407|NCT04082910|Drug|Metoprolol|Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
75737408|NCT04082910|Drug|metoprolol, infliximab, etanercept, tocilizumab and/or other agents|During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
76057017|NCT01959607|Other|CC|Single use of subject's own cigarette (CC)
76057018|NCT01959607|Other|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
75444075|NCT03811158|Device|HHHFNC|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
75444076|NCT03811158|Device|UHFOM|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
75593906|NCT04528862|Behavioral|Urban slides|participants will view a presentation of urban slides
75444077|NCT03797833|Procedure|Spinal Anaesthesia|Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
75444078|NCT03789630|Device|Continuous physiology monitoring in ambulatory setting pre and post surgery|This study will recruit 55 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
75593907|NCT01600248|Behavioral|Online ABBT for Chronic Pain in Military|Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
75593908|NCT01680068|Procedure|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
75593909|NCT01641341|Drug|Bifidobacterium infantis|once a day for seven to eight weeks
75444079|NCT03771014|Other|Early mobility|This progressive mobility pathway commenced with passive cycling within 48 hours of intubation and ventilation and progressing through assisted cycling, active cycling, bed exercises, sitting, mobilising out of bed to walking
75444080|NCT03749174|Procedure|Long acting Supraclivicular block vs Short acting Supraclavicular block|"Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block"
75593910|NCT01641341|Drug|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
75593911|NCT01641341|Drug|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
75593912|NCT01641341|Drug|Placebo|Placebo capsule will not contain active treatment ingredients.
75886255|NCT05199623|Behavioral|Olfactory training (OT)|Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
75886256|NCT05413031|Device|relative motion splint|splint with ability to move the fingers
75593913|NCT01601418|Drug|YF476|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
75593914|NCT01601418|Drug|Placebo|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
75593915|NCT01680107|Drug|d-cycloserine|
75593916|NCT01680107|Drug|placebo|
75593917|NCT01680107|Behavioral|cognitive-behaviour therapy|
75593918|NCT01680146|Dietary Supplement|PRO+FAT|
75593919|NCT01680146|Dietary Supplement|PRO|
75593920|NCT01643915|Behavioral|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
75593921|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
75593922|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
75593923|NCT01680185|Drug|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
75593924|NCT01680185|Drug|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
75593925|NCT01680185|Other|Standard of care|all covered above
75593926|NCT01643954|Procedure|robotic radical prostatectomy|robotic assisted surgery
75593927|NCT01680263|Device|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval"
76057019|NCT04186325|Procedure|DIAPHRAGMATIC exercising|inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
75593928|NCT01680263|Procedure|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
75886257|NCT05413031|Device|static splint|splint with immobility of wrist, and fingers
75737409|NCT01618786|Other|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
75886258|NCT03091777|Drug|GDC-229|GDC-229 is a vaginal gel.
75886259|NCT03091777|Drug|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
75737410|NCT01618786|Other|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
75737411|NCT00967590|Drug|RO5036505|380mg iv infusion once weekly for 8 weeks
75737412|NCT00967590|Drug|placebo|iv infusion once weekly for 8 weeks
75737413|NCT00975078|Procedure|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
75737414|NCT00975078|Drug|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
75737415|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
75737416|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
75737417|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
76057020|NCT02111603|Drug|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
75593929|NCT01601574|Behavioral|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
76057021|NCT04725851|Procedure|High concentration Oxygen therapy|FiO2 >80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
75737418|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
75737419|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
75593930|NCT01601574|Other|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
75737420|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
75593931|NCT01643993|Other|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
75737421|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
75737422|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
75737423|NCT04007016|Procedure|"a new osteotomy from the inner L shaped iliac osteotomy"|"There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL"
75886260|NCT03091777|Drug|Placebo|Inactive arm of the study
75886261|NCT04648085|Device|Trigeminal Nerve Stimulation|Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
75886262|NCT03632837|Device|Hemoadsorption|see arm description
75886263|NCT04624997|Other|biological sample|biological sample
76057022|NCT04725851|Procedure|Control: Room Air or Low concentration Oxygen|FiO2 <30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
76057023|NCT02102399|Behavioral|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
76057024|NCT02102399|Behavioral|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
75737424|NCT00980616|Drug|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
75593932|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
75737425|NCT00980694|Dietary Supplement|ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
75737426|NCT00980850|Biological|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
75737427|NCT00980850|Biological|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
76057025|NCT02111369|Drug|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
76057026|NCT02111369|Procedure|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
76057027|NCT02111213|Behavioral|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
75737428|NCT00414466|Drug|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
75737429|NCT00975234|Procedure|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
75737430|NCT00975234|Procedure|Revascularisation|Revascularisation surgery
75737431|NCT00984750|Drug|acetyl-L-carnitine/statin (simvastatin)|"acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability"
76057028|NCT02111213|Behavioral|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
76057029|NCT04736303|Device|BIS|The implementation of BIS monitoring
76057030|NCT02110901|Drug|PRT-201|
76057031|NCT02110901|Drug|Placebo|
75444081|NCT03722927|Drug|Bupivacaine|While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
75737432|NCT00984750|Drug|placebo|placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
75737433|NCT01033162|Behavioral|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|"Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:~Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)~Reduce patients' negative affect and increase their emotional well being~Improve patients' sense of social support~Improve patients' health self-efficacy~Improve patients' ratings of experience with cancer specialty care services~Improve patients' health related quality of life (HRQL)~Improve clinicians' ratings of quality of patient contacts~Reduce healthcare utilization and costs (obtained via the EMR)"
75737434|NCT00975312|Drug|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
76057032|NCT02070965|Drug|DFD01 Spray|
76057033|NCT02070965|Drug|Comp01 Lotion|
76057034|NCT02109107|Device|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
76057035|NCT02100839|Drug|AEM-28|Solution for injection
75593933|NCT01601613|Drug|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
75737435|NCT00975312|Drug|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
75737436|NCT00984906|Other|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
75737437|NCT00424528|Drug|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
75737438|NCT00424528|Drug|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
76057036|NCT02100839|Drug|Normal Saline|0.9% saline for injection
76057037|NCT02069093|Drug|Dexamethasone based mouthwash|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
75593934|NCT01601613|Drug|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
75593935|NCT01601730|Drug|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
75593936|NCT01601730|Drug|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
75593937|NCT01601730|Drug|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
75593938|NCT01601730|Drug|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
75886264|NCT05601947|Other|Structured Proprioception and Closed Kinetic Chain Exercises Group|In this group, an exercise program consisting of 3 stages, ranging from simple to difficult and including closed kinetic chain exercises and proprioceptive exercises, will be applied.
75886265|NCT05601947|Other|Wii Based Balance Training Program Group|"In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks. Balance Surf, which includes lateral weight transfer, Balance Adventure, which includes versatile balance exercises, and balance bowling for static and dynamic postural control will be implemented in the Fizyosoft Balance System. Each game will be practiced under the supervision of a physiotherapist for a total of 3 minutes, respectively, Balance surf, Balance adventure, Balance surf, Balance bowling and Balance surf, for a total of 15 minutes."
75886266|NCT05392361|Drug|gabapentin (neurontin® capsule 300mg) treatment|Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment
76057038|NCT02069093|Drug|Everolimus|Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
76057039|NCT02069093|Drug|Exemestane|Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
76057040|NCT02109029|Drug|Insulin Peglispro|Administered IV
76057041|NCT02109029|Drug|Human Insulin|Administered IV
75444082|NCT03722927|Drug|Liposomal Bupivacaine|While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
75444083|NCT03698084|Procedure|venepuncture|sample collection for analysis
75444084|NCT03698084|Procedure|nasopharyngeal swab|sample collection for analysis
75444085|NCT03696485|Biological|SCM-010|SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.
75593939|NCT01644032|Other|Teleconsultation|Teleconsultation between paramedics and an EMS physician
75593940|NCT01644071|Drug|cipralex|one time 10 mg, tablet
75593941|NCT04528589|Other|prenatal psychotherapy|Prenatal psychotherapy to break intergenerational risk of adverse childhood events
75737439|NCT00424528|Drug|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
75737440|NCT00424528|Drug|Placebo|Placebo inhalation solution and placebo inhalation powder
75444086|NCT03578198|Drug|Rituximab + MG4101|"Induction phase:~Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~MG4101 3x107 cells/kg IV Weekly (X4)~Maintenance phase~Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~MG4101 3x107 cells/kg IV q 4 weeks (X4)"
75444087|NCT03554200|Drug|Empagliflozin|Standard of Care + Empagliflozin: 10 mg (tablets) once daily
75593942|NCT01601769|Device|Vitom|Patients treated and diagnosed by vitom
75593943|NCT01601769|Device|Colposcopy|"a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.~Patients treated by colposcopy"
75737441|NCT04974996|Drug|Loncastuximab tesirine|Intravenous (IV) infusion
75737442|NCT04974996|Drug|Prednisone|Orally via tablet or capsule
75737443|NCT04974996|Drug|Rituximab|Intravenous (IV) infusion
75737444|NCT04974996|Drug|Cyclophosphamide|Intravenous (IV) infusion
75737445|NCT04974996|Drug|Doxorubicin|Intravenous (IV) infusion
75737446|NCT04974996|Drug|Vincristine|Intravenous (IV) infusion
75737447|NCT00981006|Procedure|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
75886267|NCT05392361|Drug|baclofen (baclofen Tab. 10mg) treatment|Taking baclofen (baclofen Tab. 10mg, Handok co, Seoul, Korea) medication at night.
75593944|NCT01680536|Drug|maraviroc|
75593945|NCT01601808|Drug|Placebo|Orally once a day, continuously throughout the study
75593946|NCT01601808|Drug|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
75593947|NCT01680614|Behavioral|CASI|
75593948|NCT04482153|Device|fibroscan|The Controlled Attenuation Parameter (CAP) can using transient elastography (TE) (Fibroscan®) permits to efficiently separate different grades of severity of steatosis. CAP is based on the properties of ultrasonic signals acquired by the Fibroscan®. It allows to simultaneously measure liver stiffness and CAP in the same liver volume.
75886268|NCT05338541|Drug|Tucidinostat and etoposide|Tucidinostat: 3+3 design，14 mg/m2，17.5 mg/m2，23 mg/m2 etoposide: 50mg/m2,
76057042|NCT02069015|Behavioral|Patient education|Patient education on hypertension delivered through a touchscreen kiosk.
75593949|NCT01644383|Behavioral|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
75593950|NCT01680692|Drug|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
75593951|NCT01680692|Device|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
75593952|NCT01680692|Device|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
75593953|NCT01601925|Other|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
75737448|NCT00975390|Dietary Supplement|Carbohydrate|1.2 g/kg/h
76057043|NCT04734977|Device|High-intensity laser therapy (HILT)|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session.
75593954|NCT04481880|Diagnostic Test|measuring IAP and respiratory parameters|Effect of IAP on respiratory parameters Correlation between IAP and Gastric and urinary bladder pressures
75886269|NCT05760755|Behavioral|Stick Together|The intervention consists of 12 online modules, completed flexibly during and immediately after primary cancer treatment. The intervention contains interviews with other couples, psychoeducational information, and interactive exercises on themes such as dyadic coping and communication, being diagnosed at a young age, fertility and children, and life after treatment.
76057044|NCT04734977|Device|Sham high-intensity laser therapy (Sham HILT)|Sham High intensity laser therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device using a HIRO 3 device (ASA Laser, Arcugnano, Italy).
76057045|NCT04734977|Other|Therapeutic Exercise|"As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
76057046|NCT01598129|Genetic|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
76057047|NCT02068547|Biological|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
75593955|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
76057048|NCT02068547|Biological|Bone Marrow Aspirate|
75444088|NCT03554200|Drug|Placebo|Standard of Care + Placebo: Matching Placebo (tablets) once daily
75444089|NCT03517176|Drug|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
75444090|NCT03517176|Drug|Nab-paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
75593956|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
75593957|NCT01644422|Other|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
75593958|NCT01602003|Drug|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
75593959|NCT01602003|Drug|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
75593960|NCT01602003|Drug|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
75593961|NCT01680926|Dietary Supplement|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
75737449|NCT00975390|Dietary Supplement|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
75444091|NCT03517176|Drug|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
75593962|NCT04481529|Other|Health Questionnaire|Completion of a short questionnaire noting the result of the serology and looking for elements in favor of exposure to the virus, whether professional or extra-professional.
75737450|NCT00975390|Dietary Supplement|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
75886270|NCT05335655|Drug|Dexmedetomidine injection|IV initial bolus and trans operative dexmedetomidine infusion.
75886271|NCT05335655|Drug|Sodium Chloride 0.9% infusion|IV initial bolus and trans operative infusion of 0.9% saline solution.
75886272|NCT04589351|Drug|Ezetimibe 10mg|Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
75737451|NCT00981240|Drug|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"
75737452|NCT00981318|Drug|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
76057049|NCT02108951|Drug|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
76057050|NCT02107859|Drug|Ataluren|Ataluren will be administered per dose and schedule specified in the arm.
76057051|NCT02007278|Drug|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
76057052|NCT02007278|Drug|glimepiride|
76057053|NCT02007278|Drug|Metformin|
76057054|NCT02107313|Drug|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
76057055|NCT02107313|Drug|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
76057056|NCT02028338|Combination Product|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
75737453|NCT00975468|Other|Pressure Controlled vs. Volume Controlled Ventilation during OLV|Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
75737454|NCT00984984|Drug|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
75737455|NCT00984984|Drug|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
75737456|NCT00975546|Other|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
75737457|NCT00975546|Procedure|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
75886273|NCT04589351|Drug|Placebo|Matching placebo
75737458|NCT00985062|Procedure|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
75886274|NCT05202743|Other|Observational for ALS patients|Open to ALS patients interested in mindfulness training.
75886275|NCT04580615|Device|CardiacSense1 and capnograph Respiratory rate measurement|Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
75886276|NCT02818998|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
75886277|NCT05042219|Diagnostic Test|Cardiac MRI|Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter
75886278|NCT05579015|Device|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz), as described previously. iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to ~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
75886279|NCT05579015|Other|telephone interviews|Telephone interviews will be conducted at the follow-up stage. RMDD group will receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence
76057057|NCT02028338|Combination Product|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
75444092|NCT03512964|Drug|Dolutegravir 50 MG|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing dolutegravir (tivicay) 50 mg 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
75886280|NCT05575583|Device|repetitive transcranial magnetic stimulation|The neural navigation system was used to accurately locate the stimulus target.Continuous theta short rapid pulse mode was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses.
75886281|NCT05575583|Device|pseudo repetitive transcranial magnetic stimulation|Participant in control group receive pseudo repetitive transcranial magnetic stimulation
75886282|NCT02821416|Biological|Benralizumab|Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
75886283|NCT02821416|Other|Placebo|Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
75886284|NCT03108521|Drug|Sitagliptin|100mg.QD for 3 months
76057058|NCT05089487|Procedure|Nocturnal rest (sleep study)|Proportion of patients free of severe hypoxemia without oxygen therapy during nocturnal rest .
76057059|NCT01625897|Drug|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
76057060|NCT01625897|Drug|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
76057061|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
76057062|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
76057063|NCT02106923|Drug|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
75593963|NCT01644461|Other|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
75593964|NCT01681043|Behavioral|protocol 'Quiet in the room'|"Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~nurse nearby~no visits after 10 p.m.~decreased alarm sound in ventilator and monitor~decreased light intensity~no unnecessary conversations around the patient~medication should be limited to max 1-2 times in this time period~no unnecessary therapeutic or diagnostic procedures in this time period~earplugs and sleep masks"
75593965|NCT01644539|Dietary Supplement|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
75593966|NCT01644539|Dietary Supplement|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
75737459|NCT00985062|Procedure|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
75737460|NCT00981552|Radiation|IMRT planning|
75737461|NCT00981552|Radiation|4-Field Radiation Planning|
75737462|NCT00975702|Procedure|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
75737463|NCT00985218|Device|SMART System|microfluidic embryo culture system
75737464|NCT00985218|Device|Culture dish|Standard IVF culture dish
76057064|NCT02106923|Drug|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
76057065|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
75444093|NCT03512964|Drug|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing emtricitabine 200 mg/tenofovir alafenamide 25 mg (descovy) 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
75444094|NCT03478384|Behavioral|Patient coaching|Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
75593967|NCT01644539|Dietary Supplement|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
75593968|NCT01602081|Device|reinforce soft tissue|reinforce soft tissue
75444095|NCT03476109|Drug|Randomisation to omalizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
75593969|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
75593970|NCT01193920|Other|Saline solution|Subjects received two injection of saline solution.
75593971|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
75593972|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
75593973|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
75593974|NCT01193920|Other|saline solution|Subjects received one injection of saline solution.
75593975|NCT04480983|Device|Multidetector Computerized Tomography (MDCT)|To evaluate the role of MDCT in diagnosis of non traumatic causes of acute abdomen in pediatric patients with clinical and surgical correlation.
75737465|NCT00545532|Drug|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
75737466|NCT00545532|Other|placebo|Placebo matched to oseltamivir po twice daily for 10 days
75737467|NCT00544440|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
75737468|NCT00544440|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
75737469|NCT04006860|Drug|SHC014748M Capsules|SHC014748M Capsules: 200mg
76057066|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
76057067|NCT02006732|Drug|olodaterol|fixed dose combination
76057068|NCT02006732|Drug|tiotropium|fixed dose combination
76057069|NCT02006732|Drug|placebo|
76057070|NCT02098733|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
76057071|NCT02028182|Biological|Lyral®|Alergen panel containing ascending doses of Lyral (0.10 mg/cm^2, 0.20 mg/cm^2 and 0.40 mg/cm^2) and negative control
76057072|NCT04684472|Biological|Modified anti-CD19 CAR T cells|intravenous infusion
75737470|NCT00981708|Drug|Lenalidomide, Dexamethasone and Cyclophosphamide|"Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.~Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.~Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.~The cycle is to be repeated every 28 days (4 weeks)"
75886285|NCT03992274|Other|Enhanced implementation of PrEP|During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
75737471|NCT04007718|Behavioral|Interpretation bias training|Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
75737472|NCT03920670|Device|TetraGraph (TG)|TetraGraph device is a neuromuscular transmission monitor capable of estimating the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation. Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
75886286|NCT04500509|Drug|diclofenac potassium + dinoprostone|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure by the patient
75886287|NCT04500509|Drug|diclofenac potassium + placebo|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure by the patient
75737473|NCT03920670|Device|ToFscan (TS)|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
75737474|NCT00430300|Drug|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
76057073|NCT02098109|Drug|XM02 Filgrastim|
75886288|NCT03854838|Drug|Tolipalimab|Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.
75737475|NCT00430300|Drug|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
75737476|NCT00981786|Drug|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
75737477|NCT00981786|Drug|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
75737478|NCT00975858|Procedure|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
75737479|NCT04007562|Drug|Hydroxychloroquine Sulfate|"The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:~Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.~The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose."
75886289|NCT03854838|Radiation|Reirradiation|intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
75886290|NCT05001191|Other|Gentle Human Touch|Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
75886291|NCT05760599|Drug|Candonilimab|10mg/kg, iv.drip, every 3 week
75737480|NCT04007484|Device|Hemoperfusion|Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
75737481|NCT00981864|Radiation|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
75737482|NCT00985374|Drug|RAD001|5mg or 10mg po daily
75737483|NCT00985374|Drug|RG1507|16mg/kg iv every 3 weeks
75886292|NCT05760599|Drug|Bevacizumab|15mg/kg, iv.drip, every 3 week
75886293|NCT04454255|Behavioral|FunSpeech|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week) and parent-supervised home use of a serious game. It will be recommended to use FunSpeech every day, 15 minutes per day.
75886294|NCT04454255|Behavioral|Control|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week).
75886295|NCT04442945|Drug|ANAVEX3-71|Active oral dose of ANAVEX3-71
75886296|NCT04442945|Drug|Placebo|Oral placebo
76057074|NCT02098109|Drug|Filgrastim|
76057075|NCT02098109|Procedure|Apheresis|
76057076|NCT02098109|Drug|Plerixafor|
76057077|NCT02098109|Procedure|Stem Cell Transplant|
76057078|NCT02097719|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
76057079|NCT02097719|Drug|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
76057080|NCT02097719|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
76057081|NCT02097719|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
76057082|NCT01449370|Drug|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
75886297|NCT04441073|Drug|Lignocaine|preoperative nebulization of lignocaine
75886298|NCT04441073|Drug|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
75886299|NCT03633539|Procedure|Single-incision Laparoscopic Surgery|Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
75886300|NCT03633539|Procedure|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
75444096|NCT03476109|Drug|Randomisation to mepolizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
76057083|NCT04724369|Drug|18F-MFBG|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
75737484|NCT00975936|Drug|[14C]-GSK706769|50µg [14C]-GSK706769 containing 250 nCi
75444097|NCT03463499|Drug|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
75737485|NCT00975936|Drug|Ketoconazole|200 mg Ketoconazole (Q12)
75737486|NCT00976092|Drug|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
75444098|NCT03366974|Drug|Midazolam|Midazolam 5 mg PO, Midazolam 1 mg IV
75444099|NCT03366974|Drug|Clarithromycin|Clarithromycin 500 mg bid
75444100|NCT03366974|Dietary Supplement|Grapefruit juice|Grapefruit juice 500 mL
75444101|NCT03294083|Biological|Pexastimogene Devacirepvec (Pexa-Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
75737487|NCT00976092|Drug|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
75444102|NCT03294083|Biological|Cemiplimab|Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
75737488|NCT00976092|Drug|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
75737489|NCT00976092|Drug|Heparin|i.v. bolus of 70-100 IU/kg body weight
75444103|NCT03136835|Drug|Maternal Hyperoxygenation|Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
75444104|NCT03128398|Drug|Domperidone|Availability of Domperidone to patients with serious gastrointestinal diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.
75444105|NCT03128138|Drug|SPH3127|"Drug: SPH3127 Tablet~Drug: Placebo Tablet"
75444106|NCT03119038|Drug|Bupivicaine + epinephrine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
75593976|NCT01681082|Behavioral|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
75593977|NCT04315480|Drug|Tocilizumab|single intravenous administration 8mg/Kg
75737490|NCT00985452|Other|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
75737491|NCT00985452|Other|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
75886301|NCT02036034|Device|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
75886302|NCT02036034|Device|warming blanket|warming blanket placed on torso of patient under the drape.
76057084|NCT02067533|Procedure|soft tissue repair in flexion position|
75593978|NCT01193686|Other|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
75593979|NCT04480515|Other|in-hospital mortality rate|In-hospital mortality rate during pandemic of 2020 will be compared with the in-hospital mortality rate of the last year's same time period
75593980|NCT01681160|Other|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
76057085|NCT02067533|Procedure|soft tissue repair in extension position|
76057086|NCT02066129|Drug|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
76057087|NCT02066129|Drug|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
75444107|NCT03119038|Drug|Bupivacaine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
75444108|NCT03119038|Drug|Ropivacaine|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
75737492|NCT00985530|Drug|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast & dinner) during each 6 week cycle
75737493|NCT00985530|Drug|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
75737494|NCT04006782|Device|Narrow dental implants|Insertion of narrow dental implants in multiple fixed prosthesis
76057088|NCT02066051|Device|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
75444109|NCT03119038|Drug|Ketorolac|Intraoperative periarticular injection of 30 mg
75444110|NCT03119038|Drug|Clonidine Injection|Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
75444111|NCT03099265|Drug|neoadjuvant mFOLFIRINOX|Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
75444112|NCT03099265|Drug|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
75444113|NCT03033459|Behavioral|Motivational Interviewing|"Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill."
75444114|NCT03033459|Behavioral|Psychoeducation Control|Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
75444115|NCT02975362|Other|Acupuncture Treatment|Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
75444116|NCT02975362|Other|Rehabilitation Treatment|Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
75444117|NCT02975037|Drug|Sildenafil|sildenafil 25 mg PO
75444118|NCT02975037|Drug|Clarithromycin|clarithromycin 250 mg PO
75444119|NCT02975037|Drug|Itraconazole|itraconazole 100 mg PO
75593981|NCT01681160|Other|conventional therapy|patients receive ordinary treatment for diabetic foot
75593982|NCT02886442|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
75593983|NCT02886442|Other|New adhesive strip|This is a newly developed adhesive strip
75593984|NCT01644773|Drug|Crizotinib|"Starting dose level:~Initial Treatment Plan: 130 mg/m^2 per dose~Modified Treatment Plan per Amendment 1.0: 165 mg/m^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day"
75593985|NCT01644773|Drug|Dasatinib|"Starting dose level: 50 mg/m^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day"
75593986|NCT01602159|Procedure|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
75737495|NCT04006470|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
75737496|NCT04006470|Drug|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
75737497|NCT04006470|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
75886303|NCT04343989|Drug|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
76057089|NCT02066051|Procedure|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
75444120|NCT02970591|Other|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
75444121|NCT02970591|Other|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
76057090|NCT01980992|Drug|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
76057091|NCT04085068|Other|cranioscaral treatment|dural release
76057092|NCT02065895|Device|HIGH error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
75444122|NCT02970591|Other|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
75444123|NCT02931890|Drug|Docetaxel|3 weekly course of docetaxel i.v in arm 1 and 2
75444124|NCT02931890|Drug|Oxaliplatin|3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
75444125|NCT02931890|Drug|Capecitabine|oral capecitabine in arm 1 and 2
75444126|NCT02931890|Procedure|gastrectomy|resection of gastric cancer after pre-operative chemotherapy for all arms
75444127|NCT02931890|Radiation|radiotherapy of gastric cancer|5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
75444128|NCT02931890|Drug|Paclitaxel|5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
75444129|NCT02931890|Drug|Carboplatin|5 weeks of carboplatin i.v once a week (in arm 2 and 3)
75593987|NCT01602159|Procedure|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
75593988|NCT01681199|Drug|Fluvastatin extended release tablet|
75593989|NCT04479345|Other|Questionnaire|Online questionnaire
75737498|NCT01323712|Dietary Supplement|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
75737499|NCT04911036|Other|Questionnaires|Perinatal PTSD Questionnaire State Trait Anxiety Inventory-forme Y-B Early Support Questionnaire Socio-demographic questionnaire
75737500|NCT00981942|Drug|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
75737501|NCT03927846|Behavioral|Nurse-guided Web-based Cognitive Behavioral Therapy|nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
75737502|NCT00982098|Procedure|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
75737503|NCT00976170|Drug|GC33(RO5137382)|IV administration at 6 escalating dose levels.
75737504|NCT00976170|Drug|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
75737505|NCT00982176|Other|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
75593990|NCT01681316|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
75593991|NCT01681316|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
75593992|NCT01681316|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
75593993|NCT01602276|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
75737506|NCT00982254|Drug|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
75737507|NCT00982254|Drug|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
75737508|NCT00985608|Drug|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
75737509|NCT00985608|Drug|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
75886304|NCT04343989|Drug|Clazakizumab 12.5 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
75737510|NCT00985764|Procedure|cesarean delivery|
75737511|NCT00976326|Drug|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
75737512|NCT00985842|Device|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
75886305|NCT04343989|Other|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
75886306|NCT05598073|Behavioral|Vinyasa yoga session|One hour of vinyasa yoga will be completed.
75886307|NCT04089787|Other|Intervention|Shortened antibiotic treatment of 5 days
75886308|NCT04089787|Other|Control|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
75886309|NCT02817828|Drug|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
75444130|NCT02893670|Procedure|Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation|"All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.~Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker."
75444131|NCT02812862|Drug|Spiolto® Respimat® (Tiotropium / Olodaterol)|"LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent."
75444132|NCT02734979|Device|Biobridge and lymph node transfer|Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
75444133|NCT02658656|Device|ReWalk 6.0|Exoskeletal Assisted Walking Device
75737513|NCT00985842|Device|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
76057093|NCT02065895|Device|NO error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
76057094|NCT02065895|Device|LOW error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
75593994|NCT04528394|Radiation|Photon|Photon combined with Carbon ion in Arm 1
75593995|NCT04528394|Radiation|Proton|Proton combined with Carbon ion in Arm 2
75593996|NCT04528394|Radiation|Carbon ion|Same dose and fractionation will be used in both arms.
75593997|NCT04479462|Procedure|total joint arthroplasty|The surgery includes primary, revision or partial joint arthroplasty.
75593998|NCT04528316|Behavioral|Pilates Core Stability Exercises program|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~Stage I: Warm-up: consists of four Pilates motions:~Breathing:~Rolling back:~Coccyx-curl:~Hundred breathing:~Stage II: Work-out: consists of twelve Pilates motions:~Single leg stretch:~Straight leg raise:~Basic bridge:~Bridging variation:~Quadruped:~Clap with seal motion~Mermaid twist:~Swimming:~Double leg stretch:~Shoulder bridge:~Swan dive:~Leg full front:~Stage III: Cool-down: consists of three Pilates motions:~Rest position:~Cat with arm/leg extension:~Breathing:"
75593999|NCT04528316|Behavioral|Balance Program|Total Period: 12 Weeks. The designed HUMAC program will work on the modified clinical test of sensory integration of balance (mCTSIB) with eyes open and with eyes closed, the center of pressure (COP) and the limit of stability test (LOS).
75737514|NCT00985842|Device|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
75886310|NCT03632681|Drug|Intranasal Insulin|Intranasal insulin
75444134|NCT02588846|Device|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
75594000|NCT04528316|Behavioral|Coordination|"Total Period: 12 Weeks. Coordination will be assessed using BOT2, Bilateral coordination (Sub test No.4) composed of 7 items and Upper-Limb coordination (Sub test No.7) composed of 7 items too.~The raw scores are recorded first then it is converted into point scores, then subtest total point score is obtained by adding point scores."
75594001|NCT01644812|Behavioral|Aerobic exercise|
75886311|NCT03632681|Drug|Intranasal Placebo|Intranasal placebo manufactured to mimic smell of insulin
75886312|NCT05483387|Device|Treatment with HBS 2 Resorb Mg|Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
75594002|NCT01644812|Behavioral|Stretching|
75444135|NCT02587312|Other|Very low nicotine content cigarettes|
75444136|NCT02587312|Other|Standard nicotine content cigarettes|
75444137|NCT02549677|Drug|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
75594003|NCT01681355|Other|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
75737515|NCT00985842|Device|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
75737516|NCT00985842|Device|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
75886313|NCT05597995|Drug|Sodium Tetradecyl Sulfate|subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
75444138|NCT02549677|Drug|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
75444139|NCT02549677|Drug|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
75886314|NCT04880057|Other|Resistance+Aerobic training|"The RT focuses on lower extremity workout, including leg press, hamstring curls, and calf raises. The participants start with intensity at 12 RM and finished with intensity at 8 RM after 3 weeks. There are 8 repetitions, 2 sets for each action. It will take 15 minutes to complete RT.~The AeT is composed by cycling on stationary bikes in the first week, stepping on steppers in 2nd week, and running on treadmills in the last week. Participants are asked to wear a portable heart rate monitor throughout the experiments. They have to maintain their heart rates in 60%-75% of predicted maximal heart rate (moderate intensity exercise), which has been shown to be benefit on cognition[3]. It took the participants 25 minutes to complete AeT."
75886315|NCT04880057|Other|Agility training|AT program consists of three parts: technical drills, pattern running and reactive agility training. There will be nine sessions over 3 weeks and progress the intensity, complexity or velocity every week.
75886316|NCT02817906|Drug|ITI-007|
75886317|NCT02817906|Drug|Placebo|
75886318|NCT05597605|Device|The SHINE SYSTEM|The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
75886319|NCT04338971|Device|IpsiHand Therapy|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of hometherapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
75594004|NCT04477902|Other|none - observational|online survey
75594005|NCT01602588|Drug|Hydroxychloroquine|200mg bd from 14 days post surgery until clinical or radiological progression
75594006|NCT01602588|Radiation|Radiotherapy|Short Course radiotherapy
75594007|NCT01681394|Dietary Supplement|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
75594008|NCT01681394|Dietary Supplement|Chocolate cream|
75594009|NCT04477824|Diagnostic Test|Diagnostic imaging|Ultrasonography, computerized tomography, magnetic resonance imaging
75594010|NCT01681550|Drug|Incretin-based therapy|
75594011|NCT01645085|Drug|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
75594012|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
75594013|NCT01645085|Drug|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
75444140|NCT02549599|Behavioral|Chat/Text Program|Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
75594014|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
75594015|NCT01602627|Drug|Hsp90 inhibitor AUY922|Given IV
75737517|NCT00982332|Drug|Betamethasone|betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
75886320|NCT03796650|Other|Fecal microbiota transplantation|50 g donor feces suspended in saline with added glycerol, administered by a enema kit.
75886321|NCT03796650|Drug|Vancomycin|Peroral vancomycin 125 mg q.i.d. for ten days.
75444141|NCT02549599|Behavioral|Website Content|Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
75594016|NCT01602627|Other|pharmacological study|Correlative studies
75594017|NCT01602627|Other|laboratory biomarker analysis|Correlative studies
75594018|NCT01602783|Other|11C Acetate Imaging|Single scan
75444142|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
75444143|NCT02540655|Biological|Stemchymal®|Patients will receive Stemchymal® through intravenous infusion
75444144|NCT02540655|Procedure|Excipients|Patients will receive excipients through intravenous infusion
75444145|NCT02512250|Other|Registry|
75444146|NCT02450253|Drug|Tadalafil|single dose, 20 mg capsule p.o.
75444147|NCT02450253|Drug|Placebo|single dose, matching capsule p.o.
75594019|NCT01645124|Drug|Hydroxyurea|
75594020|NCT01645124|Procedure|Phlebotomy|
75594021|NCT01602861|Drug|Spironolactone|"One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo)."
75737518|NCT00982332|Drug|isotonic sodium chloride solution (placebo)|4 ml intramuscular
75737519|NCT00976638|Other|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
75886322|NCT05597527|Drug|Fluzopari and apatinib|Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
75444148|NCT02450253|Behavioral|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
75444149|NCT02450253|Behavioral|Neuropsychological tests|"Neuropsychological tests will be performed prior to pre IMP dose MRI scan & then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart"
75444150|NCT02450253|Other|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
75594022|NCT01602861|Drug|placebo|
75594023|NCT01681667|Drug|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
75594024|NCT04474977|Other|Microvascular Decompressive Surgery|Microvascular decompression for hemifacial spasm
75594025|NCT01645163|Behavioral|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
75594026|NCT01600365|Drug|Ophthalmic gel (placebo)|Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
75594027|NCT01600365|Drug|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
75594028|NCT01602900|Drug|GSK356278|Investigational Medicinal Product
75594029|NCT01602900|Drug|Rolipram|Challenge Agent
75737520|NCT00976638|Other|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
75737521|NCT04007328|Drug|Methylprednisolone Sodium Succinate|methylprednisolone vial
75737522|NCT04007328|Drug|Placebo|Normal saline manufactured to mimic methylprednisolone vial
75444151|NCT02411812|Device|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
75444152|NCT02411812|Device|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
75444153|NCT02411812|Device|Twin-Block appliance|Group treated with Twin-Block appliance
75594030|NCT01645202|Procedure|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
75594031|NCT01645241|Drug|gonadotropins plus GnRH antagonists|
75594032|NCT01645241|Drug|ganirelix|
75594033|NCT01602939|Drug|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
75444154|NCT02263807|Procedure|MPFL Group|MPFL reconstruction or standard treatment followed by physiotherapy
75444155|NCT02263807|Procedure|Control|Arthroscopy followed by active rehabilitation
75444156|NCT02257970|Drug|Ketoprofen|
75444157|NCT02257970|Drug|Placebo|Placebo to match ketoprofen.
75444158|NCT02246413|Behavioral|RAINBOW Intervention Program|Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
75594034|NCT04528745|Diagnostic Test|Bio Impedance Spectroscopy (BIS)|Determination of fat free mass by BIS
75737523|NCT04007250|Device|FENIX™ Continence Restoration System|"The FENIX™ Continence Restoration System is indicated for use for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative therapy. The FENIX™ System Implant is placed around the external anal sphincter to augment a weak anal sphincter and restore continence.~The FENIX™ System is comprised of the following components:~FENIX™ System Implant~FENIX™ System Anal Sphincter Sizing Tool The FENIX™ System Implant consists of a series of titanium beads with magnetic cores that are connected with independent titanium wires to form an annular shape. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak anal sphincter closed."
75737524|NCT04007172|Procedure|neural therapy|Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
75444159|NCT05838690|Other|Personalized Intubation Safety (PINS) Bundle|The Personalized Intubation Safety (PINS) Bundle addresses 5 core domains that are individualized to the patient to develop a prospective, personalized and comprehensive multidisciplinary intubation plan: (1) patient risk assessment; (2) treatment threshold for intubation; (3) premedication (promoting paralytic premedication); (4) equipment (promoting video laryngoscope); (5) provider selection and escalation plan
75444160|NCT05838651|Device|MinerOss® X Plug|A xenograft composed of 80% bovine cancellous particulate and 20% bovine Type I collagen.
75444161|NCT05838651|Device|Striate+ Membrane|A non-crosslinked collagen covering used to keep bacteria out and hold the bone graft in place.
75444162|NCT05838625|Device|Digital Therapeutic|A prescription digital therapeutic in the form of a smartphone app.
75444163|NCT05838612|Other|Heat acclimation|Participants will complete a 7-day passive heat acclimation protocol consisting of immersion in warm water (~40°C) for 1 hour over 7 consecutive days.
75444164|NCT05838599|Drug|Imiquimod|5% cream applied topically 5 days/week for 6 weeks
75594035|NCT04528784|Device|Transcutaneous tibial nerve stimulation|Transcutaneous tibial nerve stimulation is a non-invasive electrical stimulation of the posterior tibial nerve, a branch of the sciatic nerve via sacral plexus. In our study the tibial nerve will be stimulated using Transcutaneous Electrical Nerve Stimulation (TENS) unit with two surface adhesive electrodes. The anode will be positioned between 5-10 cm above medial malleolus and posterior to the edge of the tibia and the cathode will be positioned distally on arch of the foot .
75594036|NCT01600404|Drug|antimuscarinic treatment|
75594037|NCT01600443|Device|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
75737525|NCT04007172|Device|Physical Therapy|Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
75737526|NCT00985920|Drug|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
75737527|NCT00985920|Drug|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
75737528|NCT00976794|Drug|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
75737529|NCT00976794|Drug|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
75737530|NCT00985998|Drug|Nimotuzumab and chemotherapy|"The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4~6cycles).~the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12~18 weeks)."
75737531|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
75737532|NCT00982566|Drug|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
75737533|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
75737534|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
75737535|NCT00976872|Drug|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
75886323|NCT04234295|Procedure|Fat Tissue Biopsy|If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
75886324|NCT02912143|Other|documentation only|
75886325|NCT05198999|Other|Aquatic-based Plyometric Exercises|The Aqua-PLYO group received the aquatic plyometric exercise training for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association
75594038|NCT01600443|Device|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
75594039|NCT01600443|Device|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
75594040|NCT01681823|Dietary Supplement|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
75594041|NCT01603017|Device|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
75594042|NCT01603017|Device|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
75886326|NCT05198999|Other|Standard Physical Therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
75737536|NCT00976872|Drug|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
75737537|NCT00977028|Drug|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
75737538|NCT00977028|Procedure|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
75886327|NCT02036112|Procedure|conventional ELAPE|device
75886328|NCT02036112|Procedure|Individual ELAPE|device
75886329|NCT05707416|Device|gallium aluminum arsenide (Ga-Al-As) semiconductor diode laser (SMARTTM PRO, LASOTRONIX, Poland)|The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
75886330|NCT05707416|Other|group B|Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
75737539|NCT04006938|Behavioral|Single Bout ('S')|Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
75444165|NCT05838599|Radiation|Radiation Therapy|2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.
75444166|NCT05838547|Drug|64Cu-25%-CANF-Comb|Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 18 months.
75444167|NCT05838547|Drug|64Cu-25%-CANF-Comb|Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
75737540|NCT04006938|Behavioral|Multiple Bout ('M')|Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
75737541|NCT00982722|Drug|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
75737542|NCT00982722|Drug|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
75737543|NCT00982800|Drug|Gabapentin|200mg 3x/day for 3 days (9 doses total)
75737544|NCT00982800|Drug|Placebo Sugar Pill|
75737545|NCT00986076|Drug|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
75737546|NCT00986076|Drug|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
75737547|NCT00977262|Other|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
75737548|NCT00977262|Other|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
75737549|NCT00977262|Other|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
75737550|NCT00984828|Drug|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
75737551|NCT00983034|Drug|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
75737552|NCT00977340|Behavioral|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
75444168|NCT05838508|Behavioral|Exercise intervention|Research participants will be assigned to two exercise conditions.
75737553|NCT00977340|Behavioral|confrontation|Confrontation
75737554|NCT00977340|Behavioral|imagination|Imagination
75737555|NCT00977418|Behavioral|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
75886331|NCT02036268|Behavioral|Standard|Standard ostomy education
75886332|NCT02036268|Behavioral|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
75886333|NCT02036268|Behavioral|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
75886334|NCT04749251|Procedure|Individualized blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids
75886335|NCT04749251|Procedure|Standard blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within a fixed range of 70-90 mmHg
75737556|NCT00977418|Other|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
75737557|NCT00983112|Drug|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
75737558|NCT00983112|Drug|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
75886336|NCT04215185|Device|Arterial LIne|Continuous non-invasive recording of CS6BP will be taken parallel to the recording of an invasive arterial line. ECG data recorded in the ICU will also be collected.
75737559|NCT04006704|Drug|D/C/F/TAF FDC placebo|Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
75886337|NCT04187495|Drug|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.~For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle)."
75886338|NCT03633383|Device|Transcatheter aortic valve|Self-expandable aortic valve prothesis
75886339|NCT05198141|Drug|Letrozole tablets|GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
75886340|NCT05198141|Procedure|laparoscopic salpingectomy|laparoscopic salpingectomy
75886341|NCT02813694|Drug|lefamulin|antibacterial agent
75886342|NCT02813694|Drug|Moxifloxacin|antibacterial agent
75886343|NCT03632161|Drug|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
75886344|NCT03632161|Drug|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
75737560|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
75737561|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
75737562|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
75737563|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
75737564|NCT00977496|Procedure|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
75594043|NCT01681862|Behavioral|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
75737565|NCT00983190|Device|Left Ventricular Assist Device (HeartMate II)|The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
75886345|NCT03631459|Drug|Kanglaite Injection/Capsules|Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
75886346|NCT03103919|Device|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
75737566|NCT00545298|Drug|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
75886347|NCT03103919|Device|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
75737567|NCT00545298|Drug|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
75737568|NCT00977652|Procedure|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
75737569|NCT00977652|Procedure|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
75737570|NCT00977730|Dietary Supplement|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
75737571|NCT00977730|Dietary Supplement|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
75737572|NCT00983268|Drug|capecitabine|1000 mg taken by mouth on the days of radiation only.
75737573|NCT00983268|Drug|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~Vorinostat,at 100 mg~Vorinostat,at 200 mg~Vorinostat, at 300 mg~Vorinostat, at 400 mg"
75737574|NCT00983268|Radiation|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
75594044|NCT04474782|Diagnostic Test|There is not an intervention|There is not an intervention
75737575|NCT00983268|Procedure|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
75737576|NCT03811236|Other|Cold exposure|Two hours of mild cold exposure using a water-perfused vest
75737577|NCT00977886|Drug|Placebo|Oral, 10 days
75737578|NCT00977886|Drug|ELB353|Oral, 10 days
75737579|NCT00977964|Other|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
75737580|NCT00977964|Other|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
75737581|NCT00977964|Other|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
75737582|NCT00977964|Other|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
75594045|NCT01681901|Procedure|ultrasound imaging|Undergo ultrasound
75594046|NCT01681940|Drug|Lamazym|ERT, i.v. infusions weekly
75594047|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
75594048|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
75594049|NCT01603173|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
75594050|NCT01603173|Drug|Quetiapine Fumarate|25 mg tablet once a day
75737583|NCT00977964|Other|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
75737584|NCT00977964|Other|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
75737585|NCT00983424|Drug|Cyclosporins|dose escalation, administered orally twice a day
75737586|NCT00983424|Drug|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
75737587|NCT00978198|Drug|ASP1517|oral
75594051|NCT01645358|Device|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
75594052|NCT01645358|Device|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
75594053|NCT01603212|Drug|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
75594054|NCT01603212|Drug|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
75737588|NCT00978198|Drug|Placebo|oral
75594055|NCT01603212|Drug|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
75737589|NCT00983658|Drug|huMAb OX40L|Intravenous repeating dose
75737590|NCT00983658|Drug|placebo|Intravenous repeating dose
75737591|NCT00983736|Drug|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
75737592|NCT00983736|Drug|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
75737593|NCT00983970|Behavioral|Interactive video game cycling|"Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session."
75737594|NCT00983970|Behavioral|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
75737595|NCT00986700|Dietary Supplement|late night meal|Three different kinds of late night meal each for 2 days.
75737596|NCT00986778|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
75444169|NCT05838469|Other|Pediatric Strip Crown and High Viscosity Glass Ionomer Cement|"Following the decision on the appropriate size of celluloid strip crown, the tooth will be isolated using roll cottons and the cavity conditioner (GC, Japan) will be applied to all surfaces for 10 seconds, washed away and dried with cotton pellets. The selected celluloid strip crown will be filled with a fluoride-releasing bulk fill hybrid glass ionomer cement (EQUIA Forte, GC, Japan) prepared by mixing for 10 seconds in an automatic mixer and placed on the tooth with light pressure. The excess material on the crown margins will be removed with a hand instrument, and the celluloid strip crown will be removed from the tooth. If necessary, the restoration will be polished using a polishing discs. After the crown surface is washed and dried, a nano-filled surface sealant (EQUIA Forte Coat, GC, Tokyo, Japan) will be applied for 10 seconds with a micro-tipped applicator and light cured for 20 seconds."
75737597|NCT00986778|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
75886348|NCT03103919|Drug|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
75886349|NCT01568203|Drug|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
75886350|NCT01568203|Drug|Placebo|Matching placebo control for AMG 579 at each dose level
75886351|NCT02036892|Behavioral|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
75886352|NCT02036892|Behavioral|Lifestyle counseling|Lifestyle counseling
75737598|NCT00986778|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
75886353|NCT04173325|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
75886354|NCT04173325|Drug|Irinotecan Injection [Camptosar]|Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
75886355|NCT05597449|Behavioral|YouTube videos on care after urologic surgery|Supplemental educational videos regarding care following pediatric urologic surgery
75886356|NCT02810964|Drug|Sulforaphane Nutraceutical|Sulforaphane Nutraceutical 6 tablets by mouth daily
75886357|NCT02810964|Drug|Identical-appearing Placebo|Identical-appearing Placebo 6 tablets by mouth daily
75886358|NCT05596123|Behavioral|Therapeutic Chinese foot massage|Participants in the TCFM group will receive six weekly 25-minute TCFM sessions by a therapist. Each session will start with an assessment of the legs and toes of the affected extremity for broken skin and lesions, which the therapist will try to avoid. The participant will be positioned with support to their foot and legs, with the sole directed downward and the therapist directly in alignment with the soles of the foot. The therapist will sequentially perform the following four steps for each TCFM session.
75886359|NCT05596123|Behavioral|Placebo massage|The same therapist will give six weekly 25-minute placebo massage sessions to participants in the placebo massage group. These sessions will include assessing the affected extremity's legs and toes for lesions and broken skin in order to avoid them during the massage, as well as gentle foot and toe rubbing without any point stimulation or other TCFM techniques.
75886360|NCT04392947|Device|Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P
75886361|NCT04392947|Device|Sham Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P without TMS being actively delivered
75737599|NCT00429364|Drug|Losartan Potassium|Losartan .3 - 1.4 mg/kg
75737600|NCT00429364|Drug|Atenolol|Atenolol .5 - 4 mg/kg
75886362|NCT05591131|Other|genetic testing|Undergo genetic testing
75886363|NCT05591131|Other|Survey Administration|Complete survey
75886364|NCT02036346|Dietary Supplement|Oral Ηydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
75886365|NCT02036346|Other|Advise on calculated oral fluid requirements|
75886366|NCT02036346|Other|No nutritional advice will be given|
75886367|NCT02810652|Other|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
75886368|NCT02810652|Other|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
75737601|NCT04758468|Behavioral|Telerehabilitation-based pelvic floor muscle training|"Telerehabilitation-based pelvic floor muscle training group will individually receive telerehabilitation-based pelvic floor muscle training under the guidance of a physiotherapist 2 sessions per week for 8 weeks. Participants will do their exercises themselves 2 times on the days where sessions are held with a physiotherapist. Participants will continue to exercise 3 times a day in the remaining days.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
75886369|NCT05197985|Behavioral|IECD Intervention|The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
75886370|NCT02742883|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
75886371|NCT05760131|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
75886372|NCT04167943|Drug|Dual cured resin modified tricalcium silicate cement|A resin based, dual cured tricalcium silicate based cement
75594056|NCT01645436|Other|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
75594057|NCT01645748|Drug|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
75737602|NCT04758468|Behavioral|Home-based pelvic floor muscle training|"The home-based pelvic floor muscle training group will do their individual exercises 3 times a day for 8 weeks.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
75886373|NCT04073147|Drug|Venetoclax|Venetoclax per os
75886374|NCT04073147|Drug|Obinutuzumab|ObintuzumabIV
75886375|NCT02707159|Drug|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
75886376|NCT05197907|Procedure|Fascial release of diaphragm muscle.|The intervention consists of deep tissue massage techniques and manual mobilization of the fascia performed within the diaphragm attachments in the area of the costal arches.
75886377|NCT05197907|Procedure|Classic massage of the abdomen.|The intervention consists of selected classic massage techniques - mainly stroking (effleurage) - performed on the superficial layers of the abdominal region
75886378|NCT04113187|Drug|Propranolol treatment|40 mg twice a day (morning and evening), per os, during three months
75886379|NCT04113187|Drug|Placebo|per os, twice a day (morning and evening) during three months
75886380|NCT03103763|Drug|Warfarin|Patients on warfarin for atrial fibrillation
75886381|NCT04092127|Other|Video Record|Video Record of the premature infant face before and during the RetCam screening of retinopathy of prematurity
75886382|NCT05197517|Drug|Rosuvastatin 10 mg|Film Coated Tablets products containing 10 mg Rosuvastatin
75886383|NCT05499559|Behavioral|Joint Academy digital treatment|The Joint Academy® (www.jointacademy.com) program for people with hand OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons, possibility for a social chat group with other patients and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three months.
75886384|NCT04011475|Drug|Tiotropium + Olodaterol|Spiolto®
75886385|NCT04011475|Drug|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
75886386|NCT04011475|Drug|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
75737603|NCT04008342|Other|Multisensory intervention|The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
75886387|NCT05063903|Other|Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition|"Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters"
75886388|NCT04212221|Drug|MGD013 monotherapy|MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
75444170|NCT05838443|Other|Self-directed mindfulness utilizing a multi-sensor EEG-supported device with neurofeedback-assisted and technology-supported meditation|Neurofeedback-assisted, technology-supported mindfulness via EEG-supported device delivered individually without the need for a facilitator or travel to training site. The device allows noninvasive neural activity recording from frontal and posterior brain regions. A dedicated smartphone application uses the EEG data to provide real-time adaptive feedback-modulating natural sounds to prompt user awareness of mind-wandering and intentional return to present experience. A smartphone app will guide patients through attention and focus on breath exercises. Patients will hear their distracted mind as the wind. Wind becomes stronger if their mind wanders, prompting patient's awareness of their wandering mind and guiding the patient back to focusing on their breath without judgment of how they are doing. Patients will be asked to practice mindfulness using the device for 20 minutes per day for 4 sessions prior to surgery.
75444171|NCT05838443|Other|Provider-directed mindfulness|"Patients will receive mental health support by a licensed social work provider who is trained in mindfulness through four 20-minute telehealth sessions. Patients will be taught cognitive behavioral therapy (CBT) techniques to reduce pain catastrophizing and increase coping efficacy, the clinician will review patient's current sleep routine and teach concepts and strategies to improve sleep. Patients will be guided through mindfulness and meditation exercises to improve pain and mood coping. Mindfulness-based instructions takes patients through quieting their mind by focusing on breath, expanding focus (i.e., at the tip of their nose full flow of the breath), with emphasis on acknowledgement of arising thoughts/emotions without judgement or emotional reaction, and return attention back to breath sensation. Principles of CBT and mindfulness will be reiterated at subsequent sessions."
75594058|NCT01645748|Drug|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
75594059|NCT01645748|Drug|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
75594060|NCT02484924|Drug|Ticagrelor|No intervention- purely observational
75594061|NCT01645826|Drug|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
75886389|NCT04212221|Drug|MGD013 in combination with Brivanib Alaninate|After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
75886390|NCT03663335|Biological|CFZ533 - MMF - CS|Comparison with standard of care immunosuppression
75886391|NCT03663335|Drug|Tacrolimus - MMF - +/- corticosteroids|Standard of care immunosupprevive regimen
75886392|NCT03632915|Drug|Levetiracetam|Standard of care
75886393|NCT03632915|Drug|Lacosamide|Standard of care
75886394|NCT03632915|Drug|Phenytoin|Standard of care
76071940|NCT03678376|Other|complaint, cognitive and functional assessments|"The evaluation with their GP is composed of (1-) Clinical impression, (2-) GP-Cog part 2 with patient or their informal caregiver and (3-) 6-CIT test.~The identification of patients at risk of NCD with the new strategy applied by the GP will be compared to the gold standard for diagnosis of NCD at the Memory Clinic, established according to Diagnosis and Statistical Manual of mental disorders (DSM-5) criteria and based on a clinical, neuropsychological evaluation and functional abilities. If needed, a secondary etiological diagnosis procedure will be undertaken following the HAS 2011 recommendation including brain MRI and biology."
75594062|NCT01645826|Drug|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
75886395|NCT03632915|Drug|Phenobarbital|Standard of care
75886396|NCT03632915|Drug|Ketamine|Standard of care
75886397|NCT03632915|Drug|Valproic Acid|Standard of care
76071941|NCT03675126|Drug|SRP-5051|SRP-5051 administered as an IV infusion.
76071942|NCT03674424|Drug|Avelumab|Chemotherapy with or without avelumab followed by surgery
75886398|NCT05346575|Behavioral|Teaching Obesity Treatments to Adult Learners (TOTAL)|TOTAL includes both video component and motivational telemedicine calls delivered via VA Video Connect (VVC) by a study interventionist. We will invite study participants to watch the 18-minute video at least once. The motivational component of TOTAL will consist of three telemedicine-based (VVC), one-on-one, 30-minute calls at 1 week, 6 months, and 12 months after randomization. This timing was selected so Veterans would have regular interactions with the interventionist within one year of initiating the intervention. Each motivational session will be tailored to where Veterans are in the treatment initiation process. Electronic outcome assessment surveys will be sent to the participants at baseline, at each motivational telemedicine visit, and for the 18 month assessment.
75886399|NCT05346575|Behavioral|Usual care|The usual care group will be electronically sent the 1-week, 6-month, 12-month, 18-month assessments. All usual care participants will be offered the opportunity to watch the educational video component of TOTAL after the final outcome assessment is performed (18 months post-randomization). Veterans in the usual care arm will also have access to the MOVE! program via referrals from the PCP or self-referral to MOVE!. If they initiate treatment in MOVE!, they may progress through MOVE! and receive obesity medications or be referred for bariatric surgery if they choose to do so.
75886400|NCT04836845|Device|Focus extracorporeal shock wave therapy|Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
75886401|NCT04836845|Device|Radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
75444172|NCT05838443|Other|Conventional Care|Control group, as defined by our institution's standard preoperative care for given procedure, which does not include psychological preparation.
75886402|NCT04836845|Device|Sham extracorporeal shock wave therapy|Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
75886403|NCT03538535|Behavioral|Go/No-Go Active Learning (GOAL)|Behavioral Activation psychotherapy adapted to engage go/no-go learning
75886404|NCT04769375|Other|Evaluation of pain|The presence of pain localization pelvic girdle pain will be questioned in the body chart. Inaddition to this, the level of the pelvic girdle pain will be evaluated by visual analog scale.
75886405|NCT04769375|Other|Application of pelvic girdle pain tests|The tests will be applied sequentially to investigate the presence and severity of the pain (Tests: Posterior Pelvic Pain Provocation, Patriarch FABER, Long Dorsal Sacroiliac Ligament Pain Provocation, Simpsis Palpation, Modified Trendelenburg and Active Straight Leg Raise)
75886406|NCT04769375|Other|Application of pelvic girdle questionnaire|Pelvic girdle questionnaire will be filled by pregnant women with pelvic girdle pain.
75886407|NCT03524729|Device|Rocker bottom shoe|Walking shoe with a anterior posterior rocker sole.
75886408|NCT03524729|Device|Ankle foot orthosis|Dynamic carbon fiber ankle brace.
75886409|NCT03524729|Device|Standard walking shoe|Standard walking shoe (control shoe) with no rocker sole.
75886410|NCT04717505|Other|Gait Assessments|"10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device."
75886411|NCT04717505|Other|Arthritis Impact Measurement Scales 2|It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
75886412|NCT04717505|Other|Visual Analogue Scale|The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
75886413|NCT04717505|Other|Standardized Mini Mental Test|Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
75886414|NCT05649605|Drug|Testosterone treatment|Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
75886415|NCT05649605|Other|Placebo treatment|Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
75444173|NCT05838417|Behavioral|REDS survey|R - Reactance, E - self-Exemption, D - Disbelief, S - Source derogation
75886416|NCT05321927|Device|Trancutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 9 pulses per burst for the last 5 minutes, with a stimulation/rest ratio of 1:2.
75886417|NCT05321927|Other|Strength training|Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
76071943|NCT03674424|Procedure|cystectomy|Cystectomy 3 to 6 weeks after last administration of chemotherapy
75444174|NCT05838365|Device|Zirconia implant|(Test group; within 7 days of implant placement) versus delayed (Control group; 8 weeks after implant placement)
75444175|NCT05838326|Device|Symmetrical high flow nasal cannula (HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio < 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%."
75594063|NCT01645865|Behavioral|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
75594064|NCT01645865|Behavioral|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
75594065|NCT01645904|Behavioral|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
75594066|NCT01645904|Behavioral|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
75886418|NCT05321927|Device|Sham stimulation|Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.
75886419|NCT04712123|Other|relapse due to S. aureus|to find out if it is the same S. aureus in both infections
75886420|NCT05312021|Drug|IMR-687|150 mg and 200 mg tablets
75886421|NCT05312021|Other|IMR-687 Placebo|Matching placebo to IMR-687
75886422|NCT05640479|Drug|Pregabalin|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
75444176|NCT05838326|Device|Asymmetrical high flow nasal cannula (DUET HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio < 300, patients will be randomly assigned to a first 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.~A 5-10min 'washout' phase using VM, between different interfaces, will be allowed."
75444177|NCT05838300|Device|Warm humidified CO2|Participants will receive warm (37°C) and humidified (95%) CO2.The humidification and warming device to be used is AlwaysPneumo® AP 50/30 InsuflowPort® (Lexion Medical, FDA approved) which is a specialized port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source
75444178|NCT05838300|Device|Dry CO2|Participants will receive standard cold (19-21 °C) and non-humidified (0%) CO2 insufflation with Airseal Insufflator
75886423|NCT05640479|Drug|Dexmedetomidine|patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
75886424|NCT05309525|Drug|Collagenase Clostridium Histolyticum-Aaes|subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
75886425|NCT05309525|Drug|Lysteda 650 MG Oral Tablet|Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
75886426|NCT03101267|Drug|ASP4070|Intradermal vaccination at 2-week intervals
75444179|NCT05838261|Procedure|Pharyngeal flap|Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap will be evaluated with patient- and parent reported outcome measures before and after the surgery.
75444180|NCT05838248|Other|antibiotic duration|Duration of antibiotic treatment post appendectomy
75594067|NCT01645904|Behavioral|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website."
75594068|NCT01645904|Behavioral|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
75886427|NCT03101267|Drug|Placebo|Intradermal vaccination at 2-week intervals
75886428|NCT04922801|Diagnostic Test|Nuclear Medicine whole-body|Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).
75886429|NCT04922801|Diagnostic Test|SPECT/CT imaging.|SPECT/CT scan at 24-48 hr post MRT
75886430|NCT04922801|Diagnostic Test|PET/CT imaging.|3-6 months Pre and post-therapy PET/CT imaging
75886431|NCT04922801|Device|Patient-led radiation monitor (SELFIE)|"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."
75886432|NCT04922801|Diagnostic Test|LAB TEST|Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
75886433|NCT04911101|Device|Excision with 7G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
75886434|NCT04911101|Device|Excision with 10G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
75886435|NCT05296187|Device|TEAS|Transcutaneous electrical acupuncture stimulation
75886436|NCT04905563|Drug|Acetaminophen-Hydrocodone|Narcotic
75886437|NCT04905563|Drug|Acetaminophen and Ibuprofen|Non-narcotic
75444181|NCT05838235|Other|Adapted Physical Activity program|The Adaptated Physical Activity program will consist of a Personalized Training Program
75737604|NCT00984048|Other|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
75737605|NCT00978354|Drug|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
75886438|NCT04886219|Other|Eye examination|"Multimodal fundus imaging (color fundus photography, optical coherence tomography (OCT))~orthoptic assessment (Visual acuity, Refraction, Cover test, Stereopsis evaluation~ocular biometry~corneal topography~monocular photographs in photopic and scotopic condition"
75886439|NCT02810418|Drug|LMB-100|Arms A1 and A2 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles Arm B1 (continuous infusion): Administered IV for 24, 48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles. Arm B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 14 day cycle for a maximum of 3 cycles.
75886440|NCT02810418|Drug|Nab-Paclitaxel|Administered intravenously (IV) on days 1 and for Arms A1, A2 and B1 on day 8 of each 14-21 day cycle for a maximum of 2 (Arms A1, A2 and B1) or 3 (Arm B2) cycles
75886441|NCT02810418|Device|Mesothelin Expression|Research blood test for Arm B1 eligibility
75886442|NCT02810418|Drug|LMB-100|A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.
75594069|NCT01645943|Procedure|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
75594070|NCT01600521|Drug|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
75594071|NCT01646060|Device|CM-1500|Blood Volume Monitor
75594072|NCT01607034|Drug|Dexpramipexole|150 mg single dose
75444182|NCT05838157|Biological|prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)|at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)
75444183|NCT05838118|Drug|Fecal Microbiota Transplantation|Biologically active human fecal fluid (donor stool) is provided in fluid form.
75594073|NCT01646099|Behavioral|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
75594074|NCT01603251|Drug|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
75737606|NCT00978354|Drug|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
75737607|NCT00987012|Dietary Supplement|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
75444184|NCT05838118|Other|Standard of Care for Chronic Kidney Disease|Patients accepted oral drug or dialytic therapy like they used to be to treat CKD.
75737608|NCT00987012|Dietary Supplement|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
75737609|NCT00984360|Drug|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
76071944|NCT03674424|Combination Product|CG|Chemotherapy 4 cycles of 3 weeks
76071945|NCT03674424|Combination Product|DD-MVAC|Chemotherapy 4 cycles of 2 weeks
76071946|NCT03674424|Combination Product|PG|Chemotherapy 2 cycles of 4 weeks
75444185|NCT05838105|Drug|GnRH agonist|125 mcg once at the day mentioned
75886443|NCT05417945|Device|JensClip transcatheter valve repair system|"Transcatheter mitral valve repair system is derived from the Edge-to-Edge technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation."
75886444|NCT02959541|Drug|Leucovorin|
75886445|NCT02736305|Drug|Regorafenib|Once a day for 21 days in a 28 days cycle
75737610|NCT03808350|Procedure|Families Invited to Be Present at Procedures|Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree
75737611|NCT03808350|Other|Placebo/Control|Family members will not be invited to remain in the ICU room
75737612|NCT00414388|Drug|Sorafenib|400mg twice daily
75737613|NCT00978588|Drug|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
75737614|NCT01037608|Drug|Sativex(Registered Trademark)|
75737615|NCT01037608|Drug|THC|
75886446|NCT05417633|Procedure|intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)|Inducing different values of monovision
75886447|NCT04849871|Radiation|External Beam Accelerated Partial Breast Irradiation|APBI simulation must take place no more than 8 weeks from final definitive breast surgery.
75886448|NCT02810340|Biological|Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.
75886449|NCT02810340|Biological|Non-Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).
75737616|NCT04006080|Biological|Vedolizumab|Intravenously administered selective leukocyte adhesion molecule inhibitor
75737617|NCT00984438|Drug|BCNU Wafer|Implantable during surgical resection into the tumor bed
75444186|NCT05838105|Drug|hCG|dose as mentioned
75444187|NCT05838105|Drug|Progesterone 100Mg Vag Tab|dose as mentioned
75444188|NCT05838079|Other|Clinical examination|Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation
75444189|NCT05838066|Drug|KN026|IV infusion
75444190|NCT05838066|Drug|HB1801|IV infusion
75444191|NCT05838066|Drug|Pertuzumab|840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion
75444192|NCT05838066|Drug|Trastuzumab|8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion
75444193|NCT05838066|Drug|Docetaxel|75 mg/m^2, D1 Q3W, IV infusion
75444194|NCT05838014|Other|Sleep deprivation|Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise
75444195|NCT05838014|Other|Normal sleep|Participants will undertake ~8 hours of normal sleep prior to completing exercise
75444196|NCT05838001|Procedure|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the breast lesion
75444197|NCT05838001|Procedure|marker clip localization|Positioning marker clip in the center of the breast lesion
75594075|NCT01603251|Drug|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
75737618|NCT00984438|Drug|Irinotecan|IV every 2 weeks for up to one year
75737619|NCT00984438|Drug|Bevacizumab|IV every 2 weeks for up to one year
76071947|NCT03672747|Device|transcranial direct-current stimulation (tDCS)|20 minutes duration using high-definition system with center-surround configuration
76071948|NCT03668613|Drug|secukinumab low dose|dose depends on the weight group
76071949|NCT03668613|Drug|secukinumab high dose|dose depends on the weight group
75594076|NCT01603251|Drug|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
75594077|NCT01646294|Drug|YM178 modified release (OCAS)|oral
75594078|NCT01646294|Drug|YM178 immediate release (IR)|oral
75594079|NCT01603329|Other|Increasing Medication Adherence through Physician Incentives and Messaging|"There are two treatments:~Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.~Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.~When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart."
75737620|NCT01037686|Radiation|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
75737621|NCT01037686|Behavioral|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
75444198|NCT05837962|Behavioral|Nursing intervention to improve knowledge and self-care behaviors in the face of HDP|"The nursing professional will perform 1 session weekly, for 4 weeks, lasting 90 minutes each. The contents that make up each of the sessions are:~Session 1. Knowledge about the risk factors, signs and symptoms, maternal and fetal complications of HDP.~Session 2. Control over behaviour, positive attitude and family and social support: essential components for conducting self-care behaviour.~Session 3. Nutritional recommendations: eating healthy helps prevent or reduce the risk of developing HDP.~Recommendations to improve sleep, rest and physical exercise: key routines in my health to prevent or reduce the risk of developing HDP.~Session 4. Mental health promotion: managing my stress, anxiety and depression levels help prevent or decrease the risk of HDP"
75444199|NCT05837949|Behavioral|MS FIT: Falls Insight Track|Participants will respond to a set of surveys every two weeks to increase communication on falls with their clinician.
75886450|NCT02810340|Biological|Menactra®|Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
76071950|NCT03650413|Drug|UTTR1147A|UTTR1147A will be administered based on disease status, as described in the protocol.
76071951|NCT03649503|Other|No intervention|
75444200|NCT05837936|Other|Total intravenous anesthesia (TIVA)|TIVA anesthetic -no inhalational gases for surgery
75444201|NCT05837936|Other|Sevoflurane initiated intravenous anesthesia (SIIVA)|SIIVA - sevoflurane anesthetic gases for surgery
75444202|NCT05837793|Behavioral|Modified frailty index|The mFI includes the following 11 items from the National Surgical Quality Improvement Program (NSQIP): diabetes; functional status (not independent); chronic obstructive pulmonary disease (COPD) or pneumonia; congestive heart failure; history of myocardial infarction; hypertension requiring medication; peripheral vascular disease or rest pain; impaired sensorium; history of either transient ischemic attack or cerebrovascular accident; history of cerebrovascular accident with neurologic deficit; and prior percutaneous coronary intervention, previous coronary surgery, or history of angina.
75444203|NCT05837780|Other|Nasoalveolar molding device|comparison between using conventionally and digitally constructed nasoalveolar molding devices
75444204|NCT05837689|Drug|Blinatumomab|IV
75594080|NCT01193608|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
75594081|NCT01193608|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
75594082|NCT01193608|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
75886451|NCT05695014|Other|Teach Back Metod|teach-back method is a way of checking understanding by asking patients to state in their own words what they need to know or do about their health. It is a way to confirm that you have explained things in a manner your patients understand.
75594083|NCT01193608|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
75737622|NCT01037686|Device|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
75737623|NCT03920280|Device|LID015385 contact lenses|Investigational silicone hydrogel contact lenses
75737624|NCT03920280|Device|Comfilcon A soft contact lenses|Commercially available silicone hydrogel contact lenses
75737625|NCT03920280|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting system
75737626|NCT00424372|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
76071952|NCT03637205|Procedure|ECLS insertion|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization
76071953|NCT03637205|Other|Revascularisation and optimal medical treatment|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
75737627|NCT00987090|Biological|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
75737628|NCT00987090|Radiation|MRI|intervention at the inclusion and 18 months after
75737629|NCT00987090|Procedure|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
75886452|NCT02036658|Behavioral|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
75444205|NCT05837572|Other|Standardized meal|"Assessment of the validity of the ES-LFPQ: Each participant will complete the ES-LFPQ in before (fasted state) and after a standardized meal (fed state).~Evaluation of the reproducibility of the ES-LFPQ: With at least one week of difference between tests, each participant will repeat the same protocol performed in the previous visit and under the same conditions."
75444206|NCT05837559|Other|Korle-Bu Modified WHO Partograph for Uncomplicated Labour|Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour
75444207|NCT05837520|Device|i-BiSSkApp (tablet application) with swallowing therapy|"The device, International Biofeedback Strength and Skill App (i-BiSSkApp) is an at-home swallowing biofeedback tool (hardware and software) to target rehabilitation of both skill and strength of swallowing function. The program utilizes submental surface electromyography coupled with a user-friendly interface to display visual feedback of swallowing strength and timing."
75444208|NCT05837520|Behavioral|Traditional behavioral swallowing therapy|Participants will receive standard behavioral swallowing exercises based on the results of a swallowing evaluation. Participants will complete daily at-home exercises with written and verbal instructions and return weekly to clinic for 12 weeks of therapy.
75444209|NCT05837468|Behavioral|BETTERapp|The BETTER app offers a 'tailor-made' lifestyle programme including the option of personal coaching for a duration of 6 weeks. The BETTER app is an automated and digitised lifestyle programme based on the previously developed and evaluated BETTER programme.
75594084|NCT01193608|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
75737630|NCT00987090|Biological|Apolipoprotein E genotyping|genotyping at the inclusion
75737631|NCT00987090|Biological|Study of cerebrospinal fluid|intervention at the inclusion
75594085|NCT01193608|Other|Placebo|Placebo, IV
75594086|NCT01646333|Behavioral|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
75594087|NCT01646333|Behavioral|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
75594088|NCT01603446|Drug|L-Arginine|NOW® L-Arginine powder
75737632|NCT04006236|Other|Experimental Infant Formula|Feed Ad Libitum
75737633|NCT04006236|Other|Control Infant Formula|Feed Ad Libitum
75737634|NCT00988104|Behavioral|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
75594089|NCT01607151|Other|Normothermia|72 hours of targeted temperature management to achieve normothermia (36-37°C)
75594090|NCT01607151|Other|Hypothermia|72 hours of targeted temperature management to achieve hypothermia (32-34°C)
75594091|NCT01646372|Other|Standard Simulation Based ACLS Refresher Teaching|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
75737635|NCT00988104|Behavioral|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
75737636|NCT00978900|Dietary Supplement|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
75737637|NCT00978900|Dietary Supplement|Water|
75737638|NCT00988182|Other|dietary intervention|whey protein
75737639|NCT00988182|Other|water control|
75737640|NCT00987168|Drug|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
75886453|NCT02036658|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
75886454|NCT05705700|Drug|Dutasteride|High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression
75886455|NCT05705700|Drug|Abiraterone|1000 mg PO daily
75886456|NCT05227547|Other|Thoracic resection surgery|Patients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.
76057095|NCT04723511|Other|Global Postural Re-education|"treatment techniques include corrective exercises both local and global to correct forward head posture.~first session will be to educate participants the treatment sequence. This will be a session of Kendall exercises as described below. This will followed be performing GPR techniques of Anterior Chain stretch in the supine frog like position for 20 minutes followed by posterior chain stretch against the wall for another 20 minutes. This is repeated in the first 6 sessions. Staring from the seventh session the time of holding each position is decreased to 15 minutes and a third position (standing against the wall) is introduced and performed for 15 minutes. Starting from the eighth session a forth position of sitting on the floor position is introduced and performed for another 15 minutes. total of a session will then take a bout 90 minutes."
76057096|NCT04723511|Other|Kendall exercises|"exercises that correct upper crossed syndrome:~Treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be 15 times repeated for 3 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be 15 times repeated for 3 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times."
76057097|NCT04723355|Device|An innovative 3-lead wireless water resistant Holter device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
76057098|NCT04723355|Device|A conventional device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
76057099|NCT04417985|Device|18F-FDG PET/CT, MRI|
76057100|NCT02106455|Drug|Sodium risedronate|Sodium risedronate tablets
76057101|NCT02006654|Drug|Placebo|Once daily, matching placebo capsules, orally
76057102|NCT02006654|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
76057103|NCT01980056|Drug|Vosaroxin|Dose level 1: Vosaroxin 50 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
75444210|NCT05837442|Other|Osteopathic Manual Therapy|Occipital release, supraclavicular release, sternum mobilization, omentum minus release, liver pumping, diaphragm mobilization, grand maneuver for 3 minutes, general osteopathic manual therapy of the hip, knee and ankle was applied to each extremity for 90 seconds for a total of 3 minutes
75444211|NCT05837429|Behavioral|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
75444212|NCT05837429|Behavioral|Aerobic Exercise Training|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
75444213|NCT05837416|Drug|blue®m Gel|Oxygen will be released after application Oxygen Releasing Oral Gel (blue®m gel) creating a partially high oxygen pressure (pO2), which aids in restoring the micro-environment for a healthy oral cavity
75444214|NCT05837416|Drug|NBF GINGIVAL GEL®|Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a nano bio fusion gel containing propolis, nano vitamin C, E and herb extract
75444215|NCT05837416|Drug|COE-PAK™|It is non eugenol periodontal dressing. It is supplied in two tubes, the contents of which are mixed immediately before use. One tube contains zinc oxide, oil, a gum, and lorothidol. The other tube contains liquid coconut fatty acids thickened with colophony resin and chlorothymol
75444216|NCT05837377|Other|Control- standard medication education|"Common Procedure:~- Student Information and Consent Form will be obtained from the students.~For the control group~Theoretical training in drug administration skills is provided.~Skill training: Skill training on intramuscular and subcutaneous injection and intravenous medication administration using task trainers in the simulation laboratory.~After the skill evaluation phase, a safe drug administration scenario will be applied."
75444217|NCT05837377|Other|Experiment- cognitive load theory based on medication education|"For the experiment group~Theoretical training will be provided based on the results of both the knowledge test and the self-efficacy test, and will be designed according to the principles of cognitive load theory.~Skills training: includes the necessary skill applications for students with task trainers and a virtual simulation designed according to the cognitive load theory for these skills.~After the skill evaluation phase, a safe drug administration scenario will be applied."
75444218|NCT05837364|Other|Development of an algorithm|Development of an algorithm to predict the risk of new onset Atrial Fibrillation
75444219|NCT05837299|Drug|IMC008|allowing 10% dose error
75594092|NCT01646372|Other|Cognitive Aid based ACLS Refresher training|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
75737641|NCT00978978|Drug|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
75737642|NCT00414310|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days.
76057104|NCT02027558|Behavioral|Insomnia treatment & PAP adherence|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
76057105|NCT02027558|Behavioral|General sleep education|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
76057106|NCT02027402|Procedure|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
76057107|NCT01448824|Drug|LY2484595|Administered orally
76057108|NCT01448824|Drug|Placebo|Administered orally
75737643|NCT00414310|Drug|Valproic Acid|50 mg/kg orally daily for 7 days
76057109|NCT01448824|Drug|Ketoconazole|Administered orally
76057110|NCT02005562|Drug|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (*) height (h)/ liter(L).
75444220|NCT05837286|Device|Oval-8 ® Orthosis|The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
75444221|NCT05837286|Other|Cortisone injection only|The control group will receive a cortisone injection and be instructed to move their fingers normally
75444222|NCT05837273|Device|Fully-immersive VR|For fully-immersive VR sets the highest level of immersion of VR technologies, presenting improvement in cognitive function in cognitive decline seniors. Fully immersive VR-based cognitive training also has a positive effect on psychological performance.
75444223|NCT05837273|Behavioral|Cognitive training|For the cognitive training, the therapy is a non-pharmacological approach, used for a series of standardized tasks to maintain or even increase person's cognitive function. The therapy can effectively improve multiple cognitive performance, such as: attention, reaction time (processing speed), working memory, and visual-spatial ability.
75737644|NCT00542880|Drug|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
75444224|NCT05837260|Other|Sample collection only|Sample collection only
76057111|NCT02005562|Drug|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
75444225|NCT05837195|Device|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
75737645|NCT00542880|Drug|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
75737646|NCT03726294|Drug|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
76057112|NCT02005562|Drug|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
76057113|NCT02005562|Drug|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
76057114|NCT02005562|Drug|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
75444226|NCT05837130|Other|Blood sample collection and an optional cerebrospinal fluid (CSF) collection|No study drug will be administered to study participants.
75444227|NCT05837130|Other|Blood sample collection|No study drug will be administered to study participants.
75737647|NCT00414076|Drug|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
76057115|NCT01448044|Drug|BMS-790052 (NS5A Replication Complex Inhibitor)|
76057116|NCT01448044|Drug|Placebo matching BMS-790052|
76057117|NCT01448044|Drug|Pegylated-interferon alfa 2a|
75444228|NCT05837078|Procedure|ridge splitting with implant placement|ridge splitting of mandibular denture followed by two implant placement
75444229|NCT05837065|Other|observing whether HCC patients having tumor micronecrosis|whether HCC patients having tumor micronecrosis or not
75444230|NCT05837026|Behavioral|Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~Outreach (via phone or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if the participant has suicidal thoughts, and (c) discuss plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals provide to patients who present with suicidal thoughts."
75444231|NCT05837026|Other|Care as Usual (CAU)|Participants will receive standard care that hospitals provide to patients who present with suicidal thoughts.
75737648|NCT00987246|Drug|Placebo Gel|Topical
75737649|NCT00987246|Drug|LAS41005|Topical
75737650|NCT00987246|Drug|LAS106521|Topical
76057118|NCT01448044|Drug|Ribavirin|
76057119|NCT02025530|Other|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
76057120|NCT01472380|Drug|efavirenz|600 mg
76057121|NCT01472380|Drug|fenofibric acid 105 mg|fenofibric acid 105 mg
76057122|NCT01978262|Biological|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
75737651|NCT01424098|Behavioral|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
75737652|NCT01033318|Drug|MK1809|single oral doses of MK1809
75737653|NCT01033318|Drug|Comparator: Losartan|single oral doses of 100 mg Losartan
75886457|NCT04796909|Behavioral|Occupational Performance coaching|The OPC intervention comprises three components: (1) connect - building parents' trust in the coach by using verbal and nonverbal strategies; (2) structure - building parents' competence by adopting a problem-solving framework of setting goals, exploring options, planning action, carrying out plans, checking performance, and generalizing; and (3) share - building parents' autonomy by reciprocally exchanging information between the coach and parents with an emphasis on eliciting parents existing knowledge. During the exploration of the options for a particular goal, collaborative performance analysis is used. The coach follows the four steps to (a) identify parents' perception of what currently happens, (b) identify what they would like to happen, (c) explore barriers and bridges to the desired performance, and (d) identify their needs for taking actions to achieve goals. Parents are guided to find strategies to facilitate their child's performance to support goal achievement.
75886458|NCT04796909|Behavioral|Parent consultation|The parent consultation consists of the use of the toolbox to provide parents with available environmental resources and strategies to enhance community participation of their child with developmental disability, followed by the understanding of current situation and the identification of problems encountered by parents. Direct informing approach will be used to instruct parents about the availability of environmental resources close to their living areas and what they can plan to do by using possible supportive strategies. In addition, information about child disability and/or developmental milestone may be provided if needed.
75444232|NCT05836961|Other|Benazir Nashonuma Program (BNP)|"Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy (1/4 of daily energy requirements for children in this age range)~Conditional Cash Transfers (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
75444233|NCT05836857|Behavioral|Cannabis (Marijuana)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.
75737654|NCT01033318|Drug|Comparator: Placebo|Placebo to MK1809
75737655|NCT04006158|Device|LED bed|Low risk FDA cleared full body LED bed
75737656|NCT00988338|Biological|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
75737657|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
75737658|NCT01033396|Drug|Allegra|Fexofenadine single dose 60 mg
75737659|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
75737660|NCT01033396|Drug|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
75737661|NCT01033396|Drug|Placebo|Placebo single dose
75737662|NCT00988416|Procedure|PET-CT|Pancreas Protocol PET-CT
75737663|NCT00979056|Drug|Rifaximin|400 mg per day, oral use, maximum duration 28 days
75737664|NCT00979056|Drug|Lactose|Coated Tablet, Oral Use
75737665|NCT04006314|Other|Autologous platelet rich plasma and dextrose solution.|"Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves."
75737666|NCT00987324|Device|Taxus stent|Implantation of paclitaxel-eluting stent
75737667|NCT00987324|Device|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
75737668|NCT00987324|Device|Conventional Balloon Catheter|Ryuijin, Trek
75737669|NCT00092677|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
75737670|NCT00092677|Drug|Comparator: Placebo|matching Placebo
75737671|NCT00988572|Other|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
75737672|NCT00979368|Drug|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
75737673|NCT00979368|Drug|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
75737674|NCT00979368|Drug|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
75737675|NCT00979368|Drug|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
75886459|NCT05416619|Device|REMO®|The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
75886460|NCT02817516|Drug|TAK-828|TAK-828 solution.
75886461|NCT02817516|Drug|Placebo|TAK-828 placebo-matching solution.
75886462|NCT05416463|Procedure|Intra-Operative Device for THA|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
75886463|NCT02498951|Procedure|Cognitive Assessment|Ancillary studies
76057123|NCT01447576|Drug|ADT|Once daily dosing during the duration of the study.
76057124|NCT01447576|Drug|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
76057125|NCT04084834|Other|Exercise|Participants will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital, receiving information about the osteoarthritis disease, symptoms and the importance of exercise and physical activity. Participants will then be given a weekly web-based exercise program (12 weeks) consisting of three aerobic exercise sessions per week. The exercise program consists of five levels, and the participants will each week be guided to the most appropriate level based on their measured physical fitness level and the weekly exercise diary. The participants will at initial assessment at Diakonhjemmet Hospital be instructed to use Borgs scale to adjust exercise level. Based on the weekly exercise diary the participants will also get motivational messages by email.
76057126|NCT01447420|Drug|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
76057127|NCT01447420|Drug|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
76057128|NCT01446874|Drug|0.12% chlorhexidine solution|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
75444234|NCT05836857|Behavioral|Cannabidiol (CBD)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education
75737676|NCT00979368|Drug|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
75737677|NCT00979368|Drug|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
75737678|NCT04651920|Genetic|Evaluation of homologous recombination deficiency score|Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
75737679|NCT00542178|Drug|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
75737680|NCT00542178|Drug|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
75886464|NCT02498951|Biological|Obinutuzumab|Given IV
75886465|NCT02498951|Other|Quality-of-Life Assessment|Ancillary studies
75886466|NCT05687214|Other|Osteopathic manipulative treatment|"Each participant in the experimental group will receive eight osteopathic manipulative treatments. Each treatment will include the following manipulations:~Pompage Cv4;~Occipital-sternal technique;~Relaxining manipulation of the diaphragmatic domes;~Pelvic and abdominal diaphragm synchronization;~Dynamogenic technique;~Mesenteric traction;~Release of colic angles;~Manipulation and mobilization of the sacrum."
75886467|NCT05416151|Other|Freeze-dried biotic|2 sticks of 3g consumed daily for 28 days
75886468|NCT05416151|Other|Maltodextrin|2 sticks of 3g consumed daily for 28 days
76057129|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
76057130|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
75737681|NCT00542178|Drug|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
75444235|NCT05836831|Drug|Tranexamic acid injection|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.
75737682|NCT00542178|Drug|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
75737683|NCT00542178|Drug|Fenofibrate|Blinded fenofibrate
75737684|NCT00542178|Drug|Simvastatin|Simvastatin 20-40 mg/d
76057131|NCT01439074|Device|Mepilex Ag|Dressing
76057132|NCT01439074|Drug|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
75444236|NCT05836805|Drug|[14C]XZP-3621|Extemporaneously compounded oral suspension solution of [14C]XZP-3621 (400 mg/200 µCi)
75737685|NCT00542178|Drug|Placebo|Placebo
75737686|NCT00987636|Drug|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients < 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients >= 18 years will receive a bodyweight-dependent dose:~Patients >40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
75737687|NCT00987636|Drug|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: <9 kg= 1mg/kg BW 9 - <16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW >23 - 34 kg= 0.95 mg/kg BW >34 kg = 0.8 mg/kg BW
75737688|NCT00987636|Drug|Treosulfan|12 g/m² d-5 to d-3
75737689|NCT00424294|Drug|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
76057133|NCT01438996|Biological|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
76057134|NCT01438840|Drug|Avatrombopag|
76057135|NCT01438840|Drug|Placebo|
76057136|NCT01438840|Drug|Standard of care|"Permitted ITP concomitant background therapies are as follows:~Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport [P-gp] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
76057137|NCT01471054|Drug|Ozurdex|"Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (>10% decrease in central macular thickness with maintenance [change in BCVA of <=1 line] or improvement of visual acuity [increase of BCVA of >1 line]) ii. Interval since last Ozurdex implant should be > 4 and < 12 months. iii. The study eye must show definite evidence of recurrence of macular edema."
76057138|NCT01471054|Drug|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
76057139|NCT01978184|Drug|gemcitabine|
76057140|NCT01978184|Drug|abraxane|
75444237|NCT05836649|Behavioral|Oculus Go headset without active intervention|VR software with non-interactive content.
75737690|NCT00424294|Drug|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States [US] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
76057141|NCT01978184|Drug|hydroxychloroquine|
75444238|NCT05836649|Behavioral|Oculus Go headset with active intervention|Participant will engage with the game display on the VR headset. Engagement time depends on the HPT limits test.
76057142|NCT01445548|Drug|Sirolimus|
76057143|NCT01977794|Drug|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
75444239|NCT05836623|Drug|Radiolabelled CB307|CB307 radiolabelled with 89-Zirconium (89Zr CB307): drug product is formulated at a concentration of 1 mg/mL (37 MBq)
75444240|NCT05836623|Drug|CB307|Trispecific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
75444241|NCT05836558|Procedure|mitral valve repair in right minithoracotomy|reparative surgery of the mitral valve accessing heart via an incision in the right 3rd or 4th intercostal space.
75444242|NCT05836545|Drug|Remimazolam|The patient with remimazolam
75444243|NCT05836545|Drug|Midazolam|The patient with midazolam
75444244|NCT05836532|Procedure|Central edge-to-edge|Suture of free margins of the mitral leaflets in central position to restore coaptation
75444245|NCT05836519|Other|Survey Navicular Drop test, International Physical Activity Questionnaire (IPAQ) Short Form, 6-minute walk test, Foot Function Index (AFI), SF-36 quality of life questionnaire, Modified borg scale|Pulse oximetry will be used to measure the oxyhemoglobin value of the participants, and a sphygmomanometer will be used for blood pressure and heart rate measurements.
75444246|NCT05836493|Procedure|Ring annuloplasty|A prosthetic ring is implanted to treat tricuspid regurgitation
75444247|NCT05836493|Procedure|Suture procedure|Suture techniques such as Kay or De Vega are used to reduce tricuspid annulus in order to treat tricuspid regurgitation
75737691|NCT00424294|Drug|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
75737692|NCT00979446|Behavioral|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
75737693|NCT00979446|Behavioral|Self-directed|Received study materials but no phone coaching
75444248|NCT05836480|Procedure|mitral valve repair|conservative surgery to treat mitral regurgitation. A mitral valve plasty is performed according to the most appropriate technique
75444249|NCT05836467|Procedure|Valvular interventions|Any kind of intervention on heart valves
75444250|NCT05836441|Radiation|Exposure to white patches|Exposure to white patches
75444251|NCT05836441|Radiation|Exposure to edge of white patches and normal skin around white patches|Exposure to edge of white patches and normal skin around white patches
75444252|NCT05836428|Other|no intervention|no intervention
75444253|NCT05836415|Procedure|Tricuspid valve annuloplasty with 3D ring|A 3D ring is implanted to treat functional tricuspid valve regurgitation
75737694|NCT00988650|Other|isocaloric diet|
75737695|NCT00988650|Other|free living conditions|
75886469|NCT02260050|Drug|WAL 801 CL dry syrup new formulation|
75886470|NCT02260050|Drug|WAL 801 CL dry syrup conventional formulation|
75444254|NCT05836389|Procedure|Pulmonary veins isoltation in bilateral thoracoscopy|Ablation of the atrial fibrillation performin isolation of the pulmonary vein. The procedure is video-assisted, access is minimally invasive: access to the heart is provided to instruments and camera via small bilateral chest incisions
75737696|NCT00988728|Drug|SCH 900435 (Org 25935)|"Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day)."
75886471|NCT05415995|Device|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
75886472|NCT02047656|Drug|LFF269|LFF269 capsules twice daily (b.i.d)
76057144|NCT01977794|Drug|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
76057145|NCT04408768|Other|standard protocol for stroke patients|Standard protocol for stroke patients
76057146|NCT02005484|Drug|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
75444255|NCT05836376|Procedure|Mitral valve annuloplasty|implantation of a prosthetic ring to treat mitral valve regurgitation
75444256|NCT05836363|Procedure|Ascending aorta replacement|The aneurysmatic ascending aorta tract is replaced with a tubular dacron prosthesis
75886473|NCT02047656|Drug|Placebo to LFF269|Placebo LFF269 b.i.d for 10 days in healthy volunteers
75444257|NCT05836350|Drug|4.8 g/m^2/day NaPB|12-week oral administration of 4.8 g/m^2/day NaPB (in the form of Pheburane) per day. Although depending on body surface area, ~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
75444258|NCT05836350|Drug|4.8 g/m^2/day placebo|12-week oral administration of 4.8 g/m^2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, ~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
75444259|NCT05836337|Device|Tattoo- Black Eye|Device name: Black eye Manufacturer: The Standard Co., Ltd
75444260|NCT05836337|Device|clip- HydroMARK|Device name: HydroMARK Manufacturer: Biopsy Sciences, LLC
75444261|NCT05836233|Drug|Pulmonary Vasodilators|"Right heart catheterization via Swan Ganz catether will be performed under optimal medical therapy within 90 days before LVAD implantation. We will record the timing between RHC and LVAD implantation.~Vasodilator challenge will be performed through intravenous nitroprusside administration and titration (by 5 minutes intervals) until symptoms (flushing or hypotension) onset or systolic systemic pressure drop below 85 mmHg (target dose).~Dobutamine or phosphodiesterase inhibitors infusion could be performed at clinician's discretion.~All haemodynamic measurements will be repeated after nitroprusside infusion and titration until the target dose."
75594093|NCT01603563|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
75737697|NCT00988728|Drug|Placebo|"Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner."
75886474|NCT04761965|Diagnostic Test|Bone marrow cellularity by mDixon-quant|if trepanobiopsy was performed during the diagnosis, then comparison with MRI Bone marrow cellularity by mDixon-quant
75886475|NCT02047890|Drug|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
75886476|NCT02047890|Drug|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
75886477|NCT02047968|Behavioral|wake therapy|
75886478|NCT02048124|Device|25g standard needle|
75444262|NCT05836207|Behavioral|Abstinence-focused Contingency Management (CM) - stand alone|Outpatient abstinence-focused contingency management (CM) as stand-alone treatment (12 weeks). Monetary incentives (vouchers) are provided for cannabis abstinence, based on twice-weekly rapid test urinalysis and an escalating reward scheme with bonuses. Urine samples are collected at the treatment centre during 15-minute sessions by a trained CM-practitioner. For each cannabis-negative urine, patients receive a monetary voucher starting at €5 and escalating to max. €35 after eight consecutive weeks of cannabis abstinence, with an additional €10 bonus after two consecutive cannabis-negative urines. The voucher-value is reset to €5 after a cannabis-positive urine test. Total earnings can be max. €675 for 12 weeks of consecutive cannabis abstinence (average: €8 p/day). Youths sign an agreement stating that vouchers must be spent on recovery-oriented goals.
75594094|NCT01603563|Behavioral|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
75737698|NCT00988728|Drug|Olanzapine|"Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day)."
75886479|NCT02048124|Device|25d ProCor needle|
75444263|NCT05836207|Behavioral|Standard Outpatient Cognitive Behavioural Therapy (CBT)|"CBT is the usual care first line treatment for CUD in youth, in the Netherlands. CBT for CUD is focused on learning cognitive, emotional, motivational and behavioral skills to reduce or cease cannabis use, and generally consists of 12 once-weekly 60-minute sessions and 'homework' exercise assignments, provided by a psychologist.~Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist. CBT-youths receive the same cannabis urine-testing procedures as CM-youths, but test results will not be disclosed to treatment staff or patient, and no rewards will be given for cannabis abstinence."
75444264|NCT05836181|Behavioral|Eye Movement Desensitization and Reprocessing|Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.
75444265|NCT05836116|Other|Evaluation of Muscle Activation|"Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application."
75886480|NCT03729102|Biological|Blood drawn after rabies vaccine booster vaccination|All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
75886481|NCT02036736|Drug|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~Sufentanil (0.15 mg / kg intravenously (IV))~Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
75444266|NCT05836077|Other|Education with pecha kucha method|Education with pecha kucha method
75444267|NCT05835726|Drug|Daratumumab|NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
75444268|NCT05835037|Drug|Zinc Acetate 25 MG|Participants will take one tablet per day (25mg Zinc acetate [Galzin]) for 1 year
75444269|NCT05835037|Drug|Placebo|Participants will take one placebo tablet per day for 1 year
75886482|NCT02036736|Drug|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~Sufentanil (0.15 mg / kg IV)~Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
75594095|NCT01646450|Drug|Icotinib|Icotinib: 125mg, oral administration, three times per day.
75886483|NCT05415839|Device|Laser|Laser
75886484|NCT05693688|Drug|Atosiban|atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.
75886485|NCT03813966|Diagnostic Test|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
75886486|NCT03814044|Device|PEEK Suture Anchors|Subjects who have undergone hip joint repair using PEEK Suture Anchors: Bioraptor Knotless Suture Anchor and SpeedLock Hip
75886487|NCT03671850|Biological|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
75886488|NCT03671850|Other|Placebo|Peripheral blood mononuclear cell, PBMC
75886489|NCT02036814|Behavioral|Program Health Education|
75886490|NCT02048280|Procedure|NAVA level|Peak inspiratory pressure will be measured at each NAVA level
75886491|NCT02048280|Other|NAVA level|Increase NAVA level every 3 minutes
75886492|NCT03562260|Procedure|bipolar release|the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture
75886493|NCT02047422|Drug|Furosemide|furosemide (doubling previous furosemide dose)
75886494|NCT02047422|Drug|metolazone|metolazone (add 2.5mg qod)
75444270|NCT05834660|Behavioral|Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)|SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts by phone at 1, 2, and 4 weeks after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
75886495|NCT02047422|Drug|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
75886496|NCT02047422|Drug|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
75886497|NCT02048358|Drug|2B3-201|
75886498|NCT02048358|Drug|Placebo|
75886499|NCT02048358|Drug|Methylprednisolone hemisuccinate|
75886500|NCT03562338|Other|Manual Therapy and Exercise (Physiotherapy Intervention)|Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.
75886501|NCT03562338|Other|Usual Care (Physiotherapy Intervention)|Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
75886502|NCT02051478|Other|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
75886503|NCT02051478|Other|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
75886504|NCT02048514|Device|The Nellix® EndoVascular Aneurysm Sealing System|
75886505|NCT02928029|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
75886506|NCT02928029|Drug|Placebo|Matching placebo
75886507|NCT02928029|Drug|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
75886508|NCT02928029|Drug|Dexamethasone|Dexamethasone is administered orally at 40 mg
75886509|NCT03562182|Other|blood draw|Blood draw (2.5mL) to assess mRNA LPCAT1 levels
75886510|NCT02048592|Dietary Supplement|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support |(Nutridrink) for another 8 weeks."
75737699|NCT00988806|Drug|Levosimendan|"Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
75737700|NCT00988806|Drug|Placebo|"Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
75737701|NCT04005768|Drug|Hydroxychloroquine Sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
75737702|NCT04005768|Drug|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
75737703|NCT00987714|Procedure|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
75737704|NCT00987792|Drug|Moxifloxacin (Avelox, BAY12-8039)|Hospitalized patients receiving Avelox according to local drug information
75737705|NCT04459260|Behavioral|Cognitive Behavior Therapy|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed specifically for targeting perfectionism (Egan et al., 2016). Includes the following components: 1) providing psychoeducation about perfectionism and creating an individualized conceptualization 2) broadening the domains for self-evaluation 3) testing out beliefs and predictions, and 4) addressing personal standards and self-criticism.~Week 1: Understanding your perfectionism.~Week 2: Your own model, values, and motivation.~Week 3: Surveys and experiments.~Week 4: Dealing with perfectionistic behaviors.~Week 5: New ways of thinking.~Week 6: Self-criticism and self-compassion.~Week 7: Self-worth.~Week 8: Maintain and continue positive change."
75737706|NCT04459260|Behavioral|Unified Protocol|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed to target the shared emotional factors in depression and anxiety disorders (Ellard et al., 2010). Fundamental to this approach is to register and become more aware of the emotions, cognitions, and physical sensations that occur in difficult situation, and to try out more adaptive ways of coping in these instances.~Week 1: Emotional symptoms.~Week 2: Understanding your emotions.~Week 3: Emotional awareness.~Week 4: Thoughts.~Week 5: Behaviors.~Week 6: Emotional exposure.~Week 7: Continued emotional exposure.~Week 8: Planning ahead."
75737707|NCT00987870|Drug|BFH772|
75737708|NCT00987870|Drug|Placebo|
75737709|NCT00987870|Drug|BFH772|
75444271|NCT05834049|Behavioral|Virtual Parental Presence on Induction of Anesthesia|Apple Inc's FaceTime™ video application will be used when the child is taken to the operating room
75737710|NCT00987870|Drug|Placebo|
75737711|NCT00987870|Drug|calcipotriol/betamethasone|
75886511|NCT02048592|Dietary Supplement|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
75886512|NCT02050074|Drug|Colesevelam|
75886513|NCT02050074|Drug|Metformin|
75886514|NCT02050074|Other|Placebo|
75737712|NCT00988026|Drug|Minocycline vs Lymecycline|Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
75737713|NCT00988962|Behavioral|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
75886515|NCT02050152|Behavioral|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
75886516|NCT02050152|Drug|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
75886517|NCT02050230|Biological|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
75886518|NCT02806986|Biological|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
75886519|NCT02050386|Other|Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds
75886520|NCT02050386|Other|Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds
75737714|NCT05578170|Drug|Pembrolizumab|Participants receive 200 mg pembrolizumab as a neoadjuvant by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles before surgery.
75886521|NCT03562104|Other|videofluoroscopy|Swallowing description in Minimally consciousness Patient
75886522|NCT03562104|Other|Wessex Head Injury Matrix scale|Wessex Head Injury Matrix scale in Minimally consciousness Patient
75886523|NCT02037360|Behavioral|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
75886524|NCT02037360|Behavioral|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
75886525|NCT02037750|Behavioral|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
75886526|NCT02050542|Procedure|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
75886527|NCT02050542|Procedure|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
75444272|NCT05834049|Behavioral|Midazolam|Preoperative midazolam (0.5 mg/kg of oral midazolam with a maximum dose of 20mg) will be given unless medically contraindicated.
75737715|NCT00989040|Drug|usual treatment: Versatis|"To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.~To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch."
75737716|NCT00989118|Procedure|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
75737717|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
75886528|NCT02048748|Device|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
75886529|NCT02048748|Device|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
75886530|NCT02048982|Behavioral|Guideline|Physicians will receive information on the Choosing Wisely Guideline
75886531|NCT02048982|Behavioral|Cost|Physicians will receive cost information.
75886532|NCT02048982|Behavioral|Victim|Physicians will receive information on an identifiable victim.
75886533|NCT02051556|Behavioral|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
75886534|NCT02051556|Behavioral|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
75886535|NCT02051556|Behavioral|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
75444273|NCT05833217|Procedure|Adipose Tissue Biopsy|After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.
75594096|NCT01607229|Other|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
75594097|NCT01646489|Drug|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
75737718|NCT00989274|Biological|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
75737719|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
75594098|NCT01646489|Drug|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
75594099|NCT01603719|Dietary Supplement|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
75886536|NCT02049060|Drug|Tivantinib|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
75886537|NCT02049216|Other|Flexible tape|Flexible, elasticised, adhesive athletic tape
75444274|NCT05833217|Diagnostic Test|Steady State Plasma Glucose (SSPG) Test|An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if participants are insulin sensitive or insulin resistant. This test is approximately 5-6 hours in length. Participants will be asked to fast for 12 hours. The insulin sensitivity test is designed to measure how well your cells remove glucose from your blood in response to insulin. During this test participants will have two small catheters (tubing) placed in their veins (I.V. lines). The total amount of blood that will be drawn during this test will be 140 mL of blood (approximately 9.5 tablespoons). Insulin is a natural hormone, and octreotide (a synthetic hormone) is a drug that temporarily blocks the secretion of insulin from your pancreas. A member of the research team is present and monitoring the results along with the nursing staff.
75444275|NCT05832021|Procedure|Open reduction and internal fixation (under WALANT)|Open reduction and internal fixation with volar Henry approach under WALANT.
75444276|NCT05832021|Procedure|Open reduction and internal fixation (under peripheral nerve block)|Open reduction and internal fixation with volar Henry approach under peripheral nerve block.
75444277|NCT05830682|Device|using a walking aid|The walking aid utilized for mobilizing patients in the intervention group during the study is a four-wheeled device that allows for movement in all directions. The height of the device can be adjusted according to the patients' height. It features a seat for resting when needed and a braking system that is controlled from the hand grips.
75444278|NCT05823857|Other|Aquatic Therapy|Participants in this experimental intervention group will perform trunk stabilization, which will be based on a variety of aquatic exercises in different positions, intended to activate the multifidus and transverse abdominis in a co-contraction. Additionally, hip exercises will be completed to promote the strengthening of the gluteus maximus, gluteus medius, and gluteus minimus muscles. The aim of these exercises is to enhance the strength and dynamic stability of the spine and its surrounding musculature in a functional and yet non-weight-bearing way. Each exercise will be performed 10 times while sustaining the muscles co-contraction for 5-10 seconds and will be progressed gradually. Each training session (60 minutes) will be supervised by a Certified Athletic Therapist and take place in the PERFORM AT Clinic/Swim Ex pool.
75737720|NCT03310944|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
75737721|NCT04804254|Drug|ABBV-623|Oral Tablets
75444279|NCT05823857|Other|Standard Care|Participants in this experimental intervention group will receive the standard LBP treatment in the PERFORM Athletic Therapy clinic.Two Certified Athletic Therapists (AT) will be conducting the sessions. The ATs will complete a thorough assessment of the eligible participants with chronic LBP and administer a range of interventions including stretching, strengthening and stabilization exercise, aerobic conditioning, and manual mobilization techniques. Other modalities could include application of ice and heat, ultrasound, and transcutaneous electrical nerve stimulation (TENS).
75444280|NCT05814744|Drug|dexmedetomidine|adding dexmedetomidine as adjuvant with bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy surgery.
75444281|NCT05814744|Drug|bupivacaine 0.25%|patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
75444282|NCT05814744|Procedure|Thyroidectomy Surgery|surgical removal of all or part of thyroid gland.
75594100|NCT01646528|Procedure|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
75594101|NCT01603758|Drug|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
75594102|NCT02279264|Device|RightSpot Infant pH Indicator|pH indicator
75594103|NCT01603797|Behavioral|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
75737722|NCT04804254|Drug|ABBV-992|Oral Tablets
75737723|NCT05712642|Drug|Intravitreal Bevacizumab|Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
75886538|NCT02049216|Other|Fixomull|
75886539|NCT02049216|Other|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
75886540|NCT03095651|Biological|MK-5160 16 nmol/kg|MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days
75886541|NCT03095651|Biological|MK-5160 32 nmol/kg|MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days
75886542|NCT03095651|Biological|MK-5160 64 nmol/kg|MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days
75886543|NCT03095651|Biological|Glargine 0.4 U/kg|Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days
75886544|NCT03095651|Biological|Placebo to Glargine|Placebo to glargine, subcutaneous injection administered daily for 12 days
75886545|NCT03095651|Biological|Placebo to MK-5160|Placebo to MK-5160, subcutaneous injection administered daily for 12 days
75444283|NCT05814744|Procedure|Ultrasound-guided intermediate Cervical Plexus Block Technique|the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.
75737724|NCT00092521|Biological|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
75444284|NCT05798221|Behavioral|Complementary self-help strategies in addition to treatment as usual|The 10-week group program consists of self-help strategies from complementary medicine approaches of TEM (Traditional European Medicine), TCM (Traditional Chinese Medicine), and TIM (Traditional Indian Medicine) in addition to treatment as usual
75444285|NCT05798221|Other|Treatment as usual|The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
75886546|NCT03095651|Drug|Dextrose|20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
75886547|NCT03095651|Biological|Glargine 0.6 U/kg|Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
75886548|NCT02808312|Drug|Cilofexor|Tablet(s) administered orally in a fed state on Day 1
75886549|NCT03561948|Procedure|Experimental group|After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
75886550|NCT03561948|Procedure|Control group|In the control group (40 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
75444286|NCT05797558|Procedure|Unilateral adrenalectomy|Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference.
75444287|NCT05797558|Drug|Medical treatment (eplerenone)|The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e > ~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
75444288|NCT05789095|Other|Rate of torque development testing of knee flexors and knee extensors using a fixated handheld dynamometer (MicroFet 2, Hoggan, Scientific L.L.C., Salt Lake City, USA), sampling rate of 100hz)|"Participants and their parents/guardian receives information about the test procedures. Written informed consent is obtained before clinical examination and testing.~Clinical testing is performed, anthropometric values are obtained and patient reported outcome measure is filled out, before the tests are performed. Cases will receive treatment for their condition and controls a movie ticket as compensation."
75444289|NCT05786820|Dietary Supplement|Pycnogenol|daily consumption of a pycnogenol-containing capsule
75444290|NCT05786820|Dietary Supplement|Placebo|Daily consumption of a placebo capsule
75444291|NCT05781308|Drug|Paclitaxel|Paclitaxel 200 mg/m² every 3 weeks
75444292|NCT05781308|Drug|Bevacizumab|Bevacizumab 15 mg/kg every 3 weeks
75444293|NCT05781308|Drug|Atezolizumab|1200 mg every 3 weeks
75886551|NCT04717193|Drug|Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
75444294|NCT05772156|Drug|Methylergonovine|Methylergonovine 200mcg Intramuscular (IM)
75444295|NCT05772156|Drug|Placebo|Matching saline placebo
75737725|NCT00092521|Biological|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
75737726|NCT00092521|Biological|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
75737727|NCT03908970|Drug|1% OPA-15406|Twice daily
75737728|NCT03908970|Drug|Placebos|Twice daily
75737729|NCT05712330|Other|non invasive ventilation samples|machine samples for bacterial culture will be performed
75737730|NCT05712330|Other|patient samples|Patient samples for sputum culture
75886552|NCT04717193|Procedure|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine|Infiltration of local anesthetic at incision sites.
75886553|NCT02050698|Procedure|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
75886554|NCT02050698|Procedure|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
75886555|NCT02050776|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
75444296|NCT05769868|Drug|Esmolol Injection [Brevibloc]|"Brevibloc® will be administered intravenously by infusion pump following the administration schedule:~Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes.~If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute.~The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg.~The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min)."
75444297|NCT05756894|Device|Neurostimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
75444298|NCT05756894|Other|Repiratory training|Respiratory exercises will be completed immediately after completing neurostimulation. Respiratory exercises will involve inspiratory muscle training performing four sets of 6-10 breaths per day with two minutes of rest.
75886556|NCT02051634|Drug|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
75886557|NCT02051634|Drug|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
75444299|NCT05727579|Other|Salt-Diet and/or Ertugliflozin|The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo
75886558|NCT05212025|Drug|Adavosertib|Taken Orally
75444300|NCT05715879|Diagnostic Test|covid infection|patients with covid infection which was proved with positive test
75444301|NCT05715879|Biological|admission to hispital|patients with sever covid disease, who was admitted in hospital
75444302|NCT05685186|Diagnostic Test|Spirometry|To assess lung function
75444303|NCT05685186|Diagnostic Test|Multiple Breath Washout (MBW)|To measure Lung Clearance Index (LCI)
75444304|NCT05685186|Diagnostic Test|Mucociliary Clearance (MCC)|To measure lung clearance after the inhalation of radiolabeled particles
75444305|NCT05685186|Diagnostic Test|CT of the chest|Low radiation to assess structural lung disease
75444306|NCT05685186|Diagnostic Test|MRI of the chest|To assess lung function and structural lung disease
75594104|NCT02279303|Behavioral|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
75594105|NCT02279303|Behavioral|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
75886559|NCT05212025|Drug|Gemcitabine|Intravenous Infusion
75594106|NCT01177228|Drug|Vedolizumab|Vedolizumab for intravenous infusion
75594107|NCT01177228|Drug|Placebo|Placebo intravenous infusion
75737731|NCT05712330|Other|parent questionnaire|parent questionnaire
75737732|NCT00092443|Biological|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
75737733|NCT00092443|Biological|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
75737734|NCT04005924|Other|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
75737735|NCT01085149|Drug|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
75737736|NCT04691622|Biological|Norovirus -specific T-cell (NST) therapy|"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."
75737737|NCT04005612|Dietary Supplement|vitamin D3|50,000 IU VD3 / week for 8 weeks
75737738|NCT04005612|Dietary Supplement|omega-3 fatty acid|300 mg of omega 3-FA once daily for 8 weeks
75737739|NCT04005612|Dietary Supplement|vitamin D3 and omega-3 fatty acid|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
75737740|NCT04005612|Other|control|no intervention
75737741|NCT00413920|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
75444307|NCT05675917|Device|MacuTest platform|"The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet)."
75444308|NCT05668117|Device|Depuy Synthes Advanced Retrograde femoral nail|The Advanced Retrograde Femoral Nailing System (RFNA) is designed to improve fixation and stabilization of distal femur and femoral shaft fractures by reducing toggle and loss of reduction.
75444309|NCT05666778|Device|Menstrual Cup|Menstrual cups are inserted vaginally to collect menstrual flow, with some designed especially for use during intercourse, which will be used in this study. Medical devices registered with the U.S. FDA, a reusable silicon cup can last up to 10 years, is cost-effective, and has reduced environmental impact.
75594108|NCT01607268|Procedure|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy [1H-MRS] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
75886560|NCT02051868|Drug|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
75886561|NCT02051868|Drug|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
75444310|NCT05652764|Other|Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients|In this study, face-to-face patient education, giving patient education booklet, preparation of symptom management card, face-to-face and telephone counseling initiatives were planned to the experimental group.
75886562|NCT02051868|Drug|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
75886563|NCT02051868|Drug|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
75886564|NCT04696757|Drug|Capecitabine|Capecitabine without surgery
75886565|NCT02049294|Biological|Omalizumab (Xolair)|
76057147|NCT02024750|Behavioral|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
76057148|NCT01597973|Drug|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
76057149|NCT01597973|Drug|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
76057150|NCT04671680|Device|LiDCO CNAP Monitoring Equipment|A continuous non-invasive arterial blood pressure monitor for rapidly changing hemodynamics.
76057151|NCT02023268|Device|T2762|1 drop in each eye 3 to 6 times daily during 84 days
76057152|NCT02023268|Device|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
75444311|NCT05650996|Behavioral|ADL/Cast Care instruction|Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated in a cast and cast care. Participants in the experimental group will also receive a handout on ADL participation and cast care.
75594109|NCT02279342|Drug|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
75737742|NCT00413920|Drug|Prednisone|Oral tablets
75737743|NCT03993964|Drug|Pyrotinib combine with SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
75886566|NCT02049294|Drug|Placebo|
75886567|NCT05155943|Device|KALPA X™|Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver. 1.0.229-0 Source control ID: 65f1dbf7) in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
76057153|NCT02047253|Drug|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
76057154|NCT02047253|Drug|Dexamethasone|Administered prior to administration of Study drug
75886568|NCT02051946|Device|Retroject Device|
75886569|NCT02051946|Drug|ethacrynic acid injection|
75886570|NCT02051946|Drug|balanced salt solution|
75886571|NCT02049528|Drug|CC-122|CC-122
75886572|NCT02049528|Drug|CC-122|CC-122
75886573|NCT02049528|Drug|CC-122|CC-122
75886574|NCT02049606|Drug|LAYLA tablet|1 Tablet twice a day
75886575|NCT02049606|Drug|CENATONE tablet|2 Tablets once a day
75886576|NCT02049684|Procedure|Patch|
75886577|NCT02037516|Device|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
75886578|NCT02037516|Drug|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
76057155|NCT02047253|Drug|Acyclovir|Administered orally twice daily
76057156|NCT04707131|Drug|LEM-S401|siRNA encapsulated in DegradaBALL®
75886579|NCT02037516|Device|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
75886580|NCT01568099|Biological|AFFITOPE® PD01A|s.c. injection
75886581|NCT01568099|Other|Control|Untreated control
75886582|NCT02050932|Dietary Supplement|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
75886583|NCT03561792|Other|Diaphragm ultrasound|In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
75886584|NCT02052024|Drug|Botox|Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
75444312|NCT05650996|Behavioral|Cast Care Instruction|Participants in the control group will watch a video instructing them on cast care. Participants in the control group will receive a handout on cast care.
76057157|NCT04707131|Drug|Placebo|Placebo
75444313|NCT05650827|Behavioral|Resistance training|10 weeks of resistance training 3 times pr. week.
75886585|NCT02052024|Drug|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
76057158|NCT02096705|Drug|Dapagliflozin|Tablet
75444314|NCT05650827|Dietary Supplement|Protein supplement|A daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight
75444315|NCT05639296|Other|Discovery learning (DL)|"DL makes the trainee practice before giving them instruction, Do-Then-Tell, thereby promoting their ability to use and build upon their existing knowledge."
75886586|NCT02037672|Drug|metformin|
75444316|NCT05613816|Procedure|Senhance Surgical System|100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System
75886587|NCT02037672|Drug|metformin and roflumilast|
75444317|NCT05603364|Combination Product|100ml carbohydrate containing 12.5g maltodextrin, fructose and glucose|Drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.
76057159|NCT02096705|Drug|Dapagliflozin Placebo|Tablet
75444318|NCT05603364|Other|Routine feeding|Patients in group C were observed with 60min of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 h, and began to eat gradually through the mouth after anal exhaust
75594110|NCT01193530|Other|Bright Light Therapy|30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
75594111|NCT01193530|Other|Dim Red Light Therapy|From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
75886588|NCT02049762|Drug|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
75444319|NCT05597254|Dietary Supplement|Probiotic with niacin and berry extract|1 capsule daily of probiotic with niacin supplementation for 8 weeks
75444320|NCT05597254|Dietary Supplement|Probiotic without niacin and berry extract|1 capsule daily of probiotic without niacin supplementation for 8 weeks
75594112|NCT01193530|Behavioral|Questionnaires|Weekly
75594113|NCT01193530|Behavioral|Study Diaries|Daily logs
75886589|NCT02049840|Device|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
75886590|NCT02037594|Behavioral|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
75886591|NCT02037594|Behavioral|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
75886592|NCT02037594|Behavioral|PrEP Information (Active Control)|Standard of Care Information about PrEP
75886593|NCT02037594|Behavioral|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
75886594|NCT02052102|Radiation|Radiation therapy|
75886595|NCT03561558|Drug|Ibuprofen D|Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
75886596|NCT03561558|Drug|Nurofen® for Children|Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
75886597|NCT02037906|Radiation|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
75886598|NCT02037906|Radiation|Constant Energy SWL|Constant dose at 20 kv
75886599|NCT02037906|Radiation|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
76057160|NCT04705571|Device|MorpheusV Applicator|1 treatment with the MorpheusV Applicator
76057161|NCT02096471|Drug|PD-0325901|
75444321|NCT05597254|Dietary Supplement|Placebo|1 capsule daily of placebo supplementation for 8 weeks
75444322|NCT05583994|Other|Optim Park Intervention|For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
75737744|NCT01037764|Procedure|alloHCT|"[ alloHCT arm ] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."
75737745|NCT01033630|Drug|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
75737746|NCT01033630|Drug|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
75737747|NCT01033630|Drug|Placebo|Image-matched placebo, made with starch.
75737748|NCT00091819|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
75737749|NCT00091819|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
75737750|NCT01326871|Drug|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
75737751|NCT01326871|Drug|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
75737752|NCT01326871|Biological|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
75737753|NCT01081405|Other|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
75737754|NCT01081483|Drug|ABT-072|See arm description for more information
75737755|NCT01081483|Drug|Placebo|See arm description for more information
75444323|NCT05579340|Other|Exercise|6 months of combined aerobic and resistance exercise
75444324|NCT05576415|Drug|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
75444325|NCT05557188|Other|Grounding|Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
76057162|NCT02096003|Drug|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
75444326|NCT05557188|Other|Sham grounding|Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
75444327|NCT05549596|Device|Ceragem Master V6 Traction|Ceragem Master V6 Traction for L2~L3
75594114|NCT01193530|Device|Red Light Litebook|Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
75594115|NCT01193530|Device|Bright Light Litebook|Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
75594116|NCT01607307|Drug|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
75737756|NCT03964129|Procedure|Avance Nerve Graft with Autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.
75886600|NCT03099161|Drug|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
75886601|NCT03099161|Biological|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
76057163|NCT02096003|Drug|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
76057164|NCT02062385|Biological|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
76057165|NCT02062385|Biological|Placebo to V260|Placebo control
76057166|NCT02062385|Biological|OPV|Oral poliovirus vaccine administered according to the standard of care
76057167|NCT02062385|Biological|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
76057168|NCT02062151|Other|Acupuncture|Acupuncture
76057169|NCT02060903|Drug|Abametapir Lotion 0.74% w/w|Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
75737757|NCT00540228|Biological|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
75737758|NCT00540228|Biological|Fluarix™|Single dose, Intramuscular injection
75737759|NCT01081561|Drug|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
75737760|NCT04004754|Drug|Miltefosine (administration is not part of study procedures)|Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
75737761|NCT04567056|Diagnostic Test|Blood sample|A separate blood sample will be taken for methylation-analyses
75737762|NCT05919901|Other|HPV Vaccine Communication Strategy|The intervention will include health promotions materials and provision of HPV vaccine
75737763|NCT05919875|Behavioral|Unguided Mindfulness-Based Cognitive Therapy|"The unguided iMBCT intervention is divided into six sessions. The sessions are an online adaptation of the regular MBCT. Subsequent sessions are unlocked gradually, once a week. The training consists of audio/video recordings and a workbook. Materials are recorded by a certified MBCT teacher and represent topics raised during regular courses:~Awareness and automatic pilot~Living in our heads~Being present in the body~Recognizing aversion~Allowing / Letting be~How can I best take care of myself?~The intervention requires daily commitment of about 30-40 minutes."
75737764|NCT05919875|Behavioral|Guided Mindfulness-Based Cognitive Therapy|"The guided iMBCT intervention consists of six online meetings in groups of maximum 25 participants. The weekly meetings will be led by an experienced and certified MBCT teacher. The course of the meeting will represent thematically the unguided condition according to the agenda:~Introduction to the topic~Guided meditation~Brief inquiry and discussion~Setting tasks for the upcoming week~To reduce the number of differences between the conditions as much as possible and narrow it down to the active participation of the teacher, the meetings will be modified version of MBCT and will last maximum 90 minutes. Between the meetings participants will be ask to practice daily 30-40 minutes mindfulness exercises."
76057170|NCT02060903|Drug|Vehicle Lotion|Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
76057171|NCT02095691|Device|Celsius® ThermoCool® Renal Denervation|The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
76057172|NCT02095535|Drug|Chlorhexidine gluconate|antiseptic
76057173|NCT04704323|Drug|CAP-100|CAP-100 (humanized antibody against C-C-chemokine receptor 7 [CCR]7)
76057174|NCT04703699|Device|Myval Transcatheter Heart Valve System|Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.
76057175|NCT02095223|Device|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
76057176|NCT02095223|Behavioral|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
75444328|NCT05549596|Device|Physical therapy with standard traction device|Physical therapy with standard traction device
75737765|NCT05919836|Procedure|Laparoscopic assisted hernia|Percutaneous assisted laparoscopic hernia
75737766|NCT05919836|Procedure|Laparoscopic hernia by purse string closure|Laparoscopic purse string closure of hernial sac
75444329|NCT05542238|Behavioral|One bout of moderate-intensity sub-maximal aerobic exercise|The intervention is a 20-min acute exercise using arm ergometer
75444330|NCT05511064|Device|Blood circulation device|Blood circulation device of CGM MB-1701
75444331|NCT05507151|Procedure|Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
76057177|NCT02095145|Other|Laboratory Biomarker Analysis|Correlative studies
75737767|NCT05919836|Procedure|Total laparoscopic dissection of hernial sac|Total laparoscopic dissection of hernial sac
76057178|NCT02095145|Other|Pharmacological Study|Correlative studies
76057179|NCT02095145|Other|Placebo|Given PO
75594117|NCT01607307|Drug|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
75594118|NCT02279381|Drug|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
75594119|NCT02279381|Other|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
75594120|NCT02279381|Other|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
75594121|NCT01607385|Drug|GSK2330672|BID, repeat doses
75594122|NCT01607385|Drug|Placebo|BID, repeat doses
75594123|NCT01607385|Drug|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
75594124|NCT01646567|Drug|SHP-141C|Topical Cream
75737768|NCT05919797|Drug|Naltrexone-Bupropion Combination|Participants receive 28 weeks of naltrexone-bupropion weight loss medication during phase two of this study.
75594125|NCT01646567|Drug|Placebo to SHP-141C|Placebo Topical Cream
75737769|NCT05919732|Drug|Bupivacaine and epinephrine infusion|"For caudal infusion group: bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg) will be administered via the catheter.~For general anesthesia group: bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg) prior to start of the surgery."
76057180|NCT02095145|Drug|Pomegranate-Extract Pill|Given PO
75594126|NCT01646567|Drug|Betamethasone Valerate|Topical cream, 0.02%
75594127|NCT01646567|Drug|Calcipotriol|Topical cream, 0.005%
76057181|NCT04722029|Biological|Adenovirus Specific T lymphocytes|ADV-VSTs is being proposed for the treatment of refractory ADV infection and/or disease in these populations using haploidentical donors for ease of donor selection, antiviral immunity, coupled with a high-throughput antigen stimulation/IFN-γ capture system (Miltenyi Biotec, CliniMACS Prodigy® System) for rapid and less costly isolation of ADV-VSTs.
76057182|NCT02059187|Drug|MK-1293|MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
75444332|NCT05506436|Device|Evident 3|It consists of brief 5-minute counselling on general physical activity recommendations and explaining the plate method for a balanced diet. Also, it includes the Evident 3 application, which is a daily dietary log that provides information on calories and diet composition and shows a reminder of the 10000 steps/day.
75737770|NCT05919719|Procedure|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Fluid expansion will be delayed while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard).~Our index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline, During abdominal compression, After the 10 to 20ml/kg crystalloid fluid expansion Abdominal compression : a sphygmomanometer will be inflated to a pressure of less than 10 mmHg and will be applied to the center of the patient's abdomen. Then, a gentle compression on the sphygmomanometer will be performed, calibrated at 22 - 26 mmHg according to the sphygmomanometer. The echocardiographic assessments will take place between 10 and 60 seconds after the start of the compression, which will therefore last less than a minute."
75886602|NCT04309565|Behavioral|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
75886603|NCT04309565|Behavioral|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
75886604|NCT04855487|Behavioral|Nurse-patient dyadic storytelling intervention|During the 5-week online intervention, adolescents/young adults with cancer will create their stories following the guiding questions and online meetings with nursing research staff. The target audience of their stories will be their primary nurses. This online dyadic storytelling intervention is designed to promote in-depth self-reflection and meaningful and therapeutic relationships within bedside nurses. The intervention is designed following the Story Theory and Pennebaker's Expressive Writing paradigm.
75886605|NCT04304339|Other|Hypercapnic respiratory failure|Patients with hypercapnic respiratory failure will be followed without any additional intervention
75444333|NCT05506436|Other|Implementation strategy|"Four sessions have been designed to obtain the implementation strategy:~First session: Presentation of the Evident 3 application and its results in clinical trials. Training in the use of the application and identification of possible areas for improvement.~Second session: Presentation of evidence-based practices on the management of obesity in Primary Care. Consensus selection of those related to health promotion and mHealth. Sharing of possible lines of improvement of the care offered in the practice.~Third session (optional): Intervention on those components (coherence, cognitive participation, collective action and reflective follow-up) of the NOMAD questionnaire, if very low scores are obtained.~Fourth session: Brainstorming on possible strategies for the implementation of the Evident 3 intervention. Analysis and evaluation of these strategies and determination of a common strategy for their implementation."
75444334|NCT05490069|Other|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and real-time chat-based support messages, delivered according to participants' preferences.
75886606|NCT03095027|Device|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
75886607|NCT03095027|Device|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
75594128|NCT01607424|Behavioral|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
75594129|NCT01646606|Procedure|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
75594130|NCT01646606|Procedure|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
75886608|NCT04639115|Drug|Ozanimod|Ozanimod
75886609|NCT04260659|Drug|Dexmedetomidine Hydrochloride [Dexdor]|Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
75886610|NCT04260659|Drug|Remifentanil [Ultiva]|Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
75594131|NCT01681979|Drug|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
75886611|NCT04260659|Drug|Ketamine [Ketalar]|Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
75886612|NCT04260659|Drug|Lidocaine [Xylocaine 2%]|Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
75886613|NCT04260659|Drug|Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]|Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
75444335|NCT05482672|Drug|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
75886614|NCT04260659|Drug|Fentanyl [Fentanyl WZF]|Rescue dosis of 100 mcg iv will be administered if hypertension > 140/90 mmHg or tachycardia > 120min occurs. If necessary rescue dosis may be repeated.
75886615|NCT05068661|Drug|Ropivacaine 0.1% Injectable Solution|DPE
75444336|NCT05482672|Behavioral|GetHealthy-OA mind-body program|The GetHealthy-OA mind-body program emphasizes increased physical activity, healthy diet and sleep habits to lessen osteoarthritis and depressive symptoms
75444337|NCT05482672|Drug|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
75444338|NCT05482672|Behavioral|Health education booklet|The booklet will containing brief summarized information that reflects the active intervention topics including the trajectory of pain and recovery for those with knee osteoarthritis, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living
75444339|NCT05472532|Procedure|Patient sampling.|"One or several bio-specimens will be sampled depending on the cohort :~Blood (40 ml)~Pleural Fluid (40 ml)~Peritoneal liquid (40 ml)~Solid tumors"
75594132|NCT01646684|Drug|SOM230|
75737771|NCT05919667|Dietary Supplement|Dairy and plant-based dairy beverages and solids|Crossover design: participants received all treatment arms in a randomized order
75886616|NCT05068661|Drug|Bupivacaine 0.25% Injectable Solution|CSE
75886617|NCT04340609|Biological|Mesenchymal Stem Cells|The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
75886618|NCT04148495|Drug|placebo of acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%"
75886619|NCT04148495|Drug|acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g"
75886620|NCT05060003|Drug|Atezolizumab|Atezolizumab is provided by Genentech.
75886621|NCT05060003|Drug|Tiragolumab|Tiragolumab is provided by Genentech.
75594133|NCT01607580|Drug|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
75737772|NCT05919641|Other|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
75737773|NCT05919615|Drug|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
75737774|NCT05919615|Drug|Normal saline|0.9% sodium chloride normal saline
75737775|NCT05919576|Device|Near infrared imaging|In the study, all volunteers are recorded with the itero Element 5D by activating the NIRI mode. The recording method does not involve ionizing radiation. 850 nm wavelength beams are used.
75737776|NCT05919563|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
75737777|NCT05919550|Drug|search for a clozapine intake|search for a clozapine intake
75737778|NCT05919498|Other|Individual semi-directive interview|"This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour."
75737779|NCT05919498|Other|Focus groups|"This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours."
75737780|NCT05919459|Behavioral|5-week online synchronous ACT intervention|Parents will meet a trained ACT counsellor to undergo five weekly sessions of ACT group training via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
75737781|NCT05919459|Behavioral|asynchronous online AIS education|A healthcare educator with a background in nursing, physiotherapy, or occupational therapy will meet with parents in five weekly 120-minute interactive AIS-related education videoconferencing via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
75737782|NCT05919446|Behavioral|Acceptance and commitment therapy (ACT)|Each session in the ACT group will include the first hour of ACT intervention followed by 1 hour of back exercise class. The ACT group will be led by a trained ACT counsellor and a trained exercise trainer.
75737783|NCT05919446|Behavioral|back exercise|The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
75737784|NCT05919407|Drug|Pyridostigmine|Participants will receive pyridostigmine 10 mg tablets.
75737785|NCT05919407|Drug|Amifampridine (base) with modified release|Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.
75737786|NCT05919407|Drug|Placebo|The placebo tablets will be identical apart from the active substance (pyridostigmine)
75737787|NCT05919407|Drug|Placebo|The placebo tablets will be identical apart from the active substance (amifampridine base)
75737788|NCT05919394|Drug|To compare in both treatment arms the percentage of patients controlled at week 52.|Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
75737789|NCT05919381|Drug|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
75444340|NCT05469295|Device|CGM MB-1701 device treatment|This is a pre-approved motorized traction device.
75444341|NCT05469295|Device|CGM MB-1701 Sham device treatment|It is manufactured in the same way as the test device and the operation pattern. However, the actual effect of the massage is minimized.
75444342|NCT05468476|Other|No intervention|No intervention
75444343|NCT05465044|Other|Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule|50% of the eligible participants will be assigned to twice-weekly hemodialysis for up to 12 months with incremental crossover to thrice-weekly hemodialysis as indicated.
75737790|NCT05919381|Drug|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
75737791|NCT05919355|Other|Offer to try Komp|The participants are offered services using the communication solution Komp. If they accept, they will receive one unit at home.
75444344|NCT05465044|Other|Thrice-Weekly Hemodialysis|50% of the eligible participants will be assigned to outright thrice-weekly hemodialysis, which will be continuation of the initial thrice-weekly schedule during the run-in period, without the option to switch to less frequent dialysis schedule representing the standard of care.
75444345|NCT05463003|Dietary Supplement|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity
75444346|NCT05458778|Device|Daily test with urine by the product|Women perform the hCG test and share the test results
75444347|NCT05456516|Behavioral|Food Rating|Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants
75594134|NCT01646723|Behavioral|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
75594135|NCT01607619|Dietary Supplement|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
75737792|NCT05919303|Radiation|CT Scan|CT scan study of abdomen
75594136|NCT01646801|Device|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
75886622|NCT05060003|Device|Signatera Assay|"To detect residual disease or to determine cancer recurrence with ctDNA~Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"
75886623|NCT04227197|Other|Down Syndrome Clinic to You (DSC2U)|DSC2U is a web-based tool for families to get up-to-date, personalized health and wellness information, based on national guidelines and expert consensus, for a person with Down syndrome.
75737793|NCT05919225|Procedure|Risk stratification before decision-making about patient hospitalization or discharge|Once AHF has been diagnosed at ED, and before decision-making about hospitalize/discharge home is taken, physicians will objectively measure the severity of decompensation, based on risk of 30-day death using MEESSI scale. As result, patient can be allocated to low, intermediate, high or very-high risk. For patients classified as low-risk, the propocol recommendation will be discharge patient to home. For patients classified as increased risk (i.e., intermediate, high or very-high risk categories), the protocol recommendation will be to hospitalize patient. Nonetheless, final decission will be left to emergency physician, and overruling (disposition against recommendation) will be allowed.
75886624|NCT03632447|Device|Leva|Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.
75444348|NCT05434286|Diagnostic Test|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin
75737794|NCT05919212|Diagnostic Test|HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment|We study the circulating changes associated with resistance to T-DXd, including changes in HER2 status,studied through a new approach called HER2-2D that simultaneously assesses HER2 amplification and overexpression in blood
76057183|NCT02059187|Drug|Lantus™|Lantus™ (insulin glargine [rDNA origin]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
75886625|NCT03632447|Device|PFDx|All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
75886626|NCT05051189|Drug|Fentanyl Citrate|Ventilatory response to fentanyl in patients with OSA Specifically: respiratory changes, CO2, RR, TV
75886627|NCT04540289|Drug|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2016 ESC guidelines for the management of acute and chronic heart failure"
75886628|NCT04540289|Device|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
75444349|NCT05410327|Other|Chokeberry (Aronia melanocarpa) juice|A water-infused chokeberry (Aronia melanocarpa) juice will be used as the intervention. The brand being used is called 'Superberries'.
75444350|NCT05409443|Procedure|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"Electrodes are positioned along the lateral sacral crest lateral to the inflection points of the S1, S2 and S3 lateral foraminal walls along first to third transverse sacral tubercles maintaining a craniocaudal line with an interelectrode distance of no more than 15mm.~The appropriate locations are confirmed in both AP and lateral views and the tines are deployed. Following injection of lidocaine, lesions are performed at 85 degrees Celsius for 180 seconds at each site for bipolar sites and 80 degrees Celsius for 90 seconds for the monopolar site. Following ablation, the tines are retracted for all electrodes prior to removal."
75444351|NCT05409443|Procedure|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|"To target the L4 medial branch and L5 dorsal ramus, an electrode will be placed in parallel between the junction of the L5 transverse process and superior articular process and the sacral ala and S1 superior articular process.~A periforaminal electrode position will be used to target the lateral branches from S1 to S3. An 22-G cannula with a 5-mm exposed tip will be directed to a location approximately 3-5mm lateral to the PSFA of S1, S2, and S3. The analog clock positions for the probes at S1 and S2 levels will be 1:00, 3:00, and 5:30 on the right, and 6:30, 9:00, and 11:00 on the left. For the S3 level the positions at 1:30 and 4:30 on the right, and 7:30 and 10:30 on the left will be used (6,18).~The appropriate locations are confirmed in both AP and lateral views. Following injection of lidocaine, monopolar RFA is performed for 90 seconds at 80 degrees Celsius at each location."
76057184|NCT02059187|Drug|Prandial insulin|Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
75444352|NCT05401409|Dietary Supplement|Beetroot juice|70mls beetroot juice (400mg nitrate) given daily for 4 weeks
75444353|NCT05401409|Dietary Supplement|Nitrate-depleted beetroot juice|70mls beetroot juice (nitrate-depleted) given daily for 4 weeks
75594137|NCT01647152|Drug|Ustekinumab|
75594138|NCT01682018|Device|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
75594139|NCT01607697|Behavioral|Mindfulness Training|Mindfulness Training
75594140|NCT01682057|Device|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
75594141|NCT01682057|Device|ROX Anastomotic Coupler System (ACS)|
75594142|NCT01604187|Drug|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
75737795|NCT05919199|Other|No intervention|No intervention
75886629|NCT05027165|Other|Non-interventional|No intervention
75886630|NCT04172597|Drug|Poziotinib Hydrochloride|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
75886631|NCT04172597|Drug|Loperamide|Loperamide as prescribed by the physician.
75886632|NCT04097873|Other|Diaphragm ultrasonography reeducation plus inspiratory training|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
75594143|NCT01604187|Drug|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
75594144|NCT01682096|Radiation|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
75594145|NCT01682096|Procedure|Exercise stress echocardiography|Limited by symptoms
75594146|NCT01607736|Behavioral|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
75737796|NCT05919186|Drug|EmbryORP®|EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
75737797|NCT05919186|Device|O2 tension 20%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%
75737798|NCT05919186|Device|O2 tension 5%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%
75737799|NCT05919121|Other|Therapeutic exercise|"Stretching exercise of posterior shoulder capsule~Strengthening exercises: consists of 6 strengthening exercises all of which have been recommended as essential for any shoulder rehabilitation program.~The remaining 2 exercises are the seated press-up and the elbow push up. Both will be performed to fatigue or for a maximum of 25 repetitions. The quality of all repetitions of each exercise will continuously monitored by the investigator of the study"
75737800|NCT05919121|Other|hydrocortisone phonophoresis|In this study, the effective area of radiation (ERA) in the mode continuous (100 percent) is 5 cm2, in 1 MHz and 0.7 W/cm2, with four ERA treated areas. Therapy lasted five minutes (three minutes in the insertion of the supraspinatus and 37 two minutes in the infraspinatus insertion) three times weekly over 6 weeks in addition to therapeutic exercises
75737801|NCT05919121|Other|hydrocortisone iontophoresis|A direct current electrical stimulation unit will be used to apply iontophoresis. The unit has two electrodes; one electrode is for the negative current, and one is for the positive current. The Active (Negative) electrode will be placed on the anterolateral aspect of the shoulder joint. The passive electrode: will be placed on the upper arm region. Intensity of the current: Between the range of 3-5 mA at the point of sensation of patient was set. Treatment duration: Calculated accordingly with intensity of current. Method of application: hydrocortisone gel 10% will be administered by applying on the active rubber electrode for each session three times weekly over 6 weeks in addition to therapeutic exercises.
75886633|NCT04097873|Other|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
75886634|NCT04087655|Behavioral|Exercise|Eight weeks of interval exercise training
75886635|NCT04015427|Device|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
75886636|NCT00446225|Drug|Erlotinib|"150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
75886637|NCT00446225|Drug|Carboplatin|"Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
75594147|NCT01682174|Other|Control Drink|
75737802|NCT05919095|Drug|Carrilizumab plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment."
75886638|NCT00446225|Drug|Gemcitabin|Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
75886639|NCT00446225|Drug|Docetaxel|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
75886640|NCT00446225|Drug|Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
75886641|NCT03080935|Drug|Evolocumab|Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
75737803|NCT05919043|Other|Upper limb-based movement priming (UL-priming)|Repetitive upper limb movements administered to the beat of a metronome.
75737804|NCT05919043|Other|Stimulation-based priming (Stim priming)|Noninvasive brain stimulation.
75886642|NCT04031105|Device|Theta-burst stimulation (TBS)|"intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~*The optimal %RMT will be evaluated in a pilot study before commencement of the main study"
75886643|NCT03976115|Drug|DDO-3055|Oral
75886644|NCT03976115|Drug|Placebos|Oral
75886645|NCT03973255|Behavioral|Rehabilitation|Posturography, Whole body vibration
75444354|NCT05401175|Other|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemoradiotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemoradiotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
75444355|NCT05393622|Device|INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION|Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
75444356|NCT05388422|Device|Application of 3D scanner to measure physical size in patients with severe cerebral palsy|Before starting the study, radiologic and clinical evaluation were performed. After measuring the patient's exact physical size by applying a 3D scanner, we manufacture hip brace in preventing progressive hip displacement in patients with severe cerebral palsy. After wearing for a week, follow-up radiologic and clinical evaluation were performed.
75444357|NCT05337995|Other|Quantified analysis of walking during a task of passage through a horizontal opening|Functional test that reproduce a task of daily living, similar to a doorway
75444358|NCT05324761|Drug|Pregabalin 75mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
75737805|NCT05919043|Other|Lower limb-based movement priming (LL-priming)|Aerobic exercise using a treadmill or recumbent stepper.
75737806|NCT05919043|Other|Sham priming|Auditory stimulation.
75737807|NCT05919017|Drug|Naltrexone implant|Naltrexone implant
75737808|NCT05919017|Drug|Placebo|Placebo
75444359|NCT05324761|Drug|Gabapentin 300mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
75594148|NCT01682174|Other|Experimental Drink|
75737809|NCT05918991|Behavioral|Daily Report Card|Behavioral consultants will meet with teachers to review daily report card implementation and effective classroom management. The consultant collaborates with the teacher to identify specific behavioral goal targets for the student's DRC based on a review of teacher ratings and teacher description of key problem behaviors. After establishing the initial DRC, the consultant will review procedures with the teacher for scoring the DRC and, importantly, providing the student with effective and consistent performance feedback. The consultant will also make a plan with the teacher to review DRC progress and revise the DRC as needed. Consultants will also meet with parents to develop a plan for reinforcing the DRC at home. The DRC will be implemented for 18 weeks. The behavioral consultants will be available to teachers and parents throughout the duration of the intervention to assist with implementation and adjustment of target behaviors and goals.
75886646|NCT04479449|Drug|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
75886647|NCT04479449|Drug|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
75886648|NCT05303207|Dietary Supplement|YOUR SUPER Detox Bundle|During days 1-5, participants will complete the 5-day Your Super Detox, consuming 2 smoothies daily (breakfast and dinner) containing Your Super Detox superfood powders.
75886649|NCT04434131|Drug|Convalescent Plasma|Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
75886650|NCT01383811|Other|Moderate Intensity Aerobic Exercise|Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
75594149|NCT01647191|Behavioral|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
75594150|NCT01647191|Behavioral|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
75594151|NCT01604304|Procedure|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
75594152|NCT01604304|Procedure|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
75737810|NCT05918991|Other|Language Intervention|The intervention protocol to be provided in each grade level will include 18 weeks of 20-25 minutes of small-group intervention 4 days per week, for a total of 72 lessons. The fifth day per week will be allocated to make-up lessons for students absent earlier in the week to maximize opportunity for each participant to receive the full dosage of lessons. Half of these lessons in each grade will be allocated to Language in Motion implementation and the other half to Dialogic Reading. Dialogic Reading is designed to increase vocabulary knowledge through shared reading of picture books. The content involves reading of 9 children's books with 108 targeted vocabulary words. Language in Motion is designed to increase syntax and grammar knowledge using science manipulatives. Daily lessons are highly scripted to introduce primary syntax targets through narrative text. Manipulation props are used to reinforce syntax targets and basic science topics.
75737811|NCT05918965|Device|transcutaneous electrical vagal neurostimulation|daily for 12 weeks
76057185|NCT02043899|Drug|[124I]meta-Iodobenzylguanidine|Single intravenous administration of [124I]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq [124I]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
76057186|NCT04719611|Dietary Supplement|Probiotic|Healthy women receive a probiotic supplement containing 6 x 10^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
75444360|NCT05318807|Other|Assessment of level of readiness and need for personalised prehabilitation|"Patients asked to complete five validated questionnaires to assess their level of need and readiness:~Cancer Behaviour Inventory brief form - to measure self-efficacy for coping with cancer~Patient Activation Measure - to measure patient activation~Modified Godin Leisure Time Exercise Questionnaire - to monitor activity~Patient Generated Subjective Global Assessment - to identify malnutrition risk~Emotions thermometer - to detect emotional disorders and identify risk"
75444361|NCT05318807|Other|Formation of a personalised prehabilitation plan|"Prior to starting treatment, at week three and at week six, each patient will be invited to see a specialist dietitian for a one hour face-to-face personalised prehabilitation appointment to:~Review the initial questionnaires to inform the personalised plan and goal setting~Complete a further four questionnaires related to quality of life, diet and exercise~Measure handgrip strength~Assess functional capacity by completing the six minute walk test~A personalised plan is then agreed using SMART goals, taking into account the patient's priorities as indicated in their Patient Generated Index."
75594153|NCT01682291|Behavioral|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
75594154|NCT01682291|Dietary Supplement|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
75594155|NCT01607931|Behavioral|Exercise|1 hour of cycling at 50% of maximum power output
75594156|NCT01604382|Drug|General Anesthesia|General Anesthesia as described above
75594157|NCT01604382|Drug|Neuraxial anesthesia|Neuraxial anesthesia as described above
75737812|NCT05918939|Biological|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|"Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARSCoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial~(1 ml per vial). The vial should be shaken well before injection."
75737813|NCT05918939|Biological|CoronaVac Biofarma COVID-1 9 Vaccine 3 µg|Control vaccine in this study is existing CoronaVacBioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
75737814|NCT05918926|Behavioral|Exercise|Individualised remote exercise intervention
75886651|NCT01383811|Other|Wait-list|The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
75886652|NCT05418959|Diagnostic Test|DermTech PLA noninvasive adhesive biopsy|The clinician will firmly press the DermTech noninvasive adhesive on the lesion and use their thumb to make five circular motions on the lesion. The adhesive patch will then be pulled off of the area. This will be repeated for an additional three patches.
75886653|NCT03787901|Other|Morula Vitrification|Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
75886654|NCT03674567|Drug|FLX475|tablet
75886655|NCT03674567|Drug|Pembrolizumab|IV infusion
75886656|NCT03503435|Behavioral|Group art therapy|Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
75737815|NCT05918874|Other|Descriptive questionnaire|Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.
75737816|NCT05918848|Device|Filme Gyno-V® Vaginal Ovules|Administration of tocopherol (Filme Gyno-V® Vaginal Ovules) for 14 days
75737817|NCT05918770|Diagnostic Test|systematic screening and early treatment|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition
75737818|NCT05918731|Behavioral|Self Management|"A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file."
75444362|NCT05318807|Other|Daily diary|Each patient will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood throughout their treatment as well as their adherence to goals. This will provide an indication of the impact of symptoms.
75737819|NCT05918718|Drug|Letrozole|assessment of the efficacy of Letrozole in treatment of ectopic pregnancy
75737820|NCT05918718|Drug|methotrexate|methotrexate
75737821|NCT05918705|Procedure|Ultrasound optic nerve sheath diameter / eyeball transverse diameter ratio|"Ocular ultrasonography will be performed once daily on patients diagnosed with sepsis associated encephalopathy at the bedside by two experienced examiners, who will be blinded to patients' clinical data, following the CLOSED protocol for ONSD sonography.~ONSD will be measured at 3 mm behind the merging point of the nerve from the papilla optic disc. The maximum external diameter of ONSD will be measured in the transverse plane perpendicular to the optic nerve and the maximum diameter of ETD (parallel lens) on this plane will be measured.~Two measurements will be taken for each eye; horizontal and vertical. The sequence for measurements will be left eye horizontal; left eye vertical; right eye horizontal; right eye vertical.~The ONSD measurements in the transversal and the sagittal plane for each eye measured by the two examiners will be averaged. Then, ETDs measurements will be averaged to obtain averaged ONSD/ETD ratio as a data to record the mean values of ONSD/ETD ratio."
76057187|NCT02043509|Behavioral|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
75444363|NCT05317403|Drug|Venetoclax|"Dose Level 0: Day 1 60 mg/m2 PO x1, Days 2-14 120 mg/m2/dose PO once daily (Max: 200 mg/day)~Dose level 1: Day 1 120 mg/m2 PO x1, Days 2-14 240 mg/m2/dose PO once daily (Max: 400 mg/day)~Dose level 2: Day 1 180 mg/m2 PO x1, Days 2-14 360 mg/m2/dose PO once daily (Max: 600 mg/day)"
75444364|NCT05317403|Drug|Azacitadine|75 mg/m2/dose IV once daily over 15 minutes
76057188|NCT04719377|Device|catheter placement|catheter placement
75444365|NCT05317403|Drug|Vorinostat|"1 year to 17.99 years old: 180 mg/m2/dose PO once daily~≥18 years old 200 mg PO BID. Doses should be separated by 12 hr (±4 hr)"
75444366|NCT05317403|Drug|Cytarabine|"2000 mg/m2/dose IV once daily over 3 hours~IT Cytarabine:~- 1.99 years old: 30 mg~- 2.99 years old: 50 mg~3 years old: 70 mg"
75444367|NCT05317403|Drug|Fludarabine|30 mg/m2/dose IV once daily over 30 minutes
75737822|NCT05918627|Drug|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
75737823|NCT05918627|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
75737824|NCT05918614|Drug|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
75737825|NCT05918614|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
75737826|NCT05918588|Drug|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
75737827|NCT05918588|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
75737828|NCT05918562|Dietary Supplement|Low fiber diet|Low fiber diet including cereal, white bread, eggs, meat, dairy
75737829|NCT05918562|Dietary Supplement|Standard clear liquid diet|Standard clear liquid diet including broth, jello, water, juice
76057189|NCT02058563|Biological|Priorix®|1 dose administered as a subcutaneous (SC) injection.
76057190|NCT02058563|Biological|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
76057191|NCT01622231|Drug|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
76057192|NCT04417439|Other|universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)|The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.
76057193|NCT02042183|Drug|Lubiprostone|12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
76057194|NCT02042183|Drug|Placebo|0 mcg soft capsules of placebo for oral administration
76057195|NCT01977482|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
75737830|NCT05918536|Diagnostic Test|evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT|Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT
75737831|NCT05918471|Dietary Supplement|Very Low Energy Diet with Liquid Supplementation|"The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~Consume 4 Optifast 900 packets each day~Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender."
75886657|NCT04407767|Behavioral|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
75444368|NCT05317403|Drug|Filgrastim|5 microgram/kg/dose subcutaneous (or IV over 15-30 min) once daily
75594158|NCT01604421|Procedure|Thermoregulation-standard care|Standard care without plastic bag. One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
75886658|NCT04407767|Behavioral|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
75444369|NCT05312242|Dietary Supplement|United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) MMS|Introduction of UNIMMAP MMS along with novel counseling strategies to increase acceptability and adherence to prenatal supplementation
75444370|NCT05312242|Dietary Supplement|Iron Folic Acid Supplement|Standard of Care Intervention
75594159|NCT01604421|Procedure|Thermoregulation with plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
75444371|NCT05298813|Biological|IBIO123|IBIO123 1 mg, 5 mg and 10 mg
76057196|NCT01977482|Drug|Placebo|Matching placebo tablet for GSK1278863
76057197|NCT01977482|Drug|rhEPO|rhEPO will be procured from local market
75444372|NCT05298813|Other|Placebo|Matching Placebo
75444373|NCT05292352|Behavioral|LFSD|"Assessment of child's usual diet to assess sugar intake in relation to the total usual diet.~Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home.~Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1."
75594160|NCT01647269|Procedure|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
75594161|NCT01682369|Biological|TIV (Aggripal)|
75737832|NCT05918419|Drug|Serplulimab|PD-1 antibody
75737833|NCT05918393|Behavioral|functional communication training|During functional communication training, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both problem behavior and communication are on extinction) will be alternated within a single session. All communication responses will be reinforced every time they occur during the signaled reinforcement intervals.
75737834|NCT05918380|Behavioral|PAL2|"Low CVD risk participants (CAC < 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education."
75737835|NCT05918380|Other|CINEMA|High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
75737836|NCT05918341|Drug|Piracetam|Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
75737837|NCT05918315|Procedure|Buccal mucosa substitution urethroplasty|Use of buccal mucosa as a substitution for urethroplasty
75737838|NCT05918289|Behavioral|Blended& integrated happy aging active aging program(BIHAAAP)|12 Weeks intervention devided in to two phases( face to face and home based)
75737839|NCT05918276|Drug|Orelabrutinib and BG|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd，C2-C7. Twenty-eight days for a cycle.~Drug: BG Bendamustin 70mg/m2, IV, d2&d3 inC1, and then d1&d2 inC2-6.Twenty-eight days for a cycle.~Obintuzumab 100mg IV, d1, 900mg d2, 1000mg d8&d15 in C1, and then 1000mg/m2 IV, d1 in C2-6. Twenty-eight days for a cycle."
75444374|NCT05290675|Diagnostic Test|Quantra QPlus System|Whole blood coagulation testing system
75444375|NCT05288829|Drug|ALXN1210 SC|All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
75444376|NCT05288829|Drug|ALXN1210 IV|All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.
75594162|NCT01682369|Biological|ATIV (Fluad)|
75594163|NCT01604460|Procedure|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
75594164|NCT01604460|Procedure|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
75594165|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
75594166|NCT01682408|Drug|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
75594167|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
75737840|NCT05918263|Behavioral|High-Intensity Interval Training Exercise Program|Home-based, virtually supervised, aerobic exercise program of 48 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
75737841|NCT05918237|Other|Arctiva|A colloidal oatmeal cream designed to stimulate healing and repair of damaged tissue naturally, working with the body instead of against it.
75594168|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
75594169|NCT01682408|Drug|Ranitidine|150 mg ranitidine
75737842|NCT05918172|Device|endotracheal cuff pressure manual measurement|The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients. Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices. The application period will continue from the day of intubation to extubation or a maximum of 14 days. Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit.
75769549|NCT03895294|Other|Health care under the strategic purchase-Clinical pathway|1) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
75594170|NCT01607970|Drug|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
75594171|NCT01608009|Drug|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
75594172|NCT01647347|Drug|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
75594173|NCT01647347|Other|Water|
75444377|NCT05288829|Drug|Placebo|All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
75444378|NCT05282368|Behavioral|PHM™ Pathway|"The technological platform referred to as Preparing Heart and Mind™ (PHM™) is designed as a patient engagement pathway. This platform includes GetWellNetwork's proprietary workflow engine, Patient Pathways™ and functionality of the Health Loop platform. Specifically, PHM™ will be created on a customized GetWellNetwork patient engagement pathway, getwell | Loop, which is a secure platform with a parent-facing app and an interactive dashboard for healthcare providers. The PHM™ getwell | Loop is a care program with chapters that incorporate interactive resources for patient information and education, trackers as touch points for psycho-social/educational support, and tailors care with condition-specific content, as well as action items."
75444379|NCT05785507|Other|PriskA tool|PriskA tool is an algorithm that generates a risk score of having PCOS.
75594174|NCT01604499|Behavioral|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
75594175|NCT01604499|Behavioral|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
75594176|NCT01682447|Other|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
75594177|NCT01604577|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
75886659|NCT05291273|Diagnostic Test|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST). The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
75594178|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
75444380|NCT05250726|Biological|MENISC-T|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of meniscus used as interposition at the STT joint
75444381|NCT05236049|Biological|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in support of intraocular implant.
75444382|NCT05233566|Drug|Ketamine|NMDA antagonist
75444383|NCT05233566|Drug|Normal saline|IV fluid acting as a placebo
75444384|NCT05229601|Drug|HFB301001|"Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation."
75444385|NCT05216848|Other|Wijma Delivery Expectancy Questionnaire|Simple questionaire identifying the level of fear of childbirth in pregnancy
75444386|NCT05216848|Other|Clinical data collection|Collection of the standard clinical data during hospitalization
75444387|NCT05210517|Drug|Empagliflozin 25 MG|25 once daily one week treatment
75886660|NCT05291273|Diagnostic Test|Prone Bridge Test|"The prone bridge test also known as the plank or hover measures the muscular endurance of the abdominal muscles. Subjects will start in the down push up position with their feet together and their hands shoulder width apart. When the test starts the subject will push up to the prone bridge position so they are resting on their hands and toes making sure they maintain a straight line from the shoulders through the hips to the knees. The outcome measure will be the time where the subject stay in this position."
75886661|NCT05291273|Diagnostic Test|Measurement of the muscle strength of the shoulder complex|Maximum isometric force of the external and internal rotators and abductors/adductors measured by a dynamometer.
75886662|NCT05418881|Device|Mobile Tracking Device (one spot)|Patients will be fitted with 4 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, FitBit Sense®, Withings ScanWatch®).
75886663|NCT05418881|Device|Mobile Tracking Device + Activity Sensor (longitudinal)|Patients will be fitted with 1 of 3 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, Withings ScanWatch®). The type of tracking device will be randomized. Additionally an Activity Tracker and one-channel ECG (Movesense®) will be worn by the patients.
75444388|NCT05210517|Drug|Benzbromaron|100 mg once daily 1 one week treatment
75444389|NCT05210517|Drug|Empagliflozin 25 MG + benzbromarone 100 mg|combined treatment once daily for one week
75444390|NCT05200000|Biological|SygeLIX-Coll-T|Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.
75594179|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
75594180|NCT01604031|Biological|B-CLL Vaccine|Patients will receive a fixed dose (2X10^7) of IL-2 secreting B-cells together with (2X10^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
75594181|NCT01604031|Drug|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
75594182|NCT01682525|Other|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
75737843|NCT05918172|Device|endotracheal cuff pressure automatic measurement|"The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.~Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices.~The application period will continue from the day of intubation to extubation or a maximum of 14 days Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit."
75886664|NCT03845335|Device|dental implant-supported restoration|During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
76057198|NCT02058095|Drug|Tadalafil|"Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil."
75737844|NCT05918068|Drug|Metformin 500 mg/day|Metformin 500 mg/day in addition to non-pharmacological therapy
75737845|NCT05918068|Combination Product|Metformin 500 mg/day plus vitamin B6 300 mg/day|Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy
75737846|NCT05918068|Other|non-pharmacological therapy|non-pharmacological therapy (healthy lifestyle modifications)
75737847|NCT05918016|Diagnostic Test|Routine cranial ultrasounds|we will use the routine cranial ultrasounds
75737848|NCT05917977|Behavioral|Collective Motivational Interviewing plus Education Materials|The participants in the intervention group will receive IGD educational materials as well as four counseling sessions of CMI intervention.
75737849|NCT05917977|Other|Control group (Education Materials)|The participants in the control group will receive IGD educational materials.
75737850|NCT05917925|Dietary Supplement|COLLAGEN (COL)|The collagen-based supplement will be ingested every day for 12 weeks at the same time.
75737851|NCT05917925|Dietary Supplement|PLACEBO (PLA)|The placebo will be ingested every day for 12 weeks at the same time.
76057199|NCT02058095|Drug|Placebo|"Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is >95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo."
75737852|NCT05917886|Other|Auditory beat stimulation: 8Hz monaural beat stimulation|Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
75737853|NCT05917860|Drug|Degarelix|Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
75737854|NCT05917860|Device|MRI-guided transurethral ultrasound ablation (TULSA)|MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) will be used to deliver whole-prostate gland treatment in accordance with the terms of TULSA marketing authorizations. The treating physicians will contour the entire prostate gland for a whole gland ablation.
76057200|NCT04718207|Device|Brain positron emission tomopgraphy (PET) - scan|Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
76057201|NCT04663022|Other|Dunn's sensory profile questionnaire|all children will complete the Dunn Sensory Profile questionnaire
76057202|NCT02023112|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
76057203|NCT02023112|Drug|Ribavirin|Capsule
76057204|NCT04670666|Drug|MADALENA ASSOCIATION|Madalena association coated tablet.
76057205|NCT04670666|Drug|METFORMIN|Metformin 1000 mg extended-release tablet.
76057206|NCT04670666|Drug|EMPAGLIFLOZIN + LINAGLIPTIN|Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
76057207|NCT04670666|Other|MADALENA ASSOCIATION PLACEBO|Madalena association placebo tablet.
76057208|NCT04670666|Other|METFORMIN PLACEBO|Metformin placebo tablet.
76057209|NCT04670666|Other|EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO|Empagliflozin + linagliptin placebo tablet.
75737855|NCT05917847|Other|Awake intubation|Awake videolaryngoscopic intubation with dexmedetomidine for sedation
75444391|NCT05199155|Biological|NerVFIX|Decellularized, freeze-dried and sterile allogeneic graft of artery or vein from umbilical cord use by the investigator as a nerve regeneration conduit
75737856|NCT05917834|Biological|Nipple sparing mastecomy with different incision placements|Nipple sparing mastectomy was performed using Radial/Peri-areolar incision or imframammary incision
75886665|NCT04986605|Device|Extracorporeal Photopheresis (ECP)|Drug Intervention using a medical device. The ECP device is already licensed in Canada. License No.7703. ECP treatment, using the drug UVADEX, will be given on 2 consecutive days every 4 weeks for a total of 26 treatment days (48 weeks).
76057210|NCT01977092|Behavioral|Motivational interviewing case management|
76057211|NCT01977092|Behavioral|Resource referrals|
75737857|NCT05917808|Other|Ready-to-eat wholegrain porridge|A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated
75737858|NCT05917769|Other|Rocabdo exercises|"The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day.~It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction. This group will only perform Rocabdo exercises."
75886666|NCT04986605|Drug|UVADEX|The phase II aspect of the study refers to the drug, methoxsalen. Methoxsalen is being used off label from the currently approved indications in the monograph. The study is proposing to use methoxsalen in combination with with extracorporeal photopheresis for the treatment of diffuse cutaneous systemic sclerosis. Treatment will be given in addition to standard of care medications for SSc.
75886667|NCT02868541|Other|Naso pharyngeal swab|Naso pharyngeal swab
76057212|NCT01976624|Drug|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
76057213|NCT02041091|Drug|Tabalumab Auto-Injector|Administered SC
76057214|NCT02041091|Drug|Tabalumab Prefilled Syringe|Administered SC
76057215|NCT04717973|Diagnostic Test|laboratory testing of CBC, serum ferritin, and vitamin B 12|"laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass."
76057216|NCT02057549|Drug|Haloperidol|Intravenous dose of haloperidol 5 mg.
76057217|NCT02057549|Drug|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
76057218|NCT02057393|Drug|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
76057219|NCT02057393|Drug|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
76057220|NCT02057393|Drug|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
76057221|NCT04698161|Other|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
76057222|NCT04698161|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
75444392|NCT05191745|Drug|Parasternal blocks|Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg
75444393|NCT05191745|Drug|Standard of care|All standard management of postoperative pain, as per local protocols
75444394|NCT05191628|Biological|Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane placed by the investigator during macular hole surgery
75444395|NCT05180994|Drug|Topical infliximab|Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
75444396|NCT05180994|Other|No topical infliximab|No treatment with infliximab.
75594183|NCT02279927|Device|Ureteroscopy|Ureteroscopy with laser stone fragmentation
76057223|NCT04698161|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
76057224|NCT02040779|Drug|Beclomethasone dipropionate breath-actuated inhaler|Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
75886670|NCT01568983|Dietary Supplement|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
75594184|NCT01682564|Drug|Candemore tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
75594185|NCT01682564|Drug|Atacand tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
75886671|NCT01568983|Dietary Supplement|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
75886672|NCT01568983|Dietary Supplement|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
75886673|NCT01383733|Drug|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
75886674|NCT01383655|Drug|Magnesium Sulfate|i.v. magnesium 40mg/kg in 20 min
75886675|NCT01383655|Drug|Placebo|NaCl
75886676|NCT01623193|Other|All-blood cardioplegia|The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
76057225|NCT02040779|Drug|Placebo breath-actuated inhaler|Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
75444397|NCT05170737|Drug|AEF0217|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 & 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 & 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD."
75444398|NCT05148299|Drug|Pegcetacoplan|20-cc glass vials-1080 mg
75444399|NCT05141175|Device|Hypertension medication algorithm|The algorithm is configured to align medication choices based on the hemodynamic findings from the ICG readings. This decision support tool was created so as to organize these medications based on their mechanism of action and is consistent with the evidence-based treatment of hypertension.
75444400|NCT05141175|Device|Impedance Cardiography|The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
75444401|NCT05141123|Procedure|Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for|Evaluate the outcomes of the preloaded stent-graft design (PLD) in the routine treatment of para-renal and thoraco-abdominal aneurysms
75594186|NCT01608048|Device|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
75737859|NCT05917769|Other|Postural correction exercises|"Posture correction exercises will be performed six times a day for six days.~Patient will be assessed on the first day and then on the last day of the treatment, i.e., on 6th day the patient will be re-assessed after they have performed posture correction exercises.~Posture correction exercises consist of chin tuck in, chest stretch, wall stretch, on your Back chest stretch and face down arm lifts."
75737860|NCT05917756|Other|Mobilization with Movement (MWM) and Tailored Therapeutic Exercise Program|The intervention consists of MWM techniques targeting the cervical and thoracic spine, and the first rib, applied by a certified physiotherapist for 8 weeks, 2 sessions per week, each session lasting 45 minutes. The intervention also includes a tailored therapeutic exercise program for the patients, comprising postural correction, stretching, and strengthening exercises. This intervention will be compared to conventional physiotherapy in the control group.
75886677|NCT01623193|Procedure|Standard cardioplegia|This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
75886678|NCT01615159|Behavioral|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
75886679|NCT02136355|Radiation|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
75886680|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
76057226|NCT02040779|Drug|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
75886681|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
75886682|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
75886683|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
75886684|NCT01013935|Other|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
76057227|NCT02056301|Drug|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
75444402|NCT05123326|Diagnostic Test|Rotational thromboelastometry|ROTEM/ Sonoclot tests will be done in all patients at enrolment and after initiating anticoagulation in those who are eligible for the same.
75444403|NCT05123326|Diagnostic Test|Genetic tests for Thrombophilia|Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.
75444404|NCT05123326|Diagnostic Test|ELISA tests/ Functional assays|Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays
75444405|NCT05119959|Other|ECD intervention for CHEUs|The bi-weekly community health worker-delivered ECD 1 hour intervention using the modules from the SUPERCDZ curriculum which is a Zambian adaptation of UNICEF's Nurturing Care Framework
75444406|NCT05119959|Other|Usual care for CHEUs|No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.
75444407|NCT05118685|Drug|Conjugated Estrogens vaginal cream 0,625mg|the particepant will receive vaginal estrogen cream one tube every night for 14 nights; then, one tube for 2 nights in 1 week (two tubes every week) for 10 weeks.
75737861|NCT05917756|Other|Conventional Physiotherapy|Conventional physiotherapy, including manual therapy (soft tissue mobilization, joint mobilization, and nerve gliding techniques) for 8 weeks, 2 sessions per week, each session lasting 45 minutes, combined with a tailored therapeutic exercise program (including postural correction, stretching, and strengthening exercises).
75737862|NCT05917743|Other|Mat Pilates|Duration: 50 minutes per session Repetitions: 8-12 repetitions per exercise Sets: 2-3 sets per exercise Rests: 30-60 seconds rest between sets Frequency: 3 times per week for 4 weeks Exercises: A series of Mat Pilates exercises targeting core strength, flexibility, and muscle control
75886685|NCT01013935|Other|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
75886686|NCT03965143|Device|3D talar augmentation|Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
75444408|NCT05118685|Combination Product|platelet rich plasma|First, a topical anesthetic cream will be applied to the vaginal wall. Delaying the PRP injection for 20 minutes after anesthetics application achieved complete or near-complete analgesia for the procedure. Peripheral blood will be drawn from the arm and centrifuged to yield 5 cc of PRP. then PRP will be administered to the anterior vaginal wall using 27-G needles once every 3 weeks for 4 times and PRP is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
75444409|NCT05112185|Behavioral|Healthy Drinks, Healthy Futures|The Healthy Drinks, Healthy Futures intervention consists of increased access to healthy beverages in childcare centers and education directed to children and their families to increase the intake of healthy beverages, including motivational beverage counseling for families and lessons for children in childcare centers.
75444410|NCT05109650|Drug|BAT6026|IV infusions
75444411|NCT05109650|Drug|BAT1308|Ⅳ infusions
75444412|NCT05108259|Drug|PBP1502|40 mg/0.4 mL single SC injection via PFS
75444413|NCT05108259|Drug|EU-licensed Humira|40 mg/0.4 mL single SC injection via PFS
75444414|NCT05108259|Drug|US-licensed Humira|40 mg/0.4 mL single SC injection via PFS
75444415|NCT05107271|Diagnostic Test|COVID-19 serosurvey|COVID-19 related antibody testing to assess immunogenicity of COVID-19 vaccines or post natural infection acquired immunity
75594187|NCT01647425|Behavioral|physician assessment|"Socio-economic conditions and general features: educational level, professional status...~Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~Assessment of current use of cannabis using the Cannabis Abuse Screening Test~Psychiatric assessment using the MINI 5.0"
75594188|NCT01604655|Procedure|Coronary CT Angiography|CCTA
75594189|NCT01604655|Procedure|Stress Test|Stress Test
75594190|NCT01604694|Procedure|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
76057228|NCT02056301|Drug|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
75444416|NCT05087823|Dietary Supplement|Lipid Challenge|For the lipid challenge, participants consume 100 grams of a long chain triglyceride emulsion in the form of liquid drink, which is the commercially available brand called Calogen, from Nutricia, Inc.
75444417|NCT05087823|Dietary Supplement|Glucose Challenge|For the glucose challenge, participants consume 75 grams of glucose in 200 milliliters of water, which is the World Health Organization (WHO) recommended drink for the Oral Glucose Tolerance Test.
75594191|NCT01682798|Dietary Supplement|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
75594192|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
75594193|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|
75594194|NCT01608126|Procedure|cervical block|"In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.~The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm)."
75594195|NCT04528550|Biological|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.
76057229|NCT01967732|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
76057230|NCT01967732|Other|CC|Single use of subject's own conventional cigarette (CC)
76057231|NCT01967732|Other|NNS|Single administration of 1 mg of nicotine
75444418|NCT05087823|Dietary Supplement|Mixed Meal Challenge|For the mixed-meal challenge, participants consume 237 milliliters of the Ensure Enlive nutrition drink , which contains 11 grams of fat, 22 grams of sugar and 20 grams of protein.
75444419|NCT05084833|Behavioral|Control|Electronic educational materials
75444420|NCT05084833|Behavioral|Patient activation|Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants
75444421|NCT05084833|Behavioral|Primary care provider activation|Faxed educational materials (e.g. current colorectal cancer screening recommendations, frequently asked questions, insurance letter template, cover letter with overview of patient's cancer treatment history) sent to primary care providers
75444422|NCT05059795|Drug|Albumin|Type of resuscitation fluid, dose and use of inotrope
75444423|NCT05055817|Other|bloody stool group|bloody stool appear in the hospitalized neonate
75444424|NCT05055817|Other|non-bloody stool group|bloody stool do not appear in the hospitalized neonate
75444425|NCT05053269|Other|good body weight growth|body weight growth after birth is consistent with the growth curve
75444426|NCT05053269|Other|poor body weight growth|body weight growth after birth is inconsistent with the growth curve
75444427|NCT05050383|Other|Pharyngeal Manometry|Catheters will be passed into the nose and advanced to the pharynx to measure airway pressures during drug-induced sleep.
75594196|NCT04528550|Drug|Placebo|Included patients will receive the same amount of saline through lumbar injection.
75594197|NCT04528472|Other|Acupuncture Treatment|stimulate acupoints to accelerate recovery
75594198|NCT04528472|Other|Regular Treatment|Oral Medicine and Rehabilitation Treatment
76057232|NCT01967576|Drug|Axitinib (AG-013736)|5 mg twice a day on a 28-day cycle.
76057233|NCT02039687|Drug|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
75444428|NCT05050383|Other|Submental Ultrasound|Ultrasound of airway soft tissues
75444429|NCT05032118|Drug|Ketamine Hydrochloride|Titratable ketamine infusion + low fixed-dose propofol.
75444430|NCT05032118|Drug|Propofol|Standard of care titratable propofol infusion.
76057234|NCT02039687|Other|Placebo|Formulation buffer
75594199|NCT01647620|Drug|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
76057235|NCT02003534|Drug|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
75886687|NCT01383577|Procedure|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
76057236|NCT02055365|Biological|Hepatitis B Vaccine (Recombinant)|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
75444431|NCT05021939|Other|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
75444432|NCT05021939|Other|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
75444433|NCT05021679|Other|AMP Implementation|Each study site will implement the Johns Hopkins AMP program at different times. The AMP program includes nursing staff training on the goals of AMP, how to complete mobility-focused outcome measures, set mobility goals, and to safely mobilize/ambulate patients. The AMP program also includes embedding these outcome measures and mobility goals into electronic medical records and producing weekly/monthly reports that show how often nursing staff score patient mobility and help patients meet daily activity goals.
75594200|NCT01647620|Drug|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
75737863|NCT05917743|Other|General Exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
75444434|NCT05000970|Device|blood pressure cuff PLUS tablet|all arms
75594201|NCT01608243|Biological|SLIT tablets of house dust mite allergen extracts|10 dosing days
75594202|NCT01608243|Biological|Matching placebo|10 dosing days
75594203|NCT04527692|Other|Questionnaire|semi-structured interviews on the quality of life
75594204|NCT01608282|Behavioral|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
75594205|NCT01608360|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
75594206|NCT01608360|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
75594207|NCT01647659|Drug|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
75886688|NCT01383577|Procedure|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
75886689|NCT02921789|Drug|Bleselumab|Intravenous infusion
75886690|NCT02921789|Drug|Basiliximab|Bolus injection
75886691|NCT02921789|Drug|Mycophenolate Mofetil (MMF)|Oral Intravenous
75886692|NCT02921789|Drug|Tacrolimus Capsules|Oral Capsule
75886693|NCT02921789|Drug|Methylprednisone|Oral or Intravenous
75886694|NCT02921789|Drug|Prednisone|Oral Tablet
75886695|NCT05420155|Procedure|Surgical resection|Surgical treatment of hepatic hydatidic cyst
75886696|NCT05419843|Other|HSCT Arm group|"Conditioning regimen Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT."
75886697|NCT01568333|Drug|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
76057237|NCT05127473|Drug|Mim8 B, 10 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
76057238|NCT05127473|Drug|Mim8 B, 100 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
76057239|NCT05127473|Drug|Mim8 B, placebo|Placebo will be used to dilute the IMP to different Mim8 concentrations
76057240|NCT02039375|Other|"Hopkins post tPA for ischemic stroke monitoring protocol"|"The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours."
76057241|NCT02054897|Drug|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
76057242|NCT02054897|Drug|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
76057243|NCT04713605|Device|Critical closing pressure detection|Observational study that determines the critical closing pressure (CrCP) of the brain by comparison of the cerebral blood flow velocity (measured by TCD) and invasive blood pressure measurement (IABP)
76057244|NCT01976312|Other|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
75737864|NCT05917730|Behavioral|Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)|"Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell."
75737865|NCT05917704|Other|Guitar then physical therapy|See arm/group descriptions
75737866|NCT05917704|Other|Physical therapy then guitar|See arm/group descriptions
75737867|NCT05917691|Procedure|Bariatric surgery|Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.
75737868|NCT05917691|Drug|General anesthetic|"Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database)."
76057245|NCT01976312|Drug|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
75737869|NCT05917691|Device|Indeterminate|Devices were indeterminate under the current study design (observational study of a deidentified database).
75737870|NCT05917652|Behavioral|Tool kit|The study team will develop and design key elements of the implementation intervention (toolkit) among a small group of burn and non-burn clinician stakeholders (4-6 total). The study team will use in-person interviews with stakeholders and a semi-structured interview guide to elicit feedback and assess face and content validity of the toolkit elements prior to deployment across the study hospitals. For those who consent to participation, the study team will conduct virtual teleconference interviews in-person using a secure videoconferencing platform while the person is not working, at a time convenient for them. Interviews will last between 45 and 60 minutes. The study team anticipates conducting 4-6 interviews to finalize toolkit elements prior to implementation.
75737871|NCT05917600|Other|APN intervention|"Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation~APN intervention is divided into five main steps:~clinical and paraclinical examinations,~appraisal of patient's knowledge,~health education on hypertension and treatments,~setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
75737872|NCT05917561|Drug|Anifrolumab Infusion Product|Anifrolumab 300mg/month infusion for 36 weeks
75737873|NCT05917561|Drug|Placebo|Placebo once a month, infusion for 36 weeks
75737874|NCT05917535|Behavioral|Mentalizing course|6 hour mental health education course about mentalizing.
75737875|NCT05917093|Behavioral|Culturally tailored HLWD|"Participants receive the culturally tailored HLWD intervention for 6 weeks~Week 0 - Baseline enrollment.~Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church."
75737876|NCT05914766|Behavioral|PATHWAYS|The PATHWAYS intervention is a psychoeducational intervention comprised of three components.
75594208|NCT01647659|Drug|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
75594209|NCT01608399|Behavioral|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
75737877|NCT05914766|Other|Enhanced usual care|The enhanced usual care condition consists of an information resource guide.
76057246|NCT02039219|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
76057247|NCT02039219|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
76057248|NCT02053493|Drug|Isosorbide Mononitrate|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
76057249|NCT02053493|Drug|Placebo|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
75444435|NCT05000970|Other|Telehealth Consult|Telehealth consult with an RN
75444436|NCT04921696|Other|RBC transfusion|RBC was transfused to the infants.
75594210|NCT01682993|Other|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
75594211|NCT01682993|Other|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
75594212|NCT01604811|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
75594213|NCT01604811|Drug|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
76057250|NCT02003144|Biological|eculizumab|
75594214|NCT01604811|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
75737878|NCT05914636|Biological|analysis of foecal microbiota|"An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed."
75886698|NCT03437005|Drug|Desonide 0.05%|Desonide 0.05% ointment topically twice daily for two weeks
75737879|NCT05914506|Diagnostic Test|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level
75737880|NCT05914480|Other|PCR for legionella ,blood ,urine cultures and from catheters or source of infection|Investigations to detect cause of sepsis as blood cultures ,urine cultures and from catheters .also PCR for legionella will be done
75444437|NCT04921696|Other|no-RBC transfusion|RBC was not transfused to the infants.
75737881|NCT05913817|Biological|AVT02 (Alvotech Biosimilar to Adalimumab)|Phase IV Study
75737882|NCT05912764|Other|Patient support|Patients will be supported by nurses before and after intervention and hospital leave
75737883|NCT05898386|Behavioral|Behaviour and Lifestyle Changes in Urinary Incontinence|"The women included in the second stage were given a pre-test before the training program. Training program included behavioral and lifestyle changes in coping with urinary incontinence~After the training program, the women applied behavior and lifestyle changes for 3 months.~3 home visits, 3 phone calls and 3 follow-ups were made."
75886699|NCT03437005|Drug|Ketoconazole 2%|Ketoconazole 2% cream topically twice daily for two weeks
75444438|NCT04913493|Procedure|Cytocam-IDF|Patients receive an extra medical imaging test perioperatively with the Cytocam-IDF
75444439|NCT04880681|Device|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
75444440|NCT04880681|Device|Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
75594215|NCT01604811|Drug|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
75737884|NCT05897866|Procedure|Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management|Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.
75737885|NCT05896644|Other|Eat Well|A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
75737886|NCT05890976|Drug|Semaglutide|Participants will receive semaglutide tablets orally once daily for 44 weeks.
75737887|NCT05890976|Drug|Semaglutide Placebo|Participants will receive placebo matched to semaglutide.
75737888|NCT05888805|Other|DIMS spectacle lens|DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
75737889|NCT05883241|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm^2 with 2.5% Diclofenac patches.
75886700|NCT03943823|Drug|Estrogen vaginal cream|Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
75737890|NCT05883241|Drug|2.5% Diclofenac Patches|Topical pain relief-gel worn during treatment via SAM patch.
75886701|NCT03943823|Drug|Trimo-San vaginal gel|Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
75444441|NCT04874597|Drug|Ocrelizumab|Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.
75594216|NCT01683032|Drug|MPH|a capsule containing 20 mg
75594217|NCT01604928|Drug|YM178|Oral
75594218|NCT01604928|Drug|tolterodine|Oral
75594219|NCT01604928|Drug|Placebo|Oral
75594220|NCT01647776|Other|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
75594221|NCT01647776|Procedure|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors [levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression] as markers of risk of developing adenoma.
75594222|NCT01647776|Other|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
75594223|NCT01683110|Drug|cabozantinib|
75594224|NCT01608438|Device|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
75444442|NCT04869345|Behavioral|LARKSPUR|This intervention used in our prior research consists of skills training exercises designed to increase the frequency of positive affect. The 6 week intervention (5 weeks of content plus one week of home practice) consists of five components: (1) Positive events and gratitude; (2) mindfulness; (3) reappraisal; (4) strength and goals; and(5) acts of kindness. Participants will have up to 8 weeks to complete this intervention.
75444443|NCT04867850|Other|Usual Care|Individual clinicians will receive an automated weekly email detailing a weekly roster of their upcoming repeat-patient visits (Index Visit) with patients at high risk of 6-month mortality as determined by a validated machine learning prognostic algorithm. Clinicians will receive a HIPAA compliant text message on the morning of the appointment reminding them to consider a serious illness conversation with patients on the list.
75737891|NCT05882812|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm^2 with 2.5% Diclofenac patches.
75886702|NCT03097289|Device|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
75886703|NCT02419742|Drug|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams*milliliter/minute [mg*mL/min]) multiplied by (Glomerular Filtration Rate [GFR] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
75886704|NCT02419742|Drug|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
75444444|NCT04867850|Other|Clinician Nudge|Clinicians will receive the usual care weekly email and text message described above under Usual Care. In addition, embedded in the weekly email, clinicians will receive performance feedback information detailing their documented SICs relative to those documented by peers.
75594225|NCT01647815|Procedure|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
75737892|NCT05882812|Device|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
75737893|NCT05882812|Drug|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
75886705|NCT02419742|Drug|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
75886706|NCT02419742|Drug|Doxorubicin|Participants will receive Doxorubicin 60 mg/m^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
76057251|NCT04661540|Drug|CM4620-IE (Injectable Emulsion)|Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion
75886707|NCT02419742|Drug|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
75886708|NCT02419742|Drug|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
75886709|NCT02409290|Drug|Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)|Drug: Locally-used WHO-approved MDR-TB regimen
75886710|NCT02409290|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
75886711|NCT02409290|Drug|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
75444445|NCT04867850|Other|Patient Nudge|Ahead of the Index Visit, high risk patients as identified by the prognostic algorithm will receive a nudge via personal text message and email consisting of a normalizing message prompting patients with a personalized link to a short electronic questionnaire on SIC topics.
75444446|NCT04862234|Drug|Dulaglutide|A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.
75444447|NCT04862234|Drug|Placebo|A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
75444448|NCT04862234|Device|Continuous glucose monitor (CGM), blinded|Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
75886712|NCT02409290|Drug|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
75444449|NCT04846738|Device|Transcranial Doppler|This device measures Mean Systolic Velocity (VMS), Tele-Diastolic Velocity (TDV) and Pulsatility Index (PI),
75886713|NCT02409290|Drug|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
75444450|NCT04846738|Device|Pupillometry.|This device measures the photomotor reflex (basic pupil diameter, percentage of variation, latent and slope of the standard photomotor reflex)
75444451|NCT04842643|Biological|IGSC 20% infusion|IGSC 20% infusion, The dose of IGSC will be established in previous study (TAK-664-3001)
75444452|NCT04821336|Other|Metabolites dosage|"On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand.~The investigators will compare the rate of deregulation between sane and malignant ones."
75444453|NCT04777747|Other|viral infection|a child is infected by virus only
75444454|NCT04777747|Other|viral and bacterial infection|a child is infected by virus and progress to bacterial infection
75886714|NCT02409290|Drug|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
75444455|NCT04775368|Other|Administering diagnosis orientation questionnaires for the screening of possible sleep disorders|Several diagnosis orientation self-questionnaires will be conducted by the patient following his or her inclusion in order to detect, among other things, possible sleep disorders.
75886715|NCT02409290|Drug|Prothionamide|Prothionamide has a bacteriostatic action.
75886716|NCT02409290|Drug|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
75886717|NCT02409290|Drug|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
75886718|NCT02409290|Drug|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
75886719|NCT02351414|Device|Total Knee Arthroplasty (EVOLUTION®)|
76057252|NCT04661540|Drug|Placebo|Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
76057253|NCT02001194|Behavioral|Individual Incentives|
76057254|NCT02001194|Behavioral|Team Incentives|
76057255|NCT02001194|Behavioral|Individual plus Team Incentives|
75886720|NCT02145494|Radiation|Radiotherapy|Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
75886721|NCT02147756|Device|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
75886722|NCT02147756|Device|Repair|
75886723|NCT05435755|Biological|hAESCs treatment|Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
75886724|NCT05435755|Biological|placebo (saline)|2 times placebo (normal saline) injections as control group
75886725|NCT02147912|Other|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
75886726|NCT02898077|Drug|Ramucirumab|Administered IV
76057256|NCT02038907|Biological|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
76057257|NCT02038907|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
75444456|NCT04747353|Device|Catheter ablation procedure with heart 3D model|Device: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
75444457|NCT04745234|Drug|Mogamulizumab|"For the first 28-day induction cycle (C1), mogamulizumab 1 mg/kg will be administered as an IV infusion through a 0.22- or 0.2-μm in-line filter over at least 60 minutes on Days 1, 8, 15, and 22.~For all subsequent 28-day cycles (C2, 3, 4, etc.), mogamulizumab 2 mg/kg will be administered as an IV infusion over at least 60 minutes on Day 1 of each subsequent therapy cycle."
75594226|NCT01605045|Other|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
75594227|NCT01605045|Other|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
75594228|NCT01683149|Drug|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
75594229|NCT01683149|Drug|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
75886727|NCT02898077|Drug|Paclitaxel|Administered IV
75886728|NCT02898077|Drug|Placebo|Administered IV
75886729|NCT03544346|Other|Exploratory brain and general health assessment|Exploratory brain and general health assessment
75594230|NCT01608555|Drug|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
75594231|NCT01647854|Procedure|Teleconsultation|Teleconsultation in prehospital emergencies
76057258|NCT02038829|Drug|Placebo|Placebo
76057259|NCT02038829|Drug|SUN101 3 mcg|SUN-101 3 mcg bid
75594232|NCT01647893|Drug|CTB-001|IV bolus or IV infusion
75594233|NCT01608633|Other|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
75594234|NCT01648010|Device|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
75594235|NCT01648010|Device|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
75594236|NCT01605201|Biological|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
75594237|NCT01683461|Behavioral|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
75886730|NCT03544892|Other|Low carbohydrate diet|60-80 g total carbohydrate per day
75886731|NCT03544892|Other|Standard of care diet|> 150 g total carbohydrate per day
76057260|NCT02038829|Drug|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
76057261|NCT02038829|Drug|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
76057262|NCT02038829|Drug|SUN-101 50 mcg|SUN-101 50 mcg bid
76057263|NCT02038829|Drug|Aclidinium|Aclidinium 400 mcg bid
76057264|NCT04693247|Device|EQ103|Refraction device
76057265|NCT02038049|Drug|VAY736|Single intravenous infusion of VAY736 (10 mg/kg)
76057266|NCT02038049|Drug|Placebo|Placebo to VAY736
76057267|NCT02052011|Drug|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
76057268|NCT02052011|Drug|Placebo|
76057269|NCT02036645|Biological|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
76057270|NCT02036645|Biological|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
76057271|NCT02036645|Biological|IV Placebo|Placebo for IV injection
76057272|NCT02036645|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
75444458|NCT04733469|Behavioral|Multimedia Psychoeducational Intervention|"The Multimedia Psychoeducational Intervention includes a multimedia educational video plus additional resources to reinforce the video content. The Multimedia Psychoeducational Intervention includes the following:~A multimedia educational video about palliative care that is individually tailored to each patient's level of education and health literacy~Take-home and online copies of the video for repeat viewing~A video summary~A question prompt list patients can use to ask clinicians more questions about palliative care~Contact information and brochures for local palliative care programs"
75444459|NCT04733469|Behavioral|Enhanced Usual Care|"Enhanced Usual Care refers to usual care plus minor enhancement to improve quality and standardization. Enhanced Usual Care includes the following:~Usual care~A packet of flyers and handouts with general information on psychosocial oncology services derived from the American Society of Clinical Oncology (ASCO), Center to Advance Palliative Care (CAPC), and American Cancer Society (ACS)"
75444460|NCT04688567|Behavioral|Patient-driven iCBT|1) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.
75444461|NCT04688567|Behavioral|Standardized iCBT (TAU)|2) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.
75594238|NCT01683461|Behavioral|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
75594239|NCT01608711|Biological|AGS-1C4D4|Intravenous Infusion
75594240|NCT01608711|Biological|gemcitabine|Intravenous Infusion
75594241|NCT01648049|Behavioral|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein & Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, & Dick, 1995).
75594242|NCT01648049|Behavioral|Treatment as usual|Standard Care - Treatment as usual
75594243|NCT02482623|Behavioral|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
75594244|NCT01683500|Device|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
75737894|NCT05882669|Other|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period).
75737895|NCT05882656|Other|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
75737896|NCT05880888|Biological|Renuva|Renuva® (MTF Biologics) is an injectable decellularized allograft adipose matrix (AAM) used to increase volume in adipose tissue.
75886732|NCT03692975|Other|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
75886733|NCT03692975|Other|Neuropsychological evaluation|cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
75886734|NCT03692975|Other|Psychological evaluation|included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
75594245|NCT01605357|Drug|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
75594246|NCT01605357|Drug|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium < 135 mmol/L) is to be corrected at the discretion of the provider.
75886735|NCT03692975|Device|MRI Evaluation|Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
75886736|NCT02145650|Other|No Intervention|There is no intervention administered in this study.
75886737|NCT02145728|Behavioral|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
75886738|NCT02145728|Behavioral|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
75886739|NCT03544034|Behavioral|HomeTeam Toolkit|"A multi-component intervention (8S's)~Safety at home through partnership.~Safety risk assessment at the admission~Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~Safety tools. Cognitive tools to support patient/family after discharge~Safety education. Enhanced Patient/ family medication safety education~Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~Safety through learning routines across the care continuum~Safety assessment after discharge"
75886740|NCT03543956|Behavioral|Questionnaire|Questionnaire
75886741|NCT02145884|Drug|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
75444462|NCT04641637|Procedure|TACE|Through a 7 French sheath placed through a single femoral arterial puncture, a guide catheter (Cobra 1 Guide Catheter, Mach 1, Boston Scientific Corporation, Marlborough, USA) is placed at the coeliac axis. From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders. The therapeutic agent was delivered under fluoroscopic control until the vasculature of the whole tumors is entirely filled, which was assessed with DSA and non-contrast CT performed at the completion of the procedure.
75444463|NCT04635917|Other|Personalized diet|Participants in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting these dietary goals, participants will be provided with nuts, fruits, and vegetables.
75444464|NCT04635917|Other|Conventional dietary advice|Participants in the CD group will receive non-personalized, conventional dietary advice by a dietitian based on the MyPlate guidelines.
75444465|NCT04612972|Biological|Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo|This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.
75886742|NCT02145962|Device|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
75886743|NCT02145962|Device|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
75444466|NCT04586868|Behavioral|An intervention development study|Assessing the acceptability for a virtual reality intervention among adolescents with psychosis
75444467|NCT04586868|Behavioral|A randomized feasibility study|Feasibility of virtual reality environment for adolescents with psychosis
75886744|NCT02148068|Procedure|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
75886745|NCT02148146|Drug|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
75886746|NCT03544814|Drug|icotinib combined with pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
75886747|NCT03544814|Drug|first icotinib and then pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
75444468|NCT04586868|Behavioral|A single-case study|The clinical efficacy of a novel VR-assisted CBT interventions for adolescents with psychosis
75444469|NCT04564391|Dietary Supplement|protein supplement|protein supplement, twice daily, 2 x 30 g of protein, 3 weeks of intervention; blinded to patients and personnel
75444470|NCT04564391|Dietary Supplement|placebo supplement|Placebo supplement, twice daily, 2 x 30 g of placebo, 3 weeks of intervention; blinded to patients and personnel
75444471|NCT04536766|Behavioral|Enhanced Sleep Health Education|The intervention comprehensively addresses poor sleep health behaviors. Personalized sleep health education will be delivered in two telephone sessions by Beds for Kids staff members. Sleep health information will consist of the following evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a family bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs. Personalization will be accomplished via direct questions to families during the education phone call related to their own barriers to achieving healthy sleep habits and goals for optimal sleep.
75444472|NCT04536766|Behavioral|Beds for Kids Standard Program|The Beds for Kids program provides beds, bedding, and written healthy sleep education to families living at or below 100% of the federal poverty line and without an individual child bed to sleep in.
75444473|NCT04534075|Biological|Capsules containing either dietary fiber or placebo|The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.
75444474|NCT04505878|Drug|Vitamin C|Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants
75444475|NCT04505189|Drug|Psilocybin|Psilocybin assisted psychotherapy
75444476|NCT04503135|Diagnostic Test|ultrasound|ultrasound of the central veins of the neck and chest and a (compression ultra-sound) CUS of the femoral veins will be performed bilaterally
75444477|NCT04496830|Device|SOMAscan|Analysis of previously donated cerebrospinal fluid using a SOMAscan assay
75444478|NCT04404881|Drug|Bevacizumab|"Induction Period (first 3 months of bevacizumab treatment):~-- Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~Maintenance Period (second 3 months of bevacizumab treatment):~Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
75886748|NCT03097133|Drug|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
75737897|NCT05874245|Drug|oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
75737898|NCT05874245|Drug|oral ketamine|will receive 6 mg/kg oral ketamine diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia
75594247|NCT01648127|Drug|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
75594248|NCT01605474|Other|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
75594249|NCT01605474|Other|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
75737899|NCT05874245|Drug|oral Midazolam|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
75737900|NCT05873257|Device|Biatain Fiber Ag applied to participants|Intervention involving a wound gelling fiber dressing with silver
75737901|NCT05870189|Behavioral|Remote CMR|12 weeks of remote CMR is done 3x/week, 45 min/session.
75594250|NCT01683539|Behavioral|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
75737902|NCT05870189|Behavioral|Remote Exercise|12 weeks of remote exercise is done 3x/week, 45 min/session.
75737903|NCT05869318|Other|ECIG own|Participants will vape using their own ecig device
75737904|NCT05869318|Other|ECIG Vuse|Participants will vape a VUSE e-cigarette (GOLD 5%)
75737905|NCT05824143|Drug|Darigabat|Oral tablet
75737906|NCT05824143|Drug|Carbamazepine|Oral tablets
75737907|NCT05813769|Dietary Supplement|Dairy protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
75737908|NCT05813769|Dietary Supplement|Plant protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
75737909|NCT05789199|Drug|Cefiderocol|Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
75737910|NCT05788965|Drug|Semaglutide|glucagon-like peptide 1 (GLP-1) receptor agonist
75737911|NCT05774223|Device|Transcranial magnetic stimulation (TMS)-active|Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
75737912|NCT05774223|Device|Transcranial magnetic stimulation (TMS)-sham|Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
75737913|NCT05763459|Drug|ABBV-CLS-7262|Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin
75737914|NCT05727332|Behavioral|Single-Sprint Training|A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
75886749|NCT03097133|Drug|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
75886750|NCT03097133|Other|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
75886751|NCT02148380|Drug|pemetrexed plus carboplatin|
75886752|NCT02148380|Drug|gefitinib|
75886753|NCT02146118|Drug|Erlotinib|Erlotinib 150 mg/day q 4 weeks
75886754|NCT02146118|Dietary Supplement|Silybin-phytosome|Silybin-phytosome 1g bid/day q 4 weeks
75594251|NCT01683539|Behavioral|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
75594252|NCT01608750|Drug|Pantoprazol|40mg/day, oral, 28 days
75737915|NCT05725863|Other|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a structured group intervention developed by Segal et al. (2002). The intervention consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
75737916|NCT05725616|Procedure|Coronary angiography|Snuff Box Approach or radial Arterial Approach at wrist for coronary angiography.
75737917|NCT05724875|Device|FLASH RT|For T1 (small) lesions: 22 Gy single dose FLASH RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose FLASH RT
75737918|NCT05724875|Device|Conventional RT|For T1 (small) lesions: 22 Gy single dose conventional RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose conventional RT
75737919|NCT05713981|Procedure|Meibomian gland (MG) expression|The procedure is performed with a sterile cotton tip applicator once in the upper and lower eyelids of the subject's choosing.
75737920|NCT05703009|Drug|Sacrosidase Oral Solution|Study drug
75737921|NCT05703009|Drug|Placebo|Placebo
75444479|NCT04342325|Biological|infusion of ADR-001 (Mesenchymal stem cell)|Once or twice with two week interval at a dose of 100 x 10 ^ 6 cells.
75737922|NCT05689749|Device|Superb Microvascular Imaging (SMI) (Toshiba)|To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
75444480|NCT04335058|Drug|Lactoferrin + Iron Supplement|Lactoferrin 100 mg twice daily +oral iron
75444481|NCT04335058|Drug|Iron Supplement|Oral iron supplement alone
75444482|NCT04325594|Procedure|Cardiac catheterization|Catheterization of the right and left heart cavities
75886755|NCT02146196|Device|4 weeks robotic assisted training with the Lokomat®|During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
75886756|NCT02146196|Device|One week robotic assisted gait training with the Lokomat®|During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
75886757|NCT05418569|Device|Intervention arm - A new smartphone application for pediatric type 1 DM|An evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM
75444483|NCT04325594|Biological|Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells|After performing cardiac catheterization, selective coronary angiography will be performed abruptly to assess the condition of the coronary canal by access through the right radial or common femoral artery on the right after 70 U/kg of heparin iv. Then 20 ml of the finished suspension (1×10(7) umbilical cord-derived mesenchymal stromal cells diluted in 20 ml of heparinized saline) will be administrated into the mouth of the left coronary artery (LCA) without occlusion of the vessel with a balloon catheter and without stopping the coronary blood flow. Cell injection will be carried out using a standard 6 Fr catheter for selective coronary angiography with perfusion for 10 minutes at a volume rate of 2 ml/min, thereby introducing 1×10(6) cells per minute
75444484|NCT04319224|Drug|Vopratelimab|Specified dose on specified days
75444485|NCT04319224|Drug|Ipilimumab|Specified dose on specified days
75886758|NCT05418569|Other|Standard diabetic eduction|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic
75886759|NCT02142140|Behavioral|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
75444486|NCT04319224|Drug|Nivolumab|Specified dose on specified days
75444487|NCT04318626|Drug|PMPBB3|F-18 PMPBB3 PET Imaging
75594253|NCT01608750|Drug|Folic Acid|5 mg/day, oral, 28 days
75594254|NCT01605513|Drug|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
75594255|NCT04528277|Drug|rifapentine plus isoniazid|receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)
75594256|NCT01605591|Procedure|the DLT bending to the right|bending the bronchial lumen of DLT 60~90 degrees in the same side with the tracheal lumen
75594257|NCT01605591|Procedure|the DLT bending to the left|bending the bronchial lumen of DLT 60~90 degree opposed to the tracheal lumen
75594258|NCT01683617|Behavioral|Coping skills and relaxation training with new technologies|
76057273|NCT02051933|Drug|Botulinum toxin type A|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
76057274|NCT02051933|Drug|sodium chloride|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
76057275|NCT02050373|Radiation|Low-Level laser|Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
76057276|NCT04711811|Biological|HB-adMSC|Hope Biosciences adipose derived autologous mesenchymal stem cell product
76057277|NCT02049437|Drug|tocilizumab|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
75886760|NCT02142140|Behavioral|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
75594259|NCT01683617|Behavioral|Traditional coping skills and relaxation training|
75594260|NCT01605630|Behavioral|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
75444488|NCT04318626|Drug|THK5351|F-18 THK5351 PET Imaging
75444489|NCT04309253|Drug|PMPBB3|F-18 PMPBB3 PET Imaging
75444490|NCT04309253|Drug|AV45|F-18 AV45 PET Imaging
75444491|NCT04307589|Other|Observation|An observational follow-up study will be implemented over a period of 2 years, consisting of 3 test occasions with a fixed time interval of 1 year in between (T0 = baseline, T1 = 12 months, T2 = 24 months). Data will be collected in participants who provide grandchild care in a non-residential grandparent context as well as in a sample of non-caregiving grandparents and a sample of middle-aged and older adults not being a grandparent. All three samples will thus be prospectively monitored over a period of 2 years.
75444492|NCT04257448|Drug|Romidepsin|Powder and solvent for solution for infusion; Intravenous use
75444493|NCT04257448|Drug|Azacitidine|Powder for suspension for injection; Subcutaneous use
75594261|NCT01605630|Behavioral|Control|standard of care
75737923|NCT05678595|Device|high-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
75737924|NCT05678595|Device|sham high-intensity laser therapy|HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
75594262|NCT01683656|Drug|niacin/laropiprant|
75594263|NCT01683656|Drug|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
75594264|NCT01605747|Dietary Supplement|Culturelle|one capsule 2x per day per feeding tube
75594265|NCT01605747|Dietary Supplement|Placebo|one placebo 2x per day per feeding tube
76057278|NCT02049437|Drug|Placebo|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
75737925|NCT05664568|Drug|Cephalexin|Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
75737926|NCT05664568|Drug|Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet|Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
75737927|NCT05664568|Other|Standard of care treatment of tuberculosis|The control group will be given standard of care treatment of tuberculosis consisting of rifampicin, isoniazid, pyrazinamide and ethambutol
75737928|NCT05659303|Procedure|Laparoscopic hysterectomy|Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
75444494|NCT04257448|Drug|nab-Paclitaxel|Powder for suspension for injection; Intravenous use
75444495|NCT04257448|Drug|Gemcitabine|Powder for solution for infusion; Intravenous use
75594266|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
75594267|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
75737929|NCT05656768|Other|Constant Routine Protocol|A constant routine protocol is used to directly examine markers of circadian rhythmicity (e.g., melatonin and core body temperature). A constant routine protocol requires an individual to remain in a dimly lit room, in a constant semi-recumbent posture, and remain awake for more than 24 hours. It is one of two gold-standard research protocols for examining circadian rhythms in humans.
75737930|NCT05614323|Other|Interview and determining taste and smell with taste strips and Sniffin' Sticks|The Patient-Generated Subjective Global Assessment (PG-SGA) Short Form will be filled in by the participants. Next, a semi-structured in-depth interview will be performed in a quiet environment. The interview will take a maximum of one hour and will take place once. Topics that will be discussed are eating-related problems, the taste and smell of the offered hospital food, the choice in hospital food, the ambience during the eating moments, the use of protein-enriched snacks, the difference between eating at home and at the hospital, personal tips- and-tricks to maintain adequate nutritional intake, and how patients' think that food enjoyment can be improved in the hospital. The interview will be recorded. At last, taste and smell will be objectively determined with respectively taste strips and Sniffin' Sticks.
75769550|NCT03895294|Other|Usual care process prior strategic purchase-clinical pathway|1) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
75886761|NCT02142140|Behavioral|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
75886762|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
76057279|NCT02035553|Drug|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
76057280|NCT02035553|Drug|Placebo|Placebo, two tablets, once daily by mouth
75444496|NCT04257448|Drug|Durvalumab|Concentrate for solution for infusion; Intravenous use
75444497|NCT04257448|Drug|Lenalidomide capsule|Hard capsule for oral use
75444498|NCT04223115|Behavioral|Digitalized CBT with phone coaching|Digitally delivered CBT intervention with weekly phone coaching
75444499|NCT04223115|Other|Psychoeducation about depression|Psychoeducational material about depression in a digitalized form
75444500|NCT04221789|Other|TB treatment assistant|Cell phone app to support self administered treatment and monitor adherence
75444501|NCT04196387|Diagnostic Test|urine culture|urine culture and antibiotic susceptibility test
75886763|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
76057281|NCT04711733|Other|Interview|The qualitative interview aims to identify the supportive care needs of patients and parents as well as their expectations with regard to a long-term follow-up.
75444502|NCT04178954|Diagnostic Test|semen fluid analysis|semen fluid analysis
75444503|NCT04105751|Device|Novel Communication System|Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
75444504|NCT04097756|Drug|LX-039 tablets|orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
75444505|NCT04093388|Diagnostic Test|Self-PAP|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
75444506|NCT04093388|Diagnostic Test|Traditional Pap smear|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
75444507|NCT04082234|Behavioral|Partnering to Achieve School Success (PASS)|Individualized parent training program delivered at child's primary care provider office. Providers use engagement and motivation strategies during each session to reinforce help-seeking behavior and family empowerment, and encourage family adherence to recommended strategies. Also includes regular communication between pass provider and PCP and development of a problem-solving partnership between parents and teachers to address school problems. Families are supported in between sessions by a Community Health Partner who contacts families to promote attendance and implementation of strategies and assist in resolving barriers to treatment. The intervention is up to 12 sessions over the course of 16 weeks depending on caregiver goals.
75594268|NCT01605786|Other|Rehydragel™ HPA|"Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group."
75594269|NCT01683695|Drug|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
75594270|NCT01683695|Drug|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
75886764|NCT02148458|Other|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
75886765|NCT02148458|Other|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
75886766|NCT02148536|Procedure|Transjugular intrahepatic portosystemic shunt|
75886767|NCT02142218|Drug|Nivolumab|
75886768|NCT03543800|Device|Cytorich PRP kit|Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added
76071954|NCT03628989|Behavioral|Use of Virtual Technology|If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
75594271|NCT01605864|Drug|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
75594272|NCT01648244|Other|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
75594273|NCT01608789|Device|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
75886769|NCT03543800|Device|PRP kit|PRP kit legally marketed in Canada for PRP
75886770|NCT02142296|Drug|Eylea|monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
75886771|NCT02148614|Drug|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
75886772|NCT02148614|Drug|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
76057282|NCT04711733|Other|Self-report questionnaire|"To assess the quality of life, anxiety/depression of former patients and relatives:~For child and adolescent patients (less than 15 years old at inclusion):~Pediatric Quality of Life Inventory Cancer module~Screen for Child Anxiety Related Emotional Disorders Revised~Children's Depression Inventory~For patients over 15 years of age at the time of inclusion and parents:~36-Item Short Form Health Survey~Hospital Anxiety and Depression Scale~To describe and evaluate the offer and use of the network of health professionals who are aware of post-treatment issues: number of consultations, speciality and location of the professionals requested following the long-term follow-up consultation, time between referral and first consultation, evaluation of the geographical accessibility of care around the patient's home."
75444508|NCT04082234|Other|Treatment as Usual (TAU)|Caregivers will work with their primary care physician to address their child's ADHD. Primary care physicians have been trained in and informed of American Academy of Pediatrics guidelines for treating ADHD. Treatment may include strategies to educate families about ADHD and evidence-based treatments, refer families to community mental health agencies that deliver evidence-based behavioral programming (other than PASS), engage families in shared decision making, titrate medication, and monitor treatment effects. In addition, families will have access to integrated behavioral health services that are typically offered at their child's primary care office.
75444509|NCT04081454|Behavioral|Workshop|one-day (6 hour) program to help children and their parents or caregivers learn how to better manage chronic pain
75444510|NCT04081454|Behavioral|Education|The parent program includes psychoeducation regarding pain in the context of adolescent development, didactic and vignette-based practice of an adaptive parent communication response style (i.e., reflective listening), and concrete tools for setting up behavior plans to scaffold an adolescent's return to function for school, sleep, daily activities, and exercise. All parents are provided with a take-home workbook inclusive of neuroscience and psychoeducational materials as well as a list of resources to further solidify the information they learned.
75594274|NCT01683773|Biological|AERAS-402|Intramuscular needle injection 1x10^11 vp
75594275|NCT01683773|Biological|MVA85A|Intradermal needle injection 1x10^8 pfu
75594276|NCT01608867|Biological|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
75594277|NCT01648478|Other|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:~A basal period (from T-30 to T0)~The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~The infusion of glucose at variable rate (so as to maintain euglycemia)"
75594278|NCT01608945|Drug|Hydrocortisone sodium succinate|100mg/day
75737931|NCT05610124|Other|Ad libitum full-fat French fries with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
75737932|NCT05610124|Other|Ad libitum instant mashed potatoes with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
75769551|NCT01260064|Procedure|Open appendectomy|The subjects will have traditional open appendectomy procedure.
75769552|NCT01260064|Procedure|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
75769553|NCT01260064|Procedure|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
75886773|NCT03889639|Drug|SAR442168|Pharmaceutical form: Film coated tablet; Route of administration: Oral
75886774|NCT03889639|Drug|Placebo|Pharmaceutical form: Film coated tablet; Route of administration: Oral
75886775|NCT03889639|Drug|Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
75886776|NCT02148692|Procedure|Higher PEEP|
75886777|NCT02148692|Procedure|Lower PEEP|
75886778|NCT02142452|Behavioral|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
75886779|NCT02142452|Other|Usual Prenatal Care|
76057283|NCT04711733|Other|Medical consultation|"To assess adherence to long-term follow-up medical consultation:~- number of patients summoned/ number of consultations carried out ; reason for refusal of long-term follow-up medical consultation To assess medical complications through clinical data collection"
76057284|NCT01445080|Other|Laboratory Biomarker Analysis|Correlative studies
76057285|NCT01445080|Other|Pharmacological Study|Correlative studies
76057286|NCT01445080|Drug|Sorafenib Tosylate|Given orally
76057287|NCT02035475|Device|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
76057288|NCT04692779|Other|Lung Ultrasound (LUS)|Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.
75444511|NCT04059406|Drug|sapablursen|sapablursen administered subcutaneously
75444512|NCT04055467|Drug|[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)|Brain imaging of alpha-7 nicotinic acetylcholine receptors
75594279|NCT01608984|Procedure|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
75444513|NCT04055467|Behavioral|Contingency Management|Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
75444514|NCT04033718|Diagnostic Test|Inpatient lab bundling|The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.
75444515|NCT04033718|Behavioral|Inpatient navigation|Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
75444516|NCT04006561|Radiation|A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy|Each freshly-diagnosed patient with primary CNS lymphoma will be treated with combined chemoradiation in a sandwiched way, in which 2 cycles of induction chemotherapy with intravenous methotrexate (MTX in a conventional dose of 1g/m2) and intrathecal MTX are followed by a complete course of hyperfractionated WBRT and then high-dose cytarabine for 2 cycles.
75444517|NCT04004169|Device|Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
75444518|NCT04004169|Device|Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
75444519|NCT04004169|Device|Stimulation-ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
75737933|NCT05610124|Other|Ad libitum macaroni pasta with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
75737934|NCT05610124|Other|Ad libitum full-fat French fries with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
75737935|NCT05610124|Other|Ad libitum instant mashed potatoes with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
75886780|NCT05418985|Behavioral|Monthly reminder message about breast self-exam.|Monthly reminder message about breast self-exam.
75886781|NCT02142530|Drug|Carfilzomib|
75886782|NCT02142530|Drug|Belinostat|
75886783|NCT05418439|Dietary Supplement|Drink Poppi Soda|Drink Poppi Vinager Soda
75886784|NCT01383343|Biological|Bevacizumab|Given IV
75886785|NCT01383343|Drug|Fluorouracil|Given IV
76071955|NCT03613909|Device|CP950 OTE Sound processor|CP950 is Off The Ear (OTE) Cochlear Implant Sound Processor
75444520|NCT03999658|Biological|STI-3031|anti-PD-L1 antibody
75444521|NCT03959566|Drug|Sutezolid|Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.
75444522|NCT03959566|Drug|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
75444523|NCT03959566|Drug|Midazolam oral solution|Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
75594280|NCT01608984|Procedure|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
75444524|NCT03948295|Dietary Supplement|Lipid Challenge|After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
75444525|NCT03946163|Dietary Supplement|cinnamon capsules|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
75444526|NCT03946163|Drug|Placebo oral capsule|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
75594281|NCT01608984|Procedure|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
75737936|NCT05610124|Other|Ad libitum macaroni pasta with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the vegetarian meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
75737937|NCT05583695|Behavioral|mindfulness-based music therapy|eight weekly sessions with a combination of both mindfulness and music therapy
75594282|NCT01648517|Drug|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
75737938|NCT05583695|Behavioral|mindfulness-based therapy|eight weekly sessions of mindfulness
75737939|NCT05583695|Behavioral|routine care|eight weekly sessions of routine care
75737940|NCT05568004|Behavioral|Combined exercise|aerobic plus resistance exercise
75886786|NCT01383343|Drug|Irinotecan Hydrochloride|Given IV
75594283|NCT01648517|Drug|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
75594284|NCT01609101|Device|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
75594285|NCT01609101|Device|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
75594286|NCT01609101|Device|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
75594287|NCT01609101|Device|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
75594288|NCT01609101|Device|King Vision® videolaryngoscope|King Vision® videolaryngoscope
75594289|NCT01609101|Device|Venner® videolaryngoscope|Venner® videolaryngoscope
75886787|NCT01383343|Drug|Leucovorin Calcium|Given IV
75594290|NCT01609101|Device|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
75886788|NCT01383343|Drug|Sorafenib Tosylate|Given PO
75886789|NCT02254850|Procedure|Flow Mediated Dilation|"Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel."
75886790|NCT02254850|Drug|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
75444527|NCT03938870|Other|L-Leucine 13C6|
75444528|NCT03909529|Drug|Digoxin 250 MCG Oral Tablet|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
75444529|NCT03909529|Drug|Spironolactone 25 mg/ 5 mL S/F Suspension|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
75444530|NCT03899844|Other|Blood collection, PiB PET/MRI, and cognitive testing|Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
75444531|NCT03884517|Drug|BAT8003|Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
75886791|NCT02254850|Drug|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
75737941|NCT05568004|Behavioral|Aerobic exercise|Only aerobic exercise
75737942|NCT05537896|Drug|Eravacycline|"Eravacycline will be continued until one of the following criteria is met:~neutrophil recovery (ANC >500, post-nadir)~febrile neutropenia~breakthrough infection~any grade 3-4 toxicity related to eravacycline use"
75886792|NCT02254850|Drug|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
75444532|NCT03875755|Dietary Supplement|Myo Inositol|One soft gel capsule containing MI 600 mg and folic acid 200 μg twice a day, until delivery.
75594291|NCT01683929|Other|glucose|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR & BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
75594292|NCT01683929|Other|sweetner|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR & BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
75594293|NCT01609179|Drug|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
75594294|NCT01648556|Other|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
75594295|NCT01605981|Drug|AMN107|
75594296|NCT01648595|Drug|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
75594297|NCT01606020|Other|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
75737943|NCT05536908|Behavioral|Residential Written Exposure Therapy|Residential Written Exposure Therapy (resWET): TAU plus 5-individual WET sessions (40-60 min each; Marx & Sloan, 2019) twice a week for two weeks and once a week for the final session, administered by WET trained psychologists, social workers, or postdoctoral residents. Treatment instructions are read, patients write for 30 minutes, and the writing is briefly processed. No formal written homework is required.
75737944|NCT05536908|Behavioral|Treatment as Usual|Treatment as Usual (DOM SUD): The DOM SUD (TAU) is a 24-bed intensive SUD residential program with a typical 28-day length of stay. The program focuses on evidence-based treatments for SUD such as Cognitive-Behavioral Therapy, Motivational Enhancement Therapy, Medication Assisted Treatment, and Contingency Management therapy. Patients diagnosed with PTSD are typically referred to outpatient PTSD treatment following DOM SUD and often attend Seeking Safety during the program. Most of the programming is group-based though Veterans also have weekly individual case management appointments.
75886793|NCT02254850|Drug|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
75886794|NCT02142686|Device|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
75886795|NCT02142686|Device|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
75886796|NCT02142686|Device|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
75886797|NCT05416645|Procedure|patients with GERD after LSG|patients with GERD after LSG
75444533|NCT03875755|Other|Placebo|One soft gel capsule of placebo (folic acid 200 μg) twice a day until delivery.
75444534|NCT03819686|Behavioral|Living ACTS website|Living ACTS: About Choices in Transplantation and Sharing video that draws from the Information-Motivation-Behavioral Skills Model of individual level behavior change. A patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching ~20-minutes of videos from the website)
75886798|NCT02148770|Device|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
75737945|NCT05528939|Device|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
75444535|NCT03819686|Behavioral|Standard transplant education procedures|Review of a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two ~10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
75737946|NCT05528939|Other|Control video game|The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
75737947|NCT05525858|Drug|Alectinib|ALK fusion or mutations, Mutations or amplification in any of the following: RET
75886799|NCT03631147|Drug|Rifaximin|400mg bid for 8 weeks
75594298|NCT01606020|Other|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
76057289|NCT04181177|Other|Cosmetic product|"Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses)."
76057290|NCT04748536|Drug|IRL201104|lyophilised powder for reconstitution for IV dosing
76057291|NCT04748536|Drug|Placebo|Matching placebo for IRL201104
76057292|NCT01438294|Other|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
75594299|NCT01648634|Drug|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is>60kg)
75594300|NCT01648634|Drug|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is>60kg)
75594301|NCT04527848|Drug|small amount of undiluted C3F8|vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
75594302|NCT01606059|Drug|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
75886800|NCT02148848|Drug|Risedronate|Take risedronate 35 mg orally every week
75444536|NCT03794323|Drug|BI 764122|Tablet
75444537|NCT03794323|Drug|Placebo|Tablet
75594303|NCT01606059|Drug|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
75594304|NCT01606293|Behavioral|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
75594305|NCT04527809|Device|tDCS-active|One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
75594306|NCT04527809|Device|tDCS-sham|One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
75594307|NCT01606332|Procedure|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
75737948|NCT05525858|Drug|Atezolizumab|"MSI high status by any method Or Any mutation in any of these genes:~MLH1 or MSH2 or MSH6 or PMS2 or EPCAM Or Any of the following mutations in POLE: R150X, P286R, P286H, S297F, Y298fs, F367S, V411, L424V, P436R, S459F, R665W, L698fs, R762W, R1519C, R1826W, D316H, D316G, R409W, L474P Or Any of the following mutations in POLD1: P112fs, A930fs, S478N Or Any mutation in the following: POLE not listed above, POLD1 not listed above, POLD2, POLD3, POLD4, POLQ or PRKDC Or Any loss of function mutations in BRCA1, BRCA2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1, RFC2, RFC3, RFC4, RFC5, PCNA, RPA1, PRA2, PRA3, PRA4, or SSBP1 High tumor mutational burden decided by KOSMOS-II MTB (TMB ≥20/Mb in local NGS or if 10-20/Mb, confirmed by central NGS te sting)"
75737949|NCT05525858|Drug|Erlotinib|"EGFR Exon 19 deletions in the region E746_E759;~Any of the following EGFR mutations:~E709A, E709G, E709K, E884K, G719A, G719C, G719S, L858R, L861Q, L833V, S768I"
75886801|NCT03265145|Drug|Stiolto Respimat|Duration - 12 months
75886802|NCT03265145|Drug|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
75886803|NCT03265145|Drug|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
75886804|NCT03265145|Drug|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
75886805|NCT03786679|Device|Ultrasling ER III orthosis|Application of orthosis and start of rehabilitation after four weeks.
75886806|NCT02146664|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
75886807|NCT02146664|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
75444538|NCT03763942|Behavioral|HealthMindr App|Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
75444539|NCT03763942|Behavioral|Control App|Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
75444540|NCT03736707|Device|Selective HFOV|Selective HFOV will only be provided with piston/membrane oscillators able to provide a real oscillatory pressure with active expiratory phase
75444541|NCT03736707|Device|CMV|CMV was delivered by time-cycled, pressure-limited ventilators
75594308|NCT01606371|Drug|Placebo|Administered orally
75594309|NCT01606371|Drug|LY2409021|Administered orally
75594310|NCT04527653|Device|Tixel|Non-invasive thermo-mechanical treatment
75594311|NCT01606410|Other|IPC|repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
75886808|NCT05402059|Drug|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Any kind of treatment or observation (no treatment) initiated or planned in accordance with current clinical practice
75886809|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
75886810|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
75886811|NCT02146742|Drug|ASP1707|oral
75886812|NCT02146742|Drug|Placebo|oral
75886813|NCT05344495|Drug|hyalase group|bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.
75444542|NCT03727906|Other|No pre-sleep arousal manipulation|As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.
75444543|NCT03727906|Other|pre-sleep arousal down-regulation|"On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process."
75594312|NCT01648712|Device|Balance surface, Carmeda heparin-coated surface|"This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.~Balance arm group recieved like intervention a Balance circuit"
75594313|NCT01648712|Device|non -heparin extracorporeal pediatric device for operation|The carmeda arm group received like intervention the Carmeda circuit
75594314|NCT01606449|Procedure|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
75594315|NCT04527536|Diagnostic Test|Neonatal hyperbilirubinemia|Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
75594316|NCT05140629|Other|Baobab fruit aqueous extract|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
75594317|NCT05140629|Other|Placebo OGTT|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
75594318|NCT01608165|Procedure|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
75594319|NCT01608165|Procedure|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
75594320|NCT01608165|Procedure|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
75594321|NCT01688544|Drug|Ilaprazole|Ilaprazole 10 mg for 7 days
75737950|NCT05525858|Drug|Trastuzumab + Pertuzumab|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y, L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 amplification or approved by the KOSMOS Molecular Tumor Board"
75737951|NCT05525858|Drug|Trastuzumab emtansine|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y,L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 oncogenic mutations; G152V, X215_splice, D277Y, G292C, N302K, V308M, G309A, S310F, S310Y, S244C, L651V, V659E, G660D, R678Q, V697L, G727A, T733I, L755A, L755P, L755S, D769H, D769Y, A775_G776insSVMA, A775_G776insYVMA (i.e.,Y772_A775dup,M774_A775insAYVME 770delinsEAYVM), G776_V777 > AVCV, G776_V777 > AVGCV, G776_V777 > VCV, G776_V777insVC, G776C, G776delinsLCT, G776L, G776dleinsVC, G776L777_G778insC, V777L, V777M, G778_Y779insGSP, P780_Y781insGSP (i.e.,G778_P780dup), L786V, N813D, R840W, V842I, T862A, R896G, E1021Q or approved by the KOSMOS Molecular Tumor Board"
75737952|NCT05525858|Drug|Vemurafenib|BRAF_V600E/D/K/R mutations
75737953|NCT05525858|Drug|Bevacizumab + Erlotinib|FH inactivating mutations or approved by the KOSMOS Molecular Tumor Board
75886814|NCT05344495|Drug|midazolam group|2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%
75886815|NCT05079386|Device|New Voice Prosthesis|Replacement of the current prosthesis with the experimental device and use the New Voice Prosthesis for the duration of two weeks with the option of leaving the device in situ until replaced for device failure or other reason, with a maximum of 12 months.
76057293|NCT01438294|Other|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
75737954|NCT05525858|Drug|Entrectinib|ROS1 gene fusion using either a fluo rescence in situ hybridization (FISH) or next-generation sequencing (NGS) or approved by the KOSMOS Molecular Tumor Board
75886816|NCT01593241|Drug|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
75886817|NCT01593241|Radiation|Involved node RT|Involved node RT
75886818|NCT01590355|Radiation|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
75886819|NCT01590355|Procedure|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
75886820|NCT05960565|Drug|Glucagon|A micro-dose of glucagon is added exactly at the same site as insulin is injected.
75886821|NCT05960539|Procedure|surgical training|surgical residency focussed on visceral robotic procedures
75594322|NCT01688583|Drug|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
75886822|NCT05960526|Drug|extract Binahong|Extract Binahong 2.5% as nasal irrigation solution
75886823|NCT05960526|Drug|Isotonic saline nasal irrigation|NaCl 0.9% as nasal irrigation solution
75444544|NCT03727906|Other|pre-sleep arousal up-regulation|"On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone)."
75444545|NCT03704805|Behavioral|Friendship bench intervention|The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.
75594323|NCT01648829|Drug|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
75594324|NCT01648829|Drug|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
75594325|NCT01688622|Behavioral|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
75594326|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
75594327|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
75594328|NCT01688700|Drug|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
75594329|NCT01684085|Behavioral|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
75594330|NCT01684085|Behavioral|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
75594331|NCT01684085|Drug|Lorazepam|Lorazepam 1 mg
75737955|NCT05525858|Drug|Pralsetinib|RET fusion or mutations; CCDC6 RET, RET V804L, RET V804M, RET M918T, KIF5B-RET, RET C634W or approved by the KOSMOS Molecular Tumor Board
75737956|NCT05524584|Drug|Fulvestrant|Given intramuscularly
75737957|NCT05524584|Drug|Anastrozole|Given orally
75737958|NCT05524584|Drug|Abemaciclib|Given orally
75737959|NCT05510739|Behavioral|Motor-cognitive home exercise supported by eHealth technology|10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels. Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.
75737960|NCT05510739|Behavioral|Individualized home exercise program|Individualised home exercise program leaflet involving one initial instruction session. Written instructions involving dose and exercise progression. No support during the 10 week period.
75737961|NCT05495503|Device|Prototype (814A-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
75737962|NCT05495503|Device|Prototype (814B-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
75737963|NCT05495503|Device|Prototype (814C-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
75737964|NCT05495503|Device|Prototype (814D-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
75886824|NCT05960487|Other|Cervical multifidus muscle area measurement at 3 levels (C4-C5, C5-C6, C6-C7)|Cervical multifidus muscle area measurement will be performed from both the side affected by radiculopathy and the unaffected side using the magnetic resonance (MR) imaging. Measurements will be made by two researchers, independent of each other.
75444546|NCT03704805|Other|Enhanced Standard of Care|Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
75886825|NCT05960474|Other|Outcomes for Patients with CMD|Our objective is to perform a retrospective/prospective descriptive study on the short term to longterm (up to 5 years of follow-up) outcomes of patients with coronary microvascular disease diagnosis invasively
75886826|NCT05960435|Other|Proprioceptive Neuromuscular Facilitation|PNF, a method used to increase the range of motion of the joint and strengthen the muscles in the newly gained range, is a holistic approach and is based on motor learning principles. PNF stretching involves isometric contraction of the target muscle in addition to static stretching.
75886827|NCT05960435|Other|Control Group Exercise|The control group will include static stretching, capsule stretching, progressive ROM exercises and strengthening exercises.
75886828|NCT05960409|Procedure|chest tube - emergency thoracotomy|chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients
75886829|NCT05960396|Behavioral|Diet intervention|investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods
75444547|NCT03667079|Other|integrated delivery of deworming and vaccination|integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)
75444548|NCT03667079|Other|Mass deworming only|Delivery of mass deworming to people only
75444549|NCT03667079|Other|Mass vaccination of dogs|Delivery of mass vaccination of dogs only
75444550|NCT03630003|Device|MOCS|"The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform."
75444551|NCT03630003|Other|Post-use interview|The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
75444552|NCT03617939|Procedure|Biospeciman Collection|Collection of blood, tissue, and other biological samples.
75886830|NCT05960383|Diagnostic Test|BioFire Pneumonia Panel Plus|Assessment of sensbility and specificity of BioFire Pneumonia Panel Plus in lung transplantation
75886831|NCT05960370|Other|Observational non intervention study|An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.
75886832|NCT05960357|Other|To inform|It includes providing all necessary information about the fetus to the pregnant woman by using the ultrasound monitor during the detailed ultrasound.
75886833|NCT05960344|Procedure|Spirometry|Supervised v unsupervised spirometry
75444553|NCT03617939|Other|Survey Assessments|Data taken from patient surveys and assessments, including quality of life.
75444554|NCT03617939|Other|Medical Chart Reviews|Data taken directly from the patients' medical charts.
75444555|NCT03610737|Device|MILD Procedure|"The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.~Other Name: MILD lumbar decompression"
75444556|NCT03610737|Other|Conventional Medical Management (CMM)|CMM can include physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
75444557|NCT03603145|Procedure|Immediate insertion|Immediate insertion of intrauterine contraception within 48 hours of medical abortion
75444558|NCT03591796|Device|HFOV|Ventilated infants were randomized to HFOV
75444559|NCT03591796|Device|CMV|Ventilated infants were randomized to CMV.
75444560|NCT03537183|Other|Exercise training|12 weeks, 3 hours a week, moderate intensity exercise training
75444561|NCT03534050|Radiation|postoperative adjuvant RT|
75444562|NCT03380546|Drug|Acarbose|Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.
75444563|NCT03380546|Drug|Prandial insulin|Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
75444564|NCT03378063|Drug|transplantation of mesenchymal stem cell|allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
75444565|NCT03378063|Drug|no transplantation of mesenchymal stem cell|MSC transplantation will be not given to preterm infants
75444566|NCT03329157|Other|Rebuilding Bridges|Psychosocial intervention to help veterans re-engage with family members called Rebuilding Bridges, developed for this project.
75444567|NCT03321929|Combination Product|LUM Imaging System|Drug: LUM015 Device: LUM 2.6 Imaging Device
75737965|NCT05494437|Combination Product|PP-01 High Dose|Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
75737966|NCT05494437|Combination Product|PP-01 Low Dose|CB1 partial agonist / GABAergic modulator
75737967|NCT05494437|Drug|Placebo|Placebo comparator
75737968|NCT05494437|Drug|Nabilone|CB1 receptor
75737969|NCT05494437|Drug|Gabapentin|GABAergic modulator
75737970|NCT05464082|Other|Functional Precision Oncology|Patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO),
75737971|NCT05444504|Device|Cup|an insertable vaginal cup ('cup')
75444568|NCT03318094|Drug|Phentolamine|Intrabrachial phentolamine will be given on the blocked day
75737972|NCT05444504|Device|Cup+|the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
75737973|NCT05423600|Procedure|BES + TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
75444569|NCT03318094|Other|Saline|Intrabrachial saline will be given this day
75444570|NCT03318094|Drug|Sodium Nitroprusside|Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine
75737974|NCT05423600|Procedure|Experimental: BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
75886834|NCT05960331|Behavioral|Autonomy supported learning|The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
75444571|NCT03268499|Drug|Cisplatin|The procedure of TACE is the same irrespective of which regimen is used.
75594332|NCT01648985|Other|Diabetes in stroke/TIA|Mostly no intervention. A small Group of the patients recieved Yoga
75594333|NCT01688817|Other|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
75737975|NCT05405309|Drug|RP-3500 in combination with Olaparib|"During dose escalation, four DLs of combination therapy of RP-3500 and olaparib may be explored. Subjects will be enrolled in cohorts of three starting with DL 1. Enrollment will be placed on hold to allow for all members of a cohort to complete the Dose Limiting Toxicity (DLT) period. Once all subjects in a cohort have completed the defined DLT evaluation period, the assignment of the dose level for the following cohort will be made per the decision algorithm.~Once RP2D is assigned continuous enrollment will begin among the 2 expansion cohorts."
75737976|NCT05387187|Drug|Pu Yang Wan Wu Tang plus Pentoxifylline|Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
75737977|NCT05387187|Drug|Pentoxifylline|Pentoxifylline 100mg TID
75886835|NCT05960331|Behavioral|Practice with predetermined feedback|Learners practice the motor task, while the feedback is provided according to their counterpartner
75444572|NCT03250624|Drug|CD5024 0.3% cream|Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm^2) once daily for 6 weeks.
75444573|NCT03250624|Drug|Placebo|Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm^2 once daily for 6 weeks.
75444574|NCT03223675|Radiation|hippocampal-sparing WBRT|
75594334|NCT01688817|Other|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
75594335|NCT01684241|Biological|RBL001/RBL002|Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
75594336|NCT01688934|Drug|V116517 50-mg tablets|Taken orally twice daily
75594337|NCT01688934|Drug|V116517 30-mg tablets|Taken orally twice daily
75594338|NCT01688934|Drug|Naproxen 500-mg capsules|Taken orally twice daily
75594339|NCT01688934|Drug|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
75594340|NCT01684319|Dietary Supplement|Formula milk free of cow's milk protein|
75737978|NCT05378139|Device|Vital signs measurements with new app|Patients vital signs are monitored through an app for the nurses to use
76057294|NCT04709471|Drug|Nicotine|Participants will reduce their nicotine intake
76057295|NCT04709471|Device|Juul e-cigarette|Participants will switch to Juul pods containing less nicotine
76057296|NCT04709471|Behavioral|Reduction|Participants will reduce the number of Juul pods that they use
75737979|NCT05365893|Combination Product|Paricalcitol, Hydroxychloroquine, Losartan|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
75886836|NCT05960279|Device|MD100|"The MD100 (Medfield Diagnostics, Gothenburg, Sweden) consists of 8 antennas and measurement electronics integrated into a single device; rechargeable ion batteries power the instrument. The radiation transmitted from the device equals approximately 1% of the radiation emitted from a mobile phone. The device is non-invasive and small enough that it can be moved around with ease.~The system transmits microwaves with an output of 0.2 milliWatts (mW) for less than 90 seconds. The power absorbed by the body is 100mW/kg which is a factor of 200 less than what is established by the existing safety standard for microwaves. A mobile phone output, by comparison, can be up to 250mW.~The patient's head is placed in the instrument during measurement while the patient is supine. The procedure takes, on average, 5 minutes to perform."
75886837|NCT05960266|Biological|Polvac Grass+Rye|Aqueous suspension of a co-precipitate of allergen extract and tyrosine
75886838|NCT05960227|Drug|Iron dextran|Administration of 1.2g of iron dextran in infusion bolus as a loading strategy.
75886839|NCT05960227|Drug|Placebo|250ml of saline 0,9% for 4 hours insusion.
75886840|NCT05960201|Drug|[18F]fluoroestradiol (FES)|F-18 FES 111~222 MBq(megabecquerel) injection
75886841|NCT05960188|Behavioral|AI Opinion|For each case, we give the radiologist a numeric score reflecting the AI's rating of the abnormality of the case.
75886842|NCT05960162|Diagnostic Test|90K|Blood test
75886843|NCT05960149|Drug|using Indocyanine Green|Nerve-sparing robot-assisted laparoscopic radical prostatectomy using Indocyanine Green
76057297|NCT04690985|Behavioral|Dietary behaviour change|The intervention consists of dietary guidance and behaviour change techniques, which will last for 15 weeks. The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive the dietary behaviour change guidance in 6 times face-to-face meetings and weekly telephone calls. They will also be asked to take daily food diary.
76057298|NCT04690985|Other|Social contact|The control group will not be required any dietary changes. The investigator will contact with the control group with the same frequency and numbers of experimental group. But the chat topic will not be related to sarcopenic obesity or dietary guidance.
75594341|NCT01684319|Dietary Supplement|Placebo|Infant formula milk
75737980|NCT05365893|Other|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
75737981|NCT05330455|Drug|GSK3965193|GSK3965193 will be administered
75737982|NCT05330455|Drug|Placebo to match GSK3965193|Placebo to match GSK3965193 will be administered
76057299|NCT02033759|Device|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
76057300|NCT02033759|Other|Anxiety Questionnaire|21 item questionnaire
76057301|NCT02033759|Other|Traditional Circumferential Measurements|
76057302|NCT01959529|Drug|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
76057303|NCT01959529|Drug|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
75594342|NCT02279576|Drug|Pazopanib|Pazopanib 800mg/day continuously administered.
75737983|NCT05330455|Drug|Bepirovirsen|Bepirovirsen will be administered
75737984|NCT05312671|Drug|Atezolizumab|Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)
75737985|NCT05312671|Drug|Carboplatin|Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
75444575|NCT03204955|Drug|Sodium chloride /sodium acetate (16.4%)|"Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy."
75444576|NCT03204955|Drug|Sodium chloride (23.4%)|Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
75444577|NCT03204955|Drug|PlasmaLyte|PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
75737986|NCT05312671|Drug|Cisplatin|Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
75594343|NCT02279576|Drug|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
75594344|NCT02279615|Drug|Mirabegron|50mg of mirabegron per day will be given.
75594345|NCT02279615|Drug|Tamsulosin|0.4mg of flomax per day.
75737987|NCT05312671|Drug|Etoposide|Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)
75737988|NCT05312671|Procedure|Cystectomy|Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).
75886844|NCT05960149|Procedure|Nerve-sparing robot-assisted laparoscopic radical prostatectomy|Nerve-sparing robot-assisted laparoscopic radical prostatectomy without the use of Indocyanine Green
75594346|NCT01689051|Other|human glucagon-like peptide 1 (7-36)amide|
75594347|NCT01689051|Other|human glucagon-like peptide 1 (9-36)amide|
75594348|NCT01684358|Device|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
75594349|NCT05140395|Diagnostic Test|ABTEST card|Pre transfusional control with the referent ABTEST card and the in study ABDTEST Card
75594350|NCT01684475|Drug|CJH1 (CLR4001)|
75886845|NCT05960123|Procedure|Tubularized Incised Plate (TIP) urethroplasty|tubularization of urethral plate with or without spongioplasty
75886846|NCT05960110|Drug|Fluoride varnish|Fluoride varnish 26200 ppm
75886847|NCT05960110|Drug|Fluoride toothpaste|Fluoride toothpaste 1450 ppm
75886848|NCT05960084|Other|screening|screening for colistin resistant E. coli
75886849|NCT05960071|Procedure|protective lung strategy with recruitment manoeuvre (RM) - steady PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2o in between RM till end of surgery.
76057304|NCT02033369|Drug|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
76057305|NCT02032901|Drug|Daclatasvir|
76057306|NCT02032901|Drug|Sofosbuvir|
75886850|NCT05960071|Procedure|protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
75886851|NCT05960045|Dietary Supplement|Direct Milk antigen reintroduction|Direct milk antigen re-introduction milk according to ESPGHAN guidelines
75886852|NCT05960045|Dietary Supplement|Milk ladder|B: Milk ladder according to the iMAP guideline which are 6 weeks of gradual reintroduction starting with baked milk not direct antigen
75444578|NCT03189485|Drug|the radiotracer 18F-AV-1451|Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed
75444579|NCT03159481|Behavioral|Usual Care + Health Promotion Intervention|Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
75444580|NCT03069326|Drug|Ruxolitinib|Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
75886856|NCT05960006|Other|No intervention|There are no risks associated with participation because only waste material (blood and ascites) will be used for analysis and no additional blood collection or paracentesis will be performed in addition to standard-of-care. Moreover, hospital admittance and discharge, indication for interventional procedures, indication/initiation/duration/dosing of ceftriaxone, indication/timing/frequency of blood withdrawal for standard of care biochemical analysis and microbiological culturing as the indication, timing, frequency and duration of paracentesis are all decided by the treating physician independent of participation in the study. There are no extra site visits nor extra days of hospital admission. There is no direct benefit for participants of this explorative study. .
75444581|NCT03069326|Drug|Thalidomide|Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
75444582|NCT03059043|Device|viscoelastic-free implantation system|Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation
75594351|NCT05140356|Device|Applied high amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week
75886857|NCT05959967|Behavioral|Vestibular Rehabilitation Exercises|The VRE group will receive exercises aimed at improving gaze stability, postural control, and balance. This includes activities like gaze stabilization exercises, balance training on different surfaces, and walking with head movements.
75886858|NCT05959967|Behavioral|General Fitness Training|The GFT group will undertake exercises to enhance cardiovascular fitness, strength, and flexibility, such as light aerobic exercises, resistance training, and stretching. The exercise sessions will be 60 minutes in duration, consisting of a warm-up phase, the main exercise phase, and a cool-down phase.
75886859|NCT05959954|Diagnostic Test|Quantitative Sensory Testing (QST)|Quantitative Sensory Testing (QST) is a non-invasive diagnostic method used to assess sensory dysfunction. The test evaluates individual thresholds and pain responses to different types of mechanical, thermal, and electrical stimuli. For this study, QST will be used to gather baseline sensory data for patients with carpal tunnel syndrome. This information will then be used to predict the progression to nociplastic pain over a one-year follow-up period.
75886860|NCT05959889|Other|Placebo|Patients will receive placebo tablets for 4 cycles of AC.
75886861|NCT05959889|Drug|Montelukast|Patients will receive motelukast 10 mg for 4 cycles of AC.
75886862|NCT05959863|Diagnostic Test|Captopril Challenge Test|Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.
75886863|NCT05959824|Device|OR-AT0222|Topical viscous gel containing tamarind seed polysaccharide and isolated pea proteins will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
75444583|NCT03059043|Device|standard viscoelastic-assisted Implantation system|This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation
75444584|NCT03015740|Other|Laboratory Biomarker Analysis|Correlative studies
75444585|NCT03015740|Biological|Nivolumab|Given IV
75444586|NCT03015740|Other|Quality-of-Life Assessment|Ancillary studies
75444587|NCT03015740|Other|Questionnaire Administration|Ancillary studies
75444588|NCT03015740|Drug|Sitravatinib|Given PO
75444589|NCT03011294|Device|Continuous positive airway pressure (CPAP)|
75594352|NCT05140356|Device|Applied low amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
75444590|NCT03011294|Device|Nasal strip|
75444591|NCT02995837|Other|Sleep Study|Overnight, video-recorded sleep study will be performed in a dedicated pediatric sleep lab. Sleep architecture, apneas and hypopneas, arterial oxygen saturation and end-tidal carbon dioxide tension will be evaluated during the sleep study. Safety measures including arterial oxygen saturation using pulse oximetry, EEG and EKG will be continuously monitored during the study.
75886864|NCT05959824|Other|Placebo|Topical placebo viscous gel will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
75886865|NCT05959798|Procedure|High power short duration ablation|Pulmonary vein isolation by high power short duration radiofrequency catheter ablation
75737989|NCT05306496|Device|Pre-shaped 4DMESH®|The 4DMESH® mesh is semi-resorbable parietal reinforcement implant made of 25% Polypropylene (non-resorbable) and 75% Poly-L-Lactic Acid (resorbable). 4DMESH® meshes are designed for the repair and reinforcement of inguinal and femoral hernias. 4DMesh is a CE-marked, class III medical device manufactured by Cousin Biotech.
76057307|NCT04681469|Drug|Niraparib|"For all patient's population:~Niraparib 200 mg/day: day -49 to day -21;~Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~Niraparib 200 mg/day: day -21 to day -7~Dostarlimab 500 mg iv: day -7~Radiological assessment (day -1, ± 3 days),~Surgery (original margin) at day 0 (±3 days)~Standard postoperative (chemo)radiotherapy according to pathologic report;~Maintenance Niraparib, 200 mg/day for 6 months~Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
76057308|NCT04416971|Procedure|AVF puncture|For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.
75444592|NCT02995837|Other|Neurocognitive Testing|Cognitive and behavioral measures including intelligence, attention, working memory, and processing speed will be assessed by a trained psychologist.
75444593|NCT02995837|Other|CBF During Wakefulness|Cerebral blood flow (CBF) will be measure using Diffuse optical and correlation spectroscopy (DOS/DCS), a non-significant risk device used to collect data for this study but not being tested as part of the protocol. Light sources and detectors which are embedded in a rubber pad will be attached to the subject's head in order to record right and left hemispheric cerebral blood flow, total hemoglobin concentration and tissue oxygen saturation. Measurements will be continuously recorded during the study and averaged for purposes of statistical analysis. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique, a standard clinical test. While CBF is being measured, subjects will wear nose clips and sit comfortably breathing through a mouthpiece while the level of carbon dioxide is adjusted over a 3-4 minute period. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
75594353|NCT04528121|Other|CoDuSe balance training and step square exercises|"The standardized intervention targeted visual, somatosensory, and vestibular aspects of balance and will be included with balance exercises~Examples of core stability exercises as follows: in supine position with knees bent, slowly slide one heel forward to straighten leg; and, in four-point kneeling position, slide one foot in a straight line away from the body and lift the leg off the floor.~Examples of dual-task exercises as walking while turning one's head and juggling a balloon.~Examples of sensory strategies as standing and walking on uneven surfaces and standing with eyes closed."
75594354|NCT04528121|Other|conventional balance training|static and dynamic balance training exercises from sitting, standing and ambulation activities
75594355|NCT01689090|Other|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
75737990|NCT05304208|Biological|Mesopher|autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
75737991|NCT05291351|Other|Crackers made with whole, coarse, or fine pea and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
75594356|NCT01689090|Other|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
75594357|NCT01689090|Other|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
75737992|NCT05291351|Other|Crackers made with whole, coarse, or fine lentil and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
75886866|NCT05959785|Procedure|Basic and light cervical mobilization exercises|This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.
75594358|NCT01684553|Behavioral|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
75444594|NCT02995837|Other|CBF During Sleep|This is the same as the CBF testing during wakefulness/daytime except that it will be done during a sleep study performed with a continuous positive airway pressure (CPAP) mask not nose clips and a mouthpiece. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique. While CBF is being measured, OSAS subjects will receive an individualized positive pressure aimed at treating obstructive sleep apnea and controls will receive a standard pressure. End-tidal carbon dioxide will be measured via a port in the mask. A constant flow of carbon dioxide will be introduced to the circuit, a slowly adjusted until the patient arouses or for a maximum of 3 minutes, whichever occurs first. One trial will be attempted in each sleep stage (slow-wave sleep and rapid-eye-movement) with a minimum of 15 minute of breathing room air between challenges. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
75594359|NCT01684553|Behavioral|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
75594360|NCT01689129|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
75444595|NCT02946242|Device|Ultrasound Exam|Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
75594361|NCT01689129|Drug|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
75444596|NCT02881242|Other|Laboratory Biomarker Analysis|Correlative studies
75444597|NCT02881242|Other|Quality-of-Life Assessment|Ancillary studies
75444598|NCT02881242|Drug|Trametinib|Given PO
76057309|NCT04690127|Other|Plyometric Exercise|Plyometric training consisting of ten different exercises [vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
75594362|NCT01684631|Device|Total Hip arthroplasty|
75594363|NCT01689168|Behavioral|Counseling|Tobacco cessation counseling
75594364|NCT01689168|Procedure|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
75594365|NCT01689285|Drug|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
75594366|NCT01689285|Drug|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
75594367|NCT01649102|Device|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:~Palindroom~Hemoglide Bard"
75594368|NCT01606527|Drug|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
75594369|NCT01684670|Behavioral|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
75594370|NCT01609335|Drug|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
75594371|NCT01609335|Drug|C-11 PiB|One time intravenous administration of 10-20 mCi
75594372|NCT01609374|Device|M6-C Artificial Cervical Disc|Total disc replacement
75594373|NCT01609374|Device|Anterior plate system with corticocancellous allograft bone|Cervical fusion
75594374|NCT01684709|Behavioral|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
75594375|NCT01649141|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
75594376|NCT01609413|Dietary Supplement|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
75594377|NCT01609413|Dietary Supplement|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
75594378|NCT02279966|Drug|Vortioxetine 10 mg|
75594379|NCT02279966|Drug|Paroxetine 20 mg|
75594380|NCT02279966|Drug|Placebo|
75594381|NCT01606644|Procedure|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
76057310|NCT04689659|Biological|chimeric antigen receptor T cell treatment|CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells. Patients who received fresh donor derived CD7 CAR T cells were given initial dose of 1×106, with an allowance of ± 20%. The dose levels may be adjusted during the study based on the specific number of cells on the day of fresh CAR T cells infusion, due to at this time all the patients have completed lymphodepleting, so we adopt the allowance of ±20% for each group of absolute infusion cells. And patients who were lower than the designed dose group were also given infusion, but they will be either assigned to the lower dose group or exclude from safety analysis of designed dose group.
75737993|NCT05291351|Other|Porridge made with oat flour or oats|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
75737994|NCT05254574|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
75737995|NCT05254574|Device|Placebo Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the placebo SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% Diclofenac patches.
75737996|NCT05254574|Drug|1% Diclofenac Topical Gel|Topical pain-relief gel
75737997|NCT05225324|Drug|Equfina 50 mg|Equfina 50 mg tablets.
75737998|NCT05219929|Drug|Tetracycline 500 Mg|500 mg three times daily
75737999|NCT05219929|Other|Placebo|Placebo for Tetracycline given same way as Tetracycline.
75738000|NCT05210530|Combination Product|VCTX210A unit|CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
75738001|NCT05205382|Other|5% nicotine|Effects of e-cigarette pods (JUUL/NJOY/SREC) with 5% nicotine concentration nicotine concentration
75738002|NCT05205382|Other|3% nicotine|Effects of e-cigarette pods (JUUL/NJOY) with 3% nicotine concentration
76057311|NCT02020967|Other|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
75738003|NCT05205382|Other|0% nicotine|Effects of e-cigarette pods (SREC) with 0% nicotine concentration
76057312|NCT01986829|Device|Microwave ablation|"Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
75594382|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in normal ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
75594383|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in elevated ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
75594384|NCT01606683|Other|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
75738004|NCT05203185|Other|Pulmonary Embolism Risk Kalculator (PERK)|Nudges are applications of behavioral science, defined as positive reinforcement and indirect suggestions that have a non-forced effect on decision making. Nudges will be to the PE CALC CDS tool to develop the new CDS tool, PERK.
75738005|NCT05202847|Procedure|pulsed radiofrequency ablation to modifined points group|Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.
75738006|NCT05202847|Procedure|pulsed radiofrequency ablation to conventional points group|Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
75738007|NCT05153148|Drug|NDI-034858|Randomized participants will receive NDI-034858 capsule orally
75738008|NCT05153148|Other|Placebo|Randomized participants will receive placebo orally
75594385|NCT01606683|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
75594386|NCT01606683|Other|No intervention|
75594387|NCT01649219|Behavioral|Exercise|
75594388|NCT01609452|Biological|Blisibimod|
75886867|NCT05959785|Procedure|Abdominal or diaphragmatic breathing exercises|The first abdominal or diaphragmatic breathing exercises will be carried out in a lying position, with the back well supported on a comfortable and firm surface, and with hips and knees flexed and feet supported. The patients take deep breaths, taking air raising the abdomen towards the ceiling, without raising the back from the horizontal plane. During expiration the navel will lower posteriorly and rise towards the thoracic region. For the second abdominal or diaphragmatic breathing exercise, the patient is seated on a firm and comfortable surface, with hips and knees flexed and feet supported. An inspiratory movement will be made in which the patient's navel will be moved outward, away from the spine. During expiration, the navel will go in the direction of the patient's spine and will rise in the direction of the thorax.
75886868|NCT05959772|Radiation|Photobiomodulation|"Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 clusters in each session. Two tapes containing four clusters each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape"
75886869|NCT05959759|Drug|Dimethyl fumarate|dimethyl fumarate enteric capsule (the initial dose is 120 mg twice a day, and after 7 days, the dose will be increased to the maintenance dose of 240 mg twice a day, for 6 months), 30 patients for this arm.
75886870|NCT05959759|Drug|Placebo|placebo with the same appearance (color, taste, size, shape), 30 patients for this arm.
75594389|NCT01609452|Other|Placebo|
75594390|NCT01649258|Drug|granisetron transdermal system|Given granisetron transdermal system patch
75594391|NCT01649258|Drug|fosaprepitant dimeglumine|Given IV
75594392|NCT01649258|Other|laboratory biomarker analysis|Correlative studies
75738011|NCT05132829|Drug|Azithromycin 1 gram IV|Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
75886871|NCT05959681|Device|Compression garment with Vari-pad microdots ink-printed on inside.|Initially, participants wear a garment with Vari-pads on one side (left or right) only and swap to a garment with Vari-pads on both sides if / when the participants notice a difference between the sides. Wearing garment 8 hours per 24 hours.
75886872|NCT05959616|Biological|Shigella sonnei 53G|Lyophilized S. sonnei 53G strain (Lot 1794)
75886873|NCT05959616|Drug|Ciprofloxacin 500 mg|Ciprofloxacin (500 mg orally twice daily for three days),
75594393|NCT01649336|Drug|MEK162, MEK inhibitor; oral|multiple dose, escalating
75738012|NCT05132829|Drug|Cefazolin and indomethacin|Perioperative standard of care with cefazolin and indomethacin
75738013|NCT05126355|Behavioral|On the Move group exercise|The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.
75886874|NCT05959603|Drug|Vancomycin|Powdered vancomycin will be locally administered once during surgery. The vancomycin will be placed in the surgical bed at several layers: around the hardware and before muscle apposition and above the fascia. This is done before the closure of the muscular fascia and skin by the neurosurgeon. The vancomycin will not be mixed in the bone graft.
75886875|NCT05959590|Drug|Ferumoxides 11.2Mg Solution for Injection|the drug will be injected at a single dose of up to 7 mg/Kg and MRI will be performed after 24 hrs.
75886876|NCT05959577|Procedure|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.
75886877|NCT05959577|Procedure|Ferguson hemorrhoidectomy|Ferguson hemorrhoidectomy
75886878|NCT05959551|Device|high definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.
75594394|NCT01649336|Drug|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
75594395|NCT01609491|Drug|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
75738014|NCT05122689|Dietary Supplement|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
75738015|NCT05122689|Dietary Supplement|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
75738016|NCT05117450|Device|Decrease per-dialytic heparin therapy|Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
75738017|NCT05104450|Behavioral|lifestyle intervention|Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
76057313|NCT01986829|Device|Cryoablation|"Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
76057314|NCT01986829|Device|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
76057315|NCT01986829|Other|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
75738018|NCT05102669|Other|analysis of immunological response|collection and analysis of SARS-CoV2 Spike specific blood cells
75738019|NCT05102669|Diagnostic Test|analysis of serum antibodies|analysis of anti-SARS-CoV2 Spike specific antibodies
75738020|NCT05099874|Device|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
75738021|NCT05063357|Drug|131I-Omburtamab|Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).
75738022|NCT05063357|Device|Convention Enhanced Delivery|The planned intervention includes surgical placement of a small caliber cannula into the tumor located in the pons using standard stereotactic techniques followed by CED of 131Iomburtamb.
75738023|NCT05050448|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
75738024|NCT05050448|Drug|1% Diclofenac Topical Gel|Topical pain-relief gel
75886879|NCT05959460|Other|Deuterium dose-to-mother method for assessing breastfeeding|Exclusive breastfedding practice was compared between maternal recall and the deuterium dose-to-mother method.
75886880|NCT05959447|Drug|Camlipixant + Gemfibrozil|Camlipixant will be administered alone as well as in co-administration with gemfibrozil
75886881|NCT05959447|Drug|Dabigatran etexilate + camlipixant|Dabigatran etexilate will be administered alone as well as in co-administration with camlipixant
75886882|NCT05959408|Procedure|Collection of throat swab|Introduction of a cotton swab for self-collection
75886883|NCT05959408|Procedure|Collection of anal swab|Introduction of a cotton swab for self-collection
75886884|NCT05959408|Procedure|Collection of first void urine|first void urine collected on urine pot
76057316|NCT01986829|Other|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
76057317|NCT01986751|Drug|Clonidine|
76057318|NCT01986751|Drug|ropivacaine|
75886885|NCT05959382|Device|Dental Loupe|Magnification aid
76057319|NCT02004847|Device|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
76057320|NCT01438060|Drug|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
76057321|NCT01438060|Drug|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
76057322|NCT01469182|Biological|SCH 39641|Rapidly dissolving tablet sublingually once daily
76057323|NCT01469182|Drug|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
76057324|NCT01444378|Device|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
76057325|NCT02020889|Biological|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
75444599|NCT02841462|Device|Intra-bursal thermal ablation|A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
75444600|NCT02791204|Device|SPECT/CT imaging following revascularization procedures|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
75444601|NCT02791204|Device|SPECT/CT imaging|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
75444602|NCT02785263|Radiation|2.15 gray and 1.8 gray. Max. 6 weeks.|
75444603|NCT02785263|Radiation|2.15 gray and 1.8 gray. Max. 5 weeks.|
75444604|NCT02717234|Other|Oral Nutrition Supplement|Oral nutrition supplement intended for consumption at 3 servings per day
75444605|NCT02655744|Radiation|Standard treatment protocol with combined chemoradiation|
75444606|NCT02638519|Other|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
75444607|NCT02638519|Other|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
75594396|NCT01609491|Drug|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
75594397|NCT01606917|Other|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
75594398|NCT01684865|Drug|Rituximab|Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
75594399|NCT01606956|Procedure|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
75444608|NCT02638519|Drug|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
75738025|NCT05030935|Device|mHealth App|In short, mHA contains three main functions for the user: a) a reminder for switching the patient position, b) training for preventive care habits and c) the possibility for patient evaluation in order to determine the need for the use of support surfaces.
75738026|NCT05013385|Drug|Spesolimab|Spesolimab
75738027|NCT05013385|Drug|Placebo|Placebo
75738028|NCT05005650|Procedure|debulking surgery|debulking surgery as primary debulking surgery or interval debulking surgery
75738029|NCT04993742|Behavioral|MOMS Intervention|Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
75738030|NCT04982198|Procedure|ROSA assisted TKA|Robotic assisted total knee arthroplasty
75738031|NCT04956250|Other|Traffic Calming Curbs|Temporary curb extensions, placed at intersections.
75738032|NCT04956250|Other|In-Street Pedestrian Sign|Yield sign placed in middle of road at intersection.
75444609|NCT02638519|Device|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
75444610|NCT02608762|Radiation|standard adjuvant local radiation therapy or cranial radiation therapy|
75738033|NCT04946344|Behavioral|Diet & Exercise|Participants will attend exercise and diet classes.
75738034|NCT04946344|Behavioral|Attention Control|Participants will attend healthy living classes and receive phone calls/emails/texts.
75738035|NCT04922606|Diagnostic Test|US ot the GSV|Ultrasound of the Great Saphenous Vein
75738036|NCT04913701|Other|Observation group 1|Subjects will be followed with 3 swabs and serological test
75738037|NCT04899388|Procedure|Pericapsular Nerve Block|regional anaesthia
75738038|NCT04899388|Procedure|Lumbar Erector Spinae Plane Block|regional anaesthia
75738039|NCT04899388|Drug|Fentanyl|intavenous
75738040|NCT04887571|Other|No Intervention - Observational Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an Acute coronary syndrome (STEMI, NSTEMI, Unstable Angina) will be recruited into the PERFUSION Registry.
75738041|NCT04880785|Drug|Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]|change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
75738042|NCT04878601|Other|Home-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
76057326|NCT02020889|Drug|Placebo|Placebo will be available as 0.9% sodium chloride
75738043|NCT04878601|Other|Facility-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
75738044|NCT04876586|Procedure|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive degenerative disc disease
75738045|NCT04874246|Drug|Vasopressin|During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.
75886886|NCT05959382|Device|Dental Operation Microscope|Magnification aid
75444611|NCT02507297|Device|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
75444612|NCT02504788|Radiation|hippocampal-sparing WBRT|
75444613|NCT02448992|Radiation|hippocampal-sparing WBRT|
75444614|NCT02376699|Drug|Intravenous (IV) SEA-CD40|Given intravenously; schedule is cohort-specific.
75594400|NCT01606956|Procedure|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
75594401|NCT01649453|Device|Pathwork® Tissue of Origin Test|
75738046|NCT04865731|Drug|Dermaprazole|Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
75738047|NCT04865731|Drug|Aquaphor|Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
75738048|NCT04813159|Device|Remote Ischaemic Conditioning (RIC)|The RIC protocol will comprise inflation of the automated RIC device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
75738049|NCT04813159|Device|Sham-control|The sham protocol will comprise low-pressure inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff used in the active arm. The sham control protocol will be repeated daily for the next 2 days.
75444615|NCT02376699|Drug|Pembrolizumab|Given intravenously; schedule is cohort-specific.
75444616|NCT02376699|Drug|Subcutaneous (SC) SEA-CD40|Given subcutaneously on Day 1 every 3 weeks
75444617|NCT02376699|Drug|Gemcitabine|1000 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
75444618|NCT02376699|Drug|Nab-paclitaxel|125 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
75594402|NCT01580163|Drug|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
75594403|NCT01580163|Drug|Methadone|Oral Solution，1mg/ml
75738050|NCT04808869|Other|Exercise|Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
75738051|NCT04781088|Drug|Lenvatinib|Given PO
75738052|NCT04781088|Drug|Paclitaxel|Given IV
75738053|NCT04781088|Biological|Pembrolizumab|Given IV
75738054|NCT04777006|Behavioral|Problem Management Plus|"PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4"
76057327|NCT01444300|Drug|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
76057328|NCT01444300|Drug|Placebo|placebo pill, bid for 12 weeks
75594404|NCT01580163|Drug|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
75594405|NCT01609647|Drug|Prasugrel|Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
75594406|NCT01609647|Drug|Clopidogrel|Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
75594407|NCT01649492|Dietary Supplement|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
75594408|NCT01580202|Drug|Entecavir|Entecavir 0.5mg daily per os
75594409|NCT01580202|Drug|Lamivudine|lamivudine 100mg daily per os
75594410|NCT01649570|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
75444619|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
75594411|NCT01685294|Behavioral|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
75769554|NCT03895060|Device|autogenous ring blockls with GBR covered by collagen membrane|"A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~The flap will then be closed using interrupted 4/0 resorbable sutures."
76057329|NCT04681001|Device|nasal spray|application of nasal spray into nostrils and mouth
76057330|NCT01443364|Biological|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
76057331|NCT02020577|Drug|Cetuximab( erbitux®)|once per week
75594412|NCT01685450|Device|Echodia® hand-held equipment|
75594413|NCT01609764|Behavioral|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
75594414|NCT01609803|Other|laboratory biomarker analysis|Correlative studies
75444620|NCT02174315|Behavioral|Contingency Management|
75444621|NCT02141542|Drug|Tremelimumab|
75444622|NCT02141542|Drug|MEDI3617|
75444623|NCT01984710|Device|Medtronic Activa PC+S System|
75444624|NCT01930955|Drug|Amoxicillin|β-lactam antibiotics
75444625|NCT01333514|Drug|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
75886887|NCT05959369|Diagnostic Test|y balance test, core endurance and strength test, foot posture ındex|First, the athlete's bare feet will be photographed on a flat surface for foot posture analysis. Modified push-up test and sit-up test will be used for core stabilization evaluation. For the endurance assessment of core muscles, lateral bridge test, static trunk extension test (Sorensen test) and trunk flexors endurance test will be used. The 'Y' balance test will be used for balance evaluation. The athlete will be asked to lie in three different directions at the same time with the other foot while balancing on one foot.
76057332|NCT02020577|Drug|Afatinib|once per day
76057333|NCT02020031|Drug|Vancomycin|
75444626|NCT01333514|Drug|aspart- Insulin|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
75444627|NCT00587561|Behavioral|Social Cognition Interaction Training|manualized group therapy
76071956|NCT03611374|Procedure|Bilateral Erector Spinae Plane Block (ESPB)|Bilateral ESPBs will be placed after anesthesia induction in eligible and consented patients who are undergoing a sternotomy for congenital heart repair. Patients will receive a local anesthetic agent through each catheter prior to surgery start. If possible, levels of the local anesthetic will be measured during the case. After surgery, patients will be admitted to the CVICU and extubation will be managed by the CVICU team. The ESPB group will have an automatic, alternating side boluses of the local anesthetic started through their nerve block catheters. Levels of the local anesthetic will be measured at intervals.
75444628|NCT00587561|Behavioral|WLC|wait-list control for 6 months, followed by the experimental group therapy
75594415|NCT01649648|Biological|Autologous cord blood|Baby's own umbilical cord blood
75594416|NCT01609881|Drug|Acuvail|Dosing of drug 3 days prior to surgery
75594417|NCT01609881|Other|Placebo|Artificial tears qid for 3 days preoperatively
75594418|NCT01649687|Biological|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells
75738055|NCT04777006|Drug|Antidepressant Therapy|"Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 < 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care."
75738056|NCT04766086|Biological|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
75886888|NCT05959304|Other|brolucizumab|There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.
75886889|NCT05959278|Other|App for vestibular rehabilitation|This app is a platform for performing conventional vestibular rehabilitation remotely
75886890|NCT05959265|Behavioral|exercise|Patients in the treatment group will undergo a 12-week intervention consisting of three 30-minute walking exercises per week during their standard cancer treatment. A personalized walking plan using fitness trackers will be provided to record each patient's daily average heart rate, step count, and additional steps and heart rate during the three 30-minute walking exercises per week to assess their activity levels. Weekly collaborations between the principal investigator and each participant will be conducted to assess step-related parameters.
75886891|NCT05959239|Drug|TB006|TB006 will be provided as single-use injectable glass vials.
75886892|NCT05959226|Behavioral|Exercise Intervention|"Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..~Exercise: under the guidance of the rehabilitation therapist, the patient gradually recovers Exercise from discharge (7-14 days after the operation) to 6 months after the operation, and should ensure at least 150 minutes of moderate intensity exercise or a combination of equivalent activities per week;"
75886893|NCT05959226|Dietary Supplement|Nutrition Intervention|(1) Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..
75886894|NCT05959187|Diagnostic Test|pharmacogenomic testing|Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response
75444629|NCT02098512|Drug|Brentuximab Vedotin|"Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1"
75444630|NCT02098512|Procedure|Allogeneic Stem Cell Transplantation|Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
75444631|NCT02098512|Drug|Reduced Intensity Conditioning|Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
75738057|NCT04766086|Biological|Tetanus, diphtheria, and acellular pertussis vaccine|Tetanus, diphtheria, and acellular pertussis vaccine
75738058|NCT04766086|Biological|Placebo|Saline control
75444632|NCT02066636|Drug|Nivolumab|
75444633|NCT02036086|Drug|Vemurafenib|Drug
75444634|NCT02036086|Drug|Cobimetinib|Drug
75444635|NCT01878435|Other|SMS reminder|
75444636|NCT01878435|Other|Travel subsidy|
75444637|NCT01878435|Other|Travel subsidy 2|
75738059|NCT04717986|Drug|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
75738060|NCT04717986|Drug|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
75738061|NCT04689529|Diagnostic Test|Preoperative imaging study|MRI, Breast ultrasound sonography, mammography
75738062|NCT04687137|Drug|TAK-743 300 mg|TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks
75738063|NCT04678102|Drug|PHI-101 administration|Escalated doses of PHI-101 will be administered to each cohort.
75738064|NCT04648436|Other|Early neurosurgical hematoma evacuation|Early neurosurgical hematoma evacuation (preferably within 2 hours)
75738065|NCT04648436|Other|Conservative treatment (best medical management)|Conservative treatment (best medical management) on the ICU or ward
75886895|NCT05959174|Device|3D printed mitchigen appliance|the process of appliance construction done by intra-oral scanning of the arch and 3d printing
75886896|NCT05959174|Device|side chair appliance|the impresion will be taken to make a cast to reconstruct the appliance
75886897|NCT05959161|Procedure|DBS|We observed the prognostic changes of patients after DBS surgery
75886898|NCT05959148|Other|Monochromatic infrared energy|The monochromatic infrared energy was delivered through an Anodyne Therapy Professional Infrared Therapy System. Light energy (parameter: a wavelength of 890 nm and radiant power at a rate of 6.24 W) was produced through 8 array diode therapy pads applied on both knees (on the medial, lateral, anterior, and posterior aspects of each knee), each including 60 super-luminescent gallium-aluminum arsenide diodes. The MIRE was applied for 40 minutes/session, three times a week, for three successive months.
75886899|NCT05959148|Other|Traditional physical therapy|The traditional physical therapy program consisted of stretching and strengthening exercises for the muscles surrounding the hip and knee, balance exercises, as well as other electrotherapeutic modalities (ultrasound and hot application).
75886900|NCT05959122|Diagnostic Test|CBC serum iron serum ferritin|"Fully automated blood cell counter (sysmex-Xs 800i) and AU 480-Chemistry auto-analyzer (Beckman Coulter Diagnostics-USA) was used for measurement of hemoglobin and serum iron levels~Chemiluminescence assay using an Abbott i2000SR analyser was used to measured serum ferritin"
75594419|NCT01609920|Drug|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
75886901|NCT05958992|Other|E-cigarette|Participants will self-administer experimenter-provided e-cigarettes
75886902|NCT05958979|Other|Control Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
75886903|NCT05958979|Other|Experimental Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
75738066|NCT04643106|Procedure|Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)
75886904|NCT05958966|Other|E-cigarette e-liquid self-administration|Participant will self-administer an experimenter-provided e-cigarette.
75886905|NCT05958953|Procedure|Induction of Labor IoL|Center-specific IOL protocols, based on international guidelines, will be used.
75886906|NCT05958940|Procedure|Bright Light Therapy|In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR < 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
76057334|NCT04179305|Behavioral|Oncolo-GIST|"Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
76057335|NCT04179305|Behavioral|Usual Care Arm|Oncologists will provide care in non-specific manner.
76057336|NCT02019719|Drug|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
76057337|NCT02019719|Drug|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
76057338|NCT02030405|Drug|Ixazomib|Given orally (PO)
76057339|NCT01975376|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
75444638|NCT01719146|Other|Specimen collection|At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
76057340|NCT01975376|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
75738067|NCT04643106|Procedure|suturing with barbed sutures during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding
75444639|NCT01486264|Biological|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
75444640|NCT01323270|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
75738068|NCT04636437|Drug|Doravirine 100 Mg|Participants will receive 100 mg tablet by mouth daily with or without food.
75444641|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
75444642|NCT01323270|Biological|Saline|0.5 mL dose, given at 0, 2 and 6 months.
75444643|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
75594420|NCT04527458|Other|Patient Characteristics|Characteristics of the patients
75594421|NCT04527458|Other|COVID-19 treatments|Specific treatments used on COVID-19 patients
75594422|NCT04527458|Other|Differences in triage|Triage criteria for treating COVID-19 patients
75594423|NCT04527458|Other|Surge capacity|Capacity of hospitals
75594424|NCT01609959|Drug|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
75594425|NCT01609959|Drug|Valsartan|Valsartan 160 mg per day
75738069|NCT04636437|Drug|Tenofovir alafenamide/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
75886907|NCT05958940|Device|Blue Light Blocking Glasses|Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
75886908|NCT05958914|Diagnostic Test|Dosage of ematic CGRP|Immunoassay kit for the evaluation of CGRP in blood
75886909|NCT05958914|Diagnostic Test|Dosage of ematic SP|Immunoassay kit for the evaluation of SP in blood
75886910|NCT05958914|Diagnostic Test|Dosage of ematic enkephalins|Immunoassay kit for the evaluation of enkephalins in blood
75886911|NCT05958914|Diagnostic Test|Dosage of ematic VIP|Immunoassay kit for the evaluation of VIP in blood
76057341|NCT01443130|Drug|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
76057342|NCT01443130|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
75594426|NCT01649726|Procedure|Apnea test - control|
75444644|NCT01300728|Drug|NewGam 10% IVIG|"Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo."
75594427|NCT01649726|Procedure|Apnea test - CPAP|
76057343|NCT04065256|Other|Personalized music|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
75444645|NCT01300728|Other|Placebo|Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
75444646|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
75594428|NCT01609998|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
75594429|NCT01609998|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
75594430|NCT04527263|Diagnostic Test|measurement of urinary 5-HIAA|urinary assessment of 5-HIAA
75738070|NCT04636437|Drug|tenofovir alafenamide/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
75738071|NCT04636437|Drug|Integrase strand transfer inhibitors|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
75738072|NCT04636437|Drug|tenofovir disproxil fumarate/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
75444647|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
75594431|NCT01649882|Procedure|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
75594432|NCT01685528|Behavioral|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
75594433|NCT01600755|Biological|Autologous Muscle-Derived Cells (AMDC)|Cell Treatment
75444648|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
75444649|NCT01299480|Biological|Vaccine|rLP2086 at visits 1 and 3, saline at visits 2 and 5
75444650|NCT01299480|Biological|Vaccine|rLP2086 at visits 3 and 5, saline at visits 1 and 2
75594434|NCT01685645|Device|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
75738073|NCT04636437|Drug|tenofovir disproxil fumarate/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
75738074|NCT04622774|Drug|IMGC936|Antibody Drug Conjugate
75738075|NCT04615078|Device|ETAPES Program|"The Chronic Care Connect Pneumology is a remote medical monitoring solution, combining:~A technical solution for the transmission and analysis of ventilator data, leading to alerts generated by an algorithm ;~An organizational solution relying on a nurse call center."
75738076|NCT04600648|Diagnostic Test|Serum insulin level|Measure levels before and after weight loss related to bariatric surgery
75738077|NCT04600648|Diagnostic Test|Serum Leptin test|Measure levels before and after weight loss related to lifestyle change weight loss
75886912|NCT05958914|Diagnostic Test|Dosage of CGRP in follicolar fluid|Immunoassay kit for the evaluation of CGRP in follicolar fluid
75886913|NCT05958914|Diagnostic Test|Dosage of SP in follicolar fluid|Immunoassay kit for the evaluation of SP in follicolar fluid
75886914|NCT05958914|Diagnostic Test|Dosage of enkephalins in follicolar fluid|Immunoassay kit for the evaluation of enkephalins in follicolar fluid
75886915|NCT05958914|Diagnostic Test|Dosage of VIP in follicolar fluid|Immunoassay kit for the evaluation of VIP in follicolar fluid
75444651|NCT01680419|Behavioral|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
75886916|NCT05958901|Other|pulmonary hypertension|The final outcome observed was a diagnosis of pulmonary hypertension.
75886917|NCT05958849|Drug|Sovalteinib Solutumab Tegeo|Soventinib in combination with solutumab and tegeo for advanced pancreatic cancer
76057344|NCT04065256|Other|Personalized music plus earplug|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
75444652|NCT01680419|Behavioral|PREP|"The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others."
75444653|NCT01680705|Other|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
75444654|NCT01681017|Behavioral|HBB/ENC Training and Equipment|See the detailed description section
75594435|NCT01649921|Drug|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
75594436|NCT01649921|Other|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
75594437|NCT01606566|Drug|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
75594438|NCT01644968|Drug|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
75594439|NCT01644968|Drug|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
75444655|NCT01681017|Other|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
75444656|NCT01681225|Other|Esophageal-pressure guided mechanical ventilation|
75444657|NCT01681225|Other|High PEEP mechanical ventilation|
75594440|NCT01644968|Drug|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
76057345|NCT01436500|Drug|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
76057346|NCT01436500|Drug|Placebo|Sterile water with 5% Dextrose
75594441|NCT01644968|Biological|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
75594442|NCT01644968|Biological|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
75594443|NCT01644968|Biological|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
75594444|NCT01644968|Biological|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
75594445|NCT01605708|Drug|REGN846|Dose 1
75738078|NCT04600180|Procedure|sigmoidoscopies and and venous blood sampling|Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.
75738079|NCT04542161|Drug|NAC 900mg/day|self administer NAC 900mg/day caplets for a four week period
75738080|NCT04542161|Drug|NAC 3600mg/day|self administer NAC 3600mg/day caplets for a four week period
75738081|NCT04542161|Drug|NAC 0mg/day (Placebo)|self administer NAC 0mg/day (placebo) caplets for a four week period
75738082|NCT04504812|Drug|Duloxetine|Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.
75738083|NCT04504812|Combination Product|Intra-Articular Injection|Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1mL depo methylprednisolone (a steroid) and 2mL 0.5% bupivacaine (an anesthetic) into the knee.
75738084|NCT04504812|Procedure|Nerve Procedure with long acting blocks|People assigned to receive this will have 1mL of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.
75738085|NCT04504812|Procedure|Nerve Procedure with nerve ablation|People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.
75886918|NCT05958836|Device|pacemaker|Micra TPS or traditional PM group
75886919|NCT05958823|Procedure|Serratus anterior plane block|Serratus anterior plane block
75886920|NCT05958823|Procedure|PECS I-II|PECS I-II
75886921|NCT05958810|Drug|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to <16kg); 2 tablets (15 to <25kg); 3 tablets (25 to <35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old)"
75886922|NCT05958810|Drug|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
75886923|NCT05958797|Drug|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance
75886924|NCT05958797|Drug|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
75886925|NCT05958784|Dietary Supplement|L-Phenylalanine|100 mg/kg
75886926|NCT05958771|Drug|ROTAVAC 5D|monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells. Each dose contains NLT 10 e 5.0 FFU
75886927|NCT05958771|Drug|Placebo|Placebo contains all the excipients of ROTAVAC 5D but without the suspension of live attenuated rotavirus
75886928|NCT05958758|Drug|Psilocybin-assisted therapy within a community of practice model (group administered)|The community of practice is 10 weeks long, meeting virtually for 2 hours each week, in a structured process, run through the Roots to Thrive treatment program. The psilocybin-assited therapy sessions occur midway through the 10-week program.
75444658|NCT01681238|Procedure|Protocol group 2|ensure SpO2≥ 92%, MAP 65-100 mmHg, HR <100 bpm, Hb> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
75886929|NCT05958745|Behavioral|Aerobic Exercise|Aerobic exercise training Program
75594446|NCT01685723|Behavioral|Counseling group|Subjects will receive brief advice based on risk communication by a nurse counselor. The brief advice will be based on a specifically-designed risk communication leaflet that warns about the risks of continued smoking for subjects' cancer treatment and prognosis. Subjects will receive a booster intervention via telephone at 1 week to assess the progress of and barriers to the subjects' action plans and identifying individual difficulties and facilitators towards quitting. They also receive a generic standard self-help smoking cessation booklet.
75738086|NCT04504812|Behavioral|Pain Coping Skills Training|Participants will be provided with a written manual that includes login information for the pain coping skills training website. They will be expected to log into the system weekly, work through the modules, and participate in skills practice. This intervention will be conducted in combination with best practices and duloxetine.
75886930|NCT05958745|Behavioral|Aerobic + resistance exercise|Aerobic + resistance exercise training Program
75886931|NCT05958732|Other|Somato-sensorial exercises therapy|It includes exercises, which is already mentioned in the arm description.
75886932|NCT05958732|Other|Conventional Therapy|It Includes routine exercises for the stroke patient the detail is already given in the arm description.
75886933|NCT05958719|Drug|Chidamide|chidamide 30mg biw, p.o, 28 days for a cycle.
75594447|NCT01685723|Behavioral|General supporting|Subjects in this group will receive a generic self-help smoking cessation booklet and standard care without risk communication. They will have the same follow-up sections as the intervention group to receive diseases support.
75886934|NCT05958719|Drug|Azacitidine|75mg/m2, continuous i.h. on day 1-7，28 days for a cycle.
75738087|NCT04504812|Other|Best Practices|Best Practice includes treatments that experts recommend for knee arthritis pain. Best Practice can include topical or oral pain relievers, a structured exercise program, and weight management if BMI is over 30. Other non-invasive treatments such as acupuncture and yoga are also included.
75738088|NCT04469595|Drug|Iluvien 0.19 MG Drug Implant|0.19 mg Fluocinolone Acetonide Intravitreal Implant
75886935|NCT05958290|Other|Discontinuation of antibiotics|Discontinuation of antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total.
75886936|NCT05958251|Other|Cicaben|Cicaben® powder is an association of special active ingredients for topical dermatological use with a healing, soothing and protective action (zinc oxide, magnesium oxide, corn starch, arnica montana extract, allantoin and undecylenic acid, arginine, glycine and proline, niacinamide).
75738089|NCT04469595|Drug|Aflibercept|2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
75738090|NCT04399460|Other|Dairy-based commercially available food products|Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses
76057347|NCT01958827|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
76057348|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 1 Hz|active rTMS delivered at 1Hz frequency over temporal cortex
75444659|NCT01681238|Procedure|Protocol group 1|The goal of this protocol is to ensure MAP> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP <8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
75886937|NCT05958043|Device|3D- printed Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
75886938|NCT05958043|Device|CAD/CAM-milled Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
75886939|NCT05956938|Device|Stroboscopic Glasses|"A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account a gradual increase in the difficulty of the task, divided into three visuomotor and anticipation components (ball size, type of trajectory and distance from the stimulus).~The training sessions will consist of 2 series, and will be based on passing a ball between two people. Every 60 passes the flicker level of the glasses will increase, starting with level 1 (6hz) and ending at level 6 (1.75hz)"
75886940|NCT05956938|Device|Action Video Game|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account an increase in the difficulty of the task gradually based on the nature of the video game. The video game selected will be ContraIII: Alien Wars, from the Nintendo Mini Classic console.
75886941|NCT05956756|Behavioral|Health and resiliency programming|Students will engage in resilience programming as part of their regular coursework including mindfulness training, lifestyle medicine interventions, and creating a coping plan.
75886942|NCT05956314|Drug|IMP Application KM-001|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
76057349|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 10 Hz|active rTMS delivered at 10 Hz frequency over temporal cortex
76057350|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz|active rTMS delivered at either 1 Hz frequency over the vertex
76057351|NCT01620086|Device|Sham control site Repetitive Transcranial Magnetic Stimulation|sham rTMS delivered at 1Hz frequency over the vertex
76057352|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz|Active 10 Hz rTMS delivered over the vertex
76057353|NCT04670653|Drug|MAGNÓLIA NASAL GEL|Magnólia nasal gel spray
75594448|NCT01605162|Drug|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
75594449|NCT01605162|Drug|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
76057354|NCT04670653|Drug|MOMETASONE FUROATE|Mometasone furoate nasal spray
76057355|NCT01436110|Drug|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
75444660|NCT01681251|Other|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|"Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV."
75594450|NCT01649999|Drug|peficitinib|oral
75594451|NCT01649999|Drug|Placebo|oral
75594452|NCT01604889|Drug|Epacadostat|
75594453|NCT01604889|Drug|Placebo|Placebo
75594454|NCT01604889|Drug|ipilimumab|ipilimumab 3 mg/kg IV
75594455|NCT01604889|Drug|ipilimumab|Doses to be determined following the completion of Phase I of the study
75594456|NCT01685762|Drug|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
75594457|NCT01685879|Other|Rice|Rice portion containing 50 g total carbohydrate
75594458|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
75594459|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
75738091|NCT04399460|Other|Restrictive Eating|Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein
75738092|NCT04370496|Procedure|Minimally invasive surgery using endoscopic stapler|Radical hysterectomy by minimally invasive surgery (laparoscopic or robotic) will be done with the help of an endoscopic stapler in cutting and suturing the uterine cervix.
75738093|NCT04331340|Other|Pharmacist review of LUTS|Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications
75738094|NCT04331340|Other|Pharmacist Provision of healthy aging leaflets|Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
75738095|NCT04294407|Other|No intervention|no intervention in this study
75738096|NCT04254796|Behavioral|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
75738097|NCT04250636|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30mg/kg
75738098|NCT04250636|Drug|10-1074-LS|Intravenous infusion of 10-1074-LS at 30mg/kg
75738099|NCT04233749|Drug|Tranexamic acid tablets|325mg of tranexamic acid twice daily for six months
75886943|NCT05956314|Diagnostic Test|Physical Examination|"A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, and at ET visit):~The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~Symptom-directed physical examinations will be performed at all other trial visits.~Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination."
75444661|NCT01681251|Other|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
75444662|NCT01681446|Drug|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
75444663|NCT01681602|Other|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
75594460|NCT01685879|Other|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
75594461|NCT01602822|Drug|3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir|TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
75886944|NCT05956314|Diagnostic Test|Vital Signs|"Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, and at ET visit. Vital signs will be measured in supine position after at least 5 minutes of rest.~Will be examined pre-dose at Visit 2 (Day 1, enrolment)."
76057356|NCT01436110|Drug|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
76057357|NCT01436110|Drug|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
76057358|NCT01619852|Drug|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
75444664|NCT01681615|Drug|Acetylsalicylate|1-2 drops
75444665|NCT01681615|Drug|Isotonic NaCl|1 drop
75444666|NCT01681797|Device|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
75444667|NCT01681875|Other|very low nicotine content cigarettes|
75594462|NCT01602822|Drug|Ritonavir, Atazanavir, Truvada|
75616289|NCT02844478|Behavioral|SBP SPANISH|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
75738100|NCT04231851|Drug|Glasdegib|Given PO
75738101|NCT04231851|Drug|CPX-351|Given IV
75738102|NCT04225897|Drug|RV521|RV521 is an RSV F protein inhibitor administered orally
75738103|NCT04225897|Drug|Placebo|vehicle administered orally
75738104|NCT04201561|Drug|sodium selenite pentahydrate|High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.
75738105|NCT04201561|Drug|Normal saline|Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
76057359|NCT01619852|Drug|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
76057360|NCT04069936|Biological|MILs™ - NSCLC|To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
76071957|NCT03608631|Drug|Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|Given IV
75886945|NCT05956314|Diagnostic Test|Serum chemistry|"Approx. 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments at the screening visit, on Days 1 (baseline), 7, and 84 (EoT), at the follow-up visit on Day 112 or ET visit. Serum chemistries will include assessment of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.~Will be examined pre-dose at Visit 2 (Day 1, enrolment)."
75444668|NCT01681953|Drug|Lamazym|ERT, i.v. infusions weekly
75886946|NCT05956314|Diagnostic Test|Hematology|Approx. 5 mL whole blood will be collected for complete blood count (CBC) at the screening visit, on Days 1 (baseline), 7, and 84 (EoT), at the follow-up visit on Day 112 or at ET visit. The CBC assessment will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute [abs.]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
75886947|NCT05956314|Diagnostic Test|Serology|Approx. 5 mL whole blood will be collected for serology assessments at the screening visit. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
75886948|NCT05956314|Diagnostic Test|Urinalysis|General urinalysis will be performed, by dipstick, at the screening visit, on Days 1 (baseline), 7, and 84 (EoT), at the follow-up visit on Day 112 and at ET visit. At least 7 to 10 mL urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
76057361|NCT04069936|Biological|nivolumab|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC
76057362|NCT04069936|Drug|tadalafil|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
76057363|NCT02000882|Drug|BKM120|
75594463|NCT01644344|Other|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
76057364|NCT02000882|Drug|capecitabine|
76057365|NCT02000882|Drug|Trastuzumab|
76057366|NCT01965938|Device|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
75594464|NCT01644344|Other|Xray|
75444669|NCT01681953|Drug|Placebo|Infusions weekly
75594465|NCT02273154|Drug|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
76057367|NCT01965938|Device|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
76057368|NCT01965860|Other|additional curriculum (E-learning + simulation)|
75444670|NCT01682239|Other|RVAP|In this arm pacemaker leads will be placed in the RV apex.
75444671|NCT01682239|Other|RVSP|In this arm pacemaker leads will be placed in the RV septum.
75444672|NCT06225388|Other|Compression socks|A pair of socks corresponding to the intervention allocated will be given to the participant, by an investigator who will not participate in the evaluation, in a dark plastic bag to avoid any visual influence. We will adopt strategies to prevent information about the socks from influencing the participants' behaviour: (1) the compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
75444673|NCT06225388|Other|Placebo socks|The compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
75444674|NCT06225375|Device|Restorelle® Flat Mesh|Pelvic organ prolapse repair using Restorelle® Flat Mesh
75738106|NCT04201561|Drug|Chemotherapy|Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
75738107|NCT04190589|Device|Robot-assisted laparoscopic extended right colectomy|An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons
75738108|NCT04162873|Drug|Celecoxib|Given PO or via feeding tube
75738109|NCT04162873|Other|Placebo|Given PO or via feeding tube
75738110|NCT04162873|Other|Quality-of-Life Assessment|Ancillary studies
75738111|NCT04162873|Other|Questionnaire Administration|Ancillary studies
75738112|NCT04151602|Behavioral|Smoked illicit drug use|The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
75738113|NCT04097184|Device|Neurostimulation with non-implanted electrodes|Neurostimulation with non-implanted electrodes
75738114|NCT04081220|Drug|IMG-7289|Single starting dose with individualized dose titrations throughout
75738115|NCT04061421|Drug|ASTX727|Taken by mouth daily during days 1-5 of every 28-day cycle.
75594466|NCT02273154|Drug|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
75738116|NCT04061421|Drug|Itacitinib|Taken by mouth daily during each 28-day cycle
76057369|NCT01965860|Other|additional E-learning|
75594467|NCT01644656|Device|ARFI ultrasound|ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
75886949|NCT05956314|Diagnostic Test|ECG test|A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84 and 112, and at ET visit After the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTC interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
75444684|NCT06225310|Drug|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in t
75594468|NCT01607541|Behavioral|BCAP peer-driven intervention (PDI)|"The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation)."
75616290|NCT02845648|Drug|anticholinergic|Initial anticholinergic therapy to all patients
75444685|NCT06225310|Drug|Ruxolitinib|elective inhibitor of Janus kinase (JAK)
75444686|NCT06225310|Drug|Methylprednisolone|Glucocorticoid, steroid
75738117|NCT04046900|Biological|Vaginal microbiome transplant|Vaginal fluid from healthy donors
75738118|NCT04046900|Drug|Oral Metronidazole|500mg oral metronidazole twice daily for 7 days
75738119|NCT04046900|Other|Sterile saline|700 uL of sterile saline placed in the vagina as a placebo intervention.
75738120|NCT03989115|Drug|RMC-4630|RMC-4630 for oral administration
75738121|NCT03989115|Drug|Cobimetinib|Cobimetinib for oral administration
75738122|NCT03989115|Drug|Drug: Osimertinib|Osimertinib for oral administration
75738123|NCT03971071|Drug|Erenumab 70 mg|Erenumab once every 4 weeks. Subcutaneous injection.
75738124|NCT03971071|Drug|Erenumab 140 mg|Erenumab once every 4 weeks. Subcutaneous injection.
75738125|NCT03971071|Drug|Placebo|Placebo once every 4 weeks. Subcutaneous injection.
75738126|NCT03946748|Drug|REGN3918|Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
75738127|NCT03937843|Drug|Carboplatin|Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
75738128|NCT03937843|Drug|Cisplatin|"Patients in cohort 2 will receive on day 1 to day 5:~a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
75738129|NCT03937843|Drug|Etoposide|"Patients in cohort 2 will receive on day 1 to day 5:~a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
76057370|NCT04415827|Diagnostic Test|bicycle ergometry test with spiroergometry|"The 1st testing will be carried out on the 28-31th day of the disease, which corresponds to the period of the expected normalization of temperature, improvement of well-being, positive dynamics of radiological (with community-acquired pneumonia) and laboratory data, the 2nd test - after 3 months, the 3rd - after 6 months and IV - after 12 months.~Load testing will be carried out on a bicycle ergometer with an initial power of 25 watts with a further increase of 25 watts every 3 minutes. The cessation of the load will be carried out upon the appearance of signs set forth in the recommendations of the World Health Organization Expert Committee (1970)"
76057371|NCT04416061|Diagnostic Test|COVID 19 Diagnostic Test|COVID 19 Diagnostic Test
76057372|NCT04666129|Drug|Relugolix|"(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day."
76057373|NCT04666129|Drug|Abiraterone|Abiraterone acetate (1000 mg [2 x 500-mg tablets]) or fine-particle abiraterone acetate (500 mg [4 x 125-mg tablets]) will be administered orally once daily.
76057374|NCT04666129|Drug|Prednisone|"(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required."
75738130|NCT03896711|Behavioral|MEMORI Corps program|Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.
76057375|NCT04666129|Drug|Methylprednisolone|For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
75444687|NCT06225297|Combination Product|Intervention package|Intervention package will include vector control through meganets (multiple insecticide-treated mosquito nets sewn together), seasonal malaria chemoprevention (SMC) extended to all ages using DHA-PQ, and behavior change communication.
76057376|NCT04666129|Drug|Apalutamide|Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
75594469|NCT01607541|Behavioral|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
75594470|NCT01644851|Behavioral|Executive function training|Computer-based training in executive functions, administered via www.lumosity.com website.
75594471|NCT01603836|Biological|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
75594472|NCT01645046|Drug|Coenzyme A|Coenzyme A 200mg per day.
75594473|NCT01645046|Drug|Coenzyme A|Coenzyme A 400mg per day.
75594474|NCT01645046|Drug|Placebo|Capsule without coenzyme A.
75616291|NCT02844166|Other|viscoelastic surface support|Patients will be placed in an ICU bed with viscoelastic surface support
75616292|NCT02844166|Other|pyramidal foam surface support|Patients will be placed in an ICU bed with pyramidal foam surface support
75616293|NCT03337906|Other|Observation|
75616294|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
75886950|NCT05956314|Diagnostic Test|Pharmacokinetics Assessments|"Blood samples for PK will be collected at screening (Day -1 to -7) at any time during the visit, on Days 7 and 84 (EoT) at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28 and 42 visit: 1 sample after the first dose, before the second dose, as late as possible in the visit, on Day 112 and ET visit: at any time during the visit.~• Altogether approx. 24 mL of blood will be withdrawn for PK at the screening and on Days 7, 28, 42, 84, and 112 or at ET visit."
75738131|NCT03896711|Other|Augmented Waitlist Control|"Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm."
75738132|NCT03839823|Combination Product|Docetaxel / Capecitabine|"Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)"
75886951|NCT05956314|Diagnostic Test|Clinical global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator at screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, and at ET visit).~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
75886952|NCT05956314|Diagnostic Test|Visual Analogue Scale (VAS) pain scale|"The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The score will be collected on every in-clinic visit during the treatment period (Days 1, 7, 28, 42, 63, 84, and ET visit).~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
76057377|NCT04666129|Drug|Docetaxel|Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
76057378|NCT04666051|Biological|Application of fibrin glue sealant|
76057379|NCT01965704|Drug|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
75616295|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
75616296|NCT00952419|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
75616297|NCT02000037|Device|IR Reflexotherapy|"18 IR reflexotherapy sessions :~Once a week for 12 weeks at the beginning of the study~Once a week for 3 weeks, 9 months after the beginning of the study~Once a week for 3 weeks, 15 months after the beginning of the study"
75616298|NCT02000037|Behavioral|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
75616299|NCT04259541|Diagnostic Test|Psychodiagnostic|Intensity and frequency of specific symptoms, signs of problems in mental health
75616300|NCT00902278|Biological|Flulaval|one 0.5-mL dose via intramuscular injection
75616301|NCT00902278|Biological|Fluvirin|one 0.5-mL dose via intramuscular injection
75616302|NCT00902278|Biological|Fluzone|one 0.5-mL dose via intramuscular injection
75616303|NCT00902278|Biological|Fluarix|one 0.5-mL dose via intramuscular injection
75616304|NCT00902278|Biological|Afluria|one 0.5-mL dose via intramuscular injection
75738133|NCT03839823|Combination Product|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day [oral] or (25 to 30 mg/m2 [IV infusion]"
75738134|NCT03839823|Combination Product|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)"
75738135|NCT03839823|Drug|Ribociclib|Dose: 600 mg (200 mg * 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
75738136|NCT03839823|Drug|Letrozole OR Anastrozole|"Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician."
75738137|NCT03839823|Drug|Goserelin|"Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant"
75738138|NCT03822702|Other|Biofeedback Training|Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.
75444689|NCT06225271|Behavioral|the combined intervention of exercise, fruit, and vitamin supplementation|"Group intervention~After each intervention, investigators will hold a 15-minute communication and discussion session for the participants. Besides, community health workers will organize at least one health education activity per week during the intervention for no less than 45 minutes.~Individual intervention~Physical activity~The participants will be gathered at the community activity center or day care center. The participants will be allowed to exercise in a way that interests them. The duration of exercise should be longer than 30 minutes.~Fruit supplementation~Consideration of seasonal supply situation and the participants' diabetic status, various types of fruit will be prepared. The fruit will be divided into 50g/100g servings. Participants will be required to eat on site.~Vitamin supplementation~During the intervention, the participants will be required to take 1 tablet of vitamin B complex plus 1 tablet of vitamin C every day."
75594475|NCT01605006|Device|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
76057380|NCT01965704|Drug|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
75594476|NCT01606215|Drug|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
75594477|NCT01606215|Drug|Placebo|Placebo
75594478|NCT01607775|Device|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
75594479|NCT01607775|Device|PMMA-cage|The in-house produced cervical cage will be implanted
75738139|NCT03822702|Other|Motor Training|Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
76057381|NCT02003365|Drug|FX006 10 mg|Extended-release formulation
76057382|NCT02003365|Drug|FX006 40 mg|Extended-release formulation
76057383|NCT02003365|Drug|TCA IR 40 mg|Immediate-release formulation
76057384|NCT01975220|Drug|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
76057385|NCT01975220|Drug|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
75594480|NCT01685957|Behavioral|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
75738140|NCT03805009|Device|Robot-Assisted Gait Training (RAGT)|The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
75738141|NCT03800927|Device|Long duration ultrasound|Low-intensity long duration ultrasound treatment
76057386|NCT01975220|Drug|25 mg Empagliflozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
76057387|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
76057388|NCT01975220|Drug|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
75886953|NCT05956314|Diagnostic Test|Peak pruritus-numerical rating scale (PP-NRS)|"The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The scores will be collected on every in-clinic visit (Days 1, 7, 28, 42, 63, 84) and at ET visit.~The PP-NRS was designed to measure peak pruritus, or worst itch, over the previous 24 hours based on the following question: On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?"
75886954|NCT05956314|Diagnostic Test|Patient global impression of change (PGI-C) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, and at ET visit.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows:~Since the start of the trial, my overall status has:~from, 1= very much improved to 7= very much worse"
75444690|NCT06225258|Dietary Supplement|Xanthohumol|Patients, who received Xanthohumol (Chmiel-Xn-Active, SALUTIS Pharmacy, Poland) as adjunctive therapy to treatment recommended by Surviving Sepsis Campaign. Xanthohumol is administrated by the nosogastric tube three times a day *every 8 hours) at the dose of 2 mg.\/kg body weight for 10 days. The first dose of Xanthohumol is administrated within 4 hours after the admission to the ICU.
75444691|NCT06225245|Device|Epidural Spinal Stimulation (ESS)|ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) [31-33]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
75444692|NCT06225232|Drug|Psilocybin combined with Psychotherapy|The intervention consists of a 9-week treatment protocol that is based on supportive psychotherapy and Motivational Enhancement Therapy. Overall, the therapy course includes 8 motivational enhancement therapy sessions and two experimental drug sessions.
75738142|NCT03797898|Other|Parent Coach|The Parent Coach intervention uses a health educator who provides anticipatory guidance, psychosocial screening/ referral, and developmental/behavioral surveillance, screening, and guidance at each well-visit. The Parent Coach uses a parent-focused, pre-visit questionnaire to customize the visit to the parents' needs. Every well-visit includes a brief, problem-focused encounter with a clinician for a physical exam and any concerns that require a clinician's attention. Finally, an automated text message service provides for periodic, age-specific messages to reinforce key health messages from Parent Coach-led well-visits.
75738143|NCT03787680|Drug|Olaparib|300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
75444693|NCT06225219|Behavioral|Counseling|To introduce a model of holistic care to the patient populations served by the GCAC through chaplain interventions that focus on spiritual and emotional health.
75444694|NCT06225206|Behavioral|donor-derived cell free DNA in liver|Determine the difference in age, gender, LFTs, IS regimen (tacrolimus/sirolimus/cyclosporin with mycophenolate mofetil (MMF) and /or prednisone) between patients who underwent liver transplant <1 year PTX and >1 year PTX
75594481|NCT01685957|Behavioral|"Ned i vaegt (NIV)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation."
75738144|NCT03787680|Drug|AZD6738|160 mg by mouth daily for days 1-7 of a 28-day cycle.
75738145|NCT03772899|Drug|Fecal Microbial Transplantation|"All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017."
75738146|NCT03743636|Drug|Nicotinamide riboside|Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
75738147|NCT03743636|Drug|Resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.
75738148|NCT03743636|Other|Placebo|Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
75738149|NCT03726775|Drug|Durvalumab|Infusion of durvalumab during RT and after RT during 6 months
75886955|NCT05956314|Diagnostic Test|Patient global impression of severity (PGI-S) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, and at ET visit.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe"
75738150|NCT03718039|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
76057389|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
75444695|NCT06225167|Behavioral|To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.|"To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.~To compare the incidence of overt GI bleeds (defined as hematemesis, bloody nasogastric tube aspirate, or melena) between patients who were on stress ulcer prophylaxis versus patients whose acid suppression therapy was discontinued through the stress ulcer prophylaxis minimization protocol."
75444697|NCT06225141|Other|Clinical Data reuse|Clinical Data reuse
75444698|NCT06225128|Other|Biobanking blood|Additional volume of 30mL (EDTA) At Screening, pre-Cycle 1 Day 1,Day 1 H8, Day 2, and Day of post-cycle 1 evaluation.
75444699|NCT06225128|Other|Bone marrow specimens|"Additional volume of 2mL (EDTA)~at screening for correlative studies and at Day 7 for smears and for correlative studies.~Day 1 and day 6 post-cycle evaluations for correlative studies.~Trephine biopsy at screening and at post-cycle 1 and 6 evaluations (performed at the same time as aspiration)"
75738151|NCT03718039|Device|Luer Lock applicator|Applicator for instillation.
75738152|NCT03718039|Device|Vial access device|Device for withdrawal of drug product.
75738153|NCT03718039|Drug|aprepitant|Aprepitant, three single doses of aprepitant will be administered orally.
75738154|NCT03688165|Device|Treadmill-based Robotic Gait Training|All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
75738155|NCT03681080|Procedure|leg crossing|As Counter maneuvre legs will be crossed and cognitive tests will be performed.
75738156|NCT03635164|Drug|Durvalumab|Patients will receive one dose of neoadjuvant durvalumab 1500 mg approximately 3-6 weeks prior to standard of care surgery. It will be given concurrently with the first dose of radiation (RT). Patients will receive up to six doses of durvalumab and radiation post-operatively.
75738157|NCT03635164|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The starting RT dose level will be given as 6 Gy for 2 fractions (12 Gy total) every other day over approximately one week to sites of gross disease only to minimize exposure to normal tissue. If toxicity develops and surgery is delayed by more than 8 weeks (qualifying as a DLT), the radiation dose will be dropped per protocol for the next set of patients. If this dose is tolerated, the dose will be increased to 6 Gy for 3 fractions (18 Gy total) for the next 3 patients.
75738158|NCT03635164|Procedure|Standard of Care Therapy|Patients will proceed to surgical resection 3-6 weeks after radiation as recommended by the ENT surgeon.
75738159|NCT03602014|Drug|Northera|Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.
75738160|NCT03602014|Other|Placebo|Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
75738161|NCT03559192|Drug|JNJ-67953964|JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
75444700|NCT06225115|Drug|KYN-5356|KYN-5356, oral tablet
75444701|NCT06225115|Drug|placebo|placebo, oral tablet
75444702|NCT06225102|Behavioral|Kegel Exercise|"Before teaching Kegel exercises, it was recommended that the person empty his bladder and wear comfortable clothing.~It was said that the person should extend his legs straight while exercising and not to contract his leg, hip and abdominal muscles and not to hold his breath while the pelvic floor muscles contract.~The relevant muscles were told to contract for 10 seconds and then relax for 10 seconds. The person was also asked to do the exercises during daily activities.~Exercise was implemented regularly 3 times a day (minimum 30-45 exercises) in the morning, noon and evening."
75738162|NCT03559192|Drug|Placebo|Matching placebo will be administered as 2 capsules orally once daily.
75738163|NCT03552718|Biological|YE-NEO-001|Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
75738164|NCT03552471|Other|Laboratory Biomarker Analysis|Correlative studies
75738165|NCT03552471|Biological|Mirvetuximab Soravtansine|Given IV
75738166|NCT03552471|Other|Pharmacokinetic Study|Correlative studies
75738167|NCT03552471|Drug|Rucaparib Camsylate|Given PO
75886956|NCT05956314|Diagnostic Test|Lesion photography|"High-quality photographic documentation of the treated lesions will be performed on Days 1, 7, 42, 63, 84, 112 and at ET visit before treatment if applicable.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022)."
75738168|NCT03542409|Other|MR Perfusion Scan|MR perfusion scan before and during surgery.
76057390|NCT04665583|Other|Prehabilitation|Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
76057391|NCT01958437|Device|Transcranial direct current stimulation (tDCS)|Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
75594482|NCT01685957|Behavioral|"Verdens bedste kur (VBK)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals."
75738169|NCT03542409|Other|2HG Spectroscopy Scan|2HG spectroscopy scan before and during surgery.
75738170|NCT03542409|Other|Standard of Care Intraoperative MRI|The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples.
75738171|NCT03533946|Drug|Rucaparib|Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until PSA progression or intolerable toxicities.
75594483|NCT01602393|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
75769555|NCT03894982|Other|Group Classes|Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
75886957|NCT05956015|Other|stable isotopes|The tracer 2H5-phenylalanine is an essential amino acid labeled with deuterium that is a stable isotope, i.e. no radiation is emitted, but the tracer can still be assessed by a combination of gas chromatography and mass spectrometry. The tracer has no measurable effects, but are used for assessment of human physiology.
75886958|NCT05955976|Other|BIOPSY|biopsy
75886959|NCT05955885|Drug|Flurbiprofen Oral Lozenge|This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.
75886960|NCT05955885|Drug|Difflam|This is a non-medicated, control lozenge that is the same flavour as the experimental lozenge that is marketed to help soothe dry, tickly throats while supporting the body's immune health.
75594484|NCT01602393|Drug|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
75594485|NCT01602393|Drug|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
75738172|NCT03525951|Behavioral|Enhanced Milieu Teaching|The parent training will incorporate the EMT strategies of responsive interaction, matched turns, language modeling, and expansions. There will be three, hour-long parent training sessions following the teach-model-coach-review format (TMCR). The TMCR framework teaching component will involve 10 minutes of verbal and visual instruction on the language stimulation target of interest. The teaching component will be followed by 15 minutes of clinician modeling of the target strategies with the child while the parent watches. The parent will then have the opportunity to practice using the strategy during naturalistic interaction with their child. The clinician will provide individualized coaching on the use of the target strategy during this 20-minute, parent-child interaction. Finally, the clinician will review the target strategies and set goals.
76057392|NCT01974752|Drug|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
75738173|NCT03525951|Other|no intervention comparison group|No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.
75738174|NCT03523585|Drug|Trastuzumab deruxtecan|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
75594486|NCT02273076|Device|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
75594487|NCT02271789|Other|problematic tooth|problematic tooth
75594488|NCT01645787|Drug|4-aminopyridine|10 mg/twice daily
75594489|NCT01645787|Drug|Placebo|Crossover study involving one trial with sugar pill (placebo)
75738175|NCT03523585|Drug|Capecitabine|Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
75738176|NCT03523585|Drug|Lapatinib|Investigator's choice Standard of Care when combined with capecitabine
75738177|NCT03523585|Drug|Trastuzumab|Investigator's choice Standard of Care when combined with capecitabine
75738178|NCT03495986|Device|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
75738179|NCT03495986|Behavioral|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
75738180|NCT03493581|Procedure|BIOPSY|re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)
76057393|NCT01974752|Drug|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
76057394|NCT01974752|Drug|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
76057395|NCT01999946|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
76057396|NCT01958281|Drug|SOF|Tablet(s) administered orally once daily
75594490|NCT02270034|Drug|Crizotinib|Crizotinib is added to Stupp method
76057397|NCT01958281|Drug|RBV|200 mg tablet administered orally once daily
76057398|NCT01958281|Drug|LDV/SOF|90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
75594491|NCT01686113|Other|NEFA|
75594492|NCT01686113|Other|Sucrose|
75594493|NCT02270190|Device|Percutaneous Tibial Nerve Stimulation (PTNS)|
75594494|NCT01686230|Other|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
76057399|NCT04665115|Drug|Ibrutinib|Given PO
76057400|NCT04665115|Other|Quality-of-Life Assessment|Ancillary studies
76057401|NCT01958125|Device|gammaCore|Vagal stimulation
76057402|NCT02002975|Drug|Pioglitazone|Pioglitazone tablets
76057403|NCT02001181|Drug|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
75738181|NCT03493581|Diagnostic Test|blood-sampled|"after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),~after 6 weeks (V2),~after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),~- after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).~after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),~after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses)."
75738182|NCT03493581|Other|feces samples|If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
75738183|NCT03485911|Drug|BCX7353 capsules|BCX7353 oral capsules administered once daily
75738184|NCT03485911|Drug|Placebo oral capsule|Matching oral capsules administered once daily
75738185|NCT03470025|Other|Psychological Intervention|"F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR."
75738186|NCT03454256|Device|Virtual Reality|Virtual Reality Rehabilitation System
75738187|NCT03446690|Drug|MI Varnish|MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
75886961|NCT05955885|Drug|Flurbiprofen 8.75 MG|This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
75886962|NCT05955846|Procedure|cataract surgery|Subjects will undergo surgery to remove cataract (natural cloudy lens) via phacoemulsification implant the IOL Both eyes will be treated one month apart. Subjects will be followed up during 12 months
75886963|NCT05955846|Device|implantation of device IOL FG-80030.1|implant the IOL in both eyes. Both eyes will be treated one month apart. Subjects will be followed up during 12 months
75886964|NCT05952752|Other|giving dexemedetomidine 12 microgram Iv dripping|Patients in the studied groups will receive either or intravenous Dexemedetomidine 12 µg
75886965|NCT05952752|Other|Dexamethsone IV|4 mg IV dexamethasone
75886966|NCT05950789|Other|Virtual reality application|"During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.~With virtual reality glasses, patients watch three-dimensional video nature images, which we determined according to the patient's preference, accompanied by music. They put on the virtual reality glasses before the process started and removed them after the process was over."
75886967|NCT05950568|Procedure|Quadratus lumborum block typen II|A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer
76057404|NCT02001181|Drug|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
75886968|NCT05950568|Procedure|Quadratus lumborum block III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
75886969|NCT05950568|Procedure|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
76057405|NCT04644679|Diagnostic Test|7-day electrocardiographic monitoring|7-day external electrocardiographic monitoring
76057406|NCT04644679|Diagnostic Test|48-hr electrocardiographic monitoring|48-hr external electrocardiographic monitoring
75738188|NCT03446690|Other|Control group|Participants received routine treatment and oral hygiene regimes. No intervention for this group.
75886970|NCT05949125|Other|Cyclophosphamide (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
75886971|NCT05949125|Other|Fludarabine (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
75886972|NCT05949125|Drug|R-TM123|Intravenous infusion over 20 days
76057407|NCT04176055|Drug|Haloperidol|haloperidol intervention
75738189|NCT03429413|Behavioral|Protect Me 4 Application + External Quality Improvement Support|Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)
75738190|NCT03429413|Behavioral|Protect Me 4 Application Alone|During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.
75738191|NCT03421964|Behavioral|Resilience/Adjustment Counseling|The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions. The RAI will be implemented by experienced, licensed therapists.
75738192|NCT03421964|Behavioral|Resilience/Adjustment Counseling with Booster Sessions|"The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions.~For the RAI+ participants, three booster sessions will be implemented. The three weekly booster sessions will be scheduled to start three months following completion of Session 7 of the RAI. The program will be implemented by experienced, licensed therapists."
75738193|NCT03410823|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
75738194|NCT03410823|Dietary Supplement|Protein|Participants will receive a whey-based protein supplement in the form of a powder containing 27.6g of protein. This dose induces maximum muscle protein synthesis post-exercise. Participants will mix the supplement in 8 oz of water (or other beverage) or soft food (e.g., yogurt, soup) and consume immediately following each exercise session with the study PT. On days when they do not have a physical therapy visit with the study PT, participants will be instructed to take the supplement at the meal time closest to the time of scheduled PT visits to maintain regular daily dosing schedule.
75738195|NCT03410823|Dietary Supplement|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at baseline to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of baseline testing Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
75738196|NCT03395717|Device|Exoskeleton-Assisted Gait Training|
75738197|NCT03395314|Drug|Ketamine|1 single dose of IV ketamine
75886973|NCT05949125|Drug|Allo-RevCAR01-T|A single dose of Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1. Allo-RevCAR01-T will not be administered again within this study.
76057408|NCT01999465|Device|Standard NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~Rate(35 Hz)~Width (300 us)~Ch1 Ramp+ (2 seconds)~On Time 1 (10 seconds)~Ch1 Ramp - (2 seconds)"
76057409|NCT01999465|Device|Sham NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~Rate(35 Hz)~Width (48 us)~Ch1 Ramp+ (0 seconds)~On Time 1 (0 seconds)~Ch1 Ramp - (0 seconds)"
76057410|NCT01982773|Behavioral|Virtual Hope Box Smartphone App|Smartphone app
76057411|NCT01982773|Behavioral|Enhanced Treatment as Usual|Printed materials
76057412|NCT01974206|Biological|ASP0113|intramuscular injection
75594495|NCT01686230|Drug|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
75594496|NCT01686269|Procedure|blood collecting|
75594497|NCT02273271|Other|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
75594498|NCT01688414|Procedure|photoacoustic imaging|Undergo PAI
75594499|NCT01688414|Procedure|fluorescence imaging|Undergo fluorescence imaging
75594500|NCT01688414|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
75594501|NCT02273349|Device|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
75886974|NCT05940350|Behavioral|Telerehabilitation Stroke Coaching of Program (TeleSCoP) group|"The sampling criteria will be assigned to the intervention (TeleSCoP) and control groups by stratified randomization (1:1) in patients with acute ischemic stroke. A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10. The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months."
75886975|NCT05933681|Device|Neural recordings and stimulation|Neural activities from the dorsolateral prefrontal cortex and implanted DBS generator will be recorded, during resting and working memory tasks, and with the DBS target turned on and off.
75886976|NCT05922566|Combination Product|fMRI + Mukbang videos|Specific video program + fMRI will be allocated to the participants in this group. The specific video program includes control videos without food information, eating and food images without sound, chewing and swallowing sound without images, and Interactive content in Mukbang. Participants will undergo structural image scans, resting state scans, and task state scans. The task-fMRI will be performed while watching Mukbang to explore the activation of brain functional areas.
75738198|NCT03395314|Drug|Midazolam|1 single dose of IV midazolam
75738199|NCT03329092|Drug|ATM-AVI|"(Creatinine clearance > 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
75886977|NCT05920733|Behavioral|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
75886978|NCT05919810|Other|Probiotic|Oral probiotic
75444707|NCT06225063|Other|Pilates|The application of pilates aims to correct real-time deviations observed in the body during movement, to maintain stability, to maintain stability, to gradually form proper sensorimotor ability and improve cervical dysfunction. Pilates is an important part but also a primary point in the stages of rehabilitation, since through it the execution of movement is encouraged earlier thus providing help for the later stages of rehabilitation. Pilates exercises concern movements at all levels of body movement and in various positions.
75738200|NCT03329092|Drug|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
75886979|NCT05919810|Dietary Supplement|Oral herbal powder supplement|oral herbal powder
75738201|NCT03329092|Drug|MER|"Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance > 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance > 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
76057413|NCT01974206|Drug|Placebo|intramuscular injection
76057414|NCT04416464|Other|COVID-19 Pneumonia|Pneumonia due to proven or suspected SARS-Cov-2 infection
76057415|NCT04659278|Dietary Supplement|Endourage 1200 mg OMD ™ Oral Mucosal Drops|The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
76057416|NCT04659278|Dietary Supplement|Isolate|The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
75594502|NCT01686308|Procedure|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
75594503|NCT01686308|Procedure|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
75594504|NCT02270268|Dietary Supplement|Pectin|Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
75594505|NCT02270268|Dietary Supplement|maltodextrin|
75594506|NCT01688531|Drug|CD0271 0.1%/CD1579 2.5% gel|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
75594507|NCT01688531|Drug|CD0271 0.1%/CD1579 2.5% gel vehicle|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
75594508|NCT02270307|Drug|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
75594509|NCT02270307|Biological|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
75594510|NCT05140772|Drug|Dipeptiven|IV administration daily for 7 days
75886980|NCT05916222|Behavioral|Dynamic Temporal and Tactile Cueing (DTTC)|DTTC is a motor-based intervention where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment follows a temporal hierarchy where children receive multisensory cueing to establish accurate movements. First, the child imitates the clinician's production. If inaccurate, the child simultaneously produces the target with the clinician while cueing is provided. Upon achieving accuracy within simultaneous productions, the target is practiced within direct imitation while the clinician adds/fades cues based on the child's productions. When the child accurately produces the target in direct imitation, the target is practiced with varied prosody. Next, the target is practiced within delayed imitation where a child produces a word following a 2-3 second delay after the clinician's production. Upon accurately producing the target at all levels, the word is practiced within spontaneous productions.
75886981|NCT05914857|Drug|Dapagliflozin 10mg Tab|Dapagliflozin Tablets, Oral, 10mg, Once daily
75886982|NCT05914857|Behavioral|lifestyle interventions|Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet
75886983|NCT05909696|Drug|rocuronium|Advanced intravenous injection of rocuronium before the succinylcholine injection
75886984|NCT05909527|Biological|CD7 CAR-T|A single infusion of autologous CD7 CAR-T cells administered intravenously
75886985|NCT05908331|Device|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
75886986|NCT05908331|Device|Plan balloon Angioplasty (POBA)|Plan balloon used to open clogged or narrow coronary arteries due to underlying atherosclerosis
75886987|NCT05908110|Behavioral|Health Communication Message|The health communication message is a single infographic developed iteratively with input from stakeholders (parents and providers). This image informs the parent that their child may have OSA, lists common nighttime symptoms parents may observe (e.g., snoring, apnea) and common daytime symptoms (e.g., hyperactivity, sleepiness) that can result from OSA. Parents are then encouraged to speak to their child's primary care provider if they observe these symptoms in their child.
76057417|NCT04659278|Other|Placebo|Total CBD = CBD + (CBD-A * 0.877). Total THC = THCA-A * 0.877 + Delta 9 THC, ND = <LOQ, T-Caryophyllene = Trans-Caryophyllene, <LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
76057418|NCT04659278|Dietary Supplement|Peppermint Oil, masking flavor|Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
76057419|NCT01999868|Biological|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh <= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh > 100 kg at study entry will receive 90 mg of ustekinumab."
76057420|NCT01999868|Biological|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection"
75886988|NCT05907811|Procedure|Neuromuscular blocker usage|The patients were followed up, the total amount of muscle relaxant used was determined, intraoperative effects and postoperative analgesic usage
75444708|NCT06225063|Other|Cognitive Functional Therapy|Cognitive component: Educating patients about their perceptions of pain, explaining diagnosis and diagnostic findings, answering questions about their problem and symptoms, progressively challenge their customers in a non-judgmental way, education for multifactorial and biopsychosocial spectrum of pain, encouraging participants to movement and for active participation in daily activities, if receiving a self-management plan participation in activities with a degree of difficulty 2-3/10, tips for more effective sleep Specific functional training: Understanding pain modification through relaxation exercises, awareness and body control, modified body positions for better control of the cervical spine with parallel relaxation of the thoracic spine to participate in fearful or painful activities, engaging in movements of daily activities Lifestyle changes: Gradual increase in physical activity based on patient preferences, stress management and social interaction
75444709|NCT06225050|Device|CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)|PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
75594511|NCT05140772|Drug|normal Saline|IV administration daily for 7 days
75594512|NCT02270385|Behavioral|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
75594513|NCT02270385|Behavioral|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
75738202|NCT03329092|Drug|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight < 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance > 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
75738203|NCT03293680|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
75738204|NCT03290261|Other|Hypnosis|3 hypnosis sessions performed at 4 - 6 weeks apart
75738205|NCT03205124|Procedure|Electrical Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
75738206|NCT03205124|Procedure|Sham Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
75738207|NCT03172975|Biological|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
75444710|NCT06225037|Device|Sedline EEG monitoring|Propofol titrated according to the raw EEG and spectrogram, aiming to maintain sedation (alpha oscillations +/- slow oscillations) and preventing burst suppression, keeping the PSI greater than 25 where possible.
75594514|NCT02270424|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
75886989|NCT05903352|Other|Stop antibiotic|Stop the antibiotic treatment on day S (stability criteria reached for 24 h or within 48 hours after the start of antibiotic treatment).
75886990|NCT05903352|Drug|Continue the antimicrobial treatment|Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).
75444711|NCT06225037|Device|Sedline EEG with output concealed|Clinician will be blinded to the sedline output but data will be collected for analysis (Sedline output will only be analysed at data analysis)
75738208|NCT03172975|Biological|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
75738209|NCT03172975|Biological|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
75444714|NCT06225011|Drug|Fluoxetine|Receive PO
75594515|NCT02270424|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
75594516|NCT02270424|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
75594517|NCT02270424|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
75738210|NCT03172975|Biological|Placebo|Physiological sterile saline solution
75738211|NCT03172975|Drug|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
75738212|NCT03172975|Other|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
75886991|NCT05903300|Other|Surveys and Questionnaires|The intervention consists of completing the MIPIM-P, QuickDash, and Brief Pain Inventory questionnaires.
75886992|NCT05902780|Drug|Caudal Bupivacaine injection|- Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
75738213|NCT03155022|Device|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of [1 min balloon inflation followed by 1 min balloon deflation] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
75738214|NCT03155022|Device|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
75738215|NCT03037879|Other|SPT|Participants in the SPT group will receive 10 training sessions over 5 weeks.
75738216|NCT03037879|Other|SPT Control|Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
75738217|NCT03037879|Other|mSMT|Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
75738218|NCT03037879|Other|mSMT Control|Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
75738219|NCT03028103|Drug|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
75594518|NCT02270424|Drug|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
75738220|NCT03028103|Drug|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
75444715|NCT06224998|Behavioral|Exercise|Exercise is the most appropriate treatment for low and moderate AIS cases due to its low cost and low risk of complications. Exercises prevent the development of many problems by controlling the severity of curvature and preventing the progression of curvature. It is thought that scoliosis exercises can delay or even prevent surgery and reduce the duration or degree of brace, especially in patients with low-to-moderate curvature during growth. One of these exercise approaches, the Schroth technique, is primarily based on isometric muscle contraction exercises that aim to rotate, lengthen and stabilize the spine. The core component of the Schroth method is autocorrection, defined as the patient's ability to reduce spinal deformity through active postural realignment of the spine in three dimensions.
75444716|NCT06224972|Device|Vlab|The study is observational, there is no intervention.
75594519|NCT02270424|Drug|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
75444717|NCT06224946|Diagnostic Test|soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio|the soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio for pre-eclampsia diagnostic
75444718|NCT06224933|Device|Augmented Reality System|Subjects will undergo image guided needle aspiration, injection, or biopsy facilitated by the Augmented Reality system. The Augmented Reality guidance system will be operated by the interventional radiologist in the MRI suite.
75594520|NCT02270424|Drug|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
75594521|NCT01686347|Drug|ropivacaine|
75594522|NCT02270541|Other|Telemedicine|In-ambulance telemedicine
75594523|NCT01686425|Procedure|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
75594524|NCT05140655|Drug|Fulvestrant|Medicine for Advanced breast cancer
75594525|NCT02270619|Biological|Endotoxin|Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
75594526|NCT02270619|Behavioral|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
75594527|NCT02270619|Other|Placebo|0.9% saline as IV bolus
75594528|NCT02270619|Other|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
75738221|NCT03028103|Drug|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
75738222|NCT03028103|Drug|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
76057421|NCT01999868|Drug|UST Placebo|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
76057422|NCT01999868|Drug|ABA Placebo|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
76057423|NCT01957579|Drug|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
76057424|NCT03511963|Drug|HLX04 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
76057425|NCT03511963|Drug|Avastin 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
76057426|NCT01999322|Drug|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
76057427|NCT01999322|Drug|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
75738223|NCT03023163|Other|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
75444719|NCT06224920|Diagnostic Test|magnetic resonance imaging|MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.
75444720|NCT06224920|Other|electroencephalography|A 20-channel resting EEG (Brain Products, Gilching, Germany) is recorded as part of routine clinical diagnostics in the Department of Psychiatry and Psychotherapy at the LMU to rule out focal neurophysiological pathologies. Within the scope of the present study, an extended examination will be carried out, which includes a 64-channel EEG, including a passive visual paradigm. After completion of the clinical evaluation, the neurophysiological changes in resting activity will be scientifically analyzed in comparison to the MRI and PET data.
75444721|NCT06224920|Diagnostic Test|blood and CSF biomarker|Aβ1-42 and 1-40, total tau protein and phosphorylated tau protein 181 (p-Tau), apolipoprotein E (APOE), soluble TREM2 protein, neurofilament light chain and glial fibrillary protein (GFAP) will be determined.
75738224|NCT03020589|Drug|Tacrolimus|See description in arm/group sections
75738225|NCT03010982|Drug|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
75444722|NCT06224920|Diagnostic Test|positron emission tomography|According to an established and standardized protocol, PET scans are performed with the TSPO receptor ligand [18F]-GE-180, [18F]flutemetamol for assessment of fibrillar Aβ 162 accumulation and the Tau ligand [18F]-PI-2620. In brief, [18F]GE-180 TSPO PET images (mean dose: 177 ± 17 MBq) with an emission window of 60-80 min after injection will be acquired to measure the activation of glial cells. [18F]Flutemetamol Aβ PET images (average dose: 182 ± 11 MBq) are acquired with an emission window of 90-110 min after injection to assess fibrillar Aβ accumulation. Dynamic [18F]PI-2620 tau PET (average dose: 186 ± 14 MBq) with an emission window of 0-60 minutes after injection are performed for quantification of tau aggregation. Static images of the late phase (20-40 min) are reconstructed. These images are used for further processing and analysis.
75738226|NCT02964208|Device|AMPLATZER™ LAA Occluder|The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
75738227|NCT02932475|Drug|Metformin|1000 mg twice a day
75738228|NCT02932475|Drug|Placebo|Delivered to match active drug
75886993|NCT05902780|Drug|Caudal Dexmedetomidine Injection|- Group D (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
75886994|NCT05901350|Drug|Levodopa|Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
76057428|NCT01996982|Device|CCS Device|Core Cooling System Device
76057429|NCT01965158|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
76057430|NCT01965158|Drug|Placebo|Placebo tablet taken orally once a day
76057431|NCT01964924|Drug|Akt Inhibitor GSK2141795|Given PO
76057432|NCT01964924|Other|Laboratory Biomarker Analysis|Correlative studies
76057433|NCT01964924|Drug|Trametinib|Given PO
76057434|NCT01964378|Drug|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
76057435|NCT01964378|Drug|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
76057436|NCT01442038|Drug|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
75886995|NCT05894967|Behavioral|C1 - Standard Perceptual Learning (SPL)|Each trial starts with a fixation point (500ms) after which a Gabor (1° radius, at cut-off SF of 25% accuracy, estimated from Pre-Test CSF, at either 45° or 135°) appears for 128ms. The task is to indicate whether the Gabor was tilted left or right. Gabor contrast will be controlled by a 3/1 staircase (converging on approximately ~80% contrast threshold) across all training sessions.
76057437|NCT01442038|Drug|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
75444723|NCT06224920|Diagnostic Test|neuropsychological test|Trained psychologists at the Memory Clinic of the LMU Hospital administered the CDR, CERAD-NB and Mini-Mental State Examination (MMSE). The CERAD-NB battery was used to generate a total score for the six subscales: semantic fluency (animals/60 s), modified Boston naming test, lexical items, construction practice, lexical items retrieval, and lexical items discrimination, with higher scores indicating better performance.
75594529|NCT05140616|Drug|Chidamide|After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
75738229|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
75738230|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
75444724|NCT06224907|Biological|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
75738231|NCT02893553|Drug|Midodrine Hydrochloride|study 1 will be single blind. study 2 will be blinded randomized-control trial.
75444725|NCT06224894|Other|Music Therapy|Music Therapy
75444726|NCT06224894|Other|antiemetic treatment|antiemetic treatment
75594530|NCT01688570|Drug|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
75594531|NCT01688570|Drug|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
75594532|NCT01688570|Drug|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
75444727|NCT06224881|Drug|Ascorbic acid|2 gm every 8hrs for 4 days
75444728|NCT06224868|Other|insufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.
75594533|NCT02270697|Device|Array|Applications of oligonucleotide array in diagnosis.
75738232|NCT02893553|Drug|Pyridostigmine Bromide|study 1 will be single blind. study 2 will be blinded randomized-control trial.
75738233|NCT02893553|Drug|Mirabegron|study 1 will be single blind. study 2 will be blinded randomized-control trial.
75738234|NCT02893553|Other|Placebo|placebo will only be used for study arm 2, the randomized blinded phase.
75738235|NCT02886936|Device|iFIT Transtibial Prosthesis|Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
75738236|NCT02886936|Device|iFIT Transfemoral Prosthesis|Transfemoral amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
75886996|NCT05894967|Behavioral|C2 - Long Training (LT)|Will be the same as the SPL with the exception that each session in LT will be twice as long as in SPL.
75886997|NCT05894967|Behavioral|C3 - Short Staircases (SS)|"Will be largely the same as SPL with the only difference being a change to the adaptive procedure. SS will use so-called short-staircases, which are initialized at 60% contrast with steps of .05 log units and employs a 3/1 staircase that after every 40 trials is reset (the short in short-staircases) back to 60% contrast."
75886998|NCT05894967|Behavioral|C4 - Mixed Difficulty (MD)|This condition will be identical to SPL with the exception that two staircases - one a 2/1 staircase producing difficulties centered around 60-70% accuracy, the other a 4/1 staircase producing difficulties centered around 85-95% accuracy - will be utilized to control the stimuli.
75886999|NCT05894967|Behavioral|C5 - Noise Training (NT)|The NT condition will be the same as SPL with the exception that contrast thresholds will be estimated in 5-different levels of external noise (10%, 15%, 20%, 25%, 30%).
75887000|NCT05894967|Behavioral|C6 - Training with Flankers (TWF)|TWF will be reasonably different from the standard SPL task. Here, on 50% of trials a target Gabor will be presented at either 45° or 135° (as in SPL) and will be flanked by two collinear Gabors. On the remaining 50% of trials, flankers will be present without a target. TWF is thus a yes/no detection task, which is necessary since the collinear flankers fully indicate the target orientation. In different 20-trial mini-blocks the flankers will appear either lambda, 1.5 lambda, or 2 lambda from the target (i.e., closer or further from the target) and target contrast will be controlled by a 3/1 staircase separately for each spacing.
75887001|NCT05894967|Behavioral|C7 - Parafoveal Training (PT)|The PT condition is the baseline for C8-C11 (all of which involve parafoveally presented targets). In PT, we utilize the same task as in SPL, however, in PT, in addition to central training, targets will also appear in one of two peripheral locations (5° eccentricity; angles = 135° and 270°). The location of targets will be randomized trial-wise so as to discourage eye-movements and independent 3/1 staircases will be run at each location. By training only 2 peripheral locations we can measure the extent to which training gives rise to location transfer (e.g., in transfer tasks examining performance at 8 different locations - 2 trained locations and 6 untrained locations). Furthermore, training at the central location facilitates comparisons between PT and SPL.
76057438|NCT01998919|Drug|erlotinib [Tarceva]|150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
75444729|NCT06224868|Other|desufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.
75738237|NCT02756702|Device|All-Poly|Implantation of the VEGA PS using all-polyethylene tibia components
75444731|NCT06224842|Drug|mitoxantrone liposome 16 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
75444732|NCT06224842|Drug|mitoxantrone liposome 18 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
76057439|NCT01998919|Drug|placebo|orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
75444733|NCT06224842|Drug|mitoxantrone liposome 20 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
75444734|NCT06224829|Procedure|Pain Inducing Massage|60 seconds of direct pressure to the neck resulting in 5/10 pain . This will be repeated four times for a total of 240 seconds
76057440|NCT01998919|Drug|gemcitabine|1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
76057441|NCT01998919|Drug|cisplatin|75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
76057442|NCT01998919|Drug|carboplatin|5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
75444735|NCT06224829|Procedure|Pain Free Massage|60 seconds of direct pressure to the neck resulting in 0/10 pain . This will be repeated four times for a total of 240 seconds
75444736|NCT06224829|Procedure|Cold Water Bath|Participants will place their hand in a cold water bath maintained at 6 to 8 degrees Celsius for 60 seconds. This will be repeated four times for a total of 240 seconds.
75444737|NCT06224816|Device|Custom 3D mask (3DM) application in neonate|Premature infants with a birth weight less than 1500 g r first received 3D mask during 4 hour, then crossed over to traditional mask.
76057443|NCT01964300|Biological|peginterferon alfa-2b|Given subcutaneously (SC)
75887002|NCT05894967|Behavioral|C8 - Stimulus Variety (SV)|"The base task for SV is the PT condition. However, SV employ 20 trial mini-blocks of different SFs (.75, 1.5, 3, 6, 12, 24 cpd) and locations (45°, 135°, 225°, 315° - i.e., more locations than PT, but not the full set tested in the transfer battery) with separate staircases for each SF and location. Orientations will also be drawn from a larger set (22.5°, 45°, 67.5° - for which participants respond clockwise and 112.5°, 135°, 157.5° - for which participants respond counter-clockwise) and will vary on a trial-by-trial basis. This design holds-out 4 locations and 2 orientations to address transfer."
75887003|NCT05894967|Behavioral|C8a - Complex Features (CF)|This is the same as C8, however we will use band-pass filtered stimuli similar to what has been done by a number of groups including Hussein et al.
75887004|NCT05894967|Behavioral|C9 - Exogenous Attention Training (ExAT)|Stimuli will be presented in a similar manner as in PT. However, in ExAT, a 100% valid cue, a small black dot - 48ms duration with an 96ms SOA prior to stimulus onset - will appear above the target location on each trial.
75887005|NCT05894967|Behavioral|C10 - Endogenous Attention Training (EnAT)|Stimuli will be presented in a similar manner as in PT. However, in EnAT, a 100% valid cue (letter UL, LR; standing for upper left and lower right, respectively) - 150ms duration with an 500ms SOA prior to stimulus onset - will appear at the fixation point.
75887006|NCT05894967|Behavioral|C11 - Multisensory Facilitation (MF)|MF utilizes the same basic task structure as in ExEAT, however, rather than a visual cue, an auditory cue will be used (50ms, 1000hz tone with sound location determined by convolving sound with generic head-related transfer function, kemar large ears.
75594534|NCT01686464|Drug|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
75887007|NCT05894967|Behavioral|No Contact Control|"While not a training condition one type of experience that could be part of a condition is a no contact control (i.e., where participants do no training activities over the same rough time span as for the other training tasks)."
75887008|NCT05894018|Drug|Fluzoparib|150mg, orally, bid
75887009|NCT05894018|Procedure|Radioactive particle implantation|Radioactive iodine-125 seeds implantation
76057444|NCT01964300|Other|laboratory biomarker analysis|Correlative studies
76057445|NCT01964222|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
75444738|NCT06224816|Device|Traditional mask (TM) application in neonate|Premature infants with a birth weight less than 1500 g r first received traditional mask during 4 hours, then crossed over to 3D mask.
75594535|NCT01686464|Device|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2~3.0 L / min for the same duration during all acupuncture sections.
75594536|NCT01686542|Procedure|CPVI plus renal sympathetic modification|CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
75594537|NCT01686542|Procedure|CPVI|CPVI alone to reduce atrial arrhythmia recurrence.
75594538|NCT02270931|Device|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
75887010|NCT05893407|Diagnostic Test|Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging|Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
75444739|NCT06224803|Dietary Supplement|Compound plant extracts|Total supplement including bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder.
75444740|NCT06224803|Dietary Supplement|Indigestible dextrin|Indigestible dextrin as placebo intervention
75444741|NCT06224790|Drug|Pirfenidone|Capsule Pirfenidone 1200mg/ day in divided doses for 3 months
75594539|NCT02270970|Biological|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
75738238|NCT02734485|Device|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
75738239|NCT02734485|Device|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
75594540|NCT05140733|Procedure|lumbar foraminal decompression|lumbar foraminal decompression with endoscopic instruments.
75738240|NCT02507687|Drug|Bimatoprost SR|Up to two Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
75738241|NCT02507687|Drug|Sham Bimatoprost SR|Up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
75738242|NCT02507687|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
75738243|NCT02507687|Procedure|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
75887011|NCT05892497|Other|Tecartherapy|The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
76057446|NCT04416230|Behavioral|massage|The massage included 30 minutes of gentle friction, kneading, stroking, and passive touch on the infant's accessible upper extremities, lower extremities, head, face, and back.
75594541|NCT05140733|Procedure|Fusion surgery|Fusion surgery for patients with foraminal stenosis
75594542|NCT01688648|Drug|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
75594543|NCT01688648|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
75594544|NCT02271009|Drug|AllerT|Ultrafast immunotherapy
75594545|NCT02271009|Drug|Placebo|placebo control
75738244|NCT02383407|Device|Medtronic Deep Brain Stimulation|
75738245|NCT02321501|Drug|Ceritinib|Given PO
75738246|NCT02321501|Drug|Everolimus|Given PO
75738247|NCT02321501|Other|Laboratory Biomarker Analysis|Correlative studies
75738248|NCT02321501|Other|Pharmacological Study|Correlative studies
75738249|NCT02237079|Drug|Bazedoxifene/Conjugated Estrogens (BZA/CE)|Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
75738250|NCT02237079|Drug|Placebo Oral Tablet|Daily placebo tablet
75738251|NCT02162511|Device|CliniMACS CD34+ cell enrichment and T-cell depletion|
75444742|NCT06224790|Other|Placebo|2 Capsules 3 times a day for 3 months
75444743|NCT06224777|Biological|5% Albumin (human) Solution|Albumin is a biological product derived from human blood donors.
75444744|NCT06224777|Drug|Paeds solution|Paeds solution contains dextrose 4.3%, and Sodium Chloride 0.18%
75444745|NCT06224764|Other|Mother and Father questionnaires|Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
75444746|NCT06224751|Diagnostic Test|Near logMAR letter acuity|Comparison of gold standard printed tests and computerised versions
75444747|NCT06224751|Diagnostic Test|Near LogMAR word acuity|Comparison of gold standard printed tests and computerised versions
75444748|NCT06224751|Diagnostic Test|Red Green Stereoacuity|Comparison of gold standard printed tests and computerised versions
75444749|NCT06224751|Diagnostic Test|Auckland Optotype/Auckland Vanishing Optotypes|Comparison of gold standard printed tests and computerised versions
75444750|NCT06224751|Diagnostic Test|Vanishing Optotype Sloan Letters|Comparison of gold standard printed tests and computerised versions
75738252|NCT01992861|Procedure|Computed Tomography|Undergo FDG PET/CT
75738253|NCT01992861|Procedure|Diffusion Weighted Imaging|Undergo DW MRI
75887012|NCT05888675|Drug|Weifuchun|The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.
75887013|NCT05882084|Dietary Supplement|Astaxanthin 6 mg daily|Astaxanthin at 6 mg is given for daily ingestion and compared against placebo.
75887014|NCT05882084|Dietary Supplement|Placebo|Placebo
75887015|NCT05870462|Drug|Semaglutide Pen Injector|"0.25 mg/week (non-therapeutic dose) during Weeks 1-4~0.50 mg/week during Weeks 5-8~1.0 mg/week during Weeks 9-24~Participants experiencing side effects (e.g. nausea, stomach pain, constipation, diarrhea, vomiting) at the maximum dose (1.0 mg/week) may be down-titrated to 0.50 mg/week.~Participants who had been receiving a dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin) will stop taking their DPP-4 inhibitor upon randomization to this arm."
75887016|NCT05861102|Drug|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
76057447|NCT04416230|Behavioral|quiet time|During quiet time, the infant received a 30 minute quiet time (QT) period during which non-essential caregiving tasks were restricted. During QT, clinicians were asked to avoid direct clinical caregiving activities, i.e. activities requiring physical contact with the infant.
75738254|NCT01992861|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
75738255|NCT01992861|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
76057448|NCT04416074|Behavioral|An online 5-week professional identity group psychotherapy|This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
75594546|NCT01686659|Device|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin [SpHb] and Pleth Variability Index [PVI]) to the clinicians in the operating room
75594547|NCT02271048|Device|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
75594548|NCT01686698|Dietary Supplement|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
75738256|NCT01992861|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
75444751|NCT06224751|Diagnostic Test|Letter Contrast Sensitivity|Comparison of gold standard printed tests and computerised versions
75444752|NCT06224751|Diagnostic Test|Low Contrast Letter Acuity|Comparison of gold standard printed tests and computerised versions
75594549|NCT01686698|Other|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
75738257|NCT01992861|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
75738258|NCT01897610|Drug|Immuncell-LC|intravenous dripping of 200ml(10^9~2x10^10 lymphocytes/60kg adult) for 1 hour
75738259|NCT01895517|Other|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
75738260|NCT01895517|Other|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
75444753|NCT06224738|Biological|human HER2-targeted CAR-M cells|The human anti-HER2 chimeric antigen receptor macrophages (anti-HER2 CAR-M cells) independently developed use adenoviral vector system to genetically engineer autologous macrophages to express CAR molecules containing single-chain antibodies, which specifically bind to the human HER2 antigen to recognize and kill tumor cells.
75887017|NCT05861102|Drug|Placebo|Participants will receive matching placebo orally twice daily for 16 weeks
75887018|NCT05830500|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
75594550|NCT01688687|Procedure|Endoscopic submucosal dissection|
75594551|NCT02271126|Device|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
75594552|NCT02271126|Device|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
75594553|NCT02271126|Drug|Heparin|Anticoagulation provided to patients in ECMO
75887019|NCT05830292|Device|Diffuse reflectance spectroscopy (DRS) probe|The spectroscopic DRS probe, either sterilised or covered with a sterile probe cover, will be used on the tissue as part of the patient's operation, inside the body itself.
76057449|NCT04416074|Other|Message push|Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
76057450|NCT01467700|Drug|Ramelteon SL|Ramelteon SL tablets
76057451|NCT01467700|Drug|Placebo|Ramelteon placebo-matching tablets
76057452|NCT01972724|Drug|Pioglitazone|Pioglitazone tablets
76057453|NCT01972724|Drug|Metformin|Metformin as prescribed in clinical practice
76057454|NCT01972724|Drug|Sulfonylurea|Sulfonylurea as prescribed in clinical practice
75738261|NCT01572532|Other|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
76057455|NCT01441960|Drug|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
75738262|NCT01439659|Behavioral|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
76057456|NCT01441960|Drug|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
76057457|NCT04508062|Procedure|pectopexy operation|Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.
75594554|NCT05140577|Other|Maximal voluntary isometric strengthening|The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds
75738263|NCT01439659|Dietary Supplement|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
76057458|NCT04508062|Procedure|uterosacral ligaments plication operation.|At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
75738264|NCT01267448|Drug|Glipizide XL|The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
75594555|NCT02271165|Drug|Immunoglobulin (Hizentra)|
76057459|NCT04062838|Drug|Dextrose 50|As above
75738265|NCT01267448|Drug|Saxagliptin + Metformin XR|The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
75738266|NCT01267448|Drug|Metformin XR|The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
76057460|NCT04408534|Other|mode of noninvasive ventilation|administration of during 3 hours each 4 cycles
76057461|NCT01955707|Drug|natalizumab|Administered as described in the treatment arm
76057462|NCT01955707|Drug|Placebo|Matched placebo
76057463|NCT01435798|Drug|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
75444755|NCT06224712|Behavioral|Arogya Sangama|Using human-centered design, the investigators will work wit the community to develop a prototype Arogya Sangama model to identify methods to bring GPTF and HWC service providers to create ideas, systems, processes, services, and delivery strategies for the GPTFs. They will help identify and prioritize interventions and address barriers to usability. There will also be capacity building of GPTFs to implement the interventions identified.
75444756|NCT06224699|Drug|Toothpaste Product|Use of toothpaste with or without sodium carbonate at 67%
75594556|NCT01686737|Behavioral|Iyengar Yoga|"12 weeks of Iyengar yoga~2 weekly sessions of 60 minutes"
75594557|NCT01686737|Behavioral|Walking|"12 weeks of walking~2 weekly sessions of 60 minutes"
75594558|NCT02271204|Drug|Ibandronic acid|As prescribed by physician
75738267|NCT01265030|Drug|Sirolimus|"Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"
75738268|NCT00901511|Procedure|Baseline WLL|Scheduled bilateral WLL
76057464|NCT01972568|Drug|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
76057465|NCT01972568|Drug|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
76057466|NCT01972568|Drug|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
76057467|NCT01955161|Drug|Placebo|Once daily, matching placebo capsules, orally
75738269|NCT00901511|Drug|Sargramostim|Inhaled GM-CSF
75887020|NCT05829421|Other|Impairment-specific occupational therapy (OT) intervention|"In parallel with standard practice, patients receive an OT intervention adapted to the specific underlying cognitive impairments that are likely to disturb their performance of ADLs.~The intervention is individualised through a 3-step process: a) a list of dysfunctional ADL process skills is forwarded by the OT to the neuropsychologist (NP), b) the NP identifies the cognitive impairments which are most likely to cause the dysfunctional ADL process skills through a cognitive assessment, c) based on the identified cognitive impairments, the NP and the OT select in collaboration the cognitive strategies that are most likely to benefit the individual patient from a pre-prepared intervention manual. Because of the large heterogeneity in how cognitive impairments impact on ADL performance, the exact way of implementing the selected cognitive strategies into the practice of the individual patient is left to the OT´s clinical judgement."
75444757|NCT06224686|Other|conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.
75444758|NCT06224686|Other|motor imagery based on action observation treatment|First, the therapist explained the purpose and principle of the intervention method to the patient, keeping the surrounding environment quiet and comfortable to avoid the patient's mood fluctuations due to external interference. Then start the treatment, the video recorded in advance was given to the patient to watch, the playback device is a ipad. The content includes lip and tongue muscle relaxation exercises, healthy people eating, chewing, swallowing, drinking and other images. At the same time, the guidance was played, which was consistent with the content in the video. The video was played 3 times consecutively for 30 min each time, once a day for 14 days.
75444759|NCT06224673|Drug|ARX788|Given IV
75594559|NCT05140460|Behavioral|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR)|The intervention entails distribution of a children's book with a cultural pride theme and the cultural pride parent book-sharing guide. Intervention participants select and receive a developmentally appropriate (baby, toddler, or preschool) book that features African American, Latino, Asian or diverse cultural pride perspectives.
75738270|NCT00901511|Procedure|Rescue WLL|Unscheduled bilateral WLL
75594560|NCT05140460|Behavioral|Reach Out and Read (ROR)|The control condition involves distribution of a standard ROR book and book-sharing advice. Distributed books are developmentally appropriate (baby, toddler, or preschool).
75594561|NCT02271282|Drug|Toremifene|
75738271|NCT00534196|Radiation|Permanent iodine-125 (Brachytherapy)|Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
75738272|NCT00500500|Drug|EGb 761® (Tanakan®)|
75738273|NCT00202813|Device|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
75738274|NCT00117143|Drug|Romiplostim|Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
75738275|NCT00004180|Drug|rosiglitazone maleate|
75594562|NCT02271282|Drug|Placebo|
75594563|NCT02271282|Drug|GHRH/Ghrelin combined Injection|
75738276|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
75738277|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
75738278|NCT00988494|Drug|Placebo ophthalmic solution|Topical ocular application
75444760|NCT06224673|Procedure|Computed Tomography (CT)|Undergo CT or Positron Emission Tomography(PET)/CT
75444761|NCT06224673|Procedure|Biospecimen Collection|Undergo collection of blood samples
75594564|NCT02271321|Other|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
75594565|NCT01686893|Device|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
75594566|NCT01686893|Device|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
75738279|NCT05347290|Device|Rampart IC, M1128|Rampart IC, M1128 aims to address the challenge of radiation protection in the cardiac catheterization laboratory without the burden of wearing a heavy lead apron. Rampart M1128 is a compactly designed, portable, fully adjustable system that provides radiation protection for interventionalists and their technicians. It has independently adjustable flexible panels, allowing interventionalists multiple vascular access points, including right radial, bi-lateral femoral, and bi-lateral pedal. Participants in this arm will conduct catherization procedures using only the Rampart System, and radiation exposure will be measured using real-time dosimeters.
75738280|NCT05347290|Device|Lead Apron and Ancillary Shield|Participating providers in this arm will use conventional skirt and vest, thyroid collar, and 100% use of 2 types of ancillary shields. Most wrap-around skirts and vests were (0.25-0.5 mm) Pb. Thyroid shields were 0.5 mm Pb equivalent. Under the table lead x 2. Radiation exposure will be measured using real-time dosimeters.
76057468|NCT01955161|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
75738281|NCT05347290|Device|Rampart IC, M1128 and Lead Apron|Participating providers will use both the lead apron and the Rampart Shield. Radiation exposure will be measured using real-time dosimeters.
75738282|NCT00539994|Drug|retapamulin|200mg BID retapamulin 3 days
75444762|NCT06224660|Genetic|SRD-001|SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.
75594567|NCT01580111|Biological|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
75738283|NCT00539994|Drug|Retapamulin|200mg BID retapamulin 5 days
75738284|NCT00539994|Drug|Placebo|200mg BID placebo 5 days
75738285|NCT05711706|Other|Su Jok Application|Su Jok massage appplication
75738286|NCT04004676|Behavioral|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time
75738287|NCT04004676|Behavioral|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
75887021|NCT05822440|Drug|PF-07817883|Single oral dose (period 1) or co-administered with itraconazole (period 2)
75887022|NCT05822440|Drug|Itraconazole|Interacting drug which will be given for 7 days in period 2
75594568|NCT01688804|Behavioral|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
75594569|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 1
75738288|NCT05711550|Device|Real Neurofeedback|Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
75738289|NCT05711550|Device|Sham Neurofeedback|The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
75887023|NCT05822141|Dietary Supplement|Fish Oil|For 12 weeks subjects will ingest 6 capsules per day of fish oil (7.8 g/day total omega--3 fatty acids: 3.75 g/day EPA and 1.5 g/day DHA)
75887024|NCT05822141|Dietary Supplement|Placebo|For 12 weeks subjects will ingest 6 capsules per day of olive oil (each capsule contains 990 mg of olive oil)
75594570|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 2
75594571|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 3
75594572|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 1
75594573|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 2
75594574|NCT02271360|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
75887025|NCT05819203|Device|Healsea Babykids|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
75887026|NCT05819203|Device|Placebo|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
75887027|NCT05819190|Device|Healsea Rescue*|Subjects will be administered with Healsea Rescue* by spraying 2 puffs in each nostril 2 times per day during 7 days.
75887028|NCT05819190|Device|Placebo|Subjects will be administered with isotonic saline nasal spray indistinguishable from the Healsea Rescue* by spraying 2 puffs in each nostril 2 times per day during 7 days.
75887029|NCT05817526|Drug|BMAC/ collagen|Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect
75887030|NCT05817526|Procedure|Autograft harvesting from chin|Autograft
75887031|NCT05814341|Drug|Citrate|Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
75887032|NCT05812079|Diagnostic Test|skin biopsy examined by ELISA technique|skin biopsy examined by ELISA technique
75738290|NCT04005222|Drug|SELENIUM|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
75887033|NCT05805839|Drug|C-11 ER176 Radiotracer|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
75887034|NCT05805839|Drug|C11 Pittsburgh Compound B|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).
75738291|NCT04005222|Drug|MELATONIN|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
75887035|NCT05805839|Diagnostic Test|PET/CT scan|Imaging of entire brain
75887036|NCT05805839|Diagnostic Test|MRI|Magnetic Resonance Imaging of the Brain
75887037|NCT05795114|Behavioral|Reach Out, Stand Strong, Essentials for New Mothers (ROSE) Program|A 5-part interpersonal therapy based intervention
75887038|NCT05790772|Behavioral|Vigorous Exercise|50 minutes of running on a treadmill
75887039|NCT05790252|Drug|Buprenorphine Transdermal Matrix Patch|Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
75887040|NCT05790252|Other|Sham patch|Bandage applied at time of induction initiation and removed at 48 hours.
75887041|NCT05784480|Diagnostic Test|Checklist for evaluation of reversible causes|Prehospital evaluation by checklist and diagnostic testing for reversible causes of OHCA using point-of-care blood gas analysis, saliva toxicological screen and ultrasound and post-hoc toxicological analysis of blood using mass spectrometry
75887042|NCT05782985|Diagnostic Test|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)|Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
75594575|NCT02271360|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
75887043|NCT05781555|Device|Experimental: DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. The study objectives are to collect data on the general safety and efficacy of DaRT among patients who do not fit the entry criteria of existing investigational trials.
75887044|NCT05780593|Other|Manual Therapy|After the baseline assessment, each intervention group will be given physical therapy treatment. The group A will receive Manual Mobilization of the Lumbosacral Spine followed by passive stretching of the hip abductors of both sides of the body. The patient then will be asked to stand on the inclined board for 01 minute with feet 3 to 4 inches apart hands placed on the wall at the level of shoulder joints. After 01-minute patient will be asked to leave the inclined board. The patient will be advised to do this 01-minute inclined board standing for three times a day at home. All the patients in Group A will receive this treatment regime for two weeks.
75887045|NCT05780593|Other|Inclined Board Standing|The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.
75887046|NCT05779397|Device|Masimo RAD-GT|Non-contact infrared thermometry device
75887047|NCT05779280|Other|THDA + Acetyl Zingerone Topical Product|A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily
75887048|NCT05779280|Other|THDA|A skin care product with THDA (VitaSynol® C) used twice daily
75594576|NCT01687049|Drug|Red yeast rice|
75887049|NCT05771805|Other|Vagus nerve stimulation with task oriented training|VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
75887050|NCT05771805|Other|Task oriented training|Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
75594577|NCT02271399|Drug|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
75738292|NCT05711472|Other|birth ball exercise|birth ball exercise used in childbirth
75738293|NCT04441710|Other|Questionnaire|Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
75738294|NCT01563744|Procedure|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
75738295|NCT01563744|Procedure|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
75738296|NCT00098839|Drug|L-asparaginase|Given IM
75738297|NCT00098839|Drug|doxorubicin hydrochloride|Given IV
75738298|NCT00098839|Drug|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
75738299|NCT00098839|Drug|vincristine sulfate|Given IV
75738300|NCT00098839|Biological|epratuzumab|Given IV
75738301|NCT00098839|Drug|cytarabine|Given IT
75738302|NCT00098839|Drug|prednisone|Given orally
76057469|NCT01441414|Biological|PF-04856884|15 mg/kg/week intravenously [IV] until toxicity or disease progression
76057470|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
76057471|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
76057472|NCT01971554|Drug|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
75738303|NCT00098839|Drug|pegaspargase|Given IM
75444763|NCT06224647|Behavioral|Mobile Transdiagnostic Emotion Regulation Intervention|"The intervention aims to provide a tailored and engaging way for users to manage and comprehend their emotional well-being.~It consist of 5 components:~Daily tracking of emotions~A suite of exercises placed in six categories facilitating adaptive ER skills (i.e., upregulation of positive effect, self-compassion, cognitive defusion and cognitive restructuring, mindfulness, breathing techniques),~A self-assessment module where users can complete surveys evaluating their states (e.g., wellbeing) and traits (e.g., perfectionistic tendencies),~A personal toolkit area (i.e., each exercise is represented by an object commonly found in a student's room. Users can collect objects of favoured exercises in the virtual ROOM, enabling them quick access to exercises they liked / found helpful),~A recommendation system linking users to the content based on their specific needs or preferences"
75738304|NCT00098839|Drug|dexrazoxane hydrochloride|Given IV
75738305|NCT00098839|Drug|methotrexate|Given IT
75738306|NCT00098839|Drug|etoposide|Given IV
75738307|NCT00098839|Drug|cyclophosphamide|Given IV
75738308|NCT00098839|Drug|leucovorin calcium|Given IV
75738309|NCT00098839|Biological|filgrastim|Given SC
76057473|NCT01971554|Drug|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
76057474|NCT04411459|Other|Invasive mechanical ventilation|Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia
76057475|NCT04664335|Other|questionnaire|if no Reply to questionnaire, telephone interview
76057476|NCT01955083|Device|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
75594578|NCT02271399|Drug|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
75444764|NCT06224621|Procedure|Percutaneous Endocardial Septal Radiofrequency Ablation|Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
75594579|NCT01689038|Drug|F17464|Single dose
75594580|NCT02271438|Drug|Ibrutinib|Participants will receive a single oral dose of 12 capsules (12*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6*140 mg capsules) of ibrutinib in Treatment B.
75594581|NCT02271438|Drug|Moxifloxacin|Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
75738310|NCT02531191|Drug|peficitinib|oral
75738311|NCT01087177|Other|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
75738312|NCT01081639|Drug|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
75738313|NCT01081639|Drug|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
75738314|NCT01081717|Drug|systemic non-biological treatments|as prescribed
75738315|NCT01081717|Biological|anti-TNF biologics|as prescribed
75738316|NCT01081717|Biological|golimumab|as prescribed
76057477|NCT01955083|Device|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
75738317|NCT01081717|Biological|non-anti-TNF biologics|as prescribed
75738318|NCT01081717|Other|general population|non-treated cohort
75738319|NCT03963973|Drug|RDN-929 oral capsule|low, medium and high dose
75738320|NCT03963973|Drug|Placebo oral capsule|matching placebo dose
75594582|NCT02271438|Drug|Ibrutinib-matching placebo|Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
75887051|NCT05766280|Behavioral|iCareer Soft Skills Training for Employment|The telehealth iCareer intervention will be delivered during regular educational or vocational services (i.e., services from the Office of Disability Services (ODS) and/or from the school or college counseling center). Six modules of Soft Skills Training (SST), four group sessions for each module with 60 to 90 min for each session (depending on group size) will be delivered by trained project staff (graduate counseling student assistant or graduate counseling intern) via HIPAA-compliant Zoom videoconferencing. If participants are unable to join by Zoom videoconferencing, telephone (a format widely used in Cognitive Behavior Therapy (CBT) for Post Traumatic Stress Disorder (PTSD) treatment delivery and in CBT for depression) will be utilized. Ethical guidelines for providing telehealth over videoconferencing or phone will be followed.
75887052|NCT05757999|Drug|Magnesium Sulphate|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
75887053|NCT05757999|Drug|Saline|The patients will be pretreated with either an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min. before induction of anesthesia.
75887054|NCT05755958|Device|HIFU treatment in rectal Endometriosis|HIFU treatment of rectal endometriosis
75887055|NCT05755958|Device|SHAM HIFU procedure|SHAM HIFU procedure
75887056|NCT05751122|Other|Dynamic flex cast with neurodevelopmental treatment|"Neurodevelopmental therapy in combination with dynamic flex cast to treat experimental group.~Three times a week, 1 hour session per day.~Dynamic flex casting is casting which manipulate bone alignment and maintains range of motion or sustained stretch. Casting will be changed weekly for 3 months.~Neuro developmental approach is individualized treatment which is attuned to each child's specific problems, aims and goals.~Key elements in NDT are: facilitation (using sensory inputs to improve motor performance), management of compensatory motor behavior, and an overall management strategy (a 24-hour interdisciplinary management approach) NDT involves task specific postures and movements."
75887057|NCT05751122|Other|Rigid Ankle foot Orthosis with neurodevelopmental treatment|"Rigid ankle foot orthosis will be applied to ankle joint at the start of intervention.~Neurodevelopmental treatment will be applied to both groups with protocol; Three times a week, 1 hour session per day.~Assessment on 1st day,6th week and 12th week"
75444765|NCT06224608|Biological|Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)|"1.0ml/bottle, containing 2.5μg/ml low dose, 5μg/ml medium dose, and 10μg/ml high dose of active ingredient.~Take 0.1ml and inject it into the center of the front 1/3 of the palm side of the forearm by the Montessori method Single dose administration."
75738321|NCT01085305|Behavioral|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
75738322|NCT01085305|Behavioral|TAU|Usual treatment for behavioral disorders
75738323|NCT01085383|Drug|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
75738324|NCT03811093|Device|Care as Usual Group|"Each participant randomly assigned to the Care As Usual Group will undergo nine therapy sessions over three weeks using a fully functioning invisa-RED Technology Elite device."
75738325|NCT03811093|Device|Sham Group|"Each participant randomly assigned to the Sham Group will undergo nine therapy sessions over three weeks using a non functioning invisa-RED Technology Elite device."
75887058|NCT05748782|Other|Baska Mask|The Baska mask (Logikal Health Products PTY Ltd., Morisset, NSW, Australia) is a supraglottic airway device introduced in 2012 with many innovations that might be expected to overcome these derangements.
75887059|NCT05748782|Device|Endotracheal tube|BASKA Mask
75738326|NCT01087255|Device|Electronic Pillbox Monitoring System|Daily exposure for six months
75738327|NCT01087411|Behavioral|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
75887060|NCT05739747|Other|Questionnaire|"All patients should complete the following questionnaires:~On the day of surgery:~Patient registration.~Complete medical history.~Gendolcat scale (including the Spanish version of the SF-12 scale).~Spanish version of the catastrophizing scale."
75887061|NCT05739747|Other|Questionnaire|The investigators should complete a questionnaire during the surgical procedure specifying the anesthetic technique used, drugs and doses used and record any incident during the surgical procedure
75738328|NCT01087411|Behavioral|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
75738329|NCT01087411|Dietary Supplement|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
75738330|NCT01087411|Dietary Supplement|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
75738331|NCT00485589|Drug|Methotrexate|Oral repeating dose
75738332|NCT00485589|Drug|Ocrelizumab|Intravenous repeating dose
75738333|NCT00485589|Drug|Placebo|Intravenous repeating dose
75738334|NCT01014273|Procedure|Percutaneous Coronary Intervention|
75738335|NCT01018797|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
75738336|NCT01015599|Behavioral|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
75738337|NCT00490971|Drug|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
75887062|NCT05739747|Other|Questionnaire|The investigators should complete a questionnaire 24 hours after surgery to assess the possible presence of postoperative pain as well as the intensity and need for rescue analgesia.
75738338|NCT00490971|Drug|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
75738339|NCT00490971|Drug|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
75738340|NCT00686075|Biological|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
75738341|NCT00686075|Other|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
75887063|NCT05739747|Other|Questionnaire via telephone call|At 3 months, patients will be called and a structured questionnaire will be completed to assess the presence of chronic postoperative pain.
75738342|NCT00686075|Biological|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
75738343|NCT00686075|Other|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
75887064|NCT05739747|Other|Physical examination|Those women who, after the telephone call, are considered to have chronic post-surgical pain will undergo a physical examination to confirm it. The type of pain and its intensity will also be evaluated. The impact on their daily physical activity and quality of life will be evaluated by means of a questionnaire.
75887065|NCT05734300|Procedure|Combined Endoscopic Laparoscopic Surgery (CELS)|"The main surgical advantage in this procedure is the ability to view the colon intra- and extraluminal simultaneously. The laparoscopic approach enables manipulation and mobilization of the colon, while the endoscopic view secures that the resection is complete and not overlapping the ileac valve or creating stenosis.~Compared to the traditional oncological colon resection, the CELS resection is a minimally invasive procedure - organ sparing procedure leading to a reduced surgical stress response."
75887066|NCT05734300|Procedure|Standard resection|In this study standard resection of the colon will be performed according to complete mesocolic excision (CME) principles.
76057478|NCT01955005|Behavioral|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
75738344|NCT00686075|Biological|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
75738345|NCT00686075|Other|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
75738346|NCT00686075|Biological|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
75738347|NCT00686075|Other|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
75738348|NCT00686075|Biological|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
75738349|NCT00686075|Other|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
75738350|NCT02562677|Device|Transcutaneous Trigeminal Nerve Stimulation|
75738351|NCT02563613|Behavioral|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
75738352|NCT02563613|Behavioral|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
75738353|NCT02563613|Other|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
75738354|NCT00750347|Drug|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
75738355|NCT00750425|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
75738356|NCT02563457|Other|periodontal manual treatment|periodontal manual treatment
75738357|NCT02563457|Other|no periodontal manual treatment|blood sampling
75738358|NCT00745589|Drug|sevelamer hydrochloride|First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
75887067|NCT05731921|Behavioral|The exercise program with the 'Empathy Dress'|The experimental group will be given an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week, by the researchers.
75887068|NCT05729646|Drug|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
75738359|NCT00750503|Behavioral|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
75444768|NCT06224582|Drug|Yinxingmihuan oral solution|Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.
75887069|NCT05729646|Drug|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
75887070|NCT05729646|Drug|S1|S-1 orally intake as perioperative chemotherapy
75444769|NCT06224582|Drug|Placebo|The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
75887071|NCT05726240|Drug|Ghrelin|Treatment in the intervention group will consist of intravenous acylated ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term) infusion in 30 minutes, twice daily, for five days. This treatment will be additional to standard treatment, including intravenous thrombolysis, if indicated.
75887072|NCT05726201|Diagnostic Test|ultrasound|Point-Of-Care Ultrasound (POCUS) As an Early Screening Tool for Diagnosing Skull Fractures In Children With Mild Closed Head Injuries
75887073|NCT05698485|Other|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
75887074|NCT05698485|Other|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
75887075|NCT05698485|Other|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
75887076|NCT05688527|Other|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
75887077|NCT05688527|Other|Toning Essence|DermResults Advanced Toning Essence w/ Mineral Booster twice daily
75887078|NCT05688527|Other|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
75887079|NCT05688527|Other|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
75887080|NCT05688527|Other|Eye Cream|DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
75444770|NCT06224569|Other|Black tea flavoured, whole tea (black tea) drink|Black tea powder containing 50.002 mg of caffeine and 11.470 mg of theanine, to be dissolved in 200 ml boiling water.
75444771|NCT06224569|Other|Black tea flavoured, caffeine-only drink|50.002 mg of caffeine in a black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
75444772|NCT06224569|Other|Black tea flavoured, placebo drink|A black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
75444773|NCT06224569|Other|Green tea flavoured, whole tea (green tea) drink|Green tea powder containing 30.583 mg of caffeine and 11.107 mg of theanine, to be dissolved in 200 ml boiling water.
75887081|NCT05687890|Drug|Placebo of SC0062|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
75738360|NCT00750581|Drug|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
75887082|NCT05687890|Drug|SC0062 low dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
75887083|NCT05687890|Drug|SC0062 medium dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
75444774|NCT06224569|Other|Green tea flavoured, caffeine-only drink|30.583 mg of caffeine in a green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
75594583|NCT02271438|Drug|Moxifloxacin-matching placebo|Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
75738361|NCT00685763|Radiation|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
75738362|NCT00745667|Procedure|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
75887084|NCT05687890|Drug|SC0062 high dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
75887085|NCT05674344|Device|Masimo Temperature device|Non-invasive temperature device
75887086|NCT05661409|Drug|Sugammadex|"Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated."
76057479|NCT01955005|Other|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
76057480|NCT01954927|Drug|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
76057481|NCT01954927|Drug|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
75738363|NCT00745667|Procedure|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
75444775|NCT06224569|Other|Green tea flavoured, placebo drink|A green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
75594584|NCT02271516|Radiation|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
75594585|NCT02272595|Other|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
75594586|NCT02272595|Other|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
75738364|NCT00745745|Device|Device Implantation|ICD lead implantation
75738365|NCT00750659|Drug|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
75738366|NCT02561663|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
75738367|NCT02561663|Other|Placebo|
75738368|NCT00098293|Drug|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
75738369|NCT00098293|Drug|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
75738370|NCT00098293|Drug|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
75738371|NCT04056065|Drug|Normal Saline|In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
76057482|NCT01954771|Behavioral|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
76057483|NCT01954771|Other|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
75887087|NCT05661409|Drug|Placebo|Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
75887088|NCT05652803|Behavioral|bibliotherapy-based psychoeducation program|In this study, the researcher aimed to gain awareness, skills and attitudes in order to help the participants reduce the negative consequences of depression and hopelessness. Based on the general purpose, a separate target has been established for each session of both intervention types. For bibliotherapy-based psychoeducation, story texts compatible with the goals were added to each session, and the psychoeducation part was supported by bibliotherapy. Considering the ability of the elderly to attend the training regularly, their attention and coordination, it was decided that the study would consist of 6 sessions and each session would be 60 minutes on average.
76057484|NCT01997281|Dietary Supplement|dietary fiber-enriched cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~one serving of steamed egg is added for dinner and breakfast"
75738372|NCT04056065|Drug|Centhaquine|In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
76057485|NCT01997281|Other|conventional cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
76057486|NCT04663087|Device|XSTAT|XSTAT application will follow the manufacturer's guidance, with injection into bleeding junctional wounds. A sufficient number of sponges are used to fill the injury void. Repeated XSTAT application is performed in the event of persistent bleeding. The trial packs will contain two devices.
76057487|NCT04663087|Other|Standard of Care|As currently provided by EMS services
75738373|NCT00923741|Drug|Talactoferrin|
75738374|NCT00923741|Procedure|Apheresis|
75738375|NCT04055285|Procedure|Sympathetic Renal Denervation|Catheter-based sympathetic renal denervation (RDN) using radiofrequency, ultrasound, or perivascular injection of neurotoxic agents such as alcohol has been introduced as a minimally invasive alternative treatment option for patients with resistant hypertension. RDN consists of endovascular catalysis of the kidney sympathetic nerves running in the wall of the renal arteries.
75738376|NCT04055285|Device|Implantable Loop Recorder|Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
75738377|NCT00685685|Drug|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
75738378|NCT00685685|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
75738379|NCT01087567|Drug|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
75738380|NCT01087567|Drug|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
75444776|NCT06224556|Combination Product|Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program|"Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.~The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).~Saliva sample will be collected and analyzed."
75738381|NCT00684671|Biological|Twinrix|Intramuscular injection, single dose in left deltoid.
75738382|NCT00684671|Biological|Engerix-B|Intramuscular injection, single dose in left deltoid.
75738383|NCT00684671|Biological|Havrix|Intramuscular injection, single dose in right deltoid.
75887089|NCT05652803|Behavioral|psychoeducation program|The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
75887090|NCT05645887|Drug|Human albumin|Human albumin from day 0 to 7 if serum albumin concentrations <35g/l.
75887091|NCT05645887|Other|Saline solution|Saline solution from day 0 to day 7.
76057488|NCT01953913|Drug|Afatinib|Patient will receive afatinib once daily
76057489|NCT01971476|Drug|volasertib|intravenous administration on day 1of a treatment course
76057490|NCT01996904|Procedure|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
76057491|NCT01996904|Procedure|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
75444777|NCT06224543|Device|SubtleGAD|SubtleGAD is an image processing software developed to enhance MR images acquired with low dose gadobutrol.
75738384|NCT00684671|Biological|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
75738385|NCT00684671|Biological|Vaqta|Intramuscular injection, single dose in right deltoid.
76057492|NCT01970540|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
76057493|NCT01970540|Drug|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
76057494|NCT01963676|Device|tDCS|
75444778|NCT06224543|Drug|Gadobutrol|Gadavist is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
75444779|NCT06224530|Drug|Levetiracetam|Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.
75444780|NCT06224530|Drug|Placebo|Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
75738386|NCT03859323|Drug|SHP681|Participants will receive SC injection of SHP681 in the abdomen.
75444782|NCT06224504|Behavioral|routine health education|guided the diet of patients, and introduced the knowledge of the disease in detail
75444783|NCT06224504|Behavioral|psychological nursing|hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
75444784|NCT06224504|Behavioral|MBSR therapy|Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
75444785|NCT06224504|Behavioral|exercise therapy|Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
75594587|NCT02271555|Drug|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
75594588|NCT02271555|Drug|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
76057495|NCT01963676|Device|Sham stimulation|
76057496|NCT01996826|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
76057497|NCT01996826|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
76057498|NCT01996748|Drug|DF277|Two administrations daily for 7 days
76057499|NCT01996748|Drug|Placebo|Two administrations daily for 7 days
75444786|NCT06224491|Other|Reflex locomotion according to Vojta|Tactile stimulation according to Vojta´s reflex locomotion
75444787|NCT06224478|Other|Measurement of palatal mucosa thickness on CBCT scans|Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients
75444788|NCT06224465|Other|aerobic exercises|"Antiaging diet instruction :Be aware of the amount of calories, Reduce overall fat and sugar intake, Drink at least 10 glasses of water every day in order to remain healthy.~d. Eat a variety of complex carbohydrates and vegetables instead of bread, rice, and corn."
75594589|NCT02271555|Drug|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
75594590|NCT02271672|Device|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
75594591|NCT02271672|Device|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
75594592|NCT01687205|Drug|1% Tenofovir Gel|
75594593|NCT02271711|Other|Laboratory Biomarker Analysis|Correlative studies
75738387|NCT03859323|Other|Placebo|Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
75738388|NCT00750971|Procedure|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
75444789|NCT06224452|Drug|ibrutinib exposure|We will extract all atrial fibrillation cases involving adult patients associated with ibrutinib exposure with an available ibrutinib daily dose
75594594|NCT02271711|Biological|Natural Killer Cell Therapy|Given autologous ex-vivo expanded NK cells IV
75594595|NCT01689194|Drug|genexolPM + cisplatin|
75594596|NCT02271750|Procedure|lumbar puncture|for spinal fluid
75594597|NCT01687361|Dietary Supplement|branched-chain amino acids (BCAA) supplementation|
75594598|NCT01687361|Drug|PLACEBO|
75738389|NCT00751049|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
75738390|NCT00751049|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
75887092|NCT05634291|Other|Standard of care|Standard of care as prescribed by healthcare provider.
75738391|NCT00751985|Other|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
76057500|NCT01621178|Drug|Dulaglutide|Administered SC
75444790|NCT06224439|Procedure|hypobaric spinal anaesthesia|0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
75738392|NCT00751985|Other|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
75738393|NCT00751985|Other|Control|The participant is being informed about their allocation to the control group.
75738394|NCT03857841|Biological|UNEX-42|UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.
75738395|NCT03857841|Biological|Phosphate-buffered saline|Phosphate-buffered saline
75738396|NCT01014429|Drug|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
75738397|NCT00500331|Drug|GSK189075|Experimental Drug
75594599|NCT02271828|Procedure|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
75738398|NCT00500331|Drug|pioglitazone|Active Control
76057501|NCT01621178|Drug|Insulin glargine|Administered SC
76057502|NCT01621178|Drug|Insulin lispro|Administered SC
75444791|NCT06224439|Procedure|lumbar plexus block|ultrasound and nerve stimulator will be used for lumbar plexus block
75444792|NCT06224426|Other|Normobaric high-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=80% through endotracheal intubation, with a gas flow rate set at 1.5 L/min.
75444793|NCT06224426|Other|Normobaric low-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=30% through endotracheal intubation, with a gas flow rate set at 1.5 L/min.
75444794|NCT06224413|Other|No Intervention|This is non-interventional study.
75444795|NCT06224400|Drug|ENC1018 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
75444796|NCT06224400|Drug|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
75594600|NCT01689272|Procedure|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
75594601|NCT02271867|Procedure|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
75594602|NCT01687439|Drug|Endostar|7.5mg/m2, D1-14
75594603|NCT01687439|Drug|Vinorelbine|25-30mg/m2, D1,8
75594604|NCT01687439|Drug|Cisplatin|25 mg/m2, D1-3
76057503|NCT01962974|Biological|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
75594605|NCT01687439|Radiation|Radiotherapy|
75594606|NCT01588704|Drug|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
75444797|NCT06224400|Drug|ENC1018 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
75738399|NCT00500331|Other|Placebo|Placebo Comparator
76057504|NCT01962896|Drug|Erlotinib|
76057505|NCT01962896|Drug|Sirolimus|
76057506|NCT01970462|Drug|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
76057507|NCT01970462|Drug|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
76057508|NCT01958671|Drug|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
76057509|NCT01958671|Drug|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
76057510|NCT01958671|Drug|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
76057511|NCT01958671|Drug|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
75444798|NCT06224400|Drug|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
75444799|NCT06224387|Drug|CTS2190 capsules|subjects will receive CTS2190 orally under fasting condition once a day (QD), with 21 days as a cycle.
75444800|NCT06224348|Drug|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
75444801|NCT06224348|Drug|Placebo|Pharmaceutical form: injection solution Route of administration: SC injection
75444802|NCT06224348|Drug|Topical corticosteroids|Pharmaceutical form: Topical formulation Route of administration: Topical
75444803|NCT06224348|Drug|Topical calcineurin inhibitors|Pharmaceutical form: Topical formulation Route of administration: Topical
75738400|NCT01015755|Behavioral|combined therapy treatment|mouth care
75738401|NCT01019109|Device|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
76057512|NCT01958671|Drug|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
76057513|NCT01958671|Drug|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
76057514|NCT01995266|Drug|Asunaprevir|
76057515|NCT01995266|Drug|Daclatasvir|
76057516|NCT01969058|Drug|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
75444804|NCT06224335|Diagnostic Test|intra-abdominal pressure with Femfit® device during (jumps on the ground, jumps on a trampoline, weightlifting, slow running, fast running|Change in intravaginal and intra-abdominal pressure assessed by Femfit® , leakage of urine in grams assessed by inovative pad test during 5 sports activities.
75738402|NCT00499863|Drug|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
75738403|NCT00499863|Drug|Placebo|Placebo patch
76057517|NCT01968980|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
76057518|NCT01968980|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
76057519|NCT01961882|Drug|OCV-501|
76057520|NCT01961882|Drug|Placebo|
76057521|NCT04174118|Drug|belcesiran|belcesiran will be administered subcutaneously (SC) at dose levels planned.
76057522|NCT04174118|Drug|Placebo|Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
76057523|NCT01968434|Device|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
76057524|NCT01968434|Drug|carbocisteine cough syrup|Mucolytic
76057525|NCT04659902|Dietary Supplement|Protein form|Protein form and absence or presence of calcium manipulated
76057526|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
76057527|NCT01946438|Biological|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
75887093|NCT05634291|Device|Nottingham AR smartphone app with active intervention|AR software treatment delivered by smartphone app and developed by VRx Medical (VRx) using established principles of illusion therapies (e.g. mirror therapy) for pain management.
75887094|NCT05627531|Behavioral|Narrative Medicine|Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
75887095|NCT05626738|Device|ENDORAIL|In case caecal intubation time is longer than 10 minutes, the balloon catheter is inserted in the tool channel, advanced beyond the colonoscope tip and filled with Ferromagnetic Fluid. By applying the Endorail Handpiece over the patient abdomen, the balloon can be magnetically anchored. The anchored balloon guide allows to straighten the scope and the colon itself. The colonoscope can thus be easily moved back and forward along the anchored guide to facilitate colonoscope positioning and colonoscopy completion. Afterward, Endorail is removed and the straightened colonoscope can be easily pushed forward to achieve colonoscopy completion according to standard endoscopic technique.
75594607|NCT01687634|Behavioral|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
75594608|NCT01687634|Behavioral|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
75887096|NCT05621239|Biological|BNT162b2|BNT162b2 half dose and full dose
76057528|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
75444806|NCT06224309|Diagnostic Test|18F-BL40 PET/CT|Vital signs will be recorded prior to the BL40 injection. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the 18F-BL40 from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
75594609|NCT01588743|Drug|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
75594610|NCT01689311|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
75594611|NCT01689311|Drug|Ergonovine|Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
75594612|NCT01689311|Drug|Prostaglandin F2alpha|Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
76057529|NCT01946438|Biological|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
75594613|NCT01689311|Drug|Misoprostol|Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
75594614|NCT01588782|Drug|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
75887097|NCT05614908|Other|11 weeks of immobilization|"Patients wear a scotch cast for the first 4 weeks. After that they are provided with a ROM-WALKER to be worn for the next 7 weeks, during which the ROM-walker is slowly moved from 30 degrees of plantarflexion up to 0 degrees. During the first 10 weeks, patients are not allowed any weight-bearing on the injured leg.~From week 11 they are allowed 30 kg of weight-bearing in the ROM WALKER, and from week 12 full weight-bearing with a 1 cm heel lift in their shoes."
75887098|NCT05587127|Behavioral|Cognitive Behavioral Therapy|Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.
76057530|NCT01946282|Other|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
75594615|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
75594616|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
76057531|NCT01946282|Other|FIT plus $5 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
76057532|NCT01946282|Other|FIT plus $10 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
76057533|NCT01945580|Procedure|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
76057534|NCT01945034|Drug|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
76057535|NCT01945034|Drug|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
76057536|NCT01945034|Drug|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
76057537|NCT01945034|Drug|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
76057538|NCT04655768|Device|Palmar Plate Fixation|Patients are treated by surgery (palmar plate)
76057539|NCT04638062|Other|1.Post Isometric Relaxation|"For Upper Trapezius In supine position Neck flexion, contra-lateral full side bending followed by slight ipsilateral rotation will be provided towards the side being treated. while asking the patient to shrug the stabilized shoulder and contraction will be maintained for 7- 10s. Repeating it 3-5 times.~For Levator Scapulae Step One In supine position while lifting the patients neck in full flexion, lateral flexion and rotation with 7-10s isometric contraction away from side to be treated will be provided.~Step Two The patient will be instructed to take head backwards to the table while at the same time asking the patient to slightly shrug the shoulder and resistance will be provided. Repeating it 3-5 times.~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
76057540|NCT04638062|Other|1.Myofascial Release therapy|"For Upper Trapezius In sitting position Myofascial Release of Trapezius will be performed unilaterally with soft fist or elbow sinking and then taking up the line of tension from mid belly of Trapezius, to the acromion process, while the patient drops the head forward and will slowly rotate the head from side to side. While providing the resistance to contralateral side of rotation. Repeating for 2-3 times.~For Levator Scapulae In sitting position applying same unilateral muscle release as Trapezius, but the line of tension will be to the inferior border of Scapulae slightly laterally and will ask the patient to drop the head forward to increase resistance on Levator muscle. Repeating it 2-3 times~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
76057541|NCT04636970|Other|Home training program|Subjects randomized to the IG will participate at home training program that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after.
75444807|NCT06224309|Diagnostic Test|18F-FDG PET/CT|"The patient will return on another day for the 18F-FDG PET/CT scan. A fasting period of 6 hours is required before this scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
75444808|NCT06224309|Diagnostic Test|Routine Blood Draw - Phase 1 only|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after 18F-BL40 administration.
75444809|NCT06224296|Device|DFPP|One session of blood purification using DFPP to remove inflammatory cytokines in peripheral blood.
75444810|NCT06224296|Device|DFPP|One session of blood purification using DFPP to remove lipids in peripheral blood.
75444811|NCT06224296|Device|DFPP|One session of blood purification using DFPP to remove toxic metal ions.
75594617|NCT02272062|Other|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
75594618|NCT02276456|Behavioral|Follow-up Appointment- early vs standard|Patient will undergo early follow-up (within 7 days of discharge) of discharge
75594619|NCT02273427|Drug|BIIL 284 BS|
75594620|NCT02273427|Other|high fat meal|
75594621|NCT02273427|Other|low fat meal|
75594622|NCT02272101|Dietary Supplement|Vitamin D versus placebo|Cross-over design
75594623|NCT01689467|Dietary Supplement|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
75594624|NCT01689467|Dietary Supplement|Placebo|Placebo (1g/day)
75887099|NCT05586217|Other|INCENTIVE SPIROMETRY|"Sit up and hold the device.~Then Place the mouthpiece spirometer in mouth and make a good seal over the mouthpiece with lips.~Breathe out (exhale) normally.~Breathe in (inhale) slowly. A piece in the incentive spirometer will rise as you breathe in. And try to get this piece to rise as high as you can.~Usually, there is a marker placed by your doctor that tells you how big of a breath you should take.~A smaller piece in the spirometer looks like a ball or disk.~Your goal should be to make sure this ball stays in the middle of the chamber while you breathe in.~If you breathe in too fast, the ball will shoot to the top.~If you breathe in too slowly, the ball will stay at the bottom. Hold your breath for 3 to 5 seconds. Then slowly exhale."
75887100|NCT05586217|Other|Active cycle of breathing|"Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways"
75887101|NCT05563636|Device|standard pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 37-41 V, time 120 s.
76057542|NCT01618214|Drug|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
76057543|NCT01917968|Device|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
75444812|NCT06224283|Procedure|Cryoablation|Cryoablation, a technique used in interventional radiology, involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors
75444813|NCT06224270|Biological|Adjuvanted Recombinant Zoster Vaccine (RZV)|The RZV vaccine is indicated for prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ. Patients with IBD on immunosuppressive therapy are at increased risk for HZ.
75444814|NCT06224257|Drug|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
75444815|NCT06224244|Radiation|Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 40 Gy
75444816|NCT06224244|Radiation|Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 43 Gy
75738404|NCT04475835|Drug|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is <225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
75444817|NCT06224218|Procedure|Single Port Robotic Surgery|Single port Robotic surgery will remove the whole prostate
75444818|NCT06224218|Procedure|Laser Surgery|Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.
75738405|NCT04475835|Drug|Heparin|Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT <225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
75738406|NCT01014507|Drug|8 cycles BEACOPPesc plus oral contraceptive|
75738407|NCT01014507|Drug|8 cycles BEACOPPesc plus Goserelin|
76057544|NCT01917968|Procedure|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
76057545|NCT01917656|Drug|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
75738408|NCT00484185|Drug|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
76057546|NCT01917656|Drug|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
76057547|NCT01917656|Drug|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
76057548|NCT01944722|Device|BD Onclarity™ HPV assay on BD Viper™ LT|The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
76057549|NCT01944722|Procedure|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
76057550|NCT04415918|Drug|Bezlotoxumab Injection|A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
76057551|NCT01917344|Other|MRI|
76057552|NCT02017535|Drug|Fluoxetine|Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
75444819|NCT06224205|Other|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
75738409|NCT00097981|Drug|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
75444822|NCT06224153|Other|3-day dietary record|This is the conventional ingesta assessment. It will be performed twice during the study.
75444823|NCT06224153|Other|Food Frequency Questionnaire (FFQ)|This questionnaire is used to obtain information on the frequency of foods and drinks consumed over a period of time (1 week, 1 month...). It will be performed twice during the study.
75594625|NCT02272218|Procedure|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
75887102|NCT05563636|Device|high-voltage long-term pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 50-90 V, At the beginning, the patient will feel a severe burning sensation in the original pain area, and slowly after the patient tolerates it. Increase the voltage and gradually increase to the maximum voltage that the patient can tolerate (up to 70-90 V) until the end of 900 s.
76057553|NCT02017535|Behavioral|Interpersonal Psychotherapy|Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
75594626|NCT02272335|Behavioral|Group Sessions|"10 weekly sessions:~CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
75594627|NCT02278133|Drug|WNT974|
75594628|NCT02278133|Drug|LGX818|
75594629|NCT02278133|Biological|Cetuximab|
75594630|NCT02277704|Drug|TNX-102 SL|
75594631|NCT02277704|Drug|Placebo|
75594632|NCT00107172|Procedure|surgery|
75594633|NCT00107172|Radiation|brachytherapy|
75738410|NCT00097981|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
76057554|NCT01944098|Drug|Lidocaine|
76057555|NCT01944098|Drug|Placebo|
75594634|NCT01687868|Drug|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
75594635|NCT01687907|Behavioral|Music|
75594636|NCT02272374|Procedure|AVF creation|
75594637|NCT02272374|Procedure|TCC placement|
75594638|NCT02272374|Procedure|AVG creation|
75738411|NCT00097981|Drug|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
75738412|NCT01015911|Drug|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
76057556|NCT02017223|Device|Knowme Device Wear|
76057557|NCT01944020|Device|CPAP|use of CPAP each night for 2 months
76057558|NCT01943552|Drug|placebo|normal saline
76057559|NCT01943552|Drug|ipratropium bromide|ipratropium bromide
76057560|NCT01915940|Drug|Bimatoprost|Bimatoprost ocular insert
76057561|NCT01915940|Drug|Timolol 0.5%|Timolol 0.5% solution
76057562|NCT01915940|Drug|Placebo Eye Drops|Placebo topical eye drops
76057563|NCT01915940|Device|Placebo Ocular Insert|Ocular insert without any active drug
76057564|NCT01914926|Drug|Metoprolol|
76057565|NCT01914926|Drug|Diltiazem|
76057566|NCT02016755|Biological|HGF Plasmid|Intramuscular injection in the affected limb.
75738413|NCT03997149|Behavioral|Acute Laboratory Stressor|The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
75738414|NCT03997149|Behavioral|Low affect video|The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
75738415|NCT01016145|Drug|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
75738416|NCT01016145|Drug|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
75738417|NCT03741283|Other|Optimisation of nutrition and medication|"Inter-professional optimisation of medication prescribing:~Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~Dysphagia: occupational therapy intervention.~Oral cavity problems: odontological intervention.~Depression: geriatric intervention.~Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention."
75738418|NCT01016223|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
75738419|NCT01016223|Drug|placebo|Matched placebo swallowed two puffs twice daily
75887103|NCT05561881|Other|popliteal artery and the capsule of the posterior knee (IPACK) block|ultra-sound visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to the lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
75887104|NCT05561881|Other|genicular nerves block|ultra-sound transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, A20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming placing of the needle next to each genicular artery a total amount of 20 ml local anesthetic in equal increments at multiple sites.
75887105|NCT05558735|Other|urine collection|urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
75887106|NCT05558735|Other|canine detection|urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
75887107|NCT05557136|Device|Multistranded stainless steel fixed retainer|Multistranded stainless steel fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
75887108|NCT05557136|Device|Polyether-Ether-Ketone (PEEK) fixed retainer|Polyether-Ether-Ketone (PEEK) fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
75887109|NCT05553509|Other|PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY|SURGICAL DEBRIDEMNT
75887110|NCT05551273|Drug|Selgantolimod|1.5 mg tablet
76057567|NCT05119166|Dietary Supplement|Vitamin B3|ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
75444826|NCT06224127|Device|active heat|Users receive an active Soovu heating pod(s).
75444827|NCT06224127|Drug|Active c tactile fiber stimulation|Hair brushes that activate c tactile fibers
75444828|NCT06224127|Device|sham heat|A Soovu heating pod(s) in the subtherapeutic temperature range
75444829|NCT06224127|Device|Sham c tactile fiber stimulation|Hair brushes that do not activate c tactile fibers
75444830|NCT06224114|Device|Coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a coloured-light torch to the study eye.
75887111|NCT05551273|Drug|Placebo|Matching placebo tablet
76057568|NCT05119166|Biological|Azithromycin|"ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.~VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant."
75444831|NCT06224114|Device|Different coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a different coloured-light torch to the study eye.
75444833|NCT06224088|Other|VV ECMO|treatment with VV ECMO in the ICU
75594639|NCT01688024|Drug|Mitomycin C|
75594640|NCT01688024|Drug|Normal saline|
75594641|NCT01689506|Drug|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
75594642|NCT01689506|Drug|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
75594643|NCT02272452|Device|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
75738420|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
75738421|NCT01087645|Drug|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
75594644|NCT01689545|Behavioral|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
75887112|NCT05543551|Other|Diaphragmatic breathing with Resistance Training|"Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees."
75738422|NCT01087645|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
75594645|NCT01689545|Behavioral|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
75887113|NCT05543551|Other|diaphragmatic breathing with out resistance training|"Diaphragmatic Breathing:~Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~Place one hand on your upper chest and the other on your belly, just below your rib cage.~Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
75887114|NCT05541653|Other|Financial Well-being Interventions|Tax preparation; access to public benefits; financial counseling and microgrants
75887115|NCT05541653|Other|Place-based Interventions|Vacant lot greening; abandoned house remediation; trash cleanup; and tree planting.
75887116|NCT05523206|Other|No intervention|No intervention
75444834|NCT06224075|Behavioral|Task-specific training|"Participants in the intervention group will receive the treatment established for the control group and nursing care based on task-specific training. The intervention was designed with the aim of improving inhaler management in COPD patients. The content of the tasks will be adapted to the different types of devices present in the patient's therapeutic regimen, mainly pressurized cartridge and dry powder devices.~In order to carry out the intervention, several tasks related to education, assessment and/or training will be established with the aim of improving the ability to use the prescribed inhalers. The tasks have been classified into 3 blocks: technique execution, device cleaning and medication administration."
75594646|NCT01689545|Behavioral|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
75594647|NCT01689545|Behavioral|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
75594648|NCT04059861|Diagnostic Test|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
75594649|NCT01689623|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
75738423|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
75738424|NCT01087645|Drug|placebo|Subjects will be randomised to receive a single dose of placebo
75738425|NCT04151121|Behavioral|MBCT (Mindfulness Based Cognitive Therapy)|MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
75594650|NCT01689623|Drug|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
75594651|NCT01689623|Drug|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
75738426|NCT04151017|Other|Autologous fibrin glue|Conjunctival graft fixation with autologous fibrin glue
75738427|NCT04151017|Other|Suture|Graft fixation using 10.0 mononylon
75738428|NCT01019265|Drug|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
75738429|NCT03963661|Behavioral|c-SIGHT (computorized spatial innatention grasping home-based therapy)|C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
75887117|NCT05509218|Behavioral|Mobile-delivered personalized feedback|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.
75887118|NCT05508698|Behavioral|Precommitment Nudge|Ask participants to commit to a decision about getting a flu shot
75887119|NCT05508698|Behavioral|Salience|Additional text and icon in the flu shot alert makes the pre-visit questionnaire response salient to the clinician, which could facilitate action or further discussion with the patient
75887120|NCT05507931|Dietary Supplement|1 Serving of broccoli sprouts|Participants will take 1 serving of broccoli sprouts daily for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
75887121|NCT05507931|Dietary Supplement|3 Servings of broccoli sprouts|Participants will take 3 servings of broccoli a day for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
76057569|NCT05119166|Dietary Supplement|Fortified food supplement|"VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.~MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label)."
76057570|NCT01942148|Drug|Aripiprazole|
76057571|NCT02030015|Drug|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
75594652|NCT04055142|Procedure|electrocoagulation|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
75594653|NCT04055142|Drug|cidofovir 1% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
75594654|NCT04055142|Drug|sinecatechins 10% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
75594655|NCT02272569|Device|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
75594656|NCT01688258|Procedure|Diagnostic swab|
75594657|NCT02272608|Other|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
75738430|NCT01087879|Drug|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
75887122|NCT05502081|Drug|Casirivimab and Imdevimab Drug Combination|antiviral Monoclonal Antibodies
75594658|NCT01688297|Biological|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
76057572|NCT02030015|Other|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
75594659|NCT01688297|Biological|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
75738431|NCT01087879|Drug|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
75738432|NCT01087879|Drug|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
75738433|NCT01019421|Drug|Lu AE58054|Add-on treatment to donepezil
75738434|NCT01019421|Drug|Placebo|Add-on treatment to donepezil
75738435|NCT01085695|Drug|rabeprazole|10 mg normal tablet
75738436|NCT01085695|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
75887123|NCT05502081|Drug|Remdesivir|antiviral drug
75887124|NCT05502081|Drug|Favipiravir|antiviral drug
75887125|NCT05494385|Drug|Preoperative Gabapentin/Postoperative Placebo|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to placebo every 12 hours. The placebo is encapsulated to appear identical to the active drug. This group will have oxycodone 5 mg every 6 hours as needed for pain.
75594660|NCT04054323|Behavioral|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
75594661|NCT05138354|Other|Low Level laser therapy|MLS® device (ASA Srl, Vicenza, Italy) IR laser with two synchronized sources (laser diodes) and a wavelength of 808 nm to deliver the intervention. The laser probe will be held vertically in contact with the skin to deliver the irradiation at three mandibular condyle points (front, behind and over) and one point at the external acoustic meatus. The irradiation will be applied with a laser bean of 3.14 cm² diameter for 14 seconds at each place using a pulse rate of 1500 Hz, pulse duration of 100ns, and energy density: 16 J/cm².
75738437|NCT01085695|Drug|rabeprazole|Type 2 granule containing rabeprazole 10 mg
75738438|NCT01085695|Drug|rabeprazole|Type 3 granule containing rabeprazole 10 mg
75738439|NCT00572195|Device|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
75738440|NCT01088035|Drug|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
75738441|NCT03961477|Other|Interferential therapy|Exercise therapy
75738442|NCT01085851|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
75738443|NCT01085851|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
75738444|NCT00751127|Drug|PhXA41|One drop in the affected eye once daily for six months.
75738445|NCT00751127|Drug|timolol|One drop in the affected eye twice daily for six months.
75887126|NCT05494385|Drug|Preoperative Gabapentin/Postoperative Gabapentin|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to gabapentin every 12 hours. The gabapentin is encapsulated to appear identical to the placebo. This group will have oxycodone 5 mg every 6 hours as needed for pain.
75887127|NCT05494073|Procedure|ACL Reconstruction with Hybrid Remnant Repair|The intervention includes the incorporation of the host ACL remnant into the graft. The intervention hopefully
75887128|NCT05494073|Procedure|ACL Reconstruction without Hybrid Remnant Repair|ACL reconstruction without preservation or incorporation of host ACL remnant
75738446|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
75887129|NCT05486286|Device|NCKU-NG system|A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes. This system consists of a camera and light source that can be inserted into the commercial NG tube to view live video during feeding tube placement. Manual air insufflation may aid feeding tube placement and improve visualization of anatomic landmarks. After the procedure, an abdominal X-ray is done to confirm the position of the feeding tube.
75887130|NCT05483712|Device|Brass Mesh Bolus|During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
75887131|NCT05482997|Dietary Supplement|Whey Protein Concentrate|whey-based protein powder 32g powder mixed with 8-12 oz water
75887132|NCT05482997|Dietary Supplement|Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein|plant-based protein powder. 32g powder mixed with 8-12 oz water
75887133|NCT05471973|Other|Multidisciplinary Team|Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
75887134|NCT05471973|Other|Outreach Visits|An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
75887135|NCT05471973|Other|Multifaceted Intervention|These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
75887136|NCT05471973|Other|Measurement and Feedback|The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
75887137|NCT05471414|Behavioral|Whole-food, Plant-Based Diet|Pre-packaged, plant-based meals (prepared by Plantable) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals using Plantable's assistance.
75887138|NCT05471414|Behavioral|General Nutritional Counseling|"All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls."
75594662|NCT05138354|Other|Myofascial release|Patients will be positioned in supine in a treatment table. The therapist seated beside the patient at the side of affected temporomandibular joint to apply gross release technique for masseter, pterygoid and temporalis muscles. At each point, the therapist applied the technique for 90 seconds and repeated 5 times during the session (5 seconds of rest between each repetition).(15) The therapist worn gloves to deliver the intraoral myofascial release. In case the patient reported any latex allergies, the gloves were replaced by a latex free model.
75738447|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
75738448|NCT00572039|Behavioral|PST|PST will be delivered in subjects' homes over the course of 6 weeks.
75738449|NCT00572039|Behavioral|ST|ST will be delivered in subjects' homes over the course of 6 weeks.
75738450|NCT00751283|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
75738451|NCT00752063|Drug|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
75738452|NCT00751361|Device|Rheopheresis / double filtration plasmapheresis|Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
75738453|NCT00684593|Drug|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
75738454|NCT00684593|Other|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
75738455|NCT00752141|Drug|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
75738456|NCT00752141|Drug|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
75738457|NCT00752141|Other|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
75887139|NCT05469555|Procedure|High Resolution Oesophageal Manometry|High Resolution Oesophageal manometry assesses how well the muscles of the oesophagus are working when you swallow. It also checks the relaxation of the valves at the top and bottom of the oesophagus.
75738458|NCT03879317|Device|Continuous NIRS monitoring|Septic shock patients who have continuous NIRS and blood pressure monitoring at same time will be included. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
75887140|NCT05468398|Device|Soothe VR|The Soothe VR system is manufactured by Applied VR. It is a HIPAA-compliant platform and has been validated by randomized control trials. It has not yet been reviewed by the FDA.
75738459|NCT00752375|Drug|Trimethoprim Sulfamethoxazole|"Children >3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
75887141|NCT05459519|Drug|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
75887142|NCT05459519|Drug|Placebo|Placebo, 4 capsules each time, twice daily
75887143|NCT05459519|Drug|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
75444835|NCT06224075|Other|Usual care|All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
75444836|NCT06224062|Biological|SARS-CoV-2|Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.
75444837|NCT06224062|Biological|Adenovirus (AdV)|Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors
75444838|NCT06224062|Biological|Rhinovirus|RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study
75594663|NCT05138354|Other|Standard care|"Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~Lateral movements of the jaw (3 sets of 10 repetitions).~Jaw relaxation exercise (3 sets of 10 repetitions).~Chin tuck (10 repetitions, holding 10s each).~Resisted opening of the mouth (3 sets of 10 repetitions).~Resisted closing of the mouth (3 sets of 10 repetitions).~Stretching exercise for mandibular muscles."
75594664|NCT02272647|Drug|IM Saline Placebo (0.25 ml)|
75887144|NCT05455294|Drug|Navitoclax|See Arm Description
75594665|NCT02272647|Drug|IM Estradiol valerate (2.5 mg)|
75594666|NCT02272647|Drug|IM Saline Placebo (0.5 ml)|
75594667|NCT02272647|Drug|IM Estradiol valerate (5.0 mg)|
75887145|NCT05455294|Drug|Venetoclax|See Arm Description
75887146|NCT05455294|Drug|Decitabine|See Arm Description
75444839|NCT06224062|Biological|No Intervention|no infection
75594668|NCT02272647|Drug|Oral Micronized Progesterone|
75594669|NCT02272647|Drug|Oral Placebo|
75594670|NCT02272647|Drug|Ghrelin (0.3 ug/kg)|
75594671|NCT02272647|Drug|Medroxyprogesterone - Acetate|
75594672|NCT02272647|Drug|Oral Placebo|(in lieu of Medroxyprogesterone)
75594673|NCT01689818|Other|exercise training|exercise training program which included aerobic exercise for 3 times per week.
75594674|NCT02272764|Drug|Itraconazole|Administered orally in a crossover design
75594675|NCT02272764|Drug|ALKS 5461|Administered sublingually in a crossover design
75594676|NCT01689896|Drug|Testosterone Gel|
75738460|NCT00752375|Drug|placebo|"Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
75738461|NCT00751517|Drug|Methotrexate|
75887147|NCT05442346|Biological|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103
75887148|NCT05437796|Device|Hypnotic virtual reality support using hypnosis software Hypno-VR®|Hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
76057573|NCT02029235|Drug|Acetaminophen/Ibuprofen|Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
76057574|NCT02029235|Drug|Acetaminophen/Hydrocodone|Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
76057575|NCT01617434|Drug|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
76057576|NCT01617434|Drug|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
76057577|NCT01940900|Drug|E10030|
76057578|NCT01940900|Drug|ranibizumab|
76057579|NCT01940900|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
76057580|NCT01940354|Device|AccuCath IV Catheter System|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
76057581|NCT01940354|Device|Conventional IV Catheter System|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
75444840|NCT06224049|Biological|hNeo-T|After subject screening, peripheral blood mononuclear cell （PBMC） donors matching half or more of the subject's HLA matching will undergo blood collection to prepare hNeo-T injection. hNeo-T injection is expected to be ready for clinical study 35-39 days after blood collection. In this study, bridging therapy is allowed before chemotherapeutic treatment, and it is up to the investigators to decide whether to use it and the time and program of bridging therapy. Lymphocyte clearance pretreatment was performed before hNeo-T injection transfusion. If the absolute value of lymphocyte (LYM) before pretreatment is <0.8×10^9/L and meets the criteria for cell reinfusion, no pretreatment is required and subsequent cell reinfusion can be performed directly.
75444841|NCT06224049|Drug|Cyclophosphamide|Lymphocyte clearance pretreatment was performed before hNeo-T injection transfusion
75444842|NCT06224049|Drug|Fludarabine|Lymphocyte clearance pretreatment was performed before hNeo-T injection transfusion
75444843|NCT06224036|Drug|JDB0131|"JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
75594677|NCT01689896|Drug|Placebo Gel|
75594678|NCT01316094|Drug|ASP1941|oral
75594679|NCT01316094|Drug|placebo|oral
75594680|NCT01689935|Drug|20 % Aminolevulinic Acid|topical medication for ALA-PDT and i-PDT
75594681|NCT01689935|Device|Red light only|Red Light therapy
75738462|NCT00751517|Drug|Cyclophosphamide|
75887149|NCT05437796|Device|No Hypnotic virtual reality|Group without Hypnotic virtual reality
75887150|NCT05399095|Behavioral|Supine positioning: 5 days|Supine positioning for 5 days after DMEK
75887151|NCT05399095|Behavioral|Supine positioning: 1 days|Supine positioning for 1 days after DMEK
76057582|NCT01940120|Device|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
76057583|NCT01911260|Dietary Supplement|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
76057584|NCT01911260|Other|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
76057585|NCT02015819|Biological|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
76057586|NCT02015819|Drug|flucytosine|Given orally
76057587|NCT02015819|Drug|leucovorin calcium|Given orally
76057588|NCT02015819|Other|pharmacological study|Correlative studies
76057589|NCT02015819|Other|laboratory biomarker analysis|Correlative studies
75594682|NCT01689935|Device|Blue light only|Blue light only
75594683|NCT01316133|Drug|tacrolimus|oral
75594684|NCT01684826|Radiation|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
75594685|NCT01684826|Radiation|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
75594686|NCT01316172|Behavioral|5 Cs|education on consultation
75738463|NCT00751595|Biological|Tat protein|Biologically active recombinant Tat protein
75738464|NCT00685373|Drug|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
75738465|NCT02561117|Drug|Metronidazole|Administration once daily
75738466|NCT00684515|Drug|Vorapaxar 2.5 mg|Oral tablets; once daily for 60 days.
75738467|NCT00684515|Drug|Vorapaxar 1 mg|Oral tablets; once daily for 60 days
75738468|NCT00684515|Drug|Placebo|oral tablets; once daily for 60 days
75738469|NCT00684515|Drug|Aspirin 75-150 mg|oral tablets; once daily for 60 days
76057590|NCT01939496|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
76057591|NCT01939496|Drug|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
76057592|NCT01939028|Procedure|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
75738470|NCT00751751|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
75594687|NCT05654064|Drug|Remifentanil-dexmedetomidine|Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
75738471|NCT00751751|Drug|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
75887152|NCT05396014|Behavioral|Enhanced Self-Care (ESC)|The Enhanced Self-Care intervention will be comprised of educational modules on evidence-based cognitive-behavioral self-management skills for pain. These modules will be provided digitally for self-administration over a period of 12 weeks. There will be no therapist associated with the delivery of these educational materials; however, after the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment. Additionally, the walking program module will utilize Fitbit step tracking to allow participants to monitor their walking progress.
75887153|NCT05396014|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a form of cognitive behavioral therapy that is well established for the treatment of chronic pain. The goal of ACT is to build psychological flexibility thereby interrupting pain avoidance behavior patterns. Participants randomized to ACT will take part in 12 sessions over the course of 12 weeks. Sessions will be delivered as a combination of 4 remote face-to-face visits with a therapist and 8 therapist-supported online sessions (self-directed online modules supported by provider coaching). Online sessions will focus on helping participants accept pain, connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. During face-to-face sessions with the therapist, participants will be encouraged to share their experience of skills practice and mastery, provide examples of skill use at home, and describe what barriers they encountered.
75887154|NCT05396014|Behavioral|Evidence-Based Exercise and Manual Therapy (EBEM)|Licensed physical therapists (PTs) or Doctors of Chiropractic (DCs) will rely on evidence-based guidance to direct decision-making on the particular type of manual and exercise therapy that may be best suited to an individual study participant. Special attention will be paid to the clinician's choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions. A total of 10 sessions will be provided over an 8-week treatment period. Two sessions per week are provided in the first two weeks followed by weekly sessions over the next 6 weeks. Treatment sessions will last approximately 60 minutes each.
75887155|NCT05396014|Drug|Duloxetine|Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for use in Chronic Low-Back Pain, and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low back pain. Study participants will be treated with duloxetine for 12 weeks during the active treatment phase. At the time of randomization, the approved drug pharmacy at each study site will dispense between 185 and 192 duloxetine 30 mg capsules and provide to participants. This will ensure enough capsules to maintain up to a 60 mg dosage through the 12-week intervention phase and to taper the dose in the 13th week if needed.
75887156|NCT05393882|Radiation|Computed tomography coronary angiogram|"Preparation~Rate control with oral beta-blockers or calcium channel blockers to achieve the target heart rate of 60 to 70 beats per minute~Sublingual Nitroglycerin to be given on table if not contraindicated, 5 minutes prior to scanning~18G angiocath at a large antecubital vein for intravenous contrast injection~Scanning procedure Contrast CT angiogram (Retrospective gating)~Contrast medium and injection protocol: 75ml Omnipaque 350 with 50ml saline chaser~Automatic triggering started at the aorta of the level of left main coronary artery when the relative reached 100~Scanning coverage: From the thoracic inlet to diaphragm"
75594688|NCT05654064|Drug|Dexmedetomidine-fentanyl|Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
75594689|NCT01689233|Drug|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
75594690|NCT01689233|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
75738472|NCT00490815|Drug|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
75738473|NCT00490815|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
75738474|NCT01016301|Other|Pharmacist service|Medication Review, medication report
75738475|NCT01014663|Behavioral|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
75887157|NCT05392868|Device|SDF|38% silver diamine fluoride solution
75887158|NCT05392868|Device|KNO3|5% potassium nitrate solution
76057593|NCT01939028|Procedure|sentinel lymph node biopsy|Undergo SLN biopsy
76057594|NCT01939028|Drug|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
76057595|NCT01939028|Drug|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
76057596|NCT01939028|Procedure|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
76057597|NCT01939028|Procedure|lymphadenectomy|Undergo para-aortic lymphadenectomy
75738476|NCT01014663|Behavioral|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
75738477|NCT01019499|Other|berry products|"effects of berry consumption on cardiovascular indicators~two portions daily"
75738478|NCT01019499|Other|control products|two portions daily
75738479|NCT04453137|Biological|Adalimumab originator|Subcutaneous injection every other week
75594691|NCT02272881|Procedure|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
75594692|NCT02272881|Procedure|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
75738480|NCT04453137|Biological|Adalimumab biosimilar|Subcutaneous injection every other week
75738481|NCT03855189|Drug|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
75738482|NCT03855189|Drug|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) [336 mcg total dose per day] for 4 weeks.
75738483|NCT03855189|Drug|Placebo|Placebo nasal spray administered for 4 weeks.
75887159|NCT05390788|Other|Application Of Neuromuscular Bands; Kinesio Taping|"Kinesio tape is a specialized elastic and adherent adhesive tape that mimics the elasticity of skeletal muscle, in that it can be extended up to 140% of its original length, before application to the skin, without allowing restrictions in the range of motion. of structures. Subsequently, it provides a tensile (shear) force on the skin, consisting of a fabric with special characteristics, such as air permeability and water resistance, and can be used for repeated days. Kinesio will be applied from a point 10 cm below the anterior superior iliac spine and divided in a Y shape above the patella, ending at the tibial tuberosity; from the upper third of the medial thigh to the medial border of the patella; from the greater trochanter of the femur, ending at the lateral margin of the patella."
75887160|NCT05381779|Other|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
75444844|NCT06224036|Drug|Delamanid|Delamanid is a new drug developed by Otsuka Pharmaceutical Co., Ltd. in Japan to treat multidrug resistant tuberculosis. In 2014, Delamanid was conditionally approved for marketing by the European Medicines Agency and recommended for use in adult MDR-TB patients who cannot form an effective regimen due to drug resistance or tolerance reasons. In the same year, WHO recommended that Delamanid be conditionally used for long-term treatment of adult MDR-TB. In 2016, the WHO recommended widening the age range for Delamanid to 6-17 years old. In March 2018, Delamanid was listed in China.
75444845|NCT06224036|Drug|Ethylpyrazine rifampicide (II)|Ethylpyrazine rifampicide (II) is suitable for the first two months of intensive treatment of pulmonary tuberculosis with short-term therapy. This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol hydrochloride (C10H24N2O2 · 2HCl) per tablet.
75738484|NCT03853551|Drug|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.
75444847|NCT06224010|Other|Respiratory drive and effort assessment|The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients
75594693|NCT01687985|Drug|BLI801 laxative - low dose|BLI801 laxative - oral solution
75594694|NCT01687985|Drug|BLI801 laxative - high dose|BLI801 laxative - oral solution
75594695|NCT01686620|Drug|BIOD-123|
75594696|NCT01686620|Drug|Lispro (Humalog)|
75738485|NCT00423670|Drug|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
75738486|NCT00423670|Drug|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
75738487|NCT00423670|Drug|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
75738488|NCT00423670|Drug|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
75738489|NCT03996759|Diagnostic Test|Laboratory diagnostic medicine|Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
75738490|NCT01016379|Genetic|DNA analysis|
75887161|NCT05381779|Other|High Intensity Interval Training Group|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
75887162|NCT05381779|Other|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
75887163|NCT05367882|Diagnostic Test|ELISA|collection of blood samples from critically ill COVID-19 patients, then serum samples are collected after centrifugation measuring IL-6, IL-10 and IP-10 by ELISA
75887164|NCT05357560|Biological|Matrix-M with RH5.2 VLP and/or R21|3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints
75887165|NCT05356585|Genetic|SignateraTM assay|A customized tumor-informed ctDNA test that, after receiving the tumor tissue, examines whole exome sequencing of a biopsied tumor to find the somatic tumor-derived mutations. From those mutations, the 16 most clonal mutations are used to create a personal assay
75444848|NCT06223984|Drug|pulse steroid and nanogam|patients received pulse steroid and ivig treatments in addition to standard treatment.
75738491|NCT01016379|Other|biologic sample preservation procedure|
75738492|NCT01016379|Other|laboratory biomarker analysis|
75444851|NCT06223958|Drug|OTX-TKI (axitinib implant)|Intravitreal Injection of OTX-TKI (axitinib implant)
75444852|NCT06223958|Drug|Aflibercept|Injection of 2mg (0.05mL) of aflibercept
75444853|NCT06223945|Diagnostic Test|Prevention algorithm|Development of an algorithm for the prevention of thrombohemorrhagic complications
75594697|NCT01685255|Drug|Epacadostat|
75444854|NCT06223932|Drug|Molnupiravir|COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
75594698|NCT01685255|Drug|tamoxifen|
75594699|NCT01684163|Drug|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
75594700|NCT01684163|Drug|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
75594701|NCT01684163|Drug|Placebo|Intravenous administration of normal saline into arm.
75594702|NCT05653284|Drug|AK130|IV infusion, specified dose on specified days.
75594703|NCT01680965|Drug|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
75594704|NCT02272920|Procedure|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
75594705|NCT02272959|Behavioral|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
75594706|NCT02272959|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
75594707|NCT05140304|Device|OCT angiography|OCT angiography of foveal avascular zone in diabetic retinopathy
75594708|NCT01683188|Drug|vemurafenib + HD IL-2|
75594709|NCT01339923|Biological|rMenB + OMV NZ vaccine|3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
75594710|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (3.5, 5 months of age) plus booster (11 months of age)
75594711|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (6, 8 months of age) plus booster (11 months of age)
75594712|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses 2 months apart
75738493|NCT01019577|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
75738494|NCT05072535|Drug|HA121-28 tablet B|HA121-28 tablet B 200 mg
75738495|NCT05072535|Drug|HA121-28 tablet A|HA121-28 tablet A 200 mg
75738496|NCT03996681|Drug|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
75738497|NCT01019655|Drug|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
75738498|NCT01019733|Procedure|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
75594713|NCT01339923|Biological|Meningococcal C oligosaccharide conjugated vaccine|Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
75594714|NCT01339923|Biological|Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.|Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
75594715|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 3, 5, 12 rMenB + OMV vaccine
75887166|NCT05345769|Biological|AM712(ASKG712)|AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
75887167|NCT05345392|Behavioral|Mindfulness-Based Intervention (MBI)|The mindfulness-based intervention is based on mindfulness-based stress reduction and mindfulness-based cognitive therapy, borrowing publicly available materials from the Mindfulness in Schools Program and Acceptance and Commitment Therapy. The MBI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
75887168|NCT05345392|Behavioral|Health and Wellness Intervention (HWI)|The control intervention is inspired by the Health Enhancement Program that has been adapted for youth 11-14 years old, using brief, engaging, and age-appropriate activities to address topics related to physical and mental health. HWI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
75887169|NCT05345158|Procedure|Robotic Retroperitoneal Lymph Node Dissection (RPLND)|Robotic RPLND performed using the DaVinci robotic surgical system.
75594716|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 13,15 rMenB + OMV vaccine
75594717|NCT04615832|Device|Toffee Full Face Mask|Full face mask for PAP therapy applied in a home environment
75594718|NCT05652036|Biological|Intradetrusor Botox Injections|100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
75738499|NCT00483717|Drug|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
75738500|NCT00483717|Drug|Placebo|Intranasal (IN) placebo
75887171|NCT05339997|Other|6 minute walk test,|submaximal exercise test used to evaluate the functional capacity of patients
76057598|NCT01938716|Drug|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
75738501|NCT00406354|Drug|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
75887172|NCT05304689|Diagnostic Test|test for quantitative index of interleukins in the oral fluid|collection of oral fluid and determination of the content of cytokines by test systems in patients with postoperative wound
75887173|NCT05298891|Other|Usual clinical practice + hypoproteic diet|"Diet will be composed by:~energy equal to daily energy expenditure (estimated by indirect calorimetry * physical activity factor)~fats 28-35%~carbohydrates 50-60%~proteins 0,7-0,8g/kg of body weight 10-13% Diet will be given to the patient after the first visit and the study will start once the patient begins the diet."
75887174|NCT05271643|Behavioral|Cognitive Behavioral Therapy (CBT)|CF-CBT-A is an 10-session program for adolescents with cystic fibrosis introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained mental health clinician on their CF team who will guide them through learning and practicing coping skills. Parents/guardians involvement will be encouraged. A parent/guardian will attend the baseline and final session, have the opportunity for a mid-program check-in, and receive a workbook of psychoeducational material that parallels the adolescent workbook, featuring tips for supporting their teens, and weekly e-mail communication.
75887175|NCT05269888|Other|Blood Test 1|"Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
75887176|NCT05269888|Other|Blood Test 2|"Blood test 2 - At 18 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
75887177|NCT05263557|Dietary Supplement|Dehydroepiandrosterone (DHEA)|Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.
75887178|NCT05263557|Dietary Supplement|11-ketoandrostenedione (11KA4)|11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.
76057599|NCT01937390|Drug|Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation|Respimat® inhaler and cartridge Solution for inhalation
76057600|NCT01937390|Drug|Indacterol 300 µg|inhalation powder
76057601|NCT01937390|Drug|Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule|HandiHaler® device Inhalation powder, hard capsule
76057602|NCT01937390|Drug|Indacterol 150 µg|inhalation powder
75594719|NCT05651334|Device|Active repetitive Transcranial Magnetic Stimulation|Active stimulation
75594720|NCT05651334|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham stimulation
75594721|NCT05650905|Device|Dynamic Vessel Analyzer (DVA)|Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
75594722|NCT05650905|Device|Fourier domain optical coherence tomography (FDOCT)|Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
75738502|NCT00406354|Drug|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
75738503|NCT01037842|Drug|Mitiglinide|"mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks"
75738504|NCT01037842|Drug|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
75887181|NCT05219110|Other|Infusion of 200% maintenance fluids as balanced crystalloid IV solution|Infusion of 200% of maintenance fluids x 24 hours provided, ideally, as a balanced crystalloid (PlasmaLyteTM, Ringer's Lactate) IV solution. Electrolytes and dextrose may be administered as required and desired by the clinical care team; customized solutions are permitted if so desired. Intravenous fluid solutions containing < 130 mEq/L sodium may increase risk for hyponatremia and may be less effective in achieving intravascular volume expansion and should be avoided.
75738505|NCT01037920|Behavioral|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
75738506|NCT01037920|Behavioral|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
75738507|NCT00483405|Biological|cetuximab|250 mg/m2, intravenously, once per week
75887182|NCT05219110|Other|Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution|Administration of less than or equal to 110% of maintenance fluids as oral or balanced crystalloid IV solution.
75887183|NCT05212948|Drug|S-268019-b|Solution for IM injection
75887184|NCT05212948|Drug|Placebo|Saline solution for IM injection
75594723|NCT05650905|Device|Optical coherence tomography (OCT)|Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
75594724|NCT05650905|Device|Laser Speckle Flowgraphy (LSFG)|Normalized blur and Relative flow volume will be assessed using the LSFG
75594725|NCT05650905|Diagnostic Test|Proteomics and Metabolites in Plasma, tear fluid and finger sweat|Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
75594726|NCT05140109|Other|Arm 1: Cognitive-dissonance based program|The first four sessions focus on body image and the last four sessions on eating behavior.
75594727|NCT05140109|Other|Arm 2: Mindfulness-based program|The sessions focus on different contents as body image, eating behavior and emotion regulation.
75594728|NCT05140109|Other|Arm 3: Person-centered program|The sessions are not structured. Participants can bring any subject they need to talk.
75594729|NCT04195919|Drug|Evogliptin 5mg|Participants receive Single oral administration of Evogliptin 5mg on day1
75594730|NCT04195919|Drug|Evogliptin 5mg|"Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period"
75594731|NCT01380093|Drug|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
75887185|NCT05212155|Behavioral|family-based behavioral treatment (FBT)|Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
75887186|NCT05201300|Drug|Remimazolam Besylate 6 mg/kg/hr|Patients will receive remimazolam at 6 mg/kg/hr by continuous infusion until loss of consciousness.
75887187|NCT05201300|Drug|Remimazolam Besylate 12 mg/kg/hr|Patients will receive remimazolam at 12 mg/kg/hr by continuous infusion until loss of consciousness.
75887188|NCT05201300|Drug|Propofol|Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
75887189|NCT05176106|Behavioral|CHW Incentives Intervention|The intervention comprises of an incentives package provided to VHTs who are active in the intervention-randomized parishes. It will comprise of items that will motivate them and support their work as VHTs in the community.
76057603|NCT04651712|Diagnostic Test|POC-PCR|The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
76057604|NCT04685681|Behavioral|Hiking challenge|The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
76057605|NCT04685681|Other|Activity list|The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
75594732|NCT01380093|Drug|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
75594733|NCT01380093|Drug|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
75738508|NCT00483405|Drug|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
75738509|NCT00483405|Drug|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
75738510|NCT00483327|Drug|Megestrol Acetate|
75738511|NCT01019811|Procedure|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
76057606|NCT04685057|Dietary Supplement|Placebo|Intervention with a daily dose of placebo for 6 months
75887190|NCT05164783|Combination Product|Sanacoach Parkinson (SCP)|A web-based monitoring tool for patients with PD, using questionnaires. It includes nine parts: 1) A 89-question, quarterly questionnaire about PD-symptoms. 2) Questionnaire responses are converted to scores on 16 PD-related domains. Both the current score and the score's change compared to the previous questionnaire are visible. 3) An interim evaluation is sent after 6 weeks with questions on any domains where a patient indicated problems. 4) A medication monitor can be initialized by the treating physician to evaluate the effect of a therapeutic change. 5) A consultation preparation module allows patients to indicate which topics they want to discuss during an outpatient visit. 6) Patients can ask for 'calling advise' if they are unsure whether to contact their physician. 7) Patients and healthcare providers can send each other text messages. 8) Interactive learning modules about PD. 9) Annual evaluation regarding patient satisfaction, self-management and healthcare consumption.
76057607|NCT04685057|Dietary Supplement|Probiotic|Intervention with a daily dose of probiotic for 6 months
76057608|NCT04685057|Dietary Supplement|Follow-up probiotic|Intervention with a daily dose of probiotic for 6 months
76057609|NCT02028767|Drug|Empagliflozin 2.5 mg|Empagliflozin 2.5 mg tablet
75594734|NCT01686854|Behavioral|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
75738512|NCT00684203|Drug|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
75594735|NCT01686854|Other|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
75738513|NCT00684203|Drug|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
75738514|NCT00684203|Drug|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
75738515|NCT00684203|Drug|Clopidogrel|100 mg two or three times daily for 60 days.
75738516|NCT00423592|Drug|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
75738517|NCT04055987|Behavioral|Visual biofeedback, auditory feedback and models|The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
75738518|NCT01037998|Drug|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
75738519|NCT00752687|Drug|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
75738520|NCT00752687|Drug|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
75738521|NCT02561429|Procedure|SPT|SPT of histamine concentration 1, 5 and 10 mg/ml
75738522|NCT00751907|Drug|atorvastatin|40mg daily for 4 months
75738523|NCT00751907|Drug|Placebo|Matching placebo daily for 4 months
75738524|NCT00752843|Drug|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
75738525|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
76057610|NCT02028767|Drug|Empagliflozin 10 mg|Empagliflozin 10 mg tablet
76057611|NCT02028767|Drug|Metformin 500 mg|Metformin 500 mg tablet
75738526|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
75738527|NCT00752921|Drug|etoricoxib|120 mg
75738528|NCT00752921|Drug|placebo|placebo
76057612|NCT02028767|Drug|Empagliflozin/Metformin FDC|12.5 mg Empagliflozin / 500 mg Metformin
76057613|NCT01959932|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
76057614|NCT01959932|Other|Smoking abstinence (SA)|SA for 5 days in confinement
75738529|NCT00683657|Drug|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
75738530|NCT00683657|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
75738531|NCT00755885|Drug|abiraterone acetate|
75738532|NCT00755885|Other|laboratory biomarker analysis|
75738533|NCT00755885|Other|pharmacogenomic studies|
75738534|NCT00755963|Drug|estradiol valerate|Progynova® 21; 2mg/d
75738535|NCT00755963|Drug|micronized progesterone|Utrogestan®; 200mg/d
75738536|NCT00755963|Drug|placebo|maltodextrin
75738537|NCT00752999|Drug|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
75738538|NCT00752999|Drug|Placebo|Placebo tablet, oral, twice-a-day
75738539|NCT00756041|Drug|TAK-128|TAK-128 100 mg tablet, orally, once daily for up to 1 year.
75738540|NCT00753155|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
75738541|NCT00756197|Device|Cryo Spray Ablation Group 1|Cryo Spray Ablation
75738542|NCT00756197|Device|Cryo Spray Ablation Group 2|cryo spray ablation
75738543|NCT00753311|Drug|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
75738544|NCT00756431|Device|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
75738545|NCT00756431|Device|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
75738546|NCT00756587|Device|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
75738547|NCT00756587|Device|Bottle Feeding|receiving all feeding by bottle
75738548|NCT00756743|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
75887191|NCT05163275|Diagnostic Test|Video recording and EMG|"The visible and infrared cameras will be positioned in front of the patient (150 cm from the patient's face). EMG electrodes will also be placed on the wings of the nose and the parasternal intercostal muscles. The pressure and flow sensors will finally be positioned at the level of the airways. EMG, respiratory and video recording will begin 15 minutes before the start of the ventilatory weaning trial. Just before the weaning test, a measurement of dyspnea will be carried out. After 15 minutes of baseline recording, patients will be placed in a ventilatory bondage test. Dyspnea will be measured every 5 minutes during the weaning test. After 30 minutes of testing, the ventilatory weaning test is stopped. Patients will then be placed on ventilatory assistance with the same parameters used before the weaning test. An additional 15-minute recording after the end of the ventilatory weaning test will also be made. The recording will therefore last 1 hour in total"
75887192|NCT05155280|Other|PET imaging using [11C]DASB radioligand.|Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.
75887193|NCT05155280|Behavioral|Eye Tracker|"The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach."
75887194|NCT05152771|Other|KETOGENIC DIET|"This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.~These patients are usually already admitted in the hospital for initial diagnosis and management. Therefore the initiation of the diet will be in the hospital during their admission if the parents/ caregivers agrees. A minimum of 2-3 days would be required to train the parents/caregivers."
75887195|NCT05139589|Other|None, observational|Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery
76057615|NCT01959932|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
76057616|NCT04416893|Diagnostic Test|RT-PCR SARS-Cov2|nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR
76057617|NCT04416893|Diagnostic Test|Sars-Cov2 serology|A microsample of blood will be taken for serology
76057618|NCT04651244|Diagnostic Test|MRI|Gold standard for identifying inflammatory changes in patients with acute pyelonephritis
76057619|NCT04651244|Diagnostic Test|Ultrasound performed by a radiologist|US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).
76057620|NCT04651244|Diagnostic Test|Point of care ultrasound|Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
76057621|NCT02028065|Drug|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
76057622|NCT02028065|Drug|Placebo|Placebo administered as a single IV bolus over 10 seconds
75444856|NCT06223893|Device|CirrhoCare management system|"This is a UKCA-marked, digital-therapeutic system consisting of:~clinical-grade, cirrhosis monitoring sensors and a smartphone app,~a clinical team-facing, decision-facilitating dashboard, and~CyberLiver's platform incorporating hepatic algorithms.~The CirrhoCare kit consists of: - Apple watch - iPhone with an in-built CirrhoCare app - a digital Bluetooth-linked system comprised of: ~Wellue BP monitor, ~Wellue weighing scale ~Bluetooth thermometer.~The CirrhoCare management system also includes:~The clinician dashboard: All participant data collected through the app will be reviewed by the clinical team via the clinician dashboard.~The CirrhoCare algorithm: This algorithm will advise the clinical team if the participant is at high, medium, or low risk of developing a particular outcome event, based on monitoring data collected each day from the participant which is compared to the baseline values and average values collected over the first week of monitoring."
75444857|NCT06223880|Drug|AXS-05|"Up to 10 weeks in open-label period;~Up to 26 weeks in double-blind period"
75444858|NCT06223880|Drug|Bupropion|Up to 26 weeks in double-blind period
75594736|NCT04099199|Diagnostic Test|Click Sexual Health Test|The Click Diagnostics device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
76057623|NCT04683965|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1
75616305|NCT02854293|Other|Booklet-Question List|"Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.~Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients"
75616306|NCT02845726|Other|Stent examination, urinary analysis, USSQ questionnaire|
75738549|NCT00756743|Drug|Placebo|Placebo capsules q12 hours for 10 days
75738550|NCT00753389|Other|None (anesthesia)|anesthesia
75738551|NCT00753467|Drug|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
75738552|NCT00753467|Drug|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
76057624|NCT04683965|Drug|TAS-102|TAS-102, capsule, 35mg/m2, bid,p.o, d1~5,d8~12
76057625|NCT04683965|Drug|Bevacizumab|Bevacizumab 5 mg/kg d1,d14
75738553|NCT00753467|Drug|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
75738554|NCT00482703|Drug|Dasatinib|tablets, Oral, 100 mg, once daily
75738555|NCT00482703|Drug|dasatinib|tablets, Oral, 50 mg, twice daily
75887196|NCT05139433|Behavioral|Telepsychotherapy|"5 weekly psychotherapy sessions that will cover the following contents: psychoeducation on stress responses, family communication, relaxation and mindful techniques, emotion recognition, management of irritability, behavioral activation and cognitive restructuring. The sessions will be implemented via the internet by a trained psychologist. Participants will also have access to the psychoeducational videos described at intervention 2"
75738556|NCT00757055|Drug|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate < 60 bpm.
75738557|NCT00757055|Drug|Placebo|No active treatment given
75887197|NCT05139433|Behavioral|Psychoeducational Videos|15 educational videos to be watched by the families. There will be one video about psychoeducation on stress responses, one about family communication, four about mindfulness and relaxation techniques, two about emotion recognition, one about management of irritability, one about behavioral activation, three about healthy routines, one about cognitive restructuring, and one about management of anxiety crisis.
75444859|NCT06223867|Device|Jaspr App + JAH|With assistance form a research coordinator, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subject will continue to have access to the coping skills and videos via a mobile app after discharge.
75444860|NCT06223867|Behavioral|ETAU|Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge
75738558|NCT04052867|Drug|Lignocaine|Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine
75444862|NCT06223841|Drug|IAP0971|IAP0971 should be subcutaneous injected，q3w
75444863|NCT06223828|Drug|Azithromycin|10mg/kg/dose (max dose 500mg) once daily for 3 days
75444864|NCT06223802|Behavioral|biodex training|women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
75594737|NCT04083326|Device|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
75444865|NCT06223776|Procedure|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
75444866|NCT06223763|Procedure|Cytoreductive surgery|Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.
75738559|NCT04052867|Drug|Normal saline|An equivalent volume of normal saline is given
75444867|NCT06223763|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy refers to chemotherapy administered before the primary treatment in cancer management. The goals include reducing tumor size, treating micrometastases, assessing treatment response, converting inoperable tumors to operable ones, and preserving organs or tissues.
75594738|NCT04059926|Other|insert apossing lumen metal stent|insert apossing lumen metal stent
75738560|NCT00757133|Procedure|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
75738561|NCT00757133|Procedure|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
75738562|NCT00482391|Biological|trastuzumab|
75738563|NCT00482391|Drug|cyclophosphamide|
75738564|NCT00482391|Drug|doxorubicin hydrochloride|
75738565|NCT00482391|Drug|lapatinib ditosylate|
75887198|NCT05119439|Drug|Mifepristone + 2 doses of misoprostol 800 mcg|Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
75887199|NCT05065346|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
76057626|NCT02015195|Other|Acetic Acid (5%)|
76057627|NCT02015195|Other|Sodium Bicarbonate Slurry (50%)|
76057628|NCT02015195|Other|Papain Slurry (70%)|
75738566|NCT00482391|Drug|paclitaxel|
75738567|NCT00482391|Other|laboratory biomarker analysis|
75738568|NCT00753779|Drug|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
75738569|NCT00753779|Drug|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
75738570|NCT00757211|Genetic|polymorphism analysis|
75738571|NCT00757211|Other|laboratory biomarker analysis|
75738572|NCT00757211|Other|questionnaire administration|
75887200|NCT05041569|Other|MRI sequences|perform additional sequences added by research
75887201|NCT05040503|Biological|Blood sampling at inclusion|"Sampling of 2 tubes of 3 ml:~patient: H0: 0-6h post-admission~healthy volunteer: at inclusion"
75444868|NCT06223763|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.
75444869|NCT06223750|Other|population-based screening for chronic kidney disease|Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
75738573|NCT00757289|Biological|PRP Injection|PRP Injection
75738574|NCT00757289|Biological|Corticosteroid Injection|Corticosteroid Injection
75444870|NCT06223737|Diagnostic Test|EOS x-ray|After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
76057629|NCT02015195|Other|Ammonia (10%)|
75738575|NCT00757367|Drug|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
75738576|NCT00757523|Drug|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
75738577|NCT00757523|Drug|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
75444871|NCT06223737|Diagnostic Test|Motion capture|"The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand"
76057630|NCT02015195|Drug|Lidocaine (4%)|
75738578|NCT00753857|Other|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
75738579|NCT00753857|Other|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
75738580|NCT00423046|Biological|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
76057631|NCT02015195|Other|Isopropyl Alcohol (70%)|
75444874|NCT06223711|Radiation|Thoracic Radiochemotherapy|Radiotherapy to the primary tumor including mediastinal lymph node metastases is delivered in single fractions of 1.8Gy once daily up to a cumulative dose of 63.0Gy by intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT).
75738581|NCT00423046|Biological|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
75738582|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
75738583|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
75738584|NCT00757679|Drug|Milnacipran|capsules
75738585|NCT00757679|Drug|Placebo|capsules
75738586|NCT02561351|Other|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
75738587|NCT00754091|Device|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
75738588|NCT00496587|Drug|Capecitabine|800 mg/m^2 By Mouth Twice Daily On Days 1-21.
75887202|NCT05040503|Biological|Blood sampling at 24 hours|Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)
75887203|NCT05040503|Other|Data collection|clinical and biological medical data for patients and general health data for healthy volunteers
75887204|NCT05036512|Drug|GBT021601|Administered orally with water as a single dose in the morning.
75887205|NCT05020392|Drug|BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells|BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10^6/kg on day 0 and day 1 respectively.
75887206|NCT05020392|Drug|Fludarabine-based chemotherapy + CAR-T-CD19 Cells|Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10^6/kg on day 0 and day 1 respectively.
76057632|NCT02015195|Other|Hot Tap Water (40 degrees Celsius)|
76057633|NCT02015195|Other|No treatment|
76057634|NCT02015039|Drug|BoNT Injections|
75738589|NCT00496587|Drug|Gemcitabine|900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15.
75738590|NCT00496587|Drug|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
75444875|NCT06223711|Drug|durvalumab|Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment
75738591|NCT00757835|Drug|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
75887207|NCT05006430|Biological|Fecal Microbiota Transplantation|It's an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors.
75738592|NCT00757835|Drug|latanoprost/timolol fixed combination drops|once in the evening
75887208|NCT05006430|Other|Placebo|Placebo will be identical to the investigational product but will not contain fecal material.
76057635|NCT02015039|Procedure|Occupational Therapy|
76057636|NCT02025725|Drug|Metoclopramide Nasal Spray|nasal spray formulation of metoclopramide
76057637|NCT02025725|Drug|Placebo Nasal Spray|nasal spray formulation with vehicle only
76057638|NCT02025179|Drug|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
76057639|NCT02025179|Device|Vibration|Vibration 10 min/day for 12 months
75444876|NCT06223711|Radiation|Stereotactic radiotherapy of further tumor locations|Stereotactic radiotherapy is delivered to the up to four further tumor locations during durvalumab maintenance therapy and will be performed according to local standards with established dose and fractionation schemes in ablative doses depending on the affected organ system.
75444877|NCT06223711|Drug|Chemotherapy|Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
75594739|NCT04826705|Device|Drug-coated Balloon|To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.
75594740|NCT04829084|Behavioral|Pre-post educational intervention|To Increase the attendance of patients with Diabetes Mellitus, for retinal screening at REMEH by providing health education intervention to selected physicians and establishing a referral pathway
75738593|NCT04052633|Radiation|intraoperative cholangiography|success or failure of cholangiography
76057640|NCT02013791|Drug|Vehicle|Vehicle of cyclosporine administered as per protocol
75444878|NCT06223698|Drug|Letrozole|Letrozole 2.5 mg daily
75444879|NCT06223698|Drug|Anastrozole|Anastrozole 1 mg daily
75444880|NCT06223698|Drug|Exemestane|Exemestane 25 mg daily
75444881|NCT06223698|Drug|Tamoxifen|Tamoxifen 20 mg daily
75738594|NCT01038076|Behavioral|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
75738595|NCT00757913|Dietary Supplement|n-3 enriched nutrition|
75738596|NCT01038154|Drug|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
75444882|NCT06223685|Drug|Rifaximin 200 MG|Dosage 3x2 tablets per day 14 days
75594741|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
75738597|NCT02560727|Device|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
75738598|NCT02560727|Device|colonoscope|FMT via colonoscope is the most common approach.
75887210|NCT05004883|Behavioral|Regulation of Cues Enhanced|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to treat high Food Responsiveness and low Satiety Responsiveness. BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure exercises.
76057641|NCT02013791|Other|Sham|Sham administered to non-study eye as per protocol on Day 1
76057642|NCT02013791|Drug|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
76057643|NCT02024867|Drug|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
76057644|NCT01953601|Drug|Verubecestat 12 mg (Parts 1 and 2)|Verubecestat 12 mg oral tablet, given once daily.
76057645|NCT01953601|Drug|Verubecestat 40 mg (Parts 1 and 2)|Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.
76057646|NCT01953601|Other|Placebo (Part 1)|Placebo matching verubecestat, given once daily as an oral tablet.
75738599|NCT00757991|Genetic|polymorphism analysis|
75738600|NCT00757991|Other|laboratory biomarker analysis|
75738601|NCT00757991|Other|questionnaire administration|
75738602|NCT00405652|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
75887211|NCT05004883|Behavioral|Behavioral Weight Loss|The BWL program includes dietary, physical activity, and behavioral change recommendations. All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories, and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
75738603|NCT04052321|Other|3D optical surface scan|A 3D optical surface scan is acquired utilizing a handheld 3D scanner. Such a scanner is comparable to an ordinary photo camera, however, it also records depth.
75738604|NCT01324180|Drug|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
75738605|NCT01324180|Drug|Vincristine|1.5 mg/m^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
75738606|NCT01324180|Drug|Dexamethasone|"10 mg/m^2/day divided BID~Take dexamethasone by mouth days 2-15"
75738607|NCT01324180|Drug|PEG-asparaginase|"2500 IU's/m^2/day~Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~Patients will receive Erwinase® 25,000 IU/m^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
75738608|NCT01324180|Drug|Doxorubicin|60 mg/m^2/day IV over 15 minutes on day 2
75887212|NCT05004883|Behavioral|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
75887213|NCT04992468|Drug|Ovulation triggering with GnRH-a+rhCG|recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)
75887214|NCT04992468|Drug|Ovulation triggering with GnRH-a|rFSH 225-300 IU (Gonal-F®/Puregon®/Ovaleap®/ Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®)
75887215|NCT04990674|Behavioral|REMOTION|REMOTION is an internet-based program focusing on emotion regulation and aimed at reducing patient symptom severity and improving emotion regulation. It consists of six modules and the structure is based on the extended process model of emotion regulation by Gross (2015). The intervention is currently being studied in an outpatient psychotherapy setting (Bielinski et al., 2020).
75594742|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
75738609|NCT01324180|Drug|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
75738610|NCT02560649|Drug|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
75738611|NCT02560649|Drug|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
75738612|NCT02560649|Drug|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
75887216|NCT04990674|Behavioral|TAU|Treatment as usual (TAU), refers to standard treatment in an acute inpatient care setting at the Universitäre Psychiatrische Dienste Bern. This treatment includes different standard inpatient psychiatric care components (integrative psychiatric care).
76057647|NCT01952665|Device|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
76057648|NCT01952665|Device|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
76057649|NCT01952041|Behavioral|Device: Smartphone|
76057650|NCT01952041|Behavioral|Treatment as usual|
75594743|NCT01379937|Biological|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
75616307|NCT02844322|Drug|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
75738613|NCT02560649|Drug|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
75738614|NCT02560649|Drug|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
75738615|NCT02560649|Drug|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
75738616|NCT02560649|Drug|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
76057651|NCT04416529|Behavioral|Tele-MBCT|Please see arm/group description.
75738617|NCT02560649|Drug|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
75738618|NCT00758147|Device|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
75738619|NCT04052165|Procedure|Glaucoma Implant|
75738620|NCT04052009|Other|Conventional gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
75738621|NCT04052009|Other|End-effector based gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
75738622|NCT04052009|Other|combined training (conventional and end-effector-based)|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
75738623|NCT00754403|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
75738624|NCT00754403|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
76057652|NCT04668235|Drug|AZVUDINE|5 tablets QD + standard treatment for up to 14 days
75738625|NCT00754481|Other|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) were maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who were hypothermic (temperature < 35 ºC) when randomized to the normothermia group were rewarmed slowly using the servo-controlled mattress. Patients who were hyperthermic following randomization to the normothermia group were actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers were administered as needed intravenously in both groups of patients to prevent shivering.
75738626|NCT00754481|Other|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) were cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe was placed in the esophagus and its position confirmed using a chest radiograph. Patients were placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reached 34.0ºC, the ice and second cooling blanket was removed and esophageal temperature was maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO were cooled using the extracorporeal circuit cooling-device. Rewarming was done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC was reached. Thereafter temperature was recorded but not controlled by surface cooling.
76057653|NCT04668235|Drug|AZVUDINE placebo|5 tablets QD + standard treatment for up to 14 days
76057654|NCT01951573|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
75444883|NCT06223685|Dietary Supplement|Probiotic|2x1 capsules per day. 12 weeks.
75444884|NCT06223672|Other|Walnuts|56g of walnuts consumed each day for 7 days
75444885|NCT06223672|Other|Simply White Diary-free chocolate bar|68g of the white chocolate style-bar each day for 7 days
75444886|NCT06223659|Drug|Eutectic Mixture of Local Anesthetics|Apply topically to skin
75738627|NCT02560571|Device|ultrasound|
75444887|NCT06223659|Drug|Placebo Administration|Apply topically to skin
75594744|NCT01379937|Biological|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
75594745|NCT03720392|Drug|FMT|FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
75444888|NCT06223659|Other|Questionnaire Administration|Ancillary studies
75444889|NCT06223646|Biological|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
76057655|NCT01951573|Device|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
75444890|NCT06223633|Device|PK Papyrus Covered Coronary Stent System|PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
75594746|NCT03720392|Drug|Placebo|a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
76057656|NCT02023697|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
76057657|NCT01951417|Drug|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
76057658|NCT01951417|Other|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
76057659|NCT01951417|Other|Foam Wash|Foam Wash (twice daily)
76057660|NCT01951261|Procedure|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
75594747|NCT01379781|Behavioral|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
76057661|NCT02023151|Drug|Omalizumab|
76057662|NCT04643743|Device|Endarterectomy|Endarterectomy is a surgical procedure to remove the atheromatous plaque material, or blockage, in the lining of an artery constricted by the buildup of deposits. It is carried out by separating the plaque from the arterial wall.
76057663|NCT01979185|Drug|Simvastatin|
76057664|NCT01979185|Drug|SSP-004184SS|
75738628|NCT02560571|Other|blood test|
75738629|NCT00758225|Drug|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients > 45 kg: 900 mg/day (2 tablets 3 times a day)
75738630|NCT00754715|Drug|AZD2516|Solution administered once orally
75738631|NCT00754715|Drug|Placebo|Solution administered only once
75887217|NCT04984343|Radiation|Radiation Therapy|"Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have >72 hours between beginning of each fraction."
75738632|NCT02561039|Drug|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
75738633|NCT00422734|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 12 weeks
75738634|NCT00422734|Drug|Placebo|placebo tablet taken by mouth once a day for 12 weeks
75738635|NCT02560415|Device|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
75738636|NCT02560415|Behavioral|Comparator|Treatment as usual
75887218|NCT04981548|Other|no intervention|no intervention
75738637|NCT03916198|Drug|Polydeoxyribonucleotides|Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
75444891|NCT06223620|Other|review performance of water soluble contrast|review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
75444892|NCT06223594|Other|Intravenous Fluid Therapy|Evaluate the safety and efficacy of the Dallas acute pancreatitis protocol(DAPP) order set on Acute pancreatitis(AP) patients receiving aggressive, goal-directed Intravenous fluid(IVF )therapy.
75444893|NCT06223581|Other|ECHO in sever asthma patient|Evaluation of cardiac burden in patients with sever bronchial asthma
75738638|NCT03916198|Drug|Normal saline|Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
75738639|NCT00422422|Drug|Brivaracetam|"Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~~0.4 mg/kg bid for Week 1~~0.8 mg/kg bid for Week 2~~1.6 mg/kg bid for Week 3~For subjects <8 years:~~0.5 mg/kg bid for Week 1~~1.0 mg/kg bid for Week 2~~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~~0.8 mg/kg bid for Week 4~~0.4 mg/kg bid for Week 5~For subjects <8 years:~~1.0 mg/kg bid for Week 4~~0.5 mg/kg bid for Week 5"
75594748|NCT04820972|Drug|Antiplatelet Agents|using antiplatelet agents in 3 days after surgery
75738640|NCT00413374|Drug|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
75738641|NCT00682643|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray
75738642|NCT00682643|Drug|vehicle placebo nasal spray|placebo
75738643|NCT00758381|Drug|Sorafenib 400 mg po bid, continuously|"NEXAVAR*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010"
75738644|NCT00758381|Drug|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
75738645|NCT05436119|Dietary Supplement|GrowBaby|Virtual group educational visits will cluster women in the same trimester of pregnancy teaching trimester-specific diet and lifestyle modification, further customized to the individual using limited micronutrient and gene variant analysis. Each woman will receive base multi-nutrient and probiotic supplementation with customization if identified needs cannot be met with diet and lifestyle modification alone.
75738646|NCT00754871|Drug|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
75887219|NCT04975100|Drug|Sarcosine and SSRI|Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
75887220|NCT04975100|Drug|Placebo and SSRI|Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
75887221|NCT04970342|Drug|Placebo (Lactose) Capsule|Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
75594749|NCT03558854|Drug|Acetylsalicylic acid|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
75594750|NCT03558854|Drug|Placebo oral capsule|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
75594751|NCT03545126|Other|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
75594752|NCT01335477|Drug|placebo|placebo matching BIBF 1120 BID
75594753|NCT01335477|Drug|BIBF 1120|BIBF 1120 BID (twice daily)
75738647|NCT00754871|Drug|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
75738648|NCT00754871|Drug|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
75738649|NCT00754871|Drug|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
75738650|NCT00755027|Drug|Rasagiline|rasagiline 1 mg daily, oral use, during 12 weeks
75738651|NCT05435807|Behavioral|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
75738652|NCT00421408|Dietary Supplement|Whey protein supplement|40-g whey protein supplement daily for 18 months
75738653|NCT00421408|Dietary Supplement|Placebo|Placebo supplement daily for 18 months
75738654|NCT02560337|Drug|Cabazitaxel|
75738655|NCT01038388|Drug|Bortezomib|1.3mg/m² given IV or subcutaneously
75887222|NCT04970342|Drug|0.75 mg Alprazolam Capsule|Single dose on one of the three study visits, orally administered 40 minutes prior to cannabis dose
75887223|NCT04970342|Drug|Cannabis (6.18% THC / <0.025% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (6.18% THC / <0.025% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose on one of the three study visits.
75887224|NCT04970342|Drug|Cannabis (0%/ THC / 0% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
75887225|NCT04959981|Drug|ERAS-007|Administered orally
75887226|NCT04959981|Drug|ERAS-601|Administered orally
75594754|NCT03389438|Biological|autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
75594755|NCT04829474|Other|Survey|It is a survey that the patient and doctor must complete.
75738656|NCT01038388|Drug|Lenalidomide|25 mg given PO
75887227|NCT04959981|Drug|Osimertinib|Administered orally
75887228|NCT04959981|Drug|Sotorasib|Administered orally
75738657|NCT01038388|Drug|Dexamethasone|20 mg given PO
75738658|NCT01038388|Drug|Vorinostat|100, 200, or 300 mg given PO
75738659|NCT02560259|Other|Physiotherapy|Physiotherapy
75444899|NCT06223542|Procedure|Biopsy|Undergo biopsy
75444900|NCT06223542|Procedure|Biospecimen Collection|Undergo collection of blood
75444901|NCT06223542|Procedure|Computed Tomography|Undergo CT
75444902|NCT06223542|Procedure|Magnetic Resonance Imaging|Undergo MRI
75444903|NCT06223542|Drug|UAE Inhibitor TAK-243|Given IV
75444904|NCT06223529|Behavioral|Therapeutic Instrumental Music Performance|Exercises using musical instruments to improve hemiparetic hand and arm function
75444905|NCT06223516|Drug|Subcutaneous (SC) ABBV-383|SC Injection
75444906|NCT06223516|Drug|Intravenous (IV) ABBV-383|IV Infusion
75594756|NCT04828850|Procedure|Endobronchial ultrasound transbronchial needle aspiration lymph node staging|EBUS-TBNA in clinical N0 NSCLC patients
75594757|NCT01371825|Drug|Sebelipase alfa (SBC-102)|Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
75594758|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
75594759|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
75738660|NCT02560259|Other|Conservative treatment|Conservative treatment
75738661|NCT05435183|Device|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
75738662|NCT05435183|Device|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
75738663|NCT04050059|Drug|EMLA cream|EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
75738664|NCT04050059|Drug|2% lidocaine|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
75738665|NCT05435105|Behavioral|Virtual reality|Distraction method
75738666|NCT05435105|Behavioral|Local cold-vibration|Distraction method
75738667|NCT00679913|Procedure|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
75738668|NCT00679913|Procedure|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
75738669|NCT02560103|Other|Transmeridian travel across multiple time zones|
75887229|NCT04951193|Behavioral|Behavioral Activation Therapy app|Goal2QuitVaping focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
75738670|NCT00482001|Drug|donepezil|
75594760|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
75887230|NCT04951193|Behavioral|Treatment as Usual|Participants will be provided educational material about quitting vaping nicotine with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
75738671|NCT00482001|Drug|Placebo (cornstarch)|
75887231|NCT04933162|Dietary Supplement|High Protein and Low Fiber Diet|Protein intake will be increased to be >40% calories from protein, and the fiber intake will remain <15gm/day.
75887232|NCT04933162|Dietary Supplement|Low Protein and High Fiber Diet|Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to <10% total calories from protein.
75887233|NCT04906941|Device|MRI|"SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment.~* Sense 2 * 2: 9min33s"
75887234|NCT04901377|Combination Product|Estradiol valerate/ Dienogest|Combined hormonal contraceptive (combined oral contraceptives, COCs)
75887235|NCT04881357|Other|test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
75887236|NCT04881357|Other|control group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
75444907|NCT06223503|Behavioral|Transitional Pain Service|The Transitional Pain Service (TPS) is a novel perioperative surgical home approach that consists of comprehensive pain management and care coordination before, during and for at least 6-months after surgery for Veterans at risk for chronic opioid use (COU).
75738672|NCT00490035|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
75738673|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
75738674|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
75738675|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
75738676|NCT01014897|Device|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
75738677|NCT01016457|Device|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
75738678|NCT00404248|Drug|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
75738679|NCT00404248|Other|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
75738680|NCT00421174|Drug|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
75887237|NCT04871737|Biological|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
75887238|NCT04865367|Other|Exposure to culture media|Exposure to culture media
75887239|NCT04795245|Drug|afatinib|afatinib
75887240|NCT04788394|Other|data review|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection [40].~Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
76057665|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
75444908|NCT06223490|Procedure|Cryolipolysis|To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.
75444909|NCT06223477|Other|Platelet-rich Fibrin|PRF will be injected distal to the canine on the experimental side.
75444910|NCT06223477|Other|Vitamin D3|Vitamin Dꝫ will be injected distal to the canine on the experimental side
75594761|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
75594762|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
75594763|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
75594764|NCT01371747|Drug|losartan|losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
75738681|NCT00421174|Drug|Placebo plus corticosteroid|"Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated."
75738682|NCT00496197|Drug|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
75738683|NCT00496197|Drug|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
75444911|NCT06223451|Device|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that can alter the excitability of the motor area by generating a magnetic field through a coil. Low-frequency stimulation (<1 Hz) applied with rTMS has inhibitory effects. Repetitive transcranial magnetic stimulation has a neurorehabilitative role as it can modulate the excitability of targeted brain areas. Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation.Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.
75594765|NCT01371747|Drug|spironolactone|Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
75444912|NCT06223451|Device|Sham Repetitive Transcranial Magnetic Stimulation|Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
75594766|NCT03321617|Drug|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
75594767|NCT01371708|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
75738684|NCT00496197|Drug|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
75738685|NCT03996993|Drug|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
75738686|NCT03996993|Radiation|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
75738687|NCT01019889|Drug|SCRT|4 capsules,three times daily, for 7days or within symptom disappearance
76057666|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
75594768|NCT01335399|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
75594769|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
75594770|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
75594771|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
75594772|NCT01335399|Drug|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
75594773|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
75738688|NCT01019889|Drug|YPS|4 capsules, three times daily, for 7days or within symptom disappearance
75738689|NCT01019889|Drug|Placebo|4 capsules, three times daily, for 7days or within symptom disappearance
75738690|NCT01015053|Procedure|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
75738691|NCT01015053|Procedure|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
75738692|NCT00495495|Device|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
75887241|NCT04788394|Other|data comparing|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory-confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection [40].~Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
75887242|NCT04749901|Other|Psycho-emotional and semiological measures|Surveys, interviews and measures
75887243|NCT04742101|Drug|S65487 and azacitidine|Treatment cycle of combination of S65487 and azacitidine during 4 weeks preceded by ramp-up doses. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.
75887244|NCT04738422|Drug|Alkaline glycine|Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
76071958|NCT03597555|Drug|Sodium Oxybate Oral Solution 500 MG/ML|"First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
75887246|NCT04715984|Other|Neurophysiology recordings|Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a working memory task evaluated
75887247|NCT04715984|Procedure|Neural stimulation|Neural stimulation will be delivered during a working memory task and its impact on task performance quantified
75887248|NCT04707937|Other|Online education|Access to online modules about brachytherapy education in addition to receiving regular standard of care education
75887249|NCT04707937|Other|Regular standard of care education|Access only to regular standard of care education
75887250|NCT04706728|Other|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.
75594774|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
75594775|NCT03176615|Dietary Supplement|Experimental diet|The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
75738693|NCT00495495|Device|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
75738694|NCT00404092|Drug|caspofungin|i.v.
75594776|NCT01366521|Biological|Mepolizumab|Monoclonal antibody
75738695|NCT00481767|Biological|Cervarix|The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
75738696|NCT00481767|Drug|Placebo Al(OH)3|Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
75738697|NCT04261491|Procedure|scaling and root planing|scaling and root planing
75594777|NCT04825262|Drug|Tacrolimus|Starting dose based on CYP3A5 genotype
75594778|NCT04825145|Other|Pregnancy|Pregnancies complicated by preeclampsia
75616308|NCT02844322|Drug|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
75738698|NCT00489489|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
75738699|NCT00489489|Drug|Placebo (for Teriflunomide)|"Film-coated tablet~Oral administration"
75738700|NCT00489489|Drug|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
75738701|NCT00489411|Drug|duloxetine hydrochloride|Given orally
75738702|NCT00489411|Other|placebo|Given orally
75738703|NCT00420784|Drug|Telaprevir|tablet
75738704|NCT00420784|Drug|Ribavirin|tablet
75738705|NCT00420784|Drug|Pegylated Interferon Alfa 2a|Solution for injection
75738706|NCT00420784|Drug|Matching Placebo|Tablet
75887251|NCT04706728|Other|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.
75444913|NCT06223425|Behavioral|virtual reality Situation-Based Flipped Learning|Situation-Based Flipped Learning, and Gamification have gained attention as promising tools to engage nursing students and promote a deeper understanding of complex concepts. This study aims to investigate the effectiveness of combining these strategies in a virtual reality Situation-Based Flipped Learning environment with elements of Gamification on nursing students' learning attitudes, problem-solving abilities, and empathetic skills.
75887252|NCT04706728|Other|Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment
76071959|NCT03597555|Drug|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
75594779|NCT01335009|Biological|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
75594780|NCT04824365|Drug|Sodium Pyruvate|Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
75594781|NCT04824365|Other|Saline|Subjects will use a saline nasal spray 3x daily for 14 days.
75594782|NCT01366443|Procedure|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
75594783|NCT01366443|Procedure|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
75738707|NCT00420628|Drug|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
75738708|NCT00420628|Drug|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
75738709|NCT03993808|Behavioral|Revision of congregate meal menus and recipes to align with parameters of DASH eating plan|On a programmatic level, congregate meal menus and recipes have been adapted to align with DASH eating. The changes, which include the introduction of additional servings of fruits, vegetables, seeds, grains, replacement of simple or processed carbohydrates with healthier alternatives, introduction of more fish, reduction in added salt, and replacement of animal fats and butter with olive oil, will be phased-in in stages over 6 weeks, concurrent with the start up the study's educational programs addressing nutrition, BP, and medication adherence. The fully DASH-aligned menus will begin by week 7. The dietary intervention affects all seniors eating congregate meals at the center, not only those enrolled in this protocol to study the impact of DASH implementation.
75738710|NCT03993808|Behavioral|On-site blood pressure monitoring|At baseline (Month 0), and at Months 1, 3, and 6 after the full implementation of the DASH aligned congregate meals, participants will have blood pressure measured by professionals, on-site at the senior center, following established standard procedures. They will receive verbal and written information about their blood pressure results, and encouragement to share the results with their providers.
75738711|NCT03993808|Behavioral|Home self blood pressure monitoring|Provision of personal Omron 10 home blood pressure monitoring device, training in proper use, and schedule for home self monitoring of BP over the course of the study.
75738712|NCT03993808|Behavioral|Medical adherence education|One required educational session with the community pharmacist to learn about medication adherence strategies
75738713|NCT03993808|Behavioral|Nutrition Education|One required educational session to review the elements of the DASH eating plan, how to overcome barriers to healthy eating, recipes, cooking demonstrations and materials for household members.
75738714|NCT00489255|Drug|Tigan®|Oral capsule, 300mg three times daily
75738715|NCT00489255|Drug|Placebo|Oral capsule, three times daily
76071960|NCT03596242|Other|SMS System|Participants will receive usual care +SMS texting and phone calls to monitor their blood pressure and medication adherence
76071961|NCT03596242|Behavioral|blood pressure control education|standard blood pressure control education given during visits
75444914|NCT06223412|Behavioral|virtual based climate change program|The Interactive digital-based educational program Sessions:
75594784|NCT01366443|Procedure|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
75444915|NCT06223399|Other|Imaging-based programming|Preferred contact point(s) and settings for DBS programming will be determined based on the visualization of the electrodes in the patient-specific anatomy and the volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function). This will be determined with help of the software program Brainlab with the GUIDE XT module.
76057667|NCT01946191|Behavioral|24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.|Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.
76057668|NCT01946191|Behavioral|Online self-monitoring|Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
75594785|NCT01332630|Drug|TPI 287|"Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I."
75594786|NCT01332630|Drug|Dexamethasone|6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
75594787|NCT01332630|Drug|Benadryl|12.5-25 mg intravenous (IV) push 30-60 minutes prior
75594788|NCT01332630|Drug|Ranitidine|As H2 blocker 1mg/kg IV 30-60 minutes prior
75594789|NCT04822961|Drug|Placebo|Senaparib-matched placebo capsules
75594790|NCT04822961|Drug|Senaparib|20 mg capsules
75594791|NCT01366209|Drug|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
75594792|NCT01366209|Drug|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
75594793|NCT01600001|Drug|KWA-0711|
75594794|NCT01600001|Drug|Placebo|
75738716|NCT00413218|Drug|Isavuconazole|Administered by intravenous infusion.
75738717|NCT00413218|Drug|Caspofungin|Administered by intravenous infusion.
75594795|NCT01365546|Biological|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
75594796|NCT04828421|Dietary Supplement|Lactobacillus rhamnosus and Bifidobacterium lactis|Probiotics
75594797|NCT04828421|Dietary Supplement|Placebo|Placebo
75594798|NCT01600040|Radiation|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
75594799|NCT01365507|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
75594800|NCT02995694|Drug|Estradiol|Estradiol Vaginal Cream
75594801|NCT02995694|Drug|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
75594802|NCT02995694|Drug|Reference|Estrace Vaginal Cream
75594803|NCT01365468|Drug|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
75594804|NCT04827836|Procedure|Cooled eye drops and povidone-iodine|Cooled oxybuprocaine HCl 0.4% and lidocaine HCl 2% eye drops and cooled povidone-iodine (cul-de-sac 5% povidone-iodine and 10% povidone-iodine).
75738718|NCT00413218|Drug|Voriconazole|Administered by intravenous infusion.
75887253|NCT04705025|Behavioral|Cognitive Behavior Therapy|Undergo CBSM using the BNT001 app
75887254|NCT04705025|Other|Interview|Complete interview
75887255|NCT04705025|Other|Quality-of-Life Assessment|Ancillary studies
75887256|NCT04705025|Other|Questionnaire Administration|Ancillary studies
75887257|NCT04693013|Device|Virtual Reality for Anxiety Reduction|Virtual Reality for Anxiety Reduction during suturing of perineum
75594805|NCT01357980|Biological|Botulinum toxin type A|750 U intra detrusor injection on Day 1 (single dose)
75738719|NCT02303392|Drug|Selinexor|Given PO
75738720|NCT02303392|Drug|Ibrutinib|Given PO
75738721|NCT02303392|Other|Pharmacological Study|Correlative studies
75738722|NCT02303392|Other|Laboratory Biomarker Analysis|Correlative studies
75738723|NCT03994042|Device|Mental imagery neurofeedback training|Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
75738724|NCT00420316|Biological|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
75738725|NCT00420316|Biological|Placebo (primary vaccination study)|Two liquid oral doses of placebo
75887258|NCT04688749|Diagnostic Test|Electrical Impedence Spectroscopy DermaSense|Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.
75887259|NCT04679402|Other|Carbon monoxide 200 ppm in air|Low dose carbon monoxide
75887260|NCT04665557|Behavioral|Dove Confident Me Indonesia Single Session|"Dove Confident Me Indonesia Single Session is an adaptation of Dove Confident Me Global Single Session, designed to be facilitated by schoolteachers or school counsellors. Dove Confident Me Indonesia includes four interactive activities (to be delivered in a single 90-minute session) as well as a homework challenge and commitment pledge. The programme incorporates three primary techniques to improve Indonesian adolescents' body confidence and self-esteem: (1) psychoeducation, (2) media literacy, and (3) cognitive dissonance as well as two secondary techniques: (4) self-affirmation and (5) cognitive reframing. As the curriculum was adapted to be delivered in Indonesian schools with limited resources, videos or PowerPoint presentations are not included. Instead, a detailed teacher guide and student worksheets are provided.~Due to COVID-19, the intervention will be delivered online via video conferencing platform."
75887261|NCT04654507|Drug|Dexamethasone Oral|Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
75887262|NCT04654507|Drug|Placebo|Placebo
75887263|NCT04654039|Other|Other: Non intervention|Non intervention
75887264|NCT04646655|Drug|Enoxaparin|subcutaneous injections
75887265|NCT04629443|Drug|S 64315 (also referred as MIK665) and azacitidine|"The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days."
75887266|NCT04627922|Drug|N-Acetyl cysteine|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers with current tobacco use disorder and cannabis use will be randomized to receive NAC 3600 mg per day over 8 weeks.
75887267|NCT04627922|Other|Placebo comparator|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers and cannabis users with current tobacco use disorder will be randomized to receive placebo per day over 8 weeks.
75594806|NCT01357980|Drug|Placebo|Intra detrusor injection on Day 1 (single dose)
75594807|NCT01332318|Drug|XP13512|XP13512 once daily for 16 days
75738726|NCT03993886|Device|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
75738727|NCT03993886|Other|Activity Monitor|commercially available accelerometer to be worn on wrist
75738728|NCT03993886|Other|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
75738729|NCT03993886|Other|ECG|Commercially available electrocardiogram machine
75887268|NCT04627922|Behavioral|Cognitive behavioral therapy (CBT)|Participants in both groups will receive 8 weekly cognitive behavioral therapy sessions for substance use disorder targeting both tobacco and cannabis use.
75887269|NCT04609332|Diagnostic Test|Endothelial damage and angiogenic biomarkers|Blood samples for biomarkers study
75887270|NCT04608110|Drug|ASTX030|In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
75887271|NCT04581226|Diagnostic Test|Lung ultrasound|All children will be studied in the supine position. LUS will be performed with the portable device MicroMax (Sonosite, Bothell, Washington, USA) using a linear probe of 6 to 12 MHz. All ultrasound scans will be performed by the same anesthetist, who has experience of more than 30 lung ultrasound scans in pediatric patients. Each hemithorax will be divided into six regions, using three longitudinal lines (parasternal, anterior and posterior axillary) and two axial lines (one above the diaphragm and the other 1 cm above the nipples)
75887272|NCT04577716|Diagnostic Test|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
75887273|NCT04577716|Diagnostic Test|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
75887274|NCT04577716|Diagnostic Test|12-month CT Aortic Angiogram|CT scan to assess aortic morphology and the stent graft
75594808|NCT01332318|Drug|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
75594809|NCT01332318|Drug|Placebo|XP13512 placebo once daily for 16 days
75594810|NCT02071901|Drug|eltrombopag olamine|Given PO
75594811|NCT01331109|Drug|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
75594812|NCT01865396|Behavioral|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
75594813|NCT01865396|Behavioral|Standard oncologic care|Patients will receive standard oncologic care.
75594814|NCT01357551|Behavioral|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
75738730|NCT03993886|Other|respiratory rate sensor|Commercially available respiratory rate sensor.
75738731|NCT00494871|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL [creatinine clearance] >= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
75738732|NCT00494871|Drug|Warfarin|Participants orally administered a warfarin potassium tablet (INR [international normalized ratio] target was 1.6-2.6 for patients >70 years and 2.0-3.0 for patients <70 years)
75738733|NCT00494871|Drug|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
75738734|NCT00494871|Drug|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
75887275|NCT04577716|Other|24-month review|This will consist of a telephone consultation with the study participant and review of electronic clinical records
75887276|NCT04576416|Other|AI augmented training and clinical feedback|"The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( >10 years of experience) through a web-based review system developed by our group."
75887277|NCT04572269|Other|No Intervention|This protocol does not involve an intervention of drug/device, diet, exercise or PAP compliance.
75887278|NCT04569487|Procedure|Biopsy|Muscle biopsy from vastus lateralis (100-200 mg from non-dominant leg)
75887279|NCT04562883|Other|The way of Cumulus-oocyte complexes (COC) culture|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
75887280|NCT04540588|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
75887281|NCT04534127|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
75887282|NCT04532242|Behavioral|Cognitive reappraisal|Participants will be trained to follow instructions to look/respond naturally or use cognitive reappraisal to reframe or reconsider a negative picture to decrease negative emotion.
75887283|NCT04521413|Drug|CFI-402411|CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
75887284|NCT04521413|Drug|Pembrolizumab|Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
75887285|NCT04516057|Drug|Nabilone|After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
75887286|NCT04516057|Other|Placebo|After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
75594815|NCT01640483|Other|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
76057669|NCT01946191|Behavioral|Real-time updates to Primary Care physicians|Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
75594816|NCT01357239|Drug|AFQ056|
75594817|NCT01357239|Drug|Placebo|
75594818|NCT04820582|Other|Delphi Questionnaire|Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
75594819|NCT00903500|Behavioral|Daily physical activity, pedometer and counseling|Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
75738735|NCT00420238|Drug|Etanercept (Enbrel)|50 mg injection once weekly
75738736|NCT00420238|Other|Placebo|placebo
75738737|NCT01016925|Procedure|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
75738738|NCT03994432|Behavioral|intervention group|"follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model."
75738739|NCT00420004|Drug|LY2216684|3-mg and 6-mg tablets
75738740|NCT00420004|Drug|Placebo|
75738741|NCT00420004|Drug|Escitalopram|10-mg capsules
75738742|NCT00494481|Drug|Vandetanib (ZD6474)|once daily oral dose
75738743|NCT00494481|Drug|Docetaxel|intravenous infusion
75738744|NCT01040494|Drug|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
76057670|NCT01937312|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
76057671|NCT01937312|Drug|Vehicle|Inactive ingredients used as a placebo comparator
76057672|NCT01937312|Drug|Prostaglandin analogue|
75594820|NCT00737321|Procedure|Samples will be collected|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
75738745|NCT01040494|Drug|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
75738746|NCT01017081|Other|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
75738747|NCT01017081|Other|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
75887287|NCT04507464|Behavioral|Ecological Momentary Intervention|Participants will wear a Fitbit that has been programmed to deliver a notification (a buzz) when activity has ceased for more than 10 minutes. They will receive suggestions on their Illumivu mEMA smartphone app on how to replace sitting time with PA such as standing up 5 times or taking 20 steps, or even performing a short (20 seconds) preferred dance routine. Fitbit data will be captured in real-time via the iCardia platform. Participants will receive reminders from their smartphones to enter real-time feedback on activity options selected and how successful they were in adopting the option. These data will allow tracking of underlying preferences for behaviors and to tailor the program accordingly.
75887288|NCT04484571|Device|Neuroexsos elbow module|The treatment group will be further divided into two levels (sub-groups), based on pathological severity: Level 1 corresponds to an FM score equal or below 28, and Level 2 with FM greater than 28. The two sub-groups will receive different combinations of robotically assisted passive mobilization (PM) and active mobilization (AM) treatment modalities, according to their differing clinical needs
75887289|NCT04483245|Biological|Blood sampling|Blood sampling
75444916|NCT06223399|Other|Threshold assessment-based programming|The preferred contact point(s) and settings for DBS programming will be determined according to current clinical practice. During the threshold assessment, the amount of electrical current needed to generate symptomatic improvement and the amount of electrical current needed to generate adverse-effects are determined for every contact point of both DBS leads by increasing current with 0.5 mA steps from 0 to approximately 5.0 mA. With each step, severity of Parkinson symptoms and presence of possible adverse-effects are assessed. For each side (i.e., left and right), the contact point with the most favorable trade-off between clinical improvement and adverse effects will be used for stimulation.
75887290|NCT04474613|Diagnostic Test|Liquid biopsy|Liquid biopsy done on a blood draw, taking approximately 7 days
75887291|NCT04441892|Device|QTc Meter|Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
75594821|NCT01351350|Drug|MLN0128|MLN0128 capsules
75594822|NCT01351350|Drug|paclitaxel|paclitaxel intravenous infusion
75594823|NCT01351350|Drug|trastuzumab|trastuzumab intravenous infusion
75594824|NCT02271503|Drug|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
75594825|NCT02271503|Drug|IPX203 180 mg|IPX203 containing 45 mg carbidopa and180 mg levodopa
75594826|NCT02271503|Drug|IPX203 270 mg|IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
75594827|NCT02271503|Drug|Rytary 195 mg|Rytary 48.75Mg-195Mg Extended-Release Capsule
75887292|NCT04436497|Drug|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
75887293|NCT04436497|Drug|Matching Placebo|"Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
75887294|NCT04434755|Other|health care professionals' exposure to bioethical issues|health care professionals were differentiated considering the work context and the type of patients cured
75887295|NCT04424641|Biological|GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.|GEN1044 will be administered intravenously in cycles of 21 days.
75887296|NCT04421846|Other|Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)|Collection of biological samples and clinical/paraclinical data
75887297|NCT04414345|Drug|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
75887298|NCT04414345|Drug|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily"
75887299|NCT04403633|Other|mobile health educational tool|Interactive educational tool delivered on iPad
75594828|NCT02271503|Drug|Rytary 145 mg|Rytary 36.25Mg-145Mg Extended-Release Capsule
75594829|NCT04526405|Diagnostic Test|SARS-CoV-2 S1/S2 IgG|SARS-CoV-2 S1/S2 IgG analysis
75594830|NCT01350999|Drug|omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
75594831|NCT01350999|Drug|Eicosapentaenoic acid-ethyl (EPA)|EPA-E capsules
75594832|NCT02275559|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
75594833|NCT02275559|Behavioral|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
75594834|NCT04526522|Other|No intervention|No intervention
75738748|NCT01038544|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
75738749|NCT01038544|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
75738750|NCT00097591|Drug|Prasugrel|Administered orally
75738751|NCT00097591|Drug|Clopidogrel|Administered orally
75738752|NCT01082029|Drug|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
75738753|NCT01082029|Drug|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
75444917|NCT06223386|Behavioral|Designed on-line course A with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided at the beginning of the 3-month intervention. Participants can consult with the dietitian via the APP on their mobile phones during the intervention period. These materials will encompass dietary and physical activity guidelines by the government in Taiwan.
75444918|NCT06223386|Behavioral|Designed on-line course B with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education.
75738754|NCT00419926|Drug|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
75738755|NCT00419926|Drug|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
75594835|NCT02270021|Other|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
75594836|NCT02270021|Other|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
75594837|NCT01350804|Biological|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
75594838|NCT01350804|Biological|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
75738756|NCT00419926|Drug|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
75738757|NCT01038622|Drug|L-arginine|5-day L-arginine treatment
75738758|NCT01038622|Drug|placebo|5-day placebo treatment
75738759|NCT00080119|Drug|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
75738760|NCT00080119|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
75887300|NCT04393103|Drug|Intralipid, 20% Intravenous Emulsion|"Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~Group A (Control Group) : Follow Up of 30 patients.~Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart."
76057673|NCT04648904|Radiation|Radiotherapy|A total dose of 26 Gy in 5 fractions will be given once daily over 5 consecutive weekdays (or within 10 consecutive weekday to allow for treatment delays, interruptions, logistical problems, scheduling issues and weekends/holidays).
76057674|NCT04622384|Other|Dialysis weaning|Dialysis weaning as planned by the attending ICU-physician.
76057675|NCT04632836|Other|quality of life questionnaires|responses for quality of life questionnaires (WHOQOL-BREF questionnaire, study specific questionnaire, PSQI index, HADS scale)
76057676|NCT01935128|Drug|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
76057677|NCT01934972|Other|CR + DCS (D-cycloserine)|CR + DCS
76057678|NCT01934972|Other|CR + placebo|CR + placebo
76057679|NCT01959230|Drug|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
76057680|NCT01959230|Drug|Vehicle|Ophthalmic solution to be applied as directed.
75444919|NCT06223386|Behavioral|Designed on-line course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 3 months.
75594839|NCT01350804|Biological|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
75594840|NCT04526249|Device|rapid pulse confirmation device|device used to detect pulsatile blood blood during and after cardiac arrest
75738761|NCT00080119|Drug|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
75738762|NCT00419380|Drug|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment [dornase alfa (Pulmozyme®)]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
75738763|NCT03961633|Behavioral|AWARE intervention|"will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes."
75738764|NCT01082107|Other|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
75738765|NCT01085929|Procedure|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
76057681|NCT01959230|Drug|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
76057682|NCT01959230|Drug|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
76057683|NCT01909778|Drug|BI 201335|single oral doses
76057684|NCT01977937|Drug|Gabapentin 250mg/5mL NDC:59762-5025-01|
76057685|NCT01977937|Drug|Simple Syrup|
76057686|NCT02015663|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
76057687|NCT01978093|Biological|Hib-MenCY-TT (MenHibrix®)|4 doses administered intramuscularly (IM) in the right upper anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 in the HibCY Group.
75738766|NCT01085929|Procedure|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
75444920|NCT06223386|Behavioral|Designed on-line course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 6-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 6 months.
75738767|NCT00413062|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
76057688|NCT01978093|Biological|Pediarix®|3 doses administered IM in the left upper anterolateral thigh at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper anterolateral thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper anterolateral thigh at Month 4 in the PedHIB Group.
76057689|NCT01978093|Biological|Rotarix®|2 doses administered orally at Day 0 and Month 2 each in the HibCY Group and PedHIB Group.
76057690|NCT01978093|Biological|Prevnar 13®|4 doses administered IM in the left lower anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 each in the HibCY Group and PedHIB Group.
75738768|NCT00413062|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
75444923|NCT06223360|Drug|Benfotiamine|300mg Benfotiamine capsules
75444924|NCT06223360|Drug|Benfotiamine|600mg Benfotiamine capsules
75444925|NCT06223360|Drug|Placebo|Placebo capsules to mimic benfotiamine 300mg, 600mg capsules
75594841|NCT02274818|Behavioral|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~No more than 80 hours of work per week (when averaged over 4 weeks)~1 day off in 7 (when averaged over 4 weeks)~In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
75738769|NCT01082185|Device|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
76057691|NCT01978093|Biological|PedvaxHIB®|3 doses administered IM in the right upper anterolateral thigh at Day 0, Month 2 and Month 10-13 in the PedHIB Group.
76057692|NCT01978093|Biological|Havrix®|2 doses administered IM in the left upper anterolateral thigh at Month 10-13 and Month 16-19 each in the HibCY Group and PedHIB Group.
76057693|NCT01951105|Drug|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
76071962|NCT03580759|Behavioral|PREHAB|After three supervised training sessions, subjects will be asked to participate in a daily exergaming activity tailored to their physical activity capabilities and needs. Subjects will be taught to rate their perceived exertion and monitor their target heart rate using a Fit Bit Charge HR. Daily exercise diaries will be used to monitor subject-perceived progress throughout the intervention period.
75594842|NCT04448418|Other|web based survey|Assess specific health care needs for the transpopulation during the COVID-19 outbreack using a newly created questionnaire and some validated questionnaries (Impact of Event Scale-Revised, BECK Depression Inventory and the Self-rated Health SF-12)
75594843|NCT01350492|Behavioral|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
75594844|NCT02270957|Biological|Abatacept|
75594845|NCT02270957|Other|Placebo|
75594846|NCT01350414|Device|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
75594847|NCT04523753|Procedure|emergency endoscopy|emergency endoscopy for gastrointestinal bleeding situation before or after surgery
75594848|NCT01350336|Device|Alair System|Treatment of airways with the Alair System
75594849|NCT04827290|Behavioral|Low-AGE diet|Low-AGE diet during 24 months
75738770|NCT01034878|Drug|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
75738771|NCT01082263|Drug|Lurasidone HCl|Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
75738772|NCT02208544|Procedure|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
76071963|NCT03575364|Device|ClotTriever|Thrombectomy
76057694|NCT01951105|Drug|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
76057695|NCT01951105|Drug|Placebo|Take two placebo capsules three times a day for 12 weeks.
75738773|NCT02208544|Device|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
75887301|NCT04393103|Drug|Intravenous Atropine Sulfate|Atropine will be administered to ALL PATIENTS in Group A and group B by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till complete atropinization. Following this, an infusion of 10-20% of the atropinizing dose was given every hour.
75594850|NCT04827290|Behavioral|High-AGE diet|High-AGE diet during 24 months
75594851|NCT04826315|Behavioral|COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
75594852|NCT04823702|Biological|Aldafermin|Biological: Aldafermin (NGM282) Subcutaneous Injection
75594853|NCT01349049|Drug|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
75594854|NCT01349049|Drug|PLX3397|The drug product is available in capsule form, to be taken orally.
75738774|NCT02208544|Radiation|FDG-PET/CT|Head and Neck FDG-PET/CT
76057696|NCT01958918|Drug|Ranibizumab|0.5 mg intravitreal injection
76057697|NCT01958918|Drug|Aflibercept|2 mg intravitreal injection
76057698|NCT01945489|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
76057699|NCT01945489|Drug|Normal saline|Normal saline (placebo) injected into the detrusor.
76057700|NCT04173559|Behavioral|Activity Intervention|After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
76057701|NCT01934894|Drug|cabazitaxel|
76057702|NCT01934894|Drug|lapatinib|
76057703|NCT01950169|Drug|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
76057704|NCT01950169|Other|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
76057705|NCT01950169|Dietary Supplement|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
76057706|NCT01934504|Procedure|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
76057707|NCT01950013|Behavioral|Auditory training program|Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
76057708|NCT01950013|Behavioral|Sham Comparator: Active Control|This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
76057709|NCT04632524|Drug|MgSO4|Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
76057710|NCT01949155|Drug|OTO-201|Single, intratympanic injection
75594855|NCT04522700|Procedure|scapular free flap|use of scapular free flap to reconstruction post maxillectomy defect to provide bony support
75594856|NCT04829864|Behavioral|STEP|"The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child."
75594857|NCT01348854|Device|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
75738775|NCT00494091|Drug|Temsirolimus (CCI-779)|20 mg/m2 IV TEMSR weekly (Japan, n=6)
75738776|NCT00494091|Drug|Temsirolimus (CCI-779)|25 mg IV TEMSR weekly (all other pts)
75738777|NCT01017159|Drug|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
76057711|NCT01949155|Drug|Sham|Simulated single, intratympanic injection
76071964|NCT03575026|Behavioral|Music-with-movement|Subjects will listen their preferred music and move their body actively with music
75444926|NCT06223347|Diagnostic Test|Chromoendoscopy|"Chromoendoscopy: is a dye based staining of colonic mucosa. NBI: is an optical image enhancing technology that allows a detailed inspection of vascular and mucosal patterns, providing the ability to predict histology during real-time endoscopy.~TXI: is a digital technique that enhance texture and color of the tissues to be more visible."
75738778|NCT00494013|Drug|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
75738779|NCT00494013|Drug|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
75594858|NCT04522310|Other|MR-Pro-ADM|Dosage of MR-pro-ADM
75444927|NCT06223334|Other|No intervention|observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.
75738780|NCT00079339|Radiation|radiation therapy|Undergo radiotherapy
75738781|NCT00079339|Drug|tipifarnib|Given orally
75444928|NCT06223321|Diagnostic Test|Computed Tomography in congenital heart diseases|"● CT examination will be done by~160 MDCT Toshiba Machine or 128 MDCT GE machine or 160 MDCT Philips Machine:~We used the following parameters during cardiac CT scanning:~Pitch of 1.3, helical thickness of 0.5 mm and coverage of 32 cm.~The radiation dose set to 80-100 kvp.~Tube current from 10 to 40 mA/kg.~The gantry rotation speed at 0.35-.4 sec.~ECG gated Retrospective With MA modulation.~Wide FOV.~A scout will be taken and dual-phase injection conducted using non ionized contrast material. The total contrast volume is 1.5-3 ml/kg.~Scanning begins when contrast filled the LV by bolus tracking.~All images were transferred to workstation multiplanar reformation (MPR), maximum (MIP) and minimum (MinIP) intensity projections and volume rendering images will be performed for reporting."
75738782|NCT00493779|Procedure|Blood Collection|4 weeks
75594859|NCT01348776|Device|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
75594860|NCT01348698|Procedure|Tumor tissue biopsy|Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.
75594861|NCT01348698|Procedure|Surgery|Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
75738783|NCT01088191|Biological|MSB-CAR001 Combined With Hyaluronan|"Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan"
75738784|NCT01088191|Drug|Hyaluronan|Hyaluronan alone
75738785|NCT01082341|Biological|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
75594862|NCT04520477|Diagnostic Test|Bio Impedance assesement (BIA)|BIA every 5 minutes od the test protocol. Patients stood up for 5 minutes, laid down for 70 minutes, followed by 5 minutes in a seated position and ending with 30 minutes standing. BIA was done every 5 minutes.
75594863|NCT04520477|Diagnostic Test|Blood and salava sample|Blood Samples were done at the initation of the protocol, and every 10 minutes after ingestion of the deutarated water
75594864|NCT04520477|Dietary Supplement|Ingestion of deuterated water|15 minutes after the intiation of the test protocol, participants drink an amount of deuterated water corresponding with 0.25% of their TBW calculated using the Watson Formula
75738786|NCT01017315|Drug|Baby talcum|50 grams apply locally prior cast application
75738787|NCT00541866|Drug|Voreloxin injection and cytarabine|"Dose-escalation Phase~Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous [IV] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
75738788|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination."
75738789|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once."
75738790|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing."
75738791|NCT00493467|Drug|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of ^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
75738792|NCT00493467|Drug|Rituximab|250 mg/m^2 Intravenously Over 4-6 Hours On Days 1 and 8.
76057712|NCT01909466|Drug|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
76057713|NCT01977625|Drug|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
75444929|NCT06223308|Drug|HB0028|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).
75444930|NCT06223295|Procedure|Focal therapy|"Focal therapy selectively treats a specific part of the prostate while preserving the rest of the gland in men with prostate cancer.~Focal therapy with ultrasound ablation (HIFU/TULSA) or irreversible electroporation (IRE) followed by an intensive MRI follow-up scheme at 12, 24, 36, 48 and 60 months, prostate biopsy at 12 months (and also when indicated) and PSA monitoring"
75887302|NCT04368195|Procedure|Erector spinae block|Erector Spinae Plane Block (ESPB) - first recently described for the treatment of thoracic neuropathic pain, is a peri-paravertebral regional anesthesia technique that has since been reported as an effective technique for prevention of postoperative pain in various surgeries (10-12). In ESPB, local anesthetic is reported to be administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces.
75444931|NCT06223295|Procedure|Usual care|standard radical treatment; prostatectomy or radiotherapy with follow-up according international guidelines (PSA monitoring and imaging when indicated).
75594865|NCT04520477|Diagnostic Test|Urine sample|A urine sample is taken at the initiation and after termination of the protocol.
75594866|NCT01348542|Drug|Trazodone|50 mg once a day, for 3 months
75738793|NCT00090493|Biological|MAGE-A3|vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
75738794|NCT00090493|Biological|MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY|Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
75887303|NCT04335370|Other|Blood Draw|"Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~Prior to start of infusion~End of infusion~One hour after end of infusion~Three hours after end of infusion~Eight hours after start of infusion"
75738795|NCT01088347|Drug|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
75738796|NCT01088347|Drug|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
75887304|NCT04334629|Drug|Ibuprofen|Lipid ibuprofen 200 mg
75887305|NCT04296890|Drug|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
75887306|NCT04276090|Device|Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.|Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
75594867|NCT01348542|Behavioral|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
75594868|NCT04827758|Procedure|Screening and diagnostic tests for sarcopenia|"All of the following tests and questionnaires will be performed :~SARC-F questionnaire,~measurement of muscle strengh by a grip test,~measurement of muscle mass by impedancemetry (ASM/size2),~4-meter walking speed test,~Timed-Up and Go (TUG) test,~ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires."
75594869|NCT04447677|Other||
75738797|NCT01088347|Radiation|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
75738798|NCT04329702|Behavioral|Coping skills training mobile app with call from CST therapist|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.
75738799|NCT04329702|Behavioral|Coping skills training mobile app only|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
75887307|NCT04276090|Drug|Hepatic artery infusion pump floxuridine and dexamethasone|Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump
75444932|NCT06223282|Other|short inter-set rest resistance exercise|Subjects in short inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 60 sec of rest between sets.
75444933|NCT06223282|Other|medium inter-set rest|Subjects in medium inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 120 sec of rest between sets.
75594870|NCT04447638|Procedure|Tracheostomy with aerosol box in COVID-19 positive patients|Patients who underwent percutaneous tracheostomy with aerosol box in COVID-19 positive patients. The patients age, gender, hospitalization diagnosis, number of intubated days, anesthetic agents used during the procedure, neck ultrasonography data before and during the procedure, and complications were recorded.
75594871|NCT04826471|Device|DermoRelizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
75594872|NCT04447248|Device|QDSP Protocol|Computerized expert system for fetal monitoring, based on cardiotocogrpaphy
75444934|NCT06223282|Other|long inter-set rest|Subjects in long inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 180 sec of rest between sets.
75594873|NCT04519190|Diagnostic Test|Prolonged continuous single-lead ECG monitor|We use Smartpatch, a listed ambulatory electrocardiographic system that can continuously record and save patients' cardiac rhythm for up to 45 days.
75887308|NCT04276090|Drug|Systemic chemotherapy for colorectal liver metastases|Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)
75444935|NCT06223282|Other|medium inter-set rest with failure|Subjects in long inter-set rest trial performed 3 sets per exercise, repeated to failure with load of 70%-1RM with 120 sec of rest between sets.
75444936|NCT06223269|Drug|Skin Xenotransplant|"realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area."
75594874|NCT04519190|Diagnostic Test|Intermittent ECG monitor|When using Smartpatch, we can set time markers by pressing the button on the device. We ask our subjects to press that button twice a day and also when they feel any discomfort. Analyzing the ECG 1 minute after those time markers can serve as a surrogate for intermittent ECG monitor.
75738800|NCT05220930|Other|Foot bath for heel warming|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap.
75738801|NCT05220930|Other|Ineffective heel warming with thermofor|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
75738802|NCT04302558|Behavioral|Exercise Blood Flow Restriction training|While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow
75738803|NCT04302558|Behavioral|SHAM Exercise Blood Flow Restriction training|While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
75738804|NCT04268004|Behavioral|FP Decision Tool and Discussion|The intervention will be administered by a trained interventionist. The interventionist will administer the digital FP Decision Tool to families in the intervention arm. The tool asks questions examining each AYA's thoughts or feelings regarding parenthood and fertility preservation. The parent version asks the same questions, plus additional questions asking the parent to rate their son's feelings on certain topics (i.e., whether their son wants to have a child, whether their son would be as happy with an adopted child versus a biological child). Items are coded based on the domains of the Health Belief Model (perceived benefits, perceived barriers, perceived threats, self-efficacy, and cues to action). Items are scored and the trained interventionist will facilitate a guided discussion based on the family's responses and discrepancies.
75738805|NCT05692440|Device|Intracept Procedure|Intraosseous radiofrequency ablation of the basivertebral nerve
75738806|NCT05692050|Drug|Epcoritamab|Subcutaneous Injection
75738807|NCT04004832|Diagnostic Test|there is not any intervention procedure|there is not any intervention procedure
75887309|NCT04276090|Drug|Systemic chemotherapy for intrahepatic cholangiocarcinoma|Patients will receive disease-appropriate systemic chemotherapy for intrahepatic cholangiocarcinoma (gemcitabine/oxaliplatin or gemcitabine alone)
75887310|NCT04273139|Drug|IBRUTINIB|Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days
75444937|NCT06223269|Procedure|Autograft(ing)|Autograft(ing) is the current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin, i.e. autologous (self) skin harvesting, from an uninjured site on the patient and using it to cover the original burn wound.
75594875|NCT04519190|Diagnostic Test|Routine practice|Perform pulse palpation and also ECG if irregular rhythm is found.
75887311|NCT04273139|Drug|Venetoclax|Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.
75887312|NCT04248023|Behavioral|Practice Facilitation|A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
75887313|NCT04244370|Device|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
75738808|NCT04221828|Drug|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
75887314|NCT04207437|Device|Vibration therapy|vibration therapy using hand held vibration device
76057714|NCT01977625|Other|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
75444938|NCT06223256|Drug|NBL-028|Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
75444939|NCT06223243|Other|Stingless bee honey mouthrinse|Three bottles of 90ml of stingless bee honey of 20% concentration was given to each subject. This mouthrinse preparation was instructed for subjects to be taken 30ml each, thrice daily for three days.
75444940|NCT06223243|Other|normal saline mouthrinse|Subjects were instructed to rinse with 30ml of normal saline (0.9% concentration) thrice daily for three days.
75444941|NCT06223243|Other|chlorhexidine mouthrinse|Subjects were instructed to rinse with 30ml of chlorhexidine mouthrinse thrice daily for three days.
75738809|NCT05138328|Device|Treatment of basal cell carcinoma with Nd:YAG laser under imaging guidance of optical coherence tomography (OCT)|This will use optical coherence tomography (OCT) to assess the margins of basal cell carcinoma. Treatment will be completed by Nd:YAG laser.
75444943|NCT06223217|Other|Surveys and Questionnaires|The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale
75887315|NCT04207359|Dietary Supplement|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
75887316|NCT04195503|Procedure|Liver Transplantation|Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
75444944|NCT06223204|Other|Controlled euglycemia, hypoglycemia and hyperglycemia|EIT measurements are collected in different glycemic states (euglycemia, hypoglycemia and hyperglycemia). Venous blood glucose is measured using a gold-standard glucose analyzer.
75444945|NCT06223191|Other|Brief Negotiated Interview|"The BNI is a specialized brief intervention for the medical setting, has foundations in motivational interviewing techniques. The BNI helps health care providers explore health behavior change with patients in a respectful, non-judgmental way within a finite time period. The BNI is in the form of an algorithm, or script, that guides providers through the health intervention with carefully phrased key questions and responses, all at the providers' fingertips"
75444946|NCT06223191|Other|Narrative Interview|The Narrative Interview is a therapeutic approach that aims to motivate the individual's conscious and transformative knowledge, skills, and capabilities. This interview is based on the technical components of narrative therapy, where the patient narrates their story, using externalizing language and considering social and political aspects related to the issue. It will focus on exploring past and present feelings, thoughts, and actions.
75594876|NCT04822766|Procedure|Hematopoietic stem cell transplantation|patients will undergo allo-HSCT after consolidation therapy (or completion of other appropriate non-palliative strategy) according to standard procedures of the transplant center (choice of donor, conditioning regimen, GVHD and infection prophylaxis). The use of novel therapies (such as sorafenib, midaustorine, venetoclax, etc.) will be allowed as post-transplantation maintenance strategy.
75887317|NCT04193475|Other|Analysis|No intervention planned. Novel analysis of echocardiographic data.
76057715|NCT01944631|Device|Placebo|Nasal spray saline
76057716|NCT01944631|Device|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
76057717|NCT01948063|Drug|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
76071965|NCT03575026|Behavioral|Usual care|Social activity acts as control with similar dose and intensity with intervention arm
76057718|NCT01948063|Dietary Supplement|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
75444950|NCT06223165|Behavioral|Floreciendo (Foundations, Condoms & Contraception, Family Strengthening, and Gender & Relationships)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
75444951|NCT06223165|Behavioral|Floreciendo (Foundations, Condoms & Contraception, and Family Strengthening)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
75444952|NCT06223165|Behavioral|Floreciendo (Foundations, Condoms & Contraception, Gender & Relationships)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
75594877|NCT04822766|Drug|Best chemotherapy treatment|patients will be treated according to the standard procedures of the treating center for this type of population. Patients will receive the best available treatments (including additional conventional chemotherapy or other non-palliative therapies such as 5-azacytidine, decitabine, venetoclax, midaustorine, enasidenib, etc.).
75594878|NCT05139953|Other|No intervention|No intervention
75594879|NCT04445961|Diagnostic Test|Respiratory mechanics measurement|Measurement of peak inspiratory pressure, plateau pressure, calculation of static compliance and driving pressure
75594880|NCT04445961|Diagnostic Test|Gas exchange measurement|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio and alveolar dead space
75887318|NCT04159168|Behavioral|Facial Affect Sensitivity Training (FAST)|The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.
75594881|NCT04828265|Biological|Aldafermin|Single dose of aldafermin
75594882|NCT01346592|Biological|Trivalent split influenza vaccine (TIV)|
75594883|NCT01346592|Biological|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
75594884|NCT01346592|Biological|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
76057719|NCT01995071|Drug|ABT-493|Tablet
76057720|NCT01995071|Drug|ABT-530|Tablet
76057721|NCT01995071|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
76057722|NCT01995071|Drug|Ribavirin (RBV)|Tablet
76057723|NCT01994837|Drug|ABT-199|Tablet
76071966|NCT03571308|Drug|R-CHOP + acalabrutinib|Patient will be given R-CHOP and acalabrutinib
75444953|NCT06223165|Behavioral|Floreciendo (Foundations, Family Strengthening, and Gender & Relationships)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
75887319|NCT04159168|Behavioral|Implicit Gaze Training task (Active control condition)|"This computerized task was developed to target implicit training of eye gaze but not facial emotion recognition per se via real-time feedback and incentives. On each trial, a fixation cross is followed by an emotional face with eyes directed either left, straight ahead, or right (balanced across expressions), followed by a response key. The child's task is to say which direction the eyes are looking (e.g., 1 or left). Stimuli are black and white standardized photographs of men and women models from the Ekman Pictures of Facial Affect each displaying the 3 gaze directions for 6 emotion expressions."
75738810|NCT04221750|Behavioral|Lifestyle therapy|Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced ~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
75738811|NCT04221750|Drug|Metformin Hydrochloride|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
75887320|NCT04134689|Device|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
75887321|NCT04134689|Other|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
75887322|NCT04105842|Device|Delfilcon A|Participants wear delafilcon A contact lenses on a daily disposable basis.
75444954|NCT06223165|Behavioral|Floreciendo (Foundations and Condoms & Contraception)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them."
75594885|NCT05139758|Diagnostic Test|Biodex Balane System|The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
75594886|NCT04822610|Procedure|interscalene block|peripheral nerve block
75738812|NCT04221750|Drug|Placebo|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
75738813|NCT04221750|Behavioral|Healthy Lifesylte|Group educational sessions that focus on healthy diet, exercise, and social support once a month
75738814|NCT04182126|Other|Regular long-lasting insecticidal nets|Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
75444955|NCT06223165|Behavioral|Floreciendo (Foundations and Family Strengthening)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
75594887|NCT04822610|Procedure|suprascapular block + axillary block|peripheral nerve block
75594888|NCT04516928|Diagnostic Test|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
75594889|NCT04516928|Other|Questionnaire|A questionnaire on socio-demographical status, health status and lifestyle habits during the pandemic will be filled by the participants at Day 0.
75594890|NCT01346514|Behavioral|Intensive Addiction/Housing Case Management|AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
75738815|NCT04182126|Other|LLIN plus Piperonyl butoxide-treated LLIN|Olyset Plus: containing 2% permethrin and 1% PBO
75887323|NCT04092803|Other|Virtual Reality|The system includes a VR headset with VR software already loaded in to it.
75887324|NCT04088734|Drug|ABO-102|Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10^13 vg/kg
75887325|NCT04081688|Drug|Atezolizumab 1200 MG in 20 ML Injection|Given IV every 3 weeks (cycle is 21 days)
75887326|NCT04081688|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT between cycle 1 and cycle 2 (each cycle is 21 days)
75887327|NCT04081688|Drug|Varlilumab 3 mg/kg|Given IV every 3 weeks (cycle is 21 days)
75738816|NCT04182126|Other|Long-lasting microbial larvicide|Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet
75738817|NCT04182126|Other|Indoor residual spraying with micro-encapsulated pirimiphos-methyl|each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year
75738818|NCT04145466|Behavioral|High-fat diet|"The high-fat diet will consist of ~40% energy from fat and ~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of ~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
75738819|NCT04145466|Behavioral|High-carbohydrate diet|"The high-carbohydrate diet will consist of ~20% of energy from fat and ~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of ~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
75738820|NCT00481065|Biological|MF59-eH5N1|
75738821|NCT00481065|Biological|eTIV_a|
75738822|NCT00481065|Biological|MF59-eH5N1 + eTIV_a|
75444956|NCT06223165|Behavioral|Floreciendo (Foundations and Gender & Partner Relationships)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
75738823|NCT01017393|Drug|Ketamine|
75444957|NCT06223165|Behavioral|Floreciendo (Foundations)|• Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.
75444958|NCT06223152|Other|parental support|parental support
75444959|NCT06223139|Diagnostic Test|Handgrip strength|Handgrip strength will be measured by 3 efforts.
75444960|NCT06223126|Other|Combined oral contraception|Women, who want to start taking birth control pills will get a prescription for oral contraception at the discretion of their own attending physician
75444961|NCT06223126|Other|Discontinuation of a combined oral contraception|Cessation of the use of combined oral contraceptives
75444962|NCT06223113|Device|EyenableTM PA60AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.
75444963|NCT06223100|Drug|Eravacycline|There is no other intervention.
75444964|NCT06223087|Other|winter swimming|Intervention involves bathing/swimming in cold water during the winter months in open waters
75444965|NCT06223074|Other|IV Methylprednisolone administration|Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse
75444966|NCT06223074|Drug|Nasal Methylprednisolone (MT)|Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
75444967|NCT06223048|Drug|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
75594891|NCT01346514|Behavioral|Housing Support Group|The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
75594892|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
75594893|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
75594894|NCT02893995|Drug|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
75594895|NCT02893995|Drug|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
75594896|NCT01342887|Drug|cyclosporine|Given IV
75738824|NCT01017393|Drug|ketamine free|
75738825|NCT00493311|Drug|IV Placebo|IV Placebo
75738826|NCT00493311|Drug|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
75738827|NCT00493311|Biological|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
75594897|NCT01342887|Drug|pravastatin sodium|Given PO
75594898|NCT01342887|Drug|mitoxantrone hydrochloride|Given IV
75594899|NCT01342887|Drug|etoposide|Given IV
75594900|NCT01342887|Procedure|bone marrow aspiration|Correlative studies
75594901|NCT04445415|Diagnostic Test|COVID-19 antibodies testing|antibodies aganist COVID-19 detected in the serum of patients
75594902|NCT01342341|Drug|Parafon Forte|"Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit"
75594903|NCT01340664|Drug|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
75594904|NCT01340664|Drug|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
75444968|NCT06223035|Other|Exercise|Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
75444969|NCT06223022|Behavioral|Proactive nurse-led telephone follow-up|An intervention nurse call the patients regularly with predetermined intervals and give support
75738828|NCT00571649|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
75444970|NCT06223009|Drug|cNP8|cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
75444971|NCT06223009|Other|Placebo|Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo.
75444972|NCT06222996|Behavioral|vaccine hesitation training|Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
75444973|NCT06222983|Procedure|CEA or CAS|After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness
75738829|NCT00571649|Drug|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
75738830|NCT00571649|Drug|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
75738831|NCT00571649|Drug|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
75594905|NCT01340664|Drug|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
75738832|NCT05434793|Device|RJ-LASER, LASERPEN®; Reimers & Janssen, Germany|The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
75738833|NCT05434715|Procedure|Thyroidectomy|removal of the thyroid gland
75462853|NCT01869010|Other|Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls|This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
75738834|NCT05434403|Device|Vagus nerve stimulation|vagus nerve electrical stimulation through ear skin
75738835|NCT05434403|Device|sham vagus nerve stimulation|sham vagus nerve electrical stimulation through ear skin
75738836|NCT00546572|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
75738837|NCT00546572|Biological|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
75738838|NCT03917472|Drug|Brolucizumab|Intravitreal injection
75738839|NCT03917472|Drug|Aflibercept|Intravitreal injection
75738840|NCT00681863|Drug|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
75594906|NCT01340664|Drug|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
75594907|NCT04824014|Diagnostic Test|4FMFES-PET|Intravenous 4FMFES injection, followed with PET imaging
75594908|NCT01340625|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
75594909|NCT01340625|Drug|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
75594910|NCT04823468|Dietary Supplement|Abbott®Ensure|Abbott®Ensure: 55.8 g each time, three times a day, from the beginning to the end of radiotherapy
75738841|NCT00681863|Drug|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
75738842|NCT00681863|Drug|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
75738843|NCT00681863|Drug|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
75738844|NCT00681863|Drug|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
75738845|NCT02559791|Biological|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
75738846|NCT02559791|Drug|Placebo|Matching placebo once monthly for 2 months
75738847|NCT05677620|Radiation|Pharyngeal Computed Tomography|To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
75738848|NCT05677620|Drug|Drug-Induced Sleep Endoscopy (Propofol)|The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
75738849|NCT05677620|Device|Mandibular Advancement Device|A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
75738850|NCT00681629|Drug|Quetiapine XR|400-800 mg, oral, bid
75738851|NCT00681629|Other|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
75738852|NCT00969176|Drug|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
75738853|NCT05669586|Drug|Antitumor therapy guided by organoid drug sensitivity test|Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
75444975|NCT06222957|Other|None (Observational study)|Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
75444976|NCT06222944|Drug|Anlotinib|Anlotinib: 12mg PO, QD, D1-14, Q3W;
75444977|NCT06222944|Drug|TQB2450|TQB2450: 1200 mg, IV, D1, Q3W
75444978|NCT06222944|Drug|Albumin-Bound Paclitaxel|125mg/m2 IV D1,8，Q3W
75444979|NCT06222931|Device|Triplanar vibrating platform|Mechanical vibration emitted by triplanar vibrating platforms
75444980|NCT06222931|Device|Side-alternating vibrating platform|Mechanical vibration emitted by side-alternating vibrating platforms
75444981|NCT06222931|Other|Sham vibration|Simulated vibration
75444982|NCT06222918|Procedure|Deep Margin Elevation (G-ænial Universal Injectable)|Deep margin elevation (DME), or coronal margin relocation (CMR), is a procedure used to raise or reposition sub-gingival margins into supra-gingival margins using several materials to increase marginal integrity and bonding strength
75738854|NCT00969254|Drug|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pílulas de Lussen®~** Drug B: placebo."
75738855|NCT00969254|Drug|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pyridium®~** Drug B: placebo."
75444983|NCT06222905|Other|non interventional|non interventional
75444984|NCT06222892|Drug|Camlipixant|Camlipixant will be administered.
75444985|NCT06222879|Drug|HRS-8080; SHR-A1811|Participants will receive HRS-8080 and SHR-A1811
75444986|NCT06222879|Drug|HRS-8080; SHR-A2009|Participants will receive HRS-8080 and SHR-A2009
75594911|NCT04823468|Radiation|Intensity Modulated Radiation Therapy|The prescribed dose was 68-76 Gy to Planning target volume of the primary tumor (PTVnx), 66-70 Gy to Planning target volume of the cervical lymph node (PTVnd), 60-64 Gy to planning target volume 1 (PTV1), and 50-54 Gy to planning target volume 2 (PTV2) in 30-33 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
75594912|NCT04823468|Drug|cisplatin|80-100 mg/m² cisplatin given intravenously every 3 weeks concurrently with radiotherapy.
75738856|NCT00921791|Device|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
75594913|NCT04511273|Drug|Follow up of female sexual function|Mirabegron 50mg once daily for treatment of overactive bladder symptoms
75738857|NCT00921791|Device|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
75738858|NCT00921791|Behavioral|Pharmaceutical care|consultations with the pharmacists
75738859|NCT00921791|Other|Usual care|Consultation with the physician.
75738860|NCT04503252|Other|Blood samples for the measurement of the concentration of cefazolin|Blood samples for the measurement of the concentration of cefazolin will be collected on the 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (usually within 4 weeks after inclusion; only in patients on outpatient continuous parenteral antibiotic treatment).
75444987|NCT06222879|Drug|SHR-A2009; SHR-1316|Participants will receive SHR-A2009 and SHR-1316
75887328|NCT04068155|Device|DaRT- Diffusing Alpha-emitters Radiation Therapy|Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles
75887329|NCT04064814|Drug|Flunarizine 5mg|Flunarizine 5mg once daily,orally for 12 weeks
75887330|NCT04064814|Drug|Alpha lipoic acid 300mg|Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
75887331|NCT04060966|Behavioral|Cold-Pressor Task (CPT)|The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.
75887332|NCT04060966|Behavioral|Control CPT|The control CPT involves participants submerging their dominant forearm in warm water (~30°C) for 3 minutes.
75444988|NCT06222866|Diagnostic Test|Anticoagulation monitoring|Evaluation of different monitoring modalities to find the most appropriate anticoagulation monitoring tool for UFH therapy
75444989|NCT06222853|Biological|anti-CD19-CAR-T cells|Three dose groups (1×105/kg, 3×105/kg, 5×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
75444990|NCT06222840|Other|Electro-clinical analysis of epileptic seizures|Electro-clinical analysis of epileptic seizures
75594914|NCT01340196|Drug|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
75738861|NCT04503252|Other|S. aureus culture isolate|The S. aureus culture isolate will be subjected to exact cefazolin MIC determination and to measurement of the level of cefazolin tolerance.
75738862|NCT04503252|Other|structured telephone interview|Structured telephone interview for Patient follow- up after 30 days
75887333|NCT04060966|Device|fMRI|Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
75887334|NCT04041609|Drug|LYR-210|A single administration of LYR-210 depot
75887335|NCT04041609|Other|Sham comparator|Sham comparator
75887336|NCT04008563|Procedure|Bariatric Surgery|Patients who are randomized to the intervention group will receive a progestin intrauterine device and be referred for bariatric service to undergo bariatric surgery within 3 months of their study consent.
75444991|NCT06222840|Other|Electro-encephalographic cases|Electro-encephalographic connectivity analysis compared to controls
75444992|NCT06222840|Other|Clinical datas analysis|Clinical datas analysis
75738863|NCT04503252|Other|Sub-study quantitative measurement of Torque Teno virus|An additional EDTA sample will be drawn for quantitative polymerase chain reaction (PCR) of TTV DNA and analyses of cytokines and other parameters of the activation state of the immune system.
75738864|NCT04503252|Other|Sub-study investigating cefazolin concentrations in sweat|For each visit of included patients, a sweat sample will be collected via a CE certified Macroduct Sweat Collector. Eccrine sweat glands of the lower forearms are stimulated by pilocarpine (a parasympathomimetic) as well as a local current for 5min. Sweat is subsequently collected by capillary containers during 30min and transferred to small tubes on dry ice. Sweat sample analysis is conducted using mass spectrometry.
75887337|NCT04002479|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
75887338|NCT04001478|Diagnostic Test|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
75887339|NCT03995082|Other|Patient Reported Outcome Measure Survey result feedback|Patients will receive a graph of their results from the PROM survey each time they complete a survey
75887340|NCT03992352|Diagnostic Test|Age 60+ with planned HCT for Hematologic Malignancy|questionnaires, geriatric assessments
75444993|NCT06222840|Other|Electro-encephalographic control|Electro-encephalographic connectivity analysis compared to cases
75462854|NCT01869023|Drug|Gemcitabine|Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
75462855|NCT01869023|Drug|Cisplatin|Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
75462856|NCT01869036|Drug|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
75462857|NCT01869036|Drug|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
75462858|NCT01869062|Device|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
75462859|NCT01869062|Device|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
75462860|NCT01869088|Drug|Recombinant Human Adenovirus Type 5 Injection|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery
75444994|NCT06222827|Drug|Satralizumab Prefilled Syringe|Satralizumab is supplied as prefilled syringe with 1 millimeter of solution for subcutaneous injection corresponding to 120mg of satralizumab. During the first period (double blind period), satralizumab will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
75444995|NCT06222827|Drug|Placebo Comparator|Placebo prefilled syringe is identical in composition to satralizumab, but does not contain the satralizumab active agent. It is identical in appearance and packaging to satralizumab. During the first period (double blind period), placebo will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
75444996|NCT06222814|Procedure|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft
75444997|NCT06222814|Procedure|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)
75738865|NCT00969410|Biological|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
75738866|NCT00969488|Other|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
75738867|NCT03485430|Behavioral|Tapering|Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering in an outpatient setting. Follow-up to doctor after four months.
75738868|NCT00679367|Drug|dexamethasone|40 mg once weekly
75738869|NCT00679367|Drug|lenalidomide|10 mg/day D1-21
75738870|NCT00679367|Drug|melphalan|5 mg/m2 D1-4
75738871|NCT00969566|Drug|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
75738872|NCT00973544|Other|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
75738873|NCT00755495|Drug|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
75738874|NCT00755495|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
75738875|NCT00755495|Drug|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
75738876|NCT00755495|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
75738877|NCT00964184|Drug|Metformin|
75738878|NCT00964184|Behavioral|Lifestyle modification|
75887341|NCT03989011|Diagnostic Test|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celsius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
76057724|NCT02010593|Drug|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-[[4-[(2,4,6-trimethylphenyl)amino]-2- pyrimidinyl]amino]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
75444998|NCT06222801|Drug|Tumor necrosis factor alpha|Antitumor agent. Immunomodulatory agent.
75444999|NCT06222801|Drug|Interferon gamma|Immunostimulating agent.
75738879|NCT04005300|Dietary Supplement|standard enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
75738880|NCT04005300|Dietary Supplement|restricted enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
75738881|NCT00969644|Drug|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
75738882|NCT00969644|Drug|Pegvisomant|s.c. injections once daily (10-15 mg/day)
75738883|NCT05646420|Other|Blood sampling|A blood sample of 15 ml will be collected for each patient.
75738884|NCT00969800|Device|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
75738885|NCT00969800|Device|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
75738886|NCT05061888|Other|Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables|Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.
75738887|NCT05061888|Other|Smart Intervention for Stress Managment|Will receive a Smart Intervention on stress management practices and strategies.
75738888|NCT04008914|Other|retrospective observation|Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
75738889|NCT04073394|Behavioral|Standard Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.
75738890|NCT04073394|Behavioral|Modified Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.
75738891|NCT00964262|Drug|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
75738892|NCT00964262|Drug|Placebo|Plcacebo of each doasage, single subcutanoeus injection
75594915|NCT04827212|Behavioral|Companion|"Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time."
75738893|NCT00973778|Other|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
75738894|NCT05623410|Biological|ATGC-110|ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
75738895|NCT05623410|Biological|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
75445000|NCT06222788|Device|Convertible Plasma Jet|NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)
75445001|NCT06222775|Behavioral|Group session 1|"This session will have 3 editions in which the 50 participants of the experimental group will be distributed, with about 16 to 17 participants per edition.~Its objective is to know the group and their expectations, in addition to providing basic knowledge about diabetes and a healthy lifestyle."
75445002|NCT06222775|Behavioral|Group session 2|"The sessions for the 5 groups will take place within 2 weeks. Two weeks after the 1st session, the 2nd session-workshop will be scheduled with no more than 10 participants. For this, 5 groups will be made. An attempt will be made to ensure that the participants in the groups remain stable.~Its objective is to pave the way for the change to a healthy eating lifestyle and provide patients with sufficient knowledge so that with theory they can prepare a daily group menu according to the caloric needs of each of the participants."
75738896|NCT00964340|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
75738897|NCT00964340|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
75445003|NCT06222775|Behavioral|Group session 3|Its general objective is to motivate the change towards healthy eating. And the specific ones develop a weekly menu according to calorie needs.
75738898|NCT04004598|Behavioral|golf training|12 weeks of training by Professional Golf Association professional
75738899|NCT00973934|Device|Magstim Theta|
75738900|NCT00973934|Device|Thymatron System IV|
75738901|NCT00970112|Procedure|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
75738902|NCT00964418|Drug|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
75738903|NCT00964418|Drug|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
75738904|NCT00974012|Drug|Divalproex Sodium|500 mg ER Tablet
75738905|NCT00974012|Drug|Depakote®|500 mg ER Tablet
75738906|NCT04009226|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
76057725|NCT02010593|Drug|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
75738907|NCT00964574|Drug|INSULIN GLULISINE (HMR1964)|"Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day"
75738908|NCT00964574|Drug|INSULIN GLARGINE|"Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening"
75738909|NCT04008680|Other|EQ-5D-5L survey internal consistency|To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
75738910|NCT00970346|Drug|OligoG CF-5/20|Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
75738911|NCT03937778|Behavioral|Deep pressure block|Apply deep pressure block by using blood pressure cuff.
75738912|NCT03935126|Diagnostic Test|Diagnostics|Diagnostics
75738913|NCT00964652|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
75738914|NCT00970580|Drug|BIIB022 With Paclitaxel and Carboplatin|Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
75738915|NCT00974168|Radiation|Cumulative BED ≤ 100|Radiation
75738916|NCT00974168|Radiation|Cumulative BED ≤ 130 Gy2|Radiation
75738917|NCT04009304|Behavioral|OSNAP|Afterschool practice and policy change to support healthy eating and physical activity
75738918|NCT00974324|Drug|endostar and CHOP|"endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone"
75594916|NCT04826744|Other|Standard dermatology consultation|"with clinical examination, score filling such as SCORAD and DLQI~Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history~Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72.~ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)"
75887342|NCT03989011|Diagnostic Test|Arterial stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~Peripheral pressure parameters~Central and abdominal aneurysm pressure parameters (derived using a transfer function)~Cardiac output parameters (SEVR, ED)~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
75887343|NCT03967626|Device|external cooling with the xxxxx device|external cooling with the xxxxx device
75594917|NCT04137315|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
75887344|NCT03940963|Device|AxoGuard® Nerve Cap|Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
75594918|NCT02893332|Radiation|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
75738919|NCT00545714|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
75887345|NCT03940963|Procedure|Standard Neurectomy|Surgical excision of symptomatic neuroma
75445004|NCT06222775|Behavioral|Group session 4|Its general objective is to reinforce a healthy lifestyle-eating, and the specific ones are to learn to read labels, preparing a weekly menu in a group.
75887346|NCT03938987|Biological|autologous CD19-directed chimeric antigen receptor (CAR) T-cells|Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
75738920|NCT00545714|Drug|Fludarabine|Fludarabine 25 mg/m^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
75738921|NCT00545714|Drug|Rituximab|Rituximab 375 mg/m^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
75887347|NCT03924414|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
75887348|NCT03924414|Other|Placebo|Normal Saline 100 ml (placebo) IV infusion
75445005|NCT06222775|Behavioral|Group session 5|Its general objective is to reinforce lifestyle-physical activity. And the specific objectives are to recognize that it is a moderate physical activity and the goal to achieve of recommended physical activity per week and plan a week of physical activity.
75738922|NCT00970658|Drug|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
75738923|NCT00970658|Drug|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
75738924|NCT00964730|Drug|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
75738925|NCT00964730|Drug|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
75887349|NCT03914703|Procedure|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
75445006|NCT06222775|Behavioral|Group session 6|Its general objective is to reinforce a lifestyle-healthy eating and physical activity. And the specific ones are to reinforce the concept of physical activity in diabetes, what to do with hypoglycemia and adjust diet and exercise to current weight and needs.
75445007|NCT06222775|Behavioral|Group session 7 to 8|The objective will be to maintain a healthy lifestyle and adjust menus and physical activity to current caloric needs, in addition to sharing experiences.
75594919|NCT02893332|Drug|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
75738926|NCT00964730|Drug|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
76057726|NCT01994291|Drug|Ranibizumab|"Intravitreal Injection supplied as:~10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~Adminstered once a month for 12 weeks"
76057727|NCT01994291|Drug|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks"
75887350|NCT03910933|Other|elearning patient information|The videos will standardize patient teaching about anticoagulants, warfarin, INR testing, and warfarin safety for Patient Self-Testing, and Patient Self-Management. eKITE, will provide a user-friendly interface to provide health education about anticoagulation. eKITE will teach concepts to the patient, facilitate sustained patient knowledge (6 month evaluation), reduce stress associated with learning, actively engage patients in their anticoagulant management (preference, satisfaction and knowledge).
75887351|NCT03904927|Other|Radiation, Surgery or Radiofrequency ablation|Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.
75887352|NCT03904927|Drug|Systemic therapy|"First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy."
75445008|NCT06222775|Behavioral|Group session 9|"In the final session, a certificate of adherence to healthy living will be delivered, reminding you to continue with the acquired habits and attend scheduled consultations and tests.~The days of the sessions are indicative, but they must be held in the week when the specified period of time between session and session is met."
75445009|NCT06222775|Behavioral|Control Intervention 1|They will be given written information about the convenience of moderate physical activity and they will be informed of the importance of following an appropriate diet for diabetes and we will encourage weight loss.
75445010|NCT06222775|Behavioral|Control Intervention 2|Your controls will be carried out according to the usual diabetes protocol established in the individual scheduled diabetes consultation reviews.
75738927|NCT00974402|Behavioral|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
75738928|NCT00539838|Drug|Prednisone|Oral repeating dose
75738929|NCT00539838|Drug|Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
75738930|NCT00539838|Drug|Methylprednisolone|Intravenous repeating dose
75738931|NCT00539838|Drug|Ocrelizumab|Intravenous repeating dose
75738932|NCT00539838|Drug|Placebo|Intravenous repeating dose
75738933|NCT00970892|Drug|Warfarin dose titration|Dosage
75738934|NCT00964808|Drug|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
75887353|NCT03886181|Device|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
75887354|NCT03868787|Device|TENS|TENS units are small, inexpensive, portable, battery-powered devices which deliver mild, alternating electrical currents via electrodes positioned on the skin near the anticipated dermatomal distribution of pain.
75887355|NCT03868787|Device|Sham TENS|Non-active TENS unit
75738935|NCT00964808|Drug|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg * 2 pr. day until time to discharge from the Hospital or latest at day 12.
75738936|NCT00970970|Other|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
75738937|NCT03765450|Drug|Infliximab|Patients will receive infliximab at the discretion of their physician as part of standard of care.
75738938|NCT00974558|Device|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
75738939|NCT05258084|Behavioral|sexual minority awareness training|sexual minority awareness training is planned as 4 interviews (1 interview per week) for a total of 4 hours. Gender and sexuality-related terminologies and concepts will be discussed in the 1st meeting. Expression of sexual identity and gender transition processes will be examined in the 2nd meeting. In the 3rd meeting, the determining factors in the inadequate utilization of health services by LGBT individuals will be discussed. In the 4th meeting, what can be done to create a safe and health-friendly environment for LGBT individuals and healthcare professionals will be discussed.
75738940|NCT00974636|Dietary Supplement|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
75738941|NCT00974636|Dietary Supplement|Usual Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
75594920|NCT04443699|Behavioral|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
75445011|NCT06222775|Behavioral|Control Intervention 3|These patients will also be given a written document about living with diabetes, advice on physical activity, and a pre-established diet will be given according to the number of calories needed previously calculated
75445012|NCT06222775|Behavioral|Control Intervention 4|In addition to verbal recommendations. This document will be made after the act of assigning the control or experimental group.
75445013|NCT06222762|Other|Experimental arm|Personalized follow-up in adapted physical activities
75594921|NCT04328493|Drug|Chloroquine phosphate|"Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days"
75594922|NCT02893449|Behavioral|Social adaptation|"Questionnaire to fill-in.~The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program."
75594923|NCT02893449|Behavioral|Intensive care management|In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.
75594924|NCT02893449|Procedure|Deep brain stimulation|
75738942|NCT00974714|Drug|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
75738943|NCT00974714|Other|placebo|oral placebo 2 g twice a day for 14 weeks
75738944|NCT00971126|Drug|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
75738945|NCT00971360|Other|conversion disorder|Proinflammatory cytokine levels in conversion disorder
75738946|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) three times weekly
75738947|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) once daily for one week
75738948|NCT00964964|Drug|placebo|Placebo injected s.c. (under the skin) four times weekly
75738949|NCT04183998|Other|Trans-spinal Electrical Stimulation (tsES)|Stimulation will be achieved with two self-adhesive stimulation electrodes attached to the dorsal aspect of the neck overlying the cervical vertebrae and two self-adhesive rectangular return electrodes placed over the shoulders. Spinal motor evoked potentials (sMEP) induced by trans-spinal electrical stimulation (parameters, 1 Hz with a 0.1-1 ms pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10 to 200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-40 Hz and 20-100 milliampere.
75738950|NCT00965042|Drug|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
75738951|NCT00974792|Biological|pegfilgrastim|
75738952|NCT00974792|Biological|rituximab|
75738953|NCT00974792|Drug|cyclophosphamide|
75445014|NCT06222749|Drug|Intranasal oxytocin administration|24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).
75738954|NCT00974792|Drug|cytarabine|
75738955|NCT00974792|Drug|doxorubicin hydrochloride|
75738956|NCT00974792|Drug|etoposide phosphate|
75738957|NCT00974792|Drug|ifosfamide|
75738958|NCT00974792|Drug|leucovorin calcium|
75738959|NCT00974792|Drug|methotrexate|
75738960|NCT00974792|Drug|vincristine sulfate|
75738961|NCT03659214|Behavioral|Questionnaires|Answering 4 questionnaires : anxiety, depression, quality of life and adherence
75445015|NCT06222749|Drug|Intranasal placebo administration|Nasal spray solution; Placebo will be administered as the placebo controlled condition.
75445016|NCT06222736|Other|Rocabado Exercises|Patients trained by Rocabado Exercises
75445017|NCT06222736|Other|Servical Core Exercises|Servical Core Exercises
75445018|NCT06222723|Drug|Dexamethasone|Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
75445019|NCT06222723|Drug|Ribavirin|Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
75445020|NCT06222710|Procedure|Pharmacoacupuncture with ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type with ultrasound guiding
75445021|NCT06222710|Procedure|Pharmacoacupuncture without ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type without ultrasound guiding
75594925|NCT04508270|Behavioral|Early mobilization|Mobilization as soon as patients can, which is not limited on walking
75594926|NCT05139641|Behavioral|Counseling to preserve fertility|Counseling to preserve fertility VS Control group
75738962|NCT00971438|Procedure|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
75738963|NCT03657888|Behavioral|Family Club Denmark (FCD)|Participation in Family Club Denmark
75738964|NCT03657888|Other|Wait-list control|Participants on the waiting list
75738965|NCT00965120|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
75738966|NCT00965120|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
75887356|NCT03856320|Behavioral|Educational Video|An educational video describing obesity treatment options available in the VA.
75594927|NCT04443231|Device|Optical Coherence Tomography Angiography|AngioVue (Optovue, Fremont, CA, USA) was used to capture the OCTA images before ICL surgery and at 3 months follow-up.
75594928|NCT01600118|Device|Extracorporeal shockwave therapy|1000 impulses
75594929|NCT01600118|Device|No extracorporeal shockwave|0 impulses, acoustic effect
75445022|NCT06222697|Drug|Damoctocog-alfa-pegol (Jivi, BAY94-9027)|Follow clinical practice/administration. No drug is provided to participants due to the observational nature of the study.
75445023|NCT06222684|Other|Music therapy|Women applying for mammography screening will receive music therapy for 5 minutes before the procedure, during the mammography scan and for 5 minutes after the procedure.
75445024|NCT06222671|Drug|608|608 subcutaneous (SC) injection.
75594930|NCT04504799|Device|Body composition measurement with HAG-BIA scale|Bio-impendance analysis
75594931|NCT04395963|Device|Tobii Pro Glasses 50 Hz wearable wireless eye tracker|This system can measure eye movements using cameras integrated into the eyeglasses which record the corneal reflection of infrared lighting to track pupil position, mapping the subject's focus of attention on video recordings of the subject's field of vision (gaze).
75738967|NCT00965120|Drug|Placebo (saline)|Systemic infusion of placebo (saline).
75738968|NCT00971516|Procedure|Implant placement|dental implant placement
75738969|NCT00971516|Procedure|Implants surgery|dental implant surgery
75887357|NCT03846388|Diagnostic Test|follicular stimulating hormone|in the serum of our patients
75887358|NCT03846388|Diagnostic Test|Anti-mullerian hormone|in the serum of our patients
75887359|NCT03846388|Radiation|Basal antral follicle count|by ultrasound
75887360|NCT03804671|Drug|BI 730357|Oral dose
75887361|NCT03804671|Drug|BI 730357 mixed with [C-14] BI 730357 BS|Intravenous dose
75887362|NCT03804255|Other|Survey Administration|Complete surveys
76057728|NCT01994291|Drug|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
76057729|NCT01994291|Drug|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
75445025|NCT06222671|Drug|608|608 subcutaneous (SC) injection.
76057730|NCT02094677|Device|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
76057731|NCT02094677|Device|etafilcon A|Participants were randomized to wear etafilcon A control lens.
75445026|NCT06222671|Drug|Placebo|Placebo subcutaneous (SC) injection.
75445027|NCT06222658|Device|pharmaco-mechanichal thrombectomy|pharmaco-mechanichal thrombectomy in acute limb ischemia
75462861|NCT01869088|Procedure|Transartery Chemoembolization|Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
75462862|NCT01869127|Device|Shoes|A unisex canvas slip-on with a sturdy sole.
75462863|NCT01869140|Device|spinal manual therapy|spinal manipulation either manual or instrumental (activator)
75462864|NCT01869166|Biological|CART-EGFR|
75462865|NCT01869179|Behavioral|Community of Voices choir program|Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.
75462866|NCT01869179|Behavioral|Wait-list control group|
75462867|NCT01869205|Device|Endobronchial valve|One-way endobronchial valves are placed in segmental bronchi of the most hyperinflated and least perfused lobe of the emphysematous lungs on computed tomography (CT). Before the procedure, we confirm that the target lobe has no collateral ventilation with other lobes using Chartis® System (Pulmonx, Inc. Redwood City, CA, USA).
75462868|NCT01869231|Dietary Supplement|olive oil|
75462869|NCT01869231|Dietary Supplement|olive oil and chewing gum|
75462870|NCT01869231|Dietary Supplement|chewing gum|
75462871|NCT01869231|Dietary Supplement|water|
75462872|NCT01869257|Device|Triclosan coated suture|The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
75462873|NCT01869257|Device|regular suture|The control arm will have the abdominal wound sutured with a regular non-coated suture
75462874|NCT01869283|Other|Kinesiotherapy|
75462875|NCT01869283|Other|Ultrasound|
75462876|NCT01869283|Other|Diadynamic currents|
75462877|NCT01869296|Procedure|higher flow rates|higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
75462878|NCT01869296|Procedure|lower flow rates|lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
75462879|NCT01869309|Drug|Prasugrel|Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
75462880|NCT01869309|Drug|Ticagrelor|Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
75462881|NCT01869322|Device|Sling and Swathe|Sling and Swathe immobilization of humeral shaft fracture.
75462882|NCT01869322|Device|Coaptation Splint|Coaptation splint immobilization of humeral shaft fractures.
75462883|NCT01869335|Device|radiography|
75462884|NCT01869335|Device|MRI (magnetic resonance imaging)|
75462885|NCT01869387|Device|Non-invasive ventilation|
75462886|NCT01869426|Dietary Supplement|VSL#3 drops|
75462887|NCT01869426|Dietary Supplement|VSL#3 drops placebo|
75462888|NCT01869452|Behavioral|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
75887363|NCT03714828|Drug|Injection of TVEC into target lesions - week 1-2|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient."
75887364|NCT03714828|Drug|Injection of TVEC into target lesions 3wks after 1st injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL withapproximately 1.15 mL in a 2 mL vial for the second and subsequent doses."
75887365|NCT03714828|Drug|Injection of TVEC into target lesions 2wks after 2nd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
75887366|NCT03714828|Drug|Injection of TVEC into target lesions 2wks after 3rd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
75594932|NCT05139524|Other|Evidence of past or recent RVF exposure|Detection of RVF exposure.
75887367|NCT03675815|Drug|Darunavir (DRV) 800 milligram (MG) Oral Tablet|800 milligrams (mg) orally once daily for 96 weeks
75887368|NCT03675815|Drug|Ritonavir 100 MG Oral Tablet|100 mg orally once daily for 96 weeks
75594933|NCT04442217|Behavioral|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
75887369|NCT03675815|Drug|N(t)RTIs|Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
75594934|NCT04395651|Device|PET/CT|It is a prospective clinical study that will include patients known to have lung cancer and referred to nuclear medicine unit to perform 18F-FDG PET/CT for staging and therapy planning as well as patients referred for assessment of response of therapy and restaging.
75594935|NCT01327599|Drug|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
75594936|NCT05139407|Diagnostic Test|Teaching intervention|Different teaching methods are used to teach the experimental group and the control array in the classroom.
75594937|NCT04502147|Procedure|Laparoscopic Splenectomy|Laparoscopic splenectomy by ligating the splenic artery
75738970|NCT00971594|Behavioral|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of ~0.2-0.4 kg/wk
75738971|NCT00971594|Behavioral|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
75738972|NCT00971672|Other|Questionnaire filling and laboratory analysis|"A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis."
75887370|NCT03675815|Drug|Dolutegravir 50 MG Oral Tablet|50 mg orally once daily for 96 weeks
76057732|NCT02094677|Device|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
76057733|NCT04667195|Other|Clinical assessment|"Within 4 hours of admission to the emergency department, clinical assessment will include:~Demographics,~comorbidity,~symptoms,~objective findings,~triage at admission,~blood test results,~urine test results"
76057734|NCT04674371|Other|central venous catheter insertion|Every operator should perform the CVC Insertion Procedure according to his common clinical practice.
76057735|NCT01993823|Drug|G238|Five drops into the ear canal twice daily for 14 days
75594938|NCT04328415|Radiation|Cerebral scintigraphy|Radioactive tracer 99mTc-DTPA
75594939|NCT04395534|Procedure|Complete mesocolic excision|
75594940|NCT04395066|Diagnostic Test|CD55|CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.
75594941|NCT04498871|Drug|Nilotinib|Nilotinib is recommended to be administered orally on a continuous schedule at a dose of 400 mg twice daily. The patient should be instructed to take each morning dose of nilotinib 2 hours after a light breakfast (e.g., toast and jam), with no oral intake other than water for 1 hour after dosing. It is recommended that the patient take nilotinib doses every 12 hours with a glass of water. The evening dose of nilotinib should be taken at least 2 hours after dinner with no oral intake other than water for 1 hour after dosing.
75594942|NCT02893215|Other|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
75594943|NCT04439877|Behavioral|Peri-implant disease diagnosis|Diagnosis of peri-implant disease
76057736|NCT01993823|Drug|Clotrimazole|Five drops into the ear canal twice daily for 14 days
75738973|NCT00679289|Drug|HDI|20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression
75738974|NCT00679289|Drug|KW2871|5 mg/m^2 IV every 2 weeks until disease progression
75738975|NCT00679289|Drug|KW2871|10 mg/m^2 IV every 2 weeks until disease progression
75738976|NCT00679289|Drug|KW2871|20 mg/m^2 IV every 2 weeks until disease progression
75738977|NCT00679211|Drug|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
76057737|NCT04673123|Other|Core stabilization exercises|"In our study, core stabilization exercises to be applied in the intervention group are arranged according to the patients with stroke and will be at three different difficulty levels. Exercises will be done on the back (hooked) and sitting positions where the risk of falling is low. First of all, activation of the transversus abdominis muscle, which is the basis of core stabilization, will be taught to patients. With this activation at the first level, the healthy side, at the second level the affected side, and at the third level, reciprocal upper and lower extremity movements will be requested. In addition to these, there will be exercises to bridge and curl up in supine position, and weight transfer in sitting position. In order to increase the difficulty level of the exercises, first of all, the number of exercises will be increased and then it will be asked to move on to the next level."
75594944|NCT04497896|Other|Repair of open globe injury|repair of corneal, corneoscleral, or scleral wounds
76057738|NCT04673123|Other|Multifactorial Education Program|The content of this program includes rehabilitation practices that are routinely applied in stroke rehabilitation and that patients will receive at the specified hospital. In the content of these applications; patient-specific upper and lower extremity stretching, and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training are included. he content of multifactorial fall prevention training includes the first brochure titled '' General Recommendations for the Prevention of Fall in Chronic Stroke Patients '', which will include general recommendations for preventing falling according to the fall risk factors specific to the stroke, and the recommendations to minimize the risk of falling in the home. A second brochure titled 'Suggestions for Making Your Home Safer' will be given. The information in these brochures will also be communicated to patients face to face verbally
75594945|NCT05139329|Diagnostic Test|Imaging|To better understand the prevalance of further imaging for evaluation of myocarditis, all patients with negative workup will be included and see what number of patients undergo further CMRI, FGD-PET, or speckle tracking echocardiography. Patients will then be categorized as those with myocarditis with positive diagnosis, negative diagnosis or unknown.
75594946|NCT04497194|Other|not applicable (observational study)|not applicable (observational study)
75594947|NCT01193257|Drug|Orteronel|Orteronel tablets
75887371|NCT03675815|Drug|TDF 300 MG Oral Tablet|300 mg orally once daily for 96 weeks
75887372|NCT03675815|Drug|3TC 300 MG Oral Tablet|300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
76057739|NCT01993667|Drug|Low Dose Acetazolamide|Administration of low dose acetazolamide
76057740|NCT01993667|Drug|Normal Dose Acetazolamide|Administration of normal dose acetazolamide
76057741|NCT01992107|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
76057742|NCT01992107|Biological|TIV1c|Licensed Influenza Vaccine
76057743|NCT01992107|Biological|TIV2c|Novartis Investigational Vaccine
75594948|NCT01193257|Drug|Prednisone|Prednisone tablets
75594949|NCT01193257|Drug|Orteronel Placebo|Orteronel placebo-matching tablets
75594950|NCT02893371|Drug|Lithium Carbonate|Exposure to all dosages and delivery forms.
75594951|NCT02893371|Drug|Lamotrigine|Exposure to all dosages and delivery forms.
75594952|NCT02893371|Drug|Valproic Acid|Exposure to all dosages and delivery forms.
75594953|NCT02893371|Drug|Oxcarbazepine|Exposure to all dosages and delivery forms.
75594954|NCT02893371|Drug|Carbamazepine|Exposure to all dosages and delivery forms.
75738978|NCT00545948|Drug|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
75738979|NCT00545948|Drug|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
75738980|NCT00755573|Drug|Pregabalin|Pregabalin 300 mg - 600 mg BID
75738981|NCT00755573|Drug|placebo|Regime as described for pregabalin
75738982|NCT00971906|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant,or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups
75738983|NCT00755651|Procedure|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
75738984|NCT00974948|Procedure|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
75738985|NCT02559869|Drug|[18F] GE-180|PET Tracer Ligand
75887373|NCT03675815|Drug|FTC 200 MG Oral Cap|200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
75445029|NCT06222632|Other|Mind diet intervention|These participants will receive four nutrition information sessions, 60 minutes per session, on four consecutive weekdays at the participating community centre. A 7-day sample menu will be developed and explained to the participants as a reference. A nutritionist with the help of a research assistant will conduct each session. The nutritionist-to-participant ratio for each session will be 1:10, 1:11 or 1:12. The following topics will be covered: (1) overview of the MIND diet; (2) discussion with the participants about their ability, motivation and opportunity to adopt the MIND diet; and (3) instruction on how to adopt the MIND diet and how to fill out a logbook for adherence checks.
75738986|NCT00975026|Procedure|Massages ± Stretches|Chair Massage
75738987|NCT00971984|Other|Medical records summary|Summary of Medical files and laboratory results.
75738988|NCT00975104|Drug|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
75738989|NCT00975104|Drug|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
75738990|NCT00975104|Drug|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
75738991|NCT00975104|Drug|Placebo|Placebo IV QW
76057744|NCT04673045|Device|Active Electrical stimulation|The intensity of stimulation will be set within the subject's tolerance level. The amplitude was adjusted to produce muscle contraction without affecting the patient's comfort. The cathode electrode will be placed over the common peroneal nerve as it passes over the head of the fibula and the anode will be placed on mid-muscle belly on one third of the line between fibular head and medial malleolus on paretic limb.
76057745|NCT04673045|Device|Sham Electrical Stimulation|For sham group, the current intensity will gradually decreased after few seconds to 0. Therefore, the participant will experience a passage of current on the muscle at the beginning but received no current for the rest of the stimulation period. The participants will be informed that the stimulation below the sensory level.
76057746|NCT01934192|Drug|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
76057747|NCT01934192|Drug|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
75462889|NCT01869465|Other|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
75594955|NCT02893371|Drug|Ziprasidone|Exposure to all dosages and delivery forms.
75594956|NCT02893371|Drug|Risperidone|Exposure to all dosages and delivery forms.
75738992|NCT00679055|Drug|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
75594957|NCT02893371|Drug|Quetiapine|Exposure to all dosages and delivery forms.
75594958|NCT02893371|Drug|Olanzapine|Exposure to all dosages and delivery forms.
75594959|NCT02893371|Drug|Aripiprazole|Exposure to all dosages and delivery forms.
75738993|NCT00679055|Drug|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
75738994|NCT04008290|Drug|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
76057748|NCT01934192|Drug|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
75594960|NCT02893371|Drug|Fluoxetine / Olanzapine|Exposure to all dosages and delivery forms.
75594961|NCT02893371|Drug|Haloperidol|Exposure to all dosages and delivery forms.
75594962|NCT02893371|Drug|Perphenazine|Exposure to all dosages and delivery forms.
75594963|NCT02893371|Drug|Clozapine|Exposure to all dosages and delivery forms.
75738995|NCT04008290|Drug|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
75738996|NCT02559167|Drug|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
76057749|NCT01934192|Drug|Placebo IV|Placebo will be administered IV every 6 hours
75594964|NCT02893371|Drug|Asenapine|Exposure to all dosages and delivery forms.
76057750|NCT01933880|Drug|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
76057751|NCT01933880|Other|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
76057752|NCT04647578|Device|GT3X Actigraph accelerometer.|GT3X Actigraph accelerometer during 7 days
76057753|NCT04620980|Diagnostic Test|targeted resequencing|The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).
75445030|NCT06222632|Other|Mind plus FB intervention|The sessions will include four nutritional sessions about the MIND diet and four FB sessions. The participants will be instructed on the MIND diet as previously mentioned. In addition, the MIND-FB participants will undertake four 2 h FB sessions in a country park on four consecutive weekends during daytime hours. The FB sessions will take place during the day if it is sunny, cloudy or lightly raining. The distance covered on each forest visit will be 1-2 kilometres. If it is raining heavily, the session will be cancelled. The participants will gather at the entrance of the country park on the day of FB. The participants will gather at the entrance of the country park on the day of FB. An FB coach will brief the participants and begin the forest trip with a set of experiences on the forest environment. The participants will also be instructed to self-practice FB for 2h per session at weeks 8 &amp; 12 of the intervention.
75445031|NCT06222632|Other|Usual care|Participants will receive a health talk and be given pamphlets provided by the Department of Health and/or Hospital Authority about the protective factors and risk factors of CVDs.
75445032|NCT06222619|Procedure|Potal vein embilization|Portal vein of involved bile duct is embolized to increase the volume of remnant liver.
75445033|NCT06222606|Procedure|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize parathyroid glands during surgery.
75445034|NCT06222398|Device|Exoskeleton|The study will include one group of patients who are current exoskeleton users.
75445035|NCT06221930|Behavioral|attexis|Participants will receive access to the digital health intervention attexis in addition to TAU.
75594965|NCT02893371|Drug|Lurasidone|Exposure to all dosages and delivery forms.
75594966|NCT02893371|Drug|Paliperidone|Exposure to all dosages and delivery forms.
75594967|NCT02893371|Drug|Mirtazapine|Exposure to all dosages and delivery forms.
75738997|NCT00975182|Drug|GDC-0941|Oral repeating dose
75738998|NCT00975182|Drug|erlotinib HCl|Oral repeating dose
75738999|NCT05271071|Diagnostic Test|Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
75739000|NCT00972062|Other|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
75739001|NCT00972062|Other|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
75739002|NCT05270291|Procedure|rectal swab|rectal swab
75594968|NCT02893371|Drug|Bupropion|Exposure to all dosages and delivery forms.
75594969|NCT02893371|Drug|Desvenlafaxine|Exposure to all dosages and delivery forms.
75594970|NCT02893371|Drug|Duloxetine|Exposure to all dosages and delivery forms.
75594971|NCT02893371|Drug|Venlafaxine|Exposure to all dosages and delivery forms.
75739003|NCT00972140|Drug|Formoterol|Formoterol-HFA pMDI 12µg twice daily
75739004|NCT00972140|Drug|Formoterol|Formoterol-DPI 12 µg twice daily
75739005|NCT05261945|Other|Routine Physical Therapy|Routine Physical Therapy treatment with hot pack, TENS, and ultrasound helps in improving and relaxing the muscle spasm and soft tissue elasticity along pain reduction.
75887374|NCT03672695|Combination Product|S 64315 (also referred as MIK665) and venetoclax|"The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy."
75887375|NCT03669133|Drug|Vitamin E|Vitamin E 800 IU/daily
75887376|NCT03669133|Drug|Placebo|Matching placebo daily
75887377|NCT03647969|Drug|Nivolumab|"Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks"
75887378|NCT03647969|Drug|Ipilimumab|1mg/kg i.v. d1 over 30 minutes every 6 weeks
75887379|NCT03647969|Drug|mFOLFOX|Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
75887380|NCT03647969|Drug|FLOT|"Docetaxel at a dose of 50 mg/m² iv over one hour (day 1), Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin* at a dose of 200 mg/m² iv over one hour (day 1), Fluorouracil at a dose of 2600 mg/m² iv over 24 hours (day 1) every 2 weeks~* Note: Leucovorin can be replaced by sodium folinate that is given according to local guideline."
75887381|NCT03644186|Drug|Paclitaxel|Chemotherapy plus HER2 Blockade
75445038|NCT06221683|Drug|Homoharringtonine|3mg/m2/day for weighing >10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours
75445039|NCT06221683|Drug|Cytarabine|100mg/m2/q12h for weighing >10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing >10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;
75445040|NCT06221683|Drug|Etoposide|100mg/m2/d for weighing >10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
75445041|NCT06221683|Drug|Venetoclax|100mg/m2/d for weighing >10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd
75445042|NCT06221683|Drug|Mitoxantrone hydrochloride liposome|5mg/m2/d for weighing >10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
75594972|NCT02893371|Drug|Citalopram|Exposure to all dosages and delivery forms.
75594973|NCT02893371|Drug|Escitalopram|Exposure to all dosages and delivery forms.
75594974|NCT02893371|Drug|Fluoxetine|Exposure to all dosages and delivery forms.
75594975|NCT02893371|Drug|Fluvoxamine|Exposure to all dosages and delivery forms.
75739006|NCT05261945|Other|Manual Therapy And Routine Physical Therapy|Mulligan is consider one of the most effective technique of mobilization.it is also important treatment for neck pain so that many physiotherapist used mulligan by including several methods such as Natural Apophyseal Glides or Sustained Natural Apophyseal Glides.
75739007|NCT05261945|Other|Stretching Exercises And Routine Physical Therapy|Regular stretching helps increase your range of motion in the joints, improves blood circulation and posture and alleviates muscular tension throughout the body.
75739008|NCT00972218|Biological|Adalimumab|Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
75739009|NCT05230901|Other|Standard of Care|Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).
75739010|NCT05230901|Drug|Spironolactone 25mg|"Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication ."
75739011|NCT05230901|Drug|Dihydralazine|"Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)"
75739012|NCT02559557|Other|Educational Intervention|Participate in focus groups
75739013|NCT02559557|Other|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
75739014|NCT02559557|Other|Quality-of-Life Assessment|Answer questionnaires
75739015|NCT02559557|Other|Questionnaire Administration|Answer questionnaires
75739016|NCT00972296|Device|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
75887382|NCT03644186|Drug|Trastuzumab|Chemotherapy plus HER2 Blockade
75887383|NCT03644186|Drug|Pertuzumab|Chemotherapy plus HER2 Blockade
75887384|NCT03644186|Drug|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
75887385|NCT03644186|Drug|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
75887386|NCT03644186|Drug|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
75887387|NCT03644186|Drug|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
75887388|NCT03622814|Behavioral|Partners at Meals|The focus of the intervention is to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals.
76057754|NCT02008877|Drug|ganetespib|Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
76057755|NCT02008877|Drug|Sirolimus|4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
75445043|NCT06221683|Drug|Recombinant Human Granulocyte Colony-Stimulating Factor|5ug/kg/d, d1-10, s.c., qd, at 1pm
75594976|NCT02893371|Drug|Paroxetine|Exposure to all dosages and delivery forms.
75594977|NCT02893371|Drug|Sertraline|Exposure to all dosages and delivery forms.
75594978|NCT02893371|Drug|Vilazodone|Exposure to all dosages and delivery forms.
75594979|NCT02893371|Drug|Doxepin|Exposure to all dosages and delivery forms.
75594980|NCT04495595|Other|No intervention|There is no intervention due to the observational, cross-sectional design of the study
75887389|NCT03622814|Behavioral|Enhanced Usual Condition|Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites will receive training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month. The Project Manager will attend the monthly support group for family members about communication. The administrator of the EUC RCC will be interviewed every 6 months the project is in place.
75887390|NCT03616470|Drug|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
75887391|NCT03616470|Drug|Placebo|Saline, 0.9% Sodium Chloride
75887392|NCT03593759|Drug|Prednisone or Prednisolone|Oral prednisone/prednisolone tablet
75887393|NCT03593759|Drug|Methotrexate|Oral, subcutaneous, or intramuscular methotrexate
75594981|NCT02886559|Drug|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
75887394|NCT03567577|Drug|Solnatide 25 mg powder for reconstitution for solution for inhalation|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
75887395|NCT03567577|Drug|0.9% Saline Solution|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
75887396|NCT03557905|Device|RM 0.5|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
75594982|NCT05138978|Drug|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
75594983|NCT05138978|Drug|Colgate Cavity Protection|Toothpaste
75739017|NCT03908099|Behavioral|Fit-For-Fertility program|The Fit-for-Fertility Program aims at implementing progressive and sustainable lifestyle changes. Participants will attend individual sessions with a dietitian and a kinesiologist every 6 weeks for the first 6 months, then every 8 weeks for the 6 following months, and then every 12 weeks until end of the study. Follow-up by telephone/e-mail will be offered between in-person meetings. These professionals will be trained in motivational counselling skills. Participants will also benefit from weekly group sessions divided into 2 parts: 1) Workshops covering 8 different topics (45 minutes) addressing healthy lifestyle and 2) Supervised classes of physical activity where one of 8 different types of exercise (45 minutes) will be practiced. Women will be required to attend all 8 different sessions within the first 6 months. Pregnant women will be met to set new lifestyle objectives specific to pregnancy, including optimal gestational weight gain based on the Institute of Medicine guidelines.
75887397|NCT03557905|Device|RM 0.3|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.3.
75594984|NCT04495049|Device|Alcon Vivity or Vivity Toric IOL|Patients who previously underwent cataract surgery with the Alcon Vivity or Vivity Toric IOL in both eyes.
75594985|NCT04391400|Diagnostic Test|nasal pharyngeal (NP) swab samples|These donors will be from a population of patients who are already providing nasal pharyngeal (NP) swab samples in universal transport media (UTM) for COVID-19 testing at LabPMM LLC.
75594986|NCT04391400|Diagnostic Test|peripheral blood draw|"From patients suspected of SARS-CoV-2 viral infections.~At least 2mL to 5mL of peripheral blood.~Collected in EDTA tubes.~Shipped to ambient LabPMM, LLC within 2 days.~Specimen Collections:~Collected at the same time as the NP specimen sent for COVID-19 testing.~Collected two to three weeks post the original patient's COVID-19 testing."
75887398|NCT03548155|Drug|Berberine|Berberine 300mg（three times a day） plus any atypical antipsychotic drug
75887399|NCT03548155|Drug|atypical antipsychotic|Any atypical antipsychotic drug as the basic treatment
75887400|NCT03548155|Drug|placebo|The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
75594987|NCT04391166|Other|Non invasive visual acuity testing|This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.
75594988|NCT04436484|Diagnostic Test|Peripheral blood sampling|Non-interventional study
75887401|NCT03516708|Drug|Epacadostat|Patients will receive epacadostat at the designated dose level starting the day of radiation therapy, throughout the chemotherapy, and until the day of surgery. If the patient dose not proceed with the surgery, epacadostat will be discontinued after the last biopsy is performed, and after the investigator confirms non-operative management plans.
75887402|NCT03516708|Radiation|Short-course radiation|Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
75887403|NCT03516708|Drug|CAPOX chemotherapy|CAPOX is typically capecitabine at 1000 mg/m2 PO BID (Days 1-14 of each 3-week cycle) and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts. Patient will receive a total of 6 cycles of CAPOX chemotherapy.
75887404|NCT03512899|Procedure|Right internal jugular access.|Implantation using percutaneous puncture.
75887405|NCT03512899|Procedure|Left internal jugular access.|Implantation using percutaneous puncture.
75887406|NCT03512899|Procedure|Right axillary vein access.|Implantation using percutaneous puncture.
75887407|NCT03512899|Procedure|Left axillary vein access.|Implantation using percutaneous puncture.
75887408|NCT03501173|Other|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
75887409|NCT03494556|Other|Data Collection|Paramedic will use data collected during routine care to complete four risk stratification tools.
75887410|NCT03457701|Drug|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
76057756|NCT01933334|Drug|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
76057757|NCT01908140|Drug|Aclidinium Bromide / Formoterol Fumarate|
76057758|NCT01908140|Drug|Salmeterol / Fluticasone|
76057759|NCT02008565|Drug|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
75445044|NCT06221683|Drug|Idarubicin Hydrochloride|3mg/m2/day for weighing >10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.
75445045|NCT06221683|Drug|Sorafenib|100mg/m2/day for weighing >10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd
76057760|NCT02008565|Drug|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
75739018|NCT03908099|Other|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months. The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
76057761|NCT02008565|Behavioral|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
75445046|NCT06221683|Drug|Gilteritinib|20mg/m2/day for weighing >10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd
75445047|NCT06221683|Drug|Avapritinib|50mg/m2/day for weighing bodyweight >10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
75445048|NCT06221644|Diagnostic Test|[18F]SynVesT-1 PET/CT|60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent [18F]SynVesT-1 PET/CT for synaptic density assessment
75445049|NCT06221462|Drug|Sintilimab|200mg, every 3 weeks, 3 cycles, in the neoadjuvant setting, and adjuvant 200mg,every 3 weeks no more than one year
75445050|NCT06221462|Drug|Anlotinib|8mg, orally, D1-14, every 3 weeks, 2 cycles in only neoadjuvant setting
75445051|NCT06221332|Other|% 0.25 bupivakain 20cc|Pregnant women in group S will be given 0.25% bupivacaine, 10 cc on each side.
75445052|NCT06221332|Other|20 cc saline|Pregnant women in Group K will be given 10 cc of saline on both sides.
75739019|NCT03927950|Drug|escitalopram|escitalopram 10-20mg per day 12 weeks
75739020|NCT03927950|Drug|bupropion|bupropion 150-300mg per day 6 weeks
75739021|NCT00678899|Device|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
75887411|NCT03457701|Drug|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
75445053|NCT06221319|Other|sacral erectör spinae plane group|sacral erectör spinae plane will be applied to patients in Group S
75445054|NCT06220903|Other|Complex Decongestive Therapy|"Manual Lymph Drainage: Cervical region lymph drainage and abdominal region lymph drainage (especially combined with abdominal breathing) were applied.~Skin Care: Moisturizing creams with a pH of 5.5 were applied to the extremities before bandaging.~Multilayer Bandaging: Short pull bandage application was applied in a gradient manner.~Exercise: Joint range of motion exercises, breathing exercises (abdominal breathing), decongestive exercises, and self-drainage techniques were taught.~Compression Stocking: After the decongestion phase was over, flat knit compression stockings were recommended according to the patient's extremity."
75887412|NCT03457701|Drug|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
75887413|NCT03457701|Drug|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
75887414|NCT03403231|Behavioral|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
75739022|NCT00965432|Drug|STX107|Single dose of an oral suspension
75739023|NCT03827993|Behavioral|dedicated sexual health clinic appointment|Intervention will consist of a dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This provider will perform a focused history and physical, and will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
75887415|NCT03347292|Drug|Regorafenib(Stivarga, BAY73-4506)|Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
75445055|NCT06220682|Diagnostic Test|The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs|using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay
75594989|NCT05138861|Drug|TP-03 (Lotilaner Ophthalmic Solution), 0.25%|A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
75739024|NCT00972452|Behavioral|Exercise|short period of exercise training (5-10 days)
75887416|NCT03347292|Drug|Pembrolizumab|200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
75887417|NCT03269526|Drug|EGFR BATs after standard of care chemo|Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
75887418|NCT03182426|Drug|Plerixafor|Systemic CD34+ stem cell mobilization for beta-cell repair
75887419|NCT03182426|Drug|Alemtuzumab|T-cell depletion
75887420|NCT03182426|Drug|Anakinra|Anti-inflammatory
75445056|NCT06220344|Biological|Honey Dressing|Honey Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
75445057|NCT06220344|Drug|Iodine Dressing|Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
75445058|NCT06220318|Drug|C019199|The C019199 will be taken orally, once a day
75445059|NCT06220318|Drug|Sintilimab|Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.
75445060|NCT06220071|Other|Case series review of clinical and radiographic data|Extraction of clinical and radiographic data related to patients' history from medical records
75594990|NCT05138744|Other|Behavioral activation using virtual reality|The investigators will encourage behavioral activation (increase in the number and time of conducted activities) situating the person in motivating situations using virtual reality
75739025|NCT00965510|Behavioral|care coordination|patients receive care coordination to improve their type II diabetes
75445061|NCT06219759|Other|Observational study|Observational study.
75739026|NCT00972686|Drug|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
75594991|NCT04390659|Procedure|myomectomy|The myomectomy was done by conventional technique but timing of myomectomy either before or after delivery of the baby varied between different cases .Infusion of oxytocin during the operation and for 24 h later.
75739027|NCT00921869|Drug|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
75739028|NCT00965588|Biological|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
75887421|NCT03182426|Drug|Etanercept|Anti-inflammatory
75887422|NCT03182426|Drug|Liraglutide|Beta-cell regeneration
75887423|NCT03102593|Drug|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
75887424|NCT03102593|Other|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
75887425|NCT03078946|Drug|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
75887426|NCT03078946|Drug|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
75887427|NCT02974621|Biological|Bevacizumab|Given IV
75887428|NCT02974621|Drug|Cediranib|Given PO
75887429|NCT02974621|Drug|Cediranib Maleate|Given PO
75887430|NCT02974621|Drug|Olaparib|Given PO
75445062|NCT06219668|Procedure|Omentopexy group|Omentopexy and Clips on staple line during LSG
75445063|NCT06218758|Other|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
75445064|NCT06218745|Other|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
75445065|NCT06218537|Diagnostic Test|Test group|Contains protease from KREON capsules, activated by adding sodium bicarbonate.
75445066|NCT06218537|Diagnostic Test|Control group|Contains only sodium bicarbonate.
75887434|NCT02915601|Drug|Sodium bicarbonate|
75887435|NCT02915601|Drug|Placebo|
75887436|NCT02878473|Procedure|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
75887437|NCT02760238|Other|Observational|
75887438|NCT02743741|Drug|Lutetium-177 Octreotate|Radiopharmaceutical
75887439|NCT02694978|Drug|Ferumoxytol|
76057762|NCT02008565|Behavioral|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
76057763|NCT01907906|Device|Mirasol System for Whole Blood|LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
76057764|NCT01907828|Device|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
75739029|NCT04008992|Drug|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
76057765|NCT01907828|Device|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
75445067|NCT06217198|Behavioral|Deprexis|Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.
75445068|NCT06217120|Drug|Colchicine|Colchicine 0.5 mg daily
75739030|NCT04008992|Other|Placebo|Placebo matching BMS-986259
75739031|NCT04008992|Diagnostic Test|P-Aminohippurate|Diagnostic Agent
75739032|NCT04008992|Diagnostic Test|Iohexol|Diagnostic Agent
75445069|NCT06217120|Drug|Placebo|Placebo once daily
75445070|NCT06215755|Drug|VRG50635|Specified dose on specified days
75445071|NCT06215352|Other|Chrono-nutrition factors|Dietary records would be used to assess the chrono-nutrition factors such as night eating, breakfast skipping, meal frequency, and daily fasting.
75445072|NCT06212479|Diagnostic Test|MRI Scan|Whole Body MRI Scan
75445073|NCT06212388|Biological|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
75445074|NCT06212388|Drug|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
75445075|NCT06212388|Drug|Pembrolizumab|Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
75739033|NCT05248490|Other|pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization
75739034|NCT00972842|Drug|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
75887440|NCT02694978|Drug|FCM|
75887441|NCT02663518|Drug|PF-0791800 (TTI-621)|Monotherapy
75887442|NCT02663518|Drug|PF-07901800 (TTI-621) plus Rituximab|Combination therapy
75887443|NCT02663518|Drug|PF-07901800 (TTI-621) plus Nivolumab|Combination therapy
75887444|NCT02563002|Drug|mFOLFOX6|Regimen consists of oxaliplatin 85 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
75887445|NCT02563002|Drug|FOLFIRI|Regimen consists of irinotecan 180 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-FU 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
75887446|NCT02563002|Biological|pembrolizumab|MK-3475 SCH 900475 KEYTRUDA®
75887447|NCT02563002|Biological|bevacizumab|
75887448|NCT02563002|Biological|cetuximab|
75887449|NCT02454933|Drug|AZD9291|Once daily tablet 80 mg
75887450|NCT02454933|Drug|MEDI4736|10mg/kg q2w (IV) infusion
75887451|NCT02430480|Drug|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
75887452|NCT02430480|Drug|Enzalutamide|160mg orally, daily for 24 weeks
75887453|NCT02430480|Device|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
75887454|NCT02263274|Device|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
75887455|NCT02207439|Drug|Nelfinavir (Viracept®) 1250 mg|Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).
75887456|NCT02207439|Other|Chemoradiation|Period 2: Concurrent Chemoradiation (70 Gy over 7 weeks) with Nelfinavir (1250 mg bid)
75887457|NCT01796197|Drug|Trastuzumab|
75887458|NCT01796197|Drug|Pertuzumab|
75887459|NCT01796197|Drug|Paclitaxel|
75887460|NCT01796197|Drug|Doxorubicin|
75887461|NCT01796197|Drug|Cyclophosphamide|
75887462|NCT01796197|Procedure|Mastectomy|
75887463|NCT01796197|Radiation|Radiation Therapy|
75887464|NCT01689766|Drug|Technetium Tc 99m EC20|
75887465|NCT01205048|Device|Emervel Classic Lidocaine|20 mg/mL + 0.3% lidocaine
75887466|NCT01205048|Device|Juvederm® Ultra|24mg/mL
75887467|NCT01052779|Drug|Ferumoxytol|IV Ferumoxytol
75887468|NCT01052779|Drug|Iron Sucrose|IV Iron Sucrose
75445076|NCT06212284|Drug|Citalopram 20mg|Doses were delivered in gelatine capsules filled with microcrystalline cellulose.
75594992|NCT04493294|Radiation|Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis|Low dose whole lung radiotherapy may decrease the cytokines storm related to the viral infection and may improve survival by decreasing the need for artificial ventilation
75887469|NCT00785525|Drug|Filgrastim|PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
75887470|NCT00743262|Device|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
75887471|NCT00591370|Drug|Temozolomide (TMZ)|One group treatment study
75887472|NCT03064763|Drug|Talimogene laherparepvec|Talimogene laherparepvec will be administered as an intralesional injection.
75887473|NCT02782676|Device|Investigational Healon5 OVD|ophthalmic viscosurgical device
76057766|NCT01907516|Device|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
76057767|NCT01907516|Behavioral|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
76057768|NCT01931462|Device|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
76057769|NCT01931150|Drug|Topical Dapsone 5% Gel|
76057770|NCT01931150|Other|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
76057771|NCT01931150|Drug|oral antibiotics|
76057772|NCT01930214|Device|Percutaneous Coronary Intervention|Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
75445077|NCT06212284|Drug|Placebo|Doses were gelatine capsules filled with microcrystalline cellulose
75445078|NCT06212232|Procedure|Piezoelectric surgery|Application of a new piezoelectric technique in third molar surgery
75445079|NCT06211257|Other|Dematerialized Personalized Care Plan (ePCP)|Post-treatment support with standard support combined with dematerialized support
75445080|NCT06209476|Diagnostic Test|Experimental|Eligible subjects with sphere component of the subjective spherocylindrical refraction between +1.50 to -6.00D (inclusive) and 2.00D or less astigmatism in the right eye will be unilaterally measured with the WAM-5500 autorefractor by 3 testers.
75445081|NCT06207734|Drug|Continuation of CDK4/6 inhibitor Palbociclib|Continuation of CDK4/6 inhibitor Palbociclib
75445082|NCT06207734|Drug|Discontinuation of CDK4/6 inhibitor Palbociclib|Discontinuation of CDK4/6 inhibitor Palbociclib
75445083|NCT06207734|Drug|Continuation of CDK4/6 inhibitor -Palbociclib|Continuation of CDK4/6 inhibitor -Palbociclib
75445084|NCT06207734|Drug|Discontinuation of CDK4/6 inhibitor -Palbociclib|Discontinuation of CDK4/6 inhibitor -Palbociclib
75594993|NCT02893176|Drug|macitentan|
75594994|NCT02893176|Drug|placebo (for macitentan)|
75887474|NCT02782676|Device|Healon5 OVD|ophthalmic viscosurgical device
75887475|NCT03033095|Drug|Etanercept ® 50 mg|The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
75887476|NCT02471339|Behavioral|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
75887477|NCT02142842|Biological|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
75887478|NCT03632057|Device|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
75887479|NCT03632057|Device|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
75887480|NCT05075720|Dietary Supplement|Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
75887481|NCT05075720|Dietary Supplement|Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
75887482|NCT05075720|Dietary Supplement|Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
75887483|NCT02931851|Other|ICU Families Website|Professionally developed website for relatives of ICU patients
75887484|NCT02931851|Other|Placebo|Standard Information provided online
75887485|NCT02146820|Device|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
75887486|NCT02142920|Drug|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
76057773|NCT01958294|Device|MICHI Neuroprotection System|
76057774|NCT01906346|Drug|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
76057775|NCT01906346|Drug|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
76057776|NCT01958060|Drug|BI 1034020|intravenous part
76057777|NCT01958060|Drug|Placebo to BI 1034020|intravenous part
76057778|NCT04618874|Diagnostic Test|Rapid on-site evaluation|Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).
75887487|NCT03544112|Behavioral|Employ a multifaceted approach to facilitate clinical protocol implementation|Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
75887488|NCT03544112|Drug|Initiate BUP (SL-BUP or XR-BUP) in the ED|The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
76057779|NCT04645004|Drug|Aspirin 81Mg Non-enteric coated Tab|one tab daily
76057780|NCT01929980|Drug|Bortezomib|
76057781|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing <50 kg.
75445085|NCT06207734|Drug|Continuation of CDK4/6 inhibitor Abemaciclib|Continuation of CDK4/6 inhibitor Abemaciclib
75445086|NCT06207734|Drug|Discontinuation of CDK4/6 inhibitor Abemaciclib|Discontinuation of CDK4/6 inhibitor Abemaciclib
75445087|NCT06206707|Procedure|Faecal Microbiota Transplantation (FMT)|Capsule FMT
75594995|NCT05138627|Other|oral cryotherapy|Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
75594996|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
75594997|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
75594998|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
75739035|NCT00972920|Procedure|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
75739036|NCT00975494|Drug|Sildenafil|
75739037|NCT00975494|Drug|Placebo|
75739038|NCT00975572|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
75887489|NCT05346809|Drug|Isatuximab|Isatuximab in IV form 10 mg/kg doses
75445088|NCT06206707|Procedure|Placebo|Placebo capsules
75594999|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
75595000|NCT01193218|Drug|BI 10773|BI 10773 tablets low dose once a day
75595001|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
75595002|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
76057782|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
75595003|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
75595004|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-high dose once a day
75887490|NCT05346809|Other|Standard Procedures|Standard procedures (standard of care) for transplant
76057783|NCT01929044|Drug|654-II (anisodamine)|10mg injection
76057784|NCT01929044|Drug|Buscopan® (hyoscine butylbromide)|20mg injection
75445089|NCT06206603|Diagnostic Test|Intestinal biopsies|Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.
75595005|NCT01193218|Drug|BI 10773|BI 10773 tablets high dose once a day
75739039|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
75739040|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
75739041|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
76057785|NCT01903460|Drug|LUM001|
76057786|NCT01903460|Drug|Placebo|
76057787|NCT01957202|Drug|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
76057788|NCT01957202|Drug|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
75595006|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
75739042|NCT00975572|Biological|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
75739043|NCT00975572|Biological|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
75887491|NCT02142998|Other|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
75887492|NCT02142998|Other|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
75887493|NCT01383785|Other|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
76057789|NCT01957202|Drug|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
76057790|NCT01957202|Drug|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
75445090|NCT06206603|Diagnostic Test|Blood sample|A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.
75445091|NCT06204848|Device|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
75445092|NCT06204276|Device|Experimental: Asymmetrical high-flow nasal cannula|Asymmetrical high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and inspired oxygen fraction (FiO2) will be adjusted to maintain oxygen saturation by pulse oximetry (SpO2) >/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
75445093|NCT06204276|Device|Active comparator: Conventional high-flow nasal cannula|Conventional high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and FiO2 will be adjusted to maintain SpO2 >/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
75445094|NCT06202274|Device|Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE|Subjects will receive up to twelve (12) treatments at minimum treatment interval of 2 weeks and maximum treatment interval of 12 weeks.
75445095|NCT06201741|Radiation|[131I]/[18F]/[68Ga]ZT-111|[131I]/[18F]/[68Ga]ZT-111, single dose
75595007|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
75595008|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
75739044|NCT00678587|Drug|Eltrombopag|75 mg, once daily, oral
75739045|NCT00678587|Drug|Placebo|placebo, once daily, oral
75739046|NCT00972998|Drug|Phenyephrine|Phenyephrine coated suppositories
75739047|NCT00965666|Drug|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
76057791|NCT01616654|Drug|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
76057792|NCT01616654|Drug|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
76057793|NCT01616654|Drug|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
75595009|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
75595010|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-low dose once a day
75595011|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
75595012|NCT04389645|Diagnostic Test|IP-10 in CDS protocol|Dynamic IP-10 measurements in hospitalized COVID-19 positive patients
75595013|NCT00592098|Drug|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
75595014|NCT00592098|Drug|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
75595015|NCT01193101|Drug|LCZ696|LCZ696
75595016|NCT01193101|Drug|Placebo|matching placebo to LCZ696
75595017|NCT04472078|Diagnostic Test|Serological Assay or IgG for SARS-CoV-2|Serological Assay for detection of IgG for SARS-CoV-2
76057794|NCT01616654|Drug|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
76057795|NCT01616654|Drug|Vehicle cream|Vehicle cream applied once daily
76057796|NCT01902290|Biological|Placebo|Placebo administered subcutaneously
76057797|NCT01902290|Biological|Brodalumab|Brodalumab administered subcutaneously
76057798|NCT01927562|Device|Fractyl Duodenal Remodeling System|
75595018|NCT02887846|Device|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 < 0,40, Pa CO2 < 65 mmHg, pH> 7.20, MAP (mean airway pressure) <7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 < 0.30 at 24 hours and above, free oxygen will be introduced.
75739048|NCT00965744|Device|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
75739049|NCT00973076|Drug|AZD8055|Tablets, orally administered, twice daily
75739050|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 18%-protein diet|
75739051|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 35%-protein diet|
75739052|NCT00975728|Dietary Supplement|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
75739053|NCT04049747|Procedure|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]
75739054|NCT04049747|Procedure|Focal therapy|Focal therapy (high intensity focused ultrasound or cryotherapy)
75739055|NCT04049747|Procedure|Focal therapy after Finasteride 5Mg tablets for 12 weeks|finasteride 5mg tablets 12 weeks prior to focal therapy
75739056|NCT04049747|Procedure|Focal therapy after Bicalutamide 50Mg tablets for 12 weeks|Bicalutamide 50mg per day - 12 weeks prior to focal therapy
75739057|NCT00973154|Drug|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
75445096|NCT06199232|Drug|HAIC+targeted therapy+PD-1 inhibitor|"HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w."
75445097|NCT06196905|Drug|MT-2990|i.v. infusion
75445098|NCT06195956|Other|exercise|Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months
75445099|NCT06193889|Biological|KYV-101|Anti-CD19 CAR-T cell therapy
75739058|NCT00965822|Other|North American ginseng|3 day, once daily, dosing
75739059|NCT00965822|Other|Placebo|3 day, once daily dosing
75445100|NCT06193889|Drug|Standard lymphodepletion regimen|Standard lymphodepletion regimen
75595019|NCT04328805|Drug|Ibuprofen tablets|oral tablet
75739060|NCT04822025|Biological|MVC-COV1901 (High-Dose)|Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
75739061|NCT04822025|Biological|MVC-COV1901(Mid-Dose)|Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
75887494|NCT01383785|Other|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
76057799|NCT01467466|Drug|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
75595020|NCT02886364|Behavioral|Adapted Safe Childbirth Checklist|The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
75595021|NCT01192516|Behavioral|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
75595022|NCT01192516|Behavioral|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
75595023|NCT04471883|Procedure|Percutaneous coronary interventions|Percutaneous coronary interventions in coronary bifurcation lesions
75739062|NCT00965900|Procedure|Endoscopic band ligation|"Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
75595024|NCT04329000|Drug|Esomeprazole 40mg|On-demand Esomeprazole 40 mg QD
76057800|NCT01467466|Drug|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
75595025|NCT04329000|Drug|Esomeprazole|Continuous Esomeprazole 40 mg QD
75739063|NCT00965900|Drug|Propranolol|"start with 20 mg of propranolol b.i.d~Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
75887495|NCT01383785|Other|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
75887496|NCT02146898|Other|Position|
75887497|NCT02146976|Drug|propofol|introvenious infusion of propofol
75887498|NCT02146976|Drug|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
76057801|NCT01467466|Drug|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
75445101|NCT06192160|Drug|Isoniazid|INH 300 mg will be administered as one tablet orally once daily.
75445102|NCT06192160|Drug|Rifampicin|RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
75445103|NCT06192160|Drug|Pyrazinamide|PZA will be administered as 500 mg tablets, based on weight, orally once daily.
75445104|NCT06192160|Drug|Ethambutol|EMB will be administered as 400 mg tablets, based on weight, orally once daily.
75445105|NCT06192160|Drug|Bedaquiline|BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
75445106|NCT06192160|Drug|Pretomanid|Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
75445107|NCT06192160|Drug|Linezolid|LZD 600 mg will be administered as one 600 mg tablet orally once daily.
75445108|NCT06192160|Drug|TBI-223|TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
75445109|NCT06192160|Drug|Sutezolid|SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
75445110|NCT06192160|Drug|TBI-223|TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
75445111|NCT06192160|Drug|Sutezolid|SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
75595026|NCT01192399|Biological|Eculizumab|
75595027|NCT01176916|Drug|Aromasin (exemestane)|the dosage, frequency and duration base on the LPD approved by SFDA.
75595028|NCT04328922|Other|Fecal microbial transplantation|Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/
75595029|NCT04328922|Other|Placebo capsuls|capsules of glycerol and saline (placebo).
75595030|NCT01192204|Drug|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
75595031|NCT01192204|Drug|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
75595032|NCT01192126|Device|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
75595033|NCT01192126|Device|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
75595034|NCT04433403|Other|pathogenic microorganism|Detection of pathogenic microorganisms in adult severe pneumonia by second generation sequencing
75887499|NCT02365883|Device|Photoacoustic Imaging System|manufactured by Endra
76057802|NCT01467466|Drug|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
76057803|NCT01441180|Drug|GS7977|drug intervention
75595035|NCT04433286|Other|Questionnaire|"This is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. A subsequent translation in different Language will provided based on geographical distribution. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous.~The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice."
75595036|NCT04468802|Other|Case fatality rate|Mortality rate caused by SARS CoV-2
75595037|NCT02894268|Drug|Doxycycline|Doxycycline 100g po bid
75445112|NCT06191666|Behavioral|Group-based education and discussion|Group-based education and discussion (60 minutes each per week, virtual and in-person) based upon guidelines for nutrition for cancer survivorship (e.g., follow a plant-based diet with a variety of vegetables, fruits, whole grains, and legumes; limit alcohol intake; reduce consumption of highly processed foods and foods high in salt; achieve a weekly calorie deficit of approximately 3500 kcal for weight loss)
75595038|NCT02894268|Drug|Furazolidone|Furazolidone 100mg po bid
75595039|NCT02894268|Drug|Esomeprazole|Esomeprazole 20mg po bid
75445113|NCT06191666|Behavioral|Individual 1:1 counseling|Individual 1:1 counseling sessions (30 minutes each per month, virtual) with an RD to review progress and address barriers
75445114|NCT06191666|Behavioral|Group based behavioral skills development and cooking demonstrations|Group-based behavioral skills development sessions and cooking demonstrations (60-90 minutes each per month, in-person) to focus on behavior change techniques (e.g., self-monitoring, goal setting) and nutrition skills (e.g., recipe development, label reading).
75595040|NCT02894268|Drug|Colloidal Bismuth Subcitrate|Bismuth 20mg po bid
75595041|NCT02894268|Drug|Sensitivity antibiotics|Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
75595042|NCT02893683|Other|Paris Visual Learning Test|
75595043|NCT01600625|Drug|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
75595044|NCT04386954|Procedure|observational study|observation study
75595045|NCT01600664|Behavioral|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
75595046|NCT01600664|Behavioral|Convertible PC|Participants will be using the convertible PC without the interactive computer game
75595047|NCT02893839|Other|Prick to prick test|
75595048|NCT01600742|Drug|Vorinostat|"Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
75595049|NCT01600742|Drug|Placebo|"Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
75739064|NCT00965900|Procedure|EBL+Propranolol|"EBL~Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~Propranolol~start with 20 mg b.i.d~Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
75595050|NCT04431804|Other|silver nanoparticle|fungicidal effect of silver nanoparticles on aspergillus isolates
75595051|NCT04430829|Diagnostic Test|Weight-Bearing CT arthrography|A 20ml mixture of 5ml 0.5% ropivacaine, 5ml preservative-free sterile saline, and 10ml of non-ionic iodinated contrast media (e.g. iohexol 240) will be instilled into the knee joint of each patient prior to WBCTa imaging of the knee (LineUp, CurveBeam, LLC).
75595052|NCT04430829|Diagnostic Test|Knee MRI|MRI will be acquired (in-plane 0.25mm x 0.25mm, and 1.00mm slab thickness/separation and In-plane 0.25mm x 0.25mm, and 2.00mm slab thickness/separation)
75595053|NCT01327482|Drug|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
75445115|NCT06191666|Behavioral|BfitBwell|This program consists of a supervised exercise program developed by a cancer exercise specialist and based upon the NCCN guidelines for physical activity during cancer survivorship and other recommendations.
75445116|NCT06188741|Drug|Selumetinib|Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID
76057804|NCT01441180|Drug|RBV|drug intervention
75445117|NCT06187168|Procedure|exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.|This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
75445118|NCT06184399|Drug|Ivermectin 1.5 mg ODT|Oro-dispersible tablets of 1.5 mg ivermectin
75445119|NCT06184399|Drug|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
75445120|NCT06184399|Drug|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
75445121|NCT06184399|Drug|Placebo IVM ODT|Placebo for ivermectin ODT
75445122|NCT06182566|Procedure|Convergent ablation|Staged hybrid ablation with CONVERGENT epicardial ablation with ablation of the ligament of Marshall and left atrial appendage clip, followed in second stage by endocardial catheter ablation including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
75445123|NCT06182566|Procedure|Catheter ablation|Pulmonary vein isolation using commercially available catheters; including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
75595054|NCT04430205|Procedure|Adhesive restoration protocol|"The canal walls were etched with 37% orthophosphoric acid for 30 seconds with use of a microbrush.~The primer was applied on the wet canal walls, with a microbrush several times, after checking by drying the canal, that the appearance of the dentine was shiny and not opaque or chalky.~The next step was the application of bonding with a microbrush, blowing in the fracture line to make sure it is not loaded with bonding.~Flow composite was used to make it penetrate the fracture line with the help of a 0.06 mm k-file.~The canals were filled with dual composite parts more deeply, light cured at the canal entrance and pulp chamber; the following phase was the coronal restoration with a sandwich technique, covering the cusp with composite."
75595055|NCT04490291|Other|chronic pain team|enrollment in chronic pain team at study site
75445124|NCT06179212|Diagnostic Test|Exercise Tests|Patients will complete 4 different cardiopulmonary exercise tests in random order.
75739065|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
75739066|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
75739067|NCT00973232|Drug|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
75445126|NCT06171633|Behavioral|E-STOP online educational program (treatment condition)|Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.
75445127|NCT06171633|Behavioral|E-STOP online educational program (control condition)|Participants access online video modules through an online learning platform. Program includes authorship ethics only.
75739068|NCT00973232|Drug|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
75445128|NCT06170905|Dietary Supplement|Whey protein-preload OGTT|Intake of 25 g whey protein diluted in water 30 minutes prior to the start of a regular 75 g oral glucose tolerance test
75445129|NCT06169969|Device|magnetic therapy|Kegel exercises
75445130|NCT06168318|Drug|VH4004280 Formulation A|Oral administration of VH4004280 Formulation A in fasted or fed conditions.
75445131|NCT06168318|Drug|VH4004280 Formulation B|Oral administration of VH4004280 Formulation B in fasted or fed conditions.
75445132|NCT06168318|Drug|VH4004280 Formulation C|Oral administration of VH4004280 Formulation C in fasted or fed conditions.
75445133|NCT06168318|Drug|VH4004280 Formulation D|Oral administration of VH4004280 Formulation D in fasted or fed conditions.
75445134|NCT06168318|Drug|VH4004280 Formulation E|Oral administration of VH4004280 Formulation E in fasted or fed conditions.
75595056|NCT04490291|Other|chiropractic team|enrollment in chiropractic team/intervention at study site
75595057|NCT04385823|Device|patients receiving nasal high flow|patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow
75595058|NCT04429386|Procedure|Bariatric surgery|Laparoscopic bariatric surgery including gastric bypass and sleeve gastrectomy
75595059|NCT02893488|Drug|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
75595060|NCT02893488|Drug|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
75595061|NCT02893488|Drug|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
75595062|NCT04328883|Drug|Aspirin|Oral and inhaled ASA formulations
75595063|NCT04464356|Device|mechanical circulatory support|mechanical circulatory support: cardiopulmonary bypass, extracorporeal membrane oxygenation(ECMO), left ventricular assist device
75887500|NCT02147054|Drug|Rocuronium|
75887501|NCT02147054|Drug|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
76057805|NCT01441102|Drug|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
76057806|NCT04061980|Drug|Binimetinib|Given PO
76057807|NCT04061980|Drug|Encorafenib|Given PO
76057808|NCT04061980|Biological|Nivolumab|Given IV
76057809|NCT01467076|Drug|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
75887502|NCT02149082|Device|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
75595064|NCT04385472|Radiation|3T MRI|The main method used will be 3 Tesla MRI, which is a high resolution imaging technique. The participants will be asked to undergo musculoskeletal MRI scanning (pelvis and lumbar spine).MRI is a non-invasive procedure which excludes the risk of radiation (in comparison to other imaging modalities: X-ray, CT
75887503|NCT02149160|Drug|FRM-0334|
75595065|NCT01600196|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
75595066|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
75595067|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
75739069|NCT00973232|Drug|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
75739070|NCT00973232|Drug|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
75595068|NCT04464083|Diagnostic Test|IOP Measurment|To determine IOP readings before and after accelerated corneal collagen crosslinking (CXL)
75595069|NCT01600235|Drug|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
75445135|NCT06165341|Drug|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
75445136|NCT06165341|Drug|Placebo|Fazirsiran matching placebo.
75739071|NCT00973232|Drug|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
75739072|NCT03440099|Other|Resistance exercise training|16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
75595070|NCT02893254|Drug|IBI303|12 cycles. IBI303: 40 mg, iH
75595071|NCT02893254|Drug|Adalimumab|12 cycles. Adalimumab: 40mg, iH
75595072|NCT02893137|Device|Optune|For further information see www.optune.com
75739073|NCT04049435|Device|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
75739074|NCT00973310|Other|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
75887504|NCT02149160|Drug|Placebo|
75887505|NCT02149238|Dietary Supplement|flavanol|
75739075|NCT00973388|Drug|Telaprevir; Moxifloxacin; Placebo|
75595073|NCT02893137|Procedure|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
75595074|NCT04429581|Other|Anthropometry|
75739076|NCT04762823|Device|Cerebellar transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
75739077|NCT04762823|Device|Sham cerebellar transcranial direct current stimulation|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.
75887506|NCT02149238|Dietary Supplement|methylxanthine|
75887507|NCT02149238|Dietary Supplement|flavanol + methylxanthine|
75887508|NCT02149316|Procedure|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
75887509|NCT02149316|Procedure|control|a deflated cuff placed on the right upper arm
75887510|NCT02149394|Other|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
75739078|NCT04728815|Behavioral|TAU - Phase 1|4-8 weeks of TAU treatment
75739079|NCT04728815|Behavioral|CAMS - Phase 1|4-8 weeks of CAMS treatment
75739080|NCT04728815|Behavioral|DBT - Phase 1 and 2|up to 16 weeks of DBT treatment
75739081|NCT04728815|Behavioral|CAMS - Phase 2|Up to 8 weeks of CAMS treatment
75739082|NCT04728815|Behavioral|DBT - Phase 2|Up to 8 weeks of DBT treatment
75739083|NCT00965978|Drug|ONO-5920 / YM529|oral
75739084|NCT00975962|Drug|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
75739085|NCT00975962|Procedure|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
75739086|NCT00966056|Drug|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
75739087|NCT00966056|Device|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
75739088|NCT00976040|Other|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
75739089|NCT04008212|Other|Fusion imaging|Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
75445147|NCT06153797|Behavioral|PATH-C|PATH-C, a phone-delivered positive psychology intervention for caregivers of patients undergoing HSCT, consists of the following nine sessions: 1) Enhancing gratitude and increasing awareness for physical activity; 2) Expressing gratitude and goal setting for physical activity; 3) Integrating gratitude and goals for physical activity; 4) Personal strengths and environmental scan to enhance physical activity; 5) Enhancing strengths via reflection on past successes; 6) Integrating strengths to enhance well-being and physical activity; 7) Engaging in enjoyable and meaningful activities; 8) Promoting optimism and integrating long-term activity habits; 9) Integrating meaning for sustainable physical activity goals. Each session takes about 30 minutes, and a trained interventionist will guide participants to complete the sessions.
75595075|NCT04462991|Diagnostic Test|corneal topography|In all patients, TCT will be measured first by WaveLight® Oculyzer™II Pentacam HR and second by The Optovue AS-OCT .
75595076|NCT04383171|Device|Motomed cycle ergometer (MOTOmed letto2 - Reck, Reckstr 1-5, Betzenweiler 88422, Germany).|
75595077|NCT04382508|Other|Questionnaire|A weekly questionnaire will be filled in
75595078|NCT04460339|Other|Swimming participants in the 25-km|The 25-km race was the French national Open Championship event and participants were the swimmers registered for the race who volunteered to participate in this study
75595079|NCT04425954|Procedure|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
75595080|NCT04482491|Procedure|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
75595081|NCT04379622|Other|Dietary intake, body composition, lifestyle, and CVD risk factors|Dietary intake, body composition, lifestyle, and CVD risk factors
75595082|NCT04458701|Device|Hemodynamic monitoring|This is a comprehensive hemodynamic management strategy that would-be initiated in the operating room post-bypass and then continued for the first 12 hours in the intensive care unit
75595083|NCT04328220|Diagnostic Test|chest ultrasound|"A point-of-care lung ultrasound exam will be performed within 24h of admission to PICU and serial follow up according to each case.~chest x-ray will be performed for comparison with ultrasound findings."
75739090|NCT03523728|Drug|Venglustat|Pharmaceutical form: capsule; Route of administration: oral
75739091|NCT03523728|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
75739092|NCT00979706|Drug|HAART|"Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year."
75739093|NCT00979706|Drug|HAART + Immunotherapy|"Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year."
75739094|NCT00979784|Behavioral|Better Weight|Standard cognitive behavioral treatment focused on dietary & exercise behavior
75887511|NCT02149394|Other|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
75887512|NCT02143076|Behavioral|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
75445148|NCT06152744|Other|Monitoring membrane lung function at different altitudes|The altitude in Beijing is 100m, while the altitude in Xining, Qinghai is 2600m. We will monitor the partial pressure of post-ML arterial oxygen in ECMO patients in these two locations and evaluate whether the normal values of membrane lung function are consistent in different altitudes.
75887513|NCT02143076|Behavioral|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
75887514|NCT02143076|Behavioral|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
75887515|NCT02147210|Other|biological analysis|
75595084|NCT04379232|Biological|Screening test for covid ( RT PCR and CT Chest)|Each patient was screened before surgery with RT PCR and CT Chest. Post operatively, if symptoms, patients are tested with RT PCR and CT Chest
75739095|NCT00979784|Behavioral|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
75739096|NCT00979862|Drug|Cediranib Maleate|Given PO
75595085|NCT04424277|Other|diaphragm ultrasound|respiratory loading
75739097|NCT00979862|Drug|Cilengitide|Given IV
75739098|NCT00979862|Other|Laboratory Biomarker Analysis|Correlative studies
75739099|NCT00966134|Other|exposure to high altitude|
75739100|NCT00976118|Drug|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
75887516|NCT00107978|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
75887517|NCT00107978|Drug|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
75887518|NCT03543644|Other|Sugar-sweetened beverage (SSB)|SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
75887519|NCT03543644|Other|Non-nutritive sweetened beverages (NSB)|NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
76057810|NCT01467076|Drug|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
76057811|NCT01466062|Drug|Palivizumab|
75739101|NCT00976118|Drug|placebo|matching placebo to masitinib
75595086|NCT04378491|Other|Collection of clinical measurements|"Collection of clinical measurements:~Active and passive range of motion (ROM) of the knee, hip and ankle Joint bilaterally.~Passive patellar translation in 30° of flexion billaterally in quadrants of translation.~Patellar apprehension test (Fairbank's Test) and the Moving Patellar Apprehension (MPAT) test for the diagnosis of patellar instability. The Fairbank's Test is performed in 30° of Flexion while the MPAT is performed while flexing the knee from 0° to 90°."
75739102|NCT00966212|Behavioral|parent education|Especially for Daughters audio-cd parent education
75739103|NCT00980252|Behavioral|Cognitive Behavioral Therapy|Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
75739104|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
75739105|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
75739106|NCT04004052|Other|Ultrasound guided injection|
75739107|NCT04004052|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|
75739108|NCT04004052|Other|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
75739109|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
75739110|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
75739111|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
75739112|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
75739113|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
75739114|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
75595087|NCT04378491|Other|Collection of data for muscle strength|"Collection of data for muscle strength:~Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic Flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (3 x 5 repetitions) Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight"
75595088|NCT04378491|Other|Collection of EMG Data|"Collection of EMG Data:~Surface electrodes will be placed bilaterally on the vastus medialis and lateralis rectus femoris, biceps femoris and semitendinosus muscles following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles). Simultaneously with the muscle strength measurements, EMG data will be collected using a 12-channel EMG system (myon AG, Schwarzenberg, Switzerland, sampling rate 2400 Hz)."
75739115|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
75445153|NCT06148597|Procedure|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA)|application local anesthetic between internal oblique and transversus abdominis muscle at the level of 10th costal cartilage
75739116|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
75739117|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
75739118|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
75739119|NCT01563822|Biological|Follicular fluid|The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
75739120|NCT04007822|Behavioral|Pain Navigator Tool|The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
75739121|NCT03980340|Behavioral|Short Nap Intervention|Study participants may be asked to have a 1-2 hour nap in between the breath analysis tests.
75739122|NCT03980340|Behavioral|No Nap Intervention|Study participants may be asked to sit or lay down remaining awake for 1-2 hours in between breath analysis tests.
75739123|NCT04007978|Genetic|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
75887520|NCT03543644|Other|Water|Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
75445154|NCT06144944|Drug|Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Pyrotinib 320 mg orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
75445155|NCT06144944|Drug|Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Placebo orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
75445156|NCT06143891|Drug|Belumosudil|Pharmaceutical form:Tablet-Route of administration:oral
75739124|NCT00980876|Drug|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
75739125|NCT00980876|Drug|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
75739126|NCT04004130|Other|Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space
75739127|NCT00981032|Behavioral|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
75739128|NCT00981032|Behavioral|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
75739129|NCT00981110|Device|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
75739130|NCT00981110|Device|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
75739131|NCT00981266|Device|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
75739132|NCT00976430|Procedure|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
75739133|NCT00976742|Behavioral|Endurance exercise training|
75739134|NCT03813654|Behavioral|8-h Afternoon-Evening Sleep|8 consecutive hours time in bed during the afternoon/evening.
75739135|NCT03813654|Behavioral|8-h Free Sleep|8 consecutive hours time in bed at any time.
75739136|NCT00989898|Other|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
75739137|NCT05400954|Procedure|Breast reconstruction with silicone breast implant|(i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant.
76057812|NCT04504864|Drug|low-dose aspirin|50mg aspirin is used to prevent recurrent stroke.
76057813|NCT04504864|Drug|conventional-does aspirin|100mg aspirin is used to prevent recurrent stroke.
75445157|NCT06143891|Drug|Placebo|Pharmaceutical form:Table-Route of administration:oral
75445158|NCT06143891|Drug|Prednisone|Pharmaceutical form:Tablet-Route of administration:oral
75445159|NCT06143891|Drug|Prednisolone|Pharmaceutical form:Tablet-Route of administration:oral
75445160|NCT06142955|Device|MAGSTIM Rapid2 TMS system|The device will administer TMS pulses in bursts at fixed intervals for a total of 600 pulses over 190 seconds after first assessing the participants motor threshold (MT). During the sham stimulation condition, the TMS coil will be tilted 90° tangential to the scalp during the administration so that the orientation is not biologically active and will not elicit a muscle contraction. This sham condition will look and sound just like real TMS.
75445161|NCT06139523|Device|Investigational contact OCT system|Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
75595089|NCT04378491|Other|Collection of Clinical Scores|"Collection of Clinical Scores:~patient's pain, range of motion and ability to perform daily living activities will be assessed using the Kujala Anterior Knee Pain Scale, Lysholm Knee Score, visual analog scale score (VAS) and the Tegner Activity Score"
75739138|NCT05400954|Procedure|Breast conserving surgery/Mastectomy/Autologous reconstruction|(iv) simple mastectomy without reconstruction, (v) autologous reconstruction and (vi) breast conserving surgery,
75739139|NCT05400954|Procedure|Breast Augmentation|(vii) cosmetic augmentation with silicone breast implants
75739140|NCT00989976|Behavioral|normal sleep times|8.5 h bedtimes
75595090|NCT04378491|Other|Collection of Imaging Data - Radiological measurements|Collection of Imaging Data - Radiological measurements: Xrays and MRIs which were already performed as part of the original diagnostic and follow-up procedures pre- and postoperative will be reviewed and analysed.
75595091|NCT04457024|Other|classification statistics|Without any intervention
75739141|NCT00989976|Behavioral|bedtime restriction|4.5 h restricted bedtimes
75595092|NCT04328454|Other|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19
75595093|NCT04423497|Other|Balance Evaluation Systems Test|Balance Evaluation Systems Test application
75739142|NCT00990054|Drug|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
75739143|NCT00990132|Device|Home mechanical ventilation|Nocturnal non-invasive ventilation
76057814|NCT04501276|Drug|ADG116|For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
75887521|NCT02781818|Drug|Triamcinolone Acetonide 10mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
75595094|NCT00592137|Dietary Supplement|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
75595095|NCT00592137|Dietary Supplement|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
75739144|NCT00990132|Device|Long term oxygen therapy|LTOT established as per national guidelines
75739145|NCT05361564|Drug|Brigatinib|After 7-day lead-in 90mg/day, brigatinib 180mg/day from 4 to 10weeks(optimal duration: 6 weeks)
75739146|NCT05399472|Diagnostic Test|Dorsiflexion lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the participant stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The participant is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The participant steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
75739147|NCT05399472|Diagnostic Test|Jack Test|The Jack Test will be used to measure the first toe dorsiflexion under load. The examiner pulled the proximal phalanx of the hallux to dorsiflexion with his hand until the maximal amount of mobility was reached with the subject standing. The static arm of the goniometer was placed along the first metatarsal longitudinal axis while the free movable arm followed the proximal phalanx of the hallux axes.
75445162|NCT06139523|Device|Investigational noncontact OCT system:|"The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by:~Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt)~The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety."
75445163|NCT06136559|Drug|Nemtabrutinib|Administered orally
75445164|NCT06136559|Drug|Ibrutinib|Administered orally
75445165|NCT06136559|Drug|Acalabrutinib|Administered orally
75595096|NCT00592137|Dietary Supplement|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
75595097|NCT04455776|Drug|Propofol|Sedation by propofol
75595098|NCT04135092|Biological|Individual Patient TCR Transduced PBL|Day 0: Cells will be infused at a dose not to exceed .5e11 in 400 mL IV on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
75739148|NCT05360004|Drug|Chinese herbal medicine|CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
75739149|NCT05359926|Other|Experimental|Early urethral foley removal after the surgery
75739150|NCT05359926|Other|Active comparator|Delayed urethral foley removal after the surgery
75739151|NCT05361408|Drug|Zoledronic acid, once|Intravenous infusion of 5mg zoledronic acid, once
75739152|NCT05361408|Drug|Zoledronic acid, twice|Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
75739153|NCT03227406|Behavioral|Sleep deprivation|Subjects are kept awake all night.
75739154|NCT03227406|Behavioral|Nap|Participants are given a 90-minute nap opportunity in the early afternoon.
75887522|NCT02781818|Drug|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
75595099|NCT04135092|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
75595100|NCT04135092|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2 /day IVPB daily over 30 minutes for 5 days.
75595101|NCT04135092|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
75595102|NCT04135092|Drug|Pembrolizumab|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Day -2 and then every 3 weeks until time of disease progression.
75595103|NCT00592215|Drug|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
75595104|NCT04479137|Diagnostic Test|PCR for COVID-19|Novel Coronavirus 2019 DNA will be analyzed by PCR in nasopharyngeal swab
75595105|NCT00592332|Drug|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
75595106|NCT00592332|Other|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
75595107|NCT04422444|Diagnostic Test|Questionnaires|Participants will answer questionnaires in three areas: physical/functional, emotional status and cognitive status
76057815|NCT04501276|Drug|ADG106|For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
75445166|NCT06132763|Behavioral|Hydration Intervention|"Teacher & student ambassadors: serve as hydration role models, identify Hydration Heroes, monitor filter lights on hydration stations, & update the water meter visual.~Kick-off event: event to kick off the hydration intervention to include water bottles distribution with a station to personalize, experiential activities, and information about the intervention.~Social marketing: student-developed marketing campaign Make water your superpower will be placed in high-traffic areas of the school. Hydration Headquarters will be located in the lunchroom displaying a water meter illustrating bottle refills from the school's hydration stations.~Behavioral reinforcement: on random days, students drinking water and/or with a water bottle will receive small incentives.~Education and outreach: Hydration Tip Sheets, hydration signage in classrooms, and hydration trivia on hydration stations. Teachers will deliver 1 hydration lesson per month that align with Standards of Learning."
75445167|NCT06132763|Other|Control - Assessments Only|Assessments only
75445168|NCT06132503|Drug|LP-284|LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
75445169|NCT06131801|Other|1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.|Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.
75595108|NCT04477382|Dietary Supplement|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.|Subjects suffering from house dust mite (HDM) allergic rhinoconjunctivitis who are reacting positively to chamber exposure with HDM are reevaluated in the exposure chamber 3 months after taking food supplements.
75595109|NCT04375644|Other|Questionnaires on psychological quality of life|Assessement of evolution of the psychological quality of life of health professionals during the confinement period linked to the COVID-19 pandemic by two questionnaires (one during the confinement period and the second one month after the end of the confinement period)
75595110|NCT04454021|Procedure|hip arthroscopy|hip arthroscopy was performed when symptoms were not alleviated by nonsurgical treatment
75595111|NCT04453592|Other|No intervention assigned as part of this study.|"The intervention included in this study is part of routine medical care, and not assigned as a result of study participation. This study includes only the addition of a measurement; the bent knee fall out test. Therefore, we believe this study design is observational, and in line with the provided observation study design definition: Observational: studies in human beings in which biomedical and/or health outcomes are assessed in predefined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.~See uploaded study protocol for further details."
76057816|NCT04501276|Drug|anti PD1 drug|For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
76057817|NCT04060342|Drug|GB1275|Oral
76057818|NCT04060342|Drug|nab-paclitaxel and gemcitabine|IV infusion
76057819|NCT04060342|Drug|pembrolizumab|IV infusion
75595112|NCT04477226|Diagnostic Test|Transvaginal ultrasound scan|Transvaginal ultrasound is done to measure the cervical length, as per Fetal Medicine Foundation guidelines
75595113|NCT04453397|Drug|TNB-383B|TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
75595114|NCT01600274|Drug|Dienogest-Ethinyl Estradiol (test product)|One tablet of Test
75595115|NCT01600274|Drug|Dienogest-Ethinyl Estradiol (reference product)|One tablet of Reference
75595116|NCT01176565|Drug|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
75595117|NCT04374123|Diagnostic Test|Serological screening for IgG and IgM antibodies against COVID-19|Serum evaluation for IgG and IgM antibodies against COVID-19 in patients in the endoscopy unit during the COVID 19 pandemic
75595118|NCT01600313|Dietary Supplement|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
75445170|NCT06128421|Dietary Supplement|Individual nutritional support|Nutritional products and route（oral, parenteral）is possible to reach goals
75445171|NCT06118905|Drug|Denosumab 60 MG/ML|Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV
75445172|NCT06118905|Drug|Zoledronic Acid 5Mg/Bag 100Ml Infusion|Subjects to receive Zoledronic Acid 5mg IV and Denosumab placebo
75445173|NCT06113328|Biological|MK-6194|MK-6194 administered subcutaneously (SC)
75445174|NCT06113328|Drug|Placebo|Placebo comparator to MK-6194 administered SC
75739155|NCT03069690|Behavioral|HABITpreg|"Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
75445175|NCT06111781|Drug|Relugolix 120 MG [Orgovyx]|ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
75445176|NCT06111781|Radiation|SBRT standard of care radiotherapy treatment|SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
75887523|NCT02781818|Drug|Normal Saline|Normal saline 0.1 mL will be administered intralesionally at the selected site.
75887524|NCT02149550|Other|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
75595119|NCT01176292|Device|Rotating Platform High-Flex Cruciate Substituting TKA|
75595120|NCT01176292|Device|Rotating Platform Cruciate Substituting TKA|
75595121|NCT04310410|Combination Product|combined radiotherapy and MR-HIFU|Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases. This treatment will take place in a short time frame of 3 hours to maximum 4 days. Patients will be followed up until 4 weeks after treatment. During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events. At day 3 the patient's experience with the combined treatment will also be inquired.
75595122|NCT04315675|Behavioral|Guided Imagery Intervention|The participant listens to a selected Guided Imagery for 21 consecutive days.
75595123|NCT04315675|Behavioral|Cognitive Power Intervention|The participant develops a plan to achieve healthy outcomes and reviews plan for 21 consecutive days.
75445184|NCT06101394|Drug|Cetuximab-IRDye800|Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab-IRDye800 over 30 minutes to 1 hour.
75595124|NCT04315675|Behavioral|Combined Guided Imagery and Cognitive Power Intervention|The participant completes 21 days of selected Guided Imagery in combination with the development of a plan to achieve healthy outcomes and reviews the plan for 21 days.
75595125|NCT01600469|Drug|DAOI-B|250-1500 mg/day, oral, for 24 weeks
75595126|NCT01600469|Other|Placebo|placebo, oral, for 24 weeks
75595127|NCT01113541|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
75887525|NCT02149550|Other|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
75445185|NCT06098508|Other|Osteopathic Manual Treatment|This study will be using osteopathic manual therapy as the primary intervention. Osteopathic manual therapy (OMT) is a hands-on treatment that is performed by a specially trained physician known as a Doctor of Osteopathic Medicine (DO). This treatment can be used to diagnose and treat somatic dysfunctions, which are palpable areas of tightness, misalignment, and/or restricted motion within the musculoskeletal system and its related vascular and neural structures. A combination of myofascial release, strain/counterstain, soft tissue, balanced ligamentous release, facilitated positional release and muscle energy techniques will be used for the OMT treatment.
75445186|NCT06098508|Other|Sham Treatment|The sham treatment will include a hands-on evaluation typically used to diagnose somatic dysfunctions, but no treatment will be performed. The sham treatment will assess the upper extremities/scapulae, ribs, cervical spine, thoracic spine, thoracic inlet, and occipital-atlantal regions.
75445187|NCT06098456|Drug|EGCG, FA, HA, B12|Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg
75445188|NCT06097897|Device|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
75595128|NCT04417608|Procedure|Infraclavicular brachial plexus block|Ultrasound-guided infraclavicular brachial plexus block
75616309|NCT01998633|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
75739156|NCT03069690|Behavioral|HABITpost|"Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
75887526|NCT02149550|Other|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
75887527|NCT02149550|Other|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
75887528|NCT02149550|Other|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
75595129|NCT04451252|Procedure|Fluoroscopically guided lumbar medial branch nerve radiofrequency denervation.|"While in prone position, lumbar facet joints are identified by fluoroscopy. 18 gauge needles are then advanced aiming to the medial branch of lumbar facet joints. Correct positioning is confirmed by anteroposterior and lateral fluoroscopy. Then, the needles are attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz (hertz), 1ms, 0,6V (volts). In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms (millisecond) and twice the voltage that produced sensitive response. After correct positioning and repositioning the needles if needed, conventional radiofrequency ablation of medial branch nerves is performed using the following settings: 90 seconds, 80º Celsius degrees.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation."
75739157|NCT00990366|Device|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
75739158|NCT05590572|Drug|Sulfatinib|(1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
75595130|NCT04451252|Procedure|Fluoroscopically guided lumbar facet joint injection.|With the patient in prone position and guided by fluoroscopy, lumbar facet joints are identified. The 22 french needles are then advanced aiming to the lumbar facet joints. Correct positioning is confirmed with anteroposterior and lateral fluoroscopy. A mixture of 3 ml of ropivacaine 0,2% + 1 ml (40 mg) of triamcinolone (trigon depot) is prepared. 1 ml of the mixture is injected in each lumbar facet joint through the needles. Four facet joints are selected for therapy. Some patients receive bilateral and other unilateral but contiguous facet joint infiltration. The selection of target facet joints is made based on clinical and radiological findings.
75595131|NCT04451252|Procedure|Fluoroscopically guided lumbar epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the interlaminar approach using a loss of resistance technique for the identification of the lumbar epidural space. When loss of resistance is encountered, 1 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 4 ml of ropivacaine 0,1%, 2 ml (12 mg) of betamethasone and 2 ml of saline serum is injected in the epidural space. The lumbar level to which it infiltrates depends on each patient.
75616310|NCT02845570|Other|68Ga-DOTANOC PET/MRI|
75616311|NCT02845570|Other|18F-FDG PET/MRI|
75739159|NCT05590572|Drug|Etoposide|(1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
75739160|NCT05590572|Drug|Isophosphamide|(1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
75739161|NCT05359614|Device|CoolSculpting Elite combined with CoolTone Treatments|Coolsculpting treatment combined with Cooltone treatments for the banana roll region of the buttocks.
75887529|NCT02149550|Other|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
75887530|NCT02149628|Drug|propofol|
75739162|NCT05359614|Device|CoolSculpting Elite|Coolsculpting treatment alone for the banana roll region of the buttocks
75739163|NCT03050502|Device|Chest tube drain|This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
75887531|NCT02149628|Drug|Desflurane|
75445193|NCT06094296|Drug|BMS-986315|Specified dose on specified days
75445194|NCT06094296|Drug|Nivolumab|Specified dose on specified days
75445195|NCT06094296|Drug|Pemetrexed|Specified dose on specified days
75887532|NCT02147366|Behavioral|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
75887533|NCT02147366|Behavioral|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
75887534|NCT02927873|Biological|RSV (GSK3389245A) low dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
75445196|NCT06094296|Drug|Cisplatin|Specified dose on specified days
75445197|NCT06094296|Drug|Carboplatin|Specified dose on specified days
75445198|NCT06094296|Drug|Paclitaxel|Specified dose on specified days
75595132|NCT04451252|Procedure|Fluoroscopically guided caudal epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the sacral hiatus using a loss of resistance technique for the identification of the epidural space. When loss of resistance is encountered, 2 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 7 ml of ropivacaine 0,2%, 2 ml (12 mg) of betamethasone and 7 ml of saline serum is injected in the epidural space.
76057820|NCT01435018|Drug|Etoposide (ET)|"Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade >= 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade >= 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.~Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
75595133|NCT04451252|Procedure|Fluoroscopically guided pulsed radiofrequency of the lumbar dorsal root ganglion.|With the patient in prone position and guided by fluoroscopy, a 18 gauge needle is advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root. Then, the needle is attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz, 1ms, 0,6V. In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms and twice the voltage that produced sensitive response. After correct positioning is confirmed, pulsed radiofrequency ablation of lumbar dorsal root ganglion is performed using the following settings: 4 minutes, 42ºC (degrees Celsius).
75595134|NCT04451252|Procedure|Fluoroscopically guided transforaminal epidural corticosteroid injection or lumbar selective root block.|With the patient in prone position and guided by fluoroscopy, a 22 french needle is then advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt along the course of the lumbar root when the needle touches the nerve. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root.
75739164|NCT03050502|Other|Expectant management|This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
75739165|NCT00990444|Drug|Insulin in Dextran Matrix|Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
75739166|NCT00990522|Procedure|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
75739167|NCT00990600|Other|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
75739168|NCT02897076|Drug|betamethasone 24 mg|
75739169|NCT02897076|Drug|12mg betamethasone +placebo|
75887535|NCT02927873|Biological|RSV (GSK3389245A) middle dose formulation vaccine|2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
75445200|NCT06084884|Biological|AZD5851|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD5851.~During AZD5851 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD5851 product, subjects will receive treatment with AZD5851 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD5851 administered by intravenous (IV) infusion."
75445201|NCT06084338|Radiation|stereotactic ablative radiotherapy|Metastasis directed
75445202|NCT06084338|Drug|Pluvicto|PSMA targeted radiopharmaceutical therapy
75445203|NCT06084338|Drug|topical testosterone|Topical testosterone 1.62% gel
76057821|NCT01435018|Drug|Bleomycin and Vincristine (BV)|"BV was administered on day one of each chemotherapy cycle.~Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below.~Bleomycin sulfate was administered at a dose of 15 units/m^2 over 10 minutes every 3 weeks.~Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
75595135|NCT04450823|Other|no intervention|no intervention study, survey amongst health workers
75595136|NCT04372368|Biological|COVID-19 Convalescent Plasma|1-2 units of COVID-19 convalescent plasma will be administered over 1 to 2 hours (rate of 100 to 200 mL/hr)
75445204|NCT06081465|Drug|VG290131|The study drug and matching placebo will be administered orally.
75445205|NCT06077773|Drug|Oral EP262|Once daily
76057822|NCT01435018|Drug|Paclitaxel (PTX)|Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m^2 body surface area (BSA) every 3 weeks.
75445206|NCT06077773|Drug|Placebo|Once daily
75445207|NCT06072482|Drug|Avacopan|Administered orally.
75445208|NCT06072482|Drug|Placebo|Administered orally.
75445209|NCT06072482|Drug|Standard of Care|All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
75445210|NCT06071767|Biological|ChAdOx1.tHIVconsv1|Administered as 0.4 mL intramuscularly (IM) at Week 0
75445211|NCT06071767|Biological|ChAdOx1.HIVconsv62|Administered as 0.3 mL IM at Week 0
75445212|NCT06071767|Biological|MVA.tHIVconsv3|Administered as 0.3 mL IM at Week 4
75595137|NCT04417413|Device|Fotona ProlapLase|Non-ablative SMOOTH mode intravaginal Er:YAG teratment for pelvic organ prolapse
75445213|NCT06071767|Biological|MVA.tHIVconsv4|Administered as 0.5 mL IM at week 4
75445214|NCT06071767|Drug|Vesatolimod (VES)|VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
75445215|NCT06071767|Drug|GS-5423|Administered via intravenous (IV) infusion at week 7
75445216|NCT06071767|Drug|GS-2872|Administered via IV infusion at week 7
75445217|NCT06071767|Biological|MVA.tHIVconsv4|Administered 0.5 mL IM at week 60
75445218|NCT06071767|Biological|Placebo|Placebos for vaccines, VES, and bnAbs
75887536|NCT02927873|Biological|RSV (GSK3389245A) high dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
75595138|NCT04372173|Diagnostic Test|analysis of the concentration of the clotting factors in patients who underwent primary hip arthroplasty|"Blood samples were taken before surgery, 6 hours, two, four, and six days after the procedure. Venous blood samples were taken from peripheral veins.~All analyzed parameters (fibrinogen, factor II, factor VIII, factor X, D-dimer) were determined using an ACL TOP 500 CTS automated coagulation analyzer.~All patients were operated on by a single surgical team, with cementless hip replacements implanted, and without tranexamic acid administered in the perioperative period. All patients underwent venous thromboembolic complications prophylaxis.~The following data were collected: age, body mass index, gender, perioperative risk assessment scale according to the American Society of Anesthesiologists score, blood transfusions, hemoglobin levels before surgery and two days post-surgery, instances of thromboembolic complications. Because of the observational nature of this study no changes in the treatment of patients were made."
75887537|NCT02927873|Drug|Placebo|2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
75739170|NCT05590182|Device|Angiography|"Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention."
75445220|NCT06067555|Device|MicronJet|MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
75445221|NCT06067555|Biological|Fluzone® Quadrivalent|Intradermal injections of 0.3mL
75445222|NCT06067555|Biological|Fluzone® Quadrivalent|Intramuscular injection of 0.3mL
75445223|NCT06067555|Other|Bacteriostatic Saline|Intradermal injection of 0.3mL (control)
75445224|NCT06067230|Biological|mRNA-1345|Sterile liquid for injection
75739171|NCT00990678|Drug|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
75739172|NCT00990678|Drug|Vitamin D|tablets, vitamin D3, 30 microgram daily
75887538|NCT01383629|Behavioral|Counselling|Preoperative counselling
75887539|NCT02460419|Drug|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
75739173|NCT00990678|Drug|Calcium|tablets, 400 mg calcium, 3 times daily
75739174|NCT05265468|Other|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
75887540|NCT02460419|Other|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
75739175|NCT05265468|Other|Lewit Group|Isometric muscular exercise acompained with stretching technique
75445226|NCT06066021|Other|health educational sessions in diabetic patients type 2.|Professionals from different areas will be invited to carry out the sessions at Visit 2, namely on: mental health, physical activity, nutrition and self-care.
75595139|NCT04450277|Procedure|Emergency surgery|Emergency surgery vs conservative management
75739176|NCT05265468|Other|Chaitow Group|Isometric muscular exercise acompained with stretching technique and diaphragmatic breathing
75739177|NCT05265468|Other|Placebo Group|No pain positioning of participants
75887541|NCT01220999|Drug|CS-1008|CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111^In (5-7 mCi).
75887542|NCT03513731|Device|Adipose-derived stem cell injection|ADRC injection into the facet joint
75887543|NCT03513731|Drug|Corticosteroid injection|Corticosteroid injection into the facet joint
75887544|NCT01568411|Drug|TD-1211|Period 1
75887545|NCT01568411|Drug|TD-1211+ itraconazole|Period 2
75739178|NCT05359458|Behavioral|Emotional Freedom Liberation Technique|The investigators will apply Emotional Freedom Liberation Technique
75887546|NCT00142415|Drug|111-In-DOTA-cG250|On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
75445227|NCT06065488|Device|ankle kinesio tap|Kinesio Tape is popular among athletes and non-athletes for its ability to protect, support, and promote activity in overworked muscles. Few people are aware, however, that its healing benefits don't end there. Research studies show that taping ankle with Kinesio Tape actually improves ankle range of motion.
75445228|NCT06065449|Drug|Radiation Therapy|"Arm 1: standard 8 Gy delivered in a single fraction or 20 Gy delivered in 5 fractions~Arm 2: 16 Gy delivered in a single fraction or 27 Gy delivered in 3 fractions prescribed to planning target volume (PTV)."
75595140|NCT01113502|Drug|Eltrombopag|Oral formulation taken daily
75595141|NCT04474652|Other|Single Blood Draw from each participant|Health Professionals will seek informed consent and take a single blood collection from the participant. This will take place during the patient's visit to the breast one stop clinic as part of their routine urgent breast referral pathway.
75595142|NCT04416789|Other|Exercise programme|1 session of trampolining/dry sports (1.5 hours) and 1 session of supervised swimming (1.5 hours) per week for 10 weeks.
75595143|NCT01113463|Drug|TPI 287|Starting dose of 160 mg/m^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
75595144|NCT02886403|Other|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
75739179|NCT05590104|Procedure|Hysteroscopic CS scar defect repair|Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis.
75739180|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
75595145|NCT02886403|Other|New adhesive strip|A newly developed adhesive strip
75595146|NCT01112917|Device|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
75595147|NCT01112917|Procedure|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
75595148|NCT00591708|Dietary Supplement|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
75739181|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
75739182|NCT00538590|Device|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
75739183|NCT00538590|Drug|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
75739184|NCT00990834|Drug|simvastatin|simvastatin 80 mg PO daily for one to eight months.
75739185|NCT05589636|Dietary Supplement|Bergamot Juice|Bergamot Juice (35% in water)
75739186|NCT00990990|Drug|PNU-100480|100 mg BID for 14 days
75739187|NCT00990990|Drug|Placebo|to match 100 mg BID for 14 days
75739188|NCT00990990|Drug|PNU-100480|300 mg BID for 14 days
75739189|NCT00990990|Drug|Placebo|to match 300 mg BID for 14 days
75739190|NCT00990990|Drug|PNU-100480|600 mg BID for 14 days
75739191|NCT00990990|Drug|Placebo|to match 600 mg BID for 14 days
75739192|NCT00990990|Drug|PNU-100480|1200 mg QD for 14 days
75739193|NCT00990990|Drug|Placebo|to match 1200 mg QD for 14 days
75887547|NCT00142415|Drug|177-Lu-DOTA-cG250|On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m^2 in the initial cohort.
75739194|NCT00990990|Drug|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
75739195|NCT00990990|Drug|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
75739196|NCT00990990|Drug|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
75739197|NCT00990990|Drug|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
75739198|NCT00990990|Drug|Linezolid|300 mg QD for 4 days (open label)
75739199|NCT05361096|Other|Educational approach (Flipped learning)|"In the intervention group, the out-of-class stage started one week before the in-class stage of the relevant week. The researchers covered the topic of the week asynchronously in the virtual classroom in the learning management system. Students have been able to log into the system at anytime and anywhere and study the course video and other course materials repeatedly.~The in-class stage is the session in which the students in the intervention group come together with the researcher synchronously and conduct an online lesson. It was conducted one session per week for four weeks. The course was carried out synchronously on the Zoom platform during the in-class stage."
75887548|NCT01383551|Behavioral|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
75887549|NCT03631745|Behavioral|NAMI Mental Health 101 and NAMI FaithNet|"Congregants of Intervention Churches will receive:~NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families."
75887550|NCT05420363|Other|different walking surfaces|different surfaces materials and textures as sand ,grass, air mattress , foam mattress ,gravels and Rollator
75739200|NCT05589558|Procedure|consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)|TRUS-guided biopsy - extensive number of biopsies taken transrectally involving peripheral and transitional zones (8-12 cores); cognitive biopsy - targeted biopsy with MRI information and TRUS guidance but without fusion technology (2-4 cores); fusion biopsy - targeted biopsy with MRI information using MRI/TRUS fusion technology (2-4 core); transperineal template mapping biopsy - systematic transperineal TRUS-guided biopsy with special template use to aid accurate placement of biopsy needles (more than 20 cores).
75739201|NCT04003662|Device|Vital Signs Measurement|Vital signs are measured twice with standard of care equipment while recording digital video data at the same time.
75887551|NCT05420363|Other|traditional gait training over hard surface only|The children will receive gait training over hard surface and even ground only and bare feet without wearing any foot ware or orthosis
75445229|NCT06063499|Behavioral|Healthy Minds Program for Addictions|The Healthy Minds Program for Addictions is a 6-week, hybrid version of the original Healthy Minds Program (HMP), in which all lessons are adapted from the original lessons available in the app and delivered exclusively in person over weekly group sessions. The HMP has >100 guided audio practices that address 4 constituents of wellbeing: awareness, connection, insight, and purpose. Study participants will have access to specific practices from the HMP that are particularly relevant to the needs of populations with substance use disorders and trauma.
75445230|NCT06061796|Procedure|prone position|"patient kept in prone position until the following criteria have been reach for 4 consecutive hours:~ratio P/F > 150 mm Hg~FiO2 < 60%~PEEP ≤ 10 cm d'H2O"
75445231|NCT06061211|Other|TREADMILL(PRECOR 964i treadmill) with TENS|"TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: PRECOR 964i treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min."
75445232|NCT06058377|Procedure|Biospecimen Collection|Undergo optional collection of tissue and/or blood
75445233|NCT06058377|Drug|Cyclophosphamide|Given IV
75739202|NCT00991146|Drug|canakinumab|canakinumab
75739203|NCT05589324|Behavioral|3D-printed writing aids task|Briefly explain how to wear assistive devices, confirm that the case understands how to operate, and conduct a writing task test. Situation includes no wearable assistive device,three pen placement designs with different angles (5 degrees, 20 degrees, and 30 degrees). Record the writing speed, legibility, posture, and satisfaction of the assistive device after each writing task, etc.
75739204|NCT00991224|Biological|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
75739205|NCT00991224|Biological|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
75739206|NCT00991224|Other|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
75739207|NCT00466947|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
75739208|NCT00466947|Biological|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
75739209|NCT00466947|Biological|Engerix-B|Intramuscular injection, 3 doses
75739210|NCT00466947|Biological|Infanrix hexa|Intramuscular injection,3 doses
75739211|NCT00466947|Biological|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
75445234|NCT06058377|Drug|Doxorubicin|Given IV
75595149|NCT00591708|Dietary Supplement|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
75595150|NCT01176058|Drug|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
76057823|NCT01435018|Drug|Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)|"The following ART regimens were used:~EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing"
75445235|NCT06058377|Biological|Durvalumab|Given IV
75445236|NCT06058377|Other|Genetic Testing|Undergo MammaPrint testing
75445237|NCT06058377|Procedure|Mammography|Undergo mammography
76057824|NCT01419184|Drug|Daptomycin|
75445238|NCT06058377|Drug|Paclitaxel|Given IV
75595151|NCT01606982|Drug|MDV3100|oral
75595152|NCT04328766|Drug|DWC202005, alone|DWC202005, as a single dose
75595153|NCT04328766|Drug|DWP14012 + DWC202005|DWP14012 and DWC202005, as a single dose
75595154|NCT04328766|Drug|DWP14012 + DWC202005, after multiple doses of DWP14012|DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
75595155|NCT01600781|Dietary Supplement|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
75595156|NCT01600820|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
76057825|NCT01419184|Drug|Vancomycin|
75445239|NCT06058377|Other|Quality-of-Life Assessment|Ancillary studies
75445240|NCT06056596|Drug|Lamivudine 300 MG|Drug to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
75445241|NCT06056596|Drug|Placebo|Dose to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
75445242|NCT06053216|Other|Indirect calorimetry|Weekly indirect calorimetry measurements using the Q-NRG+ device will be used to guide energy delivery up to day 28 of hospital admission.
75595157|NCT01600820|Other|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
75595158|NCT01600820|Other|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
75595159|NCT01600859|Drug|E2609|"E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg~E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg~According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo"
75595160|NCT01600859|Drug|Placebo for E2609|"Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo"
75445243|NCT06053216|Other|Indirect calorimetry (Standard care nutrition arm)|Weekly indirect calorimetry measurements using the Q-NRG+ device will be conducted up to day 28 of hospital admission. In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry measurements.
75887552|NCT03631901|Drug|oral melatonin|Both melatonin and diazepam were given only during the febrile illness.
75445245|NCT06051617|Drug|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for up to 36 months.
75445246|NCT06051617|Drug|Placebo|One capsule daily for up to 36 months.
75445247|NCT06050083|Behavioral|Hypnosis audio recordings|Hypnosis recordings created by the investigators that guide participants through using hypnosis to manage chronic pain.
75445248|NCT06044935|Other|Standard Diet|Consisting of 15% protein, 35% fat, and 50% carbohydrate, matching the macronutrient composition of a typical American diet
75445249|NCT06044935|Other|Ketogenic Diet|Consisting of a macronutrient composition of 15% protein, 80% fat, and 5% carbohydrate
75445250|NCT06044935|Dietary Supplement|Placebo|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
75595161|NCT04328142|Other|Qigong group|Traditional Chinese Medicine exercise programme
75595162|NCT04328142|Other|Physiotherapy|Physiotherapy exercise programme
75595163|NCT01607099|Procedure|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
75595164|NCT02273765|Drug|Tenofovir + lamivudine + raltegravir|"In this arm, patients will receive the following medications :~Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food"
75616312|NCT02844400|Device|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
75616313|NCT02844400|Other|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
76057826|NCT01417234|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
76057827|NCT01417156|Drug|Nintedanib|150 mg bid
76057828|NCT01417156|Drug|Pirfenidoneone|Existing treatment
76057829|NCT01417078|Drug|Diazepam|single-dose; dosage in mg, based on patient body weight
76057830|NCT01954394|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
75739212|NCT00991380|Behavioral|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
75595165|NCT02273765|Drug|Tenofovir + lamivudine + efavirenz|"In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight."
75739213|NCT00991380|Behavioral|Usual Care|Control
75887553|NCT03631901|Drug|oral diazepam|Both melatonin and diazepam were given only during the febrile illness.
76057831|NCT01954394|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
76057832|NCT01464424|Drug|Travoprost 0.004% ophthalmic solution|
75595166|NCT04370184|Procedure|Ultrasound guided Costoclavicular Brachial Plexus Block|Ultrasound images from patients scheduled for upper limb surgery under costoclavicular brachial plexus block (one kind of regional anesthesia) have been routinely collected at our institute. These images will be reviewed.
75595167|NCT00591747|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
75595168|NCT00591747|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
75595169|NCT01607177|Behavioral|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
75595170|NCT02279888|Device|CardioMEMS HF System|Pulmonary artery pressure sensor
75595171|NCT04414332|Other|Data collection only|This registry is to capture high quality patient safety and effectiveness data on use of the Angiovac device for 3 separate, but overlapping conditions; a) Iliofemoral and Caval DVT, b) Right heart masses, and c) PE. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the angiovac catheter deployed into the vascular system.
75595172|NCT02489591|Device|Oral appliance|Patients will bring their prescribed oral appliance.
75616314|NCT03097276|Procedure|blood sample|blood sample will be collected
75616315|NCT03097276|Radiation|CT scan|CT scan
75739214|NCT00537810|Drug|Sibutramine|15 mg daily
75739215|NCT00537810|Drug|Placebo|Daily
75739216|NCT00537810|Behavioral|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
75739217|NCT00537810|Behavioral|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
75739218|NCT05589246|Device|regional analgesia with cryolesia|The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
75739219|NCT05589168|Behavioral|Triage nurse|Triage nurse joins 911 call
75739220|NCT05589168|Behavioral|No triage nurse|Triage nurse does not join 911 call (business as usual)
75739221|NCT01017471|Procedure|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
75739222|NCT05589012|Biological|Cell line and virus|C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
75887554|NCT03631589|Biological|MSCs|mesenchymal stem cells therapy
75887555|NCT01383395|Drug|simvastatin/cilostazol|
75887556|NCT05419661|Other|Operational Pre-Planning|Using a 3D printer, printing of the patient's aneurysm from the segmented 3D images obtained during the initial assessment and thus allowing a simulation of the embolization procedure. This pre-operative planning (PPO) carried out in real conditions aims to anticipate the possible complications that could be encountered on the same day of treatment.
75887557|NCT05084651|Drug|Ganaplacide|Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
76057833|NCT01464424|Drug|Bimatoprost 0.01% ophthalmic solution|
75445251|NCT06044935|Dietary Supplement|Nicotinamide Riboside|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
75595173|NCT02489591|Device|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
75595174|NCT01607333|Drug|Lamotrigine use|Lamotrigine prescription during the study period
75739223|NCT05589012|Biological|Infection of human placental culture explants|"Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air."
75739224|NCT05589012|Biological|Determination of viral load in tissues by qRT-PCR|"The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV."
75595175|NCT02892981|Other|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
75595176|NCT01601015|Other|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
75595177|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
75595178|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
75595179|NCT01601015|Other|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
76057834|NCT01902134|Drug|Placebo|Placebo single oral dose (first 8 hours)
76057835|NCT01902134|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
76057836|NCT01902134|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
76057837|NCT01902134|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
76057838|NCT01902134|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
76057839|NCT01902134|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
76057840|NCT01902134|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
76057841|NCT05110586|Other|Electrotherapy|Applications will be applied for 4 weeks, 5 days a week
75445258|NCT06040710|Device|POSEIDON size estimation software with the EndoMind polyp detection system|Polyp size estimation using the POSEIDON software and bounding boxes of the EndoMind polyp detection system.
75445259|NCT06033586|Drug|Open-label rusfertide|subcutaneous rusfertide
75595180|NCT02893098|Drug|Humia inj.|"Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks"
75739225|NCT01355094|Device|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
75887558|NCT05084651|Combination Product|Lumefantrine|Treatment A/Period 1: 480 mg (2 x 240 mg sachets) at Hour 0 on Day 1 Treatment B/Period 2: 480 mg (2 x 240 mg sachets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
75887559|NCT05084651|Drug|Itraconazole|200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
76057842|NCT01954082|Drug|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
75887560|NCT05419271|Procedure|home hemodialysis session with 9L internal convection|home hemodialysis session with 9L internal convection
76057843|NCT01954082|Drug|Placebo|% glucose(dextrose)
75595181|NCT02893098|Drug|High hyal Plus inj.|Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
75595182|NCT01601054|Device|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
76057844|NCT01417000|Biological|GVAX Pancreas|
76057845|NCT01417000|Biological|CRS-207|
75595183|NCT01607528|Dietary Supplement|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
75595184|NCT01607528|Dietary Supplement|Placebo|A similar looking and tasting powder with no active substances
75595185|NCT01601093|Drug|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
75595186|NCT01601093|Drug|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
75887561|NCT01825187|Device|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
75887562|NCT01825187|Device|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
75887563|NCT01825187|Other|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
75887564|NCT02781584|Drug|SEL|Administered orally once daily
75887565|NCT02781584|Drug|FIR|Administered orally once daily
75887566|NCT02781584|Drug|CILO|Administered orally once daily
75887567|NCT02781584|Drug|FENO|Administered orally once daily
76057846|NCT01417000|Drug|Cyclophosphamide|
76057847|NCT01416142|Device|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
76057848|NCT01416142|Device|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
75595187|NCT01601093|Drug|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
75595188|NCT04328571|Dietary Supplement|OLE enzymatically treated|OLE (Olive leaf extract ) enzymatically treated + maltodextrin
75887568|NCT02781584|Drug|VAS|Administered orally two times daily
75887569|NCT02149706|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
75887570|NCT02149706|Biological|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
75595189|NCT04328571|Dietary Supplement|OLE + probiotic|OLE (Olive leaf extract) co-administered with probiotic
75739226|NCT01355094|Device|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
75739227|NCT05588232|Procedure|scheduled outpatient interventions in interventional cardiology|coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
75595190|NCT04328571|Dietary Supplement|OLE|OLE (Olive leaf extract) + maltodextrin
75595191|NCT04366830|Drug|Remestemcel-L|Participants will receive remestemcel-L in two infusions of 2 x 10^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
75595192|NCT01175824|Drug|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
75739228|NCT00991614|Device|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
75739229|NCT05358054|Other|Mobilization with movement lateral Glides and Conventional Physiotherapy|"(The Mobilization with movement technique is(lateral glide) applied to the patient by a physiotherapist to patients at supine level position.~First we identify pain free region each patients. The lateral humerus above the condyle of elbow joint are fixed by therapist. Then therapist ask to patients perform the active movement ten times. The same procedure repeats number of 3 sets, 10 number of repetition. The rest of interval fifteen to twenty seconds with in the sets Grip strength (pain Free Strength ) was evaluated in kilogram using a dynamometer. The measurements using dynamometer patients posture is erect sit position , the elbow at 90 degree flexion , shoulder would be abducted , rest of joint forearm and wrist in neutral during measurements.~conventional therapy list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching"
75739230|NCT05358054|Other|Progressive Resistance Exercises and Conventional Physiotherapy|4 STEPS Progressive resistive EXERCISES have a 4 step to application Step 1 Clenching fist strongly, resisted wrist Flexion, Extension, wrist rotation with a stick) Step 2 The therapeutic band exercised performed at wrist Flexion(WF), Wrist Extension(WE), Wrist Ulnar Deviation(WED) , and Wrist Radial Deviation(WRD).Step 3 Patient asked to perform combined wrist rotatory movements using e.g. table top as a support. Step 4 Soft ball compressing exercises, Transferring buttons from cup into another, Twisting a towel into the roll, Hand Rotating both directions at table AND CONVENTIONAL PHYSIOTHERAPY and list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching
75739231|NCT01287936|Biological|SB623|SB623, a modified stem-cell product
75887571|NCT03544658|Procedure|Dental prophylaxis|Professional dental prophylaxis including dental scaling and dental polishing with prophylactic paste
76057849|NCT01415986|Drug|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
76057850|NCT01415986|Device|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
75887572|NCT03544658|Procedure|Tooth color assessment by the participant|Tooth color assessment using the VITA Classical shade guide. Assessment will be done with normal light conditions and with a light correcting device
75887573|NCT03544658|Procedure|Tooth color assessment by the investigator|Tooth color assessment using the VITA Classical shade guide and the VITA Toothguide 3D Master. Assessment will be done with normal light conditions and with a light correcting device
75595193|NCT01175824|Drug|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
75595194|NCT01175824|Drug|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
75595195|NCT02482532|Biological|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
75595196|NCT01607684|Device|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
75595197|NCT01601210|Drug|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
75595198|NCT01175707|Drug|Daptomycin|
75595199|NCT01175707|Drug|Vancomycin|
75445271|NCT06027840|Drug|Varenicline|Varenicline prescription will follow the standard induction period: varenicline 0.5 mg once per day for Days 1-3, varenicline 0.5 mg twice per day for Days 4-7, then varenicline 1 mg twice per day (when varenicline reaches peak efficacy for tobacco cessation). Participants will remain on varenicline for 12 weeks total. Dose adjustments (e.g., reduction to 0.5 mg twice per day if 1 mg is not well tolerated) will be allowed at the discretion of the clinical pharmacist/APRN/physician.
75616316|NCT01987635|Device|MEMO 3D ring|The experimental MEMO 3D ring is placed.
75616317|NCT01987635|Device|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
75595200|NCT01601249|Procedure|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
75595201|NCT02892903|Device|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
75739232|NCT05586984|Procedure|Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.
75595202|NCT01112059|Drug|Doxycycline|100 mg twice a day for 8 days
75595203|NCT01112059|Other|placebo|placebo
75739233|NCT05586984|Procedure|Transvaginal sacrospinous fixation|Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.
75739234|NCT00991692|Other|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
75739235|NCT05583786|Diagnostic Test|Tracing intracoronary electrocardiogram|icECG ST-segment shift remission time (τ-icECG) tracing during reactive-hyperemia, obtained immediately after a 1-minute upstream coronary artery balloon occlusion.
75739236|NCT00991770|Other|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
75739237|NCT00991770|Other|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
75739238|NCT00989352|Drug|Methotrexate|3g/m² i.v. max. 9 times
75739239|NCT00989352|Drug|Lomustine|110 mg/m² p.o., max. 3 times
75595204|NCT01175668|Drug|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores <8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
75616318|NCT01987635|Procedure|3D Echocardiography|
75739240|NCT00989352|Drug|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
75739241|NCT00989352|Drug|Rituximab|375 mg/m² i.v., max. 10 times
75739242|NCT05566626|Device|Hyperspectral retinal image|Hyperspectral image of both eyes
75739243|NCT05566626|Drug|Mydriacyl Ophthalmic Product|Mydriatic drops before retinoscopy
75616319|NCT05337904|Device|On-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is on."
76057851|NCT01415908|Device|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
75739244|NCT00989430|Behavioral|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
75739245|NCT00989508|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
75445272|NCT06027840|Behavioral|Counseling|Tobacco Treatment Service clinicians will deliver weekly counseling sessions, monitor participants for adverse events, and record participants' weekly cigarette and e-cigarette use. At the first counseling session clinicians will review medication proper use instructions, and potential side effects and strategies to address them at the first counseling session. Study medication refills will be distributed at 4-week intervals. Sessions will focus on quit plan preparation, supportive and practical cessation counseling, resetting quit dates, and relapse prevention.
75445273|NCT06027840|Behavioral|Guided Self-Change Booklets|The booklet includes information on how to reduce and quit both cigarettes and e-cigarettes on their own, how to prevent relapse, how to set a quit date, and how to enroll in text-based support resources.
75595205|NCT01175668|Drug|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
75445274|NCT06027216|Device|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
75595206|NCT01601327|Drug|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
75595207|NCT01601327|Drug|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
75595208|NCT01601327|Drug|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
75595209|NCT01607723|Other|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
75595210|NCT01607723|Other|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
75595211|NCT01601366|Device|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
75595212|NCT01601366|Drug|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
75595213|NCT04412226|Device|aerosol box|The aerosol box is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cube that covers the patient's head during the endotracheal intubation. Operator can intubate the patient through the two holes for arms.
75595214|NCT04412226|Device|transparent sheet|The transparent sheet is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cover that covers the patient's head and body during the endotracheal intubation. Operator can intubate the patient through the space under the cover
75595215|NCT01607762|Drug|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
75595216|NCT01607762|Drug|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
75595217|NCT01607762|Drug|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
75595218|NCT01607762|Drug|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
75595219|NCT01607762|Drug|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
75595220|NCT04412031|Other|non applicable|non applicable
75595221|NCT04327869|Device|Magnetically controlled capsule endoscopy|The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
75595222|NCT01601405|Drug|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
75595223|NCT01601405|Drug|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
75595224|NCT01607840|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
75595225|NCT04327947|Other|Hyaluronic acid - Research product 1|Health care product (intimate gel)
75739246|NCT00989508|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
75739247|NCT05408442|Other|No intervention|No intervention
75739248|NCT05408364|Dietary Supplement|probiotic or natural yoghurt|Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt
75739249|NCT05408364|Procedure|SRP|Scalling and root planing
75739250|NCT05408286|Behavioral|administration of questionnaires|administration of questionnaires
75739251|NCT05360394|Device|Paclitaxel Coated Balloon|CAS treated with PCB only
75739252|NCT05360394|Device|Paclitaxel Coated Balloon and Stent Graft|CAS treated with PCB first before deployment of stent graft
75445275|NCT06025656|Diagnostic Test|Leg Lateral Reach Test|"To conduct the leg reach test, participants began by positioning themselves with their arms hanging at their sides. They were then guided to raise the leg under assessment and extend it across the opposite leg to make contact with a wooden bar, employing trunk rotation in the process. During each trial, participants were consistently motivated to ensure that both shoulders remained in contact with the floor and to stretch their tested leg as far as they could along the length of the wooden bar. If a participant was unable to sustain contact between their foot and the wooden bar for a duration of 5 seconds at the point of maximal reach, or if both shoulders lifted off the floor, that specific trial was considered invalid and not included in the analysis.~Each participant completed three repetitions of this test for both the right and left sides, and the average of their reach distances was subsequently calculated for assessment."
75445276|NCT06024668|Device|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
75445277|NCT06024408|Drug|ALN-PNP|Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
75595226|NCT04327947|Other|Hyaluronic acid - Research product 2|Health care product (intimate gel)
75595227|NCT04327947|Other|Hyaluronic acid - Comparator product|Health care product (intimate gel)
75739253|NCT00090259|Drug|Losartan 50 mg|50-mg losartan oral tablet
75739254|NCT00090259|Drug|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
75445278|NCT06024408|Drug|Placebo|Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
75739255|NCT01082497|Behavioral|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
75887574|NCT03544658|Procedure|Tooth color assessment with SpectroShade|Tooth color assessment using SpectroShade (dental spectrophotometer). Color will be registered in VITA Classical and VITA Toothguide 3D Master and CIELab parameters
75887575|NCT02147678|Drug|Etomidate|
75887576|NCT02147678|Drug|Propofol|
75445279|NCT06023641|Drug|Vincristine|"Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15"
75445280|NCT06023641|Drug|Dactinomycin|"Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1"
75445281|NCT06023641|Drug|Cyclophosphamide|"Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1"
75445282|NCT06023641|Procedure|Surgical Resection|Low, Intermediate and High-risk
75595228|NCT01601444|Device|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
75739256|NCT03961711|Procedure|Telemedicine|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
75445283|NCT06023641|Procedure|Proton beam radiation or external beam radiation or brachytherapy|Low, Intermediate and High-risk
75739257|NCT03961711|Procedure|In-Person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
75887577|NCT02147678|Drug|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2~0.4 μg/kg/min.
75887578|NCT02147678|Drug|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
76057852|NCT01415908|Other|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
76057853|NCT01415518|Drug|Drug: Budesonide/formoterol (Symbicort Turbuhaler|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
75595229|NCT01601483|Drug|MC-1101|1% Ophthalmic Solution TID
75595230|NCT01601483|Drug|MC-1101 Vehicle|Ophthalmic solution, TID
75595231|NCT01607918|Drug|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
75595232|NCT01607918|Drug|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
75595233|NCT04363125|Diagnostic Test|Pathology result|Pathology result of rectal biopsy
75595234|NCT04362774|Device|ORBERA365|Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)
75739258|NCT00079183|Drug|sirolimus|Given PO
75739259|NCT03961243|Biological|YUVA-GT-F901|Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
76057854|NCT01415518|Drug|Drug: ipratropium (AtroventTM)|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
76057855|NCT01415518|Drug|theophylline SR|theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
75887579|NCT02151344|Biological|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
75739260|NCT01589341|Other|laboratory biomarker analysis|Correlative studies
75739261|NCT01086085|Drug|Adefovir|Adefovir 10 mg po once daily for 36 weeks
75739262|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
75887580|NCT02151344|Biological|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
75887581|NCT02151422|Behavioral|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
75887582|NCT02151500|Behavioral|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
75887583|NCT03543488|Diagnostic Test|Neuromuscular and functional capacity tests|"The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests."
75887584|NCT02149784|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy'
75887585|NCT02155634|Drug|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
75887586|NCT02151578|Other|home/community case management|
75887587|NCT02151656|Drug|F17464|
75887588|NCT02151656|Drug|Placebo|
75445284|NCT06023641|Drug|Liposomal irinotecan|Intermediate and High-risk Administer by IV infusion over 90 minutes, 1 dose on day 1 Liposomal irinotecan should be premedicated with dexamethasone (or an equivalent corticosteroid) if not contraindicated. Premedication with diphenhydramine and an H2 receptor antagonist (i.e., famotidine) are also encouraged.
75445285|NCT06023641|Drug|Vinorelbine|Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
75445286|NCT06023641|Drug|Temozolomide|High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
75445287|NCT06023641|Drug|Filgrastim, peg-filgrastim|"Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose [for patients < 45 kg] or 6 mg/dose [for patients ≥ 45 kg] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy."
75445288|NCT06022822|Procedure|Biopsy|Undergo biopsy
75445289|NCT06022822|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
75445290|NCT06022822|Drug|Placebo Administration|Given PO
75445291|NCT06022822|Dietary Supplement|Urolithin A Supplement|Given PO
75739263|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
75595235|NCT01607996|Procedure|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
75595236|NCT01607996|Drug|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
75595237|NCT01601561|Drug|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose."
75595238|NCT04361682|Procedure|Surgical Drain Management|
75595239|NCT01601717|Drug|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
75739264|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
75595240|NCT01601717|Drug|Placebo|Matching placebo pill administered once per day for 10 days.
75739265|NCT01088425|Other|Observation|"Alberta infant motor scale~Griffiths test~Kauffmann ABC"
75739266|NCT01086163|Drug|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
75739267|NCT01589419|Drug|veliparib|see arm description
75739268|NCT01589419|Drug|capecitabine|see arm description
75739269|NCT01589419|Radiation|radiation|see arm description
75739270|NCT00676403|Drug|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
75739271|NCT00676403|Drug|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
75739272|NCT00676403|Drug|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
75739273|NCT00676403|Drug|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
75739274|NCT00676403|Drug|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
75887589|NCT03543020|Radiation|radiation therapy to brain|OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
75445294|NCT06014567|Procedure|Magnetic Resonance Imaging|"A single (≤45 minutes) brain MRI will include T1w and T2w imaging to assess the morphology and structure of the brain, as well as inflammatory processes. Diffusion-weighted imaging will be used to gain information about internal brain connectivity related to brain functions. MRI, MR angiography (MRA) and fMRI pulse sequences will also be acquired to detect vascular pathologies and brain lesions. T2w morphological images of the whole spine will also be obtained.~A single (≤45 minutes) MR imaging investigation to include cardiovascular, abdominal, and musculoskeletal regions. MRI will be performed to assess the structure and function of these body regions and organs, including functional imaging of the heart. These investigations will include T1w and T2w imaging to assess morphology and structure, mapping studies of T1, T2 and T2*, perfusion imaging and cine imaging to assess the heart dynamically."
75739275|NCT00676403|Drug|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
75739276|NCT01086241|Procedure|2D Mammogram|Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
75739277|NCT01086241|Procedure|Tomosynthesis|Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
75739278|NCT00078325|Drug|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
75445295|NCT06012136|Drug|VH4004280|VH4004280 will be administered.
75739279|NCT00078325|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
75739280|NCT00078325|Drug|Placebo|Matching placebo tablets once daily in the morning
75739281|NCT03963271|Diagnostic Test|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan.
75739282|NCT03963193|Drug|Etoposide|Etoposide 100mg/m^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m^2 ivggt on days 1, 2, 3, repeated every 21 days.
75739283|NCT03963193|Drug|Irinotecan|Irinotecan 65 mg/m^2 ivggt on days 1, 8, Cisplatin 30 mg/m^2 ivggt on days 1, 8, repeated every 21 days.
75739284|NCT01088581|Drug|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
75445296|NCT06012136|Drug|Placebo|Placebo will be administered.
75445297|NCT06012136|Drug|VH4011499|VH4011499 will be administered.
75445298|NCT06009055|Drug|Remimazolam|0.3mg/kg，injection completed in 30 seconds
75739285|NCT01082653|Biological|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
75445299|NCT06009055|Drug|Propofol|2mg/kg，injection completed in 30 seconds
75445300|NCT06008574|Other|AmDTx-PCSP|Step-by-step program modules including meditation training and other activities relevant for people living with cancer
75445301|NCT06008574|Other|AmDTx-2048|"Cognitive training exercise called 2048.AmDTx-2048 is a modified version of a popular game called 2048. It is a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value."
75887590|NCT02155790|Device|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
76057856|NCT04058392|Biological|Camu Camu Capsules|Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
75445302|NCT06008574|Other|Questionnaires|Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)
75595241|NCT01601756|Device|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
75595242|NCT01601756|Device|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
75739286|NCT03961867|Drug|Docetaxel|"S-1 (BSA <1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; >1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Docetaxel 40mg/m2/3w from the second to the seventh cycles."
75739287|NCT03961867|Drug|Oxaliplatin|"S-1 (BSA <1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; >1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Oxaliplatin 130mg/m2/3w from the first to the eight cycles."
75739288|NCT03962179|Device|VACStent|Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
75887591|NCT02151734|Drug|KALOMIN™ Tab.|
75887592|NCT02151734|Drug|Umckamin syrup|
75887593|NCT02151812|Device|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
75887594|NCT02151812|Device|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
75445303|NCT06007508|Drug|Insulin Glargine|Long-acting insulin
75595243|NCT04327830|Other|Decisional needs assessment|Assessment of decision-making needs
75595244|NCT01601795|Drug|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
75595245|NCT01601795|Drug|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
75595246|NCT04360590|Device|pressure support ventilation versus neurally adjusted ventilatory assist|All patients underwent three mechanical ventilation modes, lasting 1 hour each: pressure support mode, neurally adjusted ventilatory assist and again pressure support ventilation
75595247|NCT01608035|Procedure|Sciatic catheter|presurgical sciatic catheter insertion
75739289|NCT00077857|Drug|capecitabine (Xeloda®)|825 mg/m^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
75739290|NCT00077857|Drug|docetaxel (Taxotere®)|75 mg/m^2 intravenous on day 1 of each 3 week cycle
75595248|NCT01608035|Procedure|Stump catheter|intraoperative placed stump catheter
75595249|NCT01601912|Drug|Atomoxetine|40 mg, 1 application
75595250|NCT01601912|Drug|Citalopram|20 mg, 1 application
75595251|NCT02489201|Drug|donafenib tosilate tablets|200mg,bid
75595252|NCT04410939|Diagnostic Test|Reverse transcription polymerase chain reaction|PCR test is performed from the oropharyngeal and nasal swab samples taken before admission to each pregnant to prevent contamination from the pregnant women hospitalized in this clinic. In addition, the same test is done before each operation and before the operation. The aim of the study is to scan these tests retrospectively and to determine the rate of positive COVID-19 cases in asymptomatic pregnant women. The results will determine the importance of the measures to be taken in the pregnant and undergoing pregnant women.
75595253|NCT01601951|Other|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
75739291|NCT01086397|Procedure|Urine sample collection|All subjects have non-invasive urine sample collection performed
75739292|NCT00545402|Drug|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
75595254|NCT01111825|Drug|Temsirolimus|"28 day treatment cycle Phase 1~Weekly intravenously (IV) on days 1, 8, 15, and 22~Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22"
75595255|NCT01111825|Drug|Neratinib|"28 day treatment cycle~• 240 mg orally daily"
75595256|NCT01608191|Behavioral|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
75739293|NCT00545402|Drug|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
75739294|NCT00545402|Drug|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
75595257|NCT01175590|Drug|Besivance|Ocular administration to affected eye for 7 days
75595258|NCT01175590|Drug|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
75739295|NCT00545402|Drug|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
75739296|NCT00545402|Drug|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
75739297|NCT03963115|Drug|Epinephrine or normal saline|epinephreine or normal saline coated syringe before drawing allergen for injection.
75739298|NCT01583023|Drug|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
75445304|NCT06004622|Other|Calgary Family Intervention Model|under two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasted about 20 minutes and was conducted by a single researcher to maintain consistency. The scheduling of these sessions took into consideration the physiological and emotional stability of the participants. If any issues or difficulties arose during the course of the sessions, they could be paused. The confidentiality and privacy of the discussion content were ensured. The intervention took place in a dedicated room within the intensive care unit, providing sufficient space and privacy.
75445305|NCT06000059|Behavioral|Radio Drama|An hour long radio drama adapted from from a previous community-led theater intervention
76057857|NCT04057846|Device|EUS guided transgastric drainage|Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
75595259|NCT01601990|Drug|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
75595260|NCT01601990|Drug|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
75595261|NCT01175473|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
75739299|NCT01583023|Device|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
75445306|NCT05998629|Device|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
75445307|NCT05998629|Other|Standard of Care laboratory procedure for measurement of sweat|a skin-interface sweat measurement using a smart-watch type device
75739300|NCT01583023|Other|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
76057858|NCT04767412|Device|aerobic exercise training, inspiratory muscle training|All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
76057859|NCT01393600|Drug|NBI-98854|12.5 mg powder in bottle once daily for 14 days
76057860|NCT01393600|Drug|NBI-98854|50 mg powder in bottle once daily for 14 days
76057861|NCT01393600|Drug|Placebo|Solution containing no active substance
76057862|NCT01432756|Behavioral|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
76057863|NCT04767568|Diagnostic Test|Blood sample|"In cohort A: Blood sample n°1 (PBMC, plasma, ctDNA) previous colonoscopy. If no cancer lesions: STOP. If cancer lesion detected : Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery.~In cohort B: Blood sample n°1 (PBMC, plasma, ctDNA) collected before surgery. Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery"
76057864|NCT04767568|Other|Tumor tissue|In each cohort, tumor tissue will be collected from the surgical specimen.
75445308|NCT05995535|Drug|LFX/PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg"
75445309|NCT05995535|Drug|LFX/PLA-PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg"
75595262|NCT01175473|Device|Pen auto-injector|
75595263|NCT01175473|Drug|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
75595264|NCT01175473|Device|Pre-filled pen injector|
75595265|NCT01175473|Drug|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
75595266|NCT01602107|Other|Pelvic Floor muscle strengthening exercises|Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
75595267|NCT01602146|Other|ultramarathon running|"blood samples before and after ultramarathon~urinary samples before and after ultramarathon~voluntary ant electrically muscular forces measuring before and after ultramarathon~Broadband ultrasound Attenuation before and after ultramarathon"
75595268|NCT01111552|Drug|Escitalopram|Escitalopram oral capsules.
75739301|NCT01583023|Device|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
75739302|NCT00976976|Drug|docetaxel, capecitabine, cisplatin|Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
75445312|NCT05995340|Device|ELAPR002f Injectable Gel|Intradermal Injections
75445313|NCT05995340|Other|Saline Control|Intradermal Injections
75595269|NCT01111552|Drug|Aripiprazole|Aripiprazole oral capsules.
75595270|NCT01111552|Drug|Placebo|Study drug matching placebo capsule.
75595271|NCT01602185|Drug|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
75445314|NCT05994287|Drug|Aspirin|The patients received aspirin in a dose of 100 mg orally daily.
75445315|NCT05994287|Drug|Ketorolac|The patients received ketorolac in a dose of 90 mg mg orally daily.
75445316|NCT05994287|Drug|Celecoxib|The patients received celecoxib in a dose of 400 mg orally daily.
75445317|NCT05992428|Drug|DA-8010 5mg|[Part 1] DA-8010 5mg + Paroxetine 20mg [Part 2] DA-8010 5mg + Mirabegron 50mg
75595272|NCT01602185|Drug|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
75595273|NCT01602185|Drug|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
75595274|NCT02886208|Behavioral|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
75739303|NCT00977054|Drug|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
75739304|NCT00977054|Drug|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
75739305|NCT00966524|Procedure|Endotracheal intubation|Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
76057865|NCT04767178|Drug|Ibuprofen (Sanofi, Istanbul, Turkey)|Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
76057866|NCT04767178|Drug|Paracetamol (GlaxoSmithKline, Istanbul, Turkey)|Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
76057867|NCT01432600|Drug|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
76057868|NCT01432600|Drug|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
75445318|NCT05992428|Drug|Paroxetine 20mg|[Part 1] DA-8010 5mg + Paroxetine 20mg
75445319|NCT05992428|Drug|Mirabegron 50mg|[Part 2] DA-8010 5mg + Mirabegron 50mg
75445320|NCT05991401|Drug|DA-8010 5mg|[Period 1] DA-8010 5mg [Period 2] DA-8010 5mg, Clarithromycin 500mg [Period 3] DA-8010 5mg, Rifampicin 600mg
75445321|NCT05991401|Drug|Clarithromycin 500mg|[Period 2] DA-8010 5mg, Clarithromycin 500mg
75445322|NCT05991401|Drug|Rifampicin 600mg|[Period 3] DA-8010 5mg, Rifampicin 600mg
75445323|NCT05988970|Other|Blood samples will be collected at two times before the treatment initiation:|"at 4:00 a.m.~at 10:00 a.m.~Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable)."
75445324|NCT05988762|Other|Supramaximal Walkout|Walkout set performed at 110% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
75595275|NCT05062720|Radiation|Local consolidative therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
75595276|NCT01602302|Drug|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
75595277|NCT05098171|Biological|Signal Switch Receptor Modified TIL|Adoptive transfer of 2x10^8-1x10^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
75595278|NCT02893956|Procedure|echocardiography with postural support|
75595279|NCT02893956|Procedure|echocardiography with standard condition (usual)|
75595280|NCT01602458|Procedure|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
75595281|NCT01602458|Procedure|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
75595282|NCT02893722|Drug|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
75739306|NCT00977132|Drug|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
76057869|NCT01432600|Drug|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
76057870|NCT01432444|Drug|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
75595283|NCT02893722|Drug|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
75595284|NCT01602497|Device|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
75445325|NCT05988762|Other|Submaximal Walkout|Walkout set performed at 30% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
76057871|NCT01432366|Other|SC anti-TNF|Subcutaneous (SC) anti-TNF
76057872|NCT01415440|Drug|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
76057873|NCT01415440|Drug|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
76057874|NCT04049890|Other|FAI-O|"Administration of Family Adjustment Inventory in the version Only-child"
76057875|NCT04049890|Other|FAI-S|"Administration of Family Adjustment Inventory in the version Sibling"
76057876|NCT04049890|Other|Personal Data Questionnaire|This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year
75445334|NCT05984654|Procedure|Platelet rich plasma therapy|"Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma."
75445335|NCT05984199|Biological|VCAR33|Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy
75445336|NCT05972720|Drug|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
75595285|NCT01602497|Device|sham rTMS|Patients will undergo ten session of sham rTMS.
76057877|NCT02076412|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
75887595|NCT02155868|Other|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood < 35 mmHg; mean arterial pressure < 60 mmHg; central venous pressure > 10 mmHg; cardiac index < 2.0 l/min/m2; mixed venous oxygen saturation < 60%; hemoglobin < 65 g/L during cardiopulmonary bypass or hemoglobin < 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
75739307|NCT00977132|Drug|Lenalidomide|"5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
75739308|NCT00977210|Drug|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
75887596|NCT02155868|Other|Standard treatment|Standard treatment
76057878|NCT02076412|Drug|Placebo|Placebo tablet PO bid (morning and evening)
76057879|NCT04048252|Other|Focus group creation|Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention
76057880|NCT04048252|Other|Workshop|Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
76057881|NCT01932788|Drug|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
76057882|NCT01932788|Drug|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
75887597|NCT02151890|Biological|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
75887598|NCT02151968|Procedure|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
75595286|NCT01608269|Drug|Abacavir/Lamivudine|one tablet once a day
75595287|NCT04407156|Other|acute kidney injury|AKI in COVID positive cases
76057883|NCT01414738|Radiation|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
76057884|NCT01414114|Drug|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
76057885|NCT01393444|Device|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
75445337|NCT05972720|Drug|Cyclophosphamide Monohydrate (Conditional therapy)|Lymphodepletion chemotherapy
75445338|NCT05972720|Drug|CRG-022 cells (Experimental drug)|Investigational agent
75445339|NCT05972629|Drug|SAR444836|Infusion pump, intravenous infusion (IV)
75445340|NCT05968430|Drug|lorundrostat|lorundrostat once daily for 48 weeks
75445341|NCT05968430|Drug|lorundrostat|lorundrostat once daily for 4 weeks
75445342|NCT05968430|Drug|Placebo|Placebo once daily for 4 weeks
75595288|NCT01602536|Behavioral|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
75739309|NCT00545792|Drug|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
75739310|NCT00977288|Drug|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
75739311|NCT00977288|Drug|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
75739312|NCT00977288|Drug|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
75739313|NCT00966602|Drug|VX-809|VX-809 capsule, once daily for 14 days
75739314|NCT00966602|Drug|VX-770|VX-770 tablet, once every 12 hours for 14 days
75739315|NCT00966602|Drug|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
75739316|NCT00966602|Drug|Placebo|Matching Placebo
76057886|NCT01431976|Drug|Lamictal|No comparison
76057887|NCT01413958|Drug|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
76057888|NCT01413958|Drug|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
75887599|NCT02151968|Procedure|Ultrasound-Guidance|"Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
75739317|NCT00977366|Other|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
76057889|NCT01413958|Drug|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
76057890|NCT02985502|Other|pancreatogenic diabetes|pancreatogenic diabetes
75887600|NCT02776670|Other|Propylene glycol, 0.6% eye drops|
76057891|NCT01413178|Drug|Busulfan|Test dose (32 mg/m^2) on day -9 then 130 mg/m^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
75739318|NCT00977366|Other|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
75739319|NCT00966680|Other|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
75739320|NCT00977444|Drug|kondrium|intraarticular injections once month
75739321|NCT00977444|Drug|kondrium f|intraarticular injections once month
75887601|NCT02776670|Other|Lubricant eye drops|
75887602|NCT02149862|Other|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
75887603|NCT02149940|Other|heart-failure related pharmaceutical intervention|
76057892|NCT01413178|Drug|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
75595289|NCT01602536|Behavioral|Twitter|Twitter quit-smoking group
75595290|NCT04407117|Behavioral|Lock-down and social distancing|Lock-down and social distancing during COVID-19 pandemic
75595291|NCT01602575|Behavioral|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
75739322|NCT00977444|Drug|methyl prednisolone (corticosteroid)|intraarticular injections once month
75739323|NCT04093934|Behavioral|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
75739324|NCT00966758|Procedure|Computed Tomography|1 low dose CT scan is taken
76057893|NCT01413178|Other|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
75595292|NCT01608347|Drug|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
76057894|NCT01413178|Drug|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
76057895|NCT01413178|Drug|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
76057896|NCT01413178|Procedure|Stem cell transplant|Stem cell infusion on Day 0.
76057897|NCT01799889|Drug|Entospletinib MM|Entospletinib MM tablet administered orally
76057898|NCT01799889|Drug|Entospletinib SDD|Entospletinib SDD tablet administered orally
76057899|NCT01412944|Drug|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
76057900|NCT01412944|Drug|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
75595293|NCT01608347|Drug|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
75595294|NCT04404933|Other|Treatment algorithm for OIC|Treatment Algorithm for OIC
75595295|NCT01608386|Procedure|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
75595296|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
75595297|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
75739325|NCT00966758|Procedure|Single Photon Emission Computed Tomography|1 SPECT scan is taken
75739326|NCT00977600|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
75739327|NCT00977600|Drug|Ammonul|
75739328|NCT00977600|Drug|Buphenyl|
75887604|NCT03744260|Diagnostic Test|Patients undergo ultrasound and lumbar MRI|Patients undergo ultrasound, physical therapy exam and MRI before and after the radiofrequency ablation procedure that they are getting as part of their regular care.
75887605|NCT02150018|Other|non invasive ventilation|
76057901|NCT03025906|Drug|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
75445346|NCT05953077|Behavioral|Conversational recasting|The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.
75445347|NCT05952804|Biological|Immune Globulin Infusion (Human), 10% Solution|Given IV
75595298|NCT01602770|Drug|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
75595299|NCT04405284|Other|use and exposure to disinfectants during the coronavirus pandemic|The use of disinfecting products in deep house cleaning by women during the coronavirus lockdown.
75595300|NCT01603004|Other|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
75595301|NCT04328610|Procedure|LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique|Patients will receive a lymphatic-venous anastomosis at time of their required Axillary Dissection
75595302|NCT01608464|Drug|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
75739329|NCT00966836|Drug|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
75739330|NCT00966836|Drug|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
75739331|NCT00966836|Drug|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
75739332|NCT00966836|Drug|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
75445348|NCT05952804|Biological|Anti-CD19-targeting CAR-T Cells|Given CAR-T treatment
75445349|NCT05952804|Other|Saline|Given IV
75445350|NCT05952804|Procedure|Biospecimen Collection|Undergo blood sample collection
75595303|NCT01608464|Drug|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
75595304|NCT01603160|Behavioral|Quality Improvement|"There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized."
75739333|NCT00967070|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
76057902|NCT03025906|Drug|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
75445351|NCT05952804|Other|Survey Administration|Ancillary studies
75445352|NCT05952804|Other|Electronic Health Record Review|Ancillary studies
75445353|NCT05947851|Drug|Nemtabrutinib|5 and 20 mg tablets
75445354|NCT05947851|Drug|Venetoclax|10, 50, and 100 mg tablets
75445355|NCT05947851|Biological|Rituximab|100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
75445356|NCT05944016|Drug|Dapagliflozin|Dapagliflozin (standard dose 10 mg p.o. once daily)
75445357|NCT05944016|Drug|Placebo|Placebo (standard dose p.o. once daily)
75739334|NCT00967070|Drug|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
75739335|NCT00977678|Other|open access gastroscopy|access to gastroscopy without preceding appointment
75739336|NCT00977678|Other|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
75739337|NCT00977756|Drug|Raltegravir (RAL)|400 mg twice daily (BID)
75445358|NCT05939531|Behavioral|BOUNCE Program|Intervention arm: Bone-building exercises will be incorporated into the standard post-stroke exercises, as well as Nutritional intervention consisting of individualized diet plan based on calorie requirement, high-quality protein intake, vitamin D, Calcium and micronutrients with a one-to-one virtual session.
76057903|NCT04055272|Behavioral|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
75445359|NCT05939531|Behavioral|Standard Care|Standard post-stroke care
76057904|NCT04053712|Drug|Glucagon|GlucaGen(R), Novo Nordisk, DK
76057905|NCT04053712|Device|Closed-loop system|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
75445360|NCT05938023|Drug|ATL1102 25mg|Dose and scheduled as specified in the Arm description
75445361|NCT05938023|Drug|ATL1102 50mg|Dose and scheduled as specified in the Arm description
75445362|NCT05938023|Drug|Placebo|Dose and scheduled as specified in the Arm description
75445363|NCT05937581|Drug|CSL040|IV Administration
75445364|NCT05937581|Drug|Placebo|0.9% w/v NaCI, IV Administration
75445365|NCT05935358|Drug|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
75445366|NCT05933577|Biological|V940|IM injection
75445367|NCT05933577|Biological|Pembrolizumab|IV infusion
75445368|NCT05933577|Other|Placebo|IM injection
75445369|NCT05933265|Drug|LP-184|LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.
75445370|NCT05932862|Drug|XL309 (ISM3091)|XL309 will be administered orally once daily.
75445371|NCT05930431|Behavioral|Physical activity variety intervention|The counseling in the variety condition will serve many purposes. The first session will concentrate on informing participants on the importance of having variety in their physical activity routine and how to access the variety of physical activities available to them. The variety condition will be instructed to complete at least three different HIIT workouts per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting variety in physical activity but also to support participants' basic psychological needs.
75445372|NCT05930431|Behavioral|Physical activity consistency comparison condition|The counseling in the consistency condition will serve many purposes. The first session will concentrate on informing participants the importance of having consistency in their physical activity routine and how to access the HIIT workout available to them. The consistency condition will be instructed to complete the provided HIIT workout three times per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting consistency in physical activity but also to support participants' basic psychological needs.
75739338|NCT00977756|Drug|Atazanavir (ATV)|300 mg daily
75739339|NCT00977756|Drug|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
75739340|NCT00977756|Drug|Tenofovir (TDF)|300 mg daily
75739341|NCT00977756|Drug|Etravirine (ETV)|200 mg BID
75739342|NCT00977756|Drug|Darunavir (DRV)|Dosing by weight
75445378|NCT05915039|Other|Computer Assisted Learning (CAL) Module|The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.
75445379|NCT05913388|Drug|GB1211|Administered orally twice daily at 400mg.
75445380|NCT05913388|Drug|Pembrolizumab|Administered at a fixed dose of 200 mg every 3 weeks intravenously.
75445381|NCT05913388|Drug|Placebo|Administered orally twice daily at 400mg.
75595305|NCT04404699|Diagnostic Test|Stimulation TcPO2 test|"During measurement of TcPO2 in various angiosomes the stimulation test will be performed. We modify the Ratschow test (elevation of the lower limbs, rhythmic flexion and extension in talocrural joints for 2 minutes, then return to horizontal position). TcPO2 is measured continuously. Depending on the type of detected flows by DUS in the evaluated arteries supplying the relevant angiosome, in which TcPO2 values are measured, the patients and their angiosomes will be divided into 2 baseline groups - group M with monophasic flows or arterial obliterations and group T with triphasic flows.~We will compare macrocirculation parameters-systolic pressure on dorsalis pedis artery (DPA), posterior tibial artery (PTA) and their doppler indexes. The resting TcPO2, the minimal TcPO2 found during the stimulation test, their delta (resting TcPO2 - minimal TcPO2) and the percentage decrease in TcPO2 will be compared between the study groups, as well as the duration of TcPO2 recovery."
75595306|NCT01608503|Procedure|lung deflation|lung was deflated during respiration cycle
75595307|NCT01608503|Procedure|lung inflation|lung was inflated during respiratory cycle
75595308|NCT04404270|Diagnostic Test|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
75739343|NCT00977756|Drug|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
75739344|NCT00977756|Drug|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
75739345|NCT00981344|Other|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
75887606|NCT02150096|Other|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
75616320|NCT05337904|Device|Off-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is off."
75887607|NCT02150096|Other|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
75887608|NCT02150096|Other|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
75739346|NCT04938206|Procedure|The Clinical Decision Rule|The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
75739347|NCT00981500|Procedure|gastric bypass|Roux-en-Y gastric bypass
75739348|NCT00981500|Procedure|gastric banding|laparoscopic adjustable gastric banding
76057906|NCT01798485|Drug|Docetaxel|Docetaxel, 75 mg/m^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
76057907|NCT01798485|Drug|Ganetespib|Ganetespib, 150 mg/m^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
76057908|NCT01767597|Other|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
75616321|NCT02854137|Drug|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
75616322|NCT02854137|Drug|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
75616323|NCT00630981|Behavioral|Psychotherapy|Specific psychotherapy for dissociative disorders
75739349|NCT00981500|Procedure|sleeve gastrectomy|vertical sleeve gastrectomy
75739350|NCT00967148|Drug|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
75887609|NCT04906226|Behavioral|Self-foot massage|The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
75887610|NCT02150174|Behavioral|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
75739351|NCT00981734|Other|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
75887611|NCT02156024|Drug|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
75887612|NCT02150252|Drug|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
75616324|NCT00630981|Drug|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
75887613|NCT02152202|Other|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
75887614|NCT02152202|Other|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
75887615|NCT02152280|Drug|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
75887616|NCT02152280|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
75445385|NCT05905783|Drug|Placebo|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
75445386|NCT05905783|Drug|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
75616325|NCT05243134|Other|Collect the clinical data|We analyze the influence of the anatomic deformity on the clinical efficacy at the follow-up.
75595309|NCT04404270|Behavioral|Questionnaire|"Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3).~The questionnaire includes:~medical data (height, weight, smoking, history of intense stress);~socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.);~clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19;~use of care, hospitalization, work stoppage in the last 3 months;~contact with people who are symptomatic or proven COVID-19."
75595310|NCT04404270|Diagnostic Test|Anti-SARS-CoV2 serological controls and serum neutralization|Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
75595311|NCT01608542|Drug|Fostamatinib 100mg|oral tablet
75445388|NCT05902338|Other|Music|"L400 Over Ear Music Headset Glowing Cat Ear Headphones 7 branded headphones will be used for musical measurements (70-80 bpm music)."
75595312|NCT01608542|Drug|Fostamatinib 200mg|oral tablet
75739352|NCT04007588|Drug|Nivolumab|Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
75739353|NCT04007588|Drug|BMS-986205|BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
75739354|NCT04007588|Drug|Ipilimumab|Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
75739355|NCT00977912|Dietary Supplement|Probiotic supplementation|one capsule containing probiotics per day added to milk
76057909|NCT01767597|Other|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
75445389|NCT05900154|Biological|RSVpreF 120 µg|RSVpreF standard dose level
75445390|NCT05900154|Biological|RSVpreF 60 µg|RSVpreF low dose level
75739356|NCT00977912|Dietary Supplement|Milk containing placebo|one capsule containing placebo per day added to milk
75887617|NCT02255084|Behavioral|Group 1 remove self sample kit at gp consulting room or perform pap smear|"Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.~Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
76057910|NCT01767519|Biological|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
75445391|NCT05900154|Other|placebo|Placebo
75595313|NCT01608698|Drug|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
75595314|NCT01608698|Drug|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
75739357|NCT00967304|Other|"Application of theMen continue and HER DOO2 rule"|"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."
75739358|NCT00978146|Drug|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
75739359|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
75739360|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
75739361|NCT00982046|Device|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
75739362|NCT00982046|Device|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
75445392|NCT05899127|Drug|Lidocaine|1.5mg/kg induction，1.5 mg/kg/h maintenance
75445393|NCT05899127|Drug|0.9%NaCl|2mg/kg induction，1.5 mg/kg/h maintenance
75739363|NCT00982046|Device|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
75739364|NCT00982046|Device|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
75739365|NCT00982046|Device|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
75739366|NCT00982046|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
75887618|NCT02255084|Behavioral|Group 2 perform self sample at home or pap smear|"Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
75739367|NCT00967382|Drug|dalteparin sodium|"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
75887619|NCT02150330|Drug|Dehydroepiandrosterone (DHEAS)|
75887620|NCT02255162|Drug|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
75887621|NCT02255162|Genetic|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
75739368|NCT00982124|Drug|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
75739369|NCT04007354|Other|Ventilation method|Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.
75739370|NCT00982202|Drug|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for ~18months
75739371|NCT00982202|Drug|Placebo|1 to 3 tablets daily for ~18 months
75739372|NCT00967460|Behavioral|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
75739373|NCT00978224|Dietary Supplement|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
75739374|NCT00978224|Dietary Supplement|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
75739375|NCT00967538|Drug|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
75739376|NCT00978302|Drug|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
75887622|NCT02255162|Drug|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
75887623|NCT02152436|Other|Simulation - based curriculum|Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
75887624|NCT02152514|Drug|Intrathecal Morphine/Sufentanil|
75887625|NCT02152514|Device|PCA|
75887626|NCT02261090|Drug|Formulation B: Pramipexole Slow release (SR) tablet|
75887627|NCT02261090|Drug|Formulation C: Pramipexole Slow release tablet|
75887628|NCT02261090|Drug|Formulation D: Pramipexole Slow release tablet|
75887629|NCT02261090|Drug|Formulation E: Pramipexole Slow release tablet|
75739377|NCT00978302|Drug|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
75739378|NCT00978302|Drug|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
75887630|NCT02261090|Drug|Formulation F: Pramipexole Slow release tablet|
75887631|NCT02261090|Drug|Formulation G: Pramipexole Slow release tablet|
75887632|NCT02261090|Drug|Formulation H: Pramipexole Slow release tablet|
75887633|NCT02261090|Drug|Pramipexole immediate release (IR) tablets|
75887634|NCT03542396|Behavioral|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
75739379|NCT00978302|Drug|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
75739380|NCT00978302|Drug|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
75739381|NCT00978302|Drug|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
75739382|NCT00978302|Drug|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
75739383|NCT00984776|Other|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
75739384|NCT00978536|Other|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
75739385|NCT00978614|Drug|Neramexane|"Dosage form:~25 mg immediate release [IR] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"
75739386|NCT00982358|Drug|Valsartan|
75739387|NCT00982358|Other|Placebo|
75739388|NCT00982436|Drug|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
75739389|NCT00982436|Radiation|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
75739390|NCT00982436|Drug|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
75445398|NCT05897593|Device|GlenXRose Augmented Reality Acquired Brian Injury Therapies|Rehabilitation therapies for ABI have been developed for augmented reality implementation. These include various games to interact within an augmented environment while conducting rehabilitation therapy.
75445399|NCT05897190|Biological|SARS-CoV-2 mRNA vaccine (RBMRNA-405)|Dose A
75739391|NCT00982748|Behavioral|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
76057911|NCT01767519|Drug|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
75445400|NCT05897190|Biological|CoronaVac®|Dose B
75445401|NCT05896566|Drug|Giredestrant|Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
75445402|NCT05896566|Drug|Triptorelin|Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
75445403|NCT05896566|Drug|Anastrozole|Anastrozole: 1 mg daily, PO from day 1 until the day of re-biopsy/surgery.
75445404|NCT05894681|Other|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS
75445405|NCT05890313|Diagnostic Test|Mini Mental State Examination|MMSE is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is of three to four years of schooling. It is validated in the general Portuguese population and can discriminate normal cognition from dementia.
75445406|NCT05890313|Diagnostic Test|Montreal Cognitive Assessment|MoCA is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is, at least, of four years of schooling. It is validated in general Portuguese population and can discriminate MCI from dementia.
75445407|NCT05890313|Device|Brain on Track (version BOT.0.0.0 03.03.2023)|Brain on Track is a class I web-based software medical device, accessible on most platforms, including desktops and laptops. It is designed to allow periodic self-administered cognitive tests to be performed, enabling a cognitive assessment and continuous monitoring of the cognitive state of the patient remotely. It is based on the classic tests of neuropsychological assessment and allows assessing the main areas of cognition through a test lasting approximately 22 minutes. The stimuli that integrate each subtest are randomized between sessions, which reduces the effect of learning and allows the accomplishment of serial assessments.The test is available in three versions, adapted to different levels of schooling: 1-4 years, 5-9 years and 10+ years. The performance in each test is compared with normative population data and performance over time. For each test performed, Brain on Track presents a cumulative risk score for the presence of cognitive impairment.
75739392|NCT00982826|Drug|ABT-072|See Arms information for a detailed description.
75739393|NCT00982826|Drug|Placebo|See Arms information for a detailed description.
75739394|NCT00978692|Device|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
75739395|NCT00978692|Device|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
75739396|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
75739397|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
75739398|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
75739399|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
75739400|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
75739401|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
75739402|NCT00984854|Drug|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
75739403|NCT00978770|Drug|systemic chemotherapy|
75739404|NCT00978770|Procedure|diffusion-weighted magnetic resonance imaging|
76057912|NCT01767519|Drug|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
76057913|NCT01767519|Drug|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
76057914|NCT01797783|Device|Nelfilcon A multifocal contact lens with comfort additive|
76057915|NCT01797783|Device|Nelfilcon A multifocal contact lens|
75445412|NCT05878184|Drug|SC291|SC291 is an allogeneic CAR-T cell therapy
75445413|NCT05873686|Drug|NXP900|NXP900 is an orally administered SRC/YES1 kinase inhibitor
75445414|NCT05870800|Drug|Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2|Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPEOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)
75445415|NCT05870800|Drug|Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
76057916|NCT01766817|Drug|BMS-986020|
75445416|NCT05870800|Drug|Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
75739405|NCT00978770|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
75739406|NCT00978770|Procedure|magnetic resonance spectroscopic imaging|
75739407|NCT00978770|Procedure|neoadjuvant therapy|
75739408|NCT00545168|Drug|Spinosad|10 minute topical application of product, followed by a complete rinse off.
76057917|NCT01766817|Drug|Placebo matching with BMS-986020|
75445417|NCT05870787|Diagnostic Test|Swede score colposcopy|New colposcopy method: with application of acetic acid, supplemented with a systematic scoringsystem (Swede score) including Lugols iodine, and collection of cervical biopsies.
75445418|NCT05856331|Drug|INBRX-101|A1PI, Recombinant, Bivalent Fc Fusion Protein
75445419|NCT05856331|Drug|Zemaira|Alpha1-Proteinase Inhibitor (Human)
75739409|NCT00545168|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
75739410|NCT00545168|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
75739411|NCT00982904|Drug|Fexinidazole/Placebo|
75739412|NCT04869020|Device|Otoband|Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
75739413|NCT04869020|Device|Sham A|Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
75739414|NCT04869020|Device|Sham B|Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
75739415|NCT00984932|Drug|Rosuvastatin|40 mg of rosuvastatin daily
75739416|NCT00983138|Drug|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
75739417|NCT00544544|Drug|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
75739418|NCT05015270|Diagnostic Test|Medications or percutaneous coronary intervention|In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed
76057918|NCT01797705|Device|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
75595315|NCT04133805|Dietary Supplement|viscous fiber|ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin
75595316|NCT01603199|Dietary Supplement|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
75595317|NCT01603238|Drug|[14C]-LC15-0444|A single oral administration of [14C]-LC15-0444 50 mg, containing 4.9 MBq [14C]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
75595318|NCT01175083|Biological|GSK1024850A (Synflorix)|2, 3 or 4 intramuscular injection
75739419|NCT04810364|Radiation|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
75739420|NCT00979160|Drug|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
75739421|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
75739422|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
75739423|NCT00979316|Drug|Placebo|Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
75739424|NCT00979316|Drug|Moxifloxacin|Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
75887635|NCT02152592|Drug|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
75887636|NCT02152592|Drug|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
75595319|NCT01175083|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
75595320|NCT01175083|Biological|Polio Sabin|4 oral doses
75595321|NCT02489708|Behavioral|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
75595322|NCT04403061|Diagnostic Test|Cytokines measurement|Quantification of plasma cytokine levels of human GM-CSF, IFN-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNF-α using multiplex technol-ogy (quantitative measure).
75739425|NCT00983450|Other|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
75739426|NCT00983450|Other|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity [Celnik et al., 2008]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
75739427|NCT00983684|Device|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
75887637|NCT02152748|Genetic|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
75887638|NCT03543332|Diagnostic Test|Measures of physical activity and kinesiophobia|Groups will be compared regarding kinesiophobia with TSK heart.
75887639|NCT01307423|Drug|Apremilast 20mg|Apremilast 20mg twice daily, orally
75887640|NCT01307423|Drug|Apremilast 30mg|Apremilast 30mg twice daily, orally
75887641|NCT01307423|Drug|Placebo|Placebo
75887642|NCT04849052|Behavioral|MASTERY|In MASTERY, participants will have interactive, two-way text message 'sessions' (5-10 minutes of two-way text communication with an automated text-message program) once weekly for 12 weeks. Furthermore, study trainers will conduct 4 brief calls with participants (Weeks 1, 4, 7, and 12) to introduce the program, assess progress, answer questions, and provide support.
75887643|NCT04849052|Behavioral|Attentional Control|Participants in the control condition will also receive text messages once per week. To ensure time matching, the program will have 4 phone check-ins (on physical activity) as in MASTERY.
75887644|NCT03542318|Other|Pulmonary Rehabilitation|A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
75595323|NCT04403061|Diagnostic Test|Cellular response|SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).
75595324|NCT04403061|Diagnostic Test|TLRs activation measurement|After specific cell activation through TLR7/8 receptors, such as resiquimod, ORN R-0002, ORN R-0006, ORN R-1263, ORN R-2336, and controls as Poly (I:C), the release of IFNa, IFNg, TNFa, IL12, and IL6 will be analyzed (quantitative measure).
75445420|NCT05855603|Procedure|Cardioneuroablation|"Ganglionated plexi will be localized using an empirical anatomical approach and/or a fractionated electrogram-based strategy.~Point-by-point ablation will be performed using radiofrequency energy and an irrigated tip contact force sensing ablation catheter in a power control mode (35-50 W; AI, 350-500; LSI, 4.5-5.5). The right superior GP (RSGP), left superior GP (LSGP) and posterior left GP (PMLGP) will be targeted during CNA. Radiofrequency applications in other GPs will be left at the discretion of the operator.~At the end of the procedure, another EP study and atropine test will be performed. Clinical endpoints for completion of the CNA will be: 1) a HR increase >20% if the CNA was performed under general anesthesia/deep sedation; 2) improved electrophysiological parameters; 3) significant reduction in atropine response (HR increase <10% after atropine); and 4) in case of using extracardiac vagal stimulation, lack of response."
75595325|NCT04403061|Diagnostic Test|KIR phenotype evaluation|Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.
75595326|NCT02881333|Genetic|Blood samples|
75595327|NCT04310254|Procedure|EDTA and CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
75595328|NCT04310254|Procedure|EDTA Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
75595329|NCT04310254|Procedure|CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
75595330|NCT02480972|Procedure|magnetic resonance imaging|"multiparametric MRI as follows:~diffusion weighted imaging using multiple b-values~Fat quantification sequence~perfusion MRI using ECCM agent~MR elastography~------------------------------------~routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)"
75595331|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
75595332|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
75595333|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
75595334|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
75595335|NCT01608737|Drug|BI 201335|BI 201335 once daily low dose for 24 weeks
75739428|NCT00983684|Radiation|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
75739429|NCT00983840|Other|Family Eats|8-session web-based program on healthy eating for African American families
75739430|NCT00983996|Drug|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
75445421|NCT05855603|Device|Permanent pacemaker therapy|All patients in the pacemaker group will receive a dual-chamber pacemaker that has the ability to be programmed in the DDD-CLS algorithm mode (or failing this, a dual-chamber pacemaker with RDR algorithm).
75739431|NCT00983996|Drug|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
75739432|NCT00984074|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
75595336|NCT02886130|Dietary Supplement|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
75595337|NCT02886130|Dietary Supplement|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
75595338|NCT02881606|Device|Naso-alveolar molding (NAM)|
75595339|NCT02881606|Device|Computer aided design NAM (CAD/NAM)|
75595340|NCT01608776|Device|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
75739433|NCT00984074|Procedure|diffusion tensor imaging|
75739434|NCT00984074|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
75739435|NCT00984074|Procedure|functional magnetic resonance imaging|
75739436|NCT00984074|Radiation|intensity-modulated radiation therapy|
75739437|NCT00984074|Radiation|radiation therapy treatment planning/simulation|
75739438|NCT00985244|Drug|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
75887646|NCT02156336|Drug|Ranolazine|Oral administration, BID; for a maximum of 51 days.
75739439|NCT00985244|Drug|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
75739440|NCT00979472|Drug|Solifenacin|oral
75739441|NCT04007120|Drug|RVT-1601|Inhaled RVT-1601 administered once daily over two days
75739442|NCT00984152|Drug|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
75595341|NCT01608776|Other|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
75595342|NCT04402554|Behavioral|Cannabis questionnaire|The effectiveness and use of cannabis in the management of chronic pain has been well known for many years, but has so far been illegal and therefore largely unacknowledged. We hypothesize that the use of cannabis in this population of patients with chronic joint or spinal pain is not anecdotal and responds to a need to further improve the overall management of patients. The objective of our anonymous questionnaire is to estimate the prevalence of cannabis use in patients with chronic inflammatory rheumatism.
75739443|NCT00984152|Drug|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
75739444|NCT00985322|Drug|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
75739445|NCT00985322|Drug|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
75445422|NCT05854784|Drug|Afamelanotide 16 MG|Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.
75739446|NCT00984230|Other|BSF|feeding amount according to individual baby need
75739447|NCT00984230|Other|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
75739448|NCT00984230|Other|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
75595343|NCT01111474|Other|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval) at the cervical region of the sensitive tooth
75739449|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
75887647|NCT02156336|Drug|Placebo|Oral administration, BID; for a maximum of 51 days.
75887648|NCT03542240|Dietary Supplement|Curcumin|500 milligram daily supplement
75887649|NCT02778074|Behavioral|Internet cognitive behavioural therapy|A nine-week tailored I-CBT program for patients with CVD. The CBT program consists of the components of psychoeducation, relaxation, problem-solving and behavioural activation.
76057919|NCT01797081|Biological|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
75595344|NCT01111474|Radiation|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1Joule/cm^2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (795nm).
75616326|NCT02854371|Drug|gadoxetic acid enhanced liver MRI|"Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution."
75616327|NCT02854371|Drug|ICG R15|ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
75616328|NCT02845180|Procedure|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
75616329|NCT02845414|Drug|CD133KDEL (dCD133KDEL)|Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
75616330|NCT02845492|Other|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
75616331|NCT02845492|Other|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
75616332|NCT00952341|Drug|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
75616333|NCT00952341|Drug|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
75616334|NCT00952341|Drug|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
75616335|NCT00952341|Drug|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
75616336|NCT00952341|Drug|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
75616337|NCT02845024|Drug|Doxycycline Group|Oral doxycycline 100mg was taken within 15 days
75616338|NCT02845024|Drug|placebo Group|Oral placebo was taken within 15 days
75616339|NCT05242588|Biological|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
75616340|NCT05242588|Biological|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
75616341|NCT02852733|Other|end-of-life emergencies' management|
75616342|NCT02853903|Biological|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
75616343|NCT04269525|Biological|UC-MSCs|After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
75616344|NCT05242120|Other|Survey to access the impact of COVID 19 on anesthesia residency|This is a cross-sectional study using an online survey will be conducted on 75 anesthesia residents in Cairo University hospitals. Invitations were sent to residents' groups on WhatsApp. Study objectives were clearly explained at the beginning of the survey, and the participants were encouraged to roll out the survey to as many physicians as possible. This survey contains 62-question, divided into four main sections
75616345|NCT00602277|Other|Laboratory Biomarker Analysis|Correlative studies
75616346|NCT00602277|Biological|Wild-type Reovirus|
75616347|NCT05241964|Biological|PRP|4~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.
75739450|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
75739451|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
75595345|NCT01608932|Procedure|Telemonitoring for frail patients with chronic diseases|"Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms."
75739452|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
75445429|NCT05842967|Biological|RSVpreF|120-µg
75445430|NCT05842967|Other|Placebo|Placebo
75445431|NCT05837767|Radiation|Stereotactic body radiotherapy|The primary site requiring palliative radiotherapy will receive conventional SBRT dosing of SBRT (or an alternate standard-of-care schedule).
75595346|NCT01603433|Device|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
75739453|NCT00984386|Drug|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
75739454|NCT00984464|Biological|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
75887650|NCT02778074|Behavioral|Moderated Discussion Forum|Participants will be allocated to an internet moderated discussion forum during 9 weeks. Patients will discuss issues related to cardiovascular disease. A new topic will be discussed every week. After 9 weeks, those in the moderated discussion forum will be offered to perform the I-CBT program.
75445432|NCT05837767|Radiation|Lattice Radiation Therapy|A second metastatic site (GTV volume at least 100 cc) will receive elective palliation with a lattice RT pattern (LRT).
75445433|NCT05832281|Drug|Purysis CBD|Participants will receive Purysis, or synthetic CBD, which will be compared to placebo
75445434|NCT05832281|Drug|Placebo|Placebo for Purysis
75739455|NCT00984464|Drug|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
75739456|NCT00984464|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
75739457|NCT00988130|Other|laboratory biomarker analysis|
75739458|NCT00988130|Other|questionnaire administration|
75739459|NCT00988130|Procedure|assessment of therapy complications|
75739460|NCT00988130|Procedure|high-intensity focused ultrasound ablation|
75739461|NCT00988130|Procedure|quality-of-life assessment|
75887651|NCT00911183|Biological|filgrastim|Given subcutaneously
75887652|NCT00911183|Biological|pegfilgrastim|Given subcutaneously
75887653|NCT00911183|Biological|rituximab|Given IV
75887654|NCT00911183|Drug|cyclophosphamide|Given IV
75887655|NCT00911183|Drug|liposome-encapsulated doxorubicin citrate|Given IV
75887656|NCT00911183|Drug|prednisone|Given orally
75445435|NCT05831579|Radiation|Proton GRID Radiotherapy|The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
75445436|NCT05828511|Drug|Linvoseltamab|Linvoseltamab will be administered by intravenous (IV) infusion
75445437|NCT05826353|Drug|Ripasudil|K-321 ophthalmic solution
75445438|NCT05826353|Drug|Placebo|Placebo ophthalmic solution
75445439|NCT05824013|Diagnostic Test|thromboelastography (TEG®6s)|blood samples for conventional coagulation test were obtained in vacutainer tubes from an arterial line. Two blood citrate samples (3 ml, sodium citrate solution, Vacuette® Blood Tubes) were also collected for the laboratory conventional coagulation tests (aPTT, INR, D-dimer levels, Antithrombin III) and TEG®6s assessment. The TEG parameters include reaction time (R), clot formation time (K), angle or α (K angle), maximum amplitude (MA), and amplitude at 30 minutes (LY30)
75445440|NCT05823974|Biological|Flu mRNA|Different formulations of Flu mRNA (GSK4382276A) study intervention is administered intramuscularly in the non-dominant upper deltoid to YA and OA participants in Phase 1 and Phase 2, at Day 1.
75739462|NCT00985478|Drug|SLV342|25 mg once daily - Maximal Tolerated Dose
75739463|NCT00985478|Drug|placebo|matching placebo
75739464|NCT00988286|Procedure|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
75739465|NCT05593250|Drug|SHR-1905|subcutaneous
75739466|NCT05593250|Drug|placebo|subcutaneous ,placebo
75887657|NCT00911183|Drug|vincristine sulfate|Given IV
75887658|NCT05414435|Behavioral|Reading of informed consent form|Patients that adequately read informed consent forms
75887659|NCT05056805|Other|Aerobic Exercise|Receive aerobic exercise encouragement
75887660|NCT05056805|Other|Dietary Intervention|Consume high protein snack/meal/shake
75595347|NCT01603511|Device|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
76057920|NCT01797081|Biological|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
76057921|NCT01797081|Other|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
75739467|NCT04454372|Other|demographic and clinical data obtained from hospital's electronic medical record.|This retrospective observational study. . Demographic and severity data will include age, sex, SAPS 3 and SOFA scores at admission, nutritional risk determined by NRS-2002 and commodities. Clinical and laboratory data on arrival at the ICU including PaO2 / FIO2, blood count and PCR D-dimer, ferritin, fibrinogen, DHL. Drug interventions including use of hydroxychloroquine, corticosteroids, heparin, tocilizumab. Characteristics of invasive and non-invasive respiratory support, use of prone position and ECMO and vasoactive drugs. The main complications, acute kidney injury requiring renal replacement therapy, secondary infectious complications will be documented as well as the outcomes.
75739468|NCT00985556|Drug|capecitabine|Given orally
75445441|NCT05823974|Combination Product|Control 1|Control 1 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control group from Phase 1, at Day 1 and to participants in Control YA group from Phase 2, at Day 1.
75445442|NCT05823974|Combination Product|Control 2|Control 2 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control OA group from Phase 2, at Day 1.
75445443|NCT05819424|Dietary Supplement|Yeast Fermentate (EpiCor)|"Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding"
75739469|NCT00985556|Drug|oxaliplatin|Given IV
75739470|NCT00985556|Drug|tegafur-gimeracil-oteracil potassium|Given orally
75739471|NCT04780490|Other|liberal fluid management|10 ml/ kg/ hr Ringer's lactate solution
75739472|NCT04780490|Other|restrictive fluid management|2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion
75739473|NCT05542160|Dietary Supplement|Pumpkin seed extract (IRK-19)|Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
75445444|NCT05818930|Diagnostic Test|REMI|Diagnostic monitoring
75739474|NCT04445246|Drug|Inhaled ILOPROST|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
75739475|NCT00541346|Drug|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
75739476|NCT00988520|Drug|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
75739477|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
75595348|NCT04400955|Diagnostic Test|Audiometry tablet diagnostic tool and web-based test|as above
75739478|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
75739479|NCT00988520|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
75739480|NCT00988520|Drug|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
75887661|NCT05056805|Other|Nutritional Intervention|Receive nutritional consultation and guidelines
75595349|NCT01603550|Other|Sleep Deprivation|Sleep Deprivation
75595350|NCT01603550|Other|Energy Restriction|Energy Restriction
75595351|NCT04399590|Other|Interficial Intelligence|Interficial Intelligence
76057922|NCT01794117|Drug|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
76057923|NCT01766037|Device|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
76057924|NCT01766037|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
75445445|NCT05817890|Drug|Fadraciclib|Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-CYC065 Following a Single Oral Dose in Healthy Male Subjects
75445446|NCT05814666|Drug|Danvatirsen|Danvatirsen is a STAT3 targeting drug.
75445447|NCT05814666|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
75739481|NCT00985634|Device|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
75739482|NCT00985634|Device|Control|Vessel loops
75739483|NCT00985868|Drug|multikinase inhibitor AT9283|
75739484|NCT00985868|Other|enzyme-linked immunosorbent assay|
75595352|NCT01603667|Drug|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
75739485|NCT00985868|Other|immunohistochemistry staining method|
75739486|NCT00985868|Other|laboratory biomarker analysis|
75739487|NCT00985868|Other|pharmacological study|
75739488|NCT05498090|Drug|Fenofibrate 145 mg|Fenofibrate 145 mg PO daily for 4 weeks
75739489|NCT00077623|Drug|epoetin alfa or beta|iv 3 times weekly, as prescribed
75739490|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
75739491|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
75739492|NCT00541034|Biological|rituximab|
75445454|NCT05804838|Other|Mindfulness stress reduction program group|Conscious Awareness Based Stress Reduction program will be applied to women in this group, which will last for 8 weeks. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Psychological Well-Being Scale, Beck Depression Scale, Prenatal Attachment Scale and Conscious Awareness Scale will be administered to the pregnant women who make up the intervention group before the implementation of the Mindfulness-Based Stress Reduction program. The intervention group will receive 1 session per week. Each session will last 80 minutes. After completing the 8-week MBSR program, data collection forms will be re-applied to the pregnant women in the intervention group and posttest-1 measurements will be made. After the posttest-1 measurements, the pregnants in the intervention group will be given posttest-2 measurements of the pregnants in the intervention group, 1 month after the measurements.
75445455|NCT05804383|Drug|BMS-984923|Capsules
75445456|NCT05804383|Drug|Placebo|Capsules
75445457|NCT05803603|Behavioral|Stipend and Social Work Supports|Same as arm description
75595353|NCT01603667|Drug|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
75739493|NCT00541034|Drug|cyclophosphamide|
75739494|NCT00541034|Drug|pentostatin|
75739495|NCT00986024|Behavioral|aerobic exercise|carried out 3 times per week for 12 weeks
75739496|NCT00986024|Behavioral|strength training|carried out 3 times per week for 12 weeks
75739497|NCT01090375|Other|Exercise|
75739498|NCT01090375|Other|Non Exercise|
75739499|NCT00540644|Drug|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
75739500|NCT00540644|Drug|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
75739501|NCT00540644|Drug|Prednisone|50 mg p.o. Q.O.D.
75739502|NCT05450900|Drug|Choriogonadotropin Alpha|drug, active
75739503|NCT05450900|Dietary Supplement|biotin|supplement, oral
75739504|NCT05450900|Other|Microcellulose filler|supplement, oral
75739505|NCT04004858|Radiation|External beam radiation therapy|Patient will receive 60Gy in 20 fractions as per standard practice
75739506|NCT00988754|Behavioral|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
75739507|NCT00988910|Drug|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
75739508|NCT00988910|Drug|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
75739509|NCT00986336|Drug|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
75739510|NCT00986336|Drug|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
75739511|NCT00986336|Drug|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
75739512|NCT00986336|Drug|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
75739513|NCT00989222|Procedure|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
75739514|NCT00989222|Procedure|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
75445462|NCT05788432|Device|Sequent Please Neo|Patients in whom treatment with (Sequent Please Neo) has been attempted
75739515|NCT00989300|Drug|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
75445464|NCT05781295|Device|TaurolockTM|The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.
75445465|NCT05781295|Device|Physiological serum|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
75445466|NCT05781152|Biological|infliximab, adalimumab|Anti-TNF therapy guided by therapeutic drug monitoring
75739516|NCT00989300|Drug|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
75739517|NCT00989300|Other|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
75739518|NCT04005014|Other|Myopia prediction algorithm|Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
75595354|NCT01603745|Drug|Zoely|1 pill every day
75595355|NCT01603745|Drug|Yasmin|1 pill every day
75595356|NCT02691585|Other|Music Intervention|A raga will be played for 10 minutes & data collected.
75595357|NCT01174264|Other|Pharmacological Study|Correlative studies
75595358|NCT01174264|Drug|Vismodegib|Given PO
75595359|NCT01603784|Behavioral|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at ~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
75739519|NCT03437720|Drug|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
75739520|NCT03437720|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
75739521|NCT03393182|Procedure|TLDG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
75739522|NCT03393182|Procedure|LADG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
75739523|NCT04005950|Device|Scalpel Bougie technique|ScalpelCric Set
75887662|NCT05056805|Other|Quality-of-Life Assessment|Ancillary studies
75887663|NCT05056805|Other|Questionnaire Administration|Ancillary studies
75739524|NCT04005950|Device|modified Scalpel Bougie technique|ScalpelCric Set plus speculum
75739525|NCT00986414|Drug|AFQ056|
75739526|NCT00986414|Drug|AFQ056|
75739527|NCT00986414|Drug|AFQ056|
75739528|NCT00986414|Drug|AFQ056|
75739529|NCT00986414|Drug|AFQ056|
75739530|NCT00986414|Drug|Placebo|
75739531|NCT05712668|Behavioral|Preoperative counseling|Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
75739532|NCT05712668|Behavioral|Asynchronous telemedicine|An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
75887664|NCT05056805|Other|Resistance Training|Complete strengthening exercise
75739533|NCT01563614|Radiation|Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
75445470|NCT05777486|Behavioral|TikTok Ads - With Food|TikTok posts from influencers promoting food.
75445471|NCT05777486|Behavioral|TikTok Ads - Without Food|TikTok posts from influencers who are not promoting food.
75739534|NCT01563614|Drug|Lomustine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
75739535|NCT01563614|Drug|Liposomal cytarabine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
75739536|NCT00543296|Drug|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
75739537|NCT00543140|Device|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
75739538|NCT00543062|Drug|Inhaled placebo|Inhaled Staccato placebo (0 mg)
75739539|NCT00543062|Drug|Oral placebo|Oral placebo (identical to 400 mg moxifloxacin)
75739540|NCT00543062|Drug|Inhaled prochlorperazine 5 mg|Staccato prochlorperazine 5 mg, single dose
75739541|NCT00543062|Drug|Inhaled prochlorperazine 10 mg|Inhaled prochlorperazine 10 mg, single dose
75445473|NCT05771428|Drug|ABBV-552|Oral Capsule
75739542|NCT00543062|Drug|Oral moxifloxacin|Oral moxifloxacin 400 mg, si/ngle dose
75739543|NCT05235074|Biological|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
75739544|NCT03911960|Behavioral|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch
75445474|NCT05771428|Drug|Placebo for ABBV-552|Oral Capsule
75739545|NCT03911960|Behavioral|Enhanced Usual Care|2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
75739546|NCT05222594|Other|Behavioral tasks during intracranial monitoring|Participants will listen to sentences and stories while neural data are recorded through electrodes placed for clinical purposes.
75739547|NCT04005092|Device|hCPAP versus HFNC|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
75739548|NCT04004624|Device|Ablation|Cardiac Ablation
75739549|NCT03360578|Device|Garmin|A commercial grade health wearable
75739550|NCT04006574|Other|Exercises|Core stabilization
75739551|NCT05192720|Dietary Supplement|Andosan|See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.
75739552|NCT05192720|Dietary Supplement|Placebo|drinking water with food colour
75445475|NCT05770895|Biological|GS-2829|Administered intramuscularly
75445476|NCT05770895|Biological|GS-6779|Administered intramuscularly
75445477|NCT05770895|Biological|Placebo for GS-2829|Administered intramuscularly
75445478|NCT05770895|Biological|Placebo for GS-6779|Administered intramuscularly
75739553|NCT04006184|Other|Chart review|Retrospective review of medical records at a single site with six physicians
75739554|NCT00986804|Drug|Decitabine|
75739555|NCT05712122|Procedure|stellate block|stellate blockade effect on Ventricular arrytmia
75739556|NCT00676091|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
75739557|NCT00676091|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
75739558|NCT02558933|Dietary Supplement|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
75739559|NCT02558855|Other|Thrust Joint Manipulation of the Lumbar Spine|
75739560|NCT02558855|Other|Non-thrust Joint Manipulation of the Lumbar Spine|
75739561|NCT00812201|Device|No intervention is used. Collection of signals only.|Device received per standard of care.
75445479|NCT05763563|Behavioral|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo CART-T therapy. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously.
75445480|NCT05763563|Behavioral|Aerobic Exercise|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
75445481|NCT05753956|Drug|5 Methoxy N,N Dimethyltryptamine|GH002 administered via i.v. bolus injection(s)
75445482|NCT05753956|Drug|Placebo|GH002 placebo administered via i.v. bolus injection
75445483|NCT05753501|Drug|ABBV-101|Oral:Tablet
75739562|NCT00678041|Drug|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
75739563|NCT00678041|Drug|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
75739564|NCT04331561|Behavioral|sensory re-weighting|Participants will be supported in quiet standing by a safety harness and crisscrossing strap system. A cervical collar will be used to maintain consistent alignment between the head and trunk. A virtual reality headset is used to create a virtual environment in which visual stimuli will be presented. Three different body positions will be used during training: earth-vertical and clockwise and counterclockwise tilted 16º in the frontal plane. Sensory re-weighting will be driven by priming upregulation of somatosensory cues. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity.
75739565|NCT03903822|Drug|PF-06700841|PF-06700841 topical cream
75739566|NCT03903822|Drug|Vehicle (Placebo)|Vehicle topical cream
76057925|NCT04413903|Procedure|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
75445484|NCT05753319|Other|Physiotherapy in the emergency department after a fall|Realization of a physiotherapy assessment.
75445485|NCT05748197|Biological|ADCLEC.syn1 CAR T cells|There are 4 planned flat-dose levels: 25 × 10^6, 75 × 10^6 , 225 × 10^6 , and 450 × 10^6 CAR T cells and 1 de-escalation dose: 10 × 10^6 CAR T cells.
75445486|NCT05748197|Drug|Conditioning chemotherapy|Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
75445487|NCT05748158|Behavioral|Weight loss|"A behavioral lifestyle program, up to 20 weeks in duration, based on interventions shown to be successful for weight loss such as the Diabetes Prevention Program (DPP), Action for Health in Diabetes (Look AHEAD), and Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy Study (CALERIE). Weekly sessions, led by experienced interventionists, will provide education and behavioral strategies for weight loss focused an energy-reduced diet and physical activity.~Participants must meet the following milestones to continue in the study:~> 3% weight loss by 4 weeks after the start of the intervention~> 5% weight loss by 20 weeks after the start of the intervention~> 7% weight loss between weeks 20 and 37~After achieving >7% weight loss and weight stability between weeks 20 and 37, participants are observed, without further intervention, for 52 weeks."
75445488|NCT05747027|Procedure|Laparoscopic abdominal ventral rectopexy|Laparoscopic abdominal ventral rectopexy is an established surgical technique used to restore rectal support in women with obstructive defecatory syndrome (ODS). It is the most common surgery used to treat ODS. It involves a series of small cuts in the abdomen and the use of mesh to hold the rectum in the correct position.
75445489|NCT05747027|Procedure|Transvaginal sacrospinous rectopexy|Transvaginal sacrospinous rectopexy is an innovative procedure which has shown to be safe and effective in the treatment of stool entrapment. This is a mesh-free and vaginal route procedure.
75445490|NCT05746559|Drug|Placebo|Participants will receive a single weight-based dose of placebo via intravenous infusion.
75445491|NCT05746559|Drug|Ravulizumab|Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.
75445492|NCT05745480|Other|Opioid Misuse Screening with an Addiction Consult Service|Opioid Misuse Screening with an addiction consult service for brief intervention/motivational interviewing (MI), medication assisted treatment (MAT), or referral to substance use treatment as an outpatient.
75445493|NCT05745376|Behavioral|Farm to ECE programming|Students and parents at this center will receive program elements described in arm descriptions.
75445494|NCT05743881|Biological|mRNA-1345|Sterile liquid for injection
75445495|NCT05743881|Biological|mRNA-1365|Sterile liquid for injection
75445496|NCT05743881|Biological|Placebo|0.9% sodium chloride (normal saline) solution for injection
75445497|NCT05743881|Drug|Nimenrix|Solution for injection
75445498|NCT05738902|Other|Assessment of compliance to ERAS.|Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.
75445499|NCT05734586|Other|EAT-10 (Eating assessment Tool) screening questionnaire|After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
75445500|NCT05734586|Procedure|Protective measures for the upper airways|"In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures"
75445501|NCT05734040|Biological|OVX836 480µg|One single administration intramuscularly at Day 1
75445502|NCT05734040|Biological|Fluarix Tetra|One single administration intramuscularly at Day 1
75445503|NCT05734040|Biological|Afluria Quad|One single administration intramuscularly at Day 1
75445504|NCT05734040|Biological|Placebo|One single administration intramuscularly at Day 1
75445505|NCT05732961|Drug|Luspatercept|Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
75595360|NCT01603784|Behavioral|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
75739567|NCT00677807|Drug|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
75739568|NCT00677807|Drug|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
75739569|NCT04003350|Drug|Oxycodone|Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
75739570|NCT04003350|Drug|Tramadol|Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
76057926|NCT01765569|Drug|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
76057927|NCT01765569|Drug|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
76057928|NCT04414605|Drug|Gu Ben Hua Yu Fang decoction (Chinese herbal medicine)|Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
75595361|NCT01603784|Behavioral|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
75739571|NCT04003350|Drug|Tylenol|Tylenol 1000 mg: take as needed every 8 hours
75887665|NCT03631121|Drug|Basalin to Lantus|continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
75887666|NCT01568489|Drug|HL-009 Liposomal Gel|a semi-transparent red-color gel and is supplied as a laminated tube
75887667|NCT03392519|Other|Chronic stroke|MRI data acquisition and behavioral test
75887668|NCT05023226|Procedure|RM|RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.
75595362|NCT01603784|Behavioral|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
75445506|NCT05726864|Drug|ELI-002 7P|ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
76057929|NCT04414605|Drug|Secukinumab Auto-Injector [Cosentyx]|Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
76057930|NCT01609257|Biological|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
75595363|NCT01174186|Drug|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
75739572|NCT04003350|Drug|Meloxicam|Meloxicam 15 mg as need once per day
75739573|NCT04003350|Drug|Gabapentin|•Gabapentin 200 mg with morning and evening Tylenol dose
75739574|NCT04003350|Drug|Metaxalone|Metaxalone 800mg TID
75887669|NCT05023226|Procedure|LPVS|LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight [PBW]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
75887670|NCT01568567|Dietary Supplement|Lactobacillus Reuteri DSM 17938|One stick pack in the morning and one stick pack afternoon/evening for 28 days.
75887671|NCT03542162|Biological|Healaflow|For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
75445509|NCT05721261|Device|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.
75739575|NCT04003350|Drug|Esomeprazole 20mg|Esomeprazole 20mg daily
75887672|NCT05420597|Drug|Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w. Then a total dose of 70Gy in 35 fractions was administered, with concurrently weekly cisplatin (30mg/m2 qw).~At 3-6 weeks post-radiotherapy, maintenance Toripalimab was administered for 8 cycles (240mg d1 q3w, in total 8 cycles)."
75887673|NCT02775344|Device|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
75887674|NCT05420441|Device|Phonophoresis with chitosan|Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
76057931|NCT01609257|Biological|Saline Comparator|2 doses IM 28 days apart
76057932|NCT04569357|Drug|Prospecta|Oral administration.
76057933|NCT04569357|Drug|Placebo|Oral administration.
75445510|NCT05721261|Device|Sham Temporary Peripheral Nerve Stimulation System|Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
75595364|NCT01609049|Drug|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
75739576|NCT00748007|Drug|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
75739577|NCT00748163|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
75739578|NCT00748163|Drug|sunitinib malate|
75739579|NCT00748319|Other|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
75739580|NCT00748397|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
75739581|NCT00687401|Biological|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
75739582|NCT00485693|Drug|Bupivacaine HCl|150 mg Bupivacaine HCl
75739583|NCT00485693|Drug|SKY0402|600 mg SKY0402 (study drug)
75739584|NCT00748475|Behavioral|Neurofeedback|
75739585|NCT00538902|Biological|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
76057934|NCT01609023|Drug|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
75595365|NCT01609049|Drug|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
75739586|NCT00538902|Biological|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
75739587|NCT00538902|Biological|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
75739588|NCT00541970|Biological|Cervarix|Intramuscular injection, different dosing /schedule
75739589|NCT00541970|Drug|Placebo|Intramuscular injection, different dosing /schedule
75739590|NCT00687323|Drug|temozolomide|
76057935|NCT01765179|Drug|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
75595366|NCT02893566|Behavioral|Mi Band Step Challenge|
75595367|NCT02893527|Behavioral|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
75595368|NCT01609088|Dietary Supplement|Erythritol-containing beverage|Orange flavored beverage containing erythritol
75739591|NCT00989742|Drug|Doxycycline|50mg od
75739592|NCT00989742|Drug|Placebo|50mg od
75445511|NCT05714826|Other|Preop Intervention and Monitored Recovery|Perioperative Optimization of Senior Health (POSH) Program; patient monitoring by device orientation, initial intake, education; ERAS protocol, inpatient geriatric co-management; and remote monitoring with Acticare device; post-op continuity of care
75595369|NCT01173718|Device|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
76057936|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
75445512|NCT05714826|Other|Usual Care|ERAS, Usual referral and recovery care, and Standard follow-up protocol
75595370|NCT01603862|Procedure|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
76057937|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
75739593|NCT05408208|Drug|Intralesional Injection of Methotrexate|"One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment ."
75595371|NCT01609127|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
75739594|NCT05408208|Drug|Triamcinolone Acetonid|One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
76057938|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
76057939|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
75739595|NCT02559245|Other|Descurainia Sophia|
76057940|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
76057941|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
75445518|NCT05706870|Drug|GN-037|GN-037
75445519|NCT05706870|Drug|Clobetasol 17-propionate|Clobetasol 17-propionate
75445520|NCT05706870|Drug|Placebo|Placebo
75445521|NCT05704933|Drug|Nivolumab|Nivolumab is a monoclonal antibody o PD-1 protein, which is normally express on the surface of activated T cells. The interaction of PD-1 with its ligand (PD-L1) on T cells decreases their cytotoxic activity, helping protect normal cells in the setting of chronic inflammation. Tumor cells can utilize mechanisms to evade T cell mediated cytotoxicity by expressing PD-L1 on their surface or on the surface of T cells. Nivo, by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, allows T cells to remain active.
75595372|NCT01609127|Drug|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
75595373|NCT01609127|Drug|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
75595374|NCT01603901|Device|Regulated Negative Pressure-Assisted Wound Therapy Device|Negative pressure will be applied in the usual way that is normally applied in our Medical Center
75739596|NCT02559245|Other|Ficus carica|
75739597|NCT05358756|Drug|SACT-1|Single administartion of 150mg SACT-1
75739598|NCT05358756|Drug|EDURANT 25Mg Tablet|Single administartion of six EDURANT 25mg tablets (Total 150mg)
75739599|NCT00758615|Behavioral|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
75739600|NCT00758693|Drug|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
75739601|NCT00758693|Drug|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
75739602|NCT01564212|Other|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
75739603|NCT01564212|Other|laminar airflow with surgical drapes|
75739604|NCT01564212|Other|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
76057942|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
76057943|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
75595375|NCT01603979|Biological|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
75595376|NCT00592020|Procedure|Short Transverse Incision|Short Transverse Incision for kidney transplantation
75595377|NCT00592020|Procedure|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
75739605|NCT01564212|Other|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
76057944|NCT01793883|Drug|40 mg Laninamivir Octanoate|
76057945|NCT01793883|Drug|80 mg Laninamivir Octanoate|
76057946|NCT01793883|Drug|Placebo|
75445522|NCT05704933|Drug|Ipilimumab|Ipilimumab is a recombinant, human antibody to CTLA-4.[18-20] CTLA-4 regulates T cell activation by binding with CD80 or CD86 with higher affinity than CD28, resulting in blockage of the co-stimulation signal and preventing further T cell activation. Blockade of CTLA-4 results in further T cell activation.
75739606|NCT05092646|Biological|Axolotl Ambient|Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
75887675|NCT05420441|Device|Phonophoresis with glucoasmine|Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
75739607|NCT05092646|Drug|"Drug/Placebo: 0.9% Normal Saline"|"Drug/Placebo: 0.9% Normal Saline"
75739608|NCT05407896|Other|myKIDNEY decision aid|Patients and caregivers will be counselled using myKIDNEY decision aid which includes a video. Patients will be asked to complete a values clarification exercise (VCE). If a caregiver is recruited without their patient, he/she will be asked to complete the VCE on patient's behalf (i.e., surrogate). At the end of VCE, the participant will be given real-time feedback on which treatment might be the best fit for the patient. With the patient's consent, this information will be shared with the treating physician who can then make recommendations based on the patient's preferences.
75739609|NCT00989820|Drug|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
75887676|NCT05420441|Procedure|Conventional Physical Therapy|Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
75887677|NCT05598593|Drug|cytarabine+thiotepa+ fludarabine + busulfan|cytarabine+thiotepa+ fludarabine + busulfan intravenous injection
75887678|NCT01569269|Behavioral|Yoga Intervention|"The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).~Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.~The conclusion of the session will be comprised of 10 minutes of relaxation."
76057947|NCT01792635|Drug|PF-05175157|PF-05175157 will be administered at 200 mg twice a day for 43 days.
76057948|NCT01792635|Drug|Placebo|Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
76057949|NCT01953692|Biological|Pembrolizumab|IV infusion
76057950|NCT01953692|Drug|Lenalidomide 20 mg|oral capsule
75445523|NCT05704933|Drug|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a human monoclonal antibody to LAG-3, currently under investigation.[6] Relatlimab is an antibody (IgG4 isotype) that has a stabilizing hinge mutation for attenuated Fc receptor binding to decrease or get rid of the possibility of antibody-mediated and/or complement-mediated target cell killing. Rela binds to an epitope on LAG-3 with high affinity and specificity, with subsequent blockade of LAG-3 and its interaction with its ligand, MHC class II. This antibody displays compelling in vitro functional activity in reversing LAG-3 that facilitates inhibition of an antigen-specific murine T cell hybridoma overexpressing human LAG-3 . Relatlimab was also shown to improve the activation of human T cells in superantigen stimulation assays when added either alone or in combination with Nivolumab.
75445524|NCT05704933|Procedure|Standard of Care Craniotomy|Participants will undergo craniotomy for surgical resection of melanoma brain metastases.
75445525|NCT05700201|Behavioral|Lifestyle / Healthy Behavior Intervention|12-session healthy lifestyle program focused on physical activity, nutrition, sleep, and stress management.
75445526|NCT05700201|Other|standard care|Standard care (psychotherapy)
75739610|NCT00748631|Device|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
76057951|NCT01953692|Drug|Lenalidomide 25 mg|oral capsule
75595378|NCT01609166|Drug|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
75595379|NCT01609166|Drug|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
75595380|NCT01609205|Biological|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
75595381|NCT01604057|Drug|ZT-034 Low Dose Nasal Spray|Nasal Spray
75595382|NCT01604057|Drug|ZT-034 Mid Dose Nasal Spray|Nasal Spray
75595383|NCT01604057|Drug|ZT-034 High Dose Nasal Spray|Nasal Spray
75595384|NCT01604057|Drug|Teriparatide|20 mcg subcutaneous daily
76057952|NCT01791153|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
75739611|NCT04742114|Device|use the face mask with Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
75739612|NCT04742114|Device|use the face mask without Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
76057953|NCT01791153|Drug|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
76057954|NCT01791153|Drug|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
76057955|NCT01791153|Drug|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
76057956|NCT01791153|Drug|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
76057957|NCT01791153|Drug|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
76057958|NCT01926782|Drug|Placebo (for alirocumab)|Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
75445530|NCT05695209|Behavioral|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
75445531|NCT05694364|Drug|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
75445532|NCT05694364|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
75445533|NCT05694364|Biological|PRGN-3007|PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
75445534|NCT05691465|Procedure|Biospecimen Collection|Undergo collection of blood
75445535|NCT05691465|Procedure|Computed Tomography|Undergo CT scan
75445536|NCT05691465|Drug|Lutetium Lu 177 Dotatate|Given IV
75445537|NCT05691465|Procedure|Positron Emission Tomography|Undergo PET
75445538|NCT05683834|Drug|Matrix-M1 Adjuvant|Matrix-M1 is composed of 2 types of 40 nm-sized particles each with a different saponin fraction (fraction A and fraction B) combined with cholesterol and phospholipid.
75445539|NCT05683834|Drug|EBV gp350-Ferritin Vaccine|The EBV gp350-Ferritin vaccine is composed of Helicobacter pylori non-heme ferritin fused to EBV gp350 which self-assembles to form a nanoparticle. The vaccine is supplied in single-use vials at a concentration of 250 micrograms/mL in 1.7 mM KH2PO4, 5 mM Na2HPO4, 150 mM NaCl, 5% sucrose, pH 7.4 (diluent).
75445540|NCT05683834|Other|Placebo Comparator|Normal Saline
75445541|NCT05683691|Device|Vanquish System|Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
75445542|NCT05681442|Drug|continuous pivotal βL-AB|continuous pivotal βL-AB
75445543|NCT05681442|Drug|intermittent pivotal βL-AB|intermittent pivotal βL-AB (IID = control group)
75445544|NCT05681442|Drug|AG infusion most 1 dose|AG infusion most 1 dose (AMT group )
75595385|NCT01604057|Drug|Placebo|Nasal Spray
75595386|NCT04331223|Other|Observation|observational
75595387|NCT01604096|Other|Multifaceted information campaign|"Following is the description of the multifaceted intervention:~brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~posters (same distribution as brochures)~short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~radio-spots transmitted in local radio stations~advertisements in local newspapers~banners on websites of local newspapers~newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
75595388|NCT01604174|Other|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
75739613|NCT00758849|Drug|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
75739614|NCT00758849|Drug|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
76057959|NCT01926782|Drug|Alirocumab|Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
76057960|NCT01926782|Drug|Statin|Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
76057961|NCT01926626|Drug|Nicotine Patch|"Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)"
76057962|NCT01926626|Drug|Moclobemide|"Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)"
75887679|NCT01569269|Behavioral|Meditation Intervention|The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
76057963|NCT01953224|Behavioral|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
75739615|NCT05334186|Behavioral|Telehealth Reasoning Training|The current study is explores the feasibility and preliminary relative effectiveness of a telehealth-delivered inductive reasoning intervention. The results of the study can help to provide insight on whether a telehealth-adapted reasoning training shows promise with older adults and can also be used to power future clinical trial studies to more definitively evaluate the effectiveness of telehealth delivered training.
76057964|NCT01953224|Device|Smartphone|
76057965|NCT01900730|Drug|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
75445545|NCT05681442|Drug|AG infusion for 5 days|AG infusion for 5 days (ACT Group)
75445546|NCT05677360|Behavioral|HPV MISTICS -Provider Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.
75445547|NCT05677360|Behavioral|HPV MISTICS - Parent Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.
75445548|NCT05677360|Behavioral|HPV MISTICS- HPV Vaccine Champion Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses
76057966|NCT01900730|Drug|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
76057967|NCT01900730|Behavioral|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
75595389|NCT01604174|Other|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
75595390|NCT04330014|Behavioral|vaccine|affect vaccination on children
75595391|NCT01609244|Device|Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
75595392|NCT01609244|Device|servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
75595393|NCT01609283|Biological|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~Group 1: single intrathecal dose of 1 x 107 cells~Group 2: single intrathecal dose of 5 x 107 cells~Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~Group 4: single intrathecal dose of 1 x 108 cells~Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
75595394|NCT00592566|Drug|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
75595395|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
75595396|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
75595397|NCT01609322|Behavioral|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
75595398|NCT01609322|Behavioral|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
75739616|NCT05070884|Other|The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer|Evaluate response to neoadjuvant treatment in advanced breast cancer
75739617|NCT05357820|Drug|AB-106, Itraconazole|single dose AB-106 at Day1, Itraconazole QD at Day14~Day28, single dose AB-106 at Day17
75739618|NCT05357820|Drug|AB-106, Rifampicin|single dose AB-106 at Day1, Itraconazole QD at Day14~Day32, single dose AB-106 at Day21
75887680|NCT01569269|Behavioral|Reiki|The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
75887681|NCT01569269|Other|Holistic Education|The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
75887682|NCT02777918|Behavioral|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
76057968|NCT01900730|Behavioral|Pill Diary|Patient given a pill diary to record the time each dose taken.
76057969|NCT01900730|Behavioral|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
76057970|NCT01952834|Dietary Supplement|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
76057971|NCT01952834|Drug|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
75595399|NCT04310800|Procedure|LIFT-plug technique|Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
75595400|NCT00592644|Procedure|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
75595401|NCT00592644|Procedure|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
75739619|NCT00748787|Drug|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
75739620|NCT00748787|Drug|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
75739621|NCT05712044|Drug|Folic Acid 5 MG|Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
75739622|NCT05360316|Device|ESWT|extracorporeal shock wave therapy
75739623|NCT04059731|Dietary Supplement|Nutrition supplement|Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
75739624|NCT05407740|Other|no intervention study|no intervention study
75887683|NCT05337449|Other|silver diamine fluoride|silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries
76057972|NCT04643912|Diagnostic Test|Vibration Device|Device which causes the bone to vibrate and records the spectrum of that vibration
76057973|NCT01952054|Drug|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
76057974|NCT01925768|Drug|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
76057975|NCT01925768|Drug|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
76057976|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
76057977|NCT01431274|Drug|tiotropium|low dose
76057978|NCT01431274|Drug|olodaterol|one dose only
76057979|NCT01431274|Drug|tiotropium|high dose
75739625|NCT00986960|Drug|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
75739626|NCT00986960|Drug|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
75739627|NCT00758927|Drug|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
75739628|NCT00758927|Drug|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
75739629|NCT05711966|Device|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
75739630|NCT05711966|Device|Less invasive surfactant administration (LISA)|SurfCath™ tracheal instillation catheter, or a 4- 6 F end-hole catheter, according to local protocols will be used for surfactant administration
75739631|NCT05407506|Diagnostic Test|THYROID AI|thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
75739632|NCT00759005|Drug|propranolol and cortisol|
75739633|NCT04360070|Drug|Ketamine Hydrochloride|Parenteral General Anesthetic
75739634|NCT00748943|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
75739635|NCT04354688|Device|T3 Certain Tapered Implant|Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
76057980|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
76057981|NCT01431274|Device|Respimat|Respimat inhaler
76057982|NCT01991795|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
76057983|NCT01991795|Drug|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
75445569|NCT05673109|Drug|AC176|AC176 will be given orally (PO) on a 28-day cycle.
76057984|NCT02076100|Drug|Ruzasvir|Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
75739636|NCT00749021|Drug|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
75887684|NCT05337449|Other|conventional composite resin restoration|Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
75887685|NCT02156414|Procedure|Radical Prostatectomy|Radical Prostatectomy
75887686|NCT02156414|Procedure|Extended Lymphadenectomy|Extended Lymphadenectomy
75887687|NCT02150720|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
75595402|NCT01604330|Drug|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
75887688|NCT02150720|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
75887689|NCT02150720|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
75887690|NCT04835714|Drug|BI 1701963|BI 1701963
75887691|NCT04835714|Drug|BI 3011441|BI 3011441
75445570|NCT05665595|Biological|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
75445571|NCT05665595|Biological|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
76057985|NCT01411852|Drug|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
75739637|NCT00749021|Drug|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
75739638|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
75739639|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
75445575|NCT05662306|Drug|Aripiprazole Lauroxil|1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
75445576|NCT05662306|Behavioral|Computerized cognitive and functional skills training|Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.
75445577|NCT05660746|Device|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
75445578|NCT05660746|Drug|Infliximab|"Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool."
75445579|NCT05655689|Drug|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
75595403|NCT01604330|Drug|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
75595404|NCT00622830|Drug|SB-480848 (Darapladib)|
75595405|NCT01609361|Other|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
75739640|NCT04733846|Other|data collection|Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
75887692|NCT05234957|Procedure|Bilateral Lateral Rectus Recession|Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
75887693|NCT02150798|Other|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
75887694|NCT02150798|Other|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
75887695|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
75887696|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
75445580|NCT05655689|Drug|Ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
75445581|NCT05655689|Drug|Gentamicin 1.4% + vancomycin 5%|In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
75445582|NCT05655689|Drug|Natamycin 5% Oph Susp|In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
75445583|NCT05655689|Drug|Voriconazole 1%|In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
75595406|NCT01173679|Drug|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
75595407|NCT01173679|Drug|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
75595408|NCT01173679|Drug|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
75595409|NCT02881528|Drug|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
75595410|NCT02881528|Drug|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
75595411|NCT01609439|Drug|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
75595412|NCT01609439|Drug|Placebo|Placebo
75595413|NCT01110382|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
75595414|NCT01110382|Drug|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
75595415|NCT01110382|Drug|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
75595416|NCT01110382|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
75887697|NCT02153138|Device|Endo-pat 2000|"The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:~The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.~The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution"
75595417|NCT01110382|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
75595418|NCT01604369|Procedure|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
75595419|NCT00592917|Dietary Supplement|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
75595420|NCT01609517|Drug|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
75595421|NCT04309903|Other|Manual therapy|Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 * 10 repetitions, 20 sec of per reps and 10 sec of interval.
75595422|NCT02881489|Other|Biological: Cell-based therapy|Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.
75445584|NCT05655689|Drug|Natamycin 5% + voriconazole 1%|In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
75445585|NCT05655689|Drug|Natamycin 5%+ ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
75445586|NCT05655689|Drug|Voriconazole 1% + ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
75887698|NCT02153138|Device|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
75887699|NCT02153138|Device|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
75887700|NCT03542864|Dietary Supplement|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
76057986|NCT01411852|Drug|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
76057987|NCT01411774|Behavioral|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
75739641|NCT05407350|Diagnostic Test|Ultrasound, Colonoscopy, MRE|After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine [DICOM] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.
75739642|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
75739643|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
75595423|NCT01604447|Procedure|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
75595424|NCT01604447|Procedure|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
75595425|NCT00593073|Behavioral|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
75595426|NCT00593073|Behavioral|General Reminder Message|General CRC health education message and reminder to get screened.
75595427|NCT02892669|Other|non interventional study|non interventional study
75595428|NCT01609595|Drug|sodium 2,2 dimethylbutyrate|Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
75595429|NCT00593151|Other|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
75739644|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
75739645|NCT04005560|Other|no interventional study|no interventional study
75739646|NCT04901442|Device|Aetrex L700 Speed orthotic|An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body & help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
75739647|NCT00987038|Drug|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
75739648|NCT00987038|Drug|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
75739649|NCT00761033|Behavioral|music|
75887701|NCT03542864|Other|Control|Progress registration of body composition values
75887702|NCT03542864|Other|Data analysis|Statistical analysis of all data
75887703|NCT01383239|Other|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
75595430|NCT00593151|Biological|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
75595431|NCT01609634|Other|Test Product|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
75595432|NCT01609634|Other|Control Product 1|Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
75595433|NCT01609634|Other|Control Product 2|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
75739650|NCT05711810|Drug|Nifedipine 30 MG|Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
75595434|NCT00593190|Drug|Gas SF6 (Sulfur Hexafluoride)|ONCE
75595435|NCT01604525|Behavioral|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
75595436|NCT01604525|Behavioral|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
75595437|NCT01604525|Other|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
75739651|NCT05711810|Diagnostic Test|Kangzhu BPCB0A-3A|The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.
75739652|NCT05711810|Behavioral|Low Mobility|The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.
75595438|NCT04327128|Device|LifePod|The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
75595439|NCT02485496|Device|Endovascular abdominal repair|
75595440|NCT04327167|Behavioral|Video and questionnaire|Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.
75595441|NCT00593307|Other|high GI|high GI and high carb breakfast
75595442|NCT00593307|Other|Low GI|low GI, high carb breakfast
75595443|NCT00593307|Other|Low GI Low Carb|low GI low carb breakfast
75595444|NCT00593307|Other|High GI Low carb|high GI low carb breakfast
75595445|NCT01173601|Drug|LY2216684|
75595446|NCT01173601|Drug|Placebo|
75595447|NCT01173601|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
75595448|NCT01609673|Drug|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
75595449|NCT01604642|Other|blood tests and muscular biopsies|blood tests and muscular biopsies
75595450|NCT01604681|Dietary Supplement|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
75595451|NCT01604681|Dietary Supplement|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
75595452|NCT01173523|Drug|STA-9090|
75595453|NCT01609712|Procedure|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
75595454|NCT00593424|Other|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
75739653|NCT05711810|Drug|Enalapril Maleate 10Mg Tab|The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
75445593|NCT05652205|Drug|Linaclotide|Capsule; oral
75445594|NCT05652205|Drug|Placebo for Linaclotide|Capsule; oral
75445595|NCT05649722|Drug|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
75445596|NCT05649722|Drug|Placebo|Oral placebo inhalation using a capsule-based dry powder inhaler device.
75595455|NCT00593424|Other|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
75739654|NCT05711810|Drug|Lansoprazole 30Mg Ec Cap|The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
75739655|NCT05711810|Drug|Metoprolol Succinate|Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
75595456|NCT01173055|Drug|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
75887704|NCT01383239|Other|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
76057988|NCT01411774|Drug|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
75739656|NCT05711810|Dietary Supplement|Coenzyme Q10|200 mg per day is used for supplement with the cardiac interventions.
75739657|NCT05711810|Dietary Supplement|d-alpha tocopherol acetate|The 268 mg twice per day dietary healthcare is the patient's usual daily use.
75739658|NCT05711810|Dietary Supplement|Omega-3|The 900 mg twice per day dietary healthcare is the patient's usual daily use.
75739659|NCT05711810|Drug|Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release|Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
75595457|NCT01173055|Drug|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
75739660|NCT05711810|Drug|Superoxide Dismutase|Superoxide Dismutase is used to substitute the missing of antiviral drugs.
75739661|NCT00759083|Drug|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
75739662|NCT04864236|Device|Novel isolation device to contain aerosol|"The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso."
75739663|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
75739664|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
75595458|NCT04327440|Biological|RTS,S/AS01 malaria vaccine|Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
75739665|NCT00761111|Behavioral|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
75739666|NCT03899064|Drug|Induction: Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
75739667|NCT03899064|Drug|Induction: Application of MC2-01 Cream, no irradiation|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
75739668|NCT03899064|Drug|Induction: Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
75887705|NCT02156570|Drug|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg <75kg, 1200mg >/= 75 kg) Treatment will be for 6 weeks in all participants.
75739669|NCT03899064|Drug|Induction: Applications of MC2-01 vehicle, no irradiation|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
75595459|NCT04327440|Other|PBO bed nets|PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
75595460|NCT01609829|Procedure|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
75595461|NCT00593502|Drug|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; > 40 kg, 75 mg twice daily, for 5 days
75595462|NCT00593502|Drug|placebo|The dosage of placebo will be similar to the active drug
75739670|NCT03899064|Drug|Challenge: Application of MC2-01 Cream, irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
75595463|NCT01609868|Dietary Supplement|Powder protein modular|Infants will receive powder protein modular to achieve 4 grm/kg/day
75595464|NCT01609868|Dietary Supplement|Liquid protein modular|Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
75739671|NCT03899064|Drug|Challenge: Application of MC2-01 Cream, no irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
75739672|NCT03899064|Drug|Challenge: Applications of MC2-01 vehicle, irradiation|Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
75739673|NCT03899064|Drug|Challenge: Applications of MC2-01 vehicle, no irradiation|Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
75739674|NCT03899064|Drug|Challenge: Control, irradiation|No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
75739675|NCT03742908|Drug|Cefazolin/clindamycin|Local implant immersion and/or breast pocket irrigation
75739676|NCT05357274|Diagnostic Test|Diagnostic testing|Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
75769556|NCT03889054|Behavioral|Education program|"The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~Plan of action in an exacerbation.~Education related to COPD.~Information on pharmacological medication.~Management of the exacerbation.~Management of stress and / or anxiety.~Nutritional recommendations.~Physical exercise recommendations.~Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts."
75595465|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
76057989|NCT01411774|Drug|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
75739677|NCT05407116|Other|NCI PRO-CTCAE Questionnaire / EORTC QLQ-C30 Questionnaire|"PROs data will be collected prospectively via electronic questionnaires (PRO-CTCAE™), which is a patient-reported outcomes measurement system created to assess symptomatic toxicity in patients of cancer clinical research. PRO-CTCAE items evaluate frequency, severity, interference, amount, presence/absence symptoms. Each symptomatic adverse effect is measured by 1-3 features. GI items included nausea, vomiting, flatulence, bloating of the abdomen, constipation, diarrhea, abdominal pain, and loss of control of bowel movements. Urinary symptoms include the urge to urinate suddenly, frequency, urine colour change, loss of urine control (leakage).~Patients will also self-report health-related quality of life (QoL) in real-time, electronic PRO questionnaires (EORTC QLQ CX24, EN 24, C30) about QoL. Question 29 and 30 ask the patients to rate their overall health and QOL respectively during the past week on a scale between 1-7, where one is equivalent to very poor and seven is excellent."
75445601|NCT05639153|Drug|DR30303|DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
75445602|NCT05637203|Behavioral|THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)|"THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls."
75445603|NCT05637203|Behavioral|Discharge / Safety Planning|"A written safety plan completed with the person~Mental health appointment scheduled within seven days~One phone follow-up call within 30 days"
75445604|NCT05633667|Drug|Zimberelimab (ZIM)|Administered intravenously
75445605|NCT05633667|Drug|Domvanalimab (DOM)|Administered intravenously
75445606|NCT05633667|Drug|Sacituzumab govitecan-hziy (SG)|Administered intravenously
75595466|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
75595467|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
75595468|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
75739678|NCT04003194|Other|Pinto Beans|The intervention was 1/2 cup of pinto beans each day.
75739679|NCT04003194|Other|Green Beans - control|The control was 1/2 cup of green beans each day.
75739680|NCT05406960|Dietary Supplement|Tea infusion|Herbal tea infusion will be administrated by the oral route before food
75445607|NCT05633667|Drug|Etrumadenant (ETRUMA)|Administered orally
75739681|NCT05406882|Drug|Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules|Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
75739682|NCT01564134|Biological|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
75445608|NCT05633667|Drug|Carboplatin|Administered intravenously
75445609|NCT05633667|Drug|Cisplatin|Administered intravenously
75445610|NCT05633667|Drug|Pemetrexed|Administered intravenously
75445611|NCT05633667|Drug|Paclitaxel|Administered intravenously
75445612|NCT05633667|Drug|Nab-paclitaxel|Administered intravenously
75445613|NCT05633667|Drug|Docetaxel|Administered intravenously
75445614|NCT05633667|Drug|Nivolumab|Administered intravenously
75445615|NCT05630872|Drug|Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC|Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.
75445616|NCT05630872|Drug|DTG 50 mg orally QD plus TDF/3TC|DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).
75445617|NCT05630872|Drug|2HPZM|Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen
75445618|NCT05630872|Drug|2HPM|Daily rifapentine-moxifloxacin plus isoniazid regimen
75595469|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
75739683|NCT05357196|Drug|PT-112|"Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg."
75769557|NCT03894826|Drug|Vorinostat 100 MG|Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks
76057990|NCT01411228|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
76057991|NCT01410604|Drug|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
75887706|NCT05208749|Device|Rotablation of shockwave|Patients will be randomized to treatment with rotablation or shockwave
75445620|NCT05626257|Other|Xolair|There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
75445621|NCT05625932|Drug|Tinzaparin|Patients < 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients > 100 kg will receive a fixed dose of 8000 IU daily.
75445622|NCT05624554|Drug|Nemtabrutinib|65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met
75445623|NCT05624554|Drug|Fludarabine|25 mg/m^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles
75445624|NCT05624554|Drug|Cyclophosphamide|250 mg/m^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles
75595470|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
75739684|NCT05232630|Drug|Fenfluramine|"Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day [or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks."
75739685|NCT03902574|Drug|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
75739686|NCT03902574|Drug|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
75739687|NCT03902574|Drug|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
75887707|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
75887708|NCT05188547|Device|Video education|Participants will be shown a video educating them on anesthesia and perioperative instructions.
75887709|NCT02153294|Procedure|low tidal volume|Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
75887710|NCT02153294|Procedure|high tidal volume|Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
76057992|NCT01410604|Drug|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
75445625|NCT05624554|Drug|Bendamustine|Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m^2. Subsequent doses may be escalated up to 90 mg/m^2, if applicable and as per local guidelines
75445626|NCT05624554|Biological|Rituximab|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles
75595471|NCT00593580|Drug|placebo|placebo
75595472|NCT00593580|Drug|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
75595473|NCT01604759|Device|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
75887711|NCT05598437|Device|Dry eye device|Dry eye analysis
75887712|NCT02153372|Other|BMC2012|
75887713|NCT02767856|Device|IO-therapy Glasses|
75887714|NCT03087851|Drug|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
75887715|NCT02156726|Drug|low-dose FCR|FCR with attenuated dose of fludarabine and cyclophosphamide
76057993|NCT01991483|Drug|LY2928057|Administered intravenously
76057994|NCT01991483|Drug|Placebo|Administered intravenously
76057995|NCT01410448|Drug|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
76057996|NCT01410448|Drug|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
75739688|NCT04646850|Other|Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).
76057997|NCT01410448|Drug|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
75445627|NCT05624554|Biological|Truxima|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles
75739689|NCT01564290|Dietary Supplement|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
75739690|NCT01564290|Drug|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
75739691|NCT01004874|Drug|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
75445628|NCT05624554|Biological|Ruxience|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles
75445629|NCT05624554|Biological|Riabni|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles
75739692|NCT01004874|Drug|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
75595474|NCT01609946|Device|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
75595475|NCT01609946|Procedure|Cytology (FNAB) or Surgery|
75595476|NCT04327011|Biological|Toca 511 vector|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
75595477|NCT04327011|Drug|Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine|Toca FC is an extended-release formulation of flucytosine.
75595478|NCT00593619|Drug|Iron dextran|300mg in 250cc normal saline given over 2 hours
75595479|NCT00593619|Drug|Iron sucrose|300mg in 250cc normal saline given over 2 hours
75739693|NCT01004874|Radiation|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
75445631|NCT05618808|Drug|REGN9933|Participants will receive a single dose of REGN9933 by IV infusion
75445632|NCT05618808|Drug|Enoxaparin|Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
75445633|NCT05618808|Drug|Apixiban|Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
75595480|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
75739694|NCT01004874|Drug|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
75739695|NCT05356026|Other|Online postpartum follow-up|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
75769558|NCT03889210|Other|HVMN Ketone|Water-based, flavoured sport beverage
75769559|NCT03889210|Other|Placebo|Water, stevia, malic acid, and thickening agent
75769560|NCT02527642|Other|embryo culture in buffered media|compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
75887716|NCT02153450|Drug|metformin hydrochloride|Given PO
75887717|NCT02153450|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
76057998|NCT01410448|Drug|Steroids|Steroids were administered according to local clinical practice.
75445634|NCT05614739|Drug|LOXO-435|Oral
75445635|NCT05614739|Drug|Pembrolizumab|IV
75887718|NCT05598281|Drug|AMG 510|Oral tablet
75739696|NCT04002804|Biological|Dendritic Cells Vaccine|"Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient."
75887719|NCT05598281|Drug|Digoxin|Oral tablet
75887720|NCT05598203|Behavioral|Operative group of nutrition education|The intervention will be carried out with operational nutritional education groups. Three meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished.
75887721|NCT03979417|Other|Blood draw and liver resection|The samples are transferred to the research unit for immunological studies.
75887722|NCT03956407|Device|Repetitive peripheral nerve stimulation|Active repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For active stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
76057999|NCT01943851|Drug|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
76058000|NCT01430104|Drug|Teriparatide|Administered subcutaneously during the Treatment Period
76058001|NCT01430104|Drug|Aspara-CA 600 mg|Administered orally throughout the study
76058002|NCT01430104|Drug|Alfarol 1.0 µg|Administered orally throughout the study
76058003|NCT01990859|Biological|Ipilimumab|
76058004|NCT02093897|Biological|rVIII-SingleChain|
75739697|NCT05355948|Device|MEMO Patch PLUS for 1 day|Individuals randomized to one-day monitoring will wear MEMO Patch PLUS for 1 day. After that, confirm the monitoring result and carry out a fixed schedule.
75445637|NCT05608265|Device|OSNAT 800 IO|Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
75595481|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
75595482|NCT00593658|Drug|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
75595483|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 ->FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)"
75595484|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
75595485|NCT02892747|Behavioral|Educational Program|
75595486|NCT01604954|Behavioral|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
75595487|NCT01604954|Behavioral|Calorie-label|"A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers."
75595488|NCT01604954|Behavioral|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
75739698|NCT05355948|Device|MEMO Patch PLUS for More than 8-days|Individuals randomized to More than 8-days monitoring will wear MEMO Patch PLUS for 8 days ~ 14 days at their voluntarily. After that, confirm the monitoring result and carry out a fixed schedule.
75739699|NCT04302818|Behavioral|SKOLKONTAKT|N=21 participants are offered manualized and structured group training SKOLKONTAKT. The intervention includes 12 weeks, 3 sessions (50 minutes) per week.
75739700|NCT04302818|Behavioral|Social activity group|N=21 participants. The active comparison group includes 12 weeks, 3 sessions (50 minutes) per week. Sessions will include socially oriented activities such as board games, sports or baking as well as a recommended, general agenda.
75769561|NCT01258816|Drug|Elacytarabine for infusion|Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.
75739701|NCT00987116|Drug|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
75739702|NCT04866680|Procedure|Personalized Circulating DNA follow-up|FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
75887723|NCT03956407|Device|Sham Repetitive peripheral nerve stimulation|Sham repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For sham stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
75887724|NCT03092375|Drug|Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|daily
75739703|NCT05711732|Diagnostic Test|MyCare Oncology Busulfan Assay Kit|This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.
75887725|NCT03092375|Drug|Ribavirin 200Mg Tablet|Weight-based 1000-1200 mg
75739704|NCT04006340|Combination Product|triple therapy|esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
75739705|NCT04006340|Combination Product|quadruple therapy|esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days
75887726|NCT04983485|Other|Observational|Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
75887727|NCT01995513|Drug|Enzalutamide|160 mg by mouth once daily
75887728|NCT01995513|Drug|Abiraterone|1000 mg by mouth once daily
75887729|NCT01995513|Drug|Placebo for Enzalutamide|Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
75739706|NCT04006340|Diagnostic Test|dual-priming oligonucleotide-based multiplex (DPO)-PCR test|Resistance of clarithromycin 23S rRNA point mutation
75739707|NCT05711654|Behavioral|Health coaching|Coaching interview will be held with patients at regular intervals.
75739708|NCT04005326|Procedure|quadratus lumborum block; (Anterior QLB or QLB III)|The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
75739709|NCT04005326|Procedure|suprainguinal fascia iliaca block|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest & iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
75887730|NCT01995513|Drug|Prednisone|5 mg by mouth twice daily
75887731|NCT04953377|Behavioral|PFMT educational intervention|an educational intervention to learn about the pelvic floor and how to train it
75887732|NCT05038761|Device|CGM System|"Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days."
76058005|NCT01990313|Device|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
76058006|NCT01947517|Device|Parasol Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
76058007|NCT01947517|Device|Superflex Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
76058008|NCT02006927|Device|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
76058009|NCT01947283|Behavioral|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
76058010|NCT01947283|Behavioral|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
76058011|NCT02006693|Device|XEN® Gel Stent|The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
75595489|NCT04327050|Procedure|Magnetic anchored guided endoscopic submucosal dissection|Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
75595490|NCT02892786|Other|Circulating Tumor Cells|"Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years."
75739710|NCT04005326|Procedure|Subarachnoid block|"Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study."
75739711|NCT04004702|Drug|Levetiracetam|Levetiracetam 500mg twice a day
75887733|NCT05038761|Procedure|Standard Venous Blood Glucose Test|Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
75445638|NCT05605899|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
75595491|NCT01601522|Procedure|Peanut protein|500 mg
75595492|NCT01601522|Procedure|Oat flour|500 mg Oat flour
75595493|NCT01601522|Drug|Antihistamine|Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid
75595494|NCT02892552|Radiation|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
75739712|NCT00542828|Biological|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
75739713|NCT04731974|Drug|Melatonin 3 MG|Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.
75739714|NCT04731974|Other|Placebo|Participants in the placebo group will be instructed to take liquid placebo pill 1 hour prior to their habitual fall asleep time daily for 30 days.
75769562|NCT03888820|Drug|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
75769563|NCT03888820|Drug|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
75887734|NCT05598125|Device|electronic cigarette (e-cigarette)|
75887735|NCT05598125|Device|conventional tobacco cigarette|
76058012|NCT02006693|Procedure|Cataract Surgery|Participants diagnosed with a cataract elected to have cataract surgery.
75595495|NCT02892552|Radiation|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
76058013|NCT01976845|Drug|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
76058014|NCT01976845|Drug|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
75445639|NCT05605899|Drug|Cyclophosphamide|Administered intravenously
75445640|NCT05605899|Drug|Fludarabine|Administered intravenously
75445641|NCT05605899|Drug|Etoposide|Administered intravenously
75445642|NCT05605899|Drug|Rituximab|Administered intravenously
75445643|NCT05605899|Drug|Doxorubicin|Administered intravenously
75445644|NCT05605899|Drug|Vincristine|Administered intravenously
75445645|NCT05605899|Drug|Prednisone|Administered orally
75595496|NCT00593775|Procedure|assisted hatching|assisted hatching with laser
75595497|NCT01604993|Other|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
75595498|NCT01604993|Other|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
75595499|NCT04329507|Diagnostic Test|Breath test|collection of an exhaled breath sample
75595500|NCT00593853|Drug|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
75595501|NCT00593853|Drug|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
75595502|NCT01607294|Drug|ETC-1002|ETC-1002 Daily for 4 weeks
76058015|NCT01976845|Drug|Saline|Saline 2 ml IV, in the pre-op area as a premedication
76058016|NCT01989689|Drug|Etanercept|Etanercept 50mg twice weekly
76058017|NCT01989689|Drug|Placebo|
76058018|NCT01943539|Device|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
76058019|NCT04416373|Diagnostic Test|RT PCR SARS-CoV-2|Positive SARS-CoV-2 RT PCR in nasopharyngeal/oral swab tests or presence of IgM in blood samples
76058020|NCT04638595|Other|Observation|This project seeks to recruit 25 male and 25 female typically developing children between the ages of 3 and 18 years of age. Non-invasive measurements of movement patterns will be collected during common activities of daily living over a single data collection session.
75887736|NCT03180359|Biological|Recommended vaccine scheme according to French Vaccine Schedule 2015|"BCG~Measles mumps rubella (MMR)~Varicella (chicken pox)~Rotavirus~Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~Yellow Fever~Diphteria tetanus poliomyelitis whopping cough (DTwP)~Haemophilus influenzae type b~Hepatitis B~Meningococcus conjugate~Pneumococcus~Human papillomavirus~Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
75887737|NCT00948129|Other|Laboratory Biomarker Analysis|Correlative studies
75887738|NCT00948129|Behavioral|Smoking Cessation Intervention|Undergo standard of care smoking cessation intervention
75887739|NCT00948129|Behavioral|Telephone-Based Intervention|Undergo telephone based smoking cessation intervention
75887740|NCT00948129|Other|Tobacco Cessation Counseling|Undergo smoking cessation counseling
76058021|NCT01942993|Drug|Vemurafenib|Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
75595503|NCT01607294|Drug|Placebo|Placebo Daily for 4 weeks
75595504|NCT01601600|Drug|BYM338|BYM338
75595505|NCT01601600|Drug|Placebo|BYM338 Placebo
75739715|NCT04533074|Biological|Single-visit regeneration protocol|In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.
75887741|NCT01382771|Drug|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
76058022|NCT01989455|Drug|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
75887742|NCT01382771|Drug|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
75595506|NCT00593931|Other|fMRI|Functional Magnetic Resonance Imaging without contrast
75595507|NCT01605110|Drug|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
75595508|NCT01605110|Drug|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
75595509|NCT00594048|Device|Resperate|Use of the device 15 minutes a day for 9 weeks
75887743|NCT04819451|Other|Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF)|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the patient wards in a special container. Finally, it will be used in the CSF replacement. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
75595510|NCT00594048|Device|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
75595511|NCT00594087|Drug|eszopiclone|eszopiclone 2mg or 3mg at bedtime
75595512|NCT00594087|Other|placebo|2 mg or 3 mg at bedtime
75595513|NCT01605305|Drug|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
75595514|NCT00594126|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
75595515|NCT00594243|Behavioral|Mindfulness based stress reduction program|8-week mindfulness based stress reduction program
75595516|NCT00594243|Other|Wait-list control|No treatment given.
75595517|NCT01605344|Drug|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
75595518|NCT01605344|Drug|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
75595519|NCT04358211|Biological|Biological: COVID-19 convalescent plasma|One unit of ABO compatible COVID-19 convalescent plasma
75595520|NCT01605383|Biological|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
75595521|NCT01605383|Procedure|Standard treatment|Isolated core decompression
75887744|NCT02927171|Other|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
76058023|NCT01989455|Drug|Placebo|Placebo: normal saline solution.
75595522|NCT00594282|Device|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
75595523|NCT00594321|Device|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
75595524|NCT00594321|Device|standard vertebroplasty|standard vertebroplasty
75595525|NCT01605422|Other|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
75739716|NCT04533074|Biological|Multiple-visits regeneration protocol|In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
75739717|NCT04722692|Diagnostic Test|Delayed SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~Transcutaneous signal~Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~SLN identification in situ~SLN excision and signal ex vivo~Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer."
75739718|NCT04722692|Diagnostic Test|Late SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~Transcutaneous signal~Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~SLN identification in situ~SLN excision and signal ex vivo~Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer."
75739719|NCT05711342|Behavioral|Aggression|"The intervention consists of 10 lessons:~Motivation - where are you now?~Where do you want to go?~Circle of aggression.~Thoughts.~Emotions.~Bodily sensations.~Techniques for self-control.~Asking for help.~Assertiveness.~Relapse-prevention. Each lesson consists of multiple components, i.e. written text, assignments and videos with therapists and/or experts by experience. After each lesson, the therapist sends written feedback on the assignments to the patient. Because 'Aggression' is a blended intervention, each lesson is briefly discussed in an in-person treatment session. Generally, participants work on one lesson per week."
75739720|NCT05711342|Behavioral|Treatment as usual|In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.
75739721|NCT05710796|Behavioral|Difference in gender, response to disease, diagnostic test values|Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
75887745|NCT04933253|Procedure|Saline irrigation|Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
75887746|NCT04878419|Other|Virtual Educational Program|Multiple virtual interactive sessions to provide education/knowledge about Type 1 Diabetes Mellitus care
75595526|NCT01607372|Drug|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
75595527|NCT01607372|Device|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
75595528|NCT01607372|Other|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
75595529|NCT01608581|Other|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
75595530|NCT04130568|Diagnostic Test|INO survey|Garvin's Learning organisation tool
75595531|NCT00594360|Behavioral|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
75595532|NCT01605578|Procedure|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
75595533|NCT00593463|Drug|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
75595534|NCT00593463|Drug|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
75595535|NCT00593463|Drug|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
75595536|NCT00593463|Drug|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
75595537|NCT00593463|Drug|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
75887747|NCT01382693|Behavioral|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
75887748|NCT01382693|Behavioral|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
75887749|NCT01304511|Drug|Orgalutran|
75595538|NCT00593463|Drug|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
75595539|NCT00593463|Drug|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
75887750|NCT03087617|Device|Imbio Smoking Cessation Report|Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
75595540|NCT00593463|Device|Saline|Saline: I.M. injection may possibly be given
75595541|NCT00593463|Drug|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
75739722|NCT04266470|Device|Lara Scan|"Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan."
75739723|NCT04266470|Diagnostic Test|PET/CT Scan - Pre-treatment and Post-treatment|The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
75739724|NCT00987350|Device|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
75739725|NCT00987350|Device|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
75739726|NCT00987350|Biological|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
75739727|NCT00987428|Procedure|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
75739728|NCT00987428|Procedure|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
75739729|NCT00987506|Device|XIENCE V®|Participants with placement of a XIENCE V® EESS
75739730|NCT04567082|Diagnostic Test|Examination of saliva|Collection of saliva samples
75739731|NCT04518722|Radiation|CT Scan|Dual-energy mid-tibia CT, high-resolution single energy MDCT imaging of the distal tibia (ankle), and low radiation hip CT scans
75887751|NCT03087617|Behavioral|Smoking Cessation Counseling|45 minute counseling session with a tobacco treatment specialist.
75887752|NCT03087617|Other|Usual Care|Usual Care for Lung Cancer Screening patients.
76058024|NCT01942837|Drug|Enzalutamide|Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.
76058025|NCT01987895|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
75595542|NCT00594438|Device|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
75739732|NCT04518722|Radiation|DXA Scan|Basic DXA scans will be performed to measure areal BMD and body composition measures at the whole body, spine, and hip
75739733|NCT04518722|Other|Steroid Intake Questionnaire|Questionnaire designed to quantify lifetime oral glucocorticoid intake
75739734|NCT00987662|Drug|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg.
76058026|NCT01987895|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily.
76058027|NCT01987895|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
75739735|NCT00987662|Drug|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg
75739736|NCT00987740|Device|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
75739737|NCT00987818|Other|Procalcitonin measurement|Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
75739738|NCT05690126|Dietary Supplement|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
75887753|NCT00103610|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
75887754|NCT00103610|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
75739739|NCT05690126|Dietary Supplement|Maltodextrin|Food supplements are taken during 6 weeks by healthy volunteers
75739740|NCT00987896|Device|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
75887755|NCT01568801|Behavioral|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
75445647|NCT05598294|Procedure|Mobilization recommendations|Standard mobilization recommendations will be given to all patients, and feedback will be given to the intervention group to increase the number of steps 4 times a day according to the daily targeted number of steps.
75739741|NCT00090103|Drug|dutasteride 0.5mg once daily for 4 years|combination or single agent
75739742|NCT00090103|Drug|tamsulosin 0.4mg once daily for 4 years|combination agent or single agent
75739743|NCT01088659|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
75739744|NCT01088659|Drug|placebo|orally daily, 96 weeks
75739745|NCT01088659|Drug|tenofovir|245mg po daily, 96 weeks
75739746|NCT03962257|Other|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
75739747|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
75739748|NCT00087607|Drug|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
75739749|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
75739750|NCT00087607|Drug|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
75739751|NCT01088737|Drug|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
75739752|NCT00069823|Drug|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
75739753|NCT00069823|Drug|Placebo proton pump inhibitor|Placebo proton pump inhibitor
75739754|NCT01088815|Drug|Gemcitabine, nab-Paclitaxel, GDC-0449|"One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
75739755|NCT00086515|Drug|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
75739756|NCT00086515|Drug|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
75739757|NCT00086515|Drug|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
75739758|NCT00086515|Drug|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period [Phase A], from Visit 5 (Week 6) to Visit 8 (Week 24)
75739759|NCT01090609|Device|Stent implantation|Stent implantation
75887756|NCT02151188|Dietary Supplement|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
75887757|NCT02151188|Device|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
75445648|NCT05590247|Behavioral|Intermittent Fasting Diet|Patients will follow the 16: 8 traditional intermittent fasting model, where they may only consume calories during 1 continuous 8-hour period of the day. Water may be consumed during fasting.
75595543|NCT00594438|Device|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
75739760|NCT00541658|Drug|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
75739761|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
75739762|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
75739763|NCT04384952|Other|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
75739764|NCT04384952|Other|Dyslexic's Holiday Workbook|Use of a special Dyslexic's holiday book, no parent-guided training.
75739765|NCT04334174|Drug|Brentuximab Vedotin|Brentuximab Vedotin will be dosed at 1.8 milligram (mg) per (/) kilogram (Kg) of participants body weight will be infused intravenously every three weeks for up to ten infusions.
75887758|NCT05597579|Diagnostic Test|DAPAR Tests (IQ equivalent test)|This study will compare DAPAR scores before and after the onset of the psychotic illness.
75887759|NCT02156960|Drug|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
75887760|NCT02156960|Drug|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
75887761|NCT02156960|Drug|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
75445649|NCT05581407|Biological|TETRALITE|LiteVax Adjuvanted Seasonal Influenza Vaccine
75445650|NCT05579639|Other|Xylitol|Xylitol wipes
75445651|NCT05579639|Other|Placebo|Placebo wipes
75739766|NCT00987974|Drug|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
75739767|NCT00987974|Drug|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
75739768|NCT00987974|Drug|placebo|placebo for 3 days.
75739769|NCT00987974|Drug|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
75739770|NCT00987974|Drug|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
75739771|NCT00987974|Drug|placebo 7 days|placebo 7 days
75445658|NCT05573022|Other|Pre-consultation electronic patient decision aid|This group is invited to access an electronic version before the consultation. The group of colorectal cancer patients is also introduced to a paper-based version by the clinician in the consultation.
75595544|NCT02270138|Behavioral|Movement-to-music video program|Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
75739772|NCT04324580|Other|Splint|Participants will have their open reduction internal fixation of distal radius fractures treated with volar locked plating. for 2 weeks. Which will be replaced by a custom thermoplastic splint for 5 weeks.
75739773|NCT04324580|Behavioral|Formal Physical Therapy|Participants will also receive a prescription for formal physical therapy. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks.
75887762|NCT03630965|Other|CPR Video|"A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale."
75739774|NCT04324580|Behavioral|Self directed physical therapy|Participants will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
75739775|NCT04324580|Other|Soft dressing (No Splint)|Participants will have their open reduction internal fixation of distal radius fractures placed in a soft dressing which will be kept in place for 2 weeks.
75739776|NCT04229888|Device|LipiFlow|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
75739777|NCT04229888|Device|Light Based (Sham) Treatment|A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.
75739778|NCT04004546|Behavioral|Health literacy-based intervention|Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
75445659|NCT05573022|Other|In-consultation paper-based patient decision aid|This group is introduced to a paper-based version by the clinician in the consultation
75445660|NCT05570123|Dietary Supplement|Flexofytol Forte|standardized exclusive dry extracts of Curcuma longa and Boswellia serrata. 2 tablets a day, one in the morning, one in the evening
75445661|NCT05570123|Dietary Supplement|Placebo|2 tablets a day, one in the morning, one in the evening
75445662|NCT05566847|Other|Physician Education|The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
75445663|NCT05566847|Other|Accountable Population Manager outreach|Patients will be referred to an Accountable Population Manager (APM) for proactive outreach, including supporting medication adherence and educational and overall support for T2D management. An APM is a non-physician clinician (for example, a clinical pharmacist) supporting diabetes management.
75445664|NCT05566769|Device|NMOSDCopilot smartphone application|NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladder and bowel dysfunction, depression
75739779|NCT04236284|Device|Home-based tDCS|tDCS is a non-invasive neuromodulation technique that has been used to improved cognitive functions. It will be administered with a constant current intensity of 2 mA57 for 20 min per session/ 10 sessions total daily for 2 weeks (Monday to Friday). The device is a Soterix 1x1 tDCS mini-CT Stimulator (Soterix Medical Inc., NY) with headgear and 5 _ 7 cm saline-soaked surface sponge electrodes.
75739780|NCT04236284|Behavioral|Prolonged Exposure Therapy|Prolonged Exposure Therapy is a treatment for PTSD that includes the following components: a) psycho-education about the common reactions to traumatic events and presentation of the treatment rationale (sessions 1 and 2), b) repeated in vivo exposure to traumatic stimuli (in vivo exercises are assigned as homework during sessions 3 through 11), c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 through 11; patients listen to session audiotapes for homework between sessions), and d) relapse prevention strategies and further treatment planning (session 12).
75739781|NCT04005248|Diagnostic Test|HCV IgG test|An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
75739782|NCT03519074|Drug|TS-1 combined with cisplatin|Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
75739783|NCT02661542|Drug|FF-10502-01|
75739784|NCT05659316|Other|MRI imaging|Knee MRI imaging
75739785|NCT03907280|Drug|BI 1265162 (T1)|oral solution
75739786|NCT03907280|Drug|BI 1265162 (T2)|Solution for inhalation
75739787|NCT03907280|Drug|BI 1265162 (R)|concentrate for i.v. solution
76058028|NCT01987895|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
75445665|NCT05565950|Biological|AI-09|Botulinum toxin, Type A, intramuscular injection, administered once at baseline
75445666|NCT05565950|Biological|Vehicle|Vehicle Formulation
75445667|NCT05564936|Device|ME&MG mobile application|ME&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
75739788|NCT03907280|Drug|BI 1265162 (T3)|Solution for inhalation
75739789|NCT04004468|Behavioral|Resistance Training|Standard barbell resistance training programs
75739790|NCT03730454|Device|Transanastomotic Tube (5FR)|5FR tube left in place for 5 days after completion of esophageal anastomosis.
75739791|NCT03730454|Other|No Transanastomotic Tube|No transanastomotic tube used during repair
75739792|NCT04120376|Behavioral|Contraception Counseling|Each participant will receive a 10 minute confidential contraception counseling session with an APP in the Emergency Department
75739793|NCT03644732|Procedure|SEEG Group|Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
76058029|NCT02005445|Device|CPAP|Continuous positive airway pressure
76058030|NCT02005445|Behavioral|HLSE|Healthy living and sleep education
75739794|NCT04108130|Other|Preoperative Education|Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
75739795|NCT04108130|Procedure|Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization|PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
75739796|NCT04108130|Other|Individualization of Neuromuscular Blockade|Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
75739797|NCT04108130|Procedure|Postoperative Incentive Spirometry|Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
75739798|NCT04108130|Behavioral|Postoperative Ambulation|Participants will be encouraged to adhere to prescription of early ambulation.
75887763|NCT02153606|Drug|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
75887764|NCT02153606|Other|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
75739799|NCT03905642|Drug|Arikayce™|Amikacin (aminoglycoside) in a liposomal formulation.
76058031|NCT01618669|Drug|Regadenoson|Administered as an intravenous (IV) bolus
75739800|NCT04499300|Other|Data collection from medical files|Data collection from medical files
75739801|NCT03518294|Behavioral|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
75739802|NCT05613374|Device|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
76058032|NCT01618669|Procedure|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
75739803|NCT05613374|Other|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program include the following:~Postural reactions exercises. (using balance board, balance beam, and manual balance perturbations)~Indoor open environment gait training exercises (over ground gait training exercises.). (using obstacles,cones , stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
75739804|NCT03743012|Other|Integrated cardiac rehabilitation|Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
75887765|NCT03631511|Procedure|direct pulp capping with RetroMTA|The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
75887766|NCT02157038|Device|Pedometer|
75887767|NCT02157038|Device|MRI|
75887768|NCT02153762|Drug|Locoid Lipocream|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
76058033|NCT01390948|Drug|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
76058034|NCT01390948|Radiation|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
76058035|NCT01390948|Drug|Temozolomide (TMZ)|75 milligrams per square meter (mg/m^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m^2/day) x 12 cycles, 1st cycle 150 mg/m^2/days 1-5, escalated to 200 mg/m^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
76058036|NCT02005211|Drug|AZD3293|Oral solution
76058037|NCT02005211|Drug|Placebo|Oral solution
76058038|NCT03842722|Device|Protoporphyrin IX - Triplet State Lifetime Technique|Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.
75445675|NCT05552469|Drug|DFV890|DFV890 Single Agent
75445676|NCT05539053|Drug|N Acetylcysteine A|paclitaxel + N-Acetylcysteine orally short course
75445677|NCT05539053|Drug|N Acetylcysteine B|paclitaxel +N Acetylcysteine orally long course
75739805|NCT03743012|Other|Usual Care|Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
75739806|NCT04004156|Device|PerQdisc® Nucleus Replacement Device.|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
75739807|NCT04038476|Diagnostic Test|Standard monitoring + transcutaneous CO2 monitoring|The transcutaneous CO2 Monitoring measures the CO2 partial pressure of the skin and in condition of good circulation these values approximate the arterial/venous CO2 partial pressure. The sensor is placed on the forehead. The physician adapts the sedation Management according to the transcutaneous CO2 monitoring.
75445678|NCT05536804|Drug|Tirzepatide|Administered SC
75445679|NCT05536804|Drug|Placebo|Administered SC
75739808|NCT04038476|Diagnostic Test|Standard monitoring|The transcutaneous CO2-sensor is also positioned on the patients' forehead, but the transcutaneous CO2-monitoring is not available for the physician to adapt the sedative management.
75739809|NCT03504020|Device|ECG Belt Research System|The ECG Belt Research System is used to identify the best vector and programming parameters.
75887769|NCT02153762|Drug|Hylatopic Plus|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
75739810|NCT04126538|Drug|pirfenidone capsule|In the patient group, pirfenidone capsule was taken orally once for 400mg
75739811|NCT04126538|Drug|pirfenidone capsule|Healthy subjects took pirfenidone capsule 400mg once orally
75445680|NCT05536011|Drug|Pitolisant|Exposure to at least one dose of pitolisant at any time during pregnancy
75445681|NCT05536011|Drug|Comparator Products|Exposure to at least one dose of a comparator product at any time during pregnancy
75445682|NCT05534620|Drug|Treosulfan|IV infusion
75739812|NCT04004234|Drug|Manganese Chloride|Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
76058039|NCT01429792|Drug|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
76058040|NCT01429792|Drug|ribavirin [Copegus]|standard treatment, orally daily
75445683|NCT05534620|Drug|Fludarabine|IV infusion
75445684|NCT05533697|Biological|mRNA-4359|Intramuscular Injection
75445685|NCT05533697|Biological|Pembrolizumab|Intravenous infusion
75445686|NCT05529251|Radiation|Radiotherapy boost|"Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~20 Gy if no more disease is visible (node < 1 cm in large diameter)~24 Gy for nodes <= 2 cm~30 Gy for nodes > 2 cm"
75445687|NCT05529251|Drug|Carboplatin AUC7|Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
75445688|NCT05529251|Drug|3 cycles of EP|3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
75445689|NCT05528133|Radiation|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
75445690|NCT05528133|Radiation|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
75739813|NCT04004234|Drug|nab-paclitaxel|Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
75739814|NCT04004234|Drug|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
75739815|NCT04004234|Drug|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
75445691|NCT05527977|Behavioral|Compensation Incentives to improve Clinical Documentation|"The investigators have identified six Diagnoses of Interest for the initiative. For each Diagnosis of Interest, the investigators have specified a series of clinically significant diagnostic details. Each physician will receive a compensation bonus from a pool of $20,000 based on the absolute number of times that he or she appropriately documented a Diagnosis of Interest.~The investigators will use SQL Server Management Studio 18.0 to create an initial dataset using ICD-10 codes from office visits during which a Diagnosis of Interest was addressed. The investigators will compare documentation during the 12-week against a 6-week period prior to the intervention. The 6-week period will not be used to determine compensation bonuses. Two blinded research assistants will review H&P's and progress notes from extracted visits to tabulate the number of times that clinical documentation met expectations."
76058041|NCT04034446|Biological|CD19-CD22 CAR-T cells|0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
75739816|NCT04095416|Device|ACE compression wrap|Bilateral lower extremity ACE compression wraps
75595545|NCT02270216|Procedure|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
75595546|NCT02270216|Procedure|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
75595547|NCT00592410|Drug|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
75595548|NCT01605656|Behavioral|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
75595549|NCT01605656|Behavioral|Questionnaires|"Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete."
75887770|NCT04687631|Drug|mFOLFOXIRI plus Cetuximab|cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
75887771|NCT04687631|Drug|mFOLFOXIRI Plus Bevacizumab|bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
75739817|NCT00990080|Biological|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
75739818|NCT00990158|Drug|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
75739819|NCT00990158|Drug|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
75739820|NCT02736344|Device|BioNIR Ridaforolimus Eluting Coronary Stent|
75739821|NCT02682992|Device|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
76058042|NCT01409434|Drug|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
76058043|NCT01940887|Drug|E10030|
75887772|NCT02159300|Behavioral|experience brain activity recording|Intervention: experience brain activity recording
75887773|NCT05597501|Behavioral|manual-based group interventions|weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis&logotherapy
75887774|NCT04833023|Drug|Haldol 2mg/ml oral solution|"Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
76058044|NCT01940887|Drug|bevacizumab or aflibercept|Patients are randomized to receive either bevacizumab or aflibercept
76058045|NCT01940887|Drug|E10030 sham injection|Pressure on the eye with a syringe with no needle
75739822|NCT05279066|Device|Biostrap Wristband|The Biostrap Wristband device is a non-invasive optical sensor that monitors changes in arterial pulse volume using Photoplethysmography (PPG). PPG is frequently used in wearable sensors to detect heart rate as well as other metrics such as heart rate variability (HRV) and respiratory rate. The raw biosignals recorded by the wristband device will be further processed to estimate the ejection fraction and cardiac output.
76058046|NCT01925612|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
76058047|NCT01925612|Drug|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
76058048|NCT01925612|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
76058049|NCT01925612|Drug|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
76058050|NCT01925612|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
76058051|NCT01925612|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
75445692|NCT05516134|Behavioral|SAFE at Home|The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app
75739823|NCT01563770|Dietary Supplement|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
75445694|NCT05508984|Device|Amma Cooling Caps|"Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen."
75445695|NCT05508282|Behavioral|Reading Bees app and children's book to enhance parent-infant reading quality (0-2 month visit)|The reading intervention will be provided at the baseline clinic well-visit (0-2 months), and is based on the SHARE/STEP approach.
75445696|NCT05508282|Behavioral|Reading Bees app and children's book to encourage alternatives to digital media (6-month visit)|The digital media (screen time) intervention will be provided at the 6-month clinic well-visit and is based on Baby Unplugged materials (book and app content).
75739824|NCT01563770|Dietary Supplement|Placebo|3 placebo capsules, twice daily for four consecutive weeks
75739825|NCT00412984|Drug|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
75739826|NCT00412984|Drug|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
76058052|NCT01925612|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
76058053|NCT02093663|Drug|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to <= 35 kg; 1800 mg/day for participants weighing > 35 kg to <= 50 kg; 2400 mg/day for participants weighing > 50 kg to <= 90 kg.
76058054|NCT02093663|Drug|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to <= 23 kg; 2400 mg/day for participants weighing > 23 kg to <= 35 kg; 3600 mg/day for participants weighing > 35 kg to <= 50 kg; 4800 mg/day for participants weighing > 50 kg to <= 90 kg.
75739827|NCT00539864|Biological|FluBlok Influenza Vaccination|0.5mL dose for intramuscular injection
75739828|NCT00539864|Biological|TIV (Fluzone) Influenza Vaccination|0.5mL dose for intramuscular injection
75739829|NCT04003376|Device|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
75739830|NCT04003376|Drug|Triamcinolone Acetonide 10mg/mL|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide
75739831|NCT04003376|Biological|platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
76058055|NCT01408888|Biological|LY2189265|Administered subcutaneously
76058056|NCT01408888|Drug|Sitagliptin|Administered orally
75595550|NCT01605656|Behavioral|Focus Groups|"Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes."
75445698|NCT05493709|Drug|Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
75887775|NCT04833023|Drug|Olanzapine Actavis 5mg orodispersible tablet|"Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
75887776|NCT02159378|Other|Fructosamines|
75595551|NCT00594477|Radiation|IMRT|
75739832|NCT04003376|Drug|vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
75739833|NCT01563848|Procedure|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
75595552|NCT02270294|Other|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
75739834|NCT01563848|Procedure|Implantation of loop recorder|"The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events"
75445699|NCT05493280|Device|MOXI|Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.
75887777|NCT02159456|Other|Continuous enteral feeding via infusion pump|
75595553|NCT02270294|Other|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
75595554|NCT00592449|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
75887778|NCT02159456|Other|Intermittent enteral feeding via gravity-based infusion|
75887779|NCT03091439|Drug|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
75595555|NCT00592449|Behavioral|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
75595556|NCT04328064|Drug|Rosuvastatin calcium 40mg|Active drug -Rosuvastatin
75887780|NCT03091439|Drug|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
75887781|NCT02153840|Drug|PSORI-CM01（YXBCM01） granule|
75887782|NCT02153840|Drug|placebo|
75887783|NCT03631823|Other|Chemotherapy with temozolomide or no chemotherapy|This study is just an observational study.
75887784|NCT02157272|Drug|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
75887785|NCT05597423|Other|Massage|The massage will be applied for 16 minutes on the quadriceps, calf, hamstrings and lower back bilaterally with 4 different pressures.
76058057|NCT01918033|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
75445700|NCT05492500|Drug|Main cohort: Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
75445701|NCT05492500|Drug|Main cohort: Ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
75445702|NCT05492500|Drug|Main cohort: ponsegromab high dose|Ponsegromab high dose subcutaneous injection
75445703|NCT05492500|Other|Main cohort: Matched placebo|Matched placebo subcutaneous injection
75445704|NCT05492500|Drug|Open-label, PK Cohort: ponsegromab low dose|ponsegromab low dose subcutaneous injection
75445705|NCT05492500|Drug|Open-label, PK Cohort: ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
75445706|NCT05492500|Drug|Open-label, PK Cohort: ponsegromab high dose|Ponsegromab high dose subcutaneous injection
75445707|NCT05489679|Drug|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
75445708|NCT05486208|Drug|LY3844583|Administered SC and/or IV.
75595557|NCT04328064|Drug|Placebo oral tablet|40 mg placebo for 12 months
75445709|NCT05486208|Drug|Placebo|Administered SC and/or IV.
75445710|NCT05477576|Drug|RYZ101|RP3D as determined in Phase 1b
75445711|NCT05477576|Drug|Everolimus 10 mg|Everolimus 10 mg daily by mouth
75445712|NCT05477576|Drug|Sunitinib 37.5 MG|Sunitinib 37.5 mg daily by mouth
75595558|NCT01605734|Procedure|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
75595559|NCT01605734|Drug|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
75595560|NCT02270372|Biological|ONT-10, Varlilumab combination|"ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27."
75739835|NCT01563848|Procedure|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
75739836|NCT04086212|Drug|Icodextrin, xylitol and carnitine solution for peritoneal dialysis|Patients will receive a long dwell exchange for three days.
75739837|NCT04086212|Drug|EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution|Patients will receive a long dwell exchange for three days.
75739838|NCT05404490|Drug|Bupivacain|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
75739839|NCT05404490|Drug|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
75739840|NCT05359874|Drug|Bevacizumab-IRDye800CW|In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
75739841|NCT05359796|Biological|Chronic hyperglycemia|For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.
75739842|NCT05359796|Biological|Residual islet function|For each follow-up, fasting and stimulated C-peptide levels will be measured.
75739843|NCT05359796|Genetic|Genetic variation|Genetic variations of interest will be detected with the blood sample collected at baseline.
75739844|NCT05359796|Dietary Supplement|Dietary constitutes|For each follow-up, the dietary constitutes for the past 3 days will be recorded.
75739845|NCT05359796|Genetic|Microbiome composition and function|For each follow-up, the fecal and oral samples will be collected for measurement.
75739846|NCT05359796|Biological|Metabolome composition|For each follow-up, the serum and urine samples will be collected for measurement.
75445713|NCT05477576|Drug|Octreotide LAR 60 MG Injection|High-dose octreotide LAR 60 mg Q4W by i.m. injection
75445714|NCT05477576|Drug|Lanreotide 120Mg Sa Susp Inj Syringe|High dose frequency lanreotide 120 mg Q2W by deep s.c. injection
75445715|NCT05474014|Procedure|superior trunk block|Local anesthetic injection will be applied to the superior trunk of the brachial plexus accompanied by ultrasonography.
75445716|NCT05474014|Drug|intravenous patient-controlled analgesia|Analgesics will be given using a patient-controlled analgesia device.
75445717|NCT05473520|Drug|Doxycycline|A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
75445718|NCT05473520|Drug|Placebo|Placebo + standard anti-tuberculous treatment
75739847|NCT05359796|Biological|Composition of peripheral blood immune cells|For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
75595561|NCT01605773|Drug|repaglinide|Dose individually adjusted and conducted according to labeling
75595562|NCT01605773|Drug|glyburide|Dose individually adjusted and conducted according to labeling
75595563|NCT00592527|Drug|insulin detemir|
75595564|NCT01605851|Device|Closure, Foramen Ovale|
75595565|NCT02270528|Behavioral|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (~5 minutes)
75595566|NCT02270528|Behavioral|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
75595567|NCT00594555|Drug|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
75595568|NCT00594555|Drug|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
75739848|NCT05359718|Other|Questionnaire|Questionnaire
75739849|NCT00990392|Drug|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
75887786|NCT05597423|Other|Placebo|The cream will be applied to the quadriceps, calf, hamstring and lower back bilaterally and the participant will wait 16 minutes lying down in the supine position.
75887787|NCT04729712|Procedure|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Erector Spinae block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the erector spinae plane prior to surgical incision. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
75887788|NCT04729712|Procedure|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Paravertebral block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the paravertebral space after the thoracoscopic ports have been sited. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
75887789|NCT01382537|Device|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
75887790|NCT01382537|Device|InterX 5000|Placebo treatment
75887791|NCT02154074|Drug|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
75887792|NCT02154074|Drug|Isoflurane|inhale Isoflurane 1.5MAC
75887793|NCT02154074|Drug|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
75887794|NCT02154074|Drug|normal saline|the same volume of saline + Isoflurane during operation
75887795|NCT02154152|Drug|Homoeopathic Medicine causticum 200c|
75887796|NCT03086447|Device|Investigational Contact Lens|Senofilcon C Toric
76058058|NCT01918033|Drug|Placebo|Matching placebo to desloratadine 5 mg tablets
75887797|NCT03086447|Device|Marketed Contact Lens|Air Optix for Astigmatism
75445720|NCT05466279|Drug|remazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.
75445721|NCT05466279|Drug|Propofol|Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus
75445722|NCT05466279|Drug|Midazolam|Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
75445723|NCT05462639|Drug|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
75739850|NCT00990392|Other|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
75739851|NCT05590988|Other|Tablet-based training|"Each task is performed for one minute, followed by a 2-minute break. After the task has been performed three times, there is a 5-minute break. The training block is then carried out twice more. This means that three blocks are carried out for each therapy unit."
75739852|NCT05590988|Other|ergotherapeutic training|A task is performed for one minute at a time, followed by a 2-minute break. Once three rounds have been completed, there is a 5-minute break. As in the intervention group, there are a total of three training blocks.
75739853|NCT05590910|Other|Music|Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
75739854|NCT03367754|Other|Placebo|Placebo
75739855|NCT03367754|Drug|Pembrolizumab|Pembrolizumab, 200 mg, or placebo via intravenous (IV) infusion, single dose.
75739856|NCT03335072|Drug|Azithromycin|Mass Drug Administration
75739857|NCT01563926|Drug|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
75739858|NCT05590520|Procedure|Botulinum injection|Botox injection to be injected in internal anal sphincter to see the curative response in comparison to gtn cream application
75887798|NCT02159534|Other|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
75887799|NCT02159612|Other|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
75595569|NCT01605929|Procedure|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
75739859|NCT05590520|Drug|GTN OINTMENT|0.2%GTN applied on anal canal.
75739860|NCT05590442|Other|Tests|Cognitive assessments and olfactory tests
75739861|NCT01034956|Device|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
75595570|NCT00594594|Other|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
75739862|NCT01040884|Other|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
75739863|NCT05590052|Device|Bipolar Electrosurgery|Achievement of hemostasis using bipolar electrosurgery
75739864|NCT05590052|Device|Thermocautery|achievement of hemostasis using thermocautery
75739865|NCT01580878|Drug|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
75445724|NCT05459636|Device|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
75739866|NCT01580878|Drug|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
75739867|NCT01580878|Drug|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
75739868|NCT05589974|Drug|Verteporfin|Chronic CSC are receiving one treatment before the observation period.
75739869|NCT00673049|Drug|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
75739870|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
75739871|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
75739872|NCT04003844|Drug|Immunoglobulin G|single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
75739873|NCT04003844|Drug|Acetylsalicylic acid|Coadministration
75739874|NCT05589584|Drug|N acetyl cysteine with weight reduction|high dose 2400mg/day
75739875|NCT05359484|Diagnostic Test|Uroflowmetry|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.
75739876|NCT00412750|Drug|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
75445725|NCT05459636|Device|Very-low-resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
75739877|NCT00412750|Drug|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
75739878|NCT05361278|Other|Chlorhexidine solution|"Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~Irrigate the root canal with 3 ml of the solution after using the last file.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
75739879|NCT05361278|Other|Activated chlorhexidine solution|"Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~Irrigate the root canal with 3 ml of the solution after using the last file with activation using an ultrasonic irrigation head.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
75739880|NCT05361278|Other|Chlorhexidine gel|"Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~Irrigate the root canal with 3 ml of the gel after using the last file.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
75739881|NCT05361278|Other|Activated chlorhexidine gel|"Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~Irrigate the root canal with 3 ml of the gel after using the last file with activation using an ultrasonic irrigation head.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
75739882|NCT05361278|Other|Sodium hypochlorite solution|"Irrigate the root canal with 1 ml of 5.25% sodium hypochlorite solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~Irrigate the root canal with 3 ml of the solution after using the last file.~Irrigating the canal with 3 ml of 5% sodium thiosulfate solution to remove residual of sodium hypochlorite.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
75445726|NCT05458128|Drug|Pitolisant|"Pitolisant 4.45 mg tablets~Pitolisant 17.8 mg tablets"
75739883|NCT00764855|Procedure|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
75739884|NCT05589506|Device|Removable partial denture PEEK|A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
75887800|NCT02933801|Drug|ODM-201|ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
75887801|NCT02933801|Other|Placebo|Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
76058059|NCT01408732|Drug|Sclerotherapy|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
75887802|NCT04794725|Procedure|Blood sampling|blood samples from venepuncture (10mL)
75445729|NCT05457257|Drug|olaparib|300 mg (2x 150 mg tablets) twice daily
75445730|NCT05457257|Drug|enzalutamide|160 mg (4 x 40 mg capsules) once daily
75887803|NCT04787393|Device|Heartfelt device|The Heartfelt device uses a system of scanner in a compact device to generate depth images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit, For the measurements to take place, the participant walks in the field of view of the device, measurments are only taken when the patients has bare feet and no slippers/shoes, so the location of the device in the home is choosen to match this requirement. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.
76058060|NCT01408732|Other|Standard Treatment|Normal standard of care followed by Drug interevention
76058061|NCT04033978|Behavioral|Cognitive remediation|10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
76058062|NCT04033978|Behavioral|psychosocial rehabilitation|10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
76058063|NCT04626037|Behavioral|WECS Relational Toolkit|The Cuddle and Calm Book, The Mommy Baby Book, mother and child mutual narrative, the Bottle of Emotions, and the WECS for emotional connection, make up the WECS Relational Health toolkit.
75595571|NCT02270606|Radiation|intensity-modulated radiation therapy|Undergo IMRT
75595572|NCT02270606|Drug|fluorouracil|Given IV
75595573|NCT02270606|Drug|oxaliplatin|Given IV
75595574|NCT02270606|Drug|leucovorin calcium|Given IV
75595575|NCT02270606|Procedure|therapeutic conventional surgery|Undergo total mesorectal excision
75445731|NCT05457257|Drug|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
75445732|NCT05457257|Drug|Prednisone|5mg(5mg x 1 tablet) twice daily
75445733|NCT05456581|Behavioral|'Scotoma awareness' Training|In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.
75595576|NCT00594633|Other|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
75595577|NCT02270762|Other|Rest in bed|
75595578|NCT02270762|Other|Passive verticalization|
75595579|NCT02270762|Other|Rest in bed|
75595580|NCT01605968|Device|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
75739885|NCT00759317|Drug|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
75739886|NCT00764933|Behavioral|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
75739887|NCT00764933|Other|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
75739888|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
75739889|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
75445734|NCT05456581|Behavioral|Control Training|The task will be performed in the control group without the visible scotoma.
75595581|NCT01605968|Device|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
75739890|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
75739891|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
76058064|NCT01390402|Drug|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
75739892|NCT01041040|Drug|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
75887804|NCT04787393|Device|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records if they wish to do so.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.~The data from the scales will be reviewed retrospectively, as the comparison in this study is with standard care, not with enhanced provision of care, which would be the case if we were using automatic reporting of weights."
75887805|NCT04666025|Procedure|Biospecimen Collection|Undergo collection of nasopharyngeal swabs, blood, and saliva samples
76058065|NCT01390402|Drug|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
75445735|NCT05456256|Drug|LP-300|LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
75445736|NCT05456256|Drug|Pemetrexed|Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
75595582|NCT04355013|Device|Core emperature monitoring|Monitoring core temperatures with probes placed in the arterial outlet and venous inlet of extracorporeal pump, pulmonary artery, bladder, nasopharinx and forehead using a doublé-sensor probe
75595583|NCT01606046|Device|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
75595584|NCT01606046|Drug|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
75595585|NCT02892630|Other|No intervention|
75595586|NCT01606085|Behavioral|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
75739893|NCT00765011|Drug|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
75739894|NCT00765011|Procedure|H&N surgery|Rescue surgery
76058066|NCT01390402|Procedure|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
76058067|NCT01390402|Drug|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
76058068|NCT01390402|Drug|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
76058069|NCT01390402|Procedure|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
75445737|NCT05456256|Drug|Carboplatin|Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
75595587|NCT01606085|Behavioral|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
75739895|NCT01035034|Procedure|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
75739896|NCT01035034|Procedure|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
75739897|NCT00765089|Procedure|Isolation of pulmonary veins with Bipolar radiofrequency ablation|
75887806|NCT04666025|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
76058070|NCT01390402|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
75739898|NCT00765167|Drug|Fluoride|Brush half mouth twice daily for four days
75445741|NCT05438602|Drug|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
75445742|NCT05438602|Drug|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
75739899|NCT00765167|Drug|Triclosan|Brush half mouth daily for four days
75887807|NCT04666025|Other|Electronic Health Record Review|Medical charts are reviewed
76058071|NCT01390402|Drug|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
76058072|NCT01390402|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
76058073|NCT01976299|Device|AVERT|
76058074|NCT01428076|Drug|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
75445743|NCT05438602|Drug|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
75445744|NCT05438602|Drug|Placebo for ritonavir|Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
75445745|NCT05436093|Drug|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
75445746|NCT05432817|Behavioral|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
75445747|NCT05432817|Behavioral|Therapist-facilitated Support group|Therapist-facilitated Support: group therapy oriented toward providing general support networks and communities of individuals with similar experiences. Sessions will also focus on establishing trust, open communication, and developing therapeutic alliance with group members and the therapist facilitator. Occurs over 12 sessions.
75739900|NCT00765167|Drug|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
75739901|NCT00765167|Drug|Fluoride|Brush half mouth daily for four days
75739902|NCT00759551|Drug|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
75739903|NCT00759551|Drug|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
75887808|NCT04666025|Other|Questionnaire Administration|Complete questionnaire
75887809|NCT05460455|Drug|Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo|HB0034 and Placebo
75887810|NCT03104413|Drug|placebo for risankizumab IV|placebo for risankizumab administered as intravenous (IV) infusion.
75887811|NCT03104413|Drug|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
75887812|NCT03104413|Drug|risankizumab IV|risankizumab administered as intravenous (IV) infusion.
75887813|NCT05451875|Device|Non-invasive monitoring|Comparison of VitalTracer monitoring devices with invasive and/or non-invasive gold standard reference
76058075|NCT01900652|Drug|Emibetuzumab|Administered IV
76058076|NCT01900652|Drug|Erlotinib|Administered Orally
75595588|NCT00594828|Device|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
75445748|NCT05428826|Drug|Prednisone|Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
75445749|NCT05422222|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination for oral administration.
75595589|NCT00594828|Device|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
75595590|NCT02270801|Drug|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
75595591|NCT04327713|Dietary Supplement|fish oil supplement|daily fish oil supplement vs. placebo
75595592|NCT01606163|Biological|GC1102|"Description: GC1102 IV bolus injection during 10~ 30 seconds.~Amount: group1-3ml, group2-5ml, group3-8ml~Subject number: group1-8, group2-8, group3-8~Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
75739904|NCT00759551|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
75887814|NCT04536155|Other|questionnary SF36|"This is a validate questionnary:~Ware et al,1992, McHorney et al, 1993, McHorney et al, 1994 French version : Author : Alain Leplège; et coll. En 2001"
75887815|NCT04536155|Other|Hospital Anxiety and Depression Scale|this is a validate scale: author: Zigmond A.S., Snaith R.P. in 1983
75887816|NCT04536155|Other|Chronic Pain Acceptance Questionnaire|"This is a validate questionnaire:~Fish, R., McGuire, B.E., Hogan, M., Stewart, I. & Morrison, T. (2010)."
76058077|NCT02093351|Drug|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
76058078|NCT02093351|Drug|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
76058079|NCT02093351|Drug|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
76058080|NCT02093351|Drug|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
75445750|NCT05421741|Drug|Antibiotic coated intramedullary Nail|"Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube."
75595593|NCT01606163|Other|JW normal saline|"Description: Normal saline IV bolus injection through 10~ 30 seconds.~Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~Subject number: 9~Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
76058081|NCT02093351|Procedure|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
76058082|NCT02078284|Biological|CPP|One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
75445751|NCT05421741|Other|Standard Intramedullary Nail|Standard Intramedullary Nail
75595594|NCT02892942|Drug|Gonal-F®|225 to 450 IU/d; from day 2 of menstrual cycle onward
75595595|NCT02892942|Drug|Cetrotide®|0.25 mg/day, starting on day 6 of Gonal-F®.
75595596|NCT02892942|Drug|Cetrotide®|1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
75739905|NCT00759551|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
76058083|NCT02078284|Biological|LSP|
75445752|NCT05414474|Other|Reference|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes
75445753|NCT05414474|Other|Ascorbic acid (AA) 500 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 500 mg AA
75739906|NCT00759551|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
75739907|NCT00759551|Drug|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
76058084|NCT02092961|Drug|Fostamatinib|Fostamatinib 100mg twice daily.
76058085|NCT02092961|Drug|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
76058086|NCT02092961|Drug|Placebo of Fostamatinib|Placebo bid for 6 weeks.
76058087|NCT02092961|Drug|Placebo of Adalimumab|Placebo injection once every two weeks.
76058088|NCT01898078|Drug|Alisertib|Alisertib ECT
75739908|NCT00759551|Drug|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
75739909|NCT03905096|Drug|BI 425809|Film coated tablet
75739910|NCT03905096|Drug|Donepezil|Film coated tablet
75887817|NCT04536155|Other|digital pain scale|this is a validate scale A.N.A.E.S. February 1999
75887818|NCT01382147|Drug|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
75887819|NCT03630887|Device|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room during different time periods.
75887820|NCT01382069|Drug|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
75887821|NCT01382069|Drug|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
76058089|NCT01987817|Biological|AR101 powder provided in capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
76058090|NCT01987817|Biological|Placebo powder provided in capsules|Study product formulated to contain only inactive ingredients for use as defined in the protocol
76058091|NCT01940497|Drug|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
75595597|NCT02270879|Procedure|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
76058092|NCT01940497|Drug|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
76058093|NCT01940497|Drug|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
75595598|NCT00594867|Drug|Acetaminophen - 4 grams per day + Placebo|Acetaminophen - 4 grams per day + Placebo
75739911|NCT02557919|Other|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
75739912|NCT02557919|Other|Usual Best Practice|.5 day training on tobacco control and emerging products.
75739913|NCT00412360|Biological|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
75739914|NCT00412360|Biological|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
75739915|NCT00412360|Radiation|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
75739916|NCT00412360|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
76058094|NCT01940497|Drug|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
75595599|NCT00594867|Drug|Aspirin - 325 mg per day + Placebo|Aspirin - 325 mg per day + Placebo
75595600|NCT00594867|Drug|Acetaminophen 4 gram per day + Aspirin 325 mg per day|Acetaminophen 4 gram per day + Aspirin 325 mg per day
75595601|NCT01606241|Drug|Cyclophosphamide|Given PO
75595602|NCT01606241|Other|Laboratory Biomarker Analysis|Correlative studies
75595603|NCT01606241|Biological|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
75595604|NCT04353453|Device|Study Procedure for Participants That Were Not in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~Sitting down for 10 minutes,outdoor walking for one minute and repeat this sequence four times At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
75887822|NCT01381991|Device|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
75887823|NCT01381835|Drug|TMC435|150 mg capsule once daily for 7 days
75887824|NCT04429685|Drug|Ketamine|Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline
75887825|NCT04429685|Drug|Saline (placebo)|Saline (placebo)
75595605|NCT04353453|Device|Study Procedure for Participants That Were Included in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~Going from the indoor facility to the car and driving for 30 minutes at least. Subject drove the car in city streets under light traffic conditions. At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
75887826|NCT04411277|Device|Application of the FreeStyle Libre Flash Glucose CGM.|Assessment of glycemic control and hypoglycemia, adherence to therapy and CGM use.
75887827|NCT04411277|Diagnostic Test|InBody 270 multifrequency bioimpedance|analysis of body composition to calculate appendicular skeletal muscle.
75887828|NCT01379417|Dietary Supplement|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
75887829|NCT01384279|Drug|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
75739917|NCT00412360|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
75739918|NCT00412360|Drug|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
75739919|NCT00412360|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if > 50 kg or 15 mg/kg IV q 8 hours if < 50 kg beginning the morning of Day -3.
75887830|NCT01568879|Other|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
75887831|NCT01568879|Other|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
75887832|NCT01383265|Procedure|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
75887833|NCT01383265|Procedure|Water method|Control method will use plain water with water method for screening colonoscopy
75445754|NCT05414474|Other|Ascorbic acid (AA) 80 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe + 80 mg AA
75739920|NCT00761423|Biological|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
75739921|NCT00761423|Biological|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
75887834|NCT01381601|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
75887835|NCT05216965|Drug|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
75887836|NCT02823353|Drug|Fenofibrate|Fenofibrate 200mg/day
75887837|NCT02823353|Drug|UDCA|UDCA 13-15mg/kg/day
75887838|NCT04509193|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)
76058095|NCT01924364|Device|Tissue Genesis Cell Isolation System™ (TGI CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
75739922|NCT03957967|Other|video taken|Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
75887839|NCT04509193|Drug|Warfarin|Participants receive warfarin (per written prescription, medication administration or self-report of medication use)
75887840|NCT01379339|Drug|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
76058096|NCT01924364|Procedure|Standard of care fat grafting|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
75445755|NCT05414474|Other|Coffee|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes + 150 mL coffee
75445756|NCT05414474|Other|Breakfast|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 1 bread roll (~100 g) with butter and honey + 1 cup of plain yoghurt (180 mL) + 1 cup of coffee (150 mL) + 1 glass of orange juice (250 mL)
75445757|NCT05414474|Other|Afternoon|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe isotopes administered in the afternoon
75445758|NCT05413304|Drug|pre-operative abemaciclib|pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
75445759|NCT05413304|Device|Device for Cerebral Fluid Dialysate Collection|post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48-hours to assess CNS drug entry and targeted inhibition with abemaciclib
75739923|NCT00761501|Drug|PN400|Oral
75445760|NCT05413304|Device|Ashion Analytics GEM ExTra|resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
75595606|NCT00595023|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
75739924|NCT00761501|Drug|Naproxen (Proxen S)|Oral
75739925|NCT00761501|Drug|Naproxen (Naprosyn E)|Oral
75739926|NCT01564160|Dietary Supplement|Fish Oil|Source of omega-3 fatty acids.
75739927|NCT01564160|Dietary Supplement|PCSO-524|Extract of Greenshell Mussel
76058097|NCT01987505|Drug|Rituximab|1400 mg will be injected subcutaneously (SC).
75739928|NCT01088893|Drug|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
75739929|NCT03026036|Radiation|PET Scan with Raclopride|A subsample (21 per group) will complete the PET imaging.
75887841|NCT01379339|Drug|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
75445761|NCT05413304|Drug|abemaciclib + temozolomide|abemaciclib 150mg po BID and temozolomide 200mg/m2 po daily x 5 days in 28 day cycles (temozolomide 150mg/m2 po daily x 5 days for cycle 1)
75445771|NCT05399381|Device|Transcranial alternating current stimulation (tACS)|Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.
75739930|NCT00759629|Other|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
75739931|NCT00759629|Other|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
75739932|NCT01088971|Dietary Supplement|Duolac7S|1 capsule two times everyday for 6 weeks
75739933|NCT01088971|Dietary Supplement|starch|1capsule two times everyday for 6 weeks
75739934|NCT00990860|Drug|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
76058098|NCT01923896|Behavioral|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
75739935|NCT00990860|Procedure|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
75739936|NCT02558543|Drug|Stromal Vascular fraction|
75739937|NCT02558543|Drug|Ringer lactate|
75739938|NCT01035190|Drug|Budesonide|Inhalation, 200 µg/puff
75739939|NCT01090687|Radiation|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
75739940|NCT01090687|Device|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
76058099|NCT01923896|Drug|d-cycloserine (DCS)|
75739941|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
75739942|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
75739943|NCT02557841|Device|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
75445775|NCT05369208|Drug|Avatrombopag Oral Tablet|Avatrombopag 20 mg given once daily (initial dose). Dose adjustments will be determined by the physician and in accordance with the overseas Doptelet prescribing information.
75445776|NCT05364424|Drug|Glofitamab|Participants will receive intravenous (IV) glofitamab for up to 3 cycles.
75445777|NCT05364424|Drug|Obinutuzumab|Participants will receive IV obinutuzumab on Cycle 1 Day 1.
75445778|NCT05364424|Drug|Tocilizumab|Participants will receive IV tocilizumab as necessary to manage cytokine release syndrome (CRS) events.
75445779|NCT05364424|Drug|Rituximab|Participants will receive up to 2 doses of IV rituximab.
75739944|NCT00765479|Dietary Supplement|soy protein isolate|Given orally
75739945|NCT00765479|Other|placebo|Given orally
75739946|NCT01035268|Procedure|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
75739947|NCT00571103|Drug|acamprosate|Two 333mg tablets taken three times daily.
75739948|NCT03742934|Other|Short peptide|Short peptide formula during bowel preparation
75739949|NCT03742934|Other|Liquid diet|Liquid diet during bowel preparation
75739950|NCT00991016|Drug|PF-04805712|ascending single and multiple doses starting at 30 mg
76058100|NCT01923896|Drug|Placebo|lactose powder
76058101|NCT02004353|Device|Cochlear® Hearing Implants|Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
76058102|NCT01938625|Drug|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
76058103|NCT01938625|Drug|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
75739951|NCT03993652|Behavioral|Kids FIRST|family- and school-based intervention to reduce unhealthy screen-time and snacking
76058104|NCT01938625|Drug|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
76058105|NCT01938625|Drug|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
75445780|NCT05364424|Drug|Ifosfamide|Participants will receive IV ifosfamide for up to 3 cycles.
76058106|NCT01938625|Drug|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
76058107|NCT04416815|Other|Integrating Health promotion with and for Older People - eHealth|The intervention will be delivered for 6 months on top of usual care. It will be provided by HCPs. If needed one home visit to install the digital platform will be conducted. A HCP will introduce how to use the digital platform and create a personal account. The intervention starts with a person-centred phone-call where a health plan is co-created and potential team members to support this are identified and invited. The health plan includes the older persons' goals, internal and external resources, and need of support from health and/or social-services. This plan will be the point of departure for the forthcoming dialogue. A digital platform will open up for extended and safe communication and visualize the health planning between the older person and team-members in different settings. The older person and the HCP and involved team members on the digital platform will regularly evaluate the health plan and commonly agreed goals.
75595607|NCT04352985|Device|Toraymyxin PMX-20R (PMX Cartridge)|The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.
75595608|NCT02270918|Drug|Kcentra|IV infusion
75595609|NCT02270918|Drug|Apixaban|
75595610|NCT02270918|Drug|Placebo|
75739952|NCT02558777|Other|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
75445781|NCT05364424|Drug|Carboplatin|Participants will receive IV carboplatin for up to 3 cycles.
75739953|NCT01089049|Dietary Supplement|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
75739954|NCT01038934|Procedure|samples collected by buccal cytobrush|
75739955|NCT00765557|Drug|MiraLAX|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
75445782|NCT05364424|Drug|Etoposide|Participants will receive IV etoposide for up to 3 cycles.
75445783|NCT05363111|Biological|Actinium Ac 225-DOTA-Daratumumab|Given IV
75445784|NCT05363111|Biological|Daratumumab|Given IV
75445785|NCT05363111|Biological|Indium In 111-DOTA-Daratumumab|Given IV
75445786|NCT05358886|Drug|BPN14770/ zatolmilast|25mg BID BPN14770
75445787|NCT05358886|Drug|Placebo|Placebo
75445788|NCT05357482|Radiation|TBI|300 cGy total body irradiation (TBI, day -2)
75445789|NCT05357482|Drug|Hydroxyurea|Optimized 4-12 weeks prior to planned transplant date
75595611|NCT02270996|Other|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
75445790|NCT05357482|Biological|briquilimab|briquilimab, anti-CD117 monoclonal antibody at 0.6mg/kg at day -11 prior to infusion of allogeneic HSCs
75739956|NCT00765557|Drug|Placebos|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
75739957|NCT02828618|Procedure|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
75887842|NCT01379339|Drug|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
75887843|NCT01379339|Drug|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
75887844|NCT01379339|Drug|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
75887845|NCT01383187|Procedure|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
75887846|NCT01383187|Procedure|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
75887847|NCT02782247|Device|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.~It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal < 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis >11.5kPa. It cannot be used in patients with ascites."
75595612|NCT00595062|Radiation|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
75445791|NCT05357482|Drug|Filgrastim (G-CSF)|May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.
75445792|NCT05357482|Drug|Sirolimus|For immune suppression (day -1)
75445793|NCT05357482|Biological|Alemtuzumab|Alemtuzumab 1 mg/kg of alemtuzumab divided over 5 days (-7 through -3),
75445794|NCT05357482|Drug|Plerixafor|For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
75595613|NCT01580189|Dietary Supplement|Whey protein|18g protein, immediately after training, 9 weeks
75595614|NCT01580189|Dietary Supplement|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
75595615|NCT01580189|Dietary Supplement|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
75739958|NCT02828618|Procedure|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
75739959|NCT02828618|Procedure|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
75595616|NCT00595140|Drug|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
75595617|NCT00595140|Drug|combination with somatostatin analogue octreotide|s.c., 100µg, one time
75739960|NCT02828618|Procedure|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
75739961|NCT02828618|Drug|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
75739962|NCT01086553|Drug|budesonide|9mg budesonide OD
75739963|NCT01086553|Drug|budesonide|3mg budesonide TID
75739964|NCT01041352|Device|laryngeal mask|LMA Proseal
75739965|NCT01041352|Device|endotracheal tube|Unomedical endotracheal tube
75739966|NCT00765635|Drug|drops intilation (Taponoto ® )|four drops, unique doses
75739967|NCT00765635|Drug|drops intilation (Otocerum®)|four drops, unique doses
75739968|NCT00765635|Drug|drops intilation (Placebo)|Placebo
75739969|NCT02810990|Drug|Bosutinib|"Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 > 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
76058108|NCT01975675|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
76058109|NCT01975675|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
76058110|NCT01975285|Drug|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
75445795|NCT05356741|Drug|AMX-818|Administered as IV infusion
75887848|NCT02782247|Device|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
75445796|NCT05356741|Drug|pembrolizumab|Administered as IV infusion
75445797|NCT05337943|Behavioral|CBT-I|Weekly sessions with a therapist to improve sleep for 8 weeks.
75887849|NCT02697383|Drug|Ixazomib (MLN9708)|
76058111|NCT01975285|Drug|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
76058112|NCT01974895|Biological|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
75445798|NCT05337943|Device|Bright Light Therapy|Daily light therapy for 30 minutes for 8 weeks.
75445799|NCT05333822|Dietary Supplement|Bashan|a vegetable plant based compound drink add after three meals for 14 days
75739970|NCT01041430|Other|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
75739971|NCT01041430|Other|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
75739972|NCT00069277|Drug|E7389|
75739973|NCT00765713|Device|Nasal continuous positive airway pressure|Nocturnal
75739974|NCT01041508|Drug|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry.
76058113|NCT01974895|Biological|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
76058114|NCT01974817|Biological|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
76058115|NCT04415749|Biological|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine
76058116|NCT04415749|Other|Placebo|Normal saline
76058117|NCT04624399|Drug|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
76058118|NCT01915849|Drug|LIK066|LIK066 15 mg, 50 mg and 150 mg
76058119|NCT01915849|Drug|Placebo|
76058120|NCT01915771|Drug|lomitapide|20 mg dose
76058121|NCT01938391|Device|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
76058122|NCT01915303|Drug|Pasireotide with or without cabergoline|The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
76058123|NCT01987427|Drug|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
75445800|NCT05333822|Other|water|water as placebo
75445801|NCT05332535|Behavioral|serious game based web application education|serious game based web application education for nursing students
75445802|NCT05325671|Procedure|transarticular multimodal drug infiltration|as described previously
75445803|NCT05321316|Drug|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
75739975|NCT01041508|Radiation|Total Body Irradiation|"Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines."
75739976|NCT01041508|Other|Stem Cell Infusion|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
75887850|NCT02697383|Drug|Dexamethasone|
75445804|NCT05317416|Drug|Elranatamab|BCMA-CD3 bispecific antibody
75445805|NCT05317416|Drug|Lenalidomide|Immunomodulatory drug
75445806|NCT05317416|Drug|Lenalidomide|Immunomodulatory drug
75739977|NCT01041508|Drug|Cyclosporins|"Cyclosporin (CSP) should be started on day -1 after completion of Clofarabine. CSP levels should be maintained between 300-400 ng/ml.~Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs). Age > 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)"
75739978|NCT01041508|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) will be at 15 mg/kg, based on adjusted body weight, every 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant.
75739979|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
75739980|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
75887851|NCT01383031|Procedure|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
75887852|NCT01383031|Procedure|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
75887853|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
76058124|NCT01987427|Drug|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
75445807|NCT05317416|Drug|Elranatamab|BCMA-CD3 bispecific antibody
75739981|NCT00765869|Other|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
75739982|NCT00766025|Drug|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
75887854|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
75887855|NCT05422547|Diagnostic Test|Immunoscore Colon Test|Immunoscore® is a tissue-based immune test that measures the host's immune response at the site of the tumor. It is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from resections of localized colon cancer. The test uses whole slide imaging and artificial intelligence algorithms for assessment of the type, density, and location of T cells in FFPE tumor sections to determine an individual Immunoscore® for each patient.
75887856|NCT03631303|Device|Cardiac stimulation through the device leads|During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
75887857|NCT05422469|Device|Medtronic Percept RC neurostimulator|Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
75887858|NCT04173949|Drug|Ramipril 2.5 MG|3 month of treatment with daily Ramipril 2.5 MG
75887859|NCT04150133|Other|Low Residue Diet|Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
75887860|NCT01382017|Drug|Lacosamide|Lacosamide 200 or 400 mg
75887861|NCT01382017|Drug|Placebo|Placebo
75887862|NCT01382017|Drug|Carbamazepine|Carbamazepine 600 mg
75887863|NCT01381523|Drug|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
76058125|NCT01987427|Drug|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
76058126|NCT01937299|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
76058127|NCT01937299|Drug|Vehicle|Inactive ingredients used as a placebo comparator
76058128|NCT01937299|Drug|Travoprost 0.004% ophthalmic solution|
75445808|NCT05316129|Drug|Follicle Stimulating Hormone Receptor T Cells|Participants will receive an infusion of autologous t cells genetically modified ex vivo to express the FSHR-specific 4-1BB/CD3ζ CER.
75445809|NCT05316116|Drug|Siltuximab|Siltuximab will be given on day 1 of each cycle. The dose will be 11 mg/kg given over 1 hour by intravenous infusion. Each cycle is three weeks (+-3 days).
75445810|NCT05314517|Drug|Namilumab|Namilumab administered subcutaneously
75739983|NCT01039012|Other|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
75739984|NCT01039012|Other|Standard Care|Participant follow the standard care recommended by their physician.
75739985|NCT04049357|Device|Camera Capsule Endoscopy/ PillCam|Camera Capsule Endoscopy in screening
75739986|NCT02732834|Behavioral|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
75739987|NCT02732834|Behavioral|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
75739988|NCT02732834|Behavioral|Audio recordings of clinical consultations|
75739989|NCT02732834|Behavioral|Questionnaire|Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
75739990|NCT02732834|Behavioral|2-hour empathic communication skills training|2-hour empathic communication skills training
75887864|NCT01381523|Drug|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
75887865|NCT01382953|Device|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
75887866|NCT04233047|Drug|Fostemsavir|Fostemsavir 600 mg extended release tablets, administered 600 mg twice daily, will be supplied for compassionate use for the identified individual patient.
75887867|NCT01381445|Drug|GW870086 0.2%|White to slightly coloured opaque cream
75887868|NCT01381445|Drug|GW870086 2%|White to slightly coloured opaque cream
76058129|NCT02003963|Behavioral|Klub Kinect|"Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.~The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention."
75445811|NCT05314517|Drug|Placebo|Placebo administered subcutaneously to match namilumab dosing
75445812|NCT05313321|Device|Primary total hip arthroplasty receiving the Insignia Stem|Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
75739991|NCT02732834|Behavioral|Standardized Patient Assessments|pre-training SPA, post-training SPA
75739992|NCT02732834|Behavioral|Training evaluation|Clinicians will complete an evaluation assessing the empathic communication training module.
75739993|NCT02732834|Behavioral|Patient recruitment|6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
75445814|NCT05308654|Drug|ABBV-453|Oral; Tablet
75445815|NCT05308654|Drug|Dexamethasone|Oral Tablet
75445816|NCT05308654|Drug|Daratumumab|Subcutaneous Injection
75445817|NCT05308654|Drug|Lenalidomide|Oral Capsule
75595618|NCT00595140|Drug|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
75595619|NCT02271035|Drug|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
75595620|NCT02271035|Drug|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
75595621|NCT01606358|Drug|Carboplatin and / or taxol chemotherapy|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
75595622|NCT04352517|Other|Online Survey|Online survey completion through google app.
75595623|NCT02271074|Other|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
75595624|NCT02271074|Behavioral|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
75739994|NCT00766103|Other|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
75739995|NCT05577572|Dietary Supplement|Probiotics packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1~10 and Probiotics packets is taken from day 1~56.
75739996|NCT05577572|Dietary Supplement|Placebo packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1~10 and Placebo packets is taken from day 1~56.
75739997|NCT00760097|Device|Transcranial direct stimulation|sessions of 20 minutes each
75887869|NCT01381445|Drug|Clobetasol Propionate|White cream
75887870|NCT01381445|Drug|Placebo|White to slightly coloured opaque cream
75887871|NCT05421845|Behavioral|mobile-based combining with hospital-based lifestyle interventions|The same as that stated in arm descriptions.
75887872|NCT01568957|Behavioral|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
75887873|NCT01379261|Procedure|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
75595625|NCT02271074|Other|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
75445818|NCT05304078|Behavioral|Telehealth Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.
75445819|NCT05304078|Behavioral|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
75887874|NCT05421767|Procedure|nerve stimulation guided renal denervation procedure|RNS-in
76058130|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
76058131|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
75445820|NCT05301283|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Participants will be treated with intensity modulated radiation therapy (IMRT) with photons, which is FDA (U.S. Food and Drug Administration) approved radiation delivery system.
75739998|NCT00766181|Behavioral|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
75739999|NCT05358002|Procedure|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
75445821|NCT05301283|Diagnostic Test|MRI|Participants will receive pretreatment diagnostic MRIs to generate MRI habitats. These images will identify radioresistant cells within tumor.
75445822|NCT05301140|Device|Vivistim System|VNS Paired with rehabilitation movements
75445823|NCT05299554|Drug|Chronocort|Hydrocortisone modified-release capsule 5 mg and 10 mg
75740000|NCT04048577|Drug|Dosing Interruption of Natalizumab|Planned 12 week dosing interruption of natalizumab
75887875|NCT03083639|Drug|Esomeprazole Capsule|Esomeprazole Capsule
76058132|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
76058133|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
76058134|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
76058135|NCT01790295|Drug|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
76058136|NCT01597557|Drug|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
75445824|NCT05298423|Biological|pembrolizumab/vibostolimab|Administered as an intravenous (IV) infusion
75445825|NCT05298423|Biological|durvalumab|Administered as an IV infusion
75445826|NCT05298423|Drug|cisplatin|Administered as an IV infusion
75445827|NCT05298423|Drug|pemetrexed|Administered as an IV infusion
75445828|NCT05298423|Drug|etoposide|Administered as an IV infusion
75595626|NCT00595218|Behavioral|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
75595627|NCT00595218|Other|Patient Preference Results|Knowledge of Patient Preference Results
75887876|NCT03083639|Drug|Esomeprazole Tablet|Esomeprazole Tablet
75887877|NCT02927431|Drug|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
75887878|NCT02927431|Drug|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
75887879|NCT02927431|Drug|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
75887880|NCT02927431|Drug|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
75887881|NCT03083483|Device|transcranial direct current stimulation (tDCS)|tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
75445829|NCT05298423|Drug|carboplatin|Administered as an IV infusion
75445830|NCT05298423|Drug|paclitaxel|Administered as an IV infusion
75445831|NCT05298423|Radiation|thoracic radiotherapy|Administered as an external beam radiation
75445832|NCT05295771|Procedure|Gingival Phenotype Modification|Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.
75740001|NCT00991250|Biological|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
75887882|NCT05421221|Device|Sniffin' sticks Duftquartett|"4-odor training set over 12 weeks with Sniffin' sticks Duftquartett"
75887883|NCT05027893|Drug|Moxifloxacin 400 mg Oral Tablet|All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
75887884|NCT05027893|Drug|Cefixime 400 mg Oral Tablet|All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
75887885|NCT05027893|Other|Placebo|All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
75887886|NCT04113083|Other|Blood sampling for cholestanol analysis|Blood sampling will be performed by Düzen Laboratories group for cholestanol
75887887|NCT01381783|Procedure|Phacoemulsification|Phacoemulsification under topical anesthesia
75445833|NCT05284552|Drug|Tinzaparin Injectable Solution|Subcutaneous injection
75445844|NCT05282277|Drug|Transdermal Estradiol|Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
75445845|NCT05282277|Drug|Micronized Progesterone|Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
75595628|NCT01606397|Drug|Placebo|Administered orally (capsule)
75595629|NCT01606397|Drug|LY2409021|Administered orally (capsule)
75595630|NCT00595257|Device|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
75595631|NCT02271113|Drug|GMI-1271|
76058137|NCT01597557|Other|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
76058138|NCT01914757|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
75740002|NCT00991250|Drug|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
75740003|NCT00762047|Device|Durasphere FI|Durasphere Injection
75740004|NCT00762047|Device|Sham|Sham injection with anesthesia
75740005|NCT00418522|Drug|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
75740006|NCT00418522|Drug|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
75887888|NCT01381367|Biological|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
75887889|NCT01381367|Drug|Normal Saline|normal saline, 0.5ml given subcutaneously
75887890|NCT04989361|Procedure|Soluble Hyaluronic Acid Microneedle|The soluble hyaluronic acid microneedle eye mask is a nanometer-sized microneedle made of water-soluble hyaluronic acid, which can directly inject the active ingredients into the dermis, and after being absorbed and dissolved by the skin, it can achieve the purpose of improving the water content and elasticity of the skin.
75887891|NCT04989361|Procedure|Non-fractional laser|he non-ablative fractional laser use 1565nm fiber laser, which acts on the target base in the dermis-water. The beam penetrates the epidermis and acts on the dermis. Using the principle of focal light and heat, the tissue cells are heated to initiate the repair process, which promotes increased collagen synthesis, thereby Achieve the effect of firming the skin and improving wrinkles.
75887892|NCT01381289|Drug|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
75887893|NCT01382875|Other|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
75887894|NCT05420987|Dietary Supplement|Jing Si herbal tea liquid packet|Jing Si herbal tea includes eight Taiwan native-grown herbs: such as mugwort leaves, fish needle grass, Ophiopogon japonicus, platycodon, perilla leaves, chrysanthemum, and licorice
75887895|NCT04899193|Drug|Pergoveris FD|Participants will be administered with 900 IU of recombinant human follicle-stimulating hormone (r-hFSH) and 450 IU of recombinant human luteinizing hormone (r-hLH) freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
75887896|NCT04899193|Drug|Pergoveris Liquid|Participants will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Pergoveris Liquid) as subcutaneous injection using disposable pen-injector on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
75887897|NCT04899193|Drug|Gonal-f|Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
75887898|NCT04899193|Drug|Luveris|Participants will be administered with 450 IU of lutropin alfa (Luveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
75445846|NCT05282277|Drug|Matching Placebo Patch|Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
75887899|NCT01381705|Biological|rituximab|
76058139|NCT01914757|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
75887900|NCT01381705|Genetic|DNA analysis|
75887901|NCT01381705|Genetic|gene expression analysis|
76058140|NCT02003573|Drug|decitabine iv|decitabine iv fixed dose
76058141|NCT02003573|Drug|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
75445847|NCT05282277|Drug|Raclopride C11|All Participants will receive two PET-MR scans using [11C]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
75445848|NCT05280821|Dietary Supplement|daily ferrous sulfate|Daily intake of 100 mg ferrous sulfate capsules for 3 months
75445849|NCT05280821|Dietary Supplement|alternate day ferrous sulfate|Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
75595632|NCT02271113|Drug|Placebo|
75595633|NCT02271113|Drug|Enoxaparin Sodium (Lovenox®)|
75595634|NCT04349904|Diagnostic Test|Near-Focus Narrow Band Imaging|High Definition White Light Endoscopic Imaging followed by Near-Focus Narrow Band Imaging and target biopsy of 6 areas of the duodenum (2 from the first part and 4 from the second part of the duodenum)
75595635|NCT02271152|Procedure|FAST mapping and ablation|
75595636|NCT02271152|Procedure|PVI|
75595637|NCT01606514|Behavioral|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
75887902|NCT01381705|Genetic|polymorphism analysis|
75445850|NCT05270213|Drug|RBS2418|RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
75740007|NCT00991328|Procedure|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
75887903|NCT01381705|Other|laboratory biomarker analysis|
75887904|NCT01381705|Other|medical chart review|
75887905|NCT03613675|Device|Video games|"The 4 videos games consists of:~Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes)."
76058142|NCT01914679|Device|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
76058143|NCT01789281|Drug|Everolimus|Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
75445851|NCT05266703|Other|Isotopically labelled iron sulfate 15mg|test drink: water containing isotopic iron solution with vitamin C
75445852|NCT05261633|Device|Diffusion Weighted Magnetic Resonance Imaging|Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
75445853|NCT05259150|Behavioral|Health for Hearts United Planning for Health|Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, & Move Around More) and plan for their health ministry and cardiovascular health program to congregants.
76058144|NCT01789281|Drug|Sandostatin LAR Depot|Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
75595638|NCT00595296|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
75595639|NCT02271191|Drug|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
75595640|NCT02271269|Behavioral|Value Pricing Subsidies|"Usual care for glaucoma~Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points."
76058145|NCT01923740|Device|XIENCE V EECSS|Subjects receiving XIENCE V
76058146|NCT01923740|Device|Absorb BVS System|Subjects receiving Absorb BVS System
76058147|NCT01789203|Drug|Ciprofloxacin|Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
76058148|NCT01789203|Drug|placebo|Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
76058149|NCT01789047|Drug|Topiramate|Topiramate as adjunct to amantadine
76058150|NCT01789047|Drug|Placebo|Placebo control
76058151|NCT01789047|Drug|Amantadine|Existing treatment for all participants
76058152|NCT01788423|Device|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
75740008|NCT00762125|Behavioral|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
76058153|NCT01617187|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
76058154|NCT01617187|Drug|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
76058155|NCT01617187|Drug|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
76058156|NCT01617187|Drug|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
76058157|NCT01759407|Drug|Ropivicaine|
76058158|NCT01759407|Drug|Epinephrine|
76058159|NCT01787331|Drug|Itraconazole|Given PO
75595641|NCT00595374|Drug|insulin detemir|
75887906|NCT03085927|Behavioral|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
76058160|NCT01787331|Other|Laboratory Biomarker Analysis|Correlative studies
76058161|NCT01787331|Other|Pharmacological Study|Correlative studies
75595642|NCT00595374|Drug|insulin NPH|
75595643|NCT00595374|Drug|insulin aspart|
75595644|NCT01606553|Device|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
75740009|NCT00762125|Behavioral|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
75740010|NCT00762125|Behavioral|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
75740011|NCT00762281|Device|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
75740012|NCT00760175|Biological|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
75740013|NCT02703662|Device|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
75740014|NCT02703662|Device|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
75740015|NCT00762437|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
75740016|NCT02557763|Device|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
75887907|NCT03085927|Behavioral|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
75887908|NCT05418803|Drug|YHP1807 Tab. 2.5mg|Rivaroxaban 2.5mg
75887909|NCT05418803|Drug|YHR1901 Tab. 2.5mg|Rivaroxaban 2.5mg
75887910|NCT04401709|Drug|Gemcitabine/Capecitabine|gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 ~ 21 days for 4 weeks
75887911|NCT04401709|Drug|Capecitabine|total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 ~ 14 days for 3 weeks
75595645|NCT01606553|Device|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
75595646|NCT04328025|Other|Peer-delivered HIV self-testing, STI self-sampling and PrEP|Peer delivery of combination HIV prevention interventions to transgender women.
75595647|NCT02271308|Behavioral|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
75595648|NCT04349670|Procedure|GPOEM - gastric per-oral endoscopic myotomy|Endoscopic section of the pyloric muscle with submucosal tunnel technique.
75595649|NCT01606592|Behavioral|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
75595650|NCT01606592|Behavioral|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
75595651|NCT01606592|Other|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
75595652|NCT00595569|Behavioral|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
75595653|NCT02271347|Drug|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
75740017|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
75740018|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
75740019|NCT00766337|Drug|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
75740020|NCT01564004|Other|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
76058162|NCT01757847|Behavioral|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
75887912|NCT02472665|Drug|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
75887913|NCT04392583|Device|ENTACT Septal Staple system|The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
75887914|NCT04497987|Drug|Bamlanivimab|Administered IV.
75887915|NCT04497987|Drug|Placebo|Administered IV.
75887916|NCT04497987|Drug|Etesevimab|Administered IV.
75887917|NCT01381627|Drug|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
75887918|NCT01381627|Drug|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
75887919|NCT04726813|Behavioral|MyADHD|The main goals of the intervention are to help participants with better functioning in daily life; offer strategies that will lead to stress reduction and reduce inattention and improve quality of life.The intervention includes: a short introductory chapter (open to everyone), followed by a start module (goal setting), followed by 6 different themed optional modules. Module content is based on GMT, DBT and CBT techniques and is tailored towards key concerns and difficulties experienced adults with ADHD as informed by previous research (focus-groups, lived experience groups) and experiences from group GMT and DBT.
75595654|NCT04348734|Diagnostic Test|pleural ultrasound|Patients will benefit from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm
75887920|NCT04726813|Behavioral|Psychoeducation|Participants in the control condition will be assigned to psychoeducation modules (see Table 2) and will receive restricted access to the platform. They can contact or be contacted if their symptoms levels increases.
75595655|NCT01172938|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
75595656|NCT01172938|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
76058163|NCT01757847|Behavioral|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
76058164|NCT01787097|Drug|Symbicort® total dose 400ug/12ug|Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose
76058165|NCT01787097|Drug|Symbicort® total dose 800ug/24ug|Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose
76058166|NCT01787097|Drug|Formoterol 24ug|Turbuhaler
76058167|NCT01787097|Drug|BUD total dose 800ug|Turbuhaler
76058168|NCT04414371|Other|Yoga|Yoga Namaskar and Nadi Shuddhi
76058169|NCT01757691|Drug|Fingolimod 0.5mg/daily|
76058170|NCT01757691|Drug|Placebo|
76058171|NCT01786707|Biological|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
76058172|NCT01786707|Other|Hyperbaric oxygen therapy|
76058173|NCT01786707|Drug|Insulin|Insulin dose as per clinical management
76058174|NCT01786707|Drug|Metformin|Metformin dose as tolerated
76058175|NCT01786629|Drug|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
76058176|NCT01786629|Drug|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
76058177|NCT01786551|Drug|Eplerenone|50 mg daily for 14 days
76058178|NCT01973569|Drug|denosumab|denosumab administered subcutaneously
75445854|NCT05259150|Behavioral|Health for Hearts United Preparing for Health|Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool & Recognition.
75445855|NCT05259150|Behavioral|Health for Hearts United Delivery of Health|The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).
75445856|NCT05259150|Other|Health for Hearts United Comparison Group Health Ministry Development|Participants (health leaders) have meetings to develop the health ministry. Research participants (church congregants) do not receive cardiovascular health program.
75445857|NCT05254743|Drug|Pirtobrutinib|Administered orally.
75445858|NCT05254743|Drug|Ibrutinib|Administered orally.
75445859|NCT05251675|Behavioral|Physician Led Professional Coaching|This is a one-on-one intervention between a physician coach and an individual physician. This is meant to help coaches attain valued professional or personal development.
75445860|NCT05251675|Behavioral|Delayed Physician Led Professional Coaching|This intervention will include professional one-on-one professional coaching delayed from the active comparator group.
76058179|NCT01973569|Drug|placebo|placebo administered subcutaneously to match denosumab
75445861|NCT05239728|Drug|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
75445862|NCT05239728|Biological|Pembrolizumab|400 mg via IV infusion
75445863|NCT05239728|Drug|Placebo|Oral tablet
75445864|NCT05239000|Other|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy.
75445865|NCT05239000|Other|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits.
75445866|NCT05233956|Device|LNG IUS|Avibela®: Levonorgestrel intrauterine system (LNG IUS) containing 52mg of LNG, released in the uterine cavity at approximately 19mcg per day.
75887921|NCT04487691|Biological|Nebulized Platelet Lysate|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and platelet lysate (PL), maximizing the patients baseline platelet levels (~2-4x baseline) will be produced in a clean room setting using the Regenexx, LLC proprietary lab protocols (PL-M) utilizing a double lysis technique. From that sample, a high growth factor lysate will be created using a double lysis technique, and a sample will be retained to quantify the protein profile of the PL via ELISA quantitative analysis. The PL will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the platelet lysate following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
75445867|NCT05233956|Drug|COCs|FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
75887922|NCT04487691|Other|Nebulized Sterile Saline|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and donated for research purposes to keep patient blinded to group allocation. Sterile normal saline to mimic the appearance of the platelet lysate will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the sterile saline following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
75887923|NCT01382641|Device|Hoya AF-1 IOL|The patients will be assessed for three months
75887924|NCT01382641|Device|Revital vision|The patients will be assessed for three months.
75887925|NCT04694833|Behavioral|Motor and cognitive virtual reality-based assessments|Motor and cognitive testing in virtual reality
76058180|NCT01973491|Drug|ATX-MS-1467|Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
76058181|NCT01951586|Drug|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
76058182|NCT01951586|Drug|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
75445868|NCT05233098|Device|Technetium-99m macroaggregated albumin (Tc-99m MAA)|Patients who are being evaluated for TheraSphere administration.
75445869|NCT05226663|Procedure|Computed Tomography|Undergo [18F]FFT PET/CT
75595657|NCT01172938|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
75595658|NCT01172938|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
75595659|NCT02271464|Drug|Maintenance:BEVACIZUMAB|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)"
76058183|NCT01951586|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
76058184|NCT01951586|Drug|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
75445870|NCT05226663|Radiation|Fluorine F 18 Fluorthanatrace|Given IV
75740021|NCT00762593|Device|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
75740022|NCT00762593|Device|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
75740023|NCT00991562|Drug|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
75740024|NCT00762671|Drug|Ebselen|150 mg BID for 2 weeks
75740025|NCT00762671|Drug|Placebo|Placebo 1 po BID for 2 weeks
75740026|NCT05306483|Procedure|Ventricular septal defect closure surgery|Ventricular septal defect closure surgery
75445871|NCT05226663|Procedure|Positron Emission Tomography|Undergo [18F]FFT PET/CT
75445872|NCT05226507|Drug|NXP800|NXP800 is an anti-neoplastic, oral small molecule.
75445873|NCT05225558|Drug|Delpazolid|BID, PO
75445874|NCT05225558|Drug|Vancomycin|IV infusion per 2020 IDSA guideline
75445875|NCT05225558|Drug|Placebo of Delpazolid|BID, PO
75740027|NCT05306483|Procedure|Ventricular septal defect closure catheter|Catheter closure of VSD
75740028|NCT02558387|Drug|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
75740029|NCT00766805|Drug|EVL + Propranolol + Isosorbide 5 mononitrate|Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
75740030|NCT00766805|Other|EVL alone|
75740031|NCT00766883|Behavioral|Problem Solving Education|
75740032|NCT00766961|Procedure|Trans-catheter arterial embolization|Trans-catheter arterial embolization
75887926|NCT04694833|Behavioral|Motor and cognitive virtual reality-based serious games|Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
75595660|NCT02271464|Drug|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~CAPECITABINE 500 mg/tid orally, continuously,~CYCLOPHOSPHAMIDE 50 mg/day orally, continuously."
75740033|NCT00766961|Procedure|Surgery|Surgery
76058185|NCT01951586|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
76058186|NCT04643678|Drug|Anakinra|Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care
76058187|NCT04643678|Other|Standard of Care|Patients will receive the Standard of Care therapy as per the local treatment protocol
76058188|NCT04641728|Drug|Pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
76058189|NCT04641728|Drug|Olaparib|olaparib 300 mg twice daily (BID)
76058190|NCT01785849|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
75595661|NCT00595608|Drug|Sterimar Spray|Post-op nasal spray, three times a day
76058191|NCT01785849|Drug|Placebo|Administered intravenously (IV) three times per week.
75595662|NCT00595608|Drug|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
75595663|NCT04326894|Drug|25 mg/week oral methotrexate tablets|
75595664|NCT04326894|Drug|25mg/week oral placebo tablets|
75595665|NCT02271542|Drug|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
75595666|NCT00595647|Device|Drug eluting stent|Implantation of stent
75740034|NCT00762749|Drug|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
76058192|NCT01756833|Drug|Doxycycline|100 mg po bid
75595667|NCT00595647|Device|Bare metal stent|Implantation of stent
75740035|NCT00403546|Drug|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
75595668|NCT04315402|Other|prospective, descriptive study via survey|"Survey administered at check out.~Patient's rate of follow-up data gathered via chart review."
75595669|NCT01109992|Drug|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
75595670|NCT01109992|Drug|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
75595671|NCT02892357|Drug|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
76058193|NCT01756833|Drug|Placebo|capsule identical to the doxycycline capsule
76058194|NCT01617967|Drug|Patisiran|Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks [Q3W]: Day 0 and Day 21) and an alternative premedication regimen.
76058195|NCT01785615|Drug|Atorvastatin|80mg
76058196|NCT01785615|Other|Placebo|80mg
76058197|NCT01756053|Drug|ABT-089|Selective neuronal nicotinic receptor agonist.
76058198|NCT01756053|Drug|Placebo|Matched placebo capsules supplied by study drug supplier.
75595672|NCT02892357|Drug|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
75595673|NCT00595686|Drug|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
75595674|NCT02271620|Procedure|nasal allergen provocation test|nasal allergen provocation test
75740036|NCT00403546|Drug|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
75740037|NCT00403546|Drug|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
75740038|NCT00767117|Drug|Etravirine; Lopinavir; Ritonavir|
75887927|NCT00974571|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
76058199|NCT04576299|Other|Group 1|Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
75887928|NCT00974571|Drug|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
75887929|NCT00974571|Drug|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
75887930|NCT02766608|Drug|BFF MDI 320/9.6 μg|Blinded Treatment
75887931|NCT02766608|Drug|BFF MDI 160/9.6 μg|Blinded Treatment
75887932|NCT02766608|Drug|FF MDI 9.6 μg|Blinded Treatment
75887933|NCT02766608|Drug|BD MDI 320 μg|Blinded Treatment
75887934|NCT02766608|Drug|Symbicort® TBH 400/12 μg BID|Open Label
75887935|NCT01382485|Other|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
75887936|NCT01382485|Other|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
75887937|NCT03630731|Drug|chidamide|For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year
75887938|NCT01382407|Drug|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
75887939|NCT02235857|Device|LIPOSORBER® LA-15 System|LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
75887940|NCT01382329|Biological|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
75887941|NCT03325231|Other|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
76058200|NCT01785069|Device|Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection|Surgical implant
76058201|NCT01784523|Drug|Hydroxychloroquine|
75595675|NCT00595725|Other|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
75595676|NCT02271659|Radiation|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
75595677|NCT02271659|Radiation|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
75740039|NCT02558621|Device|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
75740040|NCT00760565|Drug|RO4905417|3mg/kg iv every 28 days for 3 infusions
75595678|NCT01109524|Drug|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
75595679|NCT01109524|Drug|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
75595680|NCT01109524|Drug|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
75740041|NCT00760565|Drug|RO4905417|20mg/kg iv every 28 days for 3 infusions
75740042|NCT00760565|Drug|RO4905417|7mg/kg iv every 28 days for 3 infusions
75740043|NCT00760565|Drug|placebo|3mg/kg iv every 28 days for 3 infusions
75740044|NCT00760565|Drug|placebo|7mg/kg iv every 28 days for 3 infusions
75740045|NCT00760565|Drug|placebo|20mg/kg iv every 28 days for 3 infusions
75740046|NCT00403390|Drug|Brand Name Levothyroxine (Synthroid)|Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
75740047|NCT00403390|Drug|Generic formulation of Levothyroxine|Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
76058202|NCT01784211|Drug|LY2605541|
76058203|NCT01784211|Drug|Insulin Glargine|
76058204|NCT01783821|Drug|Budesonide|Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
76058205|NCT01783821|Drug|Placebo|Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
76058206|NCT01783821|Drug|Formoterol|Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
76058207|NCT01783743|Other|TT Training Program and TT Screening Card|The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
76058208|NCT01608321|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
75887942|NCT03317119|Other|Laboratory Biomarker Analysis|Correlative studies
75887943|NCT03317119|Drug|Trametinib|Given PO
75887944|NCT03317119|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
75887945|NCT05347589|Other|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range.
76058209|NCT01608321|Device|Sham device|Placebo Device that simulates active rTMS treatment
76058210|NCT01608087|Drug|BI 695502|BI 695502 single i.v. infusion
76058211|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
76058212|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
76058213|NCT01912963|Drug|Pertuzumab|
76058214|NCT01912963|Drug|Trastuzumab|
76058215|NCT01912963|Drug|eribulin|
76058216|NCT01912807|Drug|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
76058217|NCT01912807|Drug|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
76058218|NCT01782885|Procedure|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
76058219|NCT01782885|Drug|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
76058220|NCT01912729|Behavioral|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
76058221|NCT01912729|Behavioral|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
76058222|NCT01754493|Drug|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
76058223|NCT01972789|Drug|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
76058224|NCT01934335|Drug|Vandetanib|
75595681|NCT02271737|Behavioral|Training HC/VHSG, Health Education, and Supportive Supervision|1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
75740048|NCT00767273|Procedure|PET Scan|
75740049|NCT00767273|Drug|FLT|
75740050|NCT00767273|Drug|FDG|
75740051|NCT00762905|Device|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
76058225|NCT01934335|Other|Placebo|
76058226|NCT01912339|Device|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
75595682|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
75595683|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
76058227|NCT01912339|Procedure|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
75595684|NCT01109173|Other|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
75595685|NCT01109173|Other|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
76058228|NCT01911793|Device|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
76058229|NCT04632511|Device|MetaSAMP|Rectal Sampler
75445876|NCT05211869|Behavioral|T1D-CATCH|"As defined by the CDC, a CHW is a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities. CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities.~CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology."
75445877|NCT05209737|Procedure|Trendelenburg position|A 10-degree head-down position will be used in this group
75595686|NCT02271776|Dietary Supplement|Galactooligosaccharide|The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
75445878|NCT05209737|Procedure|Semirecumbent position|A 30-degree head-up position will be used in this group
75445879|NCT05203445|Drug|Olaparib|Olaparib 300 mg orally BID
75595687|NCT02271776|Dietary Supplement|maltodextrin|
76058230|NCT01933789|Behavioral|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
75595688|NCT04327596|Procedure|RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter|Ablation of AF is standard of care in the management of patients with paroxysmal or persistent AF. The most common triggers initiating AF arise from pulmonary veins (PV) and successful electrical isolation of PV's can significantly reduce the burden of AF. Therefore, the main objective in patients undergoing ablation of AF is to achieve PV isolation.
75595689|NCT02271971|Dietary Supplement|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
75740052|NCT00762905|Device|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D & C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
75740053|NCT00762983|Drug|loratadine|"Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to < 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified."
76058231|NCT01910389|Drug|Tadalafil|
76058232|NCT01910389|Drug|Placebo for tadalafil|
76058233|NCT01970995|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
76058234|NCT01970995|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
76058235|NCT01970995|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
75595690|NCT02271971|Dietary Supplement|Placebo|A daily placebo capsule during 6 weeks.
75740054|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
75740055|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
75740056|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
75740057|NCT00403234|Drug|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
75740058|NCT00767429|Device|fall risk detector|fall risk detector: stumbles, specific fall related movements, falls
76058236|NCT01970527|Biological|Ipilimumab|Given IV
75740059|NCT00760721|Behavioral|Educational Small Group Session|1 hour small group health-related discussion
76058237|NCT01970527|Other|Laboratory Biomarker Analysis|Correlative studies
76058238|NCT01970527|Other|Pharmacological Study|Correlative studies
76058239|NCT01970527|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75445880|NCT05203445|Drug|Pembrolizumab|Pembrolizumab 400 mg intravenously q6weeks
75445881|NCT05195151|Dietary Supplement|Taking capsule containing probiotics or placebo|The probiotics capsule containing two strains of probiotics.
75595691|NCT04344639|Other|the incidence, risk factors, treatment, prognosis of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country|With this project, which is planned as a national multicenter prospective study, the incidence of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country and the risk factors associated with the disease, especially the detailed feeding history of the patient (when the first feeding is nourished, antibiotics and other treatments that are being used). Most epidemiological data such as the most common stage of the disease, treatment, prognosis, comparison with the data of other countries will provide important information for the neonatal health of our country.
75445882|NCT05186740|Device|ProVee Urethral Expander System|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
76058240|NCT01931995|Device|TMS positively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
75445883|NCT05186740|Procedure|Urethral Access Sheath|The Urethral Access Sheath is introduced into the prostatic urethra to simulate the placement of the ProVee Expander.
75445884|NCT05181540|Biological|AB-205|Allogeneic genetically engineered human umbilical vein endothelial cells
75595692|NCT02273024|Behavioral|Exercise|
75595693|NCT02272088|Behavioral|physical activity-moderate|cross -over of moderate and intense physical activity
75445885|NCT05181540|Other|Placebo|Placebo
75445886|NCT05163808|Drug|zatolmilast|Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo
75445887|NCT05163808|Drug|Placebo|Placebo
75445888|NCT05162599|Device|Diagnostic study, experimental evaluative cross-sectional study|This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
75445889|NCT05147298|Other|eHealth phone program|The automated eHealth phone program uses text to speech technology to deliver educational content to increase awareness, confidence, and motivation for physical activity.
75445890|NCT05147298|Other|Environment program|The environment surrounding the PHDs will be changed to make it more amenable to walking by creating walking trails and walking maps and using Healthy Living Advocates (HLA)-led walking groups within the community. Also advocating for changes to the built environment.
75445891|NCT05134831|Diagnostic Test|Rhinomanometry|"At Day 0, before the hyaluronic acid injection, the patient's nasal breathing is assessed by 4-phase rhinomanometry (bilaterally: right nostril AND left nostril).~At Month 1, the patient's nasal breathing is re-assessed by 4-phase rhinomanometry, in the same conditions as Day 0."
75595694|NCT02272088|Behavioral|Intense physical activity|cross -over of moderate and intense physical activity
75445892|NCT05132933|Procedure|PEEP trial - Electrical Impedance Tomography|Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation
76058241|NCT01931995|Procedure|TMS to negatively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
75445893|NCT05130216|Other|Genicular Nerve Radiofrequency Ablation|Radiofrequency Ablation (RFA)
75445894|NCT05128825|Drug|ZN-c3|ZN-c3 is an investigational drug.
75445895|NCT05126238|Drug|Lithium Carbonate|In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
75445896|NCT05126238|Drug|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
76058242|NCT01408576|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
76058243|NCT01408576|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
75595695|NCT01172821|Drug|placebo|Placebo that represents BI drug
75595696|NCT01172821|Drug|placebo|Placebo that represents comparator
75595697|NCT01172821|Drug|placebo|Placebo that represents comparator
75595698|NCT01172821|Drug|tiotropium Respimat® low dose|IMP
75595699|NCT01172821|Drug|placebo|Placebo that represents BI drug
75595700|NCT01172821|Drug|tiotropium Respimat® high dose|IMP
75595701|NCT01172821|Drug|50 mcg salmeterol HFA MDI|Active comparator
75595702|NCT01172821|Drug|placebo|Placebo that represents comparator
75595703|NCT02272127|Drug|icotinib|
75595704|NCT02272205|Other|Retrospective analysis of records|
75595705|NCT01172275|Drug|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
75595706|NCT01172275|Other|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
75445897|NCT05117255|Behavioral|Negative Emotions and Addiction Tools Program (NEAT)- Cognitive Behavioral Therapy|The program provides simplified clinical, learning and neuroscience-based education about the vicious cycle in which negative affect serves to motivate drinking, which, in turn, worsens negative affect. Participants also learn how each of three skills (breathing control, cognitive restructuring, problem solving) was designed to disrupt a specific element of the vicious cycle that includes physiological, psychological and behavioral processes.
76058244|NCT01427920|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
76058245|NCT01427608|Drug|Sertraline + Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
76058246|NCT01427608|Drug|Sertraline + Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
76058247|NCT01408030|Drug|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
76058248|NCT01408030|Drug|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
76058249|NCT01408030|Drug|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
76058250|NCT01408030|Drug|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
76058251|NCT04407832|Device|heat probe or hemoclip|for hemostasis
75595707|NCT02272283|Device|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
75595708|NCT05036356|Other|Headspace App|"A mobile-application (app) focusing on teaching and sustaining mental well-being."
75740060|NCT04049201|Procedure|elective surgery|investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
75445898|NCT05117255|Behavioral|Progressive Muscle Relaxation Training (PMRT)|PMRT is a standard stress management coping skill that entails tensing and releasing specified muscle groups to obtain deep muscle relaxation.
76058252|NCT04407832|Device|heat probe or hemoclip|for hemostasis
76058253|NCT02985424|Other|18F-FDG PET/CT|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
76058254|NCT01897532|Drug|Placebo|placebo matching tablets
76058255|NCT01897532|Drug|Linagliptin|
76058256|NCT04641026|Other|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
76058257|NCT04641026|Other|Deuterium oxide-labelled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
75740061|NCT04049201|Drug|Midazolam|Oral Midazolam
75445899|NCT05098210|Biological|Neoantigen Peptide Vaccine|Given IM
75445900|NCT05098210|Biological|Nivolumab|Given IV
75445901|NCT05098210|Drug|Poly ICLC|Given IM
75445902|NCT05096390|Drug|Axitinib Oral Tablet [Inlyta]|Axitinib 5 up to 10mg twice a day
75445903|NCT05096390|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
75445904|NCT05070858|Drug|Pozelimab + Cemdisiran|Subcutaneous administration as described in the protocol
75445905|NCT05070858|Drug|Cemdisiran|SC administration as described in the protocol
75445906|NCT05070858|Other|Placebo|SC administration as described in the protocol
75445907|NCT05070858|Drug|Pozelimab|SC administration as described in the protocol
75595709|NCT05034952|Drug|VX-548|Tablets for oral administration.
75595710|NCT05034952|Drug|HB/APAP|Capsules for oral administration.
75595711|NCT05034952|Drug|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
75595712|NCT05034952|Drug|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
75740062|NCT04049201|Device|Interactive Tablet|interactive Tablet containing many cartoon's videos
75740063|NCT00767663|Drug|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
75740064|NCT00767663|Drug|placebo|placebo twice daily, minimal three days pretreatment
75740065|NCT00767741|Device|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
75740066|NCT00763295|Other|T-Spot.TB test|diagnostic test
76058258|NCT04641026|Other|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
76058259|NCT04641026|Other|Deuterium oxide-labelled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
76058260|NCT01923428|Drug|AZD1722|
76058261|NCT01923428|Drug|Placebo|
76058262|NCT04627376|Other|Multimodal education and support program for cancer related cachexia prevention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
76058263|NCT01896128|Drug|Armodafinil|
76058264|NCT01896128|Drug|Placebo|inactive pill manufactured to mimic Armodafinil 150 mg tablet
76058265|NCT01949870|Drug|Cisplatin|day1 and day8 at each cycle
76058266|NCT01949870|Drug|Gemcitabine|day1 and day8 at each cycle
76058267|NCT01949870|Drug|Selumetinib|25mg/day, 50mg/day and 75mg/day
75887946|NCT05347589|Other|post isometric relaxation of the Quadratus lumborum|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
75887947|NCT05347355|Other|Spencer technique along with conventional treatment|"Subjects in this group will receive conventional exercises and 7 stages of Spencer technique: (A) extension, (B) flexion, (C) circumduction with compression, (D) circumduction with traction, (E) abduction, (F) internal rotation, (G) lymphatic pump.~Spencer technique will be used to increase range of motion of the glenohumeral joint. The patient will be positioned lying on the side with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand will provide force into the restrictive barrier of shoulder in 7 different movements. These will be shoulder extension, circumduction with distraction, abduction, adduction with internal rotation and glenohumeral pump. During all the movements, patient will be asked to use muscle energy against the slight resistance offered by the therapist for 3-5 seconds. The exercise will be repeated 3-5 times with rest intervals over 3 sessions per week on alternate days for 4 weeks."
75887948|NCT05347355|Other|Gongs Mobilization along with conventional treatment|The Gong's mobilization can be done either in high sitting or in side-lying position with the affected shoulder upward. The subject's shoulder will be abducted at 90° so that the humerus will be maintained at vertical position. The elbow joint will be flexed and maintained at 90°; the therapist will maintain this position by placing his/her hand below the subject's elbow. The humeral head will be pressed from anterior to posterior direction with the other hand. The therapist will hold the vertical axis of the humerus by maintaining the shoulder in abduction and the elbow in 90°. The therapist will raise his own body by slightly pulling on the anterior capsule and this pull will be maintained for 10-15 seconds and then relax for five seconds and will be performed for about two to three minutes. At this moment the subject will be asked to perform shoulder abduction with no external rotation, while elbow flexion will be maintained throughout.
75887949|NCT02157350|Procedure|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
75887950|NCT03252535|Biological|Cellavita HD lower dose|The participants will receive a total of 9 intravenous administrations of 1x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
76058268|NCT01949480|Procedure|Thoracotomy|
76058269|NCT01949480|Procedure|Video-Assisted Thoracoscopic Surgery (VATS)|
75740067|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
75740068|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 3 weeks followed by 1 week of placebo.
75740069|NCT00402688|Drug|levofloxacin|500mg tablet once daily for 4 weeks.
75445910|NCT05067283|Drug|MK-1084|Oral dose
75595713|NCT00596037|Drug|Growth hormone - LB03002|
75595714|NCT02272322|Device|cystocele repair with biomesh soft prolaps and endofast reliant|
75740070|NCT04049045|Drug|Empagliflozin 25 mg|Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
75740071|NCT04049045|Drug|Placebo|matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
75445911|NCT05067283|Biological|Pembrolizumab|Intravenous infusion of 200 mg
75445912|NCT05067283|Drug|carboplatin|Per label
75445913|NCT05067283|Drug|pemetrexed|Per label
75445914|NCT05067283|Biological|cetuximab|Per label
75445915|NCT05067283|Drug|oxaliplatin|Per label
75445916|NCT05067283|Drug|leucovorin|Per label
75445917|NCT05067283|Drug|5-fluorouracil|Per label
75445918|NCT05065905|Drug|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
75445919|NCT05056064|Other|Oral exercise|exercise remain tongue
75595715|NCT04310371|Behavioral|3-month lifestyle intervention|"Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.~There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only."
75595716|NCT02881372|Other|Oral food desensitization|The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
75887951|NCT03252535|Biological|Cellavita HD higher dose|The participants will receive a total of 9 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
75887952|NCT03252535|Other|Placebo|The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
75887953|NCT04356495|Dietary Supplement|Vitamins|2 tablets daily from the first day (day 0) to day 9
76058270|NCT01949090|Biological|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
76058271|NCT01949090|Biological|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
76058272|NCT01948076|Device|resident with GE vscan|resident with GE vscan
76058273|NCT01922258|Drug|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
75445920|NCT05050799|Device|Central Venous Access|The Surfacer® Inside-Out® Access Catheter System is intended to obtain central venous access to facilitate catheter insertion into the central venous system for patients with upper body venous occlusions or other conditions that preclude central venous access by conventional methods.
75445921|NCT05043389|Other|myofunctional therapy program|Exercise oral cavity muscle
75445922|NCT05020873|Other|Crizanlizumab|Prospective observational study. There is no treatment allocation. Patients administered crizanlizumab, that have started before inclusion of the patient into the study will be enrolled.
75445923|NCT05017571|Drug|Colchicine|Colchicine 1 capsule (0.6 mg) per day
75445924|NCT05017571|Drug|Placebo|Placebo 1 capsule per day
75887954|NCT04356495|Drug|Telmisartan|1 tablet daily from the first day (day 0) to day 9
76058274|NCT01406938|Drug|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
76058275|NCT01406938|Drug|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
76058276|NCT01405924|Drug|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
76058277|NCT01405924|Drug|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
76058278|NCT01405924|Drug|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
76058279|NCT01405924|Drug|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
76058280|NCT01426438|Drug|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
76058281|NCT01426438|Drug|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
76058282|NCT01426438|Drug|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
76058283|NCT04407910|Combination Product|AIRFLOW® Master device +Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
76058284|NCT04407910|Combination Product|rubber-cup+Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
76058285|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
75445931|NCT05014724|Drug|Rozanolixizumab|Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.
75887955|NCT04356495|Drug|Ciclesonide|2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
75887956|NCT04356495|Drug|interferon β-1b|A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
75887957|NCT03542084|Other|Unsolicited endocrine e-consult|The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
76058286|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
76058287|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
76058288|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
76058289|NCT01425814|Drug|Reference|Dry powder inhalation (capsule),single dose
76058290|NCT01425814|Drug|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
76058291|NCT01782495|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
76058292|NCT01782495|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
76058293|NCT01782495|Drug|ribavirin|tablet
76058294|NCT01922102|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
76058295|NCT01922102|Drug|Ranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
76058296|NCT01922102|Drug|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
76058297|NCT01405768|Drug|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
76058298|NCT01405768|Drug|Non-buffered lidocaine|
76058299|NCT01913353|Biological|MVA BN®|0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection
76058300|NCT01913353|Biological|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
75887958|NCT03230695|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
76058301|NCT01754259|Drug|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
75887959|NCT03230695|Device|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
75887960|NCT03230695|Device|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
76058302|NCT01754259|Drug|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
76058303|NCT04574505|Dietary Supplement|Eufortyn Colesterolo Plus|Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.
76058304|NCT04574505|Dietary Supplement|Placebo|Placebo
76058305|NCT04618406|Device|PICO VAC|PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.
75445932|NCT05003531|Drug|IBI112 dose 2|Participants will receive placebo or dose 2 IBI112 SC
75445933|NCT05003531|Drug|IBI112 dose 4|Participants will receive placebo or dose 4 IBI112 SC
75445934|NCT05003531|Drug|IBI112 dose 1|Participants will receive placebo or dose 1 IBI112 SC
75445935|NCT05003531|Drug|IBI112 dose 3|Participants will receive placebo or dose 3 IBI112 SC
75445936|NCT05003531|Drug|placebo|Participants will receive placebo SC
75740072|NCT00763373|Other|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
75740073|NCT00760799|Procedure|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
75740074|NCT01035580|Drug|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
75740075|NCT01035580|Drug|curcumin|all patients received the drug
75740076|NCT03993730|Device|ICD|Insertion of ICD in patients with LVEF <45% and LGE on CMR.
76058306|NCT04618406|Other|Standard care|Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
75740077|NCT03993730|Device|ILR|Insertion of ILR in patients with LVEF <45% and LGE on CMR.
75740078|NCT01041586|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
75740079|NCT00671879|Drug|Carisoprodol SR 700 mg|700 mg twice daily tablet
75740080|NCT00671879|Drug|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
75740081|NCT00671879|Drug|Placebo|placebo tablet
75740082|NCT01039168|Behavioral|Workplace dialogue|
76058307|NCT01405456|Drug|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
76058308|NCT01405456|Other|placebo and lifestyle|placebo pill daily and lifestyle counseling
76058309|NCT04031794|Device|Extra Corporeal Membrane Oxygenator (ECMO)|Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
76058310|NCT01404988|Behavioral|Telephone-Delivered BI|Behavioral Intervention will be delivered over the phone.
76058311|NCT01404988|Behavioral|Telephone-Delivered BEI|Behavioral and Environmental Intervention will be delivered over the phone
75445937|NCT04998110|Other|Ambulatory Supportive Care|Ambulatory supportive care visits monthly for six months - a monthly visit with an ambulatory palliative care provider educated in kidney disease
75740083|NCT01039168|Other|Care as usual|
75887961|NCT05654961|Other|Use of telemedicine|Use of telemedicine (any type: telephone only, non-invasive, implantable-cardioverter-defibrillator-based, invasive) in heart failure management
76058312|NCT01404988|Other|Telephone-Delivered API|Attention Placebo Intervention will be delivered over the phone
76058313|NCT04043026|Drug|Statin|Any statin therapy
75445938|NCT04995003|Genetic|T cells or CAR T cells|"There are 2 dose levels:~Dose Level 1 (1x10^8 cells/m2) and Dose Level -1 (5x10^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur."
75445939|NCT04995003|Drug|Pembrolizumab Injectable Product|2 mg/kg/dose (max 200 mg/dose) every 3 weeks
75445940|NCT04995003|Drug|Nivolumab Injectable Product|3 mg/kg/dose (<40kg) or 124 mg (≥40 kg) every 2 weeks
75595717|NCT04326855|Other|Incremental shuttle walking protocol (ISWT)|Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
75740084|NCT00770393|Procedure|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
75887962|NCT02154230|Dietary Supplement|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
75445942|NCT04983810|Drug|Fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
75887963|NCT02154230|Dietary Supplement|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
75887964|NCT01384045|Other|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
75887965|NCT04724941|Other|No intervention|No intervention
76058314|NCT01389232|Device|SeriScaffold® Surgical Scaffold|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
76058315|NCT01404208|Drug|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
76058316|NCT01404208|Drug|Placebo|Sugar pill
75445943|NCT04982445|Drug|CABENUVA|CABENUVA will be administered IM at infusion centers/ASAs
75445944|NCT04976634|Drug|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
75445945|NCT04976634|Drug|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
75445946|NCT04976634|Drug|Lenvatinib|Lenvantinib dose for HCC is 8 mg QD for body weight <60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
75445947|NCT04975139|Device|RS-fMRI|Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain
75445948|NCT04970966|Device|PuraSinus|A randomized ethmoid cavity in the patient will have PuraSinus applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
75887966|NCT04200963|Drug|IK-175|Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
75887967|NCT04200963|Drug|IK-175 and nivolumab|Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
75887968|NCT02157428|Drug|Flumazenil|
76058317|NCT01617668|Drug|LCL161|LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
75445949|NCT04970966|Device|Bioresorbable Nasal Dressing|PosiSep X will be applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
75595718|NCT04326855|Other|Endurance shuttle walking (ESW) protocol|Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
76058318|NCT01617668|Drug|paclitaxel|"Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2"
76058319|NCT01425268|Device|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
76058320|NCT01425268|Procedure|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
75445950|NCT04967469|Drug|Calcitriol|end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
75595719|NCT04326855|Other|First Intermittent shuttle walking protocol|All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
75595720|NCT04326855|Other|Second Intermittent shuttle walking protocol|To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
75740085|NCT00770393|Procedure|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
75740086|NCT03994276|Dietary Supplement|Chickpea powder|Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
75740087|NCT01036048|Device|drug eluting stent|pts with cabg disease treated with drug eluting stent
75740088|NCT01036048|Device|bare metal stent|pts with cabg disease treated with bare metal stent
75445951|NCT04967469|Drug|Alfacalcidol 0.5 MCG Oral Capsule|end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
75740089|NCT00767897|Drug|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
75445952|NCT04967001|Diagnostic Test|PSMA PET|68Ga-PSMA PET
75445953|NCT04960709|Drug|Durvalumab|Anti- PD-L1 Antibody
75445954|NCT04960709|Drug|Tremelimumab|Human IgG2 mAb
75887969|NCT02157428|Drug|saline|
75887970|NCT01383967|Drug|LY2979165|Administered orally
75887971|NCT01383967|Drug|placebo|Administered orally
75887972|NCT02254928|Drug|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
75445955|NCT04960709|Drug|Enfortumab Vedotin|Nectin-4-directed antibody and microtubule inhibitor conjugate
75445956|NCT04960709|Procedure|Radical Cystectomy|For cisplatin-ineligible or cisplatin-refusal patients
75445957|NCT04958226|Drug|Capivasertib|Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.
75445958|NCT04958226|Drug|Midazolam|Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
75887973|NCT01383889|Other|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
75740090|NCT00767975|Drug|isoniazid , randomized, open label|isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
75887974|NCT00960141|Drug|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
75887975|NCT00960141|Drug|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
75595721|NCT04326855|Other|Focus group study|Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
75740091|NCT00767975|Drug|rifampin, randomized, open label|rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
75740092|NCT00768131|Drug|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
75740093|NCT00768131|Drug|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
75887976|NCT00960141|Drug|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
75887977|NCT02771522|Device|Calcivis System|Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. Both black & white and luminescent images images of the teeth are taken. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
75887978|NCT00759655|Biological|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
75887979|NCT00518869|Drug|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
75740094|NCT00768131|Drug|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
75740095|NCT00401830|Drug|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
75740096|NCT00401830|Other|Placebo|Matching placebo tablet administered twice daily
75887980|NCT02255006|Device|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
75740097|NCT05285033|Drug|Lurbinectedin|Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
75740098|NCT00768209|Drug|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
75887981|NCT02255006|Device|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods."
75740099|NCT02557685|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
75740100|NCT00401752|Drug|Esomeprazole|
75887982|NCT02255006|Drug|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
75887983|NCT02255006|Drug|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
75887984|NCT02771366|Drug|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
75887985|NCT02771366|Other|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
75887986|NCT03396471|Drug|Pembrolizumab|200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
75887987|NCT03396471|Radiation|External Beam Radiation Therapy|20-30 Gy over five fractions for up to two cycles.
75887988|NCT00103142|Biological|falimarev|Given subcutaneously and intradermally
75740101|NCT00401752|Drug|Ranitidine|
75740102|NCT04048967|Behavioral|Professional development|professional development of preschool staff
75740103|NCT00770471|Drug|temozolomide|
75740104|NCT00770471|Drug|veliparib|
75740105|NCT00770471|Genetic|DNA methylation analysis|
75887989|NCT00103142|Biological|inalimarev|Given subcutaneously and intradermally
75445959|NCT04947722|Behavioral|PREVENT Program|A standardized PREVENT educational program will be offered to each intervention LTC home and health-care staff. The curricula includes video modules with fracture-prevention care recommendations and an orientation to the Fracture Prevention Toolkit. Using the Fracture Risk Scale (i.e., a clinical decision support tool embedded in the RAI-MDS 2.0), the LTC team will identify residents at high-risk for fracture and will implement the fracture prevention recommendations into care plans on an individual resident basis.
75740106|NCT00770471|Genetic|gene expression analysis|
75740107|NCT00770471|Genetic|mutation analysis|
75740108|NCT00770471|Genetic|proteomic profiling|
75740109|NCT00770471|Other|high performance liquid chromatography|
75740110|NCT00770471|Other|immunoenzyme technique|
75740111|NCT00770471|Other|laboratory biomarker analysis|
75740112|NCT00770471|Other|mass spectrometry|
75740113|NCT00770471|Other|pharmacogenomic studies|
75740114|NCT00770471|Other|pharmacological study|
75740115|NCT00770471|Procedure|adjuvant therapy|
75740116|NCT00770471|Radiation|radiation therapy|
75740117|NCT01039324|Other|Reports|Primary care event reports and patient letters
75740118|NCT01039324|Other|Reports and Notices|Primary care event reports, patient letters and care manager notices
75740119|NCT01039324|Other|Usual care|This is the study's control group
75740120|NCT00539240|Drug|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
75740121|NCT00539240|Drug|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast & Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
75740122|NCT00539240|Drug|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
75740123|NCT00770627|Dietary Supplement|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
75887990|NCT00103142|Biological|sargramostim|Given subcutaneously
75887991|NCT00103142|Biological|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
75887992|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
75887993|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
75887994|NCT00943683|Drug|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
75887995|NCT00943683|Drug|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
75887996|NCT02154308|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
75887997|NCT03738644|Other|Monitoring with near-infrared spectroscopy|"No interventions are used. Stroke patients are examined with near-infrared spectroscopy (NIRS). NIRS examinations are done with Octamon system (Artinis Medical Systems, Elst, The Netherlands) consisting of 8 transmitters emitting infrared light of 760 and 850 nm and 2 receivers measuring oxygenated and deoxygenated hemoglobin in the frontal cortex.~Examination protocol can be found in detailed description."
75887998|NCT03542006|Drug|Brinzolamide Ophthalmic|Topical brinzolamide given bd for 3 months
75887999|NCT02157740|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
75888000|NCT02154464|Drug|Paracetamol|
75595722|NCT02272400|Other|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
75595723|NCT02273102|Drug|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
75595724|NCT02273102|Drug|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
75595725|NCT02272478|Drug|Arm A Mylotarg plus DA Versus CPX-351|Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
75595726|NCT02272478|Drug|Arm B Vosaroxin and Decitabine|If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
75740124|NCT00417976|Drug|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
75740125|NCT00417976|Drug|Bevacizumab|10 mg/kg every 2 weeks.
75740126|NCT00417976|Drug|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
75740127|NCT00770705|Drug|Phenoxybenzamine|The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
75740128|NCT00770705|Other|Standard surgical approach|Historical controls
75740129|NCT00991718|Drug|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
75740130|NCT00991718|Drug|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
75740131|NCT00991718|Drug|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
75740132|NCT01036282|Behavioral|Computerized Cognitive Skill Training|Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
75888001|NCT02154464|Drug|Placebo|
75888002|NCT00911547|Drug|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
75888003|NCT00911547|Drug|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
75888004|NCT00911547|Drug|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
75888005|NCT00911547|Drug|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
75888006|NCT02159690|Drug|Enzalutamide|160mg
75888007|NCT02159690|Drug|Abiraterone acetate|1000mg
75888008|NCT02159690|Drug|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
75888009|NCT02159690|Drug|Dutasteride|0.5mg
75888010|NCT02159690|Drug|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
75888011|NCT02154542|Device|Neurovent Monitor XIII|
75888012|NCT03696771|Drug|NJH395|Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
75888013|NCT02157818|Drug|midazolam|
75888014|NCT02157818|Drug|Dexmedetomidine|
75740133|NCT01036282|Behavioral|CRT and Social Cognition|Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
75740134|NCT04048733|Device|patchy-type wireless 12-lead ECG|Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
75740135|NCT01036360|Other|metabolic chamber|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
75740136|NCT00991796|Drug|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
75740137|NCT00991796|Drug|Placebo|Placebo
75888015|NCT02154620|Procedure|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
75888016|NCT02154620|Device|Synthes TCP volar plate|
75888017|NCT03542786|Dietary Supplement|Probiotic|"The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~Lactobacillus plantarum CECT7484~Lactobacillus plantarum CECT7485~Pediococcus acidilactici CECT7483"
75888018|NCT03542786|Dietary Supplement|Prebiotic|"ProSeed prebiotic is a non-commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~Partially Hydrolyzed Guar Gum (PHGG)~Inulin HPD~Oat Beta-Glucans~Pectin~Inulin Low Protein Diet (LPD)~Polydextrose~Maltrodextrins"
75888019|NCT03542786|Dietary Supplement|Placebo|It is a non-commercialized product. It is composed of the same excipients as the probiotic and the prebiotic. It will be supplied by the promoter and manufactured in ALIFARM S.A.
75888020|NCT02154698|Other|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
75888021|NCT02154698|Other|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
75740138|NCT00991796|Drug|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
75740139|NCT00991796|Drug|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
75888022|NCT00899379|Drug|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
75888023|NCT00899379|Drug|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
75888024|NCT04984538|Other|Pharmacogenomic Testing|Cheek swab as a part of routine care
75888025|NCT02255318|Device|Taurolock|
75888026|NCT02255318|Drug|Placebo|
75888027|NCT04326439|Drug|Cytarabine|100 mg/m²/dose every 12 hours IV Days 1-10
75888028|NCT04326439|Drug|Daunorubicin|50 mg/m²/dose IV Days 1, 3, 5
75740140|NCT00673673|Drug|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
75888029|NCT04326439|Drug|Erwinase|25,000 International Units/m²/dose IM Days 2, 9
75888030|NCT04326439|Drug|Etoposide|150 mg/m²/dose IV Days 1-5
75595727|NCT02272478|Drug|Arm D Small molecule or Not|The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
75595728|NCT02272478|Drug|Arm C DA V FLAG-Ida V DAC|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
75595729|NCT02272478|Drug|Arm E CPX-351 (200 V 300)|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
75888031|NCT04326439|Drug|Gemtuzumab ozogamicin|Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.
75888032|NCT04326439|Procedure|Stem cell transplantation (SCT)|Transplantation of multipotent hematopoietic stem cells from bone marrow
75888033|NCT04326439|Drug|Sorafenib|200 mg/m2/dose daily, rounded to accommodate tablet size. The maximum dose will be 400 mg. Days 7 through 34.
75888034|NCT02255240|Behavioral|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
75445960|NCT04938245|Device|Spinal Cord Stimulation|"Intraoperatively, stimulation at 12 Hz will be performed as the leads are moved into the targeted position. Amplitude will be increased to 15 mA maximum total until a response is seen on any electrode and held for 10 seconds. Stimulation and recording will be performed using the Neuralynx stim/record system.~Post-operatively, the electrodes will be tested for impedance by the clinical system and then they will be connected to the Neuralynx stim/record system. Electrode stimulation patterns will be applied with increasing amplitude until ECAPs responses are seen on recording electrodes. 42 Hz stimulation will be performed with an amplitude sweep of 0mA-10mA. At each amplitude, stimulation will be applied for 4 seconds followed by 2 seconds of rest. Pulse width will be varied from 30-450 microseconds to test effective amplitude. Bursting stimulation will be applied to detect differences in ECAPs as above."
75445961|NCT04931563|Biological|Anifrolumab|Intravenous infusion (IV)
75595730|NCT02272478|Drug|Arm F DA V IDAC|Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
75740141|NCT00673673|Drug|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
75740142|NCT00770783|Device|Thymatron|Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
75740143|NCT00770783|Device|Tonica MagPro MST|100% power, vertex placement, 3 times per week for 4 weeks
75888035|NCT03541928|Drug|HSV-Tk|"Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells."
76058321|NCT01425190|Drug|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
75445962|NCT04931563|Drug|placebo|Intravenous infusion (IV)
75445963|NCT04929483|Drug|BIO89-100|Subcutaneous injection
75445964|NCT04924075|Drug|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
75595731|NCT02272517|Drug|Vortioxetine 10-20 mg|
75595732|NCT02272517|Drug|Escitalopram 10-20 mg|
75595733|NCT02272673|Dietary Supplement|Honey|The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).
75740144|NCT00763685|Drug|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
75740145|NCT04048655|Drug|Neostigmine, Combinations|All patients have neostigmine induced recovery of neuromuscular block.
75740146|NCT02557997|Other|Blood tube bottom analyses|
75888036|NCT03541928|Drug|Valacyclovir|The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.
76058322|NCT01388530|Device|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
76058323|NCT01895270|Drug|Isradipine|Isradipine extended release formulation
76058324|NCT01895270|Drug|Placebo|Placebo will consist of microcrystalline cellulose.
76058325|NCT01424722|Device|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
76058326|NCT01424644|Biological|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®."
75740147|NCT00768677|Drug|topiramate|
75740148|NCT00770939|Device|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
75740149|NCT04003064|Diagnostic Test|Blood|3ml blood
75740150|NCT05257694|Procedure|Surgery|hepatectomy
75740151|NCT05257694|Procedure|Ablation (Microwave ablation or Radiofrequency ablation)|image-guided ablation
75740152|NCT02557451|Other|Surgery|
75740153|NCT02557451|Other|Intravitreal injections of gas|
75740154|NCT02557451|Procedure|injections of an antiangiogenic|
75740155|NCT05408936|Drug|SGLT2 inhibitor|Patients receive an SGLT2 inhibitor as part of theirn routine care.
75740156|NCT02558153|Device|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
75740157|NCT02558153|Device|standard PTA|Percutaneous angioplasty performed with a standard balloon
75740158|NCT04048187|Device|Phone Application|Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
75740159|NCT05408858|Behavioral|LGBTQ-affirmative cognitive behavioral group therapy|10 sessions of supportive, LGBTQ-affirmative psychotherapy
75888037|NCT03541928|Drug|Bicalutamide|"The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain."
76058327|NCT01424644|Biological|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®."
75445965|NCT04923542|Radiation|Stereotactic Radiosurgery (SRS)|Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
75445966|NCT04923542|Drug|Abemaciclib|Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
75888038|NCT03541928|Drug|Leuprolide Acetate|Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
76058328|NCT01920854|Drug|soluble ferric pyrophosphate|
76058329|NCT01920854|Drug|Placebo|
76058330|NCT01403194|Device|CPAP/BiPAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
76058331|NCT01403116|Drug|Oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
76058332|NCT01403116|Drug|topical testosterone gel|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
76058333|NCT01402570|Dietary Supplement|Glutathione|glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
76058334|NCT03025204|Biological|Enamel Matrix Proteins|EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
75445967|NCT04923542|Drug|Endocrine therapy|Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
75595734|NCT02272712|Behavioral|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
75595735|NCT02272751|Behavioral|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
75595736|NCT02272751|Behavioral|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
75595737|NCT04344132|Procedure|Scalp Block|standard practice of controll the pain after surgery. Block of the nerve emergences.
75595738|NCT00596076|Behavioral|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
75888039|NCT03541928|Radiation|Brachytherapy, External beam radiotherapy|On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.
76058335|NCT03025204|Procedure|Open Flap Debridement|After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
76058336|NCT01753401|Drug|Acthar|Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
76058337|NCT01753401|Drug|Placebo|Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
76058338|NCT01753401|Drug|Steroid Drug|The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
76058339|NCT01618916|Drug|LY3015014|Administered SC
76058340|NCT01618916|Other|Placebo|Administered SC
76058341|NCT01753323|Drug|KAF156|KAF156 was supplied as tablets for oral use.
76058342|NCT04566939|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
76058343|NCT04566939|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the shoulder at the physician's discretion.
75740160|NCT01041742|Procedure|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
75740161|NCT00763763|Drug|Imatinib mesylate|imatinib 600 mg/day for 2 years
75740162|NCT00763763|Drug|Interferon|45 micrograms per week during 2 years
75888040|NCT03541928|Procedure|Radical prostatectomy|approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.
75888041|NCT00145795|Drug|Kaletra + Current Dual NRTI Backbone|
75888042|NCT00145795|Drug|Current Regimen|
75740163|NCT00763763|Drug|Vincristine|2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
75740164|NCT00763763|Drug|Dexamethasone|40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
75740165|NCT04003298|Device|Electric toothbrush|Electric toothbrush and power interdental device
75740166|NCT04003298|Device|Control|Oscillating-rotating
75740167|NCT01041820|Behavioral|Exercise|Children will be exposed to a 10-week exercise intervention
75740168|NCT00763841|Device|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
75740169|NCT00763841|Device|Sham|
75740170|NCT01037140|Drug|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
75740171|NCT01037140|Drug|placebo|oral placebo tablets similar to active comparator
75888043|NCT01379365|Device|Cryo-Touch III|Percutaneous treatment with the device
75888044|NCT02771210|Biological|Secukinumab|Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
75888045|NCT02771210|Drug|Secukinumab Placebo|Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
75888046|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
75888047|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
76058344|NCT04566939|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Gyunwoo (LI15), Gyunryo(TE14), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
76058345|NCT04566939|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
76058346|NCT04566939|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
76058347|NCT04566939|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
76058348|NCT04566939|Procedure|Herbal hot pack|Herbal hot pack treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75888048|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
76058349|NCT04566939|Procedure|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
76058350|NCT04566939|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
76058351|NCT01894568|Drug|Insulin Peglispro|Administered SC using a prefilled pen.
76058352|NCT01894568|Drug|Insulin Glargine|Administered SC using a prefilled pen
75740172|NCT05357456|Behavioral|Cognitive function assessment; functional magnetic resonance imaging|cognitive function measurement
75740173|NCT05357456|Procedure|laparoscopic adrenal surgery|Only a subgroup of the autonomous cortisol secretion patients will have the laparoscopic adrenal surgery
75445970|NCT04912089|Behavioral|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
75445971|NCT04903795|Drug|hEGFRvIII-CD3 (BRiTE)|Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
75595739|NCT02272829|Behavioral|Choacot: Behavioral Intervention for Chronic Opioid Use|This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.
75888049|NCT01382095|Biological|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
76058353|NCT01894568|Drug|Oral Antihyperglycemic Medications (OAMs)|Administered orally
75445972|NCT04897022|Drug|Pembrolizumab|Fixed dose of pembrolizumab 200mg IV q3 weeks
75595740|NCT02272829|Other|Health Education|
75595741|NCT00596115|Drug|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
75888050|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
76058354|NCT01618838|Radiation|CyberKnife radiosurgery|"Treatment Planning:~Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the Planning Treatment Volume (PTV) and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively."
75595742|NCT02272868|Biological|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
75595743|NCT02272868|Drug|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
75595744|NCT02272868|Drug|rifaximin+omeprazole+miralax|
75595745|NCT02892864|Other|Neuromuscular Retraining and Virtual therapy|Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
75740174|NCT00069121|Drug|Capecitabine|1000 milligrams per square metre of body surface area (mg/m^2) orally twice daily on days 1-15 of each 3-week cycle.
75740175|NCT00069121|Drug|Oxaliplatin|130 mg/m^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
75740176|NCT00069121|Drug|Leucovorin (LV)|Administered by one of two regimens, as specified in the arm description.
75445973|NCT04897022|Radiation|IMPRINT|The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
75445974|NCT04895761|Biological|DPX-Survivac|"DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5."
76058355|NCT01920152|Biological|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
76058356|NCT01920152|Device|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
76058357|NCT01752933|Drug|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
76058358|NCT01752855|Biological|New formulation adalimumab|New formulation adalimumab 40 mg every other week
76058359|NCT01402492|Drug|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
76058360|NCT01402492|Drug|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
76058361|NCT01402102|Dietary Supplement|Aged garlic powder|Aged garlic powder(6.0g/day)
76058362|NCT01402102|Dietary Supplement|Placebo powder|Placebo powder(6.0g/day)
76058363|NCT04029220|Behavioral|Parent Peer Navigation|Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
76058364|NCT01423084|Biological|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
76058365|NCT04042168|Diagnostic Test|In Check Dial test|In Check Dial test will test the ability to actuate the inhaler.
75595746|NCT02892864|Other|Oro-myo-functional classical rehabilitation|"Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation."
75445975|NCT04895761|Drug|Letrozole 2.5mg|Aromatase inhibitor all arms will receive
75445976|NCT04895761|Drug|Cyclophosphamide 50mg|oral chemotherapy used in the neoadjuvant setting for Arm C only
75595747|NCT02272907|Other|Injection of saline solution into specimen to test bursting pressure.|A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
75595748|NCT02892825|Other|Music|headphones with music
75445977|NCT04895761|Radiation|XRT 10Gy x2|Directed radiation at week 4 for Arm B only
75740177|NCT00069121|Drug|5-Fluorouracil (5-FU)|Administered by one of two regimens, as specified in the arm description.
75740178|NCT00768911|Drug|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
76058366|NCT04026334|Device|V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline|-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
75595749|NCT02892825|Other|No Music|headphones without music
75595750|NCT02273453|Drug|Songha® Night|
76058367|NCT01894256|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
76058368|NCT01780935|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
76058369|NCT01894100|Device|Shoe lift correction for leg length inequality|Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
76058370|NCT02334982|Drug|TAK-137|TAK-137 tablets
75595751|NCT02273453|Drug|Oxazepam|
75595752|NCT02273453|Drug|Placebo|
75595753|NCT01108510|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
75595754|NCT01108510|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
75595755|NCT01108510|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
75888051|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
75740179|NCT00768911|Drug|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
75740180|NCT00768911|Procedure|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
75445981|NCT04883970|Other|124I-18B10(10L) PET/CT|Study participants will undergo 124I-18B10(10L) PET/CT scans
75445982|NCT04883346|Drug|Liraglutide|Liraglutide by subcutaneous injection administered daily. Dose will be initiated at 0.6mg per day and increased to a maximum of 3.0 mg per day as tolerated.
75740181|NCT01860404|Drug|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
76058371|NCT02334982|Drug|Placebo|TAK-137 placebo-matching tablets
75445983|NCT04874961|Dietary Supplement|Tensiofytol®|standardized olive extract
75595756|NCT01108510|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
75595757|NCT01108510|Drug|COBI placebo|Placebo to match COBI administered orally once daily
75595758|NCT01108510|Drug|RTV placebo|Placebo to match RTV administered orally once daily
75595759|NCT04343781|Other|observation|observation of clinical symptoms related to COVID-19 disease
75740182|NCT01860404|Drug|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
75740183|NCT00769145|Drug|Ranibizumab|0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
75888052|NCT00898677|Drug|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
75888053|NCT00898677|Drug|Comparator: Placebo|placebo to rizatriptan
75445984|NCT04874961|Other|Placebo|contains excipients only
75445985|NCT04863885|Drug|Ipilimumab|Participants will receive Ipilimumab 3 mg/kg
75595760|NCT02273258|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
75595761|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
75595762|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
75740184|NCT00399802|Drug|ZA|Single ZA 4 mg IV infusion at the start of treatment
75740185|NCT00399802|Drug|Odanacatib|Once-daily odanacatib 5 mg tablet for 4 weeks
75740186|NCT00399802|Drug|Odanacatib matching placebo|Once-daily odanacatib matching placebo for 4 weeks
75740187|NCT00399802|Drug|ZA matching placebo|Single IV infusion of ZA matching placebo given at the start of treatment
75740188|NCT00763997|Drug|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
75740189|NCT00763997|Drug|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
75740190|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
75740191|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
75740192|NCT00763997|Drug|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
75740193|NCT00763997|Other|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
75740194|NCT00771095|Behavioral|podcasting|
75740195|NCT00771251|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
75740196|NCT00771251|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
75445986|NCT04863885|Drug|Nivolumab|Participants will receive Nivoumab 1mg/kg
75445987|NCT04863885|Drug|Sacituzumab govitecan|Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
75445988|NCT04863417|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area
75445989|NCT04863417|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
75445990|NCT04858334|Procedure|Biospecimen Collection|Undergo collection of blood
75445991|NCT04858334|Procedure|Computed Tomography|Undergo CT or CT/MRI
75445992|NCT04858334|Procedure|Magnetic Resonance Imaging|Undergo CT/MRI
75595763|NCT02273414|Drug|BIIL 284 BS - rising dose|
75595764|NCT02273414|Drug|Placebo|
75595765|NCT02881411|Other|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
75595766|NCT02881411|Other|Fibromyalgia coping skills programme|Exercise, education programme
75595767|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
75740197|NCT00399568|Drug|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
75740198|NCT00399568|Drug|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
75740199|NCT03960853|Procedure|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation-volume guaranteed in operation
75740200|NCT03960853|Procedure|volume controlled ventilation|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
75740201|NCT01326949|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
76058372|NCT03025516|Device|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
75445993|NCT04858334|Drug|Olaparib|Given PO
75740202|NCT01326949|Procedure|ET+NSBB|"ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0)."
75445994|NCT04858334|Drug|Placebo Administration|Given PO
75445995|NCT04854096|Drug|NS-018|Experimental
75595768|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
75595769|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
75595770|NCT05018494|Other|experimental treatment|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
75740203|NCT00764075|Device|Beutel TM|application of BeutelTM
75740204|NCT00764075|Other|standard|standard procedure will be applied but no Beutel TM software
75740205|NCT00764075|Device|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
75445996|NCT04854096|Drug|Best Available Therapy|Active Comparator
75445997|NCT04848688|Drug|Moxidectin 2 mg|Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.
75445998|NCT04848688|Drug|Ivermectin 3 mg|Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
75445999|NCT04848688|Drug|Placebo|Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
75446000|NCT04838769|Device|REZŪM|Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
75595771|NCT05018494|Other|common treatment|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
75595772|NCT05015686|Biological|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
75740206|NCT01039558|Drug|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
75740207|NCT01039558|Drug|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
75888054|NCT04315285|Behavioral|Treadmill gait training with verbal instruction|Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
75888055|NCT01381393|Drug|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
75888056|NCT02154776|Drug|LEE011|3 weeks on and 1 week off
75740208|NCT01039558|Drug|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
75888057|NCT02154776|Drug|Buparlisib|daily
75888058|NCT02154776|Drug|Letrozole|2.5 mg daily;
75888059|NCT04967157|Dietary Supplement|Placebo supplement|Cellulose
75888060|NCT04967157|Dietary Supplement|Citicoline supplement|Cognizin®
75888061|NCT03388749|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
75888062|NCT02770820|Biological|Aldesleukin|Given SC
75888063|NCT02770820|Biological|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
75888064|NCT02770820|Other|Laboratory Biomarker Analysis|Correlative studies
76058373|NCT03025516|Device|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
75446001|NCT04838769|Drug|alpha blocker and 5-alpha reductase inhibitor|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
75740209|NCT03900728|Device|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
75446002|NCT04822753|Procedure|Platelet Rich Plasma injection to the lumbar facet joint|Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.
75446003|NCT04799288|Drug|Teriflunomide|Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.
75888065|NCT01377571|Biological|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
75888066|NCT04051359|Other|Low carbohydrate (130 g) diet|Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (~130 grams of carbohydrates)
75888067|NCT02154854|Drug|Tacrolimus targeted half-dose|
75888068|NCT02154854|Drug|Tacrolimus targeted plain dose|
75888069|NCT01377493|Dietary Supplement|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
75888070|NCT02160080|Drug|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
76058374|NCT01422850|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
75446004|NCT04795661|Drug|Pembrolizumab|Administered intravenous (IV)
75446005|NCT04785586|Behavioral|Healthy Weight Coaching|Lifestyle intervention based on Healthy Weight Coaching (HWC) is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
75446006|NCT04785586|Behavioral|Individual meetings|Individual sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
75740210|NCT03900728|Device|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
75888071|NCT05422495|Behavioral|training with Cycléo device (COTTOS ®),|8 weeks of training
76058375|NCT01422538|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
76058376|NCT01422538|Drug|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
75888072|NCT05422495|Other|non intervention|non intervention
75595773|NCT05015686|Biological|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
76058377|NCT01422538|Other|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
76058378|NCT04025866|Other|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
76058379|NCT04025866|Other|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
76058380|NCT01422382|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
76058381|NCT01422382|Drug|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
76058382|NCT04025788|Device|Magmaris Resorbable Magnesium Scaffold (RMS)|Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.
75446007|NCT04785586|Behavioral|Group meetings|Group sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
75446008|NCT04776941|Behavioral|Behavioral Intervention|Read positive messages
75446009|NCT04776941|Behavioral|Behavioral Intervention|Write about positive experiences
75446010|NCT04776941|Behavioral|Behavioral Intervention|Write about neutral topics
75446011|NCT04776941|Behavioral|Behavioral Intervention|Read neutral messages
75446012|NCT04776941|Other|Quality-of-Life Assessment|Ancillary studies
75446013|NCT04776941|Other|Questionnaire Administration|Complete questionnaires
75740211|NCT03900728|Device|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
75740212|NCT04994912|Drug|EI-001|EI-001 IV infusion
75740213|NCT04994912|Other|Placebo|Placebo IV infusion
76058383|NCT01401322|Drug|Lenalidomide|50 mg; po
76058384|NCT01387594|Procedure|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
76058385|NCT01387594|Drug|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
76058386|NCT01401010|Drug|Doripenem|500 mg every 8 hours
76058387|NCT01401010|Drug|doripenem|1000 mg every 8 hours
76058388|NCT01400932|Drug|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
76058389|NCT01400932|Drug|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
76058390|NCT01400698|Drug|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
75446014|NCT04770870|Device|Hintermann Series H3 Total Ankle Replacement System|Intervention will include receiving the FDA approved Hintermann Series H3 Total Ankle Replacement System, to include a tibial component, a polyethylene inlay, and a talar component.
75595774|NCT05015686|Biological|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
75595775|NCT05015686|Biological|Placebo|Sodium chloride and distilled water
75595776|NCT02881645|Behavioral|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
75740214|NCT01324258|Drug|GSK1120212|Part1 and Part2
75740215|NCT01324258|Drug|Gemcitabine|Part2
75740216|NCT00769457|Device|Access Arm|Active OptiVol-System with CareAlert via CareLink
75740217|NCT01037296|Procedure|catheter ablation|ablation procedure performed with Hansen robotic navigation system
75740218|NCT01037296|Procedure|catheter ablation|Ablation will be performed as normal treatment
75740219|NCT05120999|Device|Train of four measurement|Use of either TetraGraph or TOFScan to measure the neuromuscular blockade
75740220|NCT00068419|Drug|tamoxifen citrate|Given orally
75740221|NCT00068419|Drug|sulindac|Given orally
75740222|NCT00068419|Other|laboratory biomarker analysis|Correlative studies
76058391|NCT01400698|Drug|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
76058392|NCT01400698|Other|Observation only|Subjects were only observed.
76058393|NCT01890746|Drug|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects > 60 years: daunorubicin dose was adjusted to 60mg /m2.
76058394|NCT01890746|Drug|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
76058395|NCT01890746|Drug|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were <100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were <100 Gi/L.
76058396|NCT01890746|Drug|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were <100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were <100 Gi/L.
75595777|NCT04327245|Other|Intervention ingest a 5000 mg of D-tagatose|"Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids."
75740223|NCT01039636|Drug|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
76058397|NCT04614350|Biological|Markman Biologics Microsurfaced ADM|an ADM which has been scored (microsurfaced)
75446015|NCT04763343|Drug|Ketamine Hydrochloride|Ketamine hydrochloride will be given as an intravenous infusion using a standard regimen given in most studies conducted: 0.5 mg/kg over 40 minutes. Ketamine infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of<4, and >50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
75446016|NCT04763343|Drug|Saline|Subjects randomized to placebo will be administered a saline (0.9% sodium chloride) drip for 40 minutes. Saline placebo infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of<4, and >50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
75446017|NCT04763343|Behavioral|CAMS Therapy|CAMS weekly sessions will also be started immediately as an inpatient at the start of the study while receiving ketamine or saline. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk < 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
75595778|NCT04327245|Other|Intervention ingest a 15,3 mg of stevia|"Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
75595779|NCT01588769|Biological|ALECSAT cell based immunotherapy|I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
75595780|NCT00596310|Other|CT|Screening CT
75595781|NCT04327401|Drug|Dexamethasone|Dexamethasone administration for 10 consecutive days after randomization.
75740224|NCT00769535|Genetic|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
75740225|NCT00769613|Biological|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
75740226|NCT00769613|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
75740227|NCT00769613|Biological|therapeutic allogeneic lymphocytes|
75740228|NCT00769613|Genetic|polymerase chain reaction|
75740229|NCT00769613|Other|flow cytometry|
75740230|NCT00769613|Other|immunological diagnostic method|
75740231|NCT00769613|Other|laboratory biomarker analysis|
75740232|NCT01037374|Other|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
75740233|NCT00764153|Procedure|Bipolar hemiarthroplasty|Lateral approach. FWB.
75740234|NCT00764153|Procedure|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
75446018|NCT04761393|Procedure|Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI|Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds
76058398|NCT04614350|Biological|AlloDerm|AlloDerm tissue matrix
75888073|NCT03541538|Device|Global manipulation|The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
75888074|NCT03541538|Device|Especific manipulation|The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
75888075|NCT05422183|Drug|Envafolimab|400mg，sc，d1，Q3W
75888076|NCT05422183|Drug|Lenvatinib|8 mg(BW<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W
75595782|NCT01340027|Drug|Mirabegron|oral
75740235|NCT01042054|Other|Standard optimised recovery protocol.|"Epidural analgesia for the first 48 hours postoperatively.~Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~Optimised recovery protocol followed throughout."
75740236|NCT01042054|Other|Wound catheter plus patient-controlled analgesia.|"Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~Sham epidural catheter applied to the patient's back for purposes of blinding.~Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~Optimised recovery protocol followed throughout."
75888077|NCT05422183|Drug|VP-16|50 mg/d, po,d1-14，Q3W
76058399|NCT01422304|Drug|Sugammadex|Sugammadex 4 mg/kg intravenously
76058400|NCT01422304|Drug|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
76058401|NCT01422304|Drug|Placebo to neostigmine|Normal saline (NaCl 0.9%)
75595783|NCT01340027|Drug|Solifenacin succinate|oral
75595784|NCT01340027|Drug|Placebo|oral
75595785|NCT01327053|Drug|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
75740237|NCT02557373|Dietary Supplement|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
75740238|NCT02557373|Dietary Supplement|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
76058402|NCT01422304|Drug|Placebo to sugammadex|Normal saline (NaCl 0.9%)
76058403|NCT01387516|Behavioral|Motivational Intervention|The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
76058404|NCT01387516|Behavioral|Relaxation Therapy|The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.
76058405|NCT01387516|Behavioral|Cognitive Behavioral Therapy|The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
75888078|NCT03318549|Diagnostic Test|Visual Performance tests|The overall goal of this proposal is to improve our understanding of functional disability in glaucoma by using virtual reality tests to investigate objective performance during simulated daily life activities.
75888079|NCT03318549|Device|Brain-computer interface for assessment of multifocal steady-state visual evoked potentials|The brain-computer interface (BCI) device consists of a modified virtual reality goggle integrated with wireless no-prep electroencephalogram (EEG). The portable BCI is able to objectively measure multifocal steadystate visual evoked potentials in response to brain stimulation through presentation of visual stimuli in the goggle.
75888080|NCT00702585|Drug|Org 36286|Org 36286 single-dose subcutaneous injection
75888081|NCT00702585|Drug|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
75888082|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
75888083|NCT02160158|Drug|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
76058406|NCT01387516|Behavioral|Self-Help Programming|"The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
76058407|NCT03812146|Behavioral|PC-TIME|PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
76058408|NCT03812146|Behavioral|PC-TAU|PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
76058409|NCT01421134|Drug|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
76058410|NCT01421134|Drug|Placebo|Placebo
76058411|NCT01894022|Drug|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
76058412|NCT01615328|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
75595786|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
75595787|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
75595788|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
75595789|NCT04342767|Device|EZ Debride®|EZ Debride ® is intended for the mechanical debridement of topical wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post Mohs' surgery, post-laser surgery, podiatric, wound dehiscence) trauma wounds (abrasions, lacerations, second-degree burns and skin tears), draining wounds and tunnelled /undermined wounds.
75740239|NCT01757626|Biological|Hu3F8 With GM-CSF|Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 & 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m^2/day (day -4 to day 0), & at 500 mcg/m^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
75769564|NCT01153594|Behavioral|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
76058413|NCT01615328|Device|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
76058414|NCT01387282|Drug|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
76058415|NCT01387282|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
76058416|NCT01386970|Drug|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
76058417|NCT01890434|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
76058418|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
76058419|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
75446038|NCT04747795|Drug|Vitamin C|IV
75446039|NCT04747795|Drug|Normal saline|IV
76058420|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
76058421|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
75888084|NCT02160158|Drug|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
75888085|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
76058422|NCT01385566|Biological|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
76058423|NCT01385566|Biological|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
76058424|NCT05365984|Diagnostic Test|end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）|The measurement of end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）is conducted in the process of risk evaluation.
76058425|NCT05365984|Other|Internet Plus technology|The Internet Plus technology is applied in the process of follow-up management.
76058426|NCT01780545|Drug|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
76058427|NCT01780545|Drug|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
76058428|NCT01780389|Drug|Open-label flexibly dosed milnacipran|
75446040|NCT04738487|Biological|Pembrolizumab/Vibostolimab|Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).
75595790|NCT01588808|Behavioral|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
75446041|NCT04738487|Biological|Pembrolizumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).
75446042|NCT04736706|Biological|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
75446043|NCT04736706|Drug|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
75595791|NCT01107925|Drug|prasugrel|Administered orally, daily for 12 days
75595792|NCT01107925|Drug|clopidogrel|Administered orally, daily for 12 days
75595793|NCT04310293|Other|Femara,Grotwth hormone,HMG|NOVEL THERAPY
75769565|NCT03894748|Drug|Botulinum Toxin Type A|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
75769566|NCT03894670|Other|Standard mixed breakfast meal|"The standard mixed breakfast meal consists of:~150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate"
75769567|NCT03894670|Other|SmartBar™|SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
75769568|NCT01151644|Biological|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
75769569|NCT01153750|Drug|Glivec|
75769570|NCT03894592|Other|Virtual reality|Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
75769571|NCT03894436|Combination Product|Ultrasound assessment of diaphragm thickness in B-mode|assess the thickness of diaphragm needed as a tool for prediction of extubation and proper timing of weaning from mechanical ventilation in the ICU which is measured by B mode ultrasound in ventilated cancer patients
75769572|NCT00187278|Device|Biventricular Pacing|Biventricular Pacemaker implant
75769573|NCT00187278|Device|RV Pacing|Standard Pacemaker implant
75769574|NCT03888664|Drug|gamma interferon|1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
76058429|NCT04573569|Behavioral|Behavioral testing|Patients recruited for this study have already undergone surgical implantation of invasive electrodes for purpose of localizing and characterizing electrographic seizures as part of the second phase of surgical epilepsy evaluation. Patients who consent and complete enrollment will then be asked to complete cognitive and behavioral tasks on a portable computer or tablet PC while the invasive electrodes remain implanted. Tasks typically require the patient to think or act and then respond by interacting minimally with the portable computer. These tasks are performed at the will of each patient during their stay in the intensive care unit while surgical electrodes remain.
75595794|NCT01339559|Drug|Brivaracetam|"Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor."
75740240|NCT01757626|Biological|Hu3F8 With GM-CSF|As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
75446044|NCT04736706|Biological|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
75446045|NCT04736706|Drug|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
75446046|NCT04731363|Dietary Supplement|xylitol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.
75446047|NCT04731363|Dietary Supplement|erythritol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.
75740241|NCT00764231|Behavioral|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
75769575|NCT03894124|Drug|Doravirine|Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.
75769576|NCT01258972|Device|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
75888086|NCT02160158|Drug|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
75888087|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
75888088|NCT02160158|Drug|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
76058430|NCT01778985|Drug|Premarin|
76058431|NCT01778985|Other|Placebo|
76058432|NCT01778751|Behavioral|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
75446048|NCT04731363|Dietary Supplement|xylitol, 5g|Intervention is a drink consisting of 300mL of water containing 5g of xylitol as a single oral dose.
75446049|NCT04731363|Dietary Supplement|glucose, 30g|Intervention is a drink consisting of 300mL of water containing 30g of glucose (dextrose) as a single oral dose.
75446050|NCT04729959|Biological|Atezolizumab|Given IV
75446051|NCT04729959|Procedure|Biospecimen Collection|Undergo blood sample and tumor tissue collection
75888089|NCT02160158|Drug|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
75888090|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
75888091|NCT02160158|Drug|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
75888092|NCT05421871|Behavioral|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
75446052|NCT04729959|Procedure|Conventional Surgery|Undergo surgery
75888093|NCT05421871|Behavioral|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
76058433|NCT01865084|Drug|Tadalafil|Administered orally
75888094|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
75595795|NCT00596544|Behavioral|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
75595796|NCT00596544|Behavioral|questionnaires|Those women who have a FSFI score > 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
75595797|NCT01588847|Procedure|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
75595798|NCT01588847|Procedure|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
76058434|NCT01865084|Drug|Placebo|
76058435|NCT01778127|Behavioral|Activity Monitor|Measurement of physical activity.
75595799|NCT04339530|Other|Normal weight and overweight adults|Association between vitamin D levels and insulin resistance
75888095|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
75446053|NCT04729959|Radiation|Fractionated Stereotactic Radiation Therapy|Undergo FSRT
75595800|NCT00107900|Drug|DU-176b|
75595801|NCT00596583|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
75595802|NCT00596583|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
75595803|NCT01339052|Drug|BKM120|
75888096|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube|
75888097|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes|
76058436|NCT01778127|Behavioral|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
76058437|NCT01778127|Behavioral|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
76058438|NCT01892540|Diagnostic Test|positron emission tomography/computed tomography|Undergo PET/CT
76058439|NCT01892540|Diagnostic Test|PET/MRI|Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
76058440|NCT01892540|Device|Position Device|
76058441|NCT01385098|Dietary Supplement|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
76058442|NCT01398514|Drug|Escitalopram|Escitalopram 10mg/day or matched pill placebo
75446054|NCT04729959|Procedure|Magnetic Resonance Imaging|Undergo MRI
75446055|NCT04729959|Biological|Tocilizumab|Given IV
75446056|NCT04728893|Drug|Nemtabrutinib|Nemtabrutinib tablets administered PO QD.
75446057|NCT04715425|Procedure|Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation|Bilateral pulmonary vein isolation using radiofrequency energy
75446058|NCT04715425|Procedure|Catheter pulmonary vein isolation without additional lesions|Bilateral pulmonary vein isolation using radiofrequency energy
75446059|NCT04710134|Biological|Reslizumab|Reslizumab 3,4, or 5 mg/kg IV q4 weeks
75446060|NCT04708886|Drug|Romosozumab|Year 1 study drug
75595804|NCT01339052|Procedure|Surgery|Surgery
75740242|NCT00764231|Behavioral|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
75740243|NCT05408234|Other|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
75616348|NCT01909089|Drug|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
75740244|NCT01042132|Procedure|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
75888098|NCT01381315|Procedure|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur <3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
76058443|NCT01398358|Behavioral|Parents of Preschoolers Series|"The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.~The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home."
76058444|NCT01398358|Behavioral|Incredible Years Series|"The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.~For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.~Teachers are trained in classroom management strategies."
76058445|NCT03025282|Drug|CD10367 3% Solution - Non-desquamated zone|Once daily application for 3 weeks
76058446|NCT03025282|Drug|CD10367 1% Solution - Non-desquamated zone|Once daily application for 3 weeks
76058447|NCT03025282|Drug|CD10367 solution placebo - Non-desquamated zone|Once daily application for 3 weeks
76058448|NCT03025282|Drug|Betneval ointment - Non-desquamated zone|Once daily application for 3 weeks
76058449|NCT03025282|Drug|CD10367 3% Solution - Desquamated zone|Once daily application for 3 weeks
76058450|NCT03025282|Drug|CD10367 solution placebo - Desquamated zone|Once daily application for 3 weeks
76058451|NCT01778049|Drug|BI 10773|Empagliflozin active
76058452|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
76058453|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
76058454|NCT01778049|Drug|BI 10773|Empagliflozin active
76058455|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
75446061|NCT04708886|Drug|Alendronate|Year 2 study drug
75740245|NCT01042132|Procedure|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
75446062|NCT04700137|Other|Caring Contacts Plus Introductory Phone Call (CC+)|One introductory semi-structured caring phone conversation with a follow-up specialist to check-in, establish a personal connection, and provide resources at the 0-2 week time-point followed by 11 non-demanding, caring text or email messages sent over the course of 6 months.
75740246|NCT00068107|Drug|Replagal|enzyme replacement therapy
75769577|NCT01258972|Device|POBA|Balloon angioplasty
75888099|NCT01381315|Procedure|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative-that the lymphedema rate is <0.13 for subjects undergoing ALND-if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
76058456|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
76058457|NCT01778049|Drug|BI 10773|Empagliflozin active
76058458|NCT01778049|Drug|BI 10773|Empagliflozin active
75446063|NCT04700137|Other|Caring Contacts without an introductory phone call (CC)|Eleven non-demanding, caring text or email messages sent over the course of 6 months. Participants will not know or have spoken to the follow-up specialist who sends the caring messages.
75446064|NCT04693468|Drug|Axitinib|Given PO
76058459|NCT01778049|Drug|BI 10773|Empagliflozin active
76058460|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
75740247|NCT04048811|Drug|HSK3486|The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
75888100|NCT02160236|Drug|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
75446065|NCT04693468|Drug|Crizotinib|Given PO
75446066|NCT04693468|Drug|Palbociclib Isethionate|Given PO
75888101|NCT02160236|Drug|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
75888102|NCT02160236|Drug|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
75446067|NCT04693468|Drug|Talazoparib Tosylate|Given PO
75888103|NCT03273855|Other|Fecal microbiota transplantation|The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
75446068|NCT04693169|Drug|11C-Choline|1、PSMA137 labeled with [Al18F] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the [Al18F]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
75446069|NCT04688593|Device|MobileLink|Patients who receive a MobileLink hip prosthesis system will be followed-up for 10 years.
75446070|NCT04678297|Behavioral|Physical activity + emotion regulation intervention|The intervention meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention will be led by certified instructors trained in working with back pain patients. The instructor leads participants through a series of physical activity exercises at a slow-moderate pace. Participants will be asked to practice every day for 20 minutes to maximize the benefit of the intervention. Participants also receive a home practice manual containing some basic, safe postures that can be performed on days they are not attending the formal in-person sessions.
75446071|NCT04678297|Behavioral|Physical activity control intervention|The interventions meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention is designed to require a similar amount of physical exertion. Classes involve conventional exercises appropriate for patients with CLBP, including a comprehensive set of exercises that stretch all the major muscle groups, with an emphasis on the trunk and legs. The intervention will include all 12 stretching exercises used in the exercise intervention of previous studies that have successfully used it in comparison to yoga, plus 3 additional stretches (hip internal rotators, hip adductors and hip flexion).Participants will be asked to practice every day for 20 minutes home as well. Printed handouts will be provided to facilitate home practice. In addition, a video demonstrating all the exercises will be provided to assist participants in practicing safely. Classes will be led by a licensed physical therapist who has previous experience leading exercise classes.
76058461|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
75446072|NCT04675515|Behavioral|Intensive Tobacco Treatment|Bi-weekly tobacco treatment counseling and regular carbon monoxide monitoring
75446073|NCT04667767|Other|WASH kit|WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.
75446074|NCT04667767|Other|Standard treatment|National standard outpatient treatment for uncomplicated severe acute malnutrition
75446075|NCT04662255|Drug|Pirtobrutinib|Oral
75595805|NCT04327323|Device|CCM device implantation|CCM implantation involves the introduction of two active fixation stimulation leads, fixed on the interventricular septum, and connected to the CCM generator (Optimizer Smart IV, Impulse Dynamic, and any subsequent versions of the same device) inserted in the subcutaneous or submuscular pocket. The implantation is ususally performed using vascular access via right or left cephalic or subclavian vein. The CCM signal consists of 2-3 biphasic pulses lasting 10 msec (total duration of about 20 ms) with an amplitude between 4.0 and 7.5 V, delivered during the absolute refractory period of the ventricle, at a distance of 40 msec from ventricular sensing. The CCM device is compatible with other pacing and defibrillation devices already implanted in the patient; at the time of the implantation, the devices are checked in order to confirm the absence of interference between the devices. The patient is instructed to charge the device battery weekly.
75595806|NCT04338360|Biological|COVID-19 convalescent plasma|COVID-19 convalescent plasma
75595807|NCT00107315|Biological|bevacizumab|
75446076|NCT04662255|Drug|Ibrutinib|Oral
75446077|NCT04662255|Drug|Acalabrutinib|Oral
76058462|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
76058463|NCT01778049|Drug|BI 10773|Empagliflozin active
75446078|NCT04662255|Drug|Zanubrutinib|Oral
76058464|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
75595808|NCT00107315|Drug|capecitabine|
75595809|NCT01335971|Drug|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
76058465|NCT01777581|Drug|Milnacipran|
76058466|NCT01777581|Drug|Placebo|
76058467|NCT01864148|Drug|BIIB033|
76058468|NCT01864148|Other|Placebo|
76058469|NCT01864148|Drug|Avonex|
75888104|NCT03273855|Other|Placebo: fecal microbiota transplantation|The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
75888105|NCT05421559|Procedure|thyroidectomy|removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
75888106|NCT02154932|Drug|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
75595810|NCT01335971|Dietary Supplement|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
75888107|NCT02154932|Drug|single dose misoprostol|1 dose, 1 hours, prior surgery
76058470|NCT01751139|Procedure|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
75595811|NCT01335971|Other|Placebo|Microcrystalline cellulose once daily by mouth
75595812|NCT00596661|Device|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
75595813|NCT04337892|Device|Standard of Care4|The current standard of care for surgical planning for the participating investigator surgeon is to use Zeiss Veracity Surgical, so this same method will be used for the surgery actually performed on participating patients.
75595814|NCT00107276|Drug|capecitabine|
75595815|NCT00107276|Drug|cyclophosphamide|
75616349|NCT02844790|Drug|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
75616350|NCT05337358|Procedure|endocrown|endocrown
75616351|NCT02845102|Other|Pre-Post Feasibility|The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
75740248|NCT04048811|Drug|Propofol|The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
75446079|NCT04658771|Device|MR-HIFU treatment|"MR-HIFU is an innovative technology that allows for non-invasive thermal ablation of tissues and tumors by integrating an external high intensity focused ultrasound (HIFU) transducer with a conventional MRI scanner.~The focused ultrasound transducer is placed outside of the body and generates and focuses acoustic energy to heat tumors or other pre-defined focal regions of tissues inside the body. Because the acoustic energy is precisely focused over tiny areas of tissue, potential thermal injury to surrounding tissues is minimal. Cell death inside the selected treatment area occurs via coagulative necrosis while avoiding injury to intervening and adjacent tissues."
75740249|NCT04048811|Drug|Propofol HSK3486|The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
75740250|NCT01564082|Device|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
75740251|NCT00764387|Drug|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
75740252|NCT00764387|Drug|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
75740253|NCT03957889|Other|Educational simulation|
75740254|NCT01086631|Drug|Rituximab|
75740255|NCT04909502|Drug|EHP-101 25 mg OD|25 mg OD during the first 28 Days of the trial
75740256|NCT04909502|Drug|EHP-101 25 mg BID|25 mg BID during the first 28 Days of the trial
75740257|NCT04909502|Drug|EHP-101 50 mg OD|After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
75740258|NCT04909502|Drug|EHP-101 50 mg BID|After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
75740259|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
75740260|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
75740261|NCT00769847|Procedure|Endoscopic strip craniectomy|Surgery
75740262|NCT00394654|Biological|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
75740263|NCT00394654|Other|Placebo|Placebo administered as a single intravenous infusion
75740264|NCT01086787|Other|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
75769578|NCT03888508|Other|SIT|"sensory integration therapy along with standard therapy.~Primary care giver will be trained to perform sensory integration therapy at home.~. Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home~Daily sessions of approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 days in a week will be done."
75769579|NCT00256308|Drug|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
75740265|NCT04048265|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
75446080|NCT04655404|Drug|Larotrectinib|"Larotrectinib monotherapy x2 cycles followed by disease evaluation~Larotrectinib with or without chemotherapy backbone"
75446081|NCT04655404|Procedure|Larotrectinib surgical|"Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~Larotrectinib with or without chemotherapy backbone"
75740266|NCT03900416|Behavioral|Mindfulness App|Mindfulness exercises will last 1-12 minutes. Each one asks participants to focus on something (e.g., breath, sounds, physical sensations) using guided instruction.
75888108|NCT05421403|Procedure|adenotonsillectomy|all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade >2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated
76058471|NCT01751139|Other|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
76058472|NCT04415138|Device|Robotic-assisted mitral valve repair|Mitral valve repair using robotic technology (DaVinci X platform)
76058473|NCT01890122|Drug|Alogliptin|Alogliptin tablets
75446082|NCT04648358|Drug|Bupivacaine|The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
75446083|NCT04648358|Drug|Dexamethasone combined with bupivacaine|The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
76058474|NCT01890122|Drug|Metformin HCl|Metformin HCl capsules
76058475|NCT01890122|Drug|Alogliptin and Metformin Fixed-Dose Combination (FDC)|Alogliptin and metformin FDC tablets
76058476|NCT01890122|Drug|Alogliptin Placebo|Alogliptin placebo-matching tablets
76058477|NCT01890122|Drug|Metformin Placebo|Metformin placebo-matching capsules
76058478|NCT01890122|Drug|Alogliptin and Metformin FDC Placebo|Alogliptin and metformin FDC placebo-matching tablets
75740267|NCT02557607|Device|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
76058479|NCT01397890|Drug|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
76058480|NCT01397890|Drug|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
75888109|NCT05421403|Behavioral|Lifestyle intervention|After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of ~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
75888110|NCT02158286|Other|Measuring emptying rate from the gastric tube|
76058481|NCT01777269|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
76058482|NCT01777269|Drug|Placebo|Take one capsule daily
75888111|NCT02961465|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
75888112|NCT03659773|Biological|immune biomarkers to evaluate vaccine response in HSCT recipients|a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
75446085|NCT04633434|Behavioral|The Talk Parenting Skill for Alexa|In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
76058483|NCT04616456|Drug|[F-18]PBR06|PET radiopharmaceutical
76058484|NCT04616456|Drug|Verdiperstat|verdiperstat targets microglial inflammation in the brain
76058485|NCT05365360|Device|LaserCap SD|LaserCap SD
76058486|NCT05365360|Device|Sham LaserCap|Sham LaserCap
75446086|NCT04632238|Behavioral|Metrics-driven quality improvement (MDQI)|The intervention broadly consists of training and coaching to clinic staff and leadership on 1) clinical quality measure monitoring; 2) clinical practice process change management; and 3) use of tools for shared decision making and patient treatment progress monitoring.
75595816|NCT04326777|Procedure|Ballon pulmonary angioplasty|Percutaneous vascular access for BPA is via the femoral vein using Seldinger technique. A 5Fr sheath is inserted into the vein, through which a 6Fr long introducer sheath is advanced into the pulmonary artery. Subsequently, a 6Fr guiding catheter is advanced into the pulmonary artery being treated. Generally, selective pulmonary angiography should be performed to evaluate lesion feature before BPA. Then a 0.014-inch guidewire is used to cross the lesion, a balloon catheter of an appropriate diameter is selected to dilate the lesion.
76058487|NCT05365360|Device|LaserCap HD+|LaserCap HD+
75595817|NCT01335698|Drug|Atazanavir Sulphate|
76058488|NCT04016272|Device|Active tDCS|tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.
75595818|NCT01335698|Drug|Ritonavir|
76058489|NCT04016272|Device|Sham tDCS|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
75740268|NCT00769925|Behavioral|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
76058490|NCT04371250|Other|Survey and Questionnaire|Resilience and Loneliness questionnaires
76058491|NCT01751061|Behavioral|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
76058492|NCT01751061|Other|Usual care|usual ICU care
76058493|NCT01777191|Drug|Ixekizumab Auto-Injector|Administered SC by auto-injector
75740269|NCT00769925|Behavioral|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
76058494|NCT01777191|Drug|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
76058495|NCT01896050|Drug|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
76058496|NCT01896050|Drug|Tamoxifen|Patients were treated with tamoxifen for up to one year
76058497|NCT01775787|Drug|Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor|Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco & Menthol Flavor for 7-10 days or Tobacco & Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
75595819|NCT00596700|Device|Given® Diagnostic System including PillCamTM SB Capsules|"Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.~An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa"
75616352|NCT00946881|Drug|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
76058498|NCT01775553|Drug|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
75446087|NCT04629326|Other|68Ga-WL12 PET/CT|WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning
75446088|NCT04623593|Procedure|ACDF|Standard operative treatment for anterior cervical discectomy. Through a right or left-sided approach the disc space contents are resected. The endplates are prepared with curettes and the disc space contents are removed. The posterior longitudinal ligament is opened. The dura is visualized to ensure adequate decompression. A cage is implanted in the disc space. The disc removal and cage implantation can be performed at a single level or at multiple levels. The wound is closed in layers, after a prevertebral wound drain is placed.
75446089|NCT04623593|Procedure|ACDA|The start of the procedure is the same as in the ACDF group. After the discectomy, a cervical disc prosthesis is placed in the disc space instead of a cage, in accordance with the manufacturer's protocol for implantation and endplate preparation. The disc removal and arthrodesis implantation can be performed at a single level or at multiple levels. Wound closure is similar to the ACDF procedure.
75616353|NCT01214642|Drug|pegfilgrastim|Administered subcutaneously
75740270|NCT00770003|Drug|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
75888113|NCT03541772|Dietary Supplement|Oncoxin-Viusid®|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments
75888114|NCT03541772|Dietary Supplement|Placebo|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
75888115|NCT01381237|Behavioral|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
75616354|NCT01214642|Drug|LY2523355|Administered intravenously
75740271|NCT00770003|Drug|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
75888116|NCT03542630|Diagnostic Test|salivary MMP8 test|All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response
75888117|NCT03542630|Other|periodontal examination|Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.
75888118|NCT03542630|Other|blood tests|All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
76058499|NCT01775475|Drug|cyclophosphamide|Given IV
75446090|NCT04605380|Other|Virtual reality online world|Virtual patient with open fracture inside a virtual world
75888119|NCT01377415|Drug|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
75888120|NCT02678403|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
75888121|NCT02678403|Device|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
75888122|NCT02155088|Drug|BYL719|Dose escalation beginning at 250 mg/day
75446091|NCT04589468|Other|Exercise|Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
75740272|NCT00771329|Drug|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
75740273|NCT00771329|Other|Placebo (sterile normal saline)|Single IV dose of Placebo
75740274|NCT00771485|Drug|FM-602|Study of Efficacy of Bowel Preparation Before Colonoscopy
75740275|NCT00771485|Drug|Marketed Bowel Cleanser|Marketed bowel cleanser
75740276|NCT04002752|Drug|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
75888123|NCT02155088|Drug|Gemcitabine|Dose escalation beginning at 800 mg/m^2
76058500|NCT01775475|Drug|doxorubicin hydrochloride|Given IV
75740277|NCT04002752|Drug|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
75446093|NCT04562129|Drug|Interleukin-2|High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)
75446094|NCT04562129|Drug|Ipilimumab|Low dose Ipilimumab given at time of HD IL2 administration on day 1 of the first 2 cycles of each course.
75446095|NCT04562129|Drug|Nivolumab|Nivolumab will be given at a dose of 480 mg IV week 7 of each course.
75740278|NCT00770159|Drug|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
75446096|NCT04560725|Drug|11C-Choline|11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the [68Ga]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
75446097|NCT04560335|Behavioral|Coach to FIt|"CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about~15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly."
75446098|NCT04560335|Behavioral|Treatment as Usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
75446099|NCT04557423|Behavioral|Community-Based Education|A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
75595820|NCT04327362|Device|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
75616355|NCT02856633|Device|Vitaliti|
75740279|NCT00770159|Drug|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
75616356|NCT05241652|Other|Inspiratory Muscle Training with an intensity of 50% MIP|Patients received IMT exercise program at a 50% MIP intensity for 12 weeks
75616357|NCT05241652|Other|Inspiratory Muscle Training with an intensity of 10% MIP|Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
75740280|NCT00399490|Drug|RN624 (PF-04383119)|50 mcg/kg
75769580|NCT00256308|Procedure|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
75769581|NCT01153828|Drug|Retapamulin|Prescription for retapamulin
75888124|NCT02155088|Drug|(nab)-paclitaxel|125 mg/m^2 dose
75888125|NCT03625635|Other|Individualized food-based intervention|Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
76058501|NCT01775475|Drug|vincristine sulfate|Given IV
76058502|NCT01775475|Drug|prednisone|Given PO
76058503|NCT01775475|Drug|lomustine|Given PO
76058504|NCT01775475|Drug|etoposide|Given PO
76058505|NCT01775475|Drug|cyclophosphamide|Given PO
76058506|NCT01775475|Drug|procarbazine hydrochloride|Given PO
75446100|NCT04557423|Behavioral|Navigation to Screening|Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
75446101|NCT04557423|Behavioral|HPV Self-Sampling|An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
75888126|NCT02160392|Procedure|Endometrial biopsy|Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
75446102|NCT04554602|Diagnostic Test|Fusion ultrasound|Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.
75446103|NCT04553536|Drug|Esketamine, Sulfentanil or/and Remifentanil|The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
75446104|NCT04548219|Drug|Mirikizumab|Reference and test formulations of mirikizumab administered as a SC injection.
75446105|NCT04533750|Procedure|Computed Tomography|Undergo CT or PET/CT
75446106|NCT04533750|Other|Fludeoxyglucose F-18|Given IV
75446107|NCT04533750|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75595821|NCT04327362|Behavioral|Prolonged Exposure Therapy|All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
75595822|NCT02892474|Procedure|Hybrid Coronary Revascularization (HCR)|Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
75740281|NCT00770237|Behavioral|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
75740282|NCT00770237|Behavioral|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
75740283|NCT02557529|Behavioral|Progressive Resistance Training|12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
75740284|NCT02557529|Behavioral|physical activity|Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
75740285|NCT02557529|Behavioral|Diet diary|Weekly diet diary during the 12-weeks intervention
75740286|NCT00764543|Device|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
75446108|NCT04533750|Procedure|Magnetic Resonance Imaging|Undergo MRI
75446109|NCT04533750|Drug|Peposertib|Given PO
75888127|NCT02160470|Behavioral|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
76058507|NCT01775475|Other|laboratory biomarker analysis|Correlative studies
75446110|NCT04533750|Procedure|Positron Emission Tomography|Undergo PET/CT
75446111|NCT04523818|Drug|Capecitabine|Given PO
75446112|NCT04523818|Drug|Fluorouracil|Given IV
75446113|NCT04523818|Radiation|Radiation Therapy|Undergo radiation therapy
75446114|NCT04523818|Procedure|Therapeutic Surgical Procedure|Undergo standard of care surgery
75446115|NCT04516967|Drug|Avatrombopag|Oral avatrombopag Tablet
75446116|NCT04516967|Drug|Placebo|Placebo comparator tablet
75446117|NCT04474847|Drug|Abatacept|Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
75595823|NCT02892474|Procedure|Coronary Artery Bypass Grafting (CABG)|Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
75595824|NCT04336839|Procedure|Portal vein resection / reconstruction|Portal vein resection and reconstruction, with or without concommitant arterial resection
75446118|NCT04474847|Drug|Placebo|Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
75446119|NCT04458766|Behavioral|Monetary incentives|This intervention will assess the efficacy of subjects using the Wellth mobile phone application to provide reminders to take their statin medication, and receiving monetary incentives for taking their medication as prescribed.
75446120|NCT04437368|Drug|GT005; Low Dose|Part 1 of the study will test two doses of GT005: Low Dose and High Dose.
75446121|NCT04437368|Drug|GT005; High Dose|Part 1 of the study will test two doses of GT005: Low Dose and High Dose.
75595825|NCT00107120|Drug|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
75595826|NCT00107120|Drug|Placebo|Placebo once daily for up to 8 weeks
75595827|NCT00596778|Other|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
75595828|NCT00596856|Behavioral|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
75740287|NCT00398866|Drug|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
75740288|NCT00398866|Drug|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
75740289|NCT00398866|Drug|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
75740290|NCT00771563|Drug|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
75740291|NCT00771563|Drug|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
75769582|NCT01153828|Drug|Co-prescription of retapamulin and topical mupirocin|Same day prescriptions for retapamulin and topical mupirocin
75769583|NCT01153828|Drug|Co-prescription of retapamulin and topical fusidic acid|Same day prescription for retapamulin and fusidic acid.
75888128|NCT02160470|Behavioral|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
75595829|NCT01335464|Drug|placebo|placebo matching BIBF1120, BID
75595830|NCT01335464|Drug|BIBF 1120|BIBF1120 BID (twice daily)
75595831|NCT00622947|Procedure|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
75595832|NCT00622947|Procedure|Sham-rTMS|The coil is angled 90 degrees away from the scalp
75595833|NCT04333056|Other|Biometric measurement agreement|Patients scheduled for cataract surgery were measured with both ss-OCT devices. The following biometry parameters were compared: anterior keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and axial length (AL).
75446122|NCT04437368|Drug|GT005; Low Dose|Part 2 of the study will test one dose: Low Dose.
75446123|NCT04428151|Drug|Lenvatinib|20 mg once daily, taken as oral capsules
75446124|NCT04428151|Biological|Pembrolizumab|200 mg 30-minute IV infusion on day 1 of each 21-day cycle
75446125|NCT04428151|Drug|Docetaxel|75 mg/m^2 administered as an IV infusion on day 1 of each 21-day cycle
75446126|NCT04428151|Drug|Capecitabine|1250 mg/m^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets
75446127|NCT04428151|Drug|Paclitaxel|80 mg/m^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
75446128|NCT04428151|Drug|Cetuximab|400 mg/m^2 loading dose, followed by 250 mg/m^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
75446129|NCT04428151|Drug|Lenvatinib|24 mg once daily, taken as oral capsules
75446130|NCT04417699|Drug|TAS 102|Oral medication over Days 1-5
76058508|NCT01774929|Drug|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
75595834|NCT00107042|Biological|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
75595835|NCT00107042|Biological|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
75446131|NCT04417699|Drug|Oxaliplatin|Administered by intravenous infusion over 2 hours on day 1
75595836|NCT00596895|Dietary Supplement|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
75446132|NCT04414306|Other|In-person cancer screening education|Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
75446133|NCT04414306|Other|Online educational video and website module|Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
75595837|NCT00596973|Procedure|Surgical Treatment|Ileal transposition with sleeve gastrectomy
75595838|NCT02891772|Procedure|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
75595839|NCT00106964|Biological|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
75616358|NCT02856243|Drug|new antiviral therapy|
76058509|NCT01888874|Drug|GLPG0634|GLPG0634 capsules.
76058510|NCT01888874|Drug|Placebo|Placebo capsules.
75446134|NCT04414306|Other|Online educational video|Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
76058511|NCT01749735|Device|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
76058512|NCT01749735|Device|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
76058513|NCT01749735|Device|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
75446135|NCT04414306|Other|Message from healthcare system and online educational video and website module|Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
75446136|NCT04413097|Procedure|Delayed Cord Clamping with Low Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.
75595840|NCT00106964|Biological|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
75595841|NCT00106964|Biological|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle."
75740292|NCT04780802|Procedure|The balloon catheter is placed at the various arterial feeders of the tumor|use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
76058514|NCT01749033|Other|Group 1 Classic|"Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual."
75595842|NCT02892435|Device|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
75595843|NCT02892435|Device|conventional dressing|positioning conventional dressing
75595844|NCT00106184|Drug|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
75595845|NCT00106184|Drug|Placebo|"Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1"
75595846|NCT00598923|Drug|topiramate|100 mg twice per day for 3 months
75595847|NCT00598923|Drug|topiramate|100 twice per day for 6 days after loading dose of phenytoin
75595848|NCT00598923|Drug|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
75740293|NCT00775073|Drug|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
75740294|NCT00398632|Drug|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
75740295|NCT03993418|Dietary Supplement|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
75888129|NCT02160470|Behavioral|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
75888130|NCT02160470|Behavioral|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
75888131|NCT02160548|Drug|Standard care|Standard management for OP poisoning
75446137|NCT04413097|Procedure|Delayed Cord Clamping with High Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.
75446138|NCT04404075|Other|SkinTracker Mobile App|a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
75446139|NCT04390763|Biological|NIS793|anti-TGFb antibody
75446140|NCT04390763|Biological|Spartalizumab|anti-PD-1 antibody
75446141|NCT04390763|Drug|gemcitabine|SOC chemotherapy
75740296|NCT04048031|Dietary Supplement|Nutrafol Supplement Capsules|NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
75446142|NCT04390763|Drug|nab-paclitaxel|SOC chemotherapy
75446143|NCT04378075|Drug|Vatiquinone|Vatiquinone will be administered per the treatment arm description.
75446144|NCT04378075|Other|Placebo|Vatiquinone-matching placebo will be administered per the treatment arm description
75888132|NCT02160548|Drug|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
75888133|NCT02160548|Drug|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
75888134|NCT02158598|Drug|Vitamin D chewable tablet supplementation|
75888135|NCT02158598|Drug|Vitamin D pill supplementation|
75888136|NCT03082729|Drug|Apremilast|Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
75888137|NCT02513043|Drug|medical abortion|medical abortion
75888138|NCT02160704|Drug|Enclomiphene citrate|25 mg daily for 16 weeks
75888139|NCT02160704|Other|Placebo|placebo daily for 16 weeks
75888140|NCT03541382|Device|OraQuick® HIV Self-Test|"Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC."
75740297|NCT04048031|Other|Placebo Capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
76058515|NCT01749033|Other|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer.
75740298|NCT04734548|Drug|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
75740299|NCT04734548|Other|Placebo|White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
75740300|NCT01589146|Drug|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
75595849|NCT02892318|Drug|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
75595850|NCT02892318|Drug|Guadecitabine|Guadecitabine 60 mg/m^2 SC on Days 1-5 of every 28-day cycle.
75595851|NCT01334918|Drug|regadenoson|Administered by intravenous bolus.
75595852|NCT01334918|Radiation|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Administered by intravenous infusion
75595853|NCT01334918|Radiation|Contrast|Administered by intravenous infusion.
75595854|NCT01334918|Procedure|Single Photon Emission Computed Tomography|Procedure/Surgery
75595855|NCT01334918|Procedure|Multidetector Computed Tomography|Procedure/Surgery
75740301|NCT00775151|Drug|amlodipine 10 mg tablet|
75740302|NCT04694300|Drug|Naproxen|"440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days."
75740303|NCT04694300|Drug|Acetaminophen|1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
75740304|NCT04694300|Drug|Tramadol|50 mg by mouth every 6 hours as needed for pain
76058516|NCT01749033|Other|Group 3 ELL-PIC|Group 3 (ELL-PIC): Using the ELL-PIC technique
75740305|NCT02556983|Radiation|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
75740306|NCT04002596|Device|ExAblate Neuro Thalamotomy Treatment|Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
75740307|NCT00764621|Procedure|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
75740308|NCT00764621|Procedure|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
76058517|NCT01774305|Drug|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
76058518|NCT01774305|Drug|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
75740309|NCT00764621|Procedure|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
75740310|NCT01043770|Behavioral|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
76058519|NCT01737021|Other|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
76058520|NCT01397422|Drug|ADS-5102 (extended release amantadine HCl)|Oral capsules to be administered once daily at bedtime, for 8 weeks
75446151|NCT04339062|Drug|Cemiplimab|Cemiplimab: via IV, flat predetermined dosage every 21 days.
75446152|NCT04339062|Drug|Everolimus|Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while eceiving Cemiplimab
75446153|NCT04339062|Drug|Sirolimus|Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
75446154|NCT04339062|Drug|Prednisone|40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
75446155|NCT04330729|Drug|Acetylsalicylic acid|Se arm description
75446156|NCT04322383|Drug|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
75595856|NCT00598962|Drug|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
75595857|NCT00598962|Drug|Rifabutin/rifampin|
75595858|NCT00599001|Drug|SD-101|Single subcutaneous escalating dose
75595859|NCT00599001|Drug|placebo|placebo
75595860|NCT04052516|Drug|Icosabutate|Icosabutate oral capsule once daily
75595861|NCT04052516|Drug|Placebo|Matching placebo oral capsule
75595862|NCT00597051|Drug|ARD-0403|
75595863|NCT00599040|Behavioral|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
75595864|NCT00599040|Behavioral|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
75595865|NCT00599040|Behavioral|Dairy diet|participants are given a high dairy, reduced calorie diet
75595866|NCT01332968|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
75740311|NCT00771641|Procedure|conventional surgery|
75740312|NCT00771641|Radiation|low-LET cobalt-60 gamma ray therapy|
75888141|NCT03542552|Drug|Magnesium Sulfate|Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
76058521|NCT01888640|Device|TENS|"TENS Parameters: Active TENS and Placebo TENS~TENS Frequency - 2-125 Hz~TENS Pulse Width - 200 µs~TENS Intensity - Maximal tolerable intensity~Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~Administration - Daily~TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care"
76058522|NCT01736475|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
76058523|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
76058524|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
75446157|NCT04318327|Biological|PHE885|Infusion
75446158|NCT04304066|Other|18F-WL12 PET or 68Ga-WL12 PET|WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
75595867|NCT01332968|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
75888142|NCT03542552|Drug|Nifedipine|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
75595868|NCT01332968|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
75888143|NCT02158676|Dietary Supplement|Prebiotic|Fructooligosaccharides
75888144|NCT02158676|Dietary Supplement|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
75888145|NCT02158676|Other|Placebo|Maltodextrin
76058525|NCT01736475|Biological|PEGylated Recombinant Factor VIII|On-demand treatment
76058526|NCT01863758|Biological|Human-cl rhFVIII|Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
76058527|NCT01863680|Drug|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent [%] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
76058528|NCT01863680|Drug|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
76058529|NCT01863680|Drug|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
76058530|NCT01863680|Drug|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
76058531|NCT01747629|Drug|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
76058532|NCT01747629|Drug|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
76058533|NCT04170920|Device|LifeExtend-AI|"LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
76058534|NCT01863368|Other|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
76058535|NCT01863368|Other|Systane® ULTRA lubricant eyedrops|
75595869|NCT01332968|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
75740313|NCT00771641|Radiation|low-LET electron therapy|
75740314|NCT00771641|Radiation|low-LET photon therapy|
75740315|NCT00771641|Radiation|radiation therapy|
75769584|NCT03968952|Other|SMARThealth Pregnancy|Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
75769585|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection before vitrectomy
75769586|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection after vitrectomy
75888146|NCT02155166|Drug|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
75888147|NCT02155166|Drug|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
75888148|NCT02158754|Diagnostic Test|Corus CAD (ASGES)|
75888149|NCT00398931|Drug|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
75888150|NCT00398931|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
76058536|NCT01863368|Other|OPTIVE® lubricating eyedrops|
76058537|NCT01886690|Drug|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
76058538|NCT01886690|Drug|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
76058539|NCT01886378|Drug|UX007|
76058540|NCT04616378|Other|Phase 2 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
76058541|NCT04616378|Other|Phase 2 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
76058542|NCT04616378|Other|Phase 3 No Prosthesis|No prosthetic device is attached.
76058543|NCT04616378|Other|Phase 3 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
76058544|NCT04616378|Other|Phase 3 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
76058545|NCT01885208|Drug|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
75595870|NCT01332968|Drug|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
76058546|NCT01885208|Drug|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
76058547|NCT01859702|Drug|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
75595871|NCT01332968|Drug|Bendamustine|Bendamustine 90 mg/m^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
76058548|NCT04599686|Drug|ADT|On the day of enrollment, luteinizing hormone-releasing hormone agonist (LHRHa) was given for ADT.
76058549|NCT04599686|Radiation|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT) (3-5 fractions).
76058550|NCT01835132|Device|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
76058551|NCT01747551|Drug|Oxaliplatin|
76058552|NCT01747551|Drug|Leucovorin|
76058553|NCT01747551|Drug|Fluorouracil|
75446172|NCT04260191|Drug|AMG 910|IV Infusion
75446173|NCT04248543|Device|qMRI with Gadoteridol contrast agent|quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.
76058554|NCT01747551|Drug|Ziv-aflibercept|
76058555|NCT01736397|Drug|Ferric Citrate|Dose depends on serum phosphorus levels collected at each study visit.
76058556|NCT01736397|Drug|Placebo|
76058557|NCT01859390|Drug|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
76058558|NCT01859390|Dietary Supplement|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
76058559|NCT01858766|Drug|SOF|400 mg tablet administered orally once daily
76058560|NCT01858766|Drug|VEL|Tablet administered orally once daily
76058561|NCT01858766|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76058562|NCT01734993|Drug|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
76058563|NCT01745367|Drug|Tivozanib Hydrochloride|
76058564|NCT01745367|Drug|paclitaxel|
76058565|NCT01745367|Drug|Placebo|
76058566|NCT01733121|Drug|NBI-98854|25 mg capsule
76058567|NCT01733121|Drug|NBI-98854|50 mg capsule
75888151|NCT02160938|Other|3-year follow-up|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~The Vineland-II Adaptive Behavior Scale (VABS)~Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~Children will also be photographed (for review by the study dysmorphologist)"
75888152|NCT02155400|Device|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
76058568|NCT01733121|Drug|Placebo|
76058569|NCT01744977|Behavioral|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
75595872|NCT01332968|Drug|Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m^2 every 2 months during maintenance period.
75740316|NCT05408078|Device|SLEEPexpert|"SLEEPexpert 1.0 is the first version of an online Program to treat Insomnia. The internet-based self-help platform used for the implementation of CBT-I in this study has been developed by the University of Bern (Prof. Dr. Thomas Berger), has been used successfully in previous trials and has received a CE mark in 2018.~The device is intended for patients with mental disorders and insomnia who are treated for mental disorders in a hospital or an outpatient unit. No specific training is needed to operate the application.~There is no available clinical research data to date on exactly this product. However, the therapeutic content that is used in this study is based on Cognitive Behavioral Therapy for insomnia (CBT-I). This intervention has been found to be highly effective and without lasting adverse effects in many studies and is recommended for the treatment of insomnia in current clinical guidelines."
75595873|NCT00599079|Drug|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
75595874|NCT04326816|Procedure|Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)|
75595875|NCT00597129|Biological|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
75740317|NCT05408078|Other|TAU plus sleep monitoring|Treatment aus Usual and a Sleep Monitoring App will be used. This is already described in the Arm Section
75740318|NCT05408000|Drug|ketofol vs propofol|Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia
75740319|NCT00771719|Drug|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
75740320|NCT05407922|Procedure|Laparoscopy vs Non-laparoscopy approach|Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen
75740321|NCT00771797|Dietary Supplement|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
76058570|NCT01383928|Drug|Ixazomib|Ixazomib capsules
76058571|NCT01383928|Drug|Lenalidomide|Lenalidomide capsules
76058572|NCT01383928|Drug|Dexamethasone|Dexamethasone Tablets
76058573|NCT04023604|Other|Controlled diet with beef raised without antibiotics|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised without antibiotics.
76058574|NCT04023604|Other|Controlled diet with beef produced in conventional systems|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised with antibiotics.
75888153|NCT02155400|Device|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
76058575|NCT05365048|Other|Local Tailoring implementation strategy|"The local-tailored approach will be guided by a structured process involving the following: (1) convening a local HPV vaccine project team, (2) conducting a local diagnostic process to identify top barriers, (3) selecting from a menu of intervention options that will be offered in this study, categorized by core function (i.e., the forms and functions menu) that address top local barriers, and (4) deploying the selected interventions. The barrier assessment and intervention customization are key processes for the local-tailored strategy, which allow clinics to devote resources to respond to unique local barriers in addition to common barriers."
75595876|NCT01332851|Behavioral|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
75740322|NCT00771797|Dietary Supplement|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
75740323|NCT00673361|Drug|Concurrent decrescendo biochemotherapy regimen|"Temozolomide: 200mg/m^2, daily, PO, days 1-4~Vinblastine: 1.5mg/m^2, daily, IV, days 1-4~Cisplatin: 20mg/m^2, daily IV, days 1-4~IL (interleukin)-2: - 18 milli-International unit (MIU)/m^2, IVCI (intravenous continual infusion), day 1~9 MIU/m^2, IVCI, day 2~4.5 MIU/m^2, IVCI, days 3 & 4~Interferon (IFN) alpha: 5 MIU/m^2, daily, SC (subcutaneously), days 1-5~5-day inpatient regimen, to be repeated every 21 days"
75740324|NCT00673361|Drug|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
75740325|NCT00393718|Drug|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
75740326|NCT00393718|Drug|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
75740327|NCT00393718|Drug|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
75888154|NCT01593111|Other|Environmental Intervention|Home-based environmental intervention
76058576|NCT05365048|Other|Prescribed Strategy|"The prescribed strategy is the standard implementation approach used by most health systems. Our prescribed approach will be guided by the evidence-based, award-winning 4 Pillars™ Practice Transformation Program for improving vaccination rates in the outpatient setting. The 4 Pillars™ address 4 main functions, i.e., convenience, communication, office systems, and motivation to guide the selection of interventions. For adolescent HPV vaccination, the 4 Pillars has demonstrated moderate effectiveness."
75446174|NCT04236336|Device|TSV dental implant|Qualified patient will be those patients who have been newly diagnosed with needing a dental implant (or more than one) in one or more edentulous areas in the maxilla and/or mandible.
75740328|NCT00393718|Drug|placebo|glibenclamide placebo. Given orally once or twice daily.
75769587|NCT01073358|Procedure|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
75446175|NCT04222673|Behavioral|Peer Specialist Suicide Prevention|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
75446176|NCT04205786|Dietary Supplement|Vitamin B12|Vitamin B12, orally, 2500 mcg, daily, for 90 days
75446177|NCT04205786|Other|Blood collection|"Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~Serum B12 levels~CRP~Homocysteine level~MMA"
75446178|NCT04205786|Other|Brief Pain Inventory - Short Form survey|Brief Pain Inventory - Short Form survey
75595877|NCT01332851|Behavioral|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
75595878|NCT00599235|Drug|sildenafil|50mg 3 times daily for 7 days
75888155|NCT03541694|Biological|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
75888156|NCT02158832|Device|Acupuncture + Electrical Stimulation|"2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current >sensation threshold & maintained at a level that is comfortable/painless & does not elicit skeletal muscle contractions (~5mA, <10mA).~Needle locations are in the vicinity of nerves that supply the affected upper limb:~EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', ~15⁰ perpendicular to the skin, ~15⁰ lateral to the midline. Depth: ~1.5 cm (secure anchorage).~EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' ~15⁰ perpendicular to the skin, ~15⁰ medial. Depth: ~1.5 cm (secure anchorage)."
75888157|NCT02155478|Device|ISERT 250 (HOYA, Japan): a standard IOL|
75595879|NCT00599235|Drug|hydralazine|25mg 3 times daily for 7 days
75595880|NCT00599235|Drug|placebo|3 times daily for 7 days
75595881|NCT04058834|Drug|NNC0385-0434|Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)
75595882|NCT04058834|Drug|Placebo (NNC0385-0434)|Healthy volunteers will receive one injection s.c.
75595883|NCT04055168|Drug|AZD6615|AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
76058577|NCT05367388|Drug|APL-101|"APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc."
76058578|NCT05367388|Drug|PLB-1001|"PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd."
75888158|NCT02155478|Device|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL|
76058579|NCT01382602|Biological|AMDC-USR|AMDC-USR Treatment
75446179|NCT04205786|Other|FACT-ES Trial Outcome Index (Version 4)|FACT-ES Trial Outcome Index (Version 4)
75446180|NCT04205786|Other|Questionnaire to Assess Adherence to Aromatase Inhibitors|Questionnaire to Assess Adherence to Aromatase Inhibitors
75446181|NCT04205786|Other|Demographics Questionnaire|Demographics Questionnaire
75888159|NCT04956003|Behavioral|45-minute daily physical activity|45-minute daily physical activity session as an integral part of learning (during regular school sessions)
75446182|NCT04188288|Device|Experimental feedback|Participants provided with feedback of target brain activation patterns (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
75446183|NCT04188288|Device|Control feedback|Participants provided with control type of feedback (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
75595884|NCT04055168|Drug|Placebo|Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
75595885|NCT01332305|Drug|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
75595886|NCT01332305|Drug|Placebo|Placebo orally once daily
75595887|NCT00599274|Drug|Interferon beta-1a|injection once a week
75595888|NCT00599274|Drug|Interferon beta-1a|injection three times a week
75595889|NCT01332227|Drug|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
75595890|NCT01332227|Drug|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
75740329|NCT00669071|Drug|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
75740330|NCT00669071|Drug|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
76058580|NCT01382602|Biological|Placebo|Placebo treatment
76058581|NCT05893420|Device|eCARTv5 clinical deterioration monitoring|eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts the likelihood of critical illness onset.
76058582|NCT05893420|Other|Standard of care control|Standard of care is the health system's clinical best practices and workflows for identifying high-risk patients for clinical deterioration, including other tools already built into the electronic health record (EHR). Hospitals that do not implement eCARTv5 will be compared as a control against hospitals that do implement eCARTv5.
76058583|NCT05893368|Other|Sharing all key aspects associated with the quality of life in a single digital environment|"A digital platform called DNMLAB (DNMLAB) offers the possibility of sharing all key aspects associated with the quality of life in a single digital environment by activating:~a digital narrative diary in which the patient has the opportunity to share with the multidisciplinary team her needs, critical issues~report Patient-Reported Outcome Measures (PROMs) aimed at detecting health-related quality of life (i.e. QLQ-C30-B23 EORTC).~digital narrative diary focused on three main areas of health-related behavior-nutrition, physical activity, and sleep habits-aimed at personalizing and reshaping lifestyle, daily behaviors and, if required, the care pathway.~The patient will be guided by narrative prompts, but at the same time will always be free to share all aspects related to her lifestyle that she deems useful, in addition to those detected, to benefit from a personalized care approach."
76058584|NCT05893316|Diagnostic Test|urine sample collection|The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.
76058585|NCT05893303|Other|1st Group|1st group is going to undergo scapula-oriented PNF techniques (diagonal) which are anterior elevation and posterior depression - posterior elevation and anterior depression with 20 repetitions with rhythmic initiation and repeated contractions facilitation techniques during all patterns. In addition to PNF techniques, gait training is going to be applied as standing with balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
76058586|NCT05893303|Other|2nd Group|2nd group is going to undergo only gait training and balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
76058587|NCT05893290|Other|Therapeutic Exercise Group|Therapeutic exercise sessions will begin with a short educational talk that provides information on proper body mechanics, and the benefits of exercise, followed by simple warm-ups and three different stretching and five different strengthening exercises that emphasize hip, abdominal, and back muscles. The frequency of repetitions of each stretching and strength exercise will be 10 with a holding time of 10 sec. Each set of strengthening exercises will be followed by a different set of stretching exercises. Sessions will end with a short unguided period of deep slow breathing.
76058588|NCT05893290|Other|Therapeutic Exercise+Basic Body Awareness Therapy Group|This group will receive BBAT as well as therapeutic exercises. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
75595891|NCT01332227|Drug|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
75595892|NCT01332227|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
75595893|NCT00599352|Dietary Supplement|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
75740331|NCT00398320|Drug|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
75740332|NCT00398320|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
75595894|NCT00599391|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
75595895|NCT01332149|Drug|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
75595896|NCT01332149|Drug|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
75595897|NCT00599430|Dietary Supplement|Placebo|Inert excipient
75595898|NCT00599430|Dietary Supplement|Lactobacillus acidophilus NCFM|1e10 CFU/day
75740333|NCT00398320|Drug|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
75740334|NCT00670007|Biological|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
75740335|NCT00775307|Drug|PAZOPANIB|400 mg/day (24 weeks)
75740336|NCT00775307|Drug|Placebo|Placebo 400 mg/day (24 weeks)
76058589|NCT05893212|Behavioral|Nature based facilitated group intervention|The Nature-group programme included learning more about local outdoor areas and nature itself, the biotopes visited were chosen to provide a various nature experience, including forests, farmland, lakes, and seashore. Accompanied by nature guides the group practiced simple sensorial exercises that enhance the contact with nature and its microbiome.
76058590|NCT05893212|Behavioral|Exercise in group|The Sports-group participated in an exercise programme and met weekly in community sports facilities. Exercise we define as a planned, structured, repetitive, and purposeful form of physical activity that aims for improvement or maintenance of one or more components of physical fitness. The sports programme was planned and executed by professional sports leaders in cooperation with health professionals and included both aerobic and anaerobic exercise as well as team sports, content was planned according to current best practice and considered the participants physical ability.
76058591|NCT05893199|Device|Clinical monitoring using the Ti.Care app (https://ti.care/es)|Clinical monitoring using the Ti.Care app (https://ti.care/es)
76058592|NCT05893199|Other|Usual care|usual follow-up in primary care both arms
75595899|NCT00599430|Dietary Supplement|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
75595900|NCT02892240|Other|No intervention. Observational study|
75595901|NCT04326270|Device|Nasal interface|Randomized to initial interface of nCPAP prongs or infant cannula
75595902|NCT04054427|Device|IOL implantation experimental|Implantation of trifocal IOL POD L GF consisting of hydrophobic material
76058593|NCT05892900|Device|Transcutaneous vagus nerve stimulation (tVNS)|The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve
75595903|NCT00599469|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
75595904|NCT04054505|Dietary Supplement|EZPAK|One packet with breakfast for three months
75595905|NCT04054505|Dietary Supplement|Placebo|One packet with breakfast for three months
76058594|NCT05892900|Device|Sham transcutaneous vagus nerve stimulation (Sham tVNS)|The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
76058595|NCT05892848|Diagnostic Test|serum ostecalcin,serum sclerostin and parathroid profile|evaluation of bone turnover markers in blood
75595906|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
75595907|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
75595908|NCT00597324|Procedure|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
75595909|NCT01330628|Device|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
75595910|NCT01330628|Procedure|Balloon angioplasty|standard balloon catheters for PTA
75595911|NCT02892279|Other|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
76058596|NCT05892822|Other|Amyotrophic Lateral Sclerosis|All ALS patients included in this group.
76058597|NCT05892809|Other|use an incubator cover|Vital signs of term and preterm newborns were measured separately and with and without an incubator cover.
76058598|NCT05892783|Other|manual treatment|soft tissue mobilization applied by the therapist on the plantar fascia of both legs and self massage and stretching using foam roller and self stretching.
76058599|NCT05892731|Other|with depression|age-related hearing loss with depression
76058600|NCT05892731|Other|without depression|age-related hearing loss without depression
76058601|NCT05892705|Drug|Dexmedetomidine Injection [Precedex]|intrathecal injection of 5 mcg dexmedetomidine
76058602|NCT05892692|Behavioral|Ecological Momentary Intervention|Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.
75446194|NCT04145115|Biological|Ipilimumab|Given IV
75446195|NCT04145115|Procedure|Magnetic Resonance Imaging|Undergo MRI
75446196|NCT04145115|Biological|Nivolumab|Given IV
75446197|NCT04144517|Drug|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
75446198|NCT04144517|Drug|Pembrolizumab|IV infusion over 30 minutes administered on Day 1 of each cycle
75740337|NCT05407298|Other|Non applicable|Non Applicable
76058603|NCT05892627|Dietary Supplement|PoZibio|PoZibio (50 x 10^9 CFUs/ CAPSULE)
75888160|NCT00920361|Drug|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
75446199|NCT04140942|Behavioral|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
75446200|NCT04140942|Behavioral|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
75740338|NCT00775385|Drug|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
76058604|NCT05892627|Dietary Supplement|Placebo|Placebo
75595912|NCT02892162|Procedure|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
75595913|NCT01330433|Device|CoSeal Surgical Spray Group|"A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~Patients weighing < 3kg will receive 1ml of CoSeal~Patients weighing 3-10kg will receive 1-2ml of CoSeal~Patients weighing >10kg will receive 2-4ml of CoSeal"
75595914|NCT00597363|Device|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH & Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
75595915|NCT00597363|Other|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
75740339|NCT00775385|Drug|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~ERCC1 high : no treatment~ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
75740340|NCT05407220|Drug|HCP1904-1|take it once per period
75740341|NCT05407220|Drug|HCP1904-3|take it once per period
75740342|NCT04003688|Drug|Magnesium sulfate through real weight group|Magnesium sulfate dose 40 mg/kg of actual patient's weight
75740343|NCT04003688|Drug|Placebo group|Saline solution (instead of magnesium sulfate, as in the other groups)
75740344|NCT04003688|Drug|Magnesium sulfate through ideal corrected weight group|Magnesium sulfate dose 40 mg/kg of ideal corrected patient's weight
75740345|NCT00775541|Dietary Supplement|Vitamin C|One IV infusion of 2 gm vitamin C
75740346|NCT05406986|Other|care bundle application|The patients in the experimental group will be given care according to the current care bundle for 14 days
75740347|NCT00764777|Device|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
75446205|NCT04090567|Drug|Cediranib|Given PO
75446206|NCT04090567|Drug|Ceralasertib|Given PO
75446207|NCT04090567|Drug|Olaparib|Given PO
75740348|NCT00779129|Drug|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
75740349|NCT00779129|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
75446208|NCT04088331|Device|AMS 800 Artificial Urinary Sphincter|The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.
75740350|NCT00779207|Behavioral|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
75740351|NCT00779207|Behavioral|weight loss|10 percent weight loss through diet and behavioral modification
75888161|NCT02161094|Behavioral|Give incentives to physicians based on their patient's HbA1c improvement|
75888162|NCT02161094|Behavioral|Give incentives to patients based on their own HbA1c improvement|
75888163|NCT00651807|Drug|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
75888164|NCT00651807|Drug|Placebo|Every day one tablet up to 8 weeks
75888165|NCT01381081|Biological|platelet-rich plasma|a single intra-articular injection
76058605|NCT05892601|Other|Maternal kisses|"The parents of the children in the experimental group were informed about the process before the application. The parents were asked to approach their child immediately after the invasive procedure was over, call out Let me kiss it better and kiss the child from a point not close to the place where the invasive procedure was applied. Kisses were delivered by the mother, free of oral ulcers, with a standard 5-second pressing of both lips on the affected body part followed by an exaggerated puckering sound. Pain, fear, and anxiety scales were administered to the intervention group at the 1st and 5th minutes after the application. Invasive interventions have been applied by researchers who have been working as nurses in the emergency room for 4 years."
75595916|NCT00599508|Dietary Supplement|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
76058606|NCT05892575|Behavioral|improving quality of life, coping with urinary incontinence and kegel exercise training|Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months.
76058607|NCT05892562|Other|No intervention|As this study is purely observational, no intervention is involved.
76058608|NCT05892536|Procedure|dental regenerative endodontics|regenerative procedures performed in necrotic mature permanent teeth
76058609|NCT05892484|Device|Thermal Imaging|Thermal Imaging device used to evaluate fracture in those presenting with proposed wrist fracture in the emergency department.
75446209|NCT04083378|Procedure|Ablation Therapy|Undergo standard of care ablation
75446210|NCT04083378|Procedure|Image-Guided Therapy|Undergo software-aided imaging (Morfeus)
75446211|NCT04083378|Other|Quality-of-Life Assessment|Ancillary studies
75446212|NCT04083378|Other|Questionnaire Administration|Ancillary studies
75446213|NCT04075799|Other|high-intensity interval training|The HIIT protocol consists of 8 weeks using stair climbing three times per week. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will comprise 6-12 x 30-seconds bouts of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. Post-exercise the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks. The first (week 1) and final week (week 8) of the exercise program will be monitored by a trained exercise physiologist. During supervised visits, heart rate and rating of perceived exertion (OMNI scale) will be measured at the end of each bout and after active recovery. Subjects will have the option to request further monitoring if desired.
75595917|NCT00599508|Dietary Supplement|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
75595918|NCT00599508|Dietary Supplement|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
75595919|NCT00599508|Dietary Supplement|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
75740352|NCT00779363|Device|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
75740353|NCT00535496|Drug|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
75740354|NCT00772187|Drug|morphine|Single dose: 0.1-0.5 mg
75740355|NCT00772187|Drug|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
75740356|NCT00772187|Drug|general anesthesia (fentanyl)|general anesthesia alone
75740357|NCT00772265|Biological|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
75888166|NCT01381081|Drug|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
76058610|NCT05892484|Diagnostic Test|X-RAY|Routine X-RAY
76058611|NCT05892471|Drug|ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
76058612|NCT05892471|Drug|Propofol injection|Patients in propofol group received 1.5 mg/kg propofol for induction of anesthesia
76058613|NCT05892445|Behavioral|Graphic Warning Labels|Based on a thorough review of the literature on e-cigarette risks and adverse effects, a graphic designer will be contracted to create ten experimental aversive health warnings related to e-cigarettes. These warnings will be exported as high-quality images and shown to participants in the intervention group prior to questions that obtain data on the primary endpoint.
75888167|NCT05583513|Diagnostic Test|MLHFQ (Minnesota Living with Heart Failure Questionnaire)|The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL
75888168|NCT05583513|Diagnostic Test|KCCQ (the Kansas City Cardiomyopathy Questionnaire)|The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
75888169|NCT02161250|Dietary Supplement|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
75888170|NCT02161250|Dietary Supplement|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
75888171|NCT03344887|Other|RBC Transfusion from male donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
75888172|NCT03344887|Other|RBC Transfusion from female donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
75888173|NCT02161328|Other|EIT belt|
75888174|NCT03541148|Dietary Supplement|Oncoxin-Viusid|Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.
75888175|NCT01377337|Drug|sodium bicarbonate|"1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion)."
75888176|NCT05655039|Other|Rehabilitation|Stroke Rehabilitation Program
75888177|NCT02158910|Drug|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
75888178|NCT01381003|Genetic|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
75888179|NCT05058339|Other|Survey Administration|Complete survey
75888180|NCT05225649|Behavioral|Behavior Change Intervention|Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
75888181|NCT02158988|Procedure|HIPEC|"HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied."
75888182|NCT05225493|Behavioral|Peer to peer feedback|HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
75888183|NCT05225493|Diagnostic Test|HIV rapid test|Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
75888184|NCT02159144|Other|cold stress|
75888185|NCT02764190|Behavioral|I-ACT with Check Yourself|
75888186|NCT02161796|Drug|FG-4592|Oral
75888187|NCT02161796|Drug|Placebo|Oral
76058614|NCT05892367|Other|Transbrachial Access for Interventions|Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
76058615|NCT05892354|Dietary Supplement|Enteral immunonutrition|Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.
75446214|NCT04074031|Device|Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)|The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
75595920|NCT00599508|Dietary Supplement|berry placebo powder|berry placebo powder administered daily for 16 weeks
76058616|NCT05892354|Dietary Supplement|Standard enteral nutrition|Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
76058617|NCT05892328|Other|Watermelon Flesh Dose 1|1 cup watermelon flesh, ~152g, 7 days/week over a 4-week period
76058618|NCT05892328|Other|Watermelon Flesh Dose 2|2 cups watermelon flesh, ~304 g, 7 days/week over a 4-week period
76058619|NCT05892328|Other|Control|304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
75595921|NCT01330316|Drug|BI 201335|BI 201335 for 24 weeks
75595922|NCT01330316|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
75888188|NCT03541070|Device|Kinesiology tape|Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
75888189|NCT03077659|Drug|NanoPac®|Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
75446215|NCT04073563|Device|Infuse™ Bone Graft (Infuse™)|(Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))
75595923|NCT00599547|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
75595924|NCT01316198|Dietary Supplement|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
75888190|NCT05225181|Behavioral|perform physical exercise|one 60-min session of physical training
75595925|NCT01316198|Dietary Supplement|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
75595926|NCT00599586|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
75595927|NCT01316237|Drug|GS-6620|GS-6620 tablet, 50 mg QD
75595928|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD
75446216|NCT04073563|Device|Intervertebral body fusion device and Medtronic posterior Fixation Systems|Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System
75740358|NCT00772265|Biological|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
76058620|NCT05892315|Procedure|Repeated subgingival instrumentation|Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
75446217|NCT04069624|Behavioral|MOUD Pre-Treatment Telehealth|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
76058621|NCT05892315|Procedure|Supragingival scaling|Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
76058622|NCT05892289|Procedure|Robotic assisted proximal gastrectomy with double-flap technique|Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p and 11d).The double-flap technique is used for the digestive tract reconstruction.
75446218|NCT04069624|Behavioral|MOUD Pre-Treatment Telehealth and Peer Navigator|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
75446219|NCT04069624|Other|Services as Usual|Medications to treat opioid use disorder (MOUD) pre-treatment.
75595929|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD
75595930|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
75595931|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
75595932|NCT01316237|Drug|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
75595933|NCT01316237|Drug|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
75740359|NCT04002128|Other|Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.|Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
75740360|NCT00779441|Drug|Zolpidem 10mg tablets|
75740361|NCT00989378|Behavioral|baseline study|normal bedtimes
75740362|NCT02556437|Drug|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
75740363|NCT02556437|Drug|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
75740364|NCT04946006|Drug|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
75595934|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900mg , BID
75595935|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900 mg
75595936|NCT02892084|Device|tDCS|Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
75595937|NCT02892084|Device|Sham tDCS|"Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill."
76058623|NCT05892263|Other|early feeding|Enteral force feeding with 5% dextrose injection within 24 hours after operation
76058624|NCT05892224|Procedure|Laparoscopic sleeve gastrectomy|Obese patients of different subtypes were all expected to undergo bariatric surgery
75740365|NCT00779597|Behavioral|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
76058625|NCT05892198|Procedure|surgery|surgery with primary closure, Rhomboid flap , or Rotational flap
75446220|NCT04066361|Other|Chatbot|Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit
75888191|NCT05225181|Behavioral|cognitive training|one 60-min session of cognitive training
75446221|NCT04066361|Other|Video Education|Brief video designed to mirror the educational components of a traditional genetic counseling visit
75446222|NCT04041310|Biological|GAd-209-FSP low dose|GAd20-209-FSP IM vaccine, low dose
75740366|NCT00775619|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
76058626|NCT05892185|Device|GELA|GELA glaucoma implant
75740367|NCT00775697|Drug|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
75740368|NCT00775697|Drug|Montelukast|montelukast 4 mg day for 4 weeks
75888192|NCT05225181|Behavioral|control group|perform body stretching(15min) and health education courses(90min)
76058627|NCT05892185|Device|XEN|XEN gel stent implant
76058628|NCT05892146|Drug|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
76058629|NCT05892146|Drug|Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
76058630|NCT05892120|Behavioral|the MedAdhere app|The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study
75446223|NCT04041310|Biological|MVA-209-FSP low dose|MVA-209-FSP IM vaccine, low dose
75446224|NCT04041310|Biological|GAd-209-FSP high dose|GAd20-209-FSP IM vaccine, high dose
75740369|NCT05357066|Drug|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
75888193|NCT05052723|Drug|Cabozantinib|Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
75888194|NCT05052723|Drug|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
76058631|NCT05892107|Procedure|Toy Group|After meeting the children in the toy group, the toy will be given to the children to play 1 minute before the procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
76058632|NCT05892107|Procedure|Mask group with cartoon characters|The nurse who will open the vascular access with the children in the cartoon character mask group will meet the child 1 minute before the procedure with a cartoon character mask on his/her face.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
76058633|NCT05892107|Procedure|Control group|In the control group, the nurse who will open the vascular access will meet the child 1 minute before the procedure with a white mask on her/his face. Children in the control group will be subjected to routine procedures before blood collection.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
76058634|NCT05892068|Drug|Tucatinib|Standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
75446225|NCT04041310|Biological|MVA-209-FSP high dose|MVA-209-FSP IM vaccine, high dose
75446226|NCT04041310|Biological|GAd20-209-FSP, RP2D|GAd20-209-FSP IM vaccine, RP2D
75446227|NCT04041310|Biological|MVA-209-FSP, RP2D|MVA-209-FSP IM vaccine, RP2D
75446228|NCT04033146|Device|Strengthening muscle contractions during walking|The investigators will use ankle-exoskeletons to systematically alter the behavior of participant muscle contractions. For example, participants will walk in a robotic device that adds a spring in parallel with their lower limb that will help the participants generate a stronger propulsive push-off and may reduce the effort of walking.
75446229|NCT04017546|Drug|CYC065|intravenous infusion
75446230|NCT04017546|Drug|Venetoclax|oral capsule
75595938|NCT00597480|Drug|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
75595939|NCT00597480|Drug|rhGH norditropine simple Xx|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
75595940|NCT01326702|Drug|Bendamustine Hydrochloride|Given IV
75595941|NCT01326702|Other|Pharmacological Study|Correlative studies
75595942|NCT01326702|Biological|Rituximab|Given IV
75595943|NCT01326702|Drug|Veliparib|Given PO
75595944|NCT05654129|Other|saliva samples|saliva samples (non-invasive, in the sites evaluated during the partial survey) will be perform by one of the investigators .
76058635|NCT05892055|Other|Procedure|All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
76058636|NCT05892042|Drug|Rivaroxaban 15 MG [Xarelto]|Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
76058637|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with a subepithelial connective tissue graft
76058638|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
76058639|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with a collagen membrane
76058640|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with a Cytoplast
75595945|NCT05654129|Other|medical questionnaire|a complete medical questionnaire will be carried out (general, lifestyle and quality of life) will be perform by one of the investigators .
76058641|NCT05892003|Other|Phase 1 Control|Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
76058642|NCT05892003|Other|Phase 2 High Fibre Weight Loss|High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
76058643|NCT05892003|Other|Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss|High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
76058644|NCT05891964|Drug|Secukinumab Injection|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
75446231|NCT04013802|Biological|HLA-matched VSTs|"An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3)."
75446232|NCT03981640|Other|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
75595946|NCT00599625|Drug|Pravastatin|80mg administered daily for 6 consecutive weeks
75595947|NCT05661474|Drug|Fitostimoline ® hydrogel group|Treatment of DFUs with Fitostimoline® hydrogel every day for 12 weeks.
75595948|NCT05661474|Drug|Saline gauze group|Treatment of DFUs with saline gauze every day for 12 weeks.
75595949|NCT00599664|Drug|OMS201|OMS201 irrigation solution during surgery
75595950|NCT00599664|Drug|Vehicle|Vehicle irrigation solution during surgery
76058645|NCT05891938|Other|H2 gas inhalation|H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
75595951|NCT04326699|Procedure|Bilateral SIJ injection|under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ
75595952|NCT02891655|Other|immuno-histo-chemical analysis|in vitro immuno-histo-chemical analysis of corneal epithelium
75595953|NCT05653310|Drug|Tradipitant|Tradipitant Capsule
75595954|NCT05653310|Drug|Placebo|Placebo Capsule
75616359|NCT02690740|Other|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
75616360|NCT02852499|Other|Urine sampling|
75616361|NCT02852499|Other|Carry a GPS and BET|
75616362|NCT02852499|Other|Carry pollution sensor|
75616363|NCT02852499|Other|Sampling at the maternity|
75616364|NCT02852499|Other|Self-questionnaires|
75616365|NCT02852499|Other|Sampling in partum period|Meconium and a strand of hair.
75616366|NCT04410328|Drug|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
76058646|NCT05891925|Other|Audiobook App|"The intervention will consist of the use of the audiobook application (with poems) for 4 weeks. Here, the application will record the following data autonomously:~older adult id,~date, hour and time that the older adult listened to each poem,~poems listened.~Initially, two questionnaires will be applied to the older adults: one to measure their digital skills (DIGCOMP), and another to assess their well-being prior to the experience with the audiobook application (Part A).~After two weeks of application use, a follow-up will be carried out, in order to answer any questions that may arise from the use of the application, and explain again the objectives of the research, if necessary. This follow-up will be initially done by telephone, and in person if required.~After four weeks, the older adult will be invited to a meeting at the Community Rehabilitation Center at Concepción, Chile, to answer the well-being questionnaire (Part B) and the usability questionnaire (SUS)."
76058647|NCT05891912|Other|Technological devices intervention (use of tablet and big screen with games oriented to training physical and cognitive function)|"The treatment will be performed in 30 min sessions, twice a week during 12 weeks. the weekly sessions will include the following games:~1 session per week: 15min small TABLET and 15min LIGHTS game.~1 session per week: 15min TABLE TABLET and 15min game of VINTAGE."
76058648|NCT05891769|Drug|18Fluorocholine|18F Fluorocholine 5 mCi ± 20% administered intravenously.
76058649|NCT05891704|Procedure|Hand therapy Rehabilitation intervention program that incorporate cultural reference|The intervention will provide a conventional hand therapy rehabilitation intervention program that incorporates cultural reference based on Focused Acceptance and commitment Therapy ( FACT).
76058650|NCT05891704|Procedure|Conventional Hand therapy Rehabilitation intervention program|The intervention will provide a conventional hand therapy rehabilitation intervention program
76058651|NCT05891691|Behavioral|Music Activities, Yoga, Massage|The program begins with music and dance movements using percussion instruments (rhythm stick, stone triangle, drum, cymbal, tambourine, maracas, etc.) and body percussion. In this phase, the children will follow the instructions of the researcher. The goal is to warm up the bodies and musically experience the beginning of the program After the warm-up, yoga postures are combined with breathing techniques that focus on developing awareness of body sensations and feelings.The daily program ends with massage. During the massage application, the children sit in a circle. The massage is performed by the children observing the movements of the researcher on their arms and legs and applying them on their own arms and legs.Yoga postures, breathing techniques, and massage practices are accompanied by stories to ensure children's active participation, encourage their development, and facilitate their acquisition of new approaches.
76058652|NCT05891665|Procedure|Corticotomy|A corticotomy procedure will be applied with some osteoperforations during the surgical exposure of the impacted canine. Then this will be followed after 8 weeks with another surgical stimulation using piezosurgery.
76058653|NCT05891665|Procedure|Traditional traction of the impacted canine without corticotomy|In this group of patients, the traction of the impacted canine will be performed traditionally without the involvement of additional surgical intervention.
75446233|NCT03981640|Other|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
75595955|NCT05649878|Drug|Evaluation of bioavailability of methylprednisolone succinate administered intravenously|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
75616367|NCT04410328|Other|Standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
75616368|NCT01214252|Device|Permacol Surgical Implant|Permacol Surgical Implant
75616369|NCT02852577|Drug|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
76058654|NCT05891652|Procedure|modified thoracoabdominal nerve block through perichondrial approach|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
75595956|NCT05649878|Drug|Evaluation of bioavailability of methylprednisolone succinate administered intranasally|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
75595957|NCT01327703|Drug|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
75595958|NCT01327703|Drug|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
76058655|NCT05891561|Drug|Pertuzumab|4 cycles of taxane, pertuzumab, trastuzumab
75595959|NCT01380080|Drug|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
76058656|NCT05891535|Procedure|Robot assisted radical cystectomy without mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
76058657|NCT05891535|Procedure|Robot assisted radical cystectomy with mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
76058658|NCT05891457|Combination Product|Nutritional Intervention|"Severe acute malnourished children were provided with appropriate nutritional therapy/treatment that include supplementation of a high-calorie diet; i.e., F-100 milk and khichuri-halwa for nutritional rehabilitation.~Egg milk and micronutrient supplementation for recovery from severe stunting following standard guidelines for facility based management and recently conducted community based nutrition intervention studies.~Wasted children were treated with suitable local nutritional management (NM), such as infant and young child feeding practices (IYCF), providing MNP and nutrition education."
75595960|NCT01380080|Drug|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
76058659|NCT05891444|Device|High frequency transcranial random noise|High frequency tRNS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
76058660|NCT05891444|Device|Sham high frequency transcranial random noise|In the sham condition, tRNS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
75595961|NCT01380080|Drug|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
76058661|NCT05890378|Other|Testing water|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
75446234|NCT03981640|Other|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
76058662|NCT05890066|Procedure|single-port laparoscopy|Compare the effectiveness and safety between single-port and multi-port laparoscopic surgery
75446235|NCT03979001|Other|complete ophthalmological examination|"collection:~ophthalmological history and current treatments~occular tension measurement~measurement of visual acuity (Snellen chart)~Axial length measurement~Photograph of the posterior segment of the eye~3x3 and 6x6 macular and papillary OCT angiography"
75446236|NCT03963960|Device|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
75595962|NCT01380080|Drug|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
76058663|NCT05889949|Drug|Sorafenib|oral sorafenib
75595963|NCT01380080|Drug|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
75595964|NCT01380080|Drug|Isoniazid|INH 300 mg orally once daily
75595965|NCT01379768|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
75595966|NCT01379768|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
75595967|NCT01379768|Device|Clear Care Cleaning and Disinfection Solution|Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
75595968|NCT04444505|Other|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
75595969|NCT04444739|Other|radiographic data collection|From existing radiological Images (upright standing X-ray and supine MRI of the lumbar spine), specific radiographic parameters will be extracted
75595970|NCT02894333|Behavioral|behavioral observation|
75595971|NCT01379573|Drug|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
75595972|NCT01379534|Drug|TKI258|
75595973|NCT01371851|Drug|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
76058664|NCT05889949|Drug|Lenvatinib|oral lenvatinib
76058665|NCT05889858|Other|Data collection|Data collection
76058666|NCT05888987|Biological|PCR multiplex by FilmArray|PCR multiplex by FilmArray system on corneal swabbing sample
76058667|NCT05887804|Biological|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
76058668|NCT05887804|Biological|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
76058669|NCT05887804|Drug|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
76058670|NCT05880303|Procedure|Nonsurgical periodontal therapy|Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
76058671|NCT05879952|Behavioral|TAU + BTsN session|BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.
76058672|NCT05879952|Behavioral|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
76058673|NCT05875103|Diagnostic Test|linguistic processes|"Linguistic processes are assessed by performance score on the following tests:~naming tests : BNT 34 (Colombo & Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)~vocabulary test (Mill Hill - Deltour, 1993),~repetition tests (Gremots - Bézy et al., 2016),~articulatory speed (Majerus, 2014 ; Roussel et al., 2012)~semantic matching task adapted from the PPT (Howard & Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),~semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),~phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)"
75446237|NCT03963960|Device|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
75446238|NCT03952585|Procedure|Biopsy|Undergo tissue biopsy
75595974|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
75595975|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
75446239|NCT03952585|Procedure|Biospecimen Collection|Undergo blood sample collection
75446240|NCT03952585|Drug|Cisplatin|Given IV
75446241|NCT03952585|Procedure|Computed Tomography|Undergo CT
75446242|NCT03952585|Other|Fludeoxyglucose F-18|Receive FDG
75446243|NCT03952585|Radiation|Image Guided Radiation Therapy|Undergo IGRT
75446244|NCT03952585|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75446245|NCT03952585|Procedure|Magnetic Resonance Imaging|Undergo MRI
75446246|NCT03952585|Biological|Nivolumab|Given IV
75595976|NCT01371734|Drug|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
75595977|NCT01365494|Biological|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
76058674|NCT05874999|Other|Supramaximal High-Intensity Interval Training at 60% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 60% of maximum mean power output for 6 seconds (MPO6) with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of maximum aerobic power (MAP) obtained during maximal incremental cardiopulmonary exercise test (CPET) on a stationary bicycle."
76058675|NCT05874999|Other|Moderate-Intensity Continuous Training|"MICT is performed against a load of 60% of MAP obtained during a maximal incremental CPET on a stationary bicycle.~Duration MICT: 20 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
75446247|NCT03952585|Procedure|Positron Emission Tomography|Undergo PET
75446248|NCT03952585|Other|Quality-of-Life Assessment|Ancillary studies
75446249|NCT03952585|Other|Questionnaire Administration|Ancillary studies
75446250|NCT03939637|Drug|Eltrombopag|"Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~Children 1 to 5 years: Initial: 25 mg once daily~Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity [e.g., Chinese, Japanese, Korean, Taiwanese])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily."
75595978|NCT00637169|Other|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
75595979|NCT04443218|Device|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient mitral valve.
75595980|NCT04443140|Diagnostic Test|PCR, lung ultrasound|PCR for Covid-19
75595981|NCT04442360|Behavioral|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
75595982|NCT04442204|Other|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health
75595983|NCT04441268|Procedure|primary IOL implantation|implant IOL in capsular bag after cataract extraction
75595984|NCT04328870|Other|oxytocin and spinal anesthesia|start oxytocin 10 IU/200 ml saline at the insertion of the spinal anesthesia
75595985|NCT04328870|Other|General anesthsia|General anesthesia alone.
75595986|NCT04329026|Device|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
75595987|NCT04329026|Device|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
75595988|NCT00591539|Procedure|Carotid Ultrasound|Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
76058676|NCT05874999|Other|Supramaximal High-Intensity Interval Training at 80% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 80% of MPO6 with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
76058677|NCT05873608|Other|Educational video|Testing an educational video
76058678|NCT05873608|Other|Interview|Participate in interview
76058679|NCT05873608|Other|Observation|Undergo observation
76058680|NCT05873075|Other|Intravascular laser irradiation of blood|Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
76058681|NCT05867446|Behavioral|pecha kucha|pecha kucha training
75446251|NCT03939637|Drug|Steroids|Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
75446252|NCT03939637|Drug|IVIG|IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
75446253|NCT03939637|Drug|Rho(D) Immune Globulin|Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
75595989|NCT00591617|Other|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
75595990|NCT04328987|Procedure|cold snare polypectomy|Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.
75595991|NCT04432844|Procedure|Biplanar Ultrasound guided Internal Jugular Vein Cannulation|Using Philips EPIQ elite ultrasound system with a high-frequency 3D and 4D volume linear array transducer (USG XL 14-3) to obtain the biplanar imaging of Internal jugular vein cannulation.
75595992|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
75446254|NCT03938324|Behavioral|PiCASO Intervention Group|This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence.
76058682|NCT05842265|Other|Self acupressure|patients will do self acupressure
75595993|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
76058683|NCT05838209|Drug|test|Ozone oil used as an adjunctive of scaling and root planing and control,
76058684|NCT05838209|Drug|Control|saline solution 0.09% used as an adjunctive as scaling and root planing
75446255|NCT03938324|Behavioral|Sham Comparator: Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
75740370|NCT05357066|Drug|Placebo|Administration of the placebo (oxygen-air mixture [FiO2 ≈0.3]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
75740371|NCT02556905|Drug|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
75446258|NCT03919071|Procedure|Biospecimen Collection|Undergo collection of blood
75446259|NCT03919071|Drug|Dabrafenib Mesylate|Given PO
75446260|NCT03919071|Procedure|Lumbar Puncture|Undergo lumbar puncture
75446261|NCT03919071|Procedure|Magnetic Resonance Imaging|Undergo MRI
75446262|NCT03919071|Radiation|Radiation Therapy|Undergo RT
75446263|NCT03919071|Drug|Trametinib Dimethyl Sulfoxide|Given PO
75446264|NCT03917927|Device|Eztetic dental implant|narrow diameter dental implant
75595994|NCT02893748|Device|HyGIeaCare Prep|Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
75595995|NCT02893748|Procedure|Colonoscopy|Screening colonoscopy as per standard of care.
75595996|NCT02893748|Drug|polyethylene glycol (PEG)|PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
75595997|NCT01357850|Drug|GSK716155|GSK716155
75595998|NCT01357850|Drug|Placebo|Placebo
75595999|NCT01357655|Drug|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
75596000|NCT01357655|Drug|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
75596001|NCT01357616|Drug|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
75596002|NCT01357616|Drug|Brinzolamide 1% ophthalmic suspension|
75596003|NCT01357616|Drug|Timolol 0.5% ophthalmic solution|
76058685|NCT05834972|Device|Ultrasound-guided percutaneous dilatational tracheosyomy|All of the participants will be examined two times. First, the landmark-guided technique will be performed. Then, the ultrasound-guided technique will be performed.
76058686|NCT05821049|Other|UPI65 (Low Dose)|Red colored Capsules
76058687|NCT05821049|Other|UP165 (High Dose)|Red colored Capsules
76058688|NCT05821049|Other|Placebo|Red colored Capsules
76058689|NCT05820737|Dietary Supplement|EF2001 (Low dose)|One capsule to be consumed once a day
75740372|NCT02556905|Drug|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
75740373|NCT00772421|Device|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
75596004|NCT01357577|Behavioral|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
75446268|NCT03891602|Behavioral|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
75446269|NCT03891602|Behavioral|Patient Trust in the Medical|"Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84."
75596005|NCT01351025|Drug|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
75596006|NCT01351025|Drug|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
75596007|NCT01351025|Drug|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
75596008|NCT01349036|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
75596009|NCT01348763|Drug|Maraviroc|Maraviroc 150 mg daily
75740374|NCT00539006|Drug|FPNS|fluticasone propionate nasal spray
75740375|NCT00539006|Drug|FFNS|fluticasone furoate nasal spray
76058690|NCT05820737|Dietary Supplement|EF2001 (High dose)|One capsule to be consumed once a day
76058691|NCT05820737|Dietary Supplement|beLP1 (Low dose)|One capsule to be consumed once a day
76058692|NCT05820737|Dietary Supplement|beLP1 (High dose)|One capsule to be consumed once a day
75596010|NCT01348763|Drug|Truvada|daily until 10. day then stop
75596011|NCT01348763|Drug|Darunavir|daily until 10. day then stop
75596012|NCT01346969|Drug|EXC 001|Single-dose administered by injection four different times
75596013|NCT01346969|Drug|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
75596014|NCT01346969|Drug|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
75596015|NCT01346969|Drug|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
75596016|NCT04424498|Procedure|Absorbable Rods and Kirschner Wires|A Boyd incision was applied in all patients; olecranon fractures were reduced first and fixed with Kirschner wires. Then, the displaced radial neck fractures were reduced and fixed using absorbable rods.
75740376|NCT00539006|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
76058693|NCT05820737|Dietary Supplement|Placebo|One capsule to be consumed once a day
76058694|NCT05809505|Diagnostic Test|360-degree Turn Test|The 360-degree turn test is a measure of dynamic balance. The person tested turns in a complete circle (360 degrees) while the time to complete and/or the number of steps to complete the turn is recorded.
76058695|NCT05809505|Other|Expanded Disability Status Scale|The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with multiple sclerosis. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.
76058696|NCT05809505|Other|Perceived Exertion|The Borg Rating of Perceived Exertion (RPE) is a way of measuring physical activity intensity level. Perceived exertion is how hard you feel like your body is working. It is based on the physical sensations a person experiences during physical activity, including increased heart rate, increased respiration or breathing rate, increased sweating, and muscle fatigue. Although this is a subjective measure, your exertion rating based on a 6 to 20 rating scale, may provide a fairly good estimate of your actual heart rate during physical activity.
76058697|NCT05808725|Drug|Amlodipine Freeze-Dried Powder for Oral Solution 5 mg|Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed
76058698|NCT05808725|Drug|Norvasc 5 mg tablets of Pfizer Labs|Norvasc 5 mg is given to R Fasting
75446270|NCT03891602|Behavioral|Decision Conflict Scale - Lung Cancer Screening|"The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict."
75446271|NCT03891602|Behavioral|Shared Decision Making Questionnaire - Patient|"Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94."
75446272|NCT03891602|Behavioral|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
75446273|NCT03891602|Behavioral|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
75596017|NCT04424342|Other|Pre-test procedure|The Turkish version of CPQ8-10 was subjected to a preliminary test on a group of 20 children, who were not included in the final study, in order to discuss the intelligibility of the items and to determine comprehension problems for children of this age group
76058699|NCT05803798|Device|IPL+LLLT|preventive treatment by IPL+LLLT (EYE-LIGHT) before laser refractive surgery
76058700|NCT05792540|Drug|Fluoxetine 20 mg|Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
76058701|NCT05792540|Drug|Dapagliflozin 10mg Tab|Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance
76058702|NCT05792540|Drug|Atorvastatin 80mg|Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
75446274|NCT03878121|Biological|Ad4-Env145NFL|10^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.
75446275|NCT03878121|Biological|Ad4-Env150KN|10^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.
75446276|NCT03878121|Biological|VRC-HIVRGP096-00-VP (Trimer 4571) with alum|500-mcg dose of protein boost vaccine formulated for intramuscular administration.
75446277|NCT03872908|Device|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
75446278|NCT03872908|Device|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
75446279|NCT03871257|Drug|Carboplatin|Given IV
75446280|NCT03871257|Procedure|Magnetic Resonance Imaging|Undergo MRI
75446281|NCT03871257|Other|Quality-of-Life Assessment|Ancillary studies
75446282|NCT03871257|Other|Questionnaire Administration|Ancillary studies
75446283|NCT03871257|Drug|Selumetinib Sulfate|Given PO
75446284|NCT03871257|Drug|Vincristine Sulfate|Given IV or IV push
75596018|NCT04424342|Other|Test re-test|The Turkish version of CPQ8-10 was administered to 50 children who were asked to complete the questionnaire on their own without any assistance. These 50 children were interviewed for a second time within two weeks to measure the reliability of the test-retest
75596019|NCT01346774|Drug|Cranberry powder capsules|2 cranberry powder capsules twice a day
75596020|NCT01346774|Drug|Placebo powder capsules|2 placebo capsules twice a day
75596021|NCT01346696|Device|OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)|
75596022|NCT01346540|Drug|BIBF 1120|VEGF inhibitor
75596023|NCT01346540|Drug|Placebo|BIBF 1120 placebo
75596024|NCT01342913|Drug|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
75596025|NCT01342913|Drug|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
75596026|NCT04423250|Other|impact of the intervention of a clinical pharmacist with expertise in sterile medical devices on non-compliances related to the use of sterile medical devices|- Failure to trace, Lack of product information, absence of product in the operating room
75596027|NCT01342796|Biological|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
75596028|NCT01342796|Biological|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
75596029|NCT01342640|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
75888195|NCT05578131|Procedure|high flow nasal oxygen|In the intervention group, pre-oxygenation was provided using HFNO via Optiflow THRIVE™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) until SpO2 on pulse oximetry was > 95% and for at least 3 min. A flow of 0.5 l/kg/min-1 was used until induction agents had been administered, and then increased to 2 l/kg/min-1. Nasal oxygenation was continued without ventilation of the lungs while waiting for neuromuscular blockade, and during placing, replacing or repositioning the airway. Anaesthetists were free to carry out bag-mask ventilation of the lungs if they considered this necessary to maintain safe oxygen saturations. After securing the airway, the patient was connected to a circle circuit primed with 100% oxygen and the FIO2 was continued at 100% for a period of at least five more minutes. Relevant times were recorded, including start of pre-oxygenation and start of induction of anaesthesia.
76058703|NCT05788198|Other|Integrated care|"The intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are:~empowering and engaging people and communities;~strengthening governance and accountability;~reorienting the model of care;~coordinating services within and across sectors;~creating an enabling environment."
76058704|NCT05780307|Drug|IMM2520|IMM2520 will be administered once a week intravenously at Day 1, Day8, Day 15 and Day 22 each cycle for up to 48 weeks.
75446285|NCT03870802|Other|Characterization of breast stem & immune system cells infiltrated in the mammary gland|Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.
75596030|NCT01342484|Drug|placebo|comparison of different dosages of drug (low vs high) vs placebo
75446286|NCT03865589|Diagnostic Test|Ultrasound Elastography|Ultrasound shear wave elastography
75446287|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
75446288|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
75596031|NCT01342484|Drug|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
75596032|NCT01342484|Drug|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
75596033|NCT01342445|Drug|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
75446289|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
75446290|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
75446291|NCT03846193|Device|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
75596034|NCT01342445|Drug|Placebo|
75596035|NCT01342211|Biological|Placebo|Intravenous placebo monthly during treatment phase.
75596036|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
75596037|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
75596038|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
75596039|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
75596040|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
75446292|NCT03846193|Device|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
75446293|NCT03846193|Device|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
75596041|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
75446294|NCT03828513|Device|High flow nasal cannula oxygen is applied|Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
75888196|NCT05578131|Procedure|face mask|In the control group, pre-oxygenation was provided using 100% oxygen via a sealed facemask and a circle-absorber anaesthetic circuit primed with 100% oxygen by installing a ventilation bag to the mouthpiece filter and ventilating the circuit with 100% oxygen. Anaesthetists were free to carry out bag-mask ventilation of the lungs once induction medications had been administered.
75596042|NCT01342211|Drug|Satin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
75596043|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
75596044|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
75596045|NCT01342094|Drug|DE-111 ophthalmic solution|
75596046|NCT01342094|Drug|Timolol ophthalmic solution 0.5%|
75596047|NCT01342094|Drug|Placebo ophthalmic solution|
75596048|NCT01340768|Drug|Sitagliptin|One 100 mg tablet taken orally once daily
75740377|NCT00539006|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
75740378|NCT00776087|Device|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
75740379|NCT00776087|Device|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
75740380|NCT00776165|Biological|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
75740381|NCT00776165|Biological|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
75740382|NCT00989456|Behavioral|Self management education programme|"The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.~After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh."
75596049|NCT01340768|Drug|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
75596050|NCT01340768|Drug|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
75596051|NCT01340651|Drug|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
75596052|NCT04423016|Device|Near Infrared Spectroscopy monitoring|Non-invasive continuous monitoring of cerebral oxygenation
75596053|NCT04423016|Device|Electrical velocimetry and pulse oximetry|Non-invasive continuous monitoring of cerebral oxygenation
75888197|NCT05417737|Other|Ozone therapy|Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
75888198|NCT05576571|Diagnostic Test|Met-score|methylation analysis
75888199|NCT05224947|Other|Infant Formula|Two infant formulas differing in composition
76058705|NCT05773573|Device|Experimental group|The experimental group will have a hyrax rapid maxillary expander anchored on the 2nd deciduous molars (V)
76058706|NCT05773573|Device|Control group|The control group will have a hyrax rapid maxillary expander anchored on the 1st permanent molars (6)
76058707|NCT05756010|Device|EMG|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises
76058708|NCT05742412|Device|Video streaming (smartphone camera)|Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
76058709|NCT05742412|Device|Telephone (telephone microphone)|Usual care: Audio-based-only communication using telephone during emergency medical dispatch
76058710|NCT05740033|Procedure|Split-Thickness Skin Graft for Radial Forearm Donor Site Closure|This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.
76058711|NCT05740033|Procedure|Hatchet Flap for Radial Forearm Donor Site Closure|The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.
76058712|NCT05736107|Drug|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
76058713|NCT05736107|Other|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
76058714|NCT05729412|Other|Mentioned|If prescription is properly filled for specific details than it is compliance
75446295|NCT03828513|Device|High flow nasal cannula oxygen is not applied|Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
75446296|NCT03811015|Procedure|Biospecimen Collection|Undergo blood sample collection
75596054|NCT01340495|Radiation|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
75446297|NCT03811015|Drug|Cisplatin|Given IV
75446298|NCT03811015|Procedure|Computed Tomography|Undergo CT or PET/CT
75446299|NCT03811015|Procedure|Echocardiography|Undergo ECHO
75446300|NCT03811015|Other|Fludeoxyglucose F-18|Receive FDG
75446301|NCT03811015|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75446302|NCT03811015|Biological|Nivolumab|Given IV
75446303|NCT03811015|Other|Patient Observation|Undergo observation
75596055|NCT01340300|Behavioral|Exercise training|Two supervised exercise sessions per week
75596056|NCT01340300|Drug|Metformin|Oral metformin QD for two weeks, then BID
76058715|NCT05701826|Drug|HRS3797|HRS3797 for injection, low dose
76058716|NCT05701826|Drug|HRS3797|HRS3797 for injection, medium dose
76058717|NCT05701826|Drug|HRS3797|HRS3797 for injection, high dose
76058718|NCT05700214|Drug|Ropivacaine injection|30ml of 0.375% ropivacaine
76058719|NCT05700214|Drug|Lidocaine IV|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
76058720|NCT05693779|Behavioral|Home exercise training|"Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study."
76058721|NCT05676918|Behavioral|Positive Psychology Intervention|PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
76058722|NCT05676918|Behavioral|Cognitive Behavior Therapy|CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
75446304|NCT03811015|Procedure|Positron Emission Tomography|Undergo PET/CT
75446305|NCT03796767|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75446306|NCT03796767|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75446307|NCT03796767|Procedure|Metastasectomy|Undergo salvage oligometastasectomy
75446308|NCT03796767|Other|Quality-of-Life Assessment|Ancillary studies
75596057|NCT01340300|Other|Educational information|educational information
75596058|NCT01340066|Drug|UISH001|sublingual dosing, 1 drop 3 times a day
75596059|NCT01340066|Drug|matching placebo|sublingual dosing,1 drop 3 times a day
75446309|NCT03796767|Other|Questionnaire Administration|Ancillary studies
76058723|NCT05623657|Other|Trunk Stabilization Exercise Training Group|The adolescents in this group who are involved in archery sports will be given 40 minutes of exercise training 2 days a week for 8 weeks. Exercise training will be applied as 5-10 minutes warm-up, 15-30 minutes trunk stabilization exercises, 5-10 minutes cooling down, and stretching exercises. The number of repetitions and difficulty levels of the exercises will gradually increase in the 3rd and 6th weeks.
75740383|NCT00989456|Behavioral|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
75888200|NCT02807883|Drug|Blinatumomab|Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
76058724|NCT05623657|Other|Game Based Exercise Program Group|At least 4 different games selected from Xbox 360 Kinect® games will be applied to adolescents practicing archery sports in this group for a total of 40 minutes with the physiotherapist. The games will be selected from games that include movement patterns similar to the exercises of the trunk stabilization exercise group. Game-based exercise training is planned to be performed twice a week for a total of 8 weeks.
75596060|NCT02893904|Device|EEG monitoring|Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
75446310|NCT03796767|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75740384|NCT04521374|Behavioral|Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein|Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
75740385|NCT04047329|Other|general anesthesia or neuraxial anesthesia|
75740386|NCT00779753|Dietary Supplement|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
75740387|NCT00537056|Procedure|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
75740388|NCT00537056|Procedure|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
75740389|NCT00537056|Drug|F-18 Fluoro-deoxi-glucose|15 mCi iv
75596061|NCT02893904|Device|Target Controlled Infusion|Steady state effect site concentrations of remifentanil administrated to all patients.
75596062|NCT04397627|Procedure|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
75596063|NCT04309825|Procedure|transgastrostomal endoscopy|Placement the endoscope through the g-tube port and not through the mouth of a patient undergoing an upper gi endoscopy
75596064|NCT05010850|Device|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
75596065|NCT05010850|Procedure|Stoma Creation|Protective ileostomy
76058725|NCT05622383|Other|aromatherapy|aromatherapy,
76058726|NCT05622383|Other|music concert|music concert
76058727|NCT05622383|Other|aromatherapy and music concert,|aromatherapy and music concert,
76058728|NCT05600686|Drug|Cyclophosphamide|Given IV
76058729|NCT05600686|Drug|Doxorubicin|Given IV
75596066|NCT05010655|Device|Use of Eko DUO Electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
75740390|NCT00537056|Drug|Gadolinium-DTPA|0.1 mmol/kg iv
76058730|NCT05600686|Drug|Etoposide|Given IV
75740391|NCT00537056|Drug|Sunitinib|50 mg/day po
75740392|NCT00779831|Drug|120 mg Pseudoephedrine hydrochloride extended release tablets|
75740393|NCT04494698|Device|Duotherm VibraCool Back Device|Active New multimodal pain device
75446326|NCT03785834|Procedure|Punch Biopsy|The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
75446327|NCT03780894|Drug|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|Administration of 2 mg of FC together with RBC and TXA
75446328|NCT03780894|Biological|Red blood cells concentrate|Administration of 2 red blood cells concentrates together with FC and TXA
75446329|NCT03780894|Drug|Tranexamic Acid|Administration of 1g of TXA together with FC and RBC
75446330|NCT03765073|Biological|Multivalent Group B streptococcus vaccine|Various formulations at three dose levels
75446331|NCT03765073|Biological|Placebo|Saline control
75446332|NCT03763162|Drug|Bortezomib|Given SC
75740394|NCT04494698|Device|TENS 8-channel unit|LG Smart TENS unit
76058731|NCT05600686|Biological|Loncastuximab Tesirine|Given IV
76058732|NCT05600686|Drug|Prednisone|Given PO
76058733|NCT05600686|Biological|Rituximab|Given IV
75446333|NCT03763162|Biological|Daratumumab|Given IV
75446334|NCT03763162|Drug|Dexamethasone|Given IV or PO
75446335|NCT03763162|Drug|Ixazomib|Given PO
75446336|NCT03763162|Other|Quality-of-Life Assessment|Ancillary studies
75446337|NCT03761095|Drug|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm.
75446338|NCT03761095|Drug|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm.
75446339|NCT03742895|Drug|Olaparib|Olaparib 300 mg administered BID as two, 150 mg oral tablets.
75446340|NCT03739723|Other|Resource allocation to improve surgical learning environments|If a hospital/program is assigned to the intervention arm, they will receive numerous resources including a program-specific learning environment and resident well-being report, a Wellness Toolkit, coaching webinars, and in-person/virtual conferences to help improve their surgery learning environment and residents' well-being.
75446341|NCT03739554|Drug|CYC065|intravenous infusion
75446342|NCT03739554|Drug|Venetoclax|oral capsule
75596067|NCT01107535|Biological|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
75596068|NCT02881294|Drug|SUVN-G3031|
75596069|NCT02881216|Device|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
75740395|NCT00776321|Drug|Eprotirome|
75740396|NCT00776321|Drug|Placebo|
76058734|NCT05600686|Drug|Vincristine|Given IV
75446343|NCT03729271|Drug|Rifaximin|Rifaximin will be given during weeks 2-4
75446344|NCT03729271|Device|Glucose and lactulose hydrogen breath testing|Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
75596070|NCT02881216|Device|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
75596071|NCT04309747|Procedure|nanosecond knife liver cancer ablation|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
76058735|NCT05581082|Other|Pragmatic, exploratory study of Precision Medicine|This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
76058736|NCT05564338|Drug|Sitravatinib|Administered orally
75446345|NCT03721822|Drug|[18F]NOS|[18F]NOS is an investigational radiotracer which each subject will have one [18F]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
75446346|NCT03719768|Drug|Avelumab|Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
75446347|NCT03719768|Radiation|Whole Brain Radiotherapy|Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
75446348|NCT03701399|Drug|troriluzole|200 mg by mouth
75446349|NCT03701399|Drug|Placebos|200 mg by mouth
75596072|NCT02881060|Dietary Supplement|Alcohol|
75740397|NCT00535262|Drug|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
75740398|NCT00776399|Device|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
75740399|NCT00989534|Behavioral|Fixed restricted bedtimes|Sleep restricted to 5 hours per night for 8 nights
75740400|NCT00989534|Behavioral|Sleep restriction with circadian misalignment|Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
75888201|NCT02807883|Procedure|Hematopoietic Cell Transplantation|Hematopoietic progenitor cell infusion
76058737|NCT05564338|Drug|Tislelizumab|Administered intravenously
75446350|NCT03699709|Behavioral|Budgeting, purchasing and cooking educational intervention|Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
76058738|NCT05564338|Drug|sitravatinib-matching placebo|administered orally
76058739|NCT05564338|Drug|tislelizumab-matching placebo|administered intravenously
75446351|NCT03689972|Drug|Natalizumab|Natalizumab 300 mg SC injection or IV infusion.
75446352|NCT03666845|Procedure|Sciatic nerve block|Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
75446353|NCT03662100|Biological|LY3074828|Administered SC
75446354|NCT03662100|Drug|LY3074828|Administered SC
75446355|NCT03662100|Device|Auto-injector (AI)|AI to administer LY3074828
75446356|NCT03662100|Device|Prefilled syringe (PFS)|PFS to administer LY3074828
75446357|NCT03656133|Radiation|Radiotherapy fractionation|Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)
75446358|NCT03648905|Drug|13N-Ammonia|a perfusion imaging agent
75446359|NCT03648905|Drug|18F-DOPA|is a positron-emitting analog of the catechol amino acid, levodopa
75740401|NCT00772499|Drug|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
75596073|NCT02881060|Dietary Supplement|Placebo|
75446360|NCT03648905|Drug|11C-Methylreboxetine (11C-MRB)|11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.
75596074|NCT00592085|Behavioral|Questionnaires|Participants will use a computer to complete a series of questionnaires.
75596075|NCT00592085|Behavioral|Motivational Relapse Prevention Counseling|Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
75596076|NCT00592085|Behavioral|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
75596077|NCT04328168|Procedure|ROM exercises, stretching, positioning, gait training|
75888202|NCT04051281|Behavioral|Letter|Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
75446361|NCT03648905|Drug|18F-Dopamine|is a positron-emitting analog of the catecholamine, dopamine
75446362|NCT03616587|Drug|AZD9833|Part A: AZD9833 monotherapy dose escalation.
75446363|NCT03616587|Drug|AZD9833|Part B: AZD9833 monotherapy expansion.
75446364|NCT03616587|Drug|AZD9833 with palbociclib|Part C: AZD9833 in combination with palbociclib dose escalation
75446365|NCT03616587|Drug|AZD9833 with palbociclib|Part D: AZD9833 in combination with palbociclib expansion
75446366|NCT03616587|Drug|AZD9833 with everolimus|Part E: AZD9833 in combination with everolimus dose escalation
75446367|NCT03616587|Drug|AZD9833 with everolimus|Part F: AZD9833 in combination with everolimus dose expansion
75446368|NCT03616587|Drug|AZD9833 with abemaciclib|Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation
75446369|NCT03616587|Drug|AZD9833 with abemaciclib|Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion
75446370|NCT03616587|Drug|AZD9833 with capivasertib|Part I: AZD9833 in combination with capivasertib dose escalation
75446371|NCT03616587|Drug|AZD9833 with capivasertib|Part J: AZD9833 in combination with capivasertib dose expansion
75596078|NCT04328168|Procedure|by two physiotherapist under the supervision of a doctor|
75596079|NCT02880943|Drug|XOFIGO|"XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg."
75596080|NCT02881021|Other|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
75596081|NCT02881021|Device|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
75596082|NCT04328519|Other|observation|observation
75596083|NCT02893982|Radiation|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
75596084|NCT04417010|Procedure|Radiofrequency ablation|Both groups of patients underwent radiofrequency ablation
75596085|NCT04425941|Other|artificial intelligence diagnosis|artificial intelligence prediction of colorectal polyp histology
75596086|NCT00597792|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
75740402|NCT00772499|Drug|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
75740403|NCT00989690|Drug|docetaxel|
75740404|NCT00989690|Drug|erlotinib hydrochloride|
75740405|NCT00989690|Drug|pemetrexed disodium|
75740406|NCT00989690|Genetic|fluorescence in situ hybridization|
75740407|NCT00989690|Genetic|mutation analysis|
75740408|NCT00989690|Genetic|proteomic profiling|
75740409|NCT00989690|Other|immunohistochemistry staining method|
75740410|NCT00989690|Other|laboratory biomarker analysis|
75740411|NCT00989690|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
75740412|NCT00989690|Procedure|breath test|
75740413|NCT00779987|Drug|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
76058740|NCT05550818|Other|High Ultra Processed Food Diet|Participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
76058741|NCT05550818|Other|No Ultra Processed Food Diet|Participants will be provided and consume a diet containing no UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
76058742|NCT05536284|Drug|Bisoprolol Fumarate Tablets|Antihypertensive drug used for acute coronary syndrome patients
76058743|NCT05534386|Behavioral|Cancer survivorship care intervention|A one-off face-to-face assessment and personal advice by members of a multidisciplinary team
75596087|NCT00597948|Behavioral|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
76058744|NCT05534386|Behavioral|Step-up targeted personalized intervention|To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.
76058745|NCT05534386|Behavioral|First stage control intervention|A set of skill-based pamphlets will be given.
76058746|NCT05534386|Behavioral|Second stage control intervention|Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet
75446372|NCT03616587|Drug|AZD9833 with ribociclib|Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation
75740414|NCT00779987|Drug|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
75740415|NCT04819022|Device|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
75446373|NCT03616587|Drug|AZD9833 with ribociclib|Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion
75446374|NCT03616587|Drug|AZD9833 with anastrozole|Part M: AZD9833 in combination with anastrozole dose escalation
75446375|NCT03616587|Drug|AZD9833 with anastrozole|Part N: AZD9833 in combination with anastrozole dose expansion
75446376|NCT03605550|Drug|PTC596|Oral tablets
75888203|NCT03082261|Device|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
75888204|NCT04051047|Drug|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
75888205|NCT04051047|Procedure|Tumor biopsy and blood draw|As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
75888206|NCT00102440|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 52 weeks.
75888207|NCT00102440|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 52 weeks.
75888208|NCT00102440|Drug|Allopurinol|Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
75888209|NCT02742363|Other|Collecting data|Collecting data from patient records
76058747|NCT05527756|Other|Scar Cosmesis Assessment and Rating (SCAR) scale|The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms
75446377|NCT03605550|Radiation|Radiotherapy|Cycle1
75446378|NCT03593473|Drug|Intranasal Oxytocin|Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
75446379|NCT03593473|Drug|Placebo|Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
75446380|NCT03552276|Drug|SUNPG18_07 I|injection
75446381|NCT03552276|Drug|SUNPG18_07 II|injection
75446382|NCT03552276|Drug|SUNPG18_07 III|injection
75596088|NCT02892006|Behavioral|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
75596089|NCT00598104|Drug|QAX576|
75596090|NCT00598104|Drug|Placebo|
75596091|NCT02891928|Device|Rocker sole shoes|Measure of walk testing Measure of standing position
75596092|NCT02891928|Device|Normal shoes|Measure of walk testing Measure of standing position
75596093|NCT04207632|Drug|Botulinum toxin type A injection|Ultrasound-guided BoNT-A injection in biceps brachii or brachialis
75596094|NCT00598260|Procedure|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
75596095|NCT00598338|Drug|Prucalopride|4 mg o.d.
75596096|NCT00598338|Other|Placebo|o.d.
75596097|NCT04326348|Drug|TQ05105|TQ05105 is a JAK2 inhibitor.
75596098|NCT00598416|Behavioral|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
76058748|NCT05527756|Other|Numerical rating scale (NRS)|The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.
76058749|NCT05514210|Behavioral|heart team meeting and discussion|When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.
75596099|NCT00598572|Drug|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
75446386|NCT03535688|Drug|D-cycloserine|200 mg twice daily
75446387|NCT03535688|Drug|Placebo|twice daily
75446388|NCT03520647|Drug|Cyclophosphamide|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
75446389|NCT03520647|Other|Peripheral Blood Stem Cells|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
75596100|NCT04326426|Drug|Tradipitant|Neurokinin-1 antagonist
75596101|NCT04326426|Drug|Placebo|Matching placebo
75596102|NCT00598728|Behavioral|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
75740416|NCT04819022|Device|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
75740417|NCT04819022|Device|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
75740418|NCT03875027|Procedure|proximal femur replacement|patient with proximal femur fracture or those in whom previous surgery on hip is failed and treated with replacement of proximal femur implant
75740419|NCT00074581|Drug|Atazanavir|300 mg taken orally once daily
76058750|NCT05511519|Drug|ATI-450|Oral, small molecule MK2 inhibitor
76058751|NCT05511519|Drug|Placebo Oral Tablet|Placebo tablet manufactured to match ATI-450 in appearance
75446390|NCT03511118|Drug|Tranexamic acid (TXA)|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446391|NCT03511118|Drug|labetalol|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446392|NCT03511118|Drug|metformin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446393|NCT03511118|Drug|nifedipine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446394|NCT03511118|Drug|clindamycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446395|NCT03511118|Drug|oxycodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446396|NCT03511118|Drug|azithromycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75596103|NCT00598884|Behavioral|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
75596104|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
75740420|NCT00074581|Drug|Didanosine|400 mg taken orally once daily
75740421|NCT00074581|Drug|Efavirenz|600 mg taken orally once daily
75740422|NCT00074581|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
75596105|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
75446397|NCT03511118|Drug|escitalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446398|NCT03511118|Drug|sertraline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446399|NCT03511118|Drug|ondansetron|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75596106|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
75888210|NCT05224791|Procedure|Roux-en-Y Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
75740423|NCT00074581|Drug|Lamivudine|300 mg taken orally once daily
75740424|NCT00074581|Drug|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
75740425|NCT00074581|Drug|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
75888211|NCT05224791|Procedure|Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption"
75888212|NCT01380847|Genetic|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
75888213|NCT05224167|Drug|Melatonin 5 MG Sublingual Tablet|Melatonin 5 mg 12 hours and 2 hours prior to surgery
76058752|NCT05503446|Other|Peanut in common foods or supermarket-sourced cow's milk (CM)|Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol
76058753|NCT05497921|Device|handLITE LED device|handLITETM is a home use wearable LED phototherapy device. The device consists of a flexible silicone glove that contains red and near infrared light emitting diodes (LEDs) and a controller. The LEDs generate the light. The glove is worn on the hand and is held in place by an adjustable Velcro strap.
75888214|NCT05224167|Drug|Hydroxyzine|Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
76058754|NCT05445674|Combination Product|Plasma Exchange Procedure|Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline
76058755|NCT05445674|Other|Sham Plasma Exchange Procedure|For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
75596107|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
75740426|NCT00074581|Drug|Stavudine|Dosage depends on weight
75740427|NCT00074581|Drug|Tenofovir disoproxil fumarate|300 mg taken orally once daily
75740428|NCT00074581|Drug|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
75888215|NCT01377259|Other|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
75446400|NCT03511118|Drug|Ciprofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75596108|NCT00599742|Behavioral|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
75596109|NCT00599742|Behavioral|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
75596110|NCT00599820|Drug|Intravitreal Bevacizumab|
75616370|NCT02852577|Drug|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
75740429|NCT00776477|Drug|clopidogrel and aspirin|clopidogrel 75mg daily and aspirin 100mg daily
75740430|NCT00776477|Drug|aspirin|aspirin 100mg daily
75740431|NCT04692116|Device|ExAblate treatment|Subthalamotomy using the ExAblate
75740432|NCT00772655|Drug|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 [if platelets are below 150000/µl only 11 MBq/kg are administered).
75596111|NCT00599898|Drug|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
75740433|NCT00772655|Drug|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
75740434|NCT04299542|Procedure|Percutaneous lung biopsy using conventional MDCT|Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).
75446401|NCT03511118|Drug|Doxycycline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446402|NCT03511118|Drug|Levofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446403|NCT03511118|Drug|Methylphenidate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75888216|NCT05223933|Behavioral|Proactive community case management|CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
75446404|NCT03511118|Drug|Sumatriptan|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446405|NCT03511118|Drug|Citalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75740435|NCT04299542|Procedure|Percutaneous lung biopsy CBCT|CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
75740436|NCT01086865|Drug|Apetiviton BC|"Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily."
75888217|NCT05223777|Device|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
75888218|NCT05223777|Device|Traditional Handheld Mallet|The handheld mallet traditionally used in total hip arthroplasty.
75446406|NCT03511118|Drug|Cyclobenzaprine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446407|NCT03511118|Drug|Furosemide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446408|NCT03511118|Drug|Gabapentin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446409|NCT03511118|Drug|Hydrochlorothiazide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75616371|NCT05337202|Device|HeartSDK|The photoplethysmography (PPG) application enables patients to perform a finger tip heartbeat measurement and automatic analysis
75596112|NCT00599898|Drug|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
75740437|NCT01090843|Procedure|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
75740438|NCT01090843|Device|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
75596113|NCT00599976|Procedure|Pulmonary vein isolation|Pulmonary vein isolation
75596114|NCT00600054|Biological|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
75740439|NCT01090843|Device|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
75888219|NCT05409547|Drug|PEG-rhG-CSF|PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.
75888220|NCT04994535|Drug|OnabotulinumtoxinA|Injection
75888221|NCT04994535|Drug|Placebo|Injection
75888222|NCT03909607|Drug|Ketamine 0.75 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
75888223|NCT03909607|Drug|Ketamine 1.0 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
75888224|NCT03909607|Drug|Ketamine 1.5 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
76058756|NCT05441137|Behavioral|Ride-On Cars Training with Different Postures|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
75740440|NCT00780299|Device|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
75740441|NCT00780299|Procedure|CVVH|hemofiltration intermittent dialysis
75740442|NCT03895034|Device|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
76058757|NCT05441137|Behavioral|Conventional Therapy|The other independent OT will be responsible for providing conventional therapy based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks.
75446410|NCT03511118|Drug|Hydroxyurea|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75596115|NCT00600210|Drug|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
75740443|NCT03960931|Other|Aquatic rehabilitation|Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
75740444|NCT03960931|Other|Land based physical activities|Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
75888225|NCT02498925|Behavioral|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
75446411|NCT03511118|Drug|Rosuvastatin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446412|NCT03511118|Drug|Topiramate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446413|NCT03511118|Drug|Trazodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446414|NCT03511118|Drug|Valganciclovir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446415|NCT03511118|Drug|Venlafaxine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446416|NCT03511118|Drug|Verapamil|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446417|NCT03511118|Drug|Remdesivir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446418|NCT03511118|Drug|Anakinra|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446419|NCT03511118|Drug|Tocilizumab|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446420|NCT03511118|Drug|Fluvoxamine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75740445|NCT03960931|Other|Conventional rehabilitation|Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
75740446|NCT00776633|Drug|aspirin|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
75740447|NCT00776633|Drug|clopidogrel|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
75888226|NCT02762084|Drug|Patidegib|
75888227|NCT02762084|Drug|Vehicle gel|
75888228|NCT03902509|Drug|Pirfenidone|pirfenidone capsule made in China
75888229|NCT03902509|Drug|basic treatment|glucocorticoid and expectant treatment etc.
75888230|NCT05223543|Diagnostic Test|Blood sample|extraction of blood samples from women undergoing ovarian cystectomy or oophorectomy due to suspected Dermoid cyst and analysing plasma for antibodies
75740448|NCT00776633|Drug|oral anticoagulation|
75740449|NCT01093963|Drug|Lisdexamfetamine|oral; 20-70mg/day
75740450|NCT01093963|Drug|Placebo|oral; 20-70mg/day
75740451|NCT03956563|Device|Youlaser MT Group 2|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the control arm will receive 3 simulated laser treatments every 30 days.~A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject."
75740452|NCT03956563|Device|Youlaser MT Group 1|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the active arm will receive 3 laser treatments with the laser: one treatment administration every 30 days."
75740453|NCT00776711|Drug|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
75740454|NCT00776711|Drug|VRC-AViDNA036-00-VP|
75596116|NCT00600210|Drug|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
75740455|NCT00336128|Behavioral|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
75740456|NCT00336128|Behavioral|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
75740457|NCT03956485|Other|Type of center|Tertiary versus non-tertiary
75740458|NCT03743090|Diagnostic Test|Polysomnography.|A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
75740459|NCT00772811|Drug|Flu-Mel|"Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~Melphalan will be administered following the completion of Fludarabine infusion at day -2."
75888231|NCT02159222|Procedure|Additional physical therapy|
75740460|NCT03961087|Drug|Coenzyme Q10|Coenzyme Q10 will be given twice
75740461|NCT03961087|Drug|MECLOFENOXATE|MECLOFENOXATE will be given as 500 mg once daily.
75740462|NCT03960775|Drug|dexmedetomidine|Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
75740463|NCT03960775|Drug|saline|Saline infusion during same time period.
75740464|NCT00536978|Drug|ARA-C|100 mg/m^2 IV Daily Over 1 Hour for 4 Days
75740465|NCT00536978|Drug|BCNU|300 mg/m^2 IV Over 1 Hour for 1 Day
75740466|NCT00536978|Drug|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
75740467|NCT00536978|Drug|Cyclophosphamide|1000 mg/m^2 IV Daily Over 1 Hour for 3 Days
75740468|NCT00536978|Drug|Etoposide|100 mg/m^2 IV Daily Over 3 Hours for 4 Days
75740469|NCT00536978|Drug|Fludarabine|30 mg/m^2 IV Daily Over 1 Hour for 3 Days
75740470|NCT00536978|Drug|Melphalan|100 mg/m^2 IV Over 30 Minutes for 1 Day.
75740471|NCT00536978|Drug|Rituximab|375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks.
75740472|NCT00536978|Other|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
75740473|NCT00536978|Radiation|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
75740474|NCT00536978|Drug|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
75740475|NCT00536978|Drug|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
75740476|NCT00536978|Procedure|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
75740477|NCT05356832|Diagnostic Test|Pelvic Floor Health Knowledge Quiz|It is a questionnaire to measure the knowledge level of the participants about pelvic floor health.
75740478|NCT03809611|Drug|UNR844-Cl|1.5% Ophthalmic solution for topical ocular administration
75740479|NCT03809611|Drug|Placebo|placebo
75888232|NCT01380613|Behavioral|Workshop|10 session intervention
75888233|NCT01380613|Behavioral|Workshop control|1 session intervention on standard HIV/STD information
75446421|NCT03511118|Drug|Amoxicillin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446422|NCT03511118|Drug|Bupropion|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75596117|NCT00600210|Radiation|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
75888234|NCT02166632|Procedure|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
75888235|NCT02166632|Procedure|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
75596118|NCT00600366|Drug|biphasic insulin aspart|
75596119|NCT00600444|Procedure|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
75888236|NCT03625401|Drug|AD-35 60mg group|AD-35 60mg QD
75446423|NCT03511118|Drug|Duloxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75596120|NCT00600444|Procedure|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
75888237|NCT03625401|Drug|Placebo group|Placebo: 3 placebo of AD-35 30mg tablets
75596121|NCT04326114|Device|Inspiratory training device|Inspiratory training by a Power-breath device
75888238|NCT02161952|Drug|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
75446424|NCT03511118|Drug|Hydrocodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75596122|NCT04326114|Device|Expiratory training device|Expiratory training a Winner-flow device
75740480|NCT05360342|Drug|Vitamin K supplement|Single dose of vitamin K supplement
75596123|NCT01326546|Biological|Therapeutic HBV vaccine|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
75596124|NCT01326546|Drug|entecavir|0.5mg,per day,oral intake.
75740481|NCT00989846|Other|biomarker|measuring serum-biomarkers
75740482|NCT05356754|Device|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals.
75596125|NCT01326546|Other|placebo|Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
75616372|NCT05234476|Behavioral|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
75740483|NCT03807739|Drug|GDC-0134 F09 Formulation|Participants will receive a single oral dose of GDC-0134 reference capsule F09.
75740484|NCT03807739|Drug|GDC-0134 F15 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
75740485|NCT03807739|Drug|GDC-0134 F16 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
75740486|NCT05290220|Drug|HLX07|1500 mg
75740487|NCT05290220|Drug|HLX10|300 mg
75888239|NCT02161952|Drug|Matched equivalent placebo|
75888240|NCT05223465|Other|Survey|Google form distributed for students and faculties
75888241|NCT03590145|Diagnostic Test|Clinical examination|Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
75888246|NCT05202249|Procedure|muscle layer fixation of thoracic drainage tube|The thoracic drainage tube is fixed on the muscle layer of the uniport
75888247|NCT04984161|Other|education|The aim of this project is to examine the effect of stoma care education on the knowledge and skill levels of pediatric surgery nurses about stoma care.
76058758|NCT05440123|Other|screening for bronchopulmonary cancer|The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
76058759|NCT05437393|Device|Deep brain stimulation|Deep brain stimulation of the centromedian nucleus (bilateral)
76058760|NCT05435612|Device|cochlear implant|Patients enrolled in the study undergo the cochlear implant surgery.
76058761|NCT05429099|Procedure|Virtual Surgical Planning (VSP)|The 3D reconstruction model, not requiring sterilization, will be sent directly to the SS. Prior to surgery, the SS will prebend a titanium fixation plate to the reconstruction model. Both the surgical cutting guides and titanium plate will be sterilized prior to use in surgery. If the planned resection cannot proceed (possibly due to tumour growth), the surgical team will note the reason for abandonment and conduct a standard FHS. Intraoperatively, the SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide is applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized by joining it to blood vessels in the neck.
75740488|NCT05290220|Drug|HLX04|15mg/kg
75740489|NCT05290220|Drug|lenvatinib|12 mg (BW≥60 kg) or 8 mg (BW <60 kg)
75888248|NCT04979403|Other|Physiotherapy|Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
75888249|NCT03705039|Other|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
76058762|NCT05429099|Procedure|Free-Hand Surgery|The SS will adopt their standard procedure for the mandibular resection and reconstruction. This typically involves bending a titanium fixation plate, harvesting of the bony flap, and shaping of the segments all intraoperatively based on the SS's judgement.
76058763|NCT05424198|Procedure|Cervical Medial Branch Radiofrequency Ablation|The skin and superficial tissues will be anesthetized at each site with 1-2 mL of lidocaine. Prior to the ablation up to 2 mL of lidocaine may be used at each site to ensure adequate pain control during the ablation. Once in position, a radiofrequency ablation lesion will be made using a 30 second ramp-up time to a maximum temperature of 80 °C, followed by an additional 90 seconds at maximum temperature.
75596126|NCT00600522|Procedure|Ultrasound-guided hepatectomy|"After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended."
75446425|NCT03511118|Drug|Levetiracetam|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75596127|NCT00600600|Drug|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
75596128|NCT00600678|Dietary Supplement|ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)|Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
75596129|NCT00623064|Drug|cisplatin|
75596130|NCT00623064|Drug|gemcitabine hydrochloride|
75596131|NCT00623064|Drug|lapatinib ditosylate|
75596132|NCT00623064|Other|pharmacological study|
75740490|NCT01583257|Behavioral|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
75740491|NCT03956329|Other|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
75446426|NCT03511118|Drug|Paroxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446427|NCT03511118|Drug|Buprenorphine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
75446428|NCT03446417|Drug|ZN-e4|Oral dose, tablet, daily dosing
75596133|NCT00623142|Drug|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
75596134|NCT00623220|Other|N2O|EMONO
75596135|NCT00623220|Other|oxygen|oxygen
75596136|NCT00600912|Drug|SMOFlipid®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
75769588|NCT01260220|Procedure|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
75446429|NCT03445858|Drug|Pembrolizumab|Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
75446430|NCT03445858|Drug|Decitabine|Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
75446431|NCT03445858|Radiation|Hypofractionated Index Site Radiation|Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
75596137|NCT00600912|Drug|2-ClinOleic 20%®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
75596138|NCT00600990|Drug|GW597599|
75596139|NCT00601068|Other|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
75888250|NCT03705039|Other|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
75446432|NCT03442556|Drug|Carboplatin|Given IV
75446433|NCT03442556|Drug|Docetaxel|Given IV
75446434|NCT03442556|Other|Laboratory Biomarker Analysis|Correlative studies
75446435|NCT03442556|Drug|Rucaparib Camsylate|Given PO
75446436|NCT03442556|Drug|Rucaparib|Given PO
75446437|NCT03433274|Device|Tendyne Mitral Valve System|Mitral valve replacement
75596140|NCT00601224|Behavioral|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
75596141|NCT00601224|Behavioral|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
75446438|NCT03433274|Device|MitraClip System|Percutaneous mitral valve repair using the MitraClip system.
75446439|NCT03389802|Biological|APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|"APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the MTD is reached or until dose level 3 (0.6 mg/kg) is complete without MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
75446440|NCT03389802|Biological|APX005M treatment for newly diagnosed DIPG patients|"The starting dose of APX005M for the DIPG patients will be one dose level below the RP2D determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
75446441|NCT03377023|Drug|Nivolumab|Intravenous nivolumab every 2 weeks.
75446442|NCT03377023|Drug|Ipilimumab|Intravenous ipilimumab every 6 weeks.
75446443|NCT03377023|Drug|Nintedanib|Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
75446444|NCT03317392|Procedure|Biopsy|Undergo tissue biopsy
75446445|NCT03317392|Procedure|Biospecimen Collection|Undergo blood sample collection
75446446|NCT03317392|Procedure|Computed Tomography|Undergo CT
75596142|NCT00601302|Drug|Amlodipine|
75596143|NCT00601536|Drug|Lithium|
75596144|NCT02891460|Device|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
75596145|NCT02891460|Device|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
75596146|NCT02891694|Other|in vitro immuno-histo-chemical analysis of corneal epithelium|
75596147|NCT00601614|Drug|temozolomide|
75596148|NCT00601614|Drug|vandetanib|
75596149|NCT00601614|Other|immunoenzyme technique|
75888251|NCT03704961|Behavioral|music and audiobook listening|
76058764|NCT05409391|Device|Insulin Titration System|A noval insulin titration system, which is based on deep learning
75446447|NCT03317392|Other|Laboratory Biomarker Analysis|Correlative studies
76058765|NCT05395819|Procedure|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within < 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
76058766|NCT05395819|Procedure|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
75596150|NCT00601614|Other|laboratory biomarker analysis|
75596151|NCT00601692|Drug|cisplatin|Given IV
75596152|NCT00601692|Drug|docetaxel|Given IV
76058767|NCT05395364|Behavioral|Intervention program BeE-school|The intervention program will be co-developed and directed to school professionals. It will be based on the promotion of health literacy and lifestyles.
76058768|NCT05383911|Behavioral|Shared Decision Making Intervention|We are currently developing a shared decision making intervention for AYAs with SCD to provide decision supports for disease-modifying therapies. As the intervention is currently in development, additional details will be provided once development and usability testing phases have been completed.
76058769|NCT05381454|Drug|Mitoquinone/mitoquinol mesylate|Mitoquinone/mitoquinol mesylate
76058770|NCT05368428|Other|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
76058771|NCT05367063|Drug|Canagliflozin 100mg or Sitagliptin 100mg|70 eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.
76058772|NCT05364242|Biological|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
75596153|NCT00601692|Drug|irinotecan hydrochloride|Given IV
75596154|NCT00601692|Radiation|radiation therapy|Given 5 days a week for 3 weeks
75888252|NCT05322447|Drug|L Carnitine ( low dose)|will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
75888253|NCT05322447|Drug|L-Carnitine ( high dose)|will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
76058773|NCT05360771|Device|SnowyTM PFO closure system|Percutaneously occlusion of PFO with SnowyTM PFO closure system
76058774|NCT05360771|Device|Cardi-o-fix PFO occluder|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
75446448|NCT03317392|Procedure|Magnetic Resonance Imaging|Undergo MRI
75446449|NCT03317392|Drug|Olaparib|Given PO
75446450|NCT03317392|Other|Quality-of-Life Assessment|Ancillary studies
75446451|NCT03317392|Radiation|Radium Ra 223 Dichloride|Given IV
75888254|NCT05006781|Drug|DAOIB|The DAOIB dose in each group will be fixed during the 24 weeks duration
75446452|NCT03311126|Drug|Bendamustine|Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of CLL and for indolent B cell NHLs progressing during or within 6 months of rituximab or a rituximab - containing regimen.
75596155|NCT04208022|Other|Respiratory evaluation|Hypermobility and Respiratory evaluation
75596156|NCT00601770|Biological|IC41|injection
75596157|NCT00602004|Drug|losartan|losartan 50 mg a day
75596158|NCT00602082|Drug|capecitabine|
75596159|NCT00602082|Drug|cisplatin|
75596160|NCT00602082|Drug|streptozocin|
75596161|NCT00602082|Genetic|DNA analysis|
75596162|NCT00602082|Genetic|RNA analysis|
75596163|NCT00602082|Genetic|protein analysis|
75596164|NCT00602082|Genetic|proteomic profiling|
75596165|NCT00602082|Other|laboratory biomarker analysis|
75596166|NCT01325532|Device|Active CES|CES current
75596167|NCT01325532|Device|Sham CES|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
75596168|NCT04327752|Other|dermatological consultation|Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.
75596169|NCT04126356|Procedure|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.
75596170|NCT05063695|Other|Multimodal Erector spinae catheter protocol|Patients either received multimodal epidural or ESP protocol
75446453|NCT03311126|Drug|Obinutuzumab|Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 mAb.
75888255|NCT03704727|Dietary Supplement|Probiotic|Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10^10 CFU/g Streptococcus thermophilus
75446454|NCT03309033|Procedure|Biospecimen Collection|Undergo collection of blood samples
75596171|NCT01171963|Biological|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
76058775|NCT05358548|Drug|Paclitaxel|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
76058776|NCT05358548|Drug|Pemetrexed|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
75888256|NCT03704649|Behavioral|Participatory video|Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
75888257|NCT05278377|Behavioral|"Apprenti en Action program"|"The Apprenti en Action program aims to teach students how to read and follow recipes, prepare and cook various foods using various culinary techniques, and apply food safety practices. Students are also taught the basics of healthy food, nutrition, and cooking."
75888258|NCT04907799|Behavioral|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
75888259|NCT04907799|Other|Standard advice control|Initial nutrition consultation without subsequent counseling
76058777|NCT05358548|Drug|5Fluorouracil|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
75446455|NCT03309033|Other|Questionnaire Administration|Complete questionnaire
75446456|NCT03301064|Behavioral|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
75596172|NCT01171963|Biological|Placebo|Oral administration
75596173|NCT01171963|Biological|Infanrix™|Intramuscular administration
75596174|NCT01171963|Biological|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
75616373|NCT05234476|Behavioral|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
75616374|NCT01214174|Drug|IBI-10090|
75616375|NCT04201990|Drug|Camrelizumab and Apatinib|Camrelizumab, iv, Q3W; Apatinib, po, QD
75616376|NCT00901342|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
75616377|NCT00632866|Drug|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
75616378|NCT00632866|Drug|Placebo|Placebo : 2cp/ day since 24 weeks
75616379|NCT00901186|Drug|RFB002|0.5 mg
75616380|NCT00901186|Procedure|Laser photocoagulation|
75446457|NCT03301064|Other|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
75446458|NCT03300505|Drug|ARRx|Given intravenously (IV)
75446459|NCT03300505|Drug|Enzalutamide|Given by mouth (PO)
75446460|NCT03295240|Drug|BR-I (bendamustine, rituximab, ibrutinib)|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
75446461|NCT03295240|Drug|VEN (Venetoclax)|The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
75446462|NCT03280225|Other|External facilitation|"Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation."
75446463|NCT03264235|Device|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.~Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
75446464|NCT03264235|Other|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
75446465|NCT03223883|Drug|Curcumin|Oral supplement for 12 months
75446466|NCT03223883|Other|Placebo|Oral placebo for 12 months
75888260|NCT04050735|Other|Alcohol, ethyl, moderate dose|Moderate oral dose of ethyl alcohol
75596175|NCT04315207|Behavioral|Telephone call|"All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
75616381|NCT01213472|Biological|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
75616382|NCT05040880|Drug|Telmione plus 80/12.5mg|Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
75888261|NCT04050735|Other|Placebo|Placebo beverage
75888262|NCT04784559|Drug|Plitidepsin|"Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes."
76058778|NCT05358548|Drug|Carboplatin|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
75446469|NCT03194893|Drug|Alectinib|Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
75446470|NCT03194893|Drug|Crizotinib|Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
75446471|NCT03188510|Biological|LY3074828|Administered SC
75596176|NCT04315207|Behavioral|In-person meeting|"All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
76058779|NCT05358548|Drug|Pembrolizumab|It is a type of immunotherapy and works by helping your immune system to kill cancer cells
75888263|NCT04784559|Drug|Dexamethasone|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
75596177|NCT01171183|Drug|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
75446472|NCT03173937|Biological|Omidubicel (former CordIn)|Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn (TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn (TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn (TM) Non-cultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.
75596178|NCT01171183|Drug|Placebo|Placebo
75596179|NCT04315441|Diagnostic Test|STEPS and AUDIT questionnaires|assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.
75596180|NCT04315051|Drug|Cohort 1 J. Lividum|Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails
75446473|NCT03173937|Device|Miltenyi CliniMACS(R) CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device system that is designed for the in vitro enrichment of CD34+ target cells from heterogeneous hematologic cell populations. The process of CD34+ cell selection results in simultaneous passive depletion of donor lymphocytes, potentially obviating the need for immunosuppressive drugs to prevent GVHD.
75446474|NCT03129880|Behavioral|Weekly Voice Therapy|Participants will be randomized to receive weekly voice therapy
75446475|NCT03129880|Behavioral|Intensive Voice Therapy|Participants will be randomized to receive multiple sessions of voice therapy in one day.
75888264|NCT04784559|Drug|Remdesivir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
75888265|NCT04784559|Drug|Favipiravir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
75888266|NCT03704571|Drug|Polyethylene Glycol|"In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens."
75888267|NCT03704493|Diagnostic Test|Video Group|A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
75888268|NCT04050657|Other|appointment interval|To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
75888269|NCT03704337|Dietary Supplement|Commercially Available Food Bar|Active
75446476|NCT03120780|Drug|Fentanyl 20 mcg|20 mcg fentanyl in 10 mL 0.125% bupivacaine
75446477|NCT03120780|Drug|Fentanyl 100 mcg|100 mcg fentanyl in 10 mL 0.125% bupivacaine
75446478|NCT03120312|Procedure|total hip replacement|primary hip replacement patients during past 5 years．
75446479|NCT03118505|Device|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
75446480|NCT03118505|Device|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
75888270|NCT03704337|Dietary Supplement|Placebo|Placebo
76058780|NCT05348564|Behavioral|Direct contact of family members for cascade screening of relevant variants|Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
76058781|NCT05346250|Behavioral|Non-exercise control|12 month lifestyle education
76058782|NCT05346250|Behavioral|Moderate intensity exercise|12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.
76058783|NCT05346250|Behavioral|Vigorous intensity exercise|6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
76058784|NCT05343364|Drug|Vonoprazan|Oral Tablet
76058785|NCT05342038|Device|T-02|Stent retriever
76058786|NCT05329415|Diagnostic Test|TB Drug Levels|TB drug levels at 1-2 time points at weeks 2, 8 and 16
76058787|NCT05308238|Behavioral|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
76058788|NCT05308238|Behavioral|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
76058789|NCT05299671|Behavioral|Video consultation|During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
76058790|NCT05288972|Device|Mattress 1|A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
76058791|NCT05288972|Device|Mattress 2|A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
76058792|NCT05281666|Device|Absorbable Surgical Gut Suture material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using absorbable surgical gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
76058793|NCT05281666|Device|Non-absorbable Nylon Suture Material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using non-absorbable nylon gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their sutures will be removed at the 2-week follow-up visit. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
76058794|NCT05276739|Behavioral|Bright Light|6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake).
76058795|NCT05276739|Behavioral|Time-restricted eating|6.5-hour restricted meal window (4 meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode.
76058796|NCT05276739|Behavioral|Dim light|dim light (<3 lux) throughout the 16-hour wake episode
76058797|NCT05276739|Behavioral|12-h meal window|12-hour restricted meal window (4 meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
76058798|NCT05275803|Dietary Supplement|Probiotics|The participant would receive non-surgical periodontal treatment, after which the participant uses probiotics (BioGaia Prodentis, L. reuteri DSM 17938+L. reuteri ATCC 5289, 0.8g, qn) for another 30 days.
75446481|NCT03102125|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
75596181|NCT04315051|Other|Placebo Gel|Subject to apply Placebo Gel daily on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails.
75446482|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (<) 65 kg.
75596182|NCT04315129|Diagnostic Test|Smart Catheter Biosensor|A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
75446483|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
75446484|NCT03100149|Drug|Placebo|RO7046015 placebo will be administered to all participants in the indicated arm.
75596183|NCT01169779|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
75596184|NCT01169779|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
75446485|NCT03077841|Other|Laboratory Biomarker Analysis|Correlative studies
75446486|NCT03077841|Radiation|Partial Breast Irradiation|Undergo hypofractionated partial breast irradiation
75596185|NCT01169779|Device|Pen auto-injector|
75596186|NCT01169779|Drug|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
75596187|NCT01169779|Drug|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c <8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c >=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
75596188|NCT01169701|Drug|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
75596189|NCT01169701|Drug|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
75596190|NCT01169701|Drug|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
75596191|NCT01168999|Other|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
75596192|NCT01168999|Other|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
75596193|NCT01168999|Other|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
75888271|NCT04910763|Behavioral|Resistance Exercise|Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
75888272|NCT03704259|Other|Ceramic coating|coating the laparoscope lens with commercial brand ceramic coating, bought from car service centers specialized in such applications
75888273|NCT03704181|Drug|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
75596194|NCT01167907|Device|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
75888274|NCT03704181|Drug|Placebo Oral Tablet|placebo twice day for one year
75446487|NCT03077841|Other|Questionnaire Administration|Ancillary studies
75888275|NCT03625011|Drug|Gabapentin|This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.
75888276|NCT04891965|Biological|ART24|Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10^9 CFU/capsule. Subjects will receive 1 capsule daily.
75446488|NCT03075527|Drug|Tremelimumab|Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.
75446489|NCT03075527|Drug|Durvalumab|Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
75446490|NCT03068624|Biological|Aldesleukin|Given SC
75446491|NCT03068624|Biological|Autologous CD8+ SLC45A2-specific T Lymphocytes|Given via hepatic arterial infusion via central catheter
75446492|NCT03068624|Drug|Cyclophosphamide|Given IV
75446493|NCT03068624|Biological|Ipilimumab|Given IV
76058799|NCT05275803|Dietary Supplement|Control|The participant does not use probiotics after non-surgical periodontal treatment.
76058800|NCT05274477|Drug|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
75446494|NCT03033992|Device|Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)|The Optune, a.k.a. Tumor Treating Fields (TTFields), will be worn for a minimum of 18 hours a day, with a recommendation of 22 hours/day for at least 23 days in a 28-day cycle. Cycle 1 includes 7 days training period, followed by 28 days treatment (total 35 days). The patients will receive multiple 28-day cycles of continuous Optune treatment. In the absence of treatment related serious adverse events or disease progression, Optune will continue up to 26 cycles.
75888277|NCT04891965|Drug|Placebo|Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
75446495|NCT03033992|Combination Product|Concurrent Optune and RT followed by Optune System alone|In Stratum II patients will be treated with standard of care focal RT concurrently with Optune followed by Optune treatment. This study specifies a 1 cm clinical target volume margin.The duration of the first cycle of therapy will be from Day 1 of RT to 14 days after completion of RT (approximately 8 weeks total). Subsequent cycles of therapy will be 28 days in duration. The Optune device will be worn for a minimum of 18 hours/day, with a recommendation of 22 hours/day. For the phase I part, the initial treatment will involve RT delivery with Optune arrays remaining in place but turned off. If this is not tolerated, two treatment de-escalation levels are planned, Specifically, Level -1: remove the Optune arrays during RT delivery and reapply daily after RT; Level -2: initiate Optune therapy after completion of RT. The established safe treatment approach from phase I will be investigated for feasibility and efficacy in phase II. Treatment with Optune may continue for up to 5 years.
75446496|NCT02997228|Drug|Atezolizumab|Given IV
75740492|NCT03956329|Other|Individualised Digital Intervention|Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
75446497|NCT02997228|Biological|Bevacizumab|Given IV
75740493|NCT01583413|Procedure|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
75888278|NCT03701841|Drug|PEG-rhG-CSF|All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles
75888279|NCT03701685|Procedure|nerve flap|sensory reconstruction via a nerve graft included in the flap
75888280|NCT04775355|Procedure|Biospecimen Collection|Undergo collection of stool and urine
75888281|NCT04775355|Other|Electronic Health Record Review|Medical records are reviewed
75888282|NCT04775355|Other|Quality-of-Life Assessment|Complete quality of life questionnaires
75888283|NCT04775355|Other|Questionnaire Administration|Complete questionnaires
75888284|NCT02763644|Drug|LFG316 active drug|LFG316
75888285|NCT02763644|Other|Standard of care treatment|SoC (site specific)
75888286|NCT02162030|Behavioral|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
75888287|NCT03703713|Drug|Sodium chloride|Treatment with Sodium chloride
76058801|NCT05274477|Drug|Placebo|no active component
76058802|NCT05274282|Other|Animation Therapy|Stop-motion movie shooting process designed for improving attention skill and regulating hyperactive and impulsive behaviours.
76058803|NCT05268016|Drug|ME3183|ME3183 capsule
76058804|NCT05268016|Drug|Placebo|Placebo capsule
76058805|NCT05262556|Drug|NP-101 (TQ Formula)|Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
75446498|NCT02997228|Procedure|Biospecimen Collection|Undergo collection of blood samples
75446499|NCT02997228|Procedure|Computed Tomography|Undergo CT or CT/PET
75740494|NCT00536744|Device|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
75740495|NCT00536744|Other|Sham|Non-energized (inactive - Sham) application + standard of care
75888288|NCT04722627|Drug|AT-752|Parallel Assignment
75596195|NCT01167907|Drug|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
76058806|NCT05262556|Drug|Nivolumab (3mg/kg)|Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.
76058807|NCT05262556|Drug|Ipilimumab (1mg/kg)|Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
75596196|NCT01166659|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
75596197|NCT02886169|Other|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
75740496|NCT01094041|Other|Gluten free diet|A 4-week gluten free diet provided
75446500|NCT02997228|Drug|Fluorouracil|Given IV
75446501|NCT02997228|Drug|Leucovorin|Given IV
75446502|NCT02997228|Procedure|Magnetic Resonance Imaging|Undergo MRI
75446503|NCT02997228|Drug|Oxaliplatin|Given IV
75596198|NCT02886169|Other|high saturated fat meal|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
75596199|NCT01115491|Drug|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
75740497|NCT01094041|Other|Gluten rich diet|A 4-week gluten rich diet is provided
75740498|NCT04076072|Device|Utravit High-Speed 10000 cpm Beveled Probe|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
75888289|NCT04722627|Drug|Placebo|Parallel Assignment
75888290|NCT04728555|Procedure|Game about radiotherapy|A digital pedagogical game about radiotherapy
76058808|NCT05261503|Other|HEP|The Homeostasis-Enrichment-Plasticity (HEP) intervention group will receive 45 minutes of face-to-face environmental enrichment-based intervention one day per week and online home support once a week for 12 weeks.
76058809|NCT05261503|Other|Traditional Phsical Therapy|The Traditional Physical Therapy group will receive a 45-minute intervention, two days a week for 12 weeks.
76058810|NCT05244070|Drug|BMS-986403|Specified dose on specified days
76058811|NCT05244070|Drug|Fludarabine|Specified dose on specified days
75446504|NCT02997228|Procedure|Positron Emission Tomography|Undergo CT/PET
75446505|NCT02997228|Other|Quality-of-Life Assessment|Ancillary studies
75446506|NCT02997228|Other|Questionnaire Administration|Ancillary studies
75446507|NCT02960022|Drug|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
75446508|NCT02960022|Drug|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
75888291|NCT03625167|Other|Treatment with petrolatum|Petrolatum is applied twice daily to the intervention arm.
75888292|NCT04893759|Drug|Pelcitoclax|Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle
75888293|NCT04576689|Drug|IBE-814 70ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
75888294|NCT04576689|Drug|IBE-814 140ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
75888295|NCT04575909|Behavioral|Aprosodia Intervention|Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
75446509|NCT02960022|Drug|prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
75446510|NCT02931253|Drug|Metformin|Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.
75596200|NCT01115491|Drug|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
75740499|NCT04076072|Device|standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
75740500|NCT04026230|Drug|Atorvastatin 80mg|Capsules including 80 mg of atorvastatin
75740501|NCT04026230|Drug|Placebo oral capsule|Similar capsules as in the atorvastatin arm, but without the active ingredient
75888296|NCT04575909|Behavioral|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention [if relevant]), hobbies, and other similar topics.
76058812|NCT05244070|Drug|Cyclophosphamide|Specified dose on specified days
75740502|NCT03884504|Device|Ventricular Assist Device System|Ventricular Assist Device System
75888297|NCT04573491|Genetic|Pharmacogenetic test|genotyping for genes that affect drug metabolism
75888298|NCT04573491|Other|Medication review|systematic and interdisciplinary method aiming to increase quality of medication treatment
75596201|NCT01113931|Drug|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
75596202|NCT01113931|Drug|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
75596203|NCT04310761|Procedure|one single blastocyst transfer, both fresh and warmed|Ultrasound guided transvaginal embryo transfer.
75596204|NCT02881879|Biological|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
75596205|NCT02881177|Drug|Oxytocin|40 IU
75596206|NCT02881177|Drug|Placebo|40 IU
75596207|NCT04187677|Procedure|Sensory Training|The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.
75596208|NCT04187677|Other|classical hand therapy|classical hand therapy
75596209|NCT02881723|Procedure|Surgery|
75740503|NCT00536510|Drug|laropiprant/niacin (MK0524A)|"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization"
75888299|NCT03701607|Other|PD-L1 group|PD-L1 expression is evaluated using immunohistochemical assay
75888300|NCT04718727|Drug|Placebo|oral Placebo tablets one-hour preoperatively
76058813|NCT05236777|Drug|Natalizumab|Administered as specified in the treatment arm.
76058814|NCT05231473|Other|Nurse Enhanced Recovery After Surgery participation|Bellvitge University Hospital will include the NEC participation along Enhanced Recovery After Surgery program.
76058815|NCT05222607|Drug|IncobotulinumtoxinA|IncobotulinumtoxinA injections for aesthetic indications.
76058816|NCT05201833|Behavioral|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status
75446511|NCT02926911|Other|Surgery|Surgery +/- radiation choice for endocrine therapy
75446512|NCT02926911|Other|Active Monitoring|Choice for endocrine therapy
75446513|NCT02830724|Drug|Cyclophosphamide|"For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV"
75446514|NCT02830724|Drug|Fludarabine|"For Phase I, Days -7 to -5:~Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB~For Phase II, Days -7 to -3:~25 mg/m(2)/day x 5 days IVPB"
75596210|NCT02881723|Radiation|Radio- chemotherapy|
75596211|NCT04187599|Device|Paragon CRT®100 Contact Lens|Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
75616383|NCT05040880|Drug|Micardis plus 80/12.5mg|Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
75740504|NCT00536510|Drug|Comparator: placebo|"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization."
76058817|NCT05201833|Behavioral|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
76058818|NCT05201833|Procedure|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
76058819|NCT05201833|Procedure|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
75596212|NCT02880787|Drug|Rocuronium|Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
75740505|NCT04526600|Other|Fidget ball|Access to a prototype 'smart' fidget ball with pressure sensors embedded, that produces touch traces and transmits real time data
75596213|NCT02880787|Device|Neuromuscular monitoring with TOFScan® and TOF-Watch SX®|Each monitor on one arm
75596214|NCT02880709|Dietary Supplement|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
75740506|NCT04496258|Behavioral|Positive Emotion Induction|Participants are expected to have a positive emotional response to the more positive beach scene.
75740507|NCT04496258|Behavioral|Neutral Emotion Induction|Participants are expected to have a neutral emotional response to the neutral office scene.
75740508|NCT04424264|Drug|Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid|TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600*/300 mg daily from screening until enrolment (days -15 to 0)
75596215|NCT04309435|Behavioral|Self-esteem intervention|See relevant study arm for description
75596216|NCT04309435|Behavioral|Self-stigma intervention|See relevant study arm for description
75740509|NCT04424264|Drug|Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid|TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/*300 mg daily (days 1 to ≤ 56)
75740510|NCT04424264|Drug|Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz|TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg <70kg, 750mg >70kg
75740511|NCT05355662|Other|Age|The study was retrospective and did not involve the application of interventions.
75740512|NCT00398086|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
75740513|NCT00398086|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
75769589|NCT01260220|Procedure|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
75888301|NCT04718727|Drug|5 mg Olanzapine Tablets|oral 5 mg Olanzapine tablets one-hour preoperatively
75596217|NCT04309435|Behavioral|Jumping to conclusions intervention|See relevant study arm for description
75888302|NCT04718727|Drug|10 mg Olanzapine Tablets|oral 10 mg Olanzapine tablets one-hour preoperatively
76058820|NCT05177354|Device|Inceptiv|Implantable Neurostimulator with Neuro Sense
76058821|NCT05167409|Drug|Evorpacept (ALX148)|IV QW
76058822|NCT05167409|Drug|Cetuximab|IV QW
76058823|NCT05167409|Drug|Pembrolizumab|IV Q3W
76058824|NCT05156164|Device|Kinesio Tape Group|The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
76058825|NCT05156164|Device|Control Group|KT application on the deltoid but without support function
75596218|NCT04309435|Behavioral|Control procedure (assessment only)|See relevant study arms for description
76058826|NCT05155761|Device|FeetMe® Monitor|"Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days."
76058827|NCT05145426|Device|Low Intensity Focused Ultrasound|Application of LIFU
75596219|NCT01107379|Device|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
75596220|NCT01106911|Device|tomosynthesis and screening mammography|All eligible subjects will undergo both full field digital mammography and digital breast tomosynthesis.
75740514|NCT05280860|Procedure|ultrasound-guided bilateral rectus sheath block|Bilateral RSB was guided by ultrasound before surgery after the completion of general anesthesia, First, the probe is placed transversely and perpendicular to reveal the anterior, hypoechoic, and posterior rectus sheath of the hyperechoic rectus abdominis. Moving the probe outward to reveal the sound images of the lateral margin of the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. After the scanning, the needle was inserted from any segment of the probe under the guidance of real-time ultrasound; the tip reached between the rectus abdominis muscle and the posterior sheath of the rectus abdominis muscle. After no blood was extracted, 1 ~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct, If the needle tip was correctly positioned, 0.5 % ropivacaine 10 mL of local anesthetic was injected on each side. The same anesthesiologist was performed bilateral RSB under ultrasound guidance.
75888303|NCT03703557|Diagnostic Test|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.
76058828|NCT05130437|Biological|mRNA-3927|mRNA-3927 dispersion for IV infusion
75888304|NCT03703557|Diagnostic Test|Odour sampling|Analyzed by the dogs of Curie Institute at the training centers
75888305|NCT03703479|Other|autologous blood clot made from the patient own clot without any additive|advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
75888306|NCT03701529|Drug|Sevoflurane|1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.
75888307|NCT03701529|Drug|Propofol|2-5 mcg/ml of propofol is used for maintenance of anesthesia.
75446515|NCT02830724|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
75888308|NCT04050891|Device|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
75888309|NCT04553133|Drug|PF-07104091 monotherapy dose escalation|PF-07104091 will be administered orally
75446516|NCT02830724|Biological|Anti-hCD70 CAR transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).
75888310|NCT04553133|Drug|PF-07104091 + palbociclib + fulvestrant|PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
75888311|NCT04553133|Drug|PF-07104091 + palbociclib + letrozole|PF-07104091 will be administered orally in combination with palbociclib and letrozole
75888312|NCT04553133|Drug|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 will be administered orally
75888313|NCT04553133|Drug|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 will be administered orally
75446517|NCT02819882|Other|No intervention|
75446518|NCT02812524|Drug|Intratumoral Ipilimumab|Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
76058829|NCT05129891|Drug|Semaglutide D|Tablet given orally
76058830|NCT05129891|Drug|Semaglutide G|Tablet given orally
76058831|NCT05129891|Drug|Semaglutide H|Tablet given orally
75446519|NCT02796937|Biological|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
75446520|NCT02784496|Other|Long-term Follow-up|Undergo follow-up assessment
75446521|NCT02784496|Other|Quality-of-Life Assessment|Ancillary studies
75596221|NCT01106677|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
75596222|NCT01106677|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
75596223|NCT01106677|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
76058832|NCT05129891|Drug|Semaglutide I|Tablet given orally
76058833|NCT05129891|Drug|NNC0385-0434 B|Tablet given orally
76058834|NCT05129891|Drug|NNC0385-0434 C|Tablet given orally
76058835|NCT05129891|Drug|NNC0385-0434 D|Tablet given orally
76058836|NCT05129891|Drug|NNC0385-0434 E|Tablet given orally
75446522|NCT02784496|Drug|Ruxolitinib|Given PO
75446523|NCT02734004|Drug|Olaparib|Olaparib
75446524|NCT02734004|Drug|MEDI4736|MEDI4736
75446525|NCT02734004|Drug|Bevacizumab|Bevacizumab
75596224|NCT01106677|Drug|Metformin immediate release|The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
75888314|NCT04553133|Drug|PF-07104091 + Fulvestrant (post CDK4/6)|PF-07104091 will be administered orally in combination with fulvestrant
75446526|NCT02697448|Drug|propofol|Participant receives propofol as anesthetic for cardiac ablation.
75446527|NCT02697448|Drug|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
75446528|NCT02688712|Drug|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
75596225|NCT04309045|Behavioral|DBT|Today, the most well-known and established treatment for borderline personality disorder is Dialectical Behavior Therapy (DBT) that developed by Marsha Linhan in the 1990s. DBT is currently used in other disorders such as: eating disorders, addictions, impulse control problems and bipolar disorder. Various studies have found a beneficial effect for this treatment in various areas: decreased suicidal thoughts and attempts and self-harm behaviors, improvements in suicide attempts, anger levels, impulsive behaviors, depressive symptoms, The use of drugs, the percentage of dropouts from treatment, number Hospitalization and general function.
75740515|NCT04364360|Dietary Supplement|Sulforaphane extract|2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
75740516|NCT04361942|Biological|Mesenchymal Stromal Cells|Intravenous injection of 1 million MSV cells/Kg diluted in 100 ml saline
75888315|NCT04553133|Drug|PF-0704091 + Fulvestrant (post CDK4/6)|PF-07104091 + fulvestrant (post 4/6) dose expansion
75446529|NCT02688712|Drug|Capecitabine|Antimetabolite chemotherapy
75446530|NCT02688712|Drug|Fluorouracil|Antimetabolite chemotherapy
75446531|NCT02688712|Procedure|Tumor specific mesorectal excision|Tumor specific mesorectal excision
75446532|NCT02687360|Device|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
75446533|NCT02687360|Device|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
75740517|NCT04361942|Other|Placebo|Intravenous injection of 100 ml saline containing no cells
75888316|NCT03703245|Other|Sodium bicarbonate|Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.
75888317|NCT03703245|Other|Control Dentifrice|Negative control dentifrice containing 0% w/w sodium bicarbonate
75888318|NCT03701451|Drug|Demethylated drug decitabine|Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
75888319|NCT04703985|Dietary Supplement|Enteral Nutrition|Protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
75888320|NCT03703089|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
76058837|NCT05120466|Behavioral|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
75740518|NCT00536198|Drug|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
75740519|NCT00536198|Drug|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
75740520|NCT00393484|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
75740521|NCT00393484|Drug|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
75740522|NCT00393484|Drug|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"
76058838|NCT05120466|Behavioral|Usual health education curriculum|The school's regular health education curriculum includes classroom lectures, hands on activities and group work.
75740523|NCT00393484|Drug|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
75740524|NCT00667823|Drug|Macitentan|Tablet, oral administration, 10 mg dose once daily
75888321|NCT03703089|Drug|nab-paclitaxel|Administered by intravenous infusion over 30-40 minutes.
75888322|NCT03703011|Device|Accelerometers positioned at the wrinkle, the hip, and the ankle|Accelerometers are positioned at the wrinkle, the hip, and the ankle. The subject stands and walks 10 meters, followed up by a physiotherapist in the physiotherapy area. The accelerometers are triggered by a smartphone. The protocol is filmed (without the face), and 2 physicians will watch the film and count the steps blind to the results of the accelerometers (and blind to each-other steps counts)
75446534|NCT02677922|Drug|AG-120|Specified dose on specified days
75446535|NCT02677922|Drug|Azacitidine|Specified dose on specified days
75446536|NCT02677922|Drug|AG-221|Specified dose on specified days
75446537|NCT02641847|Drug|docetaxel|
75446538|NCT02641847|Drug|doxorubicin or epirubicin|
75446539|NCT02641847|Drug|cyclophosphamide|
75446540|NCT02641847|Drug|gemcitabine|
75446541|NCT02641847|Drug|cisplatin|
75446542|NCT02597348|Procedure|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
75596226|NCT04309045|Behavioral|DDP|DDP treatment is part of a trend of dynamic therapies to treat borderline personality disorder. The DDP focuses on deficiencies in the emotional experience processing and is performed in the form of weekly, individual sessions with a trained therapist over a 12-18 month period. Treatment is based on the need to correct three neurocognitive functions responsible for adaptive processing of emotional experiences: association (the ability to recognize, understand their existence, and experience a sequence of emotional experiences), attribution (the ability to make complex attributions about the self and others), and the ability to make realistic attribution, about the self and the other. Interventions that activate these three functions are the basis for DDP treatment.
75740525|NCT00397930|Procedure|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
75596227|NCT04309045|Other|control group|Patients on the waiting list for treatment, or patients in the hospital under routine care.
75596228|NCT04309357|Drug|Alteplase|Alteplase in dose 0.9 mg/kg in acute ischemic patient with indications of thrombolytic therapy
75596229|NCT04309279|Behavioral|Zentangle|Zentangle is a mindful doodling process in which participants draw repetitive, structured patterns on small pieces of paper. The patterns consist of combinations of dots, lines, and curves.
75888323|NCT03701373|Drug|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA<1.25 m2), 50 mg (1.25≤BSA<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
75888324|NCT03701373|Other|Observation|Observation without anti-tumor treatment
75888325|NCT03702933|Dietary Supplement|D-serine|dosage
75888326|NCT02807844|Drug|MCS110|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
75888327|NCT02807844|Drug|PDR001|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
76058839|NCT05096117|Drug|ASP8062|ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
76058840|NCT05096117|Drug|Placebo|1 x per day for 6 weeks
75740526|NCT00397930|Procedure|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
75888328|NCT03702855|Drug|Tetrabenazine Tablets 25 mg|
75888329|NCT04542681|Drug|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo/normal saline
75888330|NCT04542681|Drug|MANP - 1st Cycle|Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
75888331|NCT04542681|Drug|MANP - 2nd Cycle|Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
75888332|NCT02052180|Drug|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
75888333|NCT02052180|Drug|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
75888334|NCT03561402|Drug|Teriflunomide|Each patient will receive 1 tablet (14 mg) on a daily basis.
75888335|NCT02053428|Procedure|percutaneous image-guided gastrostomy|
75888336|NCT02166710|Device|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
75888337|NCT02166710|Device|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
75888338|NCT02053506|Dietary Supplement|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
75888339|NCT02053506|Dietary Supplement|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
75888340|NCT02053506|Dietary Supplement|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
75888341|NCT02763254|Biological|baltaleucel-T|Autologous EBV-specific T cells
75888342|NCT02053662|Procedure|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
75888343|NCT04694781|Drug|LVGN6051|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
75888344|NCT04694781|Drug|Pembrolizumab|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
75888345|NCT02166866|Other|Quality of Life Questionairre and Education|
75888346|NCT03624855|Other|Bone or joint infection due to Pseudomonas aeruginosa|Description of bone or joint infection on implant due to Pseudomonas aeruginosa
75888347|NCT02805972|Drug|Naloxone|4 mg / 0.1 ml
75888348|NCT02805972|Drug|Placebo|0.1 ml
76058841|NCT05083130|Behavioral|a wake prone positioning|The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position for at least 8 hours per day. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers.
75446543|NCT02567799|Drug|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
76058842|NCT05072093|Behavioral|PrEP discontinuation intervention|Men taking daily oral PrEP (Truvada) will receive a monthly screener through the mobile app. If answers to screener questions indicate a participant is at risk for PrEP discontinuation, then a peer navigator will deliver a motivational interviewing intervention and a clinician will consult with the participant. These efforts are intended to avert PrEP discontinuation.
76058843|NCT05072093|Drug|Offering of on-demand oral PrEP|For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to take it immediately before/after a sexual encounter. It is hoped that this will serve as an alternative to daily oral PrEP use that is desirable for some people.
76058844|NCT05072093|Drug|Offering of STI PEP|All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses. At a dosage of 200 mg to be taken in a single dose ideally within 24 hours of possible exposure (e.g. condomless anal sex) and no later than 72 hours after exposure. Participants will be dispensed enough pills to allow for up to 3 weekly doses of 200mg doxycycline (i.e. 6 pills/week) for 3 months (the interval between STI testing visits).
76058845|NCT05072093|Drug|Injectable PrEP|For men who are interested in injectable PrEP, they will be referred to local providers to access Apretude (Cabotegravir injection) every two months. In the study, their use of the medication will be monitored through monthly surveys during which they have the option to indicate interest in switching to oral PrEP.
75446544|NCT02567799|Drug|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
75596230|NCT02880397|Drug|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
75596231|NCT02880397|Drug|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
75596232|NCT01106287|Drug|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
75596233|NCT01106287|Drug|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
75740527|NCT05356676|Other|Isometrics|"Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well."
75888349|NCT03702699|Device|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
75446545|NCT02567799|Drug|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg*min/mL will be administered by intravenous drip two times, 21 days apart."
75596234|NCT04309123|Device|TransAeris System|The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
75596235|NCT04308343|Drug|Methotrexate|Drugs to treat undisturbed ectopic pregnancies
75596236|NCT04308343|Drug|Letrozole|Drugs to treat undisturbed ectopic pregnancies
75596237|NCT04308343|Drug|cetrotide|Drugs to treat undisturbed ectopic pregnancies
75888350|NCT03032523|Diagnostic Test|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
75740528|NCT05356676|Other|Combination Therapy|"In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks."
75740529|NCT00397540|Procedure|PEIT|Percutaneous Ethanol Injection Therapy
75740530|NCT00397540|Procedure|RFTA|Radiofrequency Thermal Ablation
75740531|NCT03993496|Diagnostic Test|Abdominal Aortic Aneurysm Sac Pulsatility|"Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~Prior to EVAR deployment~After EVAR deployment, but before balloon affixation to the aortic wall~After EVAR deployment and after affixation"
75740532|NCT00536120|Biological|BG00002 (natalizumab)|
75740533|NCT00536120|Biological|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
76058846|NCT05065840|Behavioral|CDC 4 Pillars Program|The CDC's 4 Pillars Transformation Program (4 Pillars Program) is a robust and empirically supported strategic approach that promotes the uptake of adult vaccinations and addresses facilitators and barriers at the patient, provider, and clinic level. This multi-level, evidence-based intervention has been successfully utilized to increase HPV vaccination in the general population and is primed to be tested in the high-risk HIV population, particularly PLWH in the rural South. This proposal seeks to expand the success of the 4 Pillars Program and tailor, refine, and implement in the HIV positive population who are at extraordinarily high risk for HPV-related cancers and can obtain the most benefit from the vaccine.
75740534|NCT00536120|Biological|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
75740535|NCT00057811|Drug|doxorubicin hydrochloride|Given IV, IT, or orally
75888351|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
76058847|NCT05057273|Drug|BT-11|Oral once daily tablet
76058848|NCT05057273|Drug|Active comparator|Biologic
76058849|NCT05049733|Drug|CBD 1mg/Kg|Participants will ingest soft gel tablets containing CBD 1mg/Kg
76058850|NCT05049733|Drug|CBD 2mg/Kg|Participants will ingest soft gel tablets containing CBD 2mg/Kg
76058851|NCT05049733|Drug|CBD 4mg/Kg|Participants will ingest soft gel tablets containing CBD 4mg/Kg
76058852|NCT05049733|Drug|Placebo CBD|Participants will ingest soft gel tablets containing placebo for CBD
76058853|NCT05047718|Biological|COVID-19 vaccine Pfizer (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
76058854|NCT05047718|Biological|COVID-19 vaccine Pfizer (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
76058855|NCT05047718|Biological|COVID-19 mRNA Vaccine Moderna (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
75446546|NCT02567799|Radiation|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
75888352|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)|A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.
75888353|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
76058856|NCT05047718|Biological|COVID-19 mRNA Vaccine Moderna (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
76058857|NCT05027633|Drug|Pembrolizumab|given by IV
76058858|NCT05027633|Drug|Docetaxel|given by IV
76058859|NCT05027633|Drug|Cisplatin|given by IV
76058860|NCT05027633|Drug|Carboplatin|given by IV
75446547|NCT02552953|Drug|CYC065|
75596238|NCT01104493|Biological|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
75596239|NCT01104493|Other|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
75596240|NCT01104415|Drug|Telotristat etiprate|Telotristat etiprate capsules orally three times daily.
75596241|NCT01099579|Drug|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to <10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to <15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to <25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
76058861|NCT04993183|Behavioral|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
75446548|NCT02532452|Biological|Viral Specific VST Infusion|"VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~Blood adenovirus PCR ≥ 1,000~Blood CMV PCR ≥ 500~Blood EBV PCR ≥ 9,000~Plasma BKV PCR >1,000~Plasma JC Virus PCR > 1,000~Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~Evidence of PML or other CNS infection due to JC virus"
76058862|NCT04983108|Other|No Intervention|No intervention. This is an observational Study
75446549|NCT02466321|Procedure|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
75740536|NCT00057811|Drug|cyclophosphamide|Given IV
75888354|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
76058863|NCT04975893|Biological|mRNA-1647|No investigational product will be administered in this extension study.
76058864|NCT04966559|Drug|Placebo treatment|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
76058865|NCT04966559|Drug|Naldemedine 0.2 MG Oral Tablet|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
76058866|NCT04954820|Drug|Lutathera|2 additional infusions of Lutathera®
76058867|NCT04936529|Dietary Supplement|β-glucan|"Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with ~2 weeks on, ~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with ~2 weeks on, ~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1."
75740537|NCT00057811|Drug|methotrexate|Given IV or IT
76058868|NCT04936529|Drug|GM-CSF|"Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1."
76058869|NCT04936529|Biological|OPT-821|Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.
76058870|NCT04920253|Device|Study Device Debridement|debritom+ water jet debridement
75446550|NCT02465398|Procedure|Fracture Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Fracture System
75740538|NCT00057811|Drug|rasburicase|Given IV
75596242|NCT01099579|Drug|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
75596243|NCT01099579|Drug|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
75596244|NCT01099579|Drug|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
75596245|NCT01103713|Drug|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
75596246|NCT01103479|Behavioral|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
75740539|NCT00057811|Drug|leucovorin calcium|Given IV or orally
75740540|NCT00057811|Drug|prednisone|Given IV or orally
75740541|NCT00057811|Drug|methylprednisolone|Given IV or orally
75740542|NCT00057811|Biological|filgrastim|Given subcutaneously
75740543|NCT00057811|Biological|rituximab|Given IV
75740544|NCT00057811|Drug|cytarabine|Given IT
75740545|NCT00057811|Drug|etoposide|Given IV
75888355|NCT03701217|Drug|Eltrombopag|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
75888356|NCT02052258|Drug|Oxytocin|
76058871|NCT04920253|Device|SOC Debridement|Sharp Scalpel
76058872|NCT04907643|Device|PICO G2 4k|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
76058873|NCT04898621|Dietary Supplement|75g fructose solution|Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.
75740546|NCT00057811|Drug|vincristine sulfate|Given IV
76058874|NCT04898621|Dietary Supplement|150g fructose solution|Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.
75888357|NCT03701139|Procedure|posterior capsulotomy|After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.
76058875|NCT04860752|Device|Transcatheter Aortic Valve Implantation (TAVI)|Subjects will undergo TAVI
75740547|NCT00057811|Drug|hydrocortisone sodium succinate|Given IT
75740548|NCT00057811|Other|laboratory biomarker analysis|Correlative studies
75740549|NCT03502148|Drug|PRV111 (Cisplatin Transmucosal System)|Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
75740550|NCT03957811|Other|Whole body Vibration exercise|Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
75888358|NCT03701139|Procedure|laser capsulotomy|A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
75888359|NCT02053740|Drug|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
75888360|NCT02053740|Drug|Routine western medicine|
75740551|NCT01090999|Other|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
75888361|NCT03702543|Behavioral|SymTrend, Inc.|Use of SymTrend and Apple Health apps with feedback and strategies provided.
76058876|NCT04851613|Drug|Afuresertib|The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
76058877|NCT04835168|Drug|BT-11 low|Oral
76058878|NCT04835168|Drug|BT-11 high|Oral
75446559|NCT02339571|Procedure|Biospecimen Collection|Undergo blood sample collection
75740552|NCT02530801|Drug|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
75740553|NCT02530801|Drug|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
75740554|NCT01091077|Dietary Supplement|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
75740555|NCT01094275|Drug|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
75740556|NCT05355506|Device|Application|Knowledge & record
75888362|NCT02053818|Drug|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
75888363|NCT02053818|Drug|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
75888364|NCT03702387|Procedure|standard intravenous regional anesthesia (IVRA) with reapplication of esmach|his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
76058879|NCT04835168|Drug|Placebo|Oral
76058880|NCT04812743|Behavioral|Colorectal Health Research Champions|"20 Colorectal Health Research Champions will be recruited from the VCU Massey Cancer Center Catchment Area (66 counties in Virginia) The Colorectal Health Research Champions will receive training in four specific areas during group educational sessions.~Colorectal Health Research Champions will be asked to disseminate the four defined messages on at least two occasions to small groups in their social network in a venue of their choice (house chats, faith-based, social gatherings, family gatherings, etc.). We ask that each CHRC participant host 2 chats with 5-10 people in attendance at each chat. We expect that at least 200 participants will be invited to chats through 10 CHRCs."
76058881|NCT04801420|Biological|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
76058882|NCT04801420|Biological|Placebo|PBS (Phosphate Buffered Saline)
76058883|NCT04783272|Diagnostic Test|Photoacoustic Computed Tomography (PACT) Imaging|PACT will be completed prior surgery.
76058884|NCT04746794|Behavioral|Population-level screening|"The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified."
76058885|NCT04726462|Other|Functional exercises|The exercise program is planned as a function-oriented exercise program aimed at improving balance skills, increasing lower extremity muscle strength and functions.
76058886|NCT04726462|Other|Posture exercises|The exercise program was planned by focusing on posture exercises in order to increase the postural smoothness of the participants.
76058887|NCT04723264|Behavioral|Food protocols|"Participants will engage in several activities (i.e. offering a variety of foods and age appropriate games, etc.) regarding eating behaviors.~Participants will be asked to videotape interactions using a secure system. An alternative option may be provided if this videotaping is not acceptable."
76058888|NCT04706676|Behavioral|Integrative neuromuscular training (INT)|"Integrative neuromuscular training (INT), contains a multifaceted range of developmentally appropriate activities that incorporate general and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility. INT can be camouflaged as games and play or performed as structured strength and conditioning program, depending on the participant's age, motor skill level and diagnosis. The intervention is designed to enhance health- and skill-related components of physical fitness.~Parents or guardians will receive education in conducting INT at home, alongside an exercise-kit consisting of training equipment corresponding to the child's age and fitness level (fitness ropes, medicine ball, dumbbells).~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
75446560|NCT02339571|Procedure|Computed Tomography|Undergo CT scan
75446561|NCT02339571|Procedure|Echocardiography|Undergo ECHO
75446562|NCT02339571|Biological|Ipilimumab|Given IV
75446563|NCT02339571|Procedure|Magnetic Resonance Elastography|Undergo MRI
75596247|NCT01103479|Behavioral|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
75596248|NCT01103323|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
75446564|NCT02339571|Procedure|Multigated Acquisition Scan|Undergo MUGA
75596249|NCT01103323|Drug|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
75446565|NCT02339571|Biological|Nivolumab|Given IV
75596250|NCT01103323|Other|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
75596251|NCT01103245|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg daily
75596252|NCT01103245|Drug|Aliskiren 150 mg (ALI 150)|Aliskiren 150mg daily
75596253|NCT01103245|Drug|Spironolactone (SPL 25)|spironolactone 25mg daily
75596254|NCT01103245|Drug|Aliskiren 300 mg (ALI 300)|Aliskiren 300mg daily
75596255|NCT01103245|Drug|Spironolactone 50 mg (SPL 50)|Spironolactone 50 mg daily
76058889|NCT04706676|Behavioral|Active control group: home-based training program|"The active control group is offered a home-based training program consisting of combined aerobic, strength and stretching exercises. Further, they will receive monthly motivational consultations, as described below, concerning the training program. The use of the home-based training program will be monitored through exercise journals.~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
75596256|NCT04307875|Diagnostic Test|Blood pressure measurement (sphygmomanometer)|measuring blood pressure with standard sphygmomanometer
75446566|NCT02339571|Biological|Sargramostim|Given SC
75446567|NCT02306954|Biological|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
75446568|NCT02306954|Radiation|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
75446569|NCT02299141|Drug|Nintedanib|
75596257|NCT04307875|Diagnostic Test|Blood glucose measurement|measuring blood glucose using standard measurement devices
75596258|NCT04307875|Other|psychometric tests|WHODAS 2.0, PHQ-9, CAPS-5
75596259|NCT02878837|Drug|Dexmedetomidine|
75596260|NCT02878837|Drug|Midazolam|
75596261|NCT02880007|Radiation|External Beam Radiation Therapy|45 Gy pelvis / 25 fr
75596262|NCT02880007|Radiation|PDR Brachytherapy|1 puls/hour ; 12 Gy / day
75596263|NCT02880007|Drug|Cisplatin|increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
76058890|NCT04706676|Behavioral|motivational counseling session|"Each child and their parents will participate in a monthly 30-minute motivational counseling session to adjust the intervention and training program according to the child's physical capacity and preferences. Further, the session will determine potential barriers towards performing physical exercise using the Self-efficacy for Exercise Scale.~The sessions are based on the principles in Self-Determination Theory that includes a spectrum of external and internal motivation factors for engaging in exercise. Each session will provide guidelines to increase the general activity levels and adjust the intervention according to the child's preferences and presence of symptoms."
76058891|NCT04699968|Drug|SHR-1701，Famitinib|SHR -1701, Intravenous ；Famitinib, oral
75596264|NCT01098487|Drug|Eltrombopag olamine|Thrombopoietin receptor agonist
75596265|NCT02880085|Drug|Local anesthetic|local injection
75596266|NCT00591890|Drug|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
76058892|NCT04699968|Drug|SHR-1701|SHR -1701, Intravenous
76058893|NCT04667455|Diagnostic Test|Biomarker analysis at enrolment|Controls will be compared to cases using biomarker analyses and non-invasive cardiac imaging techniques to improve risk stratification of cases
76058894|NCT04667455|Diagnostic Test|Biomarker analyses throughout the study|Controls will be compared to cases using biomarker analyses and non-invasive cardiac imaging techniques to improve risk stratification of cases
76058895|NCT04629521|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
76058896|NCT04628026|Drug|Venetoclax|Induction cycle 1: Venetoclax will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-12 (after a 1/2/3 day ramp-up phase) (as determined during run-in phase) Induction cycle 2: Venetoclax will be administered orally QD, daily dose: 100mg/200mg/300mg, patients not in CR/CRi: days 1-12 (after a 1/2/3 day ramp-up phase) or patients in CR/CRi: days 1-14 (without ramp-up) (as determined during run-in phase) Consolidation phase: Venetoclax will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-14 (as determined during run-in phase)
75740557|NCT01094353|Procedure|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
75596267|NCT02878993|Device|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
75596268|NCT01098097|Biological|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
75596269|NCT01098097|Drug|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
75740558|NCT01094353|Procedure|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
75740559|NCT01089205|Drug|Metformin|
75740560|NCT02866682|Drug|Prograf|Brand Drug for the duration of the study.
75740561|NCT02866682|Drug|Tacrolimus|Generic
75740562|NCT02822924|Procedure|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
75740563|NCT01089439|Drug|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
75740564|NCT01089439|Drug|Placebo|placebo
75740565|NCT02774642|Behavioral|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
75740566|NCT02774642|Behavioral|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
75446586|NCT02088060|Drug|Cannabidiol|Cannabidiol capsules
76058897|NCT04628026|Drug|Placebo|Induction cycle 1: Placebo will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-12 (after a 1/2/3 day ramp-up phase) (as determined during run-in phase) Induction cycle 2: Placebo will be administered orally QD, daily dose: 100mg/200mg/300mg, patients not in CR/CRi: days 1-12 (after a 1/2/3 day ramp-up phase) or patients in CR/CRi: days 1-14 (without ramp-up) (as determined during run-in phase) Consolidation phase: Placebo will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-14 (as determined during run-in phase)
76058898|NCT04628026|Combination Product|Standard chemotherapy|"Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6, and daunorubicin 60 mg/m2 IV (days 1-3). Patients >60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6 without daunorubicin.~Consolidation chemotherapy option 1 consists of one cycle of mitoxantrone (10mg/m2 IV) and etoposide (100mg/m2 IV) (ME) days 1-5 (patients ≤60 yrs) or days 1-3 (patients >60 yrs). Consolidation chemotherapy option 2 consists of intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are >60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients >60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment."
76058899|NCT04628026|Other|Autologous stem cell transplantation|Busulfan/Cyclophosphamide will be administered as conditioning regime. Patients may proceed to autologous HCT when they have reached CR/CRi/MLFS after at least two cycles of chemotherapy and performance status permits continuation with high-dose chemotherapy. Venetoclax will not be added to or given after the conditioning regimen.
75446587|NCT02088060|Drug|Olanzapine|Olanzapine capsules
75596270|NCT01097863|Device|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
75888365|NCT03031899|Procedure|Biopsy|rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
75446588|NCT02088060|Drug|Placebo Cannabidiol|Placebo cannabidiol capsules
75596271|NCT01097863|Device|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
75596272|NCT01097863|Device|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
75596273|NCT04407572|Other|Serum zinc, vitamin d vitamin b12 levels .|Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.
75596274|NCT04406090|Other|Mechanical Trombectomy|Stent retriever for treatment of cerebral arterial occlusions
75740567|NCT00992030|Drug|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
75740568|NCT00992030|Radiation|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
75740569|NCT00992342|Drug|PF-03893787|oral solution, 5 mg, QD for 14 days
75740570|NCT00992342|Drug|PF-03893787|oral solution, 15 mg, QD for 14 days
75888366|NCT03031899|Diagnostic Test|Rose Bengal|the lesions stained positive were subjected to biopsy
75888367|NCT03031899|Diagnostic Test|toluidine blue|the lesions stained positive were subjected to biopsy
75740571|NCT00992342|Drug|PF-03893787|oral solution, 50 mg, QD for 14 days
75740572|NCT01976390|Drug|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
75740573|NCT01976390|Drug|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
75740574|NCT00570713|Drug|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
75740575|NCT00570713|Drug|Placebo|As per package insert.
75446589|NCT02088060|Drug|Placebo Olanzapine|Placebo olanzapine capsules
75446590|NCT02078427|Biological|ADVATE|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
75446591|NCT02078427|Biological|ADYNOVI|Antihemophilic Factor (Recombinant) Pegylated
75446592|NCT02073968|Drug|Carboplatin|Given IV
75446593|NCT02073968|Procedure|Computed Tomography|Undergo PET-adjusted IMRT
75446594|NCT02073968|Radiation|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
75596275|NCT04404920|Other|Questionnaire|"Novel questionnaire about oral symptoms (Oral symptom assessment scale / OSAS), and validated questionnaire about physical and psychological symptoms (Memorial Symptom Assessment Scale / MSAS)."
75888368|NCT03700983|Dietary Supplement|Nutri-PEITC jelly|an edible, easily to swallow nutritious gel containing a bioactive compound PEITC
75446595|NCT02073968|Drug|Paclitaxel|Given IV
75888369|NCT03700905|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor including neck dissection according to standard of care
75446596|NCT02073968|Procedure|Positron Emission Tomography|Undergo PET-adjusted IMRT
75888370|NCT03700905|Radiation|Adjuvant radio(-chemo)therapy|Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)
75888371|NCT03700905|Drug|Neoadjuvant Nivolumab|Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
75888372|NCT03700905|Drug|Adjuvant Nivolumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
76071967|NCT03565575|Behavioral|Interactive tablet-based quiz|"Intervention participants play an interactive tablet based quiz including the following information components:~Risks of HIV infection under different scenarios such as between two hypothetical individuals and with different behaviours.~Interactive counselling on key facts around PrEP, its usability and local availability~All individuals will have the option to sign up for contact by a nurse from the health clinic to discuss PrEP further and make an appointment for a visit. Participants will also be given a PrEP referral letter which they can present directly at one of the participating study clinics to begin PrEP. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
75446597|NCT02073968|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
75446598|NCT01983241|Biological|Alpha-1 MP|
75446599|NCT01983241|Other|0.9% Sodium Chloride for Injection, USP|
75596276|NCT04405232|Other|Non-interventional|Observational study
75446600|NCT01696994|Other|Laboratory Biomarker Analysis|Correlative studies
75446601|NCT01696994|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
75446602|NCT01696994|Procedure|Ultrasound Imaging|Undergo TVU
75446603|NCT01696981|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
75446604|NCT01696981|Procedure|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
75446605|NCT01696968|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
75446606|NCT01696968|Procedure|X-Ray Imaging|Undergo a chest x-ray
75596277|NCT04404452|Device|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart and lung sounds using electronic stethoscopes
75596278|NCT04328636|Drug|Nebulized Magnesium Sulfate|Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
75596279|NCT04328636|Drug|Intravenous Magnesium Sulfate|Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
75596280|NCT04403828|Other|Survey|a cross-sectional, online survey-based study administered to Dentist in Egypt. A 20-item questionnaire developed and distributed using Google Forms.
75596281|NCT02893826|Drug|EG-1962 (nimodipine microparticles)|
75596282|NCT02893826|Drug|Enteral Nimodipine|
75596283|NCT00591968|Device|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
75596284|NCT00592046|Drug|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
75446609|NCT01247207|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
75446612|NCT01155050|Device|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
75596285|NCT02893280|Drug|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
75596286|NCT02893436|Procedure|Surgery with tracheal intubation curarisation|
75888373|NCT03700905|Drug|Adjuvant Nivolumab and Ipilimumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
75888374|NCT03702153|Procedure|Abdominal wall reconstruction|The repair of abdominal wall defects with polypropylene mesh
75888375|NCT03700827|Other|Resistance Training|High-intensity Resistance Training Group
75888376|NCT03700827|Other|Aerobic Training|Aerobic Interval Training Group
75888377|NCT03700749|Drug|2% chlorhexidine + non-coated suture|"Interventions:~2% alcoholic chlorhexidine non-coated suture"
75888378|NCT03700749|Drug|2% chlorhexidine + coated suture|"Interventions:~2% alcoholic chlorhexidine triclosan coated suture"
75888379|NCT03700749|Drug|10%povidone-iodine + non-coated suture|"Interventions:~10% povidone-iodine non-coated suture non-coated suture"
75888380|NCT03700749|Drug|10%povidone-iodine + coated suture|"Interventions:~10% povidone-iodine triclosan coated suture"
75888381|NCT03086369|Drug|Olaratumab|Administered IV
75888382|NCT03086369|Drug|Nab-paclitaxel|Administered IV
75888383|NCT03086369|Drug|Gemcitabine|Administered IV
75888384|NCT03086369|Drug|Placebo|Administered IV
76071968|NCT03555708|Other|Physical Therapy|Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
75446613|NCT01155050|Behavioral|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
75596287|NCT02893358|Drug|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
75446614|NCT01155050|Device|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
75740576|NCT00570713|Drug|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
75888385|NCT03700593|Device|Single Port Robotic Colorectal Surgery|Single Port Robotic Colorectal Surgery
75888386|NCT00101582|Drug|Placebo|
76071969|NCT03554473|Drug|M7824|Arm A &amp; B: 2400mg IV over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
75446615|NCT01148563|Device|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
75446616|NCT01050504|Other|Cytology Specimen Collection Procedure|Correlative studies
75446617|NCT01050504|Other|Laboratory Biomarker Analysis|Correlative studies
75446618|NCT00906997|Procedure|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
75446619|NCT00906997|Procedure|Colonoscopy|Every 10 years, with sedation.
76071970|NCT03554473|Drug|Topotecan|Arm B: 1 mg/m2 IV over 30 minutes days 1-5 on a 3-week cycle.
75740577|NCT04002440|Combination Product|AMIA with SHARESOURCE Connectivity Platform|The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
75740578|NCT04002440|Device|HomeChoice PRO|Usual care
75446621|NCT00587886|Behavioral|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
75596288|NCT02893358|Drug|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
75616384|NCT00900796|Other|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
75740579|NCT05294939|Dietary Supplement|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
75740580|NCT05294939|Dietary Supplement|Control product consumption|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, 90g of carbohydrates should be consumed every hour.
75888387|NCT00101582|Drug|palifermin|
76071971|NCT03554473|Drug|Temozolomide|Arm C and progressive disease patients on Arm A: 200 mg/m2 PO days 1-5 on a 4-week cycle
75616385|NCT01213082|Drug|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
75888388|NCT00101582|Drug|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m^2 on Days 1, 22, and 43.
76058900|NCT04628026|Other|Allogeneic stem cell transplantation|Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
75740581|NCT00773045|Other|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
75446622|NCT00587886|Behavioral|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
75446623|NCT00002540|Other|Laboratory Biomarker Analysis|Correlative studies
75446624|NCT00002540|Procedure|Medical Examination|Undergo DRE
75740582|NCT00556946|Drug|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
75769590|NCT01071720|Drug|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
75888389|NCT00101582|Radiation|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
75888390|NCT05326373|Drug|Stannous fluoride|brush twice daily with stannous fluoride toothpaste for 8 weeks
75446625|NCT00002540|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
75462890|NCT01869465|Behavioral|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
75462891|NCT01869491|Drug|Compound Sodium Alginate Double Action Chewable Tablets|2 tablets four times daily
75462892|NCT01869491|Drug|Matching placebo tablets|2 tablets four times daily
75462893|NCT01869504|Device|Balloon-tipped intercostal drain|Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
75462894|NCT01869517|Other|intrastromal corneal ring segments (Keraring) implantation|
75462895|NCT01869517|Other|Intrastromal corneal continuous ring (Myoring) implantation|
75462896|NCT01869543|Other|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
75462897|NCT01869543|Other|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
75462898|NCT01869556|Drug|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
75462899|NCT01869556|Drug|Ergot|Ergot 0.25mg IV
75462900|NCT01869556|Drug|Carboprost|Carboprost 0.25mg IM
75462901|NCT01869569|Drug|Pregabalin|At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
75462902|NCT01869569|Drug|Placebo|At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
75462903|NCT01869608|Procedure|oral glucose tolerance test 2 days post-partum|Screening for type 2 diabetes after gestational diabetes mellitus.
75462904|NCT01869621|Drug|Metformin|6 days treatment with metformin to steady-state
75462905|NCT01869660|Behavioral|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
76058901|NCT04614454|Device|High Frequency Impulse Therapy|The home TENS unit device is an at-home transcutaneous electrical nerve stimulation unit in that it provides non-invasive transcutaneous electrical impulses to reduce pain. It is a small, wearable device that utilizes both high and low frequencies to create a nerve-block effect based on the same gating theory.
76058902|NCT04614454|Device|High Frequency Impulse Therapy - Sham|This device looks like the experimental device but does not provide the electrical current.
76058903|NCT04605861|Drug|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
76058904|NCT04605861|Drug|Placebo|Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
75446626|NCT01682486|Device|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
75446627|NCT01682486|Procedure|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
75446628|NCT01682577|Drug|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
75740583|NCT00776867|Drug|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
75740584|NCT02556515|Procedure|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
75740585|NCT02556515|Procedure|Total joint replacement|Total joint replacement
75888391|NCT03370107|Device|rTMS|Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
75888392|NCT01379105|Other|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
76058905|NCT04575220|Other|12 weeks of bicycle exercise|Subjects will conduct monitored exercise, three sessions per week for 12 weeks.
75596289|NCT04390802|Drug|5-aminolevulinic acid|Study participants who are deemed surgical candidates for management of their pituitary lesion will drink 20mg/kg 5-ALA 2-4 hours preoperatively. They will then be taken to the operation room and undergo general anesthesia. Intraoperative blood draw may occur from lines places for anesthesia purposes at any time during the operation. In alignment with the neurosurgeon's practice and discretion, the sella will be accessed and opened. During the surgical exploration of the sella, the surgeon will attempt to identify the pituitary mass. The location of the tumor will be assessed using the blue-light filtered microscope or endoscope. These steps will be documented photographically during the operation. A biopsy of the fluorescent region will be taken to confirm pituitary adenoma histopathology. The tumor will then be maximally resected. The tumor sample will be used for further clinical testing as part of the patient's routine care.
75616386|NCT01213082|Drug|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
76058906|NCT04569266|Other|Specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
75446629|NCT01682577|Drug|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
75446630|NCT01682707|Procedure|laryngoscopy|tracheal intubation with two different techniques, track light and laryngoscopy.
75446631|NCT01682707|Procedure|track light|
75740586|NCT02556515|Device|Elektra prosthesis|Elektra prosthesis
75740587|NCT05356286|Device|epidural electrical stimulation|Electrical spinal cord stimulation will be used to modulate respiratory function during general anesthesia.
75446632|NCT01683227|Behavioral|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
75446633|NCT01683227|Behavioral|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
75446634|NCT01683240|Device|cholangioscopy (Frimberger)|cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
75596290|NCT04328480|Drug|Colchicine|"The colchicine dosage schedule will vary according to the following scenarios:~In patients not receiving Lopinavir/Ritonavir~Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~The next day 0.5 mg bid for 14 days or until discharge.~In patients receiving Lopinavir/Ritonavir~Loading dose of 0.5 mg (day 1)~After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube."
75740588|NCT00780377|Drug|Bradykinin|Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
75740589|NCT05219942|Drug|Glargine|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR > 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR <60 dose = 0.19 IU/kg/day.
75888393|NCT01379105|Other|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
75888394|NCT02166944|Drug|tamoxifen 40 mg daily for one year|both arms with riluzole daily
76071972|NCT03552783|Behavioral|FFL + Cognitive Behavioral Therapy|Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.
75446635|NCT01683357|Procedure|Hepatectomy|"Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.~If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).~Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy."
75446636|NCT01683578|Other|Variable Ventilation|
75446637|NCT01683643|Behavioral|SBIRT|Screening, brief intervention, and referral to treatment.
75446638|NCT01683643|Behavioral|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
75446639|NCT01683669|Other|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
75446640|NCT01683669|Other|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
75446641|NCT01683760|Drug|Fluconazole|Prophylactic fluconazole administration in VLBW infants
75740590|NCT05219942|Other|normal saline|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous saline instead of insulin glargine will be given in the control group.
75740591|NCT04002206|Other|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
75740592|NCT04002206|Other|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
75740593|NCT04002284|Drug|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
75446642|NCT01683851|Device|Isolite System|A type of isolation system used in dentistry. It protects soft tissues, and also has a mouth prop, which helps keep mouth open.
75446643|NCT01684124|Other|conservative O2 therapy|target lower O2 saturation
75446644|NCT01684124|Other|standard care|
75446645|NCT01684280|Genetic|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
75446646|NCT01684488|Behavioral|YRI|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 10 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
75740594|NCT00669617|Drug|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
75596291|NCT04328480|Other|Local standard of care|Local standard of care for COVID-19 SARS moderate /high-risk patients
75740595|NCT00669617|Drug|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
75740596|NCT00669617|Drug|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
76071973|NCT03552783|Behavioral|Fathers for a Lifetime (FFL) only|"The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~Personal responsibility~Personal responsibility to your child~Responsibility to your family and community"
76071974|NCT03548792|Radiation|RSA radiostereometric analysis|Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
75596292|NCT04382222|Procedure|prenatal ultrasound|prenatal cardiac ultrasound
75596293|NCT00592202|Device|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
75596294|NCT04375358|Biological|Blood and urine samples|To measure the clearance of creatinine, urea, potassium, magnesium, sodium, chlorine...
75462906|NCT01869673|Device|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
75740597|NCT00669617|Drug|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
76058907|NCT04569266|Other|No specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
76058908|NCT04564443|Other|Medaxis Debritom+|Advanced micro fluid jet therapy to clean and stimulate wound
75596295|NCT04374266|Diagnostic Test|physical examination, and computerized tomography|physical examination, and computerized tomography was performed during routine follow-up
75446647|NCT01684488|Other|EducAid educational programming|EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
75446648|NCT01684514|Device|Confocal laser endomicroscopy|"Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image."
75446649|NCT01684644|Behavioral|New Forest Parenting Programme|
75740598|NCT00669617|Drug|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
75446650|NCT01684644|Behavioral|Treatment as usual|
75446651|NCT01684813|Drug|Prasugrel.|Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
75596296|NCT02893124|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
75596297|NCT04370678|Behavioral|Change in preference to surgery under COVID-19 pandemic.|Under the COVID-19 pandemic all arthroscopic procedures were cancelled. We wished to describe if patients experienced a change in preference to surgery under this period.
75740599|NCT00669617|Drug|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
75740600|NCT04000724|Behavioral|Text Messaging (Text+Step)|Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
75740601|NCT04000724|Behavioral|WebApp (App+Step)|Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
75740602|NCT04000724|Behavioral|Information/No Step|Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
75740603|NCT03979352|Drug|empagliflozin|Treatment with empagliflozin 25mg orally once a day
75740604|NCT03979352|Device|artificial pancreas|Insulin delivery via a closed loop single-hormone artificial pancreas system.
75769591|NCT01258192|Drug|albumin-bound paclitaxel plus cisplatin|neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
76058909|NCT04564443|Other|Sharp Surgical Debridement|Scalpel or Curette to clean and debride wound
76058910|NCT04564443|Other|Additional Outer Dressing Application|Application of moisture retentive dressing, and a multi layer compression dressing
76071975|NCT03548792|Behavioral|Clinical comparison|ActivePAL, walking speed
76071976|NCT03539731|Drug|Fluorine F 18 DASA-23|Given IV
75596298|NCT04369508|Radiation|permanent brachytherapy|"Briefly, the patient had a general anesthesia and PPB was performed by using the real-time intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon."
75740605|NCT00780767|Device|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
76058911|NCT04564443|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
76058912|NCT04564443|Other|Fibracol Wound Dressing|Application of a collagen alginate dressing
76058913|NCT04560140|Behavioral|Narrative and Skills-building Intervention|The intervention is grounded in Narrative Theory and Bandura's principles of Self-efficacy and Outcome Expectation. It will consist of eight individual sessions over six months delivered by a facilitator. Participants will be facilitated to narrate their survival experiences and rebuild core life skills.
76058914|NCT04553822|Other|Assisted autogenous drainage group (DAA)|DAA, is used when the patient is not able to perform this technique autonomously and is assisted by the physiotherapist. Its greatest utility is in infants and preschoolers. The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes. The physiotherapist must ensure that the child takes 2 to 3 controlled breaths, close to the residual level, with the objective that the expiratory flow displaces the secretions, located distally, towards the central airways.
76058915|NCT04553822|Other|Group prolonged slow expiration (ELPr)|Passive expiratory aid technique applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
75446652|NCT01684813|Drug|Clopidogrel|Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
75446653|NCT01684982|Device|everolimus eluting stent|experimental arm of a comparison between drug eluting stents
75446654|NCT01684982|Device|sirolimus eluting stent|control arm of a comparison between drug eluting stents
75446655|NCT01685034|Biological|"Allergy immunotherapy (allergy shots)"|
76058916|NCT04553822|Other|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer. Once the nebulization is finished, you will wait 30 minutes in a closed room.
75446656|NCT01685151|Drug|Ramelteon SL (Dose 1)|Ramelteon tablets for sublingual administration
75446657|NCT01685151|Drug|Ramelteon SL (Dose 2)|Ramelteon tablets for sublingual administration
76058917|NCT04549532|Behavioral|Targeted Multidomain|Participants in the T-MD intervention group will be prescribed targeted interventions to address each individual's symptoms, impairments, and functional limitations in the areas of anxiety/mood, cognitive, migraine/headache, ocular, vestibular, sleep, autonomic. The length of the intervention period will be 4 weeks or until RTA, whichever comes first.
76071977|NCT03539731|Procedure|Positron Emission Tomography|Undergo PET scan
75446658|NCT01685151|Drug|Placebo|Placebo
75446659|NCT01685307|Dietary Supplement|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
75596299|NCT04327778|Procedure|Music Therapy|Automate music therapy every two weeks
75446660|NCT01685489|Drug|Docetaxel, PSK®|
75446661|NCT01685489|Drug|Docetaxel, Placebo|
75446662|NCT01685775|Procedure|Transvaginal/transumbilical|
75446663|NCT01685775|Procedure|Needlescopic with 3 trocars|
75446664|NCT01686087|Behavioral|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
75446665|NCT01686087|Procedure|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
75446666|NCT01686100|Procedure|No touch technique|The vein graft is harvested with its surronding tissues.
75446667|NCT01686100|Procedure|Conventional technique|The vein graft is stripped from its surrounding tissues.
75446668|NCT01686139|Biological|ABMD-MSC|10-20 x 10^6 cells/20mL
75446669|NCT01686178|Behavioral|Anti-smoking social marketing campaign|We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
75446670|NCT01686204|Other|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
75446671|NCT01686204|Other|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
75446672|NCT01686386|Drug|Bendamustine|Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
75596300|NCT02892968|Procedure|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
75446673|NCT01686386|Drug|Lenalidomide|Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
75596301|NCT02892968|Procedure|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
76058918|NCT04549532|Behavioral|Behavioral Management|1.3. Usual Care (Controls) Group Participants randomized to the usual care (control) group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
75596302|NCT04368338|Diagnostic Test|COVID-19 RT-PCR|Polymerase chain reaction tests after reverse transcription for the detection of viral Covid-19 RNA (RT-PCR)
75596303|NCT04368338|Procedure|lung ultrasound|lung ultrasound is standard practice to diagnose acute respiratory failure in Emergency room
75740606|NCT00773201|Drug|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
75888395|NCT03238677|Behavioral|Speech Motor Chaining without Biofeedback|These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
76058919|NCT04530630|Drug|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.
76058920|NCT04528511|Device|Continuous Electronic Monitor|All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
76058921|NCT04506606|Procedure|Afferent block|Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
76058922|NCT04469764|Drug|Abemaciclib|Given PO
76058923|NCT04469764|Drug|Anastrozole|Given PO
76058924|NCT04469764|Drug|Letrozole|Given PO
75596304|NCT02893046|Other|No intervention|
75596305|NCT04359992|Other|Extra blood sample|3 extra blood samples at day 0, 2 and 7
76058925|NCT04460794|Behavioral|Ballet-inspired workouts|8 weeks, delivered by volunteers with a self-directed resource package
75596306|NCT04358042|Other|Brief Psychiatric Rating Scale|The Abbreviated Psychiatric Rating Scale is a clinical scale for measuring symptomatic change in psychiatric inpatients for various conditions. It includes an accurate and complete description of the major characteristic symptoms. It is based both on patient responses and on observations made during the interview by the clinician. The usual reference period is the last two weeks.
75596307|NCT04358042|Other|Depression, Anxiety and Stress Scale|"evaluation of 3 dimensions of psychological distress: depression, anxiety and stress. The scale consists of 21 items and the patient is instructed to choose for each item the one that best corresponds to his or her experience over the past week, on a scale of 0 (does not apply to me at all) to 3 (applies entirely to me, or the vast majority of the time). A score is calculated for each dimension according to a predefined rating."
76058926|NCT04460794|Other|Usual care|Usual care and general recommendations on basic stretching and leg exercises for stroke survivors
76058927|NCT04457895|Behavioral|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)"
75446674|NCT01686386|Drug|Dexamethasone|Phase I and Phase II Dexamethasone fixed dose 40 mg/die
75446675|NCT01686594|Drug|8-methoxypsoralen|8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
75446676|NCT01686776|Other|123 I-HSA + 125 I HSA|Compare and validate the method of measuring albumine turnover rate
75446677|NCT01687192|Biological|HPV prophylactic vaccine Gardasil|3 injections: at Inclusion visit then 2 and 6 months after.
75462907|NCT01869673|Device|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
75462908|NCT01869712|Other|Cupping therapy|
75462909|NCT01869712|Other|Acupuncture|
75740607|NCT05355194|Other|Kinesiotape|"Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles."
76058928|NCT04457895|Other|no intervention|no yoga session at home and no yoga -therapeutic educatuion session
76058929|NCT04457310|Drug|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
75740608|NCT05355194|Other|Pelvic Tilts|Patients will be asked to lie in a supine position with legs bent and toes facing forward. Afterward, they will be instructed to pull their belly inwards while pushing pelvis towards the ceiling and keep hip muscles tightened. This position will be maintained for 5 seconds with 3 sets of 20 repetitions. Pelvic tilts must be performed throughout the menstrual cycle.
76058930|NCT04457310|Drug|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
76058931|NCT04457310|Drug|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
76058932|NCT04457310|Drug|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
76058933|NCT04457310|Other|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
76058934|NCT04432922|Other|Hospitalized Patients for COVID-19 Infection|Face to face semi-directed interviews about perceptions, representations and experiences of septic isolation, including nine opened-questions.
76058935|NCT04416737|Other|Ultra-rapid insulin|Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
76058936|NCT04414202|Procedure|tumorectomy with axillary dissection (sentinel lymph node)|All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
76058937|NCT04414202|Radiation|per-operative partial irradiation|20 Gy of per-operative partial irradiation at the tumor site during the surgery
76058938|NCT04381468|Drug|Pepinemab|Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
76058939|NCT04381468|Drug|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
75616387|NCT01213082|Drug|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
75740609|NCT03905174|Device|custom made device|surgical intervention to place custom made orthopaedic device
76058940|NCT04376333|Behavioral|Cognitive-Behavioral Treatment|Cognitive-behavioral coping skills training
76058941|NCT04376333|Behavioral|Individualized Assessment and Treatment Program|Experience-sampling based cognitive behavioral coping skills assessment and training
76058942|NCT04376333|Other|Standard Conservative Care|Standard conservative dental care for orofacial pain
75740610|NCT05064527|Device|wearable biosensor|The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.
75888396|NCT03238677|Behavioral|Biofeedback|Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
75888397|NCT03238677|Behavioral|Distributed Practice|2 sessions per week for 10 weeks
76058943|NCT04364607|Drug|Neostigmine|Participants will receive 0.5 mg IM neostigmine
75446678|NCT01687465|Procedure|Argon laser trabeculoplasty|With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
76058944|NCT04364607|Drug|NaCl 0.9%|Participants will receive IM NaCl 0.9% as a placebo
76058945|NCT04348383|Drug|Defibrotide|6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
76058946|NCT04348383|Drug|Placebo|Placebo 250 cc every 6 hours for 7 or15 days
76071978|NCT03529695|Behavioral|Standard HVP Curriculum|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
75446679|NCT01687465|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
75446680|NCT01687517|Drug|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
75446681|NCT01687556|Other|topical EGCG application on acne|two times application of topical EGCG on acne lesion
75462910|NCT01869738|Device|MGuard Prime|
75462911|NCT01869738|Device|(BMS/DES)|
75616388|NCT04073290|Drug|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
75616389|NCT04073290|Drug|Placebo oral tablet|Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
75616390|NCT04073290|Drug|Lactulose 667 milligram/milliliter Oral Solution|Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
75888398|NCT03238677|Behavioral|Massed --> Distributed Practice|Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
75888399|NCT03540836|Drug|Relacorilant (3x100 mg softgel capsules)|A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
75740611|NCT05064527|Behavioral|Treatment as usual (TAU)|Patients will receive treatment as usual at the child and adolescent mental health center. TAU can range from waitlist to one session of psychoeducation to group or individual psychotherapy to medication.
75740612|NCT05064527|Behavioral|Exposure and response prevention (ERP)|One ERP session will be offered in Week 0 and Week 8.
75740613|NCT05355038|Behavioral|lifestyle modification (dietary modification)|low glycemic index diet the researcher gave detail information about (importance of LGI diet, component of food, number of meals and snake, example of food taken in breakfast, lunch, dinner and snake in between, food allowed and not allowed). After that, the researcher required from the woman to make an example of food for one day according to her income level, if correction of the content of food needed, the researcher will explain this point again.
75740614|NCT05355038|Behavioral|lifestyle modification (physical activity)|health teaching about choose between two types of exercise to be selected according to the ability of GDM women to perform : brisk walking or seated arm exercise or selected both. Brisk walking should be performed for at least half an hour three time /week, while, seated arm exercise done three time after each meal for10 minute in each time. The researcher given a detail information about both types and its importance in decreasing blood glucose level, also how to perform and what should be done in case of appearance of fatigue manifestation during exercise, and the women have choice for perform both or selected one to perform according to your health condition.
75462912|NCT01869751|Drug|Prucalopride|Treatment with prucalopride for slow-transit constipation
75740615|NCT05355038|Behavioral|lifestyle modification( self glucose monitoring)|self-glucose monitoring the researcher explain the important of monitoring blood glucose level and instruct the women about how to perform self- glucose measuring, recording way of the result in schedule and to bring this result in the next antenatal visit. The women who have digital blood glucose monitoring instructed to measure it at least 5 time/day. while, the women who didn't have digital blood glucose monitoring measure went to nearest pharmacy to measure blood glucose at least one time per day especially when the woman felt the signs and symptoms of hypo or hyperglycemia and recorded the result in paper or sent the result in whatsapp for the researcher if you have whatsapp application. In addition to give the woman instruction about sings symptoms of hypoglycemia and hyperglycemia and the proper ways for management
75740616|NCT00777413|Drug|Minocycline 100mg Tablets|
75740617|NCT05199974|Procedure|Midline abdominal closure|Abdominal Closure in Emergency Midline Laparotomy
75740618|NCT05189912|Device|Specimen retrieving bag|Specimen retrieving bag was used to retrieve resected polyps.
75740619|NCT05189912|Behavioral|Sucking polyps to the instrument channel port|Remove the colonoscope suction valve and connect a polyp trap to suction onto the instrument channel port.
75740620|NCT02556827|Other|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
75888400|NCT03540836|Drug|Relacorilant (3x100 mg hard-shell capsules)|A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
75888401|NCT03540836|Drug|Relacorilant (6x50mg hard-shell capsules)|A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
75888402|NCT05274737|Device|Novel sling|The novel sling was designed and created by the principal investigator to address these concerns of the traditional slings that are currently available for postsurgical protection and immobilization after shoulder surgery. It is anticipated that the novel sling will allow the patient to be more active and more comfortable while still providing a safe healing environment after a shoulder injury or shoulder surgery.
76058947|NCT04332926|Other|Tobacco product administration and assessment|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
76058948|NCT04316286|Procedure|Tele-multidisciplinary care|Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists
76058949|NCT04316286|Other|Standard care|Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
75446682|NCT01687751|Drug|Dexmedetomidine|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~The study drug will be started at a rate of 1.0 mL/hr.~The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
75596308|NCT04358042|Other|Impact of Event Scale-Revised|is a 22-item self-questionnaire that measures perceived stress in reference to a traumatic event during the previous 7 days. Each item is rated on a scale ranging from 0 (not at all) to 4 (extremely) and 3 sub-scores of post-traumatic symptoms are calculated: Revivification, Avoidance, Psychophysiological Activation, as well as a total score of severity of the state of stress. Acute Stress Disorder (ASD) and Post-Traumatic Stress Disorder (PTSD) share the same symptoms, the former lasting between 3 days and one month, while the latter is diagnosed when symptoms persist beyond one month. Since the exposure to the stressful event will have occurred less than a month ago, this questionnaire here will help identify a state of acute stress. A total R-ESI score equal to or greater than 33 suggests a significant level of symptoms
75740621|NCT02556827|Device|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
75888403|NCT05274737|Device|Traditional abduction sling|An abduction sling is the most common type of sling utilized to protect patients after rotator cuff surgery and total shoulder of arthroplasty and can be considered the current standard of care.
75888404|NCT02255630|Other|Cycling Exercise|
75888405|NCT02163122|Procedure|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
75888406|NCT02163122|Other|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
75888407|NCT02163122|Biological|Cat allergen (FelD1)|
75888408|NCT04507269|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
75446683|NCT01687751|Drug|Midazolam|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~The study drug will be started at a rate of 1.0 mL/hr.~The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
75740622|NCT02556827|Device|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
75888409|NCT04507269|Drug|Placebo|Saline given by subcutaneous injection
75888410|NCT02162264|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
75888411|NCT03700515|Drug|Erythropoietin|Subjects receive weekly infusions of EPO
76058950|NCT04301622|Device|Primary Knee implants|Primary knee arthroplasty
76058951|NCT04299828|Other|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the role of immune cells in coagulopathy.
75740623|NCT02556827|Device|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
75740624|NCT05162690|Drug|Dapagliflozin 10 milligram|10mg per day of Dapagliflozin will be given to the patients
75740625|NCT05162690|Other|Placebo|Metformin DPP4 inhibitors
75740626|NCT00773435|Biological|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
75740627|NCT00773435|Other|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
75740628|NCT00992576|Drug|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
75740629|NCT00992576|Drug|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
75740630|NCT00777569|Drug|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
75740631|NCT00777569|Drug|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
75888412|NCT03700515|Drug|Placebo|Subjects receive weekly infusions of saline
76058952|NCT04294472|Drug|MAU868|MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
76058953|NCT04294472|Other|Placebo|250 mL D5W placebo IV to be labeled to match that of MAU868
76058954|NCT04285476|Diagnostic Test|Signature of microRNA for patients with bethesda classification 3, 4 or 5|If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.
76058955|NCT04283409|Other|Graded activity|Exercise therapy using principles of cognitive behavioral therapy and education
76058956|NCT04283409|Other|Motor Control Exercises|Exercise therapy using principles of motor control and motor learning and education
76058957|NCT04263792|Drug|[18F]fluoropropyl-trimethoprim|[18F]Fluoropropyl-Trimethoprim, also known as [18F]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).The use most relevant to this protocol is for imaging bacterial infection in human subjects. The parent compound, trimethoprim (TMP) is a well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder. An immediate clinical use for TMP radiotracers is imaging of pathologic bacteria that are the cause of human infection.
76058958|NCT04261361|Behavioral|CBCBT intervention|8 group CBT sessions and 4 weekly follow-up calls
76058959|NCT04261361|Behavioral|Adherence counseling|All participants in both CBCBT and ETAU groups will have one session of Life-Steps, a stand-alone CBCBT intervention designed to improve adherence to medical recommendations and individualized DM self-management goals.
76058960|NCT04261361|Behavioral|Psycho-education package|Printed materials of a DM self-management education program will be delivered to both the CBCBT and ETAU groups.
76058961|NCT04233918|Drug|Evinacumab|Part A: Single IV dose Part B & C: IV dose Q4W
76058962|NCT04230564|Drug|azacitidine|Patients taking azacitidine
76058963|NCT04230564|Drug|venetoclax|patients taking venetoclax
76058964|NCT04230564|Drug|glasdegib|patients taking glasdegib
76058965|NCT04230421|Device|The Monsenso system with feedback|See description under intervention
76058966|NCT04230421|Device|The Monsenso system without feedback|See description under intervention
76058967|NCT04230421|Device|CAG Bipola and mood monitoring only|See description under intervention
75446684|NCT01687777|Biological|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
75446685|NCT01687777|Biological|OrthADAPT|
75740632|NCT00777569|Drug|Nicotine Lozenge|4 mg nicotine lozenge
76058968|NCT04210089|Device|Total Contact Soft Cast|"The total contact soft cast will consist of wound dressing of choice to the ulcer and a plantar foot accommodative offloading felt pad for all foot ulcers, with 4x4 gauze pads added to the arch to create a rocker bottom for metarsophalangeal joint (MPJj) and plantar heel ulcers. The next layers will be:~Unna boot from MPJs to just below the knee,~Sterile Kerlix from MPJs to just below the knee~Sterile 4 inch Kling wrap from the MPJs to just below the knee,~Four inch coban from MPJs to just below the knee, and~Ace wraps from MPJs to just below the knee"
76058969|NCT04210089|Device|Cam Boot|Removable Diabetic cam boot will be used in patients willing and capable of using it. If patient does not want to use Diabetic cam boot then surgical shoe or regular shoe would be options.
76058970|NCT04190862|Drug|E-CEL UVEC|Injection of E-CEL UVEC
76058971|NCT04187040|Procedure|Study intervention: 3-step hand hygiene technique|"3-step hand hygiene technique:~Covering all surfaces of the hands (based on own judgement)~Rotational rubbing of fingertips in the palm of the alternate hand~Rotational rubbing of both thumbs"
76071979|NCT03529695|Behavioral|Obesity Prevention|Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
75740633|NCT00777647|Other|Sugar-sweetened soft drink|One litre a day for six months.
75888413|NCT05113277|Behavioral|Tonic Immobility Psychoeducation (TIP)|TIP is a 45-minute computerized psychoeducation intervention aimed at addressing maladaptive cognitions and emotions associated with TI while using educational and behavioral techniques commonly used in the treatment of trauma-related disorders. Throughout the psychoeducation program vignettes will be presented to clarify concepts and promote participant engagement. In addition, practice exercises and rating scales will be integrated, where applicable, to increase the interactive nature of the program. The following modules will be addressed in the TI psychoeducation intervention: education, myth busting, and behavioral experiments.
75446686|NCT01687881|Other|Chiropractic|Chiropractic Spinal Manipulative Therapy
75446687|NCT01687881|Other|Sham Chiropractic|Sham manipulation
75446688|NCT01688362|Biological|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
75596309|NCT04358042|Other|Connor-Davidson Resilience Scale 10 items (CD-RISC 10)|"Self-questionnaire composed of 10 items, evaluating the resilience capacities of patients. Resilience may act as a moderator against the symptoms of PTSD. This instrument uses a 5-point Likert-type response scale ranging from 0 Not true at all to 4 True most of the time."
75596310|NCT04327856|Procedure|Cataract Surgery|The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
75462913|NCT01869790|Other|Different fat types|Saturated, monounsaturated fats
75462914|NCT01869803|Drug|gemtuzumab ozogamicin|Given IV
75462915|NCT01869803|Other|laboratory biomarker analysis|Correlative studies
75462916|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
75596311|NCT04352426|Other|Exercise Test|Tests were conducted to evaluate exercise capacity.
75462917|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
75462918|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
75596312|NCT04349540|Other|no intervention|no intervention
75740634|NCT00777647|Other|Aspartame-sweetened soft drink|One litre a day for six months.
75740635|NCT00777647|Other|Semi-skimmed milk|One litre a day for six months
75740636|NCT00777647|Other|Water|One litre a day for six months.
75740637|NCT00777725|Device|FibroScan|Liver scan, similar to an ultrasound.
75740638|NCT02556593|Radiation|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
76058972|NCT04187040|Procedure|Control intervention: 6-step hand hygiene technique|"6-step hand hygiene technique (according to the WHO Guidelines on Hand Hygiene in Health Care, First Global Patient Safety Challenge):~Rubbing hands palm to palm~Palm to palm with fingers interlaced~Right palm over left dorsum with interlaced fingers and vice versa~Back of fingers to opposing palms with fingers interlocked~Rotational rubbing of left thumb clasped in right palm and vice versa~Rotational rubbing backwards and forwards with clasped fingers of right hand in left palm and vice versa"
76058973|NCT04182022|Behavioral|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.
76058974|NCT04182022|Behavioral|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
75446689|NCT01688362|Drug|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
75446690|NCT01688375|Drug|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
75596313|NCT04348682|Diagnostic Test|Positron Emission Tomography (PET) Imaging|A single dose activity of 5 mCi (accepted range of 3-7 mCi) of 68Ga-PSMA-11 will be intravenously administered to patient as a bolus injection. After 50-100 minutes of uptake time, the patient will undergo a whole body (skull to mid-thighs) PET/CT imaging.
75596314|NCT04343456|Procedure|Salvage surgery with massive debulking|For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.
75596315|NCT04340648|Device|Vital GlucoseDetect|11 time points for blood glucose measurements over 210 min including the ingestion of a standardized meal 30 min after the first blood glucose measurement.
75596316|NCT04340726|Procedure|One time abutment|
75596317|NCT04336280|Other|Symptom questionnaire|Arabic version of the International Prostate Symptom Score: Known and validated questionnaire to quantify and qualify the severity of symptoms of the lower urinary tract
75446691|NCT01688427|Behavioral|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
75888414|NCT05113277|Behavioral|Health Education Training (HET)|The Healthy Education Training intervention was developed as a 45-minute online intervention that provides education about physical health habits that can impact mental health, such as diet, exercise, and sleep. This intervention has been used in prior clinical trials to control for effects of general education, general coping techniques, and use of technology. Participants in past clinical trials have reported that HET is engaging and beneficial. However, HET is not expected to have an effect on the main symptom outcomes of the current study (guilt, shame, PTSD symptoms).
76058975|NCT04170660|Diagnostic Test|Diagnostic test|During a vascular check-up usually prescribed, an additional blood sample is taken to allow the determination of the sFlt1/PlGf ratio.
76058976|NCT04162678|Procedure|Biospecimen Collection|Undergo collection of blood via HD-SCA fluid biopsy
75596318|NCT04336280|Diagnostic Test|Urodynamics|Urodynamics: the standard diagnostic tool, it includes invasive recording of the pressure that is produced when the bladder muscle contracts via pressure sensors introduced in the urinary bladder through special types of urethral catheters.
75596319|NCT04334252|Other|Questionnaire|Questionnaire
76058977|NCT04162678|Other|Laboratory Biomarker Analysis|Correlative studies
76058978|NCT04162678|Procedure|Liquid Biopsy|Undergo collection of blood via HD-SCA fluid biopsy
75596320|NCT02892812|Biological|Pneumococcal conjugate vaccine|
75596321|NCT00592670|Drug|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
75740639|NCT02556593|Radiation|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
75888415|NCT03702075|Other|self-administered program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
75888416|NCT03700359|Drug|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
75888417|NCT03700359|Drug|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
75888418|NCT03700359|Drug|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
75888419|NCT02047955|Procedure|Shoulder Arthroplasty|
75888420|NCT02167178|Other|Administration of 0.9% NaCl solution|Volunteers administered 0.9% NaCl solution in 250ml boluses
75596322|NCT00592670|Drug|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
75596323|NCT00622856|Behavioral|psychological intervention|Psychological intervention
75596324|NCT00622856|Behavioral|Diabetes education|5 sessions with diabetes nurse
75888421|NCT02167178|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
75888422|NCT02167178|Other|Measurement of microvascular blood flow|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
75888423|NCT02167178|Other|Administration of gelofusine|Volunteers administered gelofusine in 250ml boluses
75888424|NCT01379027|Behavioral|Pure self-help Internet CBT for depression|Internet, CBT, Depression
75888425|NCT01379027|Behavioral|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
75888426|NCT01379027|Behavioral|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
75888427|NCT03625089|Drug|Atorvastatin|"Group 1 patients will be prescribed statin when FRS > 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom."
75446692|NCT01688427|Behavioral|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
75446693|NCT01688453|Behavioral|Standard care management|The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
75462919|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
75596325|NCT00592748|Radiation|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
75596326|NCT04327232|Drug|Spironolactone 25mg|Mineralocorticoid Receptor Antagonists
75596327|NCT04327232|Drug|Placebo oral tablet|Placebo
75596328|NCT00593138|Drug|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
75888428|NCT01378949|Drug|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
75888429|NCT01378949|Drug|Morphine|Morphine 1 mg/cc
75888430|NCT03701997|Device|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
75888431|NCT03540446|Device|First Relief Treatment|To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
75596329|NCT00593216|Device|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
75888432|NCT01381133|Behavioral|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
75446694|NCT01688453|Behavioral|The strengthened care management|"The strengthened care management is the addition of the standard care management and of additional interventions.~The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.~The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation."
75446695|NCT01688778|Behavioral|Telemedicine|"Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.~Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks."
76058979|NCT04162678|Other|Medical Chart Review|Review of medical chart
76058980|NCT04161781|Drug|18F-BMS-986229 Injection|Single injection prior to scan
75446696|NCT01689064|Procedure|Stamm Approach|
75446697|NCT01689064|Procedure|Posterior Septectomy|
75446698|NCT01689077|Other|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
75446699|NCT01689753|Device|TEGO connector®|
75596330|NCT04326998|Procedure|solvent|using solvent (GuttaClear) in procedure
75596331|NCT04326998|Procedure|non-solvent|non-solvent
75596332|NCT00593294|Behavioral|Physical exercise|45 minutes each day for three times/week for 6 months
75596333|NCT00593294|Drug|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
75596334|NCT00593294|Dietary Supplement|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
75596335|NCT00593528|Device|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
75596336|NCT00593528|Device|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
76058981|NCT04161781|Drug|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
75446700|NCT01689753|Drug|Trisodium citrate|
75446701|NCT01690026|Behavioral|Motivation interviewing based brief intervention|
75596337|NCT00593528|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
75596338|NCT04327076|Device|Using robot system of endotracheal intubation and airway cleaning|"Using the control screen to control the machine, the device first extends the intubation guide rail to the mouth of the patient's oropharyngeal ventilation tube, first sends the magnetic guide strip into the epigarynx, and at the same time, extends the magnetic anchoring unit to the patient's neck. The external magnetic anchoring unit can sense and attract the magnet on the magnetic guide strip. At this point, the machine can send the guide strip into the respiratory tract.~Then, the control machine sends the tracheal intubation into the airway along the guide strip, and completes the balloon inflation to complete the endotracheal intubation operation.~During or after the operation, when the sputum suction operation is needed, the parameters of the sputum suction machine are set on the operation screen to start the sputum suction operation, and the suction robot completes the sputum suction operation automatically."
75596339|NCT02892578|Other|electrocardiogram|
75446702|NCT01690026|Behavioral|Standard Intervention|
75462920|NCT01869855|Procedure|Subdural Drainage|
75596340|NCT00593996|Other|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
75596341|NCT00594074|Other|white wine|3.25 ounces of white wine twice a day with lunch and dinner
75596342|NCT00594152|Drug|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
76058982|NCT04161781|Diagnostic Test|PET/CT Scan|Whole-body PET/CT (80 mA)
76058983|NCT04143269|Device|Non-invasive transcutaneous vagus nerve stimulation|Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.
76058984|NCT04143269|Device|Sham vagus nerve stimulation|"Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.~The sham device produces a slight vibrating sensation, but do not provide any vagal nerve activation"
75596343|NCT00594698|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
75596344|NCT00594776|Device|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
75446703|NCT01690039|Drug|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
75446704|NCT01690065|Drug|Nilotinib+AD induction|"• Post-remission consolidation chemotherapy~4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).~Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation"
75596345|NCT00595010|Behavioral|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
75596346|NCT00595166|Device|Vaginal Speculum Sheath|Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
75446705|NCT01690091|Drug|Metformini hydrochloridum (Siofor 1000 tbl, Berlin)|"Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
75596347|NCT00595244|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
75596348|NCT00595322|Other|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains < 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
75596349|NCT00595712|Procedure|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
75596350|NCT00595712|Procedure|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
75596351|NCT00596024|Dietary Supplement|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
75596352|NCT00596024|Dietary Supplement|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
75596353|NCT00596180|Drug|HBOT|total body exposure to greater than atmospheric pressure oxygen
75596354|NCT00596258|Drug|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
75596355|NCT02892266|Other|Assessment of adherence, mental health, behavioral, quality of life and biological constructs|
75596356|NCT00596336|Drug|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
75596357|NCT00596336|Drug|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
75596358|NCT00596414|Procedure|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
75446706|NCT01690091|Drug|placebo|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
75446707|NCT01690104|Drug|Rifampicin|
75596359|NCT00596414|Drug|placebo|
75596360|NCT00596414|Drug|midazolam|
75446708|NCT01690104|Drug|Placebo|
75462921|NCT01869855|Procedure|Subperiosteal Drainage|
75596361|NCT00596414|Drug|midazolam + pethidine|
75596362|NCT00596492|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
75596363|NCT00596492|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
75596364|NCT00596570|Procedure|PCI|Percutaneous coronary interventiom
75596365|NCT00596648|Drug|XL184|Capsules administered orally daily
75596366|NCT00596648|Drug|erlotinib|Tablets administered orally daily.
76058985|NCT04104529|Other|Biological collection|The biological collection will also include samples of blood samples collected before and during treatment.
75888433|NCT01381133|Behavioral|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
76058986|NCT04104529|Other|tumor collection|Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
75596367|NCT00596726|Device|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
75740640|NCT02556593|Drug|erlotinib|erlotinib 150mg daily
76058987|NCT04085536|Procedure|Dental and medical treatment|If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
76058988|NCT04085172|Drug|Guanfacine hydrochloride (TAK-503)|In both Part A and Part B of the study participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 52 weeks.
76058989|NCT04085172|Drug|Atomoxetine hydrochloride|Participants in Part A of the study will receive Atomoxetine hydrochloride oral capsule once daily for 52 weeks.
76058990|NCT04085172|Other|Placebo|In Part A participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks.
76058991|NCT04081545|Drug|Opioid Anesthetics|see arm/group description
75446709|NCT01690169|Drug|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
76058992|NCT04081545|Drug|Non Opioid Analgesics|see arm/group description
75596368|NCT00596804|Drug|veltuzumab|once weekly intravenous dosing for 4 weeks
76058993|NCT04076527|Drug|UDCA|Routine data is collected for UDCA therapy.
76058994|NCT04076527|Drug|Ocaliva|Routine data is collected for OCA therapy.
76058995|NCT04064697|Drug|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
76058996|NCT04063215|Biological|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
76058997|NCT04060251|Device|CyMedica e-vive™ System; CY-1000|"All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical."
75446710|NCT01690169|Drug|placebo|A single dose of oral placebo administered.
75596369|NCT00622934|Drug|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
76058998|NCT04060251|Other|iGetBetter telemedicine physical therapy|Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
76058999|NCT04048876|Drug|CC-90001|oral
76059000|NCT04048876|Drug|Placebo|oral
75596370|NCT00622934|Drug|placebo|placebo
75596371|NCT00596882|Other|Message Prime|Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
75596372|NCT00596882|Other|Message Prime|Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
75596373|NCT00597194|Procedure|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
75740641|NCT00535730|Biological|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
75740642|NCT00535730|Biological|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
75740643|NCT00535730|Biological|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
75740644|NCT00780923|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
75446711|NCT01690182|Dietary Supplement|Study test meal 1|Volunteers will be fed with a high volume, high energy density test meal.
75446712|NCT01690182|Dietary Supplement|Study test meal 2|Volunteers will be fed with a high volume, low energy density test meal
75446713|NCT01690182|Dietary Supplement|Study test meal 3|Volunteers will be fed with a low volume, high energy density test meal
75446714|NCT01690195|Drug|ABT-126|See arm description
76059001|NCT04036279|Procedure|Total Hip Arthroplasty|
76059002|NCT04001751|Behavioral|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga."
75888434|NCT01381133|Behavioral|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
76059003|NCT03976011|Device|Transcutaneous Laryngeal Ultrasonography|"TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.~The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments."
75446715|NCT01690208|Other|EMERALD|"Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule."
75446716|NCT01690208|Other|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment & explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
75446717|NCT01690221|Drug|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
75596374|NCT00597350|Dietary Supplement|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
75596375|NCT02892032|Behavioral|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
75446718|NCT01690221|Drug|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
75888435|NCT01381055|Drug|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
76059004|NCT03975959|Other|QMRP questionnaire|a single consultation for test and questionnaires for a duration of 20 minutes
76059005|NCT03967990|Other|Refined cornmeal flour|48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
76059006|NCT03967990|Other|50/50 refined cornmeal-bran mix|48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
75446719|NCT01690234|Procedure|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
75446720|NCT01690234|Procedure|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
75446721|NCT01690247|Drug|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
75446722|NCT01690247|Drug|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
75446723|NCT01690260|Drug|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
75446724|NCT01690260|Procedure|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
75446725|NCT01690286|Drug|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
75596376|NCT02892032|Behavioral|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
75888436|NCT01381055|Drug|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
75888437|NCT01380977|Behavioral|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
75888438|NCT02163278|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
76059007|NCT03967990|Other|Whole grain cornmeal flour|48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
75740645|NCT02556125|Device|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
75740646|NCT05354960|Other|Questionnaire validation|Validation and cultural adaption of the German version of the LIMB-Q
75740647|NCT00781001|Drug|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
75740648|NCT00992654|Drug|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
75740649|NCT02556047|Device|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N&S
75740650|NCT05252234|Other|Observation of hemodynamic status and post operative pain|No intervention
75740651|NCT00773591|Drug|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
75446726|NCT01690286|Drug|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
75446727|NCT01690286|Drug|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
75446728|NCT01690286|Drug|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
75888439|NCT02163278|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
75888440|NCT02167334|Device|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
75888441|NCT02167334|Procedure|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
75888442|NCT03122613|Dietary Supplement|Curcumin|3g of Curcumin per day
76059008|NCT03944785|Drug|XADAGO (safinamide)|XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
76059009|NCT03921424|Biological|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
76059010|NCT03921424|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
75446729|NCT01690312|Dietary Supplement|Fish Oil|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
75446730|NCT01690312|Dietary Supplement|Placebo|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
75446731|NCT01690325|Drug|Docetaxel|
75446732|NCT01690325|Drug|Trastuzumab|
75446733|NCT01690325|Drug|Bevacizumab|
75446734|NCT01690325|Drug|Epirubicin|
75446735|NCT01690325|Drug|Cyclophosphamid|
75446736|NCT01690338|Drug|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
75446737|NCT01690338|Drug|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
75446738|NCT01690338|Drug|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
75446739|NCT01690351|Drug|PF-05089771|Oral dispersion TS formulation- fasted
75888443|NCT03122613|Drug|Placebo|3g of Curcumin Placebo per day
75888444|NCT03700281|Behavioral|Messaging|The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.
75446740|NCT01690351|Drug|PF-05089771|Capsules TS formulation- fasted
75446741|NCT01690364|Other|MEP monitoring with continuous infusion of vecuronium during general anesthesia|MEP monitoring with continuous infusion of vecuronium during general anesthesia
75446742|NCT01690364|Other|MEP monitoring with continuous infusion of cisatracurium during general anesthesia|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
75446743|NCT01690377|Biological|PDC or myDC|PDC or myDC; first patient 0.3 * 10E6 PDC; second and third 1 * 10E6 PDC; fourth and fifth 3 * 10E6 PDC.
75446744|NCT01690390|Drug|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
75446745|NCT01690390|Drug|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
75446746|NCT01690403|Drug|rifapentine (M000473)|"Pharmaceutical form:tablet~Route of administration: oral"
75446747|NCT01690403|Drug|EFZ EMT TDF|"Pharmaceutical form:tablet~Route of administration: oral"
75446748|NCT01690416|Procedure|Traditional palpation technique|
75446749|NCT01690416|Procedure|Ultrasound DNTP|
75446750|NCT01690429|Device|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
75446751|NCT01690442|Behavioral|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
75888445|NCT03700281|Behavioral|Incentive|Participants will be eligible for a gift card to a local grocery store chain as an incentive for obtaining an influenza vaccine
75888446|NCT03630575|Procedure|Umbilical cord blood and hair collection|At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
75596377|NCT00597662|Device|polylactide-caprolactone-trimethylenecarbonate copolymer|Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
75740652|NCT00992810|Procedure|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
75596378|NCT00597662|Device|Icodextrin 4%|1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
75888447|NCT03540368|Drug|Tranexamic acid injection|Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
75888448|NCT03540368|Other|Placebo|Administering placebo or sodium chloride 0,9% intravenously
75888449|NCT02162342|Other|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
75446752|NCT01690442|Behavioral|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
75740653|NCT00992810|Procedure|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
75740654|NCT00995306|Drug|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks"
75446753|NCT01690468|Drug|Triciribine|Triciribine (15, 25, 30, 35, or 45 mg/m^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
75740655|NCT00992888|Device|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
75740656|NCT05351372|Radiation|Ultra-low dose protocol|
75740657|NCT05351372|Radiation|Standard dose protocol|
75446754|NCT01690468|Drug|Carboplatin|Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
75446755|NCT01690494|Behavioral|PACT|Couple-based behavioral HIV/STI preventive intervention
75446756|NCT01690494|Behavioral|TAU|Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
75596379|NCT00597974|Procedure|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
75596380|NCT00597974|Device|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson & Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson & Johnson), Wallstent® (Boston Scientific Medi-Tech)
75888450|NCT03086135|Device|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
75888451|NCT02162498|Behavioral|Feeding buddies|"The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.~The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations."
75446757|NCT01690507|Drug|Decitabine|20 mg/m²/day for 5 days
75596381|NCT00597974|Other|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
75596382|NCT00597974|Procedure|Angiography|(non-experimental) Coronary angiography
75596383|NCT00598052|Drug|Escitalopram|10mg/day
75740658|NCT00666965|Drug|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
75740659|NCT05350358|Device|LeMaitre Cardial Dialine II|Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
75740660|NCT00781157|Drug|Phenylephrine bolus|"The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose."
75769592|NCT01073436|Other|Discontinuation of therapy|Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
75446758|NCT01690507|Drug|Cytarabine|
75446759|NCT01690507|Drug|aclacinomycin|
75446760|NCT01690507|Drug|Granulocyte colony-stimulating factor|
75446761|NCT01690507|Other|HLA haploidentical mononuclear cells infusion|
75446762|NCT01690533|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
75446763|NCT01690559|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
75446764|NCT01690572|Device|Paclitaxel coated balloon catheter|Dilatation of the target lesion
75446765|NCT01690572|Device|"uncoated balloon catheter sprinter legend"|Dilatation of the target lesion
75446766|NCT01690585|Drug|Ferinject 1000 mg|
75446767|NCT01690585|Drug|Sodium chlorure 0,9 %|
75462922|NCT01869881|Drug|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
75888452|NCT03700125|Procedure|ECMO resuscitation|Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
76059011|NCT03921424|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
75446768|NCT01690598|Drug|Veliparib|Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
76059012|NCT03915912|Behavioral|Mindfulness meditation|The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
76059013|NCT03896230|Drug|Ketamine Injectable Product|Three different doses of ketamine will be administered.
76059014|NCT03878316|Drug|Instranasal Oxytocin|Intranasal Oxytocin - concentrated formulation - 35 IU per dose
76059015|NCT03861117|Procedure|Assisted strategy|Daily spontaneous breathing trial (SBT) with 7 cmH2O pressure support and 5 cmH2O positive end-expiratory pressure are performed to assess weanability. In case of success, a SBT with T-piece is performed to determine if the patients is at high risk of extubation failure. In this case and/or in the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
76059016|NCT03861117|Procedure|Non assisted strategy|Daily spontaneous breathing trials (SBT) with T-piece are performed to assess weanability. In the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
76059017|NCT03860571|Drug|Placebo|Oral tablet
76059018|NCT03860571|Drug|BT-11|Oral tablet
76059019|NCT03854929|Drug|Ciprofloxacin|"Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor"
75596384|NCT04207814|Biological|biological sample|biological samples will be taken from the subjects included
75596385|NCT00598130|Biological|Fleece|Fibrin Patch
75596386|NCT00598286|Drug|[18F]FMPEP-d2|
76059020|NCT03854929|Drug|Azithromycin|"Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis."
76059021|NCT03852628|Drug|2mg Buprenex and 380mg Vivitrol|Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX
76059022|NCT03852628|Drug|Placebo (SL pill qd, IM injection q4weeks)|Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
76059023|NCT03847142|Other|ASTHMAXcel mobile application|ASTHMAXcel is a mobile application (patient-facing) that delivers guideline-based asthma education.
76059024|NCT03847142|Other|Outpatient primary care|Usual care delivered through the outpatient primary care setting
75596387|NCT04326296|Drug|PD-L1 Monoclonal Antibody Combined With Lenalidomide|PD-L1 monoclonal antibody was administered by intravenous drip every 3 weeks.Lenalidomide was administered orally, 25mg once a day on days 1-21 of each repeat cycle of 28 days.
75596388|NCT04328324|Procedure|Endoscopy|Diagnostic upper Git endoscopy
75596389|NCT00598676|Device|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
75596390|NCT00598676|Device|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
75596391|NCT00598676|Device|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
75596392|NCT04326218|Other|Blood sample|"Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~anti-PLA2R1 and anti-THSD7A antibodies~anti-PLA2R1 and anti-THSD7A epitopes~HLA typing"
75596393|NCT00598910|Drug|Omacor|n-3 PUFA
75596394|NCT00598910|Drug|Placebo|Placebo
75596395|NCT04326374|Drug|TransCon hGH|Once weekly subcutaneous injection
75596396|NCT04326374|Drug|daily hGH|Once daily subcutaneous injection
75888453|NCT02163590|Other|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
76059025|NCT03833531|Behavioral|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
76059026|NCT03833531|Behavioral|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
75596397|NCT04326140|Device|mirror therapy|The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
76059027|NCT03826524|Drug|Epinephrine|Epinephrine 1mg 1:10000 (10cc) per dose
75446769|NCT01690598|Drug|Topotecan|2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
75446770|NCT01690611|Procedure|Treadmill Walking|"Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails."
75446771|NCT01690611|Other|Visual Feedback|Real time feedback regarding body motion while walking.
75446772|NCT01690624|Drug|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
75446773|NCT01690637|Drug|Oseltamivir phosphate suspension|
75446774|NCT01690637|Drug|Placebo|
75769593|NCT01260298|Device|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
75769594|NCT01326078|Drug|propofol|3 - 4 mg/kg IV, adjustment dose if necessary
75888454|NCT02163590|Other|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
75888455|NCT02163590|Other|Placebo|Intervention that mimics the experimental procedures
75888456|NCT02167568|Genetic|Genetic|
75888457|NCT02255396|Other|ESTRADIOL|
75888458|NCT02163668|Other|Yoga Group|8 months of Yoga training
75888459|NCT02167646|Procedure|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
75596398|NCT04326140|Device|robotic-assisted training|The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
75888460|NCT02163980|Drug|Caudal ropivacaine + normal saline|
75888461|NCT02163980|Drug|Caudal ropivacaine + dexmedetomidine|
75888462|NCT02164058|Device|TandemHeart System|
75888463|NCT02164058|Procedure|Percutaneous coronary intervention|
75888464|NCT02164136|Procedure|L-PANP-TME|
75888465|NCT02164136|Procedure|O-PANP-TME|
75888466|NCT01380821|Radiation|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
75446775|NCT01690650|Drug|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
75446776|NCT01690676|Dietary Supplement|Epicatechin|
75596399|NCT04326140|Device|sham mirror therapy|The mirror was masked. The intervention was the same as the mirror therapy.
75596400|NCT00599066|Device|study cases|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
75596401|NCT00599144|Procedure|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
75596402|NCT00599144|Procedure|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
75596403|NCT00599144|Procedure|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
75596404|NCT00599222|Biological|ranibizumab|0.5 mg intravitreal injection
75596405|NCT00599222|Procedure|TTT|Transpupillary thermotherapy (TTT)
75596406|NCT00599222|Procedure|Sham TTT|Sham Transpupillary thermotherapy (TTT)
75596407|NCT01326962|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
75596408|NCT01326728|Biological|Allogeneic stem cell transplant|Donors will undergo cell collection and recipients will receive cells (allotransplant).
75740661|NCT00995462|Behavioral|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
75740662|NCT00777959|Drug|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
75888467|NCT02162654|Procedure|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
75888468|NCT02162654|Procedure|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
75888469|NCT04733222|Other|Perturbation training|"The treadmill perturbation training will be performed on a computer-controlled treadmill. The perturbation will be induced by fast forward (slip) or backward (trip) accelerations of the treadmill at specific gait cycle timings. The perturbations will be delivered randomly to enhance the unpredictability. A ceiling-mounted body-harness ensures the safety of the participants.~Participants will be assigned to three initial sessions of treadmill slip- and trip-perturbation training on two days separated by a week and a booster-session after six months. On day 1, participants will first undergo a session 1 with 40 slip perturbations and then a session 2 with 40 trip perturbations. On day 2, participants will undergo a session 3 with 20 slip and 20 trip perturbations in random order. The booster-session after six months will be similar to session 3 (20 of each perturbation in random order)."
75888470|NCT04733222|Other|Treadmill walking|Participants allocated to the walking group will walk at a self-selected pace on a computer-controlled treadmill for the same amount of time as the treadmill perturbation training participants.
75888471|NCT01378793|Behavioral|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
75888472|NCT01378793|Behavioral|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
75888473|NCT02162888|Drug|Test Product (Bendamustine)|
75888474|NCT04494867|Device|Core Warming|Esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment.
75446777|NCT01690676|Dietary Supplement|Microcrystalline cellulose|
75446778|NCT01690689|Device|Implant surgery|surgery
75446779|NCT01690702|Drug|Epirubicin|
75446780|NCT01690702|Drug|nab-Paclitaxel|
75446781|NCT01690702|Drug|Cyclophosphamide|
75446782|NCT01690702|Drug|Docetaxel|
75446783|NCT01690741|Drug|Nerofe|Nerofe administered intravenously 3x/week
75888475|NCT04494867|Other|Standard of Care|Standard temperature management and treatment
75888476|NCT01569035|Drug|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
75446784|NCT01690754|Other|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
75446785|NCT01690767|Drug|2% lidocaine gel|Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
75446786|NCT01690767|Drug|Health Care Lubricating Jelly|Non-medicinal lubrication gel
75462923|NCT01869881|Drug|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
75740663|NCT00777959|Drug|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
75888477|NCT02762708|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
75888478|NCT02762708|Behavioral|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
75888479|NCT02762708|Drug|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
75888480|NCT02762708|Drug|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
75888481|NCT03699969|Radiation|Hypofractionated dose escalated VMAT|measure the local control, progression free survival and overall survival
75888482|NCT03841565|Biological|Daratumumab|Given IV
75888483|NCT03841565|Drug|Dexamethasone|Given PO
75888484|NCT03841565|Drug|Pomalidomide|Given PO
75888485|NCT02162966|Drug|High Dose Colistin|High Dose Colistin
75888486|NCT02162966|Drug|Standard Dose Colistin|Standard Dose Colistin
76059028|NCT03811769|Other|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
76059029|NCT03811769|Procedure|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
76059030|NCT03761446|Behavioral|Bed rest|The participant will remain in bed rest for 10 complete days.
75446787|NCT01690780|Drug|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
75446788|NCT01690780|Drug|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
75740664|NCT00777959|Drug|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
75446789|NCT01690819|Procedure|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
76059031|NCT03741426|Drug|Olaparib|Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
76059032|NCT03741426|Drug|Cediranib|Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
76059033|NCT03741426|Drug|Durvalumab|Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
76059034|NCT03707158|Behavioral|Therapist-led Face-to-Face Cognitive-Behavioral Therapy|Participants receiving face-to-face cognitive-behavioral therapy will participate in therapist-led, office-based or telehealth CBT treatment for up to 16 weeks. Sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
75446790|NCT01690819|Procedure|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
75446791|NCT01690832|Drug|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
75446792|NCT01690832|Drug|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
75596409|NCT00599378|Behavioral|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
75596410|NCT01097707|Drug|LY500307|Administered orally, daily for 24 weeks
75596411|NCT01097707|Drug|Placebo|Administered orally, daily for 24 weeks
75596412|NCT00599456|Dietary Supplement|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
75596413|NCT00599456|Dietary Supplement|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
75596414|NCT00599534|Drug|Montelukast|4 mg oral tablets
75596415|NCT00599534|Drug|Placebo|5mg tablets
75596416|NCT00599612|Drug|GW856553|A dose of 10mg GW856553 containing 50µCi of [14C]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
75740665|NCT00995540|Drug|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
75888487|NCT02839317|Biological|Biological|comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
75888488|NCT04697420|Procedure|Thoracic paravertebral block|Thoracic paravertebral block is a technique in which , the local anesthetic agent is injected in the paravertebral space to anesthetise the spinal nerves after emerging from the vertebral canal in order to provide analgesia in the thoracic and upper abdominal area .
76059035|NCT03707158|Behavioral|Digital Cognitive-Behavioral Therapy|Participants receiving digital cognitive-behavioral therapy will complete an online, largely self-administered CBT program for up to 16 weeks with 8 modules and adjunctive therapist phone support. Treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
76059036|NCT03691480|Procedure|simple exsufflation|simple exsufflation
76059037|NCT03691480|Procedure|Fuhrman catheter and ambulatory care|Fuhrman catheter and ambulatory care
76059038|NCT03636282|Behavioral|Hockey FIT Program (Immediate Delivery)|"Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools."
76059039|NCT03623633|Drug|denosumab|denosumab 60 milligrams subcutaneously every 6 months
76059040|NCT03623633|Drug|alendronate|alendronate 70 milligrams weekly
76059041|NCT03623633|Drug|raloxifene|raloxifene 60 milligrams daily
75446793|NCT01690845|Device|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
75446794|NCT01690858|Other|blood sample|blood sampling at inclusion and throughout pregnancy when pregnant
75596417|NCT00599690|Procedure|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
75596418|NCT00599768|Other|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
75596419|NCT02878759|Device|Wristbot|The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
75596420|NCT00600002|Biological|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
75740666|NCT00995540|Drug|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
75446795|NCT01690871|Drug|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
76059042|NCT03623347|Other|TMZ and BEV induction before chemoradiotherapy|New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.
76059043|NCT03602976|Drug|Ursodeoxycholic Acid|weight-based dosing
75446796|NCT01690884|Drug|Adenosine|Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
75446797|NCT01690897|Behavioral|Mindfulness-based treatment|The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
75740667|NCT00995540|Drug|Placebo|Placebo tid subcutaneous injection for 12 weeks
75740668|NCT00778037|Drug|Cyclobenzaprine hydrochloride 10 mg tablet|
75740669|NCT00778115|Drug|Loperamide HCl 2 mg and simethicone 125 mg tablets|
76059044|NCT03601247|Device|silicone gel|"Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day"
75740670|NCT02557217|Drug|NP202|Active
76059045|NCT03595072|Other|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
76059046|NCT03582579|Behavioral|Training in Virtual Reality|Action Video Game Based Training in Virtual Reality
75446798|NCT01690897|Behavioral|Sex therapy, education, and support treatment|The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
75740671|NCT02557217|Other|Placebo|Placebo
75446799|NCT01690936|Dietary Supplement|Almonds 43g/day|43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
75446800|NCT01690949|Drug|PUR118|inhaled PUR118, BID
75740672|NCT03474224|Device|Ev1000 Clinical Platform from Edwards Lifesciences|The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
75740673|NCT00993122|Drug|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
75740674|NCT00778193|Drug|Naproxen|1 tablet 500mg BID for 8 days
75740675|NCT00778193|Drug|Aspirin|1 tablet 81mg QD for 8 days
75740676|NCT00778193|Drug|Celecoxib|1 capsule 200mg QD for 8 days
75740677|NCT00778193|Drug|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
75888489|NCT04697420|Procedure|Transversus abdominis plane block|Transversus abdominis plane block is a technique is mostly done under ultrasound guidance to identify the transversus plane between the internal oblique muscle and the transverses abdominis muscle , the space in which the neurovascular supply of the anterior abdominal wall is present , and hence the injection of local anesthetic agent in this space results in anesthesia of the anterolateral aspect of the abdominal wall.
75740678|NCT00778193|Drug|Placebo|1 capsule BID for 8 days
75888490|NCT04919525|Device|TrainPain|Participants will use gamified sensory perceptual training technology once daily for 28 days. This will involve participants completing a 15 minute sensory training session using the provided technology and viewing a 5 minute web based pain management lesson; additionally, participants will receive daily text messages. The device used in this study has two components. The first is a video game that can be downloaded onto any smartphone device. The second component is two vibrational devices that can be attached to the arms, legs, upper back, and lower back.
75888491|NCT03540290|Procedure|Modification of the implant supported prostheses in order to facilitate oral hygiene|Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
76059047|NCT03582579|Behavioral|Training on a computer screen|Action Video Game Based Training on a computer screen
75446801|NCT01690962|Other|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
75446802|NCT01690962|Dietary Supplement|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
75446803|NCT01690975|Drug|Placebo|Placebo - single dose at start of each treatment period
75446804|NCT01690975|Drug|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
75446805|NCT01690975|Drug|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
75446806|NCT01691001|Drug|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
75446807|NCT01691001|Drug|normal saline|
75446808|NCT01691040|Drug|NOX-H94|intravenous injection
75446809|NCT01691040|Drug|Placebo solution|intravenous injection
75740679|NCT00778271|Drug|Gabapentin 400mg capsules|
75740680|NCT00778349|Drug|Metformin solution 100 mg/mL|
75740681|NCT00995618|Drug|Tranilast|Tranilast tablets, 300 mg, QD
75740682|NCT00995618|Drug|Febuxostat|Febuxostat Tablets, 40 mg, QD
75446810|NCT01691053|Drug|Spironolactone|50mg once daily
75446811|NCT01691053|Drug|Placebo|Placebo
75446812|NCT01691066|Behavioral|Infant Toddler Years PRT|
75446813|NCT01691118|Drug|Fimasartan|
75446814|NCT01691118|Drug|Antihypertensive treatment|
75446815|NCT01691131|Other|Exercise training|Comparison of high intensity exercise training on land versus water.
75446816|NCT01691157|Other|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
75446817|NCT01691157|Other|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
75446818|NCT01691170|Other|Stretching Hamstring|
75446819|NCT01691170|Other|Quadriceps Strengthening|
75888492|NCT01595321|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
75888493|NCT01595321|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine|Vaccine will be administered one day after cyclophosphamide (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
76059048|NCT03581227|Other|CAPTURE Tool|CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements
76059049|NCT03554174|Drug|Low Dose Psilocybin|0.1 mg/kg psilocybin capsule
76059050|NCT03554174|Drug|Placebo|microcrystalline cellulose capsule
76059051|NCT03554174|Drug|Medium Dose Psilocybin|0.3 mg/kg psilocybin capsule
75446820|NCT01691209|Device|Phoenix (BAY81-2996)|Topical formulation applied to the skin
76059052|NCT03540680|Other|Blood punction|"For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood."
75596421|NCT02891720|Device|Proteus Sensor System|The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
75596422|NCT00600158|Drug|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
75740683|NCT00995618|Drug|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
75596423|NCT00600158|Drug|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients > 70 kg)
75596424|NCT00600236|Procedure|blood sample|
75740684|NCT00778427|Drug|metformin hydrochloride 1000 mg tablets|
76059053|NCT03530969|Behavioral|Self-Efficacy Assessment|"Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training."
76059054|NCT03530969|Behavioral|UCLA Geriatrics Attitudes Scale|The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
76059055|NCT03530969|Behavioral|Course Evaluations|The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
76059056|NCT03530969|Behavioral|The Consultation and Relational Empathy (CARE) questionnaire|The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
75446821|NCT01691209|Drug|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
75596425|NCT04325984|Drug|Dexamethasone|To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
75596426|NCT02891642|Device|Immunomagnetic Detection|Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
75596427|NCT00600470|Behavioral|Doctor-office collaborative care (DOCC) management|DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
75740685|NCT00773981|Procedure|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
75888494|NCT01595321|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first vaccine dose (Arm 2) or within 6-10 weeks of surgery (Arm 1).
75888495|NCT01595321|Drug|FOLFIRINOX|FOLFIRINOX will be administered over 6 cycles starting at least 14 days after SBRT (Arms 1 and 2) and at least 28 days after the first vaccine (Arm 2).
75888496|NCT03699891|Device|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
75888497|NCT02167724|Other|Bucco-dental examination|
75596428|NCT00600470|Behavioral|Treatment as usual (TAU)|TAU involves routine care: psychoeducation and referral to outside providers.
75888498|NCT02167724|Other|Blood sample|
75740686|NCT03889886|Drug|SDP-4 Ophthalmic Solution (0.1%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
75740687|NCT03889886|Drug|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
75740688|NCT03889886|Drug|SDP-4 Ophthalmic Solution (3.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
75446822|NCT01691222|Device|Double lumen endotracheal tube tracheostomy|"Percutaneous tracheostomy in this study will be performed with the use of a dedicated double-lumen endotracheal tube.~The dedicated double-lumen endotracheal tube (Deas S.R.L, Italy) has an upper and a lower lumen. The upper one will be occupied by flexible fiberoptic bronchoscope while the lower one is exclusively dedicated to patient ventilation during the procedure. The lower lumen has a a semi-elliptical cross section. This tube will be placed in the patient airway with a direct laryngoscopy. After this intubation, a percutaneous dilatational tracheostomy will be performed with the standard techniques recognised in the literature."
75446823|NCT01691235|Device|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
75888499|NCT02167724|Other|Clinical and social questionnaire|
75888500|NCT03699813|Other|Comparison of two approaches to bleeding management|
75888501|NCT02164214|Drug|etanercept Treatment|
75888502|NCT03698565|Other|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
75888503|NCT03768947|Other|Heat therapy via hot water immersion|Participants will be asked to participate in a 4-week heat therapy intervention, which consists of ~12-15 visits (45 min each) of immersion in to a hot tub.
75888504|NCT03699735|Device|Bolero B90-SP|Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
76059057|NCT03530969|Behavioral|Consumer Assessment of Health Care Providers and Systems Program (CAHPS)|"Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)"
76059058|NCT03530969|Behavioral|Patient activation measure (PAM) scale|The PAM scale contains 22 items that assess patient engagement in their care process.
75596429|NCT04326062|Other|Main Study|The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.
75596430|NCT04326062|Other|PROM Study|For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
75596431|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
75740689|NCT03889886|Drug|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
75888505|NCT02164292|Procedure|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
75888506|NCT03722849|Drug|Adenosine Triphosphate|Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
75888507|NCT03722849|Drug|Capsaicin|Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
75888508|NCT03722849|Other|Functional Brain Imaging|Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
75888509|NCT03699657|Device|DSM|Monopolar RFA using dual switching mode (DSM)
75888510|NCT03699657|Device|SSM|Monopolar RFA using single switching mode (SSM)
75888511|NCT03699657|Device|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
75888512|NCT02170844|Drug|BIBR 1048 MS|
75888513|NCT02170844|Drug|Placebo of BIBR 1048 MS|
75596432|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
76059059|NCT03508440|Procedure|Intratympanic injection|Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
75596433|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
75596434|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
75596435|NCT00600626|Drug|biphasic insulin aspart|
75596436|NCT00600626|Drug|insulin NPH|
75888514|NCT03624465|Device|Levita Magnetic Surgical System|Device for use as a surgical tool.
76059060|NCT03508440|Drug|Prednisone|Oral Steroid
76059061|NCT03445845|Drug|Secukinumab|Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
76059062|NCT03445845|Drug|TNF blocker|"TNF blocker (originator or biosimilar) :~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~etanercept: 50mg per week in subcutaneous injection,~adalimumab: 40mg every other week in subcutaneous injection,~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow."
76059063|NCT03445845|Biological|blood specimen|Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
76059064|NCT03422861|Drug|Nabilone|Treatment regimen will involve nabilone capsule administration starting with 1mg BID orally first administered on POD #0. The patient will be continued on this medication for 72 hours
75446824|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, single, 1 day
75446825|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, twice a day, 14 days
75446826|NCT01691274|Drug|PF-04895162|Tablets, to be decided, twice a day, 14 days
75446827|NCT01691274|Drug|Placebo|Tablets, twice a day, 14 days
75596437|NCT00600626|Drug|insulin aspart|
75596438|NCT00623090|Behavioral|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
75596439|NCT00623090|Behavioral|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
75596440|NCT00623090|Behavioral|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
75596441|NCT00623168|Drug|Ribavirin|7 Day multiple dosing regime based on weight and dosage day
75596442|NCT00623246|Behavioral|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
75596443|NCT00623246|Behavioral|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
75888515|NCT02170922|Drug|BIBR 1048 MS tablet|
75888516|NCT02170922|Drug|BIBR 1048 MS solution|
76059065|NCT03422861|Drug|Placebos|Treatment regimen will involve placebo capsule administration, identical in colour, shape, size, taste and smell to the nabilone capsules, starting orally first administered on POD #0. The patient will be continued on this medication for 72 hours
76059066|NCT03421496|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
76059067|NCT03421496|Drug|Placebo|Matching oral solution
75446828|NCT01691287|Behavioral|Michael Method|
75446829|NCT01691300|Other|ACT PET/CT|Old tracer but new indication
75446830|NCT01691352|Procedure|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
75446831|NCT01691352|Procedure|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
75596444|NCT00600860|Other|No interventions|Only registration of clinical practice
75596445|NCT00601016|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
75596446|NCT00601094|Biological|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
75596447|NCT00601328|Drug|Calcitriol|
75596448|NCT00601406|Genetic|gene expression analysis|
75888517|NCT03698253|Drug|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
76059068|NCT03421496|Drug|Vigabatrin|Powder suspension
76059069|NCT03321786|Other|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
75446832|NCT01691365|Dietary Supplement|vitamins|a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
75740690|NCT00774059|Device|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
76059070|NCT03306992|Behavioral|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
76059071|NCT03278106|Other|Laboratory Biomarker Analysis|Correlative studies
75446833|NCT01691365|Drug|Placebo|Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
75596449|NCT00601406|Genetic|gene rearrangement analysis|
76059072|NCT03278106|Drug|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
75596450|NCT00601406|Genetic|polymorphism analysis|
75740691|NCT03888482|Device|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
75740692|NCT03888482|Device|Somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
75740693|NCT00995696|Behavioral|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
76059073|NCT03255252|Drug|Cisplatin injection|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
75446834|NCT01691391|Behavioral|(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles|Patients will be treated with cetuximab or panitumumab. Two [18F-]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin and tumor biopsies for kinase activity profiles.
75446835|NCT01691404|Dietary Supplement|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
75446836|NCT01691404|Dietary Supplement|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
75446837|NCT01691404|Dietary Supplement|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
76059074|NCT03255252|Combination Product|radiotherapy|A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
76059075|NCT03254420|Device|Calypso beacon implant|Calypso beacon implant before radiotherapy
75446838|NCT01691417|Device|Intermittent Sequntial Pnumatic Compression Leg Sleeves|
76059076|NCT03254420|Radiation|moderate hypofractionation Radiotherapy|moderate hypofractionation Radiotherapy
76059077|NCT03240523|Drug|Vilaprisan (BAY1002670)|Orally, 2 mg, once daily
76059078|NCT03230747|Device|Edwards SAPIEN M3 System|SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
76059079|NCT03214198|Drug|Vonoprazan|Vonoprazan tablets
75446839|NCT01691443|Procedure|pressure sensor and wrist shaker, not marked CE, developped by Texisense|
75446840|NCT01691456|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
75446841|NCT01691469|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
75446842|NCT01691495|Drug|Fondaparinux|Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
75446843|NCT01691547|Drug|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
75446844|NCT01691547|Drug|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
75596451|NCT00601406|Other|laboratory biomarker analysis|
75596452|NCT00601406|Radiation|radiation therapy|
75596453|NCT02891486|Procedure|Spinal surgery|Elective spinal surgery performed
75596454|NCT00601562|Drug|Zidovudine|
75596455|NCT00601874|Drug|Pilocarpine|
75596456|NCT01326104|Biological|TTRNA-xALT|TTRNA-xALT 3 x 10^7/kg by intravenous injection once.
75596457|NCT01326104|Biological|TTRNA-DCs|TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
75596458|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
75596459|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
75740694|NCT00993278|Dietary Supplement|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
75740695|NCT00993278|Dietary Supplement|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
75740696|NCT00667355|Biological|adalimumab|40 mg or 80 mg every other week, subcutaneous
75740697|NCT00778505|Drug|Propofol|closed-loop administration using bispectral index as the controller
75740698|NCT00778505|Drug|remifentanil|closed-loop administration using bispectral index as the controller
75740699|NCT00778505|Drug|Propofol|manual administration according bispectral index values
75740700|NCT00778505|Drug|Remifentanil|manual administration according bispectral index values
75740701|NCT00532844|Drug|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
76059080|NCT03192215|Drug|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
76059081|NCT03192215|Drug|Aspirin|Aspirin 81 mg by mouth once daily.
75740702|NCT00532844|Drug|Sapropterin Dihydrochloride and Vitamin C|Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
75596460|NCT01097629|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
75740703|NCT00778583|Drug|Nitrofurantoin 100 mg capsules|
75740704|NCT00778661|Drug|amoxicillin 400mg + clovalunic acid 57.5mg tablets|
76059082|NCT03052608|Drug|Lorlatinib|ALK-positive NSCL treatment
75740705|NCT00993356|Drug|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
76059083|NCT03052608|Drug|Crizotinib|ALK-positive NSCL treatment
76059084|NCT03027804|Procedure|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
76059085|NCT02914639|Drug|SF0166 Topical Ophthalmic Solution|
76059086|NCT02865018|Drug|cetirizine|
75740706|NCT00993356|Procedure|Transsphenoidal surgery|
76059087|NCT02852538|Behavioral|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
76059088|NCT02795143|Drug|Isotretinoin|
75888518|NCT03698253|Genetic|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
75446845|NCT01691547|Drug|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
75446846|NCT01691547|Drug|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
75446847|NCT01691586|Device|Remote patient monitoring|Remote monitoring of ICD and heart failure data
75446848|NCT01691586|Other|In-Clinic check-ups|Calender-based In-Clinic ICD check-up
75462924|NCT01869894|Procedure|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
75888519|NCT03698253|Genetic|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
75888520|NCT03698253|Genetic|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
75888521|NCT02167958|Drug|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) * (Wt in kg) * (0.85 if female) / (72 * Cr)~Fludarabine dosage should be reduced per standard of care."
76059089|NCT02795143|Other|Placebo|
76059090|NCT02790736|Drug|propranolol|active treatment
76059091|NCT02790736|Drug|Placebo|inactive pill
76059092|NCT02736981|Behavioral|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
76059093|NCT02736981|Behavioral|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
76059094|NCT02736981|Behavioral|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
76059095|NCT02704208|Behavioral|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
75596461|NCT01097629|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
76059096|NCT02704208|Behavioral|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
76059097|NCT02664337|Other|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
75462925|NCT01869894|Procedure|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
75596462|NCT01097629|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
75596463|NCT00602108|Procedure|adjuvant therapy|
75596464|NCT00602108|Procedure|conventional surgery|
75596465|NCT00602108|Radiation|hypofractionated radiation therapy|
75596466|NCT00602108|Radiation|intraoperative radiation therapy|
75596467|NCT04325516|Behavioral|Daily activities|"Participants will perform four tasks in a randomized order:~sit to stand~dorsi flexion of the foot~knee extension~hip extension"
75596468|NCT04308031|Drug|Ivabradine 5 mg [Corlanor]|Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
75596469|NCT04308031|Drug|Digoxin 0.25 mg|Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)<60 Max dose: 0.25 once daily (QD)
75596470|NCT01324622|Device|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
75888522|NCT02167958|Drug|Cyclophosphamide|"Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide [50mg/kg] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~."
75446849|NCT01691625|Other|concurrent chemoradiotherapy plus DC-CIK immunotherapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period."
75446850|NCT01691625|Other|Concurrent chemoradiation only|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation."
75446851|NCT01691651|Procedure|Subcutaneous injection of botulinum toxin type A|Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
75446852|NCT01691651|Drug|Botulinum Toxin Type A|2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
75446853|NCT01691664|Radiation|Only radiation therapy|Patients only radiation therapy after surgery
75446854|NCT01691664|Other|Radiation therapy plus DC-CIK cellular therapy|Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
75446855|NCT01691677|Drug|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
75446856|NCT01691677|Drug|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
75446857|NCT01691703|Device|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
75446858|NCT01691716|Drug|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
75446859|NCT01691716|Behavioral|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
75446860|NCT01691742|Drug|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
75446861|NCT01691742|Drug|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
75596471|NCT01324622|Procedure|laminectomy|standard procedure
75740707|NCT00781547|Drug|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
75740708|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
75740709|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
75740710|NCT00774293|Drug|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
75740711|NCT00774293|Drug|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
75888523|NCT02167958|Drug|Mesna|"Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
75888524|NCT02167958|Radiation|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
75740712|NCT04000958|Drug|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
75888525|NCT02167958|Other|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
75446862|NCT01691742|Drug|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
75446863|NCT01691807|Drug|ofatumumab|treatment for NHL
75446864|NCT01691807|Drug|bendamustine|treatment for NHL
75446865|NCT01691872|Drug|Retigabine|Retigabine
75596472|NCT01096849|Drug|levofloxacin|
75596473|NCT01096849|Drug|plazomicin|
75596474|NCT01096849|Drug|placebo|
75596475|NCT02878447|Radiation|External beam radiotherapy|External beam radiotherapy will be prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue at 3.5Gy weekly for 5 fractions to a maximum of 17G
75596476|NCT04307173|Drug|KBL693|"Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
75446866|NCT01691911|Procedure|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
75446867|NCT01691924|Drug|PBF-509|
75596477|NCT04307173|Drug|KBL693|"Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
75596478|NCT04915261|Behavioral|Lenient Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
75446868|NCT01691924|Drug|Placebo|
75740713|NCT04000958|Drug|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
75740714|NCT00778739|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
75740715|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
75888526|NCT02167958|Drug|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
75888527|NCT02167958|Drug|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
75888528|NCT02167958|Drug|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is > 1,000/mm3 for three consecutive days.
75888529|NCT03698175|Behavioral|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
75888530|NCT03698175|Behavioral|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
75888531|NCT01384331|Drug|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
75888532|NCT03699423|Drug|0.01% atropine eye drops|0.01% atropine sulphate
75888533|NCT03699423|Drug|0.02% atropine eye drops|0.02% atropine sulphate
75596479|NCT04915261|Behavioral|Strict Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
75596480|NCT01324388|Biological|LY2189265|Administered subcutaneously
75888534|NCT03699423|Drug|0.03% atropine eye drops|0.03% atropine sulphate
75446869|NCT01691937|Procedure|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
75446870|NCT01691937|Procedure|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
75596481|NCT01324388|Drug|Metoprolol|Administered orally
75596482|NCT01324388|Drug|Lisinopril|Administered orally
75596483|NCT01324388|Drug|Placebo|Administered subcutaneously
75596484|NCT01102777|Behavioral|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
75596485|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
75596486|NCT02878681|Drug|Ranibizumab|0.5 mg intravitreal injections
75596487|NCT02878681|Drug|Aflibercept|2 mg intravitreal injections
75596488|NCT02879461|Procedure|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
76059098|NCT02664337|Other|Standard treatment information|Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
75740716|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
75740717|NCT00781625|Dietary Supplement|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
75740718|NCT03190460|Other|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
75740719|NCT03190460|Other|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
75888535|NCT02164448|Drug|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
75446871|NCT01691937|Procedure|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
75740720|NCT00993434|Behavioral|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
75740721|NCT00993434|Behavioral|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
75740722|NCT00781703|Other|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
75740723|NCT02557061|Procedure|Colorectal surgery (resection)|Colorectal surgery (resection) is done for patient with colorectal cancer
75888536|NCT02164448|Drug|the control group|saline infusion from induction of anesthesia to end of surgery
75888537|NCT03612713|Drug|Oxycodone Medication First|Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
75888538|NCT03612713|Drug|Placebo First|Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
75888539|NCT02164526|Other|Routine therapy|Routine therapy
75888540|NCT03697941|Procedure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
75596489|NCT01324310|Drug|Romidepsin|Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
75596490|NCT01324310|Drug|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
75596491|NCT05645666|Behavioral|Well-being therapy|Well-being therapy is a short-term, organized and problem-oriented treatment program that is based on Riff's psychological well-being model. Its purpose is to help patient in order to improve His/her functions in six dimensions; personal growth, environmental mastery, purposefulness of life, and autonomy, self-acceptance and positive relationships with others Therapists help patients find well-being experiences in their present and past lives and pay attention to these experiences, no matter how small or short they are.
75740724|NCT02557061|Biological|Blood sampling|Pre-operative blood sampling is done for patient with colorectal cancer
75888541|NCT03697941|Procedure|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
76059099|NCT02663739|Device|Zenith® TXD|Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
76059100|NCT02663362|Other|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
76059101|NCT02516670|Dietary Supplement|Ascorbic Acid|Given IV
76059102|NCT02516670|Drug|Docetaxel|Given IV
75446872|NCT01691963|Device|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
76059103|NCT02516670|Other|Laboratory Biomarker Analysis|Correlative studies
76059104|NCT02516670|Other|Pharmacological Study|Correlative studies
75740725|NCT00781781|Drug|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
75740726|NCT00666263|Biological|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
76059105|NCT02516670|Other|Placebo|Given IV
76059106|NCT02516670|Other|Quality-of-Life Assessment|Ancillary studies
76059107|NCT02345629|Procedure|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
75596492|NCT04325672|Biological|Convalescent Plasma|Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers >1:64.
75596493|NCT01102231|Drug|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
75596494|NCT01102231|Drug|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
75596495|NCT01102231|Radiation|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
75740727|NCT00666263|Biological|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
75740728|NCT00667277|Drug|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
75888542|NCT01380509|Drug|Metronidazole|Capsules, single-dose, fasting
75888543|NCT01380509|Drug|Flagyl|Capsules, single-dose, fasting
75888544|NCT03699267|Other|US-guided Bilateral TAP block|
75446873|NCT01691976|Drug|Oestrogen Patches|
75596496|NCT04308733|Device|Anodal tDCS|patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
76059108|NCT02345629|Behavioral|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
75888545|NCT01378715|Drug|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
75888546|NCT04818515|Drug|Atogepant|Oral; Tablet
76059109|NCT02345629|Procedure|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
76059110|NCT02345629|Procedure|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
76059111|NCT02315898|Drug|Treatment-inhaled tPA|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
76059112|NCT02285842|Device|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
75446874|NCT01691976|Drug|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
75446875|NCT01691989|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
75596497|NCT02879539|Device|MP3000 sound coding strategy or ACE strategy with lower stimulation|
75446876|NCT01691989|Drug|placebo|oral doses once a day for 26 weeks
75596498|NCT01094743|Device|galyfilcon A prototype lens|Silicone hydrogel contact lens
75596499|NCT01094743|Device|lotrafilcon B lens|Silicon Hydrogel contact lens
75596500|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg|PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
75740729|NCT00774527|Drug|Cyclophosphamide-fludarabine-anti thymocyte globulin|"Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2."
75888547|NCT04818515|Drug|Ubrogepant|Oral; Tablet
75888548|NCT02760602|Drug|Solanezumab|Administered IV
75888549|NCT02760602|Drug|Placebo|Administered IV
75888550|NCT04129073|Other|Intensive care treatment|Intensive care treatment; Utilization of neuroprognostication tools
75596501|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg|PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
75596502|NCT01095835|Drug|Lamivudine (LAM)|Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
75888551|NCT04687241|Drug|Almonertinib|The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.
75888552|NCT04687241|Drug|Placebo Almonertinib|Placebo Almonertinib
75888553|NCT00976131|Drug|CoQ10|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)"
75446877|NCT01692002|Dietary Supplement|Sodium propionate|Sodium propionate capsule or tablet
75446878|NCT01692002|Dietary Supplement|Sodium Chloride|Placebo capsule or tablet
75446879|NCT01692002|Procedure|Oral glucose tolerance test|
75446880|NCT01692002|Procedure|Intravenous glucose tolerance test.|
75446881|NCT01692015|Other|Questionnaire on dietary history|
75446882|NCT01692015|Other|Questionnaire on nosebleed severity|
75446883|NCT01692015|Other|One week food diary generated by weighing foods|
75446884|NCT01692015|Procedure|Blood tests for full blood count, albumin, and indices of nutritional status|
75446885|NCT01692041|Drug|ivy leaves dry extract|5 ml twice daily po
75446886|NCT01692041|Drug|Placebo|5 ml per os twice daily
75596503|NCT02878525|Procedure|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
75596504|NCT02878525|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
75596505|NCT04308577|Other|Ketogenic diet with added MCT|The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.
75596506|NCT04308811|Biological|platelet rich plasma|Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions
75596507|NCT04308811|Combination Product|amniotic membrane graft group|amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions
75740730|NCT00778973|Drug|sertraline 100 mg tablets|
75740731|NCT00774605|Drug|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
75740732|NCT00774605|Drug|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
76059113|NCT02280525|Drug|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
76059114|NCT02280525|Drug|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
76059115|NCT02280525|Drug|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
75740733|NCT00779051|Drug|Zolpidem 10mg tablets|
75888554|NCT00976131|Other|CoQ10 Placebo|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)"
75888555|NCT00976131|Drug|Doxorubicin|Standard of care chemotherapy medication used to treat cancer.
75888556|NCT00976131|Drug|Cyclophosphamide|Standard of care chemotherapy medication used to treat cancer.
75888557|NCT01384253|Other|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
75888558|NCT01384253|Biological|trastuzumab|4 mg/kg.
76059116|NCT02280525|Drug|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
76059117|NCT02280525|Procedure|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
76059118|NCT02280525|Drug|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
76059119|NCT02274805|Procedure|Adults presenting for surgery in the neck area|
75596508|NCT04308811|Device|Intrauterine balloon|intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions
75596509|NCT02879773|Radiation|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
75888559|NCT03697863|Procedure|Noninvasive Respiratory Support|Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
76059120|NCT02157883|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
76059121|NCT02157883|Drug|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
76059122|NCT02157883|Drug|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
75596510|NCT04908865|Drug|Belimumab|Belimumab will be administered.
75596511|NCT04908865|Drug|Standard therapy|Standard therapy will be continued.
75888560|NCT03631277|Device|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
76059123|NCT02149667|Device|total hip arthroplasty implant|
75596512|NCT04308421|Device|Red light|Low irradiation 650 nm +/- 5 nm red light
75596513|NCT01324232|Drug|AVP-923-45|AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
75596514|NCT01324232|Drug|AVP-923-30|AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
75740734|NCT00774683|Drug|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
75740735|NCT02556281|Biological|Blood sampling|Blood sampling is done for patient with colorectal cancer
75740736|NCT00782015|Dietary Supplement|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
75740737|NCT00782015|Dietary Supplement|Placebo Comparator:|NCEP Step 2 diet
76059124|NCT02133898|Other|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
76059125|NCT02091141|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
76059126|NCT02091141|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
76059127|NCT02091141|Drug|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
75888561|NCT03631277|Drug|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
75888562|NCT02171000|Drug|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
75888563|NCT01378637|Device|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
75888564|NCT03697785|Device|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
75888565|NCT02261168|Other|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
75888566|NCT03699189|Behavioral|Immediate ANAIS|"ANAIS is a structured therapeutic education programme aimed at providing the patients with the necessary skills to manage their diabetes independently and confidently. The programme particularly promotes dietary freedom, in an intensive insulin regime, by enabling effective carbohydrate counting and accurate prandial insulin dose adjustment and avoiding hypoglycaemia.~ANAIS was organised as a five day (Monday to Friday), seven-hour, outpatient programme using principles of adult education, with explicit learning objectives, in a group setting."
76059128|NCT02091141|Drug|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
75596515|NCT01324232|Drug|AVP-923-20|AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
75596516|NCT01324232|Drug|Placebo|Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
75596517|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
75596518|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
75740738|NCT00774839|Behavioral|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
75596519|NCT04841083|Device|Allay Lamp|The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10 lux) narrow band (20 nm) green light (peak wavelength 520 nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k).
75596520|NCT04306783|Other|In-home sensor monitoring|-Installed and maintained by Foresite Healthcare
75888567|NCT02164604|Drug|intravitreal injection of 0.03ml ranibizumab|
75596521|NCT05350891|Procedure|endoscopic surgery|endoscopic surgery combined with adjuvant immunotherapy with/without chemotherapy
75596522|NCT01094119|Device|heated blanket|heated blanket
75596523|NCT01094119|Device|heated pad|patients will be warmed with a heated pad during surgery.
75596524|NCT01323920|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 IV
75888568|NCT04380831|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
75888569|NCT04380831|Drug|Cyclophosphamide|Undergo HSCT
75888570|NCT04380831|Radiation|Intensity-Modulated Radiation Therapy|Undergo TBI using IMRT
75888571|NCT04380831|Procedure|Total-Body Irradiation|Undergo TBI using IMRT
75888572|NCT02168114|Other|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
76059129|NCT02091141|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
76059130|NCT02091141|Drug|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
76059131|NCT02091141|Drug|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
75740739|NCT00782093|Drug|volociximab|volociximab intravitreal injection
75740740|NCT00784433|Dietary Supplement|alcohol|150 cc
75596525|NCT01323920|Drug|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
75596526|NCT01323920|Drug|Methotrexate|Methotrexate 15 mg/m^2 IV
75596527|NCT01093885|Drug|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
75740741|NCT00774917|Device|Numen|Numen Co-Cr coronary stent implant
75740742|NCT00784511|Dietary Supplement|cholecalciferol|4000 IU/d
75740743|NCT00784511|Other|microcrystalline cellulose|1/d
75888573|NCT02168114|Procedure|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
75446887|NCT01692080|Behavioral|Asthma education|Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
75446888|NCT01692093|Dietary Supplement|KM110329|KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
75596528|NCT02878369|Procedure|Doppler measurement of blood flow in the outflow tract of the left ventricle and the femoral artery,Reading blood pressures displayed on the monitor.|
75596529|NCT01101997|Device|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
75596530|NCT00597597|Drug|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
75596531|NCT02891967|Other|bulk fill composite|cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
75596532|NCT02891967|Other|Nano resin composite (K Z350 xt)|cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
75596533|NCT00598065|Other|PET/CT|Synchronized PET/CT Imaging
75740744|NCT00784589|Drug|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
75740745|NCT00784589|Drug|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
75888574|NCT04676048|Biological|ASC618|ASC618 will be given as a single IV infusion
75888575|NCT03697473|Other|Nordic hamstring exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
76059132|NCT02091141|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
75446889|NCT01692093|Dietary Supplement|Placebo|Placebo
75446890|NCT01692106|Procedure|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
75446891|NCT01692132|Drug|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
75446892|NCT01692145|Drug|KCT-0809|
75446893|NCT01692145|Drug|Placebo|
75446894|NCT01692184|Drug|50 mg AVL-292|
75446895|NCT01692184|Drug|100 mg AVL-292|
75446896|NCT01692184|Drug|200 mg AVL-292|
75446897|NCT01692184|Drug|350 mg AVL-292|
75446898|NCT01692184|Drug|Placebo capsules|
75446899|NCT01692210|Drug|Dexmedetomidine|After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
75596534|NCT02892045|Device|MMG|neuromuscular monitoring device
75596535|NCT04326621|Other|Pressure Release Technique (PRT)|A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
75596536|NCT04326621|Other|Control|exercises
75596537|NCT04207827|Behavioral|xSmoker app|xSmoker - mHealth intervention consisted of using the app xSmoker
75596538|NCT04207827|Behavioral|SMS|Text messages with content based on the Motivation and Problem Solving approach and informed by our prior work.
75596539|NCT04207827|Other|Usual Care|Usual postnatal care
75596540|NCT00598299|Procedure|venous puncture|venous puncture
75596541|NCT00598299|Other|obtain serum from perripheral blood or cord blood|obtain serum from perripheral blood or cord blood
75596542|NCT00598377|Drug|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
75740746|NCT00789893|Device|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis & assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st & 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, & the 2nd will be one month ± 2 weeks from last day of radiation.
75446900|NCT01692223|Behavioral|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety & Depression Scale (HADS), revised Impact of Events Scale (IES-R), & a questionnaire about their health behaviors, to establish baseline distress levels & health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider & discuss resultant therapeutic & management recommendations for the participants & their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
75888576|NCT03697473|Other|Hip extension exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
75888577|NCT04571645|Drug|Dociparastat sodium|Dociparstat is a glycosaminoglycan derived from porcine heparin.
75446901|NCT01692249|Other|immediate spa therapy|, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
75446902|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.
75446903|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.
75446904|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.
75446905|NCT01692288|Behavioral|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
75446906|NCT01692314|Other|Resistance training|
75446907|NCT01692327|Dietary Supplement|High fat meal|
75446908|NCT01692353|Other|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
75446909|NCT01692366|Drug|SAR302503|"Pharmaceutical form:Capsule~Route of administration: oral"
75446910|NCT01692379|Device|Solitaire FR device|Mechanical embolectomy in anterior large vessel occlusion
75446911|NCT01692379|Other|Medical treatment|Standard of care in acute ischemic stroke including intravenous rTPA
75740747|NCT00784667|Drug|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
75740748|NCT00784667|Drug|Erlotinib|100mg orally daily continuously
75740749|NCT00784745|Drug|Dexamethasone|2mg morning and night for 5 days.
75740750|NCT00534638|Biological|Cervarix|Intramuscular injection, 3 doses
75740751|NCT00534638|Biological|Engerix-B|Intramuscular injection, 3 doses
75740752|NCT00996008|Drug|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
75740753|NCT00996008|Drug|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
75740754|NCT00993512|Drug|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
75888578|NCT04571645|Other|Placebo|0.9% Normal Saline
75888579|NCT04050267|Drug|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
75888580|NCT04050267|Other|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
76059133|NCT02071290|Device|Pneumatic tourniquet|"Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning"
76059134|NCT02066181|Other|Laboratory Biomarker Analysis|Optional correlative studies
76059135|NCT02066181|Other|Placebo Administration|Given PO
76059136|NCT02066181|Other|Quality-of-Life Assessment|Optional ancillary studies
76059137|NCT02066181|Drug|Sorafenib Tosylate|Given PO
76059138|NCT01970865|Drug|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
75596543|NCT04326543|Diagnostic Test|Swanson, Noolan and Phelham - IV edition (SNAP-IV); Conners' Parent Rating Scales (CPRS)|"Ratings on the Swanson, Nolan and Pelham Evaluation Scale - IV (Bussing et al., 2008), were assessed during baseline visit for participants at the time of research assessment, to exclude the presence of ADHD symptoms in the healthy subjects. This scale is composed of 26 items for ADHD symptoms and ODD and was administered at baseline and at follow-up visit.~Temperament assessment: we used the Mary Rothbart's Temperament Questionnaire, a caregivers' report measure designed to provide a detailed assessment of temperament.~ADHD Rating scales: the Long Version of Conners' Parent Rating Scale (Conners et al., 1998) was used to quantify ADHD comorbidity symptoms, as ODD and Anxiety traits, in the children and adolescents with ADHD.~Salivary cortisol: Sampling was performed during one ordinary weekday between 7 and 8 o'clock, within 60' after nocturnal awakening."
75446912|NCT01692405|Device|NaviGo Bx™|The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
76059139|NCT01970865|Drug|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
76059140|NCT01928576|Drug|Azacitidine|
76059141|NCT01928576|Drug|Entinostat|
75446913|NCT01692405|Procedure|biopsy sponge pad|the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
75446914|NCT01692418|Drug|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
75446915|NCT01692418|Drug|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
75596544|NCT04326387|Diagnostic Test|SAMBA II (Diagnostic for the Real World)|Point of care Isothermal-PCR Viral RNA Amplication for virus detection
75596545|NCT04326387|Diagnostic Test|Public Health England Gold Standard|Reverse Transcription PCR
75596546|NCT04326387|Diagnostic Test|Cambridge Validated Viral Detection Method|Reverse Transcription PCR
75740755|NCT00993512|Drug|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
76059142|NCT01928576|Drug|Nivolumab|
76059143|NCT01911091|Behavioral|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
76059144|NCT01880060|Behavioral|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; >20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
75446916|NCT01692431|Dietary Supplement|EPA|High fat meal containing EPA
75446917|NCT01692431|Dietary Supplement|DHA|High fat meal containing DHA
75446918|NCT01692431|Dietary Supplement|Placebo|High fat meal containing negligible EPA/DHA content
75596547|NCT04326387|Diagnostic Test|Radiological Detection|Chest X-ray & CT Scan detection of viral infection in the lungs
75596548|NCT00598533|Device|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
75596549|NCT00598533|Device|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
75596550|NCT00598845|Procedure|Tumor biopsy study|Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
75740756|NCT00993512|Other|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
75888581|NCT03086057|Behavioral|PrEPare for Work: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
75446919|NCT01692457|Drug|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
75888582|NCT03086057|Behavioral|PrEPare for Work: Adherence Training and Counseling (Stage 2)|Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
75888583|NCT03697317|Behavioral|Televideo Lifestyle Coaching|Six month total intervention: Three months of weekly 1-hour televideo healthy lifestyle coaching sessions involving 30 minutes of structured physical activity and 30 minutes of nutrition education and daily healthy lifestyle habit tracking. This is followed by 3 months of healthy lifestyle habit tracking only.
75888584|NCT03697317|Behavioral|Enhanced Usual Care|Six months of healthy lifestyle habit tracking with access to written diet and physical activity materials.
76059145|NCT01880060|Behavioral|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
75446920|NCT01692470|Drug|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
75446921|NCT01692483|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
75888585|NCT02759120|Drug|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight < 50 kilograms or 100mg twice daily if weight > 50 kilograms for up to 36 months
75888586|NCT02759120|Other|No Intervention: Standard of Care|Standard of care
75888587|NCT01569113|Drug|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
75888588|NCT01569113|Drug|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
76059146|NCT01869114|Drug|Sirolimus|Given PO
75446922|NCT01692483|Drug|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
75446923|NCT01692522|Procedure|Intubation|visualized blind intubation
76059147|NCT01869114|Drug|Azacitidine|Given IV
76059148|NCT01843751|Drug|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
75596551|NCT04207671|Procedure|Complete omission of chest tube|No chest tube implacement
75596552|NCT04207671|Procedure|Improved drainage strategy|A two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-remove
75596553|NCT00599703|Other|fMRI Scan, pre- and post language evaluation|All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
75740757|NCT00996086|Device|CRT device implant|CRT device-recipients
76059149|NCT01815983|Other|Videolaryngoscopy review.|Review of video recordings.
76059150|NCT01756248|Drug|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
76059151|NCT01744652|Drug|Crizotinib|"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
75446924|NCT01692535|Procedure|Intubation|Intubation with one of the six videolaryngoscopes
75446925|NCT01692548|Other|Neurofeedback|
75446926|NCT01692574|Behavioral|Behavior Modification for Weight Loss|
75740758|NCT00993590|Behavioral|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
75446927|NCT01692574|Behavioral|Alternative Approach to Weight Loss|
75446928|NCT01692574|Behavioral|Cognitive-Behavior Therapy for Depression|
75446929|NCT01692574|Behavioral|Depression Support and Education|
75446930|NCT01692587|Other|Protein restrictive diet|To begin a reduced protein diet
75446931|NCT01692652|Drug|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
75446932|NCT01692652|Other|warm compress only group|
75446933|NCT01692678|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
75596554|NCT00599781|Genetic|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
75596555|NCT00599859|Dietary Supplement|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
75740759|NCT00662129|Biological|bevacizumab|
75740760|NCT00662129|Drug|gemcitabine hydrochloride|
75740761|NCT00662129|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
75740762|NCT00996242|Drug|L-lysine|6 g/day for four weeks
75740763|NCT00996320|Other|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
75888589|NCT04435821|Drug|[18F]FTC-146|Participants will be injected with 0.08 mCi/kg [18F]FTC-146. A whole-body PET/MRI scan will be performed after injection.
75888590|NCT03699033|Radiation|2.5 Gy/fraction|Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
75446934|NCT01692678|Drug|Dacarbazine|Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
76059152|NCT01744652|Drug|Dasatinib|"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."
76059153|NCT01711541|Drug|Carboplatin|Given IV
76059154|NCT01711541|Drug|Cisplatin|Given IV
75446935|NCT01692704|Drug|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."
75596556|NCT00599859|Dietary Supplement|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
75596557|NCT00599937|Drug|ATRA|early introduction of ATRA
75446936|NCT01692769|Drug|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
75446937|NCT01692769|Drug|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
75446938|NCT01692808|Drug|Vitamin D3 3000 UI daily|Vitamin D3 will be administered as an adjunct to corticosteroids or enteral nutrition at the doses of 3000 UI daily or 4000 UI daily
75596558|NCT00599937|Drug|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
75596559|NCT02891421|Behavioral|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
76059155|NCT01711541|Drug|Fluorouracil|Given IV
75446939|NCT01692808|Drug|Vitamin D3 4000 UI daily|This arm is intended for those at diagnosis treated with Corticosteroid or in Remission
76059156|NCT01711541|Drug|Hydroxyurea|Given PO
75446940|NCT01692821|Drug|100% oxygen breathing|100% oxygen breathing - 30 minutes
75446941|NCT01692821|Drug|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
75446942|NCT01692821|Drug|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
75446943|NCT01692834|Drug|Sandimmune® Injection|
76059157|NCT01711541|Other|Laboratory Biomarker Analysis|Correlative studies
76059158|NCT01711541|Drug|Paclitaxel|Given IV
76059159|NCT01711541|Other|Placebo Administration|Given PO
75596560|NCT02891421|Other|Standard Care|Standard Care: Participants received standard care
75596561|NCT00600093|Drug|Amantadine|IV Amantadine 200mg *1/d at the beginning of surgery and 24 hours following surgery
75596562|NCT00600249|Drug|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
75596563|NCT00600249|Drug|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
76059160|NCT01711541|Radiation|Radiation Therapy|Undergo radiation therapy
76059161|NCT01711541|Drug|Veliparib|Given PO
76059162|NCT01584102|Behavioral|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
76059163|NCT01584102|Behavioral|group fitness classes only|15 weeks biweekly group fitness
76059164|NCT01370512|Drug|Droxidopa|100 mg tablets by mouth three times a day
76059165|NCT01370512|Drug|Pyridostigmine|60 mg tablets by mouth three times a day
76059166|NCT01370512|Other|Placebo|Looks exactly like the study drug but contains no active ingredients
76059167|NCT00944632|Drug|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
76059168|NCT00944632|Drug|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
76059169|NCT00717795|Behavioral|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
76059170|NCT00717795|Behavioral|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
75596564|NCT00600327|Device|EndoTex™ NexStent™|EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
76059171|NCT00584883|Drug|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
76059172|NCT00215813|Drug|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
76059173|NCT00179465|Drug|Tiagabine|Up to 36 mg daily
76059174|NCT00179465|Drug|Placebo|Placebo
75446944|NCT01692834|Drug|NeuroSTAT®|
75596565|NCT00600327|Device|Filter Wire EZ™|EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
75446945|NCT01692860|Other|Energy Restriction|Subjects consume 750 kcal/d of energy below their need
76059175|NCT00134030|Drug|Cisplatin|Given IV
75596566|NCT00600405|Drug|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
76059176|NCT00134030|Drug|Doxorubicin Hydrochloride|Given IV
76059177|NCT00134030|Drug|Etoposide|Given IV
76059178|NCT00134030|Drug|Ifosfamide|Given IV
76059179|NCT00134030|Drug|Methotrexate|Given IV
75446946|NCT01692873|Procedure|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
75596567|NCT00600405|Drug|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
75596568|NCT00600561|Behavioral|MBSR|Mindfulness-Based Stress Reduction Intervention
75446947|NCT01692886|Biological|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
75446948|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
75446949|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
75596569|NCT01324830|Drug|day 1 to day 5|low to high dose
75596570|NCT01324830|Drug|day 1 to day 14|low to high dose
75596571|NCT02891577|Procedure|Ultrasonography|At the time of ICU admission, among critically ill patients with shock, the investigators will measure the diameter of the common femoral vein and that of the inferior vena cava by ultrasonography.
75740764|NCT00993746|Drug|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
76059180|NCT00134030|Biological|Peginterferon Alfa-2b|Given subcutaneously
76059181|NCT00134030|Other|Quality-of-Life Assessment|Ancillary studies
75446950|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
75740765|NCT00993746|Drug|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
75740766|NCT00789971|Drug|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
75740767|NCT00789971|Drug|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
75740768|NCT00996398|Other|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
75740769|NCT00782405|Drug|quetiapine|XR, 150-300mg
75740770|NCT00782405|Drug|mirtazapine|30-45 mg
76059182|NCT00134030|Other|Questionnaire Administration|Ancillary studies
75596572|NCT00600639|Device|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
75740771|NCT04000646|Other|standard care|standard care non-pharmacologic interventions during anesthesia induction
75740772|NCT04000646|Other|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
76059183|NCT00134030|Procedure|Therapeutic Conventional Surgery|Undergo amputation or limb salvage surgery
75596573|NCT00600639|Drug|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
75596574|NCT00600639|Drug|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
75596575|NCT00623025|Drug|Creon 25000|6 to 9 capsules Creon 25000 per day
75596576|NCT00623025|Drug|Placebo|6 to 9 capsules placebo per day
76059184|NCT01382446|Drug|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
75888591|NCT03699033|Drug|Carboplatin|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
75888592|NCT03699033|Drug|Paclitaxel|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
75596577|NCT00600795|Other|CSF collection|CSF collection at time of VPS insertion
75596578|NCT00602160|Drug|FAHF-2 (TM)|"We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy."
75740773|NCT05250362|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|"MYELOABLATIVE CONDITIONING REGIMEN: Patients with myeloid malignancies receive busulfan on days -7 to -4, fludarabine IV over 1 hour on days -7 to -3, cytarabine IV over 4 hours on days -7 to -3. Patients with lymphoproliferative disorders receive busulfan on day -7 to -4, cladribine IV over 1 hour on days -7 to -3, gemcitabine IV over 4 hours on days -7 and -3.~TRANSPLANT: Patients undergo PBSC transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, cyclosporin IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO BID beginning on day 5 for 30 days.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28."
75596579|NCT00600873|Drug|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
75740774|NCT00790283|Device|PTCA with stent implantation|"Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure."
75888593|NCT03697239|Drug|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
75596580|NCT04325997|Device|laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for laryngoscope intubation
75596581|NCT04325997|Device|video laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for video laryngoscope intubation
75596582|NCT01324440|Biological|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
75596583|NCT01324440|Biological|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
75740775|NCT00996554|Procedure|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
75740776|NCT00996554|Procedure|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
75888594|NCT03697239|Drug|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
75888595|NCT03697239|Drug|Cisplatin|25mg/m2 in 500*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
75446951|NCT01692912|Other|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28<2.6
75446952|NCT01692925|Drug|turoctocog alfa|Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
75446953|NCT01692925|Drug|turoctocog alfa|Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
75888596|NCT03697239|Drug|Gemcitabine|1000mg/m2 in 500*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
75888597|NCT03629015|Biological|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
75446954|NCT01692977|Other|neuropsychological assessment|
75446955|NCT01692990|Dietary Supplement|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
75446956|NCT01693003|Drug|Indacaterol|150 µg d.o. during the first 3 weeks
75446957|NCT01693003|Drug|Tiotropium|150 µg d.o. during 3 weeks
75446958|NCT01693016|Device|non-invasive measurement of Hb|
75446959|NCT01693016|Procedure|taking blood samples|
75596584|NCT00598611|Drug|desloratadine|singel dose, oral, 20 mg
75596585|NCT00598611|Drug|desloratadine|single dose, oral, 5 mg
75596586|NCT04325724|Other|General evaluation|Demographic characteristic, psoriasis duration, disease duration, treatments
75596587|NCT04325724|Other|Dermatological evaluation|treatment and evaluation
75888598|NCT02164682|Procedure|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
76059185|NCT01382446|Other|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
75596588|NCT04325724|Other|Rheumatological evaluation|joints, enthesis, tendons, and other ultrasound abnormalities
75596589|NCT04325724|Other|para clinical data|biological data, medical imaging data
75596590|NCT04325724|Other|Patient reported outcomes (PROs)|Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
75740777|NCT00782561|Drug|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
75740778|NCT02996396|Device|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
75740779|NCT00785135|Device|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
75740780|NCT00785135|Device|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
75740781|NCT00993902|Procedure|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
75740782|NCT00993902|Procedure|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
75740783|NCT02555735|Drug|Standard of Care Chemotherapy|Physician's Choice Chemotherapy Treatment (non-guided)
75740784|NCT05343260|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
75740785|NCT05343260|Drug|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
75740786|NCT01564472|Other|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
75740787|NCT04001660|Procedure|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
75740788|NCT04001816|Other|Orthodontic Brackets|Self ligating and Conventional brackets
75740789|NCT00664859|Drug|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
75740790|NCT00996788|Drug|Rebamipide|Rebamipide 100 mg tid for 28 days
75740791|NCT00785369|Device|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
75888599|NCT02164682|Procedure|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
75888600|NCT01378559|Other|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
75888601|NCT03698955|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
75888602|NCT03698955|Other|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
75888603|NCT02164760|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
75888604|NCT01380431|Drug|Lisinopril|Tablets, 40 mg, single oral dose
75596591|NCT00601185|Procedure|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
75740792|NCT01564550|Drug|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
75740793|NCT01564550|Drug|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
75888605|NCT01380431|Drug|lisinopril|Tablets, 40 mg, single, oral dose
75888606|NCT01380431|Drug|Lisinopril|50% of subjects received the Par formulated product.
75888607|NCT03697161|Drug|OV101 (gaboxadol)|OV101 (gaboxadol)
75888608|NCT02168192|Behavioral|Simulation-Debrief|Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
75888609|NCT02168192|Behavioral|Traditional lecture|Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
75740794|NCT01564550|Other|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
75740795|NCT01564550|Other|no diet|The subjects will ingest a non-restricted diet prior to the study day.
75740796|NCT00785447|Other|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
75740797|NCT00790439|Drug|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
75740798|NCT00790439|Drug|Heparin|Anticoagulant
75888610|NCT02171156|Drug|nintedanib|soft gelatin capsule
75888611|NCT01380353|Drug|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner [B].
76059186|NCT01382212|Drug|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
76059187|NCT01381900|Drug|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
76059188|NCT01381900|Drug|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
75888612|NCT02168348|Other|biological examination at consultations at 3 and 6 months|
76059189|NCT01381900|Drug|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
75446960|NCT01693042|Biological|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (> 3 months) infarct area
75740799|NCT00790439|Drug|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
76059190|NCT01381900|Drug|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
75446961|NCT01693055|Device|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
75446962|NCT01693081|Drug|VR040/Aspirair® inhaler|Dry Powder inhaled apomorphine
75446963|NCT01693081|Drug|placebo|
75446964|NCT01693133|Other|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
75446965|NCT01693133|Other|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
75446966|NCT01693146|Device|Nasal oxygen insufflation with a TNI® 20 oxy device|Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
75446967|NCT01693146|Device|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
75446968|NCT01693159|Device|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
75740800|NCT00790439|Drug|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
75740801|NCT00790439|Drug|Tacrolimus|Calcineurin inhibitor
75740802|NCT00790439|Drug|Cyclosporine|Calcineurin inhibitor, immunosuppressant
75888613|NCT01384175|Procedure|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
75888614|NCT01384175|Procedure|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
76059191|NCT01381900|Drug|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
76059192|NCT01744665|Drug|nilotinib|Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
75446969|NCT01693159|Other|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
75446970|NCT01693172|Behavioral|Early mobilization program|Early postoperative supervised aerobic exercise, resistance and flexibility training
75740803|NCT00790439|Drug|Daclizumab|Monoclonal IL-2 receptor blocker
75740804|NCT00790439|Drug|Basiliximab|Monoclonal IL-2 receptor blocker
75740805|NCT00790439|Biological|Allogeneic Pancreatic Islet Cells|
75740806|NCT00785603|Drug|Paroxetine|tablets of 20 mg paroxetine
75740807|NCT00785603|Drug|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
75740808|NCT00785603|Drug|Tramadol|Capsules of 50 mg tramadol
75740809|NCT00570401|Drug|dasatinib|
76059193|NCT03025126|Other|Multimedial Rehabilitation|
75740810|NCT00785681|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
75888615|NCT01384175|Procedure|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
75888616|NCT02171312|Device|iDETECT Assessment|The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
75596592|NCT00598143|Behavioral|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
75596593|NCT00598143|Behavioral|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
75740811|NCT00785759|Drug|AH110690 (18F) Injection|All subjects will receive an I.V. dose of [18F]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of [18F]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
75740812|NCT00785837|Other|Aquatic Physical Therapy|The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
75888617|NCT02171312|Behavioral|Routine Balance and Vestibular Testing|A clinician will assess balance and vision by standard of care routine tests for neurologic function.
75888618|NCT02168426|Procedure|Guardix|Applying 6g of guardix during abdominal surgery
75888619|NCT02168426|Procedure|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
75888620|NCT01380275|Drug|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
75888621|NCT01380275|Drug|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
75740813|NCT00785915|Drug|AZD6765|single administration and once daily for 5 days
75888622|NCT02171390|Drug|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
75888623|NCT02171390|Drug|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
75888624|NCT03697005|Other|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
76059194|NCT03025126|Other|Usual care program|Usual care at home program according to healthcare professional's advice
76059195|NCT05367232|Drug|ICP-033 tablet|Administered orally, once a day, 28 days per cycle
76059196|NCT04560933|Procedure|Blood sample collection|Blood sample collection
76059197|NCT01744197|Drug|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
76059198|NCT05369416|Other|Low sodium diet|Subjects will be started on a low sodium (food will be provided) for two weeks.
76059199|NCT05369416|Other|high sodium diet|Subjects will be started on high sodium diet (regular diet supplemented with salt tablets to reach a daily intake of > 4200 mg/Day) for two weeks.
76059200|NCT04565301|Drug|Dexamethasone|adductor canal block
76059201|NCT04565301|Drug|neostigmine|adductor canal block
76059202|NCT04565301|Other|NaCl solutions|adductor canal block
75596594|NCT00601263|Drug|Anti-Asthma Herbal Medical Intervention (ASHMI)|We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
75740814|NCT00785915|Drug|Placebo|single administration and once daily for 5 days
75740815|NCT00785993|Other|Vitrification of oocytes for IVF treatment|
75740816|NCT00785993|Other|Protocolary IVF treatment with fresh donor oocytes|
75740817|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
75888625|NCT03697005|Other|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
75888626|NCT01378481|Drug|Vorinostat|Given PO
76059203|NCT01732107|Drug|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
75446971|NCT01693198|Procedure|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
75446972|NCT01693211|Device|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
76059204|NCT01743027|Drug|AL-4943A ophthalmic solution|
75446973|NCT01693211|Device|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
75446974|NCT01693224|Device|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
75596595|NCT04325490|Drug|Liquid powder|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
75446975|NCT01693224|Device|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
75596596|NCT04325490|Drug|Hydrocortisone cream 1%|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
75446976|NCT01693224|Device|Cepheid Xpert MTB/Rif assay|
75446977|NCT01693237|Other|Group psychotherapy|20 sessions of systemic and narrative group therapy
75596597|NCT00601341|Other|lumbosacral joint manipulation|lumbosacral joint manipulation
75596598|NCT00601341|Other|lumbar passive range of motion|lumbar passive range of motion
75596599|NCT00601341|Other|No active intervention|Lie on exam table for 3 minutes
75596600|NCT00601497|Device|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
75596601|NCT00601575|Drug|Lithium|
75446978|NCT01693237|Other|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
75596602|NCT00601653|Behavioral|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
75596603|NCT00601653|Behavioral|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
75888627|NCT01378481|Radiation|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
75596604|NCT00601809|Other|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
75596605|NCT00601809|Drug|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
75740818|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
75740819|NCT00532298|Biological|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
75888628|NCT01378481|Other|Laboratory Biomarker Analysis|Correlative studies
75888629|NCT01378481|Other|Pharmacological Study|Correlative studies
75888630|NCT01378481|Procedure|Therapeutic Conventional Surgery|Undergo neurosurgery
75888631|NCT02168582|Behavioral|physiotherapy as usual in primary care|
75888632|NCT02171468|Drug|Dabigatran high dose|
76059205|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
75596606|NCT00601887|Drug|Meloxicam|
75596607|NCT02891499|Procedure|Low-level laser therapy|"Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm."
75596608|NCT02891499|Procedure|Mediate force application|Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
75596609|NCT01325493|Drug|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
76059206|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.1%|
76059207|NCT01743027|Drug|AL-4943A ophthalmic solution vehicle|
76059208|NCT01380730|Biological|Evolocumab|Administered by subcutaneous injection
76059209|NCT01380730|Other|Placebo to Evolocumab|Administered by subcutaneous injection
75740820|NCT00532298|Biological|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
75740821|NCT04047017|Drug|Apatinib|250mg, po, qd
75740822|NCT04047017|Drug|Camrelizumab|200mg, q2w
75740823|NCT00997022|Drug|Sorafenib|"Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)"
75740824|NCT00786149|Other|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
75740825|NCT00786149|Other|Varenicline without counseling|Brief advice, one time during initial session
75888633|NCT02171468|Drug|Dabigatran low dose|
75888634|NCT03502031|Drug|Renin-Angiotensin (RAAS) alone|maximal RAAS blockade alone for 24months.
75888635|NCT03502031|Drug|Renin-Angiotensin (RAAS) blockers in combination with Spironolactone|maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
75888636|NCT02168738|Drug|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
75888637|NCT02168738|Drug|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
75888638|NCT02168738|Drug|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
75888639|NCT02171546|Drug|Dabigatran etexilate capsules|
75888640|NCT02171546|Drug|Quinidine sulfate tablets|
75888641|NCT02171546|Drug|Fexofenadine tablets|
75888642|NCT04385693|Procedure|Pulpotomy|Pulpotomy using bioactive bioceramic cement of 1.5 mm layer of a newly FDA approved calcium-based silicate cement (Nusmile NeoPutty) will be placed on the pulp chamber floor and canals' orifices for pulp and root therapy. Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health.This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, complete caries removal and then access to the pulp chamber using drills.
75888643|NCT04385693|Procedure|Extraction and placement of space maintainer|If during the pulpotomy procedure, hemostasis is not obtainable, or signs of advanced pulp degeneration such as dark and limited or no bleeding from canals, the pulp will be diagnosed as chronically inflamed or necrotic, and tooth will be extracted. As part of the standard of care after extractions of primary molars, space maintenance will be assessed, and a space maintainer fabricated if indicated. Extracted teeth will serve as controls, and information regarding the need or not of space maintenance.
75888644|NCT02171624|Drug|dabigatran etexilate|
75888645|NCT02171624|Drug|quinidine|
76059210|NCT05364034|Other|Urban Afforestation Intervention Program|An afforestation intervention program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
76059211|NCT04010968|Drug|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~if BM MRD at M9 < 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
76059212|NCT04010968|Drug|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
76059213|NCT01395784|Drug|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
75740826|NCT00997100|Drug|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
75740827|NCT02555501|Other|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
75740828|NCT02555501|Radiation|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
75740829|NCT04001738|Other|Direct Transfer to Angio Suite|Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
75740830|NCT00993980|Procedure|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
75740831|NCT00993980|Procedure|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
75740832|NCT02725814|Other|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
75888646|NCT03705351|Device|Tumor Treating Fields|Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.
75446979|NCT01693276|Drug|Gemcitabine|"gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.~Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks."
75446980|NCT01693276|Drug|Abraxane|Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
75446981|NCT01693276|Radiation|Radiation Therapy|IMRT Dose escalation: 60 Gy (2 Gy/fraction)
75446982|NCT01693289|Drug|metformin plus letrozole|
75888647|NCT03705351|Drug|Temozolomide|Patients will be given temozolomide according to routine treatment dosing and schedule.
75446983|NCT01693289|Procedure|ovarian drilling|
75446984|NCT01693302|Other|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
75446985|NCT01693315|Drug|AMA0076|
75446986|NCT01693315|Drug|Placebo|
75888648|NCT03705351|Radiation|Radiation Therapy|Patients will be given radiation therapy according to routine treatment dosing and schedule.
75888649|NCT02691767|Drug|pazopanib|
75888650|NCT03696849|Other|polished emax Press|lithium disilicate glass ceramic crowns subjected to polishing only
75888651|NCT04360083|Other|Collected data from Rhône RéPPOP database|BMI Z-scores at the start and the end of RéPPOP care programs.
75888652|NCT04360083|Other|telephonic questionnaire|Collected data though the telephonic questionnaire : current declared BMI Z-score.
75888653|NCT04398849|Biological|Licenced 4CMenB Vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
75888654|NCT03696693|Device|acoustic vocal analysis|Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
75888655|NCT03698721|Procedure|Transurethral Resection of Prostate|Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.
75888656|NCT04263207|Other|No intervention|No intervention
75888657|NCT03692793|Other|Pulmonary rehabilitation|Patients will perform continuous aerobic training (treadmill walking) during 30min (60% of the 6MWT mean speed) and progression according to dyspnea (4-6 of the modified Borg scale). Upper limbs resistance training will be performed using the modified diagonals from the proprioceptive neuromuscular facilitation method (2 sets of 2min). Lower limbs strength training will be performed for quadriceps and triceps sural (2 sets of 10 repetitions), with progression when the patients report that the exercise are ´easy´. All the muscle exercised and the breathing accessory muscles will be stretched for 30s. Eleven educational sessions will be delivered addressing topics related to COPD self-management.
75888658|NCT03692637|Biological|anti-Mesothelin Car NK Cells|anti-Mesothelin Car NK Cells injection
75888659|NCT03692559|Other|full aseptic dressing|Replacement of the central venous catheters in the dressing process
75446987|NCT01693328|Drug|PecFent® (fentanyl) nasal spray|
75740833|NCT00410410|Drug|abatacept (ABA)|"Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57 (ABA 30/~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months"
75740834|NCT00410410|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
75740835|NCT00410410|Drug|abatacept|"~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued"
75446988|NCT01693341|Other|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
75446989|NCT01693354|Device|Mid-dilution HDF|Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
75446990|NCT01693354|Device|HF dialysis|Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
75446991|NCT01693393|Drug|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
75446992|NCT01693419|Drug|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m² IV on day 1, 8~Erlotinib 100 mg/day PO on day 1~S-1 60 mg/m²/day PO on day 1-14"
75446993|NCT01693432|Drug|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~Docetaxel 60 mg/m²IV on day 1~S-1 80 mg/m2/day PO on day 1-14"
75888660|NCT03705195|Drug|Gliclazide|Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 & 5.
75596610|NCT01325493|Drug|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
75596611|NCT01323972|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)|4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
75446994|NCT01693445|Drug|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~Oxaliplatin 85 mg/m²IV on day 1~Irinotecan 120 mg/m² IV on day 1~S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
75596612|NCT01325337|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
75596613|NCT01325337|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
75888661|NCT03705117|Biological|V565|Capsules for oral administration
75596614|NCT01325337|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
75596615|NCT01325337|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
75596616|NCT01325337|Drug|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
75596617|NCT01324947|Drug|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
75596618|NCT01101841|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
75596619|NCT01101841|Drug|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
75596620|NCT04952545|Drug|ALXN2050|Oral tablet.
75596621|NCT04952545|Drug|Placebo|Oral tablet.
75596622|NCT01324401|Drug|Peanut flour OIT|Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
75596623|NCT02877511|Drug|BAY987517|Applied liberally to the skin (Formulation: Y73-161
75596624|NCT02877511|Drug|Sunscreen Lotion (Y65-110)|Applied liberally to the skin
75596625|NCT05645679|Device|Hybrid Argon Plasma Coagulation System|Hybrid Argon Plasma Coagulation System
75596626|NCT01323660|Drug|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
75888662|NCT00101192|Biological|cetuximab|
75888663|NCT00101192|Drug|cisplatin|
75596627|NCT01323660|Drug|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
75596628|NCT01323660|Drug|GSK573719 125|125mcg QID
75740836|NCT00997178|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
75740837|NCT00997178|Other|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
75740838|NCT00782951|Drug|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
75740839|NCT00782951|Drug|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
75740840|NCT00782951|Drug|Placebo|single IV dose of placebo after dental impaction surgery
75740841|NCT00997256|Drug|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
75740842|NCT00997256|Drug|film-coated sugar-pill|3 x 2 tablets / day over 3 days
75888664|NCT03688269|Drug|Intravenous dexamethasone|Intravenous injection of 8mg/2ml dexamethasone
75888665|NCT03688269|Drug|Intravenous saline|Intravenous injection of 2ml Saline 0.9%
76059214|NCT01380184|Drug|ridaforolimus|4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
75446995|NCT01693458|Behavioral|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
75446996|NCT01693497|Behavioral|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
75446997|NCT01693497|Behavioral|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
75596629|NCT01323660|Drug|GSK573719 62.5|62.5mcg QID
75596630|NCT01323660|Drug|GW642444 25|25mcg QID
75596631|NCT01323660|Device|placebo|Comparator QID
75596632|NCT01324323|Drug|Romidepsin|14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
75740843|NCT02555813|Drug|Abraxane|Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
75888666|NCT03688269|Drug|Perineural ropivacaine|Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
75888667|NCT03688191|Drug|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
75740844|NCT02555813|Drug|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
75888668|NCT02255708|Other|Proprioceptive Neuromuscular Facilitation - PNF|
75888669|NCT03540602|Dietary Supplement|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
75888670|NCT03540602|Other|Placebo Oral Capsule [CEBOCAP]|Rice flour
75888671|NCT02164838|Drug|Axitinib|
75888672|NCT03688113|Behavioral|Tinnitus application|Use of tinnitus application
75888673|NCT02171702|Drug|BIBW 2992|
75888674|NCT03031431|Device|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
75596633|NCT01324323|Drug|Rifampin|600 mg oral once daily on Days 4-8
75888675|NCT03540056|Diagnostic Test|Ultrasound|We use ultrasound to measure the PRF and the testicular volumes.
75888676|NCT03696615|Other|Tabata Kettlebell Swing Workout|See description of experimental arm.
75596634|NCT05344963|Drug|Sodium-GLucose coTransporter-2 inhibitors|Evaluation of the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and three-dimensional echocardiography (optional), in patients with HFrEF after treatment with the SGLT2i drugs Dapagliflozin and Empagliflozin
75596635|NCT05645601|Biological|CD19-CAR-NK|The relapsed/refractory B-cell hematologic malignancies patients will receive FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy followed by 3 infusions of JD010 cells up to 2 dose levels (5x10^6/kg, 2x10^7/kg) after FC chemotherapy.
75596636|NCT02879227|Drug|Cisplatin|Arm cisplatin : 75mg/m2, day n*1 and day n*22, And radiotherapy 50 Gy, 2Gy/f
75888677|NCT03696615|Other|Control|see description of control arm
75888678|NCT02171780|Drug|BI 1744 CL|
75888679|NCT02171780|Drug|Placebo|
75888680|NCT03540524|Drug|GLPG2451 dose regimen A|GLPG2451 oral suspension, daily.
75888681|NCT03540524|Drug|GLPG2451 dose regimen B|GLPG2451 oral suspension, daily.
75888682|NCT03540524|Drug|GLPG2222|GLPG2222 tablet for oral use, daily.
75888683|NCT03540524|Drug|GLPG2737|GLPG2737 capsules for oral use, daily.
75888684|NCT03539978|Other|SM-THINk|Patients will receive the SM-THINk enhanced discharge method.
75596637|NCT02879227|Drug|Oxaliplatin|85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
75596638|NCT05645445|Device|virtual reality|patients who include intervention gruop during the ESWL process, patients will be shown videos with virtual reality glasses, which include nature and landscapes, giving people a feeling of comfort and peace, and making them feel like they are inside.
75596639|NCT01323582|Drug|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
75740845|NCT00994058|Device|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
75740846|NCT00997412|Drug|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
75740847|NCT00997412|Drug|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
75888685|NCT02255864|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
76059215|NCT01395394|Drug|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
76059216|NCT01395394|Other|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
76059217|NCT05362552|Other|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
76059218|NCT00002826|Drug|paclitaxel|
76059219|NCT00002826|Drug|valspodar|
76059220|NCT01395316|Drug|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
75596640|NCT01323582|Drug|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
76059221|NCT04331938|Drug|Regional anesthetic SPG block-bilateral|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
76059222|NCT05362084|Procedure|lumbar medial branch block|lumbar medial branch block
76059223|NCT01742091|Drug|LY2541546 - SC|Administered SC
76059224|NCT01742091|Drug|LY2541546 - IV|Administered IV
76059225|NCT01742091|Drug|Placebo - SC|Administered SC
76059226|NCT01742091|Drug|Placebo - IV|Administered IV
76059227|NCT01731951|Drug|Imetelstat|Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
76059228|NCT04560777|Other|CO-OP intervention|"The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents."
76059229|NCT01731171|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
76059230|NCT01731171|Dietary Supplement|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
76059231|NCT01741701|Drug|Oxaloacetate (OAA)|
76059232|NCT01741701|Drug|Placebo|
76059233|NCT01741545|Biological|Pegylated-Interferon-lambda|
76059234|NCT01741545|Drug|Ribavirin|
75446998|NCT01693510|Behavioral|Exercise and Nutrition Intervention|Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
75446999|NCT01693536|Behavioral|Lifestyle counselling|as in Arm Description
75447000|NCT01693549|Drug|Cabazitaxel|
75596641|NCT00626041|Other|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
76059235|NCT01741545|Drug|Daclatasvir|
76059236|NCT01884350|Drug|Apixaban|
76059237|NCT01614795|Biological|Cixutumumab|Given IV
76059238|NCT01614795|Other|Laboratory Biomarker Analysis|Correlative studies
76059239|NCT01614795|Drug|Temsirolimus|Given IV
76059240|NCT01834586|Drug|Anesthetic Topical Adhesive Synera|"For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week"
76059241|NCT01614249|Dietary Supplement|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
76059242|NCT01614249|Dietary Supplement|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
75888686|NCT02168894|Procedure|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
75888687|NCT02168894|Procedure|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
75888688|NCT02168894|Behavioral|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
75888689|NCT02171936|Other|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
75888690|NCT05142488|Biological|Covid -19 (recombinante) vaccine|Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
76059243|NCT01597778|Biological|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
75447001|NCT01693575|Device|Pupil expansion with APX 100 device|Patients with small pupils (<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
75447002|NCT01693588|Other|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
75447003|NCT01693627|Device|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
75447004|NCT01693627|Device|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
75447005|NCT01693627|Device|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
75447006|NCT01693627|Device|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
75447007|NCT01693640|Drug|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
75447008|NCT01693666|Behavioral|Lifestyle intervention|"To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
75888691|NCT02172014|Drug|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
75888692|NCT02172014|Drug|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
75447009|NCT01693679|Drug|Telbivudine, Lamivudine, Adefovir ,Enecavir|investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
75888693|NCT02168972|Device|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
76059244|NCT01597778|Biological|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
76059245|NCT01614093|Drug|Oxytocin|Single dose intranasal oxytocin (24 IU)
76059246|NCT01614093|Drug|Placebo|Placebo- Sugar pill
76059247|NCT01834274|Drug|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
76059248|NCT01834274|Drug|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
76059249|NCT01834274|Drug|Sitagliptin|Sitagliptin tablets
76059250|NCT01834274|Drug|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
76059251|NCT01834274|Drug|Metformin|Metformin tablets
75447010|NCT01693705|Procedure|Tracheostomy|
75740848|NCT04047407|Device|Suprathreshold pain stimulation|"Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized."
75740849|NCT00997490|Drug|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
75888694|NCT02165150|Other|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
75888695|NCT02165228|Behavioral|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
75888696|NCT02165228|Behavioral|Nutrition Enhancement|Nutrition education class and behavioral intervention
75888697|NCT02172092|Drug|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
76059252|NCT01739595|Drug|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
76059253|NCT01739595|Drug|Placebo|Oral capsule taken one time daily for 3 months
76059254|NCT01833494|Drug|PA21|
75447014|NCT01693770|Procedure|MRgFUS|Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
75447015|NCT01693809|Drug|Caffeine|
75447016|NCT01693822|Drug|Axitinib|"Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
75447017|NCT01693874|Behavioral|MBSR|Mindfulness-Based Stress Reduction
75740850|NCT00997490|Drug|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
75888698|NCT02261246|Procedure|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
76059255|NCT01738971|Other|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
76059256|NCT01738971|Other|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
76059257|NCT01738581|Device|Repetitive Transcranial Magnetic Stimulation|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
76059258|NCT01738581|Behavioral|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
76059259|NCT01738581|Behavioral|Non-specific Therapy|A non-specific massage and stretching program directed to the hand, wrist and forearm
76059260|NCT01738503|Drug|RBP-6000|18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.
76059261|NCT01738503|Drug|Subutex|Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.
75740851|NCT00783107|Drug|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
75740852|NCT00783107|Drug|Placebo|
75740853|NCT00997568|Device|PET-511BTM|Transesophageal Transducer
76059262|NCT01738191|Drug|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
75596642|NCT05367765|Drug|Flumatinib|Flumatinib 600mg orally daily
76059263|NCT01738191|Drug|Placebo|
75447018|NCT01693874|Behavioral|control (health education)|health education
75447019|NCT01693913|Behavioral|cognitive behavioral exercise and nutrition over|
75447020|NCT01693913|Behavioral|nutrition and exercise education|
75447021|NCT01693926|Behavioral|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
75447022|NCT01693926|Behavioral|placebo|
75596643|NCT05367765|Drug|Imatinib|Imatinib 400mg orally daily (Reference drug instructions)
75596644|NCT05645367|Other|No intervention|This is a post-hoc analysis of a cross-sectional study.
75447023|NCT01693939|Device|FS200 Femtosecond Laser|
75596645|NCT02891382|Behavioral|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
75740854|NCT00783185|Behavioral|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
76059264|NCT01737879|Drug|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
76059265|NCT01737879|Drug|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
75447024|NCT01693952|Biological|blood draw|
75596646|NCT02891382|Behavioral|Goal setting|Goals for weight loss and change in levels of HbA1c
75596647|NCT02891382|Behavioral|Companion Support|Patient has a companion/team support partner to support achieving goals.
75596648|NCT02891382|Behavioral|Individual Reward|The cash reward is given to the patient with diabetes.
75596649|NCT02891382|Behavioral|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
75596650|NCT01323621|Drug|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
75740855|NCT00783185|Behavioral|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
75740856|NCT00783341|Drug|GAP-134|
75740857|NCT00783341|Drug|placebo|
75740858|NCT00534404|Drug|Nicotine patches|Participants will wear nicotine patches.
75740859|NCT00534404|Behavioral|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
75740860|NCT00534404|Behavioral|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
75740861|NCT00393094|Biological|Bevacizumab|10 mg/kg intravenous injection
75740862|NCT00393094|Drug|Irinotecan hydrochloride|125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
75740863|NCT04047485|Diagnostic Test|Visual Acuity|During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
75447025|NCT01693978|Behavioral|Prolonged Exposure Therapy|"Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, & Rothbaum, 2007)."
75740864|NCT04047485|Diagnostic Test|CAM (Confusion Assesment Method)|"During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated."
75740865|NCT04047485|Diagnostic Test|CATQUEST 9-SF|The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
75740866|NCT04047485|Diagnostic Test|OCT|Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
75740867|NCT04047485|Diagnostic Test|6CIT|This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
75888699|NCT02165306|Behavioral|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
75888700|NCT02165306|Behavioral|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
75447026|NCT01693978|Behavioral|Voucher-Based Reinforcement|Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
75447027|NCT01693991|Behavioral|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
75596651|NCT01323621|Drug|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
75596652|NCT01323621|Drug|Double-dummy placebo|inhalation powder
75596653|NCT01323621|Drug|Salbutamol as needed|inhalation powder
75596654|NCT00623298|Behavioral|Narrative Exposure Therapy|
75596655|NCT00623298|Behavioral|group IPT|
75596656|NCT00623298|Other|6 months-baseline|
75596657|NCT01323192|Drug|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
75596658|NCT01323192|Drug|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
75596659|NCT01323387|Device|Interbody Fusion|allograft spacer + anterior plate
75596660|NCT05645289|Drug|Minodronate|The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
75596661|NCT05645289|Drug|Alendronate|The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
75596662|NCT00623259|Biological|MVA-mBN120B|
75740868|NCT04047485|Diagnostic Test|Barthel Index|To evaluate the everyday independence of the subject and it's trend durin the follow-up
75740869|NCT04047485|Diagnostic Test|Endothelial Microscopy - Cornea|Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
75740870|NCT01043848|Procedure|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
75740871|NCT00783653|Drug|Sunitinib|25 mg or 37,5 mg daily dose until DLT
75740872|NCT00409786|Behavioral|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
75888701|NCT02169206|Radiation|Bilateral shoulder anteroposterior radiography|"Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~In the same position, the patient only elevates the arm up to 90 degrees of abduction."
75888702|NCT03539120|Other|Follow up for survival|No intervention, this is an observational study of survival outcomes.
75888703|NCT02169362|Device|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)|Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
75888704|NCT02172170|Drug|BI 10773 single rising dose|
75888705|NCT02172170|Drug|Placebo|
76059266|NCT01879683|Drug|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
76059267|NCT04415307|Other|Acupuncture|Acupuncture over acupoints.
76059268|NCT04415307|Other|Far-Infrared heat-patch attachment|Far-Infrared heat-patch attachment over acupoints.
75596663|NCT02891343|Other|2-hour period of hypoxia|During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
76059269|NCT04415307|Other|Acupuncture and Fir-Infrared heat-patch attachment|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
75596664|NCT01321749|Procedure|Remote ischemic preconditioning (RIPC)|The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
75596665|NCT01320033|Drug|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
75740873|NCT00786305|Drug|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
75888706|NCT02255942|Other|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
75888707|NCT02255942|Other|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
75888708|NCT02255942|Other|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
75888709|NCT02255942|Other|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
75888710|NCT03029247|Drug|Daprodustat|Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
76059270|NCT04415307|Other|Far-Infrared heat-patch attachment over acupoints without electric current passing.|Far-Infrared heat-patch attachment over acupoints without electric current passing.
76059271|NCT01605825|Drug|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
76059272|NCT01605825|Drug|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
76059273|NCT04558905|Other|Face-to-face medical visits|Face-to-face medical visits
76059274|NCT04558905|Other|Alternating face-to-face medical visits and video medical consultations|Alternating face-to-face medical visits and video medical consultations
76059275|NCT04558749|Other|State-trait anxiety inventory scale|This scale is composed of two parts, part one measures anxiety traits and part two measures anxiety state. Each part comprises 20 statements. This scale is a (4) point scale, with a score ranging a minimum of 20 grades to a maximum of 80 grades.
75447028|NCT01693991|Behavioral|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
75447029|NCT01694017|Drug|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
75447030|NCT01694017|Drug|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
75447031|NCT01694030|Other|Attachment security priming|
75740874|NCT00786305|Drug|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
75888711|NCT03029247|Drug|Epoetin alfa|Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
75888712|NCT03696459|Drug|JNJ-53718678, 2000 mg|Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
76059276|NCT04558749|Other|Edinburgh Postnatal Depression Scale (EDPS)|The EPDS is a self-report measure that focuses on the cognitive symptoms of depression. It excludes somatic items that might generate false positives both during pregnancy and after childbirth.7 The EPDS consists of 10 items, each scored 0-3 points, with a potential scale score of 0-30.
76059277|NCT01727505|Device|Sequence A: Conventional-Volume Guarantee|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
75447032|NCT01694043|Other|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
75447033|NCT01694043|Other|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
75447034|NCT01694056|Other|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
75447035|NCT01694056|Other|Control diet|4 weeks high mixed protein diet (20 en%)
75447036|NCT01694082|Behavioral|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
75447037|NCT01694082|Behavioral|Brief brochure and assessment control|
75447038|NCT05289778|Other|Survey|Students will complete structured questionnaires in classroom settings, and parents will complete telephone interviews in the absence of their children.
75447039|NCT05289726|Drug|Traditional chinese medicine TDX105|Experimental group Traditional chinese medicine TDX105
75447040|NCT05289726|Drug|Placebo|he control group received placebo granules mixed with dextrin and food coloring
75447041|NCT05289700|Device|HBOT in Hyperbaric chamber|HBOT is the administration of oxygen (FIO2 = 100%) at a pressure higher than atmospheric pressure (2 ATA). The pressure increase is achieved by introducing compressed air into the hyperbaric chamber. This study will use a hyperbaric chamber that is already marketed, licensed and used in other diseases.
75447042|NCT05289700|Device|Hyperbaric chamber for placebo|Hyperbaric chamber is the same chamber used for HBOT, but here with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers. All other aspects of the procedure are identical to those of the intervention. As in the intervention arm, there will be a compression period (although shorter), of 5 min, followed by 85 min at 1.3 ATA, then a decompression period of 5 min (total duration of 95 min).
75447043|NCT05289609|Procedure|Liver Transplantation|Individuals with end-stage liver disease will be subjected to liver transplantation from deceased or living donors
75447044|NCT05289531|Procedure|Rectal Resection Patients|Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery
75447045|NCT05289518|Device|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 220mmHg and 5-min deflation.
75447046|NCT05289518|Device|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
75447047|NCT05289466|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
75447048|NCT05289466|Procedure|Oncoplastic partial mastectomy|Breast Conserving Therapy
75447049|NCT05289453|Procedure|lens extraction by phacoemulsification|lens extraction by phacoemulsification
75447050|NCT05289401|Other|ultrasound guided blocks|Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric
75447051|NCT05289388|Diagnostic Test|Lactate/CRT index|index will be calculated as the product of multiplying the CRT and serum lactate
75447052|NCT05289336|Procedure|Transoral Laser Microsurgery|
75447053|NCT05289219|Behavioral|EXPOBAR|Each session will start with 5 minutes of warm-up and finalization with 10 minutes of a cool-down, with work of flexibility and proprioception. The maintenance of balance and postural stability may be compromised in obese individuals, depending on the degree of obesity, although the support base provided by the position of the foot is proportional to the structural morphology of each subject. Flexibility is also gradually impaired in obese individuals and of course, these changes may be related to postural changes aggravated by a sedentary lifestyle and biological aging itself alongside all metabolic alterations inherent to the pathology of obesity (Benetti et al., 2016). And the warm-up and the cool-down will be developed as the component of training with the evolution by phases, both in time and in intensity. The first phase will include 20 minutes of interval training, encompassing circuit strength training. Each phase will have an increment of 10 minutes in the central block.
75447054|NCT05289128|Device|Experimental group|10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
75596666|NCT01320033|Drug|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
75596667|NCT01320033|Drug|Placebo|Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
75888713|NCT03696459|Drug|JNJ-53718678, 3000 mg|Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
75888714|NCT03696459|Drug|JNJ-53718678, 4500 mg or Dose to be decided|Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
75596668|NCT01101061|Drug|Romosozumab|Administered by subcutaneous injection
75596669|NCT01101061|Drug|Placebo|Administered by subcutaneous injection
75888715|NCT03696459|Drug|JNJ-53718678 500 mg|Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
75447055|NCT05289128|Device|Sham Control|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
75740875|NCT00790517|Behavioral|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
75740876|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
75888716|NCT03696459|Drug|JNJ-53718678 Placebo|Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
75447056|NCT05289115|Device|Experimental group/ Active HD-tDCS|Patients enrolled in this group will received 20 minutes of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) during 10 sessions. It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
75447057|NCT05289115|Device|Control Group / Sham Group|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
75447058|NCT05289102|Other|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.
75447059|NCT05289102|Other|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
75596670|NCT04325295|Procedure|Laparoscopic ovarian drilling|LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached > 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
75616463|NCT04201678|Procedure|EPIAA Group (Extrapedicular infiltration anesthesia)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
75740877|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
75740878|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
75740879|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
75740880|NCT00786383|Biological|IMC-1121B|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
75888717|NCT03696459|Drug|Moxifloxacin 400 mg|Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
75888718|NCT03696459|Drug|Moxifloxacin Placebo|Participants will be administered moxifloxacin matching placebo in Part 2.
75888719|NCT03696381|Other|Real tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. During the first 20 minutes of each cognitive training session, patients will receive bi-frontal and bi-parietal tRNS. It has a start and end ramp of two seconds in each case to avoid the slight unpleasant sensation that occurs in the first moments of the introduction of direct current DC.
75447060|NCT05289011|Other|Interviews and questionnaires|"Evaluation of inflammatory rheumatism~Dietary survey~International Physical Activity Questionnaire IPAQ~BASDAI self-questionnaire~Assessment of quality of life by ASQol questionnaire~Assessment of fatigue by FACIT questionnaire~Assessment of digestive symptoms~Collection of demographic and general data~Collection of treatment"
75447061|NCT05288959|Device|Session 2: Single-pulse TMS (spTMS)|Uni-focal TMS (MagVenture, Farum, Denmark) is delivered to one brain area while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The targeted brain areas and TMS intensities may vary across runs. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coil.
75596671|NCT04325295|Drug|Recombinant FSH (rFSH)|A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
75740881|NCT00786383|Biological|1121B|"Cohort 2~8mg/kg I.V., once every other week for 4 weeks"
76059278|NCT01727505|Device|Sequence B: Volume Guarantee-Conventional|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
75447062|NCT05288959|Device|Sessions 3 - 5: Paired associative stimulation (PAS)|During each PAS run, bi-focal TMS (MagVenture, Farum, Denmark) is delivered to two brain areas while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The asynchronies between the two TMS coils are kept constant within each session but differ across sessions. Within each session, to observe PAS effects on connectivity, uni-focal spTMS is delivered to the stimulated areas before and after the PAS modulation while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. In addition, resting-state EEG/EMG and a behavioral measure (bimanual task coordination) are recorded before and after the PAS modulation. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coils.
75447063|NCT05288881|Biological|ANX105|Participants will receive single-ascending doses of ANX105 administered by IV infusion.
75447064|NCT05288881|Drug|Placebo|Participants will receive matching placebo administered by IV infusion.
75447065|NCT05288816|Drug|ALXN1210|Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
75447066|NCT05288738|Drug|Dexmedetomidine 1 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml
75596672|NCT02891187|Behavioral|Telephone follow-up|Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
75596673|NCT02891187|Behavioral|Outpatient Clinic Visits|Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
75596674|NCT05644743|Device|gemcitabine + cisplatin|Gemcitabine intravenous drip, day 1, 8； Cisplatin intravenous drip, day 1； 3 weeks is a cycle, and 6 cycles are used continuously.
75740882|NCT00786383|Biological|1121B|"Cohort 3~10 mg/kg I.V., once every other week for 4 weeks"
75740883|NCT00786383|Biological|1121B|"Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks"
75447067|NCT05288738|Drug|Dexmedetomidine 2 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml
75447068|NCT05288725|Biological|Bone Marrow Derived MSCs|Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.
75447069|NCT05288725|Drug|Corticosteroid|The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog [40 mg/dL], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.
75447070|NCT05288725|Device|Bone Marrow Aspirate|The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.
75447071|NCT05288465|Drug|Cerebrolysin|Patients prescribed for Cerebrolysin treatment due neurological disease are invited to donate a scalp punch biopsy prior to and after completing the prescribed treatment.
75740884|NCT00786383|Biological|1121B|"Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks"
75740885|NCT01042444|Device|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
75447072|NCT05288426|Other|No intervention|This is an observational study, with no intervention.
75740886|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
75740887|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
75740888|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
75740889|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
75740890|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
75888720|NCT03696381|Other|Sham tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. We will apply a sham tRNS for the first 20 minutes of each cognitive training session. The subjects will receive sham tRNS and will perform the same type of cognitive training as the rest of patients and will receive the same type of adverse reaction questionnaire. Subjects receiving simulated stimulation will receive the same type of ramps at the beginning and end of the session to ensure triple-blind maintenance .
75888721|NCT03624153|Behavioral|Robotic-assisted intervention|Participants received the 12-session robot-assisted intervention 3 sessions a week for 4 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
75740891|NCT00783731|Drug|Low dose midazolam|
76059279|NCT04564677|Device|Ifabond (Péters surgical)|Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
75447073|NCT05288387|Procedure|Spinal cord stimulation|High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord and this activation leads to blood pressure elevation.
75447074|NCT05288270|Device|Aramis|"ARAMIS is composed of two computer-controlled, symmetric and interacting exoskeletons able to compensate the inadequate strength and accuracy of the paretic arm movements, of which it measures residual motor function, and the effect of gravity during rehabilitation. It acts through motion capture of the movements of the unaffected arm. In so doing, the patient is able to replicate the movements of the healthy arm with the paretic arm in synchronous, asynchronous or active-assisted manner. The robot-assisted neurorehabilitation using ARAMIS consists in 60-min sessions for 8 weeks,structured as follows:~1 to 4 weeks: asynchronous exercises of repletion by the paretic arm of basic exercises 20 times for a total of 200 repetitions per session;~5 to 8 weeks: replaced by synchronous exercises (100/session) with active-assisted modality."
75447075|NCT05288270|Other|Conventional therapy|The control group will receive conventional rehabilitation consisting in passive mobilization of upper and lower limbs, coordination respiratory exercises, cardiovascular conditioning in the setting posture, conditioning in the upright posture, exercises for the trunk control.
75596675|NCT01317615|Drug|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
75596676|NCT01317615|Drug|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
76059280|NCT04564053|Drug|LNA043|Single intra-articular injection on Day 1
76059281|NCT04564053|Drug|Placebo|Single intra-articular injection on Day 1
75596677|NCT01317615|Drug|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
75596678|NCT02891109|Biological|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
75740892|NCT00409708|Drug|Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|
75740893|NCT00409708|Behavioral|Behavior Therapy|
75740894|NCT00790985|Dietary Supplement|flavocoxid|medical food
75740895|NCT00790985|Drug|Naproxen|antiinflammatory drug
75740896|NCT01044082|Procedure|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
76059282|NCT01726803|Other|Early Physical Therapy with Usual Care|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
75740897|NCT01044082|Procedure|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
75888722|NCT03624153|Behavioral|Conventional rehabilitation intervention|Participants received the 12-session conventional rehabilitation intervention 3 sessions a week for 4 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
75740898|NCT01324336|Drug|6-Mercaptopurine|75 mg/m2/dose/day
75740899|NCT00783887|Other|Blood sample|Blood sample of 5 ml
75740900|NCT01039870|Procedure|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
75740901|NCT01039870|Procedure|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
75888723|NCT03624075|Other|application of kinesio taping|application of kinesio taping in the rectus femoris muscle and in the medial and lateral region of the knee
76059283|NCT01726803|Other|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
76059284|NCT01726335|Drug|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
75740902|NCT00784121|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
75740903|NCT04047173|Radiation|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 33-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
76059285|NCT01877421|Drug|2 mg KSL-W|
76059286|NCT01877421|Drug|4 mg KSL-W|
76059287|NCT01877421|Drug|6 mg KSL-W|
76059288|NCT01877421|Drug|10 mg KSL-W|
76059289|NCT01877421|Drug|20 mg KSL-W|
75447076|NCT05288244|Other|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
75447077|NCT05288244|Other|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
75740904|NCT04047173|Procedure|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 2 times.
75740905|NCT01324492|Drug|RAD001|
75740906|NCT01042834|Other|Air pollution study on healthy volunteers.|"The subjects are examined three times:~First the volunteers get used to equipments.~Second and third the volunteers sleep in a pollution or purified air."
76059290|NCT01877421|Drug|30 mg KSL-W|
76059291|NCT01877421|Drug|50 mg KSL-W|
75447078|NCT05288244|Other|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
75447079|NCT05288192|Drug|Suprachoroidal triamcinolone acetonide (SCTA) injection|Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.
75447080|NCT05288179|Drug|Pirfenidone Capsules|After randomization, the experimental group took pirfenidone capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
75447081|NCT05288179|Drug|placebo capsules|After randomization, the experimental group took placebo capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
75740907|NCT01039948|Biological|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
75740908|NCT01039948|Drug|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
75740909|NCT00391846|Drug|Captopril|
75740910|NCT00391846|Drug|Enalapril|
76059292|NCT01877421|Drug|75 mg KSL-W|
75740911|NCT00391846|Drug|Lisinopril|
75740912|NCT00391846|Drug|Ramipril|
75740913|NCT00391846|Drug|Trandolapril|
75740914|NCT00391846|Drug|Bisoprolol|
75740915|NCT00391846|Drug|Carvedilol|
75740916|NCT00391846|Drug|Metoprolol succinate|
75740917|NCT00391846|Drug|Candesartan|
75740918|NCT00391846|Drug|Valsartan|
75740919|NCT00391846|Drug|Eplerenone|
75888724|NCT03692247|Other|Smartphone-based Music Intervention|The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
76059293|NCT01877421|Drug|100 mg KSL-W|
76059294|NCT01877421|Other|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
75596679|NCT05644509|Biological|Oncolytic Virus Injection（Revottack）+PD-1|Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
75596680|NCT01078675|Drug|rosuvastatin calcium|5 mg, oral, once daily, 24 months
75740920|NCT00391846|Drug|Spironolactone|
76059295|NCT01726023|Drug|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
76059296|NCT01726023|Drug|metronidazole|Metronidazole 500mg/100ml solution for infusion
76059297|NCT01726023|Drug|Meropenem|Meropenem powder for solution for infusion 1000mg
76059298|NCT01877265|Drug|LY2605541|
76059299|NCT01877187|Drug|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
76059300|NCT04609761|Drug|Privigen Injectable Product (Intravenous Immunoglobulin)|Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
75447082|NCT05288127|Drug|Talazoparib|"The recommended dose is 1 mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs. Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the if evidence of response or clinical benefit to talazoparib is noted.~Missing dose If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~Dose adjustments:~To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered."
75447083|NCT05291585|Device|the dedicated venous sinus thrombectomy stent|the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.
75596681|NCT01078675|Drug|rosuvastatin calcium|10 mg, oral, once daily, 24 months
75740921|NCT00391846|Drug|Diuretics|
75740922|NCT00391846|Drug|HF treatment according to Swedish guidelines|
75740923|NCT00391846|Procedure|Blood samples|
75740924|NCT00391846|Procedure|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
75596682|NCT01078675|Drug|rosuvastatin calcium|20 mg, oral, once daily, 24 months
75596683|NCT04301791|Other|nutritional status|impact of nutritional status on clinical outcome of children admitted in PICU
75596684|NCT02878135|Procedure|fast application|
75596685|NCT02878135|Procedure|slow application|
75596686|NCT04875793|Diagnostic Test|Stool for Occult Blood Test and Colonoscopy with comprehensive medical checkups|participants will be drawn from all public government institutions inside Tabuk city(outreach). The institution head will be requested to give wellness cards to the eligible employee to receive comprehensive testing for free in addition to CRC test in selected public health centres.
75740925|NCT00448630|Other|No intervention|Non-interventional study
75740926|NCT01042990|Other|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
75740927|NCT00534248|Biological|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
75740928|NCT00534248|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
75740929|NCT00994136|Drug|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
75740930|NCT00997724|Procedure|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
75740931|NCT00997802|Device|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
76059301|NCT01858532|Drug|Atrasentan|Film-coated tablet
76059302|NCT01858532|Drug|Placebo|Film-coated tablet
76059303|NCT01883492|Device|Femoral Stem|JMDN classification/Class III device
76059304|NCT01883492|Device|Acetabular Cup|JMDN classification: Class III device
76059305|NCT01883492|Device|Acetabular Liner|JMDN classification: Class III device
76059306|NCT01832480|Drug|MTZ 500 mg twice daily x 7 days|MTZ 500 mg twice daily x 7 days
76059307|NCT01832480|Drug|MTZ 2 g|MTZ 2 g
76059308|NCT04613960|Drug|Magnesium sulfate|MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
76059309|NCT04613960|Drug|normal saline|Placebo treatment
75888725|NCT03692169|Procedure|Half-dose photodynamic therapy|Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
75888726|NCT03624309|Drug|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
75888727|NCT03624309|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1)
76059310|NCT04598984|Diagnostic Test|serum adipokines|Level of serum adipokines will be measured with flow cytometry
75447084|NCT05291585|Device|balloon catheter thrombectomy|Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
75447085|NCT05291572|Behavioral|speech therapy only|fluency shaping technique
75447086|NCT05291572|Device|hyperbaric oxygen therapy|chamber system using oxygen with pressure
75447087|NCT05291572|Drug|medical treatment|brain stimulant
75447088|NCT05291455|Drug|Lacosamide|lacosamide will be given
75447089|NCT05291455|Drug|Phenobarbital|phenobarbital will be given
75447090|NCT05291429|Device|OVR Health's VR experience|Virtual reality experience
75596687|NCT02877199|Other|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
75596688|NCT02879149|Device|AUGMENT® Bone Graft|AUGMENT® Bone Graft
75596689|NCT02879149|Procedure|Standard of Care|Autologous Bone Graft
75596690|NCT02877277|Dietary Supplement|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
75596691|NCT02877277|Dietary Supplement|Placebo|Oral intake of placebo tablet daily for 56 days
75447091|NCT05291416|Diagnostic Test|densitometry/ handgrip dynamometer|all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer
75447092|NCT05291312|Procedure|Adenoidectomy with endoscopic assisted coblation (EACA) and Adenoidectomy with conventional curettage (CCA)|IN the (EACA) group slight head flexion position will be given to the patients and Boyle-Davis retractor will be placed to keep the mouth open. The soft palate will be elevated upward by inserting a plastic feeding catheter.. IN the (CCA) group, by orotracheal intubation , Boyle-Davis mouth retractor will be used to provide mouth opening
75596692|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
75596693|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
75596694|NCT04306705|Drug|Tocilizumab|Administered as an intravenous infusion.
75596695|NCT04306705|Other|Standard of care|Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
75596696|NCT04306705|Procedure|Continuous renal replacement therapy|Catheter insertion site is femoral vein.
75596697|NCT01322490|Biological|PROSTVAC-V|
75596698|NCT01322490|Biological|PROSTVAC-F|
75596699|NCT01322490|Drug|GM-CSF|
75596700|NCT01322490|Other|GM-CSF Placebo|
75596701|NCT01322490|Biological|Placebo|PROSTVAC V/F Placebo
75596702|NCT02877355|Drug|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
75888728|NCT03624387|Other|Painting Sessions|During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
75888729|NCT04050111|Biological|Stromal-vascular fraction|Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
76059311|NCT04598282|Device|Prokera Slim|Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.
75596703|NCT01314261|Drug|ABT-267|5 mg or 25 mg tablets
75596704|NCT01314261|Drug|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
75596705|NCT01314261|Drug|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
75596706|NCT01314261|Other|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
75596707|NCT02891616|Drug|fludeoxyglucose F 18|
75596708|NCT02891616|Device|Positron emission tomography-computed tomography|
75596709|NCT02891616|Drug|18F-fluorothymidine|
75596710|NCT02891616|Device|Positron emission tomography-magnetic resonance imaging|
75596711|NCT01321710|Behavioral|Sleep hygiene|"This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy."
75740932|NCT00391768|Drug|oseltamivir (Tamiflu®)|Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
75740933|NCT00391222|Drug|Olanzapine|Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
75740934|NCT00391222|Drug|Placebo|Intramuscular injections of placebo every 2 weeks and oral placebo daily
75740935|NCT00391222|Drug|Risperidone Long Acting Injectable (LAI)|Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
75888730|NCT03687879|Other|Questionnaires|Reporting of medical gestures or acts, speech, embarrassing or hurtful attitudes during pregnancy follow-up or during hospitalization outside childbirth, or during childbirth or immediate after birth among women giving birth in one of the 26 maternity hospitals in the period of observation period.
75888731|NCT03696147|Device|Magnetic resonance imaging|Diffusion weighted sequence of MRI
75888732|NCT03687801|Behavioral|Online hearing support|The intervention group will follow an online hearing support for five weeks
75888733|NCT03687801|Behavioral|Standard care|The control group will follow standard care during the time the intervention group receives online haring support
75888734|NCT03687645|Diagnostic Test|Hyperpolarised MRI|Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
75888735|NCT03692091|Procedure|Subacromial Injection|Injection in to subacromial space in the shoulder from anterior portal
75888736|NCT03695991|Procedure|percutaneous nephrostomy|The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
75888737|NCT03692013|Drug|Losartan|Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
75888738|NCT03687489|Device|Abdominal Aortic Aneurysm Stent Graft System|Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
75447093|NCT05291195|Device|Laser-device group|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the laser-device groups, the adjuvant treatment approaches were performed either by means of photodynamic therapy (HELBO, Photodynamic Systems GmbH) or high power diode laser (940nm, Biolase ® Technology, CA, USA). Performing photodynamic therapy the root canals were filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Germany) for 2 min following irradiation of diode laser (HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW)) for 60 s. Performing only diode laser the root canals were be irrigated with a diode laser (λ = 940 maximal power 10W) for 60 s."
75596712|NCT01321710|Behavioral|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
75596713|NCT01321710|Drug|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
75888739|NCT04313283|Behavioral|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders.
75888740|NCT03695835|Drug|Immunotherapeutic Agents|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
75596714|NCT01321008|Radiation|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
75596715|NCT01321008|Drug|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
75740936|NCT01043068|Drug|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
75740937|NCT00409006|Drug|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
75888741|NCT03695835|Device|Ablation|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
75888742|NCT03691701|Other|strict blood pressure control|Home SBP target < 120 mmHg or 90th percentile for age and height (whichever is lower)
75888743|NCT03695757|Biological|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
75888744|NCT03695757|Biological|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
75888745|NCT03687255|Drug|cefepime/AAI101 combination|cefepime 2 g / AAI101 500 mg
75888746|NCT03687255|Drug|Piperacillin/tazobactam|piperacillin 4 GM / tazobactam 500 MG
76059312|NCT04598282|Other|Standard of Care|Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
76059313|NCT01858376|Dietary Supplement|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
76059314|NCT01831856|Drug|1g of F373280|Oral administration, one capsule each evening with dinner.
76059315|NCT01831856|Drug|Placebo|Oral administration, one capsule each evening with dinner.
75447094|NCT05291195|Drug|Essential Oil|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)"
75447095|NCT05291195|Drug|Sodium hypochlorite group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
75447096|NCT05291104|Dietary Supplement|Folic acid, choline chloride|In this study, we divide intervention group into two groups which received folic acid (FA) or choline chloride (CC) supplement. Each subgroups contain 20 subjects, including 10 men and women. According to Recommended Daily Nutrient Allowance, FA recommended intake is 400 ug / day and choline recommended intake in men and women is 450 and 390 mg / day. From phase 1 to phase 3 stage, for every 10 days, subjects are given 2-fold, 4-fold and 8-fold recommended intake dose of FA or CC. All supplement solve in 240 ml cranberry juice.
75447097|NCT05291052|Drug|Tislelizumab|Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1
75447098|NCT05291052|Drug|Lenvatinib|Lenvatinib 8 mg (for patient weight < 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W
75447099|NCT05291052|Drug|Oxaliplatin|"Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
75596716|NCT01321008|Drug|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
75596717|NCT01321008|Drug|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
75596718|NCT01321008|Drug|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
75596719|NCT05661396|Behavioral|Serious game rehabilitation|Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
75596720|NCT01323530|Drug|Eribulin mesylate|Intravenous (IV) bolus or infusion.
75740938|NCT00409006|Drug|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
75740939|NCT00409006|Drug|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
76059316|NCT01831544|Device|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
76059317|NCT01857206|Biological|Mammalian cell based flu vaccine|
76059318|NCT01857206|Biological|Egg based flu vaccine|
76059319|NCT01882088|Drug|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
76059320|NCT01881776|Procedure|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
76059321|NCT01708161|Drug|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
76059322|NCT01708161|Drug|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
76059323|NCT04557033|Other|Mindfulness intervention|My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
76059324|NCT01707693|Behavioral|Lifestyle Physical Activity Intervention|Physical Activity Information given plus Behavioral counseling using motivational interviewing & follow-up
76059325|NCT01707693|Behavioral|Information / Attention Comparison|Physical Activity information given & follow-up, no behavioral counseling
75447100|NCT05291052|Drug|Capecitabine|"Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
75447101|NCT05291013|Procedure|Gastric byspass|Test will be before and 9-12 month after gastric bypass
75596721|NCT01323530|Drug|Capecitabine|Oral film-coated tablets.
75596722|NCT05645198|Drug|Oozfix|Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
75740940|NCT00534092|Device|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
75740941|NCT00997880|Drug|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
75740942|NCT00997880|Drug|Rosuvastatin calcium10mg|Rosuvastatin 10mg
75596723|NCT05645198|Drug|Greenplast|Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
75596724|NCT04325438|Other|Pharmaceutical Care|"Pharmaceutical care interventions are categorised into 2 aspects:~Pharmacists' expertise aspect: medications review, identification and solution for the drug-related problem, adverse events, and other medication-related clinical problems. Therapeutic drug monitoring (TDM) is performed for any dose adjustment to the Rifampicin.~Motivational behavioral intervention to improve medication adherence (i.e. medications information and counseling to study participants)."
75596725|NCT02891252|Procedure|outpatient procedure|
75596726|NCT01313637|Drug|GSK573719/GW642444 125/25mcg|125/25mcg
75596727|NCT01313637|Drug|GSK573719 125mcg|125mcg
75596728|NCT01313637|Drug|GW642444 25mcg|25mcg
75596729|NCT01313637|Drug|Placebo only|Placebo
76059326|NCT01722669|Drug|isoquercetin or quercetin|Single dose PK/PD study
76059327|NCT01707147|Drug|Trajenta tablet|Linagliptin
76059328|NCT01876251|Drug|PF-03084014|Tablet, 10 mg, twice a day
76059329|NCT01876251|Drug|PF-03084014|Tablet, 50 mg, twice a day
76059330|NCT01876251|Drug|PF-03084014|Tablet, 100 mg, twice a day
76059331|NCT01876251|Drug|Docetaxel|Solution for IV infusion 75 mg/m^2, every 3 weeks
76059332|NCT01876251|Drug|Docetaxel|Solution for IV infusion 100 mg/m^2, every 3 weeks
76059333|NCT01875471|Device|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
75888747|NCT03695523|Behavioral|PLAY (PhysicaL ActivitY) Policy Intervention|An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
75888748|NCT03687177|Other|With visual cue and nurses informed|Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
75888749|NCT03687177|Other|Without visual cue and nurses informed|Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
75888750|NCT03691545|Behavioral|interactive sessions|This arm will receive personalized health coaching (behaviour change counseling)
75888751|NCT03691467|Device|immediate dental implant|immediate dental implant placement in freshly extracted socket.
75888752|NCT03691467|Drug|Hyaluronic Acid|topical application of hyaluronic acid
75888753|NCT03968211|Biological|Salmonella typhi polysaccharide vaccine|Salmonella typhi polysaccharide vaccine
75888754|NCT03695289|Behavioral|iOTA SMI|Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.
75596730|NCT01320722|Drug|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
75596731|NCT01320722|Drug|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
75596732|NCT01320722|Drug|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
75596733|NCT01320722|Drug|Placebo|Placebo soft gel once per week for 8 weeks
75596734|NCT01320722|Drug|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
75596735|NCT01313559|Drug|Pasireotide|Given IM
75596736|NCT01313559|Drug|Everolimus|Given PO
75888755|NCT03695289|Behavioral|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.
75888756|NCT02165540|Other|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
75888757|NCT02165618|Other|Medication review, based on but not limited to the RASP list|"Systematic approach:~Medication reconciliation~Applying the RASP list~Expert review (not based on the RASP list)~Multidisciplinary discussion"
75740943|NCT00408928|Drug|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
75740944|NCT00997958|Drug|Mycophenolate mofetil|"Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days)."
75888758|NCT02165696|Other|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
75888759|NCT02165696|Other|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
75888760|NCT03539588|Device|trigger point dry needling|placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
75596737|NCT01313559|Other|Laboratory biomarker analysis|Correlative studies
75596738|NCT02891330|Behavioral|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
75596739|NCT00623337|Behavioral|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy & 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify & refer sick babies
75596740|NCT02891031|Drug|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
75596741|NCT02891031|Drug|Placebo|500 mg twice daily after meal for 6 weeks
75596742|NCT04325750|Procedure|TECAR Therapy|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
75596743|NCT04325750|Other|Placebo|simulated TECAR Therapy (machine off)
75596744|NCT04325360|Procedure|Cathodal Transcranial Direct Current Stimulation|20 minutes of cathodal stimulation at 2mA, with cathode electrode placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system), the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
75447102|NCT05291000|Behavioral|The Role of Training and Reminder Wristwatche in Hypertension (RoT-ReWiH)|The present study revealed that multiple interventions such as home visits to elderly hypertensive patients, training program, telephone counseling, and the use of medication reminder wristwatch are effective in increasing treatment adherence and self-efficacy, and in controlling blood pressure. In this direction, health professionals working in primary care are recommended that they make regular home visits, encourage patients to take responsibility for health, and organize regular and interdisciplinary training and counseling programs in the management of hypertension.
75888761|NCT03539588|Device|Electrical Stimulation|uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
75888762|NCT03695211|Procedure|Conventional landmark technique|inject at the midpoint of the posterior border of the sternocleidomastoid muscle
75888763|NCT03695211|Procedure|Precise block technique|inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
76059334|NCT01875471|Device|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
75447103|NCT05290948|Drug|intravitreal injection of bevacizumab with acetazolamide tablets|intravitreal injection of bevacizumab with acetazolamide tablets
75447104|NCT05290948|Drug|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
75447105|NCT05290935|Drug|Anti-PD-1 antibody camrelizumab|Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months
75447106|NCT05290935|Drug|Albumin-bound paclitaxel|Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
75596745|NCT04325360|Procedure|Sham Transcranial direct current stimulation|Participants will received 20 mins of Sham stimulation, where stimulation will happen for the first 30 seconds and in the last 30 seconds of the intervention (at 2mA), with no stimulation in the between time. The cathode electrode will be placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system),the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
75447107|NCT05290922|Diagnostic Test|DNA methylation testing|The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation.
75888764|NCT03687099|Other|no intervention|Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival
75596746|NCT02890953|Drug|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
75888765|NCT02165774|Device|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
75888766|NCT02165774|Device|Turning ON the neuromodulator|
75888767|NCT02165852|Procedure|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
75888768|NCT02165852|Procedure|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
76059335|NCT01875237|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
76059336|NCT01875237|Drug|Melphalan|140 mg/m2 by vein on Day -2.
76059337|NCT01875237|Drug|Alemtuzumab|50 mg by vein on Day -1.
76059338|NCT01875237|Procedure|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 10^6 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
75596747|NCT02890953|Drug|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
75888769|NCT03695133|Behavioral|Group-based interventions|"Group-based interventions Elderly women will have a walk for physical activity for 12 weeks, three days a week. It is planned that each of the sightseeing, picnic, theater and cinema activities will be done twice. The topics that elderly women need most for group educations will be determined. Group educations will be held once every four weeks approximately three hours.~Individual interventions After the pre-tests are applied to the women in the intervention group, the home environment and the individual's health problems will be assessed, interventions will be implemented and the results will be evaluated during home visits at online. During the home visit to the elderly women and twelve-week intervention period, each woman will meet four times and initiatives will be implemented."
75596748|NCT05644652|Other|designed physical therapy program|"it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~Flexibility exercises to restore joint mobility of soft tissues.~Static and dynamic balance exercises~Functional strengthening exercises.~Functional gait training."
75596749|NCT05644652|Other|Nordic walking|it will be conducted according to the guidelines of the International Nordic Walking Federation
75596750|NCT02890875|Other|Ethanol lock|
75447108|NCT05290909|Other|The protocol of blended and problem-based learning|The protocol of blended and problem-based learnin: The online platforms used in this research are the school's iLMS platform, online digital learning, and online opinion exchange platform. It will use online resources (Google, open educational resources, YouTube copyrighted medical micro-movies, and audio-visual materials), and the theme will be elderly care or emerging Multimedia resources on infectious themes, as well as real-time interaction with kahoot or Slido electronic whiteboards, will be uploaded to the office3655The One website. Drive is provided by the school (the school account is used to store course resources) and the system of digital theoretical course concepts in advance. Broadcasting, video (such as: values and conflicts; ethics and morality; patient rights and responsibilities; nurses' rights and responsibilities; ethical theory; basic ethical principles; ethical dilemmas and ethical decision-making; etc.), pre-recorded and stored on the Internet Road platform iLMS.
75447109|NCT05290909|Other|The traditional problem-oriented teaching model|The traditional problem-oriented teaching model: There will be two PBL case introductions throughout the semester, with face-to-face teaching in physical classrooms.
75888770|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
75888771|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
75888772|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
75888773|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
75888774|NCT03695055|Drug|Maintenance therapy post-HSCT|Rituximab vs DPP/DCEP-G vs observation
75888775|NCT03694977|Drug|MCS110/PDR001 combination|MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
75596751|NCT02890875|Other|Heparin lock|
75596752|NCT04324970|Device|Tookie Vest|Tookie Vest
75596753|NCT01312779|Device|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
75596754|NCT01312467|Drug|metformin hydrochloride|
75596755|NCT01310127|Drug|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
75596756|NCT01310127|Drug|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
75596757|NCT01309893|Device|Investigational Lens|Lenses worn on a daily wear basis for one week
75596758|NCT01309893|Device|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
75596759|NCT01318902|Drug|Ixazomib|Ixazomib capsules.
75596760|NCT01318902|Drug|Dexamethasone|Dexamethasone tablets.
75888776|NCT02172248|Drug|BI 10773|
75740945|NCT00998036|Drug|Temsirolimus|"Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg"
76059339|NCT01875237|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
76059340|NCT01875237|Drug|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
75888777|NCT02172248|Drug|Metformin|
76059341|NCT01875237|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
76059342|NCT01875237|Procedure|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
76059343|NCT01875237|Drug|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade > 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
75447110|NCT05290896|Device|Phacoemulsification|Phacoemulsification for senile cataract.
75447111|NCT05290831|Device|VitalPatch|The VitalPatch continuously monitors skin temperature, activity, and electrocardiography.
75447112|NCT05290649|Diagnostic Test|clinical assessment|mini mental test, pulmonary function test, respiratory muscle strength test, trunk impairment scale, timed up and go test, barthel index
75596761|NCT05644938|Procedure|Standard workflow|The SW group was either transferred to angiosuite or received rTPA, if indicated, after the results of Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission.
75596762|NCT05644938|Procedure|One-stop|The OS group transferred directly to ﬂat-detector computed tomography to consider recanalization by either intervention or recombinant Tissue Plasminogen Activator (rTPA) in the angiosuite.
75740946|NCT00998036|Drug|Cisplatin|Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
75888778|NCT03691233|Drug|Clinical audit on diagnosis and management of neonatal shock|intervenous
75888779|NCT03691155|Other|The Crohn's Diet|All recruited participants will be educated on the Crohn's Diet and instructed to adhere to the study diet for 14 days.
75888780|NCT02172326|Drug|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
75596763|NCT05644860|Combination Product|Nanohybrid Compisite Group (Filtek Z250)|Orthodontic brackets shall be bonded with Nano hybrid composite
75740947|NCT00998036|Drug|Erlotinib|"Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg"
75740948|NCT05309876|Behavioral|Lifestyle tool|Regular use of the digital Lifestyle tool
75740949|NCT05254808|Drug|Fosfomycin|Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
75740950|NCT05254808|Drug|Nitrofurantoin|Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
75740951|NCT02275286|Drug|Trabectedin|"Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery."
75888781|NCT02169596|Drug|Ticagrelor|Blood tests taken for flow cytometry
76059344|NCT01875237|Drug|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
76059345|NCT01875237|Behavioral|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
76059346|NCT01874535|Drug|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
76059347|NCT01722045|Drug|Intravitreal Aflibercept Injection (IAI)|
75447113|NCT05290636|Other|Teaching intervention program|Using an action research approach, The investigators designed a pair of geriatric nursing and practicum courses and recruited a class of in-service nursing students through convenience sampling in a college setting. The intervention was an 18-week course in geriatric nursing that meets once a week in the classroom and internship practice in settings used for training nursing students. The investigators collected data using quantitative indicators (attitude measurements) and qualitative textual analysis. The quantitative data were analyzed by paired t-testing using SPSS 21.0 software.
75596764|NCT05644860|Combination Product|Conventional Composite Group (Transbond XT)|Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
75596765|NCT01313858|Drug|Simponi®|
75596766|NCT01313858|Drug|Methotrexate|Given concomitantly with Simponi®
75596767|NCT05644704|Other|Lower extremity and core muscle training|Lower extremity training: single leg balance training Core muscle training: pelvic control training
75596768|NCT05644548|Other|No intervention|No intervention
75596769|NCT01090765|Drug|TRC105|
75596770|NCT01313780|Drug|Oxycodone/Naloxone|Dose and administration : Upto 40mg B.I.D per daily.
75596771|NCT01313780|Drug|Oxycodone(single compound)|Dose and administration : Upto 40mg B.I.D per daily.
75596772|NCT01090453|Biological|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
75596773|NCT01090453|Biological|Prevenar 13®|3 co-administered doses
75596774|NCT01090453|Biological|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
75596775|NCT01090453|Biological|Menjugate®|3 co-administered doses
75596776|NCT01090453|Biological|Rotarix™|Oral, two doses
75596777|NCT01171534|Device|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
75596778|NCT01171534|Device|Vessel loop|Vessel loops and staples for fasciotomy closure
75596779|NCT01170598|Other|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
75596780|NCT01170364|Drug|Sibutramine|1 week of active sibutramine (15mg)
75596781|NCT01170364|Drug|Placebo|2 weeks of placebo
76059348|NCT01721109|Drug|EVG/COBI/FTC/TDF|150/150/200/300 mg STR administered orally once daily with food
76059349|NCT01874145|Drug|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
75596782|NCT01170208|Device|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
75596783|NCT01313624|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
75596784|NCT01313624|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
76059350|NCT01874145|Drug|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
76059351|NCT04415385|Drug|Camrelizumab|200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.
76059352|NCT04415385|Drug|Apatinib|250 mg, orally once a day. Take about half an hour after a meal with warm water.
75596785|NCT05324410|Drug|VX-840|Solution for oral administration.
76059353|NCT01720797|Device|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
76059354|NCT01720797|Drug|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
75888782|NCT02169596|Other|EndoPAT - endothelial assessment|
76059355|NCT01720797|Other|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
76059356|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
76059357|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
76059358|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
76059359|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
76059360|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
76059361|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
75447114|NCT05290571|Other|Modified Otago Exercise Program with music|Our study attempts to establish a new home-based exercise option incorporating mOEP with video, music and lyrics. Our new approach shares the same aims with Exergames and video-supported methods - to increase the exercise motivation of elderlies, hence their physical performance. Based on the video-supported approach in one previous study, we add in the component of music therapy. Music-based exercise interventions could produce positive outcomes on both physical, such as gait, balance and fall risk and level of physical activities and psychological, including exercise adherence, perceived exertion, thus extending exercise duration. However, exact mechanisms have not been revealed and it may be limited by personal preferences on music. In our video, the music we chose is of brisk rhythm, slightly delightful melody and higher pitch, which all help to shape a cheerful and relaxing atmosphere for the elderlies.
76059362|NCT01881620|Device|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
76059363|NCT01830920|Drug|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
76059364|NCT01830920|Drug|Placebo|A normal saline solution identical in appearance to the active drug solution
76059365|NCT01881230|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
76059366|NCT01881230|Drug|Carboplatin|Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
76059367|NCT01881230|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day treatment cycle.
76059368|NCT01856582|Biological|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
75596786|NCT05324410|Drug|Placebo|Placebo matched to VX-840 for oral administration.
75596787|NCT02877043|Procedure|resection pulmonaire|
75596788|NCT02891018|Device|paclitaxel controlled release balloon catheter Vasoguard TM|
75596789|NCT02891018|Device|paclitaxel release coronary balloon catheter SeQuent Please|
75596790|NCT01169350|Radiation|fludeoxyglucose F 18|Undergo 18F FDG and 18F FMISO PET/CT scans
75596791|NCT01169350|Other|18F-fluoromisonidazole|Undergo 18F FDG and 18F FMISO PET/CT scans
75596792|NCT01169350|Procedure|positron emission tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
75596793|NCT01169350|Procedure|computed tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
75596794|NCT01169350|Other|laboratory biomarker analysis|Correlative studies
75596795|NCT00623324|Drug|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
75888783|NCT02166008|Drug|Repamipide|
75888784|NCT02166008|Drug|Placebo|
76059369|NCT01829360|Behavioral|Treatment (interactive book reading, dialogic reading, shared book reading)|Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.
76059370|NCT01856114|Drug|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
75596796|NCT00623324|Drug|Placebo|Placebo tablets to match the number of active tablets
76059371|NCT01856114|Other|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
75740952|NCT02275286|Radiation|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
75740953|NCT04000412|Device|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
76059372|NCT01856114|Behavioral|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
75447115|NCT05290571|Other|Modified Otago Exercise Program|Otago Exercise Program (OEP) was developed by Otago Medical School in New Zealand as a tailor-made home-based fall prevention program to improve the balance performance of community-dwelling elderlies over 1 year. It comprises of 3 main components: 5 lower limb strengthening, 12 balance retraining and walking exercises. In the original program, the intensity was set as moderate with up to 4 difficulty levels for strengthening and balance exercises, in terms of ankle cuff weights and number of repetitions, and level of support respectively. It also stated that the frequency was at least 3 times a week for the former two exercises and at least 2 times per week for walking exercises; while the total duration was expected to make up to an hour, including 30-minute walking exercises.
75447116|NCT05290545|Other|PBSCs|PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10^8 total nucleated cells/kg recipient ideal body weight.
75596797|NCT01169038|Drug|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
75596798|NCT04315012|Other|receive mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
75740954|NCT00998114|Behavioral|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
75740955|NCT00998192|Biological|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
75740956|NCT00998192|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
75740957|NCT00998192|Drug|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
75740958|NCT00998270|Procedure|Autologous bone marrow transplantation|"Autologous transplantation:~Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days"
75740959|NCT00998270|Procedure|Allogeneic bone marrow transplantation|"Allogeneic~Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days"
75888785|NCT02166086|Procedure|Endoscopy|Endoscopy involving advanced imaging techniques
75888786|NCT02169752|Drug|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
75888787|NCT02172404|Device|Placebo capsule administered via the HandiHaler®|
76059373|NCT01855958|Procedure|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
76059374|NCT01855958|Procedure|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
76059375|NCT01855412|Other|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
76059376|NCT01614470|Drug|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
76059377|NCT01614470|Drug|Placebo|oral use, administered twice a day (q12h)
76059378|NCT01880528|Drug|lisinopril|Given PO
76059379|NCT01880528|Drug|placebo|Given PO
76059380|NCT01854944|Drug|Brexpiprazole 1mg to 4mg|
76059381|NCT01829048|Drug|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
76059382|NCT01829048|Drug|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
76059383|NCT01829048|Drug|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
75740960|NCT00998348|Behavioral|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
75740961|NCT03742856|Combination Product|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
76059384|NCT01829048|Drug|Placebo|Placebo Q12h
76059385|NCT01854710|Drug|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
76059386|NCT01854710|Drug|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
76059387|NCT01854710|Drug|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
76059388|NCT01854710|Drug|Oral placebo|Oral capsule identical in appearance to moxifloxacin
76059389|NCT01828034|Drug|Gemcitabine|
76059390|NCT01828034|Drug|Cisplatin|
75740962|NCT00994526|Other|Ham|Ham : 180 g per day during 4 days
75740963|NCT00994526|Other|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
75888788|NCT02172404|Device|Ipratropium metered dose inhaler (MDI)|
75888789|NCT03538964|Procedure|toric intraocular lens|cataract surgery with implantation of an toric intraocular lens
75888790|NCT03538964|Procedure|non toric intraocular lens|cataract surgery with implantation of a non toric intraocular lens
76059391|NCT01828034|Drug|MEK162|
76059392|NCT01853696|Drug|loteprednol etabonate|
76059393|NCT01853696|Drug|prednisolone acetate 1%|
76059394|NCT01871805|Drug|Alectinib|Participants will receive alectinib as described in the arm descriptions.
75447117|NCT05290545|Other|Cord|The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10^8 nucleated cells/kg and 0.15×10^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.
75888791|NCT02166164|Other|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
75888792|NCT02166164|Other|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
76059395|NCT01719861|Drug|Desipramine HCL|Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
76059396|NCT01853618|Drug|Tremelimumab|3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
76059397|NCT01853618|Procedure|RFA|Performed on Day 36
76059398|NCT01853618|Procedure|TACE|Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
76059399|NCT01853618|Procedure|Cryoablation|Performed on Day 36
76059400|NCT01853462|Other|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
76059401|NCT01853462|Other|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
76059402|NCT01719783|Biological|LAIV H5N2|2 doses provided intranasally
76059403|NCT01719783|Other|Placebo|2 doses of placebo provided intranasally
76059404|NCT04415619|Procedure|Xenograft bone substitute (Osteo-biol)|Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
76059405|NCT01853384|Biological|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
76059406|NCT01853384|Other|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
76059407|NCT01878890|Drug|Efavirenz 600mg|Efavirenz 600 mg (oral daily intake)
76059408|NCT01878890|Drug|Efavirenz 1200 mg|Efavirenz 1200mg (oral daily intake)
76059409|NCT01878890|Drug|Efavirenz 1800 mg|Efavirenz 1800mg (oral daily intake)
76059410|NCT01878890|Drug|Efavirenz 2200 mg|Efavirenz 2200mg (oral daily intake)
76059411|NCT04415606|Device|QuikClot Control+|Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
76059412|NCT01827332|Drug|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
76059413|NCT01827332|Drug|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
76059414|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
76059415|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
75740964|NCT00994526|Other|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
75447118|NCT05290545|Other|BMSCs|BMSCs of donor will be collected and infused at least 0.5×10^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.
75740965|NCT00998504|Dietary Supplement|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
75740966|NCT00998504|Dietary Supplement|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
75740967|NCT00788684|Drug|rituximab|IV infusion once weekly for four doses
75740968|NCT00788684|Drug|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
75740969|NCT00454220|Other|Placebo|33 patients to placebo + 131-I arm
75740970|NCT00454220|Drug|MRrhTSH|33 patients to 0.01 mg MRrhTSH + 131-I arm
75740971|NCT00454220|Drug|MRrhTSH|33 patients to 0.03 mg MRrhTSH + 131-I arm
75447119|NCT05290532|Other|Individualized exercise training|The intervention will consist of a multicomponent exercise training program, which will composed of supervised progressive resistance exercise training, aerobic and anaerobic exercises. This training period consist on 2 training sessions of 40 minutes (Warm up 5´+ aerobic exercise 15´+ anaerobic exercise 15´+ stretching 5´)per week during 4 weeks after one week of discharge
75888793|NCT02166164|Other|Heat-pain-detection threshold|"The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.~4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements."
75447120|NCT05290519|Other|plant and animal protein|plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks
75447121|NCT05290506|Drug|Dipeptidyl-Peptidase IV Inhibitors|All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
75447122|NCT05290480|Other|expiratory muscle training|participants performed expiratory muscle training according to their maximum expiratory pressure that measured earlier in addition to conventional chest physiotherapy
75740972|NCT00998972|Drug|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
75740973|NCT00390910|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
75447123|NCT05290480|Device|Insentive spirometry|participants performed deep breating exercise with insentive spirometry in additional to convantional chest physiotherapy
75447124|NCT05290441|Procedure|None involvement|No EGFR involvement
75740974|NCT00390910|Biological|Infanrix hexa|Intramuscular injection, 3 doses
75740975|NCT00998816|Drug|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
75740976|NCT05219084|Drug|hip denervation|Lidocaine 2% 2ml was injected into each genicular nerve
75740977|NCT05219084|Drug|intra-articular hydration|10 ml; of normal; saline were injected inside the hip joint
75740978|NCT05219084|Drug|Combined group|hip denervation and intra-articular hydration were conducted together
75740979|NCT05219084|Drug|Control group|Normal; saline was injected subcutaneously
75888794|NCT02169908|Device|Thermotest|
75888795|NCT02169908|Device|von Frey hairs|
75888796|NCT02166320|Device|Partially covered SEMS|
75888797|NCT02166320|Device|Fully covered SEMS|
75740980|NCT05133908|Behavioral|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
75740981|NCT05133908|Behavioral|dCBTi-ADHD|The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
75888798|NCT02166398|Drug|UI15AML055MT|tab, PO
75888799|NCT02166398|Drug|Amosartan 5/50|tab, PO
75888800|NCT00109538|Drug|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
75888801|NCT00109538|Other|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
75888802|NCT02172482|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
75888803|NCT02169986|Behavioral|electronic reminders|
75888804|NCT02172560|Drug|Tiotropium|
75888805|NCT00106808|Drug|Muraglitazar|
75888806|NCT00106808|Drug|Pioglitazone|
76059416|NCT01719003|Drug|Empagliflozin low dose qd|Empagliflozin low dose once daily
75888807|NCT02166554|Other|Saline|On the day of initial surgery
75447125|NCT05290428|Diagnostic Test|DNA methylation testing|All cervical cytology samples will be tested for PAX1 and JAM3 methylation
76059417|NCT01719003|Drug|Empagliflozin high dose qd|Empagliflozin high dose once daily
75596799|NCT01167634|Behavioral|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
76059418|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
75447126|NCT05290415|Diagnostic Test|DNA methylation testing|DNA CDO1 and CELF4 methylation testing
75447127|NCT05290376|Procedure|surgical placement of long dental implants|Two interforaminal implants were placed in the canine region
75888808|NCT02166554|Device|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
75447128|NCT05290376|Device|overdenture supported by RTX attachment system|Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture
75447129|NCT05290337|Drug|zanubrutinib|BTK inhibitor
76059419|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
75447130|NCT05290324|Drug|Midazolam|Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
75447131|NCT05290311|Behavioral|cognitive behavioural therapy|Cognitive behavioural therapy (CBT) was given according to the protocol of Safren (2004, 2005). Each participant followed one session of 60 minutes per week, for 10 to 16 weeks. Psychotherapists giving CBT had at least a master diploma.
75447132|NCT05290298|Dietary Supplement|NITRATE|Multi-component nutritional formula
75447133|NCT05290298|Dietary Supplement|PLACEBO|Placebo
75447134|NCT05290272|Device|ViFIVE Digital Care Progrma|ViFive DCP (Digital Care Program) is a highly structured, protocolized, and individually tailored intervention consisting of personalized exercise therapy modules. ViFive DCP is delivered by a physical therapy team consisting of DPTs and a personal coach. The DCP consists of ten modules and its advancement will be determined by each patient's progress after the treatment team's review every week.
75447135|NCT05290051|Genetic|Optical Genome Mapping (Bionano®)|Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.
75447136|NCT05290051|Genetic|Longread sequencing (Nanopore®)|Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
75447137|NCT05290012|Other|Dark Chocolate|A daily consumption of 36 g dark chocolate (400 mg/day flavanol) was made. No Cocoa/chocolate product was consumed other than the intervention product.
75447138|NCT05289986|Drug|DELSTRIGO 100Mg-300Mg-300Mg Tablet|"Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~- TDF/3TC/DOR)"
76059420|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
75447139|NCT05289921|Biological|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle
75447140|NCT05289895|Other|No intervention|This study was an observational trial without any intervention
75596800|NCT01167634|Behavioral|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
75596801|NCT01167634|Behavioral|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
75596802|NCT00624754|Drug|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
75596803|NCT00624754|Drug|lactose|Lactose 2 puffs b.i.d for 1 month
75596804|NCT02886052|Behavioral|Therapist guided Internet-CBT for insomnia|
75596805|NCT02886052|Other|Active control|
75596806|NCT01166386|Behavioral|FANCI|comprehensive neurobehavioral sessions with therapist administrating treatment components
75596807|NCT01166386|Behavioral|FANCI|Watching DVDs chosen by participants on various topics.
75596808|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
76059421|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
76059422|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
76059423|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
76059424|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
76059425|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
75596809|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
75740982|NCT00999050|Procedure|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
75447141|NCT05289843|Other|Rosmarinus Officinallis|Root canal Irrigants
75447142|NCT05293028|Drug|F527|0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
75447143|NCT05293015|Other|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
75447144|NCT05292924|Procedure|Early SCC|Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
75447145|NCT05292885|Diagnostic Test|Gadopentetate Dimeglumine Injection|Patients with liver fibrosis after liver transplantation receive multi-parameter magnetic resonance scanning, percutaneous liver biopsy (or FibroScan).
75447146|NCT05292742|Drug|Pyrotinib+Trastuzumab+Capecitabine|Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine
75740983|NCT00533702|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
75888809|NCT02170142|Device|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
75447147|NCT05292742|Drug|Trastuzumab+Pertuzumab/Trastuzumab|Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose
75447148|NCT05292677|Drug|Steroid/Anesthesia Mixture|Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.
75447149|NCT05292677|Drug|Placebo|2 mL of Normal Saline
75447150|NCT05292651|Procedure|PCI|percutaneous coronary intervention
75447151|NCT05292573|Drug|Metformin|During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.
75447152|NCT05292495|Drug|HR17031 injection|HR17031 injection; administered subcutaneously.
75447153|NCT05292430|Other|Specimen Collection|collection of diseased and non-diseased tissue, blood, and other body fluids
75447154|NCT05292170|Other|Heat acclimation|10 consecutive days of heat acclimation
75888810|NCT02172638|Procedure|Fast-Track Protocol|
75447155|NCT05292157|Procedure|shoulder arthroplasty|range of motion (in degrees) measured in annual postoperative follow-up
75447156|NCT05292027|Radiation|low-dose radiotherapy|On the first and second days of induction chemotherapy, lymph nodes were irradiated with 0.5Gy bid for 4 times.
75447157|NCT05291962|Other|Retrospective observational study|Data from anesthesia charts and electronic medical records of 14 patients with SMA type I, II and III who underwent procedural sedation,such as; the demographics data of the patients (age, gender, weight, American Society of Anesthesiologist (ASA) Physical Status), which anesthetic agent was used and their doeses, during of anesthesia, presence of scoliosis, by whom the procedure was performed etc. was reviewed.
75447158|NCT05291910|Drug|Inetetamab|Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
75447159|NCT05291910|Drug|Toripalimab|240mg intravenously every 3 weeks
75740984|NCT00533702|Drug|Dacarbazine|1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
75888811|NCT02172638|Procedure|Usual management|
75888812|NCT03538886|Procedure|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
75888813|NCT03538886|Procedure|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
75447160|NCT05291910|Drug|Albumin-Bound Paclitaxel|130mg/m2, IV , D1, D8, q3w
75447161|NCT05291793|Drug|Tenoxicam 20 Mg Powder for Solution for Injection Vial|Tenoxicam 20 Mg Powder is mixed with dissolving solvent then administered intraarticularly
75596810|NCT01313312|Biological|Botulinum toxin type A|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
75596811|NCT01114672|Drug|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
75596812|NCT01114672|Drug|Placebo|oral placebo once weekly
75888814|NCT03539510|Behavioral|HF-ACP Website|Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
75740985|NCT00408694|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
76059426|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
75447162|NCT05291793|Drug|Methylprednisolone|Methylprednisolone 40 Mg (suspension) administered intraarticularly
76059427|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
76059428|NCT01853228|Drug|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
75740986|NCT00408694|Biological|Bevacizumab|Given IV
75447163|NCT05291793|Drug|Saline|2ml sterile saline administered intraarticularly
75447164|NCT05291780|Radiation|Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures.~Participants will SABR once a day for 5 days, Monday through Friday (around 1 week)."
75447165|NCT05291702|Procedure|PCNL|Percutaneous nephrolithotomy ( Extraction of the renal stones using the nephroscope/ Ureteroscope )
75740987|NCT00408694|Drug|Cisplatin|Given IV
75740988|NCT00408694|Drug|Fluorouracil|Given IV
75740989|NCT00408694|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75447166|NCT05295134|Dietary Supplement|Placebo|Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
75447167|NCT05295134|Dietary Supplement|Candida cylindracea lipase (225,000 FIP lipase units per day)|Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
75740990|NCT03993340|Device|Rescue stenting|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
75740991|NCT00999128|Drug|GDC-0941|Oral repeating dose
75740992|NCT00999128|Drug|rabeprazole|Oral repeating dose
75740993|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
75740994|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
75740995|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
75740996|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
75740997|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
75740998|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
75596813|NCT01114516|Drug|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
75740999|NCT00999284|Drug|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
75447168|NCT05295134|Dietary Supplement|Candida cylindracea lipase (450,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
75741000|NCT01043224|Drug|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
75596814|NCT01114438|Device|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
75741001|NCT01044238|Drug|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
75888815|NCT03538730|Behavioral|Memory Reframing|The intervention will draw from existing narrative-based interventions, past pain memory reframing interventions and findings from our recent data. Specifically, parents will be taught to reminisce with their children about the in-hospital and post-surgery periods by encouraging children to provide more explanations, using less utterances about pain, avoiding repetitions, emphasizing positive aspects of the child's surgery memory (e.g., when children used coping methods such as deep breathing, when they got a treat), and enhancing children's self-efficacy regarding their ability to cope with pain.
75888816|NCT02172716|Procedure|Nonsurgical periodontal treatment|"All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed."
75447169|NCT05295134|Dietary Supplement|Candida cylindracea lipase (675,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
75447170|NCT05295069|Behavioral|A nursing care program was applied for the intervention group under the guidance of Levine's conservation model.|Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
75888817|NCT03694899|Behavioral|phone contact|patients will be called prior to their outpatient appointment
75447171|NCT05294952|Genetic|real time PCR|diagnostic test
75596815|NCT01313078|Drug|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
75888818|NCT03687021|Drug|Progesterone|Different routes of administration of progesterone; Whether there is endometriosis
75888819|NCT02170454|Procedure|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
75888820|NCT02174744|Other|numeric pain rating scale|
75888821|NCT03694743|Device|2Shape rotary system|root canal preparation
75596816|NCT00625690|Other|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
76059429|NCT01853228|Drug|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
75596817|NCT00625690|Procedure|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
75596818|NCT00625690|Procedure|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
75741002|NCT01044238|Drug|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
75741003|NCT01043380|Drug|Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
75741004|NCT01043380|Drug|Lipitor (Atorvastatin) monotherapy|The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
75596819|NCT00625690|Procedure|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
75888822|NCT02172794|Drug|Tiotropium|
75888823|NCT02172794|Drug|Placebo to tiotropium|
75888824|NCT02172794|Drug|Salmeterol|
75888825|NCT02172794|Drug|Placebo to salmeterol|
75596820|NCT01114360|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
75596821|NCT01114360|Drug|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
75596822|NCT01310036|Drug|Erlotinib|Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
75596823|NCT01309100|Device|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
75596824|NCT01309100|Device|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
75596825|NCT01309100|Device|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
75741005|NCT01044316|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
75741006|NCT01044394|Drug|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
75741007|NCT01040104|Other|Skin sample|Taken from regularly discarded tissue during routine operation
75741008|NCT01040104|Other|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
75596826|NCT01075321|Drug|everolimus|Given orally
75596827|NCT01075321|Drug|lenalidomide|Given orally
75596828|NCT01075321|Other|laboratory biomarker analysis|Correlative studies
75596829|NCT01075321|Genetic|polymorphism analysis|Correlative studies
75596830|NCT01075321|Other|immunohistochemistry staining method|Optional correlative studies
75596831|NCT01075321|Genetic|microarray analysis|Optional correlative studies
75596832|NCT01075321|Genetic|fluorescence in situ hybridization|Optional correlative studies
75596833|NCT01114204|Drug|Ferumoxytol|IV Ferumoxytol
75741009|NCT01040104|Other|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
75888826|NCT04173819|Biological|3BNC117-LS-J|300mg
75596834|NCT01114204|Drug|Iron Sucrose|IV Iron Sucrose
75596835|NCT01075243|Drug|Paracetamol 1000 mg|Paracetamol 1000mg
75741010|NCT01040104|Other|Blood taking|Blood taking on day 0
75741011|NCT01040104|Other|Blood taking|Blood taking on day 90
75888827|NCT04173819|Biological|10-1074-LS-J|300mg
75888828|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J|30mg/kg of each
75888829|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
75888830|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
76059430|NCT01853228|Drug|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
75596836|NCT01075243|Drug|Paracetamol 650 mg|Paracetamol 650 mg
75596837|NCT01075243|Drug|Placebo|Placebo
75596838|NCT01308476|Procedure|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
75741012|NCT01043458|Drug|ABT-126|ABT-126 Low Dose & ABT-126 High Dose
75888831|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
75888832|NCT04173819|Biological|Placebo|0.9% Saline
75888833|NCT04173819|Biological|Placebo|Buffer Solution
75888834|NCT03539354|Device|Temporary spinal cord stimulation|Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
76059431|NCT01705587|Drug|teriparatide|20 microgram once-daily subcutaneous injection
75447172|NCT05294926|Drug|Rocuronium|After applying standard monitoring of pulse oximetry, ECG, noninvasive blood pressure, general anesthesia will be induced with fentanyl 1 µg/kg and propofol 2-3 mg/kg and Rocuronium 0.6 mg/kg will be administered for muscle relaxation after loss of consciousness, under the guidance of neuromuscular blockade monitoring. Tracheal intubation will be performed at a train-of-four count of 0. After that end-tidal carbon dioxide and temperature will be continuously monitored during the procedure. Mechanical ventilation will be instituted with o2:air of 4 L/min, tidal volume of 6-8 ml/kg and respiratory rate appropriate to achieving end-tidal carbon dioxide of 30-35 mmHg. no positive end-expiratory pressure; and inspiratory/expiratory ratio 1: 2. The patient's position will then be changed from supine to prone. Ephedrine 4 mg (if mean arterial pressure < 60 mmHg and heart rate < 40 bpm), or atropine 0.5 to 1.0 mg (if heart rate < 40 bpm) are used to prevent hypotension or bradycardia
75596839|NCT01308476|Procedure|control group|no daily SMS to remind of treatment with tiotropium
75596840|NCT01078441|Drug|liposomal doxorubicin|Given IV
75596841|NCT01078441|Drug|bortezomib|Given subcutaneously.
75741013|NCT01043458|Drug|Placebo for ABT-126|Matching Placebo for Arms 1 & 2
75741014|NCT00396136|Device|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
75741015|NCT00530894|Device|Edwards SAPIEN Transcatheter Heart Valve|
75741016|NCT00530894|Device|Surgical Valve Replacement|
75741017|NCT00530894|Other|medical management and/or balloon aortic valvuloplasty|
75596842|NCT01078441|Drug|dexamethasone|Given orally
75596843|NCT01078441|Drug|cyclophosphamide|Given IV
75596844|NCT01308008|Behavioral|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
75596845|NCT01308008|Behavioral|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
75596846|NCT04325048|Device|Cordio App|Adult patients positive to COVID-19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app
75596847|NCT02890706|Device|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
75596848|NCT00626665|Drug|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
75596849|NCT05644106|Device|personal sound amplification product, hearing aid|the device for hearing gain in sensorineural hearing loss
75596850|NCT01113892|Device|vascular grafts|All devices will be used to treat patients with peripheral arterial occlusive disease
75596851|NCT02877979|Drug|DS003 vaginal tablet|The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
75596852|NCT02877979|Drug|Placebo|
75596853|NCT00626353|Other|Home-based rehabilitation|Rehabilitation at home during hospital stay and after discharge
75596854|NCT00626353|Other|Standard care|Standard care during hospital stay and in the municipality after discharge
75741018|NCT00300898|Procedure|Nucleoplasty|
75741019|NCT00300898|Procedure|Percutaneous decompression|
75741020|NCT00300898|Procedure|Intervertebral electrothermal disc decompression (IDET)|
75741021|NCT00300898|Behavioral|Conservative treatment|
75888835|NCT03539354|Procedure|Coronary artery bypass grafting|Standart coronary artery bypass grafting procedure.
76059432|NCT01718535|Device|Spartan FRX CYP2C19 Test System|
75888836|NCT03539354|Drug|B-blockers|Standart b-blocker therapy will be administered in each group for AF prophylactics
75447173|NCT05294926|Device|nerve stimulator|Neuromuscular blockade monitoring will be established and continuously monitored after induction using the Train Of Four (TOF) at the adductor pollicis muscle on the opposite hand and wrist to radial artery cannulation. Two surface electrocardiography electrodes will be placed on cleaned skin overlying the ulnar nerve, with one electrode positioned on the ulnar side of the flexor carpi radialis tendon and the other positioned 3cm proximal to the first. The transducer is then positioned with the flat side against the thumb. Supramaximal stimuli will be applied after autonomic calibration of acceleromyograph after an initial tetanic stimulus. After confirming a train-of-four ratio of 95 to 105%, neuromuscular blockade monitoring will start. The train-of-four mode of supramaximal stimulation (0.2 ms duration, frequency 2 Hz, two s duration) will be applied at 15 s intervals, which last until the end of anaesthesia.
75447174|NCT05294913|Behavioral|Contextualized Wish-Outcome-Obstacle-Plan (WOOP) intervention|This intervention will ask students to identify socio-culturally integrated academic or personal goals, so that students may be able to better strategize obstacle-overcoming to attain their future academic aspirations and modulate negative emotions or environments and associated physiological responses.
75447175|NCT05294913|Behavioral|Placebo|The placebo control group will receive a 5- to 10-minute online goal-setting video tutorial and confirm that they have completed it by filling out an online check-list.
75447176|NCT05294887|Drug|Bisoprolol|beta-adrenergic receptor blocker
75447177|NCT05294887|Drug|Diltiazem|calcium channel blocker
75447178|NCT05294887|Drug|Placebo|Placebo
75447179|NCT05294874|Other|gait training|walking forward, sideway and backward walking on balance board
75447180|NCT05294861|Other|YesMdiet|In the YesMdiet, participants will consume Milk and Dairy products
75447181|NCT05294861|Other|NoMdiet|In the YesMdiet, participants will not consume Milk and Dairy products, only other sources of protein
75447182|NCT05294822|Procedure|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|Islet transplantation was completed using percutaneous transhepatic portal vein puncture. After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
75447183|NCT05294783|Procedure|ACL reconstruction|ACL reconstruction is a standard surgery for ACL injured patients
75447184|NCT05294744|Drug|N-acetylcysteine|"Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h."
75447185|NCT05294666|Drug|Cyclosporine|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
75447186|NCT05294666|Drug|tacrolimus|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
75447187|NCT05294601|Other|High-Intensity Interval Training|high intensity exercise with games
75741022|NCT03474094|Combination Product|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery|"W1,W2, W3, W4 & W5: RADIOTHERAPY. A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6 and W9: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W11: SURGERY. Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent"
75447188|NCT05294601|Other|Medium-Intensity Interval Training|medium intensity exercise with games
75741023|NCT03474094|Combination Product|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy|"W1 and W4: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W7, W8, W9, W10 & W11: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized."
75741024|NCT03474094|Combination Product|Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.|"W1,W2, W3, W4 & W5: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W11 and W14: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval"
75888837|NCT03686943|Other|Family pharmacy|Observation of the family pharmacy in elderly group
75888838|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
75888839|NCT02174900|Drug|Artemether-Lumefantrine (AL) combination|
75888840|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
75888841|NCT02170610|Drug|BIBR 1048 MS|
75888842|NCT02170610|Drug|Pantoprazole|
75888843|NCT03686865|Device|dental implants|extraction sockets regenerated with xenograft
75447189|NCT05294536|Drug|Liraglutide injection,RD12014|single dose, s.c. injection
75741025|NCT01004120|Dietary Supplement|Bimuno|5.5g daily intake
75741026|NCT01004120|Dietary Supplement|Maltodextrin|5.5g daily intake
75596855|NCT04305847|Other|perioperative satisfaction assessment|Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
75596856|NCT02881684|Device|Aspiration Therapy (AspireAssist®)|Use of the AspireAssist device in aspiration therapy
75888844|NCT02173106|Drug|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
75596857|NCT02881684|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
75888845|NCT03932721|Drug|Evolocumab 140 MG/ML|Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
75596858|NCT02876731|Device|PET-CT|NaF PET-CT
75596859|NCT02876731|Device|MRI|DWMRI
75596860|NCT04310332|Drug|1L-PEG|"The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
75447190|NCT05294536|Drug|Liraglutide injection,Victoza|single dose, s.c. injection
75447191|NCT05294497|Other|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
75596861|NCT04310332|Drug|4L-PEG|"The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
75741027|NCT01043536|Radiation|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
75741028|NCT01043536|Drug|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
75741029|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
75741030|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
75741031|NCT01004198|Drug|Ringers Lactate solution|Ringers Lactate solution for Injection
75741032|NCT01004276|Other|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
75888846|NCT00106340|Drug|vildagliptin|
75888847|NCT00106340|Drug|glimepiride|
75888848|NCT00106340|Drug|Metformin|
75888849|NCT00106340|Drug|Vildagliptin matching placebo|
75447192|NCT05294497|Other|Product B|Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine
75741033|NCT03742778|Behavioral|Incentivizing reflection|Participants receive bonus incentives for reflecting on their workouts
75741034|NCT03742778|Behavioral|Incentivizing exercise|Participants receive bonus incentives for exercising
75888850|NCT00106340|Drug|Glimepiride matching placebo|
75888851|NCT04167969|Drug|(64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots|Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
75888852|NCT04167969|Diagnostic Test|PET/MRI|Imaging will be performed using the GE Signa PET/MRI.
75888853|NCT04167969|Other|Blood and urine sampling|Staff will perform the IV blood draws and collect urine samples
75888854|NCT04167969|Procedure|laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection|Surgery will be performed within 24 h of the third PET/MRI scan.
75447193|NCT05294497|Other|Product C|Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine
75447194|NCT05294497|Other|Product D|Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine
75447195|NCT05294497|Other|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
75447196|NCT05294497|Other|Product E|Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
76059433|NCT01705509|Drug|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
76059434|NCT04551183|Other|Surgeons CT scan analysis|Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)
75741035|NCT01004588|Dietary Supplement|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
75888855|NCT02255786|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
75741036|NCT01004588|Dietary Supplement|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
75741037|NCT00056407|Drug|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
75741038|NCT00056407|Drug|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
75447197|NCT05294484|Drug|Indapamide 1.5 MG SR|the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
75447198|NCT05294445|Procedure|Ablation of atrial fibrillation (AF)|Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)
75447199|NCT05294406|Drug|Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine|Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)
75447200|NCT05294393|Drug|Placebo Comparator: N/S 0.9%|12 ml N/S 0.9% at the end of surgery
75447201|NCT05294393|Drug|Ropivacaine 10%|12 ml solution of 100mg ropivacaine at the end of surgery
75447202|NCT05294393|Drug|Ropivacaine 10% plus magnesium sulphate 10mg/kg|12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery
75447203|NCT05294315|Procedure|Bi-level erector spinae block|erector spinae block at 4th and 6th transverse process
75447204|NCT05294315|Procedure|Single level erector spinae block|erector spinae block at 4th transverse process
75447205|NCT05294198|Dietary Supplement|Beetroot extract|Beetroot extract capsule
75447206|NCT05294094|Behavioral|blended learning|The blended learning course consists of two parts. The first part is an online course with case studies and instructional videos providing basic clinical diagnostic knowledge and the ability to conduct structured clinical interviews. In the second part, learners get to discuss the course content with a teacher, practice their interviewing skills with other students and make a transfer to a real face-to-face diagnostic situation with an actor simulating a patient.
75447207|NCT05294094|Behavioral|teaching format as usual|The teaching format as usual represents the usual teaching of clinical diagnostic knowledge and the ability to conduct structured clinical interviews. Also in this intervention students also have the opportunity to discuss the course content with a teacher, practice their interviewing skills with other students and conduct a structured interview with an actor simulating a patient.
75447208|NCT05293990|Radiation|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
75741039|NCT00388726|Drug|E7389|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
75741040|NCT00388726|Drug|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
75447209|NCT05293977|Behavioral|Routine care by the dispensing pharmacist|Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
75596862|NCT01090063|Drug|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
75596863|NCT00625768|Drug|AS1409|Study drug
75596864|NCT01113580|Biological|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
75596865|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
75596866|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
75596867|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
75596868|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
75447210|NCT05293977|Behavioral|Pharmaceutical education/counseling about prescribed antibiotic|Patient in the intervention group was provided with pharmaceutical education about his/her prescribed antibiotic by the trained clinical pharmacist. To prepare the education about antibiotics, the 10 most commonly prescribed antibiotics were determined in advance from hospital records: Amoxicillin or Amoxicillin/Clavulanic acid, Ciprofloxacin, Levofloxacin, Azithromycin, Cefuroxime, Cephalexin, Clindamycin, Doxycycline, Metronidazole, Trimethoprim/Sulfamethoxazole. Standard education points about antibiotics include (i) mechanism of action and/or use, (ii) correct administration method, (iii) correct timing, (iv) possible adverse effect and self-management intervention methods when faced with side effects, (v) what to do in case of missing any dose.
75741041|NCT01043614|Behavioral|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
75888856|NCT03538496|Drug|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
75888857|NCT03694665|Other|Lung recruitment maneuver|A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
75447211|NCT05293899|Diagnostic Test|exome sequencing approach|Depending on the primary results in the proteomic and the metabolic profiling, this pilot study will search for genetic associations, using an exome sequencing approach to individuals. The findings will be compared to individuals without depression, and to relatives of depressed patients who suffer from autoimmune diseases.
75741042|NCT01043692|Other|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
75741043|NCT03957655|Biological|SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
75741044|NCT01091233|Procedure|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
75741045|NCT02530723|Other|power training|Resistance training machines with CAM devices will be used for training.
75741046|NCT00387790|Drug|motexafin gadolinium|Given IV
75741047|NCT00387790|Radiation|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
75741048|NCT00073021|Drug|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
75741049|NCT00073021|Drug|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
75741050|NCT01091311|Device|Blephasteam|Eye lid warming goggles
75741051|NCT00407758|Drug|enzastaurin hydrochloride|
75741052|NCT01583725|Procedure|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
75741053|NCT01583725|Behavioral|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
75741054|NCT01094509|Behavioral|Tai Chi|Tai Chi classes and exercises
75888858|NCT03538418|Other|WAT|The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
75596869|NCT01306214|Drug|BI 10773|BI 10773 low dose once daily
75596870|NCT01306214|Drug|BI 10773|BI 10773 high dose once daily
75741055|NCT01094509|Behavioral|Guided autobiography|Autobiographical writing in class and at home
75741056|NCT01094509|Behavioral|Qigong|Qigong classes and exercises (exploratory)
75741057|NCT01094509|Behavioral|Successful aging|Seminar series on the theme of successful aging
75741058|NCT01094509|Behavioral|Combination|Combination of Tai Chi exercises and autobiographical writing
76059435|NCT04551183|Device|PRAEVAorta CT scan analysis|CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
75741059|NCT01094509|Behavioral|Comparison|No assigned behavioral activity (exploratory)
75888859|NCT03686787|Drug|Tranexamic Acid|A split face study of oral tranexamic acid in combination with laser treatment
75888860|NCT02174978|Biological|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
75888861|NCT02174978|Other|P falciparum Controlled Human Malaria Infection (CHMI)|
75888862|NCT03694587|Drug|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
76059436|NCT01853072|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
76059437|NCT01853072|Other|Nepafenac vehicle|Inactive ingredients used as placebo comparator
76059438|NCT01853072|Drug|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
76059439|NCT01877720|Device|noninvasive respiratory support with NAVA mode and PSV|
76059440|NCT01870869|Device|Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection|Surgical implant
75447212|NCT05293873|Biological|autologous bone marrow-derived mononuclear cell transplantation|Bm-MNC will be transplanted at baseline, and the second transplantation will be performed 6 months after the first transplantation
75447213|NCT05293873|Other|Rehabilitation therapy|Rehabilitation therapy
75447214|NCT05293808|Drug|aspirin 100 mg bis in die|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
75596871|NCT00623402|Drug|Sorafenib|2x 400 mg orally per day (4 tablets)
75596872|NCT00623402|Drug|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
75596873|NCT01077739|Drug|fluorouracil (5FU)|standard FOLFOX regimen
75596874|NCT01077739|Drug|leucovorin|standard FOLFOX regimen
75596875|NCT01077739|Drug|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
75596876|NCT01077739|Drug|capecitabine [Xeloda]|standard XELOX regimen
75596877|NCT01077739|Drug|oxaliplatin|standard XELOX or FOLFOX regimen
75596878|NCT02876497|Other|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
75741060|NCT01094587|Procedure|Gastroschisis closure with suture|
76059441|NCT01877408|Procedure|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
76059442|NCT01877408|Device|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
76059443|NCT01717287|Drug|Raltegravir Film-coated Tablet|
76059444|NCT01717287|Drug|Raltegravir Chewable Tablet|
76059445|NCT01717287|Drug|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
76059446|NCT01827254|Other|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
75447215|NCT05293808|Drug|aspririn 200 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
75447216|NCT05293808|Drug|aspirin 100 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
75447217|NCT05293795|Behavioral|3D printed model|Mother is given 3D printed model of fetus' face
75596879|NCT01306058|Drug|TRC 105|15 mg/kg intravenous (IV) every 2 weeks
75741061|NCT01094587|Procedure|Gastroschisis closure without suture|
75741062|NCT01584115|Biological|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
75741063|NCT01584115|Biological|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
76059447|NCT01824602|Drug|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
76059448|NCT01824602|Drug|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
75596880|NCT01306058|Drug|Sorafenib|400 mg twice a day (bid) continuously in a 28 days cycle
75596881|NCT00626509|Drug|sunitinib malate|
75741064|NCT01089673|Other|data collection|retrospective data collection
75447218|NCT05293795|Behavioral|Placebo|Mother is given a picture of 3D ultrasound of fetus
76059449|NCT01824602|Drug|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
75741065|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
75447219|NCT05293704|Drug|Mizoribine|Orally administered at 3-4 mg/kg/d, once every 12 hours; When body weight ≤50 kg, each dose of 75 mg; Weight & gt At 50 kg, the dosage was 100 mg each time.
75741066|NCT00531752|Drug|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
76059450|NCT01824602|Drug|Placebo|Placebo sugar pills
75447220|NCT05293652|Other|Iontophoresis|Hydrocortisone iontophoresis
75596882|NCT00626509|Procedure|adjuvant therapy|
75596883|NCT00626509|Procedure|neoadjuvant therapy|
75447221|NCT05293652|Other|Phonophoresis|Hydrocortisone Phonophoresis
75447222|NCT05293652|Other|traditional PT program|Ultrasound and deep friction massage
75447223|NCT05293574|Drug|norethisterone acetate|Norethindrone, a progesterone agonist
75596884|NCT00626509|Procedure|therapeutic conventional surgery|
75741067|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
75741068|NCT00395746|Drug|sulfonylurea|SU agent
76059451|NCT01704651|Drug|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.
76059452|NCT01704651|Drug|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
75596885|NCT02876653|Other|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
75596886|NCT02876965|Procedure|Muscle Stretching|Subjects completed one stretching session on the main muscle groups of the body weekly.
75596887|NCT02876965|Procedure|Physical Exercise|Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
75596888|NCT02877901|Drug|long acting tolterodine 4 mg|receive one tablet at bed time for 4 weeks
75447224|NCT05293301|Device|Use of Periodontal Endoscope (Perioscopy®) to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using a Periodontal Endoscope or Perioscopy® for enhanced visualization, on teeth in one half of the mouth
75447225|NCT05293301|Device|Use of traditional loupes to enhance magnification to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using tradional loupes for enhanced visualization on teeth, in the other half of the mouth
75596889|NCT02877901|Drug|placebo|one tablet at bed time
75596890|NCT04306159|Procedure|Subcostal TAP|Subcostal transversus abdominis plane block
75741069|NCT00395746|Drug|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
75741070|NCT00395746|Drug|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
75447226|NCT05293275|Device|EaseVRx Virtual Reality Headset|Virtual reality device with 360 degree visualization of various scenery and interactive modules
75447227|NCT05293262|Procedure|Endourological surgery|Includes ureteral stent insertion, ureteroscopies and retrograde intrarenal surgeies
75447228|NCT05293119|Drug|JAK-2 inhibitor|In this trial, one group will receive the tofacitinib 5 mg twice daily
75447229|NCT05293119|Drug|Topical corticosteroid|Mometasone furoate 0.1% ointment once daily
75596891|NCT04306159|Procedure|Modified RSB|Rectus Sheath Block under the guidance of surgical incision
75596892|NCT04306159|Other|General anesthesia|Traditional general anesthesia management
75596893|NCT01305200|Drug|supersaturated calcium phosphate rinse|Mouth rinse
75596894|NCT01305200|Other|placebo|Mouth rinse
75596895|NCT01305200|Other|questionnaire administration|Ancillary studies
75596896|NCT01305200|Procedure|quality-of-life assessment|Ancillary studies
75741071|NCT00994838|Other|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
75741072|NCT00055471|Drug|ZD4054 10 mg|1 x 10 mg oral tablets once daily
75741073|NCT00055471|Drug|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
75741074|NCT00055471|Drug|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
75888863|NCT03694587|Drug|Aktren® 200 mg überzogene Tabletten (Ibuprofen)|one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
75888864|NCT03539276|Behavioral|Knowledge exchange|OptimaMed
75596897|NCT01305044|Behavioral|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
75596898|NCT01305044|Behavioral|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
75596899|NCT01304498|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine
75741075|NCT01004900|Procedure|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
75741076|NCT01004900|Drug|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
76059453|NCT01876706|Device|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
75596900|NCT01304498|Biological|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine
75741077|NCT01583491|Procedure|autologous platlet rich fibrin|one dose immediate after surgery
75741078|NCT01583491|Procedure|one side in control group|control group insert any things after surgery
75447230|NCT05293054|Other|Application of autologous fibrin matrix (Obsidian)|"When the patient is anaesthetized, 120 ml venous blood is collected for preparation of the autologous fibrin matrix. The blood is processed in the Vivostat® unit for 30 minutes making a 5-6 ml concentrate ready for application by use of a specific endoscopic kit device.~When the rectal cancer resection is completed and the specimen is extracted, the Obsidian will be applied using minimal invasive technique and the endoscopic kit device.~Step 1: 1.5-2ml. Obsidian is applied onto the rectal stump, with the circular stapler device inserted into the rectal stump. The circular stapler is then closed, but not yet fired.~Step 2: 2.5-3ml Obsidian is applied 360 degrees around the anastomosis, while taking care not to increase tension on the anal intestine end. The circular stapler is then fired and removed. The water-air-leak test is performed according to standard clinical practice. Step 3: The remaining part of the Obsidian is then sealed 360 degrees around the anastomosis."
75447231|NCT05297006|Dietary Supplement|The infants who drank milk powder were given a dietary intervention four months before|The infants who eat milk powder were randomly divided into two groups: group containing new compound functional ingredients and group without new compound functional ingredients
75741079|NCT04001348|Device|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75741080|NCT04001348|Device|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75741081|NCT04001348|Device|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
76059454|NCT01876082|Drug|PAZOPANIB treatment|"Pazopanib~800 mg per day~oral administration~at least 1 hour before or 2 hours after a meal,~until disease progression or for 12 months maximum"
76059455|NCT01876082|Drug|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
75447232|NCT05296967|Behavioral|chewing|patients are asked to chew chewing gum X 3/ day
75596901|NCT01077193|Procedure|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
75447233|NCT05296863|Combination Product|Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|"Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
75596902|NCT05644028|Behavioral|Emotion Regulation Intervention for ADHD|The intervention will be based on principles from dialectic behavioral therapy. The overall aim of the intervention is to improve emotion regulation skills. The intervention will consist of eight face-to-face group sessions and a digital companion app that the participants can use to practice skills between the sessions. The groups will include mindfulness-based exercises, homework review, introduction to new skills, and peer discussions.
75741082|NCT04001348|Device|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75596903|NCT04299139|Other|chiropractic treatment|There is no intervention. Data that has been collected during the time a patient was attending a chiropractor. This data will be evaluated
75888865|NCT03694509|Other|Breakfast tea with full fat milk|Assessment of gastric emptying using ultrasound. Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
75888866|NCT03694509|Other|Water|Water 250ml.
75888867|NCT02175056|Biological|HL2351|Dose-escalation For 5 level dose groups A ~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.
75888868|NCT02175056|Biological|Kineret(Anakinra)|Active comparator(group F) is implemented in parallel with dose groups A~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
75888869|NCT02173184|Biological|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
75888870|NCT02173184|Biological|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
75888871|NCT03694431|Other|Tech-supported HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
75888872|NCT03694431|Other|Standard HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
75447234|NCT05296863|Combination Product|Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.
75888873|NCT02170766|Drug|BIBR 1048 low1|
75888874|NCT02170766|Drug|BIBR 1048 low2|
75888875|NCT02170766|Drug|BIBR 1048 medium|
75447235|NCT05296863|Combination Product|Placebo and 5% Minoxidil|"Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
75447236|NCT05296824|Procedure|Cryoballoon ablation for the treatment of atrial fibrillation|Cryoballoon ablation for the treatment of atrial fibrillation
75447237|NCT05296811|Procedure|Lateral Arm Free Flap|Primary Reconstruction of intraoral defects by use of Lateral Arm Free Flap.
75447238|NCT05296707|Other|Inspıratory muscle training|"The MIP/MEP value of the group that will receive inspiratory muscle training was determined and Thershold IMT training was given with 30%.~In the training, the subjects were asked to sit in a relaxed position with their upper chest and shoulders relaxed.~After the nose clip was attached, the children were asked to inhale and exhale by tightly closing the mouthpiece of the instrument with their lips.~A 30-minute training session was carried out for 6 weeks, with 10-15 repetitive breathing apparatus and 5-10 seconds rest breaks every day."
75447239|NCT05296707|Other|Used routine medicine|After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.
75596904|NCT02876029|Other|Reference|the reference product used
75596905|NCT02876029|Other|Test product|The test Product used
75888876|NCT02170766|Drug|BIBR 1048 high|
75447240|NCT05296707|Other|Control group|A healthy child compatible with the age and sex of the patient group was evaluated once.
75596906|NCT05661110|Other|Observational|All patients will be treated with standard of conversion treatment with HIPEC combined PD1/PDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.
75888877|NCT02170766|Drug|Pantoprazole|
75888878|NCT04156659|Biological|Tisagenlecleucel|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
75888879|NCT03538340|Procedure|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
75888880|NCT03538340|Procedure|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
75888881|NCT03694119|Drug|Phenelzine|Phenelzine
75888882|NCT03694119|Drug|Tyramine|Tyramine
75888883|NCT03694119|Drug|Phenelzine placebo|Phenelzine placebo
75888884|NCT03694119|Drug|ozanimod placebo|ozanimod placebo
75888885|NCT03694119|Drug|ozanimod|ozanimod
75888886|NCT02178254|Drug|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
75888887|NCT02178254|Drug|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
75888888|NCT02173262|Drug|G-CSF|
75888889|NCT02173262|Drug|Ciprofloxacin|
75888890|NCT02175134|Other|Blood and Ascites ELISPOT|
75888891|NCT03537638|Behavioral|Multicomponent intervention|Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
75447241|NCT05296499|Diagnostic Test|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing using cycle ergonomenter
75447242|NCT05296499|Diagnostic Test|Exercise cardiac MRI|Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET
75596907|NCT01074931|Drug|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
75596908|NCT04306003|Other|ERAS pathway|See ERAS pathway arm description.
75741083|NCT04001348|Device|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75447243|NCT05296499|Other|6 minute walk test|6MWT
75447244|NCT05296499|Diagnostic Test|Blood tests|FBC, U&E, LFTS
75596909|NCT04306003|Other|Standard Perioperative Care|See control arm description.
75596910|NCT00626587|Device|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
75596911|NCT04774159|Drug|Colchicine 0.5 MG Oral Tablet|"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."
75596912|NCT04774159|Drug|Colchicine-Placebo|Colchicine-Placebo tablet
75741084|NCT04001348|Device|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75741085|NCT04001348|Device|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75888892|NCT04150653|Device|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
75447245|NCT05296499|Other|Quality of life questionnaires|SF36, EQ5D, VEINES-QoL/Sym
75447246|NCT05296499|Other|Repeat baseline assessments|repeat baseline
75447247|NCT05296499|Diagnostic Test|MR venogram|MRI scan of venous system
75447248|NCT05296486|Procedure|phacovitrectomy surgery with silicone oil tamponade|Patients in this study will receive phacovitrectomy surgery with silicone oil tamponade.
75447249|NCT05296486|Procedure|phacovitrectomy surgery with gas tamponade|Patients in this study will receive phacovitrectomy surgery with gas tamponade
76059456|NCT01704495|Drug|AZD5069|AZD5069 oral capsules self-administered twice daily.
76059457|NCT01704495|Drug|Placebo|Placebo oral capsules self-administered twice daily.
76059458|NCT01716663|Device|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
76059459|NCT01716585|Drug|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
75447250|NCT05296486|Procedure|phacovitrectomy surgery with balanced saline solution tamponade|Patients in this study will receive phacovitrectomy surgery with balanced saline solution tamponade
75447251|NCT05296486|Procedure|phacoemulsifacation surgery without vitrectomy|Patients in this study will receive phacoemulsifacation surgery without vitrectomy.
75447252|NCT05296369|Drug|Folic acid|Folic acid was added during the period prior to concurrent chemoradiotherapy
75596913|NCT02877745|Other|Stratification, no intervention|
75596914|NCT01303172|Biological|IMM-101|"IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.~A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine."
75447253|NCT05296291|Device|High-translucent monolithic zirconia Bridge|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
75596915|NCT01303172|Drug|Gemcitabine|"Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.~Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol."
75741086|NCT04001348|Device|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
76059460|NCT01716585|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
76059461|NCT01716585|Drug|Placebo for ABT-450/r/ABT-267|Tablet
76059462|NCT01716585|Drug|Placebo for ABT-333|Tablet
76059463|NCT01716585|Drug|Placebo for ribavirin|Capsule
76059464|NCT01852292|Drug|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
75447254|NCT05296291|Device|Zirconium oxide ceramics Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
75447255|NCT05296291|Device|Metal-ceramic Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
75447256|NCT05296200|Device|Hyperbuoyancy Floatation|Subjects are laid supine upon a HBF waterbed encased within a wooden frame partially (50%) filled with water (at 36ºC to maintain thermal comfort) super-saturated with magnesium sulphate. Thus, subjects are buoyant, sinking passively into the bed in proportion to their segmental mass.
75447257|NCT05296174|Other|cognitive-oriented intervention program|The experimental group was offered six 40-minute courses once a week.
75447258|NCT05296174|Other|health education activities program|The control group was offered health education activities once a week.
75596916|NCT01302938|Drug|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
76059465|NCT01852292|Drug|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
76059466|NCT01852292|Drug|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m^2.
76059467|NCT01715805|Drug|Cariprazine|Cariprazine capsules 1.5 to 4.5 mg/day
75447259|NCT05296044|Drug|JT-003|Subjects take the investigational products once a day for 24 weeks.
75596917|NCT01302938|Drug|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
75596918|NCT05643872|Drug|PTX-022|QTORIN rapamycin 3.9% anhydrous gel
75596919|NCT01302548|Device|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
75596920|NCT01302548|Procedure|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
75596921|NCT01302392|Drug|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days [Days 1, 2, 8, 9, 15, 16] for individual subjects).
75596922|NCT01302392|Drug|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
75596923|NCT01076647|Drug|insulin degludec|Will be injected subcutaneously (under the skin) once daily three times weekly.
76059468|NCT01715805|Drug|Placebo|Dose-matched placebo capsule once per day
76059469|NCT01715805|Drug|Antidepressant Therapy (ADT)|ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
76059470|NCT01852214|Drug|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
75447260|NCT05296044|Drug|JT-003 Placebo|Subjects take the investigational products once a day for 24 weeks.
76059471|NCT01852214|Drug|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
76059472|NCT01393990|Drug|LY2228820|Administered orally
76059473|NCT01393990|Drug|Midazolam|
75596924|NCT01076647|Drug|insulin glargine|Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
75596925|NCT04306081|Drug|Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
75596926|NCT04306081|Other|Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
76059474|NCT01393990|Drug|Tamoxifen|
76059475|NCT05366374|Other|Swallowing assessment with Swallis DSA™ Device|The WALLIS DSA™ investigative device is designed to capture and display pharyngolaryngeal activity in subjects with or at risk of swallowing disorders. The DM is non-invasive: a miniaturized microphone and accelerometer are integrated into the form of a necklace, which will be positioned around the patient's neck to capture the vibroacoustic signals of swallowing during mealtime.
76059476|NCT00210184|Drug|Irinotecan associated to fluorouracil and leucovorin|
76059477|NCT00210106|Device|Ablathermy|
76059478|NCT05368480|Other|Senior Companion Program|Receives a companion to socialize with them, help with daily tasks, etc.
76059479|NCT00210964|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
76059480|NCT00210964|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
75447261|NCT05296005|Drug|Capecitabine|Given PO
75447262|NCT05296005|Drug|Docetaxel|Given IV
75447263|NCT05296005|Drug|Fluorouracil|Given IV
75447264|NCT05296005|Drug|Leucovorin|Given IV
75447265|NCT05296005|Drug|Oxaliplatin|Given IV
75596927|NCT01074307|Drug|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
75741087|NCT04001348|Device|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75741088|NCT04001348|Device|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
76059481|NCT00210652|Drug|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
75447266|NCT05296005|Radiation|Radiation Therapy|Undergo radiotherapy
75447267|NCT05296005|Procedure|Surgical Procedure|Undergo surgical resection
75447268|NCT05295836|Other|PLACEBO|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.
76059482|NCT05369104|Biological|Anti-Staphylococcus aureus Bacteriophages|Single intra-articular injection
76059483|NCT05365126|Behavioral|Complete Vocal Technique Voice Therapy|A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
76059484|NCT05362162|Procedure|cervical plexus block|local anesthetic agent injection into the either Superficial or intermediate area
76059485|NCT02985268|Device|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
76059486|NCT02985268|Drug|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
75741089|NCT04001348|Device|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75741090|NCT04001348|Device|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75741091|NCT04001348|Device|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75741092|NCT04001348|Device|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75741093|NCT04001348|Device|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75888893|NCT04147923|Dietary Supplement|Floradapt Mature Immune Defense + Multivitamin|The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of >1 x 10^9 CFU. Participants will also consume a multivitamin.
75888894|NCT04147923|Dietary Supplement|Placebo + Multivitamin|No active ingredients + a multivitamin supplement
75888895|NCT03690687|Procedure|Primary anastomosis|
75888896|NCT03690687|Procedure|Delayed anastomosis|
76059487|NCT02985268|Device|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
75888897|NCT03690687|Procedure|Enterostomy|
75447269|NCT05295836|Dietary Supplement|GLYCEROL|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
75888898|NCT02173418|Drug|Phrenic nerve block with Ropivacaine|
75888899|NCT02173418|Drug|Phrenic nerve block with saline|
75888900|NCT03686709|Diagnostic Test|Post therapy PET/CT Imaging|whole-body PET/CT following Y90 radioembolization
75888901|NCT02173496|Other|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
75888902|NCT02173574|Drug|DEB025|
75888903|NCT02173574|Drug|EDP239|
75888904|NCT03932331|Drug|Acalabrutinib|Acalabrutinib 100 mg orally twice daily
75888905|NCT02178488|Drug|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
75888906|NCT02178488|Other|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
75888907|NCT03686631|Behavioral|Smartphone Arm|"The smartphone arm will have an associated smartphone application, available in kiosk mode, that will remind and encourage patient to utilize the spirometer and provide a gamified application for that patient to do so."
75888908|NCT02173652|Drug|BI 1356, high dose|
75888909|NCT02173652|Drug|BI 1356, low dose|
75888910|NCT03694041|Drug|SAD: APX-115|Drug: APX-115 SAD APX-115 SAD for 1day
75888911|NCT03694041|Drug|SAD: Placebo|Drug: Placebo Placebo for 1day
75888912|NCT03694041|Drug|MAD: APX-115|Drug: APX-115 MAD APX-115 MAD repeatedly administered.
75888913|NCT03694041|Drug|MAD: Placebo|Matching study drug will be repeatedly administered.
75888914|NCT03694041|Other|Food effect: fasted and fed|A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
75888915|NCT03694041|Other|Metabolic probe with or without APX-115|A metabolic probe will be administered with and without APX-115.
75888916|NCT02173730|Drug|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
75888917|NCT02173730|Drug|Pantoprazole|Pantoprazole tablet 40 mg
75888918|NCT03686553|Other|laboratory-based data collection|laboratory-based surveillance of SSI
75888919|NCT03686475|Other|Biodentine|pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
75888920|NCT03686475|Other|MTA pulpotomy|MTA pulpotomy
75888921|NCT02175446|Drug|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
75888922|NCT03686319|Other|Reflexology|Reflexology: foot massage
75888923|NCT03686241|Procedure|Tibiotalocalcaneal (TTC) arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
75888924|NCT03686241|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
75888925|NCT02178644|Drug|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
76059488|NCT05630560|Other|Psychotherapy treatment|The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
76059489|NCT04022122|Procedure|Usual Care follow-up in a heart failure program.|Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
76059490|NCT03593434|Drug|hyperpolarized Xenon gas|This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.
76059491|NCT04019314|Procedure|Blood Collection|Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
76059492|NCT04019314|Procedure|Blood Volume Analysis|A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
75741094|NCT04001348|Device|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
75741095|NCT03956251|Procedure|Combined Mineralized/Demineralized Putty Allograft|At time of extraction, 15 test patients will receive ridge preservation using Combined Mineralized/Demineralized Putty Allograft
75741096|NCT03956251|Procedure|Demineralized Putty Allograft|At time of extraction, 15 control patients will receive ridge preservation using Demineralized Putty Allograft
76059493|NCT05366608|Diagnostic Test|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
76059494|NCT03995992|Behavioral|sport|10 days of sport (diving or multisport), once training per day
75741097|NCT00395512|Drug|Alogliptin|Alogliptin tablets.
75741098|NCT00395512|Drug|Pioglitazone|Pioglitazone tablets.
75741099|NCT00395512|Drug|Placebo|Matching placebo tablets.
75741100|NCT03956017|Drug|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
75741101|NCT03956017|Drug|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
75741102|NCT00994916|Drug|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
75741103|NCT01005212|Drug|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
75741104|NCT00999440|Drug|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
75888926|NCT03686163|Drug|Nerve Growth Factors|the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
75888927|NCT03686163|Drug|normal saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
76059495|NCT03995056|Behavioral|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
76059496|NCT03792958|Drug|CM082|CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
76059497|NCT04407520|Other|No patient treatment is associated with the study|No patient treatment is associated with the study.
76059498|NCT05632588|Other|Observational study|Observational surveillance study
76059499|NCT04407208|Biological|Convalescent plasma|The minimum titer of specific antibody is 1/80
75741105|NCT00054691|Drug|Iressa|250 mg by mouth daily
76059500|NCT03025360|Drug|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
75741106|NCT02530879|Drug|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
76059501|NCT04766554|Device|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions|In the intervention group, an alarm threshold below 15% of the baseline rSO2 value will be established. Based on the predetermined algorithm the rSO2 will be maintained at or above 85% of the baseline measurements. If the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed to restore rSO2 to baseline levels.
76059502|NCT05632510|Diagnostic Test|The Edinburgh Postnatal Depression Scale (EPDS)|The Edinburgh Postnatal Depression Scale (EPDS) is a self-administered questionnaire of 10 items, is recommended by the NICE guideline and French National Authority for Health for screening peripartum women, validated in French and well accepted.
76059503|NCT03025048|Behavioral|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
76059504|NCT03599050|Behavioral|Audiotaped Counseling Session|Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
75447270|NCT05295745|Behavioral|Cognitive remediation therapy and multidisciplinary intervention|"The Randomized Controlled Trial will comprise of multidisciplinary intervention and remediation cognitive therapy which will be conducted with obese diagnosed adults of 19-60 years old. The enrolled patients will be randomized in a two-arm control trial with repeated measures and follow-up of three months. The experimental group participants will receive the intervention, while the control group remains on a waiting list.~Nutritional and physical activity plus cognitive remediation therapy sessions to improve the thoughts style, problem-solving, planning and organization, the emotions and body image are included"
75447271|NCT05295719|Dietary Supplement|Omega-3 polyunsaturated fatty acid|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA)
75447272|NCT05295719|Behavioral|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
75447273|NCT05295719|Dietary Supplement|Safflower oil|4 grams safflower oil (AlaskOmega®) per day
76059505|NCT03593512|Procedure|Deep brain stimulation|Bilateral deep brain stimulation of the pedunculopontine nucleus
75741107|NCT02530879|Behavioral|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
75741108|NCT02530879|Other|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
75447274|NCT05295719|Behavioral|Flexibility training|30 min of stretching 3 days/week for 6 weeks
75447275|NCT05295680|Drug|Hymecromone|Hymecromone 400 mg 3 times daily by mouth.
75447276|NCT05295667|Diagnostic Test|Doppler measurement in combination with amniotic fluid volume|Ultrasonographic evaluation
75447277|NCT05295576|Procedure|non surgical periodontal therapy|Scaling and root planing
75447278|NCT05295563|Other|Evaluation|Gastrocnemius muscle morphology (cross-sectional area, muscle thickness, fascicle length, pennation angle), muscle stiffness, muscle vascularization and functionality of children with CP will be evaluated.
75741109|NCT03957499|Drug|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
75741110|NCT03957499|Drug|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
75741111|NCT03957499|Drug|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
75741112|NCT00387712|Other|Velocity based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
75888928|NCT02256098|Device|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
75741113|NCT00387712|Other|Duration based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
75741114|NCT01091389|Procedure|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
75741115|NCT01040338|Drug|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
75741116|NCT01089829|Other|Foot examination|"Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system"
75888929|NCT02256098|Device|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
75888930|NCT03690609|Dietary Supplement|CytoQuel|3 capsules daily.
75888931|NCT03690609|Dietary Supplement|CytoQuel|2 capsules twice daily.
75888932|NCT02173808|Biological|levonorgestrel butanoate|
76059506|NCT03595462|Other|Snack|"Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be ~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be ~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat."
76059507|NCT03595462|Other|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
76059508|NCT03990532|Radiation|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
76059509|NCT03990532|Radiation|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
75447279|NCT05295381|Device|cough machine (CM)|Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
75447280|NCT05295381|Device|abdominal weight training (AWT)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
75447281|NCT05295329|Drug|Compound Danshen Dropping Pills|use Compound Danshen Dropping Pills
75447282|NCT05295329|Drug|Placebo|use placebo
75447283|NCT05295316|Other|Life Stressor Checklist Revised (LSC-R) (Appendix 1)|Evaluation of stress factor as risk factor for fibromyalgia development
75741117|NCT01091545|Radiation|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
75888933|NCT03690531|Device|Take-Pause virtual reality|Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
75447284|NCT05295303|Device|Remote integrated post-MI management system|The home-based remote integrated post-MI management system comprises (1) a patch-based long-term Holter monitoring system HC3A250 (BISA Technologies (Hong Kong) Limited, Hong Kong SAR, China), (2) a handheld single-lead electrocardiogram (ECG) recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China), (3) a blood pressure monitor, (4) a patient-facing smartphone application specially designed for the study, and (5) a web-based clinical management system for clinicians
75447285|NCT05294900|Drug|paclitaxel/carboplatin|"Induction chemotherapy : total 2 cycle every 3weeks as below:~Paclitaxel 175mg/m2~Carboplatin AUC5"
75447286|NCT05286398|Procedure|Palatoplasty|Surgical closure of palatal defect
76059510|NCT03990064|Other|musicotherapy|receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
76059511|NCT05632042|Behavioral|lifestyle modification (exercise and control of diet)|erectile dysfunction (ED) psoriatic men with metabolic syndrome that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
76059512|NCT03595306|Dietary Supplement|Prebiotic A - inulin|Pre-weighed packages will be given twice daily for 5 days.
76059513|NCT03595306|Dietary Supplement|Prebiotic B - galactooligosaccharides(GOS)|Pre-weighed packages will be given twice daily for 5 days.
76059514|NCT03595306|Dietary Supplement|Prebiotic C - wheat dextrin|Pre-weighed packages will be given twice daily for 5 days.
76059515|NCT05631652|Device|PillSense System|The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
76059516|NCT03599830|Other|Cognitive test passations|"Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences"
76059517|NCT03594916|Device|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
76059518|NCT03594916|Device|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
76059519|NCT03989362|Drug|Vopratelimab|Specified dose on specified days
76059520|NCT03989362|Drug|Ipilimumab|Specified dose on specified days
75447287|NCT05286398|Diagnostic Test|Addition silicone impression|diagnostic impression for maxillary arch
76059521|NCT04009096|Biological|ChAd63 PvDBP and MVA PvDBP|one dose of 5 x 10^10 vp ChAd63 PvDBP and one dose of 2 x 10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
76059522|NCT03594838|Other|HCV viremia testing approaches|Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
76059523|NCT05631106|Behavioral|High Intensity Interval Resistance Training|During each group exercise session, the participants will be guided through a 5-minute warm-up, supervised to perform two sets of machine-based leg press, chest press, seated row, and shoulder press exercises at 30% of 1-RM, and guided through a cool-down. Each exercise set will be 40 -seconds in length with instructions to perform as many repetitions as possible followed by a 20-second rest in between sets and a three-minute rest between exercises.
75741118|NCT03955939|Drug|LY3295668 Erbumine|Administered orally.
75741119|NCT03955939|Drug|Endocrine therapy|Administered according to label instructions.
75447288|NCT05281679|Other|Low-intensity resistance exercise with blood flow restriction group (L-BFR)|The blood flow restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 40% of 1-RM. The SB protocol consists of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min recovery interval between sets and 3-min between exercises. Blood flow to the active muscle during training will be restricted by a blood flow restriction band (tourniquet) placed at the proximal end of the lower limbs. When the subjects performed training with BFR, the proximal portions of their lower limbs will be compressed at the pressure of 120-160 mmHg by electronically controlled air pressure belts. The air pressure belt will be inflated before the exercise and will remain inflated during one-minute intervals between the sets and will be deflated during the three-minute interval between the exercise.
75741120|NCT03955939|Drug|Midazolam|Administered orally.
75888934|NCT03690531|Device|Passive Distraction|Standard or passive distraction technique, lasting 5 minutes.
75741121|NCT01094665|Procedure|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
75888935|NCT02256020|Other|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
75741122|NCT01091623|Other|training|
75741123|NCT01091623|Other|training|
75741124|NCT01091623|Other|training|
75741125|NCT01094821|Drug|ATI-7505|3 mg three times daily for 9 days
76059524|NCT05631106|Behavioral|Stretching, Balance, and Range of motion|The stretching, balance, and range of motion intervention will include a rotating and varied routine of stretching exercises for large and small muscle groups, and activities to improve balance and range of motion. Participants will attend this intervention twice a week with each session lasting 30 minutes.
76059525|NCT03599596|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
75447289|NCT05281679|Other|High-intensity resistance exercise without blood flow restriction group (H-BFR).|The high-intensity restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 80% of 1-RM. The SB protocol consist of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min rest interval between sets and 3-min between exercises.
76059526|NCT03599596|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
75741126|NCT01094821|Drug|Placebo|Placebo capsule three times daily for 9 days
75888936|NCT02256020|Other|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
75447290|NCT05276154|Other|thermoviscous bulkfill composite (Viscalor)|a relatively new product of composite resin which is transformed from high viscosity to low viscosity by the action of head produced by a heating device.
75447291|NCT05275647|Drug|BOTOX 100U in normal saline|LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
75447292|NCT05275647|Drug|Normal saline|LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
76059527|NCT04407130|Drug|Ivermectin + Doxycycline + Placebo|"Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5"
75596928|NCT01074307|Drug|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
75596929|NCT01076335|Drug|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
75596930|NCT01076335|Drug|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
75888937|NCT03690297|Device|Linked Color Imaging|Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
75447293|NCT05274126|Behavioral|Patient group/Passvers|"Passvers intervention aims at :~helping patients followed in the centers, presenting a Severe and Persistent Mental Disorder (schizophrenia, mood disorder, autism spectrum disorder, etc.), at risk or in a situation of psychological disability, to enroll in a rehabilitation program towards recovery.~supporting the emergence and construction of projects by the people themselves, and to accompany them to realize them.~Encouraging the use of resources in their environment and common law mechanisms (city hall, department, associations, etc.) for better social integration.~encouraging involvement in care understood as useful tools for the realization of the personal project.~Passvers also aims at :~promoting a change in professional practices within the team, in favor of recovery-oriented practices based on the concept of engagement or empowerment.~allowing cooperation between health and social structures aiming at destigmatizing mental illness."
75596931|NCT01309737|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
75596932|NCT01309737|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
75741127|NCT01094821|Drug|ATI-7505|10 mg ATI-7505 three times daily for 9 days
75741128|NCT01094821|Drug|ATI-7505|20 mg ATI-7505 three times daily for 9 days
75741129|NCT00072475|Drug|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or > tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
75447294|NCT05274035|Drug|Perampanel|"For children ≥4 years old, the initial dose is 2 mg per day, the titration interval is ≥2 weeks, the daily dose is increased by 2 mg each time (based on clinical response and tolerability), and the maintenance dose is ≥4 mg per day, up to a maximum dose of 12 mg per day.~For children <4 years old, the initial dose is 0.04 mg/kg per day, the titration interval is ≥ 2 weeks, the daily dose is increased by 0.04 mg/kg each time (based on clinical response and tolerability), and the maintenance dose is ≥ 0.08 mg/day per day kg, the highest dose is 0.24 mg/kg per day.~According to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
75447295|NCT05273905|Diagnostic Test|Ultrasound derived Avi|Assess the Avi of carotid arteries, hepatic arteries, renal arteries and central retinal arteries.
75447296|NCT05273242|Drug|Artesunate Injection|"Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies."
75596933|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
75596934|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
75596935|NCT01074229|Drug|Placebo|placebo injection
75596936|NCT01074229|Drug|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
75596937|NCT01074229|Drug|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
75596938|NCT01106014|Drug|Selexipag|Selexipag 200 µg tablets
75596939|NCT01106014|Drug|Placebo|Placebo tablets matching selexipag
75596940|NCT01073605|Drug|Genotonorm|0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
75596941|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
75596942|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
75596943|NCT01073293|Biological|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
75741130|NCT02530645|Behavioral|OnTrack|
75741131|NCT02530645|Behavioral|Treatment as Usual|
76059528|NCT04407130|Drug|Ivermectin + Placebo|Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5
76059529|NCT04407130|Drug|Placebo|Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
75741132|NCT02530645|Behavioral|Brief Motivational Interviewing|
75741133|NCT01094899|Radiation|Radiography|Radiography, microscanner, osteodensitometry
75741134|NCT01094899|Other|Urine and Blood sampling|mainly dosage of bones metabolism
76059530|NCT03599440|Other|Pressure line extensions|"Two types of extension lines are connected:~Perfusor® line 150cm (polyethylene)~conventional arterial extension line"
76059531|NCT03599284|Drug|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
76059532|NCT03599284|Drug|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
76059533|NCT03599284|Drug|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
75741135|NCT01094899|Other|Echography|body bones echography
75741136|NCT01091701|Biological|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
75741137|NCT01091701|Other|Plasmalyte-A|Single IV dose of Plasmalyte-A
75741138|NCT03960229|Other|MicroFluidic Sperm Sorting Chips|sperm selection of IVF treatment
75741139|NCT03960229|Other|Gradient-Density Centrifugation|sperm selection of IVF treatment
75741140|NCT00066469|Biological|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: < 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: < 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
76059534|NCT03599284|Drug|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
76059535|NCT04407052|Drug|Double trigger|Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
76059536|NCT04407052|Drug|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
76059537|NCT03024814|Drug|Acetaminophen|"The first group will receive acetaminophen as the following~Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
76059538|NCT03024814|Drug|Dextrose 5|"The second group will receive placebo (D5W) as the following~Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
76059539|NCT03024502|Drug|EPP-AF Gel 1%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
75888938|NCT04132401|Diagnostic Test|algorithm|The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
75888939|NCT02173886|Drug|Bupropion SR and XL|
76059540|NCT03024502|Drug|EPP-AF Gel 2%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
75447297|NCT05272995|Diagnostic Test|IIEF-5|The participants will be asked to complete a validated IIEF-5 questionnaire, an abridged version of the IIEF. The IIEF is a validated, brief and reliable self-administered questionnaire for assessing erectile function. Moreover, this tool is easily administered in clinical setting and demonstrates adequate sensitivity and specificity for detecting treatment-related changes in erectile function in patients with erectile dysfunction (ED).According to Rosen et al the abridged five-item version of the 15-item IIEF possesses favorable properties for detecting the presence and severity of ED for the preceding 6 months. The IIEF-5 consists of five questions, each of which is scored on a five-point ordinal scale and ED may be classified into five categories based on the calculated scores.
75447298|NCT05272800|Device|Spectroscopy Bioimpedance Analysis|Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).
75447299|NCT05272800|Other|Clinical Examination alone|The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.
75741141|NCT00066469|Drug|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
75447300|NCT05271825|Device|Broadband amplification from hearing aids|Amplification from 125 Hz to 10 kHz
75447301|NCT05271825|Device|Band-limited amplification from hearing aids|Amplification from 25 Hz to 3-4 kHz
75888940|NCT03690219|Other|no intervention|no intervention
75741142|NCT00066469|Drug|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
75741143|NCT00066469|Drug|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
76059541|NCT03024502|Drug|Clotrimazole|Administration intravaginal of clotrimazol, 1x/day, 7 days
76059542|NCT03024580|Drug|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
75741144|NCT01094977|Drug|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
75741145|NCT01094977|Drug|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
75741146|NCT01094977|Drug|Saline Placebo|
75888941|NCT02173964|Drug|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
75888942|NCT02173964|Drug|water|same amount of water for pinverin administration
76059543|NCT03024580|Drug|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
76059544|NCT03024580|Drug|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
76059545|NCT03024580|Drug|Exemestane 25 MG|Exemestane 25 mg PO daily
76059546|NCT03024580|Drug|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
76059547|NCT03024580|Drug|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
76059548|NCT03599128|Other|43.3 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
75596944|NCT01073293|Biological|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
75888943|NCT03690141|Drug|tomivosertib (eFT508)|This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
75596945|NCT01073293|Biological|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
75596946|NCT01105936|Drug|Paracetamol|665 mg sustained release paracetamol caplets
75888944|NCT02175602|Drug|Escitalopram|10 milligrams administered each morning
75888945|NCT02175602|Drug|Sertraline|50 milligrams administered each morning
75888946|NCT02175602|Drug|DCV 3DAA FDC|Fixed dose combination (daclatasvir [DCV] 30 milligrams, asunaprevir [ASV] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
75741147|NCT01095055|Biological|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly
75888947|NCT02175602|Drug|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
75888948|NCT03686085|Drug|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
75741148|NCT01095055|Biological|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly
75888949|NCT03686085|Drug|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
75888950|NCT03693963|Device|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
75447302|NCT05271097|Other|MyLink2Care app full functionality|Participants will be shown how to download the app and use the assessment tool.
75741149|NCT01095133|Drug|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
75447303|NCT05271097|Other|MyLink2Care app major intervention features inactivated|Participants will be shown how to download the app and use the assessment tool.
75447304|NCT05270850|Procedure|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
75447305|NCT05270850|Procedure|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula
75596947|NCT01105936|Drug|Placebo|Placebo caplets
75596948|NCT01309659|Drug|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
75596949|NCT01309659|Drug|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
75596950|NCT04989166|Dietary Supplement|Nano-curcumin|Nano-curcumin soft gels
75741150|NCT01095133|Drug|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
75888951|NCT02754440|Device|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
75888952|NCT03690063|Other|Follow up|Follow up of treatment, behavior, co-morbidity
75596951|NCT04989166|Drug|Placebo|Placebo
75596952|NCT04870411|Biological|Blood sample|Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination
76059549|NCT03599128|Other|86.6 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
76059550|NCT03599128|Other|173 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
76059551|NCT03599128|Other|Placebo|Reconstituted in water and given to subjects
76059552|NCT03594682|Other|Intervention/treatment|"experimentalgroup initial dose：~250mg qod~250mg qd/500mg qd by turn~500mg qd control group： 750mg qd"
76059553|NCT01851590|Device|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
76059554|NCT01851590|Drug|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
76059555|NCT01851590|Drug|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
76059556|NCT03598972|Other|intervention|elementary analysis
76059557|NCT03598816|Drug|Durvalumab|-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
76059558|NCT03598816|Drug|Tremelimumab|-Tremelimumab will be administered first
76059559|NCT03598816|Device|TDS-IM v1.0 System|-Integrated electroporation device
75447306|NCT05270317|Procedure|Bone Graft Cultivation and Harvesting|Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.
75888953|NCT03689829|Drug|MOR106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).
75888954|NCT03689829|Drug|Placebo|Corresponding placebo s.c. injections.
76059560|NCT03598816|Biological|Neoantigen DNA Vaccine|-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
76059561|NCT03598816|Procedure|Research blood draw|-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
76059562|NCT05633758|Drug|Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
76059563|NCT05633758|Drug|Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of administration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
76059564|NCT03598738|Drug|Esomeprazole 40mg|Esomeprazole 40mg oral tablet, once a day
75741151|NCT01092013|Behavioral|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
75741152|NCT01092013|Behavioral|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
75741153|NCT01092013|Behavioral|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
76059565|NCT03594292|Device|FASTFORWARDTM Bunion|The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.
76059566|NCT03594292|Procedure|Conventional surgery|The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
75888955|NCT02174042|Drug|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
76059567|NCT03594214|Diagnostic Test|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
76059568|NCT04004182|Dietary Supplement|Fruit bar with addition of polyphenols|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols
76059569|NCT04003948|Drug|Ibogaine Hydrochloride|Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
75741154|NCT00387088|Device|Respimat|
75741155|NCT00387088|Drug|Tiotropium|
75741156|NCT01095211|Drug|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
75741157|NCT01089985|Drug|Autologous serum eyedrops|3 times a day for the duration of the study
75741158|NCT00053365|Drug|irofulven|Given IV
75888956|NCT03693885|Other|Oxytocin challenge test (OCT)|Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h and doubled every 10 min until three uterine contractions per 10-min interval are induced, at which point it will be stopped.
75888957|NCT02174120|Drug|propofol|
75888958|NCT02174120|Drug|etomidate|
75596953|NCT05320705|Drug|Intra Operative Dexmedetomidine|Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
75596954|NCT04305535|Dietary Supplement|Peptidic+Probiotic|"Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~Bifidobacterium animalis subsp. lactis BPL1,~Lactobacillus rhamnosus BPL15,~Lactobacillus rhamnosus CNCM i-4036~Bifidobacterium longum ES1"
75596955|NCT04305535|Dietary Supplement|Peptidic+Placebo|Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo
75596956|NCT04305535|Dietary Supplement|Polymeric+Placebo|Polymeric oral nutritional supplement and a placebo
75596957|NCT04305223|Procedure|Dry Needling|Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).
75596958|NCT04305223|Other|Upper extremity stretching program|A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter
75888959|NCT03922893|Other|Family History Information|The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.
75888960|NCT03922893|Genetic|ORAGENE|Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.
76059570|NCT05633368|Other|Questionnaires|"Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~Patient Health Questionnaire (PHQ-9)~Clinical Global Impression (CGI)~Scaling question regarding depressive symptomatology"
75596959|NCT01104766|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
75596960|NCT01104766|Drug|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
75596961|NCT01104766|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
75596962|NCT04305379|Procedure|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction including a Medial Umbilical Ligament Sling plus Intussusception
75888961|NCT03922893|Genetic|Blood|For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis
75888962|NCT03922893|Other|Skin Biopsy|In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
76059571|NCT03598582|Drug|Epoetin Zeta|"Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol."
76059572|NCT03593980|Dietary Supplement|Cranberry juice|400ml cranberry juice
75596963|NCT04305379|Procedure|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction with Intussusception Only
75888963|NCT02175914|Drug|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
75888964|NCT03693729|Device|HD-tDCS|Participants will complete a metamemory and memory task
75888965|NCT02753816|Drug|Tranexamic Acid|
75888966|NCT02753816|Drug|Placebo Comparator|
75888967|NCT03689751|Other|LSCS Video|LSCS video created depicting the patient journey for elective LSCS patients.
75888968|NCT03689751|Other|TVT/TOT Video|TVT/TOT video created depicting the patient journey for elective TVT/TOT patients.
75888969|NCT03689673|Other|Data collection|
76059573|NCT03976882|Drug|Hetrombopag|Hetrombopag
75888970|NCT02178878|Genetic|Progress, Pain|Progress, Pain
76059574|NCT03976882|Drug|Placebo|Placebo
76059575|NCT03024736|Other|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in~the treatment of opioid-maintained pregnant women"
75888971|NCT03689517|Other|placebo|participants took placebos (pills made by starch) that were told to be an effective analgesic.
75888972|NCT03689517|Device|orthodontic elastic separators|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.
76059576|NCT04747990|Procedure|Early Definitive Treatment|defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)
76059577|NCT03598504|Device|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
76059578|NCT02985346|Biological|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
76059579|NCT02979730|Other|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
76059580|NCT02979730|Other|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
76059581|NCT01852058|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.
75888973|NCT03685851|Procedure|DSAEK type corneal transplant|All surgeries were performed by the same surgeon and according to the same protocol
75888974|NCT02179034|Drug|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
75888975|NCT02179034|Other|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
76059582|NCT05633134|Procedure|Arteriography and precision preoperative embolization|Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
76059583|NCT05633134|Procedure|Arteriography|Arteriography of pelvic tumors 0-24 hours prior to surgery.
75888976|NCT02179034|Other|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
76059584|NCT03593668|Drug|Metformin|"2-week dose adjustment period（0-2weeks）[before meals] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po."
76059585|NCT03593668|Drug|Benaglutide|"2-week dose adjustment period（0-2weeks） [before meals] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH"
75888977|NCT03623997|Other|Iron stable isotope labeled iron(II) sulfate|Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
76059586|NCT05632900|Procedure|Endoscopic ultrasound guided drainage of walled off pancreatic necrosis|It is Therapeutic procedure to treat walled off pancreatic necrosis.
76059587|NCT03598348|Drug|Apatinib+Capecitabine|Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
75596964|NCT02880280|Drug|Human Menopausal Gonadotropin|Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
75596965|NCT02880280|Drug|Human Chorionic Gonadotropin|Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
75596966|NCT04304287|Procedure|Preoperative autologous blood donation, 14 days before surgery|
75888978|NCT02174588|Drug|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
75888979|NCT02174588|Drug|propofol|propofol are used for sedation drug
76059588|NCT03598348|Drug|Apatinib|Apatinib 250mg po Qd
76059589|NCT03598192|Procedure|TAP|The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%
75888980|NCT03693573|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
75888981|NCT03693573|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
76059590|NCT03598192|Procedure|PVB|The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
76059591|NCT03598192|Drug|Ropivacaine|Ropivacaine has been treated the both group
76059592|NCT03598192|Drug|Sufentanil|Sufentanil has been included in Arm/Group Descriptions
76059593|NCT03597958|Genetic|Next generation sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
75447307|NCT05269797|Behavioral|Nurse-led health coaching re: heart failure self-care management|A focus group meeting will be arranged with the nurse participants to provide training on the study intervention specific to the Nurse-led health coaching intervention. The intervention involves identifying barriers and finding strategies and solutions to self-care management, while employing a self-care HF management tool of adjusting diuretic dosing (ADD) according to the congestive cardiac calendar (designed in collaboration with nurses in Phase 1). It will be essential for the nurses to document key information pertaining to the rationale for these decision-making strategies or solutions. This is in comparison to the standard of care in primary health care of nurses not taking a standardize approach towards health coaching and the patient being instructed by the practitioner to take a set diuretic dosing (SDD).
76059594|NCT04003246|Radiation|Thoracic RT and Durvalumab|1500mg every 4 weeks [Q4W] intravenous [IV], first dose within 3 days of RT initiation
76059595|NCT04003246|Drug|Consolidative Durvalumab|1500mg every 4 weeks [Q4W] intravenous [IV] up to one year
75447308|NCT05269576|Other|Clinical practice|Period of 5 days where medical students carry out hospital clinical practices with real patients supervised by professionals who teach them at the same time.
75447309|NCT05269576|Other|Clinical simulation|Clinical simulation classes through 2 sessions of 5 simulated cases each day. All students actively participate in one or two of the simulation cases and observed and discussed all the cases in the debriefings of all of them.
75596967|NCT04304287|Procedure|Preoperative autologous blood donation, 72 hours before surgery|
75596968|NCT04304287|Procedure|Without preoperative blood donation|
75596969|NCT02879968|Other|Non-interventional study|
75596970|NCT04743271|Other|High-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
75596971|NCT04743271|Other|Low-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
75596972|NCT01104376|Drug|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
75888982|NCT02176304|Drug|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
75888983|NCT02176304|Drug|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
75888984|NCT02176460|Drug|Colchicine|0.5mg twice daily for 16 weeks
75888985|NCT02176460|Drug|Placebo|1 tablet twice daily
75888986|NCT03623919|Other|FallSensing multiplayer games|"FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance."
75888987|NCT02179112|Procedure|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
76059596|NCT00218296|Drug|Usual Care Group|Nicotine replacement therapy
76059597|NCT00218296|Other|Reduction Group|Subject selects preferred method for reduction.
76059598|NCT00217672|Biological|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
76059599|NCT00217672|Drug|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
76059600|NCT03593122|Device|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
76059601|NCT03597880|Other|obese patients|underwent bariatric surgery
76059602|NCT03592966|Dietary Supplement|Wild Blueberry Powder|Freeze-dried whole fruit blueberry drink.
76059603|NCT03592966|Dietary Supplement|Placebo|Freeze-dried placebo powder
76059604|NCT03597802|Other|Exercise at workplace - Three times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
76059605|NCT03597802|Other|Exercise at workplace - Four times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
76059606|NCT03597724|Other|Questionnaire composed of 13 choice questions.|In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
76059607|NCT00216736|Drug|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
75741159|NCT00387010|Drug|Fentanyl Buccal Tablets|"Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.~Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.~Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily."
76059608|NCT00216736|Drug|placebo|Single dose oral placebo at ED discharge
76059609|NCT03592810|Other|Settings of the extracorporeal membrane oxygenation (ECMO)|Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
76059610|NCT01850030|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
76059611|NCT01850030|Drug|Micronized Progesterone 600 mg|Intravaginal micronized progesterone 200 mg capsules tid
76059612|NCT01850030|Drug|Placebo progesterone|Placebo intravaginal micronized progesterone 200 mg capsules tid
76059613|NCT01850030|Drug|Placebo dydrogesterone|placebo oral dydrogesterone 10 mg tablets tid
76059614|NCT00215644|Drug|Matuzumab|Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
76059615|NCT00215644|Drug|Epirubicin|Participants will receive epirubicin 50 milligrams per square meter (mg/m^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
76059616|NCT00215644|Drug|Cisplatin|Participants will receive cisplatin 60 mg/m^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
76059617|NCT00215644|Drug|Capecitabine|Participants will receive capecitabine 1250 mg/m^2 daily in a 21-day cycles up to a maximum of 8 cycles.
75741160|NCT01092091|Biological|Pegylated Recombinant Human Arginase I|Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
75741161|NCT01092169|Other|No intervention|
75741162|NCT03960385|Biological|CYD-TDV|Dengue vaccine
75888988|NCT03693495|Diagnostic Test|ellume·lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.
76059618|NCT03597490|Combination Product|Multimodal physical therapy with exercise|Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
76059619|NCT04747756|Other|Virtual Village|The purpose of this study is to create a virtual village for people aging with HIV, and to pilot test the virtual village intervention as a final step.
76059620|NCT03597412|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
76059621|NCT03597412|Drug|Monorova|Rosuvastatin 20mg
76059622|NCT03592732|Other|Blood sample|Blood sample
76059623|NCT01870401|Device|Lutonix DCB|
76059624|NCT01870401|Device|Uncoated PTA Catheter|
75447310|NCT05269264|Diagnostic Test|Assessor A (first measurement): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
75596973|NCT01104376|Drug|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
76059625|NCT03597334|Behavioral|aerosol therapy|Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
76059626|NCT04414839|Device|Digital Intubation (Two-finger)|In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.
76059627|NCT04414839|Device|Video Laryngoscopy|In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
76059628|NCT00213148|Drug|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
76059629|NCT00213148|Drug|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
75596974|NCT02875873|Drug|Plasma-Lyte|Plasma-Lyte will be used for fluid expansion and maintenance
75596975|NCT02875873|Drug|Saline 0.9%|Saline 0.9% will be used for fluid expansion and maintenance
75741163|NCT00386776|Other|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
75741164|NCT01092247|Other|Nutritional support with Standard diet|Nutritional support with Standard diet
75741165|NCT01092247|Other|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
75741166|NCT00065065|Drug|Rosiglitazone|4mg orally twice daily for 12 weeks
75741167|NCT00065065|Drug|Placebo|pill that looks identical to rosiglitazone
75888989|NCT03693495|Diagnostic Test|Bacterial Culture|Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.
75888990|NCT03693495|Diagnostic Test|Polymerase Chain Reaction (PCR)|Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
75596976|NCT02875873|Other|Slow infusion speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.
75596977|NCT02875873|Other|Fast Infusion Speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
75741168|NCT00386308|Drug|Tranexamic acid tablets|3900 mg/Day
75741169|NCT00386308|Drug|Placebo tablets|
75741170|NCT00064987|Procedure|Testicular biopsy|Outpatient surgical procedure.
75741171|NCT00064987|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
75741172|NCT00064987|Drug|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
75888991|NCT02176538|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days
75447311|NCT05269264|Diagnostic Test|Assessor B: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
75596978|NCT02880202|Other|Massage Therapy|The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
75741173|NCT00374452|Other|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
76059630|NCT00213148|Drug|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
76059631|NCT00213148|Drug|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
76059632|NCT00213148|Drug|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
76059633|NCT01704261|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
75596979|NCT02880124|Dietary Supplement|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
75596980|NCT02880124|Behavioral|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
75741174|NCT00374452|Other|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
75741175|NCT00064753|Drug|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
75741176|NCT00064753|Device|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
75596981|NCT02880124|Procedure|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
75741177|NCT00374140|Drug|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
75741178|NCT00665561|Drug|Maraviroc along with an optimized background antiretroviral drug regimen|Maraviroc prescribed per approved local label.
75741179|NCT00665561|Drug|Optimized background antiretroviral drug regimen without maraviroc|Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
75741180|NCT04064086|Other|Comprehensive Pre-ESRD Patient Education (CPE)|Structured education session/s
75888992|NCT02176538|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
75888993|NCT03623841|Other|Dual-task training|Participants in experimental group will do dual-task training via exer-game which combined with treadmill
75888994|NCT03623841|Other|Treadmill training|Participants in control group will do treadmill training only
75888995|NCT02256254|Drug|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
75888996|NCT02256254|Drug|Placebo|2 placebo capsules every evening for 14 days
76059634|NCT01704261|Drug|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
76059635|NCT01704261|Drug|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose >=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
76059636|NCT01704261|Drug|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose >=1500 mg
76059637|NCT01715571|Device|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary."
75741181|NCT04064086|Other|Provision of the freely available resources for Kidney Disease Education|freely available resources
75741182|NCT03955705|Drug|Nefopam 20 mg/ml|Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
75741183|NCT03955705|Drug|Normal saline|0.9% Sodium chloride (normal saline or NSS)
75888997|NCT02256332|Dietary Supplement|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
75888998|NCT02256332|Dietary Supplement|High dose plant based ingredient|Reference food with high dose of plant based ingredient
75888999|NCT02256332|Dietary Supplement|Reference food format|Reference food without plant-based ingredient
75889000|NCT03689361|Combination Product|MRI|Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion).
75889001|NCT03689361|Diagnostic Test|MRI control|MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion)
75889002|NCT03689361|Other|telephone consultation|telephone consultation
75889003|NCT02176616|Procedure|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
75889004|NCT02176616|Procedure|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
75596982|NCT02880124|Procedure|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
75596983|NCT02880124|Other|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
75889005|NCT03689283|Other|Dry Needling|Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle
75889006|NCT03689283|Other|Sham Dry Needlling|Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
75596984|NCT02880124|Other|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
75889007|NCT02182076|Drug|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
75889008|NCT03693417|Device|Heated circuit on|Heated circuit will be turned on.
75889009|NCT03693417|Device|Heated circuit off|Heated circuit will be turned off.
75889010|NCT02179268|Drug|sertraline|50mg, 50-150mg/d,qd for one year
75889011|NCT02179268|Drug|citalopram|20mg, 20-40mg/d,qd,for one year
75889012|NCT02179268|Drug|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
75889013|NCT02179268|Drug|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
75889014|NCT02179268|Behavioral|control|50min, every week for three months, every month, for nine months
75889015|NCT02182154|Drug|BIBF 1120 ES|
75889016|NCT03693339|Drug|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
75889017|NCT02176694|Behavioral|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
75889018|NCT03689127|Device|Heated breathing circuit on|Heated breathing circuit will be turned on.
75889019|NCT03689127|Device|Heated breathing circuit off|Heated breathing circuit will be turned off.
75889020|NCT02176772|Other|Stable iron isotopes, non-drug intervention|
75889021|NCT03538184|Procedure|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
75889022|NCT03538184|Procedure|Drill|Preparation of implant beds entirely with conventional implant drills
75889023|NCT02182232|Drug|BIBF 1120|
75889024|NCT02182232|Drug|Paclitaxel|
75889025|NCT02182232|Drug|Carboplatin|
75889026|NCT04356560|Diagnostic Test|COVID-19 test, polymerase chain reaction for SARS-CoV-2|surveillance
76059638|NCT00212758|Drug|Nutropin AQ|Nutropin AQ
76059639|NCT04549545|Device|Vivaer ARC Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session.
75741184|NCT03154138|Device|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
75889027|NCT02179502|Drug|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
75889028|NCT02179502|Drug|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
75889029|NCT02179502|Drug|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
75741185|NCT03154138|Device|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
75741186|NCT01090219|Procedure|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
75741187|NCT01090297|Device|S8 Spirit 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
75889030|NCT02179502|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
75889031|NCT02182310|Drug|BI 201335 low dose|
75889032|NCT02182310|Drug|BI 201335 placebo|
75889033|NCT02182310|Drug|Moxifloxacin|
75889034|NCT02182310|Drug|BI 201335 high dose|
75889035|NCT02176850|Drug|Micardis®|
75889036|NCT02177006|Behavioral|Sun Protection Program|"The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
75889037|NCT02177084|Device|PTNS|
75889038|NCT02179580|Drug|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
75889039|NCT02179580|Drug|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
75889040|NCT02182388|Drug|Placebo|
75889041|NCT02182388|Drug|BI 207127 NA powder for solution|
75889042|NCT02182388|Drug|BI 207127 NA tablet|
75447312|NCT05269264|Diagnostic Test|Assessor A (second measurement: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
75741188|NCT01090297|Device|Somnosmart 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
75741189|NCT01090297|Device|Remstar Auto|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
75741190|NCT03955549|Behavioral|Insight Enhancement Program (IEP)|"IEP is comprised of 8 sessions, administered twice weekly, across a one month period. The session duration is 60-90 minutes. IEP will be administered in a group format with 8-12 patients in each group.~During sessions, different topics representing 8 different stages of illness are discussed according to a chronological schedule. These stages are presented on an Illness March Graph (IMG) and include: Stage I: Personality formation, Stage II: Pre onset confusion, Stage III: Prodroma, Stage IV: The illness, Stage V: Resistance, Stage VI: Remission, Stage VII: Maintenance, Stage VIII: Relapse. Patients actively participate through the exchange of their own experiences and interpretations, which are then reinterpreted by the therapist and by the patients themselves."
75741191|NCT03955549|Behavioral|Metacognitive Training for Psychosis (MCT)|The training consists of eight modules that are administered within the framework of a group intervention program that involves eight 1-hour group sessions with 4 to 10 patients in each group. MCT is manualized and currently available in thirty languages and can been downloaded via the following web address: http://www.uke.de/mct. Among the problematic thinking styles recognized as potential contributors to the development of delusions are attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
75889043|NCT03537326|Drug|Budesonide|Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
75889044|NCT02182466|Device|Colon capsule endoscopy|
75769595|NCT03894358|Dietary Supplement|FeFum and 7.5 g prebiotic mixture|"The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture~The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:~Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.~Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically."
75889045|NCT02182544|Drug|WAL801CL dry syrup|
75889046|NCT02182544|Drug|Ketotifen fumarate dry syrup|
75889047|NCT02182544|Drug|Ketotifen fumarate dry syrup placebo|
75889048|NCT02182544|Drug|WAL 801 CL dry syrup placebo|
75889049|NCT03537248|Device|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
75889050|NCT03537248|Device|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
75889051|NCT02177240|Device|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
75889052|NCT02177240|Device|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
75447313|NCT05269264|Diagnostic Test|Assessor A (2 weeks later): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
75447314|NCT05269121|Biological|Phage Therapy|Patient will undergo a DAIR procedure. After the DAIR, phage therapy will be administered in conjunction with antibiotic treatment.
75447315|NCT05269095|Procedure|Spinal anesthesia only|Patients will receive spinal anesthesia with 2-3 ml 0.5% (10-15 mg) hyperbaric bupivacaine plus 25 ug fentanyl at the L3/4 interspaces.
75889053|NCT02179658|Drug|OPT-80|oral
75889054|NCT02179658|Drug|vancomycin|oral
75889055|NCT02177318|Drug|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
76059640|NCT04549545|Device|Sham|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
75769596|NCT03894358|Dietary Supplement|FeFum and 3 g prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion
75447316|NCT05269095|Biological|Spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.
75447317|NCT05269095|Biological|Ultrasound-guided Adductor Canal block (ACB) technique with infiltration of the interspace between popliteal artery and the capsule of posterior knee block ('PACK)|Adductor Canal block (ACB) technique will be performed using 16 ml bupivacaine 0025% As regarding the Popliteal artery and the capsule of posterior knee block ('PACK), it will be performed Using 16 ml bupivacaine 0.25%
75447318|NCT05268783|Procedure|EORTC QLQ-C30|Quality of life questionnaire that has to be completed every 6 months
75447319|NCT05268783|Procedure|EORTC QLQ-GI.NET21|Quality of life questionnaire that has to be completed every 6 months
75447320|NCT05268783|Procedure|Satisfaction survey|Questionnaire regarding satisfaction of care that has to be completed on Day 1.
75447321|NCT05267938|Drug|Topical Anesthetic|The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
75447322|NCT05267938|Drug|Local anesthetic|After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
75447323|NCT05267431|Drug|Biological Drug|Different biological drugs
75447324|NCT05266248|Other|250 mg encapsulated caffeine|Zero calorie 500 ml (16.9 oz) flavored, carbonated energy beverage
75447325|NCT05265585|Diagnostic Test|Ultrasound - Cardiac Acquisition|"The evaluation of the algorithm takes place on patients with an indication for echocardiography.~This examination is done in a standard way with the potential specific explorations related to the indication of the examination. During the echocardiography, the operator records the search phase for the following reference views:~Parasternal window (Parasternal long axis, Parasternal minor axis)~Apical window (Apical 4 cavities, Apical 3 cavities, Apical 2 cavities~Sub costal window, Sub costal 4 cavities, Inferior vena cava)"
75596985|NCT02880124|Procedure|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
75889056|NCT03693261|Procedure|Coronary artery bypass grafting (CABG)|CABG, as part of the standard medical care
75447326|NCT05264584|Drug|Isotonic saline|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
75447327|NCT05264584|Drug|N-acetyl cysteine|all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
75447328|NCT05264584|Drug|Febuxostat 80 MG|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
75596986|NCT02880124|Behavioral|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
76059641|NCT03982342|Device|Cather closure of patent ductus arteriosus (PDA)|Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.
76059642|NCT03982342|Other|Conservative management of patent ductus arteriosus (PDA)|"Infants with a hemodynamically-significant patent ductus arteriosus randomized to this group will be treated by fluid restriction and possible diuretic use to reduce PDA symptoms, and allow time to permit the PDA to close or become reduced in size to the point where it is no longer considered hemodynamically-significant."
75462926|NCT01869894|Procedure|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
75596987|NCT01072357|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
75596988|NCT01072357|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
75596989|NCT01072201|Drug|Triclosan and Fluoride|Brush twice daily
75596990|NCT01072201|Drug|Fluoride|Brush twice daily
75769597|NCT03894358|Dietary Supplement|Fefum and no prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
75769598|NCT01155310|Drug|Helium/Oxygen 78%/22%|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
75889057|NCT03693261|Procedure|Valve replacement|cardiac surgery for aortic or mitral valve replacement as part of their standard medical care
75447329|NCT05264155|Behavioral|GameBus (mHealth app)|Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
75447330|NCT05263687|Diagnostic Test|Maximal exercise test|Each participants will conduct a spirometry test and exercise test on treadmill (using Modified Bruce Protocol) or cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange, ECG, gas volume in addition rating of perceived exertion will be asked.
75447331|NCT05263167|Drug|Sodium Aescinate|sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
75889058|NCT03685695|Other|Laboratory Biomarker Analysis|Correlative studies
75889059|NCT03685695|Device|Monitoring Device|Wear Fitbit Charge 2
75889060|NCT03685695|Other|Physical Activity|Complete aimed walking steps
75889061|NCT03685695|Other|Quality-of-Life Assessment|Ancillary studies
75447332|NCT05263167|Drug|Placebo|250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
75447333|NCT05262959|Drug|Donafenib, PD-1|Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
75889062|NCT03685695|Other|Questionnaire Administration|Ancillary studies
76059643|NCT03592420|Behavioral|Interdisciplinary multicomponent interventions|
76059644|NCT03592420|Behavioral|Usual care|standard care
76059645|NCT01824290|Drug|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
75447334|NCT05262959|Procedure|TACE|TACE will be performed by the investigator based on the patient's tumor status.
75447335|NCT05262686|Drug|Belimumab|Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
75462927|NCT01869907|Drug|Minocycline|100 mg once daily by mouth during 14 days
75462928|NCT01869907|Drug|placebo|once daily by mouth during 14 days
75596991|NCT01103362|Drug|flibanserin|all patients will receive open-label flibanserin 100mg
75596992|NCT00591929|Other|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
75596993|NCT04412993|Other|withdraw blood samples|withdraw blood sample from gorup O donors
75596994|NCT04412135|Other|spirituality|Patients will take three questionnaires (FACIT-Sp, Euroqol 5 dimensions and ESAS)
75741192|NCT03955549|Drug|Treatment As Usual (TAU)|"Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
75741193|NCT00786461|Procedure|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
75889063|NCT02177396|Drug|Telmisartan|
75889064|NCT02177396|Drug|Valsartan|
75889065|NCT02177396|Drug|Placebo|
75889066|NCT02030054|Drug|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
75889067|NCT02030054|Drug|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
75889068|NCT02182622|Drug|Docetaxel|
75596995|NCT04208009|Behavioral|Advance care planning animated videos|Four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
75596996|NCT01103284|Drug|DiaPep277|1.0 mg dose in 0.5 mL of solution
75889069|NCT02182622|Drug|Prednisone|
75889070|NCT02182622|Drug|LDE225|
75889071|NCT02182700|Drug|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
76059646|NCT01824290|Drug|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
75741194|NCT00786461|Procedure|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
75741195|NCT00786695|Drug|esomeprazole|esomeprazole (40 mg o d) for 14 days
75447336|NCT05262686|Drug|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
75447337|NCT05261334|Procedure|contour augmentation|early implant placement with contour bone augmentation
75447338|NCT05259540|Drug|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
75447339|NCT05258968|Other|Education on the Injeti Model of Self-Esteem|1 hour educational session
75447340|NCT05254028|Procedure|filiform needle|Manual acupuncture using filiform needles
75447341|NCT05238870|Other|Interviews for the needs analysis. No intervention.|To develop the education and training package, a needs-analysis is necessary. The clinicians' training needs will be established through interviews.
75741196|NCT00786695|Drug|Placebo|Identical looking Placebo, same regimen, for 14 days
75741197|NCT00786851|Drug|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
75741198|NCT00786929|Procedure|Catheter drainage|
75447342|NCT05236608|Drug|Nivolumab|Administered together with ADG106 via intravenous infusion.
75447343|NCT05236608|Drug|ADG106|Administered as an intravenous infusion over 90 minutes.
75741199|NCT00786929|Drug|Conservative treatment|
75741200|NCT00663923|Procedure|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
75741201|NCT00787007|Drug|S-equol|capsule, oral, single dose
76059647|NCT01824290|Drug|ERA as specific PAH treatment|All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
75462929|NCT01869907|Drug|Amitriptyline|25mg once daily by mouth during 14 days
75741202|NCT00787007|Drug|Placebo|capsule, oral, single dose
75741203|NCT00787163|Procedure|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
75741204|NCT00791063|Other|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
75741205|NCT00784355|Procedure|Laparoscopic cholecystectomy|Surgery
75741206|NCT00795119|Device|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
76059648|NCT03596944|Drug|Statin|Prescribed with statins for primary prevention
75462930|NCT01869920|Behavioral|Intervention group|Education on breastfeeding
75462931|NCT01869920|Behavioral|Usual care|Usual care
75462932|NCT01869933|Drug|OC-10X|
75741207|NCT00787397|Behavioral|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
75741208|NCT00791141|Drug|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
76059649|NCT03592342|Drug|Clobetasol Propionate|Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
76059650|NCT01715415|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
76059651|NCT01715415|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
75447344|NCT05225402|Drug|Hemodynamic measurements during reduction in Norepinephrine and fluid boli.|"Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP<40.~While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV>10%.~As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP."
75889072|NCT02182778|Drug|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
75889073|NCT02182778|Drug|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
75447345|NCT05224232|Device|Access Socket|During a period of 4 weeks, patients will live in their usual environment with the soft socket (Access-Socket)
75447346|NCT05224232|Device|Rigid socket|During a period of 4 weeks, patients will live in their usual environment with their usual rigid socket
75447347|NCT05223517|Device|Acupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted to 60-70mm in Ciliao and Huiyang, 6-10 mm in Shenmen and 10-20mm in other acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times (except for Ciliao) to achieve deqi sensation and manipulated every ten minutes during 20-minute maintenance in prone and supine position respectively.~Participants receive acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
76059652|NCT01715415|Drug|Placebo for ABT-450/r/ABT-267|Tablet
75462933|NCT01869946|Drug|Ropivacaine|
75462934|NCT01869985|Drug|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
75462935|NCT01870011|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
75462936|NCT01870011|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
75462937|NCT01870024|Drug|Clonazepam|clonazepam 0,015 mg/kg
75596997|NCT01103284|Drug|Placebo|"40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
75596998|NCT04409249|Diagnostic Test|imaging, blood tests|PCR and CT results, hemogram, urea, creatinine, AST, ALT, LDH, D-Dimer, ferritin, lipase, amylase, CRP, procalcitonin, albumin, total protein, coagulation tests-PT, APTT, Fibrinogen-, Troponin T, CK , electrolytes, blood gas, bilirubins
75596999|NCT04134221|Diagnostic Test|Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow
75597000|NCT02893709|Drug|Omeprazole|Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
75597001|NCT04972396|Drug|ALT-801|Injected subcutaneously (SC)
75597002|NCT04972396|Drug|Metformin|Taken by mouth (PO)
75597003|NCT04972396|Drug|Atorvastatin|Taken by mouth (PO)
75597004|NCT04972396|Drug|Warfarin|Taken by mouth (PO)
75597005|NCT04972396|Drug|Digoxin|Taken by mouth (PO)
75597006|NCT04972396|Drug|Ethinylestradiol and Levonorgestrel|Taken by mouth (PO)
75741209|NCT04046783|Device|patch|an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
75741210|NCT04046393|Device|"Taiwan Scientific noninvasive blood pressure meter TS-0411"|measure autonomic nerve
75741211|NCT04046393|Device|Meridian Energy Analysis Device(MEAD)|measure meridian energy
75741212|NCT04046393|Procedure|bacteria culture|use culture swab to culture nasal discharge
75741213|NCT04046393|Procedure|nasopharyngoscopic examination|use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
75741214|NCT04046393|Combination Product|TCM nasal irrigation|Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
76059653|NCT01715415|Drug|Placebo for ABT-333|Tablet
75889074|NCT03688971|Drug|Omiganan|Omiganan Topical Gel
75741215|NCT00386152|Drug|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
75447348|NCT05223517|Device|Sham Acupuncture|"Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 20-minute maintenance in prone and supine position respectively.~Participants receive sham acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
75889075|NCT03688971|Drug|Ketoconazole|Ketoconazole Cream
75462938|NCT01870024|Drug|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
75462939|NCT01870024|Drug|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
75597007|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
75597008|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
75741216|NCT00386152|Drug|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
75741217|NCT00787475|Other|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
75741218|NCT00787553|Drug|cefazolin|2.0 g, IV, 2 hours before surgery
75741219|NCT00787553|Drug|tinidazole|2.0 g orally, 12 hours before surgery
75741220|NCT00787553|Drug|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
75741221|NCT00795353|Drug|Amevive exposure|Commercial alefacept prescribed by Physician
75741222|NCT00791297|Drug|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
75741223|NCT00385918|Device|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
75889076|NCT03688971|Drug|Placebo|Vehicle
75889077|NCT03536624|Behavioral|6 days spa residential program|6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
75889078|NCT03693027|Dietary Supplement|PTx800 lozenges|PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
75889079|NCT03693027|Dietary Supplement|Placebo control|The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
75889080|NCT02179814|Drug|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
75889081|NCT02179814|Drug|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
75889082|NCT02179814|Drug|Placebo|Placebo at the second, third and fourth medication intake time point
75889083|NCT03688893|Device|Laser Application for Dental Bleaching|The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
75889084|NCT03688815|Diagnostic Test|myocardial perfusion scintigraphy|Myocardial perfusion scintigraphy as it is described in the international literature.
75889085|NCT02179970|Drug|Plerixafor|A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
75447349|NCT05220826|Procedure|Post surgical embolization of middle meningeal artery with liquid embolic agents (ethylene vinyl alcohol copolymers as Onix, Squid, Phil or Libro)|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
75447350|NCT05217251|Other|frontal alpha asymmetry in EEG|frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.
75597009|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
75597010|NCT04407533|Other|Diet tracking and survey|Mobile AI-based food diary application and online questionnaires
75741224|NCT00385918|Other|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
75741225|NCT02554409|Biological|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
75741226|NCT00791375|Behavioral|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
75741227|NCT00385840|Biological|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
75741228|NCT00385840|Biological|FluarixTM|Single dose, intramuscular injection
75597011|NCT02877589|Other|hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)|
75597012|NCT04309162|Other|Soft tissue therapy|Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
75597013|NCT04328597|Procedure|Inguinal hernia repair|Inguinal hernia repair (open, laparo-endoscopic, robotic)
75741229|NCT01045876|Drug|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
75462940|NCT01870024|Drug|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
75597014|NCT01089361|Drug|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
75597015|NCT01089361|Drug|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
76059654|NCT01715415|Drug|Placebo for ribavirin|Capsule
76059655|NCT00211510|Device|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
75741230|NCT01045876|Other|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
76059656|NCT00211510|Device|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
75597016|NCT04399811|Diagnostic Test|Near-infrared Vision Photograph|The near-infrared image will be recorded (by a infrared camera connected to a laptop) for each enrolled patient
75597017|NCT01102972|Drug|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
75597018|NCT01102972|Drug|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
75597019|NCT02893319|Behavioral|Feeding and growth differences, 5oz vs 8oz bottle|Group A: 5oz bottle Group B: 8oz bottle
75597020|NCT04328753|Drug|Super Oxide water|Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
75597021|NCT04328753|Drug|Chlorhexidine mouthwash|CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
75597022|NCT04328753|Other|Distilled water|act as a negative control in this study
75462941|NCT01870037|Drug|Placebo (PBS-20% sucrose)|
75462942|NCT01870037|Drug|hMaxi-K|Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
75462943|NCT01870050|Drug|Dapsone gel - verum|
75462944|NCT01870089|Device|SmartCare/PS-NIV Drägerwerk Lübeck Germany|
75597023|NCT04328363|Behavioral|Intervention|Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.
75597024|NCT04963894|Other|Home functional balance physiotherapy|Experimental physiotherapy program is carried out at home to improve the balance of people with Parkinson's disease through exercises that simulate everyday functional contexts.
75741231|NCT01044550|Procedure|Laparoscopy|Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
75741232|NCT01044550|Other|Clinical follow up|Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
75741233|NCT00385762|Drug|paroxetine|paroxetine 10-40mg daily x 5 weeks
75741234|NCT00385684|Drug|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
75741235|NCT00385684|Drug|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
75741236|NCT00385684|Drug|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
75889086|NCT03538028|Biological|INCAGN02385|INCAGN02385 administered as an intravenous infusion over 30 minutes.
75889087|NCT03537950|Drug|PLC|Single oral dose of PLC.
75462945|NCT01870102|Drug|Pelubiprofen IR (Pelubiprofen 30mg) TID|
75462946|NCT01870102|Drug|Pelubiprofen SR (Pelubiprofen 45 mg) BID|
75462947|NCT01870115|Dietary Supplement|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
75597025|NCT04963894|Other|Conventional physiotherapy|Conventional control physiotherapy program is carried out face-to-face in a rehabilitation gym and in groups of 6 people. The conventional program of physiotherapy includes conventional therapeutic goals of rehabilitation in people with Parkinson's disease.
75597026|NCT02879500|Other|Diet beverages|
75597027|NCT04388579|Other|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
75597028|NCT01088503|Drug|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
76059657|NCT01869777|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
76059658|NCT04199260|Device|papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
75889088|NCT03537950|Drug|CBD|Single oral dose of cannabidiol (CBD) - 600mg.
75889089|NCT03537950|Drug|CBDV|Single oral dose of cannabidivarin (CBDV) - 600mg.
76059659|NCT03596710|Procedure|Image Guided Biopsy|Undergo image guided biopsy
75597029|NCT01087489|Drug|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
75447351|NCT05214313|Behavioral|Music Therapy|"The standardised music therapy protocol of 45 minutes will include at each session :~10 min of musical listening in a soothing environment (relaxation chair and reduced and coloured lighting) in sensory isolation (with headphones) and aimed at relaxation as a preamble to the active phase of the protocol~Active phase: (25 min)~5 min of receptive music therapy linked to a given emotion, different at each session (joy, sadness, anger and fear) aimed at emotional management (feeling and distancing),~20 minutes of active music therapy with instrumental and vocal improvisation that solicits the body physiologically,~10 minutes of musical listening in sensory isolation for a state of rest.~The entire protocol is carried out with the permanent perception of heartbeats set to a physiological frequency of 50 to 100 BPM."
75741237|NCT01044628|Device|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be >90%
75447352|NCT05213871|Other|Instrument-assisted soft tissue mobilization|For IASTM, the subject will be seated in a comfortable position. The subject's forehead will be rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2T blade will be cleaned with an alcohol pad. The M2T blade will be used, at an angle of 45 without causing discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. Subjects will be instructed to put an ice pack on the area if they feel any burning sensations after the session. This procedure will be repeated twice a week for four weeks.
75447353|NCT05213871|Other|Myofascial release therapy|Firstly, the subject will lay supine with no pillow under his/ her head then the subject will rotate his/her head and neck away from the side which will be treated. Therapist will sit or stand at the corner, edge or top of the treatment table and therapist will place one hand proximal to the shoulder with skin on skin and therapist's fingers pointing towards the subject's elbow on the same side. Other hand of the therapist will be placed inferior to the subject's jaw (body of the mandible), using it as a handle, with fingers pointing towards the top of the subject's head. Then therapist will lean into the subject to the tissue depth barrier, wait and follow each subtle release three-dimensionally. Therapist should avoid forcing the tissue or slipping or gliding over the skin. The technique should be applied for at least five minutes for optimal results. This procedure will be repeated twice a week for four weeks.
75741238|NCT01044628|Device|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
75741239|NCT00661661|Drug|CP-690,550|5 mg BID up to 10 mg BID until launch
75741240|NCT00791453|Behavioral|Education|Patients will receive literacy appropriate health information.
75741241|NCT00038467|Drug|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
75741242|NCT00038467|Drug|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
76059660|NCT01714947|Drug|[^14C]-alisertib|[^14C]-alisertib oral solution
76059661|NCT01714947|Drug|alisertib|Alisertib enteric coated tablets
76059662|NCT03596632|Drug|Fenebrutinib|200-mg (100 µCi) oral solution 14C/12C]-fenebrutinib
76059663|NCT03596554|Other|Descriptive study|Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).
76059664|NCT04198636|Drug|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
76059665|NCT04198636|Drug|Xgeva 120 MG in 1.7 ML Injection|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
76059666|NCT04414995|Drug|Paracetamol injection and Ibuprofen injection|Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
76059667|NCT04414995|Drug|Paracetamol injection and normal saline|Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
76059668|NCT04414995|Drug|Ibuprofen Injection and normal saline|Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
75447354|NCT05213871|Other|Postural correction exercises (PCE)|Postural correction exercises will be applied for patients in groups A and B. This program will be conducted according to the protocols of exercise will be performed as 3 sets of 10 repetitions each for 2 times/ week for 4 weeks. The patients will be instructed to continue the exercises as a daily home program to influence the self-correction kinesthetic awareness. Exercises will be performed while the patients in a neutral sitting posture
76059669|NCT03591718|Drug|BI 456906|Solution for injection
75447355|NCT05210413|Drug|Spartalizumab in Pediatric cohort|Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).
75447356|NCT05210413|Drug|Low-dose Pazopanib in Pediatric Cohort|Oral pazopanib treatment at a fixed dose of 225mg/m²/day
75447357|NCT05210413|Drug|Spartalizumab in Adult cohort|Infusion of 400 mg of spartalizumab on Day1 of each cycle.
75447358|NCT05210413|Drug|Low-dose Pazopanib in Adult Cohort|Oral pazopanib treatment with a fixed dose of 400 mg/day
75462948|NCT01870115|Dietary Supplement|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
75462949|NCT01870128|Drug|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
75597030|NCT01087489|Drug|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
75597031|NCT04306627|Drug|Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment|comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
75889090|NCT03685617|Device|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
76059670|NCT03591718|Drug|Placebo|solution for injection
76059671|NCT01869699|Drug|Acetaminophen|acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
76059672|NCT01869699|Drug|Placebo|Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
76059673|NCT04198480|Drug|JMT103|2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
76059674|NCT01714635|Device|Tecnis Multifocal Intraocular Lens|
76059675|NCT01714635|Device|Monofocal Intraocular Lens|
76059676|NCT03596398|Genetic|GLA gene|Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
75597032|NCT04306471|Drug|Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.
75889091|NCT03685617|Device|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
75889092|NCT02182856|Drug|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
75889093|NCT02182856|Drug|Ipratropium 500 µg|
75889094|NCT02182856|Drug|Salbutamol sulphate 3 mg|
75769599|NCT01155310|Drug|Air/Oxygen|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
75769600|NCT03892876|Diagnostic Test|Auditory High Frequency Tetanizing Stimulation|50 ms tone pips presented at high frequency for 120 seconds
75889095|NCT02182856|Drug|Salbutamol sulphate 6 mg|
75447359|NCT05208073|Behavioral|Cosmetic therapy|The cosmetic therapy in this study is once a week, 60 minutes each section for a total of 6-week. Cosmetic therapy uses the teaching materials to teach the subjects skincare and makeup operation steps and use the 10-minute limb stretching to relax their minds before the activity, and then lead the research subjects to use cotton pads to apply lotion and lotion. , female subjects used powder, eyebrow pencil, and lipstick (or lip balm) to complete weekly different-themed activities and hairstyling, while men performed weekly different theme activities and hairstyling.
75447360|NCT05208060|Biological|MV130|Treatment administered sublingually
75447361|NCT05208060|Other|Placebo|Treatment administered sublingually
75462950|NCT01870128|Drug|Methotrexate|Methotrexate 15 to 25 mg PO per week
75769601|NCT03892876|Diagnostic Test|Sham Comparator|auditory tone pips with interstimulus interval (ISI) 1 sec
75889096|NCT03685383|Device|Cytosorb removal column in eCPR|In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.
75889097|NCT03685383|Device|standard eCPR (va-ECMO)|Standard treatment in eCPR with a established va-ECMO system.
76059677|NCT01713933|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
76059678|NCT03759106|Other|home written exercise program|exercises such as picking up objects, placing objects, frequently prescribed at discharge
76059679|NCT03759106|Other|telerehabilitation/exergame system|Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
76059680|NCT01868997|Drug|teprotumumab|
76059681|NCT01868997|Drug|normal saline|
76059682|NCT01875848|Drug|buprenorphine/naloxone|partial opioid agonist
76059683|NCT01875848|Drug|opioid dose escalation|up to 25% increase in patient's current opioid dose
76059684|NCT04588142|Dietary Supplement|Probiotic|Non-elite athletes receive probiotic for 6 weeks
76059685|NCT04588142|Dietary Supplement|Placebo|Non-elite athletes receive placebo for 6 weeks
76059686|NCT04198402|Biological|Biological sampling|Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
75889098|NCT02182934|Drug|Ginsana|
75889099|NCT02182934|Drug|Placebo|
75447362|NCT05205629|Drug|Donafenib combined with TACE|Donafenib(200mg bid po) combined with TACE
75741243|NCT01095367|Procedure|Seprafilm™|"Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort."
75447363|NCT05204784|Procedure|Rheopheresis treatment|After obtaining venous access, anticoagulated blood is pumped through a plasmafilter. The plasma is then run through the Rheofilter and large plasma proteins are removed. Finally, cells are reinfused, and blood is returned to the patient.
75447364|NCT05204784|Drug|Intravenous Infusion|Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard
75447365|NCT05203705|Drug|SHR2285 tablet|SHR2285 tablet; dose 1, for 12 days
75889100|NCT03692949|Drug|LY3451838|One dose administered (IV)
75447366|NCT05203705|Drug|SHR2285 tablet|SHR2285 tablet; dose 2, for 12 days
75447367|NCT05203705|Drug|SHR2285 tablet|SHR2285 tablet; dose 3, for 12 days
75447368|NCT05203705|Drug|SHR2285 tablet|SHR2285 tablet; dose 4, for 12 days
75889101|NCT03692949|Drug|Placebo|Administered IV
75889102|NCT03692949|Drug|Placebo|Administered SC
75889103|NCT03692949|Drug|LY3451838|One dose administered SC
75889104|NCT02183012|Drug|Ibuprofen extrudate|
75447369|NCT05203705|Drug|Enoxaparin|Enoxaparin, for 12 days
75447370|NCT05202561|Biological|RNA tumor vaccine|Subjects will receive single dose of RNA tumor vaccine injection on day 1, day 4, day 7, and day 14, each dose of 600 ng.
75447371|NCT05202561|Biological|RNA tumor vaccine+Navuliumab|RNA tumor vaccine+Navuliumab Subjects will receive maintenance therapy with a PD-1 inhibitor in addition to monotherapy with the RNA tumor vaccine injection. Subjects received a single dose of RNA vaccine injection on day 1, day 4, day 7, and day 14, with each dose of 600 ng. Inhibitors, accept the Navuliumab on day 14, the recommended dose is 3 mg/kg, intravenous injection every 2 weeks.
75741244|NCT00051025|Drug|ONTAK|
75741245|NCT01095445|Drug|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
75741246|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
75889105|NCT02183012|Drug|Ibuprofen lysinate|
75889106|NCT02183012|Drug|Ibuprofen|
75889107|NCT03688737|Other|low level laser|LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
75889108|NCT03688737|Other|placebo|placebo like device as it like low level laser device shape but with no effect to blind the intervention
75889109|NCT02180048|Dietary Supplement|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
75889110|NCT02180048|Dietary Supplement|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
75597033|NCT04306471|Other|Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months|The study subjects randomized to the control study arm will receive monthly subcutaneous injections of placebo 1 mL x 3 in the abdomen, thigh or upper arm. The study placebo prefilled injector pens are to be provided by Amgen.
75889111|NCT02180048|Dietary Supplement|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
75889112|NCT03688659|Drug|Vancomycin and gentamycin|intravenous
75889113|NCT02180126|Other|Follow-up|Follow-up of of patients with borderline positive ANCA test results
75889114|NCT03683043|Drug|Long GnRH agonist protocol|"8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used."
75889115|NCT03683043|Procedure|Embryo transfer|Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
75889116|NCT02180204|Drug|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
76059687|NCT04198168|Drug|IV crystalloid fluid bolus|The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).
75597034|NCT04758481|Radiation|primary tumour radiotherapy|The study subjects will undergo primary tumour radiotherapy.
75597035|NCT04758481|Radiation|stereotactic body radiotherapy|The study subjects will undergo stereotactic body radiotherapy.
75597036|NCT04758481|Radiation|maintenance radiotherapy|The study subjects will undergo maintenance radiotherapy.
75597037|NCT04296253|Genetic|SNP polymorphisms of the promoter regions pro - and anti-inflammatory cytokines and angiogenic growth factor|blood sampling
75889117|NCT02180204|Drug|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
75889118|NCT03685227|Other|Yoga Nidra|This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
75462951|NCT01870128|Drug|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
75889119|NCT02183090|Drug|Meloxicam ampoule|
75889120|NCT02183090|Drug|Meloxicam tablet|
76059688|NCT03973294|Device|EIT-measurement|"The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface."
76059689|NCT03591172|Drug|Propolis|Using propolis as a final irrigation in revascularization
76059690|NCT03591172|Drug|Nano-propolis|Using Nano-propolis as a final irrigation in revasculariztion
76059691|NCT03591172|Drug|saline|Using saline as a final irrigation in revasculariztion
75462952|NCT01870141|Behavioral|Cognitive-Behavioral Intervention|"1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:~self-monitoring~problem solving~goal definition~cognitive restructuring~activation of personal and social resources"
75462953|NCT01870154|Behavioral|Training|The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
75597038|NCT04304989|Other|mHealth program|mobile health applications
75597039|NCT04304989|Other|usual care|usual care
75597040|NCT02877667|Device|planar acoustic wave device|accessory to laser treatment
75741247|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
75889121|NCT03685071|Other|role of CBC as prognostic tool in sepsis.|"Our study will be conducted on children who admitted to PICU in Assuit University Hospital .CBC parameters as TLC , platelet count , and Hb will be evaluated at time of admission , another CBC will be done at 5th day and another one at day of discharge or last one before death.~patients will be classified into three groups according to the outcome(discharge, mortality and has morbidity sequel.)~correlation between the outcome and CBC will be done."
75741248|NCT00660179|Drug|placebo|Matching placebo, once daily
75741249|NCT00050167|Drug|Paclitaxel|80 mg/m^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
75741250|NCT00050167|Drug|Docetaxel|75 mg/m^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
75447372|NCT05196009|Behavioral|mHealth peer navigation and social support|Peer navigation, asynchronous support via SMS, Motivational Interviewing, virtual social support group focused on mental health and substance use, linkage and follow-up
75889122|NCT02752802|Device|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
75447373|NCT05193825|Device|Remote Programming|Patients in the experimental group (Group B) will have their internal pulse generators (IPGs) adjusted through a novel software that allows for remote DBS programming (NeurosphereTM Virtual Clinic)
75447374|NCT05193825|Device|Standard Programming|Patients in the active comparator group (Group A) will have their internal pulse generators (IPGs) adjusted through a standard procedure at their caregivers institution.
75447375|NCT05192733|Other|Survey|This is a cross-sectional practice survey. There is no intervention.
75447376|NCT05192629|Drug|Dexmedetomidine|Premedication by intranasal dexmedetomidine
75447377|NCT05192629|Drug|Midazolam|Premedication by intranasal midazolam
75447378|NCT05191550|Behavioral|Virtual reality brain tumor simulation|"Task: Complete removal of a simulated tumour - distinguishable by colour and haptic properties - with minimal bleeding and damage to surrounding healthy brain using two surgical instruments (Cavitron Ultrasonic Aspirator and Bipolar pincers) of the NeuroVR (CAE Healthcare) surgical simulator.~Intervention: A single 28-minute simulation session, including six virtual subpial tumour resection attempts. Five simple practice scenarios (3 minutes per task) and one complex realistic scenario (13 minutes). Pre- and post-questionnaires to obtain participant demographics and assess face and content validity of the simulated tasks."
75597041|NCT01082965|Drug|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
75597042|NCT01082965|Drug|Placebo|matching placebo
75889123|NCT04059471|Biological|Yellow fever vaccine, Institut Pasteur|Full dose and 500IU/dose
76059692|NCT04197622|Drug|Hydrochlorothiazide|12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
76059693|NCT03592654|Behavioral|infant telehelp|Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
76059694|NCT03596008|Dietary Supplement|Active drink|The freeze-dried strawberry powder (25 g) in active drink
75462954|NCT01870167|Drug|co-amoxiclav|a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.
75462955|NCT01870167|Dietary Supplement|Placebo|Placebo
75597043|NCT01102426|Drug|Plitidepsin|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
75597044|NCT01102426|Drug|Dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
75597045|NCT04304365|Other|Follow-up clinic visit|Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.
75741251|NCT00050167|Drug|Capecitabine|1500 mg/m^2 by mouth Twice Daily x 2 Weeks
75741252|NCT01095523|Procedure|Laparotomy+ HIPEC +/- CRS|
75741253|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
75741254|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
75741255|NCT01092325|Drug|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
75741256|NCT01092325|Drug|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
75741257|NCT01092325|Drug|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
75741258|NCT01092325|Drug|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
75741259|NCT03957265|Procedure|Tapered abutment connection|Rehabilitation of completely edentulous patients with overdentures prostheses.
76059695|NCT03596008|Dietary Supplement|Placebo drink|Placebo drink
76059696|NCT03595930|Drug|Arnuity|ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
76059697|NCT03595852|Drug|Cefazolin|Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
76059698|NCT03595852|Drug|Placebos|IV normal saline will be given to patients 30-60 minutes prior to incision
76059699|NCT03591016|Other|Recording number of IV attempts|Recording number of IV attempts in the operating room
76059700|NCT03595696|Other|Core Muscle Strength Training|Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
76059701|NCT04197466|Other|Pelvic Floor Exercise Group|The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..
76059702|NCT04197466|Other|Kinesio tape|Kinesio tape application will be performed by ligament technique to the sacral region.
75741260|NCT01096927|Drug|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
75597046|NCT04304365|Other|Text message|Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.
75597047|NCT04304365|Other|Low Sensitivity Pregnancy Test (LSPT)|Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
75741261|NCT01092403|Drug|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
75889124|NCT04077099|Drug|REGN5093|Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
75889125|NCT02180282|Device|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
75889126|NCT02177474|Behavioral|Telephone based peer support|
75889127|NCT02180360|Other|Capoeira training group|"Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol."
75889128|NCT02177552|Drug|Carboplatin|
75889129|NCT02177552|Drug|Docetaxel|
75741262|NCT01092403|Drug|Placebo|Placebo once daily by inhalation
75741263|NCT00660023|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
75889130|NCT02177552|Drug|Capecitabine|
75889131|NCT02177552|Drug|Epirubicin|
75889132|NCT02177552|Drug|Oxaliplatin|
75889133|NCT03682653|Drug|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
75889134|NCT03682653|Drug|Placebo|a single dose of Placebo will be administered to infants between their 8-27th days of life
75889135|NCT04548128|Device|HeartMate 3 Left Ventricular Assist System (HM3 LVAS)|This clinical trial investigates implant of the HM3 LVAS by techniques other than full median sternotomy.
75889136|NCT03684993|Drug|Arabic, Gum|natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
75889137|NCT03684993|Drug|Licorice Root|natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
75889138|NCT03684993|Drug|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
75447379|NCT05191121|Behavioral|FTP Alone|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins).
75447380|NCT05191121|Behavioral|FTP+Con-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing conventional parameter FES.
75462956|NCT01870180|Device|EyeBag|fabric bag of beads which can be heated in a microwave
75462957|NCT01870180|Other|Placebo|
75741264|NCT03953521|Device|intermittent Theta burst stimulation|Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
75741265|NCT00787709|Behavioral|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
75889139|NCT03684915|Device|Rotary files|using rotary files in cleaning root canals of infected primary molars
75889140|NCT02177630|Other|Endomyocardial Biopsy|
75889141|NCT04059315|Other|surgical treatment of facial bone fracture|oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
75889142|NCT04062279|Diagnostic Test|serum alpha synuclein autoantibodies, motor and non motor scales|measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
75741266|NCT02554955|Drug|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
75889143|NCT03623685|Diagnostic Test|measurement of uterocervical angle|We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
75889144|NCT02756078|Device|TEST Contact Lens|
76059703|NCT04197466|Other|Electrical stimulation|External electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
76059704|NCT04197388|Device|Inspiratory muscle training device|Inspiratory muscle training, 6 cycles of 30 breaths for 12 weeks.
75462958|NCT01870206|Biological|Trivalent OPV Birmex|Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
75462959|NCT01870206|Biological|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
75462960|NCT01870219|Drug|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
75462961|NCT01870219|Drug|Ketamine|ketamine was given to 1mg/kg ıv bolus
75462962|NCT01869582|Device|Fetoscope, Fetal heart rate|
75462963|NCT01869582|Device|Upright Resuscitator, Resuscitation|
75462964|NCT01869582|Device|Doppler, Fetal heart rate|
75741267|NCT02554955|Drug|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
75741268|NCT02554955|Drug|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
75741269|NCT00062647|Drug|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
75741270|NCT00062647|Drug|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
75741271|NCT00570323|Drug|Arimidex|Aromatase inhibitors
75741272|NCT00570323|Drug|Faslodex|Hormone Receptor
75741273|NCT00791531|Drug|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
75889145|NCT02756078|Device|CONTROL Contact Lens|
75889146|NCT02030132|Behavioral|Feedback compared to 75th percentile|
75889147|NCT02030132|Behavioral|Forgiveness|
76059705|NCT03590860|Drug|LY3322207|Administered by SC injection
76059706|NCT03590860|Drug|Placebo|Administered by SC injection
75447381|NCT05191121|Behavioral|FTP+WPHF-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing wide pulse, high frequency parameter FES.
75741274|NCT00788099|Drug|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
75889148|NCT02030132|Behavioral|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
75889149|NCT02030132|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
75889150|NCT02183246|Drug|Porfiromycin|
75447382|NCT05189444|Drug|Vonoprazan|20mg bid
75447383|NCT05189444|Drug|Amoxicillin|0.75g tid
75597048|NCT04308772|Behavioral|Web-based Physiotherapy|Participants will receive an exercise programme, based on those patients usually get in the form of an exercise leaflet, delivered via a web-based physio website (www.giraffehealth.com). Participants will be asked to complete their exercise programme as prescribed (at least once each day) and to fill out an online exercise diary which the physiotherapist can see remotely from the clinical site.
75889151|NCT02183246|Drug|Placebo|
75889152|NCT02183246|Radiation|Radiotherapy|
75889153|NCT02183324|Drug|Low dose of BI 1356 BS|
76059707|NCT04197154|Behavioral|Threat manipulation (control, no threat)|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
76059708|NCT04197154|Behavioral|Threat manipulation|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.
76059709|NCT04197154|Behavioral|Conditioning of moderate pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to 'baseline' pain of lower intensity."
75741275|NCT00788099|Drug|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
75447384|NCT05189444|Drug|Esomeprazole|20mg bid
75741276|NCT00795587|Drug|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
75741277|NCT00788177|Drug|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
75741278|NCT00661505|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
75597049|NCT02879422|Genetic|genetic analysis|
75597050|NCT02879656|Procedure|non-operative treatment|conservative treatment with 5 weeks cast immobilization
75597051|NCT02879656|Procedure|operative treatment|surgery with volar locking plate with modified Henry's volar approach
75597052|NCT02881138|Drug|RC48-ADC|
75741279|NCT04047095|Dietary Supplement|Immunonutrients + normal daily meal|"Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g)."
75741280|NCT04047095|Dietary Supplement|Normal daily meal|Normal daily meal (75-80 g protein)
75889154|NCT02183324|Drug|Medium dose of BI 1356 BS|
75889155|NCT02183324|Drug|High dose of BI 1356 BS|
75889156|NCT02183324|Drug|Placebo|
75889157|NCT02183402|Drug|Digoxin|
75889158|NCT02183402|Drug|BI 1356|
75889159|NCT02183480|Drug|Linagliptin, low dose|
75889160|NCT02183480|Drug|Linagliptin, medium dose|
75889161|NCT02183480|Drug|Linagliptin, high dose|
75889162|NCT05141864|Biological|Acmella oleracea gel|Study group will use Acmella oleracea gel during the digital rectal examination.
75889163|NCT05141864|Drug|Lidocaine 2 % Topical Cream|Control group will use lidocaine 2% gel during the digital rectal examination.
75889164|NCT05141864|Other|Ultrasound gel|Control group will use ultrasound gel during the digital rectal examination.
75889165|NCT02177864|Dietary Supplement|Fiber|
75447385|NCT05189444|Drug|Amoxicillin|1.0g bid
75447386|NCT05189444|Drug|Clarithromycin|0.5g bid
75447387|NCT05189444|Drug|Bismuth potassium citrate|0.22g bid
75447388|NCT05186662|Other|patient education|patients in experimental group were asked to join a WeChat group, which was governed by experienced gastroenterologists. Relevant knowledge of H. pylori eradication was released in the group chat irregularly. Patients in WeChat group were allowed to ask questions at any time during the whole treatment process, soon afterwards, suggestions were given.
75447389|NCT05186662|Other|patient education|Patients in the control group received verbal education and a specifically designed printout with detailed instructions.
75447390|NCT05185011|Drug|TPN171H|10 mg TPN171H tablets，single dose
75447391|NCT05175274|Drug|Colchicine|Colchicine 0.5mg/tablet
75447392|NCT05175274|Drug|Placebo|matching placebo
75447393|NCT05165199|Drug|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
75447394|NCT05163015|Other|Data collection|Description: quality of life assessment
75889166|NCT02177864|Other|Placebo (low fiber bar)|
75889167|NCT02180516|Drug|Meloxicam|
75889168|NCT02180516|Drug|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
75889169|NCT03537872|Behavioral|Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies|"In addition to the control condition strategies (marked PS), the MF intervention includes additional strategies (marked MF):~STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)"
75889170|NCT03537872|Behavioral|Public Sector (PS) Health Facilities TB/HIV Integration Strategies|STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers
75889171|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
75889172|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
75889173|NCT02183636|Drug|Linagliptin tablet|5 mg
75889174|NCT02183636|Drug|pioglitazone tablet (Actos®)|45 mg
75889175|NCT05141786|Drug|MRG002|Administrated intravenously
75889176|NCT02180750|Other|Memory Work Therapy|
75889177|NCT02180750|Other|Standard care|Pediatric clinic, ART
75889178|NCT02183714|Drug|Songha Night ®|
75889179|NCT02183714|Drug|Placebo|
75889180|NCT02256410|Device|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
75889181|NCT02256410|Other|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
75889182|NCT02183948|Drug|Oxytocin|
75889183|NCT02183948|Drug|Placebo|
76059710|NCT04197154|Behavioral|Conditioning of high pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to pain of lower intensity."
76059711|NCT04197154|Behavioral|Extinction|"During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages ON and OFF) to pain stimuli of only lower intensity."
75447395|NCT05160194|Behavioral|Positive Parenting Intervention|"The highly interactive GROW Program consists of 5 core modules and 1 optional, supplemental session. Each session is expected to take 15-20 minutes to complete, and at the end of each module, parents record a 5 minute special play time video interacting with their child to demonstrate the skills they learned in the session. Each online module is followed by a meeting with a trained therapist who will discuss their special play time video and the skills they are learning. Parents make their way through the 5 core modules sequentially before accessing the supplemental session that may be relevant to them."
75889184|NCT02184026|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
75889185|NCT03537716|Device|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
75889186|NCT05141630|Procedure|sentinel lymph node biopsy or targeted axillary dissection alone|sentinel lymph node biopsy or targeted axillary dissection alone
75889187|NCT05141084|Other|Education, lifestyle|The weight loss program itself is the intervention, which will involve lifestyle modifications and intervention.
75889188|NCT02178020|Device|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
75889189|NCT02178020|Device|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
75889190|NCT04530032|Other|ketogenic/modified Atkins diet|ketogenic/modified Atkins diet use
75889191|NCT04530032|Other|Standard diet|standard (normal) diet use
75889192|NCT02184104|Dietary Supplement|Caffeine|
76059712|NCT04191382|Drug|Amcenestrant (SAR439859)|Pharmaceutical form: Capsules, Route of administration: Oral
76059713|NCT04191382|Drug|Letrozole|Pharmaceutical form: Tablets, Route of administration: Oral
76059714|NCT01703091|Drug|Ramucirumab|Administered IV
76059715|NCT01703091|Drug|Placebo|Administered IV
76059716|NCT01703091|Drug|Docetaxel|Administered IV
75889193|NCT02184182|Procedure|VLS ablation/portal ligation/hepatectomy|"Step1:~exploratory laparoscopy to exclude extrahepatic disease~right portal vein ligation if surgically feasible~RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight > 0.5~- laparoscopic/laparotomic right trisectionectomy"
75889194|NCT02184260|Drug|Metamizole|
75597053|NCT04308460|Procedure|arthrocentesis|lavage of the temporomandibular joint was done
75597054|NCT04308460|Procedure|operative arthroscopy|operative intervention inside the temporomandibular joint was done using arthroscope
75597055|NCT02879734|Other|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
75889195|NCT02184260|Drug|Placebo|
75889196|NCT02178176|Behavioral|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
75597056|NCT02879344|Other|Blood draw|
75597057|NCT02879266|Biological|TetraVax-DV TV005|Contains 10^3 plaque-forming units (PFUs) of rDEN1Δ30, 10^4 PFUs of rDEN2/4Δ30(ME), 10^3 PFUs of rDEN3Δ30/31-7164, and 10^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm
75597058|NCT02879266|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
75597059|NCT04308850|Drug|Vitamin D drops|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
75889197|NCT02178176|Behavioral|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
75597060|NCT04308538|Procedure|Standard Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using standard tables
75597061|NCT04308538|Procedure|Reduced Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using reduced numbers
75597062|NCT02880904|Other|Photography|Photos will be taken of the vulvar lichen sclerosus lesions.
75889198|NCT05140928|Other|Dadiah Pudding|Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy
75889199|NCT05140928|Other|Pudding without Dadiah|Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy
75889200|NCT02180984|Device|TMS|Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
75447396|NCT05157555|Other|Data collection|Description: quality of life assessment
75447397|NCT05153278|Biological|Packed red blood cells|Standard treatment for iron deficiency anemia (control)
75447398|NCT05153278|Drug|Intravenous drug|Experimental treatment for iron deficiency treatment
75447399|NCT05150548|Other|No Intervention|Not applicable, non-interventional study
75447400|NCT05133427|Device|TOOsonix system ONE-M|All selected BCC areas will be treated by high intensity focused ultrasound
75447401|NCT05129137|Drug|nefopam hydrochloride 30mg X2|nefopam hydrochloride 30mg X2
75447402|NCT05129137|Drug|paracetamol 500 mg X2|paracetamol 500 mg X2
75447403|NCT05129137|Drug|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
75462965|NCT01869582|Device|Standard Resuscitator, Resuscitation|
75462966|NCT01870232|Procedure|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
75462967|NCT01870245|Drug|ACHN-975|Intravenous multiple dose
75597063|NCT02880670|Drug|BMS-986142|
75597064|NCT01101334|Drug|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
75597065|NCT01101334|Drug|erlotinib|Erlotinib; One 150mg tablet administered once daily
75889201|NCT02181062|Behavioral|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
75889202|NCT03684837|Dietary Supplement|Vitamine D supplementation|a vitamine D dose for week
75741281|NCT00788333|Drug|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
76059717|NCT03023644|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
75741282|NCT00788333|Drug|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
75447404|NCT05126251|Drug|Tangningtongluo tablet|Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome. The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes. (0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
75447405|NCT05126251|Behavioral|lifestyle intervention|Avoid overeating, avoid large intake of high-calorie, high-fat foods, live a regular life, avoid sitting for a long time, strengthen exercise and reduce weight.
75462968|NCT01870245|Drug|placebo|Intravenous multiple dose
75597066|NCT02880748|Other|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
75597067|NCT02880748|Other|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
75597068|NCT01327547|Drug|Maraviroc|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
75597069|NCT01327547|Drug|Placebo|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
75597070|NCT04387643|Dietary Supplement|Ayurvedic Kadha|Kadha (also called Kwath and Kashaya) is a type of ayurvedic formulation prepared by boiling herbs in water. Water and herbs are main ingredients of these preparations. The preparation of Kadha uses dry herbs, which are dried under the sun or in the shade, as directed for the individual herb. Then, the herbs are pounded to form a coarse powder
75741283|NCT00922103|Procedure|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
75741284|NCT00922103|Procedure|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
75741285|NCT00795899|Drug|Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab|"Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d"
75741286|NCT00795977|Biological|dendritic cells, OK-432|Single Group Assignment
75889203|NCT03684837|Other|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
75889204|NCT03902691|Drug|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
75741287|NCT00796055|Drug|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
75741288|NCT00796133|Drug|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
76059718|NCT01712685|Drug|18F-VM4-037|Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
76059719|NCT01712685|Procedure|PET/CT|
75597071|NCT04386785|Device|Radiofrequency (RF) Thermal Ablation of Incompetent Perforator Veins|The physician operator will access the IPV and advance the device to the target treatment position using ultrasound guidance. After providing local anesthesia to the vein and surrounding tissues, thermal ablation energy is delivered to the vein wall. After treatment is complete, the device is removed and vessel closure confirmed with duplex ultrasound.
76059720|NCT04195516|Other|web based training,individual counseling, using reminders|"Health Promotion Model based Health Promotion Program will be applied to the experimental group. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.~Within the context of the Web Based Health Promotion Program, 8 weeks of training to improve healthy eating and physical activity behaviors, individual counseling will be given.~Colorful picture reminders will be sent to the experimental group through Whatsapp groups.~At the end of the intervention, cognitive and physical measurements of the students will be done at 1st, 3rd and 6th months."
76059721|NCT03590782|Other|Erector Spinae Block|An ultrasound guided erector spinae block will be performed.
75597072|NCT01308567|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
75597073|NCT01308567|Drug|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
75597074|NCT01308567|Drug|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
75741289|NCT00796211|Drug|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
75741290|NCT00796211|Drug|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
75741291|NCT00796211|Drug|Nortriptyline|0.1% nortriptyline HCl topical cream
75741292|NCT00796211|Drug|Calcipotriol|0.005% calcipotriol topical cream
75741293|NCT00796211|Other|Placebo|Vehicle of CRx-197 topical cream (placebo)
76059722|NCT05103267|Device|Tauropace|TauroPace™ contains disinfecting substances to eradicate environmental microbial contamination on the surface of cardiac implantable electronic devices (CIEDs). The surface of the CIED is moistened with TauroPace™ during the implantation procedure to create a hostile environment on the surface of the CIED.
76059723|NCT03023800|Procedure|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
76059724|NCT03023800|Procedure|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
76059725|NCT03590548|Diagnostic Test|gausher disease|lab investigation and radio logical
75447406|NCT05121740|Drug|Plitidepsin 1.5 mg / day|Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
75447407|NCT05121740|Drug|Plitidepsin 2.0 mg / day|Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
75447408|NCT05121740|Drug|Plitidepsin 2.5 mg / day|Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
75447409|NCT05114473|Other|Workshops|Several face-to-face workshops given by a researcher
75447410|NCT05114473|Other|Online-accessed material|Access to a website containing the educational program
75462969|NCT01870258|Other|ANN prediction of myocardial infarction|
75597075|NCT00592163|Drug|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (>8 hours between doses) for 3 weeks followed by 1 week of rest
75597076|NCT00592241|Device|"Adi Insulin Pump Usability"|no intervention
75597077|NCT04375007|Other|Routine care|Physiotherapy intervention in routine care
75597078|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
75597079|NCT02890719|Drug|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
75597080|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
76059726|NCT04196998|Drug|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
76059727|NCT04196998|Drug|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
75597081|NCT02890719|Drug|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
75597082|NCT02890719|Drug|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
75741294|NCT00792233|Other|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
75741295|NCT00788567|Drug|mycophenolate mofetil|1
75741296|NCT00792311|Procedure|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
76059728|NCT04196998|Drug|Tenofovir alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
76059729|NCT04197232|Other|clinical evaluation|- In children: general clinical evaluation, birth weight, APGAR, ECG, admission to ICU, hospital admissions in perinatal age, presence of malformations; complete blood count, inflammatory index, complement, antibiotic treatment, brain ultra-sound, presence of infection, presence of sepsis, presence of necrotizing enterocolitis, growth curve, presence of recurrent infections, developmental milestones, response to vaccines, admission to hospital in the first year of life.
76059730|NCT04196452|Drug|Ipilimumab|Specified dose on specified days
75447411|NCT05110898|Drug|fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg|Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.
75447412|NCT05110898|Drug|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
75447413|NCT05101590|Device|Monitored by HDA|Participants undergoing elective major surgery with an arterial line as part of their standard care and additional monitoring with HDA as part of their care.
75447414|NCT05098730|Behavioral|Strategy Training|Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.
75447415|NCT05096780|Other|Flavored caffeinated beverage|16.9 oz (500 cc), carbonated, zero calorie
75447416|NCT05096325|Device|YpsoPump® insulin pump system|The subjects will receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data. Data will then be analysed in silico comparing the new occlusion detection algorithm with the common occlusion detection algorithm.
75462970|NCT01870271|Behavioral|Developmentally adapted cognitive processing therapy|
75462971|NCT01870284|Drug|Ixekizumab|Administered SC
75597083|NCT05644275|Other|Data collection (demographic, clinical, functional and biomechanical outcomes in patients after ACL injury (conservative therapy and/or surgery) in patients of different ages and healthy controls)|Analysis of existing data from previous research projects MechSens (EKNZ 2019-01315) and RetroBRACE I and II (EKNZ 2019-00491 and EKNZ 2020-00551) as descriptive statistics (mean, standard deviation, range) for all parameters (for female or male patients with ACL injury and healthy subjects).
75741297|NCT00788645|Behavioral|COPD self care advice|Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
75889205|NCT03902691|Drug|ESPO|Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
75889206|NCT03808155|Drug|Tamsulosin|The drug ist taken once a day per os five days prior to the operation and two days after the operation.
75889207|NCT03808155|Drug|Placebo Oral Tablet|The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
75889208|NCT03677583|Other|Duckweed|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
75597084|NCT04373681|Other|patient-administered questionnaires|patient-administered questionnaires
75889209|NCT03677583|Other|Spinach|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
75889210|NCT02752958|Drug|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
75447417|NCT05096065|Drug|Leuprolide Oral Tablet - 120 mg - QD- Treatment A|"If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level <20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions."
75889211|NCT02185664|Procedure|landmark technique|The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
75889212|NCT02185664|Device|Static Ultrasound technique|Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
75889213|NCT02185742|Behavioral|Strength Based Case Management|
75741298|NCT00788645|Behavioral|Poor weather forecast warning|Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
75447418|NCT05096065|Drug|Leuprolide Oral Tablet - 80 mg - QD - Treatment B|"If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level <20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
75597085|NCT04324983|Other|Blood sample|"Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination."
75741299|NCT00792389|Other|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
75889214|NCT02181218|Drug|Romidepsin|
75889215|NCT02181218|Drug|Gemcitabine|
75889216|NCT02181218|Drug|Oxaliplatin|
75889217|NCT02181218|Drug|Dexamethasone|
75447419|NCT05096065|Drug|Leuprolide Oral Tablet - 60 mg - QD - Treatment C|For up to 29 consecutive days with food-intake restrictions
75741300|NCT00792389|Other|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
75741301|NCT00788723|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
75889218|NCT02181218|Drug|Pegfilgrastim|
75889219|NCT02184650|Other|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
75889220|NCT03536234|Drug|Triptorelin acetate depot|3.75 mg triptorelin depot (monthly injections). 3 doses in total
75889221|NCT03682497|Drug|AZD9977|AZD9977 capsules taken orally for 28 days.
75889222|NCT03682497|Drug|Spironolactone|Spironolactone tablets taken orally for 28 days.
75889223|NCT02950922|Drug|RVT-501 0.2% ointment|
75889224|NCT02950922|Drug|RVT-501 0.5% ointment|
75889225|NCT02950922|Other|Vehicle ointment|Placebo comparator
75889226|NCT04059627|Device|Heart Track|"Description of the device: Wearable heart rate sensors are used in Heart-track, and a receiver on a smartphone app. Real-time wireless heart rate data is sent to paired mobile device with a wireless distance of up to 10m. The sensor is able to monitor a heart rate range of 30 to 240 beats per minute.~Another component of Heart-track is a Heart-track mobile app which captures and reflect real-time heart rate from the heart rate sensor. The mobile app also includes warm-up and cool down exercises that are gamified and supported on a smart-phone running on Android or iOS platforms.~The HR sensor will be purchased by our collaborator, Immersive Play Pte Ltd."
75889227|NCT02184728|Device|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
75889228|NCT03469791|Procedure|Surgical treatment of Degenerative Spondylolisthesis|
75889229|NCT02184806|Procedure|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
75889230|NCT02184806|Procedure|heterotopic graft|"put under the skin~the ovarian fragments can be put under the skin of the abdomen"
75889231|NCT02185898|Other|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
75741302|NCT00788801|Drug|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
75447420|NCT05096065|Drug|Leuprolide Oral Tablet - 60 mg - BID - Treatment D|"If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level <20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
75889232|NCT02185898|Other|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
75889233|NCT02185898|Other|Electronic cigarette #1|Electronic cigarette
75889234|NCT02185898|Other|Electronic cigarette #2|Electronic cigarette
75889235|NCT02185898|Other|Electronic cigarette #3|Electronic cigarette
75889236|NCT02185898|Other|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
75889237|NCT02185976|Other|cartoon|5 different cartoons which will be recorded on a tablet PC.
75889238|NCT02186054|Device|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
75889239|NCT02030444|Procedure|PET-MRI and EBUS-TBNA|
76059731|NCT03590392|Biological|ChAdOx1 Chik|ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
75447421|NCT05096065|Drug|Leuprolide Oral Tablet - 40 mg - BID - Treatment E|For up to 29 consecutive days with food-intake restrictions
75447422|NCT05094544|Radiation|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
75447423|NCT05092789|Other|Kinesio taping group|"Participants in this group will receive treatment through standardised therapeutic kinesio taping along with conventional therapy.~Tape will place over the posterior cervical extensor muscle, from insertion to the origin, with the patient's neck in cervical contralateral side-bending and rotation.~Duration of kinesio tape will be of 48 hours with 50-100% tension.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions."
75462972|NCT01870284|Drug|Placebo|Administered SC
75462973|NCT01870284|Drug|Adalimumab|Administered SC
76059732|NCT01867671|Biological|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
76059733|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
76059734|NCT01867671|Biological|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
76059735|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
75462974|NCT01870310|Procedure|Catheterised renal denervation|
75462975|NCT01870323|Behavioral|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
75741303|NCT00662909|Drug|Mirabegron|Oral
75741304|NCT00662909|Drug|Placebo|Oral
75741305|NCT00050011|Drug|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
75741306|NCT00050011|Drug|Letrozole|Participants received Letrozole 2.5 mg daily.
75741307|NCT00661427|Biological|cetuximab|Cetuximab 500 mg/m^2 IV over 2 hours every other week
75741308|NCT00661427|Biological|cetuximab|Cetuximab 750 mg/m^2 IV over 3 hours every other week
75741309|NCT00049543|Drug|gefitinib|Given PO
75741310|NCT00049543|Other|placebo|Given PO
75741311|NCT00049543|Other|laboratory biomarker analysis|Correlative studies
75889240|NCT03684681|Behavioral|Peer Navigator Intervention|A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
75889241|NCT03684681|Behavioral|Social Work Intervention|A hospital social workers uses their own previous training to help people meet their goals.
75889242|NCT03677505|Device|KoMAC videolaryngoscope|Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope
75889243|NCT03677505|Device|Macintosh Laryngoscope|Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
75889244|NCT02805660|Drug|Mocetinostat - 50 mg|Participants received mocetinostat three times weekly as an oral capsule.
75889245|NCT02805660|Drug|Mocetinostat - 70 mg|Participants received mocetinostat three times weekly as an oral capsule.
75889246|NCT02805660|Drug|Mocetinostat - 90 mg|Participants received mocetinostat three times weekly as an oral capsule.
76059736|NCT03992950|Other|Maneuvers for occluding esophagus|Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
76059737|NCT04028206|Dietary Supplement|Hydroxymethylbutyrate|Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.
75741312|NCT03955393|Other|18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
75741313|NCT00048997|Radiation|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
75741314|NCT00048997|Other|Observation|
75741315|NCT01092481|Drug|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
75447424|NCT05092789|Other|Cervical thrust manipulation group|"Participants of this group will receive treatment via cervical thrust manipulation along with conventional therapy.~For mid cervical spine thrust manipulation, the patient will be in supine lying position,with cervical spine in neutral position.~The therapist will cradle the patients head with the other hand. Gentle ipsilateral cervical side flexion and contralateral rotation will introduce until tension will perceive in target tissues at contact point. A high velocity, low amplitude thrust manipulation, will direct upward and medially in direction of subject's contralateral eye.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This intervention protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions with 1 month follow up."
75597086|NCT05644197|Other|Multidisciplinary program|"Multidisciplinary program:~APA interventions: 12 weeks Each week at home, cardio-respiratory endurance sessions for muscle strengthening and balance work from the Autohome interface (Neuradom) and one week supervised by an APA teacher.~Nutrition interventions: A group nutrition workshop at the Hôpital Privé de Provence.~Psychological intervention:~5 sessions of 1h30 in group, the first session will take place at the Private Hospital of Provence and the others by videoconference.~An individual session the week following the last group session.~-Visit with the urologist, 5 weeks after the prostatectomy."
75741316|NCT01097083|Drug|Coriolus Versicolor|
75889247|NCT02805660|Drug|Mocetinostat - Recommended Phase 2 Dose (70 mg)|Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).
75447425|NCT05092789|Other|Conventional therapy group|"Participants of this group will receive only conventional therapy which will include:~Hot pack for 10 minutes Stretching Exercises of neck muscles. For sternocleidomastoid stretching, the subject will ask to sit or stand facing forward, exhale and slowly turn your head to right, by keeping shoulder relaxed and down,inhale and return to the center, then turn to look at your left shoulder, ask to hold this position for 30 seconds and do 3 repetitions.~For Trapezius stretching, patient is seated upright, therapist then passively move right ear to right shoulder.~This study includes interventional protocol of 6 weeks. The session will be given twice a week making it a total of 12 sessions with 1 month follow up."
75447426|NCT05087836|Device|Sensor at forehead area|NIRS sensor attached at forehead area.
75447427|NCT05087836|Device|Sensor at temporal area|NIRS sensor attached at temporal area.
75741317|NCT01097161|Behavioral|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
75741318|NCT01097239|Device|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
75889248|NCT02805660|Drug|Durvalumab - 1500 mg|Participants received durvalumab as an intravenous infusion every 4 weeks.
75889249|NCT02186132|Drug|Atropine 0.6 mg|Atropine 0.6 mg intravenous
75889250|NCT02186132|Drug|Atropine 1.2 mg|Atropine 1.2 mg intravenous
75889251|NCT03682419|Procedure|VKA Patients|Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
75741319|NCT03955315|Biological|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
75741320|NCT03955315|Procedure|Sham|Needle puncture under the muscular layer in front of the intervertebral disc
75741321|NCT00035815|Drug|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
75741322|NCT00035815|Drug|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
75741323|NCT00662831|Drug|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
75741324|NCT00662831|Drug|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
75889252|NCT03682419|Procedure|Non-VKA Patients|Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
76059738|NCT04028206|Device|Low-magnitude High Frequency Vibration (LMHFV)|Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
75741325|NCT00788879|Behavioral|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
75447428|NCT05083572|Drug|Colonic lavage with polyethylene glycol|The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
75447429|NCT05083572|Dietary Supplement|Probiotic|The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
75447430|NCT05083572|Drug|Antibiotic|"The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course."
75447431|NCT05076435|Drug|Isotonic crystalloids|"Types of fluids in both intervention groups:~Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy."
75447432|NCT05075772|Drug|BI 765080|BI 765080
75597087|NCT02893007|Other|Brief family-centered care (BFCC) program|The therapist provided the 4-session BFCC program twice a week for each dyad. The core principles treated family as a single unit and provided individually tailored interventions to improve family function through psychoeducation, social and emotional support, and actively raising questions to facilitate constructive awareness and changes. It was initially held to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
75597088|NCT04325061|Drug|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization
75741326|NCT00788879|Behavioral|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
75741327|NCT00796601|Drug|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
75741328|NCT00796601|Drug|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
75447433|NCT05074615|Other|Cranio-Cervical Flexion Training|"Participants of this group will receive conventional training along with Cranio-cervical flexion training:~The pressure cuff is placed behind the neck just next to the occiput and inflated up to a baseline pressure of 20 mmHg. The patient is asked to perform Cranio-Cervical Flexion (CCF) to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the patient is instructed to maintain the contraction for 10 sec for 10 repetitions with brief rest periods between each contraction i.e., 3-5 seconds. Once a set of 10 repetitions of 10 sec is achieved at one target level, the exercise is progressed to train at the next target level up to the final target level at 30 mmHg.~Conventional therapy will be given along with home plan. Exercise protocol will consist of 30 minutes. Exercise will have total 3 sessions/week for 3 weeks."
75447434|NCT05074615|Other|Conventional Therapy|"Participants of this group will receive only conventional therapy and home plan will be given which includes;~Hot pack placed on the posterior neck for 15 minutes.~Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks"
75447435|NCT05070312|Biological|MEDI3506|MEDI3506
75447436|NCT05070312|Drug|Placebo|Placebo
75597089|NCT02893085|Biological|bile sample analysis|tumor mutation profile tumor genotype
75597090|NCT02893085|Biological|biochemical markers, VEGF and MMPs, in bile samples|
75597091|NCT01307319|Drug|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
75889253|NCT02030522|Behavioral|Accelerated Resolution Therapy (ART)|"The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on."
75889254|NCT02181764|Drug|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
75889255|NCT03536156|Other|Four intra-oral optical impression taken successively|"Four intra-oral optical impression images will be taken successively on a patient:~Optical impressions are designed to record adjacent implant site teeth and peri-implant soft tissue PEI using an Optical Camera. The optical camera works like a camera and does not come into contact with the patient's mucous membranes or teeth. The images obtained are saved in STL format on an anonymized file.~The 4 aligned surfaces thus obtained will be cut using a 3D image processing software. A fixed cylinder will extract the PEI from the 4 surfaces. The volume of these 4 PEIs at T0 min, T30 sec, T2 min and T5 min will be calculated using a software"
75741329|NCT00796679|Drug|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH <500pg/mL or 2 microgram once daily if iPTH >=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
75447437|NCT05058794|Other|Blood flow Restriction/Resistance Training|During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and limb occlusion pressure (LOP) was calculated in the body position that the Blood flow Restriction (BFR) stimulus would be applied. Blood Flow Restriction BFR pressure was set at 50% occlusion. Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.
75447438|NCT05058794|Other|Conventional Therapy Group|Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.participants will perform 2 sets with 15 repetitions in (0 to 90 degree.)
75447439|NCT05058547|Device|SWEPPE|In the smartphone application SWEPPE the individual can create an action plan, perform daily registrations of health aspects, self-monitoring of health aspects and goals, have access to a library with evidence-based facts and a coach, and possibility to share information with the employer.
75447440|NCT05034068|Drug|0.15% bezaydamine hydrochloride.|0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.
75447441|NCT05034068|Device|low power laser with a wavelength of 870 nm|the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2
75447442|NCT05031195|Other|1st tertile, 2nd tertile, 3rd tertile|Patients will be divided into 3 groups according to the preoperative NLR value.
75447443|NCT05030870|Device|Capnography monitoring|Standard monitoring and capnographic monitoring.
75447444|NCT05030870|Device|Standard monitoring|Standard monitoring but no capnographic monitoring
75447445|NCT05030025|Combination Product|abacavir, dolutegravir and lamivudine dispersible tablets|Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
75447446|NCT05030025|Combination Product|Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine|Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
75597092|NCT01307319|Drug|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
75597093|NCT04367519|Diagnostic Test|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography was performed with the patients placed in supine position with closed eyes. A layer of ultrasound gel was applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine was placed on the temporal area of the eyelid with the hand holding it resting on the forehead of the patient. The probe is then adjusted to a suitable angle in order to display the entry of the optic nerve into the globe. ONSD is then measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. it was performed for all enrolled parturients within 24 hour before delivery and at 24 hour post-delivery.
75597094|NCT05644119|Device|V- loop Bonded Orthodontic Retainer|The V- loop bonded retainer is a unique design that not just provides tooth stability but also allows flossing with ease.
75741330|NCT02554643|Other|Diet|Nutrition intervention, once a week during 12 weeks
75741331|NCT02554643|Other|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
75741332|NCT02554643|Other|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
75741333|NCT02555423|Drug|Local anaesthetic - chirocaine|
75889256|NCT02184884|Device|MACE after OPCAB|
75889257|NCT02184884|Device|without MACE after OPCAB|
75889258|NCT03536780|Drug|Avelumab and Gemcitabine|"Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"
75889259|NCT02052336|Drug|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
75889260|NCT02052336|Drug|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
76059739|NCT04028206|Behavioral|Elastic-band Exercise|"Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching."
76059740|NCT04601649|Behavioral|PrEP Talk|The study is designed to provide education, support, and referrals for PrEP.
76059741|NCT03590236|Other|Graded exposure therapy|Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
75447447|NCT05019924|Dietary Supplement|Semaine|The dietary supplement is designed, and marketed commercially to be taken in servings of two capsules per day, up to four times per day (a total of 8 capsules daily). Most consumers, however, will only take a serving three times per day, or one with each major meal (breakfast, lunch and dinner).
76059742|NCT03590236|Other|Physiotherapy|Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
76059743|NCT01702311|Drug|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
76059744|NCT04196608|Drug|Ceftolozane/tazobactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
75741334|NCT00792779|Drug|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
75741335|NCT00662363|Drug|Lubiprostone|24 µg po BID given with meals for 6 days
75741336|NCT00662363|Drug|Senna|2 tabs daily for 6 days
75741337|NCT02555033|Other|Resistance training|traditional resistance training
75741338|NCT02555033|Other|Instability resistance training|training under unstable conditions
76059745|NCT04196608|Drug|imipenem- relebactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
75741339|NCT00796835|Drug|ER OROS Paliperidone|
75741340|NCT04887155|Behavioral|Cognitive behavioral therapy (CBT)|Group-based transdiagnostic cognitive-behavioral treatment
75741341|NCT00792857|Drug|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
75741342|NCT00792857|Drug|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
75741343|NCT00796913|Other|Stop medication|Stop medication Stop medication + se supplement
75741344|NCT02554175|Drug|Propofol|Propofol was administered to achieve target propofol Ce
75741345|NCT00789269|Drug|rhubarb|14 days of rhubarb
75741346|NCT00789269|Drug|placebo|14 days of placebo
76059746|NCT04022200|Device|Paclitaxel DCB|The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
76059747|NCT04196296|Behavioral|Psychoeducation|Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
76059748|NCT04196296|Behavioral|Motivation|Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
75447448|NCT05018026|Behavioral|Nutri-Grade labels|All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
75597095|NCT05644119|Device|Straight Wire Retainer|The straight wire retainer is a fixed bonded orthodontic retainer. This involves attaching a metal wire to the back of the teeth to keep it in position.
75597096|NCT04365725|Drug|Remdesivir|Compassionate provision
75447449|NCT05016687|Drug|CUR-N399|CUR-N399 will be administered as oral capsules.
75597097|NCT04365335|Behavioral|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
75597098|NCT04365335|Biological|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: DHEA, cortisol and chromogranine A levels
75597099|NCT04365335|Other|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
75597100|NCT04365335|Behavioral|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
75597101|NCT02892929|Behavioral|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
75447450|NCT05016687|Drug|Placebo|Placebo capsules matching CUR-N399 will administered.
75447451|NCT05014750|Other|None intervention|There is no intervention included in this study.
75447452|NCT05013567|Drug|Ibuprofen gel|Ibuprofen gel 5% topically four times a day
75447453|NCT05013567|Other|Placebo|Placebo gel topically four times a day
75447454|NCT05010408|Other|Flavored carbonated soft drink (CSD) at different sweetness levels|Beverage
75447457|NCT05006014|Procedure|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the single rooted teeth to be extracted as a reference and as aid for apical engagement
75447458|NCT04998708|Other|Relaxation technique|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM)32. We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
75462976|NCT01870323|Behavioral|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
75889261|NCT02052336|Drug|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
75889262|NCT02181920|Drug|Metamizole|
75889263|NCT02181920|Drug|Diclofenac|
75889264|NCT02181920|Drug|Diclofenac placebo|
75889265|NCT02181920|Drug|Metamizole placebo|
76059749|NCT04552743|Drug|MGTA-145|A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.
75741347|NCT00793013|Device|Volume-Cycled Assist-Control (AC) mode|"Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 < 40%~Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min~Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg & setting positive end-expiratory pressure (PEEP) based on level of initial FiO2~Inspiratory to Expiratory ratio set at 1:1 to 1:3~If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased~Mgmt of PEEP will be conducted as per the ARDSnet Protocol~Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%~Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol"
75597102|NCT02892929|Behavioral|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
75741348|NCT00793013|Device|Airway Pressure Release Ventilation (APRV) mode|"Ventilation uses Drager Model X1~Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels~Time periods for the high & low pressure levels can be set independently~Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume~Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min~Spontaneous frequency will be targeted for 6 to 18 breaths/per min~If spontaneous breathing is achieved,level of sedation will be decreased~If spontaneous respirations are >20 breaths/min, sedation will be increased~If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased"
75462977|NCT01870336|Device|Combined treatment of medial knee osteoarthritis|
75889266|NCT02185118|Drug|oxygen|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
75597103|NCT04328051|Other|Dental Implant Placement|Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.
75889267|NCT02185118|Drug|Sevoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
75889268|NCT02185118|Drug|Isoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
75597104|NCT01080391|Drug|Dexamethasone|40 mg orally or IV on days 1, 8, 15, 22
75597105|NCT01080391|Drug|Lenalidomide|25 mg orally on days 1-21
75889269|NCT02186288|Other|High-flow nasal cannula oxygen|
75889270|NCT02807376|Device|Surgeon's 'standard of care' stapler|
75889271|NCT02807376|Device|Ethicon Powered Vascular Stapler|
75462978|NCT01870349|Procedure|Gingival Crevicular Fluid Sampling|Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
75462979|NCT01870362|Drug|Probiotic (Inersan)|
75462980|NCT01870362|Drug|Placebo|
75462981|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm
75462982|NCT01870427|Drug|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
75889272|NCT02256566|Behavioral|emotional memory training exercise|
75597106|NCT01080391|Drug|Carfilzomib|20 mg/m², 27 mg/m² intravenously
75597107|NCT04359407|Other|Prone positioning|Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone
75597108|NCT00592397|Other|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
75889273|NCT02256566|Behavioral|memory training exercise|
75889274|NCT02186366|Other|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
75447459|NCT04990505|Diagnostic Test|lung ventilation/perfusion scintigraphy|"Chest CT-scan will be performed with blocked inspiration.~Lung ventilation/perfusion scintigraphy imaging will be performed within 24hrs after CT pulmonary angiography, 410MBq of Technegas will be inhaled by patients and ventilation tomography performed thereafter. Then, 185MBq 99mTc-macroaggegates will be injected intravenously followed by the perfusion tomography.~A combined CT acquisition will be performed.~The day following lung ventilation/perfusion scintigraphy, 740MBq of Tc99m labeled albumin will be intravenously administered.~Cardiac gated-blood-pool scintigraphy will be then performed in best septal left anterior oblique and left profile according to specific parameters.~45-60 min after injection, a non-gated tomographic acquisition over the lungs will be done, with the same parameters than for PS SPECT, resulting in a late albumin acquisition."
75447460|NCT04989621|Drug|Orelabrutinib and Rituximab|Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.
75597109|NCT04356365|Other|Cross-sectional study investigating the association of NPIs with mental health|Cross-sectional study investigating the association of NPIs with mental health
75597110|NCT04327817|Device|Multifidus stimulator|"Patient eligible for the study and have provided consent will have a baseline PET scan. Multifidus ReActiv8 Stimulator will be inserted using standard treatment for lumbar pain at Barts Health NHS Hospitals.~All patients who receive the Reactiv8 system will continue to receive multifidus stimulation 20Hz for the next 6 months as per standard of care of multifidus stimulation; at the end of this period, the patients will undergo PET scanning and questionnaires. Thereafter, stimulation will continue and 3rd PET scan will be performed at 1year post implant."
75597111|NCT04747483|Other|Extension Oriented Treatment Approach|"The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
75597112|NCT04747483|Other|EOTA+ Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
75597113|NCT04351451|Procedure|thyroidectomy|total thyroidectomy
75889275|NCT02186366|Drug|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
75889276|NCT02053974|Drug|Spironolactone|Spironolactone
75889277|NCT02053974|Other|Placebo|Placebo
75447461|NCT04989621|Drug|Orelabrutinib|Orelabrutinib 150mg po qd
75889278|NCT02185196|Drug|Vitamin D3|20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
75889279|NCT02185196|Drug|Placebo|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
75889280|NCT02052492|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
75889281|NCT02181998|Drug|Full dose tenecteplase|
75447462|NCT04989049|Drug|Folic Acid 5 MG|folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
75447463|NCT04989049|Other|placebo|an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
75447464|NCT04988178|Other|Data extraction from medical files|Data extraction from medical files
75447465|NCT04987021|Device|Cochlear Implant (CI)-CI500 series, CI600 series or Freedom series cochlear implants|The Remote Assist (RA) System is intended to support clinicians to conduct a remote programming session with their CI recipients.
75889282|NCT02181998|Drug|Unfractioned heparin|
75889283|NCT02181998|Drug|Enoxaparin|
75447466|NCT04984044|Dietary Supplement|Vitamin D3|"Dietary supplement:Vitamin D3~1 capsule of Vitamin D3 (40,000IU) weekly for 8 weeks with antidiabetic drug"
75889284|NCT02054052|Drug|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
75447467|NCT04984044|Dietary Supplement|Placebo|1 capsule weekly for 8 weeks with antidiabetic drug
75889285|NCT03810222|Other|N/A (Observational Study)|This is an observational study and does not include interventions. Exposure is TBI.
76059750|NCT04552743|Drug|Plerixafor|An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).
76059751|NCT03590158|Behavioral|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
75741349|NCT00789425|Dietary Supplement|Standardized Extract of Olive Polyphenols|"Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.~A supplement with 1000 mg calcium per day will be supplied together with the active treatment."
76059752|NCT03590080|Drug|Methylprednisolone|
76059753|NCT03593278|Drug|ACT-246475|Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
76059754|NCT04028362|Drug|Neuromuscular Blocking Agents|Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
76059755|NCT03023410|Procedure|VERASENSE|Sensor-Assisted Revision TKA
76059756|NCT03594058|Drug|Solabegron modified release tablets, low dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
75447468|NCT04984031|Diagnostic Test|ELISA assessment of apoptosis markers in gingival crevicular fluid|Gingival crevicular fluid (GCF) samples will be collected to assess the level of caspase-3,8,9 and apoptosis inducing factor (Aif)
75447469|NCT04983979|Drug|Sodium Zirconium Cyclosilicate|sachets of 5g or 10g given OD titrated to serum potassium
75447470|NCT04983979|Drug|Placebo|matched placebo given titrated according to potassium at a dose to 5 or 10g
75447471|NCT04976244|Procedure|Intravitreal injection|Intravitreal injection to the regimen pro re nata
75447472|NCT04976166|Behavioral|Education|More informed and detailed education
75447473|NCT04976166|Behavioral|Education|Shared decision making
75447474|NCT04976166|Behavioral|Education|education as usual
75447475|NCT04975802|Other|Placebo|10 oz (296 ml) cherry flavored still beverage
75447476|NCT04975802|Dietary Supplement|Coffeeberry|10 oz (296 ml) cherry flavored still beverage
75447477|NCT04975802|Dietary Supplement|Caffeine|10 oz (296 ml) cherry flavored still beverage
75741350|NCT00789425|Dietary Supplement|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
75741351|NCT00793091|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
75741352|NCT00793091|Drug|Placebo|4 drops applied daily for 120 days
75741353|NCT00789503|Dietary Supplement|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
75889286|NCT02186444|Other|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
76059757|NCT03594058|Drug|Solabegron modified release tablets, high dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
76059758|NCT03594058|Drug|Matching Placebo|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
76059759|NCT01712061|Drug|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
76059760|NCT01712061|Drug|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
75889287|NCT02186444|Other|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
76059761|NCT03591094|Drug|PTI-428|Active
75447478|NCT04972747|Other|skin care with sunflower oil|The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.
75447479|NCT04971811|Other|Snack with energy density less than 1.5 kcal/g|Snack meal with snack food having energy density less than 1.5 kcal/g
75447480|NCT04971811|Other|Snack with energy density greater than 1.5 kcal/g|Snack meal with snack food having energy density greater than 1.5 kcal/g
75447481|NCT04971395|Drug|XTMAB-16 2mg/kg|Biological XTMAB-16 IV infusion single dose
75447482|NCT04971395|Drug|Placebo|Placebo; IV infusion single dose
75447483|NCT04971395|Drug|XTMAB-16 4mg/kg|Biological XTMAB-16 IV infusion single dose
75447484|NCT04969562|Behavioral|Emotional Freedom Technique|Emotional Freedom Technique (EFT, Emotional Freedom Technique) is a psychophysiological interpretation that combines elements of cognitive behavioral therapy (CBT), exposure therapy, and somatic stimulation using acupuncture points.
75447485|NCT04968782|Other|Patients with acute appendicitis|No intervention, single survey
75447486|NCT04964700|Drug|Natalizumab|Monthly Infusions
75447487|NCT04961372|Other|Survey|PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment
75447488|NCT04960683|Device|Lokomat training|"Control group will receive the routine conventional physiotherapy treatment and the treatment for this group consists of the following:~Conventional therapy protocol:~5 sessions of 45 minutes a week, each session includes:~5 minutes of stretching exercise~20 minutes of strengthening exercise~10 minutes of balance exercise~10 minutes of gait training~Experimental group will receive 45 min of Lokomat in addition to the conventional approach (as explained above). Since Lokomat appointments can be only 8 per day, it is planned to have two groups of 8 participants for 4 weeks each. The Lokomat training include the following:~5 sessions of 45 minutes of conventional therapy (same as above) per week~5 sessions of 45 minutes on Lokomat per week"
75447489|NCT04956172|Device|NeuroCatch Platform 2|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
75447490|NCT04950868|Drug|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
75447491|NCT04947137|Drug|Tc99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
75597114|NCT04350983|Behavioral|Increased physical activity|PAP and enhanced individual support by physiotherapist to increase physical activity
75741354|NCT00789659|Other|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
75889288|NCT02051322|Device|Jet Nebulizer|
76059762|NCT03591094|Drug|Placebo|Placebo
76059763|NCT04195672|Device|NIPE (MDoloris®) and CBS values|"During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care"
75741355|NCT00797069|Other|standard nutritional product (medical food)|once during crossover
76059764|NCT03592186|Behavioral|Parenting Wisely+|Parenting Wisely+ experimental intervention
75597115|NCT04348721|Other|online survey|"An online survey including 8 case-vignettes was sent to international liver transplant surgeons who had published on liver transplantation. The first part is related to surgeon's own experience. In the second part, the surgeons were asked to rate the difficulty of various situations in liver transplantation on a scale of 1 to 10 (level 1 was labeled as easier, and level 10 was labeled as difficult). In the third part, 8 case-vignettes corresponding to 8 clinical real-life situations are submitted to experts"
76059765|NCT03592186|Behavioral|Treatment as Usual|Treatment as Usual
75597116|NCT04327739|Other|Intervention 1 Exercise|• Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles
76059766|NCT03598114|Behavioral|Program Sustainability Action Planning Model and Training Curricula|The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
76059767|NCT03599674|Behavioral|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
75447492|NCT04944667|Diagnostic Test|TAVR planning|TAVR planning without VR vs after VR
75597117|NCT04327739|Other|Intervention 2 Exercise and INIT|"Exercise programme same as Intervention Group 1 and~Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique"
75741356|NCT00797069|Other|nutritional product for diabetes (medical food)|once during crossover
75741357|NCT00797069|Other|diabetes specific experimental nutritional product (medical food)|once during crossover
75741358|NCT00793247|Drug|PRU-PLA-PRU-PLA|
75741359|NCT00793247|Drug|PLA-PRU-PLA-PRU|
75741360|NCT00793247|Drug|PLA-PRU-PRU-PLA|
75741361|NCT00793247|Drug|PRU-PLA-PLA-PRU|
75741362|NCT00797303|Drug|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
75741363|NCT00800579|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
75741364|NCT00800579|Drug|Placebo|Inhaled volume-matched placebo in sterile saline
75741365|NCT00661271|Behavioral|Mindfulness-based stress reduction (MBSR)|8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice, with one retreat session.
75741366|NCT00661271|Behavioral|Healthy topics|8 week health education program with one retreat session
75447493|NCT04941989|Drug|HTL0022562|HTL0022562
75447494|NCT04941989|Drug|Placebo|Placebo
75447495|NCT04939116|Drug|ANG-3070|Orally administered tyrosine kinase inhibitor capsule
75447496|NCT04939116|Drug|Placebo|Orally administered placebo capsule
75447497|NCT04938804|Device|Low-dose computed tomography|The Low-dose computed tomography is conducted according to the guideline suggested by American College of Radiology.
75741367|NCT00800657|Procedure|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
75741368|NCT00800657|Procedure|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
75741369|NCT00922181|Device|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
75447498|NCT04935593|Other|The RENEW Intervention|An game-based intervention that will provide lessons and activities in social-awareness, self-management, self-awareness, relationships and decision making in effort to strengthen social, emotional and behavioral competence. The intervention will be administered tri-weekly for 20 minutes each session.
75447499|NCT04930614|Other|Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour|Digital survey to estimate the associated risk factors for HIV infections in transgender and non-binary people in Flanders and Brussels (Belgium)
75447500|NCT04929405|Behavioral|ADAPT|ADAPT, is multi-modal to promote a targeted approach to individual parental bereavement experiences and is not time or geographically limited. ADAPT is based on the theoretical foundations of the Adaptive Leadership (AL) framework. Our interdisciplinary team developed a web-based, multi-modal intervention, labeled ADAPT, that incorporates varied self-management strategies including: A: Asking for assistance (option to connect with child's healthcare team); DA: Developing Adaptive ability (self-management tools: e.g. stress reduction, legacy building); P: Accessing Pertinent online resources (grief support networks/websites); and T: Tracking one's health (self-administered surveys for grief, sleep, anxiety, and depression). Parents can download ADAPT on any digital device (phones/computers) using a Quick Response (QR) bar code or weblink.
75741370|NCT00922181|Device|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
75741371|NCT00661193|Drug|carboplatin|given IV
75447501|NCT04928144|Drug|SHJ - Low concentration|Topical ophthalmic
75741372|NCT00661193|Drug|erlotinib hydrochloride|given orally
75447502|NCT04928144|Drug|SHJ - Mid concentration|Topical ophthalmic
75741373|NCT00661193|Drug|paclitaxel|given IV
76059768|NCT04195360|Other|Standardized mobilization procedure|5 minutes bed rest (h1), followed by 3 minutes passive leg raise (PLR), followed by 5 minutes bed rest (h2), followed by 3 minutes sitting on the egde of the bed (sit), followed by 3 minutes standing/walking on the spot (sta), followed by 5 minutes bedrest (h3)
75447503|NCT04928144|Drug|SHJ - High concentration|Topical ophthalmic
75447504|NCT04928144|Drug|SHJ - Maximum tolerated|SHJ - Maximum tolerated
75447505|NCT04927793|Drug|EDP-938|[14C]EDP-938
75447506|NCT04926701|Drug|ETD001 single dose|Single ascending doses of inhaled ETD001
75597118|NCT04327739|Other|Intervention 3 Exercise and SMT|"Exercise programme same as Intervention Group 1 and~Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant."
75597119|NCT04327739|Other|Control|Participants allocated to this group received general consulting istructions and a home based general exercise sheet
75741374|NCT04046315|Diagnostic Test|CMR|GLS measurement with CMR
76059769|NCT04195282|Other|Plasma exchange|Patients will receive treatment of plasma exchange for three times in two weeks. The volume of fresh frozen plasma used in plasma exchange is about 2000 millilitre per time.
75447507|NCT04926701|Drug|Placebo single dose|Single doses of inhaled placebo
75597120|NCT01070329|Drug|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
75741375|NCT00797537|Procedure|Echography|Echography
75447508|NCT04926701|Drug|ETD001 multiple twice daily doses|Ascending doses of inhaled ETD001 administered twice daily
75447509|NCT04926701|Drug|Placebo multiple twice daily doses|Doses of inhaled placebo administered twice daily
75597121|NCT01070329|Drug|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
75597122|NCT04327661|Drug|Tradipitant High Dose|Oral Capsule
75597123|NCT04327661|Drug|Tradipitant Low Dose|Oral Capsule
75597124|NCT04327661|Drug|Placebo|Oral Capsule
75741376|NCT00800813|Behavioral|Penile Exam, Peyronie's Plaque and Erectile function assessment|"At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level."
75741377|NCT00793481|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
75741378|NCT00800969|Procedure|FDG-PET-CT|Radiologic standard procedure
75741379|NCT00801047|Drug|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
75741380|NCT00801047|Drug|Remifentanil|40-50 mic per 1-2 min via PCA
75741381|NCT00801125|Drug|natalizumab|
76059770|NCT04195282|Other|RL-1 Novel Human-derived Bio-artificial Liver Treatment|Patients will receive RL-1 Novel Human-derived Bio-artificial Liver treatment for three times in two weeks. The volume of plasma exchanged in the system is about 4000 millilitre per time.
76059771|NCT04029766|Drug|HSK3486|
76059772|NCT04193644|Behavioral|Mindfulness and Self-Compassion focussed exercises during walking training|Mindfulness and Self-Compassion focussed exercises during walking training with moderate intensity
76059773|NCT04193644|Behavioral|Walking training|Walking training with moderate intensity
76059774|NCT04195048|Other|Risk factors|Risk factors: modifiable and unmodifiable risk factors
76059775|NCT04195126|Device|CytoSorb haemadsorption device|CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
76059776|NCT04190290|Other|Physiotherapy Adapted Program|3 days / week mobilisations and respiratory exercises and body image exercises
75597125|NCT01069861|Drug|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
75741382|NCT00801203|Drug|IRCT|Up to two administrations of the IRCT during a single cough testing session
76059777|NCT04190290|Diagnostic Test|Evaluation and Control|Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
76059778|NCT04194736|Other|Ultrasound scan|"First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan."
76059779|NCT04197544|Procedure|endoFAVI|EndoFAVI creation to patients that require vascular access for hemodialysis.
76059780|NCT04194892|Biological|Pegilodecakin|Administered SQ
76059781|NCT04028752|Biological|Blood collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in the arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
76059782|NCT04197778|Drug|DDO-3055 tablet|DDO-3055 tablet, 2 single doses separated by 6 days.
76059783|NCT04194658|Drug|Letrozole 2.5mg|Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
76059784|NCT04194502|Diagnostic Test|Transesophageal echocardiogram (TEE)|All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
75447510|NCT04926701|Drug|ETD001 multiple once daily doses|Doses of inhaled ETD001 administered once daily
75447511|NCT04926701|Drug|Placebo multiple once daily doses|Doses of inhaled placebo administered once daily
75741383|NCT00801281|Drug|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
75741384|NCT00801281|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
75741385|NCT00801281|Drug|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
76059785|NCT04194580|Behavioral|Phisical activity intervention|The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
76059786|NCT04028518|Drug|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."
76059787|NCT04028518|Drug|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."
76059788|NCT04028518|Drug|Alteplase for Injection|"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."
76059789|NCT03023956|Procedure|Locking plates were used for proximal humeral fractures.|
76059790|NCT04028440|Biological|Autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
76059791|NCT04748068|Device|7-Fr Glidesheath Slender|The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
75447512|NCT04919239|Biological|RUTI®|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
75447513|NCT04919239|Biological|Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid muscle.
75597126|NCT04344197|Other|global survey|surgery questionnaire
75741386|NCT00801281|Drug|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
75741387|NCT00801281|Drug|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
75741388|NCT00801281|Drug|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
75741389|NCT00801359|Procedure|Phacoemulsification|
75889289|NCT02051322|Device|Trunk Mask Nebulizer|
76059792|NCT04748068|Device|Cordis 7-Fr radial sheath|Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
75597127|NCT02892851|Device|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :~Parameter setting~Cross-over double-bind (ON/OFF)~Open Phase (ON)"
75447514|NCT04917367|Procedure|exploratory surgery|"For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies."
75462983|NCT01868880|Drug|Ivabradine plus beta-blocker (bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
75597128|NCT04304521|Procedure|Lung recruitment maneuver|Lung recruitment maneuver is used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. LRM induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume.
75597129|NCT04327427|Other|Aspirin|Outcome Analysis of Aspirin in liver transplantation
75597130|NCT02875405|Procedure|Posterior left pericardiotomy|Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
75597131|NCT04306549|Other|Bulk-Fill and Microhybrid Composite Resins|Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
75741390|NCT00801359|Drug|BSSPlus solution|
75741391|NCT00801359|Drug|Lactated Ringer's solution|
75889290|NCT02051322|Device|Aerobika Nebulizer|
75889291|NCT02185352|Drug|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
75889292|NCT02051400|Device|the McGrath® MAC video laryngoscope|
75889293|NCT02051400|Device|the GlidesScope® Ranger video laryngoscope|
75889294|NCT02051400|Device|the Macintosh laryngoscope|
75889295|NCT02054208|Biological|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
75889296|NCT02054208|Other|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
75741392|NCT00801437|Drug|Xalacom|Xalacom 1 drop into the affected eye daily
75741393|NCT00801515|Drug|Maraviroc|150 mg twice per day
75741394|NCT00797615|Behavioral|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
75741395|NCT00797615|Behavioral|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
75889297|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
75889298|NCT02052726|Biological|Placebo|Placebo administered at Month 0, 1, and 3.
75889299|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
75889300|NCT02052726|Biological|placebo|Placebo administered at Day 1, 8, and 30.
75889301|NCT02185430|Drug|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
75889302|NCT02185430|Drug|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
75889303|NCT03536390|Drug|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
75889304|NCT03536390|Drug|Placebo|Placebo
76059793|NCT04190914|Other|pulp regeneration for necrotic primary teeth|a pulp regeneration procedure will be applied for necrotic primary teeth with different intracanal medication compared to conventional pulpectomy used in treatment for necrotic primary teeth
76059794|NCT01711983|Device|GORE® CARDIOFORM Septal Occluder|Percutaneous Atrial Septal Defect Closure
76059795|NCT04747678|Drug|Ivermectin|retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
76059796|NCT04028128|Dietary Supplement|Cocoa group|Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
76059797|NCT04028128|Dietary Supplement|Placebo group|The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
75741396|NCT00797693|Drug|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
76059798|NCT04027660|Device|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~Administration of Articain 1:200.000~No flap procedure~Place a Zirconia Implant on the alveolar post extraction socket~Place xenograft biomaterial in the jumping gap~Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~Final Impression with a IOS~Placement of the Final Crown~3 month post crown post op~3 IOS will be made for volumetric evaluation :~before tooth extraction~3 month of Osseointegration for final impression~3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
76059799|NCT04194112|Diagnostic Test|immediate urine cytology|Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
76059800|NCT04191928|Drug|Apixaban|Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
75447515|NCT04916743|Other|Intradialytic exercise group|Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions. To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 5 Repetitions Maximum (5RM) for resistance protocols. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale). All protocols are tailor-made based on each individual's needs and physical abilities.
75447516|NCT04914377|Drug|TQ Formula/Tab|TQ Formula will be administered as an oral dose daily. The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).
75447517|NCT04912960|Device|Mechanical ventilation|Optimum PEEP
75447518|NCT04911439|Other|Low Arousal|This group will see affective images of the International Affective Picture System with low arousal level
75447519|NCT04911439|Other|Medium arousal|This group will see affective images of the International Affective Picture System with medium arousal level
75447520|NCT04911439|Other|High arousal|This group will see affective images of the International Affective Picture System with high arousal level
75447521|NCT04911257|Device|Cervical or Lumbar Spinal fusion|This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing certain Stryker Interbody Systems.
75447522|NCT04904172|Device|Masimo O3 Regional Oximetry|wo electrodes will be attached to the forehead area and connected to the Near Infrared Spectroscopy device after the consent of the patients who apply to Ege University Hospital Emergency Service with acute ischemic stroke and who are planned to have intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments, and / or their caregivers.
75447523|NCT04903821|Drug|BAY3427080|Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
75447524|NCT04902235|Drug|Experimental: CRH administration|CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
75447525|NCT04902235|Drug|Control: Placebo administration|Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
75597132|NCT04338347|Biological|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Extracellular Vesicles (EVs) from Cardiosphere-Derived Cells (CDCs)
75597133|NCT02875717|Drug|Acetylsalicylic acid|
75597134|NCT02875717|Drug|low molecular weight heparin|
75597135|NCT04337957|Other|geriatric nephrology|Collection of the geriatrician's opinion
75597136|NCT02875639|Drug|Yiqi prescription|
75889305|NCT03561480|Drug|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
75597137|NCT02875639|Drug|Huoxue prescription|
75597138|NCT02875639|Drug|Buyang huanwu decoction|
75597139|NCT02875639|Drug|QISHEN YIQI DRIPPING PILLS|
75597140|NCT02875639|Drug|Placebo 1|Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
75597141|NCT02875639|Drug|Placebo 2|Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
75741397|NCT00797771|Device|"Adi Insulin pump"|insulin delivery will be defined by the physician
75741398|NCT00797849|Device|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
75889306|NCT03561480|Drug|0.9% Normal Saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
76059801|NCT04193332|Device|NIR optical imaging camera|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery using parathyroid gland autofluorescense
76059802|NCT04193722|Drug|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a multiperson hyperbaric oxygen chamber. Standard hyperbaric oxygen therapy provided as reimbursed by insurers.
75447526|NCT04900480|Other|Direct access to publicly subsidized physiotherapy|This pilot project introduces temporary exemption on the legal required GP referral for public subsidy for treatment in general physiotherapy.
75447527|NCT04899843|Dietary Supplement|Zinc sulphate tablet 20 mg|Zinc sulphate tablet 20 mg daily orally for 8 weeks along with topical retinoids.
75447528|NCT04899843|Dietary Supplement|Placebo tablet 20 mg|Placebo tablet 20 mg daily orally for 8 weeks along with topical retinoids
75741399|NCT00797849|Device|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
75447529|NCT04897802|Drug|Experimental: GLP1-RA (exenatide) administration|a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours
75447530|NCT04897802|Drug|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide
75447531|NCT04892628|Other|Progressive resistance training|Resistance training of upper limb and lower limb muscles. Resistance will be increased on a weekly basis. Dumbbells and therabands will be used to provide resistance.
75447532|NCT04892628|Other|Aerobic training|The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.
75447533|NCT04891523|Dietary Supplement|Probiotics-O (Burgerstein)|Topical oral treatment with the probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein) in form of a lozenge, daily, during 3 weeks.
75447534|NCT04891523|Other|Placebo [inactivated Probiotics-O (Burgerstein)]|Topical oral treatment with the placebo [inactivated probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein)] in form of a lozenge, daily, during 3 weeks.
75597142|NCT04334837|Diagnostic Test|Copper Cu 64 Dotatate|The drug product contains Copper Cu 64 Dotatate filled in a glass vial, closed with butyl rubber stopper secured with an aluminum crimp seal. The drug product will be delivered by Curium to the clinical site. The EAP drug will be administered as an intravenous bolus injection. The dose will be administered according to the schedule detailed in the protocol.
75597143|NCT04741711|Procedure|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.
75741400|NCT00793559|Drug|terlipressin|1 mg of terlipressin one time only
75741401|NCT00793559|Drug|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
75741402|NCT00797927|Drug|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
75597144|NCT04741711|Procedure|Usual care without ultrasound guidance|Usual care (i.e. without ultrasound guidance)
75597145|NCT04327349|Biological|Convalescent Plasma|Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
75741403|NCT00797927|Other|no intervention|keep the original conventional antipsychotic agent for 28 days
75889307|NCT02190188|Device|Wedge Insole 5mm|
75889308|NCT02190188|Device|Knee Brace|
76059803|NCT04193800|Other|10-week rotation in primary care setting|Ten paramedics underwent a 10 week rotation into a GP practice in the Leeds area of South Yorkshire, England.
76059804|NCT02080312|Drug|Magnevist (gadopentetate dimeglumine)|
76059805|NCT04027582|Other|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
76059806|NCT04199884|Behavioral|Active IU-focused Psychoeducation Intervention|This paradigm was an IU-focused psychoeducation intervention wherein participants were provided psychoeducation about the nature of IU and anxiety, given strategies to cope with fear of uncertainty, and provided examples and information as to how they can expose themselves to uncertainty.
75597146|NCT04333121|Other|weight|we can monitoring the growth of the infants by weight gain degree
75597147|NCT04331015|Diagnostic Test|Pure tone audiometry|pure tone audiometry
75741404|NCT00798005|Drug|XRP0038 (NV1FGF)|
75741405|NCT00801593|Procedure|Steroid injection into the TMJs.|In case of otherwise noncontrollable TMJ involvement steroids are injected into arthritic TMJs under MRI guidance.
75741406|NCT02554097|Procedure|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
75741407|NCT02554097|Procedure|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
75741408|NCT02554097|Procedure|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
75447535|NCT04889807|Other|measure of EtCO2 variation|measure of EtCO2 (end tidal carbon dioxide) variation after an 15 seconds end-expiratory occlusion test
75741409|NCT02554097|Procedure|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
75889309|NCT03561870|Drug|Olaparib 150 MG|Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
75889310|NCT02054286|Biological|THV01-1|Intramuscular injection of THV01-1 (week 0)
75889311|NCT02054286|Biological|THV01-2|Intramuscular injection of THV01-2 (week 8)
75889312|NCT02054286|Biological|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
75889313|NCT02186756|Other|EMG-Biofeedback and Usual care|Please refer to arm description
75447536|NCT04882384|Procedure|Pericapsular Nerve Group Block|This will be a peripheral nerve block.
75447537|NCT04882332|Other|sampling for diabetes control parameters|Intravenous blood withdrawal for a sample of fasting blood glucose (FBG), 2 hr postprandial blood glucose (2 hr -PPG), fasting lipids {total cholesterol (TC), triglycerides (TAG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)}, glycosylated hemoglobin (Hb A1c) ,fasting insulin level and Vitamin B 12 levels
75447538|NCT04882332|Other|Sampling for vitamin B12 level|Intravenous blood sampling for a sample of vitamin B12 level
75597148|NCT00593099|Drug|Bupropion|BUP [as the intermediate-release (IR) formulation] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg [as BUP SR formulation] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
75597149|NCT00593099|Drug|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
75741410|NCT00793715|Procedure|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
75741411|NCT00793715|Procedure|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
75741412|NCT00801671|Procedure|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
75889314|NCT02184338|Drug|BIBR 1017 BS powder|
75889315|NCT02184338|Drug|Placebo|PEG 400
75889316|NCT02190344|Device|8-channel paddle coil|MRI Coil
75889317|NCT02054364|Behavioral|FBT and CRT|
75889318|NCT02054364|Behavioral|FBT and art therapy|
75889319|NCT03807648|Other|Data Inclusion|Patients in this group will be included in the project
75889320|NCT02186912|Device|Nobel Active, Nobel Procera IBO|
75597150|NCT00593177|Drug|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
75597151|NCT00593255|Drug|soluble human insulin|
75889321|NCT02186990|Drug|propofol|2,5 mg/kg
75889322|NCT02186990|Drug|etomidate|0,3 mg/kg
75889323|NCT02186990|Drug|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
75889324|NCT05657028|Drug|Dexmedetomidine|-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
75597152|NCT00593255|Drug|insulin aspart|
75597153|NCT00593255|Drug|insulin NPH|
75741413|NCT04045925|Other|Taïso|Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
75741414|NCT00801749|Behavioral|sleep|
75741415|NCT02553785|Device|Revivent TC|
75741416|NCT00798083|Drug|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
75889325|NCT05657028|Drug|Lidocaine IV|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
75889326|NCT02187068|Drug|Dexmedetomidine|Dexmedetomidine administered intravenously
75889327|NCT02054442|Drug|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
75889328|NCT02054442|Drug|Methotrexate|
75889329|NCT02185586|Procedure|laparoscopic cholecystectomy|
75889330|NCT02038296|Procedure|transarterial chemoembolization|
75889331|NCT02053038|Device|iFR|Treatment guided by instantaneous wave-free ratio
75889332|NCT02053038|Device|FFR|Treatment guided by Fractional Flow Reserve
75889333|NCT02053194|Behavioral|Pharmacist-led educational intervention|1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
75889334|NCT02190578|Device|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
75597154|NCT02892773|Device|Incentive Spirometry|"A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.~Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.~The 10-breath cycle will be repeated 3 times per therapy session.~Each I.S. therapy session will last about 15 minutes, 3 times per day.~Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery."
76059807|NCT04199884|Behavioral|Health-focused Psychoeducation Intervention|This intervention is a health-focused psychoeducation intervention wherein participants learn ways to engage in healthy behaviors, such as getting adequate sleep, eating healthier, and exercising regularly.
75741417|NCT00794027|Behavioral|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
76059808|NCT04199806|Other|Questionnaire review|Review data from questionnaires received about MMS experience.
75447539|NCT04882189|Diagnostic Test|Imaging|Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.
75889335|NCT03536078|Other|home phototherapy|
76059809|NCT04027504|Dietary Supplement|Fitabisc|Biscuits containing antioxidants
75597155|NCT02892773|Device|EzPAP® Positive Airway Pressure|"A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.~Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~The 10-breath cycle will be repeated 3 times.~Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.~Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery."
75741418|NCT00794027|Behavioral|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
75741419|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
75741420|NCT00798239|Other|Iliac crest autograft|autograft
75741421|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
75889336|NCT02804178|Drug|ATR-101|125-1000 mg twice per week
76059810|NCT04027738|Other|PRP|The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
75889337|NCT02190734|Other|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
75447540|NCT04880460|Dietary Supplement|Magnesium Glycinate tablet 200mg|Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs
75447541|NCT04880460|Dietary Supplement|Placebo tablet 200mg|Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs
75447542|NCT04876924|Drug|BBP-711|BBP-711, oral suspension
75447543|NCT04876924|Drug|Placebo|Placebo matching BBP-711
75447544|NCT04871425|Drug|Ketamine|IV ketamine
75447545|NCT04871425|Drug|Fentanyl|IV fentanyl
75597156|NCT00593723|Radiation|IMRT|
75597157|NCT00593801|Drug|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
75741422|NCT00798395|Drug|Org 50081|1.5 mg on day 1-7
75741423|NCT00798395|Drug|Org 50081|4.5 mg on Day 1-7
75741424|NCT00798395|Drug|Placebo|Once daily on Day 1-7
75741425|NCT00798395|Drug|zopiclone|Single dose of 7.5 mg
75741426|NCT00801905|Drug|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
75741427|NCT00801905|Other|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
75741428|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
75889338|NCT02190734|Other|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
76059811|NCT04199494|Other|Antibiotic Stewardship Program|The patient do the routinely preoperative lab tests, including the rectal swab (RS). The Antibiotic Stewardship Program (ASP) has been shown to effectively reduce unnecessary antibiotic use and optimize the treatment of infectious diseases. To be successful, multiple aspects should be considered in the ASP. Initially, the infection control specialists will follow the routine activity of each department in order to define what could immediately be improved. Internal antibiotic prophylaxis and therapy guidelines will be defined and shared between groups. The RS, collected at the preoperative testing, is evaluated by the infection control specialist. In case of identification of MDR bacteria, each patient will receive a tailored AP based on the antibiograms of the RS. In any case, the infection control specialist will choose the best solution for the patient avoiding the key antibiotics
76059812|NCT04193488|Behavioral|MTP block|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasagital scan, the block needle (50 mm 22 Gauge) will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
76059813|NCT04193488|Behavioral|ESP block|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
76059814|NCT04193488|Behavioral|No Block group|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
76059815|NCT03023098|Device|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
76059816|NCT03023098|Device|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
75447546|NCT04871217|Diagnostic Test|68Ga-NODAGA-RGD PET-imaging|Patients will undergo cardiac 68Ga-NODAGA-RGD PET in order to detect myocardial αVβ3 integrin expression 3-14 days after an acute myocardial infarction or within 4 weeks before and 2 weeks after re-opening of chronic coronary occlusion. Echocardiography of cardiac function will be performed at the time of PET imaging and repeated 6 months later.
75447547|NCT04869605|Diagnostic Test|1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin ratio|the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes
75447548|NCT04860791|Other|questionnaires|Patients will complete the MSWDQ-23 in French, as well as the DEX, questionnaire for the evaluation of executive dysfunction in daily life, to evaluate their cognitive complaints and the SF36 questionnaire to evaluate their quality of life
75597158|NCT00593801|Drug|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
75597159|NCT00593879|Drug|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
75597160|NCT00594113|Other|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
75597161|NCT00594113|Other|Touch screen intervention|Touch screen intervention
75597162|NCT00594191|Drug|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
75597163|NCT00594191|Drug|Placebo|Placebo with the same characteristics of the drug and at the same dose
75597164|NCT00594269|Drug|Risperidone|Discontinuation
75741429|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
75741430|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|2.5mg po daily
75741431|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
75889339|NCT02190734|Other|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
75889340|NCT02054598|Behavioral|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
75889341|NCT02190812|Device|Forearm supporter|The forearm supporter be use in tennis elbow.
75889342|NCT02190812|Device|Grip ball|
75889343|NCT02054676|Radiation|Cone-Beam Computed Tomography preoperative evaluation.|"Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. i-CAT, Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):~Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;~Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).~All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible."
76059817|NCT03962686|Drug|statin Oral Tablet plus PCSK9i|Patients in the third study cohort will receive for statin oral therapy plus 140 mg twice a month PCSK9i therapy via subcutaneous injection before to practice surgical intervention for carotid artery obstruction.
75447549|NCT04858750|Device|Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy|During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.
75889344|NCT02054676|Procedure|Intraoperative edentulous jaw segment parameters evaluation.|"Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.~Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).~The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:~implant drill slippage deeper than planned;~implant threads coverage;~etc."
75889345|NCT02054676|Device|Endosseous dental implant placement.|"Endosseous dental implant (e.g. Bone Level SLA implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.~Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.~Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.~Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).~Bone and soft tissue augmentation are made if necessary after dental implant placement."
76059818|NCT04193020|Other|Surveillance card|Surveillance card and additional examination to find novel markers and better assess the existing ones
75741432|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
75447550|NCT04855045|Drug|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
75447551|NCT04838977|Behavioral|RESET|Therapy
75447552|NCT04838197|Other|Questionnaires and Surveys|Quantitative questionnaires will measure and quantify the importance of the various factors (e.g., intensity of dependence, duration of care, health literacy, physical well-being, emotional well-being, social well-being, and financial well-being) that contribute to caregiver burden both preoperatively and postoperatively at 48 hours, 1 week, 2 weeks, and 1 month.
75447553|NCT04835584|Drug|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
75447554|NCT04835584|Drug|Dasatinib|Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
75741433|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|150mg po monthly
75741434|NCT00048061|Dietary Supplement|Calcium|500 mg/day
75741435|NCT00048061|Dietary Supplement|Vitamin D|400 IU/day
75741436|NCT00802061|Behavioral|Sleeping position in glaucoma patient|
75741437|NCT00802139|Drug|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
75741438|NCT00802139|Drug|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
75741439|NCT00802217|Drug|Civamide|5 mg liquid filled softgel capsules
75889346|NCT02054676|Radiation|Dental implant position evaluation.|"Periapical radiograph (e.g. Kodak RVG 6100 Intraoral Digital Imaging System, Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.~Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).~Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined."
76059819|NCT04199338|Other|The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis|"In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test."
76059820|NCT04192864|Procedure|Lingually based triangular flap|"A lingually based triangular flap was used to remove the impacted third molar. An incision was made adjacent to the distal surface of the mandibular second molar and extended along the sulcus to the distobuccal corner of the mandibular second molar, an oblique vestibular incision was made and extended into the vestibular fornix of the mandible. Aligned with the mesiobuccal cusp of the second molar.~It was continued posterosuperior towards the anterior border of the mandibular ramus An incision will be made from the anterior border of the mandibular ramus to the distal surface of the mandibular second molar."
75447555|NCT04835584|Drug|Nilotinib|Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
75447556|NCT04831502|Drug|TAK-906|TAK-906 Tablets.
76059821|NCT04192864|Procedure|Buccally based triangular flap|The impacted teeth was removed using a buccal based triangular flap. It will be extended along the sulcus to the distobuccal corner of the second molar . The incision was continuous, with a relieving vertical incision, oblique into the mandibular vestibular fornix, aligned with the mesiobuccal cusp of the second molar.
76059822|NCT04027270|Other|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
76059823|NCT04027192|Drug|BAY2328065 LSF|20 mg/mL LSF (liquid service formulation), orally
76059824|NCT04027192|Drug|BAY2328065 tablet|50 mg tablet, orally
76059825|NCT04027192|Drug|Placebo LSF|Matching Placebo LSF, orally
76059826|NCT04027192|Drug|Placebo tablet|Matching Placebo tablet, orally
76059827|NCT04027192|Drug|Midazolam|1 mg per day, orally
76059828|NCT04406506|Device|nasogastric|• The insertion of NG tubes were performed by the ICU physician and the position was checked by auscultation of gas from 50 ml syringe by injecting 20 ml of air in the NG and by X-ray abdomen to be sure from the site of NG tube
75447557|NCT04831502|Drug|TAK-906|TAK-906 Capsules.
75597165|NCT00594269|Drug|Escitalopram|Discontinuation
75447558|NCT04828434|Other|Virtual Individual Cognitive Simulation Therapy|Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.
75447559|NCT04819854|Drug|EP395|capsule for oral treatment
75447560|NCT04819854|Drug|Placebo|capsule for oral treatment
75462984|NCT01868880|Drug|betablocker titration|Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
75462985|NCT01870440|Drug|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
75462986|NCT01870466|Drug|Cilostazol|cilostazol bid for 7 days
75462987|NCT01870466|Drug|Simvastatin|simvastatin qd for 7 days
75462988|NCT01870466|Drug|Rosuvastatin|rosuvastatin qd for 7 days
75597166|NCT00594269|Drug|Citalopram|Discontinuation
75597167|NCT00594269|Drug|Sertraline|Discontinuation
75597168|NCT00594269|Drug|Paroxetine|Discontinuation
75889347|NCT02054676|Drug|Medications.|"Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days."
75889348|NCT02054676|Procedure|Late postoperative soft tissue evaluation.|"Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.~The time after surgery is case depending before provisional and final crown placement.~Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.~Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving."
75889349|NCT02256956|Drug|Amitriptyline|25 mg / day for 10 days
75447561|NCT04816747|Biological|Autologous PRP|Participants enrolled in this study will be managed with intradiscal and/or intra-articular injections of autologous PRP according to features of underlying pathology. Participants featuring FJS will be prior to PRP diagnostically and therapeutically injected with local anesthetic in order to verify FJS as the etiology of experienced pain. Injected PRP solution volume is designed to be 0.5-1 ml and 0.5 ml in cases of intradiscal and intra-articular injection, respectively. All participants are planned to receive a single dose of PRP, whilst a maximum of two compromised discs and four facet joints will be treated in each patient.
75447562|NCT04809012|Biological|STI-3031|STI-3031 is an anti-PD-L1 antibody
75447563|NCT04807985|Device|JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
75447564|NCT04807725|Genetic|Analysis of genetic polymorphisms|For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).
75447565|NCT04807725|Other|Biochemical analysis|For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.
75462989|NCT01870479|Other|Live music|
75597169|NCT00594347|Biological|Pneumo 23|Vaccine (Pneumo 23)
75597170|NCT00594347|Biological|Prevnar|Vaccine (Prevnar)
75597171|NCT04326959|Biological|Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
75597172|NCT04326959|Biological|Conditioned Medium|Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
75597173|NCT04326959|Biological|Triamcinolone Acetonide|Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
75597174|NCT01306929|Drug|pridopidine|45mg bid
75597175|NCT02892617|Other|Bacteriological analysis of disc|
75741440|NCT00802217|Drug|Civamide|5 mg x 2 liquid softgel capsules
75741441|NCT04808141|Device|Digital program|Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
76059829|NCT04406506|Device|nasojejunal|"The nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~Patients were placed in right lateral position"
76059830|NCT04406506|Drug|(erythromycin 250 mg IV bolus)|prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus
76059831|NCT04193098|Biological|CTL|CTL injection
76059832|NCT04193098|Biological|Toripalimab|Toripalimab injection
76059833|NCT04192942|Other|protocol of management of major burn in intensive care unit|primary assessment first aid management laboratory investigation radiological investigation surgical intervention
76059834|NCT04021186|Other|Prevention of hyperglycemia|Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
75741442|NCT04808141|Other|Conventional PT|Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled PT sessions.
76059835|NCT04026724|Drug|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
75741443|NCT03955159|Dietary Supplement|Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
75741444|NCT00802295|Drug|Gonadotrophins|Administration of standard ovarian stimulation protocol
75462990|NCT01870479|Other|Taped music|
75462991|NCT01870492|Drug|Activase|Patients treated with Activase
75741445|NCT00802295|Drug|Low dosis Gonadotrophin|
75741446|NCT03954925|Procedure|Anatomic anterior cruciate ligament with short hamstring graft technique|ACL and short hamstring graft
75741447|NCT03954925|Procedure|Anatomic anterior cruciate ligament with a standard hamstring graft technique|ACL with standard hamstring graft
75741448|NCT00802373|Drug|Solifenacin succinate|oral
75741449|NCT00802373|Drug|Tolterodine|Oral
75741450|NCT01092715|Procedure|Spinal mobilization|Non thrust mobilization to the cervical spine
75741451|NCT01092715|Procedure|Massage|Sedative massage to cervical paraspinal muscles
75889350|NCT02256956|Drug|Tolterodine|Placebo 1 mg / day for 10 days
76059836|NCT04026802|Other|In-Bed Resistance Training Device|Physical Therapy using the in bed training device
76059837|NCT04026802|Other|Standard of Care|Does not include early implementation of physical therapy
76059838|NCT04020796|Dietary Supplement|Beetroot juice|Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
76059839|NCT03832348|Device|PET scan imaging|3 PET scans will be performed after each 3 first infusions of Pembrolizumab
76059840|NCT04026100|Biological|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10^6), medium dose (2×10^6), and high dose (3×10^6).
76059841|NCT04192552|Other|PAUSE Perioperative DOAC Management|"Apixaban & Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl <50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure."
76059842|NCT04192552|Other|ASRA Perioperative DOAC Management|"Apixaban & Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl >80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~*Low-dose heparin bridging can be used if at high A-TE risk"
76059843|NCT04020640|Other|no intervention|Measure human intake using stable isotope technique
76059844|NCT04192162|Other|Mud therapy application|Aplication the mud pack therapy from 20 minutes
76059845|NCT04192162|Other|Sulfur water application|Aplication the sulfur water in bath from 20 minutes
76059846|NCT04192162|Other|Hygienic water|Exercise in hygienic water
75447566|NCT04801459|Procedure|Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction|In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
75597176|NCT02892695|Biological|anti-CD19 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
75741452|NCT01092715|Procedure|Neck exercises|Range of motion exercises to include foraminal opening
75741453|NCT03957109|Procedure|general anesthesia|
75447567|NCT04799405|Device|tDCS|"Daily sessions (28 daily sessions): The device will be used to apply 30 minutes of tDCS to the participant with MDD's scalp in each of 28 daily sessions.~Thereafter, participants with MDD will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:~First taper phase: three 30 minutes tDCS sessions applied every other day;~Second taper phase: three 30 minutes tDCS sessions applied one every third day;~Third and final taper phase: three final 30 minutes tDCS sessions applied one every fourth day."
75462992|NCT01870492|Device|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
75597177|NCT02892539|Radiation|Coronary Angiography|
75741454|NCT03952975|Other|Vaginal bleeding|Vaginal bleeding was classified into four categories according to the timing. Intraoperative bleeding (defined as bleeding that occur during the LEEP procedure), early postoperative bleeding (defined as bleeding that occur between end of the LEEP procedure and home discard), late postoperative bleeding (defined as bleeding that occur within two weeks after the home discard, and required hemostatic interventions such as electrocauterization, gauze packing, or cervical suturing, excluding menstrual bleeding), and persistent postoperative bleeding (defined as vaginal bleeding that occurs more than 2 weeks after the procedure with or without required hemostatic interventions, excluding menstrual bleeding).
75741455|NCT00802451|Drug|Mesalamine|
75741456|NCT03956953|Drug|BMS-986165|Dose 1 or Dose 2 on Day 1, and from Days 5-19'
76059847|NCT03022942|Other|GROUP Costal mobilization & Diaphragm Release|Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
75597178|NCT00594503|Drug|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
75597179|NCT00594581|Drug|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
75597180|NCT00594737|Drug|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
76059848|NCT03022942|Other|GROUP Manual Diaphragm Release|The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
76059849|NCT04191694|Other|Chewing Gum|Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
76059850|NCT04191694|Drug|Ondansetron 4 MG|Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
75597181|NCT00594893|Procedure|Mini Incision Approach|Mini Incision Approach
75597182|NCT00594893|Procedure|2 Incision Approach|2 Incision Approach
76059851|NCT04191850|Procedure|Single Port Video-Assisted Thoracoscopic Surgery|Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
75447568|NCT04798131|Other|Active neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will continuously receive visual feedback computed from the fMRI signal analyzed with the hallucinations decoder. Patients will be trained to maintain the brain state associated with the no-hallucination state using appropriate coping strategies. A 5th fMRI scan will be performed at 1 month post-treatment.
75889351|NCT02187536|Drug|Telmisartan|
75597183|NCT00594971|Other|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
75597184|NCT00594971|Other|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
75889352|NCT02187536|Drug|Simvastatin|
75889353|NCT02187536|Drug|Telmisartan placebo|
75889354|NCT02256722|Drug|KUC 7483 CL|
75741457|NCT03956953|Other|Placebo|Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
75741458|NCT00798473|Drug|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
75889355|NCT02256722|Drug|Bisoprolol|
75889356|NCT02256722|Drug|Propranolol|
75597185|NCT00595049|Drug|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
75741459|NCT00798473|Other|IV saline infusion|
75741460|NCT01583881|Procedure|renal denervation|Renal denervation
75741461|NCT03955003|Behavioral|Group Drumming|Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
75889357|NCT02256722|Drug|Acipimox|
75889358|NCT02256722|Drug|Salmeterol|
75889359|NCT05655624|Other|Pursed lip Breathing along Mat Pilates|Experimental Group: will be treated with Pursed lip Breathing along Mat Pilates Training.
75889360|NCT05655624|Other|pursed lip breathing without Mat Pilates Training|Control Group will be treated pursed lip breathing without Mat Pilates Training
75889361|NCT02190890|Procedure|Dry needling|
75889362|NCT02190890|Procedure|Control|
75889363|NCT02056314|Other|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
75889364|NCT02056314|Other|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
75889365|NCT02190968|Behavioral|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
75889366|NCT02190968|Behavioral|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
75447569|NCT04798131|Other|Sham neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will receive a random feedback and a 5th run at 1 month post-treatment.
75447570|NCT04795440|Procedure|Testicular biopsy|Performance of a testicular biopsy with the intention of obtaining spermatozoa for the insemination of oocytes with the ICSI technique.
75447571|NCT04794036|Other|Asynchronous telerehabilitation programme|Home-based physical rehabilitation programme using a telerehabilitation platform
75447572|NCT04794036|Other|Rehabilitation programme|Home-based physical rehabilitation programme by means of an explanatory booklet
75741462|NCT03955003|Other|Attention Control|This is intended to control for time, place, and group affect.
75741463|NCT03955237|Procedure|Drug: dextrose containing infusion|Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
75741464|NCT04045769|Drug|Saroglitazar magnesium 4mg|1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
75462993|NCT01870518|Device|Bilateral GPi DBS|
75462994|NCT01870518|Device|Bilateral STN DBS|
75597186|NCT00595205|Other|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
75741465|NCT04045769|Drug|Placebos|5 tablets of placebo to be administered orally
75741466|NCT04045769|Drug|Moxifloxacin 400mg|1 tablet of 400 mg Moxifloxacin to be administered orally
75741467|NCT04045769|Drug|Saroglitazar magnesium 20 mg|5 tablets of 4 mg Saroglitazar magnesium to be administered orally
75741468|NCT01095601|Drug|Avanafil|"Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~Treatment B: 2x100 mg Formulation II avanafil tablet, fed~Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
75889367|NCT02056470|Device|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
75889368|NCT02056470|Device|Total Knee Replacement|total Knee replacement implant
75889369|NCT02056470|Device|Freedom Total Knee System|Total Knee replacement implant
75889370|NCT02187614|Drug|Diclofenac|
75889371|NCT02187614|Drug|Morphine|
75889372|NCT02187614|Drug|Paracetamol|
75889373|NCT02187614|Drug|Placebos|
76059852|NCT04191772|Other|Periodized, home-based running program|All participants will perform a home-based supervised exercise training program. Participants will receive weekly training instructions using a smartphone-based heart rate monitor application (Polar® app). Training sessions will involve running and the design of the training program will be based on linear periodization, where aerobic capacity is built firstly through a period of high-volume/low-intensity training before the proportion of high-intensity training is increased. The total duration of the exercise program will be 12 months with three weekly training sessions. Training progression will be dependent on initial VO2max values and running experience. VO2max classification is based on reference values described in V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics.
75447573|NCT04792957|Diagnostic Test|immunohistochemical methods|The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.
75447574|NCT04790773|Other|Amazon Alexa based voice recording patient education|Amazon Alexa based voice recording of medication education material
75447575|NCT04788329|Behavioral|"Prepare for Surgery, Heal Faster Program"|This NYU program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel. The program uses five steps to ease stress-related symptoms prior to surgery and improve help recovery time. By practicing deep relaxation, it is possible to reduce anxiety and promote a feeling of calmness. The patient swill be enrolled in the course preoperatively and will be ask to continue these meditations for ten weeks.
75447576|NCT04788329|Behavioral|Wim Hof Method|Patients will be enrolled in Wim Hof Method, a breathing/meditation program. This is a free online program, developed by a man named Wim Hof and his techniques. On this website, he explains the origins and methods behind his teachings ( https://www.wimhofmethod.com/iceman-wim-hof. ). Patients in this group will take the online free course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively. The three pillars of the WHM are 1) breathing/meditation, 2) stretching exercises and 3) gradual cold exposure. The patients will be told to concentrate on the breathing and meditation component, they may not be able to participate in the cold exposure (cold showers, ice baths) in the immediate post op period because of the open wounds.
75447577|NCT04787653|Device|Otoband|Participants with Tinnitus will wear the Otoband set at an effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
75447578|NCT04787653|Device|Placebo|Participants with Tinnitus will wear the Otoband set at a non-effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
75462995|NCT01870544|Dietary Supplement|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
75462996|NCT01870544|Dietary Supplement|Placebo|placebo will be administered daily for 44 days
75462997|NCT01870570|Other|Reference Glucose|
75462998|NCT01870570|Other|Food Product A: Corn Flakes|
75462999|NCT01870570|Other|Food Product B: Ginger Bread|
75741469|NCT03953365|Procedure|Prophylactic Mesh|Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
75741470|NCT00798629|Biological|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
75741471|NCT01097317|Drug|carboplatin|
75741472|NCT01097317|Drug|vinorelbine tartrate|
75463000|NCT01870570|Other|Food Product C:Sandwiched Breakfast Biscuit|
75463001|NCT01870570|Other|Food Product D: Crackers Nature|
75463002|NCT01870570|Other|Food Product E: Breakfast Biscuit|
75463003|NCT01870570|Other|Food Product F: White Bread|
75741473|NCT01097317|Other|neuromuscular electrical stimulation|
75741474|NCT01097317|Other|physiologic testing|
75741475|NCT01097317|Procedure|fatigue assessment and management|
75741476|NCT01097317|Procedure|quality-of-life assessment|
75741477|NCT04046705|Procedure|Allogeneic matched related haematopoietic stem cell transplantation|Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
75889374|NCT02030678|Drug|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG [40 mg] and 171231AG [100 mg]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
75889375|NCT02054832|Dietary Supplement|Glycosade|
76059853|NCT04026022|Drug|Fentanyl Transdermal System|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
76059854|NCT04026022|Drug|Placebo|Placebo plaster in the ER or PACU
76059855|NCT04020406|Biological|Antibacterial Activity|Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
76059856|NCT04020328|Drug|Leflunomide 20 mg+prednisone 0.5mg/kg/d|Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR<50ml/min
76059857|NCT04020094|Combination Product|MVA-BN-Brachyury|"Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle."
76059858|NCT04025476|Drug|Steroids|IV and oral steroids
76059859|NCT04025320|Other|Intraneural Facilitation|Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
76059860|NCT04025320|Other|Sham|A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
76059861|NCT01874288|Drug|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
76059862|NCT02080468|Drug|lomitapide|20 mg
76059863|NCT02080468|Drug|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
76059864|NCT04020016|Drug|Nalbuphine ER|Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.
75447579|NCT04787380|Device|Heartfelt device|"The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition."
75447580|NCT04787198|Drug|hypertonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
76059865|NCT04020016|Drug|Nalbuphine ER -|Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
76059866|NCT02985112|Device|FFR and IVUS-NIRS|
76059867|NCT04025164|Radiation|Hypofractionated Radiotherapy|daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
76059868|NCT04025164|Radiation|Conventional fractionated Radiotherapy|daily fractions, 2 Gy per fraction, five fractions per week
76059869|NCT04191226|Diagnostic Test|Multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
76059870|NCT04021966|Procedure|Vaginal laser application|"One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa."
76059871|NCT01874054|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
76059872|NCT01874054|Drug|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
76059873|NCT01873742|Other|STIC feedback system|This condition includes the use of the STIC feedback system.
76059874|NCT04766242|Other|Spiritual healing|"The spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient's body, known as power points, outside the patients clothing. The consultation might also include possible life-style advice. The treatments will last for 45-60 minutes each time."
76059875|NCT04766242|Other|Usual care|The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.
76059876|NCT01873586|Procedure|Posterolateral Fusion|
76059877|NCT04024774|Biological|Biological samples|blood samples, urine samples, tissue samples
76059878|NCT04024774|Genetic|Genetic test|anamnesis and NGS sequencing
76059879|NCT04025398|Behavioral|Cognitive remediation program|Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
76059880|NCT04025398|Behavioral|Control group|"Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)"
76059881|NCT04029610|Procedure|Local anesthesia with lidocaine and adrenalin.|Local anesthesia with lidocaine and adrenalin.
76059882|NCT04029610|Drug|lidocaine and adrenalin|lidocaine and adrenalin
76059883|NCT04029610|Drug|lidocaine and arterial blockage|lidocaine and arterial blockage
75447581|NCT04787198|Drug|isotonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
75447582|NCT04785781|Other|without masks|apply a bicycle ergometer test protocol to individuals without a mask
76059884|NCT04024852|Other|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
76059885|NCT04026880|Drug|Testosterone Enanthate|25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
76059886|NCT04026880|Drug|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks
76059887|NCT04190992|Other|E-based & personalized breast reconstruction surgery decision aid|This decision aid contains information regarding surgical options, including breast reconstruction and mastectomy, such as the advantages and disadvantages, the complication probabilities of each option, a value clarification exercise for the patient's self-evaluation, and a summary of the participant's decision-making process.
76059888|NCT04190992|Other|Usual care|A pamphlet introduce the introduction of types of surgery
76059889|NCT04191070|Device|infrazygomatic miniscrew|class II correction by distalization using infrazygomatic crest miniscrew
76059890|NCT04191070|Device|zygomatic miniplate|class II correction by distalization using zygomatic miniplate
76059891|NCT04190602|Device|NeoChord Artificial Chordae Delivery System, Model DS1000|The intended use of the device is for the placement of artificial chordae when the natural chordae tendinae have become elongated or ruptured due to degenerative valve disease.
76059892|NCT04024384|Drug|Daratumumab|Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
75741478|NCT04046705|Other|Standard arm|In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
76059893|NCT04023916|Drug|Sintilimab-R-CHOP|"Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable."
76059894|NCT04023838|Procedure|artery puncture and coronary angiography|We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
76059895|NCT04023760|Drug|Apixaban|Study subjects given a single-dose of apixaban 10 mg.
76059896|NCT03022786|Other|Order set|Inpatient order set and ambulatory care guide offer guidance on initial compression to decrease edema, obtaining gradient compression stockings, how to access evaluation by vascular medicine for pain or dermatology for evaluation of allergic contact dermatitis if itch persists, etc
76059897|NCT03022786|Other|Motivational Interviewing training for home health aides|"Home Care aides trained about use of compression stockings and use of motivational interviewing as a tool to help patients make behavior changes to reduce leg swelling. This is part of our 'tool kit'.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
76059898|NCT03022786|Other|Tools & Education|Engaged physical therapists to evaluate patients for ability to don stockings, to assess need for strengthening exercises or leg exercises to improve venous return. This is part of our 'tool kit'
76059899|NCT04020952|Other|"st.st 0.019×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
76059900|NCT04020952|Other|"st.st 0.016×0.022 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
76059901|NCT04020952|Other|"st.st 0.017×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
76059902|NCT03961750|Other|OTAGO|12 Week exercise class programme
76059903|NCT04020718|Behavioral|Brief telephone advice plus tailored text messages|All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
75447583|NCT04785781|Other|Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)|apply a bicycle ergometer test protocol to individuals with a surgical mask
75447584|NCT04785781|Other|FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)|apply a bicycle ergometer test protocol to individuals with a FFP2\N95 mask
75447585|NCT04780763|Other|Milk product fermented by lactic bacteria or not fermented|2 bottles of 100g consumed daily during 28 days
75447586|NCT04777279|Behavioral|individual physical exercise group|The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.
75447587|NCT04777279|Dietary Supplement|individual Branched-Chain Amino Acids supplements group|The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.
75447588|NCT04777279|Other|combination of physical exercise and nutrition supplements group|The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
75447589|NCT04776382|Other|EMME (Eye Movement Modeling Examples)|Trainees of this group will watch an EMME (Eye Movement Modeling Examples)-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
75447590|NCT04775537|Device|OssiMend™ Bioactive Moldable|Lumbar Spine fusion with OssiMend™ Bioactive Moldable
75447591|NCT04774315|Drug|Omalizumab|omalizumab 300mg SQ every 4 weeks as part of standard of care
75447592|NCT04769479|Drug|acoramidis|acoramidis
75447593|NCT04768361|Behavioral|Behavioral Activation without Mindfulness|"Behavioral Activation without Mindfulness includes functional analysis as key to defining out-of-session and activation strategies as central to mood change."
75889376|NCT03677349|Procedure|neurorrhaphy|"During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1."
76059904|NCT04020718|Drug|Mailed nicotine replacement therapy|Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
75889377|NCT02187692|Behavioral|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
76059905|NCT04020718|Behavioral|Proactive telephone coaching|Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
76059906|NCT04027348|Drug|Dexamethasone|Given IV
75889378|NCT02058732|Other|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
76059907|NCT04027348|Drug|Metoclopramide|Given IV
76059908|NCT04027348|Drug|Octreotide|Given IV
76059909|NCT04195204|Drug|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia and once daily for 7 days after surgery.
76059910|NCT04195204|Drug|Placebos|Investigators administrated intravenously saline solution as a placebo
76059911|NCT04406350|Procedure|Intraoperative tight control of respiratory end-tidal gases|Control of ET CO2 and ET O2 during conduct of anesthesia.
76059912|NCT04023136|Procedure|partial hepatectomy by laparotomy on healthy or pathologic parenchyma.|Preoperative flow and MRI + intraoperative measures of flow and pressures
76059913|NCT04023214|Diagnostic Test|Peripheral (digital) arterial tonometry|This will be measured using the EndoPAT system (Itamar Medical)
76059914|NCT04023292|Drug|Endocrine therapy|Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
75447594|NCT04768361|Behavioral|Behavioral Activation with Mindfulness|"Behavioral Activation with Mindfulness includes functional analysis as key to defining out-of-session and activation strategies and mindfulness as central to mood change."
75447595|NCT04768335|Behavioral|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the links between source memory deficits and externalization abilities in healthy control subjects. Results of this Arm 2 will be compared to those of Arm 1.
75447596|NCT04767802|Drug|PTG-300|Hepcidin mimetic
75447597|NCT04767503|Drug|Propofol|Maintence of anestheisa with propofol guided by the bispectral index in the range 40-60.
75447598|NCT04767503|Drug|Desflurane|Maintence of anestheisa with desflurane guided by the bispectral index in the range 40-60.
75447599|NCT04761263|Other|Task-oriented circuit training|The task-oriented circuit training program consisted of 14 workstations. Time spent at each station will be 1.5 minutes. The children will complete the activity at one station and move to another station. The whole circuit will be completed in 21 minutes and it will be repeated twice per session with 3 minutes rest interval between the 2 circuits. Children will be encouraged to work as hard as possible at each workstation and will also be given verbal feedback and instructions aimed at improving performance. The progression of the task will be considered according to each child's ability and progressed as tolerated. Progressions include increasing the number of repetitions and increasing complexity of the exercise performed at each workstation, such as the distance reached in standing, reducing the height of the chair during sit-to stand, changing the height of blocks or by increasing speed of movement.
75463004|NCT01870622|Procedure|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
75889379|NCT03684603|Behavioral|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
75889380|NCT03684603|Behavioral|melody only during motor training|sequence of tones which are presented to the patient using earphones
75889381|NCT02187770|Device|IMED-4|Non invasive recording electrode used to assess lung fluid
76059915|NCT04023292|Drug|Endocrine therapy|Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
76059916|NCT03948958|Other|Evaluation of the catheter function|Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
75741479|NCT01097473|Procedure|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
75741480|NCT00802763|Device|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
75889382|NCT02054988|Other|caffeine|"After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay [Accumetrics, San Diego, California]) was measured at baseline and after 10-days of coffee intake."
76059917|NCT03948958|Other|Catheter tip location, thrombus, sleeve and device damage visualization|Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
76059918|NCT03948958|Other|Catheter-related colonization|TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
76059919|NCT03948958|Other|patient-reported outcome measures (PROM) related to the presence of the TIVAD|PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
76059920|NCT03948958|Other|Macroscopic evaluation of the port chamber and catheter|Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
76059921|NCT04198090|Behavioral|SGM Competency Training Program|A validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for oncology
75447600|NCT04761263|Other|Selected Physical therapy program|"Facilitation of balance reactions from standing position including; standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing and standing on balance board.~Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~Gait training activities including: walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~Facilitation of protective reaction from standing position by pushing the child in different directions.~Facilitation of rising mechanism through changing position as well as returning back to the original position e.g.: from lying to standing and from sitting to standing.~Strengthening exercises for back and abdominal muscles as well as upper and lower limbs.~Jumping in place and jumping a board."
75463005|NCT01870622|Procedure|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
75463006|NCT01870635|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
75463007|NCT01870635|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
75741481|NCT01095679|Drug|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
75741482|NCT01095679|Drug|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
75741483|NCT00794183|Device|CRT device settings|Comparision of A-V delay settings
75741484|NCT01092793|Dietary Supplement|Krill|Encapsulated oil from the antarctic crustacean Krill
75889383|NCT02054988|Other|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
75889384|NCT03682341|Genetic|endometriosis|patients with or without ovarian endometriosis
75889385|NCT02055066|Drug|ARGX-111|
76059922|NCT02703688|Behavioral|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
76059923|NCT02703688|Other|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
75741485|NCT01092793|Dietary Supplement|Fish oil|Encapsulated, raffined cod-oil
75741486|NCT00794261|Drug|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
75741487|NCT00794261|Drug|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
75741488|NCT03953287|Drug|Paracetamol|A randomized, cross over design
75741489|NCT02554565|Procedure|Tumor biopsy|Tumor biopsy before treatment
76059924|NCT04190758|Other|Care as usual|No intervention will be given. The study will follow the effects of care as usual.
76059925|NCT04023448|Procedure|transverse coloplasty pouch|a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
76059926|NCT04022902|Other|No intervention|This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
76059927|NCT02704312|Radiation|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
76059928|NCT02080546|Procedure|Cut-Coag|"Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode."
76059929|NCT02080546|Procedure|V-mode|"Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures."
76059930|NCT02080546|Device|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
75597187|NCT00595283|Behavioral|Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
75741490|NCT02554565|Procedure|Blood sampling|Blood sample before, during and after treatment
76059931|NCT04022824|Other|OSA|Patients with OSA (apnea hypopnea index ≥15) based on sleep study
75741491|NCT01092949|Device|MRI|MRI, 45 minutes
75741492|NCT00803075|Device|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
75741493|NCT03952819|Diagnostic Test|serum sclerostin|blood samples obtained
75741494|NCT00803153|Procedure|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
75597188|NCT00595283|Behavioral|Developmental Education Parenting Intervention (DEPI)|DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
75597189|NCT04326881|Drug|SHR-1314|single dosing
75597190|NCT00595673|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
76059932|NCT04022824|Other|Non-OSA|Patients without OSA (apnea hypopnea index <15) based on sleep study
76059933|NCT03023254|Other|Hydrotherapy|3-week Avène hydrotherapy
76059934|NCT03022240|Drug|Propofol|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
76059935|NCT03022240|Drug|Sevoflurane|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
76059936|NCT03022240|Drug|Ametop|Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.
76059937|NCT03022240|Drug|Ondansetron|Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
75889386|NCT03684525|Procedure|Extraction of primary canines|"At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
75889387|NCT04615754|Dietary Supplement|Hyperketonemia - use of ketone (3-OHB) infusion|The effect of intravenous ketone supplement
76059938|NCT02701738|Dietary Supplement|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
76059939|NCT04022434|Dietary Supplement|Placedo|Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
76059940|NCT04022434|Dietary Supplement|Alanine|Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
76059941|NCT04196374|Genetic|Genomic Sequencing|Whole Genome Sequencing and reporting of actionable genomic results for genes included on the ACMG secondary findings list.
76059942|NCT04196686|Device|VR/AR|VR/AR headset with either passive or active content such as playing a game or watching a movie
76059943|NCT04196686|Other|Ice Bath|Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
76059944|NCT03957850|Behavioral|Cognitive Reappraisal Training|The training procedure is adapted from a study by Denny & Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.
76059945|NCT03957850|Behavioral|Control Training|The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
75741495|NCT02530333|Other|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
75463008|NCT01870648|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
75741496|NCT01097551|Drug|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
75741497|NCT01097551|Drug|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
75741498|NCT01097551|Drug|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
75741499|NCT01097551|Device|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
75741500|NCT00803309|Drug|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
75741501|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
75741502|NCT00803309|Drug|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
75741503|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
75889388|NCT04615754|Dietary Supplement|Placebo - use of saline infusion|Saline is infused as an comparator
75889389|NCT02058810|Device|Nasal high flow|
75889390|NCT02058810|Device|Conventional nasal oxygen|
76059946|NCT04192318|Behavioral|Bridging the Gap|Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
75597191|NCT02892461|Procedure|Umbilical cord milking|As same as that in arm descriptions.
75597192|NCT00595829|Drug|XL019|XL019 capsules administered orally
75597193|NCT00595985|Drug|sorafenib|sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
75597194|NCT00596063|Biological|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
75889391|NCT03677271|Behavioral|Physical Activity|
75889392|NCT02191124|Drug|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
75889393|NCT02191124|Drug|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
75889394|NCT03677193|Behavioral|Playing ICP game|Participants will play the ICP game from their home this is expected to be 30 min * 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
76059947|NCT04192318|Other|Communities that Care (CTC)|In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.
76059948|NCT04192318|Other|Treatment as usual|Treat and release
76059949|NCT02704390|Drug|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
75597195|NCT00596063|Biological|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
75597196|NCT00596141|Device|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
75597197|NCT00596219|Drug|celecoxib|celecoxib
75597198|NCT00596297|Drug|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
75597199|NCT00596297|Procedure|pars plana vitrectomy|4 weeks after baseline
75597200|NCT00596375|Procedure|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
75597201|NCT00596375|Drug|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
75597202|NCT00596531|Drug|Acamprosate|Oral administration, 666 mg, tid, for 4 months
75597203|NCT00596531|Drug|Placebo|Oral administration of 2 pills, tid, for 4 months
75597204|NCT00596609|Drug|Intrathecal Morphine|"In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
75889395|NCT02193698|Drug|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
75889396|NCT03682185|Behavioral|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
75889397|NCT03682185|Behavioral|Timed Activity Intervention|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.
76059950|NCT04147390|Drug|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
76059951|NCT04147390|Drug|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
75889398|NCT02191202|Drug|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
75889399|NCT03561168|Diagnostic Test|Change in plan of care based on MRI results|"Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results."
75889400|NCT02055300|Drug|LY03005|
75889401|NCT02055300|Drug|Placebo|
75889402|NCT02055300|Other|Meal|
75889403|NCT02055300|Drug|Pristiq|
75889404|NCT02056860|Procedure|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
75889405|NCT02056860|Procedure|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
75889406|NCT02056860|Procedure|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
75447601|NCT04759898|Device|transcranial direct current stimulation (noninvasive recording)|Subjects will enter the EEG lab and be seated in a chair. The 26-electrode EEG array will be placed using a conductive paste. The electrodes will be connected to a clinical grade EEG machine used in standard of care routine EEG monitoring. Next, a soft cloth cap will be placed over the subject's head with the tDCS electrodes pre-positioned in place. The cap will be positioned so that the tDCS electrodes cover the scalp without disturbing the underlying EEG electrodes. Conducting gel will be applied in direct contact with the scalp to facilitate stimulation. In addition, lidocaine jelly will be added topically to provide local anesthesia. The tDCS electrodes will be connected to a low-current generator. Participants receive 2.0 milliamps in electrical stimulation from the tDCS machine for 20 minutes. The device will be manually controlled by study personnel assisting with the experiment. A virtual reality environment will be utilized to collect kinematic data during the study.
75463009|NCT01870648|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
75463010|NCT01870661|Device|Long axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
75597205|NCT00596765|Behavioral|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
75597206|NCT00596843|Behavioral|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
75889407|NCT02056860|Procedure|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
75889408|NCT02056860|Procedure|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
75889409|NCT02191280|Drug|Antistax®, low dose|
76059952|NCT02706964|Device|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
75889410|NCT02191280|Drug|Antistax®, high dose|
75889411|NCT02191280|Drug|Placebo|
75889412|NCT03684369|Device|Transcutaneous electrical nerve stimulation|Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
75889413|NCT03684291|Procedure|Mode of Mechanical Ventilation|Adjustment of mechanical ventilation mode
75889414|NCT02193854|Device|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
75889415|NCT02055378|Drug|Atropine|topical 0.125% atropine eye drops
75889416|NCT02055378|Device|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
75889417|NCT04558190|Drug|Intralipid, 20% Intravenous Emulsion|Lipid infusion
75889418|NCT04558190|Dietary Supplement|MitoQ|Oral administration of MitoQ capsules
75889419|NCT04558190|Drug|Salbutamol|Beta2-agonist infusion
76059953|NCT02706964|Device|Magnetic resonance imaging|A brain MRI will be performed.
75447602|NCT04759898|Device|sham transcranial direct current stimulation (noninvasive recording)|Subjects receiving sham undergo the same setup as the stimulation group with the exception that sham subjects experience stimulation for one minute only (30 second ramp-up to 2 milliamps immediately followed by 30 second ramp-down to 0 milliamps for the remaining 19 minutes). This provides similar sensory feedback to sham subjects that treatment subjects experience. The same electrode array, soft cloth cap, conducting gel application, and lidocaine are applied as in a stimulation subject. The tDCS electrodes will be connected to a low-current generator. A virtual reality environment will be utilized to collect kinematic data during the study.
75741504|NCT03953209|Drug|Spironolactone 50Mg Tablet|Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
75741505|NCT03953209|Drug|Spironolactone 100Mg Tablet|Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
75741506|NCT03953209|Drug|Spironolactone 200Mg|Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
75889420|NCT03441321|Other|Lifestyle and Values Intervention|Participate in Facebook group focusing on avoiding tanning and promoting healthy body image
75889421|NCT03441321|Other|Lifestyle Intervention|Participate in Facebook group focusing on other health topics
75889422|NCT03441321|Other|Survey Administration|Ancillary studies
75889423|NCT03676959|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
76059954|NCT02706964|Device|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
76059955|NCT02708758|Behavioral|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
76059956|NCT02708680|Drug|Entinostat|An orally available histone deacetylases inhibitor (HDAC).
76059957|NCT02708680|Drug|Atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
76059958|NCT02708680|Drug|Placebo|A pill containing no active drug ingredient
75463011|NCT01870661|Device|Short axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
75741507|NCT01583959|Drug|Folic Acid|Folic acid tablets 5 mg
75741508|NCT01583959|Drug|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
75741509|NCT00803387|Drug|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
75741510|NCT03952897|Other|balneotherapy|10 days of balneotherapy with immersion techniques using Fitero spa water.
75741511|NCT02553551|Drug|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
76059959|NCT03931642|Drug|RCHOP|"D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO."
76059960|NCT03931642|Drug|Blinatumomab|Blinatumomab by continuous vein infusion
76059961|NCT04147312|Drug|Fufang E'Jiao Jiang|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
75463012|NCT01870674|Drug|YH12852|
75463013|NCT01870674|Drug|Prucalopride|
75463014|NCT01870674|Drug|Placebo|
75889424|NCT03676959|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
75889425|NCT03676959|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
75889426|NCT02059044|Other|ISTOP-ADE|Interactive Voice Response System + Pharmacist
76059962|NCT04147312|Drug|placebo containing low-dose fufang E'Jiao Jiang|placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
76059963|NCT03931564|Procedure|PRESERFLO Microshunt implantation|The intervention consists of the microshunt implantation augmented with mitomycin C application.
76059964|NCT03931564|Procedure|Trabeculectomy|The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.
75447603|NCT04759898|Device|transcranial direct current stimulation (invasive recording)|Subjects are brought into the operating room. The scalp is prepped with a sterilizing solution. Following infiltration with local anesthetic and incision, a 6-contact electrocorticography strip is inserted into the burr hole covering primary motor cortex. Electrocorticography strip terminals are connected to an amplifier for signal recording. Gas-sterilized transcranial direct current stimulation electrodes are placed on the scalp directly overlying primary motor cortex. tDCS electrodes are connected to a low-current generator. During electrocorticographic recording, stimulation is turned on while subjects are asked to flex each arm. At the conclusion of the experiment, the electrocorticography strip and tDCS electrodes are removed and the surgery proceeds as planned.
76059965|NCT04146766|Combination Product|eHealth|The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month
76059966|NCT04021342|Dietary Supplement|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
76059967|NCT04021342|Dietary Supplement|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
76059968|NCT04021888|Other|Exercise|Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
76059969|NCT04021420|Device|SONOCLOUD|"The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~an implantable ultrasound transducer,~a needle connection device,~an external radiofrequency generator, and~an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa)."
76059970|NCT04021420|Drug|Nivolumab Injection|Nivolumab (flat dose: 240mg, 30 minutes infusion)
75447604|NCT04754477|Device|Active Osseointegrated Steady-State Implant System (OSI)|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound process
76059971|NCT04144582|Drug|Sintilimab Combined With Docetaxel Monotherapy|Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
76059972|NCT01611974|Drug|Maribavir|Tablet for oral administration
75447605|NCT04749186|Device|Compuflo Epidural Training Instrument|The intervention will consist of a Structured Didactic Model. It will include the following: two standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
75447606|NCT04748497|Other|Standardization of evaluation and follow-up|"Standardization of evaluation and clinical and sportive follow-up of athletes.~Made-to-measure technical supports will be tested regarding the Paralympic regulations."
75447607|NCT04748458|Device|Conical tapered stem|Implantation of conical tapered stem
75447608|NCT04739956|Other|The Hospital and Anxiety Depression Scale|Patients and partners will be asked to complete the questionnaire at three time points: 1) On classification of PUL at time zero once blood is taken, 2) at the 48-hour time point after blood is taken (if 48 hour bloods are required for the patient); and 3) after definitive diagnosis and management.
76059973|NCT04147078|Biological|DC vaccine subcutaneous administration|subcutaneous administration
75447609|NCT04739956|Other|Point of care testing (POCT)|Patients will have 1ml sample of blood taken for POCT at two time points: 1) On classification of PUL at time zero at the same time as when routine blood samples taken; and 2) at the 48-hour time point at the same time as when routine blood samples are taken (if 48 hour bloods are required).
75447610|NCT04736875|Diagnostic Test|Doppler ultrasound study|Transcutaneous Doppler ultrasound (DUS) study was performed at the mid brachial artery to assess diameter, VF and RI, and at the mid segment of the efferent vein to assess the diameter and wall thickness.
75463015|NCT01870687|Drug|20mg VAC BNO 1095 FCT|
75597207|NCT00596843|Behavioral|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
75597208|NCT00622973|Other|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
75597209|NCT00622973|Other|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
75597210|NCT04326647|Other|Kinesiotaping|We used kinesiotaping in gastrocnemius and lumbar back
75889427|NCT04917146|Other|Self-administered questionnaires for relatives (caregivers=CG)|"Sociodemographic and medical information for the patient and the CG. SF36 questionnaire for the quality of life (physical, mental) of family CGs This assessment will be supplemented by specific questions relating to: physical health, emotional state, personal and leisure activities of the caregiver.~The CG's knowledge and representations of the disease : questions adapted from the Brief-IPQ disease representation questionnaire.~Questions will also focus on the caregiver's reactions to the patient's illness.~We have constructed a questionnaire to assess the main areas of aid in the context of SSc: emotional, domestic help, administrative, medical, for trave (16 items and an open question).~The CG Reaction Assessment-CRA questionnaire to assess the positive and negative dimensions of helping (24 items). It assesses five dimensions: self-esteem, financial impact, impact on health, impact on time and lack of family support.~The reason for the assistance provided."
75889428|NCT03755973|Drug|CFA|Long-acting exogenous ovarian stimulation
75889429|NCT03755973|Drug|rFSH|Daily rFSH
75889430|NCT03755973|Procedure|Fixed daily rFSH dosing protocol of 200-300 IU|The dose of daily rFSH is fixed at 200 or 300 IU
76059974|NCT04146688|Other|Music Balance Board|The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
76059975|NCT01848938|Behavioral|Smartphone treatment with PFMT|A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
76059976|NCT04146454|Other|Smartphone-based balance exercises|A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
75597211|NCT04326647|Other|Exercise|Exercises about balance and gait
75597212|NCT00596999|Procedure|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
75597213|NCT00597077|Other|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
76059977|NCT04149418|Other|Yogurt|Low-fat flavored yogurt
75597214|NCT00597077|Other|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
76059978|NCT04149418|Other|Control food|Low-fat flavored soy pudding
76059979|NCT01871870|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
76059980|NCT02080780|Drug|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
76059981|NCT02080780|Drug|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 & Day 8 to the perianal area (~2.5 cm [1 inch]; ~8.5 mg)
75889431|NCT03755973|Procedure|Step-down daily rFSH dose|The dose of daily rFSH is progressively reduced
75889432|NCT02055534|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
76059982|NCT01871558|Drug|Vildagliptin|50 mg b.i.d
76059983|NCT01871558|Drug|Metformin|metformin is to be kept unchanged
76059984|NCT01871558|Drug|sulfonylurea (SU)|
76059985|NCT01871558|Drug|Basal Insulin|
76059986|NCT01711359|Drug|Baricitinib|Administered orally
76059987|NCT01711359|Drug|Methotrexate|Administered orally
76059988|NCT01711359|Drug|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
76059989|NCT01711359|Drug|MTX Placebo|MTX placebo administered orally once weekly.
76059990|NCT01711359|Drug|Folic Acid|Administered orally every day
76059991|NCT04149496|Combination Product|in vitro maturation of oocytes|Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
75597215|NCT04326803|Biological|Hepatitis B recombinant vaccine|Administration of 20 mcg of hepatitis B recombinant vaccine im at month 0, 1 and 2
75597216|NCT02892227|Procedure|Transmitral flow estimation|Estimation of the transmitral flow of the inferior vena cava and its variations
75597217|NCT00597233|Drug|insulin aspart|
75597218|NCT00597233|Drug|soluble human insulin|
75597219|NCT00597233|Drug|insulin NPH|
75597220|NCT00597311|Radiation|radiotherapy|"Short term radiotherapy 5x5 Gy during 5 days~Chemoradiotherapy 50 Gy + 5Fu/Lv"
75597221|NCT01064401|Biological|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
75597222|NCT01064401|Drug|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
75597223|NCT01064401|Biological|Interferon beta-1a|Interferon beta-1a for intramuscular injection
75597224|NCT01064401|Drug|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
76059992|NCT04140136|Dietary Supplement|Tocotrienols|Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
76059993|NCT04140136|Dietary Supplement|Placebo|The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
75889433|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
75889434|NCT03681717|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
76059994|NCT04146532|Drug|Aspirin 500 MG|Single 500mg aspirin capsule.
75889435|NCT03623451|Drug|Chinese Medicine Formula|Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
75889436|NCT02056938|Drug|Anti-Thymocyte Globulins treatment|
75447611|NCT04735315|Other|Preterm birth|The study compares young adult subjects born premature (< 29 weeks) versus term > 37-41 weeks)
75447612|NCT04734444|Device|SonoClear ACF|The SonoClear ACF is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
75447613|NCT04726124|Device|Microwave Ablation Therapeutic Apparatus|The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.
75447614|NCT04725539|Procedure|hypoxic exposure|"Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4*4min (FiO2 = 12%) and 3*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5*5min (FiO2 = 10%) and 4*3 min (FiO2 = 21%)~one night at 1900m"
75447615|NCT04722744|Procedure|screwmented metal frameworks|Intervention group: in which the edentulous area will be restored with 3-implant, screwmented CAD/CAM frameworks constructed based on planned implant positions
75447616|NCT04722679|Drug|Non-VKA Oral Anticoagulants (NOAC)|Follow clinical practice.
75597225|NCT00597389|Drug|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
75889437|NCT02056938|Drug|Basiliximab treatment|
76059995|NCT04146532|Drug|Placebo|Single 500mg placebo capsule.
76059996|NCT03929224|Drug|Medicinal honey|Treat healing surgical site with medicinal honey
76059997|NCT03929224|Drug|Bacitracin|Treat healing surgical site with bacitracin
76059998|NCT04146610|Drug|an antibody drug conjugate|Multiple dose grouping
76059999|NCT02985034|Procedure|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
76060000|NCT03925870|Drug|KN046|Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
75447617|NCT04721730|Behavioral|PLH-YC|There will be 5 weekly 2-hour sessions. The optimised PLH-YC uses a participatory, non-didactic approach to engage parents. Parents learn positive parenting skills and how to manage child behaviour problems. The program includes Session 1: One-on-One Time and Say What You See, Session 2: Praise and Rewards, Session 3: Instructions, Redirect, Rules, and Routines, Session 4: Ignore and Consequences, Session 5: Reflection and Moving On. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
75463016|NCT01870687|Drug|Placebo|
76060001|NCT04146376|Other|Use of a postpartum diary and additional blood draws|"A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
76060002|NCT04146376|Drug|VWF replacement therapy with Wilate|This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are <100% in the third trimester of pregnancy
76060003|NCT04146376|Drug|Tranexamic acid|This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
76060004|NCT04146376|Other|Use of a postpartum diary and additional blood draws.|"A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
76060005|NCT01710657|Drug|Lacosamide 50 mg|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated tablet~Concentration: 50 mg~Route of Administration: Oral use"
76060006|NCT01710657|Drug|Lacosamide 100 mg|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated tablet~Concentration: 100 mg~Route of Administration: Oral use"
76060007|NCT01710657|Drug|Placebo|Matching oral Placebo tablets twice daily for 16 weeks.
76060008|NCT04142710|Device|Telemedicine: tablet and possibly tools to perform measurements|Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
75889438|NCT02059200|Behavioral|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
75889439|NCT03536000|Diagnostic Test|Fetal echocardiography using the aCMQ-Strain method|Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
75889440|NCT02191670|Drug|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
75889441|NCT02188082|Drug|IvabRadine hemisulfate Sustained-release Tablets|
75889442|NCT02188082|Drug|placebo|
75889443|NCT02057094|Dietary Supplement|Protein, High-Protein, and Control|
75889444|NCT02917941|Drug|Ixazomib|Ixazomib capsules
76060009|NCT04765930|Other|Q-switched nd:YAG laser toning|Q-switched nd:YAG laser toning for melasma.
76060010|NCT05582044|Other|Lower-body Negative Pressure (-25 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
75597226|NCT02892071|Drug|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
75889445|NCT02917941|Drug|Lenalidomide|Lenalidomide capsules
75889446|NCT02917941|Drug|Dexamethasone|Dexamethasone Tablets
75889447|NCT02055690|Drug|Pazopanib|Tyrosine Kinase Inhibitor
75889448|NCT02055690|Drug|Fosbretabulin|Vascular Disrupting Agent
75889449|NCT04301258|Other|Articular cartilage repair|Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
75889450|NCT03684135|Other|Cosmetics|"Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource"
75889451|NCT02038608|Device|PET|
75889452|NCT02193932|Other|EEG Triggered fMRI using Micro Maglink|
75889453|NCT03741699|Drug|Pre-treatment with rLH (Luveris 75 IU),|Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
75889454|NCT03535064|Other|Hand Hygiene Workshop|Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
75889455|NCT02055846|Procedure|Realisation of blood sample, urinary sample and tumor biopsy|
76060011|NCT05582044|Other|Lower-body Negative Pressure (-15 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
76060012|NCT05582044|Other|Lower-body Neutral Pressure (0 mmHg)|In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
76060013|NCT03906682|Behavioral|RAP Club|RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
75889456|NCT03733041|Device|rTMS|This group will receive rTMS treatment
75889457|NCT03733041|Device|Sham|This group will receive sham treatment
75889458|NCT03733041|Other|No intervention|This group will receive no intervention
75889459|NCT02191748|Procedure|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
75889460|NCT02191748|Drug|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
76060014|NCT03906682|Behavioral|Healthy Topics|Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
76060015|NCT03021772|Drug|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
76060016|NCT03021772|Drug|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
76060017|NCT04149886|Procedure|cardiac ganglion plexus ablation(cardioneuroablation)|Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
76060018|NCT04149886|Device|Permanent pacemaker implantation|DDD permanent pacemaker will be implanted in the paticipants.
75447618|NCT04721730|Behavioral|Lecture|Lecture on parenting. This is a 26-slides power-point presentation that was developed by the University of Bremen for the purpose of this study. Duration: 1 to 1.5 hours. Content: 1) Stages of child development; (2) Potential risk factors for child emotional or behaviour problems; (3) Resources and protective factors; (4) Tips: What parents can do to promote children's development.
75447619|NCT04709042|Procedure|Chordal tension measurement|"The chordal tension measurement will be performed during surgery. The neochordae are connected to the measuring device through crocodile clips (e.g. machine-patient interface).We start to apply traction on the chordae that is in the center of the flailing area thanks to a millimeter screw and under TEE control. After obtaining a stable tension (plateau value), the other chordae are then tracked, one at a time, with an individual screw. When we achieve an equivalent tension on all chordae, a traction on all chordae is applied thanks to the principal screw under TEE control until obtaining a perfect coaptation. When the correction is optimal (good echocardiographic result, chordal tension low and equally spread on each chordae), the measurements are then stopped, and the chordae are fixed at the apex of the left ventricle at the optimal length."
75447620|NCT04709042|Other|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
75447621|NCT04703010|Device|Electroencephalography-Near infrared spectroscopy|Brain activity will be measured using 128-channel EEG and 2 channel NIRS during tactile stimulation (15 minutes sequence of vibrations) while the newborn is asleep.
75447622|NCT04703010|Device|Magnetic resonance imaging|Structural (T1-T2), siffusion tensor imaging and blood-oxygen level dependant signal will be acquired in a subset of 40 subjects (20 minutes while asleep)
75447623|NCT04703010|Behavioral|Psychometric testing|Cognitive evaluation at age 2 (Parental questionnaires on sensory profiles, executive functions and neurodevelopmental disorders screening, child tests : movement assessment battery, Laby, Head-toes-shoulders-knees)
75597227|NCT02892071|Device|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
75597228|NCT02892071|Device|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
76060019|NCT05584774|Procedure|PELDAN|percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
76060020|NCT05581654|Procedure|Salpingectomy|Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
76060021|NCT05581576|Drug|Pitolisant|Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
76060022|NCT04149262|Drug|Fiasp|Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
76060023|NCT04149262|Drug|Novorapid|Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
76060024|NCT04149262|Device|640G pump|MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
75447624|NCT04698096|Other|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
75447625|NCT04698096|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
76060025|NCT03647800|Biological|APVO436|APVO436
75447626|NCT04698096|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
75741512|NCT02553551|Drug|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
75741513|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
75447627|NCT04696380|Drug|Nicotine|Participants will sample high vs low nicotine.
75447628|NCT04696380|Device|JUUL e-cigarette|Participants will sample preferred vs non-preferred JUUL flavors.
75447629|NCT04695366|Other|No intervention|No intervention
75447630|NCT04694196|Device|Dentulous subjects|Determine the occlusal plane using CN in anterior border of ramus
75447631|NCT04681859|Device|High Flow Nasal Oxygen (HFNO) treatment|Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.
75447632|NCT04681859|Device|Continuous Positive Airway Pressure (CPAP) therapy using OxyJet|Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.
75447633|NCT04677517|Device|Modification of active microphone positioning|"Patient will pass the experimental tests described above with 3 different active microphone positions :~on the cochlear implant processor;~on the antenna~in front of the external ear canal~Patient will pass the tests 1 week after each microphone position change, so that they can get used to the new position in their everyday life."
75447634|NCT04677517|Behavioral|SPHERE protocol|"Patient's 3D localization in noise will be assessed thnks to a 3D localization system called SPHERE based on virtual reality.~Data from spatial hearing perception will be recorded in three-dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D (the 3d-D value), hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure."
76060026|NCT04145908|Procedure|midline mesh reinforcement|augmentation of midline closure by nonabsorbsble mesh
75447635|NCT04677517|Behavioral|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value
75597229|NCT00597467|Device|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
75597230|NCT00597467|Device|Acuvue 2 Soft Contact Lens|Control device
75597231|NCT01306617|Drug|ABT-450|tablets
75741514|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
75741515|NCT00803621|Other|Toxoplasma PCR assay|Toxoplasma PCR assay
75741516|NCT01095913|Drug|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
76060027|NCT05581420|Drug|Ferrous fumarate|Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.
76060028|NCT05581420|Drug|MonoFer|Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
75597232|NCT01306617|Drug|ABT-333|tablets
75597233|NCT01306617|Drug|ribavirin|tablets
75597234|NCT01306617|Drug|ritonavir|capsules
75597235|NCT00597623|Other|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
75741517|NCT00803699|Dietary Supplement|placebo|daily placebo capsules for 12 months
75597236|NCT00597623|Other|Placebo|syringes under cutaneous vol = 8 ml
75597237|NCT00597779|Device|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
75741518|NCT00803699|Dietary Supplement|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
75889461|NCT03676881|Device|Computerized cognitive battery: Cognigram (CG)|is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
76060029|NCT05581342|Diagnostic Test|Punch biopsy (3mm)|In case of suspicion of recurrence or a voluntary control biopsy; a punch biopsy (3mm) was obtained conform regular care.
76060030|NCT05581264|Behavioral|Diabetes Self-Management Education Program|diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
75741519|NCT03952741|Behavioral|Physical Therapy|
75741520|NCT00798785|Drug|ATG-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver."
76060031|NCT03022474|Behavioral|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
76060032|NCT03021070|Other|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
76060033|NCT04149340|Drug|Cataract surgery|Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
76060034|NCT03021226|Behavioral|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
76060035|NCT03021226|Behavioral|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
76060036|NCT03021226|Behavioral|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
75447636|NCT04677517|Behavioral|Quality of life questionnaire|The Speech, Spatial and Qualities of Hearing Scale short-form with 15 items (SSQ15) questionnaire is performed in order to evaluate auditory abilities of patients in different daily life situations.
75447637|NCT04677517|Behavioral|Likert scale|This subjective evaluation will be added to evaluate difficulties and self-confidence felt by participants during the SPHERE protocol and the French Matrix Test.
75447638|NCT04677348|Procedure|Pericapsular nerve group (PENG) block|ultrasound-guided PENG block with 0.3% ropivacaine 20cc
75447639|NCT04677348|Procedure|Fascia iliaca compartment block (FICB)|ultrasound-guided suprainguinal FICB with 0.3% ropivacaine 30cc
75447640|NCT04672772|Drug|Cetuximab|Weekly cetuximab at starting dose, that could be switched to biweekly
75447641|NCT04672772|Drug|Paclitaxel|Paclitaxel at starting dose of 80 mg/m2
75447642|NCT04671082|Drug|Tolperisone Hydrochloride|TID
75447643|NCT04671082|Drug|Placebo|TID
75447644|NCT04669587|Drug|ZB716|Pharmaceutical form: capsule Route of administration: oral
75447645|NCT04669587|Drug|Palbociclib|Pharmaceutical form: capsule Route of administration: oral
75447646|NCT04668092|Other|Functional dry needling|functional dry needling applied to hamstring for 1 minute and post interventional data collected
75447647|NCT04662359|Diagnostic Test|Ultrasound Assessment|Patients will undergo an ultrasound scan to assess the severity of their rheumatoid arthritis.
75597238|NCT04326569|Other|Blood sample|Blood sample to quantify copeptin
75597239|NCT02874625|Procedure|Dental restoration|
75597240|NCT02875795|Procedure|automatic speech processing tool|
75597241|NCT00597857|Drug|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
75597242|NCT00597857|Drug|placebo|receipt of a placebo pill for 16 days
75597243|NCT00627133|Drug|levetiracetam|2 gram iv load, 500mg bid
75741521|NCT00798785|Drug|ATG-Rituximab-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
75889462|NCT03676881|Device|The NeuroCatch™ Platform (NCP)|the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
76060037|NCT02984956|Device|pleth variability index|
76060038|NCT04148794|Behavioral|echo-assisted advanced life support|"Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes"
75769602|NCT01153906|Other|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
76060039|NCT05580952|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
76060040|NCT03904498|Drug|Tolcapone|Tolcapone 100 mg tablets
76060041|NCT03904498|Drug|Placebo|Placebo tablets
76060042|NCT04405960|Drug|Alfacalcidol 1 MCG Oral Capsule|The subjects in the intervention group were given 1 µg oral capsule alphacalcidol once daily Subjects in the control group were given placebo once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
76060043|NCT04405960|Drug|Sugar pill|The subjects in the control group were given placebo containing simple sugar oral capsule once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
75597244|NCT01306305|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
75597245|NCT00598013|Drug|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
75597246|NCT04303429|Drug|FOLFOX/XELOX/Capecitabine|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
75889463|NCT02191826|Drug|SOM0226|Oral
75597247|NCT00598091|Drug|gemcitabine|1000mg/m2, Days 1, 8, 15
75597248|NCT00598091|Drug|dasatinib|50mg, PO, QD
76060044|NCT04405804|Drug|Ivabradine 5Mg Tab|"Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight < 40 kg 2.5 mg/day in patients between 3-18 years with weight > 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight < 40 kg 15 mg/day in patients between 3-18 years, weight > 40 kg"
76060045|NCT04145206|Behavioral|Flamenco dance|evaluation of ankle injuries in the flamenco dancers
75447648|NCT04661592|Device|NeuroCatch Platform|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
75447649|NCT04661410|Behavioral|Reward Re-Training|A brief, 10-session group-based behavioral treatment that is designed to indirectly change binge eating by directly focusing on building a more rewarding life. RRT hypothesizes that reductions in binge eating will occur as life becomes more rewarding because individuals will no longer need to rely on binge eating as a primary source of momentary reward. RRT notes that in order to live a satisfying life, individuals need to experience an adequate amount of reward in two overlapping yet distinguishable domains: momentary reward (i.e., the active experience of pleasure in the moment) and sustained reward (i.e., a deeper and more long-lasting sense of fulfillment and meaning that arises from building a personally valued life). A key aspect of RRT is an emphasize on building lasting and meaningful social relationships given the clear evidence that social connectedness can enhance both momentary reward and sustained reward.
75447650|NCT04661410|Behavioral|Supportive Therapy|A brief, 10-session group-based treatment that is designed to instill hope and optimism and to increase social connection and support through a non-directive group leader that allows the patients to determine the focus of each session. The group leader will act as an empathetic provider by using reflective listening, eliciting and validating affect, and offering empathic comments.
75597249|NCT00598091|Drug|gemcitabine|1000mg/m2, days 1, 8, 15
76060046|NCT04145128|Drug|AG881|AG-881 tablets.
76060047|NCT03945604|Drug|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
76060048|NCT05580484|Procedure|Second surgery|The primary outcomes were adhesion severity and adhesion area in the lower ab-dominal cavity, as determined through direct visual observation of a laparotomy wound or laparoscopic observation from stoma closure wound.
76060049|NCT03944356|Drug|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
76060050|NCT04148716|Procedure|additional biopsies|additional biopsies during a fibroscopy planned in the care
76060051|NCT03582436|Procedure|Kidney transplantation|"For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis"
75597250|NCT00598091|Drug|dasatinib|50mg, PO, BID
75597251|NCT00623415|Drug|Flupirtine|300 mg daily (divided in two doses)
75597252|NCT00623415|Drug|Placebo|twice daily
75597253|NCT02874703|Other|Cardiac MRI/MRS|
75597254|NCT04326725|Drug|Plaquenil 200Mg Tablet|health workers under risk who took this medications
75597255|NCT01038427|Drug|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
75597256|NCT01038427|Drug|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
76060052|NCT01701063|Drug|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
76060053|NCT01701063|Drug|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
76060054|NCT01701063|Drug|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
75597257|NCT01038427|Drug|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
75597258|NCT00598169|Biological|rituximab|375mg/m2 on Day 1
75597259|NCT00598169|Drug|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
75769603|NCT01260376|Drug|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
75741522|NCT00798785|Drug|ATG-basilixumab-MMF-TAC|"First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
76060055|NCT04406116|Device|Microwave coagulation using HS1 Instrument|Microwave therapy at 5.8 GHz
76060056|NCT04145050|Other|Carbohydrate dosing|The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.
76060057|NCT03941314|Device|Supera® Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
75447651|NCT04659941|Biological|BCG vaccine|Using aseptic methods, 1 mL of Sterile Water for Injection, is added to one vial of vaccine. Gently swirl the vial until a homogenous suspension is obtained. Avoid forceful agitation which may cause clumping of the mycobacteria. Drop the immunizing dose of 0.1 mL of BCG VACCINE from the syringe and needle onto the cleansed surface of the skin.
75447652|NCT04659941|Biological|0.9% sodium chloride (NaCl) saline solution|A 0.1 ml of 0.9% NaCl saline solution applied intradermally in the lower insertion of the deltoid muscle of the right arm will be used as placebo, except contraindications or impossibilities.
75447653|NCT04658953|Other|Ultrasound guided infiltration|In the patient in prone position, an infiltration guided by ultrasound will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
75447654|NCT04658953|Other|Fluoroscopy guided infiltration|In the patient in prone position, an infiltration guided by fluoroscopy will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
75447655|NCT04658823|Drug|HOV-12020 (Palm tocotrienols complex)|Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily
75447656|NCT04658823|Drug|Placebo|Oral Softgel capsule containing soybean oil; 1 capsule twice daily
75447657|NCT04657380|Behavioral|PLAN-e-PSY mobile application|"The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops"
75597260|NCT00598169|Drug|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x [creatinine clearance + 25]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
75597261|NCT00598169|Drug|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
75597262|NCT00598169|Drug|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
75597263|NCT00598169|Drug|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
75889464|NCT01333956|Drug|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
75889465|NCT01333956|Drug|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
76060058|NCT03941314|Device|EverFlex™ Self-Expanding Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
76060059|NCT04144816|Other|Not applicable (no intervention)|Not applicable (no intervention)
75447658|NCT04657380|Behavioral|Control Group|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
75597264|NCT00598169|Genetic|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
75741523|NCT00798785|Procedure|omentum|"Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels >= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum."
75741524|NCT01095991|Drug|AZD1656|Oral tablet bd,
75447659|NCT04655885|Behavioral|Optimization of cardiac flow by base water-electrolyte supply|optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
75741525|NCT01095991|Drug|Sitagliptin|Oral tablet od
75889466|NCT01333956|Drug|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
75889467|NCT01333956|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
76060060|NCT04144660|Device|Extracorporeal Membrane Oxygenation|Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
76060061|NCT01700985|Drug|122-0551|Applied twice daily for two weeks
76060062|NCT01700985|Drug|Vehicle|Applied twice daily for two weeks
76060063|NCT04148404|Procedure|Normothermic group|"Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP)."
76060064|NCT04144426|Behavioral|Normal diet|Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
75447660|NCT04655885|Behavioral|Control arm|increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
75447661|NCT04649515|Biological|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 1,500 mg of TY027
75447662|NCT04649515|Biological|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 2,000 mg of TY027
75447663|NCT04649515|Other|0.9% saline|Placebo
75447664|NCT04648371|Other|Cognitive Remediation and Transcranial Direct Current Stimulation|"Cognitive Remediation (CR) is a well-established psychosocial group intervention that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.~Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation method that can be safely administered to awake outpatients. It does not require general anesthesia or surgical implantation. It utilizes low intensity electrical current (e.g., 2 mA) either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode."
76060065|NCT04144426|Behavioral|Modified diet|Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
76060066|NCT03920722|Drug|Rituximab|1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
76060067|NCT03920722|Drug|placebo|Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
75447665|NCT04641221|Behavioral|Weekly Yoga Classes|All participants are invited to attend weekly yoga classes.
75447666|NCT04640818|Drug|Cladribine Oral Tablet|Treatment according to the label and medical prescription
75597265|NCT00598169|Genetic|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
75597266|NCT00598247|Drug|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
75597267|NCT00598325|Biological|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
75597268|NCT00598403|Drug|cefditoren pivoxil|400 mg, oral, single dose during 3 days
75597269|NCT00598403|Drug|Ciprofloxacin|250 mg, oral, twice a day for 3 days
75597270|NCT00598637|Device|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
75741526|NCT00798863|Procedure|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
75741527|NCT00798941|Behavioral|mouth care|mouth spray, mouth swab, moisturizer
75741528|NCT00798941|Behavioral|pain intervention|music and massage
76060068|NCT05580094|Other|general anesthesia only.|induction of general anesthesia by propofol and maintenance sevoflurane.
76060069|NCT05580094|Other|general anesthesia plus supraclavicular block.|induction of general anesthesia by propofol and maintenance sevoflurane then the patients will receive the supraclavicular block with bupivacaine 0.5 ml per kg.
76060070|NCT05586100|Drug|Toripalimab+cetuximab|"Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing <50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
75447667|NCT04640818|Drug|Rituximab|Treatment according to the label and medical prescription
75447668|NCT04640818|Drug|Ocrelizumab|Treatment according to the label and medical prescription
75447669|NCT04635449|Other|Age-specific information booklet and targeted telephone call|age-specific information, complemented by a follow-up targeted telephone call to reduce psychological sequelae in the child and their parents after PICU discharge.
75447670|NCT04625777|Behavioral|Mindfulness Based Stress Reduction|"Mindfulness Based Stress Reduction (MBSR) teaches several different kinds of meditation. MBSR is offered as an online course through Duke Integrative Medicine and is based on the national model first developed by Jon Kabat-Zinn at the University of Massachusetts. It includes exercises in awareness of breath, body scans, walking meditation, choiceless open awareness, Loving Kindness Meditation, and bringing awareness to the present moment. The MBSR Distance Learning course consists of 8 weekly sessions via video conference and includes meditation instruction, periods of guided practice, and group discussion."
75597271|NCT00598637|Device|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
75597272|NCT00598715|Device|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
75597273|NCT00598715|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
75597274|NCT00598793|Drug|biphasic insulin aspart|
75597275|NCT00598793|Drug|insulin glargine|
75597276|NCT00598793|Drug|metformin|
76060071|NCT05587270|Other|Web based surveys|A web-based survey will explain the purpose, aims, and ethical rights, as well as how to complete the questionnaire online. Further, information about, and an invitation to participate in the DXA-scan will be included with this information. Upon electronic consent by both parent and athlete (or just athlete if of consenting age (15 y o a)), access to the multi-section questionnaire will be granted. Contact details of the researchers will be available in case of difficulties comprehending the questions. Following completion, the participants' data will be sent to a secure database for analysis. Participants will be ensured of the confidentiality of the study and will be free to withdraw from the study. Parents will also be asked to provide their consent if participants age is under 14.
76060072|NCT05587270|Radiation|DXA|All participants will be invited to complete a DXA scan at baseline. DXA is to date the most reliable way of examining the long-term physical consequences of RED-S.
75741529|NCT00803855|Drug|AZD1446|oral, single dose
76060073|NCT04148248|Other|No intervention|There is no intervention for this study
76060074|NCT05585008|Device|two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))|retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
76060075|NCT05584852|Other||no intervention
75447671|NCT04625777|Behavioral|Daily Examen spiritual practice|"The Daily Examen is a simple but powerful prayer used by Jesuits every day. It takes only 10-15 minutes and can be used to reflect on positive emotions, move past negative emotions, and align one's work with God's work. The Examen directs the person praying to focus on a five-step routine:~Become aware of God's presence;~Give thanks to God for everything in your life;~Review the events of the day guided by the Holy Spirit;~Look at what went well or wrong in the past day; if at fault, ask God for forgiveness; and~Look toward tomorrow - what one thing should you do? Listen to what God is telling you."
76060076|NCT05585086|Other|Peppermint Oil Inhalation|Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
76060077|NCT03904030|Other|Rehabilitation with or without Anti-Gravity Treadmill|The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
75447672|NCT04625777|Behavioral|Stress inoculation combination|This intervention includes a combination of stress inoculation and general stress reduction activities focused on physiology, with exercises that bypass the brain and work directly on the body to mitigate the symptoms of stress. This system is based on Stress Inoculation Training, which uses breathing to prepare people in advance for stressful episodes and recovery skills for following such episodes. The techniques include a variety of breathing, blood flow, and tension control methods, as well as ways to conduct deep tissue massage on oneself to release muscle tension. The awareness aspect involves understanding stress biology and learning to spot the symptoms of stress in oneself and others.
75597277|NCT00598793|Drug|pioglitazone|
75597278|NCT04325945|Device|Low level laser therapy|808nm low level laser therapy on acupuncture points
75597279|NCT00599105|Procedure|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
75597280|NCT01037413|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
75741530|NCT00794807|Drug|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
75741531|NCT00794885|Drug|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
75741532|NCT00794885|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
75597281|NCT01037413|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
75741533|NCT00803933|Drug|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
75889468|NCT03623607|Other|Diabetes Survival Skills Education|Application of human factors and education principles to refine and optimize an DSSE program for delivery to inpatients with type 2 diabetes (D2Go - IN) using a table-based e-learning platform ; utilization of implementation science to inform design of implementation processes for delivery within nursing unit workflow; establishment of a D2Go program toolkit; and evaluation of the feasibility and preliminary impact of the program when delivered by nursing unit staff on medical-surgical units (MSUs) to adults with type 2 diabetes. Barriers and facilitators of the D2Go - Inpatient program's reach, effectiveness, adoption, implementation and maintenance (RE-AIM)(31) were explored
75447673|NCT04624087|Behavioral|food-specific go/no-go computerized training|Participants will perform the computerized food specific go/no-go training a designated number of times over a four week duration (frequency varies by group). Each training session will last approximately 10 minutes and occur on different days of the week.
75447674|NCT04624087|Behavioral|nonfood-specific go/no-go computerized training|Participants will perform the computerized general go/no-go training 1 time per week over a four week duration. Each training session will last approximately 10 minutes and occur on different days of the week.
75741534|NCT00803933|Drug|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
75889469|NCT02055924|Drug|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
75447675|NCT04622332|Drug|SIR1-365|Route of administration: oral
75889470|NCT02191904|Other|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
75447676|NCT04622332|Drug|Matching Placebo|Route of administration: oral
75889471|NCT02188238|Other|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
75889472|NCT02057328|Drug|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
75447677|NCT04616027|Drug|PF-06882961 20 mg|PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
75597282|NCT00599183|Other|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
75597283|NCT01326845|Drug|Deferasirox|
75597284|NCT02873845|Other|Preliminary validation of the COBQoL questionnaire|
75889473|NCT02057328|Drug|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
75889474|NCT02188316|Device|Jumbo forceps|comparison of different polypectomy devices
75889475|NCT02188316|Device|Hot biopsy forceps|comparison of different polypectomy devices
75597285|NCT01062763|Drug|spironolactone|25 to 50 mg once daily
75597286|NCT01062763|Drug|placebo|addition of placebo 1 to 2 tablets daily
75597287|NCT00599261|Procedure|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
75597288|NCT00599417|Drug|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
75597289|NCT00599417|Drug|placebo|placebo controlled
75597290|NCT00599573|Drug|ondansetron|Ondansetron 4mg BID for six weeks
75741535|NCT02553707|Drug|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
75741536|NCT00804011|Other|ATC|Automatic tube compensation
75741537|NCT00804011|Other|PSV|Pressure support ventilation
75597291|NCT00599651|Device|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
76060078|NCT03902938|Biological|Biodesign Otologic graft|Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.
75597292|NCT00599651|Other|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
75597293|NCT01048099|Procedure|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
75597294|NCT01048099|Drug|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
75597295|NCT01048099|Drug|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
75597296|NCT00599807|Dietary Supplement|Vitamin D3 (cholecalciferol)|the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
75597297|NCT00599885|Drug|telmisartan|telmisartan 40-80mg once per day for 8 months
75741538|NCT00799175|Drug|ropivacaine, ketorolac and epinephrine|In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
75741539|NCT00799175|Drug|saline|In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
75741540|NCT00799331|Drug|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
76060079|NCT03902938|Other|Autograft temporalis fascia|Patient's mastoid cavity will be covered with covered with autograft.
76060080|NCT05583136|Device|Parietal tACS combined with visuo-attentional training|Parietal tACS combined with visuo-attentional training
76060081|NCT05583136|Device|Sham (placebo) tACS combined with visuo-attentional training|Sham (placebo) tACS combined with visuo-attentional training
76060082|NCT05583136|Device|Sham (placebo) tACS combined with phonics training|Sham (placebo) tACS combined with phonics training
75597298|NCT00599885|Drug|valsartan|valsartan 80-160mg once per day for 8 months
76060083|NCT01710501|Drug|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
76060084|NCT01710501|Biological|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
75597299|NCT00599963|Drug|paricalcitol|paricalcitol 1 mg/day
75597300|NCT01303965|Drug|Sirolimus|Start on Day -3 and continue for 1 year
75597301|NCT01303965|Drug|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
75597302|NCT01303965|Drug|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
75597303|NCT00600041|Drug|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
75597304|NCT00600041|Drug|Placebo|Identical infusion manner like experimental arm
75597305|NCT01045993|Device|Heat Device|8-Hour Heatwrap
75597306|NCT01045993|Device|Sham Device|Inactive wrap worn for 8 hours
75597307|NCT01045993|Drug|marketed analgesic|2 x 200 mg ibuprofen tablets
76060085|NCT01710501|Drug|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
75447678|NCT04614506|Device|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
75447679|NCT04614506|Device|Electroencephalogram (EEG)|These will be an ambulatory EEG recordings that span 24 hours and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
75597308|NCT01045993|Drug|Placebo|2 x placebo tablets
75447680|NCT04611100|Device|ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)|Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent
75597309|NCT00600197|Behavioral|back school|A kind of educational program for low back pain
75597310|NCT02890563|Device|Class II Compression Stockings|
75741541|NCT00799331|Drug|placebo|Oral suspension.
75741542|NCT00804089|Procedure|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
75741543|NCT00804089|Procedure|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
75741544|NCT00804089|Procedure|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
75741545|NCT00656513|Drug|Pilocarpine|5mg by mouth 3 times a day for 12 weeks
75741546|NCT00656513|Procedure|ALTENS|Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
75447681|NCT04609657|Other|Flavored carbonated soft drink (CSD)|Beverage
75741547|NCT04017221|Drug|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
75741548|NCT04017221|Drug|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
75741549|NCT04017221|Drug|Other treatment combinations|Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
75741550|NCT00804245|Procedure|needle biopsy|Biopsy of positive findings found on CT scan
75889476|NCT02057484|Drug|Tacrolimus|oral
75889477|NCT02191982|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
76060086|NCT01710501|Drug|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
76060087|NCT05583058|Other|Hormone Overdose and Misuse|This is an observational study. Hormone Overdose and Misuse is an exposure.
76060088|NCT04144270|Other|Evaluation of muscle mass and muscle function|Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
76060089|NCT04144114|Dietary Supplement|ProHydrolase®|Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
75447682|NCT04608916|Procedure|Using surgical diathermy to make skin incision|Using surgical diathermy to make skin incision during shoulder arthroplasty
75447683|NCT04608916|Procedure|Using scalpel blade to make skin incision|Using scaple blade to make skin incision during shoulder arthroplasty
75447684|NCT04607876|Other|Technological Facilitator|See Enhanced Intervention Arm for full description.
75447685|NCT04607876|Other|Standard of Care|Risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
75597311|NCT04325867|Other|Tele-medicine platform|Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).
75597312|NCT05643963|Other|Dietary regimens|Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.
75741551|NCT00804245|Drug|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
75447686|NCT04606784|Biological|Ampion|Ampion, nebulized for inhalation
75447687|NCT04606784|Other|Standard of Care|Standard of Care
75741552|NCT00805883|Procedure|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
75741553|NCT00804323|Procedure|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
75741554|NCT04045847|Biological|CD147-CART|Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
75741555|NCT00804401|Drug|Naproxen Tablets, 500 mg|
75741556|NCT00804479|Other|No intervention.|
75741557|NCT00655889|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of biopsy from palate~Papillary priming procedure~Seven injection treatments to target sites~Performance of study assessments (investigator and subject)"
75741558|NCT00806039|Other|Early Renal Involvement|Renal Consultation
75741559|NCT00804791|Other|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
75741560|NCT00804791|Other|Unisol 4 Saline Solution|saline solution for irrigating the cornea
75889478|NCT02192060|Other|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
75741561|NCT02553239|Device|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
75741562|NCT00806117|Radiation|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks~Lateral: 2 cm lateral to the bony margin of the pelvis~Superior: Between L5 and S1~Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
75741563|NCT00806117|Other|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
75741564|NCT00806117|Other|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135~175mg/m2 over 3 hours Cisplatin 60~75mg/m2
75741565|NCT00804869|Device|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
75889479|NCT02192060|Other|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
75889480|NCT02188394|Drug|Anesthetic blockades with bupivacaine|
75741566|NCT00804869|Device|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
75889481|NCT02188394|Drug|Isotonic saline injection|
75889482|NCT02192138|Procedure|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
75889483|NCT02192138|Device|Pleural catheter|
75889484|NCT02192138|Device|Pleural manometer|
75447688|NCT04606160|Behavioral|Single Session Problem-Solving Intervention|The intervention will be a researcher led 30-45 minute session using the problem-solving module from the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Issues (MATCH-ADTC protocol.
75447689|NCT04603690|Dietary Supplement|Complementary therapy|A daily supplementation of 168 mg curcumin, 260 mg quercetin and 360 IU of vitamin D3 (cholecalciferol) for 14-days
75447690|NCT04603690|Drug|Standard of care|This arm will receive standard of care as per the hospital guidelines
75447691|NCT04598360|Procedure|Heart-Lung-Machine|blood sample before and during a single Heart-Lung-Machine procedure
75597313|NCT00600509|Drug|Levetiracetam|
75597314|NCT01303419|Device|CE-BMRI|Contrast-enhanced breast imaging using Magnetic Resonance
75597315|NCT01303419|Device|DE-CEDM|Breast imaging using Dual-energy, contrast-enhanced digital mammography
75597316|NCT01326533|Drug|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
75597317|NCT01326533|Other|Placebo|Thirteen weeks of oral placebo provided as capsules
75597318|NCT00600587|Drug|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
75741567|NCT02553083|Drug|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
75889485|NCT01333722|Drug|Hydrocodone/Acetaminophen Extended Release|
75889486|NCT01333722|Drug|Placebo|Placebo tablet
75447692|NCT04590651|Procedure|Cataract surgery|Routine phacoemulsification cataract surgery using the Alcon Centurion® device.
75447693|NCT04590651|Procedure|Cataract surgery with extra anterior chamber angle aspiration|Routine phacoemulsification cataract surgery using the Alcon Centurion® device. At the end of the case a one minute extra anterior chamber angle aspiration will be preformed after the removal of the viscoelastic agent.
75597319|NCT00600587|Drug|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
75597320|NCT01045447|Drug|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
75597321|NCT01045447|Drug|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
75889487|NCT02188472|Drug|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
76060090|NCT04144114|Dietary Supplement|Whey protein|Subjects received 25g of whey protein powder mixed to together in a drink
76060091|NCT04144114|Dietary Supplement|Placebo|Placebo
75447694|NCT04588857|Drug|Dexamethasone|The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.
76060092|NCT01700829|Drug|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
75447695|NCT04588857|Drug|Saline|The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
75741568|NCT02553083|Drug|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
75741569|NCT02553083|Drug|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
75741570|NCT02553083|Drug|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
75741571|NCT02553083|Drug|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
76060093|NCT01700829|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
76060094|NCT04143880|Drug|Progesterone|intramuscular injection intranasal administration
76060095|NCT04143880|Other|saline|intramuscular injection intranasal administration
76060096|NCT04144192|Drug|Lidocaine patch 1.8%|
75741572|NCT02553083|Drug|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
75741573|NCT00804947|Drug|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
75741574|NCT02553005|Procedure|Acupuncture|
75889488|NCT02188472|Drug|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
75889489|NCT02188472|Drug|Placebo|Placebo: 2 tablets should be taken twice daily
75889490|NCT02188550|Drug|everolimus and letrozole|"This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally"
75889491|NCT02038374|Procedure|biopsies|
75889492|NCT02059590|Drug|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|Intravenous
75889493|NCT02192216|Behavioral|Exercise|
76060097|NCT04144192|Drug|Lidocaine 5% patch|
76060098|NCT04144192|Drug|Lidocaine 2% Injectable Solution|
75597322|NCT00600665|Behavioral|PAINReportIt|A pain assessment data collection tool
75597323|NCT00600665|Behavioral|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
75597324|NCT00600665|Behavioral|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
75597325|NCT04324827|Device|Graston Technique|FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.
75889494|NCT02056002|Other|Usual Care|- Standard CPAP educational training
76060099|NCT01710345|Drug|Sufentanil NanoTab 20 mcg|
76060100|NCT01710345|Drug|Sufentanil NanoTab 30 mcg|
76060101|NCT01710345|Drug|Placebo NanoTab|
76060102|NCT04143568|Other|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
76060103|NCT03022006|Drug|elbasvir, grazoprevir|
76060104|NCT04148092|Drug|ripretinib|orally administered solid dosage form
75447696|NCT04580212|Behavioral|Poultry hygiene intervention|The intervention will consist of a series of participatory training exercises designed to accomplish three main goals: (1) increase awareness of health risks and lost livelihood benefits of current poultry management practices, (2) build practical skills for poultry management, and (3) build supportive community norms by facilitating savings group discussions on poultry management. The intervention will be delivered through three activities: (1) triggering exercise designed to raise awareness of both the health risks of the current practices and the economic potential of a more active poultry management approach, and ultimately to motivate participants for behavior change, (2) poultry management training activity based on local needs and norms, and (3) periodic follow-on coaching to reinforce messages from the initial training and emphasize action planning, monitoring of plan execution, and troubleshooting.
75741575|NCT00806273|Device|Vista Ultrasonic Bleach Bypass System|The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
75447697|NCT04579081|Device|Contour Neurovascular System|Intrasaccular flow disruptor/divertor
75597326|NCT04324827|Other|Dynamic stretch exercise|Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
75447698|NCT04575467|Drug|CBL-514|CBL-514 will be administered via injection into the thigh subcutaneous adipose layer.
75447699|NCT04573075|Procedure|Ghost ileostomy|a loop of the small bowel is marked with a silicone strap and externalized through the abdominal wall to avoid a loop ileostomy
75741576|NCT00806273|Device|Needle Irrigation|irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
75741577|NCT00805103|Radiation|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
75741578|NCT00655733|Drug|HMPL-004|HMPL-004 1200 mg/d
75447700|NCT04573075|Procedure|loop ileostomy|a protective loop ileostomy is applied after after colorectal resection and forming of a primary anastomosis
75447701|NCT04573075|Procedure|no outlet|no further intervention is used after colorectal resection and forming of a primary anastomosis
75447702|NCT04569448|Drug|Brexpiprazole|Adjunctive variable dose (1-3 mg/day) Brexpiprazole
75447703|NCT04568733|Behavioral|Pilates exercise session|The Pilates session will consist of warm-up exercises (e.g. breathing, arm circle, cat and camel spinal rotation etc.) and basic mat exercises (e.g. one leg stretching, double leg stretching, the hundred, saw, rolling like a ball, swimming, pelvic curl etc.). The Pilates session will be presented to the participants via pre-recorded video.
75447704|NCT04568733|Behavioral|Treadmill walking at 3.2 kph|Participants will walk on a treadmill at 3.2 kph (2 mph) speed for 10 minutes.
75447705|NCT04568733|Behavioral|Treadmill walking at 4.8 kph|Participants will walk on a treadmill at 4.8 kph (2 mph) speed for 10 minutes.
75597327|NCT00623051|Procedure|Male Circumcision|
75597328|NCT00623129|Other|questionnaire administration|
75597329|NCT00623129|Procedure|electroacupuncture therapy|
75597330|NCT00623129|Procedure|management of therapy complications|
75597331|NCT00623129|Procedure|quality-of-life assessment|
75597332|NCT02875249|Other|patients stool collection|patients stool collection
75597333|NCT00623207|Drug|Atropine|I.V Atropine 0.5mg up to 2 mg
75741579|NCT00655733|Drug|Placebo|Placebo 1200 mg/d
75741580|NCT00806429|Procedure|transvaginal appendectomy|patient undergoes transvaginal appendectomy
75741581|NCT00657371|Device|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
75741582|NCT00805259|Behavioral|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
75741583|NCT00806507|Procedure|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
75741584|NCT00806507|Procedure|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
75741585|NCT04017065|Device|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
76060105|NCT04143334|Diagnostic Test|Conventional survey|
75447706|NCT04544930|Behavioral|therapist-guided|Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
75447707|NCT04544891|Other|blood sampling|Blood will be collected every 3 days until Day 28, discharge, or death
75597334|NCT00600899|Procedure|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
75741586|NCT00805337|Device|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
75741587|NCT00806663|Drug|sunitinib added to FOLFIRI|sunitinib 37 mg once daily (4 weeks on/2 weeks off)
75741588|NCT00805415|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
75741589|NCT00805415|Drug|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
75447708|NCT04543760|Other|Prone position|prone positioning in spontaneous ventilation
75447709|NCT04543760|Other|Supine position|supine positiong in spontaneous ventilation
75741590|NCT02553863|Procedure|Acupuncture|Acupuncture for 30min [twice weekly for 8 weeks]
75741591|NCT02553863|Procedure|Standard care|Standard care
76060106|NCT05582824|Other|Blood and urine test|Daily blood and urine samples
76060107|NCT02335216|Device|Implantation with the commercially available Axium neurostimulator|
76060108|NCT04148326|Other|No Intervention|There is no intervention for this study.
76060109|NCT04147936|Dietary Supplement|AXA1665|Dietary supplement: AXA1665
75447710|NCT04542980|Diagnostic Test|SARS-CoV2 Autoantibody detection|Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2
76060110|NCT04147936|Dietary Supplement|Placebo|Placebo
76060111|NCT04148014|Behavioral|An Adjunctive Emotion Regulation Skills Training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 5 weeks to young adults with eating disorders together with treatment as usual
75447711|NCT04532619|Behavioral|Fathering Through Change|Fathering Through Change is an adaptation of Parent Management Training Oregon. This pilot provides a limited version of Fathering Through Change via text messaged and emailed weekly video content and includes individual coaching calls.
75447712|NCT04531085|Procedure|Operative treatment|Surgery
75447713|NCT04531085|Procedure|Long arm cast|cast immobilization
75447714|NCT04530435|Device|PEP flute|Participants are advised to use a PEP flute at least three times daily at an appropriate resistance. Ideally, each session consists of 15 breaths (for approximately 1 minute) repeated twice at an upright position.
75447715|NCT04530279|Procedure|Clinical assessment|Clinical assessment of burn depth and the percentage of total body surface area (TBSA) burnt with any method
75597335|NCT00600899|Procedure|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
75597336|NCT04205617|Other|produce prescription and nutrition education|Participants will receive diabetic appropriate groceries, diabetes education classes led by volunteer doctors and nurses, cooking demonstrations, shared meals, 1:1 and group coaching by dietitians.
75597337|NCT00600977|Drug|Doxorubicine|9mg/m² J1 J4 2 COURSES
75597338|NCT00600977|Drug|Doxorubicine pegylated|40 MG/M² J1 2 courses
75597339|NCT01301625|Device|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
75597340|NCT00601055|Behavioral|Problem Solving-Rx Adherence (PSA)|In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
75597341|NCT00601055|Behavioral|PID-C|In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
75447716|NCT04529499|Drug|AVIGAN|Patients will be randomized to the favipiravir + supportive care group in a 1:1 ratio
75447717|NCT04529499|Drug|Placebo Comparator|Patients will be randomized to the placebo + supportive care group in a 1:1 ratio
75447718|NCT04528433|Behavioral|Medical-education-community Collaborated Intervention|The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.
75889495|NCT02056002|Other|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy~Standard CPAP educational training~Eight phone conversations with Peer Buddy over 3 months~Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~- Home visit to collect CPAP information~Three Month Visit:~Questionnaires~Psycho Motor Vigilance Test (PVT) Video Game~Collect CPAP information~Measure weight~Measure blood pressure~Six Month Visit:~Questionnaires~PVT (Video game)~Collect CPAP information~Measure Weight~Measure Blood Pressure~Evaluate the program and Peer Buddy"
75447719|NCT04528433|Behavioral|routine clinical care|Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
75447720|NCT04523428|Drug|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
75597342|NCT00601133|Other|Walking Test|"Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back~Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later"
75597343|NCT00601133|Other|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
75597344|NCT00601133|Behavioral|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
75597345|NCT00601133|Behavioral|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
75597346|NCT00601211|Drug|Pilocarpine|
75741592|NCT00799565|Genetic|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
75597347|NCT00601289|Drug|temozolomide|
75741593|NCT00806741|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
75741594|NCT00806741|Drug|Phenylephrine|1μg/kg/min, infusion period 20 minutes
75741595|NCT00806741|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
75741596|NCT00806741|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
75741597|NCT00806741|Device|Goldmann applanation tonometer|intraocular pressure measurements
75889496|NCT02056002|Other|Usual Care|- Educational Brochures
75597348|NCT00601289|Genetic|DNA methylation analysis|
75889497|NCT02056002|Other|Usual Care|- Educational DVD videos mailed to participant
75889498|NCT02192294|Drug|Oral Bosutinib|a single dose of 500 mg oral bosutinib
75889499|NCT02192294|Drug|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
75597349|NCT00601289|Genetic|microarray analysis|
75597350|NCT00601289|Genetic|protein expression analysis|
75597351|NCT00601289|Genetic|proteomic profiling|
75597352|NCT00601289|Other|laboratory biomarker analysis|
75597353|NCT04301947|Other|Standard warm-up protocol|Stationary cycling and lower limb stretching exercises
75597354|NCT04301947|Other|Gluteal activation warm-up protocol|Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
75597355|NCT02891525|Dietary Supplement|50g glucose|
75597356|NCT02891525|Dietary Supplement|25g fructose|
75597357|NCT02891525|Dietary Supplement|220mg acesulfame-K|
75597358|NCT02891525|Dietary Supplement|250mL tap water|
75597359|NCT04304053|Drug|Treatment and prophylaxis|"Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7."
75597360|NCT04304053|Other|Standard Public Health measures|Isolation of patient and contact tracing as per national guidelines.
75597361|NCT00601445|Behavioral|Amount of sleep and wake|4 groups with different patterns of sleep and wake
75741598|NCT00806741|Other|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
76060112|NCT04143022|Device|acupuncture press needle|Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
75741599|NCT00806897|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
75741600|NCT00805649|Procedure|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
75741601|NCT00805649|Procedure|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
76060113|NCT04143256|Other|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
75447721|NCT04508504|Procedure|Preop PENG block|Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.
75447722|NCT04508504|Procedure|Placebo block|Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.
75447723|NCT04508504|Drug|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the preop PENG block
75447724|NCT04508504|Drug|Normal Saline|5 mL 0.9% Normal saline will be injected for the Placebo block
75741602|NCT00805649|Drug|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
75741603|NCT00805649|Drug|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
75741604|NCT00805649|Procedure|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
75741605|NCT00805649|Drug|triamcincolone|intravitreal injection of 8 mg triamcincolone
75741606|NCT00799799|Biological|NK cells|NK cells infusion after immunosuppressive chemotherapy
75741607|NCT00806975|Device|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
75741608|NCT00809315|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
75741609|NCT00809315|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
76060114|NCT04143256|Other|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
75447725|NCT04507633|Behavioral|ROMA therapy(reminiacence therpy, orientation, music, and art)|An intervention comprising reminiscence of annual festivals, orientation, and familiar music listening and singing, and animation interaction to improve cognitive functions, depressive symptoms and behaviors problems.
75741610|NCT03870971|Other|blood glucose measurement|After the patient has performed the manual reading, the investigator or staff member will obtain another capillary blood sample and a reference reading by means of the YSI 2300 Stat plus analyzer will be performed and recorded. If patients need more than one attempt to get a successful blood glucose reading, the number of attempts will be documented. A questionnaire needs to filled by the participant
75741611|NCT00807053|Drug|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
75741612|NCT00807053|Drug|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
76060115|NCT04143256|Other|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
76060116|NCT04143256|Other|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
76060117|NCT04143256|Other|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
75741613|NCT00807053|Drug|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
75741614|NCT00807053|Drug|Placebo|Placebo
75741615|NCT00809393|Drug|tranexamic acid|10 mg/kg
75741616|NCT00809393|Drug|tranexamic acid|30 mg/kg
75889500|NCT05620134|Drug|JK08|Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
76060118|NCT04143256|Other|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
75447726|NCT04503382|Other|Kindness Media|As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.
75447727|NCT04501094|Drug|Bintrafusp alfa (M7824)|1200 mg administered intravenous (IV) every two weeks
75597362|NCT00601679|Other|NT-proBNP guided care|knowledge of NT-proBNP results
75741617|NCT00799955|Procedure|Placebo block|100 micrograms of spinal morphine
75889501|NCT02188628|Device|H-Man|H-man is a portable end-effector planar upper limb robot.
75889502|NCT02188628|Other|Additional Conventional Therapy|Repetitive goals based arm therapy
75447728|NCT04490707|Drug|Azacitidine|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine
75447729|NCT04490707|Drug|Lenalidomide|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
75597363|NCT00601757|Behavioral|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
75597364|NCT00601757|Behavioral|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
75597365|NCT00601913|Drug|erlotinib hydrochloride|
75597366|NCT00601913|Genetic|protein analysis|
75597367|NCT00601913|Genetic|western blotting|
75597368|NCT00601913|Other|immunohistochemistry staining method|
75597369|NCT00601913|Other|laboratory biomarker analysis|
75597370|NCT00601913|Other|liquid chromatography|
75597371|NCT00601913|Other|mass spectrometry|
75597372|NCT00601913|Procedure|neoadjuvant therapy|
75597373|NCT00601913|Procedure|therapeutic conventional surgery|
75597374|NCT00601991|Biological|VEGF Trap|Drug under investigation
75597375|NCT00601991|Procedure|Bone marrow biopsy|To determine response to treatment
75597376|NCT00601991|Procedure|bone marrow aspiration|To determine response to treatment
76060119|NCT04143256|Other|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
76060120|NCT04143256|Other|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
76060121|NCT04143256|Other|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
76060122|NCT04143256|Other|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
76060123|NCT04143412|Drug|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
76060124|NCT05582278|Drug|D-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
76060125|NCT05582278|Drug|HAIC|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
76060126|NCT05582278|Drug|Lenvatinib|12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight <60 kg
76060127|NCT05582278|Drug|tislelizumab|tislelizumab 200 mg, every 3 weeks.
76060128|NCT05582122|Biological|HPV16 Ct-DNA dosing|"Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.~ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.~ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.~DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma."
76060129|NCT04147702|Other|Balance analysis|Balance analysis is assessment method to estimate deterioration of postural control.
76060130|NCT01710033|Drug|Placebo|Placebo tables twice daily (BID) for 28 days
76060131|NCT01710033|Drug|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
76060132|NCT01710033|Drug|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
76060133|NCT01710033|Drug|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
76060134|NCT04148170|Procedure|Endodiathermy Probe and Intubation Versus Intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
76060135|NCT01822496|Radiation|Radiation Therapy|30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
76060136|NCT01822496|Drug|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22."
76060137|NCT01822496|Drug|Cisplatin|50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
76060138|NCT01822496|Drug|Crizotinib|250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
75597377|NCT00601991|Procedure|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
75447730|NCT04489485|Behavioral|Teen Depression Module used for care|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, and treatment using the Teen Depression Module and offered a depression chabot. Suicide screening will be conducted.
75741618|NCT00799955|Procedure|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
75741619|NCT00807131|Behavioral|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
75741620|NCT00807131|Behavioral|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
76060139|NCT01822496|Drug|Erlotinib|150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
76060140|NCT01822496|Drug|Etoposide|50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
76060141|NCT01822496|Drug|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
75447731|NCT04488913|Other|RACE-IT Pathway|This care pathway includes the evaluation of suspected acute coronary syndrome with high-sensitivity troponin I testing and further prognostication as needed with a modified HEART score
75447732|NCT04488913|Other|Standard of Care|Standard of care protocol that uses the 99th percentile troponin values for evaluation of suspected acute coronary syndrome and further prognostication using the HEART score
75597378|NCT01301391|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
76060142|NCT03936088|Device|"Intervention -- Headspace mindfulness application"|"Patients will be provided with a pre-paid 12-week subscription to the mindfulness application, and provided an in-person demonstration on how to use it, and the subscription license code will be recorded for the purposes of tracking use after the conclusion of the study. The intervention group will be asked to use the mindfulness app 10 minutes per day/5 days per week. To standardize Pack usage across all participants, users will be asked to complete the Headspace Essentials, Pain Management, and Physical Health Session Packs."
76060143|NCT03936088|Device|"Control -- My Water Balance application"|My Water Balance calculates an individual's recommended daily water requirements and assists users in tracking their daily fluid intake. The control group will be asked to log their water intake for the duration of the study, with requested use of 5 days per week to create an equal control. This application is free to download and use. There are options for in-app purchases and application upgrades, though users will be advised against doing so. Information logged in the application may be stored on a third party server; however, no application data will be extracted by the study team. Application use will be reported via weekly surveys, alone.
75447733|NCT04486170|Other|Education provided via a video format|The intervention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room and the investigator will step outside. At the conclusion of the video, the investigator will return into the patient room and provide a pamphlet with similar information that was discussed in the video for them to take home.
75447734|NCT04482738|Other|High-calorie meal|Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.
75447735|NCT04476433|Other|Ten Vida (10Vida)|10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.
75447736|NCT04472468|Device|Percutaneous Balloon Pericardiotomy|"Subxiphoid approach under fluoroscopic guidance is used.~An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space.~Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections."
75447737|NCT04464577|Drug|Fluconazole|Specified Dose on Specified Days
75447738|NCT04464577|Drug|Bupropion|Specified Dose on Specified Days
75447739|NCT04464577|Drug|Itraconazole|Specified Dose on Specified Days
75597379|NCT00602069|Behavioral|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
75447740|NCT04464577|Drug|BMS-986235|Specified Dose on Specified Days
75447741|NCT04453384|Drug|XAV-19|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
75447742|NCT04453384|Drug|Placebo|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
75447743|NCT04440774|Biological|CHIK low dose|A single dose of 5x10^9 vp ChAdOx1 Chik
75447744|NCT04440774|Biological|CHIK mid dose|A single dose of 2.5x10^10 vp ChAdOx1 Chik
75447745|NCT04440774|Biological|CHIK high dose|A single dose of 5x10^10 vp ChAdOx1 Chik
75447746|NCT04440774|Biological|ZIKA low dose|A single dose of 5x10^9 vp ChAdOx1 Zika
75447747|NCT04440774|Biological|ZIKA mid dose|A single dose of 2.5x10^10 vp ChAdOx1 Zika
75447748|NCT04440774|Biological|ZIKA high dose|A single dose of 5x10^10 vp ChAdOx1 Zika
75597380|NCT00602069|Behavioral|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
75597381|NCT01036321|Drug|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
75597382|NCT01036321|Drug|Methyl cellulose blend|Placebo - Take 2 capsules daily
75741621|NCT00807131|Behavioral|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
75741622|NCT00807131|Behavioral|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
75741623|NCT00658775|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
75741624|NCT00658775|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
75447749|NCT04440774|Biological|Saline placebo|A single dose of isotonic saline solution (0.9%)
75447750|NCT04427397|Other|Sulcular Bristle Tip Technique (SBTT)|Tooth brushing should begin on the distal of the most posterior tooth on one side of the mouth and proceed anteriorly and then posteriorly overlapping areas to the most distal surface of the most posterior tooth on the contra lateral side. The lingual is done in like fashion ending where the brushing began. The opposing arch is brushed in the same manner. When moving from one area to the next, disengage the brush bristles entirely off the teeth to allow them to straighten, and then reposition the brush in the next overlapping area. Do not to drag the bristle tips from one area to the next area. For the lingual of the anterior teeth, the narrow portion of the brush is used with the exact same technique as described above. For the lingual of the mandibular molars, the angulation of the toothbrush bristles to the tooth needs to be somewhat more perpendicular to the tooth than on the buccal to ensure that the bristle tips enter the gingival crevice.
75447751|NCT04418362|Other|Neurofeedback training|A home-based self-administered neurofeedback intervention taking place 4-6 times per week for 8 weeks.
75447752|NCT04416867|Device|splint and home exercise|Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
75447753|NCT04416867|Device|RESWT|RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
75597383|NCT04325633|Drug|1: Naproxen|Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
75597384|NCT04325633|Drug|2: Standard of care|Standard of care
75597385|NCT04126889|Other|questionnaire survey|questionnaire survey
75741625|NCT00807287|Procedure|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
75889503|NCT02057796|Device|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"The following point-of-care TB tests will be systematically performed:~Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.~TB treatment will depend on the result of the tests:~Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1)."
76060144|NCT01867047|Drug|ACE-I Cessation group|"Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
76060145|NCT01867047|Drug|ACE-I Continuation group|"Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
76060146|NCT03588988|Drug|Dexmedetomidine IV infusion|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
75447754|NCT04416867|Device|physical therapy|20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks
75447755|NCT04414618|Drug|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
75447756|NCT04414618|Drug|Placebo|Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
75447757|NCT04412824|Drug|Intravenous blood draw|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
75447758|NCT04412057|Drug|CERC-002|Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
75597386|NCT04324749|Other|Roasted peanuts (group A)|After 2 weeks following a peanut-free diet, the participants of this group consume 25 g/ day of whole skin roasted peanuts (RP) within the habitual diet during 6 months.
75597387|NCT04324749|Other|Peanut butter (group B)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of peanut butter (PB) within the habitual diet during 6 months.
75741626|NCT00807287|Procedure|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
75447759|NCT04412057|Drug|Placebo|Administered once subcutaneously
75597388|NCT04324749|Other|Control (group C)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of control supplement (containing the same proportion of macronutrients as peanuts and peanut butter) within the habitual diet during 6 months.
75597389|NCT01061359|Drug|Epirubicin: Observational Study|Observational: Chemotherapy
75597390|NCT05643417|Drug|HAIC、Bevacizumab、Camrelizumab|HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
75597391|NCT02891369|Other|No intervention. Descriptive study|
75597392|NCT04303975|Other|clinical measurements|Only clinical parameters were recorded, no intervention was made.
75741627|NCT00800033|Behavioral|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
75741628|NCT00800033|Dietary Supplement|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
75741629|NCT00800111|Procedure|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
75741630|NCT00488631|Biological|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
75741631|NCT00488631|Biological|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
75741632|NCT00488631|Biological|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
75741633|NCT00488631|Biological|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
76060147|NCT03588988|Drug|Normal saline|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
75741634|NCT00809549|Drug|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
76060148|NCT05581888|Device|trifocal intraocular lens|Binocular implantation of two different trifocal intraocular lens in high myopic cataracts
75597393|NCT05643339|Diagnostic Test|microvascular flow imaging|microvascular flow imaging
75741635|NCT00809627|Drug|Caffeine|Caffeine 500 mg IV
76060149|NCT04414137|Other|Description of eosinophilic pneumonia due to daptomycine|Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
75741636|NCT00809627|Drug|saline|Normal saline
76060150|NCT05580172|Drug|RH324|polymolecular
76060151|NCT05586178|Behavioral|Reminder that facilitates action|Patients will receive a text message reminding them that they can now get the bivalent COVID-19 booster and facilitating action. The message will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find local pharmacies that carry the bivalent booster).
75741637|NCT00809705|Drug|Placebo|sc once weekly for 12 weeks
76060152|NCT05586178|Behavioral|Consistency framing|The message will leverage the psychological principle of consistency. It will highlight to patients that based on medical records, they have completed a COVID-19 vaccine primary series, have done a great job protecting their health, and can now get the bivalent booster.
76060153|NCT05586178|Behavioral|Information provision about the uniqueness of the bivalent booster|The message will contain information about how the bivalent booster differs from previous doses patients have received and why it is valuable.
76060154|NCT05586178|Behavioral|Information provision about bivalent booster eligibility|The message will clarify to patients that regardless of whether they are at high risk, received the original boosters, or previously got COVID-19, they are eligible for the bivalent booster based on their medical records, and the updated booster will be valuable for them.
76060155|NCT05586178|Behavioral|Information provision about the severity of COVID-19 symptoms|The message will contain information about the often underestimated chances of people developing severe or long-lasting COVID-19 symptoms. The message will also mention that the bivalent booster can reduce such chances.
76060156|NCT01821560|Drug|Baclofen|
76060157|NCT01821560|Drug|placebo|
76060158|NCT01871402|Drug|000-0551 Lotion|
76060159|NCT01871402|Drug|Vehicle Lotion|
76060160|NCT03588832|Diagnostic Test|Evaluation Upper Extremity patterns.|The procedure involves evaluating subjects who meet the eligibility criteria and agree to participate in the study by signing informed consent. The study includes a measurement, applying a registration form, the Barthel scale and the FIM scale.
75597394|NCT00602147|Other|laboratory biomarker analysis|Blood or cheek cells wil be collected.
75597395|NCT04303741|Drug|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
75597396|NCT04303741|Drug|Apatinib|Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
75741638|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
75741639|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 12 weeks
75741640|NCT00655499|Drug|Panitumumab|6 mg/kg
75741641|NCT00655499|Drug|Irinotecan hydrochloride|180 mg/kg
75741642|NCT00655499|Genetic|Chromogenic in situ hybridization|
75741643|NCT00655499|Genetic|Fluorescence in situ hybridization|
75741644|NCT00655499|Genetic|Gene expression analysis|
75741645|NCT00655499|Other|Laboratory biomarker analysis|
75741646|NCT00809861|Procedure|volar locking plating|open reduction and internal fixation
75741647|NCT00809861|Procedure|external immobilisation|closed reduction and external fixation
75741648|NCT00800189|Radiation|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
75741649|NCT00654875|Drug|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
75741650|NCT00654875|Drug|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
75889504|NCT02057796|Drug|ART (Atripla, Truvada, Efavirenz, Combivir)|"ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2"
75889505|NCT02057796|Drug|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
75889506|NCT03681171|Other|Therapeutic Dance|Participants attended therapeutic ballet sessions three times per week for six weeks.
76060161|NCT04607174|Other|Pathologic group|"Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb."
76060162|NCT05580328|Drug|Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy|Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
75447760|NCT04408807|Other|Speculum-free (SpF) fundoscopy|Indirect ophthalmoscopy without the use of eyelid speculum and scleral indentation
75447761|NCT04408807|Other|Speculum (Sp) fundoscopy|Indirect ophthalmoscopy with the use of eyelid speculum and scleral indentation
75597397|NCT04303741|Drug|Eribulin|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
75597398|NCT05643261|Other|Muscle and technique training|The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.
75597399|NCT00626977|Drug|ropivacaine|15 ml of ropivacaine 0.125% peridural once
75889507|NCT03676569|Biological|ADRC transplantation in autoimmune refractory epilepsy|
75889508|NCT02059746|Other|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
75447762|NCT04408482|Device|Biliary cannulation|Cannulation of biliary duct by sphincterotome
75463017|NCT01870700|Drug|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
75463018|NCT01870700|Drug|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
75597400|NCT00626977|Drug|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
75741651|NCT00800267|Drug|latanoprost 0.005%|placebo in the morning and latanoprost .005% in the evening
75741652|NCT00800267|Drug|fixed combination latanoprost-timolol|one drop in the morning and placebo in the evening
75741653|NCT00800267|Drug|timolol 0.5%|one drop in the morning and evening
75741654|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
75741655|NCT00809939|Drug|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
75741656|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
75741657|NCT00809939|Drug|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
75889509|NCT02192450|Drug|Insulin aspart/glargine|
75889510|NCT02192450|Drug|Insulin aspart/degludec|
75889511|NCT03680937|Other|Gavi , Merck® (automated vitrification instrument)|Gavi, Merck ® permits semi-automated vitrification with closed system.
76071980|NCT03529448|Drug|TN-TC11G|"TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered."
75741658|NCT00807443|Drug|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp & Dohme. A dose of 400 mg will be administered every 12 hours
75447763|NCT04402658|Drug|Inhaled salbutamol|Participants will inhale 800 μg salbutamol (or placebo) using a standard metered dose inhaler used for asthma treatment, and a standard spacer device will be used to allow optimal delivery of the drug to the lung. The inhaler delivers 100 μg of salbutamol with each actuation (i.e., 8 puffs/actuations gives 800 μg) with inhalation time being approximately ~2 min (10 breaths) and the manufacturer's user instructions will be followed. Although complete uptake of salbutamol cannot be concluded as any salbutamol left in the spacer, mouth or remaining in the lung will be not measured. This dose of Salbutamol is chosen because it is the highest dose permitted by the World Anti Doping Agency (WADA).
75741659|NCT00807521|Drug|Dexamethasone|Single high dose bolus of dexamethasone before surgery
75741660|NCT00807521|Drug|Placebo|Placebo for dexamethasone
75741661|NCT00810173|Behavioral|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
75447764|NCT04402060|Drug|APL-9|Complement (C3) Inhibitor
75447765|NCT04402060|Other|Vehicle Control|Normal saline of equal volume to active arm
75447766|NCT04393766|Drug|Normal Saline|normal saline(crystalloids)
75447767|NCT04391179|Drug|Dipyridamole 100 Milligram(mg)|Drug will be given for 14 days while in the hospital.
75447768|NCT04391179|Drug|Placebo oral tablet|Placebo will be given for 14 days while in the hospital.
75447769|NCT04388228|Other|Extended audit and feedback in GPs electronic health record|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~A low cognitive load of the feedback where the results will be presented with the help of graphs.~Action plans to improve the quality of registration~A push system to minimize the effort the GP must make to consult the feedback."
75741662|NCT00922259|Biological|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
75741663|NCT00800423|Drug|Brimonidine Tartrate 0.2%|"Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye"
75741664|NCT00800423|Drug|Timolol maleate 0.5%|"timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye"
75447770|NCT04388150|Diagnostic Test|Upper gastrointestinal endoscopy and biopsy|Gastroscope with technology of VIST video intelligent staining technology for taking biopsies
75447771|NCT04386304|Drug|(+)-Epicatechin|(+)-Epicatechin is a synthetic flavanol
75447772|NCT04386096|Other|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
75463019|NCT01870752|Procedure|Transplantation of previously cryopreserved ovarian tissu|
75463020|NCT01870765|Device|non-invasive ventilation|non-invasive ventilation via face mask
75463021|NCT01870765|Device|high-flow oxygen|high-flow oxygen via nasal cannula
75463022|NCT01870765|Procedure|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
75463023|NCT01870791|Drug|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
75463024|NCT01870804|Drug|Rosuvastatin|
75463025|NCT01870804|Drug|Atorvastatin|
75463026|NCT01870817|Dietary Supplement|Home jejunostomy feeding|
75741665|NCT00800501|Drug|sNN0029|Continuous ICV infusion at one of three dose levels
75741666|NCT00800501|Drug|Placebo|Continuous ICV infusion
75741667|NCT00807677|Drug|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
75597401|NCT04302883|Diagnostic Test|Transesophageal Echocardiography (TEE)|Ultrasound of heart chambers via esophagus
75597402|NCT04302883|Diagnostic Test|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
75597403|NCT00623571|Other|Treatment of elderly patients in a GMW|
75597404|NCT00623571|Other|Treatment of elderly patients in GHHS|
75597405|NCT00627211|Procedure|CO2 insufflation|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
75597406|NCT04303819|Drug|Exenatide treatment|12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.
75597407|NCT01301079|Drug|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
75597408|NCT01301079|Drug|Saline|Patients in group N (placebo) was administrated saline during surgery.
75597409|NCT04303039|Drug|ABP-671|ABP-671 Tablet 1.0 mg
75741668|NCT00651755|Drug|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
75741669|NCT00651755|Drug|Cyclophosphamide|750 mg/m^2 By Vein On Day 1
75889512|NCT03680937|Other|Vitrification|Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
75597410|NCT05271721|Drug|epidural transforaminal injection of magnesuim sulfate|transforaminal fluroscopic guided
75597411|NCT05271721|Drug|epidural transforaminal injection of dexmedtemodine|transforaminal fluroscopic guided
75597412|NCT05271721|Drug|transforaminal epidural injection of dexamethasone|transforaminal fluroscopic guided
75741670|NCT00651755|Drug|Doxorubicin|25 mg/m^2 By Vein Over 48 Hours On Days 1-2
75741671|NCT00651755|Drug|Vincristine|2 mg By Vein On Day 1
75741672|NCT00651755|Drug|Prednisone|100 mg PO for 5 Days
75741673|NCT00651755|Drug|Rituximab|375 mg/m^2 By Vein On Day 1.
75741674|NCT00651755|Drug|Ondansetron|8 mg daily for 2 days
75889513|NCT03535454|Other|working hours|weekly working hours
76071981|NCT03529448|Drug|Temozolomide Oral Product|"During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
75741675|NCT02552381|Other|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
75741676|NCT02552771|Procedure|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
75741677|NCT02552771|Procedure|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
75889514|NCT03676491|Other|Music Intervention|Music intervention
75889515|NCT03680703|Behavioral|Guided Self-Help Behavioral Weight Loss|Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
75463027|NCT01870830|Other|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
75463028|NCT01870882|Behavioral|Attentional retraining|
75463029|NCT01870882|Behavioral|Control condition|
75463030|NCT01870895|Drug|YM060|oral
75463031|NCT01870895|Drug|Placebo|oral
75463032|NCT01870908|Drug|tacrolimus|
75463033|NCT01870908|Drug|biological agents|
75463034|NCT01870934|Device|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
75463035|NCT01870947|Behavioral|Exercise on stationary recumbent exercise cycle|
75463036|NCT01870947|Behavioral|Health Education|"Informational brochure (Better Health and You, Weight Control Information Network, June, 2004)"
75463037|NCT01870947|Behavioral|Questionnaires|
75463038|NCT01870947|Procedure|Neuroimaging|Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.
75463039|NCT01870947|Procedure|Genetic and Biomarkers|Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
75597413|NCT01036165|Device|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
75597414|NCT05642871|Radiation|DKI and APT|DKI and APT in patients with ovarian malignancy before and after treatment
75597415|NCT01301001|Drug|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
75597416|NCT01301001|Drug|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
75597417|NCT01300923|Drug|Acamprosate|
75597418|NCT05642559|Other|questionnaire|Assessment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) impact on HRQoL of the explored population and relationship with clinical variables. Development of a web application of the questionnaire.
75597419|NCT01300767|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
75597420|NCT01300767|Device|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
75597421|NCT01300767|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
75597422|NCT05642481|Diagnostic Test|Therapeutic drug monitoring in plasma of mother and child and in breastmilk|Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
76060163|NCT04415450|Behavioral|Nutrition Education counseling|In the context of health education program, an educational intervention was developed by the research team based on a training module. The nutrition education contained introductory messages and focused on meanings of healthy diet, eating a variety of food, eating well with the locally available food, hazards of maternal malnutrition, important supplements to be taken during pregnancy, harmful substances to be avoided, and measures of alleviating common discomforts associated with nutrition during pregnancy. The training program was carried out in the form of counseling using printed materials and flip charts for pictorial representation. Self-reading of leaflets containing the core messages for every topic prepared in the native language of the participants was also employed as the women in the study had one each.
75741678|NCT00810251|Device|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
76060164|NCT03901300|Behavioral|Fundamental Motor Skills App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.
75741679|NCT00807755|Drug|Carboplatin|Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.
75741680|NCT00807755|Drug|Etoposide|80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
75889516|NCT02188940|Behavioral|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
75889517|NCT02188940|Behavioral|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
75889518|NCT02188940|Behavioral|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
76060165|NCT03901300|Behavioral|Unstructured Physical Activity App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
76060166|NCT03588676|Other|Melatonin|5mg Melatonin
76060167|NCT03588676|Other|Placebo|5mg Placebo capsule
76060168|NCT03467542|Device|PHIL® Liquid Embolic System|The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
75447773|NCT04386096|Other|Mehealth for ADHD software with no medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician report card; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
75597423|NCT02890173|Drug|CS-3150|
75597424|NCT02890173|Drug|Eplerenone|
75597425|NCT01300455|Drug|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
75597426|NCT01300455|Drug|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
76060169|NCT01846442|Drug|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
76060170|NCT01846442|Drug|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
75597427|NCT05642169|Behavioral|HIIT|"The training sessions will have a frequency of 3 times per week (Monday, Wednesday and Friday) and the duration will be between 39 to 54 minutes, depending on the training week.~The training program will be developed with the own body weight of each participant. Therefore, a progression according to the needs of this population will be fulfilled. The session model could be multi-joint exercises with self-loads, where the difficulty of the exercises will be worked progressively. Throughout the main part of each workout, 30 seconds of work will be performed at the corresponding intensity and 30 seconds of rest. Halfway through the total repetitions, there will be 2 minutes of recovery."
75889519|NCT02188940|Other|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
75597428|NCT05642169|Behavioral|HIIT+PA|In relation to the 2 groups that will perform HIIT, the HIIT+AF will have to complete 10.000 steps per day. In this way, they will be focusing on increasing their daily physical activity. In addition, this group will perform the same HIIT training programme as the other experimental group.
75889520|NCT02188940|Other|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
75889521|NCT03560856|Drug|Fulvestrant + palbociclib|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
75889522|NCT03676413|Drug|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
76060171|NCT01846442|Drug|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
76060172|NCT01846442|Drug|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
75447774|NCT04381169|Drug|Lactated Ringer Solution|Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
75447775|NCT04376684|Biological|Otilimab|Otilimab will be administered once via IV route.
76060173|NCT03586570|Drug|Aprocitentan 25mg|Oral tablets in strength of 25 mg
75447776|NCT04376684|Biological|Placebo 1|Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
75447777|NCT04376684|Biological|Placebo 2|Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
76060174|NCT03586570|Drug|Placebo|Oral tablets matching aprocitentan tablets
75447778|NCT04376684|Drug|Standard of care|All participants will receive standard of care as per institutional protocol.
75597429|NCT05642169|Behavioral|CON|This group will not suffer any changes in their lifestyle
75597430|NCT01107418|Drug|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
75597431|NCT01107418|Drug|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
75597432|NCT01107418|Drug|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
75741681|NCT00807755|Drug|RAD001|Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
75741682|NCT00813527|Drug|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
75741683|NCT00813527|Drug|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
75741684|NCT00654641|Procedure|Negative pressure wound closure|Applying negative pressure to primary wound closure
76060175|NCT03588598|Drug|SHC014748M|a selective PI3Kδ inhibitor
76060176|NCT03588364|Other|Osteopathic Manipulation|Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
75447779|NCT04375683|Drug|Flumatinib|Flumatinib 600mg per day, taken on empty stomach
75447780|NCT04368832|Other|Remote consultation|One or more consultation is conducted by phone or teleconsultation during prenatal monitoring
75447781|NCT04367987|Diagnostic Test|Heart Rate Variability|Heart rate and RR interval Post-anonymized analysis of heart rate variability using the KUBIOS software
75597433|NCT01107418|Drug|RO5185426|960 mg orally twice daily, from day 22 onward
75597434|NCT01107418|Drug|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
75597435|NCT05642091|Device|ultrasound Elastography|application of shear wave force by ultrasound elastography
75597436|NCT05641779|Device|pigtail|pigtail catheter insertion in chest in the pleural cavity
75597437|NCT01101178|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
75597438|NCT01101178|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
75597439|NCT05639205|Diagnostic Test|Lateral Flow Device|Regular asymptomatic staff testing with a Lateral Flow Device including support payments if unwell.
75597440|NCT05637645|Procedure|Midline Approach|In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
75597441|NCT05637645|Procedure|Paramedian Approach|The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
75597442|NCT05637645|Procedure|Taylors approach|his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
75741685|NCT00654641|Procedure|Standard wound closure|Standard wound closure
75741686|NCT00810485|Drug|ADX10059|oral administration
75741687|NCT00810485|Drug|ADX10059|oral administration
75741688|NCT00810485|Drug|ADX10059|oral administration
75741689|NCT00810485|Drug|ADX10059 Matching Placebo|oral administration
75741690|NCT00810563|Drug|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
75447782|NCT04363905|Dietary Supplement|Placebo|100 mg lactose per day for 6 weeks
75447783|NCT04363905|Dietary Supplement|Ferrous sulfate|20 mg per day of elemental iron for 6 weeks
75447784|NCT04362891|Procedure|Cosmetic lip augmentation|The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.
75447785|NCT04356742|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg, orally, once daily, up to 24weeks
75447786|NCT04356742|Drug|Placebo|Dapagliflozin Placebo, orally, once daily, up to 24weeks
75447787|NCT04356742|Drug|Evogliptin 5mg|Evogliptin 5mg, orally, once daily for background therapy
75889523|NCT03676413|Drug|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the study
75889524|NCT03676413|Drug|Placebo|twice daily inhalation throughout the study
75447788|NCT04356742|Drug|Metformin≥1000mg|Metformin≥1000mg, orally, daily for background therapy
75447789|NCT04353284|Drug|Camostat Mesilate|Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.
75597443|NCT05637021|Other|Carbon dioxide insufflated during colonoscopy|Carbon dioxide is insufflated to dilate the bowel lumen during colonoscopy.Record the amount of gas insufflated during colonoscopy.
75741691|NCT00810563|Drug|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
75741692|NCT00807911|Drug|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
75741693|NCT00807911|Drug|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
75741694|NCT00808145|Drug|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
75741695|NCT00922337|Device|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
75741696|NCT02552459|Drug|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
75741697|NCT02552459|Drug|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
75741698|NCT02552459|Drug|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
75741699|NCT02552459|Drug|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
75741700|NCT00810953|Drug|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
76060177|NCT03588208|Other|Progressive resistance training program|Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.
76060178|NCT03588208|Other|Educational Program|Structured education program were performed during one hour class once a week for five weeks
76060179|NCT01709721|Drug|Hydromorphone Hydrochloride|Opioid for chronic pain
75597444|NCT00623649|Drug|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
75597445|NCT00623649|Drug|Placebo|Dose escalation study with a full review of all safety data following each cohort.
75447790|NCT04353284|Other|Placebo|Placebo taken orally, 4 times daily, for 7 days.
75889525|NCT02257034|Other|Taichi|
75447791|NCT04350892|Procedure|Roux-en-Y Gastric Bypass (RYGB)|"This surgery is often called gastric bypass. It is a weight-loss surgery that involves creating a small stomach pouch and bypassing part of the small intestine.~If you decide with your doctor to have gastric bypass, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the Roux-en-Y gastric bypass."
75447792|NCT04350892|Procedure|Sleeve Gastrectomy (SG)|"Sleeve gastrectomy, is a weight-loss surgery that involves removing about 80% of the stomach.~If you decide with your doctor to have sleeve gastrectomy, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the sleeve gastrectomy."
75447793|NCT04350892|Behavioral|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Participants will be placed on a 800 kcal/day diet for meal replacement (Optifast) provided by the investigator for 12 weeks. Participants will be monitored weekly by the study dietician and medical staff.
75597446|NCT01101022|Drug|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
75889526|NCT02257034|Other|Dance|
75889527|NCT03561324|Device|Imaging Beta Probe (IBP)|Using IBP for imaging of PET positive lymph nodes
75597447|NCT01101022|Other|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
75597448|NCT05627193|Other|Teleclinic|Instead of visiting surgeon after travelling from far flung areas for a post surgery follow up appointment, the follow up visit will be done using telephone.
75597449|NCT05627193|Other|Physical Clinic|Patients will have to travel to come physically to hospital to meet the operating surgeon.
75741701|NCT00811031|Drug|Taxotere|75 mg/m^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
75741702|NCT00811031|Drug|Prednisone|5 mg twice a day by mouth.
75741703|NCT02552537|Drug|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
75741704|NCT02552537|Drug|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
75741705|NCT00811109|Device|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
76060180|NCT01709721|Device|Programmable Implantable pump|Programmable Implantable pump delivering intrathecal hydromorphone
76071982|NCT03529448|Radiation|Radiotherapy|All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
75597450|NCT05622435|Device|T10070, Plastic tube with a roll-on applicator filled with an ointment|6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.
76071983|NCT03526250|Other|Laboratory Biomarker Analysis|Correlative studies
75597451|NCT01299909|Behavioral|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
75597452|NCT01299909|Behavioral|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
75597453|NCT01299909|Behavioral|Quitline|Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
75597454|NCT02879110|Dietary Supplement|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
75597455|NCT02879110|Other|Placebo|Placebo tablet is composed of starch.
75741706|NCT00811109|Device|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
75741707|NCT00811109|Device|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
75741708|NCT00811265|Device|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
75741709|NCT00808223|Biological|alefacept|IM injection
75741710|NCT00811343|Biological|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
75889528|NCT03676335|Drug|CsA eye gel|The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
75889529|NCT03676335|Drug|CsA for eye emulsion|The CsA for eye emulsion of 0.4 ml: 0.2 mg
75889530|NCT03676335|Drug|Hypromellose Eye Drops|Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
75889531|NCT04841486|Other|Data collection|evaluation of women's stress
75889532|NCT02260128|Other|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
75889533|NCT02192840|Procedure|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
76071984|NCT03526250|Drug|Palbociclib|Given PO
76060181|NCT03588520|Diagnostic Test|Home Blood Pressure Monitoring|Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
76060182|NCT03588052|Procedure|VISTA using PRF|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
76071985|NCT03526250|Other|Pharmacological Study|Correlative studies
75447794|NCT04348864|Diagnostic Test|COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|An immunodiagnostic rapid (5-20 minute) test detects circulating antibodies in the blood, serum or plasma of individuals who have been infected with the novel coronavirus SARS-COV-2 as detected by rapid antigen test or LAMP/PCR-based molecular test taken from nasopharyngeal swab samples in the recent past.
75447795|NCT04348864|Other|Telemedicine|Imaging of the test using the software application COVIDscanDX and upload to server by the subject and phone, video or messaging consult with a clinician for interpretation and instructions establishes the telemedicine (i.e. virtual point-of-care).
75463040|NCT01870986|Biological|PF-06410293|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
75741711|NCT04045535|Other|Physical Activity Program|Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.
75741712|NCT04045535|Other|Usual care|Usual clinical care based on current clinical practice guidelines.
75741713|NCT00811421|Drug|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
75741714|NCT00811421|Drug|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
75889534|NCT03676179|Procedure|patella denervation|patella denervation
75741715|NCT00811421|Drug|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
75889535|NCT03676179|Procedure|patella non-denervation|patella non-denervation
75889536|NCT02058030|Device|Insertion of ProSeal laryngeal mask airway|"The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed"
75741716|NCT00811421|Drug|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
75741717|NCT00811421|Drug|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
75741718|NCT00808301|Other|Gluten-free products|Gluten-free bakery products containing oatmeal.
75889537|NCT02189096|Other|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
75741719|NCT00808379|Drug|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
75741720|NCT00808379|Radiation|Additional Radiation boost to the primary tumor volume|15-20Gy
75741721|NCT00569777|Device|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
75741722|NCT00569777|Device|Placebo Lens|contact lens without drug
76060183|NCT03588052|Procedure|VISTA using SCTG|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
75447796|NCT04338100|Procedure|Follow-up at 14 days|Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death)
76060184|NCT01866657|Drug|Vasoconstrictor Agents|cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
76060185|NCT01866657|Other|Head/neck repositioning|Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
76060186|NCT01866657|Other|Increase ETCO2|Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
76060187|NCT01866657|Other|IV fluid bolus|Administer IV fluids to increase preload and cardiac output
76060188|NCT01866657|Drug|Additional anesthesia|By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
75447797|NCT04337619|Behavioral|Behavioral Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
75597456|NCT04207515|Procedure|Procedures of wisdom tooth removal surgery under conscious sedation|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
75741723|NCT00808535|Procedure|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
76060189|NCT01866657|Biological|RBC transfusion|By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
76060190|NCT01866657|Drug|Increase FiO2|Increase FiO2 to improve oxygen delivery to tissue
75741724|NCT00811811|Behavioral|Behavioral neurocardiac training|6 training sessions scheduled over 8 weeks
75741725|NCT00811811|Behavioral|Autogenic relaxation training|6 training sessions scheduled over 8 weeks
76060191|NCT03587350|Device|Shimmer monitoring|The shimmer monitor, monitors movement and the range of movement.
76060192|NCT03581344|Diagnostic Test|Repetition of Re-staging|Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
75447798|NCT04337619|Behavioral|Mindful Acceptance|Integration of acceptance and willingness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
75447799|NCT04337619|Behavioral|Values|Integration of values clarification and awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
75447800|NCT04337619|Behavioral|Mindful Awareness|Integration of mindfulness and present-moment awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
75741726|NCT00569231|Drug|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
75741727|NCT00654095|Drug|Ezetimibe|Ezetimibe 10 mg once daily
75741728|NCT00654095|Drug|atorvastatin|atorvastatin 20 mg once daily
76060193|NCT03020836|Behavioral|Referral to primary care physician for hypertension control|Referral to primary care physician for hypertension control
76060194|NCT03020836|Behavioral|Referral to smoking quit line|Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
76060195|NCT01700205|Other|Type of Formula|infant formula
75447801|NCT04330807|Other|Handgrip fatigability test|"Dynamometric and electromyographic assessment: patient is sitting on a chair, back upright, humerus vertically placed and forearm landing parallel to a support. Dominant arm is chosen for test and electrodes placement.~The assessment is divided in 4 phases for a total of 30 minutes duration: Warm-up, determination of reference force settings (fast sub-maximal contractions and maximal voluntary contractions), fatigability period and rest."
75447802|NCT04330807|Other|Questionnaires|Assessment of subjective fatigue with Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Multidimensional Fatigue Inventory (MFI-20) questionnaires
75447803|NCT04328012|Drug|Losartan|administered 14 days
75741729|NCT04016831|Behavioral|Mapping Enhanced Counseling (MEC)|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
75741730|NCT04016831|Other|Mapping Approaches to Prepare for Implementation Transfer (MAP-IT)|an implementation intervention to explore and address agency preparation needs in order to promote implementation success
75889538|NCT02189096|Other|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
75447804|NCT04328012|Drug|Placebo|administered 14 days
75447805|NCT04322058|Other|The Dads' Club|The core intervention is Core 24/7 workshop attendance
75447806|NCT04310150|Drug|Collastat|hemostatic agent that combine porcine-derived collagen thrombin
75447807|NCT04310150|Device|Floseal|hemostatic agent that combine bovine-derived gelatin
75447808|NCT04307498|Behavioral|Intensive Outpatient Program - Prolonged Exposure|Prolonged Exposure for Posttraumatic Stress Disorder (PE for PTSD; Foa, Hembree, & Rothbaum, 2007) is an empirically supported behavioral therapy that utilizes exposure-based interventions to target the psychological mechanisms (i.e., avoidance; maladaptive cognitive changes) thought to maintain trauma-related symptoms. IOP-PE includes 15 days of PE treatment delivered over three consecutive weeks. The standard outpatient PE protocol has modified with seven treatment augmentations to meet the unique needs of post-9/11 veterans.
75447809|NCT04306848|Device|Temporary Continuous Glucose Monitoring System|This is a feasibility study evaluating the potential to utilize a continuous glucose monitoring system (CGMs) on a temporary basis, during participation in an intensive therapeutic lifestyle medicine program, to help improve the compliance with healthy lifestyle changes for people with Type 2 diabetes (T2DM) and prediabetes (PD).
75447810|NCT04303897|Device|XEN Glaucoma Stent|Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
75447811|NCT04303663|Procedure|Fibular Plate|ORIF with Plating
75447812|NCT04303663|Procedure|Fibular Nail|CRIF +/- ORIF with Fibular nail
75463041|NCT01870986|Biological|Humira (adalimumab-EU)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
75463042|NCT01870986|Biological|Humira (adalimumab-US)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
75463043|NCT01871025|Other|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
75463044|NCT01871025|Other|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
75741731|NCT00808691|Other|Critical care|Standard care for each group of patients
75741732|NCT00811967|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
75741733|NCT00811967|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
75741734|NCT02552615|Other|body awareness therapy|
75741735|NCT02552615|Other|core stabilization exercises|
75741736|NCT02552615|Other|traditional exercises|
75889539|NCT03683979|Behavioral|Interpretation Bias Modification|A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.
75463045|NCT01871064|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
75597457|NCT04207515|Procedure|Procedures of wisdom tooth removal surgery under local anesthesia|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
75597458|NCT04324515|Procedure|Robotic gastric bypass with or without cholecystectomy|Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy
75597459|NCT02880826|Behavioral|Measure the culture of safety in the reanimation units|
75741737|NCT00812045|Drug|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
75741738|NCT00812045|Drug|Placebo|
75741739|NCT04046159|Drug|Low-dose tamoxifen|Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
76060196|NCT03589690|Dietary Supplement|Alpha lipoic acid|22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
76060197|NCT03589690|Dietary Supplement|Placebo|Participants will be supplemented with 600 mg/day placebo (Starch).
75741740|NCT04046159|Radiation|Whole breast radiotherapy|Ipsilateral breast tumor recurrence and side effect
75741741|NCT00650585|Behavioral|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
75463046|NCT01871103|Procedure|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
75463047|NCT01871116|Behavioral|POWER-remote|Web-based weight loss program.
75597460|NCT02879188|Other|Physical Therapy|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
75597461|NCT02879188|Other|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
75463048|NCT01871116|Behavioral|Self-directed|"Pamphlet entitled Aim for a Healthy Weight will be given."
75597462|NCT01298661|Other|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
75597463|NCT01100944|Drug|PXD101with cisplatin+doxorubicin+cyclophosphamide|PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
75741742|NCT02552069|Device|Tritanium® cup|
75741743|NCT00653939|Drug|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
75741744|NCT00653939|Drug|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
75741745|NCT00653939|Drug|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
75741746|NCT00653939|Drug|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
76060198|NCT03589534|Diagnostic Test|home pregnancy test|Each participant will use 4 different home pregnancy tests
76060199|NCT03589456|Other|No intervention|There are no interventions associated with this registry as it is purely observational.
75597464|NCT01100320|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
75597465|NCT01100320|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
75597466|NCT04309708|Device|Nimodipine pump infusion|Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
75741747|NCT00812123|Drug|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
75741748|NCT00812123|Drug|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
75741749|NCT00812123|Drug|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
75741750|NCT00812123|Drug|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
76060200|NCT01700049|Drug|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
76060201|NCT03587194|Drug|Otezla|Otezla 30mg BID
76060202|NCT01699815|Drug|Acetaminophen|
76060203|NCT03586960|Device|Peak Force Measurement|Force will be measured at 5,10, and 30 minutes
76060204|NCT03589222|Drug|Selinexor|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
75447813|NCT04299061|Diagnostic Test|International Physical Activity Questionnaire|"This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. Walking = 3.3 METs Moderate Intensity = 4.0 METs Vigorous Intensity = 8.0 METs Total MET-minutes/week = Walk (METs*min*days) + Mod (METs*min*days) + Vig (METs*min*days)~1. Low: • No activity is reported OR • Some activity is reported but not enough to meet Categories 2 or 3. 2. Moderate: • 3 or more days of vigorous activity of at least 20 minutes per day OR • 5 or more days of moderate-intensity activity and/or walking of at least 30 minutes per day OR • 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of at least 600 MET-minutes/week. 3. High: • Vigorous-intensity activity on at least 3 days and accumulating at least 1500 MET-minutes/week"
75447814|NCT04299061|Diagnostic Test|Pittsburgh Sleep Quality Index|"The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep. It differentiates poor from good sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month.The client self rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of 5or greater indicates a poor sleeper."
75447815|NCT04299061|Other|Physical Activity Awareness Questionnaire - prepared by the researchers|It consists of 13 questions to assess the physical activity level awareness of students. The questionnaire was prepared by the researchers therefore it does not have a validation.
75447816|NCT04299061|Diagnostic Test|Perceived Stress Scale|The Perceived Stress Scale (PSS) is a classic stress assessment instrument that helps understand how different situations affect feelings and perceived stress. The questions in this scale ask about feelings and thoughts during the last month. It consists of 14 questions.
75447817|NCT04294914|Other|Cold Pressor Test|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
75447818|NCT04294914|Other|Cold Pressor Test + Virtual Reality|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
75447819|NCT04294147|Drug|Galcanezumab|Administered SC
75597467|NCT01100086|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken without food
75597468|NCT01100086|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
75597469|NCT01297959|Drug|E-101 Solution 300 GU/ml|8 mL of E-101 Solution
75597470|NCT01297959|Drug|Saline solution|Saline solution matched to E-101
75741751|NCT00812123|Procedure|Protocol biopsies|protocol kidney biopsies at month one and three
75741752|NCT00808925|Other|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
75597471|NCT04187716|Drug|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
75741753|NCT00809081|Procedure|Enteral Feeding and Total Parental Support|"Enteral Feeding : 20ml/hr on POD1~Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)"
75889540|NCT03683979|Behavioral|Control Training Program|A sham training program that is similar in design and delivery to the experimental training condition.
75889541|NCT02189174|Drug|CLR457|
75889542|NCT01370694|Drug|MK-8808|
75889543|NCT01370694|Drug|cyclophosphamide|
75889544|NCT01370694|Drug|vincristine|
75889545|NCT01370694|Drug|prednisolone|
75889546|NCT03680547|Other|patient with sickle cell disease|assess degree of renal affection in patientswith sickle cell disease attending Assuit university Children hospital by estimating some predictors of glomerular and tubular dysfunction.
75889547|NCT02256878|Drug|BIRT 2584 XX|
76060205|NCT03589222|Drug|Daratumumab|daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
75741754|NCT00646451|Drug|pregabalin (Lyrica)|75 mg bid to 300 mg bid based on per subject tolerability
76060206|NCT03589222|Drug|Bortezomib|bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
76060207|NCT03589222|Drug|Dexamethasone|dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
76060208|NCT01866423|Drug|orteronel|Given PO
76060209|NCT01866423|Other|laboratory biomarker analysis|Correlative studies
76060210|NCT01846208|Drug|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
75447820|NCT04294147|Drug|Erenumab|Administered SC
75447821|NCT04289454|Other|Flavor additive|Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant
75447822|NCT04269707|Drug|Ferric carboxymaltose|IV iron
75447823|NCT04264637|Drug|Azelastine hydrochloride (BAYR9258)|Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.
75741755|NCT00646451|Drug|placebo|up to 4 capsules bid as tolerated
75889548|NCT02256878|Drug|Amitriptyline|
75889549|NCT03676101|Biological|9-valent HPV Recombinant Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
76060211|NCT01846208|Drug|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
76060212|NCT04166799|Device|Mepitel Film|Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
76060213|NCT03586804|Other|dual task|mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
76060214|NCT03589066|Drug|LY03003|28 mg intramuscular suspension
76060215|NCT01845974|Device|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
76060216|NCT01845974|Device|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
75447824|NCT04264637|Drug|Placebo|Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
76060217|NCT03020368|Biological|Leeches|
75447825|NCT04264234|Diagnostic Test|Vaginal Ultrasonography|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.
75447826|NCT04264234|Diagnostic Test|Magnetic Resonance Imaging|Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.
75447827|NCT04263649|Device|Peripherally Inserted Central Catheter|insertion of a Peripherally Inserted Central Catheter (PICC)
75447828|NCT04263246|Dietary Supplement|PhytoDyNAmic|PhytoDyNAmic (6 capsules per day)
75447829|NCT04263246|Dietary Supplement|Inulin|Inulin (6 capsules per day)
75447830|NCT04245306|Other|computerized test for pragmatic inferences|Computerized tests
75447831|NCT04244240|Behavioral|BEARNI Tool|"BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available."
75447832|NCT04240197|Device|CompuFlo|The occurrence of epidural pulse waves with CompuFlo and with standard pressure trnsducer
75447833|NCT04239976|Device|FitBit|Wear FitBit for gait assessment test
75447834|NCT04239976|Other|Gait Assessment Test|Undergo gait assessment test
75741756|NCT02552849|Other|No intervention|
75741757|NCT02552927|Device|Chest shield with aluminum foil (CALF)|
75741758|NCT02552927|Device|SHIELD|
75741759|NCT00813683|Other|Acupuncture stimulation|"Acupuncture by stimulation of 67 Bladder point"
75741760|NCT00813683|Other|Acupuncture stimulation|"Acupuncture stimulation of 45 Stomach point (sham)"
75741761|NCT00809237|Drug|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
75741762|NCT00813839|Other|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
75889550|NCT03676101|Biological|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
75889551|NCT02058186|Drug|oral vitamin D|
76060218|NCT03020368|Drug|Diclofenac|
76060219|NCT03020290|Device|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
76060220|NCT03442582|Biological|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
76060221|NCT03581422|Drug|hCG administration before embryo transfer|Thawed embryo transfer with ovulation triggered by hCG
76060222|NCT03581266|Other|Rye/Wheat|Mechanistic study of glucose kinetics after ingestion two kinds of bread
75447835|NCT04239976|Other|MC5-A Scrambler Therapy|Undergo scrambler therapy
75447836|NCT04239976|Other|Quality-of-Life Assessment|Ancillary studies
76060223|NCT05702944|Drug|Phenoxybenzamine|Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
75447837|NCT04239976|Procedure|Quantitative Sensory Testing|Undergo quantitative sensory test
75447838|NCT04239976|Other|Questionnaire Administration|Ancillary studies
75447839|NCT04238091|Drug|Fecal material transfer therapy|"Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not."
76060224|NCT05702866|Diagnostic Test|Transcutaneous oximetry|Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
75447840|NCT04238091|Procedure|4mm Punch Biopsy of Scalp|For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
76060225|NCT03581110|Diagnostic Test|computed tomography|noncontrast-enhanced chest computed tomography
76060226|NCT04765618|Procedure|bariatric surgery|laparoscopic sleeve gastrectomy,or gastric bypass
75597472|NCT00626080|Drug|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
75889552|NCT02058186|Drug|Placebo|
76060227|NCT03586180|Behavioral|Medical Clowning for children|Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
76060228|NCT03580876|Drug|addition of azathioprine|impact of addition of azathioprine after a switch of a second anti-TNF agent
76060229|NCT03580876|Drug|Switch to a second anti-TNF drug alone|Switch to a second anti-TNF drug alone without addition of azathioprine
76060230|NCT03580798|Procedure|Delayed graft|8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
76060231|NCT03580798|Procedure|Simultaneous graft|At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
76060232|NCT03586024|Drug|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
75447841|NCT04238091|Diagnostic Test|Blood draw|Blood will be collected by a standard venipuncture procedure. 60-80cc of blood will be drawn from a patient per blood draw occurrence. Blood samples will be transferred to the research facility. Samples will be used to either stained with cell surface antibodies for fluorescence acquisition cell sorting (FACS) analysis (FACS experiments will allow for assessment of the subset and activation status of immune cells involved in AA or other cutaneous disorder pathology) or to extract DNA for the purposes of exome or genomic sequencing or genotyping of disease associated genes
76060233|NCT05702632|Device|1- Reciprocal electrical stimulation|A specialized programmable electrical stimulation device was used (Uniphy is the manufacturer of Phyaction787; Uniphy, Eindhoven, the Netherlands). The device has two channels that can alternatively stimulate two opposing groups of muscles (reciprocate).
76060234|NCT05702632|Device|TheraTogs orthotic treatment|A sleeveless top vest and two pairs of shorts with two thigh cuffs and limb cuffs each make up the TheraTogs strapping system which is applied to the children in the TheraTogs group. The TheraTogs suit is providing breathable, comfortable- Latex over the torso and thigh, as well as free toileting. For infection control and size fitting problems, participants are not allowed to share their TheraTogs with other patients. TheraTog's orthotic undergarment and strapping system were worn under their regular clothes, so it was neither distracting nor irritating.
75597473|NCT00626080|Drug|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
75597474|NCT04309240|Drug|Rivaroxaban|Rivaroxaban 10mg orally per day for 90days
75597475|NCT02878954|Other|No intervention (Observational study)|"160 patients will be recruited to:~Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~Perform a six-minute walk test Comparison between men and women will be performed."
75597476|NCT02878954|Other|Control session|"Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes."
75597477|NCT02878954|Other|Exercise session|40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
75597478|NCT04309318|Procedure|Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
75889553|NCT02189330|Drug|Tafamidis|20 mg of current commercial formulation.
76060235|NCT05702632|Procedure|traditional physical therapy program|Facilitation of balance and gait training
76060236|NCT03354520|Behavioral|Tailored Videos|web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).
76060237|NCT03354520|Behavioral|OSA Treatment|Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.
76060238|NCT03354520|Behavioral|Standard Videos|Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website
75447842|NCT04238091|Procedure|Skin Microbiome sampling|Skin microbiome will be collected using skin swabs at the time of recruitment according to established protocols outlined by the Human Microbiome Project. Sterile (germ-free) techniques will be used for collection of all specimens, with careful avoidance of contamination of collection area by gloved hands. The sites that will be sampled are (in sequence): Lesional AA skin, non-lesional scalp skin, retro-auricular crease, ante-cubital fossa, and anterior nares. Skin surface specimens will be collected with a Catch-All Sample Collection Swab swab that looks similar to a q-tip and is, moistened with sterile solution. Skin will be swabbed approximately 50 times along the scalp, behind your ear and on your arm, and twisted 2 times around the front of the nose.
75447843|NCT04238091|Procedure|Hair Microbiome Sampling|Hair follicle microbiome (bacteria that live in the hair follicle) will be collected as follows: several hairs will be plucked from the scalp at a time using tweezers, once plucked the bulbs of the hairs will be cut using sterile surgical scissors and processed. Approximately 10-15 hairs will be plucked for processing. The number of hairs plucked may be increased depending on the number of hairs containing bulbs. Up to 50 hairs may be plucked, as long as the subject is able to tolerate it. Only several hairs will be plucked at a time in order to minimize pain and discomfort of the procedure.
75447844|NCT04238091|Drug|Pre-FMT Antibiotic Cocktail|For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
75597479|NCT04309318|Procedure|High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
75597480|NCT01035229|Drug|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
75597481|NCT01035229|Drug|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
75889554|NCT02189330|Drug|Tafamidis|12.2 mgA free acid tablet.
75889555|NCT02189330|Drug|Tafamidis|20 mg new soft gelatin capsule.
75889556|NCT02189330|Drug|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
75889557|NCT02189330|Drug|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
75889558|NCT03676023|Drug|Tranexamic Acid|Inhalation of Transexamic acid in age adjusted dosing
75741763|NCT02552693|Other|Enhanced training, supervision and support|"The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
75741764|NCT02551913|Behavioral|Control|the adolescents will not receive any specific intervention
75741765|NCT02551913|Behavioral|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
75741766|NCT00817505|Drug|AZD1656|Single dose oral tablet
75741767|NCT00817505|Drug|AZD1656|Single dose oral suspension
75741768|NCT00817583|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
75741769|NCT00817583|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
75741770|NCT00817661|Dietary Supplement|Vitamin A|10000 IU Vitamin A or placebo per week
75741771|NCT00817661|Dietary Supplement|Placebo|10000 IU Vitamin A or placebo per week
76060239|NCT03580642|Device|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
75889559|NCT02059824|Device|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
75889560|NCT03633279|Drug|Branched chain amino acid|Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
75889561|NCT03633279|Drug|Placebo|an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
75889562|NCT02189408|Biological|Platelet rich plasma|
75889563|NCT02257190|Behavioral|Control|One hour of rest.
75889564|NCT02257190|Behavioral|IW3|A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
76060240|NCT03585868|Other|Placebo|Beverage with no flavonoids
75741772|NCT00642707|Drug|PRO 140 (humanized monoclonal antibody to CCR5)|
75741773|NCT00642707|Drug|Placebo Comparator|
75741774|NCT02551523|Drug|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
75741775|NCT02551523|Drug|Standard of care combinational antiretroviral therapy|
75741776|NCT00814151|Other|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
75741777|NCT00817739|Drug|Leuprorelin|Leuprorelin injection
75741778|NCT00817739|Drug|Flutamide|Flutamide tablets
75741779|NCT00817895|Drug|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
75889565|NCT02257190|Behavioral|IW1|A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
76060241|NCT03585868|Other|Flavonoids|Flavonoids-enriched cacao beverage
76060242|NCT03585868|Dietary Supplement|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
76060243|NCT03585634|Behavioral|Dads in Gear Program|
76060244|NCT03163264|Behavioral|Peer Assisted Lifestyle|Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
76060245|NCT03163264|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
76060246|NCT03886324|Combination Product|GIE Medical Drug Coated Balloon|Stricture patients treated by DCB
75447845|NCT04238091|Drug|Bowel Prep|The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
75447846|NCT04237155|Other|Questionnaire|Subjects will complete a verbal material scoring questionnaire
75447847|NCT04237155|Other|Cognitive tests|Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference
75447848|NCT04236531|Other|Cognitive tests and neuroimaging|comparison of cognitive performances and brain anatomy
75447849|NCT04231825|Device|Transcranial alternating current stimulation|Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
75447850|NCT04223479|Drug|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
75741780|NCT00817895|Drug|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
75741781|NCT00817895|Procedure|TACE|All patients will accept TACE one month after tumor was resected.
75741782|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 1.5microg|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
76060247|NCT01865487|Biological|H56ug/IC31nmol|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
76060248|NCT01865487|Biological|Placebo|Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
76060249|NCT03585556|Drug|Intravitreal anti-VEGF|Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
76060250|NCT03585556|Biological|Intravitreal AAVCAGsCD59|An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
76060251|NCT03585556|Drug|Oral prednisolone|A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
76060252|NCT05702398|Drug|Vitamin A|1,000 μg retinyl palmitate twice a day for 6 months
76060253|NCT05702398|Drug|Nicotinamide|500 mg NAM twice a day for 6 months
76060254|NCT05702398|Other|Other: Placebo|Identical placebo pills twice a day
76060255|NCT01699503|Behavioral|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
76060256|NCT01709409|Drug|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
76060257|NCT01709409|Drug|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
75741783|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
75447851|NCT04223479|Drug|Placebos|The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
76060258|NCT01698879|Drug|Mylotarg|"Cohort 1 version 1.0. GO: 6mg/m^2 (maximum 10 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 1.0 version 2.0: GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 2: G-CSF: 150 mcg/m^2, SC, days 0 to 7. GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO."
75447852|NCT04219878|Behavioral|Know@Home|Participants randomly assigned to the Know@Home arm will access the features of Know@Home by downloading the app or accessing the website. The contents were developed to serve as a comprehensive mobile HIV prevention platform for MSM or TGW, with HIV prevention and care information and links to resources. This intervention arm provides an toolkit that allows users to access information about prevention services as their needs change. Participants will have access to Know@Home for the study period. The Know@Home arm will offer participants the opportunity to order free condoms and lubricant as well as an at-home sexually transmitted infection (STI) testing kit.
75447853|NCT04219878|Other|Self-test Kit|All participants will be shipped two at-home HIV self-tests. They will also receive a link to a previously-produced video that fully describes the specimen collection process, pointing out common errors and providing tips for successful collection. Participants will interact with study staff through phone, email, or text. Information to schedule a video HIV testing and counseling session with study staff will be made available to participants in all arms via a website, email, and/or text.
75447854|NCT04212117|Other|The Patient Activated Learning System (PALS)|Randomization into PALS arm.
75447855|NCT04212117|Other|WebMD|Randomization into WebMD arm.
75741784|NCT00814229|Biological|H9N2 whole virus vaccine vaccine, IM, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
75741785|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 45microg|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
75741786|NCT00814229|Biological|H9N2 whole virus vaccine, alum, IM, 1.5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
75741787|NCT00814229|Biological|H9N2 whole virus, alum, IM, 5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
75741788|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 15 microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
75889566|NCT02058342|Behavioral|Active Play at Home|The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
75889567|NCT03680391|Procedure|Cesarean section|"Both groups cesarean section will be held with the same technique:~spinal anethesia~pfennenstiel imcision~lower segment cesarean section~suturing uterus in two layers while exterionezed~gentle manibulation~no towels in gutters will be used"
75889568|NCT03680313|Procedure|Hypertension outpatient treatment|Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
76060259|NCT02335294|Drug|TRV130|Rescue: Ibuprofen, oxycodone
76060260|NCT02335294|Drug|Morphine|Rescue: Ibuprofen, oxycodone
75741789|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 45microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
75741790|NCT00814229|Biological|H9N2 virosome vaccine, IM, 1.5microg|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
76060261|NCT02335294|Drug|Placebo|Rescue: Ibuprofen, oxycodone
76060262|NCT01698801|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
76060263|NCT01698801|Drug|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
76060264|NCT03580252|Other|Correlation analyses for the outcomes|No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
75889569|NCT02260206|Drug|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
75889570|NCT02192918|Behavioral|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
76060265|NCT04548297|Other|Assessment|Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level
76060266|NCT03585166|Procedure|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
76060267|NCT03585166|Procedure|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
76060268|NCT05702242|Procedure|IUD removal with no visible strings|Removal with either alligator forceps or MVA
76060269|NCT05702242|Device|Alligator forceps|IUD removal with alligator forceps
76060270|NCT05702242|Device|Manual Vacuum Aspirator|IUD removal with MVA
76060271|NCT01682811|Drug|Part 1 Levulan injection|Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
76060272|NCT01682811|Drug|Part 1 Levulan surface application|Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
75447856|NCT04186793|Behavioral|Guided Grocery Shopping (GGS)|"The GGS group will be scheduled for 4 weekly sessions to co-shop with the study Registered Dietitian (RD) or clinical research coordinator (CRC). The primary shopper for the household will be required to attend all 4 sessions. The study participant will be required to attend at least 1 session and other family/household members will be encouraged to attend. The weekly sessions will take place at the family's primary grocery store. During each session, the RD will facilitate selection of low free sugar foods and guide the primary shopper on menu planning for a low free sugar diet. In the 4th session, the primary shopper will be asked to shop independently while being observed by the RD/CRC. Prior to checking out, the RD/CRC will approve and/or correct their shopping choices.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
75741791|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 5microg|influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
75741792|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 15microg|influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
75741793|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 45microg|influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
76060273|NCT01682811|Drug|Part 1 Levulan surface application twice|Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
75741794|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
75741795|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
76060274|NCT01682811|Drug|Part 1 Levulan surface application twice with microneedling|Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
76060275|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
76071986|NCT03519412|Drug|temozolomide (induction),|temozolomide is administered to MGMT promoter methylation-positive MMRp patients orally, once daily, at the dose of 150-200 mg/m2/day for 5 consecutive days of each treatment cycle A treatment cycle will comprise 5 days of temozolomide administration (Day 1 to 5) followed by 23 days of rest for a total of 28 days (4 weeks) period (dose-schedule: 150 mg/m2 day 1-5 q28),until disease progression or unacceptable toxicity whichever comes first.
75447857|NCT04186793|Other|Diet Provision Group|"This intervention will be applied to each family and will target foods and beverages that contain free sugars added to food by consumer, cook, or manufacturer, but preserve the family's other food group choices. During the 4 week long intervention, families will be able to choose meals from a list of foods similar to their usual diet. Groceries for each week will be delivered to the family. Each child will be provided with a lunch bag and instructed to bring lunch to school to maintain the study diet.~Families will have the opportunity to choose from a list of pre-prepared evening meals that are similar to what they consumed before study initiation but without free sugars. The families will be instructed to not eat any food outside of the assigned diet.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
75597482|NCT01035229|Other|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
75597483|NCT02880436|Other|air pollution|impact of various pollution agents above threshold and their correlation with acute myocardial infarctions are analyzed
75597484|NCT01106404|Device|RestoreSensor Neurostimulation System|"Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF."
75597485|NCT02880592|Other|Affinity Allograft|fresh hypothermically stored human amniotic membrane
75741796|NCT00568685|Drug|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
75889571|NCT02192918|Behavioral|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
75889572|NCT02192918|Behavioral|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
75741797|NCT00568685|Drug|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
75889573|NCT03535610|Device|Uterine Embolization|Uterine Embolization with PVA Microspheres
75889574|NCT03535532|Procedure|unilateral laparoscopic adrenalectomy|unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
75889575|NCT03535532|Drug|standard medical treatment|standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
75889576|NCT02058576|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
75741798|NCT00568685|Drug|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
75447858|NCT04183621|Diagnostic Test|high resolution impedance manometry|Two detailed swallow assessments to be carried out at between 2-4 months and 8-10 months of age
75447859|NCT04182841|Device|RheOx|RheOX is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
75597486|NCT02880592|Other|Standard of care|offloading, debridement, infection management using appropriate dressings
75597487|NCT01059799|Drug|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
75597488|NCT01059799|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
75741799|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
75741800|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
75741801|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
76060276|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
76060277|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
76060278|NCT03585088|Device|surgical pleth index|All patients applied surgical pleth index after recovery of spontaneous breathing at the time of peritoneum and skin closure under Bispectral index score <=60.
75741802|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
75889577|NCT02058576|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
75447860|NCT04181619|Dietary Supplement|Coffeeberry beverage|One exposure of 300 mg coffeeberry extract in a 300 ml flavored still beverage prior to exercise session
75447861|NCT04181619|Other|Comparator beverage|One 300 ml still beverage, color and flavor matched to experimental beverage prior to exercise session
76060279|NCT03321760|Radiation|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
76060280|NCT03580096|Other|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
76060281|NCT03580096|Other|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
75741803|NCT00814385|Biological|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
75741804|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
75741805|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
75741806|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
75741807|NCT00814385|Biological|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
75741808|NCT04044911|Behavioral|Task model (CogWatch)|
75741809|NCT04045457|Procedure|dry needling|insertion of needle into active myofascial trigger point
75889578|NCT03675867|Other|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise
75889579|NCT02192996|Dietary Supplement|Probiotic|blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
76060282|NCT03580018|Drug|Tranexamic Acid Powder|Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
75447862|NCT04179565|Behavioral|Healthy Children Healthy Families|The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
75447863|NCT04178772|Device|Acuvue Moist Multifocal Contact Lens JJVC Marketed Contact Lens|JJVC Marketed Contact Lens
75447864|NCT04226976|Device|Otoband|Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
75447865|NCT04226976|Device|Placebo Device|Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
75741810|NCT02551601|Other|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
75889580|NCT02058654|Drug|Creatine|Creatine powder (5 g)
75889581|NCT02058654|Drug|Placebo|Bulking agent powder (5 g)
75447866|NCT04178187|Drug|Caps Lactolevure|One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
75447867|NCT04178187|Drug|Caps Placebo|Caps Placebo
75741811|NCT00061945|Drug|allopurinol|Given PO
76060283|NCT03580018|Procedure|Post-anterior cruciate ligament reconstruction (ACLR)|Post-anterior cruciate ligament reconstruction (ACLR)
76060284|NCT03584854|Drug|15-methyl prostaglandin F2α|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."
76060285|NCT03584854|Drug|Methylergonovine Maleate|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."
76060286|NCT04765540|Behavioral|Low Intensity Nudges|"A bundle of 'low-intensity' passive interventions, including:~Large Mirrors & hand-shaped sign posts pointing to the station"
76060287|NCT04765540|Behavioral|High Intensity Activities|"A bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks for handwashing station users, a community message board & general encouragement"
76060288|NCT04765540|Behavioral|BRAC's business-as-usual|A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.
75447868|NCT04169490|Other|Placebo Cream Base Emulsion Moisturizer|Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days
75741812|NCT00061945|Drug|cyclophosphamide|Given IV
75597489|NCT02874547|Behavioral|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
75597490|NCT01106248|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
75597491|NCT01059175|Device|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
75597492|NCT01059175|Device|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
75741813|NCT00061945|Drug|daunorubicin hydrochloride|Given IV
76060289|NCT03586336|Device|ReDS-Guided|ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge
75741814|NCT00061945|Drug|vincristine sulfate|Given IV
75741815|NCT00061945|Drug|dexamethasone|Given PO and as eye drops
75741816|NCT00061945|Drug|asparaginase|Given SC
75741817|NCT00061945|Biological|filgrastim|Given SC
75741818|NCT00061945|Drug|imatinib mesylate|Given PO
76060290|NCT03586336|Device|Usual Care|ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
76060291|NCT03584698|Drug|Misoprostol 100Mcg Tab|women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
76060292|NCT03584698|Drug|Evening Primrose Oil 1000 MG|women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
75447869|NCT04169490|Other|FS2 Emulsion Moisturizer|Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
75447870|NCT04169490|Other|Active Comparator Onion Skin Extract Gel (Mederma)|Topical onion skin extract gel (Mederma) applied b.d. for 120 days
75447871|NCT04169490|Other|Active Comparator Silicone Gel (Kelo-Cote)|Topical silicone gel (Kelo-Cote) applied b.d. for 120 days
75447872|NCT04169490|Other|Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer|Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
75447873|NCT04169451|Drug|Letrozole|Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
75597493|NCT04301869|Drug|Antibiotics|Oral versus intravenous therapy
75741819|NCT00061945|Drug|methotrexate|Given IT, IV, and PO
75741820|NCT00061945|Drug|cytarabine|Given IV
75741821|NCT00061945|Drug|trimethoprim-sulfamethoxazole|Given PO
75741822|NCT00061945|Drug|mercaptopurine|Given PO
75741823|NCT00061945|Drug|leucovorin calcium|Given IV and PO
75741824|NCT00061945|Biological|alemtuzumab|Given SC
75741825|NCT00061945|Drug|acyclovir|Given PO
75741826|NCT00061945|Other|laboratory biomarker analysis|Correlative studies
76060293|NCT03588130|Drug|EscharEx (5% EX-02 formulation)|Active arm
76060294|NCT03588130|Drug|Gel Vehicle|Control arm
75447874|NCT04169438|Other|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Topical vehicle white (bone) color, oil/water emulsion moisturizer.
75447875|NCT04169438|Other|FS2 Emulsion Moisturizer + Petrolatum|Topical FS2 white (bone) color, oil/water emulsion moisturizer.
75597494|NCT04301479|Drug|hydrocortisone sodium succinate|Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
76060295|NCT03588130|Drug|Non-surgical standard of care (NSSOC)|Santyl (Enzymatic debridement) or commercially approved Hydrogel
76060296|NCT05702008|Other|Rabies Information Education and Communication Material|The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1&ipp=All&lang=1&level=2&sublinkid=502&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
76060297|NCT03584620|Other|Inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
76060298|NCT03584620|Other|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
76060299|NCT05703178|Behavioral|Online Pain Coping Skills Training|The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.
75447876|NCT04161040|Behavioral|Performance-based incentives|Participants will earn $1 per minute of engagement in physical activity.
75447877|NCT04159818|Drug|Nivolumab|240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards
75447878|NCT04159818|Drug|Cisplatin|40mg/m2, weekly for two weeks
75447879|NCT04159818|Drug|Low dose doxorubicin|15mg flat dose, weekly for 8 weeks
75447880|NCT04157881|Drug|RABEprazole 20 Mg Oral Delayed Release Tablet|Absorption of APO-Dabigatran measured with and without influence of rabeprazole
75597495|NCT04301479|Drug|Saline|Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
75597496|NCT01297491|Drug|BKM120|Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
75741827|NCT00061945|Other|pharmacological study|Correlative studies
75741828|NCT00817973|Dietary Supplement|Casein|
75889582|NCT03680235|Other|Informational Intervention|Receive standard information about breastfeeding and pregnancy
75447881|NCT04157881|Drug|APO-Dabigatran 150mg|Absorption of APO-Dabigatran post single dose
75447882|NCT04148651|Device|The CO2RE® System|The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN) for the treatment of leukoplakia (vulvar dystrophies).
75463049|NCT01871129|Drug|Dexmedetomidine|Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.
75597497|NCT04303585|Procedure|SAP block|The anesthesiologist performs SAP block immediately before surgery under ultrasound guide
75741829|NCT00817973|Dietary Supplement|Whey|
75741830|NCT00817973|Dietary Supplement|Cod|
75741831|NCT00817973|Dietary Supplement|Gluten|
75741832|NCT00818051|Radiation|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
75741833|NCT01097941|Biological|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
75889583|NCT03680235|Other|Informational Intervention|Receive information about breastfeeding and cancer
75889584|NCT03680235|Other|Interview|Participate in focus groups
76060300|NCT05703178|Other|Education|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
76060301|NCT03584308|Dietary Supplement|Viusid®|The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
76060302|NCT03584308|Dietary Supplement|Glizigen®|The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
75889585|NCT03680235|Other|Survey Administration|Ancillary studies
76060303|NCT03584308|Dietary Supplement|Viusid Placebo|The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
76060304|NCT03584308|Dietary Supplement|Glizigen Placebo|The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
76060305|NCT01682031|Dietary Supplement|selenomethionine|Given PO
75889586|NCT03535220|Combination Product|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
75889587|NCT02660424|Drug|VX-150|
75889588|NCT02660424|Drug|Placebo|
76060306|NCT01682031|Other|placebo|Given PO
76060307|NCT01682031|Drug|cisplatin|Given IV
76060308|NCT01682031|Radiation|radiation therapy|Undergo radiotherapy
76060309|NCT01682031|Procedure|quality-of-life assessment|Ancillary studies
76060310|NCT03584230|Behavioral|Assigned to positive group|See arm description
75463050|NCT01871129|Other|Saline (placebo)|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
75889589|NCT02189564|Behavioral|Feedback about good performance|
75889590|NCT02189564|Behavioral|Feedback about good performance + money|
76060311|NCT03584230|Behavioral|Assigned to negative group|See arm description
76060312|NCT03020134|Drug|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
76060313|NCT03020134|Drug|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
76060314|NCT03020134|Drug|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
76060315|NCT03020134|Drug|Placebo|Placebo
75463051|NCT01871155|Dietary Supplement|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement"
75463052|NCT01871168|Procedure|TAP block|Infusion of 0.5-1% lidocaine
75463053|NCT01871168|Procedure|Sham TAP block|Infusion of saline
76060316|NCT03020056|Drug|Phacolin eye drops|After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
76060317|NCT03020056|Procedure|cataract surgery|After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
76060318|NCT05701774|Drug|DCCR|Once daily oral administration
76060319|NCT03584074|Drug|Pregabalin 75mg|Orally taken twice daily for 8 weeks
76060320|NCT03584074|Drug|Celebrex 200Mg Capsule|Orally taken once daily for 8 weeks
75447883|NCT04142736|Other|Prone Position|The best-fitting and most-tolerated oxygen interface will be used in the prone position--this could be different from patient to patient, and different from what is used in the supine position, and could differ between patients but also institutions (i.e., depending on the availability of masks with or without a reservoir bag and with or without the Venturi system, HFNO, CPAP or NIV). The patient will be placed in the prone position for at least 2 hours, which may be prolonged if the patient is comfortable or interrupted if the patient presents any criteria for prone position discontinuation. After the prone position period, the patient will be rotated to the semi-recumbent supine position for at least 2 hours and a maximum of 4 hours. This 2-hour time frame will depend on nursing availability, need for hygiene, complementary explorations, or diet.
75447884|NCT04139252|Other|No intervention|No intervention
75597498|NCT04303585|Procedure|ESP block|The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
75597499|NCT04324593|Device|Peripheral intravenous analysis (PIVA) algorithm|An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
75597500|NCT01106092|Biological|GSK2036874A vaccine|Intramuscular, single dose
75597501|NCT01106092|Biological|Zilbrix™/Hib vaccine|Intramuscular, single dose
75447885|NCT04136990|Procedure|Isolated ACL reconstruction|Isolated ACL reconstruction using the bone-patellar tendon autograft.
75597502|NCT01106092|Biological|Poliorix™|Intramuscular, single dose
75597503|NCT01097668|Biological|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
75597504|NCT04307290|Drug|Dexmedetomidine Hydrochloride, or Saline|drug infusion from 10 min before the start of surgery to the end of surgery
75889591|NCT02189564|Behavioral|Feedback about average performance|
76060321|NCT03584386|Device|V-CAMS (aka Jaspr)|V-CAMS is an integrated software system for use on any device by suicidal patients.
76060322|NCT03583996|Combination Product|HepQuant SHUNT Liver Diagnostic Test|One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
76060323|NCT03583918|Device|HighThroughput Micro Coring Device|Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
76060324|NCT03583762|Diagnostic Test|Mass spectrometry|Molecular diagnostic test for bacterial identification from bacterial colony
76060325|NCT03583762|Diagnostic Test|Microarray assay|Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
76060326|NCT03583294|Other|MRI pelvic|Pelvic MRI
76060327|NCT05701696|Diagnostic Test|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
76060328|NCT05701696|Diagnostic Test|Widespread pain index|Total the number of painful body areas
76060329|NCT05701696|Diagnostic Test|Symptom severity scale|The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms
75447886|NCT04136990|Procedure|ACL + LEAT reconstruction|ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
75447887|NCT04136262|Drug|Tripterygium wilfordii Hook F (TwHF)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
75447888|NCT04136262|Drug|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
75447889|NCT04136262|Other|Dummy Tripterygium wilfordii Hook F (TwHF)|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
75447890|NCT04133922|Drug|GLP-1|glucagon-like peptide 1
75447891|NCT04133922|Drug|Insulin|we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
75447892|NCT04133922|Drug|Dextrose 20 % in Water|We are using Dextrose to maintain Euglycemia during the insulin clamp
75447893|NCT04133077|Biological|blood samples collection|Serology and genetic analyses will be performed in patients blood samples
75447894|NCT04118049|Other|BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel.|BiopHreshTM is a vaginal probiotic supplement that is offered over the counter and contains four different lactobacilli strains (L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus). RestoreTM is a moisturizing personal lubricant that has been on the market for three years. Participants will use 1 probiotic capsule with RestoreTM gel nightly three times weekly.
75447895|NCT04118049|Other|Standard Care|Standard care arm is standard care for pessary use. Pessary maintenance will be performed standardly by their provider.
75447896|NCT04117516|Procedure|Open surgery|"Open carpal tunnel release will be performed, in the theatre, with tourniquet, under local anesthesia and sedation, through a short longitudinal volar classical approach of the hand, that allows to visualize the complete division of the ligament."
75447897|NCT04117516|Procedure|Percutaneous surgery|Percutaneous carpal tunnel release will be performed, ambulatory, with a percutaneous scalpel, through a short transverse volar approach, 1-2cm proximal to the wrist, under Wide Awake Local Anesthesia with No Tourniquet.
75447898|NCT04115761|Biological|autologous dendritic cells|The total 10 doses (1 mL/dose; 2±0.5 × 10^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
75447899|NCT04115059|Drug|Dasatinib|Oral, daily, dosing per protocol, once a day for cycle
75447900|NCT04114890|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
75447901|NCT04113304|Behavioral|Parenting Young Children Check-up (PYCC)|The PYCC intends to motivate parents to learn behavioral parenting strategies to reduce child disruptive behavior.
75597505|NCT04902430|Procedure|Power chain and Crimpable hook for En-Masse Retraction|"Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew"
75597506|NCT04902430|Procedure|T- Loop|Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
75597507|NCT01325207|Radiation|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
75597508|NCT01324349|Device|Veriset Hemostatic Patch|Topical hemostat
75597509|NCT01324349|Device|Fibrin Sealant (TachoSil®)|Topical hemostat
75597510|NCT01095250|Drug|AIN457|
75597511|NCT01095250|Drug|AIN457|
75447902|NCT04104828|Biological|Allergovit|Grass/tree-allergen extract with aluminium adjuvant for treatment of allergic rhinitis
75447903|NCT04104828|Biological|Polvac|Grass/tree-allergen extract with MCT adjuvant for treatment of allergic rhinitis
75447904|NCT04104828|Biological|Pollinex Quattro|Grass/tree-allergen extract with MCT-MPLA adjuvant for treatment of allergic rhinitis
75447905|NCT04085042|Device|PIVC pack|The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
75447906|NCT04082676|Drug|Hyperbaric bupivacaine spinal|In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
75447907|NCT04082676|Drug|Hyperbaric bupivacaine spinal|In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
75447908|NCT04081233|Procedure|surgical stabilization|Surgical procedure utilizing any commercially available internal rib fixation system
75447909|NCT04081233|Procedure|Usual care|Usual care typically consists of breathing exercises and pain control,often including opioids
75463054|NCT01871181|Procedure|Ilioinguinal block|0.25% bupivacaine will be administered on a mg/kg basis
75463055|NCT01871181|Procedure|Local infiltration|Surgeon will infiltrate incision area with local anesthetic before closure.
75597512|NCT01095250|Drug|AIN457|
75597513|NCT01095250|Drug|Placebo|
75597514|NCT01324271|Device|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
75597515|NCT04325711|Drug|CSPCHA131|CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
75597516|NCT01095094|Drug|ritonavir|Given orally
75597517|NCT01095094|Drug|lopinavir|Given orally
75597518|NCT01323647|Biological|PoliorixTM|Single dose, intramuscular administration
76060330|NCT05701696|Other|Fibromyalgia impact questionnaire|A tool to assess health status in fibromyalgia
76060331|NCT05701696|Diagnostic Test|Hospital Anxiety and Depression Scale|An instrument for detecting depression and anxiety
76060332|NCT05701696|Diagnostic Test|Self-Leeds Assessment of Neuropathic Symptoms and Signs|An instrument used to identify pain of neuropathic origin
76060333|NCT03153826|Other|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
76060334|NCT03158818|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
76060335|NCT03156556|Behavioral|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
75447910|NCT04073667|Behavioral|Exercise|"Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~Teaching the correct scapular position, D. Postural correction exercises;~Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~a. Joint position sense:~Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty."
75447911|NCT04070131|Other|Horse-Assisted Rehabilitation|One hour weelky session of hippotherapy.
75447912|NCT04053569|Dietary Supplement|Table Grape supplement|5g/Kg of table grape for four weeks with dietary recommendations along with a strict restriction of fruits and limitation of other foods containing polyphenols.
75741834|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
75741835|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
75741836|NCT00642473|Drug|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
75447913|NCT04048642|Behavioral|DASH|7 days of a DASH diet
75447914|NCT04048642|Behavioral|Whole-Food, Plant-Based|7 days of a WFPB diet
75741837|NCT00642473|Drug|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
75741838|NCT00642473|Other|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
75741839|NCT00818129|Drug|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
75741840|NCT00818129|Drug|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
75741841|NCT00645671|Drug|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
75741842|NCT00645671|Drug|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
75741843|NCT00366340|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
75741844|NCT00366340|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
75741845|NCT03992326|Other|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
76060336|NCT04405336|Drug|tab block|injection of tab block to women who are doing cs
76060337|NCT04405336|Drug|PCA|giving women PCA
76060338|NCT04405336|Drug|women who will not receive tab block or PCA|no tab block or PCA will be given
76060339|NCT03583138|Drug|buprenorphine|To provide buprenorphine for 12 months for those who are interested in receiving it.
76060340|NCT03153514|Biological|Obinutuzumab|"Obinutuzumab i.v.~[Day 0 = day of stem cell transplant]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)"
76060341|NCT03583060|Behavioral|Mindful Awareness in body-oriented therapy|teaches interoceptive awareness skills for self care
76071987|NCT03519412|Biological|pembrolizumab (treatment)|pembrolizumab is administered to MGMT-IHC-negative, MGMT promoter methylation-positive MMRp patients with TMB>20 Mut/Mb after Temozolomide treatment, and to MMRd. Patients receive pembrolizumab IV , 200 mg Q3W, Day 1 of each 3 week cycle for maximum 35 cycles, until disease progression or unacceptable toxicity whichever comes first.
75447915|NCT04036994|Device|Photobiomodulation therapy|All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
75447916|NCT04032782|Drug|HM15136|10 mg/mL as protein in prefilled syringes
75597519|NCT01323647|Biological|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
75597520|NCT01094782|Other|Acupuncture|Subjects receive 6 acupuncture treatments for neck or back pain.
75597521|NCT01094782|Other|Sham Acupuncture|Subjects receive 6 sham acupuncture treatments for neck or back pain.
75597522|NCT05645315|Drug|TQB2618 injection and TQB2450 injection|TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
75597523|NCT04325555|Drug|PrEP|The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
75741846|NCT03992326|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
75741847|NCT03992326|Drug|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
75889592|NCT03680079|Other|Group education sessions|Peer support and interaction both in-person during group education sessions and online via social media platforms
75889593|NCT02060448|Behavioral|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
75889594|NCT02060448|Behavioral|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
75889595|NCT03675633|Diagnostic Test|FEUrea|FEUrea in decompansated liver cirrhosis
75447917|NCT04032782|Drug|Placebo of HM15136|Placebo in prefilled syringes
75447918|NCT04030520|Behavioral|POPPi behavioral intervention|behavioral intervention with offer of HIV self test
75741848|NCT03992326|Drug|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
75741849|NCT03992326|Other|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
75889596|NCT03517254|Dietary Supplement|Glutamine|At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
75889597|NCT03517254|Other|Strength training program|One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
75889598|NCT03517254|Other|Placebo|Maltodextrin powder to mimic glutamine,
75889599|NCT03517254|Other|Dietary recommendations|All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
75447919|NCT04030520|Behavioral|POPPi behavioral intervention|behavioral intervention
75447920|NCT04012177|Dietary Supplement|Balanced-energy protein (BEP)|Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
75447921|NCT04012177|Drug|Azithromycin Tablets|Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.
75447922|NCT04012177|Drug|Choline Bitartrate|Pregnant women randomized in Arm D will received 450 mg of Choline orally once daily, starting from week 20 weeks of pregnancy until birth outcome
75447923|NCT04012177|Drug|Nicotinamide|Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
75447924|NCT04011995|Behavioral|Intermittent caloric restriction|"The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
75597524|NCT05645237|Radiation|radiotherapy|Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
75597525|NCT00623285|Drug|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
75597526|NCT00623285|Drug|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
75741850|NCT01049386|Other|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
75741851|NCT01049386|Procedure|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
75741852|NCT01045954|Drug|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
75597527|NCT02878720|Device|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation"
75597528|NCT01097044|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
75447925|NCT04011995|Behavioral|Low carbohydrate diet|"During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
75597529|NCT01097044|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
75741853|NCT01046032|Drug|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
75741854|NCT01046032|Drug|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
75741855|NCT01046188|Other|Knowledge Questionnaire|Administered before and after teaching intervention
75889600|NCT02189876|Behavioral|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
75447926|NCT04011995|Behavioral|Health education on reducing the cardiometabolic risk|Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
75447927|NCT04004910|Other|Plasma soluble TNF receptor pulldown|The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
75741856|NCT01046188|Other|Perceived Stress Scale|Administered before and after teaching intervention
75741857|NCT01046188|Other|Satisfaction questionnaire|Administered after the intervention and at study completion
75741858|NCT01046188|Other|Web-based IVF teaching|Web-based IVF teaching
75741859|NCT01046188|Other|Didactic lecture|Didactic lecture
75741860|NCT00061633|Drug|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
75741861|NCT00061633|Drug|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
75741862|NCT00645593|Drug|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
76060342|NCT03020524|Biological|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
76060343|NCT03020602|Other|Laboratory Biomarker Analysis|Correlative studies
75447928|NCT04004910|Other|Plasma soluble TNF receptor pulldown + chemotherapy|"The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the Immunopheresis® procedure is combined with low dose chemotherapy to potentially enhancing the latter's cytotoxic effect."
75447929|NCT04004910|Drug|Chemotherapy Drugs, Cancer|Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
75889601|NCT02189876|Behavioral|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
75889602|NCT03675555|Drug|Mirtazapine|Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
75889603|NCT03675555|Drug|Dexamethasone phosphate|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
75889604|NCT03675555|Drug|Placebo|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
75889605|NCT02190032|Device|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
75889606|NCT02190032|Device|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
75447930|NCT04002193|Other|volume expansion|To assess fluid responsiveness
76060344|NCT03020602|Other|Pharmacological Study|Correlative studies
76060345|NCT03020602|Drug|Ubidecarenone Injectable Nanosuspension|Given IV
76060346|NCT03582982|Behavioral|Eccentric overload exercise|12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.
76060347|NCT03153670|Other|fMRI|DBS patients will undergo fMRI scanning. For each patient, scans will be performed using a selection of DBS settings. fMRI responses will be analysed to evaluate brain responses on different DBS settings. These results will be provided to the programming clinician to guide them choose the optimal setting for each patient at the clinician's discretion.
76060348|NCT03582904|Procedure|tDCS|real or sham tDCS delivered to primary motor cortex
76060349|NCT01567527|Drug|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
76060350|NCT01567527|Drug|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
75447931|NCT04000334|Other|MAP increased to optimize cerebral blood flow|MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
75889607|NCT03679923|Dietary Supplement|NEM® brand eggshell membrane|Dietary supplement for the support of joint health.
75889608|NCT03679923|Dietary Supplement|Placebo|Placebo
75889609|NCT02060994|Other|No intervention|No intervention
75889610|NCT02194166|Drug|Trastuzumab|Trastuzumab IV or SC will be administered as described.
75889611|NCT02194166|Drug|Paclitaxel|Paclitaxel will be administered in accordance with local hospital practice.
75889612|NCT02194166|Drug|Docetaxel|Docetaxel will be administered in accordance with local hospital practice.
75889613|NCT03679845|Drug|Sarilumab|Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
75889614|NCT02061072|Other|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
75889615|NCT02194244|Drug|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
75889616|NCT02194244|Drug|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
75889617|NCT03679533|Dietary Supplement|Freeze-Dried Cranberry Powder|Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.
75889618|NCT03679533|Dietary Supplement|Placebo|Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
75447932|NCT04000334|Other|MAP between 65 and 85 mmHg|MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
75447933|NCT03998410|Device|Lung Doppler Signals|Recording Doppler ultrasound on the right chest wall
75447934|NCT03993249|Biological|Nivolumab|standard of care chemoradiotherapy + Nivolumab
75447935|NCT03993249|Other|chemoradiotherapy|standard of care chemoradiotherapy
75447936|NCT03991611|Other|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
75447937|NCT03991611|Other|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
75447938|NCT03991611|Other|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
75889619|NCT02194322|Drug|BIBN 4096 BS - in single rising doses|
75889620|NCT02194322|Drug|Placebo|
75889621|NCT03675399|Other|Supra-threshold isometric exercise|The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
75889622|NCT03675399|Other|Infra-threshold isometric exercise|The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
75889623|NCT02195882|Procedure|Exercise program of the scapular muscle stabilizers|
75889624|NCT02193308|Drug|Telmisartan/Amlodipine FDC|
75889625|NCT02193308|Drug|Telmisartan|
75889626|NCT02193308|Drug|Amlodipine|
75889627|NCT03683199|Procedure|Rhinoplasty|"The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts."
75889628|NCT02195960|Dietary Supplement|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
75889629|NCT02195960|Dietary Supplement|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
75889630|NCT02060604|Drug|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
75889631|NCT02060604|Drug|Ranibizumab|3 monthly ranibizumab, then as needed
75889632|NCT03679455|Drug|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
75889633|NCT02193386|Other|No intervention, no follow-up, only registration|Usual Care
75889634|NCT02193386|Other|Intervention period|Predefined intervention program
75889635|NCT03315143|Drug|Sotagliflozin|Sotagliflozin was administered as a tablet(s), orally once daily.
75447939|NCT03991611|Other|6 months follow-up to assess the prevalence of PTSD symptoms|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 items during the telephone follow-up, 6 months after ICU discharge .
75447940|NCT03991611|Other|1 year follow-up to assess psychiatric morbidity|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
76060351|NCT03582670|Behavioral|Strategy Training|Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.
75447941|NCT03990883|Device|Princess Filler Lidocaine|correction of nasolabial folds
75447942|NCT03984890|Drug|Vitamin D3|Vitamin D3 drops 800IU/d for 3 months
75447943|NCT03984890|Drug|Traditional treatment of CGD and TB|Anti-tuberculosis drugs, interferon-gamma
75447944|NCT03982459|Behavioral|decision support tool|computerized online decision support tool
75447945|NCT03980834|Behavioral|ParentCorps FUNdamentals|is a series of large-group experiential PD days (in groups of 25-40 participants from across all schools) which takes place in the first summer prior to implementation. Leaders participate in a 2-day FUNdamentals series with leaders from other schools.
75447946|NCT03980834|Behavioral|ParentCorps 101 E-learning|is a self-paced interactive web-based series with 7 modules intended to help facilitators build confidence and mastery of evidence-based practices.
75447947|NCT03980834|Behavioral|Training|group-based series to prepare facilitators (mental health professionals and teachers) to implement Programs with fidelity and to ensure high levels of exposure by parents and students. Mental health professionals are supported to facilitate the Program for Parents (day and after-school versions) with fidelity. Pre-K teachers and assistants are supported to implement the Program for Students in the classroom. In addition, early childhood staff (including Kindergarten teachers as needed) is trained to facilitate the Program for Students during after-school hours in parallel with the Parenting Program. All facilitators receive training on engaging parents to participate
75597530|NCT01322009|Drug|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
75597531|NCT01322009|Drug|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
75597532|NCT01321697|Procedure|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
75597533|NCT01320683|Drug|oxaliplatin|Given IV
75597534|NCT01320683|Drug|leucovorin calcium|Given IV
75597535|NCT01320683|Drug|fluorouracil|Given IV
75597536|NCT01320683|Biological|bevacizumab|Given IV
75597537|NCT01320683|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
75597538|NCT01320683|Other|laboratory biomarker analysis|Correlative studies
75597539|NCT01320683|Other|pharmacological study|Correlative studies
75889636|NCT03315143|Drug|Placebo|Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
75597540|NCT01320683|Drug|irinotecan hydrochloride|Given IV
75889637|NCT02194400|Biological|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
75597541|NCT01320293|Drug|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
75741863|NCT00645593|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
75741864|NCT00645593|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
75741865|NCT01093261|Drug|Placebo|"Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days."
75741866|NCT01093261|Drug|Hydrocortisone Fludrocortisone|HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
75597542|NCT05661383|Device|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.~Pleasant odorants will be delivered using passive diffusers placed in the room dedicated to the iTBS protocol, during the all-treatment duration. During the inclusion phase, 10 odors known to be pleasant will be presented to the subject. The 3 best rated by the subject will be chosen for olfactory stimulations. During the iTBS session, a randomly selected odor from the 3 will be presented at the same time as the iTBS treatment."
75597543|NCT05661383|Device|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session."
75597544|NCT01318811|Drug|Dilute unfractionated heparin|Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
75597545|NCT01318811|Drug|Standard concentration unfractionated heparin|Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
75889638|NCT02062086|Dietary Supplement|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
75889639|NCT03675165|Behavioral|Best Possible Self|A writing exercise developed in 2001 by Laura King. The frequency of engagement with the exercise is down to the user's discretion though we recommend to them to write things down once every week for the duration of the study.
75889640|NCT02194478|Behavioral|Meditation|30 minute, 8 week meditation
75447948|NCT03980834|Behavioral|Coaching|is one-on-one support provided in-vivo and from a distance (phone, text, email) to help users apply evidence-based practices in daily interactions with students and parents, and to support high levels of implementation fidelity and exposure. All Pre-K teachers and mental health professionals facilitating ParentCorps receive four on-site coaching visits and 10 30-minute calls for the remaining sessions in the first year for each cycle of implementation.
75447949|NCT03978780|Procedure|Erector spinae plane block|80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
75447950|NCT03978780|Procedure|Placebo Block|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
75447951|NCT03978104|Dietary Supplement|Okara biscuits|Consumption of okara-enriched biscuits together with habitual diet.
75889641|NCT02061228|Device|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
75447952|NCT03978104|Dietary Supplement|Bio-okara biscuits|Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.
75889642|NCT04715204|Other|High Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density >0.9 kcal/mL. Formula with caloric density of >1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
75889643|NCT04715204|Other|Standard Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density >0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
75597546|NCT05644847|Other|Whole Body Vibration Training|WBV training will be performed on a commercial vibrating platform (Healthmate HM01-08VF Gym Fitness Equipment Step Vibration Machine, China), which produces vertical sinusoidal vibrations. Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training. The vibration speed level will be progressed from level 5 to level 10 during the course of the treatment sessions
75597547|NCT05644847|Procedure|Core Stability Training|Core stability exercises will include pelvic bridge, straight leg bridge, modified kneeling with elbow support and leg lifts and squats, with 60 seconds rest interval between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets on a weekly basis. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises.
75597548|NCT05644769|Other|Determine the presence of Human sequence Ang-(1-12) on no medication|Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
75889644|NCT04715204|Other|Formula-75/Formula-100|"Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml"
75889645|NCT02060682|Device|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
75597549|NCT05644769|Drug|Human sequence Ang-(1-12) on Lisinopril 40mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
75447953|NCT03978104|Dietary Supplement|Control biscuits|Consumption of control biscuits together with habitual diet.
75447954|NCT03973528|Drug|traditional Chinese medicine: tonifying kidney Wan|traditional Chinese medicine : tonifying kidney Wan
75447955|NCT03968081|Behavioral|Cyberball|a ball tossing playing game in which the experimentor can control the number of throws received by the participants
75447956|NCT03966742|Procedure|Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis|"Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe."
75447957|NCT03966638|Procedure|Intra-meniscal injection of platelet-rich plasma|Intra-meniscal injection of platelet-rich plasma under echographic control
75447958|NCT03965260|Biological|Bacterial samples from blood or peritoneal liquids|"For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance."
75741867|NCT02550977|Drug|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
75741868|NCT03832738|Drug|JTE-451 Tablets|Active drug tablets containing JTE-451
75741869|NCT03832738|Drug|Placebo Tablets|Placebo tablets matching in appearance to the active drug tablets
75741870|NCT01045018|Drug|Placebo|placebo 400 mg
75741871|NCT01045018|Drug|Mesalamine|
75741872|NCT01045018|Drug|Mesalamine|
75447959|NCT03956498|Other|Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy|"Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24."
75741873|NCT00267904|Other|Coffee|Caffeinated coffee and decaffeinated coffee ingestion
75741874|NCT00267904|Other|Banana|Banana ingestion
75741875|NCT00267904|Other|Olives|Olives ingestion
75741876|NCT00267904|Other|Temp. manip.|Manipulate temperature at skin of the back
76060352|NCT03582670|Behavioral|Process Training|Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.
76060353|NCT03582670|Behavioral|Control Group|Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training
76060354|NCT03159988|Drug|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
76060355|NCT03159988|Behavioral|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
76060356|NCT03582592|Behavioral|Fluid Distribution Timetable|It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
76060357|NCT03582358|Other|Food weighing|Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
76060358|NCT03159598|Device|Tissue Glu|Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
76060359|NCT03159598|Device|Drain|Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
76060360|NCT03159598|Other|Questionnaires|Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
76060361|NCT01818752|Drug|Carfilzomib|Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
76060362|NCT01818752|Drug|Bortezomib|Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
75741877|NCT01049464|Drug|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
75741878|NCT01049464|Drug|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
76060363|NCT01818752|Drug|Melphalan|Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
75597550|NCT05644691|Other|Lipikar Baume AP+M|application of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment
76060364|NCT01818752|Drug|Prednisone|Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
76060365|NCT03582280|Drug|Amorphous Calcium Carbonate (ACC) - Amor|Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
76060366|NCT03582202|Procedure|Nutritional assessment and therapy|Nutritional screening, nutritional plan, follow-up and instructions on discharge
76060367|NCT03582202|Procedure|Standard care|Nutritional handling by nurse
75597551|NCT05644691|Other|Usual emollient|application of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment
76060368|NCT03159520|Behavioral|Advice sheet|Advice on management of post orthodontic pain
75597552|NCT01093846|Drug|AIN457|300mg every 4 weeks
75597553|NCT01093846|Drug|AIN457|300mg every 2 weeks
75597554|NCT01093846|Drug|Placebo AIN457|Placebo to AIN457
75597555|NCT01315847|Drug|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
75597556|NCT01315847|Drug|[11C]MK-4232|Single intravenous doses of ~300 MBq [11C]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
75741879|NCT01046266|Drug|RO5083945|700mg iv weekly
75741880|NCT01046266|Drug|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
75741881|NCT00046891|Drug|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
75741882|NCT00046891|Other|Placebo|Patients will take 1 tablet BID
75741883|NCT01045330|Behavioral|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
75741884|NCT00365794|Drug|Topical testosterone gel 10 g/day|Testosterone gel therapy for 20 weeks
75889646|NCT02194556|Drug|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
75889647|NCT02194556|Drug|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
75741885|NCT03954457|Behavioral|A-CWS|The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.
75889648|NCT03679377|Device|Mandibular slotplate|Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After testing of the plates they are removed and the osteotomy is fixated with three bicortical screws.
75741886|NCT03954457|Behavioral|Standard Care Control|The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
75741887|NCT00383500|Device|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
75889649|NCT02062242|Other|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
75741888|NCT00383500|Device|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
75889650|NCT02062242|Other|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
75447960|NCT03956394|Diagnostic Test|UltraFast ultrasound|The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.
75447961|NCT03952182|Other|Spinal Orthosis (LSO, TLSO)|spinal orthosis prescribed for specific spinal fracture (TLSO for thoracic or high lumbar fracture, LSO for lumbar fracture)
75447962|NCT03952182|Other|No orthosis|no orthotic given for spinal fracture. These patient's will be given a bending restriction
75447963|NCT03929588|Device|Hand-held device supported by a mobile application|Hand-held device supported by a mobile application to obtain refractive error of the eye.
75889651|NCT02062242|Other|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
75889652|NCT02062242|Other|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
75889653|NCT02194634|Drug|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
75889654|NCT02194634|Other|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
75447964|NCT03929588|Device|Phoropter|Manual refraction and ETDRS chart
75447965|NCT03929588|Device|Autorefractor|Automated refraction
75447966|NCT03928678|Procedure|enhanced recovery after surgery program in colorectal cancer surgery|to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
75447967|NCT03924700|Procedure|Biportal endoscopy|Biportal endoscopic spine surgery (BESS)
75447968|NCT03924700|Procedure|Microdiscectomy|Using microscope for discectomy
75447969|NCT03924427|Drug|BMS-986165|Oral tablet administration
75447970|NCT03922451|Drug|piperacillin-tazobactam|Administered for infection treatment or prophylaxis per hospital protocol
75447971|NCT03922451|Drug|Cefazolin|Administered for infection treatment or prophylaxis per hospital protocol
75447972|NCT03908073|Device|Transcutaneous vagal nerve stimulation|The use of a transcutaneous vagal nerve stimulator by the participant
75741889|NCT03954301|Diagnostic Test|Anthropometric measures|Q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles were measured with a goniometer. The height from the ground of the navicula was calculated by caliper, using the Navicular drop test. Metatarsal width was also calculated with this device. Medial longitudinal arch angle, metatarsal width and nacivular drop tests were performed under weight-bearing and non-weight-bearing conditions.
75447973|NCT03907735|Other|Myometrial tissue sample collection|Myometrial tissue samples by core needle biopsy under ultrasound guidance
75889655|NCT02194634|Procedure|Laser|Laser treatment at first month, then repeated as needed.
75889656|NCT02194634|Other|Sham laser|Sham laser at first month, then repeated as needed.
76060369|NCT03159832|Drug|SHR3824|All subjects were given SHR3824 20mg only one time.
76060370|NCT03582046|Device|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
76060371|NCT03582046|Device|Mean Arterial Pressure (MAP)|Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
76060372|NCT05701462|Diagnostic Test|biopsy under sonographic gidance|pleural biopsy under sonographic guidance
75447974|NCT03907332|Other|Home visits|An experimental design, a cluster randomized controlled trial (RCT) will be used. A total of 20 clusters will be randomized with block randomization of electoral areas with a) resident staff midwives and b) resident Community Health Nurse midwifes. All women residing in an electoral area will receive the same intervention for practicality and to prevent contamination.
75447975|NCT05802732|Diagnostic Test|Stool Antigen test|Correlation between the result of endoscopic biopsy and stool antigen test
75447976|NCT05802706|Other|No intervention.|No intervention.
75447977|NCT05802667|Diagnostic Test|Tryptase|Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa
75447978|NCT05802641|Radiation|SBRT|Participants with early lung cancer receive single fraction (30Gy/1f) or multiple fractions of SBRT（36Gy/3f).
75447979|NCT05802537|Other|Home-based exergame program|The home-based exergame program was conducted at the participants' homes for 50 min, three times a week, for eight weeks. Online education on fall prevention and musculoskeletal health management was provided once a week for 50 minutes, one day a week, for 8 weeks.
75447980|NCT05802524|Diagnostic Test|Neurowave Group|"Neurosensory stimulation will consist in the administration of pairs of stimuli consisting of emotionally significant images and sounds in the personal life history (two rare stimuli) alternating with neutral images and sounds devoid of emotional significance (two distracting stimuli"
75741890|NCT01098019|Drug|Xeomin|Patients will receive Xeomin only at Day 0.
75741891|NCT01098019|Drug|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
75741892|NCT03956641|Other|Adaptated Physical Activity|Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
75741893|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
75889657|NCT03679143|Drug|ZSP1273 100 mg|ZSP1273 tablet administered orally once daily under fasted condition
75889658|NCT03679143|Drug|Placebo 100 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
75889659|NCT03679143|Drug|ZSP1273 200 mg|ZSP1273 tablets administered orally once daily under fasted condition
75889660|NCT03679143|Drug|Placebo 200 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
75889661|NCT03679143|Drug|ZSP1273 400 mg|ZSP1273 tablets administered orally once daily in the fasting state
75447981|NCT05802511|Device|Exablate treatment|Exablate treatment for Neuropathic Pain
75447982|NCT05802498|Device|IRMA|For patients in an advanced state of illness, advanced neuromotor rehabilitation treatment included 1) robot therapies, 2) specific water courses (e.g. walking pools, hydrokinesiotherapy pools, etc.), 3) advanced cognitive treatments (e.g. virtual reality courses); 4) augmentative immersive therapy in a virtual environment; 5) courses also dedicated to social reintegration and inclusive activities (theatre-therapy, art-therapy, dance-therapy, agro-therapy, etc.).
75447983|NCT05802485|Other|collection of blood and tumor samples|"The study consists of the collection of a 25 ml blood sample:~Before the start of treatment~Approximately 2 months after the start of induction chemotherapy~At the end of induction chemotherapy~Prior to local treatment (radiotherapy, surgery)~At the time of tumor progression~At the time of collection of tumor material:~During the initial diagnostic biopsy~On the operating room in case of surgery~During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities."
75597557|NCT05644535|Diagnostic Test|Cerebrospinal fluid densitometry|After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
75741894|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
75741895|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
76060373|NCT04405492|Device|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Evaluated point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Clinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different clinical samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
76060374|NCT04405492|Device|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken (D0). A follow-up at D15, M1, M3, M6, M9 will be done. At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.~Cinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
76060375|NCT04405492|Device|Capillary and salivary sampling|Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.
76060376|NCT05701384|Drug|Lazertinib|160mg po qd
75447984|NCT05802472|Other|Polyphenolic beverage from extract of Vachellia farnesiana|During Visit 2. A single infusion of the polyphenolic extract was administered orally. The dose (1.2 mg/kg body weight) of lyophilized extract, which was diluted in water, was calculated considering each participant's weight.
75597558|NCT05644535|Diagnostic Test|blood routine examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.
75597559|NCT05644535|Diagnostic Test|Blood electrolyte examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
75741896|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
75741897|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
75889662|NCT03679143|Drug|Placebo 400 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
75889663|NCT03679143|Drug|ZSP1273 600 mg|ZSP1273 tablets administered orally once daily under fasted condition
75889664|NCT03679143|Drug|Placebo 600 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
75889665|NCT03679143|Drug|ZSP1273 900 mg|ZSP1273 tablets administered orally once daily in the fasting state
75889666|NCT03679143|Drug|Placebo 900 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
75889667|NCT03679143|Drug|ZSP1273 1200 mg|ZSP1273 tablets administered orally once daily in the fasting state
76060377|NCT04142554|Drug|Parsaclisib|Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
76060378|NCT01362608|Drug|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
75597560|NCT04325399|Other|Volitional help sheet|
75597561|NCT01093534|Drug|Placebo|Matching solifenacin placebo tablet
75889668|NCT03679143|Drug|Placebo 1200 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
75741898|NCT01049542|Drug|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
75447985|NCT05802472|Other|Placebo|During Visit 2. 250 ml of single potable water was administered orally.
75447986|NCT05802459|Other|EORTC QLQ-C30|central generic questionnaire associated with different disease specific modules
75889669|NCT03679143|Drug|ZSP1273|ZSP1273 tablets administered orally once daily under fasted or fed condition
75447987|NCT05802459|Other|EORTC QLQ-OG25|module to assess the quality of life in patients with esophagogastric disease.
75447988|NCT05802459|Other|GIQLI|Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.
75447989|NCT05802459|Other|SWAL QoL|Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.
75447990|NCT05802459|Procedure|Videofluoroscopy|It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.
75447991|NCT05802446|Other|Real-time fMRI Neurofeedback|Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant. With this feedback on brain activity, subjects can learn to control the activity of selected brain areas. Trial after trial, participants develop their individual strategies to voluntarily regulate the signal. The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback. By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
75447992|NCT05802433|Dietary Supplement|Vitamin D3 supplement|10µg vitamin D3 supplement per day for 90 days
75741899|NCT01049620|Drug|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
75741900|NCT00059839|Drug|doxorubicin hydrochloride|Given IV
75741901|NCT00059839|Drug|mercaptopurine|Given by mouth
75889670|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
76060379|NCT01362608|Drug|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
75597562|NCT01093534|Drug|solifenacin|Tablet for oral administration
75597563|NCT01314911|Drug|Oseltamivir|Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
75597564|NCT01314911|Drug|Placebo|Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
75597565|NCT02891057|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-036)
75597566|NCT01093222|Drug|Erlotinib Hydrochloride|Given PO
75597567|NCT01093222|Drug|Sorafenib Tosylate|Given PO
75741902|NCT00059839|Drug|methotrexate|Given IV and intrathecally
75741903|NCT00059839|Drug|prednisone|Given by mouth
75889671|NCT03679143|Drug|ZSP1273 Low Dose|ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
75889672|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
75889673|NCT03679143|Drug|ZSP1273 Median Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
76060380|NCT03581968|Device|Artificial Pancreas|"The system is composed of 3 main components:~Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump."
76060381|NCT03159286|Behavioral|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
76060382|NCT03159286|Behavioral|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
76060383|NCT03159286|Behavioral|Control|Participants view social networking site profiles with no alcohol content.
76060384|NCT03581890|Other|Socioeconomic position|"Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~age- and sex-adjusted available income the year before surgery~Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~Urbanicity (in four officially, predefined categories)."
76060385|NCT03159364|Biological|pathogen-specific CTLs|Patients will receive approximately 1x10^5~1x10^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
76060386|NCT01871090|Device|Unpaired remote monitoring transmitter|Unpaired remote monitoring transmitter
75447993|NCT05802381|Dietary Supplement|protein supplement|20 gram protein supplement per day
76060387|NCT03158974|Drug|East Indian Sandalwood Oil Cream|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
76060388|NCT04142008|Device|Walk with Me app|For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
76060389|NCT05703022|Other|Aerobic interval training|The intervention will start between 7 and 21 days after heart valve surgery. While hospitalized the participants will perform supervised aerobic interval training comprised 4x4 minute, 3 times per week. Intensity will start at 60% of maximum heart rate in the first week, around 13-14 in Borg RPE-Scale. The workload will be gradually increased as the participant tolerance improves, but not above 85% of maximum heart rate or 16-17 in Borg RPE Scale.
76060390|NCT03159052|Drug|SHR3824|Once daily, 52 weeks
76060391|NCT03159052|Drug|Placebo|Once daily, 24 weeks
76060392|NCT03158584|Drug|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
76060393|NCT03265366|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
76060394|NCT03265366|Device|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
76060395|NCT03158506|Drug|HMS5552|[14C]-labelled HMS5552
76060396|NCT03156712|Dietary Supplement|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
76060397|NCT03158662|Other|Survey|Survey Study
76060398|NCT04765228|Drug|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles
76060399|NCT04765228|Drug|Anlotinib|Anlotinib
76060400|NCT04141540|Genetic|Molecular analyses|Comparaison of the molecular profil between two monozygotic twins carrying a deletion 22q11.2
76060401|NCT04141462|Genetic|blood sample|blood test
76060402|NCT04141384|Device|Modular Interactive Tiles System, MITS|The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
76060403|NCT04140994|Device|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
76060404|NCT03158350|Other|Instructed Brushing Method|Stationary Bristle Technique
76060405|NCT03158428|Other|CSD170202AA|A moist snuff product
75447994|NCT05802381|Behavioral|nutrition counseling|nutrition counseling for guidance of food intake
75447995|NCT05802368|Other|virtual reality group|a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.
75447996|NCT05802368|Other|exercise group|Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
75597568|NCT02878018|Drug|Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula|Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
75597569|NCT02878018|Drug|angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
75597570|NCT01313663|Drug|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
75597571|NCT01313663|Drug|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
75447997|NCT05802355|Other|Manual Diaphragm Release|The participant was supine, with his or her limbs relaxed. With the therapist's forearms aligned toward the participant's shoulders, the therapist gradually increased the depth of contact inside the costal margin during the subsequent respiratory cycles.
75447998|NCT05802355|Other|control group|Respiratory re-training was given to participants in control group in form of slow and deep diaphragmatic breathing, exhalation through the nose with pursed lips (the participants were trained to emphasis on expiratory pressure against pursed lips), Breathing control and breathing-hold exercises, and Relaxation techniques:
76060406|NCT03158428|Other|CSD170202AB|A moist snuff product
75447999|NCT05802342|Drug|Monosialotetrahexose ganglioside sodium injection|The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
75448000|NCT05802329|Drug|OCU200 Low Dose|Intravitreal Injection
75448001|NCT05802329|Drug|OCU200 Medium Dose|Intravitreal Injection
75597572|NCT05644457|Genetic|Circulating tumour DNA dynamics|Circulating tumour DNA (ctDNA) can be identified in patients with a wide variety of cancers and has been shown to allow early prediction of disease relapse after treatment with curative intent in HNSCC.
75741904|NCT00059839|Drug|vinblastine sulfate|Given IV
75741905|NCT00059839|Drug|vincristine sulfate|Given IV
75741906|NCT00059215|Drug|Prasugrel (CS-747)|Administered orally
75741907|NCT00059215|Drug|Clopidogrel|Administered orally
75741908|NCT01096147|Device|Spinal cord stimulation with eight polar electrode|In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
75741909|NCT00058825|Biological|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
75741910|NCT00058825|Drug|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
75741911|NCT00058825|Procedure|Stem Cell Transplant|Day 0: Donor stem cells infused.
75741912|NCT00058825|Radiation|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
75741913|NCT00058825|Drug|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
75741914|NCT00364858|Drug|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
75741915|NCT01098409|Drug|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
75741916|NCT01098409|Drug|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
75889674|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
76060407|NCT04140916|Device|Midline catheter|Peripherally inserted short intravenous catheter
76060408|NCT04140916|Device|PICC-line catheter|Peripherally inserted long intravenous catheter
76060409|NCT04140760|Other|Symprove|A liquid probiotic
75597573|NCT01092832|Drug|voriconazole|"Subjects 12 - <18 yrs (excluding subjects 12 - 14 yrs weighing <50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - <12 yrs, and subjects 12 - 14 weighing <50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
75597574|NCT05661305|Other|Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
75597575|NCT02878564|Drug|Praziquantel|40 mg/kg, PO (orally administered tablets)
75597576|NCT04325477|Device|Nolix Device|The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
75597577|NCT02891135|Other|SLATE|Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
75597578|NCT04308070|Device|AQUABEAM System followed by catheter without hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.
75597579|NCT04308070|Device|AQUABEAM System followed by catheter with hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.
75597580|NCT04307914|Radiation|External beam radiotherapy|The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.
75741917|NCT03956719|Drug|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.
75741918|NCT03956719|Procedure|abdominal liposuction|50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
75741919|NCT02535208|Other|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR < 0.73.
75741920|NCT02535208|Other|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
75741921|NCT01093495|Device|CPAP|CPAP
75741922|NCT01093495|Device|Nasal Cannula|Nasal Cannula
76060410|NCT04140760|Other|Symprove placebo product|An inert placebo
75889675|NCT03679143|Drug|ZSP1273 High Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
76060411|NCT01818596|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
76060412|NCT03156400|Other|Exercise Stress Test|Gradual increase in treadmill grade while collecting respiratory gases.
75889676|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
75889677|NCT02061462|Procedure|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
75889678|NCT02030912|Drug|3 doses of amoxicillin daily for 7 days|
75741923|NCT02535052|Biological|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
75889679|NCT02030912|Drug|2 doses of minocycline daily for five days|
75889680|NCT02030912|Other|2 doses of placebo daily for five days|
75889681|NCT03675009|Other|Educational Programming|Green Cleaning educational programming to day care staff.
75889682|NCT02196116|Other|PET|PET Scan with [18F]-Flutemetamol
75741924|NCT03741205|Device|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
75741925|NCT02534974|Device|NOSTEN|
75889683|NCT02196116|Other|MRI|
75889684|NCT02196116|Other|neuropsychological tests|
75889685|NCT02060916|Drug|PAZ320|Single-center pilot study, open label dose escalation design
75741926|NCT03953989|Drug|Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die|Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
75448002|NCT05802329|Drug|OCU200 High Dose|Intravitreal Injection
75448003|NCT05802316|Device|tracheal intubation using videolaryngoscope with a hyperangulated blade or standard intubation videolaryngoscopy (VL) and direct laryngoscopy (DL)|In the awake group tracheal intubation performed by an videolaryngoscope with a hyperangulated blade. In the asleep group the standard intubation were performed by videolaryngoscopy (VL) and direct laryngoscopy (DL)
75448004|NCT05802303|Drug|17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)|In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06% w/w) 2 puffs thrice a day (each application contains 1.25 mg with 0.75 mg of the drug).
75741927|NCT01096225|Biological|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
75741928|NCT01049698|Behavioral|Resistance Training|3 d/wk resistance training
75741929|NCT01049698|Behavioral|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
75889686|NCT02257268|Behavioral|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
75889687|NCT02063256|Dietary Supplement|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
75889688|NCT02063256|Other|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
76060413|NCT03158194|Behavioral|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
75448005|NCT05802303|Drug|Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)|In the oral Estradiol group, all women will be given 2 mg of Estradiol valerate tablets, one tablets thrice a day within 30 days of injection triptorelin depot. Endometrial assessment will be performed on D10 of HRT. Please see the flow diagram (in the annexure) for details.
75448006|NCT05802290|Drug|Nivolumab 240 MG in 24 ML Injection|nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
75448007|NCT05802277|Diagnostic Test|Hamstring muscles function assessment|Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.
75597581|NCT04307914|Procedure|MR-HIFU|MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.
75597582|NCT02890979|Other|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
75597583|NCT02890979|Other|Laboratory Biomarker Analysis|Correlative studies
75597584|NCT02890979|Other|Quality-of-Life Assessment|Ancillary studies
75597585|NCT02890979|Device|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
75741930|NCT02535130|Device|Positive expiratory pressure|
75741931|NCT02535130|Drug|amikacine nebulization|
75741932|NCT03803059|Device|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
75741933|NCT01046500|Dietary Supplement|myo-inositol|2 grams twice a day
75741934|NCT01046500|Drug|Metformin|pill, 250 mg, twice a day
75889689|NCT02797080|Drug|interferon γ-1b|ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
76060414|NCT03156634|Other|PALS|PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
76060415|NCT03156634|Other|WebMD|WebMD is an internet based health information source.
75741935|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
75741936|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
76060416|NCT04415216|Device|percutaneous coronary intervention|Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
75597586|NCT01313273|Drug|Lanreotide, non steroidal anti androgens and LHRH-a|"Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression."
75741937|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
75741938|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
75889690|NCT02196194|Drug|Tiotropium|
76060417|NCT04405882|Procedure|topographic guided trans epithelial excimer laser|In this retrospective study 8 eyes affected by cornea ectasia of 8 patients (mean age 31.50±14.73 years) underwent simultaneous CCR and CXL. Preoperative and 6 month postoperative uncorrected distance visual acuity (UDVC) and distance corrected visual acuity (DCVA) were measured using the Efficacy and Safety index. Objective and subjective quality of vision were respectively evaluated through preoperative and 6 month postoperative corneal morphological irregularity index (CMI), National Eye Institute Visual Function NEI-VFQ25 and NEI-VFQ39 questionnaires.
76060418|NCT03157570|Behavioral|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
75597587|NCT01313273|Drug|Non steroidal anti androgens and LHRH-a|Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
75597588|NCT01091974|Drug|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
75741939|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
75741940|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
75741941|NCT01098565|Device|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
75741942|NCT03956875|Other|yoga|yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
75741943|NCT01098643|Other|computer-assisted intervention|
75741944|NCT01098643|Other|medical chart review|
75741945|NCT01098643|Other|questionnaire administration|
75741946|NCT01098643|Other|survey administration|
75741947|NCT01096381|Other|laboratory biomarker analysis|Blood collection
76060419|NCT03157726|Procedure|Transurethral plasmakinetic enucleation of prostate|Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
76060420|NCT03157726|Procedure|transurethral resection of prostate|"Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH."
75597589|NCT01091974|Drug|Placebo Comparator|Placebo for 47 days
75597590|NCT01091974|Behavioral|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
75741948|NCT01096381|Other|questionnaire administration|Survey regarding baseline health and activity level.
75597591|NCT01313117|Drug|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
75597592|NCT01313039|Drug|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
75597593|NCT05644379|Drug|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
75597594|NCT05644379|Drug|Regorafenib|Regorafenib 80mg, po, orally once daily
75741949|NCT00372424|Drug|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
75741950|NCT00372424|Drug|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
76060421|NCT03156322|Drug|5 mL epidural initiation volume (bupivacaine + fentanyl)|5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
76060422|NCT03156322|Drug|10 mL epidural initiation volume (bupivacaine + fentanyl)|10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
76060423|NCT03156322|Drug|20 mL epidural initiation volume (bupivacaine + fentanyl)|20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
75741951|NCT00372424|Drug|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
76060424|NCT05682664|Other|Luchtbrug Junior (online monitoring)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
75889691|NCT03534830|Diagnostic Test|MRI|pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
75889692|NCT02915835|Drug|Riociguat|riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
75889693|NCT02915835|Drug|Placebo|Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
75889694|NCT02194712|Other|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
75889695|NCT01370616|Drug|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
75448008|NCT05802251|Diagnostic Test|Ultrasonographic parameters|cervical length. placental thickness. distance placental edge from internal os of the cervix
75448009|NCT05802212|Drug|Metformin intervention for 12 weeks|PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed.
75889696|NCT01370616|Drug|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
75889697|NCT01370616|Drug|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
75889698|NCT01370616|Drug|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
76060425|NCT05682664|Other|Usual care|Routine outpatient clinical visits every 3 months.
76060426|NCT04140682|Device|PAV+ mode|PAV+ mode by using Puritan-Bennett 840 ventilator
76060427|NCT04140682|Device|PSV mode|PSV mode by using Puritan-Bennett 840 ventilator
76060428|NCT03156088|Device|"Sacral Neuromodulator InterStim"|
76060429|NCT03021382|Other|data collection, non-intervention|
75448010|NCT05802186|Procedure|Computed Tomography|Undergo CT
75448011|NCT05802186|Procedure|Magnetic Resonance Imaging|Undergo MRI
75448012|NCT05802186|Procedure|Positron Emission Tomography|Undergo PET
75448013|NCT05802186|Other|Quality-of-Life Assessment|Ancillary studies
76060430|NCT03156166|Procedure|fiberoptic bronchoscope|Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
76060431|NCT04140058|Drug|Ondansetron|ondansetron was administered 20 minutes prior to spinal anesthesia.
76060432|NCT04140058|Drug|Normal saline|Placebo of 10 mL normal saline was administered.
76060433|NCT03157648|Other|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
75448014|NCT05802186|Other|Radiology, Treatment Planning|Undergo radiation planning with AI-directed analysis for dose recommendation
75448015|NCT05802186|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75448016|NCT05802186|Procedure|X-Ray Imaging|Undergo x-ray imaging
75597595|NCT01091662|Drug|Eslicarbazepine acetate 1600 mg|1600 mg once per day
75597596|NCT01091662|Drug|Eslicarbazepine acetate 1200 mg|1200 once per day
75597597|NCT01312961|Drug|Dupilumab|Solution for injection, one subcutaneous injection.
75597598|NCT01312961|Drug|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
75741952|NCT01098721|Drug|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
75889699|NCT02196272|Behavioral|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:~- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
76060434|NCT02899078|Drug|Ibrutinib|Given PO
75448017|NCT05802160|Behavioral|Good Start Matters - Parenting intervention|The Good Start Matters - Parenting intervention is a 2-month mobile-Health (mHealth) parenting program that aims to improve parenting practices and child health behaviors among British Columbian families of preschoolers. This intervention uses a familial approach and blends the best practices and evidence to promote positive parenting regarding 3 main areas: nutrition, physical activity, and screen-time; which altogether aim to support the development of healthy habits among young children. The mHealth app releases new material on a weekly basis and participants' engagement with the app takes about 30 minutes per week.
75889700|NCT02688881|Drug|sirolimus|Rapamune
75889701|NCT02196350|Behavioral|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
75889702|NCT02196350|Behavioral|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
75889703|NCT02196350|Behavioral|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
75889704|NCT02197208|Procedure|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
75889705|NCT02197208|Procedure|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is >/= 17 mm and the endometrium measures >/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
75889706|NCT02197208|Device|ultrasound|
75889707|NCT02062476|Dietary Supplement|Lactobacillus GG|
76060435|NCT02899078|Drug|Nivolumab|Given IV
76060436|NCT01670344|Procedure|Treatment with investigational method (virtual implant positioning system)|
76060437|NCT01670344|Procedure|Treatment with surgical standard of care|
76060438|NCT04747444|Other|Anti-Gravity Treadmill|Treadmill in which the body weight percent placed on the lower extremities can be controlled
76060439|NCT04764760|Device|Wing shaped Tensiflex prosthesis|Curative inguinal hernia repair techniqque
76060440|NCT01670734|Drug|alirocumab SAR236553 (REGN727)|"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous"
76060441|NCT03155776|Diagnostic Test|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
76060442|NCT03155464|Procedure|Order of two elements of surgical procedure|Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.
76071988|NCT03517761|Biological|Bone Marrow Concentrate treatment|While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.
75448018|NCT05802147|Behavioral|skin-to-skin contact|skin-to-skin contact
75597599|NCT01312961|Drug|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
75597600|NCT01312961|Drug|Fluticasone monotherapy|Oral inhalation twice daily.
75597601|NCT01312961|Drug|Albuterol|Oral inhalation as needed.
75597602|NCT01312961|Drug|Levalbuterol|Oral inhalation as needed.
75597603|NCT04914208|Device|DIY face mask|Participants are wearing a DIY face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
75741953|NCT03952507|Drug|JNJ-64417184 600 (Oral Tablet Formulation)|Participants will receive 600 mg of JNJ-64417184 as oral tablet.
75741954|NCT03952507|Drug|JNJ-64417184 (Oral Suspension Formulation)|Participants will also receive JNJ-64417184 600 mg as oral suspension.
75741955|NCT02872792|Device|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
75741956|NCT02872792|Other|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
76060443|NCT03155464|Drug|Indocyanine Green|Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
76060444|NCT01670890|Drug|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
75889708|NCT04243889|Device|NEOX Cord 1K applied fetoscopically|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
75889709|NCT03630497|Drug|Comparison of BN201 treatment with Placebo|Single Dose or Multiple Dose of BN201 IV administration
75889710|NCT02197286|Drug|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
76060445|NCT01670890|Drug|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
76060446|NCT01676428|Radiation|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions <5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
75741957|NCT02530411|Drug|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
76060447|NCT04577794|Drug|GLPG3970|GLPG3970 powder and solvent for oral solution reconstituted prior to use.
75741958|NCT02530411|Drug|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
75741959|NCT00372190|Device|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
75741960|NCT00372190|Procedure|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
75889711|NCT02197286|Drug|Placebo|Daily dose of a single gelatin placebo capsule.
75889712|NCT01378247|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
75889713|NCT03674775|Other|DART QI Program Participation|Antibiotic prescribing data will be collected at multiple time points both before and after the initiation of the intervention.
76060448|NCT04577794|Drug|Placebo|Placebo powder and solvent for oral solution reconstituted prior to use.
76060449|NCT04551196|Drug|Alternating Acetaminophen and Ibuprofen|Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
76060450|NCT04551196|Drug|Combined Acetaminophen and Ibuprofen|Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
76060451|NCT04510168|Drug|11C-ER176|PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)
76060452|NCT04510168|Drug|[F-18]MK-6240|PET imaging to measure tau; target imaging dose of 4 to 5 mCi
76060453|NCT04510168|Drug|Florbetaben|PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi
76060454|NCT04510168|Other|Magnetic Resonance Imaging|Brain MRI
75448019|NCT05802134|Dietary Supplement|Fruit and vegetable supplement|Weekly food kits including culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) and staple items to support DASH diet compliance
75597604|NCT04914208|Device|Surgical face mask|Participants are wearing a surgical face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
76060455|NCT03155152|Other|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
75448020|NCT05802134|Behavioral|Dietary and chronic disease management education|Intensive education for chronic disease management: participants will receive education on hypertension management, which will include an interprofessional health appointment with a medical professional to discuss medication compliance, and resources from an occupational therapist for chronic disease management strategies, and 2 nutrition appointments with a Registered Dietitian regarding the DASH Diet (initial education and follow-up at 2 weeks)
75448021|NCT05802121|Drug|Apple Cider Vinegar|"Each patient will be instructed to take 6 enteric slow-release acetate capsules (equivalent of 500 mg/ capsule containing 25 mg acetate x 6 capsules) per day for 3 months~https://www.webbernaturals.com/en-ca/apple-cider-vinegar-500-mg-capsules/"
76060456|NCT03155152|Other|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
76060457|NCT01671124|Other|Soline capsule|
75448022|NCT05802121|Drug|Placebo|Each patient will be instructed to take 6 placebo capsules per day for 3 months
75448023|NCT05802108|Drug|Evolocumab combined with statins|The experimental group was treated with evolocumab combined with statin for lipid-lowering
75597605|NCT04914208|Device|FFP2 respirator mask|Participants are wearing a FFP2 respirator mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
75597606|NCT04914208|Other|Waiting for 4 hours without wearing a mask|Participants do not wear any face mask for 4 hours (beginning between 8 and 9 a.m.).
75741961|NCT01096459|Procedure|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
75741962|NCT01093729|Drug|HM11260C|HM11260C 0.5mcg/kg or Placebo
75741963|NCT01093729|Drug|HM11260C|HM11260C 2mcg/kg or Placebo
75741964|NCT01093729|Drug|HM11260C|HM11260C 4mcg/kg or Placebo
75741965|NCT01093729|Drug|HM11260C|HM11260C 8mcg/kg or Placebo
75741966|NCT01093729|Drug|HM11260C|HM11260C 14mcg/kg or Placebo
76060458|NCT03155230|Other|no intervention|no intervention
76060459|NCT04764838|Other|Yoga|"Breath Awareness Training (5 minutes) Asanas (20 minutes)~Bending sideways in Mountain Stance~Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)"
76060460|NCT04457674|Behavioral|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
76060461|NCT04457674|Behavioral|Sleep Hygiene Education (SHE)|SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
75597607|NCT04914208|Other|Use of fluoridated toothpaste|Participants use fluoridated toothpaste.
75597608|NCT00626158|Drug|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
75597609|NCT00626158|Drug|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
75741967|NCT03992794|Diagnostic Test|Measurement of MR-proADM|It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
76060462|NCT01923298|Drug|Estradiol|
76060463|NCT03155386|Other|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~The intensity of lesion enhancement~The presence and type of artefacts on the recombined images.~The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
76060464|NCT01671436|Behavioral|Central Meditation and Imagery Therapy|
75741968|NCT01327027|Drug|Vasopressin, Arginine, ADH|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
75741969|NCT01327027|Drug|Placebo; Sterile Saline|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
75741970|NCT01046656|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
75741971|NCT01093807|Drug|Placebo|once daily for 10 weeks
75741972|NCT01093807|Drug|Lercanidipine|10 mg once daily for 10 weeks
75741973|NCT01093807|Drug|Lercanidipine|20 mg once daily for 10 weeks
76060465|NCT05629156|Other|No intervention implemented. Observational study only|Observational study only. Injuries and illnesses and exposure is registered using standardized paper forms.
76060466|NCT01671514|Dietary Supplement|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
76060467|NCT01671514|Other|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
76060468|NCT05196022|Other|Cochlear implant|G2 will receive a cochlear implant during the study
75448024|NCT05802108|Drug|Statin|the control group was treated with statin only for lipid-lowering
75597610|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
75889714|NCT02197442|Drug|Valsartan|
75741974|NCT01093807|Drug|Enalapril|10 mg once daily for 10 weeks
75889715|NCT03672669|Genetic|Advanced Platelet Rich Fibrin (A-PRF)|blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
75889716|NCT03672669|Genetic|Leukocyte- and platelet-rich fibrin (L-PRF)|blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
75741975|NCT01093807|Drug|Enalapril|20 mg once daily for 10 weeks
76060469|NCT01671592|Biological|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
76060470|NCT04402606|Other|Evaluation on skin toxicities|Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
76060471|NCT01671670|Other|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
75448025|NCT05802082|Other|The Modified Yale Preoperative Anxiety Scale (m-YPAS) of children|Postoperative 0,5,10,15,30,45,60.and 120 minutes , PAED and WBYAS values
75741976|NCT01093807|Drug|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
75448026|NCT05802043|Behavioral|Cognitive Stimulating Interventions|a quasi-experimental research design.The study subjects of group 1, the study group, will receive the proposed interventions, the cognitive stimulation interventions through small groups of study subjects receiving 12 sessions of group activities (2 sessions/week, approximately 45- 60 minutes/session). A group size of 6 to 8 will be conducted. The interventions group will be conducted in activity rooms within the elderly club.
75597611|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
75597612|NCT01310777|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
75597613|NCT01310777|Drug|Brinzolamide 1% ophthalmic suspension|
75597614|NCT01310777|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
75597615|NCT01310699|Device|Olympus Colonoscope CFHQ190AL|Technically improved colonoscope with close focus high definition narrow band imaging.
75741977|NCT01093807|Drug|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
75741978|NCT01093807|Drug|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
75741979|NCT01093807|Drug|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
75741980|NCT01046812|Drug|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
75741981|NCT01046890|Drug|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
75889717|NCT02194790|Behavioral|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
75889718|NCT02062788|Dietary Supplement|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
76060472|NCT01671670|Other|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
76060473|NCT03154840|Drug|Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU|Investigate the Relative Bioavailability among Different Eutropin Formulations
76060474|NCT04404790|Drug|Anfibatide 5 IU/60kg|5 IU/60kg IV administration of Anfibatide with 5 minutes
76060475|NCT04404790|Drug|Anfibatide 5 IU/60kg +0.002 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
76060476|NCT04404790|Drug|Anfibatide 5 IU/60kg +0.004 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
76060477|NCT04404790|Drug|Anfibatide 5 IU/60kg +0.008 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
76060478|NCT04404790|Drug|Anfibatide 7 IU/60kg|7 IU/60kg IV administration of Anfibatide with 5 minutes
76060479|NCT04404790|Drug|Anfibatide 7 IU/60kg +0.002 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
76060480|NCT04404790|Drug|Anfibatide 7 IU/60kg +0.004 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
75597616|NCT01310075|Device|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
75889719|NCT02196428|Other|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
76060481|NCT04404790|Drug|Anfibatide 7 IU/60kg +0.008 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
76060482|NCT03154762|Device|NIPPV|Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
76060483|NCT03154762|Device|CPAP|4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
76060484|NCT03154918|Drug|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
76060485|NCT01671904|Drug|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter [mg/m^2]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
75597617|NCT01310075|Device|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
75597618|NCT01309997|Drug|imatinib mesylate|Given PO
75741982|NCT01096615|Dietary Supplement|Placebo|"Description:~- capsule size 3~Composition of the product:~45 mg of microcristalline cellulose,~132 mg of maltodextrin,~3 mg of magnesium stearate.~Composition of the capsule:~46 mg of hypromellose,~1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
75597619|NCT01309997|Biological|rituximab|Given IV
75597620|NCT01309919|Device|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
75597621|NCT01309919|Other|Diary|Subjects will keep a bleeding diary for three months
75741983|NCT01096615|Dietary Supplement|Lactobacillus paracasei LP-33|"Description:~minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~capsule size 3 1 capsule daily together with a meal, with a glass of water."
75741984|NCT01046968|Dietary Supplement|Lepticore|300 mg twice daily
75889720|NCT02061618|Behavioral|Bollywood Dance Exercise|
76060486|NCT01671904|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams [mg]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
75597622|NCT04325165|Device|DBS Implantation|Bilateral implantation of PPN DBS electrodes
75597623|NCT01309841|Drug|NKTR-118|12.5 mg oral tablet once daily
75597624|NCT01309841|Drug|NKTR-118|25 mg oral tablet once daily
75597625|NCT01309841|Drug|Placebo|Oral tablet once daily
75597626|NCT01308749|Drug|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
75597627|NCT01308749|Drug|Placebo|Placebo Nasal Spray
75597628|NCT01307891|Drug|Abraxane alone|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
75597629|NCT01307891|Drug|Abraxane + Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
75597630|NCT05644301|Drug|Celecoxib|Oral capsule, 200 mg, twice daily, for 12 weeks
75741985|NCT01047046|Other|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
75741986|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose
75448027|NCT05802017|Other|Allergen-specific substitute diet|Substitution of IgG4 allergen-specific reactive foodstuffs for equivalent foodstuffs with similar nutritional value.
75448028|NCT05801991|Device|Neurolens|neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision.8 This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer.
75448029|NCT05801991|Device|Placebo spectacle lens|Plano (no power) spectacle lenses will be assigned to the placebo group
75448030|NCT05801965|Device|A digital solution for patients with Cancer|A digital program that provides holistic lifestyle intervention as well as disease education.
76060487|NCT01671904|Drug|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m^2) on Day 1 of Cycle 1 and 500 mg/m^2 administered on Day 1 of Cycles 2-6.
75448031|NCT05801965|Other|Standard of care for patients with Cancer|Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
75448032|NCT05801952|Device|Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System|The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).
76060488|NCT01671904|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
75448033|NCT05801926|Device|Heel2Toe[TM] sensor|Heel2Toe is a new generation of wearables that provides real-time auditory feedback when the person takes a good step, one in which the step is initiated with a strong heel strike.
75448034|NCT05801900|Drug|Ketorolac group|30 min preoperatively then every 8 hours postoperatively
75597631|NCT05644301|Drug|Minocyclin|Oral capsule, 100 mg, twice daily, for 12 weeks
75597632|NCT05644301|Drug|Placebo|Oral capsule, no active substance, twice daily, for 12 weeks
75597633|NCT04324931|Other|Biomechanical corrections|Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.
75597634|NCT04324931|Other|Conventional Physiotherapy|Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
75448035|NCT05801900|Drug|Ibuprofen group|30 min preoperatively then every 8 hours postoperatively
75448036|NCT05801887|Device|Extracorporeal shockwave device|"Extracorporeal shockwave device generates true shock waves which are characterized by a sudden rise in pressure followed by an exponential decay.~This is different from the commercially available shockwave devices in which they use piezoelectric based mechanisms which generate high frequency waves."
75448037|NCT05801887|Device|No ESWT|the osteoblast like cells are not exposed to shockwaves
75448038|NCT05801874|Diagnostic Test|Movement analysis|Qualitative and quantitative computerized and instrumental assessment of gait and posture.
75448039|NCT05801848|Diagnostic Test|[18F]NaF PET/CT scan|Patients will have their lower back scanned using [18F]NaF PET/CT
75597635|NCT02890745|Drug|Empagliflozin|
75597636|NCT02890745|Drug|Placebo|
75597637|NCT01307579|Drug|Caspofungin Acetate|Given IV
75597638|NCT01307579|Drug|Fluconazole|Given IV or PO
75597639|NCT01307579|Other|Laboratory Biomarker Analysis|Correlative studies
75597640|NCT01057693|Drug|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
75597641|NCT01057693|Drug|Placebo|Placebo is supplied as capsules and given 3 times daily.
75448040|NCT05801822|Diagnostic Test|serum T.S.H level test|, the blood samples will be collected and to be assessed for the routine antenatal screening CBC, random blood sugar, HBV and HIV, the same blood sample will be used to asses TSH level.
75597642|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
75597643|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
75597644|NCT02875171|Drug|Anthracycline administration|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
75448041|NCT05801783|Drug|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
75597645|NCT01307501|Device|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
75597646|NCT04325009|Drug|Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab|"st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab"
75741987|NCT01098877|Drug|PF-04634817|Oral solution, 1mg, single dose
75741988|NCT01098877|Drug|PF-04634817|Oral solution, 3mg, single dose
75448042|NCT05801744|Behavioral|Operant conditioning|In this training, individuals with post-stroke hemiparesis are trained to increase the amount of reciprocal inhibition in their paretic leg. By increasing the amount of reciprocal inhibition, the paretic ankle in people post-stroke may exhibit less foot drop.
75741989|NCT01098877|Drug|PF-04634817|Oral solution, 10mg, single dose
75597647|NCT04325009|Drug|Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab|"st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~th period: single oral administration of 1 tablet of Lipitor 80mg Tab"
75741990|NCT01098877|Drug|PF-04634817|Oral solution, 30mg, single dose
75741991|NCT01098877|Drug|PF-04634817|Oral solution, 100mg, single dose
75741992|NCT01098877|Drug|PF-04634817|Oral solution, 300mg, single dose
75741993|NCT01098877|Drug|PF-04634817|Oral solution, 600mg, single dose
75741994|NCT01098877|Drug|PF-04634817|Oral solution, 900mg, single dose
75741995|NCT01098877|Drug|PF-04634817|Oral solution, up to 900mg, single dose after food
75741996|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose after food
75741997|NCT00044083|Other|Placebo|Placebo: One capsule 3 times a day from Day 1 to Day 7
75741998|NCT00044083|Drug|Tolcapone|Tolcapone: One capsule 3 times a day from Day 1 to Day 7
75741999|NCT00058123|Drug|poly ICLC|
75742000|NCT00022633|Drug|gemcitabine hydrochloride|
75742001|NCT00022633|Drug|paclitaxel|
75448043|NCT05801731|Other|Intervention|"The low GI snack is a biscuit with a Glycemic Index of 23.8 ± 3.3. The low GI snack contains plain flour, fibre, plant-based protein, vegetable oil and a low GI sweetener.~The interventional snacks (control, experimental) are matched for caloric content."
75448044|NCT05801731|Other|Control|The normal GI snack is a biscuit with a Glycemic Index of 54.4 ± 6.3. The control snack is formulated using basic ingredients for a biscuit recipe consisting of all-purpose flour, butter, sugar, vanilla flavour, baking soda, egg and salt.
75742002|NCT00021541|Drug|tipifarnib|Given orally, 200 mg/m^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
75742003|NCT00021541|Other|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
75742004|NCT01100827|Other|EGFR mutation status in patients|
75448045|NCT05801718|Diagnostic Test|Growth parameters & body mass index|measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference& skin fold thickness and measuring body mass index.
75448046|NCT05801692|Procedure|Weaning of mechanical ventilation|Weaning of mechanical ventilation is the time when the patient is ready for separation from ventilatory support until breathing without invasive support
75448047|NCT05801640|Other|Facilitated Tucking Position|The fetal position was given by the researcher. In the fetal position, the lower and upper extremities of the baby were kept in the flexed position by hand and placed in the side-lying position close to the midline.
75448048|NCT05801640|Other|Reiki|Reiki was applied to areas called chakras (forehead, throat, heart, stomach, feet and hands). A total of 15 minutes were applied in the form of 12 minutes touches in each chakra region.
75448049|NCT05801627|Drug|SAL067|SAL067 6mg(2 tablet) and Metformin ≥1500mg
75448050|NCT05801627|Drug|Placebo|Placebo (2 tablet) and Metformin ≥1500mg
75889721|NCT04102280|Device|Dialyser|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
75889722|NCT03560622|Device|multi-modality neuroimaging|multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
76060489|NCT03154684|Other|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~Inspection of the environment at the patient's home~Care and autonomy support~Social life support~Secondary prevention strategies:~Home exercise program (3x/weeks)~Protein enriched food preparation (20g whey protein/day)~Support to take vitamin D supplementation (2000 IU/day)~Recommendation and support to eat calcium rich foods~Motivation to be physically active"
75448051|NCT05801588|Other|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
75742005|NCT00021229|Drug|imatinib mesylate|"Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses."
75742006|NCT00021229|Radiation|local irradiation therapy|"Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib."
75742007|NCT00372112|Drug|GW642444|GW642444H
75742008|NCT00372112|Other|Placebo|Placebo administered twice daily
75742009|NCT02746588|Other|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
75742010|NCT02731144|Other|Peptamen intense|
75597648|NCT01034137|Drug|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
75597649|NCT01034137|Drug|placebo MTX|orally weekly
75742011|NCT02731144|Other|Novasource senior|
75742012|NCT02688790|Drug|Dalbavancin|
75889723|NCT03534674|Dietary Supplement|vitamin D3|a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
75889724|NCT02063334|Dietary Supplement|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
75889725|NCT02063334|Dietary Supplement|Placebo|
75597650|NCT01034137|Drug|placebo TCZ|iv every 4 weeks
75597651|NCT01034137|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
75597652|NCT04302805|Drug|Privigen|Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.
75597653|NCT04302805|Drug|Thymoglobulin|All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
75597654|NCT04302805|Other|Plasma Exchange|All patient will undergo Plasma Exchange before transplantation.
75889726|NCT02031068|Behavioral|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~Sub-maximal aerobic training for up to 15 minutes~Light coordination and sport-specific exercises for up to 10 minutes~Visualization and imagery techniques~Home program~A physiotherapist will supervise the rehabilitation."
75597655|NCT02874469|Other|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
75742013|NCT01047124|Other|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
75742014|NCT00488475|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
75889727|NCT02031068|Behavioral|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
75448052|NCT05801588|Other|Usual care|The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
75448053|NCT05801575|Drug|Chinese Herbal Medicine (CHM) teabag|Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.
75448054|NCT05801536|Device|SCONE|This is a noninvasive (nonsurgical) electrical neuromodulation device to reactivate and retrain the neurons and neural networks in the spinal cord to improve function after neurological trauma. The device will be used to stimulate the cervical spinal cord as participants practice tasks involving upper limb control.
75448055|NCT05801523|Procedure|laparoscopic ethanol sclerotherapy|ethanol (96%) sclerapy of endometrioma - endometrioma is filled with ethanol via foley catether, left for 10 min and than aspirated, endometrioma is washed with saline
75597656|NCT02874079|Other|Blood sample and cotton skin swabs|
75597657|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
76060490|NCT03154684|Other|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
75742015|NCT01020279|Drug|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d."
75597658|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
76060491|NCT03732118|Device|Eye-tracker Mobile EBT|Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
75742016|NCT01020279|Drug|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
76060492|NCT01672138|Procedure|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall
75742017|NCT01020357|Drug|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
76060493|NCT01672138|Procedure|scar homogenization|PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.
76060494|NCT01672138|Procedure|Non-PV triggers ablation|PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
76060495|NCT04040452|Drug|Continuous ketorolac|Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
76060496|NCT03154450|Device|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
75742018|NCT01020357|Drug|placebo|normal saline
75742019|NCT01017627|Other|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
76060497|NCT03154450|Device|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
76060498|NCT04027894|Drug|Rifamycin SV MMX|200 mg Rifamycin SV-MMX® (CB-01-11)
76060499|NCT04027894|Drug|Placebo to Rifamycin SV-MMX|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
76060500|NCT01672216|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
75448056|NCT05801523|Procedure|laparoscopic cystectomy of endometrioma|cystectomy of endometrioma - removal of endometrioma from ovary surgically
75448057|NCT05801497|Procedure|Balneotherapy|"The patients in the BT group will be treated with 12 daily immersion in a bathtub or in a pool at a 37-38°C or with a combination of bath and mud-packs to carry out in a period of two weeks.~The application of mud-packs will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will have 20-30 minutes of bed rest. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica."
75448058|NCT05801484|Other|Linezolid continuous infusion|Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
75597659|NCT01056289|Drug|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
75597660|NCT01039675|Drug|500mcg/25mcg once daily|GSK573719/GW642444
76060501|NCT01672216|Device|EMG-biofeedback alone|
76060502|NCT03154216|Behavioral|Exercise|90 minutes of moderate-intensity walking exercise on a treadmill
76060503|NCT03154216|Other|Drink|Beverage to be consumed after exercise
76060504|NCT03985150|Other|Biomechanical analysis of femoralis superficialis atherosclerotic tissue|Tissue collection during above-knee amputation; mechanical testing of tissue; microstructural testing of tissue
76060505|NCT03985150|Radiation|CT or MR angiogram|Obtaining in vivo geometry of diseased artery
76060506|NCT03977272|Drug|Combination drug|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
76060507|NCT03977272|Drug|Chemotherapy|modified-FOLFIRINOX
76060508|NCT03154528|Diagnostic Test|serum vitamin D level by ELISA|The study will include 60 patients with androgenetic alopecia (30 males & 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
76060509|NCT03947398|Device|BLIMP balloon|Using BLIMP balloon to cross lesion
76060510|NCT03947398|Device|Low profile balloon|using low profile balloon to cross lesion
76060511|NCT01672372|Dietary Supplement|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
76060512|NCT01672372|Dietary Supplement|Placebo Max Stress B|
75597661|NCT01039675|Drug|Placebo once daily|Inactive, excipients only
75597662|NCT02875093|Drug|ADI-PEG 20|Investigational Medicine
75597663|NCT02875093|Drug|Cytarabine|low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
75597664|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
75597665|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
75597666|NCT01033825|Drug|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
76060513|NCT03154372|Other|Expert supervised practice with validated metrics|
75889728|NCT02194946|Drug|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
75889729|NCT02194946|Drug|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
75889730|NCT02063490|Behavioral|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
75742020|NCT01017627|Other|No change from normal routine|Normal unit policy for labs and anemia treatment
75742021|NCT00042991|Drug|gefitinib|Given orally
75448059|NCT05801458|Procedure|Modeling Resin Insertion Technique|One drop of modeling resin will be dispensed into a clean mixing well. Following the placement of the resin composite into the prepared site, a composite instrument (round-ended plugger with a diameter of 2 mm) will be dipped into the modeling resin. With modeling resin on the instrument, the resin composite is sculpted and manipulated to the desired shape. This will be repeated with each increment. Each increment will be polymerized for 20 sec with a LED light-curing unit.
75742022|NCT00042991|Radiation|radiation therapy|Undergo standard brain irradiation
75742023|NCT00042991|Other|pharmacological study|Correlative studies
75889731|NCT03792438|Diagnostic Test|Transvaginal 3D Power Doppler Ultrasound|Samsung H60 ultrasound machine with 4-9 MHz volume transducer using VOCAL system and Histogram Facility
75889732|NCT02062866|Procedure|Purse-String|"The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound."
75597667|NCT01033825|Drug|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
75597668|NCT01033825|Drug|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
75597669|NCT01033825|Drug|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
75742024|NCT00042991|Other|laboratory biomarker analysis|Correlative studies
75742025|NCT01022385|Dietary Supplement|24-hour low-residual diet|
75742026|NCT01017783|Behavioral|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
75742027|NCT01017783|Behavioral|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
75742028|NCT01017783|Behavioral|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
75742029|NCT00466167|Drug|Pramipexol Extended Release|
75597670|NCT01033825|Drug|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
75742030|NCT00466167|Drug|Pramipexol Immediate Release|
75742031|NCT00466167|Drug|Placebo|
75597671|NCT01033747|Drug|Deferasirox|10 mg/kg or 30 mg/kg orally daily
75889733|NCT02062866|Procedure|Second Intent|The wound will not be sutured, and allowed to heal on its own.
76060514|NCT03154372|Other|self guided practice with validated metrics|
76060515|NCT01676506|Drug|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
76060516|NCT01676506|Procedure|Ranibizumab Injection|
76060517|NCT03154294|Drug|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
75597672|NCT01033747|Drug|Deferasirox|5 mg/kg or 30 mg/kg orally daily
75597673|NCT00627055|Drug|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
75597674|NCT00627055|Drug|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
75742032|NCT01017939|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
75742033|NCT01017939|Drug|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
75742034|NCT01017939|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
75742035|NCT01017939|Drug|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
76071989|NCT03517761|Other|Sham Control|Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
75597675|NCT02875015|Drug|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
75448060|NCT05801458|Procedure|Conventional resin composite Incremental Placement Technique|A three-step etch-and-rinse adhesive system will be used according to the manufacturer's instructions. 37.5% phosphoric acid (Kerr Co, Orange, CA, USA) will be applied to the enamel and dentin for a period of 30 s and 15 s, respectively. Subsequently the cavities will then be rinsed with an air/water spray for 15 s. A layer of primer will be applied to the dentin for 30 sec, afterward gentle air-drying for 5 sec. Then, the bond (AdheSE adhesive) will be applied on the enamel and dentin and light cured with a LED curing unit for about 30 sec. Tetric N-Ceram will then be applied using an incremental filling technique, each increment will not exceed 2mm in thickness. Each increment will be polymerized for 20 sec with a LED light-curing unit.
75448061|NCT05801393|Radiation|CT, MRI|"HRCT with no IV contrast administration and bone algorithm. Intra thecal injection of contrast, then CT in prone position to obtain direct coronal cuts.~MR cisternography using a three dimensional constructive interference in steady state (3D-CISS) sequence."
75597676|NCT02875015|Drug|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
75597677|NCT02875015|Procedure|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
75597678|NCT01091428|Drug|Alisertib|Alisertib tablets
75597679|NCT01091428|Drug|Paclitaxel|Paclitaxel intravenous infusion
75742036|NCT00480441|Drug|Dronabinol|10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
75742037|NCT00480441|Behavioral|BRENDA therapy|weekly therapy sessions for 6 weeks
75742038|NCT00480441|Drug|Placebo|4 capsules daily for 2 weeks followed by a 1 week taper
75742039|NCT01022463|Drug|Ivabradine|Ivabradine 5 mg BId for 4 weeks
75742040|NCT01022463|Drug|Atenolol|50 mg od for 4 weeks
75742041|NCT00488319|Drug|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
75742042|NCT01018017|Drug|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
75448062|NCT05801380|Drug|AChE inhibitor monotherapy|This is a drug treatment using Donepezil only
75597680|NCT04307758|Other|Muscle Strength Assesment-Make Test|For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
75597681|NCT04307758|Other|Muscle Strength Assesment-Break Test|For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
75597682|NCT04307680|Device|Peritron perineometer|Perineometry will be used to assess quality of each observed treatment modality.
75597683|NCT04307524|Procedure|laparoscopic repair|laparoscopic suture repair of cesarean scar niche
75597684|NCT04307524|Drug|medical treatment in the form of combined hormonal contraception|"patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare"
75742043|NCT01018017|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
75742044|NCT01018251|Other|3'-deoxy-3'-[18F]fluorothymidine|Given IV
75742045|NCT01018251|Procedure|Positron Emission Tomography/computed tomography|
75742046|NCT01018251|Radiation|FLT-PET/CT|
75448063|NCT05801380|Drug|AChE inhibitor and NMDA receptor antagonist combination therapy|This is a drug treatment combining Donepezil and Memantine
75597685|NCT04307602|Other|Exercise - High Intensity Interval Training (HIIT)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children
75597686|NCT04307602|Other|Exercise - Submaximal Steady State Training (SST)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled
75597687|NCT01096342|Drug|dinaciclib|Given IV
75597688|NCT01096342|Other|laboratory biomarker analysis|Correlative studies
75597689|NCT01039519|Drug|Ganetespib|Ganetespib 200 mg/m^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
75597690|NCT04874740|Other|No intervention|No intervention
75889734|NCT02195024|Procedure|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
75889735|NCT02195102|Device|Transcatheter aortic valve Replacement|
75889736|NCT03533972|Drug|Ashwagandha|ashwagandha capsules given to the subjects twice daily after meals for 1 month
75889737|NCT03533972|Other|Placebo|placebo capsules given twice daily after meals for 1 month
75597691|NCT01096186|Drug|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
75889738|NCT02916927|Drug|Ketamine IV Infusion|Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
75889739|NCT02916927|Drug|Ketamine IV push|Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
75889740|NCT02197598|Drug|nalmefene|
75597692|NCT01096186|Drug|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
75597693|NCT01096186|Drug|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
75597694|NCT01096186|Drug|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
75597695|NCT01032889|Drug|Deoxycholic acid injection|
75597696|NCT01032889|Drug|Placebo|Phosphate buffered saline placebo for injection
75597697|NCT04301713|Other|Evaluation of rik of falls|An evaluation of the risk of falls will be carried out in the elderly in the province of Salamanca. This will attempt to identify the risk of falling as well as to be able to establish protocols for action of a preventive and rehabilitative nature.
75889741|NCT02196662|Drug|IBD98-M:|single adiministration
75889742|NCT02196662|Drug|IBD98-M without HA|single adiministration
75889743|NCT02196662|Drug|Delzicol|single adiministration
75448064|NCT05801367|Drug|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
75448065|NCT05801367|Drug|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
75448066|NCT05801354|Drug|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
75597698|NCT04307368|Other|FODMAP diet|8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
75742047|NCT01018329|Procedure|Magnetic Resonance Imaging|
75742048|NCT01018329|Procedure|Diffusion Tensor Imaging|
75742049|NCT01018329|Procedure|Magnetic Resonance Spectroscopic Imaging|
75742050|NCT01018329|Procedure|Dynamic Contract-Enhanced magnetic resonance imaging|
75448067|NCT05801354|Drug|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
75448068|NCT05801328|Device|Ending of the wires on Erich arch bar in the occlusal direction|The wires of the Erich arch bar will be placed on the occlusal direction
75448069|NCT05801302|Device|Foam rolling (shorter volume)|A single intervention will be performed (3 sets of 30 seconds, with between-sets intervals of 30 seconds).
75597699|NCT04307368|Other|Elimination-rotational diet|During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
75597700|NCT04307368|Other|Classic diet|8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
75742051|NCT01018329|Procedure|Diffusion-weighted magnetic resonance imaging|
75742052|NCT00463047|Drug|Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone|Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
75889744|NCT02195180|Drug|ERY001|
75889745|NCT02195180|Drug|Gemcitabine|
75448070|NCT05801302|Device|Foam rolling (longer volume)|A single intervention will be performed (3 sets of 60 seconds, with between-sets intervals of 30 seconds).
75448071|NCT05801289|Drug|Quetiapine|Giving the drug to group Q
75448072|NCT05801276|Diagnostic Test|Methylation assay|Methylation assay of CDO1 and HOXA9 genes in plasma circulating tumor DNA
75597701|NCT01049503|Other|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
75889746|NCT02195180|Drug|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
75597702|NCT04292353|Other|Cognitive tests and Patient Reported Outcome|
75889747|NCT03672591|Other|Renal clearance examination|Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
75448073|NCT05801263|Diagnostic Test|CDO1 and HOXA9 methylation assay|CDO1 and HOXA9 methylation assay in plasma circulating tumor cells
75448074|NCT05801250|Behavioral|AI Platform|AI platform can help patients evaluate the adequacy of bowel cleansing without the aid of caregivers.
75889748|NCT03623529|Drug|LJPC-501 (angiotensin II)|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
75597703|NCT01029925|Drug|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
75889749|NCT03623529|Drug|Placebo|Placebo Arm
75889750|NCT02197676|Drug|SGI-110 administration|"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
75597704|NCT04302415|Drug|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
75889751|NCT02916693|Drug|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
75889752|NCT02195336|Device|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
75597705|NCT02873533|Other|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
75597706|NCT04302649|Drug|peritoneal dialysate at 37°C temperature|during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
75448075|NCT05801185|Other|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
75448076|NCT05801133|Drug|Pirfenidone|200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
75448077|NCT05801107|Drug|WX-0593|WX-0593 Tablets 60 mg QD，once daily for 7 days, followed by 180 mg of WX-0593 tablets,once daily in a 21-days cycle.
75597707|NCT04301557|Drug|PD-1 Antibody|PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
75597708|NCT04301557|Drug|Oxaliplatin|Oxiliplatin 130mg/m^2 (100mg/m^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
75597709|NCT04301557|Drug|Capecitabine|Capecitabine 1000mg/m^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
75597710|NCT04301557|Radiation|External beam radiotherapy|Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
75597711|NCT04301557|Procedure|Total mesorectal excision|Total mesorectal excision
75889753|NCT02195336|Drug|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
75889754|NCT02195336|Drug|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
75889755|NCT03679065|Drug|Paracetamol|Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
75889756|NCT03679065|Drug|Dexamethasone|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
75448078|NCT05801094|Drug|QL1604|QL1604 3 mg/kg Q3W
75448079|NCT05801068|Drug|Factor Xa Inhibitor|Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
75597712|NCT02874313|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
75597713|NCT02874313|Drug|Pharmacological treatment|Conventional pharmacological treatment with oral antidiabetic drugs or insulin
75889757|NCT03679065|Drug|Placebo|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
75597714|NCT02874313|Other|Conventional anti-diabetic diet recommendations|
76060518|NCT03154294|Drug|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
75597715|NCT01029691|Device|Positive Airway Pressure|Women will use positive airway pressure until delivery
75742053|NCT00487695|Device|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
75742054|NCT00487695|Device|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
75889758|NCT02196740|Drug|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
76060519|NCT03154294|Drug|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
76060520|NCT03154606|Other|Micellar Casein (#1)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
75448080|NCT05801055|Drug|Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone|The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
75448081|NCT05801016|Behavioral|Emerging Technologies and Training in Neurosciences|Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall
75448082|NCT05801003|Device|Predilation with cutting balloon.|PCI will be performed under OCT guidance. Predilation of the lesion will be done with cutting balloon.
75448083|NCT05801003|Device|Predilation with conventional balloon|PCI will be performed under OCT guidance. Predilation of the lesion will be done with conventional balloon (semi-compliant or non-compliant)
75448084|NCT05800977|Biological|Prizloncabtagene autoleucel|Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
75448085|NCT05800912|Other|Narrative photography|"Students were shown real-life written stories, audio, and videos using a private online platform. The training activity included four modules: i) heart transplantation waiting list; ii) life expectancy, fear of death, and organ rejection; iii) post-transplant physical and functional limitations; and iv) lack of knowledge of physical exercise patients can perform.~The students were encouraged to think about how they would feel if they had undergone heart transplantation. Afterward, they had to communicate these feelings using up to three photographs and reflective explanatory text.~Two weeks later, the students met a heart transplantation expert patient followed by an educator-guided debate. Students' images were shared and discussed. Moreover, students were encouraged to explain their feelings and their acquired skills (two hours)."
75597716|NCT02874157|Biological|blood draw|
75597717|NCT01029535|Device|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
75597718|NCT04290481|Other|oxygen saturation and perfusion index screening|Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.
75597719|NCT04301167|Behavioral|befriending|Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
75742055|NCT00487539|Biological|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
75742056|NCT00487539|Biological|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -> 50 mg arm group and at Week 2 for Golimumab 200 mg -> 100 mg arm group.
75742057|NCT00487539|Biological|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -> 100 mg arm group and at Week 2 for Golimumab 400 mg -> 200 mg arm group.
75742058|NCT00487539|Biological|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -> 200 mg arm group.
75742059|NCT00487539|Biological|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -> 50 mg arm group.
75742060|NCT01018407|Behavioral|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen & Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
75889759|NCT02196740|Drug|creosote|Pulp removal,Root canal irrigation and disinfection
76060521|NCT03154606|Other|Micellar Casein (#2)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
76060522|NCT03154606|Other|Calcium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
76060523|NCT03154606|Other|Sodium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
76060524|NCT03154606|Other|Milk Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
76060525|NCT03154606|Other|Pure Protein Blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
76060526|NCT03154606|Other|Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
76060527|NCT03154606|Other|Native Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
75742061|NCT01018407|Behavioral|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
75742062|NCT00486837|Drug|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
76060528|NCT03154606|Other|Soy Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
76060529|NCT03154606|Other|Pea Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
76071990|NCT03514433|Other|TRIP Patient Navigation Intervention|The TRIP intervention will replace the current standard of care at the 6 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
75889760|NCT02197754|Other|Controlled diet|"Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives."
76060530|NCT03154606|Other|Native Whey: Micellar Casein (50:50) blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
75597720|NCT04302571|Behavioral|combined aerobic and resistance physical activity|Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
75597721|NCT04302571|Behavioral|sham exercise|general recommendation to perform regular aerobic physical activity
75597722|NCT02874235|Behavioral|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
75597723|NCT02874235|Behavioral|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
75448086|NCT05800912|Other|Traditional learning|"A participatory lecture was carried out, in which cardiac rehabilitation in heart transplantation patients was explained. Then, there was an educator-guided debate about protocols and actions (one hour).~Second, the students autonomously prepared clinical cases on physical limitations, physical exercise, risk factors, and life after transplantation (two hours).~Two weeks later, the clinical session was held among students (2 hours). They adopted the roles of physical therapists or transplant patients to work on: i) post-transplant physical and functional limitations; ii) lack of knowledge of the physical exercise the patient can perform; iii) control of cardiovascular risk factors; iv) life post-transplant."
75448087|NCT05800899|Behavioral|Brief Motivational Interviewing|Standard non-adapted brief motivational interviewing based on motivational interviewing.
75448088|NCT05800899|Behavioral|Culturally adaptation brief motivational interviewing|culturally adapted brief motivational interviewing based on motivational interviewing.
75597724|NCT04301635|Procedure|Maxillo-mandibular Advancement + Counterclockwise rotation|Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
75597725|NCT01028053|Drug|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
75597726|NCT04301245|Other|Educational program|"The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment."
75597727|NCT04607317|Behavioral|Exercise program|a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day)
75597728|NCT04607317|Behavioral|Health Coach|The coach will work directly with each participant during their once-weekly virtual 1:1 meeting to progress intensity and duration. Participants will meet with the coach to review a brief social cognitive theory-based module, which will provide education on core behavior change concepts and the benefits of physical activity for those with epilepsy. The coach will review the previous week's exercise during meetings, and will then work with the participant to revise and reset goals for the coming week.
75742063|NCT04199247|Behavioral|Sub symptom aerobic exercise|Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
75742064|NCT00486759|Drug|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
75742065|NCT00486759|Drug|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
75889761|NCT02195492|Drug|Synvisc®|
76060531|NCT03154606|Other|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
76060532|NCT01672450|Drug|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
76060533|NCT01672528|Other|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
75889762|NCT02195570|Other|Quit Smoking Now (QSN)|"The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse."
75597729|NCT04607317|Behavioral|Health Information|Participants will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
75889763|NCT02195570|Behavioral|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
75889764|NCT03678987|Diagnostic Test|P-MPA concentration|We will calculate AUC_0-12 of MPA based on 4 measurements of P-MPA
76060534|NCT01672528|Other|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
75889765|NCT03678987|Drug|mycophenolic acid|Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
76060535|NCT03154060|Device|Abbott FreeStyle Libre Flash Glucose Monitoring sensors|Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
76060536|NCT01854268|Drug|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
76060537|NCT01672606|Drug|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
76060538|NCT01594281|Drug|Ranibizumab 0.5 mg|Pre-filled syringe for intravitreal injection
75597730|NCT04300621|Drug|OTF 1|Participants will receive (S)-ketamine administered sublingually through OTF 1.
76060539|NCT01594281|Procedure|Panretinal laser photocoagulation|PRP treatment following DRS guidelines
76060540|NCT05025124|Device|Entia Liberty|Home monitoring system
76060541|NCT04764526|Other|Protein-enriched ice cream|Offering two protein-enriched ice creams
76060542|NCT05565820|Other|Vamousse Spray 'n' Go|Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).
76060543|NCT05565820|Drug|Nix Creme Rinse Lice Treatment|1% permethrin lotion for topical application.
76060544|NCT03153904|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
76060545|NCT03153904|Other|Monitoring and Feedback System|For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.
75597731|NCT04300621|Drug|OTF 2|Participants will receive (S)-ketamine administered sublingually through OTF 2.
75597732|NCT04300621|Drug|OTF 3|Participants will receive (S)-ketamine administered sublingually through OTF 3.
75597733|NCT04300621|Drug|OTF 4|Participants will receive (S)-ketamine administered sublingually through OTF 4.
75742066|NCT00486759|Drug|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
75742067|NCT00486759|Drug|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
75597734|NCT01023217|Drug|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
75597735|NCT01023217|Drug|Entecavir|Entecavir 1 mg/day orally
75597736|NCT01023217|Drug|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
75597737|NCT01095796|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
75597738|NCT01095796|Drug|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
75597739|NCT01095796|Drug|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
75889766|NCT02197832|Procedure|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
75889767|NCT02197832|Procedure|control procedure|Using pipelle catheter without entering the uterine cavity.
75742068|NCT00486603|Drug|hydroxychloroquine|see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
75889768|NCT02197832|Device|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
75889769|NCT03672513|Dietary Supplement|Placebo Comparator|Oral administration of 1 daily capsule containing lactose
75889770|NCT03672513|Dietary Supplement|Zinc Supplement|Oral administration of 1 daily capsule containing 50 mg/day of Zn
75889771|NCT03672513|Dietary Supplement|Magnesium supplement|Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
75889772|NCT02195648|Other|Suboccipital inhibition|"Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles."
75889773|NCT02919345|Drug|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
75889774|NCT02919345|Drug|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
75889775|NCT02195726|Procedure|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
75889776|NCT02195726|Procedure|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
75889777|NCT02919189|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
75889778|NCT02195804|Drug|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
75597740|NCT01095796|Drug|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
75742069|NCT00486603|Drug|temozolomide|TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
75742070|NCT00486603|Other|pharmacological study|Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
75742071|NCT00486603|Radiation|Radiation|Radiation during the first six weeks of treatment Monday-Friday
75742072|NCT00486291|Drug|VI-0521|phentermine 15mg/topiramate 100mg
75889779|NCT02195804|Drug|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
75889780|NCT02195804|Drug|Ranitidine hydrochloride|
75889781|NCT03672435|Drug|Topical Solution|proparacaine 0.5% eye drop
75889782|NCT03534128|Other|Evaluation of the effect of cues on virtual spatial navigation using a virtual district|Evaluation of the effect of cues on virtual spatial navigation using a virtual district
75889783|NCT03674463|Drug|LCAR-B4822M CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
75889784|NCT03674385|Dietary Supplement|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
75889785|NCT03674385|Drug|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
75889786|NCT03674385|Drug|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
75597741|NCT01023061|Drug|abiraterone acetate|Given PO
75597742|NCT01023061|Drug|prednisone|Given PO
75597743|NCT01023061|Drug|leuprolide acetate|Given via injection
75597744|NCT01023061|Other|laboratory biomarker analysis|Correlative study
75597745|NCT01023061|Radiation|external beam radiation therapy|Undergo radiotherapy
75597746|NCT01023061|Drug|goserelin acetate|Given via injection
75597747|NCT01027897|Drug|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
75597748|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
75742073|NCT00486291|Drug|Placebo|matched placebo
75742074|NCT00474045|Drug|insulin detemir|Treat-to-target, dose titration, s.c. (under the skin) injection
75742075|NCT00474045|Drug|NPH insulin|Treat-to-target, dose titration, s.c. (under the skin) injection
75742076|NCT00474045|Drug|insulin aspart|Treat-to-target, dose titration, s.c. (under the skin) injection
75742077|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
75742078|NCT01020825|Drug|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
75889787|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
75889788|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
76060546|NCT01566981|Procedure|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
75889789|NCT02574455|Drug|Sacituzumab govitecan|10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.
76060547|NCT01672684|Procedure|support group therapy|Complete at-home group video calling support sessions
76060548|NCT01672684|Other|educational intervention|Receive an educational workbook journal
75448089|NCT05800886|Other|Early mobilization and tea consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea (black tea 2 g, caffeine amount: 45-55 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
76060549|NCT01870778|Drug|RLX030|1 mg/mL solution in 6 mL vials
75597749|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
75889790|NCT02574455|Drug|Eribulin|Administered IV over 2 to 5 minutes at a dose 1.4 mg/m^2 at North American sites and 1.23 mg/m^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m^2 and 0.67 mg/m^2 for North American and European sites, respectively).
75889791|NCT02574455|Drug|Capecitabine|1000 to 1250 mg/m^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
75889792|NCT02574455|Drug|Gemcitabine|800 to 1200 mg/m^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.
75889793|NCT02574455|Drug|Vinorelbine|25 mg/m^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
75889794|NCT02196896|Other|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
75889795|NCT02196896|Other|Information|The patients receive online information about depression once a week for 90 days.
75889796|NCT03533894|Device|colic capsule|colic polyp diagnosis
75889797|NCT02197988|Drug|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
75889798|NCT02197988|Drug|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
76060550|NCT01870778|Drug|Placebo|Matching placebo solution to serelaxin
76060551|NCT05496322|Device|Continuous Non Invasive Blood Pressure Monitoring|Continuous non-invasive arterial pressure monitoring
76060552|NCT05496322|Device|Intermittent Non Invasive Blood Pressure Monitoring|Intermittent non-invasive arterial pressure monitoring
76060553|NCT04964050|Drug|Capozide|Capozide will be administered as per the treatment sequence.
76060554|NCT04964050|Drug|ACE-Hemmer-Ratiopharm|ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.
76060555|NCT03541330|Other|semi-directive interview|semi-structured interview conducted by a clinical psychologist
76060556|NCT03526900|Drug|Atezolizumab|"Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."
76060557|NCT03427294|Other|Delphi study|Delphi study on the optimal rehabilitation pathway following lumbar arthrodesis
76060558|NCT03420742|Drug|Midazolam|Midazolam syrup.
76060559|NCT03420742|Drug|Brigatinib|Brigatinib tablets.
76060560|NCT01672840|Dietary Supplement|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
76060561|NCT01672840|Dietary Supplement|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
76060562|NCT02370706|Drug|PIM447|pan-pim inhibitor
76060563|NCT02370706|Drug|Ruxolitinib|JAK1/JAK2 inhibitor
76060564|NCT02370706|Drug|LEE011|CDK4/6 inhibitor
76060565|NCT01818284|Drug|Filgrastim|5 µg/kg in the morning daily for 4 days.
76060566|NCT01818284|Drug|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
75889799|NCT03672357|Procedure|Laparoscopic liver resection|Laparoscopic hepatectomy
75889800|NCT03672357|Procedure|Open liver resection|Traditional open hepatectomy
75889801|NCT02795832|Drug|ZPL-5212372 1% w/w Ointment BID|
76060567|NCT01818284|Procedure|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
76060568|NCT02081014|Drug|G-Pen Mini™ (glucagon injection)|stable, pre-mixed, liquid glucagon for subcutaneous injection
76060569|NCT01673074|Drug|(PDT) Photodynamic therapy|photosensitizer
76060570|NCT01673152|Dietary Supplement|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
76060571|NCT01673152|Dietary Supplement|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
75597750|NCT04300465|Behavioral|10 week MySlainte Program|"The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí."
75597751|NCT02873611|Device|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
75597752|NCT02873611|Procedure|genicular ablation procedure|
75597753|NCT02873299|Other|10 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
75597754|NCT02873299|Other|20 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
75597755|NCT01027273|Behavioral|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
75742079|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
75742080|NCT01018485|Drug|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
75597756|NCT01027273|Behavioral|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
75742081|NCT00462501|Biological|bevacizumab|
75742082|NCT00462501|Drug|fluorouracil|
75742083|NCT00462501|Drug|leucovorin calcium|
75742084|NCT00462501|Drug|oxaliplatin|
75742085|NCT00462501|Procedure|conventional surgery|
75742086|NCT00462501|Radiation|radiation therapy|
75742087|NCT03996603|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
75889802|NCT02795832|Drug|Placebo Ointment BID|
76060572|NCT05405842|Device|Transauricular Vagal Nerve Stimulation|TENS 7000 is a handheld device used to deliver electrical impulses for nerve stimulation to help modulate and treat chronic pain. The manufacturer, Roscoe, has regulatory approval for the use of nerve stimulator therapy in the acute and/or prophylactic treatment of headaches, migraines, sciatica, muscle spasms, acute and chronic pain, and improve circulation. It is FDA approved in the USA for the above indications, but has not been approved for use in gastrointestinal diseases such as gastroparesis or functional dyspepsia. It has been registered as an investigational new device in various clinical trials. The purpose of this protocol is to provide vagal nerve stimulation to patients with gastroparesis, functional dyspepsia, and healthy controls as a comparison.
76071991|NCT03514017|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
76071992|NCT03514017|Drug|Ibrutinib|Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
75742088|NCT01018641|Biological|SA3Ag vaccine|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1."
75742089|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
75889803|NCT02196974|Procedure|cryobiopsy|
75889804|NCT03678909|Procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
75889805|NCT02201030|Biological|NBP606|A single intramuscular injection into the thigh
75597757|NCT04300933|Behavioral|Electroencephalogram-based neurofeedback|In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.
75597758|NCT01022203|Behavioral|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
75742090|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
75889806|NCT02201030|Biological|Prevnar13|A single intramuscular injection into the thigh
75889807|NCT03674073|Biological|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
75742091|NCT01018641|Biological|SA3Ag followed by Placebo|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo."
75742092|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
75742093|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
75889808|NCT03674073|Procedure|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
75889809|NCT02198534|Device|Methodology of visual acuity assessment|
76071993|NCT03513406|Drug|Sugammadex|Sugammadex is indicated for the reversal of neuromuscular blockade.
76060573|NCT01673230|Procedure|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
75448090|NCT05800886|Other|Early mobilization and coffee consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee (ınstant coffee 2 g, caffeine amount: 60/80 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
76060574|NCT03153358|Drug|Icotinib|icotinib 125 milligram three times a day
76060575|NCT03153358|Radiation|SBRT|given radiation for the primary lesion
76060576|NCT03025594|Drug|Gonyautoxins|Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty
76060577|NCT03025594|Drug|Chirocaine ketorolac epinephrine|Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
75742094|NCT01018641|Biological|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
75742095|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
75889810|NCT03678597|Other|Medium Supplemented with Latrunculin B|A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
75889811|NCT02198066|Other|Dry Sterile Dressing|Described in Arm Description.
75889812|NCT02198066|Other|Metallic Silver Dressing|Described in Arm Description.
75889813|NCT02198066|Other|Ionic Silver Dressing|Described in Arm Description.
76060578|NCT04404946|Other|phenylephrine infusion|in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
76060579|NCT04404946|Other|norepinephrine infusion|in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
76060580|NCT04404946|Other|placebo infusion|in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
76060581|NCT01673542|Drug|Lidocaine-Prilocaine 5%|
76060582|NCT01673542|Drug|DEXERYL|
76060583|NCT04804540|Drug|Vedolizumab IV|Vedolizumab IV infusion
76060584|NCT03713710|Behavioral|Pap testing|Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department
76060585|NCT03713710|Behavioral|Choice|Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
76060586|NCT02634268|Behavioral|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
75742096|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
75742097|NCT01018641|Biological|SA3Ag with no booster in stage 2|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive no vaccine."
75742098|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
75742099|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
75742100|NCT01018641|Procedure|Placebo with no booster in stage 2|"In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.~In stage 2 the subject will receive no vaccine."
76060587|NCT01610492|Drug|belimumab|10mg/kg administered intravenously
76071994|NCT03513406|Drug|Neostigmine|Neostigmine is indicated for the reversal of neuromuscular blockade.
75597759|NCT01022203|Other|PTSD Family Education|The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
75597760|NCT01296711|Biological|CDP6038 (olokizumab)|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
75597761|NCT04324281|Other|Investigation|cadaveric dissection
75597762|NCT05661045|Procedure|low-flow anesthesia|Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
75597763|NCT01294917|Device|Multi-purpose disinfecting solution|For the cleaning, rinsing, and storage of soft contact lenses.
75597764|NCT01294917|Device|Clear Care|Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
75597765|NCT01294917|Device|Opti-Free RepleniSH|Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
75597766|NCT01294683|Drug|Simvastatin|
75597767|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|
75597768|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant (N/LRPT)|
75597769|NCT01294683|Drug|Placebo|
75597770|NCT01294449|Device|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
75742101|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
76060588|NCT02369770|Device|stretching and active movement training|A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.
76060589|NCT01673776|Device|PulsioFlex® Monitoring|"goal directed therapy according to PulsioFlex® Monitoring- measurements~femoral catheter~extended perioperative monitoring~nutritional supplementation, (if necessary)"
76060590|NCT01817582|Drug|Lotemax|Lotemax gel will be administered as per the dose and schedule specified in the arms.
76060591|NCT01817582|Drug|Restasis|Restasis emulsion will be administered as per the dose and schedule specified in the arms.
76060592|NCT01817582|Drug|Soothe® Lubricant Eye Drops|
76060593|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
75597771|NCT01294449|Device|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
75597772|NCT01293123|Drug|Raltegravir|raltegravir 400 mg PO twice daily
75597773|NCT01293123|Drug|Efavirenz|efavirenz 600 mg PO once daily
75597774|NCT01292187|Drug|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
75597775|NCT01292187|Drug|Oral placebo at dinnertime|Oral placebo at dinnertime.
75597776|NCT01292187|Drug|Oral calcitonin at bedtime|Oral calcitonin at bedtime
75597777|NCT01292187|Drug|Oral placebo at bedtime|Oral placebo at bedtime
75597778|NCT01026493|Drug|temozolomide 60 mg x 21 days|Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
75597779|NCT01026493|Drug|temozolomide 75 mg x 21 days|Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
75597780|NCT01026493|Drug|ABT-888 20 mg x 21 days|20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
75597781|NCT01026493|Drug|ABT-888 40 mg x 21 days|40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
75597782|NCT01026493|Drug|Temozolomide 150 mg x 5 days|150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
75742102|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
75742103|NCT01018719|Device|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
75742104|NCT00383188|Drug|placebo|Capsule, once daily (QD) for 12 weeks
75742105|NCT00383188|Drug|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
75742106|NCT00383188|Drug|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
75742107|NCT00383188|Drug|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
75597783|NCT01026493|Drug|ABT-888 40 mg x 5 days|40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
76060594|NCT01594125|Drug|Nintedanib low dose|twice daily oral dosing
75597784|NCT01026103|Device|Tri Staple Technology stapler|This is a single arm study.
75597785|NCT02873767|Drug|PR1|"Active substance: UCB4019~Route of Administration: subcutaneously"
76060595|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
75597786|NCT02873767|Other|PL1|"Active substance: Placebo~Concentration: 0.9 % saline~Route of Administration: subcutaneously"
75742108|NCT00383188|Drug|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
76060596|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
76060597|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
76060598|NCT04792684|Diagnostic Test|Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel|Evaluate the performance of a preliminary panel of biomarkers
76060599|NCT01673932|Biological|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
76060600|NCT01673932|Procedure|surgery|
76060601|NCT02986113|Behavioral|MAPS tailored multimedia patient activation program|
76060602|NCT02986113|Behavioral|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
76060603|NCT02986113|Behavioral|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
76060604|NCT02986113|Behavioral|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
76060605|NCT04404868|Other|Normal clinical practice|There are no experimental interventions. The procedures are in line with normal clinical practice.
76060606|NCT04604288|Biological|HB-adMSC|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
76060607|NCT04775134|Diagnostic Test|Lung biopsy|Biopsy of residuary material from a medically indicated pulmonary resection
76060608|NCT01870076|Behavioral|Healing Touch|
75597787|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
75597788|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
75597789|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
75597790|NCT01291173|Drug|Placebo|Placebo capsule taken once daily for up to 11 weeks
75597791|NCT02873455|Other|Short video clip including the circumstance of operation theater, and surgeon's interview|
75597792|NCT02872519|Drug|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Given by IV
75597793|NCT02872519|Procedure|Positron Emission Tomography|Undergo scan
75597794|NCT02872519|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
75597795|NCT01291017|Drug|PD0332991|PD0332991 125 mg PO days 1 - 21
75597796|NCT01290315|Drug|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
75597797|NCT01290315|Drug|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
75742109|NCT01021059|Biological|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
75742110|NCT00462345|Drug|rituximab|1000 mg i.v. on Days 1 and 15
75742111|NCT00462345|Drug|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
75742112|NCT00462345|Drug|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
75742113|NCT00462345|Dietary Supplement|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
76060609|NCT01870076|Behavioral|Healing Touch, Sham|
76060610|NCT01870076|Behavioral|Control, Presence|
76071995|NCT03513406|Drug|Glycopyrrolate|Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
76071996|NCT03504163|Drug|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.
75597798|NCT01289847|Biological|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
75597799|NCT04830748|Other|Mechanical knee traction|Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).
75597800|NCT04830748|Other|Therapeutic exercises|"Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force."
75597801|NCT02877784|Procedure|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
75742114|NCT01025115|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
76060611|NCT01592721|Biological|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
76060612|NCT02125396|Other|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
76060613|NCT02125396|Other|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
75889814|NCT03673995|Dietary Supplement|Myo-inositol+L-tyrosine|PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
75889815|NCT03673917|Other|Educational video|The educational video on skin cancer for cosmetologists
76060614|NCT01613378|Other|No intervention|No intervention administered in this study
75597802|NCT02877784|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
75889816|NCT03673917|Other|Control video|A publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer
75889817|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
75889818|NCT01378091|Drug|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
76060615|NCT01592409|Drug|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
75889819|NCT01378091|Drug|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
75889820|NCT01378091|Drug|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."
75448091|NCT05800886|Other|Early mobilization and warm water consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water (37 centigrade) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
75742115|NCT01025115|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
75889821|NCT02794974|Other|cervical plexus block|ultrasound-guided application of 20ml ropivacaine 0.75%
75889822|NCT02794974|Other|facial nerve block|ultrasound-guided application of 5ml prilocaine 1%
75889823|NCT02794974|Other|perivascular block|ultrasound-guided application of 5ml prilocaine 1%
75597803|NCT02877784|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
75889824|NCT03673839|Other|Animal Proteins (crossover)|Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
75889825|NCT03673839|Other|Plant-based protein blends type 1 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
75889826|NCT03673839|Other|Plant-based protein blends type 2 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
75889827|NCT03673839|Other|Plant-based protein blends type 3 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
75448092|NCT05800886|Other|Ongoing treatment|The first mobilization and oral intake of the patients in the control group started at the 8th hour.
75448093|NCT05800847|Drug|Gabapentin|Gabapentin will be administered for 2 days at 100 mg q8h for titration to avoid side effects. The next 12 days, gabapentin will be taken at 300 mg q8h.
75597804|NCT01021813|Drug|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
75597805|NCT01021813|Drug|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
75742116|NCT01022541|Drug|Capecitabine|"Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above."
75742117|NCT01022541|Drug|Oxaliplatin|"Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.~(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)~Courses as per detailed description above."
75742118|NCT01022541|Drug|Bevacizumab|"Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.~The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes~Courses as per detailed description above."
75742119|NCT01022541|Procedure|Liver metastasectomy|Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
75742120|NCT01045408|Dietary Supplement|Berry extract|Berry extract for weeks
75597806|NCT01025635|Drug|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
75597807|NCT01025635|Drug|Vehicle foam|Applied topically twice daily for 12 weeks
75597808|NCT04300387|Behavioral|multidisciplinary care|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
75597809|NCT01021423|Drug|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
75597810|NCT01021423|Other|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
75597811|NCT02872207|Drug|BAY 987516 (Y65-122)|5 µL in one eye
75597812|NCT02872207|Drug|BAY 987516 (Y65-118)|5 µL in one eye
75742121|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
75597813|NCT02872207|Drug|Control|5 uL in other eye
75597814|NCT02873143|Other|No intervention|No intervention
75742122|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
75597815|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
75597816|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
75597817|NCT01020799|Drug|AZD7268|15 mg, oral, twice daily (BID)
75448094|NCT05800847|Drug|Placebo|Placebo will follow the same dosing pattern as gabapentin to allow for blinding. Placebo will be encapsulated with a gelatin capsule to mimic the look of gabapentin.
75448095|NCT05800808|Procedure|High Intensity Intervals|8x4 min cycling bouts at 85% of VO2peak
75597818|NCT01020799|Drug|Escitalopram|20 mg, oral, once daily (QD)
75597819|NCT01020799|Drug|Placebo capsules|Placebo capsules to match AZD7268
75597820|NCT01020799|Drug|Placebo tablets|Placebo tablets to match encapsulated escitalopram
75742123|NCT01047202|Biological|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
75448096|NCT05800808|Procedure|Moderate Exercise|81 minutes of cycling at 50% VO2peak
75448097|NCT05800795|Device|Er: YAG laser|surface treatment with Er: YAG laser for heating abutments
75448098|NCT05800795|Device|plasma spray|surface treatment with plasma spray for heating abutments
75597821|NCT02872597|Drug|Ipratropium|
76060616|NCT01592409|Drug|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
75597822|NCT02872597|Drug|0.9% Sodium Chloride|
75597823|NCT02872597|Drug|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
75597824|NCT02872597|Drug|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
75597825|NCT04299919|Procedure|Minimally invasive treatment|All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
75597826|NCT04299919|Procedure|Hepatectomy|All hepatocellular carcinoma (HCC) patients received hepatectomy.
75742124|NCT01047280|Dietary Supplement|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
75742125|NCT01047280|Dietary Supplement|Safflower oil|3.5 g/d of safflower oil
75742126|NCT01047280|Dietary Supplement|G-c9, t11|3.5 g/day of c9, t11 CLA
75742127|NCT02672956|Procedure|Ten mm trocar|
76060617|NCT02081638|Drug|Aspirin|Daily Asprin daily
75448099|NCT05800756|Drug|pyrotinib combined with trastuzumab, dalpiciclib and letrozole|Six 4-week cycles of dalpiciclib orally, 125mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28, and pyrotinib orally, 320mg, day 1-28, and trastuzumab, injection, 8 mg/kg loading dose in cycle 1, 6mg/kg in cycles 2-6, intravenous drops, 1 cycle on day 1-21.
75448100|NCT05800197|Drug|Tamoxifen 20mg|Selective estrogen receptor modulator
75448101|NCT05800197|Drug|Anastrozole 1mg|Aromatase Inhibitor
75448102|NCT05800197|Drug|Letrozole 2.5mg|Aromatase Inhibitor
75742128|NCT01047514|Behavioral|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
76060618|NCT02081638|Drug|Atorvastatin|Daily Atorvastatin Daily
76060619|NCT04603508|Drug|BERLIM 25/10 association|Berlim 25/10 association coated tablet.
76060620|NCT04603508|Drug|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
75448103|NCT05800197|Drug|Goserelin|Gonadotropin Releasing Hormone (GnRH) agonist
75448104|NCT05800197|Drug|Triptorelin|Gonadotropin Releasing Hormone (GnRH) agonist
75448105|NCT05798962|Procedure|Biopsies|Biopsies from the pathological muscle and healthy, unaffected muscle
75448106|NCT05798741|Procedure|Hardware removal|The surgery of hardware removal after an ORIF of an ankle fracture
75448107|NCT05798637|Other|Standard of care|No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)
75448108|NCT05797857|Other|Exercise Training|A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.
75448109|NCT05797597|Drug|Aspirin 300 Mg Oral Tablet|8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks
75448110|NCT05797597|Drug|Placebo|8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks
75597827|NCT01288989|Biological|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
75597828|NCT01020487|Drug|Paricalcitol|Paricalcitol capsules taken with water.
75597829|NCT01020487|Drug|Placebo|Placebo capsules taken with water
75597830|NCT02872675|Dietary Supplement|HOST-DM059|"Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
75597831|NCT02872675|Dietary Supplement|Maltodextrin|Placebo Comparator: Maltodextrin.
75742129|NCT01047592|Drug|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
76060621|NCT04603508|Drug|ROSUVASTATIN CALCIUM|Rosuvastatin 10 mg coated tablet.
76060622|NCT04603508|Other|BERLIM 25/10 ASSOCIATION PLACEBO|Berlim 25/10 association placebo coated tablet.
76060623|NCT04603508|Other|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
75742130|NCT01047592|Drug|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
75742131|NCT01047592|Drug|placebo|placebo,oral, for 12 weeks
75597832|NCT04299217|Dietary Supplement|Zynamite®|Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.
75742132|NCT01049854|Drug|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
75742133|NCT01049854|Drug|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
75742134|NCT01049854|Drug|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
75742135|NCT01049854|Drug|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
76060624|NCT04603508|Other|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin placebo coated tablet.
75742136|NCT01045486|Drug|ATP mixed probiotics|- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
75742137|NCT01045486|Drug|Placebo|- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
75742138|NCT01045564|Biological|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
76060625|NCT01674166|Drug|prucalopride|single dose 0.03 mg/kg prucalopride open label
76060626|NCT02235688|Drug|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
76060627|NCT02235688|Drug|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
76060628|NCT02235688|Drug|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
76060629|NCT02235688|Drug|gemcitabine|
76060630|NCT01676584|Drug|RO6811135|single ascending doses sc
75597833|NCT04299217|Other|Placebo|Placebo comparator (carrier)
76060631|NCT01676584|Drug|placebo|single doses sc
76060632|NCT03152578|Other|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
75597834|NCT02873065|Drug|Ilaprazole|
75597835|NCT02873065|Drug|Esoprazole|
75597836|NCT02872831|Device|22G SharkCore™ needle|The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
75597837|NCT02872831|Device|22G BNX EUS-FNA Needle|Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
75742139|NCT00453999|Drug|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
75742140|NCT00453999|Drug|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
75742141|NCT00453999|Drug|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
75742142|NCT00453921|Drug|Methylphenidate|Dosage dependent on weight
75742143|NCT00453921|Behavioral|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
75742144|NCT00453921|Other|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
75742145|NCT03995745|Behavioral|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
76060633|NCT03152578|Other|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
75597838|NCT00628225|Behavioral|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
75448111|NCT05797324|Other|Luminette|Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm
75448112|NCT05797324|Other|Sham|Sham protocol (white light <100 lux equivalent).
75448113|NCT05796102|Procedure|PET-MRI|"A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position.~Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment"
75448114|NCT05795348|Diagnostic Test|Personalised Musculoskeletal Modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop and inform personalised musculoskeletal models
75448115|NCT05795335|Drug|CDK4/6 inhibitor|CDK4/6 inhibitors
75742146|NCT00382720|Drug|Docetaxel + Oxaliplatin|"Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1"
75448116|NCT05794776|Device|BurstDR stimulation|BurstDR spinal cord stimulation
75597839|NCT00628225|Behavioral|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
75889828|NCT02201186|Other|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
75448117|NCT05794776|Device|Tonic stimulation|Tonic spinal cord stimulation
75448118|NCT05794776|Device|No stimulation|Stimulator is switched off
75448119|NCT05794750|Drug|AK104 injection|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
75597840|NCT01024855|Device|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
75889829|NCT02063568|Drug|Oxytocin|
75889830|NCT02257502|Drug|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
75889831|NCT01380119|Biological|V7|experimental arm
75597841|NCT01014013|Drug|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
75889832|NCT01380119|Other|placebo|placebo pill
75597842|NCT01014013|Drug|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
75889833|NCT02063646|Dietary Supplement|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
76060634|NCT03152578|Other|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
75448120|NCT05794750|Procedure|TME surgery|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
75448121|NCT05794750|Drug|Capecitabine|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
75597843|NCT02872051|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
75597844|NCT02872051|Other|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
75597845|NCT01013701|Drug|fluticasone furoate|nasal steroid spray
75597846|NCT01013701|Other|placebo|nasal steroid vehicle without drug
75597847|NCT00628303|Biological|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
75597848|NCT00628303|Other|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
75742147|NCT00382720|Drug|Docetaxel + Oxaliplatin + 5-FU|"Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1."
75742148|NCT00382720|Drug|Docetaxel + Oxaliplatin + Capecitabine|"Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously."
75889834|NCT02063646|Dietary Supplement|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
75889835|NCT02198144|Other|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
76060635|NCT01065532|Device|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
76060636|NCT01065532|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
76060637|NCT01674244|Behavioral|Integrative Exercise|
76060638|NCT01674244|Behavioral|Monitor Only Waitlist|
75889836|NCT03678519|Diagnostic Test|Pulmonary function test|Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
76060639|NCT03152734|Procedure|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
76060640|NCT01697319|Drug|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
76060641|NCT03152812|Procedure|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
76060642|NCT01674322|Drug|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
76060643|NCT04746898|Other|Virtual Reality Training|Students received their basic life support application training through virtual reality glasses with special software.
76060644|NCT04746898|Other|High Fidelity Simulation Training|Students received their basic life support application training through high fidelity simulator mannequins.
76060645|NCT04746898|Other|Low Fidelity Simulation Training|Students received their basic life support application training through low fidelity simulator mannequins.
76060646|NCT03152344|Procedure|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value >12 seconds).
76060647|NCT03152500|Device|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
76060648|NCT03152500|Device|Acrysof SN60WF IOL|IOL in the bag
76060649|NCT03885310|Device|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
76060650|NCT04764916|Drug|Liposomal bupivacaine|Liposomal bupivacaine will be used as adductor canal block
76060651|NCT04764916|Drug|Bupivacaine Hydrochloride|This is the facility's standard of care medication for this procedure
75597849|NCT01020019|Drug|Dronabinol|Dronabinol: 20 mg/TID
76060652|NCT04676386|Diagnostic Test|Primary Immune Response (PIR) test by Biodesix, Inc.|Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
76060653|NCT01674790|Behavioral|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
76060654|NCT01674790|Behavioral|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
76060655|NCT01674790|Behavioral|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
75597850|NCT01020019|Drug|Placebo|Placebo control
76060656|NCT01674790|Behavioral|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
76060657|NCT01674868|Drug|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
76060658|NCT01674868|Drug|placebo|subjects will take one pill po daily for 90 days.
76060659|NCT01674946|Other|saline|intraduodenal perfusion
76060660|NCT01674946|Other|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
76060661|NCT01674946|Other|oleanolic acid|intraduodenal perfusion
76060662|NCT01674946|Dietary Supplement|oleic acid|intraduodenal perfusion
76060663|NCT01675024|Drug|Rotigotine, Period 1|"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
76060664|NCT01675024|Drug|Rotigotine, Period 2|"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
75448122|NCT05794750|Drug|Oxaliplatin|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
76060665|NCT02081950|Biological|Enoxaparin sodium|comparison of 2 different administration of drug
76060666|NCT03878212|Other|mHealth application with interactivity|a mHealth device with interactivity with nurse case manager
75448123|NCT05792293|Drug|Atorvastatin 40 Mg Oral Tablet|40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects
75448124|NCT05792293|Other|Placebo|Placebo
75742149|NCT01025349|Drug|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
75742150|NCT01022697|Other|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
76060667|NCT03878212|Other|mHealth application|a mHealth device
76060668|NCT04404322|Other|IPT A Suicide Crisis Intervention|The intervention is comprised of five weekly sessions followed by monthly emails to the patients and their parents over a period of three months. The first session is aimed at introducing the intervention, assessing depression and suicidal risk and building a safety plan. The safety plan consists of a prioritized list of coping strategies that the patient can use when suicidal risk is increased. The second session is focused on reviewing the patient's interpersonal relationships (using the closeness circle and interpersonal inventory) and conceptualizing the interpersonal problem area. Sessions 3-4 focus on developing and practicing interpersonal, emotional and behavioral coping strategies relevant for suicidal risk. Lastly, in session 5, patient and therapist go over the process and main issues which were worked on, emphasizing relapse prevention by going back to the safety plan. First and fifth sessions always involve the parents.
76060669|NCT04404322|Other|Treatment As Usual|patients receive an integrative combination of psychodynamic, supportive and cognitive behavioral therapy, usually lasting between 10-30 weeks
75448125|NCT05788263|Other|neuroscience based aproach|exercise for pain
75448126|NCT05785689|Drug|Dexmedetomidine|To reduce postoperative agitation
75448127|NCT05785689|Drug|Placebo|Placebo bolus saline
75448128|NCT05784025|Device|AlterG|Experimental device reducing weight perception by inducing a no-gravity environment which facilitates the execution of rehabilitation programs
75448129|NCT05772117|Behavioral|Chatbot-delivered interventions tailored to stage of changes|Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.
75448130|NCT05772117|Behavioral|Chatbot-delivered standard interventions|Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
75597851|NCT01020019|Drug|Lofexidine|Lofex: .6 mg/ TID
75597852|NCT00627835|Drug|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
75597853|NCT00627835|Drug|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
75597854|NCT00627835|Drug|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
75597855|NCT00627835|Drug|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
75597856|NCT00627835|Drug|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
75597857|NCT01024465|Device|ReShape Duo Balloon|ReShape Duo Balloon
75597858|NCT02872363|Other|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
76060670|NCT01675180|Other|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
76060671|NCT01675180|Other|Control|No intervention
75889837|NCT01383941|Drug|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
76060672|NCT03152422|Diagnostic Test|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
76060673|NCT03155932|Drug|APD334|APD334 active treatment for 24 weeks.
76060674|NCT01675258|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
75448131|NCT05770219|Drug|TAK-755|TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
76060675|NCT01675414|Other|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
75597859|NCT02872363|Other|Intervention B - Priority|"SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
76060676|NCT01675570|Drug|RX-10045|One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
75742151|NCT01021371|Behavioral|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
75889838|NCT02450123|Drug|sunitinib|
75889839|NCT02063802|Drug|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
76060677|NCT01675570|Drug|Vehicle for RX-10045|One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
76060678|NCT01675648|Drug|Lofexidine|
75448132|NCT05765864|Diagnostic Test|Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3|The questionnaires will cover general and demographic data, information on previous treatments, medication received, mental disorder at discharge (ICD), psychosocial situations (ICD), physical illnesses (ICD), COVID status (vaccinated, recovered, tested), use of psychoactive substances, history of self-harm, suicide attempts, school performance, experience with peers, sexual orientation and identity, residence, family composition, family history of mental disorders, self-harm and suicide attempts.
75448133|NCT05765864|Diagnostic Test|Columbia Suicide Severity Rating Scale (CSSRS)|"The questionnaire is scientifically supported, has the most evidence of utility and efficacy, and is internationally accepted. It has been translated into more than 100 different languages, including Slovene. It is easy to use, suitable for all age groups and adapted for successful use outside the hospital setting, for example in schools, colleges, police, military and elsewhere. It contains 2 screening questions on suicidality and 4 more specific questions, 6 items in total.~Posner K, Brown GK, Stanley B, et al. Am J Psychiatry 2011;168:1266-77."
75597860|NCT04299607|Diagnostic Test|DPP Fever Panel II assay and DPP Micro Readers|Detection of common causes of acute febrile illnesses in Asia
75597861|NCT04205461|Procedure|Programmed ventricular stimulation|Programmed ventricular stimulation before pulmonary valve replacement. Voltage and activation mapping of right ventricle in a subset of patients.
75597862|NCT04300699|Other|Functional Geriatric Assessment|A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
75597863|NCT01024387|Drug|AMG 479|
75597864|NCT01019317|Drug|Cytarabine|0.5 grams/m^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients > 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 3).
75742152|NCT01022775|Procedure|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
76060679|NCT01675648|Drug|Diazepam|
76060680|NCT01675648|Drug|Placebo for Lofexidine|
76060681|NCT01675648|Drug|Placebo for Diazepam|
76060682|NCT03872518|Device|Urovac|The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. There is also a removable cloth-covered platform to reduce spills.
76060683|NCT01566435|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
76060684|NCT01566435|Drug|Cisplatin|
76060685|NCT01566435|Drug|Fluorouracil|
76060686|NCT01566435|Radiation|Intensity modulated radiation therapy|
75889840|NCT02063802|Dietary Supplement|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
75889841|NCT02063802|Drug|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
75742153|NCT01022775|Procedure|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
75742154|NCT00453063|Drug|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
75742155|NCT00453063|Drug|Placebo|Two sprays in each nostril once daily in the morning
75889842|NCT02063802|Behavioral|Healthy habits program|
75889843|NCT03672045|Drug|Carbetocin|carbetocin administered IV, over 1 minute following delivery of the fetal head
75889844|NCT02198300|Procedure|Coronary angioplasty with stent implantation|
75889845|NCT02198300|Drug|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
75889846|NCT03673761|Other|MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing|3.Dixon, T2 mapping MRI microRNAs
75889847|NCT03560232|Drug|Ceftriaxone|See arm description
75889848|NCT03560232|Drug|Ampicillin/sulbactam|See arm description
75448134|NCT05765864|Diagnostic Test|The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT)|"used for research purposes to assess the core characteristics of NSSI (form, frequency, function) as well as the secondary characteristics of NSSI (habituation, context of NSSI, perceived impact on life and treatment).~Whitlock J, Exner-Cortens D, Purington A. Psychol Assess 2014;26:935-46."
75889849|NCT03560232|Drug|Piperacillin/tazobactam|See arm description
75448135|NCT05765864|Diagnostic Test|Experiences in Close Relationships-Relationship Structures (ECR-RS)|"Assesses the pattern of attachment to attachment figures (friend, romantic partner, mother, father) in adults and adolescents. The questionnaire has been officially translated into Slovene and used with several samples of Slovene adults and adolescents.~Fraley RC, Waller NG, Brennan KA. J Pers Soc Psychol 2000;78:350-65."
75597865|NCT01019317|Drug|Fludarabine|15 mg/m^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients > 65 years and 3 days in patients with PS > 3).
75742156|NCT00371566|Drug|Lapatinib oral tablets|
75742157|NCT00371566|Drug|Placebo|
75742158|NCT00382408|Biological|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
75597866|NCT01024309|Procedure|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
75597867|NCT01024309|Procedure|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
75597868|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
75597869|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
75889850|NCT03560232|Drug|Cefazolin + Gentamicin|See arm description
75889851|NCT03560232|Drug|Clindamycin + Gentamicin|See arm description
75889852|NCT02196935|Other|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
75889853|NCT03533192|Behavioral|It's Your Game...Keep it Real|It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
75597870|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
75597871|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
75889854|NCT02201342|Drug|Udenafil|Drug
75889855|NCT02063958|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
75889856|NCT03560544|Behavioral|Breaking up sitting|"A three-part behaviour change intervention, including:~Supportive organisational culture and knowledge of consequence of prolonged sitting~Environmental Modification~Behavioural Changes"
76060687|NCT01566435|Drug|Cetuximab|
76060688|NCT01566435|Procedure|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
76060689|NCT03868228|Procedure|Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)|Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
76060690|NCT01675726|Other|questionary on quality of life|
75448136|NCT05765864|Diagnostic Test|Trauma Symptom Checklist for Children (TSCC)|"The questionnaire helps to assess children's/adolescents' experiences of various traumatic experiences, such as physical or sexual violence, peer violence, loss, witnessing violent acts, natural disasters, etc. The questionnaire consists of 6 clinical scales (Anxiety, Depression, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), Sexual Concerns) and 2 validity scales. 6 clinical scales (Anxiety, Depressiveness, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), and 2 validity scales) are included.~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikotravmatiziranostiotrokinmladostnik. aspx"
75448137|NCT05765864|Diagnostic Test|Personality Assessment Inventory-Adolescent (PAI-A)|"An objective-type self-assessment questionnaire for assessing personality in adolescents. It has 264 items to be answered on a 4-point scale. 22 independent scales are obtained (Inconsistency, Rarity, Negative impression, Positive impression, Physical complaints, Anxiety, Anxiety-related disorders, Depressiveness, Mania, Paranoid, Schizophrenia, Borderline traits, Antisocial traits, Alcohol problems, Drug problems, Aggressiveness, Suicidal ideation, Stress, Lack of support, Refusal to deal, Dominance, Warmth).~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikzaocenoosebnosti-oblikazamladostnike-PAI-A.aspx"
75742159|NCT00382408|Other|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
75742160|NCT00371254|Drug|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg <6 months)
76060691|NCT01675804|Other|Computerized cognitive rehabilitation|- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
75448138|NCT05765864|Diagnostic Test|Inventory Of Statements About Self-Injury; ISAS|"A self-assessment questionnaire used for research purposes to assess the basic characteristics of NSSI (form, frequency, function, time to event). It also assesses the desire to stop. The questionnaire has been previously translated into Slovene and used in a population of adolescents with self-injurious behaviour.~Glenn CR, Klonsky ED. One-year test-retest reliability of the Inventory of Statements about Self-Injury (ISAS). Assessment. 2011 Sep;18(3):375-8. doi: 10.1177/1073191111411669."
76060692|NCT01675804|Drug|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
75742161|NCT00371254|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg <6 months)
76060693|NCT01675804|Other|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
76060694|NCT01696929|Drug|Tocilizumab|"Therapeutic/Pharmacologic Class of Drug:~Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.~Type of Dosage Form:~Concentrate for solution for infusion.~Route of Administration:~Intravenous (i.v.) infusion."
76060695|NCT04649008|Diagnostic Test|3T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 3 Tesla.
76060696|NCT04649008|Diagnostic Test|Intracranial electroencephalography recordings|Epilepsy patients may undergo implantation of intracranial electroencephalography (iEEG) electrodes for localization of epileptogenic foci, which also provide a means to record localized brain activity during memory or other tasks for research purposes.
75597872|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
75597873|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
75597874|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
75597875|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
75597876|NCT02877472|Device|porous tantalum rod|Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
76060697|NCT04649008|Diagnostic Test|7T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 7 Tesla.
75597877|NCT02877472|Procedure|core decompression|Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
75597878|NCT02877238|Drug|Sevoflurane plus remote ischemic preconditioning|Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
75742162|NCT00452673|Drug|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
75742163|NCT00452673|Drug|Capecitabine|Tablets, Oral, 660 - 1250 mg/m^2 twice a day (BID). Treatment may continue until disease progression.
76060698|NCT03865654|Other|Communication Tool|Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
75448139|NCT05765864|Diagnostic Test|The Level of Personality Functioning Scale-Brief Form 2.0; LPFSBF 2.0|"A short, user-friendly instrument that gives a quick impression of the expression of personality pathology. It consists of 12 items grouped into two higher-order domains: self-functioning and interpersonal functioning. Participants are asked to rate the 12 items on a four-point Likert scale ranging from 1 (completely false) to 4 (completely true). A total score (sum of all items), a self-functioning score (sum of items 1-6) and an interpersonal functioning score (sum of items 7-12) can be calculated. Satisfactory internal consistency and promising construct validity have been demonstrated. Sensitivity to change after three months of treatment was high.~Weekers LC, Hutsebaut J, Kamphuis JH. The Level of Personality Functioning Scale-Brief Form 2.0: Update of a brief instrument for assessing level of personality functioning. Personal Ment Health 2019;13:3-14."
75742164|NCT00461253|Device|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
75742165|NCT00461253|Device|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
75742166|NCT00469833|Drug|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
75742167|NCT00382174|Drug|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
75597879|NCT02877238|Drug|Total intravenous anesthesia plus remote ischemic preconditioning|Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
75597880|NCT01288911|Drug|enzalutamide|capsules
75597881|NCT01288911|Drug|bicalutamide|tablets
75742168|NCT00382174|Drug|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
75742169|NCT00641537|Drug|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
76060699|NCT01696773|Other|Tangerine tomato juice|Post-prandial feeding study
75742170|NCT00641537|Drug|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
76060700|NCT01696773|Other|Red tomato juice|Post-prandial feeding study
76060701|NCT03158740|Behavioral|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
75597882|NCT01288443|Drug|Alirocumab|Two SC injections in the abdomen only.
75597883|NCT01288443|Drug|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
75597884|NCT01288443|Drug|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
75597885|NCT04324203|Other|Three-dimensional Virtual Reality and Horticultural Therapy|VR is a realistic, three-dimensional, and virtual environment formed by a combination of computer software and hardware
75597886|NCT01288209|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
76060702|NCT03158740|Behavioral|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
75597887|NCT01288209|Drug|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
75889857|NCT03963830|Behavioral|MOVE UP|Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; >250 pounds = 1800 kcal/d).
75889858|NCT02201498|Procedure|Pulpotomies with Formocresol/OZE and Biodentine|
75889859|NCT02061852|Device|Simeox|
75597888|NCT01288209|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
75742171|NCT00641537|Drug|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
75742172|NCT00641537|Drug|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
75742173|NCT00641537|Drug|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
75889860|NCT02061852|Procedure|Physiotherapy|
75889861|NCT02201576|Drug|Bortezomib|"Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
76060703|NCT03865498|Behavioral|Twitter for Hispanic caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
76060704|NCT03865498|Behavioral|Twitter for African American caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
76060705|NCT01696695|Drug|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
76060706|NCT01696695|Drug|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
76060707|NCT01676038|Procedure|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
76060708|NCT01676038|Procedure|Conventional Total Knee Arthroplasty|Conventional technique.
76060709|NCT05261386|Drug|CBT-008|Cyclodextrin
76060710|NCT04617340|Other|Multifaceted clinical pharmacy intervention|"Assessing patient and caregiver preferences~Medication reconciliation on admission~Performing a comprehensive medication review before discharge~Promoting safe transition~4.a. Compiling a patient friendly medication list~4.b.Optimizing communication with healthcare providers in primary care:~4.b.i.Providing a copy of the medication list for the community pharmacist~4.b.ii. Contacting the general practitioner by phone~4.b.iii. Contacting, if applicable the home care nurse or the nurse from the nursing home by phone.~5.A motivation interview will take place before discharge with patients and caregivers~6.Post-discharge follow-up: 6.a.Follow-up call to discuss potential drug therapy issues, therapy adherence and to resolve any pending issues 6.b.A telepharmacology service will be provided to primary healthcare professionals as a means to consult the ward-based clinical pharmacists and/or research team after discharge."
76060711|NCT03862066|Other|Blood collection|5 milliliters (mL) of blood will be collected at the time of surgery
75742174|NCT01025583|Dietary Supplement|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
76060712|NCT03862066|Other|Tissue collection|Left over tissue will be collected at the time of surgery
75448140|NCT05765864|Diagnostic Test|Borderline Personality Features Scale, BPFSC-11|"The BPFS-C-11 includes BPD indicators such as affective instability, identity problems and negative attitudes. Responses to the items are on a 5-point Likert scale ranging from 'not at all true' to 'always true'. Studies have shown construct validity of interpretations of BPFS-C-11 scores through positive associations with other measures of BPD and positive associations with measures of BPD correlates, including emotional dysregulation. In a recent sample, the Cronbach's α over 4 years of follow-up was 0.86, 0.85, 0.86 and 0.90, respectively. The scale has been officially translated into Slovenian and will be used with the permission of the authors. It is intended for use by children and adolescents aged 9-11 years and consists of 11 items.~Sharp, C., Steinberg, L., Temple, J., Newlin, E. An 11-Item Measure to Assess Borderline Traits in Adolescents: Refinement of the BPFSC Using IRT . Personality Disorders: Theory, Research, and Treatment 2014;5(1):70-78."
75448141|NCT05765864|Other|Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV)|"It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. The evaluation is efficient and takes less than five minutes. The nurse in charge of each patient completes the DASA-YV once a day.~Dutch SG, Patil N. Validating a Measurement Tool to Predict Aggressive Behavior in Hospitalized Youth. J Am Psychiatr Nurses Assoc 2019;25:396-404."
75448142|NCT05765864|Other|Adolescent Self-Harm Risk Scale; ASHRS|It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. This is the scale we developed for the present study. It will be used to assess and predict the short-term risk of self-harm behaviour during hospitalisation (assessment at admission) and the long-term risk after discharge (assessment at discharge).
76060713|NCT03861988|Drug|Ketamine|0.5 mg/kg over 40 minutes, intravenous.
75597889|NCT01288053|Biological|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
75597890|NCT02889783|Other|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
75597891|NCT01287195|Drug|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
75597892|NCT01287195|Drug|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
75597893|NCT01287117|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
75597894|NCT01287117|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
75889862|NCT02201576|Drug|Plasma exchanges and intravenous immunoglobulins|"Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)"
75463056|NCT01871233|Drug|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
75463057|NCT01871272|Procedure|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
75597895|NCT01287039|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
75597896|NCT01287039|Drug|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
75742175|NCT01025583|Dietary Supplement|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
75742176|NCT03840135|Drug|Polyoxidonium 6 mg/ml|"Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
75889863|NCT02201654|Other|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
75742177|NCT03840135|Other|Placebo|"Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
75742178|NCT00814541|Drug|Bortezomib|
75742179|NCT00814541|Drug|Doxorubicin|
75889864|NCT02061930|Procedure|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
75889865|NCT03533738|Other|Food sequence 1|Vegetables first then meat & rice together
75889866|NCT03533738|Other|Food sequence 2|Meat first then vegetables & rice together
75889867|NCT03533738|Other|Food sequence 3|Vegetables first then meat followed by rice
75889868|NCT03533738|Other|Food sequence 4|Vegetables first followed by meat and rice together
75889869|NCT03533738|Other|Food sequence 5|Rice first followed by vegetables & meat together
75889870|NCT01377857|Behavioral|Monetary Incentive|$1, $5, or $10 incentive
75889871|NCT01377857|Behavioral|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
75889872|NCT01377857|Behavioral|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
75889873|NCT02198378|Drug|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
75889874|NCT02198378|Drug|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
75742180|NCT00814541|Drug|Dexamethasone|
75742181|NCT01021527|Other|Comparator: Treatment A|No Treatment
75742182|NCT01021527|Drug|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
75742183|NCT01021527|Drug|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
75742184|NCT01021527|Procedure|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
76060714|NCT03861988|Drug|Normal saline (placebo)|Normal saline infusion over 40 minutes, equivalent volume to ketamine infusion.
76060715|NCT01670266|Drug|ONO-9054|
75889875|NCT02063100|Drug|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
75448143|NCT05765864|Diagnostic Test|Lifetime Incidence of Traumatic Events questionnaire (LITE)|"Is a short checklist for screening and assessing the exposure to trauma in children and adolescents. It covers a broad range of potentially upsetting situations that can cause trauma to children and adolescents, such as a car accident, fire, death of a family member, exposure to threats, sexual assault, or witnessing violence. The questionnaire had been validated on a Slovene population of children and adolesscents.~Greenwald R, Rubin A. Assessment of posttraumatic symptoms in children:~development and preliminary validation of parent and child scales. Res Soc Work Pract. (1999) 9:61-75. doi: 10.1177/104973159900900105 Uršicˇ K, Bucik V, Klemencˇ icˇ S, Bratina N, Battelino T, Dovcˇ K and Drobnicˇ Radobuljac M (2021) Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia. Front. Psychiatry 12:665315. doi: 10.3389/fpsyt.2021.665315"
76060716|NCT01670266|Drug|Placebo|
76060717|NCT03755440|Drug|PD-1 antibody (SHR-1210)|PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
76060718|NCT01676194|Other|Intra-arterial administration of DC BeadsR|
76060719|NCT03860974|Drug|Serratus Plane block (single injection)|A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
76060720|NCT03860974|Drug|Paravertebral block (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery). For paravertebral blocks without axillary involvement, this will be at the T3 and T5 levels. For paravertebral blocks with axillary involvement, this will be at the T2 and T4 levels. For unilateral PVBs, 10 mL of local anesthetic will be injected per level. For bilateral paravertebral blocks, 8 mL of local anesthetic will be injected per level.
76060721|NCT01565889|Drug|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
75448144|NCT05765864|Genetic|Genetic methods|DNA isolation, Sequencing, Libraries preparation, Analisys; Bioinformatics (Base Calling, Variant Calling, Quantification and evaluation of short tandem repetitions, Methylation sites detection).
75448145|NCT05758909|Device|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
75742185|NCT00814619|Biological|panitumumab|Given IV
75742186|NCT00814619|Drug|capecitabine|Given orally
75742187|NCT00814619|Procedure|therapeutic conventional surgery|Patients undergo surgical resection
75742188|NCT00814619|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
75742189|NCT01023009|Procedure|vitrectomy|
75889876|NCT02063100|Drug|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
76060722|NCT01565889|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
76060723|NCT01565889|Drug|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
76060724|NCT01565889|Drug|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
75889877|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
75889878|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
75889879|NCT02063100|Drug|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
75889880|NCT01377779|Drug|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
75889881|NCT01377779|Drug|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
75889882|NCT02198846|Device|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
75889883|NCT02198846|Drug|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
75889884|NCT01379885|Behavioral|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
75889885|NCT01379885|Behavioral|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
75889886|NCT02198924|Drug|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
75889887|NCT02198924|Drug|placebo|control patients are supplied with the corresponding placebo with the same instructions.
75448146|NCT05753644|Procedure|stellate ganglion blocks|At the level between C6 and C7, a 25-gauge needle is inserted laterally, and the needle tip is placed posterior to the carotid artery and anterior to the longus colli muscle using an in-plane approach.
75448147|NCT05753644|Drug|Ropivacaine|5 mL of 0.5% ropivacaine injected in the plane of the right stellate ganglion
75448148|NCT05753644|Drug|Sham treatment|5 mL of saline injected in the plane of the right stellate ganglion
75742190|NCT01025661|Other|Chiropractic care|Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.
75742191|NCT01025739|Device|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
75742192|NCT00641147|Drug|Curcumin|Given PO
76060725|NCT01565889|Drug|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
76060726|NCT01565889|Drug|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
76060727|NCT01565889|Drug|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
76060728|NCT01565889|Drug|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
75448149|NCT05735314|Other|consultation with a specialist|The intervention consists of consultation with a specialist, use of a nurse navigator to help patients with appointments and help them understand their condition, and use of a data query of the electronic health record (EHR) to identify abnormal test results to make sure they are appropriately addressed.
75448150|NCT05735314|Other|Usual care|Usual care involves primary care physicians ordering additional tests and referrals to evaluate patients with new anemia and decreased glomerular filtration rate (GFR) .
75463058|NCT01871298|Other|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
75463059|NCT01871324|Behavioral|Lifestyle counseling|group therapy
75742193|NCT00641147|Other|Laboratory Biomarker Analysis|Correlative studies
75889888|NCT02201732|Procedure|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
75889889|NCT02201732|Procedure|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
75889890|NCT05462093|Device|Liver Multiscan sequences|Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
75742194|NCT00641147|Other|Placebo|Given PO
75742195|NCT00460239|Drug|Buprenorphine|Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
75742196|NCT00460239|Drug|Morphine|Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
75742197|NCT00460239|Drug|Placebo|Intramuscular; double blind; once per week
75889891|NCT05462093|Device|Liver Multiscan analysis|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
75597897|NCT02889939|Other|UC + ETT|"UC: A 3-week UC period, where the participants were not offered any new rehabilitation activities but were allowed to continue their regular treatment for a maximum of 3 hours per week.~ETT: The rehabilitation facilities were located in a climate that allowed and encouraged both indoor and outdoor activities. The ETT was individually tailored. Participants exercised in the same room/place as the other participants in groups of 4-9. Physical exercise was scheduled 3.5-6 hours per day, 5½ days per week for 3 weeks. The training was characterized by repetitive mass practice of gradually increasing difficulty and noncompensatory strategies, such as enforcing use of the affected side.~Beyond scheduled activities, participants were encouraged to physically engage themselves in a challenging outdoor environment."
75889892|NCT05462093|Device|MRCP+|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
75889893|NCT02201888|Behavioral|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
76060729|NCT01565889|Drug|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
76060730|NCT01565889|Drug|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
76060731|NCT01565889|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
75742198|NCT01021605|Device|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
76060732|NCT01696071|Drug|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
76060733|NCT01696071|Drug|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
76060734|NCT03855280|Drug|APVO101|APVO101: 35 - 75 IU/kg; twice weekly
76060735|NCT01591863|Drug|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
76060736|NCT03851302|Other|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
76071997|NCT03504163|Drug|Bacillus Calmette-Guérin (BCG)|Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
75742199|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
75742200|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
75742201|NCT03839355|Drug|Apixaban|Dosage either 5mg or 2.5mg for 2 years
75742202|NCT03839355|Drug|Warfarin|Dosage assessed by your treating physician for 2 years
75742203|NCT00382018|Drug|chemotherapy|No administration details available
75889894|NCT02201888|Other|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
76060737|NCT03851302|Other|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
75742204|NCT00640601|Drug|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
75742205|NCT03838731|Drug|REGN1908-1909|Single subcutaneous (SC) dose of REGN1908 and REGN1909
76060738|NCT03851302|Other|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
76060739|NCT03850756|Diagnostic Test|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
76060740|NCT03850756|Diagnostic Test|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
76060741|NCT03850756|Diagnostic Test|Tobacco consumption|In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
76060742|NCT01591785|Drug|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
75597898|NCT05584527|Other|Heat exposure (32°C)|"The participants will be exposed to heat (32°C) for 24 hours in a climatic apartment.~During the exposure,~food intake and energy expenditure will be measured~several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~sleep brain activity will be monitored using a headband~urine and saliva samples will be collected."
75597899|NCT05584527|Other|Cold exposure (16°C)|"The participants will be exposed to cold (16°C) for 24 hours in a climatic apartment.~During the exposure,~food intake and energy expenditure will be measured~several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~sleep brain activity will be monitored using a headband~urine and saliva samples will be collected."
75889895|NCT02201888|Other|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
75889896|NCT02065440|Drug|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
75889897|NCT02065440|Drug|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
75889898|NCT02202122|Other|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
75742206|NCT03838731|Drug|Placebo|Single subcutaneous (SC) dose of matching placebo
75742207|NCT02551133|Drug|dexamethasone|1 hour before surgery
75742208|NCT00814853|Device|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
75742209|NCT00818285|Device|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
76060743|NCT01591785|Drug|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
76060744|NCT04773639|Behavioral|Multi-Modal Palliative Care Intervention|An innovative muli-modal palliative care intervention that addresses the lack of advance care planning and unmet psychosocial needs commonly experienced by patients with metastatic cancer.
75889899|NCT02064348|Drug|semaglutide|Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
75597900|NCT05584527|Other|Thermoneutral exposure (24°C)|"The participants will be exposed to a thermoneutral environment (24°C) for 24 hours in a climatic apartment.~During the exposure,~food intake and energy expenditure will be measured~several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~sleep brain activity will be monitored using a headband~urine and saliva samples will be collected."
76060745|NCT04773639|Behavioral|Usual Care Control Condition|The control condition includes usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
75448151|NCT05733663|Diagnostic Test|Endoscopic procedure with duodenal biopsy|"In all patients the investigators will analyse coeliac serology, DQ-genotype, and results of two duodenal biopsy sampling (one at diagnosis before starting the GFD and another sampling during follow-up with GFD) for assessment of both histopathology and intraepithelial lymphocyte subpopulations by T-cell flow cytometry. In addition, clinical, serological, and histological response to GFD will be evaluated.~T-cell flow cytometry assay is performed as previously described by our group in previous studies. In all patients, an additional duodenal biopsy sample is taken from the second-third portion of the duodenum at the same endoscopic procedure that for histopathology. The normal cut-off values for the IEL cytometric pattern in our laboratory are CD3+TCRγδ+ IEL ≤8.5% (≤mean + 2SD) and CD3- IEL ≥10% (10th percentile). The cut-offs define four intraepithelial lymphogram patterns: normal, isolated decrease in CD3- cells, isolated increase in TCRγδ+ cells, and the coeliac lymphogram."
75448152|NCT05729243|Drug|Cytisine|Cytisine is a nicotinic acetylcholine receptor partial agonist and is a natural health product approved by Health Canada. Cytisine has been used for a long time in Europe for smoking cessation.
75448153|NCT05729243|Other|Placebo|A placebo identical in appearance to cytisine will be used
75448154|NCT05722132|Behavioral|One cycle|Message Design Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
75597901|NCT05575245|Device|Drug-eluting Stent|Drug-eluting Stent angioplasty
75597902|NCT05575245|Device|Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
75597903|NCT05572203|Dietary Supplement|Intrinsically labelled protein|It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
75597904|NCT01285401|Drug|VigantOL oil plus interferon beta-1a (Rebif)|VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day [mcg/day]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
75597905|NCT01285401|Drug|Placebo plus interferon beta-1a (Rebif)|Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
75448155|NCT05722132|Behavioral|4 cycles|Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
75448156|NCT05722132|Behavioral|5 Dollar Incentive|"Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program. The introductory message will mention that participants will receive $5 if they enroll in the program or that they should look out for messages with a $ sign at the beginning that will provide an incentive if they respond."
75448157|NCT05722132|Behavioral|Raffle Incentive|"The incentive message (indicated with a leading $ sign) will invite participants to respond, and participants that do so will be included in a random drawing depending on the condition. The incentive message for the opportunity to win will contain a link to a website that provides full details of the timing of the drawing, the chances of winning, and when notification of winners will be made."
75448158|NCT05756504|Drug|Ketorolac|Injection ketorolac 30 mg IV x TDS will be given to each patient in each group.
75448159|NCT05756504|Drug|Tramadol|Injection Tramadol 25-50 mg IV x TDs wil be given to each patient in this group. Maximum dose will be 400 mg/ day
75597906|NCT01285401|Biological|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
75597907|NCT01285323|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
75597908|NCT01285323|Drug|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
75597909|NCT02889705|Other|Ultrasonographic examination|
75597910|NCT01284621|Drug|BI 10773|medium dose, oral administration
76060746|NCT03658798|Procedure|Functional Electrical Stimulation|Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
76071998|NCT03500458|Behavioral|Sleep Extension|Participants will be asked to increase time in bed at least 1 hour more than baseline
76060747|NCT03654040|Biological|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
76060748|NCT03654040|Procedure|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
76060749|NCT03654040|Drug|cyclophosphamide|40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
76060750|NCT03654040|Drug|mesna|"Mesna is administered:~Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~In conjunction with the cyclophosphamide, per institutional practice with CTX."
75597911|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
75742210|NCT00452439|Drug|Actonel (Risedronate)|35 mg (pill) by mouth weekly
76060751|NCT03654040|Drug|everolimus|EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
76060752|NCT01695993|Device|Acupressure bands|Bilateral acupressure wrist bands
76060753|NCT01695993|Other|Expectancy-neutral handout|The expectancy neutral handout has neutral information regarding the acupressure bands
76060754|NCT01695993|Behavioral|Expectancy-neutral MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
76060755|NCT01695993|Other|Expectancy-enhancing handout|The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
76060756|NCT01695993|Behavioral|Expectancy-enhancing MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
76060757|NCT01565343|Drug|florbetapir F 18|IV injection, 370MBq (10mCi)
76060758|NCT03740932|Diagnostic Test|Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
76060759|NCT00003460|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
75597912|NCT01284621|Drug|BI 10773|medium dose oral administration
75597913|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
75597914|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
75597915|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
75597916|NCT04323813|Diagnostic Test|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
75742211|NCT00452439|Dietary Supplement|Calcium|500 mg by mouth twice a day for a total of 24 months.
75742212|NCT00452439|Dietary Supplement|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
75742213|NCT02550899|Procedure|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
75742214|NCT02550899|Procedure|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
75597917|NCT02890017|Other|postoperative hotel|"Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.~Postoperative consultation at 1 and 3 months."
75597918|NCT02890017|Other|conventional hospitalization|Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
75597919|NCT01283139|Biological|Sifalimumab 200 mg|Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
75597920|NCT01283139|Biological|Sifalimumab 600 mg|Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
75889900|NCT02064348|Drug|placebo|Solution for s.c. injection or tablets for oral administration
75889901|NCT02064348|Drug|moxifloxacin|Tablets for oral administration
76060760|NCT03646786|Device|Virtual reality tests|"The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe"
75597921|NCT01283139|Biological|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
75597922|NCT01283139|Other|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
75597923|NCT01281969|Drug|Gamunex Intravenous Immunoglobulin|2.0 gm/kg total, IV (in the vein), over 2 days
75742215|NCT02550899|Procedure|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
75448160|NCT05701735|Behavioral|CECIL Patient Decision Aid|"The CECIL patient decision aid explicitly identifies the disease, the index decision, and the treatment options, describes the positive and negative features and consequences of each option, and guides the patient in examining personal values and preferences, to arrive at a quality and realistic decision.~The decision aid will be developed and validated according to the guidelines and standards published by the International Patient Decision Aids Standards (IPDAS) Collaboration."
75597924|NCT01281969|Drug|Placebo|Normal saline, IV (in the vein), over 2 days
75448161|NCT05697510|Drug|Siltuximab|Administration of siltuximab at day 8 of induction following a classical induction; 3 dose levels : 7, 9 and 11mg/kg
75448162|NCT05691569|Other|doll therapy|empathy dolls
75448163|NCT05686980|Drug|ABBV-552|Oral Capsule
75597925|NCT01281813|Drug|Darunavir|Participants will receive darunavir (per parent study) as oral suspension.
75448164|NCT05685095|Behavioral|Physical training|Supervised gait training program 3 times a week, 12 weeks
75448165|NCT05674474|Drug|Vorasidenib|Administered orally as tablets.
75597926|NCT01281813|Drug|Ritonavir|Participants will receive ritonavir (per parent study) as oral solution/suspension.
75597927|NCT04325139|Other|Questionnaire|Before colonoscopy, the following information was obtained by the colonoscopists through asking patients: the characteristics of last stool, the time of drinking first dose of laxative, the time of first defecation, the time of drinking last dose of laxative. The beginning time of colonoscopy was also recorded. During withdrawal phase, the quality of bowel preparation was evaluated based on BBPS scale.
75597928|NCT01090414|Drug|Idelalisib|Idelalisib tablets or capsules administered orally
75597929|NCT01090102|Drug|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
75742216|NCT00814931|Drug|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
75742217|NCT00814931|Drug|Placebo|matching oral liquid suspension placebo twice a day for 8 days
75742218|NCT01023087|Drug|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
75742219|NCT01023087|Drug|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
75742220|NCT00815009|Behavioral|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
75742221|NCT00815009|Behavioral|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
75742222|NCT00815009|Behavioral|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
75742223|NCT00381940|Drug|ifosfamide|Given IV
75742224|NCT00381940|Drug|bortezomib|Given IV
75742225|NCT00381940|Drug|vinorelbine tartrate|Given IV
75742226|NCT00381940|Biological|filgrastim|Given IV or SC
75742227|NCT00818597|Device|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
76060761|NCT03646630|Procedure|Quadratus Lumborum Block|Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%
76060762|NCT03646630|Procedure|Caudal Block|caudal block with 1 ml/kg of bupivacaine 0.25%.
75597930|NCT01090102|Drug|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
75597931|NCT02877160|Drug|AL-794 suspension|
75597932|NCT02877160|Drug|AL-794 tablet|
75597933|NCT02878096|Drug|[14C]-SK-1404|In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.
75742228|NCT00818675|Drug|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
75597934|NCT01287897|Drug|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
75597935|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
75597936|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
75597937|NCT02877940|Device|ProSeal Laryngeal mask airway|ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
75597938|NCT02877940|Device|Laryngeal Tube Suction- Disposable|LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
75597939|NCT02877940|Device|i-gel|i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
75597940|NCT04306978|Other|CareLink Express RM system|CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
75597941|NCT04306978|Other|Standard follow-up|Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
75597942|NCT01090024|Drug|BI 671800|BI 671800
75742229|NCT00818675|Drug|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
75448166|NCT05674266|Device|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
75448167|NCT05674266|Device|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
76060763|NCT03842956|Procedure|Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe|We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
75463060|NCT01871337|Behavioral|Paula method|The Paula method will be taught to the participants by several registered Paula instructors. Subjects allocated to this intervention will receive one 45-minute group session per week for 12 weeks (with up to 30 minutes for personal questions regarding the exercises). This length of time is crucial because it has been demonstrated that it take three months for women to adequately learn the exercises in order for them to practice independently at home. Participants will be encouraged to practice daily for 15 minutes and report their at- home training.
75742230|NCT00818675|Drug|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
75742231|NCT00364156|Drug|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
75742232|NCT00364156|Drug|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
75742233|NCT00818831|Drug|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
75742234|NCT00452361|Drug|Sirolimus+MMF or MPS or AZA+Steroid|Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
75742235|NCT00452361|Drug|Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid|"The maintenance dose of:~MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~continued for the entire 104-week period of randomized therapy~subsequently discontinued~restarted after discontinuation"
76060764|NCT04763122|Other|not applicable as it is a retrospective study|It is a retrospective study
76071999|NCT03492944|Drug|Ultrasound Microbubble Contrast Agent|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
75463061|NCT01871350|Dietary Supplement|Daily intake for 10 weeks (+/- 2 weeks)|
75597943|NCT01090024|Drug|Placebo|Placebo matching BI 671800
76072000|NCT03492944|Device|Ultrasound Imaging|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
75597944|NCT04868890|Biological|Ampion|Inhaled Ampion
75597945|NCT04868890|Other|Placebo|Inhaled Placebo
75597946|NCT01281189|Drug|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
75597947|NCT01281189|Drug|Placebo|Oral tablet twice daily for up to 18 months.
75597948|NCT02877862|Behavioral|mAGIC app|7-day app to encourage uptake of genetic counseling
75597949|NCT04306666|Other|Regional anesthesia|Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
75448168|NCT05668143|Behavioral|Virtual reality|The Patient Information Form and the State Anxiety Scale will be administered to the patients just before the surgery. The researcher will measure the patient's respiratory, blood pressure, pulse and oxygen saturation values on the monitor just before the start of the operation and every 15 minutes after the operation, and the vital signs will be recorded in the follow-up form. Virtual reality glasses will be put on the patient immediately after anesthesia is given to the patient by the anesthesiologist. Glasses will be worn during the total knee replacement surgery. Total knee replacement surgery takes an average of 60 minutes. During the surgery, patients will be shown nature and landscape images with virtual reality glasses. Virtual reality glasses will be removed immediately after the operation and the State Anxiety Scale and vital signs follow-up form will be applied before the patient is sent to the service from the operating room.
75448169|NCT05660187|Other|Multiple Sclerosis Clinical Care Delivery via telehealth|Intervention includes clinical care delivered via telehealth
75448170|NCT05660187|Other|Multiple Sclerosis Clinical Care Delivery via standard in clinic visits|Intervention includes clinical care delivered via standard in clinic visits
75448171|NCT05657925|Drug|ondansetron 8 mg|Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
75597950|NCT04818892|Diagnostic Test|Serological Assay for SARS-CoV-2|LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.
75448172|NCT05657925|Drug|Matching placebo|Matching placebo will be identical in appearance to the active treatment pill
75448173|NCT05656495|Drug|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly|lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
75448174|NCT05656495|Drug|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled|lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
75448175|NCT05656495|Drug|Standard of care|The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
75448176|NCT05653388|Other|Plasma Collection|Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes
75597951|NCT02877628|Other|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
75448177|NCT05651893|Behavioral|re-examination|During colonoscopy, the left colon was examined a second time in the forward view.
75448178|NCT05651893|Behavioral|extended withdraw time|During colonoscopy, the left colon was examined with double basic withdrawal time in the forward view.
75448179|NCT05650060|Drug|Secukinumab|all patients with psoriasis who received secukinumab
75597952|NCT01280955|Drug|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
75597953|NCT00623883|Procedure|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
75597954|NCT00623883|Procedure|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
75597955|NCT01280721|Drug|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
75597956|NCT04323969|Behavioral|Specific Modification Target|Participants will be instructed to increase their baseline foot progression angle by 15 degrees. Visual feedback during practice will be delivered using a mirror and guideline (tape placed on mirror). Verbal feedback will be incorporated to encourage participants to perform the modified foot progression angle as accurately as possible.
75597957|NCT04323969|Behavioral|Self-directed Modification|Participants will be instructed to modify their foot progression angle as much as is comfortable. A mirror will be used during practice for visual feedback, but no specific target or guide will be provided.
75597958|NCT02889471|Procedure|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
75597959|NCT02889471|Procedure|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
75742236|NCT03334318|Other|Mean blood glucose|Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
75742237|NCT03334318|Other|Blood glucose CV|Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
75742238|NCT03334318|Other|% time 70-180 mg/dL|Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
75742239|NCT03334318|Other|% time below 54 mg/dL|Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
75742240|NCT03334318|Other|% time above 180 mg/dL|Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
75448180|NCT05649904|Device|IRRAflow with Active Fluid Exchange System|"IRRAflow® Active Fluid Exchange System is an intracranial drainage system intended for use by professional medical hospital personnel, trained and experienced in neurosurgical medical care.~The intracranial pressure is kept at a safe level by draining excessive intracranial fluid. The system incorporates an irrigation support mechanism, used to irrigate the system in a controlled, programmed manner to minimize catheter occlusion. Additionally, a manual bolus can be given to facilitate keeping the catheter clear of occlusion or to clear the catheter of occlusion if one is present. This mechanism works by producing a bolus pulse using short periods of high flow (i.e. flow pulses)."
75889902|NCT02202200|Drug|PD- 0332991|"PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients"
75448181|NCT05649904|Device|External Ventricular Drain|The External Ventricular Drain (EVD) is used standard of care at the study site for ventricular drainage.
75597960|NCT05560581|Behavioral|Digital self-efficacy training|Prior to the app participation, participants will receive psychoeducation on self-efficacy and will be instructed to define two autobiographical self-efficacy memories (own achievements, e.g., completion of an exam, success in a sporting event). During the week of app participation, they will be prompted three times per day and asked to perform an imagination task. Step by step, they will recall one of their autobiographic self-efficacy memories and focus on their character traits and abilities that were relevant for their achievement.
75448182|NCT05634733|Other|Treatment of Sepsis|Patients will have standard care of sepsis
75448183|NCT05625321|Behavioral|Educational Group Weight Loss Classes|Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.
75448184|NCT05625321|Behavioral|Home Gardening Intervention|Participants will receive tools to establish their own home garden, increasing their access to fresh fruits and vegetables.
75889903|NCT02064504|Drug|GSK961081|Dry white to off white powder
75889904|NCT02064504|Drug|Fluticasone furoate|Dry white powder
75597961|NCT05560581|Behavioral|Ecological Momentary Assessment|Participants will receive questions on mood and social/virtual contacts 3 times per day.
75889905|NCT03790254|Other|systematic review|
76060765|NCT03836872|Device|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
76060766|NCT03836326|Other|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
75597962|NCT01087762|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
75597963|NCT01087762|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
75597964|NCT01087762|Other|Placebo|Matching Placebo to CZP injection.
75597965|NCT04306354|Drug|Oxytocin nasal spray|Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
75889906|NCT02202356|Drug|ALS-008176|
75889907|NCT02202356|Drug|Placebo|
75889908|NCT02065674|Drug|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
75448185|NCT05622604|Behavioral|pray.com app (autonomous use)|Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
75597966|NCT04306354|Drug|placebo nasal spray|Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
75597967|NCT04306276|Drug|Dienogest 2 MG|Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF
75889909|NCT03560154|Other|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
75889910|NCT01569425|Other|Dietary intervention|High Calorie breakfast and high calorie dinner
76060767|NCT03836326|Other|Control|Routine care provided by health professionals in the NICU
76060768|NCT03836248|Other|Osteopathic treatment|"5 osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and treatment of necessary elements and a control of osteopathic treatment at the end of the session."
75889911|NCT02199158|Procedure|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
75889912|NCT02067936|Drug|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
76060769|NCT03836248|Other|Sham osteopathic treatment|"5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed."
76060770|NCT03836248|Other|Current practice Medication treatment|Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
75597968|NCT01078168|Drug|Acitretin|30mg per day from Day 1 to Day 28
76060771|NCT04762420|Other|Dose of sugammadex according to SSD and QSD|At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
75889913|NCT02067936|Drug|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
75889914|NCT02067936|Drug|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
75889915|NCT02067936|Drug|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
75889916|NCT05461937|Behavioral|Getting things done after stroke|A two-session, online rehabilitation intervention focussing on cognitive executive functions supplemented with weekly homework tasks.
76060772|NCT04747132|Other|Telegeriatric intervention|Individualized, comprehensive and specialized counseling for older adults through the Internet
76060773|NCT03642106|Behavioral|Unidos Se Puede|The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
76060774|NCT03834142|Device|NSS-2 Bridge|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
75597969|NCT01078168|Drug|Placebo|Placebo
75889917|NCT05461937|Behavioral|Stroke psychoeducation|A two-session, online stroke psycho-education intervention supplemented with weekly homework tasks.
75597970|NCT01086358|Drug|Triptan|Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
75597971|NCT01086358|Drug|Treximet 85Mg-500Mg Tablet|Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
75597972|NCT01277601|Drug|TDF|TDF 300 mg tablets administered orally once daily
75597973|NCT01277601|Drug|Peg-IFN|Peg-IFN 180 µg administered via subcutaneous injection once weekly
75597974|NCT01277523|Drug|tiotropium high dose|2 actuations once daily
75597975|NCT01277523|Drug|placebo|2 actuations once daily
75597976|NCT01277523|Drug|tiotropium low dose|2 actuations once daily
75597977|NCT01081834|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
75597978|NCT01081834|Drug|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
75889918|NCT02916446|Biological|Viaskin Peanut 250 mcg|
75889919|NCT02916446|Biological|Placebo|
75889920|NCT03788928|Diagnostic Test|serum mitochondrial DNA|serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis
75889921|NCT01377545|Procedure|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
75889922|NCT01377545|Procedure|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
76060775|NCT03737032|Device|Intermittent Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
75597979|NCT01081834|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
75597980|NCT01276509|Drug|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
76060776|NCT03737032|Device|Continuous Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
75889923|NCT01379807|Drug|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
75597981|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
75597982|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
75597983|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
76060777|NCT03737032|Device|Sham Theta Burst Stimulation|For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
76060778|NCT03833440|Drug|Durvalumab (MEDI4736)|"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
76060779|NCT03833440|Drug|Monalizumab (IPH2201)|"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
75889924|NCT02031380|Device|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
75597984|NCT01079962|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
75597985|NCT01079962|Drug|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
76060780|NCT03833440|Drug|Oleclumab (MEDI9447)|"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
76060781|NCT03833440|Drug|Ceralasertib (AZD6738)|"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
76060782|NCT03833440|Drug|DOCETAXEL|"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
76060783|NCT03833440|Drug|Savolitinib|"600 mg QD~1 cycle = 28 days"
76060784|NCT01677442|Procedure|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
75597986|NCT01274637|Drug|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
75597987|NCT01079806|Drug|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
75597988|NCT01079806|Drug|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
75597989|NCT00626314|Biological|myoblast|autologous myoblast
75597990|NCT00626314|Biological|sham|sham injection procedure
75597991|NCT04299178|Device|X-PLO2R POC|Portable Oxygen Concentrator (POC)
75597992|NCT00626470|Procedure|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
76060785|NCT01677442|Procedure|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
76060786|NCT01695135|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
76060787|NCT01695135|Drug|Placebo|Placebo (4 tablets) taken orally once daily
75742241|NCT03334318|Other|% time above 250 mg/dL|Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
75742242|NCT03334318|Other|MAGE (Mean amplitude of glucose excursions)|Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
75742243|NCT03334318|Other|LBGI (Low Blood Glucose Index)|Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
75742244|NCT03334318|Other|HBGI (High Blood Glucose Index)|High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
75742245|NCT03334318|Drug|Allopurinol|Oral allopurinol tablets administered in the PERL Clinical Trial
75597993|NCT02876770|Dietary Supplement|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
75597994|NCT02876770|Dietary Supplement|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
75597995|NCT01077622|Drug|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
75889925|NCT02064660|Device|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
75889926|NCT02202512|Drug|Placebo|tablets
75597996|NCT01313676|Drug|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
75889927|NCT02202512|Drug|Cimetidine|
75889928|NCT02202512|Drug|Placebo|tablets
75742246|NCT03334318|Drug|Placebo|Oral placebo tablets administered in the PERL Clinical Trial
75742247|NCT00640289|Drug|Fibrogammin P|Prophylaxis treatment
75742248|NCT00818909|Other|Systane|Systane prescription
75742249|NCT01049932|Drug|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
75742250|NCT00818987|Other|Open reduction internal fixation; reduction and immobilization|
75742251|NCT01047670|Drug|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
75742252|NCT00819065|Drug|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
75769604|NCT03888586|Device|Trigger Point Dry Needling Technique|The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
75889929|NCT02202512|Drug|Placebo|tablets
75889930|NCT02202512|Drug|BI 1060469 high dose|tablets
75889931|NCT02202512|Drug|BI 1060469 low dose|tablets
75889932|NCT02202512|Drug|Naproxen|
75889933|NCT02202512|Drug|BI 1021958|tablets
76060788|NCT01695135|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
75597997|NCT01313676|Drug|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
75889934|NCT02065752|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
75889935|NCT02065752|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
75889936|NCT02065752|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
75889937|NCT02065752|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
75889938|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
75889939|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
76060789|NCT01610414|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
76060790|NCT01610414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
75597998|NCT01313676|Drug|vilanterol|25mcg given once daily via novel dry powder inhaler
75597999|NCT01313676|Other|Placebo|placebo comparator once daily via novel dry powder inhaler
75598000|NCT02891304|Other|Quarterly Feedback|Learning curves received quarterly vs. annually
76060791|NCT03832114|Drug|LNP023|Increasing doses of LNP023 up to 200 mg.
75889940|NCT02202668|Device|TRS|"TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines."
76060792|NCT01564407|Drug|ICX-RHY-013|"Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~Empty control no injection~Vehicle only (0.5 ml of HypoThermosol solution)~5 million cells / cm² , single administration at Day 0~5 million cells/ cm² , single administration at week 4~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks"
75742253|NCT00819065|Drug|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
75742254|NCT01047748|Drug|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
76060793|NCT03830944|Diagnostic Test|Blood sampling|Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
76060794|NCT03830944|Diagnostic Test|transthoracic echocardiography|Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
75742255|NCT01047748|Drug|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
75742256|NCT01047826|Procedure|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
75598001|NCT05661318|Other|Risk assessment|Collect clinical, laboratoary and genetics data from the participants after informed consent
75598002|NCT02890914|Other|Transvaginal Ultrasound Educational DVD|"American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®"
75742257|NCT01047826|Procedure|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
75742258|NCT00568451|Drug|carboplatin|AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
75742259|NCT00568451|Drug|paclitaxel|100mg/m^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
75742260|NCT00568451|Drug|temozolomide|150mg/m^2 at cycle 1, 200mg/m^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
75889941|NCT02064738|Behavioral|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
75889942|NCT02202824|Other|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
75598003|NCT00623376|Drug|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
75889943|NCT05461781|Procedure|distal radial artery|primary percutaneous coronary intervention via distal radial aretry
75598004|NCT00623376|Drug|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
75598005|NCT01313286|Drug|LY2608204 Reference|Administered orally
75742261|NCT00459537|Drug|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
75742262|NCT00459537|Drug|amorolfine nail lacquer|5 % amorolfine nail lacquer
75598006|NCT01313286|Drug|LY2608204 Test|Administered orally.
75742263|NCT00819299|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
75742264|NCT03850509|Drug|OPS-2071|OPS-2071 300 mg, tablets, orally, BID.
75742265|NCT03850509|Drug|Placebo|OPS-2071-matched placebo, tablets, orally, BID.
75742266|NCT00635999|Behavioral|Applied relaxation and self-control desensitization|Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.
75889944|NCT05461781|Procedure|proximal radial aretry|primary percutaneous coronary intervention via proximal radial aretry
75889945|NCT05057442|Other|Proprioception assessment, functionality assessment|Proprioception assessment, functionality assessment
75889946|NCT05461625|Procedure|ACL reconstruction|Anterior cruciate ligament reconstruction
75889947|NCT05461625|Other|ALL anatomic|anatomic anterolateral ligament reconstruction
75889948|NCT05461625|Other|ALL tenodesis|anterolateral ligament teondesis
75889949|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
75889950|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
75889951|NCT03560076|Other|SBIRT Training and Implementation Strategies|A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
75889952|NCT02206490|Drug|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
75889953|NCT02206490|Drug|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
75889954|NCT02068170|Drug|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
76060795|NCT03830944|Diagnostic Test|Late Gadolinium-Enhancement Cardiac Magnetic Resonance|Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
76060796|NCT03830944|Diagnostic Test|Coronary Angio Computed Tomography|Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
75889955|NCT02203058|Other|Pursed-lips breathing|Expiration with pursed-lips during functional capacity tests.
75889956|NCT02203058|Other|No pursed-lips breathing|To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
75889957|NCT02206568|Drug|URAL|
75889958|NCT02068248|Dietary Supplement|Soluble Fibre|
75889959|NCT02203136|Procedure|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
75889960|NCT02203136|Procedure|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
75889961|NCT02068326|Behavioral|Mentalization Based Treatment|
75889962|NCT02068326|Behavioral|Treatment As Usual|Treatment As Usual
75889963|NCT02206646|Drug|Metalyse|
75889964|NCT03788148|Device|Stent, red blood cell transfusion|BMS (Bare Metal Stent) and DES (drug-eluting stent) transplants with periprocedural red blood cell transfusion
75889965|NCT02419417|Drug|BMS-986158|Specified dose on specified days
75889966|NCT02419417|Biological|Nivolumab|Specified dose on specified days
75889967|NCT02206724|Radiation|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
75889968|NCT02203214|Device|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
75889969|NCT02068404|Drug|Nifedipine|
75889970|NCT02257658|Drug|Doxycycyline|
76060797|NCT03749902|Drug|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
75598007|NCT05644392|Drug|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
75889971|NCT02257658|Behavioral|Incentive|
75889972|NCT02068482|Drug|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
75889973|NCT02206802|Drug|5% minoxidil topical foam|5% minoxidil topical foam
75742267|NCT00635999|Other|Cognitive therapy (CT)|CT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CT will include 14 weekly sessions.
75742268|NCT00635999|Behavioral|Cognitive-Behavioral Therapy|Includes all of the techniques in the other 2 interventions.
75889974|NCT02065986|Drug|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
75889975|NCT02068560|Drug|dDAVP infusion|
75889976|NCT01377103|Drug|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
75889977|NCT01377103|Drug|Placebo|
75889978|NCT02206958|Behavioral|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
75889979|NCT02068638|Procedure|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
75742269|NCT03866421|Diagnostic Test|MR spectroscopy of the liver|Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
76060798|NCT03749902|Drug|Oxytocin|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~The oxytocin group will not receive misoprostol after the membranes have ruptured."
75598008|NCT05644392|Drug|Regorafenib|Regorafenib 80mg, po, orally once daily
75742270|NCT03866421|Diagnostic Test|Fibroscan of the liver|Transient Elastography for Measurement of liver fibrosis.
75889980|NCT02068638|Procedure|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
75889981|NCT02068638|Procedure|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
75889982|NCT02068638|Procedure|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
75889983|NCT01377025|Drug|Placebo|two tablets in the morning and two in the evening.
76060799|NCT01590771|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
76060800|NCT01590771|Drug|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
76060801|NCT01590771|Drug|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
76060802|NCT01590771|Drug|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
76060803|NCT01590771|Drug|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
76060804|NCT03735940|Other|Spot monitoring device, excl. Sham|o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
75598009|NCT01313208|Drug|etanercept|Administered by subcutaneous injection once weekly.
76060805|NCT03830242|Diagnostic Test|<Sup>18<Sup>F-FDG PET/CT dynamic scan|The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
76060806|NCT03830242|Diagnostic Test|B-ultrasonography|The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
76060807|NCT04764058|Drug|Tienam 500|Imipenem and cilastatin sodium
76060808|NCT04764058|Device|Infusion|Health caregivers give the drug to the patients and monitoring the infusion rate
76060809|NCT04763824|Behavioral|Telementoring with Practice Facilitation|We are attempting to provide education and encourage practice change
75598010|NCT01313208|Drug|Placebo|Placebo subcutaneous injection
75598011|NCT01313208|Drug|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
75598012|NCT01312428|Device|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
75598013|NCT01312428|Device|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
75598014|NCT01075984|Drug|Posaconazole|
75598015|NCT01075984|Drug|Dextrose 5% in water|
75742271|NCT03866421|Device|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
75742272|NCT03866421|Diagnostic Test|Oral glucose tolerance test (OGTT)|OGTT with incretin hormones. Measured for three hours.
75742273|NCT03866421|Diagnostic Test|Intra venous glucose infusion (IIGI)|This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.
75742274|NCT03866421|Radiation|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
75742275|NCT03866421|Biological|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
75742276|NCT03866421|Other|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
75742277|NCT00819377|Drug|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
75742278|NCT00819377|Drug|Normal saline|5 ml normal saline by inhalation over 15 min
75742279|NCT01023165|Procedure|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
75742280|NCT01025895|Procedure|acl reconstruction - double bundle technique|
75742281|NCT01025895|Procedure|acle reconstruction - single bundle technique|
75742282|NCT01023243|Other|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
76060810|NCT03638674|Other|DXA + CT|Two dual-energy X-ray scans + CT scan
75889984|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
75889985|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
75889986|NCT02207036|Behavioral|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
75742283|NCT01023243|Other|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
75598016|NCT04306198|Device|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with lag screw as proximal fixation
75889987|NCT02207036|Behavioral|Smokefree.gov|referral to the NCI Smokefree.gov website
75889988|NCT03630757|Other|Treatment|In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
75889989|NCT02203292|Behavioral|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb < 9.0 g/dL
75889990|NCT02203292|Behavioral|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb < 7.0 g/dL
75598017|NCT04306198|Device|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a helical blade as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with helical blade as proximal fixation
75598018|NCT02876536|Device|TENS|The effect of TENS device will be compared in case and control groups.
75598019|NCT01024231|Drug|BMS-936558 (MDX1106-04)|
75742284|NCT01023321|Drug|GLPG0555|single ascending doses, oral solution
75742285|NCT01023321|Drug|placebo|single dose, oral solution
75742286|NCT01023321|Drug|GLPG0555|multiple dose, oral solution, 7 or 14 days
75742287|NCT01023321|Drug|placebo|multiple dose, oral solution, 7 or 14 days
75742288|NCT03762915|Drug|minocycline HCl microspheres|Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
75742289|NCT00469209|Drug|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
75742290|NCT00469209|Drug|Velcade (Bortezomib)|"Arm 1 (Level 1):~1.0 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
75742291|NCT00469209|Drug|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
75742292|NCT00469209|Drug|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
75889991|NCT02066064|Procedure|Standard Colonoscopy|Standard Colonoscopy
75889992|NCT02066064|Procedure|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
75889993|NCT05353075|Other|Sub Occipital Muscle Inhibition|The therapist sits at the head end of the table, palms beneath the subject's head, pads of his fingertips on the posterior arch of the atlas, which will be palpated by the therapist between the external occipital protuberance and the spinous process of the axis vertebra. The therapist locates the gap between the occipital condyles and the spinous phase of the C2 vertebra with the middle and ring fingers of both hands the therapist then rests the base of the skull on his or her hands, with toward the therapist. The pressure will be held at the same level for four minutes until tissue relaxation will be achieved. The subject will be asked to keep his eyes closed during the SMI technique to prevent eye movements disturbing the Sub occipital muscle tone.
75889994|NCT05353075|Other|Sub Occipital Inhibition with Hold Relax Agonist Contraction|Therapist will passively flex the lower extremity with knee extended to the end range of Hip Flexion. Once the end range of motion will attain the patient will apply a 10second isometric force against the therapist manual resistance. After the isometric contraction of hamstring the patient will ask to perform a concentric contraction of opposing muscle (hip flexors) for 10 seconds. As the patient performs the concentric contraction the therapist takes up the slack into any ROM that was gained keeping limb into new stretch position for 10-15 seconds and then rest for 5 seconds. Three repetitions of this technique will be performed on each subject.
75769605|NCT03888586|Other|Deep Friction Massage Technique|For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
75889995|NCT02207192|Other|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position."
75889996|NCT03579121|Other|Pharmacogenomic (PGx)|Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
75889997|NCT03579121|Other|Review results|Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
75889998|NCT02203370|Device|NIRS - Near-infrared spectroscopy|
76072001|NCT03481387|Device|Aortic Valve Replacement with Perceval S sutureless heart valve|Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
75889999|NCT05037786|Behavioral|Infographic|Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic
75890000|NCT05037786|Behavioral|Powerpoint|Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
75890001|NCT02203448|Device|Facet Wedge spinal system|
75890002|NCT02066142|Device|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
75598020|NCT01024231|Drug|Ipilimumab|
75890003|NCT02066142|Device|Ultrasound|
75598021|NCT01077544|Drug|Nilotinib|"Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water."
75598022|NCT04297969|Diagnostic Test|"objective pediatric vision screen GCK glow fixation"|2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
75598023|NCT04543201|Behavioral|Early START visit using checklist over telephone or zoom|"Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey"
75742293|NCT01322919|Procedure|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
75742294|NCT00635219|Drug|Placebo|capsules; daily; orally
75742295|NCT00635219|Drug|Vortioxetine (Lu AA21004)|2.5 mg/day; encapsulated tablets; orally
75742296|NCT00635219|Drug|Vortioxetine (Lu AA21004)|5 mg/day; encapsulated tablets; orally
75742297|NCT00635219|Drug|Vortioxetine (Lu AA21004)|10 mg/day; encapsulated tablets; orally
75890004|NCT02068872|Procedure|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
75890005|NCT02342275|Drug|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
75890006|NCT02342275|Drug|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
75890007|NCT04988568|Other|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where patients will be interviewed.
75890008|NCT02207270|Behavioral|Same day discharge|Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
75890009|NCT02207270|Behavioral|Overnight Stay|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard or routine care. Patients randomized to overnight stay will be discharged the following morning to receive a follow up phone call at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
75890010|NCT02068950|Behavioral|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
75890011|NCT01827553|Drug|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m^2 2 h infusion, folinic acid 400 mg/ m^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m^2 for 90 minutes, bolus application 5-FU 400 mg/m^2 followed by 46h infusion of 5-FU 2400 mg/m^2)
76072002|NCT03471078|Drug|Avatrombopag|Oral avatrombopag tablet
75598024|NCT02871583|Procedure|lichtenstein|tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
75598025|NCT02871583|Procedure|Kugel|preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
76060811|NCT03636724|Behavioral|E-intervention|The 10-week e-health intervention will target HAPA-based social-cognitive variables of PA and FVI. Particularly, Week 1: risk perception and outcome expectancies; Week 2: goal setting; Week 3: development of action plans; Week 4: revision and adjustment of previous action plans; Week 5: development of coping plans; Week 6: revision and adjustment of previous coping plans; Week 7: development of perceived social support; Week 8: revision and adjustment of previous social support. Week 9-10: self-monitoring. Self-efficacy will be a fixed intervention variable involved from week 2 to week 10. Additionally, some behaviour change techniques will be employed in the intervention in order to facilitate the implementation and maintenance of behaviour.
76060812|NCT01563237|Device|MIDI Arrow|Implantation of MIDI Arrow
76060813|NCT03735316|Drug|Hydroxocobalamin|5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
75598026|NCT02871817|Other|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
76060814|NCT03735316|Procedure|Cardiopulmonary Bypass|Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.
76060815|NCT03735316|Drug|Placebos|Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
75890012|NCT01827553|Radiation|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
76060816|NCT01694433|Drug|Calcipotriene|1g daily BID
75742298|NCT00635219|Drug|Duloxetine|60 mg/day; encapsulated capsules; orally
75742299|NCT03987477|Behavioral|Interpretation bias modification program|Brief online program aimed at the modification of negative interpretation biases.
75742300|NCT03987477|Behavioral|Waiting list|Waiting list procedure for the control group.
75742301|NCT00363766|Drug|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
75890013|NCT01827553|Drug|Chemotherapy, gemcitabine|5 cycles of 300 mg/m^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m^2/d
75598027|NCT04299763|Dietary Supplement|Oat Beta-glucan as a Supplement in Type 2 Diabetics|44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
75598028|NCT02871427|Drug|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
75598029|NCT01012999|Drug|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
75598030|NCT00628381|Dietary Supplement|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
75742302|NCT00468819|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
75742303|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
75742304|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
76060817|NCT01694433|Drug|Placebo|1g daily BID
76060818|NCT01694121|Behavioral|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
76060819|NCT01694121|Behavioral|Comparison|general health intervention for men, not inclusive of HIV or relationship health
76060820|NCT03729388|Other|Prognosis factor associated with good outcome.|Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up.
76060821|NCT01676662|Device|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
76060822|NCT01676662|Device|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
76060823|NCT01693185|Drug|Remifentanil|continuous infusion 0.4 mcg/kg/min
76060824|NCT01693185|Drug|Midazolam|bolus injection
76060825|NCT01693185|Drug|Meperidine|bolus injection for 30 sec 1.0 mg/kg
75890014|NCT01827553|Drug|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
75890015|NCT02207348|Drug|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
76060826|NCT01693185|Drug|placebo (for remifentanil)|normal saline mimic diluted remifentanil
75598031|NCT00628381|Dietary Supplement|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
75742305|NCT01026129|Drug|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
75890016|NCT02066454|Drug|Apixaban|2.5mg x 2 per day during 6 months
75742306|NCT01026207|Device|Polysomnography|Sleep study polysomnography compared with portable monitoring
76060827|NCT01693185|Drug|placebo (for midazolam)|normal saline mimic to midazolam injection
76060828|NCT01693185|Drug|placebo (for meperidine)|normal saline mimic meperidine injection
76060829|NCT03630640|Drug|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
75890017|NCT03526484|Behavioral|Standard of Care|The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
76060830|NCT03629470|Other|Standard Conservative Treatment|Range of motion exercises, medication and activity modification.
75598032|NCT04297813|Combination Product|Advanced medicinal Therapy (MSC combined with biomaterial)|Augmentation of alveolar ridge with MSC and biomaterial
75598033|NCT04297813|Procedure|Autologous bone graft|Augmentation of the alveolar ridge with bone graft
75598034|NCT00637663|Drug|Entecavir|entecavir 0.5 mg QD
75598035|NCT00637663|Drug|Lamivudine|lamivudine 100 mg QD
75742307|NCT01026285|Drug|Risperidone Long-Acting injectable or oral antipsychotics|According to label
75742308|NCT01026363|Drug|Ergocalciferol|Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
75742309|NCT01026363|Drug|Calcitriol|0.25 mcg tablet once daily for 14 days
75742310|NCT01026441|Device|Vela100 (Aesthetic)|6 treatments once a week
75890018|NCT03526484|Behavioral|Experimental|The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
75890019|NCT02207426|Drug|Tobramycin|
75890020|NCT00777491|Drug|induction cisplatin|15 mg/m^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
75890021|NCT00777491|Drug|induction 5-fluorouracil|400mg/m^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
75890022|NCT00777491|Drug|induction gemcitabine|27 mg/m^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
75890023|NCT00777491|Radiation|Induction BID radiation therapy|Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
76060831|NCT03629470|Other|Nerve Gliding Exercises|Taught by occupational therapist. These exercises involve motions of the wrist, arm and neck. Subjects will be instructed to perform exercises regularly following the occupational therapists' protocol
76060832|NCT03629080|Biological|HB-101 vaccine|HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
76060833|NCT03629080|Biological|placebo|Saline will be used for placebo.
76060834|NCT03628534|Device|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
76060835|NCT03820882|Device|Catfish|Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.
76060836|NCT03820882|Device|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
76060837|NCT03815500|Behavioral|Enhanced Education|Enhanced educational curriculum will involve learning modalities including 3D modeling, video, and visual-aid enhanced text for references to improve caregiver and patient understanding of wound packing techniques.
76060838|NCT03625726|Biological|Thrombin generation assay (in vitro)|One blood sample.
76060839|NCT03625024|Behavioral|Cognitive-behavioral therapy|Individual cognitive-behavioral therapy, including homework and behavioral change methods.
76060840|NCT04403854|Diagnostic Test|MRI|If possible with spectroscopy
76060841|NCT04403854|Procedure|Spinal Tap|together with CSF pressure estimate
76072003|NCT03471078|Drug|Placebo Oral Tablet|Placebo comparator tablet
75598036|NCT04299529|Diagnostic Test|In-vitro urinary diagnostic test|Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
75448186|NCT05622604|Behavioral|pray.com app (meditative prayer condition)|Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
75890024|NCT00777491|Radiation|Induction QD radiation therapy|Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
75890025|NCT00777491|Radiation|Consolidation BID radiation therapy|Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
75598037|NCT01017601|Biological|Seneca Valley virus-001|Given IV
75890026|NCT00777491|Radiation|Consolidation QD radiation therapy|Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
75890027|NCT00777491|Drug|consolidation gemcitabine|27 mg/m^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
75598038|NCT01017601|Other|placebo|Given IV
75598039|NCT04297735|Other|Standard of care group|Visits every 6 months is standard of care.
75598040|NCT04297735|Behavioral|Telemedicine group|Conduct monthly telemedicine 'skype' visit
75598041|NCT04297735|Behavioral|Telemedicine|Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
75890028|NCT00777491|Drug|consolidation 5-fluorouracil|400 mg/m^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
75890029|NCT00777491|Drug|consolidation cisplatin|15 mg/m^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
75598042|NCT01016977|Drug|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
76060842|NCT03814954|Drug|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
75463062|NCT01871363|Radiation|chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
75598043|NCT01016977|Drug|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
75598044|NCT02871661|Drug|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
75598045|NCT02871661|Other|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
75598046|NCT02871661|Device|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
75598047|NCT01012765|Drug|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
75598048|NCT01012765|Drug|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
75598049|NCT01012765|Drug|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
75890030|NCT00777491|Procedure|radical cystectomy|Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
75890031|NCT00777491|Procedure|Post-Induction Chemoradiotherapy Endoscopic Response Evaluation|Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
75890032|NCT00777491|Drug|adjuvant gemcitabine|1000 mg/m^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
75890033|NCT00777491|Drug|adjuvant cisplatin|70 mg/m^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
76060843|NCT03814954|Drug|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
76060844|NCT03813160|Drug|Lenabasum 20 mg|oral capsule
76060845|NCT03813160|Drug|Lenabasum 5 mg|oral capsule
75598050|NCT00628459|Dietary Supplement|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
75598051|NCT00627913|Procedure|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
76060846|NCT03813160|Drug|Placebo|oral capsule
75742311|NCT01322997|Device|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
75742312|NCT01322997|Behavioral|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
75598052|NCT00627913|Procedure|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
75742313|NCT01322997|Device|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
75598053|NCT01010503|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
75742314|NCT01023399|Drug|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
75742315|NCT01026519|Drug|REGN88|Single dose of REGN88 and 43 day follow up.
75742316|NCT01026519|Other|Placebo|Placebo to match REGN88 administration
75769606|NCT01262014|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
75769607|NCT03886012|Device|Otoband|The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.
75769608|NCT03886012|Device|Otoband sham|The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.
75769609|NCT01152034|Behavioral|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
75769610|NCT01259050|Drug|Zinc and Copper|Optizinc 90 mg/d Copper 1 mg
75769611|NCT03886090|Behavioral|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice
75769612|NCT03886090|Behavioral|rest|Seated rest following motor skill practice
75769613|NCT03886090|Behavioral|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in a horizontal position.
75769614|NCT03888430|Procedure|PtcCO2 measure during intubation|Transcutaneous measure during intubation. Non invasive measure without any risk according to the literature
75769615|NCT03888196|Dietary Supplement|Panax Ginseng Supplementation|500 mg/day of Panax Ginseng
75769616|NCT03888196|Dietary Supplement|Placebo Supplementation|500 mg/day of Cellulose
75769617|NCT03892486|Other|The high PUFA diet group|Assumptions of nutritional intervention: in a randomized manner volunteers will be assigned to one of two groups: a control group which will receive general nutritional recommendations, based on the Polish nutrition pyramid, and the intervention group which will receive nutritional recommendations, based on the Polish nutrition pyramid and will consume at least 4 tablespoons of olive oil or 30 grams of nuts every day for 12 weeks.
75769618|NCT00255840|Behavioral|Monitoring by an HIV-trained medical doctor|Participants will receive care from an HIV-trained medical doctor
75769619|NCT00255840|Behavioral|Monitoring by an HIV-trained primary care nurse|Participants will receive care from an HIV-trained primary care nurse
75769620|NCT00255840|Drug|Efavirenz|600 mg tablet taken orally daily
75769621|NCT00255840|Drug|Lamivudine|150 mg tablet taken orally daily
75890034|NCT02207582|Device|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
75890035|NCT02207582|Device|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
75598054|NCT00628537|Device|BION stimulation|"BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises."
75742317|NCT00451191|Drug|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
76060847|NCT03812848|Other|Anticoagulation Stewardship Program|"A clinical-pharmacist led anticoagulation stewardship program that includes:~Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients."
76060848|NCT03619252|Biological|Vaccination with pneumococcal conjugate vaccine (PCV13)|Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.
76060849|NCT03619252|Drug|Standard Antibacterial Prophylaxis|Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
75742318|NCT00451035|Drug|LBH589|
75890036|NCT02069106|Dietary Supplement|Pro-Omega LDL|
76060850|NCT03717142|Combination Product|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
76060851|NCT03807856|Drug|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
75742319|NCT00468585|Drug|Capecitabine|
75742320|NCT00468585|Drug|Bevacizumab|
75742321|NCT01021839|Procedure|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
75890037|NCT02069106|Other|Placebo|
76060852|NCT03807856|Other|Standard of Care|Daily vital signs, lab work and one outpatient clinic visit
76060853|NCT03807154|Behavioral|ICBT|A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.
76060854|NCT03807154|Behavioral|IPT|A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
76060855|NCT03716284|Procedure|Electromagnetic navigation bronchoscopy (ENB)|ENB is carried out by a ENB system（LungCare, China) with/without other guided bronchoscopy techniques and/or ROSE, which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
75890038|NCT02199392|Drug|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
76060856|NCT03806530|Drug|Gabapentin|100 mg capsule
76060857|NCT03806530|Drug|Ropinirole|0.50 mg capsule
75890039|NCT03630445|Other|Isomaltooligosaccharides (IMOs)|Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
75890040|NCT03630445|Other|Xtend® sucromalt|Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
75890041|NCT03630445|Other|Combination of IMOs and Xtend® sucromalt|A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
75890042|NCT03630445|Other|Raw corn starch|Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
75890043|NCT03630445|Other|Maltodextrin|Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
75890044|NCT02069262|Other|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
75890045|NCT01379495|Behavioral|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
75890046|NCT05320627|Drug|Edoxaban|Eligible patients will receive Edoxaban tablet once a day for 12 weeks
75890047|NCT03559920|Drug|Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery|The investigators sedate the patients in the ICU for several days after head & neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
75890048|NCT03559920|Drug|Sedate using propofol.|Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
75742322|NCT01026597|Drug|REGN727|5 IV cohorts (dose 1, 2, 3, 4, and 5)
75890049|NCT02203760|Drug|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
75890050|NCT02203760|Drug|Pazopanib|Pazopanib 800 mg orally once daily
75890051|NCT02064972|Other|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
75890052|NCT03703271|Drug|Methotrexate|single-agent 5-day methotrexate, two weeks a cycle
75890053|NCT03703271|Procedure|hysteroscopic repeat curettage|Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
75890054|NCT03532802|Drug|Metoprolol Succinate|"week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~week: steady state treatment with the maximum tolerated dose of the 1.week."
75890055|NCT03532802|Drug|Placebo oral capsule|"week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~week: steady state treatment with the maximum tolerated dose of the 1. week"
75742323|NCT01026597|Drug|Placebo|5 IV cohorts (dose 1, 2, 3, 4, and 5)
75742324|NCT00450801|Drug|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
75890056|NCT03430531|Drug|Lidocaine|Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
75890057|NCT02066532|Drug|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
76060858|NCT03806530|Drug|Placebo Gabapentin|Placebo capsule
75598055|NCT00627991|Drug|Valsartan|
75598056|NCT05006053|Other|Interviews/Focus groups|Qualitative study (no intervention delivered)
75598057|NCT04297657|Other|Counselling|o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
75598058|NCT04472845|Radiation|1 week RT|RT will be delivered over 1 week
75598059|NCT04472845|Radiation|2 week RT|RT will be delivered over 2 week
75742325|NCT00450801|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
75890058|NCT02066532|Drug|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab > 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
75890059|NCT05763329|Drug|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1|Patients will receive Lemborexant 5 mg per day on the first day of sleep test
75890060|NCT05763329|Drug|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2|Patients will receive Lemborexant 5 mg per day on the second day of sleep test
75890061|NCT05763329|Drug|Placebo Day 1|Patients will receive placebo on the first day of sleep test
75890062|NCT05763329|Drug|Placebo Day 2|Patients will receive placebo on the second day of sleep test
75890063|NCT03532724|Device|Patient Self-Management of VKA therapy|Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA
75890064|NCT02065050|Other|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
76060859|NCT03806530|Drug|Placebo Ropinirole|Placebo capsule
75742326|NCT00450801|Drug|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
75742327|NCT00450801|Drug|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
75742328|NCT00450801|Drug|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
76060860|NCT03608020|Drug|BMX-001|Manganese butoxyethyl pyridyl porphyrin
75598060|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
75742329|NCT00450801|Drug|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
75890065|NCT04088513|Drug|Aspirin|This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
75890066|NCT04088513|Drug|Clopidogrel|This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
75890067|NCT02207660|Drug|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
75890068|NCT02069340|Drug|zoledronic acid|Given IV
75890069|NCT02069340|Other|pharmacological study|Correlative studies
75890070|NCT02199548|Other|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
75890071|NCT02069418|Radiation|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
75742330|NCT00450801|Drug|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
75742331|NCT00450801|Drug|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
75463063|NCT01871376|Drug|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
75742332|NCT00450801|Drug|Thalidomide|Maintenance therapy.
75742333|NCT00450801|Drug|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
75463064|NCT01871454|Radiation|stereotactic ablative radiotherapy (SABR)|standard of care radiation therapy
75463065|NCT01871454|Drug|Pentoxifylline|pentoxifylline
75463066|NCT01871467|Drug|Sargramostim|
75463067|NCT01871480|Drug|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
75742334|NCT00450801|Drug|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
75890072|NCT02069418|Radiation|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
75598061|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
75598062|NCT01006291|Drug|insulin glargine|Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
75598063|NCT02871349|Drug|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
75742335|NCT00450801|Drug|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
75890073|NCT02207738|Device|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
75890074|NCT02207738|Device|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
75890075|NCT04422847|Device|3D obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
75890076|NCT02208128|Drug|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
76072004|NCT03469960|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
76060861|NCT03608020|Radiation|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy per standard of care.
75742336|NCT00450801|Drug|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
75890077|NCT04411771|Behavioral|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or MI. The common theme is that they are principle-based rather than manual-based and focus on behavioral change in relation to a problem that is perceived both possible to affect and relevant to the patient, rather than focusing on a specific diagnosis or condition. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. Usually a BI treatment consists of 1-4 appointments with several weeks apart and ends when the patient feels that they are moving in the right direction.
76060862|NCT00003820|Drug|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
75463068|NCT01871480|Drug|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
75463069|NCT01871493|Drug|LY2605541|Administered subcutaneous (SQ)
75463070|NCT01871493|Drug|Insulin Lispro|Administered SQ
75463071|NCT01871584|Device|Colon cleansing by hydrotherapy|The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.
75463072|NCT01871597|Device|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
75742337|NCT00450801|Drug|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
75742338|NCT01023555|Other|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
75742339|NCT01023633|Drug|Oxaliplatin, LV, 5-FU|"Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W"
75463073|NCT01871610|Drug|[18F]AV-45 PET amyloid binding imaging|
75742340|NCT01026675|Procedure|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
75742341|NCT00458211|Drug|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
75742342|NCT00450723|Drug|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
75742343|NCT00450723|Procedure|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
76060863|NCT01693029|Drug|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
76060864|NCT01693029|Drug|US-licensed epoetin alfa|Solution for subcutaneous injection.
76060865|NCT01589445|Drug|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
75463074|NCT01871623|Procedure|Segmental Le Fort I osteotomy|comparison the stability of segmental Le Fort I osteotomy with conventional approach of one-piece Le Fort I osteotomy
75463075|NCT01871623|Procedure|One-piece Le Fort I Osteotomy|conventional approach
76060866|NCT01589445|Drug|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
76060867|NCT01588509|Drug|Romosozumab|Administered by subcutaneous injection
76060868|NCT01588353|Drug|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
76072005|NCT03469960|Drug|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
75463076|NCT01871636|Procedure|Endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
75463077|NCT01871636|Procedure|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
76060869|NCT01588197|Behavioral|Attention/Distraction Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
75890078|NCT04411771|Behavioral|Guided self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering shCBT will need four days of reading and two days of training to be able to make initial assessments and problem profiling and use the self-help books.
75598064|NCT02871349|Drug|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
76060870|NCT01588197|Behavioral|Stimulus Quality/Severity Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
75598065|NCT02871349|Device|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
75742344|NCT00450723|Procedure|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
76060871|NCT01588197|Behavioral|Control Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
76060872|NCT01561989|Dietary Supplement|cholecalciferol|Given PO
75742345|NCT00450723|Procedure|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
75742346|NCT00450723|Procedure|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
75742347|NCT00450723|Radiation|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
75742348|NCT01026753|Behavioral|Refrigerator Magnet|The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
75598066|NCT01012609|Other|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
76060873|NCT01561989|Other|questionnaire administration|Ancillary studies
76060874|NCT01561989|Biological|trivalent influenza vaccine|Given IM
75742349|NCT00467961|Combination Product|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
75742350|NCT03996213|Other|head down position|Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
75742351|NCT03996213|Other|leg elevation position|Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
75742352|NCT04889157|Drug|PF-06882961|Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
75742353|NCT04889157|Drug|Placebo|3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
75742354|NCT00457821|Drug|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
75742355|NCT00457821|Drug|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
75742356|NCT00457821|Drug|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
75742357|NCT00457821|Drug|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
75742358|NCT00633893|Drug|Apixaban|Tablets, Oral, twice daily, 12 months
75742359|NCT00633893|Drug|Placebo|Tablets, Oral, twice daily, 12 months
75742360|NCT02550587|Behavioral|satisfaction|anesthesia satisfaction rates
75742361|NCT02550665|Drug|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
75742362|NCT00819455|Behavioral|Experimental|Active Life style modification-motivation by I.T technology
75742363|NCT00819455|Behavioral|Control arm (usual care/standard care arm)|Life style modification only once
75742364|NCT00819533|Device|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
76060875|NCT00004054|Drug|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
76060876|NCT00004054|Drug|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
75598067|NCT04297501|Drug|Antiretroviral Therapy|All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
76060877|NCT00004054|Drug|etoposide|50 mg/m^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
75598068|NCT04298749|Drug|GX-P1 or Placebo (dose level 1)|GX-P1 dose level 1 or placebo
76060878|NCT00004054|Drug|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
76060879|NCT00004054|Drug|paclitaxel|135 mg/m^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
76060880|NCT00004054|Drug|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
75598069|NCT04298749|Drug|GX-P1 or Placebo (dose level 2)|GX-P1 dose level 2 or placebo
75742365|NCT00819611|Behavioral|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
75742366|NCT00819611|Behavioral|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
75890079|NCT03119883|Other|5-Carbon C 13-labeled Glutamine|Given IV
75890080|NCT03119883|Procedure|Biospecimen Collection|Undergo collection of blood
75598070|NCT04298749|Drug|GX-P1 or Placebo (dose level 3)|GX-P1 dose level 3 or placebo
75598071|NCT04298515|Diagnostic Test|Nesfatin-1|Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
75598072|NCT01012219|Drug|niacin (+) laropiprant|open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
75598073|NCT01012219|Drug|Comparator: aspirin|81 mg oral tablet once daily for 7 days
75598074|NCT01012219|Drug|Comparator: clopidogrel|75 mg oral tablet once daily for 7 days
75598075|NCT01012219|Drug|Comparator: laropiprant|40 mg oral tablet once daily for 7 days
75598076|NCT01012219|Drug|Comparator: placebo|placebo oral tablet once daily for 7 days
75742367|NCT04044677|Device|tDSC-active|10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation
75742368|NCT04044677|Device|tDCS-sham|10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
75742369|NCT00819845|Drug|carvedilol|carvedilol vs ramipril
75742370|NCT00819845|Drug|ramipril|carvedilol vs ramipril
75742371|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
75742372|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
75769622|NCT00255840|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
75769623|NCT00255840|Drug|Nevirapine|200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
75769624|NCT00255840|Drug|Stavudine|Tablet taken orally daily. Dosage depends on weight.
75769625|NCT01154062|Drug|Pazopanib|Pazopanib tablet
75890081|NCT03119883|Procedure|Biospecimen Collection|Undergo collection of bone marrow aspirate samples
75890082|NCT03119883|Other|Uniformly-labeled [13C]glucose|Given IV
75890083|NCT02069496|Biological|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
75890084|NCT02066610|Other|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
76060881|NCT00004054|Radiation|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
76060882|NCT00004054|Drug|warfarin|To keep international normalized ratio (INR) > 1.5 and < 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
76060883|NCT01587885|Drug|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
76060884|NCT01587885|Drug|Omeprazole 20 mg|Tablets, orally
76060885|NCT01587651|Drug|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
76060886|NCT01587651|Drug|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
76060887|NCT01587651|Drug|Ticagrelor Maintenance Dose|one 90mg film coated tablet
76060888|NCT03800992|Other|assessment of perception and evaluation of physicians advisory skills per questionnaire|questionnaire according to SPIKES - a Six-Step Protocol for Delivering Bad News to be completed by parents and children (older than eleven)
76060889|NCT04763434|Drug|dexamethasone; dexmedetomidine; ropivacaine|Ultrasound-guided multilevelTPVB is performed at the end of lobectomy
76060890|NCT04763668|Other|Pregnant HIV positive women on ARTs|Cardiovascular disease risk in pregnant HIV positive women on ARTs
76060891|NCT04763668|Other|Babies born to HIV positive mothers on ARTs|cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
75890085|NCT02066610|Other|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
75890086|NCT02066610|Other|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
75890087|NCT02066610|Other|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
75890088|NCT03077711|Drug|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
75890089|NCT03077711|Drug|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
75598077|NCT04298125|Behavioral|Exercise in Pregnancy|Women in this group will participate in psychical activity 3 times per week in their community setting.
75742373|NCT00820001|Behavioral|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
75769626|NCT01155544|Behavioral|Behavioral Intervention|Preventing recurrence of substance use.
75890090|NCT03673683|Behavioral|SANDWICH protocol|A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness
75890091|NCT03673683|Behavioral|Usual care|Usual sedation and weaning management that is not protocol based
75890092|NCT03533426|Procedure|Serratus anterior plane catheter block|Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.
75890093|NCT03533426|Procedure|Patient controlled analgesia|The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
75890094|NCT02069574|Procedure|non-surgical periodontal therapy|
75890095|NCT04374019|Drug|Ivermectin|"Ivermectin:~Days 1-2: Weight < 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight > 75kg: 5 tabs (15 mg total daily dose)"
75890096|NCT04374019|Drug|Camostat Mesilate|Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
75890097|NCT04374019|Dietary Supplement|Artemesia annua|Days 1-14: tea or coffee pod TID (1350 mg total daily dose)
75890098|NCT04374019|Drug|Artesunate|Days 1-14:
75890099|NCT02199704|Other|Self Directed Positive Parenting Program|"Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders & Turner, 1999) and up to ten sessions of support. This is a case series study."
75890100|NCT03678363|Other|Tai chi chuan|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
75598078|NCT01011907|Drug|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
75598079|NCT01011907|Drug|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
75598080|NCT01011673|Drug|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
75598081|NCT01011673|Drug|Ketorolac|ketorolac 30mg IVSS
76060892|NCT04747210|Behavioral|contextual one-on-one coaching|Training workshop and coaching one-on-one
76060893|NCT04747210|Behavioral|Trainig workshop|Ten-hour training workshop.
76060894|NCT04762966|Drug|Metformin|Level of Metformin blood concentration
75890101|NCT02069652|Behavioral|Lifestyle Counseling|Lifestyle Counseling
75890102|NCT02199782|Other|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
75890103|NCT02069808|Drug|Follistim|Follicle stimulating hormone promotes recruitment of follicles for ovulation.
75890104|NCT02069808|Drug|Ganirelix|GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
75890105|NCT02069808|Drug|Menotropins|Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
75598082|NCT01011439|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
75598083|NCT01311024|Biological|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
75890106|NCT02069808|Drug|Leuprolide|Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
75890107|NCT02069808|Procedure|Transvaginal ultrasound guided needle aspiration of oocytes|
75890108|NCT03678207|Other|Anesthesiologist phone call|Patients receiving ambulatory surgery with no prior diagnosis of hypertension but have elevated blood pressure prior to surgery. Patients will receive a phone call from a participating anesthesiologist 1-3 days after surgery notifying them of their high blood pressure and obtaining oral consent to participate in the study. Patients will receive reminders via mail about following up with their PCP.
75890109|NCT02199860|Drug|SD I|
75598084|NCT01311024|Biological|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
75598085|NCT02871193|Drug|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
75598086|NCT02871193|Drug|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
75463078|NCT01871636|Device|HybridKnife|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
75598087|NCT02871193|Other|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
75742374|NCT00820001|Behavioral|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
75463079|NCT01871649|Drug|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
75463080|NCT01871649|Drug|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
75463081|NCT01871662|Drug|Legalon® SIL (Silibinin)|Silibinin 20 mg/Kg/day
75463082|NCT01871662|Drug|Pegylated interferon alfa2b|1.5 µg/kg once-weekly
75463083|NCT01871662|Drug|Ribavirin|At weight-based dose 800-1400 mg/day (BID, OS)
75463084|NCT01871675|Drug|IPI-145|
75463085|NCT01871675|Drug|Rituximab|
75742375|NCT00820001|Other|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
75742376|NCT00820001|Other|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
75890110|NCT02199860|Drug|SD II|
75890111|NCT02199860|Drug|Placebo|
75890112|NCT03673605|Drug|Rivaroxaban 15 mg|Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
75890113|NCT03673605|Drug|Warfarin|Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
75890114|NCT02069886|Drug|deferasirox|125, 250, 500 mg dispersable tablets
75890115|NCT04311463|Drug|Paroxetine hydrochloride|Paroxetine hydrochloride will be administered.
75890116|NCT04311463|Drug|PAXIL (Paroxetine hydrochloride )|PAXIL will be administered.
75890117|NCT02203994|Device|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
75890118|NCT03070587|Behavioral|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
75598088|NCT01310868|Drug|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
75890119|NCT02065128|Other|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
75890120|NCT03678051|Behavioral|Treatment as Usual (TAU)|Standard of care residential treatment
75598089|NCT01310868|Drug|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
75598090|NCT01310868|Radiation|Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
75598091|NCT01310868|Drug|Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
75598092|NCT01310868|Drug|Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
75598093|NCT01273155|Drug|Belinostat|Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
75598094|NCT05557851|Combination Product|Minnelide|Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
75598095|NCT01005901|Drug|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
75742377|NCT00457743|Drug|Sunitinib malate (SU011248)|SU011248
75742378|NCT00820079|Drug|ADX10059|oral administration
75742379|NCT00820079|Drug|ADX10059 Matching Placebo|oral administration
75742380|NCT00820157|Procedure|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
75742381|NCT00820157|Procedure|TACE|TACE alone or TACE followed by downstage resection for MNHCC
75890121|NCT03678051|Behavioral|TAU+CBT4CBT|45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
75890122|NCT01569503|Device|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
75463086|NCT01871675|Drug|Bendamustine|
75463087|NCT01871688|Behavioral|pelvic floor rehabilitation program with neuromodulation|pelvic floor rehabilitation program with neuromodulation
75463088|NCT01871701|Drug|Escitalopram|Escitalopram
75463089|NCT01871701|Drug|Quetiapine|Quetiapine
75463090|NCT01871701|Drug|Moxifloxacin|Moxifloxacin
75463091|NCT01871701|Other|Placebo|Placebo
75463092|NCT01871740|Drug|Enalapril maleate and folic acid tablets|Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
75463093|NCT01871740|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
75890123|NCT04296565|Behavioral|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff
75598096|NCT01005901|Drug|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
75742382|NCT00820313|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
75890124|NCT04296565|Behavioral|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
75742383|NCT04044599|Drug|Gynoflor|VAGİNAL GYNOFLOR
75890125|NCT03677895|Drug|Hyaluronic Acid|Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
75890126|NCT04295005|Drug|Empagliflozin|film coated tablet
75890127|NCT04295005|Drug|DPP-4i|film coated tablets
75890128|NCT04295005|Drug|Sitagliptin|film coated tablet
76060895|NCT03602560|Drug|seladelpar 5-10 mg|Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
76060896|NCT03602560|Drug|seladelpar 10 mg|Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
76060897|NCT03602560|Drug|Placebo|One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
76060898|NCT03597256|Device|Restylane Defyne|Intradermal injection
76060899|NCT03596788|Dietary Supplement|Carbohydrate Beverage|The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)
76060900|NCT03596788|Dietary Supplement|Placebo Beverage|The placebo beverage will contain aspartame.
75598097|NCT02889549|Drug|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
75742384|NCT01023867|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
75890129|NCT04295005|Drug|GLP-1-RA|subcutaneous injection or tablet
75890130|NCT03174353|Drug|Lanreotide Prefilled Syringe|All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
75598098|NCT02889549|Drug|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
75598099|NCT04968925|Device|ACUVUE Oasys 1-Day|TEST
75598100|NCT04968925|Device|Precision 1|CONTROL
75890131|NCT02260284|Other|Yaotong points acupuncture|Patients receive the treatments of Yaotong points penetration
76060901|NCT01691859|Drug|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
75598101|NCT01266993|Biological|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
75598102|NCT01266993|Biological|Menjugate|Intramuscular, 1 dose
76060902|NCT00779116|Drug|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
75598103|NCT04282525|Other|ECMO for hemodynamic or respiratory indication|ECMO for hemodynamic or respiratory indication
75598104|NCT01309386|Drug|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
76060903|NCT00779116|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
76060904|NCT03794284|Diagnostic Test|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
76072006|NCT03465748|Device|OrthoK|orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
76072007|NCT03464955|Behavioral|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
75890132|NCT02260284|Other|the usual care|participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
75890133|NCT02260284|Other|standardized acupuncture|Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
75598105|NCT01309386|Drug|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
75890134|NCT03673449|Device|SilkBridge|SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
75890135|NCT05214235|Drug|Hypoglycemic Drugs|Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
75890136|NCT02204306|Genetic|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
75742385|NCT00820391|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
75742386|NCT00820391|Behavioral|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
75598106|NCT04295317|Drug|PD-1 blocking antibody SHR-1210|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
75598107|NCT04295317|Drug|Capecitabine|Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
75742387|NCT03696303|Other|Urinary antigen detection assay|Screening for Ag level in S. pneumoniae urinary antigen detection assay.
75742388|NCT00820469|Drug|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
75742389|NCT00820469|Drug|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
75890137|NCT03439319|Device|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
75890138|NCT03439319|Other|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
75890139|NCT05208151|Other|Creative Drama Education|Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.
75890140|NCT02199938|Other|Identification and characterization of molecular markers in musculoskeletal tumors|
75890141|NCT04080947|Drug|Control group|patients received matching-image placebo once daily at bedtime for 12 weeks.
75890142|NCT04080947|Drug|Montelukast group|patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.
75598108|NCT01266603|Drug|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
75598109|NCT01266603|Biological|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
75598110|NCT04295551|Drug|Lopinavir / ritonavir tablets combined with Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
75598111|NCT04295551|Drug|Lopinavir/ritonavir treatment|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
75598112|NCT01309308|Procedure|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
75598113|NCT01309308|Other|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
75598114|NCT01266291|Drug|vigabatrin|Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
75742390|NCT00450411|Radiation|125-Iodine|Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
75890143|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
75742391|NCT00450411|Radiation|103-palladium|Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
75742392|NCT00815243|Procedure|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
75890144|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
75890145|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
75890146|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
75890147|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
76060905|NCT02073435|Behavioral|Donor pain management|"The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~Bowel preparation (e.g. Colace or Golytely)~Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is > 500cc)~I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression"
76060906|NCT01676740|Drug|Iron Supplement,|Pills to be swallowed
75890148|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
76060907|NCT01676740|Drug|Placebo|Daily administration of active drug or placebo
75598115|NCT00628771|Behavioral|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
75742393|NCT00815243|Procedure|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
75742394|NCT02551289|Other|Gluten free diet|Patients will follow a gluten free diet
75742395|NCT00815321|Biological|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
75742396|NCT00815399|Drug|Pioglitazone|15-45 mg/die
75742397|NCT00815399|Drug|Metformin|500-2000 mg/die
75742398|NCT00644969|Drug|placebo|Randomization 2:1 treatment to placebo
75598116|NCT00628771|Behavioral|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
75742399|NCT00644969|Drug|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
75742400|NCT00815477|Behavioral|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
75598117|NCT01004263|Drug|rizatriptan benzoate|Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
75598118|NCT01308762|Biological|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
75598119|NCT01308762|Biological|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
75598120|NCT01308762|Biological|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
75598121|NCT01265823|Biological|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
75598122|NCT02890836|Drug|Antihypertensiva, mainly Metyldopa|
75598123|NCT01004185|Drug|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM & 2 Asacol 400mg PM; 33-<54kg = 5 Asacol 400 mg AM & 4 Asacol 400mg PM; 54-<90kg = 6 Asacol 400mg AM & PM
75598124|NCT01004185|Drug|Asacol 400 mg|17-<33kg = 2 Asacol 400mg & 1 placebo AM, 1 Asacol 400mg & 1 placebo PM; 33-<54kg = 3 Asacol 400mg & 2 placebo AM, 2 Asacol 400mg & 2 placebo PM; 54-<90kg = 3 Asacol 400mg & 3 placebo AM & PM
75598125|NCT01265511|Drug|Placebo|Oral tablets given bid for 28 days
75598126|NCT01265511|Drug|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
75598127|NCT01265511|Drug|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
75598128|NCT01265511|Drug|Copegus|tablets given bid for up to 48 weeks
75742401|NCT00815477|Behavioral|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
75890149|NCT02066688|Drug|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
75890150|NCT02066688|Drug|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
75890151|NCT02066688|Drug|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
75890152|NCT05763251|Other|therapy duration|the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy
76060908|NCT01691781|Drug|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
75598129|NCT04325178|Other|Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.|Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
75742402|NCT02551445|Behavioral|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
75742403|NCT00815555|Other|There is no intervention - this is an observational study|
75742404|NCT04016909|Procedure|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
75742405|NCT00812279|Other|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
75890153|NCT03671733|Drug|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
75890154|NCT03671733|Drug|Exenatide|10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
76060909|NCT04111731|Procedure|Cryoballoon pulmonary vein isolation|Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.
76060910|NCT04111731|Procedure|Radiofrequency pulmonary vein isolation|Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases
75598130|NCT04325100|Behavioral|Switch - Individual sessions|"Participants follow the Switch intervention through individual sessions (1 hour, twice a week, for around 2 months).~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual can be obtained from the main investigator (in French)."
75598131|NCT04325100|Behavioral|Switch - Group programme|"Participants follow the Switch group programme (2 hours, twice a week, for around 2 months).~During the group sessions, a powerpoint presentation and different media are used to present the different parts of the motivation model. Participants learn the different strategies (e.g., cognitive defusion, pleasure anticipation, problem solving) through individual and group exercises.~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual and the presentation material can be obtained from the main investigator (in French)."
75598132|NCT04324788|Other|Group 1|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
75890155|NCT03671733|Drug|Exenatide Microspheres for Injection|Exenatide 2 mg injection once weekly for 12 weeks.
75598133|NCT04324788|Other|Group 2|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
76060911|NCT04111731|Procedure|Repeat electrophysiological study|All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility
76060912|NCT04111731|Procedure|Left atrial posterior wall isolation|The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
75598134|NCT01264965|Drug|long acting oxycodone|10mg twice daily
75598135|NCT01264965|Drug|extra strength acetaminophen|1,000 mg twice daily
75598136|NCT05644236|Other|mouthwash|After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hrs before the visit.
75598137|NCT02890680|Procedure|Platelet-rich fibrin|
75742406|NCT00812279|Other|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
75742407|NCT00812279|Other|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
75742408|NCT04046081|Drug|Dichloroacetate|6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
75890156|NCT02200016|Procedure|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
75890157|NCT02200016|Procedure|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
75890158|NCT02200016|Device|B Braun Contiplex S catheter|
75598138|NCT02890680|Procedure|Control group|
75890159|NCT03119363|Device|AYO light glasses (Experimental)|The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
76060913|NCT01561755|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
76060914|NCT01561755|Drug|Placebo|Placebo - 2gr/kg over 2 days of saline
76060915|NCT03789214|Drug|Placebo oral capsule|Placebo Sleep Medication
76060916|NCT03789214|Drug|Low Dose Suvorexant|Low Dose Suvorexant
76060917|NCT03789214|Drug|High Dose Suvorexant|High Dose Suvorexant
76060918|NCT01585155|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
76060919|NCT04124367|Drug|Cerebrolysin|30 ml once daily (+70 ml 0.9% saline)
76060920|NCT04124367|Device|non-invasive brain stimulation|2 mA/35 cm² for 2x20 minutes, once daily
75890160|NCT03119363|Device|AYO light glasses (Comparator)|The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
75890161|NCT02070042|Drug|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
75598139|NCT01264887|Drug|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
75598140|NCT01306968|Drug|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
75598141|NCT01306968|Other|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
75742409|NCT00812435|Drug|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
75890162|NCT02070042|Drug|Placebo|Placebo capsules (olive oil) twice a day
75598142|NCT04323423|Behavioral|interrupting sedentary behaviour with light physical activity|replacing sitting with light walking bouts at different frequencies/durations
75742410|NCT00812513|Drug|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
75742411|NCT00812591|Procedure|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
75890163|NCT04059081|Drug|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
75890164|NCT03671655|Device|Drug-eluting stent|Drug eluting stent which are nitinol stent coated with Paclitaxel drug
76060921|NCT04124367|Drug|Placebo|100 ml once daily 0.9% saline
76060922|NCT04124367|Device|sham intervention|0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
75742412|NCT00812747|Other|observation|
75742413|NCT00820547|Biological|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
75742414|NCT00820547|Drug|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
75890165|NCT03671655|Device|Bare metal stent|Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
75890166|NCT02204384|Other|HFD Meal: High fiber from food|High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
75890167|NCT02204384|Dietary Supplement|HFS Meal: High fiber from supplement|High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
75890168|NCT02204384|Other|UF Meal: usual amount of fiber|Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
75890169|NCT01377311|Procedure|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
75890170|NCT02208440|Procedure|Best Repair of torn Rotator Cuff|
75890171|NCT02208440|Device|InSpace™ system|
76072008|NCT03451916|Drug|PLX-PAD|PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
75742415|NCT00820547|Drug|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
75598143|NCT05644158|Procedure|Revascularization|Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .
75598144|NCT05644158|Other|Exercise therapy|Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
75598145|NCT01264419|Device|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
75598146|NCT04323345|Dietary Supplement|Natural Honey|Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.
75598147|NCT04323345|Other|Standard Care|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
75890172|NCT03671577|Behavioral|Building Closer Friendships|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
75890173|NCT02200094|Drug|Low dose of Telmisartan, once daily|
75598148|NCT01263873|Device|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
75598149|NCT01263873|Device|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
75598150|NCT01263639|Other|Orthopaedic Attending Biosketch Card|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies."
75598151|NCT01263639|Other|Standard of care - No biosketch card|Standard of care
75448187|NCT05616637|Diagnostic Test|Navicular Drop Test|While participants in sitting position, the navicular tuberosity (NT) will be palpated.The most distal protruding portion of the medial NT will be marked. Participants will be asked to stand with equal weight on both feet. The new distance will be measured. The navicular drop test (NDT) results will then be obtained by comparing the measured values between the sitting and standing positions. Each measurement will be repeated three times and the average of the 3 measurements will be calculated. The expression in mm of the distance between the two marks will be considered the amount of ND. The amount of navicular fall of 10 mm or more will be interpreted as pes planus. Measurements will be made on both extremities. As a result of the measurements, if pes planus is present in a single extremity, that extremity, if it is present in both extremities, the extremity with higher NDT or if it is equal on both sides, the dominant extremity will be tested.
75598152|NCT01011283|Drug|decitabine|decitabine 20 mg/m^2 /day intravenous (IV) infusion for 5 days every 28 days
75598153|NCT01011283|Drug|azacitidine|azacitidine 75 mg/m^2 /day subcutaneous (SC) injection for 7 days every 28 days
75598154|NCT01263561|Procedure|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
75598155|NCT01263561|Procedure|trabeculectomy|trabeculectomy filtering surgery
75598156|NCT01009099|Other|breathing retraining|breathing retraining using a metronome
75598157|NCT01009099|Other|exercise training|treadmill exercise training
75598158|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
75598159|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
75742416|NCT00820547|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
75742417|NCT00820547|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
75742418|NCT00815867|Drug|epoetin beta (NeoRecormon ®)|"comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections"
75742419|NCT00820625|Procedure|pulmonary vein isolation|common pulmonary vein isolation procedure
75742420|NCT00820625|Procedure|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
75742421|NCT02550509|Device|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
75742422|NCT02550509|Device|elastography|elastography to patient with stoke
75890174|NCT02200094|Drug|High dose of Telmisartan, once daily|
75890175|NCT01370538|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
75890176|NCT03623295|Other|Blood sample|Blood withdrawal.
75890177|NCT03623295|Other|Questionnaire|Online questionnaire about the bleeds that patients experienced in the past.
75598160|NCT01263483|Drug|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
75890178|NCT03623295|Other|MRI-imaging|MRI imaging of joints.
75598161|NCT01306890|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
75598162|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
75598163|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
75598164|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
75890179|NCT03623295|Other|Physical examination|Physical examination of joint status.
75890180|NCT03248297|Drug|Azithromycin|Azithromycin tablet
75890181|NCT03248297|Drug|Azithromycin and amoxicillin|azithromycin and amoxicillin
75890182|NCT03248297|Drug|Placebo|Placebo tablet
75890183|NCT02208518|Procedure|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
75890184|NCT02208518|Device|EUS-elastography|
75890185|NCT02199626|Device|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
75598165|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
75598166|NCT02871973|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
75598167|NCT02871973|Behavioral|Handout|Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
75598168|NCT01263093|Drug|Clopidogrel|
75598169|NCT01263093|Drug|LY2216684|
75598170|NCT01010971|Drug|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
75598171|NCT01010971|Drug|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
75598172|NCT01010971|Drug|Placebo|Placebo HFA Nasal Aerosol once daily
75598173|NCT01306656|Drug|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week"
75890186|NCT02208596|Drug|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
75890187|NCT02208596|Drug|propofol|
75890188|NCT02208596|Drug|Etomidate|
75890189|NCT02070120|Drug|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
75890190|NCT02070120|Procedure|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
75890191|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
75890192|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
75890193|NCT03673215|Drug|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
75890194|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
75890195|NCT03673215|Drug|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
75890196|NCT03673215|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
75890197|NCT03673215|Drug|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
75890198|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
75598174|NCT01306656|Other|Placebo|"Month 1: Placebo once a week~Months 2-6: Placebo once a week"
75598175|NCT01306656|Dietary Supplement|Vitamin D|Daily multivitamin with 400 IU vitamin D.
75598176|NCT04327908|Other|Questionaire TESS and MSTS|answering TESS and MSTS questionnaire
75598177|NCT01008943|Biological|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
75598178|NCT02871271|Dietary Supplement|IQP-AS-121|
75598179|NCT04205071|Drug|Lorcaserin|Given PO
75598180|NCT04205071|Drug|Lorcaserin Hydrochloride|Given PO
75598181|NCT04205071|Other|Questionnaire Administration|Ancillary studies
75598182|NCT01003639|Drug|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
75598183|NCT01003639|Drug|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
75598184|NCT01003639|Behavioral|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
75463094|NCT01871753|Other|Anti-Infective Agents|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
75742423|NCT00815945|Drug|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
75742424|NCT00815945|Drug|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
75742425|NCT00820703|Drug|Nexagon®|
75742426|NCT00820703|Drug|Nexagon® vehicle|
75890199|NCT03673215|Drug|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
75890200|NCT02200172|Other|Melatonin|Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
75890201|NCT02200172|Other|Placebo|
75463095|NCT01871779|Other|Standard Treadmill Exercise|Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
75463096|NCT01871779|Other|Intermittent treadmill & resistance training|Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
75463097|NCT01871792|Drug|Pitavastatin|
75463098|NCT01871792|Drug|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
75463099|NCT01871818|Behavioral|Combined program|Combined program with physiotherapy, endurance training and resistance training
75463100|NCT01871818|Behavioral|Physiotherapy in private practice|Physiotherapy in private practice
75598185|NCT01003249|Drug|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
75742427|NCT00820781|Procedure|Portacaval shunt|Subject taken to the operating room and undergoes portacaval shunt surgery
75742428|NCT00820781|Procedure|Sclerotherapy|Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
75742429|NCT00644423|Drug|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
75742430|NCT00644423|Drug|Placebo|Matching Placebo
76072009|NCT03451916|Drug|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).
75742431|NCT00820859|Behavioral|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
76060923|NCT01560507|Drug|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
76060924|NCT01560507|Drug|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
75742432|NCT00820859|Behavioral|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
75742433|NCT04644497|Procedure|ACL-reconstruction|Surgery technique in skeletally immature patients
75890202|NCT03673137|Device|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
75890203|NCT03673137|Drug|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical [Hainan] Co., Ltd. Haikou, China] was administered by intravenous infusion at a dose of 1000 mg/m2.
75890204|NCT02066766|Other|No treatment given|Patients will fill out a questionnaire by interview.
75742434|NCT00812825|Drug|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
75742435|NCT00812825|Drug|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
75742436|NCT00812825|Drug|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
75890205|NCT02204540|Behavioral|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
75890206|NCT02066844|Drug|Celestone|2cc
75890207|NCT02066844|Drug|Lidocaine|5cc
76060925|NCT01560507|Drug|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
76060926|NCT03785470|Other|Fructose and physical inactivity|Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
76072010|NCT03435952|Drug|Pembrolizumab|200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.
75463101|NCT01871831|Device|6 blood glucose monitoring systems for self-testing|
75463102|NCT01871844|Drug|ITF2984 (500, 1000, 2000 mcg bid for 7 days)|
75463103|NCT01871844|Drug|octreotide 50 mcg tid|
75463104|NCT01871844|Drug|Placebo|
75463105|NCT01871857|Drug|Hypertonic saline and epinephrine|
75463106|NCT01871857|Drug|Normal saline and epinephrine|
75463107|NCT01871883|Procedure|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
75463108|NCT01871883|Procedure|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
75742437|NCT00812825|Drug|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
75742438|NCT00812825|Drug|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
75742439|NCT00820937|Procedure|Single photon emission computed tomography and Magnetic Resonance Imaging|
75742440|NCT00628355|Drug|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
75742441|NCT00628355|Procedure|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
75742442|NCT00627497|Procedure|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
75742443|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
75890208|NCT03669783|Drug|treatment Vincristin|1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
75890209|NCT03669783|Drug|treatment Actinomycin-D|1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
75890210|NCT03669783|Drug|treatment Doxorubicin|1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
75742444|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
75890211|NCT03669783|Drug|treatment Carboplatin|1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
75890212|NCT03669783|Drug|Etoposide|1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
75890213|NCT02204618|Device|cochlear implantation|
75890214|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
75890215|NCT02067078|Drug|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
75890216|NCT02067078|Drug|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
75890217|NCT02067078|Drug|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
75742445|NCT00627497|Device|Fusion|Posterolateral Interbody Fusion
76060927|NCT03591328|Diagnostic Test|Coronary CT angiography|"Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings."
75742446|NCT00648167|Drug|ferric citrate|ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
75742447|NCT00812903|Behavioral|Exercise|Training exercises chosen with background in knowledge of intelligent training
75742448|NCT03691623|Drug|EDP-938 Dose 1|Oral suspension for 5 days
76060928|NCT03694600|Diagnostic Test|Multi-analyte blood Test|intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
75742449|NCT03691623|Drug|EDP-938 Dose 2|Oral suspension for 5 days
75742450|NCT03691623|Drug|Placebo|Oral suspension for 5 days
75890218|NCT03673059|Drug|OTC Eczema Moisturizer Regimen|Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
76060929|NCT03690700|Other|BFRE|BFR will be performed in the aBFRE group by use of pneumatic occlusion cuffs placed proximally on the thigh close to the inguinal fold, using an occlusion pressure corresponding to 40 % of seated arterial occlusion pressure (AOP). The individual AOP will be documented at baseline using doppler ultrasound (Siemens ACUSON S2000TM). Previous studies have shown that this pressure level can promote significant muscle adaptations to a similar degree and are associated with significantly less discomfort than higher occlusion pressures. The occlusion pressure of the participants in sham BFRE group will be 10mmHg.
75598186|NCT01003249|Drug|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
75742451|NCT03691623|Drug|EDP-938 Dose 3|Oral suspension for 5 days
76060930|NCT03686566|Drug|13C-glucose|Includes standard pre-operation nursing care, 13C-glucose infusion and finger stick/IV glucose checks and storage of blood sample approximately every 30 minutes
76060931|NCT03686566|Other|No glucose infusion|Only includes standard pre-operation nursing care
76060932|NCT03684538|Other|Probiotics|Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
75742452|NCT03691623|Drug|EDP-938 Dose 4|Oral suspension for 5 days
75742453|NCT03691623|Drug|Placebo|Oral suspension for 5 days
76060933|NCT03684538|Other|Zinc|Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
75463109|NCT01871896|Device|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
75598187|NCT04297033|Drug|Lovastatin|lovastatin 40mg/d 12m
75742454|NCT00647699|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
75742455|NCT00647699|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
75742456|NCT00813059|Drug|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
76060934|NCT03684538|Other|Probiotics & Zinc|Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
75463110|NCT01871922|Drug|Placebo|Saline
75463111|NCT01871922|Drug|Atropine|Atropine
75598188|NCT04297033|Drug|Placebo|placebo
76060935|NCT03684538|Other|Standard care|initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
76060936|NCT03682978|Drug|Arbaclofen|Arbaclofen tablet.
75463112|NCT01871935|Drug|Remifentanil|Anaesthesia with remifentanil/propofol.
75463113|NCT01871935|Drug|Sufentanil|Anaesthesia with sufentanil/propofol
75598189|NCT01001767|Drug|Lovaza|Lovaza one gram twice a day for 24 weeks
75598190|NCT01001767|Drug|Placebo|Placebo
75598191|NCT04338295|Device|Tattoo machine (SOL Nova Device)|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
75742457|NCT01323075|Procedure|Truncal block|Patients will have a truncal block during hand or wrist surgery.
75742458|NCT00467649|Drug|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
75742459|NCT00467649|Drug|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
76060937|NCT03682978|Drug|Placebo|Placebo tablet.
76060938|NCT03676192|Drug|CT-16|15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
75742460|NCT00467649|Drug|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
76060939|NCT03676192|Drug|Avastin|15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
76060940|NCT01584843|Drug|GSK1358820|IM injection of Botulinum Toxin Type A
76060941|NCT03580408|Drug|Nivolumab|240 mg
76060942|NCT03580408|Drug|Vinblastin|6mg/m²
76072011|NCT03435952|Biological|Clostridium Novyi-NT|"Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8.~Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10^4 spores followed by dose escalation."
75742461|NCT01023945|Drug|ASP1941|oral
75742462|NCT01023945|Drug|Placebo|oral
75742463|NCT00450333|Drug|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
75742464|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
75742465|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
76060943|NCT01560429|Procedure|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
76060944|NCT01560429|Procedure|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
75598192|NCT04294537|Procedure|TAP Block|At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal oblique and transveralis fascia
75598193|NCT04294537|Procedure|LIA local infiltration|At the end of surgery 0,5% levobupivacaine 1.5 mg/kg, equally distributed between ports, injected in the skin and subcutaneous tissue during wound closure.
75598194|NCT04294537|Procedure|General anesthesia|"General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv."
75742466|NCT00450333|Drug|Dynepo|subcutaneous, Q2W for 24 weeks
75742467|NCT00643565|Drug|Standard chemotherapy|As prescribed
75742468|NCT00643565|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
76060945|NCT03895593|Other|rescue fecal microbiota transplantation|Fecal microbiota transplantation refers to the infusion of fecal microbiota from healthy donor into patients' gastrointestinal tract. The delivering ways for FMT include but are not limited to gastroscopy, colonoscopy, edema, nasogastric tube, transendoscopic enteral tube, and etc.
75742469|NCT00643487|Procedure|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
75742470|NCT00816179|Procedure|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
76060946|NCT01582971|Other|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
76060947|NCT04762732|Device|NPWT|Wound of ALT donor site will be cared under PREVENA™ Incision Management System for 5 days post-operatively.
75742471|NCT02551211|Procedure|blood drawn|blood drawn
75742472|NCT02551211|Procedure|surgical resection of cancer|
75742473|NCT00450255|Biological|ziv-aflibercept|Given IV
75742474|NCT00450255|Other|pharmacological study|Correlative studies
76060948|NCT04762732|Device|Traditional wound care|Wound of ALT donor site will be covered by vaseline gauze coated with tetracycline ointment (Genuine Chemical Pharmaceutical, Tao-Yuan, Taiwan), and layers of gauze.
75890219|NCT03673059|Other|Cosmetic Moisturizer Regimen|Subjects were assigned to use a non-fragranced, dry skin daily moisturizer twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group A) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
75890220|NCT05461235|Drug|Pembrolizumab|2mg/kg or 200mg,iv,q3w
75890221|NCT05461235|Drug|Nivolumab|3mg/kg or 240mg,iv,q2w
76060949|NCT03766750|Drug|LIMA association|1 coated tablet, oral, once a day.
76060950|NCT03766750|Drug|Tradjenta|1 coated tablet, oral, once a day.
75463114|NCT01871948|Other|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
75463115|NCT01871961|Drug|Methotrexate (Metoject® prefilled pen)|
75463116|NCT01871974|Drug|FK949E|oral
75598195|NCT04294537|Drug|Postperative analgesia|"During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours."
75463117|NCT01871987|Drug|FK949E|oral
75742475|NCT00816335|Procedure|PET/CT scan|For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
75742476|NCT00816335|Drug|18F-FDG Injection|Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
75742477|NCT00816335|Procedure|Preoperative 18F-FDG PET/CT Scan|Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
75890222|NCT05461235|Drug|Sintilimab|200mg,iv,q3w
75890223|NCT05461235|Drug|Toripalimab|3mg/kg or 240mg,iv,q2w
76060951|NCT03766750|Drug|Forxiga|1 coated tablet, oral, once a day.
76060952|NCT03576586|Behavioral|Brief computerized intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
76060953|NCT03576586|Behavioral|Attention placebo control|Brief cognitive task plus usual care in the maternity department
75463118|NCT01872000|Procedure|Cataract surgery|
75463119|NCT01872013|Drug|ASP7991|oral
75463120|NCT01872013|Drug|Placebo|oral
75463121|NCT01872026|Drug|ASP7991|oral
75463122|NCT01872039|Drug|Perdipine injection|IV
75463123|NCT01872052|Device|Acutus Medical System Mapping|Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
75463124|NCT01872065|Drug|ARC-520|
75463125|NCT01872065|Drug|Placebo|
75463126|NCT01872091|Other|cryotherapy by immersion|
75463127|NCT01872091|Other|Control group|
75890224|NCT05461235|Drug|Camrelizumab|200mg,iv,q2w or q3w;3mg/kg,iv,q3w
75890225|NCT05461235|Drug|Tislelizumab|200mg,iv,q3w
75890226|NCT05461235|Biological|NK-Cell or DC-Cell|50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10^6 cells/Kg) was completed on day 14.
75890227|NCT02204696|Procedure|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
75890228|NCT02070198|Drug|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
76060954|NCT04762810|Drug|Cyclophosphamide and glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
75742478|NCT00816335|Drug|18F-FDG for patients with Bladder Cancer|Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
76060955|NCT04762810|Drug|Glucocorticoids|Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
76060956|NCT03674242|Drug|eryaspase (L-asparaginase encapsulated in red blood cells)|IV infusion 100 U/kg
76060957|NCT03674242|Drug|Gemcitabine|IV infusion 1000 mg/m2
76060958|NCT03674242|Drug|Carboplatin|IV infusion AUC2
76060959|NCT04762654|Other|Modified Child Dental Anxiety Scale (MCDASf)|The MCDASf is self-reported dental anxiety measure effective among children aged 5-12 years.11 The scale has eight questions about 'going to the dentist generally,' 'having teeth examined,' 'teeth being scraped and polished,' 'injections in the gum,' 'fillings,' 'having a tooth taken out,' 'being put to sleep for treatment,' and 'having a mixture of gas and air that will help you feel comfortable for treatment but will not make you sleep.' The scores of each question ranged from 1 'relaxed' to 5 'very worried.' The scores are also represented by cartoon faces varied according to emotions and anxiety levels. The total scores can range from 8 to 40.
76060960|NCT04762108|Other|Standard of care|Patients will be given standard of care as per their clinical needs
75598196|NCT04296721|Behavioral|Intensive weigh-loss program|Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.
75598197|NCT04296721|Behavioral|Standard Dietary recommendations|Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
75598198|NCT04294615|Other|FMT through a naso-jejunal tube|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
75890229|NCT02070198|Drug|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
75890230|NCT02070198|Drug|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
75890231|NCT03672981|Behavioral|Exercise Intervention|Undergo resistance training program and cardiovascular exercise
75890232|NCT03672981|Other|Quality-of-Life Assessment|Ancillary studies
75890233|NCT03672981|Other|Questionnaire Administration|Ancillary studies
75890234|NCT03672981|Behavioral|Telephone-Based Intervention|Participate in phone calls with exercise physiologist
75890235|NCT02208674|Other|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
75890236|NCT03672903|Device|Weight Vest|A vest with added weights up to a maximum of 15 kg.
76060961|NCT04761952|Drug|azathioprine|daily orally
76060962|NCT04761952|Drug|infliximab|intravenously, at 0, 2,6 weeks with every 8-week-interval later
76060963|NCT04761952|Drug|N-3 Polyunsaturated Fatty Acids|Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E&DHA-E; per capsule one at a time, Three times a day.
76060964|NCT03760432|Procedure|Laser Custom Corneal Collagen Cross-Linking|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for smoothing the anterior corneal surface and removing any present opacities. The surgeon uses the OCT data to plan treatment parameters while preserving at least 360 microns of residual corneal stroma using a phototherapeutic keratectomy procedure. After the laser procedure, adjunctive MMC or saline solution will be applied to the cornea in accordance with the group to which the treated eye is randomized. The CXL procedure is then performed following the FDA-approved CXL regimen by Avedro, Inc.
76060965|NCT03673072|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
76072012|NCT03435952|Drug|Doxycycline|Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
75890237|NCT02067156|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
75890238|NCT04058613|Drug|ALB Protein, Human|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
76060966|NCT03673072|Drug|Cisplatin|Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
76060967|NCT03673072|Procedure|Oncologically radical margin-free (R0) resection|Oncologically radical margin-free (R0) resection
76060968|NCT03673072|Drug|Adjuvant chemotherapy|Can be selected by Investigator's Choice
76060969|NCT01677208|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
75742479|NCT00816335|Procedure|Surgical Procedure|Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
75598199|NCT04294615|Other|FMT through TET|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
75598200|NCT02871037|Drug|PF-05221304|Single or repeated, escalating dose of PF-05221304
75598201|NCT02871037|Other|Placebo|single or repeated dose of placebo
75598202|NCT04295629|Procedure|Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia|The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
75890239|NCT04058613|Other|placebo|placebo
75890240|NCT02067234|Other|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
75890241|NCT02067234|Behavioral|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
76060970|NCT01677208|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
75598203|NCT04295629|Procedure|Ilioinguinal nerve block|Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
75890242|NCT02801747|Behavioral|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
76060971|NCT01677208|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
76060972|NCT01690299|Drug|Apremilast|Apremilast 30 mg tablet orally BID
76060973|NCT01690299|Drug|Etanercept|Etanercept 50 mg evaluator/subject-blinded SC QW injection
76060974|NCT01690299|Drug|Placebo tablet|Placebo tablets BID
76060975|NCT01690299|Drug|Placebo injection|Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
75890243|NCT03533270|Procedure|Urethroplasty|Surgical repair of Urethral injury
75890244|NCT03671499|Behavioral|Social Cognitive Theory based text messages|Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
75890245|NCT02070432|Drug|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
75890246|NCT02208752|Other|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
76060976|NCT03570814|Drug|Administration of Albendazole on Day 1|Participants will receive Albendazole 400mg on study day 1.
75890247|NCT02067312|Other|Thai massage|
76060977|NCT03570814|Drug|Administration of Ivermectin on Day 1|Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
75890248|NCT02200406|Drug|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
76060978|NCT03570814|Drug|Administration of Azithromycin on Day 1|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
76060979|NCT03570814|Drug|Administration of Azithromycin on Day 15|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
75890249|NCT03782298|Device|Spyromite, Dynomite, Raptomite, Footprint Ultra PK SL|Observational, post-market, clinical follow-up study
75890250|NCT02204852|Drug|Iloprost+eptifibatide|
76060980|NCT00723736|Drug|Desloratadine|2.5 ml (1.25 mg) once daily
76060981|NCT00305344|Procedure|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
76060982|NCT00305344|Biological|Cord blood|Develop Cord blood vaccine
75742480|NCT00816335|Procedure|Specimen PET/CT Scan|Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
75742481|NCT00450177|Drug|Ferrous Sulfate|Iron group
75742482|NCT00450177|Drug|Placebo Oral Tablet|Placebo group
75742483|NCT00816569|Device|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
75890251|NCT02204852|Drug|Placebo|
75890252|NCT02071836|Behavioral|Right Turns web application|
75890253|NCT02071836|Behavioral|Treatment as usual|
75890254|NCT02204930|Drug|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
75890255|NCT02200484|Behavioral|Combined parent training and obesity prevention program|
75890256|NCT02200484|Behavioral|Wellness program (active contact control)|
75890257|NCT02070510|Drug|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
75890258|NCT02070510|Drug|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
75890259|NCT02070510|Drug|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
75890260|NCT02070510|Drug|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
76060983|NCT03569566|Other|Age, Genes, Training, Tickbourne Disease and Endurance|Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
76060984|NCT01690143|Drug|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
76060985|NCT01690143|Drug|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
76060986|NCT05347498|Drug|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
75890261|NCT02258126|Other|Multidisciplinary intervention program|"Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
76060987|NCT05347498|Drug|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
75598204|NCT04282681|Other|Accelerometer Live-Streaming Tool|The only 'intervention' that will take place is the placement of the XLS tool(s) on the upper left chest and/or left wrist of the patient.
75742484|NCT00813137|Drug|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1~7, D15~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
75742485|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on saturated fat.
75890262|NCT02070666|Behavioral|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure < 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~Fraction of inspired oxygen inspired oxygen fraction (FiO2) > 0.21 to maintain oxygen saturation 90-92%.~PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~Plateau pressure ≤ 25 cmH2O"
75890263|NCT02070666|Behavioral|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~· FiO2 > 0.21 to maintain oxygen saturation 90-92%.~PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~Plateau pressure ≤ 25 cm H2O."
75890264|NCT02070666|Other|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
76060988|NCT05347420|Diagnostic Test|The visual Neuropad test and the quantitative Neuropad test|The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.
76060989|NCT03669250|Drug|CVN058|3-way crossover
75598205|NCT01306032|Drug|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
75890265|NCT02200562|Drug|ipilimumab and dabrafenib|
75890266|NCT02205008|Procedure|surgery|Total or subtotal gastrectomy with D2
75890267|NCT02205008|Drug|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (<1.25m2:40mg, 1.25-1.5m2:50mg, >1.5m2:60mg, bid)
75598206|NCT01306032|Drug|Cyclophosphamide|
75598207|NCT01263015|Drug|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
75598208|NCT01263015|Drug|Atripla|Atripla once daily on an empty stomach
75598209|NCT01263015|Drug|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
75890268|NCT02205008|Drug|Early postoperative intraperitoneal chemothgerapy|"operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq"
75890269|NCT02067546|Device|Experimental toilet seat|
75890270|NCT02067546|Device|Standard toilet seat|
76060990|NCT03669250|Drug|Placebos|Placebo
75598210|NCT01263015|Drug|Abacavir/Lamivudine Placebo|matching placebo taken once daily
75742486|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
75742487|NCT01024023|Device|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
75890271|NCT02067624|Other|Thai massage|
75890272|NCT02208908|Other|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
75890273|NCT02072070|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
75890274|NCT02072070|Drug|Placebo|Placebo control(Normal Saline)
75890275|NCT02205086|Other|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
75890276|NCT02200640|Drug|High dose of Micardis®, once daily|
75742488|NCT00816647|Procedure|Patellofemoral stabilizing surgery|Comparison of surgical techniques
76060991|NCT03553732|Other|Registry|Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
76060992|NCT03668938|Other|Occupational Therapy|The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
75742489|NCT01024179|Device|Polymer-based sirolimus-eluting stent (Partner stent )|Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
75890277|NCT02200640|Drug|Low dose of Micardis®, once daily|
75890278|NCT02200640|Drug|Low dose of COZAAR®, once daily|
76060993|NCT03668938|Other|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
75598211|NCT01263015|Drug|Dolutegravir placebo|matching placebo taken once daily
75598212|NCT01263015|Drug|Atripla placebo|matching placebo taken once daily on an empty stomach
75890279|NCT02200640|Drug|High dose of COZAAR®, once daily|
75890280|NCT02200640|Drug|Placebo|
75890281|NCT02067702|Procedure|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
75890282|NCT02200718|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
75598213|NCT04323267|Device|Limber Digital Application|A mobile application was recently developed to address these needs. The application provides evidence-based, symptom specific home-exercise video programs for MSK conditions, as well as clinically-validated outcome measures for tracking progress.
75598214|NCT04323267|Behavioral|Physical therapy Therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
75598215|NCT04322877|Procedure|Temporary pacing Study|Temporary delivery of CRT
75742490|NCT00821483|Drug|Frovatriptan|2.5mg, qd
75598216|NCT04322877|Radiation|Thoracic CT|As part of non-invasive mapping protocol
75598217|NCT04322877|Diagnostic Test|Acute hemodynamic study|Measurement of invasive dP/dTmax
75598218|NCT04322877|Diagnostic Test|Non-invasive body surface mapping|Cardioinsight body surface mapping
75598219|NCT04322877|Diagnostic Test|Invasive catheter-based mapping|Invasive electroanatomical mapping
75742491|NCT01021995|Drug|echinacea|drops, 0.9 ml, tid for 4 months
75890283|NCT02200718|Biological|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
75890284|NCT02070900|Device|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
75890285|NCT02070900|Other|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
75890286|NCT02208986|Drug|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
75890287|NCT02200796|Other|Control Meal|High carbohydrate meal
75890288|NCT02200796|Other|Low Protein Meal|Omelet with 15 g of protein
75890289|NCT02200796|Other|Moderate Protein Meal|Omelet with 30 g of protein
75890290|NCT02200796|Other|High Protein Meal|Omelet with 45 g of protein
75890291|NCT02067780|Drug|Levofloxacin 500mg|One tablet per day for 7days.
75890292|NCT02205164|Drug|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
76072013|NCT03421145|Device|3M™ Oral Rinse|The Investigational Rinse contains a sugar-based surfactant using a proprietary formula. The intended use of the product is to help prevent and reduce plaque accumulation on the teeth and related gum-tissue inflammation (gingivitis).
76072014|NCT03421145|Other|Vehicle Control Oral Rinse|The Placebo Comparator oral rinse is similar to the Experimental Oral Rinse only it does not contain the active ingredient.
76072015|NCT03421145|Device|PerioShield™ Oral Health Rinse|PerioShield™ Oral Health Rinse (0.2% delmopinol hydrochloride) is marketed in the US and was purchased for use in this study.
75742492|NCT01021995|Drug|placebo|drops, 0.9 ml tid for 4 months
75742493|NCT02551367|Drug|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
75742494|NCT02551367|Drug|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
75890293|NCT02205164|Drug|Palonosetron|Aloxi 0.25mg
76060994|NCT03567850|Behavioral|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
75598220|NCT04322799|Procedure|Device: Randomization between prosthetic components|Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
75890294|NCT02072304|Behavioral|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
76072016|NCT03421145|Other|Water|Purified bottled water containing no active ingredients.
75742495|NCT02551367|Drug|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
75742496|NCT00813371|Device|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
75598221|NCT04322175|Drug|Meloxicam|Meloxicam Eye Drops
75742497|NCT00813371|Device|ARDSnet protocol|ARDSnet protocol
75598222|NCT01305564|Device|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
75742498|NCT03848949|Device|Evenup|Orthotic which increases effective leg length.
75742499|NCT00821561|Drug|Nexagon®|
75742500|NCT00821561|Drug|Nexagon® vehicle|
75742501|NCT00821639|Behavioral|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
75742502|NCT00813449|Drug|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
75598223|NCT04322331|Other|no intervention|no intervention
75742503|NCT00813449|Drug|dacarbazine plus placebo (control group)|dacarbazine plus placebo
75742504|NCT00816725|Behavioral|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
75598224|NCT04322253|Drug|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
75598225|NCT04324671|Device|nasofibroscopy|"Flexible videorhinolaryngoscope, PAL 11101VP*, 4.2 mm diameter. Using a computerized system including:~Light source: Explor ENT (HAL250). The software allowed audio, video recording and retrieval of recorded material."
75598226|NCT04322409|Device|Neuromuscular Electrical Stimulation|"5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session."
75742505|NCT00821717|Drug|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
75742506|NCT00821717|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
75742507|NCT00822029|Drug|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
75890295|NCT02072304|Behavioral|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
75742508|NCT00822029|Other|PLACEBO|patient receiving one tablet (oral use) placebo by week
75742509|NCT00816803|Procedure|Autologous bone marrow transplant|
75890296|NCT02257814|Behavioral|Incredible Years Teacher Training|
76060995|NCT03668626|Other|Family-centered intervention program (FCIP)|This program included in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention emphasized modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.
76060996|NCT01677364|Drug|Oxytocin|Arm - Induction of labour
76060997|NCT03566524|Dietary Supplement|Citrulline|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
76060998|NCT03566524|Dietary Supplement|Alanine|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
76060999|NCT03563248|Drug|FOLFIRINOX|"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
76061000|NCT03563248|Drug|Losartan|Losartan is a drug that is used to lower blood pressure
76061001|NCT03563248|Drug|Nivolumab|Nivolumab is an antibody that may cause programmed cell death of cancer cells
75890297|NCT02257814|Behavioral|Preschool PATHS|
76061002|NCT03563248|Radiation|SBRT|Radiation therapy is believed to increase the likelihood of response of immunotherapy
76061003|NCT03563248|Procedure|Surgery|definitive surgical resection
75598227|NCT04322409|Device|Transcutaneous Electrical Nerve Stimulation|5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
75598228|NCT04321785|Other|Placebo|placebo capsule (mannitol)
75598229|NCT04321785|Other|Caffeine|caffeine capsule (80 mg of caffeine plus mannitol)
75598230|NCT05648175|Behavioral|e-CBT|The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.
75598231|NCT05648175|Behavioral|e-CBT + Phone Call|In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.
75598232|NCT05648175|Behavioral|e-CBT + Phone Call + Pharmacotherapy|In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.
75598233|NCT01305408|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
75598234|NCT01305408|Drug|Placebo|Matching placebo tablets, taken orally, once daily in the morning
75598235|NCT01261611|Biological|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
75598236|NCT01261611|Biological|Botulinum toxin type A|I.M. injection on day 1 of treatment cycle 1.
75598237|NCT01261611|Drug|Placebo|I.M. injection on day 1 of treatment cycle 1.
75742510|NCT00816803|Procedure|Physical therapy|
75742511|NCT00467259|Drug|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
75890298|NCT02257814|Behavioral|Tools of the Mind|
75890299|NCT03559998|Other|lecture|"Empathy (1 hour)~Doctor- patient relationship (1, 5 hour)"
75890300|NCT03559998|Other|Simulation using Role play|"serious illness announcement~abuse demand management~reticent patient management"
75890301|NCT03559998|Other|Discussion group|Share about clinical work experience and elaboration about psychoaffective and relational challenge
75890302|NCT03559998|Other|Simulation using Simulated patient|"HIV announcement~Refuse of antibiotic prescription"
75890303|NCT02076282|Other|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast"
75890304|NCT02200952|Drug|recombinant LH|recombinant LH twice/day for 10 days from pick up
76061004|NCT03663400|Diagnostic Test|GWAS analysis by Illumina BeadChip|will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
76061005|NCT04403776|Drug|tofacitinib MR 11 mg|Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
75890305|NCT02071212|Drug|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
75890306|NCT03396770|Procedure|Standard clinical routine|Patient management is carried out according to the usual service protocol
76061006|NCT04403776|Drug|tofacitinib IR 5 mg|Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
76061007|NCT03559348|Drug|chemotherapy: TS-1, Leucovorin and Gemcitabine|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
76061008|NCT01679938|Behavioral|primary obesity prevention|"Training of child care providers.~Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
76061009|NCT03541018|Procedure|Type of repositional maneuvre|Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
76061010|NCT04762030|Drug|Durvalumab Anlotinib Carboplatin Nab-paclitaxel|"Neoadjuvant treatment (durvalumab+carboplatin+nab-paclitaxel + anlotinib) will start within 1-3 days from enrollment. 2 cycles will be administered at 21-day (+/- 3 days) intervals (QW3). Then, two cycles of combined durvalumab and anlotinib (QW3) will be administered prior to surgery. Before surgery, a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 5rd-7th week from day 1 cycle 4 of neoadjuvant treatment (day 35-49 after day 1 of cycle 4). Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Twelve cycles of durvalumab adjuvant treatment (Q4W) will be administered."
76061011|NCT04761874|Other|Telestroke|In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
76061012|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
76061013|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
76061014|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
75890307|NCT03396770|Procedure|Nephrocheck test|"Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass~If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated.~If the test is negative, patient management is carried out according to the usual protocol.~A second test is realized 6 hours after the first test whatever the result of it."
76061015|NCT01559259|Drug|Ibuprofen|Two caplets of ibuprofen 200 mg
76061016|NCT01559259|Drug|Placebo|Two caplets of placebo
76061017|NCT01679548|Procedure|Single-port LAVH|LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
75890308|NCT02072382|Drug|Metformin|metformin 850mg twice a day for eight weeks
75890309|NCT02072382|Drug|Placebo|
75890310|NCT02209220|Device|Positive airway pressure for the treatment of OSA|
76061018|NCT01679548|Procedure|Three-port LAVH|Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
76061019|NCT03538912|Other|Biomarker strategy|EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
75890311|NCT02072460|Other|electromyography|
75890312|NCT02072460|Other|electroencephalography|
75890313|NCT02072460|Other|approaches from psychophysics|
75742512|NCT00467259|Drug|Placebo patch|placebo patch, changed twice a week for 52 weeks
75742513|NCT00816881|Device|flutter mucus clearance device|five minutes every session, four sessions per day
75742514|NCT01022151|Drug|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L [group P]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
75890314|NCT02205242|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
75890315|NCT02205242|Device|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
76061020|NCT03538912|Other|Routine strategy|EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
75742515|NCT01022151|Drug|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL [group A2]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
75742516|NCT01022151|Drug|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL [group A3]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
75890316|NCT02205242|Drug|Placebo|
75890317|NCT02071368|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
75890318|NCT02071368|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
75890319|NCT02071368|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
75890320|NCT02071368|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
76061021|NCT03537118|Procedure|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
75890321|NCT02205320|Biological|DRL_PG|
75890322|NCT02205320|Biological|Pegfilgrastim Form A|
75890323|NCT02205320|Biological|Pegfilgrastim Form B|
75890324|NCT02076360|Behavioral|Preoperative Video|Patients will watch preoperative instructional video
75890325|NCT03402841|Drug|Olaparib|300 mg twice daily - oral
75890326|NCT02209298|Device|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
75890327|NCT02072616|Other|Pancreatic adenocarcinoma diagnosis|
75890328|NCT02209376|Biological|CART-EGFRvIII T cells|
75890329|NCT02072694|Other|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
76061022|NCT03088306|Drug|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
75742517|NCT01022151|Drug|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL [group A4]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
75598238|NCT04321629|Combination Product|autologous adipose tissue transfer|experimental group: liposuction, adipose tissue preparation and intra-articular injection
75598239|NCT04321629|Combination Product|PRP injections|control group: blood collection, blood preparation and intra-articular PRP injection
75598240|NCT04321863|Other|Faecal calprotectin (FC)|FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).
75742518|NCT01022151|Drug|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL [group A5]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
75742519|NCT01022151|Drug|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL [group D]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
75742520|NCT01022229|Dietary Supplement|Compound Natural Health Product|"15-35 mg zinc citrate~150-350 mg magnesium lactate~30-70 mg pyridoxine hydrochloride~150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
75742521|NCT01022229|Dietary Supplement|Placebo|Placebo
75890330|NCT02072694|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
75890331|NCT02205398|Drug|INC280|
75890332|NCT02205398|Drug|cetuximab|
75890333|NCT02071524|Drug|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
75890334|NCT02071524|Drug|Cristalloid administration|Only Ringer Lactate administration
75890335|NCT02220608|Biological|Bortezomib|
75890336|NCT02220608|Drug|G-CSF|
75890337|NCT02076438|Dietary Supplement|Probiotics|Randomized to receive probiotics or placebo
75890338|NCT02209688|Drug|ESR 1150 CL|
75890339|NCT02209688|Drug|Placebo|
75890340|NCT02076516|Device|Drug-eluting stent: CORACTO®|
75890341|NCT02220686|Behavioral|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
75890342|NCT03630367|Drug|Dexamethasone|Intramuscular injection 8 mg
75890343|NCT03630367|Drug|L-Carnitine 1G/5mL Injection|slow intravenous injection
75890344|NCT02258282|Drug|Etanercept|
75890345|NCT02258282|Drug|Control|
75890346|NCT01376869|Dietary Supplement|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
75890347|NCT01376869|Other|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
75890348|NCT02076594|Drug|Docetaxel|Powder for solution for infusion
75890349|NCT02076594|Drug|Epirubicin|Solution for infusion
75890350|NCT02076594|Drug|Oxaliplatin|Powder for solution for infusion
75890351|NCT02076594|Drug|Capecitabine|Film coated tablets
76061023|NCT03088306|Drug|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
76061024|NCT03088306|Drug|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
76061025|NCT03088306|Drug|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
76061026|NCT03088306|Drug|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
75742522|NCT01027455|Device|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
76061027|NCT03088306|Drug|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
76061028|NCT03088306|Drug|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
76061029|NCT03088306|Drug|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
76061030|NCT01672762|Drug|ipragliflozin|oral
76061031|NCT03088384|Drug|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
76061032|NCT01677598|Drug|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
76061033|NCT01676350|Procedure|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
76061034|NCT01677754|Drug|RO4602522|Participants will receive RO4602522 orally once daily for 12 months.
76061035|NCT01677754|Drug|Placebo|Participants will receive placebo for RO4602522 orally once daily for 12 months.
75742523|NCT01027455|Procedure|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
75890352|NCT02258360|Other|Therapeutic hypothermia|Therapeutic hypothermia with a target temperature between 32-34°C.
75890353|NCT04175509|Drug|Rectal acetaminophen|Rectal 1300mg
75890354|NCT04175509|Drug|Intravenous acetaminophen|Intravenous 1000mg
75890355|NCT02220842|Drug|Atezolizumab|During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
75890356|NCT02220842|Drug|Obinutuzumab|During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
76061036|NCT01677754|Drug|Donepezil|Stable dose as background medication
76061037|NCT01677754|Drug|Memantine|Stable dose as background medication in combination with AChEIs
76061038|NCT01677754|Drug|Rivastigmine|Stable dose as background medication
76061039|NCT01677754|Drug|Galantamine|Stable dose as background medication
76061040|NCT03419572|Other|Data collection|Only available evaluations as decided by the investigator based on local clinical practice will be collected.
76061041|NCT01670032|Drug|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
75742524|NCT01027455|Procedure|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
75742525|NCT01566045|Procedure|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
75742526|NCT01566045|Procedure|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
75890357|NCT02220842|Drug|Tazemetostat|Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
76061042|NCT01670032|Drug|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
76061043|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
76061044|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
75598241|NCT04321863|Other|quantitative Faecal Immunochemical Testing (qFIT)|Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).
75598242|NCT04321863|Other|Serum and faecal zinc|Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
75742527|NCT01566123|Radiation|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
75890358|NCT02072850|Device|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
76061045|NCT03088228|Diagnostic Test|gingival crevicular fluid collection|
75890359|NCT02072850|Other|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (< 12 hours, days 2, 7-10 and at 6 months).
75890360|NCT02205554|Drug|Omnitram|Nine 20 mg doses administered every 6 hours
75890361|NCT02205554|Drug|Tramadol|Nine 50 mg doses administered every 6 hours.
75890362|NCT02205554|Drug|Placebo|Nine doses administered every 6 hours.
75890363|NCT02076672|Drug|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
75890364|NCT02076750|Dietary Supplement|Vitamin D3 (cholecalciferol)|
75890365|NCT05262608|Drug|Olaparib|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily
75890366|NCT02073006|Dietary Supplement|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
75890367|NCT02205632|Device|MPS II|
75598243|NCT04321707|Radiation|15O-H2O PET/MR|All included patients will have a 15O-H2O PET/MR scan performed at baseline and a scan performed after NAC, prior to cystectomy.
75890368|NCT01380457|Drug|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
75890369|NCT01380457|Drug|Marinol|Capsules, 10 mg, single-dose, fasting conditions
75890370|NCT02071602|Drug|CD-NP|Randomized 1:1:1
75890371|NCT02205710|Other|Computerized cognitive training|
75890372|NCT02205710|Other|Computerized games|
75890373|NCT05159089|Behavioral|Socioecological model apply to reduce physical activity drop out in type 2 diabetes patients|"To implement this model this intervention aims to address three key elements: 1) prepare the user; 2) structure the action; and 3) design the context.~These goals will be worked in each session of Nordic Walking during the warm-up and cool-down and, if necessary, during the session (as long as it's non-stop or slowing down)."
75890374|NCT05159089|Behavioral|Nordic Walking|Sessions will be progressive: the first month will long 30 minutes, the second month 35 minutes, and the third month 40 minutes (without 10 minutes warm-up and 10 minutes cool-down each session). The track will not have more than 100 accumulate high and will allow doing 5 kilometers without stopping. The meeting point will be between the Biomedical Research Park (Barcelona) and Hospital del Mar (nearby CAP Sant Joan). All sessions will be conducted by an instructor of nordic walking physiotherapists.
75890375|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|"A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point."
76061046|NCT01670500|Drug|Cisplatin|administered intravenously every 3 weeks for 4 doses
76061047|NCT01670500|Drug|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
75598244|NCT04321083|Diagnostic Test|INVOS|INVOS monitoring brain o2 saturation
75598245|NCT04321161|Drug|Bicanorm|"Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)"
75742528|NCT01566123|Radiation|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
75742529|NCT00449865|Drug|creatine|"Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo."
75742530|NCT00449865|Other|placebo|an inactive substance
75742531|NCT00449787|Drug|Sumatriptan 100 mg|Sumatriptan 100mg tablet
75742532|NCT00449787|Drug|Naproxen|Naproxen 500mg tablet
75742533|NCT01566201|Drug|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
75742534|NCT01566201|Drug|placebo|water for injection
75742535|NCT01566279|Drug|Everolimus|All patients will receive everolimus 10mg q.d.
75742536|NCT00449163|Biological|Bevacizumab|
75742537|NCT00449163|Drug|Floxuridine|
75890376|NCT05239052|Other|computer task intervention|subject received programs for upper arm movement training with providing computer screen task activities
75598246|NCT04207125|Behavioral|Multilevel psychotherapeutic intervention programme|"Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes."
75598247|NCT04320771|Drug|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
75598248|NCT04320693|Drug|IMMU-132|IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles
75742538|NCT00449163|Drug|Irinotecan|
75598249|NCT05555433|Other|NO INTERVENTION|no intervention
75598250|NCT05554107|Other|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists and/or physicians with special interest in POTS.
75742539|NCT00449163|Drug|Leucovorin|
75742540|NCT01026987|Drug|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
75890377|NCT05239052|Other|conventional long-term care services|stroke subjects with wheelchair users receive conventional long-term care services
75742541|NCT01026987|Drug|AMD3100|
75742542|NCT01026987|Procedure|Leukapheresis|
75742543|NCT01026987|Procedure|Stem Cell Infusion|
75890378|NCT05138107|Other|Synochi Scar Spray Cosmetic|Application of the cosmetic on each skin graft in a blinded fashion in different sections for a 9 month duration.
75742544|NCT00448539|Drug|Rufinamide|Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
75742545|NCT01024257|Radiation|beta-irradiation|
75742546|NCT01024257|Procedure|conjunctival autograft|
75742547|NCT00457665|Drug|Nelfinavir|
75742548|NCT00457665|Drug|Efavirenz|
75890379|NCT05138107|Other|Synochi Scar Spray Placebo|Application of the placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.
75890380|NCT02071758|Biological|LEISH-F3 + SLA-SE|
76061048|NCT01670500|Drug|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
75742549|NCT00447603|Drug|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
75890381|NCT02071758|Biological|LEISH-F3 + GLA-SE|
75890382|NCT01380301|Drug|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
75742550|NCT00447603|Drug|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
75742551|NCT00447603|Drug|Placebo for Losartan|
75742552|NCT00447603|Drug|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
75742553|NCT00447057|Drug|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
75742554|NCT00447057|Drug|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
75742555|NCT00447057|Drug|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
75742556|NCT00447057|Drug|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
75890383|NCT01380301|Drug|Miltefosine alone|short course (half)
76061049|NCT01678612|Other|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
76061050|NCT03525574|Drug|VX-445|Fixed-dose combination (FDC) tablets (VX-445/TEZ/IVA)
76061051|NCT03525574|Drug|TEZ|FDC tablets (VX-445/TEZ/IVA)
76061052|NCT03525574|Drug|IVA|FDC tablets (VX-445/TEZ/IVA)
76061053|NCT03525574|Drug|IVA|IVA tablet
75890384|NCT02205866|Other|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
75890385|NCT02076828|Drug|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
75598251|NCT00624039|Other|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
75598252|NCT05523141|Drug|ASC10|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner"
75598253|NCT05523141|Drug|Placebo|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner"
75598254|NCT01304706|Drug|Fluocinolone Acetonide|0.2 μg/day
75598255|NCT05661240|Device|Tumor treating fields（EFE-P100）|Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.
75598256|NCT05661240|Drug|Docetaxel injection|Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.
75742557|NCT01027533|Other|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
75742558|NCT01027611|Drug|proparacaine HCL 0.5%|
75890386|NCT02076828|Drug|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
75890387|NCT02076828|Drug|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
75890388|NCT02221076|Device|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
75890389|NCT02076984|Procedure|Laparoscopic incisional or ventral hernia repair|
75598257|NCT05661162|Device|CR 500™ SINGLE-DOSE GEL|CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
75598258|NCT04324866|Diagnostic Test|Nasopharyngeal swab|Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
75890390|NCT05078359|Diagnostic Test|Prostate Magnetic resonance Imaging|Magnetic resonance imaging (MRI) uses a magnetic field, radiofrequency pulses, and a computer to produce detailed pictures of the organ. Prostate MRI evaluate the presence and extent of prostate cancer and determine whether it has spread around the organ
75890391|NCT02221154|Dietary Supplement|Inofolic®|
75890392|NCT02221154|Other|Gonadotropins; Folic Acid|standard ovarian stimulation
75598259|NCT00624117|Behavioral|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
75598260|NCT05370651|Device|BTL Emsella Chair|Subjects will sit on the device. The RNC will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
75598261|NCT02889003|Drug|Pioglitazone + TKI|
75598262|NCT01303380|Drug|Canakinumab|
75598263|NCT01008553|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
75742559|NCT01027611|Drug|proparacaine HCL 0.5% + 4% lidocaine solution|
75742560|NCT01027611|Drug|3.5% viscous lidocaine gel|
75742561|NCT01024413|Drug|erlotinib|study arm.erlotinib 150 mg oral till disease progression
75742562|NCT01024413|Drug|gefitinib|study arm.gefitinib 250 mg oral till disease progression
75742563|NCT03577587|Dietary Supplement|Silitidil for 21 days|daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
75742564|NCT03577587|Dietary Supplement|Placebo for 21 days|daily ingestion of Placebo preparation over time period of 3 weeks
75742565|NCT00446511|Drug|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
75742566|NCT00446511|Drug|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
75742567|NCT00446511|Drug|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
76061054|NCT03418402|Device|Airseal®|Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
75598264|NCT01008553|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
75598265|NCT00623454|Behavioral|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
75598266|NCT05137041|Device|ITP FIRTECH|Infrared Therapy Patch
75742568|NCT00446511|Drug|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
75742569|NCT01024491|Drug|paroxetine|daily dose of paroxetine 15mg for 12 weeks
75742570|NCT01024491|Drug|paroxetine|active daily treatment with paroxetine 20 mg
75463128|NCT01872104|Procedure|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
75742571|NCT01024491|Drug|placebo|active daily treatment with placebo
75890393|NCT02079870|Drug|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
75890394|NCT02079870|Drug|placebo|Solution for subcutaneous (s.c. - under the skin) injection
75890395|NCT01378897|Device|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
75890396|NCT02209844|Drug|BI 44847|
75890397|NCT02209844|Drug|Placebo|
76061055|NCT03418402|Device|Standard insufflator|Standard insufflator
75890398|NCT02073084|Drug|K-877 Low Dose|K-877 Low Dose
75890399|NCT02073084|Drug|Moxifloxacin|
75598267|NCT05014503|Other|Adaptive Therapeutic gaming|All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
75742572|NCT00446199|Drug|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
75742573|NCT00446199|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
75742574|NCT00446199|Drug|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
75742575|NCT00446199|Drug|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
75890400|NCT02073084|Other|Placebo|
75890401|NCT02073084|Drug|K-877 High Dose|K-877 High Dose
75890402|NCT03899701|Procedure|PEC I and PEC II blocks|Participants will get a PEC I block with 10ml of 0.375% ropivacaine and a PEC II block with 20ml of 0.375% ropivacaine using ultrasound guidance.
75890403|NCT02221388|Drug|BI 671800 HEA, 200 mg tablets|
75890404|NCT02221388|Drug|BI 671800 HEA EC, 200 mg tablets|
76061056|NCT03087682|Diagnostic Test|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
76061057|NCT03087526|Genetic|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
76061058|NCT02405260|Drug|TTP399 400 mg|once daily
76061059|NCT02405260|Drug|TTP399 800 mg|once daily
75742576|NCT01027689|Drug|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
75742577|NCT01027689|Drug|alprazolam test sublingual tablet|1 mg tablet, single dose
75890405|NCT02221388|Drug|BI 671800 HEA, 50 mg tablets|
75890406|NCT02221388|Drug|BI 671800 ED, 100 mg capsules|
75890407|NCT02221388|Other|Standard meal|
75890408|NCT03787849|Drug|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
75890409|NCT03787849|Drug|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
75890410|NCT02073240|Behavioral|Enhanced TB IC Package|"Facilities randomized to the intervention group will receive:~Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility~Audits and Feedback of performance~A TB IC collaborative membership~A standardized unit-level daily checklist of critical IC activities"
75890411|NCT05262218|Drug|PBF-680 10mg|PBF-680 10mg administered orally once a day
75742578|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
75890412|NCT05262218|Drug|Placebo|Placebo administered orally once a day
75890413|NCT03669705|Procedure|Omitting axillary surgery in early breast cancer|Before the Sentinel Node era all invasive breast cancer was recommended to have axillary dissection but after the introduction of national breast cancer screening this guideline statement was challenged by this national Swedish cohort.
75890414|NCT03671343|Behavioral|Physical rehabilitation|It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
75890415|NCT02205944|Other|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg & Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
75890416|NCT03671265|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
75890417|NCT03671265|Radiation|IMRT or VMAT|The IMRT or VMAT technique was used in our study.
75890418|NCT03671265|Drug|Apatinib|Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
75890419|NCT02077218|Procedure|computed tomography|Undergo cardiac CT
75890420|NCT02077218|Other|cytology specimen collection procedure|Undergo collection of blood samples
75890421|NCT02077218|Other|laboratory biomarker analysis|Correlative studies
75890422|NCT02077218|Other|questionnaire administration|Ancillary studies
75890423|NCT03729427|Procedure|Erector Spinae Plane Block|Erector Spinae Plane block for patents undergoing rib cartilage grafting surgeries
75890424|NCT03671187|Other|Exercise|8 week exercise program
75890425|NCT02073318|Other|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
75890426|NCT02073318|Other|Upper extremities exercise|"4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks"
75742579|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
75742580|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
75742581|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
75742582|NCT01027767|Device|Molecular Breast Imaging|Molecular Breast Imaging
75890427|NCT02209922|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
76061060|NCT02405260|Drug|Sitagliptin 100 mg|once daily
76061061|NCT02405260|Drug|Placebo|once daily
75742583|NCT01027923|Drug|Plerixafor|
75742584|NCT01027923|Drug|Mitoxantrone|
75742585|NCT01027923|Drug|Etoposide|
75742586|NCT01027923|Drug|Cytarabine|
75742587|NCT01565733|Drug|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
75742588|NCT01565811|Procedure|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
75742589|NCT01027065|Drug|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
75598268|NCT05014503|Other|Non-adaptive Therapeutic gaming|All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
75742590|NCT01027065|Drug|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
75742591|NCT00456495|Drug|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
75742592|NCT00445341|Drug|Flavopiridol|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
75890428|NCT02209922|Device|Sham|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
75742593|NCT03846453|Biological|HL036 Ophthalmic Solution|HL036 Ophthalmic Solution
75742594|NCT03846453|Biological|Placebo|Placebo vehicle solution
75890429|NCT03671031|Procedure|isolated roux loop|Isolated roux loop reconstruction following pancreaticoduodenectomy
76061062|NCT03519646|Drug|Eliglustat|"This is a 3-year study and the enrollment time of this study is 24 months.~The participants have to receive the investigational agent, Cerdelga~The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~No need for fasting before use, but can't take with grapefruit juice.~Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test."
75742595|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
75742596|NCT00444951|Biological|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
75742597|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
75742598|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
75742599|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
76061063|NCT02984722|Drug|Metformin|
75448188|NCT05616637|Other|Lower Extremity Length Measurement|Lower extremity length will be recorded to normalize dynamic balance test data. The person will lie in the supine position. The distance between the umbilicus and the anterior superior of the spina iliaca will be measured in cm with the help of a tape measure. If there is no asymmetry, it will be assumed that there is no rotation in the pelvis, and it will be started to measure the length of the lower extremity. If pelvic asymmetry is detected, the pelvic position will be corrected manually. Then, the most inferior point of the spina iliaca anterior superior and the most distal point of the medial malleolus will be marked and measured and recorded. Lower extremity length and data in 3 different directions will be used in cm. The purpose of using formulas is to easily provide comparisons with other studies using the same type of data. The data obtained from the formula is expressed as a percentage of the length of the limb.
75463129|NCT01872117|Other|Shortwave therapy|Will be conducted in four stages, on different days: i) lower limb in extension and application of 180° for 20 min, ii) Lower limb knee flexion of 90° and application for 20 min; iii) lower limb extension in 180° without application iv) lower limb knee flexion of 90° without application.
75463130|NCT01872117|Other|Microwave therapy|Will be held in two stages, on different days: i) lower limb in extension with angle of 180° and application for 20 min, ii) lower limb in extension of 180° without application.
75742600|NCT00444795|Drug|sunitinib malate|Sunitinib : dosing not pre-determined
76061064|NCT02402530|Drug|Placebo|Matching placebo administered as intravenous infusion.
76061065|NCT02402530|Drug|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
76061066|NCT03087370|Other|No intervention|No intervention
75742601|NCT03846219|Drug|IMU-838 (30 mg/day)|"Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily."
75890430|NCT03671031|Procedure|single loop|Conventional single loop reconstruction following pancreaticoduodenectomy
75890431|NCT02881957|Drug|Cholecalciferol|
75890432|NCT02881957|Other|Placebo|Oral syrup placebo
75890433|NCT02073396|Diagnostic Test|Blood test|Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
75890434|NCT02206022|Drug|Remifentanil|Pain's evaluation for Remifentanil Group
76061067|NCT03087292|Other|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
75463131|NCT01872143|Device|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
75463132|NCT01871311|Drug|Nilotinib + Cetuximab|"Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly~Three dose levels for nilotinib:~Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID~Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity."
75463133|NCT01872156|Other|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
75890435|NCT02206022|Drug|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
76061068|NCT02401750|Drug|Oxycodone Naltrexone (a)|
75742602|NCT03846219|Drug|IMU-838 (45 mg/day)|"Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily."
75742603|NCT03846219|Drug|Placebo|"Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose."
75890436|NCT02073552|Drug|Polyethylene glycol 4000|- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
75890437|NCT02073552|Drug|Macrogol 3350 plus ascorbic acid|- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
75890438|NCT03022461|Other|Long term follow-up|
76061069|NCT02401750|Drug|Oxycodone Naltrexone (b)|
76061070|NCT02401750|Drug|Placebo|Matches both experimental drugs
76061071|NCT02400736|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is the evidenced based model of supported employment.
75463134|NCT01872156|Other|Control Group|The group control will act according to usual management.
76061072|NCT02400736|Other|Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)|Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
76061073|NCT03086980|Other|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
76061074|NCT03086980|Other|Treatment as Usual|Usual Care will be provided.
76061075|NCT03086668|Procedure|Conventional Jaw thrust Group|a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique
76061076|NCT03086668|Procedure|Fingers hook Group|a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
76061077|NCT01689519|Drug|Placebo|Placebo supplied as tablets
76061078|NCT01689519|Drug|Vemurafenib|Vemurafenib supplied as tablets
76061079|NCT01689519|Drug|Cobimetinib|Cobimetinib supplied as tablets
75463135|NCT01872182|Drug|ALS-L1023|daily twice for 12 weeks
76061080|NCT01689363|Drug|Hyaluronidase|Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
75890439|NCT02210156|Dietary Supplement|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
76061081|NCT01689363|Drug|Histamine|Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
75742604|NCT03846219|Drug|IMU-838 (10 mg/day)|"Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable."
75448189|NCT05616637|Other|Y Balance Test|While the individual tries to balance on one bare foot at the midpoint of the assembly, the individual will also be asked to reach as far as possible with the other foot in the anterior, posteromedial and posterolateral directions, touch the tip of the toe, and then immediately return to the starting position without disturbing the balance. The test will be evaluated for 3 repetitions. Situations where the participant will be requested to repeat the test: the foot on the ground passes the reference point or the heel lifts off the ground, perturbations caused by the environment, contact of the foot with the ground, and loss of balance when returning to the starting position. 10 seconds between 3 repetitions during testing will be given. Each participant will be given the right to try 6 times before starting the test in order to eliminate the possible learning parameter. The test will be repeated 3 times in each direction and the closest distance in cm will be recorded.
75742605|NCT00455325|Drug|Placebo Comparator: First Intervention (3 weeks)|once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
75742606|NCT00455325|Drug|Active Comparator: Second Intervention (3 weeks)|Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
75742607|NCT00455325|Drug|Active Comparator: Third Intervention (3 weeks)|Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
75742608|NCT00455325|Drug|Active Comparator: Fourth Intervention (3 weeks)|Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
75742609|NCT01028079|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
75742610|NCT01028079|Drug|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
75742611|NCT01028079|Drug|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
76061082|NCT01689363|Drug|Saline|Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
76061083|NCT04410471|Diagnostic Test|CLIA of IgG and IgM against SARS-Cov-2|Report of clinical data
76061084|NCT02072421|Procedure|PCI|
76061085|NCT01558635|Device|Cardioblate CryoFlex Surgical Ablation|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
76061086|NCT01558635|Procedure|Mitral Valve surgery|Classic mitral valve surgery was performed
76061087|NCT01558635|Device|Medtronic Reveal XT Insertable Cardiac Monitor|During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period
76061088|NCT01558635|Procedure|MAZE III|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
76061089|NCT00089986|Drug|Intravenous GR270773- Phospholipid Emulsion|
76061090|NCT00089986|Other|Placebo|
75448190|NCT05611229|Drug|Nivolumab|Nivolumab
75598269|NCT04971915|Other|minimalist footwear|The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
75448191|NCT05611229|Drug|Pembrolizumab|Pembrolizumab
75890440|NCT02210156|Other|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
75890441|NCT02080026|Biological|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
75742612|NCT01028157|Behavioral|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
76061091|NCT03507946|Device|Dermawrap - combined 460nm, 633nm and 830nm LED therapy|Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
75890442|NCT02080026|Biological|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
75890443|NCT02080026|Drug|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
75890444|NCT02080026|Drug|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
76061092|NCT03504124|Other|Multicomponent intervention|An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
76061093|NCT03503344|Drug|Apalutamide|Given PO, 240 mg per day (4 x 60mg tablets)
76061094|NCT03503344|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
76061095|NCT03455686|Other|Hyperpolarized 129Xe MRI|Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
75742613|NCT01028157|Behavioral|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
75742614|NCT01024725|Other|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
75448192|NCT05611229|Combination Product|Dabrafenib+Trametinib|Dabrafenib+Trametinib
75448193|NCT05611229|Combination Product|Ipilimumab+Nivolumab|Ipilimumab+Nivolumab
75448194|NCT05611229|Combination Product|Vemurafenib+Cobimetinib|Vemurafenib+Cobimetinib
75890445|NCT02206178|Drug|N-acetylcysteine combination with acetaminophen|
75448195|NCT05611229|Combination Product|Encorafenib+Binimetinib|Encorafenib+Binimetinib
75890446|NCT02206178|Drug|Placebo|
75890447|NCT02080104|Drug|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
75890448|NCT02211326|Behavioral|Genotype-guided dosing algorithm for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.
76061096|NCT03086824|Device|magnetic resonance-guided focused ultrasound|
76061097|NCT03455140|Drug|PEG- BCT-100|PEGylated recombinant human arginase 1
75448198|NCT05601154|Drug|Crest Cavity Protection toothpaste|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
75448199|NCT05601154|Drug|Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
75742615|NCT01323231|Behavioral|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
75742616|NCT01024803|Device|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.~Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
75890449|NCT02211326|Behavioral|Standard initiation dose for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
75890450|NCT02077452|Drug|HMS5552|
75890451|NCT02077452|Drug|Placebo|
75890452|NCT03462979|Device|Immunochromatographic lateral flow test|The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
75448200|NCT05601154|Drug|Colgate PreviDent 5000+ toothpaste|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
75890453|NCT02073630|Other|active cerebellar stimulation|
75890454|NCT02073630|Other|sham cerebellar stimulation|
75448201|NCT05601154|Drug|Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
75448202|NCT05599035|Device|repititive transcranial magnetic stimulation|a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
75448203|NCT05585632|Biological|mRNA-1010|Sterile liquid for injection
75448204|NCT05585632|Biological|mRNA-1345|Sterile liquid for injection
75448205|NCT05585632|Biological|mRNA-1273.214|Sterile liquid for injection
75448206|NCT05585632|Biological|mRNA-1045|Formulation for injection
75448207|NCT05585632|Biological|mRNA-1230|Formulation for injection
75448208|NCT05580705|Other|Routine Physical Therapy|The Routine Physiotherapy treatment will include Transcutaneous Electrical Nerve Stimulation, Hot pack, Range of Motion (ROM) Exercises and Muscle Strengthening Exercises
75463136|NCT01872182|Drug|placebo|daily twice for 12 weeks
75890455|NCT02206256|Drug|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
75890456|NCT02206256|Behavioral|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
75890457|NCT04749290|Other|Study Formula|Study infant formula for term infants containing OPO and CPP
75890458|NCT02691793|Drug|Sunitinib|sunitinib 37.5mg QD
75890459|NCT05764603|Drug|MRI|MR ARTHROGRAPHY AND CT ARTHROGRAPHY IN PATIENT WITH KNEE OSTEOARTHRITIS
75890460|NCT02073786|Device|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
75890461|NCT02073786|Device|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
75890462|NCT04747886|Behavioral|WW Only|WW is a structured behavioral weight management program that focuses on diet, physical activity and mindset skills. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories. Specifically, the WW program assigns SmartPoints values to foods based on calories, sugar, saturated fat and protein. In addition, particular foods are assigned a points value of zero (0) to encourage a healthier eating pattern (e.g. fruits, vegetables, non-fat yogurt, fish).
75742617|NCT00443781|Procedure|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
75742618|NCT00443781|Procedure|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
75742619|NCT01024881|Procedure|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
75890463|NCT04747886|Behavioral|WW + PolyRules!|In addition to WW, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
76061098|NCT03086512|Device|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
76061099|NCT03086512|Device|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
76061100|NCT03452878|Behavioral|Aggressive behavior|Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
76061101|NCT03501082|Other|L Reuteri PB-W1 Strain|L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
75598270|NCT04901169|Drug|Angiotensin II|Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of > 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
76061102|NCT03501082|Other|L. Reuteri DSM20016T Strain|L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
75598271|NCT04901169|Drug|Saline|Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of > 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
76061103|NCT03501082|Other|Placebo|2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions
76061104|NCT03501082|Other|Non-Industrialized-Type Diet|Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
76061105|NCT05346640|Device|Cionic Neural Sleeve|Adaptive, functional electrical stimulation
76061106|NCT03086278|Drug|AST-008|AST-008 is a toll-like receptor 9 agonist.
75598272|NCT04896333|Other|Interaction and exposure with the Robot EBO|The participants will interact with the Robot EBO. The robot will be control by an operator that will conduct a dialogue. The dialogue will include questions related to the social, leisure, activities of daily living and informative areas.
75742620|NCT01024881|Procedure|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
75742621|NCT00443703|Drug|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
75448209|NCT05580705|Other|Vibration Therapy|Vibration Therapy will include a vibration device of brand Manipol, model number RK-001. It has 360 degree off-centered axis with a frequency of 2500 times per minute. It will be applied on sole of the foot for about 15 mins.
75448210|NCT05574816|Device|Phi-Bra prototype measurements|"The bra prototype will be placed on the patient's breast. The patient will stay in a half-lying position during 15 min, the time duration of the measurements. Measurements will not be painful.~Measurements will only be realized one time during the first and unique visit of the patient."
75598273|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.
75890464|NCT03132415|Behavioral|Get Connected|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.
75598274|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.
75598275|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.
75598276|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
75742622|NCT00443703|Drug|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
75890465|NCT03132415|Behavioral|HIV Test Locator|The investigators will use a HIV/STI testing locator as the attention-control condition. The test locator provides a list of HIV testing sites in a city or zipcode.
75890466|NCT02221544|Device|Low-frequency repetitive Transcranial Magnetic Stimulation|"Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain."
75890467|NCT02221544|Device|rTMS maintenance|Same treatment as in rTMS treatment intervention, but only once a week for a month
75890468|NCT02221544|Device|Sham|Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
75890469|NCT02221544|Device|Sham maintenance|The same as Sham stimuli intervention, but once a week for a month
75890470|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
75890471|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
75448211|NCT05566665|Diagnostic Test|Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol|"The antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will follow the standard clinical practice.~The concentration of ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will be measured at specific timepoints in plasma samples and bronchoalveolar lavage samples, and a PK analysis and modeling will be carried out ."
75598277|NCT04724109|Drug|Equfina|Equfina oral tablets.
75598278|NCT04606407|Device|LungFit™|Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
75890472|NCT02221622|Drug|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
75448212|NCT05550454|Device|Automatic Mechanical Ventilation|"Ventilation settings:~Mode: (S)Continuous Mandatory Ventilation Rate: 10 b/min. Tidal Volume: 500 ml (male), 450 ml (female) I:E=1:1 Positive end expiratory pressure (PEEP): 5 cmH2O Flow trigger: off Oxygen: 100% Alarms: Pressure 70 cmH20, Tidal volume 100 ~ 1,000 ml"
75598279|NCT04565145|Drug|Kava Dietary Supplement|Participants will be given three 75mg kava capsules per day for one week
75598280|NCT04565145|Drug|Placebo|Participants will be given three placebo capsules per day for one week
75598281|NCT02888847|Device|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
75742623|NCT00443703|Drug|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
75742624|NCT00443703|Drug|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
75742625|NCT00381706|Biological|cetuximab|given IV
75448213|NCT05550454|Device|Manual Ventilation|Ambu-bagging (It is recommended in the guidelines as a ventilation method.) Methods: 10 times per minutes by medical personnel
75598282|NCT02888847|Device|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
75598283|NCT04320537|Other|abstinence from use of marijuana and other abused drugs|abstinence from use of marijuana use and other abused drugs
75742626|NCT00381706|Drug|ECF|epirubicin and 5-fluorouracil given IV
75742627|NCT00381706|Drug|IC|cisplatin and irinotecan given IV
75742628|NCT00381706|Drug|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
75742629|NCT01045642|Drug|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
75742630|NCT00535236|Biological|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
75742631|NCT00535236|Biological|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
75742632|NCT05357430|Drug|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.
75890473|NCT02221622|Drug|Placebo injection (intravenous solution)|Placebo intravenous infusion
75598284|NCT04479267|Drug|Prednisone|Given PO
75598285|NCT04479267|Drug|Prednisolone|Given IV
75890474|NCT02077686|Behavioral|Education - Diabetes and Travel|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible."
75890475|NCT01380223|Drug|placebo|I.V. infusion of placebo for 8 hr
75890476|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
75742633|NCT05357430|Drug|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.
75742634|NCT05357430|Drug|Propofol|0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
75890477|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
75890478|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
75890479|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
75448214|NCT05529160|Device|FERTI LILY Conception Cup|The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.
75448215|NCT05521984|Drug|Dapagliflozin|Commercially available
75448216|NCT05521984|Drug|Carmustine|Standard of care
75448217|NCT05503823|Device|tACS or tRNS and TMS|A light electrical current will be applied to the scalp of the participants via 2 electrodes. The resting and active motor threshold will be measured before, right after, after 30 minutes, and after 1 hour of receiving the tACS or tRNS.
75890480|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
75890481|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
75598286|NCT04479267|Drug|Methylprednisolone|Given IV
75598287|NCT04479267|Biological|Rituximab|Given IV
75598288|NCT04479267|Drug|Polatuzumab Vedotin|Given IV
75598289|NCT04479267|Drug|Cyclophosphamide|Given IV
75598290|NCT04479267|Drug|Doxorubicin Hydrochloride|Given IV
75598291|NCT04320459|Diagnostic Test|Bath Ankylosing Spondylitis Metrology Index (BASMI)|It characterises the spinal mobility of patients with ankylosing spondylitis. Cervical rotation, tragus-wall distance, lateral lumbar flexion, anterior lumbar flexion (modified schober), intermalleolar distance were measured. The total score of the 5 measurements was taken, the score range was 0-10, the low score meant that the spinal movement was better.
75598292|NCT04320459|Diagnostic Test|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|It assess the disease activity. It was evaluated with a 6-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
75598293|NCT04320459|Diagnostic Test|Bath Ankylosing Spondylitis Functional Index (BASFI)|It assess functional status. It was evaluated with a 10-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
75598294|NCT04320459|Diagnostic Test|Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)|"It evaluates quality of life. Each statement on the ASQoL (18-item) is given a score of 1 or 0. A score of 1 is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL)."
75890482|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
75890483|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
75890484|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
75890485|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
75890486|NCT02074020|Drug|Blisibimod|Administered via subcutaneous injection once per week
75890487|NCT02074020|Drug|Placebo|Administered via subcutaneous injection once per week
75890488|NCT05764525|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
75890489|NCT05764525|Drug|Placebo|IV infusion of 0 mg of VVZ-149
75890490|NCT02213276|Other|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
76061107|NCT03086434|Other|Culturally Tailored Intervention|School-based substance use prevention
75890491|NCT02213276|Other|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
75890492|NCT02074098|Device|Macintosh laryngoscope|Direct Laryngoscope
75890493|NCT02074098|Device|Glidescope|Videolaryngoscope-1
75890494|NCT02074098|Device|Airwayscope|Videolaryngoscope-2
76061108|NCT03086434|Other|Standard Substance Abuse Education|Class room program
76061109|NCT03497806|Biological|CP101|Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
76061110|NCT01689207|Drug|Avibactam (AVI)|PART A: AVI IV infusion
75598295|NCT04320459|Diagnostic Test|Toronto Alexithymia Scale-20 (TAS-20)|It assess alexithymia. It is a 20 item questionnaire and each item is evaluated in a Likert type scale with five intervals (1= strongly disagree, 5=strongly agree). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.
75890495|NCT05764447|Behavioral|Combined qigong Baduanjin and self-administered acupressure|The intervention will combine Baduanjin (BQ) and acupressure. The general design of the combination intervention is for BQ to be performed first (20 min), followed by self-administered acupressure (10 min). BQ comprises eight simple standardized movements. The combination of these simple body movements, breath control, and mindful meditation is designed to improve qi function.The acupressure protocol comprises six acupoints, i.e., Hegu, Quchi, Zusanli, Sanyinjiao, Qihai, and Taichong, which are the most commonly used acupoints in acupuncture trials for relieving CIPN according to previous reviews. These acupoints, based on TCM theory, are beneficial for strengthening the origin of qi and directing its flow to the upper and lower extremities. A massage pen will be used to stimulate the acupoints because participants with CIPN may have difficulty applying pressure with their hands/fingers.
75598296|NCT04320459|Diagnostic Test|Beck's Depression Inventory (BDI)|It assess depression status. It is a 21-question multiple-choice self-report inventory, each set is ranked in terms of severity and scored from 0 to 3 with a total summed score range of 0-63. Higher scores indicate greater depressive severity. Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression.
75598297|NCT02888769|Behavioral|Text Messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
75598298|NCT05523531|Other|Self-administered questionnaires|"Neuropathic Eye Pain Questionnaire~5-item Dry Eye Evaluation Questionnaire (DEQ-5)~Visual Impact Assessment Questionnaire~Concise Ophthalmic Pain Questionnaire~Questionnaire to evaluate the effectiveness and tolerance of treatments~Chronic pain questionnaire"
75598299|NCT05523531|Procedure|Bilateral ophthalmologic examination|"Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~Lipiview® test~Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy"
75598300|NCT04320303|Biological|expanded NK cells|Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
75598301|NCT04121169|Drug|IM-01|Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
75598302|NCT04066959|Behavioral|Motivational Enhancement System (MES)|MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
75890496|NCT05764447|Behavioral|Wait-list Control|The participants will receive usual care alone during the study period and will be offered the training after the last follow-up.
75890497|NCT02221856|Procedure|Motion View|Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
75890498|NCT02221856|Procedure|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
75890499|NCT02080182|Drug|Acetylcysteine|
75890500|NCT02080182|Drug|placebo acetylcysteine|
75890501|NCT02224898|Behavioral|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
75890502|NCT02080338|Device|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
75890503|NCT02750930|Drug|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
75890504|NCT02750930|Device|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
75890505|NCT02080416|Drug|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
75890506|NCT05462665|Behavioral|theory training|theory training
75890507|NCT05462665|Behavioral|theory and simulation training|theory and simulation training
75890508|NCT02080494|Drug|Tranexamic Acid|
75890509|NCT02224976|Behavioral|Intensified Training|Volunteers will increase exercise training by 30% from baseline
75890510|NCT02213744|Drug|MM-302|
75890511|NCT02213744|Drug|Gemcitabine|
75890512|NCT02213744|Drug|Capecitabine|
75890513|NCT02213744|Drug|Vinorelbine|
75890514|NCT02213744|Drug|Trastuzumab|
75890515|NCT02077764|Procedure|OCT and coronary angiography|
75890516|NCT02077764|Procedure|Right heart cat.|
75890517|NCT02077764|Radiation|PET|
75890518|NCT02077764|Procedure|Echocardiography|
75890519|NCT02077764|Procedure|exercise test|
75890520|NCT02077764|Other|blood samples|
75890521|NCT01378741|Drug|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
75890522|NCT01378741|Drug|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
76061111|NCT01689207|Drug|Aztreonam (ATM)|PART A: ATM IV infusion
76061112|NCT01689207|Drug|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
75448218|NCT05503485|Behavioral|Existential group treatment|The existential group treatment follows a manualised structure focusing on aging-related challenges related to existential themes such as story of life, freedom, loneliness, and death. In order to support patients in finding new, productive ways of engaging in the existential process of aging literary texts, therapy practices and assignments between the sessions are used and each group will be accompanied by two therapists who facilitate the group climate, gently bring the group back on topic and help group members to see different ways of dealing with existential concerns related to aging.
75448219|NCT05503485|Behavioral|Supportive telephone calls|"The supportive caller will provide empathetic basic support, equivalent to the telephone support provided within the Swedish non-governmental organization Mind's Äldrelinjen. No psychotherapeutic techniques will be applied and there will be no interventions beyond the phone call itself."
75598303|NCT04066959|Behavioral|Question Prompt List (QPL)|A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
75598304|NCT04066959|Behavioral|Text Message Reminders (TXT)|TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
75598305|NCT04021017|Drug|Estradiol Hemihydrate Transdermal System|Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
76061113|NCT01689207|Drug|Placebo|PART A, PART B, PART C: matching placebo IV infusions
75448220|NCT05497323|Drug|Combination Cream|The combination cream consists of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA, were applied every morning by group 2 and group 3.
76061114|NCT00089284|Drug|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
76061115|NCT00089284|Drug|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
75448221|NCT05497323|Drug|Adapalene 0,1% cream|Adapalene 0,1 % cream were given to subjects to be applied every night in group 1 and group 3, and intermittently every two nights in group 2.
75598306|NCT04323111|Procedure|metzenbaum's technique|surgical procedure for correction of caudal end nasal septal deviation
75598307|NCT03764553|Drug|Liposomal Irinotecan|Iv liposomal irinotecan
75598308|NCT03764553|Drug|Carboplatin|IV Carboplatin
75890523|NCT02080650|Device|Mesenchymal-marker based ferrofluid (c-MET)|
75890524|NCT02080650|Device|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
75890525|NCT02077842|Device|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
75890526|NCT02077842|Device|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
75890527|NCT02461849|Drug|Imatinib|Imatinib 400mg qd daily
75890528|NCT02225054|Drug|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
75890529|NCT02225054|Drug|Ropivacaine|15 ml 0.5%
75890530|NCT02225054|Drug|Normal Saline|1 mL 0.9%
75890531|NCT02080728|Drug|Ropivacaine 500mg/100ml Naropeine|
75598309|NCT03764553|Drug|Capecitabine|PO Capecitabine
75890532|NCT02080728|Drug|0.9% sodium chloride BAXTER|
75890533|NCT05136794|Other|Data collection|complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay
75598310|NCT03764553|Drug|Oxaliplatin|IV Oxaliplatin
75890534|NCT05095298|Drug|Vaccine, COVID19|It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
75890535|NCT02222012|Device|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
75890536|NCT02222012|Device|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
76061116|NCT00089284|Drug|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
75598311|NCT03764553|Drug|5-fluorouracil|IV 5-fluorouracil
75598312|NCT03764553|Drug|Leucovorin|IV Leucovorin
75598313|NCT04319991|Dietary Supplement|Probiotics product|This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
75598314|NCT04320225|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
75598315|NCT04320147|Device|Artemia|Before prostate biopsy, all patients be preceded by mpMRI.MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
75598316|NCT02888925|Other|Mooney test|
75742635|NCT00370552|Drug|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
75598317|NCT02888925|Other|Benton Face Recognition test|
75598318|NCT02888925|Other|Face inversion effect test|
75598319|NCT02888925|Other|Face composite effect test|
75598320|NCT02888925|Other|Cambridge Face Memory Test|
75598321|NCT02888925|Other|Matching different view test|
75598322|NCT02888925|Other|Memorizing and recognition of new faces test|
75598323|NCT02888925|Other|Memorizing and recognition of new objects test|
75598324|NCT02888925|Other|Recognition of celebrities and access to semantic information test|
75598325|NCT02888925|Procedure|Lobectomy|In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
75598326|NCT03219177|Behavioral|Patient education regarding indications for opioid use and side effects of opioid use after hand surgery|Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.
75598327|NCT03219177|Other|Standard of care post-operative counseling|Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
76061117|NCT03497104|Other|Surplus blood tests|Surplus blood donation
76061118|NCT01688973|Drug|Erlotinib Hydrochloride|150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
76061119|NCT01688973|Other|Laboratory Biomarker Analysis|Correlative studies
75890537|NCT02214758|Other|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
76061120|NCT01688973|Drug|Tivantinib|360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
76061121|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 72 weeks
76061122|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 48 weeks
76061123|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
75448222|NCT05495087|Device|IHT Treatment|IHT Treatment: IH exposure to 10% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
75742636|NCT00370552|Drug|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
75742637|NCT00370552|Drug|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
76061124|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
76061125|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 72 weeks
75448223|NCT05495087|Other|Sham-IHT Control|Sham-IHT Control: Exposure to 21% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
75448224|NCT05494450|Device|ExufiberAG+|confirm performance and safety of the Exufiber Ag+ dressing in medium to high exuding chronic wounds
75742638|NCT00537030|Drug|Asparaginase|Given IM
75742639|NCT00537030|Other|Laboratory Biomarker Analysis|Correlative studies
75742640|NCT00537030|Other|Pharmacological Study|Correlative studies
75742641|NCT01047904|Device|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
76061126|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
75448225|NCT05490563|Drug|SLS-005|SLS-005
75448226|NCT05490563|Drug|Placebo|Placebo (sodium chloride injection, 0.9%, USP)
76061127|NCT03492658|Drug|Abatacept|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
76061128|NCT03492658|Drug|Methotrexate|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
75890538|NCT03078907|Drug|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
75598328|NCT05608941|Other|Respiratory muscle training|The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.
75598329|NCT05608941|Other|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
75598330|NCT02866071|Drug|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
75598331|NCT02866071|Drug|Placebo-Comparator|50mg IN Placebo
75742642|NCT05357352|Other|NAFLD/NASH|the characteristics of patients with advanced fibrosis in a community-based referral center.
75742643|NCT00381238|Drug|rosiglitazone|Extended Release Tablets
75742644|NCT04639596|Behavioral|Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity, bowling, (SRT).|This study will be a prospective randomized controlled trial (RCT) of Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity (bowling) among Veterans with psychiatric and/or substance use disorders.
75742645|NCT05355714|Device|Sofwave|High-Frequency Non-Focused Ultrasound Device
75742646|NCT05355714|Device|Ultherapy|Microfocused Ultrasound with Visualization
75742647|NCT05260476|Other|Reablement|The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
75742648|NCT04928820|Procedure|Computed Tomography|Undergo PET/CT
75742649|NCT04928820|Other|Gallium Ga 68 Gozetotide|Given IV
75742650|NCT04928820|Procedure|Positron Emission Tomography|Undergo PET/CT
75742651|NCT03896022|Device|Acupressure with Beads|Single-use gold-plated 1.2mm beads/balls attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
75742652|NCT03896022|Device|Acupuncture with Needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
75742653|NCT03896022|Device|Placebo Adhesive Disks|Single-use adhesive disks without needles or beads.
75742654|NCT04430946|Diagnostic Test|Standardized test meal|A test meal of ~700 kcal consisting of protein and fat will be consumed within 10 minutes
75742655|NCT03831880|Drug|Genotropin|Genotropin (dose [mg] at time of enrollment) given subcutaneously once daily
75742656|NCT03831880|Drug|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
75742657|NCT00924456|Behavioral|Transcendental Meditation program|a natural effortless mental technique
75890539|NCT03078907|Drug|Placebo|Matching film coated tablets
75890540|NCT02225210|Drug|Dexmedetomidine|Loading dose:0.4μg.kg-1 Maintenance dose :0.2~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
75890541|NCT02225210|Drug|Midazolam|Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
75890542|NCT02225210|Drug|Fentanyl|Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
75890543|NCT02216942|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
76061129|NCT05347108|Procedure|laser-assisted neural decompression (LAND) procedure|"The LAND procedure is a minimally invasive spinal decompression procedure that uses a focused laser beam to reduce and remove disc herniations that are causing nerve compressions and impingements within the spinal canal. It is performed in an outpatient setting and the patient receives local anesthesia.~The LAND procedure has been performed extensively over the past 2-years on hundreds of patients, so including patients that have previously had the surgery allows for additional data points and improved reporting."
75742658|NCT04429152|Drug|Doravirine/Lamivudine/Tenofovir|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination
75598332|NCT02888613|Procedure|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
75742659|NCT04257552|Behavioral|Healthy Beyond Pregnancy|Web-based application grounded in tenants of behavioral economics.
75598333|NCT02888613|Procedure|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
75742660|NCT04257552|Behavioral|Pre-Scheduled Postpartum Visit|Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
75448227|NCT05482711|Other|Time Restricted Eating Intervention|All participants will be asked to adhere to suggested fasting and feeding periods throughout the 8 week study period. These participants will self-monitor eating and sleeping habits as well to present to study staff at checkpoints. Self-reported information will be used during group-mediated intervention sessions throughout the duration of the study, as well.
75742661|NCT04257552|Other|Attention Control|Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
75448229|NCT05460130|Behavioral|Simplified Hepatitis C Virus (HCV) Treatment Protocol|A simplified, low-barrier, locally contextualized, HCV treatment protocol delivered by trained front-line health care providers (primary care physicians and mid-level providers) serving hard-to-reach-populations.
75598334|NCT02890524|Device|night guard|60 days before and after intervention with the night guard
75598335|NCT02890524|Device|placebo night guard|60 days before and after intervention with the placebo night guard
75598336|NCT02890602|Drug|Darbepoetin alfa|Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
75742662|NCT04001400|Drug|Rabeprazole 20mg bid|Rabeprazole 20mg tablet b.i.d.
75742663|NCT04001400|Drug|Rabeprazole 20mg qd|Rabeprazole 20mg tablet q.d.
75742664|NCT04219566|Device|VeNS|Non-invasive electrical vestibular nerve stimulation
75742665|NCT04219566|Device|Placebo device|Sham non-invasive electrical vestibular nerve stimulation
75742666|NCT00380692|Drug|Atomoxetine|
75742667|NCT00380692|Drug|Placebo|
75742668|NCT05355636|Behavioral|Fertility Management Counseling|counseling
75742669|NCT04285866|Drug|Durvalumab|Durvalumab after chemoradiotherapy
75742670|NCT01047982|Dietary Supplement|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
75742671|NCT01047982|Other|folic acid 400 mcg|2 pills a day
75769627|NCT03972228|Combination Product|Microdevice loaded with 19 chemotherapeutic agents|The microdevice containing 19 FDA-approved chemotherapeutic agents will be placed in the suspected tumor tissue at the time of surgical resection. Multiple chemotherapeutic agents will passively diffuse into local, confined regions (several microns) of the surrounding microenvironment. The agents are released at approximately one millionth of a systemic dose. The device(s) will be removed for analysis at the time of resection, which will be performed for clinical indications independent of enrollment in this study.
75890544|NCT02216942|Drug|Endodontic treatment using Guedes Pinto|Endodontic treatment using Guedes Pinto paste
75742672|NCT05355558|Diagnostic Test|[18F]FLT-PET/MRI body scan|"[18F]FLT-PET/MRI body scan will be done at~Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy.~Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy).~At these visits:~Obtain vital signs and weight in kg before FLT administration.~Record the dose of FLT received and injected. (**specify dose: 1mCi per 10kg. Maximum injected dose: < 10mCi per patient.)~Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT.~Perform a saline flush following the FLT injection.~Body PET/MRI will be performed after FLT injection.~Time of injection of FLT and time of scan will need to be recorded."
75598337|NCT02890602|Drug|R-CHOP|R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
75598338|NCT01259115|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
75598339|NCT01259115|Drug|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
75598340|NCT01259115|Drug|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
75598341|NCT01302366|Drug|TBL12|
75598342|NCT02888379|Drug|TOP1288|
75598343|NCT02888379|Drug|Placebo (for TOP1288)|
75890545|NCT02225288|Drug|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
75598344|NCT01302054|Drug|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
75890546|NCT05462275|Device|Intubation using 3-cuffed double lumen endotracheal tube|After patient's position, 3-cuffed double lumen endotracheal tube is intubated without fiberoptic bronchoscopy guidance
76061130|NCT03086122|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
76061131|NCT03085966|Biological|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
76061132|NCT03085654|Drug|Oxytocin nasal spray|Intranasal administration of oxytocin 24 international units per dose.
75448230|NCT05460026|Other|Routine Physical Therapy|Participants will receive routine physical therapy which includes ultrasound, nerve gliding, tendon mobilization, stretching, mobility and strengthening exercises for the wrist. Each session will last for 30 minutes with 12 sessions on alternate days (3 sessions / week).
75448231|NCT05460026|Other|Powerball Exercises|Participants will be using the Powerball™ for 5 minutes per hand, 3 times a week along with routine physical therapy exercises.
75598345|NCT01302054|Drug|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
75598346|NCT01301508|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
75598347|NCT01301508|Drug|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
75598348|NCT01301508|Drug|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
75598349|NCT01301508|Drug|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
75598350|NCT01301274|Drug|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
75598351|NCT01301274|Drug|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
75598352|NCT02890446|Behavioral|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks"
75598353|NCT05643612|Diagnostic Test|Deep learning algorithm|A sequential two-stage 3D spleen injury detection framework to identify splenic injury in the CT scans
75448232|NCT05446207|Other|Routine Physiotherapy and Task-oriented Training|The routine physiotherapy treatment will include TENS and Hot pack. The task oriented training for lower extremity will include walking training on the ground, equal weight bearing sit-to-stand exercises, resistance exercises e.g. leg press, leg extension, and leg curl and reaching tasks for improving balance. There will be a rest period of 5 minutes between each set of training.
75448233|NCT05446207|Other|Music Therapy and Task oriented Training with Routine Physiotherapy|Relaxing Music will be provided through headphones having voice cancellation property for 15 minutes.
75448234|NCT05431972|Device|Cardea SOLO|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
75448235|NCT05431972|Device|12 Lead EKG|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
75448236|NCT05431387|Drug|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
75448237|NCT05431387|Drug|Placebo|film-coated oral tablets containing matched placebo
75598354|NCT05643456|Procedure|surgery|"69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking."
75742673|NCT00536874|Drug|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
75742674|NCT00536874|Drug|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
75742675|NCT00536874|Genetic|protein expression analysis|
75742676|NCT00536874|Genetic|proteomic profiling|
75448238|NCT05431387|Behavioral|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
75448239|NCT05419310|Other|Rehabilitation - core strengthening|Physical rehabilitation based on core strengthening
75448240|NCT05419310|Other|Rehabilitation - rehabilitation pilates|Physical rehabilitation based on rehabilitation pilates
76061133|NCT03085654|Drug|Placebo nasal spray|Intranasal administration of placebo 24 international units per dose.
75448241|NCT05419310|Other|Elastic taping application|Application of elastic taping
75890547|NCT02225444|Other|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
75890548|NCT05462197|Behavioral|Qigong Wuqinxi|Wuqinxi is an exercise method developed by the ancient Chinese physician Hua Tuo by combining the ancient guide, breathing, and imitating the shapes of five animals, such as tiger, deer, bear, ape, and bird, combined with the zang-fu and meridian theory of traditional Chinese medicine. There have been studies in the past proven that this exercise can achieve health-promoting effects
75890549|NCT02217020|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
75598355|NCT05367726|Other|patients having had skin coverage of the knee|the cutaneous cover is not always optimal to protect the prosthesis, an act of reconstructive plastic surgery is then necessary
75890550|NCT03249714|Drug|Ofatumumab|Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)
75598356|NCT05643222|Device|red tint contact lenses|to compare the performance of these lenses.
75598357|NCT00623532|Behavioral|Mind-body exercises|
75890551|NCT03249714|Drug|Matching placebo of ofatumumab|Matching placebo in pre-filled syringes
75890552|NCT05764291|Behavioral|FIT-TEENS|FIT-TEENS is a digital behaviour change intervention which provides information on physical activity and behaviour change support towards physical activity, presented in multimedia format through an online learning platform (EdApp). The contents is developed in Malay language and consist of 10 self-paced modules and activities. The objectives of FIT-TEENS are for the participants to be able to 1) review the definitions and health benefits of physical activity 2) provide an overview of physical activity guidelines 3) write a SMART goal about physical activity 4) be aware of barriers to physical activity and how to overcome them.
76061134|NCT03085732|Drug|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
76061135|NCT00087568|Drug|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
75448242|NCT05404217|Other|LN-OS-22|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
75448243|NCT05404217|Other|Maltodextrin|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
75448244|NCT05375968|Diagnostic Test|Measurement of Splanchnic venous capacitance(SVC)|Effect of glucose on splanchnic venous capacitance in Postural Orthostatic Tachycardia Syndrome
75598358|NCT00623532|Behavioral|Adapted Tai-chi|
75598359|NCT05367648|Dietary Supplement|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
75598360|NCT05367648|Other|Placebo|Placebo comparator
75598361|NCT05642910|Drug|Azvudine|Patients received Azvudine orally, for 7 consecutive days (7 doses in total)
75598362|NCT05642910|Drug|Paxlovid group|Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
75598363|NCT05642754|Other|Overall uncertainty language|We are testing different forms of information about overall study uncertainty and margin of error around main result
75598364|NCT05642364|Behavioral|Joviality(TM)|5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display
75742677|NCT00536874|Other|diagnostic laboratory biomarker analysis|
75742678|NCT00536874|Procedure|adjuvant therapy|
75742679|NCT00536874|Procedure|neoadjuvant therapy|
75742680|NCT00536874|Procedure|therapeutic conventional surgery|
75742681|NCT04275102|Other|SPARK|Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.
75742682|NCT00991848|Drug|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
75769628|NCT01586416|Behavioral|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
75769629|NCT03885856|Other|single row repair technique|single row repair technique
75598365|NCT05642364|Other|Inert Virtual Reality|Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.
75598366|NCT01300650|Drug|Anakinra|Anakinra 100 mg subcutaneous injection daily
75598367|NCT01300572|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
75598368|NCT01300572|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
75598369|NCT01300572|Drug|Cyclosporine|Given PO or IV
75598370|NCT01300572|Drug|Fludarabine Phosphate|Given IV
75598371|NCT01300572|Biological|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
75598372|NCT01300572|Other|Laboratory Biomarker Analysis|Correlative studies
75598373|NCT01300572|Drug|Mycophenolate Mofetil|Given PO or IV
75598374|NCT01300572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
75598375|NCT01300572|Other|Pharmacological Study|Correlative studies
75598376|NCT01300572|Radiation|Total-Body Irradiation|Undergo TBI
75598377|NCT01300572|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
75742683|NCT05281068|Drug|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
75742684|NCT05281068|Drug|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
75890553|NCT02217098|Procedure|GIC Restorations|Restorations using Glass Ionomer Cement
75890554|NCT02217098|Procedure|Carbomer Restorations|Restorations using Glass Carbomer
75598378|NCT05642286|Device|ALLVAS® robotic-assisted PCI|ALLVAS® robotic-assisted PCI
75598379|NCT01077154|Drug|Placebo|Administered subcutaneously for up to 5 years
75598380|NCT01077154|Drug|Denosumab|Administered subcutaneously for up to 5 years
75598381|NCT05642130|Other|exersice program (Muscle energy technique)|Post isometric relaxation for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks, In addition to the program designed for control group
75598382|NCT05642130|Other|exersice program (stretching and strengthening exercises ) In addition to postural advices|static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices
75598383|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
75598384|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
75598385|NCT01258101|Drug|ribavirin|800 mg orally daily
75598386|NCT01258101|Drug|ribavirin|400 mg orally daily
75742685|NCT00380068|Drug|Ambrisentan|Oral tablets taken once daily.
75742686|NCT00991926|Drug|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
75890555|NCT02217098|Procedure|Compomer Restorations|Restorations using Compomer
75890556|NCT02218502|Other|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
76061136|NCT00087568|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
76061137|NCT04402762|Drug|Ovine Enoxaparin|The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.
75598388|NCT04319835|Device|OnZurf Probe|
75598389|NCT05640804|Drug|CTTQ Dasatinib tablet|Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.
75598390|NCT05640804|Drug|Sprycel Dasatinib tablet|Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.
76061138|NCT04402762|Drug|Enoxaparin Prefilled Syringe [Lovenox]|The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.
76061139|NCT03487900|Diagnostic Test|Colonoscopy|Colonoscopy for CD patients in clinical remission
76061140|NCT00085540|Drug|depsipeptide|Given IV
76061141|NCT01677676|Biological|FP-01.1|IM injection
76061142|NCT01677676|Biological|FP-01.1-Adjuvant|IM injection
75742687|NCT00991926|Other|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
76061143|NCT02984488|Procedure|single visits|Endodontic treatment is done and completed in a single visit using protaper next rotary system.
75448245|NCT05370378|Other|Hold Relax with Agonist Contraction|"Participant will be in prone lying and heating pad will be applied on gluteal region for 10 to 15 minutes.~Passive sustained stretch to piriformis will be applied for 10 seconds.~The participant will be asked to actively contract the muscle for about 10 seconds (isometric contraction) and then relax.~Immediately after that participant is ask to again actively contract the muscle against therapist resistance for 6-10 seconds.~Ask the participant to relax while therapist will apply stretch the muscle to its new tissue tension barrier position and this position will be maintained for 30 seconds.~This maneuver is repeated for 3 to 4 repetitions, each starting from where the previous finished."
75448246|NCT05370378|Other|Active Release Therapy|"Specific muscle will be warmed up by applying heating pad for 10 to 15 minutes.~Patient will be positioned prone lying and the therapist will be standing at the side of affected limb.~Therapist will apply deep pressure at the area of tenderness while patient will actively move the limb from internal to external rotation repeatedly.~This maneuver will take about 15 minutes to complete in one session and will be applied alternatively 3 days a week for two weeks.~After this, cold pack is applied and general ROMs and strengthening exercises are performed to prevent soreness"
75890557|NCT02218502|Other|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
75598391|NCT05639478|Other|Foot-related exercises|Face to face foot-related exercises, supervised by physiotherapist and based in the specific software (Sistema de Orientação do Pé diabético, SOPED) and or booklet, in addition to self-care recommendations and foot care by international consensus. The maximum duration of a session is 40 min and should be be performed 1-2 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the physiotherapist. The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression.
75598392|NCT00623610|Procedure|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
75742688|NCT01048060|Procedure|Bone marrow specimen banking|
75742689|NCT04230954|Drug|Cabozantinib 40 MG oral once a day|Cabozantinib 40 mg oral once a day
75742690|NCT04230954|Drug|Pembrolizumab 200 mg IV every 3 weeks|Pembrolizumab 200 mg IV every 3 weeks
75742691|NCT05265702|Device|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 12 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
75890558|NCT02218502|Other|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
75890559|NCT02218502|Other|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
75890560|NCT05461651|Procedure|Knee arthroplasty|total or unilateral knee arthroplasty
76061144|NCT02984488|Procedure|two visits|Endodontic treatment is done and completed in two visits using protaper next rotary system.
76061145|NCT01688739|Drug|Erenumab|Administered by subcutaneous injection or intravenous injection
76061146|NCT01688739|Drug|Placebo|Administered by subcutaneous injection or intravenous injection
76061147|NCT03085264|Behavioral|Community Health Worker|Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
76061148|NCT00084838|Biological|filgrastim|
76061149|NCT00084838|Drug|cisplatin|
76061150|NCT00084838|Drug|cyclophosphamide|
76061151|NCT00084838|Drug|cytarabine|
76061152|NCT00084838|Drug|dexrazoxane hydrochloride|
76061153|NCT00084838|Drug|doxorubicin hydrochloride|
76061154|NCT00084838|Drug|etoposide|
76061155|NCT00084838|Drug|leucovorin calcium|
75890561|NCT02080806|Device|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
75890562|NCT02225522|Other|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
76061156|NCT00084838|Drug|methotrexate|
75890563|NCT04749589|Diagnostic Test|iron deficiency|Its not an intervention. Its an observational study. The groups are defined based on their iron status
75598393|NCT00623688|Device|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
75598394|NCT00623688|Device|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
75598395|NCT01300338|Device|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
75890564|NCT02222168|Drug|BI 409306|medium dose, oral administration
75890565|NCT02222168|Drug|BI 409306|medium dose, oral administration
75890566|NCT02222168|Drug|BI 409306|medium dose, oral administration
75742692|NCT04127838|Behavioral|Low Vision Occupational Therapy|Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
75742693|NCT04081974|Other|Distal leg perfusion|On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
75890567|NCT04748731|Behavioral|Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms|a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting
75890568|NCT04748731|Behavioral|Psycho-Educational Intervention|Reception of psycho-educational materials
75890569|NCT03283722|Device|Profile 3D™ and CG Future® annuloplasty system|Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
75890570|NCT05236478|Other|CoviMouv' program|"An initiation to physical rehabilitation at the hospital center the first week, 3 sessions of 1 hour.~A tele-rehabilitation program led by an Adapted Physical Activity (APA) teacher for 3 weeks with 3 sessions of 1 hour per week.~All the sessions are led by a professional of adapted physical activity and will be personalized and adapted to the functional tests carried out during the initial evaluation.~Therapeutic education video-workshops weekly: about (i) the pathophysiology of fatigue in COVID-19, (ii) returning to work, (iii) lifestyle: sleep, physical activity and diet.~The medical follow-up will be carried out remotely with 1 weekly teleconsultation with a physiologist.~Psychological and / or dietetic follow-up, if necessary, during the program: 1 weekly teleconsultation At the end of the program, each participant is invited to contact the sport-health platform in order to continue the Adapted Physical Activity (APA) practice near home for 2 months."
76061157|NCT00084838|Drug|temozolomide|
76061158|NCT00084838|Drug|therapeutic hydrocortisone|
75598396|NCT01300338|Device|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
76061159|NCT00084838|Drug|vincristine sulfate|
76061160|NCT00084838|Radiation|radiation therapy|
76061161|NCT00084838|Drug|Dactinomycin|
76061162|NCT01558089|Drug|etanercept|according to SmPC and clinical practice
76061163|NCT01558089|Drug|methotrexate|according to SmPC and clinical practice
75598397|NCT02890290|Dietary Supplement|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
75598398|NCT02890290|Dietary Supplement|Placebo|Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
75598399|NCT01300260|Biological|LY2189265|Administered subcutaneously
75598400|NCT01300260|Drug|Placebo|Administered subcutaneously
75890571|NCT05236478|Other|Control|The CoviMouv' program is not presented to theses patients They have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
75742694|NCT03981432|Behavioral|REST-Fixed|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive a fixed meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75742695|NCT03981432|Behavioral|REST-AdLib|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75742696|NCT03981432|Behavioral|EX-AdLib|condition with an acute exercise set 30 minutes before the lunch meal that will be served ad libitum This will be a 30-minute exercise set at 65% of their capacities (cycling), 30 minutes before lunch.
75742697|NCT00536484|Drug|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
75742698|NCT00536484|Drug|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
75742699|NCT00370396|Biological|Synflorix|1 dose injected IM in the right thigh or deltoid.
75742700|NCT00370396|Biological|Prevenar|1 dose injected IM in the right thigh or deltoid.
75742701|NCT00370396|Biological|Infanrix hexa|1 dose injected IM in the right thigh or deltoid.
76061164|NCT01581021|Device|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
75598401|NCT01300260|Drug|Insulin|Administered intravenously
75598402|NCT01300260|Drug|Glucose|Administered intravenously
75598403|NCT01300260|Drug|Glucagon|Administered intravenously
75742702|NCT00992004|Dietary Supplement|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
75742703|NCT00992082|Drug|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
76061165|NCT01581021|Device|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
75448247|NCT05345782|Drug|MARCAINE AND BETAMETHAZONE 1|Laparoscopic Hypo gastric Neural Plexus Block
75448248|NCT05345782|Drug|MARCAINE AND BETAMETHAZONE 2|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block
75448249|NCT05335473|Drug|Eribulin and Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
75598404|NCT01256385|Biological|Cetuximab|Given IV
75448250|NCT05300984|Other|Topical Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
75448251|NCT05300984|Other|Topical Cream with 0.5% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
75448252|NCT05300984|Other|Topical Cream with 1% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
75598405|NCT01256385|Other|Laboratory Biomarker Analysis|Correlative studies
75742704|NCT00992082|Drug|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
75769630|NCT03885856|Other|double row repair technique|double row repair technique
75890572|NCT02925117|Drug|Upadacitinib|Tablet for oral use
75890573|NCT02925117|Drug|Placebo|Tablet
75890574|NCT04634149|Drug|BMS-986036|Specified dose on specified days
76061166|NCT03085342|Diagnostic Test|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
76061167|NCT04410003|Biological|Fecal microbial transplant|Fecal microbial transplant
75448253|NCT05300542|Other|Topical Placebo Cream|Application of test products before and after irradiation
75448254|NCT05300542|Other|Topical Cream with 0.5% Active|Application of test products before and after irradiation
75448255|NCT05300542|Other|Topical Cream with 1% Active|Application of test products before and after irradiation
75598406|NCT01256385|Drug|Temsirolimus|Given IV
75598407|NCT05609760|Other|SIMAP|Pictographic depiction of medical indications alongside standard communication of these recommendations.
75598408|NCT05609760|Other|Usual Care|Standard communication by medical staff of treatment indications for asthma. An informative leaflet will be delivered as well.
75598409|NCT00637182|Drug|Anastrozole|
75598410|NCT04324398|Other|Cryotherapy|cold application
75598411|NCT01298778|Drug|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
75598412|NCT01298778|Drug|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
75598413|NCT01298778|Drug|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
76061168|NCT00084682|Drug|romidepsin|Given IV
75598414|NCT01298700|Drug|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
75598415|NCT01298700|Drug|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
75598416|NCT01297920|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
75598417|NCT01297920|Drug|Brinzolamide ophthalmic suspension, 1%|
76061169|NCT01556997|Drug|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
75448256|NCT05299814|Behavioral|Behavioral Parenting Intervention|8 session evidence based parenting intervention
75448257|NCT05297903|Drug|XmAb20717|10mg/kg IV
75448258|NCT05286879|Behavioral|Patient Navigator|Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period
75448259|NCT05286879|Behavioral|Mobile Health Unit|Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
76061170|NCT01556997|Drug|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
76061171|NCT01556997|Drug|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
75598418|NCT01297920|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
75598419|NCT01255761|Biological|Certolizumab Pegol (CZP)|"400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52"
75598420|NCT04326972|Device|ultrasound|• All patients with inclusion criteria do for them chest ultrasound .
75598421|NCT01297062|Drug|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
75598422|NCT01297062|Drug|Moxifloxacin|Oral Moxifloxacin (400 mg)
75598423|NCT01297062|Drug|Placebo comparator|IV Placebo (matching volume of placebo)
75598424|NCT01254747|Device|Delefilcon A contact lens|Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
75598425|NCT01254747|Device|Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
75598426|NCT01254747|Device|Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
75742705|NCT00455013|Drug|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
75742706|NCT00455013|Drug|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
75598427|NCT01254747|Device|Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)|Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
75742707|NCT00455013|Drug|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
75598428|NCT01296672|Drug|Finasteride|Finasteride 5mg every day by mouth for 3 months
75598429|NCT01296672|Drug|Placebo|Placebo every day by mouth for 3 months
75598430|NCT01254669|Behavioral|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
75598431|NCT04324476|Drug|Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine|Drug: Bevacizumab 5mg/kg, iv, 30min, d1, 2w; Drug: Oxaliplatin 85mg/㎡, iv, 120min, d1, 4W; Drug: Irinotecan 150mg/㎡, iv, 90min, d15, 4w; Drug: Capecitabine 1000mg/㎡, bid, d2-8, 2w.
75598432|NCT04321473|Procedure|PCI on left main|PCI on left main coronary stenosis
75598433|NCT04206969|Behavioral|Transcultural psychotherapy|In addition to usual care, the participants receive transcultural psychotherapy
75598434|NCT04206657|Drug|1mg KHK7580|Single oral dose administration of 1mg KHK7580
75598435|NCT04206657|Drug|3mg KHK7580|Single oral dose administration of 3mg KHK7580
75598436|NCT04206657|Drug|6mg KHK7580|Single oral dose administration of 6mg KHK7580
75598437|NCT04206657|Drug|12mg KHK7580|Single oral dose administration of 12mg KHK7580
76061172|NCT00082888|Other|Laboratory Biomarker Analysis|Correlative studies
76061173|NCT00082888|Drug|Tipifarnib|Given PO
76061174|NCT03482986|Behavioral|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
76061175|NCT04403152|Other|Post-operative rehabilitation|Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
75890575|NCT05056298|Other|Custom made insole|Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot
75890576|NCT05056298|Other|Strengthening exercises of extrinsic foot muscles|Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
75890577|NCT05056298|Other|Strengthening exercises of intrinsic foot muscles|The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
75890578|NCT05056298|Other|Standard insole|Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
75890579|NCT02074332|Behavioral|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight&obese students Family physical activities Parent involvement
75890580|NCT02074332|Behavioral|Health education|Knowledge of obesity prevention and control
75890581|NCT04102735|Device|Under-the-nose facemask|Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
75890582|NCT04102735|Device|Over-the-nose facemask|Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
75890583|NCT02080962|Radiation|30 Gy in 5 fractions|5 fractions of 600 cGy, once a day, five times a week - TDF: 89
75890584|NCT02080962|Radiation|40 Gy in 10 fractions|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
75890585|NCT01379911|Other|Yogurt|
76061176|NCT04403152|Other|Post-operative mobilization|Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
76061177|NCT03085186|Drug|Crizotinib|
76061178|NCT03084874|Behavioral|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
76061179|NCT03084952|Drug|18-Methoxycoronaridine|Drug under evaluation for leishmaniasis treatment
76061180|NCT03084952|Drug|Glucantime|Leishmaniasis standard drug in Brazil
76061181|NCT00082810|Drug|fulvestrant|Given intramuscularly
75448260|NCT05286658|Behavioral|MEG/EEG|"The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete."
75448261|NCT05286658|Behavioral|MRI|An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.
75448262|NCT05286658|Behavioral|Speaking Tasks|The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
75598438|NCT04206657|Drug|6mg KHK7580 for 8days|multiple oral dose administration of 6mg KHK7580 for 8days
76061182|NCT00082810|Drug|tipifarnib|Given IV
76061183|NCT04402918|Diagnostic Test|biological samples day of delivery|mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
76061184|NCT03085108|Other|No Intervention|No Intervention
76061185|NCT01678066|Device|Bilateral cardiac output|
76061186|NCT03445000|Drug|Alectinib|"Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose."
76061187|NCT03085030|Drug|Antioxidant Formula|Antioxidant tablet will be taken by the patients
76061188|NCT03085030|Drug|Placebo|The placebo will be taken by the patients
76061189|NCT03444064|Biological|PolyTregs|Treatment group receive PolyTregs 6 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
76061190|NCT03443128|Drug|Vinorelbine|During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
76061191|NCT03437746|Drug|injection of methylprednisolone at anesthetic induction|intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
76061192|NCT03437746|Biological|Blood samples|Blood samples (D0, D1, D2, D3, D4)
75742708|NCT00455013|Drug|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
76061193|NCT03084562|Other|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
75448263|NCT05270980|Other|Cohorting|"The cohorting strategy will result in pairing serology-positive staff with serology-negative residents and serology-negative staff and serology-positive residents to the degree that penetration of serologic presumed immunity allows this pairing to be positive. Any resident who refuses serology testing will be treated as if they are serology negative as the safest strategy for risk of unwanted exposure."
75448264|NCT05268588|Behavioral|MESSSSAGE intervention|group mHealth education and social support intervention
76061194|NCT03479710|Biological|FMT infusion|Fecal microbiota transplantation via OGD
76061195|NCT01577745|Biological|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
76061196|NCT01678378|Behavioral|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
76061197|NCT03084250|Drug|Peginterferon Alfa-2A|180μg/week, 48 weeks; 135μg/week,48weeks
76061198|NCT03084250|Drug|Adefovir, entecavir,tenofovir, either of them|Adefovir, entecavir,tenofovir, either of them is ok
75448265|NCT05268263|Device|Artificial Intelligence Algorithm|The enrolled population will include patients with a history of lung pathologies. Artificial intelligence-based models are developed for classification of wheezes, crackles and normal lung sounds. These AI models will be tested and assessed on local lung sounds clinical data.
75448266|NCT05265767|Biological|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene administered by IV infusion following conditioning regimen.
75448267|NCT05259904|Drug|L-citrulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
75448268|NCT05259904|Drug|Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
75448269|NCT05254015|Behavioral|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.
75448270|NCT05254015|Behavioral|Case Management|Case management includes linking to resources, monitoring health, and safety hazards.
75448271|NCT05252130|Device|NoaScope|Smart digital stethoscope
75448272|NCT05242302|Procedure|nerve transfer|the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.
75448273|NCT05232773|Procedure|Assessment|Evaluation of clinical and kinematic parameters
75598439|NCT01295814|Drug|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
75598440|NCT01295814|Other|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
75598441|NCT01254045|Drug|placebo|intranasal placebo (48 international units)
75769631|NCT03885778|Drug|Besifovir dipivoxil|150mg Besifovir dipivoxil, single dose, oral
76061199|NCT01688037|Drug|NBI-98854|25 mg capsule
75448274|NCT05227339|Device|RAE|Subjects in the interventional group will have access to the RAE Health mobile app which receives continuous physiologic data from a wearable device. Algorithms embedded in the RAE app detect stress and craving events, and trigger mobile phone notifications when detected. Notifications are paired to real-time mindfulness based interventions.
75448275|NCT05224505|Other|GNT0006|Single intravenous infusion
75742709|NCT00455013|Drug|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
75742710|NCT00363298|Drug|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
75598442|NCT01254045|Drug|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
75448276|NCT05224505|Other|Day 0: Placebo|Single intravenous infusion
75890586|NCT05235152|Other|Usual individual physiotherapy care|"Usual and individual physiotherapy care guidelines were developed through a round-table discussion involving experts in musculoskeletal health. From the round-table discussion, the consensus as reflecting best-practices for the rehabilitation of musculoskeletal rehabilitation supported an active exercise rehabilitation approach which includes strengthening and neuromuscular training exercises. Furthermore, the following treatments are considered in addition to active exercises:~Range of motion: active, active-assisted, passive, repeated movements (Mulligan or McKenzie);~Stretching / manual therapy: mobilizations, manipulation, neural mobility, active release therapy;~Individual proprioceptive training."
75890587|NCT05235152|Other|Group-supervised physiotherapy training programs|Three group-supervised physiotherapy training programs (The lumbar, the upper extremity and the lower extremity training programs) were developed for military members with musculoskeletal conditions. They are composed of stations that each include several exercises of varying levels of difficulty. Group size will vary between 5 to 20 participants for one physiotherapist, and each military member performs his/her own exercises. During a typical session, the participant and therapist will choose one exercise to perform per station according to two main criteria: severity of the condition and the ability to perform the exercises optimally. The level of supervision is adapted to the participant's needs and performance. Progression in the programs leads to the execution of exercises that simulate functional and occupational tasks.
75890588|NCT02077920|Drug|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
75742711|NCT00363298|Drug|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
75448277|NCT05224505|Other|Day 0: GNT0006|Single intravenous infusion
75448278|NCT05224505|Other|Day 365 (year 1): Placebo|Single intravenous infusion
75448279|NCT05224505|Other|Day 365 (year 1): GNT0006|Single intravenous infusion
75448280|NCT05219799|Drug|Propranolol Hydrochloride|Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures
75448281|NCT05219799|Drug|Isoproterenol|Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness
75890589|NCT02077920|Drug|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
75890590|NCT02077920|Device|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
75890591|NCT02077920|Device|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
75890592|NCT03630133|Device|Intracept System Ablation|Radiofrequency ablation using Intracept System
75448282|NCT05219799|Drug|Phentolamine Mesylate|This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).
75448283|NCT05219799|Drug|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
75742712|NCT05261412|Other|Standard Consent|Participants in the control arm will undergo Standard Consent which will consist of paper PIL provided by EIDO healthcare followed by a verbal discussion (standardized by following a checklist of topics to discuss) with the responsible consultant surgeon and signing of the consent form. The time taken to read the PIL (self-recorded by the patient) will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
75448284|NCT05215951|Drug|osimertinib|Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration
75598443|NCT01254045|Drug|oxytocin 48IU|intranasal oxytocin (48 international units)
75598444|NCT04324320|Diagnostic Test|medical assessment|"medical assessment includes the collection of~sociodemographic data~anthropometric data (weight, height, body mass index)~medical data~psycho-oncologic basis assessment (PO-BADO questionnaire)~pain assessment (VAS: visual analogue scale)~3 functional tests:~handgrip strength~6 Minute Walking Test~Timed Get up and Go Test"
76061200|NCT01688037|Drug|NBI-98854|50 mg capsule
75890593|NCT05232890|Other|Datterino tomato purée from hydroponic technology|Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
75890594|NCT05232890|Other|Datterino tomato puree from conventional cultivation|Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
75890595|NCT02081040|Other|Not applicable (observational study with no active intervention)|
75890596|NCT03630523|Biological|Influvac Tetra|Tetravalent seasonal flu vaccination 2018/2019
75890597|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
75890598|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
75448285|NCT05205538|Other|Sprint interval exercise training|A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.
75598445|NCT04324320|Diagnostic Test|psychological assessment|"psychological assessment includes several standardized screening and assessment questionnaires and tools:~quality of life: SF-36~anxiety, depression, stress: Hospital Anxiety and Depression Scale (HADS-D)~subjective stress perception: Perceived Stress Scale (PSS-10)~resilience: resilience scale (RS-13)~fatigue: Brief Fatigue Inventory (BFI)~disability related to pain: Pain Disability Index (PDI)~workability: Work Ability Index - short version (WAI-K)~psychological assessment based on the checklist of the International Diagnoses (IDCL) for ICD-10 and the ICD-10 checklist of symptoms for psychological disorders (SCL))"
75598446|NCT01075282|Drug|Insulin Glargine|
75598447|NCT01075282|Drug|LY2189265|
75598448|NCT01075282|Drug|Metformin|
75598449|NCT01075282|Drug|Glimepiride|
75890599|NCT02225756|Drug|Placebo|Oral administration for a short time of placebo
75448286|NCT05199467|Behavioral|Health Coaching|Health coaches help people focus on goals, identify strengths and values, and work towards building the kind of life they wish to live.
75448287|NCT05199467|Behavioral|VA Benefits Information|Printed materials with information on VA benefits.
75598450|NCT04324242|Other|abdominal hallowing maneuver|abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
75598451|NCT04324086|Device|Calcium hydroxide with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide
75598452|NCT04324086|Device|Calcium hydroxide with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide
75890600|NCT02074488|Other|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
75890601|NCT02074488|Other|Informational Brochure|Informational Brochure on falls prevention
75890602|NCT02220062|Procedure|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5~10cc ethanol would be performed as bilateral injections at the celiac trunk.
76061201|NCT01688037|Drug|Placebo|
76061202|NCT03084484|Dietary Supplement|Kiwifruit addition to the diet|Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
76061203|NCT03084484|Procedure|Non Surgical periodontal treatment|Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
76061204|NCT03084406|Other|Centervention-ATOD (CV-ATOD)|A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
75598453|NCT04324086|Device|Calcium hydroxide with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide
75890603|NCT02220062|Procedure|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
75890604|NCT02074566|Other|Cryoballoon ablation|PVI using cryoballoon
75598454|NCT04326582|Other|Observation|Determine of percentage of each type of arthritis in children, it's prognosis and outcome of treatment in comparison with international guidelines
75742713|NCT05261412|Other|Digital health education tool (dHET)|Participants randomized to the intervention dHET will receive the dHET followed by a verbal discussion (as above) and signing of the consent form. The dHET will be delivered on a tablet computer and facilitated by a research assistant who will ensure all technological issues are overcome but will not engage with the participant with regard facilitating better understanding of the content. The digital offering will be interactive; participants will be able to traverse through each section at their own pace with the ability to re-visit sections. It also contains a two-minute narrated animation of the procedure, which can played, rewinded or fast forward. The time spent reading each section of the dHET and time spent watching the animation will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
75742714|NCT05254548|Drug|ACT-539313|100 mg ACT-539313 (hard capsules) will be administered twice per day in period 2 (morning and evening of Day 8), period 3 (morning and evening of Day 9 to 14) and period 4 (morning and evening of Day 15).
75742715|NCT05254548|Drug|Flurbiprofen|One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
75742716|NCT05254548|Drug|Omeprazole|A single dose of omeprazole 20 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
75742717|NCT05254548|Drug|Midazolam|A single dose of midazolam 2 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
75742718|NCT00363142|Drug|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
75598455|NCT01253811|Drug|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
75598456|NCT01295580|Device|ARTZ|Hyaluronic acid (five 2.5 mL injections)
75598457|NCT01295580|Device|DUROLANE|Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)
75598458|NCT01253577|Device|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
75598459|NCT01253577|Device|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
75598460|NCT02876692|Device|Machine perfusion|Deceased donor kidneys were preserved by hypothermic machine perfusion
75598461|NCT01295034|Dietary Supplement|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
75598462|NCT01295034|Drug|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
75598463|NCT01253421|Drug|amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
75598464|NCT01253421|Drug|placebo|single-dose placebo capsule
75598465|NCT01077076|Drug|Zegerid|Zegerid taken once daily for 11 days.
75598466|NCT01077076|Drug|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
75598467|NCT01077076|Other|Placebo|Placebo taken once daily for 11 days.
75742719|NCT00363142|Drug|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
75742720|NCT05246982|Drug|HLX07+HLX10+oxaliplatin+capecitabine|HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
75890605|NCT02225834|Drug|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
75890606|NCT02077998|Radiation|carbon C 14 oxaliplatin|Given IV
75890607|NCT02077998|Drug|oxaliplatin|Given IV
75742721|NCT05246982|Drug|HLX07|HLX07 1500mg q3w
75742722|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
75742723|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
75742724|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
75890608|NCT02077998|Other|laboratory biomarker analysis|Correlative studies
75598468|NCT02876848|Other|OPTIMUM e-health tool|"If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:~Contact you over the phone or in person to provide medical advice on how to better take your pills,~Contact your pharmacist(s) and other doctors about your anti-cancer treatment."
75742725|NCT04002492|Behavioral|Bodyweight training|Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
75742726|NCT00454857|Other|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
75742727|NCT00454857|Other|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
75890609|NCT05461183|Other|Retrospective database analysis|This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
75890610|NCT02225912|Other|PrevinC|
76061205|NCT03084328|Dietary Supplement|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
75890611|NCT02225912|Drug|placebo|
75448288|NCT05182294|Device|AIRVO 2, the new asymmetric nasal cannula|The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..
75890612|NCT02074644|Procedure|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
75598469|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
75598470|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
75598471|NCT02876224|Drug|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
75598472|NCT02876224|Drug|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
75598473|NCT02876224|Drug|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
75598474|NCT01294800|Drug|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
75598475|NCT01294800|Drug|Placebo tablet to match Preladenant|tablets taken orally BID
75598476|NCT01294644|Drug|Deoxycholic acid injection|
75742728|NCT00454857|Other|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
75890613|NCT02074644|Procedure|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
75890614|NCT02222324|Drug|Placebo|8 placebo tablets matching E2609
75890615|NCT02222324|Drug|E2609|E2609 will be administered as 8 tablets
76061206|NCT03707314|Procedure|Angiography with follow-on revascularisation if indicated|Angiography with follow-on revascularisation (if indicated)
76061207|NCT01678534|Drug|Allogenic mesenchymal stem cells from adipose tissue|
76061208|NCT01678534|Drug|Placebo|
76061209|NCT01678690|Drug|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
76061210|NCT01679080|Drug|Zoledronic acid|antiresorptive and calcium and vitamin D
76061211|NCT01679080|Drug|Teriparatide|anabolic and calcium and vitamin D
75890616|NCT02222324|Drug|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
75890617|NCT02220140|Behavioral|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
75890618|NCT02074800|Drug|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
75890619|NCT02074800|Drug|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
75742729|NCT05243004|Other|Phone Nurse consultation|"A phone call will be made by the nurse 72 hours before the surgery. During this phone call, the nurse :~underlines the preoperative preparation instructions (skin preparation, fasting period, specific medical instructions given by the anesthesiologist, administrative instructions)~ensures that the reason for hospitalization is understood~answers the patient's questions."
75742730|NCT02534818|Drug|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
75448289|NCT05168839|Drug|FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).|"In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist.~The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera.~A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits.~An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded."
75448290|NCT05161468|Drug|Lidocaine injection|2ml of 1% lidocaine will be drawn into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
75448291|NCT05161468|Drug|Corticosteroid Injection|1 ml of triamcinolone acetonide (40 mg/ml) will be drawn with 1 ml normal saline into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
75448292|NCT05161468|Drug|Protein Rich Plasma(PRP) Injection|30 ml of acid-citrate-dextrose (ACD) will be drawn into a 30 ml syringe to coat the syringe. 3 ml will be left in the syringe and then 27 ml of blood will be drawn via standard venipuncture. The 30 ml mixture of blood and ACD will then be prepared in the Peak PRP system as described in the manufacturer's instruction (PEAK® PRP System). After preparation, PRP will be withdrawn (2 mls) into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
75598477|NCT01294644|Drug|Placebo|Phosphate buffered saline placebo for injection
75598478|NCT01293240|Device|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
75598479|NCT01253265|Drug|LY2439821|Administered subcutaneously
75598480|NCT01253265|Drug|Placebo|Administered subcutaneously
75598481|NCT01293084|Drug|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
75598482|NCT01293084|Drug|7% saline|5mL 7% saline inhaled once over 20 minutes
75598483|NCT01293006|Drug|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants <65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
75598484|NCT01293006|Drug|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
75742731|NCT02534818|Drug|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
75742732|NCT04002024|Other|Moisturizer with active ingredients|Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day
75742733|NCT04002024|Other|Placebo|Placebo: 1 fingertip unit to cover one side of the face twice a day
75742734|NCT01027299|Device|Biventricular pacing|Optimised temporary biventricular pacing.
75742735|NCT05355324|Other|no intervention|no intervention
75742736|NCT01028313|Drug|LBH589|20 mg PO three times weekly
75742737|NCT01028313|Drug|Methylprednisolone|1 mg/kg/day PO continuously
75742738|NCT04001712|Drug|Caffeine Citrate|caffeine citrate is given early to preterm neonates in need of respiratory support
75890620|NCT02074800|Drug|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
75890621|NCT04504045|Drug|Metformin|500 mg tablet
75890622|NCT04504045|Drug|Caffeine|As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
76061212|NCT01679080|Other|No active treatment|Calcium and vitamin D
75890623|NCT04504045|Drug|Efavirenz|As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
75890624|NCT04504045|Drug|Losartan|As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
76061213|NCT01679158|Device|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
76061214|NCT03083782|Drug|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
75448293|NCT05153382|Behavioral|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly meetings and individual therapy conducted in 60 minute biweekly sessions. Family participation in skills training is highly encouraged. Skills training proceeds as follows: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants by cell phone for in-vivo skills coaching between sessions.
75890625|NCT04504045|Drug|Omeprazol|As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
75448294|NCT05133726|Other|Text4Support|Daily supportive text messages
75890626|NCT04504045|Drug|Metoprolol|As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
75448295|NCT05133726|Other|Peer support|Meeting with peers who have lived experiences with similar diagnoses but are in recovery
75890627|NCT04504045|Drug|Midazolam|As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
76061215|NCT03083782|Drug|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
76061216|NCT03083782|Drug|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
75448296|NCT05133544|Device|Endocuff with AI|Use of endocuff with computer assisted polyp detection
75448297|NCT05133544|Device|AI alone|Use of computer assisted polyp detection
75742739|NCT03794193|Procedure|Radical resection of colon cancer|The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.
76061217|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
75598485|NCT02335749|Device|The ZELTIQ System|The CoolSculpting System with a Small Area Applicator will be used to deliver treatments.
76061218|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
76061219|NCT03083860|Device|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
75598486|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
75742740|NCT05355246|Other|assisted sit-up exercises|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and maximum of 10 repetitions, two times a day and two days a week. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting treatment session.
76061220|NCT03402334|Behavioral|Patient counseling for HCV associated CVD risk factors|Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
76061221|NCT03087994|Behavioral|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
76061222|NCT03087994|Behavioral|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance once during the study
75598487|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg / L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
75890628|NCT02225990|Other|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
75890629|NCT02225990|Other|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
75742741|NCT05355246|Other|swiss ball pikes exercises|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend her hips and try to pull her feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting the treatment session.
75742742|NCT01028469|Device|Artelon MTP Spacer|Metatarsophalangeal hemi-implant
75890630|NCT02225990|Other|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
75448298|NCT05124886|Other|Moderately High Oxalate (MOx) Diet|Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
75448299|NCT05120947|Radiation|42 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.2 Gy.
75448300|NCT05120947|Radiation|39 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.875 Gy.
75448301|NCT05120947|Radiation|32.5 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 6.5 Gy.
75448302|NCT05108389|Diagnostic Test|Viscoelastic haemostasis monitor output|Observational
75742743|NCT01027377|Drug|rFVIIIFc|Single dose
75742744|NCT01027377|Drug|rFVIIIFc|Single dose
75742745|NCT00992160|Drug|GW597599|GW597599 15mg tablet
75742746|NCT00992160|Drug|Placebo|Placebo to match GW597599 15mg tablet
75742747|NCT00379912|Drug|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
75742748|NCT00379912|Drug|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
75448303|NCT05104762|Device|plasmapheresis device|Group 1: 54 patients of Guillian Barrie syndrome undergo plasma exchange (5 sessions)
75598488|NCT01253187|Drug|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
75598489|NCT01252563|Drug|Amlodipine|Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
75742749|NCT00379912|Drug|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
75742750|NCT05239650|Drug|HLX07|1000mg
75742751|NCT05239650|Drug|HLX10|200mg
75890631|NCT02225990|Other|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
75890632|NCT03283488|Drug|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
75890633|NCT03283488|Drug|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
75890634|NCT02258204|Drug|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
75890635|NCT02258204|Drug|Placebo|
75598490|NCT01292226|Drug|mycophenolate mofetil|1 g PO BID for 24 weeks
75598491|NCT01292226|Drug|antibody induction|According to manufacturer recommendation
75448304|NCT05104762|Drug|Intravenous immunoglobulin|group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.
75598492|NCT01292226|Drug|Cyclosporine|According to manufacturer recommendation
75598493|NCT01292226|Drug|corticosteroid|According to manufacturer recommendation
75598494|NCT04207047|Device|Genius|"The Infini Radiofrequency System (K121481) is the predicate device. It is a minimally invasive radiofrequency device that employs a bipolar microneedle electrode system indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles.~The Genius system is substantially equivalent to the Infini device with a digitally controlled direct drive mechanism for needle insertion and an improved needle design for easier needle insertion. The active tip of the Genius system is the substantially equivalent to the Infini device. The handpiece of the Genius system has also been redesigned to be lighter and more ergonomic."
75448305|NCT05098665|Combination Product|Telemonitoring service|Patients in the active arm will receive a cellular network connected set of digital scales, and instructed to take their weight each morning at the same time. This device (BodyTrace) automatically uploads each daily weight reading to a central database. A clinical algorithm is applied to detect those at risk of acute and subacute decompensated heart failure. Patients are contacted within 24-48 hours of being flagged as at risk by a heart failure specialist. A clinical history is taken, and medication review undertaken, in line with a protocol. Diuretics are adjusted as per the protocolised changes, or for patients at ceiling of treatment, referral for local specialist review is made. A third protocol for follow-up is then followed to close the loop of intervention.
75448306|NCT05094297|Behavioral|Investigate the effects of an exercise intervention on U.S. Veterans.|Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.
75598495|NCT04207047|Device|eC02|The eCO2 Laser System (K091115) is indicated for use in dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Additionally, the 120 micron and 300 micron spot sizes are used in the treatment of wrinkles; rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. The fractional 90 degree BellaV handpiece is intended to provide fractional CO2 treatment of skin and is not yet cleared.
75598496|NCT04207047|Device|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery as follows:
75598497|NCT04207047|Device|LaseMD|The LaseMD Laser System (K171009) is a 1927 factional thulium laser indicated for use in dermatological procedures requiring the coagulation of soft tissue, treatment of actinic keratosis, and treatment of benign pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and ephiledes (freckles). The cleared LaseMD system is a 5W system.
75598498|NCT04207047|Device|LaseMD Flex|There are two new versions of the LaseMD system to be used in this study that are uncleared and investigational use only. The only change from the cleared system to the one of the LaseMD systems to be used in this study is that the watts have been increased to 20W and a new tip configuration with a larger 250+ um spot size. The other LaseMD system to be used in this study is the LaseMD FLEX. It also has 20W with larger spot size, a modified flat-top beam profile (as opposed to a Gaussian beam profile) and a faster scan rate. All other technical specifications remain the same as the cleared device.
75598499|NCT01290822|Device|BiVP|Biventricular pacing
75598500|NCT01290822|Device|AAI Pacing|Atrial pacing
75598501|NCT01075048|Drug|Tivantinib|ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
75598502|NCT01075048|Drug|Placebo|Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
75598503|NCT01075048|Drug|Cetuximab|Cetuximab 500 mg/ m^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
75598504|NCT01075048|Drug|Irinotecan|60 minutes after cetuximab, Irinotecan 180 mg/m^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
76061223|NCT03083392|Procedure|treatment of chronic maxillary sinusitis using DIVA system|chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
75448307|NCT05084339|Diagnostic Test|CGM|blinded CGM used at 4 different time points in pregnancy
75598505|NCT01290666|Device|Fistula Plug|Bioabsorbable fistula plug
75598506|NCT01252251|Drug|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
75598507|NCT01289574|Drug|ASC-J9|Cream for twice daily topical application to the face
75598508|NCT02888301|Procedure|Computed Tomography|Undergo 18F-clofarabine PET/CT
75598509|NCT02888301|Radiation|Fluorine F 18 Clofarabine|Given IV
75598510|NCT02888301|Procedure|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
75598511|NCT00624273|Drug|Sildenafil therapy|oral use
75742752|NCT05239650|Drug|mFOLFOX6|OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
75742753|NCT00379834|Drug|Cosopt|Cosopt twice daily in both eyes
75890636|NCT04448743|Other|Blood sample|20 Ml blood sample
76061224|NCT03083392|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply saline lavage to the maxillary sinus
76061225|NCT03471442|Procedure|Paravertebral block|Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
75742754|NCT04001322|Other|Community engagement|The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
75742755|NCT04001322|Other|IRISS advert for opt-in|A module to advertise and demonstrate how individuals can opt-in to IRISS to receive the messages will be included in the community engagement sensitization meetings.
75742756|NCT04001322|Other|One-time SMS broadcast on immunization|General broadcast of SMS messages on the importance of immunization to all active mobile phone subscribers in the intervention LGAs
76061226|NCT03471442|Procedure|Erector spinae plane block|Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
75742757|NCT04001322|Other|Scheduled weekly SMS reminder of health facility RI schedule to community leaders|"Traditional and religious leaders who have a phone or access to a phone and have been registered on IRISS will receive SMS messages on the immunization session schedule of the health facilities in their communities, so they can disseminated the information through their town announcers to inform parents and caregivers. For example, Ribah clinic is holding a vaccination session tomorrow from 8am to 2pm. Please take your child there to vaccinate them and encourage your neighbors to vaccinate their children."
75742758|NCT04001322|Other|Scheduled bi weekly RI messages to community leaders|"Traditional and religious leaders who own or have access to a phone and have been registered on IRISS will receive SMS messages on immunization, to share same with community members. The message categories are: 1) Educational messages that provide facts and increase knowledge, e.g. Have you heard of Penta vaccine? It protects against 5 diseases: they are diphtheria, whooping cough, tetanus, HiB and Hepatitis B. 2) Informative messages that dispel myths about immunization, e.g. Getting more than one vaccine at the same time does not harm a child. It is very important to completely receive all vaccine doses for full protection. 3) Normative messages to promote positive norms, e.g. Our religious leaders have immunized their children, what are we waiting for? 4) Motivational messages to inspire action, e.g. Each visit to the health center for vaccination will reap many health benefits. Say YES to good health, be on time and complete your child's vaccination."
75742759|NCT04001322|Other|Responsive individualized child vaccination schedule reminder to caregivers who opt-in|"Parents and caregivers who voluntarily registered their child's information into IRISS will receive a reminder, a day before, about their child's due vaccines and the schedule of vaccination sessions in the health facilities within their locality (wards), e.g. Greetings! Amina is due for Penta 1 tomorrow, kindly visit Ribah clinic. They vaccinate on Mondays and Thursdays."
75742760|NCT04001322|Other|Responsive one-time SMS message on hand washing to those that erroneously register on IRISS|"If individuals from control LGAs encounter IRISS adverts inadvertently and erroneously register into IRISS expecting a message, to avoid a loss in trust if no message is sent, they will receive a one-time general message about the importance of hand-washing, e.g. Wash your hand with soap and water every time you finish from to the toilet, to maintain clean hands and avoid germs that make you sick."
75742761|NCT00992316|Drug|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
75890637|NCT02226068|Drug|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
76061227|NCT03471442|Drug|General anesthetic|General anesthesia administered as per preference of intra-operative attending anesthesiologist
76061228|NCT03471442|Drug|Opioids|Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
76061229|NCT03471442|Drug|Anesthetics, Local|Weight-based dosing of this local anesthetic mixture.
76061230|NCT01679392|Drug|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
76061231|NCT01679470|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
76061232|NCT04279912|Device|Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis|The intervention is MRIgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
76061233|NCT03083158|Drug|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
75448308|NCT05075941|Other|Vaccination coverage|proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population
75448309|NCT05052112|Other|E-PR-01|Active arm
75448310|NCT05052112|Other|E- PR-02|Placebo arm
75448311|NCT05051618|Behavioral|POWER-MS|"The POWER-MS intervention includes both aerobic exercise and resistance exercise:~Aerobic Exercise:~The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention.~Resistance Exercise:~Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level."
76061234|NCT04277416|Device|Total Hip Arthroplasty|To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
76061235|NCT03083236|Other|Standard PBI|Standard Parent Based Intervention (PBI)
75890638|NCT02226068|Other|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
75598512|NCT02874976|Device|Active and Active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
75598513|NCT02874976|Device|Active and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
75598514|NCT02874976|Device|Placebo and active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
75742762|NCT00379210|Behavioral|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
76061236|NCT03083236|Other|Enhanced|Enhanced Parent Based Intervention (EPBI)
75742763|NCT00379210|Behavioral|Nutrition Education course|8-week course in nutrition
75742764|NCT00992472|Drug|Prochlorperazine suppositories, 25mg|
75742765|NCT00992472|Drug|Compazine® suppositories, 25mg|
75742766|NCT03453840|Drug|Artemether-lumefantrine|Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: <15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; >=35kg, 4 tablets.
75890639|NCT02081274|Procedure|Surgery for congenital heart disease|
75890640|NCT05424991|Behavioral|comedy movie group|The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
76061237|NCT03082924|Device|Control group|Neither cycle training nor inspiratory muscle training.
76061238|NCT03082924|Device|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
75890641|NCT02081352|Other|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
75890642|NCT02081352|Other|Standard care|
76061239|NCT03082924|Device|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
75890643|NCT02222402|Behavioral|INTRA-DIALYTIC EXERCISE TRAINING|
75890644|NCT01378585|Drug|DLBS1033|3 x 490 mg DLBS1033 daily
75890645|NCT01378585|Drug|Placebo|3 x 1 tablet daily
75890646|NCT02220218|Drug|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
76061240|NCT03082924|Device|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
75448312|NCT05051618|Behavioral|FLEX-MS|The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
75598515|NCT02874976|Device|Placebo and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
75598516|NCT04305964|Device|Nastent® (a distally perforated soft silicon nasal tube)|Insertion of the Nastent® to nostril during sleep hours
75598517|NCT04305964|Diagnostic Test|Polygraphy with WatchPAT™ 300|WatchPAT™ 300 is an innovative diagnostic Home Sleep Apnea Test (HSAT) that utilizes the proprietary Peripheral Arterial Tone signal (PAT™) to enable simple, accurate and reliable sleep apnea testing.
75742767|NCT05356650|Other|Mulligan Mobilization|The patient will be in a prone position. With one hand, the physiotherapist will fix the sacrum and place the fingers of her other hand under the anterior superior iliac spine. The therapist then pull the ilium on the sacrum and will instruct the patient to do press-ups. Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
75598518|NCT01252095|Drug|PG545|PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
75598519|NCT04306042|Drug|Nivolumab or Pembrolizumab|Nivolumab or Pembrolizumab
75742768|NCT05356650|Other|PNF|"PNF stretching will be performed using contract-relax techniques of agonists in supine, prone and side-lying. Contract-relax will be applied with a 6-second contraction with 80% force of the maximal isometric contraction on the muscles (iliopsoas, hamstrings and gluteal muscles) and will be followed by a 15-second passive static stretching in the opposite direction of that muscles. Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.~Patient will be in supine, prone, side lying. Both groups will receive a baseline treatment (Moist Heat Pack for 10 minutes and 10 minutes of Ultrasound (0.75 MHz, continuous wave)"
75890647|NCT02220218|Drug|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
75598520|NCT04305886|Other|Discussion Guide|Written list of prompts to facilitate discussion
75742769|NCT00378898|Device|BRAVO capsule|
75742770|NCT00378898|Procedure|Fluoroscopy|"one time xray to determine evacuation of bravo"
75448313|NCT05049070|Diagnostic Test|Mobile medical application to self administer a subjective refraction test|GoEyes is a software as a medical device and mobile medical application, which is downloaded to a smartphone and is a self-administered subjective refraction test that measures the refractive error of the user's eyes in the home environment without any contact or help from health care professionals
75598521|NCT04305730|Behavioral|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
75890648|NCT02220218|Drug|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
75890649|NCT03559452|Procedure|Eccentric exercise|300 eccentric contractions of the knee extensors
75890650|NCT02081430|Procedure|CT Manipulation|
75890651|NCT02081430|Procedure|Upper trapezius stretch|
75890652|NCT02222480|Drug|Fimasartan|
75890653|NCT02222480|Drug|Hydrochlorothiazide|
75890654|NCT02222480|Drug|Placebo|
75598522|NCT04305730|Behavioral|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
75598523|NCT01074658|Device|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
75598524|NCT01074502|Drug|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
75598525|NCT01289028|Drug|Nilotinib|
75598526|NCT04305652|Other|The Progressively Lowered Stress Threshold Model|PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
75598527|NCT02875990|Biological|Blood sample|
75598528|NCT04777474|Diagnostic Test|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy - studied imaging technique
76061241|NCT01679704|Dietary Supplement|Food products|
75448314|NCT05049070|Diagnostic Test|Standard of care refraction test|Standard of care subjective manifest refraction test performed by a healthcare professional
75448315|NCT05044455|Behavioral|Cognitive Behavioural Therapy (CBT)|A 9 week CBT group, 2 hours weekly, is delivered by trained Peer facilitators to mothers randomized to this arm.
75448316|NCT05037708|Procedure|Manual lymphatic drainage|"Subjects are randomly assigned to group 1. Group 1 receives treatment A* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B** was applied to group 1 for 4 weeks.~*Treatment A consists of manual lymphatic drainage.~**Treatment B consists of no treatment"
75598529|NCT04777474|Diagnostic Test|Narrow band imaging|The study subjects will undergo narrow band imaging - comparator procedure
75598530|NCT04777474|Diagnostic Test|IMAGE1S imaging|The study subjects will undergo IMAGE1S imaging - comparator procedure
75598531|NCT02890056|Behavioral|H2GO!|
75448317|NCT05037708|Procedure|Manual lymphatic drainage|"Subjects are randomly assigned to group 2. Group 2 receives treatment B** for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A* was applied to group 2 for 4 weeks.~*Treatment A consists of manual lymphatic drainage.~**Treatment B consists of no treatment"
75448318|NCT05032092|Diagnostic Test|Next Generation Sequencing|Molecular analysis of liquid biopsy.
75448319|NCT05032092|Diagnostic Test|Next Generation Sequencing|Molecular analysis of tissue biopsy.
75598532|NCT04303312|Other|Benzydamine Hydrochloride|Patients will rinse by mouth three times daily for 20 days
75598533|NCT04303312|Combination Product|Solcoseryl and pumpkin seed oil|Patients will receive by mouth three times daily for 20 days
75598534|NCT05590026|Drug|Pectointercostal and ESP block|Both Pectointercostal at between 4th and 5th costa and ESP block will apply at thoracal 6 level to the patient.
75598535|NCT04303546|Device|arterial stiffness measurements|We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB
75598536|NCT05579184|Drug|[177Lu]Ludotadipep|"Patients will receive 100 mCi of [177Lu]Ludotadipep every 8 [±1] weeks (up to 6 times)~Test article code/name: [177Lu]Ludotadipep~Administration route: intravenous injection~Total dose strength: 4 to 6 x 3.7 GBq~Dosage form: solution for injection"
75742771|NCT00378898|Other|sham BRAVO capsule placement|
75598537|NCT04303624|Other|Health sciences survey|Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
75742772|NCT01045720|Drug|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
75890655|NCT03669471|Other|Testing of performance|"The cross-sectional evaluation will involve assessment of:~Hip muscle function~Single leg jump performance~Self-reported hip and groin function~Evaluation of return to sport~Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk."
75890656|NCT02081508|Behavioral|Interference onset|Temporal duration of interference onset.
75890657|NCT02258438|Behavioral|Uninterrupted sitting|Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
75890658|NCT02258438|Behavioral|Sitting + 1 bout of activity|Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
75890659|NCT02258438|Behavioral|Sitting + microbursts of activity|Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
75598538|NCT04305574|Behavioral|Use of social media during COVID-19|Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
75598539|NCT01250925|Drug|ReNu MultiPlus® MultiPurpose Solution|Contact lens care regimen
75742773|NCT01045720|Drug|Placebo|Placebo (starch)
75890660|NCT03670875|Dietary Supplement|Agave inulin|Will be provided in dehydrated apple cubes
75598540|NCT01250925|Drug|OPTI-FREE® RepleniSH®|Contact Lens care regimen
75598541|NCT01250925|Drug|Clear Care®|Contact lens care regimen
75742774|NCT00992550|Drug|Cigarette|
75448320|NCT05032092|Genetic|Biomarker Monitoring|Biomarker Monitoring of study patients receiving matched therapy.
75448321|NCT05027425|Drug|Durvalumab|1500 mg IV, Q4W
75742775|NCT00992550|Drug|Hookah|
75448322|NCT05027425|Drug|Tremelimumab|300 mg IV, 1 dose on day 1 of only the first cycle
75448323|NCT05027425|Procedure|Liver Transplant|minimum 72-day washout from the end of immunotherapy, patients will undergo liver transplant.
75448324|NCT05025826|Other|Phycocare|Phycocare every day during 9 months (except days of chemotherapy: no Phycocare)
75448325|NCT05025826|Other|Placebo|Placebo every day during 9 months (except days of chemotherapy = no Placebo)
75448326|NCT05012020|Device|mHealth Remote Monitoring platform|Clinic Portal and Mobile Application for remote monitoring of Chronic Kidney Disease patients and patients on Peritoneal Dialysis
75598542|NCT01285908|Drug|Intravenous Norepinephrine Infusion|
75742776|NCT05354700|Drug|HLX07|HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
75742777|NCT05354700|Drug|HLX10|HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
75742778|NCT05354700|Drug|carboplatin and etoposide|chemotherapeutics
75742779|NCT03339258|Drug|Doxazosin Mesylate, Extended Release|Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
75890661|NCT03670875|Dietary Supplement|Curcumin|Will be provided in capsules
75890662|NCT03670875|Dietary Supplement|O3FA|Will be provided in capsules
75890663|NCT03670875|Behavioral|Control|Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
75890664|NCT02078076|Device|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
75890665|NCT02226146|Biological|Bertilimumab|
75890666|NCT01379677|Drug|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
75890667|NCT01379677|Drug|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
75598543|NCT05577234|Other|Animal-assisted intervention|The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation. Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.
75598544|NCT05577234|Behavioral|Venham scale modified by Veerkamp|The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
75598545|NCT01250769|Device|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
75598546|NCT01250769|Device|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
75598547|NCT05574270|Device|IC-8 Intraocular Lens (IOL)|A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
75598548|NCT01074268|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
75598549|NCT01074268|Drug|insulin detemir|Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
75598550|NCT01074268|Drug|insulin aspart|Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
75890668|NCT02220296|Drug|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
76061242|NCT04273360|Other|Systematic use group|Patients in this group will be subjected to initial systematic PR, which will be re-evaluated every day every day between day 0 and day 14
75448327|NCT05003648|Drug|Pramipexole|Participants will be started on 0.125 mg pramipexole for the first week. If this dose is well tolerated but not effective, the dose can be increased to 0.25 mg for the following week. If this dose is well tolerated but not effective, the dose can be further increased to 0.5 mg for the remainder of the 2-month period.
75448328|NCT05003648|Drug|Placebo|Matching placebo
75448329|NCT04996849|Other|Data Capture|Data collected
75448330|NCT04996849|Other|Questionnaire Administration|Ancillary studies
75448331|NCT04958460|Drug|Placebo|Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening
75448332|NCT04958460|Other|BF688|Administrated 1 pack each morning and evening (5×109 CFUs per day)
75598551|NCT04303234|Other|Artinibsa|local anaesthetic solution with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.
75598552|NCT04303234|Other|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
75742780|NCT03339258|Drug|Placebo|Placebo, or inactive pill.
75890669|NCT02220296|Drug|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
75890670|NCT02220296|Drug|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
75890671|NCT02220296|Drug|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
75890672|NCT03670719|Other|Manual Therapy and Exercise|Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
75890673|NCT03670719|Other|Exercise|Exercises for the cervical spine
76061243|NCT04273360|Other|Restrictive use group|Patients in this group will be subjected to PR only in case of severe agitation, defined by a RASS ≥ +3 on any given day between day 0 and day 14
76061244|NCT03083080|Procedure|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
76061245|NCT03083080|Drug|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
76061246|NCT03083080|Drug|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
75448333|NCT04952623|Other|Rotator Cuff Related Shoulder Pain E-Learning Program|The RCRSP e-learning program is designed according to the ADDIE Instructional Design Model in light of current literature.
75448334|NCT04943172|Device|Hancock-Jaffe bioprosthetic venous valve (VenoValve®)|Surgical implantation of the VenoValve device
75598553|NCT01074190|Drug|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
75598554|NCT01074190|Drug|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
75598555|NCT01074190|Drug|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
75598556|NCT01073566|Device|Finesse|Finesse Insulin Delivery Patch
75598557|NCT01073566|Device|Pen/Syringe (Usual injection device)|Pen/Syringe
75598558|NCT01072396|Drug|Tiotropium|double blind randomized crossover
75890674|NCT02074878|Drug|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
76061247|NCT03080038|Other|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
75598559|NCT01072396|Drug|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
75598560|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
75598561|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
75598562|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
75598563|NCT02876146|Drug|Benzimidazole|Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
75598564|NCT02874586|Other|Plasma exchange combination of immunosuppressive regimens|
75890675|NCT02074878|Drug|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
75890676|NCT02074878|Drug|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
75890677|NCT02258672|Other|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
75448335|NCT04913168|Other|Front Line Worker Pilot Project|13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
75448336|NCT04898816|Procedure|closure of wound using n- butyl 2-octyl cyanoacrylate tissue adhesive|Application of cyanoacrylate tissue adhesives over the surgical wound
75448337|NCT04898816|Procedure|closure of wound using braided silk suture|suturing the surgical wound using braided black silk
75448338|NCT04880278|Drug|Nabilone|Half of the participants (30 individuals) will receive nabilone 1mg. Nabilone will be placed in opaque capsules with dextrose filler and administered by mouth only once (around 120 minutes prior to fMRI scanning).
75598565|NCT02875756|Procedure|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
75598566|NCT02875756|Procedure|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
75742781|NCT04002570|Other|blood samples collection|blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
75742782|NCT00992628|Device|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
75742783|NCT00992628|Device|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
75890678|NCT01379599|Behavioral|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
75890679|NCT02220374|Other|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
75890680|NCT02081664|Behavioral|lifestyle intervention|
75598567|NCT04305418|Other|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
75598568|NCT02875678|Drug|ABX-1431|Single-dose ABX-1431
75598569|NCT02875678|Drug|Placebo|Single-dose matching placebo
75742784|NCT00378508|Drug|mAb hOKT3gamma1(Ala-Ala), Teplizumab|This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
75890681|NCT03075163|Procedure|Acupressure|"Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team."
75890682|NCT03075163|Drug|Ondansetron|Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
75890683|NCT02258750|Dietary Supplement|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
76061248|NCT04761562|Drug|Platelet- and extracellular vesicle-rich plasma|PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
76061249|NCT04761562|Procedure|Control group|Edges of the tympanic membrane perforation will be refreshed and the tympanomeatal flap raised. Under the tympanic membrane perforation, a guide (fascia of the temporalis muscle, perichondrium, cartilage or fat) will be placed. An absorbent gelatin sponge will be placed under the guide and on the outer surface of the reconstructed tympanic membrane.
75890684|NCT02258750|Other|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
75890685|NCT02220530|Drug|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
75890686|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
75890687|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
75890688|NCT02075034|Drug|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
75890689|NCT03670563|Other|Short foot exercise protocol|Exercises that target intrinsic foot muscles
76061250|NCT05346328|Drug|Injection of A166|4.8 mg/kg for each 21 (±3) -day cycle
76061251|NCT03082690|Drug|DuoGel|1% IQP-0528 in gel formulation
75598570|NCT02874820|Radiation|[11C]BU99008|Baseline and blocked scans
75598571|NCT02874820|Drug|Idazoxan|Idazoxan dose up to 80mg
75598572|NCT04305028|Drug|Rivaroxaban|Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet
76061252|NCT04403230|Procedure|Retreatment of teeth prepared without finish line|Retreatment of teeth treated using biologically oriented preparation technique (BOPT). The sample (149 teeth) was divided into two groups: Seventy four teeth restored with crowns, and 75 teeth supporting fixed partial dentures (FPD).
76061253|NCT03082300|Drug|naquotinib|Oral
75598573|NCT04305028|Drug|Aspirin|Aspirin 75-100 mg once daily, tablet
75598574|NCT04304794|Procedure|Administration of iodinated contrast media|Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
75742785|NCT00378508|Drug|Placebo Arm|
75742786|NCT00992706|Drug|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
75742787|NCT00992706|Drug|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
75742788|NCT02534740|Drug|tafamidis|relative bioavailability
76061254|NCT03082768|Drug|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two [18F]MNI-968 injections and PET scans.
75742789|NCT02534740|Drug|tafamidis|fasted
75742790|NCT02534740|Drug|tafamidis|fed
75742791|NCT01580956|Other|VARIABLE-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
75742792|NCT01580956|Other|STANDARD-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
75598575|NCT04304794|Drug|Prophylactic administration of antithyroid drugs before iodinated contrast media exposure|13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
75598576|NCT01285518|Drug|PF-05231023|0.5 mg QD IV x 1 day
75598577|NCT01285518|Drug|PF-05231023|1.5 mg QD IV x 1 day
75598578|NCT01285518|Drug|PF-05231023|5 mg QD IV x 1 day
75598579|NCT01285518|Drug|PF-05231023|15 mg QD IV x 1 day
75598580|NCT01285518|Drug|PF-05231023|50 mg QD IV x 1 day
75598581|NCT01285518|Drug|PF-05231023|100 mg QD IV x 1 day
75598582|NCT01285518|Drug|PF-05231023|200 mg QD IV x 1 day
75890690|NCT03670563|Other|Short foot exercise plus NMES|Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
75742793|NCT00454779|Drug|Cisplatin|chemotherapy arm
75890691|NCT02567175|Drug|Domperidone|
75890692|NCT02226380|Drug|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
75598583|NCT01285518|Other|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
75742794|NCT00454779|Drug|Panitumumab|experimental arm
75742795|NCT00454779|Drug|Docetaxel|chemotherapy arm
75890693|NCT02078388|Drug|Doxorubicin|
75448339|NCT04880278|Drug|Placebo|Half of the participants (30 individuals) will receive placebo capsules that are opaque and contain only dextrose. Placebo capsules will be administered by mouth only once (around 120 minutes prior to fMRI scanning).
75890694|NCT02222636|Drug|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
75890695|NCT02222636|Drug|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
75890696|NCT02222636|Drug|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
75890697|NCT02222636|Drug|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
75448340|NCT04858425|Drug|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
75448341|NCT04858425|Drug|Placebo|Matched placebo tablets 400 mg 3 times daily for 14 days
75598584|NCT01073020|Device|Allergan Adjustable Gastric Band Surgery|
75598585|NCT01073020|Other|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group
75598586|NCT01073020|Procedure|Roux-en-Y Gastric Bypass (RYGB) Surgery|
75598587|NCT01073020|Other|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group
75598588|NCT02875600|Other|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
75598589|NCT02874664|Drug|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
75890698|NCT02222636|Drug|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
75448342|NCT04824820|Behavioral|Vibrator|Clitoral stimulation
75448343|NCT04811365|Other|Screening|After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms
75598590|NCT02889744|Device|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
75598591|NCT04754308|Diagnostic Test|Spirometry|The method of examination, Spirometry, is non-invasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
75598592|NCT00623844|Behavioral|physical activity|activity program at kindergarten 5 * 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
75598593|NCT04207554|Device|Test Device-Strip Format|Sponsor's investigational device
75742796|NCT00454779|Drug|Cisplatin|experimental arm
75742797|NCT00454779|Drug|Docetaxel|experimental arm
75742798|NCT00992862|Drug|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
75742799|NCT00992862|Drug|Univasc® 15mg Tablets|
75742800|NCT00992940|Procedure|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
75598594|NCT04207554|Device|Test Device-Cassette Format|Sponsor's investigational device
75598595|NCT04207554|Device|Predicate Device|Commercially available device
75742801|NCT00992940|Procedure|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
75890699|NCT04058223|Device|Hemorrhoidopexy|stapled hemorrhoidopexy
75598596|NCT02875522|Other|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
75448344|NCT04801771|Device|Inspire Upper Airway Stimulation (UAS) System|The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.
75742802|NCT02416206|Drug|BeEAM|BeEAM
75742803|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
75598597|NCT02874196|Procedure|Standard arthrography|
75598598|NCT02874196|Procedure|Dual energy arthrography|
75742804|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
75448345|NCT04775719|Other|Patient-Specific Prediction of Functional Outcome|Information sheet that describes whether a patient is more likely to improve on or maintain their current preoperative function.
75742805|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
75742806|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
75448346|NCT04775719|Other|Standard Pre-Operative Total Knee Arthroplasty Information|Standard of care information that is routinely provided at patient preadmission appointments.
75448347|NCT04762758|Drug|(RS)-baclofen, naltrexone hydrochloride and D-sorbitol|oral fixed dose combination
75448348|NCT04762758|Drug|Placebo|liquid oral solution
75448349|NCT04717908|Drug|Bedaquiline|400 mg once daily for 2 weeks then 200mg 3 times per week;
75448350|NCT04717908|Drug|Pyrazinamide|1500 mg daily
75448351|NCT04717908|Drug|Linezolid|600 mg daily
75448352|NCT04717908|Drug|Cycloserine|≤50kg 500 mg daily, >50kg 750mg daily;
75448353|NCT04717908|Drug|Clofazimine|100 mg daily;
75448354|NCT04715685|Behavioral|40 minute session|The 40 minute session will include all of the content contained in the 20 minute session, but will include a greater explanation of each of the mind and body skills, followed by in vivo practice of each skill with the nurse. Sessions will also include review of home practice for each group.
75598599|NCT02874196|Procedure|Arthro-tomosynthesis|
75598600|NCT02874196|Procedure|Arthro-tomography|
75598601|NCT02874196|Procedure|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
75598602|NCT01284114|Drug|Aliskiren|150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
75598603|NCT02875444|Other|Angio-CT|
75742807|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
75742808|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
75742809|NCT00439569|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
75742810|NCT00443079|Drug|IdB 1016 (Siliphos)|1 pill 3 times daily x 6 weeks
75742811|NCT00443079|Drug|Matched placebo|1 pill 3 times daily x 6 weeks
75890700|NCT03559374|Other|Vanadis NIPT system|A novel cost effective not NGS (next-generation sequencing) test, based on imaging single DNA molecules for high precision NIPT (non-invasive prenatal testing)
75890701|NCT04058145|Drug|AMD3100|AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
75890702|NCT04058145|Drug|Pembrolizumab|"Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor."
75890703|NCT02230982|Drug|nintedanib|soft gelatin capsule
75742812|NCT01033929|Biological|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
75890704|NCT02075112|Drug|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
75890705|NCT02075112|Radiation|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
75448355|NCT04715685|Behavioral|20 minute session|For participants randomized to the 20 minute session, content will include pain education, followed by brief explanations of each of the mind and body skills, in vivo diaphragmatic breathing practice and demonstration of use of biofeedback card. Sessions will also include review of home practice for each group.
75448356|NCT04715685|Behavioral|home practice e-health|Participants will be provided and instructed on access to a migraine-specific interactive web portal, Migraine e-Health. This web-based tool actively guides participants in practicing evidence-based mind and body skills. Use of the Migraine -e-Health application for the high dose capitalizes on teaching participants mind and body skills while increasing accessibility due to implementation on mobile devices.
75742813|NCT02188836|Device|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
75742814|NCT02188836|Device|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
75742815|NCT00993174|Procedure|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
75742816|NCT00993174|Procedure|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
75890706|NCT02075112|Drug|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
75890707|NCT03078751|Drug|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth."
75890708|NCT03078751|Drug|Adjuvant endocrine therapy|Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
76061255|NCT03082456|Diagnostic Test|Molecular breast imaging|Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
76061256|NCT03082456|Diagnostic Test|Mammography|During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
75598604|NCT01283334|Drug|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
75598605|NCT01283334|Drug|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
75598606|NCT01283334|Drug|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
75598607|NCT01282866|Device|LightSheer Duet|LightSheer Duet HS handpiece
75742817|NCT02088372|Device|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
75890709|NCT03078751|Drug|Placebo|"Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth."
75890710|NCT02223026|Drug|Linagliptin/metformin FDC|
75890711|NCT02223026|Other|high-fat, high caloric meal|
75890712|NCT02075190|Other|Therapeutic Computerized intervention|Remediation training intervention
75890713|NCT02075190|Other|Nontherapeutic computerized intervention|Online gaming intervention
76061257|NCT03082456|Diagnostic Test|Breast ultrasound|Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
76061258|NCT04761172|Procedure|Intraoperative near-infrared fluorescence imaging using indocyaninegreen|ICG administration before/during surgery and using near-infrared fluorescence imaging for intra-operative detection and identification of GISTs
75598608|NCT01071070|Drug|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
75598609|NCT04304716|Drug|Regional Anesthesia|Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
75742818|NCT05348616|Other|epidemiology|To review of medical records to describe diagnosis and severity of the disease.
75890714|NCT02226614|Device|University of Edinburgh head cooling device|head cooling
75598610|NCT01282476|Drug|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
75448357|NCT04715685|Behavioral|home practice handout|Participants will be given a handout of commercially available free apps relevant to the mind body skills introduced.
75598611|NCT02889822|Drug|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
75598612|NCT04323618|Device|Breathe Well|
75598613|NCT04323696|Procedure|Staple line suturing reinforcement methods - Plication and Over-sewing|Sleeve gastrectomy procedure will be performed laparoscopically. The greater curvature of the stomach will be mobilised, and stomach will be sleeved using 39F calibration tube as the stent using 5-6 60 mm-stapler reloads depending on the length and thickness of the stomach. The staple-line is then reinforced using 3/0 absorbable sutures continuously throughout the staple-line. The two staple-line suturing methods in this study include over-sewing (through and through) and plication (Lembert).
75598614|NCT01282164|Procedure|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
75598615|NCT01282164|Procedure|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
75598616|NCT01250379|Drug|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
75742819|NCT05348616|Other|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
75742820|NCT00993252|Procedure|CT Scan|CT scan
75742821|NCT03190278|Biological|UCART123v1.2|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
75598617|NCT01250379|Drug|Chemotherapy|Standard chemotherapy (doublets not allowed)
75742822|NCT02553915|Other|Placebo|Soybean oil placebo
75448358|NCT04715685|Behavioral|phone call|The dose of phone call will occur about 4 weeks following the face-to-face mind and body introduction session and will last approximately 5-10 minutes. The phone call will be used to promote adherence to home-practice and answer questions related to skill use/home practice completion.
75448359|NCT04712656|Device|CPAP therapy|CPAP treatment of obstructive sleep apnea.
75742823|NCT02553915|Drug|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
75742824|NCT02553915|Drug|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
75742825|NCT02553915|Drug|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
75890715|NCT02075268|Drug|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
75890716|NCT01378507|Behavioral|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
75890717|NCT02078466|Other|Assessment of functional ability and follow-up at home|Assessment of functional ability and follow-up at home
75890718|NCT01378351|Other|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
75890719|NCT02223104|Device|Flexima Active|
75890720|NCT02223104|Device|Sensura|
75448360|NCT04711850|Drug|Imlifidase|Immunoglobulin G degrading enzyme of Streptococcus pyogenes
75890721|NCT01379443|Other|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
75598618|NCT01072630|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
75598619|NCT01072630|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
75598620|NCT04304638|Radiation|radiation or chemo-radiation|standard treatment for stage III lung cancer
75598621|NCT04304638|Drug|EGFR-TKI Inhibitor|the standard treatment for stage IV lung cancer with EGFR mutation
75598622|NCT04302532|Drug|Coenzyme Q10|antioxidant used to decrease oxidative stress and improve fertility prospects
76061259|NCT01679860|Procedure|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:~CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
75598623|NCT04302532|Drug|clomiphene citrate|ovulation induction drug
75598624|NCT01281306|Drug|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
75598625|NCT01281306|Drug|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
75598626|NCT01281306|Drug|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
76061260|NCT01679860|Drug|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:~CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
76061261|NCT05346952|Drug|TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection|PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
75598627|NCT01281306|Drug|Placebo|Placebo was supplied as tablets in blister cards.
75598628|NCT04304560|Drug|Dapagliflozin 10 MG|inhibitor of sodium-glucose cotransporter 2
75598629|NCT04304560|Drug|Placebo oral tablet|Similar Placebo oral tablet
75598630|NCT00626860|Biological|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
75598631|NCT04643470|Drug|Zanubrutinib|Administered as specified in the treatment arm
75598632|NCT04643470|Drug|Placebo|Placebo to match zanubrutinib
75598633|NCT01250145|Drug|LY333334|Transdermal patch
75598634|NCT01250145|Drug|Placebo|Transdermal patch
75890722|NCT02231138|Drug|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
76061262|NCT03089788|Other|Home-based test|Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
75598635|NCT04323384|Device|Biotene® Oralbalance Moisturizing Gel|Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.
75598636|NCT01067326|Drug|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
75598637|NCT01067326|Drug|Placebo|1 pill per day by mouth for 4 months
75598638|NCT04319601|Drug|Rituximab|a new chemotherapy regimen
75598639|NCT01279200|Other|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
75598640|NCT01279200|Other|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
75598641|NCT04640896|Drug|Trigger point injection with bupivacaine|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
75598642|NCT04640896|Drug|Trigger point injection with normal saline|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
75598643|NCT04640896|Drug|Lidocaine skin wheal|"Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.~However, this skin wheal is not considered a trigger point injection."
75598644|NCT01273818|Drug|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
75598645|NCT01273818|Drug|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
75598646|NCT01273818|Drug|Gentamicin|80 mg gentamicin application intraoperatively
75598647|NCT01245387|Drug|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
75598648|NCT01037218|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
75598649|NCT01037218|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
75598650|NCT01038856|Drug|Erlotinib|Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
75742826|NCT04001868|Procedure|Suboccipital inhibition|With the patient in the supine position and the therapist sitting at the head of the bed with the elbows resting on its surface. The therapist palpates the cervical spinous processes and slides the fingers upwards until contacting the posterior projection of the posterior arch of the atlas. Then, flexing the metacarpophalangeal at 90 degrees slowly raises the skull. The therapist's hands should remain together and the base of the skull should rest on his palms pressing with the index, middle and ring fingers of each hand in a sustained manner, but without causing pain. This pressure must be maintained during 4 minutes.
75742827|NCT04001868|Procedure|Placebo technique|A superficial contact in the same area as the intervention, to rule out the exteroceptive effect associated with the therapist's contact.
75742828|NCT01034007|Combination Product|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
75742829|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
75742830|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
76061263|NCT03089788|Other|Skin test|Skin Prick Tests will be performed with registered cat allergen extract.
76061264|NCT03089632|Other|Gluten-free diet|One-month gluten-free diet
76061265|NCT03081442|Drug|Misoprostol|600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
75598651|NCT04302688|Other||
75448361|NCT04665895|Drug|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals|twice daily inhalation throughout the study
75598652|NCT01066546|Drug|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
75598653|NCT02874118|Behavioral|Fried scale for frailty assessement|
75598654|NCT02873572|Behavioral|step 1: online assessment|Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
75598655|NCT02873572|Behavioral|step2: biomarkers of gamblers/gamers|"For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:~psychiatric assesment and~registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015)."
75742831|NCT03994107|Drug|Pegylated Liposomal Doxorubicin|"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."
76061266|NCT03081442|Device|Intrauterine contraceptive device IUCD|"bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus ."
75448362|NCT04665895|Drug|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK|twice daily inhalation throughout the study
75448363|NCT04665895|Drug|Placebo|twice daily inhalation throughout the study
75448364|NCT04643145|Procedure|Flexible ureteroscopy for renal calculi less than 20 mm|Patients with renal calculi less than 20 mm will be managed by flexible ureteroscopy. at the end of the procedure, they will be randomized to receive either temporary ureteral catheter for 2 days or indweeling double J stent for 2-4 weeks
75448365|NCT04638231|Other|Supportive messages|Daily supportive messages via SMS or email
75448366|NCT04617912|Device|Long AFOV PennPET Explorer|A long-axial field-of-view (LAFOV) time-of-flight PET scanner, developed at the University of Pennsylvania, being tested for real-world applications.
75448367|NCT04607941|Other|Questionnaires|Self-administered questionnaires
75742832|NCT03994107|Drug|Albumin-bound paclitaxel|220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
75742833|NCT03994107|Drug|Trastuzumab|8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
75742834|NCT03119766|Drug|Kolofort|Oral administration
75598656|NCT01272804|Drug|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
75742835|NCT03119766|Drug|Placebo|Oral administration
75890723|NCT02075424|Other|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
76061267|NCT04402450|Procedure|Ultrasound-guided suprainguinal fascia iliaca nerve block|After an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.
76061268|NCT04402450|Procedure|Ultrasound-guided pericapsular nerves group of the hip block|After an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.
75890724|NCT05111119|Behavioral|Making PrEP Smart|"The Making PrEP Smart intervention is a mobile-based application with the following components:~Notification-based PrEP Reminders and Adherence Self-Monitoring~HIV self-testing facilitation, interpretation of results, and testing support~HIV partner testing facilitation, interpretation of results, and testing support~Nearby HIV clinic contact information"
76061269|NCT03089710|Other|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
75598657|NCT01272804|Drug|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
75742836|NCT03474393|Other|systematic intensive therapy|intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
75742837|NCT03469713|Drug|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
75742838|NCT00993486|Biological|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
75448368|NCT04607941|Other|Phone interviews|A small amount of subjects will be selected at random for phone interviews.
75448369|NCT04604743|Behavioral|Intervention, TBN|The intervention will target adolescents aged 15-17 years who have not received at least one dose of the HPV vaccine. The intervention has yet to be named; this will occur through the conduct of Aim 1. Our intervention, when developed, will improve knowledge of HPV, COVID-19, the HPV vaccine, and the COVID-19 vaccine (Information), reduce stigma and distrust improving motivation (Motivation), leading to improved vaccine confidence and higher vaccination rates and lower vaccine hesitancy (Behavioral Skills). Each one of these three change objectives will be encapsulated in its own Zoom-based session with the near peer interventionist. We anticipate that each modular session will be no longer than seven minutes; thus, the entire three module intervention will be no longer than twenty-one minutes long.
75598658|NCT01269918|Drug|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
75598659|NCT01269918|Drug|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
75742839|NCT00427635|Drug|Esomeprazole|
75890725|NCT02075502|Behavioral|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
75890726|NCT02075502|Procedure|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
75890727|NCT02075502|Procedure|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
75890728|NCT02477384|Procedure|8mm-TIPS|
75598660|NCT05658666|Behavioral|Video feedback intervention (in Dutch: Video Interventie Ouderenzorg)|The video feedback trainer assesses the interaction between the person with dementia and the caregiver and acquires agreement from the caregiver on the goals of the intervention. Caregivers are trained during several feedback sessions using personal video footage of interaction between the person with dementia and the caregiver. The feedback focuses on basic interaction and attunement principles, and the team feeling competent. Recording starts with a nondemanding situation, enabling the caregiver to become aware of the principles they already apply and to learn how these principles can be used in more demanding situations. Subsequently, video footage is recorded in 1 to 3 situations, depending on the progress, of increasing difficulty, with about 4 weeks between 2 recordings. After each recording, a 1-hour feedback session is held. The intervention concludes with separate, 30-minute sessions for the formal and informal caregivers evaluating the intervention.
75598661|NCT01036594|Drug|Ketoconazole|200mg during first week of study (run-in phase), then 400mg po tid
75598662|NCT01036594|Drug|Hydrocortisone|"Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has <30% PSA decline, patient goes off study."
75598663|NCT01036594|Drug|Dexamethasone|"Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
75448370|NCT04600479|Diagnostic Test|Evaluation of the prevalence of HCV, HBV and HIV viral infections|"Assessment of prevalence HCV, HBV and HIV prevalence estimations. Sociodemographic and clinical data will be collected from the patient's medical record and through self-questionnaires completed by the patient. A systematic screening by 3 RDTs (HCV, HBV and HIV) will be proposed in the specific framework of the SaPHIR study.This is a screening performed on capillary blood (TOYO VHC ®, TOYO VHB ® and INSTI HIV 1 / HIV 2 ®), to obtain a result in less than 30 minutes.~In case of confirmation of the diagnosis of viral hepatitis or HIV infection, the final result will be transmitted and explained to the patient by the referring doctor, who will organize the adapted care pathway and prescribe the DAA for the simple patients. The complex patients will be referred to the specialist to consider starting an appropriate treatment.~Evaluation of care pathway and barriers to care for hepatitis C. Only patients with positive HCV RDT participating in this follow-up."
75890729|NCT02477384|Procedure|Endoscopic variceal ligation|
75890730|NCT02477384|Drug|Propranolol|
76061270|NCT03080818|Dietary Supplement|Probiotic - Lactobacillus Rhamnosus GG|2 capsules per day for 90 days
75598664|NCT05657886|Other|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
75742840|NCT00993642|Drug|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
75742841|NCT01564446|Other|Participants will receive a internet based secure message confirming adherence to post-discharge medication regimen|Participants will receive a internet based secure message via My HealtheVet (MHV), The VA's online medical record and secure messaging portal. The message will specify post-discharge prescribed medications and inquire about adherence to these medications.
75742842|NCT01028547|Drug|dexamethasone|single Bolus dose of dexamethasone 8mg
75742843|NCT01028547|Other|normal saline|2 ml 0.9% saline
75742844|NCT04001790|Behavioral|Project Search plus ASD Supports|Nine month job training program embedded on Fort Eustis military base.
75890731|NCT02477384|Device|8mm ePTFE-covered stent|
76061271|NCT03080818|Other|Placebo|2 placebo capsules per day for 90 days
76061272|NCT03080662|Device|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
76061273|NCT03080662|Device|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
76061274|NCT03431194|Drug|midodrine|oral midodrine tablets 5 mg
76061275|NCT03431194|Drug|Placebo|
76061276|NCT03080740|Drug|Clindamycin palmitate hydrochloride dispersible tablet|300mg, oral after meal, twice daily, a total of 7days
76061277|NCT03080740|Drug|Metronidazole Tablet|400mg, oral after meal , twice daily, a total of 7days
75598665|NCT05657886|Other|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
75598666|NCT02874352|Device|high resolution impedance manometry with Automated Impedance Manometry analysis|
75598667|NCT04302610|Device|Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,|A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments
75598668|NCT04302610|Device|Sham treatment|Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
75598669|NCT04301908|Drug|interferon|Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
75448371|NCT04559230|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
75742845|NCT01031355|Drug|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
75742846|NCT01031355|Drug|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
75742847|NCT01031355|Drug|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
75742848|NCT00993720|Drug|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
75742849|NCT00993720|Drug|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
75742850|NCT00993720|Other|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
76061278|NCT03084094|Device|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
76061279|NCT03464500|Dietary Supplement|Mitopure 500mg|Mitopure containing softgels
76061280|NCT03464500|Dietary Supplement|Mitopure 1000mg|Mitopure containing softgels
76061281|NCT03464500|Dietary Supplement|Placebo|Placebo containing softgels
76061282|NCT03399994|Device|device implantation during coronary angioplasty|device implantation during coronary angioplasty
76061283|NCT04279990|Other|No intervention: assessment of GI function|"Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria."
76061284|NCT03080584|Other|acupuncture|12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
76061285|NCT03089242|Other|observation of microRNA expression|no intervention
76061286|NCT03089164|Diagnostic Test|Right heart catheterization|Each patient will have variables measured supine, sitting and standing positions
76061287|NCT04402372|Device|Novel bidirectional cannula (BiflowTM, LivaNova, Italy)|We are going to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for CPB during minimally invasive surgery
76061288|NCT03081832|Drug|Oxytocin|Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
76061289|NCT03081832|Other|Control|Not treated.
76061290|NCT03081754|Radiation|Doppler velocimetry|Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
76061291|NCT03081520|Behavioral|Affective response MIT|Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
75448372|NCT04549792|Drug|Ustekinumab|Each subject will receive ustekinumab at Baseline (Day 0) and Months 1, 3, 5, 7, 9, and 11. During the LTE, subjects will receive injections every 8 weeks for one year: Month 13, Month 15, Month 17, Month 19, Month 21, and Month 23. Subjects will come back in for a follow-up visit at Month 25 for an end of study visit (no drug administration).
75448373|NCT04545554|Drug|Romosozumab|Participants will receive 3 doses of romosozumab via a subcutaneous (SC) injection.
75598670|NCT01036438|Device|Mepilex Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
75598671|NCT01036438|Device|Mepilex without Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
75598672|NCT04304248|Drug|Albumin-bound paclitaxel, Carboplatin, Toripalimab|Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
75742851|NCT03006666|Behavioral|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
75742852|NCT03006666|Behavioral|Data Only|The teams randomly allocated will not have access to Community Health Workers.
75742853|NCT00427011|Drug|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
75742854|NCT03891264|Drug|Cannabidiol|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
75742855|NCT00439179|Drug|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
75742856|NCT00439179|Drug|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
75742857|NCT00439179|Drug|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
75742858|NCT00439179|Drug|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
75742859|NCT01034241|Dietary Supplement|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
75742860|NCT01034241|Dietary Supplement|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
75742861|NCT01034241|Dietary Supplement|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
75742862|NCT01034241|Dietary Supplement|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
75742863|NCT01031511|Behavioral|Cognitive Behavioural Therapy|16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
75448374|NCT04545554|Dietary Supplement|Calcium|All participants will receive daily supplements of elemental calcium.
75742864|NCT01031511|Other|Social Recreational|16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
75742865|NCT00438399|Drug|C. propionate - Corticosteroid 1|Twice daily application
75742866|NCT00438399|Drug|C. propionate- Corticosteroid 2|Twice daily application
75742867|NCT00438399|Drug|C. propionate -Corticosteroid 3|Twice daily application
75742868|NCT00438399|Drug|Corticosteroid 1- C. propionate|Twice daily application
75742869|NCT00438399|Drug|Corticosteroid 2 - C. propionate|Twice daily application
75742870|NCT00438399|Drug|Corticosteroid 3 - C. propionate|Twice daily application
75742871|NCT00426231|Behavioral|Navigation by a health worker|Help provided by health worker to navigate medication access programs
75742872|NCT00426231|Behavioral|Information control|Information about medication access programs provided to the participant and their healthcare provider
75742873|NCT03386409|Behavioral|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
75742874|NCT03386409|Behavioral|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
75448375|NCT04545554|Dietary Supplement|Vitamin D|All participants will receive daily supplementation with vitamin D.
75448376|NCT04523519|Behavioral|Video directly observed therapy with contingency management|PrEP adherence will be assessed by visual recognition software during video capture and reviewed for confirmation by study staff, ensuring that videos demonstrate study medication dosing by participant. Participants will receive small financial incentives upon confirmation of dosing.
75448377|NCT04523519|Behavioral|Integrated Next-Step Counseling|Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
75598673|NCT01268046|Drug|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
75598674|NCT01268046|Drug|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
75448378|NCT04518657|Behavioral|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
75890732|NCT03709771|Diagnostic Test|Ambulatory Blood Pressure Measurement|"Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure."
75598675|NCT01268046|Drug|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
75598676|NCT01268046|Drug|placebo oral capsule|placebo oral capsule administered daily for one month.
75598677|NCT04302298|Device|Virtual Reality|A machine which immerses the participant in a simulated environment where they can perform a procedure.
75598678|NCT00627484|Procedure|Gastric bypass|NOTE: the surgery is not paid for by the study
75598679|NCT00627484|Procedure|Gastric banding|NOTE: the surgery is not paid for by the study
75598680|NCT00627484|Procedure|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
75598681|NCT00627484|Behavioral|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
75742875|NCT00425607|Drug|Lonafarnib|Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
75742876|NCT00437073|Drug|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
76061292|NCT03081520|Behavioral|Affective response HAIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
76061293|NCT03081520|Behavioral|Affective response HIIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
75448379|NCT04518657|Behavioral|Wellness for MS (WellMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing wellness in people with MS.
75598682|NCT01267266|Drug|saracatinib|Given orally
75598683|NCT01267266|Other|hydrocortisone/placebo|Given orally
75598684|NCT01034176|Drug|levofloxacin|500 mg tablet, daily, 30 days
75598685|NCT01034176|Drug|placebo|no dose, tablet, daily, 30 days
75598686|NCT02889432|Drug|Oral Melatonin 10mg|
75598687|NCT02889432|Drug|Placebo|
75598688|NCT04323540|Procedure|Peri-implantitis reconstructive surgery|"For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap."
75742877|NCT00437073|Drug|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
75742878|NCT00437073|Drug|lapatinib|lapatinib administered 1250mg once daily orally
75742879|NCT00425373|Drug|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
75742880|NCT00425373|Drug|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
75448380|NCT04500574|Drug|Latanoprost eluting contact lens|The latanoprost-contact lens will be worn in one eye for one week.
75448381|NCT04500574|Drug|Topical Latanoprost|A commercial contact lens with no drug will be worn in one eye for one week.
75448382|NCT04487457|Other|Blood samples|Blood samples
75598689|NCT01033942|Drug|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
75598690|NCT01033942|Drug|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
75598691|NCT01033942|Behavioral|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
75598692|NCT01062256|Drug|Placebo|One placebo tablet administered orally as a single dose
75598693|NCT01062256|Drug|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
75598694|NCT01062256|Other|Buckwheat Honey|10 mL administered orally as a single dose
75598695|NCT01029886|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly
75598696|NCT01029886|Drug|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
75598697|NCT02874274|Behavioral|Standard of Care|
75742881|NCT00425373|Drug|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
75742882|NCT00425373|Drug|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
75742883|NCT00425373|Drug|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
75742884|NCT00425373|Drug|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
75598698|NCT02874274|Behavioral|Home Visit Program (HVP)|The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
75598699|NCT01244763|Drug|Roxadustat|Oral capsule
75598700|NCT01244061|Drug|Varenicline|Varenicline 1mg twice daily
75742885|NCT00425373|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
75890733|NCT02075580|Behavioral|psychological support (interactive/cognitive strategies)|"cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
75890734|NCT05001295|Procedure|Physical Activity|Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
75890735|NCT02075736|Procedure|KTP laser|
75598701|NCT01244061|Drug|Placebo|Matched placebo twice daily
75890736|NCT02075736|Procedure|TUR-P|device
75890737|NCT02226770|Device|Implantable Cardioverter Defibrillator (ICD)|
75890738|NCT04335253|Drug|EOS884448|Multiple Ascending Dose
75448383|NCT04441593|Behavioral|Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)|Videoconferencing intervention to reduce alcohol use and chronic pain interference and severity
75448384|NCT04441593|Behavioral|Treatment as Usual|Psychoeducation and Information about Treatment Resources
75448385|NCT04428736|Behavioral|Disclosure Toolkit|"Participants will receive a Disclosure Toolkit consisting of a family letter, gene information chatbot, and informational website to aid in communicating their genetic test results with at-risk relatives."
75448386|NCT04416282|Drug|Terlipressin|Injection terlipressin 2 mg/24 hours infusion
75890739|NCT02231216|Procedure|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
75890740|NCT02231216|Procedure|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
75890741|NCT02231216|Procedure|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
75890742|NCT03633721|Drug|Cannabis|7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
75598702|NCT01243671|Biological|Adalimumab|
75598703|NCT04319679|Device|Extracorporeal shockwave therapy|6 times during 2 weeks
75598704|NCT04319679|Device|Sham therapy|6 times during 2 weeks
75598705|NCT01240785|Drug|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
75598706|NCT01240785|Drug|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
75598707|NCT01240551|Drug|F-18 NaF|All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
75598708|NCT01239381|Radiation|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
75598709|NCT01266876|Drug|Alirocumab|Alirocumab two SC injections in the abdomen only.
75598710|NCT01266876|Drug|Placebo|Placebo two SC injections in the abdomen only.
75598711|NCT01033240|Drug|CS-1008 2 mg/kg|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg.
75598712|NCT01033240|Drug|Sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
75598713|NCT01033240|Drug|CS-1008 6/2 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 2 mg/kg/week maintenance dose on a once-a-week basis.
75742886|NCT00425373|Drug|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
75742887|NCT00425373|Drug|Placebo|4 tablet and 2 capsule placebos taken once daily
75742888|NCT03742479|Device|Restylane® Silk|Injectable Hyaluronic Acid (HA)
75742889|NCT01031589|Drug|TMC278 (Rilpivirine) LA; Placebo|
75742890|NCT03894540|Drug|IPN60090|Oral capsules given daily
75742891|NCT03894540|Drug|pembrolizumab|An intravenous solution in single-use vial to be diluted for infusion.
75890743|NCT03633721|Other|Placebo|0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
75890744|NCT02081898|Dietary Supplement|LCD|approximate 100 kcal/d caloric deficit
75890745|NCT02226848|Drug|Erythropoeitin|
75598714|NCT01033240|Drug|CS-1008 6/6 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 6 mg/kg/week maintenance dose on a once-a-week basis.
75598715|NCT01033240|Drug|CS-1008 4 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 4 mg/kg if tolerated.
75598716|NCT01033240|Drug|CS-1008 6 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 6 mg/kg if tolerated.
75448387|NCT04416282|Biological|Albumin|i/v albumin 1g/Kg/day
75598717|NCT01266018|Drug|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m^2 (36.8 mg/m^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
75448388|NCT04395469|Drug|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after radiation treatment.
75448389|NCT04383886|Other|stress and anxiety questionnaire|Emergency department staff will be asked to fill in questionnaires in order to measure their stress and anxiety level, their propensity to have a burn-out, their consumption of psychoactive substances such as alcohol, tobacco, coffee or anxiolytic, their sleep disorder.
75890746|NCT02081976|Behavioral|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
75448390|NCT04375150|Drug|Tyrosine kinase inhibitor (TKI)|TKIs
75598718|NCT01032382|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
75598719|NCT01032382|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
75598720|NCT01029652|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
75890747|NCT02081976|Other|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
75448391|NCT04375150|Drug|Immuno-oncology (IO)|IOs
75448392|NCT04321291|Other|Generic information leaflet|The information about the biosimiliars is realized only by the transmission of the information leaflet in addition to the information given by the investigator.
75448393|NCT04321291|Other|Individual information by nurse on biosimilars|Delivery of the same information leaflet, completed if asked by the patient, by individual meeting with specialist nurse, including generic and standardized informations on specificities, advantages and current scientific knowledge about biosimilars in inflammatory rheumatic diseases. This is in addition to the information given by the investigator
75448394|NCT04231513|Drug|E2814|E2814, intravenous infusion.
75598721|NCT01029652|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
75598722|NCT01029652|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
75598723|NCT01029652|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
75598724|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
75598725|NCT01029340|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
75448395|NCT04231513|Drug|E2814-matched placebo|E2814-matched placebo, intravenous infusion.
75448396|NCT04231032|Other|Asynchronous dual chamber pacing (DOO) with paced ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
75448397|NCT04231032|Other|Asynchronous atrial pacing (AOO) with intrinsic ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
75448398|NCT04191538|Procedure|Conditioning electrical stimulation|Percutaneously, a small needle will be placed alongside the median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
75598726|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
75598727|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
75598728|NCT04301752|Diagnostic Test|MoCA|Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were <26. Maximum score is 30.
75598729|NCT04304170|Dietary Supplement|VES002|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
75598730|NCT04304170|Other|Placebo|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
75598731|NCT01265550|Device|Nissen fundoplication|laparoscopic antireflux surgery
75742892|NCT03894540|Drug|paclitaxel|An intravenous solution in single-use vial to be diluted for infusion.
75890748|NCT03575611|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75890749|NCT02231294|Drug|Sifrol®|
75890750|NCT04962139|Drug|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
75890751|NCT04962139|Other|Vehicle Cream|ON101 Cream Placebo
75890752|NCT02223416|Drug|RGB-10|
75598732|NCT01265550|Drug|baclofen|"Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved."
75742893|NCT03894540|Drug|IPN60090 single administration|Oral capsules given once
75598733|NCT01265550|Drug|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
75598734|NCT01265394|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
75890753|NCT02223416|Drug|Teriparatide|
75598735|NCT02889354|Behavioral|Cognitive-behavioral therapy|
75742894|NCT00993876|Drug|citalopram|20 to 30 mg per day for 4 weeks
75742895|NCT00993876|Drug|reboxetine|4 to 8 mg per day for 4 weeks
75742896|NCT00993876|Behavioral|interpersonal psychotherapy|
75742897|NCT04002336|Behavioral|Traditional Voice therapy|Traditional method of voice therapy
75742898|NCT04002336|Behavioral|Voice Therapy App|Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
75742899|NCT05175612|Device|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
75742900|NCT05088018|Other|Cannabigerol|Cannabigerol is a non-psychoactive cannabinoid obtained from the cannabis plant.
75742901|NCT05088018|Other|Placebo|A placebo form of the same swallowable tablet with no cannabigerol
75742902|NCT00535626|Device|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
75742903|NCT00994032|Procedure|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
75742904|NCT00994032|Other|Medical treatment|standard antalgic medical treatment
75890754|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
75890755|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
75890756|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
75890757|NCT02082054|Drug|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
75890758|NCT02082054|Drug|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
75890759|NCT02231372|Drug|Berodual® Respimat® solution for inhalation|
75890760|NCT04923529|Drug|TAS 102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery"
75890761|NCT03559296|Diagnostic Test|Ultrasonographic assessment of postmastectomy lymphedema|Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
75890762|NCT02884544|Drug|HLD100|Treatment
75890763|NCT02226926|Drug|Aggrenox|
75890764|NCT02226926|Drug|Persantin Retard|
75890765|NCT02226926|Drug|Acetylsalicylic acid|
75890766|NCT02075892|Dietary Supplement|Mushroom Blend|Scivation
75890767|NCT02075892|Dietary Supplement|Placebo|
75890768|NCT02227004|Diagnostic Test|Perform MRI in patients with pacemaker or ICD|Perform MRI in patients with pacemaker or ICD
75890769|NCT02924883|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion
75890770|NCT02924883|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
75742905|NCT05252286|Other|video watching|"Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance."
75890771|NCT02924883|Other|Placebo|Placebo matched to atezolizumab
75890772|NCT02075970|Drug|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."
75448399|NCT04191538|Procedure|Postoperative electrical stimulation|Immediately following carpal tunnel release, needles for electrical stimulation will be placed alongside the visualized median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
75448400|NCT04191538|Procedure|No electrical stimulation|Patients will receive sham stimulation (needles placed, no current delivered) pre- and post-operatively; however, no current will ever be delivered to the nerve. This is the control cohort.
75598736|NCT01029262|Drug|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
75598737|NCT01029262|Other|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
75598738|NCT04301284|Drug|CAD-1883|150 mg filled capsules
75598739|NCT04301284|Drug|Placebos|capsules
75598740|NCT02875210|Procedure|Laximeter measurement|
75598741|NCT02873416|Drug|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
75598742|NCT02873416|Biological|Precision Cells|Precision Cells DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
75742906|NCT05252286|Other|paper group|In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
75742907|NCT05252286|Other|oral education group|the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
75742908|NCT00994188|Procedure|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
75890773|NCT02075970|Drug|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
75890774|NCT03432325|Device|Neural Enabled Prosthesis|Surgically implanted neural enabled prosthesis
75890775|NCT02231450|Drug|Lu AE58054 encapsulated film-coated tablets|
75448401|NCT04169204|Diagnostic Test|Measurement of microcirculation|As a simple clinical test, every patient will receive the assessment capillary refill time and mottling-score. Additionally, repetitive measurements of lactate will be done. The SDF-camera (MicroVision Medical®, Amsterdam, Netherlands) will measure sublingual microcirculation at different time points (Admission and 24h).
75890776|NCT02078622|Other|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
75448402|NCT04152551|Drug|Risedronate Oral Tablet|Oral bisphosphonate
75448403|NCT04126161|Procedure|CT|standard of care CT prior to primary hip replacement
75448404|NCT04126161|Device|Ultrasound|Ultrasound scan together with standard of care CT prior to primary hip replacement
75448405|NCT04112498|Drug|relatlimab|Specified dose on Specified days
75448406|NCT04112498|Drug|nivolumab|Specified dose on Specified days
75448407|NCT04112498|Drug|rHuPH20|Specified dose on Specified days
75598743|NCT01028560|Biological|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
75598744|NCT01028560|Other|Standard of care|standard of care asthma and allergy treatment
75598745|NCT01061710|Drug|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
75742909|NCT00995280|Device|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
75742910|NCT00995280|Device|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
75742911|NCT05224518|Behavioral|elastic band training|elastic band training include stretching exercises
75742912|NCT00994266|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
75448408|NCT04104893|Drug|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
75742913|NCT00994266|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
75890777|NCT02259062|Other|Music with brief mindfulness intervention|Music listening with mindfulness therapy
75448409|NCT04069533|Biological|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
75742914|NCT05302674|Other|Hot Dry|98°F (36.7°C) and 20% relative humidity environment
75890778|NCT02259062|Other|Music listening alone|
75742915|NCT01646814|Drug|PL2200|PL2200, containing 325 mg aspirin active ingredient
75448410|NCT04064749|Behavioral|Text messages|The brief intervention includes providing feedback on the individual's gambling score; providing an educational fact about the relationship between problem gambling and financial well-being; talking with the individual about the 'pros' and 'cons' of gambling with suggested strategies that could potentially reduce their gambling behaviors; and concluding with an action oriented closing question. Participants in the intervention group will also receive up to five text messages a week for one month.
75598746|NCT01028014|Drug|Pseudoephedrine|Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
75598747|NCT01028014|Drug|Tamsulosin|Tamsulosin 0.4mg by mouth daily for 2 weeks
75598748|NCT01028014|Drug|Imipramine|Imipramine 25mg daily by mouth for 2 weeks
75598749|NCT01028014|Drug|Cyclobenzaprine|Cyclobenzaprine 10mg daily by mouth for 2 weeks
75598750|NCT01028014|Drug|Lactose capsule|Lactose capsule 1 by mouth daily for 2 weeks
75598751|NCT01028014|Drug|Solifenacin|Solifenacin 5mg by mouth daily for 2 weeks
75742916|NCT01646814|Drug|Aspirin tablets|325 mg aspirin tablets (USP)
75742917|NCT00994344|Drug|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
75742918|NCT00994344|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
75742919|NCT00994500|Drug|vorinostat|Given orally
75742920|NCT00994500|Drug|bortezomib|Given IV
75742921|NCT00994500|Other|pharmacological study|Correlative studies
75742922|NCT00994500|Other|laboratory biomarker analysis|Correlative studies
75742923|NCT01416636|Drug|Treprostinil sodium|
75742924|NCT00995358|Biological|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
75890779|NCT02259062|Other|Audiobook listening|
75890780|NCT02078700|Other|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
75598752|NCT04300972|Diagnostic Test|Body/weight adaption|contrast media dose is adapted to weight and body type
76061294|NCT03080506|Device|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
75742925|NCT00994578|Behavioral|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
75598753|NCT04300972|Diagnostic Test|Standard dose|a fixed amount of contrast media is used, independently of weight and body type
75742926|NCT00994578|Behavioral|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
75598754|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
75598755|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
75742927|NCT00994578|Behavioral|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
75598756|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
75742928|NCT00995592|Behavioral|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
75742929|NCT00994656|Device|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
75742930|NCT00999180|Procedure|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
75742931|NCT00999180|Procedure|Saline and Kinesiotherapy|Saline and Kinesiotherapy
75742932|NCT03889704|Device|Omnistim® FX²|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. The device mimics physiologic patterns of neuron firing.
76061295|NCT03394456|Other|diabetes program|Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)
75448411|NCT04057339|Behavioral|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietitian.
75448412|NCT04057339|Behavioral|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 8-10-hr eating window.
75448413|NCT04042051|Drug|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 [according to the dose escalation scheme]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
75448414|NCT04042051|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
75448415|NCT04033991|Drug|Sunitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
75598757|NCT01264770|Drug|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
75598758|NCT01264770|Drug|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
75890781|NCT05763277|Diagnostic Test|Early response evaluation|Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
76061296|NCT03394456|Other|telehealth training and support for Community Health Workers|weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
75598759|NCT02873650|Drug|dabrafenib|Single dose of 100 mg dabrafenib on Day 1
76061297|NCT05345938|Drug|Mitoxantrone Hydrochloride Liposome|Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
76061298|NCT03080350|Drug|Fentanyl sublingual|Fentanyl sublingual
76061299|NCT03080350|Drug|Fentanyl ev|Fentanyl ev
76061300|NCT03080350|Drug|Placebo sublingual|Placebo sublingual
75598760|NCT04301128|Other|Experimental|Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
75598761|NCT04301128|Other|control|Patients in the control group were informed same informations verbally and given an education book.
75598762|NCT04301050|Other|Yoga Intervention|Weekly 75-minute yoga classes.
75598763|NCT01027702|Biological|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10^4, 4 x 10^4, 5 x 10^4, 6 X 10^4, 8 x 10^4, and 10 X10^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
75742933|NCT00999258|Drug|sirolimus|"The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care."
75742934|NCT05210712|Device|RS001.2 Respiree Cardio-Respiratory Monitor|The RS001.2 Respiree Cardio-Respiratory Monitor is intended as a noninvasive multiparameter monitor on the adult population
76061301|NCT03080350|Drug|Placebo ev|Placebo - NaCL 0,9% ev
76061302|NCT03080428|Diagnostic Test|Genomic test|genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
75598764|NCT01302080|Drug|sertraline|Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
75598765|NCT01302080|Behavioral|psychotherapy|Non-interventional study- as above
75598766|NCT01238991|Biological|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
75742935|NCT00994734|Drug|Mifepristone|home administration of mifepristone
75890782|NCT02227082|Radiation|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
75890783|NCT02227082|Drug|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
75890784|NCT03670485|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
76061303|NCT03080194|Drug|paliperidone palmitate|Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
76061304|NCT03080194|Drug|control group|Subject in control group will be applied with oral antipsychotics or other conventional medication.
76061305|NCT03080116|Drug|ARN-509|240mg/day (4x60mg tablets, Oral administration: OS)
75598767|NCT01238991|Biological|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
75598768|NCT01238991|Biological|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
75598769|NCT05643716|Behavioral|Aerobic Exercise|The aerobic exercise intervention is described in the Aerobic Exercise Arm description.
75598770|NCT01238835|Device|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
75598771|NCT02888457|Other|Nasopharyngeal sampling with a swab|
75598772|NCT01032070|Drug|erlotinib|oral
75598773|NCT01032070|Drug|etoposide|oral
75598774|NCT01237899|Drug|LY2623091|Administered orally.
75598775|NCT01237899|Drug|Placebo|Administered orally.
75598776|NCT01237899|Drug|Eplerenone|Administered orally.
75598777|NCT01264380|Drug|RO5185426|Single oral dose, fasted
75598778|NCT01264380|Drug|RO5185426|Single oral dose, with high fat meal
75890785|NCT02227160|Behavioral|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
75742936|NCT00995826|Drug|CS-8958|Inhaled CS-8958
75742937|NCT00995826|Other|Placebo|Inhaled placebo
75742938|NCT00994812|Drug|metformin|The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
75742939|NCT00994968|Drug|cyclophosphamide|
75742940|NCT00994968|Drug|docetaxel|
75742941|NCT00994968|Drug|doxorubicin hydrochloride|
75742942|NCT00994968|Drug|tegafur-gimeracil-oteracil potassium|
75890786|NCT02227160|Behavioral|Outpatient counseling and support groups|Usual mental health care
75890787|NCT02223494|Drug|Terbogrel|
75890788|NCT03373435|Drug|exendin 9-39|Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
75890789|NCT03373435|Other|Placebo|Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
75890790|NCT03670407|Procedure|Ovarian tissue fragmentation|Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.
75890791|NCT01369680|Drug|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
76061306|NCT03080116|Drug|Degarelix|1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
76061307|NCT03080116|Other|Placebo|4 tablets, per OS
75598779|NCT01264380|Drug|RO5185426|Continuous administration, orally twice daily
75598780|NCT01263444|Drug|Brinzolamide 1% / timolol 0.5% Fixed Combination|
75598781|NCT01263444|Drug|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
75598782|NCT01263054|Device|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
75598783|NCT01263054|Other|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
75742943|NCT00994968|Procedure|neoadjuvant therapy|
75742944|NCT00994968|Procedure|therapeutic conventional surgery|
75742945|NCT03887442|Drug|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
75742946|NCT03887442|Drug|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
75742947|NCT00995982|Biological|VRC-FLUDNA056-00VP|
75890792|NCT03670329|Device|URGO2875|Dressing
75890793|NCT04780321|Biological|Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1
75890794|NCT04780321|Drug|Placebo|30 patients receipt placebo intravenous infusion on day 1
75890795|NCT02078778|Device|CPAP|3 months of CPAP treatment
75890796|NCT03669393|Drug|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
75890797|NCT03670173|Drug|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
75890798|NCT02076204|Behavioral|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
75890799|NCT03670095|Drug|Lactose-free memantine|Lactose-free memantine tablet, 10 mg; orally as a single dose
75890800|NCT03670095|Drug|Memantine|Lactose-containing memantine tablet, 10 mg, orally as a single dose
75890801|NCT01378039|Drug|comparison of treatment effect on different markers|inhaled budesonide (400 µg BD) or placebo BD
75890802|NCT02078856|Drug|A3384|
76061308|NCT03081598|Drug|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
76061309|NCT03081598|Other|Placebo|Placebo soft gelatine capsule
76061310|NCT04401670|Other|HPV screening and triage tests|The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt [Hologic, Inc., Bedford, MA, USA] and a visual inspection by acetic acid (VIA) by a nurse.
75742948|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day."
75890803|NCT02473341|Drug|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
75890804|NCT02473341|Drug|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
75890805|NCT03240679|Device|Acell MatriStem® Surgical Matrix|Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
75890806|NCT01377961|Drug|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|"After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.~The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks."
75890807|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
75890808|NCT01377961|Other|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
75890809|NCT01377961|Other|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
75890810|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
75890811|NCT01377961|Other|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
75742949|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort."
75890812|NCT02074956|Biological|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
75890813|NCT02074956|Biological|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
75448416|NCT04033991|Drug|Axitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
75890814|NCT03558750|Biological|Nivolumab|Given by IV
75448417|NCT04004741|Procedure|Osteopathic Manipulative Treatment|"The purpose of this research is to investigate the effect of osteopathic manipulative treatment (OMT) focused on somatic dysfunctions commonly associated with arrhythmias on the amount of quantifiable arrhythmias as recorded on a diagnostic device.~It is known that OMT has a stabilizing effect on the autonomic nervous system, which plays a key role in regulating heart rate and blood pressure. This increases parasympathetic tone and decreases sympathetic tone, which generally stabilizes the heart with an antiarrhythmic effect.~Previous work has been done showing that osteopathic treatment is a beneficial adjunctive therapy for paroxysmal atrial fibrillation and decreased symptoms, though has not been proven to be helpful for patients with heart failure.~While the effect of OMT on the neurology has been studied, we would like to further research the effect OMT specifically has on arrhythmias using more quantifiable data from implanted devices."
75890815|NCT03558750|Biological|Rituximab|Given by IV
75890816|NCT03558750|Drug|Lenalidomide|Given by mouth
75448418|NCT04004741|Procedure|Light Touch Therapy|The physician will contact various areas of the body for 120 seconds each to expose the subject to a similar environment as the interventional group, without stimulating the autonomic nervous system.
75448419|NCT03991156|Device|Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|Audio Visual System
75598784|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses."
75598785|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses"
75742950|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort."
75890817|NCT02083302|Behavioral|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
75890818|NCT02083302|Behavioral|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|"Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention."
75890819|NCT02083302|Behavioral|SCREAM Theater Dose 4|Booster Session
75890820|NCT03559140|Procedure|Applied saline solution at 2.5 oC (Cryotherapy group)|Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
75890821|NCT03559140|Procedure|Applied saline solution at 8oC (Cryotherapy )|Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
75890822|NCT03559140|Procedure|Applied saline solution at room temperature (No cryotherapy)|Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
75890823|NCT02082366|Device|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
75890824|NCT02082444|Other|Skipping lunch|
75890825|NCT02082600|Other|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
75890826|NCT02082600|Other|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
75890827|NCT02078934|Procedure|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
75448420|NCT03991156|Other|Quality of Life Survey, PedsQL3.0|Quality of life survey using the PedsQL 3.0 Cancer Module
75448421|NCT03991156|Other|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF).[24] is a survey to measure anxiety
75448422|NCT03961360|Drug|Aspirin 81 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
75598786|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses."
75448423|NCT03961360|Drug|Aspirin 162 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
75742951|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
75890828|NCT03558594|Behavioral|Hypnosis|Behavioral Condition
75890829|NCT03558594|Behavioral|Mindfulness|Behavioral Condition
75890830|NCT02751320|Drug|0.425 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
75890831|NCT02751320|Drug|0.85 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
75448424|NCT03941769|Biological|Recombinant Interleukin-7|Given IM or SC
75448425|NCT03924401|Drug|Abatacept|All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
75890832|NCT02751320|Drug|0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
75598787|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses."
75890833|NCT02751320|Other|0 ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
75890834|NCT02751320|Drug|1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
75890835|NCT02751320|Drug|0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
75890836|NCT02079012|Behavioral|10-week walking program|
75890837|NCT02082756|Drug|Bifidobacterium viable pharmaceutics|
75598788|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses"
75598789|NCT01031836|Drug|MEDI-545 600|"Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses."
75890838|NCT02082756|Drug|Berberine Hydrochloride|
75448426|NCT03922386|Device|XFINE leads|Pacemaker subjects with at least one XFINE passive lead
75448427|NCT03865342|Behavioral|Noom Coach DPP|Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
75448428|NCT03853915|Diagnostic Test|[18-F]- FDG - PET|[F-18]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, [F-18]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
75742952|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
75742953|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
75890839|NCT02223572|Radiation|hip Xray|
75890840|NCT04615845|Biological|Cellgram-DC-PC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
76061311|NCT04401670|Behavioral|HPV self-sampling|"The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler [Preventive Oncology International, Cleveland, OH, USA]."
76061312|NCT03088774|Other|Information material|Online web-application developed together with patients with low back pain
76061313|NCT03089008|Other|Eccentric exercises|
75448429|NCT03849820|Device|Robotic-assisted partial nephrectomy|Application of the da Vinci surgical robot to assist the partial nephrectomy
75448430|NCT03849820|Other|Open partial nephrectomy|Open surgery to conduct the partial nephrectomy
76061314|NCT03089008|Other|Stretching exercises|
76061315|NCT03081286|Procedure|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
76061316|NCT03081286|Procedure|Fat graft|The harvested lipoaspirate is injected at the site of pain.
75890841|NCT02259140|Procedure|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
75890842|NCT02259140|Procedure|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
75742954|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
75890843|NCT03559764|Biological|Anti-BCMA CAR T cells|Transparent colorless or slightly yellow liquid
75890844|NCT02082834|Other|abdominal MDCT examination|
76061317|NCT03081286|Procedure|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
75598790|NCT04301440|Device|The emission of electromagnetic with the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
75448431|NCT03838510|Behavioral|REBOOT|The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
75448432|NCT03813355|Device|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) during 20 sessions
76061318|NCT04279678|Procedure|Mitral valve repair|surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
76072017|NCT03418779|Drug|The Yi-Qi-Qing-Jie herbal compound|The compounds are blends of individual herbal extracts from YQF (consisting of Astragalus membranaceus, Saposhnikovia divaricata (turcz.) Schischk, Flos lonicerae, Angelica sinensis, Dioscorea nipponica, Hedyotis diffusa Willd, rhubarb, Spatholobus suberectus, with the effect of reinforcing Qi and activating blood, clearing away heat and poison, dissolving dampness and downbearing turbid) dissolved in 150 ml boiled water and taken orally twice a day for the duration of the treatment and follow-up phases.
75448433|NCT03791216|Other|Fasting blood draw for lipid assessments|Fasting blood draw for lipid assessments
75448434|NCT03788811|Device|ERG assessment (RSPA)|Processing and analysis of retinal signals
75598791|NCT04301440|Device|The emission of electromagnetic without the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
75598792|NCT01237587|Drug|Duloxetine|Administered orally
75598793|NCT01237587|Drug|Placebo|Administered orally
75598794|NCT01031680|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
75890845|NCT02259218|Other|laboratory biomarker analysis|Correlative studies
75890846|NCT01377883|Other|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.~Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
75890847|NCT01377883|Behavioral|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
75890848|NCT02083458|Procedure|Catheterization of the axillary vein.|
75890849|NCT02231528|Device|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
75890850|NCT02231528|Device|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
75890851|NCT02079090|Drug|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
75890852|NCT02079090|Drug|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
75448435|NCT03779490|Device|Transcatheter Tricuspid Valve Repair|Transcatheter Tricuspid Valve Repair with Edwards Cardioband TR
75448436|NCT03769285|Drug|Nicotinamide|Oral nicotinamide (500 mg) twice daily for at least 52 weeks
75598795|NCT01031680|Drug|Placebo|Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
75598796|NCT01031446|Drug|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
75598797|NCT01031446|Drug|everolimus|Taken daily by mouth.
75890853|NCT04931641|Dietary Supplement|Galacto-oligosaccharides|Prebiotic galacto-oligosaccharides (GOS)
75890854|NCT04931641|Other|Maltodextrin|Maltodextrin (placebo)
75890855|NCT04931641|Dietary Supplement|Ferrous fumarate|50 mg iron as ferrous fumarate
75742955|NCT00999414|Drug|Carfilzomib|"Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.~Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.~For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2."
75890856|NCT04937270|Device|High frequency therapy (5 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 5 minutes using a 500 kHz resistive electric transfer (RET).
75890857|NCT04937270|Device|High frequency therapy (7 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 7 minutes using a 500 kHz resistive electric transfer (RET).
75890858|NCT04937270|Device|High frequency therapy (9 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 9 minutes using a 500 kHz resistive electric transfer (RET).
75890859|NCT04937270|Device|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
75890860|NCT02079168|Drug|RXI-109|
75890861|NCT02079168|Drug|Placebo|
75890862|NCT04898959|Other|Filling out Questionaire|Filling out the Arabic Activity Specific Balance Confidence (A-ABC) and the Arabic Prosthetic Mobility Questionnaire twice at 2-3 week intervals
76061319|NCT04402528|Behavioral|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers/childcare providers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
76061320|NCT01610336|Drug|INC280|During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
76061321|NCT01610336|Drug|Gefitinib|Gefitinib 250 mg taken once daily
75448437|NCT03769285|Drug|Placebo oral capsule|Matching placebo taken twice daily for at least 52 weeks
75448438|NCT03749187|Drug|PARP Inhibitor BGB-290|Given PO
75448439|NCT03749187|Drug|Temozolomide|Given PO
75448440|NCT03743051|Drug|Anamorelin Hydrochloride|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
75448441|NCT03743051|Drug|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
75598798|NCT01031446|Drug|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
75742956|NCT00999492|Device|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
75742957|NCT00996138|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
75448442|NCT03710902|Diagnostic Test|ECG monitoring for 3 weeks|A 3-week continuous ECG monitoring to detect occult AF.
75448443|NCT03710902|Other|Self-monitoring of BP and self-titration of antihypertensive medication|One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
75598799|NCT01031446|Other|laboratory biomarker analysis|Blood collection
75598800|NCT02873728|Procedure|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
75742958|NCT00995046|Drug|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
75742959|NCT00995046|Drug|FVIII|"1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done."
75742960|NCT00995124|Drug|NeutraLice Lotion|Head lice topical application to be applied once for 10 minutes.
75742961|NCT00995124|Drug|NeutraLice Advance Solution|head lice application to be applied once for 10 minutes
75448444|NCT03707236|Behavioral|Teledermatology visits|Patients in the treatment arm will be taught by study staff how to take the standardized photos of themselves at treatment week 4 (prior to initiation of teledermatology visits). For patients in the treatment arm, the teledermatology visits will be managed by the study staff. A monthly teledermatology visit will consist of sending facial and truncal (if affected) clinical images to a the study staff using Patient Gateway. Once this is completed, the patient and a member of the study staff will have a scheduled telephone appointment during which the provider will screen for any adverse events and will provide counseling as outlined in iPledge guidelines. The patient will also be asked to verbally complete a monthly survey assessing acne severity, quality of life, cost attributable to the appointment, time missed from school/work, satisfaction with treatment. All photographs will be uploaded in LMR/EPIC in the patient's medical record.
75448445|NCT03698201|Other|Non-interventional|Translational, observational study
75448446|NCT03642132|Drug|Chemotherapy + avelumab followed by avelumab + talazoparib|"Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib"
75448447|NCT03642132|Drug|Chemotherapy followed by talazoparib maintenance|"Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib"
75448448|NCT03642132|Drug|Chemotherapy + bevacizumab followed by bevacizumab|"Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab"
75448449|NCT03632330|Drug|Dexmedetomidine|Dexmedetomidine group
75448450|NCT03632330|Drug|Midazolam|Midazolam group
75448451|NCT03632330|Drug|Propofol|Propofol group
75448452|NCT03632330|Drug|Midazolam/Propofol|Midazolam/Propofol group
75448453|NCT03585946|Drug|Site specific standard of care comparison|Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
75448454|NCT03575949|Procedure|Computed Tomography|Undergo FDG PET/CT
75448455|NCT03575949|Other|Fludeoxyglucose F-18|Given IV
75448456|NCT03575949|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
75448457|NCT03572764|Drug|CPX-351|-CPX-351 will be provided by Jazz Pharmaceuticals
75448458|NCT03572764|Procedure|Research skin biopsy|"-And/or buccal swab~Pre-treatment~Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)"
75448459|NCT03572764|Procedure|Research blood draw|"Pre-treatment~Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~Post-consolidation 1 (if applicable)~Post-consolidation 2 (if applicable)~Post-transplant Day 30 (if applicable)~Post-transplant Day 100 (if applicable)"
75448460|NCT03572764|Procedure|Research bone marrow aspirate|"Pre-treatment~Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~Post-consolidation 1 (if applicable)~Post-consolidation 2 (if applicable)~Post-transplant Day 30 (if applicable)~Post-transplant Day 100 (if applicable)"
75890863|NCT02227472|Other|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
75890864|NCT02227472|Other|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
75448461|NCT03568045|Device|standard light|usual care
75448462|NCT03568045|Device|10,000 lux bright light, 4 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to noon.
75598801|NCT02873728|Other|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
75598802|NCT01030900|Biological|Campath|campath plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and rituximab every 3 weeks for up to 6 cycles
75598803|NCT01030900|Biological|Rituximab|rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and campath every 3 weeks for up to 6 cycles
75448463|NCT03568045|Device|10,000 lux bright light, 8 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to 4pm.
75448464|NCT03560752|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given via injection
75598804|NCT01030900|Drug|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles
75598805|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
75598806|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
75598807|NCT04288882|Device|Enteroscopy|Role of Balloon-Assisted Enteroscopy (BAE) in management of Small Intestinal Disorders
75598808|NCT02873494|Device|PHYSIOFLOW - PF05 Lab1TM|
75742962|NCT00995124|Drug|Moov Head Lice Solution|Single application for head lice with 10 min application time.
75742963|NCT04001010|Drug|PPP011|1 capsule inhaled 3 times a day with a vaporizer device
75742964|NCT04001010|Drug|Placebo|1 capsule inhaled 3 times a day with a vaporizer device
75742965|NCT00999570|Other|Specialty training for knee surgeons|
75448465|NCT03558802|Other|questionnaire|questionnaire
75890865|NCT02083536|Radiation|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
75890866|NCT02083536|Drug|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
75890867|NCT03629899|Device|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
75890868|NCT02231606|Other|Free Glasses|Provide free glasses
75598809|NCT04694872|Other|Telerehabilitation Based LSVT BIG Exercise Protocol|Lee Silverman Voice Treatment-LOUD therapy is a protocol involving intensive speech therapy, which was initiated at the Lee Silverman Parkinson Center between 1987-1989 to heal hypophonia in individuals with PD. LSVT-BIG, on the other hand, is a protocol derived from LSVT-LOUD, used in neurorehabilitation, consisting of focused large-amplitude functional movements performed with great effort. Maximal Daily exercises consist of seven standard exercises. Functional component tasks, on the other hand, will be created for movements in which the patient has difficulty in daily life activities selected individually based on his complaints. In hierarchical tasks, daily life activities with difficulties will be studied with large amplitudes. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
75890869|NCT02231606|Other|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
75890870|NCT02231606|Other|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
75890871|NCT02083614|Procedure|to clamp or release the catheter for 2 days before removal|
75598810|NCT04694872|Other|Telerehabilitation Based Functional Balance and Mobility Exercise|"These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.~Exercises will get harder with each passing week and its progression will be adjusted to the patient."
75890872|NCT04629937|Other|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
75598811|NCT01026454|Drug|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
75448466|NCT03558048|Diagnostic Test|Blood draw|Subjects will have their blood drawn during clinic visits over the course of the study period to measure their serum prostate specific antigen levels.
75448467|NCT03506061|Drug|Trikafta|Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.
75598812|NCT01026454|Drug|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
75598813|NCT01026220|Biological|bleomycin sulfate|Given IV or SC
75448468|NCT03486821|Radiation|Hypofractionated Radiation|All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
75598814|NCT01026220|Drug|doxorubicin hydrochloride|Given IV
75598815|NCT01026220|Drug|liposomal vincristine sulfate|Given IV
75598816|NCT01026220|Drug|vinorelbine tartrate|Given IV
75598817|NCT01026220|Drug|cyclophosphamide|Given IV
75598818|NCT01026220|Drug|etoposide phosphate|Given IV
75598819|NCT01026220|Drug|prednisone|Given IV
75598820|NCT01026220|Biological|filgrastim|Given IV or SC
75598821|NCT01026220|Drug|ifosfamide|Given IV
75890873|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
75890874|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
75890875|NCT02083692|Drug|Metformin|
75890876|NCT04573699|Device|CNT-HF|A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.
75598822|NCT00627562|Device|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
75598823|NCT04301362|Diagnostic Test|Thrombosis biomarkers|Blood samples shall be prepared according to the manufacturer's instructions and stored at -80°C until analysis. Thrombin generation will be measured using the commercial kit STG®-Tromboscreen kit (Stago). The D-dimers will be quantified using STA LIATEST® D-DI PLUS (Stago).
76061322|NCT03086200|Behavioral|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
75598824|NCT01026142|Drug|Capecitabine|1000 mg/m2 po twice daily for 14 days every 3 weeks
75598825|NCT01026142|Drug|Capecitabine|1250 mg/m2 po twice daily for 14 days every 3 weeks
75598826|NCT01026142|Drug|Pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
75742966|NCT04000542|Other|Pharmacist Intervention|The pharmacist will record a 30 second rhythm strip from patients using the KardiaMobile device and calculate the QTc interval using the Bazett calculation formula. The pharmacist will discuss the result with the patient and if necessary, will contact the prescriber to effect a medication change. If the QTc interval is greater than the 99th percentile, (470 ms for males, 480 ms for females) the pharmacist must contact the prescriber. The pharmacist will record any prescription changes which resulted from the intervention and the prescriber response. The pharmacist will email the rhythm strip (with study participation number) to a secure email at the Northeast Iowa Family Practice Center (NEIFPC). Rhythm strips will be archived for future potential research evaluation in a secure, electronic file.
75598827|NCT01026142|Drug|Trastuzumab|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
75598828|NCT06055582|Dietary Supplement|Bread|81g (3 slices) harvest gold white bread as standard food.
75598829|NCT06055582|Dietary Supplement|Mango|250g of mango pulp of each mango variety was given to the subjects.
75890877|NCT02227550|Drug|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
75890878|NCT02227550|Drug|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine >= 1.5 mg/dl (133mM), <= 60 kg body weight or age >= 80 years.
75890879|NCT02206035|Drug|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
75890880|NCT02206035|Drug|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m^2 Days +3, +6 and +11.
75890881|NCT02206035|Drug|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
75890882|NCT02227628|Dietary Supplement|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
75890883|NCT02227628|Dietary Supplement|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
76061323|NCT05689138|Other|Oral and Fecal Sample Collection|No interventions
76061324|NCT05685550|Drug|Toposide capsules combined with anrotinib and Emvolizumab group|Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd*14d,every 21 days until disease progression or adverse reactions that were tolerated.
75448469|NCT03458611|Behavioral|Active Intervention|An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent & Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.
75598830|NCT06055569|Other|Rehabilitation protocol: AOT+NMES|Action observation and neuromuscular electrical stimulation followed by motor execution
75598831|NCT06055569|Other|Rehabilitation protocol: Action Observation Therapy (AOT)|Action observation followed by motor execution
75598832|NCT06055569|Other|Observation of motor-neutral stimuli (MNO)|Motor-neutral observation followed by motor execution
75598833|NCT06055543|Dietary Supplement|Fortimel|2 bottles/day of the high energy ONS
76061325|NCT05689060|Other|mulling Straight leg raising technique|Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.
75890884|NCT02082990|Behavioral|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
75890885|NCT02082990|Behavioral|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
76061326|NCT05689060|Other|post facilitation stretch|Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
76061327|NCT03088696|Other|stimulation|activation of the acupuncture point
76061328|NCT03088696|Other|no stimulation|no activation of the acupuncture point
76061329|NCT01613222|Device|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
76061330|NCT03088462|Other|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
76061331|NCT03088462|Behavioral|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
76061332|NCT03088462|Behavioral|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
75890886|NCT02079324|Biological|GX-051|intratumoral injection
75598834|NCT06055517|Radiation|Pulsed low dose-rate radiotherapy (pLDRT)|Radiation treatment will be carried out with high-energy photons (6MV) using intensity modulated radiation therapy (IMRT) or volumetric arc radiation therapy (VMAT). The daily dose is 2 Gy, divided into 10 subfractions of 0.2 Gy spaced by 3 minutes. The cumulative dose will be individualized for each patient and can range from a minimum of 40 Gy to a maximum of 60 Gy.
75598835|NCT06055504|Other|Control Strategy|ICDs will be implanted in all patients according to current recommendations
75598836|NCT06055504|Other|Personalized precision ICD implantation Strategy based in genetic findings and CMR results|Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
75598837|NCT06055465|Drug|Sacituzumab Govitecan|"4 cycles, each cycle lasting for 3 weeks~10mg/kg given every day 1 and day 8 each cycle~IV infusion"
75890887|NCT02258828|Drug|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
75890888|NCT02258828|Drug|Placebo|Matched placebo
76061333|NCT05345860|Other|The MRD strategy for high risk or MRD+ TNBC patients|"Standard adjuvant chemotherapy + additional chemotherapy:~BRCA positive patients: standard adjuvant chemotherapy + olaparib~BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once."
75890889|NCT02746471|Device|Reveal LINQ|
75890890|NCT02083068|Biological|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
75890891|NCT02083068|Biological|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
75890892|NCT02083068|Biological|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
75890893|NCT02228018|Device|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
75890894|NCT02228252|Other|Whey protein|
76061334|NCT05345860|Other|The MRD strategy for high risk or MRD+ HER2+ patients|"Standard adjuvant chemotherapy + intensive targeted therapy:~Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once."
76061335|NCT05345860|Other|The MRD strategy for high risk or MRD+ ER+ patients|"Standard adjuvant chemotherapy + intensive endocrine therapy:~Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once."
76061336|NCT05345860|Other|The MRD strategy for low risk and MRD- TNBC patients|"Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice."
76061337|NCT05345860|Other|The MRD strategy for low risk and MRD- HER2+ patients|"Standard adjuvant chemotherapy + standard targeted therapy:~Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice."
75890895|NCT02228252|Other|Casein|
75890896|NCT02228252|Other|Gluten protein|
75890897|NCT04525573|Device|LLLT Combination Red/Gold/IR Therapy|Three LLLT combination treatments per week over the course of two consecutive weeks, and a final follow up on day-15 (total of 7 treatments).
75890898|NCT02083770|Behavioral|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
75890899|NCT02228330|Procedure|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
75598838|NCT06055465|Drug|Pembrolizumab|"4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~200mg fixed dose every day 1 each cycle~IV infusion"
76061338|NCT05345860|Other|The MRD strategy for low risk and MRD- ER+ patients|"Standard adjuvant chemotherapy + standard endocrine therapy:~Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice."
76061339|NCT03323866|Drug|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
75890900|NCT04524715|Device|Non-invasive red LLLT treatment to chest of patient.|Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
75742967|NCT00999648|Other|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
75742968|NCT00999648|Other|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
75890901|NCT04524715|Device|Sham Device Treatment|Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
75742969|NCT04000698|Drug|Preparative regimen|"Preparative chemotherapy before allogeneic HSCT~Fludarabin~Cytarabine~Venetoclax~Daratumomab~Vecanoid Condition~treosulfan~fludarabine~thiophosphomide~Venetoclax~Plerixafor GVHD prophylaxis~abatacept~tocilizumab~rituximab~HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
75742970|NCT00996294|Procedure|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
75742971|NCT01004016|Drug|KPS-0373|
75742972|NCT01004016|Drug|Placebo|
75742973|NCT04000932|Drug|Local platelet rich plasma (PRP) injection-T-Lab PRP kit|Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.
75890902|NCT02083848|Other|7T MRI|Ultra high field magnetic resonance imaging
75448470|NCT03458611|Behavioral|Placebo Intervention|The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.
75448471|NCT03453619|Drug|APL-2|APL-2 administered as a daily subcutaneous infusion for 48 weeks
75448472|NCT03452930|Radiation|Radiation Therapy|Undergo RT
75448473|NCT03452930|Drug|Tinostamustine|Given IV
75598839|NCT06055426|Other|bed bath application|Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
75890903|NCT04933370|Other|Stimulation parameters|Different device stimulation parameters
75890904|NCT02223728|Behavioral|Lifestyle|
75890905|NCT02223728|Behavioral|Health Education|
76061340|NCT03323866|Drug|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
76061341|NCT05688670|Procedure|Regional Anesthesia|Bilateral pecto-intercostal fascial plane block (PIFB) and unilateral rectus sheath block (RSB) with Ropivacaine 0.2%
76061342|NCT05688670|Procedure|Wound infiltration|Surgeon-delivered wound infiltration with Ropivacaine 0.2%
76061343|NCT05688670|Drug|Ropivacaine 0.2% Injectable Solution|Ropivacaine 1.5 mL/kg will be used for both interventions
75448474|NCT03396653|Behavioral|Peer-delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
75890906|NCT02079402|Drug|Isotonic crystalloids|
75890907|NCT02591953|Procedure|Ultrasound-guidance|Using ultrasound-guidance to perform a corticosteroid injection
75890908|NCT02591953|Procedure|Landmark-guidance|Using landmark-guidance to perform a corticosteroid injection
75890909|NCT02591953|Drug|Methylprednisolone|Corticosteroid used in injection (40 mg)
75890910|NCT02591953|Drug|Lidocaine 1%|Anesthesic used in injection
75598840|NCT06055413|Combination Product|Remote patient monitoring (RPM) bundle|"Patient-families will be given a remote patient monitoring (RPM) bundle with tools to measure objective and subjective information about the child at home that are shared with the home ventilator provider team through an electronic dashboard. The tools include a device to measure carbon dioxide, a digital tablet, a digital weight scale, and a digital application that connects to the child's electronic health record. Each child will be assigned an individualized remote monitoring schedule (timing and data type) based on their indication for ventilation and ventilator regimen at enrollment."
75598841|NCT06055400|Device|AR-US|The ultrasound imagery is projected onto the glasses, and participants use the AR-US throughout the entire CVC placement procedure
75598842|NCT06055387|Behavioral|Frailty intervention measures|"Providing specialized guidance:~Physical Function and Fall History:~Prioritizing home safety for those with physical impairments.~Arranging rehab consultations when necessary.~Nutrition:~Assessing diets and offering education.~Pre-treatment nutritionist assessments.~Monitoring weight, intervening if >5-10% loss, or >10% loss.~Social Support:~Evaluating the needs of those without family support.~Referring to social services and introducing care resources.~Cognition:~Detecting cognitive issues, addressing reversible causes.~Assessing decision-making and medication self-administration.~Refer to specialists when needed.~Polypharmacy and Comorbidity:~Collecting medication data, ensuring adherence.~Noting chronic illnesses.~Collaborating with specialists or pharmacists for complex cases.~Psychological:~Providing weekly support for psychological concerns.~Refer to specialists for assessments and treatment options."
75598843|NCT06055374|Drug|BxC-I17e|Pharmaceutical form : solution for injection
75598844|NCT06055374|Drug|Placebo|Pharmaceutical form : solution for injection
75598845|NCT06055361|Drug|BxC-I17e|Pharmaceutical form : solution for injection
76061344|NCT05684848|Device|Resveratrol + CMG|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
75742974|NCT04000932|Drug|Local steroid injection-Diprospan ®, Schering Plough|The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
75742975|NCT01004094|Behavioral|simple goal setting|This group will set goals only
75742976|NCT01004094|Behavioral|goal setting plus action intentions|This group will set goals and form action intentions (plans)
75742977|NCT01004094|Behavioral|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
75742978|NCT01004094|Behavioral|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
75742979|NCT00999882|Drug|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
75598846|NCT06055361|Drug|Placebo|Pharmaceutical form : solution for injection
75598847|NCT06055348|Drug|SC0191|SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.
75598848|NCT06055348|Drug|Gemcitabine|Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
75598849|NCT06055348|Drug|Paclitaxel|Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
75598850|NCT06055335|Other|Medium flow anesthesia|Group MeFA; after reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
75598851|NCT06055335|Other|Minimal flow anesthesia|Group MiFA; after reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
75598852|NCT06055322|Behavioral|Adapted Dialectical Behavior Therapy|DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
75742980|NCT00996528|Behavioral|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
75742981|NCT05170230|Drug|Terlipressin|intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy
76061345|NCT05684848|Device|Isotonic solution|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
76061346|NCT03322618|Biological|blood samples|7 tubes of 6 ml (42 ml of blood )
75742982|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
76061347|NCT03390244|Device|Foldable Capsular Vitreous Body Implant|Vitrectomy augmented with the implantation of the FCVB implant
76061348|NCT04761484|Procedure|Vascular access on admission|PIVC insertion
75598853|NCT06055283|Other|Aerobic exercise|The training group will receive aerobic exercise and the intensities will be controlled considering the percentage of estimated maximum heart rate. The training will be performed with a cycle ergometer with a total of 40 minutes of intradialytic aerobic exercise in the training group. To reduce the effects of intolerance to aerobic exercise, a week of adaptation will be performed, with a frequency of three sessions, in the first two hours of hemodialysis, lasting 40 minutes at maximum heart rate intensity of up to 74% and BORG up to 4 (low intensity). Afterwards, the patients will perform the prediction training for 12 weeks, at the frequency of three training sessions per week in the first two hours of hemodialysis. Each training session will start with a 5-minute warm-up at low intensity, 30 minutes of main training with maximum heart rate intensity 55% to 74% and BORG 5 to 7 (moderate intensity) and will end with a 5-minute cool-down at low intensity.
75448475|NCT03396653|Behavioral|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
75448476|NCT03339908|Device|Thalamotomy by gamma Knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
75598854|NCT06055270|Procedure|Stellate Ganglion Block|All SGBs will be performed by a board-certified anesthesiologist and pain management specialist with extensive experience performing SGBs. The laterality of the SGB will be randomized between the left and right sides of the neck. Participants will be asked to abstain from eating and drinking for 8 hours prior to the SGB. Using ultrasound guidance, the transverse process of the C6 vertebra is identified. Color-doppler is used to identify blood vessels. A 27-gauge needle is used to anesthetize the superficial skin with 1% lidocaine. Then, a 21-gauge ultrasound needle is advanced using an in-plane technique from lateral to medial with careful avoidance of neurovascular structures. After negative aspiration, 8 mL of 1% Lidocaine is deposited beneath the prevertebral fascia and above the Longus coli muscle into the stellate ganglion.
75598855|NCT06055270|Other|Placebo|The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine
75598856|NCT06055257|Drug|modified PENTOCLO (mPENTOCLO)|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) treatment phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added."
75598857|NCT06055257|Drug|sham mPENTOCLO|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) of sham treatment phase (placebo)."
75598858|NCT06055244|Drug|Amantadine|Subjects will be give amantadine 100 mg twice daily.
75448477|NCT03253289|Drug|Meclizine Oral Tablet|All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 28 (up to 35) days.
75448478|NCT03227705|Drug|Prometrium|Intravaginal use, off label, of Prometrium
75742983|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
75742984|NCT01004328|Other|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
75890911|NCT01938495|Device|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
75742985|NCT01000116|Procedure|Fibrin glue|Tissucol 2 ml
75890912|NCT02223806|Behavioral|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
75890913|NCT02223806|Behavioral|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
75890914|NCT02084004|Drug|Bifidobacterium viable pharmaceutics|
75742986|NCT01000116|Procedure|Tacks|Protacks
75742987|NCT00996684|Drug|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
75448479|NCT03227705|Device|Dr. Arabin, cerclage pessary perforated|A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
75448480|NCT03178032|Biological|DNX-2401|Brain infusion of the virus through the cerebellar peduncle
75742988|NCT00996684|Drug|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
75742989|NCT00996762|Drug|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
75742990|NCT05162196|Radiation|SBRT|24Gy/3F
75598859|NCT06055192|Other|Survey|Survey
75742991|NCT05162196|Drug|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
76061349|NCT03320668|Other|Otago Exercise Program (OEP)|"A nurse/physiotherapist supported by an instructor-trained professional will give Otago Exercise Program (OEP) education to 10-people groups in 5 sessions (1st, 2nd, 4th and 8th week and one reinforcement session after 6 months). Telephone calls to participants will be made during non-training months (following a predefined telephonic interview protocol) to follow up. The OEP reduces the number of falls and fall-related injuries, improving balance and strength, confidence in performing everyday activities without falling. Whilst it has been shown to be effective in 4 controlled trials in New Zealand, it has not been tested in a primary care setting in Spain for feasibility, impact, acceptability and cost-effectiveness."
76061350|NCT03366298|Combination Product|Epipen 0.3mg|Epipen 0.3mg auto-injector
76061351|NCT03366298|Combination Product|Emerade 300mcg|Emerade 300mcg auto-injector
76061352|NCT03366298|Combination Product|Emerade 500mcg|Emerade 500mcg auto-injector
75742992|NCT05162196|Drug|Niraparib|200mg qd
75742993|NCT04000464|Behavioral|CLIPP|Diabetes Prevention program and Comprehensive Lifestyle Improvement Program consisting of low calorie diet, physical activity, sleep optimization and stress management
76061353|NCT03320512|Behavioral|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
76061354|NCT03320512|Behavioral|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
75742994|NCT01000194|Dietary Supplement|High fat meal|A high fat milkshake containing 55g of fat
75742995|NCT01004484|Other|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving), once daily.
75448481|NCT03167307|Drug|Omega 3 fatty acid|Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
75890915|NCT02084004|Drug|Berberine Hydrochloride|
75890916|NCT02223884|Drug|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
75598860|NCT06055166|Drug|Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))|Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles
75448482|NCT03167307|Drug|Placebo oil|medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
75616391|NCT05017558|Diagnostic Test|point of care|"HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~Low risk (maternal VL <1000 cp/ml): NVP for 6 weeks.~virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support"
75448483|NCT03150004|Drug|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|"Subjects will be started on CLAG-M regimen, which consists of the following:~Cladribine 5 mg/m^2 IV over two hours on days 1-5;~Cytarabine 2 gm/m^2 IV over four hours on days 1-5~Mitoxantrone 10 mg/m^2 IV on days 1-3;~G-CSF at a dose of 300 μg on days 0-5."
75448484|NCT03150004|Drug|Cladribine and Cytarabine (CLLDAC) Regimen|"Cladribine 5 mg/m^2 IV over two hours on days 1-5;~Cytarabine 20 mg/m^2 subcutaneous injection on days 1-10;"
75742996|NCT01004484|Other|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
75742997|NCT01004562|Other|informational intervention|
75742998|NCT00997074|Drug|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
75742999|NCT01004796|Genetic|cytogenetic analysis|
75743000|NCT01004796|Genetic|microarray analysis|
75743001|NCT01004796|Genetic|mutation analysis|
75743002|NCT01004796|Other|immunohistochemistry staining method|
75890917|NCT02223884|Drug|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
75890918|NCT02079480|Drug|BMS-986090|
75890919|NCT02079480|Drug|Placebo matching with BMS-986090|
75890920|NCT02079480|Drug|Keyhole limpet hemocyanin|
75890921|NCT02569489|Drug|HBI-8000|
75890922|NCT02569489|Drug|Trastuzumab|
75890923|NCT02569489|Drug|Paclitaxel|
75890924|NCT02079558|Drug|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
76061355|NCT03320512|Behavioral|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
75598861|NCT06055153|Drug|RC48+PD-1+platinum-based|"Phase I: Three subjects with HER2 overexpression (IHC 2+/3+) were initially enrolled. If dose-limiting toxicity (DLT) was observed in two of the three subjects, the study was continued from dose 1 to dose 2. If ≤1 DLT is observed in 3 subjects, continue to enroll 3 patients, and if ≤2 DLT is observed in 6 subjects, proceed to the second phase. If > 2 cases of DLT are observed in 6 subjects, adjust to dose 2 for phase 2.~Dose 1: RC48 2.5mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~Dose 2: RC48 2.0mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~The second stage: sample size expansion stage. RP2D obtained at stage 1 continues to be enrolled in up to 20 patients until disease progression or intolerable toxicity occurs."
75448485|NCT03082534|Drug|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
76061356|NCT05683522|Other|Sub-omohyoidal Plane Block|The ultrasound guided sub-omohyoidal plane block will be performed. Patients in this group will be given 15 mL of local anesthetic into the interfascial plane under the omohyoid muscle. This block will be performed preoperatively.
76061357|NCT05683522|Other|Cervical Plexus Block|A cervical plexus block will be applied by applying 10 mL of local anesthetic under ultrasound guidance. This block will be done before the surgery.
76061358|NCT05683522|Other|Costoclavicular Block|Costoclavicular brachial plexus block will be applied by administering 20 mL of local anesthetic under ultrasound guidance. This block will be performed preoperatively.
76061359|NCT05688514|Device|Innovalve MR system|Innovalve MR system
76061360|NCT03315598|Procedure|Electroacupuncture|lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
75598862|NCT06055127|Procedure|osseodensifiction internal sinus lift / sticky bone graft material|"The osteotomy for the osseodensification internal sinus lift begins with a twist drill advanced at 800 rpm with saline irrigation to within 1-2 mm from the sinus floor. Next, a series of osteotomy drills are used in the same fashion at 800 rpm to widen the osteotomy. The final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation occurs haptic feedback at this point infracture of the sinus has taken place. After infracture, injection of the graft material into the osteotomy site will occur. The final osteotomy drill is used to guide the graft apically. This process is repeated in an incremental fashion to lift the membrane. Once enough space has been created below the antral membrane, implant insertion will occur then suturing."
76061361|NCT05688358|Diagnostic Test|serum levels of interleukin-17A in JIA|IL17 A by Enzyme linked immunosorbent assay method
76061362|NCT03386734|Procedure|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
75743003|NCT01004796|Other|immunologic technique|
75743004|NCT01004796|Other|mass spectrometry|
76061363|NCT03386734|Procedure|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
76061364|NCT04401124|Other|no intervention|no intervention
75448486|NCT03081663|Procedure|Quads-Sparing Approach|Quadriceps-sparing mid-vastus approach for total knee arthroplasty
75448487|NCT03081663|Procedure|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
75448488|NCT03056339|Drug|Fludarabine|30 mg/m2 by vein on Days -5 to -3.
75448489|NCT03056339|Drug|Cyclophosphamide|300 mg/m2 by vein on Days -5 to -3.
75448490|NCT03056339|Drug|Mesna|300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
75448491|NCT03056339|Biological|iC9/CAR.19/IL15-Transduced CB-NK Cells|"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.~Starting dose: 10E5"
75743005|NCT00997308|Drug|AZD1446|Solution, oral, for 4 weeks
76061365|NCT03364270|Drug|PET/CT Imaging with [F-18] RGD-K5|PET Imaging/scan with [F-18] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
76061366|NCT03364114|Device|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
76061367|NCT03364114|Device|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
76061368|NCT04401514|Device|Rocking chair therapy|20 min long rocking therapy with music cure. The therapy can be extended if needed
76061369|NCT03082066|Other|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
75743006|NCT00997308|Drug|Placebo|
75743007|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
75448492|NCT03056339|Drug|AP1903|If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
75448493|NCT03008122|Other|Placebo|Placebo
75448494|NCT03008122|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
75743008|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
76061370|NCT04279288|Device|Hilotherm mask|a cooling mask used to treat localized swelling and bleeding
75743009|NCT01000740|Genetic|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
75890925|NCT02079558|Drug|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
76061371|NCT01612676|Drug|FE 202158|
75448495|NCT02977884|Behavioral|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
75448496|NCT02912897|Biological|Cellular therapy with EBV specific autologous CTL infusion|CTL infusions at D0, M3 and M6
75448497|NCT02847130|Other|Informational Intervention|Participate in focus group
75448498|NCT02847130|Other|Interview|Undergo one-on-one interviews
75448499|NCT02847130|Other|Medical Chart Review|Review of medical chart
75448500|NCT02847130|Other|Questionnaire Administration|Ancillary studies
75598863|NCT06055127|Procedure|piezoelectric internal sinus lift / sticky bone graft material|"In the PISE technique, an ultrasonic piezoelectric device (acteon), to which a specialized tip is attached, is used to break the sinus floor. Developed for sinus lift by the crestal approach, the Intralift™ Kit makes it possible to undertake dental non invasive surgery in full safety.~The diamond-coated tips, of increasing diameters (from 1.35mm to 2.80mm), are designed to drill and gradually widen the access canal to the sinus membrane. The sterile spray cools the tips down to avoid any rise in temperature, which could lead to oral tissue damage.The membrane elevation is achieved using the TKW5 by means of microcavitation. Thanks to the ultrasonic frequency modulation, the risk of membrane damage is limited. Moreover, the cavitation effect enables excellent visibility of the operating field."
75743010|NCT01000740|Genetic|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
75743011|NCT05249712|Drug|Darolutamide 300 mg|600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.
75743012|NCT05249712|Other|Androgen deprivation therapy|The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.
75743013|NCT01005030|Other|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
75743014|NCT01000896|Drug|AZD0530|film coated tablet, PO, daily
75743015|NCT01000896|Drug|Carboplatin|intravenous, 3 weeks
75743016|NCT01000896|Drug|paclitaxel|intravenous, 3 weeks
75743017|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
75743018|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
75743019|NCT00425061|Other|placebo|placebo
75743020|NCT04000308|Drug|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
75890926|NCT03629821|Other|Ballet|The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
75890927|NCT04058379|Radiation|CT scan|3 ct scans : D0, D1 and D3
75890928|NCT04057755|Drug|botulinum toxin A|
76061372|NCT05424172|Behavioral|Stage-I, Group 1: Self monitoring using Non-interactive App|Participants in Group 1 will have minimal features that affect compliance (notifications, rewards, EMA, etc.) and no modifications to their exercise program after initial prescription.
75890929|NCT04057755|Drug|NaCl|
75743021|NCT04000308|Drug|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
75743022|NCT01005186|Behavioral|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
75890930|NCT02139709|Dietary Supplement|Ganglioside|
75743023|NCT00997542|Drug|Allopurinol|
75743024|NCT00997542|Drug|Placebo|
75743025|NCT01001130|Drug|fluticasone furoate group|patients who are administered fluticasone furoate at least once
75890931|NCT02139709|Dietary Supplement|Placebo|
75890932|NCT03669315|Device|Transcranial Magnetic stimulation|Neuromodulation tool
75890933|NCT04527367|Procedure|Innovative medical technologies in invasive cardiology and cardiac surgery|A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.
75598864|NCT06055114|Diagnostic Test|Microscopic examination of vaginal discharge|Using gram-stained smears to detect vaginal secretions, and then the concentration and diversity of bacterial flora are observed using a microscope.
75743026|NCT01005264|Device|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
75890934|NCT03669003|Biological|Gelfoam slurry|Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.
75598865|NCT06055101|Drug|DEXMEDETOMIDINE|"DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water."
75598866|NCT06055101|Drug|Neostigmine|Neostigmine is an indirect cholinomimetic agent. It produces its primary effects by inhibiting the action of AChe, which hydrolyzes acetylcholine (ACh) to choline and acetic acid. By inhibiting AChe, the indirect-acting drug increases the concentration of spinal endogenous ACh. This drug is, in effect, amplifiers of endogenous ACh and act primarily where ACh is physiologically release. It combines reversibly with AChe by the formation of an ester linkage, which lasts about 30 minutes. The pharmacokinetic of neostigmine administered by bolus injection is linear with respect to bolus injection.
75743027|NCT01005264|Device|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
75743028|NCT00424827|Drug|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
75890935|NCT03669003|Procedure|CT-guided percutaneous lung biopsy|Biopsy of a lung nodule under CT guidance.
75890936|NCT04429399|Other|decrease the positive end expiratory pressure (PEEP)|decrease the PEEP going from high (according to ExPress Trial) to low level
75448501|NCT02764086|Radiation|Radiation|Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
75448502|NCT02759094|Device|Treatment with RefluxStop|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
75448503|NCT02758054|Behavioral|Patient Navigation|Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
75448504|NCT02757911|Genetic|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
75448505|NCT02732275|Drug|DS-3201b|
75448506|NCT02671305|Procedure|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
75890937|NCT04429399|Other|mechanical features assessment|evaluation of the mechanical features of respiratory system
75890938|NCT04429399|Other|shunt assessment|evaluation of the pulmonary shunt during two different ventilation setting
75890939|NCT05763745|Diagnostic Test|Point of Care Ultrasound|Use Point of Care Ultrasound to evaluate the gastric content/bleed prior to upper endoscopy
75890940|NCT04313959|Drug|Ropivacaine 0.2% Injectable Solution|Single-shot ultrasound-guided erector spine plane block of 0.2% ropivacaine
75890941|NCT04313959|Drug|Ropivacaine 0.2% + Dexamethasone|Addiction of 5 mg/ml dexamethasone in 0.2% ropivacaine solution
75890942|NCT03073213|Drug|Ixekizumab|Administered as subcutaneous (SC) injection
75890943|NCT03070483|Drug|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
75890944|NCT03892993|Other|Decision Aid|Use decision aid
75890945|NCT03892993|Other|Questionnaire Administration|Ancillary studies
75890946|NCT04386187|Other|GSH Foods|The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).
75890947|NCT04386187|Other|Nutrition education about glutathione sources in the diet|Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.
75890948|NCT04386187|Other|Standard of care nutrition education for type 2 diabetes|The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.
75890949|NCT04107727|Drug|Quizartinib|"Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
75890950|NCT04107727|Drug|Placebo oral tablet|"Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
75890951|NCT04107727|Drug|Cytarabine|"Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days."
75448507|NCT02671305|Procedure|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
75890952|NCT04107727|Drug|Idarubicin|Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
75890953|NCT05763433|Other|upper extremity bone surgery|any ambulatory upper limb bone surgery carried out under axillary PNB
75890954|NCT01074151|Drug|duloxetine|any exposure to duloxetine that occurred during pregnancy
75890955|NCT05762809|Diagnostic Test|Tampa Scale of Kinesiophobia (TSK-17)|The Tampa Scale of Kinesiophobia (TSK-17) was developed as a self-reported checklist to measure fear of pain during movement and fear of reinjury. The TSK-17 consists of 17 questions. Standardized answer options are given as a 4-point Likert scale, and each question is assigned a score from 1 to 4. A normalized score between 17 and 68 points is calculated. A score of 37 or over indicates kinesiophobia.
75890956|NCT05762809|Diagnostic Test|Knee injury and Osteoarthritis Outcome Score (KOOS)|The KOOS consists of five subscales - Symptoms (S), Pain (P), Functional activities of daily living (ADL), Sport and Recreation Function (Sport/Rec) and Knee-Related Quality of life (QOL) - and total KOOS Outcome (O) scores. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
75890957|NCT05762809|Diagnostic Test|Oxford Knee Score (OKS) scoring|OKS consists of 12 questions. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A score of 40-48 indicates no symptoms or satisfactory joint function, 30-39 moderate knee arthritis, 20-29 moderate to severe knee arthritis, and 0-19 severe knee arthritis.
75448508|NCT02639754|Behavioral|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
75890958|NCT05762809|Diagnostic Test|Quadriceps and hamstring muscle isokinetic strength|Quadriceps and hamstring muscle strength at 60˚/s and 180˚/s were measured with an isokinetic dynamometer. For 180˚/s, five trial and fifteen testing repetitions were used, and for 60˚/s, three trial and three testing repetitions were used. The resting time between trial and testing was two minutes, between different speeds one minute, and between legs two minutes. The maximum peak torques were used in the statistical analysis.
75448509|NCT02639754|Behavioral|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
75448510|NCT02636517|Biological|Fecal Microbiota Transplant|Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
75890959|NCT05762809|Diagnostic Test|Single-leg hop test|The single-leg hop test (SLHT) for distance was used for lower limb functional testing. The test started with the participant standing on one leg, toes behind a marked line, and hands on hips throughout to avoid aiding the jump by swinging the arms. The participant was instructed to jump as far as possible and land on the same leg without losing balance. If the patient made contact with the ground with the contralateral limb, lost balance, or made additional hops after landing, the distance was not measured and the jump void. The distance was measured from the starting line to the heel of the leg being tested. For both legs, three trials and three jumps for maximal effort were allowed. The longest distance for both the left leg and the right leg were used in the statistical analysis.
75890960|NCT05762809|Diagnostic Test|Y-balance test|The Y-balance test (YBT) (Move2Perform, United States) for anterior reach was used to measure dynamic balance. Participants performed three trials to familiarize themselves with the test, and then undertook three tests. The test started with the participant standing barefoot on the testing kit. The patients had to push a wooden box with the contralateral leg as far as possible with continuous movement and return to their starting position without losing balance. The longest distance achieved was used in the statistical analysis.
75890961|NCT05762809|Diagnostic Test|Anthropometric measurements|Body mass (kg) and height (cm) were measured, and the body mass index (BMI) was calculated as kg/m2.
76061373|NCT05424172|Behavioral|Stage-I, Group 2: Self monitoring using Interactive App|Participants in Group 2 will use the version of the exercise app that has been modified based on the findings from Phases 1 and 2 of this study. Group 2 will be able to use the full features of the interactive app including notifications, ability to submit videos, and non-synchronous messaging/communicating with the researcher. Additionally, participants in Group 2 will be asked to complete 2-5 EMA-based surveys daily to gain information about the participant's barriers and facilitators to exercise. The information from the EMA questionnaires will be used to progress and modify the exercise program at regular intervals for each participant in Group 2.
76061374|NCT05424172|Behavioral|Stage-II, Groups 1a/2a: E-Coaching 2x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions two times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
76061375|NCT05424172|Behavioral|Stage-II, Groups 1b/2b: E-Coaching 4x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions four times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
76061376|NCT05415358|Other|Blood and tissue samples|Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of pembrolizumab discontinuation.
75448511|NCT02553733|Drug|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
75598867|NCT06055101|Drug|Bupivacaine|"The onset of sensory blockade following spinal block with bupivacaine is very rapid (within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases.~The conduction of nerve impulses along nerve fibers is related to changes in the electrical gradient across the nerve membrane and movement of predominantly sodium ions (but also potassium ions) from intracellular to extracellular fluid and vice versa. Bupivacaine work by reversibly blocking specific areas of the nerve cell membrane, known as sodium channels. It contains a mixture of ionized and un-ionized particles which, when injected into body tissues, make more un-ionized particles available, which are lipid soluble and able to penetrate the nerve cell membrane."
75616392|NCT00632788|Other|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
76061377|NCT01869764|Drug|omega-3 fatty acid|Given PO
75448512|NCT02553733|Drug|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
75448513|NCT02552394|Drug|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
75448514|NCT02462187|Drug|NVN1000 8% Gel|once and twice daily
75448515|NCT02462187|Drug|NVN1000 16%|once daily
75448516|NCT02462187|Drug|Vehicle|placebo comparator
75598869|NCT06055036|Behavioral|Black Impact Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with >5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
75890962|NCT05203783|Other|McKenzie Exercises|"McKenzie exercises: The McKenzie set consists of 5 exercises.~Prone-lying~Prone-extension~Prone press ups~Progressive extension with pillows~Standing extension"
76061378|NCT01869764|Other|placebo|Given PO
76061379|NCT01869764|Other|laboratory biomarker analysis|Correlative studies
76061380|NCT05396248|Behavioral|Memory Retraining Exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
76061381|NCT05396248|Behavioral|Placebo Control Memory Exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
76061382|NCT01842620|Drug|Metformin|Oral antidiabetic agent
75598870|NCT06055023|Drug|ZL-82 12.5mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
75598871|NCT06055023|Drug|ZL-82 25mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
75743029|NCT01001286|Behavioral|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
75743030|NCT01028625|Behavioral|Cognitive Behavior Therapy|CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
76061383|NCT04400266|Drug|B+MEL|Buspirone and Melatonin
76061384|NCT04746742|Procedure|Tunneled Femoral Catheter (TFC) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
76061385|NCT04746742|Procedure|Femoro-femoral Arteriovenous graft (FF-AVG) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
76061386|NCT04348162|Other|Cocoa flavanols and berries anthocyanins|Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health
75448517|NCT02462187|Drug|NVN1000 24%|once daily
75448518|NCT02351869|Drug|Nitrous Oxide|
76072018|NCT03418779|Drug|Immunosuppressants|Immunosuppression therapy comprises oral prednisolone (0.5-0.8 mg/kg/day; exact dose decided by the investigator, maximum dose not exceeding 60 mg/day) for 8 weeks, then tapered by 5-10 mg/day every 4 weeks, with a total treatment period of 24-32 weeks. Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8-1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks, total dose of not exceeding 8 g (exact dose decided by the site investigator). If severe CTX-related adverse events occur, such as alanine transaminase (ALT) exceeding the upper limit of two times, infections requiring hospitalization, granulocytes < 3.0 × 109/L and platelets < 50.0 × 109/L, CTX will stop being administered, symptoms will be treated, and adverse events recorded. Also, the frequency of detection will be increased to once every 2 weeks and the affected participant will be withdrawn if persistent infection or myelosuppression occurs.
75448519|NCT02351869|Drug|Midazolam|
75448520|NCT02342535|Behavioral|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
75448521|NCT02330289|Behavioral|Normative report card|Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers as well as a link to a website tracking lab ordering for the team in real time compared to peer teams.
75598872|NCT06055023|Drug|ZL-82 50mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
75743031|NCT01028625|Other|Heart Failure Self-care Education|Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
75743032|NCT01001364|Drug|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
75890963|NCT05203783|Other|Kinesio Tape Application|Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
75890964|NCT02786329|Drug|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
75890965|NCT02786329|Drug|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
75890966|NCT02786329|Drug|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
75890967|NCT02786329|Drug|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
75890968|NCT04025905|Behavioral|Social Cognition Training|Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.
75890969|NCT04025905|Behavioral|Informations|informations about work environment, social environment, stress management, sleep management, treatments
75890970|NCT05761327|Other|Mediterranean Diet|In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
75890971|NCT05761327|Dietary Supplement|Curcumin Supplementation|Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.
75448522|NCT02311582|Biological|MK-3475|-Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).
75448523|NCT02311582|Device|MRI-guided laser ablation|
75448524|NCT02311582|Procedure|Surgical resection/debulking|"Optional~Standard of care"
75448525|NCT02311582|Procedure|Biopsy|"If no surgical resection/debulking~Phase II patients only"
75598873|NCT06055023|Drug|ZL-82 100mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
75598874|NCT06055023|Drug|ZL-82 200mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
75598875|NCT06055023|Drug|ZL-82 300mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
75598876|NCT06055023|Drug|ZL-82 450mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
75598877|NCT06055023|Drug|ZL-82 600mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
75598878|NCT06055010|Other|No interventions|Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
75598879|NCT06054932|Drug|LK101 injection|LK101 administrated Q2W as the prime dose, and Q3W in the boost phase
75598880|NCT06054932|Drug|LK101 injection|LK101 administrated QW as the prime dose, and Q3W in the boost phase
75598881|NCT06054919|Drug|Cholecalciferol|vitamin D3
75598882|NCT06054906|Drug|sintilimab+metronomic PLOF|"Drug: Sintilimab 200mg iv d1 Q3W, 2cycles~Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles~Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles~Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles"
75743033|NCT01001364|Drug|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
75743034|NCT03994185|Device|Placement of WRAPSODY stent graft|Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
75598883|NCT06054854|Biological|Extra blood sampling, Non-invasive or leftover samples or medical waste|"Extra blood sampling, Urine, Saliva, Stool, Superficial nasal swamp sampling. Bronchoalveolar lavage fluid, Mediastinal node or mass, Peripheral nodule aspiration supernatant, Pleural fluid, Cerebrospinal fluid collection (leftover samples or medical waste).~Blood will be collected in larger quantity during a blood test planned as part of the patient's care.~Non-invasive or leftover samples or medical waste will be collected on top of the usual diagnosis and during follow-up, depending on the case."
75743035|NCT01031667|Drug|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
75743036|NCT03885726|Device|Precision Flow Plus|High velocity nasal insufflation
75743037|NCT03885726|Device|Treatment as Usual|Conventional therapy per institution
75743038|NCT03995277|Dietary Supplement|Biotin|Daily intake of 10 mg or 50 µg per day
75448526|NCT02311582|Procedure|Blood draw for research purposes|"Phase II patients only~Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, 36, and at the end of treatment"
75890972|NCT05761327|Dietary Supplement|Resveratrol Supplementation|Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
75890973|NCT05203549|Procedure|Tumor biopsy|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
75890974|NCT05202925|Other|Musical Training Program|a weekly 45-minute lesson, one-to-one musical training
75890975|NCT02231762|Drug|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
75890976|NCT02231762|Drug|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
75890977|NCT04540484|Other|Screening|Blood test screening for covid
75890978|NCT01687335|Other|answering questionnare in differents time of the treatment|
75448527|NCT02311582|Procedure|Cervical lymph node fine needle aspiration|"Optional~Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure"
75448528|NCT02237820|Drug|Dexamethasone|6 mg/day of Oral Dexamethasone
75448529|NCT02237820|Drug|Prednisone|40 mg/day of Oral Prednisone
75448530|NCT02225704|Drug|Radium-223 and enzalutamide|
75890979|NCT01676181|Procedure|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
75890980|NCT01676181|Procedure|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
75890981|NCT04614051|Biological|Cellgram-DC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC(Autologous dendritic cell) subcutaneous injection near the upper arm lymph nodes
75890982|NCT03623217|Behavioral|Qualitative interviews with participants|For the development and validation of a questionnaire.
75890983|NCT03668145|Procedure|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
75890984|NCT02228486|Device|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
75890985|NCT02228486|Behavioral|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
75448531|NCT02186678|Other|PET-CT|
75448532|NCT02160353|Drug|Abiraterone acetate, Prednisolone|
75448533|NCT02152358|Drug|Aciclovir|Intravenous 15 mg/kg/d during 14 days
75448534|NCT02152358|Drug|Ganciclovir|intravenous 10 mg/kg/d for 14 days
75448535|NCT02152358|Drug|Placebo|
75448536|NCT02151019|Radiation|IMRT|IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
75448537|NCT02150408|Other|PET-CT|
75448538|NCT02120040|Other|evaluation of anxiety with psychosocial scales|
75448539|NCT01916148|Drug|18F-DOPA|18F-DOPA is a PET scan radiotracer.
75448540|NCT01855685|Genetic|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
75890986|NCT03668925|Radiation|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
75743039|NCT01034319|Behavioral|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
75598884|NCT06054841|Behavioral|Postpartum follow up card|The intervention will consist of a card given to patients at time of discharge. One side of the card will list the patient's name and a list of recommended postpartum follow-up appointments based on their diagnoses at the time of discharge. The back of the card will list relevant phone numbers to assist patients with scheduling.
75890987|NCT01191957|Drug|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg"
75890988|NCT01191957|Drug|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
75743040|NCT01034319|Behavioral|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
75743041|NCT00997776|Other|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
75743042|NCT00997776|Other|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
75598885|NCT06054841|Other|Control|No deviation from standard discharge education
75598886|NCT06054828|Behavioral|mHELP@ICU|"The 14-day mHELP@ICU consists of the following three components:~Cognitive engagement twice daily: Participants will receive orienting communication, plus one of the following training on attention, memory, or function execution.~Physical activity once daily: Participants will receive a passive range of motion(ROM) and/or anti-gravity ROM exercise if tolerated.~Feeding monitor daily: The exact feeding data will be abstracted from medical records."
75598887|NCT06054802|Device|eCAP|eCap™ has the look and feel of a regular prescription bottle and records real-time adherence data, tracking each opening with the date and time.
75743043|NCT01034475|Drug|CPI-613|"This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient & traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is >Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme."
75743044|NCT00997854|Other|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
75743045|NCT04000386|Other|zinc oxide nanoparticles coated socks|zinc oxide nanoparticles coated socks were given to subjects for 2 weeks
75890989|NCT01913912|Drug|LDX.|"In this study 3 different doses of LDX will be used:~30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
75890990|NCT01913912|Drug|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
75890991|NCT01913912|Device|computer task (Go/No-Go task)|
75598888|NCT06054789|Drug|68Ga-PSMA-33|Subjects will receive one injection of 68Ga-PSMA-33/PSMA-617 (3-7mCi ), a PET radiopharmaceutical selective for Prostate-Specific Membrane Antigen. 68Ga-PSMA-33/PSMA-617 injection will be followed by a 10 ml saline flush.
75890992|NCT01913912|Device|EEG|event-related potentials (ERP) and heart rate measurements
75616393|NCT04975828|Diagnostic Test|albumin creatinine ratio -EGFR-fundus examination- coronary angiography.|albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.
75616394|NCT03936790|Other|Ropivacaine|In case of successful spinal anaesthesia, the dose of spinally administered ropivacaine will decrease by 0.375 mg for the next participant.In case of unsuccessful spinal anaesthesia, the dose of spinally administered ropivacaine will increase by 0.375 mg for the next participant.
75890993|NCT01913912|Device|pupil size measurements (by using eye tracking)|
75890994|NCT02232230|Drug|Provenge|
75890995|NCT02276066|Other|Iohexol|Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.
75890996|NCT02276066|Other|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.
75890997|NCT02276066|Other|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.
75890998|NCT01050855|Drug|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
75598889|NCT06054737|Procedure|SPA THERAPY|"Balneotherapy program Four balneotherapy sessions per day, 6 days a week during 3 weeks~The balneotherapy sessions included:~10- minute walking session in a specially designed pool with tracks in semideep (80 cm) cool (30°C) water (training of muscle pump function under water compression);~20-minute whirlpool bath session with automatic air or submarine bath if hypodermis (aimed at relaxation and mobilization of the superficial skin volume flow); followed by a 10-minute hydrojet bath (2 sessions) with customized underwater strong massaging jets (mobilization and softening of the sclerotic subcutaneous tissues);~Fresh thermal water compresses at 24°C. The cool temperature of the compresses also has an analgesic and decongestant effect. This treatment is carried out last and is followed by a rest for a total duration of 60 minutes"
75598890|NCT06054711|Other|joint puncture|Patients reporting complications such as pain hindering mobility or affecting quality of life, or any other symptoms suspecting prosthesis failure or infection will undergo joint fluid aspiration.
75598891|NCT06054698|Drug|HRS9531 injection|HRS9531 injection , QW，36 weeks
75743046|NCT04000386|Other|placebo socks|placebo socks were given to subjects for 2 weeks
75743047|NCT00998088|Other|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
75890999|NCT01050855|Drug|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
75743048|NCT00998088|Drug|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
75448541|NCT01851018|Radiation|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
75743049|NCT00998088|Device|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
75743050|NCT00998088|Device|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
75448542|NCT01851018|Radiation|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
75448543|NCT01822444|Other|Biomarker analysis|
75448544|NCT01819064|Drug|Atropine|intravenous atropine affect on heart rate
75448545|NCT01817751|Drug|sorafenib tosylate|Given by mouth
75743051|NCT00998088|Other|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
75743052|NCT00998088|Other|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
75891000|NCT01050855|Drug|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
75891001|NCT04459286|Drug|Nitazoxanide and atazanavir/ritonavir|1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal
75891002|NCT04459286|Other|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
75891003|NCT00744081|Drug|Glivec|
75743053|NCT00998088|Device|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
75743054|NCT03994341|Diagnostic Test|A FLIR Thermovision a320M thermal IR camera|"Clothing removed if necessary~ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~Axillary temperature prior to starting the thermographic imaging.~Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~After surface cooling, thermal imaging will be recorded for ~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~After ~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~Axillary temperature to ensure temperature stability, any clothes will be put back on."
75891004|NCT00744081|Drug|Mitoxantrone|
75891005|NCT00744081|Drug|Topotecan|
75891006|NCT00744081|Drug|AraC|
75743055|NCT00377962|Drug|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
75743056|NCT00377962|Drug|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
75891007|NCT03669939|Other|Communication Strategy|Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
75891008|NCT03669939|Other|Standard of Care|The standard information about the CDC Guidelines and no other information that is available through the study.
75891009|NCT02229110|Other|Signal|Automatic signal in the electronic medical record
75743057|NCT00377962|Drug|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
75891010|NCT03023397|Biological|Der f|Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
75891011|NCT02229188|Behavioral|Problem Solving Therapy|Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
75891012|NCT02229188|Behavioral|Evolution|Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
75891013|NCT02229188|Behavioral|Words|Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
75891014|NCT02223962|Behavioral|Physical activity|Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
75891015|NCT02229266|Biological|NK cells|
75891016|NCT02229266|Drug|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
76061387|NCT05658172|Diagnostic Test|Determination of tumormarkers (CA27.29, CEA, CA125)|CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
75743058|NCT00377962|Drug|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
75743059|NCT00424749|Drug|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m^2.
75743060|NCT00424749|Drug|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
75598892|NCT06054698|Drug|HRS9531 injection Placebo|HRS9531 injection Placebo，QW，36 weeks
75598893|NCT06054672|Device|Subthreshold Electrical stimulation|We will use a electrotherapy device to deliver subthreshold Electrical stimulation
75598894|NCT06054633|Dietary Supplement|L-arginine tablet|L-arginine, 2 g, three times daily, for 12 weeks
75598895|NCT06054633|Dietary Supplement|Placebo tablet|Identical inert placebo, three times daily, for 12 weeks
75598896|NCT06054607|Dietary Supplement|High-amylose maize starch+acetate/butyrate|High-amylose maize starch (HAMS), commercially available as Hylon VII (Ingredion, Inc.), to which the SCFA acetate or butyrate has been chemically added. Hylon VII is a HAMS containing ~70% amylose and used in a variety of food products. To produce SCFA-enriched HAMS, Hylon VII is chemically modified through esterification with the SCFA acetate or butyrate.
75598897|NCT06054607|Other|Low-amylose maize starch|Rapidly digestible low-amylose maize starch (0% amylose, 100% amylopectin) sold commercially as AMIOCA (Ingredion, Inc).
75743061|NCT01031745|Behavioral|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
75743062|NCT01031745|Other|Prize bowl drawings|"Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives."
75743063|NCT01048216|Radiation|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
75743064|NCT01048294|Device|Original Energy Light,|9000 lux, 30 minutes in the morning
75743065|NCT01048294|Device|Original Energy Light prototype|9000 lux 20 minutes in the morning
75891017|NCT01944566|Biological|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
76061388|NCT05658172|Diagnostic Test|Determination of CTC levels|CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
75598898|NCT06054581|Behavioral|health seeking behavior|health seeking behavior in the form of wound management and receving anti rabies immunization
75448546|NCT01817751|Drug|valproic acid|Given by mouth
75448547|NCT01817751|Drug|sildenafil citrate|Given by mouth
75448548|NCT01810861|Other|There is no intervention in this study|This is a non-interventional study.
75448549|NCT02744053|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
75743066|NCT01048294|Device|Original Energy Light prototype|9000 lux 30 minutes in the morning
75891018|NCT02224040|Drug|ceftriaxone|
75891019|NCT02224040|Drug|ceftriaxone and azithromycin|
75891020|NCT02224040|Drug|azithromycin|
75891021|NCT02224040|Drug|azithromycin and cefixime|
75891022|NCT04448834|Drug|Blinatumomab|liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
75891023|NCT04429178|Other|ultrasound|portal vein pulsatility fraction (percent) measured with ultrasound
75891024|NCT02224118|Drug|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
75448550|NCT02744053|Other|Laboratory Biomarker Analysis|Correlative studies
75448551|NCT02744053|Radiation|Scintimammography|Undergo MBI
75448552|NCT02744053|Drug|Technetium Tc-99m Sestamibi|Given via injection
75448553|NCT01725633|Behavioral|Progressive Stretching Group|Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
75598899|NCT06054542|Other|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the DESQ
75616395|NCT03936790|Other|Fentanyl|A fix dose of fentanyl (15 mcg) will be co-administered spinally to all participants.
75743067|NCT03246022|Other|continuous positive airway pressure|Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
75891025|NCT02224118|Drug|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
75891026|NCT02224118|Drug|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
75891027|NCT02224118|Drug|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
75891028|NCT02224118|Drug|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
76061389|NCT05658172|Diagnostic Test|Determination of ctDNA levels|Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
75743068|NCT00424593|Drug|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
75743069|NCT00424593|Drug|Placebo|every day (QD), by mouth (PO), 13 weeks
75743070|NCT01031823|Behavioral|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
75743071|NCT00369382|Drug|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
75743072|NCT00369382|Drug|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
75448554|NCT01725633|Behavioral|Nonlinear Aerobic Training|Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
75743073|NCT01324648|Behavioral|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
75448555|NCT01725633|Other|Blood draw|At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
75448556|NCT01725633|Other|Cardiopulmonary Exercise Testing (CPET)|At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
75891029|NCT04415684|Device|Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
75891030|NCT04415684|Device|No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
75448557|NCT01706913|Other|Dermatology consult|
75448558|NCT01604122|Other|No drug|No drug.
75448559|NCT01604122|Other|No drug|No drug.
75891031|NCT02232308|Drug|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
75743074|NCT01324648|Behavioral|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
75891032|NCT02232308|Drug|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
75891033|NCT02232308|Drug|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
75891034|NCT02229500|Dietary Supplement|Inulin|
75891035|NCT02229500|Dietary Supplement|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
75891036|NCT02229500|Dietary Supplement|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
75891037|NCT02229734|Radiation|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
75891038|NCT02229734|Drug|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
75598900|NCT06054490|Behavioral|Self-management|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses self-management techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state. In addition, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
75598901|NCT06054490|Other|Home exercises|It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises
75743075|NCT01324648|Other|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
75743076|NCT00424515|Drug|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
75891039|NCT02224196|Other|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
75891040|NCT02224196|Other|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
75891041|NCT02258516|Behavioral|CHIME 3-M|behavioral intervention for self-management in heart failure
75598902|NCT06054412|Device|Neuroptimal (Zengar, Inc.) Neurofeedback|Mothers in the Neurofeedback Training group will complete one training session (lasting approximately 33 minutes) a week for a total of 12 weeks, using the Neuroptimal (Zengar, Inc.) neurofeedback device.
75743077|NCT01581112|Biological|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
75891042|NCT02258516|Behavioral|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
75891043|NCT04333160|Drug|JTA-004|Patients will undergo a single intra-articular injection of JTA-004 into the knee joint
75891044|NCT04333160|Device|Hylan G-F 20|Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint
75448560|NCT01564056|Drug|HORMONOTHERAPY|"Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
75448561|NCT01564056|Drug|CHEMOTHERAPY then HORMONOTHERAPY|"CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~Docetaxel 75 mg/m² IV infusion at hospital every 21 days~Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)~Myocet® 60 mg/m² IV infusion at hospital every 21 days~Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
75743078|NCT03994263|Device|ITind device implant|device implanted for 5-7 days
75891045|NCT04333160|Other|placebo|Patients will undergo a single intra-articular injection of placebo into the knee joint
75891046|NCT02224352|Device|Functional neuromuscular electrical stimulation|
75891047|NCT04778774|Procedure|Nerve block|Two different nerve block types, Adductor canal block group and Femoral nerve block group
75891048|NCT02224430|Device|schizophrenia/schizoaffective disorder.|Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
75891049|NCT02258906|Drug|ulinastatin|
75743079|NCT00377260|Drug|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
75743080|NCT00377260|Drug|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
75743081|NCT00441441|Drug|fluticasone propionate|fluticasone propionate 100mcg HFA
75743082|NCT00441441|Drug|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
75448562|NCT01549730|Procedure|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
75891050|NCT02258906|Drug|normal saline|
75598903|NCT06054386|Other|Attentional Bias Modification Training (ABMT)|The ABMT is aimed to modify attentional bias for negative stimuli in social anxiety by deliberately inducing the participant's attention to positive or neutral stimuli. In the training, after a pair of facial stimuli (e.g., threatening-neutral, neutral-neutral) are presented, a left or right arrow appears in one of the location. Participants are instructed to press the button in the correct direction as quickly and accurately as possible.
75743083|NCT00436917|Drug|zoledronic acid|zoledronic acid
75743084|NCT00436917|Procedure|Letrozole as adjuvant therapy|standard care
75743085|NCT00436605|Drug|dasatinib|
75743086|NCT01034787|Drug|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
75743087|NCT01323543|Device|Elaspine™|Implantation of device
75743088|NCT01028781|Drug|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
75448563|NCT01349322|Radiation|Standard fractionation whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
75448564|NCT01349322|Radiation|Hypofractionated whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
75598904|NCT06054386|Other|General Attention Control Training|The general attention control training aimed to improve participants' general attention control ability by asking them to press a left or right arrow in the correct direction. The basic design of attention control training is the same as the ABMT, but the attention control training does not aim to alter the direction of attention toward or away from certain stimuli.
75598905|NCT06054347|Other|VINELAND II|Standardised questionnaire filled by the investigator during an interview with the parents or with the patient himself if capable of it. Duration 1 hour to 1 hour and a half.
75743089|NCT01031901|Drug|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
75743090|NCT01031901|Drug|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
75743091|NCT01031901|Drug|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
75891051|NCT02258984|Device|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
76061390|NCT05658172|Other|Biobanking of blood samples|To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
75743092|NCT00368992|Biological|cetuximab|Given IV
75743093|NCT00368992|Drug|paclitaxel|Given IV
75743094|NCT00368992|Biological|bevacizumab|Given IV
75743095|NCT00376246|Drug|Ezetimibe|
76061391|NCT05687656|Device|InnovaMatrix AC porcine placental ECM therapy|All eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care moist wound therapy and offloading
76061392|NCT04746664|Behavioral|Nutritional counselling|Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
75891052|NCT04325906|Device|high flow nasal cannula (HFNC)|HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
75598906|NCT06054321|Drug|stepwise pharamacotherapy|In the stepwise pharamacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
75743096|NCT00368836|Device|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
75891053|NCT04325906|Procedure|Prone positioning (PP)|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.
75891054|NCT02229812|Drug|alteplase|
75891055|NCT02229890|Drug|alteplase|
75448565|NCT01349322|Radiation|Concurrent boost|15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.
75448566|NCT01349322|Radiation|Sequential boost|6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
75448567|NCT01326832|Device|Primoris|Total hip arthroplasty with the new Primoris femoral component
75448568|NCT01284829|Other|FDG-PET scan|
75598907|NCT06054321|Drug|antidepressant monotherapy group|In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
75743097|NCT03992716|Drug|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
75743098|NCT03992716|Drug|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
75743099|NCT01050010|Other|MRI|dedicated extremity MRI
75743100|NCT01050088|Dietary Supplement|sucrose solution|5cc 5% sucrose solution P/O
75743101|NCT01050088|Dietary Supplement|Saline|5cc saline p/o
75743102|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
75891056|NCT02230046|Drug|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
75891057|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
75891058|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
75891059|NCT02230202|Other|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
75891060|NCT02230202|Other|single blood draw|single blood draw of approximately 45 mL.
75743103|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
75448569|NCT01222390|Device|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
75891061|NCT02224586|Device|light treatment|clinical routine treatment according to the doctor's advice
75448570|NCT01182415|Procedure|Autologous stem cell transplant|Autologous stem cell transplant following high-dose chemotherapy
75448571|NCT01182415|Drug|High-dose chemotherapy|High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
75448572|NCT01164150|Radiation|45 Gy/25 fractions|Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
75743104|NCT00375934|Drug|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
75743105|NCT00375934|Drug|Placebo|Oral placebo capsule, every 6 hours
75891062|NCT02224742|Device|LeucoPatch|LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
75891063|NCT02224742|Other|Usual care|"Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.~Components of usual wound care include:~Formal assessment of ulcer and surrounding skin~Provision of any necessary off-loading~Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)~Appropriate dressing products~Appropriate antibiotic therapy~Nutrition and self care~Optimal glycaemic control~Revascularisation if deemed clinically necessary~Continued close observation"
75891064|NCT03068455|Biological|nivolumab|Specified Dose on Specified Days
75891065|NCT03068455|Biological|ipilimumab|Specified Dose on Specified Days
75891066|NCT02230280|Other|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
75448573|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
75743106|NCT01052584|Drug|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
75743107|NCT01052584|Drug|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
75891067|NCT03067987|Device|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~."
75891068|NCT02259296|Procedure|Lower eGFR for AVF construction|Lower eGFR patients (eGFR<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
75891069|NCT02259296|Procedure|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
75448574|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
76061393|NCT03359356|Drug|Dupilumab|A total of 24 doses
75743108|NCT01052584|Drug|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
75743109|NCT01050166|Other|Transplantation of labeled islets|
75743110|NCT01050244|Dietary Supplement|Whole soybean soymilk powder|
75743111|NCT01050244|Dietary Supplement|Whole milk powder|
75743112|NCT02534506|Drug|Urelumab|
75448575|NCT00951535|Other|questionnaire administration|
75743113|NCT02534506|Drug|Nivolumab|
75743114|NCT01050322|Drug|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
75743115|NCT01050322|Drug|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
75743116|NCT01050322|Drug|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
75598908|NCT06054282|Behavioral|"Ready for Tonsillectomy educational mobile application"|"The Ready for Tonsillectomy mobile application provides child-focused, procedure-specific education developed with feedback from patients, caregivers, and pediatric otolaryngologists. The application guides patients and their families through each aspect of the surgical experience, including reasons for tonsillectomy, how to prepare for surgery, anesthesia, and postoperative recovery. Diverse characters focus on the child's perspective in the treatment process, showing what happens at each step. Written at an early elementary reading level (available in English or Spanish), the text is integrated with graphics and animations. The application aims to promote active learning and equip patients with positive expectations and coping strategies as they approach surgery. It also prepares caregivers to navigate their child's surgery and optimize recovery. Notifications provide key information and reminders for caregivers to promote adherence and address common questions."
75598909|NCT06054243|Behavioral|CBT-I|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psychoeducation about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
75743117|NCT01048450|Radiation|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
75743118|NCT01048450|Procedure|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
75743119|NCT01048450|Procedure|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
75743120|NCT01048528|Behavioral|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
75891070|NCT02232854|Behavioral|Depression training/supervision program|"The intervention will be composed of:~Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.~After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.~Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.~Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment."
75891071|NCT04207736|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
75891072|NCT04207736|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
75743121|NCT03990844|Dietary Supplement|Okra seed|Noodle enriched with 10% and 20% Okra seed flour.
75743122|NCT02534662|Device|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
75743123|NCT00642941|Drug|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
75743124|NCT00531960|Drug|Erlotinib|150 mg, PO, daily
75743125|NCT00531960|Drug|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
75743126|NCT00531960|Drug|Standard platinum-based chemotherapy|At the discretion of the investigator
75743127|NCT01001676|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
75743128|NCT01001676|Device|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
75743129|NCT00816959|Drug|R-mabHDI and ABVD|"The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles."
75743130|NCT00816959|Drug|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
75743131|NCT01001754|Drug|PEG-rIL-29|Weekly SC injections in combination with ribavirin for up to 48 weeks
75743132|NCT01001754|Drug|Peginterferon alfa-2a|Weekly SC injections in combination with ribavirin for up to 48 weeks
75743133|NCT01001754|Drug|Ribavirin|Daily oral administration (400-600 mg BID)
75743134|NCT00825851|Drug|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
76061394|NCT03359356|Drug|Placebo|A total of 24 doses
76061395|NCT05687422|Procedure|100μm laser spot diameter micropulse laser|100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
75891073|NCT02232932|Procedure|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
75743135|NCT00825851|Drug|Placebo patch|
75743136|NCT00825851|Behavioral|Smoking cessation|
75598910|NCT06054243|Behavioral|CBT-A|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The CBT-A treatment is modified from the Coping Cat programme, which incorporates psychoeducation and the core behavioural strategies and cognitive skills for managing anxiety (e.g. exposure, relaxation training, cognitive restructuring).
75743137|NCT00825851|Behavioral|Continuous smoking|subjects smoke 20 cigarettes per day
75743138|NCT00361504|Drug|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
75743139|NCT00361504|Drug|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
75891074|NCT02232932|Procedure|RESECTION|Intent-to-treat R0 liver resection
75891075|NCT02230358|Procedure|Regional anesthesia|Regional anesthesia
75891076|NCT02230358|Procedure|General anesthesia|General anesthesia
75891077|NCT02230358|Device|Transcranial Doppler ultrasonography|6x for 4 hours
75891078|NCT02230358|Procedure|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
75891079|NCT02230358|Procedure|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
75891080|NCT02230358|Procedure|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
75891081|NCT02230358|Behavioral|Neurological Control|perioperative, 2-3 days, as done in clinical routine
75598911|NCT06054178|Drug|Fluorescein Sodium|Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
75891082|NCT02230358|Behavioral|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
75891083|NCT02230358|Device|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
75891084|NCT02230436|Other|Early drain removal|Removing drain(s) on postoperative day 3
75891085|NCT02230436|Other|Late drain removal|Removing drain(s) on postoperative day 4 or later
75891086|NCT02230514|Drug|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery"
75891087|NCT02230514|Other|autologous iliac crest|Autologous iliac crest in association with surgery
75448576|NCT00951535|Procedure|quality-of-life assessment|
75448577|NCT00951535|Radiation|image-guided radiation therapy|
75448578|NCT00951535|Radiation|intensity-modulated radiation therapy|
75448579|NCT00951535|Radiation|radiation therapy treatment planning/simulation|
75448580|NCT00812669|Biological|pegfilgrastim|
75448581|NCT00812669|Biological|rituximab|
75891088|NCT02230514|Procedure|Surgery|Standard surgery for non-union fractures
75891089|NCT04132466|Device|Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system|defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
75891090|NCT02233010|Other|The level of NGAL after pre op,post op 4hr, post op 12hr|
75448582|NCT00812669|Drug|cyclophosphamide|
75448583|NCT00812669|Drug|fludarabine phosphate|
75448584|NCT00812669|Genetic|cytogenetic analysis|
75448585|NCT00812669|Genetic|fluorescence in situ hybridization|
75448586|NCT00812669|Genetic|gene expression analysis|
75448587|NCT00812669|Genetic|mutation analysis|
75448588|NCT00812669|Genetic|protein expression analysis|
75448589|NCT00812669|Other|flow cytometry|
75448590|NCT00812669|Other|laboratory biomarker analysis|
75891091|NCT04098848|Other|Cycling exercise|Intradialytic cycling exercise for 30 minutes a time
75891092|NCT03518138|Drug|Q-122|oral capsule of Q-122
75891093|NCT03518138|Drug|Placebo|oral capsule of placebo
75891094|NCT04066634|Device|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
75891095|NCT03494504|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered once.
75891096|NCT03494504|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered once.
75891097|NCT03494504|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered once.
75891098|NCT04049864|Biological|DNA vaccine|conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
75891099|NCT04049864|Biological|Salmonella oral vaccine|suspension 10^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
75891100|NCT04049864|Drug|Lenalidomide|Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
75598912|NCT06054152|Drug|PD-1 inhibitor based immunotherapy|Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
75891101|NCT03475706|Drug|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
75891102|NCT03475706|Drug|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
75891103|NCT03475706|Drug|Matching Placebo|twice daily for 12 weeks.
75598913|NCT06054139|Other|Refeeding Syndrome|Patients who developed Refeeding Syndrome despite proper nutrition while receiving treatment in the ICU
75598914|NCT06054100|Drug|Colchicine Tablets|Colchicine oral tablets loading dose of 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
75891104|NCT04035200|Drug|V117957 tablets|V117957 tablets taken orally at bedtime
75598915|NCT06054087|Procedure|Basal therapy+EA|"Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.~Main acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). Supporting acupoints: for pain in the upper limbs, add Baxie, Quchi (LI11), Shousanli (LI10), Hegu (LI4), and Ashixue; for pain in the lower limbs, add Bafeng, Neiting (ST44),Kunlun (BL60). Operation: Acupuncture needles of size 25*40mm will be used. The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject."
75743140|NCT04446611|Diagnostic Test|First antenatal care + test-of-cure|Single point-in-time molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and infection-specific test-of-cure 3 weeks post-treatment. Women with a positive test-of-cure will be re-treated. As CT/NG is a combined Xpert test, women who present with an incident infection (newly diagnosed infection) will be treated and managed accordingly.
75891105|NCT04035200|Drug|Placebo|Tablets to match V117957
75891106|NCT03997838|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
75743141|NCT04446611|Diagnostic Test|First antenatal care + week 30-34 gestation (no test-of-cure)|Repeated molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and at week 30-34 gestation. No test-of-cure will be conducted for women with positive test results; however, additional treatment will be provided to women with persistent/recurrent vaginal discharge.
75891107|NCT03997838|Drug|Placebo|IV infusion of 0 mg of VVZ-149
75598916|NCT06054087|Other|Basal therapy|Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.
75891108|NCT03986138|Drug|gadopiclenol|Single intravenous bolus injection
75891109|NCT03986138|Drug|Gadobutrol 1 MMOLE/ML Intravenous Solution|Single intravenous bolus injection
75891110|NCT02234336|Procedure|Noncontrast echocardiography|
75891111|NCT02234336|Procedure|Contrast Echocardiography|
75448591|NCT00802711|Radiation|3-dimensional conformal radiation therapy|Given twice a day for 10 fractions
75448592|NCT00802711|Radiation|brachytherapy|Given twice a day for 10 fractions
75448593|NCT00797719|Other|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
75448594|NCT00160979|Procedure|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
75891112|NCT02234336|Procedure|Cardiac magnetic resonance imaging|
75891113|NCT02234492|Drug|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
75891114|NCT01529996|Procedure|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
75891115|NCT03933410|Drug|KB195|KB195 is a novel glycan
75891116|NCT04950842|Biological|JB-101|induced T cell with suppressive function
75891117|NCT03303170|Device|Sebacia Microparticles|Topical microparticle suspension
75891118|NCT03303170|Device|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
75891119|NCT03928184|Drug|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1
75891120|NCT03928184|Drug|Placebo|Healthcare professional-administered intra-articular injection; performed on Day 1
75891121|NCT02259374|Procedure|TAP BLOCK 0.2% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
75891122|NCT02259374|Procedure|TAP BLOCK 0.4% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
75891123|NCT03204422|Other|No intervention|no any other intervention
75891124|NCT03197870|Drug|AKB-9778|Subcutaneous AKB-9778 15mg
75891125|NCT03197870|Drug|Placebo|Subcutaneous Placebo
75891126|NCT04921982|Drug|Propranolol|Oral administration of Propranolol, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse once a week for six consecutive weeks.
75891127|NCT04921982|Drug|Placebo|Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.
75891128|NCT04889222|Device|INVSENSOR00050|Noninvasive pulse oximeter sensor
75891129|NCT04889222|Device|RD SET SpO2|Noninvasive pulse oximeter sensor
75891130|NCT04874324|Drug|WCK 2349 Oral|1 dose given orally twice daily at 12 hourly interval for five days.
75891131|NCT04874324|Other|Placebo Oral|Subjects will receive matching placebo
75891132|NCT04866056|Drug|Jaktinib|Jaktinib PO BID
75891133|NCT04866056|Drug|azacitidine|Azacytidine SC
75891134|NCT03911102|Biological|DaxibotulinumtoxinA for injection|Intramuscular injection
75616396|NCT04782700|Other|Steroid Taper (Prednisone)|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
75743142|NCT00826085|Drug|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
75743143|NCT01002144|Other|blood sampling|
75743144|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
75743145|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
75743146|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
75891135|NCT04789148|Drug|Oxytocin nasal spray|4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo
75448595|NCT03903315|Other|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.
75743147|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
75743148|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
75448596|NCT03895541|Diagnostic Test|SuperSonic image|3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
75448597|NCT03893253|Other|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
75743149|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
75616397|NCT04745884|Device|Non-invasive bilateral monitoring of ICP waveform|Brain4care non-invasive bilateral monitoring of ICP waveform
75891136|NCT03892772|Drug|SAS0421a|treatment will be given for 3 days
75891137|NCT03892772|Drug|SAS0421b|treatment will be given for 3 days
75891138|NCT03892772|Drug|SAS0421c|treatment will be given for 3 days
75891139|NCT03892772|Drug|placebo|placebo will be given for 3 days
75891140|NCT03172910|Drug|Ciraparantag|Ciraparantag (administered over 10 minutes)
76061396|NCT05687422|Procedure|200μm laser spot diameter micropulse laser|200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
76061397|NCT04760704|Biological|Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration|Specific T cells and specific antibodies assessment
75891141|NCT03172910|Drug|Placebo|Saline for injection
76061398|NCT01931839|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
76061399|NCT01931839|Drug|Ivacaftor|Film-coated tablet, oral use
76061400|NCT01842308|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
76061401|NCT01842308|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
75616398|NCT05336734|Behavioral|Psychotherapy|see group description
75743150|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
76061402|NCT01842308|Drug|Carfilzomib|Given IV
75448598|NCT03893253|Other|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
75743151|NCT00361270|Behavioral|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
75891142|NCT03172910|Drug|Rivaroxaban|Rivaroxaban 20 mg given once per day (QD) in the morning
75891143|NCT04684940|Biological|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
75891144|NCT03881852|Drug|AXS-12 (Reboxetine)|Dosed orally, twice daily for up to 3 weeks
75891145|NCT03881852|Drug|Placebo|Dosed orally, twice daily for up to 3 weeks
75616399|NCT03711448|Drug|prednisone treatment|tapering prednisone regimen
75616400|NCT03711448|Drug|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
75616401|NCT03711448|Other|questionnaires|HAQ ; SF-36 ; FACIT-fatigue
75743152|NCT00826163|Drug|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
75891146|NCT03818828|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
76061403|NCT01842308|Other|Laboratory Biomarker Analysis|Correlative studies
76061404|NCT01842308|Drug|Melphalan|Given IV
76061405|NCT01931059|Drug|Risperidone|We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.
76061406|NCT01931059|Other|Placebo|We gave oral liquid without active risperidone (pt and provider were both double blinded)
76061407|NCT01841762|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
76061408|NCT03301636|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
75743153|NCT00998166|Drug|Pemetrexed, Cisplatin, Bevacizumab|"Pre-hydration for 1-1/2 hours at 250 ml/hour~Pemetrexed 500 mg/m2 IV over 10 minutes~Return to hydration for 30 minutes at 250 ml/hour~Cisplatin 75mg/m2 IV over 60-120 minutes~Bevacizumab 15mg/kg IV over 90 minutes"
75743154|NCT03990922|Procedure|Continuous Paravertebral block with ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
75743155|NCT03990922|Procedure|"Continuous Paravertebral block with saline"|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
75743156|NCT03990922|Drug|Patient-controlled analgesia with morphine|Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
75743157|NCT01005342|Other|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
75743158|NCT01005342|Other|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
75891147|NCT03818828|Other|Profore Compression Therapy|Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
75891148|NCT03818828|Other|Cadexomer Iodine dressing|During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
75891149|NCT03124862|Device|ARM sensor|Acoustic Monitoring sensor that monitors respiratory rate
75891150|NCT02804282|Combination Product|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
75891151|NCT03789656|Drug|Paltusotine|Paltusotine, capsules, once daily by mouth
75448599|NCT03889314|Drug|Rosuvastatin 20mg|Statin Therapy
75448600|NCT03889314|Other|Placebo|Placebo
75743159|NCT01005342|Other|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
75743160|NCT01005342|Other|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
75743161|NCT01005342|Other|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
75891152|NCT00974870|Procedure|needling treatment|Needling treatment applied to half of the face at each study visit
76061409|NCT03301636|Drug|Nivolumab|Nivolumab will be administered intravenously every 2 weeks starting on day 1.
76061410|NCT03301636|Drug|Indoximod|Indoximod will be administered orally every 12 hours starting at Day 1
75891153|NCT02233244|Drug|CTX-4430|
75891154|NCT02233244|Drug|Midazolam|
75448601|NCT03884166|Diagnostic Test|bronchoscopy|Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance
75448602|NCT03884153|Device|CRP apheresis|"selective CRP apheresis by use of the PentraSorb-CRP"
75448603|NCT03877575|Other|No specific intervention. Collection of clinical data|
75598917|NCT06054074|Behavioral|Positive Appreciation of Body Functionality Induction|The positive induction takes place in a virtual environment of a dressing room and includes the following methods to induce positive appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a higher positive body image. 2) A green virtual costume, representing their body at that time in the past and the positive attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (green costume) to preserve the induction effect.
75616402|NCT03711448|Biological|Blood samples|Additional blood samples for immunomonitoring
75743162|NCT01005342|Other|Control|No fiber was added to control meal (250 g black-currant beverage)
75743163|NCT00822263|Drug|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
75891155|NCT02259530|Behavioral|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
75891156|NCT02234648|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
75891157|NCT02234648|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
75891158|NCT02234726|Behavioral|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
75891159|NCT02234804|Device|Xience Prime Stent|
75891160|NCT02234804|Device|Medtronic Resolute Integrity stent|
75891161|NCT02234804|Procedure|Angiography|
75743164|NCT00822263|Drug|Placebo|Control for study
75891162|NCT02234804|Procedure|OCT|
75891163|NCT02234882|Drug|Rosuvastatin|
75891164|NCT02234882|Drug|BMS-663068|
75891165|NCT05627726|Device|PelviSense-assisted pelvic floor muscle training group|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays electrical activity measured in PFMs on the user's mobile device. The reusable, wearable EMG sensor is non-invasive and can be attached to the user's perineal region. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts. The mobile app can store data for up to 7 days, allowing participants to monitor their progress over the last 7 days in a graphical format.
75743165|NCT03992170|Drug|Daratumumab|Daratumumab is a human monoclonal antibody (mAb) IgG1 that binds to the highly expressed CD38 protein on the surface of multiple myeloma cells and, at various levels, also in other types of cells and tissues. The CD38 protein has multiple functions, such as receptor-mediated adhesion, signal transduction activity and enzymatic activity.
75743166|NCT04044755|Other|Myopia prediction algorithm|Candidate predictors mainly includes age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
75891166|NCT05627726|Other|Active comparator|Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
75891167|NCT02234960|Drug|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
75891168|NCT02235038|Behavioral|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
75891169|NCT02235038|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
75891170|NCT02235038|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
75743167|NCT05154474|Other|Standard|Standard follow-up with clinical exams, functionnal test at baseline, Ct scan MNA, IPAQ, SARC-F and SarQOL questionnaires
75891171|NCT02235116|Other|Survey|
75448604|NCT03877211|Other|speech audiometry in noise|Subjects will be asked to repeat lists of words played by speakers in a noisy environment generated by the same speakers. A percentage of correct recognition is calculated for each list.
75891172|NCT03727334|Behavioral|Online Spatial Navigation Training|Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
75891173|NCT03727022|Drug|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
75891174|NCT03727022|Drug|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
75891175|NCT02259452|Procedure|SPECT Lung Perfusion Scan|
75891176|NCT02259452|Procedure|SPECT Heart Perfusion Scan|
75891177|NCT02259452|Procedure|Pulmonary Function Tests|
75891178|NCT02259686|Drug|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
75891179|NCT02259686|Drug|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
75448605|NCT03877211|Other|Psychophysical tuning curves in forward masking|Sounds of variable center frequency are used as maskers, and a tone with a fixed frequency at a fixed level is the target. What is tested here is the level of masker that just masks the target.
75743168|NCT00817037|Drug|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
75743169|NCT00817037|Drug|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
75891180|NCT02259686|Drug|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
75743170|NCT00817037|Drug|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
75743171|NCT00998244|Other|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
75891181|NCT02259686|Drug|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
75891182|NCT02259686|Drug|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
75891183|NCT02259764|Drug|KUC 7483 CL - single rising dose|
75891184|NCT02259764|Drug|Placebo|
75743172|NCT00817115|Device|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
75743173|NCT00998322|Biological|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
75743174|NCT00998322|Drug|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
75891185|NCT02259764|Other|standardized high fat meal|
75891186|NCT02233322|Dietary Supplement|Iron|All subjects will receive iron supplementation based on iron levels in the blood
75891187|NCT02233400|Drug|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
75891188|NCT03067441|Drug|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
75891189|NCT03687632|Biological|ST266|1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
75891190|NCT02235194|Dietary Supplement|Amino Acid and chromium-picolinate containing drink|Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
75891191|NCT02235194|Dietary Supplement|Placebo Drink|Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
75891192|NCT03684278|Drug|Infusion of 5 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
75891193|NCT03684278|Drug|Infusion of 10 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
75891194|NCT03684278|Other|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
75598918|NCT06054074|Behavioral|Negative Appreciation of Body Functionality Induction|The negative induction takes place in a virtual environment of a dressing room and includes the following methods to induce a lower appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a lower positive body image. 2) A red virtual costume, representing their body at that time in the past and the negative attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (red costume) to preserve the induction effect.
75598919|NCT06054048|Other|Telemedicine|"Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients."
75891195|NCT02726659|Drug|Celecoxib|Adjunct celecoxib
75598920|NCT06054035|Drug|Dapagliflozin (Forxiga®)|Dapagliflozin 10 mg once daily for 2 years. Route of administration: oral.
75891196|NCT02726659|Drug|Placebo|Adjunct placebo
75891197|NCT03660878|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
75598921|NCT06054035|Drug|Placebo matching Dapaglifolzin|Placebo matching Dapaglifolzin once daily for 2 years. Route of administration: oral.
75891198|NCT03660878|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
75598922|NCT06054035|Behavioral|Lifestyle Intervention|Patients receive a conventional lifestyle intervention (one in depth individual session at the beginning and standard care information on a healthy lifestyle at every visit thereafter).
75598923|NCT06054022|Device|high flow nasal cannula|high flow nasal cannula provides heated and humidified gas to the airways via nasal prongs at a prescribed accurate fraction of inspired oxygen (FiO2) ranging from 0.21 to 1.0 and with a higher flow rate of up to 60 litres per minute
75743175|NCT04044833|Behavioral|Health life style behaviour ,|Training: applying Personal Information Form, HLBS-II, and MSQ to the intervention and control groups determined randomly and distributing the Student Follow-up Schedules; c) Providing trainings to the intervention group; d) Monitoring the weights, BMIs, and menstrual symptoms of intervention and control groups; and e) After the Training: Applying HLBS-II and MSQ scales to intervention and control groups, collecting the follow-up schedules, and providing training to the control group and all other students. Trainings: First stage: 120 minutes basic training per week for four weeks (40 minutes on diet, 40 minutes on physical activity, and 40 minutes on menstrual symptoms)
75743176|NCT00367744|Drug|Rosiglitazone|Rosiglitazone 4mg BID
75743177|NCT00367744|Drug|Placebo|Placebo for rosiglitazone
75598924|NCT06054022|Device|nasoprong oxyen 2Litres per minute|nasoprong @L/min will deliver approximately a FiO2 of 0.3. subsequently, if incremental O2 is needed, patient will be provided with ventimask 40% and so forth
75891199|NCT03660878|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
75891200|NCT05197543|Diagnostic Test|Biomechanical rupture risk assessment|3D computational model is created from CT angiographic images available during standard AAA diagnostic process. Vascular wall stress is assessed based on the 3D model using Finite element method to identify highly stressed parts of AAA and results are compared to populational wall strength information (gathered from previous large histological study), thus rupture risk (stress/strength ratio) of each particular AAA is estimated. Other relevant factors such as gender, blood pressure, presence of intraluminal thrombus etc. are used during the calculation as well.
75743178|NCT01002222|Drug|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
75743179|NCT01002300|Drug|intranasal oxytocin|Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
75598925|NCT06053996|Radiation|Hepatopulmonary radio-sterilization|Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases
75891201|NCT04452578|Procedure|Procedure: Heart Transplantation|A HCV negative or previously successfully treated recipient who recieves a HCV positive graft will be monitored. Patients who recieve an HCV graft will be treated for HCV according to accepted protocols.
75891202|NCT05190211|Other|Telerehabilitation exercise program|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
75891203|NCT05190211|Other|Videobased exercise program|After 1 session of online simultaneous exercise training in the company of a physiotherapist via videoconference on the smart phone, an exercise video including the exercises will be sent to them and the patients will be asked to do their exercises 3 days a week. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling them once a week.
75891204|NCT03951961|Drug|Midostaurin|50mg Midostaurin bid for 12 months
75598926|NCT06053970|Other|Assessing postural responses induced by visual stimulation (Visual Evoked postural responses, VEPR)|"The intervention will last 60 minutes and will include an assessment of the Berg Balance Scale (BBS), the collection of stabilometric data, the collection of the numerical difficulty scale, the Fast Motion Sickness Scale (FMS) and will end with a break after exposure to VR.~The various conditions will be carried out in this order:~Eyes open with VR headset simulating a static environment~Eyes closed with VR helmet off~Eight measurements on a stabilometry platform will be taken for each of the VR signals, in random order"
75598927|NCT06053957|Procedure|early mobilization|early mobilization program
75598928|NCT06053931|Behavioral|white noise music|"Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=5NFHiKMCPvw&t=6478s)."
75743180|NCT01005498|Dietary Supplement|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
75598929|NCT06053931|Behavioral|lullaby music|"Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=h0QO8bgysPg)"
76061411|NCT01841060|Procedure|Percutaneous radiofrequency ablation (RFA)|Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
75743181|NCT01005498|Dietary Supplement|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
75598930|NCT06053918|Other|additional follow-up extension at home|additional interview when leaving the sector, and the extension of follow-up of the patient at home
75891205|NCT03940105|Behavioral|Packout|Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
75598931|NCT06053892|Diagnostic Test|Puncture|Shoulder puncture with the newly designed technique using AR to overlie the US image to the imaged anatomical structures in comparision to standard US and flurosopic-guidance.
76061412|NCT04414592|Other|human umbilical cord mesenchymal stem cells|Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
76061413|NCT04602494|Drug|Varenicline|varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
75598932|NCT06053879|Other|Biofeedback electrical stimulation|biofeedback stimulation for faecal incontinence post Posterior Sagittal Anorectoplasty
76061414|NCT04602494|Drug|Placebo|Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
75598933|NCT06053814|Drug|NS-050/NCNP-03|NS-050/NCNP-03 solution for IV infusion.
75598934|NCT06053814|Drug|Placebo|NS-050/NCNP-03 placebo-matching solution for IV infusion.
75598935|NCT06053788|Diagnostic Test|PocDoc|Point of care digital lipid test
75598936|NCT06053762|Behavioral|Peer-facilitated tobacco cessation|Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes
75598937|NCT06053762|Behavioral|Self-navigated tobacco cessation|Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves. Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
75598938|NCT06053671|Genetic|Blood and nasal swab sampling|Genetic screening of DNA samples (blood, mucosal swab, brain tissue) from 60-100 patients with histologically confirmed diagnosis of FCDIIA/B identified from Epilepsy Surgery Databases.
75743182|NCT00822341|Drug|TG-0054|0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion
75743183|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
75891206|NCT02232542|Drug|Duloxetine - low dose|
75891207|NCT02232542|Drug|Duloxetine - high dose|
75891208|NCT02232542|Drug|Placebo|
75891209|NCT02620033|Behavioral|Yoga therapy|
75448606|NCT03877211|Other|Electrically-evoked Auditory Brainstem Response (EABR)|Channel interaction assessment using eABRs (auditory nerve responses). The method consists of two measurements: 1) eABR measurements with stimulation by a single electrode of the cochlear implant at 70% of the dynamic range (four different electrodes are tested); 2) Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range. A comparison of the eABRs obtained by these two measurements, indicates the electrical and neural interactions between the electrodes.
75598939|NCT06053229|Device|percussive massage|30 minutes of percussive massage will be administered twice per day during the 10 day immobilization period using a percussive massage device
75891210|NCT02235350|Other|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
75448607|NCT03877211|Other|Tonal audiometry|Tonal audiometry will be performed with headphones
75891211|NCT02235350|Other|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
75891212|NCT05181787|Diagnostic Test|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
75891213|NCT05181787|Diagnostic Test|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
75891214|NCT04348136|Drug|JR-141|IV infusion, 2.0 mg/kg/week
75598940|NCT06053229|Combination Product|Leg Immobilization|All subjects will have their left leg immobilized using an immobilization brace for 10 days
75448608|NCT03877211|Other|Auditory canal examination|Otoscopic examination of external auditory canal and eardrum
75598941|NCT06052033|Procedure|CO2|CO2 laser treatment is a surgical procedure that employs a high-powered carbon dioxide laser beam to precisely ablate cervical lesions. The laser is applied with a depth of 7-10mm and a width of 3-5mm beyond the lesion area in a single session. This intervention aims to address persistent low-grade cervical lesions associated with high-risk HPV infection.
75891215|NCT04306250|Procedure|Apical prolapse fixation - anterior access|The surgery is done in anterior access
75891216|NCT04306250|Procedure|Apical prolapse fixation - posterior access|The surgery is done in posterior access
75891217|NCT02600923|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
75891218|NCT02600923|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
75598942|NCT06050824|Drug|Comparing Load and Concomitant therapy|Levofloxacin - Omeprazole - nitazoxanide - doxycycline
75598943|NCT06050499|Device|Microdialysis catheter + biosensor|"Microdialysis catheter from linton instrumetal 63 MD Catheter"
75598944|NCT06049459|Device|Optical Correction|Optical correction (if needed)
75598945|NCT06049459|Device|Therapeutic Dichoptic Virtual Reality Games|Virtual Reality Game play for amblyopia treatment
75743184|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
75743185|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
75743186|NCT00822419|Drug|lidocaine|lidocaine cream 5%
75743187|NCT00822419|Drug|ketamine|ketamine 5%
75743188|NCT00822419|Drug|non-drug cream|will be put on the skin
75891219|NCT02232776|Drug|Losartan|Dose of Losartan : 0.7mg/kg once daily.
75891220|NCT03847519|Drug|ADXS-503|A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
75598946|NCT06040775|Device|Theta Burst Transcranial magnetic Stimulation using real MCF-B65 coil|"Site of stimulation will be predetermined at Dorsolateral prefrontal cortex of non-dominant side using the BeamF3 method.1 burst will be - 3 pulses at 50 Hz, burst will be set at 5Hz i.e. interburst interval 200ms .~At100% of resting motor threshold of dominant side - 5 trains (each 40sec on and 20 sec off) will be given at each session with a pause of 1 minute in between 2 trains Standard therapy with Applied Behavior Analysis and sensory integration would continue"
75598947|NCT06040775|Device|Sham magnetic stimulation using sham MCF-B65 coil|"Similar set parameters using a sham coil which simulates sound and tactile effect of real coil but no electromagnetic induction is produced.~Standard therapy with Applied Behavior Analysis and sensory integration would continue"
75743189|NCT01050400|Genetic|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
75598948|NCT06040307|Procedure|SPI (Surgical Pleth Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by SPI during general anesthesia in the experimental arm.
75598949|NCT06039982|Other|no intervention|no intervention
75598950|NCT06036251|Other|Questionnaires|Self-reported quality of life (QOL) measures completed online
75891221|NCT03847519|Drug|Pembrolizumab|a programmed death receptor-1 (PD-1)- blocking antibody.
75891222|NCT02221687|Dietary Supplement|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
75891223|NCT02221687|Dietary Supplement|Control formula|Standard milk formula without pre and probiotic
75891224|NCT02235428|Drug|Ipratropium bromide|
75448609|NCT03874312|Diagnostic Test|Linear ultrasound (US) assessment of the internal jugular vein|Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.
75891225|NCT02235428|Drug|Placebo|
75448610|NCT03873792|Diagnostic Test|Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women|Physician diagnoses a history of asthma or eczema or allergic rhinitis
75463137|NCT01872195|Other|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
75463138|NCT01872221|Procedure|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
75463139|NCT01872234|Device|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
75743190|NCT01006044|Biological|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
75463140|NCT01872286|Device|AKE-1|
75463141|NCT01872286|Device|Pillcam SB2|
75463142|NCT01872351|Drug|Nutraceuticals|
75743191|NCT00817193|Behavioral|Physical Activity|Physical Activity program
75743192|NCT00817193|Behavioral|Wellness|Wellness program
75743193|NCT02534428|Other|wool clothing|superfine merino wool ensembles for baby wear
75743194|NCT01002534|Drug|Vardenafil|Nasal instillation of Vardenafil
75743195|NCT01002534|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
75891226|NCT02235428|Drug|Salbutamol|
75891227|NCT02235506|Procedure|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
75891228|NCT02235506|Procedure|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
75891229|NCT02235506|Device|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
75891230|NCT02235506|Device|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
75891231|NCT03070171|Drug|dabigatran etexilate|single dose
75891232|NCT02262572|Drug|Telmisartan /HCTZ - compression tablet (DC)|
75891233|NCT02262572|Drug|Telmisartan /HCTZ - dry granulation tablet (DG)|
75891234|NCT02262572|Drug|Telmisartan /HCTZ - present commercial formulation|
75891235|NCT02235584|Drug|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
75891236|NCT05174377|Diagnostic Test|CT-scan algorithm|CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation
76061415|NCT03379402|Other|Specimens collection|"On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.~Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3."
76061416|NCT04587050|Diagnostic Test|Human papillomavirus testing|HPV test from cervical sample using Cepheid GeneXpert HPV
76061417|NCT04587050|Diagnostic Test|Cervical cytology|Cervical cytology
76061418|NCT04587050|Diagnostic Test|HPV serology|HPV type specific serology (16/18) using ELISA from serum samples
76061419|NCT05640232|Drug|CDE100 association|Experimental drug.
75891237|NCT02235662|Drug|TFV IVR|
75891238|NCT02235662|Drug|TFV/LNG IVR|
75891239|NCT02235662|Other|Placebo IVR|
76061420|NCT05640232|Drug|Buscopan® Composto association|Active comparator.
75891240|NCT05167981|Other|RETAINWORKS|The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
75448611|NCT03873194|Other|Meditation|Participants will be instructed to find a comfortable position, with a straight back, feeling the general state of their bodies (tensions, pains, heat, cold, etc.), to relax and pay attention to their own breathing, being aware of the air that gets into and out of the lungs. The women will be told that whenever their attention disperses (to another focus such as a thought, a sound, a body sensation, a judgment, etc.) they should go back to the original focus (breathing) with no feeling/judgment about the loss of focus. The practice involves focus and attention exercises and the gradual insertion of other anchors (focus points) as participants improve their skills in this practice.
76061421|NCT04414904|Other|Exposure: Covid-19 infection|Previous history of COVID-19 infection.
76061422|NCT05627518|Drug|Linaprazan glurate|100 mg
76061423|NCT01814696|Device|MedSentry System|Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
76061424|NCT01970371|Drug|plazomicin|
75448612|NCT03873194|Other|conventional treatment|"Early prenatal care, when possible, is recommended as the first measure. Prenatal appointments usually take place fortnightly or weekly for hypertensive pregnant women. Extensive lab testing including specific tests for the first trimester, as well as tests for the diagnosis of superimposed pre-eclampsia and for the evaluation of lesions in target organs.~Drug treatment is only used when non-drug measures against hypertension are inefficient to decrease blood pressure levels and diastolic pressure is 90 mmHg or higher (in the first half of pregnancy) and over 100 mmHg (after 20 weeks)."
75598951|NCT06033807|Diagnostic Test|QuantiFERON-TB Gold (QFT) test|Participants will be tested by QuantiFERON-TB Gold (QFT) test to see if they have ever infected by MTB. Those with positive results will proceed to sputum Xpert MTB/RIF, physical examination and chest CT scan, as well as sputum culture if necessary to distinguish latent TB infection (LTBI) from ATB. X-ray scan is conditional on age above 15 years with a positive QuantiFERON-TB Gold (QFT) test result.
75598952|NCT06024096|Drug|Atorvastatin|"Atorvastatin is a lipid-lowering agent of the statin family that functions by blocking a rate-limiting enzyme, Hydroxymethylglutaryl-CoA (HMG-CoA) reductase, in lipid metabolism. This agent is commonly used for primary and secondary prevention of dyslipidemia. Participants will be asked to take Atorvastatin 80 mg daily at night, for 4 weeks prior to the vaccination, and continue the statin therapy for 4 weeks after vaccination.~The 80mg dose of atorvastatin allows for evaluation of the immunologic effects of statin medication with a short duration of therapy prior to vaccination."
75891241|NCT02262650|Drug|Telmisartan|
75891242|NCT02262650|Drug|Clopidogrel|
75891243|NCT02235740|Drug|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
75891244|NCT02235740|Drug|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
76061425|NCT01970371|Drug|colistin|
76061426|NCT01970371|Drug|meropenem|
76061427|NCT01970371|Drug|tigecycline|
76061428|NCT01970371|Drug|antibiotic of Investigator's choice|
76061429|NCT03300466|Device|GP0045|Hyaluronic acid gel
76061430|NCT03300466|Device|Comparator|Hyaluronic acid gel
76061431|NCT01868594|Drug|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
76061432|NCT01868594|Drug|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
76061433|NCT03300232|Behavioral|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
76061434|NCT05686876|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
75598953|NCT06024096|Biological|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
75891245|NCT03629431|Procedure|Prophylactic non-invasive ventilation|"The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions."
76061435|NCT01616953|Biological|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
76061436|NCT01616953|Procedure|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
76061437|NCT05619718|Behavioral|Awareness, Courage, and Love Groups|Groups based on the Awareness, Courage, and Love framework from functional analytic psychotherapy
76061438|NCT05619718|Other|Mutual Help Meetings|Groups based on treatment as usual where patients gather to discuss how they can help others on the ward, and make requests for how others can help them.
76061439|NCT03293524|Genetic|GS010|GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
75598954|NCT06023485|Other|stress ball use during subcutaneous injection|The effect of stress ball use on pain during subcutaneous injection
75598955|NCT06013917|Device|Cardiac Monitoring|FDA cleared ECG monitoring device that will be used to obtain ECG recordings and capture cardiac arrhythmias/events from participants
75598956|NCT06011200|Biological|MCV4|1 dose of MCV4 on Day 0
75891246|NCT03629431|Procedure|postoperative standard care|Standard care received postoperatively
75598957|NCT06011200|Biological|MSPV4|1 dose of MSPV4 on Day 0
75598958|NCT06007924|Drug|Avutometinib|Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off
76061440|NCT03293524|Drug|Placebo|The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
76061441|NCT01867658|Device|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
76061442|NCT05613946|Drug|Lumason|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
76061443|NCT05613946|Drug|Optison|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
76061444|NCT05613946|Drug|Definity|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
75598959|NCT06007924|Drug|Defactinib|Defactinib 200 mg twice daily 3 weeks on/1 week off
75598960|NCT05993936|Device|mobile application|A mobile application developed by researchers for the problems experienced in the postpartum period and downloaded from the play store.
75598961|NCT05983718|Device|Surgical Guide|For this case, after the patient is given anesthesia, the guide will be placed on the teeth. All the drillings will be performed through the guided path. There will be no need for raising flap according to flapless surgery. At the end of the operation, the operation site will be checked and hemostasis will be provided. The operator will record the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
75743196|NCT00817271|Drug|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
75743197|NCT00817271|Drug|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
75743198|NCT01052896|Drug|Gabapentin|300mg po TID
75743199|NCT01052896|Drug|Placebo|Look-alike of gabapentin 300mg given po tid
75891247|NCT05163925|Device|Eurosets ECMO Life System|"ECMOLIFE System in combination with ECMOLIFE Centrifugal Pump and ECC (extra-corporeal-circulation) Tubing Set is intended to pump blood through the extracorporeal circuit to provide extracorporeal circulation.~ECMOLIFE System must be used only in combination with ECMOLIFE Centrifugal Pump.~ECMOLIFE System is intended to operate in the following hospital environments: Operating Room, Catheter Laboratory, Emergency Room, Intensive Care Unit and during intra-hospital patient transportation from one to another Unit.~ECMOLIFE System is intended to be used by qualified healthcare professionals specifically trained in the field of extracorporeal circulation: Perfusionists (Thoracic Cardiovascular Surgery - OR), Intensivists, ICU Nurses (ICU), Emergency physicians / Intensivists (ER), Cardiologist (CathLab)."
75743200|NCT00822497|Behavioral|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
75891248|NCT04476836|Other|Animal-Assisted Therapy|Animal-Assisted Therapy is when animals are used in goal-directed treatment sessions. These goals can be physical, mental, emotional or social.
75448613|NCT03870880|Drug|Risperidone ISM 75 mg|Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.
75598962|NCT05983718|Procedure|Guide-pin-assisted Freehand surgery|The regular protocol of the implant surgery will be followed. Before the surgery begins, the patient will be given anesthesia to ensure they are comfortable and pain-free during the procedure. Doctors will go through the digital planning to understand the desired angulation. Then the bony bed will be prepared raising flap from targeted area. Then a guide-pin will be inserted by drilling and through radiographic image the direction will be confirmed. Following the hole of the guide-pin, the implant will be inserted. At the end of the operation, the raised flap will be sewn and hemostasis will be provided. The operator records the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
75598963|NCT05983354|Drug|Oral metoclopramide and ibuprofen|10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml normal saline IV administered over 15 minutes.
75598964|NCT05983354|Drug|Intravenous metoclopramide and ketorolac|10 mg of metoclopramide IV in 50 ml normal saline, 10 mg ketorolac IV in 50 ml normal saline administered over 15 minutes, with 2 placebo tablets.
75598965|NCT05971914|Procedure|Autogenous tooth derived particulate graft and a novel split thickness papilla curtain flap|Extracted deciduous teeth were prepared immediately after removal according to the manufacturer's instructions with the Bonmaker® device. Ready to use autogenous tooth bone graft (ATB) was mixed with fibrin glue in 3D planned and printed plastic cuvettes to obtain a sticky graft closely matching the shape and extent of the bony defect. The preshaped sticky ATB graft was inserted and compacted in the cleft defect. Subsequently, the tension-free split thickness flap was repositioned by shifting all buccal surgical papillae mesially to the adjacent or the second adjacent interproximal space, depending on the horizontal extent of the cleft.
75598966|NCT05969548|Device|active 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
75598967|NCT05969548|Device|active 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
75598968|NCT05969548|Device|active 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
75743201|NCT00822497|Behavioral|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
75743202|NCT01002690|Drug|Etoricoxib|90 mg/day orally for 10-13 days
75891249|NCT02604680|Drug|BLI1100-1|BLI1100-1 Topical gel
75743203|NCT01048684|Drug|Mannitol|Variation of mannitol dose
75743204|NCT01048684|Drug|Mannitol|Variation of mannitol dose
75743205|NCT01002768|Drug|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
75743206|NCT01002768|Drug|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
75891250|NCT02604680|Drug|BLI1100-2|BLI1100-2 Topical gel
75891251|NCT02604680|Drug|BLI1100-3|BLI1100-3 Topical gel
75743207|NCT01048762|Other|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
75448614|NCT03870880|Drug|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
75448615|NCT03863782|Other|No intervention|No specific intervention. Collection of clinical data
75448616|NCT03862261|Other|Integrated pediatric TB services|"pediatric TB services will be integrated into key child healthcare services: maternal neonatal and child health (MNCH) services, under-5 clinic, pediatric outpatient services, nutrition services, pediatric antiretroviral therapy (ART) services and primary health care:~Integration of the screening into all the child health care services with introduction of a specific case detection tool and updated presumptive TB register.~Improvement of diagnosis capacities and their integration in all levels of care and all services."
76061445|NCT04401046|Other|Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later|The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
76061446|NCT03375892|Other|Deep Inspiration Breath Hold during Radiation|The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered.
76061447|NCT03375892|Other|Free breathing during radiation|The patient will be instructed to breathe freely.
76061448|NCT01867580|Device|V.A.C.Ulta with Prontosan instillation|NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
75598969|NCT05969548|Device|sham 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
76061449|NCT01867580|Device|V.A.C.Ulta without instillation|NPWT only
75743208|NCT01048762|Other|home training|one instruction in home based exercise training
76061450|NCT05686720|Drug|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10^6 cells, then increased to 5.0×10^7 and 2.0×10^8 cells. The infusion is given every 2 weeks.
75448617|NCT03861377|Drug|Remifentanil R2|0,7 microg/kg
75448618|NCT03861377|Drug|Remifentanil R4|1,1 microg/kg
75448619|NCT03861377|Drug|Remifentanil R8|1,7 microg/kg
75448620|NCT03858816|Other|Mixture probiotics|The mixture probiotics capsule
75598970|NCT05969548|Device|sham 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
75598971|NCT05969548|Device|sham 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
75598972|NCT05960708|Drug|YH35324|Subcutaneous injection of YH35324
75743209|NCT01002846|Procedure|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
75448621|NCT03858816|Other|Placebo|The placebo contains the same excipient ingredients but without the live bacteria.
75448622|NCT03858010|Diagnostic Test|Wheeze and me questionnaire|validation of questionnaire assessing disease control and quality of life in preschool children with recurrent wheeze
75448623|NCT03857893|Device|Dynamic Quadripolar Radio-Frequency treatment|"Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology."
75743210|NCT00826397|Procedure|Acupuncture|Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
75891252|NCT02604680|Drug|BLI1100-4|BLI1100-4 Topical gel
75891253|NCT02604680|Drug|Placebo|Placebo - Topical gel
75891254|NCT03629353|Procedure|endotracheal intubation|After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
75891255|NCT03629353|Procedure|high flow nasal cannula|After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
75448624|NCT03857893|Drug|pH-Cream|1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
75448625|NCT03854461|Behavioral|Personalised dietary advice and educational material|As within arm/group description
75448626|NCT03854461|Behavioral|Educational material|As within arm/group description
75448627|NCT03844100|Drug|efficacy and safety of CNU® Capsule|All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
75598973|NCT05960708|Drug|Omalizumab|Subcutaneous injection of Omalizumab
75743211|NCT00826397|Procedure|Sham Acupuncture|The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
76061451|NCT04414982|Behavioral|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
76061452|NCT04414982|Behavioral|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
76061453|NCT04400734|Other|No intervention, observational study|no intervention
76061454|NCT05604742|Drug|Belimumab (Benlysta)|Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
75891256|NCT05762731|Diagnostic Test|Low dose CT thorax|A multi-detector row CT scanner with minimum section collimation of ≤1 mm and minimum number of data acquisition channels ≥ 16will be employed.
75598974|NCT05960708|Drug|Placebo|Subcutaneous injection of None of active ingredient
75598975|NCT05959291|Other|Discontinuation of Anti-HER-2 Maintenance Treatment|Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
75891257|NCT05762731|Diagnostic Test|Low dose CT thorax|Control subjects will also proceed to CT thorax, and outcome measures be compared to subjects
75448628|NCT03836144|Dietary Supplement|Potassium citrate|
75743212|NCT00998478|Other|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
75743213|NCT01050478|Drug|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
75743214|NCT01050478|Drug|Benzodiazepine|Participants may receive the benzodiazepine lorazepam [0-7.5 milligram (mg) per day] as needed for sedation or rescue medication at the investigator's discretion.
75743215|NCT00822575|Device|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
75891258|NCT05496686|Drug|4.7 microCi 225Ac-MTI-201|4.7 microCi intravenous solution
75598976|NCT05959044|Drug|Folic Acid Tablet|oral 5mg tablet two times daily for 8 weeks
75598977|NCT05959044|Other|Placebo|orally 5mg two times daily for 8weeks
75598978|NCT05955924|Drug|Nicotinamide|Oral nicotinamide (500 mg) twice daily
76061455|NCT03290326|Device|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
75448629|NCT03817892|Other|Guidance of the External Chest Compression|The CPRmeter® device is positioned on the patient's chest with a disposable adhesive. In the situation of guidance of the External Chest Compression the rescuers have access in real time on the screen to visual feedback on the quality of the External Chest Compression performed and indications of possible corrections to improve the quality of the External Chest Compression . In the case of non-guidance of the External Chest Compression , a mask is position on the screen in order to hide the feedback information.
75598979|NCT05955924|Drug|Placebo|Matching placebo capsule twice daily
75598980|NCT05954962|Drug|Progesterone 200 MG|"The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation."
75598981|NCT05954962|Drug|Ganirelix Acetate|The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.
75598982|NCT05943691|Drug|hetrombopag 5mg po qd|hetrombopag 5mg po qd for 8 weeks, combining with dexamethasone 40 mg qd for 4 days
75598983|NCT05943691|Drug|High-dose Dexamethasone|dexamethasone 40 mg qd for 4 days
75598984|NCT05935930|Drug|Propofol 10 MG/ML Injection|Propofol infusion
75598985|NCT05935930|Drug|Sevoflurane Inhalation Liquid|Sevoflurane inhalation
75598986|NCT05935176|Biological|MCV4|2 dose of MCV4 on Day 0 and Month 1
75598987|NCT05935176|Biological|MCV4|2 dose of MCV4 on Day 0 and Month 3
75598988|NCT05931575|Drug|Fasudil hydrochloride|Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
75598989|NCT05931575|Drug|Placebo|0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
75891259|NCT05496686|Drug|9.5 microCi of 225Ac-MTI-201|9.5 microCi intravenous solution
75891260|NCT05496686|Drug|19 microCi of 225Ac-MTI-201|19 microCi intravenous solution
76061456|NCT05300776|Diagnostic Test|M-ROSE analysis|"The M-ROSE analysis process consists of 3 procudures.~Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion<1%, columnar epithelial cell proportion <5% .~Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils > 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds."
75891261|NCT05496686|Drug|38 microCi of 225Ac-MTI-201|38 microCi intravenous solution
75891262|NCT05496686|Drug|76 microCi of 225Ac-MTI-201|76 microCi intravenous solution
75891263|NCT05496686|Drug|152 microCi of 225Ac-MTI-201|152 microCi intravenous solution
75891264|NCT05496686|Drug|254 microCi of 225Ac-MTI-201|254 microCi intravenous solution
75448630|NCT03817892|Other|Rhythm of a relay 4 minutes|The duration or rhythm of a relay is the time during which a rescuer performs External Chest Compression before being relayed by another rescuer. This time is 2 minutes in non intervention group according to the current guidelines and 4 minutes in experimental group.
75598990|NCT05927714|Other|Amnion-chorion Membrane|Amnio-chorion membranes specifically for palatal wound healing following free soft tissue autografts (FTSA) procedures.
75743216|NCT00826475|Behavioral|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
75891265|NCT05496686|Drug|424 microCi of 225Ac-MTI-201|424 microCi intravenous solution
75743217|NCT00826475|Behavioral|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
75891266|NCT05496686|Drug|564 microCi of 225Ac-MTI-201|564 microCi intravenous solution
75891267|NCT05496686|Drug|750 microCi of 225Ac-MTI-201|750 microCi intravenous solution
75891268|NCT05496686|Drug|998 microCi of 225Ac-MTI-201|998 microCi intravenous solution
75598991|NCT05927714|Other|ActCel Cellulose Gauze|When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.
75598992|NCT05919524|Radiation|Prostate SBRT (stereotactic body radiation therapy) with focal boost|"Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT~mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL.~Additional urethra and bladder trigone sparing constrains~Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking"
75448631|NCT03811574|Drug|Semaglutide|Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
75743218|NCT00998556|Drug|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
75743219|NCT01052974|Drug|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
75743220|NCT00817427|Other|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
75891269|NCT05496686|Drug|1327 microCi of 225Ac-MTI-201|1327 microCi intravenous solution
75891270|NCT02235818|Device|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
75891271|NCT02235818|Device|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
75891272|NCT03135704|Device|"Re Spine"|A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
75891273|NCT03135704|Other|Physiotherapy|Usual protocol for treatment of low back pain
75891274|NCT03644017|Device|WRAPSODY Stent Graft Placement|The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
75891275|NCT00158054|Behavioral|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
75891276|NCT00158054|Behavioral|Referred depression care|Physician notified of depression symptoms, usual care followed.
75891277|NCT04476524|Other|Quality improvement|All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
75598993|NCT05918744|Behavioral|Sleep Extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
75891278|NCT05075044|Biological|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
76061457|NCT03351556|Behavioral|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
76061458|NCT03351556|Behavioral|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
76061459|NCT03350386|Drug|FYU-981|Single administration
76061460|NCT03350386|Drug|Oxaprozin|Repeated administration
75598994|NCT05907525|Drug|Remimazolam|"To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
76061461|NCT04761016|Other|Usual Care|The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.
75743221|NCT00817427|Other|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
75743222|NCT00998634|Drug|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
75743223|NCT04044989|Device|Laser|Diode laser device was used for photobiomodulation
76061462|NCT04761016|Other|I-POP + CHW navigation|Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
75448632|NCT03811574|Drug|Placebo (semaglutide)|Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
75448633|NCT03796416|Drug|Misoprostol|used at a rate of 25 mcg Q4hours for cervical ripening.
75448634|NCT03796221|Behavioral|Parenting videos|Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
75743224|NCT04044989|Device|light-emitting diode (LED)|LED device was used for photobiomodulation
75743225|NCT04044989|Device|Placebo|Diode laser device was used for placebo effect
75743226|NCT01003002|Drug|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
75743227|NCT01008774|Device|Paxman Cooling Machine|Scalp cooling procedures
75743228|NCT01008774|Device|Cold Caps|Scalp cooling procedures
75743229|NCT01008930|Procedure|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
75743230|NCT01003158|Drug|AZD8931|Tablet Oral bid
75743231|NCT01003158|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off
75891279|NCT05078125|Device|Holter monitoring|24 hours Holter monitoring
75891280|NCT03135964|Device|filler dressing of NPWT|a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
75891281|NCT05762653|Diagnostic Test|Endoscopic ultrasound|Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
75891282|NCT01413529|Behavioral|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
75891283|NCT01413529|Behavioral|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
75891284|NCT01337960|Behavioral|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
75891285|NCT01337960|Behavioral|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
75891286|NCT01337960|Behavioral|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
75598995|NCT05907525|Drug|1% propofol|"To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
75598996|NCT05901220|Behavioral|Healthy lifestyle|An educational programme to promote healthy lifestyle will be performed.
75891287|NCT03136042|Other|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
75891288|NCT03136042|Other|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
75891289|NCT03136042|Other|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
75598997|NCT05898750|Dietary Supplement|MorDom|oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)
75891290|NCT02571998|Drug|Omiganan (CLS001) Topical Gel|
75891291|NCT02571998|Drug|Vehicle Topical Gel|
75891292|NCT04379986|Device|Senbiosys|The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
76061463|NCT04279444|Dietary Supplement|BKR-017|BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
75891293|NCT05202691|Other|Group 1 (Physical Therapy+Magnetic Field Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain) adding a Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany)
75891294|NCT05202691|Other|Group 2 (Physical Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain)
75891295|NCT02784002|Drug|Ridinilazole|
75891296|NCT02784002|Drug|Fidaxomicin|
75743232|NCT01003236|Drug|placebo|140 mg placebo tablets, 3 times per day for 3 months
75448635|NCT03796221|Behavioral|Standard pediatric obesity treatment|Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
75891297|NCT04362046|Procedure|Hysteroscopic uterine resection|"Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications."
75891298|NCT05202613|Drug|Doravirine|Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
75891299|NCT02233556|Drug|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~Mismatch negativity(MMN)~P50"
75891300|NCT04932733|Other|Exercises|The elderly participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
75891301|NCT04932733|Other|Young isometric exercise|The young participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
75891302|NCT00881920|Biological|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10^7 cells/m^2 CAR-Kappa~Group 2: 1x10^8 cells/m^2 CAR-Kappa~Group 3: 2x10^8 cells/m^2 CAR-Kappa"
75891303|NCT05228132|Device|Pristine™ Long-Term Hemodialysis Catheter|Placement of the Pristine™ Long-Term Hemodialysis Catheter Placement.
76061464|NCT03371056|Biological|Bacteriological analyses on clinical samples performed with swabs|Bacteriological analyses will be performed to assess the InSPIRe kit
76061465|NCT05345548|Diagnostic Test|Cold Pressor test|Cold Pressor test will be done for 3 minute duration maximum
76061466|NCT03283462|Dietary Supplement|Mitopure|Mitopure (Urolithin A) containing softgels
76061467|NCT03283462|Dietary Supplement|Placebo|Placebo containing softgels
76061468|NCT04400968|Procedure|Auricular therapy|The auricular therapy points were selected following the protocol for dysmenorrhoea described by Oleson (Oleson, 2008). These points were (the name of the European cartography is specified by the name of the point): Shenmen [FT2], uterus [FT5], sympathetic [HI4], kidney [CS6], heart [CI4], endocrine [IT2] and thalamus [PC2].
75448636|NCT03795558|Drug|Etelcalcetide|Up-Titration
75448637|NCT03790098|Behavioral|Restorative-Flow Yoga|Restorative yoga consists of a series of gentle poses, supported by props, with an emphasis on breathing and relaxing; as opposed to stretching or contracting muscles, it is designed to support muscles. Flow yoga consists of a series of linked poses synchronized with the breath.
75599005|NCT05890586|Drug|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
75599006|NCT05890586|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
75599007|NCT05888480|Other|The end-of-life communication skills training|Training methods include lectures, video demonstrations, and simulation in small groups (4-5 trainees per group with multidisciplinary roles). Written and audiovisual learning materials will be offered. Each session will be 150 minutes, including lectures and video demonstration (90 min/session) and simulation and feedback (60 min/session). One session will be conducted in two weeks. Totally there will be four sessions completed in 8 weeks.
75599008|NCT05888480|Other|Routine training activity|Routine training activities arranged by relevant departments in hospitals
75743233|NCT01003236|Drug|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
75743234|NCT03883386|Drug|Loratadine|10 mg in a capsule
75743235|NCT03883386|Drug|Placebo|Administered via capsule
75743236|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
75743237|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
75743238|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
75743239|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
75743240|NCT00424047|Drug|CC-5013 plus dexamethasone|25 mg daily for 21 days every 28 days.
75599009|NCT05885334|Other|control|Caregivers will not receive any educational solution different than what is done by routine in centers. After six months, performance in caregivers tasks will be video recorded.
75599010|NCT05885334|Other|Virtual Reality|Caregivers will receive a educational solution of virtual reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
75891304|NCT04914637|Procedure|Cervical interlaminar epidural steroid injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 cc 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the rest room after the procedure and followed up for any complications.
75891305|NCT04914637|Procedure|Dry needling|Dry needling will be applied to the active trigger points for the patients in this group. After cleaning the area of interest with an antiseptic solution, dry needling will be applied with the fast-in/fast-out technique for the active trigger point. During needle maneuvers, local contractions (local twitch response-LTR) are obtained and rapid needle movements are continued until the contractions end. Afterwards, the needle is removed and compression is applied to ensure hemostasis in the relevant area.
75891306|NCT04914637|Procedure|Sham dry needling|Although the method of intervention is like dry needling, the only difference is that the blunt end of the needle is used and it does not penetrate the skin.
75891307|NCT02235896|Behavioral|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
75891308|NCT04905433|Behavioral|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
75891309|NCT04905433|Behavioral|Cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
75891310|NCT04264390|Behavioral|Movement-to-music|Movement-to-music is a physical activity program that was developed onsite at a state-of-the-art adapted fitness facility. The program includes movements that are coupled with music to enhance muscular strength, cardiorespiratory capacity, flexibility, and balance. For this study, the program will be packaged into playlists of exercise videos that will be given to participants. Participants will be instructed to complete the prescribed videos 3 times per week. Participants will also be asked to attend 4 behavioral coaching calls with a telecoach. The goals of the behavioral coaching calls will be to address issues with the technology components of the program and promote physical activity participation within the community and adherence to the movement-to-music videos.
75891311|NCT02235974|Behavioral|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
75891312|NCT02235974|Behavioral|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
75891313|NCT02235974|Behavioral|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
75891314|NCT02235974|Behavioral|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
75891315|NCT04240288|Other|Procalcitonin-guided antibiotic treatment|Antibiotics will be administered based on the procalcitonin lab results.
75891316|NCT04240288|Other|Standard of Care Antibiotic Treatment|Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
75891317|NCT02236052|Biological|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
75891318|NCT02236052|Biological|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
75891319|NCT02236052|Biological|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
75891320|NCT02236052|Biological|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
75448638|NCT03785457|Other|Repetitive Trunk Extension|Subjects will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds (Figure 2), repeated five times with 15-second rest breaks.
75448639|NCT03785457|Other|Sustained Trunk Extension|Subjects will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks.
75448640|NCT03785106|Drug|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
75448641|NCT03785106|Drug|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
75448642|NCT03782142|Drug|Tenofovir|TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)
75448643|NCT03782142|Drug|Rilpivirine|NNRTI
75448644|NCT03782142|Drug|Prezcobix|PI
75448645|NCT03782142|Drug|Dolutegravir|II
75448646|NCT03776695|Biological|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)
75448647|NCT03776695|Other|Placebo|0.9% Saline
75891321|NCT02236052|Biological|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
75891322|NCT02236052|Biological|Placebo|A single dose of placebo
75891323|NCT04238494|Diagnostic Test|Nuclear magnetic resonance (NMR)|Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
75891324|NCT03077737|Behavioral|Choose to Change|Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).
75891325|NCT03077737|Behavioral|Enhanced usual care|Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.
75891326|NCT03062449|Drug|L-Serine|Gummy containing L serine dose
76061469|NCT04400968|Procedure|kinesio tape|Before the tape application, the skin surface was removed of hair when needed and cleansed. The tapes were applied at 25% of tension and were placed horizontally covering the area between the antero-superior iliac spines and the postero-superior iliac spines and vertically from the navel to the symphysis pubis. All bandages were adhered to the skin with a technique type I with a space augmentation. The centre of the tape was removed and applied at 25% of tension. Afterwards, the rest of the protector were removed and the laterals anchors of the tape were adhered with no tension. The participant maintained a slight extension of the trunk while the tape was applied on the anterior aspect of the truck and a slight flexion while the tape was applied in the posterior aspect of the trunk.
76061470|NCT04400968|Procedure|Auricular therapy Placebo group|Sham auricular therapy
75448648|NCT03897920|Other|Doppler ultrasound assessment of renal arteria resistive index|A high frequency probe will be used together with the use of color or power Doppler to help vessel localization. As resistance to blood flow progressively increases from the hilar arteries toward the more peripheral parenchymal vessels, renal arteria resistive index (RRI) will be done at the level of the arcuate or interlobar arteries, adjacent to medullary pyramids. Measurements will be repeated in different parts of both organs (superior, median, and lower) when at least three reproducible waveforms have been obtained. An RRI will be calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and the mean value of three measurements at each kidney is usually considered. An RRI value 0.60 ± 0.01 (mean ± SD) is usually taken as normal with a value of 0.70 being considered the upper normal threshold
75448649|NCT03772977|Behavioral|Brain Health Champion|A health coach embedded within an existing clinical care team
76061471|NCT04400968|Procedure|kinesio tape Placebo group|Sham kinesio tape
75743241|NCT00424047|Drug|Dexamethasone plus Placebo|Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
75891327|NCT03062449|Other|Placebo Gummy|Gummy with no dosing of L Serine
75891328|NCT04233268|Diagnostic Test|Rapid Pathogen Detection|Rapid assays for pathogen detection on bronchoalveolar lavage fluid
75891329|NCT05202457|Procedure|Elective surgery|Patient undergoing elective or urgent surgery
75891330|NCT04085146|Procedure|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
75891331|NCT04085146|Procedure|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
75891332|NCT02800915|Other|Service innovation with focus on multidisciplinary collaboration|The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
75891333|NCT04908592|Drug|Dexamethasone|Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
75891334|NCT04908592|Other|Placebo|Patients will receive 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
76061472|NCT05686330|Device|Apple Watch|Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
76072019|NCT03418779|Other|Optimized Supportive Care|"The optimized supportive care included:~Lifestyle: low-salt, restricted protein dietary with sufficient calorie supply, smoking cessation, moderate alcohol consumption and keeping a healthy weight~The use of renin-angiotensin system blockade: lowering blood pressure to a target below 135/85 mmHg, during which treatment was adjusted to ensure that patients were receiving the maximum labelled or tolerated dose of RAS blockade~Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c≤ 7.0%~Received uricosuric agents or xanthine oxidase inhibitors as necessary to achieve serum uric acid <6 mg/dL in female, <7 mg/dL in male"
75448650|NCT03770299|Biological|Nivolumab|Specified dose on specified days
75448651|NCT03770299|Drug|Vinorelbine|Specified dose on specified days
75448652|NCT03770299|Drug|Gemcitabine|Specified dose on specified days
75448653|NCT03770299|Drug|Docetaxel|Specified dose on specified days
75448654|NCT03770299|Drug|Pemetrexed|Specified dose on specified days
75448655|NCT03770299|Drug|Cisplatin|Specified dose on specified days
75743242|NCT00530790|Drug|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
75743243|NCT02869971|Device|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
75743244|NCT02869971|Drug|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
75891335|NCT02761603|Behavioral|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
75891336|NCT02761603|Behavioral|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
76061473|NCT03368716|Behavioral|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
76061474|NCT05686174|Dietary Supplement|MBS217|Soybean Fermented Extract (MBS217)
76061475|NCT05686174|Dietary Supplement|Placebo|Without active ingredient
76061476|NCT05685940|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
76061477|NCT05685940|Procedure|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
75448656|NCT03770299|Drug|Carboplatin|Specified dose on specified days
75448657|NCT03770299|Drug|Paclitaxel|Specified dose on specified days
75891337|NCT01567033|Behavioral|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
75891338|NCT04783948|Other|Brace Treatment|Compliance to brace compression used for the correction of pectus carinatum will be evaluated.
76061478|NCT05567458|Drug|Luspatercept|Specified dose on specified days
76061479|NCT05567458|Drug|Placebo|Specified dose on specified days
76061480|NCT03344692|Drug|Alirocumab|prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution
75448658|NCT03770299|Other|Observation|Observation by the investigator
75448659|NCT03760835|Drug|Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)|Treatment of congenital adrenal hyperplasia
75599011|NCT05885334|Other|Augmented reality|Caregivers will receive a educational solution of augmented reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
75599012|NCT05885334|Other|360 videos|Caregivers will receive a educational solution of 360 degrees videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
75743245|NCT01032057|Drug|capecitabine|
75743246|NCT01032057|Drug|gemcitabine hydrochloride|
75743247|NCT01032057|Procedure|quality-of-life assessment|
76061481|NCT03344692|Other|Placebo|prefilled pen containing 1 ml of solution without Praluent
75448660|NCT03760835|Drug|Dual release hydrocortisone (plenadren)|Treatment of congenital adrenal hyperplasia
75448661|NCT03759496|Biological|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
76061482|NCT03343132|Behavioral|Standard locomotor therapy|Typical clinical therapy.
76061483|NCT04278820|Drug|TQA3526|Tablet(s) administered orally once daily
76061484|NCT04278820|Drug|Placebo to match TQA3526|Tablet(s) administered orally once daily
75448662|NCT03759184|Drug|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6
75448663|NCT03759184|Drug|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at the maximum tolerated dose or the maximum administered dose of 2 mcg/kg/day on days 1-5 of cycles 1-6
75448664|NCT03759184|Biological|Obinutuzumab|Intravenous (IV) Obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1: then 1,000 mg on day 4 of each subsequent cycle
75743248|NCT01032057|Radiation|3-dimensional conformal radiation therapy|
75743249|NCT01003314|Biological|AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine|Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later
76061485|NCT05305924|Other|Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
76061486|NCT05305924|Other|No Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
76061487|NCT05685862|Device|Laser Speckle Contrast Imaging using the PerfusiX-Imaging device|Patient will undergo the standard-of-care gastric conduit procedure and in addition, peroperative Laser Speckle Contrast Imaging of the gastric conduit and eosophagus will be performed.
76061488|NCT05298436|Other|Follow-up interview|All participants will be followed up at defined time points post-stroke by face-to-face or telephone interview or postal questionnaire.
76061489|NCT05556148|Drug|Otrivine Congestion Relief|0.1% Nasal Spray (Xylometazoline Hydrochloride)
75599013|NCT05877300|Combination Product|Cellspan™ Esophageal Implant-Adult (CEI)|The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stromal cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.
75599014|NCT05875246|Behavioral|Micro-interventions|Group 1: No intervention Group 2: Brief stress reduction messages Group 3: App based stress reduction audio activity
75448665|NCT03747640|Device|Self Transcranial Direct Current Stimulation (tDCS)|tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., New York; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.
75599015|NCT05873946|Diagnostic Test|intraoperative ultrasound|Use of 2D non-navigated intraoperative ultrasound as an operative adjunct
75599016|NCT05873881|Drug|Colchicine 0.5 MG|Oral colchicine 0.5 mg daily
76061490|NCT05555524|Other|Baby oil|"Before each application~Hand hygiene will be done~Skin care will be done to the affected area and the area is thoroughly dried.~Participants will wear a hospital gown and seated comfortably on their bed.~Gentle massage with the cool baby oil will be applied on the itching area and is continued for 15-20 min.~Message will be applied for three times a week before each hemodialysis session for 12 weeks"
76061491|NCT05555524|Other|Placebo|"Before each application~Hand hygiene will be done~Skin care will be done to the affected area and the area is thoroughly dried.~Participants will wear a hospital gown and seated comfortably on their bed.~Gentle massage with the cool distilled water will be applied on the itching area and is continued for 15-20 min.~Message will be applied for three times a week before each hemodialysis session for 12 weeks"
76061492|NCT03342586|Diagnostic Test|Resting State fMRI (rsfMRI)|rsfMRI before receiving High-dose chemotherapy with autologous stem cell transplantation/HDC-ASCT (pre-HDC-ASCT), at approximately 3 months (+/- 2 weeks) after HDC-ASCT (early post-HDC-ASCT) and approximately 6months (+/- 2 weeks) after HDC-ASCT (late post-HDC-ASCT).
76072020|NCT03418779|Other|Yi-Qi-Qing-Jie herbal compound placebo|Patients will receive Yi-Qi-Qing-Jie herbal compound placebo instead for the duration of the treatment and follow-up phases. The major component of the placebo is malt dextrin which looks, smells and tastes like YQF compound, and it comes in packaging with a similar appearance to YQF compound; it is also dissolved in 150 ml boiled water and taken orally twice a day.
75599017|NCT05873881|Drug|Colchicine placebo|Placebo colchicine daily
75891339|NCT04783987|Other|Walking asessments|Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
75891340|NCT05762497|Other|Moldable adhesive|Patients were provided with the new adhesives and a short questionnaire on current ASV use. After a week, they were contacted by telephone to verify any doubts/problems. At the end of the two weeks, the patient was again administered a questionnaire to evaluate the new moldable adhesive (while using the ASV).
75448666|NCT03747640|Behavioral|mindfulness-based meditation|The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.
75599018|NCT05873881|Drug|Thiamine Mononitrate 300 mg|Thiamine Mononitrate 300 mg daily
75599019|NCT05869656|Behavioral|Fluid restriction|Oral fluid restriction of 1000ml per day
75743250|NCT01003314|Biological|AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge|Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
75599020|NCT05869656|Behavioral|Free fluids|Continue care without any oral fluid restriction
75599021|NCT05867381|Device|HEPA filtration|HEPA filters with the capacity to reduce PM2.5 levels
75599022|NCT05867381|Device|Sham filtration|Sham filtration use the same appearance of air purifier but with HEPA filter removed.
75599023|NCT05866159|Other|Kinesiotape using Rocktape®|Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
75599024|NCT05866159|Other|Sham taping|sham taping with Rocktape®, with no tension.
75743251|NCT00530088|Drug|porfimer sodium|IV
75743252|NCT00530088|Drug|Photdynamic Therapy (PDT)|
75743253|NCT01009008|Device|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
75599025|NCT05866055|Drug|VX-973|Suspension for oral administration.
75599026|NCT05866055|Drug|Placebo|Suspension for oral administration.
75599027|NCT05866055|Drug|Midazolam|Syrup for oral administration.
75599028|NCT05864625|Drug|Remimazolam besylate|During induction, patients allocated to the remimazolam group will receive remimazolam 6mg/kg/h with remifentanil TCI 1~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combied with remifetanil.
75891341|NCT04759768|Drug|Nalmefene Hydrochloride|3mg nasal spray
75891342|NCT04759768|Drug|Nalmefene|1mg intramuscular injection
75891343|NCT04754113|Other|prone position|patient was helped into the prone position, patient received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 5% NaCl solution was injected via the central venous catheter
76061493|NCT03342586|Other|Auditory Attention and Executive Functions Test|"Trail Making Test (Parts A & B): Part A is a timed test of visual scanning and graphomotor speed; AT: 3 minutes. Part B is a timed measure of set-shifting; Administration Time (AT): 5 minutes. Test-retest reliabilities=0.64-0.94.~Brief Test of Attention-BTA assesses auditory working memory; AT: 10 minutes. Test-re-test reliability=0.70.~Controlled Oral Word Association Test-COWAT is a timed measure of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S). The subject is allowed 60 seconds per letter, and the resultant score is the total number of words produced. Test-retest reliability=0.88. AT: 5 minutes."
76061494|NCT03342586|Other|Memory Test|The Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R is a test of verbal learning and memory.
76061495|NCT03342586|Other|Motor Speed Test|Grooved Pegboard Test (GPT)-Dominant Hand and Non-Dominant Hand. It is a timed test of manual dexterity, in which the time to completion is scored separately for each hand.
75599029|NCT05864625|Drug|Propofol/ Sevoflurane|During induction, patients allocated to the P/S group will receive propofol 1% 1-2mg/kg with remifentanil TCI 1~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with sevoflurane and remifentanil.
75599030|NCT05855837|Other|Ready to Eat Cereal|Cereal products available in retail stores
76061496|NCT03342586|Other|Self Reported Quality of Life Questionnaire|The Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR Version 4) consists of 46 questions with five domains assessing physical well-being, social/family well-being, emotional well-being, functional well being, additional concerns. The neuropsychological and QOL assessments will be performed by a neuropsychologist or by a trained RSA under the neuropsychologist's direct supervision.
75599031|NCT05854160|Procedure|Electrical Pulse Train Stimulation|sEEG provides the ability to stimulate neural circuits via implanted electrodes by delivering mild intra-cranial electrical stimulations in different brain structures to estimate their impact on cognitive tasks.
75743254|NCT01006434|Other|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
75448667|NCT03747640|Device|Sham Self Transcranial Direct Current Stimulation (tDCS)|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
75448668|NCT03747640|Behavioral|sham meditation|For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
75599032|NCT05853744|Drug|lavender essential oil inhaled using cotton balls|cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
75599033|NCT05853744|Drug|lavender essential oil inhaled using face mask|These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer throughout a face mask. A cotton ball soaked with water was put 10 cm next to the patient.
75599034|NCT05853744|Drug|Distilled water|inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
75599035|NCT05852769|Drug|BMS-986196|Specified dose on specified days
75743255|NCT01003470|Other|acupuncture|Xing Nao Kai Qiao Acupuncture
75743256|NCT01003470|Behavioral|rehabilitation|Kinesitherapy
75743257|NCT01003470|Other|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
75743258|NCT01003548|Device|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
75743259|NCT01003548|Device|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
75743260|NCT01006668|Drug|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
75743261|NCT01006668|Drug|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
75891344|NCT04721392|Other|Mental fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
75891345|NCT04721392|Other|Control (documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team.
75891346|NCT04745455|Other|Infant formula containing prebiotics, probiotics and postbiotics|Infant formula containing prebiotics, probiotics and postbiotics
75891347|NCT05738200|Other|Nordic Hamstring Exercise|A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
75891348|NCT05738122|Other|60-Day self-guided Emotion Regulation Journal|A 60-day self guided journal with activities designed to be completed daily to improve an individual's emotion regulation abilities and habits
75891349|NCT05201677|Procedure|Supplement of perfusion fluid through the subiris suspensory ligament space from the lateral incision|After the capsule is filled with viscoelastic material, if the IOP is less than 10 mmHg, the investigators will supply the perfusion fluid through the subiris suspensory ligament space from the lateral incision.
76061497|NCT03340246|Procedure|Delayed sclerotherapy|See arm descriptions
76061498|NCT03340246|Procedure|Immediate phlebectomy|See arm description
75891350|NCT05738044|Other|No intervention|No intervention
75891351|NCT04676191|Device|Sleepiz One+|Simultaneous sleep study with polysomnography and Sleepiz One+
75743262|NCT01003626|Procedure|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
75743263|NCT01003626|Device|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
75743264|NCT01003704|Procedure|Lower extremity amputation|
75891352|NCT04676191|Device|Polysomnography|Simultaneous sleep study with polysomnography and Sleepiz One+
75891353|NCT02570282|Drug|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
75891354|NCT02570282|Drug|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
75891355|NCT05737888|Other|fMRI Neurofeedback|15 intervention sessions on a 3T MRI scanner.
75891356|NCT05737888|Other|EEG Neurofeedback|15 intervention sessions with a standard EEG-cap with 64 active electrodes.
76061499|NCT04279132|Behavioral|POSTOPERATIVE COGNITIVE DYSFUNCTION|NEURON SPECIFIC ENOLASE LEVELS IN LUMBAR DISC HERNIECTOMY WITH GENERAL ANESTHESIA MODALITIES
76061500|NCT05552248|Device|LumbarBelt SOFT 300|15 patients will be included in this group and will used the medical device LumbarBelt SOFT 300 during sport practice (at least 2 sport sessions per week), for 12 weeks.
76061501|NCT05552248|Other|Control group LumbarBelt SOFT 300|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt SOFT 300), for at least 2 sport sessions per week during 12 weeks.
75599036|NCT05852769|Drug|Caffeine|Specified dose on specified days
75599037|NCT05852769|Drug|Montelukast|Specified dose on specified days
75599038|NCT05852769|Drug|Flurbiprofen|Specified dose on specified days
75599039|NCT05852769|Drug|Omeprazole|Specified dose on specified days
75599040|NCT05852769|Drug|Midazolam|Specified dose on specified days
75599041|NCT05852769|Drug|Digoxin|Specified dose on specified days
75599042|NCT05852769|Drug|Pravastatin|Specified dose on specified days
76061502|NCT05552248|Device|LumbarBelt MID 500|15 patients will be included in this group and will used the medical device LumbarBelt MID 500 during sport practice (at least 2 sport sessions per week), for 12 weeks.
76061503|NCT05552248|Other|Control group LumbarBelt MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt MID 500), for at least 2 sport sessions per week during 12 weeks.
75891357|NCT05737888|Behavioral|Cognitive Behavioral Therapy|10 intervention sessions of CBT group therapy, as per local university hospital standard of care.
75743265|NCT04000230|Behavioral|TCIT|"TCIT consists of the following:~CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks."
75743266|NCT04000230|Behavioral|Booster|Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
75743267|NCT05734326|Device|Ultrasound elastography|ultrasound elastography (USE) is emerging as a promising additional tool to discern malignant thyroid nodules, allowing increased diagnostic accuracy, Due to its ability to assess stiffness as an indicator of malignancy, USE has recently become an additional tool for thyroid nodule differentiation, in combination with conventional US and FNA [18].
75891358|NCT02564744|Drug|Debio 1562|Safety run in: Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle. Parts 2 and 3: Cohort A- Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle. Cohort B- Debio 1562 weekly (QW) will be given at a total dose of 0.8 milligram per kilogram (mg/kg) IV over a 21-day cycle. Participants receiving QW regimen will be allowed to switch to Q3W regimen during Coronavirus Disease 2019 (COVID-19) pandemic.
75891359|NCT02564744|Drug|Rituximab|Rituximab will be given on the same day as Debio 1562, Q3W IV at a dose of 375 mg/m^2 on Day 1 of a 21-day cycle in all participants.
75891360|NCT05201599|Device|Flexible ureteroscope with intelligent control of renal pelvic pressure|After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.
75891361|NCT03110536|Diagnostic Test|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.~The questionnaire also contains clinical cases that require triage coding."
75891362|NCT03110536|Other|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
75891363|NCT02564588|Drug|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
75891364|NCT02564588|Drug|Placebo|Placebo once daily
76061504|NCT04400422|Dietary Supplement|Lipano formula|Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD
76061505|NCT04278430|Device|transcranial direct current stimulation|"The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge."
76072021|NCT03418038|Dietary Supplement|Ascorbic Acid|Given IV
76072022|NCT03418038|Drug|Carboplatin|Given IV or PO
76072023|NCT03418038|Drug|Cisplatin|Given IV or PO
75599043|NCT05852353|Other|Digital Pediatric Bladder Health Patient Education Curriculum|"Bladder Basics is designed to be a digital health intervention to improve knowledge of healthy bladder practices. It is a video-based bladder health curriculum based on 1) principles of Urotherapy 2) stakeholder need for a gold-standard resource 3) behavioral change theory 4) education design standards for inclusion as a comprehensive school health program (CSHP).~The overall mission of the course is to teach children and their families about pediatric bladder health. The development of the course has followed the NIH's Clear & Simple standards for patient education. The 7 video lesson plan spans 60 minutes total. The course is designed to support families awaiting medical care, which would provide the continued support. In addition, one lesson shares solutions to common home and school-based barriers to behavioral change. The 4 healthy bladder practices that are promoted are- 1) pee every 3 hours 2) drinking water 3) daily poop without straining 4) toilet postures."
76072024|NCT03418038|Drug|Cytarabine|Given IV or PO
75743268|NCT00360568|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
75743269|NCT00360568|Device|CADD-Legacy® 1400 ambulatory infusion pump|
76072025|NCT03418038|Drug|Dexamethasone|Given IV or PO
76072026|NCT03418038|Drug|Etoposide|Given IV or PO
76061506|NCT04278430|Device|Sham tDCS|Five children with LSIH were randomly allocated to this group. All participants received sham tDCS for 3 weeks on alternate days and completed 10 treatment sessions. The sham tDCS followed preparatory procedures similar to that used for the experimental group, except that the device was disconnected after the initial increase of the current. Children usually started the activity without noticing that the device was disconnected. The children were assessed at baseline, during the 5th and 10th sessions, and during a follow-up that was scheduled for 4 months later.
76061507|NCT05537974|Procedure|Endotracheal aspiration|Clearance of endotracheal secretions via a catheter.
76072027|NCT03418038|Drug|Gemcitabine Hydrochloride|Given IV or PO
75599044|NCT05851196|Other|Proprioceptive training|A physiotherapist tailors the exercises to the patient's functional demands and pain- or fear-inducing activities. Guided by the therapist, patients look for ways to integrate the exercises into their daily life activities. Each week, patients receive feedback from the physiotherapist, and the training program is gradually progressed. The patients are instructed to perform the exercises daily, integrated into their daily activities, hobbies, and work. The program contains: (1) exercises to improve the sense of posture and movement, (2) exercises to correct the reference frame from which patients control posture and movement, (3) muscle control exercises, (4) exercises to increase variability in postures and movement patterns, (5) functionality: patients search for ways to correct and integrate alternative postures and movement patterns into their daily life, (6) high training frequency and high load, (7) focus on sensing, localizing and differentiating, rather than movement control.
75448669|NCT03736876|Behavioral|About Us|Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
75743270|NCT00360568|Device|PEG tube|percutaneous endoscopic gastrostomy tube
75743271|NCT00360568|Device|J-tube|jejunal tube
75891365|NCT03110302|Behavioral|Prolonged exposure|PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
75891366|NCT04665817|Diagnostic Test|CT-QFR|CT-QFR is a novel method for evaluating the functional significance of coronary stenosis. It is calculated by coronary computed tomographic angiography images.
75891367|NCT04665817|Diagnostic Test|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two. angiographic projections.
75891368|NCT04665817|Diagnostic Test|FFR|FFR measured by pressure wire is the gold standard for evaluating the functional significance of coronary stenosis.
75891369|NCT04049500|Other|Digital Diabetes Prevention Program (dDPP)|dDPP tool suite to integrate with the EHR and clinical workflows
75891370|NCT05759767|Drug|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
75891371|NCT05759767|Drug|Placebo|Children in this group will receive placebo once daily for 3 weeks after ESWL session.
75891372|NCT02561234|Drug|Co-ArgI-PEG|Administered IV
75448670|NCT03736603|Behavioral|PIPA Intervention Bundle 1|"The PIPA intervention bundle 1 includes:~Pathway Implementation Toolkit~Local Multidisciplinary Champions~Audit and Feedback~Educational Seminars/Webinars~Practice Facilitation"
75891373|NCT03949036|Other|Crystalloid fluid administration with the target of stroke volume variation ≤ 12%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
75448671|NCT03736603|Behavioral|PIPA Intervention Bundle 2|"The PIPA intervention bundle 2 includes:~Pathway Implementation Toolkit~Local Multidisciplinary Champions~Audit and Feedback~Educational Seminars/Webinars~Practice Facilitation~Mobile App"
75743272|NCT00436215|Drug|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
75743273|NCT00436215|Drug|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
75743274|NCT03742674|Other|Follow up|No intervention
75743275|NCT01006746|Other|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
75743276|NCT01028859|Drug|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 ~ mg/m2; Day 1, Day 8 every 3 weeks
75743277|NCT05734248|Procedure|Facial filler injection|Hyaluronic acid will be injected on the cheek, based on the aesthetic evaluation of the face.
75743278|NCT05602974|Radiation|stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy
75743279|NCT05602974|Other|regular follow-up|regular follow-up
75891374|NCT03949036|Other|Crystalloid fluid administration with the target of stroke volume variation ≤ 6%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
75891375|NCT04606693|Other|Treatment of SAHS|Patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
75891376|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
76072028|NCT03418038|Drug|Ifosfamide|Given IV or PO
76072029|NCT03418038|Other|Laboratory Biomarker Analysis|Correlative studies
76072030|NCT03418038|Drug|Oxaliplatin|Given IV or PO
75599045|NCT05850364|Biological|Sabin Strain Inactivated Poliovirus Vaccine|Totally 1440 healthy infants of 6 weeks old (42-47 days) are planned to be enrolled, and then randomized in a 1:1:1:1 ratio into four groups, i.e., co-administration group 1 (group C1), co-administration group 2 (group C2), staggered administration group 1 (group S1) and staggered administration group 2 (group S2). Participants in group C1 and C2 will receive sIPV at 6,10, 14 weeks old, administered concomitantly with routine infant vaccine (may include DTP-HepB-Hib vaccine, PCV10 or rotavirus vaccine in accordance with the local routine vaccination schedule). Participants in group S1 will receive sIPV at 6,10,14 weeks old, and receive routine infant vaccines at 8,12,16 weeks old. Participant s in group S2 will receive routine infant vaccines at 6,10,14 weeks old, and receive sIPV at 8,12, 16 weeks old.
75891377|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
75448672|NCT03727750|Drug|Gemtuzumab Ozogamicin|Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
75448673|NCT03727152|Drug|generic single tablet TAF/FTC/DTG|HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
75891378|NCT02750306|Drug|Suvorexant|10 mg tablet (may be increased to 20 mg tablet)
75891379|NCT02750306|Drug|Placebo|Placebo to suvorexant
75891380|NCT03941704|Dietary Supplement|Pulse-based diet|Low Glycemic Index
75891381|NCT03941704|Dietary Supplement|Regular diet|Moderate Glycemic Index
75891382|NCT03845140|Drug|L-PZQ ODT|Participants will receive single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.
75891383|NCT03845140|Drug|Biltricide®|Participants will receive single oral dose of Biltricide® 40 mg/kg crushed tablet on Day 1.
75891384|NCT03845140|Drug|L-PZQ ODT|Participant will receive single oral dose of L-PZQ ODT 60 mg/kg as decided by the IDMC.
75891385|NCT00238862|Procedure|Amniotic membrane transplantation|
75891386|NCT00238862|Drug|Autologous serum/BSS 20%|
75891387|NCT01816165|Drug|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
75891388|NCT01816165|Drug|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
76061508|NCT05093374|Drug|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF."
76061509|NCT05093374|Drug|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
75599046|NCT05848700|Drug|SEP-363856|SEP-363856 Tablet
75743280|NCT00441363|Drug|Bromocriptine Mesylate|0.8 mg tablet
75599047|NCT05848700|Drug|Placebo|Placebo Tablet
75743281|NCT05139186|Device|Artificial Intelligence|Artificial intelligence
75743282|NCT03992248|Behavioral|Time restricted feeding|Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.
75743283|NCT03992248|Behavioral|Control|Eating for at least 14hrs per day.
75743284|NCT05734170|Dietary Supplement|Chia Seeds and instant oatmeal breakfast|The final group was to consume one packet of instant oatmeal with two tablespoons of chia seeds mixed in with oatmeal for breakfast for 30 days.
75743285|NCT05734170|Dietary Supplement|Cheerio Breakfast|Patients were instructed to consume one serving of Cheerios according to package instructions each morning for 30 days.
75891389|NCT03136822|Other|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
75891390|NCT03136822|Device|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
75891391|NCT04476680|Dietary Supplement|Vitamin D|Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
75891392|NCT04952350|Drug|Atorvastatin 40 Mg Oral Tablet|Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
75891393|NCT04952350|Other|Placebo|A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
75891394|NCT05376202|Drug|Cetuximab-IRDye800CW|Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
75448674|NCT03719417|Procedure|Unicompartmental Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery.
75448675|NCT03719417|Procedure|Extensive Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery with an additional surface being replaced concurrently
75891395|NCT03890588|Other|CKD enhanced clinical decision support|The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
75891396|NCT04812808|Drug|Bazedoxifene 20 mg|"Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events."
75891397|NCT01780675|Radiation|Radiation Prophylactic Cranial Irradiation|
76061510|NCT05249374|Drug|Recombinant Human Serum Albumin|10 g/bottle (20%, 50 mL)
75743286|NCT05734170|Dietary Supplement|Instant Oatmeal breakfast|The second group was assigned to consume one packet of instant oatmeal for 30 days.
75743287|NCT01006824|Other|Capsule endoscopy|Capsule endoscopy
75743288|NCT01006824|Other|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
75743289|NCT05734092|Device|Traditional orthodontic treatment|As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
75743290|NCT05734092|Device|Low-Level Laser|"The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage."
75743291|NCT04000074|Behavioral|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
75891398|NCT01780675|Radiation|Radiation Hippocampal Avoidance PCI|
76061511|NCT05249374|Drug|Human serum albumin|10 g/bottle (20%, 50 mL)
76061512|NCT05247580|Other|Hicks self-confidence scale, Karasek survey, Maslach Burnout Inventory|Questionnaires (Hicks self-confidence scale, Karasek questionnaire, Maslach Burnout Inventory) sent to hospital staff caregivers before and after (at 3 and 6 months) their SUrVIS training.
75743292|NCT04000074|Behavioral|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
75891399|NCT02262884|Device|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
75448676|NCT03719170|Behavioral|PPI De-prescribing Program|The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.
75448677|NCT03718052|Procedure|Early valve surgery (EVS)|Early valve surgery (EVS) within 72 hours of randomization
75448678|NCT03718052|Procedure|Conventional Care|Conventional care according to the 2015 European guidelines.
75891400|NCT02262884|Device|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
75891401|NCT03888872|Device|High tone power therapy|"1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week."
75891402|NCT03888872|Other|Selected Physical Therapy Program|"Selected physical therapy program: (For both groups).~Wobble board training:~Active range of motion exercises (AROM):~Gentle manual stretching exercises for both UL & LL:~Graduated gait training:"
75891403|NCT04788550|Combination Product|Fluoridated toothpaste|Group 1 will act as control group. Participants will be advised to brush twice daily using fluoridated toothpaste during the follow up periods. No other fluorides supplements will be allowed to use.
75891404|NCT04788550|Combination Product|fluoride varnish (5% sodium fluoride)|Approximately 0.5-1.0ml fluoride varnish will be applied on the tooth surface (labially) with the paint-on method fom canines to canines. No other fluorides supplements will be allowed to use.
75891405|NCT04788550|Combination Product|CPP-ACP plus crème group|Pea size CPP-ACP plus crème on the tooth surfaces using a clean fingers twice daily after brushing their teeth with fluoridated toothpaste. No other fluorides supplements will be allowed to use.
76061513|NCT04278742|Other|Patient education|Using a collaborative approach to engage patients in their own care, allowing patients to continue to have full control of their treatment. The clinician and patient co-creates the treatment plan.
76061514|NCT03338218|Drug|Volulyte 6%|Solution for infusion
76061515|NCT03338218|Drug|Ionolyte|Solution for infusion
76061516|NCT04400032|Biological|Mesenchymal Stromal Cells|The Mesenchymal Stromal Cells will be administered intravenously
76061517|NCT05262088|Other|video recording of general movements|"Video recording of general movements of children aged 3-5 days, then 4-5, 8-9, 12-13, 16-17, 20-22 weeks of life.~At the age of 12 weeks of life, an assessment will be made on the Motor Optimality Scale (MOS)."
76061518|NCT05226910|Device|tDCS and intensive therapies|This intervention will consist in the combination of tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
76061519|NCT05226910|Device|Sham and intensive therapies|This intervention will consist in the combination of sham tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
75448679|NCT03717428|Device|Daily Weighing Group|The Experimental group will weigh themselves everyday
75448680|NCT03717428|Device|Control group|This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
75448681|NCT03715829|Drug|PF-06651600|Induction dose 1. Oral tablet taken QD
75448682|NCT03715829|Drug|PF-06651600|Induction dose 2. Oral tablet taken QD
75448683|NCT03715829|Drug|PF-06651600|Maintenance dose A. Oral tablet taken QD
75448684|NCT03715829|Drug|PF-06651600|Maintenance Dose B. Oral tablet taken QD
75891406|NCT01677988|Drug|Neo-adjuvant Chemotherapy|"Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
75891407|NCT01677988|Radiation|Chemoradiation|"Chemoradiation may be administered at selected approved CTN sites.~Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~Unresectable → Off study. Subsequent treatment per patient's primary MD.~Resectable → Continue to Registration #3 for Surgical Resection"
75599048|NCT05848518|Other|Rehabilitation program|The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)
75599049|NCT05847387|Diagnostic Test|V-Check|Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
75743293|NCT00530712|Device|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
75891408|NCT01677988|Procedure|Surgical Resection|"Meets criteria for resectable* →pancreaticoduodenectomy (POD)~At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
75891409|NCT03864536|Behavioral|Cognitive Prescriptions|Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
75891410|NCT04538599|Drug|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
75891411|NCT02233634|Drug|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
75891412|NCT02233634|Other|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
75891413|NCT02233634|Other|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
75448685|NCT03715829|Drug|PF-06651600|Maintenance Dose C. Oral tablet taken QD
75448686|NCT03715829|Drug|placebo|placebo
75891414|NCT04692220|Other|Detection of Adverse Drug Events or Drug-Related Problems|Detection of Adverse Drug Events or Drug-Related Problems
75891415|NCT04508413|Other|KB295|KB295 is a novel glycan
75891416|NCT02233712|Biological|G17DT|
75891417|NCT04689490|Diagnostic Test|Cardiopulmonary exercise test|Only diagnostic tests
75891418|NCT04506853|Device|MED-EL Cochlear Implant System|Cochlear implant and audio processor
75891419|NCT02262962|Other|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
75891420|NCT02233790|Drug|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
76061520|NCT05524948|Other|Experimental Dentifrice|Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.
75599050|NCT05845918|Behavioral|PRISEM CEP|Participants in PRISEM CEP will undergo assessment and goal setting during the intake process to ensure that the program meets their needs. All participants partake in lifestyle programs in individual or group-based in-person activities that address cognitive, physical, social, and functional independence, education, and well-being goals.
75616403|NCT00885703|Drug|Fluconazole|"Step 1: [For participants randomized to Fluconazole] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: [For participants randomized to Ampho B only] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally."
75743294|NCT05733858|Device|tRNS|For tRNS, the electrical current is delivered alternatively (an alternating current). The stimulation intensity will be set as 1.5 to 2 mA (based on the tolerance of participants). The stimulation frequency will be random frequencies ranging from 101 and 640 Hz.The stimulation period of tRNS and tDCS will be 20 minutes.
75743295|NCT05733858|Device|tDCS|For tDCS, the electrical current is delivered in a continuous and consistent manner (direct current). The stimulation intensity will be the same as that of tRNS (1.5 to 2 mA based on the tolerance of participants), which is safe for stroke patients.The stimulation period of tRNS and tDCS will be 20 minutes.
75448687|NCT03715829|Drug|PF06700841|Oral tablet taken QD
75448688|NCT03715829|Device|narrow-band UVB phototherapy|Phototherapy will be combined with PF-06651600
75448689|NCT03712254|Drug|Fosphenytoin|Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
75891421|NCT02233790|Drug|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
75891422|NCT02547818|Drug|ALZT-OP1a|1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
75891423|NCT02547818|Drug|ALZT-OP1b|Anti-inflammatory
75891424|NCT02547818|Other|Placebo ALZT-OP1a|Non-active capsules
75599051|NCT05845918|Behavioral|PRISEM Remote|"Participants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants driving the direction and acting as peer support to one another."
75599052|NCT05833685|Other|no intervention|no intervention
75599053|NCT05832736|Procedure|Robotic hemi-prostatectomy with urethral preservation|Robotic hemi-prostatectomy with urethral preservation
75599054|NCT05828277|Drug|repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
75599055|NCT05827718|Behavioral|Method of Contact|Behavioral Intervention studied here is the method of contact (text vs. email vs. email+text).
75599056|NCT05827718|Behavioral|Source of Contact|Behavioral Intervention studied here is source of contact (personal physician vs. research team)
75599057|NCT05827718|Behavioral|Framing Method (Appeal to Altruism)|"Behavioral Intervention studied here is the framing method appeal to altruism"
75891425|NCT02547818|Other|Placebo ALZT-OP1b|Non-active tablets
75891426|NCT04457440|Behavioral|Intensive Lifestyle Intervention|This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.
76061521|NCT05524948|Other|Reference Dentifrice|Standard fluoride dentifrice containing 0.243% sodium fluoride.
76061522|NCT01839656|Drug|nusinersen|Administered by intrathecal (IT) injection
76061523|NCT03335332|Behavioral|High intensity exercise|The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
76061524|NCT03335332|Behavioral|Moderate intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
76061525|NCT05047900|Diagnostic Test|Rapid antigen testing kit|COVID-19 Saliva Antigen Rapid Test Tigsun COVID-19 Speichel Antigen-Schnelltest
75448690|NCT03712176|Behavioral|Lifestyle alteration|Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
75448691|NCT03711175|Procedure|Subscapularis repair|Utilizing fiberwire, high tensile strength suture
75448692|NCT03711175|Device|Shoulder implant|Reverse shoulder arthroplasty device
75448693|NCT03704441|Drug|Bupivacaine|bupivacaine dose
75448694|NCT03678259|Drug|124I-p5+14 Injection|124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge
75599058|NCT05827718|Behavioral|Framing Method (Social Proof or Perceived Scarcity)|"Behavioral Interventions studied here are the framing methods social proof and perceived scarcity"
75599059|NCT05827718|Behavioral|Framing Method (Opt-Out)|"Behavioral Intervention studied here is the opt-out framing method"
75599060|NCT05827718|Behavioral|Incentive Structure|Behavioral Interventions studied here are gain-framed vs. loss-framed incentives as well as guarantees incentives vs. lottery incentives.
75599061|NCT05809700|Drug|Freshly manufactured 35 kDa hyaluronan fragment|"This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded."
75891427|NCT04457440|Behavioral|Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention|This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
75891428|NCT02234024|Dietary Supplement|Supplementation of dairy-derived concentrated gangliosides.|
75891429|NCT02520076|Drug|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~Pre-transplant Day -1~Post-transplant Day 3~Post-transplant Day 7~Post-transplant Day 14"
75891430|NCT03752918|Drug|MDMA|A single dose of 1.5mg/kg will be administered once orally.
75891431|NCT03752918|Drug|Niacin|A single dose of 250mg will be administered once orally.
75891432|NCT04259320|Device|Beeswax containing barrier|Use beeswax containing barrier on each nipple after each breastfeeding.
75891433|NCT04259320|Biological|Breast milk|Apply breast milk on each nipple and areola after each breastfeeding.
75891434|NCT04058158|Drug|SB12 (proposed eculizumab biosimilar)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
75891435|NCT04058158|Drug|Soliris (eculizumab)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
75891436|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
75891437|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
75891438|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
75891439|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
75599062|NCT05808127|Behavioral|PainTracker|The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
75891440|NCT02546960|Biological|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
75891441|NCT02546960|Drug|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
75891442|NCT02234102|Device|Endoscopically guided laser ablation HeartLight system|
75891443|NCT02263196|Other|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
75448695|NCT03676153|Other|Nurse-provided guidance|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
75448696|NCT03676153|Other|Integrative medicine treatment program|Integrative medicine treatment program
75448697|NCT03660839|Drug|Artefenomel (OZ439)|Pharmaceutical form: Granules for oral suspension Route of administration: Oral
75448698|NCT03660839|Drug|Ferroquine (SSR97193)|Pharmaceutical form: Capsule Route of administration: Oral
75448699|NCT03660241|Drug|PF-04965842|PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
75448700|NCT03651102|Drug|Thalidomide and Hydroxyurea|Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day
75891444|NCT02263196|Other|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
76072031|NCT03418038|Other|Placebo Administration|Given normal saline IV
76072032|NCT03418038|Other|Questionnaire Administration|Ancillary studies
75448701|NCT03649802|Dietary Supplement|Low dose vitamin D3|Low dose arm-800 IU given daily
75448702|NCT03649802|Dietary Supplement|High dose vitamin D3|High dose arm-5000 IU given daily
75448703|NCT03641664|Behavioral|Family Centered Treatment|Family Centered Treatment® (FCT) is a promising practice for providing home-based services to families at-risk for their children being removed from home.
76072033|NCT03418038|Biological|Rituximab|Given IV
75743296|NCT05733858|Device|sham stimulation|For the sham stimulation condition, the electrode placement will be the same as the other real eletrical stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds to provide sensory feeling without actually stimulating the brain.
76061526|NCT01839188|Biological|PR5I|Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed [DTaP], Hepatitis B [HB; Recombinant DNA], Inactivated Poliovirus [IPV], and Haemophilus influenzae type b [Hib] conjugate vaccine [adsorbed]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
76061527|NCT01839188|Biological|Pediacel®|Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed [DTaP], Inactivated Poliovirus [IPV], and Haemophilus influenzae type b [Hib] conjugate vaccine [adsorbed]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
76061528|NCT01839188|Biological|NeisVac-C®|Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
76061529|NCT01839188|Biological|RotaTeq®|Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
76061530|NCT01839188|Biological|Prevenar 13®|Pneumococcal polysaccharide conjugate vaccine [PCV; 13-valent, adsorbed]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
75891445|NCT03343834|Biological|biological collection|"At D0:~blood samples~saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation"
75448704|NCT03641664|Behavioral|Level II or Level III Out of Home Placement|Residential care for children with emotional, behavioral, and/or mental health in North Carolina who have experienced a level of dysfunction that makes it impossible to function at an age appropriate level in their own homes or in a lower level of care. These services can be provided in a variety of locations from urban to rural, from facility based to community based and from public sector to private sector. This service provides a structured and supervised environment for the acquisition of skills necessary to enable the child to improve level of functioning to achieve and/or to maintain the most realistic level of independent function where earlier treatment gains are somewhat fragile and the child is subject to regression.
75599063|NCT05793060|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine 50 Mcg
75599064|NCT05793060|Drug|Dexamethasone Phosphate|Dexamethasone 4 mg
75448705|NCT03635385|Procedure|Apheresis technics|Blood draw will be performed for anti bodies dosages
75448706|NCT03634943|Other|Patients with Nutritional Support|Evaluation of Enteral Nutrition or Parenteral Nutrition or both administered to the patients needing artificial Nutritional Support
75448707|NCT03626792|Other|Hypertensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
75448708|NCT03626792|Other|Normotensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
75448709|NCT03616041|Device|Second-generation colon capsule endoscopy system|The PillCam (TM) Colon 2 which is a second-generation colon capsule endoscopy system, developed by Medtronic Inc. Colon capsule endoscopy, in contrast to current generation small bowel capsules, is capable of visualizing the entire lumen and mucosa from esophagus to rectum. This can be crucial for patients being screened or evaluated for colon disorders. This new generation of colon capsule endoscopy has a battery life of at least 10 hours and preserves energy using adaptive frame rate technology.
75599065|NCT05788848|Behavioral|VRCT|The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled and will utilize the VRCT over seven weeks within their home.
75599066|NCT05786300|Device|NMES+|"The Treatment Group will follow the rehabilitation protocol with the addition of the NMES+.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz."
75891446|NCT05160506|Drug|Hydrocortisone|Hydrocortisone is a steroid (corticosteroid) medication.
75891447|NCT05160506|Drug|Placebo|50ml of 0.9% NACL will serve as the placebo
75891448|NCT02236286|Behavioral|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
75891449|NCT05094778|Procedure|a single-portal palm approach|a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.
75891450|NCT02509598|Drug|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
76061531|NCT05223088|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
76061532|NCT05223088|Drug|Apatinib Mesylate|Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
76061533|NCT05223088|Drug|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
75891451|NCT02509598|Drug|Vital Blue Dye (optional)|A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
75891452|NCT02509598|Procedure|Lymph Node Mapping|Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
76061534|NCT05223088|Drug|Tegafur|Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
75448710|NCT03607318|Behavioral|iASIST|Integrated Alcohol and Suicide Intervention for Suicidal Teens
75743297|NCT05733858|Behavioral|digital MT|For the digital MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand while looking at the real-time image on the computer screen. The activities practiced during digital MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen). The amount of time exposed to intransitive and transitive movements will be balanced for each participant. The participants will practice 30 intransitive and 30 transitive tasks over the 20 training sessions, and the actual movements will be selected based on each individual's ability and his/her needs.
75891453|NCT02926573|Drug|Gabapentin|
75448711|NCT03579628|Drug|AsiDNA|"All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue."
75599067|NCT05786300|Procedure|Rehab|"The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
75891454|NCT02926573|Drug|Placebo|
75891455|NCT04477018|Dietary Supplement|Iron bis-glycinate chelate and vitamin C|28 mg iron; 240 mg vitamin C
75448712|NCT03579329|Procedure|Total Knee Arthroplasty|Effect of Total Knee Arthroplasty on Sarcopenia in Patients with Osteoarthritis in the Knee
75448713|NCT03575104|Drug|Daridorexant|Daridorexant will be administered as tablets, orally, once daily in the evening.
75448714|NCT03575104|Other|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
75891456|NCT04477018|Dietary Supplement|Iron bis-glycinate chelate|28 mg iron only
75891457|NCT04477018|Dietary Supplement|Placebo|Matched placebo
75448715|NCT03573557|Device|Pink Pad|Pink Pad made by Xodus Medical Inc. used for patients in steep Trendelenburg position during surgery.
75448716|NCT03573557|Device|Bean Bag|Vac-Pac Bean Bag made by Olympic used for patients in steep Trendelenburg position during surgery.
75448717|NCT03573557|Device|Gel Pad|Gel Pad used for patients in steep Trendelenburg position during surgery.
75448718|NCT03573115|Drug|Adapalene-Benzoyl Peroxide Gel 0.1-2.5%|Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
75891458|NCT02236442|Other|Recommendation to use global headache treatment protocol|"The global treatment protocol is :~Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~Provide a sound-proof helmet to the patient.~Provide a light-blocking google to the patient.~If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient."
75448719|NCT03569982|Other|Integrative medicine care|Including acupuncture, relaxation/breathing, and manual/touch modalities
75448720|NCT03569475|Drug|Levomilnacipran ER|Levomilnacipran extended-release oral capsules
75448721|NCT03569475|Drug|Fluoxetine|Fluoxetine oral capsules
75448722|NCT03569475|Drug|Placebo|Matching placebo oral capsules
75599068|NCT05773092|Drug|Oral S-1 + Oral Osimertinib|S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.
75743298|NCT00626795|Drug|TD1414 2% cream|BID 7 days
75448723|NCT03565380|Other|12-week community-based multi-model Tai Chi rehabilitation program|Participants will receive 12 x 90 minute sessions of supervised exercises over 12 weeks. In addition to usual care, supervised exercise will be held at the Center of Sports Training and Rehabilitation inside the University and each class will be restricted to no more than 8 participants to ensure sufficient personalized attention. Each training session involves warm-up together with stretching of lower extremity muscles, strengthening exercises of the major lower extremity muscle groups by Theraband, balancing exercise, Tai Chi training, and rest/ cool-down. All lower-extremity exercises will be performed bilaterally.
75448724|NCT03565380|Other|Usual post-operative care|No intervention will be provided
75599069|NCT05759962|Drug|LQT-1213|LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
75599070|NCT05759962|Other|Placebo|Matching Placebo
75599071|NCT05758935|Other|Rule-based chatbot intervention with therapist-guidance|The intervention is a mobile application designed as a rule-based chatbot. The chatbot will present psychoeducational text, videos and ask questions based on cognitive behavioral techniques. The adolescents will receive weekly therapist support within the mobile application, in addition to weekly contact by phone. The intervention has a duration of six weeks, with a total of six modules.
75616404|NCT00885703|Drug|Amphotericin B|Step 1: [For participants randomized to Ampho B] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
75448725|NCT03565380|Other|Untreated asymptomatic controls|No intervention will be provided
75891459|NCT05737654|Other|Exercise with augmented reality glasses|Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
76061535|NCT01838876|Drug|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
75599072|NCT05745402|Behavioral|Mobility Checkup for older adults|The Mobility Checkup (MC) for older adults is a 45-minute preventative physical therapy visit designed to maintain mobility during aging. It has two parts, measurement (25 minutes) and education (20 minutes). The 5 standardized measures of physical performance in the MC are Walking speed, single leg stance time (balance), Five rep sit to stand (muscular endurance, transitions), 6-meter walk test (general endurance), and Timed up from floor test (transitions). Participants are provided education structured into 4 elements. 1. They are told their performance scores 2. They are shown how their performance scores on each of the measures compare to age and sex-referenced normative values 3. They are provided information about what their performance predicts about their health 4. They are referred to an appropriate provider if there was a health or safety concern during their MC or they are educated to follow the recommendations for physical activity that are recommended by the CDC.
75891460|NCT02261402|Other|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
75448726|NCT03550144|Behavioral|Awe Walk|To examine the effect of weekly awe walks in cognitively healthy older adults.
75599073|NCT05743842|Device|TriSalus™ TriNav™Infusion System|Given by Infusion
75599074|NCT05743842|Diagnostic Test|Angiogram|X-ray photograph
75891461|NCT03629275|Combination Product|CTX0E03 Drug Product and delivery device|Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.
75599075|NCT05743842|Procedure|Y90-radioembolization procedure|procedure
75599076|NCT05734781|Other|Not Application as this is a qualitative study|Not Application as this is a qualitative study
75743299|NCT00626795|Drug|TD1414 2% cream|TID 7 days
75743300|NCT00626795|Drug|Bactroban® (mupirocin) 2% cream|BID 7 days
75743301|NCT01007214|Procedure|Prostatectomy|Elective prostatectomy
75743302|NCT00826553|Drug|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
75891462|NCT03629275|Drug|Placebo|Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
76061536|NCT01838876|Drug|Antidepressant Therapy (ADT)|ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
76061537|NCT03279250|Drug|Abiraterone Acetate|Given PO
76061538|NCT03279250|Drug|Apalutamide|Given PO
75599077|NCT05734443|Behavioral|non-treadmill trip training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.
75743303|NCT00826553|Drug|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
75616405|NCT04210258|Device|Etermis 3|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling facial moderate wrinkles (marionette lines) and/or to increase lip volume
75743304|NCT00626639|Drug|Placebo|Administered by intravenous (IV) bolus injection
75743305|NCT00626639|Drug|palifermin|Administered by intravenous (IV) bolus injection
75743306|NCT00626639|Radiation|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation [one fraction per day])
76061539|NCT03279250|Biological|Gonadotropin-releasing Hormone Analog|Given IM
76061540|NCT03279250|Drug|Prednisone|Given PO
76061541|NCT03279250|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
76061542|NCT01838642|Drug|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
76061543|NCT05007418|Biological|STI-1492|Anti-CD38 A2 KOKI DAR T cells
75448727|NCT03550144|Behavioral|Control Walk|To examine the effect of weekly walks in cognitively healthy older adults.
75448728|NCT03549962|Procedure|TKA|Total Knee Arthroplasty
75448729|NCT03546556|Drug|Fluorothymidine (FLT)|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
75448730|NCT03545191|Drug|Daridorexant 25 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
75891463|NCT05737498|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
76061544|NCT05240170|Device|RIRS|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
76061545|NCT05240170|Device|SWL|Patients who underwent SWL at our institution in the past five years. According to (a) the type of renal anomaly (rotation, position, or rotation/position anomaly), (b) the size of the stone (±5 mm), (c) location of the stone (lower polar or non-lower polar), and (d) density of the stone (>800 HU or ≤800 HU), matched cases will be selected for comparison.
76061546|NCT01611194|Drug|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
76061547|NCT01611194|Drug|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
76061548|NCT05181046|Device|Nanodropper adaptor|The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
76061549|NCT05181046|Other|Original eyedrop bottle/No Nanodropper|The original eyedrop bottle dispenses standard eyedrops.
75743307|NCT00626639|Drug|Cisplatin|100 mg/m^2 intravenously (IV) on days 1, 22 and 43.
76061550|NCT01813058|Drug|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~placebo i.e. saline 0.9% (intravenous injection)~intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
76061551|NCT01813058|Drug|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~TXA as previously described."
75599078|NCT05734443|Behavioral|treadmill trip training|Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
75599079|NCT05728073|Procedure|ERCP|Patients separated to two groups according to having a ERCP history before the operation
75743308|NCT00626561|Drug|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
75743309|NCT00626561|Drug|Paclitaxel|60 mg/m^2 IV weekly on days 1, 8, 15, and 22.
75743310|NCT00822653|Device|Calf Muscle Pump Stimulation|Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
75743311|NCT00822731|Drug|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
75743312|NCT03859661|Dietary Supplement|Fitabisc|Fitabisc is a chocolate cookie with vanilla cream filling which contains the most important antioxidants Vitamin C, Vitamin E, and the mineral Selenium. Fitabisc is not commercially available and for the purposes of this study it will be manufactured by Calerrific Ltd, which already produces a biscuit called CalBisc 100 as a simple calorie and nutritional supplement. Production takes place in a BRC Global Standard Grade A certified bakery operated by Farringford Foods in Portadown, Northern Ireland.
75599080|NCT05713279|Drug|SOC|"In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator."
75599081|NCT05707455|Other|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
75743313|NCT00826631|Procedure|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
75743314|NCT03880266|Drug|Glycopyrronium cloth, 2.4%|Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium
75743315|NCT03880266|Drug|Vehicle|Pre-saturated 100% polypropylene, nonwoven, fabric cloth
75743316|NCT00423891|Drug|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
75891464|NCT05201131|Procedure|Rezum|Rezum
75448731|NCT03545191|Drug|Daridorexant 50 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
75448732|NCT03545191|Other|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
75448733|NCT03543514|Other|TRIMODAL PREHABILITATION|"Trimodal prehabilitation application in the form of:~Control with the 6-minute walking test and podometer of physical activity~Dietary advice to be able to perform a hyperproteic diet~Mindfullnes to improve the emotional level."
75891465|NCT02261480|Other|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
75891466|NCT02261480|Other|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
75599082|NCT05699733|Device|mechanical traction for knee joint|All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions
75891467|NCT05759611|Other|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session
76061552|NCT05163262|Other|sexuality questionnaire|Questionnaire evaluating the sexuality of head trauma victims by comparing their sexual focus, the quality of their relationship, their self-esteem, their mood before the trauma to their current situation
76061553|NCT01867424|Drug|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
75891468|NCT05759611|Other|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
75891469|NCT00158860|Drug|Valaciclovir|1g once daily
75743317|NCT00830609|Drug|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb>12 g/dL if required over 20 additional weeks (Arm B2)
75891470|NCT00158860|Drug|Placebo|placebo
75743318|NCT00830609|Drug|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb>12g/dl over 4 or 24 weeks
75743319|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 24 weeks
75891471|NCT02234258|Behavioral|Cognitive behavioral social skills|
75599083|NCT05690659|Other|device and exercise|cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging
75599084|NCT05676359|Other|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
75599085|NCT05676359|Other|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
75599086|NCT05676359|Other|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
75743320|NCT00830609|Drug|ribavirin|ribavirin 800 mg/day for 24 weeks
75891472|NCT02234258|Behavioral|Psychoeducation|
75891473|NCT05201053|Diagnostic Test|Exploratory for different markers|Test biomarkers for development of mild, moderat or severe disease
75891474|NCT03629665|Behavioral|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
75891475|NCT03629665|Device|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
75891476|NCT02490488|Drug|Masitinib|
75891477|NCT02490488|Drug|Gemcitabine|
75891478|NCT02490488|Drug|Placebo|
76061554|NCT04986514|Other|Bio-banking without genetic analysis|For patients included in SCLERO-BIOBANK study, 2 blood samples will be collected at each SSc evaluation (usually once a year), in addition to the routine care blood collection.
76061555|NCT05491330|Drug|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
76061556|NCT05491330|Drug|Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
76061557|NCT05491330|Drug|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
75599087|NCT05676359|Other|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
76061558|NCT04601168|Device|kneeSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
76061559|NCT01811732|Drug|Delafloxacin|Delafloxacin
76061560|NCT01811732|Drug|Vancomycin|Vancomycin
76061561|NCT01811732|Drug|Aztreonam|Aztreonam
76061562|NCT01811732|Drug|Placebo|Placebo
76061563|NCT05146648|Device|Gondola AMPS|One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
76061564|NCT04400344|Other|No intervention|No intervention
76061565|NCT04399720|Procedure|Root canal treatment|Root canal treatment using a standard manual k file instrumentation and carrier-based root canal filling technique
76061566|NCT01836458|Drug|KAE609|Patients will receive KAE609 single dose at a different dose level in each cohort.
76061567|NCT05139004|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo AHSCT
76061568|NCT05139004|Biological|Basiliximab|Given IV
76061569|NCT05139004|Drug|Fludarabine Phosphate|Given IV
76061570|NCT05139004|Drug|Indium In 111-DOTA-Basiliximab|Given IV
76061571|NCT05139004|Drug|Melphalan|Given IV
76061572|NCT05139004|Biological|Palifermin|Given IV
76061573|NCT05139004|Radiation|Total Lymphoid Irradiation|Undergo TMLI
76061574|NCT05139004|Radiation|Total Marrow Irradiation|Undergo TMLI
75599088|NCT05676359|Other|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
75599089|NCT05676359|Other|Rheumatic disease comorbidity index|It is rated from 0 to 9 and comprises 11 comorbid conditions including lung disease, cardio-vascular disease, hypertension, diabetes, fracture, depression, cancer, and gastrointestinal ulcer
76061575|NCT05139004|Biological|Yttrium Y 90 Basiliximab|Given IV
76061576|NCT04073992|Behavioral|cognitive behavioral treatment of insomnia|A behavioral modification program consisting of 8 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
76061577|NCT01811186|Drug|Oxycodone/naloxone|Oxycodone/naloxone titration
75599090|NCT05676359|Other|Living will questionnaire|A questionnaire with 17 items about knowledge of the living will.
75599091|NCT05676359|Other|Perceptions of Health Outcomes Questionnaire|A questionnaire with 7 items about the probability of quitting the job, getting an infectious disease, requiring emergency medical attention, hospitalization or intensive care, dependence and death.
75599092|NCT05674903|Device|Verum stimulation with Diadem prototype|Diadem prototype device delivers focused low-intensity ultrasound stimulation
75599093|NCT05674903|Device|Sham stimulation with Diadem prototype|Diadem prototype device delivers active sham, unfocused low-intensity ultrasound stimulation
75599094|NCT05664932|Biological|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
75599095|NCT05664932|Biological|ZF2001|Intramuscular injection of ZF2001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
75599096|NCT05663086|Biological|One dose group|The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
75599097|NCT05663086|Biological|Two doses group|The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
75599098|NCT05663086|Biological|Aged 18-59 years|The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
75599099|NCT05663086|Biological|Aged 60 years old and above|The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
75743321|NCT00830609|Drug|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
76061578|NCT04414436|Behavioral|GYNEA- digital coping program for women after gynaecological cancer|6 modules with relevant information and tools for coping after cancer
76061579|NCT03240328|Biological|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
76061580|NCT04746196|Other|Serum galectin-3 concentration was measured.|Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
76061581|NCT01866098|Drug|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
76061582|NCT01866098|Drug|Placebo|
76061583|NCT04919356|Genetic|G2019S LRRK2|No cost genetic testing for G2019S LRRK2
76061584|NCT04399798|Drug|Baricitinib|4 mg/day for 7 days
76061585|NCT04897360|Behavioral|Increased breathing|hyperventilation to lower ETCO2
76061586|NCT04897360|Other|sharpened Romberg test (SRT)|Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
76061587|NCT04889326|Other|Retrospective data and biological samples|Analysis of data and biological samples collected during hospitalization:
76061588|NCT04885972|Drug|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
76061589|NCT04885972|Drug|Zilretta|Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.
76061590|NCT04885972|Drug|Placebo|Vehicle solution
76061591|NCT03985540|Behavioral|Behavorial; memory exercise|Memory training twice a week for 5 weeks.
76061592|NCT03985540|Behavioral|Placebo; memory exercise|Placebo Memory training twice a week for 5 weeks
76061593|NCT03985540|Behavioral|Behavioral: speed exercises|Speed training twice a week for 5 weeks.
76061594|NCT03985540|Behavioral|Placebo speed training|Placebo Speed training twice a week for 5 weeks.
75891479|NCT02261558|Other|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
75891480|NCT02261558|Other|Clinical Vocal Improvisation|* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
75891481|NCT02471222|Drug|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
75599100|NCT05659836|Device|Abbott SCS Systems|Patients will be implanted with Abbott spinal cord stimulation (SCS) systems (both trial and permanently-implanted systems) and provided with wearable sensors, and software applications presented on a mobile device.
75743322|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
75743323|NCT00822809|Drug|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
75743324|NCT00822809|Drug|Prednisolone|25 mg premedication
75743325|NCT00830687|Device|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
76061595|NCT04347772|Dietary Supplement|Oral Nutrition Support|Intensive Nutrition Intervention
75599101|NCT05637814|Diagnostic Test|SpO2/PIx Measurement and ML Algorithm|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured and an online ML inference model will be used to classify a newborn as healthy versus CCHD as new pulse oximetry data is collected.
75891482|NCT02471222|Other|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
76061596|NCT03263026|Drug|Enzastaurin Hydrochloride|R-CHOP + Enzastaurin (Kinenza®) 125 mg
75599102|NCT05623423|Other|(Admira Fusion, Voco GmbH, Germany)|cavity margins will be extended to the proximal area, incisal edge, facial and lingual surfaces All enamel margins will be beveled at a 45° angle to the external cavosurface.(approximately 0.5-2.0 mm) An impression for the upper anterior teeth will be taken to produce a silicon palatal index The proximal margins of the restorations will be achieved using the Unica anterior matrix teeth will be etched using 37% phosphoric acid gel for 30 s then rinsed with air water for 20 s A single coat of universal bond cured using and LED light curing unit for 10 s Using the chosen enamel shade of the ORMOCER Resin Composite a thin layer (0.5-1 mm) Unica matrix will used to produce the proximal margins of the restorations Contouring, finishing and polishing of the restoration will be done Dental floss and finishing strips will be used Rubber dam will then be removed and occlusion will be checked using an articulating paper
76061597|NCT03263026|Other|R-CHOP + placebo|R-CHOP + placebo
75599103|NCT05623423|Other|Methacrylate Based Composite|The exact same steps as in the intervention will be done but using the chosen shades of Methacrylate Based Composite Resin. (Ceram.X Spectra ST, Dentsply Sirona, UK)
75599104|NCT05615051|Device|Surface decontamination procedure aiming at reconstructive therapy|Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
75599105|NCT05613842|Drug|Copper-64 labelled SAR-Bombesin|radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
75743326|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
75743327|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
76061598|NCT04858360|Drug|Emla 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.
75743328|NCT00822887|Drug|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
75743329|NCT00822887|Radiation|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
75743330|NCT02549651|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
75743331|NCT02549651|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
75743332|NCT02549651|Drug|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
75891483|NCT05094310|Device|Acupuncture|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
75891484|NCT02649062|Biological|NGM282|
75891485|NCT02649062|Other|Placebo|
76061599|NCT04858360|Drug|EMLA 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.
75891486|NCT05094076|Radiation|chest x ray|The chest radiographs obtained will be classiﬁed according to the International Labor Organization (ILO) System for Classiﬁcation of Radiographs for Pneumoconiosis [ILO, 1980]. Film quality, profusion, and shape and size of opacities will be evaluated by this method. Radiographic evidence of silicosis was deﬁned as a profusion score of 1/0 or greater
75891487|NCT05093998|Drug|AV5080|oral hard gelatin capsules
75891488|NCT05093998|Other|Placebo|Hard gelatin capsules with a white body
75891489|NCT02264756|Other|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
75891490|NCT03067129|Drug|Glecaprevir/Pibrentasvir Adult Formulation|Co-formulated film-coated tablet (100 mg/40 mg)
75891491|NCT03067129|Drug|Glecaprevir + Pibrentasvir Pediatric Formulation|Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
75891492|NCT03136120|Drug|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
75891493|NCT03136120|Procedure|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
75891494|NCT01625390|Drug|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
75448734|NCT03537365|Dietary Supplement|Bovine Colostrum (BC) / intervention group|"Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first."
75891495|NCT01625390|Drug|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
75891496|NCT01625390|Drug|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
75891497|NCT01679236|Behavioral|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
75448735|NCT03537365|Dietary Supplement|FM85 / control group|"Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed."
75599106|NCT05603533|Other|Music and video-based group exercise therapy|Each exercise session will last up to 45min. The participants will follow this group exercise therapy twice a week for four months.
75599107|NCT05600101|Behavioral|Care.Coach|"Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates."
75599108|NCT05595720|Device|hight intenisty laser|7W(LAZR-207)/15W(LAZR-215&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
75599109|NCT05592951|Dietary Supplement|Crystal Light (once serving)|Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.
75616406|NCT04210258|Device|Etermis 4|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling deep and severe volume loss (nasolabial folds and/or marionette lines) and/or to increase lip volume
75891498|NCT01679236|Behavioral|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
75891499|NCT01625234|Drug|Phase I: X-396 (ensartinib)|Oral, ALK inhibitor
75891500|NCT01625234|Drug|Phase II: X-396 (ensartinib)|Expanded Cohort
75891501|NCT02264834|Drug|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
76061600|NCT04858360|Other|Vehicle cream for 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.
75891502|NCT02264834|Drug|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
75891503|NCT02264834|Procedure|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
76061601|NCT04858360|Other|Vehicle cream for 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.
75599110|NCT05592951|Dietary Supplement|Liquid IV with amino acids (one serving)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
75743333|NCT03999762|Device|sample prep|Effectiveness of a sample preparation protocol
76061602|NCT04858360|Other|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
75599111|NCT05592951|Dietary Supplement|Liquid IV with amino acids (two servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
75743334|NCT03999372|Biological|Hyaluronan binding system|Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
75743335|NCT03999372|Other|ICSI|Normal ICSI procedure
76061603|NCT01865552|Biological|SB4|SC administration
76061604|NCT01865552|Biological|EU sourced Enbrel|SC administration
76061605|NCT01865552|Biological|US sourced Enbrel|SC administration
76061606|NCT03205072|Device|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
75463143|NCT01872377|Radiation|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
76061607|NCT01809314|Drug|Epoetin beta|Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
76061608|NCT02984332|Other|Lower limb immobilisation (leg brace)|
75599112|NCT05592951|Dietary Supplement|Liquid IV with amino acids (three servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
75599113|NCT05589051|Dietary Supplement|Drink|Consume one tablet fully dissolved in 8 ounces. Take 2 tablets per day for adults (morning and evening) for 4 weeks
75599115|NCT05583747|Device|iTBS|rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. iTBS is a briefer form of patterned rTMS that has been shown to be effective against MDD, despite a stimulation period of 1-3 min rather than 30-40 min.
76061609|NCT01803464|Device|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
76061610|NCT01803464|Drug|Botox|Children who are candidates to receive Botox as part of their standard of care.
76061611|NCT01808690|Drug|Metformin|
76061612|NCT01808690|Drug|Placebo|
76061613|NCT04583618|Biological|Pneumococcal Conjugate Vaccine - formulation 1|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
75599116|NCT05579119|Drug|Sitagliptin 100mg|Sitagliptin 100 mg po once daily.
76061614|NCT04583618|Biological|Pneumococcal Conjugate Vaccine - formulation 2|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
75599117|NCT05579119|Drug|Glargine|Glargine once daily.
75599118|NCT05579119|Drug|Lispro|Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
75599119|NCT05575180|Drug|Acetazolamide 250Mg Tab|Oral acetazolamide
75599120|NCT05575180|Drug|Methazolamide Pill|Oral Methazolamide
75599121|NCT05575180|Drug|Placebo|Oral placebo
75616407|NCT04554784|Other|Conventional|Patients' condition will be continue managed by pain specialists with regular follow-ups and continue patients' active concurrent pain treatment such as taking analgesics, physiotherapy, massage, chiropractor.
75743336|NCT00826709|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
75743337|NCT00822965|Other|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
75743338|NCT00822965|Other|Phone Interviews|2 follow-up phone interviews.
75743339|NCT00822965|Behavioral|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
76061615|NCT04583618|Biological|Pneumococcal Conjugate Vaccine - formulation 3|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
76061616|NCT04583618|Biological|Pneumococcal 13 - valent conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
76061617|NCT04583618|Biological|Pneumococcal Vaccine Polyvalent|Pharmaceutical form:Solution for injection Route of administration: intramuscular
76061618|NCT04588870|Device|Pre operative computer based cochlear implant surgical simulation|Prior to surgery, the surgeon will perform virtual cochlear implant surgery on patient specific imaging data within a computer simulation program. The surgeon will be able to iterate the procedure on the simulator until achieving the best electrode array location is achieved with respect to scalar location and modiolar distance. A written and graphical surgical plan will then be developed that the surgeon can use in the actual surgery.
75891504|NCT05762419|Drug|Etoposide; Oral, 50 Mg|Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
75891505|NCT05762419|Device|Focused ultrasound with neuro-navigator-controlled sonication|Focused ultrasound sonication will be performed a maximum of three times a week for two weeks with two weeks of rest.
75891506|NCT04568408|Device|Xiaomi MiBand 5|Comparison of sleep-monitoring device against polysomnography (PSG)
75891507|NCT04458103|Device|Percutaneous RVAD|ProtekDuo or Impella RP
75891508|NCT02264912|Drug|antiplatelet drugs - P2Y12 antagonists|
75891509|NCT01437722|Drug|1% SPL7013 Gel|vaginal gel
75891510|NCT01437722|Drug|3% SPL7013 Gel|vaginal gel
75891511|NCT01437722|Drug|placebo gel|vaginal gel
75891512|NCT02263352|Drug|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
75891513|NCT02263352|Device|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
76061619|NCT04413734|Drug|Combination therapy|Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin
76061620|NCT04413734|Drug|Mono-chemotherapy|Gemcitabine plus Cisplatin by intravenous infusion
76061621|NCT03229798|Drug|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
75743340|NCT05733468|Drug|Theracal LC|After hemorrhage control , 1-1.5mm of TheraCal LC will be placed on the radicular pulp stumps followed by light curing, followed by the placement of IRM and composite restorative material after 2 weeks
75743341|NCT05733468|Drug|MTA|After hemorrhage control , a small ball like consistency of 2-3mm of MTA will be placed on the radicular pulp stumps, followed by the placement of IRM and composite restorative material after 2 weeks
76061622|NCT03229798|Combination Product|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
75599122|NCT05571033|Behavioral|Spinal reflex conditioning|Each participant will serve as their own control. The intervention is 30 sessions. The first 6 sessions are baseline measures of reflexes. The remaining sessions will engage participants in learning how to decrease their reflex activity in their calf muscle on the more-affected leg. Each intervention visit will involve 20 trials in which participants do not get visual feedback about their performance, then 225 trials with visual feedback.
75599123|NCT05549232|Device|Hypoxic Red Blood Cells|Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced
75743342|NCT00830843|Drug|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
75743343|NCT00830843|Drug|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
75743344|NCT00826787|Drug|Levetiracetam|750 mg tablet
76061623|NCT04808908|Biological|N-803|N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
76061624|NCT03927742|Behavioral|Shade + app with messaging|Shade wearable device and application with UV messaging activated
76061625|NCT03927742|Behavioral|Shape + app without messaging|Shade wearable device and application without UV messaging activated
75743345|NCT00823121|Procedure|freezing embryos by vitrification|vitrification by Cryotop method
75743346|NCT00823121|Procedure|fresh embryo transfers|fresh embryo transfers
75743347|NCT00823121|Drug|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
75743348|NCT00823121|Drug|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
75891514|NCT01435226|Drug|GS-5885|"Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD"
75891515|NCT01435226|Drug|GS-9451|"Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD"
75891516|NCT01435226|Drug|tegobuvir|tegobuvir 30 mg BID
75891517|NCT01435226|Drug|placebo to match tegobuvir|tegobuvir placebo BID
75891518|NCT01435226|Drug|placebo to match RBV|Ribovirin placebo BID
75891519|NCT01435226|Drug|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
75891520|NCT01679002|Drug|BIA 2-093|
75891521|NCT01679002|Drug|Oxcarbazepine|
75891522|NCT01428362|Drug|VI-1121|
75891523|NCT01428362|Drug|Placebo|
75891524|NCT02261870|Device|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
75891525|NCT04409509|Biological|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
75891526|NCT04409509|Drug|Placebo|CSL312 diluent administered intravenously
75891527|NCT02262104|Behavioral|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
75891528|NCT02262104|Behavioral|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
75891529|NCT02263430|Device|Deep Brain Stimulation|
75891530|NCT02610296|Drug|QPI-1002|IV injection
75891531|NCT02610296|Other|Placebo|isotonic saline
75891532|NCT04401865|Combination Product|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
75891533|NCT05206903|Other|Questionnaires|Questionnaires about pandemia process
75891534|NCT02263586|Behavioral|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
75891535|NCT02609048|Drug|Placebo Comparator|Placebo Capsule (2 taken once daily)
75599124|NCT05537376|Behavioral|SUicide Prevention by Peers Offering Recovery Tactics|Following the completion of a comprehensive mental health evaluation by a licensed VA provider, which includes a suicide safety plan, if a Veteran is having active thoughts of suicide or made a suicide attempt in past three months, they may be eligible for SUPPORT. In SUPPORT, the Peer Specialist and Veteran co-create a personalized suicide-focused recovery plan (SUPPORT Plan) in flexible, 50-minute weekly encounters. The SUPPORT Plan includes modules that focus on valuing recovery, building a hope kit and daily plan, setting recovery goals, and looking ahead to enhance the Veteran's safety plan. Learning strategies are incorporated into each module to promote salience and recall of intervention material. The Peer Specialist works closely with the Veteran's treatment team and uses the most recent safety plan in the Veteran's chart to help complete the SUPPORT Plan as well as reinforce the usage of the Veteran's safety plan.
75891536|NCT02609048|Drug|Experimental: Seladelpar / MBX-8025 50 mg|MBX-8025 50 mg capsule (1 taken once daily)
76061626|NCT04805944|Drug|Dolutegravir|Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
75743349|NCT00823121|Drug|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
75743350|NCT00423813|Drug|placebo|Oral Solution
75599125|NCT05533918|Behavioral|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
75599126|NCT05533918|Behavioral|Patient Navigation (PN)|"Patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation, Request PN and No PN. Each person will be randomly assigned between the two types."
75599127|NCT05533359|Behavioral|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
75743351|NCT00423813|Drug|Xyrem®|two doses
75743352|NCT01007604|Device|Peristaltic pulse PCD|Daily use for two hours
75743353|NCT01007604|Other|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
75743354|NCT03687372|Drug|A-101|hydrogen peroxide topical solution 45%
75743355|NCT03687372|Other|vehicle|vehicle as a topical solution
75743356|NCT00626405|Biological|bevacizumab|Given IV over 30-90 minutes
75743357|NCT00626405|Drug|carboplatin|Given IV over 30 minutes
75743358|NCT00626405|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
75743359|NCT00626405|Drug|temozolomide|Oral temozolomide on days 1-5
75891537|NCT02609048|Drug|Experimental: Seladelpar / MBX-8025 200 mg|MBX-8025 100 mg capsules (2 taken once daily)
75891538|NCT02262182|Other|KP group|
75891539|NCT02262182|Other|KM group|
75891540|NCT02265068|Drug|Ticagrelor|Treatment of ACS patients with Ticagrelor
75891541|NCT02262338|Drug|AGT-182|Recombinant HIRMAb-IDS
75891542|NCT01678924|Drug|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
75891543|NCT01678924|Drug|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
75891544|NCT02265302|Drug|BIIL 284 oral solution|
75891545|NCT02265302|Drug|BIIL 284 wetability improved formulation (WIF) tablets|
75891546|NCT02265302|Drug|Placebo|
75891547|NCT02263742|Behavioral|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
75891548|NCT02263742|Behavioral|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
75891549|NCT02265380|Device|Placement of IV catheter|
75891550|NCT02262416|Drug|leuprolide|normal saline
75891551|NCT01577654|Drug|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
75448736|NCT03533712|Dietary Supplement|Fortified balanced energy-protein (BEP) supplement|"The product contains the following target nutrients:~Total energy: 250-500 kcal per daily serving~Fat content: 10-60% of energy intake~Protein content: 16 g (range 14-18 g) with a Digestible Indispensable Amino Acid Score (DIAAS) of ≥ 0.9~Carbohydrate (CHO) Content: no specific recommendations, relative to fat and protein content.~Trans Fats: <1% energy intake Micronutrients include the following: A, D, E, K, B1 (thiamin), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), B9 (folate), B12 and C; minerals: iron, zinc, iodine, calcium, phosphorous, copper, and selenium.~The final composition of macro en micronutrients will be available after the acceptability testing (phase 1) and will be determined by 1) the product type and 2) the preferred taste."
75599128|NCT05533359|Behavioral|Conversational Agent (CA)|Patients in the CA condition will receive a link to an automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.
75599129|NCT05533359|Behavioral|Patient Navigation (PN)|"Participants in the PN condition will receive a call from a Community Health Worker to assist with the process of receiving a COVID test. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation. A person can be randomly assigned to either type, or no PN, or a combination of the two types."
76061627|NCT04805944|Drug|Bictegravir|Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
76061628|NCT04805944|Drug|Dolutegravir|Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
75599130|NCT05530954|Other|Mineral trioxide aggregate (MTA)|Materials for Vital Pulp Capping
75599131|NCT05530954|Other|Hard setting Calcium Hydroxide (Dycal)|Materials for Vital Pulp Capping
75599132|NCT05522205|Other|Regulated cannabis access in pharmacies|The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
75599133|NCT05518929|Drug|Ciprofol|The sedation of gastrointestinal endoscopy with Ciprofol
75599134|NCT05518929|Drug|Propofol|The sedation of gastrointestinal endoscopy with Propofol
75599135|NCT05518708|Drug|BI 3032950|BI 3032950
75599136|NCT05518708|Drug|Placebo|Placebo
75743360|NCT05454306|Device|Anser Clavicle Pin|The Anser Clavicle Pin is an intramedullary device that has been studied in 20 patients in an EU-based prospective case series.28 A 100% union rate was found. The Constant-Murley score at 1-year was 96.7 (SD 5). The Disabilities of Arm, Shoulder and Hand score was 5.1 (SD 10). There were no infections, neuropathy of the supraclavicular nerve or hardware irritation requiring removal of hardware. Three device-related complications (15%) occurred including plastic deformation, protrusion and hardware failure. VAS satisfaction was 8.9 (SD 1) at the 1-year follow up.
75743361|NCT05733234|Device|Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia|Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface
75599137|NCT05511649|Device|continuous electronic monitor|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University will receive 24-hour continuous cardiac monitoring until discharge.
76061629|NCT04805944|Drug|Dolutegravir|Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir
76061630|NCT04805944|Drug|Bictegravir|Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
76061631|NCT03906292|Drug|Imatinib|Imatinib 400 mg QD and asciminib 60 mg QD
76061632|NCT03906292|Drug|Nilotinib 300 mg|Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
76061633|NCT03906292|Drug|Dasatinib|Dasatinib 100 mg QD and asciminib 80 mg QD
76061634|NCT03906292|Drug|Asciminib|Asciminib 80 mg QD Monotherapy
75599138|NCT05510050|Dietary Supplement|Aloe Vera Extract 1|2 capsules taken daily for 30 days
75599139|NCT05510050|Dietary Supplement|Control|2 capsules taken daily for 30 days
75599140|NCT05510050|Dietary Supplement|Aloe Vera Extract 2|2 capsules taken daily for 30 days
75599141|NCT05498961|Other|Gallstone characteristics|stone size, number, the thickness
75743362|NCT05733234|Drug|Mechanical Treatment|Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
75743363|NCT00826865|Drug|Levetiracetam|750 mg tablet
75448737|NCT03533712|Dietary Supplement|Fe and folic acid supplement|Routine iron and folic acid supplementation.
75891552|NCT01577654|Drug|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
76061635|NCT04399642|Procedure|Arthroplasty|All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision
76061636|NCT04399564|Device|temporary hemodialysis catheters|Vascular access using temporary vs.long-term hemodialysis catheters
75599142|NCT05492136|Procedure|Additional margin coagulation|After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
75743364|NCT01007682|Other|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
75743365|NCT00830921|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
75891553|NCT01577654|Drug|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
75599143|NCT05488340|Drug|LBP-EC01 0.1 x IV dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
75599144|NCT05488340|Drug|LBP-EC01 0.01x IV Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
75599145|NCT05488340|Drug|LBP-EC01 IV Infusion Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
75448738|NCT03529838|Other|Combined exercise|The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
75891554|NCT01577654|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
75599146|NCT05488340|Drug|Placebo|Dose regimen selected from Part 1 of placebo (Tris buffer).
75599147|NCT05488340|Drug|LBP-EC01|Dose regimen selected from Part 1 of LBP-EC01 (1x10^10 - 1x10^13 PFU) per dose.
75599148|NCT05488340|Drug|TMP/SMX|TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
75599149|NCT05484596|Procedure|Measuring VA Coupling|Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
75599150|NCT05481216|Other|COVID-19|Diagnosed with COVID-19 infection
75599151|NCT05481216|Other|HIV-1 infection|Diagnosed with HIV-1 infection
75599152|NCT05479617|Other|Deep learning model|Use of deep learning model to predict individual patients disease course
75599153|NCT05477069|Device|Innovative medical device for sampling small intestine content|Ingestion of the medical device by the volunteer
75599154|NCT05477004|Drug|Ketamine|A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
75891555|NCT02608502|Biological|RSV-F Vaccine|
75891556|NCT02608502|Biological|Phosphate Buffer Placebo|
75448739|NCT03524911|Behavioral|CHFFF nutrition education|
75448740|NCT03523520|Drug|Methylnaltrexone Bromide 150 mg Oral Tablet|Methylnaltrexone Bromide 150 mg Oral Tablet
75599155|NCT05453058|Diagnostic Test|plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort|"Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice).~These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice."
75599156|NCT05450029|Drug|Sintilimab|6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
75599157|NCT05449132|Drug|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
75599158|NCT05449132|Drug|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
75599159|NCT05439434|Other|Fear of Pain Questionnaire for Children Short Form|administering the questionnaire twice, one week apart.
75891557|NCT02262494|Procedure|portable venous compression ultrasonography|venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)
75891558|NCT02262494|Procedure|venous compress ultrasonography|venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)
75891559|NCT02262494|Procedure|Doppler ultrasound of the lower limbs|Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
75891560|NCT03278548|Drug|Volulyte 6%|Solution for infusion
75599160|NCT05428267|Other|questionnaire|Completion of questionnaires (IIEF5/FSFI, SF 36, Fatigue Scale Score, Self Esteem Inventory, Hospital Anxiety and Depression Scale) during the pre-transplant consultation, then during a consultation 6 months after transplantation
75599161|NCT05428267|Other|blood collection|Collection of 2 tubes of 5mL of blood during a scheduled blood draw in the patient's care pathway. This sample will also be taken after the transplant (6 months later)
75599162|NCT05422001|Drug|low dose ketamine|"Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml"
75599163|NCT05422001|Drug|Placebo (saline)|Isotonic Saline
75891561|NCT03278548|Drug|Ionolyte|Solution for infusion
76061637|NCT04399564|Device|long-term hemodialysis catheters|long-term hemodialysis catheters
75891562|NCT02265458|Behavioral|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
76061638|NCT03672526|Device|measure of injection pressure by compuflo|injection pressure mesured by Compuflo
76061639|NCT03229174|Drug|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
76061640|NCT03229174|Drug|Placebo|Placebo (sugar pill)
75448741|NCT03523520|Drug|Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1|Methylnaltrexone Bromide 12 MG Subcutaneous Solution
76061641|NCT03227926|Drug|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
76061642|NCT03227926|Diagnostic Test|Molecular Screening|Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
75448742|NCT03523520|Drug|Naloxegol 25 MG Oral Tablet|Naloxegol 25 MG Oral Tablet
75891563|NCT01423058|Drug|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
75448743|NCT03518242|Drug|Cyclophosphamide|Given PO
75448744|NCT03518242|Drug|Methotrexate|Given PO
75448745|NCT03518242|Drug|Capecitabine|Given PO
75448746|NCT03518242|Procedure|Biospecimen Collection|Undergo biospecimen collection
75448747|NCT03501719|Drug|Number of drugs in the ART regimen|Triple therapy vs. dual therapy vs. monotherapy
75448748|NCT03500549|Drug|Pegcetacoplan|Complement (C3) Inhibitor
75891564|NCT01575470|Biological|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
75448749|NCT03500549|Drug|Soliris|Complement (C5) Inhibitor
75599164|NCT05408676|Device|electric stimulation therapy|Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)
75891565|NCT02236364|Device|Contour, Bayer Healthcare, LLC|Blood glucose measurement
75891566|NCT05735782|Diagnostic Test|Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome|Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group
75599165|NCT05399082|Device|Cryoprobe biopsy|A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
75891567|NCT05735782|Diagnostic Test|Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome|Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group
75891568|NCT03135392|Procedure|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
75448750|NCT03495557|Procedure|Control|Fascial closure with simple polydioxanone suture 2/0 stitches
76061643|NCT03227770|Device|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
76061644|NCT03227770|Device|hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
75448751|NCT03495557|Device|Experimental|Onlay polypropylene mesh placement (MN mesh)
75448752|NCT03481608|Other|Lauric acid (coconut oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.
75448753|NCT03481608|Other|No Lauric acid (olive oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.
75599166|NCT05399082|Procedure|Forceps biopsy|Biopsy forceps used to collect tissue
76061645|NCT03227146|Biological|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
76061646|NCT03227146|Biological|STSG|Transplantation of autologous split-thickness skin graft to the control area
76061647|NCT03615742|Other|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
76061648|NCT03615742|Drug|Budesonide|1.6mg of budesonide from a Turbuhaler.
76061649|NCT03615742|Other|Filtered Air|Exposure to HEPA filtered air, as a control.
76061650|NCT03615742|Other|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
76061651|NCT04562194|Device|NeVa Stent Retriever|mechanical neurothrombectomy
75599167|NCT05398068|Other|Exercises and Diet|"Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. For the Mediterranean diet protocol planned in training groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned.~A 10-week exercise training will be planned for the training group.~Aerobic exercise sessions will be planned as a 5-minute warm-up - 20-minute bicycle ergometer - 5-minute cooling-down program. The intensity of exercise will be planned to be of medium intensity according to the heart rate reserve (40-50%). According to the Modified Borg Scale, walking will be given 3 days a week at a intensity of 4-6, also as a home exercise.~Strengthening exercises will be planned with reference to 10 RM (repetition maximum) with theraband for large muscle groups (10 repetitions-3 sets)."
75599168|NCT05398068|Other|Diet|Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. A regular diet program will be planned for 10 weeks for the control group. . For the Mediterranean diet protocol planned in control groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned. After that, after 1 week, patients will be re-evaluated for compliance by a dietitian. And than, each patient included in the study will be evaluated for 2 weeks during the treatment period.
75599169|NCT05388461|Other|electroconvulsive therapy|electroconvulsive therapy
75599170|NCT05386342|Device|TufTex Over-the-Wire Embolectomy Catheter|The OTW Catheter can be used for the removal of emboli and thrombi. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
75891569|NCT03135392|Procedure|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
76061652|NCT04398472|Behavioral|KIND Challenge|The KIND challenge consists of nominating an activity to complete over a 4 week period. The activities involve doing an activity with others in your neighbourhood. These activities are positive, engaging and feasible to the average individual. Activities adhere to relevant country or state department health and safety guidelines. For example; having a chat with a neighbour online, or bringing in rubbish bins for an elderly neighbour.
75599171|NCT05386277|Device|TufTex Single Lumen Embolectomy Catheter|The SLC Embolectomy Catheter is indicated for the removal of arterial emboli and thrombi
75891570|NCT03135392|Procedure|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
75891571|NCT02265536|Drug|LY3022855|Administered IV
76061653|NCT01363297|Drug|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m^2 to 2.0 mg/m^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m^2."
76061654|NCT04758598|Device|Direct Selective Laser Trabeculoplasty (DSLT)|DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
75891572|NCT04413292|Diagnostic Test|ELISA assays and Westren blot analysis of survivin and fibulin-3 expression|expression analysis of biomarkers
75891573|NCT01418222|Drug|5-FU|Intravenous repeating dose
75891574|NCT01418222|Drug|FOLFOX regimen|Intravenous repeating dose
75891575|NCT01418222|Drug|Placebo|Intravenous repeating dose
75448754|NCT03480217|Behavioral|Multifaceted Implementation Strategy|"Key components include:~educational presentations to primary care providers at grand rounds~patient information materials on ABPM and HBPM~training registered nurses to assist providers with teaching patients to conduct HBPM~information on how to order ABPM and HBPM to clinicians, nurses and front desk staff via huddles, emails, and other electronic communications~a computerized EHR-embedded clinical decision support tool that prompts providers to recall the USPSTF hypertension guidelines and facilitates ordering of HBPM and ABPM for guideline-eligible patients~periodic feedback to primary care providers about clinic-level success with appropriately ordering ABPM and HBPM for eligible patients~an accessible, culturally-adapted and locally tailored ABPM service"
75448755|NCT03463018|Dietary Supplement|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
75448756|NCT03463018|Dietary Supplement|Placebo|Placebo tablet containing matching excipients to the active intervention
75891576|NCT01418222|Drug|bevacizumab [Avastin]|Intravenous repeating dose
75891577|NCT01418222|Drug|leucovorin|Intravenous repeating dose
75891578|NCT01418222|Drug|onartuzumab [MetMAb]|Intravenous repeating dose
75891579|NCT05092906|Other|LP with complementary hypnoanalgesia|The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.
75891580|NCT05092906|Other|LP with standard of care|"The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~EMLA (Lidocain+Prilocain) Cream/Patch~Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~Nitrous oxide"
75891581|NCT01413932|Drug|HT-2157|QD oral dosing
75891582|NCT01413932|Drug|Placebo|QD oral dosing
75891583|NCT02925793|Drug|DS107|
75891584|NCT02925793|Other|Vehicle cream|
75891585|NCT01256762|Drug|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
75891586|NCT01256762|Drug|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
75891587|NCT01256762|Drug|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
75743366|NCT00358150|Drug|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067[active moiety of eliglustat in plasma] trough plasma concentration was greater than or equal to [>=]5 nanogram per milliliter [ng/mL] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than [<] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
75743367|NCT00830999|Behavioral|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
75743368|NCT00830999|Behavioral|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
75743369|NCT00830999|Behavioral|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
76061655|NCT04758598|Device|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
75891588|NCT03135158|Other|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
75891589|NCT02268188|Other|education|Attend classes as part of Harvesting Health program
76061656|NCT04757116|Device|iTind|The iTind is implemented for 5-7 days
75599172|NCT05377489|Drug|RTX-GRT7039|RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
75599173|NCT05373992|Behavioral|Screen Time Restriction (ST-Restricted)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. Following the first 72-hours of restricted screen-time, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
75599174|NCT05373992|Behavioral|Aerobic Exercise (AE)|Engage in 30-minutes of aerobic exercise daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
75891590|NCT02268188|Other|nutrition intervention|Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program
75891591|NCT02268188|Behavioral|exercise intervention|Use FitBit to log daily steps as part of Harvesting Health program
75891592|NCT02268188|Other|questionnaire administration|Ancillary studies
75891593|NCT02268188|Other|laboratory biomarker analysis|Correlative studies
75891594|NCT02268188|Other|quality-of-life assessment|Ancillary studies
75891595|NCT04351945|Procedure|Blood test|Hormone levels will be measured just before transplantation, and three day after the transplantation. In case of the donors hormone levels will be defined during the explantation.
75891596|NCT05761717|Drug|Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection|Subcutaneous Injection
76061657|NCT04757116|Procedure|UroLift|UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
76061658|NCT04756804|Drug|70% v/v Isopropyl Alcohol Surgical Solution|Patient preoperative skin preparation
75891597|NCT01252628|Drug|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
75891598|NCT01252628|Drug|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
75891599|NCT01252628|Drug|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
76061659|NCT04756804|Drug|2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol|Patient preoperative skin preparation
76061660|NCT03199924|Drug|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
76061661|NCT03199924|Drug|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
76061662|NCT03199924|Drug|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
75891600|NCT01252628|Drug|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
75891601|NCT05206669|Behavioral|Health Messages|Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
75891602|NCT01239758|Biological|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
75891603|NCT01239758|Biological|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
75599175|NCT05373992|Behavioral|Screen-time restricted plus aerobic exercise (STR+AE)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) while concurrently engaging in daily aerobic exercise in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed STR+AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
75891604|NCT01239758|Biological|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
75891605|NCT05206045|Other|Standard of care|Standard of care for patients with Sezary Syndrome
75743370|NCT00830999|Behavioral|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
75743371|NCT00830999|Behavioral|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
75599176|NCT05373992|Behavioral|Stretching Only|Participants will be instructed to follow a prescribed stretching program for the first 72-hours following the initial clinic visit. Following the first 72-hours of prescribed stretching, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
75599177|NCT05370404|Other|Prescription by surgical team|The surgical team prescribes medications to the patient
75599178|NCT05370404|Other|Recommendation by surgical team|The surgical team recommends the patient to take over-the-counter medications
75599179|NCT05363631|Drug|Selenomethionine (SLM)|Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
75599180|NCT05363631|Drug|Axitinib|Axitinib is a small molecule tyrosine kinase inhibitor.
75599181|NCT05363631|Drug|Pembrolizumab|Pembrolizumab is a type of immunotherapy
75599182|NCT05362110|Drug|HCP1803-3|Take it once daily for 8 weeks orally.
75743372|NCT00831077|Drug|ORM-14540|i.v.
75599183|NCT05362110|Drug|RLD2002|Take it once daily for 8 weeks orally.
75599184|NCT05362110|Drug|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
75599185|NCT05362110|Drug|HPP2004|Placebo drug. Take it once daily for 8 weeks orally.
75599186|NCT05361551|Procedure|Liver ablation|Ablation needle placement An image-guidance device be used for planning of the procedure and for placement of the ablation needle
75599187|NCT05357833|Drug|Ferumoxytol infusion|Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
75599188|NCT05357833|Drug|Gadoteridol|Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
75599189|NCT05357833|Diagnostic Test|MRI Brain and Cervical Spine|3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
75743373|NCT00831077|Drug|ORM-12741|i.v.
75743374|NCT01007760|Other|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
75743375|NCT00823355|Drug|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
75743376|NCT00823355|Drug|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
75743377|NCT00823355|Drug|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
75743378|NCT00823355|Drug|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
75891606|NCT01236638|Drug|Momelotinib|Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
75891607|NCT04349371|Drug|Chloroquine|Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.
75891608|NCT04349371|Drug|Placebo oral tablet|Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
75891609|NCT01410188|Drug|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
75891610|NCT01410188|Drug|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
75891611|NCT01410188|Drug|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
75891612|NCT01408082|Drug|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
75891613|NCT01408082|Drug|Azasite|Azasite twice daily for 2 weeks
75891614|NCT01408082|Drug|Dexamethasone|Dexamethasone twice daily for 2 weeks
75891615|NCT01408082|Other|Vehicle|Vehicle twice daily for 2 weeks
75743379|NCT03999450|Behavioral|brief motivational intervention (BMI)|The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
75891616|NCT03071263|Drug|Patiromer|2 packets/day starting dose, administered orally
75891617|NCT03071263|Drug|Placebo|2 packets/day starting dose, administered orally
75599190|NCT05351203|Procedure|caudal block|". Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
75599191|NCT05351203|Procedure|Erector spinae block|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
75743380|NCT03999450|Behavioral|cognitive behavioral therapy|This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
75743381|NCT01049074|Other|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
75743382|NCT01049074|Other|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
75448757|NCT03441776|Other|Generalized Vestibular Rehabilitation Treatment|These treatment visits are available twice a week and each visit lasts 45 minutes. Individuals receiving GVRT are allowed to choose the frequency at which they want to attend and the program is designed for each subject to complete 8 visits within a period between 4 and 8 weeks. The ideal number of patients receiving treatment at each class is from 3 to 6 but the system has capacity for a maximum of 8. GVRT is a standard of care treatment option and is not considered research.
75599192|NCT05316701|Biological|Orca-T|engineered donor allograft
75743383|NCT05427630|Drug|THC ~2.5%|Cannabis flower containing THC ~2.5%
75743384|NCT05427630|Drug|THC ~5%|Cannabis flower containing THC ~5%
75743385|NCT05427630|Drug|THC ~10%|Cannabis flower containing THC ~5%
75599193|NCT05316701|Biological|Standard-of-Care|unmanipulated donor allograft
75599194|NCT05316506|Other|Anticipated Discomfort Language|This language involves pain descriptors provided from physician to patient during procedure.
75599195|NCT05316506|Other|Objective Descriptive Language|This language involves neutral/objective descriptors provided from physician to patients during procedure.
75743386|NCT05427630|Drug|Sham Cannabis|Cannabis flower from which the THC and CBD have been extracted
75743387|NCT01050556|Other|Placebo|daily, 24 weeks
75743388|NCT01050556|Dietary Supplement|folic acid|400 ug/d for 12 or 24 weeks
75743389|NCT01050556|Dietary Supplement|folic acid|800 µg/d for 12 or 24 weeks
75743390|NCT01050556|Dietary Supplement|creatine|3 mg/d for 12 weeks
75743391|NCT01050556|Dietary Supplement|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
75743392|NCT05890014|Dietary Supplement|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
75743393|NCT05889975|Device|interdental brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
75743394|NCT05889975|Device|single tufted brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
75743395|NCT05889975|Device|water irrigator|using water irrigator after manual tooth brushing twice daily with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation for 30 days
75743396|NCT05889962|Procedure|Pudendal nerve block|Patients who are randomized in the pudendal block group will receive bilateral pudendal nerve block with ropivacaine.
75891618|NCT03071263|Drug|Spironolactone|25 mg tablet/day starting dose, administered orally
75891619|NCT04462484|Behavioral|videoconference|The intervention is a person-directed, individual, primary occupational intervention. It will be carried out via videoconference in six sessions of 45 minutes (on a weekly basis). Through guided dialogue, individual difficulties and opportunities of each subject will be examined in order to gain self-awareness of personal characteristics (strengths, limitations, maximum workload capacity) in their particular set of job demands and resources. Participants are encouraged to adopt the set of self-care strategies in each dimension, adapting them to their specific context. Activities will be carried out in Spanish by the researcher.
75891620|NCT02268266|Device|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
75891621|NCT01546532|Drug|RLX030|RLX030 as intravenous infusion for 24 hours.
75891622|NCT01546532|Drug|Placebo|Intravenous infusion of Placebo over 24 hours
76061663|NCT01908907|Dietary Supplement|DHA oil|Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
75599196|NCT05295589|Procedure|Computed Tomography|Undergo CT scan
75599197|NCT05295589|Drug|Copanlisib Hydrochloride|Given IV
75599198|NCT05295589|Procedure|Magnetic Resonance Imaging|Undergo MRI
75599199|NCT05295589|Drug|Olaparib|Given PO
75599200|NCT05295589|Drug|Paclitaxel|Given IV
75599201|NCT05295589|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75599202|NCT05295589|Drug|Topotecan Hydrochloride|Given IV
75599203|NCT05294965|Drug|Fenoterol|Intravenous infusion
75743397|NCT05889962|Procedure|Placebo block|Patients who are randomized in the placebo group will receive bilateral pudendal block with normal saline.
75743398|NCT05889923|Device|With EDU|using the EDU to perform the procedure
75743399|NCT05889910|Procedure|Health education workshop|"The intervention will consist of 5 initial sessions, plus a reinforcement session at 6 months. The sessions will last 2 hours and will preferably be distributed one day a week.~The objective of the intervention is to reduce the fear of falling and falls in people over 65 years of age who live in the community. To this end, nursing interventions will be included to improve the knowledge, skills and attitudes of the participants regarding the improvement of their functional capacity, the prevention of falls and their preventive measures, as well as the improvement in the management of anxiety and coping with the fear of falling and falls.~The activities carried out during the intervention have been extracted from standardized nursing interventions through the Nursing Interventions Classification (NIC).~The following interventions and activities will be addressed: 1665, 5612, 6490, 6486, 4700, 5820 and 5230."
75743400|NCT05889884|Device|Extended maxillary fixed retainer|Bonding extended maxillary fixed retainer from right first maxillary premolar to left maxillary first premolar for 6 months then assessment of relapse using 3D superimposition , little index , lateral cephalometric assessment along with PDL assessment with quality of life ,function and speech assessment
75743401|NCT05889871|Drug|Standard endocrine therapy plus Apatinib|Standard endocrine therapy plus Apatinib
75891623|NCT04314115|Other|Mindfulness|Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.
75891624|NCT04314115|Other|Systemic therapy|Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
76061664|NCT01908907|Dietary Supplement|(MCT) Control oil|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
76061665|NCT04398940|Drug|TQ-B3139|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
76061666|NCT04632199|Drug|111In-IPN01087 Low dose|Administered once via slow intravenous injection.
76061667|NCT04632199|Drug|111In-IPN01087 High dose|Administered once via slow intravenous injection.
75599204|NCT05294965|Other|Mild cold exposure|Body surface cooling
75599205|NCT05290714|Behavioral|Mentalization-Based Treatment for Children (MBT-C)|MBT-C will involve 12 paralel individual sessions with the parents and children separately conducted by two different therapists.
75599206|NCT05290714|Behavioral|Parenting and Social Skills Group|Parenting/social skills groups will be co-led by two therapists and involve 12 group therapy sessions with the parents and their children separately (10 parents and children per group).
75599207|NCT05289713|Procedure|appendectomy|Laparoscopic appendectomy is performed within 18 hours after randomization in the surgery group. Patients in the symptomatic treatment group are carefully monitored and the same intervention (laparoscopic appendectomy) is performed in case of treatment failure.
75599208|NCT05287867|Biological|Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)|Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.
75743402|NCT05889832|Diagnostic Test|measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops)|"Resting heart rate (HR), heart rate variability (HRV) and breathing rate (BR) will be measured (estimated) with the use of remote photoplethysmography (1-minute face video analysis with Shen.AI Vitals software).~Reference measurements will be taken simultaneously (chest ECG for the calculation of HR and HRV; impedance pneumography for BR)."
75891625|NCT04314115|Other|Cognitive behavioral therapy and positive psychology|Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
76061668|NCT03826498|Biological|CP CB-MNC injection|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
75743403|NCT05889806|Other|Observational Study Only. NO Intervention.|Observational Study Only. NO Intervention.
75448758|NCT03441776|Other|Individualized Vestibular Rehabilitation Treatment|Individuals receiving IVRT are scheduled depending on their individual needs and PT availability. These visits require one-on-one time with a PT. Individuals are commonly seen by the PT 3 times at two week intervals. These visits last 30 minutes and include PT evaluation designed to instruct patients on exercises for them to perform on their own. IVRT is a standard of care treatment option and is not considered research.
75448759|NCT03438838|Procedure|Laparoscopic Heller's myotomy|"Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach"
75448760|NCT03438838|Procedure|Anterior Fundoplication|The Fundus was sutured with 3 stitches on either side of the esophagus to right and left crus of diaphragm using ethibond(1-0) beside intervening stitch over esophagus. Width of fundoplication is kept approximately at 2cm. The proximal short gastric vessels were divided only if the fundus is insufficiently mobile
75599209|NCT05287867|Other|Sham procedure|"Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything."
75599210|NCT05280743|Drug|Oxycodone|exposure to opioids after Cesarean Section
75599211|NCT05278520|Procedure|Total hip arthroplasty|Hip joint replacement surgery. Elective for RA and OA cases.
75599212|NCT05267899|Drug|WGI-0301|WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
75743404|NCT05889767|Other|Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)|"All participants will complete two exercise sessions:~VO2 max test on a cycle ergometer~Moderate exercise session (45 minutes at 65% measured VO2 max)"
75743405|NCT05889728|Drug|[68Ga]GA-NeoB|Is a positron emission tomography (PET) imaging agent, intended as a selection tool for [177Lu]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).
75743406|NCT05889676|Diagnostic Test|VEMP by bone conduction|New bone conducted VEMP elicited by transducer B250
75891626|NCT02265614|Genetic|PGS|
75891627|NCT02263898|Drug|Raf kinase inhibitor LGX818|Given PO
75891628|NCT02263898|Drug|binimetinib|Given PO
75891629|NCT02263898|Other|laboratory biomarker analysis|Correlative studies
75891630|NCT04310839|Procedure|Colectomy|colectomy due to neoplastic (stage 1) or diverticulosis
75891631|NCT01403636|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
75891632|NCT03629509|Behavioral|BEFORE decision aid|Implementation of the BEFORE decision aid in clinical practice
75891633|NCT03629509|Behavioral|BEFORE decision aid|Implementation of the BEFORE decision aid on RUBY communication portals
76061669|NCT03826498|Other|Standard therapy|The standard therapy can include drugs, special psychology training etc.
76061670|NCT04746430|Drug|Dexamethasone|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
76061671|NCT04277650|Other|Machine learning algorithm|machine learning directed identification of radiotherapy or chemoradiotherapy patients at high-risk for emergency department acute care and/or hospitalization
76061672|NCT03832270|Behavioral|Parents InC|Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.
75448761|NCT03435185|Procedure|Lidocaine injections|Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.
75448762|NCT03435185|Procedure|Saline injections|Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve
75448763|NCT03423069|Dietary Supplement|Diet low in FODMAPs|A strict restriction of all high FODMAP foods for the time of observation. All these foods will be identified by appropriate nutritional visits and alternatives will be suggested to ensure the diet is nutritionally adequate.
75769166|NCT01250314|Other|Biological, biochemical and genetic samples|"*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~Homocysteine~IGF1~Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way."
76061673|NCT03832270|Behavioral|Incredible Years|Also based on social learning theory but focus is not specifically on ADHD.
76061674|NCT03258892|Other|Educational Intervention|Receive STG
76061675|NCT03258892|Other|Quality-of-Life Assessment|Ancillary studies
76061676|NCT03258892|Other|Survey Administration|Ancillary studies
75599213|NCT05255913|Drug|Nanosilver|preventive material for arresting caries
76061677|NCT04277494|Other|Clorethyl cold spray® (Vapocoolant spray)|From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application.
76061678|NCT04277572|Procedure|Aortic valve replacement|Aortic valve surgery
76061679|NCT04430842|Drug|QBS10072S|QBS10072S targets cancers with high LAT1 expression.
76061680|NCT04686838|Behavioral|READyR II: A|Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.
75599214|NCT05255913|Drug|Silver diamine fluoride|preventive material for arresting caries
75599215|NCT05248386|Drug|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
75599216|NCT05248386|Drug|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
76061681|NCT04686838|Behavioral|READyR II: B|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.
76061682|NCT04677010|Other|Cycle exercise|10 weeks of cycle exercise on a cycle ergometer with motor.
76061683|NCT04277806|Behavioral|New Oral feeding process|From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
76061684|NCT04666402|Other|Blood tests for Single Nucleotide Polymorphisms|This extra test would be performed on participants assessed in the specialist liver clinic. This test would require an extra 5ml of blood to be taken at the time of routine blood tests for clinical purposes.
75599217|NCT05247320|Drug|Sotalol Injection|Standard of care IV sotalol infusion for atrial arrhythmias
75599218|NCT05245695|Other|Observational study, no intervention|Observational study, no intervention
75599219|NCT05238714|Drug|venglustat|Powder for Oral solution
75599220|NCT05228496|Drug|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
75599221|NCT05228496|Drug|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 1 cycle of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
75769167|NCT03907696|Other|Anti-stigma interventions curriculum|educational curriculum aimed at reducing stigma
75891634|NCT03629509|Behavioral|BEFORE decision aid|Review impact of BEFORE decision aid implementation in clinical practice
75891635|NCT05200663|Drug|Tab Tamoxifen 10 mg|Tablet tamoxifen 10mg twice a day for 6 months.
75891636|NCT05200663|Drug|Tab Tamoxifen 10mg,Cap vitamin E 400mg|Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
75891637|NCT02268344|Device|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
75891638|NCT05758519|Drug|QLS1128|QLS1128
75891639|NCT05758519|Drug|Placebo|Placebo
75891640|NCT02268422|Drug|Buprenorphine|7 day patch
75891641|NCT05758363|Dietary Supplement|Consumption of dietary supplement.|Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.
76061685|NCT04666402|Diagnostic Test|Faecal microbiome analysis|This test will be undertaken for all participants who give consent and are assessed through the new liver care pathway, in the community liver assessment clinic. All participants will be given the equipment to take a stool sample at the time of presentation at the community liver assessment clinic and asked to return the sample to the clinic. The sample will be processed to remove genetic material so the microbiome can be identified.
76061686|NCT04666402|Diagnostic Test|Serum for diagnostic biomarkers|Blood samples will be taken alongside blood taken for clinical assessment. In total, an extra 5ml of blood. These samples will be used to explore novel blood biomarkers using ELISA and mass-spectroscopy techniques in the University of Manchester.
75448764|NCT03423069|Dietary Supplement|Specific dietary advice for IBS|Dietary recommendations such as limitation of alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoidance of chewing gums and sweeteners containing polyols; small and frequent meals; avoidance of stressful conditions and eating slowly.
75599222|NCT05223855|Other|Physiotherapeutic hydrotherapy treatment|"Physiotherapeutic hydrotherapy treatment The intervention consists of physiotherapeutic one-on-one treatment in a 34-36 degrees centigrade hot water, where the participants are placed supine in the water supported by the physiotherapist as well as buoyant aqua noodles. The physiotherapist supports and moves the participants in the water and adapts to the participant's reaction.~The combination of heat, water, movement and touch affects the musculoskeletal and neuromuscular systems and thus has a depth-relaxing effect (Schoedinger, 2010)."
75599223|NCT05214599|Drug|Budesonide Gel|Twice daily regimen
75599224|NCT05194345|Behavioral|Autism Eats nutrition intervention|The Autism Eats intervention group will spend about 8.5 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, and a 60-minute exit interview). The Autism Eats intervention group EI provider will spend about 12 hours over 5 months (two 90-minutes training sessions, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, 10-minute fidelity checklist completion after each session, and a 60-minute exit interview).
75769168|NCT03973710|Dietary Supplement|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
75769169|NCT03973710|Dietary Supplement|Placebo controls|placebo with a similar appearance to probiotics supplement
75891642|NCT05758363|Other|Consumption of control product|Consumption of 1 capsule per day of control product of identical appearance with breakfast.
75448765|NCT03417349|Device|Sofia|The SOFIA™/ SOFIA™ PLUS Catheter will be used in removal/aspiration of emboli and thrombi following the CE marked Instructions For Use. Enrollment into the study does not change the routine care at the site provided to the patient requiring mechanical thrombectomy treatment.
75448766|NCT03411889|Diagnostic Test|MRI scanning|MRI scanning during tear drainage
75448767|NCT03410342|Other|LFV|1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
75891643|NCT01522196|Drug|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
75891644|NCT01522196|Other|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
75891645|NCT01236404|Drug|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
75891646|NCT01236404|Drug|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
75891647|NCT05758285|Other|AI-Based Prediction of Treatment Engagement and Outcomes|AI-based algorithms and prediction models of treatment engagement and outcomes based on data from the Online Therapy Unit by Prof. Heather Hadjistavropoulos will be trained to predict symptom improvement of patients from pre- to post-digital psychotherapy intervention and to predict patients' engagement with the digital psychotherapy intervention and to predict patient drop out probability. For prediction model estimation, state of the art AI-based algorithms, such as XGBoost, is used . XGBoost is a machine learning method developed by refining previously established decision-tree-based methodologies. Data is split into training and testing sets (e.g., 80/20 split).
75891648|NCT02268578|Device|Transcranial Direct Current Stimulation|2mA tDCS
75599225|NCT05194345|Behavioral|We Can! enhanced usual care|We Can! EUC control group will spend about 3 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, one 25-30 minute nutrition session, and a 60-minute exit interview). We Can! EUC control group EI provider will spend about 4.5 hours over 5 months (two 90-minutes training sessions, one 25-30 minutes session, 1-2-minute written material distribution at their 9 weekly EI sessions, and a 60-minute exit interview).
75891649|NCT02268578|Procedure|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
75891650|NCT04220671|Biological|measles vaccine|Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection
75891651|NCT04220671|Other|Saline|0.9% NaCl
75891652|NCT01400594|Drug|HTU-520 Patch|Terbinafine hydrochloride patch
75891653|NCT01400594|Other|Placebo Patch|Treatment with Placebo Patch
75891654|NCT05049343|Drug|SAGE-904|SAGE-904 oral solution.
75891655|NCT05049343|Drug|Placebo|Placebo oral solution.
75891656|NCT05049343|Drug|Ketamine|Ketamine intravenous (IV) infusion.
75599226|NCT05192343|Device|Virtual Reality and nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the virtual reality and nature sounds application group watched a video with a nature view with virtual reality glasses and listening nature sounds.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women include in the virtual reality and nature sounds application group will make to watch a video with a nature view with nature sounds for 15 minutes before and during the HSG procedure.~Each woman was shown the same video."
75891657|NCT01569919|Biological|TroVax®|Dose of 1 x 10^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
75891658|NCT01569919|Drug|Pemetrexed|500 mg/m^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
75891659|NCT01569919|Drug|Cisplatin|75mg/m^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
75891660|NCT01569919|Dietary Supplement|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
75448768|NCT03410342|Other|HFV|4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
75891661|NCT01569919|Dietary Supplement|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
75891662|NCT01569919|Drug|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
75448769|NCT03410342|Other|CC|4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
75448770|NCT03383380|Drug|Rapamycin|Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.
75891663|NCT05205187|Procedure|Healthy control specimen collection|Collecting blood and feces from healthy population.
75891664|NCT05205187|Procedure|Non-Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Non-Borrmann IV patients.
75891665|NCT05205187|Procedure|Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Borrmann IV patients.
75891666|NCT01399580|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
75891667|NCT01399580|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
75891668|NCT04069585|Device|RHA® Redensity with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
75891669|NCT04069585|Device|RHA® Redensity with lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
76061687|NCT03771430|Behavioral|Osteoarthritis education, exercise and CBT|"Osteoarthritis Education~60-min session by AktivA trained PT)~Signs/symptoms, risk factors, weight control, treatment~Importance of physical activity~Appropriate activity & training modalities~Exercise and CBT Support~60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~Warm-up session~Strengthening exercises~Functional exercises~Stretching~Monitoring of CBT progress~Review of CBT lessons learned~Integration of CBT skills~Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~Pain causes & prevention~Pain management~Health promotion & stress reduction at home & work~Adapting for leisure & work~Controlling flare-ups~Maintaining & improving results"
76061688|NCT03771430|Procedure|Total Knee Arthroplasty|Standard total knee arthroplasty will be performed.
76061689|NCT03197662|Drug|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
76061690|NCT03197662|Drug|Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
75599227|NCT05192343|Other|nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses will put on and training was given to continue. After the groups were formed, a nature-based sound was played to the women in the nature sounds group before and during the HSG shooting.~Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes."
76061691|NCT04391062|Drug|Gliolan|patient will receive 5-ALA 4 to 6 hours before surgery
76061692|NCT04391062|Device|Intraoperative PDT|"The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes)."
76061693|NCT04384276|Other|The Weigh Easy System|By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.
75891671|NCT03969433|Device|TMSi Porti|Data collections
75448771|NCT03373097|Biological|GD2-CART01|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
75599228|NCT05189275|Dietary Supplement|Daily Beverage Intervention|Individuals will consume one of 4 beverages, daily for 8 weeks.
75599229|NCT05187910|Behavioral|Speech Therapy|Training with a Speech Language Pathologists for voice disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
75448772|NCT03366792|Device|Artemis™ software system|Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
75448773|NCT03350997|Behavioral|Trial 2 Exercise|During the exercise session, subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
75891672|NCT03969433|Device|Bloomlife sensor|Data collections
75599230|NCT05187910|Behavioral|Swallowing Therapy|Training with a Speech Language Pathologists for swallowing disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
75599231|NCT05187910|Behavioral|Upper Airway Therapy|Training with a Speech Language Pathologists for upper airway disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
76061694|NCT04384276|Other|Retrospective Control|No interventions will be administered to the historical control group.
76061695|NCT03247582|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
76061696|NCT01808612|Drug|Fluoxetine|
75599232|NCT05183204|Drug|Paxalisib|Patients will receive paxalisib starting at a dose of 45 mg/day. If well tolerated after 28 days, the dose of paxalisib will be increased to 60 mg/day.
75599233|NCT05183204|Drug|Metformin|Patients will receive metformin on Cycle 1, Day 1 at a starting dose of 850 mg QD, and if tolerated, will be increased to 850 mg BID on Cycle 2, Day 1 (1700 mg/day). If that dose is tolerated, metformin will be increased to 850 mg TID (2550 mg/day) beginning on Cycle 3, Day 1.
75599234|NCT05183204|Other|Ketogenic Diet|The ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis starting on Cycle 1, Day 1 and continuing throughout the trial.
76061697|NCT01808612|Drug|Placebo|
76061698|NCT01908829|Drug|mirabegron 25 mg|Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
76061699|NCT01908829|Drug|mirabegron 50 mg|Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
76061700|NCT01908829|Drug|solifenacin 5 mg|Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
76061701|NCT01908829|Drug|solifenacin 10 mg|Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
75599235|NCT05181748|Biological|Autologous platelet rich plasma|Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.
75448774|NCT03350997|Behavioral|Trial 1 Exercise|During the exercise session, subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
75891673|NCT00157196|Biological|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide [L-BLP25]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
76061702|NCT01908829|Drug|mirabegron 25 mg matching placebo|Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
75599236|NCT05181644|Device|EmoLED treatment|Treatment with the EmoLED device consists of irradiating each area of 5 cm in diameter of the lesion for 60 seconds; if the lesion is larger than 5 cm in diameter, the applications will be repeated up to cover the entire area of interest. EmoLED treatment is additional to the standard therapy for the patient.
75599237|NCT05181644|Procedure|current Standard of Care|The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
75599238|NCT05179928|Procedure|Erector Spinae Plane Block (ESPB)|Postoperative Bilateral Ultrasound-guided ESPB
75599239|NCT05179928|Procedure|Rectus Sheath Block (RSB)|Postoperative Bilateral Ultrasound-guided RSB
76061703|NCT01908829|Drug|mirabegron 50 mg matching placebo|Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
75599240|NCT05179603|Drug|THOR-707|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
76061704|NCT01908829|Drug|solifenacin 5 mg matching placebo|Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
76061705|NCT01908829|Drug|solifenacin 10 mg matching placebo|Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
75599241|NCT05179603|Drug|Pembrolizumab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
75891674|NCT00157196|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
75599242|NCT05178173|Other|Placebo Comparator: Sterile Water|Sterile Water Placebo Comparator
75599243|NCT05178173|Other|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
76061706|NCT04277338|Drug|SPECT|One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
76061707|NCT01773122|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
76061708|NCT01773122|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
76061709|NCT01773122|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
75891675|NCT00157196|Other|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
75891676|NCT03066193|Drug|Dronabinol and Palmitoylethanolamide|Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
75891677|NCT02265926|Device|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
76061710|NCT01773122|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
76061711|NCT01808534|Drug|palifosfamide|Given IV
76061712|NCT01808222|Drug|FACBC|Participants will receive a bolus of anti-[18F]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
76061713|NCT04343482|Device|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing
76061714|NCT01772576|Device|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
76061715|NCT03192358|Diagnostic Test|Videofluoroscopic Swallowing Examination|During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.
76061716|NCT03192358|Other|Tongue Strength Measurement|"We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy)."
76061717|NCT03218800|Combination Product|Ertapenem|"Dose: 1g per day if creatinine clearance > 30mL/min or 500 mg per day if creatinine clearance < 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes."
75891678|NCT03922321|Drug|RVT-1401|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
75891679|NCT02263976|Drug|BEA 2180 BR|
75891680|NCT02263976|Drug|Placebo|
75891681|NCT02263976|Device|Respimat® A 4|
76061718|NCT01802216|Procedure|Scaling and root planing|non-surgical periodontal disease treatment
76061719|NCT01802216|Drug|Minocycline|antibiotic microspheres
76061720|NCT04760158|Other|Exercise|Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
76061721|NCT03621904|Drug|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
75891682|NCT02263976|Drug|Methacholine Chloride|methacholine challenge test
75891683|NCT02263976|Drug|Spiriva|
75891684|NCT02264054|Drug|[14C]talsaclidine, oral|
76061722|NCT01808144|Drug|lesinurad|Tablets, 400 mg once daily (QD)
75448775|NCT03348020|Procedure|Blood Donation|Subjects will donate blood within ~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.
75448776|NCT03342053|Drug|RO7234292 (RG6042)|Intrathecal injection
75599244|NCT05178173|Other|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
75891685|NCT02264054|Drug|[14C]talsaclidine, iv|
75891686|NCT01503944|Drug|18F-AV-133|185 MBq
75891687|NCT01503944|Drug|18F-AV-45|185-370 MBq
75891688|NCT01382654|Drug|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
75891689|NCT01382654|Drug|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
75891690|NCT01382654|Drug|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
75891691|NCT01382654|Drug|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
76061723|NCT01808144|Drug|lesinurad|Tablets, 200 mg QD
76061724|NCT01808144|Drug|febuxostat|Tabletsm 80 mg QD
76061725|NCT01801982|Other|non-interventional|non-interventional
76061726|NCT02085070|Drug|MK-3475|IV MK-3475
76061727|NCT01808066|Device|Groundskeeper|Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
76061728|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
76061729|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
76061730|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
76061731|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
75599245|NCT05164341|Drug|metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
75743407|NCT05889598|Other|Ballistic Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40%1RM, the ballistic training group will complete eccentric phase hack squat exercise in approximately 3 seconds and the concentric phase as fast as possible with throwing type contractions. If participants can, participants will be allowed to take off in the concentric phase. To maintain high velocity in this group, lower loads will be used compared to the conventional group. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
75769170|NCT03915028|Other|Spa therapy|"The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~Cure of Drink (in addition to 4 daily cares)~Bath in running water: Bath~Bath in running water: Pool at 32 ° C~Bath with aerobain~Immersion shower bath~Shower of high pressure under immersion in swimming pool~General penetrating shower~General jet shower~Local jet shower~Local mud bath at the feet~Single poultice~Multiple poultice~Compress~Mobilization pool~Massages under water"
76061732|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
76061733|NCT01801436|Drug|Bortezomib|Bortezomib 1.3 mg per (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
76061734|NCT01771250|Biological|Insulin Peglispro|Daily doses administered SC.
75448777|NCT03325777|Behavioral|Approach Bias Retraining|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
75599246|NCT05164341|Drug|Placebo|Placebo
75599247|NCT05163249|Drug|Osimertinib|osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
75599248|NCT05163249|Drug|Savolitinib|savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
75599249|NCT05162820|Dietary Supplement|100 mg Solarplast|100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days
75599250|NCT05162820|Dietary Supplement|Placebo|rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days
75769171|NCT03972618|Behavioral|Installation of water filtration system for filtering existing water source|Installation of water filtration system and education on hand washing.
76061735|NCT01771250|Biological|Insulin Glargine|Daily doses administered SC.
76061736|NCT01770860|Device|6660|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
76061737|NCT01770860|Device|4314|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
76061738|NCT01770860|Device|8336|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
76061739|NCT01770860|Device|4840|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
75743408|NCT05889598|Other|Conventional Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at Loughborough University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40% of 1RM, the conventional training group will complete eccentric and concentric phases of hack squatting exercises for approximately 3 seconds each, with appropriate breathing techniques. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
75743409|NCT05889455|Drug|Sildenafil|Oral administration of 100mg
75891692|NCT01382654|Drug|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
75891693|NCT01378676|Drug|Placebo (Part A)|Placebo tablets once daily for 14 days (Part A)
75599251|NCT05155293|Drug|AVT06 (proposed aflibercept biosimilar)|Patients will receive IVT injections of AVT06
75891694|NCT01378676|Drug|CK-2017357 (Part A)|One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
76061740|NCT03568708|Drug|Transdermal Estrogen|In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
76061741|NCT04305106|Drug|Bevacizumab|Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
75891695|NCT01378676|Drug|CK-2017357 (Part A)|Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
75891696|NCT01378676|Drug|CK-2017357 (Part A)|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
75891697|NCT01378676|Drug|Riluzole 50 MG (Part B)|One 50 mg tablet once daily for 14 days (Part B)
75891698|NCT01378676|Drug|Placebo (Part B)|Placebo tablets once daily for 14 days (Part B)
75599252|NCT05155293|Drug|Eylea® (Aflibercept)|Patients will receive IVT injections of Eylea®
75599253|NCT05153343|Drug|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
75599254|NCT05153343|Drug|flonoltinib 50mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
75599255|NCT05153343|Drug|flonoltinib 100mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
75743410|NCT05889455|Other|Placebo|Placebo
75891699|NCT01378676|Drug|CK-2017357 (Part B)|One 125 mg tablet once daily for 14 days (Part B)
75448778|NCT03325777|Behavioral|SHAM Training|SHAM Training
75448779|NCT03314506|Other|Exercise|Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
75448780|NCT03302520|Device|NovoMax, BioAlpha Inc, Seong-nam, Korea|CaO-SiO2-P2O5-B2O3 glass ceramics spacer
75891700|NCT01378676|Drug|CK-2017357 (Part B)|Two 125 mg tablets once daily for 14 days (Part B)
75891701|NCT01378676|Drug|CK-2017357 (Part B)|Three 125 mg tablets once daily for 14 days (Part B)
76061742|NCT04305106|Other|Placebo|Placebo (7.5mg/kg BW) + Saline (100ml) The placebo drug will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
76061743|NCT04305106|Other|Standard care|Standard care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
75448781|NCT03302520|Device|PEEK cage|PEEK cage
75448782|NCT03297476|Diagnostic Test|High-risk subtype detection panels|The designed detection technology were used to identify the high-risk patients cohort.
75599256|NCT05153343|Drug|flonoltinib 150mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
75743411|NCT05889442|Drug|Levcromakalim|Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
75743412|NCT05889442|Other|Placebo|Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
75891702|NCT01377662|Drug|OND-PR002 and MPh-IR|"Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR"
75891703|NCT01377662|Other|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
75891704|NCT01371578|Drug|GS-5885 tablet|30 mg active tablet
75891705|NCT01371578|Drug|GS-9451 tablet|two active 100 mg tablets
75891706|NCT01371578|Biological|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
75448783|NCT03285139|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
75599257|NCT05153343|Drug|flonoltinib 225mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
75599258|NCT05153343|Drug|flonoltinib 325mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
75891707|NCT01371578|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
75891708|NCT01225640|Drug|PNU-100480|600 mg twice daily (BID) for 14 days
75891709|NCT01225640|Drug|PNU-100480|1200 mg once daily (QD) for 14 days
75891710|NCT01225640|Drug|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
75891711|NCT01208168|Drug|NAB001|nail lacquer, once daily, 52 weeks
75891712|NCT01208168|Drug|Vehicle alone|nail lacquer, once daily, 52 weeks
75891713|NCT01677910|Drug|Telotristat etiprate|Telotristat etiprate tablets.
75743413|NCT05889429|Diagnostic Test|MRI scans|The MRI protocol will include standard anatomical, functional, and diffusion imaging, and spectroscopy sequences.
76061744|NCT01603875|Biological|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
76061745|NCT01770392|Drug|Nintedanib|single dose administration
76061746|NCT01770392|Drug|Rifampicin|single dose once daily for 7 days
76061747|NCT01770392|Drug|Nintedanib|single dose administration
76061748|NCT02020564|Behavioral|Speed of Processing Training|
76061749|NCT02020564|Behavioral|Placebo Control|
76061750|NCT01603641|Biological|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
76061751|NCT02018692|Dietary Supplement|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
76061752|NCT02018692|Dietary Supplement|Placebo:Starch|Starch powder
76061753|NCT03492112|Device|HCV RNA Point of Care|Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
75448784|NCT03283241|Device|Zolidd One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
75448785|NCT03283241|Device|One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
75599259|NCT05151263|Drug|Acetyl Salicylate|Aspirin is an effective antiplatelet agent, exhibiting its action by irreversibly inhibiting platelet cyclooxygenase-1 enzyme, thus preventing the production of thromboxane A2 (TXA2). It has been used in the primary and secondary prevention of thromboembolic vascular events
75599260|NCT05151263|Diagnostic Test|Optical Platelet Aggregation test|The evaluation of platelet aggregation was performed using an optical aggregometer (AggRAM, using fresh citrated blood. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 190 g for 5 min. The platelet count was adjusted to 200,000 to 300,000 platelets/mm3. Platelet-rich plasma (250 μl) was deposited in each equipment channel, and the activators adenosine diphosphate, epinephrine, collagen, and arachidonic acid were used according to the manufacturer's instructions. aspirin resistance was defined as platelet aggregation ≥ 20% with arachidonic acid and ≥70% with adenosine diphosphate.
76061754|NCT03492112|Drug|Sofosbuvir/velpatasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
76061755|NCT03492112|Drug|Glecaprevir/pibrentasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
76061756|NCT04397380|Device|Thermography|Measure Temperature using Thermal Camera
76061757|NCT04397380|Device|Tympanic Temperature|Measure Temperature using Tympanic Temperature
75448786|NCT03262909|Device|GelrinC|Patients will undergo GelrinC implantation.
76061758|NCT01556763|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
75448787|NCT03262909|Other|Microfracture historical control arm|Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
75599261|NCT05130814|Device|blue light photobiomodulation|1 minute irradiation of blue light performed with EmoLED device.
75599262|NCT05130814|Procedure|cleansing|cleaning of the wound area with saline or ringer's lactate
75599263|NCT05130814|Combination Product|hyaluronic acid gauze plus polyurethane foam|every 48 hours or as needed
75599264|NCT05130814|Drug|zinc cream or hyaluronic acid sodium salt + metallic silver|applied to prevent and/or treat the skin maceration of the surrounding area
75599265|NCT05130814|Procedure|topical treatment|topical treatment indicated for that stage of the lesion
75769172|NCT01581918|Drug|Carbamazepine|Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
76061759|NCT01556763|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
76061760|NCT01556763|Drug|Placebo|Matching placebo was administered as one capsule per day for 21 days.
76061761|NCT01556763|Drug|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole [10 to 30 mg/day], olanzapine [10 to 20 mg/day], paliperidone [3 to 12 mg/day], or risperidone [2 to 16 mg/day]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
76061762|NCT04397146|Dietary Supplement|Oral Nutrition Supplement (ONS)|Consumption of a portion of 300-320kcal (based on a standard single serve for ONS products) with a two hour follow-up. Products include: 2 Prototype Oral Nutrition Supplements (ONS) with 2.4kcal/ml and respectively 9.6% protein and 14.4% protein; 6 Commercially available Oral Nutrition Supplements with varying energy and protein levels.
76061763|NCT01576575|Drug|Buprenorphine Control|Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
75599266|NCT05130814|Procedure|bandage|"it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system"
76061764|NCT01576575|Drug|Buprenorphine + Rifampin|Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
76061765|NCT01576575|Drug|Buprenorphine + Grapefruit juice|Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
76061766|NCT01576575|Drug|Buprenorphine + Ketoconazole|Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine
75599267|NCT05130294|Dietary Supplement|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
76061767|NCT05051566|Drug|LY3502970|Administered orally.
76061768|NCT05051566|Drug|Esomeprazole|Administered orally.
76061769|NCT01555983|Drug|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
76061770|NCT01576341|Drug|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
75448788|NCT03261817|Behavioral|Physical activity (APA)|"2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition"
75599268|NCT05130294|Dietary Supplement|Placebo|MCT oil
75599269|NCT05124457|Drug|Insulin Detemir|Patients are to receive insulin detemir
75599270|NCT05124457|Drug|Insulin NPH|Patients are to receive insulin NPH
75599271|NCT05116865|Biological|HH-120 Dose 1|Dose level 1 of HH-120
75599272|NCT05116865|Biological|HH-120 Dose 2|Dose level 2 of HH-120
75599273|NCT05116865|Biological|HH-120 Dose 3|Dose level 3 of HH-120
76061771|NCT03451630|Behavioral|High-Touch|Intensive, in-person support.
75448789|NCT03261817|Behavioral|Health Education program (HE)|2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
75448790|NCT03259581|Combination Product|Transarterial chemoembolization|Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.
75448791|NCT03242772|Drug|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.
75448792|NCT03242772|Behavioral|ESDM informed parent coaching|All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
76061772|NCT03451630|Behavioral|High-Tech|Remote care management and self-directed digital tools.
76061773|NCT03451630|Behavioral|Usual Care/Optimal Discharge Planning|Transition to other Health Plan disease management programs.
76061774|NCT04247464|Procedure|Fasting|Food intake restriction
76061775|NCT04241224|Device|Atherectomy|Endovascular treatment of peripheral arterial disease
75448793|NCT03242772|Drug|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
75599274|NCT05116865|Drug|Placebo|Placebo to match
75891714|NCT01677910|Drug|Placebo-matching telotristat etiprate|Placebo-matching telotristat etiprate tablets.
75891715|NCT01499420|Biological|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
76061776|NCT03411070|Device|Implanted Medical Device|Undergo SCOUT reflector placement
76061777|NCT03411070|Procedure|Therapeutic Conventional Surgery|Undergo surgery
76061778|NCT03331978|Behavioral|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
76061779|NCT04398004|Drug|Clarithromycin|Treatment with 500 mg Clarithromycin orally twice daily for seven days
75599275|NCT05104385|Other|Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines|Based on the Turkish Ministry of Health regulations, any research protocol involving use of any drug/vaccine needs to be presented in a clinical trial format, and is presented to the clinical research ethical boards accordingly. Otherwise, the study has no intervention (to the exposure status) involved. Selection, administration, number of doses applied and the period between vaccine doses are beyond the capacity the study team.
75891716|NCT01499420|Biological|Placebo|Single intravenous doses of normal saline (0.9%)
75891717|NCT01498328|Drug|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
75891718|NCT01498328|Drug|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
76061780|NCT03284242|Procedure|Apheresis|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
76061781|NCT01687413|Radiation|Intensity-modulated radiation therapy (IMRT)|
76061782|NCT01687413|Drug|Cisplatin|
76061783|NCT04181320|Device|Venous Leg Ulcer Standard of Care with Granulox|Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
76061784|NCT01555671|Drug|Meperidine|0.5 ml meperidine injection intravenously injected in randomly selected patients
76061785|NCT01555671|Drug|Saline|0.5 ml saline solution injection intravenously injected in randomly selected patients
76061786|NCT03255616|Other|mechanical stimulation|mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients
76061787|NCT03255616|Other|vibrotactile stimulation|non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
75891719|NCT01498328|Drug|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
75891720|NCT04537936|Behavioral|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
76061788|NCT03226756|Drug|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
76061789|NCT01801358|Drug|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
76061790|NCT01801358|Drug|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
76061791|NCT01807598|Drug|Brentuximab vedotin|
76061792|NCT01801280|Drug|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
76061793|NCT01801280|Drug|Pantoprazole|Daily dose: 40mg. Application together with CellCept® or Myfortic® .
76061794|NCT01801280|Drug|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
75448794|NCT03236311|Drug|SAR407899|Pharmaceutical form: Capsule Route of administration: Oral
76061795|NCT01769456|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
76061796|NCT01769456|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
76061797|NCT01769378|Drug|Placebo|Administered SQ
76061798|NCT01769378|Drug|Dulaglutide|Administered SQ
75448795|NCT03236311|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
75448796|NCT03236311|Drug|Adenosine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
75448797|NCT03236311|Drug|Regadenoson|Pharmaceutical form: Solution for injection Route of administration: Intravenous
75448798|NCT03236311|Drug|13N-ammonia|Pharmaceutical form: Solution for injection Route of administration: Intravenous
75448799|NCT03236311|Drug|82Rubidium|Pharmaceutical form: Solution for injection Route of administration: Intravenous
75448800|NCT03234686|Drug|Deferiprone 600mg delayed release tablets|The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
75599276|NCT05101239|Device|MRI imaging exam|3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)
75599277|NCT05096195|Drug|Denosumab 60 mg/ml|Details described in intervention arm/group description section.
75599278|NCT05096195|Other|Calcium and vitamin D prophylaxis|Details described in intervention arm/group description section.
75599279|NCT05096195|Diagnostic Test|Monitoring of post-injection calcium and phosphate|Details described in intervention arm/group description section.
75599280|NCT05093959|Drug|Metformin|An extended release formulation will be used which improves compliance and reduces GI side effects.
75891721|NCT04537936|Behavioral|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
75743414|NCT05889429|Behavioral|clinical assessments|Several clinical assessments will be performed to evaluate the recovery of motor functions. Initially and for screening, the cognitive ability will be assessed using the Montreal Cognitive Assessment (MoCA), and visuospatial neglect will be assessed using the Star Cancellation Test (SCT). eligible participants that meet all inclusion criteria will undergo a series of clinical function tests during each test session (t1-t4) to assess clinical outcomes.
75769173|NCT03907306|Procedure|Wound healing|The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
75599281|NCT05093959|Drug|Placebo|Placebo is a biologically inert substance placed in capsules to match appearance of active intervention
75891722|NCT04537936|Behavioral|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
75891723|NCT04537936|Behavioral|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
76061799|NCT01769378|Drug|Glimepiride|Administered PO
75599282|NCT05093504|Device|Sham comparator|Sham comparator in similar position to the investigational device, but NOT integrated into the cardiopulmonary bypass (CPB) circuit
76061800|NCT01807520|Biological|Secukinumab|Study treatment was provided in pre-filled 1 mL syringes.
76061801|NCT01807520|Biological|Placebo|Placebo was provided in pre-filled 1 mL syringes.
75448801|NCT03234686|Drug|Placebo Oral Tablet|The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
75891724|NCT02266082|Other|No intervention|There is no intervention in this study.
75891725|NCT04537000|Diagnostic Test|clinical condition score|A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)*body weight *5.
75891726|NCT01497704|Drug|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
75448802|NCT03229629|Behavioral|Behavior change communication|Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks
75891727|NCT03135626|Drug|Biodentine|
75891728|NCT03135626|Drug|ProRoot (Aggregate)|
75891729|NCT03135626|Drug|MTA Plus|
75448803|NCT03229629|Other|Food Voucher (Monetary)|Monthly voucher worth 200 birr(~$10) every month for the duration of 6 month
75448804|NCT03226795|Other|" Information-Motivation-Behavioral skills  intervention."|"information -> Reminders of medication: mobile application~Motivation -> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients~Behavioral skills -> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments"
75599283|NCT05093504|Device|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
75599284|NCT05087303|Other|Types of Telemedicine Delivery Models|Each arm delivers standard sickle cell care using a different model based on patient location.
75599285|NCT05087290|Other|Cases|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
75891730|NCT03135626|Drug|Ferric Sulfate 20 % Dental Gel|
75891731|NCT05732116|Other|PTSD|Series scales, including GHQ-12, PCL-6, and CAPS-5 will be used to screen and diagnose the development of PTSD in surgeons and anesthesiologists at 3 time points, baseline (time 0), 3 m, and 6 m.
76061802|NCT01806896|Drug|PF-02545920|"Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Treatment for 28 days."
76061803|NCT01806896|Drug|Placebo|"- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
76061804|NCT01806896|Drug|PF-02545920|"5mg dose~Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
76061805|NCT01806896|Drug|Placebo|"Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
76061806|NCT01768676|Drug|avanafil|100 mg
76061807|NCT01768676|Drug|Placebo|
75448805|NCT03223974|Device|Paclitaxel DCB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for >30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
75448806|NCT03223974|Device|DES|MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
75448807|NCT03208153|Procedure|Invasive|Coronary angiogram and revascularization if anatomically feasible
75599286|NCT05087290|Other|Controls|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
75599287|NCT05074667|Device|Continuous Glucose Monitor|Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care
75599288|NCT05074667|Other|Patient Reported Outcome Questionnaires|Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.
75599289|NCT05070871|Dietary Supplement|Hydrolyzed Collagen|Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.
75599290|NCT05070871|Other|Placebo|Pure maltodextrin.
75769174|NCT01582542|Drug|Desmopressin|"Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured."
76061808|NCT01555125|Drug|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
75448808|NCT03208153|Procedure|Conservative|Conservative
75448809|NCT03194581|Device|Cerebral oxygenation|Evaluate cerebral oxygenation using normoxic challenges
75448810|NCT03192046|Device|Carbon Fiber Ankle Foot Orthosis (AFO)|Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
75448811|NCT03192046|Other|Standardized walking/exercise program|standardized walking/exercise program without any brace or AFO
75599291|NCT05070871|Dietary Supplement|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.
75599292|NCT05066477|Dietary Supplement|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.
75599293|NCT05066477|Other|Placebo|Pure maltodextrin
75599294|NCT05064722|Device|Self Forming Magnets (SFM)|To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
75599295|NCT05056246|Drug|AMG 133|Solution for injection
75599296|NCT05054556|Diagnostic Test|Labaratory tests|"Estimation of serum levels of the following parameters:~galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes"
75769175|NCT03907384|Behavioral|Mat Pilates training|This group completed 12-weeks of training
75769176|NCT01582620|Procedure|Telestroke|remote videoconference consultations
76061809|NCT01555125|Drug|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
76061810|NCT01555125|Drug|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
76061811|NCT01768286|Drug|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
76061812|NCT01768286|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76061813|NCT01800968|Drug|Liraglutide|Active Drug
76061814|NCT01800968|Drug|Placebo|Placebo
75891732|NCT02266160|Drug|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
75599297|NCT05049824|Device|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact metabolic disease indicators
75599298|NCT05044468|Drug|Lidocaine|Given via injection
76061815|NCT01799720|Dietary Supplement|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
76061816|NCT01799720|Dietary Supplement|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
76061817|NCT01799720|Drug|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
75448812|NCT03191253|Other|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
75448813|NCT03190369|Device|Hylan G-F 20 (GZ402662/SAR402662)|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
75448814|NCT03190369|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
75448815|NCT05438342|Biological|Autologous Adoptive immune cells|Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.
75448816|NCT05438342|Device|Thermotron RF-8EX|Hyperthermia for 40-50 minutes
75448817|NCT05438342|Drug|Chemotherapy，checkpoint immunotherapy, targeted therapy|The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines
75599299|NCT05044468|Drug|Liposomal Bupivacaine|Given via injection
75599300|NCT05044468|Other|Questionnaire Administration|Ancillary studies
75599301|NCT05015452|Device|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
75599302|NCT05013450|Drug|Dupilumab|three q3w cycles
75599303|NCT05013450|Drug|PD-1/PD-L1 blockade|SOC immunotherapy with PD-1/PD-L1 blockade
75599304|NCT04989283|Biological|Atezolizumab|Given IV
75599305|NCT04989283|Procedure|Biopsy|Undergo tumor biopsy
75891733|NCT02266160|Other|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
75891734|NCT05731570|Behavioral|Cognitive rehabilitation|Set of restorative and compensatory strategies to rehabilitate cognitive function combined with emotional regulation techniques.
75891735|NCT01491932|Drug|AFQ056|AFQ056 will be supplied as oral capsules.
75448818|NCT05438108|Combination Product|SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab|SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab
75599306|NCT04989283|Procedure|Biospecimen Collection|Undergo blood sample collection
75599307|NCT04989283|Drug|Carboplatin|Given IV
75599308|NCT04989283|Drug|Cisplatin|Given IV
75891736|NCT05731102|Diagnostic Test|Electronic version of the Composite International Diagnostic Interview 5th version (E-CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders among college and university students
76061818|NCT01687257|Drug|SOF|SOF 400 mg tablet administered orally once daily
76061819|NCT01687257|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75891737|NCT03911713|Drug|VX-561|VX-561 tablets for oral administration.
75891738|NCT03911713|Drug|IVA|150-mg film-coated tablet for oral administration.
75891739|NCT03911713|Drug|Placebo|Placebo matched to IVA.
75891740|NCT03911713|Drug|Placebo|Placebos matched to VX-561.
76061820|NCT01806740|Drug|Gadoterate meglumine|Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
76061821|NCT01687101|Drug|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
76061822|NCT01968967|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
76061823|NCT01968967|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
76061824|NCT01554579|Drug|Gefapixant|BID
76061825|NCT01554579|Drug|Sugar Pill|Placebo
75448819|NCT05437952|Dietary Supplement|Taurine and Exercise (Tau+Ex)|"Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks"
75891741|NCT05730244|Drug|Cassia alata extract|1 ml Cassia alata extract
75891742|NCT05730244|Drug|Placebo|1 ml placebo solution
75448820|NCT05437952|Other|Placebo and Exercise (PL+Ex)|"Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks."
75891743|NCT02264132|Drug|Pramipexole ER tablet|
75891744|NCT02264132|Drug|Pramipexole IR tablet|
75891745|NCT01366820|Drug|NNZ-2566|"Solution for intravenous infusion.~Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours."
75891746|NCT01366820|Drug|Placebo|Sodium Chloride 0.9% Injection
75891747|NCT05728762|Device|Novel LEDs|LEDs with a continuous spectrum of 430-780 nm.
75891748|NCT03910153|Dietary Supplement|MSPrebiotic|MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
75891749|NCT03910153|Other|Placebo|Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
75891750|NCT01192880|Drug|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
75891751|NCT01192880|Drug|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
75891752|NCT01192880|Drug|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
76061826|NCT01806662|Drug|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
76061827|NCT01806662|Other|Placebo|Injection of placebo
76061828|NCT01930123|Drug|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO (nothing by mouth) after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have had an historical standard of care liver biopsy in the past and will have IV fructose Magnetic Resonance biomarker measures in the morning."
76061829|NCT01930123|Other|Blood Draw|Fasting bloodwork will be obtained before and after the IV fructose challenge.
76061830|NCT01930045|Drug|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
76061831|NCT01930045|Drug|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
76061832|NCT04631263|Device|Hyaluronic Acid|Injectable gel. Chin correction and augmentation for retrusion
75448821|NCT05437952|Dietary Supplement|Taurine (Tau)|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
75448822|NCT05437952|Other|Placebo (PL)|Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
76061833|NCT01929343|Drug|lidocaine following cue-induced craving|as described in Arm Description
75743415|NCT05889390|Device|Oncotherm EHY-2030|Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
75743416|NCT05889390|Drug|Paclitaxel|weekly paclitaxel for 12 weeks
75743417|NCT05889390|Drug|Carboplatin|added to weekly paclitaxel if patient has triple-negative breast cancer
75891753|NCT03629197|Behavioral|Communication skills training|Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
75743418|NCT05889390|Drug|Cyclophosphamide/Doxorubicin|according to the AC protocol
75743419|NCT05889390|Procedure|Breast cancer removal surgery|Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
75743420|NCT05889377|Procedure|Socket preservation|Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.
75769177|NCT03913000|Drug|ID-085|Hard capsules for oral administration formulated at a strength of 200 mg
75891754|NCT03629197|Other|Attention control|Physician will review materials based on CDC opioid prescribing guidelines.
75891755|NCT04540744|Drug|FDC of macitentan/tadalafil (10 mg/20 mg)|FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.
75891756|NCT04540744|Drug|Macitentan 10 mg|Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
75891757|NCT04540744|Drug|Tadalafil 20 mg|Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
75891758|NCT05375734|Drug|Tislelizumab in combination with anlotinib|Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
75891759|NCT01489046|Drug|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
75891760|NCT01489046|Drug|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
75891761|NCT01489046|Drug|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
75891762|NCT01489046|Drug|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
75891763|NCT01489046|Drug|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
75891764|NCT01489046|Drug|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
75891765|NCT01489046|Drug|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
75891766|NCT02266238|Device|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
75891767|NCT02266238|Device|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
75891768|NCT02266238|Procedure|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
75599309|NCT04989283|Procedure|Computed Tomography|Undergo PET/CT scan
75599310|NCT04989283|Drug|Etoposide|Given IV
75599311|NCT04989283|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
75599312|NCT04989283|Procedure|Magnetic Resonance Imaging|Undergo MRI
75599313|NCT04989283|Drug|Paclitaxel|Given IV
75599314|NCT04989283|Drug|Pemetrexed|Given IV
75599315|NCT04989283|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75599316|NCT04989283|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75599317|NCT04988841|Drug|MaaT013|study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
75599318|NCT04988841|Drug|Ipilimumab|Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)
75599319|NCT04988841|Drug|Nivolumab|AntiPD1 ( immunothérapy)
75599320|NCT04988841|Drug|MoviPrep|Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
75599321|NCT04988841|Drug|Normacol|hypertonic enema solution
75599322|NCT04988841|Drug|Placebo of Maat013|expérimental drug placebo of MaaT013
75599323|NCT04978571|Device|percutaneous electrical nerve-field stimulation, PENFS|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
75891769|NCT05012488|Other|Comparison of gait and foot pressure|The spatio temporal gait parameters of the patients will be evaluated with Zebris (Zebris Medical Limited , Germany) FDM (Force Distribution Measurement ) treadmill system. The system has production of 3D motion analysis and force measurement technologies for biomechanics. When the treadmill is in static and dynamic condition, strong pressure distribution measurement will be taken.
75891770|NCT02264210|Drug|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
75743421|NCT05889364|Diagnostic Test|"AI-based x-ray analysis and triage (normal/tuberculosis suspected)"|All included x-rays will be analysed by the AI-based system. Then results will be compared with opinions of 2 experienced radiologists (they make peer-review of all included images independently of each other).
75743422|NCT05889351|Drug|Vehicle gel, 4 + 4 applications or 4 + 2 applications|Control arm/placebo
75743423|NCT05889351|Drug|LTX-109 3% gel, 4 + 4 applications|Cohort 1 active treatment
75743424|NCT05889351|Drug|LTX-109 3% gel, 4 + 2 applications|Cohort 2 active treatment
75743425|NCT05889338|Drug|adalimumab and methotrexate|Adult patients (> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate
75743426|NCT05889325|Procedure|DEB-TACE plus HAIC|the patients received HepaSphere DEB-TACE plus HAIC
75743427|NCT05889312|Diagnostic Test|18F-FSPG PET/CT in NSCLC|Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
75891771|NCT01423396|Other|optimal care of VRF|VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
75891772|NCT01423396|Other|standard care|AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
75891773|NCT02264288|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
75891774|NCT02264288|Biological|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
75891775|NCT02264288|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
75891776|NCT02264288|Other|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
75891777|NCT01401556|Other|case management|
75891778|NCT01401556|Other|Multifaceted quality improvement intervention|
75891779|NCT01180634|Drug|MP-376 (Levofloxacin solution for Inhalation)|240 mg of MP-376 administered BID for 28 days
75891780|NCT01180634|Drug|Placebo|same volume and frequency as study drug
75891781|NCT05697250|Other|Laser power settings (Thulium Fiber Laser)|Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).
75891782|NCT02264366|Behavioral|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
75448823|NCT05437913|Other|Psychological intervention (self-compassion based)|4 weeks intervention for both primary caregivers and adolescents with T1D will be done online through videoconferencing and will be based on three validated protocols that use self-compassion (MSC and MSC Teens).
75599324|NCT04978571|Device|percutaneous electrical nerve-field stimulation, PENFS (sham device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
75599325|NCT04978571|Device|percutaneous electrical nerve-field stimulation, PENFS (COVID active device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
75891783|NCT05693506|Other|Cooking workshops|Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants
76061834|NCT01929343|Drug|lidocaine following neutral stimulus|as described in Arm Description
76061835|NCT01929343|Drug|saline|as described in Arm Description
76061836|NCT01968811|Device|Avance Foam dressing kit|
75891784|NCT02268890|Drug|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
76061837|NCT01806584|Biological|SRM003|One time implant (3 SRM003 pieces) on surgery day.
76061838|NCT01806584|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
76061839|NCT01798706|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
76061840|NCT01798706|Drug|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
75599326|NCT04977778|Drug|Fatty Acids Compounds (F.A.G.) Mouthwash|Fatty Acids Compounds (F.A.G.) Mouthwash
75599327|NCT04977778|Drug|Stannous Fluoride (SF) Mouthwash|Stannous Fluoride (SF) Mouthwash
75599328|NCT04973254|Other|CAB-RPV LA|Monthly administration of injectable HIV medication
75891785|NCT04918108|Biological|inflammatory response|laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)
75891786|NCT02268968|Drug|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
75891787|NCT04480294|Drug|HRS5091|"Single dose in group 1-5~Multiple doses in group 6-9"
75743428|NCT05889312|Diagnostic Test|18F-FSPG PET/CT in HNSCC|Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
75743429|NCT05889299|Drug|OMS906 study drug|OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
76061841|NCT01798706|Drug|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide >10 mg, gliclazide >160 mg), meglitinides (except repaglinide >6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
75599329|NCT04973254|Other|Standard treatment within an HIV clinic|Standard of care for HIV positive patients will be provided in the HIV clinic that may include HIV medication or may include oral medications.
75891788|NCT01359566|Drug|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
75599330|NCT04964505|Drug|Azacitidine|Given IV or SC
75599331|NCT04964505|Drug|Uproleselan|Given IV
75599332|NCT04964505|Drug|Venetoclax|Given PO
75599333|NCT04950153|Behavioral|Peer navigation|Peer navigators will navigate youth with HIV to provide assistance and support to optimize adherence to antiretroviral treatment (ART)
75743430|NCT05733156|Radiation|SBRT + LDRT|Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
75743431|NCT05889247|Other|Circulating tumor DNA treatment monitoring|A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
75891789|NCT01359566|Drug|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
75891790|NCT01359566|Drug|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
76061842|NCT04156126|Other|Blood Collection|Blood Collection
76061843|NCT04397926|Drug|Individualized neoantigen peptides vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
75743432|NCT05889208|Device|Prophylactic pacemaker implantation|Pacemaker implantation prior the TAVI-procedure
76061844|NCT01767194|Biological|Dinutuximab|Given IV
76061845|NCT01767194|Drug|Irinotecan Hydrochloride|Given IV
76061846|NCT01767194|Other|Laboratory Biomarker Analysis|Optional correlative studies
76061847|NCT01767194|Biological|Sargramostim|Given SC or IV
76061848|NCT01767194|Drug|Temozolomide|Given PO
75448824|NCT05437874|Drug|Natural Water|"355 ml of regular coke, diet coke or mineral water should be drunk.~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
75448825|NCT05437861|Behavioral|Brief Intervention|A short conversation with the participant regarding their use of opioids will be conducted. During the conversation the participants potential drug dependency will be uncovered. Further the pros and cons of weaning of the medication will be explained and a new treatment plan will be proposed.
75599334|NCT04950153|Behavioral|SMS Text messaging|Short Message System (SMS) text messages to remind and encourage youth to adhere to their ART
75599335|NCT04950153|Behavioral|Social Media Engagement|HIV testing outreach using social media platforms to promote HIV testing.
75599336|NCT04950153|Behavioral|Testing Peer Navigation|Peer navigators will conduct HIV testing outreach and linkage to care to at-risk youth
75599337|NCT04945707|Drug|Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]|Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject <50 kg, 20 mg/kg
75891791|NCT01359566|Drug|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
75891792|NCT04904770|Device|Scoop stretcher|Already included in arm/group description
75891793|NCT04904770|Device|Vacuum mattress|Already included in arm/group description
75891794|NCT04379284|Other|Biospecimen collection|"Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab."
75891795|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
75891796|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
75891797|NCT01356914|Drug|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
76061849|NCT01767194|Drug|Temsirolimus|Given IV
76061850|NCT04398784|Dietary Supplement|Freeze Dried Blueberry Powder - 71717|Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.
75743433|NCT05889169|Other|Neurorehabilitation|Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)
76061851|NCT04398784|Dietary Supplement|USHBC Blueberry Placebo Formula #114|Blueberry flavor- and color-matched placebo powder.
76061852|NCT01575873|Drug|Denosumab|Administered by subcutaneous injection once every 6 months
75891798|NCT01356914|Drug|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
76061853|NCT01575873|Drug|Placebo for risendronate|Administered orally once a day
76061854|NCT01575873|Drug|Risendronate|Administered orally once a day
76061855|NCT01575873|Drug|Placebo for denosumab|Administered by subcutaneous injection once every 6 months
76061856|NCT03216928|Diagnostic Test|Blood test|
75891799|NCT04885816|Device|Drug Eluting Balloon (DEB)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter."
76061857|NCT04276636|Drug|Caltrate Pill|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
75891800|NCT04885816|Device|Drug Eluting Stents (DES)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines."
75891801|NCT03135314|Dietary Supplement|cocoa flavanol|7 days intake of cocoa flavanol supplement (naturex)
76061858|NCT04397224|Diagnostic Test|Device interrogation|Ventriculo-ventricular conduction time measurement using device analyzer
75599338|NCT04945707|Drug|Placebo|Normal saline
75891802|NCT03135314|Dietary Supplement|placebo|7 days of placebo intake
75891803|NCT04865614|Drug|Etomidate|Use of etomidate
76061859|NCT03028545|Behavioral|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
76061860|NCT00002644|Drug|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
76061861|NCT00002644|Other|Placebo|Placebo 20Mg Tab
75448826|NCT05437783|Drug|Azithromycin Dihydrate|exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
75616464|NCT04201678|Procedure|ESP Group (Erector Spina Block)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
75743434|NCT05889143|Drug|Ezetimibe/Rosuvastatin|Patient treated with Crezet Tablet
75743435|NCT05889130|Other|Resistant Exercise|"The exercises were planned to be performed in 3 sets, 10 repetitions in each set, with 3 minutes rest between sets. Before starting the main exercises, it was planned to do 1 set of the same exercises without weight as a warm-up and cool-down exercise.~Exercises were planned as lower extremity hip abduction, adduction, flexion and extension, straight leg raise, terminal knee extension, ankle flexion and bridge exercises. During the exercises, it was planned to be combined with breathing, paying attention to respiratory control."
75891804|NCT04865614|Drug|Sevoflurane|Use of sevoflurane
75891805|NCT01483898|Biological|Ixmyelocel-T|On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
76061862|NCT01575561|Drug|Lurasidone|Lurasidone 20-80 mg taken orally once daily
76061863|NCT03574480|Behavioral|Intervention (training in use of a Smartphone application)|The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
76061864|NCT03574480|Behavioral|Control (Advice on healthy diet and physical activity recommendations)|Advice on healthy diet and physical activity recommendations
76061865|NCT03089086|Biological|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to <3 months apart in adolescents.
75891806|NCT01483898|Other|Placebo|On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
76061866|NCT04112758|Other|High-intensity interval training|2 times weekly for 5 weeks Circuit training with 4 stations
76061867|NCT04087876|Drug|derazantinib|derazantinib will be administered orally
76061868|NCT04087642|Diagnostic Test|Intraoperative Crede manoeuver|In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
76061869|NCT04087642|Diagnostic Test|Preoperative prolapse reduction cough stress test|In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
76061870|NCT04746352|Procedure|BES-SMFR|For the BES intervention, it was performed using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive. BES was performed once every 2 days for 4 weeks.
76061871|NCT04746352|Procedure|BES|First, a standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use. Second, patients were required to participate in intensive training regarding myofascial release techniques. Following the training, SMFR was regularly performed by at home for 5 minutes daily for 4 weeks. SMFR was confirmed with patients at all their follow up visits.
75599339|NCT04942106|Other|Arm 1 - Side-lying position followed by Supine position|Infants will be observed for two bottle feedings in a single day when they are receiving at least 30% and no more than 50% of feedings orally. In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
75743436|NCT05889091|Other|HRQOL instruments|These instruments include Face Q for Appearance, Eating & drinking, Swallowing, and Saliva (patient-reported); the Neck Dissection Impairment Index (patient-reported); the Long-term ENT-Subjective/Objective/Management/Analysis (LENT-SOMA) for skin-subcutaneous tissue, muscle-soft tissue, mucosa - oral and pharyngeal, salivary gland, and mandible (patient- and clinician-reported); modified barium swallow study (8-point penetration aspiration scale).
75743437|NCT05889091|Other|LENT SOMA instrument|LENT SOMA instrument will also be provided to summarize objective quality-of-life-related measures recorded at 12 months postoperatively, including interincisor distance (mm); neck range of motion measured in degrees of flexion, extension, lateral flexion, and rotation to both sides; and shoulder range of motion, measured in degrees of abduction.
75743438|NCT05889078|Behavioral|A 4-week walking intervention|Participants will walk along a predetermined route 3 times per week for a period of 4 weeks, answering a pre- and post-intervention questionnaire as well as weekly questionnaires measuring their affect and other variables related to wellbeing. Participants will be randomly assigned to one of two conditions (nature vs urban setting), determining whether the predetermined route they will walk is in a nature or urban setting.
76061872|NCT03164122|Drug|injection of microfat and plasma rich platelet PRP|intra-articular injections
76061873|NCT03164122|Device|MRI|MRI 3T
76061874|NCT04397770|Drug|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
75448827|NCT05437744|Other|Cyanoacrylate glue|8 sockets that will be treated by immediate implant placement and sealed by a Cyanoacrylate glue.
75448828|NCT05437744|Other|Platelet-rich fibrin (PRF)|8 sockets that will be treated by immediate implant placement and sealed by PRF.
75616465|NCT00653341|Drug|insulin glargine|
75616466|NCT00653341|Drug|NPH human insulin|
75891807|NCT04847908|Other|Single high-intensity interval exercise intervention|Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy. Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between. Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
75891808|NCT05377918|Other|Diary|spiritual diary group and diary gruop will write a diary
76061875|NCT04397770|Drug|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
76061876|NCT04397770|Drug|Temozolomide Injection|Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
76061877|NCT03082846|Radiation|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
75448829|NCT05437731|Other|Coated titanium mesh|patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.
75448830|NCT05437731|Other|Uncoated titanium mesh|patients will undergo reconstruction using the conventional uncoated titanium mesh.
75448831|NCT05437718|Other|Ropivacaine|Thoracic paravertebral block(TPVB) is performed on the patients who undergo the thermal ablation therapy.
76061878|NCT03082846|Drug|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
76061879|NCT03213418|Behavioral|Contingency management|Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
75599340|NCT04942106|Other|Arm 2 - Supine position followed by Side-lying position|Infants will be observed for two bottle feedings in a single day when they are receiving at least 30% and no more than 50% of feedings orally. In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
75743439|NCT05889065|Procedure|Conventional Physical Therapy|"group A will receive conventional physical therapy including~10~ultrasound(1.5w/cm2~,3 MHz continuous type, duration 10 minutes),hot packs (on affected region of shoulder for 10 minutes),shoulder ROM, stretching exercises, and joint mobilization five times per week for two weeks with 40 minutes duration of each session. Maitland mobilization will be given in supine position.~· After giving glenohumeral joint distraction, caudal, dorsal, and ventral glides will be given at a rate of 2-3 oscillation/second for 1 to 2 minutes to patients. Grade I or II rhythmic oscillations will be applied in free range."
75743440|NCT05889065|Procedure|PNF techniques|In this group 20 repetitions of diagonal scapular pattern (anterior elevation and posterior depression, posterior elevation and anterior depression) with 20 seconds rest period will be given to subjects. PNF techniques of rhythmic initiation and repeated contractions will be used in all patterns, applied for 40 minutes.
75743441|NCT05889052|Drug|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
75743442|NCT05889026|Device|Extracorporeal shock wave therapy|Stimulation was given to the brachial muscle, 1000 times, 4Hz, and energy flux density was 0.030mJ/mm2.
75743443|NCT05889026|Procedure|Botulinum toxin treatment|The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
75891809|NCT02269046|Other|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
75891810|NCT02269046|Drug|Simvastatin|10mg/d,p.o,12 weeks.
75891811|NCT02269046|Other|Therapeutic Lifestyle Change|"Reduced intakes of saturated fats (<7% of total calories) and cholesterol (<200 mg per day)~Therapeutic options for enhancing LDL lowering~Weight reduction~Increased physical activity"
75891812|NCT01483742|Drug|RO5024048|1000 mg orally bid, 24 weeks
76061880|NCT02929810|Behavioral|sleep extension|
75891813|NCT01483742|Drug|danoprevir|100 mg orally bid, 24 weeks
75891814|NCT01483742|Drug|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
75891815|NCT01483742|Drug|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
75891816|NCT01483742|Drug|ritonavir|100 mg orally bid, 24 weeks
75891817|NCT03065023|Drug|MK-4621|IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
75891818|NCT04720066|Diagnostic Test|Ultrasound test|point of care ultrasound performed by PEM physicians to limping children presenting to the PED compared to radiologist performed ultrasound test.
75891819|NCT04691128|Drug|Desflurane|After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.
75891820|NCT04691128|Drug|Propofol|After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
75891821|NCT04207918|Radiation|Radiotherapy|44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
75891822|NCT04207918|Drug|Nimotuzumab|400mg, by intravenous infusion once a week in 4-6 weeks.
75891823|NCT04207918|Drug|S-1|40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
76061881|NCT02929810|Behavioral|sleep maintenance|
76072034|NCT03409588|Drug|Adempas|After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
76072035|NCT03404297|Other|Locally sourced compression therapy|The dressing is made up of a zinc oxide impregnated compression wrapping
75891824|NCT02269202|Drug|Midazolam, tablet|
75891825|NCT02269202|Drug|Crobenetine, i.v. infusion|
75891826|NCT02269202|Drug|Placebo|
75891827|NCT02266316|Device|Air warming mask|Mask that warms air at the mouth
75891828|NCT04655638|Device|High Flow Nasal Therapy|High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.
76072036|NCT03387085|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
75743444|NCT05889000|Other|questionnaire responses|questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
76061882|NCT05249764|Other|Supervised Home Based Exercise Training|Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.
75891829|NCT04655638|Device|Conventional Oxygen Therapy|Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.
75891830|NCT02266394|Drug|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
76061883|NCT05249764|Other|Unsupervised stretching and breathing exercises|Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
76061884|NCT04276324|Other|Resistance training|Ten weeks of resistance training
76061885|NCT04276324|Other|Testing sessions|Testing sessions
76061886|NCT05240482|Procedure|ST36 acupuncture|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
76061887|NCT04746118|Behavioral|DIET CHANGE|Nutritional supervision will be carried out individually based on the Food Guide for the Brazilian Population, ensuring an accessible, hygienic and contextualized diet according to the subject's culture and physiology. The protocol includes an initial assessment to define the meal plan and individual reassessments every four weeks. In the first evaluation participants will receive an eating plan with a 20% reduction in the total calories consumed or even the equivalent of their daily energy needs with a distribution of macronutrients comprised of 65% carbohydrate, 15% protein and 20% fat. The intention is to promote a reduction in weekly consumption by about 2000 kilocalories (Kcal). The prescription and diet control plan will include and be conducted by a team coordinated by a clinical nutritionist.
76061888|NCT04746118|Behavioral|PHYSICAL ACTIVITY|The physical activity program will consist of daily walking sessions performed outdoors and on a flat surface suitable for hiking. Each session will last 70 minutes and will be performed between 55% -60% of the maximum oxygen consumption (VO2), six times a week, for 24 weeks, with alternate on-site supervision on odd days and remote monitoring on even days. On-site supervision will be carried out by a team coordinated by a Physical Education teacher and implemented at two times in the morning and another two in the afternoon with meeting points previously defined. At the end of each supervised walking session, 20 minutes of exercise will be performed using the equipment available at the Senior Citizens Academy set up in public squares in the region so that the total expenditure of calories spent weekly with physical activities reach about 2000 kilocalories.
76061889|NCT04746118|Other|INTEGRATIVE PRACTICES|The health integrative practices will includes Mind-Fullness, auriculotherapy and laying on of hands. A suitably qualified professional, using it use a practical manual so that the practice became uniform among the subjects, will apply the practice of Mind-Fullness in weekly 1-hour sessions to individuals. The practice of auriculotherapy will be applied to individuals by a professional qualified to perform the technique, which consists in the selection of auricular points according to the health problems presented and the therapeutic objectives that are to be achieved, followed by the insertion of the mustard seed at specific points in the ear over a six-month period. The laying on of hands will be carried out by properly trained individuals.
76061890|NCT02783716|Procedure|Subcutaneous adipose tissue collection|During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest
76072037|NCT03387085|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
75743445|NCT05888922|Drug|Minoxidil Tablets|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
76072038|NCT03387085|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
76072039|NCT03387085|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
75891831|NCT02266394|Procedure|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
75743446|NCT05888922|Drug|Minoxidil Topical|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
75891832|NCT03614923|Biological|Etokimab|Administered by subcutaneous injection
75891833|NCT03614923|Biological|Placebo|Administered by subcutaneous injection
75448832|NCT05437666|Other|Education and booklet|The education program was given both an educational presentation accompanied by a physiotherapist once a week for six weeks and a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
75448833|NCT05437666|Other|Booklet|The control group will be given a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
75448834|NCT05437653|Other|Nutritional Drink A|300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
75448835|NCT05437653|Other|Nutritional Drink B|300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
75599341|NCT04935879|Drug|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
75599342|NCT04935879|Drug|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
75599343|NCT04926896|Procedure|Traditional iliac crest bone harvesting surgery|The experimental group and the control group do not have special requirements; perform the surgery according to the normal operation methods of different sites.
75599344|NCT04926896|Procedure|Minimally invasive bone harvesting surgery|Minimally invasive bone harvesting surgery
75599345|NCT04924491|Biological|Autologous thyTreg|Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
75599346|NCT04923230|Behavioral|Cannabis Actions and Practices Resource for Parents|The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
75743447|NCT05888922|Drug|Placebo oral tablet|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
75743448|NCT05888922|Drug|Vehicle solution|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
76061891|NCT02783716|Diagnostic Test|Peripheral arterial tonometry (PAT)|Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)
75891834|NCT03614923|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
75891835|NCT01353248|Drug|GS-5885|tablet, 30 mg QD
75891836|NCT01353248|Drug|Tegobuvir|capsule, 30 mg BID
76061892|NCT02738788|Other|Intubation|"The patient's airway will be visually assessed and photographed while the patient is resting comfortable in bed with the head up at 30-45 degrees and classified into one of 4 MMS categories. Digital photographs will be taken and the stored image prepared by the investigators in such a way that the patient cannot be individually identified (mouth only).~Neck circumference will be measured at the level of the thyroid cartilage using a tape measure, with temporary ink marks on the skin to allow for subsequent measurements at the same point.~After the patient has been extubated and recovered in the PACU for 30 minutes, their airway will be re-assessed and documented. These evaluations will be repeated at 2, 3, and 4 hours, as well as the next morning."
75448836|NCT05437627|Diagnostic Test|The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults|"Assessment of stuttering severity: The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults will be applied for assessment of severity of stuttering. (3).~Automatic detection and severity assessment of stuttering using MATLAB version 8.1.0.604 R2013a (7). Stuttering detection system has three main steps which are acoustic processing, feature extraction and classification/recognition"
75448837|NCT05437614|Procedure|Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by Micropulse diode laser cyclophotocoagulation
75448838|NCT05437614|Procedure|Cyclocryoablation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by cyclocryoablation
75743449|NCT05888818|Other|Cold application|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
75891837|NCT01353248|Drug|GS-9451|tablet, 200 mg QD
75891838|NCT01353248|Drug|ribavirin tablet|(weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
75891839|NCT01353248|Drug|GS-5885|tablet, 90 mg QD
75891840|NCT05095636|Drug|Apatinib Mesylate|oral Apatinib once everyday
76061893|NCT05241886|Other|anthoropometric measurement, SARC- F questionnare|SARC-F, CC, MUAC
75891841|NCT05095636|Drug|Camrelizumab|intravenous camrelizumab 200mg once every two weeks
76061894|NCT03145168|Other|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
76061895|NCT03145168|Other|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
75448839|NCT05437549|Procedure|MRI|MRI prior to PVI, acutely after PVI, and 3 months after PVI
75448840|NCT05437523|Other|Constipation Action Plan|The author team previously developed and assessed this constipation action plan using the universal precautions approach to produce a tool which could optimize knowledge transfer from clinicians to patients, and support stepwise home self-management of functional constipation. The Uniformed Services Constipation Action Plan can be freely downloaded at the following web link: https://wrnmmc.libguides.com/pediatrics/USAP
75743450|NCT05888766|Drug|Rimegepant 75 milligrams|At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.
75743451|NCT05888740|Device|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf
76072040|NCT03387085|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
75743452|NCT05888714|Device|Experimental FES cycling|Using the experimental, new FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
75743453|NCT05888714|Device|Comparator FES cycling|Using the comparator, marketed FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
76061896|NCT05249140|Device|Repetitive Transcranial Magnetic Stimulation|rTMS involves a safe, non-invasive, painless application of a magnetic field over the skull to a target brain area in order to change its activity and function.
76061897|NCT05241808|Behavioral|Girls Can...Move!|Girls Can...Move! is an 8-week intervention designed to increase physical literacy and physical activity among middle school aged girls. One-hour, in-person sessions will be held twice per week for a total of 16 sessions. Each session involves: a brief educational lesson related to physical activity participation, a 30-minute group physical activity session, and a take-home challenge. The physical activities will prioritize enjoyment of physical activity and promote the development of movement competence. These activities may include: yoga; Zumba; Pilates; strength training; kick boxing; circuit training; etc.
75743454|NCT05888714|Other|Conventional physical therapy|Conventional physical therapy for muscle strengthening, for 16 treatment sessions (twice a week, for 8 weeks).
75743455|NCT05888649|Behavioral|Community Clusters|Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
75891842|NCT05756959|Device|PBM|PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia
75891843|NCT05756959|Device|Peripheral defocus spectacles|plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina
75891844|NCT05756959|Device|Single vision spectacles|Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
75891845|NCT02264444|Other|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
75891846|NCT05095558|Biological|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
75891847|NCT01343966|Drug|MABT5102A|Repeating subcutaneous injection
75891848|NCT01343966|Drug|MABT5102A|Repeating intravenous infusion
76061898|NCT01609790|Biological|Bevacizumab|Given IV
76061899|NCT01609790|Other|Laboratory Biomarker Analysis|Correlative studies
76061900|NCT01609790|Other|Pharmacological Study|Correlative studies
76061901|NCT01609790|Other|Placebo Administration|Given IV
76061902|NCT01609790|Biological|Trebananib|Given IV
76061903|NCT01767116|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
76061904|NCT01767116|Drug|Ribavirin|Capsule
76061905|NCT01767116|Drug|Placebo for ribavirin|Capsule
75448841|NCT05437523|Other|Standard of care without constipation action plan|Standard of care without constipation action plan
75448842|NCT05437497|Drug|Remimazolam Injection|The experimental group was sedated with remimazolam
75448843|NCT05437497|Drug|Propofol Injection|The control group was sedated with propofol
75448844|NCT05437484|Behavioral|Peer-led BASICS|"The peer-led BASICS session consisted in a face-to-face 50-minute motivational interview. In this meeting, the peer counsellor oriented the participant using a personalized graphic feedback sheet, with topics including participant's drinking pattern; level of intoxication; perceived and actual descriptive drinking norms, alcohol expectancies; drinking consequences; individual risk factors; financial costs; alcohol caloric consumption, and hours of exercise required to burn those calories, and protective behavioral strategies. Participants received a copy of the personalized feedback, a personalized BAC card, and a tips sheet.~BASICS facilitators were volunteer undergraduate nursing students from who attented a pre-training course and showed being competent to conduct BASICS-based motivational interview and knowledgeable about alcohol."
75448845|NCT05437471|Drug|GNRH Analoge, Duphaston, Letrozole|GNRH Analoge, Duphaston, Letrozole
75891849|NCT01343966|Drug|placebo|Repeating subcutaneous injection
75891850|NCT01343966|Drug|placebo|Repeating intravenous infusion
76061906|NCT01574703|Drug|placebo|All dosing to have taken place per study A3051123
76061907|NCT01574703|Drug|varenicline tartrate|All dosing to have taken place per study A3051123
76061908|NCT01574703|Drug|bupropion hydrochloride|All dosing to have taken place per study A3051123
76061909|NCT01574703|Drug|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
76061910|NCT03028623|Procedure|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
76061911|NCT03028623|Procedure|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
76061912|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
75599347|NCT04923165|Device|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
75599348|NCT04923165|Diagnostic Test|biochemical analyses|ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;
75599349|NCT04923165|Device|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip
75599350|NCT04923165|Diagnostic Test|nutritional assessment, MNA|nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
75599351|NCT04917848|Other|Tele-Geriatric Oncology program|Participants will be scheduled to meet with a Geriatric Nurse Practitioner (GNP) or Geriatric Registered Nurse (GRN) via the program's telemedicine platform. The telemedicine encounters with the GNP/GRN may occur every 2 weeks over 3 months, for a total of 6 visits. Visits 1 and 6 are mandatory, and visits 2-5 are on an as needed basis.
75599352|NCT04917224|Radiation|Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)|Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.
75599353|NCT04917224|Radiation|Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)|Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.
75891851|NCT03540277|Behavioral|"Experimental: Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
75599354|NCT04901624|Behavioral|Family Risk Messaging|"Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19."
75599355|NCT04901624|Behavioral|Personal Risk Messaging|"Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19."
75891852|NCT03540277|Behavioral|"Experimental: Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
75599356|NCT04901624|Behavioral|Loss Protection|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.
75448846|NCT05437432|Procedure|VITA AMBRIA|25 onlay restroations will be fabricated from Vita-ambria glass ceramic press system.
75448847|NCT05437432|Procedure|IPS e.max press|25 onlay restroations will be fabricated from IPS e.max glass ceramic press system.
75891853|NCT05095480|Drug|Red Yeast Rice Pill|Taking Lesstat
75891854|NCT05095480|Drug|Placebo|Placebo receiving group
75891855|NCT04438408|Other|questionaires|patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.
75891856|NCT06091891|Drug|Tranexamic acid|Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.
75891857|NCT06091891|Drug|Tranexamic acid infusion under ROTEM-guidance|If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
75891858|NCT06091878|Other|Observation|Observational study, no intervention
75891859|NCT06091852|Dietary Supplement|Intrinsically labelled milk protein|20 grams of protein dissolved in 500 mL of water
75448848|NCT05437367|Other|Scapular Stabilization exercises|Therapeutic exercises
75448849|NCT05437367|Other|Postural correction exercises|Therapeutic exercises
75448850|NCT05437341|Biological|bi-4SCAR PSMA/CD70 T cells|Infusion of bi-4SCAR PSMA/CD70 T cells at 10^6 cells/kg body weight via IV
75448851|NCT05437328|Biological|bi-4SCAR GD2/CD56 T cells|Infusion of bi-4SCAR GD2/CD56 T cells at 10^6 cells/kg body weight via IV
75448852|NCT05437315|Biological|bi-4SCAR GD2/PSMA T cells|Infusion of bi-4SCAR GD2/PSMA T cells at 10^6 cells/kg body weight via IV
75599357|NCT04901624|Behavioral|Lottery Incentive|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
75891860|NCT06091839|Other|suturing technique in arteriovenous fistula creation for hemodialysis|End-to-side AV anastomosis was created in upper limb between cephalic vein and brachial or radial artery
75891861|NCT06091826|Drug|NFL-101|Subcutaneous injections
75891862|NCT06091826|Drug|Placebo|Subcutaneous injections
75891863|NCT06091800|Other|biochemical analysis|GCF and serum samples were collected from the participants for biochemical analysis.
75891864|NCT06091787|Drug|Ursodeoxycholic acid|Tablet Ursodeoxycholic acid 450mg per orally twice daily from Post operative day 1 to post operative day 10.
75891865|NCT06091787|Other|Standard Medical Treatment|Standard Medical Treatment
76061913|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
75448853|NCT05437302|Device|prism spectacle|a prism is dispensed in prescription glasses
75448854|NCT05437237|Diagnostic Test|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. For this purpose the Waveguard touch dry electrode EEG cap and compatible eego mini amplifier (ANT Neuro B.V., Hengelo, Netherlands) are used to record and amplify the EEG signal, respectively. Both products are CE marked as medical devices in the European Union and will be used within the intended use as described in the user manuals.
75448855|NCT05437224|Drug|Ambrisentan|eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
75448856|NCT05437185|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
75448857|NCT05437185|Device|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
75599359|NCT04873895|Drug|Axitinib 5 MG|axitinib 5 mg po BID until progression or intolerance
75599360|NCT04873895|Drug|Hydroxychloroquine Pill|hydroxychloroquine 600 mg po BID until progression or intolerance
75891866|NCT06091774|Device|CHD therapy through iATROS medical device|The intervention to be carried out in the treatment group is the use of the therapy control for the treatment of CHD played out via the iATROS medicine product. Patients will receive a suitable and medical device certified measuring device for recording vital parameters. The iATROS app is downloaded to the patient's smartphone and the app is activated by entering a code that identifies the user as a participant in the study. When using the app for the first time, the patient is guided through the first steps of using the app and asked to transfer his or her health data to the app. The therapy control by means of the medication product takes place over the entire duration of the study.
75891867|NCT06091748|Drug|68Ga-DOTATOC|Detection of somatostatin positive lesions in GEP-NETs
75891868|NCT06091709|Other|Multimodal Exercises and Education delivered through tele rehabilitation|Participants will follow the MEET-R that will include stretching, strengthening and core stabilization exercises, and education material pertaining to the proper posture during work.
75891869|NCT06091709|Other|Selafcare|The control group is allowed to opt for self-care management of back pain in the form of medications, rest, conventional physiotherapy, and a home exercise plan. They are also allowed to change their self-care management during the study period; information about the use of the alternative management will be recorded. The information on self-care management will be gathered after 6 weeks at the end of the intervention
75891870|NCT06091696|Other|inspiratory muscle training|inspiratory muscle training will be done by using a pressure threshold loading device (Threshold Inspiratory Muscle Training, Respironics, Pittsburg, PA, USA). By using a spring-loaded one-way valve, this device provides air flow-independent resistance to inspiration at a detectable intensity.
76061914|NCT01686633|Drug|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
76061915|NCT04413669|Procedure|white light bronchoscopy & autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out，and Take a biopsy for abnormal bronchial mucosa
76061916|NCT01685697|Procedure|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
75743456|NCT05888636|Other|ChIP-seq, NGS, ATAC-seq|Bone narrow sampling
75743457|NCT05888623|Device|Computer Assisted Detection|Computer-aided polyp detection system that utilizes artificial intelligence (AI) during colonoscopy
75743458|NCT05888584|Other|Research readiness tool|Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
75743459|NCT05888558|Device|Body fluid diagnosis|miRNAs derived from exosomes in the serum
75891871|NCT06091683|Procedure|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|"Laparoscopic exploration of the abdominal cavity with dissection of adhesions and biopsies of suspect findings (if needed).~PIPAC will be administered with oxaliplatin (92 mg/m2 body surface area in 150 ml dextrose solution) for 30 minutes under the following spraying conditions: cytostatic application at a rate of 30 ml/min, pressure of 1380 kilo-pascal over 30 minutes, and temperature of 22°C. One hour before the beginning of PIPAC, intravenous infusion of 5-fluorouracil (400 mg/m2) and folinic acid (20mg/m2) will be initiated. Standard protectionist procedures will be adopted to avoid contamination of operators and the environment with nebulized chemotherapy."
75891872|NCT06091670|Other|No intervention|There is no intervention. The research is cross-sectional-descriptive type.
75891873|NCT06091644|Device|AirAngel® 3D printed videolaryngoscope|This is a mannequin study that aims to compare a videolaryngoscope produced with 3D printing with a Storz videolaryngoscope and a Macintosh direct laryngoscope in the hands of inexperienced users in terms of ease of use, glottic imaging and intubation success.
75448858|NCT05437133|Device|Custom fabricated elbow extension orthosis|custom low temperature thermoplastic orthosis (Splint) holding the elbow in maximum extension at night
75599361|NCT04873895|Procedure|trans arterial chemoembolization|segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
75448859|NCT05437081|Behavioral|Latino Emerging Adults (LEA)|The LEA program involves two components, one for emerging adults (aged 18-23 years old) focused on identity development linked to cultural and familial strengths, and a parent component focused on support for emerging adult children. Each session is 4 sessions.
75891874|NCT06091631|Procedure|Magnesium sulfate vaporization|pre-opeative magnesium sulfate vaporization
75891875|NCT06091618|Procedure|new technique of ejaculatory preserving laser prostatectomy|"laser will be employed to preform vaporization. The ejaculatory preserving procedure will be done in the following steps:~Setting a mark cut 1 cm proximal of the verumontanum as orientation. Complete resection of the middle lobe to the abovementioned mark. Vaporization of lateral lobes to the capsule and the ventral side to the level of the verumontanum with avoidance of paracollicular digging.~Circular resection of the internal bladder neck. Apical resection utilizing the colliculus seminalis as a distal resection border and maintaining a 1cm safety area for preservation of ejaculation.~Total removal of prostate cuts and final check to confirm that there are no obstructive components."
75891876|NCT06091618|Procedure|conventional technique of laser vaporization of the prostate|conventional laser vaporization of the prostate
75891877|NCT06091605|Procedure|Soft tissue augmentation around dental implants.|Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.
75891878|NCT06091592|Other|Serum autotaxın levels|Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.
75891879|NCT06091579|Drug|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a Plastiape capsule-based dry powder inhaler.
75891880|NCT06091579|Drug|Placebo|Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
75448860|NCT05436990|Drug|Pembrolizumab, Vactosertib|Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
75448861|NCT05436977|Diagnostic Test|coronary OCT|Intermediate coronary lesions will be evaluated by OCT
75448862|NCT05436977|Diagnostic Test|68GaDOTATATE PET/CTCA|Intermediate coronary lesions will be evaluated by68GaDOTATATE PET/CTCA
75448863|NCT05436938|Combination Product|Jing Si herbal tea liquid packets use|with or without Jing Si herbal tea liquid packets use
75448864|NCT05436847|Other|Proprioceptive Training|Proprioceptive Training using increased joint to joint approximation through ankle weights and joint splints.
75599362|NCT04869436|Drug|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
75599363|NCT04860492|Dietary Supplement|Renalof 325mg|RENALOF® is a preparation that contains active Agropyron repens extract. It is designed with specific antioxidant compounds triggered by a bio-catalyst process that enables improved control of the production mechanism of anti-stress molecules. RENALOF® contains extracts of couch grass (triticin, potassium salts, agropyron, silicic salt, inositol, vanillin, saponin, mucilage, iron, and others trace elements), mannitol, corn starch and magnesium silicate. The magnesium in RENALOF® inhibits stone formation by inhibition of growth of crystals and aggregation.
75743460|NCT05888467|Other|supervised infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
75891881|NCT06091553|Drug|Duloxetine alone|30 mg once daily for 1 week, then 60 mg once daily
75891882|NCT06091553|Drug|Duloxetine augmented with gabapentin|30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime
75448865|NCT05436847|Other|Routine Physical Therapy|Neurodevelopmental treatment- age appropriate
75448866|NCT05436821|Device|Auricular vagus nerve stimulation|Autonomic nerve system regulation
75448867|NCT05436821|Device|Sham Auricular Vagus Nerve Stimulation (AVNS)|Sham Auricular Vagus Nerve Stimulation (AVNS)
75599364|NCT04860154|Drug|Hematoporphyrin|Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
75599365|NCT04856085|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
75599366|NCT04856085|Drug|VIR-3434|VIR-3434 given by subcutaneous injection
75743461|NCT05888467|Other|supervised non-infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
75743462|NCT05888467|Other|Control group|Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
75743463|NCT05888376|Device|Vascular access catheter to support dialysis or CRRT|A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
75891883|NCT06091553|Drug|Duloxetine augmented with amitriptyline (as combined therapy)|10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily
75891884|NCT06091527|Behavioral|Yoga practice|90-minute group yoga classes twice weekly for 12 weeks.
75743464|NCT05888363|Other|No Intervention|Difference in outcomes in patients with rectal foreign bodies removed in the emergency department or in the operating room.
75743465|NCT05888298|Procedure|Greater occipital nerve radiofrequency|Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
75743466|NCT05888285|Procedure|Erector spina plane block|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection
75891885|NCT06091527|Behavioral|Education|90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
75891886|NCT06091514|Device|CS Medical Watch|The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF).
75599367|NCT04856085|Drug|PEG-IFNα|PEG-IFNα given by subcutaneous injection
76061917|NCT01685697|Procedure|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
76061918|NCT03028233|Behavioral|Healthy Lifestyle|A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
75599368|NCT04844931|Procedure|RIC + PostC + Standard PCI|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery
75599369|NCT04844931|Procedure|Standard PCI|Standard PCI
75599370|NCT04844749|Drug|VERU-111|Based on the safety and antitumor activity of VERU-111 in the Phase 1b/2 clinical study, VERU-111 is initiating this Phase 3 clinical study of VERU-111 for the treatment of metastatic castration resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent
75599371|NCT04844749|Drug|Enzalutamide, Abiraterone|Enzalutamide and abiraterone were chosen as active comparators are both are FDA approved for the treatment of metastatic castration resistant prostate cancer
75891887|NCT06091514|Other|Specific questionnaire|Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF)
76061919|NCT03028233|Behavioral|Positive Parenting|A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
75599372|NCT04831606|Procedure|debridement|Cleaning of the wound area
75599373|NCT04831606|Device|Offloading|Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
75599374|NCT04831606|Device|Advanced dressing|Protect the wound with Advanced dressing
75599375|NCT04831606|Device|Blue Light Photobiomodulation|2 minutes irradiation of blue light performed with EmoLED device
75599376|NCT04814134|Device|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
75743467|NCT05888285|Procedure|Erector spina bale block and pulsed radiofrequency|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection and pulsed radiofrequency treatment
75891888|NCT06091488|Other|Orthopure|Reconstruction of the anterior cruciate ligament of the knee in the patient.
75891889|NCT06091475|Drug|Other|Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
76061920|NCT02395120|Behavioral|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
76061921|NCT02395120|Behavioral|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
76061922|NCT02395120|Behavioral|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
76061923|NCT02395120|Behavioral|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
76061924|NCT02395120|Behavioral|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
76072041|NCT03387085|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
75891890|NCT06091462|Other|Virtual Reality Based Interactive Therapeutic Dementia Patient Education Program|"Virtual reality is an interactive three-dimensional environment where computer simulation-based fictions and the real and virtual worlds are combined.~Within the scope of this training, in the content of the module on the subject of Dementia; dementia definition, risk factors, signs and symptoms, complications, treatment and nursing care and patient and/or caregiver education. exists. After applying the dementia module, students complete the program by switching to a virtual reality-based simulation program for dementia."
75891891|NCT06091449|Other|High fidelity simulation|Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).
75599377|NCT04814134|Other|Standard of care|Available standard treatment
75599378|NCT04812730|Other|2D versus 3D analysis of EOS stereo radiographic analysis|The use of EOS stereo radiographic analysis and health related quality of life scores to measure the distance of the center of acoustic meati in the transversal plane with respect to the gravity line
75599379|NCT04812730|Other|Static versus dynamic analysis|The use of clinical postural tests and instrumented movement analysis to evaluate the importance of muscle fatigue and compensation mechanisms
75891892|NCT06091449|Other|Virtual reality|"For the virtual reality-based simulation application, students can log in to the virtual reality-based simulation program prepared in line with the Diabetes Mellitus scenario using their username and password; They will receive modular training integrated into the simulation. The expected time for students to complete the modular training is 30 minutes. Students who complete the module will be asked to take a 10-minute break and then participate in a virtual reality-based simulation application.The application of high-fidelity simulation is the same in both groups."
75599380|NCT04812730|Other|Pre- versus postoperative analysis|The use of EOS stereo radiographic imaging and motion analysis to understand the compensation mechanisms in trunk, pelvis and lower limbs and the correlation between primary and secondary mechanisms.
75743468|NCT05888272|Behavioral|Stress managment|The Doing What Matters in Times of Stress self-help manual materials and lay helper scripts utilized in the study are rooted in the principles of Acceptance and Commitment Therapy (ACT). They are designed to improve psychological flexibility which refers to an individual's ability to adapt to changing situations, reallocate mental resources, shift perspectives, and balance competing priorities. The ACT approach teaches individuals how to manage challenging thoughts and emotions through mindfulness techniques, while also guiding them to live in alignment with their personal values.
75743469|NCT05888259|Other|foot insole|The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
75599381|NCT04812730|Other|Reliability of the dynamic evaluation|Repeated measurements of the different aspects of the dynamic evaluation protocol (strenght measurements of trunk muscles, balance evaluation and movement analysis) will serve to evaluate the test-retest reliability and intra-rater reliability of the different protocols
75743470|NCT05888220|Other|warm salt water bath|Warm water and warm salt water bath were applied to the hands and feet of the patients. It is a non-pharmacological intervention
75891893|NCT06091436|Drug|GenSci094|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
75891894|NCT06091436|Drug|Placebo RecFSH / follitropin alfa|powder-injection, but without the active ingedient, SC injection . Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
76061925|NCT01685229|Device|Balloon sinus dilation|Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.
75891895|NCT06091436|Biological|Biological: RecFSH / Follitropin alfa (Days 1 to 7)|Daily SC injections with 150IU or 225IU recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
75891896|NCT06091436|Drug|Placebo GenSci094|Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
76061926|NCT01685229|Drug|Medical Management|Subjects who select to continue on medical management rather than have a BSD procedure.
76061927|NCT03141424|Drug|Tapering of inhaled corticosteroid (ICS) treatment|Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
76072042|NCT03387085|Biological|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
75448868|NCT05436782|Other|core strengthening exercises|•Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval
75448869|NCT05436782|Other|Routine physical therapy|•Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
75448870|NCT05436743|Drug|K-Y Jelly, Topical Gel soaked packs|Topical Gel used as lubricant
75448871|NCT05436743|Other|Water soaked packs|Water soaked packs for reduction of postoperative sore throat
75891897|NCT06091436|Biological|RecFSH / Follitropin alfa (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.
75891898|NCT06091436|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
75743471|NCT05888194|Device|Mucogyne® gel|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
75769178|NCT03913156|Other|B2970 Metabolic Texture Modified Protein Substitute|The study product is a powdered phe-free protein substitute supplemented with long chain polyunsaturated fatty acids (LCP's), containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements and has been designed for use in the management of proven PKU in children aged 6 months to 5 years.
76061928|NCT03028389|Procedure|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
76061929|NCT03614494|Drug|Piroxicam 40 mg|Additional co-treatment
75891899|NCT06091436|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
76061930|NCT03614494|Drug|Levonorgestrel 1.5mg|Standard treatment
76061931|NCT03028155|Drug|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
76061932|NCT03028155|Drug|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
76061933|NCT01551693|Drug|STA-9090|
76061934|NCT01922518|Procedure|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
76061935|NCT01922518|Procedure|Apex pacing|Put RV lead around the apex
76061936|NCT04276402|Procedure|Irradiation of implants with 808nm laser|Irradiation of implants with 808nm laser
76061937|NCT01574157|Drug|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
76061938|NCT01574157|Drug|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
76061939|NCT04276246|Device|dental implants and retentive implant components|retentive components (Group A Test), which are connected to the implants to retain the RPD
75891900|NCT06091436|Drug|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
75891901|NCT06091410|Biological|Omicron-containing COVID-19 vaccine|The COVID-19 vaccine approved for use in the 2023-2024 season
75599382|NCT04783506|Other|Observational Study|There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.
76061940|NCT04276246|Device|dental implants and supportive implant components|supportive components (Group B Control), which are connected to the implants to support the RPD
76061941|NCT05247892|Procedure|Ultrasound-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under ultrasound-guidance
76061942|NCT05247892|Procedure|Fluoroscopic-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under fluoroscopy-guidance
76061943|NCT05245708|Drug|Intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
75616467|NCT03542812|Drug|L-Citrulline|The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
75769179|NCT03912766|Diagnostic Test|serum copeptin|routine surgical method using resectoscope inserted into the urinary bladder
75891902|NCT06091410|Biological|influenza vaccine|inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season
75891903|NCT06091384|Other|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths per day at 75% of maximal inspiratory pressure, six days a week, during 6 weeks.
75891904|NCT06091345|Drug|Midodrine|• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10%
75891905|NCT06091345|Biological|albumin|• Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is < 3.5 gm/dl
75891906|NCT06091345|Other|Standard Medical Treatment|Standard Medical Treatment
76061944|NCT05245708|Drug|intranasal placebo|Each subject will be assigned to intranasal placebo.
76061945|NCT01574079|Other|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
76061946|NCT01574079|Other|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
75769180|NCT01251328|Procedure|General anaesthesia|general anaesthesia is performed according to the hospitals standard
75616468|NCT02642263|Drug|Carbetocin|Postpartum uterotonic drug
75616469|NCT02637115|Dietary Supplement|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
75769181|NCT01251328|Procedure|Sedation|Sedation is performed according to the hospitals standard
75599383|NCT04758637|Behavioral|Overdose Notification|We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
75743472|NCT05888181|Other|Mobile app-based self-management intervention|"The self-management program, accessible via a smartphone app, comprises several components. First, the app contains an RA-specific educational program presented as videos in 16 weekly modules. Second, the app provides patients with tailored lifestyle advice, both as part of the educational program and in the form of personalized messages from a certified health coach. Third, the study app includes remote monitoring features underpinned by goal-setting principles. For instance, participants can use the app to log daily steps and physical activity, as well as their diet, sleep, and mental health. Personal goals, as well as physical challenges and meditation or mindfulness exercises, can be set up within the app to encourage behavioral change.~Finally, patient-reported disease burden can be monitored within the study app via the RAID instrument. Based on random allocation to one of both intervention groups, the RAID will be prompted either weekly (group A) or monthly (group B)."
75743473|NCT05888168|Procedure|CABG|All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.
75743474|NCT05888142|Behavioral|in clinic pain VR reduction exercises|"During the first two weeks of treatment, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality."
76061947|NCT05249686|Other|Manual Therapy + Dry Needling|"Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ)."
76061948|NCT05249686|Other|Manual Therapy|Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
75891907|NCT06091332|Drug|Sirolimus|Sirolimus is an mTORC1 inhibitor that has received approval from the U.S. Food and Drug Administration (FDA) and has recently been successfully used to treat lymphatic malformations and venous/lymphatic malformations associated with the same PIK3CA GOF mutations.
75891908|NCT06091332|Drug|Starch flake|The placebo is composed of starch material and is formulated at 0.5 grams per tablet.
75891909|NCT06091280|Device|Respiratory Muscle Strength Trainers|Devices provided to each participant. Resistance loading set at less than 50% of the peak inspiratory and peak expiratory flow rate.
75891910|NCT06091241|Procedure|Pre-operative Erector Spinae Plane block prior to DIEP surgery|After obtaining informed consent to participate in the study, patients will be randomized by a computer 50/50 to either the Erector Spinae Plane group or the Transversus Abdominus Plane group at the time of their surgical clinic visit prior to their scheduled surgery. Then on the morning of surgery, the Erector Spinae Plane group will receive a bilateral ultrasound-guided Erector Spinae Plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected below the fascia of the erector spinae muscle group.
75891911|NCT06091241|Procedure|Pre-operative Transversus Abdominus Plane blocks prior to DIEP surgery|On the morning of surgery, the patients in the TAPs group will receive a bilateral ultrasound-guided Transversus Abdominus plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected into the transversus abdominus plane above the transversus abdominus muscle.
75891912|NCT06091228|Other|tongue scraper|tongue cleaning with gentle strokes twice a day covering the whole surface of the tongue
76061949|NCT01922596|Drug|Ropivacaine|
76061950|NCT01922596|Drug|Placebo|
76061951|NCT01573767|Drug|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
76061952|NCT01573767|Drug|Placebo|Placebo inhalation powder during treatment period
76061953|NCT01573767|Drug|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
76061954|NCT04397068|Procedure|phaco-vitrectomy|phaco-vitrectomy. No other involvement drug or device. Standard of care procedure
75448872|NCT05436730|Device|Ambulatory blood pressure measurement device|Assessment of the 24-h blood pressure profile
75448873|NCT05436730|Device|Sphygmocor|Assessment of the arterial stiffness
75448874|NCT05436730|Device|VaSera-VS|Assessment of the arterial stiffness
75448875|NCT05436730|Device|Somnocheck|Assessment of the sleep breath disturbances
75448876|NCT05436704|Procedure|EUS-FNB|EUS-FNB
75891913|NCT06091202|Behavioral|CORPs Intervention|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 1 month. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 1-month follow-up, and a qualitative interview at 1-month follow-up to help inform the larger clinical trial."
75891914|NCT06091202|Behavioral|Minimally Enhanced Usual Care (MEUC)|Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 1 month. The primary outcome is a change in pain interference.
75891915|NCT06091163|Behavioral|Ketogenic Diet|"A Ketogenic Diet (KD) is a high-fat and very low-carbohydrate intake. Participants will follow a modified KD (estimated 20-50g carbohydrates/day based on a 2000 kcal diet) without energy restriction. Participants will test for ketosis in their morning urine at least twice a week to monitor adherence.~To support adherence in people with depression, delivered pre-prepared KD meals (3 meals per day) and additional ketogenic snacks will be sent to participants. A registered dietitian will provide weekly 30-minute nutritional counselling sessions. The dietitian will schedule appointments and assess the participants' experience with adhering to the KD diet, troubleshoot as required, give guidance on how to prevent or overcome side effects of KD diets, and keep record of participants' ketosis level and suicide risk."
75743475|NCT05888142|Behavioral|In clinic VRpain reduction exercises + VR homeworks|"During the first two weeks of treatment, participants will use commercially available VR during in clinic physical therapy exercises, and during homeworks to help reduce their pain and improve functionality."
75891916|NCT06091163|Behavioral|Phytonutrient Diet|Participants in the control group will receive the same degree of dietetic input and be told that their diet is a modified fat and phytonutrient diet. The photo diet aims to increase vegetable consumption, reduce saturated fat intake and increase poly- and mono-unsaturated fat intake. Participants in the control group will receive food vouchers (£20 every two weeks) to help purchase these items. This aims to be a plausible placebo dietary treatment for depression. There is no clear evidence that these manipulations will change depression severity. The dietitian will create written materials to explain the diet and suggest foods by colour with supporting recipe suggestions.
75743476|NCT05888129|Procedure|surgery after neoadjuvant chemotherapy|surgery after neoadjuvant chemotherapy
75891917|NCT06091150|Procedure|Endovascular management of direct carotid-cavernous fistula|Coiling and embolization of direct carotid-cavernous fistula
75891918|NCT06091098|Other|Dynamic CO2|2% inspired CO2 for 2-4 breaths
75891919|NCT06091098|Other|Sham CO2|Air
75743477|NCT05888077|Other|ESWL_LL|Extracorporeal shock wave lithotripsy using latest lithotripter and laser lithotripsy for difficult Bile duct stones
75891920|NCT06091085|Drug|Acetazolamide|Administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
75891921|NCT06091085|Drug|Placebo|Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
75891922|NCT06091072|Other|Image-guided navigation|A patient-specific 3D model will be created using an available pre-operative SPECT/CT scan. Pre-operatively, three electromagnetic patient trackers will be attached to the patients' skin, close to the pelvis, allowing tracking the patient's position during surgery. After anesthesia and before the skin disinfection procedure, the patient is placed in the final surgical position, where an intra-operative CBCT scan is performed required for the image-guided surgery workflow. During surgery, the preoperative images and 3D model will be visible for the surgeon together with a blunt-tip electromagnetic pointer enabling surgical navigation during robotic surgery. Anatomical structures will be used to validate the accuracy of the navigation. When the target is identified by the surgeon, the pointer is used to store the location digitally. Scheduled standard clinical 99mTc will be used as validation for target(s) identification.
75891923|NCT06091033|Dietary Supplement|Fermented rice|1,000 mg of black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks
75891924|NCT06091033|Dietary Supplement|placebo|1,000 mg of a placebo for 8 weeks
75891925|NCT06090994|Drug|Huaier granule|Oral administration, 10g once, 3 times a day, starting within 1-2 months after surgery. Please refer to the medication manual for specific usage. Continuous use for at least 6 months.
75891926|NCT06090981|Drug|Bovine surfactant|Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
75891927|NCT06090955|Drug|Dexmedetomidine Injection [Precedex]|The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
75891928|NCT06090955|Drug|Lidocaine IV|The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
75891929|NCT06090955|Drug|normal saline|The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
75891930|NCT06090942|Other|Smartphone-based cognitive training|Smartphone-based cognitive training
75891931|NCT06090929|Device|STN-DBS|STN-DBS was implanted according normal process
75891932|NCT06090916|Other|Best Practice|Receive standard nutrition care
75599384|NCT04725513|Device|Shockwave Therapy|Participants will receive shockwave therapy once a week for three weeks
75743478|NCT05888038|Device|virtual reality|virtual reality
75599385|NCT04725513|Device|Photobiomodulation Therapy|Participants will receive photobiomodulation therapy twice a week for three weeks
75599386|NCT04725513|Other|Physical Therapy|Participants will enroll in physical therapy and complete an at-home exercise protocol
75599387|NCT04717050|Behavioral|Progressive combine training (PCT)|8 month exercise program with 4 month follow up.
75599388|NCT04717050|Behavioral|Attention Control (AC)|12 month stretching program
75891933|NCT06090916|Other|Dietary Intervention|Participate in weekly support sessions with diet prescription
75891934|NCT06090916|Other|Medical Chart Review|Ancillary studies
75891935|NCT06090916|Other|Medical Device Usage and Evaluation|Record dietary and physical activity using MyFitnessPal smartphone app
76061955|NCT04396678|Behavioral|PrEP standard of care+behavioral intervention|The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
76061956|NCT03133546|Drug|Osimertinib|"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration."
76061957|NCT03133546|Drug|Bevacizumab|Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
76061958|NCT01551303|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
76061959|NCT01551303|Drug|Placebo|Matched nasal spray placebo
75599389|NCT04699201|Procedure|Hincisional hernia prevention by onlay prosthesis trocar closure|Hincisional hernia prevention by onlay prosthesis trocar closure
75743479|NCT05888025|Behavioral|Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)|MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
75599390|NCT04699201|Procedure|laparoscopic cholecystectomy|Laparoscopic cholecystectomy with or without common bile duct exploration
75599391|NCT04699201|Diagnostic Test|Abdominal ultrasound|Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
75599392|NCT04689009|Device|EmoLED|The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.
75743480|NCT05888012|Device|basket catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The basket catheter is made of nickel-titanium wires which can be manipulated to trap and withdraw stones.
75743481|NCT05888012|Device|balloon catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The balloon catheter is made of latex, which is inflated after passing the stone, thus pushing the stone outwards.
75743482|NCT05887973|Behavioral|The T.R.I.G.G.E.R Project|"The T.R.I.G.G.E.R Project includes the following core components to address root causes of gun violence:~Summer Employment~Social and Emotional Learning~Future Orientation~Adult and Peer Support~Critical Consciousness~Civic Efficacy and Engagement"
75891936|NCT06090916|Other|Nutritional Assessment|Undergo malnutrition screening
75616470|NCT02637115|Dietary Supplement|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
75891937|NCT06090916|Other|Questionnaire Administration|Ancillary studies
75891938|NCT06090903|Procedure|Biospecimen Collection|patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.
75891939|NCT06090903|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
75891940|NCT06090903|Other|Medical Chart Review|Review Medical Chart
75891941|NCT06090890|Drug|Colchicine|Add 0.5mg QD orally and start using it within 48 hours after intervention.
75891942|NCT06090890|Drug|Prednisone|0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.
75891943|NCT06090890|Drug|Aspirin|Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.
75891944|NCT06090890|Drug|P2Y12 Receptor Antagonist|Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.
76061960|NCT01550757|Behavioral|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
75891945|NCT06090890|Drug|Lipid-lowering drug|Formulate the lipid-lowering drug regimen with LDL-C<1.4mmol/L as the target on the basis of moderate intensity or above statins.
75891946|NCT06090877|Device|US and shear wave elstography|using B mode US to assess ulnar nerve echogenicity, measuring its cross sectional area and assess any other anatomical abnormalites Measuring ulnar nerve stiffness using shear wave elastography All measurements done at the cubital tunnel, 2 cm proximal and distal to it compare findings with electrodiagnostic studies and intra operative findings
76061961|NCT01685073|Drug|Zolpidem extended-release|nightly administration of zolpidem extended-release
76061962|NCT01685073|Behavioral|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
75599393|NCT04689009|Procedure|current Standards Of Care|"The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out."
76061963|NCT01922674|Procedure|Standard open tension-free inguinal hernia repair with mesh|
75599394|NCT04685408|Behavioral|TEAM|TEAM is informed by principles of social cognitive theory TEAM uses nurses and peer educator dyads (PEDs) composed of patients and their care partners to co-deliver an intervention intended to help reduce future stroke risk. Team begins with one 60-minute 1:1 orientation session, in which the nurse and PED meet with the patient and his/her care partner. This is followed by 6 hour-long group sessions with 6-8 patients and their care partners held approximately weekly. The first orientation session will be done approximately 1 week post baseline, followed by group sessions were done at 2, 4, 6, 8, 10 and 12 weeks post-baseline.
75616471|NCT02637115|Dietary Supplement|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
75743483|NCT05887960|Other|CBC and flow cytometry test for monocyte|all groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population
76061964|NCT01922908|Biological|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
75743484|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 1.8%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
75891947|NCT06090851|Dietary Supplement|herbal nitrate Pralines with nitrate|consumption of herbal pralines with nitrate
75891948|NCT06090851|Dietary Supplement|herbal nitrate Pralines without nitrate|consumption of herbal pralines without nitrate
75891949|NCT06090838|Procedure|Balloon Pulmonary Angioplasty (BPA)|A balloon pulmonary angioplasty is a minimally invasive intervention procedure to remove blood clots from the pulmonary arteries.
75616472|NCT02637115|Dietary Supplement|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
75891950|NCT06090825|Other|Observational study|Observational study
75891951|NCT06090812|Other|Ultrasound evaluation|Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
75891952|NCT06090786|Diagnostic Test|MRD assessment|Bone marrow withdrawal for MRD quantification
75891953|NCT06090760|Behavioral|Mindfulness|"Mindfulness is paying attention in a particular way: on purpose, in the present moment, and non-judgmentally (Kabat-Zinn 1994, 4) and has five facets: awareness, nonjudgement, nonreactive, observe, and describe (Baer et al., 2006)."
75891954|NCT06090747|Behavioral|Hybrid lifestyle educational multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention. The information will be shared via digital tools such as mail, WhatsApp, zoom workshops, educational videos, Joven, Fuerte y Saludable webpage, Joven, Fuerte y Saludable mobile app, and face-to-face educational sessions."
76061965|NCT01922908|Biological|Placebo Comparator|Normal saline
76061966|NCT05240950|Drug|Anti-CEA CAR-T Cells|"The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10^6/kg, 3×10^6/kg, and 6×10^6/kg using a standard 3+3 design and preliminarily observe the efficacy."
75599395|NCT04685408|Behavioral|ETAU|ETAU will consist of an orientation visit with a nurse who will provide patient-education materials on stroke risk adapted from the American Heart Association materials and cover common risk factors such as hypertension, obesity, high salt/high fat diet and diabetes. Patients will also receive basic written information in their language of preference and tailored to the reading level of most patients at the clinic. Patients will be offered the opportunity to bring a family member with them to this visit who may also ask questions and who can assist them with understanding written materials for those with limited literacy. The nurse in ETAU will then follow-up with participants with a series of 9 brief phone calls spaced out over the course of 6 months (approximately every 2 weeks during months 1 and 2, then approximately monthly thereafter). Content will reinforce materials provided in the orientation visit and the nurse will be available to answer questions that may arise.
76061967|NCT05241574|Radiation|Radiotherapy boost|Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
75891955|NCT06090747|Behavioral|Hybrid lifestyle personalized multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention and personalized lifestyle intervention based on their clinical evaluation. Based on clinical records participants will be sent to nutritional, psychological, rehabilitation, and Mindfulness intervention. Educational and motivational strategies include digital tools such as mail, WhatsApp, zoom workshops, educational videos, the Joven, Fuerte y Saludable webpage, and the Joven, Fuerte y Saludable mobile app. And individualized follow-up through Mobile apps such as AVENA"
75891956|NCT06090708|Dietary Supplement|yogurt with probiotic bacteria|Children in probiotic study group were received 15 mg/kg of market available fresh probiotic yogurt after stopping vomiting every four to six hours for three consecutive days beside to the standard hospital care and the prescribed medication for acute gastroenteritis.
75891957|NCT06090682|Device|Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)|We observed the changes in cognitive function of patients before and after different brain stimulation treatments, and further compared the effects of different brain stimulation treatments on cognitive function of PD patients and the related mechanisms according to whether DBS surgery was performed or TMS therapy was given only according to the surgical indications.
76061968|NCT05241574|Drug|Additional consolidation chemotherapy|Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
76061969|NCT01923142|Biological|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
76061970|NCT01923142|Biological|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
76061971|NCT05241184|Diagnostic Test|Multiparametric stress CMR protocol|Multiparametric stress CMR protocol
75599396|NCT04665180|Diagnostic Test|Primary knee arthroplasty|Patients who return to work after primary knee arthroplasty
75599397|NCT04628871|Biological|SB-318|No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
75599398|NCT04628871|Biological|SB-913|No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
75599399|NCT04628871|Biological|SB-FIX|No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
75599400|NCT04620889|Device|AV Access|Arteriovenous shunting for blood access.
75599401|NCT04620889|Device|PVP|Bypass or reconstruction of diseased or occluded blood vessels
75599402|NCT04615403|Drug|Travoprost|Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision
75599403|NCT04604899|Biological|human retinal progenitor cells|single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)
75599404|NCT04586049|Device|MRI|Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.
75599405|NCT04586049|Device|Transcranial Doppler Ultrasound|Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.
75599406|NCT04586049|Other|Sympathetic Nerve Activity|Participants will undergo sympathetic nerve activity testing while participating in a breathing test.
75599407|NCT04577014|Drug|Retifanlimab|"Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)"
75599408|NCT04577014|Drug|Gemcitabine|"Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
75891958|NCT06090656|Drug|Bevacizumab combined with Sintilimab|Bevacizumab combined with sintilimab, sindilizumab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
75743485|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 5%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
75743486|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 1.8%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
75743487|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 5%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
75891959|NCT06090656|Procedure|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization, patients were treated with cTACE, and the efficacy was assessed by repeat CT/MRI 1 month after the initial treatment, and if the tumor still had arterial phase enhancement, TACE treatment could be supplemented until treatment failure and withdrawal of consent.
75891960|NCT06090643|Other|Best Practice|Recieve CRC screening usual care
75891961|NCT06090643|Other|Consultation|Recieve consultation with clinic staff
75891962|NCT06090643|Other|Educational Intervention|Recieve education and training on CRC screening
75891963|NCT06090643|Other|Electronic Health Record Review|Ancillary studies
75891964|NCT06090643|Other|Fecal Immunochemical Test|Recieve FIT kit with culturally tailored instructions
75599409|NCT04577014|Drug|Docetaxel|"Phase I:~Dose Level 1 - 75 mg/m2 Dose Level 0 - 75 mg/m2 Dose Level -1 - 60 mg/m2 Dose Level -2 - 50 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
75599410|NCT04567784|Drug|Cannabidiol (CBD)|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
75891965|NCT06090643|Behavioral|Feedback|Recieve feedback on CRC screening
75891966|NCT06090643|Behavioral|Health Education|Recieve CRC screening recommendations
75891967|NCT06090643|Other|Support Education Activity|Utilize clinical decision support tool
76061972|NCT05241028|Drug|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
76061973|NCT01572909|Drug|Bendavia (MTP-131)|0.05 mg/kg/hr
76061974|NCT01572909|Drug|Placebo|Identically appearing placebo
76061975|NCT01572675|Drug|etorocoxib|Administered as 30 mg or 60 mg oral film-coated tablets
76061976|NCT01572675|Drug|celecoxib|Administered as 100 mg or 200 mg oral hard capsules
76061977|NCT05929937|Drug|Opioids|Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)
76061978|NCT05929937|Other|No opioids|Standard of care, patients will not receive a prescription for opioids.
75891968|NCT06090643|Other|Text Message-Based Navigation Intervention|Recieve text message reminders
75891969|NCT06090630|Procedure|Diffusion Weighted Imaging|Undergo DWI-MRI
75599411|NCT04567784|Drug|Placebo|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
75599412|NCT04566107|Behavioral|mHealth intervention|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses mobile health (m-Health) technology for daily messages and reminders to promote self-monitoring activities. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine).
75616473|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
75616474|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
75891970|NCT06090630|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopic imaging
75891971|NCT06090552|Behavioral|Increasing intensity of ACP-related messaging prior to surgical visit|Behavioral interventions to observe how the different arms of advanced care planning helps participants aged 65 or older.
75891972|NCT06090526|Diagnostic Test|"pancreatic stone protein PSP measurement"|Blood samples will be collected for biomarker (PCT, CRP, and PSP) measurements in admission and 24 hours, 72 hours from admission and patients will be followed until death or discharge from the ICU or for 30 days, whichever occurred.
75891973|NCT06090500|Procedure|Cryotherapy|preoperative submucosal infiltration injection of cold saline solution (2-5 degrees Celsius)
75599413|NCT04566107|Behavioral|mHealth Plus|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses tailored self-management strategies (action planning, goal setting, and individual identified support needs) and mobile health (m-Health) technology for virtual visits, daily messages, and self-monitoring activities. The investigators will test the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the m-health platform. The NP will evaluate physiological and psychosocial status while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine). Participants will receive reminders through the platform.
75599414|NCT04559620|Other|Maternal voice|Maternal voice (song/ words) played in the incubator for 30mins x4/day x 7 days
75599415|NCT04545177|Device|NICO Myriad and Tissue Preservation System (TPS)|Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
75599416|NCT04539574|Procedure|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
75599417|NCT04539574|Other|Questionnaire Administration|Ancillary studies
75743488|NCT05887921|Procedure|Inguinal Lymphadenectomy|arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
75743489|NCT05887908|Drug|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam
75743490|NCT05887908|Drug|co-administration of aztreonam and nacubactam|2 g aztreonama and 1 g nacubactam
75599418|NCT04531046|Drug|axicabtagene ciloleucel|Patient-specific (autologous) product cryopreserved in cryostorage bag
75599419|NCT04517604|Device|Magventure MagProx100 with MagOption|iTBS will be delivered utilizing the MagVentrure MagPro X100 with MagOption stimulator that includes active and placebo coils (C-B60 Butterfly coils). Only the active setting will be used.A MagVenture C-B60 coil will be used to deliver single pulse TMS to the non-dominant MC to identify the ab-ductor pollicis brevis (APB) muscle coordinates. The integrated Localite neuronavigation system will be used.
75599420|NCT04511806|Other|Registry|This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
75599421|NCT04494503|Drug|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
75599422|NCT04494503|Drug|Rituximab|Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
75599423|NCT04494503|Drug|Ibrutinib|Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
75743491|NCT05887908|Drug|imipenem/cilastatin|1 g imipenem/1 g cilastatin
75616475|NCT00656227|Drug|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
75743492|NCT05887869|Behavioral|Telehealth solution|Telehealth solution offered for nutrition education and breastfeeding support.
75891974|NCT06090500|Procedure|Diclofenac sodium|preoperative submucosal infiltration injection of Diclofenac sodium (25mg/ml)
75891975|NCT06090500|Procedure|Dexamethasone sodium phosphate|preoperative submucosal infiltration injection of dexamethasone sodium phosphate (4mg/ml)
75743493|NCT05887778|Drug|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the supraclavicular brachial plexus block
75743494|NCT05887778|Drug|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
75891976|NCT06090487|Diagnostic Test|myocardial function after surgery|This group includes (15) patients who will have 200 mg twice daily oral (5) sacubitril-valsartan 1 month before the operation. transthoracic echo will be done before and after surgery, also total dose if inoptropic drugs will be noted
75743495|NCT05887778|Drug|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
75743496|NCT05887674|Behavioral|Diet intervention|Low inflammatory-index diet
75891977|NCT06090435|Behavioral|Therapeutic exercise plus motor imagery|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a motor imagery intervention (which consists of imagining the same movements but not performing them for real).
75891978|NCT06090435|Behavioral|Therapeutic exercise plus action observation|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added an action observation intervention (which consists of observing the same movements but not performing them for real).
76061979|NCT05929924|Dietary Supplement|Extra virgin olive oil|EVOO will be included in the participant's daily diet for 6 months
76061980|NCT05929872|Other|Non-invasive brain stimulation|ACTIVE transcranial direct current stimulation( tDCS)
76061981|NCT05929872|Other|Sham non-invasive brain stimulation|SHAM tDCS
76061982|NCT05929794|Drug|Metronidazole 0.75% Topical Gel|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
76061983|NCT05929794|Drug|Metronidazole 0.75% Topical Cream|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
76061984|NCT05929794|Diagnostic Test|Transdermal water loss measurement|Baseline measurements of transepidermal water loss will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied).
76061985|NCT05929794|Diagnostic Test|Electrical Resistance|Baseline measurements of electrical resistance will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied). In all study periods the measurements will also be repeated at 48 hours and 96 hours, when metronidazole product and occlusive coverings are removed from the skin.
76061986|NCT05929794|Diagnostic Test|Skin color measurement|Baseline measurements of skin color will be made at 3 sites on the upper arm.
75599424|NCT04485611|Behavioral|Supervised aerobic + resistance training and nutritional support|The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements]]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
76072043|NCT03387085|Biological|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
76072044|NCT03387085|Biological|haNK for Infusion|NK-92 [CD16.158V, ER IL-2]
76072045|NCT03387085|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
76072046|NCT03387085|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
76072047|NCT03387085|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75616476|NCT02636803|Drug|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
75616477|NCT02636803|Drug|albendazole|group receives one 400 mg dose of albendazole
75743497|NCT05887674|Behavioral|Exercise|Guided muscle strength training and stretching exercises
75743498|NCT05887674|Behavioral|Cognitive training|Cognitive training will be implemented in person
75891979|NCT06090435|Behavioral|Therapeutic exercise|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a sham action observation intervention (which consists of observing planets in space).
75743499|NCT05887661|Procedure|hypovolemic phlebotomy|hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
75891980|NCT06090422|Drug|Ketamine Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
75891981|NCT06090422|Drug|Midazolam Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
75891982|NCT06090409|Other|Implementing free/subsidized agricultural produce to encourage a plant-based diet.|Providing educational material on the benefits of a plant-based diet, simple recipes, food swaps and free/subsidized produce.
75891983|NCT06090357|Other|Plantar pressure|Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.
76061987|NCT05929794|Other|Micropatch application|All subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm (color only measured at baseline). Two sites will have micropatch application + metronidazole product with occlusive covering. One site will have micropatch application + occlusive covering, no metronidazole product. Micropatch application will only occur on day 1 (a micropatch is a patch of 50 microneedles). Transepidermal water loss and electrical resistance are repeated after micropatch application and removal. At 48 hours occlusive coverings and metronidazole are removed; electrical resistance measurements are repeated. Metronidazole product and fresh occlusive patches are reapplied. At 96 hours patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis.
76061988|NCT05929755|Drug|Depo-Medrol|steroid
76061989|NCT05929755|Drug|Gel-Flow NT|hemostatic agent
76061990|NCT05929690|Other|Self-acupuncture|Participants be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total).
75599425|NCT04483713|Behavioral|Educational Workshop|"The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires."
75599426|NCT04483713|Behavioral|Educational Workshop plus J. H. N. EBP Guide Tools|"In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination."
75599427|NCT04477304|Behavioral|Opioid Naive, OR|Visits where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days and clinician is on the clinic list as a treating member of the clinic
75599428|NCT04477304|Behavioral|At-risk for long-term use, OR|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days and clinician is on the clinic list as a treating member of the clinic
75599429|NCT04477304|Behavioral|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days and clinician is on the clinic list as a treating member of the clinic
75599430|NCT04451226|Drug|Fezolinetant|Oral
75599431|NCT04448873|Drug|Sirolimus|After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
75616478|NCT02535871|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
75891984|NCT06090331|Diagnostic Test|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
75891985|NCT06090318|Drug|Milademetan|260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
75891986|NCT06090318|Drug|Atezolizumab|1680mg administered every 4 weeks
75891987|NCT06090292|Device|Real TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz).
75891988|NCT06090292|Device|Real FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left hand opponens pollicis, first lumbrical and first dorsal interosseous muscles. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
75891989|NCT06090292|Device|Sham TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz) however the ultrasound head will be flipped so that the active side faces away from the scalp.
76061991|NCT05929638|Behavioral|lavender oil|The patients participating in the study were provided with the steps of applying lavender oil by inhalation, the points to be considered during the application, and the application was done in the same way by all patients.
76072048|NCT03387085|Drug|Cisplatin|cis-diamminedichloroplatinum(II)
75599432|NCT04442724|Procedure|Fiducial marker placement|placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection
75891990|NCT06090292|Device|Sham FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left biceps and long finger flexors. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
75891991|NCT06090253|Behavioral|Gerotechnology enhanced multi-component exercise|Intervention courses will be divided into 3 categories: Musculoskeletal training course, Neuromuscular and fall prevention training course, and cardiometabolic training course. The courses will be enabled by wearable technology, digital platform and visual display. Each of the courses will be 8 weeks in length (1 session per week), and 60 minutes per session.
75891992|NCT06090253|Behavioral|Home-based exercise|The proposed elderly home gym training services will be conducted by professional fitness instructors and tailor-made for the participants. 4 personal training sessions will be assigned (once per week, 45 to 60 minutes per session).
75891993|NCT06090253|Behavioral|Walking exercise|Two interventions will be provided: A) Walk-focused intervention, B) Disease-related walk intervention for participants with chronic diseases.
75891994|NCT06090253|Behavioral|Slow sports and exercise|Participants will receive 10 training sessions (once or twice per week, 2 hours per session) conducted by professional fitness instructors. The training programs can be selected according to the participants' preference, including water exercises, stretching/fitness/gymnastics, slow walking/jogging, sports massage, Tai Chi, Yoga, etc.
75891995|NCT06090253|Behavioral|Football|The Football Training Programme will be arranged (10 training sessions+1 game day per stage, 4 stages per season). held on artificial turf football pitch or indoor sport facilities in 5 regions
75891996|NCT06090214|Diagnostic Test|Liquid biopsy|For cases: 60 mL blood sample (40 ml for CellSave analysis and 20ml for collection) at visit1 then 20 ml for CellSave analysis at visit2 and visit3 For controls: 40 ml (20ml for CellSave analysis and 20ml for collection) at visit1
76061992|NCT05929625|Device|BTL-585-2 RF+US|The subjects of RF+US group will receive four simultaneous RF+US treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
76061993|NCT05929625|Device|BTL-585-2 RF|The subjects of RF only study group will receive four RF treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
76061994|NCT05929586|Other|"The combined C-it DU-it intervention: community data use for ANC"|"Combining data linkage (C-it) with work improvement teams for community data use (DU-it) to improve antenatal clinic uptake. Our short name C-it DU-it (pronounced see-it; do-it) is an acronym intended to convey 'seeing' linked data (C-it) and 'doing' or acting on the data (DU-it)"
75599433|NCT04442724|Diagnostic Test|Multiparametric MRI (mpMRI)|In this study, mp-MRI is defined as MRI that includes T1 & T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.
75743500|NCT05887648|Behavioral|SinDance|"One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise."
75599434|NCT04438304|Drug|64Cu-SARTATE|64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.
75599435|NCT04393376|Diagnostic Test|PSA Glycomics Assay|PSA Glycomics Assay will be performed on urine and blood samples
75599436|NCT04368429|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)|Pharmaceutical form: Liquid solution Route of administration: IM
75599437|NCT04368429|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration: IM
75599438|NCT04364750|Dietary Supplement|L-Histidine|1 capsule (0.6g) twice daily
75599439|NCT04364750|Dietary Supplement|High-FODMAP beverage|High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.
75891997|NCT06090201|Other|3-Tesla brain MRI and a comprehensive neuropsychological assessment|Patients with a moderate to severe form of congenital haemophilia A or B or a severe form of von Willebrand disease will be consecutively recruited in the study during a routine follow-up visit at the Haemostasis and Transfusion Department of the Lille University Hospital.
75599440|NCT04364750|Dietary Supplement|Low-FODMAP beverage|Low-FODMAP beverage (10g glucose) consumed twice daily.
75599441|NCT04364750|Dietary Supplement|Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.|Total of 50 billion CFU/capsule taken twice daily.
75599442|NCT04364750|Other|Placebo|Enteric coated capsule with no active ingredient, taken twice daily
75599443|NCT04356326|Drug|Aspirin 150 mg|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
75599444|NCT04356326|Drug|Placebo|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
75599445|NCT04349046|Device|Total hip arthoplasty (THA)|Total hip arthroplasty (THA) is a common operative treatment where an arthritic, degenerative or fractured hip joint is replaced with a prosthetic device if conservative options are unable to relieve pain and debilitating symptoms. THA was traditionally performed on patients over 60 years old, but now includes young and active patients, as well as very old ones thanks to the continuous improvement in implant design. Major indications of THA include osteoarthritis, rheumatoid arthritis, avascular necrosis and hip fractures. The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.
75599446|NCT04300049|Drug|Glucagon Infusion|Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.
75599447|NCT04300049|Other|Saline|Study participants will receive saline infusion for 12 hours.
75599448|NCT04278729|Drug|Apixaban 5 MG|1 - 5 mg tablet taken orally twice a day
75599449|NCT04259788|Other|AHEI diet|Main intervention is the consumption of an AHEI diet for 12 weeks.
75599450|NCT04234204|Drug|Fezolinetant|Oral
75599451|NCT04234204|Drug|Placebo|Oral
75599452|NCT04227574|Other|Zero Time Exercise training + WhatsApp anti-inertia reminders|"Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.~In addition, WhatsApp anti-inertia reminders will be sent daily by the research assistant to remind and encourage the participants to practice the Zero Time Exercise."
75743501|NCT05887635|Device|RF Vapor Ablation|RF Vapor ablation of the duodenum
75743502|NCT05887622|Dietary Supplement|Potassium chloride supplement|Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
76061995|NCT05929560|Other|Conventional impression|Palatal impressions obtained using an irreversible hydrocolloid impression material
75599453|NCT04227574|Other|Zero Time Exercise training alone|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
75599454|NCT04226716|Behavioral|Assessment of postural control, body perception and psychosocial factors|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception and psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events)
75599455|NCT04224181|Radiation|Cardiac PET|A scan examining blood flow to the heart
75599456|NCT04224181|Radiation|99mTc-tilmanocept SPECT/CT|A scan to look at inflammation in the arteries
75599457|NCT04224181|Radiation|Contrast Enhanced Coronary and Aortic Computed Tomography Angiography|A scan of the heart and surrounding blood vessels
75599458|NCT04220970|Other|BIA-ALCL|Observational : no intervention
75599459|NCT04216017|Drug|kenalog|Cortisone injection into shoulder
75599460|NCT04216017|Drug|Lidocaine|Lidocaine injection into shoulder
75599461|NCT04206813|Drug|Gardasil 9 2 dose regimen|a 2-dose regimen of Gardasil 9 at 0 and 6 months
75599462|NCT04206813|Drug|Gardasil 9 3 dose regimen|standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
75599463|NCT04206813|Drug|Gardasil 9 rescue dose|A rescue dose of Gardasil 9 will be given at 12 months
75599464|NCT04191421|Biological|Siltuximab|Given IV
75599465|NCT04191421|Biological|Spartalizumab|Given IV
75599466|NCT04179903|Other|Physical activity|Physical Activity program is performed in a group in a gym and at home
75599467|NCT04142125|Drug|Rivaroxaban 2.5 Mg Oral Tablet bid|Pts will receive rivaroxaban + aspirin
75599468|NCT04142125|Drug|Acetylsalicyclic acid 81 mg tablet qd|Pts will receive ASA
75599469|NCT04133194|Drug|Mesalazine|1600 mg Asacol [mesalazine]
75599470|NCT04133194|Drug|Mesalazine|800 mg Asacol [mesalazine]
75743503|NCT05887622|Dietary Supplement|Placebo|Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
76061996|NCT05929560|Other|Digital impression|after obtaining stone models from conventional impression material, stone models were scanned using the I700 (Medit) scanner and Patients were directly scanned intraorally using an intraoral 3D scanner Subsequently, the printed 3D model scan data of the seven patients were then used for standard triangulated language (STL)
76072049|NCT03387085|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75891998|NCT06090188|Other|A Culture-Based Multicomponent Cognitive Training Program|Activities of the program were structured, cognitive, leisure activities based on Chinese and Taiwanese culture for cognitively impaired older people. Activities contained structured brain-exercise activities and musical activities. The structured brain-exercise activities included playing musical instruments or singing, playing board games, and classes in Chinese, sciences, sociology, physical education, cooking, and math. Chinese and Taiwanese cultures were included within the structured brain-exercise activities curriculum, such as food, clothing, architecture, places of interest, folklore, etiquette, celebrations, religion, art, etc. Participants began with a musical exercise, then had 20-30 minutes of physical exercise with 5 minutes of warm-up at the beginning and 5 minutes of cool down. The program was provided for at least 40-60 minutes, twice a week, for 8 weeks via RAs and day centre caregivers.
76061997|NCT05929521|Other|C-PrEP+|Rather than a one-on-one PrEP care visit, a cohort of 8-12 patients meet with the same providers at each visit for individual health assessments, linkages to services, and 75-90 minutes of group interactive learning and skill-building that centers patients' experiences. This approach to healthcare has great potential meet sex workers' HIV prevention needs, including optimal use of PrEP
75448877|NCT05436691|Other|Information and Coping with Anxiety Training|Informing and Coping with Anxiety Training was given to the experimental group before the operation through a prepared booklet.The information booklet about the training was created by the researchers by reviewing the current literature. The booklet provides information for patients scheduled for hysterectomy about how to cope with surgery-related anxiety. The booklet provides information on what the hysterectomy is, why it is performed, what risks it has, what should be done before, during and after the hysterectomy, what rules the patient should comply with after hysterectomy, in which cases she should present to the health institution, what changes she might experience in her social, physical, sexual and emotional life after the surgery. The booklet also provides information about discharge training and coping with anxiety.
75599471|NCT04123379|Drug|Nivolumab|q4w, dosed twice before surgery and three times following recovery from surgery by injection
75599472|NCT04123379|Drug|BMS-813160|300mg oral twice a day for 28 days
75599473|NCT04123379|Drug|BMS-986253|2400mg once by injection
75599474|NCT04122183|Other|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
75599475|NCT04104750|Other|assessment scales (BFI, QLQ, TESS)|the patient's Fatigue will be measured during the treatment period with antiblastic drugs and part of the followup period. To this end the BFI scale validated in Italian will be used (Mendoza et al 1999; Catania et al, 2013) which includes 9 items with a score for each of 0 to 10 and a consequent total score from 0 to 90. The measurement will take place in 4 times: the day of enrollment, 6 months, 12 months and 24 months after enrollment.the quality of life of patients measured by the EORTC QLQ C-30 scale (Aaronson et al, 1993) and the level of autonomy measured by the TESS scale (Davis et al, 1996) in 4 steps: the enrollment day , at 6 months, at 12 months and at 24 months from enrollment.
75599476|NCT04104360|Dietary Supplement|Galacto-oligosaccharides|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
76072050|NCT03387085|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
75599477|NCT04104360|Dietary Supplement|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
75743504|NCT05887050|Dietary Supplement|Active|Blend of chromium, amla fruit extract, and citrus bioflavonoids
75743505|NCT05887050|Dietary Supplement|Placebo|Maltodextrin tablet
75743506|NCT05886283|Procedure|phacoemulsification|"we started with a clear corneal incision of 2.2 mm at 9 o'clock and a port incision of 1 at 2 o'clock. Continuous Circular Capsulorhexis of 6 mm was performed under the same ophthalmic viscosurgical device. A hydro dissection was performed, then followed by phacoemulsification.~the Nucleus has been treated using 2 different techniques After bimanual infusion/aspiration cortex removal and Visco expansion of the capsular bag, a hydrophobic single-piece: AcrySof acrylic IOL was implanted."
75599478|NCT04103567|Other|Biological collection|Fecal samples collected at different times : during inclusion consultation with surgeon, after neoadjuvant treatment and before surgery.
75599479|NCT04101630|Behavioral|Activity Monitoring|Monitoring with FitBit
75599480|NCT04101539|Device|OPTIMA-guided catheter ablation|Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
75599481|NCT04101539|Device|Standard PVI|Standard PVI for AF.
75743507|NCT05886283|Procedure|utrasound phacoemulsification|US group:The nucleus was held with the phaco tip at a high vacuum. The phaco choppe was drawn towards the phaco tip to cleave it by a manual separation between the two instruments. The fragments were then aspirated with phaco power. The standard parameters used during phacoemulsification were a vacuum level of 500 mmHg, pressurized irrigation of 90 mmHg, and 40% of phaco power
75743508|NCT05886283|Procedure|nanolaser phacoemulsification|Laser group: The nucleus was fragmented using the shockwaves emanating from the phaco tip and then aspirated. The phaco chopper was used to accelerate the mechanical fragmentation of the nucleus and minimize the dissipated energy.
75743509|NCT05885789|Procedure|Intubation in Bed-Up-Head-Elevated (BUHE) position|Comparing laryngoscopic view in paediatric patients during sniffing position and BUHE position
75743510|NCT05885581|Other|Arm A Grow Well|"the preliminary efficacy of the adapted intervention on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.~the feasibility of implementing the intervention and its acceptability among mothers and caregivers.~the feasibility of collecting infant anthropometric data."
75743511|NCT05885581|Other|Arm B Healthy Steps|Group B: Healthy Steps and will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
75743512|NCT05884515|Diagnostic Test|SARS CoV-2 antigen tests|The intervention is to compare antigen tests
75743513|NCT05883774|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is applied using a transcranial magnetic stimulator with a figure-of-8 coil once per day for 10 consecutive days. rTMS is delivered to the right dorsolateral prefrontal cortex (DLPFC) at a frequency of 1 Hz for 20 minutes (1200 total pulses).
75743514|NCT05883774|Device|Sham Repetitive Transcranial Magnetic Stimulation|Sham-rTMS is performed in the same way as the treatment group except that the coil is rotated 90° away from the scalp.
75891999|NCT06090149|Device|PHASE 1 Lowenstein medical BiLevel Prisma 25ST device: withount oxygen support.|"The patient will be invited to enter the study's first phase using the Lowenstein medical BiLevel Prisma 25ST device without additional oxygen support. The study will be conducted within 1-3 days. If patients fail to achieve proper blood oxygen saturation without oxygen supplementation, patient will be selected to proceed to the next step - oxygen-enriched positive airway pressure intervention~During monitoring TA, RR, HR, SpO2, as well as CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
75743515|NCT05883072|Behavioral|Exploring AI-Chatbot|All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
75743516|NCT05883007|Radiation|Accelerator-based BNCT with borofalan(10B)|Patients will be treated with BNCT regulated as 12, 15, or 18 Gy-Eq of the mucosal maximum dose.
75599482|NCT04095598|Diagnostic Test|Comparative Ankle Tomography with Stress Maneuvers|All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.
75743517|NCT05882617|Other|implants supported overdentures|implant supported and retained with different number of implants retained by ball attachments
75743518|NCT05882188|Procedure|Oil-based contrast|oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
75892000|NCT06090149|Device|PHASE 2. Continous/Bilevel positive airway presure with additional oxygen support by Devilbiss 525 KS oxygen concentrator|"The patient will be invited to enter the third phase of the study with rapid oxygen titration. Titration occurs in an inpatient department where the patient is connected to the Lowenstein medical BiLevel Prisma 25ST device with oxygen support during the daytime. As part of the study, the patient will be supplied with oxygen by Devilbiss 525 KS oxygen concentrator at a dosing interval of 1-10 L/min. Every 2 hours oxygen support will be increased by 2L/min.~During monitoring TA, RR, HR, SpO2, and CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
75892001|NCT06090136|Drug|TPN171H|5 mg TPN171H tablets，single dose,oral
75892002|NCT06090123|Drug|TPN171H|"Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10."
75892003|NCT06090123|Drug|Itraconazole|Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
75599483|NCT04095260|Other|Pre-season strength and conditioning program|The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
75599484|NCT04091438|Drug|TAK-925|TAK-925 IV infusion.
75599485|NCT04091438|Drug|TAK-925 Placebo|TAK-925 placebo-matching IV infusion.
75599486|NCT04084769|Biological|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: IM
75616479|NCT02535871|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
75599487|NCT04084769|Biological|Meningococcal Group B vaccine (Trumenba®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
75599488|NCT04084769|Biological|Meningococcal group B vaccine (Bexsero®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
75892004|NCT06090123|Drug|Rifampicin|Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
75448878|NCT05436574|Other|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the elderly population housed in the establishments of UNIVI group.
75892005|NCT06090097|Device|KneeBRIGHT System|The KneeBRIGHT system includes electromyogram sensors and video game software that leads participants through physical therapy exercise.
75892006|NCT06090097|Other|Control Exercise|The control group will complete a 10-week regimen of conventional PT exercise
76061998|NCT05929508|Other|Ischemic Preconditioning|A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
75448879|NCT05436509|Biological|bi-4SCAR CD19/79b T cells|Infusion of bi-4SCAR-CD19/79b T cells at 10^6 cells/kg body weight via IV
75448880|NCT05436496|Biological|bi-4SCAR CD19/70 T cells|Infusion of bi-4SCAR CD19/70 T cells at 10^6 cells/kg body weight via IV
75892007|NCT06090032|Device|Ultrasound|We will use ultrasongraphy as a part of assessment in respiratory intensive care unit patients with ventilator associated pneumonia
75448881|NCT05436405|Procedure|Trans-pedal access for endovascular revascularization in complex infra-popliteal lesions in critically ischemic limb|"Briefly, conventional femoral access will be conducted in the traditional manner and involve the sheath while the catheter was introduced close to the proximal degree of lesion.~Access to a pedal vessel: Using a 21-guage needle or by utilizing a micro puncture access set. Such vessel is recognized using the US probe. such approach performed in 54 patients.a fluoroscopy might enable a good possibility for efficient access. In addition, it was suggested to utilize micro-puncture needle supposed to have echogenic pattern as the tip of regular needle is very hard to visualize utilizing the duplex US probe. Also, use of straight fluoroscopy or road mapping may offer a better chance for successful access, this method is done in 31 cases . Another method is open method (cut down) on tibial vessels, this method is done in 11 cases."
75892008|NCT06090006|Other|Screening package|Y-Check is a novel intervention delivering a health check-up and where indicated will provide on-the-spot care and referral for common conditions on two occasions in adolescence (in young adolescents (10-14 year-olds) - soon after the onset of puberty - and again in older adolescents (15-19 year-olds) - when many adolescents become, or are soon to become, sexually active). It will also provide health promotion information and materials to support positive behaviours and healthy lifestyles during adolescence and beyond. Adolescents will only be screened for conditions that have an accurate, low-cost, acceptable screening test and a locally accessible, effective intervention. The conditions selected for screening will be chosen to reflect the local epidemiological contexts (e.g. screening for malaria will only take place in high malaria endemic areas).
75892009|NCT06090006|Diagnostic Test|Psychosocial and mental health disorder screening|HEEADSSS stands for Home, Education/Employment, Eating, Activities, Drugs, Sexuality, Suicide/Depression, and Safety (Klein et al., 2014) and Patients´ Health Questionnaire - Adolescent (PHQ-A), Generalised Anxiety Disorder (GAD-9) and counselling and referral where indicated
75892010|NCT06090006|Diagnostic Test|Alcohol, tobacco and substance use screening|World Health Organization (WHO) ASSIST-Y tool (Humeniuk, 2016) and referral where indicated
75892011|NCT06090006|Behavioral|Diet and physical activity screening|HEEADSSS (Klein et al., 2014) and counselling and advice
75448882|NCT05431738|Device|Gastroesophageal stent placement|A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control
75599489|NCT04068311|Other|Geriatric Screening tools|Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
75599490|NCT04059224|Drug|Trametinib|Trametinib 2 mg once a day by mouth.
75599491|NCT04059224|Drug|Dabrafenib|Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
75616480|NCT02634385|Procedure|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
75599492|NCT04045210|Other|Psychological Support Based on Positive Suggestions|Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1 to intervention by ICU doulas or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 3 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention.
75599493|NCT04013685|Biological|Orca-T (formerly TregGraft)|engineered donor allograft
76061999|NCT05929456|Drug|Cetuximab-IRDye800|patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.
75743519|NCT05882188|Procedure|ExEm Foam|ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
76062000|NCT05929443|Other|END-IT intervention for nursing homes|Complex intervention, as described in the arm/group descriptions
75892012|NCT06090006|Diagnostic Test|Underweight and overweight screening|MUAC (Middle Upper Arm Circumference), BMI (Body Mass Index) followed by Counselling and advice +/- referral where indicated
75599494|NCT04002518|Device|Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.|Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.
75599495|NCT03994861|Diagnostic Test|Assessment of disability and behavior (by questionnaires)|Assessment of disability and behavior (by questionnaires)
75599496|NCT03958903|Device|Amygdala recording and stimulation using Neuropace RNS|Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
75599497|NCT03958903|Behavioral|Behavioral tasks|Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
75616481|NCT02634385|Procedure|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
76062001|NCT05929417|Other|END-IT intervention for the community setting|The intervention was described in the arm/group descriptions.
76062002|NCT05929365|Procedure|colonoscopy|determine the mutation profile of resected colorectal neoplasia
76062003|NCT05929339|Drug|Oxytocin|Intravenous oxytocin
76062004|NCT05929326|Diagnostic Test|complete blood count, PT, aPTT, fibrinogen tests|Pregnant women who are eligible for the study will have their blood collected to run complete blood count, PT, aPTT, fibrinogen tests
76062005|NCT05929313|Device|OrbusNeich Scoreflex TRIO|To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters
76062006|NCT05929313|Device|OrbusNeich Scoreflex NC|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
76062007|NCT05929248|Drug|Telitacicept|160mg once a week for 48 weeks
75448883|NCT05429229|Drug|VisuXL®|It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol succinate), one drop is applied in each eye every 4 hours for a month.
75448884|NCT05429229|Drug|Lagricel PF®|It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.
75448885|NCT05429229|Drug|Humylub PF®|It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
75448886|NCT05427643|Procedure|study group|dental implant procedure under local anesthesia
75448887|NCT05427643|Procedure|control group|dental implant procedure under local anesthesia
75448888|NCT05426811|Drug|Regorafenib|Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks
75448889|NCT05426811|Drug|Raltitrexed|Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks
75448890|NCT05426369|Biological|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein for injection (Strength: 1 mg/ml, 0.5ml/vial)
76062008|NCT05929248|Drug|conventional therapy|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
75599498|NCT03940508|Behavioral|Making Connections Intervention|The MCI is a one to two session intervention that addresses barriers to mental health treatment and helps adolescents build skills to get the most out of their treatment experience. It is designed to be delivered by a trained clinician in conjunction with an evidence-based treatment.
75599499|NCT03940508|Behavioral|IPT-A|IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
76062009|NCT05929248|Drug|Placebo|Used once a week in combination with standard treatment
76062010|NCT05929209|Diagnostic Test|Assessment of disease biomarkers|Assessment of serum, histological and radiological biomarkers
76062011|NCT05929196|Diagnostic Test|In vitro full blood diagnostic test.|Participant will donate approximately 5 ml blood sample. Later in a laboratory the sample will be processed in the microwave metamaterial sensor for non invasive blood glucose monitoring and standard biochemical analyzer. Specific dielectric properties and scattering parameters will be measured for blood glucose level determination.
76062012|NCT05929144|Other|MRI sequences testing|Testing different MRI sequences in order to optimize them
75599500|NCT03918850|Drug|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
76062013|NCT05929118|Other|Aquatic Rehabilitation|Reviewing the existing literature studies and related books, and combining the post-operative rehabilitation process of ACLR with the opinions of experts from the China Aquatic Rehabilitation Association, the Aquatic rehabilitation program of this study was designed.
75448891|NCT05426148|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®|The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.
75448892|NCT05422352|Dietary Supplement|Carnosine|Patients who will receive carnosine supplementation 500mg capsules (Now foods) in combination with Vitamin B complex (B1+B6+B12, 150 mg+100 mg+1 mg, respectively, Neurovit, European Egyptian Pharm. Ind., Egypt), two tablets per day
75892013|NCT06090006|Diagnostic Test|Anemia|Hemocue. Iron and folic-acid supplementation (3 months supply) if anaemic. If severely anaemic (<8g/dl) refer to health facility.
75599501|NCT03918850|Drug|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
75599502|NCT03916978|Biological|Autologous PRP intra ovarian infusion|Autologous PRP intra ovarian infusion
75599503|NCT03916978|Biological|Autologous PFP intra ovarian infusion|Autologous PFP intra ovarian infusion
75599504|NCT03914170|Drug|Folfirinox + cetuximab|Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
75599505|NCT03911739|Drug|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
75599506|NCT03911739|Drug|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
76062014|NCT05929118|Other|Land-based Rehabilitation|Peking University Third Hospital Anterior Cruciate Ligament (ACL) Postoperative Rehabilitation Guidelines.
76062015|NCT05929105|Procedure|artificial intelligence (AI)-assisted three-dimensional preoperative planning technology|In the AI planning group, AI was used to assist in the 3D planning to complete the preoperative design. Preoperative planning was performed by two experienced surgeons and without the chief physician to ensure that the results of the preoperative planning did not affect the selection of intraoperative procedures and prosthesis size.
76062016|NCT05929105|Other|X-ray film template for 2D planning|A traditional X-ray film template was used to complete the preoperative design in the traditional planning group. The position and size of the prosthesis, the level of femoral neck osteotomy, the length of the LLs and the restoration of eccentricity were estimated by X-ray. A plastic template provided by the manufacturer was used to take the line of the lower edge of the teardrop on both sides as the horizontal reference line, and the acetabular template was placed at 40 abduction on the inner edge of the teardrop so that the lower edge of the acetabular cup was adjacent to the teardrop. An appropriate type of acetabular component was selected to fill the acetabulum and maintain coverage, and the femoral component that best matched the femoral medullary cavity was chosen. The height of the osteotomy was determined, and the planning model was recorded after the surgeons were happy with the placement and outcome.
75599507|NCT03902080|Drug|Vibegron|oral administration
75599508|NCT03902080|Drug|Placebo|oral administration
75599509|NCT03890367|Biological|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
75599510|NCT03890367|Biological|Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
75599511|NCT03890367|Biological|Meningococcal group C polysaccharide Conjugate vaccine adsorbed|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75616482|NCT02634463|Drug|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
75892014|NCT06090006|Behavioral|Oral health screening|Questions on oral health and visual inspection followed by advice, gift of toothpaste and toothbrush, fluoride varnish application +/- Silver Diamine Fluoride application +/- referral
75892015|NCT06090006|Behavioral|Circumcision screening|Question on circumcision status. Visual inspection. Referral for Voluntary Medical Male Circumcision) where uncircumcised (males only)
75892016|NCT06090006|Behavioral|Risky behaviours|Question (s) on sexual activity and other risky behaviours, followed by Risk reduction counselling, Provision of condoms, Provision of modern contraceptives (emergency contraception, depot injections, oral contraceptive pill) (females only) PreExposure Prophylaxis (PrEP) (females only)
75892017|NCT06090006|Diagnostic Test|HIV testing|HIV oral mucosal self-test +/- confirmatory blood-based rapid diagnostic test followed by Counselling + referral to treatment where indicated
75892018|NCT06090006|Diagnostic Test|STI (CT, NG, TV) testing|Chlamydia Trachomatic (CT) /Neisseria Gonorrhea (NG) test on urine sample, Trichomoniasis Vaginalis (TV) test and treatment where indicated
75892019|NCT06090006|Behavioral|Immunization screening|Question on Human Papilloma Virus (HPV) immunisation history. Review of vaccination card. Followed by referral to immunization
75892020|NCT06090006|Diagnostic Test|Visual impairment screening|Peek Acuity or Snellen Tumbling-E and Refer to specialist if indicated
76062017|NCT05929053|Other|Vaccine Education Program Based on Integrated Change Model|Vaccine Education Program Based on Integrated Change Model The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people.
75892021|NCT06090006|Diagnostic Test|Hearing screening|"HearScreen smartphone app +/- HearTest plus Inspection for presence of wax and wax removal.~Refer to specialist if indicated"
76062018|NCT05929040|Behavioral|mindful cognitive intervention|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
76062019|NCT05929014|Device|Bilateral-Transcranial direct current stimulation (bilateral-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal and anodal electrodes will be applied over the right and left primary motor areas, respectively.
75892022|NCT06090006|Diagnostic Test|Physical impairment screening|Questions on physical impairment. Jump or squat test Functional reach test Referral to specialist if indicated
75892023|NCT06090006|Diagnostic Test|Uncontrolled epilepsy screening|Questions on experience of convulsions followed by referral to specialist if indicated
75892024|NCT06090006|Diagnostic Test|Pre-hypertension screening|Blood pressure measured using digital sphygmomanometer followed by counselling and advice if indicated
75892025|NCT06089993|Other|Exercise|"The total volume of exercise is 40 repetitions of each of the 4 exercises. The participant is instructed to perform a maximum of 10 repetitions each set, with 1'30'' rest between sets and between exercises. The researcher provides instructions and verbal encouragement. The total duration of the exercise bout is between 1 hour and 1 hour and 15 minutes.~Part 1: Before and after the exercise condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
75448893|NCT05419765|Diagnostic Test|Peripheral blood withdrawn|"Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression"
75448894|NCT05400304|Diagnostic Test|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
75599512|NCT03882268|Behavioral|MIYCN interventions|"Capacity building for health providers and nutrition counselors (training on MIYCN SBCC from A&T).~Dedicated room for MIYCN counseling at health facilities with standardized layouts, displays of government IYCF logo, and other specifications.~Availability of standardized MIYCN-specific BCC materials and job aids.~Standardized MIYCN counseling services (counseling on diet diversity and quantity, IFA and calcium supplementation, weight gain monitoring, exclusive and early initiation of breastfeeding, complementary feeding, and water, sanitation and health) provided by a dedicated MIYCN counselor hired by A&T.~Dedicated community worker hired by A&T to identify and mobilize beneficiaries needing services in the community (via satellite clinic outreach, distribute MIYCN flyers, and provision of MIYCN education via phone or home visits).~Supportive supervision of MIYCN counselors and community workers by program and facility managers, and field supervisors."
75892026|NCT06089993|Other|Rest|"The participant remains in sedentary activities such as reading or using a laptop.~Part 1: Before and after the rest condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
76062020|NCT05929014|Device|Cathodal-Transcranial direct current stimulation (cathodal-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal electrode will be attached over the left primary motor area while the anodal will be applied over the right supraorbital.
75448895|NCT05393089|Drug|AGN-190584|Eye drops
75599513|NCT03877549|Drug|Dexamethasone|Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
75448896|NCT05393089|Drug|Vehicle|Eye drops
75599514|NCT03871673|Dietary Supplement|Sweet manioc starch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
75599515|NCT03871673|Dietary Supplement|Cornstarch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
75599516|NCT03868124|Combination Product|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions
75599517|NCT03868124|Drug|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
76062021|NCT05929014|Device|Sham bilateral-tDCS|Sham bilateral-tDCS
76062022|NCT05929014|Device|Sham cathodal-tDCS|Sham cathodal-tDCS
76062023|NCT05928988|Drug|SHR8554；Itraconazole|Drug: SHR8554 Administered as specified in the treatment arm Drug: Itraconazole Administered as specified in the treatment arm
76062024|NCT05928975|Other|MT+ PNE with MI|"The manual therapy treatment approach entailed the management of symptoms based on the clinical judgment of the attending physiotherapist. The physiotherapist selectively employed techniques such as spinal mobilization/manipulation, soft tissue massage, supervised exercises and muscle and neural mobilization, while excluding the utilization of electrophysical modalities. The participants will receive 10 Manual Therapy sessions of 30 minutes within a period of 4 weeks.~The pain neuroscience education program is based on previous clinical studies and available educational materials and is enhanced by motivational interviewing techniques. The program consisted of 4 individualized educational sessions, each lasting 30 minutes. All key aspects of pain neurophysiology were explained and discussed. At the end of the first session, participants will be provided with informational handouts to support the educational process."
76062025|NCT05928975|Other|MT|"Participants in this group will be given the same MT program as MT + PNE with MI group without the application of PNE."
76062026|NCT05928975|Other|Control|The participants in the control group will be provided with written instructions for performing general exercises at home. These exercises will consist of gentle stretching exercises specifically targeting the low back muscles, as well as relief positions and breathing relaxation exercises.
76062027|NCT05928949|Other|pilates exercises|Pilates is a system of repetitive exercises performed on a yoga mat or other equipment to promote strength, stability, and flexibility. Pilates exercises develop the body through muscular effort that stems from the core.
76062028|NCT05928936|Drug|Sodium Bicarbonate|Participants take 650-1300 mg of sodium bicarbonate orally twice daily. Serum bicarbonate levels are measured at baseline and then every 2-4 weeks throughout the trial. Doses will be adjusted or held to avoid metabolic alkalosis.
75599518|NCT03861923|Other|Dry needling|Trigger point dry needling to trigger points in the shoulder or parascapular muscles using monofilament needle (i.e., acupuncture needle). Clean needle approach using sterile needles.
75599519|NCT03861923|Other|Sham Dry Needling|Sham needle approach using a finishing nail in a tube sheath. The finishing nail will be placed over the trigger point so that the patient perceives a sharp sensation. The tube (not the nail) will be moved up and down to mimic the action of needling.
75599520|NCT03861923|Other|Therapeutic Exercise|Exercise including flexibility, range of motion, strengthening will be provided by the treating physical therapist based on the impairments identified.
75599521|NCT03833141|Other|Survey Administration|Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.
75599522|NCT03824184|Procedure|manipulation of endometrium|Manipulation of endometrium with saline
75599523|NCT03803332|Behavioral|Exposure Therapy|Psychotherapy including imaginal and in vivo exposure for PTSD.
75599524|NCT03803332|Behavioral|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.
76062029|NCT05928936|Behavioral|Exercise Training|"Exercise training consists of progressive, interval-based Spin exercise on stationary bicycles three times per week for 12 weeks, led by a certified exercise physiologist. The duration of each session begins at 20 minutes and is increased by 1 to 2 minutes as tolerated to a goal of 45 minutes per session. Exercise intensity begins at low levels (50% of maximal heart rate reserve (HRR)) and increases by 5% every week to a goal of 75% maximal HRR. Each session includes a 5-min warm up, then an interval-based, work-out phase that includes steady up-tempo cadences, sprints, and climbs, followed by a 5-minute cool down."
76062030|NCT05928936|Drug|Placebo|Participants take placebo pills to match 650-1300 mg of sodium bicarbonate orally twice daily.
75599527|NCT03752099|Drug|VERU-111|VERU-111
75743520|NCT05882149|Dietary Supplement|Single strain probiotic|"Sugar-free chewing gum with single strain probiotic and zinc.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
76062031|NCT05928819|Procedure|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
75743521|NCT05882149|Dietary Supplement|Placebo|"Sugar-free chewing gum.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
75599528|NCT03747458|Drug|OPN-375|OPN-375, BID
75599529|NCT03733249|Drug|Rimiducid|Rimiducid is administered to treat chronic graft versus host disease
75599530|NCT03733249|Biological|rivogenlecleucel|donor T-cells modified with iCasp safety switch
75599531|NCT03720717|Drug|Baclofen 10mg|Baclofen administration pre-operatively
75599532|NCT03720717|Other|Placebo|Placebo administration
75743522|NCT05881382|Drug|Dutogliptin + Filgrastim|dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
75743523|NCT05881382|Drug|Placebo|Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
75599533|NCT03705078|Procedure|Transjugular Portosytemic Shunt (TIPS)|The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
75599534|NCT03705078|Procedure|glue obliteration|The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
75599535|NCT03704415|Procedure|Extended endoscopic sinus surgery|ESS of all sinuses
75599536|NCT03704415|Procedure|Limited endoscopic sinus surgery|Partial ethmoidectomy
75599537|NCT03701321|Drug|Bortezomib|Given SC
75599538|NCT03701321|Biological|Daratumumab|Given IV
75743524|NCT05879393|Dietary Supplement|OMNi-BiOTiC® Active|Multistrain probiotic
75743525|NCT05879393|Other|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
75743526|NCT05879094|Other|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
75892027|NCT06089941|Other|circulating tumoral DNA detection|blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse
75892028|NCT06089902|Procedure|unroofing or other surgery if needed|unroofing of coronary artery
75892029|NCT06088875|Drug|Nebulization|Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation. Patients in group S will receive saline 10 ml nebulization
75892030|NCT06088875|Drug|Spray-as-you-go|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization. Patients in group N will receive saline via spray-as-you-go technique
75892031|NCT06088836|Drug|Retrolaminar block group|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency linear ultrasound probe (6-11 MHz) was placed into a longitudinal orientation in the paraspinous line 1 cm from the midline. Lamina appeared as a continuous line interrupted by the intra laminar spaces.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done Then, an 18-gauge Tuohy needle was inserted in plane 1 cm lateral to the spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina."
75599539|NCT03701321|Drug|Dexamethasone|Given PO
75892032|NCT06088836|Drug|Erector spinae plane block group.|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles"
75599540|NCT03701321|Drug|Venetoclax|Given PO
75599541|NCT03687710|Behavioral|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
75599542|NCT03678129|Drug|AZD7325_10|Single oral dose (10mg)
75599543|NCT03678129|Drug|AZD7325_20|Single oral dose (20mg)
75599544|NCT03678129|Drug|Placebo|Single oral dose placebo (capsule)
75599545|NCT03678129|Drug|Clobazam|Single dose (5mg)
75599546|NCT03661684|Drug|Prednisone|40 mg po q day of Prednisone for 3 days
75599547|NCT03620071|Other|GoalKeeper|Mobile-health communication tool for parents of children with medical complexity
75599548|NCT03620071|Other|Standard Care|Standard Clinical Care
75743527|NCT05875415|Other|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
75743528|NCT05875415|Other|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
75743529|NCT05866601|Other|Role-playing for learning the clinical interview|"Thirty-one first-year physiotherapy students will carry out the role-playing methodology to learn how to take a clinical history in physiotherapy.~Before and after the realization, they will be measured by means of a validated questionnaire in Spanish, the language in which they study, the variable of empathy and anxiety."
75892033|NCT06088511|Behavioral|e-Health System with nutritional advice|"A 12-week intervention consisting of a 4-weekly group-based, face-to-face supervised sessions, and an 8-week self-management phase will be arranged to the experimental group. The features of the System will be introduced to the users and their family members in the first two face-to-face sessions. The users and their family members will then be able to start using the System with the mobile app. In the other two sessions, all participants in the experimental group will learn how to accurately complete their dietary records in the e-Health System and will be provided with nutritional advice.~For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants are required to fill in their dietary record in the e-Health System every day, and will be provided with nutritional advice to improve high-quality protein and leucine intake, which is essential for muscle building."
75599549|NCT03585153|Other|Non-contrast magnetic resonance imaging|subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
75599550|NCT03561376|Drug|Topical zinc oxide vs. petrolatum post-surgical scars|"Following linear closure on non-scalp skin with scar length > 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery."
75599551|NCT03560037|Device|Endocuff Vision Assisted Colonoscopy|Detachable device that is fixed to the end of colonoscope. The device has single-row of soft, hair-like projections that flatten colonic folds during colonoscope withdrawal which can aid in detection of colon polyps.
75743530|NCT05857345|Other|Collection of breastmilk|Collection of breastmilk and other information about the participant
75743531|NCT05854472|Other|smartphone based application use|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
75743532|NCT05848817|Device|Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK
75743533|NCT05845931|Dietary Supplement|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
75743534|NCT05843708|Drug|Vorasidenib 40 mg Oral Tablet|"Single oral dose of 1×40 mg vorasidenib tablet administered :~under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)"
76062032|NCT05928793|Behavioral|mindfulness practices|"Mindfulness, according to Kabat-Zinn, is to pay attention to the present moment in a purposeful way, without judgment. Being conscious involves both attention and awareness. Conscious awareness is an observer in the background of the state of consciousness, constantly observing the inner and outer environment. It is to direct our awareness and attention to our experiences in the present moment in an accepting way with our whole body and thoughts."
76062033|NCT05928780|Drug|A1:SG with SHR3680|SG 10mg/kg d1, 8；SHR3680 240mg qd，3 weeks is a cycle
76062034|NCT05928780|Drug|A2:SG|SG 10mg/kg d1, 8
76062035|NCT05928780|Drug|B1:SG with SHR1210|SG 10mg/kg， d1, 8；SHR1210 200mg，d1，q3w；
76062036|NCT05928780|Drug|B2:SG|SG 10mg/kg， d1, 8
76062037|NCT05928780|Drug|C1:SG with SHR3162|SG 10mg/kg d1, 8；SHR3162，150mg，QD ，3 weeks is a cycle
76062038|NCT05928780|Drug|C2:SG|SG 10mg/kg d1, 8
76062039|NCT05928780|Drug|D1:SG with VEGFRI|SG 10mg/kg，d1, 8；BP102 15mg/kg，d1，3 weeks is a cycle
76062040|NCT05928780|Drug|D2:SG|SG 10mg/kg d1, 8
75599552|NCT03550443|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
75599553|NCT03550443|Drug|Placebo|Capsules containing an inert placebo
75743535|NCT05843708|Drug|Ciprofloxacin 500 mg Oral Tablet|Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
75743536|NCT05843708|Drug|Vorasidenib 10 mg Oral Tablet|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
75743537|NCT05841563|Drug|PM54|"PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54.~Route of administration: Intravenous infusion"
75743538|NCT05840991|Device|elastic bandage|3M™ Coban™ elastic bandage
75743539|NCT05840991|Device|compression stocking|Class 2 compression full-length stocking (23-32mm Hg)
75892034|NCT06088511|Behavioral|The Exercise Training|For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants in the experimental group will also be suggested to continually practise exercise training at home for 30 minutes at least 5 times per week. Participants can review the self-learning exercise videos embedded in the System. The exercise trainings include: a) progressive resistance training to improve muscle strength; and b) brisk walking exercise to maintain walkability.
75892035|NCT06088446|Procedure|Supplementary anesthetic injections|Supplementary anesthetic injections after failed primary nerve block
76062041|NCT05928754|Diagnostic Test|care strategy|"Uveitis patients:~Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7."
76062042|NCT05928728|Drug|Colchicine|Colchicine 0.5 mg once daily
76062043|NCT05928728|Drug|Placebo|Placebo once daily
76062044|NCT05928715|Other|Finger feeding|The newborn will receive every expressed breast milk or formula support during the day with the finger feeding method.
76062045|NCT05928702|Procedure|temperature-elevating armbath|Hydrotherapeutic Approach
76062046|NCT05928637|Drug|D745, D759, D150|QD, PO for 5 days
76062047|NCT05928546|Drug|Quercetin|"Intra-pocket application of quercetin nanoemulgel :~After conventional periodontal treatment, the teeth were isolated by cotton rolls for intra pocket application of the gel.~That gel was injected in periodontal pocket using syringe with blunt cannula till the gel excess exit from the pocket ."
75599554|NCT03536052|Device|Virtual Heart Guided Ablation|If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
75599555|NCT03520712|Biological|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
75599556|NCT03497637|Diagnostic Test|measurement of FFR|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
75599557|NCT03497637|Diagnostic Test|measurement of Pd/Pa|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
75599558|NCT03486938|Drug|Placebo Oral Tablet|Placebo oral tablet
75448897|NCT05360524|Procedure|Laminectomy alone versus laminectomy and fusion|"laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.~Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis."
75599559|NCT03486938|Drug|AGB101 220 mg tablet|220 mg AGB101 active compound
75599560|NCT03483844|Diagnostic Test|GE CT 750 HD|Low-dose dual-energy CT imaging
75599561|NCT03469271|Drug|1,25 (OH)2 D3|0.25 micrograms, taken daily for eight weeks, orally
75743540|NCT05836844|Device|The Anchorsure System®|Sacrospinous ligament fixation performed with the Anchorsure Device
75743541|NCT05836142|Procedure|progressive pressure release|Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
75743542|NCT05835843|Other|In-Person and Remote Disease Assessment|Disease severity will be assessed during the in-person visit and standardized digital photographs of different body regions and/or the full body will be collected for remote evaluations by external dermatologists.
75743543|NCT05833035|Drug|BI 1291583 mixed with [C-14] BI 1291583|BI 1291583 mixed with [C-14] BI 1291583
75892036|NCT06087510|Drug|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative analgesia.
75892037|NCT06086067|Other|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
75892038|NCT06085599|Behavioral|Progressive relaxation exercises|The progressive muscle relaxation technique involves suggestive stretching and relaxation in sixteen different muscle groups of the body. This technique is based on tensing each muscle group for approximately 10 seconds and then abruptly releasing this tension.
75892039|NCT06083207|Drug|IBI3003|Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
75892040|NCT06082258|Other|Training in the management of functional disorders|Theoritical and practical training of GP in long COVID and somatic symptom disorders management
75743544|NCT05814822|Behavioral|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.
75743545|NCT05814822|Behavioral|Sleep Hygiene Education (SHE-TM)|Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.
75892041|NCT06082258|Other|Reimbursement of 3 long consultations|3 long consultations (1 hour) reimbursed for each patient
76072051|NCT03387085|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
75448898|NCT05304182|Device|EYESTAR 900|The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.
75599562|NCT03469271|Other|Inspiratory isometric resistance training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).
75599563|NCT03469271|Drug|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
75599564|NCT03469271|Other|Sham Inspiratory Isometric Resistance Training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.
75599565|NCT03469271|Device|Threshold Inspiratory Muscle Trainer (IMT)|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.
75599566|NCT03458260|Drug|Pixantrone|6 cycles - dose = 80mg/m²
75599567|NCT03458260|Other|Ifosfamide|6 cycles - 1500 mg/m2
75599568|NCT03458260|Other|Etoposide|6 cycles - 150 mg/m2
75599569|NCT03458260|Other|Rituximab|6 cycles - 375 mg/m2
75599570|NCT03458260|Procedure|Transplant|after 2 or 6 cycles
75599571|NCT03438188|Other|Practice Quit Attempt|Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
75599572|NCT03431467|Device|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
75599573|NCT03430921|Device|Enlighten™ Laser and a MLA Attachment|Subjects will receive treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment.
75599574|NCT03425279|Biological|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
75599575|NCT03425279|Biological|PD-1 inhibitor|PD-1 inhibitor
75448899|NCT05304182|Device|LENSTAR LS 900|"The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'."
75448900|NCT05286866|Procedure|Dental implant bed preparation|Drilling an osteotomy for placement of a dental implant
75599576|NCT03381573|Drug|Roflumilast|Roflumilast
75599577|NCT03376672|Drug|Ixazomib|All patients will have similar induction and consolidation treatment with the same regimen.
75599578|NCT03376672|Drug|Lenalidomide|All patients will have similar induction and consolidation treatment with the same regimen.
75599579|NCT03376672|Drug|Dexamethasone|All patients will have similar induction and consolidation treatment with the same regimen.
75599580|NCT03357445|Other|Avantage Reload cup|Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty
75599581|NCT03355209|Drug|ZX008 0.2 or 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
75599582|NCT03355209|Drug|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses.
75599583|NCT03302234|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
75599584|NCT03302234|Biological|Ipilimumab|Administered as an IV infusion every 6 weeks (Q6W)
75599585|NCT03302234|Other|Placebo|Normal saline solution administered as an IV infusion Q6W
75599586|NCT03290937|Biological|Cetuximab|Given IV
75743546|NCT05796297|Device|Transcutaneous Capnography|Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation
75743547|NCT05790590|Diagnostic Test|Double low dose CT|Simultaneous reduction of both radiation dose and contrast media dose
75743548|NCT05790590|Diagnostic Test|Standard dose CT|CT with standard radiation dose and contrast media dose
75743549|NCT05783843|Behavioral|Pictorial Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different pictorial warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
75892042|NCT06080542|Procedure|Aerobic|This session will consist of an aerobic training session performed on a cycle ergometer.
75892043|NCT06080542|Procedure|High-intensity interval training|This session will consist of a HIIT performed with elastic bands
75892044|NCT06073301|Device|Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)|Acellular Fish Skin, used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
75892045|NCT06073301|Other|Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)|Acellular Human Cadaver , used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
75892046|NCT06071143|Biological|KDSTEM Inj.|"Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10^8 cells/10mL/2 syringes)~High dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10^8 cells/30mL/6 syringes)"
75892047|NCT06068153|Drug|Sotorasib|Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.
75892048|NCT06068153|Drug|Lenvatinib|Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.
75892049|NCT06067542|Procedure|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
75448901|NCT05195099|Other|respiratory treatment|Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects.
75448902|NCT05019482|Behavioral|University-based intervention to promote PA and reduce ST|"This intervention was realized with all college student and involved:~Design-based innovative workshops during the first week;~8-weeks program of Physical Activity constructed by users~Information session focusing on the promotion of active behaviors~Feedback provided to the users with an individualized report"
75448903|NCT04970381|Drug|Rivaroxaban|Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks
75599587|NCT03290937|Drug|Irinotecan Hydrochloride|Given IV
75599588|NCT03290937|Other|Pharmacodynamic Study|Correlative studies
75599589|NCT03290937|Biological|Utomilumab|Given IV
75448904|NCT04932226|Device|cloth mask|Buff bandana double layer worn over nose and mouth
75448905|NCT04932226|Device|surgical mask|standard surgical mask
75599590|NCT03285321|Drug|Nivolumab|480mg
75599591|NCT03285321|Drug|Nivolumab|240mg
75599592|NCT03285321|Drug|Ipilimumab|1mg/kg
75599593|NCT03283254|Behavioral|Practical Resources for Effective Postpartum Parenting|A preventive psychotherapy intervention for Postpartum Depression
75599594|NCT03283254|Behavioral|Enhanced Treatment As Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community, clinical monitoring
75599595|NCT03272373|Device|NexGen TM Monoblock Tibia|Primary cementless tibia total knee arthroplasty
75599596|NCT03272373|Device|NexGen TM Modular Tibia|Primary cementless tibia total knee arthroplasty
75599597|NCT03247023|Device|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
75743550|NCT05783843|Behavioral|Text Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different text-only warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
75892050|NCT06053463|Device|Daily disposable multifocal soft contact lens|Daily disposable multifocal soft contact lens that will be worn for 1 month.
75892051|NCT06049810|Drug|IBI112|Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 on week 20 & Dose 1 IBI112 through week 44
75599598|NCT03245892|Drug|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
75743551|NCT05783843|Behavioral|No Warnings (Control)|Participants will be shown a single package without a warning. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study.
75743552|NCT05777356|Diagnostic Test|Urine collection and assessment of dietary intake by food frequency questionaire|urinary iodine, creatinine and methylmalonic acid, iodine and vitamin B12 dietary intake from foods and supplements
75743553|NCT05775718|Drug|Zoster Vaccine Recombinant|Injection
75743554|NCT05768607|Procedure|Quality of Life QUESTIONNAIRE (SF36)|Units of a scale of the patients will be compared pre and postoperatively by using SF36
75892052|NCT06049810|Drug|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 on week 20 & placebo through week 44 by subcutaneous injection
76062048|NCT05928546|Device|scaling and root planing|- Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
75448906|NCT04932226|Device|FFP2 respirator|filtering facepiece 2 respirator
75448907|NCT04915560|Device|Connected T-shirt|Ware of a connected T-shirt
75448908|NCT04895046|Drug|Niraparib|300 mg taken orally (all cycles)
75892053|NCT06049810|Drug|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 on week 20 & placebo through week 44
75892054|NCT06049810|Drug|IBI112|Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 on week 20 & Dose 1 IBI112 through week 44
75892055|NCT06049810|Drug|IBI112|Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 through week 44
75599599|NCT03245892|Drug|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
75892056|NCT06049810|Drug|IBI112|Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 through week 44 by subcutaneous injection
75892057|NCT06049420|Behavioral|Lifestyle counseling and coaching|Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.
75892058|NCT06046703|Other|Daily nutritional intake|Nutritional intake with a focus on vitamin B12, but also other micronutrients and macronutrients
75448909|NCT04895046|Drug|Dostarlimab|500 mg (cycles 1-4) intravenously
75448910|NCT04895046|Drug|Dostarlimab|1000 mg (cycle 5+) intravenously
75448911|NCT04837105|Other|Serious game ARROW CP|"ARROW CP is developed for Microsoft Hololens headset. Feedback on gait performance are delivering to the participant in real time and with delay. Participants have to walk at their maximal speed during sprint session."
75448912|NCT04837105|Other|Treadmill|Participant walk on a treadmill at 80% of their maximal speed during maximum 20 minutes (+5 min warm-up / 5 min cool-down)
75599600|NCT03245892|Procedure|Cytoreductive surgery|Cytoreductive surgery
75599601|NCT03245892|Drug|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks x 3-6 cycles in the neoadjuvant setting (maximum 2 doses of ipilimumab)
75599602|NCT03243591|Other|Livionex gel|Brushing area of mucositis with gel
75743555|NCT05768607|Procedure|INCONTINENCE IMPACT QUESTIONNAIRE (IIQ-7)|Units of a scale of the patients will be compared pre and postoperatively by using IIQ-7
76062049|NCT05928533|Other|clean and boost enamel cleanser of vista apex , RE GEN universal adhesive from vista apex , RE GEN Bio active flowable composite form vista apex|the clean and boost use to clean the tooth surface after cavity preparation without causing severe form of hypersensitivity then the RE GEN universal adhesive is applied by using a brush and cured with the RE GEN flowable composite for 20 seconds. Curing both together increase the bioactivity of the material.
76072052|NCT03387085|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
75448913|NCT04805398|Biological|CM310|300 mg every two weeks
75448914|NCT04805398|Biological|Placebo|300 mg every two weeks
75599603|NCT03243591|Other|Aquafresh gel|Aquafresh gel
75892059|NCT06046625|Other|Regular care with additional administration of a semi-structured interview|"Patients receiving regular care. In addition, a semi-structured interview is conducted.~The semi-structured interviews take place once after completion of the care pathway (after all appointments for check-ups associated with the treatment). The interview contains questions about the experience of patients with the care, the needs in this care, the experiences with the information received, the support/guidance, the turnaround time, the treatment received and areas for improvement."
75599604|NCT03228537|Drug|Atezolizumab|Given IV
75599605|NCT03228537|Drug|Cisplatin|Given IV
75599606|NCT03228537|Procedure|Extrapleural Pneumonectomy|Undergo EPP
75892060|NCT06045221|Drug|Orforglipron|Administered orally
76062050|NCT05928507|Diagnostic Test|Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections|"The FINDER FLU A/B, RSV, SARS-CoV-2 Test real-time RT-PCR test for the qualitative detection of viral RNA from RSV, FLU A, FLU B and SARS-CoV-2 in nasopharyngeal (NP) specimens from individuals suspected of respiratory tract infection by their healthcare provider.~Nucleic acids from respiratory viruses identified by this test are typically detectable in nasopharyngeal swabs (NP) during the acute phase of infection. The detection and identification of specific viral nucleic acids from individuals signs is an indication of the presence of the identified microorganism and assist in the diagnosis of respiratory infection when considered alongside other clinical and epidemiological information."
76062051|NCT05928481|Other|Simulation-based postpartum bleeding management training|Postpartum hemorrhage management practices were applied to the students in the intervention group on a high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the Midwifery department.
75599607|NCT03228537|Drug|Pemetrexed Disodium|Given IV
76062052|NCT05928468|Biological|LYB002V14|Participants receiving one or two boost doses of LYB002V14 after a three-dose primary series of inactivated COVID-19 vaccine.
76062053|NCT05928468|Biological|LYB002V14A|Participants receiving one or two boost doses of LYB002V14A after a three-dose primary series of inactivated COVID-19 vaccine.
76062054|NCT05928468|Biological|LYB002CA|Participants at 18-59 years old receiving two boost doses of LYB002CA after a three-dose primary series of inactivated COVID-19 vaccine.
76062055|NCT05928455|Biological|LYB001|Experimental: The LYB001 vaccine was administered through intramuscular injection at doses of 30ug or 60ug in a 0.5mL volume.
76062056|NCT05928455|Biological|CoronaVac|Active Comparator: The CoronaVac vaccine was administered through intramuscular injection in a 0.5mL volume.
75743556|NCT05768607|Procedure|UROGENITAL DISTRESS INVENTORY (UDI - 6)|Units of a scale of the patients will be compared pre and postoperatively by using UDI - 6
75743557|NCT05768477|Other|Consultation|Consultation with the pain specialist, which might entail prescription of medication of vitamins.
75743558|NCT05768477|Procedure|Interventions|Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation
75743559|NCT05768477|Drug|Baxter therapy|Ketamine or Linisol baxter therapy
75743560|NCT05768477|Behavioral|Interdisciplinary therapy|Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
75743561|NCT05754918|Device|TnoFs then TFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without fine structure coding then with fine structure coding
76072053|NCT03387085|Procedure|SBRT|Stereotactic Body Radiation Therapy
75743562|NCT05754918|Device|TFS then TnoFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with fine structure coding then without fine structure coding
75743563|NCT05750160|Other|music therapy|Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
75743564|NCT05743946|Drug|Trikafta|Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
75743565|NCT05742789|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
75743566|NCT05742789|Drug|Isoflurane|В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.
75448917|NCT04721444|Diagnostic Test|Machine Learning Classification of parenchymal lung change cause|Arms A & B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.
75599608|NCT03228537|Procedure|Pleurectomy|Undergo PD
75599609|NCT03228537|Radiation|Radiation Therapy|Undergo RT
75599610|NCT03218137|Drug|Adenosine|Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
75599611|NCT03217266|Drug|Navtemadlin|Given PO
75599612|NCT03217266|Radiation|Radiation Therapy|Undergo radiation therapy
75599613|NCT03211442|Radiation|Radiotherapy|Breast cancer patients treated with radiotherapy
75599614|NCT03202303|Drug|Cannabidivarin|Weight-based dosing of 10 mg/kg/day of CBDV
75599615|NCT03202303|Drug|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo
75599616|NCT03161522|Drug|Capecitabine|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
75892061|NCT06045221|Drug|Semaglutide|Administered orally
75892062|NCT06044285|Other|Dietary change (low ultra-processed food)|"This study incorporates within- and between-subject comparisons. All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Food is provided by the study team for 7 days in accordance with a low UP diet.~Visit 3 and the following week comprise the dietary adherence period, during which all participants receive instructions for a low UP diet to follow on their own. All participants will complete remote assessments at 1 week, 1 month, and 3 month follow-up."
75599617|NCT03161522|Drug|Chemotherapy|Receive induction chemotherapy
75599618|NCT03161522|Procedure|Conventional Surgery|Undergo surgery
75892063|NCT06044285|Other|Dietary change (high ultra-processed food)|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Food is provided by the study team for 7 days in accordance with a high UP diet.~Visit 3 and the following week comprise the dietary adherence period, during which all participants receive instructions for a low UP diet to follow on their own. All participants will complete remote assessments at 1 week, 1 month, and 3 month follow-up"
75892064|NCT06044246|Biological|PRF membrane|Placing implant with PRF membrane treatment
75892065|NCT06038565|Device|RAM cannula ventilator CPAP|RAM cannula ventilator CPAP
75892066|NCT06038565|Device|Occlusive interface bubble CPAP|Occlusive interface bubble CPAP
75892067|NCT06037070|Biological|Platelet Rich Fibrin|PRF will be injected inside the hole that prepared to place dental implant
75892068|NCT06032182|Behavioral|CRESTR Intervention|15 1-hour sessions of CRT + SRT
75892069|NCT06032182|Behavioral|CRESTR Control|15 1-hour sessions of SRT alone
75892070|NCT06030505|Other|No intervention required by the protocol|No visits or samples will be taken specifically for this study. This research involves only prospective or retrospective data collection in relation to the usual hospital management of the child included. Similarly, patient follow-up will be strictly within the framework of their usual hospital care in relation to their pathology.
75892071|NCT06026917|Drug|Toludesvenlafaxine hydrochloride sustained-release tablets|D1~D6, 40mg/ tablet, 1 tablet per time, once a day, D7~D10, 80mg/ tablet, 1 tablet per time, once a day, D11~D42, 80mg/ tablet, 2 tablets per time, once a day. For subjects who cannot tolerate 160mg, the dose may be reduced to 80mg/ dose once daily. After the number of subjects receiving 160mg/ dose reached 6, the remaining subjects received D11~D42, 80mg/ tablet, one tablet each time, once a day.
75892072|NCT06022406|Biological|FMT capsules|Formulation: 80-100g of healthy donor stool processed, frozen and encapsulated in gelatin capsules (modified Kao et al, 2017).
75892073|NCT06022406|Biological|Placebo capsules|Formulation: microcrystalline cellulose, for equivalence in weight and color, will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
76062057|NCT05928442|Device|in vitro diagnostic medical device|Collection of 2 saliva samples at inclusion.
76062058|NCT05928442|Behavioral|Completion of a self-questionnaire|Completion of a self-questionnaire on symptom and quality-of-life at inclusion.
75599619|NCT03161522|Drug|Fluorouracil|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
76062059|NCT05928442|Device|in vitro diagnostic medical device|Collection of 1 saliva sample at the follow-up visit.
75599620|NCT03161522|Radiation|Radiation Therapy|Undergo RT
75599621|NCT03160274|Genetic|Genetic screening|Germline and/or tumor samples will be screened for mutations
75599622|NCT03157102|Device|HFNC|"Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher & Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 >92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). ."
75616483|NCT02634463|Other|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
75743567|NCT05742789|Drug|Sevoflurane|в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
76072054|NCT03385928|Drug|Tranexamic Acid|Investigational product given within 2 hours of symptom onset
76072055|NCT03385928|Drug|Normal saline|Placebo given within 2 hours of symptom onset
75743568|NCT05729607|Procedure|Vertical soft tissue augmentation|Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
75743569|NCT05729607|Procedure|Vertical soft tissue augmentation|Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
76072056|NCT03382340|Drug|Imx-110|a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin
75599623|NCT03157102|Device|Standard Oxygen Treatment|"Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion."
76062060|NCT05928429|Device|Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA|Patients in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).
75743570|NCT05723822|Device|Walkasins|"Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components:~A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet.~A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system."
75743571|NCT05721846|Drug|Nivolumab|3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle
75743572|NCT05721846|Drug|Ipilimumab|1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days)
75743573|NCT05721846|Radiation|SBRT|SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1
75743574|NCT05721846|Biological|TGFβ-B-15 peptide|Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)
75743575|NCT05715489|Procedure|Comparison of pre and postoperative POP-Q values of the patients|Pectopexy Without Using Mesh will be applied to the patients and POP-Q values will be compared pre and postoperatively
75743576|NCT05715489|Procedure|Comparison of pre and postoperative PISQ-12 scores of the patients|Pectopexy Without Using Mesh will be applied to the patients and PISQ-12 scores will be compared pre and postoperatively
75743577|NCT05704712|Behavioral|Monetary Incentives|Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.
75743578|NCT05688696|Drug|Orelabrutinib (Low Dose)|Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy
76062061|NCT05928416|Diagnostic Test|Saliva sample|"During the inclusion visit :~a neurological examination is taken~a saliva sample is taken"
75599624|NCT03155100|Drug|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
76062062|NCT05928416|Diagnostic Test|Saliva sample|"During the inclusion visit :~a saliva sample is taken"
75599625|NCT03155100|Drug|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
76062063|NCT05928364|Procedure|Buccal mucosa for proximal ureter stricture|Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping
75599626|NCT03155100|Drug|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
75599627|NCT03126630|Biological|Anetumab Ravtansine|Given IV
75599628|NCT03126630|Other|Laboratory Biomarker Analysis|Correlative studies
75743579|NCT05688696|Drug|Orelabrutinib (High Dose)|Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy
75599629|NCT03126630|Biological|Pembrolizumab|Given IV
75743580|NCT05688696|Drug|Orelabrutinib Placebo|Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy
75743581|NCT05688254|Behavioral|FOREST-A|The internet-based psychosocial intervention will be delivered. The intervention comprises six modules: introduction, relaxation, psychological detachment, mastery, control, and summary, within psychoeducation and exercises in each module. The interactions with psychologists will be on demand. The whole intervention duration will be 4 weeks.
75743582|NCT05671237|Other|bilateral infraorbital+infratrochlear block|we will perform bilateral infraorbital+infratrochlear nerve block
75743583|NCT05613725|Other|Blood sample collection|Blood sample collection
75599630|NCT03126630|Other|Pharmacological Study|Correlative studies
75743585|NCT05597085|Drug|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL
75743586|NCT05577481|Combination Product|sham iTBS combined with antidepressants|Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
75743587|NCT05577481|Combination Product|iTBS combined with antidepressants|Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
75599631|NCT03125720|Other|Image fusion of SPECT MPI and fluoroscopy venography|In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
75892074|NCT06018831|Other|Urine and Ultrasound Screening|When an infant was born, he/she will receive the first urine and ultrasound screening in 3 months in Kunshan/Qidong City Maternal and Child Health Hospital.In Kunqi Cohort, 9,000 will complete 3 years follow-up(urine screening once every year, another ultrasound screening in 24-30 months). Urine sample (50ml) will be stored only once within one year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study.1,000 children will complete 6 year follow-up(receive urine and ultrasound screening once every year). Urine sample (50ml) will be stored once a year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study. The 14 urine test items include: leukocytes, urobilinogen, microalbumin, protein, bilirubin, glucose, ascorbic acid, specific gravity, ketone bodies, nitrite, creatinine, pH, occult blood, and urinary calcium. Ultrasound test will screen for kidneys, ureters and the bladder.
75892075|NCT06014697|Diagnostic Test|Optical Coherence Tomography|Assessment of the lesion with a non-invasive OCT scan according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
75743588|NCT05574634|Behavioral|Tablet based adaptive multimodal attention practice program|An adaptive at-home tablet-based program that includes variants of the Flanker Task, the Stroop Task, and a Visual Tracking Task. Each session of practice will include up to ten minutes with each of these task types, and the tasks will increase in difficulty in a way that further taxes attention (such as through more distractors or more incongruent trials) as participant performance improves.
75743589|NCT05574634|Behavioral|Tablet based adaptive criterion task practice program|An adaptive, at-home tablet-based variant of the criterion task, that is, the selective attention/distraction task used during the scanning portion of the human participant portions of the study, that takes up to 25 minutes to complete each session.
75743590|NCT05557474|Other|Early-stage lung cancer prognostic kit -- ELISA|blood sample with ELISA
75743591|NCT05557474|Other|Early-stage lung cancer prognostic kit -- IHC|surgical tumor part with IHC
75743592|NCT05544981|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
75892076|NCT06014697|Other|Clinical assessment|Clinical assessment of the lesion by a dermatologist according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
75892077|NCT06012929|Drug|ONC201|ONC201 is an oral medication given once per week
76062064|NCT05928338|Behavioral|Peer-supported, WhatsApp-assisted lifestyle modification intervention|The lifestyle modification intervention, supported by peers and WhatsApp voice calls aimed to assist participants in making dietary modifications, increasing physical activity, and achieve a weight loss of 5% of their initial body weight as well as avoid weight gain. A trained nutritionist delivered the intervention after the baseline assessment individually or in groups that covered six sessions related to dietary modifications, physical activity, set-up goals and action plans, and peer assignments and then once monthly for a year using WhatsApp voice calls to the participants and peers.
76062065|NCT05928286|Drug|Remaxol|The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
76062066|NCT05928273|Device|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
76072057|NCT03374254|Biological|Pembrolizumab|200 mg Pembrolizumab solution for IV infusion Q3W
76072058|NCT03374254|Drug|Binimetinib|tablet orally BID at 30 or 45 mg depending upon DLT profile
75448918|NCT04721444|Diagnostic Test|Machine Learning Classification of recurrence and non-recurrence|Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment
75448919|NCT04704011|Other|2-1-1 United Way Healthy Missouri Hotline|This federally funded, free service connects callers with appropriate community services to help address their unmet basic needs.
75448920|NCT04704011|Other|National Comprehensive Cancer Network (NCCN) Distress Thermometer|Study participants will be asked to rate the amount of distress that they have experienced in the past week (scale of 0 to 10, 10=extreme distress) and indicate areas of concern including practical basic needs and family, emotional, spiritual, and physical problems. They will also be asked to rate the amount of distress (scale 0-10) that they attribute to their abnormal cervical cancer screen.
75599632|NCT03066908|Device|Sinopsys® Lacrimal Stent|Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
75599633|NCT03060473|Drug|Azithromycin|Azithromycin 1 gm PO once
75599634|NCT03060473|Drug|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
75743593|NCT05544981|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
75599635|NCT03060473|Drug|Ampicillin|Ampicillin 2 gm IV every 6 hours for 2 days
75599636|NCT03060473|Drug|Amoxicillin|Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
75599637|NCT03047213|Drug|Sapanisertib|Given PO
75599638|NCT03025386|Other|logatoms test|A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
75892078|NCT06004726|Other|School-based Substance abuse Prevention Programme (SSPP)|"Module 1 :Introduction~Orientation about Training Programme using PowerPoint slides~Psychoeducation and Video Assisted Teaching to enhance awareness of substance abuse.~Distribution of informational booklet on basics about substance abuse~Module 2:~Role play to develop a positive attitude towards the prevention of substance abuse.~Case-based scenario to increase resistance to peer pressure.~Demonstration of drug refusal techniques.~Module3:• Storytelling on Life skills Training Components (Problem solving, Emotion Management)~Module 4:• Demonstration of Life skills training components (Communication skills, Decision making skills, Creative thinking skills, Stress Management strategies )"
76062067|NCT05928247|Behavioral|Functional Communication Training (FCT)|During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. For participants with challenging behavior determined to be maintained by social-positive reinforcement (attention and/or tangible), we also will typically recommend using a multiple schedule FCT (mult-FCT) to signal when reinforcement is available and to thin the schedule of reinforcement to render the treatment more practical for caregivers to implement. For participants with challenging behavior determined to be maintained by social-negative reinforcement (escape), we will recommend using a chained schedule FCT (chained-FCT).
75448921|NCT04704011|Other|Basic needs survey|11-item survey with questions regarding safety, housing, food, and financial needs
75743594|NCT05516069|Other|Our Healthbox (smart vending machine or interactive dispensing system)|Our Healthboxes or interactive dispensing systems (IDS) will be placed in various locations across Canada and will house HIV self-test kits (provided by REACH), harm reduction supplies (provided by the provincial governments / local community based organizations; e.g. sterile drug use kits for safer injection, naloxone kits, syringes), other community determined needs (including but not limited to hats, mittens and/or socks, rapid Covid-19 antigen kits, KN95 masks). Individuals will be able to access the HIV self-test kits and harm reduction and other materials directly from the machine. Our Healthbox will also provide health information, and a support services directory for people to find the health care they need - in their community.
75448922|NCT04704011|Other|2-1-1 survey|This brief, 5-minute survey will be performed either in person or by phone after the participants arrive to their colposcopy appointment or after 6 weeks of their scheduled visit if they are nonadherent. The research team will ask patients regarding any changes in the status of their unmet basic needs (resolved, improved, worsened, or stayed the same) and how useful they found the 2-1-1 resource.
75599639|NCT03025386|Other|Electroencephalography|Mesure of the mismatch negativity wave
75599640|NCT02991625|Other|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
75743595|NCT05499585|Other|Whole Dairy|2 1/2 servings of whole dairy per day
75448923|NCT04704011|Other|Usual Care Reminder Call|-Automated phone call two weeks before their colposcopy appointment
75892079|NCT06004284|Other|control|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
75599641|NCT02991625|Other|Waitlist|These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.
75599642|NCT02991625|Other|Healthy Controls|Healthy control participants will not receive a placebo drug or be put on a waitlist.
75599643|NCT02983578|Drug|Danvatirsen|Given IV
75599644|NCT02983578|Biological|Durvalumab|Given IV
75599645|NCT02949284|Drug|Abiraterone Acetate|Given PO
75599646|NCT02949284|Drug|Androgen Receptor Antagonist ARN-509|Given PO
75599647|NCT02949284|Biological|Gonadotropin-releasing Hormone Analog|Given SC
75599648|NCT02949284|Drug|Prednisone|Given PO
75599649|NCT02949284|Other|Quality-of-Life Assessment|Ancillary studies
76062068|NCT05928247|Behavioral|Non-Contingent Reinforcement (NCR)|During NCR, we will deliver the functional and competing reinforcers on time-based schedules and use multiple and chained schedules to signal when noncontingent reinforcement is available (similar to multiple- and chained-FCT).
76062069|NCT05928247|Behavioral|Competing Items and Response Blocking|We will conduct a competing stimulus assessment (CSA) to identify items that produce at least an 80% reduction in challenging behavior when the participant is engaged with them. We will evaluate conditions in which participants have free access to the item(s), when engagement with the item(s) is prompted, and when challenging behavior is physically blocked. Treatment will include one or more of the following components: non-contingent reinforcement informed by the CSA, reinforcing adaptive behavior, and blocking challenging behavior. We will also use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of the this treatment. The ending duration of the S-delta component will be based on input from caregivers and the participant's school personnel.
76062070|NCT05928247|Behavioral|Research Units in Behavioral Intervention (RUBI) protocol|Caregivers of participants with mild challenging behavior will receive training on a variety of topics, such as prevention strategies and functional communication training, throughout implementation of the RUBI protocol.
75599650|NCT02949284|Other|Questionnaire Administration|Ancillary studies
75599651|NCT02949284|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
75599652|NCT02891954|Drug|Canagliflozin|Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
75599653|NCT02860702|Other|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
75599654|NCT02860702|Other|Human/Bovine Milk|Bovine milk derived fortification
75599655|NCT02835313|Behavioral|FAST|Subjects participate in fast walking training 3x/week for 12 weeks.
75599656|NCT02835313|Behavioral|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
75599657|NCT02835313|Behavioral|SAM|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
75599658|NCT02766231|Device|Physica CR|Cruciate tretaining total knee replacement
75599659|NCT02766231|Device|Physica PS|Posterior Stabilized total knee replacement
76062071|NCT05928208|Diagnostic Test|no intervention|no intervention
76062072|NCT05928169|Drug|Topical and systemic drugs|Recruitment and follow-up will be independent on the type of treatment
75448924|NCT04677829|Biological|PNT001|30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg
75448925|NCT04677829|Biological|%5 dextrose for infusion|30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg
75448926|NCT04672551|Behavioral|EMDR Treatment|Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
75448927|NCT04657198|Biological|RSVPreF3 OA investigational vaccine (GSK3844766A)|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).
75448928|NCT04645836|Behavioral|New management mode|"New management mode intervention: Pharmaceutical care~SMS text messages and Phone Calls~Behavioural Educational leaflet~Self-Administered Therapy A financial incentive for mobile use"
75599660|NCT02754596|Drug|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
75599661|NCT02754596|Drug|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
75448929|NCT04599647|Biological|PVSRIPO|PVSRIPO (5x10^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
75448930|NCT04590586|Drug|Standard of care|Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
75599662|NCT02754596|Drug|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
75599663|NCT02744898|Drug|Carboplatin AUC|
75599664|NCT02744898|Drug|Abraxane|100mg/m2
75892080|NCT06004284|Other|exercise group|The exercise training program will be applied for 8 weeks, 3 days a week and for an average of 20-30 minutes. After the maneuver is taught, stretching exercises lasting 5 minutes for warm-up purposes and posture and core exercises lasting 25 minutes will be taught. Among the stretching exercises, quadratus lumborum stretching, hamstring stretching, erector spina stretching, hip extensor stretching exercises will be applied. Posterior pelvic tilt exercise will be performed as a control and smoothing exercise for the vertebrae of the lumbar and pelvic region. Among the core stabilization exercises, bridging, plank, plank in side lying, abdominal strengthening, cross arm leg lifting exercises in crawling position will be performed. Each exercise position will be required to be maintained for 8 seconds and to do 10-15 repetitions.
75892081|NCT06003595|Other|Data collection on patient reported long-term outcome of SSRF hardware removal|One prospective follow-up visit will be performed. On this visit the patient reported long-term outcome will be documented through a health survey.
75892082|NCT05997602|Drug|FCN-159|5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
75892083|NCT05995873|Device|unilateral transcranial photobiomodulation|An 810nM LED at 240mW/cm2 is placed at either F3 or F4 for 4 minutes.
75892084|NCT05984927|Genetic|NG101 AAV gene therapy|Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
75892085|NCT05983965|Drug|Tazemetostat|Treatment: On day 1 and day 15 of the first cycle, and day 1 of all following cycles, the subject will have office visit with physical exam, vital signs, and lab tests. The subject will take tazemetostat twice a day by mouth continuously as an outpatient. If continuing on the treatment for more than 6 cycles, visits change to every 3 months.
75892086|NCT05981846|Biological|BIMERVAX|One dose of booster vaccine
75892087|NCT05981846|Biological|SIIV|One dose
76072059|NCT03374254|Drug|Oxaliplatin|85 mg/m^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
75599665|NCT02724540|Device|Bland Embolization|Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
75892088|NCT05979337|Behavioral|Empowered Relief|"This is a single-session (2-hour) behavioral intervention utilizing pain psychology principles (cognitive-behavioral therapy for pain, pain neuroscience education).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
76072060|NCT03374254|Drug|Leucovorin|400 mg/m^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
75599666|NCT02724540|Combination Product|Transarterial chemoembolization|Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
75599667|NCT02724540|Combination Product|Drug Eluting Beads Embolization|CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
75599668|NCT02652195|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
75599669|NCT02652195|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
75599670|NCT02565225|Behavioral|RheumaLive App use|
75743596|NCT05486507|Dietary Supplement|Montmorency tart cherry|US grown Montmorency tart cherry 60ml per day for 6 weeks.
75743597|NCT05486507|Dietary Supplement|Placebo|Taste matched placebo.
75743598|NCT05468515|Diagnostic Test|pulse oxygen saturation|preductal oxygen saturation
75743599|NCT05465135|Drug|Dihydroartemisinin|Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
75743600|NCT05464342|Behavioral|Evening LGI Carbohydrate Consumption Group|Participants will receive in the evening food with low glycemic index
75743601|NCT05464342|Behavioral|Evening HGI Carbohydrate Consumption|Participants will receive in the evening food with high glycemic index
75743602|NCT05464342|Behavioral|Evening NO-CHO Carbohydrate Consumption|Participants will receive in the evening a meal with no carbohydrates at all.
75743603|NCT05461157|Device|Preoperative silicone ointment|The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.
75892089|NCT05979337|Behavioral|Health Education (HE)|"This is a single-session (2-hour) health education class reviewing principles of medically indicated self-management of migraine headaches (e.g., consistent dietary and hydration habits, exercise, understanding of and adherence to medical treatment regimens).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
75892090|NCT05979337|Behavioral|Treatment as Usual|"Participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life. In addition, participants will complete daily diaries for 28 days.~If participants are interested in attending classes that were not part of this group assignment, participants will be invited to do so after completing the 6-month follow-up questionnaire."
75892091|NCT05978323|Behavioral|Brief intervention|Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
75892092|NCT05976490|Behavioral|Information and Support Intervention|Information guide and four one-on-one coaching sessions
75892093|NCT05976490|Other|Usual supportive care|Referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician
75892094|NCT05971940|Drug|Orforglipron|Administered orally.
75599671|NCT02425345|Behavioral|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
75892095|NCT05971940|Drug|Placebo|Administered orally
75892096|NCT05971849|Drug|kisspeptin 112-121|IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin
75892097|NCT05971849|Drug|GnRH|Up to one IV bolus of GnRH
75599672|NCT02398773|Procedure|Computed Tomography|Undergo PET/CT
75599673|NCT02398773|Drug|F-18 16 Alpha-Fluoroestradiol|Given IV
75599674|NCT02398773|Other|Laboratory Biomarker Analysis|Correlative studies
75743604|NCT05461157|Other|Preoperative placebo ointment|The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
75743605|NCT05442814|Procedure|Posterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by posterior approach
75743606|NCT05442814|Procedure|Anterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by anterior approach
75743607|NCT05425732|Biological|V116|0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
75743608|NCT05425732|Biological|PCV20|0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
75743609|NCT05389514|Drug|Cyclophosphamide|Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
75743610|NCT05389514|Drug|Gemcitabine|Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
75892098|NCT05970887|Biological|bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine|The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.
75892099|NCT05970887|Biological|quadrivalent influenza vaccine|The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
76072061|NCT03374254|Drug|5-Fluorouracil [5-FU]|2400 mg/m^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
75448931|NCT04590586|Drug|Apremilast|Apremilast administered orally as a tablet.
75448932|NCT04590586|Drug|Apremilast placebo|Matching apremilast placebo administered orally as a tablet.
75448933|NCT04590586|Drug|Lanadelumab|Lanadelumab administered as an intravenous (IV) infusion.
75448934|NCT04590586|Drug|Lanadelumab placebo|Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
75448935|NCT04590586|Drug|Zilucoplan|Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
75448936|NCT04590586|Drug|Zilucoplan placebo|Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
75448937|NCT04588012|Behavioral|The online self-help Program OurRelationship developed by prof. Brian Doss and prof. Andrew Christensen.|The OurRelationship program is developed by prof. Brian Doss and prof. Andrew Christensen.
75599675|NCT02398773|Procedure|Positron Emission Tomography|Undergo PET/CT
75892100|NCT05967871|Biological|Fecal Microbiota Transplant|Participants will receive approximately 50 grams of human stool/150mL (approximately 107 microbes/mL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.
75448938|NCT04588012|Behavioral|"The off line self-help course Pas på Parforholdet."|"The book Pas på parforholdet is written by Mattias Stølen Due."
75743611|NCT05389514|Drug|Pembrolizumab|Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
75892101|NCT05963022|Drug|Tirzepatide|Administered SC
75448939|NCT04564209|Other|Info Viz for Health|During the intervention, health care providers provide HIV-related health education using a mobile app that contains a bilingual database of relevant infographics.
75892102|NCT05963022|Drug|Placebo|Administered SC
75892103|NCT05962970|Drug|continuous adductor canal block (CACB) ropivacaine|The CACB group will receive an infusion of 0.2% ropivacaine 5mL/h
75892104|NCT05962970|Drug|sham continuous adductor canal block - ShACB NaCl|sham continuous adductor canal block - ShACB and ShACB group will receive an infusion of NaCl 0.9% 5mL/h.
75892105|NCT05961176|Device|Skiin pediatric band and Skiin biometric pod|Infants that meet the inclusion criteria will be equipped with a Skiin pediatric band appropriate for their chest size. Heart rate, respiratory rate, temperature, and electrocardiogram will be monitored from 2 to 12 hours through the Skiin pediatric band and a standard of care device (Phillips Intellivue MX750) commonly used in the CCCU at SickKids.
75892106|NCT05955469|Device|FS4 then TFS4 (cochlear implant)|Cochlear implant with default fitting then with tonotopy-based fitting
75448940|NCT04477707|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
75599676|NCT02350764|Drug|nivolumab|
75599677|NCT02350764|Drug|pilimumab|
75892107|NCT05955469|Device|TFS4 then FS4 (cochlear implant)|Cochlear implant with tonotopy-based fitting then with default fitting
75892108|NCT05955040|Drug|Nifedipine|Standard of care for treatment of elevated blood pressure during pregnancy
75892109|NCT05955040|Drug|Labetalol|Standard of care for treatment of elevated blood pressure during pregnancy
75448941|NCT04312009|Drug|Losartan|Losartan; 50 mg daily; oral administration
75448942|NCT04312009|Other|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
75599678|NCT02095132|Drug|Adavosertib|Given PO
75743612|NCT05389514|Biological|Cell Infusion|"Patient's T cells will be administered at a dose of between 1 x 10^9 to 5.0 x 10^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be safely administered and is capable of mediating tumor regression in some patients with metastatic cancers.~The cells are to be infused intravenously over approximately 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping."
75743613|NCT05362149|Drug|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
75743614|NCT05362149|Drug|Enzalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
75892110|NCT05954104|Drug|Calcipotriol|To evaluate the efficacy of Calcipotriol on Alopecia Areata.
75448943|NCT04252573|Device|Chimney Endovascular Aortic Sealing (ChEVAS) System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
75448944|NCT04232696|Device|Neuspera Implantable Sacral Nerve Stimulation System|Stimulation of the Sacral Nerve.
75448945|NCT04100096|Drug|Brexpiprazole|Tablet
75448946|NCT04100096|Other|Placebo|Tablet
75448947|NCT03964337|Drug|Cabozantinib|Cabozantinib 40 mg by mouth daily for 4 weeks.
75448948|NCT03964337|Procedure|Radical Prostatectomy|Radical prostatectomy as part of routine medical care.
75599679|NCT02095132|Drug|Irinotecan Hydrochloride|Given PO
75599680|NCT01922388|Device|Bilateral deep brain stimulation of the subthalamic nucleus|
75599681|NCT01919086|Drug|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m^2, days 1, 8, 15 and 22
75599682|NCT01919086|Drug|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
75599683|NCT01919086|Drug|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
75599684|NCT01908543|Drug|Ferrous sulphate 200mg oral tablet|Administration by mouth
75599685|NCT01867333|Biological|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
75599686|NCT01867333|Biological|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
75599687|NCT01867333|Biological|Enzalutamide|An androgen receptor inhibitor.
75599688|NCT01833715|Drug|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
75599689|NCT01833715|Drug|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
75599690|NCT01833715|Drug|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
75599691|NCT01650701|Drug|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
75599692|NCT01650701|Drug|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
75599693|NCT01650701|Drug|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
75892111|NCT05944224|Drug|SPH4336|SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
75599694|NCT01650701|Drug|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
75743615|NCT05362149|Drug|Apalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
75892112|NCT05944224|Drug|Cadonilimab|Intravenous infusion, 6mg/Kg,28 days/cycle
76062073|NCT05928156|Other|Myeloma Coach or CLL Coach Mobile App|"Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team.~Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources."
75743616|NCT05341882|Behavioral|Mindfulness|Participants took part in a live, facilitated Zoom-delivered training that involved learning mindfulness and education about moral injury. The participants were interviewed regarding the program.
76062074|NCT05928156|Other|Springboard Beyond Cancer informational website|Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
75892113|NCT05943340|Other|Proprioceptive exercises|Specific proprioceptive exercises for the shoulder that the patient has to do during the immobilization period.
75448949|NCT03957226|Device|e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)|The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
75448950|NCT03937466|Device|Cooling mattress pad|The cooling mattress pad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
75448951|NCT03863639|Diagnostic Test|Neuroimaging Procedures|"Subjects will complete neuroimaging procedures at 2-6-week postpartum or during hospitalization after delivery prior to discharge, which will consist of high-resolution anatomic, perfusion and resting-brain fMRI sequences; all of which will be acquired on a 3-Tesla General Electric magnetic resonance scanner~provided by the Brain Imaging and Analysis Center (BIAC) at Duke University. No contrast agent will be administered in these imaging procedures."
75892114|NCT05937672|Device|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
75599695|NCT01650701|Drug|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
75599696|NCT01534494|Drug|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
75599697|NCT01428635|Drug|Eltrombopag Olamine|Given PO
75599698|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
75743617|NCT05341882|Behavioral|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
75743618|NCT05327790|Drug|Lyophilized fecal microbiota (LFMT)|vedolizumab or ustekinumab + FMT vs placebo
75743619|NCT05327790|Other|Placebo|Placebo
75892115|NCT05935410|Behavioral|DM Social Needs|6-monthly sessions of telephone delivered, manualized education and skills training on diabetes management, and problem solving and resolution of social needs.
75892116|NCT05935410|Behavioral|Usual Care|Diabetes education materials in accordance with recommendations from the American Diabetes Association (ADA) will be mailed monthly.
75892117|NCT05931471|Other|Yogurt Intervention|Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
75892118|NCT05931367|Drug|Retatrutide|Administered SC
75599699|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
75743620|NCT05327777|Drug|Oxycodone|Investigators provided set opioid prescriptions for 10 pills each patient.
75599700|NCT01208389|Biological|voretigene neparvovec-rzyl|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
75743621|NCT05327777|Behavioral|Zero Opioid Protocol|Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
75743622|NCT05326074|Other|Animal assisted therapy cohort|A therapy dog will be present in the room during the routine outpatient psychiatric visit.
75743623|NCT05304546|Drug|Pembrolizumab|Solution for IV
75743624|NCT05304546|Drug|Encorafenib|Oral QD
75892119|NCT05931367|Drug|Placebo|Administered SC
75448952|NCT03863639|Diagnostic Test|Neuropsychological Assessment Procedures|Once identified as meeting study criteria and consented for participation, parturients will be tested during hospitalization or as outpatients for controls, and at 2-6 weeks postpartum with the following cognitive battery. Wechsler Test of Adult Reading (WTAR), CANTABeclipse Computerized Cognitive Assessment Measures, Stroop Color-Word Test, Controlled Oral Word Association Test, EuroQol, Beck Depression Inventory Revised
75892120|NCT05930405|Procedure|programmed intermittent epidural bolus|Bolus a certain amount of liquid at fixed intervals according to a predetermined procedure
75599701|NCT00968500|Behavioral|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
75448953|NCT03850483|Drug|PF-06700841|PF-06700841 topical cream
75448954|NCT03850483|Drug|Vehicle (Placebo)|Vehicle topical cream
75743625|NCT05304546|Drug|Binimetinib|Oral BID
75892121|NCT05930405|Procedure|continuous epidural infusion|continuous epidural infusion
75892122|NCT05930405|Drug|ropivacaine and sufentanil|0.15% ropivacaine and 0.4μg/ml sufentanil
75448955|NCT03612479|Behavioral|KIDFIT Healthy|The KIDFIT Healthy intervention promotes the DASH diet, physical activity, limited screen time, and adequate sleep, through a combination of traditional in-person and electronic participant contacts. See NCT03405246 for details.
75743626|NCT05267340|Behavioral|TARA|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
75892123|NCT05930158|Other|Dual Task Exercises|Cognitive exercises to be added during walking and balance exercises will be given as a dual task. Cognitive exercises will consist of exercises for memory, executive functions, calculation, information processing speed (reaction time) and working memory areas. Cognitive exercises such as grouping the words given, giving appropriate answers to the simple situations described, simple addition, subtraction, multiplication, and asking the words that the patient is asked to remember before the exercise will be used. Cognitive exercises will be performed simultaneously with walking and balance exercises.
75892124|NCT05930158|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation content; relaxation exercises, stretching exercises, strengthening exercises, walking exercises, cycling exercises, balance exercises. Exercise intensity will be planned as moderate intensity. Walking and cycling exercises will have warm-up and cool-down periods.
75892125|NCT05929079|Drug|Retatrutide|Administered SC
75892126|NCT05929079|Drug|Placebo|Administered SC
75448956|NCT03612479|Behavioral|KIDFIT Safe|The KIDFIT Safe active control provides electronic material about safe home environments and activities (e.g., sun screen, choking hazards, pet safety) for children. See NCT03405246 for details.
75599702|NCT00856037|Drug|Doxorubicin Hydrochloride|Given IV
75743627|NCT05267340|Behavioral|Psycho-Education|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components
75743628|NCT05263544|Other|measuring uterocervical angle and uterine dimensions|in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
75599703|NCT00856037|Other|Laboratory Biomarker Analysis|Correlative studies
75599704|NCT00856037|Other|Quality-of-Life Assessment|Ancillary studies
75743629|NCT05263076|Other|Uterine Transplant|Transplant of a uterus from a live or deceased donor.
75743630|NCT05243602|Drug|Switch to B/F/TAF|This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
75892127|NCT05929066|Drug|Retatrutide|Administered SC
75892128|NCT05929066|Drug|Placebo|Administered SC
75892129|NCT05929027|Behavioral|NoNo|"Participants in the G2 group will use the Twirlstone (knob-like) device to play a videogame called Nono's World. The Twirlstone is an electromechanical device that resembles a knob and a standard joystick (identical to the discontinued Atari CX-20 Controller). The knob can rotate or move in a push-pull fashion. To control the game's character (an axolotl called Nono), a signal about the knob motion is relayed to the computer wirelessly. This device has been certified by Johns Hopkins University's Clinical Engineering Services, where it was deemed less than minimum risk. The game has been custom built to allow participants to take control of the character using subtle manipulative finger movements to accomplish game-like tasks.~The investigators will use portable communication devices to carry out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
76062075|NCT05928143|Procedure|Traditional corticotomy|A flap covering the alveolar process will be elevated. Perforations will be done using surgical burs, and then the flap will be returned, and sutures will be performed.
76062076|NCT05928143|Procedure|Flapless corticotomy|Some incisions will be made in the mucosa of the alveolar process. Then these incisions will allow the working head of the piezotome to cut the bone in grooves. The whole procedure will not require flap elevation and replacement.
75599705|NCT00856037|Drug|Topotecan Hydrochloride|Given PO
75599706|NCT00788671|Other|Laboratory Biomarker Analysis|Correlative studies
75599707|NCT00788671|Device|Levonorgestrel-Releasing Intrauterine System|Undergo placement of a levonorgestrel-releasing intrauterine system
75743631|NCT05243602|Drug|Continue current regimen|Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
75743632|NCT05236010|Device|rTMS|Transcranial magnetic stimulation is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. During an rTMS session, an electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain being targeted.
75743633|NCT05236010|Device|HD-tDCS|Transcranial direct current stimulation (tDCS), is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain. A constant, low intensity current is passed through two electrodes placed over the head which modulates neuronal activity.
75448957|NCT03563742|Drug|Rilpivirine 25 mg|Participants will receive rilpivirine 25 mg tablet orally once daily.
75448958|NCT03563742|Drug|Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)|Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
75892130|NCT05929027|Behavioral|occupational therapy - self directed|"Participants 5 daily sessions over 3 weeks consisting of self-administered, unsupervised occupational therpay. Additionally, participants will have 2, <15 minutes telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. The intervention will focus on stretches, warm-up and strengthening exercises aimed at improving hand function.~The investigators will use portable communication devices for the purposes of carrying out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
75743634|NCT05236010|Other|Attention Process Training|Attention Process Training (APT) is a multi-session exercise designed to help improve the ability to focus on relevant material while ignoring irrelevant distractions. Further, it helps improve the speed of processing information.
75743635|NCT05234099|Diagnostic Test|18F-FDG Positron emission tomography - MRI|All the examinations will be performed in the supine position on the same integrated 3T PET-MRI scanner
75892132|NCT05924126|Other|empiric antibiotic therapy|septic ICU patient given broad spectrum antibiotic therapy
75448959|NCT03529799|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
75599708|NCT00788671|Other|Quality-of-Life Assessment|Ancillary studies
75599709|NCT00670852|Procedure|X-rays and CT scan|CT Scan x-rays
75599710|NCT00602797|Drug|Paclitaxel|Given IV
75448960|NCT03513237|Procedure|Cervical dilation|manual dilatation of the cervix using surgeon's finger.
75448961|NCT03473925|Drug|Navarixin|Oral capsules
76072062|NCT03374254|Drug|Irinotecan|180 mg/m^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
75448962|NCT03473925|Biological|Pembrolizumab|Intravenous infusion
75448963|NCT03424122|Drug|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
75448964|NCT03424122|Drug|Rituximab|Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
75448965|NCT03424122|Drug|Bendamustine|Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
75743636|NCT05234099|Diagnostic Test|Multiparametric ultrasound imaging|Acquisitions of respiratory muscles (diaphragm, intercostal muscles) will be performed using two 6 MHz central frequency linear transducer (SL 10-2) driven by two identical ultrafast ultrasound devices.
75599711|NCT00602797|Other|Quality-of-Life Assessment|Ancillary studies
75892133|NCT05923489|Diagnostic Test|Routine Angiography Follow-up|Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
75892134|NCT05923489|Diagnostic Test|Routine Clinical Follow-up|Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
75599712|NCT00602797|Other|Questionnaire Administration|Ancillary studies
75599713|NCT00602797|Drug|Vinorelbine Tartrate|Given IV
75599714|NCT00550615|Drug|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
75599715|NCT00550615|Drug|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
75599716|NCT00471848|Drug|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
75599717|NCT00006721|Biological|rituximab|Given IV
75448966|NCT03424122|Drug|Ibrutinib|Ibrutinib administered orally once daily.
75448967|NCT03230097|Drug|BI 409306|50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
75599718|NCT00006721|Drug|cyclophosphamide|Given IV
75599719|NCT00006721|Drug|doxorubicin|Given IV
75599720|NCT00006721|Drug|prednisone|Given orally
75599721|NCT00006721|Drug|vincristine|Given IV
75599722|NCT00006721|Radiation|tositumomab|Given IV
75599723|NCT04300582|Procedure|Cardiac catheterization standard strategy|Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients
75892135|NCT05919745|Drug|Ibuprofen 600 mg|Preoperative delivery of ibuprofen per os.
75743637|NCT05234099|Diagnostic Test|Surface electromyography|sEMG recordings will be performed in the left side on the sternocleidomastoid muscle, the intercostal parasternal muscle, and the external oblique muscle using pairs of 20-mm-diameter silver chloride surface electrodes.
75599724|NCT04300582|Procedure|Cardiac catheterization fast strategy|Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients
75599725|NCT05296876|Procedure|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to perform CEA for patients. All patients will be assessed by SSPC evaluation system before CEA. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA and the type of CEA can be selected as conventional, eversion or a shunt or patch based on the discretion of the surgeon.
75743638|NCT05234099|Diagnostic Test|Transdiaphragmatic preasure measurmement|Esophageal and gastric pressures will be measured using 8-cm balloon-catheters.
75743639|NCT05234099|Diagnostic Test|Magnetic stimulation of the phrenic nerves|In order to quantify the contractile fatigue in diaphragm induced by the ventilatory task (described below), we will use bilateral anterior magnetic stimulation of the phrenic nerves using two Magstim 200 stimulator.
75743640|NCT05234099|Diagnostic Test|Ventilation against inspiratory loading|A POWERbreathe KH2 device (POWERbreathe International Ltd) will be connected on the inspiratory side of the two-way valve. Level of inspiratory loading will be randomized in order to produce different amounts of muscle work in each subject.
75743641|NCT05192863|Other|No Intervention|This is a non-interventional study.
75743642|NCT05188521|Drug|Baricitinib (LY3009104) 2 mg|2 mg orally administered once daily for 16 weeks
75743643|NCT05188521|Drug|Baricitinib (LY3009104) 4 mg|4 mg orally administered once daily for 16 weeks
75892136|NCT05919745|Drug|Placebo|Preoperative delivery of placebo per os.
75892137|NCT05919745|Drug|Acetaminophen|Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
75892138|NCT05917223|Dietary Supplement|Milk protein ingestion|It's just an acute intervention, so the participant assigned to the Milk protein ingestion group will consume 20 g of milk protein during infusion protocol.
75892139|NCT05917223|Dietary Supplement|Cron protein ingestion|It's just an acute intervention, so the participant assigned to the Corn protein ingestion group will consume 20 g of corn protein isolation during infusion protocol.
75892140|NCT05917223|Dietary Supplement|Corn+Pea protein ingestion|It's just an acute intervention, so the participant assigned to the Corn+Pea protein ingestion group will consume 20 g of Corn+Pea protein isolation during infusion protocol.
75892141|NCT05917223|Dietary Supplement|Non-protein, low energy|It's just an acute intervention, so the participant assigned to the Non-protein, low energy group will consume 20 g of carbohydrate during infusion protocol.
75892142|NCT05913375|Radiation|Stereotactic Body Radiotherapy|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate defined with electroanatomical mapping (EAM)
75892143|NCT05909761|Drug|UPLIZNA|Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
75892144|NCT05900336|Drug|Sodium Naproxen|One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
75892145|NCT05900336|Drug|Placebo|One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
75743644|NCT05180773|Drug|Bromocriptine|Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
75743645|NCT05180773|Drug|Placebo|Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
75892146|NCT05893797|Drug|Insulin Lispro|As prescribed.
75892147|NCT05893797|Device|Tempo Smart Button|Attached to the Tempo Pen
75892148|NCT05893797|Device|Dexcom G6 CGM|Continuous glucose monitor
75892149|NCT05893797|Device|Glooko Research Medical App (RMA)|Installed on a study provided android phone.
75892150|NCT05891886|Drug|Oxygen Therapy|Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
75892151|NCT05891886|Device|Non-rebreather mask|Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
76072063|NCT03356028|Behavioral|Child and adolescent psychiatry and Epidemiology|psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
76072064|NCT03356028|Other|salivary biological collection|Saliva sampling will be done using a specific kit
75743646|NCT05180773|Drug|Guideline Directed Medical Therapy for Heart Failure (GDMT)|GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
75743647|NCT05180773|Drug|Rivaroxaban|Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
75743648|NCT05180773|Drug|Second Placebo|Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
75743649|NCT05179577|Drug|Arbaclofen|Arbaclofen Extended Release Tablets
75743650|NCT05179577|Drug|Placebo|Placebo tablets
75743651|NCT05165095|Device|Pacemaker implantation|De novo implantation, device upgrade to dual chamber or device replacement
75743652|NCT05161689|Behavioral|HUG-M+|A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
75892152|NCT05883930|Other|'Let's Move' program|"Students will complete data collection forms as part of the program. According to International Physical Activity Questionnaire (IPAQ), those who are low in activity and inactive will be assigned to the appropriate intervention program based on their sedentary lifestyle stage.~Students will enter the module system prepared according to the five different stages of change [not thinking (1), thinking (2), preparing (3), acting (4), continuing (5)] of sedentary living.~There are 12 different initiatives for each phase/module of the program. Summary and reinforcing questions are asked at the end of each trial. If participants do not answer the questions, they cannot continue with the next week's initiative.~Participants' daily step counts with the smart wristband are recorded in the program.~Daily alerts/reinforcement messages related to that week's initiative will be sent during all phases."
75892153|NCT05883930|Other|no intervention|No intervention will be applied to the control group.
75892154|NCT05882045|Drug|Retatrutide|Administered SC
75892155|NCT05882045|Drug|Placebo|Administered SC
75892156|NCT05878275|Behavioral|Parent Informational Session|Parents will receive a brochure on the importance of tummy time and limiting baby gear and watch a video on the importance of tummy time and limiting baby gear and receive support for implementing tummy time if requested.
75892157|NCT05875623|Other|MALPIP criteria|In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients
75892158|NCT05874063|Drug|Thromboprophylaxis|Thromboprophylaxis in addition of the standard chemotherapy
75892159|NCT05872620|Drug|Orforglipron|Administered orally
75892160|NCT05872620|Drug|Placebo|Administered orally
75743653|NCT05159713|Behavioral|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation."
75743654|NCT05159713|Behavioral|Treatment as Usual|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
75892161|NCT05869903|Drug|Orforglipron|Administered orally.
75743655|NCT05154760|Other|Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises|An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
75892162|NCT05869903|Drug|Placebo|Administered orally.
75892163|NCT05866432|Drug|Datopotamab deruxtecan|Will be given until PD or withdraw
75892164|NCT05856084|Biological|Low dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
76072065|NCT03356028|Behavioral|qualitative analysis of the discourse|two semi-structured interviews, the first with the teenager alone, the second with the lone parents
75743656|NCT05105087|Drug|Perflubutane Microbubble|Given subdermally
75743657|NCT05105087|Procedure|Contrast-Enhanced Ultrasound|Undergo ultrasound
75599726|NCT02873260|Biological|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^4.3 PFU/mL of rDEN2/4Δ30(ME), 10^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
75599727|NCT02873260|Biological|rDEN3Δ30|Administered at a dose of 10^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
75599728|NCT02873260|Biological|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
75599729|NCT01030666|Drug|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
75599730|NCT01030666|Drug|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
75892165|NCT05856084|Biological|High dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
75599731|NCT01030666|Procedure|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
75743658|NCT05097898|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation
75892166|NCT05856084|Biological|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
75892167|NCT05856084|Biological|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
75892168|NCT05855174|Dietary Supplement|Whey protein|Weight protein provided in a shake with carbohydrate and water
75892169|NCT05853601|Drug|Single Dose Theophylline|Subjects are given a single loading dose of theophylline, 5mg/kg IV, within 12 hours after birth. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
75892170|NCT05853601|Drug|Repeat Dose Theophylline|Subjects are given a loading dose of theophylline, 5mg/kg IV, within 12 hours of birth, and then two subsequent doses (1.2mg/kg iv) at 12 hours and 24 hours after loading dose. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
75448968|NCT03230097|Drug|Placebo|placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
75743659|NCT05097898|Procedure|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation
75743660|NCT05097898|Procedure|Blood and urine sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation
75743661|NCT05097898|Other|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24
75448969|NCT03226067|Drug|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
75448970|NCT03226067|Drug|Placebo oral capsule|Matching capsules.
75448971|NCT03190525|Other|Quality of life questionnaires|QLQ-C30
75448972|NCT02993211|Device|Bipolar transurethral standard resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
75448973|NCT02993211|Device|Bipolar transurethral en bloc resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
75448974|NCT02968940|Biological|Avelumab|Avelumab 10 mg/kg intravenously (IV) every 2 weeks
75743662|NCT05097898|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
75892171|NCT05853341|Drug|RID-TDS 13.3 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
75892172|NCT05853341|Drug|Exelon® 13.3 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
75599732|NCT01030666|Biological|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
75599733|NCT01030666|Drug|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
75743663|NCT05096130|Behavioral|Lifestyle Medicine Strategies|"LM addresses health risk factors in primary, secondary, and tertiary prevention of developing disease rather than limiting resources and medical expenditures on acute care and reacting to illness, injury, and disease.~The intervention will target the four pillars of the LM approach including physical activity, diet, stress, and sleep. Certified in LM strategies professionals will consult participants from the LM group in a biweekly base in order to improve their lifestyle habits."
75743664|NCT05091593|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional.
75743665|NCT05091593|Behavioral|Enhanced Usual Care|Usual care from health providers
75743666|NCT05089162|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation
75743667|NCT05089162|Procedure|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional
75743668|NCT05089162|Procedure|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
75892173|NCT05851586|Procedure|Supervised exercise + home exercise program|The supervised exercise + home exercise program group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist. They will also be provided with two supervised exercise sessions per month delivered in a group setting in order to ensure proper performance of the home exercise programs.
75892174|NCT05851586|Procedure|Home exercise program only|The home exercise program only group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist, without any supervised guidance on exercise performance.
75892175|NCT05851534|Behavioral|Preoperative optimisation program|Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
75743669|NCT05089162|Other|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation
75743670|NCT05089162|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
75743671|NCT05089149|Procedure|Clinical examination centered on congestion|Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
75743672|NCT05089149|Procedure|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
75892176|NCT05849805|Procedure|Intracalvaria bone marrow injection|Intracalvaria bone marrow injection Y-3 (dose was given at 32 ug/kg), continuous medication for 3 days
75892177|NCT05849805|Other|Conventional treatment|standard treatment and management according to related guidelines
75599734|NCT01030666|Drug|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
75599735|NCT01030666|Drug|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
76072066|NCT03356028|Behavioral|Parenthood|Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial
75892178|NCT05849051|Behavioral|Newly developed warnings with images at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
75892179|NCT05849051|Behavioral|FDA proposed text-only warnings at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
76062077|NCT05928130|Other|plyometric training protocol|"The plyometric training program will last for 4 weeks, with three sessions per week. The plyometric exercises will be performed immediately after a warm-up. The program will incorporate bilateral, unilateral, acyclic, cyclic, horizontal, vertical, lateral, and diagonal movements involving both slow and fast movements.~Each session will include 4-5 plyometric exercises, with 2-10 sets per exercise and 1-10 repetitions per set. The training volume will progressively increase from the 1st to the 2nd week and then the intensity will increase while the volume decreases from the 3rd to the 4th week in both intervention groups. However, the final volume will vary by 50% between the groups."
75892180|NCT05848830|Dietary Supplement|Mult-ingredient supplement|A mult-ingredient supplement containing Protein, both whey and casein, Creatine, Vitamin D, and Calcium. As well as antioxidants and other dietary supplements including Vitamin E, CoQ10, Alpha Lipoic Acid, L-Arginine, Beet Root Extract, Green Coffee Bean Extract, Green Tea Extract, Black Tea Extract, Curcumin, and Forskolin
75892181|NCT05848830|Dietary Supplement|Placebo|The placebo sachet will contain micro-crystalline cellulose (inactive compound) and will be identical in look and taste to the active supplement.
75448975|NCT02968940|Radiation|Hypofractionated radiation therapy (HFRT)|Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions
75448976|NCT02846350|Behavioral|Motivational Interviewing|"The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision"
75892182|NCT05848830|Behavioral|Concurrent exercise training|All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.
76062078|NCT05928065|Other|Collection of datas|Collection of datas: datas of physical examination (swelling, hematoma, edema), benign trauma (non deforming and closed fractures), ultrasound and radiographic images and evaluation of pain.
75599736|NCT01025752|Behavioral|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
75743673|NCT05089149|Procedure|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
75743674|NCT05089149|Other|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
75743675|NCT05089149|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
75599737|NCT01025752|Behavioral|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
75599738|NCT01030198|Device|RevLite (Laser Treatment)|
75599739|NCT02873884|Behavioral|Case-management|
75892183|NCT05835063|Behavioral|We Chatt communication tool|This arm involves the collaborative completion of a 2-page communication preferences document between a primary physician and an adolescent/young adult patient. Physicians will participate in a 1-hour training led by study principal investigator featuring didactic, multimedia, and experiential-based learning to support the facilitation of the WE CHATT intervention with patients.
75892184|NCT05835063|Behavioral|Usual/standard care|Usual/standard care will be provided. Physicians randomized to the control arm will not receive training in the WE CHATT communication intervention.
75892185|NCT05830955|Other|Lullaby group|The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
75892186|NCT05830955|Other|Breast milk group|The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
75892187|NCT05830955|Other|Control group|The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
75599740|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
75599741|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
75599742|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
75599743|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
75599744|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
75599745|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
75599746|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
75892188|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
75599747|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
75599748|NCT01301456|Biological|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
75599749|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
76062079|NCT05928052|Device|Transcutaneous Biopac Electrical Stimulator|A transcutaneous electrical stimulator sends low levels of electrical current through surface hydrogel electrodes directly to the spinal cord to improve function.
75448977|NCT02803593|Behavioral|Technology-based information and coaching/support program|The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
75599750|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
75599751|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
75599752|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
75599753|NCT01023256|Drug|MOR103|MOR103 0.3 mg/kg or placebo iv x 4 doses
75448978|NCT02803593|Behavioral|American Cancer Society information on breast cancer|The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
75448979|NCT02772068|Drug|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
75743676|NCT05073081|Other|Prehab for LSS|The 8-week prehabilitation program will be delivered online by physiotherapists, chiropractors, and kinesiologists through synchronous and asynchronous exercise sessions, along with online educational sessions.
75743677|NCT05073081|Other|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice.
75448980|NCT02772068|Other|Exercise|
75448981|NCT02755948|Biological|RSV A Memphis 37|Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops
75599754|NCT01023256|Drug|MOR103|MOR103 1.0 mg/kg or placebo iv x 4 doses
75599755|NCT01023256|Drug|MOR103|MOR103 1.5 mg/kg or placebo iv x 4 doses
75599756|NCT04303936|Device|SenseWear® armband device|"Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life, sleep"
75599757|NCT04286620|Device|LASIK|Correcting errors of refraction
75599758|NCT01023022|Other|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
75599759|NCT04324424|Drug|HMS5552|single dose of HMS5552 25mg
75599760|NCT00627718|Device|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
75743678|NCT05067842|Diagnostic Test|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
75743679|NCT05061966|Behavioral|immi|The intervention has four main content areas: 1) gender identity (the gender guide), 2) sexual orientation (the queerness guide), 3)stress and coping (the stress guide), and 4) internalized stigma (the internalized stigma guide).
75743680|NCT05061966|Behavioral|Control|The control will have access to resources on the website, but will not receive any engagement reminders, matching the conditions present in real world contexts in which web-based resource lists are available.
75892189|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
76062080|NCT05928000|Drug|Bulevirtide|BulevIrtide treatment in patients with chronic hepatitis D
76072067|NCT03356028|Behavioral|Cognitive alterations|Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents
76072068|NCT03356028|Behavioral|Impact on schooling|collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child
75448982|NCT02755948|Biological|Influenza A/California/04/2009|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
75448983|NCT02663908|Drug|Degarelix|
75448984|NCT02663908|Drug|Leuprolide|
75599761|NCT02873182|Device|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
75599762|NCT04324736|Other|no interventional study|no interventional study
75892190|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
75892191|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
75892192|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
75892193|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
75892194|NCT05821426|Device|eTrieve PE Kit|Patients will be treated with the eTrieve PE Kit
75448985|NCT02650284|Device|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
75892195|NCT05817643|Drug|BMS-984923|Oral capsule
75892196|NCT05814705|Dietary Supplement|Protein supplement|Ready-to-drink protein beverage consumed once daily for 28 days
75892197|NCT05814705|Dietary Supplement|Protein supplement with Urolithin A|Ready-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days
76062081|NCT05927987|Behavioral|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011; Tol et al., 2013). The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem-solving, stress management, behavioural activation, and accessing social support. PM+ has three core features. It is brief (five sessions given in five weeks), delivered by paraprofessionals (PM+ helpers) and transdiagnostic. The PM+ helpers will be supervised by mental health care specialists.
75448986|NCT02650284|Device|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
75448987|NCT02554487|Device|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI > 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI < 5) following stroke serve as a control group
75448988|NCT02333292|Drug|Telaprevir|Initiation of a regimen containing TVR
75448989|NCT02333292|Drug|Boceprevir|Initiation of a regimen containing BOC
75599763|NCT05643326|Device|40 Hz transcranial alternating current stimulation|42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)
75448990|NCT02333292|Drug|Sofosbuvir|Initiation of a regimen containing SOF
75448991|NCT02333292|Drug|Simeprevir|Initiation of a regimen containing SMV
75448992|NCT02333292|Drug|Daclatasvir|Initiation of a regimen containing DCV
75448993|NCT02333292|Drug|Ledipasvir|Initiation of a regimen containing LDV
75743681|NCT05037734|Device|Persona Partial Knee System|Unicompartmental Knee Replacement
75743682|NCT05027815|Biological|Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells|cryopreserved cellular therapy product in cryostor CS5, for IV infusion
75743683|NCT05003856|Other|Quality-of-Life Assessment|Ancillary studies
75743684|NCT05003856|Procedure|Radiofrequency Ablation|Undergo RFA
75743685|NCT04957758|Drug|OC-01 (varenicline) nasal spray 1.2 mg/ml|OC-01
75743686|NCT04957758|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle)
75743687|NCT04951154|Other|Bronchoscopic Biopsy|Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.
75743688|NCT04951154|Other|Blood Sample|Blood samples will be obtained to measure circulating biomarkers.
75743689|NCT04947176|Dietary Supplement|Supplement|200mg C15:0 once daily
75448994|NCT02333292|Drug|ritonavir-boosted Paritaprevir/ Ombitasvir|Initiation of a drug combination of PTV/OTV
75448995|NCT02333292|Drug|Dasabuvir|Initiation of a regimen containing DBV
75448996|NCT02333292|Drug|Velpatasvir|Initiation of a regimen containing VPV
75448997|NCT02333292|Drug|Elbasvir|Initiation of a regimen containing EBV
75743690|NCT04947176|Other|Placebo|Matching placebo once daily
75743691|NCT04940000|Other|Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).|"Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center.~At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire."
75892198|NCT05809739|Device|STYLAGE Hydro|3 sessions of injections (J0, J14 and J28)
75448998|NCT02333292|Drug|Grazoprevir|Initiation of a regimen containing GZR
75599764|NCT05643326|Device|Sham stimulation|42 sessions of sham stimulation (5 days/week for 9 weeks)
75599765|NCT05367674|Behavioral|Summer Harvest Adventure|Biobehavioral intervention focusing on nutrition and lifestyle behaviors.
75599766|NCT05367674|Behavioral|My Summer Plate (MSP)|My Summer Plate (MSP)
75599767|NCT01058668|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
75743692|NCT04920383|Drug|ALPN-202|Various doses
75743693|NCT04920383|Drug|Pembrolizumab|Varies
75892199|NCT05807997|Other|Refusal of ICU admission.|patients aged 18--99 who were presented to the general intensive care unit from January 2018 to the end of December 2023 and were not admitted.
76072069|NCT03356028|Behavioral|Sleep disorders and associated somatizations|Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
75892200|NCT05805215|Combination Product|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the hippocampus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to < 100 Hz."
75448999|NCT02203773|Drug|Posaconazole|Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
75743694|NCT04920045|Other|Red blood cell transfusion|All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
75892201|NCT05805215|Combination Product|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the Precuneus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to < 100 Hz."
75892202|NCT05805215|Combination Product|High-frequency stimulation (placebo) with Face-name association training task|High-frequency (>1 kHz) stimulation; Standardly used as a carrier frequency; Effects are expected to he high-pass filtered by neurons
75892203|NCT05803421|Drug|Orforglipron|Administered orally once daily
75892204|NCT05803421|Drug|Insulin Glargine|Administered SC once daily
75892205|NCT05803408|Other|gluten-free oats|Early vs late introduction of gluten free oats
75892206|NCT05800717|Behavioral|SCI Self-Management for AIS D|An individually administered, self-management intervention for Veterans with AIS D spinal cord injury.
75892207|NCT05800288|Drug|Propofol|Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
76072070|NCT03354728|Other|Laboratory Biomarker Analysis|Correlative studies
75449000|NCT02203773|Drug|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
75449001|NCT02203773|Drug|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
75449002|NCT02203773|Drug|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
75449003|NCT02175030|Drug|Copper IUD|Randomization to copper/Paragard IUD for emergency contraception
75449004|NCT02175030|Drug|Levonorgestrel IUD|Randomization to Levonorgestrel/Mirena IUD for emergency contraception
75599768|NCT01058668|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
75743695|NCT04919967|Behavioral|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
75599769|NCT00623558|Drug|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
75599770|NCT00623558|Drug|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
75599771|NCT00623558|Drug|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
75743696|NCT04919967|Behavioral|e-learning toolkit|A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
75743697|NCT04907201|Procedure|Cryoneurotomy|Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
75599772|NCT01301066|Drug|Pitavastatin|Pitavastatin 4 mg QD
75599773|NCT01301066|Drug|Pravastatin|Pravastatin 40 mg QD
75599774|NCT01022398|Drug|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
75599775|NCT05642624|Drug|Deoxycholic acid amphotericin B|Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
75599776|NCT05642546|Drug|NM8074|Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
75599777|NCT05642546|Drug|Placebo|Saline Placebo
75892208|NCT05799729|Drug|Ketamine|CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.
75892209|NCT05797441|Behavioral|EMPOWER|The goals of EMPOWER are to increase patients' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in TFT through the continued application of TFT skills, and encourage engagement in meaningful life activities. The program includes a Veteran workbook and four planned therapist contacts over the twelve weeks following TFT completion. The intervention includes: self-monitoring of symptoms, continued practice of TFT skills, engagement in meaningful activities, goal setting, and therapist support.
75892210|NCT05797441|Other|Treatment As Usual|The comparison condition will be TAU following completion of TFT. In the spirit of TAU, providers will not be restricted in the type or intensity of services offered. Depending on local clinic policy or norms, providers randomized to TFT may provide post-TFT treatment themselves or Veterans may be referred to other providers and/or back to the clinician who referred the Veteran to TFT. If providers would have typically discharged Veterans following TFT, that is also allowable.
75892211|NCT05796778|Procedure|subomohyoid plane block|The block needle was inserted in line with the probe in a lateral-to-medial orientation toward the suprascapular nerve. Local anesthetic solution was then injected after negative aspiration for blood to achieve circumferential spread around the neurovascular bundle
75892212|NCT05796778|Procedure|Interscalene brachial plexus block|The block needle is usually advanced in plane in a lateral-to-medial direction through the middle scalene muscle to contact the nerve roots and inject local anesthetic around them.
75892213|NCT05794828|Drug|Bupivacaine Injection|Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
75892214|NCT05784350|Drug|fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone|"group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia."
75892215|NCT05776160|Drug|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
75892216|NCT05775848|Drug|BBP-418 (ribitol)|The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets to provide 3 g BBP-418 per sachet. The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
76062082|NCT05927974|Diagnostic Test|Passive testing|Passive testing includes baseline recordings or behavioral tasks without stimulation. Examples include language tasks, cognitive, and motor tasks. Passive testing typically takes 30-60 minutes and does not require presence of an epileptologist as the tasks are of minimal or no risk.
76072071|NCT03354728|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
76072072|NCT03350126|Drug|Ipilimumab 200 MG in 40 ML Injection|"Induction therapy (12 weeks):~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W"
75449005|NCT01555541|Drug|Ofatumumab|1000 mg IV days 0, 7, 14, 21
75449006|NCT01555541|Drug|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
75449007|NCT01555541|Drug|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
75449008|NCT01398852|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
75449009|NCT01398852|Device|VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
75449010|NCT01398839|Device|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
75449011|NCT01398839|Drug|Riboflavin|Both treatment and sham groups will receive riboflavin
76062083|NCT05927974|Diagnostic Test|Active testing|"Active testing includes any study activity in which stimulation occurs. The most frequent paradigm consists of delivering small amounts of electrical stimulation through the implanted grid/strip/depth electrodes. This will be either continuous stimulation or patterned stimulation such as intermittent theta-burst . Stimulation will range between 1-8 mAmp. The duration of these pulses will last between 2-5 seconds.~Subjects may be asked to rest quietly or to perform behavioral tasks during stimulation. Since there is a risk of evoking seizure activity with active testing, presence of an epileptologist is required. Active testing will only occur once the PI/staff has communicated with the epileptologist regarding safety, feasibility, and timing of active testing. Active testing will typically take 60-90 minutes and is only performed once patients are back on their anti-seizure medications."
76062084|NCT05927961|Diagnostic Test|histopathology|There is a clear boundary between adrenal adenoma and surrounding normal tissue. There is no clear boundary between adrenal hyperplasia and surrounding normal tissues.
76062085|NCT05927948|Device|Laight therapy, NICE V3.1 device|Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.
75599779|NCT05642390|Device|Breast implant|Patients operated for breast augmentation or reconstruction.
76062086|NCT05927233|Drug|Methylprednisolone|30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
75892217|NCT05775848|Other|Placebo|A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
75743698|NCT04899934|Behavioral|mobile and technology assisted aftercare|The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.
75743699|NCT04899934|Other|Treatment as usual|Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
75743700|NCT04868110|Behavioral|High fiber diet|A registered dietitian will delivered the lessons on consuming a high fiber diet to small groups to increased engage and material retention. These lessons will last 18 weeks.
75743701|NCT04854967|Other|Rescind home oxygen order|A note will be entered in the medical record describing the participants randomization into the intervention group. The note will be signed by study staff and will accompany the discontinuation of the patient's home oxygen by a study clinician.
75599780|NCT04324346|Drug|FEC75 (or EC90) x 6|Type of Chemotherapy
75599781|NCT04324346|Drug|FEC100 + Taxotere (EC90 + Taxotere) 3+3|Type of Chemotherapy
75599782|NCT04324346|Drug|Paclitaxel|Type of Chemotherapy
75599783|NCT05642234|Procedure|Epidural Ultrasonography|In this study, we measured the intervertebral distance and skin-epidural distance with the help of ultrasonography in the thoracic and lumbar regions in sitting and rider positions.
75892218|NCT05775185|Radiation|Orbital radiotherapy|Low dose fractionated orbital radiotherapy, total dose 20 Gy in 2-week period.
76062087|NCT05927233|Drug|Saline|30 ml Normal saline
76062088|NCT05926232|Drug|Repotrectinib|Repotrectinib
75599784|NCT04300114|Drug|Fluzoparib|Fluzoparib capsules po. 150 mg twice daily
75449012|NCT00501176|Procedure|Plastic and metalic stent inserion|Patient randomizes to metal or plastic insertion prior to Whipple procedure
75449013|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
75449014|NCT03178786|Behavioral|PAT sessions|PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
75449015|NCT03174379|Procedure|Standard of Care with no acupuncture|The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
75599785|NCT04300114|Drug|Placebo|Placebo capsules po. twice daily
75599786|NCT02890238|Drug|Clomiphene citrate|50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
75599787|NCT02890238|Drug|sildenafil citrate|20mg tab from 7th-11th day of the same cycle orally 3times/day
75599788|NCT02890238|Drug|Placebo|tab from 7th-11th day of the same cycle orally 3times/day
76062089|NCT05925725|Drug|• harpagozid • boswellin = LOXACON|Exercise therapy
76062090|NCT05925595|Device|Medical Device Iniettabile Ginocchio|Knee injection of the investigational device( MD Iniettabile Ginocchio) versus active comparator (Jonexa).
75892219|NCT05773976|Device|Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil|"At baseline visit (V0), as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~Afomill Refreshing Soothing~Afomill Anti-redness Eye Drops~Iridil"
75892220|NCT05773963|Device|Irilens; Iridina; Afomill Lubricating Eye Drops|"Irilens (with 0.4% HA as key ingredient);~Iridina (with 0.4% HA as key ingredient);~Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile)."
75892221|NCT05769010|Drug|SHR-A1811|SHR-A1811: intravenous
76062091|NCT05925231|Diagnostic Test|Box and Block Test|3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test
76062092|NCT05924906|Drug|NB002|Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
76062093|NCT05922917|Device|pulsed-field ablation|application of pulsed-field energy for pulmonary vein isolation and linear ablations
76062094|NCT05921786|Device|Electrophysiological system|Electrophysiological system is used for examining voltage variation in biological samples. And multiphoton microscopy is a common type of nonlinear optical microscope.
75599789|NCT00627796|Drug|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were > 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were < 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels <1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
75892222|NCT05769010|Drug|Pyrotinib|Pyrotinib: oral
75892223|NCT05769010|Drug|Bevacizumab|Bevacizumab: intravenous
75599790|NCT05640206|Procedure|i-PRF|Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
75599791|NCT05640206|Procedure|Arthrocentesis|Arthrocentesis performed with two-needle technique
75743702|NCT04854967|Behavioral|Provider Education|A note will be entered in the medical record informing the patient's individual medical providers (i.e. primary care provider, pulmonologist) of their randomization into the intervention group. The note will include the evidence-base for oxygen use among patients with COPD.
75743703|NCT04854967|Behavioral|Patient Education|"The patient will receive a patient education page about discontinuation of home oxygen after recovery from a hospitalization that was developed by Consumer Reports in conjunction with the Choosing Wisely Campaign."
75892224|NCT05767021|Drug|Mirikizumab|Administered IV
75892225|NCT05767021|Drug|Mirikizumab|Administered SC
75892226|NCT05762146|Drug|Riociguat|Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.
75599792|NCT05639582|Other|fractal analysis|fractal analysis is a method that numerically expresses bone changes.
75599793|NCT01262976|Biological|GSK's investigational vaccine 692342|Intramuscular, 2 doses
75599794|NCT01262976|Biological|Physiological saline|Intramuscular, 2 doses
75892227|NCT05762146|Drug|Propylthiouracil|Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors
75892228|NCT05762146|Drug|Perphenazine|Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
76062095|NCT05921786|Device|Multiphoton microscope|Multiphoton microscope acquires high-resolution image based on nonlinear optics and can be used for detect biological specimens.
75599795|NCT01300286|Drug|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
75892229|NCT05756023|Procedure|the pregnancy rate at IVF / ICSI cycles|To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
75892230|NCT05753826|Drug|Adebrelimab|20mg/kg，D1，q3W
75892231|NCT05753826|Drug|Fuzuloparib|100 mg bid
75892232|NCT05747690|Device|KIO015|Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection
75892233|NCT05741918|Diagnostic Test|Fick's method|Cardiac output measurement by Fick method
75892234|NCT05741918|Diagnostic Test|Echocardiography|Cardiac output measurement by echocardiography
75892235|NCT05741047|Other|a2Milk skim milk powder|a2Milk skim milk powder (1L) containing A2 β-casein only
75892236|NCT05741047|Other|Yili skim milk powder|Yili skim milk powder (1L) containing A1 and A2 β-caseins
76062096|NCT05906862|Drug|AMT-253|Administered intravenously
76062097|NCT05904548|Device|RF Ablation|RF ablation for type I atrial flutter under iCMR guidance
76072073|NCT03350126|Drug|Nivolumab 10 MG/ML|"Induction therapy (12 weeks) :~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W~Maintenance therapy (40 weeks):~Nivolumab monotherapy IV over 60 minutes Q2W until iRECIST progression or if no PD for one year."
76062098|NCT05904132|Device|tACS device|you will receive one of four treatment conditions that include active and sham tACS. The four conditions are the following: (1) closed-loop-tACS (peak-locked), (2) closed-loop-tACS (trough-locked), (3) open-loop tACS, and (4) sham tACS. Although each subject will undergo all four treatments in four separate study visits, the order of the treatments will be randomized
75892237|NCT05740514|Behavioral|Exercise|Exercise training.
75599796|NCT05616728|Drug|EDP-235|capsule
75743704|NCT04854967|Behavioral|Teach-to-goal inhaler training|Teach-to-goal (TTG) inhaler training is a patient-centered education strategy that has been shown to decrease inhaler misuse and decrease acute care utilization. The training is tailored to the patient and meets guideline recommendations for assessment and instruction of inhaler technique. The rounds of assessment and demonstration can be completed until acceptable skill level is attained and tailored to the specific medication prescribed.
75892238|NCT05740514|Behavioral|De-training|Exercise de-training via unilateral knee immobilization.
75892239|NCT05739162|Device|Apollo Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), and endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 70-80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
75892240|NCT05739162|Behavioral|Lifestyle Intervention|Low-calorie healthy diet personalized by a dietician according to individual patients' needs and conducive to weight loss. Physical activity will be encourage and assessed.
75892241|NCT05737199|Drug|MK-3475 (pembrolizumab)|MK-3475 (pembrolizumab) 200mg IV every 3 weeks [Q3W] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.
75599797|NCT05616728|Drug|Placebo|capsule
75599798|NCT02890316|Other|Homeopathy remedy|Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.
75599799|NCT02890316|Radiation|Radiation as adjuvant therapy for breast cancer|Daily radiation therapy.
75599800|NCT01300052|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
75599801|NCT01300052|Drug|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
75599802|NCT01299896|Other|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
75599803|NCT01299896|Other|Usual Care|Standard therapy to help participants with smoking cessation.
75599804|NCT01299584|Drug|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
75599805|NCT00637208|Procedure|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
75599806|NCT01236573|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
75599807|NCT01236573|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
75599808|NCT01236573|Biological|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
76025025|NCT01958476|Drug|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally >8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores <8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
76062099|NCT05890131|Other|Digital letter|A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
76062100|NCT05880537|Other|Nexeon Arterial Venous Allograft|Nexeon AVX allograft for hemodialysis access in end stage renal disease
76062101|NCT05873218|Drug|Ephedrine|The intervention will be up to two 7.5 mg doses of ephedrine given after the placement of a combined spinal epidural with 25 mcg intrathecal fentanyl timed 3 and 15 minutes after intrathecal opiate administration.
75599809|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
75599810|NCT01236339|Procedure|LVP|Large Volume Paracentesis
75892242|NCT05732376|Behavioral|Nasopharyngoscopic Velopharyngeal Training with 3D Printed Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the 3D printed endoscopy training model. Participants will receive hands-on training on the 3D printed endoscopy training model, under the guidance of the principal investigator."
75892243|NCT05732376|Behavioral|Nasopharyngoscopic Velopharyngeal Training with Ready-Made Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the ready-made endoscopy training model. Participants will receive hands-on training on the ready-made endoscopy training model, under the guidance of the principal investigator."
75892244|NCT05732363|Device|Ultrasonography|The US muscle measurement will be performed with the handheld portable Philips Lumify Sonography connected to a Samsung tablet. The measurement will take approximately 5-10 minutes. A seven-point measurement has to be performed based on the seven-site Jackson Pollock Generalized Prediction Equations for circumference and skinfold thickness measurements.6,7
76062102|NCT05873218|Drug|Normal Saline Placebo|Placebo will be administered at matching rate.
76072074|NCT03347929|Drug|Naproxen 500 Mg|10 days treatment with Naproxen 500 mg twice daily
76072075|NCT03347929|Drug|Placebo|10 days treatment with Placebo1 tablet twice daily
75449016|NCT03174379|Procedure|Acupuncture|The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
75599811|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
75599812|NCT01262898|Drug|GSK962040 (5 mg tablet)|5 mg tablet
75449017|NCT03164889|Drug|Granulocyte Macrophage-colony Stimulating Factor|The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
75449018|NCT03164889|Drug|Entecavir|Antiviral drug for hepatitis b virus (HBV)
75449019|NCT03161444|Other|Biological sample collection|A blood sample collection for the study will be taken to each participant Each subject enrolled must have previously participated to the study CHIKVIH.
75599813|NCT01262898|Drug|GSK962040 (25 mg tablet)|25 mg tablet
75599814|NCT01262898|Drug|GSK962040 (125 mg tablet)|125 mg tablet
75449020|NCT03141190|Behavioral|Mindfulness Based Stress Reduction - modified|already described
75449021|NCT03141190|Behavioral|Active listening and reading|group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
75599815|NCT01262898|Drug|Placebo|matching placebo tablet
75599816|NCT01262820|Drug|Pazopanib|Pazopanib, 800 mg by mouth daily each 21 day cycle
75599817|NCT04323072|Procedure|Wide antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.
75892245|NCT05732363|Radiation|Dual-energy X-ray Absorptiometry|The brand of the DXA scanner is the Hologic Discovery A, which has a weight limit of 204 kilograms. During the DXA scan, patients will be exposed to radiation, which is approximately 0.2 micro Sievert (µSv) for measuring body composition. For comparison: the average amount of background radiation per hour is approximately 0.23 µSv. The DXA body composition scan will be performed according to standard protocol by a specialized technician.
75599818|NCT04323072|Procedure|Smal antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.
75743705|NCT04854967|Behavioral|Pursed lip breathing|Pursed lip-breathing will be taught to the participants randomized to the intervention arm. This simple technique relieves breathlessness and has been shown to improve functional capacity in patients with COPD. Participants will be given an instructional handout to refer to after the visit.
75743706|NCT04848636|Diagnostic Test|Cardiac Sodium and Proton MRI|Sodium-23 MRI of the Heart Proton MRI of the Heart
76025026|NCT04809181|Drug|Azacitidine in Combination With Venetoclax|Azacitidine in combination with venetoclax
76025027|NCT05737381|Other|Differential oxygen tension|By culturing the embryos in a differential O2 set-up, changing the O2 tension from reduced (5% O2) to ultralow (2% O2) from day 3 to day 5 of embryo development in vitro, we mimic the physiological differential changes in O2 as the embryo migrate from the oviduct to the uterus and develops in vivo.
76062103|NCT05858034|Other|Customized activity plan|Clients with identified challenges to successful aging (pre-frail or frail on screening) will be invited to develop an individualized activity plan to increase mobility, strength, and stamina. Plans will combine activities to improve strength (resistance training), balance (balance exercises), and stamina, and establish weekly goals. Resistance bands and pedometers will be provided. Progress will be measured by self-reported adherence to the activity plan at week 2, 4, 8, 12 and 24 (assessed by telephone at weeks 2, 4, 8 and in person at week 12 and 24). Depression questionnaire (PHQ-9), fatigue screen, exhaustion questions, and SF-12, a measure of health-related quality of life, will be administered at baseline, week 12 and 24.
76062104|NCT05858034|Other|Customized nutrition plan|Participants with nutritional needs will have the option of meeting with a nutritionist to develop a personalized nutritional plan with a goal of improving diet quality and optimizing caloric intake. Progress will be measured as above.
76062105|NCT05853380|Device|Informed Vital Core App|All subjects assigned to a single arm, pulse rate measurement will be collected, calculated, and displayed on the web based application. A conventional ECG device will also be used to collect and display the heart rate at the same time. If additional consent is obtained subjects may provide blood pressure and SpO2 measurements for the web based application.
76062106|NCT05848622|Behavioral|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
76072076|NCT03341130|Device|Mandibular Repositioning Splint|The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.
75743707|NCT04844580|Drug|Inhaled Aviptadil|Aviptadil is the synthetic analogue of the Vasoactive Intestinal Peptide (VIP), a biologically active 28 amino acid natural peptide that is endogenously synthesized in humans. It is one of the signaling molecules of the neuroendocrine immune network and has vasodilator, anti-proliferative, anti-inflammatory and immunomodulatory properties.
75743708|NCT04844580|Drug|Placebo|Aviptadil Placebo will be used for this arm.
75449022|NCT03133260|Diagnostic Test|Troponin|Troponin will be measured before surgery and postoperative at days 1,2 and 3.
76025028|NCT01057121|Drug|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
75449023|NCT03133260|Drug|Acetylsalicylic acid|100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
75449024|NCT03133260|Drug|Statin|40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
75449025|NCT03121235|Diagnostic Test|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
75599819|NCT04323228|Dietary Supplement|Oral supplement enriched in antioxidants|the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.
75599820|NCT04323228|Dietary Supplement|cellulose-containing placebo capsules|The placebo group will receive an oral supplement at the same time in the same shape/size/color.
75599821|NCT04322916|Device|RM Pressfit vitamys|Implantation of a RM Pressfit vitamys hip cup
75743709|NCT04827134|Drug|TRIUMEQ|TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
75599822|NCT04322760|Drug|Lidocaine 5% patch with Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports
75743710|NCT04827134|Drug|DOVATO|DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
75892246|NCT05721378|Procedure|Permissive Weight Bearing group|The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.
75892247|NCT05721378|Procedure|Restricted Weight Bearing group|The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
75892248|NCT05721092|Other|Pre and Post Education on practice of pneumococcal vaccination|A cross-sectional study will be conducted among 25 diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
75892249|NCT05716789|Procedure|CPR|CPR in cardiac arrest patients
75892250|NCT05715021|Procedure|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
75449026|NCT03097146|Other|comprehensive multidisciplinary stroke care|"Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies."
75599823|NCT04322760|Drug|Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%
75599824|NCT04322838|Diagnostic Test|MeDALL questionnaire for allergic diseases|Questionnaire about allergic symptoms and disease
75743711|NCT04826276|Other|smoking abstinence|participants will be asked to not smoke for at least 12 hours
75892251|NCT05712161|Device|DurAVRTM THV System|The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve
75892252|NCT05706493|Other|Non surgical periodontal treatment|Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes
75599825|NCT04322838|Diagnostic Test|Registration of allergic symptoms|Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.
75599826|NCT04322838|Diagnostic Test|Skin Prick Test|Diagnostic skin test for sensitization to allergens
75599827|NCT04322838|Diagnostic Test|Specific IgE in serum|Diagnostic test for sensitization to allergens in serum
75449027|NCT03096834|Biological|AMG334 (70 mg) Pre-Filled Syringe (PFS)|Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection
75449028|NCT03096834|Biological|Placebo Pre-Filled Syringe (PFS)|Subcutaneous injection of matching placebo
75599828|NCT04322838|Diagnostic Test|Nasal provocation test|Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)
75599829|NCT04322838|Diagnostic Test|Basophil Activation Test|Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.
75599830|NCT04322214|Drug|Cobicistat 150 MG|once daily cobicistat (150 mg QD) for 5 days
75599831|NCT04322214|Drug|Placebo|once daily lactose capsules (as aspect cobicistat capsules)
75599832|NCT04322214|Drug|GHB|single oral dose of GHB (25 mg/kg) on days 5 and 17
75599833|NCT02889276|Other|Functional Resistance Training|Supervised group-based Functional Resistance Training
75743712|NCT04826276|Other|smoking satiety|participants will be asked to smoke as usual
75743713|NCT04818593|Device|ZyMot Multi Sperm Separation Device (850 ul)|850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi device, followed by placement of 750 uL culture medium in the outlet port and throughout the upper collection chamber. The device will then be incubated in a humidified 37C CO2 incubator for 30 minutes. During incubation, the healthiest and most motile sperm will swim through the microporous filter and into the upper collection chamber, where they will be recovered via the outlet port. 500 uL of the sperm sample will be removed and placed in a separate tube for analysis and insemination.
75743714|NCT04818593|Other|Density Gradient Centrifugation|Density gradient centrifugation will be performed using a one-layer preparation of 90% Isolate in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The sperm pellet will be washed by mixing with Multipurpose Handling Medium Complete and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is removed and discarded and the pellet is re-suspended in culture medium, assessed for sperm parameters, and held at room temperature until insemination.
76062107|NCT05848622|Behavioral|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
76062108|NCT05842291|Device|Active rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
76062109|NCT05842291|Device|Sham rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days, using sham stimulation coils that comprehensively mimic the active condition. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
75599834|NCT02889276|Behavioral|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
75599835|NCT05656092|Drug|HIP0612|Test drug
75449029|NCT03065465|Device|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
75599836|NCT05656092|Drug|HPP2202|Placebo drug
75743715|NCT04811079|Other|419 nm Spectacle Filter|TEST
76062110|NCT05842291|Device|Active rTMS with long inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 50 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
75449030|NCT03065465|Other|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
75449031|NCT03065192|Drug|VY-AADC01|Single dose, neurosurgically infused, bilaterally into the striatum.
75449032|NCT03056014|Drug|N-acetyl cysteine|giving varying doses of NAC in order to determine which reduces oxidative stress.
75449033|NCT03056014|Dietary Supplement|omega 6 Fish oil ( PUFA)|giving varying doses of PUFA in order to determine which reduces oxidative stress.
75449034|NCT03056014|Dietary Supplement|Placebo|L-alanine placebo pill to determine if effect is supplement related or random effect.
75599837|NCT05656092|Drug|RLD2204|Reference drug
75449035|NCT03126812|Drug|Carboplatin|Carboplatin AUC=6
75449036|NCT03126812|Drug|Paclitaxel|paclitaxel 80 mg/m2
75449037|NCT03126812|Drug|Pembrolizumab|200 mg flat dose, starting cycle 2
75599838|NCT05656092|Drug|HPP2201|Placebo drug
75599839|NCT01057810|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
75599840|NCT01057810|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
75449038|NCT03042754|Diagnostic Test|XpertMTB/RIF|
75743716|NCT04811079|Other|437 nm Spectacle Filter|TEST
75743717|NCT04811079|Other|456 nm Spectacle Filter|TEST
76062111|NCT05841355|Other|Educate|Education sessions
76062112|NCT05841355|Other|Empower|Empowerment sessions
75743718|NCT04811079|Other|476 nm Spectacle Filter|TEST
75599841|NCT01262352|Drug|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
75599842|NCT01262352|Drug|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
75599843|NCT01299272|Drug|LY2216684|
75599844|NCT01299272|Drug|Placebo|
75449039|NCT03026972|Biological|Placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.
75449040|NCT03026972|Biological|Low dose adjuvant|Population I and polulation IV are coxal muscle injection of low dose adjuvant.
75449041|NCT03026972|Biological|High dose adjuvant|Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.
75743719|NCT04811079|Other|373 nm Spectacle Filter|CONTROL
75892253|NCT05705726|Device|ultrasound guided facia iliaca block|Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .
75892254|NCT05705726|Drug|Intravenous drug|Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
75449042|NCT03026972|Biological|Low dose vaccine|Population I and population IV are coxal muscle injection of low dose vaccine.
75599845|NCT01299272|Drug|SSRI|Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
75892255|NCT05705479|Procedure|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
75892256|NCT05705479|Procedure|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
75599846|NCT02889198|Behavioral|Go NAP SACC|Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
75599847|NCT04322292|Drug|C-CAR088|"Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10^6 CAR+T cells/kg),medium(3.0-6.0×10^6 CAR+T cells/kg) and high(6.0-9.0×10^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell."
75599848|NCT01299116|Drug|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
75599849|NCT01299116|Drug|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
75599850|NCT01299116|Drug|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
75599851|NCT01299116|Drug|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
75449043|NCT03026972|Biological|High dose vaccine|Population II,population III and population IV are coxal muscle injection of high dose vaccine .
75449044|NCT03012815|Drug|Gabapentin|Gabapentin administered as a taper
75449045|NCT03012815|Drug|Benzodiazepines|Benzodiazepines administered using a symptoms triggered protocol
75449046|NCT03012815|Drug|Divalproex Sodium|Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)
75449047|NCT03001011|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
75449048|NCT03001011|Drug|Sevelamer Carbonate (GZ419831)|"Pharmaceutical form: tablet~Route of administration: oral"
75449049|NCT02993757|Biological|CYD Dengue Vaccine|0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.
75449050|NCT02993757|Biological|CYD Dengue Vaccine|0.5 mL, SC injection at Month 1, 7 and 13, respectively.
75449051|NCT02993757|Biological|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, IM injection at Day 0 and Month 6, respectively.
75449052|NCT02980068|Drug|15N Nitrate|1,000 mg/11.8 mmol, oral, on day one, hour zero
75449053|NCT02980068|Drug|14N Nitrate|1,000 mg/11.18 mmol, oral, on day hour, hour zero
75449054|NCT02979535|Biological|CYD Dengue Vaccine|0.5 mL, SC at Day 0, Months 6 and 12
75449055|NCT02979535|Biological|CYD Dengue Vaccine|0.5 mL, SC at Months 1, 7, and 13
75599852|NCT01299116|Drug|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
75743720|NCT04804943|Device|NOA-001|NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
75743721|NCT04793516|Other|VR Therapy Game|Participants will complete 15 sessions of VR-based therapy modules developed for use in helping people with spatial neglect. These 15 sessions will be completed over 4-5 weeks.
75743722|NCT04736953|Drug|Sirolimus|Sirolimus
76072077|NCT03341130|Device|Mandibular Advancement Oral Appliance|Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
75743723|NCT04736953|Other|Placebo|Placebo
75743724|NCT04725617|Drug|Varenicline|Standard smoking cessation treatment.
75743725|NCT04725617|Behavioral|Smoking Cessation Counseling|Standard smoking cessation treatment
75743726|NCT04725617|Behavioral|Health Approach 1 to Reduce Smoking|Behavioral health intervention option 1
75743727|NCT04725617|Other|Health Approach 2 to Reduce Smoking|Behavioral health intervention option 2
75892257|NCT05703360|Device|Audiovisual Stimulation|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
75599853|NCT04321590|Dietary Supplement|Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)|Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
75599854|NCT04321902|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
75599855|NCT04207398|Procedure|Transjugular intrahepatic portosystemic shunts|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).
76062113|NCT05839158|Other|HFMT cell suspension|Perform FUE autologous hair transplantation on the patient according to the guidelines and standard procedures. During the procedure, a hollow punch is used to individually punch out follicular units from the donor area. The epidermis, some dermis tissue, sebaceous glands, and surrounding tissue of the follicular units are separated and removed before the remaining follicular tissue is implanted into the recipient area. The separated tissue is trimmed with surgical scissors to create a cell suspension. After completion of the procedure, the HFMT cell suspension is evenly applied to the treatment group surface. Double vaseline gauze is used to cover all donor areas and is then wrapped with sterile dry gauze with moderate pressure.
76062114|NCT05839158|Other|Mupirocin ointment|the Minoxidil ointment is evenly applied to the control group surface.
76062115|NCT05827549|Drug|Blincyto|Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.
75449056|NCT02979535|Biological|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
75449057|NCT02979535|Biological|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
75449058|NCT02978911|Procedure|preoperative cerebral MRI and operative findings|
76072078|NCT03340519|Device|MR Imaging|Novel MR imaging will be performed to provide bowel anatomic and functional data
76072079|NCT03336255|Behavioral|South Asian Healthy Lifestyle Initiative (SAHELI)|Culturally tailored lifestyle intervention for South Asians.
76072080|NCT03335917|Other|Hypoxia|Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
76072081|NCT03335917|Other|Exercise|Graded cycling exercise to volitional fatigue
75449059|NCT02978716|Drug|Trilaciclib|G1T28
75449060|NCT02978716|Drug|Gemcitabine|Gemcitabine
75449061|NCT02978716|Drug|Carboplatin|Carboplatin
75449062|NCT02976220|Other|Digital Education|Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
75449063|NCT02973321|Drug|SAR425899|Self-administered by SC injection using a solution for injection in cartridge.
76072082|NCT03326726|Drug|2% CHG|Chlorhexidine Gluconate
75743728|NCT04707911|Behavioral|Social Media Intervention|Social media based intervention using Instagram with up to 3 posts per day for 30 days
75743729|NCT04702737|Drug|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
75743730|NCT04685421|Drug|Bupivacaine liposome|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
75743731|NCT04683042|Device|Transcutaneous Electrical Nerve Stimulation (TENS) with PT|Use of TENS units along with routine PT therapy
75743732|NCT04683042|Other|PT only|Routine PT therapy only
75743733|NCT04680975|Drug|Belumosudil|10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
75743734|NCT04680455|Other|Online home-based strength training|Body weight exercises (i.e., squats, tricep dips, lunges, and push-ups) delivered online through Teams
75892258|NCT05702463|Drug|Aspirin 81Mg Ec Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
75892259|NCT05702463|Drug|Aspirin 40Mg Chew Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
75599856|NCT04207398|Other|Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)|Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
75599857|NCT01299038|Drug|rosuvastatin|Taken orally once a day for 4 weeks
75599858|NCT00623922|Behavioral|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
75599859|NCT04321434|Other|Hyperoxia|
75599860|NCT04321434|Other|Normoxia|
75599861|NCT04321434|Device|laser Doppler|laser Doppler
75599862|NCT04321122|Procedure|ultrasound cyclo plasty|"The ultrasonic glaucoma treatment instrument produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast."
75892260|NCT05702463|Drug|Aspirin 162 mg EC Tab once daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
75743735|NCT04673786|Biological|CT-P43|45mg or 90mg dose subcutaneous administration
75743736|NCT04673786|Biological|Stelara|45mg or 90mg dose subcutaneous administration
75743737|NCT04672798|Behavioral|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
75892261|NCT05700747|Behavioral|Health Through Activity|Six, weekly, customized sessions with licensed physical and occupational therapists.
75743738|NCT04672798|Behavioral|Treatment As Usual (TAU)|Participants in this group will receive usual care from their mental health care provider.
75743739|NCT04670783|Procedure|Surgery|Orthopedic surgery (i.e. tenotomy, tendon transfer) or percutaneous neuroablative procedures (i.e. cryoneurotomy) which will be done for upper limb refractory spasticity after being triaged by DNB.
75892262|NCT05697783|Drug|Administration of methadone instead of fentanyl patch|comparison of delirium rates in methadone vs fentanyl patch treated patients
75892263|NCT05681611|Drug|Rocuronium|Rocuronium bolus was administered, according to our protocol, to facilitate surgery and ventilation.
75892264|NCT05676684|Drug|Dapagliflozin|A: Dapagliflozin 10 mg once daily
75892265|NCT05676684|Drug|Spironolactone|B: Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
75892266|NCT05676684|Drug|Spironolactone + Dapagliflozin|C: Dapagliflozin 10 mg once daily plus Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
75892267|NCT05672680|Drug|0.25% Bupivacaine|received during TAP block
75892268|NCT05672680|Drug|Placebo|placebo equivalent
75892269|NCT05672680|Procedure|TAP block|The intervention is a transabdominal plane (TAP) block given in the abdomen to block pain receptors on nerves -during surgery can presumably decrease postoperative pain. Currently, TAP blocks are approved for use and performed based on surgeon preference (e.g. some surgeons perform them on every case, others variably, etc.).
75892270|NCT05668676|Drug|Prednisone arm|2 tabs of 20 mg prednisone per day during 7 days added to usual care medications
75892271|NCT05668676|Other|Usual care|Usual care alone as per European guidelines, which includes oxygen in case of hypoxia, low dose furosemide (40mg or daily dosage), and iv nitrates if no contra-indication.
75743740|NCT04666792|Drug|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
75743741|NCT04647929|Device|Santen PRESERFLO MicroShunt|the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
75743742|NCT04647929|Procedure|Trabeculectomy|a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
75892272|NCT05667376|Other|Local drug delivery|Local application of curcumin gel into the periodontal pocket
75892273|NCT05667376|Drug|curcumin gel|curcumin gel
75892274|NCT05661981|Device|GLYCAR Pericardial Patch|The Glycar patches are intended to be used by surgeons specialized in the field of cardiovascular surgery. The patch is intended to be used for pericardial closure, or repair and/or reconstruction of cardiovascular structures by replacing missing tissue, reinforcing weakened tissue and providing extra strength to repair tissue during healing.
75599863|NCT04321278|Drug|Hydroxychloroquine + azithromycin|Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
75449064|NCT02973321|Drug|Placebo|Self-administered by SC injection using a solution for injection in cartridge.
75892275|NCT05651828|Drug|Vismodegib 150 MG Oral Capsule|Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
75892276|NCT05631938|Drug|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
75599864|NCT04321278|Drug|Hydroxychloroquine|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
75743743|NCT04611399|Behavioral|VR for psychoeducation and relaxation|"Use of specifically developed VR contents to deliver psychoeducational content on stress and anxiety (i.e., MIND-VR) and to train on relaxation techniques (i.e., The Secret Garden)."
75892277|NCT05631327|Drug|JZP341|JZP341 will be administered as a single, intravenous infusion over 2 hours.
75892278|NCT05624957|Drug|Lidocaine epinephrine|Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
75892279|NCT05624957|Drug|Epinephrin|0.25 mg epinephrine mixed with one litre of fluid irrigation
75449065|NCT02973321|Drug|Liraglutide|Self-administered by SC injection using a pre-filled pen.
75599865|NCT01261338|Drug|olestra|non-absorbable dietary fat
75892280|NCT05624775|Behavioral|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will cook and engage virtually (with video and sound on) from their home kitchens via the digital platform. Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($20 per class = $100 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions. Recipes will provide enough food for a family of four. clinic patients
76025029|NCT02695537|Drug|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
75449066|NCT02973321|Drug|Metformin|Orally administered at a stable dose , >=1500 mg daily stable dose or maximal tolerated dose.
75743744|NCT04611399|Other|Control (CR)|The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
76025030|NCT04692389|Device|Jalosome soothing gel|This study has not got other intervention
76025031|NCT04620941|Diagnostic Test|reticulocyte/hemoglobin (Ret-He) ratio|Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
75449067|NCT02967250|Drug|ursodeoxycholic acid|Subjects will be provided ~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over ~2 weeks to a stable dose for 4 weeks.
75449068|NCT02963844|Other|Inspiratory Muscle Training|
75449069|NCT02963844|Other|Inspiratory Muscle Training Sham|
75449070|NCT02944188|Procedure|Laparoscopic right hemicolectomy plus ERAS|patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
75449071|NCT02944188|Procedure|Open right hemicolectomy plus ERAS|patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
75599866|NCT01260948|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
75599867|NCT01260948|Drug|Aricept®|10 mg Orally Disintegrating Tablet
75599868|NCT01025284|Drug|LY2523355|Administered intravenously as a 1-hour infusion
75599869|NCT01025284|Drug|Granulocyte colony-stimulating factor (G-CSF)|Administered subcutaneously
75599870|NCT01021852|Drug|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
76025032|NCT04615871|Drug|semaglutide|semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
75599871|NCT01021852|Drug|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
75892281|NCT05619432|Device|HMD: Immersive VR|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~STIMULATION:~One or more of the spheres is temporarily cued (target). Then all spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using a laser pointer, the initially cued target(s) among the eight spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
75892282|NCT05619289|Drug|Ergocalciferol|One-time, oral dose of 300,000 IU of Ergocalciferol administered via 6 capsules.
76072083|NCT03308188|Behavioral|E-health program|The Goalistics Chronic Pain Management Program, referred to as the E-health program in EMPOWER, was developed from cognitive, behavioral, interpersonal, and self-management interventions with demonstrated efficacy in traditional face-to-face or group settings. It is patient-centered, having been developed based on substantial input from people with chronic pain and chronic pain professionals.
75743745|NCT04605978|Drug|S95011 concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
75743746|NCT04605978|Drug|Placebo concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
75743747|NCT04602533|Drug|Durvalumab|Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
75743748|NCT04602533|Drug|standard of care|"Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed."
75743749|NCT04597671|Drug|Durvalumab|Durvalumab is used as standard of care
75743750|NCT04597671|Radiation|low-dose PCI|PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
75743751|NCT04584320|Other|Stool sample|Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
75743752|NCT04583969|Biological|Lenzilumab|Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.
75892283|NCT05619289|Drug|Placebo|One-time, oral dose of 6 inert capsules matched to the active comparator
75599872|NCT04300660|Other|neuropathic pain after thoracic surgery|analysis of perioperative factors implicated in the onset of postoperative pain after chest surgery and the incidence of neuropathic pain
75892284|NCT05614024|Other|Real fNIRS Neurofeedback|Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
75892285|NCT05614024|Other|Sham-Control fNIRS Neurofeedback|Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
75892286|NCT05610306|Other|Qualitative interview|Qualitative interviews to gain insight into the impact of ichthyosis on the biological, psychological, and social quality of life in adult and elderly patients.
76072084|NCT03300336|Behavioral|STRIDE|Implementation of STRIDE inpatient hospital mobility program
75449072|NCT02943785|Drug|Edoxaban-based Regimen|15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)
75449073|NCT02943785|Drug|VKA-based Regimen|Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
75449074|NCT02938143|Procedure|Exercise|The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
75599873|NCT02872636|Device|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
75599874|NCT02872870|Behavioral|auditory lexical decision task|
75599875|NCT02872870|Device|electroencephalogram|
75599876|NCT02875054|Behavioral|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
75599877|NCT02875054|Behavioral|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
75892287|NCT05604690|Biological|Avacc 10|Intranasal application of either low dose or high dose of Covid 19 vaccine.
75892288|NCT05604690|Combination Product|Outer Membrane Vesicles (OMV) : OMV alone in vehicle|OMV will be administered via intranasal route.
75892289|NCT05604690|Other|Placebo|Placebo will be administered via intranasal route.
75892290|NCT05600296|Drug|Levobupivacaine|Evaluation the postoperative analgesic effects by using ultrasound-guided spermatic cord block (SCB) and IINB in children scheduled for elective open inguinal herniotomy. The study hypothesized that, the combined block with SCB and IINB would result in more effective postoperative analgesia than the use of IINB alone.
75892291|NCT05600296|Procedure|Ilioinguinal/iliohypogastric nerve block (IINB)|Ilioinguinal/iliohypogastric nerve block (IINB)
75892292|NCT05600296|Procedure|IINB+ Spermatic cord block|IINB+ Spermatic cord block
75892293|NCT05594225|Behavioral|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
75892294|NCT05593614|Drug|ATX01 10%|A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
75892295|NCT05593614|Drug|ATX01 15%|A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
75892296|NCT05593614|Drug|Placebo|A 100 mL bottle of hydrogel formulation containing no active substance
75892297|NCT05592275|Drug|LY3540378|Administered SC
75599878|NCT02873026|Drug|Triamcinolone Acetonide|Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
75599879|NCT00627640|Drug|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
75599880|NCT00627640|Drug|Matching Placebo|Matching Placebo
75892298|NCT05592275|Drug|Placebo|Administered SC
75892299|NCT05590338|Drug|GSK1070806|Participants will receive GSK1070806
75892300|NCT05590338|Drug|Placebo|Participants will receive placebo
75892301|NCT05585580|Drug|Serplulimab|300mg d1 q3w
75892302|NCT05585580|Drug|Lenvatinib|8mg po qd
75892303|NCT05585580|Drug|Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome|135~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w
75892304|NCT05580068|Device|Hypertension therapy through iATROS medical device|"The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension.~In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better."
75892305|NCT05577819|Diagnostic Test|99mTc-pyrophosphate Scintigraphy|Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
75599881|NCT01056718|Drug|Nebivolol|Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
75599882|NCT01298570|Drug|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
75599883|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
75892306|NCT05577533|Behavioral|O-Kidia game battery|Children will be playing on a series of games with a touch screen tablet while video and digit trajectories data will be collected from this mobile device to analyze eye-, face-, sound-recognition.
75599884|NCT01298570|Drug|Placebo|Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
75599885|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
75599886|NCT01259856|Drug|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
75892307|NCT05577533|Behavioral|O-Brain|Electrical recordings and measurements - A mobile EEG headset will be used during the visit - 30 min
75892308|NCT05565742|Drug|LY3819469|Administered SC
75892309|NCT05565742|Drug|Placebo|Administered SC
75892310|NCT05564299|Diagnostic Test|Rapid 30-minute Desktop Assay|"Participants will undergo routine evaluation and specimen collection per current clinic protocols. Specimens will be processed by the rapid 30-minute desktop assay. Concurrently, specimens will be used to create a point-of-care gram stain, to be read by the clinician following the clinical encounter.~Treatment for urethritis and cervicitis will be provided based on results from the 30-minute assay.~Specimens will also be plated for Gonorrhea culture and sent to the Massachusetts Department of Public Health for additional Gonorrhea and Chlamydia polymerase chain reaction testing, as per clinic protocols."
75892311|NCT05564039|Drug|Tirzepatide|Administered SC
75892312|NCT05564039|Drug|Dulaglutide|Administered SC
75892313|NCT05561985|Drug|Itacitinib|
75892314|NCT05560958|Device|BIOTRONIK EP catheters (AlCath, MultiCath, ViaCath), external devices (Qubic RF, Qubic Stim, Qiona) and transseptal sheaths (Senovo bi-flex)|Ablations and diagnostic catheters are indicated for temporary transvenous application in patients with cardiac arrhythmias during electrophysiology study (EPS) or catheter ablation interventions. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
75743753|NCT04583969|Other|Placebo|Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.
75892315|NCT05559437|Drug|Levo-bupivacaine 0.25|The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
75892316|NCT05556525|Other|Fluorescein|Given IV
75892317|NCT05556525|Device|Image-Guided Needle Confocal Laser Endomicroscopy|Undergo nCLE
75892318|NCT05556525|Procedure|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo EBUS TBNA
75892319|NCT05556512|Drug|Tirzepatide|Administered SC
75892320|NCT05556512|Drug|Placebo|Administered SC
76062116|NCT05783297|Behavioral|Treatment Text (TXTXT)|This study will test a tailored, personalized SMS text message reminder intervention to improve adherence to ART among non-adherent youth and young adults with HIV. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the 6-month intervention period. Participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.
75599887|NCT01259856|Drug|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
75599888|NCT01259856|Drug|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
75599889|NCT01020838|Drug|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
75599890|NCT00624000|Drug|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
75599891|NCT01259466|Drug|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
75599892|NCT01259388|Drug|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
75599893|NCT01298492|Drug|PF-00547659|75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
75743754|NCT04583969|Drug|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
75743755|NCT04575857|Drug|Atorvastatin|Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.
75599894|NCT05525910|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
75599895|NCT05525910|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
75599896|NCT05525910|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
75599897|NCT05525910|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
75599898|NCT05525910|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
75599899|NCT04320654|Other|exercise|The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
75599900|NCT01297322|Other|Manual compression|Standard of Care
75743756|NCT04575857|Drug|Placebo|Participants in the control arm will receive a pill packet with placebo x 18 months.
75743757|NCT04569708|Other|Auditory stimulation|Quiet auditory stimulation timed with sleep physiology
75743758|NCT04561115|Biological|Gamunex-C|Intravenous infusion.
75892321|NCT05552664|Genetic|GIFT|GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.
75892322|NCT05552430|Device|RelieveVRx|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
75892323|NCT05548517|Behavioral|Time Restricted Eating (TRE)|9-hour eating window
75892324|NCT05548517|Behavioral|Calorie Restriction|daily calorie restriction
76062117|NCT05783297|Behavioral|Standard of Care|Standard of care ART adherence support includes adherence counseling during visits scheduled at least twice annually and appointment reminders.
75743759|NCT04561115|Biological|IVIG-PEG|Intravenous infusion.
75892325|NCT05543265|Behavioral|Default appointment scheduling|Default primary care appointment scheduling
75892326|NCT05543265|Behavioral|Targeted messaging|Patient-specific messages about the importance of postpartum care transition
75892327|NCT05543265|Behavioral|Nudge Reminders|Primary care appointment reminders
75892328|NCT05541952|Biological|BCG|Revaccination with BCG, using the immunobiological used in the Brazilian public health network, strain Russia.
75892329|NCT05540457|Device|Intermittent Non-InvasiveBlood Pressure Monitor|"Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis."
75892330|NCT05523817|Device|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.
76062118|NCT05777772|Behavioral|STOP Falls D Educational Intervention|This is one-arm, health-system embedded pragmatic pilot trial
76062119|NCT05768763|Behavioral|Community-enhanced reach activities|We will conduct a series of community engagement activities designed to reach persons at risk for HIV, undiagnosed with HIV or diagnosed, or hypertension, and fallen out of care working closely with community health system, leveraging existing mobile outreaches in the community.
75892331|NCT05521048|Drug|Doxycycline Injection [Doxy]|Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
75892332|NCT05506150|Behavioral|Interviews|"Focused conversations to understand features of a GI bleed that are important to patients and families.~Patients and family members are invited to participate in focused conversations. For interviews and focus groups, criterion sampling will be used. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data includes self-reported demographic characteristics of the patient and family members. Qualitative data about participants will be obtained through individual interviews and focused groups and project team field notes."
75892333|NCT05504083|Drug|D-0120|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
75449075|NCT02938143|Procedure|Exercise (usual care)|The control treatment is a painful heavy-load eccentric exercise program performed twice daily with 3 sets of 15 repetitions for 12 weeks on a 25° decline board. The downward component (eccentric component) will be performed with the symptomatic leg and the upward component (concentric phase) on the asymptomatic leg.
75892334|NCT05504083|Drug|Benzbromarone|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
75892335|NCT05500508|Drug|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules
75892336|NCT05500508|Drug|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.
75892337|NCT05498597|Drug|AMT-151|Administered intravenously
76062120|NCT05768763|Behavioral|Person-centered care delivery|Structured approach to provide patient-centered biomedical options for prevention. Tailored services for youth, pregnant women, and persons without viral suppression, mobile populations, with heavy alcohol use, or severe hypertension.
75743760|NCT04549779|Procedure|Low volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
75449076|NCT02936947|Device|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation
75743761|NCT04549779|Procedure|Intermediate volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
75743762|NCT04549779|Procedure|High volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
75449077|NCT02936947|Other|Free breathing|Free breathing
75449078|NCT02936947|Other|Active Breathing Control|Active Breathing Control
75743763|NCT04509245|Behavioral|Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone|During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
75743764|NCT04502706|Drug|GS-0189|GS-0189 will be administered intravenously.
75743765|NCT04502706|Drug|Rituximab|Rituximab will be administered intravenously.
75892339|NCT05493189|Other|Additional autonomous training sessions|The duration of the autonomous training will be 30 minutes, using a feedback CPR training simulator (eg Laerdal Little Anne QCPR).
75892340|NCT05485831|Drug|Epidiolex 100 mg/mL Oral Solution|As prescribed in routine clinical practice in Italy.
75892341|NCT05485532|Device|Telemonitoring System using Cosinuss° Two and/or Garmin Vivoactive 4|Development and validation of a telemonitoring system using smart devices
76072085|NCT03297307|Behavioral|Presurgical Counseling|Children will attend the presurgical counseling visits with their mother
76072086|NCT03294278|Other|ablation plus ICD|Defibrillator, radio-frequency catheter ablation
76072087|NCT03248570|Drug|Pembrolizumab|All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.
75743766|NCT04486833|Biological|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
75599901|NCT01297322|Device|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
75599902|NCT02888886|Other|Questionnaires about food habits and tobacco|
75599903|NCT02888886|Other|Spirometry|
75449079|NCT02927990|Other|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention according to standard of care
75892342|NCT05483621|Drug|Beta-hCG|Treatment of spermatogenesis
75743767|NCT04486833|Drug|osimertinib|Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
75743768|NCT04486833|Drug|Platinum-Based Chemotherapy|Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
75743769|NCT04468776|Drug|Zolpidem|Zolpidem, as prescribed by physician
75892343|NCT05482880|Other|Regular care with additionally administration of questionnaires|"Patients receiving regular care. In addition, validated questionnaires are administered at two measurement points:~after the multidisciplinary consultation, a baseline questionnaire*, the decision conflict scale and the EQ-5D-5L questionnaire are administered by phone.~1 month after completion of the treatment program (care pathway) the EQ-5D-5L, the BaSQoL and the EORTC IN-PATSAT32 questionnaires will be administered by phone.~Completing the questionnaires takes about 30 minutes each time.~*Baseline questionnaire: gender, age, marital status, education level, World Health Organization (WHO) performance status, presence of informal care, stage and treatment of cSCC, history of skin cancer, presence of current other skin cancer, and average travel time to hospital."
75892344|NCT05475418|Procedure|Adipose tissue derived exosomes|200-300ml of the subject adipose tissue before centrifugation was collected, and the extracellular vesicles were retained after tissue homogenate and filter screening. The extracellular vesicles were mixed with sterile hydrogel and applied directly to the wound surface, and the wound was covered with an inert protective dressing.
75892345|NCT05471492|Drug|Investigational Product|PF-06480605 150 mg
75892346|NCT05471492|Drug|Placebo|Placebo
75599904|NCT02888886|Other|Carotid echography|
75892347|NCT05464537|Other|Unipolar Polarity Switch Left|10-15 Left veins are randomized to Unipolar Polarity Shift, right veins are randomized to CAI-OPR-LAAP
75892348|NCT05464537|Other|Unipolar Polarity Switch Right|10-15 cases randomized to CAI-OPR-LAAP on left veins, and Unipolar Polarity Switch on right veins
75892349|NCT05462730|Drug|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
75892350|NCT05462730|Drug|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
75449080|NCT02923674|Behavioral|Weight loss|All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.
75599905|NCT02888886|Other|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
75599906|NCT00624078|Drug|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
75599907|NCT00624156|Behavioral|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
75599908|NCT00624156|Behavioral|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
75743770|NCT04468776|Behavioral|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
75743771|NCT04468776|Drug|Trazodone|Trazodone, as prescribed by physician
75743772|NCT04456673|Drug|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
75892351|NCT05459948|Device|GMK SpheriKA|"The first objective is to study the FJS of patients who were implanted a GMK® SpheriKA knee prosthesis using the kinematic alignment technique"
76062121|NCT05768763|Other|Data-enhancement to improve precision of interventions|Both community-enhanced reach and person-centered delivery will be strengthened through the strategic collection and use of data. Analysis will be conducted to enhance the effectiveness of ongoing outreach activities by identifying high yield venues and locations and local regions and persons who would benefit form more frequent or intensive outreach or services due to, eg, elevated risk of HIV infection, unsuppressed viral load, and uncontrolled HTN.
75892352|NCT05457933|Drug|Dapagliflozin|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
75892353|NCT05457933|Drug|Glargine|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
76062122|NCT05768763|Behavioral|Standard of Care|Standard of Care in Uganda and Kenya
76062123|NCT05761288|Behavioral|Intraoperative microbreaks and exercises|"Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. Intervention exercises include: chest and shoulder opener elbows in pockets, chin tuck, neck rotation, squat with truncal rotation (chair pose with prayer), and forward bend."
76062124|NCT05743543|Other|Sphenopalatine ganglion block|The block is performed with a nasoscope and the administration of a local anesthetic.
76062125|NCT05741710|Drug|Methylone|Methylone capsules, given orally, once a week for 4 weeks
75599909|NCT05396586|Behavioral|N-back|The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game
75599910|NCT05396586|Behavioral|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
75743773|NCT04456673|Drug|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
75599911|NCT05396586|Behavioral|Multisensory|The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements
75743774|NCT04456673|Drug|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
75743775|NCT04456673|Drug|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
75599912|NCT01297244|Drug|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
75616484|NCT02634463|Drug|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent [eq.] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
75743776|NCT04456673|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
75743777|NCT04416269|Drug|Oral Anti-diabetes Drugs alone|OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
75892354|NCT05456724|Drug|TO-O-1001|TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye
75892355|NCT05456724|Other|Placebo|The placebo is of same visual appearance and identical formulation as TO-O-1001, except the active component TO-168 ocular administration only one drop in one eye
75892356|NCT05450159|Behavioral|ROADskills program|Participants in the intervention arm of the study will watch a 30-minute personalized video on their driving that uses information compiled from a GPS device that will be installed in their vehicle during their baseline visit.
75892357|NCT05450159|Behavioral|Healthy Aging|Participants in active comparator arm of the study will watch a 30-min video and receive a written brochure that provide tips for maintaining a healthy lifestyle in later life, including the importance of community mobility.
75892358|NCT05447312|Other|Adaptive Music Intervention|Music that has been enhanced by frequencies that are associated with positive feelings as measured by EEG data. Music will be delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning over and above traditional music therapy.
75892359|NCT05447312|Other|Traditional Music Intervention|Music that has not been enhanced by frequencies. Music is delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning.
76025033|NCT04991129|Drug|WJ01024|5mg: WJ01024, Q4W, twice per week
76025034|NCT04991129|Drug|WJ01024|10mg: WJ01024, Q4W, twice per week
76025035|NCT04991129|Drug|WJ01024|20mg: WJ01024, Q4W, twice per week
76025036|NCT04991129|Drug|WJ01024|40mg: WJ01024, Q4W, twice per week
76025037|NCT04991129|Drug|WJ01024|60mg: WJ01024, Q4W, twice per week
76025038|NCT04991129|Drug|WJ01024|80mg: WJ01024, Q4W, twice per week
76025039|NCT04991129|Drug|WJ01024|100mg: WJ01024, Q4W, twice per week
76025040|NCT04991129|Drug|WJ01024|120mg: WJ01024, Q4W, twice per week
76025041|NCT04991129|Drug|WJ01024|140mg: WJ01024, Q4W, twice per week
76025042|NCT04991129|Drug|WJ01024|1600mg: WJ01024, Q4W, twice per week
76025043|NCT04888793|Diagnostic Test|Serologic immune response evaluation|Detection of total and neutralizing antibodies against SARS-CoV-2
75743778|NCT04416269|Drug|Basal bolus insulin|Basal insulin with glargine or detemir will be used as per the hospital formulary.
75743779|NCT04416269|Drug|Supplemental insulin|Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG >140 mg/dl.
75743780|NCT04416269|Device|Continuous glucose monitoring (CGM)|"A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes."
75743781|NCT04400292|Other|Injection of indocyanine green (ICG)dye|Patients will receive a perilesional injection of indocyanine green (ICG) before the laparoscopic phase of the esophagectomy.
75743782|NCT04400292|Device|Near-Infrared Image-Guided|Real-time near-infrared (NIR) fluorescence imaging will be performed by use of the Novadaq PINPOINT minimally invasive system with a laparoscopic camera.
75449081|NCT02923674|Behavioral|Exercise|Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.
75892360|NCT05442840|Combination Product|Behavioral and drugs already approved and available for diabetes management|Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment
76062126|NCT05741710|Drug|Placebo|Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
76062127|NCT05739994|Other|Theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
76062128|NCT05739994|Other|Sham theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
76062129|NCT05738655|Dietary Supplement|Pumpkin seed extract (Low dose)|Pumpkin seed extract standardized with specific peptides (300 mg/day)
75743783|NCT04400292|Procedure|Sentinel Lymph Node (SLN) mapping|Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy.
75449082|NCT02923674|Behavioral|Sitless|Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).
75449083|NCT02921971|Drug|SAR156597|Pharmaceutical form: Solution Route of administration: Subcutaneous
75449084|NCT02921971|Drug|Placebo|Pharmaceutical form: Solution Route of administration: Subcutaneous
75449085|NCT02908334|Drug|Sertraline|400 mg/day sertraline
75892361|NCT05438953|Biological|Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)|Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart
76062130|NCT05738655|Dietary Supplement|Pumpkin seed extract (High dose)|Pumpkin seed extract standardized with specific peptides (600 mg/day)
76062131|NCT05738655|Dietary Supplement|Placebo|Placeo (300 mg/day)
76062132|NCT05728918|Dietary Supplement|Antrodia cinnamomea mycelia|Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months
76062133|NCT05728918|Dietary Supplement|Placebo|Placebo capsule, two capsules/day (600 mg/day) for 3 months
76062134|NCT05721326|Other|Sequential EHR Communications|The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
75616485|NCT02634463|Drug|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
75743784|NCT04398017|Procedure|Transesophageal echography|Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
75743785|NCT04394351|Drug|Dupilumab|Single-use, prefilled syringe
75743786|NCT04394351|Drug|Matching Placebo|Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
75892362|NCT05434130|Behavioral|High Dose Exercise|The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
75892363|NCT05433584|Drug|Tirzepatide|Administered SC
75892364|NCT05433584|Drug|Antihyperglycemic medication|As prescribed
75449086|NCT02906397|Drug|Galunisertib 150mg by mouth twice a day|on days 1-14 of 28 day cycles
75892365|NCT05426057|Behavioral|eHealth Familias Unidas Mental Health|eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
75892366|NCT05416307|Drug|ELA026|Single or multiple daily doses of ELA026
75892367|NCT05415085|Procedure|Culprit-first PCI|PCI to the culprit artery prior to the demonstration of the whole coronary tree.
75892368|NCT05412758|Dietary Supplement|Oral Stimulant Drink|For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath
75892369|NCT05412277|Other|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.
75892370|NCT05409833|Diagnostic Test|Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD|Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis
75892371|NCT05408962|Other|Blood and urine collection, anthropometric analysis and answering to questionnaires|During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.
75892372|NCT05408611|Other|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
75892373|NCT05408611|Other|Placebo acupressure|Placebo acupressure is manual pressure applied to unreal acupressure points.
75892374|NCT05406531|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
75892375|NCT05406531|Behavioral|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
75892376|NCT05406531|Behavioral|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
75892377|NCT05400694|Other|Food|Dairy products with reduced sugar content
75892378|NCT05400590|Procedure|Peripheral venous blood sample|2.5% of body weight
75892379|NCT05400590|Procedure|Conjunctival impression|Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
75892380|NCT05392075|Biological|Pfizer COVID-19 mRNA vaccine|vaccinated people who received the Pfizer COVID-19 mRNA vaccine
76062135|NCT05668000|Other|Bluetooth-connected monitoring devices and a feedback system|"AIDA/KT-app with devices and feedback:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter and a feedback system"
75449087|NCT02906397|Radiation|Stereotactic Body Radiotherapy (SBRT)|18GY delivered in one fraction between C1D15 and C1D28
75892381|NCT05392075|Biological|Moderna COVID-19 mRNA vaccine|vaccinated people who received the Moderna COVID-19 mRNA vaccine vaccine
76062136|NCT05668000|Other|Mobile application|The mobile application provide only self-management interventions.
75449088|NCT02905669|Device|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
75616486|NCT02535403|Behavioral|ICBT|
75449089|NCT02903615|Other|Novel diet|Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
75449090|NCT02903615|Other|Standard diet|Standard diabetes diet recommendations
75449091|NCT02895906|Drug|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
75743787|NCT04374461|Drug|N-acetylcysteine|Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.
75892382|NCT05390840|Drug|MG-O-1002|MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye
75892383|NCT05390840|Other|Placebo|The placebo is 0.9% saline ocular administration 3 drops in study eye
75892384|NCT05389644|Device|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.
75892385|NCT05388760|Drug|Tralokinumab|A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment).
76062137|NCT05632562|Drug|O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI|High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
76062138|NCT05562830|Biological|Zilovertamab vedotin|Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
76062139|NCT05553444|Behavioral|Self-management intervention|"The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks."
75743788|NCT04374461|Other|Peripheral Blood|A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.
75892386|NCT05386927|Other|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.
75892387|NCT05376371|Other|CJC-TraC|CJC-TraC utilizes a nurse case manager (NCM) to coordinate the participant's transitional care through release from a correctional facility. The NCM will visit either in person or via telehealth with the participant up to 4 times while incarcerated, and up to 4 times after release.
75892388|NCT05362916|Drug|Letermovir|Participants in the treatment arm will take either 1 tablet of 480mg PO once daily or 2 tablets of 240mg PO once daily.
76062140|NCT05542121|Device|Robot-Assisted Therapy with Rehab CARES system|60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes. The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced. The 60 minutes will be broken up into 15-minute training intervals.
75449092|NCT02887651|Radiation|Cavity boost radiation|Cavity boost radiation therapy with 10 x 3 Gy for patients suffering from complete resected cerebral metastases
75449093|NCT02886286|Drug|Bupivacaine|Patient-activated intrathecal bolus for incident pain
75449094|NCT02886286|Drug|Opioid|Patient-activated intrathecal bolus for incident pain
76062141|NCT05542121|Other|Standard of Care|60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP
75743789|NCT04366258|Device|Transcranial Photobiomodulator|Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).
75743790|NCT04366258|Device|Sham|Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
75743791|NCT04344860|Drug|Recombinant Von Willebrand factor|Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
75743792|NCT04344860|Drug|Tranexamic Acid Injection [Cyklokapron]|Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
75743793|NCT04343443|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
75743794|NCT04343443|Procedure|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
75743795|NCT04343443|Procedure|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
75743796|NCT04343443|Procedure|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from hospital
75743797|NCT04343443|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
75743798|NCT04343430|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
75599913|NCT04320420|Other|Adapted Physical Activity|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~3 supervised APA sessions/week on site:~two muscle strengthening sessions, stretching, flexibility in the gym~a cardio session (Nordic Walking: outdoors)~at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~the first 3 months:~2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~1-hour cardio session/week independently~the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
75599914|NCT05183022|Device|Total30 Sphere Contact Lenses|Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.
75743799|NCT04343430|Procedure|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
75743800|NCT04343430|Procedure|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
75743801|NCT04343430|Procedure|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
75892391|NCT05358925|Other|Psychoeducational Videos|"A total of ten videos will be delivered daily Monday-Friday over approximately 2 weeks (days 1-15). The videos will each feature a mental health professional who is an expert in BPD explaining the topic in relatable language that can be understood by the general public. Each video will be approximately 10-12 minutes long, for a total of ~120 minutes of video. Videos will be shared via a hyperlink in a text message.~The psychoeducational videos will cover the following topics: the history of the diagnosis of BPD and current diagnostic criteria, challenging BPD-related stigma, developmental pathways to BPD and biological predisposition, prevalence of BPD and its common comorbid disorders, the naturalistic course of BPD without treatment, available psychotherapeutic treatment options for BPD, current research on the neurobiological and genetic markers related to BPD, the interpersonal hypersensitivity model of BPD, lifestyle changes that are beneficial for people with BPD"
75892392|NCT05358925|Other|Neuropsychological Feedback|In the second phase of the study, participants randomized to the Feedback condition will receive an email with a personalized summary of their symptom endorsement and neuropsychological performance. The feedback will include the relevant scores or sub-scores for each cognitive test (CPT, RMET, BEST, DST) from all time points. For each score and sub-score, there will be a description of the cognitive domain that the metric assesses (e.g., attention span in the CPT). The investigators will tailor the feedback to each participant's scores. The investigators may adjust the format or wording of the feedback based on participant responses (i.e., if a participant alerts the investigators that some wording is unclear or confusing). The investigators may also alter the feedback if they learn new information about the relevance or interpretability of these cognitive tests, as this is a growing field of research.
75743802|NCT04343430|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
75743803|NCT04333420|Drug|IFX-1 + BSC|Phase II study part: IFX-1 + BSC
76062142|NCT05541406|Behavioral|Proud & Empowered|Proud & Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
76062143|NCT05523830|Other|No Intervention|No intervention
75743804|NCT04333420|Drug|BSC|Phase II study part: BSC
75743805|NCT04333420|Drug|IFX-1 + SOC|Phase III study part: IFX-1 + SOC
75743806|NCT04333420|Drug|Placebo + SOC|Phase III study part: Placebo + SOC
75743807|NCT04332692|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
75743808|NCT04332692|Procedure|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
75743809|NCT04332692|Procedure|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital
75743810|NCT04332692|Procedure|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital
75743811|NCT04332692|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
75743812|NCT04282915|Other|Reducing Stigma among Healthcare Providers (RESHAPE)|Mental health service users are trained using Photo Voice to develop recovery story testimonials. They then participate in primary care providers mental health Gap Action Programme training. In addition, aspirational figures are trained to provider testimonials and conduct myth-busting.
75743813|NCT04282915|Other|mental health Gap Action Programme|The mental health Gap Action Programme is a training program for primary care providers in mental health services. The curriculum has been developed by the World Health Organization and was adapted in Nepal and certified by the Ministry of Health.
75743814|NCT04268485|Diagnostic Test|Serum KL-6 level|Serum blood biomarker which has been shown to be of interest in idiopathic pulmonary fibrosis
75743815|NCT04247165|Drug|Gemcitabine|800 mg/m2 Day 1, 8, 15: Q4W IV Infusion
75743816|NCT04247165|Drug|Nab-paclitaxel|100 mg/m2 Day 1, 8, 15: Q4W IV Infusion
75743817|NCT04247165|Drug|Nivolumab|3 mg/kg Day 1, Q4W IV Infusion
75743818|NCT04247165|Drug|Ipilimumab|1 mg/kg Day 1 Cycle 1 IV Infusion
75743819|NCT04247165|Radiation|SBRT|"Patients will be planned and treated with SBRT on a MRidian MR guided Linac.~Prescription dose shall be according to the following specifications:~Prescription dose shall be according to the following specifications:~A total dose of 24 Gy in 3 fractions (3 fractions/week) are prescribed as the mean dose to the PTV.~Pauses are accepted but the treatment should be delivered within 10 calendar days.~PTV should be covered by 95% isodose (PTV D99% >95%)."
75743820|NCT04234867|Drug|Dapagliflozin|once daily for 5 days
75743821|NCT04234867|Drug|Placebo oral tablet|once daily for 5 days
75892393|NCT05358925|Other|Non-BPD-related Educational Videos|The non-BPD-related educational videos will be matched in length and frequency to the BPD-related videos. These videos will discuss aspects of mental and physical health that are not related to BPD. Examples may include: nutrition and healthy eating, lifestyle changes to combat stress, what is psychotherapy?, prevalence of depression and anxiety in the general population, healthy sleep habits.
75892394|NCT05355623|Procedure|Vaginal Repair|Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair
75892395|NCT05347667|Other|Unilateral Resistance Exercise Leg|One leg will perform unilateral resistance exercise
75743822|NCT04234867|Other|Stress|single dose after last administration of experimental drug
75743823|NCT04234867|Other|Placebo Stress|single dose after last administration of experimental drug
75743824|NCT04219280|Drug|Quillivant XR|Long-lasting liquid solution of Quillivant XR.
75743825|NCT04219280|Drug|Placebo|Liquid solution to mimic the color and taste of Quillivant XR.
75892396|NCT05347667|Other|Control Leg|One leg will serve as a non-exercise control
76062144|NCT05514184|Dietary Supplement|PLAFOND diet|PLAFOND is a pragmatic patient-centered dietary intervention supported by dietitians who provide education and counseling in the form of Medical Nutrition Therapy (MNT) consisting of 0.6-0.8 g/kg/day dietary protein with >2/3% of the protein from plant-proteins.
76062145|NCT05511181|Device|BioWave|The BioWave device is called BioWaveGO. It is a FDA 510(k) cleared high frequency sinusoidal neurostimulator
75743826|NCT04186637|Drug|ALPN-202|Multiple dose levels and dose regimens of ALPN-202 will be administered
75743827|NCT04177693|Dietary Supplement|Epigallocatechin gallate (EGCG)|800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
75743828|NCT04177693|Drug|Clomiphene Citrate|100 mg for 5 days
75743829|NCT04177693|Drug|Letrozole|5 mg for 5 days
75743830|NCT04169009|Biological|Zostavax|Intradermal injection of Zostavax
75892397|NCT05344534|Behavioral|Leadership and Organizational Change for Implementation|LOCI is data driven leadership development and coaching for clinic managers and working with agency executives and middle managers to foster a strategic implementation climate
75892398|NCT05338892|Other|Non-Interventional|No study treatment will be administered on this study.
75892399|NCT05335408|Device|Acunex Vario intraocular lens|This is an extended depth of focus IOL, made by Teleon Surgical B.V.
75892400|NCT05335408|Device|Alcon AcrySof IQ Vivity intraocular lens|This is an extended depth of focus IOL, made by Alcon.
76062146|NCT05511181|Device|TENS|The TENS device is called Intensity 5000. It is a FDA 510(k) cleared TENS device
75743831|NCT04169009|Biological|Shingrix|Given to subjects in Arm 4 who've never had a herpes zoster vaccine
75743832|NCT04146064|Other|Breathprint analysis and patient-reported outcomes|"Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints."
75743833|NCT04129229|Device|LinguaFlex Tongue Retractor (LTR)|The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
76025044|NCT04802447|Drug|SurVaxM|Each participant will receive 4 doses of SVN53-67/M57-KLH (SurVaxM) spaced two weeks apart. This phase of treatment is known as the prime-boost phase and will take 6 weeks to complete. After completion of the prime-boost phase of treatment, the participant will receive a dose ofSVN53-67/M57-KLH (SurVaxM) every 3 months for up to two years
76025045|NCT04746989|Drug|Probenecid|Probenecid claim is used as the exposure group.
76025046|NCT04746989|Drug|Allopurinol|Allopurinol claim is used as the reference group.
75449095|NCT02865187|Dietary Supplement|Vitamin D|Vitamin D 600IU/day
76025047|NCT04446221|Other|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
76025048|NCT02691247|Biological|CLBS03 Low Dose|
75743834|NCT04118387|Drug|Acetazolamide + supplemental oxygen + PAP therapy|Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
75743835|NCT04118387|Drug|Zolpidem + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.
75743836|NCT04118387|Drug|Buspirone + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
75743837|NCT04118179|Other|Blood sample collection|A blood sample (1 tube) will be collected for the analysis of the CR signature.
75743838|NCT04105335|Drug|MTL-CEBPA|Intravenous administration
75892401|NCT05332223|Diagnostic Test|Full Polysomnography|Overnight PSG will be conducted using Alice version 6 system (Respironics, Pittsburgh, PA, USA). During PSG, the following variables will be monitored and captured. Sleep staging using electroencephalogram (four channels: C3-A2, C4-A1, O1-A2, O2-A1), electrooculogram (two channels: LOC-A2, ROC-A1), electromyogram (two channels: submental and anterior tibialis muscles). Respiratory effort using inductive plethysmograph sensors to detect thoracoabdominal movements. Oro-nasal airflow using pressure flow transducer and thermistor. Oxygen saturation using pulse oximetry and cardiac rhythm using electrocardiography. Other parameters that will also be monitored includes body position, presence of snoring and end tidal CO2 (EtCO2) measurement to detect hypercapnia. The attended PSG will be conducted in the sleep laboratory in Respiratory Unit, Hospital Taiping
75892402|NCT05325632|Biological|HER-2 pulsed DC1|Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.
75892403|NCT05325632|Drug|Trastuzumab|8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks
75892404|NCT05325632|Drug|Pertuzumab|840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.
75892405|NCT05325632|Drug|Paclitaxel|80 mg/m^2 IV paclitaxel will be given weekly weeks 7-18
75892406|NCT05325632|Procedure|Resection surgery|After week 18, participants will undergo standard of care resection surgery.
75743839|NCT04105335|Drug|Pembrolizumab|Intravenous administration
75892407|NCT05323734|Drug|Ganaxalone|GNX will be administered
75892408|NCT05323734|Drug|Placebo|Placebo will be administered
76062147|NCT05449977|Diagnostic Test|Diagnose|First, the participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, the 2-minute walk test, the International physical activity questionnaire, the SF-36 short form, and the World health organization quality of life questionnaire will be applied respectively.
75599915|NCT02890394|Other|Suboccipital inhibition technique|Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
75599916|NCT04746378|Diagnostic Test|Computed Tomography, CSD|Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software
75743840|NCT04101331|Drug|AFM13|weekly intravenous infusions of 200mg
75743841|NCT04087538|Diagnostic Test|Troponin T and I|Does the use of troponin T or I increase the number of patients referred to coronary angiography
75743842|NCT04082884|Behavioral|Very Low Carbohydrate Diet|A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 11% of total daily caloric intake.
75743843|NCT04072952|Drug|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
75743844|NCT04072952|Drug|ARV-471 in combination with palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
75743845|NCT04071470|Behavioral|Storytelling|Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP
75743846|NCT04071470|Drug|PrEP|Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
75743847|NCT04040049|Genetic|FLT190|Gene Therapy product.
75743848|NCT04032418|Biological|Pembrolizumab|Given IV
75743849|NCT04021784|Device|SDS|The patient is implanted with SDS.
75743850|NCT04021784|Device|NEMOST|The patient is implanted with NEMOST.
75892409|NCT05317000|Drug|Combination 5-azacytidine and nivolumab|The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
75449096|NCT02865187|Drug|Hormonal contraception|Hormonal contraceptives
75892410|NCT05317000|Drug|5-azacytidine|Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
75449097|NCT02861885|Other|Chromoendoscopy|Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
75449098|NCT02826707|Behavioral|SPPAC intervention|A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
75449099|NCT02824198|Biological|CYD Dengue Vaccine (5 dose formulation)|0.5 mL, Subcutaneous
75449100|NCT02824198|Biological|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
75892411|NCT05317000|Drug|Nivolumab|"Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells."
75449101|NCT02817126|Procedure|Robot-assisted resection|Arm I: Robot-assisted resection using da vinci system.
75449102|NCT02817126|Procedure|Laparoscopic resection|Arm II: Traditional laparoscopic resection.
75449103|NCT02817074|Behavioral|MIND Diet|3-year dietary counseling to adhere to the MIND diet and for mild weight loss
75449104|NCT02817074|Behavioral|Mild Weight Loss|3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
75892412|NCT05315713|Drug|Mosunetuzumab SC|Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
75892413|NCT05315713|Drug|Tiragolumab|Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
75892414|NCT05315713|Drug|Atezolizumab|Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
75449105|NCT02801045|Behavioral|art therapy|"Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~humanistic phenomenological focus~transpersonal therapeutic bound~transdisciplinarity in the artistic approach~integrative-relational specialized counseling of the grief, loss and trauma aspects."
75892415|NCT05315713|Other|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
75892416|NCT05299086|Drug|Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)|The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.
75892417|NCT05298345|Other|Anthem Strong Families TYRO Champion Program Primary Services|Primary Services: participants receive 12 hours of TYRO Leadership curricula, 6 hours of Core Communication curricula. Support Services (optional): participants choose from a menu of classes (1-3 hours) at the walk-in mini clinic to meet a variety of self-identified needs.
75892418|NCT05293145|Other|Building Futures Program Primary Services|Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops, or 16 hours of Survival Skills for Healthy Families curricula delivered over one weekend followed by 2 hours of a Reflections Workshop delivered two weeks later. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.
75892419|NCT05292963|Other|Intervention #1: Fatherhood Works Program Delivered to Participants|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
75599917|NCT04746378|Diagnostic Test|Computed Tomography, SA|Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software
75599918|NCT04746378|Diagnostic Test|Computed Tomography, 3D|Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software
76062148|NCT05449626|Diagnostic Test|Assessment|The Standardized Mini-Mental Test and Clinical Dementia Rating Scale will be administered by the physician to the healthy individuals with dementia to be included in the study.
76062149|NCT05441280|Drug|pimavanserin|pimavanserin 34mg PO at bedtime
76062150|NCT05441280|Other|Placebo|The placebo is a pill that looks like a study medication but has no medication in it
76062151|NCT05434338|Diagnostic Test|HPV detection test|Samples taken from the squamocolumnar junction using swabs (UTM Copan)
76062152|NCT05432596|Drug|ATI-1777 2.0% w/w|ATI-1777 topical solution 2.0% w/w
76062153|NCT05432596|Drug|ATI-1777 1.0% w/w|ATI-1777 topical solution 1.0% w/w
76062154|NCT05432596|Drug|ATI-1777 0.5% w/w|ATI-1777 topical solution 0.5% w/w
75449106|NCT02789098|Other|(15)-O water positron emission tomography and Biomarkers|Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
75892420|NCT05288166|Drug|Abemaciclib|Administered orally.
76062155|NCT05432596|Drug|Vehicle|Vehicle topical solution
76062156|NCT05425264|Other|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
76062157|NCT05413161|Biological|ADL-018|150 mg/mL, Solution for injection in PFS
76062158|NCT05413161|Biological|US-licensed XOLAIR|150 mg/mL, Solution for injection in PFS
76062159|NCT05413161|Biological|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
75892421|NCT05288166|Drug|Abiraterone|Administered orally.
75892422|NCT05288166|Drug|Prednisone or Prednisolone|Administered orally.
75449107|NCT02787551|Drug|Insulin glargine/lixisenatide fixed ratio combination|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
76062160|NCT05411562|Diagnostic Test|SARS-CoV-2 genomic sequencing|SARS-CoV-2 viral genomic sequencing and phylogenetic analyses
76062161|NCT05410730|Drug|SHR-1501|SHR-1501 single agent dose escalation will consist of 3 dose groups: 200 μ g、400 μ g and 600 μ g, and in combination of BCG. The administration method is intravesical instillation.
76062162|NCT05386719|Other|Prescreening|Eligible patients (history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins, reads and speaks English) complete survey for demographics, smoking status & questions about cardiovascular disease.
75449108|NCT02787551|Drug|liraglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75449109|NCT02787551|Drug|exenatide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75449110|NCT02787551|Drug|exenatide extended-release|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75892423|NCT05288166|Drug|Placebo for Abemaciclib|Administered orally.
75892424|NCT05284240|Device|Auryon Laser System|"The Auryon BTK Study is a prospective, single arm multicenter study evaluating the safety and procedural effectiveness of the Auryon laser in treating infrapopliteal disease in patients with critical limb ischemia and claudication.~The primary exposure of interest for this study is the use of the AURYON system for atherectomy."
75892425|NCT05283330|Drug|²¹²Pb-DOTAM-GRPR1|²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
75892426|NCT05279495|Device|In a double-blinded fashion, 250 mg CANNAXR cream|Determining the Efficacy of topically applied CANNAXR cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg TOPICAL CBD CANNAXR Cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
75892427|NCT05279495|Device|Topical VEHICLE cream|Determining the Efficacy of topically applied VEHICLE cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
76025049|NCT02691247|Biological|CLBS03 High Dose|
76025050|NCT02691247|Biological|Placebo|
76025051|NCT04412915|Other|Labor induction|Labor induction with oxytocin or prostagladin
76025052|NCT04383821|Device|Double-Trunk Mask|The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
76025053|NCT04383821|Device|Non-Rebreather mask|The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
76025054|NCT04520009|Behavioral|Activity Restriction|Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).
76025055|NCT04520009|Behavioral|Activity as Tolerated|Instructions advising activity as tolerated and return to work based on patient discretion
76025056|NCT04349423|Behavioral|Social Media Usage Manipulation|Behavioral Intervention of social media usage.
76025057|NCT04163393|Procedure|Percutaneous Coronary Intervention|PCI with robotic assistance
76062163|NCT05386719|Other|Screening and Enrollment|Consent
76062164|NCT05386719|Behavioral|Baseline|Behavioral Battery and Patient Reported Outcome Quality of Life questionnaires (EORTC QLQ-C30 and QLQ-BR23) Labs (Hba1c + lipid panel if not done within 12 months or if abnormal within 1 year) Abstract vitals from chart review
76062165|NCT05386719|Behavioral|Interpret BMI|Refer to Healthful Eating, Activity and Weight Program (HEAWP) if BMI ≥25 and not already on lifestyle intervention
76062166|NCT05386719|Other|Interpret HbA1c|"HbA1c results categorized as follows:~HbA1c <5.7%; HbA1c 5.7-6.4%; HbA1c 6.5%+; or Known diabetic on medication"
76062167|NCT05386719|Other|Interpret lipid panel and assess other risk factors|"Based on above categories:~HbA1c <5.7%: Any of these cardiovascular disease risk factors: current/former tobacco use, total cholesterol >200, family history of Coronary Artery Disease/Heart Attack in first degree family <55 year old male or <65 year old female, systolic blood pressure >130 HbA1c 5.7-6.4%: Refer to Primary Care Provider and consider Healthful Eating, Activity and Weight Program (HEAWP) HbA1c 6.5%+: Refer to Endocrinology if HbA1c ≥8% Known diabetic on medication: Refer to Endocrinology if HbA1c ≥7%"
76062168|NCT05386719|Behavioral|Assess 10 year risk of cardiovascular event|If risk factors are present - refer to Cardiovascular Disease Prevention Program
76062169|NCT05386719|Behavioral|Recommendations|Provide individual patient handout based on all above interventions
75743851|NCT04006522|Drug|89Zr-DFO-Atezolizumab|89Zr-DFO-Atezolizumab infusion
75892428|NCT05279326|Behavioral|Virtual SMAs|18 weeks lifestyle approach for type 2 diabetes program: Session 1 (week 0): Introduction; Session 2 (week 3): Behaviour change process; Session 3 (week 6): Medical nutrition therapy recommendations - Part 1; Session 4 (week 9): Medical nutrition therapy recommendations - Part 2; Session 5 (week 12): Medical physical Activity recommendations; Session 6 (week 15): Smoking cessation: tobacco and E-cigarettes; Session 7 (week 18): Diabetes distress.
75892429|NCT05267236|Other|Intervention #1: Treatment Group Receiving On-Demand TYRO Services|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
75892430|NCT05267236|Other|Intervention #2: Control Group Receiving In-Person TYRO Services|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
75892431|NCT05262777|Device|GP0112|Injectable gel
75892432|NCT05262777|Device|Restylane Lyft Lidocaine|Injectable gel
76062170|NCT05386719|Behavioral|Follow-Up|6 and 12 month labs (if prior abnormal) and Patient Reported Outcome questionnaires
76062171|NCT05386693|Procedure|Ilioinguinal nerve block|Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
76062172|NCT05378750|Other|Diuretic algorithm|Implementing diuretic algorithm
76062173|NCT05362955|Drug|Intravaginal 5-Fluorouracil (5-FU)|Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
76062174|NCT05353647|Biological|Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a|A single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
75892433|NCT05261802|Other|Intervention 1: AVANCE-Houston FRAMEWorks Program Weekly Workshops Spread Across 7 Weeks (spaced out format)|Participants in this arm receive 14 hours of Survival Skills for Healthy Families curricula over 7 weeks. Participants also receive employment supports and case management services.
75449111|NCT02787551|Drug|albiglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75449112|NCT02787551|Drug|dulaglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75449113|NCT02787551|Drug|Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)|Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
75599919|NCT04735692|Other|Full mouth or quadrant SRP|Full mouth or quadrant SRP
75892434|NCT05261802|Other|Intervention #2: AVANCE-Houston FRAMEWorks Program Weekend Workshops in 16-Hour Retreat (compressed format)|Participants in this arm receive 14 hours of Survival Skills for Healthy Families in a compressed format during a 16-hour weekend retreat, followed by a 2-hour reflections workshop two weeks later. Participants also receive employment supports and case management services.
75892435|NCT05256992|Other|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
75449114|NCT02782871|Device|Pneupac VR1|A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
75449115|NCT02763228|Behavioral|Aerobic Training - Fixed Schedule|Supervised aerobic training for 40 minutes 3x/week for 20 weeks
75743852|NCT04006522|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.
75892436|NCT05254834|Diagnostic Test|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
75892437|NCT05253846|Drug|Irinotecan|chemotherapy treatment
75892438|NCT05253846|Drug|Oxaliplatin|chemotherapy treatment
75892439|NCT05253846|Drug|Lederfolin|treatment
75892440|NCT05253846|Drug|5-Fluorouracil|chemotherapy treatment
75892441|NCT05253846|Radiation|Short-course radiotherapy|RT
75892442|NCT05253846|Procedure|TME|surgery
75892443|NCT05253443|Behavioral|Mentalizing Imagery Therapy and caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training and Mentalizing Imagery Therapy techniques with optional weekly group meetings.
75599920|NCT04320576|Device|Bulk-fill|Bulk-fill resin composite (bulk technique)
75892444|NCT05253443|Behavioral|Caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training with optional weekly group meetings.
76062175|NCT05343169|Behavioral|Overdose Education and Naloxone Distribution|"Education on OD risk behaviors and methods for responding to an OD, including naloxone use.~Duration and dose: Single 20-minute training at time of enrollment, provided to all participants in both arms"
76062176|NCT05343169|Behavioral|Advanced Education in Safer Substance Use, Treatment, and Self-Care|Education about misinformation about OAT, self-care, SEP services, HIV/HCV treatment Duration/dose: 9 mos., monthly ~2 hr. group sessions + ongoing access to video archive of recorded trainings.
76062177|NCT05343169|Behavioral|Social Service and Health Navigation|Help navigate access and barriers to healthcare, motivation and health goals Duration/dose: 9 mos., monthly face-to-face sessions to set goals and schedule appts, phone calls between sessions > 1x/wk.
75892445|NCT05244447|Other|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 10 weeks. Participants also receive life coaching and ongoing job readiness support.
76062178|NCT05343169|Behavioral|Peer Social Support|Support with social (re)integration, isolation, relationship building Duration/dose: 9 mos., monthly face-to-face events and phone calls/texts between sessions > 1x/wk.
76062179|NCT05339932|Other|Manual Wheelchair Skills Training|The intervention involves manual wheelchair skills training.
76062180|NCT05336396|Other|BMI|Longitudinal data will be collected to determine the effectiveness of BMI compared to traditional OHI to maintain and improve periodontal health.
75892446|NCT05244421|Other|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
76062181|NCT05281497|Behavioral|Health platform|Each participant was provided with a wearable device (a Heart Rate Smart Wristband, GSH405-B6, Golden Smart Home Technology Corporation). Each participant downloaded an app (WowGoHealth app) to connect with the health management platform (GSH AI health platform). Participants' exercise-related data, including number of steps walked, distance, consumed calories, and heart rate, were collected by the wearable devices. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics made by the Health Promotion Administration, Ministry of Health and Welfare (https://www.youtube.com/watch?v=r3xJW-b2tZY).
76062182|NCT05281497|Behavioral|Social media|We built a LINE group to inspire the intervention group.
76062183|NCT05281497|Other|exercise including an 18-minutes calisthenics|exercise including an 18-minutes calisthenics
75599921|NCT04320576|Device|Nano-fill|Nano-fill resin composite (layering technique)
75599922|NCT04554732|Drug|Keratinocyte growth factor|At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
75892447|NCT05242510|Procedure|Patching|The subject will occlude the non-dominant eye for 24 hours.
75892448|NCT05242510|Procedure|Prism Adaptation|The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
75599923|NCT04499820|Dietary Supplement|Nutrof|DHA docosahexaenoic acid Omega 3s may be of interest in cases of retinopathies.
75599924|NCT04499820|Dietary Supplement|Meralut|vitamin A, natural flavonoids, lutein and zeaxanthin
75599925|NCT04481256|Radiation|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
75599926|NCT04481256|Drug|Bintrafusp alfa|Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
75599927|NCT04481256|Drug|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
75599928|NCT04481256|Drug|Carboplatin|Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
75599929|NCT02888964|Drug|Add-on therapy|Pioglitazone therapy
75599930|NCT04416516|Biological|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
75599931|NCT04387110|Drug|Ocrelizumab|Receiving either 1infusion (600mg) or 2 infusions (300mg).
75599932|NCT04207008|Other|iBDecide Decision Support Application|The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
75616487|NCT00882115|Drug|Broccoli sprout extract (BSE)|BSE will be ingested by drinking a liquid formula containing 1.25 g BSE in a volume equaling 1 cup daily for 4 consecutive days in the BSE intervention phase.
75743853|NCT03961061|Behavioral|Brenner mFIT (standard care)|Families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and PA specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, PA, and parenting. Specialized visits with the PA specialist or dietician are scheduled as pertinent issues arise. Motivational interviewing, modified by Brenner FIT for use with families, is the key to treatment; family counselors are trained in cognitive behavioral therapy, parenting support/mindfulness, and employ these approaches to assist families in developing healthy habits.
76062184|NCT05228314|Biological|Candidate vaccine, SCB-2020S|a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
76062185|NCT05228314|Biological|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
76062186|NCT05228314|Other|Squalene based adjuvant|Squalene based adjuvant
76062187|NCT05228314|Other|CpG/alum adjuvant|CpG/alum adjuvant
75599933|NCT04122768|Behavioral|Multi-component physical activity tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
75599934|NCT04122768|Behavioral|Light coaching intervention|"A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period)."
75599935|NCT04206930|Other|Art Therapy|1 session of 2 hours per week in a closed group for 10 weeks
75599936|NCT02889042|Other|MRI and biological assessment|performing a MRI and a biological assessment
75743854|NCT03961061|Behavioral|Brenner mFIT (standard care plus mobile health components)|"Brenner mFIT includes all components of the standard Brenner FIT program in addition to six mobile health components.~The six mHealth components that will be used in addition to standard Brenner Families in Training program include-~a mobile-enabled website,~diet and physical activity tracking apps and physical activity tracker~tailored self-monitoring feedback~caregiver podcasts~animated videos for adolescent patients~social support via social media."
75892450|NCT05240742|Other|no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts|(Clinical) baseline and follow-up data will be collected in the 7 existing cohorts. These data will be aggregated (when possible). The CORFU analyses will be conducted based on the aggregated data.
75892451|NCT05239754|Other|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
75892452|NCT05237466|Behavioral|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
75892453|NCT05237466|Behavioral|Sorting Practice|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
76025058|NCT04163393|Device|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
76025059|NCT04428749|Diagnostic Test|Yale Swallow Protocol|The YSP is a three-step method consisting of an assessment of the patient's awareness, the patient's ability to follow simple instructions and finally the patient's ability to drink 90 ml water from a cup or by straw without stopping, choking or coughing.
75449116|NCT02763228|Behavioral|Resistance Training - Fixed Schedule|Supervised resistance training for 20 minutes 3x/week for 20 weeks
76025060|NCT04428749|Diagnostic Test|FEES (fiberoptic endoscopic evaluation of swallowing)|"The FEES will be performed bedside by an experienced occupational therapists. The patient will be sitting upright in a chair and be given 1) 2 spoons of applesauce, 2) 2 spoons of water, 3) several sips of water, 4) 90 ml of water. All items colored blue.~The FEES will use a single-use AMBU rhino-laryngo scope slim and the AMBU monitor. the examination will be terminated in case of aspiration below the vocal cords."
76025061|NCT04238585|Behavioral|Mobile messaging|Mobile health messages
76025062|NCT04677803|Drug|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
75449117|NCT02763228|Behavioral|Walking program|Unsupervised walking program 1-3 days/week for 52 weeks
75449118|NCT02763228|Behavioral|Aerobic Training - Flexible Schedule|Supervised aerobic training done on the participant's own schedule for 32 weeks
75449119|NCT02763228|Behavioral|Resistance Training - Flexible Schedule|Supervised resistance training done on the participant's own schedule for 32 weeks
75599937|NCT02888808|Other|Gastroscopy|Upper gastrointestinal endoscopy procedure
75599938|NCT04320108|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy 6 times during 2 weeks
75743855|NCT03948971|Procedure|Venogram|The 5 French (5F) diagnostic catheter will be navigated into the inferior then superior vena cava and then into the internal jugular bulb on the dominant venous side (as determined from the arteriographic images). Next, a 0.027 inch microcatheter will be navigated using fluoroscopic guidance into the superior sagittal sinus and a venogram will then performed by injecting a small dose of contrast. Next, the venous sinus pressure waveforms will be recorded as the catheter is withdrawn into the jugular bulb and then in the superior vena cava to obtain a central venous pressure. Once completed, the catheters will be removed and the sheaths will be removed. Manual pressure will be held at the venous access site for a few minutes. The arterial sheath will be closed based upon standard arteriogram protocol.
75599939|NCT03582150|Device|Remote Monitoring with Ambulatory Detox|"Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday."
75892454|NCT05232045|Drug|Automated urinary output collection system group (tight monitoring of urine output)|Automated urinary output collection system group (tight monitoring of urine output)
75892455|NCT05229874|Drug|carbon nanoparticles|Endoscopic injection
75892456|NCT05229874|Drug|Indocyanine green|Endoscopic injection
75599940|NCT03456726|Drug|Tazemetostat|Tazemetostat will be provided as a 200 mg oral tablet.
75599941|NCT03377478|Drug|Epclusa|Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
75743856|NCT03948776|Diagnostic Test|BodyMetrix body composition ultrasound|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
75892457|NCT05227352|Behavioral|Biophilic design experience|Recharge Rooms are immersive, biophilic private spaces featuring multisensory input that is inspired by nature.
75599942|NCT03181932|Drug|Vancomycin inhalation powder|100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects >21 years old) for 24 weeks during Period 1.
75449120|NCT02763228|Behavioral|Successful Survivorship Health Education and Support Group|Support groups will be held for one hour 3x/week for 20 weeks. Topics will include, but are not limited, to long-term side effects of treatment, stress management, coping with fear and uncertainty, body image, sexuality, and spirituality.
75599943|NCT03181932|Drug|Placebo inhalation powder|100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects >21 years old) for 24 weeks during Period 1.
75599944|NCT03181932|Drug|Vancomycin inhalation powder|In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
75892458|NCT05221970|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
75892459|NCT05221970|Behavioral|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
75599945|NCT02864862|Device|Immediate implant|
75892460|NCT05221970|Behavioral|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
75599946|NCT02864862|Biological|SCTG|
75599947|NCT02864862|Biological|ADM|
76025063|NCT04671953|Drug|BMS-986165|Specified dose on specified days
75616488|NCT00881959|Device|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
75616489|NCT00653419|Drug|buspirone HCl|Tablets, 30 mg, single-dose
75616490|NCT00653419|Drug|Buspar|Tablets, 30 mg, single-dose
75616491|NCT00884377|Drug|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
75449121|NCT02763228|Behavioral|Flexible support groups|Participants will attend 1-3 weekly group sessions of their choosing for 32 weeks.
75616492|NCT00884377|Device|ThermoMed|ThermoMed heat treatment device, one treatment
75616493|NCT00656929|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
75616494|NCT00656929|Other|Placebo|Placebo tablets
76025064|NCT04671953|Drug|Metformin|Specified dose on specified days
76025065|NCT04616105|Drug|REGN6490|Single dose of REGN6490
76025066|NCT04616105|Drug|Placebo|Placebo matching single dose of REGN6490
76025067|NCT04585061|Drug|Lidocaine Hydrochloride|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
76025068|NCT04585061|Device|Virtual reality device (Harga Miniso Vr Glass 3d terbaru)|"Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized"
76025069|NCT04585061|Dietary Supplement|Xylitol|Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized while xylitol tablet putted under tongue
75449122|NCT02747121|Behavioral|External inspection of health services|The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
75599948|NCT02888730|Drug|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
75743857|NCT03948776|Diagnostic Test|BodyMetrix body composition ultrasound only|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
75892461|NCT05215730|Device|MedCu wound dressings with copper oxide (COD)|Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
75599949|NCT02888730|Drug|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
75599950|NCT02058264|Drug|BBI-4000|
75599951|NCT01598298|Drug|duloxetine hydrochloride|Given PO
75743858|NCT03922048|Drug|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
76025070|NCT04531007|Diagnostic Test|iFR/ FFR/ IVUS/ OCT|intermediate lesion evaluation with intracoronary physiology and imaging
75449123|NCT02736136|Behavioral|joint observation and video feedback|
76025071|NCT03902717|Procedure|Minimally invasive cardiac surgery|Patients will undergo minimally invasive cardiac surgery
75599952|NCT01598298|Other|placebo|Given PO
75599953|NCT02888652|Drug|antiplatelet agents(Clopidogrel or Ticagrelor)|Clinical physicians according to patients condition to give different antiplatelet agents(Clopidogrel or Ticagrelor).We only observe clinical curative effect.
75599954|NCT01235949|Biological|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
75599955|NCT01235949|Biological|Infanrix hexa|Intramuscular injection, 3 doses
75449124|NCT02735044|Drug|Insulin glargine,300 U/mL|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter [mmol/L])
75599956|NCT01235949|Biological|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
75599957|NCT01235949|Drug|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
75599958|NCT01235949|Drug|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
75599959|NCT00691158|Drug|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
75599960|NCT00691158|Drug|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
75599961|NCT00691158|Drug|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
75599962|NCT00691158|Drug|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
75599963|NCT01235793|Drug|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
75599964|NCT01258998|Drug|Akt inhibitor MK2206|Given PO
75599965|NCT01258998|Other|laboratory biomarker analysis|Correlative studies
76025072|NCT03874091|Procedure|bilateral ESP block with 0,25% Bupivacaine+ Adrenaline|Regional anaesthesia technique performed under ultrasound guidance before surgery
75599966|NCT05601648|Drug|Psilocybin|Psilocybin (25mg tablet) plus supportive psychotherapy
75892462|NCT05204446|Behavioral|GROW Project|"(GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week."
75599967|NCT01235715|Drug|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
75892463|NCT05204446|Behavioral|GROW+ Project|"(GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention."
76062188|NCT05227521|Behavioral|Adapted H-GRASP feedback program|Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback
76062189|NCT05184985|Device|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
75449125|NCT02735044|Drug|Insulin glargine (100 units /mL)|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
75892464|NCT05198349|Drug|M1069|Participants will receive escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
76025073|NCT03874091|Procedure|ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline|Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
76025074|NCT03874091|Drug|Morphine PCA pump|Morphine given postoperatively.
76025075|NCT03786965|Other|On-pump CABG|On-pump CABG
76025076|NCT03786965|Other|Off-pump CABG|Off-pump CABG
75449126|NCT02735044|Drug|Background therapy|Fast-acting mealtime insulin analogs
76062190|NCT05184985|Device|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
76062191|NCT05183854|Biological|Pneumococcal 20-valent Conjugate Vaccine|Given IM
76062192|NCT05183854|Biological|Pneumococcal Polyvalent Vaccine|Given IM
76062193|NCT05183854|Other|Questionnaire Administration|Ancillary studies
75449127|NCT02720744|Drug|FT218|
75449128|NCT02720744|Drug|Placebo|
75449129|NCT02699515|Drug|MSB0011359C|Subjects with metastatic or locally advanced solid tumors will receive intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
75449130|NCT02695160|Biological|SB-FIX|Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
75449131|NCT02692651|Drug|Fidaxomicin|Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
75599968|NCT01235403|Drug|Lacosamide|"Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks"
75599969|NCT01024036|Drug|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
75599970|NCT01024036|Drug|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
75599971|NCT01024036|Drug|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
75599972|NCT01234467|Drug|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
76025077|NCT03786965|Other|Pump-assisted CABG|Pump-assisted CABG
76025078|NCT03786965|Other|Valve Repair Procedure without CABG.|Valve Repair Procedure without CABG (open heart procedure).
75892465|NCT05197959|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires ~ 11.5 minutes in total.
75892466|NCT05197959|Other|Sensorimotor training|Sensorimotor training is a non-invasive, non-painful procedure using nerve stimulation to cue motor action. Nerve stimulation is applied the second through the fifth digit and the median nerve at the wrist. This stimulation is used to cue a motor action. The number of stimulations will indicate the amount of movements. For example, two pulses of stimulations to the index finger would require two flexion and extension actions with the index finger. Once the stimulation occurs, the participant will flex and extend the corresponding area where the nerve stimulation was felt. This will take ~ 30 minutes to complete.
75892467|NCT05196191|Biological|VIAGENEX Max|Collagenous membrane derived from umbilical cord
75449132|NCT02692651|Drug|Vancomycin|Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
75599973|NCT01234467|Drug|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
75892468|NCT05196191|Procedure|Hibiclens wash|Antiseptic skin cleanser
75892469|NCT05194007|Drug|Frondanol|Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
75892470|NCT05194007|Drug|Placebo|Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
75892471|NCT05186077|Other|Magnetic Resonance Imaging|Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
75743859|NCT03922048|Drug|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
75449133|NCT02690246|Other|questionnaire|a questionnaire based study
75449134|NCT02688855|Device|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
75449135|NCT02688855|Device|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|Sham CMF OL1000
75449136|NCT02686658|Drug|Zimura|Zimura 20 mg/mL solution for intravitreal (IVT) injection
75449137|NCT02686658|Other|Sham|The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
75449138|NCT02677688|Biological|Autologous EBV specific CTL infusion|
75599974|NCT04300036|Dietary Supplement|longan syrup|Subjects will take 15 ml of longan syrup once a day for 3 months
75599975|NCT04300036|Dietary Supplement|Placebo syrup|Subjects will take 15 ml of placebo syrup once a day for 3 months
75743860|NCT03922048|Drug|HTX-011|Dose to be determined from Cohort 1.
75599976|NCT02875912|Behavioral|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
75743861|NCT03922048|Drug|HTX-011|Dose to be determined from Cohorts 1 and 2.
75743862|NCT03922048|Drug|HTX-011|Dose to be determined from Cohort 1 Part A.
75743863|NCT03922048|Device|Luer Lock Applicator|Applicator for instillation.
75743864|NCT03891667|Drug|Disulfiram|Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
75743865|NCT03871855|Drug|SHR-1702|Administered IV
75743866|NCT03871855|Drug|Camrelizumab|Administered IV
75892472|NCT05186077|Other|Psychiatric testing|Subjects will be evaluated using psychiatric assessments
75892473|NCT05186077|Other|Eye-Tracking|Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
75892474|NCT05186077|Other|Neuropsychology Evaluation|The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
75892475|NCT05177211|Drug|Fedratinib Pill|Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.
75892476|NCT05176132|Other|Life style intervention (dietician+ physiotherapist)|Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.
75892477|NCT05176132|Other|Self management|Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)
75892478|NCT05176132|Other|No intervention|Control groups (BMI 20-25 and BMI 25-30)
75892479|NCT05175521|Other|Eucalyptus Oil Scent|Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
75892480|NCT05175521|Other|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
75892481|NCT05170334|Drug|Binimetinib|Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
76062194|NCT05168943|Device|Nylon (Polyamide) Epidural Catheter|Nylon (Polyamide) Epidural Catheter
76062195|NCT05168943|Device|Polyurethane Epidural Catheter|Polyurethane Epidural Catheter
75743867|NCT03866174|Drug|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
76062196|NCT05167760|Drug|Apraclonidine|1-2 drops per eye every 8 hours for 2 weeks
76062197|NCT05153759|Other|Meal service|The primary goal is to pilot the feasibility of a meal service intervention in night shift workers
75743868|NCT03866174|Drug|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
75743869|NCT03866174|Other|Set and Setting (SaS) Protocol|The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
75743870|NCT03859869|Drug|Pancrelipase|Pancrelipase is administered orally as capsules with a meal or snack
75743871|NCT03859869|Drug|Placebo|Placebo is administered orally as capsules with a meal or snack
75743872|NCT03822910|Diagnostic Test|Pattern Separation Paradigm|Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
75743873|NCT03822910|Diagnostic Test|Sequential Associative Mismatch Paradigm|used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
75743874|NCT03822910|Diagnostic Test|Encoding Plasticity Paradigm|Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
75743875|NCT03799458|Device|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
75743876|NCT03799458|Device|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
75743877|NCT03764098|Drug|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
75743878|NCT03764098|Other|Placebo|Placebo
75743879|NCT03763565|Biological|Bivalent or Quadrivalent HPV vaccines|Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
75743880|NCT03763565|Other|Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
75743881|NCT03740204|Drug|17-β estradiol transdermal patches with cyclic progesterone|17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
75743882|NCT03740204|Drug|Placebo patch and pill|Placebo patch and pill
75743883|NCT03735563|Drug|Ketamine|Individuals will receive randomly either ketamine or fentanyl as a premedication
76062198|NCT05135195|Other|In-House Developed VR Platform - AMD, DR, Glaucoma|Participants will conduct experiments using commercial VR headsets and controllers. Visual impairments will be systematically simulated in VR. There are three visual impairment simulations (AMD, DR, and glaucoma) at three levels of severity (mild, moderate, or severe). Symptoms' simulation tools include a gaussian blur shader, distortion shader, and a culling mask with a gray spot in the middle.
76062199|NCT05135195|Other|In-House Developed VR Platform - Glaucoma|In the second set of experiments, a multidimensional visual impairment simulation of a single pathology (glaucoma) will be used at three levels of severity (mild, moderate, or severe). The post-processing package to simulate includes glare, difficulty in light, change adaptation, ambient occlusion, visual clutter, and overall blurred effect. The shader graph package will be used to create a distortion localized on assets surfaces only.
75449139|NCT02675699|Behavioral|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
75743884|NCT03735563|Drug|Fentanyl|Individuals will receive randomly either ketamine or fentanyl as a premedication
75743885|NCT03717402|Behavioral|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
75743886|NCT03715153|Drug|BUMETANIDE (S95008) for week 0 - 26|Oral solution dosed at 0.5 mg/mL Taken twice daily.
75743887|NCT03715153|Drug|PLACEBO for week 0 - 26|Oral solution Taken twice daily.
75449140|NCT02675699|Behavioral|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
75743888|NCT03715153|Drug|Open-Label BUMETANIDE (S95008) for weeks 26 - 52|Oral solution dosed at 0.5 mg/mL Taken twice daily.
75892482|NCT05170334|Drug|Belinostat|Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
75892483|NCT05169424|Device|Trelegy Ellipta|Trelegy Ellipta
75892484|NCT05169424|Device|Stiolto Respimat|Stiolto Respimat
75449141|NCT02674061|Biological|Pembrolizumab|Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle
75892485|NCT05169424|Drug|Tiotropium + Olodaterol (5/5 mcg)|Tiotropium + Olodaterol (5/5 mcg)
75892486|NCT05169424|Drug|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
75743889|NCT03685773|Drug|Diazoxide|"MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study."
75892487|NCT05165576|Behavioral|Child-centered communication|The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
75892488|NCT05165186|Other|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video.
75449142|NCT02672982|Other|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
75449143|NCT02672982|Other|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
75892489|NCT05155046|Drug|18F-DCFPyL|18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.
75892490|NCT05150691|Biological|DB-1303|Administered IV
75892491|NCT05150691|Drug|Pertuzumab Injection|Administered IV
76062200|NCT05134480|Procedure|Descemet membrane endothelial keratoplasty|cornea transplant procedure to replace dysfunctional endothelial cell layer
75599977|NCT01233999|Drug|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
75892492|NCT05150691|Drug|Ritonavir|Administered oral
75599978|NCT01233687|Drug|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
75599979|NCT01023958|Drug|BI 6727, IV infusion|phase II
76062201|NCT05127590|Drug|RBN-2397|Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis). Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.
75599980|NCT01233609|Drug|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
75599981|NCT01233609|Drug|Placebo|Dosage per subject weight- same schedule as the active comparator
75599982|NCT01232283|Drug|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
75892493|NCT05150691|Drug|Itraconazole|Administered oral
75449144|NCT02659124|Device|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
75599983|NCT01232283|Drug|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
75599984|NCT01232283|Other|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
75599985|NCT01232127|Drug|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
75599986|NCT01232127|Drug|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
75599987|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
75599988|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
75599989|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
75599990|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
75599991|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
75599992|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
75599993|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
75599994|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
75892494|NCT05139160|Dietary Supplement|Protein quality|the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
75892495|NCT05132491|Other|TECH-Prep Intervention|Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.
75892496|NCT05129527|Device|InspirerMundi app|"Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period."
75892497|NCT05129527|Other|Usual care|Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
76062202|NCT05116891|Drug|CAN04 (nadunolimab)|FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
76062203|NCT05116891|Drug|mFOLFOX|mFOLFOX/CAN04
75599995|NCT01258608|Drug|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
75599996|NCT01258608|Drug|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
75743890|NCT03685773|Drug|Placebo (for diazoxide)|"MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study."
75743891|NCT03685773|Drug|Nicotinic acid|Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.
75892498|NCT05126784|Biological|Denosumab|AVT03 (denosumab) or Prolia (denosumab) will be given as 1 time subcutaneous injection)
75892499|NCT05123586|Drug|LY3361237|Administered SC
75599997|NCT01258608|Drug|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
75892500|NCT05123586|Drug|Placebo|Administered SC
75599998|NCT01015612|Device|Medtronic CoreValve® System|The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
75892501|NCT05122806|Genetic|RNAseq|"Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify the ALK fusion partner and its variant and associated co-mutations.~ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be performed on blood samples"
75892502|NCT05121961|Procedure|Sacroiliac intra-articular injection|CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
75892503|NCT05114187|Other|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~Ten selected multimedia e-learning lessons;~A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete the intervention. The total time to complete is approximately 5-6 hours."
75892504|NCT05114187|Other|Education Control|"Participants in the control group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~One selected multimedia e-learning lesson;~A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete. The total time to complete is approximately 1-2 hours.~Note: All participants will receive access to all e-learning at the conclusion of the study."
75892505|NCT05108428|Drug|Capecitabine|Capecitabine 825 mg/m^2 twice daily orally 5 days per week on days of planned radiation therapy.
75892506|NCT05108428|Radiation|Radiation Therapy|Participants will receive varying doses of radiotherapy based on MRI guidance, beginning at 28-33 fractions (1.8 Gray units) .
76025079|NCT03786965|Other|Valve Repair Procedure with CABG.|Valve Repair Procedure with CABG (open heart procedure).
76062204|NCT05116891|Drug|DTX|DTX/CAN04
76062205|NCT05116891|Drug|G/C|G/C/CAN04
75892507|NCT05108428|Drug|FOLFOX regimen|Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus* (optional) 400 mg/m^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m^2 IV continuous infusion over 46 hours day 1 each cycle.
75892508|NCT05105919|Drug|Aspirin 80 mg EC Tab|Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
75892509|NCT05098509|Drug|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
75892510|NCT05098509|Drug|Placebo|Matching Placebo for RAD011
75449145|NCT02659124|Procedure|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
75892511|NCT05092451|Drug|Cyclophosphamide|Given by IV
75892512|NCT05092451|Drug|CAR.70/IL15-transduced CB-NK cells|Given by IV
75892513|NCT05092451|Drug|Fludarabine phosphate|Given by IV
75892514|NCT05089630|Biological|Pentamer (low)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
75892515|NCT05089630|Biological|Pentamer (med)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
75892516|NCT05089630|Biological|Pentamer (med)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
75449146|NCT02654314|Drug|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
75449147|NCT02654314|Other|Placebo|Blue capsule matching the melatonin arm
75449148|NCT02652611|Procedure|SI Screw Removal Surgery|
75449149|NCT02652611|Procedure|Non-screw removal treatment (non-operative management)|
75449150|NCT02634905|Other|Individual session therapeutic education|within 2 weeks after inclusion (week 0)
75599999|NCT04319874|Drug|Ganoderma lucidum|Participants take ganoderma lucidum spore powder once a day, 1000mg
75892517|NCT05089630|Biological|Pentamer (high)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
75892518|NCT05089630|Combination Product|Placebo (saline)|Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
75449151|NCT02634905|Other|Phone Call|
75449152|NCT02628444|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
75449153|NCT02628444|Biological|Placebo (Sodium chloride 0.9%)|0.5 mL, Subcutaneous
75600000|NCT04319874|Drug|Chemotherapy|Subjects are treated with conventional chemotherapy
75600001|NCT04319874|Drug|Placebos|Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
75600002|NCT01231659|Drug|Everolimus|Everolimus 10 mg (2 tablets of 5 mg) once daily
75600003|NCT01231659|Drug|Letrozole|Letrozole 2.5 mg once daily
75892519|NCT05078229|Behavioral|FOCUS|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.
75600004|NCT02875288|Drug|liposomal bupivicaine|"The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~Route of drug administration; Surgical site infiltration"
75600005|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
75892520|NCT05078229|Behavioral|Healthy Living|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
76062206|NCT05100342|Diagnostic Test|Point score prediction tool for 30-day survival|"This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days"
75892521|NCT05072977|Procedure|TransPRK|A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.
75892522|NCT05072977|Procedure|Alcohol PRK|A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
75600006|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
75600007|NCT01052428|Drug|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
75600008|NCT01052428|Drug|Placebo|Placebo 100 mg once a day for 2 years
75600009|NCT01052272|Drug|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
75600010|NCT01052272|Drug|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
75600011|NCT01052272|Drug|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
75600012|NCT01257204|Drug|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
75743892|NCT03683277|Drug|Ixazomib/Pomalidomide/Dexamethasone|"Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged <75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
75892523|NCT05068752|Drug|Vemurafenib|Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID
75892524|NCT05068752|Drug|Sorafenib|Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily
75892525|NCT05064410|Behavioral|Educational Intervention|The colorectal cancer (CRC) educational activities will include the use of NCI CRC resources and materials, including a PowerPoint presentation, and CRC educational models and displays. The CRC education will be delivered in Spanish and English, and will consist of pre and post knowledge assessments including screening and behavioral intention questions. The educational intervention will take approximately 45 minutes-1 hour.
75892526|NCT05051293|Other|serum concentration of estrogen (E1 and E2) and testosterone ratio measurement|To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
76062207|NCT05095038|Dietary Supplement|Appethyl®|Spinach extract, capsules, 5g/day, 26 weeks.
76062208|NCT05095038|Dietary Supplement|Placebo|Pea protein, capsules, 5g/day, 26 weeks.
75600013|NCT01257204|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
75600014|NCT01257204|Drug|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
75600015|NCT01257204|Drug|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
75600016|NCT01231581|Drug|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
75600017|NCT01231581|Drug|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
75600018|NCT01231581|Drug|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
75600019|NCT01050634|Drug|Aromasin (exemestane)|25mg oral tablet, daily, for >1yr
75600020|NCT01020526|Drug|pregabalin|Oral capsule 75-450 mg/day
75892527|NCT05049044|Other|Quality of Life Questionnaire-Core 30 (QLQ-C30)|The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
76062209|NCT05069038|Drug|Palbociclib 125mg|Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days on 7 days off schedule (meaning: on Days 1-21of each 28-day cycle). If a subject misses a day's dose entirely, she must be instructed not to make it up the next day but just take her regular dose at the next assigned time. If a subject vomits any time after taking a dose, she must be instructed not to retake the dose but resume subsequent dosing at the next assigned time. If a subject inadvertently takes an extra dose during a day, she must be instructed to not take the next day's dose.
75892528|NCT05042505|Drug|Dapagliflozin 10Mg Tab|Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg
75892529|NCT05042505|Drug|Sitagliptin 100mg|Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily
75892530|NCT05036876|Drug|Degludec|Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
76062210|NCT05065983|Biological|CHIKV VLP, adjuvanted|Adjuvanted formulation includes aluminum hydroxide
75892531|NCT05036876|Drug|Glargine U300|Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
75892532|NCT05031962|Device|CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in breast reconstruction
75892533|NCT05014282|Drug|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
76062211|NCT05013099|Biological|zirconium Zr 89 crefmirlimab berdoxam|Up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
76062212|NCT04983030|Biological|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
76062213|NCT04983030|Biological|MVA-BN-HIV|MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
76062214|NCT04983030|Biological|PGT121|PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
76062215|NCT04983030|Biological|PGDM1400|PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
76062216|NCT04983030|Biological|VRC07-523LS|VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
76062217|NCT04981613|Drug|Kunxian capsule|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
76062218|NCT04980391|Biological|RSV MAT|Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
75743893|NCT03665207|Drug|Insulin|When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
76062219|NCT04980391|Drug|Placebo|Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
76062220|NCT04973566|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
75743894|NCT03660683|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg PO QD
75449154|NCT02626962|Drug|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
75449155|NCT02626962|Drug|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
75449156|NCT02623998|Drug|insulin glargine|Dose is titrated to achieve fasting normoglycemia
75449157|NCT02623998|Drug|sitagliptin/metformin|Dose is titrated to 50/1000 mg bid or maximal tolerated dose
75449158|NCT02623998|Behavioral|lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
75449159|NCT02623725|Biological|CYD Dengue Vaccine (5-dose formulation)|0.5 mL, Subcutaneous
75449160|NCT02623725|Biological|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
75449161|NCT02608684|Drug|Pembrolizumab|Pembrolizumab IV solution
75892534|NCT05014282|Behavioral|Counseling|Phone counseling with the state tobacco quitline.
75449162|NCT02608684|Drug|Gemcitabine|Gemcitabine IV solution
75743895|NCT03660683|Drug|Saxagliptin 5mg|Saxagliptin 5 mg PO QD
75743896|NCT03660683|Drug|Placebo Oral Tablet|Matching Placebo Tablets
75892535|NCT05014282|Drug|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
75449163|NCT02608684|Drug|Cisplatin|Cisplatin IV solution
76062221|NCT04973566|Drug|Etanercept|Etanercept will be administered subcutaneously.
76062222|NCT04973566|Drug|Hydroxychloroquine|HCQ will be administered orally.
76062223|NCT04947579|Drug|CC-99677|Oral
75449164|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1|0.5 milliliter (mL), Intramuscular
76062224|NCT04947579|Other|Placebo|Oral
76062225|NCT04932447|Behavioral|Inspiratory Muscle Strength Training|30 breaths/ day, 5 days/week for 24 weeks.
75600021|NCT01020448|Drug|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
75743897|NCT03653637|Behavioral|Project Life Force|A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
75600022|NCT02872324|Other|Procurement questionnaires|
75600023|NCT02872168|Other|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
75600024|NCT04286230|Behavioral|Adherence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
75600025|NCT04286230|Behavioral|Persistence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
75600026|NCT01256658|Drug|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
75449165|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2|0.5 mL, Intramuscular
75600027|NCT01256502|Device|SERI® Surgical Scaffold|Breast reconstruction surgery
75449166|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3|0.5 mL, Intramuscular
75600028|NCT04319952|Device|Primary Total Hip Replacement with Metafix™ femoral stem and Trinity™ acetabular cup or TriFit-CF™/TriFit-TS™ femoral stem and Trinity™ acetabular cup implanted by a single surgeon.|The participant will undergo surgery using the hip prostheses and direct anterior surgical approach used by their surgeon-investigator. A patient-specific femoral guide, generated by the OPS™ Plan preoperatively, will be used during the surgical step of the femoral neck resection. These are not study specific procedures as the OPS™ Plan is already in use by the surgeon-investigator in their standard of care practice.
75743898|NCT03653637|Behavioral|Treatment as Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
75743899|NCT03569293|Drug|Placebo for Upadacitinib|Tablets taken orally once a day
75743900|NCT03569293|Drug|Upadacitinib|Tablets taken orally once a day
75892536|NCT05014282|Behavioral|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
75892537|NCT05010200|Biological|PGV-001|personalized genomic peptide vaccine
76062226|NCT04928014|Other|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
75449167|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4|0.5 mL, Intramuscular
75892538|NCT05010200|Biological|Poly-ICLC|immune modulator
75892539|NCT05010200|Biological|CDX-301|soluble recombinant human protein to work on stem cell
75449168|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
75449169|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine|0.5 mL, Intramuscular
75449170|NCT02584829|Drug|Avelumab|Given IV
75449171|NCT02584829|Other|Laboratory Biomarker Analysis|Correlative studies
75449172|NCT02584829|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
75449173|NCT02584829|Radiation|Radiation Therapy|Undergo radiation therapy
75449174|NCT02584829|Biological|Recombinant Interferon Beta|Given via intra-tumor injection
75600029|NCT01256190|Biological|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
75600030|NCT01256190|Device|Gelatin sponge|absorbable gelatin sponge for topical use
75600031|NCT01255722|Drug|iobitridol|single IV injection
75600032|NCT01255722|Drug|iopromide|Single IV injection
75600033|NCT01255722|Drug|iomeprol|Single IV injection
75600034|NCT02888574|Drug|Intranasal Oxytocin|Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
75892540|NCT05010174|Drug|MDR product|Observation of patients previously receiving MDR product(s)
75600035|NCT02888574|Drug|Placebo|Placebo nasal spray
75600036|NCT01231503|Biological|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
76062227|NCT04906148|Other|Advertisement content (explicit vs. implicit)|Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content
75600037|NCT01231503|Biological|Engerix-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=< 7 days of age)
75600038|NCT01231503|Biological|Tritanrix HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
75743901|NCT03566511|Drug|Diazoxide|Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
75743902|NCT03566511|Drug|Placebo|Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
75743903|NCT03525262|Radiation|30Gy (Gray) planning target volume (PTV)|PTV1_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
75743904|NCT03494179|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
75743905|NCT03472404|Procedure|Internal Brace augmented ankle Ligament reconstruction|internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.
75743906|NCT03472404|Procedure|Brostrom-Gould ankle Ligament reconstruction|Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
75743907|NCT03464136|Biological|Placebo for Ustekinumab|Participants will receive placebo as SC injection to blind adalimumab.
75743908|NCT03464136|Biological|Placebo for Adalimumab|Participants will receive placebo as IV infusion to blind ustekinumab.
75892541|NCT05007327|Other|Exposure to pollen and air pollution|For all subjects of the cohort, we will follow exposure to pollen and air pollution.
75892542|NCT04984850|Other|Oral chemotherapy information and support|Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.
75892543|NCT04983615|Drug|fentanyl-based sedation|fentanyl-based sedation instead of midazolam-based sedation in ventilated patients
75892544|NCT04983615|Drug|midazolam-based sedation|midazolam-based sedation
75892545|NCT04975308|Drug|Imlunestrant|Administered orally.
75892546|NCT04975308|Drug|Exemestane|Administered orally.
75892547|NCT04975308|Drug|Fulvestrant|Administered IM.
75892548|NCT04975308|Drug|Abemaciclib|Administered orally.
75892549|NCT04975152|Drug|Cemiplimab-Rwlc|Flat dose of cemiplimab-rwlc 350 mg IV every 3 weeks, up to 9 cycles.
75892550|NCT04962698|Behavioral|Visual motor imagery (MI)|Subjects will relax their muscles and perform conventional visual motor imagery (MI). With the guidance of audio instruction, the subjects will imagine the grasp and release motions with the right arm for 2 s in each motion in their mind. There will be no proximal muscle contraction.
75892551|NCT04962698|Behavioral|Kinesthetic MI|The same MI procedure as Visual MI will be performed, except that the subjects will focus on the kinesthetic sensation that they would feel with the imagined motions.
75892552|NCT04962698|Behavioral|Robotic-Hand Interaction with MI|Subjects will perform robotically augmented mental practice for grasp and release motions with the activation control of the proximal muscles. During this task, subjects will also imagine the kinesthetic sensation that they would feel with the corresponding motions with the right arm.
75892553|NCT04962698|Behavioral|Robotic-Hand Interaction without MI|Subjects will perform the Robot-Hand Interaction without MI.
75892554|NCT04962698|Behavioral|Virtual-Hand Interaction|Subjects will interact with visual feedback of virtual robot actions on a monitor.
75600039|NCT01231503|Biological|BCG|1 dose, intradermal route, in shoulder at birth (=< 7 days of age)
75600040|NCT01231503|Biological|OPV|4 doses, orally, at birth (=< 7 days of age) and at 6, 10 and 14 weeks of age
75600041|NCT01231503|Biological|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
75600042|NCT01230489|Biological|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
75743909|NCT03464136|Biological|Ustekinumab (6 mg/kg)|Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.
75743910|NCT03464136|Biological|Ustekinumab (90 mg)|Participants will self-administer SC injection of ustekinumab 90 mg.
75743911|NCT03464136|Biological|Adalimumab (40 mg)|Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
75743912|NCT03427450|Diagnostic Test|Blood draw|Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
75892555|NCT04962698|Behavioral|Robotic Action Observation|Subjects will relax their muscles and focus on observing the computer-controlled grasp and release actions of the robotic hand.
75892556|NCT04962698|Behavioral|Rest|Subjects will rest without a task.
75892557|NCT04958252|Drug|BI 1569912|BI 1569912
75892558|NCT04958252|Drug|Placebo|Placebo
75892559|NCT04948333|Drug|ABL001 40mg BID|One tablet of 40 mg will be taken orally twice a day (BID)
75892560|NCT04948333|Drug|ABL001 80mg QD|Two tablets of 40 mg will be taken orally once a day (QD)
75892561|NCT04948333|Drug|ABL001 200mg QD|Five tablets of 40 mg will be taken orally once a day (QD)
75892562|NCT04943965|Diagnostic Test|Ultrasound imaging|"The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~Pre-induction.~Post-induction / Pre-PAC~Post-induction / Post-PAC"
75892563|NCT04940663|Behavioral|EMA|Participants will complete surveys about their feelings and social habits through a smartphone app (EMA)
75892564|NCT04931810|Behavioral|All Nations Breath of Life|Same.
75892565|NCT04931173|Other|IVA+OA versus IVA+MBP+OA|Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery
75892566|NCT04927897|Diagnostic Test|Ultrasound|3D endorectal ultrasound.
75892567|NCT04927897|Diagnostic Test|Rectoscopy|Rigid rectoscopy.
75892568|NCT04927897|Other|Scan, e.g. CT (resection specimen)|For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.
75892569|NCT04922983|Drug|Botulinum toxin type A|A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).
75892570|NCT04922983|Behavioral|Isometric Yoga-like exercise|Extended torso and legs held diagonally by one straight arm, back against wall if necessary
75892571|NCT04922983|Behavioral|Placebo|Used as placebo
75892572|NCT04918173|Drug|Atenativ|Antithrombin concentrate
75892573|NCT04917679|Drug|Eltrombopag plus diacerein|In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10^9/L as follows: (1) if platelet count is less than 150 × 10^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10^9/L to 250 × 10^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10^9/L.
75892574|NCT04917679|Drug|Eltrombopag|In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10^9/L to 150 × 10^9/L.
75892575|NCT04905316|Drug|Canakinumab|Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
75892576|NCT04905316|Drug|Durvalumab|Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
75892577|NCT04905316|Radiation|Radiation therapy|Radiation therapy will be performed with external beam ionizing radiation as per standard of care in accordance with institutional practice. Intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist. Patients will be simulated in the treatment position with standard immobilization techniques for thoracic radiotherapy. The prescription dose will be 60 Gy (±10%) in 2Gy fractions to fields encompassing gross tumor and lymph nodes, as per institutional guidelines. The dose must satisfy institutional guidelines and minimize risk to adjacent organs at risk.
75743913|NCT03397706|Drug|VRx-3996|Taken orally once or twice daily
75892578|NCT04905316|Drug|Chemotherapy|Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
75892579|NCT04902833|Procedure|Blood Draw|Blood specimen 2-4 teaspoons
75892580|NCT04892134|Other|blood sample|40-50 ml of blood is taken
75892581|NCT04878185|Other|Exercise|Preoperative exercise
75892582|NCT04877041|Behavioral|Intradialytic Cycling|This intervention will consist of intradialytic cycling for 60 minutes 3 times per week for a total of 12 weeks.
75743914|NCT03397706|Drug|Valganciclovir|Taken orally once or twice daily
75743915|NCT03382587|Drug|Aflibercept (Eylea, BAY86-5321)|"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"
75743916|NCT03367546|Procedure|Blood and Marrow Transplant|Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
75743917|NCT04118803|Device|ICD replacement or upgrade|Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to inappropriate shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.
75600043|NCT01229397|Biological|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
75600044|NCT01229397|Biological|Inflexal V|Inflexal V 0.5 mL administrated once only
75600045|NCT05492097|Behavioral|Exercise Therapy|Traditional exercise therapy and NMES
75743918|NCT03325972|Drug|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
75600046|NCT05492097|Behavioral|Exercise Therapy and Robotic Walking Training|Traditional exercise therapy and Robotic Walking Training
75743919|NCT03325972|Other|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
76062228|NCT04906148|Other|Advertisement content (true vs. misleading)|Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
76062229|NCT04863092|Behavioral|Educational Intervention|The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
75600047|NCT01228071|Drug|testosterone gel 2%|40 mg testosterone gel 2%
75600048|NCT04319289|Other|aerobic interval training and Vitamin D supplementation,|"The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day ."
75600049|NCT04319289|Drug|Vitamin D supplementation only|One capsule containing (cholecalciferol 400 IU) was taken every day .
75600050|NCT04319289|Other|aerobic interval training only|"The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~Frequency: 3 days/week. The whole training lasting for 12 weeks"
75600051|NCT04319133|Behavioral|Fasting|Doing fasting 2 days a week within 8 weeks
75600052|NCT01008475|Drug|EMD 525797 250 mg|EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
75616495|NCT00656383|Other|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
75743920|NCT03261362|Dietary Supplement|Branched-chain amino acids reduced intake|
76062230|NCT04856189|Biological|Pembrolizumab|Given IV
76062231|NCT04856189|Drug|Selinexor|Given PO
75616496|NCT00656383|Other|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
75743921|NCT03247712|Drug|Nivolumab|Nivolumab 240mg IV q2wks or 480mg IV q4wks
75743922|NCT03247712|Procedure|Surgical Resection|Surgical Resection of Tumor
75743923|NCT03247712|Radiation|Radiation (5 days)|8Gy x 5 (Mon-Fri) GTV+3mm
75743924|NCT03247712|Radiation|Radiation (3 days)|8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
75743925|NCT03235076|Drug|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
76062232|NCT04855929|Drug|ANV419|ANV419 administered by intravenous (IV) infusion
76062233|NCT04855929|Drug|Ipilimumab|Ipilimumab administered by intravenous (IV) infusion
76062234|NCT04848558|Drug|Nipocalimab|Participants will receive IV infusion or SC injection of nipocalimab.
76062235|NCT04848558|Other|Placebo|Participants will receive IV infusion or SC injection of placebo.
76062236|NCT04846686|Biological|Placenta pathological examination|a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
76062237|NCT04845620|Drug|ARQ-151 Active|ARQ-151 Cream 0.05% - Active
75600053|NCT01008475|Drug|EMD 525797 500 mg|"Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
75743926|NCT03208049|Behavioral|Sleep Restriction Therapy|Sleep Restriction Therapy will regulate time spent in bed based on information collected from sleep diaries during evaluation and treatment. Sleep Restriction therapy is designed to improve sleep quality by matching opportunity for sleep to the amount of average total sleep calculated from sleep diaries. Once the quality of sleep has improved, sleep quantity is gradually increased by slowly increasing sleep opportunity. Stimulus control will strengthen the bed/sleep association by eliminating non-sleep activities from the bedroom.
75743927|NCT03208049|Behavioral|Cognitive Therapy|Cognitive Therapy is designed to identify maladaptive beliefs about sleep, challenge their validity, and replace them with more adaptive thinking patterns. This therapy aims to reduce sleep-related worry, anxiety, and fear. The treatment phase of the study lasts six weeks. During treatment, you will meet with a study therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
75892583|NCT04875702|Drug|Allopurinol|"For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.~For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial."
75600054|NCT01008475|Drug|EMD 525797 750 mg|EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
75892584|NCT04875702|Drug|Naproxen 250 MG|Naproxen 250 mg p.o. twice daily
75892585|NCT04875702|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg p.o. once daily
75892586|NCT04875702|Drug|Colchicine 1.2 mg|Dose escalation to 0.6 mg p.o. twice daily for patients experiencing breakthrough flares or a dose decrease (0.6 mg p.o. every other day) for patients experiencing gastrointestinal intolerance.
75892587|NCT04875702|Drug|Naproxen 500 Mg|dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.
75892588|NCT04875702|Drug|Prednisone 40 mg|For flare glucocorticoids: prednisone taper for 8 days, starting with 40mg (oral) daily.
75892589|NCT04860336|Other|Observational|Observational
76062238|NCT04845620|Drug|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
75600055|NCT01008475|Drug|EMD 525797 1000 mg|"Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
75743928|NCT03196518|Procedure|PET Imaging|PET/CT study immediately after injection
75743929|NCT03196518|Other|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes
75743930|NCT03104699|Drug|AGEN2034|Anti-PD-1 Monoclonal Antibody
75743931|NCT03060057|Device|U2 Knee™ System|The United U2 Knee™ System consists of several components and for this clinical evaluation it includes the (1) Femoral Component, (2) Tibial Insert, 3) Tibial Baseplate, and the 4) Patella.
75743932|NCT03048825|Drug|Colchicine|Colchicine 0.5 mg once daily
75743933|NCT03048825|Drug|Spironolactone|Spironolactone 25 mg once daily
76062239|NCT04844411|Drug|JNJ-67835989|JNJ-67835989 will be administered orally.
75743934|NCT03048825|Device|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
75743935|NCT03048825|Drug|Colchicine-Placebo|Matching Colchicine-placebo once daily
75743936|NCT03048825|Drug|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
75743937|NCT03039413|Drug|Copper Cu 64 TP3805|Given IV
75743938|NCT03039413|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
75743939|NCT03039413|Procedure|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
75743940|NCT03026790|Other|Medication management|Individualized management of medications for pain
75743941|NCT03026790|Other|Non-pharmacological pain management|Individualized management of non-medication pain treatment approaches
75743942|NCT03026790|Drug|Buprenorphine-Naloxone|Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
75892590|NCT04859985|Device|SELUTION SLR|Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis > 30% or FFR < 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).
75892591|NCT04859985|Device|DES|For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
75892592|NCT04859218|Procedure|RBC transfusion|two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
75892593|NCT04855435|Drug|MBS8(1V270)|The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
76062240|NCT04844411|Drug|Placebo|Matching placebo will be administered orally.
75892594|NCT04847921|Drug|Dalbavancin|long-acting lipoglycopeptide antibacterial agent
75892595|NCT04842890|Radiation|Pencil Beam Scanning Proton SBRT|The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
75892596|NCT04839523|Device|Exufiber|A sterile nonwoven wound dressing made from highly absorbent PVA fibers.
75600056|NCT01008475|Drug|Cetuximab|"Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
75616497|NCT04161937|Behavioral|Behavioural Intervention|Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
75743943|NCT03020823|Drug|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
75743944|NCT02969369|Drug|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
75743945|NCT02969369|Drug|Placebo capsule|Placebo once daily
75743946|NCT02948036|Other|Mobile-device, plasticity-based adaptive cognitive treatment|This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
75892597|NCT04839523|Device|Exufiber Ag+|A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.
75892598|NCT04837573|Behavioral|Sister Circle protocol|The intervention is an 8-week, therapeutically-informed protocol.
76062241|NCT04843527|Device|FreeStyle Libre System|FreeStyle Libre Flash Glucose Monitoring System
76062242|NCT04843527|Device|FreeStyle Libre System plus food app|FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application
76062243|NCT04816201|Other|Electroacupuncture|Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
76062244|NCT04811235|Device|Near Infra-Red Spectroscopy (NIRS) Sensor|The NIRS sensor is laid on top of the dura, at the site of the SCI, and emits near-infrared light signals into the cord to measure tissue oxygenation and tissue hemodynamics in real-time.
76062245|NCT04797650|Drug|CTP-543 matching placebo|Administered as tablets.
76062246|NCT04797650|Drug|CTP-543|Administered as tablets.
75892599|NCT04833829|Behavioral|CHIMES Intervention|"There are six components to the intervention:~Posters and other print materials to prompt providers and patients to discuss MH care engagement.~Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~Expanded MH screening procedures, including at initial intake.~Case management, emphasizing MH care engagement.~Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~Regular case review meetings."
75892600|NCT04833829|Behavioral|Standard of Care|The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
76062247|NCT04760496|Drug|Oxytocin 4 mIU/mL|Oxytocin at 4 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
76062248|NCT04760496|Drug|Oxytocin 2 mIU/mL|Oxytocin at 2 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
75892601|NCT04832321|Other|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan man with different profiles of illness severity, treatment, and treatment response.
75743947|NCT02777879|Procedure|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
75743948|NCT02770326|Biological|Fecal Microbiota Transplantation (FMT)|
75743949|NCT02761499|Device|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
75743950|NCT02735707|Drug|Ceftriaxone|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
75743951|NCT02735707|Drug|Moxifloxacin or Levofloxacin|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
75743952|NCT02735707|Drug|Piperacillin-tazobactam|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
75743953|NCT02735707|Drug|Ceftaroline|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
75743954|NCT02735707|Drug|Amoxicillin-clavulanate|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
75892602|NCT04819100|Drug|Selpercatinib|Administered orally.
75892603|NCT04819100|Drug|Placebo|Administered orally.
76062249|NCT04736472|Device|Pharmacogenetic test|Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
76062250|NCT04734145|Diagnostic Test|Breathprinting test|Consented, enrolled participants will undergo a breathprinting test (e-nose) during the presurgical visit and at the same facility as their presurgical or prebiopsy visit, before any attempt is made to obtain cytohistological diagnosis of the pulmonary nodule.
76062251|NCT04722822|Behavioral|(Intervention) Recommending HPV vaccine for patients 9-10 years of age|Providers within intervention practices will receive training which includes both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.
75892604|NCT04805203|Other|blood sample analyses|maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
76062252|NCT04722822|Behavioral|(Control) Recommending HPV vaccine for patients 11-12 years of age|Providers within control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).
76062253|NCT04705597|Drug|BGE-175|Drug
76062254|NCT04705597|Other|Placebo|Placebo
76062255|NCT04704830|Biological|R21/Matrix-M|Adjuvanted malaria vaccine
75743955|NCT02735707|Drug|Standard course macrolide|"Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.~The dosing of and route of administration is not protocolised, the following guidance is provided:~Initial IV administration of a macrolide is strongly preferred~The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
76062256|NCT04704830|Biological|Rabies vaccine|Placebo Comparator
76062257|NCT04682431|Drug|PY159 Single agent dose level 1|Dose of PY159 as a single agent given in a standard 3+3 design.
75743956|NCT02735707|Drug|Extended course macrolide|"Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).~The dosing of and route of administration is not protocolised, the following guidance is provided:~Initial IV administration of a macrolide is strongly preferred~The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
75600057|NCT01008475|Drug|Irinotecan|"Safety part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
75743957|NCT02735707|Other|No systemic corticosteroid|Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
75743958|NCT02735707|Drug|Fixed-duration Hydrocortisone|50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
75743959|NCT02735707|Drug|Shock-dependent hydrocortisone|50mg IV hydrocortisone every 6 hours while the patient is in septic shock
75743960|NCT02735707|Drug|Fixed-duration higher dose Hydrocortisone|"100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed."
75743961|NCT02735707|Other|No antiviral agent for influenza|No antiviral agent intended to be active against influenza infection is to be administered
75743962|NCT02735707|Drug|Five-days oseltamivir|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
76062258|NCT04682431|Drug|PY159 Single agent dose level 2|Dose of PY159 as a single agent given in a standard 3+3 design.
76062259|NCT04682431|Drug|PY159 Single agent dose level 3|Dose of PY159 as a single agent given in a standard 3+3 design.
75600058|NCT04294303|Other|web based telemonitoring system|Subjects in the telemonitoring group were given an iPad with installed iHealth application, a scale, and an electronic blood pressure monitor (a mobile web-based telemonitoring system). These devices were interconnected via Bluetooth. The iPad had permanent internet connection. Patients were taught to use the equipment to check and record their weight, blood pressure, and heart rate every morning, for 45 days after the hospital discharge. Data was automatically uploaded via iHealth application in a secure database.
75743963|NCT02735707|Drug|Ten-days oseltamivir|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
75743964|NCT02735707|Other|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
76062260|NCT04682431|Drug|PY159 Single agent dose level 4|Dose of PY159 as a single agent given in a standard 3+3 design.
76062261|NCT04682431|Drug|PY159 Single agent dose level 5|Dose of PY159 as a single agent given in a standard 3+3 design.
76062262|NCT04682431|Drug|PY159 Single agent dose level 6|Dose of PY159 as a single agent given in a standard 3+3 design.
76062263|NCT04682431|Drug|PY159 Single agent dose level 7|Dose of PY159 as a single agent given in a standard 3+3 design.
76062264|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 1|Dose of PY159 and given in combination with pembrolizumab
76062265|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 2|Dose of PY159 and given in combination with pembrolizumab
76062266|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 3|Dose of PY159 and given in combination with pembrolizumab
75892605|NCT04804098|Procedure|Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute non-linear compression schedule on a rotating daily basis. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
76062267|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 4|Dose of PY159 and given in combination with pembrolizumab
76062268|NCT04682431|Drug|PY159 Single agent dose expansion cohort|Dose of PY159 as a single agent given for predefined tumor histology
76062269|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 1|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
76062270|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 2|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
76062271|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 3|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
76062272|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 4|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
76062273|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 5|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
76062274|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 6|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
76062275|NCT04649073|Biological|OPC-415|OPC-415 (up to 1×10^7cells/kg) On 2 days
76062276|NCT04582201|Drug|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
76062277|NCT04563507|Radiation|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
76062278|NCT04563507|Drug|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
76062279|NCT04563507|Drug|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
76062280|NCT04542603|Drug|[11C]PiB and 18F-labeled DPA-714 PET scan|One PET with [11C]PiB and One PET with [18F]DPA-714 before chemotherapy treatment begins. One more PET with [18F]DPA-714 after completion of 3-6 cycles of chemotherapy.
75600059|NCT04294303|Other|Conventional|Subjects in the control group received the standard patient teaching, including an instruction to self-monitor their weight.
75600060|NCT02870725|Behavioral|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
76062281|NCT04534114|Drug|Fesomersen sodium (BAY2976217)|Study intervention will be injected subcutaneously.
76062282|NCT04534114|Drug|Placebo|Matching placebo to BAY2976217 will be injected subcutaneously.
76062283|NCT04517344|Other|Initial Flow Rate|Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
76062284|NCT04515641|Drug|Islatravir|Two ISL 30 mg capsules taken by mouth.
76072088|NCT03248570|Drug|Chemotherapy|At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
75449175|NCT02581306|Other|Exercise session|There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
75449176|NCT02570308|Drug|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
76072089|NCT03244189|Behavioral|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
76072090|NCT03244189|Behavioral|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
75892606|NCT04804098|Procedure|Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute linear compression schedule on a rotating daily basis with compression. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
75892607|NCT04802655|Other|Video-game based exercise - Exergame|Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.
75600061|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
75892608|NCT04802655|Other|Activity Based Exercise Group (AG)|Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
75892609|NCT04801953|Drug|NiMODipine Injectable Solution|nimodipine solution is applied to cranial nerves during resection of vestibular schwannoma
75449177|NCT02540200|Device|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
75892610|NCT04801953|Other|Placebo|Sodium chloride solution is applied to cranial nerves during surgery
75600062|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
75600063|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
75892611|NCT04797000|Drug|Eltrombopag|Eltrombopag comes in 12.5 mg & 25 mg tablets and is taken orally once per day (QD)
75892612|NCT04797000|Drug|Placebo|Placebo comes in 12.5 mg & 25 mg tablets and is taken orally once per day (QD)
75892613|NCT04795427|Drug|asciminib|Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily
75449178|NCT02540200|Procedure|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
75449179|NCT02536898|Other|Fracture Liaison Service|
75449180|NCT02536898|Other|Current treatment|
75449181|NCT02512172|Drug|Oral CC-486|
75600064|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
75892614|NCT04795427|Other|best available treatment|Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT
75600065|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
75892615|NCT04789707|Behavioral|auto-questionnaire|Patients answer the auto questionnaire in last minutes of consultation.
75600066|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
76072091|NCT03244189|Behavioral|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
76072092|NCT03237689|Drug|Hydrocortisone|Low dose hydrocortisone (10mg)
75449182|NCT02512172|Drug|Romidepsin|
75449183|NCT02512172|Drug|MK-3475|
75743965|NCT02735707|Drug|Lopinavir / Ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Note: this intervention is now closed."
75892616|NCT04781231|Device|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
75743966|NCT02735707|Drug|Hydroxychloroquine|"Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
75892617|NCT04781231|Device|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
75892618|NCT04781231|Other|Usual management of anxiety|No specific intervention
75892619|NCT04771130|Drug|BGB-11417|Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
76062285|NCT04490200|Device|VESTA respirator|The protocol will be composed by the use of the VESTA respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
76062286|NCT04490200|Device|Conventional N95 respirator|The protocol will be composed by the use of the N95 respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
76062287|NCT04474366|Drug|Ropivacaine 0.2% Injectable Solution|Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block
75743967|NCT02735707|Drug|Hydroxychloroquine + lopinavir/ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
75743968|NCT02735707|Drug|Ivermectin|Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.
75892620|NCT04771130|Drug|Azacitidine|Intravenous or subcutaneous administration for 7 days.
75892621|NCT04771130|Drug|Posaconazole|Oral administration for 8 days on second cycle only.
75892622|NCT04771130|Drug|BGB-11417|Oral administration for 28 days on a 28-day cycle.
75892623|NCT04771130|Drug|BGB-11417|Oral administration for 10 or 21 days on a 28-day
75449184|NCT02510703|Other|Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)|
75892624|NCT04765709|Combination Product|durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)|Induction therapy: durvalumab plus histology-based chemotherapy regimen (cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology).
75892625|NCT04765709|Combination Product|Durvalumab plus radiotherapy|Concomitant durvalumab and radiotherapy
75892626|NCT04765709|Biological|durvalumab|Consolidation treatment with durvalumab
75892627|NCT04764175|Behavioral|Telephone All Nations Breath of Life|Same as described above.
75892628|NCT04764175|Behavioral|Comparison Program|Same as described above.
75892629|NCT04762498|Biological|Pegloticase and Methotrexate (MTX)|16 mg IV dose of pegloticase q4 weeks co-administered with 15 mg oral dose methotrexate weekly
75892630|NCT04762498|Biological|Pegloticase and Methotrexate (MTX)|Potential higher IV dose of pegloticase (between 24-32 mg) q4 weeks co-administered with 15 mg oral dose methotrexate weekly and/or potential reduction of infusion duration
75600067|NCT02870647|Other|Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire|each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
75600068|NCT01226511|Drug|Duloxetine|Administered orally
75600069|NCT01226511|Drug|Placebo|Administered orally
75892631|NCT04761328|Behavioral|cognitive behavioral therapy|Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.
75892632|NCT04752020|Drug|Netarsudil Ophthalmic|Use of netarsudil after Descemetorhexis without endothelial keratoplasty
75600070|NCT02691351|Other|Prospective Registry|"Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~Regimen~Response Evaluation~SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection"
75743969|NCT02735707|Other|No immune modulation for COVID-19|"No immune modulating agent intended to be active against COVID-19 is to be administered.~Note: this intervention is now closed."
75892633|NCT04740333|Other|No intervention- observational study|No intervention- observational study
75892634|NCT04738097|Drug|Ticagrelor 90mg|ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.Treatment will be continue with ASA 80 until 3 months.
75743970|NCT02735707|Drug|Interferon beta-1a|"IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
75892635|NCT04738097|Drug|Clopidogrel 75 mg|ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.Treatment will be continue with ASA 80 until 3 months.
75892636|NCT04726891|Behavioral|Movement-2-Music + Social Networking Support|The primary goal of the proposed research is to conduct a 12-week pilot study of the SMART-HEALTH intervention in 30 individuals with SCI. There are several unique features of this study design, including a novel adapted exercise program (M2M), instructor-led, individualized training (M2M Live; described in D.2.1), individualized behavioral coaching, and social networking support.
75892637|NCT04717596|Other|BC4Teens Care|Healthcare providers will be trained in contraceptive counseling and provision.
75892638|NCT04712565|Device|Astra Tech Implant System Profile EV|dental implant with a sloped neck configuration
75892639|NCT04712565|Device|Astra Tech Implant System EV|dental implant with a conventional neck configuration
75892640|NCT04707716|Other|conometric concept Acuris system|implant crown retention type using friction only
75892641|NCT04707716|Other|screw retention|screw retained implant crown
75892642|NCT04707716|Other|cementation|cement retained implant crown
75600071|NCT01226121|Biological|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
75892643|NCT04670432|Drug|Hydroxyethylrutoside|500 mg film-coated tablet
75892644|NCT04666623|Drug|esketamine nasal spray|unlabeled nasal injectors, each device will deliver 28mg of esketamine in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
76062288|NCT04474366|Other|Saline (0.9%)|Saline injection as sham block in identical fashion as Pectoralis Nerve Block
76062289|NCT04465643|Drug|Nivolumab|Nivolumab 4.5 mg/kg Q3W x 2
76062290|NCT04465643|Drug|Ipilimumab|Ipilimumab 1 mg/kg Q3W x 2
76072093|NCT03237689|Drug|Placebo Oral Tablet|capsules of starch 1500 powder
76072094|NCT03233204|Drug|Olaparib|Given PO
75600072|NCT01226043|Drug|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75600073|NCT04206579|Drug|10% Dextrose|A mixture of 150 cc dextrose 10% in oral formulation
75600074|NCT04206579|Drug|Natrium Dextrose|A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation
75600075|NCT01001377|Drug|Cetuximab|Administered by intravenous infusion
75600076|NCT01001377|Drug|Panitumumab|Administered by intravenous infusion
75892645|NCT04666623|Drug|placebo nasal spray|unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
76072095|NCT03216525|Drug|Alvimopan|To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
76072096|NCT03216525|Drug|Placebo|To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
75600077|NCT01225887|Drug|Nintedanib|Given PO
75600078|NCT04326829|Drug|QL1604|QL1604, IV infusion
75600079|NCT01001299|Drug|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
75600080|NCT01001299|Drug|RO5185426|960 mg orally twice daily
75600081|NCT01296932|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
75743971|NCT02735707|Drug|Anakinra|"A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.~In patients with renal impairment, anakinra will be administered on alternate days.~Note: this intervention is now closed."
76072097|NCT03206060|Drug|Lu-177-DOTATATE|Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.
75449185|NCT02502396|Other|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
75600082|NCT01296698|Drug|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
76062291|NCT04450706|Other|Precision Medicine|"The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression."
76062292|NCT04450706|Other|Physican Decision Making|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
76062293|NCT04430439|Behavioral|Psychosocial stress|The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.
76062294|NCT04430439|Behavioral|Control non-stress|Participants will have a relaxed 15 minute conversation with a familiar research team member.
76062295|NCT04422431|Drug|Bis-Choline Tetrathiomolybdate|Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
76062296|NCT04416451|Drug|Rituximab|Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
75600083|NCT01296698|Drug|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
75600084|NCT01001221|Drug|cabazitaxel|"Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~Study part 1: 15, 20 or 25 mg/m^2 according to pre-defined dose escalation schedule~Study part 2: MTD as determined in Study part 1"
75743972|NCT02735707|Drug|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.~Note: this intervention is now closed.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period."
75743973|NCT02735707|Drug|Sarilumab|"Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.~Note: this intervention is now closed."
75743974|NCT02735707|Drug|Local standard venous thromboprophylaxis|"Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
75743975|NCT02735707|Drug|Therapeutic dose anticoagulation|"Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.~Note: this intervention is now closed."
75743976|NCT02735707|Drug|Conventional low dose thromboprophylaxis|Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
75743977|NCT02735707|Drug|Intermediate dose thromboprophylaxis|Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
75743978|NCT02735707|Drug|Continuation of therapeutic dose anticoagulation|Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.
75743979|NCT02735707|Other|No immunoglobulin|"No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.~Note: this intervention is now closed."
75600085|NCT01001221|Drug|gemcitabine|"Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~Study part 1: 700, 900 or 1000 mg/m^2 according to pre-defined dose escalation schedule~Study part 2: MTD as determined in Study part 1."
75600086|NCT01296152|Drug|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
75600087|NCT04326608|Other|physiotherapy|manual therapy and sef-care exercises
75600088|NCT02870257|Other|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
75743980|NCT02735707|Biological|Convalescent plasma|"Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.~Note: this intervention is now closed."
75743981|NCT02735707|Biological|Delayed administration of convalescent plasma|Note: this intervention is now closed.
75743982|NCT02735707|Other|No vitamin C|No high dose intravenous vitamin C is to be administered
75743983|NCT02735707|Drug|Vitamin C|Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses
75892646|NCT04654117|Other|Consultee-centered administrative consultation|The consultee-centered administrative consultation model expressly focuses on supporting providers to increase EBP implementation within their specific setting.
75892647|NCT04649398|Drug|Nimodipine|If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
75892648|NCT04648189|Drug|Cetuximab|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
75892649|NCT04622514|Other|Village doctor-led telemedicine integrated care|1. Reorienting the model of care: using of telemedicine platform and online consulting clinic; 2. Coordinating services: contract service by village doctor and on-line AF specialist; 3. Empowering and engaging people: provide village doctor ABC pathway training course; regular visit and drug delivery by village doctor (community support); patients and their family members education.
75892650|NCT04622514|Other|Enhanced usual care|1. Usual care; 2. Intensified education to patients, their family members, and their village doctors.
75892651|NCT04622085|Device|ANIMERS Chiara LA|20mg/SciVision Biotech Inc.
75892652|NCT04622085|Device|JUVÉDERM VOLUMA®|20mg/Allergan, Inc.
75892653|NCT04620681|Biological|CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes|Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent
75892654|NCT04620681|Drug|Standard of Care Chemotherapy|Standard of care cytarabine-based chemotherapy
75600089|NCT02870257|Other|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
75743984|NCT02735707|Other|No antiplatelet|"No antiplatelet agent or NSAID to be administered.~Note: this intervention is now closed."
75743985|NCT02735707|Drug|Aspirin|"Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
75892655|NCT04616326|Drug|Galcanezumab|Administered SQ
75892656|NCT04616326|Drug|Placebo|Administered SQ
75892657|NCT04613375|Diagnostic Test|Urine sample collection|Serotype specific UAD (urinary antigen detection) test
75743986|NCT02735707|Drug|P2Y12 inhibitor|"Site-selected P2Y12 inhibitor:~Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.~Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.~Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
75743987|NCT02735707|Other|No simvastatin|No simvastatin intended to be active against COVID-19 is to be administered
75892658|NCT04613375|Diagnostic Test|Saliva collection|Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR
76072098|NCT03206060|Drug|Ga-68-DOTATATE|Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
76072099|NCT03206060|Drug|F-18-FDG|F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
75600090|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
75600091|NCT01002547|Drug|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
75600092|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
75892659|NCT04612231|Behavioral|TEACCH School Transition to Employment and Postsecondary Education (T-STEP)|The T-STEP Program is a 12-week transition intervention targeting specific challenges that young adults with ASD experience in executive function, social communication, and emotion regulation including group intervention, internship, and counseling services
75892660|NCT04612231|Behavioral|Counseling Services Alone|The Counseling Services Alone Intervention will receive 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
75892661|NCT04609514|Device|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
75600093|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
75600094|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
75600095|NCT01002547|Drug|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
75892662|NCT04609514|Behavioral|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
76062297|NCT04416451|Drug|Venetoclax|"Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~Week 1: 100 mg~Week 2: 200 mg~Week 3: 400 mg~Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab."
75600096|NCT04295161|Drug|Abiraterone Acetate|Abiraterone acetate immediate release formulations
75600097|NCT04367623|Other|Brain computer interface based therapy|Participants who decide to take part will be assigned to a treatment or a control group. Both groups will have the same assessments and the same number of therapy sessions. Therapy group will have a training that consists of Brain Computer Interface controlled Functional Electrical Stimulation followed by a physical practice of the dominant upper limb, while the control group will have a physical practice only. One experimental session will last about 60 min for both groups (including setup and therapy) and participants in each group will receive 20 sessions, about 3 times per week. The expected time needed for completion of 20 sessions is 7 weeks
75600098|NCT05240911|Drug|Levothyroxine Sodium Tablets|For patients in experimental group, initial levothyroxine dose is calculated through the Poisson regression model; and for patients in comparator group, initial levothyroxine dose is calculated through 1.6 ug/kg/d.
75600099|NCT02870491|Behavioral|Free Distribution|Caretakers of children under 5-years-old will have access to free ORS and zinc
75600100|NCT02870491|Behavioral|Preemptive Delivery|Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
75600101|NCT04452253|Dietary Supplement|PS128|PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128
75600102|NCT04452253|Dietary Supplement|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
75600103|NCT04452253|Dietary Supplement|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.
75743988|NCT02735707|Drug|Simvastatin|Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation
75600104|NCT04452253|Other|Placebo|The placebo capsule contains microcrystalline cellulose.
75600105|NCT01225731|Biological|tildrakizumab|SC administration of tildrakizumab at assigned dose
76062298|NCT04406649|Drug|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
75600106|NCT01225731|Drug|Placebo|SC administration of Placebo
75600107|NCT04319211|Other|Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.|The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
75743989|NCT02735707|Other|Placebo|
75743990|NCT02735707|Drug|Eritoran|Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital
75743991|NCT02735707|Drug|Apremilast|"Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
75892663|NCT04609514|Drug|Nicotine patch|All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
75892664|NCT04609514|Behavioral|Smartphone coaching|All participants will partake in over-the-phone smartphone coaching lead by the PI or a research assistant. This will be a time for participants to bring up any technical issues they are experiencing with the study smartphone or app.
76062299|NCT04364672|Drug|[11C]PiB and 18F-labeled DPA-714 PET scan|One PET with [11C]PiB and One PET with [18F]DPA-714 before chemotherapy treatment begins. One more PET with [18F]DPA-714 after completion of 3-6 cycles of chemotherapy.
76062300|NCT04362644|Drug|PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714|Study participants will undergo PET/CT with the glucose analogue [F-18]FDG and the translocator protein (TSPO) ligand [F-18]DPA-714 in two separate imaging sessions.
75743992|NCT02735707|Procedure|Clinician-preferred mechanical ventilation strategy|Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
75892665|NCT04608149|Device|Carpediem System|Continuous renal replacement therapy
76062301|NCT04316390|Dietary Supplement|Control|study drink (two weeks)
76062302|NCT04316390|Dietary Supplement|Hesperidin|study drink + Hesperidin 600 mg (two weeks)
76062303|NCT04316390|Dietary Supplement|Vitamin C|study drink + Vitamin C 250 mg (two weeks)
75449186|NCT02499367|Drug|Nivolumab|nivolumab 3 mg/kg, every 2 weeks after induction treatment
75449187|NCT02499367|Radiation|Radiation therapy|20 Gy to metastatic lesion
75449188|NCT02499367|Drug|Low dose doxorubicin|15 mg flat dose, once weekly for 2 weeks
75449189|NCT02499367|Drug|Cyclophosphamide|metronomic schedule, 50 mg daily orally for 2 weeks
75449190|NCT02499367|Drug|Cisplatin|40 mg/m2, weekly for 2 weeks
75449191|NCT02497612|Drug|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
75449192|NCT02497612|Drug|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
75449193|NCT02497612|Other|Placebo|Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
75449194|NCT02497131|Drug|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
75449195|NCT02491333|Other|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
76062304|NCT04316390|Dietary Supplement|Hesperidin + Vitamin C|study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)
76062305|NCT04308369|Biological|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
76062306|NCT04232228|Other|No intervention|No intervention was used in this study.
75449196|NCT02491333|Other|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
75449197|NCT02491333|Drug|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
75600108|NCT01007149|Drug|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
75743993|NCT02735707|Procedure|Protocolised mechanical ventilation strategy|Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
75743994|NCT02735707|Other|No renin-angiotensin system inhibitor|No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.
75449198|NCT02491333|Drug|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
75449199|NCT02490943|Other|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
75449200|NCT02490943|Other|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
75600109|NCT01007149|Drug|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
75743995|NCT02735707|Drug|Angiotensin converting enzyme inhibitor|Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
75743996|NCT02735707|Drug|Angiotensin Receptor Blockers|Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
75743997|NCT02735707|Drug|ARB + DMX-200|"Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.~ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily."
75743998|NCT02735707|Other|No cysteamine|No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.
75743999|NCT02735707|Drug|Cysteamine|Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.
75744000|NCT02735707|Drug|Fixed-duration dexamethasone|6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
75892666|NCT04603261|Diagnostic Test|Contrast concentration in urine|"Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast."
75892667|NCT04599335|Device|2% HA|2% HA
75892668|NCT04598516|Diagnostic Test|serum creatinine assay|peak change in serum creatinine in a period of 5 days from baseline (day 0) will be determined
75892669|NCT04597892|Diagnostic Test|serum creatinine assay|point-of-care and standard laboratory assay of serum creatinine
75892670|NCT04597307|Combination Product|IN.PACT™ Admiral™ Drug Coated Balloon (DCB)|For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
76062307|NCT04171817|Drug|Chlorhexidine|The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
76062308|NCT04152863|Biological|Gebasaxturev IV|Administered as an IV infusion of 1 X 10^9 TCID50
76062309|NCT04152863|Biological|Gebasaxturev ITu|Administered as an ITu injection of 3 X 10^8 TCID50
75600110|NCT04295083|Behavioral|clay based group study|"Clay based group work sessions were applied to the experimental group for 60-90 minutes once a week for 6 weeks. The sessions are composed of structured or semi-structured activities prepared for the purpose of the literature by the researcher for the purposes such as acquiring new solutions and life skills to reduce loneliness and hopelessness of individuals aged 65 and over, and sharing their feelings, thoughts, and memories with other individuals. Clay Study Activity Booklet . Four expert opinions were obtained for the booklet created. Methods such as narration, sharing experiences, group practice, question-answer, learning by doing, imagining were used in the activity program. The physical, psychological, social and mental characteristics of the elderly were taken into consideration in the selection of these methods."
75892671|NCT04562532|Device|Microport Firehawk stent|MicroPort Firehawk biodegradable polymer rapamycin target eluting stent
76062310|NCT04152863|Drug|Pembrolizumab|Administered as an IV infusion of 200 mg
75600111|NCT00998335|Drug|Long-acting bedtime insulin detemir (Levemir)|This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
75744001|NCT02735707|Drug|Baloxavir Marboxil|Baloxavir marboxil administered on days 1 and 4 post-randomisation.
75744002|NCT02735707|Drug|Five-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
75892672|NCT04562532|Device|2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)|"Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~Sirolimus eluting stents (Orsiro- Biotronik)"
75892673|NCT04558879|Behavioral|CT|12 weeks of exercise Cardiovascular Training
75892674|NCT04558879|Behavioral|RT|12 weeks of exercise Resistance Training
75892675|NCT04547374|Other|GaH Intervention|"Patients in this cohort will be referred for management/intervention with GaH.~However, the purpose of this program is not to define, control, or evaluate the specific details of the GaH process or procedure, but to evaluate its effectiveness as an alternative clinical care path in this setting. As such, the specific details and actions of the GaH care team in each patient interaction are left to their medical discretion."
76062311|NCT04129554|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
76062312|NCT04129554|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
76062313|NCT04129554|Drug|Placebo for JNJ-73763989|Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
76062314|NCT04129554|Drug|Placebo for JNJ-56136379|Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
76062315|NCT04129554|Drug|Entecavir (ETV) monohydrate|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
76062316|NCT04129554|Drug|Tenofovir disoproxil fumarate (TDF)|TDF will be administered orally once daily up to 48 weeks as NA treatment.
76062317|NCT04129554|Drug|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
76062318|NCT04115488|Biological|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
76062319|NCT04109729|Drug|Nivolumab|"Nivolumab 480mg IV every 4 weeks for up to 2 years~• Radium-223 55 kBq/kg IV q4 weeks for 6 cycles total"
76062320|NCT04080752|Drug|JNJ-61393215|JNJ-61393215 will be administrated orally.
76062321|NCT04080752|Drug|Placebo|Matching placebo will be administered orally.
76062322|NCT04078581|Other|Questionnaire and fecal sample collection|Questionnaire and fecal sample collection in order to select donors for FMT.
75744003|NCT02735707|Drug|Ten-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
75744004|NCT02735707|Other|No endothelial modulator|No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
75892676|NCT04533646|Drug|Insulin|Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.
76062323|NCT04062344|Other|Swab|Rectal swab before and after the drug provocation testing
76062324|NCT04049513|Biological|WZTL002-1 (1928T2z CAR-T cells)|WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
76062325|NCT04049513|Drug|Cyclophosphamide and Fludarabine lymphodepleting chemotherapy|Cyclophosphamide 500 mg/m^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m^2 IV on days -5 to -3, inclusive
76062326|NCT04002180|Drug|Vedolizumab (Genetical Recombination)|Vedolizumab IV infusion
76062327|NCT03999879|Diagnostic Test|Measure of OxPhos upregulation|OxPhos upregulation [i.e., lower phosphocreatine (PCr)-to-ATP ratio levels] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
76062328|NCT03999879|Diagnostic Test|lactate (measured with 1H-MRSI)|PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
76062329|NCT03996239|Behavioral|exercise (walking)|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
76062330|NCT03996239|Other|plasma samples|Plasma samples will be obtained at baseline.
76062331|NCT03996239|Other|blood draw|fasting blood
75892677|NCT04533646|Device|Continuous glucose monitor (CGM)|Participants will be required to wear a CGM to measure glucose trends
75892678|NCT04525196|Other|Physical activity.|"The procedure under study (physical activity program) will include, each week for 12 months, two sessions dedicated to the development of aerobic capacity and a muscle building session.~The experimental group will therefore be offered 3 sessions of Physical Activity (PA) per week. The PA will be positioned in the first two hours after the start of the dialysis session. Each session will include 5 minutes of general warm-up, then 15 minutes of PA itself and finally 5 minutes of cool down period. The PA time itself will be increased as the sessions progress, according to the progress and improvement of physical capabilities of patients."
75892679|NCT04523064|Drug|Empagliflozin 25 MG|Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
75892680|NCT04511702|Biological|Pegloticase with MTX|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
76062332|NCT03992872|Biological|Chikungunya|Virus Like Particle
76062333|NCT03968419|Drug|Canakinumab|200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks
75449201|NCT02470286|Drug|SA001 60mg or Placebo|"Study Drug: SA001 60mg~Comparator: Placebo~Cohort 1 in the part 1 (Dose escalation study)"
75449202|NCT02470286|Drug|SA001 120mg or Placebo|"Study Drug: SA001 120mg~Comparator: Placebo~Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)"
75449203|NCT02470286|Drug|SA001 180mg or Placebo|"Study Drug: SA001 180mg~Comparator: Placebo~Cohort 3 in the part 1 (Dose escalation study)"
75449204|NCT02470286|Drug|SA001 240mg or Placebo|"Study Drug: SA001 240mg~Comparator: Placebo~Cohort 4 in the part 1 (Dose escalation study)"
75449205|NCT02470286|Drug|SA001 300mg or Placebo|"Study Drug: SA001 300mg~Comparator: Placebo~Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)"
75744005|NCT02735707|Drug|Imatinib|Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
75744006|NCT02703246|Procedure|abdominal morcellation|patients will be randomized to receive abdominal morcellation
75744007|NCT02703246|Procedure|vaginal morcellation|patients will be randomized to receive vaginal morcellation
75449206|NCT02469987|Drug|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
75449207|NCT02469987|Drug|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
75744008|NCT02670837|Device|Cellutome Epidermal Harvesting System|
75892681|NCT04497584|Drug|Afatinib + Prednisone|Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.
75892682|NCT04489771|Drug|Belzutifan|Oral administration
75892683|NCT04488861|Other|Non-interventional cohort study|Non-interventional cohort study
75892684|NCT04488757|Diagnostic Test|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a one hour fMRI scan with pain-induction using heat-based QST protocol.
76062334|NCT03968419|Drug|Pembrolizumab|200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
76062335|NCT03924986|Drug|Tislelizumab|200 mg administered intravenously (IV)
76062336|NCT03924986|Drug|Placebo|Placebo to match Tislelizumab
76062337|NCT03924986|Drug|Gemcitabin|1 g/m2, administered as an IV infusion within 30 minutes
76062338|NCT03924986|Drug|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
75600112|NCT00998335|Drug|Insulin detemir and pre-meal insulin aspart.|This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
75600113|NCT04204681|Diagnostic Test|Ultrasonography imaging|This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
75892685|NCT04488757|Other|Allostatic Load Composite|All participants will be asked to provide saliva samples to measure cortisol response over time and dehydroepiandrosterone (DHEA) in addition to physiological measurements such as blood pressure/pulse, height/weight, and waist-hip ratio. Measurements will be taken at baseline and 4-month follow-up.
75892686|NCT04488081|Drug|Remdesivir|Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
75892687|NCT04488081|Drug|Imatinib Mesylate|Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
75892688|NCT04488081|Drug|Dexamethasone|6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
75892689|NCT04488081|Drug|Cenicriviroc|Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
75892690|NCT04488081|Drug|Icatibant|Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
75600114|NCT02871505|Drug|Benzathine Penicillin G|
75600115|NCT01294670|Drug|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
75600116|NCT01006603|Drug|Saxagliptin|5 mg, oral tablet, once daily
75600117|NCT01006603|Drug|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
75600118|NCT02870335|Other|Manual Therapy|The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
75892691|NCT04488081|Drug|Apremilast|oral, 30 mg bid × 14 days.
75892692|NCT04488081|Biological|dornase alfa|"For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
76062339|NCT03915379|Drug|JNJ-67571244|JNJ-67571244 will be administered.
76062340|NCT03911492|Procedure|SCPP Management => 65 mmHg|A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
76062341|NCT03866902|Behavioral|Nutrition and Physical Activity Intervention|"Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play."
76062342|NCT03866902|Other|English for Second Language Intervention|"Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons."
76062343|NCT03866577|Biological|Biological: M254|M254 administered as intravenous infusion
76062344|NCT03866577|Drug|Placebo|Placebo administered as intravenous infusion
76062345|NCT03866577|Biological|Intravenous immunoglobulin (IVIg)|IVIg administered as intravenous infusion
76062346|NCT03859193|Behavioral|Nutritional Video|A 10 - 15 minute video
76072100|NCT03206060|Drug|Amino Acid solution|AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.
76072101|NCT03198494|Other|Acoustic 1Hz Stimulation|1Hz acoustic pulses delivered during sleep via headphones
76062347|NCT03835702|Other|SAM Clinic Intervention|SAM Clinic is a sleep provider led team comprised of either a sleep clinician or sleep nurse practitioner along with sleep nurses and or durable medical equipment representative. The provider interacts with each patient personally. Various modes of trouble shooting of PAP related issues are tailored to solve PAP adherence issues including mask complaints, nasal issues, pressure intolerance, anxiety, and other related barriers to PAP adherence. When the provider is seeing patients individually other patients have the opportunity to interact and offer informal interpersonal support to other participants in dealing with similar PAP issues. The provider makes an individualized follow-up plan for each patient, which may include another SAM visit or referral back to the non-sleep provider.
76062348|NCT03824041|Dietary Supplement|Aronia full spectrum - half dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
75600119|NCT02870335|Other|Proprioceptive neuromuscular facilitation|Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
76062349|NCT03824041|Dietary Supplement|Aronia full spectrum - full dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
75744009|NCT02664610|Behavioral|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
75744010|NCT02637973|Drug|Empagliflozin|25 mg once daily
75744011|NCT02637973|Drug|Placebo|once daily
75744012|NCT02583269|Diagnostic Test|Laboratory Biomarker Analysis|Correlative studies
75744013|NCT02583269|Drug|Muscadine Grape Skin Extract|Given PO
75744014|NCT02583269|Procedure|Quality-of-Life Assessment|Ancillary studies
76062350|NCT03824041|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
76062351|NCT03810807|Drug|Dacomitinib|Dose level 1 Dacomitinib, Dose level 2 Dacomitinib, Dose level 3 Dacomitinib. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
76062352|NCT03810807|Drug|Osimertinib|Dose level 1, 2 and 3 Osimertinib 40mg daily. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
76062353|NCT03784846|Behavioral|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
76062354|NCT03784846|Behavioral|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
75600120|NCT02870569|Drug|Donafenib 200mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
75600121|NCT02870569|Drug|Donafenib 300mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
75744015|NCT02546921|Drug|MOv18 IgE|The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.
76062355|NCT03756350|Device|1060nm diode laser|Non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060nm diode laser applicators which are 60x60 mm in size. There is a belt included with the system to allow for the secure application of the applicators to the treatment area.
76072102|NCT03198494|Other|Sham Background Noise|Background Noise used as a control
75600122|NCT00997321|Drug|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
75600123|NCT00997321|Drug|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
75600124|NCT01294592|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
75600125|NCT01294592|Drug|tamsulosin|Take 1 capsule daily when escalation criteria met
75600126|NCT00997243|Biological|lintuzumab|Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
75600127|NCT00997243|Drug|5-azacytidine|75mg/m2 IV/SC daily on days 1-7.
75600128|NCT02869321|Drug|Fentanyl|
75744016|NCT02546921|Drug|MOv18 IgE|The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
75744017|NCT02546921|Drug|MOv18 IgE|The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
75744018|NCT02546921|Drug|MOv18 IgE|The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
75892693|NCT04488081|Drug|Celecoxib|Oral: 400 mg BID for 7 days.
75892694|NCT04488081|Drug|Famotidine|Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
75892695|NCT04488081|Biological|IC14|intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
75892696|NCT04488081|Drug|Aviptadil|Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
75892697|NCT04488081|Biological|narsoplimab|Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
75892698|NCT04488081|Drug|Cyproheptadine|4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
75892699|NCT04488081|Drug|Cyclosporine|Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
75892700|NCT04486209|Device|transcutaneous spinal cord stimulation|electrical stimulation of the lumbosacral spinal cord through surface electrodes
75892701|NCT04480840|Drug|PLN-74809|PLN-74809
75892702|NCT04480840|Drug|Placebo|Placebo
76062356|NCT03731104|Device|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=[SpO2-rScO2]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
76072103|NCT03190915|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
75744019|NCT02546921|Drug|MOv18 IgE|The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
75744020|NCT02546921|Drug|MOv18 IgE|The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
75744021|NCT02546921|Drug|MOv18 IgE|"Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks.~Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE.~Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment."
75892703|NCT04472117|Other|usual care|Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.
75892704|NCT04472117|Other|Educational video|Watch an educational video created by the research team and.will also complete the post-video survey,
75892705|NCT04467840|Drug|Opaganib|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
75892706|NCT04467840|Drug|Placebo|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
75892707|NCT04466059|Diagnostic Test|Automated AI-Guided Diagnosis of Hematological Malignancies|In BELUGA, we want to investigate whether the automated analysis of blood (from peripheral blood and bone marrow aspirates) smears and flow-cytometry-based analyses can provide a benefit for diagnostic quality and, ultimately, patient care.
75892708|NCT04464668|Behavioral|Provider Tools|Providers will be trained to use Electronic Medical Record (EMR) tools and prompts, and an organization wide cancer control champion will be trained to motivate providers and navigate patients.
76072104|NCT03190915|Drug|Trametinib|Given PO
75449208|NCT02469987|Drug|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
75449209|NCT02460458|Drug|Von Willebrand Factor|Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
75449210|NCT02457559|Drug|Tirabrutinib|Tablets or capsules administered orally
75449211|NCT02439307|Drug|Rifaximin|1200 mg of rifaximin for 2 weeks.
75449212|NCT02439307|Drug|Placebo|Placebo for 2 weeks
75449213|NCT02437175|Dietary Supplement|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
75449214|NCT02437175|Dietary Supplement|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
75463144|NCT01872390|Other|Combination Intervention Package|CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
75463145|NCT01872390|Other|Standard of Care|Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
75892709|NCT04464668|Behavioral|Provider surveys|Remote/electronic data collection surveys will be conducted with clinic institution leaders, cancer control champions, and providers from various clinic locations to solicit feedback about implementation processes at three time points (baseline, mid-point and end of study implementation)
75892710|NCT04456699|Drug|Olaparib|300 mg BID, oral until progressive disease or end of study
75892711|NCT04456699|Drug|5-FU|2400 mg/m^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5FU (400mg/m2) can be added prior to infusional 5FU, per local standards and at the investigator's discretion
75600129|NCT02869321|Drug|Morphine Sulfate|
75744022|NCT02527681|Drug|Ceftobiprole medocaril|Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
75744023|NCT02516696|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
75600130|NCT02869321|Drug|Fentanyl placebo|
75600131|NCT02869321|Drug|Morphine Sulfate placebo|
75744024|NCT02516696|Drug|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
75744025|NCT02516696|Drug|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
75744026|NCT02513329|Drug|Bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.10 mL .5% bupivicaine will be administered.
75892712|NCT04456699|Drug|Bevacizumab|5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
75892713|NCT04456699|Drug|Capecitabine|1000mg/m^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
75892714|NCT04456699|Drug|Leucovorin/ levoleucovorin|400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) may be added to Bevacizumab + 5FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
75892715|NCT04452877|Drug|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
75892716|NCT04452877|Drug|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
75600132|NCT02869321|Procedure|Gastrostomy|
75600133|NCT01294436|Drug|Dapagliflozin|Oral Dose 5 or 10 mg
75600134|NCT04293913|Behavioral|illustrated communication material|Illustrated communication material was introduced to the patients in the intervention group. In the process (intensive care) that patients received mechanical ventilation support after the operation, agitation and sedation levels were monitored by the intensive care nurse who was to communicate with the patient using the Richmond Agitation Sedation Scale (RASS). According to this scale, having minimum -2 and maximum +2 points was accepted as the starting criteria for communication (Sessler et al., 2002). Communication was established with the illustrated communication material.
75892717|NCT04445883|Behavioral|Feeding Assistance|Patients will be receiving assistance during mealtimes. This includes assistance by opening packages, listing/explaining the food products on the tray, providing encouragement and companionship during mealtimes and directly feed patients.
75892718|NCT04444869|Drug|Cisplatin injection|Standard dose cisplatin given concurrently with radiation therapy
75744027|NCT02513329|Drug|Saline|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card. 5 mL sterile normal saline will be administered.
76062357|NCT03731104|Device|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
75892719|NCT04430569|Drug|Alteplase|Alteplase single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
75892720|NCT04430569|Drug|Placebo|Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
76062358|NCT03731104|Device|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = [π x d2 x VTI x HR] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
76062359|NCT03703635|Device|intracranial balloon angioplasty|A balloon (recommending the Neuro RX and Neuro LPS Intracranial Balloon Dilation Catheter [Sinomed Inc., Tianjin, China]) is navigated by the microwire to the lesion of the target artery.
76062360|NCT03703635|Drug|aggressive medical management|Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.
76062361|NCT03684980|Drug|Methotrexate|(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m^2
76062362|NCT03684980|Drug|Rituximab|Patients will be treated with rituximab 500 mg/m^2.
76062363|NCT03684980|Drug|leucovorin|Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
75463146|NCT01872403|Drug|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
75463147|NCT01872416|Device|Liposomal Doxorubicin Combined With ifosfamide|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
75463148|NCT01872442|Drug|Dasatinib|"Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes > 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
75600135|NCT04293211|Other|Simulation|To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
75600136|NCT02870413|Behavioral|Telelactation services|Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
75600137|NCT04296487|Other|autologous chondrocytes|autologous chondrocytes implantation (ACI)
75744028|NCT02425826|Drug|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
75744029|NCT02425826|Drug|Placebo|Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
75744030|NCT02425826|Drug|Placebo-Apremilast|At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
76062364|NCT03684980|Drug|Glucarpidase|Glucarpidase 2000 units
76062365|NCT03684512|Behavioral|Group Exercise Sessions|Remote exercise sessions delivered over group video conference
75892721|NCT04421924|Procedure|thrombelastogram|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm
75600138|NCT02869243|Drug|hrBMP4|"Patients will undergo a resection or biopsy of the tumour, confirmation of viable malignant glioma tumour cells and intratumour/interstitial placement under neuronavigational guidance of 2 or 3 catheters.~Catheters will be placed during a second procedure a few days later based upon the patient's condition.~Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66ml over up to 4-6 days. Gd-DTPA will be co-infused with BMP4 to determine the extent of intra-tumour and interstitial drug delivery. HrBMP4 will be delivered as a continuous infusion via the intracranial catheters."
75892722|NCT04421924|Procedure|standard of care|2) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
76062366|NCT03684512|Behavioral|Individual Support Sessions|Individual education/support/feedback sessions delivered over video chat
75892723|NCT04388839|Drug|Vincristine|IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg
75892724|NCT04388839|Drug|Cyclophosphamide|IV over 60 minutes with dosing ranging from 220mg to 1200mg
75600139|NCT02870179|Device|Pulse Oximeter|Measurement of physiological parameters
75892725|NCT04388839|Drug|Vinorelbine|IV push over 6-10 minutes with dosing ranging from 4mg-25mg
75449215|NCT02424409|Behavioral|2: Intervention|"The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.~A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter~A written action plan with formalized recommendations for the patient~A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.~The ED doctor at discharge will explain all these documents orally~Recommendations for an early contact with the general practitioner;~Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner."
75449216|NCT02424409|Behavioral|1: Control|patients without discharge protocol
75449217|NCT02418039|Dietary Supplement|High protein diet|It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.
75449218|NCT02418039|Dietary Supplement|Normal protein|A normal protein diet will be administrated in patients with MHE.
75449219|NCT02417974|Biological|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
75744031|NCT02406027|Drug|JNJ-54861911, 10 mg|Participants will self-administer JNJ-54861911 tablet, 10 mg (2*5 mg), orally, once daily.
75744032|NCT02406027|Drug|JNJ-54861911, 25 mg|Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
75744033|NCT02406027|Drug|Placebo|Participants will self administer placebo matching to JNJ-54861911 orally once daily.
75892726|NCT04388839|Drug|Actinomycin D|Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg
75744034|NCT02406027|Drug|JNJ-54861911, 5 mg|Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
75744035|NCT02384434|Device|THOR Laser System for Low Level Laser Therapy (LLLT)|Non-invasive, a cold laser output treatment.
76062367|NCT03684512|Behavioral|Facebook Group|Facebook group for parents to provide additional support and education
76062368|NCT03672760|Device|CardioBreathApp|Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
76062369|NCT03672760|Device|IMT PowerBreath|Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
75744036|NCT02278120|Drug|LEE011|LEE011 600 mg daily oral
75744037|NCT02278120|Drug|Tamoxifen|tamoxifen 20 mg daily oral
75892727|NCT04388839|Drug|Cyclophosphamide Pill|Based on Body Surface Area (BSA) round to nearest 25mg
75892728|NCT04383223|Behavioral|iTransition|Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
75892729|NCT04362748|Drug|AMG 256|AMG 256 administered as an intravenous (IV) infusion.
76062370|NCT03672760|Device|IMT PowerBreath Placebo|Inspiratory Muscle Training (IMT) without load
76062371|NCT03666559|Drug|Azacitidine|Chemotherapy
75600140|NCT02869477|Other|Data collection|
75600141|NCT00995371|Device|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
75744038|NCT02278120|Drug|Letrozole|letrozole 2.5 mg daily oral
75744039|NCT02278120|Drug|Anastrozole|anastrozole 1 mg daily oral
76062372|NCT03662022|Drug|Rifampicin|Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
75600142|NCT00995371|Drug|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
75600143|NCT02869555|Other|Data collection|
75600144|NCT02870023|Other|Balance training|
75600145|NCT02870023|Other|Strength training|
75600146|NCT01294358|Drug|Gemcitabine|Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
75744040|NCT02278120|Drug|Goserelin|Goserelin 3.6 mg subcutaneous injection
75892730|NCT04361240|Radiation|Proton vs Photon Radiation|Assignment to proton vs photon by randomization on RadComp parent study.
75892731|NCT04353622|Device|Exoskeleton robot for upper extremity|"Robot-assisted Treatment Program:~10 minutes elbow flexion/extension~10 minutes forearm supination/pronation~10 minutes wrist flexion/extension~10 minutes ulnar/radial deviation~Frequency: 2/week Duration: 12 sessions (6 weeks)"
75892732|NCT04353622|Other|Conventional physiotherapy|Ferquency: 2/week Duration: 12 sessions (6weeks) Each session: 50 minutes
75892733|NCT04335656|Dietary Supplement|Lactiplantibacillus plantarum|Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
75892734|NCT04335656|Other|Placebo|Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
75892735|NCT04328974|Procedure|lumbar CSF drainage|We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH & Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg [14, 15].
76062373|NCT03653741|Drug|Perampanel 6 MG|Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
76062374|NCT03649971|Drug|Guselkumab|Guselkumab SC will be administered every 4 weeks.
75600147|NCT00994279|Behavioral|Yoga|Yoga sessions
75449220|NCT02385786|Behavioral|Mindfulness-Based Cognitive Therapy|Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
75744041|NCT02278120|Drug|LEE011 Placebo|LEE011 placebo 600 mg daily oral
75449221|NCT02381652|Combination Product|Cingal|Injection into the knee
75600148|NCT00994279|Behavioral|Education|Educational Wellness Group
75600149|NCT01294046|Device|Deep Brain Stimulation of SPG for Migraine|Deep Brain Stimulation of SPG for Migraine
75600150|NCT02869711|Other|Health care quality management|
75744042|NCT02255357|Drug|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
75744043|NCT02255357|Drug|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
75744044|NCT02217943|Procedure|Roux-en-Y gastric bypass|
75892736|NCT04308109|Behavioral|Simulation|Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.
75744045|NCT02217943|Procedure|Sleeve gastrectomy|
75892737|NCT04300335|Other|Individual Exercise|Supervised body weight & resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
76062375|NCT03649971|Drug|Placebo|Placebo SC will be administered every 4 weeks.
76062376|NCT03648996|Other|Low-fructose diet, isocaloric|6 month of consumption a low fructose diet
76062377|NCT03648996|Drug|Allopurinol|6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
76062378|NCT03648996|Drug|Placebo|6 months of placebo treatment
76062379|NCT03648996|Other|Low-fructose, hypocaloric|6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
75449222|NCT02381652|Combination Product|Cingal|Injection into the knee
75449223|NCT02381652|Combination Product|Cingal|Injection into the knee
75449224|NCT02378259|Procedure|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
75449225|NCT02378259|Procedure|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
75744046|NCT02211131|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
75892738|NCT04300335|Other|Group Exercise|Supervised body weight & resistance band resistance exercises in a Group setting plus home based aerobic exercise
75892739|NCT04295499|Device|soft (hydrophilic) contact lens|The intervention is a daily wear soft contact lens
75892740|NCT04280562|Device|Sana Pain Reliever|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's normal settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
75744047|NCT02211131|Procedure|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
75744048|NCT02155647|Drug|Avelumab|Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
75744049|NCT02134587|Other|Multifaceted educational intervention|"Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~Distribution of educational material~Practical class to explain the correct fill of adverse drug events form~Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance."
76062380|NCT03627403|Drug|Selinexor|"Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. . Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly."
75449226|NCT02367794|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
75449227|NCT02367794|Drug|Carboplatin|Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
75449228|NCT02367794|Drug|Nab-Paclitaxel|Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
75744050|NCT02072772|Behavioral|Positively Smoke Free group treatment|See Arm Description
75449229|NCT02367794|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m^2 IV.
75449230|NCT02364323|Behavioral|Personalized Risk Counselling|Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
75744051|NCT02072772|Behavioral|Standard Care|See Arm Description
75744052|NCT02057107|Radiation|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
75744053|NCT02057107|Drug|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
75449231|NCT02364323|Other|Normal usual care|General education on diabetes and diabetic complications
75892741|NCT04280562|Device|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
75892742|NCT04274296|Device|Activation of Advisory|Advisory is activated which will show if driving pressure is greater or equal 15
75892743|NCT04273516|Drug|Rivaroxaban 2.5 Mg Oral Tablet|Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily
75892744|NCT04273516|Drug|Rivaroxaban placebo tablets|Placebo tablets add to ASA 80 mg daily that is standard treatment
75892745|NCT04267926|Drug|20 mg MitoQ|a third of subject will receive 20mg of oral MitoQ
76062381|NCT03586050|Device|Microwave ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
75744054|NCT02057107|Drug|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
75744056|NCT01752920|Drug|Derazantinib low dose range|Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.
75744057|NCT01752920|Drug|Derazantinib middle dose range|Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.
75892746|NCT04267926|Drug|Placebo|Subject will receive Placebo
75892747|NCT04267926|Drug|40mg of MitoQ|a third of subjects will receive 40mg of MitoQ
75892748|NCT04255433|Drug|Tirzepatide|Administered SC
75892749|NCT04255433|Drug|Dulaglutide|Administered SC
75892750|NCT04236128|Other|Mobile App|"The app will be provided to patients in hospital on post-operative day 3. On the day of discharge, the patient will be emailed a Daily Health Check and receive subsequent Daily Health Check emails on Day 1-14, 21 and 30 days following discharge. The Daily Health Check is a tailored questionnaire to elicit their symptoms and status of post-operative recovery. After the patient has completed the Daily Health Check, a Daily Health Check Summary is emailed to the patient that summarizes their responses and provides appropriate action recommendations based on their responses ranging from: (i) suggestions for educational modules, (ii) expect a call from your health care team in the next 24 hours, (iii) call your surgeon's office today or (iv) go to the nearest emergency room. The patient's Daily Health Check responses are displayed in real time on a secure website that automatically red flags extreme responses to alert the health care team to contact the patient by telephone."
75892751|NCT04231110|Biological|Fecal microbiota transplantation|Use of fecal microbiota transplantation enemas once weekly in patients who are initiating vedolizumab treatment
75892752|NCT04225819|Dietary Supplement|Vitamin D3|Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
75744058|NCT01752920|Drug|Derazantinib high dose range|Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.
76062382|NCT03585465|Drug|Vinblastine|"Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C"
75744059|NCT01752920|Drug|Derazantinib at recommended phase 2 dose (RP2D)|Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
75744060|NCT01728402|Procedure|blood draw, bone marrow procedure, or tissue biopsy|
75744061|NCT01479075|Drug|intransal insulin|4x 40mU intranasal insulin
75744062|NCT01479075|Drug|Placebo|
75744063|NCT01479075|Device|taVNS|
75744064|NCT01479075|Device|sham stimulation|
75744065|NCT01409330|Dietary Supplement|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
75744066|NCT01397279|Biological|intravenous glucose tolerance test|Administration of a 30% weight-adapted glucose bolus intravenously.
75892753|NCT04225819|Other|Placebo|Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
75892754|NCT04219904|Other|Fludeoxyglucose F-18|Given IV
75892755|NCT04219904|Drug|Gadobutrol|Given IV
75892756|NCT04219904|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
75892757|NCT04219904|Procedure|Positron Emission Tomography|Undergo PET/MRI
75892758|NCT04217330|Behavioral|Choice of home-based or centre-based pulmonary rehabilitation|Participants will be offered the choice of HomeBase, a home-based pulmonary rehabilitation program, or the traditional centre-based pulmonary rehabilitation program.
75892759|NCT04217330|Behavioral|Centre-based pulmonary rehabilitation|Participants will be offered a traditional centre-based pulmonary rehabilitation program
75892760|NCT04199871|Other|dichoptic 3D movies|dichoptic movies presented on a Nintendo 3DS
76062383|NCT03585465|Drug|Cyclophosphamide|"Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
76062384|NCT03585465|Drug|Capecitabine|"Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
75892761|NCT04196556|Behavioral|Active Families|This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
75744067|NCT01397279|Biological|hyperinsulinemic euglycemic clamp|Intravenous administration of 20% glucose and insulin over 3 hours
75892762|NCT04196556|Other|Madrid's Primary Healthcare Standardized Service portfolio|"An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook."
75892763|NCT04192773|Drug|IV Lidocaine|IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
75744068|NCT01327105|Device|TVU|Use of transvaginal ultrasound to determine location of micro-insert
75744069|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status. A member of the study team will call a subset of patients who have completed both baseline and follow-up surveys to clarify responses to previous questions. Patients will be considered lost to follow- up if surveys A or C have not been completed two years from the participant's consent date (participants who enroll but do not complete survey A are not prompted for survey C). Deviations will not be filed until the end of the study, as there are opportunities over the course of study follow- up to collect previously missing information.
75892764|NCT04182464|Other|Sucralose|Food additive used to replace sugar providing a sweet taste without calories
75892765|NCT04182464|Other|Placebo|Cornstarch without significant physiological effects
75892766|NCT04158635|Drug|Bosentan|Given PO
75892767|NCT04158635|Drug|Gemcitabine|Given IV
75892768|NCT04158635|Drug|Nab-paclitaxel|Given IV
75892769|NCT04158635|Other|Quality-of-Life Assessment|Ancillary studies
75892770|NCT04158635|Other|Questionnaire Administration|Ancillary studies
75892771|NCT04148482|Other|Dietary intervention|To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.
75892772|NCT04141761|Dietary Supplement|Visbiome|This group will receive Visbiome probiotic in powder form.
75892773|NCT04141761|Other|Placebo|This group will receive a placebo in powder form.
75892774|NCT04132362|Behavioral|Personalised music listening|People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.
76025080|NCT03735017|Other|Non-Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
75463149|NCT01872442|Drug|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
75463150|NCT01872455|Dietary Supplement|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
75463151|NCT01872455|Dietary Supplement|Usual diet|Usual diet of the patients
75463152|NCT01872468|Behavioral|Structured intervention|Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
75463153|NCT01872481|Device|rTMS|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
75892775|NCT04132362|Behavioral|Using fMRI to investigate the effect of listening to personalised music evoking positive emotional response on brain activation|12 of the recruited participants, who have symptoms and signs of mild to moderate dementia will be invited to take part in this sub-study. Using an amended version of a previously employed fMRI paradigm, each study participant will be presented inside the MRI scanner with short 30 second epochs of music (identified as evoking a positive or neutral emotional response) in a block design. Each 30 second epoch of music will be followed by a 16 second period when participants will be asked to rate subjective changes in their affective state using a computerised visual analogue scale. Epochs of positive emotional stimuli will alternate with epochs of neutral emotional stimuli in a counterbalanced order of presentation in 2 runs of 10 epochs each (5 positive and 5 neutral in each run).
76062385|NCT03585465|Drug|Nivolumab|"Arm A, B or C (First stage): 3 mg/kg IV, D1 & D15 per cycle, 28 days cycle~Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 & D15 per cycle, 28 days cycle"
76062386|NCT03523351|Radiation|Radiation Therapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
76062387|NCT03523351|Drug|Systemic Therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
76062388|NCT03523312|Radiation|Hypofractionated ablative IMRT (HFA-IMRT)|total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions
75744070|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. All three follow-up contact methods (email, postcard, call) contain the same question regarding current employment status with minor modifications in formatting. However, the employment question asked in all three follow-up contact methods is shown in the Postcard_Template document. Due to the recent COVID-19 pandemic study staff will be working from home. Therefore, calls will be made via MSK-approved platforms (e.g. Jabber, etc.). Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs. The data collected for these internal tracking logs will be managed through a REDCap database.
76062389|NCT03523312|Drug|capecitabine|Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
76062390|NCT03513614|Procedure|Tailored axillary surgery - both Arms|Axillary lymph node dissection - Arm A
76062391|NCT03513614|Radiation|Radiotherapy - Arm A|Regional nodal irradiation excluding the dissected axilla - Arm A
76062392|NCT03513614|Radiation|Radiotherapy - Arm B|Regional nodal irradiation including the full axilla - Arm B
76062393|NCT03507725|Behavioral|Meditation|"The brief mind-body intervention, specifically developed for this study, is a combination of mindfulness meditation with a specific cognitive component of guided imagery. Patient intervention, they will be given headphones connected to an MP4 player in the clinic area to listen to a pre-biopsy mindfulness exercise (10 minutes). They will then be brought into the biopsy procedure room and given a second set of headphones, guiding the patient through the mindfulness intervention during the biopsy procedure (10 minutes)."
75600151|NCT01224639|Biological|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, and TDV-4: 2 x 10^5 PFU, total virus per dose 2.2 x 10^5 PFU
75600152|NCT01224639|Biological|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, and TDV-4: 3 x 10^5 PFU, total virus per dose : 4.7 x 10^5 PFU. TDV administered intradermally.
76062394|NCT03507725|Procedure|Prostate Biopsy|Prostate needle biopsy under local anesthesia
76062395|NCT03507725|Behavioral|Questionnaires|Questionnaires completion will be by telephone interview or manual completion of paper or online REDCap instruments, depending on participant preference.
75744071|NCT01082679|Drug|Methadone|daily for 12 months
75600153|NCT01224639|Biological|Placebo|Phosphate Buffered Saline (PBS)
75600154|NCT01293968|Drug|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
75892776|NCT04132362|Behavioral|Personalised music listening in the community|1000 families affected by dementia will be invited to use our WebApp to create a personalised playlist for their loved one with dementia and share their perceptions of how the music has affected the well-being of their loved one.
75892777|NCT04119258|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy including both behavioral and cognitive interventions.
75892778|NCT04113863|Drug|all-trans retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
75892779|NCT04113863|Drug|Anastrozole 1mg|Anastrozole will be administered orally at the dosage of 1 mg/die.
75892780|NCT04086745|Drug|Baricitinib|Administered orally.
75892781|NCT04086745|Drug|TNF Inhibitor|Administered SC
75892782|NCT04073979|Device|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
76062396|NCT03503331|Drug|[C-11]PiB-PET/MRI|All study participants will undergo brain imaging with [C-11]PiB-PET/MRI. [C-11]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
76062397|NCT03483961|Biological|CHIKV VLP/unadjuvanted|Vaccine consists of virus-like particles of chikungunya virus antigens
76062398|NCT03483961|Biological|CHIKV VLP/adjuvanted|Adjuvanted formulation includes Alhydrogel
76062399|NCT03483961|Biological|Placebo|Placebo is vaccine diluent alone
75600155|NCT01293968|Drug|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
75744072|NCT01082679|Drug|buprenorphine (Suboxone)|daily for 12 months
75600156|NCT04324190|Behavioral|Guided online support program|"Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)"
75744073|NCT01008787|Behavioral|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
75744074|NCT01008787|Behavioral|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
75744075|NCT01008787|Behavioral|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
75744076|NCT01008787|Behavioral|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
75744077|NCT00976963|Drug|TMP/SMX|Take one twice daily for 3 days for urinary tract infection
75744078|NCT00976963|Drug|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediately
75744079|NCT00958633|Drug|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.~In patients randomized to the 8-week group, escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points."
75744080|NCT00958633|Drug|Wellbutrin XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~In patients randomized to the 8-week group, bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points."
75892783|NCT04071652|Device|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
75892784|NCT04026048|Behavioral|Cognitive Behaviour Therapy for Insomnia (CBT-I)|CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
75892785|NCT04023110|Drug|Carvedilol|Individually dosed carvedilol
75892786|NCT04021290|Drug|DTG/3TC FDC|DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
75892787|NCT04021290|Drug|CAR|Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
75892788|NCT04010708|Diagnostic Test|Urinary Iodine Concentration Measurement|UIC
76062400|NCT03481296|Behavioral|Advanced Control|Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
75600157|NCT04324190|Behavioral|WHO recommendations (waiting condition)|"During the waiting period, a german translation of the WHO recommendations Coping with stress during the 2019-nCoV outbreak is provided"
75600158|NCT02869867|Other|refrigerated cushion|refrigerated cushion
75744081|NCT00911560|Biological|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, & 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), & continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic & bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood & bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or >2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
76062401|NCT03481296|Behavioral|Culturally-Adapted Decision Support Navigation Intervention|Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
75892789|NCT03998618|Behavioral|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
75892790|NCT03998618|Behavioral|Education/Support|Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
75892791|NCT03984084|Other|no intervention|no intervention
75892792|NCT03973281|Device|Materna Prep Device|Materna Prep Device
75892793|NCT03973281|Other|Standard of Care (SOC)|Standard of Care (SOC)
75892794|NCT03971591|Behavioral|Immediate Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
75892795|NCT03959098|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
75892796|NCT03959098|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
76062402|NCT03477513|Radiation|Radation Therapy|Personalized Radiation Therapy
76062403|NCT03459807|Drug|Anti-Hypertensive medications|Use of standard Anti-Hypertensive medications
76062404|NCT03459807|Procedure|Dry Weight Adjustment|The participant's target post-dialysis dry weight is adjusted
76072105|NCT03190863|Behavioral|Motor imagery combined with neurofeedback (MINF)|"7 individuals with C6-C7 tetraplegia randomize in the experimental group consisting in motor imagery practice combined with visual neurofeedback (NF - i.e. performance of the imagined movement).~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. After each imagined movement, the NF based on brain activity measured by electroencephalography is display on a screen."
75600159|NCT04292665|Behavioral|Classical Massage|During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.
75744082|NCT00911560|Biological|oral β-glucan|Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
75744083|NCT00902590|Other|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
76062405|NCT03449238|Drug|Pembrolizumab|Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
76062406|NCT03441477|Device|Nidek Tonoref III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
76062407|NCT03441477|Device|Haag-Streit Goldmann Manual Tonometer|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
76062408|NCT03441477|Device|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
75600160|NCT04292665|Behavioral|Benson Relaxation Exercise|During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.
75600161|NCT04292665|Other|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
75600162|NCT01293032|Procedure|Neoadjuvant Therapy|Undergo neoadjuvant therapy
75449232|NCT02363998|Drug|Lofexidine|All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
75600163|NCT01293032|Procedure|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
75600164|NCT01293032|Other|Laboratory Biomarker Analysis|Correlative studies
75600165|NCT01293032|Genetic|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
75600166|NCT01293032|Drug|Systemic Chemotherapy|Undergo chemotherapy
75600167|NCT01293032|Drug|Tamoxifen Citrate|Undergo hormonal therapy
75600168|NCT01293032|Drug|Aromatase Inhibition Therapy|Undergo hormonal therapy
76062409|NCT03439293|Drug|Ixazomib|Ixazomib capsule.
75744084|NCT00902590|Other|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
76062410|NCT03439293|Drug|Daratumumab|Daratumumab IV infusion.
76062411|NCT03439293|Drug|Dexamethasone|Dexamethasone tablets.
75744085|NCT00748254|Procedure|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on finger joints with any of the scanning methods described above.
75744086|NCT00748254|Procedure|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on finger joints with any of the scanning methods described above.
76062412|NCT03433742|Other|Blood levels drawn|The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
76062413|NCT03423979|Device|Optilume™ BPH Prostatic DCB Dilation Catheter|BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
76062414|NCT03423979|Drug|Paclitaxel|paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
75449233|NCT02353832|Device|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
75449234|NCT02353728|Drug|Nilotinib|
75449235|NCT02351583|Device|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
75449236|NCT02351583|Device|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
75600169|NCT01292876|Device|Extracellular Matrix|Extracellular Matrix
75600170|NCT01224171|Drug|vedolizumab|Vedolizumab for intravenous infusion
75600171|NCT01224171|Other|Placebo|Placebo intravenous infusion
75600172|NCT01292486|Device|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
75600173|NCT01223937|Drug|Desmopressin|
75600174|NCT01223937|Drug|Placebo|
75600175|NCT01290224|Other|scrambler therapy|Undergo MC5-A therapy
75600176|NCT01290224|Procedure|sham intervention|Undergo sham procedure
75600177|NCT01290224|Other|questionnaire administration|Ancillary studies
75600178|NCT01223235|Biological|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
75600179|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
75600180|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
75600181|NCT01290068|Device|Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
75600182|NCT00998881|Drug|Teneligliptin 20 mg|
75600183|NCT00998881|Drug|Placebo|
76062415|NCT03420430|Biological|GL-ONC1|
76062416|NCT03298178|Procedure|TAVR|All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea
76062417|NCT03298178|Procedure|SAVR|All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea
76062418|NCT03239210|Drug|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
75449237|NCT02345070|Drug|SAR156597|Pharmaceutical form: solution for injection Route of administration: subcutaneous
75600184|NCT01222767|Drug|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
75600185|NCT00993967|Drug|idebenone|Idebenone 1350 mg/d, patients < or equal 45 kg Idebenone 2250 mg/d, patients > 45 kg
75600186|NCT04278079|Procedure|Pars Plana Vitrectomy with Internal Limiting Membrane peel|Pars plana vitrectomy with staining and peeling of internal limiting membrane
75744087|NCT00591981|Behavioral|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
75744088|NCT00393783|Biological|MAB HER 2 (HERCEPTIN)|Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
75744089|NCT00074269|Biological|anti-thymocyte globulin|
75892797|NCT03959098|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, hinchang medical co., Korea).
75892798|NCT03959098|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be dministered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
75449238|NCT02345070|Drug|placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
75449239|NCT02325466|Drug|Aspirin|Aspirin 81mg
75449240|NCT02325466|Drug|Ticagrelor|ticagrelor 90 mg
75600187|NCT04259359|Drug|Insect Venom|Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
75600188|NCT04204603|Drug|CKD-506|Tablets for oral administration
75600189|NCT04204603|Drug|Placebo|Tablets for oral administration
75600190|NCT01222533|Drug|Tiotropium medium|Tiotropium inhalation solution medium dose
75600191|NCT01222533|Drug|Tiotropium low|Tiotropium inhalation solution low dose
75600192|NCT01222533|Drug|Tiotropium high|Tiotropium inhalation solution high dose
75600193|NCT01222533|Drug|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
75744090|NCT00074269|Biological|filgrastim|
75744091|NCT00074269|Biological|graft-versus-tumor induction therapy|
75744092|NCT00074269|Biological|therapeutic allogeneic lymphocytes|
75744093|NCT00074269|Drug|cyclosporine|
75744094|NCT00074269|Drug|fludarabine phosphate|
75744095|NCT00074269|Drug|melphalan|
75892799|NCT03959098|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75892800|NCT03959098|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75892801|NCT03959098|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
75892802|NCT03959098|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
76062419|NCT03239210|Drug|Placebo|placebo equivalent
76062420|NCT03227224|Drug|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
76062421|NCT03227224|Drug|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
76062422|NCT03196466|Biological|Valproic acid|titration
75449241|NCT02325466|Drug|Aspirin Placebo|
75449242|NCT02325466|Drug|Ticagrelor Placebo|
75449243|NCT02323100|Drug|Ravicti low dose|8 am, 4pm and midnight
75449244|NCT02323100|Drug|Ravicti high dose|8 am, 4pm and midnight
75449245|NCT02323100|Drug|Placebo|8 am, 4pm and midnight
75449246|NCT02322710|Device|Urgotul: Low-adherent dressing|
75449247|NCT02322710|Device|TulleGras M.S.: Vaseline gauze|
75449248|NCT02303548|Drug|Sodium bicarbonate|Administer Sodium bicarbonate 50 mEq IV over 2 minutes
75449249|NCT02303548|Drug|Normal saline|Placebo
75449250|NCT02300493|Behavioral|Experimental|Asked to weigh themselves
75449251|NCT02292654|Drug|Olipudase alfa|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
75600194|NCT01222533|Drug|Tiotropium placebo|Placebo inhalation solution
75600195|NCT01221753|Drug|docetaxel|
75744096|NCT00074269|Drug|methotrexate|
75744097|NCT00074269|Procedure|peripheral blood stem cell transplantation|
75744098|NCT00423735|Drug|Dasatinib|Given PO
75744099|NCT00423735|Other|Pharmacological Study|Correlative studies
75744100|NCT00626327|Biological|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
75744101|NCT00626327|Biological|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
76062423|NCT03196466|Biological|carbamazepine|titration
76062424|NCT03196466|Biological|phenobarbital|titration
76062425|NCT03196466|Biological|phenytoin|titration
76062426|NCT03196466|Biological|levetiracetam|titration
76062427|NCT03196466|Biological|lamotrigine|titration
76062428|NCT03196466|Biological|topiramate|titration
75600196|NCT01221753|Drug|cisplatin|Given intravenously on day 1 of each cycle
75600197|NCT01221753|Drug|5-FU|
75600198|NCT01221753|Radiation|IMRT|
75600199|NCT01221753|Drug|cetuximab|
75744102|NCT00626327|Biological|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
75744103|NCT01032213|Drug|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
75892803|NCT03956277|Device|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
75892804|NCT03937726|Other|Boiled peanut|Desensitisation using boiled peanut for induction and initial updosing
75892805|NCT03937726|Other|Defatted roasted peanut flour|Desensitisation using defatted peanut flour for induction and initial updosing
75449252|NCT02283281|Drug|Tetrahydrocannabinol|1:1 THC to CBD standardized extract from cannabis plant
75600200|NCT01221753|Drug|carboplatin|
75600201|NCT01221597|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
75600202|NCT01221597|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
75892806|NCT03927638|Behavioral|sit/stand|Subjects will be asked to both sit and stand during a single trial.
75892807|NCT03924791|Drug|Lidocaine|In combination with dexamethasone or methylprednisolone acetate
75600203|NCT01221363|Behavioral|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
75600204|NCT01221285|Biological|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
75892808|NCT03924791|Drug|Methylprednisolone Acetate|In combination with lidocaine
75892809|NCT03924791|Drug|Dexamethasone|In combination with lidocaine
75892810|NCT03916237|Other|Home assessment|Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
75892811|NCT03916237|Other|Home remediation|Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)
75892812|NCT03916237|Other|Referral to Medical Legal Partnership|Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)
75892813|NCT03916237|Other|Regular School Based Health Asthma Care|Regular care in the School Health Program
75892814|NCT03915548|Behavioral|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
75892815|NCT03915548|Behavioral|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
76062429|NCT03196466|Biological|oxcarbazepine|titration
75449253|NCT02283281|Drug|Dummy oromucosal|drops containing only Olive oil vehicle without the active compound (i.e.: without Cannabis oil)
75449254|NCT02257749|Other|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
75449255|NCT02257749|Other|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
75600205|NCT02888223|Biological|SCT800|
75600206|NCT02888223|Biological|Xyntha|
75600207|NCT01014988|Drug|zanamivir aqueous solution|Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
75600208|NCT04299724|Biological|Pathogen-specific aAPC|The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections.
75744104|NCT01032213|Drug|normal saline|Group S received the same volume of isotonic saline as same method.
75744105|NCT00357994|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
75744106|NCT00357994|Drug|Placebo gel|
75744107|NCT00357994|Drug|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
75744108|NCT00357994|Drug|Placebo (PBO) oral capsules|
75744109|NCT00357994|Device|CADD-Legacy® 1400 ambulatory infusion pump|
75744110|NCT00357994|Device|PEG tube|percutaneous endoscopic gastrostomy tube
75744111|NCT00357994|Device|J-tube|jejunal tube
76062430|NCT03196466|Biological|stiripentol|titration
76062431|NCT03196466|Biological|clobazam|titration
75600209|NCT01014910|Other|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
75600210|NCT01014910|Device|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
75600211|NCT04298866|Other|Experimental Arm|"3T MRI, maximum 1H30 long duration, including diffusion tensor imaging, susceptibility weighted imaging, multiparametric acquisitions, without contrast perfusion acquisitions.~7T MRI, maximum 1H30 long duration, including contrast enhanced acquisitions~Neuropsychological battery including chronometric measures obtained through a computer interface"
75744112|NCT00823433|Drug|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
75892816|NCT03879447|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.
75892817|NCT03879447|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
75744113|NCT00423657|Drug|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
75892818|NCT03879447|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
75892819|NCT03879447|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
75600212|NCT02872480|Other|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
75892820|NCT03879447|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75892821|NCT03879447|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75892822|NCT03879447|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
75892823|NCT03879447|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
75600213|NCT04297930|Device|Paul Glaucoma Implant Surgery|This group of patients had glaucoma surgery with the Paul Glaucoma Implant
75600214|NCT01019980|Drug|Diclofenac potassium|Diclofenac potassium
75600215|NCT01019980|Drug|Acetaminophen|Acetaminophen
75600216|NCT00993499|Drug|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
75600217|NCT00993499|Drug|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
75892824|NCT03872401|Drug|Evolocumab|Administered subcutaneously using an autoinjector pen.
75600218|NCT04293367|Other|High Intensity Interval Training (HIIT)|"HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery)."
75600219|NCT01014442|Drug|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
75600220|NCT00628264|Drug|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
75600221|NCT00628264|Drug|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
75744114|NCT00423657|Drug|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
75744115|NCT00423657|Drug|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
75744116|NCT00831155|Drug|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
75744117|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
75744118|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
75744119|NCT02533414|Device|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
75744120|NCT02533414|Device|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
75744121|NCT01029015|Procedure|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
75744122|NCT01029015|Procedure|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
76062432|NCT03196466|Biological|brivaracétam|titration
76062433|NCT03196466|Biological|felbamate|titration
76062434|NCT03196466|Biological|lacosamide|titration
76062435|NCT03196466|Biological|rufinamide|titration
76062436|NCT03196466|Biological|gabapentine|titration
76062437|NCT03196466|Biological|pregabaline|titration
75600222|NCT04298398|Behavioral|Mindfulness Based-Cognitive Therapy (MBCT)|MBCT is a program developed by Zindel Segal, Mark Williams and John Teasdale. During MBCT patients learn to decenter their negative thoughts and feelings, allowing the mind to move from an automatic thought pattern to conscious emotional processing. Mindfulness practices included in this program are breath awareness, body scan, sitting and walking meditation, and mindful yoga. The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
75744123|NCT01050712|Drug|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
75744124|NCT01050712|Drug|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
75744125|NCT02550119|Drug|Aprepitant|Given PO
75744126|NCT02550119|Drug|Dexamethasone|Given PO or IV
75744127|NCT02550119|Drug|Dolasetron Mesylate|Given PO or IV
75449256|NCT02243033|Device|MR-guided laser focal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
75449257|NCT02239354|Combination Product|VC-01™ Combination Product|Biologic and Device
75449258|NCT02234310|Biological|rFIXFc|Adjustments to the dose and interval of rFIXFc was made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There was an option to start study dosing as episodic treatment (on-demand).
75744128|NCT02550119|Drug|Placebo|Given PO
75744129|NCT02548403|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
75744130|NCT02548403|Drug|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
75744131|NCT00823589|Other|Blood test and clinical test|Blood test and clinical test
75744132|NCT00367432|Drug|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
75892825|NCT03872401|Drug|Placebo|Administered subcutaneously using an autoinjector pen.
75892826|NCT03860883|Procedure|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
76062438|NCT03196466|Biological|sultiame|titration
76062439|NCT03196466|Biological|tiagabine|titration
76062440|NCT03196466|Biological|vigabatrine|titration
76062441|NCT03196466|Biological|mesuximide|titration
76062442|NCT03196466|Biological|primidone|titration
76062443|NCT03196466|Biological|perampanel|titration
76062444|NCT03196466|Biological|ethosuximide|titration
76062445|NCT03196466|Biological|zonisamide|titration
76062446|NCT03196466|Biological|cannabidiol|titration
76062447|NCT03196466|Other|genetic polymorphisms|genetic polymorphisms
75449259|NCT02162563|Drug|FOLFOX/ FOLFIRI with bevacizumab|"FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
75463154|NCT01872481|Device|Sham rTMS|A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
76062448|NCT03184870|Drug|BMS-813160|Specified dose on specified days
76062449|NCT03184870|Biological|Nivolumab|Specified dose on specified days
76062450|NCT03184870|Drug|Nab-paclitaxel|Specified dose on specified days
76062451|NCT03184870|Drug|Gemcitabine|Specified dose on specified days
76062452|NCT03184870|Drug|5-fluorouracil (5-FU)|Specified dose on specified days
76062453|NCT03184870|Drug|Leucovorin|Specified dose on specified days
76062454|NCT03184870|Drug|Irinotecan|Specified dose on specified days
76062455|NCT03122522|Drug|ipilimumab|ipilimumab 3mg/kg
76062456|NCT03122522|Drug|nivolumab|nivolumab 1mg/kg
76062457|NCT03108846|Drug|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
76062458|NCT03108846|Drug|Placebo|Masked placebo
76062459|NCT03086343|Drug|Abatacept|IV infusion
76062460|NCT03086343|Drug|Placebo for abatacept|IV infusion
76062461|NCT03086343|Drug|Upadacitinib|15 mg extended release tablet
76062462|NCT03086343|Drug|Placebo for upadacitinib|Film-coated tablet
76062463|NCT03074734|Other|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
75892827|NCT03860883|Procedure|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
75892828|NCT03859466|Device|Shockwave Therapy|The cardiac shockwave system consists of a table-top device (Nonvasiv Medical GmbH, Konstanz, Germany) and a sterile single-use applicator releasing electrohydraulic shockwaves (Heart Regeneration Technologies GmbH, Innsbruck, Austria). Prior to use, the applicator is inserted into a sterile cover containing ultrasound gel. In order to ensure acoustic coupling between the applicator and the myocardium, continuous saline rinsing is applied throughout the procedure.
75892829|NCT03854799|Drug|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
75892830|NCT03854799|Drug|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
75892831|NCT03854799|Radiation|EXTERNAL---BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
75744133|NCT01086670|Other|Physical Exercise|Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or over-training effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions. Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses.
75744134|NCT01053052|Device|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
75744135|NCT01050868|Device|Accu-Chek Combo Kit mg DE/de|
75892832|NCT03851380|Behavioral|Psychological / Functional Assessment|Psychological and functional assessment battery to characterize participants.
75449260|NCT02162563|Drug|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
75449261|NCT02162563|Drug|FOLFOX/ FOLFIRI with panitumumab|"FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
75449262|NCT02158403|Other|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
75744136|NCT00623363|Drug|piclozotan|piclozotan, intravenous (IV) infusion
75744137|NCT00623363|Drug|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline) intravenous (IV) infusion
75892833|NCT03851380|Other|Structural and Functional MRI|Structural and functional magnetic resonance imaging session.
75892834|NCT03851380|Device|Transcranial Magnetic Brain Stimulation and MR Image Guidance|MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.
75892835|NCT03851380|Device|Transcranial Electrical Stimulation (tES)|Home-based Transcranial Direct Current Stimulation
76062464|NCT02904226|Drug|JTX-2011|Specified dose on specified days
76062465|NCT02904226|Drug|Nivolumab|Specified dose on specified days
75600223|NCT04298398|Behavioral|Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|EFT-CR is an evidence-based approach to psychotherapy, which combines aspects of person-centered, gestalt and existential therapies with contemporary emotion theory and dialectical constructivism (Elliott et al, 2004, Rice & Greenberg, 1984). On EFT-CR, therapist follows the client experience and guides the process, proposing therapeutic tasks when specific client behaviors occur. EFT-CR uses a set of emotion change principles which guide a process of emotional deepening process, from undifferentiated distress to secondary reactive emotions to primary maladaptive emotions to core pain and thence to primary adaptive emotions and emotional transformation (Elliott & Greenberg 2016). The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
75892836|NCT03840668|Device|USB Eye Mask|To evaluate the acceptance of the USB eye mask via questionnaire and also to monitor the use of USB eye mask over a period of 2 months.
75892837|NCT03829787|Device|Eye tracking|Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
75449263|NCT02154568|Drug|hyperpolarized helium MRI of the chest|Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
75600224|NCT04298398|Other|Treatment as usual (no intervention)|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
75744138|NCT00827177|Drug|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If < 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
75744139|NCT00823667|Other|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
75600225|NCT04297774|Behavioral|virtual reality treatment|18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
75892838|NCT03806283|Procedure|Omental Biopsy|The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. After delivery, during the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
75892839|NCT03802877|Behavioral|Resource bank|See intervention arm descriptions
75892840|NCT03802877|Behavioral|ePlatform|See intervention arm descriptions
75892841|NCT03802877|Behavioral|Health coach|See intervention arm descriptions
75892842|NCT03800914|Other|High intensity interval training|36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
75892843|NCT03800914|Other|Traditional pulmonary rehabilitation|30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
75449264|NCT02139436|Other|FES-row-training|
75449265|NCT02139436|Other|Arms-only-row training|
75744140|NCT00823667|Other|medical chart review|Occurs at 1 year post study enrollment
75892844|NCT03760523|Drug|Minnelide|Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
75892845|NCT03757091|Device|Laryngoscopy|Undergo video laryngoscopy
75892846|NCT03757091|Procedure|Tracheal Intubation|Undergo flexible scope intubation
75449266|NCT02139436|Other|Time Control|
75449267|NCT02127086|Other|Intervention Group|The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
75463155|NCT01872494|Other|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
75600226|NCT04297774|Behavioral|standard treatment|18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
75744141|NCT00823667|Other|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
75744142|NCT00823667|Procedure|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
75744143|NCT00823667|Procedure|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
75892847|NCT03733197|Behavioral|Culture Specific|We anticipate the culture-specific arm developed minimally will include two core components: barbers as motivational interviewers, and (2) fecal immunochemical test (FIT) kits distributed by barbers. If we choose this route for the culture-specific arm, preliminary data from our barbers suggest I teach the barbers the MI technique using content that stems from Aim 1 findings. Additional components for this arm may be developed during the APEASE process.
75892848|NCT03733197|Behavioral|Control|the (control) arm will include an informational CRC screening brochure developed by the American Cancer Society plus a FIT kit distributed by the barbers.
75892849|NCT03724136|Procedure|Intravenous Bone Marrow Stem Cell (BMSC) Fraction|14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.
75892850|NCT03724136|Procedure|Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.
75892851|NCT03724136|Procedure|Near Infrared Light|Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
75892852|NCT03714204|Behavioral|Transcendental Meditation technique|The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
76062466|NCT02904226|Drug|Ipilimumab|Specified dose on specified days
76062467|NCT02904226|Drug|Pembrolizumab|Specified dose on specified days
76062468|NCT02862431|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
75449268|NCT02120079|Drug|Lotemax|Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
76062469|NCT02862431|Drug|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
75449269|NCT02120079|Drug|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
75744144|NCT00823667|Procedure|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
75744145|NCT00423267|Drug|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
75744146|NCT00423267|Drug|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
75744147|NCT02549261|Drug|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
76062470|NCT02788045|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
76062471|NCT02788045|Biological|Ad26.Mos4.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5mL injection administered intramuscularly.
76062472|NCT02788045|Biological|Clade C gp140|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
75449270|NCT02120079|Diagnostic Test|In Vivo Confocal Microscopy (IVCM)|In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
75449271|NCT02106195|Drug|Belumosudil|
75600227|NCT04297774|Behavioral|balance training|18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
76062473|NCT02788045|Drug|Placebo|Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
75600228|NCT00996307|Biological|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
75600229|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
75892853|NCT03702920|Biological|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
75600230|NCT00996307|Biological|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
75744148|NCT02549261|Drug|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
75600231|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
75744149|NCT02549261|Drug|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
75892854|NCT03702920|Other|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
75449272|NCT02104180|Device|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
75892855|NCT03698877|Diagnostic Test|Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests|"For patients with suspected infection, PCT levels will be drawn at the time of suspected infection and again at the start of the next HD treatment.~For patients with shortness of breath, PCT and BNP levels will be drawn at the time of the complaint and again at the start of the next HD treatment."
75600232|NCT04293835|Diagnostic Test|Whether to have intestinal-related disease|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
75600233|NCT04293991|Device|High Flow Nasal Cannula|Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.
75600234|NCT04293991|Device|Non Invasive Ventilation|Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
75600235|NCT04263337|Drug|[11C] PiB|Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
75744150|NCT02549261|Radiation|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
76062474|NCT02775695|Drug|Doxycycline|Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
75744151|NCT01029093|Other|no intervention, MRI and motor skill test|Two MR Investigations at two different times
75892856|NCT03695146|Behavioral|Paced breathing|Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.
75892857|NCT03695146|Behavioral|Active relaxation|Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.
75892858|NCT03674346|Other|Hypnoanalgesia group|"The running of a hypnosis session is protocolized and is based on three times:~The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability.~The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged,~The time of return. It is time that allows the patient to regain his classic state of consciousness."
76062475|NCT02679040|Procedure|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
76062476|NCT02679040|Drug|Chemotherapy|Chemotherapy treatment
76062477|NCT02679040|Radiation|Radiation therapy|Radiation therapy
76062478|NCT02643498|Radiation|Stereotactic Body Radiotherapy (SBRT)|
75449273|NCT02104180|Device|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
75449274|NCT02097550|Other|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
75449275|NCT02075177|Drug|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
75449276|NCT02075177|Drug|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
75449277|NCT02059681|Other|Autologous bone marrow derived-CD133+ cells|Cell therapy
75449278|NCT02050919|Drug|Epirubicin Hydrochloride|Given IV
75600236|NCT04263337|Drug|[18F] PBR111|Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
75600237|NCT04263337|Drug|[18F] Flortaucipir|Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
75600238|NCT02869165|Drug|Conjugated equine estrogen topical cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
75600239|NCT02869165|Drug|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
75600240|NCT04292041|Other|Fasting mimicking diet|"3 cycles of programmed nutrition using a fasting mimicking diet (Chemolieve (R)), each cycle consisting of 4 days. Pre and post nutritional cycles, clinical and metabolic assessments are taken, as per protocol. Allowing for a 3 month washout time, the 'post' assessment is planned approximately 6 months from the initial (pre) assessment."
75600241|NCT00629161|Drug|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
75600242|NCT00629161|Drug|placebo|12 months period of placebo plus 1 month period without placebo
75600243|NCT01219959|Drug|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
75892859|NCT03674346|Other|Meopa Group|"The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure.~For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study."
75892860|NCT03672643|Drug|Crizotinib|receive crizotinib orally
75600244|NCT01219959|Drug|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
75744152|NCT01032369|Other|Nutritional intervention and physical activity|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking)."
75892861|NCT03658967|Drug|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
75892862|NCT03658967|Drug|Placebo|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
75892863|NCT03648918|Other|Blood Collection|Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
75892864|NCT03641924|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
75892865|NCT03630705|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration : Intramuscular
75600245|NCT00993421|Drug|LY377604|Given daily, orally for 24 weeks
75600246|NCT00993421|Drug|Sibutramine|given daily, orally for 24 weeks
75600247|NCT00993421|Drug|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
75600248|NCT00993421|Drug|Placebo sibutramine|given daily, orally for 24 weeks
75600249|NCT00993421|Drug|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
75892866|NCT03630705|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular
75892867|NCT03630705|Biological|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
75892868|NCT03630705|Biological|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75600250|NCT00993421|Drug|Placebo LY377604|given daily, orally for 24 weeks
75600251|NCT04292509|Device|SAP with stop before low|cross-over comparison from stop on low to stop before low
75600252|NCT04292509|Device|SAP with stop on low|cross-over comparison from stop before low to stop on low
75600253|NCT02868853|Behavioral|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
75600254|NCT02868853|Behavioral|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
75600255|NCT02868853|Behavioral|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
75892869|NCT03630705|Biological|Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine|Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
75892870|NCT03630705|Biological|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75600256|NCT01014208|Drug|OFATUMUMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
75600257|NCT01014208|Drug|RITUXIMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
75744153|NCT01032369|Other|Nutritional intervention, physical activity and behavioral treatment|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).~Behavioral treatment:~This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions."
75744154|NCT02548325|Other|Not apply|None. Just registration epidemiology dates
75892871|NCT03630705|Biological|Rotavirus Vaccine, Live, Pentavalent|Pharmaceutical form: Oral solution Route of administration: Oral
75892872|NCT03630705|Biological|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
75892873|NCT03628209|Drug|Nivolumab|Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
75892874|NCT03628209|Drug|Azacitidine|Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m^2. Dose level 3: 75 mg/m^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
75892875|NCT03628209|Procedure|Post Treatment Surgery|Resection surgery at end of Cycle 1 treatment, day 28-35.
75892876|NCT03614949|Radiation|Stereotactic body radiation therapy (SBRT)|SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
75449279|NCT02050919|Radiation|External Beam Radiation Therapy|Undergo EBRT
75600258|NCT04205578|Drug|dl-3-n-butylphthalide (NBP)|25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
75892877|NCT03614949|Drug|Atezolizumab|Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
75892878|NCT03606746|Biological|MDR-103|MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
75449280|NCT02050919|Drug|Ifosfamide|Given IV
75600259|NCT04205578|Drug|Normal Saline 0.9% Infusion Solution|100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
75744155|NCT00823745|Drug|[14C]-PF-00868554|solution, single dose
75892879|NCT03605654|Biological|MDR-102|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
75892880|NCT03605654|Drug|Immunosuppressive Agents|Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
75892881|NCT03603730|Device|taVNS|Active or inactive taVNS delivered to the external ear at a moderate, non-painful level.
75449281|NCT02050919|Other|Laboratory Biomarker Analysis|Correlative studies
75449282|NCT02050919|Drug|Sorafenib Tosylate|Given PO
75449283|NCT02050919|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
75449284|NCT02001142|Other|Exercise|single session of exercise
75449285|NCT01997463|Drug|Supervised asthma therapy in schools|Therapy observed daily in school. Asthma education by American Lung Association
75449286|NCT01976754|Drug|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
75449287|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
75449288|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
75892882|NCT03591510|Drug|Midostaurin|midostaurin 30mg/m2 bid
75892883|NCT03591510|Drug|Fludarabine|30mg/m2/day on D1-D5 of Block 2 FLADx
75892884|NCT03591510|Drug|Cytarabine|"Part 1:~2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC~Part 2:~1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC"
75892885|NCT03591510|Drug|Daunorubicin or idarubicin|daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx
75892886|NCT03591510|Drug|Mitoxantrone|10mg/m2/day D3 and D4
75892887|NCT03591510|Drug|Etoposide|100mg/m2/day D1 to D5
75600260|NCT04297540|Device|Active-tDCS group|Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
75892888|NCT03577418|Behavioral|Clinician-facilitated educational intervention|People with dementia (PWD) will complete the Preferences for Everyday Living (PELI). Care partners will complete the PELI from the perspective of the PWD (i.e., as if acting as surrogate decision-makers). Research staff will then review these assessments, highlighting areas of discrepancy in the importance of various preferences. A 30-minute preferences-based discussion will then be facilitated by the research clinician. This discussion will include review of the discrepancies identified in the assessments. The PWD and the care partners will then be encouraged to identify one area of discrepancy and to come together with a concrete action plan to resolve that area of discrepancy. A standardized document describing neuropsychiatric symptoms and reviewing the unmet needs hypothesis will be discussed with PWD and the care partners.
75744156|NCT00626093|Device|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|"Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).~Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions."
75892889|NCT03577418|Behavioral|Enhanced usual care|In addition to the usual clinical care, the standardized document describing NPS and reviewing the unmet needs hypothesis will be given to the PWD and the care partner to review.
76062479|NCT02610075|Drug|AZD1775|All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
75449289|NCT01943825|Biological|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
75449290|NCT01943825|Biological|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
75449291|NCT01913457|Radiation|Ultrasound Doppler|Doppler Ultrasound recording on external right chest wall
75449292|NCT01863186|Drug|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
75449293|NCT01863186|Drug|Placebo|Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
75449294|NCT01863186|Drug|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
75449295|NCT01828840|Drug|epidural morphine via PCEA|
75744157|NCT00357760|Biological|VEGF Trap|Given IV
75744158|NCT02548013|Other|outpatient management|patients if stable will be discharged to continue treatment at home
75744159|NCT02548013|Other|Inpatient management|patients will continue there treatment in hospital till delivery
75744160|NCT01049230|Radiation|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
75744161|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
75892890|NCT03545386|Other|Fecal microbiota transplantation|Stool from healthy donor administered via enema
75892891|NCT03545386|Other|Placebos|Saline with food coloring administered via enema
75892892|NCT03543969|Drug|Encorafenib|450 mg encorafenib daily by mouth
75892893|NCT03543969|Drug|Binimetinib|45 mg binimetinib daily by mouth
75892894|NCT03543969|Drug|Nivolumab|240 mg Nivolumab IV every 2 weeks
75892895|NCT03539458|Device|Tendyne Mitral Valve System|Mitral valve replacement
76062480|NCT02599454|Drug|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
76062481|NCT02599454|Radiation|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
76062482|NCT02559856|Drug|Apixaban|
75892896|NCT03537963|Other|mHealth Stepped-care Intervention|Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
75600261|NCT04297540|Device|Sham-tDCS group|Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
75892897|NCT03537963|Other|Educational Control Condition|General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.
76062483|NCT02559856|Drug|Rivaroxaban|
76062484|NCT02505919|Device|AQUABEAM System|The AQUABEAM system, a personalized image-guided tissue removal system, utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue.
76062485|NCT02505919|Procedure|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
76062486|NCT02482311|Drug|AZD 1775|"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food."
76062487|NCT02344680|Drug|Anti-HIV Agents|
76062488|NCT02338609|Drug|Everolimus|Blood sample and Tanner Stage assessment
75600262|NCT00628420|Drug|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
75600263|NCT00628420|Drug|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
75892898|NCT03537963|Other|Questionnaire|After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
75600264|NCT00628420|Drug|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
75600265|NCT00991939|Drug|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients < 60 kg and 40 mg/day for patients > 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
75744162|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
75744163|NCT03742336|Drug|PF-04965842|Single oral 200 mg dose of PF-04965842
75744164|NCT03742336|Drug|Dabigatran|Single 75 mg dose of dabigatran
75744165|NCT00435825|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
75744166|NCT00824057|Drug|AZD6280|oral
75744167|NCT00824057|Drug|Midazolam|oral
75892899|NCT03537963|Other|Interview|Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
75892900|NCT03537963|Other|Qualitative Interviews|To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.
75892901|NCT03537963|Other|Virtual Reality|The intervention will comprise six 360º videos of relaxing natural landscapes from which patients can choose (i.e., beaches, tropical scenes, calm thunderstorms, snowfall). Participants will also choose an audio accompaniment: a progressive muscle relaxation script, a deep breathing exercise script, a mindfulness meditation script, or scene-relevant audio (e.g., waves crashing for the beach scene).
75892902|NCT03534180|Other|Laboratory Biomarker Analysis|Correlative studies
75892903|NCT03534180|Drug|Romidepsin|Given IV
75892904|NCT03534180|Drug|Venetoclax|Given PO
75892905|NCT03519945|Drug|Mirikizumab|Administered SC.
76062489|NCT02338609|Drug|Envirolimus drug class as prescribed by Physician|At the discretion of the investigator, patients may be treated with commercially available everolimus, as per local product information/ standard of care.
75892906|NCT03511196|Drug|Adaptive Androgen Deprivation Therapy (ADT)|ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.
75892907|NCT03511196|Drug|Abiraterone|Prednisone 5 mg once a day with food.
76062490|NCT02315703|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
75892908|NCT03511196|Drug|Prednisone|Abiraterone 1000 mg daily with empty stomach.
75600266|NCT00991939|Drug|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients > 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients < 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
75600267|NCT04293445|Diagnostic Test|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
75744168|NCT00824057|Drug|Caffeine|oral
75744169|NCT01053130|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
75892909|NCT03494166|Behavioral|Start with SMSH+TIPC|See arm/group descriptions
75892910|NCT03494166|Behavioral|Start with SMSH alone|See arm/group descriptions
75892911|NCT03477591|Other|Evidence-based information|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
75892912|NCT03477591|Other|Patient Decision Aid|Patient Decision Aid for prostate cancer screening decision
75892913|NCT03477591|Other|Sham information|Educational information not specific to PSA testing or cancer screening
75892914|NCT03477539|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
75892915|NCT03477539|Biological|Daratumumab|Given IV
75892916|NCT03477539|Drug|Lenalidomide|Given PO
75892917|NCT03476837|Behavioral|Treatment|The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample and WCG's carbon monoxide. Saliva samples will be collect from one child in the home at baseline and final. Baseline saliva data and carbon monoxide monitoring will be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.
76062491|NCT02315703|Biological|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
76062492|NCT02315703|Biological|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
76062493|NCT02315703|Biological|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
75600268|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + strength training|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises
75600269|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + range of motion|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
75744170|NCT01053130|Behavioral|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
75744171|NCT02534272|Other|Stool sampling and sequencing of gut microbiota.|
75744172|NCT00574145|Procedure|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
75744173|NCT00574145|Procedure|fatigue assessment and management|duration
75892918|NCT03476837|Behavioral|Control|Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
75744174|NCT00574145|Procedure|psychosocial assessment and care|duration
75744175|NCT00574145|Procedure|quality-of-life assessment|duration
75744176|NCT00574145|Procedure|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
75744177|NCT01053208|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
75744178|NCT00831467|Biological|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
75449296|NCT01828840|Drug|epidural fentanyl via PCEA|
75449297|NCT01828840|Drug|epidural methadone via PCEA|
75600270|NCT02869087|Device|Akesys Prava Scaffold|Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
75449298|NCT01828840|Drug|intravenous morphine via PCA|
75449299|NCT01817426|Drug|Infliximab|
75600271|NCT04291807|Behavioral|Video education|Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
75600272|NCT02868697|Drug|TauroLock U 25000|taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
75600273|NCT02868697|Drug|(TauroLock Hep500)|1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis[tetrahydro-1,1,1',1'-tetraoxide], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
75600274|NCT02868385|Drug|4x Praziquantel|Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.
75600275|NCT02868385|Drug|1x Praziquantel|One praziquantel treatment (40 mg/kg) at baseline
75600276|NCT02868307|Behavioral|Answering questionnaire|
75449300|NCT01817426|Other|Placebo|
75449301|NCT01813695|Procedure|Preemptive genotyping in medical record|
75449302|NCT01813695|Procedure|Genotyping not included in electronic medical record|
75449303|NCT01741103|Drug|sitagliptin|sitagliptin 100mg by mouth once a day for 12 weeks
75449304|NCT01741103|Drug|Placebo|Take one by mouth daily for 12 weeks
75449305|NCT01722331|Drug|Tildrakizumab 200 mg|Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
75449306|NCT01722331|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg/mL PFS
75449307|NCT01722331|Drug|Matching Placebo|Matching placebo to tildrakizumab PFS
75600277|NCT00993265|Drug|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
75600278|NCT00993265|Drug|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
75600279|NCT04211389|Drug|ARQ-151 0.3% cream|ARQ-151 0.3% cream
75600280|NCT04211389|Drug|ARQ-151 vehicle cream|ARQ-151 vehicle cream
75449308|NCT01630590|Drug|Cabozantinib|Starting dose of 60 mg by mouth every day of a 21 day cycle.
75449309|NCT01630590|Drug|Androgen Ablation Therapy|Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
75449310|NCT01619085|Drug|Nintedanib|Nintedanib twice a day
75449311|NCT01612663|Device|Pain relief by Acupuncture needle at non-specific site|
75449312|NCT01612663|Device|Acupuncture needle|
75449313|NCT01612663|Device|Acupuncture needle|
75600281|NCT00993031|Drug|Lopinavir/ritonavir|LPV 200mg/r 50mg
75600282|NCT00993031|Drug|Efavirenz|600mg
75600283|NCT00993031|Drug|Zidovudine|Zidovudine 300 mg
75744179|NCT00423189|Drug|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
75744180|NCT00423189|Drug|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
75744181|NCT03991858|Other|Phone call follow-up|A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
75892919|NCT03476642|Drug|Ropivacaine|injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
75892920|NCT03476642|Drug|Epinephrine|injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
75892921|NCT03474913|Device|Upright MRI|Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
75449314|NCT01612663|Device|Acupuncture needle|
75744182|NCT03991858|Other|Telerehabilitation follow-up|A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
75449315|NCT01499095|Drug|Lantus (Insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
75600284|NCT00993031|Drug|Lamivudine|Lamivudine 150 mg
75600285|NCT01010776|Drug|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
75600286|NCT04291729|Drug|Ganovo+ritonavir+/-Interferon nebulization|Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
75744183|NCT00831545|Drug|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
75744184|NCT01051024|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
75892922|NCT03474913|Device|Standard MRI|standard of care closed 3T MRI
75892923|NCT03432286|Drug|Galcanezumab|Administered SQ
75892924|NCT03432286|Drug|Placebo|Administered SQ
75892925|NCT03378167|Biological|MICROBIOTA|Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.
75744185|NCT01051024|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
75449316|NCT01499095|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
75744186|NCT02549417|Drug|KHK7580|Oral administration
75744187|NCT00824135|Drug|Clofarabine|"One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
75892926|NCT03378167|Biological|PLACEBO|"Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist."
75892927|NCT03377816|Behavioral|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
75892928|NCT03377816|Behavioral|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
75892929|NCT03367156|Drug|Dexamethasone|Given PO
75463156|NCT01872494|Other|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
76062494|NCT02315703|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
75463157|NCT01872494|Drug|0.33% ropivacaine 250ml|
75463158|NCT01872494|Drug|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
75463159|NCT01872507|Other|Biofeedback training|usual treatment +12 biofeedback training
75600287|NCT02868775|Procedure|cystoscopy, bladder hydrodistention and bladder biopsy|
75600288|NCT00637702|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
75744188|NCT00824135|Procedure|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
75744189|NCT00824135|Other|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3"
75744190|NCT00824135|Drug|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
75744191|NCT00824135|Drug|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
75892930|NCT03367156|Other|Placebo|Given PO
75892931|NCT03367156|Other|Questionnaire Administration|Ancillary studies
76062495|NCT02242773|Device|Multi-Parametric MRI|Multi-Parametric MRI
76062496|NCT02242773|Device|MRI-Guided Biopsy|MRI-Guided Biopsy
76062497|NCT02188108|Other|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
76062498|NCT02132858|Other|cytology specimen collection procedure|Correlative studies
76062499|NCT02132858|Other|laboratory biomarker analysis|Correlative studies
76062500|NCT02049359|Other|Texting|Bidirectional texting once weekly for 12 weeks
75744192|NCT00824135|Drug|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)"
75744193|NCT00824135|Drug|Rituximab|375 mg/m2 intravenous for 1 dose total
75600289|NCT04291963|Procedure|DGG + TUN|In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation
76062501|NCT01839695|Device|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
76062502|NCT01836783|Other|Amnion Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
76062503|NCT01836783|Other|Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
76062504|NCT01698905|Drug|nilotinib|"Nilotinib was dosed by weight or body surface area.~Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water.~No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry."
76062505|NCT01608074|Procedure|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
75744194|NCT00824135|Other|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
75744195|NCT00422799|Drug|Bortezomib|Once weekly for 3 weeks
76062506|NCT01608074|Other|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
75449317|NCT01499082|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
75449318|NCT01499082|Drug|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
75449319|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
75449320|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
75449321|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
75600290|NCT04291963|Procedure|SCTG + TUN|In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
75600291|NCT04170985|Other|clinical Whole Genome Sequencing|Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.
75600292|NCT02868619|Other|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
75744196|NCT00422799|Drug|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
75744197|NCT00827333|Other|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
75744198|NCT00827333|Other|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
75744199|NCT00827333|Procedure|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
75744200|NCT00827333|Procedure|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
75744201|NCT00827333|Procedure|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
75744202|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
75744203|NCT00827411|Device|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
75744204|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
75744205|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
75744206|NCT00827411|Drug|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
75744207|NCT00435045|Drug|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
75892932|NCT03363945|Biological|MDR-101|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
75744208|NCT00435045|Drug|atorvastatin|atorvastatin + placebo
75744209|NCT01029171|Behavioral|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
75449322|NCT01488890|Biological|Yellow Fever|0.5 mL, Subcutaneous
75449323|NCT01480206|Other|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
75449324|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
75449325|NCT01436396|Biological|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
75449326|NCT01436396|Biological|Measles, mumps, and rubella (MMR) vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
75449327|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
75449328|NCT01436396|Biological|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
75449329|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
75449330|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
75600293|NCT02868619|Other|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
75600294|NCT02868619|Other|R-CMAS scale|Evaluate the anxiety
75600295|NCT00637741|Device|Everflex 200|
75600296|NCT02868931|Behavioral|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators."
75600297|NCT01018810|Drug|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
75600298|NCT01018810|Drug|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
75600299|NCT01018810|Drug|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
75600300|NCT01018810|Drug|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
75744210|NCT01029171|Behavioral|control; usual care|Usual care as prescribed by geriatrician.
75744211|NCT00441129|Device|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
75744212|NCT00441129|Device|Minimed Paradigm 512/712 Insulin pump|Minimed Paradigm 512/712 Insulin pump
75744213|NCT00622505|Drug|zoledronic acid|Zoledronic acid concentrate (4 mg/5 milliliters [ml]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
75744214|NCT02550275|Behavioral|neuropsychological test|
75744215|NCT02550275|Radiation|MRI|
75892933|NCT03346772|Biological|Influenza vaccination|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
75892934|NCT03337399|Other|Stepped PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
75600301|NCT02867917|Drug|Volcolon sugar free|1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet
75892935|NCT03337399|Other|Early Integrated PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
75744216|NCT02549183|Device|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
75892936|NCT03302299|Drug|Isoniazid 300 Mg ORAL TABLET|The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
75892937|NCT03302299|Drug|Pyridoxine 25 Mg Oral Tablet|All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
75892938|NCT03297125|Device|Standard Magnetic Resonance Imaging (MRI)|Standard MRI.
75892939|NCT03297125|Device|Advanced MRI.|Perfusion and diffusion MRI.
75892940|NCT03276962|Biological|RTS,S/AS01E (Full dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
76062507|NCT01466686|Radiation|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below.
76062508|NCT01466686|Drug|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
76062509|NCT01093196|Drug|Melphalan, Prednisone, Lenalidomide|"Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period [different doses according to the age of patients (65-75 or >75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD)."
76062510|NCT01093196|Drug|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period [day 21 to 28]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
75744217|NCT02550353|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
75892941|NCT03276962|Biological|RTS,S/AS01E (1/5th dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
75892942|NCT03276962|Biological|Rabies vaccine|Subjects will receive intramuscular injection of rabies vaccine (0.1 ml).
75892943|NCT03275805|Other|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration of bracing (for the treatment to normalization arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
75600302|NCT02867917|Drug|Metamucil Orange|1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers
75600303|NCT02867917|Drug|Psyllium Orange|1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
75600304|NCT01018732|Biological|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
75892944|NCT03275805|Other|12 week standard of care|The intervention for this arm will be standard treatment for this pathology.
75892945|NCT03262935|Drug|(vic-)trastuzumab duocarmazine|Intravenous SYD985, Q3W
75892946|NCT03262935|Drug|Physician's choice|See drug label
75892947|NCT03225625|Procedure|Paraspinal|BMSC provided by paraspinal injection, intravenous and intranasal
75892948|NCT03225625|Procedure|Paraspinal EX|BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
75892949|NCT03225625|Procedure|Paraspinal VR|BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
75892950|NCT03206762|Device|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
75449331|NCT01436396|Biological|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
75449332|NCT01436396|Biological|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
75449333|NCT01436396|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
75449334|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
75449335|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
75449336|NCT01436396|Biological|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
75892951|NCT03200847|Drug|Pembrolizumab with All-Trans Retinoic Acid|All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
75892952|NCT03190317|Other|HIV-infected Veterans who use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
75892953|NCT03190317|Other|HIV-infected Veterans who do not use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
75892954|NCT03190317|Other|Providers and staff of HIV-infected veteran|The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
75892955|NCT03184545|Device|EMS|The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
76062511|NCT01093196|Drug|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
75744218|NCT02550353|Procedure|femtosecond laser-assisted laser in situ keratomileusis|track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
75892956|NCT03184545|Other|Physical therapy|Standard physical therapy exercises
75744219|NCT00827489|Drug|HTC-867|
75744220|NCT00827489|Other|Placebo|
75892957|NCT03168815|Device|High Flow Nasal Cannula or Low Flow Nasal Cannula|HFNC vs LFNC
75449337|NCT01414777|Drug|ondansetron|Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
75449338|NCT01414777|Drug|placebo|placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
75449339|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
75449340|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
75744221|NCT00831857|Other|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
75744222|NCT00824447|Drug|Oralgen|allergen solution sublingually
75744223|NCT00824447|Other|placebo|placebo control
75744224|NCT02548169|Biological|DC Vaccine + Standard of Care Chemotherapy|"4 doses of DC vaccine at 2 weeks interval, combined with either:~Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL."
75892958|NCT03102632|Other|High Water Intake|After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
75744225|NCT04043429|Behavioral|Vision Restoration Training (VRT)|
75892959|NCT03037294|Dietary Supplement|Preoperative protein supplementation|Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
75449341|NCT01411241|Biological|Placebo|0.5 mL, subcutaneous
75449342|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
75449343|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
75892960|NCT03030417|Drug|LMP744|Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand DNA breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
75892961|NCT03019003|Drug|Oral Decitabine|Hypomethylating agent
75892962|NCT03019003|Drug|Durvalumab|anti-PD-L1
75600305|NCT01218867|Biological|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
75744226|NCT04043429|Behavioral|Vision Exploration Training (VET)|
75744227|NCT04043819|Drug|PSC-01|PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
75744228|NCT04016987|Behavioral|Automated structured education intervention based on an app and artificial intelligence|In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
75449344|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
75449345|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
75449346|NCT01411241|Biological|Placebo|0.5 mL, subcutaneously
75449347|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
75600306|NCT01218867|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
75600307|NCT01218867|Biological|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
75892963|NCT02964078|Drug|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
75892964|NCT02964078|Drug|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
75892965|NCT02956447|Drug|Kisspeptin 112-121|0.313 ug/kg IV or 0.313 ug/kg - 13.19 ug/kg SC
75892966|NCT02956447|Drug|GnRH|0.075 ug/kg IV
75892967|NCT02953457|Biological|Durvalumab|Given IV
75892968|NCT02953457|Other|Laboratory Biomarker Analysis|Correlative studies
75892969|NCT02953457|Drug|Olaparib|Given PO
75892970|NCT02953457|Biological|Tremelimumab|Given IV
75892971|NCT02948426|Biological|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
75744229|NCT00824681|Behavioral|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
75744230|NCT00824681|Other|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
75744231|NCT00832013|Drug|Propofol|See detailed description
75744232|NCT00832013|Drug|Propofol|See detailed description
75892972|NCT02942927|Other|Medication reduction|Systematic approach to reduction in polypharmacy.
75892973|NCT02936024|Procedure|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
75744233|NCT00824759|Other|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
75449348|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
75892974|NCT02936024|Procedure|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
75449349|NCT01380938|Drug|Peginterferon alpha-2a + Ribavirin|"Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight < or > 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)"
75449350|NCT01374516|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
75449351|NCT01374516|Biological|Placebo: (NaCl) 0.9% solution|0.5 mL, Subcutaneous
75449352|NCT01373281|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
75449353|NCT01373281|Biological|Placebo: Sodium chloride (NaCl) 0.9%|0.5 mL, Subcutaneous
75449354|NCT01340105|Procedure|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
75600308|NCT01218867|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
75600309|NCT01018264|Drug|solifenacin succinate (VESIcare)|up to 10mg every day orally
75600310|NCT01018264|Drug|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
75600311|NCT04318899|Behavioral|Dialectical Behaviour Therapy adapted for adolescents (DBT-A)|DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus & Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.
75744234|NCT00832169|Drug|AZD1386|1 dose of oral solution
75744235|NCT00824837|Other|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
75744236|NCT00824837|Other|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
75744237|NCT00832247|Genetic|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
75744238|NCT00832403|Other|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
75744239|NCT02550041|Other|T specific response for diagnostic of aspergillus bronchitis|
75744240|NCT00832481|Drug|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
75744241|NCT00832481|Drug|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
75892975|NCT02910700|Drug|Binimetinib|Given PO
75892976|NCT02910700|Drug|Dabrafenib|Given PO
75892977|NCT02910700|Drug|Encorafenib|Given PO
75892978|NCT02910700|Other|Laboratory Biomarker Analysis|Correlative studies
75892979|NCT02910700|Biological|Nivolumab|Given IV
75892980|NCT02910700|Other|Pharmacological Study|Correlative studies
75892981|NCT02910700|Drug|Trametinib|Given PO
76062512|NCT01091831|Drug|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
76062513|NCT01091831|Drug|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
76062514|NCT01091831|Drug|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
76062515|NCT01091831|Drug|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
76062516|NCT00481546|Genetic|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
76062517|NCT00093834|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
76062518|NCT00093834|Drug|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
76062519|NCT00093834|Drug|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
75744242|NCT04044287|Drug|200 micrograms of misoprostol|200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
75600312|NCT04318899|Behavioral|Dialectical Behaviour Therapy - Standard version (DBT)|DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.
76062520|NCT01550289|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
76062521|NCT01550289|Biological|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
76062522|NCT04277026|Behavioral|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
76062523|NCT04108143|Device|MonitorMe|MonitorMe replaces the users existing telephone and for the majority of time is used as their ordinary telephone. At a known and set time of day for 4 weeks, participants will receive an automated MonitorMe telephone call. The participant answers a health and well-being automated script by pressing key pad numbers. At the same time vital signs data are collected. The responses and vital signs data, together with confidence values are then transmitted via telephone lines to an electronic patient record.
75600313|NCT01018186|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
75600314|NCT01018186|Drug|Fluticasone propionate|Inhaled corticosteroid
75600315|NCT00987337|Drug|Filibuvir|300 mg BID
75600316|NCT00987337|Drug|Filibuvir|600 mg BID
75744243|NCT04044287|Drug|Placebo Oral Tablet|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
75600317|NCT00987337|Drug|Placebo|BID
75892982|NCT02876185|Other|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
76062524|NCT04107519|Behavioral|Goal-Directed Resilience Training|This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
76062525|NCT01968031|Drug|Istradefylline 40 mg|Istradefylline 40 mg and placebo
75744244|NCT00827801|Behavioral|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 & 8.
75892983|NCT02850575|Device|Mpact Double Mobility cup|
75449355|NCT01340105|Procedure|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
75449356|NCT01254422|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
75449357|NCT01254422|Biological|Placebo: NaCl 0.9%|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
75449358|NCT01204242|Drug|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
75449359|NCT01204242|Drug|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
75449360|NCT01187433|Biological|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
75449361|NCT01187433|Biological|NaCl 0.9%|0.5 mL, Subcutaneous
75449362|NCT01187433|Biological|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
75892984|NCT02763917|Device|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight.
75744245|NCT02549729|Behavioral|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
75892985|NCT02763917|Device|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
75892986|NCT02748408|Device|SMS femoral stem|
76062526|NCT01968031|Drug|Istradefylline 20 mg|Istradefylline 20 mg and placebo
76062527|NCT01968031|Drug|Placebo|Placebo
75744246|NCT00827879|Behavioral|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
75744247|NCT00827879|Behavioral|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
75744248|NCT00832559|Biological|CVA21|1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals.
75744249|NCT02549807|Device|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
76062528|NCT01684215|Drug|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
76062529|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
76062530|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
75449363|NCT01187433|Biological|Meningococcal A+C vaccine|0.5 mL, Intramuscular
75449364|NCT01150045|Drug|celecoxib|Patients receive celecoxib 400 mg administered by mouth, once daily.
75449365|NCT01150045|Drug|5-fluorouracil|Patients receive 400 mg/m^2 intravenous bolus then 2400 mg/m^2 continuous intravenous infusion over 46-48 hours.
75449366|NCT01150045|Other|placebo|Patients receive placebo administered by mouth, once daily.
75449367|NCT01150045|Drug|oxaliplatin|Patients receive 85 mg/m^2 intravenous over two hours.
75449368|NCT01150045|Drug|leucovorin|Patients receive 400 mg/m^2 intravenous over two hours.
75463160|NCT01872533|Other|Hypoxia Exposure|Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at ~ 15% O2 (ca. 2400 m elevation).
75463161|NCT01872546|Drug|HUMIRA 40mg|
75463162|NCT01872559|Other|3D Sonography analysis|Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
76062531|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
76062532|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
76062533|NCT01908205|Drug|Intranasal Oxytocin|
76062534|NCT01908205|Drug|Placebo|
76062535|NCT01549041|Drug|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
76062536|NCT01549041|Drug|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
75600318|NCT00992407|Drug|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
75449369|NCT01098032|Device|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate >300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
75463163|NCT01872572|Drug|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
75600319|NCT00992407|Drug|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
75600320|NCT00986479|Drug|AZD6765|Single IV infusion of 150 mg AZD6765.
75600321|NCT00986479|Drug|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
75744250|NCT03856307|Diagnostic Test|point of care ultrasound|to evaluate the reliability of simple pre-specified ultrasound findings acquired at the bedside with a hand-held apparatus with regards to five clinical scenarios most commonly encountered in the hospital, i.e. vaginal bleeding in early pregnancy, pre-eclampsia, prolonged/obstructed labor, antepartum hemorrhage (APH) and high risk pregnancies encountered in ANC.
75744251|NCT00357370|Drug|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
75892987|NCT02603562|Biological|ATYR1940|Concentrate for solution for infusion
75892988|NCT02586727|Drug|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
75892989|NCT02579239|Biological|ATYR1940|Concentrate for solution for infusion
76062537|NCT01907815|Drug|Akt Inhibitor GSK2141795|Given PO
76062538|NCT01907815|Other|Laboratory Biomarker Analysis|Correlative studies
76062539|NCT01907815|Drug|Trametinib|Given PO
76062540|NCT01548573|Drug|Dexamethasone|Given PO
76062541|NCT01548573|Procedure|Tandem autologous stem cell transplant|
76062542|NCT01548573|Drug|Cisplatin|Given IV
75463164|NCT01872572|Drug|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
75600322|NCT00986245|Drug|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
75600323|NCT00989833|Drug|budesonide|400 yg x 1
75600324|NCT00989833|Drug|terbutaline|0.4 mg as-needed
75744252|NCT00357370|Drug|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
75744253|NCT00832715|Procedure|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
75744254|NCT00825071|Drug|Dexamethasone|8 mg, Intravenous
75600325|NCT00989833|Drug|budesonide/formoterol|160/4.5 yg as-needed
75600326|NCT04292119|Drug|Lorlatinib|"Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days."
75600327|NCT04292119|Drug|Crizotinib|"Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days."
75744255|NCT00825071|Drug|Ondansetron|4 mg, intravenously
75744256|NCT00825071|Drug|normal saline|2 ml, intravenously
75892990|NCT02579239|Biological|Placebo|Concentrate for solution for infusion
76062543|NCT01548573|Drug|Doxorubicin|Given IV
76062544|NCT01548573|Drug|Cyclophosphamide|Given IV or PO
76062545|NCT01548573|Drug|Etoposide|Given IV
76062546|NCT01548573|Drug|Bortezomib|Given IV
76062547|NCT01548573|Drug|Thalidomide|Given PO
76062548|NCT01548573|Drug|Melphalan|Given IV
76062549|NCT01907737|Other|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
76062550|NCT01907737|Other|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
76062551|NCT01907737|Other|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
76062552|NCT01907737|Other|Sham PNS|No current will be delivered to the radial, ulnar and median nerves.
76062553|NCT01570491|Other|ultrasound-guided spinal anesthesia|ultrasound-guided technique for block placement
76062554|NCT01570491|Other|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
75892991|NCT02567201|Other|electrophysiological evaluation|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience
75892992|NCT02567201|Other|electrophysiological evaluation of patients|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
75892993|NCT02555358|Drug|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
75892994|NCT02555358|Drug|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
75892995|NCT02532231|Other|Laboratory Biomarker Analysis|Correlative studies
75892996|NCT02532231|Biological|Nivolumab|Given IV
75892997|NCT02497365|Drug|Besifloxacin|
76062555|NCT04118517|Other|Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults|The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing >50% of the protein.
76062556|NCT04117425|Biological|biological collection|"Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption."
75892998|NCT02497365|Drug|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
75892999|NCT02476396|Procedure|Carotid Endarterectomy or Stenting|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing."
76062557|NCT01929109|Drug|LY2409021|Administered orally
76062558|NCT01518153|Drug|Fludarabine|40 mg/m^2 by vein on Day -6 to -3.
76062559|NCT01518153|Drug|Melphalan|140 mg/m^2 by vein on Day -2.
76062560|NCT01518153|Drug|Alemtuzumab|50 mg by vein on Day -1.
75744257|NCT00827957|Device|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
76062561|NCT01518153|Procedure|Stem Cell Infusion|Reduced intensity stem cell transplant on Day 0.
75449370|NCT01098032|Drug|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
75449371|NCT01034306|Drug|CF101|orally q12h
76062562|NCT01518153|Drug|Tacrolimus|0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
75449372|NCT01034306|Drug|Placebo control|orally q12 hours
75449373|NCT01013857|Behavioral|Health coaching|Calling patients every week to discuss medication adherence
75449374|NCT01013857|Behavioral|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
75744258|NCT00827957|Device|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
75744259|NCT03987724|Other|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise|Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
75449375|NCT00993447|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
75600328|NCT04292119|Drug|Binimetinib|Binimetinib will be taken orally twice daily for 28 days.
75744260|NCT00574847|Drug|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
75744261|NCT00574847|Drug|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
75744262|NCT00348790|Drug|vatalanib|
75893000|NCT02458690|Behavioral|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
75893001|NCT02458690|Behavioral|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
75893002|NCT02458690|Drug|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.
75893003|NCT02458690|Other|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their Eskenazi Health primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
75893004|NCT02446457|Other|Laboratory Biomarker Analysis|Correlative studies
75893005|NCT02446457|Drug|Lenalidomide|Given PO
75893006|NCT02446457|Biological|Pembrolizumab|Given IV
75449376|NCT00993447|Biological|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
75449377|NCT00945009|Biological|Dactinomycin|Given IV
75449378|NCT00945009|Drug|Doxorubicin Hydrochloride|Given IV
75449379|NCT00945009|Radiation|Radiation Therapy|Undergo radiation therapy
75449380|NCT00945009|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
75893007|NCT02446457|Biological|Rituximab|Given IV
75893008|NCT02445222|Genetic|Previously treated CAR-T patients|Lentiviral-based CAR-T cell therapy
75893009|NCT02415621|Drug|Abiraterone Acetate|1000 mg by mouth (PO) every day (QD)
75893010|NCT02404402|Other|LED|Low Level Light Therapy
75893011|NCT02404402|Other|sham LED|Inactive (sham) LED treatment
76062563|NCT01518153|Drug|Methotrexate|5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
75449381|NCT00945009|Drug|Vincristine Sulfate|Given IV
75449382|NCT00942877|Drug|AZD2171|Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS).
75600329|NCT04292119|Drug|TNO155|TNO155 will be taken orally once daily for 14 days.
75600330|NCT01218477|Drug|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
75600331|NCT01218477|Drug|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
75600332|NCT04318509|Dietary Supplement|GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
75744263|NCT00828035|Procedure|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
75744264|NCT00825149|Drug|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
75893012|NCT02369562|Procedure|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
75893013|NCT02339909|Behavioral|Fixed financial incentive|"Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment."
75893014|NCT02339909|Behavioral|Probabilistic financial incentive|"Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment."
75893015|NCT02339909|Behavioral|Control|"Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter."
75893016|NCT02336217|Other|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
75893017|NCT02336217|Other|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
75893018|NCT02308280|Drug|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
75893019|NCT02257853|Other|Stress reduction intervention|Gentle chair yoga and breath work
75893020|NCT02210715|Drug|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
75893021|NCT02210715|Other|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
75893022|NCT02124421|Procedure|Cytoreductive Surgery (CRS)|Cytoreductive surgery
75893023|NCT02124421|Drug|Adjuvant Chemotherapy|Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
75893024|NCT02124421|Other|Questionnaire|Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
75600333|NCT01218243|Device|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
75744265|NCT00825149|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
75449383|NCT00896389|Procedure|Salt loading|Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will be taken every 15 minutes during this procedure. Blood and urine samples will be collected from all subjects pre- and post-infusion.
75893025|NCT02124421|Procedure|Hyperthermic intraperitoneal chemotherapy|Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
75463165|NCT01872572|Drug|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
75600334|NCT00989287|Biological|GSK2340272A|Two intramuscular injections in the deltoid region of the non-dominant arm.
75893026|NCT02124421|Drug|Carboplatin|AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
75744266|NCT00825149|Drug|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
75893027|NCT02124421|Drug|Paclitaxel|175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
75893028|NCT02124421|Drug|Paclitaxel|Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
75600335|NCT00989287|Biological|GSK2340269A|Two intramuscular injections in the deltoid region of the non-dominant arm.
75744267|NCT00825149|Drug|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
75744268|NCT00825149|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
75600336|NCT01218087|Device|Cranial cup device and Moldable positioner|The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants
75600337|NCT01218087|Device|Moldable positioner device|This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
75744269|NCT00825149|Drug|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
75744270|NCT00825149|Drug|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
75744271|NCT00825383|Other|High Fiber and Moderate Fiber Diets|Dietary
75744272|NCT00360490|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
75744273|NCT00360490|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
75744274|NCT02549105|Drug|EMLA CREAM 5 mg|EMLA CREAM APPLICATION FOR WOUND AFTER CS
75744275|NCT02549105|Drug|LIDOCAINE 1 %|LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
75600338|NCT04291339|Procedure|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
75600339|NCT04291339|Procedure|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
75600340|NCT01218009|Drug|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
75600341|NCT01218009|Drug|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
75600342|NCT04291183|Behavioral|horticultural therapy|Flowers and vegetables will be planted with the elderly. Growth of plants planted with the elderly will be observed and maintained
75600343|NCT04291417|Diagnostic Test|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
75600344|NCT00992017|Biological|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
75600345|NCT01217463|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
75744276|NCT00828269|Procedure|Comparator: Fine needle aspiration biopsy|"Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit"
75744277|NCT00833183|Drug|MAL|80 mg/g cream one administration with incubation for 90 minutes
75744278|NCT00624377|Drug|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
75744279|NCT02549963|Device|WATCHMAN Left Atrial Appendage Occlusion Device|
75893029|NCT02124421|Drug|Cisplatin|Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
75893030|NCT02081378|Drug|Asciminib (ABL001)|Asciminib will be administered orally in a dose escalation schedule.
75893031|NCT02081378|Drug|Nilotinib|Asciminib and Nilotinib will be administered orally in CML patients
75893032|NCT02081378|Drug|Imatinib|Asciminib and imatinib will be administered orally in CML patients
75893033|NCT02081378|Drug|Dasatinib|Asciminib and dasatinib will be administered orally in CML patients
75893034|NCT02076113|Procedure|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
75893035|NCT02076113|Procedure|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
75893036|NCT02076113|Procedure|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
75893037|NCT01989143|Drug|PF-06480605|Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
75600346|NCT02868151|Drug|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
75600347|NCT02868151|Drug|Zinc acetate|Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
75744280|NCT02549963|Drug|Rivaroxaban|
75600348|NCT01217307|Drug|Metformin|Metformin 500mg twice daily during 4 months
75600349|NCT01217307|Drug|Placebo|Placebo twice daily during 4 months
75600350|NCT02868073|Biological|VXA-G1.1-NN (high dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.
75600351|NCT02868073|Other|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
75744281|NCT00624065|Drug|carvedilol controlled release/lisinopril|carvedilol CR + lisinopril given as separate pills
75744282|NCT00624065|Drug|lisinopril + placebo|lisinopril plus placebo to match carvedilol CR
75744283|NCT00360412|Drug|E2007|
75744284|NCT00623831|Biological|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
75744285|NCT00833339|Drug|mifepristone|600 mg/day x 1 week
75744286|NCT00833339|Drug|placebo|placebo
75893038|NCT01989143|Drug|Placebo|Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
75893039|NCT01989143|Drug|PF-06480605|Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
75893040|NCT01989143|Drug|Placebo|Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
75449384|NCT00896389|Drug|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects. After overnight fasting and having their height, weight, and BP measured, subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. Ambulatory blood pressure will be measured and blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will repeat the 7-day HCTZ intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
75600352|NCT02868073|Biological|VXA-G1.1-NN (low dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
75744287|NCT02549885|Other|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
75744288|NCT02549885|Other|Static stretching|Static stretching of neck muscles.
75893041|NCT01989143|Drug|PF-06480605|Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
75893042|NCT01989143|Drug|Placebo|Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
75449385|NCT00880893|Biological|CYD Dengue vaccine|0.5 mL, Subcutaneous on Day 0, Months 6 and 12
75449386|NCT00880893|Biological|NaCl + influenza virus or hepatitis A vaccine|0.5 mL, Subcutaneous (Intramuscular - Hepatitis A)
75449387|NCT00875901|Radiation|Peripherally located lung tumor|12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
75449388|NCT00875901|Radiation|Centrally located lung tumor|6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
75600353|NCT01217229|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
75600354|NCT04318743|Drug|Glepaglutide|GLP-2
75744289|NCT00825617|Drug|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
75744290|NCT00825695|Dietary Supplement|cocoa|two servings of cocoa daily for one month
75744291|NCT00360334|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
75744292|NCT00360334|Drug|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
75744293|NCT00422097|Drug|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
75744294|NCT00422097|Drug|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
75893043|NCT01927250|Behavioral|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
75893044|NCT01914900|Drug|docetaxel, cisplatin, 5 fluorouracil|
75893045|NCT01742299|Drug|imatinib mesylate|Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
75893046|NCT01703455|Drug|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
76062564|NCT01518153|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
75449389|NCT00779961|Procedure|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
75449390|NCT00779961|Procedure|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
75449391|NCT00770380|Behavioral|behavioral relapse prevention counseling|Behavioral relapse prevention counseling conducted in two one-hour sessions
75600355|NCT01013740|Drug|Vinorelbine|Vinorelbine
75600356|NCT01013740|Drug|Lapatinib|Lapatinib
75600357|NCT01013740|Drug|Capecitabine|Capecitabine
75600358|NCT02872246|Drug|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
75744295|NCT00422097|Drug|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
75600359|NCT02872246|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
75449392|NCT00770380|Other|hypnosis for relapse prevention|Hypnosis for relapse prevention conducted in two one-hour sessions
75600360|NCT00627874|Device|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
75744296|NCT00422097|Drug|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
75744297|NCT00422097|Drug|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
75744298|NCT00422097|Drug|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
75744299|NCT00422097|Drug|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
75744300|NCT00422097|Drug|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
75744301|NCT02534194|Other|Image acquisition|Images of baby's face (including ear) and feet
75744302|NCT01051102|Drug|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
75744303|NCT01051102|Drug|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
75744304|NCT01053364|Device|NL-Prow interspinous spacer implant|Interspinous spacer implant
75449393|NCT00587301|Device|Lap-Band|Obesity and adolescents
75449394|NCT00579527|Biological|Cultured Thymus Tissue for Implantation (CTTI)|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
75463166|NCT01872572|Drug|Subcutaneous RB006 2.0 mg|"Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
75744305|NCT00348556|Drug|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
75744306|NCT00434967|Drug|Candesartan cilexetil|32 mg oral tablet
75744307|NCT00434967|Drug|Hydrochlorothiazide|25 mg oral tablet
75744308|NCT00434967|Drug|Candesartan/HCT 32/25 mg|
76062565|NCT01518153|Procedure|Low Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64.
76062566|NCT01518153|Procedure|High Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64.
75893047|NCT01701674|Drug|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
76062567|NCT01906489|Drug|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
76062568|NCT01906489|Drug|Placebo|Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
75463167|NCT01872572|Drug|Placebo|Placebo
75463168|NCT01872585|Behavioral|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
75463169|NCT01872624|Procedure|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
75463170|NCT01872637|Behavioral|Progressive Multi-Component Intervention|
75463171|NCT01872637|Behavioral|Usual Care|
75744309|NCT00825773|Device|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
75744310|NCT00833729|Drug|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
75744311|NCT00837239|Drug|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
76062569|NCT04620343|Procedure|A: Breathing advice with bio-feedback|Information and breathing advice with biofeedback will serve as an active comparator in this study, and time allowed for IBA and biofeedback in this study will be max 30 min. The teaching will be provided by the attending physician and the test leader. The session will follow a strict checklist. After the laryngoscope has been secured in correct position the patient will be shown his/her larynx on the screen, providing the patient with basic knowledge on laryngeal anatomy and function in a calm atmosphere before the CLE-test. After, the patients will be trained to make any symptoms abate, and a good breathing posture and how to optimally use their breathing muscles.
75744312|NCT00837239|Drug|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
75744313|NCT00837239|Drug|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
75744314|NCT00833807|Drug|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
76062570|NCT04620343|Procedure|B: Breathing advice with bio-feedback, Inspiratory muscle training (IMT)|Breathing advise and IMT. The inspiratory muscle training (IMT) will build on the information the patients have obtained during the IBA and biofeedback session. The IMT will focus on training endurance and coordination of the PCA muscle, aiming to reduce fatigue of the abducting capacity of the larynx and to enhance coordination and create a sense of laryngeal control. When performing the IMT sessions, it is of utmost importance that a functional diaphragmatic breathing pattern has been established, and that this breathing pattern is maintained throughout all the IMT sessions. Once the patient has demonstrated that he/she is able to perform breathing according to these principles, the IMT session will follow a detailed protocol while wearing a flexible laryngoscope and settings and techniques are adjusted to ensure max open larynx. The patient will perform IMT training at home as instructed and have video meetings one and three weeks after initial training to observe progress.
75744315|NCT00833885|Device|Masks|Wearing of surgical masks
75744316|NCT00833885|Device|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
75744317|NCT00833885|Other|Control|General information about virus transmission in households and basic means to prevent it
75893048|NCT01701674|Procedure|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging [MRI] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
75893049|NCT01701674|Drug|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
76062571|NCT04620343|Procedure|C: Breathing advice with bio-feedback, Speech Therapy|The training period with the speech therapist takes three days, divided into 6 sessions. The training is continued at home, implementing the techniques during physical activity and at rest. The aim of the speech therapy is to help the patients to develop a strategy on how to control his/her larynx during exercise, and to be able to continue exercising without experiencing dramatic EILO incidents. They will be informed that the best approach is to start practicing while performing low to moderate intensity exercise, and then gradually increase the intensity as they become more confident. It will be emphasized that the new breathing technique they are about to adopt will need to be repeated until it becomes adapted as a part of their automated breathing pattern. Patients will be followed up with video meetings one and three weeks after initial training to observe progress.
75744318|NCT00833963|Drug|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
76062572|NCT04620343|Procedure|D: Breathing advice with bio-feedback, IMT and Speech Therapy|All treatments as described above.
76062573|NCT04620343|Procedure|A: If CLE-test unchanged, additional IMT and Speech Therapy|All treatments as described above.
75463172|NCT01872650|Device|C-Qur|In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
75463173|NCT01872663|Procedure|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
75600361|NCT04299256|Behavioral|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
75600362|NCT01018030|Drug|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
75600363|NCT01018030|Drug|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
75893050|NCT01701674|Drug|Cyclophosphamide as Part of Lymphodepletion|
75893051|NCT01701674|Drug|Fludarabine as Part of Lymphodepletion|
75893052|NCT01701674|Drug|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
75600364|NCT01018030|Drug|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
75744319|NCT00833963|Drug|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
75744320|NCT00833963|Drug|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
75744321|NCT00837317|Dietary Supplement|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
75744322|NCT04043897|Drug|Rifaximin 550mg|Rifaximin 550mg
75893053|NCT01701674|Biological|Adoptive Cell Therapy with TIL|
75893054|NCT01599559|Other|observation|observation
75893055|NCT01599559|Radiation|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
75893056|NCT01586910|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
75893057|NCT01586910|Procedure|Surgical Aortic Valve Replacement (SAVR)|
75893058|NCT01586910|Device|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
75893059|NCT01496976|Drug|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
75893060|NCT01496976|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
75893061|NCT01496976|Drug|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
75893062|NCT01438034|Drug|kisspeptin 112-121|0.24 nmol/kg
75893063|NCT01438034|Drug|GnRH|75 ng/kg
75893064|NCT01409161|Drug|Arsenic Trioxide|Given IV
75893065|NCT01409161|Drug|Gemtuzumab Ozogamicin|Given IV
75893066|NCT01409161|Other|Laboratory Biomarker Analysis|Correlative studies
75893067|NCT01409161|Drug|Tretinoin|Given PO
75893068|NCT01401907|Other|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
75893069|NCT01140516|Drug|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
75893070|NCT01140516|Other|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
75893071|NCT01138020|Behavioral|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
75893072|NCT01138020|Behavioral|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
75893073|NCT01068210|Behavioral|Exercise Training|The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (~70%-100% VO2peak / ~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
75893074|NCT01068210|Behavioral|Progressive Stretching|The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
76072106|NCT03190863|Behavioral|Motor imagery (MI)|"7 individuals with C6-C7 tetraplegia randomized in the active comparator group consisting in motor imagery practice alone without visual NF. This means that the performance of the imagined movement is not displayed to the participants.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
75449395|NCT00579527|Other|Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation|For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
75449396|NCT00579527|Procedure|Blood Draw|Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.
75463174|NCT01872663|Procedure|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
75600365|NCT01217073|Drug|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
75600366|NCT01217073|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
75600367|NCT01217073|Drug|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
75744323|NCT00356590|Biological|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
75744324|NCT04043663|Device|Virtual Reality glasses|Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
75744325|NCT04043663|Procedure|standard perioperative care without virtual reality program|standard perioperative care without virtual reality program
75744326|NCT00837551|Drug|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
75744327|NCT00834353|Drug|ATT|
75744328|NCT03987334|Other|Virtual Reality Treatment|Experimental Group (VRT) subjects will undergo Virtual Reality Motor Control exercises based on augmented feedback of their performance.
75744329|NCT03987334|Other|Control Group|Control Group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
75600368|NCT01217073|Drug|Metformin|Metformin 500 mg oral tablet administered once or twice daily
75600369|NCT01217073|Drug|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
75893075|NCT00984399|Drug|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
75893076|NCT00775476|Drug|N-acetylcysteine|Capsules of NAC, each containing 600 mg of NAC between dosages of 2.4 g to 4.8 g daily
75893077|NCT00775476|Drug|Placebo|placebo (sugar) twice daily, daily dosage will match that of NAC that was tolerated between daily dosages of 2.4 g and 4.8 g during the open-label titration phase.
75449397|NCT00579527|Drug|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
75463175|NCT01872663|Procedure|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
75893078|NCT02915016|Biological|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
75893079|NCT02915016|Biological|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
75893080|NCT02915016|Biological|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
75893081|NCT02915016|Biological|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
75600370|NCT00985621|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
75893082|NCT03859414|Drug|Therapeutic Dose 1|CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
75893083|NCT03859414|Drug|Therapeutic Dose 2|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
75893084|NCT03859414|Drug|Supra-therapeutic Dose|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
75893085|NCT03859414|Drug|Placebo|CHF 5993 placebo pMDI
75893086|NCT01170650|Drug|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
75893087|NCT01170650|Drug|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
75893088|NCT01170650|Drug|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
75893089|NCT01170650|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
75893090|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
75893091|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
75893092|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
75893093|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
75600371|NCT00985621|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
75893094|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
75893095|NCT01168310|Drug|Formoterol Fumarate|Inhalation Solution
75893096|NCT01168310|Drug|Placebo|Inhalation Solution
75893097|NCT04464928|Other|Facebook Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Facebook Ads when triggered by user characteristics indicating elevated risk of female urinary incontinence.
75600372|NCT00985621|Drug|oxycodone|oxycodone CR, 10-40 mg q12h
75600373|NCT00985621|Other|placebo|placebo
75600374|NCT01215981|Biological|Influenza vaccine|One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
75600375|NCT01215981|Biological|Influenza vaccine|Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
75600376|NCT02887833|Other|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
75600377|NCT01215513|Drug|Degarelix|
75600378|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
76062574|NCT04620343|Procedure|Surgery 1: Supraglottoplasty - full procedure under general anesthesia|Endoscopic supraglottoplasty with carbon dioxide laser and cold steel microlaryngeal instruments. The patient is intubated with an armored laser-tube which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot is utilized. Releasing incisions are made at the anterior border of both AEFs. The depth of the incisions are limited to the cranial border of the ventricular folds. The cuneiform tubercles including their surrounding mucosa are removed in a circular pattern before the two incisions are adjoined, thus creating a drop shaped excision. Care is taken to avoid scarring. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. In case of perioperative edema of the laryngeal mucosa, corticosteroids are administrated to prevent laryngeal edema post-operatively.
76062575|NCT04620343|Procedure|Surgery 2: Supraglottoplasty - mini-invasive procedure under general anesthesia|"Endoscopic supraglottoplasty with carbon dioxide laser. The patients are intubated with an armored laser-tube, which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope (Benjamin/Lindholm) is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot are utilized. Four punctures will be made along the lateral borders of both aryepiglottic folds bilateral, thus creating a row of small punctures parallel to the rim of the aryepiglottic folds. The punctions should not be deeper than the incision in the full procedure (above); i.e. less than 5 millimeter, and care must be taken to avoid heat affecting the nervus recurrens posteriorly. Care is taken to avoid scarring and collateral thermal injury. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. No antibiotic prophylaxis is administered."
76062576|NCT01517373|Drug|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
75744330|NCT02548871|Behavioral|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
75893098|NCT04464928|Other|Google Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Google Ads when triggered by keywords relevant to female urinary incontinence.
75893099|NCT01472198|Drug|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
75744331|NCT03987256|Other|Initial rehabilitation protocol|During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
75893100|NCT01472198|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
75893101|NCT01472198|Drug|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
75893102|NCT04575610|Drug|PF-06650833|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric [NG] tube, orogastric [OG] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
75893103|NCT04575610|Drug|Placebo|Matching placebo tablets will be administered.
75893104|NCT02269358|Drug|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
75893105|NCT04504240|Drug|Famotidine 20 MG|Famotidine; tablet Famotac 20mg oral form.
75893106|NCT02266550|Drug|[14C] BILL 284 BS|
75893107|NCT04464304|Device|Smartphone|Patients will participate in a similar game to the VR cohort, but will use a smartphone device.
75893108|NCT04464304|Device|Virtual Reality (Oculus Quest)|Patients will participate in a game using VR.
75600379|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
75600380|NCT01215357|Drug|Ecopipam|50mg tablets
75600381|NCT05433441|Procedure|ESPark Intervention|The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
75600382|NCT00984295|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
75600383|NCT00984295|Biological|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
75893109|NCT02269436|Drug|sNN0029 infusion solution|4 µg/day, continuous i.c.v administration
75893110|NCT02264522|Other|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
75893111|NCT02264522|Other|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
75893112|NCT02264522|Other|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
75893113|NCT02264522|Other|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
75893114|NCT02084316|Behavioral|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
75893115|NCT02084316|Behavioral|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
75893116|NCT02269514|Other|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
75893117|NCT02269514|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
75893118|NCT02269514|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
75893119|NCT02269514|Other|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
75893120|NCT02269514|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
75893121|NCT03465982|Procedure|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
75893122|NCT03465982|Procedure|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
75893123|NCT01332812|Drug|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
75893124|NCT01332812|Other|control group|General anesthesia, without additional interventions
75893125|NCT02079792|Procedure|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
75893126|NCT02079792|Procedure|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
75893127|NCT03408652|Drug|denosumab|Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
75893128|NCT01332656|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
75893129|NCT01332656|Drug|Placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
75600384|NCT00984295|Biological|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
75600385|NCT00984295|Biological|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
75600386|NCT00984295|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
75600387|NCT04291027|Other|Land Based Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
75600388|NCT04291027|Other|Aquatic Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
75744332|NCT03987256|Procedure|Needling with PRP|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
75744333|NCT03987256|Procedure|Needling with saline solution|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
75744334|NCT00828503|Drug|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
75744335|NCT00828503|Drug|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
76062577|NCT01517373|Drug|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
75744336|NCT03990220|Dietary Supplement|Lactobacillus rhamnosus yoba 2012|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug."
75744337|NCT03990376|Other|Radioisotope I-131-labeled albumin|1 mL of radioisotope I-131-labeled albumin x 2
75744338|NCT00834509|Device|CPAP|Use CPAP for 4-6 weeks as clinically prescribed.
75744339|NCT01051180|Procedure|HALO|Ligation of haemorrhoidal arteries
75744340|NCT04322825|Device|TENS incorporated into the Mollii suit|trans cutaneous electric stimulation,
75744341|NCT03990142|Diagnostic Test|Cutaneous conductance to chlorine by SUDOSCAN|"The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®."
75893130|NCT01332656|Drug|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
75893131|NCT01332656|Drug|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
75893132|NCT02084472|Other|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
75893133|NCT02084472|Other|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
75893134|NCT02084472|Other|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
75893135|NCT02266784|Behavioral|Contingency Management (CM)|
75893136|NCT02266784|Drug|Transdermal nicotine skin patches (i.e. Habitrol)|
75893137|NCT02266784|Other|Supportive Counseling|
75893138|NCT02090790|Drug|iv dexamethasone|2 ml 8 mg iv dexamethasone
76062578|NCT01517373|Drug|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
76062579|NCT01517373|Drug|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
76062580|NCT01517373|Drug|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
75600389|NCT00628186|Device|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
75744342|NCT00834665|Biological|hTERT vaccine, GM-CSF, PCV, T cell infusion|hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
75449398|NCT00579527|Drug|Cyclosporine|"In addition to RATGAM, subjects with typical cDGA with PHA responses >50,000 cpm, or atypical cDGA with PHA response <75,000cpm (when not on immunosuppression) or <40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol."
75449399|NCT00579527|Drug|Tacrolimus|If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
75600390|NCT00628186|Device|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
75600391|NCT01017952|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
75600392|NCT01017952|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder
75600393|NCT01214655|Drug|LY2523355|Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
75893139|NCT02090790|Drug|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
75600394|NCT01017874|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
75600395|NCT01017874|Drug|Cisplatin|75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
75600396|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
75744343|NCT00834665|Biological|GM-CSF, PCV, T cell infusion|Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
76062581|NCT01517295|Drug|Hydrocodone|Dose: Standard prescribed dose Frequency: Once Duration: Once
76062582|NCT01541865|Device|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
75744344|NCT01051258|Device|AeriSeal System|AeriSeal System for Lung Volume Reduction
75600397|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
75600398|NCT04299568|Device|Anti gravity treadmill training|Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes
75600399|NCT04299568|Procedure|Physical Therapy|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization
75744345|NCT00837707|Drug|aripiprazole|Flexible dose: 5-30 mg/day
75744346|NCT02548247|Dietary Supplement|Orafti® Inulin|Dietary fiber
75893140|NCT02090790|Drug|serum physiologic|2 ml iv serum physiologic
76062583|NCT01541397|Drug|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
75600400|NCT00627952|Drug|amlodipine 10 mg|amlodipine 10 mg once daily
75600401|NCT00627952|Drug|manidipine 20 mg|manidipine 20 mg once daily
75600402|NCT00627952|Drug|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
75744347|NCT02548247|Dietary Supplement|Placebo|Maltodextrin
75744348|NCT01055938|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
75744349|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally three times a day
75744350|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally twice a day
76062584|NCT04104321|Drug|Aramchol|Aramchol 300 mg BID
76062585|NCT04104321|Drug|Placebo|Placebo BID
76062586|NCT04104165|Device|Foley Catheter|Foley catheter used for treatment of urinary retention
76062587|NCT04103775|Behavioral|Cognitive Remediation|See Cognitive Remediation Arm description.
76062588|NCT04103775|Behavioral|Active Control|See Active Control Arm description.
76062589|NCT01548417|Drug|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
76062590|NCT01548417|Drug|Sugar Pill|600 mg/day, oral pill, 7 days
76062591|NCT01546857|Drug|Placebo|Normal Saline
76062592|NCT01546857|Drug|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
75893141|NCT04959916|Behavioral|Group Metacognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT) will consist of six weekly sessions delivered by two trained trainee clinical psychologists over 1-1.5 hours. The aims of the intervention are to help participants develop knowledge that can facilitate control of worry, rumination and attention, and to modify the metacognitive beliefs that maintain these unhelpful patterns of thinking. The treatment follows a manual that has been previously evaluated in the treatment of cardiac patients suffering from anxiety and depression. Sessions include group discussions, experiential learning and homework tasks that participants will be expected to complete between sessions.
76062593|NCT04767867|Other|Pre-oxygenation|"Induction of anaesthesia after 2mins 45 seconds of pre-oxygenation with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions commenced until study conclusion.~Positive pressure ventilation commenced at Sp02 92%. Failure to intubate the patient during the first minute of apnoea results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after one minute of apnoea, and every two minutes during the apnoeic period."
76062594|NCT01540851|Behavioral|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
76062595|NCT01540851|Other|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
76062596|NCT01516749|Drug|anakinra|Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
76062597|NCT01516437|Procedure|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
76062598|NCT01516437|Procedure|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
76062599|NCT01516437|Procedure|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
76062600|NCT01515423|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
76062601|NCT01515423|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
76062602|NCT01515423|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
76062603|NCT01515423|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
76062604|NCT01515423|Drug|Placebo (20% Intralipid)|Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
76062605|NCT01515423|Drug|PP1M 50 mg eq.|Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
75600403|NCT00627952|Drug|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
75600404|NCT04299334|Procedure|adjustable neochordae Technique|"Classic ring annuloplasty will be done using Carpentier or physio ring, then neochordal placement will be done using the looping technique. The length of the chordae is adjusted to achieve the optimal length.~In this study, Surgeons use relatively short loops because of the augmentation of the length with extra loops suspended with Gortex. Placement of at least 8-12 chordae of the corresponding heads of the papillary muscle tip to achieve proper management of the prolapse and longevity of the repair."
75449400|NCT00579527|Drug|Methylprednisolone or Prednisolone|Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells >4,000cumm. Steroids are weaned as per protocol.
75600405|NCT01015768|Device|ReNu Multiplus multipurpose disinfecting solution|A new lens (PureVision) soaked 6 hours to overnight in ReNu Multiplus
76062606|NCT01515423|Drug|PP1M 75 mg eq.|Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
76062607|NCT01515423|Drug|PP1M 100 mg eq.|Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
76062608|NCT01515423|Drug|PP1M 150 mg eq.|Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
75744351|NCT00356278|Drug|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
75744352|NCT00356278|Drug|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
75449401|NCT00579527|Drug|Daclizumab|In addition, subjects with Atypical DiGeorge with PHA responses >75,000cpm while on no immunosuppression or PHA responses >40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
75600406|NCT01015768|Device|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
75600407|NCT04426630|Other|mHealth for heart failure patients in Uganda|Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
75744353|NCT00356278|Behavioral|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
75744354|NCT00356278|Drug|Placebo|Placebo will be administered in the same manner as the active drugs.
75744355|NCT00837863|Drug|Somatropin|ALTU-238 0.3 mg/kg daily
75744356|NCT00837863|Drug|Somatropin|ALTU-238 0.6 mg/kg daily
75744357|NCT00837863|Drug|Somatropin|ALTU-238 0.9 mg/kg daily
75744358|NCT00837863|Drug|Somatropin|Nutropin AQ 0.043 mg/kg daily
76062609|NCT00637156|Device|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
75893142|NCT02084550|Dietary Supplement|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
75600408|NCT01010230|Device|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
75744359|NCT00834821|Behavioral|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
76062610|NCT00637156|Device|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
76062611|NCT00637000|Drug|Buprenorphine soluble film|Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
76062612|NCT00637000|Drug|Buprenorphine/naloxone film strip|Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
76062613|NCT00637000|Drug|Placebo|Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
76062614|NCT01515189|Biological|Ipilimumab|
75600409|NCT01010230|Device|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
76062615|NCT04767399|Behavioral|protaper next|rotary systems used on patients need root canal treatment
76062616|NCT01546623|Drug|TAP-144-SR(6M)|
75600410|NCT01009840|Drug|IV busulfan|PK-directed dosing of IV busulfan for 4 days
75744360|NCT00834821|Behavioral|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
75744361|NCT03991780|Drug|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
75744362|NCT02547389|Behavioral|Community support group|
75893143|NCT02084550|Other|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
75600411|NCT01009840|Drug|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m^2.
75744363|NCT02547389|Other|Printed material Supported|
75744364|NCT01051336|Device|TARIS Placebo|
75744365|NCT01051336|Procedure|Sham Procedure|
75893144|NCT04946110|Device|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
75893145|NCT01443728|Drug|Experimental: Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
75893146|NCT01443728|Drug|Active Comparator: Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
75893147|NCT02088138|Device|Functional Electrical Stimulation|Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
75744366|NCT00837941|Drug|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
75893148|NCT02088138|Device|Functional Electrical Stimulation placebo|Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
75893149|NCT05092048|Other|questionnaire|PHQ-9 and GAD-7 questionnaire
75744367|NCT00837941|Drug|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
75744368|NCT00837941|Drug|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
75744369|NCT01053442|Dietary Supplement|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
76062617|NCT01546623|Drug|TAP-144-SR(3M)|
76062618|NCT01546155|Radiation|PET imaging|Up to a 120 minute PET scan using [11C]diprenorphine as the radiotracer
76062619|NCT00636610|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
76062620|NCT00636610|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
75600412|NCT01009840|Procedure|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
75744370|NCT01053442|Dietary Supplement|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
75744371|NCT00828659|Drug|Placebo|
75744372|NCT00828659|Drug|Active Comparator #1|
75893150|NCT01324466|Drug|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
75893151|NCT01324466|Drug|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
75893152|NCT04740346|Diagnostic Test|Computed tomography, Chest X-ray, and blood test|CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
75600413|NCT04297696|Other|Therapeutic exercises|A program including warm-up period and neuromuscular exercises is applied progressively in two phases.
75600414|NCT04205500|Other|Specific carbohydrate diet|Specific carbohydrate diet (see arm description)
75600415|NCT04420936|Behavioral|MAINTAIN PRIME Lifestyle Coaching|Participants will receive two years patient support consisting of supportive coaching via EHR patient portal and tracking tools with EHR. Participants will also receive primary care physician (PCP) support with real time progress reports with counseling tips via EHR prior to visits, notification of weight changes greater or equal to 10 pounds, and annual PCP feedback.
75600416|NCT04420936|Behavioral|Control tracking|Participants will receive two years of patient support consisting of prevention updates via EHR patient portal and tracking tools within the EHR. Participants in this group will not receive primary care physician (PCP) support.
75600417|NCT04295980|Procedure|Surgical removal of the BAVMs|Resection the BAVM nidus by microsurgery.
75600418|NCT02872090|Drug|Indacaterol|inhalation
75600419|NCT02872090|Drug|Glycopyrronium|inhalation
75744373|NCT00828659|Drug|Active Comparator #2|
75744374|NCT00828659|Drug|Active Comparator #3|
75744375|NCT00828659|Drug|Lorcaserin Dose #1|
75744376|NCT00828659|Drug|Lorcaserin Dose #2|
75744377|NCT00828659|Drug|Lorcaserin Dose #3|
75744378|NCT00356200|Drug|Fluphenazine Decanoate|"Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym."
75744379|NCT00356200|Drug|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
75744380|NCT04044053|Drug|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
75744381|NCT04044053|Drug|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
75893153|NCT05479188|Device|Cerebral oximetry|Cerebral oximetry monitoring with near-infrared spectroscopy.
75893154|NCT05479188|Device|Peripheral oximetry|Tissue perfusion monitoring with somatic near-infrared spectroscopy.
75893155|NCT05479188|Device|Cerebral autoregulation|Cerebral autoregulation monitoring with COx.
75893156|NCT05479188|Device|Sublingual microscopy|Evaluation of microcirculation with sublingual microscopy.
75893157|NCT02090868|Other|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
75463176|NCT01872663|Procedure|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
75600420|NCT02872090|Drug|Tiotropium|inhalation
75893158|NCT01312454|Drug|AL-59412C injectable solution|Concentration 1 and Concentration 2
75893159|NCT01312454|Drug|Travoprost injectable solution|
75893160|NCT01312454|Drug|AL-59412C Vehicle|Inactive ingredients used as placebo
75893161|NCT01310114|Biological|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
75893162|NCT01310114|Drug|Placebo|Thawed placebo
75893163|NCT04090918|Diagnostic Test|Cardiac examination programme 3 months after abdominal surgery|Blood- and urine sampling, electrocardiogram, wavECG (Myovista), transthoracic echocardiography, Finapres, cardiac magnetic resonance imaging
75893164|NCT02088294|Behavioral|Lifestyle Education (LS)|See arm description
75893165|NCT02088294|Behavioral|LS + Stress Reduction Guided Imagery|See Arm Description
75893166|NCT02088294|Behavioral|LS + Activity/Eating Guided Imagery|See arm description
75463177|NCT01872663|Procedure|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
75463178|NCT01872663|Procedure|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
75463179|NCT01872676|Other|Spine manipulation|
75463180|NCT01872676|Other|Manipulation sham|
75744382|NCT04044053|Drug|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
75744383|NCT04044053|Drug|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
75744384|NCT00835289|Dietary Supplement|n-3 polyunsaturated fatty acids|Omax3[TM] (Cenestra Health [TM]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
75744385|NCT00835289|Other|Placebo|3 capsules of matching corn oil placebo
75744386|NCT00838019|Procedure|Intrabone administration of umbilical cord blood|Single administration
76062621|NCT00636610|Drug|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
75600421|NCT02872090|Drug|Placebo|
76062622|NCT00636610|Drug|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
75600422|NCT02872090|Procedure|photoplethysmography|inhalation
75744387|NCT02548091|Other|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
75893167|NCT01305824|Drug|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
75449402|NCT00579527|Drug|Mycophenolate mofetil|In addition, subjects with Atypical DiGeorge with PHA responses >75,000cpm while on no immunosuppression or PHA responses >40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
75744388|NCT02548091|Procedure|Non invasive ventilation|
75600423|NCT04514458|Other|Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
75744389|NCT02548091|Procedure|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
75744390|NCT02548091|Procedure|Computed tomography (CT)|
75744391|NCT00828737|Drug|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
75744392|NCT00356122|Drug|Docetaxel|70 mg/m^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
75744393|NCT00356122|Drug|Oxaliplatin|100 mg/m^2 administered IV on Day 1 for Cycles 1-6
75744394|NCT00356122|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
75744395|NCT01056094|Drug|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
75744396|NCT00838175|Procedure|suture mediated closure|Suture mediated closure of femoral venous access
75744397|NCT03989908|Other|Microfludic noodle|In this intervention arm, subjects will be served with noodles made using microfludic technology.
75893168|NCT01305824|Drug|Placebo|Placebo administered at the time of AVF creation.
75893169|NCT01305824|Drug|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
75449403|NCT01904123|Other|Laboratory Biomarker Analysis|Correlative studies
75744398|NCT03989908|Other|Control noodle|In this intervention arm, subjects will be served with normal noodle.
75744399|NCT00828815|Drug|TMC125|
75744400|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
75744401|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
75744402|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
75744403|NCT00838253|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
75744404|NCT00838253|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
75744405|NCT00838253|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
75744406|NCT00838253|Drug|Placebo|Placebo continuous i.v. infusion for 24 hours
75893170|NCT03323749|Combination Product|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
75744407|NCT00347932|Drug|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
75893171|NCT03323749|Combination Product|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
76062623|NCT00636610|Drug|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then fluorouracil 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
75449404|NCT01904123|Other|Pharmacological Study|Correlative studies
75449405|NCT01904123|Drug|STAT3 Inhibitor WP1066|Given PO
75463181|NCT01872702|Drug|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
75463182|NCT01872728|Drug|Bilateral facial block after general anesthesia before surgery|Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
75600424|NCT04282486|Other|Telephone interview|"Primary objective: potentially inappropriate medication prevalence~Secondary objective:~Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index~A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions."
75893172|NCT03323749|Combination Product|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
75893173|NCT02084784|Drug|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
75893174|NCT02084784|Drug|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
76062624|NCT01923220|Drug|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
76062625|NCT01923220|Other|Aloe Vera Jel|To be applied topically once daily
76062626|NCT00635050|Drug|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
76062627|NCT05240404|Drug|Toripalimab|toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
76062628|NCT05240404|Procedure|Thermal ablation|The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.
76062629|NCT01923376|Drug|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
76062630|NCT01923376|Drug|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
76062631|NCT05245786|Biological|Copper Cu 64 Anti-CEA Monoclonal Antibody M5A|Given IV
76062632|NCT05245786|Procedure|Imaging Technique|Undergo imaging
76062633|NCT00634504|Drug|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
75744408|NCT00347932|Drug|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
75449406|NCT00576836|Biological|Cultured Thymus Tissue Implantation (CTTI)|Thymus tissue (from unrelated donor), thymus donor, and thymus donor's birth mother screened for safety. CTTI was done under general anesthesia. Cultured thymus tissue was implanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not >18 grams/m2 body surface area (1.0 grams/kg body weight). At time of CTTI, skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy was done to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-CTTI, subjects followed by immune evaluations, using blood samples.
75463183|NCT01872741|Procedure|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
76062634|NCT00634504|Drug|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
76062635|NCT03101254|Drug|LY3022855|LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
75463184|NCT01872741|Procedure|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
75600425|NCT04296058|Other|microvessel density|the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
75744409|NCT03990688|Drug|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
75744410|NCT03990688|Drug|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
75744411|NCT00828893|Device|navigation station|navigation station for gestures (carried out under CT) guidance
75893175|NCT02266862|Radiation|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
75893176|NCT02091024|Dietary Supplement|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
75893177|NCT02091024|Dietary Supplement|Placebo|Placebo 200mg, twice a day
75893178|NCT03135236|Behavioral|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
75893179|NCT02084862|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
75893180|NCT02084862|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
75893181|NCT03240601|Device|Transcutaneous spinal stimulation|For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
75744412|NCT02548793|Other|Education: CPR Training via Mobile App|Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
75744413|NCT02548793|Other|Education: CPR Training using the CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
75744414|NCT02547701|Drug|P-3058|
75744415|NCT00828971|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
76062636|NCT03101254|Drug|Vemurafenib|Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
76062637|NCT03101254|Drug|Cobimetinib|Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
75893182|NCT03135080|Other|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
75893183|NCT03135080|Other|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
76062638|NCT04396054|Device|Lag Screws|Method of internal fixation
76062639|NCT04396054|Device|double Y-shaped plates|Method of internal fixation
76062640|NCT00634114|Drug|Esomeprazole|10mg once daily oral administration
76062641|NCT00634114|Drug|Esomeprazole|20mg once daily oral administration
76062642|NCT00634114|Drug|Omeprazole|10mg once daily oral administration
75449407|NCT00576836|Other|Cultured Thymus Tissue Implantation with Parathyroid Transplantation|Parental parathyroid donors screened for eligibility and safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most Human Leukocyte Antigens (HLA) alleles with thymus donor. Parathyroid harvest & transplant preferably done at same time as CTTI. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of CTTI.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced & placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
75600426|NCT04295746|Other|Serious Game ShopAut|"The serious game ShopAut, is a three-dimensional game conceptually based on classic 3D life simulation games. ShopAut aims to teach players the procedure of a shopping activity; to reinforce object categorization and recognition in a supermarket; to improve attention, orientation, and problem-solving skills; and to help the player engage in simple economic transactions.~The intervention provides a virtual training with ShopAut to train, experiment, and practice behaviours and actions that can be then transferred in real-life contexts."
75600427|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
75600428|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
75600429|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
75600430|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
75600431|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
75600432|NCT00982657|Drug|Sunitinib|50 mg sunitinib daily (4 out of 6 weeks)
75893184|NCT02091180|Drug|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
75893185|NCT02091180|Drug|Control|Saline infusion
76062643|NCT00634036|Drug|pioglitazone|pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
76062644|NCT00634036|Drug|placebo|matching placebo (inert tablet)
76062645|NCT05241496|Diagnostic Test|The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration|Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
76062646|NCT01545375|Biological|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
76062647|NCT01545375|Biological|Placebo|4 doses administered intramuscularly
76062648|NCT01545375|Biological|Prevnar 13®|4 doses administered intramuscularly
76062649|NCT01545375|Biological|PedvaxHIB®|4 doses administered intramuscularly
76062650|NCT04396912|Procedure|Total thyroidectomy|Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
76062651|NCT01539837|Drug|Deferiprone 20mg|20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
76062652|NCT01539837|Drug|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
76062653|NCT01539837|Drug|Deferiprone 30mg|30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
76062654|NCT01539759|Device|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
76062655|NCT04410081|Drug|14C-lazertinib|A single oral dose of 14C-lazertinib will be administered.
76062656|NCT03153124|Other|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
76062657|NCT01923610|Biological|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
75449408|NCT00576407|Biological|Cultured Thymus Tissue for Implantation (CTTI)|Cultured thymus tissue for implantation (CTTI) (previously described as transplantation) is done using allogeneic cultured postnatal tissue from unrelated thymus donors. Thymus tissue, the thymus donor, & thymus donor's birth mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were implanted into the recipient's quadriceps. Dose was number of grams of cultured thymus tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of CTTI, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-CTTI, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
75449409|NCT00543348|Procedure|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
75893186|NCT03949738|Diagnostic Test|Near-infrared spectroscopy-based assessement of cerebral autoregulation.|"Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation."
75893187|NCT03134924|Behavioral|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
75893188|NCT03134924|Behavioral|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
75893189|NCT02084940|Drug|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
75893190|NCT05755321|Other|Skin biopsy|Skin biopsy performed during surgery.
75893191|NCT02269748|Procedure|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
75893192|NCT02269748|Procedure|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
75893193|NCT02269748|Drug|Analgesic Therapy|Ibuprofen 600 mg TID
75600433|NCT02867683|Other|Vibrotactile Feedback|Balance training Vibrotactile feedback applied to the trunk
75600434|NCT02867839|Drug|Oxaliplatin plus S-1|8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
75600435|NCT02867839|Drug|S-1 only|16 cycles of adjuvant chemotherapy with S-1 only
75600436|NCT04119973|Other|standard treatment|standard medical treatment
75744416|NCT00828971|Drug|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
75744417|NCT02547467|Other|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
75744418|NCT02548637|Procedure|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
75893194|NCT02269826|Device|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
75893195|NCT02269826|Device|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
75600437|NCT02867293|Procedure|ultrasound guided ascitic fluid drainage|
75600438|NCT02867293|Procedure|operative drainage of ascites through small skin incision after induction of anesthesia|
75600439|NCT02867293|Device|ultrasound|
75600440|NCT02867137|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
75600441|NCT02867371|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
75744419|NCT00835835|Other|Body-weight supported treadmill training +/- Lokomat assistance|walking
75744420|NCT00835835|Other|Usual Care - no active intervention|No treatment used for comparison
75744421|NCT00528996|Drug|BEA 2180 BR|Solution
75744422|NCT00528996|Drug|Tiotropium Bromide|Solution
75744423|NCT00528996|Drug|Placebo|Solution
75893196|NCT02269904|Drug|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
75893197|NCT02269904|Drug|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
75893198|NCT04540198|Behavioral|GamePlan4Care|GamePlan4Care; Experimental
75744424|NCT00838487|Other|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
75744425|NCT00838487|Other|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
75744426|NCT00359788|Drug|tiotropium|
75744427|NCT00359788|Drug|Combivent (Ipratropium/Albuterol)|
75744428|NCT00838721|Other|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
75744429|NCT00838877|Drug|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
75744430|NCT00838877|Drug|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
75893199|NCT04540198|Behavioral|Resources4Care|R4C; Active Comparator
75893200|NCT03557112|Drug|Nimotuzumab|TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
75893201|NCT03557112|Drug|Cisplatin|TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
75893202|NCT01300208|Drug|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
75893203|NCT01300208|Other|Placebo|
75893204|NCT02085018|Drug|Omeprazole|Drug
75893205|NCT02085018|Drug|Matched placebo|Matched placebo
75893206|NCT05091814|Radiation|radiotherapy|patients who recieved radiotherapy after surgical removal of the tumor
75449410|NCT00543348|Procedure|Balloon angioplasty|HIGH PRESSURE BALLOON
75600442|NCT02867215|Other|Barley bread|120g barley bread per day for 3 weeks.
75600443|NCT02867215|Other|Wheat bread|120g wheat bread per day for 3 weeks.
75600444|NCT01005316|Drug|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
75600445|NCT01005316|Drug|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
75600446|NCT01005316|Drug|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
75893207|NCT02091336|Drug|Metformin|patients treatment
75893208|NCT02091336|Drug|Glyburide|patients treatment
75449411|NCT00531232|Drug|Clofarabine|"Pharmaceutical form: Tablet,~Route of administration: Oral"
75449412|NCT00512122|Other|Withholding PN during the first week of ICU stay|Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.
75449413|NCT00512122|Drug|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E|PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
75600447|NCT01005316|Procedure|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
75600448|NCT01005316|Procedure|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
75600449|NCT01005316|Drug|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
75600450|NCT01005316|Drug|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
75744431|NCT00836147|Drug|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
75744432|NCT00836147|Drug|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
75744433|NCT05416476|Drug|Anisodine Hydrobromide|Anisodine Hydrobromide 1 mg oral tablet, twice times a day
75744434|NCT05416476|Drug|Anisodine Hydrobromide placebo|Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
75744435|NCT05732922|Device|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
75744436|NCT03878160|Other|Individual Interview|Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
75893209|NCT03805204|Procedure|Open reduction and internal fixation (ORIF)|ORIF with a forearm plate
75893210|NCT01442090|Drug|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
75893211|NCT01442090|Drug|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
75893212|NCT02085096|Behavioral|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
75893213|NCT04475042|Drug|Dapagliflozin|10mg od
75893214|NCT04475042|Drug|Placebo|Placebo
75893215|NCT02088450|Drug|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
75449414|NCT00389844|Behavioral|Exercise Trainer component of the Exercise Plus Program|With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
75893216|NCT03688828|Drug|Saccharomyces boulardii|500mg bid
75744437|NCT02534116|Procedure|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
75893217|NCT03688828|Drug|Esomeprazole|20mg bid
75893218|NCT03688828|Drug|Amoxicillin|1.0g bid
75893219|NCT03688828|Drug|Clarithromycin|0.5g bid
75893220|NCT03688828|Drug|Bismuth potassium citrate|0.22g bid
75893221|NCT03960476|Behavioral|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
75893222|NCT02091492|Drug|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
75893223|NCT02091492|Drug|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
75449415|NCT00389844|Behavioral|Plus component (motivation) of the Exercise Plus Program|Motivation only
75744438|NCT02534116|Procedure|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
75893224|NCT02266940|Drug|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
75449416|NCT00389844|Behavioral|Exercise Plus Program (exercise + motivation)|Exercise plus motivation
75744439|NCT03987490|Behavioral|Text Message|Vaccine reminder notification sent via text
75893225|NCT02266940|Drug|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
75893226|NCT04011358|Other|Sleeping Monitor|to evaluate obstructive sleep apnea
75893227|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)|6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
75893228|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (12 µg)|12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
75893229|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (25 µg)|25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
75893230|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)|The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
75893231|NCT03981952|Other|Placebo|0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
75893232|NCT02269982|Device|AR-v7 assays|
75893233|NCT02091570|Other|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
75893234|NCT03838120|Other|Procedure/Surgery: bupivakain % 0,5|In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement
76025081|NCT03735017|Other|Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
76025082|NCT01362491|Drug|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
76025083|NCT01362491|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
76025084|NCT01362491|Drug|Placebo|Single-dose of placebo
76025085|NCT02687191|Biological|PF-05230907|PF-05230907 IV bolus injection
75744440|NCT03987490|Behavioral|PostCard|Vaccine reminder notification sent via standard mail
75744441|NCT03987490|Behavioral|Standard of Care|No additional information given to parents
75744442|NCT03987490|Behavioral|Motivational Interview|Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
75744443|NCT00623597|Drug|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
75744444|NCT00623597|Drug|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
75744445|NCT05732844|Device|Intervention group with Enna pelvic ball|"The home guideline for placement of the vaginal spheres will be as described in next:~st-2nd week 15 minutes, 1 time a day nd-4th week 30 minutes, 1 time a day 4th-8th week 1 hour, 1 time a day 8th-12th week 2 hours, 1 time a day 12th-16th week 3 hours, 1 time a day"
75744446|NCT05732844|Other|Control group|According to the PERFECT score, a daily home guideline for the performance of PFMT will be requested three times a day, two types of exercises (endurance and strength), and eight repetitions of each.
75744447|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
75744448|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
76025086|NCT02687035|Device|SAPIEN S3 valve|Transcatheter aortic valve replacement
76025087|NCT04515563|Behavioral|Stretching exercise|Control Group
75893235|NCT02091648|Behavioral|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
75600451|NCT01004848|Behavioral|Peer-Led Lifestyle Education on Weight Loss|Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
76072107|NCT03190863|Behavioral|Control (C)|"7 individuals with C6-C7 tetraplegia randomized in the sham comparator group consisting in imagining geometric shapes by visualization. Shapes are successively displayed on a screen.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
75744449|NCT05732766|Biological|Hillchol vaccine|Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
75893236|NCT02091648|Behavioral|Standard Education Intervention|"This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education."
75893237|NCT04475120|Drug|liposomal lactoferrin|oral and intra-nasal formulation
75744450|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week~Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~Treatment duration: 16 weeks"
76072108|NCT03189420|Procedure|Tumor resection|The tumors will be resected in routine therapeutic surgeries
75893238|NCT04475120|Drug|SOC therapy|oral administration
75893239|NCT03821038|Biological|CYT107|IV twice a week at 10µg/kg for 3 weeks
75600452|NCT01009294|Drug|Ataluren|Oral powder
75600453|NCT01009294|Drug|Chronic Corticosteroid Therapy|Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
75893240|NCT03821038|Drug|Placebos|IV twice a week at the same volume for 3 weeks
75893241|NCT02208024|Radiation|Stereotactic Body Radiation Therapy|
75893242|NCT03664804|Other|No Study Drug was Administered in this Study|No study drug was administered in this study
75893243|NCT01155362|Biological|Human Placenta-Derived Cells PDA001 Intravenous Infusion|
75600454|NCT04205422|Procedure|BIPAP|Biphasic Intermittent Positive Airway Pressure
75600455|NCT04205422|Procedure|APRV|Airway Pressure Release Ventilation
75600456|NCT04205188|Other|therapeutic exercises|aerobic- balance -stretching and strengthening exercises
75600457|NCT01009060|Drug|GSK239512|Histamine H3 Antagonist
75600458|NCT01009060|Drug|Placebo|Placebo to match GSK239512
76072109|NCT03175159|Behavioral|IMPACT|Ten counseling sessions
76072110|NCT03175159|Behavioral|Standard of Care|Two counseling sessions
75600459|NCT00988429|Drug|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
75600460|NCT00988429|Drug|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
75744451|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week~Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~Treatment duration: 24 weeks"
75893244|NCT01155362|Drug|Vehice Control|
75893245|NCT03279718|Procedure|Periodontal Treatment|Scaling and root planing
75893246|NCT02088528|Device|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
75893247|NCT02088528|Procedure|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
75893248|NCT02272010|Other|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
75893249|NCT02272010|Other|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
75893250|NCT02091804|Behavioral|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
75893251|NCT02091804|Behavioral|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
75893252|NCT03634150|Biological|Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.|Once weekly treatment, with IV doses of Nerofe (96mg\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
75893253|NCT02085330|Device|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
76072111|NCT03143270|Drug|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
75449417|NCT00365326|Biological|Catheter-based intracoronary injection|This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
75449418|NCT00265525|Behavioral|CardioFit|CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
75600461|NCT00988429|Drug|Placebo|Placebo tablet given QD
75600462|NCT01008904|Drug|magnesium oxide|Given PO
75744452|NCT05732688|Diagnostic Test|Image-based ex-vivo drug screening platform (pharmacoscopy)|"Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds. A drug score is calculated for each compound (defined as 1 - (% target cells in drug treated conditions / % target cells under control condition)). If a drug kills all target cells specifically, the best possible score is 1. If the drug is killing all non-target cells, the score goes to negative infinite. If a drug kills both target and non-target cell populations equally, or does nothing, the score is 0."
75600463|NCT01008904|Other|questionnaire administration|Ancillary studies
75744453|NCT00838955|Drug|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
75744454|NCT00347776|Drug|azithromycin|oral antibiotic
75744455|NCT00347776|Drug|topical tetracycline|
75893254|NCT01148498|Drug|solanezumab|400mg administered once intravenously
75893255|NCT05090956|Other|mri|
75893256|NCT02092038|Drug|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
75893257|NCT02092038|Radiation|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
75744456|NCT00839033|Device|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
75893258|NCT02092038|Procedure|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
75893259|NCT02092038|Procedure|craniotomy and tumor resection|maximal safe resection
75600464|NCT01008904|Procedure|quality-of-life assessment|Ancillary studies
75893260|NCT02272166|Drug|propofol|
75600465|NCT04295590|Behavioral|Frequency comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).
75600466|NCT04295590|Behavioral|Intensity comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
75744457|NCT00839033|Device|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
75893261|NCT02272166|Drug|Sevoflurane|
75893262|NCT04438252|Diagnostic Test|ICDAS II|Index for caries detection
75893263|NCT04438252|Device|CariScan Pro|Device for early caries detection
75893264|NCT04438252|Radiation|Digital Radiograpgy|Device for digital x-ray imaging
76062658|NCT01923766|Drug|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
75893265|NCT02085564|Procedure|Peritoneal washing cytology|The methode is describes in the detailed study description
75893266|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
75893267|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
75893268|NCT01139216|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
75893269|NCT03246568|Procedure|Renal Nerve Denervation|Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.
75893270|NCT03246568|Procedure|Pulmonary vein isolation|PVI by cryo-balloon ablation without linear ablation
75600467|NCT04291261|Drug|Uvadex|Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56
75600468|NCT04291495|Diagnostic Test|ANDROSITOL®TEST|Sperm incubation with ANDROSITOL®DGN and evaluation of sperm motility and mithocondrial membrane potential
75600469|NCT04290559|Procedure|Reveal LINQ ILR implant before AF ablation|Patients will undergo insertion of a LINQ ILR before the atrial fibrillation ablation performed according to standard clinical practice.
75893271|NCT01138436|Drug|MEBO Wound Ointment (MEBO)|Topical application once a day
75600470|NCT04290793|Drug|Pyrotinib|400mg administered as continuous oral once daily from the first day of the study
75744458|NCT00829127|Drug|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
75744459|NCT00829127|Drug|Placebo|Oral suspension
75893272|NCT01138436|Procedure|Standard of Care|Application of Profore multilayer compression bandage system
75893273|NCT03115450|Device|Ultrasound|Type of imaging technology to look at organs and structures inside the body
75893274|NCT03115450|Device|Pupilometer|A device that measures pupil size and how it changes.
75893275|NCT02088684|Drug|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
75893276|NCT02088684|Drug|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
75893277|NCT02088684|Drug|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
75600471|NCT04290793|Drug|Epirubicin|90mg/m^2 d1 iv Q2W for 4 cycles
75893278|NCT02088684|Drug|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
75893279|NCT01137968|Drug|imetelstat|9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
75893280|NCT01137968|Drug|Bevacizumab|Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
75893281|NCT03557814|Device|LED appliance during mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
75600472|NCT04290793|Drug|Cyclophosphamide|600 mg/m^2 d1 iv Q2W for 4 cycles
75893282|NCT03557814|Device|LED appliance after mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
75893283|NCT03557814|Device|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
75893284|NCT02249910|Drug|semaglutide|Oral administration of 5 mg daily for one week, then escalated to 10 mg daily for one week, followed by escalation to 20 mg daily for 41 days
75893285|NCT02249910|Drug|metformin|Oral administration of 850 mg twice daily for 3 days followed by 850 mg on day 4, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
75600473|NCT04290793|Drug|Taxanes|Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
75600474|NCT04290793|Biological|Trastuzumab|the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
75600475|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
75600476|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
75600477|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
75600478|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
75744460|NCT04452136|Drug|68GA PSMA-HBED-CC|Given IV
75744461|NCT00829205|Biological|filgrastim|
75744462|NCT00829205|Biological|rituximab|
75744463|NCT00829205|Dietary Supplement|Se-methyl-seleno-L-cysteine|
75744464|NCT00829205|Drug|carboplatin|
75744465|NCT00829205|Drug|etoposide|
75744466|NCT00829205|Drug|ifosfamide|
75744467|NCT00829205|Other|laboratory biomarker analysis|
75893286|NCT02249910|Drug|digoxin|Oral administration of 0.5 mg single dose, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
75893287|NCT02249910|Drug|placebo|Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
75893288|NCT02936596|Drug|Ursodeoxycholic acid combination of immunosuppressive agents|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
75893289|NCT02936596|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid
75893290|NCT02088762|Procedure|surgical excision|comparison of safety margin 1 versus 2 cm
75893291|NCT02267018|Device|Drager VN500 Ventilator|This ventilator is capable of providing both nCPAP and NIHFV support.
75893292|NCT03557736|Behavioral|Training mode|type of exercise training completed for 12 weeks
75893293|NCT02267096|Behavioral|Telephone Counseling|The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
76062659|NCT03831724|Device|EndoFLIP™ System with FLIP Topography Module|The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
75893294|NCT02267096|Behavioral|Minimal Treatment|A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
75449419|NCT00066950|Drug|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
75449420|NCT00066950|Device|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
75449421|NCT01694134|Drug|Hydrocortancyl.|Patients will receive an intradiscal injection of hydrocortancyl.
75600479|NCT02871700|Behavioral|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
75600480|NCT02871700|Behavioral|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
75449422|NCT01694134|Drug|Lidocaine|
75744468|NCT00829205|Other|pharmacological study|
75449423|NCT01694147|Device|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
75744469|NCT02533882|Behavioral|Movement to Music|
75744470|NCT02533882|Behavioral|Adapted Yoga|
75449424|NCT01694160|Drug|Paricalcitol|Zemplar (paricalcitol) 2ug daily, oral intake
75744471|NCT00836225|Drug|ISIS 388626|"4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline"
75744472|NCT01053754|Biological|"long synacthen stimulation test"|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
75744473|NCT03987178|Behavioral|Dunk|"If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level."
75744474|NCT03987178|Other|Exposure to Hot Tub|Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
75893295|NCT02085642|Other|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
75893296|NCT02085642|Other|Sham needle|Retractable needle with no skin puncture
76025088|NCT04515563|Behavioral|Low-frequency, moderate-intensity walking group|once-a-week walking exercise at moderate intensity
76025089|NCT04515563|Behavioral|High-frequency, moderate-intensity walking group|thrice-a-week walking exercise at moderate intensity
75744475|NCT00839111|Drug|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
75744476|NCT00839111|Drug|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
76025090|NCT04515563|Behavioral|Low-frequency, vigorous-intensity walking group|once-a-week walking exercise at vigorous intensity
76025091|NCT04515563|Behavioral|High-frequency, vigorous-intensity walking group|thrice-a-week walking exercise at vigorous intensity
76025092|NCT05746507|Behavioral|Night Respite Care|(see description above)
75893297|NCT02398396|Biological|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
75893298|NCT02092194|Procedure|High Dose Online HDF|Convection volume; 33-43 L/treatment (140-180 mL/min)
75893299|NCT02092194|Procedure|Standard Dose Online HDF|convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
75893300|NCT03096808|Radiation|Adaptive Radiotherapy|ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
75893301|NCT04476056|Other|Intensified Nutritional Therapy|Intensified nutritional therapy will begin in the hospital setting and comprises intake of a commercial oral nutritional supplement (Fortimel Compact 2.4, Nutricia) twice per day as well as personalized dietary counselling. After discharge, supplementation will be continued for at least 28 days and if necessary throughout the entire study duration. Likewise, dietary counselling will be provided throughout the entire study period based on the patient's individual need. Dietary counselling is provided either face-to-face during the follow-up visits or remotely via telephone between visits.
75893302|NCT03090022|Procedure|Strattice|Intra-abdominally Fixation
75893303|NCT03090022|Procedure|Single running suture of abdominal fascia|Intra-abdominal suture
75893304|NCT02267174|Behavioral|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
75893305|NCT02085798|Other|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
75893306|NCT04474574|Device|Simultaneous recording of nocturnal SpO2|The intervention will consist in performing a simultaneous recording of nocturnal SpO2 and pulse rate for at least 4 hours with 3 different devices.
75893307|NCT05377138|Other|Online PEP/PrEP delivery|Delivery of PEP or PrEP after online consultation and HIVST image upload.
75893308|NCT05628584|Combination Product|High FODMAP diet with metformin|Controlled High FODMAP diet (15g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
75893309|NCT05628584|Combination Product|Low FODMAP diet with metformin|Controlled low FODMAP diet (3g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
75893310|NCT05628506|Drug|Potassium iodide|Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
75893311|NCT02427490|Behavioral|Problem-Solving Intervention|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
75893312|NCT02427490|Other|Unenhanced Monitoring|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
75893313|NCT05626946|Other|Observation|Observation
75893314|NCT02088918|Drug|Nateglinide|
75893315|NCT02088918|Drug|Nateglinide/Metformin|
75893316|NCT02088918|Drug|Metformin|
75893317|NCT02419378|Drug|Alemtuzumab|
75893318|NCT05628272|Other|Intravenous infusion of cord blood mononuclear cells|On the basis of the application of granulocyte stimulating factor, the research group was given intravenous infusion of umbilical cord blood mononuclear cells, each infusion ≥1×10^8, once a week
75893319|NCT05628272|Drug|application of granulocyte stimulating factor|application of granulocyte stimulating factor
75893320|NCT02092272|Behavioral|instructional exercise video source|instructional exercise video source
75893321|NCT05375500|Device|telemedicine digital therapeutic|digital therapeutics intervention for chronic pain utilizing coaching and virtual reality application
75893322|NCT01097096|Biological|CAD106|150μg and 450μg doses were reconstituted and administered via intramuscular injection
75893323|NCT01097096|Biological|Placebo|Identical placebo to CAD106 administered via intramuscular injection
75893324|NCT01097096|Biological|Alum|An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106
75893325|NCT01097096|Biological|MF59|An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
75893326|NCT02085876|Other|2 additional MRI sequences|
75893327|NCT02085876|Other|An additional blood sample|
75893328|NCT05375422|Other|SARAH|Set of exercises with components of muscle strengthening, range of motion gain and home exercises.
75893329|NCT05375422|Other|Educational intervention|Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
75893330|NCT02092428|Other|Image Quality|"The following procedures may be conducted as part of this study:~Coronary MRI scan with no contrast~Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~MRI scan with an oral beta blocker (metoprolol)~Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions."
76062660|NCT01923844|Drug|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached > 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
75449425|NCT01694173|Other|Stem cell therapy- SPD artery|A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.
75449426|NCT01694173|Other|Stem cell therapy- splenic artery|7 patients will receive stem cells infusion through splenic artery.
75449427|NCT01694173|Other|Stem cell therapy-intravenous|7 patients will receive stem cells infusion through peripheral intravenous route.
75600481|NCT02871700|Behavioral|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
76062661|NCT00633022|Drug|LOSMAPIMOD 7.5 MG|GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
75744477|NCT01053832|Device|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
75893331|NCT02092428|Other|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
76062662|NCT00633022|Drug|Placebo|Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
76062663|NCT01923922|Radiation|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
75893332|NCT02783404|Drug|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
75893333|NCT02783404|Drug|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
75600482|NCT02871076|Device|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
75600483|NCT04297462|Drug|Oseltamivir 3 days|Non-inferiority study of 3 versus 7-days duration of PEP
75600484|NCT04297462|Drug|Oseltamivir 7 days|Active comparator
75744478|NCT00836303|Behavioral|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
76025093|NCT03167749|Diagnostic Test|Laboratory test|Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
75893334|NCT05503290|Behavioral|Lullaby Project|Our proposed intervention is the randomized participation of pregnant individuals with epilepsy in the Lullaby Project coordinated by a musical institution in Toronto. The Lullaby Project is an initiative first created by Carnegie Hall's Weill Music Institute. In this program, pregnant women and/or new mothers are paired with professional musicians to compose and write personal lullabies for their child(ren). Since its inception in 2011, the project has expanded globally and have helped numerous families write original lullabies for their newborns. The Lullaby intervention is unlike traditional music therapy as patients are actively participating in the creative song-writing process, not singularly in passive listening. Through sessions, participants will be given an opportunity to share experiences, experiment with musical arrangements, write lyrics, and receive positive feedback from the musician.
75893335|NCT05096806|Other|Acupuncture|Acupuncture is a non-pharmacological technique that consists in the stimulation of specific points located in the skin surface. Points are stimulated by piercing the skin with fine needles.
75893336|NCT05096806|Device|TENS|TENS is a therapy that uses low voltage electrical current to provide pain relief. A TENS unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. The electrodes are placed at or near nerves where the pain is located or at trigger points.
75893337|NCT01097018|Drug|Capecitabine|1000 mg/m2 BID/ Days 1-14
75893338|NCT01097018|Drug|Perifosine|50 mg daily x 21 days
75893339|NCT01097018|Drug|Placebo|1 pill daily x 21 days
75893340|NCT05096650|Procedure|mesotherapy of platelet rich plasma and platelet poor plasma|Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
75893341|NCT02088996|Device|longwave diathermy on high power and interferential therapy|
76062664|NCT01929304|Other|Survey|
75449428|NCT01694173|Other|Normal saline placebo -sham procedure|7 patients will receive infusion of normal saline and will act as control groups
75449429|NCT01694212|Drug|Perioperative Diclofenac eye-drops administration|
75600485|NCT00981409|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
75893342|NCT02088996|Device|longwave diathermy on low power|
75893343|NCT05096572|Device|VIM Stimulation|Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.
75893344|NCT05096572|Device|PSA Stimulation|Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.
75893345|NCT05096572|Device|VIM+PSA Stimulation|Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.
75449430|NCT01694212|Drug|placebo|
75893346|NCT01096862|Drug|peficitinib|oral
75893347|NCT01096862|Drug|Placebo|oral
75449431|NCT01694225|Other|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
75449432|NCT01694238|Procedure|Cruciate incision|
75893348|NCT02092506|Drug|10 day triple therapy|10 day triple therapy
75893349|NCT02092506|Drug|10 day sequential therapy|10 day sequential therapy
75893350|NCT02092506|Drug|10 day concomitant therapy|10 day concomitant therapy
75893351|NCT02089074|Behavioral|Drug use counselling|
75893352|NCT01092104|Drug|TBR-652|TBR-652 25 mg
75449433|NCT01694238|Procedure|Circular incision|
75449434|NCT01694238|Other|Mesh enforced cruciate incision|
75449435|NCT01694264|Drug|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
75449436|NCT01694264|Drug|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
75449437|NCT01694290|Other|Chemical Cold Pack|
75449438|NCT01694303|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
75600486|NCT00981409|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
75893353|NCT01092104|Drug|TBR-652 Matching Placebo|Matching Placebo
75893354|NCT01092104|Drug|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
76062665|NCT01924000|Drug|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
76062666|NCT01924000|Drug|Placebo|
76062667|NCT01924078|Drug|Capecitabine|metronomic use: capecitabine 500mg/tid
76062668|NCT01924078|Drug|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
76062669|NCT01929616|Drug|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
76062670|NCT01929694|Dietary Supplement|Berocca Boost|
76062671|NCT01929694|Dietary Supplement|Placebo|
75600487|NCT04297228|Behavioral|Step by Step: A Family-Centered Healthy Lifestyle Intervention|
75744479|NCT01008228|Procedure|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
75449439|NCT01694316|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
75893355|NCT01092104|Drug|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
75893356|NCT01092104|Drug|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
75893357|NCT01092104|Drug|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
75449440|NCT01694355|Drug|Vitamin D|
75449441|NCT01694381|Drug|M5|single point mutant of serine protease prourokinase
75449442|NCT01694381|Drug|C1-inhibitor|a protease inhibitor belonging to the serpin superfamily.
75600488|NCT04298710|Behavioral|Arm Cycling|20 minutes of arm cycling exercise at light to moderate intensity.
75600489|NCT04298710|Behavioral|Leg Cycling|20 minutes of leg cycling exercise at light to moderate intensity.
75600490|NCT04298710|Behavioral|Sitting|Remain seated for 20 minutes.
75600491|NCT02865655|Procedure|Hysteroscopic|
75744480|NCT01008228|Procedure|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
75744481|NCT00836381|Drug|Tolterodine extended-release (ER) 4mg|Tolterodine extended-release (ER) 4mg once daily for 12 weeks
75744482|NCT00836381|Drug|Placebo|Identical Placebo once daily
75744483|NCT02533336|Drug|abamectin and fenpyroximate|
75893358|NCT02092584|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
75893359|NCT02092584|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
75893360|NCT01128530|Drug|JNJ-32729463|250 mg tablet twice daily
75449443|NCT01694394|Device|Implantable Cardiac Monitor (Confirm ICM model 2102)|Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
75744484|NCT00836459|Behavioral|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
75449444|NCT01694407|Drug|Tenofovir (TFV) Alone Vaginal Tablet|vaginal tablet containing 40 mg of TFV
75449445|NCT01694407|Drug|Emtricitabine (FTC) Alone Vaginal Tablet|Vaginal Tablet containing 40 mg of TFV
75449446|NCT01694407|Drug|TFV and FTC Combined Vaginal Tablet|vaginal tablet with 40 mg TFV and 40 mg FTC
75449447|NCT01694407|Drug|Placebo Vaginal Tablet|Vaginal Tablet containing no drug
75449448|NCT01694446|Other|Intraduodenal glucose or fructose|
75449449|NCT01694459|Drug|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
75449450|NCT01694459|Drug|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
75600492|NCT04297072|Drug|Rivaroxaban (Xarelto, BAY-597939)|Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
75600493|NCT04297072|Drug|VKAs|Oral anticoagulant. The prescription of drug is at the discretion of physician following the routine clinical practice.
75600494|NCT02871310|Dietary Supplement|IQP-AS-118|1 tablet in the morning
75600495|NCT02871310|Dietary Supplement|Placebo|1 tablet in the morning
75744485|NCT00836459|Behavioral|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
75893361|NCT01128530|Drug|linezolid|600 mg tablet twice daily
75893362|NCT01128530|Drug|JNJ-32729463 placebo|1 placebo tablet twice daily
75893363|NCT01128530|Drug|linezolid placebo|1 placebo tablet, twice daily
75893364|NCT02660086|Behavioral|Personalized nutrition feedback|Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
75893365|NCT02086032|Drug|1mg 17 beta-estradiol|Comparing sleeping quality between micronized progesterone and dydrogesterone users.
75893366|NCT02086032|Drug|Dydrogesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users.
75893367|NCT02086032|Drug|micronized progesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users
75893368|NCT01128452|Drug|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
75893369|NCT01128452|Drug|Placebo|HPMC Placebo capsules, once daily for 28 days
75893370|NCT02092818|Drug|Riociguat (Adempas, BAY63-2521)|The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
75893371|NCT05626868|Device|Intra abdominal pressure measurement|Device: Biometrix - Intraabdominal pressure monitoring set Intraabdominal pressure monitoring with the intended set in values of milimeters of mercury (mmHg) in real time.
75893372|NCT02267408|Other|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
75893373|NCT02267408|Other|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
76062672|NCT01924156|Biological|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
76062673|NCT01929850|Procedure|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
76062674|NCT01929850|Behavioral|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
76062675|NCT00630994|Drug|Dacogen|
76062676|NCT00630838|Drug|VSL#3|"Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding."
76062677|NCT00630838|Drug|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
76062678|NCT03126136|Device|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
75449451|NCT01694472|Biological|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
75893374|NCT05376826|Behavioral|Nurse Led Physical Therapy|Nurse Led Physical Therapy in Form of Range of Motion Exercises
76062679|NCT01924234|Drug|Morphine|
76062680|NCT01924234|Drug|Remifentanil|
75600496|NCT01008748|Drug|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke >10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
75744486|NCT03991390|Other|Visual Feedback and Core Stability exercises protocol|"This arm consists of 5 sessions per week, 60 minutes each. One session consists of 30 minutes of conventional physiotherapy and 30 minutes of Core Stability exercises and laser visual feedback exercises, on alternate days.~All sessions will be performed by the same physiotherapist."
76062681|NCT01924312|Behavioral|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
76062682|NCT00630058|Drug|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
75449452|NCT01694498|Drug|A: Desmopressin 25 µg|
75449453|NCT01694498|Drug|B. Desmopressin 50 µg|
75449454|NCT01694498|Drug|Placebo|
75744487|NCT03991390|Other|Control stroke|"This arm consists of 5 sessions per week, 60 minutes each comprising usual physiotherapy treatment.~All sessions will be performed by the same physiotherapist."
75893375|NCT03777618|Procedure|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two differents well-known flaps for gluteal augmentation
75449455|NCT01694511|Procedure|HRME+CVC|High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy
75600497|NCT01008748|Behavioral|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
75744488|NCT00829361|Other|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
75744489|NCT03829228|Dietary Supplement|Proglucamune|Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
75449456|NCT01694511|Procedure|conventional endoscopy|Conventional white light endoscopy with four-quadrant biopsy
75600498|NCT01008748|Behavioral|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
75600499|NCT01008748|Behavioral|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
75893376|NCT03902444|Device|Credo® Stent, NeuroSpeed® PTA balloon catheter|a self-expanding stent is used together with a PTA balloon catheter
75893377|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
75893378|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
75893379|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
76062683|NCT00630058|Drug|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
76062684|NCT01925794|Device|COBRA PzF|
76062685|NCT01927198|Drug|Placebo|
76062686|NCT01927198|Drug|RDEA3170 5 mg|
76062687|NCT01927198|Drug|RDEA3170 10 mg|
76062688|NCT01927198|Drug|RDEA3170 12.5 mg|
76062689|NCT01924468|Drug|Oral methylphenidate and Oral haloperidol|
75600500|NCT02865265|Procedure|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
75744490|NCT00839189|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
76062690|NCT03536416|Behavioral|My Asthma in School|The intervention will include three arms. During the theatre workshop, the children will watch a theatre performance, and engage in a discussion at the end of the play, about what they have watched. The self-management workshops will cover a range of topics identified as barriers to self-management in our earlier study, and will be delivered to children with asthma only. The control group will receive usual care during the intervention.
75744491|NCT01053910|Drug|Ramipril|tablet of Ramipril once daily
75744492|NCT00829517|Other|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
75744493|NCT00829517|Other|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
75893380|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
75893381|NCT05096026|Behavioral|Standard PCP Outreach|These patients were sent two study outreach messages. Study Outreach 1 was an electronic secure message sent on behalf of the PCP, encouraging COVID-19 vaccination and designed based on behavioral science principles. Letters were sent to patients who had not signed up for the electronic health record portal. Study Outreach 2 was a postcard sent to all patients who had not been vaccinated or made an appointment by four weeks after Study Outreach 1.
75893382|NCT05096026|Behavioral|Culturally Tailored PCP Outreach|These patients were sent messages similar to those in Standard PCP Outreach, but with additional culturally tailored content and photos.
75893383|NCT02092974|Procedure|tDCS|
75893384|NCT02092974|Drug|Citalopram|
75893385|NCT02092974|Other|sham-tDCS + placebo|
76062691|NCT01924546|Other|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
76062692|NCT01923064|Drug|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
76062693|NCT01923064|Drug|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
76062694|NCT01924624|Drug|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
76062695|NCT01924702|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
76062696|NCT01924702|Device|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
76062697|NCT01929382|Drug|interferon gamma 1b|Standard therapy vs dose titration
76062698|NCT01924780|Device|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
76062699|NCT01924780|Device|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
76062700|NCT01924780|Device|NEMOS Device sham stimulation 10 minutes|
76062701|NCT00981448|Dietary Supplement|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
76062702|NCT01926184|Behavioral|Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)|5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
75893386|NCT02093052|Behavioral|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
75893387|NCT02093052|Behavioral|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
75893388|NCT05097508|Drug|Atracurium Besylate|Anesthesia will be induced by atracurium (dose 0.5 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given
75893389|NCT05097508|Drug|Rocuronium Bromide|Anesthesia will be induced by rocuronium (dose 0.6 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given.
75893390|NCT05097508|Device|Entropy|No premedication will be given. After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system , starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
76062703|NCT01926184|Behavioral|Contingency Management (CM)|12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
76062704|NCT01924858|Drug|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of [18F]-GSK2647544 and a PET scan.
75744494|NCT03987412|Behavioral|Lifestyle intervention with APP|The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
75893391|NCT05097508|Device|train of four|After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system, starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
75893392|NCT02089152|Other|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
75893393|NCT02093130|Dietary Supplement|Pomegranate Juice|
75893394|NCT02093130|Dietary Supplement|Placebo|
75893395|NCT02089308|Drug|Test treatment : V0116 transdermal patch|
75893396|NCT02089308|Drug|Reference treatment : Nicotine transdermal patch|
75893397|NCT01678144|Device|Mitral valve repair using the Medtentia Annuloplasty Ring (MAR)|
75893398|NCT02086266|Other|PILATES|
75893399|NCT02086266|Other|PFMT and AES|
75893400|NCT02086344|Procedure|PBS|TLH plus PBS
75893401|NCT02086344|Procedure|TLH _adnexal preservation|TLH without PBS
75893402|NCT00153920|Drug|bortezomib|
75893403|NCT05095714|Other|Liver ultrasound and fast-MRI|Half-yearly liver ultrasound and fast-MRI
75449457|NCT01694537|Drug|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
75449458|NCT01694537|Drug|placebo|Placebo is made with same size and shape with study drug.
75449459|NCT01694576|Drug|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
75893404|NCT05095714|Other|Liver ultrasound|Half-yearly liver ultrasound
75893405|NCT02086422|Drug|ivabradine|
75893406|NCT02086422|Drug|Placebo|
75893407|NCT02086422|Other|Exercise|
75893408|NCT05376436|Diagnostic Test|Exercise challenge test (ECT)|Baseline demographic, clinical and rest lung functions were recorded. ECT was performed on treadmill according to fixed protocol. Clinical data during ECT was recorded. (visit 1- performed with nose clip, visit 2- performed without nose clip). Lung function were measured and recorded at fixed time after ECT and after bronchodilator administration.
75893409|NCT01073228|Drug|EVP-6124|
75893410|NCT01073228|Drug|Placebo|
75893411|NCT03558282|Other|Recession Observation|Soft tissue measurements
75893412|NCT03558282|Diagnostic Test|Crown Contour Observation|Ultrasound measures of implant crown contour.
75893413|NCT02660242|Drug|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
75744495|NCT00829595|Biological|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
75744496|NCT01054066|Behavioral|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
75744497|NCT01008384|Dietary Supplement|Vitamin D3|50,000 units taken orally once a week for 8 weeks
75893414|NCT02660242|Other|Glucose Tabs|Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
75449460|NCT01694589|Drug|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
75744498|NCT00836771|Dietary Supplement|Infant Formula|
75744499|NCT01008540|Biological|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
75744500|NCT02547155|Procedure|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
75744501|NCT02547155|Procedure|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
75744502|NCT00836849|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
75744503|NCT00836849|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
75744504|NCT03999294|Other|BMGIM Music Therapy Method|The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
75744505|NCT00839345|Drug|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
75893415|NCT02660242|Other|Basal Insulin Reduction|Basal insulin reduction to 50% 5 minutes before the start of exercise.
75893416|NCT02089386|Drug|Tamoxifen|
75893417|NCT02089386|Procedure|Endoscopy|
75893418|NCT03557580|Drug|IS-5-MN R|single orally dose under fed conditions on day 1 of treatment period 1 for group 1, on day 1 of treatment period 2 for group 2, on day 1 of treatment period 3 for group 3.
75893419|NCT03557580|Drug|IS-5-MN T1|single orally dose under fed conditions on day 1 of treatment period 2 for group 1, on day 1 of treatment period 3 for group 2, on day 1 of treatment period 1 for group 3.
75893420|NCT03557580|Drug|IS-5-MN T2|single orally dose under fed conditions on day 1 of treatment period 3 for group 1, on day 1 of treatment period 1 for group 2, on day 1 of treatment period 2 for group 3.
75893421|NCT05627960|Drug|AG-01 Compound|"Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D."
75893422|NCT02089542|Other|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
75893423|NCT01295060|Drug|Octreotide|84 mg Octreotide Implant
75893424|NCT05374876|Other|Hand Therapy Until CIPN|Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
75893425|NCT02086656|Drug|capecitabine, oxaliplatin, irinotecan and bevacizumab|perioperative COI-B
76062705|NCT01924858|Drug|[18F]GSK2647544 IV bolus|[18F]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
76062706|NCT04395820|Diagnostic Test|Lung function test|MBW
75449461|NCT01694602|Biological|(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)|Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
75449462|NCT01694615|Procedure|Cryoprobe biopsy|
75449463|NCT01694615|Procedure|Forceps Biopsy|
75449464|NCT01694628|Behavioral|CLIMB (COPD Lifestyle, Mood, and Behavior)|Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
75600501|NCT04295512|Behavioral|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based executive functioning treatment that targets flexibility, goal-setting and planning through a cognitive behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. UOT will be adapted for use in mental health service settings. Mental health therapists will be trained in UOT and deliver to youth and caregivers.
75744506|NCT00829751|Device|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
75449465|NCT01694680|Dietary Supplement|Lutein-enriched-egg beverage (NWT-02)|Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
75744507|NCT00829751|Device|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
75744508|NCT00839501|Dietary Supplement|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
75893426|NCT01294202|Drug|AT13387 and Imatinib|"In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib."
75893427|NCT05098990|Drug|Jinfukang oral liquid|Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
75449466|NCT01694680|Dietary Supplement|Placebo|color-, taste- and energy-matched powder without enriched egg-yolk
75744509|NCT00839501|Drug|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
75744510|NCT00839579|Other|1x4 min interval|Aerobic interval training
75744511|NCT00829907|Drug|ORM-12741|Single dose as a capsule, oral administration
75744512|NCT00529542|Drug|Lipitor|40mg caplets per day for six weeks
75744513|NCT00529542|Drug|Placebo|1 placebo caplet per day for six weeks.
75744514|NCT04043741|Other|Dry Needling|stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)
75744515|NCT04043741|Other|Sustain Pressure|"Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)"
75744516|NCT00621959|Drug|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
75744517|NCT00621959|Drug|placebo|0mg (matching oral tablet)for 14 days
75893428|NCT05098990|Drug|Platinum-based doublet chemotherapy|Platinum-based doublet chemotherapy as first line therapy has been shown to be efficacious against non-small cell lung cancer.
75893429|NCT02093442|Procedure|Endometrial injury|Endometrial biopsy using a pipelle de Cornier
75893430|NCT01071902|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
75449467|NCT01694693|Drug|Orencia|No Intervention
75449468|NCT01694719|Behavioral|Brief Behavioral Activation Treatment for Depression|
75449469|NCT01694719|Behavioral|Cognitive Control Training|
75744518|NCT05702736|Behavioral|logotherapy-based intervention|Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
75744519|NCT00839657|Behavioral|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
75449470|NCT01694732|Drug|Varenicline|
75449471|NCT01694732|Drug|placebo|
75463185|NCT01872754|Drug|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
75600502|NCT04289545|Dietary Supplement|Functional bread|Postprandial effects of bread containing galactomannan
75744520|NCT00839657|Behavioral|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
75744521|NCT05261568|Behavioral|PROGRESSIVE RELAXATION EXERCISE|Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
75744522|NCT02547857|Other|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
75893431|NCT01071902|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
75893432|NCT01071902|Other|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
75893433|NCT01071902|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
75893434|NCT05082766|Drug|enhanced DefenAge 8-in-1 BioSerum|DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
75893435|NCT02086734|Other|Perfusion-CT|"Baseline Perfusion CT-Scan (before AAT)~Follow-Up I Perfusion-CT Scan 7 days after start with AAT~Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
75893436|NCT01284530|Drug|TPM XR|Equivalent TDD in XR form, QD, Day 1-14
75893437|NCT03556878|Behavioral|Fitted Transdiagnostic Sleep and Circadian intervention|Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
75893438|NCT05069116|Other|Training in surgery|The study evaluates the training process of general surgery residents - in classic surgery, as well as laparoscopic surgery, from hospital activity to extracurricular activities.
75893439|NCT01126970|Drug|Velneperit 400 mg|Velneperit 400 mg q.d.
75449472|NCT01694784|Behavioral|Quantitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
75600503|NCT00628732|Drug|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
75744523|NCT03999528|Diagnostic Test|14-3-3η Protein assay|blood sampling for assessment of serum 14-3-3η Protein
75893440|NCT01126970|Drug|Orlistat 120 mg|Orlistat 120 mg t.i.d
75744524|NCT00839813|Behavioral|Yoga|10 weeks of a trauma-sensitive yoga class
75893441|NCT01126970|Drug|Orlistat Placebo|Orlistat Placebo t.i.d.
75893442|NCT01126970|Drug|Velneperit Placebo|Velneperit Placebo q.d
75893443|NCT01126970|Other|Reduced Calorie Diet|Reduced calorie diet
75893444|NCT03557424|Drug|Polyglucosamine Glucomannan normal dose (Verum)|Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
75893445|NCT03557424|Drug|Polyglucosamine Glucomannan high dose (Verum)|Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
75893446|NCT03557424|Drug|Placebo Comparator: Placebo|Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
75893447|NCT05626400|Biological|Senl-T7|Patients will be treated with CD7 CAR-T cells
76062707|NCT04395820|Diagnostic Test|Imaging|MP-MRI
76062708|NCT04395742|Other|Data collection|Only data collection
75616498|NCT00884221|Drug|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
75449473|NCT01694784|Behavioral|Qualitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
75744525|NCT00839891|Drug|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
75744526|NCT00839969|Procedure|Cystoscopy|Saline cystoscopy under general anaesthesia
75893448|NCT05057572|Drug|Carvedilol|- Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP>90, HR >55.
75893449|NCT05057572|Drug|Standard Medical Treatment|"Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)"
75893450|NCT01124708|Drug|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
75893451|NCT01124708|Drug|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
75893452|NCT02089620|Drug|Yasmin|will be used every 21 days for three months by the patient
75893453|NCT02089620|Dietary Supplement|Calver|Calver will be given daily for 3 months
75893454|NCT02089620|Drug|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
75893455|NCT02089620|Drug|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
75893456|NCT02093598|Drug|Temsirolimus|
75893457|NCT01124552|Drug|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
75893458|NCT01124552|Drug|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
75893459|NCT01124552|Other|Vehicle|Vehicle Control
75893460|NCT01124552|Drug|Placebo|Placebo Comparator
75893461|NCT02087124|Other|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
75893462|NCT05627882|Diagnostic Test|Forward viewing endoscope|Additional examination with standard forward viewing endoscope
75893463|NCT04925830|Behavioral|Heart rate variability biofeedback; haemoncephalography biofeedback|Ten 25-minute weekly heart rate variability biofeedback and 30 minute haemoencephalogrphy biofeedback sessions
75893464|NCT02087202|Drug|Magnesium Sulfate|magnesium sulfate is added to the patients
75893465|NCT02087202|Drug|ketamine|ketamine is added to the patients.
75449474|NCT01694784|Behavioral|Narrative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
75744527|NCT00839969|Procedure|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
75744528|NCT00830297|Drug|Insulatard (long-acting insulin)|In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
75893466|NCT01283594|Drug|Tozadenant (SYN115) 60 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID."
75893467|NCT01283594|Drug|Placebo|White-coated, modified-oval placebo tablets.
75744529|NCT00830297|Drug|Conventional|In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
75893468|NCT01283594|Drug|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
75893469|NCT01283594|Drug|Tozadenant (SYN115) 120 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID."
75893470|NCT01283594|Drug|Tozadenant (SYN115) 180 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID."
75893471|NCT01283594|Drug|Tozadenant (SYN115) 240 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID."
76062709|NCT00989950|Drug|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
75893472|NCT04861870|Behavioral|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho was a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engaged men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focused on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
75893473|NCT02089698|Device|Mini-flared|Mini-flared Kelman tip
75893474|NCT02089698|Device|Reversed tip|Reversed Kelman tip
75600504|NCT04289701|Other|Health Services for Systematic Hypertension Management|"The systematic hypertension management health services from the Hypertension prevention and control initiative in China project. Main services are as follows:~Healthcare provider training and patient education.~Standardized guideline-based hypertension diagnosis, treatment and management recommendation.~Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform.~Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs.~Outcome and performance evaluation quarterly.~Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients.~Certification for Honorary Hypertension Centers at county levels and establishment for hypertension clinics at primary care centers."
75600505|NCT02867449|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
75600506|NCT02867449|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
75600507|NCT02866825|Biological|IFX-1|
75744530|NCT03877224|Drug|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
75744531|NCT03877224|Other|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
75893475|NCT04437784|Procedure|Laparoscopic Trans-Abdominal Pre-Peritoneal|Laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
75893476|NCT04437784|Procedure|Open pre-peritoneal repair|Open pre-peritoneal single mesh repair with suture fixation
75893477|NCT04437784|Procedure|Bilateral Lichtenstein repair|Bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
75893478|NCT01282346|Device|SOLX Gold Shunt|Single use implant
75893479|NCT02093676|Behavioral|"experimental protocol treatment The New Authority"|
75893480|NCT04826458|Device|TreC-Onco|"At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission."
75893481|NCT04826458|Other|Paper diary|Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
75893482|NCT01281254|Drug|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
76062710|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
76062711|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
76062712|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
75600508|NCT02866825|Biological|Placebo|
75600509|NCT04290715|Other|no intervention|no intervention
75600510|NCT02870998|Other|Active learning|1-day continuing education activity consisting of a lecture on patient education.
75600511|NCT02870998|Other|Passive learning|1-day continuing education activity consisting of a brief lecture on patient education and workshops.
75744532|NCT00840125|Drug|erlotinib|150mg tablet daily
75744533|NCT00840125|Drug|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
75744534|NCT02548481|Other|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
75744535|NCT00840359|Procedure|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
75744536|NCT00840359|Procedure|Cryotherapy|Cryotherapy for 2 times 20 sec
75744537|NCT00830453|Procedure|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
75744538|NCT04016597|Device|Jaeger Masterscreen TM|Single-breath nitric oxide lung diffusing capacity
75744539|NCT04016597|Device|HypAir Medisoft|Single-breath nitric oxide lung diffusing capacity
75893483|NCT01281254|Drug|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
75893484|NCT02093754|Procedure|MRI and biopsy|
75893485|NCT02087436|Device|Taperloc Complete Microplasty|Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
75893486|NCT02087436|Device|Taperloc Complete Standard|Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
75893487|NCT05104138|Drug|Eplerenone|The patients underwent eplerenone treatment for 6 months
75893488|NCT05104138|Device|The patients underwent half fluence photodynamic therapy for 6 months|Half fluence photodynamic therapy for 6 months
75893489|NCT05627804|Other|Low-moderate intensity exercise|The participants will perform low-intensity cycling exercise at 90% lactate threshold under moderate hypoxia
75893490|NCT05627804|Other|Sprint interval training|The participants will perform sprint interval cycling exercise at a load of 7.5% bodyweight under moderate hypoxia.
76062713|NCT01924936|Behavioral|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
75449475|NCT01694784|Behavioral|Framed Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
75449476|NCT01694797|Drug|Metoprolol Succinate|
75449477|NCT01694810|Drug|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
75449478|NCT01694810|Drug|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel applied once daily 4 weeks
75600512|NCT05212441|Device|Light emitting diode therapy (LED therapy)|The patient's forearm is positioned on table with palm facuing upward during the therapy. For LEDT, the center of the light spot located at approximately 50% of landmark line from the medial epicondyle to the styloid process of the ulna, which is the center belly of ﬂexor digitorum superﬁcialis. The subject's forearm maintained in the rest state without moving during the therapy. LED is performed before exercise.
75600513|NCT05212441|Behavioral|Patient/family education program (Home program)|Patients and their families will instructed to learn the anti contracture positioning/splinting, scar massage and exercises program, application of the custom garments and inserts, and functional training to perform them on their own at home. Written and illustrative instructions and reciprocal demonstration sessions will be provided to the children and their families to ensure successful acquisition and delivery of rehabilitation skills at home program. The therapist will be reported about compliance with the home program every couple of days
75600514|NCT05212441|Procedure|Positioning & Splinting|"The wrist joint is splinted at 30 hyperextension, the MCP joint in 90 of flexion, the IP joints in extension, and the thumb in abduction. The webs of fingers kept in abduction. The hands are elevated above the level of the heart to minimize post-burn edema.~Splinting: Splints are tailored to help to maintain the functional or anti-contracture position of the injured body parts.The intervals for monitoring vary from once every hour to once every 4-6 hours, depending on types of splints and skin conditions. It is described as 10 hours on and two hours off. When the splint is taken off, active and/or passive ROM should be carried out."
75744540|NCT00528606|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
75744541|NCT00528606|Biological|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
75744542|NCT00830531|Drug|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
75744543|NCT00830531|Drug|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
75893491|NCT05627804|Other|Functional exercise|The participants will perform bodyweight exercises under moderate hypoxia.
75893492|NCT05627804|Other|Control|No exercise will be performed.
75893493|NCT04437082|Device|optical coherence tomography|imaging structural and vascular features of the eye
75893494|NCT03072043|Drug|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
75893495|NCT03072043|Drug|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m^2.
76062714|NCT04276012|Other|Multifactorial intervention|Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
75449479|NCT01694810|Drug|8% NVN1000 Topical Gel|8% NVN1000 Topical Gel applied once daily for 4 weeks
75449480|NCT01694810|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied once daily
75449481|NCT01694823|Drug|CS-ACI|"Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）"
75449482|NCT01694836|Biological|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
75893496|NCT05626010|Drug|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
76062715|NCT01925092|Drug|mifepristone|tablets
75744544|NCT05014542|Procedure|Acupuncture|Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.
75744545|NCT05014542|Drug|Conventional Medical Treatment|Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
75893497|NCT05626010|Drug|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
75600515|NCT05212441|Other|Therapeutic Exercises|"Passive ROM (PROM).~Active ROM (AROM) & Active-assistive ROM (AAROM): The exercise will focus on extending the wrist to 45 degrees, flexing the MCP joints to 90 degrees and keeping the IP joints in full extension, while maintaining a thumb web space. The exercises will performed in the following sequences; (1) MCP joints flexion and extension with the wrist in neutral or slight extension and the IP joints in neutral position. (2) IP joints flexion to only 30-40 degrees with the wrist stabilized in the neutral or slight extension, while the MCP joints held in full extension, (3) thumb and fingers abduction and adduction, and (4) thumb opposition (tip of the thumb to tip of the small finger). Each exercise was performed for 8-10 repetition, daily, for 6 days/week.~Stretching exercises: A low-load (low-intensity), long-duration stretch~Strengthening exercises: done in static mode initially and progress to dynamic strengthening using elastic bands."
75893498|NCT04766398|Drug|KHK7791|oral administration
75600516|NCT04298788|Other|Blue dishware|blue dishware is used for plates and bowls
75449483|NCT01694862|Procedure|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
75449484|NCT01694875|Device|APTIMA HPV Assay|In Vitro Diagnostics Assay
75600517|NCT02865421|Drug|stem cells|adipose tissue derived stromal vascular fraction
75893499|NCT04766398|Drug|Placebo|oral administration
75893500|NCT02093832|Other|There are no specific Intervention|are no specific Intervention
75744546|NCT00840593|Procedure|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
75893501|NCT02089854|Drug|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
75600518|NCT02865421|Drug|platelet rich plasma|platelet rich plasma transplanted in bald area at a distance
75893502|NCT05624840|Drug|Nirmatrelvir/ritonavir|Nirmatrelvir-ritonavir (Paxlovid)
75893503|NCT02093910|Drug|Monosialotetrahexosylganglioside|
75893504|NCT04636216|Behavioral|COPE parent training|Weekly 1.5 hour parent training meetings for eight weeks
75893505|NCT03557346|Device|the WAM-5500 binocular autorefractor/keratometer (Grand Seiko Co. Ltd., Hiroshima, Japan)|: Subjects underwent a basic ophthalmic examination and the accommodative response to refractive stimuli was measured. Refractive stimuli were given at 0.25 diopters (D) (4 m distance), 2D (50 cm), 3D (33 cm), and 4D (25 cm) and stimulation was applied with the eyes in binocular, monocular (dominant eye, non-dominant eye, ipsilateral, and contralateral), and pinhole conditions. In addition, changes in the astigmatic value and direction of the astigmatism axis under binocular stimulus were evaluated.
75893506|NCT04437160|Drug|Epirubicin or Pirarubicin|Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d*4cycls
75893507|NCT04437160|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2 IV, q21d*4cycls
75893508|NCT01265264|Drug|ulodesine|Oral dose administered daily for 84 days.
75893509|NCT01265264|Drug|Placebo|Oral dose administered daily for 84 days.
75893510|NCT02089932|Drug|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
75893511|NCT02089932|Drug|Placebo|
75893512|NCT05761483|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography, placement of stents using a duodenoscope and making an access through the papilla of Vater
75449485|NCT01694888|Other|lecture|Teaching documentation skill using lecture method
75449486|NCT01694914|Procedure|corneal graft|
76062716|NCT03121378|Other|Blood sample 1|Blood taken before prosthesis implantation
76062717|NCT03121378|Other|Blood sample 2|Blood taken after prosthesis implantation
76062718|NCT01920256|Other|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
76062719|NCT01920256|Other|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
76062720|NCT04347850|Other|blood sample|Collection
75893513|NCT05374486|Device|NeuroExo co-robot neurorehabilitation system|In this longitudinal study, adult subjects with hemiparesis due to chronic stroke will receive robotic-assisted upper-arm training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG). After one screening visit, two baseline visits for EEG signal screens, six onsite training sessions will be provided with the NeuroExo system, followed by 60 home therapy sessions (2 sessions per day, 5 days per week for 6 weeks). If the participant have completed at least 50 sessions of neurotherapy at home, the participant will complete a set of measurements to assess function of the affected upper arm and brain activity within 3 days after the last session for post-assessment visit, and one-month post follow-up session. The total amount of time for this study is 16-20 weeks.
75893514|NCT02093988|Drug|Topical TXA|
75600519|NCT04205344|Drug|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
75600520|NCT04205344|Drug|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
75600521|NCT01004146|Procedure|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
75600522|NCT01012414|Drug|paricalcitol|2 mcg oral paricalcitol daily
75449487|NCT01694927|Procedure|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
75893515|NCT02093988|Drug|Intravenous TXA|
75893516|NCT05221996|Behavioral|Resistance training|Resistance circuit training
75893517|NCT01037036|Drug|Latanoprost Punctal Plug Delivery System|To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
75893518|NCT01037036|Drug|Xalatan|Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
75893519|NCT05488782|Behavioral|TEAM-Red|Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference
75449488|NCT01694979|Other|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
75600523|NCT01012414|Drug|placebo|placebo
75600524|NCT00975715|Drug|TRI476|TRI476 oral suspension doses, based on body weight twice daily
75600525|NCT00975715|Drug|Placebo to TRI476|Placebo oral suspension, taken twice daily
75600526|NCT00975715|Drug|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
75893520|NCT05488782|Other|Waitlist|After the week 12 follow up visits subjects in the Waitlist group will receive the TEAM Red intervention
75893521|NCT04360694|Procedure|Incremental hemodialysis|58 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.
75893522|NCT04360694|Procedure|Conventional hemodialysis|58 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.
75600527|NCT04295668|Behavioral|Usual care|The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).
75744547|NCT00840593|Procedure|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
75744548|NCT00843947|Procedure|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
75449489|NCT01694979|Other|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
75449490|NCT01694979|Other|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
75449491|NCT01694992|Other|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
75449492|NCT01695005|Drug|LY3039478|Administered orally
75893523|NCT02250066|Other|Diet|Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid
75893524|NCT03069313|Dietary Supplement|Vitamin B12|Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
75893525|NCT02267486|Other|Standard therapy of Alzheimer Dementia (AD)|
75893526|NCT02267486|Other|Observation|
75893527|NCT02094066|Drug|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
75893528|NCT02094066|Drug|serum physiologic|preoperative 100 cc ıv serum physiologic
75893529|NCT02090010|Procedure|Seldinger technique|"The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed.~After that catheter is passed over the guidewire into the vessel."
75893530|NCT02090010|Procedure|Modified Seldinger technique|The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instantly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
75616499|NCT00884221|Drug|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
75449493|NCT01695005|Drug|Prednisone|Administered orally
75449494|NCT01695031|Behavioral|Tailored asthma management program|web-based, computer-tailored asthma management intervention delivered every week for 4 weeks
75893531|NCT01033292|Drug|BSI-201|IV infusion, 5.6 mg/kg
75449495|NCT01695031|Behavioral|Generic web-based education|Generic, web-based asthma education
75449496|NCT01695057|Drug|vorinostat|Given PO
75616500|NCT02634229|Genetic|blood sample|
75616501|NCT02153632|Drug|amantadine HCl ER|Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
75616502|NCT02153632|Drug|Placebo|subjects are given an identical placebo tablet
75744549|NCT04925622|Diagnostic Test|Complex eye movement exam|"Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice."
75449497|NCT01695057|Procedure|therapeutic conventional surgery|Undergo surgery
75449498|NCT01695057|Other|laboratory biomarker analysis|Correlative studies
75616503|NCT03524326|Drug|Lenvatinib Pill|24 mg oral daily
75616504|NCT03524326|Drug|Lenvatinib Pill|20 mg oral daily
75616505|NCT03524326|Drug|Lenvatinib Pill|14 mg oral daily
75616506|NCT03524326|Drug|Cetuximab|400mg/m2 IV, then 500mg/m2 IV weekly
75616507|NCT03524326|Drug|Lenvatinib Pill|10 mg oral daily
75616508|NCT03524326|Drug|Lenvatinib Pill|4 mg oral daily
75616509|NCT01236430|Drug|Ezetimibe|Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
75744550|NCT04926324|Drug|Niraparib|Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
75744551|NCT04926324|Drug|Dostarlimab|Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.
75744552|NCT04926324|Radiation|Short course radiation|Participants will be treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimize mean dose to femoral, pelvic, and lumbar bone marrow. The entire mesorectum will be treated to a total dose of 25 Gy.
75744553|NCT00621257|Dietary Supplement|ergocalciferol|8000 units/ml
75744554|NCT00621257|Dietary Supplement|Cholecalciferol|400 units per drop
75744555|NCT00528840|Biological|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
75744556|NCT02547077|Procedure|Wound Closure with 2-octylcyanoacrylate|
75744557|NCT02547077|Procedure|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
75744558|NCT00840671|Drug|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
75744559|NCT00840671|Drug|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
75744560|NCT00851123|Behavioral|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
75744561|NCT00851123|Behavioral|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
75744562|NCT05691114|Biological|hAESCs|human Amniotic Epithelial Stem Cells
75744563|NCT05686590|Behavioral|Augmented Reality Headset|The simulation scenario will be a pediatric hypoglycemia-induced seizure case, which will be done through an AR simulation. AR (Augmented Reality) headset, which is a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario.
75744564|NCT02545985|Device|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
75893532|NCT03068767|Dietary Supplement|Vitamin D|
75449499|NCT01695070|Drug|Melatonin|4mg prolonged release melatonin oral tablets twice daily
75449500|NCT01695096|Other|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
75449501|NCT01695096|Other|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
75449502|NCT01695109|Drug|Liraglutide|sc injections of 0.6 mg Liraglutide daily for three continuous days.
75893533|NCT02094144|Other|Brisk walking program|The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
75893534|NCT02094144|Other|physical activity habit|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
75893535|NCT02267720|Procedure|Occlusal-proximal ART restorations - Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
75893536|NCT02267720|Procedure|Occlusal-proximal ART restorations - Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
75893537|NCT05204329|Biological|MSC Secretome Eye Drops|MSC Secretome eye drop will be dispensed.
75893538|NCT02090166|Other|Blood test|a blood test will be taken from each patient
75893539|NCT01110902|Drug|Agomelatine (AGO178C)|
75893540|NCT01110902|Drug|Placebo|
75893541|NCT05204173|Drug|sintilimab, paclitaxel and S-1|Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days with one week rest.
75893542|NCT05204095|Device|Portable slit-lamp photography|The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.
75893543|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 90 mcg/actuation|E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period
75893544|NCT01025648|Drug|E004 Placebo|E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period
75893545|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 125 mcg|E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
75893546|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 220 mcg|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
75893547|NCT01025648|Drug|epinephrine inhalation aerosol, CFC propelled|epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
76062721|NCT01925248|Dietary Supplement|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
76062722|NCT01925248|Dietary Supplement|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
75449503|NCT01695109|Drug|Placebo|0.9% NaCl, 0.2 ml
75744565|NCT00851201|Behavioral|Intensive lifestyle|"The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups."
75449504|NCT01695122|Drug|Valproic Acid|
75744566|NCT00851201|Behavioral|Standard intervention|The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
75744567|NCT00844025|Behavioral|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
75893548|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 160 mcg|E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
76062723|NCT01905943|Drug|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m^2 in previously untreated participants, and bendamustine 50 mg/m^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
76062724|NCT01905943|Drug|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
76062725|NCT01905943|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m^2 p.o. QD Day 1-3 in fit participants only.
76062726|NCT01905943|Drug|Fludarabine|Fludarabine 25 mg/m^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m^2 per os (p.o.) QD Day 1-3 in fit participants only.
76062727|NCT01905943|Drug|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
75449505|NCT01695148|Dietary Supplement|β-Carotene Biofortified Maize Flour|
75449506|NCT01695148|Dietary Supplement|White Maize Flour|
75449507|NCT01695174|Drug|Xifaxan|
75449508|NCT01695187|Drug|NB-001 (0.3%)|Topical administration at least five times throughout the day
75449509|NCT01695187|Drug|Placebo|
75449510|NCT01695200|Dietary Supplement|Omega-3 fatty acids|
75449511|NCT01695213|Procedure|uncemented total hip arthroplasty|
75449512|NCT01695226|Drug|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
75449513|NCT01695226|Drug|Placebo|pre-operative placebo twice daily for two to three weeks
75449514|NCT01695252|Other|MEMOS|Patient informed clinical outcomes supervision
75744568|NCT02546531|Biological|Defactinib|
75744569|NCT02546531|Biological|Pembrolizumab|
75744570|NCT02546531|Drug|Gemcitabine|
75893549|NCT03020745|Drug|GSK3389404|GSK3389404 is available as Clear colorless to slightly yellow solution for injection.
75893550|NCT03020745|Drug|Placebo|Placebo is available as a Clear colorless solution.
75893551|NCT04960891|Drug|Tebentafusp|Concentrate solution for intravenous infusion
75893552|NCT01110746|Drug|Viaject 7|100IU/mL administered subcutaneously
75893553|NCT01110746|Drug|LISPRO|100IU/mL administered subcutaneously
75893554|NCT05208775|Procedure|PDT|"Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.~Laser irradiation:~48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts."
75893555|NCT05208775|Procedure|ESD|The patients received standard endoscopic submucosal dissection after enrollment.
75893556|NCT05623280|Drug|Indocyanine green|Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
75893557|NCT02946853|Procedure|Atrioventricular junctional (AVJ) ablation|RF energy delivery to AV node to create complete AV block
75893558|NCT02946853|Device|Cardiac resynchronization therapy - defibrillator|Insertion of device capable of providing biventricular pacing and cardiac defibrillation
75893559|NCT02267798|Other|conventional therapy|"The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.~The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors."
75744571|NCT00840983|Procedure|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
75893560|NCT02267798|Device|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles."
75893561|NCT02895841|Other|SMART app wearable|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
75449515|NCT01695265|Other|Exercie oronasal breathing (ONB)|10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
75600528|NCT04295668|Behavioral|Prehabilitation|"i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment."
75744572|NCT05205720|Procedure|Celiac plexus block|The surgeon is instructed to perform a single celiac plexus block under direct vision. 10ml 0.5% ropivacaine is injected into the nerve in both sides.
75744573|NCT05205720|Drug|Ropivacaine|Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
75449516|NCT01695265|Device|Exercie nasal breathing through the FB|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
75449517|NCT01695278|Behavioral|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
75744574|NCT00844103|Drug|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
75744575|NCT00844103|Drug|Placebo|10ml oral solution administered once a day over 10 days.
75449518|NCT01695343|Biological|KB001-A|
75449519|NCT01695343|Drug|Placebo Comparator|
75744576|NCT04907526|Biological|Autologous mononuclear cells|Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.
75744577|NCT00841061|Dietary Supplement|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
75893562|NCT02267876|Device|BD HPV Assay on Viper LT|The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
75893563|NCT02267876|Procedure|Colposcopy|The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
75893564|NCT05762185|Device|nursing consultation|nursing consultation
75449520|NCT01695356|Drug|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
75449521|NCT01695356|Drug|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
75449522|NCT01695382|Behavioral|Navigation|As per Arm description
75463186|NCT01872754|Drug|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
75463187|NCT01872780|Drug|Rosiglitazone|single oral administration of 4mg of rosiglitazone
75600529|NCT02866981|Other|Observation|
75600530|NCT00629317|Other|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
75600531|NCT00629317|Drug|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
75600532|NCT04298476|Procedure|Placement of an adductor canal nerve block|An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.
75600533|NCT02866591|Other|mammography according to an auto-compression procedure|
75600534|NCT02866591|Other|mammography according to a standard procedure|
75893565|NCT02267954|Other|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
75893566|NCT05622968|Device|Foley catheter|Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water
75893567|NCT05622968|Drug|Intravaginal prostaglandin E2|Insertion of intravaginal Dinoprostone
75893569|NCT03667989|Diagnostic Test|Assessment of cardiac sympathetic innervation by 123I-MIBG|Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
75893570|NCT01020968|Biological|Ixmyelocel-T|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
75893571|NCT01020968|Other|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
75893572|NCT02268032|Drug|DHEA|DHEA 2.2 g in vaginal ring
75893573|NCT02268032|Drug|Another Androgenic Agent (VRaA)|Testosterone 35 mg in vaginal ring
75893574|NCT02268032|Drug|Fixed combination of 2 androgenic agents (VR2A)|DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring
75893575|NCT03019965|Drug|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam administered in 30 minutes infusion.
75463188|NCT01872780|Genetic|CYP2C8 genotype|CYP2C8*11.
75463189|NCT01872806|Radiation|a dialing smartphone will be placed on the chest and the ear|
75600535|NCT02866591|Other|questionary|
75893576|NCT03019965|Drug|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam administered in 24 hours infusion.
75893577|NCT03019965|Drug|Intermittent Imipenem|Imipenem administered in 60 minutes infusion.
75893578|NCT03019965|Drug|Extended Imipenem|Imipenem administered in 6 hours infusion.
75893579|NCT03019965|Drug|Intermittent Meropenem|Meropenem administered in 60 minutes infusion.
75893580|NCT03019965|Drug|Extended Meropenem|Meropenem administered in 8 hours infusion.
75893581|NCT02268110|Other|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
75893582|NCT02268110|Other|Abdominal binding|Wearing an abdominal binder for 12 weeks
75449523|NCT01695421|Procedure|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
75893583|NCT03623061|Diagnostic Test|F-Point|F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
75893584|NCT01468831|Drug|Minocycline|100 mg of minocycline in a pink opaque capsule
75600536|NCT02871154|Other|Delaying oocyte pick up beyond 39 hours post hCG|Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
75600537|NCT03962491|Behavioral|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.
75893585|NCT01468831|Other|Placebo|Pill with inactive ingredients in a pink opaque capsule
75893586|NCT01468831|Drug|Bevacizumab|1.25 mg bevacizumab injection
75893587|NCT03667911|Other|virtual reality videos|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
75893588|NCT05627414|Drug|Disitamab Vedotin|2.5mg/kg，IV，Q3W
75893589|NCT05627414|Drug|Sintilimab|200 mg，IV，Q3W
75893590|NCT05627414|Drug|S-1|40~60mg / m2, bid, d1-14, repeated every 3 weeks.
75600538|NCT03962491|Behavioral|Daily Self-Monitoring Surveys|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
75600539|NCT02866513|Other|evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.|
75600540|NCT04290637|Other|Cold-water sea swimming|Continue sea swimming for 4-6 weeks
75600541|NCT04290637|Other|No cold-water sea swimming|Discontinue sea swimming for 4-6 weeks
75600542|NCT00978757|Drug|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
75600543|NCT00978757|Other|Placebo|saline solution
75600544|NCT01214421|Drug|Tolvaptan|Tablets of 15 or 30 mg
75744578|NCT00841061|Dietary Supplement|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
75744579|NCT03999060|Device|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
75744580|NCT04042805|Biological|Sintilimab|200mg intravenously every 3 weeks
75744581|NCT04042805|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75893591|NCT05627414|Procedure|Intraperitoneal chemotherapy with paclitaxel|Paclitaxel (PTX) was used with a dose of 60mg / m2, Q3W. （Only for patients with peritoneal metastases）
75893592|NCT03668691|Device|Robotic-arm assisted partial knee arthroplasty|Robotic-arm assisted medial unicompartmental knee arthroplasty, lateral unicompartmental knee arthroplasty, bicompartmental knee arthroplasty, patellofemoral knee arthroplasty implants. A robotic arm assisted unicompartmental or bicompartmental knee arthroplasty procedure to replace the medial or lateral and /or patellofemoral compartments of the knee.
75893593|NCT01675882|Biological|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
75893594|NCT01675882|Biological|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
75893595|NCT01675882|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
75893596|NCT01675882|Biological|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
75893597|NCT05617508|Other|Placebo|Placebo capsules administered twice daily for a total of 12 weeks.
75893598|NCT05617508|Dietary Supplement|Nicotinamide Riboside supplementation 1000mg daily in total|Nicotinamide Riboside supplementation 1000mg daily in total
75893599|NCT05617508|Dietary Supplement|Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)|Nicotinamide Riboside supplementation up to 3000mg daily in total
75893600|NCT03018249|Drug|Entinostat|Given PO
75893601|NCT03018249|Procedure|Hysterectomy|Undergo hysterectomy
75893602|NCT03018249|Other|Laboratory Biomarker Analysis|Correlative studies
75893603|NCT03018249|Drug|Medroxyprogesterone Acetate|Given IM
75893604|NCT01018550|Drug|AMG 853|AMG 853 5 mg (BID)
75893605|NCT01018550|Drug|AMG 853|AMG 853 200 mg (QD)
75893606|NCT01018550|Drug|AMG 853|AMG 853 25 mg (BID)
75893607|NCT01018550|Drug|AMG 853|AMG 853 100 mg (BID)
75893608|NCT01018550|Drug|Placebo|Placebo
75893609|NCT05380154|Drug|Botulinum Toxin A type for injection (Botulax®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects
75744582|NCT05643846|Procedure|QLB procedure after cesarean section|Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.
75893610|NCT05380154|Drug|Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.
75893611|NCT05378984|Other|before - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
75893612|NCT05378984|Other|after - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
76062728|NCT01905553|Drug|SSP-004184SS|Disodium salt
75893613|NCT05374252|Drug|PD-1 inhibitor|Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
75893614|NCT05374252|Radiation|concurrent chemoradiotherapy|Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT
76062729|NCT04629625|Biological|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
76062730|NCT04629625|Biological|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
76062731|NCT04629625|Biological|Placebo|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
76062732|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
76062733|NCT01929031|Drug|ibuprofen|tablet.
75600545|NCT04102111|Drug|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily.
76062734|NCT01929031|Drug|ibuprofen|tablet
76062735|NCT01929031|Drug|caffeine|tablet
75893615|NCT00912158|Other|standard therapy (ST)|standard medical therapy
75893616|NCT00912158|Device|CPAP|Non-invasive mechanical ventilation (CPAP)
76062736|NCT01929031|Drug|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
76062737|NCT01929031|Drug|placebo|tablet
76062738|NCT01929031|Drug|placebo|tablet
76062739|NCT01929031|Drug|caffeine|tablet
75449524|NCT01695421|Procedure|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
75449525|NCT01695421|Procedure|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
75463190|NCT01872832|Drug|RDEA3170 and Placebo|
75600546|NCT04102111|Drug|Placebo|Participants will receive oral tablets of matching placebo twice daily.
75893617|NCT00912158|Device|BIPAP|Non-invasive mechanical ventilation (BIPAP)
75600547|NCT01214187|Drug|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
75600548|NCT01214187|Other|Oxygen|Room air oxygen concentrations will be administered as placebo
76062740|NCT01929031|Drug|ibuprofen|tablet
76062741|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
76062742|NCT00989092|Biological|darbepoetin alfa|Administered subcutaneously.
76062743|NCT00988858|Drug|LY2603618|150 milligram per square meter (mg/m^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
76062744|NCT00988858|Drug|Pemetrexed|500 mg/m^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
75893618|NCT04438096|Drug|100 mg|One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
75893619|NCT04438096|Drug|200 mg|Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks
75893620|NCT04438096|Drug|300 mg|Three 100 mg pills (QD) will be orally administered for 12 weeks
75893621|NCT04438096|Drug|Placebo|Three placebo pills (QD) will be orally administered for 12 weeks
75893622|NCT01015430|Drug|Placebo (for RO4917523 ascending doses)|Placebo daily po
76062745|NCT01920334|Drug|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
76062746|NCT01920334|Drug|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
76062747|NCT04395352|Device|Endocuff Vision (ECV)|Detachable disposable (single-use) device that fits over the distal colonoscope end.
76062748|NCT01920490|Device|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
76062749|NCT01920490|Device|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
76062750|NCT04275622|Behavioral|Lifestyle including optimal exercise and diet modification.|The intervention group will receive diet education and be given exercise suggestion.
76062751|NCT01920646|Other|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
76062752|NCT00986986|Drug|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
76062753|NCT01925482|Drug|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
76062754|NCT01925482|Drug|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
76062755|NCT01925482|Drug|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
76062756|NCT01925482|Drug|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
76062757|NCT01925482|Drug|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
76062758|NCT01925482|Drug|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
75600549|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
76062759|NCT04275466|Procedure|necrotic cavity lavage|"At least two 30- to 36-Fr drainage tubes will be placed into each necrotic cavity. One of these drainage tubes will be used as the lavage tube; the other tube is designed for drainage.~Lavage will begin on the first day after debridement, and the relevant indices will be evaluated every 7 days to decide whether to continue the lavage.~1200 mL of normal saline will be lavaged into each necrotic cavity every day at a speed of 200 mL/h for 3 hours each time and for a total of two times. The start times of lavage will be 08:00 and 20:00.~The lavage and drainage volumes of the first hour and second hour of each lavage session will be calculated. The lavage of the next hour will be stopped if the lavage volume minus the drainage volume is >100 mL.~Lavage will be suspended if abdominal pain and distention occur, the maximum body temperature is >38.5ºC, or the abdominal pressure is ≥15 mmHg during the lavage procedure."
76062760|NCT01904773|Drug|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
76062761|NCT01928719|Drug|Reduced Nicotine Content Cigarettes|Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette
76062762|NCT01928719|Drug|Same Nicotine Content Cigarettes|about 11.6 mg nicotine per cigarette
76062763|NCT00986674|Biological|cixutumumab|Given IV
75449526|NCT01695421|Procedure|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
75449527|NCT01695434|Other|MRI|All subjects will undergo a MRI.
75449528|NCT01695447|Procedure|duct-to-mucosa|
75744583|NCT00841139|Drug|Perhexiline|100mg o bd
75893623|NCT01015430|Drug|Placebo (for RO4917523 fixed dose)|Placebo daily po
75893624|NCT01015430|Drug|RO4917523|RO4917523 ascending doses daily po
75893625|NCT01015430|Drug|RO4917523|RO4917523 fixed dose daily po
75893626|NCT02923245|Other|point-of-care ultrasound|
75893627|NCT05103748|Behavioral|Traditional vestibular rehabilitation|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
75893628|NCT05103748|Behavioral|Cognitive and vestibular dual task training|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
75893629|NCT04399486|Other|Physical Therapy|Physical Therapy is a therapeutic exercise, education and functional activities provided on a one to one basis with a licensed Physical Therapist to meet functional goals.
75600550|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
75744584|NCT00841139|Drug|Placebo|1 tablet bd
75744585|NCT00841217|Drug|GW501516|2.5mg/day
75744586|NCT00841217|Drug|placebo pill|
75744587|NCT00841295|Drug|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
75744588|NCT00841295|Drug|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
75744589|NCT00851435|Biological|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
76062764|NCT00986674|Drug|carboplatin|Given IV
76062765|NCT00986674|Drug|paclitaxel|Given IV
76062766|NCT00986674|Biological|cetuximab|Given IV
76062767|NCT00986440|Drug|CS-7017|CS-7017
76062768|NCT00986440|Drug|Placebo|Placebo
76062769|NCT01904383|Drug|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
76062770|NCT01920880|Other|Quantitative Sensory Testing analysis|
76062771|NCT01904149|Drug|Placebo|Placebo single oral dose (first 8 hours)
76062772|NCT01904149|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
76062773|NCT01904149|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
76062774|NCT01904149|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
76062775|NCT01904149|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
75893630|NCT03668535|Procedure|Bladder Filling|Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
75893631|NCT03668535|Procedure|Bladder deflation|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
75744590|NCT00844337|Drug|Gentamicin & Amoxicillin x 7days|"Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.~The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day."
75893632|NCT00908648|Procedure|Narrow Band Imaging|Narrow Band Imaging
75893633|NCT04437940|Diagnostic Test|Vaginal fluid Covid-19 PCR test|Vaginal fluid samples are tested for Covid-19
75893634|NCT01014806|Biological|Influenza VLP Vaccine|Single dose; 0.5mL
75893635|NCT01014806|Biological|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
75893636|NCT03667833|Other|Shoulder brace|Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
75893637|NCT05102968|Behavioral|Home-based rehabilitation supporting with the mobile application|For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.
75893638|NCT05102968|Behavioral|Supervised rehabilitation by the therapist|For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd~12th week and once two weeks at post-operative 13th~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
76062776|NCT01904149|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
76062777|NCT01904149|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
76062778|NCT00986362|Drug|Ocriplasmin|175µg ocriplasmin intravitreal injection
76062779|NCT00986362|Drug|Placebo|Placebo intravitreal injection
75449529|NCT01695447|Procedure|invagination|
75449530|NCT01695447|Device|Internal stent|Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
75449531|NCT01695460|Drug|D3 Vitamin ®|"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."
75449532|NCT01695460|Drug|Placebo|
75449533|NCT01695525|Other|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
75449534|NCT01695538|Other|Yoga|The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
75744591|NCT00844337|Drug|Penicillin & gentamicin x 2 d + Amoxicillin X 5 d|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
75893639|NCT03667755|Procedure|fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding|participants will be carbohydrate loaded with whey protein infused carbohydrate drink and started on early oral feeding post-operation
75893640|NCT01014572|Behavioral|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
75893641|NCT01014572|Drug|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
75449535|NCT01695551|Other|Data Collection Forms|Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
75449536|NCT01695564|Device|LARIAT LAA|The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.
75449537|NCT01695564|Device|WATCHMAN|The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
75449538|NCT01695577|Other|Multidisciplinary evaluation and VR|Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
75744592|NCT00844337|Drug|Standard reference therapy|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
75744593|NCT00841373|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
76062780|NCT01925560|Other|Agave Inulin|3x3 Latin square with 3 periods
76062781|NCT01925560|Other|Placebo|control- 0 (zero) grams/day inulin
76062782|NCT01890421|Drug|Gadobutrol (Gadovist, Gadavist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
76062783|NCT01925638|Drug|BAY86-9766|
76062784|NCT01925638|Drug|Ketoconazole|
76062785|NCT01925716|Other|Corn oil|corn oil 56 g/day for 21 days
75449539|NCT01695577|Other|Multidisciplinary evaluation|Multidisciplinary assessment and evaluation.
75744594|NCT00841373|Procedure|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
75744595|NCT00841451|Drug|Lovaza (Fish Oils)|Double blinded placebo controlled
75893642|NCT01014572|Behavioral|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
75893643|NCT04437316|Device|Use of Low level Laser after wisdom tooth removal|Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
75893644|NCT01013324|Drug|XL147 (SAR245408)|dosed as capsules taken orally daily
75893645|NCT04437550|Other|Exercise|high intensity exercise = 15 x 60 s sprints at 85% velocity of VO2max (vVO2max) with 60 s walking at 20% vVO2max or moderate intensity exercise = walking at 60% vVO2max
75893646|NCT00905606|Drug|Topiramate Tablets|
75449540|NCT01695590|Drug|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
75449541|NCT01695603|Device|Intellivent|
75449542|NCT01695616|Drug|Placebo|
75449543|NCT01695616|Drug|Active drug|
75449544|NCT01695681|Other|Gluten-free diet|Dietary advice by clinical dietitian
75600551|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
75600552|NCT02865031|Drug|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
75600553|NCT02864875|Drug|Fibrinogen concentrate|Receive fibrinogen concentrate 50mg/kg of body weight after randomization
75600554|NCT01003990|Drug|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
75600555|NCT01003990|Drug|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
75893647|NCT00905606|Drug|Topamax® Tablets|
75893648|NCT01002950|Drug|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
75893649|NCT01002950|Drug|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
75893650|NCT01676896|Behavioral|Asthma in-school class|
75600556|NCT01003990|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
75744596|NCT00844493|Biological|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
75744597|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
75893651|NCT01676896|Behavioral|Asthma Day Camp|
75893652|NCT01676896|Behavioral|Health Promotion in-school class|
75893653|NCT03017235|Drug|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
75449545|NCT01695694|Behavioral|supporting positive and healthy relationships|
75449546|NCT01695694|Behavioral|community support group|
75449547|NCT01695707|Drug|Pioglitazone|see Arm Description
75449548|NCT01695707|Drug|Placebo (for pioglitazone)|see Arm Description
75449549|NCT01695720|Procedure|VisionScope Imaging (VSI) Exam|The VisionScope Imaging (VSI) Exam [the system itself] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
75449550|NCT01695733|Biological|trivalent influenza vaccine|
75449551|NCT01695759|Drug|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
75600557|NCT01003990|Drug|Lopinavir/ritonavir|Tablets, Oral, 400/100 mg, twice daily, indefinitely
75744598|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
75744599|NCT00844493|Biological|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
75744600|NCT00851513|Drug|Lidocaine|local anesthetics
75893654|NCT03017235|Drug|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder|Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
75600558|NCT01003210|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
75744601|NCT00851513|Drug|Depmedrol|local steroids
75744602|NCT00851513|Other|physiological serum|important volumes of physiological serum
75744603|NCT00841607|Procedure|pancreaticojejunostomy vs pancreaticogastrostomy|
75893655|NCT00905372|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
75893656|NCT00905372|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
75893657|NCT05208788|Diagnostic Test|Biomarker test|collection of 500µl to 1 ml of a spot urine sample
75893658|NCT03017079|Dietary Supplement|semi-solid agent with standard enteral feeding|after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 minutes
75893659|NCT03017079|Other|standard enteral feeding|Intermittent enteral feeding is applied less than 60 minutes
75893660|NCT05048134|Drug|HRS2300|HRS2300 monotherapy
75600559|NCT01002820|Drug|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
75744604|NCT00844571|Other|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
75744605|NCT00841841|Drug|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
75744606|NCT02545751|Radiation|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
75893661|NCT05048134|Drug|HRS2300、 SHR-1316|HRS2300 combined with SHR-1316
75893662|NCT05048134|Drug|HRS2300、SHR-1701|HRS2300 combined with SHR-1701
75893663|NCT05048134|Drug|HRS2300、trametinib|HRS2300 combined with trametinib
75893664|NCT05048134|Drug|HRS2300、Almonertinib|HRS2300 combined with Almonertinib
76062786|NCT01925716|Other|Olive oil|olive oil 56 g /day for 21 days
75449552|NCT01695759|Drug|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
75449553|NCT01695798|Biological|Injectable polio vaccine and Bivalent oral polio vaccine|"One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone"
75449554|NCT01695824|Device|LAA occluder|The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
75463191|NCT01872845|Drug|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
75600560|NCT01012258|Biological|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
75744607|NCT02545751|Drug|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
75744608|NCT00841919|Drug|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
75893665|NCT04438928|Dietary Supplement|Elevit Pregnancy 2nd & 3rd Trimester|Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
75893666|NCT04438928|Other|Non-Supplement|Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
75893667|NCT03667677|Drug|Tandospirone + Amlodipine|The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
75893668|NCT03667677|Drug|Tandospirone placebo + Amlodipine|The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
75463192|NCT01872845|Drug|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
75463193|NCT01872858|Drug|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
75463194|NCT01872858|Drug|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
75463195|NCT01872871|Drug|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
75463196|NCT01872871|Drug|Topical anaesthetic drop with placebo|
75600561|NCT00628810|Biological|bevacizumab|
75600562|NCT00628810|Drug|fluorouracil|
75893669|NCT03667677|Drug|Tandospirone + Amlodipine placebo|The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
76062787|NCT03092284|Biological|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Direct intramyocardial injection of CSCC_ASC
76062788|NCT03092284|Biological|Placebo|Saline
75893670|NCT03667677|Drug|Tandospirone placebo + Amlodipine placebo|The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
75893671|NCT04437472|Other|CareSignal|The CareSignal software will be programmed to automatically ask a subset of the NCI-PRO-CTCAE questions using SMS depending on patient group as designated by the treating physician: (1) thoracic radiation with chemotherapy, (2) thoracic radiation alone, (3) extremity/body wall sarcoma, and (4) other.
75744609|NCT00841919|Drug|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
75893672|NCT05184296|Procedure|Extracorporeal Membrane Oxygenation (ECMO)|All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
75893673|NCT04392856|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
75893674|NCT04392856|Behavioral|Same than experimental condition (UP), after it finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
75893675|NCT00818480|Drug|YM155|continuous infusion
75893676|NCT04176718|Drug|Daratumumab|predetermined dose, intravenously, at predetermined times per cycle
75893677|NCT04176718|Drug|Carfilzomib|predetermined dose, intravenously, give 3 times per cycle
75893678|NCT04176718|Drug|Pomalidomide|predetermined dose, orally, daily per cycle
75893679|NCT04176718|Drug|Dexamethasone|predetermined dose, orally, given 8 times per cycle
75893680|NCT03134534|Procedure|VATS lobectomy|a minimal invasive surgical types for NSCLC: VATS lobectomy
75893681|NCT03134534|Procedure|RATS lobectomy|a minimal invasive surgical types for NSCLC: RATS lobectomy
75893682|NCT04154020|Procedure|Flexor tenotomy|Tenotomy(cutting) of flexor tendons is performed with needle
75449555|NCT01695824|Procedure|RFA ablation|The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
75449556|NCT01695824|Drug|Warfarin|"Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III."
75449557|NCT01695837|Behavioral|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
75893683|NCT02880371|Drug|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
75893684|NCT02880371|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
75893685|NCT00813956|Drug|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
76062789|NCT00985738|Drug|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
76062790|NCT00985738|Other|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
76062791|NCT01928485|Other|active surveillance|Undergo active surveillance
76062792|NCT01928485|Drug|Sunphenon|Given PO
76062793|NCT01928485|Other|laboratory biomarker analysis|Correlative studies
76062794|NCT01928485|Other|Questionnaire Administration|Ancillary studies
76062795|NCT00985504|Drug|Duloxetine|60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
76062796|NCT00985504|Drug|Escitalopram|10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
76062797|NCT01921036|Procedure|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
76062798|NCT01921036|Procedure|combined exercise|Moderate endurance and resistance exercise once a week over six months
76062799|NCT01921192|Drug|Folic Acid, vit B6 and B12|
76062800|NCT01921192|Drug|Placebo|
75600563|NCT00628810|Drug|irinotecan hydrochloride|
76062801|NCT04275388|Drug|Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
76062802|NCT04275388|Drug|Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
76062803|NCT01921426|Drug|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
76062804|NCT03458962|Genetic|Genetic Enrollees|Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
76062805|NCT01926106|Device|nIPPV|one of the twins was randomly allocated to nIPPV
75449558|NCT01695850|Drug|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
75449559|NCT01695850|Drug|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
75449560|NCT01695850|Drug|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
75744610|NCT00841919|Drug|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
75744611|NCT00851669|Behavioral|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
75744612|NCT00851669|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
76062806|NCT01926106|Device|nCPAP|another of the twins was allocated to nCPAP
76062807|NCT01921504|Device|Acupuncture|"Acupuncture treatment~Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 ~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
75600564|NCT00628810|Drug|leucovorin calcium|
75600565|NCT04298320|Drug|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
75600566|NCT04298320|Drug|AIN 457|AIN457 was administered 150mg or 300mg ih every 2 weeks
75600567|NCT04298164|Behavioral|START programme|Acceptance and Commitment Therapy based programme for parents of children with Autism
75600568|NCT04298164|Behavioral|Treatment as Usual|Treatment as usual in outpatient within outpatient psychology services
75600569|NCT01011946|Device|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
75449561|NCT01695876|Drug|AMG 357|Oral administration available in varying dose strength.
75449562|NCT01695876|Drug|Placebo|Matching placebo to AMG 357 containing no active drug
75449563|NCT01695902|Drug|Levosert-20|
75449564|NCT01695902|Drug|Mirena|
75449565|NCT01695915|Procedure|Transabdominal ultrasound|Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
75449566|NCT01695928|Device|Extracorporeal shockwave therapy|1000 impulses
75449567|NCT01695928|Device|ESWT placebo|0 impulses, acoustic effect
75449568|NCT01695967|Procedure|turbinate cauterization|
75463197|NCT01872884|Drug|Sevorane Remifentanil|Sevorane Remifentanil
75463198|NCT01872884|Drug|Remifentanil|Remifentanil
75463199|NCT01872897|Drug|Sodium Alginate Double Action Tablets|Four tablets as a single dose
75600570|NCT04296682|Procedure|Alveolar Ridge Preservation With Gingival Graft|Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
75600571|NCT04296760|Diagnostic Test|Rectal water-contrast transvaginal ultrasonography|Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum
75600572|NCT04296760|Diagnostic Test|Sonovaginography|Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina
75893686|NCT03667209|Other|Pain neuroscience education (PNE) and traditional exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
75893687|NCT03667209|Other|Pain neuroscience education (PNE) and suspension exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises. delivered in suspension.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
75893688|NCT01002248|Drug|Perifosine|Perifosine will be dosed as one 50 mg pill every day of each cycle.
75893689|NCT01002248|Drug|Perifosine Placebo|Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
75893690|NCT01002248|Drug|Bortezomib|Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
75893691|NCT01002248|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
75893692|NCT02837029|Other|Laboratory Biomarker Analysis|Correlative studies
75893693|NCT02837029|Biological|Nivolumab|Given IV
75463200|NCT01872897|Drug|Placebo|4 tablets as a single dose
75463201|NCT01872923|Drug|Amphinex|Photosensitiser
75463202|NCT01872923|Drug|Bleomycin|Anticancer agent
75893694|NCT02837029|Radiation|Yttrium Y 90 Glass Microspheres|Given IA
75893695|NCT04130932|Other|Ergonomic flooring|Specially designed flooring system to optimize ergonomics of participants
75463203|NCT01872923|Device|Laser|Laser that emits red light at 652 nm.
75463204|NCT01872936|Drug|Miravirsen|
75463205|NCT01872936|Drug|Telaprevir|
75463206|NCT01872936|Drug|Ribavirin|
75463207|NCT01872962|Drug|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
75600573|NCT00975481|Drug|dimebon|Oral tablet; 20 mg dimebon, single dose
75600574|NCT00975481|Drug|dimebon|Oral tablet; 40 mg dimebon, single dose
75600575|NCT00975481|Drug|dimebon|Oral tablet; 60 mg dimebon, single dose
75893696|NCT04097236|Other|Qualitative and quantitative assessment of gastric content volume with bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
75893697|NCT04097236|Other|Qualitative and quantitative assessment of gastric content volume without bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
75893698|NCT03667131|Drug|Enalapril Maleate|Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.
75893699|NCT03667131|Drug|Placebo|Placebo 5 mg tablet, every 12 hrs for 90 days.
75893700|NCT04532710|Drug|Eye Drops, Solution in Single-Dose Container|Application of eye drops
75893701|NCT05174000|Drug|Test Euthyrox®|Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.
75893702|NCT05174000|Drug|Reference Euthyrox®|Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.
75893703|NCT03666585|Other|mobile application actuated rehabilitation exercise guidance|Mobile applications (also known as mobile apps) are software programs developed for mobile devices such as smartphones and tablets, to teach full function following injury and involves restoring strength, flexibility, endurance, and power.
75893704|NCT03666585|Other|routine rehabilitation exercise guidance|the teach to practice full function following injury and involves restoring strength, flexibility, endurance, and power. It is achieved through various exercises and drills
75893705|NCT05024656|Other|AmnioExcel Plus Amniotic Membrane|AmnioExcel® Plus will be applied weekly, in conjunction with SOC, if the ulcer remains open, or up to and including Week 11, whichever comes first.
75893706|NCT05024656|Other|Standard of Care|The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.
75893707|NCT05764187|Other|Orthodontic fixed appliance therapy|Follow up of white spot lesion development using quantitative light induced fluorescence in patients bonded with ceramic brackets versus patients bonded with conventional metal brackets
75600576|NCT00975481|Drug|placebo|Oral tablet or capsule; placebo, single dose
75600577|NCT00975481|Drug|alprazolam|Oral capsule; 1 mg alprazolam, single dose
75600578|NCT00975481|Drug|alprazolam|Oral capsule; 3 mg alprazolam, single dose
75600579|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
75600580|NCT01011868|Drug|BI 10773 low dose|BI 10773 low dose
75600581|NCT01011868|Drug|BI 10773 high dose|BI 10773 high dose
75600582|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
75600583|NCT04290013|Drug|norethisterone acetate|norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
75600584|NCT04290013|Drug|tranexamic acid tablets|tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
75893708|NCT05019352|Device|CytoSorb cytokine adsorber|device for extracorporeal hemoadsorption
75616510|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/10mg FDC|Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
75616511|NCT01236430|Drug|Atorvastatin 10mg|Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
75616512|NCT01236430|Drug|Atorvastatin 80mg|Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
75893709|NCT05019352|Device|CRRT|continuous renal replacement therapy
75893710|NCT01377155|Drug|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
75893711|NCT04976374|Drug|Dexmedetomidine and Gabapentin|Administration of intravenous dexmedetomedine for post operative analgesic purposes in combination with gabapentin
75893712|NCT04976374|Other|Saline|Intravenous Saline 0.9% for placebo purposes
76062808|NCT01921582|Drug|Methylphenidate|"Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
76062809|NCT01921582|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~Phase 2 aims to reduce food intake and restructure eating-related cognitions;~Phase 3 focuses upon relapse prevention"
75893713|NCT04473560|Device|Catheter-directed thrombectomy|Using common femoral venous access the pigtail diagnostic catheter will be placed into the main pulmonary artery and an initial pulmonary angiogram will be performed to demonstrate the location and extent of thrombi in pulmonary arteries. Then pulmonary arterial pressures will be measured. Subsequently an Indigo catheter (Penumbra, Alameda, California) will be placed and a direct-aspiration first-pass technique will be performed purposefully to attach a large thrombus to the catheter tip by suction and then pull it out through the sheath. The decision to terminate the intervention will be at operator's discretion after careful evaluation of hemodynamic parameters (restoration of the systolic blood pressure≥100 mmHg, heart rate <100/min), improvement of arterial blood saturation≥ 92%, practicable clot burden reduction and total amount of aspirated blood (no more than 300 ml).
76062810|NCT02984098|Drug|Dextrose|before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
76062811|NCT03398902|Behavioral|Sleep extension|Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.
76062812|NCT03398902|Other|Habitual sleep|The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
76062813|NCT00985426|Biological|HEPLISAV-B|Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24
75600585|NCT04288999|Drug|Chemotherapy|"Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
75600586|NCT04288999|Radiation|Preoperative radiotherapy|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)"
75600587|NCT04288999|Other|Procedure|"Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection"
76062814|NCT00985426|Biological|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
76062815|NCT00985426|Other|Placebo|Placebo(saline) intramuscular (IM) injection at Week 8
76062816|NCT00985192|Drug|everolimus|
75600588|NCT01213251|Device|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
76062817|NCT00985192|Other|laboratory biomarker analysis|
76062818|NCT03392662|Device|Hemopatch|Patients received product at the discretion of their surgeon.
75449569|NCT01696019|Other|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
76062819|NCT03390010|Drug|Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
76062820|NCT03390010|Drug|Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
76062821|NCT00985114|Device|EndoBarrier|EndoBarrier implant
76062822|NCT00985114|Behavioral|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
76062823|NCT00984568|Biological|Infliximab|Infliximab intravenous infusion at a dose of 5 mg/kg.
76062824|NCT00984568|Drug|Prednisolone|Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
76062825|NCT00984568|Drug|5-aminosalicylic acid|5-ASA administered orally at a dose of 2 g/day.
76062826|NCT00984568|Drug|Azathioprine|AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
76062827|NCT02984176|Drug|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
75893714|NCT03984058|Behavioral|Lifestyle Intervention|A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP). Study participants will start lifestyle intervention on the day of initiating PAP therapy. The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices. Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons. Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks. Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
75893715|NCT00809510|Drug|ABT-089|20 mg ABT-089 taken once-daily for 6 months
75893716|NCT03856684|Behavioral|Self-sampling kit sent at home|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
75893717|NCT03856684|Behavioral|Self-sampling kit sent at home + SMS reminder|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~the receipt of the vaginal self-sample at the laboratory~the performance of a pap smear~Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
75893718|NCT03856684|Behavioral|"Letter offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~the receipt of the vaginal self-sample at the laboratory~the performance of a pap smear~Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
75893719|NCT03856684|Behavioral|"SMS offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~the receipt of the vaginal self-sample at the laboratory~the performance of a pap smear~Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
75600589|NCT01213251|Device|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
75893720|NCT00894530|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
75893721|NCT00894530|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
75893722|NCT01377077|Procedure|punchgrafting|autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
75893723|NCT01377077|Procedure|punchgrafting|autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
75893724|NCT04093336|Biological|human umbilical cord mesenchymal stem cells|The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
75893725|NCT04093336|Biological|Placebo|Placebo
75893726|NCT04093336|Other|standardized treatment|standardized treatment
75893727|NCT05552534|Other|STIR PROTOCOL|"Screening, STIR protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the tobacco-info-service brochure, initiation of a nicotine patch made by the trained emergency nurse or doctor) then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months."
76062828|NCT02984176|Drug|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
76062829|NCT03075280|Procedure|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
76062830|NCT01921738|Drug|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
76062831|NCT01921738|Drug|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
76062832|NCT01921738|Drug|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
75600590|NCT02865109|Drug|Nusinersen|Administered by intrathecal injection
75600591|NCT03934177|Dietary Supplement|Blueberry powder|Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.
75600592|NCT03934177|Dietary Supplement|Placebo powder|A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
75600593|NCT02864017|Procedure|Enteral nutrition|
75600594|NCT02864017|Dietary Supplement|L-Citrulline|
75600595|NCT02864017|Dietary Supplement|Placebo|
75893728|NCT01376999|Drug|FSH-r (Follicule stimulate hormone)|Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
75893729|NCT03010527|Drug|Bimekizumab|Subjects will receive bimekizumab injections every four weeks (Q4W)
75893730|NCT03010527|Other|Placebo|Subjects will receive Placebo injections every four weeks (Q4W)
75893731|NCT05763095|Behavioral|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
75893732|NCT00892970|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
76062833|NCT01921738|Drug|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
76062834|NCT01921816|Device|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
76062835|NCT04395976|Other|Ayurveda|The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.
76062836|NCT03092050|Behavioral|Guided Imagery and Mindfulness|This is a behavioral intervention using guided imagery and mindfulness techniques.
76062837|NCT03092050|Behavioral|Facilitated Discussion|This is a behavioral intervention that involves discussion and group support.
76062838|NCT01926418|Behavioral|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
76062839|NCT00984256|Drug|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
76062840|NCT00984256|Other|Procedure - malaria challenge|2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
76062841|NCT00984022|Device|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
76062842|NCT00984022|Device|Type of dressing - Aquacel|Aquacel dressing
76062843|NCT01926574|Behavioral|long rehabilitation program|
75600596|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
75600597|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
75600598|NCT02864173|Genetic|Whole genome small nucleotide polymorphism genotyping|
75600599|NCT04318431|Diagnostic Test|Data collection and rhinopharyngeal swab|Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
75893733|NCT00892970|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
75893734|NCT05340257|Drug|Augmentin ES|Amoxicillin and clavulanic acid in fixed dose combination will be administered
76062844|NCT01926574|Behavioral|short rehabilitation program|
76062845|NCT01926574|Behavioral|Acceptance and commitment therapy (ACT)|
76062846|NCT01922128|Drug|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
76062847|NCT01890265|Drug|Pamrevlumab|Solution for infusion
76062848|NCT01890265|Drug|Placebo|Solution for infusion
76062849|NCT01890265|Drug|Sub-Study: Pirfenidone|Pirfenidone concomitant therapy will not be provided by the Sponsor.
76062850|NCT01890265|Drug|Sub-Study: Nintedanib|Nintedanib concomitant therapy will not be provided by the Sponsor.
76062851|NCT01926652|Drug|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
76062852|NCT03073954|Other|Working memory training|"The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.~The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected."
76062853|NCT03073954|Behavioral|Standardised healthy lifestyle coaching|Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
76062854|NCT01926730|Other|Restriction diet|Selected food items will be limited in the participants diet
76062855|NCT03070444|Device|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
76062856|NCT03070444|Device|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
76062857|NCT03070444|Device|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
76062858|NCT03070444|Procedure|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
75893735|NCT03759808|Behavioral|Psychological Intervention|Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
75893736|NCT03667521|Procedure|nerve-sparing laparaoscopic sacrocolpopexy|nerve-sparing laparaoscopic sacrocolpopexy implemented after 2010
75893737|NCT02201381|Drug|Metabolic treatment|While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
75893738|NCT00803114|Drug|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
76062859|NCT03070444|Other|Questionnaire|A questionnaire is completed at the follow-up visits.
76062860|NCT01928329|Drug|Exenatide (Bydureon®)|
75600600|NCT02866435|Drug|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
75600601|NCT02866435|Drug|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
75600602|NCT02866435|Drug|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
75600603|NCT04287751|Device|CheckMeO2 Oximeter|Simultaneous recording with a current standard oximeter (Minolta i300) and prolonged recording device. Comparison of data from first night and incidence of obstructive sleep apnoea identified from additional nights of recording identified.
75744613|NCT04214327|Behavioral|Strengthening Families Program Online eLearning Game|Families (parent/caregiver and children) are to play-test a highly interactive online gamified version of the Strengthening Families Program called SFP Online, with 10 lessons that utilize three 10-minute mini-sessions and games that teach parents evidence-based parenting and family relationship skills and teach youth social, life, and alcohol and drug refusal skills. Skills are reinforced through gaming. Game points are achieved by right answers to self-correcting mini-quizzes for low-stakes failure and through actual reported home practice of the skills. The SFP parenting skills have been shown to reduce risk factors and increase protective factors that prevent youth substance abuse.
75893739|NCT00803114|Drug|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
75893740|NCT05519384|Drug|JK500 cell injection，cyclophosphamide，Fludarabine|After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/㎡/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.
75893741|NCT03489382|Other|Smartphone Assisted PST|"Emergency Departments randomized to the study intervention will receive:~Staff education incorporated into regular teaching rounds at least twice a year about the management of self-harm in the Emergency Department. This will include the dissemination of guidelines on how to ask questions about suicide, assessment of suicide risk, the creation of a management plan and how to refer patients to local mental health resources, including the study.~Written materials developed by service users for men who self-harm that outline local resources, distress centre helplines, and follow-up arrangements.~The option to refer men who self-harm to a service that will deliver smartphone-assisted PST specifically designed for men."
75893742|NCT00799292|Drug|Vasopressin|20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
75893743|NCT00794924|Dietary Supplement|VSL#3|one sachet per day, for 45 consecutive days
76062861|NCT01928329|Drug|Placebo|
76062862|NCT01922206|Behavioral|TRACK Intervention|"TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
76062863|NCT01922284|Biological|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
75744614|NCT04214327|Behavioral|SFP Home-use DVD|Family views an 11-session SFP video series online or at home using a DVD that contains the same program and lesson content as the online condition; however, the lesson material is more static without the interaction required in the gamified version of SFP Online.
76062864|NCT01922284|Biological|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
76062865|NCT01922284|Biological|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
76062866|NCT01922284|Biological|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
76062867|NCT01890109|Biological|Erenumab|Administered via subcutaneous injection.
76062868|NCT01890109|Drug|Placebo|Administered via subcutaneous injection
75744615|NCT04214327|Behavioral|Wait-Listed Control|Families receive no active intervention for 22 weeks; however, during this wait time, participants receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. Following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention
75893744|NCT00794924|Dietary Supplement|placebo|one sachet per day, for 45 consecutive days
75893745|NCT02914275|Biological|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.
75893746|NCT02914275|Biological|Comparator Quadrivalent Inactivated Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.
75893747|NCT05359978|Behavioral|To with significance activities|activities with purpose with people who are diagnosed of dementia 2 days at week during 30 minutes
76062869|NCT03108976|Other|Behavioral assessments|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
75600604|NCT01212159|Device|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
75600605|NCT00973765|Drug|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
75600606|NCT00973765|Drug|placebo|placebo 2 pills po BID x 7 days
75600607|NCT04287595|Other|Inhalation aromatherapy with orange essential oil|
75600608|NCT01211769|Drug|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
75600609|NCT01211769|Drug|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
75744616|NCT03849911|Diagnostic Test|Neurophysiological Prognosis|SEP and EEG evaluation for Neurological Prognosis of Cardiac Arrest
75744617|NCT03849911|Diagnostic Test|Multimodal Prognosis for poor early neurological outcome|Brain CT, SEP and EEG evaluation
75893748|NCT05139056|Biological|Neural Stem Cells-expressing CRAd-S-pk7|Given intracerebrally
75893749|NCT05139056|Procedure|Resection|Undergo surgical resection
75893750|NCT01941875|Drug|Progesterone Effervescent Vaginal Tablets|Experimental
75893751|NCT03667287|Procedure|Repair of parastomal hernia|Surgical repair of symptomatic parastomal hernia.
75893752|NCT05210777|Device|observation|no intervention
75744618|NCT00851981|Other|Placebo|TID
75744619|NCT00851981|Dietary Supplement|SAMe|300 mg TID
75744620|NCT00852059|Drug|Immediate release methylphenidate (Medikinet®)|Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
75893753|NCT03666429|Device|Bulb suction|Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.
75600610|NCT01211769|Drug|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
75893754|NCT03666429|Device|NoseFrida|Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.
75600611|NCT01211769|Drug|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
75600612|NCT04287673|Other|Rehabilitation involving strongly the trunk|The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
75600613|NCT04288609|Other|Intendu|Cognitive remediation using VR adaptive platform for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
75744621|NCT00852059|Drug|Extended release methylphenidate (Medikinet retard®)|Treatment: methylphenidate applied with breakfast(once daily), extended release
75893755|NCT03775408|Device|FAST|Orthopaedic surgeons will use the FAST device to facilitate entry point selection and alignment of a guidewire for intramedullary nailing of femoral shaft fractures.
75893756|NCT01814657|Drug|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
75893757|NCT01814657|Drug|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
75744622|NCT00844727|Drug|Rofecoxib|
75744623|NCT00844727|Drug|placebo|placebo pills
75893758|NCT03666975|Device|LIV 30 Hz|LivMD LIV platform
75893759|NCT00792116|Behavioral|Gum Chewing|
75893760|NCT04050033|Device|Evoke Device|Subjects will undergo treatment with Evoke Device
76062870|NCT03108976|Other|Magnetoencephalography (MEG)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
75600614|NCT04288609|Other|Paper and Pencil cognitive remediation training|Cognitive remediation using paper and pencil tasks for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
75600615|NCT04288765|Drug|Daratumumab Only Product in Parenteral Dose Form|"Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly"
75600616|NCT01211613|Procedure|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
75600617|NCT01211613|Device|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
75600618|NCT01211613|Other|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
75600619|NCT02864797|Other|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
75744624|NCT00844961|Behavioral|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
75893761|NCT01773395|Biological|GVAX|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the GVAX arm will receive GVAX vaccine.
75893762|NCT01773395|Biological|Placebo Vaccine|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the placebo arm will receive placebo vaccine.
75893763|NCT01773395|Procedure|Allogeneic Hematopoietic Stem Cell Transplant|Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor. This is given as a transfusion through a central intravenous line (IV usually placed in the chest or arm).
75893764|NCT01773395|Drug|Busulfan|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
75893765|NCT01773395|Drug|Fludarabine|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
75600620|NCT01211535|Device|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
75744625|NCT00845117|Procedure|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
75744626|NCT00528528|Drug|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
75744627|NCT00528528|Drug|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
75744628|NCT00528528|Drug|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
75893766|NCT01773395|Drug|Tacrolimus|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
75893767|NCT01773395|Drug|Methotrexate|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
75893768|NCT04437394|Diagnostic Test|flexible endoscopic evaluation of swallowing|The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.
75893769|NCT04437394|Diagnostic Test|The analysis of voice|Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.
75744629|NCT00528528|Drug|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
75744630|NCT00528528|Drug|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
75893770|NCT01000922|Drug|Regular Human Insulin|Individual dose of RHI administered subcutaneously
75893771|NCT01000922|Drug|Lispro|Individual dose of lispro administered subcutaneously
75893772|NCT01000922|Drug|VIAject|Individual dose of VIAject administered subcutaneously
75893773|NCT01000922|Drug|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
75893774|NCT01000922|Drug|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
75893775|NCT01000922|Drug|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
75893776|NCT03666039|Behavioral|Trainings app|Sensorimotor trainings app for at home Training (tablet-based)
75893777|NCT04559217|Biological|Radiopharmaceutical 68Ga-DOTATATE|Injection of 68Ga-DOTATATE followed by PET/CT acquisition
75600621|NCT01211535|Device|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
75600622|NCT01211535|Device|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
75744631|NCT00620555|Drug|gabapentin|Orally administered gabapentin
75744632|NCT02546453|Biological|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
75744633|NCT02546453|Biological|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
75744634|NCT00845273|Drug|Pegaptanib sodium|"Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )."
75744635|NCT00845351|Drug|Bexarotene|bexarotene at 300 mg/m2/day
75744636|NCT00529386|Drug|Botox|300 units
75744637|NCT02546141|Other|skimmed milk (UHT)|
75744638|NCT02546141|Other|skimmed milk (pasteurized)|
75744639|NCT02546141|Other|skimmed yoghurt|
75744640|NCT02546141|Other|full-fat milk (UHT)|
75893778|NCT04727606|Drug|Ure-Na|"Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day)~Treatment will continue for approximately 1 month."
75893779|NCT03671434|Behavioral|Research-to-Policy Collaboration|The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.
75893780|NCT03671434|Behavioral|Light Touch Policy Training|Control Researchers are provided information on policy engagement via email.
76062871|NCT03108976|Other|Magnetic Resonance Imaging (MRI)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
76062872|NCT03069976|Drug|Metronidazole|Flagyl x 14 days.
76062873|NCT00982930|Drug|Tobramycin inhalation powder|Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
76062874|NCT03069664|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
76062875|NCT03069664|Device|Covered Self-expandable Metal Stent|Pancreatic duct stent
76062876|NCT05602168|Other|experimental:Acute leukemia/myelodysplastic or myeloproliferative disease|blood sampling, bone marrow aspirate and buccal swab
76062877|NCT00981682|Drug|SER120|once a day treatment of nocturia
76062878|NCT01903993|Drug|Docetaxel|Participants received starting dose of 75 mg/m^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
76062879|NCT01903993|Drug|Atezolizumab|Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram [mg/kg]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
76062880|NCT00981292|Dietary Supplement|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
75600623|NCT04287439|Behavioral|Progressive muscle relaxation|Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
75600624|NCT04287439|Behavioral|Mindfulness meditation|Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
75744641|NCT02546141|Other|non-homogenized full-fat milk (pasteurized)|
75744642|NCT02546141|Other|full-fat cheese (semi-matured)|
75893781|NCT03666195|Combination Product|Titanium Dioxide Nanoparticles|incorporating titanium dioxide nanoparticles to PMMA, significantly decreases porosities in the denture resin, rendering titanium dioxide nanoparticles a suitable additive to denture base materials, as it also exhibits anti-microbial effects
75893782|NCT00889382|Drug|OSI-906|Administered orally
75893783|NCT00889382|Drug|Paclitaxel|Administered intravenously
75893784|NCT00489827|Drug|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
75893785|NCT00489827|Other|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
76062881|NCT00981292|Dietary Supplement|Placebo|Pharmaceutical grade silica was utilized as placebo
76062882|NCT03065140|Other|Training or detraining|A period of detraining or a supervised exercise program.
76062883|NCT01927042|Behavioral|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
76062884|NCT01927042|Behavioral|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
76062885|NCT01927510|Behavioral|Early mobilisation|
76062886|NCT00980044|Drug|Tramadol|Oral Medication
76062887|NCT00980044|Drug|Placebo|Oral Medication
76062888|NCT05601934|Other|Neurophysiological Facilitation Techniques|Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.
75616513|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/80mg FDC|Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
75744643|NCT02546141|Other|whey protein|
75893786|NCT03629314|Other|Educational pamphlet arm|Educational pamphlets will be provided to review and questionnaire will be provided to complete before and after review of the pamphlet
75893787|NCT04052607|Drug|LH Suppression|Stimulation protocols
75893788|NCT00888914|Drug|RT001|RT001
75893789|NCT00888914|Drug|RT001|RT001
76062889|NCT01927588|Drug|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
75744644|NCT02546141|Other|micellar casein|
75744645|NCT05213286|Diagnostic Test|Application of ZAQ and RAADS-R-DK|Test of the questionnaires in each of the three groups.
75744646|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
75744647|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
75893790|NCT00888914|Drug|RT001|RT001
75893791|NCT00888914|Drug|RT001|RT001
75893792|NCT00888914|Other|Vehicle Comparator|Vehicle Comparator
75893793|NCT05135936|Behavioral|Hyperthermia Group|The first hyperthermia treatment of the series is carried out for the second aptitude test, directly following the randomisation in the intervention group at the Hospital for Naturopathy and Integrative Medicine in Bamberg. The hyperthermia treatment is then carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
75893794|NCT05135936|Behavioral|Sham-Group|The number of treatments is equal to the number of treatments in the intervention group.
75893795|NCT04059003|Drug|Taxanes or/and anthracycline-based therapy|Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
76062890|NCT01927588|Drug|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
75893796|NCT05160701|Other|Medherent|Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
75893797|NCT05375188|Drug|Dexmedetomidine|DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr
75893798|NCT05375188|Drug|Normal Saline|DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
75600625|NCT04287439|Other|Attention matched control|Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
75600626|NCT02863861|Drug|Dexmedetomidine-ketamine|
75600627|NCT02863861|Drug|propofol-ketamine|
75600628|NCT05406765|Drug|Bupivacaine Injection|One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
75893799|NCT05113589|Device|PBM TREATMENT|Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed. For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear). Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions
75600629|NCT01011556|Drug|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
75600630|NCT01011556|Drug|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
76062891|NCT05601466|Drug|QN-023a|NK cell therapy
76062892|NCT05601466|Drug|Cyclophosphamid|Lympho-conditioning Agent
76062893|NCT05601466|Drug|Fludarabine|Lympho-conditioning Agent
76062894|NCT05601466|Drug|Cytarabine|Lympho-conditioning Agent
76062895|NCT01903837|Drug|Samidorphan (Low Dose)|Tablets taken once daily
75600631|NCT01211145|Drug|Placebo|Placebo nasal spray
76062896|NCT01903837|Drug|Samidorphan (Medium Dose)|Tablets taken once daily
76062897|NCT01903837|Drug|Samidorphan (High Dose)|Tablets taken once daily
76062898|NCT01903837|Drug|Placebo|Tablets taken once daily
76062899|NCT01903837|Drug|Olanzapine|Tablets taken once daily
75600632|NCT01211145|Drug|Zolmitriptan|0.5 mg nasal spray
75600633|NCT01211145|Drug|Zolmitriptan|2.5 mg nasal spray
75600634|NCT01211145|Drug|Zolmitriptan|5.0 mg nasal spray
75600635|NCT02871622|Device|BioMatrix AlphaTM|Cobalt Chromium BA9 TM drug-eluting stent
75600636|NCT00977665|Drug|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
75600637|NCT00977665|Drug|placebo|placebo tablet for 48 weeks
75600638|NCT04298008|Drug|AZD6738|AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
75893800|NCT05113589|Device|PLACEBO PBM|The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment. There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
75893801|NCT04058535|Biological|Eylea|Aflibercept
75893802|NCT04058535|Biological|ALT-L9|Aflibercept biosimilar
75893803|NCT05375110|Device|NoYA™ Radiofrequency Interatrial Shunt System|NoYA™ Radiofrequency Interatrial Shunt System include Adjustable Interatrial Shunt System and Radiofrequency Ablation Generator.
75893804|NCT00994292|Drug|YM150|oral
75893805|NCT00994292|Drug|Placebo|oral
75893806|NCT05387915|Radiation|Radiation Therapy|Undergo reduced dose radiation therapy
75893807|NCT02604433|Drug|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level.
75893808|NCT02604433|Other|Placebo|Placebo, Subcutaneous, every 21 days.
75893809|NCT04306744|Device|Vorso PROTECT System|The Vorso PROTECT System is designed to deliver targeted, imperceptible, non-invasive stimulation to the ear to treat the signs and symptoms (e.g., tender and swollen joints, pain, synovitis) of patients with rheumatoid arthritis.
75893810|NCT04306744|Device|Vorso PROTECT System - Sham (OFF)|Identical device to experimental arm, but the device will not deliver stimulation
75893811|NCT03630419|Dietary Supplement|Mito-Food Plan|Specialized anti-inflammatory diet plan based on subject's physiological results
75893812|NCT03630419|Other|Cellular Repair Therapy|the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
75600639|NCT04298008|Drug|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
75600640|NCT02871544|Other|BNP and NGAL|
75600641|NCT04295278|Diagnostic Test|MicroKine Dx system|Biomarker concentrations will be determined using the MicroKine Dx system and results will be compared to measurements taken using standard immunoassays.
75600642|NCT00628342|Drug|Esomeprazole|20mg Oral tablet once daily
75744648|NCT03875118|Behavioral|The mouth-opening training with follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
75744649|NCT03875118|Behavioral|The mouth-opening training without follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
75744650|NCT00845819|Drug|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) & nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
75893813|NCT04437004|Drug|Fenfluramine|The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.
75893814|NCT05763017|Other|Relative Motion Splint|Six weeks relative motion splint wear.
75893815|NCT05763017|Other|Metacarpophalangeal Joint Blocking Splint|Six weeks metacarpophalangeal joint blocking splint wear.
75893816|NCT03264508|Behavioral|Heat therapy|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
75893817|NCT03264508|Behavioral|Thermoneutral water immersion|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature >0.2°C.
75893818|NCT05762939|Behavioral|Chatbot|Participants in this condition were asked to use Fido, a Polish therapy chatbot, for two weeks. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
75893819|NCT05762939|Behavioral|Control (book)|Participants in this condition were told to read selected chapters from a self-help book during the two-week intervention period. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
75893820|NCT03665883|Procedure|Monopolar energy|Monopolar energy in TEP for inguinal hernia
75600643|NCT00628342|Drug|Esomeprazole|40mg Oral tablet once daily
75600644|NCT00628342|Drug|Placebo|Oral once daily
75600645|NCT04290325|Drug|HMPL-453|HMPL-453 tablet
75600646|NCT01210443|Drug|Sitaxentan|sitaxentan sodium 100 mg
75893821|NCT03665883|Procedure|Blunt dissection|Blunt dissection in TEP for inguinal hernia
75893822|NCT00992732|Drug|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
75893823|NCT00992732|Drug|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
75893824|NCT02659150|Drug|tocilizumab|subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
75893825|NCT00884234|Other|Vehicle Control|Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2
75893826|NCT00884234|Drug|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 at Baseline (Day 0) and Week 2
75893827|NCT03006393|Drug|Infliximab|One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
75893828|NCT03006393|Other|Placebo|One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
75893829|NCT03028480|Drug|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
75893830|NCT00991172|Drug|REGN475|Single Subcutaneous injection dose level 1
75893831|NCT00991172|Drug|REGN475|Single subcutaneous injection dose level 2
75744651|NCT00845819|Drug|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
75449570|NCT01696019|Other|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
75744652|NCT02546843|Drug|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
75744653|NCT02546843|Drug|Cisatracurium|cisatracurium 0.15mg/kg intravenously
75893832|NCT00991172|Drug|Placebo Injection|Placebo Subcutaneous injection
75893833|NCT05762861|Other|Experimental|Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
75893834|NCT02950012|Dietary Supplement|OPTI-BIOME™ Bacillus subtilis MB40|
75893835|NCT02950012|Other|Placebo|
75893836|NCT01376921|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
75893837|NCT01383109|Drug|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
75893838|NCT02903992|Radiation|Dual-energy X-ray absorptiometry (DXA)|Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
75893839|NCT04966871|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
75893840|NCT04966871|Biological|PfSPZ Challenge (7G8) for CHMI|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
75893841|NCT04966871|Other|Normal Saline|normal saline placebo control
75893842|NCT00882440|Drug|losartan potassium|losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
75600647|NCT02870764|Drug|Dan-shen extract|A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
75600648|NCT02870764|Drug|Placebo|200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
75600649|NCT02870764|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
75600650|NCT04287361|Other|Efficacy of intravenous clonazepam|Efficacy of intravenous clonazepam
75600651|NCT00624429|Drug|Budesonide respules|Budesonide respules 0.5 mg nebulized once a day for 4 months of the study.
75893843|NCT00882440|Drug|Placebo|Placebo capsule to losartan
75893844|NCT00882440|Drug|Enalapril|Enalapril 20 mg oral tablet taken once daily for 8 weeks
75893845|NCT03665805|Other|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of the TOFscan neuromuscular transmission monitor (iDMed, Marseille, France).
75600652|NCT02864719|Other|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
75893846|NCT02864290|Drug|ASP1235|intravenous (IV) infusion
75600653|NCT01007812|Device|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
75600654|NCT01007812|Device|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
75600655|NCT04204525|Diagnostic Test|Quantitative sensory testing|"Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials."
75449571|NCT01696019|Other|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
75449572|NCT01696019|Other|Contact and testing only|
75600656|NCT01208961|Drug|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
75744654|NCT02546843|Drug|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
75744655|NCT02546843|Drug|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
75744656|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
75744657|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
75893847|NCT05214391|Drug|Zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
75449573|NCT01696097|Behavioral|DASH diet counseling|Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
75449574|NCT01696110|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
75449575|NCT01696110|Drug|heparin|heparin monotherapy
75449576|NCT01696110|Drug|heparin plus tirofiban|combined use of heparin and tirofiban during PCI
75449577|NCT01696123|Drug|MLC601|It was described
75449578|NCT01696136|Device|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
75893848|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
75893849|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
75893850|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
75893851|NCT00880490|Drug|Inhaled placebo|single dose, inhaled
75600657|NCT01208961|Drug|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
75893852|NCT00880490|Drug|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
75893853|NCT05332990|Diagnostic Test|HFO analysis|We use an automated data-independent prospective definition of clinically relevant HFO that has been validated in data from two independent epilepsy centers.
75893854|NCT05214157|Procedure|active gas aspiration|sucking remaining Co2 from the peritoneal cavity and local anaesthetic application at port sites
75893855|NCT04549467|Drug|Lamivudine 300 MG|Experimental arm
75893856|NCT04549467|Drug|Emtricitabine / Tenofovir Disoproxil Pill|Active Comparator
75893857|NCT04957433|Diagnostic Test|Blood Specimen|Blood and Sputum Specimen Samples
75893858|NCT04284124|Other|Erector Spinae block|Patient in the prone position 20 min before induction of general anesthesia. Skin is sterilized by 10% povidone iodine. An US multifrequency convex probe (1-8 MHz) will be used for block. A 22G, 50-mm in length needle will be used and block will be performed at the T4 level of the spine using in-plane approach where a convex probe is placed 2-3 cm lateral to the spine using sagittal approach. Erector spinae muscle and the transverse processes are located and the needle will be inserted deep into the muscle. The needle is directed craniotomy-caudally. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic to monitor spread then 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic is monitored in both cranial and caudal directions
75893859|NCT03628963|Device|Concerto+|a user-centered, multifunctional and personalized eHealth platform
75893860|NCT03665727|Behavioral|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
75893861|NCT03665727|Behavioral|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
75893862|NCT03665727|Behavioral|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
75893863|NCT04215640|Device|Microfidelity (MIFI) catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.
75893864|NCT04215640|Device|Conventional ablation catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.
75893865|NCT05214079|Device|Left paratracheal pressure|Applying Left Paratracheal pressure and testing its effectiveness using gastric tube . in addition , by using the dynamometer , the CP 50 is defined.
75893866|NCT02926144|Device|Laryngoscope with video|Intubation with video-laryngoscope McGrath with use of the video feature
75600658|NCT01001572|Drug|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
75600659|NCT01001572|Drug|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
75600660|NCT01001572|Drug|Placebo|1 capsule or tablet taken orally once daily
75600661|NCT02866357|Other|No intervention|Just collection of nasopharyngeal aspirate for assessment
75600662|NCT01208415|Device|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
75600663|NCT02871232|Other|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
75616514|NCT00726856|Drug|Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate|Ezetimibe 10 mg taken daily for 3 months
75893867|NCT02926144|Device|Laryngoscope without video|Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
75893868|NCT03630341|Drug|Clomiphene Citrate 50mg|oral 50 mg tablets
75893869|NCT03630341|Drug|L-carnitine|1000 mg oral tablet
75893870|NCT03630341|Drug|Placebo Oral Tablet|oral tablets identical to L-carnitine
75893871|NCT02632396|Drug|Ixazomib|Given PO
75893872|NCT02632396|Biological|Rituximab|Given IV
75893873|NCT01872169|Other|Disordered eating screening questionnaire|
75893874|NCT04078516|Diagnostic Test|Perception Threshold Tracking (PTT)|low-current electrical stimulation of both large- and small nerve fibers.
75893875|NCT04078516|Diagnostic Test|Axon-flair mediated respons|Laser-doppler examination of small blood vessels in the peripheral skin.
75893876|NCT04078516|Diagnostic Test|Heart rate variability|4 measurements of heart rate.
75893877|NCT04078516|Diagnostic Test|Quantitative Sensory Testing (QST)|Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.
75893878|NCT04078516|Diagnostic Test|Peripheral blood pressure and transcutaneous oxygen tension|Ankle/brachial index, toe/brachial index, TcpO2.
75600664|NCT04287205|Drug|Dydrogesterone|79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
75744658|NCT00529308|Device|Transcranial Magnetic Stimulation (active)|Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
75893879|NCT04078516|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.
75893880|NCT04078516|Diagnostic Test|Questionnaires|Questionnaires for detecting painful neuropathy
75893881|NCT04078516|Diagnostic Test|Corneal Confocal Microscopy /CCM)|Confocal microscopy of the cornea measuring NBD, NFD, NFL
75893882|NCT05473754|Behavioral|SUPER digital platform|SUPER digital platform was implemented to ensure synergy between ASD families, health services, and schools through different tools to share rehabilitative and educational objectives and strategies. It was designed following the ASD International Guidelines and the recommendations of the ICF-CY and was organized into two areas: General (to promote scientific knowledge on ASD) and Personalized (restricted virtual space for groups of users following an individual with ASD).
75893883|NCT05208229|Diagnostic Test|WB-MRI|Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up
75893884|NCT05207995|Biological|Autologous tolerogenic dendritic cells|Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous.
75744659|NCT00529308|Device|Transcranial Magnetic Stimulation (sham)|Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
75744660|NCT03999840|Drug|cemdisiran|Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
75744661|NCT03999840|Drug|Placebos|The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
75744662|NCT04791540|Diagnostic Test|handgrip strenght|Muscle strenght measured with a handheld dynamometer, at admission (T0) and at decannulation time (T1)
75744663|NCT04791540|Diagnostic Test|Bioelectrical Impedance Analysis (BIA)|Muscle mass evaluated by Bioelectrical Impedance Analysis (BIA), at admission (T0) and at decannulation time (T1)
75744664|NCT04791540|Diagnostic Test|MUST|Malnutrition risk assessed by Malnutrition Universal Screening Tool (MUST), at admission (T0) and at decannulation time (T1)
75893885|NCT05207995|Other|Standard treatment according to the clinical protocols|Standard treatment of type 1 diabetes mellitus according to the clinical protocols
75600665|NCT00628576|Drug|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
75893886|NCT05102422|Drug|Propofol 1 % Injectable Suspension|Induction and maintenance of general anesthesia using the intravenous anesthetic
75893887|NCT05102422|Drug|Sevoflurane inhalant product|Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane
75893888|NCT03005067|Drug|Carbomer 980 (1146A)|Test product containing carbomer 980 gel
75893889|NCT03005067|Other|Placebo|Reference product containing vehicle without carbomer 980 gel
75744665|NCT04791540|Diagnostic Test|GLIM|Malnutrition diagnosis performed by Global Leadership Initiative on Malnutrition (GLIM) criteria, at admission (T0) and at decannulation time (T1)
75893890|NCT01088789|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.|"A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months."
75600666|NCT00628576|Drug|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
75600667|NCT01208337|Drug|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
75893891|NCT00979004|Drug|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
75893892|NCT05207839|Dietary Supplement|Milk powder|one sachet per day dissolved in 200 ml of water
75893893|NCT00788528|Drug|S-2367 (velneperit)|Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
75893894|NCT05331274|Other|exercise group|"1 stage~In a sitting position, pull the leg up and extend the knee forward~Standing, bending forward and bending the knee~Supine, tucked legs~Maintaining spinal smoothness in crawling~Prone heel pull to buttock~Stage 2~Prone on forearms-hands~Extending the supine hands to the knees~Rounding and hollowing the waist in crawling~Progressive sit-stand~Standing up from sitting and putting on and taking off socks~Reaching up while standing and maintaining the straightness of the spine~Squatting~Climbing and descending stairs~Stage 3~Maintaining standing, arms forward~Slipping hands on the bed while standing~Initiating the standing throw and maintaining the position until the final interval~Putting on and taking off socks while standing~Taking weight towards the ground from a certain height~Picking up different weights from the ground~Push-pull items~Crossing obstacles of certain height~Walking a certain distance"
75893895|NCT05331274|Other|pain training group|"The training provides participants with the opportunity to explain the central sensitization mechanism and also integrates the behavioral, psychological and environmental aspects that contribute to the persistence of pain. It is intended to teach that education reduces pain and improves endogenous pain inhibition, mental health, physical function, vitality and self-rated disability in patients with chronic pain, and reduces passive coping, kinesiophobia, and catastrophizing.~The same exercises will be applied as the exercise group."
75893896|NCT03665259|Procedure|Pure oxygen group|pre-oxygenation with 100% oxygen during induction of anesthesia
75893897|NCT03665259|Procedure|Lower oxygen group|Pre-oxygenation with 60% oxygen during induction of anesthesia
75893898|NCT05213767|Drug|TQB2916 injection|TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.
75893899|NCT03533517|Device|AccuCinch® Ventricular Restoration|AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
75893900|NCT01166737|Procedure|Tumor Debulking Surgery (surgery in recurrent ovarian disease)|Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
75600668|NCT04295122|Device|Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser|"A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion.~Phacoemulsification energy used during the cataract surgery will be recorded. If the patient has been randomised to ECP laser, the viscoelastic will be washed-out of the capsular bag. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment. Final power used and duration of surgery will be recorded."
75600669|NCT04370548|Drug|DARE-BV1clindamycin phosphate vaginal gel, 2%|One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
75600670|NCT01208181|Drug|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
75600671|NCT01208181|Drug|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
75893901|NCT00785954|Drug|KAI-9803|STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
75893902|NCT05102032|Procedure|mini invasive approach|using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
75893903|NCT05102032|Procedure|Conventional approach|laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
75600672|NCT01208181|Drug|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
75600673|NCT01208181|Drug|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
75600674|NCT02870842|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
75893904|NCT03665181|Other|use or non-use of dose modulator and bismuth mask|For each child for who the eligibility criteria are met, the CT exam is perfomed with or without dose modulator associated to with or without bismuth mask
75893905|NCT05326906|Drug|PD-1/PD-L1 inhibitors|PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)
75893906|NCT05101954|Procedure|Concentrated Growth Factors (CGF)|Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
75893907|NCT05101954|Procedure|Platelet-Rich Fibrin (PRF)|Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
76062900|NCT01927666|Dietary Supplement|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
76062901|NCT00982696|Biological|Opioid Growth Factor|250ug per kilogram weekly IV infusions
76062902|NCT00982150|Drug|Talampanel|50mg capsules tid
75600675|NCT02870842|Other|Respiratory management|Appropriate respiratory managements depending on the lung ultrasound findings
75449579|NCT01696149|Device|transcutaneous electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
75449580|NCT01696162|Other|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
75600676|NCT01208103|Biological|Bevacizumab|Given IV
75893908|NCT04765475|Behavioral|Motivational Interviewing|A culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years).
75600677|NCT01208103|Drug|Capecitabine|Given PO
75600678|NCT01208103|Drug|Oxaliplatin|Given CVC
75600679|NCT01206777|Drug|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
75600680|NCT01001494|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
75893909|NCT04765475|Behavioral|COVID-19 Symptom Monitoring System|A daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts.
75449581|NCT01696162|Other|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
75449582|NCT01696162|Other|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
76062903|NCT02984254|Device|Womac|Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
76062904|NCT02984254|Device|Lequesne|Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
76062905|NCT02984254|Device|Timed-up-and-go (TUG)|Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
75449583|NCT01696201|Behavioral|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
76062906|NCT02984254|Device|five-times-sit-to-stand-test (FTSST)|Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
76062907|NCT02984254|Device|Six-minute walk test.|Perform six-minute walk test at baseline, 3 months and 1 year
75449584|NCT01696227|Drug|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
75449585|NCT01696240|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
75600681|NCT01001494|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
75600682|NCT01001494|Drug|Placebo|Placebo twice-daily by inhalation for 24 weeks
76062908|NCT02984254|Device|functional patellofemoral neoprene brace|Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
76062909|NCT02984254|Device|neoprene sleeve brace.|Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
76062910|NCT01903525|Drug|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
76062911|NCT01903525|Drug|Placebo|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
76062912|NCT00981526|Drug|Telmisartan|"Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks."
76062913|NCT00981526|Drug|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
76062914|NCT00981526|Drug|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
76062915|NCT00981526|Drug|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
76062916|NCT05601310|Device|liquid chromatography-mass spectrometry (LC/MS) analysis|To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
76062917|NCT01927900|Dietary Supplement|HMO|
76062918|NCT01927900|Dietary Supplement|Glucose|
76062919|NCT04274920|Other|Bioactive Glass|Bioactive glass was incorporated in resin composite and its adhesive
76062920|NCT04274920|Other|Light cured calcium hydroxide|Light cured calcium hydroxide
76062921|NCT04274842|Other|observation by D-OCT|observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
75449586|NCT01696240|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
75893910|NCT04765475|Behavioral|Motivational Interviewing and COVID-19 Symptom Monitoring System|A combination of: 1) a culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years); 2) a daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts
75449587|NCT01696266|Other|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
75449588|NCT01696305|Device|Hyalobarrier|
75449589|NCT01696305|Device|Guardix-SG|
75449590|NCT01696318|Behavioral|Support for the Family Health Team|Participation in physical educator, dietitian and pharmacist in primary health care
75893911|NCT04765475|Other|Supportive Services|Provision of supportive services such as referrals to needed medical, mental or behavioral health care and delivery of a hygiene kit containing basic hygiene supplies. Participants will also be provided information on COVID-19 and nearby testing locations and basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19.
75893912|NCT00875108|Drug|VIAject™|Subcutaneous injection 25 IU/mL
75893913|NCT05100940|Procedure|Cardiac Catheterization|Cardiac Catheterization
76062922|NCT04274608|Drug|Botulinum toxin type A|Intragastric injection of Botulinum toxin type A
76062923|NCT04274608|Behavioral|Weight Management Program|12 week weight management program
76062924|NCT05601076|Procedure|fixed with the triple-buffer system|The steps were as follows: i) elastic cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) was used at the proximal 15 cm from the incision, with 5 × 2.5 cm pieces glued to the skin and fixed with the drainage tube using surgical knots; ii) the distal end of the ligation was fixed using the same method, while the ligation position was higher than the first; iii) the ligature point was fixed next to the elastic soft cotton tape (5 × 5 cm), using the high-platform method to fix the drainage tube, with the drainage tube curved; and iv) the drainage tube between the two fixed points was inserted with a specific radian.
75893914|NCT04044209|Drug|AG-120|The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
76062925|NCT05601076|Procedure|fixed using the conventional lifting platform method|In terms of the control group, two lines of flexible cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) measuring 10 × 2.5 cm were used, and the drainage tube was fixed parallel to the long axis and glued to the middle-position 360° winding tube once the drainage tube was 0.5 cm higher than the surrounding skin. Next, the drainage tube was fixed at both ends to the patient's skin using adhesive tape. Then, the tube and the adhesive plaster were overlapped vertically and horizontally, the tube was inserted, the adhesive plaster was added, and then the chest tube was fixed on the adhesive plaster by knotting the interspersed cotton rope, which was equal to indirectly fixing the tube on the patient's skin
75893915|NCT04044209|Drug|Nivolumab|On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
76062926|NCT05600998|Drug|Camrelizumab|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
76062927|NCT05607940|Procedure|blood volume loss based blood transfusion|Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.
75893916|NCT00874796|Drug|GS-9450|Taken as one capsule by mouth once daily
75893917|NCT00874796|Drug|Placebo|Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
75893918|NCT05100784|Biological|HSSA test|Human Sperm Survival Assay testing performed on different batches of different types of IVF consumables. In practice, 3 consumables from the same batch will be tested with 3 different sperms to ensure the repeatability of the result / test.
75893919|NCT02658448|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
75449591|NCT01696331|Behavioral|Text Message Reminder|Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
75449592|NCT01696344|Procedure|PVAI|
75449593|NCT01696344|Procedure|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
75449594|NCT01696370|Drug|Trimetazidine|Trimetazidine 20mg three times per day for 3 months
75449595|NCT01696370|Other|Placebo capsule|one capsule three times per day for 3 months
75449596|NCT01696383|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
75449597|NCT01696409|Dietary Supplement|400 IU vitamin D3|Take 400 IU once/day for 2 months
75449598|NCT01696409|Dietary Supplement|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
75449599|NCT01696422|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
75893920|NCT00872300|Drug|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
75893921|NCT05208853|Biological|Anti CD30 CAR-T Cell Injection|"After enrollment, subjects complete the apheresis, then complete the lymphodepletion, and then receive the dose escalation test: 1.5×10^7 cells，1.5×10^8 cells，5× 10^8 cells.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
75893922|NCT00977522|Drug|PF-03463275|30 mg Controlled Release tablet BID for 12 weeks
75893923|NCT00977522|Drug|Placebo|Placebo tablet BID
75893924|NCT05324176|Radiation|diaphragmatic ultrasound|diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.
75893925|NCT01561651|Other|Left Atrial Appendage Occlusion|Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
75893926|NCT00870818|Diagnostic Test|Blood samples for safety|serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
75893927|NCT00870818|Behavioral|Patient reported outcome questionnaires|EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
76062928|NCT05607940|Procedure|hemoglobin concentration based blood transfusion|Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
75893928|NCT00870818|Diagnostic Test|Analysis of T-cell subsets|CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
75893929|NCT03817463|Drug|Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
75893930|NCT03817463|Drug|Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor|Dipeptidyl peptidase-4 (DPP-4) inhibitor
75744666|NCT04791540|Biological|Gut microbiota|A fecal sample obtained at admission (T0) and at decannulation time (T1)
75893931|NCT05101642|Procedure|Guided Creeping Technique (GCT)|Guided Creeping Technique (GCT) is a novel minimally invasive blind tunnel
76062929|NCT04394728|Drug|Trabectedin|1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
75744667|NCT04791540|Biological|Blood Sample|A Blood sample obtained at admission (T0) and at decannulation time (T1)
75744668|NCT04791540|Other|Anthropometric measures|Measurement of weight and height (assessed only at admission) to calculate the Body Mass Index (BMI), at admission (T0) and at decannulation time (T1)
75744669|NCT05000424|Other|Clary Sage Massage Oil|This massage oil contains clary sage oil. Five drops will be used daily.
75744670|NCT05000424|Other|Inert Massage Oil|This massage oil consists entirely of plant based oils. Five drops will be used daily.
75744671|NCT03875508|Drug|Risankizumab|Risankizumab to be injected subcutaneously (SC)
75744672|NCT03875508|Device|Autoinjector|Single dose pre-filled autoinjector containing risankizumab for SC injection
75744673|NCT03998982|Drug|Glycyrrhetinic Acid|Compound glycyrrhizin tablets 75 mg three times per day, 1 month
75744674|NCT03998982|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
75449600|NCT01696422|Biological|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
75449601|NCT01696422|Other|Placebo|Route:subcutaneous
75449602|NCT01696448|Dietary Supplement|CAR-191|Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
75449603|NCT01696448|Other|Placebo|Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
75449604|NCT01696474|Drug|Bortezomib|
75449605|NCT01696487|Dietary Supplement|High oral Fructose challenge (150g per day for 28 days)|
75449606|NCT01696500|Drug|Intravenous immunoglobulin|
75449607|NCT01696526|Other|vitamin D fortified fish|fish containing vitamin D3
75744675|NCT04991766|Drug|[¹⁴C]-LY3484356|Administered orally.
75744676|NCT04991766|Drug|LY3484356|Administered orally.
75744677|NCT04991766|Drug|[¹⁴C]-LY3484356 (IV)|Administered IV.
75744678|NCT00620321|Drug|LY2181308 sodium|750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
75893932|NCT05207683|Other|echocardiography|All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.
75893933|NCT05100550|Dietary Supplement|Zinc|Zinc is given as written in the arm description, two hours after lunch
75893934|NCT05100550|Other|Control|This group will not receive zinc
75893935|NCT00970424|Drug|Placebo|placebo, oral tablet administered once daily on background of pioglitazone
75893936|NCT00970424|Drug|Dutogliptin|dutogliptin, oral tablet administered once daily on background of pioglitazone
75893937|NCT03075761|Device|Fitbit|The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.
75893938|NCT03075761|Behavioral|30-minute education session|
75600683|NCT01205685|Drug|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~Dose level 2 = 150 mg twice a day~Dose level 1 = 100 mg twice a day~Dose level -1 = 100 mg twice a day~Dose level -2 = 100 mg twice a day"
75744679|NCT00620321|Drug|cytarabine|1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
75893939|NCT05106790|Behavioral|Educational support with peer counseling|This group will receive peer counseling therapy sessions will be led by doctors who specialize in hypertension. Patients and their families will be the focus of the sessions. Face-to-face sessions will take roughly 25-30 minutes. Patients will receive spoken and written instructions based on their abilities during these sessions. The counseling sessions are geared toward overcoming both general and personal obstacles. The educational component will be delivered through smart booklets. Information on hypertension, blood pressure self-monitoring, and frequent systolic blood pressure (SBP) tests, as well as body weight and serum cholesterol values, are included in the instructional support. Food control, exercise therapy, and hypertension problems and their management will also be explored as non-pharmacological therapeutic approaches.
75893940|NCT05106790|Behavioral|mHealth intervention|"This group will receive mHealth intervention will include daily written and voice messages, and once weekly an educational-led video. This intervention module will be delivered through WhatsApp."
75893941|NCT05106790|Behavioral|mHealth intervention and Educational support with peer counseling|This group will receive both Educational support (Smart booklets) with peer counseling sessions on a monthly basis and mHealth intervention will include daily written and voice reminders, and once weekly an educational led video.
75449608|NCT01696526|Other|conventional fish|fish containing low concentrations of vitamin D3
75449609|NCT01696539|Behavioral|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
75744680|NCT00620321|Drug|idarubicin|12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
75744681|NCT00848471|Device|Quark RMR|Quark RMR calorimeter (Cosmed)
75893942|NCT03000075|Drug|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
75893943|NCT03000075|Drug|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
75449610|NCT01696539|Other|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
75449611|NCT01696552|Procedure|TKR with Positioning Guides (PSPG)|TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique
75449612|NCT01696552|Procedure|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
75449613|NCT01696578|Behavioral|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
75600684|NCT01205685|Drug|Erlotinib|"During the safety run phase of the study:~Dose Level 2 = 100 mg/d~Dose Level 1 = 100 mg/d~Dose Level -1= 75 mg/d~Dose Level -2 = 50 mg/d"
75600685|NCT01205685|Drug|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
75744682|NCT00848471|Device|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
75600686|NCT01205685|Drug|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
75616515|NCT00651274|Drug|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
75744683|NCT00852215|Device|Taxus stent|Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
75744684|NCT00852215|Device|Vision stent|Stenting with VISION coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
75893944|NCT03883516|Other|Pre-briefing with the current SE treatment guidelines|instruction of the study participants according to the evidence-based guideline for the treatment of SE published by the American Epilepsy Society prior to the simulation training
75893945|NCT03883516|Other|"Pre-briefing with a consolidated one page SE treatment guide"|"instruction of the study participants with a consolidated one page SE treatment guide prior to the simulation training"
76062930|NCT03831412|Behavioral|CBT-I|Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
75893946|NCT03883516|Other|No Pre-briefing|no instruction of the study participants prior to the simulation training
75893947|NCT00869726|Drug|dirucotide|500mg, intravenous, dosed once every six months for 18 months
75893948|NCT00869726|Drug|Placebo|intravenous, once every six months for 18 months
75893949|NCT05213065|Other|Sphenopalatine ganglion block with 0.5% bupivacaine|Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.
75893950|NCT05213065|Other|Sphenopalatine ganglion block with saline|Repetitive SPG blockade using saline delivered with the Tx360® device.
75893951|NCT03846076|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
75744685|NCT00852293|Other|A blood test|A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
75893952|NCT04423471|Diagnostic Test|Sociodemographic variables|"Sociodemographic variables: Sex / Age / Marital status / Level of studies completed / Employment status.~General clinical variables: Body mass index (BMI), Medical comorbidities and Charlson Comorbidity Index, Active drug treatments~Clinical psoriasis variables: BSA, PASI, ScalpPASI, PPPASI, DLQI, time since the diagnosis of psoriasis, previous treatments for psoriasis.~Clinical depression variables: Psychiatric diagnoses according to clinical interview and DSM-5 criteria, age of onset and time of evolution from the first episode of major depression, time of evolution of the current episode of major depression, previous treatments for depression.~Psychopathological variables: HADS, PHQ-9, MADRS, GAD-7, SHAPS, The Irritability Questionnaire, PSS, FSS, MoCA.~Immunological and biochemical variables: Acute phase biomarkers, Proinflammatory cytokines, Anti-inflammatory cytokines, HPA axis, Microglia activation, Neurogenesis.~Result variables: Changes in PASI or MADRS scores"
75893953|NCT03834532|Other|Breast reconstruction decision aid|The breast reconstruction decision aid is a web-based, interactive tool that participants will use after the first breast surgery visit and before a plastic surgery visit or surgery. The decision aid provides information about post-mastectomy breast reconstruction and helps the participant clarify their preferences related to the procedure.
76062931|NCT03831412|Behavioral|ERRT|Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
75744686|NCT00621023|Drug|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
75449614|NCT01696591|Biological|NEUROSTEM®-AD|NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
75893954|NCT03834532|Other|Educational website|The educational website contains information on healthy living with breast cancer including, physical activity and nutrition.
75893955|NCT03665649|Procedure|CD133+ cells isolation|Hematopoietic precursors from human donors will be mobilized by administering Colony Stimulating Factors (G-CSF) for 5 days (according to the clinical standard administration) and subsequently CD133+ cells will be isolated and transferred in a murine model.
76062932|NCT05607706|Behavioral|Exposure to maternal odor|Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
76062933|NCT05607628|Combination Product|Low Calorie Animal Protein Meals|Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
76062934|NCT05607628|Combination Product|Low Calorie Plant Protein Meals|Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
75893956|NCT04610450|Device|HEARO|Robotic system for otological procedures
75893957|NCT04610450|Device|OTOPLAN|Otological surgical planning software
75893958|NCT03664635|Biological|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
76062935|NCT04759378|Diagnostic Test|Upper endoscopy, esophageal manometry, 24-hour pH monitoring|upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.
76062936|NCT01927861|Drug|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
76062937|NCT05606536|Drug|Crystalloid Solutions|Locally approved crystalloid solution will be given at the predefined infusion rate
76062938|NCT05600218|Drug|No intervention - Observational study|Real life drug evaluation
76062939|NCT05602948|Behavioral|'Run, Jump & Fun' intervention|"The intervention can be designed e.g. to consist of morning sessions each schoolday (except days with PE) or with different time slots at different weekdays. Activities are mainly conducted by school personnel, but can be supplemented by activity sessions during recess once a week lead by older students. Further, to create variation and inspire teachers, external PA parties, for example instructors from local sports clubs are invited to conduct sessions for the students and deliver teaching materials.~To align with the aim of the Danish school system, activities must have a pedagogical purpose.~Both the Run, jump & fun and the Move & learn interventions have a set of strategies underpinning implementation (see Move & Learn for more details).~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
75600687|NCT04362514|Behavioral|MEPC - Multi-component exercise program related to cycling|Structured and progressive multicomponent exercise program with and without bikes. Training period will last over 3 months with 8 sessions à 60 minutes. Training sessions will address motor competence (balance, strength, cycling skills and techniques) and cognitive skills required during cycling. Furthermore, fall-related psychological concerns will be addressed.
75600688|NCT04362514|Other|HRP - health-related presentations|HRP include 3 presentations on healthy aging (one per month) with a duration of 60 minutes
75600689|NCT01205529|Drug|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
75600690|NCT02870374|Behavioral|Answering specific quality of life questionnaire in kidneys transplantation population|
75600691|NCT04295200|Other|Dry needling with electrical stimulation|Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
75744687|NCT02546687|Other|Venous blood sampling|"The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood."
75744688|NCT00842465|Biological|blood collection for hormonal status analysis|for hormonal status analysis
75744689|NCT00842465|Procedure|breast Biopsy or surgery|breast Biopsy or surgery
75744690|NCT00842465|Genetic|blood collection|blood collection for prlR gene sequencing
75600692|NCT01205451|Drug|Botulinum toxin type A|Botulinum toxin type A
75600693|NCT04294732|Drug|Bupivacaine|"bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL."
75600694|NCT04294732|Drug|Only spinal anesthesia without peripheral nerve block|Only spinal anesthesia without peripheral nerve block
75600695|NCT04294888|Device|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
75893959|NCT04414033|Device|Bubble: A New VR-AI Way of Treatment for Hot Flashes|Bubble Bubble is a virtual reality (VR) mobile application. Bubble offers a psychological intervention based upon cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) protocols. The bubble mobile application offers the intervention in a virtual reality (VR) coaching environment and in a winter wonderland setting called Frosty. Frosty provides both a virtual reality winter wonderland experience as well as guided meditation. The cold, winter-like experience is designed to help patients calm down and feel cooler.
75893960|NCT04406545|Other|evaluation of skin microvascular flow and reactivity|evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring
75893961|NCT00969722|Biological|MAb-3F8|
75893962|NCT00969722|Biological|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
75893963|NCT00969722|Biological|13-cis-Retinoic Acid|
75893964|NCT03665571|Diagnostic Test|Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
75449615|NCT01696604|Drug|GSK2849466|GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
75449616|NCT01696604|Drug|Placebo|Matching placebo capsules will be available.
75600696|NCT02887677|Drug|Dapagliflozin|Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
75600697|NCT02887677|Drug|Placebo|Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
75600698|NCT02871466|Drug|stem cells infusion|
75600699|NCT01001104|Drug|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
75744691|NCT00842465|Other|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
75744692|NCT00848627|Other|Specimen and questionnaires only|Specimen and questionnaires only
75744693|NCT00842621|Procedure|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
75744694|NCT00842621|Other|Laboratory Studies|"Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
75600700|NCT01001104|Drug|Placebo|Administered by SC injection, QW for 12 weeks.
75744695|NCT04042883|Procedure|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
75744696|NCT00848705|Behavioral|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
75744697|NCT00848861|Drug|propofol (sedation for outpatient colonoscopy)|
75893965|NCT05099614|Combination Product|Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system|1.2 mg of naloxone hydrochloride is administered to healthy adults using the SmartDose wearable auto injector and the mobile respiratory sensing system.
75449617|NCT01696617|Drug|Aripiprazole 6-week group|
75744698|NCT00848861|Drug|midazolam plus meperidine (sedation for outpatient colonoscopy)|
75744699|NCT00852371|Drug|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
75744700|NCT00852371|Drug|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
75744701|NCT00852371|Drug|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
75744702|NCT00852371|Other|Placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
75893966|NCT00968942|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
75893967|NCT00968942|Drug|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
75893968|NCT05207449|Other|Questionnaire|"The questionnaire will include:~The demographic data of the patients~Chronic disease related questions~Assessment of adherence to treatment by using Arabic validated version of Medication Adherence Report Scale (MARS)~Patients' beliefs about medication will be assessed using Arabic validated version of Beliefs about Medicines Questionnaire (BMQ)~Disease acceptance will be evaluated using: Arabic validated version of Acceptance to Illness Scale (AIS)~Assessment of health-related quality of life (HRQoL) using the Arabic version of the Pediatric Qualify of Life Inventory Generic Core Scale (PedsQL) 4.0 GCS~Assessment of readiness for transition to adult health care settings using The Transition Readiness Assessment Questionnaire (TRAQ)"
75449618|NCT01696617|Drug|Aripiprazole 8-week group|
75449619|NCT01696630|Drug|Xenon|
75449620|NCT01696630|Drug|Desflurane|
75449621|NCT01696656|Drug|Drug prescription pattern|Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
75600701|NCT04296526|Behavioral|Exercise Prescription|To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.
75600702|NCT04296526|Behavioral|Exercise Education|To organize sessions for how to proper exercise.
75600703|NCT04296526|Behavioral|Social Support|Supports such as peer influence or reminder phone messages
75616516|NCT00651274|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
75616517|NCT05335330|Other|Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia|The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the prone position. Measurements will be taken from three different points.
75893969|NCT02418689|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
75893970|NCT05207371|Biological|Biological|Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)
75600704|NCT00628888|Behavioral|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
76072112|NCT03143270|Drug|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
75449622|NCT01696669|Drug|Chemotherapy|"Vincristine, 2 mg/m^2 IV bolus, day 1.~Doxorubicin: 75 mg/m^2 per cycle, or 25 mg/m^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~Cyclophosphamide: 2100 mg/m^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm^3/L.~Ifosfamide: 1800 mg/m^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~Gemcitabine: 1000 mg/m^2 IV, 90 minutes on day 1 and 8.~Docetaxel 100 mg/m^2, 2-3 hour infusion on day 8."
75449623|NCT01696669|Procedure|Surgery|Surgical intervention aiming to completely resect the tumor with negative margins.
75449624|NCT01696669|Radiation|Radiotherapy|On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
75893971|NCT05212987|Drug|FCN-098|FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
75600705|NCT02870686|Procedure|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
75744703|NCT00842777|Behavioral|Parent manualized group treatment|"Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment"
75744704|NCT00842777|Behavioral|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
75744705|NCT00528372|Drug|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
75893972|NCT03234790|Other|Filtered Air Exposure|Exposure to Filtered air
75893973|NCT03234790|Other|Diesel Exhaust Exposure|Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
75449625|NCT01696682|Procedure|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
75893974|NCT00869336|Drug|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
75893975|NCT00869336|Drug|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
75893976|NCT00869336|Drug|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
75893977|NCT00869336|Drug|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
75893978|NCT05212675|Other|Short daily dialysis|7 days 2hours dialysis
75893979|NCT05090410|Drug|filgotinib 200mg/day|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
75893980|NCT05090410|Drug|subcutaneous tocilizumab 162mg/biweekly|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
75893981|NCT02371889|Drug|Topiramate|Max therapeutic dose of 200mg/day
75893982|NCT02371889|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
75893983|NCT02371889|Drug|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
75893984|NCT00867698|Drug|AST-120|AST-120
75893985|NCT05099458|Biological|Additional blood sampling (100 ml)|only an additional blood volume will be collected at the same time of the standard blood collection for these patients
75893986|NCT05207215|Other|Home Base Exercises|The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.
75893987|NCT05099302|Other|divert attention|In order to reduce the fears of the children who came to the waiting room before the operation, they watched cartoons and their attention was diverted to another point.
75744706|NCT00528372|Drug|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
75893988|NCT00860288|Drug|Vildagliptin|
75893989|NCT00860288|Drug|Metformin|
75893990|NCT00860288|Drug|Placebo|
75893991|NCT00860288|Drug|Sitagliptin|
75600706|NCT02870686|Procedure|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
75744707|NCT00528372|Drug|Metformin|
75744708|NCT01564680|Other|placebo|normal saline
75893992|NCT03941275|Diagnostic Test|Bi-plane fluoroscopy|In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead
75893993|NCT05099224|Behavioral|Mindfulness meditation|similar to the information included in arm/group descriptions
75893994|NCT03630029|Drug|FeS and SnPP|Escalating doses of drug will be compared for biomarker changes
75893995|NCT03072875|Device|CAMS-RAS|
75893996|NCT05212597|Drug|Sacubitril-valsartan|50mg~100mg twice daily
75893997|NCT05212597|Drug|Amlodipine-losartan|amlodipine/losartan 2.5/25mg ~ 5/100mg once daily
75449626|NCT01696682|Procedure|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
75449627|NCT01696708|Other|31-Phosphorus RMN Spectroscopy|
75449628|NCT01696786|Procedure|Oocyte cryopreservation|Oocyte (egg) cryopreservation (freezing) to preserve fertility
75449629|NCT01696799|Drug|Econazole Nitrate|
75600707|NCT04204954|Other|Tea Tree Oil Shampoo|Twice a day eyelid margin cleansing for three days.
75600708|NCT04204954|Drug|Ciprofloxacin Ophthalmic Ointment 0.3%|Applied topically in the eyelid margin every four hours for three days.
75600709|NCT04204954|Other|Baby shampoo|Twice a day eyelid margin cleansing for three days.
75744709|NCT01564680|Drug|Paracetamol|IV paracetamol infusion
75893998|NCT02450812|Drug|Radium-223-dichloride (Xofigo, BAY88-8223)|according to Summary of Product Characteristics
75893999|NCT03629717|Procedure|Ultrasound-guided core needle biopsy|Tissue collection for this research proposal will be used for research purposes only and will not inform participant care
75449630|NCT01696799|Drug|placebo|
75449631|NCT01696812|Procedure|electrode position|
75449632|NCT01696825|Drug|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
75449633|NCT01696825|Drug|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
75744710|NCT01564680|Drug|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
75744711|NCT01564836|Behavioral|Imatinib treatment discontinuing|Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
75894000|NCT03629717|Drug|Denosumab|Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
75894001|NCT03629717|Procedure|Blood draw|20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)
75894002|NCT03629717|Drug|Calcium|1200mg daily
75894003|NCT03629717|Drug|Vitamin D|800 IU daily
75894004|NCT05212519|Other||For observational research
75894005|NCT04473404|Dietary Supplement|Streptococcus salivarius DB-B5 - 2 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
75894006|NCT04473404|Dietary Supplement|Streptococcus salivarius DB-B5 - 10 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
75894007|NCT04473404|Other|Placebo|The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
75894008|NCT04250077|Behavioral|Community Reinforcement And Family Training (CRAFT)|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
75894009|NCT04250077|Behavioral|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
75449634|NCT01696825|Drug|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
75449635|NCT01696838|Other|electroacupuncture|Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
75449636|NCT01696838|Other|moxibustion|patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
75449637|NCT01696851|Other|tests and questionnaires|lung test, depression and self-efficacy questionnaires and Functional testing.
75600710|NCT04204954|Other|Blephaclean|Twice a day eyelid margin cleansing for three days.
75600711|NCT02870608|Other|lung and liver elastography measurement of fetus|
75600712|NCT04344886|Procedure|Conventional (dual-phase) SPECT/CT|Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
75600713|NCT04344886|Procedure|Multi-phase SPECT/CT|Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
75600714|NCT04344886|Procedure|Conventional minimally-invasive radio-guided parathyroidectomy|Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
75600715|NCT04344886|Procedure|Individualised minimally-invasive radio-guided parathyroidectomy|Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
75744712|NCT00527982|Drug|Celecoxib|600 mg by mouth daily for a total of 12 months.
75744713|NCT04121286|Drug|JAB-3312|JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.
75449638|NCT01696864|Device|Hand tutor rehabilitation device|A rehabilitation device for the hand
75600716|NCT00998764|Drug|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
75600717|NCT01204671|Biological|Influenza vaccine GSK2321138A|One intramuscular injection
75600718|NCT01204671|Biological|FluarixTM|One intramuscular injection
75600719|NCT01204671|Biological|Influenza vaccine GSK2604409A|One intramuscular injection
75744714|NCT00527904|Drug|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
75744715|NCT00527904|Drug|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
75744716|NCT00619619|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
75744717|NCT00852449|Other|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation > 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity < 13% and no further increases in SV
75744718|NCT00848939|Drug|treprostinil diethanolamine|Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
75449639|NCT01696864|Device|Arm tutor rehabilitation device|A rehabilitation device for the arm
75894010|NCT00781742|Drug|AZD6765|IV once per dosing day, multiple times during the treatment period
75894011|NCT00781742|Drug|Placebo|0.9% saline IV once per dosing day multiple times during the treatment period
75894012|NCT03538223|Other|Music Listening|Participants will undergo two different types of music before radiotherapy sessions
75600720|NCT02887755|Device|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
75894013|NCT03538223|Radiation|Radiotherapy|All participants will undergo radiotherapy according to breast cancer post surgery protocol
75894014|NCT04474340|Drug|COVID-19 Convalscent Plasma|The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
75894015|NCT05108350|Drug|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment T1 followed by 7 days washout and then receive treatment R1+R.
75894016|NCT05108350|Drug|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment R1+R followed by 7 days washout and then receive treatment T1.
75894017|NCT05108350|Drug|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment T2 followed by 7 days washout and then receive treatment R2+R.
75894018|NCT05108350|Drug|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment R2+R followed by 7 days washout and then receive treatment T2.
75894019|NCT05108272|Procedure|Microneedling|Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm
75894020|NCT05108272|Procedure|Percutaneous Collagen Induction|It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
75894021|NCT04596449|Other|study intervention|"The sleep structure of healthy volunteers will be recorded (9 Electroencephalograms (EEG), 2 Electrooculograms (EOG), 2 Electromyograms (EMG) and 2 Electrocardiograms (ECG)) during 1 night. The characteristics of the spindle (density, frequency and amplitude) will be automatically analyzed from purified EEG during Non Rapid Eye Movement sleep (NREM).~Volunteers will completed a neuropsychological evaluation that will evaluate Sustained attention (simple reaction time test), Vigilance (TAP Vigilance), Sustained and selective attention (CPT II), Inhibition (Stroop test), Mental flexibility (TAP flexibility) , Executive operation (Tower of London), Short-term memory (Wechsler code test).~Driving performance will be analyzed as part of a complex scenario involving attentional and high-level functions on a driving simulator."
75894022|NCT00859430|Drug|Levetiracetam|1000 mg Tablet
75894023|NCT00859430|Drug|Keppra®|1000 mg Tablet
75894024|NCT04240483|Other|Intracutaneous sterile water injections (ISWI) group|ISWI consists of 4 intracutaneous injections of 0.5 ml sterile water in the lumbosacral region while patient is in a seated position. One injection given at the posterior superior iliac spine (Point 1) on both sides and second injection at 1 cm medial, and 1-2 cm inferior to the first point on both the sides (Point 2) using an insulin needle. These points overlie the area called Michaelis' rhomboid.
75894025|NCT04240483|Other|Intracutaneous dry injections (IDI) group|Intracutaneous dry injections will be performed in the same manner described above, however, no sterile water or alternative solutions will be injected into the sites.
75894026|NCT05212285|Device|Inbody 570|Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up
75600721|NCT01202955|Drug|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
75600722|NCT01202955|Drug|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
75600723|NCT01202877|Drug|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
75744719|NCT00848939|Drug|treprostinil diethanolamine|Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
75600724|NCT01202877|Drug|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
75600725|NCT01202409|Drug|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
75600726|NCT01202175|Drug|Nebivolol|Oral nebivolol 2.5-5mg once daily
75616518|NCT00351988|Behavioral|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
75616519|NCT00351988|Behavioral|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
75744720|NCT00842933|Drug|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
75744721|NCT00842933|Drug|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
75744722|NCT00849095|Drug|budesonide/formoterol combination (PRN)|budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
75744723|NCT00849095|Drug|budesonide/formoterol combination|budesonide/formoterol 160/4.5 mcg 1 inhalation bid
75744724|NCT00849095|Drug|placebo|bid inhaled placebo
75600727|NCT01201785|Drug|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
75744725|NCT00849095|Drug|terbutaline|as needed terbutaline 500 mcg for a period of 52 weeks
75894027|NCT05212285|Device|JAMAR Dynamometer|Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up
75894028|NCT05212285|Radiation|CT scan|Chest and abdominal CT scan during each follow-up
75894029|NCT00959114|Biological|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
75744726|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
75894030|NCT00959114|Biological|ALV003 placebo|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
75600728|NCT01201317|Drug|AZD2423|20 mg tablet
75894031|NCT00857090|Drug|OMS201|"Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery"
75894032|NCT00857090|Drug|Vehicle|Stages 1-2: Vehicle irrigation solution during surgery
75894033|NCT04182919|Drug|Phlai|Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks
75894034|NCT04182919|Drug|Placebo oral capsule|Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
75894035|NCT00856934|Biological|Autologous Platelet Rich Plasma|Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
75894036|NCT00856934|Biological|Keratinocyte suspension|Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
75894037|NCT00856934|Other|Standard dressings|Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
75894038|NCT05212051|Biological|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
75894039|NCT05212051|Biological|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
75600729|NCT01201317|Drug|AZD2423|150 mg tablet
75600730|NCT01201317|Drug|Placebo|Placebo
75600731|NCT04318353|Other|early enteral feeding within 2 days postoperative|Enteral feeding within 2 days postoperative
75600732|NCT04317885|Biological|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
75600733|NCT01200069|Drug|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
75744727|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
75744728|NCT00843011|Drug|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
75600734|NCT01200069|Drug|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
75744729|NCT00849329|Drug|lapatinib|1250mg lapatinib
75744730|NCT00849329|Drug|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
75744731|NCT02545829|Drug|HIP1302|Tenofovir 292mg
75744732|NCT02545829|Drug|HGP1406|Tenofovir 300mg
75744733|NCT02545595|Drug|Sugammadex 1 mg/kg|
75744734|NCT02545595|Drug|Sugammadex 2 mg/kg|
75744735|NCT02545595|Drug|Sugammadex 4 mg/kg|
75894040|NCT00855764|Drug|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
75744736|NCT00843089|Other|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
75744737|NCT00843245|Other|No intervention|No intervention
75894041|NCT00959036|Drug|ATN-103|10 mg every 4 weeks until week 12
75894042|NCT00959036|Drug|ATN-103|10 mg every 8 weeks until week 12
75894043|NCT00959036|Drug|ATN-103|30 mg every 4 weeks until week 12
75894044|NCT00959036|Drug|ATN-103|80 mg every 4 weeks until week 12
75894045|NCT00959036|Drug|ATN-103|80 mg every 8 weeks until week 12
75894046|NCT00959036|Drug|Placebo|Placebo every 4 weeks
75744738|NCT00849563|Other|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
75744739|NCT05027178|Other|Chiropractic Care|Chiropractic care on stroke participants
75744740|NCT04840212|Other|Lavender-Sandalwood scented aromatherapy sticker|The Lavender-Sandalwood scented aromatherapy sticker will be placed on the patient gown.
75894047|NCT00959036|Drug|Methotrexate|
75894048|NCT04129723|Other|Stopping biological therapy|Stopping biological therapy The primary endpoint is clinical relapse at 12 months
75894049|NCT03628729|Other|Embrace™ WetBond™ Pit & Fissure Sealant|pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
75894050|NCT03628729|Other|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Fluoride releasing resin based pits and fissures sealant
75894051|NCT03619759|Drug|Sugammadex|Sugammadex injection as a reverse agent of neuromuscular blocking
75894052|NCT04474262|Biological|Albumin|Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)
75894053|NCT04474262|Drug|Midodrine Oral Tablet|Midodrine 7.5 mg to 10 mg TDS (keeping the target MAP above 70 mmHg).
75894054|NCT04474262|Other|Placebo|Placebo
75894055|NCT05211817|Behavioral|Complex lifestyle intervention|Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.
76062940|NCT05602948|Behavioral|'Move & Learn' intervention|"The physical activities in Move & Learn are closely linked to the subject curricula. The bodily integrating in the learning task can vary between high bodily engagement and less demanding activities.~Both the Run, jump & fun and the Move & learn interventions have a set of strategies underpinning implementation. These strategies include; 1) Initial workshops and follow-up courses for school personnel to ensure ownership, empowerment and knowledge in order to implement the interventions, 2) Teaching materials and resources, like posters, booklets etc., 3) A set of core principles for the two different interventions to ensure that the interventions are implemented as intended, and 4) Mandatory school meetings for staff and heads to ensure motivation.~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
75600735|NCT01199601|Behavioral|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
75744741|NCT01564992|Other|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
75744742|NCT00855491|Procedure|Phaco|AcrySof Single-Piece IOL
75894056|NCT05211817|Dietary Supplement|Carnosine|3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.
75744743|NCT00849719|Drug|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
75894057|NCT04418648|Drug|Toripalimab|Toripalimab consolidation (240 mg) via iv infusion once every 3 weeks. Administration of toripalimab will commence on Day 1 following randomisation to toripalimab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 6 months.
75894058|NCT03628183|Other|Hydrolysate Infant Formula 1|Feed ad lib
75894059|NCT03628183|Other|Hydrolysate Infant Formula 2|Feed ad lib
75600736|NCT01199289|Drug|AMG 827|SC injection.
75600737|NCT01199289|Drug|Placebo|SC injection.
75600738|NCT01199055|Drug|CS-7017|Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4~6 cycles (1 cycle: 3 weeks)
75600739|NCT01199055|Drug|Carboplatin|Drug: Carboplatin IV, AUC of 6 mg/mL*min, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
75894060|NCT00781118|Device|Guardian System|There is no intervention in this study. The device is a diagnostic only.
75894061|NCT05211583|Diagnostic Test|Serum progesterone levels|In order to show change of serum progesterone levels, serial venous blood sampling will be done and also transvaginal ultrasonography will be performed to show ovulation.
76062941|NCT03831178|Dietary Supplement|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
76062942|NCT03831178|Drug|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
76062943|NCT03353272|Behavioral|Patient Engagement Education and Restructuring of Cognitions|This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
76062944|NCT05602870|Diagnostic Test|non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)|A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
75600740|NCT01199055|Drug|Paclitaxel|Drug: Paclitaxel IV, 200mg/m^2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
75600741|NCT01198977|Behavioral|Brief telephone-based counseling|Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
75600742|NCT01198977|Other|Education counseling|Mailed informational video of exercise programs
75600743|NCT01198587|Drug|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
75600744|NCT01198587|Drug|Placebo oral capsule|Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
75600745|NCT01198509|Drug|doxycycline|doxycycline - 100 mg twice per day, for 2 months
76062945|NCT01927627|Drug|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
76062946|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with advanced solid tumors.
76062947|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with sarcoma.
76062948|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.
76062949|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with breast cancer.
76062950|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with esophagus cancer.
76062951|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with lung cancer.
76062952|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.
75600746|NCT01198509|Drug|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
75600747|NCT01198275|Drug|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
75600748|NCT01198275|Drug|Placebo|1.0 g of olive oil,one capsule twice a day
75744744|NCT00849719|Drug|PCA MO only|When visual analog scale [VAS] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
75744745|NCT04832256|Device|Radical-7 Pulse CO-Oximeter|COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)
75744746|NCT02546219|Other|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
75744747|NCT01565070|Drug|Biofreeze|Use of Biofreeze ointment
76062953|NCT04394104|Other|Survey|No intervention is being administered.
75600749|NCT01198275|Drug|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
75600750|NCT01198275|Drug|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
75600751|NCT01197417|Drug|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
75600752|NCT01197417|Drug|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
75600753|NCT04206267|Device|Acceledent|Device for accelerating tooth movement
75600754|NCT00977431|Drug|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
75600755|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
75600756|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
75600757|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
75600758|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
75744748|NCT01565070|Other|Placebo|Use of placebo ointment
76062954|NCT01889251|Drug|Ocriplasmin|
75894062|NCT04031599|Device|Single-hormone closed-loop system|Every 10 minutes, the glucose levels as measured by the sensor will be transferred automatically to a LG Google Nexus Smartphone that the algorithm is running on, which will calculate the recommended doses and will send them wirelessly to the infusion pump.
75894063|NCT04031599|Device|Insulin pump|Tandem Diabetes Care
75894064|NCT04031599|Device|Continuous glucose monitoring system|Dexcom G6
75449640|NCT01696890|Device|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
75600759|NCT04290169|Drug|IncobotulinumtoxinA|IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
75600760|NCT04290169|Device|Video game|"The study will include the Nintendo Switch or similar consoles that include games that require the players to move their bodies while holding motion controllers in order to progress. The games included in this project has been chosen by staff at our hospitals Virtual Gaming Lab. The participants are recommended to train 30 minutes each day, 4 days a week, during the training periods. It is expected that the amount of training will vary among the participants. Thus, each participant will be instructed to keep a training-diary and weekly report number of hours played/trained through an online reporting system created with online form, an electronic data collection system available through the University of Oslo"
75894065|NCT04031599|Drug|Aspart or Lispro|Aspart or lispro will be infused with the infusion pump
75894066|NCT04031599|Other|Carbohydrate counting|Participants will be required to enter an estimate of the carbohydrate content of their meal into the phone. Insulin boluses will be calculated based on grams of carbohydrates and participant's insulin-to-carbohydrate ratio. Carbohydrate-matching full prandial bolus will be given 5 to 10 minutes before the meal.
76062955|NCT01889251|Drug|Sham injection|
76062956|NCT05602714|Other|Collection Data|
75600761|NCT02864095|Drug|Tranexamic acid (TXA)|IV and topical administration
75600762|NCT02864095|Drug|Epinephrine|
75600763|NCT02864641|Behavioral|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
75600764|NCT04286893|Diagnostic Test|Flow mediated vasodilatation|Measurement of brachial artery diameter change before and after limb ischaemia.
75600765|NCT04286893|Diagnostic Test|High resolution ECG|Measurement HRV using high resolution ECG
75600766|NCT04286893|Diagnostic Test|Blood withdrawal|Measurement of endothelial inflammation markers
75894067|NCT04031599|Other|Simplified qualitative meal-size estimation strategy|A pre-meal partial prandial bolus will be given 5-10 minutes before the meal. The partial bolus will be based on the estimated meal size (small, regular, large and extra-large). The closed-loop system will give the remaining insulin needed based on the sensor readings. For this strategy, meal size will be defined as: small as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, extra-large meal for anything above 90g CHO.
75894068|NCT04031599|Other|3-week intervention|Glucose levels will be regulated by the single-hormone closed-loop system for 3 consecutive weeks.
75894069|NCT04031599|Other|1-hour postprandial exercise (sub-study)|60 minute exercise will be started one hour after the meal time.
75894070|NCT04031599|Other|2-hour postprandial exercise (sub-study)|60 minute exercise will be started two hours after meal time
75894071|NCT04031599|Other|Exercise announcement and meal bolus reduction (sub-study)|Meal bolus reduction of 33% at meal time and exercise announcement (increased target glucose from 6 to 9mmolL) to the CLS algorithm
75894072|NCT00954590|Drug|Dimebon (latrepirdine)|20 mg orally three times daily
75894073|NCT00954590|Drug|Placebo|Placebo orally three times daily
75894074|NCT02913105|Drug|LMB763|Hard Gelatin Capsules
75894075|NCT02913105|Drug|Placebo|Hard Gelatin Capsule
76062957|NCT05602558|Biological|LYB001|The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
76062958|NCT05602558|Biological|Placebo|Aluminium hydroxide adjuvant
76062959|NCT04394338|Other|self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia|to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
76062960|NCT01616563|Behavioral|Dietary Intervention|Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
75449641|NCT01696890|Device|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
75449642|NCT01696903|Procedure|Pancreaticojejunostomy technique|The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
75449643|NCT01696916|Procedure|6-minute walking test|submaximum exercise test
75449644|NCT01697007|Biological|HIVIS DNA vaccine|
75449645|NCT01697007|Device|Zetajet|
75449646|NCT01697007|Device|Derma Vax Electroporation|
75449647|NCT01697007|Biological|Modified Vaccinia Ankara (MVA-CDMR)|
75600767|NCT04290247|Diagnostic Test|Ultrasound|Ultrasound imaging for fracture diagnosis before conventional X-ray
75600768|NCT02863939|Device|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
75600769|NCT02863939|Other|exercise|
75600770|NCT00977197|Drug|Pregabalin|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
75744749|NCT00527748|Device|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
75894076|NCT04724759|Drug|Dexmedetomidine / Ketamine / Lidocaine|Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
75894077|NCT00771446|Biological|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
75894078|NCT00771446|Other|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
75894079|NCT05186467|Drug|intraperitoneal Magnesium sulfate|Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
75894080|NCT05186467|Drug|intravenous magnesium sulfate|Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
75600771|NCT00977197|Drug|Placebo|A matching placebo will be administered twice a day
75600772|NCT04065139|Drug|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
75894081|NCT00771134|Drug|Lu AA39959|30mg/day; 15mg B.I.D. for 8 weeks
75894082|NCT00771134|Drug|Placebo|B.I.D. for 8 weeks
75449648|NCT01697020|Drug|Mercaptopurine 20mg/ml oral suspension|50mg
75449649|NCT01697020|Drug|Mercaptopurine 50mg tablet|50mg
75600773|NCT04065139|Drug|Standard chemotherapy|Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
75744750|NCT00852605|Other|Intermittent Non-Invasive Ventilation|
75744751|NCT03998280|Device|Assessment|Neck proprioception and postural stability
75744752|NCT00619385|Drug|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
75744753|NCT00855569|Device|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
75744754|NCT00852683|Drug|Pregabalin|75 mg twice a day
75744755|NCT00852683|Drug|Placebo|75 mg twice a day
75894083|NCT00771134|Drug|Quetiapine|300mg/day for 8 weeks
76062961|NCT01616563|Behavioral|Exercise Prescription and Fitness Program|Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
75463208|NCT01872962|Radiation|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
75463209|NCT01872988|Drug|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
75463210|NCT01872988|Drug|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
75463211|NCT01873001|Drug|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
75744756|NCT00855647|Procedure|Hypo-fractionated Radiotherapy|
75744757|NCT04103255|Other|High frequency and intensive prevention program|This study is a 4 week non-randomized controlled trial (RCT)
75744758|NCT00619307|Drug|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
75894084|NCT00768482|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
75894085|NCT00768482|Drug|Sublingual Buprenorphine|16 mg/day, QD
75894086|NCT00766688|Drug|AVE5530|"one tablet in the evening with dinner~in addition to high doses of statin treatment"
75894087|NCT00766688|Drug|Placebo|"one tablet in the evening with dinner~in addition to high doses of statin treatment"
75894088|NCT05138965|Procedure|the mCP with alginates dressing|The method is to use gauzes folded onto the RVF wound surface to compact the deep wound so as to solid and durable,when the gauzes surface will be covered by alginates dressing.
75894089|NCT05138965|Procedure|only alginates dressing|Only alginates dressing will be placed above the RVF wound without any pressure.
75894090|NCT00840866|Drug|cefprozil|500 mg Tablet
75894091|NCT00840866|Drug|Cefzil®|500 mg Tablet
76062962|NCT05602324|Dietary Supplement|Lauric Acid and Berberine|intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
76062963|NCT05600608|Dietary Supplement|Oral Stimulant Drink|please see description of the drink in the arm/ group section
76062964|NCT01616173|Drug|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
76062965|NCT01616173|Drug|Dexamethasone|8mg/2mL
75463212|NCT01873001|Drug|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
75463213|NCT01873014|Drug|chinese herbs-I|two agent per day, twice a day
75463214|NCT01873014|Drug|chinese herbs-II|two agent per day, twice a day
75894092|NCT05106556|Other|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, pursed lip breathing exercise, thoracic expansion exercises, upper and lower extremity exercises, stretching the pectoral muscles, posture exercises, walking training and teaching respiratory control.
75894093|NCT05106556|Other|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure with the threshold loading method.
75894094|NCT05043116|Dietary Supplement|Cholecalciferol D3|2000 IU of Vitamin D provided as oral suspension for one year
75894095|NCT05043116|Other|Oral placebo suspension|Oral suspension with no active substance tasting like the active supplement.
75894096|NCT00840632|Drug|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fasting
75894097|NCT00840632|Drug|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fasting
76062966|NCT01616173|Drug|Saline|2mL
76062967|NCT05609734|Other|no intervention, only observational retrospective study|no intervention, only observational retrospective study
76062968|NCT05609500|Behavioral|Warfarin dosage adjustment model|Warfarin dosage adjustment model use to predict the initiation and the maintenance dose of warfarin. Variation of warfarin dose during stable maintenance phase for the same patient might be influenced more by temporal factors such as modification of drug regimens that utilize the CYP450 pathway, or dietary vitamin K intake
75616520|NCT00212836|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
75616521|NCT00212836|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
75616522|NCT00805324|Drug|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
75616523|NCT00157924|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
75616524|NCT00157924|Drug|atorvastatin|atorvastatin 10mg
75894098|NCT00840476|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
75894099|NCT00840476|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
75894100|NCT03665103|Other|Laser-assisted ICSI|Laser opening of the zona pellucida.
75894101|NCT03665025|Other|immediate implant using mixed allograft and xenograft|immediate implant using mixed allograft and xenograft in anterior area to fill jumping area
75894102|NCT00765830|Drug|vildagliptin|50mg qd
75894103|NCT00765830|Drug|Placebo|qd
75616525|NCT05335642|Procedure|EVAR|Endovascular repair of abdominal aortic aneurysms
75894104|NCT03664947|Other|exercise|After the initial evaluations, a video-based gaming console exercise program will be implemented for 8 weeks, taking into account the possibility of accepting and participating in treatment with children. Exercises applied by a Nintendo Wii Fit Plus System. Evaluations will be repeated at the end of treatment.
75616526|NCT00794794|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
75894105|NCT03664869|Drug|BCG instillation therapy|Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
75894106|NCT03664869|Drug|Sequential BCG and EMDA mitomycin C|"Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.~BCG instillation is performed as a standard instillation.~Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)"
75894107|NCT03961009|Biological|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
75894108|NCT00953420|Drug|Docetaxel|60 mg/m2 IV on Day 1
75894109|NCT00953420|Drug|Carboplatin|Target AUC of 5 (mg/ml x min) on Day 1
75894110|NCT00953420|Drug|Dexamethasone|5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
75894111|NCT00953420|Biological|EBV-specific cytotoxic T lymphocytes|1 x 10e8 cells/m2 IV over 1 to 5 min
75894112|NCT00953420|Biological|G-CSF or Peg-GCSF|If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for > 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC > 2500 cells/ul x 2 days after nadir.
75894113|NCT01602562|Drug|VACV tablets (Adults or pediatrics) or granules (pediatrics)|A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
75894114|NCT00765518|Biological|Ixmyelocel-T|CRCs will be administered via direct injection into the heart muscle.
75894115|NCT00765518|Other|Standard of Care|Because the eligible patients had no other cardiac surgery or percutaneous cardiac interventions that were likely to produce clinical improvement, SOC was limited to pharmacologic therapy, heart transplant, or ventricular assist device therapy.
75894116|NCT03135002|Other|Other|
75894117|NCT04367636|Behavioral|Behavioral: OCAT-sham|Placebo version of the online contingent attention training preceded by psycho-education movieclip.
75894118|NCT04367636|Behavioral|Behavioral: OCAT|Online contingent attention training preceded by psycho-education movieclip.
76062969|NCT03044314|Drug|Illoprost and nitric oxide administration|Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
76062970|NCT03040102|Other|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
76062971|NCT03040102|Other|Standard of Care|Standard of Care practice is used
76062972|NCT05608720|Behavioral|Information Booklet|Information Booklet prior to the dental visit
76062973|NCT05608642|Other|Intravenous hydration|500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.
76062974|NCT05608642|Other|Intravenous prednisolone|The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.
76062975|NCT05608642|Other|Intravenous lidocaine|The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
75449650|NCT01697046|Drug|Truvada and Isentress|"Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.~Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days."
75449651|NCT01697059|Drug|Piperacillin + Amoxicillin|
75449652|NCT01697085|Dietary Supplement|Sea buckthorn oil|
75449653|NCT01697085|Dietary Supplement|Placebo oil|
75616527|NCT00794794|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
75616528|NCT03612466|Drug|153Sm-DOTMP|For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 & 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
75616529|NCT03612466|Radiation|External beam radiotherapy.|The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)
76062976|NCT05608564|Procedure|Piperacillin and Tazobactam in gel form|After non-surgical periodontal treatment, the test group will receive local antibiotics.
75449654|NCT01697098|Drug|Dexamethasone 24 hours|
75600774|NCT04288297|Procedure|distal minimally invasive chevron osteotomy|With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
75600775|NCT04288219|Device|Non-Invasive Positive Pressure Ventilation|Continuous positive airway pressure delivered by face mask at 10cmH2O
75600776|NCT04288219|Drug|Nifedipine|Nifedipine 30mg, Pharmacotherapy
75600777|NCT04288219|Other|supplemental oxygen|supplemental oxygen
75600778|NCT00974311|Drug|Enzalutamide|MDV3100, 160 mg orally per day
75600779|NCT00974311|Drug|Placebo|Placebo comparator
75600780|NCT00974233|Drug|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
75600781|NCT00974233|Drug|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
75600782|NCT00974233|Drug|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
75600783|NCT02866123|Other|ultrasonography|
75600784|NCT02866123|Radiation|pulmonary radiography|
75600785|NCT00629395|Behavioral|Captain's Log Computer Program|12 Computer Program
75894119|NCT04367636|Other|psycho-education video|Both groups get to see a psycho-education video before the smartphone training starts.
75894120|NCT01945775|Drug|talazoparib|Until progression or unacceptable toxicity develops
76062977|NCT05608564|Procedure|Amoxicillin and Metronidazole|After non-surgical periodontal treatment, the control group will receive systemic antibiotics.
75894121|NCT01945775|Drug|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
76062978|NCT03036904|Drug|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
75449655|NCT01697098|Drug|Dexamethasone 12|
75449656|NCT01697111|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
75600786|NCT04270357|Procedure|Cholecystectomy|Cholecystectomy is the surgical removal of the gallbladder. Cholecystectomy is a common treatment of symptomatic gallstones and other gallbladder conditions
75600787|NCT02863627|Other|Newborn Care Pathway|consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
75600788|NCT00972595|Drug|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
75894122|NCT00839930|Drug|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
75894123|NCT00839930|Drug|Pletal®|1 x 50 mg, single-dose tablet
75894124|NCT05108038|Drug|CKD-382, D860, D027|QD, PO for 7days
75894125|NCT05051332|Drug|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm^3 defect
75894126|NCT05051332|Procedure|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate
75894127|NCT03875365|Procedure|POPE|Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
76072113|NCT03130439|Drug|Abemaciclib|Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
75449657|NCT01697111|Drug|Placebo|One tablet (no active ingredient) / day and one tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day, for the first 24 weeks and the later 28 weeks, respectively
75449658|NCT01697111|Drug|Dienogest|Dienogest 1mg twice a day (bid)
75449659|NCT01697124|Behavioral|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
75449660|NCT01697137|Behavioral|Participant Video and Provider Cueing|Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
75463215|NCT01873027|Device|OFDI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
75600789|NCT00972595|Drug|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
75600790|NCT01196091|Drug|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
75600791|NCT01196091|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
75600792|NCT01196091|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
75600793|NCT01196091|Drug|Standard of Care|
75600794|NCT01195623|Procedure|preoperative duplex examination|
75600795|NCT01195623|Procedure|Preoperative duplex|
75600796|NCT01195545|Device|Veritas® Collagen Matrix|biological mesh in hernia repair
75616530|NCT03612466|Drug|Calcium Carbonate|Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
75894128|NCT05211349|Other|Dual-Task Timed Up and Go Test (cognitive)|It evaluates balance with a simultaneous cognitive and motor task. The cognitive task of the test is serial triple subtraction while the TUG test is a motor task. Balance performance will be recorded in seconds.
76072114|NCT03123731|Behavioral|Control Arm|Wearing Physical Activity Monitor
76072115|NCT03123731|Behavioral|iSTEP|Physical Activity Intervention
75894129|NCT05211349|Other|3-m Backward Walk Test|It is used to assess fall risk and balance. It is calculated in how many seconds an individual can walk backward a marked distance of 3 meters.
75600797|NCT01194999|Device|Pubovaginal sling procedure|The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
75744759|NCT00619307|Drug|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
75744760|NCT00850187|Biological|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
75894130|NCT05211349|Other|Modified Four Square Step Test|It is a performance test that evaluates dynamic balance in stroke individuals with the ability to avoid obstacles and take steps in all directions. Balance performance is recorded in seconds.
75894131|NCT05211349|Other|Timed Up and Go Test|It is used to assess balance and functional mobility. The participant is asked to get up from the chair she/he is sitting in, walk the marked distance of 3 meters and return to her/his seat again. The elapsed time is recorded in seconds.
75894132|NCT05211349|Other|Berg Balance Test|It consists of 14 items and evaluates dynamic balance and functional mobility in stroke. The maximum score is 56. Higher scores indicate better balance.
75894133|NCT00838136|Drug|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
75894134|NCT00838136|Drug|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
75894135|NCT00944294|Drug|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
75894136|NCT00944294|Drug|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
75894137|NCT00758966|Drug|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
75894138|NCT00758966|Drug|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
76072116|NCT03123731|Behavioral|iSTEP|Physical Activity and Diet Intervention
76072117|NCT03117751|Drug|Prednisone|Given orally (PO).
75449661|NCT01697150|Device|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
75449662|NCT01697189|Behavioral|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
75600798|NCT01194531|Device|24 Chromosome Aneuploidy Screening with Parental Support|Preimplantation Genetic Screening (PGS)
76072118|NCT03117751|Drug|Vincristine|Given intravenously (IV).
75600799|NCT00972517|Biological|GSK investigational vaccine GSK2340272A|Three intramuscular injections
75600800|NCT04286737|Other|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
75600801|NCT02863549|Device|MitraClip in tricuspid valve|MitraClip in tricuspid valve
76072119|NCT03117751|Drug|Daunorubicin|Given IV.
76072120|NCT03117751|Drug|Pegaspargase|Given IV or intramuscularly (IM) .
75449663|NCT01697215|Other|AirWave|
75449664|NCT01697228|Dietary Supplement|Vitamin D|
75600802|NCT00972283|Drug|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
76072121|NCT03117751|Drug|Erwinase®|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
75449665|NCT01697241|Other|Supervised exercise|Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions
75449666|NCT01697241|Other|Patient education|The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
75894139|NCT00758966|Drug|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
75894140|NCT03750877|Procedure|median approach|spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.
75894141|NCT03750877|Procedure|paramedian approach|In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.
76072122|NCT03117751|Drug|Cyclophosphamide|Given IV.
75449667|NCT01697280|Behavioral|Vaccine promotion messages|"The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~Vaccines can save a child's life~Children who are immunized on time are less likely to become ill~Unimmunized children can become disabled for life~Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings."
75449668|NCT01697280|Other|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
75894142|NCT05107804|Other|Exercise+CR|Exercise with caloric-restriction
75744761|NCT00923897|Radiation|Palliative RT|Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
75744762|NCT00855725|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
75744763|NCT00855725|Other|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
75894143|NCT05107804|Other|Light Conditioning|Light Conditioning Exercise
75894144|NCT04336124|Drug|CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)|"Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur."
75744764|NCT00855725|Other|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
75894145|NCT03734497|Other|"Group Carotis FTc 500 ml Ringer's lactate Lafleks®"|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
75894146|NCT03734497|Other|"Group Preloading 10 ml/kg Ringer's lactate Lafleks®"|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
75894147|NCT03734497|Other|"Group Control 2 ml/kg Ringer's lactate Lafleks®"|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
75894148|NCT04841122|Device|Camera observation|Supplemental camera observation directly linked to the nurse's phone
75894149|NCT00941486|Drug|FST-100 Ophthalmic Suspension|FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.
75894150|NCT00941486|Drug|Placebo|A regimen of 2 drops 4 times a day while awake for 5 days.
75894151|NCT04836364|Other|No Intervention|There is no intervention; observation only.
76072123|NCT03117751|Drug|Cytarabine|Given IV or by subcutaneous injection (SQ).
76072124|NCT03117751|Drug|Mercaptopurine|Given PO.
76072125|NCT03117751|Drug|Dasatinib|Given PO.
76072126|NCT03117751|Drug|Methotrexate|Given IV.
76072127|NCT03117751|Drug|Blinatumomab|Given IV.
76072128|NCT03117751|Drug|Ruxolitinib|Given PO.
75894152|NCT00937352|Drug|Bapineuzumab|"0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years."
75894153|NCT01566175|Device|Neovac coronary sinus reducer|reducer
75894154|NCT03072719|Drug|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
75894155|NCT03072719|Drug|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
75894156|NCT04665700|Drug|BI 764198|BI 764198
75600803|NCT00972283|Drug|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
75600804|NCT00972283|Drug|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
75600805|NCT05366049|Other|using a medicine pacifier to give acetaminophen|While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
75600806|NCT02887599|Procedure|Blood collection|1ml of blood specimen collection
75600807|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
75600808|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
75600809|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
75744765|NCT00855725|Other|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
75744766|NCT00855881|Drug|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
75744767|NCT00850265|Device|Volumatic spacer|A spacer is a plastic device to inhaler medication
75744768|NCT00619229|Drug|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
75894157|NCT04665700|Drug|Placebo|Placebo
75894158|NCT05107414|Procedure|Total Knee Arthroplasty|Participants have previously undergone a total knee replacement surgery.
75744769|NCT00619229|Other|Placebo|Placebo/d i.v. for 15 days
75894159|NCT04594265|Dietary Supplement|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
75894160|NCT04594265|Dietary Supplement|Science in Sport Go Enegy|Dosis isocaloric to the KetoneAid Arm
75894161|NCT05107258|Diagnostic Test|The Pine Trees Health Test System|Consists of the Pine Trees Health Reader and the Pine Trees Health COVID-19 Test Kit, which contains the Pine Trees Health Cartridge, Pine Trees Health Sample Vial containing Sample Lysis Buffer and the Pine Trees Health Nasal Swab (anterior nares) for collection. The Test System is a point-of-care test used for the qualitative detection of nucleic acid from SARS-CoV-2 viral RNA in nasal swabs taken from individuals who are suspected by a healthcare professional of having COVID-19. The COVID-19 test is a rapid molecular, in vitro diagnostic test using isothermal nucleic acid amplification technology and detection of the resulting amplicon using CRISPR-mediated collateral reporter unlocking.
75894162|NCT05106400|Drug|ZTlido (Lidocaine Topical System) 1.8%|1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
75894163|NCT05106400|Drug|Salonpas (Lidocaine Patch 4%)|1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
75894164|NCT05106400|Drug|Aspercreme (Lidocaine Patch 4%)|1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
76072129|NCT03117751|Drug|Bortezomib|Given IV or subcutaneously (SQ).
75600810|NCT00969709|Drug|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
75600811|NCT01193517|Drug|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
75894165|NCT05106400|Drug|IcyHot (Lidocaine 4% + Menthol 1% Patch)|1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
75894166|NCT01433315|Behavioral|sleep restriction|restricted sleep
75894167|NCT00754988|Drug|Metformin|As prescribed
75894168|NCT00754988|Drug|Placebo (matching sitagliptin)|Once daily oral administration of placebo (matching sitagliptin).
75894169|NCT00754988|Drug|Placebo (matching taspoglutide)|Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
75894170|NCT00754988|Drug|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin.
75894171|NCT00754988|Drug|Taspoglutide|Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
75894172|NCT01416935|Other|No Amiodarone|This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
76072130|NCT03117751|Drug|Dexamethasone|Given PO.
76072131|NCT03117751|Drug|Doxorubicin|Given IV.
75894173|NCT05106322|Other|intraoperative spectrometer scan|intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta
75894174|NCT03547843|Behavioral|Group-based education|The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.
75449669|NCT01697280|Other|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
75600812|NCT01193517|Drug|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
75600813|NCT01193517|Drug|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
75600814|NCT01193517|Drug|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
75616531|NCT03612466|Drug|Mozobil|Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
75894175|NCT03547843|Behavioral|Waiting list|No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.
75449670|NCT01697293|Drug|Cyclophosphamide|Given IV
75449671|NCT01697293|Drug|Doxorubicin Hydrochloride|Given IV
75744770|NCT02544971|Behavioral|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
75744771|NCT02544971|Other|Control|Treatment as usual
75449672|NCT01697293|Other|Laboratory Biomarker Analysis|Correlative studies
75449673|NCT01697293|Drug|Paclitaxel|Given IV
75449674|NCT01697293|Procedure|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
75449675|NCT01697293|Drug|Triciribine Phosphate|Given IV
75744772|NCT02545439|Drug|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
75744773|NCT00619151|Device|Top Hat|Implant of CarboMedics Top Hat mechanical valve.
75744774|NCT00619151|Device|Regent|Implant of the St. Jude Medical Regent mechanical valve
75744775|NCT02546297|Drug|Symbicort|drug are used for 12 months
75894176|NCT03547843|Other|Standard treatment|Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
75894177|NCT05106166|Behavioral|Occupational Therapy|occupational therapy sessions are based on the joint attention
75449676|NCT01697306|Drug|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
75616532|NCT03612466|Drug|Neupogen Injectable Product|Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
75616533|NCT00142558|Drug|MK0663; etoricoxib / Duration of Treatment: 5 Days|
75744776|NCT02546297|Drug|Spiriva|drug are used for 12 months
75744777|NCT00618995|Drug|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
75744778|NCT00618995|Drug|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
75744779|NCT00618995|Drug|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
75894178|NCT05107024|Device|RFR-guided step by step balloon dilation|The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.
76072132|NCT03117751|Drug|Etoposide|Given IV.
76072133|NCT03117751|Drug|Clofarabine|Given IV.
76072134|NCT03117751|Drug|Vorinostat|Given PO.
76072135|NCT03117751|Drug|Idarubicin|Given IV.
76072136|NCT03117751|Drug|Nelarabine|Given IV.
75894179|NCT05107024|Device|Traditional balloon dilation|The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria
75894180|NCT03529981|Other|Tuned Vibroacoustic Stimulation (TVS)|TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance
75894181|NCT03529981|Other|no active intervention|No intervention will be administered
75894182|NCT05012566|Device|Juvederm|"Juvederm Volbella: 15mg/ml, it is injected 1.5ml per patient per treatment (a total of 3ml per patient split in 2 treatment sessions at a 4 months interval);~Juvederm Volifit: 17.5mg/ml, it is injected 3ml per patient per treatment (a total of 6ml per patient split in 2 treatment sessions at a 4 months interval);~Juvederm Voluma: 20mg/ml, it is injected 5ml per patient per treatment (a total of 10ml per patient split in 2 treatment sessions at a 4 months interval)"
75894183|NCT05012566|Drug|Vistabex|Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
75894184|NCT05202665|Procedure|ICON DMG Resin Infiltration (micro-invasive approach)|A plastic wedge located below the contact point to apart from the surface from adjacent tooth. A 15% HCl etching gel (Icon, DMG, Hamburg, Germany) was applied by syringe below the contact point for 120 s. After, the gel was washed off with air-water-spray for 30 s. The lesion was desiccated by air-blowing for 10 s, application of ethanol for 30 s and air-blowing again for 30 s. A resin infiltrant (Icon, DMG, Hamburg, Germany) was applied with another plastic holder during 3 min. Following the penetration, excess of material was removed by air blowing and flossing. The resin was light-cured for 40 s total from the buccal, occlusal, and lingual/palatal aspects. It was needed to reapplicate the resin infiltration for once because of infiltrating remaining porosities during 1 minute. Excess material removing process was again repeated and light cured for 40 s.
75894185|NCT05202665|Procedure|ClinproTM White Varnish, 3M ESPE Fluoride Varnish (non-invasive approach)|Tooth surfaces were cleaned thoroughly and isolated with cotton rolls. According to the manufacturer's instructions, the unit dose packages were opened, and the contents were dispensed onto the application guide and mixed to avoid the separation of sodium fluoride components. A thin coat of varnish (ClinproTM White Varnish, 3M ESPE, USA) with 22600 ppm fluoride was applied to the tooth interface with a brush tip applicator and waited for 5 minutes. Aproximal areas were coated with dental floss. The patient was instructed not to rinse or apply suction immediately after application. Patients were advised to avoid eating hard and sticky foods or drinking hot beverages for the next 2 hours, to consume a soft diet immediately after 30 minutes and to avoid brushing and flossing for the rest of the day.
75894186|NCT04268342|Other|Resistance guided treatment for gonorrhoea infection|For cases of gonorrhoea infection treated at the return visit, a nucleic acid assay will be used to determine individual eligibility for ciprofloxacin treatment
76072137|NCT03117751|Drug|Thioguanine|Participants with mercaptopurine-related pancreatitis. Given PO.
75449677|NCT01697306|Drug|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
75449678|NCT01697410|Drug|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
75449679|NCT01697410|Drug|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
75449680|NCT01697423|Drug|platelet-rich plasma|
75449681|NCT01697423|Drug|durolane|
75449682|NCT01697436|Drug|ribavirin [Copegus]|tablet under fed condition
75449683|NCT01697436|Drug|ribavirin [Copegus]|tablet under fasted condition
75600815|NCT02866045|Procedure|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
75744780|NCT00618995|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
75449684|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fed condition
75449685|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fasted condition
75449686|NCT01697475|Behavioral|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
75449687|NCT01697514|Drug|LY2940680|Capsule administered orally.
75449688|NCT01697514|Drug|LY2940680|Powder administered orally (may be sprinkled on soft food).
75449689|NCT01697553|Other|home automation pack coupled to teleassistance service|
75449690|NCT01697553|Other|Home without automation pack coupled to teleassistance service|
75449691|NCT01697605|Drug|BGJ398|
75449692|NCT01697618|Drug|biphasic insulin aspart 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
75449693|NCT01697618|Drug|biphasic human insulin 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
75616534|NCT00142558|Drug|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
75744781|NCT03685344|Drug|Loncastuximab Tesirine and Durvalumab|intravenous infusion
75744782|NCT00850811|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
75744783|NCT00856115|Other|medical chart review|Patient charts are reviewed to obtain medical data.
75744784|NCT00856115|Other|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
75894187|NCT05106010|Other|Balance Flow Yoga|The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
75894188|NCT04473638|Procedure|Arthroscopic Deltoid Repair|. A 4.5 mm arthroscopic set was used to clean the joint and assess medial and associated injuries. After deltoid injury confirmation through the method already mentioned, the medial gutter was prepared. The ideal positioning for the bone anchor in the medial malleolus followed Vega's recommendations and was located in the inferolateral quadrant created by the intersection of two lines: (1) tibia-talar joint line and (2) tangent line to the medial malleolus joint surface.(14). Sutures were passed respecting the safe zone illustrated by Acevedo at al, at the area between the posterior tibial tendon and the saphenous vein (16-25mm) (15). Sutures were passed but not tightened.
75894189|NCT05210647|Device|robotic surgery|by da Vinci Xi
75894190|NCT05106868|Device|acupuncture|Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.
75894191|NCT05764577|Procedure|DIEP flap surgery|Removal off the DIEP flap followed by closure of the rectus sheath and abdominal skin.
75894192|NCT04438772|Other|Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia|Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
76062979|NCT03036904|Drug|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
75449694|NCT01697631|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
75894193|NCT04560634|Drug|Norepinephrine|Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
75894194|NCT04560634|Device|ClearSight®, Edwards Lifescience, Irvine, CA|"All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis."
75894195|NCT00927914|Drug|Ranirestat|Ranirestat 40 mg tablets
75894196|NCT00927914|Drug|Placebo|Placebo tablets
75894197|NCT04438616|Procedure|dome magnetic attachment|"All patients will receive complete denture before implant installation .~The CBCT examination should be take~patients received infiltration local anesthesia~A crestal incision is made using No. 15 c blade .~Full sequential drilling under copious saline irrigation will be made . insertion of two implant by the contra angle handpiece with special adaptor~We connect magnetic attachment(dome) on complete denture by pick up procedure at day of implant installation.~Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~Patient satisfaction measure"
75894198|NCT04438616|Procedure|flat magnetic attachment|"All patients will receive complete denture before implant installation .~The CBCT examination should be take~patients received infiltration local anesthesia.~A crestal incision is made using No. 15 c blade~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant by the contra angle handpiece with special adaptor~We connect magnetic attachment(flat) on complete denture by pick up procedure at day of implant installation.~Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~Patient satisfaction measure in 2 weak and after 12 weak by Denture satisfaction questionnaire"
76062980|NCT03036904|Drug|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
76062981|NCT03036904|Drug|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
75449695|NCT01697631|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
75449696|NCT01697644|Drug|somatropin|3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
75449697|NCT01697644|Drug|somatropin|3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
75894199|NCT05764499|Other|Physiotherapy Scoliosis Specific Exercise (PSSE)|Patients completed 120 hours of group based PSSE over a four week time frame. Monday - Friday, 10.00-17.00.
75894200|NCT05261464|Drug|Metoprolol tartrate|Prescribe oral metoprolol tartrate according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
75894201|NCT05261464|Drug|Ivabradine|Prescribe oral ivabradine according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
75894202|NCT05261464|Drug|Diltiazem|Prescribe oral diltiazem immediate-release according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
75894203|NCT04438694|Biological|Convalescent Plasma|Convalescent Plasma
75894204|NCT04438694|Drug|Standard of Care|Standard of Care drugs administered as per Cairo University ICU protocol
75894205|NCT05210491|Other|Review of eyelid positioning in increasing brightness levels|Up to 30 seconds, three times, looking into a video camera as glare is incrementally increased.
75894206|NCT05379998|Other|Neural mobilization|Sciatic nerve mobilization (sliding technique) will be performed by a physical therapist. The sciatic nerve mobilization technique improves the nerve mobility of the hemiparetic lower limb in a nervous system patient and is helpful in increasing the ROM of the lower limbs without resistance.
75894207|NCT05379998|Other|PNF hold relax technique|Proprioceptive neuromuscular facilitation hold relaxation technique of hamstring muscle will be performed by the physical therapist three days a week for 6 weeks. In the hold relax technique after reaching the point of resistance, an isometric contraction is performed against the resistance to get a pain free response.
75894208|NCT04461730|Device|deep brain stimulation|Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation
75894209|NCT02928887|Other|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
75894210|NCT05210335|Other|Clinical pharmacist's recommendation to physicians about drug related problems|Clinical pharmacist's recommendation to physicians about drug related problems
75894211|NCT00835796|Drug|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
75894212|NCT00835796|Drug|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
75894213|NCT05106712|Drug|Vitamin D3|4000IU per day for around 12 weeks.
75894214|NCT05106712|Drug|Clomiphene Citrate|"oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
75894215|NCT05106712|Drug|Letrozole|"oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
75449698|NCT01697657|Drug|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
75894216|NCT05106712|Other|placebo|participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
75894217|NCT00835718|Drug|Comparator: MK0594 5 mg/day|MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
75894218|NCT00835718|Drug|Comparator: MK0594 1 mg/day|MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
75449699|NCT01697657|Drug|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
75894219|NCT00835718|Drug|Comparator: MK0594 1 mg/week|MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
75894220|NCT00835718|Drug|Comparator: Placebo to MK0594|Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
75894221|NCT05463185|Other|Stretching exercises|Stretching exercises along with manual lymphatic drainage
75894222|NCT05463185|Other|Soft tissue mobilization|Soft tissue mobilization along with manual lymphatic drainage
75894223|NCT05105698|Drug|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fasting)
75894224|NCT05105698|Drug|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fed)
75894225|NCT00835640|Drug|Fexofenadine 180 mg tablets|1 x 180 mg
75894226|NCT00835640|Drug|ALLEGRA® 180 mg tablets|1 x 180 mg
76062982|NCT03036904|Drug|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
76062983|NCT03036904|Drug|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
76062984|NCT03036904|Drug|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
75894227|NCT05098678|Dietary Supplement|Zinc gluconate|120 mg each tablet containing 30 mg elemental zinc
75894228|NCT05098678|Dietary Supplement|Placebo|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
75894229|NCT00752570|Drug|AMG 386|AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
75894230|NCT00752570|Drug|AMG 386 Placebo|AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
75894231|NCT00752570|Drug|FOLFIRI|"Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest."
75894232|NCT05083000|Drug|Topotecan|Topotecan hydrochloride is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitor activity. It is a well-established chemotherapeutic agent used for cancer treatment.
75894233|NCT05764421|Behavioral|motor-cognitive intervention|The intervention included physical activity and integrated cognitive training. The training was conducted in three sessions. The first session was a warm-up and wake-up preparation, in which participants massaged facial acupoints in a seated position to light music. In the middle phase of aerobic exercise, participants raised their legs in a standing position and performed mental exercises to fast-paced music. Session 1: tapping the five fingers of each hand in turn; Section 2: The thumb of both hands in turn to tap the rest of the fingers; Third section: hands five fingers cross fist; Section 4: The five fingers of both hands are stretched out in turn, and then retracted in turn. The final session was a relaxation session in which participants performed inspiratory and expiratory exercises to light music. The integrated cognitive training consisted of 15 minutes of attention training, 15 minutes of memory training, and 15 minutes of executive function training.
75894234|NCT00752258|Drug|Mentor Purified Toxin Botulinum Toxin Type A|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
75894235|NCT04384978|Behavioral|Play Serious Games with a Social Robot (Ryan)|Active Group: Game play and physical activities with Ryan, a socially assistive robot developed at DreamFace Technologies,LLC.
75894236|NCT04384978|Behavioral|Play Solitary Games Without a Social Robot|Control Group: Group 2 will play solitary games (e.g., word puzzles) and activities but will have no interaction with Ryan.
75894237|NCT02942017|Drug|Placebo|Intravenous infusion of matching placebo for SAGE-547.
75894238|NCT02942017|Drug|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547
75894239|NCT04447781|Biological|INO-4800|- Manufacturer: Inovio Pharmaceuticals Inc.
76062985|NCT05608486|Device|aerSleep II|The aerSleep® II System includes a soft silicone collar, which is placed on the anterior neck. Integrated with the collar is a vacuum pump module (VPM), which cordlessly powers the generation of negative pressure within the collar's cavity. This negative pressure pulls the underlying tissues forward, maintaining airway patency.
76062986|NCT02983942|Dietary Supplement|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
76062987|NCT02983942|Dietary Supplement|Routine diet|Routine diet is given without blood ketone requirement
75449700|NCT01697657|Drug|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
75449701|NCT01697670|Drug|Photodynamic therapy with Gliolan|Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
75894240|NCT04447781|Device|CELLECTRA® 2000|- Manufacturer: Inovio Pharmaceuticals Inc.
75449702|NCT01697683|Drug|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
76062988|NCT05608096|Device|Hemoperfusion|Commercial membrane for extracorporeal blood purification (hemoperfusion)
75449703|NCT01697683|Drug|Placebo|
75894241|NCT04447781|Other|Saline-sodium citrate (SSC) buffer|- Manufacturer: Inovio Pharmaceuticals Inc.
75894242|NCT00835484|Drug|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
75894243|NCT00835484|Drug|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
75894244|NCT04442555|Dietary Supplement|HVMN Ketone Ester|Commercially available ketone supplement
75894245|NCT04442555|Dietary Supplement|Maltodextrin|Commercially available maltodextrin supplement
75894246|NCT05105464|Drug|SYHA1815|Subjects will receive SYHA1815 orally.
75894247|NCT05202431|Behavioral|Treatment adherence|The patients were reminded to take drug by patient training, telephone follow-up, and daily sms. It was determined that the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence.
75894248|NCT04999618|Drug|Haemoblock|Delivering with transdermal patches
76062989|NCT05604898|Drug|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be administered subcutaneously.
76062990|NCT05604898|Other|Placebo|Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.
76062991|NCT05604898|Drug|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be provided at pre-specified time intervals.
76062992|NCT05604898|Other|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
76072138|NCT03117751|Drug|Asparaginase Erwinia chrysanthemi (recombinant)-rywn|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
76072139|NCT03117751|Drug|Calaspargase Pegol|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
75449704|NCT01697722|Drug|Extra-fine hydrofluoroalkane-beclometasone dipropionate|Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
75744785|NCT00856115|Other|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
75744786|NCT00856115|Other|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
75744787|NCT00856271|Drug|olmesartan medoxomil|oral tablets, once daily for 8 weeks
75744788|NCT00856271|Drug|losartan potassium|capsules, once daily for 8 weeks
75744789|NCT00856427|Radiation|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
75744790|NCT00856427|Procedure|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
75744791|NCT00856505|Drug|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
75744792|NCT02544893|Drug|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
75744793|NCT02544893|Drug|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
75744794|NCT02544893|Drug|serum physiologic|21 ml serum physiologic is applied paravertebral space
75744795|NCT02546063|Other|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
75744796|NCT00520572|Drug|AZD9056|
75744797|NCT00520572|Drug|Etanercept|
75744798|NCT00520572|Drug|Placebo|
75894249|NCT04999618|Other|Placebo|Delivering with transdermal patches
75894250|NCT00835406|Drug|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
75894251|NCT00835406|Drug|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
75894252|NCT04973098|Biological|CT0181 Cells|5 dose levels each with or without lymphocyte clearance were tentatively determined.
75894253|NCT05202275|Drug|Olanzapine|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx, 69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5 at every chemotherapy cycle.
75894254|NCT05105386|Device|SynAir-Child|Monitor the indoor pollutants and their effect on children well being
75894255|NCT00749216|Drug|Solanezumab|
75744799|NCT00573833|Other|questionnaire administration|
75744800|NCT00573833|Procedure|quality-of-life assessment|
75744801|NCT00573833|Radiation|brachytherapy|
75744802|NCT00853463|Behavioral|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
75744803|NCT00853619|Other|Service based decision support intervention|Delivering CDS via services
75744804|NCT00853697|Other|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
75744805|NCT00856817|Drug|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
75744806|NCT00856817|Drug|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
75744807|NCT00520494|Drug|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
75744808|NCT04041635|Procedure|Stimuli reduction|Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
75744809|NCT04041635|Procedure|Usual care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
75744810|NCT00853775|Other|No intervention, observational study|
75744811|NCT00861419|Drug|Sorafenib|Sorafenib 400 mg PO (BID)
75744812|NCT00861419|Drug|AMG 706|AMG 706 125 mg PO (QD)
75744813|NCT00861419|Drug|AMG 706|AMG 706 75 mg PO (QD)
75744814|NCT00861419|Drug|AMG 386|AMG 386 10 mg/kg IV (QW)
75449705|NCT01697722|Drug|ICS / LABA via separate pMDI and / or BAI inhalers|A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
75744815|NCT00861419|Drug|Sunitinib|Sunitinib 50 mg PO (QD)
75744816|NCT00861419|Drug|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
75744817|NCT00861419|Drug|AMG 386|AMG 386 3 mg/kg IV (QW)
75744818|NCT00527514|Drug|Amlodipine|Tablets
75744819|NCT00527514|Drug|Olmesartan medoxomil plus amlodipine|Tablets
75744820|NCT00861497|Drug|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
75744821|NCT00857051|Other|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
75744822|NCT00857051|Other|Film|A DVD addressing common stressors in the early postpartum.
75744823|NCT03998826|Drug|Piroxicam|20mg piroxicam
75744824|NCT03998826|Drug|Placebo|placebo
75744825|NCT00857129|Procedure|Normal Unit|low-risk patients randomised to Normal Unit
75744826|NCT00857129|Procedure|Special birth unit|Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
75894256|NCT05104684|Other|chest physical therapy|The program will consist of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment
75894257|NCT05104684|Other|routine medical treatment|medical treatment
75894258|NCT00748124|Device|PleuraSeal Sealant System|Lung Sealant Device + standard tissue closing techniques (sutures/staples)
75894259|NCT00748124|Procedure|Standard Tissue Closure Techniques|Standard tissue closure techniques (sutures/ staples) alone
75894260|NCT05201963|Procedure|Serratus Anterior Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the patient's midaxillary line in the longitudinal plane (lateral position with arm abduction), at the level of 5th rib, the indicator oriented toward the operator's left. With the rib, pleural line, overlying serratus anterior and latissimus dorsi muscles visualized, then, a 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the 5th rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.6-13-MHz, linear transducer set for small parts and a depth of 1-4 cm is used for this block(15-16).
75894261|NCT05201963|Procedure|Erector Spinae Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which skin, subcutaneous tissue, trapezius and erector spinae muscle will be visible superficial to T5 transverse process. Echogenic block needle will be inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1 ml normal saline . After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% will be performed. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used
75894262|NCT04911400|Other|Upper-lower clear plastic retainers + Class III elastics|Addition of Class III elastics to clear plastic retainers
75449706|NCT01697735|Drug|Berberine;Atorvastatin or Rosuvastatin|Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
75744827|NCT00853853|Device|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
75894263|NCT04911400|Other|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
75894264|NCT05201573|Other|Observational|This is an observational study of long term follow up data for patients who previously received the DIAM implant
75894265|NCT05462327|Procedure|Low Fresh Gas Flow in Prone Position|In the low fresh gas flow group, the flow rate was reduced to 0.5 L/min
75894266|NCT05462327|Procedure|Normal Fresh Gas Flow in Prone Position|In the normal flow rate group, the gas flow rate was reduced to 2 L/min during the maintenance phase.
75894267|NCT00744926|Drug|placebo|sc, once weekly
75894268|NCT00744926|Drug|taspoglutide|10mg sc, once weekly
75894269|NCT00744926|Drug|taspoglutide|20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
75894270|NCT03840772|Drug|Eribulin|Treatment with eribulin
75894271|NCT03838744|Drug|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy
75894272|NCT03838744|Drug|Experimental arm: Trabectedin + Olaparib|Trabectedin given in combination to olaparib
75894273|NCT05327348|Drug|Intravenous Ascorbate|Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
75894274|NCT05327348|Drug|Normal Saline 10 mL Injection|Intravenous 0.9% normal saline 8 hourly bolus infusion over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
75894275|NCT05201417|Other|adapted physical activity|The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants We will account for 24 APA sessions. We will leverage the Step Tracker phone app and pedometer to get the number of steps done, number of calories spent, Workout duration and distance walked per participant per APA session; this data will be collected weekly (after every two sessions)
75449707|NCT01697735|Drug|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
75744828|NCT00853853|Procedure|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
75894276|NCT04695106|Drug|Ticagrelor|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.
75744829|NCT04607538|Other|No intervention is made|No intervention is made. This i an observational study.
75894277|NCT04695106|Drug|Dabigatran Etexilate|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
75894278|NCT04695106|Drug|Aspirin|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
75894279|NCT04695106|Drug|Clopidogrel|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
75894280|NCT05104372|Other|Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)|Nasal washout and gargles
76062993|NCT01544595|Drug|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
75744830|NCT00853931|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
75744831|NCT00854009|Drug|BLI-489|
75744832|NCT00854009|Drug|Placebo|
75894281|NCT04032665|Diagnostic Test|Rivaroxaban|In stable CAD/PAD patients with previous PCI and DES-implantation treated with DAPT (ASA+clopidogrel) platelet rich plasma (PRP) and washed platelets as well as serum/plasma/urinary samples will be collected between 2 and 4 weeks before switching from DAPT to ASA + rivaroxaban (2,5 mg b.i.d.), between 2 and 4 weeks under monotherapy with ASA 100mg o.d., and between 2 and 4 weeks under therapy with ASA 100mg o.d. + rivaroxaban (2,5 mg b.i.d.) and treated ex vivo with rivaroxaban to asses platelet activation and function, platelet-triggered thrombin generation and platelet-dependent vascular inflammation.
75894282|NCT04516720|Other|data collection|Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death
75894283|NCT05201261|Device|ltrasonic measure|In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.
75894284|NCT03629639|Drug|Metformin|An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
75894285|NCT03577288|Behavioral|manipulation of the level of realism|"The realism of the virtual experience will be manipulated. In one condition the realism will be high and in another condition the realism will be low. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., high realism with negative stimuli, low realism with negative stimuli, high realism with positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement (only in part A) and Late Positive Potential (EEG - only in part B) will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
75894286|NCT03577288|Behavioral|manipulation of the presence and size of avatar|"The presence of avatar in the virtual experience will be manipulated. In one condition the avatar will be present and in another condition the avatar will not be present. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., with avatar and negative stimuli, without avatar and negative stimuli, with avatar and positive stimuli, etc.).~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar.~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
76062994|NCT01544595|Drug|Placebo|Placebo
76062995|NCT05600842|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
76062996|NCT04759534|Biological|protein convertase subtilisin/kexin type 9 inhibitor|IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
76072140|NCT03113968|Procedure|electroconvulsive therapy (ECT)|ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.
75600816|NCT02866045|Procedure|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
75600817|NCT02863705|Drug|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
75600818|NCT02863705|Drug|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
75600819|NCT01193283|Drug|Cyclophosphamide|30 my/kg for 4 days
75600820|NCT01193283|Drug|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
75600821|NCT00971425|Biological|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
75600822|NCT00971425|Biological|Fluarix™|1 dose intramuscular injection
75600823|NCT00971425|Biological|Placebo|1 dose intramuscular injection
75600824|NCT02863471|Drug|Gemcitabine|1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
75600825|NCT01193127|Drug|OMS302 Solution|
75894287|NCT03577288|Behavioral|manipulation of interaction|"Virtual experience condition will be manipulated. In one condition the participants will be exposed to the virtual experience in which they will be able to interact with some of the stimuli, in another condition they will not be able to interact with the stimuli (passive watching). In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., interaction possible - negative stimuli, interaction impossible - negative stimuli, interaction possible - positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
75894288|NCT03577288|Behavioral|manipulation of the nature of stimulus|The nature of the stimuli with which the participants will interact will be manipulated. During virtual experience the participants will have a choice to interact or not with the virtual environment, in one condition with animate stimuli and in another condition with inanimate stimuli. In addition, emotional category of animate and inanimate stimuli will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., condition with animate negative stimuli, condition with inanimate negative stimuli, condition with animate positive stimuli). The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
76062997|NCT05606224|Behavioral|internet-based mindfulness intervention for emotional distress|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
76062998|NCT04392700|Drug|Tenofovir disoproxil fumarate 300mg|Take the medicine once a day ，300mg/d
76062999|NCT04392700|Drug|Entecavir 0.5 mg|Take the medicine once a day，0.5 mg/d
76063000|NCT01539525|Behavioral|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
76063001|NCT01539525|Other|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
76063002|NCT02960620|Device|TheraSphere Treatment|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
76063003|NCT03827902|Device|Telcare 2.0 BGM|Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.
75600826|NCT01193127|Drug|OMS302 Mydriatic Solution|
75600827|NCT01193127|Drug|OMS302 Anti-inflammatory Solution|
75600828|NCT01193127|Drug|Balanced Salt Solution (BSS) Solution|
75600829|NCT01192815|Drug|erlotinib hydrochloride|Given orally or via gastronomy tube
75600830|NCT01192815|Radiation|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
76063004|NCT03828058|Drug|Envarsus XR|Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.
75600831|NCT01192815|Other|pharmacogenomic studies|Optional correlative studies
76063005|NCT03828058|Drug|Prograf|Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
75894289|NCT05210023|Other|NUTRIGENETIC DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be established according to certain nutrigenetic recommendations identified in the reference bibliography.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
75894290|NCT05210023|Other|CONVENTIONAL DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be in accordance with the recommendations made by the WHO (World Health Organization), the AHA (American heart association) and the NOM (Official Mexican Standards) for the treatment of obesity and dyslipidemias.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
75894291|NCT00835172|Drug|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
75894292|NCT00835172|Drug|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
75600832|NCT01192815|Other|gene expression analysis|Correlative studies
75600833|NCT01192815|Radiation|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
75744833|NCT03998592|Biological|Streptococcus pyogenes vaccine (50 µg)|Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
75894293|NCT04941755|Drug|BMS-986256|Specified dose on specified days
75600834|NCT01192815|Other|biopsy|Optional correlative studies
75894294|NCT04941755|Drug|Famotidine|Specified dose on specified days
75894295|NCT05093218|Dietary Supplement|branch chain amino acid|• Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: <5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm
75894296|NCT05093218|Other|placebo|Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
75894297|NCT05209945|Procedure|vibration|whole-body vibration, heel and soleus tendon vibrations were applied to the human body
75894298|NCT04921735|Drug|Cisatracurium|0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
75600835|NCT01192815|Other|pharmacological study|Optional correlative studies
75600836|NCT01192815|Other|laboratory biomarker analysis|Optional correlative studies
75600837|NCT01192815|Other|questionnaire administration|Optional ancillary studies
75600838|NCT01192815|Other|enzyme-linked immunosorbent assay|Optional correlative studies
75600839|NCT01192815|Other|polymorphism analysis|Optional correlative studies
75600840|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
75600841|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
75744834|NCT03998592|Biological|Streptococcus pyogenes vaccine (100 µg)|Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
75744835|NCT03998592|Biological|Streptococcus pyogenes vaccine (200 µg)|Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
75744836|NCT03998592|Other|Placebo|Placebo without active component
75894299|NCT01676116|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
75600842|NCT04317729|Device|Fujirebio INNOTEST® HCV Ab IV assay|Enzyme Immunoassay
76063006|NCT03827590|Drug|Test|three times a day for five days
75600843|NCT01307267|Drug|PF-05082566|Intravenous, Dose escalation, once per month
75744837|NCT00861731|Drug|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
75744838|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
75744839|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
75744840|NCT02544659|Drug|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
75744841|NCT00861887|Drug|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
75744842|NCT00861887|Drug|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
75744843|NCT00857441|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
75744844|NCT00857441|Device|Liberté|Bare metal stent
75600844|NCT01307267|Drug|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
75600845|NCT01307267|Drug|PF-05082566|IV, Dose escalation, once per month
75600846|NCT01307111|Drug|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
75894300|NCT01676116|Drug|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
75744845|NCT00857441|Device|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
75894301|NCT01676116|Drug|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
75894302|NCT04930796|Drug|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
75894303|NCT05200793|Drug|Empagliflozin 25 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
75894304|NCT05200793|Drug|Linagliptin 10 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
75894305|NCT05200793|Drug|Metformin 1500 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
75894306|NCT00917306|Drug|PEP005 Gel|0.05% two day treatment
75894307|NCT05191303|Device|Mobile intervention of breastfeeding counseling|The mobile intervention of breastfeeding counseling includes an evidence-based information of breastfeeding, which is based on Ten steps of breastfeeding of Baby Friendly Hospital Initiative (BFHI) and Finnish Institute for Health and Welfare recommendation. The links provide more information and videos related to breastfeeding topic. The mobile intervention of breastfeeding counseling allows the client to write comments or notes that can be used in counseling at maternity clinic or hospital. The mobile intervention of breastfeeding counseling also provides an e-mail to non-urgent questions related to breastfeeding. Questions will be answered within 3 or 4 days by a lactation consultant (IBCLC).
75894308|NCT03453502|Behavioral|Quality improvement of breast milk feeding|During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.
75894309|NCT02264899|Other|in Memento-VASCOD|"Pulse wave velocity assessment~Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~Neuropsychological testing and behaviorial and mood scales~Urinary albumin excretion measurement"
75894310|NCT05763485|Procedure|Anti reflux mucosal ablation (ARMA)|"In patients fulfilling the inclusion criteria and being randomized for ARMA, the procedure using argon plasma coagulation involves two semicircular ablations of the mucosa of the EGJ in a butterfly shape of a width of 2 cm. The approximate duration of the procedure is 30min.~Follow includes objective evaluation of reflux disease by reflux questionnaires, esophagogastroduodenoscopy, esophageal manometry, pH metry."
75894311|NCT05763485|Procedure|Sham procedure|In patients fulfilling the inclusion criteria and being randomized for sham procedure, the procedure involves esophagogastroduodenoscopy with the same set of movements and duration as the ARMA procedure without the actual ablation.
75894312|NCT03383224|Other|genotype-guided therapy|treatment based on patient's CHRNA5 rs16969968 genotype
75894313|NCT03383224|Drug|Nicotine patch|
75894314|NCT03383224|Behavioral|Smoking cessation counseling|
75449708|NCT01697761|Other|Treatment Group|patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
75894315|NCT05200637|Device|Orsiro stent|Orsiro stent
75894316|NCT05200637|Device|Xience stent|Xience stent
75894317|NCT05200637|Device|Any drug-eluting stent|Any drug-eluting stent
75894318|NCT05200169|Drug|14C-AB1010|Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
75894319|NCT03219658|Behavioral|Parenting education sessions|If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
75449709|NCT01697761|Other|Control Group|patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
75449710|NCT01697787|Drug|Amodiaquine-Artesunate|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
75463216|NCT01873027|Device|IVUS|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
75600847|NCT01307111|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
75600848|NCT01306877|Device|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
75600849|NCT01306877|Device|Endosurgery Proximate PPH03 Stapling Set|Surgical device
75744846|NCT00857441|Device|Taxus|Paclitaxel eluting stent
75744847|NCT00857519|Drug|Melphalan, Carboplatin|Intra-arterial chemotherapy.
75744848|NCT00618449|Drug|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 & Day 30 for a total of 2 doses.
75744849|NCT00618449|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
75894320|NCT05762081|Procedure|Disposable Wipes for wiping baths|A disposable wipe bath is a type of bath that is applied to bed-bound or unconscious patients and weak individuals by wiping the entire body.
75600850|NCT01191801|Drug|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
75894321|NCT05762081|Procedure|Traditional bed bath|Traditional bed bathing is a type of bathing applied to bed-bound or unconscious patients and weak individuals by wiping the entire body with soap and water.
75894322|NCT04699357|Drug|Atropine|different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children
75894323|NCT00737516|Biological|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
75894324|NCT04651387|Dietary Supplement|Ozonized oil (HOO|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered 3 times per day (after breakfast, lunch, dinner, possibly with a delay of one hour from the routine treatment) and will be prescribed for 2 weeks (14 days).~Posology: 3 HOO capsules plus 3 HOO intranasal administrations for each naris plus 3 HOO oropharyngeal administrations."
75894325|NCT05198531|Drug|TQB2858 Injection|TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.
75894326|NCT05198531|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
75894327|NCT05198531|Drug|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.
75894328|NCT05198531|Drug|Cisplatin Injection|After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
75894329|NCT02986516|Other|Randomized Cohort|Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization
75449711|NCT01697787|Drug|Artemether-lumefantrine|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
75894330|NCT02986516|Radiation|Prospective cohort|Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated
75600851|NCT01191801|Drug|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
75894331|NCT03628651|Other|Blood Sample Collection|HCC subjects will have one blood sample collected.
75894332|NCT03628651|Other|Blood Sample Collection|Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.
75894333|NCT02743520|Device|The Lifestar Act III|The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.
75894334|NCT05186207|Other|abnormal pre-pregnancy test results that need clinical intervention|The patients who need clinical intervention before or after pregnancy were divided into observation group. Doctors will formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process.
75894335|NCT05176613|Device|HF-rTMS|HF-rTMS stimulated a 70-mm, 8-shaped coil stimulator (The Magstim Company, UK, 2012) on the damaged cerebral cortex. Prior to the application of HF-rTMS, the motor point was identified that stimulates maximum thresholds on the primary motor cortex, causing flexion of the opposite index finger. If the cerebral hemisphere does not show a kinetic response even at the maximum stimulus, the motor point of the opposite hemisphere was found to be symmetrically changed. The intensity of the stimulus was 80% of the resting motor threshold, which means the motor eveked potential above which the first dorsal interosseous muscle can produce 50 μV more than five times out of 10 stimuli. The subject sat on a chair made to hold the head. The stimulation was stimulated at high frequency (10 Hz) for 2 seconds, and the rest was performed for 58 seconds for a total of 200 times for 10 minutes.
76063007|NCT03827590|Drug|Active Comparator Control 1|three times a day for five days
76063008|NCT03827590|Drug|Active Comparator Control 2|three times a day for five days
76063009|NCT03827590|Drug|Placebo|three times a day for five days
75449712|NCT01697826|Drug|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
75449713|NCT01697826|Drug|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
75600852|NCT01306643|Drug|Idelalisib|Tablet(s) administered orally twice daily
75600853|NCT04317495|Other|Computerized Cognitive Training (CCT)|After having four rTMS sessions without CCT, the patients will perform CCT (starting day 5) during the rTMS session, which typically last from 20-40 minutes. A course of rTMS therapy includes from 25-36 treatments, given daily, until the last 5-6 treatments, given as a 'taper' over 2 weeks. CCT will be paired with rTMS up until the taper begins. In addition, they will have assessments prior to and after the therapy.
75600854|NCT04317339|Drug|Zhigancao Tang granule|"Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
75600855|NCT04317339|Drug|Zhigancao Tang placebo granule|"Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
75600856|NCT05656833|Device|Fractional 1927nm Low-Powered Diode Laser|Clear & Brilliant Permea® Laser used on the side of the face randomized to receive laser
75744850|NCT00857597|Procedure|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
75894336|NCT05176613|Behavioral|ML|Motor learning was conducted for two minutes each in five sessions, and the first is the external rotation training to maximum range of the shoulder joint in sitting position. The second method is to stack cups by transferring them from the non-affected side to the affected side by transferring 25 plastic cups of five colors in sitting position with both hands inserted. Third, by pushing and pulling the ball forward and backward with the hands folded, the subject puts a 55 cm healing ball on the table in a sitting position, and pushes and pulls it forward with the upper limb. The fourth method is to insert and remove pegs from the peg board, and the target uses the affected side hand in sitting position. The fifth method is to tear a newspaper, in which the subject overlaps a newspaper on the table in a sitting position, holds it with the non-affected hand, and tears it with the hands of the damage. A total of 10 minutes of motor learning.
75894337|NCT05176613|Device|Sham-rTMS|Sham rTMS gives a small intensity of 2% of the resting motor threshold that cannot cause excitement in the motor cortex, and is set to listen to the same frequency of noise as HF-rTMS, and motor learning is applied equally. A total of 20 minutes were applied three times a week for four weeks by applying 10 minutes of Sham rTMS and 10 minutes of motor learning.
75894338|NCT04473170|Biological|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.
75894339|NCT04473170|Drug|COVID-19 standard care|UAE National Guidelines for Clinical Management and Treatment of COVID-19.
75894340|NCT02872948|Genetic|Diagnostic|
75894341|NCT01869829|Drug|Observational antifungal therapy|"Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care."
75894342|NCT02683018|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
75894343|NCT02683018|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
75744851|NCT00857597|Drug|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
75894344|NCT04472624|Other|Fasting|Acute fasting for 72 hours
75894345|NCT04472624|Other|Ketogenic diet|Intake of a ketogenic diet for 14 days
75894346|NCT03982576|Other|Nicotine replacement therapy (NRT)|4 weeks of Transdermal nicotine patches or nicotine gum
75894347|NCT03982576|Behavioral|CS-CBT intervention|4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks
75894348|NCT03982576|Behavioral|Path2Quit|Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).
75894349|NCT03982576|Behavioral|Relapse prevention program|4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov
75894350|NCT03982576|Behavioral|SmokefreeTXT|NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
75894351|NCT05167721|Biological|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells administered intrathecally
75894352|NCT05167721|Other|Placebo|Placebo administered intrathecally
75894353|NCT05081518|Drug|Lu AG06466|Lu AG06466 - capsule
75894354|NCT05081518|Drug|Placebo|Placebo - capsule
75894355|NCT05127005|Procedure|Trapeziectomy|Surgical excision of trapezoideum
75894356|NCT05127005|Procedure|Sham|Skin incision only
75894357|NCT00798265|Biological|Gardasil|.5 mL dose injected IM at 0, 2 and 6 months
75894358|NCT00798265|Behavioral|Survey|Administration of online risk behavior and knowledge survey done at week 0.
75449714|NCT01697852|Other|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
75449715|NCT01697852|Other|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
75449716|NCT01697865|Procedure|Transfer group|
75744852|NCT00857675|Drug|AAAA|Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
75744853|NCT00857675|Drug|AAPA|Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
75744854|NCT00857675|Drug|PAAA|Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
75744855|NCT00861965|Biological|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
75744856|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
75449717|NCT01697865|Procedure|Control group|
75449718|NCT01697878|Procedure|CPAP followed by atmospheric pressure|In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital
75463217|NCT01873040|Behavioral|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
75744857|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
75744858|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
75744859|NCT00857753|Drug|Fentanyl patch 25 ug/nr Sandoz|
75894359|NCT04882124|Drug|CSJ117|CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
75894360|NCT04882124|Drug|Placebo|Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
75894361|NCT03976960|Other|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
75894362|NCT03628573|Device|repetitive transcranial magnetic stimulation (MagPro X100).|accelerated rTMS.
75894363|NCT03628573|Device|Intermittent Theta burst stimulation ( iTBS)|
75894364|NCT05125913|Diagnostic Test|FMD|Measurements will be made by using ultrasound system with a 12-Mhz probe. All vasoactive medications will be withheld for 24 h before the procedure. The participants will remain at rest in the supine position for at least 15 minutes before the examination. Each subject's right arm will be comfortably immobilized in the extended position to allow consistent recording of the brachial artery 2-4 cm above the antecubital fossa. If an arteriovenous fistula is present, the contralateral arm will be used for assessment. Three adjacent measurements of end-diastolic brachial artery diameter will be made from single 2D frames. The maximum FMD diameters will be calculated as the average of the three consecutive maximum diameter measurements after hyperemia and nitroglycerin, respectively.
75894365|NCT05125913|Diagnostic Test|Arterial stiffness|Arterial stiffness assessment will be performed by applanation tonometry with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference-acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
75449719|NCT01697878|Procedure|Atmospheric pressure followed by CPAP|In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
75894366|NCT05125913|Diagnostic Test|Assessment of IMT|A high-resolution B-mode ultrasound of the common carotid arteries with scanning of the longitudinal axis until the bifurcation and of the transversal axis will be performed using ultrasonic pulse with a middle frequency of 12 MHz. For each carotid artery, two longitudinal measurements will be obtained by rotating the vessels at 180o increments along their axis. IMT will be measured at 1 cm proximal to the bifurcation on each side.
75894367|NCT05125913|Diagnostic Test|Echocardiography|Echocardiography will be performed on each patient at baseline; the measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
75894368|NCT05125913|Diagnostic Test|LUS|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
75894369|NCT05125913|Diagnostic Test|BIS analysis|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device using specific electrodes. Based on a fluid model using 50 discrete frequencies (5-1000kHz), the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
75894370|NCT05125913|Other|Biomarkers determination|Biomarkers by ELISA: IL-1, IL-6, VCAM1, Endoglin, NO and ADMA
75894371|NCT04472780|Device|Hyperbaric oxygen Therapy HBOT|HBOT therapy protocol: in an eight-seat hyperbaric chamber 40 sessions of HBOT duration: 1 hour rhythm: 5 sessions / week pressure: 1.7 ATA (7 meters) O2 concentration: 100%
75894372|NCT03768622|Procedure|surgery for pertrochanteric femoral fracture|surgical treatment for proximal femoral fracture with intramedullary nail type Gamma® Nail or similar in case of pertrochanteric fractures
75894373|NCT03768622|Procedure|surgery for femoral neck fracture|surgical treatment for proximal femoral fracture with a partial hip arthroplasty in case of femoral neck fractures
75449720|NCT01697891|Device|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
75449721|NCT01697904|Procedure|Titration of oxygen during newborn resuscitation in delivery room|
75449722|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
75449723|NCT01697943|Procedure|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
75449724|NCT01697982|Behavioral|Living with Hope Program|"The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
75449725|NCT01697982|Behavioral|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
75449726|NCT01698034|Behavioral|Volunteering|Weekly volunteering with elementary school children in after school programs
75449727|NCT01698047|Behavioral|Resiliency Class|See Arm Description
75449728|NCT01698047|Other|Case Management|See Case Management description
75449729|NCT01698060|Biological|ND1.1|
75449730|NCT01698073|Behavioral|mCOL|
75449731|NCT01698073|Other|AS+|
76063010|NCT03827668|Drug|PF-06650833 alone|In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
76063011|NCT03827668|Drug|PF-06651600 alone|In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
76063012|NCT03827668|Drug|PF-06650833 together with PF-06651600|In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
75449732|NCT01698086|Other|Vestibular rehabilitation: balance and eye movement exercises|The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
75449733|NCT01698112|Dietary Supplement|Flaxseed High Dose|26 gram flaxseed intervention
75600857|NCT05656833|Other|Topical Cysteamine|Topical Cysteamine cream will be used on the entire face.
75600858|NCT05656755|Other|Strengthening|The strengthening exercises were executed with the body weight without any additional weight and were composed of exercises like the squats, the lunges, the plank, and the mountain climbers
75894374|NCT04472546|Other|in-vivo mesure|"for acne of the face subgroup and its associated control : face and inner side of the forearm~for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
75600859|NCT05656755|Other|Running|running for two supervised training sessions of one hour, and one free session of 30 minutes per week during 24 weeks
76063013|NCT02958280|Behavioral|Fit&Sober App|Fit&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.
76063014|NCT02958280|Behavioral|Brief Advice|Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
76063015|NCT01513551|Biological|Pneumococcal Conjugate Vaccine (V114)|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
76063016|NCT01513551|Biological|PNEUMOVAX® 23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
75449734|NCT01698112|Dietary Supplement|Flaxseed Low Dose|13 grams flaxseed
75449735|NCT01698125|Procedure|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
75449736|NCT01698164|Drug|estradiol plus MPA|Participants are given estradiol and synthetic progestin.
75449737|NCT01698164|Drug|Ximingting Tablet|Participants are given phytoestrogen.
75449738|NCT01698164|Drug|estradiol plus progesterone|Participants are given estradiol and natural progesterone.
75744860|NCT00857753|Drug|Duragesic|
75744861|NCT03846401|Device|fiberoptic bronchoscopy|"Will be performed according to British Thoracic Society guidelines 2013.~-Microbiological methods The specimen (tracheal aspirate & BAL) will be collected under aseptic conditions in a sterile container and immediately sent to the laboratory for microbiological analyses.~Samples will be apply for:~Direct smear by Gram stain and ZeihlNelseen stain~Samples culturedinBact/alert bottle(BioMérieux, France).~Isolation of causative organism from positive cases by:~Subculture on MacConkey , blood , chocolate agar , Sabouroud's agar and Lowenstien Jensen media.~Identification of isolated organism and drug sensitivity test by Automated Vitek2 Compact(BioMérieux, France).~Multiplex PCR for detection of Respiratory viruses in lower respiratory tract"
75744862|NCT00854321|Drug|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
75894375|NCT04472546|Other|Scotch|"for acne of the face subgroup and its associated control : face and inner side of the forearm~for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
75894376|NCT04472546|Other|Lipid index|"for acne of the face subgroup and its associated control : face~for seborrheic dermatitis of scalp subgroup and its associated control: scalp~for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face"
75894377|NCT04472546|Other|Absorbant paper|"for acne of the face subgroup and its associated control : face~for seborrheic dermatitis of scalp subgroup and its associated control: scalp~for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead"
75894378|NCT04472546|Other|Hydratation Index|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
75894379|NCT04472546|Other|TransEpidermal Water Loss|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
75894380|NCT02675842|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
75894381|NCT02675842|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
75894382|NCT05116553|Behavioral|SDT|Standard 2 SDT (Self Determination Theory) psychological interviews.
76063017|NCT01513551|Biological|PREVNAR 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
76063018|NCT03827122|Drug|onabotulinumtoxinA|Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
76063019|NCT02956642|Device|Livongo Health System|Participants will be asked to use the Livongo Health System to manage their blood glucose.
76063020|NCT02956642|Device|iHealth Glucose Meter|Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
76063021|NCT03827356|Device|Inspiratory muscle trainer (IMT)|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
75449739|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
75449740|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
75449741|NCT01698190|Procedure|Endoscopic ultrasound guided needle tissue acquisition.|Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
75449742|NCT01698203|Drug|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
75600860|NCT05656677|Behavioral|Passive parental involvement|One parent watching a procedural painful intervention, two nurses executing facilitated tucking
76063022|NCT03827200|Drug|Ambrisentan|Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
76063023|NCT02983630|Other|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
75600861|NCT05656677|Radiation|Active parental involvement|One parent watching a procedural painful intervention and at the same time executing facilitated tucking
75894383|NCT05116553|Device|APP + CA|An APP with a CA (Conversational Agent).
75894384|NCT05187247|Device|Virtual Reality glasses|use of virtual reality glasses to reduce anxiety and pain levels
75449743|NCT01698203|Drug|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
75449744|NCT01698203|Drug|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
75600862|NCT01306331|Drug|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
75600863|NCT01306331|Drug|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
75744863|NCT00854321|Drug|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
75744864|NCT03684642|Drug|Efpeglenatide|Pharmaceutical form: solution for injection; Route of administration: SC
75744865|NCT03684642|Drug|Dulaglutide|Pharmaceutical form: solution for injection; Route of administration: SC
75744866|NCT03684642|Drug|Background therapy Metformin|Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
75894385|NCT04528108|Drug|Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine|Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
75894386|NCT04528108|Drug|Gong Xue Ning capsules|Participants of Gong Xue Ning capsules group children will be treated with Gong Xue Ning capsules, 2 capsules 3 times a day during the bleeding period. When the bleeding stops, patients will be treated with Zhi Bai Dihuang pills,8 pills 3 times a day. Participants receive this treatment for 3 months.
75449745|NCT01698229|Other|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
75616535|NCT02842606|Other|Test meal|The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
75449746|NCT01698242|Behavioral|Enhanced Training|"PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.~Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up)."
75463218|NCT01873040|Behavioral|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
75463219|NCT01873053|Drug|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
75894387|NCT04602559|Device|MOBIDERM Panty group|"In the MOBIDERM Panty group, patients wear the MOBIDERM Panty during day and night for 3 months with the possibility to add the PAD.~The protocol includes 3 visits.~Visit 1 at day 0, corresponding to the inclusion visit, includes device delivery and some clinical evaluations (clinical examination, characteristics of lymphedema, self questionnaires, pain assessment, perimeter data).~Visit 2 at 30 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance).~Visit 3 at 90 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance)."
75894388|NCT03701776|Behavioral|Aerobic Training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 6 months
75894389|NCT03701776|Behavioral|Balance Training|Standard of care
75463220|NCT01873053|Drug|Placebo|
75463221|NCT01873066|Device|Closed-loop system|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
75894390|NCT05216731|Procedure|Femoro-popliteal bypass|Under general anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
75894391|NCT05216731|Procedure|Endovascular procedure|Preparing the artery with suitable balloon angioplasty followed with stenting (using the preferred material: bare/covered/drug-coated) or drug-coated balloon angioplasty.
75463222|NCT01873066|Device|real-time CGM|Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
75463223|NCT01873079|Drug|Esomeprazole|
75463224|NCT01873079|Other|Standard care|No PPI or other study medication given
75463225|NCT01873105|Other|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
75463226|NCT05855785|Behavioral|dual task exercise|8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks
75463227|NCT05855785|Behavioral|home exercise|60-minute light intensity home exercise, 4 times a week for 8 weeks
75463228|NCT05855772|Device|Extracorporeal shock waves|Extracorporeal shock waves are non-invasive and simple treatments that are easy to apply to a wide surface and have fewer side effects with low intensity. In addition, there is an advantage of improving blood circulation through an increase in reactive blood flow and creation of new blood vessels.
75463229|NCT05855772|Behavioral|Posture Correction Exercise Program|The exercise program mainly consists of stretching and muscle strengthening exercises, which have shown improvement effects in terms of head vertebrae and pain. In order to optimize the muscle activity between pairs due to FHP, the selected exercise should focus on providing an appropriate proportion of muscle activity for each other as well as muscle strength.
75894392|NCT04436614|Dietary Supplement|Dietary Supplement:Aloe Vera with Crocus (saffron)|Dietary Supplement:Aloe Vera with Crocus (saffron) with 1L of Aloe Vera with Crocus (saffron) 1 glass bottle per 15 days
75894393|NCT04436614|Dietary Supplement|Dietary Supplement:Aloe Vera (simple)|Dietary Supplement:Aloe Vera (simple)with 1L of Aloe Vera 1 glass bottle per 15 days
75894394|NCT04436614|Dietary Supplement|Dietary Supplement:Mediterranean Diet|Dietary Supplement:Mediterranean dietary protocol Intervention:mediterranean diet
75894395|NCT04299503|Drug|Crisaborole Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
75894396|NCT04299503|Drug|Placebo Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
76063024|NCT03827278|Drug|Voriconazole|"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"
76063025|NCT03826732|Behavioral|Guided self-help based on ACT|ACT-based self-help book and regular support by trained facilitators
75600864|NCT05656287|Other|SMS texts + incentives + Wisepill device for medication monitoring|For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if >90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if >90% medication adherence.
76063026|NCT01513473|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
75600865|NCT05656287|Other|SMS texts only + Wisepill device for medication monitoring|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.
75744867|NCT04018547|Device|Patient wears a wrist sensor oximeter device for one to two nights.|Patients will be asked to complete a study questionnaires of STOPBANG, SCI-8 (Sleep Condition Indicator-8 questionnaire for insomnia), Epworth questionnaires and medical history. The clinician will record blood pressure, pulse rate and regularity, body mass index and neck circumference. Subjects will be required to wear the wrist sensor pulse oximeter for 1-2 nights. The Oxitone 1000M device measures pulse rate, blood oxygen saturation and movement. The oxygen desaturation events from the wrist sensor device will be statistically compared with the diagnosis assessed using the conventional PPG oximetry, Peripheral Arterial Tonometry and clinical assessment. (clinicians will be masked when analysing the data from the wrist sensor pulse device).
76063027|NCT01513473|Drug|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
75744868|NCT00857831|Dietary Supplement|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
75744869|NCT00854399|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
75744870|NCT00862043|Drug|Sildenafil Citrate|40 mg t.i.d.
75744871|NCT00862043|Drug|Placebo|Placebo t.i.d.
75744872|NCT00519636|Drug|FPNS|fluticasone propionate nasal spray
75744873|NCT00519636|Drug|FFNS|fluticasone furoate nasal spray
75744874|NCT00519636|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
75744875|NCT00519636|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
75744876|NCT00857909|Drug|Amiloride|1 tablet twice a day
75744877|NCT00857909|Drug|Spironolactone|1 tablet twice a day
75744878|NCT00857909|Drug|Placebo|Placebo
75744879|NCT00857909|Drug|Placebo and spironolactone|5mg twice daily
75744880|NCT00857909|Drug|Spironolactone|25mg twice daily
75744881|NCT00857987|Drug|EMS Expectorant|Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
75744882|NCT00857987|Other|Placebo|Vehicle
75744883|NCT03998514|Drug|CB4211 Dose 1|Administered by subcutaneous injection
75463230|NCT05855720|Other|FIT model project|Several statutory health insurance (SHI) funds have established contracts with hospitals for an alternative remuneration / financing of patients treated in the hospital (FIT hospital). Some of those contracts already started in 2013 and were prolonged. Some FIT contracts will start freshly (until June 2026). These contracts encourage FIT hospitals to test alternative treatment options for their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment.
75600866|NCT05656287|Other|Wisepill device for medication monitoring only|Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
75600867|NCT00624663|Drug|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
75894397|NCT05033470|Device|Dabir Mattress Overlay System|Dabir Surface mattress overlay system consists of a controller and a low-profile alternating pressure (AP) surface (placed over a non-powered mattress) with hundreds of air-filled geometric nodes arranged in rows. . The multiple rows of nodes inflate and deflate in alternating sequence every five minutes. During deflation phase, the skin and soft tissues experience reduced pressure/loading and enhanced perfusion. In conjunction with Standard of Care: Debridement, Proper moisture balance, off-loading, reduce bacterial burden and nutritional counseling.
75894398|NCT05178433|Combination Product|Use baby moisturizers by NeoChine|During continuous phototherapy, use skin basic care and protection in combination with baby moisturizing products, use the whole body twice a day, and the amount of each time is not less than 5 grams.
75600868|NCT05656209|Dietary Supplement|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3G (containing 2*10^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
75894399|NCT04251689|Drug|Mannitol|Mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
75894400|NCT04251689|Drug|Placebo|0.9% normal saline 100 ml
75600869|NCT04317573|Device|Personalised card|An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.
75600870|NCT01306253|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1"
75600871|NCT05655975|Procedure|upper gi endoscopy|In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
75894401|NCT05164393|Drug|AVX001|Topical gel treatment for once daily application
75600872|NCT02890823|Drug|Cholecalciferol|
75600873|NCT05655897|Device|GeminiOne Transcatheter Valve Edge-to-Edge Repair System|The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
75600874|NCT05655663|Other|Vascular investigation|Measure of of carotid stiffness
75894402|NCT04232423|Drug|Olanzapine 10 Mg ORAL TABLET|"Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
75894403|NCT04232423|Drug|Olanzapine 5 Mg ORAL TABLET|"Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
75894404|NCT04232423|Drug|Placebo ORAL TABLET|"Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
76063028|NCT01513473|Drug|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
76063029|NCT04346368|Biological|BM-MSCs|Participants will receive conventional treatment plus BM-MSCs(1*10E6 /kg body weight intravenously at Day 1).
76063030|NCT04346368|Biological|Placebo|Placebo
75463231|NCT05855707|Biological|WJ-MSC infusion|cellular therapy
75463232|NCT05855668|Behavioral|CBT|12 weeks of group CBT for AUD or CUD
75894405|NCT04436770|Other|Non-immersive virtual reality therapy|"Non-immersive Virtual Reality (VR) therapy exercises, based on assessment, and occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for upper extremity don't exceed 60 minutes.~For the lower extremity, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for the lower extremity don't exceed 60 minutes.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises using Mirror therapy and alone were used."
75894406|NCT04436770|Other|Standard Physiotherapy|"Standard physiotherapy program, based on assessment, plus occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~For the lower extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises were used."
75894407|NCT05104294|Diagnostic Test|Optical Coherence Tomography- Angiography|Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.
75894408|NCT05104294|Diagnostic Test|Photopic negative response|Both the implicit time and amplitude of PhNR were recorded.
75894409|NCT04367467|Other|Kidney Function Test|Cystatin-C measurement
75894410|NCT04178993|Drug|Methamphetamine|In each arm, subjects will receive doses of methamphetamine.
75894411|NCT04178993|Drug|Methylphenidate|In each arm, subjects will receive methylphenidate capsules.
75894412|NCT04178993|Drug|Placebo oral capsule|In each arm, subjects will receive placebo capsules.
75894413|NCT04178993|Drug|Duloxetine|Subjects will receive duloxetine capsules in the duloxetine arm.
75449747|NCT01698242|Behavioral|Enhanced Education|"The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.~PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.~Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month."
75449748|NCT01698255|Behavioral|ENGAGE|
75894414|NCT04795804|Dietary Supplement|Human Milk Oligossaccharide|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
75894415|NCT04795804|Dietary Supplement|Maltodextrin|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
75894416|NCT04795804|Dietary Supplement|Human Milk Oligossaccharide and resistant starch|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
75894417|NCT04436848|Other|This is a non-interventional study|This is a non-interventional study
75894418|NCT05104216|Biological|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
75449749|NCT01698255|Behavioral|Standard of Care Psychotherapy|
75449750|NCT01698346|Biological|Pertussis vaccine|Vaccination during pregnancy with a pertussis containing vaccine
75600875|NCT02887443|Drug|Raxone (idebenone 150 mg)|Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10
75600876|NCT02887443|Drug|Midazolam 2,5 mg|Midazolam (2,5 mg single oral dose) on days 1, 3 and 10
75600877|NCT04317261|Diagnostic Test|Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)|Urine sample is evaluated for RNA and urinary metabolites
75600878|NCT05359263|Drug|Dapagliflozin 10 mg|The intervention arm consists of dapagliflozin 10 mg orally once daily
75600879|NCT05359263|Drug|Placebo|The comparator arm consists of placebo orally once daily
75600880|NCT01305941|Drug|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
75894419|NCT04671472|Drug|NPC-09|The drug will be administered by the oral route with the same manner
75600881|NCT01305941|Drug|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
75600882|NCT01305941|Drug|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
75894420|NCT04671472|Drug|NPC-09 placebo|The drug will be administered by the oral route with the same manner
75894421|NCT04436536|Other|Treadmill walking training with random speed changes|Participants were asked to walk in different gait speed randomly on the treadmill (80%, 90%, 100%, 110% and 120% of preferred speed). The training speed would be changed in every 15 seconds in 2-minutes-section. 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
76063031|NCT03826810|Radiation|aPDT|For the aPDT the PapacarieMblue (Fórmula e Ação) was used. It was left for 5 minutes in the cavity. The carious tissue was removed and the application of the PapacarieMblue was repeated. The tissue was then irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ. These parameters were also applied in the vestibular root of the teeth, to try and prevent sensitivity.
75894422|NCT04436536|Other|Treadmill walking training with blocked speed changes|Participants were asked to walk in same gait speed on the treadmill per day (80%, 90%, 100%, 110% and 120% of preferred speed, respectively). 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
76063032|NCT03826810|Procedure|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
76063033|NCT03826654|Dietary Supplement|fortified oil|35 g fortified sunflower oil
76063034|NCT03826654|Dietary Supplement|Placebo|plain oil
75894423|NCT04086017|Other|Reiki therapy|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the caregivers how to perform a simple 10-minute Reiki and self-Reiki session.
75894424|NCT04570618|Device|Unblinded AlgoDx Sepsis Prediction Algorithm|When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.
76063035|NCT03109990|Drug|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
76063036|NCT03109990|Drug|Saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
76063037|NCT03826420|Behavioral|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
75894425|NCT04570618|Other|Blinded AlgoDx Sepsis Prediction Algorithm|Standard of Care, i.e. no sepsis prediction alert.
76063038|NCT03826420|Behavioral|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
76063039|NCT03826420|Behavioral|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
75894426|NCT03008980|Other|Diagnostic Test|
75894427|NCT05762003|Drug|interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab|Administered as part of routine clinical practice.
75894428|NCT04660708|Behavioral|manual physical therapy|Previously described in the arm description
76063040|NCT03825562|Behavioral|acceptance and commitment therapy, ACT|
76063041|NCT01513317|Drug|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
76063042|NCT01513317|Drug|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
76063043|NCT01513317|Drug|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
75894429|NCT03001557|Drug|Lemborexant 2.5 mg|Lemborexant 2.5 mg tablets
75894430|NCT03001557|Drug|Lemborexant 5 mg|Lemborexant 5 mg tablets
75894431|NCT03001557|Drug|Lemborexant 10 mg|Lemborexant 10 mg tablets
75894432|NCT03001557|Drug|Lemborexant 15 mg|Lemborexant 5 mg and 10 mg tablets
75894433|NCT03001557|Drug|Lemborexant-matched placebo|Lemborexant-matched placebo tablets
75894434|NCT03587480|Procedure|TME+LLND|patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)
75894435|NCT03587480|Procedure|TME+nCRT|patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
75894436|NCT03776669|Procedure|Laparoscopic sleeve gastrectomy + Hiatal hernia repair|To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.
76063044|NCT03825484|Drug|Erdafitinib|Participants will start erdafitinib 8 milligram (mg) (formulated as tablets with 3 mg, 4 mg and 5 mg dosages) orally once daily until disease progression, intolerable toxicity, withdrawal of consent or decision by the doctor to discontinue treatment. Dose will be up-titrated to 9 mg based on serum phosphate levels and if there is no drug-related toxicity.
76063045|NCT02983474|Procedure|cholecystectomy|"Laparoscopic surgery~Reverse Trendelenburg position~Skin incision and trocar insertion~CO2 gas insufflation~Intra-abdominal inspection and gallbladder exposure~Gallbladder traction~Calot triangle exposure~Cystic artery and cystic duct isolation~Gallbladder bed dissection~Bleeding control~Gallbladder extraction~Trocar removal and wound closure~Open surgery~Supine position~Skin incision~Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
76063046|NCT04105179|Device|Zimmer NexGen LPS-Flex|Patients will be randomly assigned to 1 of 2 devices
76063047|NCT04105179|Device|Smith & Nephew Journey II|Patients will be randomly assigned to 1 of 2 devices
76063048|NCT03066310|Diagnostic Test|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
76063049|NCT03825640|Behavioral|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
76063050|NCT04274452|Biological|efgartigimod|Intravenous infusion of efgartigimod
76063051|NCT04274452|Other|Placebo|Intravenous infusion of placebo
75894437|NCT03776669|Procedure|Laparoscopic sleeve gastrectomy alone|Current mainstay and standard surgical treatment for morbidly obese patients.
75894438|NCT05112094|Device|peripheral magnetic stimulation|peripheral magnetic stimulation at ipsilateral shoulder ((50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) ) + regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
75894439|NCT05112094|Other|physical therapy|regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
75894440|NCT04003220|Procedure|blood sample|The extra samples will be taken Blood sampling
75894441|NCT04003220|Procedure|Bone marrow sample|This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls
75894442|NCT03134612|Drug|Ondansetron 8 mg|
75894443|NCT03134612|Drug|Lidocain 40 mg|
75894444|NCT05203757|Procedure|ArthroCT scan|Conventional CT arthrogram as routine care
75449751|NCT01698372|Device|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
75894445|NCT05203757|Procedure|CBCT|Cone Beam CT scan.
75894446|NCT05112016|Procedure|Total mesorectal excision for rectal cancer|
75894447|NCT00831662|Drug|Diquafosol tetrasodium ophthalmic solution, 2%|One to two drops in each eye QID for 6 weeks
75894448|NCT00831662|Drug|Placebo|One to two drops in each eye QID for 6 weeks
75894449|NCT05111938|Behavioral|Friends, Family, and Food App (F3A-App)|
75894450|NCT04365985|Drug|Naltrexone|Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..
75894451|NCT04365985|Drug|Ketamine|Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. Ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.
75894452|NCT04365985|Other|Placebo|Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
75894453|NCT05111860|Drug|Bevacizumab+mFOLFOX6|Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
75894454|NCT00830336|Drug|Azithromycin|Oral Suspension
76063052|NCT03825328|Drug|Albumin-bound paclitaxel|Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
75449752|NCT01698385|Other|Diet and exercise counseling|diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
75449753|NCT01698398|Device|Incremental pump speed of CF-LVAD.|Peak oxygen consumption with fixed versus incremental pump speed.
75449754|NCT01698437|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
75449755|NCT01698450|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
75600883|NCT05658549|Drug|N-acetyl cysteine|N-acetyl cysteine dosage 600 mg and 1200 mg
75894455|NCT00830336|Drug|Zithromax®|Oral Suspension
75894456|NCT05111704|Other|Balance Body Tape|The intervention group received a three-week treatment with Balance Body Tape (BBT) (product by Babota AB), the control group received no treatment. A questionnaire regarding pain, including a Numeric Rating Scale (NRS) measuring pain intensity, and a Photographic posture analysis measurement (PPAM) of habitual sitting posture were accomplished before and after the intervention for both groups.
75894457|NCT04316689|Biological|S-488210|S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).
75894458|NCT04316689|Biological|S-488211|S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).
75894459|NCT05111470|Other|Arm throws with his dominant arm|Seated patient with different sensors on his naked torso. Patients will throw a ball with their dominant arm. The trajectories will be recorded by Vicon MX-40
76063053|NCT03825328|Drug|S-1|a combination preparation of tegafur, gimeracil, and oteracil potassium
75894460|NCT03567551|Other|Women w/ Preeclampsia w/o Visual Disturbances or Headache|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
75894461|NCT03567551|Other|Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
76063054|NCT03825328|Drug|Oxaliplatin|The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
76063055|NCT03825328|Drug|Gemcitabine|Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
75894462|NCT03567551|Other|Women w/o Preeclampsia|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
75894463|NCT00830258|Drug|Pravastatin sodium 80 mg tablets|1 x 80 mg
75449756|NCT01698476|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
75449757|NCT01698476|Drug|Placebo tablets|
76063056|NCT03057184|Behavioral|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
75449758|NCT01698541|Drug|Tacrolimus|Tested generic
75449759|NCT01698541|Drug|Tacrolimus|Original formulation used as comparator
75449760|NCT01698567|Drug|Antithrombin III|"ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)"
75600884|NCT02887365|Drug|tegafur-uracil|
75616536|NCT02842684|Device|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
75894464|NCT00830258|Drug|Pravachol® 80 mg tablets|1 x 80 mg
75894465|NCT05111158|Diagnostic Test|mfERG|mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)
75894466|NCT04334291|Combination Product|Observational (registry)|Observational study.
75894467|NCT03664479|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
75894468|NCT00724334|Drug|SAR302503 (TG101348)|orally administered, once a day
75894469|NCT03664401|Device|Kerecis Oral™|
75894470|NCT03664401|Other|Free Gingival Graft|A free gingival autograft from patient palate placed and secured on wound bed
75894471|NCT05110768|Drug|Triferic AVNU|Triferic AVNU is an iron salt that is approved for the maintenance of Hgb in chronic kidney disease patients on hemodialysis. It is experimental in this study because it has not yet been approved for patients receiving home infusion therapy
75894472|NCT05110768|Other|Placebo|normal TPN solution without FPC on alternate days with TPN supplemented with multivitamins.
75894473|NCT05215483|Behavioral|Customised testing advice|Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.
75894474|NCT05215483|Behavioral|Regular testing advice|"Government guideline testing advice: With Corona related symptoms, get tested at a test facility."
75894475|NCT05215483|Behavioral|LFT available|LFT availability: Enough lateral flow tests available at home
76063057|NCT03825016|Drug|Lidocaine Hydrochloride|Lidocaine infusion on hystroscopic media during office hystroscopy
76063058|NCT03825016|Drug|Diclofenac Sodium|Oral Diclofenac Sodium
76063059|NCT04392466|Other|walking on the treadmill|Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.
76063060|NCT03043924|Drug|Cyproterone Acetate + estradiol|"PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily"
75600885|NCT05658315|Other|ApplTree smartphone application|ApplTree is a smartphone reminder application which allows the user to enter details of future tasks and events and then prompts the user to remind them to complete these at a pre-specified time. ApplTree was designed with people who experience memory and attention difficulties in mind and has a customisable user interface design to support attention and short-term memory when entering PM tasks. ApplTree was developed by Professor Jonathan Evans and Dr Matthew Jamieson (see Jamieson et al., 2020) and is owned by the University of Glasgow.
75449761|NCT01698567|Drug|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
75449762|NCT01698580|Other|On-site exercise|The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
75600886|NCT05658159|Diagnostic Test|Vitamin D|Finger stick capillary blood sampling using test from ZRT Laboratories, Beaverton, OR
75600887|NCT05658159|Diagnostic Test|DXA scan|10 minute scan using scanner by GE Lunar, Madison, WI
75600888|NCT05658159|Other|Nutrition analysis|Analysis of 24-h recalls will be conducted by a registered dietician using Nutritionist Pro software by Axxya Systems, Redmond, WA
75600889|NCT01305239|Drug|Aromasin|Aromasin 25 mg daily.
75894476|NCT05215483|Behavioral|No LFT available|LFT availability: No lateral flow tests available at home
76063061|NCT03043924|Drug|Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet|Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
76063062|NCT03824548|Other|this is non-intervention study, there is no intervention drug or device in this study.|this is exactly a non-interventional study, no intervention during the whole study.
76063063|NCT03824314|Drug|Midazolam|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
76063064|NCT03824314|Drug|Fentanyl|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
76063065|NCT03824392|Biological|Efzofitimod 1.0 mg/kg or Placebo|Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
75600890|NCT04317027|Device|New Fighting Clothing|VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
75600891|NCT05380557|Diagnostic Test|Germline genetic testing|Germline genetic testing will be provided to each patient
75600892|NCT05658081|Procedure|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
75894477|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)~Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
76063066|NCT03824392|Biological|Efzofitimod 3.0 mg/kg or Placebo|Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
76063067|NCT03824392|Biological|Efzofitimod 5.0 mg/kg or Placebo|Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
76063068|NCT02976922|Dietary Supplement|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
75600893|NCT05658081|Procedure|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
75600894|NCT05657847|Device|Photon-counting detector-CT|CT scan
75894478|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)~Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)"
75894479|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)~Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)"
75894480|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)~Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
75894481|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)~Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)"
75894482|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)~Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)"
75894483|NCT03665415|Behavioral|NDGameSquad|The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
75894484|NCT03349775|Drug|Metformin|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
75894485|NCT03349775|Drug|Placebo|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
75894486|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
75894487|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
75894488|NCT04810780|Device|DUO Extended Set|to evaluate saftey and efficacy of DUO extended set combined with glucose sensor
75894489|NCT05203211|Procedure|Testicular sperm extraction (TESE)|During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
75894490|NCT05215249|Procedure|Transnasal humidified high-flow oxygen delivery|The Optiflow system consists of an apparatus that is capable of delivering humidified oxygen, room air, or a mixture of variable oxygen concentration. The oxygen concentration can be precisely varied from 21-100% (or 0.21 - 1.00 FiO2). The gas is warmed to 37°C with a 100% relative humidity. The humidified and warmed gas can be delivered to the patient at high-flows (up to 70 L/min) using various delivery mechanisms. The investigators will be using a nasal cannula to deliver high flow oxygen (2-3 L/kg/min) to the patient.
76063069|NCT02946658|Procedure|lipoaspiration|Closed syringe harvesting subdermal fat
75600895|NCT04317183|Drug|chamomile topical oral gel|Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.
76063070|NCT02946658|Procedure|ADcSVF|Isolation of AD-cSVF
75600896|NCT04317183|Drug|Miconazole Topical Gel|topical anti fungal agent
75600897|NCT04317183|Drug|BBC oral spray|Topical anesthetics and anti-inflammatory agent
75600898|NCT04317183|Drug|Oracure gel|Topical analgesic gel
75600899|NCT01194219|Drug|Apremilast|
75600900|NCT01194219|Drug|Placebo|Identical matching placebo
75894491|NCT04806412|Diagnostic Test|meassurement of PD-L1, ALK, EGFR|"PD-L1 test will be performed on cell-blocks using PD-L1 antibodies 22C3 and staining platform Dako Omnis (Agilent, Glostrup -Denmark).~ALK test will be performed on cell-blocks using staining platform Dako Omnis (Agilent, Glostrup- Denmark) and ALK antibodies Origene clone: OT1A4. Sample quality is assessed as for PD-L1.~EGFR mutation analysis will be performed as follows: after tumor content evaluation of hematoxylin and eosin stained slides, relevant regions are macrodissected and subjected to a standard genomic DNA extraction procedure using the GeneRead DNA FFPE Kit (Qiagen). Samples will be analysed using the GeneRead QIAact Actionable Insights Tumor Panel (Qiagen)"
75894492|NCT00829868|Drug|Zaleplon 10 mg Capsules|1 x 10 mg
75894493|NCT00829868|Drug|SONATA® 10 mg capsules|1 x 10 mg
75894494|NCT05215015|Biological|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10^9 cells.
75894495|NCT05110066|Procedure|Pulmonary endarterectomy|Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
75894496|NCT05110066|Procedure|Balloon pulmonary angioplasty|Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.
75894497|NCT05214703|Other|cold therapy application|cold therapy
75894498|NCT00721760|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
75894499|NCT00721760|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
75894500|NCT00721760|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
75600901|NCT01194219|Drug|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
75600902|NCT01304693|Biological|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
76063071|NCT02946658|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
76063072|NCT03824002|Drug|Dulaglutide|Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
75894501|NCT05109832|Drug|14C-IMP4297|14C marked IMP4297
75894502|NCT05194891|Diagnostic Test|Specular Microscopy|Phacoemulsification
75600903|NCT01304693|Biological|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
75894503|NCT04943068|Drug|Bremelanotide|Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
75894504|NCT04943068|Drug|Placebo|Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
75894505|NCT03628105|Behavioral|CR Before Exposure|"Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger & Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study."
75894506|NCT03628105|Behavioral|CR After Exposure|Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
75894507|NCT04780282|Other|Scapular Stabilization Group|Participants will apply the 5 exercises given.
75894508|NCT03628027|Device|Computerised decision support algorithm|The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
75894509|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5mL oral dose
76063073|NCT03824002|Drug|Aspart insulin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
75600904|NCT04316793|Other|Dry needling|Intramuscular insertion of an OPTIMED 40mm x 0.3mm acupuncture needle in a trigger point of the infraspinatus muscle
75600905|NCT04316793|Other|Sham needling (SN)|Intradermal insertion of an OPTIMED 40mm x 0.3mm acupuncture needle over the infraspinatus region
76063074|NCT03824002|Drug|Glargine|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
75894510|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
75894511|NCT03207815|Drug|Filgotinib|Tablet(s) administered orally
75894512|NCT03207815|Drug|Placebo to match filgotinib|Tablet(s) administered orally
75894513|NCT03207815|Drug|Prednisone|Tablet(s) administered orally
75894514|NCT05110534|Behavioral|additional oral hygiene appointments|Two additional preventive sessions including oral hygiene instructions one week before the date of the general anaesthesia treatment and at the control visit about a week after the general anaesthesia.
75894515|NCT02911935|Drug|Oral azithromycin|Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
75894516|NCT02911935|Drug|Placebo|Placebo suspension
75600906|NCT05657067|Behavioral|Emotionally Focused Family Therapy (EFFT)|The rationale behind EFFT is that mental health problems in children and adolescents often originate and/or are exacerbated by negative interaction patterns rooted in insecure attachment bonds within families. Therefore, the main treatment goal of EFFT is the development of secure attachment between parents and their children.
75894517|NCT05193487|Other|inferior alveolar nerve block|inferior alveolar nerve block using Articaine 4% with 1/200000 Adrenaline and a traditional needle injection
75894518|NCT05193487|Other|intra-osseous mandibular anaesthesia|intra-osseous mandibular anaesthesia using Articaine 4% with 1/200000 Adrenaline and a special intra-osseous injection device
75894519|NCT04294108|Other|Prolong in-hospital stay|Patients have a longer length of hospital stay than the common recommendation.
75600907|NCT05656989|Other|Periodontal clinical measurements and GCF sampling|Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
75600908|NCT01304147|Drug|Ketamine|A single dose of intranasal ketamine up to 50 mg
75894520|NCT03479762|Drug|Liraglutide|No treatment given
75894521|NCT05100394|Radiation|Laser Therapy|Therapeutic laser therapy was applied.
75894522|NCT05100394|Other|Ultrasound + Moist Heat pack + Exercises|Ultrasound therapy, a moist heat pack, and a home exercise program were given.
75449763|NCT01698580|Other|home-based exercise|Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
75600909|NCT01304147|Drug|placebo|Single dose of saline intranasal
75600910|NCT05661227|Drug|Dexmedetomidine|Whether apply DEX or not
75894523|NCT03391635|Device|Electroacupuncture|Participants will receive electroacupuncture at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
75600911|NCT05661227|Drug|0.9% Sodium chloride|Whether apply DEX or not
75894524|NCT03391635|Device|TranscutaneousElectricNerveStimulation|Participants will receive transcutaneous electric nerve stimulation at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
75894525|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
75894526|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
75894527|NCT04306211|Device|SuperNO2VA|SUPERNO2VA is nasal PAP device for oxygen delivery
75894528|NCT05079802|Drug|Double antibiotic paste mixed with chitosan nanoparticles|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with chitosan nanoparticles gel
75894529|NCT05079802|Drug|Double antibiotic paste mixed with propylene glycol|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
75894530|NCT05050669|Other|No Intervention for this observational study|No Intervention for this observational study
75894531|NCT05187091|Radiation|Swallowing and submandibular sparing IMRT|Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures & submandibular gland sparing by SWOAR-IMRT
75894532|NCT04473248|Device|Spartan COVID-19 System|PCR analysis of patient samples using the Spartan COVID-19 System
75894533|NCT05203055|Drug|Peginterferon alpha-2b|180μg/w
75894534|NCT05203055|Drug|Nucleotide Analog|Etecavir 0.5mg qd or Tenofovir 300mg qd
75894535|NCT05203055|Drug|pulse peginterferon alpha-2b|180μg/w for 8 consecutive weeks and cessation for 4 weeks
75894536|NCT05108662|Procedure|Surgery method|Patients were subdivided into two groups according to their prostate volume
75894537|NCT05186155|Procedure|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
75894538|NCT03899636|Drug|Modified FOLFIRINOX Regimen|Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
75894539|NCT03899636|Device|NanoKnife System|IRE using NanoKnife System
75894540|NCT03813862|Other|Non-interventional (observational only)|
75894541|NCT05184751|Other|colonoscopy|
75744884|NCT03998514|Drug|CB4211 Dose 2|Administered by subcutaneous injection
75894542|NCT03773380|Combination Product|Breathe Anew Survivorship Program|The feasibility will be tested of the Breathe Anew Survivorship Program
75894543|NCT03457766|Device|HIFU|Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
75894544|NCT05168371|Behavioral|Cognitive-Behavioural Therapy - Online (CBT-O)|"Face-to-face CBT was adapted for web-based self-directed therapy. CBT-O was found to be feasible and usable (Stephenson et al., 2021; Zippan et al., 2020).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to CBT; 2) The cognitive model and thought records; 3) Unhelpful thinking patterns; 4) Cognitive restructuring; 5) Behavioral experiments; 6) Self-touch and sensate focus; 7) Sensate focus with your partner; and 8) Maintaining (and extending) your gains."
75894545|NCT05168371|Behavioral|Mindfulness-Based Therapy - Online (MBT-O)|"The content of MBT-O was adapted from an efficacious face-to-face mindfulness intervention for women with Sexual Interest/Arousal Disorder (Brotto et al., 2021; Paterson et al., 2017). MBT-O was found to be feasible and usable (Brotto et al., under review).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to mindfulness; 2) Increasing awareness of physical sensations in the body; 3) Exploring movement and body image; 4) Awareness of sexual thoughts and beliefs; 5) Working with aversion, self-touch; 6) Exploring sexual sensations, knowing limits; 7) Integrating the partner into mindful touching; and 8) Maintaining (and extending) your gains."
75894546|NCT05105620|Diagnostic Test|Fluorescein Angiography|Fluorescein Angiography for pateints with diabetes using fundus camera (TRC-NW8F retinal camera; Topcon Corporation, Tokyo, Japan).
75894547|NCT05105620|Diagnostic Test|Optical coherence tomography|Optical coherence tomography for pateints with diabetes using • Topcon DRI OCT Triton device (ver.10.13; Topcon Corporation, Tokyo, Japan).
75894548|NCT04237181|Device|Filmarray PCR multiplex-PCT assay|Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
75894549|NCT05157139|Drug|Oral Capsule|Oral Capsule of vanillin & wheat germ oil
75894550|NCT03386942|Drug|Farletuzumab Ecteribulin|Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
76063075|NCT03824002|Drug|Metformin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
75449764|NCT01698580|Other|Educational and behavioural|Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
75600912|NCT05661227|Device|Tourniquet(Early)|Timing of tourniquet application
75600913|NCT05661227|Device|Tourniquet(Late)|Timing of tourniquet application
75744885|NCT03998514|Drug|CB4211 Dose 3|Administered by subcutaneous injection
75744886|NCT03998514|Drug|CB4211 Dose 4|Administered by subcutaneous injection
75744887|NCT03998514|Drug|CB4211 Dose 5|Administered by subcutaneous injection
75600914|NCT04325087|Device|iTBS|Administration of an iTBS protocol over the dlPFC
75600915|NCT04325087|Device|Placebo iTBS|Administration of a placebo TMS protocol over the dlPFC
75616537|NCT00899548|Genetic|DNA methylation analysis|laboratory analysis
75616538|NCT00899548|Genetic|microarray analysis|laboratory analysis
75616539|NCT00899548|Genetic|polymerase chain reaction|laboratory analysis
75616540|NCT00899548|Other|laboratory biomarker analysis|laboratory analysis
75616541|NCT04201366|Other|No intervention|No intervention
75616542|NCT02690818|Behavioral|Regularly scheduled LTBI medication reminder text messages|"Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication."
75744888|NCT03998514|Drug|CB4211 Dose 6|Administered by subcutaneous injection
75744889|NCT03998514|Drug|CB4211 Dose TBD|Administered by subcutaneous injection
75744890|NCT03998514|Drug|Placebo|Administered by subcutaneous injection
75744891|NCT00858065|Behavioral|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
75744892|NCT00858065|Behavioral|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
75894551|NCT04527094|Diagnostic Test|Prediction of postoperative respiratory failure using a machine learning|The performance of a machine learning model to predict postoperative respiratory failure after general anesthesia within postoperative day 7 was tested prospectively.
75600916|NCT05643989|Procedure|Stoma formation|Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.
75894552|NCT05136937|Biological|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection for 3 dose cohorts: 1×10^7 TCID50/mL, 1×10^8 TCID50/mL and 7×10^8 TCID50/mL
75894553|NCT05015569|Device|COVR Medical Garment|"COVR undergarments are available in a Half Short design for unilateral lower extremity procedures and a Bilateral (brief) style garment designed for bilateral lower extremity procedures. Either style may be worn for upper extremity, trunk, spine procedures, etc. where an undergarment would be preferred along with a standard hospital gown. The garments are available in a variety of sizes. The COVR garments can be released at the hip(s)/waistline for improved access to the lateral hip and include retractable panels for procedural access to the groin and genitals if needed by the care team."
75894554|NCT05015569|Other|Standard Patient Gown|The standard patient gown is provided to all patients in a hospital setting.
75600917|NCT05643989|Procedure|Endoscopic self-expandable metal stent placement|The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.
75894555|NCT04910230|Drug|nicotinamide|In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
75894556|NCT03069989|Drug|GSK3008348|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
75600918|NCT01303445|Drug|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
75600919|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
75894557|NCT03069989|Drug|Placebo|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
75894558|NCT03069989|Drug|[18F]-FBA-A20FMDV2|Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
76063076|NCT03824002|Drug|Repaglinide|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
76063077|NCT03823846|Drug|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
75449765|NCT01698580|Other|Management of modifiable risk factors|Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
75449766|NCT01698580|Other|Usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
75449767|NCT01698593|Drug|Bupivacaine 0.5%|
75449768|NCT01698593|Drug|Bupivacaine 0.5% + Epinephrine (1:200,000)|
75616543|NCT02842528|Behavioral|Diagnostic Interview for Genetic Studies|
75894559|NCT04894474|Drug|BI 767551 intravenous|BI 767551 intravenous
75894560|NCT04894474|Drug|BI 767551 inhalation|BI 767551 inhalation
75894561|NCT04894474|Drug|Placebo intravenous|Placebo intravenous
75894562|NCT04894474|Drug|Placebo inhalation|Placebo inhalation
75894563|NCT03438682|Device|Essure|Essure hysteroscopic sterilization
75894564|NCT03438682|Procedure|Laparoscopic sterilization|Laparoscopic sterilization via electrocautery, ring, or clip.
75894565|NCT03438682|Device|Intrauterine Device (IUD)|Intrauterine Device (IUD)
75894566|NCT04764136|Device|Scoliometer (scolioscope)|Individuals with scoliosis will participate in this study. The device will be used to determine spinal rotation on the transverse plane. Repeated measures will be taken.
75894567|NCT03619915|Diagnostic Test|Spirometry|The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
75894568|NCT03619915|Other|Functional Independence Measure|Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
75744893|NCT00854477|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
76063078|NCT03823846|Drug|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
75600920|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
75600921|NCT01303445|Drug|Omeprazole alone|omeprazole 80 once daily for 7 days
76063079|NCT03823846|Drug|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
75744894|NCT00854555|Other|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
75449769|NCT01698606|Behavioral|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
75449770|NCT01698645|Drug|PecFent® (fentanyl) nasal spray|
75449771|NCT01698671|Device|InterGard Synergy Vascular Graft|
75600922|NCT01188681|Drug|TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
75600923|NCT01188681|Drug|Bendamustine|Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
75600924|NCT01188681|Drug|15 mg/kg TRU-016 and bendamustine|TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
75744895|NCT00854555|Other|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
75744896|NCT00854633|Drug|Talactoferrin|Enteral, 150 mg/kg twice per day
75449772|NCT01698697|Drug|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
75449773|NCT01698723|Drug|Ribavirin|
75449774|NCT01698723|Drug|Placebo|
75449775|NCT01698736|Device|Membrane filtration|Membrane filtration (Polysulfone)
75894569|NCT05202977|Device|SinocrownTM Transcatheter Aortic Valve Replacement System|Subjects receiving SinocrownTM Transcatheter Aortic Valve Replacement System of Lepu Medical
75894570|NCT04995094|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
75894571|NCT04995094|Biological|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein. Pembrolizumab will be administered at 200 mg IV Q3W for 9 weeks.
75449776|NCT01698736|Device|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
75616544|NCT02842528|Behavioral|Family Informant Schedule and Criteria|
75616545|NCT02842528|Behavioral|Temperament and Character Inventory|
75894572|NCT04924387|Procedure|Exercise|All patients will start learning how to activate the abdominal muscles in the first training session. The exercise progression will be adapted according to the capacity of each patient, considering their pain levels. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rests between series will be of 30 seconds, and between exercises of 2-3 minutes.
76063080|NCT03823846|Drug|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
76063081|NCT03823846|Other|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
76063082|NCT03823846|Drug|normal analgesia pump administration|Dose of analgesia pump was added if needed.
75894573|NCT05202821|Drug|PRG Barrier Coat|3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
75744897|NCT00854633|Drug|Placebo|Oral, twice per day
75894574|NCT05202821|Drug|Fluoride varnish|First group will be receiving Fluoride varnish every 3 months
75894575|NCT05202821|Drug|MI paste|Third group will be receiving MI paste
75894576|NCT04958902|Behavioral|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
75894577|NCT02951416|Other|patient registry (observation and biomaterial sampling)|data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
75894578|NCT05201651|Dietary Supplement|Creatine Monohydrate|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.
75744898|NCT00618371|Drug|Raltegravir (MK-0518)|Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
75744899|NCT00858299|Drug|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
75894579|NCT05201651|Dietary Supplement|Maltodextrin Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
75744900|NCT00526890|Dietary Supplement|selenomethionine|Oral Twice daily
75449777|NCT01698749|Drug|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
75449778|NCT01698762|Other|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
75449779|NCT01698762|Other|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
75449780|NCT01698762|Behavioral|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
75449781|NCT01698788|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone
75449782|NCT01698827|Other|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
75449783|NCT01698866|Biological|Vaccin GenHevac B Pasteur|
75744901|NCT00526890|Drug|carboplatin|Weekly IV
75744902|NCT00526890|Drug|paclitaxel|Weekly IV
75744903|NCT00526890|Other|laboratory biomarker analysis|Correlative Study
75744904|NCT00526890|Radiation|radiation therapy|Undergoing radiation Therapy
75449784|NCT01698931|Drug|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
75449785|NCT01698931|Drug|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
75449786|NCT01698931|Drug|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
75616546|NCT02842528|Behavioral|Barratt Impulsiveness Scale|
75616547|NCT02842528|Behavioral|Wisconsin Card Sorting Test|
75616548|NCT02842528|Genetic|blood sample withdrawn|
75616549|NCT04201522|Other|Normocapnic hyperpnoea intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
75616550|NCT04201522|Other|Sham intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
75616551|NCT02842450|Device|Photos + definitions|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
75894580|NCT04826731|Other|Incentive Spirometer/Respiratory Exerciser|"A patient is considered acceptable for the Incentive Spirometer Group if the patient can use an incentive spirometer and/or a respiratory exerciser at least four times per day. A pulmonary medicine specialist will confirm the proper usage of the device."
75449787|NCT01698944|Drug|somatropin|Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
75449788|NCT01698957|Other|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.|bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
75894581|NCT04853914|Device|HIFU treatment|HIFU treatment of Benign Prostatic Hyperplasia
75894582|NCT04231409|Device|Boston Scientific Spectra WaveWriter SCS System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
75894583|NCT04684810|Behavioral|Community Lay Therapist-Administered EBT|Community Therapists Used CBT and EMDR Interventions
75744905|NCT04041167|Drug|alpha lipoic acid|alpha lipoic acid treatment
75894584|NCT02698163|Device|Nanodiamond reinforced Gutta Percha|Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
75894585|NCT02698163|Device|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
75894586|NCT04680676|Drug|BI 730357|BI 730357
75894587|NCT04680676|Drug|Placebo|Placebo
75894588|NCT04631731|Diagnostic Test|Blood screening|Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.
75894589|NCT04631731|Diagnostic Test|Tissue screening|Archival tumor tissue (FFPE) will be spatially analysed in order to define tissue heterogeneity in tumor samples regarding cancer immune cell transcriptional profiles and correlate it with the occurrence/development of immune-related adverse events.
75449789|NCT01698970|Other|1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)|1- 6 test products/day
75744906|NCT04041167|Drug|Saline|No alpha lipoic acid treatment
75744907|NCT03998124|Behavioral|Peer facilitator training|Peer facilitation of a project-based activity without staff present
75894590|NCT02941276|Device|Active Electrostimulator device|Patients who will receive a fully functioning device
75449790|NCT01698970|Other|2- excipients (150 mg) in capsule (control)|2- 6 control poducts/day
75449791|NCT01698996|Procedure|Packing vs No Packing|
75449792|NCT01699009|Other|Plant based diet|
75449793|NCT01699009|Other|an unrestricted diet|
75449794|NCT01699048|Procedure|Hybrid (MIDCAB+PCI)|Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
75449795|NCT01699048|Procedure|PCI|Multi-vessel PCI with DES
75744908|NCT03998124|Other|Usual care|Staff-led social activity
75744909|NCT00858377|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
75894591|NCT02941276|Device|Sham Electrostimulator device|Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
75894592|NCT03817190|Drug|DS107|DS107 Capsule
75894593|NCT03817190|Drug|Placebo|Placebo capsule
75894594|NCT05666245|Behavioral|Personal Protective Equipment (PPE) - Under High Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
76063083|NCT03823846|Drug|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
76063084|NCT02908750|Drug|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
75744910|NCT00858377|Drug|Arm 1- Dose Expansion|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
76063085|NCT02908750|Drug|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
76063086|NCT03823612|Drug|Clinpro Tooth Creme|The participant will be instructed to Place a pea-sized amount of Clinpro Tooth Crème on a soft bristled toothbrush and brush teeth for at least two minutes then after brushing the patient will rinse out his mouth with water and spit out. It will be used twice daily at first in the morning and before sleep.
75744911|NCT03864900|Behavioral|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
75600925|NCT01188681|Drug|20 mg/kg TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
75600926|NCT02887131|Other|Dynamic CT of the ankle|during inversion and eversion mouvement, with Aquilion One Toshiba scanner
75600927|NCT01302899|Drug|Aliskiren|Aliskiren 150 mg (Tablet)
75600928|NCT01302899|Drug|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
75600929|NCT01302899|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
75600930|NCT01302899|Drug|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
75600931|NCT01302899|Drug|Ramipril|Ramipril 10mg (Tablet)
75600932|NCT04324775|Other|Exercise + Manual Lymphatic Drainage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes
75600933|NCT04324775|Other|Exercise + Swedish massage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
75600934|NCT05643833|Other|no intervention|no intervention
75600935|NCT01187901|Drug|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
75744912|NCT00854711|Procedure|inhaled nitric oxide|80 PPM
75744913|NCT00858455|Drug|GSK1349572 and MaaloxAdvanced Maximum Strength|A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
76072141|NCT03113968|Drug|Ketamine|Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
76072142|NCT03112174|Drug|Ibrutinib|Administered orally once daily
75600936|NCT01187901|Drug|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
75600937|NCT01187901|Drug|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
75894595|NCT05666245|Behavioral|No Intervention - Under High Air Hygiene|"No intervention~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
76025094|NCT03684473|Behavioral|Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention|"8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series."
75600938|NCT01187901|Drug|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
75744914|NCT00858455|Drug|GSK1349572 and Maalox Advanced Maximum Strength|A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
75744915|NCT00858455|Drug|GSK1349572 and One A Day|A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
76063087|NCT03823612|Drug|GC tooth mousse|The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
75449796|NCT01699048|Procedure|CABG|Coronary artery bypass graft (CABG) treatment
75449797|NCT01699061|Drug|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
75744916|NCT00858455|Drug|GSK1349572|A single dose of GSK1349572
76072143|NCT03112174|Drug|Venetoclax|Administered orally once daily
75449798|NCT01699061|Drug|Placebo|Placebo tablet administered with a meal twice a day on Day 1
75449799|NCT01699074|Dietary Supplement|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
75449800|NCT01699074|Dietary Supplement|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
75449801|NCT01699074|Dietary Supplement|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
75449802|NCT01699074|Dietary Supplement|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
75449803|NCT01699074|Dietary Supplement|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
75449804|NCT01699100|Other|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
75449805|NCT01699113|Drug|YF476|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~YF476 100 mg; or~rabeprazole 20 mg; or~a combination of YF476 100 mg and rabeprazole 20 mg."
75449806|NCT01699113|Drug|Rabeprazole|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~YF476 100 mg; or~rabeprazole 20 mg; or~a combination of YF476 100 mg and rabeprazole 20 mg."
75600939|NCT01302119|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
75600940|NCT01302119|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
75600941|NCT05364411|Radiation|HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)|20 daily fractions, 5 times per week
75600942|NCT05364411|Radiation|conventional fractionated radiotherapy|35 daily fractions, 5 times per week
75600943|NCT05931900|Device|moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients|Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
75600944|NCT05927922|Drug|Oral Ibuprofen (Abbott, Egypt)|ibuprofen is analegisic drug used to relieve pain
75600945|NCT05927883|Behavioral|Indigenously Adapted Cognitive Behavioral Therapy|IACBTGA will be comprised of 8 weekly sessions. Cognitive and behavioral strategies will be provided in sessions
75600946|NCT05927857|Drug|nal-IRI /Experimental|infusional 50/60/70 mg/m2 over 90 minutes day 1, every 14 days.
75600947|NCT05927857|Drug|Ramucirumab /Experimental|infusional 8mg/kg over 60 minutes day 1, every 14 days.
75600948|NCT05927857|Drug|Trifluridine/Tipiracil /Experimental|oral 30 mg/m2/b.i.d. day 1-5, every 14 days.
75600949|NCT05927844|Drug|XH-30002 capsule|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
75616552|NCT02842450|Other|definitions only|
75744917|NCT00862355|Drug|SPARC147609|IV infusion
75744918|NCT00862355|Drug|Reference147609|IV infusion
75744919|NCT02544737|Drug|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
75894596|NCT05666245|Behavioral|Personal Protective Equipment (PPE) - Under Low Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~Low air hygiene is achieved with minimal ventilation."
75894597|NCT05666245|Behavioral|No Intervention - Under Low Air Hygiene|"No intervention~Low air hygiene is achieved with minimal ventilation."
75894598|NCT02560805|Procedure|Microneurography|Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
75894599|NCT02560805|Behavioral|Combat virtual reality video clip|Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
75894600|NCT02560805|Procedure|Handgrip Exercise|Subjects will squeeze a hand dynamometer intermittently.
75894601|NCT02560805|Procedure|Cold Pressor Test (CPT)|Subjects' hand will be submerged in cold water (~0-1°C) up to the wrist for 1 minute.
75894602|NCT02560805|Drug|Sodium Nitroprusside (SNP)|Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
75894603|NCT02560805|Drug|Phenylephrine|Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
75894604|NCT02560805|Drug|Losartan|Subjects will receive Losartan 25 mg once a day orally up to 12 weeks
75894605|NCT02560805|Drug|Atenolol|Subjects will receive Atenolol 25 mg once a day orally up to 12 weeks
75894606|NCT04615936|Other|Methylene-Blue Photodisinfection|Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
75894607|NCT04887415|Device|Respiratory strength training|Devices will be set to 70% of participants' maximum expiratory pressure and maximum inspiratory pressure. Participants will complete training 5 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory muscle strength training (a total of 50 repetitions).
75894608|NCT04544254|Procedure|Bilateral transversus thoracis muscle plane block|The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided. Twenty milliliters bupivacaine 0.5% 1mg/body weight will be injected between internal intercostal muscle and transversus thoracis muscle on both sides.
75600950|NCT05927844|Drug|Afatiinb tablet|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
75894609|NCT04544254|Procedure|Control|A needle will be place in the similar area to the transversus thoracis muscle plane block, but no drugs will be injected to the area
76025095|NCT03560297|Behavioral|SeRenade Parent-Child Music Class|Parent-Child Music Class involving parent training, peer inclusion, and musical play
76063088|NCT03823924|Procedure|Bone mineral density (BMD)|"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."
76063089|NCT04273906|Procedure|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
75600951|NCT05927831|Drug|Grape Seed Extract|Grape seed extract will be applied in the form of a gel on the tooth surface
76025096|NCT03560297|Behavioral|Delayed Intervention|Participants receive intervention after delay
75600952|NCT05927831|Device|Low-level laser therapy|The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode
75600953|NCT05927818|Diagnostic Test|Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer|Described in previous sections
75600954|NCT05927805|Other|E-bibliotherapy|Participants in the intervention group will accept eight weekly sessions of e-bibliotherapy. The e-bibliotherapy will be delivered via the e-bibliotherapy app we develop and includes eight e-bibliotherapy sessions, each focusing on one active component that may affect a caregiver's mental well-being.
75600955|NCT05927805|Other|Control|The control group will give access to the same e-bibliotherapy app, but only be authorized to access general daily living knowledge that is different from the intervention contents. They will also be asked to finish a session each week for eight weeks.
76025097|NCT02691013|Drug|Ramelteon|
75600956|NCT05927779|Drug|TFX06 tablet|TFX06 tablet taken orally
75600957|NCT05927766|Device|esophagogastroduodenoscopy|patients with upper gastrointestinal symptoms will gone to upper endoscopy and biopsy when indicated
75616553|NCT02844088|Other|Meningococcus C conjugate vaccine|
76063090|NCT04273906|Procedure|Placebo technique|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
76025098|NCT02691013|Drug|Placebo|
76025099|NCT03423407|Device|Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|FDA approved scanner
76025100|NCT03342989|Behavioral|Speed of Processing Training|This intervention is based on computer-administered tasks that are used to evaluate Useful Field of View test, which measures discrimination between visually presented stimuli in the presence of distractors
76025101|NCT03342989|Behavioral|Internet-Based Contact Control|This intervention provides social contact and mentally stimulating activities that do not target speed of processing
76063091|NCT02834104|Device|RMI|
75894610|NCT01569971|Other|Assessment|In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
75894611|NCT05175833|Combination Product|Oral probiotics|Oral gel containing streptococcus salivarius K12 and lactobacillus brevis CD2
75894612|NCT05175833|Other|Oral placebo|Oral gel containing placebo
75894613|NCT04799392|Device|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
75894614|NCT04507321|Drug|GSK3640254 Oral tablet|GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.
75894615|NCT04507321|Drug|[14C]-GSK3640254 intravenous infusion|[14C]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.
75894616|NCT04507321|Drug|[14C]-GSK3640254 powder|[14C]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.
75894617|NCT04119089|Other|Gastric ultrasound|"A first gastric ultrasound will be performed in the supine and the right lateral (RLD) decubitus position, allowing a qualitative analysis of the gastric contents (empty, liquid, solid, solid-liquid). The antral area will also be measured in both positions. The volume of gastric fluid content will be calculated according to the following formula: volume (ml) = -7,8 + (0,035 x antral area in RLD (mm²)) + 0,127 x age (month).~This examination will be immediately followed by the aspiration of gastric contents through the nasogastric tube used for enteral feeding, into 50-ml syringes, by a nurse blinded to the result of the first ultrasound examination. A second antral ultrasound examination will then be performed, by the same investigator blinded to the volume aspirated.~The occurrence of regurgitation and / or vomiting occurring within the 12 hours before and after the examination will be recorded."
76063092|NCT02834104|Other|myocardial biopsy|
76063093|NCT02834104|Biological|blood sample|
75894618|NCT03797222|Dietary Supplement|Vitamin E|Subjects will take an oral Vitamin E (alpha-tocopherol) supplement once daily with a fat-containing meal for 2 weeks. The dose will be based on subject age (150 IU if 1-3 years old, 300 IU if 4-8 years old, 450 IU if 9-17 years old, 600 IU if >17 years old). Formulations include 50 IU/mL liquid and 200 IU capsules. The liquid formulation will be used for subjects who will receive <600 IU daily, or for any subjects who prefer liquid medication to capsules.
75894619|NCT04725760|Device|BrainPort Vision Pro|"Ten hours of training over 3 to 5 days, followed by autonomous use of the device.~It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months."
75894620|NCT04118231|Other|Dry needling|Group 1: Dry needling Group 2: static stretching Group 3: IASTM
75894621|NCT04783324|Behavioral|E-Mobile Health Application|The e-mobile health application prepared by the researcher will be used. E-mobile health application include information about postpartum care.
75744920|NCT00858533|Behavioral|Health at Work workplace health advice and support|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
75894622|NCT04094753|Diagnostic Test|Blood Sample|A sober blood sample is taken to observe the following parameters: creatinin, ureum, sodium, potassium, osmolality, HDL cholesterol, LDL cholesterol, triglycerides)
75894623|NCT04094753|Diagnostic Test|Renal Function Profile|A Renal Function Profile is a 24 hour-urine collection in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. Daytime samples were taken at 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The nighttime samples were taken at 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8). The volume of each sample, and of each micturition in between, was noted to calculate the 24h, daytime and nighttime urine volume and diuresis rate.
75894624|NCT04094753|Diagnostic Test|Frequency Volume Chart|Every patient complets a frequency volume chart during 24 of 72 hours
75894625|NCT04094753|Diagnostic Test|Cystometry|This technique provide the most precise measurement of bladder and urethral sphincter behaviour during bladder filling and during voiding.
75744921|NCT00526656|Drug|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
75744922|NCT04042649|Behavioral|environmental intervention|provide environmental intervention (help sleep cycle, provide comfortable environment)
75744923|NCT00858611|Drug|VRC-FLUDNA047-00-VP|
76063094|NCT03823222|Dietary Supplement|Duckweed protein|20 grams isolated protein
76063095|NCT03823222|Dietary Supplement|Whey protein|20 grams isolated protein
76063096|NCT03823066|Device|Coach Pepper|Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
76063097|NCT02810704|Drug|Enteric Coated Aspirin|
76063098|NCT02810704|Drug|Warfarin|
76063099|NCT02810704|Drug|Rivaroxaban|
76063100|NCT04392076|Procedure|Image Guided Ablation|Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
76063101|NCT02790424|Device|Imaging devices|technological adjustment tests
75449807|NCT01699126|Device|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
75449808|NCT01699126|Drug|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
75449809|NCT01699139|Device|positional device|Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.
75894626|NCT04094753|Diagnostic Test|Questionaires|"Patients have to fulfill the following questionaires~ICIQ-Fluts for female participants or ICIQ-Mluts for male participants~TILBURG FRAILTY INDICATOR~SF-36 Quality of Life score~N- QOL"
75894627|NCT04094753|Diagnostic Test|Flow rate measurement + Observation of the post-void residual urine volume|A measurement of the urinary flow rate is observed to collect the maximum Q/s. Afterwards an observation of the PVR is done using ultrasound.
75894628|NCT04094753|Diagnostic Test|Clinical Examination|Clinical examination of the genital region. For women, coeles are described using the POPQ
75894629|NCT02742818|Device|Upper body blanket, Bair Hugger|Upper body warming blanket will be used in patients undergoing LEA and EVAR.
75894630|NCT02742818|Device|Underbody blanket, Bair Hugger|Underbody warming blanket will be used in patients undergoing LEA and EVAR.
75894631|NCT04708990|Device|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
75894632|NCT04876105|Other|Assesment of treatment preference|Multiple-choice survey questions were created by the researchers based on the studies in the literature regarding the pain and treatment preferences of the participants
75894633|NCT03069365|Drug|Glecaprevir/pibrentasvir|Film-coated tablet
75894634|NCT04480411|Behavioral|Doctorgram Patient Kit|Participants will use the Doctorgram Patient Kit for remote monitoring and remote use stethoscope.
76063102|NCT02738398|Radiation|FDG PET/CT|
76063103|NCT03822988|Other|no intervention, only complete a survey|we will ask patients to answer to a survey
76063104|NCT03822754|Biological|sIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I & type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
76063105|NCT03822754|Biological|wIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I & type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
75600958|NCT05927740|Diagnostic Test|Optic coherence tomography|Every participant was subjected to a comprehensive ophthalmologic examination which included measuring auto-refraction (average of three values, Topcon Autorefractometer model KM 8900, Japan), uncorrected visual acuity with cycloplegic refraction (with 0.5% cyclopentolate HCl), and IOP in millimeters of mercury (mmHg, Goldmann applanation tonometer). Moreover, slit-lamp biomicroscopy (HaagStreit, Bern, Switzerland) was performed, concentrating on potential corneal scarring and/or lenticular opacities.
75894635|NCT04471675|Drug|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion.
75894636|NCT04461028|Drug|Liposomal bupivacaine|20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
75600959|NCT05927727|Diagnostic Test|Ultrasound and biyopsy|Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region
75894637|NCT04461028|Drug|Bupivacaine with Dexamethasone Solution|20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
75894638|NCT00716534|Drug|ABT-869|12.5 mg ABT-869
75600960|NCT05927688|Behavioral|Therapeutic management following access by the physician to his patient's ePROs|Therapeutic management following access by the physician to his patient's ePROs
75894639|NCT00716534|Drug|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
75894640|NCT00716534|Drug|ABT-869|7.5 mg ABT-869
75894641|NCT00716534|Drug|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
75894642|NCT00716534|Drug|Paclitaxel|Paclitaxel (200 mg/m2)
75894643|NCT01024829|Radiation|Radiotherapy|Radiotherapy
75894644|NCT04623736|Behavioral|quitSTART|"All participants will have access to the Smokefree.gov Initiative smoking cessation smartphone application, quitSTART. This app is available, at no cost, to anyone who owns a smartphone and is interested in quitting smoking. All smokers who download quitSTART are asked to provide basic information about themselves (e.g., age, sex, reason to quit smoking, triggers to smoke, when users typically smoke, how users plan to celebrate success, smoking frequency, age when started smoking regularly, ethnicity, race, cigarettes smoked per day), and set a quit date. Information about cessation and challenges to help support quitting are available, as well as games and tracking features. While using the app, users can proactively report cigarette cravings, if they slipped, if they are feeling down or feeling great. If a user reports a craving, they have the option to mark the timing or location of the craving and request a reminder to resist future cravings at the same time or location."
75894645|NCT04352881|Other|Questionary patient|Assessing pain reduction using a 4-step questionary
75894646|NCT03360500|Other|EXERCISE PROTOCOL + CRYOTHERAPY|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field."
76063106|NCT03822676|Device|Prophylactic pancreatic stent|Prophylactic pancreatic stent before segmental pancreatic surgery
76063107|NCT02926222|Drug|Regorafenib|Regorafenib is formulated as tablets of 40mg for oral administration.
76063108|NCT02926222|Drug|Lomustine|Lomustine is formulated as tablets of 40mg for oral administration.
75616554|NCT00899392|Other|Emmi Pediatric Upper Endoscopy Patient Education Module|Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
75616555|NCT02842294|Drug|Bevacizumab|
76072144|NCT03112174|Drug|Placebo Oral tablet to match Venetoclax|Administered orally once daily
76072145|NCT03095066|Drug|Placebo|Administered as capsules
75894647|NCT03360500|Other|EXERCISE PROTOCOL|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises."
75894648|NCT03360500|Other|EXERCISE PROTOCOL + PLACEBO|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field."
75894649|NCT03627949|Behavioral|E-intervention|The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
75894650|NCT04554706|Behavioral|Mobile-phone delivered Treatment for Excessive Rumination|This is a one-month three-arm clinical control trial to reduce the rumination and interpersonal impairment link.
75894651|NCT05761067|Procedure|Percutaneous Coronary Intervention (PCI)|Alternative treatment
75894652|NCT02283398|Other|without RIPC|the cuff will be placed around the left arm without being inflated
75894653|NCT02283398|Procedure|RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
75894654|NCT03981731|Other|Cardiac coherence|"An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape."
75894655|NCT02283476|Drug|Endostar continuous intravenous infusion|Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
75744924|NCT00858611|Drug|Flulaval (Registered) Seasonal Influenza Vaccine|
75744925|NCT00854789|Biological|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
75894656|NCT02283476|Drug|Endostar routine intravenous infusion|Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total
75894657|NCT02283476|Drug|Gemcitabine|Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
75449810|NCT01699139|Device|lumbar corset|A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
75894658|NCT02283476|Drug|Cisplatin|Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
75894659|NCT04054570|Other|No intervention|No Intervention
75600961|NCT05927675|Behavioral|Physical activity|"The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements."
75600962|NCT05927662|Procedure|lumbar discectomy|mini-open discectomy
75616556|NCT05334862|Procedure|8 plate hemiepiphysiodesis|surgical procedure by lateral incision in proximal tibia and fixation by usuing 8 plate and screws.
75744926|NCT00858767|Dietary Supplement|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
75894660|NCT05156879|Drug|Aspirin|75mg, one time/day
75894661|NCT05156879|Drug|Drospirenone ethinyl estradiol|1 table/day, 21 consecutive days, 28 days as a cycle of use
75894662|NCT02283554|Procedure|open flap debridement (OFD)|
75894663|NCT02283554|Other|Platelet rich fibrin (PRF)|
75894664|NCT02283554|Drug|Metformin|
75894665|NCT03957070|Device|Liver Incyte|Ultrasound elasticity imaging
76072146|NCT03095066|Drug|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
75449811|NCT01699152|Drug|TG02 citrate|TG02 citrate capsules
75449812|NCT01699165|Device|Nasal filter|Active nasal filter
75449813|NCT01699165|Device|Placebo nasal filter|Placebo nasal filter
75449814|NCT01699191|Dietary Supplement|Probiotic|
75449815|NCT01699191|Dietary Supplement|Placebo|
75449816|NCT01699204|Dietary Supplement|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
75744927|NCT00858767|Dietary Supplement|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
75894666|NCT03629405|Other|C - pH 4 Cosmetic Product WO 3741|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
75894667|NCT03629405|Other|D - pH 5.8 Cosmetic Product WO 4081-1|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
75894668|NCT00641732|Drug|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
75894669|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
75449817|NCT01699204|Other|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
75894670|NCT00641732|Drug|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
75894671|NCT00641732|Drug|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
75894672|NCT00641732|Drug|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
75894673|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
75894674|NCT00641732|Drug|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
76063109|NCT01453816|Procedure|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
75449818|NCT01699204|Other|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
75616557|NCT01176604|Radiation|Yttrium Y 90 Glass Microspheres|Given via catheter
75449819|NCT01699230|Dietary Supplement|Omega 3|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
75449820|NCT01699256|Behavioral|Guideline implementation as usual|Newsletters and Invitation to Meetings
75449821|NCT01699256|Behavioral|Enhanced guideline implementation strategy|Enhanced guideline implementation strategy
75449822|NCT01699269|Other|peritumoral glial cell infiltration|
75616558|NCT02843932|Other|functional brain MRI|functional imagery during motor-perception tasks
75616559|NCT02844010|Other|weighing|
75449823|NCT01699282|Behavioral|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
75449824|NCT01699282|Behavioral|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
75616560|NCT02842138|Biological|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
75894675|NCT03845842|Behavioral|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding cannabis use.
75894676|NCT05761769|Other|no intervention|no intervention
75894677|NCT03770494|Drug|LY3405105|Administered orally.
75449825|NCT01699295|Behavioral|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
75894678|NCT00790829|Drug|transdermal nicotine patch|Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
76063110|NCT04273282|Drug|Dexycu intracameral dexamethasone|To evaluate the safety and ocular efficacy of Dexycu.
76063111|NCT04273282|Drug|Prednisolone Acetate|To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
75894679|NCT00640484|Drug|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)"
75894680|NCT00640484|Drug|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)"
75894681|NCT00640484|Drug|placebo|"placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)"
76063112|NCT04391530|Behavioral|emotional freedom technique, breathing therapy|emotional freedom technique, breathing therapy
75449826|NCT01699295|Behavioral|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
75449827|NCT01699308|Drug|Genotropin|
75449828|NCT01699321|Behavioral|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
75600963|NCT05927623|Behavioral|Multifaceted Virtual Fracture Prevention Program|"Personalized exercise prescription: Comprised of muscle strengthening and balance exercises to perform three times a week, delivered and monitored remotely via the MisterFit app, a branded version of the secure commercially available Physiotec app (physiotec.com) and monthly virtual exercise consultations.~Virtual nutrition counseling from a registered dietitian in months 2, 4 and 6: to encourage participants to meet daily targets for calcium and vitamin D (preferably from diet), and protein intake to support muscle accretion and target weight maintenance~Virtual interactive information sessions in month 4 and 8: to education participants on topics identified as important by the Misterfit patient partner advisory committee."
75600964|NCT05927623|Behavioral|Attention Control|"Encouraged to meet the 24-Hour Movement Guidelines for adults aged 65 years or older (https://csepguidelines.ca) with telephone contacts at the same frequency that the Misterfit online group receives virtual exercise consultations~Nutritional fact sheets: sent by e-mail at the same frequency that the Misterfit online group meets with the research dietitian.~Educational fact sheets: sent by e-mail at the same frequency that the Misterfit Online group has virtual interactive information sessions"
75744928|NCT00858767|Dietary Supplement|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
75449829|NCT01699321|Other|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
75600965|NCT05927597|Drug|INS1007|Oral tablets.
75744929|NCT00617903|Drug|Azelaic acid|15% foam to be applied topically twice daily
75744930|NCT00617903|Drug|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
75744931|NCT00526110|Drug|5-Fluorouracil|2.2 Gm/m^2 IV over 48 hours on Day 1.
75744932|NCT00526110|Drug|Docetaxel|20 mg/m^2 IV over 60 minutes
75744933|NCT00526110|Drug|Oxaliplatin|85 mg/m^2 IV over 120 minutes on Day 1.
75744934|NCT02544581|Other|Soberlink combined with aftercare services|Soberlink Alcohol Breath Analyzer System combined with aftercare services
75744935|NCT00858923|Device|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
75894682|NCT00640484|Drug|salmeterol|"Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)"
75894683|NCT04382248|Other|Smartphone App|An app for monitoring medications, blood pressure, exercise, healthy eating
75894684|NCT04382248|Behavioral|Tailored education|in-person coaching
75894685|NCT03949361|Diagnostic Test|Indirect calorimetry|Resting energy expenditure
75894686|NCT03949361|Diagnostic Test|Skin Temperature|Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer
75894687|NCT03949361|Diagnostic Test|Dual energy X-ray Absorptiometry (DXA)|Body composition
75894688|NCT03949361|Diagnostic Test|Blood Sampling|thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)
75894689|NCT03949361|Diagnostic Test|FDG-PET|Dynamic PET scanning of the neck-region
75894690|NCT03949361|Diagnostic Test|Capillary glucose|Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
75894691|NCT03949361|Diagnostic Test|Biopsy of supraclavicular adipose tissue (optional)|Ultrasound guided biopsy of the supraclavicular adipose tissue
75449830|NCT01699334|Behavioral|Psychoeducational video|The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
75894692|NCT03065933|Drug|extended-release clonidine|Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
76063113|NCT01453972|Behavioral|Long distanse moderate training|Moderate exercise
76063114|NCT01453972|Behavioral|Long interval training|High-intensity exercise, long duration
76063115|NCT01453972|Behavioral|Short interval training|High intensity exercise, short duration
76063116|NCT01454206|Behavioral|iSBIRT|"Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use."
76063117|NCT01454440|Drug|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure) vs placebo.
75894693|NCT00630656|Drug|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
75894694|NCT00630656|Drug|Placebo|Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
75894695|NCT04256629|Drug|Verinurad|Randomized subjects will receive oral dose of verinurad
75894696|NCT04256629|Drug|Placebo|Randomized subjects will receive oral dose of placebo
75894697|NCT04256629|Drug|Allopurinol|Randomized subjects will receive oral dose of allpurinol (Treatment A and B)
75894698|NCT04225936|Drug|BMS-986263|Single Dose
75894699|NCT05206721|Other|Open tracheal suction system flushing with chlorhexidine|After suctioning the patient's secretions, the responsible nurse inserted the SC into the CHX filled container and flushed the entire suction system with CHX.
75894700|NCT04183270|Other|Questionnaires|The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.
75894701|NCT05206019|Drug|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
75894702|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
75894703|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
75600966|NCT05927597|Drug|Placebo|Oral tablets.
75600967|NCT05927545|Procedure|Patient education and preventive exercise|Educational training program and prevention exercises about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
75600968|NCT05927545|Procedure|Patient education, preventive exercise combined with Manual Therapy protocol|Manual therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
75894704|NCT00696332|Other|placebo|capsules, placebo, 3 times a day, for 52 weeks
75894705|NCT05133401|Device|Ultrasound-guided tracheal width measurement|Ultrasound measurements will be made with a 5-10 MegaHertz linear probe positioned in the horizontal plane at the midline of the anterior neck. After identifying the vocal cords as paired hyperechoic linear structures, the probe was moved caudally to visualize the cricoid arch. The transverse air column diameter was measured at the lower border of the cricoid cartilage.
75894706|NCT04163926|Procedure|Intervention Group cataract follow up|Intervention group will have cataract follow up conducted by the referring optometrist 4-6 weeks after surgery
75894707|NCT04163926|Procedure|Usual Care consultant follow up|Usual care group - Consultant led post op follow up
75894708|NCT05125523|Drug|Sirolimus for Injection (Albumin Bound)|Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)
75894709|NCT00625664|Drug|larotaxel (XRP9881)|administered on day 1 as a 1-hour infusion
75894710|NCT00625664|Drug|gemcitabine|administered on day 1, 8 and 15 as a 30-minute infusion
75894711|NCT00625664|Drug|cisplatin|1 hour infusion administered on day 1, 30 minutes after the other treatment
75894712|NCT03628495|Device|compression|compression will be delivered using compression garment
75894713|NCT03628495|Device|occlusion|occlusion will be delivered using silicone gel sheeting
75894714|NCT04762264|Device|ProFlor inguinal hernia device|Device follow up after inguinal hernia repair with ProFlor
75894715|NCT04519528|Other|DENVER scale (under 2 years old) or Pediatric Cerebral Performance Category (PCPC) score (over 2 years old)|"The DENVER II is a measure of developmental problems in young children. It was designed to assess child performance on various age-appropriate tasks and compares a given child's performance to the performance of other children the same age. The instrument consists of 125 tasks, which broadly reflect the following areas: personal-social, fine motor-adaptive, language, and gross motor.~The target population corresponds to infants and pre-school age children.~The POPC and PCPC are global scales based on observer impressions. Scores include 1 for good, 2 for mild disability, 3 for moderate disability, 4 for severe disability, and 5 for vegetative state or coma (6 indicates death)."
76063118|NCT01454518|Procedure|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
76063119|NCT01454518|Procedure|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
76063120|NCT01454674|Other|2, 5 & 10 Vegetable doses|2,5 & 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers & tomatoes consumed for 3 week intervals
76063121|NCT01454986|Drug|ALXN1007|Single dose, IV
76063122|NCT01454986|Other|Placebo|Single dose, IV
75600969|NCT05927545|Procedure|Patient education, preventive exercise combined with BETY approach|BETY therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
75600970|NCT05927506|Behavioral|Other|Observational study of behavior cognitive and motor control
76063123|NCT02983084|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
76072147|NCT03095066|Drug|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
75894716|NCT04519528|Other|Pediatric Quality of Life Inventory™ (PedsQL)|"The PedsQL questionnaire is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model integrates seamlessly both generic core scales and disease-specific modules into one measurement system. Twenty-three items divided into different functional areas are evaluated: physical (8 items), emotional (5 items), social (5 items) and school (5 items over 4 years old; 3 items before 4 y.o).~Child self-report and parent proxy report formats of the questionnaire allows self-assessment of child over 5 years old and parents' evaluations. Items can be reverse and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0) with higher scores indicating better quality of life."
75894717|NCT04498858|Other|Patient interview|"Patient will be interviewed :~tobacco consumption~reported question asked by the dentist about his/her tobacco consumption~presence and nature of reported advices given by the dentist~presence and nature of actions proposed by dentists for patients reporting tobacco consumption, including prescription of NRT~presence and nature of the actions carried out or envisaged by these patients, including - smoking cessation~contact with the general practioner~Fagerstrom score (2 questions)~demographic variables, age, sex, level of education~satisfaction"
75894718|NCT05062655|Other|Drug reconciliation|Drug reconciliation information transmission to pharmacist interview with the patient
75894719|NCT03585322|Drug|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
75894720|NCT02947165|Drug|NIS793|Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
76063124|NCT01455142|Drug|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
76063125|NCT01455298|Other|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
76063126|NCT01455376|Drug|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
76063127|NCT01455532|Drug|Iniparib (SAR240550-BSI-201)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
75744936|NCT00859001|Drug|FM+R|Fludarabine-Mitoxantrone-Rituximab
75894721|NCT02947165|Drug|PDR001|Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
75894722|NCT02280746|Other|Gluten challenge|Intervention will be continued for at least 6 months
75600971|NCT05927480|Behavioral|Audio distraction|Music on an mp3 player will be provided to the patient for them to listen to while having the traction pin placed.
75894723|NCT02283632|Procedure|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
76063128|NCT01455532|Drug|Gemcitabine|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
76063129|NCT01455532|Drug|Carboplatin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
76063130|NCT01455532|Drug|Placlitaxel|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
76063131|NCT01455532|Drug|Pegylated liposomal doxorubicin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
76063132|NCT01455688|Drug|early HAART|Initiation of HAART within 5 days of ICU admission
75600972|NCT05927428|Drug|BRM424 Ophthalmic Solution|A topical drop of BRM424 ophthalmic solution.
75600973|NCT05927428|Drug|Vehicle|A topical drop of vehicle (minus active) ophthalmic solution.
75600974|NCT05927389|Other|Adapted Physical Activity program|The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities
75744937|NCT00859001|Drug|Zevalin (Ibritumomab Tiuxetan)|
75744938|NCT00862511|Device|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
75744939|NCT00862511|Device|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
75744940|NCT00854867|Drug|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
75744941|NCT00854867|Drug|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
75744942|NCT00859079|Drug|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
75744943|NCT00859079|Drug|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
76063133|NCT01455688|Drug|Late HAART|Initiation of HAART after ICU discharge
76063134|NCT01455844|Drug|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
76063135|NCT01455844|Other|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
76063136|NCT01455844|Drug|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
76063137|NCT01455922|Drug|ITCA 650|ITCA 650 is exenatide in DUROS
76063138|NCT01455922|Drug|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
76063139|NCT01456156|Radiation|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
76063140|NCT04391140|Other|Prone position|HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
76063141|NCT01456234|Drug|Oseltamivir|Oseltamivir 75 mg BID
76063142|NCT01456312|Drug|Peginterferon alfa-2a|Duration and combination
76063143|NCT01456312|Drug|Entecavir|combination
76063144|NCT05587114|Diagnostic Test|frozen blood plasma samples|Analysis of various biomarkers using frozen blood samples
75600975|NCT05927350|Other|Survey|Survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community
75600976|NCT05927337|Behavioral|Cognitive Behavioral Therapy (CBT) for managing Obesity|Patients included in the intervention group will be treated with a tailored cognitive behavioural therapy programme for obesity management. The programme is designed and adapted from the Individualised Cognitive Behavioural Therapy for Obesity Management programme (Dalle Grave et al., 2018), which is divided into six content modules aimed at weight loss and weight maintenance. For the purpose of the research, an abbreviated programme will be designed and used, and the content modules will remain the same as in the original version of the programme.
75894724|NCT03528382|Behavioral|Cardiac rehabilitation quality improvement system|Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises
75894725|NCT04739839|Other|survey questionnaire|Questionnaire focusing on low back pain in relation to life style, physical activity level, illness perception and quality of life.
75894726|NCT03629093|Drug|General Anesthetics|General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
75894727|NCT02283710|Drug|Pentoxifylline|Pentoxifylline 600 mg BD
76063145|NCT01456468|Drug|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
76063146|NCT01456546|Drug|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
75449831|NCT01699334|Other|Relaxation video|The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
75449832|NCT01699347|Drug|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
75449833|NCT01699360|Drug|Cyclosporine A, Tacrolimus, Sirolimus|
75600977|NCT05927298|Other|Non-interventional|Standard of care intervention
75449834|NCT01699386|Other|Control Study Formula|feed as lib
75449835|NCT01699386|Other|Experimental Study Formula|feed as lib
75449836|NCT01699399|Procedure|water immersion|
75449837|NCT01699399|Procedure|water exchange|
75449838|NCT01699399|Procedure|air insufflation|
75600978|NCT05927259|Drug|n acetyl cysteine|A patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/KgIV infusion every 4 hours up to 17 doses
75600979|NCT05927259|Drug|standard treatment|stabilization and antidotes
75600980|NCT05927246|Diagnostic Test|ECG|12 lead ecg for each participant
76063147|NCT01456546|Drug|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
76063148|NCT01456624|Drug|Megace|800mg
76063149|NCT01456624|Drug|DW-ES(B)|625mg
75449839|NCT01699412|Drug|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
75449840|NCT01699412|Drug|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
76063150|NCT01456702|Procedure|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
76063151|NCT01456858|Other|Insecticide Treated Polyethylene Sheeting|Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
76063152|NCT01456858|Other|Untreated Plastic Sheeting|Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
76063153|NCT01457092|Device|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
76063154|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
76063155|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
75894728|NCT02283710|Behavioral|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
75894729|NCT04739293|Drug|ON123300|ON 123300 hard gelatin capsules
75894730|NCT04425304|Behavioral|Group counseling|4 times
75894731|NCT04425304|Behavioral|Intensive group counseling|14 times
75894732|NCT04425304|Behavioral|Persuasive ICT support|Weekly reminders for 12 months
75894733|NCT05055947|Drug|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days
75894734|NCT00506792|Drug|QAU145|
75449841|NCT01699425|Device|Ajust sling|
75600981|NCT05927220|Diagnostic Test|Biopsy Specimens Histopathology|paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists
75600982|NCT05927194|Behavioral|Using the Connect|Using the Connect (UTC) is an innovative, game-based intervention for youth to develop skills in adulthood preparation topics such as communication, decision making and accessing information.
75600983|NCT05927181|Procedure|TAOM|In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
75744944|NCT02544425|Drug|Etoposide|Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
75744945|NCT02544425|Drug|Ifosfamide|It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
75744946|NCT02544425|Drug|Dexamethasone|It will be administered 40mg/day PO or IV D1-3
75894735|NCT00506792|Drug|Placebo|
75744947|NCT02544425|Drug|L-asparaginase|It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
75744948|NCT02544425|Drug|Busulfan|"Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6"
75894736|NCT04697797|Other|Device Programming|Intervention includes (1) pacemaker reprogramming (2) echocardiographic parameters acquisition (3) ECG recording
75744949|NCT02544425|Drug|Melphalan|"Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2"
75894737|NCT03507010|Radiation|Radiotherapy|Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).
75894738|NCT03507010|Other|Sham Radiotherapy|Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
75894739|NCT05043311|Biological|SCTV01C|intramuscular injection
75894740|NCT05043311|Other|Placebo|intramuscular injetion
75894741|NCT03258164|Biological|ASC enriched lipofilling|Fat grafts enriched with ex vivo expanded ASC
75894742|NCT03258164|Biological|Standard Lipofilling|Non-ASC enriched fat grafts
75894743|NCT03943342|Drug|Ibrutinib|Given PO
75894744|NCT03943342|Drug|Venetoclax|Given PO
75894745|NCT02280824|Procedure|CA-TAVR|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
76063156|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
75449842|NCT01699425|Device|Classical transobturator sling|Control group
75449843|NCT01699438|Drug|Mesalazine|2400 mg q.d. for 8 weeks
75449844|NCT01699438|Drug|Placebo|3 tablets q.d. for 8 weeks
75449845|NCT01699477|Device|ExAblate 4000 focused ultrasound brain intervention|Non-invasive brain intervention using MR-guided focused ultrasound
75449846|NCT01699490|Drug|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
75449847|NCT01699490|Drug|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
75894746|NCT02280824|Device|Amplatzer Duct Occluder|
75894747|NCT01569893|Other|Self-monitoring for patients with Dibetes mellitus|"Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.~The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms."
75894748|NCT03837964|Drug|BI 1291583|Tablet
75894749|NCT00694928|Drug|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
75894750|NCT00694928|Drug|butoconazole nitrate|semi-solid, single dose
75894751|NCT04424368|Device|The remote monitoring system|Usage of remote monitoring system
75894752|NCT03737591|Diagnostic Test|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
75894753|NCT04758754|Other|Training|8-weeks iso-volume active (SLKE) or passive static stretching training (PST) involving lower limb muscles
75894754|NCT00694382|Drug|Semuloparin sodium|"0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
75600984|NCT05927168|Device|TENS|TENS will be applied to the experimental group 45 minutes before the chest tube is removed and another 15 minutes after the chest tube is removed. Patients' pain scores will be evaluated using the Numerical Pain Scale (SAS) just before the TENS procedure, while the chest tube is removed, and 5 minutes after the TENS application is finished.
75894755|NCT00694382|Drug|Placebo (for semuloparin)|"0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
75894756|NCT05116228|Drug|500mg RTX Group|Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
75600985|NCT05927155|Drug|LABA|Inhalation of 4 puffs of 2,5 µg of a long-acting beta2-agonist (LABA-olodaterol) administered via a spacer device
75894757|NCT05116228|Drug|1000mg RTX Group|Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
75600986|NCT05927155|Drug|LAMA|Inhalation of 4 puffs of 2,5 µg of a long-acting muscarinic antagonist (LAMA-tiotropium) administered via a spacer device
75744950|NCT03889548|Other|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
75600987|NCT05927129|Drug|Antidepressant|Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
75600988|NCT05927129|Other|Psychotherapy IPT|The participants will receive standardized IPT treatment for 12 weeks. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
75894758|NCT05205395|Diagnostic Test|Transperineal ultrasound|Ultrasonography was used with curved linear-array transducer placed between the major labia and underneath the external urethral orifice. The measurement was done on the midsagittal plane to obtain the image of pubic symphysis, urethra, and bladder in a view. Ultrasonic measurement of the overall rest-stress distance was define as the linear distance of bladder neck position change from resting status to maximal strain.
75894759|NCT05116150|Dietary Supplement|Grape seed extract|Effects of 7 days of combined GSE with L-citrulline supplementation on hemodynamic responses at rest and during cycling exercise.
75744951|NCT00862589|Other|GLP-1 infusion|physiological effect of GLP-1
75744952|NCT04130633|Drug|Placebo|Placebo vapor (distilled water)
75894760|NCT05116150|Dietary Supplement|Placebo|Effects of 7 days of placebo supplementation on hemodynamic responses at rest and during cycling exercise.
75894761|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
75744953|NCT04130633|Drug|THC|Pure THC vapor
75894762|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
75894763|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
75894764|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
75894765|NCT04989101|Drug|Nigella|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
75894766|NCT04200664|Diagnostic Test|Hearing assessment|All study participants will undergo hearing tests, including hearing-specific questionnaires
75894767|NCT04200664|Diagnostic Test|Vestibular/balance assessment|Siderosis group participants will undergo vestibular/balance tests, including gait assessment and balance-specific questionnaires
75894768|NCT04200664|Other|Quality of life assessment|All study participants will be asked to complete a set of quality of life questionnaires
75744954|NCT04130633|Drug|Alpha-Pinene|Pure alpha-pinene vapor
75744955|NCT00859157|Procedure|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
75744956|NCT00512148|Device|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
75894769|NCT04200664|Diagnostic Test|Olfactory (smell) function testing|Siderosis group participants will undergo a formal smell identification testing by means of self-administered smell chart to identify the revealed scents
75894770|NCT04200664|Genetic|DNA bio-banking|Siderosis group participants will be asked to provide a saliva sample for DNA bio-banking
75600989|NCT05927129|Other|The combination of antidepressant and IPT|The participants will receive standardized IPT treatment for 12 weeks. Also，long-term antidepressant will be administered in accordance with clinical guidelines. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
75894771|NCT04940351|Procedure|GROUP - A: PIEZOCISION GROUP|This group will receive piezocisions after placement of initial arch wire, in between the roots of mandibular anteriors (in a vertical line) i.e., between mandibular canine and lateral incisors bilaterally, lateral incisors and central incisors bilaterally and between two cental incisors with the help of piezotome. These piezocisions will be performed on the labial cortical bone only, 4mm below the interdental papilla under 2% lidocaine with 1:100,000 epinephrine and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle. A piezosurgical microsaw with piezosurgical drill will be placed over that incision with irrigation. Then, vertical 5- to 8-mm and 3mm deep corticotomies will be perform using periapical radiographs as a guide to avoid penetrating into the adjacent roots. No subsequent sutures required.
75894772|NCT04940351|Procedure|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive MOPs after initial arch wire placement. These MOPs will be performed under local anesthesia with standard asepsis, using a self drilling 1.6mm x 8mm orthodontic mini-implants and mini-implant screw driver and no flap will be raised. MOP's will be placed on five sites i.e., interproximally between mandibular canine and lateral incisors bilaterally, central incisor and lateral incisor bilaterally and between two central incisors. Each site will receive two MOP's, first 2mm apical to alveolar crest and second 2mm below the first in a vertical line and 2mm deep into the bone. Then the mini-implant will be removed by rotating the screw driver anticlockwise and pressure will be applied to achieve hemostasis.
75894773|NCT05115916|Behavioral|MyChart Priming Message|In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
75894774|NCT05115526|Other|PEEP setting|PEEP setting according to various methods
75600990|NCT05927077|Procedure|planned surgery for weight reduction|planned surgeries will be used to collect study material to determine chemical patterns in the study participants from the different geographical regions
75744957|NCT00859235|Drug|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
75744958|NCT00859235|Other|Plain water|Mouth wash prior to procedure
75744959|NCT04523688|Biological|Autologous Dendritic Cells (DC) vaccine|10×10exp6 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
75894775|NCT05115448|Other|Bevel Position|During 6 dialysis sessions, cannulation was applied to the patients with the direction of the arterial needle in the antegrade direction and the conical tip facing upwards. In the next 6 dialysis sessions, cannulation was applied to the patients in an antegrade direction and with the conical tip facing down.
75894776|NCT00136903|Drug|Prochymal® - 2 Million cells/kg|2 million hMSCs/kg actual body weight, IV on study Days 1 and 4
75894777|NCT00136903|Drug|Prochymal®- 8 Million cells/kg|8 million hMSCs/kg actual body weight IV on study Days 1 and 4
75744960|NCT04523688|Drug|Temozolomide|Adjuvant temozolomide assumed orally from day 1 to 5 (start on week 5). Dosage: 150mg/m2/day for the first cycle and 200 mg/m2/day for subsequent cycles (q28).
75744961|NCT00862667|Drug|Treatment A|PF-00241939 300ug using Inhaler A
75744962|NCT00862667|Drug|Treatment B|PF-00241939 300ug using Inhaler B
76063157|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
76063158|NCT01457404|Behavioral|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
75449848|NCT01699529|Device|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
75449849|NCT01699555|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
75449850|NCT01699555|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
75449851|NCT01699568|Device|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
75449852|NCT01699581|Dietary Supplement|Nestle Impact Advanced Recovery|dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
75449853|NCT01699594|Drug|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
75449854|NCT01699594|Drug|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
75600991|NCT05927051|Other|Stabilization exercises|Core stability exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
75600992|NCT05927051|Other|McKenzie exercises|McKenzie exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
75894778|NCT00136903|Drug|Methylprednisolone|Methylprednisolone 2 mg/kg administered intravenously.
75894779|NCT00136903|Drug|Prednisone|Prednisone 2.5 mg/kg administered orally.
76063159|NCT01457404|Behavioral|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
75894780|NCT00136903|Drug|Cyclosporine|Administered as prescribed by the caregiver.
75600993|NCT05927051|Other|Home exercises|Home exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks
75449855|NCT01699620|Procedure|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
75600994|NCT05927038|Other|Caffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of caffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
75600995|NCT05927038|Other|Decaffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of decaffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
75600996|NCT05927025|Procedure|Hand K-files|It is used for cleaning and shaping root canals.
75616561|NCT02844244|Behavioral|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
75744963|NCT00862667|Drug|Treatment C|PF-00241939 300ug using Inhaler C
75744964|NCT02544347|Other|gingival crevicular fluid|gingival crevicular fluid was collected
75744965|NCT02544347|Other|non-surgical periodontal treatment|scaling and root planing were performed
75744966|NCT04041713|Drug|Rett-T|antioxidant cocktail
75449856|NCT01699646|Device|Neoventa S 21 ST-ANalysis of fetal heart|"Application of gold-trace scalp electrode"
75449857|NCT01699646|Procedure|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
75744967|NCT04041713|Other|Placebo|Placebo
76063160|NCT01457482|Other|Art Therapy and therapeutic conversations|Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
76063161|NCT01457482|Other|Therapeutic conversations|Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
75744968|NCT00859625|Procedure|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
75744969|NCT00511836|Drug|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
76063162|NCT01457560|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
76063163|NCT01457560|Biological|OPV|One dose administered orally
75449858|NCT01699659|Other|allergen immunotherapy|allergy shots
75449859|NCT01699672|Other|Group information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
75449860|NCT01699711|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
75449861|NCT01699724|Drug|JZoloft|50 mg tablet on Day 1 of each period
75449862|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
75744970|NCT00511836|Drug|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
75894781|NCT00136903|Drug|Tacrolimus|Administered as prescribed by the caregiver.
75894782|NCT00136903|Drug|Mycophenolate Mofetil|Administered as prescribed by the caregiver.
75894783|NCT04917029|Drug|Bupivacaine hydrochloride perineurally|Arm 1; Bupivacaine hydrochloride 40 ml 0.25% perineurally in FICB
75894784|NCT04917029|Drug|Dexmedetmidine infusion|Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h
75894785|NCT04917029|Drug|Dexmedetomidine perineurally|Arm 2:Dexmedetomidine perineurally in FICB 80µg
75894786|NCT04189510|Device|Artificial Pancreas|The Artificial Pancreas will delivery insulin in place of Multiple Daily Injections after a kidney transplant.
75894787|NCT04189510|Other|Multiple Daily Injections|Multiple Daily Injections as standard of care post kidney transplant.
75894788|NCT04098952|Other|Group 1: Manual Therapy|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
75894789|NCT04098952|Other|Group 2: Interferential massage plus Manual Therapy|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
75894790|NCT03654131|Device|MWA|Patients are allocated to one of the two arms in a 1:1 randomization
76063164|NCT04758442|Other|Additional blood sample|Included subjects will provided three blood samples to follow vancomycin concentration
76063165|NCT01457638|Procedure|Inferior turbinate surgery|During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
76063166|NCT01457638|Procedure|No iInferior turbinate surgery|During rhinoseptoplasty no intervention is done in inferior turbinates
76063167|NCT01457716|Drug|Budesonide|Single inhalation
76063168|NCT01457716|Drug|Formoterol|Single inhalation
75600997|NCT05926986|Other|Exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
75600998|NCT05926986|Other|control|No additional treatment will be practiced to the control group.
75600999|NCT05926973|Other|Enhanced cardiac arrest bundle|"Delivering shocks with the LUCAS mechanical CPR device running~After 5 shocks have been delivered placing new pads in the Anterior Posterior (AP) position~Delivering shocks using the TVAA Tempus Pro defibrillator rather than the Ambulance Service defibrillator."
75601000|NCT05926934|Device|Experimental: Single strand β-Ti fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
75894791|NCT03654131|Radiation|SBRT|Patients are allocated to one of the two arms in a 1:1 randomization
75601001|NCT05926934|Device|Experimental: SS fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
75894792|NCT00500084|Drug|Liprotamase|Administered orally
75894793|NCT05115214|Device|SpherePVI™ Catheter|Affera SpherePVI™ Multi-Ablation System
75894794|NCT05761535|Radiation|Magnetic Resonance (MR) and positron emission tomograph (PET) imaging analyses|"Regarding the neurological MR protocol, the following may be acquired:~3D T1 and T2 high-resolution sequences, acquired in a specific plane and Multiplanar reformation (MPR) reconstructed in the remaining orthogonal planes, for morphological assessment of the different structures under examination;~diffusion sequences for the evaluation of the connection between different areas within a specific organ;~perfusion sequences (ASL, arterial spin labeling) for the evaluation of perfusion without ev mdc administration;~susceptibility sequences for noninvasive assessment of vasculature and deposits of iron."
76063169|NCT01457716|Device|Easyhaler|Inhaler device
76063170|NCT01457716|Device|Turbohaler Forte|Inhaler device
76063171|NCT01457872|Behavioral|Strength-based case management|Strength-based case management
76063172|NCT01457872|Behavioral|Control condition - referral only|Referral only
76072148|NCT03085173|Biological|EGFRt/19-28z/4-1BBL CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10^5, 3 x 10^5, 1 x 10^6, and 3 x 10^6 CAR T cells/kg.
75894795|NCT03471520|Behavioral|Earplugs and eye masks|Patients in this study will be given earplugs and eye masks to be worn during sleep
75894796|NCT03060902|Behavioral|Dialectical Behavior Therapy Skills|DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
75894797|NCT03632759|Drug|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
76063173|NCT04391218|Other|Multidisciplinary Approach Group|Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
76063174|NCT04391296|Procedure|Arm I (Prepectoral), Arm II (Subpectoral)|"Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia."
76063175|NCT04346602|Other|all treatment about COVID-2019|All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
76063176|NCT01458028|Drug|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
76063177|NCT01458028|Drug|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
76063178|NCT01458262|Other|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
75449863|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
75601002|NCT05926934|Device|Experimental: Twisted fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
75894798|NCT03632759|Drug|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
75616562|NCT02841982|Procedure|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
75894799|NCT03047083|Other|Treatment patterns among AML patients|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
75894800|NCT03047083|Other|AML-related healthcare resources|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
75894801|NCT00498914|Drug|YM155|Continuous IV infusion
75894802|NCT05115058|Other|relex Smile module|
75894803|NCT02953093|Drug|Acarbose|see arm description
75894804|NCT02953093|Other|Placebo|See arm description
75449864|NCT01699776|Drug|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
75449865|NCT01699776|Drug|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
75449866|NCT01699802|Other|Inhaled anaesthetic agent|
75449867|NCT01699828|Drug|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
75894805|NCT04518280|Drug|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
75894806|NCT04518280|Drug|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
75894807|NCT04518280|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
75894808|NCT04518280|Radiation|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
75894809|NCT00498836|Drug|CP-4055|CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion
75894810|NCT00498836|Drug|Sorafenib (Nexavar)|Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing
75894811|NCT02283866|Drug|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
75894812|NCT02283866|Drug|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
75449868|NCT01699828|Drug|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
75449869|NCT01699854|Drug|capsaicin patch (qutenza)|
75449870|NCT01699854|Drug|Placebo|
75449871|NCT01699893|Other|unique arm|blood, nasal swab, skin biopsy, stool samples
75449872|NCT01699906|Other|Diet regimen to induce weight loss|Diet regimen to induce weight loss
75449873|NCT01699919|Drug|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
75894813|NCT03502187|Behavioral|Progressive Exercise Plan|The goal of PEP is to reduce back pain, disability, and improve trunk flexibility, strength and endurance through controlled, gradual, progressive back exercises. PEP teaches muscle strengthening exercises and self-management strategies to promote back fitness. PEP sessions provide a standardized self-management framework for performing the exercises at home. PEP is performed every other day/week for about ~1 hour over a period of 9 weeks. PEP consists of 3 sequential phases with each phase lasting 3 weeks. Exercises become progressively more difficult and intense, focusing on back stretching and strengthening that progressively load and unload the lumbar spine by means of flexion/extension exercises. The PEP group will perform 31 exercise sessions for 60 minutes on alternating days.
75894814|NCT03502187|Device|NeuromuscularElectricalStimulation(NMES)|The NMES treatment group will receive a portable battery-operated device, Recovery Back (Neurotech®, Minnetonka, MN) with a 2-garment site-specific system: back & abdomen. NMES muscle contractions will be elicited by an electrical impulse generated by the Recovery Back system. The device delivers a pre-set program of NMES using a symmetrical biphasic square pulse waveform. (Moore SR, Shurman J, 1997) The garments are light-weight, breathable fabric that wraps around the waist with precise placements for the reusable electrodes. The controller uses a rechargeable battery with charger supplied. The NMES protocol consists of 30-minutes of NMES stimulation alternating between the abdominal and lumbar site over 9-weeks (one day Back training, next day Abdominal training).
75894815|NCT03502187|Behavioral|Primary Care Management (PCM)|All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
75894816|NCT03058705|Drug|Hexaminolevulinate HCL|Intravesical instillation of 100 mg hexaminolevulinate HCL will be performed via foley catheter at the initiation of the procedure. Although NIRF is more sensitive than bluelight cystoscopy, the current FDA approved dose will be used. Hexaminolevulinate has a favorable safety profile at this dose.
75894817|NCT03058705|Device|Near Infrared Fluorescence (NIRF)|NIRF is a highly sensitive multi-spectral imaging modality that speeds the detection of bladder cancer fluorescence after infusion of hexaminolevinulate.
75894818|NCT04517110|Drug|Pregabalin 300 mg|Pregabalin 300 mg, capsule
75894819|NCT04517110|Drug|Pregabalin 75 mg|Pregabalin 75 mg twice daily, capsules
75894820|NCT04517110|Drug|Pregabalin 300 mg Placebo|Placebo, matching Pregabalin 300 mg capsule
75894821|NCT04517110|Drug|Pregabalin 75 mg Placebo|Placebo, matching Pregabalin 75 mg capsules
75894822|NCT04517110|Other|Usual Care|Usual Care
75449874|NCT01699932|Drug|Glimepiride+metformin (Amaryl M®) - HOE4900|"Pharmaceutical form:tablet~Route of administration: oral"
75616563|NCT02841982|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
75616564|NCT02841982|Device|PAJUNK StimuLong|
75894823|NCT00498212|Biological|1018 ISS-HBsAg-Single|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
75894824|NCT00498212|Biological|1018 ISS-HBsAg-Double|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
75894825|NCT02798263|Other|Kinesiotherapy|Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
75449875|NCT01699945|Other|This is an observational study being conducted as a substudy of antoher trial.|
75449876|NCT01699958|Behavioral|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
75449877|NCT01699971|Procedure|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
75449878|NCT01699971|Procedure|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
75449879|NCT01699971|Procedure|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
75894826|NCT02798263|Other|Acupuncture|30 minutes of classical acupuncture using predefined points.
75894827|NCT02798263|Other|Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
75894828|NCT02280980|Other|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
75894829|NCT04882553|Procedure|Diaphragmatic echography|Echography of the diaphragm at the zone of apposition. End-inspiratory and/or end-expiratory thickness of the diaphragm will be measured in M-mode.
75894830|NCT04882553|Procedure|Measurement of esophageal pressure|Pressure will be measured in the lower third of the esophagus using an esophageal balloon and pressure transducer.
75894831|NCT04882553|Diagnostic Test|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
75894832|NCT02281058|Drug|Abatacept|self-injected subcutaneous biologic medication
75894833|NCT05760911|Behavioral|Outdoor activities motivation with smartwatches|Wearing a smartwatch and receiving outdoor activity reminders and encouragement through a mini-program. The required outdoor time is at least 2 hours from Monday to Friday, and more than 2 hours on weekends.
75894834|NCT01568723|Genetic|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
75894835|NCT02784262|Drug|botox injection Multiguide|botox injection under CT/MR navigation and with the navigation tool MultiGuide
75894836|NCT05205317|Drug|Metformin Hydrochloride Sustained-release Tablets|drug
75894837|NCT05205317|Procedure|Vaginal repair|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
75894838|NCT04087330|Other|Group 1 Experimental group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.~Whole body vibration."
75894839|NCT04087330|Other|Group 2 Control group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars."
75894840|NCT04471298|Drug|Qishenyiqi dripping pills, 6 bags|28 consecutive days
75894841|NCT04471298|Drug|Qishenyiqi dripping pills, 9 bags|28 consecutive days
75449880|NCT01699997|Drug|Oxytocin|Intranasal spray with 40 IU of OXT
75449881|NCT01699997|Drug|Placebo|Intranasal spray with placebo solution
75463233|NCT05855655|Behavioral|Mindfulness-Based Queer Resilience (MBQR)|"This work aims to develop an internet-delivered MBI to address minority stress and its negative HIV-related health consequences experienced by young men who have sex with men (YMSM). This aim will examine the feasibility and acceptability of the internet-delivered mindfulness-based intervention (iMBI), called Mindfulness-based Queer Resilience (MBQR), for HIV prevention. The study will enroll and randomize a sample of 60 distressed, high-risk YMSM into one of two groups: MBQR intervention (n=30) or active control condition (n=30)."
75601003|NCT05926908|Behavioral|A Mobilisation Initiative|The Mobilisation Initiative consists of physiotherapists assisting nursing staff in mobilising patients to sit in a chair for breakfast and lunch. This intervention follows the interventions of focus group interviews, formal education, observations of patients and the environment, and awareness of mobilisation survey
75894842|NCT04471298|Drug|Qishenyiqi dripping pills, 12 bags|28 consecutive days
75894843|NCT04471298|Drug|Qishenyiqi dripping pills placebo, 6 bags|28 consecutive days
75463234|NCT05855629|Dietary Supplement|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|Lactobacillus Rhamnosus 1,5 х 10*9, Inulin 25mg, D-chiro-inositol 250mg
75463235|NCT05855629|Drug|Topical Adapalene, Benzoyl Peroxide Gel|Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
75601004|NCT05926908|Behavioral|Focus Group Interviews|Focus group interviews using a semi-structured interview guide are conducted with health care professionals at the wards to explore the acceptability and demand for the contents of the Mobilisation Initiative, including the identification of facilitators and barriers to mobilisation
75601005|NCT05926908|Behavioral|Formal Education|Formal education for all nursing staff employed at the two wards includes information on the consequences of immobilisation, with the purpose of enhancing confidence, competencies, and awareness of mobilisation
75894844|NCT04471298|Drug|Qishenyiqi dripping pills placebo, 9 bags|28 consecutive days
75894845|NCT04471298|Drug|Qishenyiqi dripping pills placebo, 12 bags|28 consecutive days
75894846|NCT05205239|Diagnostic Test|Endoluminal image analysis by capsule endoscopy|Studies will be performed after discontinuation of medications that could affect gastrointestinal motility for at least 48 hours and overnight fast. Endoluminal images were obtained with the Pillcam capsule (Pillcam SB3 video capsule; Medtronic). Images will be obtained at a fixed 2 per second rate and recorded for a total of 8 hours with the subjects lying comfortably on a hospital bed and the trunk raised 30° above horizontal. Forty-five minutes after gastric exit, participants will be instructed to ingest a liquid meal (Ensure HN; Abbott; 300 mL,1 Kcal/mL). Endoluminal images of the small bowel will be analyzed with a computer program specifically developed in our laboratory for the evaluation of intestinal motility. This previously validated program is based on computer vision techniques, which allow the detection and quantification of contractile and non-contractile patterns characterizing small bowel motility.
75894847|NCT00691964|Biological|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
75894848|NCT00691964|Biological|etanercept|SQ injection 50 mg BIW
75894849|NCT00691964|Drug|placebo|SQ placebo injections for ABT-874 and etanercept
75894850|NCT03474887|Other|Physical Consultation|Regular physician consultation at the primary care clinic.
75744971|NCT04041245|Device|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
75744972|NCT00859703|Drug|Risedronate|35mg oral risedronate once per week for 24 months
75744973|NCT00859703|Drug|Placebo|Placebo 35 mg once a week for 24 months
75744974|NCT03998436|Drug|Esmolol Hydrochloride|Galnobax-14% gel application along with Standard of Care
75894851|NCT03474887|Other|Online Consultation|An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
75894852|NCT05761457|Other|Cryopreserved autologous platelet transfusion|Autologous PLTs were collected and transfused as an individualized treatment approach, when the platelet is less than 20*10E9/L or severe bleeding occurred.
75744975|NCT03998436|Other|Only Standard of Care|Only Standard of Care treatment
75894853|NCT04522180|Drug|IONIS-GHR-LRx|IONIS-GHR-LRx will be administered by SC injection.
75894854|NCT02281214|Other|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
76072149|NCT03081390|Other|Mixed meal tolerance testing|An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
75601006|NCT05926908|Behavioral|Self-reported Level of Mobilisation|Patient's self-reported mealtime mobilisation level reported through interview-based surveys, including structured follow-up questions
75744976|NCT03998436|Other|Vehicle Gel|Vehicle gel application along with Standard of Care
75894855|NCT04520854|Other|Telehealth Protocol|"The first live-video session will orient participants to the features of the software, discuss the checklist to minimize environmental distractions, gauge how participants are managing their symptoms (pain, swelling) and provide non-pharmacological alternatives to supplement their current treatment strategies.~The second live-video session will be used re-examine how the participant is managing their symptoms (pain, swelling) and re-emphasize non-pharmacological alternatives.~The remaining live-video sessions will be focused on giving participants home-based therapeutic exercises. The therapeutic exercises will target the four main areas important to ankle sprain recovery: 1) range of motion; 2) balance; 3) gait; and 4) strength. All of the therapeutic exercises are based on previously published criteria for the rehabilitation of an LAS. The progression will start with single-plane, non-weight bearing or low-force activities and will advance at the same rate."
75894856|NCT04520854|Other|Usual Care|The usual care group will be instructed to follow their treating physicians' orders. Participants will not receive instructions on how to self-manage symptoms nor a home-based exercise program.
75463236|NCT05855616|Device|"Group chlorhexidine dressing"|Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.
75744977|NCT00855101|Drug|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
75894857|NCT05756075|Behavioral|Aerobic exercise training|Participants will follow a personalized aerobic exercise training program twice a week at the physiotherapist. The intensity of the program is based on the results of the 6MWT according to the most recent guidelines for physiotherapy for PD and COPD
75894858|NCT02281292|Biological|LKA651 ophthalmic solution|
75894859|NCT02281292|Biological|Ranibizumab ophthalmic solution|
75894860|NCT02281292|Biological|Sham injection|Mock injection administered as an empty hub without needle
75601007|NCT05926908|Behavioral|Observations of Patients and the Environment|During breakfast and lunch, the mobilisation status of all patients in the wards is observed using an observation checklist
75894861|NCT04044742|Drug|Resiniferatoxin|Receiving Resiniferatoxin injection
75601008|NCT05926908|Behavioral|Awareness of Mobilisation Survey|To assess the nursing staff's awareness of and confidence in the mobilisation of the patients, a short survey on mobilisation awareness is distributed to the nursing staff at both wards
75616565|NCT02841982|Drug|single dose ropivacaine|"0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~given immediately after the correct position of the tip of the needle has been verified."
75744978|NCT00573755|Drug|anastrozole|given orally
75744979|NCT00573755|Drug|exemestane|given orally
75744980|NCT00573755|Drug|letrozole|given orally
75744981|NCT00573755|Drug|sorafenib tosylate|given orally
75744982|NCT00573755|Other|placebo|given orally
75894862|NCT04044742|Drug|Placebo|Receiving Placebo injection
75894863|NCT00690716|Drug|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
75894864|NCT00690716|Drug|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
75894865|NCT03942484|Device|rPMS device|Pelvic floor muscle contractions will be induced by the device.
75463237|NCT05855616|Other|"Group solution"|Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
75463238|NCT05855590|Drug|Tranexamic acid|10mg/kg intravenous single dose
75463239|NCT05855590|Other|0.9% isotonic saline solution|100 ml intravenous single dose
75894866|NCT05205083|Biological|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (BBIBP-CorV), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
75894867|NCT02998671|Biological|CJM112|
75744983|NCT02545361|Drug|KAHR-102|"KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days)."
75744984|NCT02544191|Drug|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
75894868|NCT02998671|Other|Placebo|
75894869|NCT00688766|Drug|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
75894870|NCT00688766|Drug|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
75894871|NCT00688766|Other|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
75894872|NCT03390725|Behavioral|A Healthy School Start Plus intervention|Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting
75894873|NCT03723772|Drug|Insulin icodec|Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks
75894874|NCT03723772|Drug|IGlar U100|Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
75894875|NCT00495014|Drug|GSK376501|
75894876|NCT00495014|Drug|Placebo|
75894877|NCT05204771|Other|Ultrasound exam|Ultrasound exam
75894878|NCT05204771|Other|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
75894879|NCT05204771|Other|Pediatric Follow up|Pediatric Follow up
75894880|NCT05112328|Drug|Exocrine Pancreatic Enzyme|Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
75894881|NCT05112328|Drug|Placebo|Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
75894882|NCT00684944|Drug|TRx0014|Gelatin capsule, tid
75894883|NCT05112250|Device|Percutaneous Coronary Intervention|Intravascular lithotripsy (IVL)
75894884|NCT04515537|Dietary Supplement|Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),|Patient use 2 capsules 3 time a day by oral.
75894885|NCT04515537|Procedure|Infiltrtion of SVf|After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF
76063179|NCT01458496|Behavioral|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
76063180|NCT01458652|Drug|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
75744985|NCT00859859|Device|Vagus Nerve Stimulation|"Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.~Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
75744986|NCT00524316|Drug|doxorubicin hydrochloride|Transarterial chemoembolization
75744987|NCT00524316|Drug|sunitinib malate|Given Orally
75744988|NCT00524316|Other|laboratory biomarker analysis|Correlative Study
75744989|NCT00524316|Procedure|hepatic artery embolization|Surgical procedure
75744990|NCT00524316|Procedure|quality-of-life assessment|Correlative Study
75744991|NCT00860093|Other|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
75744992|NCT00860093|Drug|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
75744993|NCT00862901|Device|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
75744994|NCT00855257|Drug|Acid Nicotinique|
75744995|NCT00855257|Drug|Placebo|
75744996|NCT03861936|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.
75894886|NCT00492596|Device|AttenueX IntraVesical System|Insertion of the Solace AttenueX Intravesical System on Day 0
75894887|NCT00492596|Procedure|Sham Procedure|Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
75894888|NCT03663699|Behavioral|Exergaming|free access to the exergaming platform PlayPulse for 24 weeks
75894889|NCT04202146|Behavioral|Contingency Management + Motivational Interviewing|Seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling on cannabis use and relapse.
75463240|NCT05855564|Behavioral|mindfulness matters|Classroom program will be provided to primary one students in eight primary schools and they will receive an 8 session mindfulness matters program, developed by Eline Snel, delivered by their teachers. Each session lasts for 30 minutes. The program includes mindfulness exercises, psychoeducation, discussion and sharing activities. For students with special needs, same programs will be delivered by teachers or social workers in small groups and each groups has 4 to 7 students. Program content is consistent with the classroom program.
75601009|NCT05926895|Drug|Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space|Treatment method used in the treatment of subacromial impingement syndrome
75601010|NCT05926882|Drug|Apremilast 30mg|Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
75601011|NCT05926869|Drug|Clindamycin and Dapsone gel for 03 months|Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects
75616566|NCT02841982|Drug|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5~2mg, lock time: 10min, 1h limitation: 6~8mg
75616567|NCT02841826|Other|IUD|
75616568|NCT02841826|Other|Uterine sounding|
75894890|NCT02660827|Device|Insulin Pump|Closed Loop Algorithm
76063181|NCT01458886|Drug|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
76063182|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
76063183|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
76063184|NCT01458886|Drug|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
75894891|NCT03664557|Device|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
75894892|NCT00491738|Drug|bevacizumab|Intravenous repeating dose
75894893|NCT00491738|Drug|sunitinib|Oral repeating dose
75894894|NCT00491738|Drug|placebo|Intravenous repeating dose
75894895|NCT03664323|Biological|Evaluate the improvement in response from the end of anti-PD-1 monotherapy|Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).
75894896|NCT05114200|Procedure|Erector spinae plane block|"Patients will be placed in prone position. Mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. The application area will be visualized with General Electrics (GE) Logiq e Ultrasound device using 10-12 MHz linear probe or convex probe. Transverse process and erector spinae muscles will be visualised at the target vertebral level. Following local anesthesia (1-2 cc 2% lidocaine) application to the insertion site, a 20 gauge spinal needle will be inserted using the in-plane technique. The needle will be advanced up to the transverse process under ultrasound guidance. After confirming needle position with hydrodissection, 40 mg triamcinolone, 10 cc 0,5% bupivacaine, 10 cc radiopaque contrast agent solution will be injected. Imaging will performed in AP and lateral positions with fluoroscopy immediately and 30 minutes after the injection to evaluate intectate spread."
75894897|NCT03414489|Drug|ABC294640|
76063185|NCT02880982|Dietary Supplement|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
76063186|NCT02880982|Other|Placebo|Weekly oral placebo softgel capsule
76063187|NCT01458964|Drug|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
75463241|NCT05855551|Other|Base cash transfer|Program beneficiaries will receive a monthly transfer of 800 BDT. A government-to-person (G2P) payment system will be used, which will transfer cash on a monthly basis. Under this new system, beneficiaries will select one of the following payment channels based on convenience: mobile financial services or through a bank transfer (which women in remote areas could access through agent banking). Each month, women will receive a text message from the government informing her that the money has been credited to her account.
75616569|NCT02841826|Radiation|Transvaginal ultrasound|
75616570|NCT00633178|Behavioral|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
75616571|NCT00633178|Behavioral|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
75894898|NCT02281370|Drug|Eltrombopag|White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration
75894899|NCT02281370|Drug|Cyclosporine|Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
75894900|NCT05114122|Procedure|Vonlay Ceramic restorations|vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
75894901|NCT05114122|Procedure|Onlay Ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
75894902|NCT00680342|Drug|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
75894903|NCT00680342|Drug|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
76063188|NCT01459120|Other|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
76063189|NCT01459120|Other|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
75894904|NCT00680342|Other|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
75894905|NCT03664167|Dietary Supplement|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
76063190|NCT01459198|Biological|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10^5 or 10^6 plaque-forming units (PFU), depending on study arm.
76063191|NCT01459198|Biological|Placebo vaccine|Given intranasally once at a baseline study visit
75601012|NCT05926843|Procedure|Spinal cord stimulation surgery (device) and motor rehabilitation|The first part of the study will involve a preoperative evaluation. Participants' clinical history, neurological, neurophysiological and advanced brain/spine MRI examination will be assessed (Part 1). Subsequently, participants will undergo spinal cord stimulation surgery which involves the implantation of a medical device (Part 2). After the surgery, the research participants will be hospitalized at the Neurosurgery Unit (10 days) to monitor the incision site (Part 3). Thereafter, the patients will be moved (for at least 6 weeks) to the Rehabilitation Unit in order to identify appropriate stimulation parameters for inducing stepping and standing and for starting training. The combination of epidural stimulation with manual step/stand training will be thus evaluated (Part 4). Patients will be finally assessed by clinical evaluation, advanced MRI and neurophysiological examination to study the brain, spine and peripheral functions after six months (Part 5).
75601013|NCT05926817|Device|2D-video glasses|Patients in the placebo group watched a 15-minute relaxation-based movie on 2D-video glasses along with receiving conventional analgesia.
75601014|NCT05926817|Device|3D-VR headsets|Patients in the VR group had to participate in 15-minute interactive games wearing 3D-VR headsets along with receiving conventional analgesia.
75744997|NCT03861936|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
75744998|NCT02544269|Procedure|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
75894906|NCT05114044|Other|Core stability training|The core stability training were performed 5 days a week for 15 min over a period of 3 weeks. The conventional therapy were performed 5 days a week for 30 min (remaining time of each session) over a period of 3 weeks. Duration of each session was 45 min.
75894907|NCT05114044|Other|Conventional therapy|The conventional therapy were performed 5 days a week for 45 min over a period of 3 weeks. Duration of each session was 45 min
75894908|NCT00617552|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
75601015|NCT05926791|Other|Cosmetic product|The educated group receives the cosmetic product SPF50+ according to the randomization list established at V1 and returns the products at V2
75601016|NCT05926778|Other|Liver allograft fibrosis|Observational studies without intervention
75601017|NCT05926752|Device|SoLá therapy|SoLá therapy is a photobiomodulation device that works by stimulating mitochondria, soothing tense muscles, and promotes healing.
75601018|NCT05926752|Other|Pelvic floor physical therapy|Physical therapy is manual myofascial release, muscles stretches, and exercises designed to help myofascial pelvic pain
75744999|NCT02544269|Procedure|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
75745000|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Low Dose|Single or two-dose intramuscular injection.
75745001|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Medium Dose|Single or two-dose intramuscular injection.
75745002|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A High Dose|Single or two-dose intramuscular injection.
75745003|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Modified|Single or two-dose intramuscular injection.
75894909|NCT00617552|Drug|TZP-101|20 micrograms/kg IV 2ml/minute for 30 minutes
75894910|NCT00617552|Drug|TZP-101|40 micrograms/kg IV 2 ml/minute for 30 minutes
75894911|NCT00617552|Drug|TZP-101|80 micrograms/kg IV 2ml/minute for 30 minutes
75894912|NCT00617552|Drug|TZP-101|160 micrograms/kg IV 2ml/minute over 30 minutes
75745004|NCT00434577|Biological|Placebo|Single intramuscular injection
75894913|NCT00617552|Drug|TZP-101|320 micrograms/kg IV 2ml/minute for 30 minutes
75745005|NCT04042181|Dietary Supplement|Placebo|standard food grade excipients
75745006|NCT04042181|Dietary Supplement|Bifidobacterium longum|Target dose of 1x10^10 CFU/day, plus standard food grade excipients
75894914|NCT00617552|Drug|TZP-101|480 micrograms/kg IV 2ml/minute over 30 minutes
75894915|NCT00617552|Drug|TZP-101|600 micrograms/kg IV 2ml/minute for 30 minutes
75894916|NCT05113888|Drug|Qizhi weitong granules(High）|take orally before meals, 1 bag each time, 3 times a day.
75894917|NCT05113888|Drug|Qizhi weitong granules(Low）|take orally before meals, 1 bag each time, 3 times a day.
75894918|NCT05113888|Drug|Placebo|take orally before meals, 1 bag each time, 3 times a day.
75894919|NCT05113654|Diagnostic Test|Sleep study|Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
75745007|NCT00865085|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
75745008|NCT00865085|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
75745009|NCT00860483|Other|observational|PET Scan
76063192|NCT01459276|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
75463242|NCT05855551|Behavioral|Behavior change communication (BCC)|"The BCC strategy has two different components:~Monthly courtyard meetings: Courtyard sessions (12 to 15 women) will be organized at a place no more than 15 to 20 minutes walking distance from the beneficiary's home. Family members (husband, mother-in-law, …) are invited to join the meeting. Sessions are part of a continuous 4-session cycle. Each session will lasts 1.5 hours and will use different didactic methods. Topics include pregnancy nutrition and care, breastfeeding, importance of different micronutrients, and nutrition and care during lactation. The importance of a healthy diet during pregnancy is repeated in each session. Pregnant women receive a take-home poster that summarizes how to eat a healthy diet during pregnancy.~Home visits: Visits will cover the content of any sessions missed by pregnant women and will reinforce the messages regarding maternal diet on the take-home poster."
75894920|NCT04057365|Drug|Nivolumab|Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
75601019|NCT05926739|Device|Electrical stimulation and biofeedback group|12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.
75601020|NCT05926726|Biological|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM214 . During JWATM214 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM214 by intravenous (IV) injection.
75601021|NCT05926713|Dietary Supplement|Sarcojoint®|All participants are administered Sarcojoint® containing leucinine 1 g, arginine 1.5 g, Vitamin D 7.5μg, chondroitin 400 mg, calcium 300 mg, and glucosamine 700 mg per package, and take 1 package twice a day.
75601022|NCT05926713|Behavioral|supervised exercise|All participants are required to walk 6500 steps every day for 12 weeks, and the data are recorded by Xiaomi-smart-band.
75894921|NCT04057365|Drug|DKN-01|DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
75894922|NCT00616148|Drug|YKP3089|Oral dosage form
75601023|NCT05926700|Drug|Candonilimab|The patients were treated with Candonilimab + anlotinib, with Cadonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was orally administered for 2 weeks and stopped for a week, with 21 days as a course of treatment.
75894923|NCT00616148|Drug|Placebo|
75601024|NCT05926596|Device|Wearable Robotic Exoskeleton|"Participant preparation, placement of wearable sensors and monitoring, and wearable device fitting.~Lower-limb joint rotations and leg stretching protocol (40-60 minutes). The wearable exoskeleton and its control algorithm are evaluated to rotate leg joints and apply stretching similarly to the forces applied by nurses and caregivers when providing manual forces. Joint rotation and limb stretching is conducted while participants sit down (e.g., in a wheelchair, on a chair, on one side of a bed, or on a clinical mat) or lay down on a bed/mat. The protocol involves ankle plantarflexion and dorsiflexion, knee extension, hip flexion with the knee flexed, and toe flexion and extension (bilaterally) assisted by the exoskeleton, and each movement is repeated at a low-to-moderate rate of 10-30 cycles/minute.~Treadmilll and Overground Walking (60-90 minutes including rest periods)~Cool down (5-10 minutes)"
75894924|NCT02283944|Device|TMS|Pulsed non-invasive brain stimulation using electromagnets
76025102|NCT03274505|Other|Questionnaires|"Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~Clinical evaluation~Routine neuropsychological evaluation (for stroke patients)~Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) > 10)"
75601025|NCT05926531|Device|CBTI online programe|20 MIN VR RELAX PROGRAME
76025103|NCT02690701|Drug|Secukinumab 300 mg|"Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
75894925|NCT03622827|Combination Product|Chemoradiotherapy+ Endostar|"Chemoradiotherapy with Endostar：~Chemoradiotherapy: pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy. The external beam radiotherapy should be completed within 6 weeks.~Concurrent chemotherapy is consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks.~Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks."
75601026|NCT05926518|Procedure|blood sampling|Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.
75601027|NCT05926492|Drug|Surufatinib plus chemotherapy|"Sururfatinib: (1) for patients aged > 21 years old and ≤70 years old, sorafenib 200 mg, qd, oral, continuous administration; (2) For patients aged ≥2 years and ≤21 years, starting from the low dose of patient BSA (body surface area), Stevenson's formula developed according to the Chinese population was used: BSA = 0.0061H+0.0128W-0.1529 (H: BSA = 0.0061H+0.0128W-0.1529). Height /cm; W: body weight /kg); Chemotherapy : 1) Doxorubicin 60 mg/m2, or liposome doxorubicin 45mg/ m2, day 17; 2) Cisplatin: 100 mg/m2, day 15; 3) Ifosfamide; 2.5g/m2, day 8-12;~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
75894926|NCT00486512|Drug|0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
75894927|NCT00486512|Drug|75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
75894928|NCT00486512|Drug|placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
75894929|NCT00486512|Drug|placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
76063193|NCT01459276|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
75894930|NCT00486512|Procedure|Colonoscopy|
75894931|NCT04057989|Drug|ketamine|
75745010|NCT00434421|Drug|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters [mL], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose [0.42 mL, 1:10 wt/vol] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
75894932|NCT04093882|Diagnostic Test|Contrast agent enhanced MRI using Gadovist|By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
75601028|NCT05926492|Drug|Chemotherapy|"1) High-dose Dethotrexate: 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
75745011|NCT00434421|Drug|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
75894933|NCT03687580|Device|B-Cure Laser Pro|The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
75894934|NCT03687580|Device|Sham laser|The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
75894935|NCT00486200|Drug|ASP2151|Oral administration.
75894936|NCT00486200|Drug|valacyclovir|Oral administration of active comparator.
76063194|NCT02490904|Drug|Eplerenone|Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
76063195|NCT02490904|Drug|Placebo|Double-blinded Placebo administered for 4 days at 25mg every 12 hours
75894937|NCT00486200|Drug|Placebo|Oral administration of placebo.
75894938|NCT02284022|Device|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
76063196|NCT01459432|Other|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
76063197|NCT04390984|Drug|Apatinib Mesylate, Gefitinib|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
76063198|NCT02878408|Genetic|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
75894939|NCT04079062|Biological|ONO-4685|Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
75894940|NCT04079062|Biological|Placebo|Placebo will be administered by intravenous continuous infusion at the designated speed.
75894941|NCT04079062|Biological|KLH|KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
75894942|NCT04079062|Biological|KLH, ONO-4685|Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
75894943|NCT04079062|Biological|KLH, placebo|Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
75894944|NCT02936050|Procedure|Diagnostic ultrasound|All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
75894945|NCT00481520|Drug|SAM-531|
75894946|NCT00481520|Other|placebo|
75894947|NCT05206526|Behavioral|Dragon Boat|12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
75894948|NCT05206526|Behavioral|Home-based Exercise|12 weeks of home-based training composed by 10 exercises.
75894949|NCT05113420|Drug|Detralex|Diosmin+ Hesperidin
75601029|NCT05926414|Drug|Enavogliflozin|treated with Envlo tab. 0.3mg
75894950|NCT05113420|Drug|Troxevasin|Troxerutin
75894951|NCT00479492|Drug|CP-866,087|1 mg of CP-866,087, administered QD for 84 days
75894952|NCT00479492|Drug|CP-866,087|5 mg of CP-866,087, administered QD for 84 days
75894953|NCT00479492|Drug|CP-866,087|10 mg of CP-866,087, administered QD for 84 days
75894954|NCT00479492|Drug|placebo|placebo administered QD for 84 days
75894955|NCT05112796|Procedure|Class I extractions sites received immediate implants using the Vestibular Socket Therapy|A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision
75601030|NCT05926375|Dietary Supplement|HINEX Jelly ( jelly high protein supplement)|In self-controlled phase,which intake 400~500 kcal breakfast, or in supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg BCAA per serving) and 100~200 kcal food at breakfast per day, for 8 weeks.
75894956|NCT05112796|Procedure|class I extractions sites received immediate implants using the Partial Extraction Therapy|the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.
75745012|NCT00421707|Drug|GW876008|
75745013|NCT00421707|Other|Placebo|
75745014|NCT00796068|Drug|Cyclosporine|Given IV or PO
75745015|NCT00796068|Drug|Fludarabine Phosphate|Given IV
75745016|NCT00796068|Other|Laboratory Biomarker Analysis|Correlative studies
75745017|NCT00796068|Drug|Mycophenolate Mofetil|Given IV
75745018|NCT00796068|Radiation|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
75745019|NCT00796068|Drug|Treosulfan|Given IV
75745020|NCT00796068|Procedure|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
75745021|NCT01032447|Behavioral|Navigator Support|Standard of Care
75894957|NCT05112718|Biological|Platelet Rich Plasma Injections|"PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections."
75894958|NCT05112718|Other|Normal Saline Injections|"Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 injections at 4-6-week intervals."
75601031|NCT05926271|Drug|Clopidogrel|See arm description earlier.
76063199|NCT01459900|Procedure|Renal artery ablation|Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
76063200|NCT01459900|Procedure|Renal angiography|Renal angiography by femoral access.
76063201|NCT01459978|Other|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
75745022|NCT01029483|Other|Low carbohydrate diet|Ad libitum low carbohydrate diet (<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
76063202|NCT02874898|Behavioral|Brief Imaginal Exposure|Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
76063203|NCT02873806|Procedure|Implantation of two iStent inject micro-bypass stents|- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
76063204|NCT02873806|Drug|Topical travoprost|- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
75601032|NCT05926245|Dietary Supplement|Glutaryl Solution|Glutathione, ascorbic acid, cyclodextrin, potassium sorbate and radish root extracts
75745023|NCT01029483|Other|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
75894959|NCT00479258|Drug|Inhaled insulin (Exubera)|Inhaled insulin with dose adjusted according to premeal blood glucose
75745024|NCT01029483|Other|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at ~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
76063205|NCT02873806|Device|Two iStent inject micro-bypass stents|- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
75601033|NCT05926245|Dietary Supplement|Placebo Solution|Empty nanoparticles
75601034|NCT05926206|Drug|Devimistat|Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3
75745025|NCT03798288|Behavioral|selfBACK|Participants will use the selfBACK system and app in addition to receiving usual care
75745026|NCT03798288|Other|Usual care|Participants will receive usual care
75894960|NCT00479258|Drug|Subcutaneous Insulin (subject's prescribed)|Subcutaneous insulin with dose adjusted according to premeal blood glucose
75894961|NCT05112562|Behavioral|Computerized attentional bias modification training|In intervention is designed to train participants to disengage attention from potent e-cigarette cues and is based on the well-established attention retraining paradigm for other psychopathologies.
76063206|NCT02873806|Drug|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
75601035|NCT05926206|Drug|Modified FOLFIRINOX|Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1
75601036|NCT05926154|Procedure|Surgical tourniquet pressure selection|Limb occlusion pressure is calculated using the formulation by Graham: LOP = [(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)] + Diastolic Pressure. One group is LOP + 50 mm Hg and other one is LOP + 100 mmHg
75745027|NCT00518622|Drug|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
75745028|NCT00518622|Drug|Comparator: Placebo|MK7009 Placebo
75894962|NCT05112562|Behavioral|Placebo attention control training|This control training is very similar to the intervention's overall task structure and stimuli. The only difference is that the this control program is designed to exert no systematic manipulation on the attention deployment pattern between the two stimulus categories, thereby yielding no significant impact on the level of attentional bas toward ENDS-related cues
76063207|NCT02873806|Drug|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~Week 1: 1 drop four (4) times per day in the study eye~Week 2: 1 drop three (3) times per day in the study eye~Week 3: 1 drop two (2) times per day in the study eye~Week 4: 1 drop one (1) time per day in the study eye"
75894963|NCT05107180|Diagnostic Test|drug screen|urine sample
75894964|NCT00612170|Drug|[S,S]-Reboxetine|10 mg oral tablet once a day dosing
75894965|NCT00612170|Drug|Placebo|0 mg oral tablet once a day dosing
75894966|NCT00612170|Drug|[S,S]-Reboxetine|4 mg oral tablet once a day dosing
75894967|NCT00612170|Drug|[S,S]-Reboxetine|8 mg oral tablet once a day dosing
75894968|NCT05104996|Behavioral|Telephone Counseling|The form was used for weekly follow-up of the patients included in the experimental group. Headings were created according to the topics in the training form and/or for other problems and the problems stated by the patients were marked every week. Ongoing or eliminated problems of each patient until the time of next telephone counseling were indicated in the form. General problems in the form included drugs, pain, exercise, wound care, edema, compression socks, corset, nutrition, constipation, bathing, sleep, emergencies, back to work, sexual life, travel, visitors, climbing stairs, alcohol use/smoking, stress/anxiety, check-ups, and other issues.
75894969|NCT05099146|Behavioral|pictures|pictures with brushing technique demonstrated technique for proper brushing
75894970|NCT05099146|Behavioral|video|video of brushing technique demonstrated technique for proper brushing
76063208|NCT01890382|Dietary Supplement|Whey protein|30 g in total; twice a day (morning and evening)
75894971|NCT05099146|Behavioral|control|oral hygiene instructions provided
75601037|NCT05926141|Behavioral|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes). On any day during the week, the students will make a dish using groceries they received (1 hour).
75449882|NCT01700010|Drug|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
75601038|NCT05926128|Drug|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment with a scheduled molecular monitoring until month 24.
75745029|NCT04732182|Device|BrightGo cognitive training|Training on the BrightGo experimental device in the home
75745030|NCT04732182|Drug|Standard of Care medication for early Alzheimer's Disease|Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
75745031|NCT01009398|Other|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
75745032|NCT01009476|Drug|Galantamine|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
75894972|NCT00612014|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
75894973|NCT00612014|Drug|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
75894974|NCT00612014|Drug|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
75894975|NCT00612014|Drug|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
75894976|NCT00612014|Drug|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
75894977|NCT00612014|Drug|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
76063209|NCT01890382|Dietary Supplement|whey plus creatine|whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)
76063210|NCT01890382|Dietary Supplement|leucine supplementation|7.5 g/d in total; three times per day
76063211|NCT01890382|Dietary Supplement|soy protein|30 g in total; twice a day
76063212|NCT01890382|Dietary Supplement|creatine|6.0 g in total; twice a day
75601039|NCT05926115|Diagnostic Test|Diagnostic Ultrasound|During the initial visit, a transvaginal or transabdominal pelvic ultrasonography will be performed in all participants, based on the sexual history and consent form by trained gynecologists who are part of study investigators. A transvaginal ultrasound is the accepted and validated method to assess the ovarian morphology in the study of patients with PCOS.
75601040|NCT05926115|Diagnostic Test|Venous puncture|After an overnight fast of at least 6 hours (ideally), a 18 ml sample of venous blood will be collected from each study participant (i.e., the basal fasting sample). About 12 ml of the venous blood will be collected in plain tubes for serum cryopreservation and subsequent analysis, and the remainder in plain tubes for immediate glucose estimation in serum.
76025104|NCT02690701|Biological|Placebo|"Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
76025105|NCT04122287|Drug|Levofloxacin|levofloxacinn-tetracycline-containing quadruple regimens
76063213|NCT01890382|Dietary Supplement|placebo|
76063214|NCT01890616|Device|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
76063215|NCT01890772|Drug|Telaprevir|
76063216|NCT01890772|Drug|Peginterferon alfa-2a|
76063217|NCT01890772|Drug|Ribavirin|
75745033|NCT01009476|Drug|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
75449883|NCT01700062|Dietary Supplement|Total Parenteral Nutrition (TPN)|Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
75449884|NCT01700075|Drug|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
75449885|NCT01700075|Dietary Supplement|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
75449886|NCT01700114|Device|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
75745034|NCT00517296|Procedure|EUA with seton placement if necessary|Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
75745035|NCT00517296|Drug|adalimumab|Patients began therapy with adalimumab using clinic standards for dosing.
76063218|NCT01890772|Dietary Supplement|Vitamin D|
76063219|NCT01890850|Other|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
76063220|NCT02816788|Behavioral|Equine Assisted Therapy (EAT)|Psychotherapy incorporating use of equines (Equine Assisted Therapy; EAT) to facilitate therapy to improve the social, emotional and psychological well-being of participants and alleviate PTSD symptoms.
76063221|NCT01891006|Device|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
76063222|NCT01891006|Other|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
76063223|NCT04272112|Combination Product|IPS e.max CAD, Ivoclar Vivadent|Type: monolithic lithium-disilicate glass ceramic
76063224|NCT04272112|Combination Product|BruxZir, Glidewell|Type: high translucent zirconia
76063225|NCT04272112|Combination Product|BruxZir*, Glidewell|Type: high translucent zirconia with a mini-veneer of porcelain
75449887|NCT01700127|Other|Breastfeeding|breastfeeding encouraged versus withheld
76063226|NCT04272346|Behavioral|Writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart, and participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
76063227|NCT04272346|Behavioral|Processing + writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. For the first three writing sessions, participants will write their deepest thoughts and feelings regarding cancer diagnosis and treatment. In the final writing session, participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
75449888|NCT01700153|Other|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
75449889|NCT01700153|Other|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
75449890|NCT01700166|Biological|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
75449891|NCT01700218|Other|telemonitoring|
75601041|NCT05926076|Other|Treatment plan|Patients with different diagnoses will get different treatment options
75449892|NCT01700218|Other|control|
75449893|NCT01700231|Procedure|Liver resection|Liver resection of patient with neoplastic hepatic tumors
75449894|NCT01700244|Device|Pacemaker implant|
75449895|NCT01700257|Radiation|CT scan & Early CDT Lung test|
75601042|NCT05926050|Dietary Supplement|Treatment (CopaPrime+ (USANA Health Sciences)|Participants received and consumed 2 treatment tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained extracts of Bacopa monnieri (150 mg), Coffea arabica (50 mg), and Panax quinquefolius L. (50 mg)
75601043|NCT05926050|Other|Placebo|Participants received and consumed 2 placebo tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained microcrystalline cellulose. The size, shape and appearance of the placebo tablet was identical to the treatment tablet.
75894978|NCT05098288|Behavioral|Multicentre Pain Monitor + Unified Protocol|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMA. In terms of monitoring, the Multicentre Pain Monitor is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
75449896|NCT01700257|Other|CT scan & Early CDT Lung test|
75449897|NCT01700270|Drug|dovitinib (TKI258)|
76025106|NCT04122287|Drug|tinidazole|tinidazole-tetracycline-containing quadruple regimens
75449898|NCT01700270|Drug|fluvoxamine|perpetrator drug; 7 days of dosing
75601044|NCT05925998|Other|Observational study: no interventions|Not applicable as observational study with no intervention
76025107|NCT05746351|Drug|Dexmedetomidine|a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
75601045|NCT05925296|Device|magnetic stimulation|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex of the lower leg and supplementary motor area, whereas patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral primary motor cortex of the lower leg. In addition, patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on motor cortex.
75601046|NCT05925244|Other|Control Condition|Control (no alteration to body mass).
76025108|NCT05746351|Drug|fentanyl|a group will receive epidural Bupivacaine with fentanyl in normal labor
76025109|NCT05746351|Drug|Nalbuphine|a group will receive epidural Bupivacaine with Nalbuphine in normal labor
76025110|NCT05403437|Other|Evaluation of pain|Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).
76025111|NCT05403437|Diagnostic Test|Evaluation of pelvic girdle pain diagnostic tests|Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.
75601047|NCT05925244|Other|+12% Body Mass|Loaded walking exercise (12% increase in body mass using a weighted vest).
76063228|NCT04272346|Behavioral|Facts-only writing|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. Unlike the previous conditions, participants will not be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
76063229|NCT01891084|Drug|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
75601048|NCT05925244|Other|-12% Body Mass|Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
76063230|NCT01891084|Drug|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
76063231|NCT01891084|Drug|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
76063232|NCT01891474|Device|U-health care|voice inception technique based U-healthcare service
76063233|NCT01891708|Other|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
76072150|NCT03081390|Other|Skin conductance & cold pressor test|Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
75449899|NCT01700283|Behavioral|exercise education and walking program|12-week moderate intensity walking program
75449900|NCT01700296|Behavioral|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
75601049|NCT05924568|Other|Educational session with Keep Your Move in the Tube and PrimusRS|
75601050|NCT05924152|Drug|Adagrasib|Adagrasib
75601051|NCT05924152|Drug|Eltrombopag + adagrasib|Eltrombopag + adagrasib
75894979|NCT05068336|Diagnostic Test|desflurane anesthesia|Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
76025112|NCT05403437|Other|Evaluation of activity limitation|The Pelvic Girdle Questionnaire will be filled.
75601052|NCT05922644|Device|SCS|21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
75601053|NCT05922644|Other|Conventional|Routine brain resuscitation and rehabilitation awakening treatment.
75745036|NCT00517296|Procedure|EUS|Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
75745037|NCT00516906|Drug|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
75745038|NCT00516906|Drug|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
75745039|NCT01565304|Behavioral|POWER Through Choices|10-session group-based sexual education curriculum
75745040|NCT00523848|Drug|bortezomib|IV
75745041|NCT00523848|Drug|pegylated liposomal doxorubicin hydrochloride|IV
75745042|NCT00523848|Drug|thalidomide|Oral
75745043|NCT04711200|Drug|Adipose derived stromal cells intravenously injected|2×10^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).
75745044|NCT00617669|Drug|Docetaxel|intravenous infusion given every three weeks
75745045|NCT00617669|Drug|ZD4054|10 mg oral once daily dose
75745046|NCT00617669|Drug|Placebo|placebo oral tablet once daily
75745047|NCT00863135|Device|CPAP|continuous positive airways pressure
76025113|NCT02694757|Device|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
76025114|NCT05403281|Drug|DW6012|"Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast"
75894980|NCT05068336|Diagnostic Test|sevoflurane anesthesia|Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
75616572|NCT02841904|Device|Confocal LASER Endomicroscopy|Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
75745048|NCT00863135|Device|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
75894981|NCT00607256|Drug|[S,S]-reboxetine|S_S reboxetine dosed daily.
75894982|NCT02774590|Drug|Timolol|Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
75894983|NCT00606476|Drug|Bapineuzumab (AAB-001)|IV q13w
75894984|NCT02419456|Drug|MK-2048A IVR (Low Dose)|Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
75894985|NCT02419456|Drug|MK-2048A IVR (Original Dose)|Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
75894986|NCT01069341|Drug|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
75894987|NCT00468806|Drug|GSK598809, using [11C]-(+)-PHNO|
75894988|NCT00676832|Drug|Placebo|Placebo solid capsule dosage form administered orally once daily.
75449901|NCT01700309|Behavioral|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
75894989|NCT00676832|Drug|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
75745049|NCT04018157|Drug|"Ketamine and dexmedetomidine and propofol and 0.9%saline"|patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
75894990|NCT04057443|Other|Nutritional support|Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.
75894991|NCT04057443|Other|Physical exercise|The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.
75894992|NCT04057443|Drug|Hematologic Drug|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
75894993|NCT02685358|Behavioral|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.
75449902|NCT01700322|Procedure|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
75449903|NCT01700322|Drug|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
75449904|NCT01700322|Drug|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
75449905|NCT01700322|Drug|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
75449906|NCT01700400|Drug|Everolimus|
75616573|NCT02841514|Device|The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device|
75745050|NCT03682848|Drug|DTG + 3TC FDC|DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.
75745051|NCT00865241|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
75449907|NCT01700400|Drug|Pemetrexed|
75449908|NCT01700400|Drug|Carboplatin|
75449909|NCT01700400|Drug|Bevacizumab|
75616574|NCT02841514|Other|OTC toothpaste and an unoperated Y10 device|
75894994|NCT02685358|Behavioral|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
75894995|NCT04057521|Other|Care Coordination|Comprehensive care coordination.
75894996|NCT01909414|Biological|GEO-D03 DNA Vaccine|DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
75894997|NCT01909414|Biological|MVA/HIV62B Vaccine|MVA/HIV62B vaccine will be administered as a 1 x 10^8 TCID50 dose IM.
75601054|NCT05922176|Other|Evaluation of clinical indicators, Sample collection before& after immunotherapy|"A. Evaluation of clinical indicators before immunotherapy~Symptom Scale for Rhinitis: Total Nasal Symptom Score (TNSS), Rhnitis Quality of Life Questionnaire(RQLQ)~American house dust mite-specific immunogloblin G4 (sIgG4)~American house dust mite-specific immunogloblin E (sIgE)~B. Sample collection before immunotherapy~Skin: Skin test using minimally invasive microstructure patch stripping method~Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~C. Evaluation of clinical indicators 4 to 6 months after immunotherapy~: Treatment is performed for about 4 months, and the progress of treatment is evaluated through the evaluation of the following clinical indicators.~same as examination in 'A'~D. Sample collection after 4 to 6 months of immunotherapy same as examination in 'B'"
75894998|NCT01909414|Biological|Placebo for DNA GEO-D03|Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
75894999|NCT01909414|Biological|Placebo for MVA/HIV62B Vaccine|Placebo for MVA/HIV62B 1 x 10^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
75449910|NCT01700413|Drug|Idarubicin|
75449911|NCT01700426|Drug|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
75601055|NCT05922176|Other|Sample collection before& after immunotherapy|"B. Sample collection before immunotherapy~Skin: Skin test using minimally invasive microstructure patch stripping method~Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~D. Sample collection after 4 to 6 months of immunotherapy~Skin: Skin test using minimally invasive microstructure patch stripping method~Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)"
75745052|NCT00865241|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
75745053|NCT00863213|Procedure|Atrial fibrillation ablation|"Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested."
75895000|NCT00467402|Drug|agomelatine|
75895001|NCT00467402|Drug|placebo|
76072151|NCT03081390|Other|Flow-mediated dilation testing|At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
75449912|NCT01700426|Other|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
75449913|NCT01700478|Drug|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
75449914|NCT01700478|Drug|Vasopressin|Vasopressin was used in all patients during surgery.
75745054|NCT00863213|Drug|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
75745055|NCT00860639|Drug|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
75745056|NCT00860717|Procedure|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
75895002|NCT02996097|Device|The Lutronic electronic carbon dioxide (eCO2) Plus laser system|CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
75895003|NCT02996097|Drug|Intralesional Triamcinolone Acetonide|
75895004|NCT04054713|Diagnostic Test|Acetic acid chromoendoscopy|Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
75895005|NCT04054713|Diagnostic Test|Seattle protocol|Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
75895006|NCT03314181|Drug|Dexamethasone|Infusion; Intravenous (IV), or Tablet; Oral
75895007|NCT03314181|Drug|Daratumumab|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
75895008|NCT03314181|Drug|Venetoclax|Tablet; Oral
75895009|NCT03314181|Drug|Bortezomib|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
75895010|NCT03133832|Drug|Companion Tablet|Chinese-made drug for schistosomiasis treatment
75601056|NCT05920590|Other|PNF|"The protocol will be individualized and will last 45 minutes. The following techniques will be applied:~Application of the hold - relax technique to increase the range of motion of knee flexion.~Rhythmic initiation with the application of diagonal trunk and lower limb shapes.~Application of stabilizing reversals from a sitting and standing position.~Application of dynamic reversals from a standing position.~Rhythmic stabilization.~Combination of isotonics.~Gait retraining."
75895011|NCT00603668|Biological|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
75895012|NCT03663309|Diagnostic Test|detecting Gluten peptides in faecal and urine samples|"At each visit patient will:~Bring 4-day food diary (attached)~Fill symptoms and complaints questionnaire (attached)~Provide 24 h diet recall in case a food diary absents~Fill Biagi score questionnaire (attached)~Perform blood test of TTG~Provide stool and urine samples"
75601057|NCT05920590|Other|PNF plus Tendon Vibration|Participants in this group will be given the same exercise program as Group 1 combined with the application of tendon vibration. Tendon vibration will be applied on both quadriceps' tendons in three weekly sessions (not on the same day as the exercise program). To implement the protocol, 100 Hz frequency mechanical stimulation will be applied.
75601058|NCT05920590|Other|Conventional Home-based Physiotherapy Program|"Participants in this group will follow a conventional six-week home physical therapy program that will include:~Range exercises of the knee joint and the ankle joint of the operated limb.~Stretching of the muscles of the lower limbs.~Walking inside and outside the house.~Exercises to strengthen the muscles of the lower limbs."
75601059|NCT05914831|Radiation|Ultra-fractionated WBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast where the tumor was located.
75601060|NCT05914831|Radiation|Ultra-fractionated PBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the part of the breast where the tumor was located.
75745057|NCT00860717|Radiation|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact."
75895013|NCT00675116|Drug|GW823296|
75895014|NCT05011240|Behavioral|Paediatric Autism Communication Therapy (PACT)|PACT is a parent-mediated therapy that aims to improve children's social-communication development. During PACT, a therapist uses video-feedback of parent-child play interactions to coach the parent in how to improve their sensitivity and responsiveness to their child's social-communication and interaction behaviours and to implement evidence-based strategies that facilitate social-communication development.
75895015|NCT05011240|Behavioral|Psychoeducation|Control participants will receive monthly psychoeducation sessions led by a developmental specialist
75895016|NCT03663465|Other|Hawthorn|Hawthorn tablet
75895017|NCT03663465|Drug|SGAs|SGAs tablet
75745058|NCT03660540|Dietary Supplement|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
75745059|NCT00863291|Drug|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
75745060|NCT00863291|Drug|placebo|Placebo in a manner similar to the active comparator
75745061|NCT04689282|Biological|Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).|Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
75895018|NCT00461006|Drug|Actos|45mg po daily
75449915|NCT01700491|Drug|Epidural Catheter 0.2% ropivacaine|0.2% ropivacaine into epidural space and saline into paravertebral space
75449916|NCT01700491|Drug|Paravertebral Catheter 0.4% ropivacaine|0.4% ropivacaine into paravertebral space and saline into the epidural space
75449917|NCT01700504|Drug|Axillary lavage with gentamicin solution|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
75895019|NCT00461006|Drug|aleglitazar|0.6mg po daily
75895020|NCT02452840|Other|No Intervention|No Intervention
75895021|NCT04161430|Drug|DBPR108; Placebo matching sitagliptin|"Phase A (Weeks 1-24): DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
75895022|NCT04161430|Drug|Placebo matching DBPR108; Sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100mg once daily under fasted conditions for 24 weeks; Sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
75895023|NCT04161430|Drug|Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
75895024|NCT03663153|Other|SEMA4C high value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
75895025|NCT03663153|Other|SEMA4C low value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
75601061|NCT05910671|Behavioral|Physical Activity Phone Calls and Notebook|This intervention encouraged parents to model physical activity behaviors and co-participate in physical activity with their young child. Each week behavioral strategies for promoting physical activity change will be discussed to help parents work towards meeting their activity goals. As part of the physical activity intervention parents will receive a physical activity notebook that has newsletters, suggested activities that can be done with their child, and other material that will help the parent and child be active active together. The behavioral strategies and the information in the notebook will will be discussed weekly for 30 minutes via telephone.
75449918|NCT01700556|Other|Case Manager|"The following support will be provided by a case manager:~At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.~Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.~Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity)."
75449919|NCT01700556|Other|Assistive Technologies|The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
75895026|NCT00673478|Drug|Tiotropium+Salmeterol|
75895027|NCT00673478|Drug|Salmeterol|
75895028|NCT00673478|Drug|Tiotropium|
75601062|NCT05907343|Device|Sham TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
75601063|NCT05907343|Device|Closed-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
75895029|NCT02203474|Drug|Tiotropium HFA BAI 5 mcg|
75895030|NCT02203474|Drug|Tiotropium 18 mcg Capsule|
75895031|NCT02203474|Drug|Placebo|Placebo
75895032|NCT04053699|Drug|Von Willebrand Factor-Containing Product|Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
75895033|NCT00672386|Drug|JNJ16269110|5 mg twice daily for 12 weeks
75895034|NCT00672386|Drug|JNJ16269110|10 mg twice daily for 12 weeks
75895035|NCT00672386|Drug|JNJ16269110|15 mg twice daily for 12 weeks
75895036|NCT00672386|Drug|Placebo|twice daily for 12 weeks
75895037|NCT00672386|Drug|Metformin|Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
75895038|NCT00672386|Other|Dietary Counseling|Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
75895039|NCT05119114|Diagnostic Test|Magnetic Resonance Imaging (MRI)|A standardized multi-parametric MRI protocol will be implemented for all patients. All sequences will be acquired on a 1.5 Tesla scanner. After completion of the MRI study, the digital imaging and communication data will be sent to a diagnostic workstation for post-processing and analysis. Patients of the study will be subjected to detailed structural MRI for detection of signs of neurodegenerative changes. Volumetric high-resolution 3D scans will be used for quantitative study.
76063234|NCT01891786|Behavioral|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
76063235|NCT01891786|Behavioral|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
76063236|NCT01891942|Procedure|twitch by magstim|
76063237|NCT01892098|Dietary Supplement|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
76063238|NCT01892098|Dietary Supplement|Placebo|Cellulose pill given as placebo
76063239|NCT01892176|Dietary Supplement|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
76063240|NCT01892254|Drug|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
76063241|NCT01892254|Drug|Placebo|Placebo (to metformin)
76063242|NCT01892332|Drug|epidural block with lidocaine and fentanyl|"The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%."
76063243|NCT01892488|Drug|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
76063244|NCT01892488|Drug|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
76063245|NCT04390204|Other|intervenions|"Motor control exercises~A supervised home self-rehabilitation program"
75449920|NCT01700556|Other|light support|An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
75745062|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
75745063|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
75745064|NCT00860873|Dietary Supplement|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
75895040|NCT04056897|Biological|BCD-132, 125 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
75449921|NCT01700556|Other|3 preventive home visits by a nurse|The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
75745065|NCT00860873|Dietary Supplement|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
75895041|NCT04056897|Drug|Teriflunomide|14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
75745066|NCT00865319|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
75895042|NCT04056897|Drug|Placebo|intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
75895043|NCT04056897|Biological|BCD-132, 500 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
75895044|NCT04436302|Device|Exergame device|motor-cognitive training
75601064|NCT05907343|Device|Open-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
75745067|NCT00865319|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
75745068|NCT00861029|Drug|Pazopanib|Subjects treated with pazopanib
75745069|NCT00861029|Other|Placebo for pazopanib|Control for comparison with pazopanib
75895045|NCT02281682|Drug|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
75895046|NCT02281682|Drug|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
75449922|NCT01700595|Procedure|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
75745070|NCT00861029|Drug|Moxifloxacin|Comparator for pazopanib
75745071|NCT00861029|Other|Placebo for moxifloxacin|Placebo for moxifloxacin
75745072|NCT00865397|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
75745073|NCT00861107|Biological|AlloStim-7|intradermal injection once a week for 3 weeks
75895047|NCT02281682|Drug|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
75895048|NCT02281682|Procedure|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
76063246|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
76063247|NCT01892644|Other|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
76063248|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
75449923|NCT01700608|Drug|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
75449924|NCT01700647|Other|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
75449925|NCT01700647|Other|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
75449926|NCT01700686|Other|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
76063249|NCT01892878|Procedure|VerteLoc|Single Arm
76063250|NCT01892956|Other|Nutritional intervention|"2 dietary interventions~personalized diet based on algorithm predictions of glucose response to foods~Mediterranean-style diet"
76063251|NCT01893034|Procedure|Arthroscopic treatment of femoroacetabular impingement|
76063252|NCT01893034|Other|Physiotherapy and activity modification|
75449927|NCT01700712|Dietary Supplement|Probiotic Lactobacilli reuteri|
75745074|NCT00861107|Procedure|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
76063253|NCT02804230|Device|Neuro Ablation - Functional|MR-Guided Focused Ultrasound
76063254|NCT01901653|Drug|Rovalpituzumab tesirine (SC16LD6.5)|
76063255|NCT01925989|Biological|LY2605541|Administered SQ
76063256|NCT01925989|Biological|Insulin Glargine|Administered SQ
76063257|NCT01901419|Drug|Nitroglycerin infusion|Nitroglycerin infusion during rewarming
76063258|NCT02798536|Drug|LMB-100|Administered intravenous (IV) on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles (Arms A1 and A2) or 2 cycles (Arms B1 and B2)
76063259|NCT02798536|Drug|nab-paclitaxel|Arms B1 and B2 only. Administered intravenous (IV) on days 1 and 8 of each 21 day cycle for up to 6 cycles
75745075|NCT00861107|Biological|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
75745076|NCT00861107|Biological|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10^8 cell dose and if no toxicity dose escalates to 10^9 cell dose.
75745077|NCT00510510|Drug|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
75745078|NCT00510510|Drug|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
75745079|NCT00510510|Drug|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
76063260|NCT01901341|Drug|CB-5945|
76063261|NCT01901341|Drug|Placebo|
76063262|NCT04758286|Procedure|Emergency surgical procedures|COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
76063263|NCT04757896|Procedure|Lateral costoclavicular approach|USG guided lateral costoclavicular approach for brachial plexus block
76063264|NCT04757896|Procedure|Medial costoclavicular approach|USG guided medial costoclavicular approach for brachial plexus block
76063265|NCT01615939|Drug|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
76063266|NCT01615939|Drug|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
75745080|NCT00863525|Drug|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
75745081|NCT00863525|Drug|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
76063267|NCT02789878|Drug|Goserelin|Androgen Deprivation Therapy
76063268|NCT02789878|Drug|Prednisone|Corticosteroid
76063269|NCT02789878|Drug|Abiraterone|CYP17 inhibitor
76063270|NCT02789878|Drug|Apalutamide|Androgen-receptor antagonist
76063271|NCT01901185|Drug|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
76063272|NCT01893424|Drug|Sativex buccal spray|buccal spray
76063273|NCT01893424|Drug|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
76063274|NCT02788708|Drug|Lenvatinib Mesylate|Given PO
76063275|NCT02788708|Drug|Paclitaxel|Given IV
76063276|NCT02788708|Other|Pharmacological Study|Correlative studies
76063277|NCT01888003|Drug|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
75449928|NCT01700712|Dietary Supplement|Placebo|
75449929|NCT01700738|Procedure|gastric ring surgery|
75449930|NCT01700738|Other|nutritional help|
75449931|NCT01700751|Drug|brentuximab vedotin|
75449932|NCT01700777|Other|"HABIT-ILE"|"90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards)."
75449933|NCT01700790|Drug|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
76063278|NCT01888003|Drug|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
76063279|NCT01888003|Other|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb < 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
76063280|NCT02783560|Behavioral|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
75895049|NCT04057053|Drug|Netarsudil 0.02% Ophthalmic Solution|Use of Netarsudil 0.02% ophthalmic solution daily after surgery
75895050|NCT04589338|Other|Endurance training|This group will perform aerobic type exercises. Initially, patients will perform continuous exercises of progressive intensity in order to adapt to this kind of effort. Next, we will introduce interval exercises.
76063281|NCT02783560|Behavioral|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
76063282|NCT01893502|Behavioral|Telephone counselling from Quitline|
76063283|NCT02775214|Device|Video Laryngoscopy|
76063284|NCT02773732|Drug|Ciprofloxacin 750 MG|750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
75895051|NCT04589338|Other|Resistance training|Patients in this group will perform lower limb strengthening exercises to improve the maximum strength of different muscle groups.
76063285|NCT02773732|Drug|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
75895052|NCT04056975|Biological|Recombinant Anti-CD19m-CD3 Antibody Injection|Intravenous Infusion
76063286|NCT02773732|Drug|Ciprofloxacin 1000 MG|1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
75601065|NCT05907239|Device|Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.
75895053|NCT02281916|Drug|P28GST|3 injections of 100 µg of P28GST within 3 months (one injection per month)
76063287|NCT02773732|Drug|Ciprofloxacin 500 mg|500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
76063288|NCT04390126|Other|life questionnaires|Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
76063289|NCT04390126|Other|questionnaire|1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
76063290|NCT02769520|Drug|Pembrolizumab|200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
76063291|NCT02764528|Behavioral|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
76063292|NCT02764528|Behavioral|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
76063293|NCT02764528|Behavioral|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
75449934|NCT01700803|Drug|Povidone Iodine 10% vand cesarean section wound infections|
76063294|NCT02735512|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
76063295|NCT02735512|Other|Laboratory Biomarker Analysis|Samples undergo MDSC clinical assay
76063296|NCT02735122|Drug|acetaminophen Tablet|2 test acetaminophen 500 mg tablets
76063297|NCT02735122|Drug|acetaminophen Caplet|2 commercial acetaminophen 500 mg caplets
76063298|NCT02735122|Drug|ibuprofen Liquid-filled capsule|2 commercial ibuprofen 200 mg Liquid-filled capsules
76063299|NCT02735122|Drug|Placebo Tablet|2 placebo tablets
75449935|NCT01700803|Drug|Povidone Iodine 7.5% vand cesarean section wound infections|
75449936|NCT01700855|Procedure|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
75449937|NCT01700855|Procedure|Electroacupuncture|"Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate."
75895054|NCT03663075|Behavioral|Group information (GI)|The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
75895055|NCT03663075|Behavioral|Structured person-centered support (PCS)|The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
75895056|NCT04963504|Diagnostic Test|Rest-to-exercise|Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)
75745082|NCT05226377|Diagnostic Test|Atherogenic Index of Plasma|- The atherogenic index of plasma (AIP) is defined as the base 10 logarithms of the ratio of plasma triglyceride (TG) to high-density lipoprotein cholesterol (HDL-c) (17). AIP was employed as a predictor of cardiac risk (CR) with values of -0.3 to 0.1 are associated with low, values of 0.1-0.24 are associated with the medium, and values above 0.24 with high CR
75745083|NCT01009632|Behavioral|Resonant voice|4-hr of resonant voice exercise
75745084|NCT01009632|Behavioral|Voice rest|4-hr of complete refrain from any voice use
75745085|NCT01009632|Behavioral|Spontaneous speech|
76063300|NCT02735122|Drug|Placebo Caplet|2 placebo caplets
75895057|NCT04963504|Diagnostic Test|Sitting-to-supine|Pulmonary diffusing capacity is assessed in the sitting and supine position
75895058|NCT02284100|Behavioral|animal assisted therapy|"For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.~The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions."
75745086|NCT00863603|Other|oxygen|5 Liter/minute by nasal cannula for 6 wks
75745087|NCT00865475|Drug|AZT+3TC+ABV (Trizivir)|Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
76063301|NCT02735122|Drug|Placebo Liquid-filled capsule|2 placebo Liquid-filled capsules
75745088|NCT00865475|Drug|Switching to LPV/r monotherapy (Kaletra)|Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
75745089|NCT04685694|Drug|Misoprostol|sl 800 mcg misoprostol
75745090|NCT00870311|Drug|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
75745091|NCT01564602|Device|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
75745092|NCT00865553|Behavioral|computer-assisted smoking cessation intervention|
75895059|NCT03662763|Drug|Extended-release Guanfacine Hydrochloride (SPD503)|dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
75895060|NCT03662763|Drug|Placebo oral capsule|
75895061|NCT02141932|Procedure|Bed-side pocket size ultrasound imaging|
75895062|NCT02141932|Device|GE Ultrasound Vscan|
75895063|NCT00458978|Drug|Cediranib Maleate|Given orally
75895064|NCT00458978|Other|Laboratory Biomarker Analysis|Correlative studies
75895065|NCT04514224|Other|Gabby implementation|Iimplement an evidence-based preconception care intervention, Gabby, into community-based health settings
75895066|NCT04514224|Other|Evaluate the Gabby implementation|Assess implementation outcomes using the Proctor Implementation Outcomes Framework
75895067|NCT00458276|Drug|tezosentan|Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
75895068|NCT00458276|Drug|placebo|Placebo (i.e., normal saline) for i.v. use.
75895069|NCT03661749|Other|clean catch|clean catch technique applied to collect urine for PR/CR ratio
76063302|NCT02726542|Drug|somatropin|Norditropin (growth hormone) given by injection using a pen-device
76063303|NCT02722798|Drug|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
76063304|NCT02720848|Device|Stiffening wire|The stiffening wire will be inserted into the double/single balloon enteroscope.
76063305|NCT02720848|Device|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
76063306|NCT02718118|Device|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
76063307|NCT02718118|Device|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
75449938|NCT01700868|Other|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
75449939|NCT01700868|Other|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
75449940|NCT01700881|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
75449941|NCT01700881|Other|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
75449942|NCT01700894|Behavioral|Walking Program + Motivational Interviewing Calls|
75449943|NCT01700894|Behavioral|Walking Program + Automated Calls|
75449944|NCT01700894|Behavioral|Walking Program|
75449945|NCT01700920|Procedure|bone marrow aspirate|
75745093|NCT00865553|Other|cancer prevention|
75745094|NCT00865553|Other|educational intervention|
75895070|NCT04520074|Drug|Etoposide, Cyclophosphamide, Carboplatin/Cisplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5) d1/CDDP 30mg/m2 d1-d2+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
75895071|NCT03661671|Diagnostic Test|LCI+white light|Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
75895072|NCT00600782|Biological|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
75895073|NCT05118958|Drug|KVD824 Prototype 1 modified-release tablet|300 mg modified-release tablet
75745095|NCT00865553|Other|survey administration|
75895074|NCT05118958|Drug|KVD824 Prototype 2 modified-release tablet|300 mg modified-release tablet
75745096|NCT03560388|Other|Acupuncture and touch/relaxation|Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
75745097|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
75895075|NCT05118958|Drug|KVD824 Immediate-Release Capsule|300 mg immediate-release capsule
75895076|NCT05118958|Drug|Placebo to KVD824 Prototype 1|Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
75895077|NCT05118958|Drug|KVD824 Prototype 3 modified-release tablet|300 mg modified-release tablet
75895078|NCT00672074|Drug|Ipamorelin|IV
75895079|NCT00672074|Drug|placebo|IV
75601066|NCT05907239|Device|Placebo Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.
75601067|NCT05896306|Other|No intervention|No intervention
75601068|NCT05892653|Drug|ABM-1310|"Dose Escalation Stage: Subjects will be given oral dosing of ABM-1310 twice daily (BID) for 28-day cycles of continuous administration until progressive disease (PD), unacceptable toxicity, or other withdrawal criteria are met as clinically observed.~Dose Expansion Stage: Subjects will begin to receive oral doses of ABM-1310, BID, for 28-day cycles at a fixed dose level (as determined at the dose escalation stage) until PD, unacceptable toxicity, or other withdrawal criteria are met as clinically observed."
75745098|NCT00865631|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
75745099|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
75895080|NCT03662451|Procedure|Robotic assisted hysterectomy|Periumbilical single incision vs multiple abdominal incisions for hysterectomy
75895081|NCT05118880|Other|Peer Bullying Counseling Program based on the Interpersonal Relationship Model|"The content of the program was created by the researcher in line with the issues that peer bullying children need support based on their bullying-related characteristics in the light of the relevant literature. Education topics prepared in this framework; 'Empathy', 'Peer Bullying', 'Anger Management' and 'Happy Friendship Relationships' were determined. The main nursing problem of the research is peer bullying. The main purpose of the Peer Bullying Counseling Program is to improve the empathy skills of the bullying child, to enable them to gain the right perspective towards bullying, to develop anger control, and to help them establish happy friendships. The content of the Peer Bullying Counseling Program; drawing, brainstorming, empathy demonstration, white paper activity, educational matching game, peer bullying demonstration, case studies, educational emotion puzzle game, anger control information video were applied using educational techniques."
75895082|NCT04056507|Procedure|Immunolabeling|Immunolabeling of abnormalities observed by the cell study in flow cytometry.
75895083|NCT00455156|Drug|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
75895084|NCT05118646|Device|sublingual microcirculation,|Avoiding pressure artifacts, clear stable microvascular images were taken for a minimum of 20 seconds of the left, middle, and right sections of the tongue.
75449946|NCT01700933|Other|High-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
75449947|NCT01700933|Other|Low-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
75895085|NCT05118646|Device|hemodynamic monitoring|Arterial blood lactic acid (Lac), central venous oxygen saturation (ScvO2), hematocrit (HCT) and entral venous-to-arterial carbon dioxide partial pressure difference (Pcv-aCO2) will be measured employing a bedside blood gas machine on admission and six hours following admission.
75745100|NCT00863759|Procedure|implantation of intraocular lens (IOL)|"implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye."
75895086|NCT03661593|Other|Cataract guideline|The patients gets an IOL according to cataract guideline correcting the ametropia
75449948|NCT01700972|Procedure|Myocardial perfusion imaging|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
75895087|NCT04513834|Other|GP will receive the educational outreach visit by a DAM (healthcare representative).|GP will receive the educational outreach visit by a DAM (healthcare representative).
75601069|NCT05882370|Drug|Cadonilimab|Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
75601070|NCT05882370|Procedure|transjugular intrahepatic portosystemic shunt (TIPS)|transjugular intrahepatic portosystemic shunt (TIPS)
75601071|NCT05876182|Drug|Oral Vancomycin|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
75745101|NCT00863837|Drug|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
75745102|NCT00863837|Drug|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
75745103|NCT01009866|Biological|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
75745104|NCT00863915|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
75895088|NCT04513834|Other|Patient education material on PPI deprescribing will be sent to the patients|Patient education material on PPI deprescribing will be sent to the patients
75895089|NCT03661515|Drug|Selinexor|"According to escalation level:~Level -1: Selinexor 40 mg/day, once weekly~Level 1: Selinexor 60 mg/day, once weekly~Level 2: Selinexor 80 mg/day, once weekly~Level 3: Selinexor 100 mg/day, once weekly"
75745105|NCT00863915|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
75745106|NCT01009944|Drug|Lisinopril, Atenolol|once a day for 14 weeks
75745107|NCT01010022|Drug|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
75745108|NCT01010022|Drug|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
75895090|NCT03661515|Drug|fludarabine|fludarabine 30 mg/m2/day intravenously on days 1 to 4
75895091|NCT03661515|Drug|idarubicin|idarubicin 10 mg/m2/day intravenously on days 1 to 3
75449949|NCT01700998|Drug|Magnesium|
75449950|NCT01700998|Drug|Placebo|
75449951|NCT01701050|Other|Blood collection|Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
75449952|NCT01701076|Drug|Bendamustine|"Induction treatment phase (cycle 1-6):~Bendamustine 75 mg/m2 i.v day 1 and 2~Lenalidomide 25 mg p.o. day 1-21~Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22~Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia~Maintenance treatment phase (cycles 7-18):~Lenalidomide 25 mg p.o. day 1-21~Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22"
75449953|NCT01701089|Drug|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
75449954|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for 14 days
75449955|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for up to 17 days
75601072|NCT05876182|Other|Placebo|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
75745109|NCT04672746|Behavioral|Brief MI interaction via instant communication|Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
75895092|NCT03661515|Drug|cytarabine|cytarabine 2 g/m2/day intravenously on days 1 to 4
75895093|NCT03661515|Drug|G-CSF|G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
75895094|NCT02284256|Drug|Fibrocaps|
75895095|NCT02284256|Drug|TachoSil|
75745110|NCT04672746|Behavioral|General health information|"Telephone peer counselling+referral to treatment if required+general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
75745111|NCT00864071|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
75895096|NCT01624480|Drug|Armodafinil|The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
75895097|NCT04056429|Combination Product|BHA|BHA active ingredients include beta-tricalcium phosphate and a blood-derived component. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
75895098|NCT00670592|Drug|HCD122|
75895099|NCT05115682|Behavioral|High-intensity Intermittent Exercise|The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).
75895100|NCT02992899|Device|GammaCore/electroCore non-invasive VNS device|Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.
75895101|NCT02992899|Device|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.
75895102|NCT02992899|Drug|O-15 water|Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2[15O] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2[15O]. Subjects will receive a 20 mCi intravenous bolus of H2[15O] for each of the 14 scans during exposure to neutral and traumatic scripts.
75895103|NCT02281994|Device|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
75895104|NCT00448058|Drug|GSK372475|daily administration during the 10-week treatment phase
75895105|NCT00448058|Drug|venlafaxine|daily administration during the 10-week treatment phase
75745112|NCT00864071|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
75745113|NCT00870701|Radiation|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
75895106|NCT00448058|Drug|placebo|daily administration during the 10-week treatment phase
75895107|NCT01081210|Other|Ultrasound examination|Screening with bedside ultrasound examination
75895108|NCT03662373|Radiation|carbon ions radiation therapy|Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
75895109|NCT03662373|Radiation|protons radiation therapy|Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
75745114|NCT00870701|Other|absence of radiotherapy|absence of radiotherapy
75745115|NCT00864149|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
75895110|NCT02282072|Device|Deep brain stimulation：PINS Stimulation System|
75895111|NCT01602484|Device|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
75601073|NCT05874596|Behavioral|AI-aided clinical feedback system coupled with multi-aspect intervention basd on Behaviour Change Wheel model|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
75895112|NCT01602484|Device|Bulk splint supplies|Applying splint by using the bulk splint supplies
75895113|NCT03662295|Behavioral|Language treatment|Individual speech-language therapy sessions totaling 1.5 to 2.5 hours five days per week. Intervention activities include performing oral and written confrontation and responsive naming, writing single words to dictation, reading single words and sentences aloud, and generating written and spoken picture descriptions.
75895114|NCT04441736|Device|High flow nasal cannula|Device gives high flow oxygen comparable to non invasive ventilation
75895115|NCT05118100|Drug|Clearfil Protect Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive containing an antibacterial monomer (MDPB)
75895116|NCT05118100|Drug|Clearfil SE Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
75895117|NCT03662529|Behavioral|Four-Session Mind Freedom Plan|Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.
75895118|NCT03662529|Behavioral|Treatment as usual therapy|Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
75895119|NCT00447980|Drug|NT-501|High Dose
75895120|NCT00447980|Drug|NT-501|Low Dose
75895121|NCT03660891|Diagnostic Test|measuring neuromuscular block|During anesthesia patients are monitored with two instead of one NMT monitor. the difference in measured TOF-PTC is compared
75895122|NCT02284334|Other|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
75895123|NCT05116696|Procedure|For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery|"For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy"
75895124|NCT02284412|Drug|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
75895125|NCT02284412|Drug|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
75895126|NCT02284412|Drug|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
75895127|NCT02284490|Drug|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
75895128|NCT00583154|Drug|BLI-801|Dose 1
75895129|NCT00583154|Drug|BLI-801|Dose 2
75895130|NCT00583154|Drug|BLI-801|Dose 3
75895131|NCT00583154|Drug|BLI-801|Dose 4
75895132|NCT02207218|Drug|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
75895133|NCT02273570|Drug|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
75895134|NCT02273570|Drug|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
75895135|NCT01676818|Drug|eribulin mesylate|Given IV
75601074|NCT05873140|Behavioral|application LINE|Online lifestyle modification education for weight loss
75601075|NCT05873062|Drug|AUT00201|Single oral dose
75895136|NCT02282150|Drug|Hydrocortisone|Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
75895137|NCT02282150|Drug|Plenadren|10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
75895138|NCT01354210|Behavioral|SMS Text Message Reminder|Daily
75895139|NCT00583076|Drug|AST-120|AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
76072152|NCT03076658|Radiation|EOS imaging|The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
76072153|NCT03059121|Diagnostic Test|Dual-energy X-ray absorptiometry|
75895140|NCT05122468|Procedure|Connective tissue Harvest and CAF|A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level. In control sites, the graft will be adapted to cover each exposed root to the CEJ, and stabilized with either 6-0 resorbable sutures (with the knot placed under the papillary area) or a non-resorbable suture with the knot on the palatal side. For suturing of the graft, interrupted sutures or sling sutures (anchored to periosteum apical to the graft and hanging around the neck of the experimental teeth) may be used.
75745116|NCT00864149|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
75745117|NCT01010100|Drug|Acarbose (Glucobay, BAYG5421)|50 mg TID
75745118|NCT01010100|Drug|Placebo|50 mg TID
75895141|NCT05122468|Procedure|Connective tissue Harvest and Tunnel|"A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level.~In test sites, the graft should be slid through the tunnel. To accomplish the adequate position of the graft into the tunnel, 2 sutures are first placed, 1 at the most mesial and the other at the most distal aspect of the tunnel. The needles should pass underneath the tunnel and exit through the largest or most central gingival recession, the one through which the grafting tissue will be introduced. With these 2 sutures already inside the tunnel, the graft is bitten on both ends with vertical mattress sutures."
75745119|NCT00870779|Drug|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
75895142|NCT05122312|Drug|Olinanoseal|it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
75895143|NCT05122312|Drug|Curodont D'senz|This agent contains p 11-4 peptide in addition to fluoride
75895144|NCT00579020|Drug|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
75895145|NCT00579020|Drug|Moxifloxacin ophthalmic solution 0.5%|
75895146|NCT00579020|Drug|Dexamethasone phosphate solution, 0.1%|
75895147|NCT04530604|Drug|Defibrotide|"All patients will receive 25 milligram/kilogram/day (mg/kg/day) of defibrotide, given in 4 divided doses (approximately every 6 hours), each dose infused over 2-hours intravenously (IV).~The planned duration of study therapy is 7 days (while in the hospital), with the following qualifications:~Patients who respond to study therapy prior to day 7 (able to discontinue oxygen) will discontinue study therapy at that earlier time point.~Patients who have not responded to study therapy by day 7 of therapy, evidenced by <20% reduction (or a worsening) of the amount of supplemental oxygen they are receiving, will discontinue study therapy at day 7.~Patients who have evidence of a partial pulmonary response by day 7 (>20% reduction in supplemental oxygen requirement, but still require supplemental oxygen) may elect to continue to receive study drug through an additional 7 days of study (total 14-day therapy course)."
75895148|NCT04471142|Device|neuromuscular bandage|After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied. For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching. As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
75895149|NCT04169698|Drug|Denosumab 60 mg/ml [Prolia]|full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand
75895150|NCT04169698|Drug|Alendronate 70Mg Tab|Bisphosphonates
75895151|NCT04470752|Drug|Capsaicin 1% oral solution|Capsaicin 1.0 micrograms/ml
75895152|NCT04470752|Drug|InOrpha Solution|glycerol based suspension vehicle
75895153|NCT02273804|Drug|Topiramate|Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.
75745120|NCT04201470|Other|Blood withdrawal|Measurement of serum neurofilaments light chain and GFAP
75745121|NCT04201470|Other|MRI|Cervical and cerebral MRI without contrast injection
75745122|NCT04201470|Other|Neurologic / neuropsychologic tests - Patients|EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
75745123|NCT04201470|Other|Neurologic / neuropsychologic tests - Controls|NHPT, T25FW, CSCT
75745124|NCT01010178|Drug|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
75745125|NCT04196634|Other|Risk assessment|People on sick leave due to musculoskeletal conditions will be screened for potential risk factors for prolonged sickness absence. No intervention will be given.
75895154|NCT02273804|Drug|Placebo|Placebo will be taken orally following to the same dose regimen according to theoretical weight
75895155|NCT04142944|Device|Dexcom G6 with alert|Dexcom G6 CGM device with the predictive hypoglycaemia alert function
75895156|NCT04142944|Device|Dexcom G6 without alert|Dexcom G6 CGM device without the predictive hypoglycaemia alert function
75895157|NCT00578474|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
75895158|NCT00578474|Drug|Ofloxacin otic solution|5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
75895159|NCT00578474|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
75895160|NCT03909490|Other|Preference elicitation tool|Ranking tool to assess patient preferences for trigger finger treatment
75895161|NCT03909490|Other|handout|handout with information about trigger fingers
75895162|NCT00577148|Drug|Rimonabant|Tablet, oral administration
75895163|NCT00577148|Drug|Placebo (for Rimonabant)|Tablet, oral administration
75895164|NCT03700918|Device|DaVingiTR System|DaVingiTR Tricuspid valve annuloplasty repair device
75895165|NCT05203796|Device|Transcutaneous pulsed electrical stimulation (NuEyne 02)|Arm 1: Experimental: Experimental group: Dry eye disease patients (n=12) Device: Pulse Electrical Stimulation Pulse Electrical Stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
75895166|NCT05203796|Device|Sham stimulation|Arm 2: Sham Comparator: Comparison group: Dry eye disease patients (n=12) Device: Sham stimulation Sham stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
75895167|NCT03673228|Behavioral|Comprehensive Relapse Prevention Intervention|"This intervention consists of 4 components:~Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations"
75895168|NCT03673228|Behavioral|Standard Treatment Counseling|Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
75895169|NCT03673228|Drug|Nicotine Replacement Therapy (NRT)|Patients in both arms will be encouraged to receive NRT
75895170|NCT00664664|Drug|APD125|soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
75895171|NCT00664664|Drug|APD125|soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
75601076|NCT05873062|Drug|Placebo|Single oral dose
75895172|NCT00664664|Drug|Placebo|soft gelatin capsule, daily dosing for up to 3 weeks
75895173|NCT05122234|Biological|Injection of secretome - mesenchymal stem cell|Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.
75895174|NCT05122234|Other|Placebo|Normal saline
75895175|NCT05122234|Drug|Standard treatment of Covid-19|Standard treatment of Covid-19 based on national protocol.
75895176|NCT00439634|Drug|AVE1625|oral administration
75895177|NCT00439634|Drug|placebo|oral administration
75895178|NCT03161626|Drug|Coagadex|Plasma-driven blood coagulation factor X concentration
75895179|NCT02282228|Device|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
75895180|NCT05116462|Drug|Sintilimab|200 mg D1 IV Q3W
75895181|NCT05116462|Drug|Carboplatin|AUC 5 or 6 mg/ml/min D1 IV Q3W
75895182|NCT05116462|Drug|Nab-paclitaxel|100 mg/m2 D1, 8, 15 IV Q3W
75895183|NCT05116462|Drug|Cisplatin|75 mg/m2 D1 IV Q3W
75895184|NCT05116462|Drug|Pemetrexed|500 mg/m2 D1 IV Q3W
75895185|NCT05116462|Drug|Docetaxel|60 or 75 mg/m2 D1 IV Q3W
75895186|NCT05116462|Drug|Paclitaxel|175 or 200 mg/m2 D1 IV Q3W
75895187|NCT05116462|Drug|Gemcitabine|1000 mg/m2 or 1250 mg/m2 D1, 8 IV Q3W
75895188|NCT05116462|Drug|Placebo|20 ml D1 IV Q3W
76072154|NCT03055533|Behavioral|Headsprout reading program|Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
75895189|NCT02282306|Behavioral|TTIP-PRO|The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
75895190|NCT02277236|Radiation|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
75895191|NCT02277236|Radiation|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
75895192|NCT05116306|Drug|Hyaluronic acid|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
75895193|NCT05116306|Drug|Propylene glycol|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
75895194|NCT00570986|Drug|Placebo|Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
75895195|NCT00570986|Biological|ABT-874|200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
75895196|NCT00570986|Biological|ABT-874|100mg every 12 weeks.
75895197|NCT00570752|Other|Placebo|
75895198|NCT00570752|Drug|BMS-582949|
75895199|NCT00570752|Drug|Atorvastatin|
75895200|NCT00570752|Drug|Statin|
75895201|NCT00569972|Drug|PD 0200390|Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
75449956|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
75895202|NCT00569972|Drug|PD 0200390|Capsules, 30 mg, 3 capsules each night before bedtime; Duration - Visit 3-7 for 28 days
75895203|NCT00569972|Drug|PD 0200390|Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days
75449957|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
75895204|NCT00569972|Drug|PD 0200390|Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
75895205|NCT00569972|Drug|Placebo|Matched oral placebo for weeks 2-7.
75895206|NCT05106946|Biological|ThisCART22 cells|0.2-60 x 10^6 CAR T cells per kg body weight
75895207|NCT04250740|Other|Coffee with butter-1|250 mL brewed black coffee with hazelnut flavouring and 50 g water
75745126|NCT03998904|Procedure|Muscle preservation|Muscle preservation during graft preparation of hamstring graft
75745127|NCT03998904|Procedure|No muscle preservation|No muscle preservation during graft preparation of hamstring graft
75895208|NCT04250740|Other|Coffee with butter-II|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-I
75895209|NCT04250740|Other|Coffee with butter-III|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-II
75895210|NCT00565760|Drug|Q8003|Capsules
75895211|NCT00565760|Drug|Placebo|Capsules
75895212|NCT05121610|Procedure|The procedures include PCI, CABG and HCR|The procedures include PCI, CABG and HCR
75895213|NCT02282384|Drug|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
75895214|NCT02282384|Other|Placebo|
75895215|NCT02989389|Drug|LY3323795|Administered orally
75895216|NCT02989389|Drug|Itraconazole|Administered orally
75895217|NCT02989389|Drug|Placebo|Administered orally
75895218|NCT02653300|Biological|Oral Insulin|all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
75895219|NCT00436670|Biological|AMG 317 75 mg|75 mg SC weekly injection
75895220|NCT00436670|Biological|AMG 317 150 mg|150 mg SC once weekly injection
75895221|NCT00436670|Biological|AMG 317 300 mg|300 mg weekly SC injection
75601077|NCT05864196|Radiation|Two-Fraction Stereotactic Body Radiation Therapy (SBRT)|Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer.
75601078|NCT05848427|Other|LUSZ P|LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.
75745128|NCT01010334|Other|standard of care|All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
75745129|NCT04643418|Drug|MPB-1734|Administered once daily in a 21-day cycle
75895222|NCT00436670|Biological|Placebo|Placebo SC once weekly injection
75895223|NCT02284646|Other|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
75895224|NCT04055337|Procedure|Flap sliding|"All subjects underwent the flap sliding technique, which was performed at the Alforsan Eye Centre in Assiut, Egypt. Prior to surgery, all subjects underwent corneal imaging with anterior segment optical coherence tomography to confirm the presence of striae. All surgical procedures were performed by the same surgeon 1 or 2 days following LASIK.~Subjects were administered a topical anesthetic. Striae location and orientation were then determined after drying the corneal surface with a cellulose sponge. The sponge was used to push the LASIK flap over the stromal bed in a direction that was perpendicular to the striae. The flap was pushed from the proximal side of the striae toward the flap edge. The ultimate goal was to move striae and put the flap into its proper place. Following surgery, OCT imaging was repeated."
75895225|NCT03187509|Drug|Torsemide|These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
75895226|NCT03187509|Other|Standard Outpatient Heart Failure Management|Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
75895227|NCT05121532|Diagnostic Test|Interleukin-15 and Interleukin-22|Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo
75895228|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
75895229|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
75895230|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
75895231|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
75745130|NCT00617591|Drug|Lenalidomide|25 mg orally on days 1-21
75745131|NCT00617591|Drug|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated)
75745132|NCT00617591|Drug|Dexamethasone|40 mg orally on days on 1-4
75745133|NCT00865865|Procedure|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
75745134|NCT00865865|Procedure|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
75745135|NCT00864305|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
75745136|NCT00864305|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
75745137|NCT00864305|Drug|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
75745138|NCT00870935|Procedure|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
75745139|NCT00870935|Procedure|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
75745140|NCT00510276|Drug|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
75745141|NCT00510276|Drug|Placebo|twice a day, by mouth for 12 weeks
75745142|NCT00871091|Procedure|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
75895232|NCT04221880|Drug|Bupivacaine Hcl 0.25% Inj|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine
75745143|NCT00871091|Procedure|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
75745144|NCT00871091|Procedure|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
75895233|NCT04221880|Drug|Saline Solution for Block|Ultrasound-guided erector spinae plane block with 20 ml saline
75895234|NCT04221880|Drug|Saline Solution intravenously|Same volume saline solution bolus and infusion as Group Lidocaine
75895235|NCT04221880|Drug|Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion
75895236|NCT04055415|Biological|adipose derived mesenchymal stem cells|The MSCs of 1×10*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg.
75895237|NCT04055415|Drug|Conventional drug therapy（expectorant，bronchodilator）|Conventional drug therapy（expectorant，bronchodilator）
75745145|NCT00864617|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
75895238|NCT05218759|Drug|Anlotinib|anlotinib administration at a dose of 10 mg daily
75745146|NCT00864617|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
75745147|NCT00865943|Drug|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
75895239|NCT01922752|Drug|CEP-37440|"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."
75895240|NCT03662217|Other|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria
75745148|NCT00865943|Drug|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
75895241|NCT03662217|Other|ADA- based diet|The American standard of care dietary guidelines for diabetes.
75745149|NCT00866021|Drug|Lopinavir/ritonavir|NRTI sparing-regimen
75895242|NCT03661359|Other|Social Determinants of Health Referrals|Patients who screen positive for any of the Social Determinants of Health will be given information for referral to any of the community resources that apply to their situation.
75895243|NCT00427856|Drug|Obatoclax mesylate|Obatoclax mesylate 40mg, and 60mg
75895244|NCT00427856|Drug|Rituximab|Rituximab
75895245|NCT00427154|Drug|rosiglitazone|Tablets, 4 mg once or twice daily.
75895246|NCT00427154|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
75895247|NCT00427154|Drug|metformin|Tablets, 2000 mg/day.
75449958|NCT01701128|Other|Control group|Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
75449959|NCT01701180|Drug|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
75449960|NCT01701180|Drug|Placebo|
75449961|NCT01701206|Behavioral|HIV knowledge Intervention|
75449962|NCT01701219|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
75449963|NCT01701232|Biological|rituximab|Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
75745150|NCT00866021|Drug|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
75895248|NCT00427154|Drug|glimepiride|Tablets, 8 mg/day.
75895249|NCT03627871|Behavioral|Majority Norm|Participants receive information about exercise norms that apply to the majority of the population but are given no information about trends in this norm.
75895250|NCT03627871|Behavioral|Trending Minority Norm|Participants receive information about exercise norms that apply to the minority of the population and have recently been trending up.
75895251|NCT03627871|Behavioral|Minority Norm|Participants receive information about exercise norms that apply to the minority of the population but are given no information about trends in this norm.
75895252|NCT03627871|Behavioral|Control|Participants receive information about exercise that is unrelated to social norms or trends in social norms.
75895253|NCT03627871|Behavioral|Trending Majority Norm|Participants receive information about exercise norms that apply to the majority of the population and have recently been trending up.
75449964|NCT01701297|Drug|cotrimoxazole|Cotrimoxazole 960mg orally each day (two 480mg tablets)
75449965|NCT01701297|Drug|VSL#3 active|The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks
75895254|NCT02988219|Drug|Bupivacaine-fentanyl|Local anesthetic
75895255|NCT02988219|Device|Holter ECG monitor|3-chanel, CM5 leads
75895256|NCT02988219|Procedure|Open kidney cancer surgery|Lateral position
75895257|NCT02988219|Procedure|General anesthesia|
75601079|NCT05848050|Procedure|biological samples (blood test and lumbar puncture)|"On the day of excision of the cerebral metastasis, additional biological samples (blood test and lumbar puncture) will be taken in the operating room.~A biological sample of the tumor tissue (brain metastases of a solid cancer with contrast uptake of at least 1 cm accessible to surgical excision) will also be taken and preserved by freezing, in accordance with current practice and after obtaining their written agreement. .~Biological samples (liquid biopsies and tumour) from patients who have explicitly expressed their consent will be kept after the end of the research as part of a biobank in order to be able to carry out any additional analyses."
76063308|NCT01893580|Behavioral|Experimental: 1. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
75895258|NCT02988219|Procedure|Epidural Anaesthesia|
75895259|NCT05120674|Behavioral|NAP|During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device. The pairing of the tone with the intervention is expected to trigger benefits of the exercise in reducing nightmare disturbance during sleep.
75895260|NCT05120674|Behavioral|CPT|Cognitive Therapy for PTSD
75745151|NCT00866099|Other|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
75895261|NCT05120674|Behavioral|ERRT|ERRT asks individuals to rewrite the traumatic event that triggered their nightmares and then review the rescription before bed. This technique has been proven to drastically reduce the frequency of chronic nightmares.
75895262|NCT05120674|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia that includes behavioral and cognitive interventions related to sleep hygiene, increasing sleep drive, and modifying behaviors that result in association between laying in bed and wakeful states.
76063309|NCT01893580|Behavioral|Experimental: 2. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:~Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
76063310|NCT01893580|Behavioral|Experimental: 3. Experimental|"Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
75895263|NCT01346059|Drug|Vancomycin|Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
75601080|NCT05836168|Dietary Supplement|Omnibiotic Stress Repair|multispecies probiotic
75601081|NCT05836168|Dietary Supplement|Placebo|Placebo
75895264|NCT01346059|Drug|Saline|Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
75895265|NCT03661281|Diagnostic Test|Jebsen Taylor Hand function test|consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
75895266|NCT03661281|Diagnostic Test|Pinch strength|Measured in every splint position using a standard dynamometer
75895267|NCT03661281|Diagnostic Test|Grooved pegboard test|Time will be measured and compared between control, MP splint and IP splint
75895268|NCT03202030|Procedure|Immediate dentoalveolar restoration|Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
75895269|NCT03202030|Procedure|Demineralized bovine bone|Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
75601082|NCT05833321|Diagnostic Test|Sarcopenia diagnostic test|"measurement of impedance and physical tests (hand grip dynamometer, walking test), SEFI nutritional intake questionnaire"
75895270|NCT02284724|Procedure|Dry Needling|
75895271|NCT02284724|Procedure|Sham Needling|
76063311|NCT01893580|Behavioral|Other: 4. Usual care|"Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.~The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
76072155|NCT03047135|Drug|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
75601083|NCT05830461|Behavioral|Online psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be online and self-applied. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
75895272|NCT05204069|Drug|Instillation of cyclopentolate|Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
75895273|NCT03661203|Behavioral|Focus group|Focus group for qualitative group only
75895274|NCT03661203|Behavioral|Individual interview|Individual interview for qualitative group only
75895275|NCT03661203|Behavioral|online self questionnaire|online self questionnaire
75895276|NCT03661203|Behavioral|self questionnaire|online self questionnaire following focus group or individual interview For qualitative group only
75895277|NCT04548973|Drug|Esketamine|Esketamine
75895278|NCT04548973|Drug|Normal saline|2ml normal saline
75895279|NCT02277938|Drug|Amantadine|Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
75895280|NCT04056585|Procedure|Ultrasound guided axillary plexus block|Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
75895281|NCT04056585|Procedure|Intermittent pneumatic compression maneuver|Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
75449966|NCT01701297|Drug|VSL#3 placebo|This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
75449967|NCT01701310|Drug|Ferric carboxymaltose|A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
75449968|NCT01701310|Drug|Ferrous Sulphate|(Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
75449969|NCT01701323|Biological|Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion|Given IV
75449970|NCT01701323|Drug|Cytarabine|Given IV
75449971|NCT01701323|Drug|Filgrastim|Given SC or IV
75449972|NCT01701323|Drug|Fludarabine Phosphate|Given IV
75449973|NCT01701336|Biological|Ad6NSmut, MVA-NSmut|2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
75449974|NCT01701349|Drug|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
75449975|NCT01701349|Drug|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
75449976|NCT01701440|Device|Biofusionary Bebe|
75449977|NCT01701453|Drug|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
75449978|NCT01701466|Other|Aveeno cream|Twice a day
75449979|NCT01701466|Other|Flamazine cream|Twice a day, when there is dry desquamation
75449980|NCT01701466|Other|NeoVIDERM cream|Three times a day
75449981|NCT01701479|Drug|ch14.18/CHO|
75449982|NCT01701479|Drug|Aldesleukin|
75449983|NCT01701479|Drug|Isotretinoin|
75449984|NCT01701492|Other|Questionnaire|A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
75449985|NCT01701492|Other|Neurocognitive Evaluation|A one-time neurocognitive evaluation conducted in the Psychology Clinic
75449986|NCT01701518|Drug|Ozurdex|biodegradable 0.7mg dexamethasone implant
75449987|NCT01701531|Drug|RBCPF|
75895282|NCT05120518|Other|Collection of post mortem tissue donation|Collection of post mortem tissue from pediatric participants with cancer and non-cancer tumor types from whom post mortem tissue donation and autopsy consent is obtained.
75895283|NCT04710875|Drug|Na-lactate|intravenous
75895284|NCT04710875|Drug|Sodium chloride|Intravenous
75895285|NCT04055805|Behavioral|Observational Analysis|Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
75895286|NCT00415142|Drug|saredutant (SR48968)|oral administration (capsules)
75895287|NCT00415142|Drug|placebo|oral administration (capsules)
75895288|NCT00415142|Drug|escitalopram|oral administration (capsules)
75895289|NCT03661125|Drug|Saracatinib|AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
75601084|NCT05830461|Behavioral|Psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be delivered through printed materials. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
75601085|NCT05826834|Device|ball-rolling (Myostorm ball)|the intervention group
75745152|NCT00864695|Other|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
75895290|NCT03661125|Drug|Placebo Oral Tablet|Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
75449988|NCT01701544|Device|NBM DBS|Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
75895291|NCT00413114|Drug|Obatoclax mesylate (GX15-070MS)|
75745153|NCT00871247|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
75745154|NCT00871247|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
75895292|NCT03660579|Other|HIIT-AB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer with 5.4% alcohol.
75895293|NCT03660579|Other|HIIT-NAB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%).
75449989|NCT01701557|Other|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
75745155|NCT01010412|Device|Ultrasound (Sonosite Titan T-shaped ultrasound probe)|Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.
75449990|NCT01701557|Other|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
75449991|NCT01701583|Drug|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
75449992|NCT01701596|Procedure|Immediate rotational atherectomy (RA)|Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.
75449993|NCT01701596|Procedure|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
75745156|NCT01010412|Device|Electrical Nerve Stimulation (Stimuplex (B Braun) needle)|
75895294|NCT03660579|Other|HIIT-SW Group|Group that performed HIIT and consumed the same amount of sparkling water (0.0%).
75895295|NCT03660579|Other|HIIT-ASW Group|Group that performed HIIT and consumed sparkling water with the same amount of alcohol than the pre-established beer (5.4%).
75449994|NCT01701609|Behavioral|Cognitive Remediation Therapy|
75449995|NCT01701635|Behavioral|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
75745157|NCT04137120|Drug|Aflibercept (BAY86-5321, Eylea)|Intravitreal injection of aflibercept as scheduled by treating physician
75745158|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
75745159|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
75745160|NCT00616655|Drug|Placebo|Placebo total daily dose 0.9 mg
75895296|NCT01318915|Drug|ATG|1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.
75895297|NCT01318915|Drug|Rituximab|375 mg/m^2 IV infusion on day -6 before transplant and on day 1 after transplant.
75895298|NCT01318915|Drug|Tacrolimus|Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.
75895299|NCT01318915|Drug|Sirolimus|Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.
75895300|NCT01318915|Drug|MMF|1 g twice daily on days 0 through 12
76072156|NCT03042650|Behavioral|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
75745161|NCT00510198|Device|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
75895301|NCT04508842|Biological|CD19/CD22-Dual-STAR-T|Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
75895302|NCT04688177|Device|Body Composition|The subjects should lie in the supine position on a non-conducting surface for 5 min. 4 surface electrodes with cables will be attached to the right hand and ankle of subjects.
75895303|NCT04688177|Device|Heart rate variability|After supine quietly for 20 min, a lead I electrocardiogram will be taken for 5 min.
75449996|NCT01701635|Behavioral|usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
75601086|NCT05815810|Other|Attuned: A mobile application|Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
75601087|NCT05815810|Other|In-Person Voice Modification Therapy|Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
75601088|NCT05791071|Device|Floreo VR Building Social Connections|Floreo's VR platform consists of a VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) that are seamlessly linked in real time, allowing the therapist (or monitor) to set up lessons, change the interactive environment, and provide live verbal and VR-based guidance, feedback, and rewards to users. The lessons that will be implemented in this intervention are aimed at targeting social skills such as communication, joint attention, and social interactions.
75745162|NCT00510198|Device|Standard of Care alone (clinical assessment)|Clinical assessment utilizing standard of care, alone.
75745163|NCT00864773|Procedure|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
75745164|NCT01010490|Procedure|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
75895304|NCT04688177|Device|Grip Strength|The participants will squeeze the hand dynamometer as hard as possible with the dominant hand. 3 successive measurements will be taken.
75745165|NCT01010490|Procedure|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
75745166|NCT01010490|Procedure|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
75745167|NCT00871559|Drug|REGN421(SAR153192)|
75895305|NCT04688177|Device|Exhale Carbon Monoxide Concentration|Subjects in sitting position, performing 1 inspiration, then exhale to carbon monoxide meter.
75895306|NCT04688177|Device|Pulmonary Function Test|Subjects should be in a sitting position with a nose clip, then perform pulmonary function test. Participants should perform at least 3 acceptable attempts, but no more than 8 attempts in total.
75895307|NCT04688177|Device|Respiratory Muscle Function|Subject will perform both maximal inspiratory pressure and maximal expiratory pressure for 3 times in sitting position with the nose clip.
75449997|NCT01701648|Other|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
75449998|NCT01701661|Procedure|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
75895308|NCT04688177|Behavioral|Fagerström Test for Nicotine Dependence|Fagerström Test for Nicotine Dependence Traditional Chinese version will be adopted. It is a 6-item questionnaire that could help quantify the smoking frequency, amounts, and level of dependence.
75895309|NCT04688177|Behavioral|Seven-Day Physical Activity Recall Questionnaire|Physical activity will be measured by the Chinese Version of the Seven-Day Physical Activity Recall Questionnaire. Participants will need to recall the time (hours) they spent in various leisure activities in the past 7 days.
75449999|NCT01701661|Other|conservative treatment|Compression stockings class II
75450000|NCT01701700|Procedure|portable electronic magnifier|
75745168|NCT05227859|Procedure|Piezocision|After anesthesia, three vertical incisions will be made (3-mm depth and 8-10 mm length) mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar. The surgical procedures will be repeated after six weeks (only the mesial and distal canine incisions will be done)
75601089|NCT05791071|Device|Sham|This condition will contain the same VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) as the intervention condition, but instead of social skill lessons, only non-intervention, active VR videos such as underwater fish swimming will be shown.
75745169|NCT05227859|Device|Low-level laser|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) will be applied around the upper canine in 10 sites from buccal and palatal. The middle of the extraction site will be also irradiated in 4 sites (2 buccally and 2 palatally). The LLLT will be applied 5 times in the first month of canine retraction, then every two weeks until class I canine relationship will be achieved.
75895310|NCT04688177|Device|Cardiopulmonary exercise testing|Bruce protocol as the treadmill evaluation protocol will be adopted for cardiopulmonary exercise testing.
75601090|NCT05789238|Behavioral|ANVISA|Products carrying front-of-package labels based on Brazil's Health Regulatory Agency (ANVISA's) nutrient profile model
75601091|NCT05789238|Behavioral|PAHO|Products carrying front-of-package labels based on the Pan-American Health Organization (PAHO's) nutrient profile model
75601092|NCT05778526|Behavioral|Virtual reality|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session of the Social VR intervention lasts for a maximum of 20 minutes. The intervention contains three real-life virtual scenarios, including (1) a classroom and playground, (2) an MTR station and compartment, and (3) a supermarket and restaurant.
75745170|NCT05227859|Device|Conventional treatment|The upper canine destalization will be done using NiTi springs. The force level will be controlled every 2 weeks. Retraction will be stopped when a class I canine relationship in both sides.
75745171|NCT05227781|Dietary Supplement|L-Citrulline|8 weeks of L-Citrulline supplementation (10 grams/day)
75895311|NCT02278796|Drug|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
75895312|NCT02278796|Drug|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
75895313|NCT02987205|Device|Revanesse Ultra|NLF correction
75895314|NCT02987205|Device|Restylane|NLF Correction
75895315|NCT00411242|Drug|agomelatine|
75895316|NCT00411242|Drug|placebo|
75895317|NCT04530643|Drug|HY209 0.3%|25 subjects will be assigned to drug (HY209 0.3% gel).
75895318|NCT04530643|Drug|HY209 0.5%|25 subjects will be assigned to drug (HY209 0.5% gel).
75895319|NCT04530643|Drug|Placebo|25 subjects will be assigned to drug (Placebo).
75895320|NCT03238053|Procedure|Vaginal laser treatment|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
75895321|NCT03238053|Device|sham|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
75450001|NCT01701700|Procedure|optical aids|
75450002|NCT01701713|Device|DKI ED2011|
76072157|NCT03042650|Behavioral|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
75450003|NCT01701713|Device|Sham-TDCS|
75450004|NCT01701726|Other|acupuncture|In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
75450005|NCT01701726|Other|Sham acupuncture|In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
75450006|NCT01701739|Drug|aleglitazar|Multiple doses of aleglitazar
75450007|NCT01701739|Drug|digoxin|Single dose of digoxin
75450008|NCT01701752|Biological|FP-01.1 + Placebo|
75895322|NCT03238053|Device|laser system|FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
75895323|NCT05230420|Other|Clamping|Clamping of chest tube
75895324|NCT05230420|Other|Urine bag|Attachment of a urine bag to chest tube
75895325|NCT03622671|Procedure|Skeletonized LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
75895326|NCT03622671|Procedure|Pedicled LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
75895327|NCT05230264|Other|Elective AAA Repair|Elective AAA Repair - Observation of Stress Response
75895328|NCT02279810|Behavioral|survey|Survey
75745172|NCT05227781|Dietary Supplement|Placebo|8 weeks of Placebo (maltodextrin; 10 grams/day)
75745173|NCT05227469|Behavioral|myofunctional therapy|In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
75895329|NCT01658293|Behavioral|thermal stimulation|The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
75895330|NCT01658293|Behavioral|control group ergometer exercises|The control group will be given ergometer exercises with the similar duration as experimental group.
75895331|NCT05203913|Drug|Nivolumab|The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
75895332|NCT05203913|Drug|Nab paclitaxel|The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
75895333|NCT05203913|Drug|Cisplatin|The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
75895334|NCT05203913|Radiation|Radiotherapy|Radiotherapy will be delivered over approximately 5 weeks.The total radiotherapy dose will be: 60 Gray in 25 fractions over 5 weeks on original bladder tumour, 50 Gray in 25 fractions over 5 weeks on whole bladder and pelvic nodes if included, administered as concomitant boost. Radiation therapy will be delivered once daily (Monday-Friday) continuously without a planned break for tumour response assessment during treatment.
75895335|NCT03660501|Device|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.
75895336|NCT05230108|Procedure|Advanced Triage|Advanced triage is an intervention that allows the emergency nurse to resolve health problems of low clinical complexity. All actions are aimed at resolving a health problem based on a protocol previously agreed upon by a multidisciplinary team.
75895337|NCT00402428|Drug|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
75895338|NCT00402428|Drug|peginterferon alfa-2a|180 mcg once a week for 48 weeks
75895339|NCT00402428|Drug|Ribavirin|"1000 mg/day(for subjects <75kg) or 1200 mg/day (for subjects~=,> 75kg)"
75745174|NCT00516048|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
75895340|NCT05120206|Procedure|Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).|Non-surgical and surgical periodontal therapy in cigarette smokers and non-smokers
75895341|NCT03108339|Other|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
76072158|NCT03028857|Drug|Choline|Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
75450009|NCT01701752|Biological|FP-01.1 + TIV|
75745175|NCT00866255|Device|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
75745176|NCT04039997|Device|CPRMeter|teaching resuscitation with application of cpr feedback device
75745177|NCT04039997|Other|Manual chest compression|Manual chest compression
75745178|NCT04040855|Other|Medication review|Multi-professional medication review
75745179|NCT00866411|Procedure|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
75745180|NCT00866411|Procedure|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
75895342|NCT05120050|Device|ASP Health instrument|The instrument is an integrated device with a short processing time (measured in 2 to 3 minutes) that distributes cells from limited volume samples (measured in microliters). The process involves a novel aerosolization technique that transfers liquid sample to a glass slide via a burst of air. After the sample is deposited on the glass slide, the automated system uses an integrated heating strip to heat the specimen slide. This process is similar to using a hair dryer to dry the specimen slide in the current ROSE setting. After drying the slide, the system uses series of pumps to dispense microliters of stain reagent onto the slide to stain the cells. Currently, the system is configured to perform DiffQuik staining, which is commonly used in the ROSE process. In the future, the staining capability will be broadened to include other staining processes such as Rapid PAP, H&E staining etc.
75895343|NCT03953599|Biological|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
75895344|NCT03660267|Other|caffeine coffee|"drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
75895345|NCT03660267|Other|decaffiene coffee|"drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
75895346|NCT03660267|Other|still water|"drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
75895347|NCT03950245|Other|Placebo|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.
75895348|NCT03950245|Other|GLP-1 antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.
75895349|NCT03950245|Other|GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.
75895350|NCT03950245|Other|GLP-1 and GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
75895351|NCT02937077|Device|Medtronic Reveal LINQ|
75895352|NCT03660111|Diagnostic Test|spirometry|only measurement of spirometry
75601093|NCT05778526|Behavioral|Traditional social skills training|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session lasts for a maximum of 20 minutes. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise.
75745181|NCT05227625|Behavioral|body dissatisfaction management group|"Our group is composed of 10 weekly session of 2 hours led by a psychologist trained in the management of ED and ACT therapy.~Each group will be composed of 5 to 10 people. First of all, the group will lead the participants to better know and understand the impact of BD on the symptomatology of ED by teaching current scientific knowledge on the subject. In a second step, the group will guide the patients in the acquisition of psychological skills to deal with events related to BD and to engage in actions towards the values that give meaning to their existence."
75895353|NCT05208515|Other|independent obsteric operating center|send emergency cesarean section needing women from labor room to independent obstetric operating center
75895354|NCT05208515|Other|general operating center|send emergency cesarean section needing women from labor room to general operating center
75895355|NCT04211818|Behavioral|Eating Behavior|A dietary book will be given to the patient and will be filled by this one during 14 days
75895356|NCT04211818|Biological|Blood glucose records|A glycemic sensor will be placed at the back of the patient's arm
75895357|NCT03660033|Diagnostic Test|ECG in delivery room|See arm/group discussions
75895358|NCT00401570|Drug|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
75601094|NCT05773001|Drug|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
75895359|NCT00401570|Drug|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
75895360|NCT02284958|Behavioral|Standard|Back care advice
75895361|NCT02284958|Behavioral|Walking|Back care advice, individualized 12 week pedometer-driven walking program
75601095|NCT05765045|Diagnostic Test|Nursing triage protocol|Medically approved and supervised standing order that allows trained ER nurses to start medical imaging (RX) for adult patients with minor traumata to the limbs.
75601096|NCT05752760|Other|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
75895362|NCT05193565|Drug|Sirolimus|Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~8ng/mL
75895363|NCT05193565|Drug|Mycophenolate mofetil|Up to 1g BID(total 2g daily), PO
75895364|NCT03214887|Biological|RV-P1501|Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
75895365|NCT05189587|Device|transcranial electrical stimulation (TES)|Transcranial electrical stimulation (tES) is a noninvasive brain stimulation technique that passes an electrical current through the cortex of the brain to alter brain function. The electrical current is applied to an individual's scalp usually via two or more electrodes, and whilst a large amount of the current is conducted between electrodes through soft tissue and skull (Vöröslakos et al. 2018), a portion of the current penetrates the scalp and is conducted through the brain, where it can alter neuronal excitability. By altering the activity of brain regions involved with a behaviour of interest, investigators can observe the resulting behavioral changes and so establish a causal link between the two (Reed et al. 2018).
75895366|NCT04471922|Drug|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
75895367|NCT04471922|Drug|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
75895368|NCT04471922|Drug|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
76063312|NCT02718040|Device|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
76063313|NCT01893658|Drug|Omalizumab|administration of a single dose together with the standard treatment
75745182|NCT05227625|Behavioral|Relaxation Group|Participants will be included in a standardized relaxation program consisting of a weekly 2 hour session for 10 weeks. The group will be led by a psychologist trained in relaxation and in particular in abdominal and muscular relaxation techniques. Each group will be composed of 5 to 10 people. Initially, the therapy will lead the participants to recognize the signs of anxiety and to understand the physiological mechanisms involved. Classic techniques of anxiety management will then be introduced (cardiac coherence, abdominal and muscular relaxation, Jacobson technique, Schultz autogenic training). These techniques will be tested in session. Participants will be encouraged to practice these techniques at home.
75745183|NCT00871793|Other|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
75895369|NCT04368364|Drug|Intrathecal morphine sulfate (ITM)|Spinal anesthesia with ITM + US guided QLB single shot sham block + QLB catheters with no continuous infusion
75895370|NCT04368364|Drug|Bupivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters with no continuous infusion
75745184|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
75745185|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
75745186|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
75745187|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
75745188|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
75895371|NCT04368364|Drug|ropivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters continuously infusing 0.2% ropivacaine hydrochloride
75895372|NCT02285036|Biological|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
75895373|NCT02285036|Biological|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
75895374|NCT03659877|Behavioral|Physical activity|Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
75895375|NCT05180851|Drug|Recombinant L-IFN adenovirus injection|Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
75895376|NCT00543374|Drug|Placebo|Placebo
75895377|NCT00543374|Drug|PROCHYMAL adult human mesenchymal stem cells|intravenous infusion four times over two weeks; possibly repeated once
75895378|NCT04056195|Drug|SKI-O-703|The SKI-O-703 capsules will contain 100 mg of drug substance.
75895379|NCT04056195|Drug|Placebo oral tablet|Placebo capsules are filled with microcrystalline cellulose.
75895380|NCT02926937|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet;~Route of administration: oral"
75895381|NCT02926937|Drug|Placebo|"Pharmaceutical form: tablet;~Route of administration: oral"
76063314|NCT01893658|Drug|Prednisone|standard treatment
75745189|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
75745190|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
75745191|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
75745192|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
76063315|NCT02692768|Other|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
75601097|NCT05752760|Other|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
75895382|NCT05174533|Other|Data collection|electrocardiogram
75895383|NCT05229796|Drug|Empagliflozin 10 mg Tab|The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
75450010|NCT01701752|Biological|FP-01.1-Adjuvant + Placebo|
75450011|NCT01701752|Biological|FP-01.1-Adjuvant + TIV|
75450012|NCT01701752|Biological|Adjuvant + TIV|
75450013|NCT01701752|Biological|Placebo + TIV|
75450014|NCT01701752|Biological|FP-01.1|
75601098|NCT05741853|Behavioral|Video-Implemented Script Training for Aphasia (VISTA)|Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
75450015|NCT01701752|Biological|FP-01.1-Adjuvant|
75450016|NCT01701752|Other|Placebo|
75450017|NCT01701778|Drug|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline"
75450018|NCT01701778|Drug|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg"
75450019|NCT01701778|Drug|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline"
75450020|NCT01701778|Drug|sevoflurane|Induction and maintain anaesthesia
75450021|NCT01701791|Other|Computerized Decision Support System|
75895384|NCT04426981|Behavioral|Behavioral Activation|Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities. In the first session, participants will begin to identify domains of their life which are important to them. In the second session, participants will be assisted in creating an action plan to engage in more activities in one or more domains of importance. In session 3-8, participants will be assisted in problem solving any challenges they encountered in implementing their previous action plan and will develop a new action plan. The intervention will continue until participants achieved three action plans or reach the eight-session limit, whichever comes first.
75895385|NCT03627481|Procedure|Endoscopic sinus surgery|Endoscopic sinus surgery for nasal polyposis
76063316|NCT02692768|Other|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
75895386|NCT00151892|Drug|SPD476|2.4 g/day Once Daily (QD)
75895387|NCT00151892|Drug|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
75895388|NCT05093491|Diagnostic Test|Spirometry and ultrasonography in stroke group|Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio in the supine position in the stroke patient group. The spirometric evaluation was also performed
75601099|NCT05741853|Behavioral|Lexical Retrieval Training (LRT)|Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.
75601100|NCT05736341|Drug|Remimazolam besylate|After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.
75745193|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
75745194|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
75745195|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
75745196|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
75895389|NCT05093491|Diagnostic Test|Spirometry and ultrasonography in healthy group|Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio in the supine position in healthy individuals group. The spirometric evaluation was also performed
75895390|NCT04914091|Other|Semi-structured interviews and self-administered questionnaires|Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
75601101|NCT05736341|Drug|Midazolam|After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
75601102|NCT05724654|Dietary Supplement|Skin roasted peanuts|Study volunteers will receive daily 60 g of skin roasted peanuts for 16 weeks.
75745197|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
75745198|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
75745199|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
75745200|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
75745201|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
75745202|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
75895391|NCT02740127|Procedure|Caudal Nerve Block (CNB)|General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
75895392|NCT02740127|Drug|Ropivacaine|Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
75895393|NCT02740127|Drug|Epinephrine|Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
75895394|NCT02740127|Drug|Decadron|Decadron 10 mg by bolus injection given by anesthesiologist in OR.
75895395|NCT02740127|Drug|Clonidine|Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
75895396|NCT02740127|Drug|Propofol|General anesthesia given in the OR using Propofol titrated for induction.
76063317|NCT02692768|Other|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
75601103|NCT05723861|Device|VR|We will use the Pico Headset, a three-dimensional Gear with a connected tablet, and will be positioned on the head with elastic straps. Patients will be instructed about the VR device before their procedure and virtual experiences will initiate just before colonoscope insertion and continuously delivered throughout the procedure for max of 20 minutes. Patients will experience max of 20 minutes of VR and if colonoscopy lasts longer than 20 min, the remaining time of colonoscopy will be performed without using VR. The visualized content of VR will be chosen by the participants among three available contents including beach, nature, or mountain with relaxing music. Participants could opt out and/or request standard medications for pain at any time before or during the procedure.
75601104|NCT05690984|Drug|Dexamethasone|Dexamethasone will be used for the double purpose of premedication and therapeutic effect. On Day 1 of Cycle 1, subjects will be administered 40 mg dexamethasone as an IV infusion. On Days 8, 15, 22 of Cycle 1 and Days 1 and 15 of Cycles 2-4, dexamethasone will be given as a single oral dose of 40 mg. For Cycles 5-12, dexamethasone will be given as a single oral dose of 4 mg on Days 1 and 15.
75601105|NCT05690984|Drug|Isatuximab|Following premedication (if applicable), subjects will be given isatuximab 10 mg/kg body weight as an intravenous (IV) infusion on Days 1, 8, 15, and 22 (i.e., weekly) during Cycle 1 and on Days 1 and 15 (i.e., Q2W) during Cycles 2-12.
75745203|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
75745204|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
75745205|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
75745206|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
75895397|NCT02740127|Behavioral|Phone Call|Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
75895398|NCT05119504|Behavioral|Acceptance and Commitment|"During the 90-minute, one-on-one interventionist led session, participants will learn three inter-related acceptance-based techniques tailored for coping with physical discomfort and negative affect during physical activity. (1) cognitive defusion (i.e., disentangling physical sensations and thoughts from behavior), (2) acceptance (i.e., increasing willingness to experience unpleasant physical sensations/negative affect without trying to change or control them), and (3) valued action (i.e., evaluating the role of physical activity as a valued behavior). Participants will be taught these techniques via didactic instruction, metaphors, and experiential activities.~All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week."
75895399|NCT05119504|Behavioral|Multi-Health Behavior|The multi health behavior condition will include didactic material focused broadly on healthy lifestyle recommendations including physical activity. It will also emphasize that physical activity is one of several interconnected health behaviors including balanced diet, sleep, stress management. All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week.
76063318|NCT02688556|Drug|cyclosporine|
76063319|NCT02688556|Drug|vehicle of OTX-101|
75745207|NCT00866489|Procedure|remote preconditioning|Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
75895400|NCT05661019|Other|Obtain Myotrace measurements|IMyotrace measurement equipment, consisting of an application (i.e. non-medical software) running on a Philips laptop, Porti7 data acquisition system and software (Twente Medical Systems International (TMSi), Netherlands) (CE-approved), ECG cables, and three standard ECG (for EMG) electrodes. Also an on the shelf accelerometry sensor and respiration belt (TMSi) are used for the NRD measurement (CE-approved).
75601106|NCT05690984|Drug|Lenalidomide|On Days 1-21 for all 12 cycles, lenalidomide will be given to subjects as a single daily oral dose.
75895401|NCT05119426|Biological|Vi-TT|Single dose of vaccine administered through a mass vaccine campaign to children between 9 months and <16 years of age. The campaign will emulate vaccine delivery as would be administered in a local mass vaccination campaign.
75895402|NCT04590833|Behavioral|Supervised walking on a treadmill|Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.
75601107|NCT05688332|Drug|Voglibose + Metformin|"In treatment group B, 59 participants will also be randomly assigned to the voglibose 0.2/0.3mg TDS + metformin 500mg BD treatment combination to be taken orally daily, during or immediately after meals with dose titration at day 6 and 12 if the average fasting blood glucose (FBG) level is ≥7 mmol/L (126 mg/dL) and then dosage will be maintained for the remainder of the treatment period Participants in the intervention group initially receiving voglibose 0.2mg + metformin 500mg BD will be dose-titrated to voglibose 0.3mg +metformin 1g BD.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint."
75895403|NCT04590833|Behavioral|Supervised stretching exercise|Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
75895404|NCT04539431|Genetic|validation of new technologies|Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
75895405|NCT04472234|Other|BPA levels|BPA (Bisfenol A) in urine, blood and follicle fluid samples
75895406|NCT04450498|Biological|Yuxi Walvax MPV ACYW® vaccine|Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects > 2 years of age and have shown to be safe and immunogenic.
75745208|NCT00872105|Procedure|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
75895407|NCT04450498|Biological|Sanofi Pasteur Menactra® vaccine|The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.
75895408|NCT00654992|Drug|Erythropoietin-Beta|300 IU/kg of EPO or saline intravenously before surgery
75895409|NCT00654992|Drug|Normal Saline|300 IU/kg of normal saline intravenously before surgery
75895410|NCT05208203|Other|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
75895411|NCT02282462|Other|Reg Pressure|Regulated Suction using the Thopaz+ digital chest drainage device
75895412|NCT02282462|Other|Unreg Pressure|Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
75895413|NCT02282462|Other|Active Suction (Dig)|Thopaz+ digital chest drainage device set at -20cmH2O at the patient
75895414|NCT02282462|Other|Active Suction (Trad)|Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
75895415|NCT02282462|Other|Passive Drainage (Dig)|"Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)"
75895416|NCT02282462|Other|Passive Drainage (Trad)|"Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')"
75745209|NCT00872105|Procedure|Operative Treatment|"The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)"
75745210|NCT00876083|Drug|Ultravist (Iopromide, BAY86-4877)|Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
75895417|NCT05207969|Procedure|Instruction to urinate|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
75895418|NCT03055195|Drug|Mepolizumab 100 mg|Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
75895419|NCT03055195|Drug|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
75895420|NCT02282540|Procedure|Iodixanol to the Eustachian tube|Application of iodixanol to the middle ear for imaging of the ET.
76063320|NCT01925209|Drug|BYM338/bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
76063321|NCT01925209|Drug|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
75450022|NCT01701804|Drug|Chuna herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
75450023|NCT01701804|Procedure|Chuna manual therapy|A type of Korean spinal manual therapy administered 5~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
75450024|NCT01701804|Procedure|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10~20 acupoints once a week for 16 weeks.
75450025|NCT01701804|Procedure|Bee-venom pharmacoacupuncture|Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
75745211|NCT05225909|Device|Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope|ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
75745212|NCT00876161|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
75745213|NCT00876161|Drug|Lactose|
75745214|NCT00872417|Drug|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
75745215|NCT00872417|Drug|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
75745216|NCT00872573|Device|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
75745217|NCT00876317|Drug|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
75745218|NCT00876317|Drug|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
75745219|NCT00866645|Drug|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
75745220|NCT00866645|Drug|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
75745221|NCT00872651|Drug|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
75745222|NCT00872651|Drug|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
75745223|NCT00872807|Behavioral|Lifestyle counseling in groups|"The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.~They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months."
75745224|NCT00872807|Behavioral|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
75895421|NCT02921919|Drug|Talazoparib|Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
75895422|NCT02737553|Procedure|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
75895423|NCT02737553|Procedure|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
75895424|NCT00393068|Drug|Erlotinib|Erlotinib
75895425|NCT00393068|Drug|Bevacizumab|Bevacizumab
75895426|NCT00393068|Drug|Paclitaxel|Paclitaxel
75895427|NCT00393068|Drug|Carboplatin|Carboplatin
75895428|NCT00393068|Drug|5-FU|5-FU
75895429|NCT00393068|Procedure|Radiation therapy|Radiation therapy
75895430|NCT00393068|Procedure|Surgery|Surgery
75895431|NCT03659643|Diagnostic Test|EEG with SPR analysis|qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
75895432|NCT03658863|Procedure|endoscopic ultrasound|Evaluation of bile ducts with endoscope with special ultrasonographic function
75895433|NCT03658863|Procedure|intraoperative cholangiography|evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
76063322|NCT02684032|Drug|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
76063323|NCT02684032|Drug|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
76063324|NCT02684032|Drug|Letrozole|Letrozole at 2.5 mg daily
75745225|NCT00876473|Procedure|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator"
75745226|NCT00876551|Procedure|Endoscopic vacuum assisted closure|"Endoscopic debridement of wound using a regular biopsy forceps.~Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)~Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson & Johnson, St-Stevens-Woluwe, Belgium).~Trimming of the sponge to the specific wound size.~Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)~Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).~Sponge exchange twice a week until wound grounds are clean and closed"
76063325|NCT02684032|Drug|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
75895434|NCT03658863|Procedure|ERCP|evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
75745227|NCT00872963|Biological|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
75895435|NCT03658863|Device|Ultrasound endoscope|Endoscope with built-in ultrasound function
75769182|NCT01250392|Behavioral|The Effect of Active Choice on Nurse Visit Participation|"The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment."
75895436|NCT02280278|Procedure|Radical surgery|
75895437|NCT02280278|Drug|Adjuvant chemotherapy|
75895438|NCT02280278|Biological|Cytokine-induced killer cell immunotherapy|
75769183|NCT00420641|Drug|GSK372475|GSK372475 1.0-1.5 mg/day
76063326|NCT01614925|Device|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
76063327|NCT01614925|Procedure|Periodontal surgery|Periodontal surgery alone
76063328|NCT02388178|Drug|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
75895439|NCT02280434|Drug|CBP-307|
76063329|NCT02388178|Drug|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
75601108|NCT05688332|Drug|Glibenclamide + Metformin|"The drugs (glibenclamide + metformin), in the control or comparator group will also be taken orally, glibenclamide once a day (OD) before meals, and metformin twice a day (BD) also before meals. These drugs will also be taken with a dose-titration at days 6 and 12 if the average is FBG level will be ≥ 7 mmol/L and the dose will be maintained for the remainder of the study period.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint. In this group, participants will initially receive glibenclamide 5mg once daily (OD) + metformin 500mg BD then will be dose-titrated to glibenclamide 10mg OD + metformin 1g BD."
75895440|NCT02280434|Drug|Placebo|
75895441|NCT02285348|Procedure|Lumbar puncture|Lumbar puncture is done according to general practice
75895442|NCT00391196|Drug|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
75895443|NCT00391196|Drug|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
75895444|NCT00391196|Drug|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
75601109|NCT05685147|Genetic|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
75895445|NCT04879459|Other|Practical sessions to learn CUS exclusively on volunteers presenting a healthy gallbladder|The study days are 1 day apart for CG and IG but follow the exact same organization. Studytake place on day 0-10-30 (+/-2days). Practical sessions to learn CUS are organized either on volunteers presenting a healthy gallbladder or a pathological gallbladder (sludge, gallstones) (CG), either exclusively on volunteers presenting a healthy gallbladder (IG).
76063330|NCT02388178|Drug|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
76063331|NCT02384668|Dietary Supplement|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
75895446|NCT04861831|Other|Power Centering for Seniors intervention|Power Centering for Seniors is an innovative East-meets-West intervention (75-minute, twice weekly, supervised group classes over 12 weeks) that integrates Western best practice muscle strength and balance training components with Chinese Tai Chi/Qi Gong to improve mobility and quality of life in older, community-dwelling adults. Home practice is recommended (approximately 30 minutes three times per week on non-course days). The modularly designed course consists of four cycles with six themes repeated in each cycle. Course exercises increase in intensity throughout the twelve-week intervention period. Repetition of cycles and themes prepares participants for continuing their individualized version of the program after the group course intervention is complete. This should lead to long-term practice of the exercises learned in the intervention and to sustained positive effects of the training.
75895447|NCT03558126|Device|silicone tube|
75895448|NCT02285426|Device|Pentax EB-1990i HD-bronchoscope guided biopsy|"3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.~When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality [visual scale adapted from Herth 2009 and Zaric 2013] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control."
75895449|NCT02250144|Device|Foot orthoses|
76063332|NCT02384668|Dietary Supplement|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
75450026|NCT01701817|Other|Patients with Atrial Fibrillation|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
75450027|NCT01701843|Drug|Cromoglicate|Twice daily topical treatment for 14 days
75601110|NCT05680688|Other|Manual Therapy|"Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital."
75601111|NCT05647304|Device|RGn550 5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
75745228|NCT05193539|Behavioral|Augmented reality and virtual reality rehabilitation|"This group underwent augmented reality and virtual reality rehabilitation with 4 different systems.~The RAPAEL Smart Glove® is a wearable sensory system that contains a single 9-axis movement and position sensor with 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measures wrist movements, and 5 bending sensors that measure finger movements. The RAPAEL Smart Board® is a rehabilitation system used to improve arm function by practicing gravity-compensated movements. The RehabMaster® is a game-based Kinect sensor AR rehabilitation system which uses a 3D camera to digitize patient movements and quickly analyze their range of motion, speed, motion angle, and movement cycles. rehabilitation exercise using games to encourage active arm and trunk movements and promote successful rehabilitation. The COG-Trainer® is a VR system that uses a training device synchronized with the screen through simulation."
75745229|NCT05193539|Behavioral|Conventional occupational therapy|The group underwent standard ocupational therapy, such as range of motion and strengthening exercises for the affected upper extremity, table-top activities, and training for activities of daily living.
75745230|NCT00876629|Device|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.~The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
75745231|NCT00617357|Device|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
75745232|NCT05168501|Other|Rebreathing procedure|Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
75895450|NCT02282618|Device|Cardiac Sympathetic Blockade|
75895451|NCT04790227|Device|MRI|MRI
75895452|NCT02910219|Drug|Crofelemer|Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
75895453|NCT02250222|Drug|LGD-6972|LGD-6972 sodium salt powder in Captisol ® (betadex [β-cyclodextrin] sulfobutylether sodium, NF)
75895454|NCT02250222|Drug|Placebo (Captisol ®)|betadex [β-cyclodextrin] sulfobutylether sodium, NF
75895455|NCT00530114|Drug|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
76063333|NCT02377258|Other|Non Interventional|
75450028|NCT01701843|Drug|Placebo|Twice daily topical treatment for 14 days
75450029|NCT01701856|Drug|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
75450030|NCT01701882|Drug|tenofovir/emtricitabine/rilpivirine|
75450031|NCT01701921|Drug|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
75450032|NCT01701921|Drug|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
76063334|NCT01898923|Drug|ON101 Cream|
76063335|NCT01898923|Other|Aquacel® Hydrofiber® dressing|
76063336|NCT04251442|Device|OrthoSensor Verasense Technology|IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
75745233|NCT04039685|Other|Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
76063337|NCT04551586|Drug|ACH-0145228: Immediate Release|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
76063338|NCT04551586|Drug|ACH-0145228: Powder-in-capsule|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
75601112|NCT05647304|Device|RGn550 10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
75745234|NCT04039685|Other|Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
75895456|NCT00530114|Drug|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
75450033|NCT01701921|Drug|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
75450034|NCT01701934|Drug|Roflumilast|500 mcg, oral, once daily for 6 months
75450035|NCT01701934|Drug|Placebo|One placebo pill daily, for 6 months
75450036|NCT01701947|Biological|Hemoleven|Replacement therapy
75450037|NCT01702012|Dietary Supplement|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
75450038|NCT01702012|Behavioral|Group-Based Lifestyle Intervention|
75450039|NCT01702038|Drug|Rituximab|1000 mg administered intravenously
75601113|NCT05642962|Drug|Pertzye|Treatment with standard dose or higher dose Pancrelipase will continue for 20 weeks from enrollment. Participants will consume assigned blinded weight based Pancrelipase dose concurrent with first bite of every meal and snack for the duration of enrollment.
75601114|NCT05619445|Other|Whole Liquid Egg|Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.
75895457|NCT04769401|Other|Normal Progesterone group|Progesteron supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) as luteal phase support (referred to as day 0 of progesterone administration).
75895458|NCT04769401|Other|Low Progesterone group|Progesterone level <10 ng/mL on ET day. If serum progesterone levels were <10 ng/ml at ET day, 25 mg/d of SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day and the blood sample was taken 2 days later to check serum progesterone levels.
75895459|NCT02094222|Drug|RAVICTI|open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
75895460|NCT02280512|Device|elderly with fractures|hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
75895461|NCT03662061|Other|Assessment of the follow-up of oncological and geriatric recommendations 4 months after the RCP|"After inclusion, patient's results are discussed at a weekly onco-geriatric multidisciplinary team meeting including surgeons, geriatrics, oncologists, radiotherapist, nurse, pharmacist. Oncological and geriatric recommendations are given.~A phone call is made to the patient to evaluate the follow-up of the oncological and geriatric recommendations defined during the RCP along with their survival, autonomy and quality of life."
75895462|NCT02250378|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
75895463|NCT02250378|Procedure|therapeutic conventional surgery|Undergo wedge resection
75895464|NCT02250378|Other|laboratory biomarker analysis|Correlative studies
75895465|NCT02250378|Other|quality-of-life assessment|Ancillary studies
75601115|NCT05619445|Other|Plant-based Egg Substitute|Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
75745235|NCT04039685|Other|Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
75745236|NCT00876707|Device|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
75745237|NCT00876707|Device|ReSTOR implant|Implant of multifocal IOL ReSTOR
75745238|NCT00876707|Device|ReZoom implant|Implant of multifocal IOL ReZoom
75895466|NCT02282696|Other|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
75895467|NCT03056157|Behavioral|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
76063339|NCT01924429|Drug|Lisdexamfetamine|Escalating stepped dose titration: 30, 50 or 70mg
76063340|NCT04553848|Behavioral|Augmented Reality|Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.
75601116|NCT05597735|Drug|Tecovirimat|"The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days."
75745239|NCT00876785|Other|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
75745240|NCT00876785|Other|wheat bread based breakfast|Reference wheat bread breakfast
75601117|NCT05597735|Drug|Placebo|The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
75601118|NCT05578781|Behavioral|Music Therapy|Music Therapy is a music session with a live therapist and has been shown to reduce pain and anxiety. If effective the music medicine in this RCT will be used help design a full R01 study
75745241|NCT04040543|Dietary Supplement|lipid-based nutrient supplement containing adherence markers|The supplement will be provided once daily for 10 days
75745242|NCT04040543|Dietary Supplement|lipid-based nutrient supplement containing or not containing adherence markers|The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.
75745243|NCT04040543|Dietary Supplement|lipid-based nutrient supplement not containing adherence markers|The supplement will be provided once daily for 10 days
75601119|NCT05578781|Behavioral|Music Medicine|Music Medicine is an audio recorded music therapy session that will be played for the participant. This will be the same music session that will be played live in the music therapy session.
75745244|NCT00873197|Drug|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
75745245|NCT00873353|Drug|capecitabine + erlotinib|"6 cycles (3 weeks each one) of :~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
75450040|NCT01702064|Drug|Nilotinib|"Participants will remain on the same dose of nilotinib they have been receiving prior to enrollment on the trial. This will range from 300 mg PO BID to 400 mg PO BID.~Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose of ruxolitinib, based on the number of dose."
75450041|NCT01702064|Drug|Ruxolitinib|Dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose, based on the number of dose limiting toxicities seen at a specific dose.
75450042|NCT01702077|Procedure|Neurofeedback|
75450043|NCT01702077|Procedure|Sham feedback|
75450044|NCT01702090|Drug|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
75601120|NCT05578781|Behavioral|Control group|Control group will listen to an audio recording of text being spoken by the board certified music therapist
75745246|NCT00876941|Behavioral|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
75769184|NCT00420641|Drug|Paroxetine|Paroxetine 20-30 mg/day
75769185|NCT00420641|Other|Placebo|Placebo to Match
75745247|NCT00876941|Behavioral|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
75895468|NCT03056157|Behavioral|Present Centered Therapy|Participants randomized to the PCT arm will receive 12 sessions of therapy focused on problems occurring in the present (with no focus on trauma or re-visiting past experiences).
75745248|NCT00876941|Behavioral|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
75745249|NCT00877019|Device|Sonicare elite medium brush head|
75745250|NCT00877019|Device|Sonicare elite mini brushhead|
75745251|NCT00877019|Device|GABA Elmex sensitive extra soft toothbrush|
75895469|NCT02280590|Drug|Rosuvastatin(Cresnon®)|10mg
75895470|NCT02280590|Drug|Rosuvastatin(Crestor®)|10mg
75895471|NCT02090244|Drug|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
75895472|NCT02282774|Drug|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
75895473|NCT02282774|Drug|Sham subtenon block|
75895474|NCT02090322|Procedure|Injection of bevacizumab intravitreal (Avastin)|"The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.~When there is a Retinopathy of prematurity type 1, is the indication for the infection"
75895475|NCT03658785|Biological|TIL|On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)
75895476|NCT03658785|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.)
75895477|NCT03658785|Drug|Cyclophosphamide|On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
75450045|NCT01702103|Drug|Mometasone furoate|
75450046|NCT01702129|Drug|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
75450047|NCT01702155|Drug|DFP-10917|
75745252|NCT00877019|Device|ADA reference toothbrush|
75745253|NCT00877097|Drug|Klodronate and Kliogest|
75895478|NCT03658785|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days
75895479|NCT02282852|Device|Wireless Capsule Endoscopy|
75895480|NCT02282852|Device|Magnetically steerable capsule endoscopy|
75895481|NCT02095782|Drug|Intercalated combination of chemotherapy and erlotinib|"Primary therapy stage:~Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.~Maintenance therapy stage:~Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death."
75895482|NCT03659487|Procedure|Nissen|Laparoscopic total (Nissen) fundoplication
75895483|NCT03659487|Procedure|Toupét|Laparoscopic posterior 270 degrees partial fundoplication
76063341|NCT04553848|Behavioral|Treadmill training|The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
75450048|NCT01702168|Other|Provider training: Cognitive Processing Therapy (CPT)|
75895484|NCT02280668|Other|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
75601121|NCT05556954|Procedure|Wound debridement|"Participant that are having usual care visits for management of diabetic foot ulcers will be enrolled into this study. The procedure is done as part of standard of care. Tissue from the samples will be analyzed for this study.~Aliquoting and Deoxyribonucleic acid (DNA) extraction will be done on the specimens. Bacterial DNA from biospecimens will be isolated, quantified, amplified, and sequenced."
75745254|NCT00877097|Procedure|Placebo+ Kliogest|
75745255|NCT00877097|Drug|Bonefos|
75895485|NCT02280668|Other|the eccentric muscle damage exercise|
75895486|NCT02094378|Drug|Esketamine|84 mg esketamine administered intranasally
75895487|NCT02094378|Drug|Placebo|Placebo administered intranasally
75895488|NCT03659409|Behavioral|Mindfulness-Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
75895489|NCT03659409|Behavioral|Waitlist - Mindfulness-Based Intervention|Participants in this group will only receive the Mindfulness-Based Intervention 3-months after they have started the study and baseline measurements. While participants in the Intervention Arm are receiving the treatment, this group will receive No intervention for the first four weeks and will continue as treatment as usual until it is their turn to receive the Intervention.
75895490|NCT02285660|Procedure|4D PET-CT Scan|
75895491|NCT02285660|Other|No intervention|
75895492|NCT02095860|Drug|DCV 3DAA FDC|Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
75895493|NCT02285738|Drug|Aspirin|81mg/day for 4 weeks
75895494|NCT02285738|Drug|Simvastatin|Daily dose of Simvastatin for 4 weeks
75895495|NCT02285738|Other|Observation|participants will be observed for thrombotic evens for 4 weeks
75895496|NCT03556410|Behavioral|sleep|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
75450049|NCT01702181|Drug|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
75450050|NCT01702181|Drug|Tacrolimus|0.1% concentration of tacrolimus.
75450051|NCT01702181|Drug|Placebo|
75450052|NCT01702194|Drug|TD-1211 IV [C14]|
75450053|NCT01702194|Drug|TD-1211 PO [C14]|
75616575|NCT04533958|Device|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
75616576|NCT02841670|Device|InFo - Instant Focus (c) lens implantation|
75745256|NCT00873431|Biological|IC47|solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
75745257|NCT00877175|Drug|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
75450054|NCT01702207|Drug|Once Daily Tacrolimus|Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
75745258|NCT00867347|Procedure|therapeutic conventional surgery|Patients undergo radical cystectomy
75895497|NCT03556410|Behavioral|exercise|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
75895498|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
75450055|NCT01702207|Drug|Twice Daily Tacrolimus|Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
75450056|NCT01702220|Behavioral|CBT|6-12 sessions of CBT in person or over the phone
75450057|NCT01702220|Other|ECC|6 biweekly sessions of ECC over the telephone
75450058|NCT01702272|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
75895499|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
75895500|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
76063342|NCT04553848|Behavioral|Over ground training/standard of care|"Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:~Biomechanical Constraints~Stability Limits~Anticipatory Postural Adjustments~Reactive Postural Response~Sensory Orientation~Stability in Gait"
76063343|NCT01898299|Device|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
75601122|NCT05549960|Device|The medical device used in this study is a 980 nm wavelength diode laser with maximum output of 30 W (EUFOTON Laser Spectrum).|"EUS will be performed with a FUJIFILM EG- 580UT linear endoscope. LA will be performed with a 980 nm laser light (EUFOTON Laser Spectrum) guided by a 300 μm optical fiber (EUFOTON). AN EUS-21 gauge needle (Boston Scientific Expect Slimline) will be used for the optical fiber placement.~The protrusion of the fiber end from the needle tip should be 5 mm. After the correct placement of the fiber inside the tumor, the ablation treatment can start. Once inside the lesion, the needle will be slightly retracted, and the fiber will be gently pushed out of the needle tip by a length of 5 mm. The fiber will be placed at the top of the lesion, and the laser will be turned on. The laser settings estimated by the mathematical model will be used. The total number of ablations will depend on the radiological characteristics of the lesion and location. Special attention must be paid to have 1 cm between the fiber tip, the walls of the main vessels, and any metal stents that may be present."
76063344|NCT01898299|Device|Sham tDCS|Sham (inactive) tDCS treatment
75895501|NCT02090400|Drug|Bazedoxifene|20 mg Oral daily for 12 months
75601123|NCT05541978|Other|Multiple myeloma|We will explore the multiple myeloma associated thrombosis risk.
75895502|NCT02090400|Drug|Calcium/Vit D|Calcium 500 mg / 400 IU Vit D
75601124|NCT05535348|Behavioral|Relaxation Response Resiliency Program for Father of CYSHCN|Virtually delivered psycho-educational resiliency training program for fathers of CYSHCN
75601125|NCT05526833|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed on the scalp of the subject's head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
75450059|NCT01702285|Drug|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
75450060|NCT01702324|Drug|DD-25|A topical DD-25 cream at 0.025% concentration.
75895503|NCT04471610|Other|Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day|Serial measurements of NT-proBNP, sodium, potassium, and creatinine in the NT-proBNP-group vs. no serial measurements in control group. In the intervention group the body weight, vital parameters, therapy changes and adverse events are documented the above mention serial measurement every second business day.
75450061|NCT01702337|Other|Prevalence-based model|Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
75895504|NCT02090478|Other|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
75895505|NCT02090478|Other|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
76063345|NCT04550650|Other|Training groupe|Using virtual training
76063346|NCT04550650|Other|PNF|PNF technique was used
76063347|NCT04550650|Other|Spinning grp|They only worked with spinning bikes.
76063348|NCT04550650|Other|Balance|Balance development was done
76063349|NCT01886287|Drug|Octreotide LAR|Octreotide LAR as outlined in Treatment Arm.
75450062|NCT01702350|Drug|GSK2251052|Oral formulation of an an antibacterial
75450063|NCT01702376|Drug|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
75616577|NCT02841592|Other|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
76063350|NCT04559386|Other|Survey|Questionnaire
75895506|NCT03134846|Drug|Cetuximab-IRDye800CW|Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
76063351|NCT04395118|Behavioral|Mailed Outreach|The investigators will randomize elevated LFT patients (~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
75450064|NCT01702376|Drug|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
75450065|NCT01702376|Drug|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
75450066|NCT01702376|Drug|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
75450067|NCT01702389|Drug|Remifentanil|
75895507|NCT02094456|Procedure|Endoscopic clipping of diverticula|Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
75895508|NCT02094456|Procedure|Follow-up colonoscopy|Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
75895509|NCT04471688|Diagnostic Test|infectious disease screening|Explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening
75895510|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
75895511|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
75601126|NCT05492032|Device|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
76063352|NCT04628065|Behavioral|#BabyLetsMove|This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
75601127|NCT05492032|Device|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
76063353|NCT04393870|Other|Foccusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
76063354|NCT02707588|Drug|Pembrolizumab|"200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
75601128|NCT05492032|Behavioral|Cognitive training|Participants will complete an online cognitive training program consisting of 10 consecutive daily weekday training sessions while they receive either the active or sham tDCS stimulation. Each training session will last for 20 minutes. The online cognitive training program will comprise five exercises assessing information processing speed and executive function capacities. Each exercise will take approximately 4 minutes to complete. Given many studies, across different neurological/neuropsychiatric diagnoses, especially for people with autism, it has long been established that social skills and functioning are closely related, and multiple studies have shown that executive function training can improve social functioning in autism or vice versa (i.e. social skills training improves executive functioning in autism), it is reasonable to include cognitive training in this tDCS protocol.
75601129|NCT05488431|Drug|Bempedoic acid|Bempedoic Acid is an oral first-in-class small molecular adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor which lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Inhibition of ACL by bempedoyl-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of LDL receptors and concomitant suppression of hepatic fatty acid biosynthesis. BA has been studied in >4300 individuals and is currently being studied in >14,000 individuals in CLEAR Outcomes (NCT02993406).
76063355|NCT02707588|Drug|Cetuximab|"Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
75601130|NCT05488431|Other|Placebo|Placebo
75745259|NCT00867347|Radiation|radiation therapy|Patients undergo radiotherapy
75745260|NCT00420927|Biological|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
75745261|NCT00420927|Drug|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
75745262|NCT00420927|Biological|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
76063356|NCT02707588|Radiation|Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
75745263|NCT00573443|Drug|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
75745264|NCT00573443|Drug|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
75745265|NCT00573443|Drug|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
75745266|NCT01029561|Device|CPAP|Treatment with Continuous Positive Airway Pressure
75745267|NCT01029561|Behavioral|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
75745268|NCT05225831|Biological|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|A single infusion of CD19 and CD22 CAR-T cells.
75745269|NCT05225831|Drug|Cyclophosphamide,Fludarabine|Given
75895512|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
76063357|NCT05602480|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
75895513|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
75895514|NCT02095938|Drug|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
75895515|NCT04471376|Drug|Sugammadex|Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
76063358|NCT05602480|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
76063359|NCT05604586|Dietary Supplement|N-acetylcysteine|100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
76063360|NCT05604586|Dietary Supplement|Placebo|100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
75895516|NCT02094690|Device|Therabite|10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
75895517|NCT02094690|Device|Hyperboloid|5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
75745270|NCT00873509|Drug|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
75745271|NCT00873509|Drug|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
75895518|NCT02285894|Other|Inspiratory hold|Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
75895519|NCT02285972|Drug|saline|before the anesthesia induction, 2mL saline iv injection
75895520|NCT02285972|Drug|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
75895521|NCT02285972|Drug|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
76063361|NCT05604430|Device|731 Series Ventilator|FDA cleared ventilator indicated for use in the management of acute or chronic respiratory failure or during resuscitation.
76063362|NCT05604352|Device|DiaSole|Diabetic ulcer offloading insole
76063363|NCT05604118|Drug|Aspirin|1 week of aspirin supplementation prior to sampling
75745272|NCT00873509|Drug|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
75895522|NCT02096016|Procedure|Human Papilloma Virus test from the vaginal vault|Surveillance after surgical treatment of early stage cervical cancer
75895523|NCT03134300|Diagnostic Test|Cytokine from blood|Blood draw- one intraoperative, one 3 weeks postoperative
76063364|NCT03030274|Device|Occlutech AFR device|Catheter-guided placement of an AFR device following balloon atrial septostomy.
75745273|NCT00873587|Procedure|Chest tube pull on inspiration|Pull chest tube on Inspiration
75745274|NCT00873587|Procedure|Expiration|Pull chest tube on Expiration
75745275|NCT00867425|Behavioral|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
75769186|NCT01251406|Drug|Placebo|Daily subcutaneous administration for 8 hours a day for 10 days
75769187|NCT01251406|Drug|rhNRG-1 Dose 1|Daily subcutaneous administration for 8 hours a day for 10 days
75895524|NCT02096094|Procedure|Standardization phase|Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
75895525|NCT02096094|Procedure|Control bath|Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
75895526|NCT02096094|Procedure|Bath with chlorhexidine|Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
75601131|NCT05467228|Device|vibro-tactile stimulation (VTS)|To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
75601132|NCT05436925|Device|Dexcom G6 sensor Continuous Glucose Monitor (CGM)|The device used as part of the study is to obtain results for glucose testing for research only and not for diagnostic purposes.
75745276|NCT00877253|Drug|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
75895527|NCT02921763|Drug|Dydrogesterone|
75895528|NCT02094768|Dietary Supplement|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
75895529|NCT02094768|Dietary Supplement|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
75601134|NCT05405283|Biological|2nd booster with Comirnaty® (Pfizer-BioNTech)|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of Comirnaty® (Pfizer-BioNTech) vaccine as a second booster
75601135|NCT05405283|Biological|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK vaccine as a second booster
75601136|NCT05392179|Drug|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
75601137|NCT05392179|Drug|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
75895530|NCT03658473|Drug|550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
75601138|NCT05904223|Diagnostic Test|Respiratory Panel PCR Sputum|Multiplex PCR Respiratory Panel from Biomerieux used on Patients Sputum
75601139|NCT05382208|Drug|Doxycycline|Doxycycline 100 mg orally twice a day.
75601140|NCT05382208|Drug|Placebo|Matching placebo orally twice a day.
75601141|NCT05378841|Procedure|Surgical Denervation|This is an outpatient procedure performed under local anesthesia (depending on the anesthesiologist's decision), which lasts about 30 minutes.
75601142|NCT05377359|Device|Recordings of Hearing Aids with Open Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled to open domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
75601143|NCT05377359|Device|Recordings of Hearing Aids with Closed Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with closed domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
75601144|NCT05377359|Device|Recordings of Hearing Aids with Novel State 1|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its first state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
75601145|NCT05377359|Device|Recordings of Hearing Aids with Novel State 2|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its second state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
75745277|NCT00877253|Drug|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
75745278|NCT00877253|Drug|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
75745279|NCT05225753|Diagnostic Test|hemoglobin serum value|post-operative anemia evaluated with hemoglobin serum value
75745280|NCT00877331|Behavioral|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
75895531|NCT03658473|Drug|550 mg naproxen + placebo + 20 mg rabeprazole|Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
75601146|NCT05377320|Other|Clinical Decision Aid|The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
76063365|NCT04759222|Diagnostic Test|vascular occlusion test|The VOT was performed five times in each patient, before the induction of general anesthesia (baseline, T0), 30 min after the induction of general anesthesia (T1), 30 min after applying CPB (T2), 10 min after injection of protamine (T3), and after sternal closure (T4). Before induction of anesthesia, an NIRS sensor was placed on the thenar eminence and an automated tourniquet was placed around the upper arm. The arterial catheter was placed in the contralateral radial artery and the baseline blood pressure was measured. When the baseline tissue oxygen saturation (StO2) was stabilized, the automatic tourniquet was inflated to 50 mmHg over the patient's baseline systolic blood pressure and maintained for 5 min. After the 5-min ischemic period, the tourniquet rapidly deflated to 0 mmHg. StO2 data were continuously recorded during the VOT procedure.
75601147|NCT05377320|Other|Standard Care|Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
75601148|NCT05365269|Behavioral|Proactive Automatized Lifestyle intervention|Multi-behavioral; including individually-tailored, theory-based, repetitive, ipsative and normative feedback.
75601149|NCT05355779|Other|Not Application as this is a qualitative study|Not Application as this is a qualitative study
76063366|NCT04760080|Other|pre-treatment data|"We will evaluate in all patients pre-treatment data :~Melanoma staging at treatment initiation~Melanoma characteristics at initial diagnosis~Number and location of metastasis~Performans status~Demographic information"
76063367|NCT04760080|Other|during study treatment|"We will evaluate in all patients during study treatment :~Rate of adverse events~Type of adverse events~Radiological response to treatment by CTscans that are routinely performed every three months."
76063368|NCT01885195|Drug|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
76063369|NCT03337594|Drug|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
76063370|NCT03337594|Drug|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
76063371|NCT03337594|Procedure|Surgery|Cardiac surgery
75601150|NCT05354453|Drug|BI 1839100|BI 1839100
76063372|NCT04393792|Drug|Povidone-Iodine|0.23% three times daily (tds) for 3 days
75601151|NCT05354453|Drug|Placebo|Placebo
75601152|NCT05354453|Drug|allyl isothiocyanate (AITC)|allyl isothiocyanate (AITC)
75601153|NCT05344378|Behavioral|ATTAIN NAV Technology-Enhanced Family Navigation Model|The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.
75601154|NCT05333341|Behavioral|TCM|TCM care is remotely-delivered and medium-term (up to 12 months), with the objective of improving CP and OUD/misuse symptoms primarily through medication management.
76063373|NCT04393792|Drug|Normal saline|0.9% three times daily (tds) for 3 days
76063374|NCT04120714|Device|Active tDCS|active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions
75601155|NCT05333341|Behavioral|TCM plus COPES|Pharmacist will assist participants engagement with the COPES program that will augment the effectiveness of TCM alone. COPES is a 12-week, Interactive Voice Response (IVR)-facilitated program of CBT for CP and common sequelae (depressive symptoms, sleep difficulties, low physical activity). Ongoing COPES engagement will be tracked by the COPES system. The primary components of the intervention are: 1) a self-help handbook containing the rationale and instructions for using ten pain self-management skills and their corresponding weekly skill practice goals; 2) a pedometer-facilitated walking program; 3) daily, automated IVR calls to collect pain interference, sleep quality, pedometer-measured step count, and adherence to the pain coping skill practice ratings; and 4) weekly, two to four minute pre-recorded, personalized therapist messages based on participant IVR-reported data.
75601156|NCT05312164|Device|HF-OCT Imaging|Subjects undergo HF-OCT imaging of stenosed coronary arteries
75601157|NCT05312164|Device|FFR Pressure Wire|Subjects undergo FFR physiology assessment of stenosed coronary arteries
75601158|NCT05312164|Device|Angiography|Subjects undergo angiography imaging of stenosed coronary arteries
75601159|NCT05303116|Diagnostic Test|Brainscope modified EEG and cognitive testing|Modified EEG performed using BrainScope device along with cognitive testing performed with BrainScope device and other surveys.
75601160|NCT05286151|Behavioral|Rhythm discrimination|Participants will complete a rhythm discrimination task once per year for 3 years.
75745281|NCT00873665|Other|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
75745282|NCT00873665|Other|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
75745283|NCT00877409|Drug|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
75769188|NCT01251406|Drug|rhNRG-1 Dose 2|Daily subcutaneous administration for 8 hours a day for 10 days
75601161|NCT05282095|Other|Follow up|Participants will be followed up at baseline, 3th, 6th, 9th and 12th months with HPV viral integration tests, HPV genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopies and biopsies will be performed on the participants at 6 - and 12-month follow-up.
75895532|NCT03658473|Drug|550 mg naproxen + 300 mg rebamipide + placebo|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
75895533|NCT03658473|Drug|550 mg naproxen + placebo + placebo|Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
75745284|NCT00877409|Drug|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
76063375|NCT04120714|Device|Placebo tDCS|inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions
76063376|NCT04120714|Other|Questionnaires|"visual analogue scale (VAS)~impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~Go-No go test~HAM-D scale~SF-12 quality of life scale"
76063377|NCT04129762|Other|Diet without NCS|"A standard diet in terms of macronutrients will be calculated.~55% Carbohydrates~20% protein~25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS."
75769189|NCT00257556|Drug|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
75895534|NCT02096250|Other|NaFeEDTA|
75895535|NCT02096250|Other|Ferrous fumarate|
75895536|NCT02096250|Other|NaFeEDTA + ferrous fumarate|
76063378|NCT04129762|Other|Diet with NCS|"A standard diet in terms of macronutrients will be calculated.~55% Carbohydrates~20% protein~25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS."
76063379|NCT04129684|Other|Probiotics|subgingival delivery and lozenges
75601162|NCT05223218|Other|Schirmer strip, a Class I Medical Device typically used to test for dry eye.|Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.
76063380|NCT01896895|Drug|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
76063381|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
76063382|NCT01896895|Drug|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
76063383|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
76063384|NCT03026764|Procedure|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
75601163|NCT05203900|Dietary Supplement|Infant formula with Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the investigational formula. After obtaining the informed consent, the investigational formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
75601164|NCT05203900|Dietary Supplement|Infant formula without Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the control formula. After obtaining the informed consent, the control formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
75601165|NCT05198700|Dietary Supplement|Probiotic Formulation|Participants will be asked to take one sachet daily, containing 1 billion CFU of the probiotic formula. Sachets must be dissolved in warm water or mother's milk before consumption.
75769190|NCT00257556|Drug|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
75769191|NCT03907228|Dietary Supplement|RHT-3201|PROBIOTIC
76063385|NCT03026764|Procedure|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
76063386|NCT04129606|Diagnostic Test|Computed tomographic cystography|CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
76063387|NCT04129372|Behavioral|New Foods Take Time|New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
76063388|NCT02315872|Drug|ACTH|ACTH injections twice weekly for 28 weeks.
76063389|NCT02315872|Drug|Placebo|Placebo injections twice weekly for 28 weeks.
76063390|NCT04128826|Other|Resistance Training|Using the cable machine, shoulders will be flexed to 180° for both (PROM & FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.
75769192|NCT03906916|Diagnostic Test|1,3-β-D-glucan quantification|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis
75895537|NCT02286050|Other|CF Nursing Program|
75895538|NCT03659331|Dietary Supplement|Zinc|blood tests will be performed: GGT SGOT, SGPT, LDH, A.P. Direct and indirect bilirubin, blood proteins, cholesterol, P.T. and a complete blood count.
75895539|NCT02094846|Behavioral|Voice messages|Voice messages reinforced with self-efficacy
75895540|NCT02096328|Drug|POL7080|Intravenous infusion
75895541|NCT02283008|Behavioral|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
75601166|NCT05198700|Dietary Supplement|Placebo|Participants will be asked to take one sachet containing the placebo daily. Sachets must be dissolved in warm water or mother's milk before consumption.
75895542|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
76063391|NCT04128982|Procedure|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
76063392|NCT04128202|Behavioral|Sunnyside|The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
75745285|NCT00873899|Device|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
75601167|NCT05159076|Behavioral|Behavioral Intervention to Increase Physical Activity|"The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active.~The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time."
75745286|NCT00873977|Device|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
75745287|NCT00874133|Procedure|Acupuncture|Acupuncture treatment for 12 weeks.
75745288|NCT00874133|Drug|Motilium|20 mg motilium thrice daily
75745289|NCT00867737|Drug|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
75745290|NCT00867737|Drug|Symbicort 160/4.5 pMDI|"Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks"
75745291|NCT00874211|Procedure|assessment of therapy complications|By dental and medical assessments.
75601168|NCT05141513|Radiation|High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)|After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.
75601169|NCT05135546|Drug|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
75601170|NCT05135546|Drug|Placebo|6 ml of 0.9% solution of NaCl for inhalation
75601171|NCT05117099|Behavioral|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be offered.
75895543|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
75601172|NCT05112640|Device|INSORB: subcuticular stapling device|Under the skin stapling device that delivers absorbable staples
75601173|NCT05112640|Device|Subcuticular monocryl suture manufactured by Ethicon|Under the skin suture placed by hand
75745292|NCT00877643|Other|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
75745293|NCT00877643|Other|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
75745294|NCT00874289|Other|NGAL kit|Kit to test NGAL levels in heart failure patients
75895544|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
75895545|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
75895546|NCT02922153|Device|Cryoanalgesia|AtriCure® cryoICE cryo-ablation system
75895547|NCT02922153|Drug|Standard of Care|Institutional SOC for pain management will be followed.
75450068|NCT01702402|Behavioral|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
75450069|NCT01702402|Other|Comparison Group|A comparison area received standard government health services.
75895548|NCT02283086|Behavioral|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
75895549|NCT03555630|Diagnostic Test|Thromboelastogram|Blood sample processing for thromboelastogram
75895550|NCT02286440|Other|AssureRx GeneSight genotyping results|
75895551|NCT02286440|Other|Treatment as usual|
75895552|NCT02094924|Drug|GSK587323|Single dose of FDC tablet formulation to be taken orally.
75895553|NCT02094924|Drug|FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg|Single dose of FDC tablet formulation to be taken orally
75450070|NCT01702415|Drug|Zoledronic acid|Single dose, intravenous solution 5mg
75450071|NCT01702415|Drug|Placebo|
75895554|NCT02286206|Drug|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
75895555|NCT03578731|Device|app|"The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~Interview during regular consultation with doctor~Web-App for gathering doctors data~Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~Well-being through a patient rating on a visual analog scale~Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app"
75601176|NCT05085834|Drug|Zinc Gluconate|Two 45 mg capsules once daily
75895556|NCT02096406|Drug|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
75895557|NCT02096406|Drug|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
75450072|NCT01702467|Drug|GSK2647544|Capsules containing 0.5mg to 50mg of GSK2647544.
75450073|NCT01702467|Drug|Placebo|Matching placebo capsules.
75450074|NCT01702480|Drug|GSK2981710|Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
75450075|NCT01702480|Drug|Placebo|Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
75450076|NCT01702493|Drug|Cap SRT2104|Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
75450077|NCT01702493|Drug|Tab SRT2104 slow release|New 250 mg SRT2104 mesylate salt slow release tablet
75450078|NCT01702493|Drug|Tab SRT2104 intermediate release|New 250 mg SRT2104 mesylate salt intermediate release tablet
75450079|NCT01702493|Drug|Tab SRT2104 fast release|New 250 mg SRT2104 mesylate salt fast release tablet
75601177|NCT05085834|Drug|Placebo|Two placebo capsules once daily
75616578|NCT02841592|Other|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
75616579|NCT02841436|Device|Irreversible Electroporation (IRE) System|
75450080|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1|SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
75450081|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1 single alternative dose|SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
75616580|NCT02843776|Other|Questionnaires completion|
75616581|NCT02841358|Biological|Blood sampling|
75616582|NCT02841358|Biological|Biopsy|
75895558|NCT00387686|Drug|rhBMP-2/CPM|
75895559|NCT00387686|Drug|rhBMP-2/CPM|
75895560|NCT00387686|Drug|rhBMP-2/CPM|
75895561|NCT00387686|Drug|rhBMP-2/CPM|
75895562|NCT03659253|Diagnostic Test|Oral Fluid Based Self Testing|The intervention will introduce provider supervised and unsupervised self-testing as an option for early HIV diagnosis among MSM community in Denpasar Bali Indonesia.
75895563|NCT03659253|Procedure|Simplified ART Initiation|In this intervention, there will be a change in the clinical practice of ART initiation. In the current practice, clients are asked to perform full pre-ART laboratory examination (complete blood count, liver and renal function tests) before decision of ART initiation. In this intervention, the study participants who are already confirmed as HIV positive and meet specific clinical criteria (see below) will initiate ART (antiretroviral therapy) immediately (after clients' approval) without having to perform full pre-ART laboratory examination. Here, laboratory criteria for initiating ART will be simplified and specific laboratory examination, I.e. creatinine test will be delayed in two weeks after ART initiation.
75895564|NCT03659253|Procedure|CBO AND BROTHEL-BASED ART SERVICE|The CBOs involved in this intervention are Kebaya and Vesta. Kebaya is an CBO working for Transgender (TG) community. It serves as community gathering place for TG and others, as HIV testing site on regular bases, and also as shelter for homeless HIV patients. The proposed intervention Is that HATI Project will provide HIV testing and treatment in the community, CBO and brothel in collaboration with nearby Puskesmas.
75745295|NCT04040465|Drug|Aspirin|Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
76072159|NCT03028857|Dietary Supplement|Placebo|Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
75601178|NCT05081596|Behavioral|PATH-Pain|"The goals of PATH-Pain are to: 1) Teach problem solving skills to reduce negative emotions, by using emotion regulation and problem- solving strategies to overcome these difficulties. 2) Use compensatory strategies and environmental adaptation tools (notes, checklists, calendars, etc.) to avoid limitations resulting from memory problems, help improve emotion regulation, and create an easier environment to live in. If found helpful and participant agrees, a tablet application called WellPATH will be used to help the subject with emotion regulation techniques. The tablet will be given at the beginning of treatment and will be returned at the end of treatment. 3) Invite caregiver participation, when appropriate.~Subjects in the PATH-PAIN group will receive 8 weekly sessions (first 8 weeks) with a study therapist and 6 monthly phone sessions (3 individual and 3 group) for 9-36 weeks. Each session will last approximately 50 minutes."
75895565|NCT03659253|Behavioral|SMS REMINDER|HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.
75616583|NCT02843698|Drug|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
75616584|NCT02843698|Drug|Normal saline|Normal saline
75745296|NCT03842813|Device|DES-CRE8|Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.
75745297|NCT00874445|Device|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
75895566|NCT03659253|Procedure|MOTIVATIONAL INTERVIEWING|"The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence"
75895567|NCT02096484|Behavioral|Group Metacognitive Therapy|
75616585|NCT00690898|Drug|Lanreotide autogel 120 mg|12 months
75895568|NCT02096484|Behavioral|Mindfulness Meditation Therapy|
75450082|NCT01702506|Drug|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
75601179|NCT05066113|Device|Radiofrequency-Based treatment|"RF-based treatments use electrothermolysis to deliver heat energy to targeted structures in the skin, such as hair follicles or glands by the use of insulated needles. The investigators will use radio frequency based treatment on a pre-selected skin area (about 3cm x 3cm or 1 ¼ x 1 ¼ inches in size) on either your left or right underarm that is eligible for assessment, study treatment, and biopsy.~Participants will receive clinical assessments, photography, questionnaires, up to 3 treatments of RF-based selective electrothermolysis to pre-selected areas of the axillary skin, up to 2 4-mm skin biopsies for up to 5 study visits."
75601180|NCT05053087|Drug|Ropivacaine Continuous Infusion|0.2% continuous infusion 6mL/hr
75450083|NCT01702506|Drug|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
75450084|NCT01702506|Drug|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
75745298|NCT00420849|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
75745299|NCT00420849|Drug|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
75601181|NCT05053087|Drug|Ropivacaine Intermittent Bolus|0.2% intermittent bolus infusion 8mL every 2 hours
75601182|NCT05053087|Drug|Placebo|Saline filled catheter
75601183|NCT05046873|Drug|Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
75601184|NCT05046873|Drug|semaglutide 1.34 mg/mL (placebo)|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
75601185|NCT05046873|Drug|Semaglutide 1.34 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
75601186|NCT05046873|Drug|NNC0480-0389 A 10 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
75745300|NCT00617279|Device|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
75895569|NCT03515317|Behavioral|LoRETA Z-score NF|LoRETA Z-score NF will be conducted using a 19-lead cap (Electrocap, Inc), which will be placed on the head according to the standard approach of the international 10-20 system with linked ear and ground reference. After the caps will be less than 5 kΩ. During each session, the participants will sit in front of a computer screen on which predesigned games or animations related to the LoRETA Z-score training are played and instructions regarding the inhibitory and reward aspects of the training are taught.
75895570|NCT03515317|Behavioral|theta/beta NF|The goal of theta/beta NF is to increase the beta power(13-20 Hz) and simultaneously inhibit the theta power (4-8 Hz) relative to a baseline assessed at the beginning of a training session. The electrodes will be placed on Fz and Cz with a linked ear model(A1). The study will use both visual and auditory feedback. Each participant will sit in front of a computer screen on which predesigned games or animations related to the training criteria are played and instructions regarding the inhibitory and reward aspects of the training are taught. The threshold will be set according to 5-min baseline EEG measurements before each session. The thresholds are the mean amplitude of the beta and the theta in 5-min baseline EEG.
75895571|NCT02286284|Device|Apheresis for extracorporal removal of sFlt-1|
75601187|NCT05038982|Drug|Abrocitinib|During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
75895572|NCT03104283|Drug|Apatinib|take apatinib orally until disease progression or appearance of unbearable toxicity
75895573|NCT00529178|Drug|Pravastatin|
75450085|NCT01702584|Procedure|stent assisted embolization|stent assisted embolization and anti-thrombotic management
75601188|NCT04992650|Procedure|Fat grafting|Fat grafting
75895574|NCT03659175|Other|SIBO|SIBO: Small intestinal bacterial overgrowth, refers to a bacterial overgrowth due to organic or functional stasis in small intestine, leading to the change in number or types of bacteria in small intestine.
75601189|NCT04983966|Drug|Desﬂurane|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
75601190|NCT04983966|Drug|Remimazolam|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
75601191|NCT04983797|Device|OPTRELL Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
75601192|NCT04980872|Drug|Miransertib|Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
75745301|NCT00617279|Procedure|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
76072160|NCT03011398|Procedure|Orthobiologic Procedures|To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.
75601193|NCT04972942|Drug|Daratumumab|"Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~Induction: DARA IV weekly x 8 doses (Weeks 1-8)~Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~Maintenance: DARA every 4 weeks (Stop at Day +270)"
75601194|NCT04953897|Drug|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
75745302|NCT00877721|Device|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
75745303|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
75601195|NCT04935775|Other|Untrained Touch|Subject's feet, ankles, and lower legs are touched and rubbed during a bone marrow biopsy procedure.
75601196|NCT04917406|Drug|Application of lidocaine together with dexamethasone|Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
75745304|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
75895575|NCT03556644|Radiation|CTCA imaging|All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
75450086|NCT01702597|Device|Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)|Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
75450087|NCT01702597|Other|Physiotherapy|Patients will receive a standardized physical therapy.
75450088|NCT01702610|Radiation|IMRT Technique|
75895576|NCT03077061|Procedure|Open flap debridement|Open flap debridement using saline as irrigation
75895577|NCT03077061|Device|Bone replacement graft|Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
75895578|NCT03556566|Biological|Tableted vaccine (V3-OVA) containing ovarian cancer antigens|One pill of V3-OVA per day for three months
75895579|NCT00382460|Drug|PRAVASTATIN SODIUM|
75895580|NCT00523328|Drug|BG9924|dosage administered as per Biogen-idec protocol
75895581|NCT02920983|Device|somofilcon A|contact lens
75895582|NCT02920983|Device|nelfilcon A II 2|contact lens
75895583|NCT02920983|Device|omafilcon A ll 2|contact lens
75450089|NCT01702610|Radiation|IMRT and accelerated hypofractionation technique|Intervention is the technique and accelerated fractionation used to treat GBM
75450090|NCT01702610|Radiation|neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component
75450091|NCT01702610|Drug|Temozolomide and Accelerated Hypofractionation RT|
75450092|NCT01702623|Drug|Oxcarbazepine|
75450093|NCT01702636|Drug|Tranexamic Acid|
75450094|NCT01702636|Drug|Placebo|
75601197|NCT04917406|Device|Application of ultrasound as physical therapy|The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and a 1MZ head.
75616586|NCT02841202|Drug|oral contraceptive pills|
75616587|NCT02841124|Other|interviews|face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
75769193|NCT03906916|Drug|Micafungin|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
75769194|NCT03907150|Diagnostic Test|Strain ultrasound|Post-interpretation of recorded ultrasound loops
75895584|NCT00523250|Drug|AR-102 0.003% Ophthalmic Solution|
75895585|NCT00523250|Drug|AR-102 0.005% Ophthalmic Solution|
75895586|NCT00523250|Drug|AR-102 0.01% Ophthalmic Solution|
75895587|NCT00523250|Drug|AR-102 0.03% Ophthalmic Solution|
75895588|NCT00523250|Drug|AR-102 Vehicle Ophthalmic Solution|
75895589|NCT02095080|Dietary Supplement|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
75895590|NCT02654002|Drug|Cilofexor|Tablets administered orally
76072161|NCT02994576|Drug|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
76072162|NCT02983357|Radiation|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
75895591|NCT02654002|Drug|Placebo|Tablets administered orally
75601198|NCT04916639|Device|Device: Physiomer undiluted seawater nasal spray|"In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~Nasal wash four times every day~These washes are to be carried out in each nostril~By continuously pressing the spray for 3 seconds in each nostril~Subjects are recommended to distribute the 4 nasal washes as follows:~1st : morning~2nd : midday~3rd : afternoon~4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other symptoms."
75745305|NCT00874601|Drug|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
75745306|NCT00874679|Drug|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
75745307|NCT00420381|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
75745308|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
75745309|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
75895592|NCT02286596|Device|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
75895593|NCT02286596|Device|dextran sulfate adsorption|Lipid apheresis for 3 hours
75745310|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
75895594|NCT02098824|Drug|Galantamine|Single administration of capsule containing 16 mg of Galantamine
76063393|NCT04128202|Behavioral|Sunnyside Plus|Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
75895595|NCT02098824|Drug|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
76063394|NCT04128592|Device|diagnosing noisy breathing in infants and toddlers|breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
76063395|NCT04128280|Procedure|TUDP|a surgery: transurethral dilation of prostate with a columnar balloon
76063396|NCT04128280|Procedure|TUIB|a surgery: transurethral incision of bladder neck
75450095|NCT01702649|Drug|RPX2003 (Biapenem)|"Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.~Single dose followed by multiple dose, three times a day."
75450096|NCT01702649|Drug|Placebo|"Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day."
76063397|NCT04127812|Behavioral|Savor the Flavor|A series of five interactive classroom lessons focused on mindfulness in eating.
76063398|NCT04127890|Dietary Supplement|ELO Water|oxygen-enriched water
76063399|NCT04127890|Dietary Supplement|Placebo drinking water|bottled drinking water
75450097|NCT01702662|Device|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
75450098|NCT01702675|Drug|ACH15 50 mg|ACH15 50mg capsule
75450099|NCT01702675|Drug|ACH15 250 mg|ACH15 250mg capsule
75450100|NCT01702675|Drug|ACH15 500mg|ACH15 500 mg capsule
75895596|NCT02098824|Drug|Placebo|Single administration of capsule containing placebo
75895597|NCT03659097|Procedure|periodontally accelerated osteogenic orthodontics|Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
76063400|NCT04128046|Procedure|PRFM injection|Using a 27-gauge microcannula, a total of 4 mL of PRFM was injected intradermally into the mid-cheek and NLF (2 mL for each site) on one side of the face.
75895598|NCT02098902|Behavioral|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
75895599|NCT03658317|Diagnostic Test|renal arterial resistive index|done by dupplex on renal arteries
75895600|NCT03658317|Diagnostic Test|uric acid level|serum sample for doing the test
75895601|NCT03658317|Diagnostic Test|serum urea and creatinine|serum samples for doing the test
75895602|NCT03658317|Diagnostic Test|24 hours urinary proteins|urine collected over 24 hours for doing the test
75895603|NCT03658317|Diagnostic Test|lipogram|serum sample for doing the test
75895604|NCT03658317|Diagnostic Test|HbA1c level|serum sample for doing the test
75895605|NCT03658317|Diagnostic Test|urine analysis|urine sample for doing the test
75895606|NCT03658317|Diagnostic Test|abdominal ultrasonography|done by the ultrasonography device
75895607|NCT02286752|Drug|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
76063401|NCT04128046|Procedure|Saline injection|Using a 27-gauge microcannula, a total of 4 mL of saline was injected intradermally into the mid-cheek and NLF (2 mL for each site) on the contralateral side of the face.
75745311|NCT00874835|Device|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
76063402|NCT04128124|Other|processing signals of airway pressure and airway flow to calculate entropy|processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
75450101|NCT01702675|Drug|ACH15 - 1000mg|ACH15 500mg capsule - two 500mg capsules in single dose
75745312|NCT00617201|Drug|atomoxetine|Once daily oral dosing
75745313|NCT00617201|Drug|placebo|Once daily oral dosing - matched placebo
75895608|NCT02286752|Drug|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
75895609|NCT02096562|Other|Patients use compression stockings for 10 days after surgery|patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
75895610|NCT02096562|Other|normal therapy - no compression stockings|the patients receive the common therapy according to S2 guidelines
75895611|NCT05103592|Diagnostic Test|Tartrate- resistant Acid Phosphatase marker|marker could be diagnostic for osteoporosis
76063403|NCT04393714|Procedure|Alveolar ridge preservation after extraction|atraumatic extraction followed by graft material insertion
75745314|NCT00420303|Drug|Etanercept|50 mg injection once weekly
75745315|NCT00420303|Other|Placebo|placebo
75745316|NCT00617123|Drug|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
75745317|NCT00617123|Drug|Placebo|matching placebo oral tablet
75745318|NCT00877955|Drug|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
75745319|NCT00877955|Drug|alprazolam sublingual tablet test|0.5 mg tablet, single dose
75895612|NCT03659019|Other|Quality of life questionnaires|During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.
75895613|NCT02095236|Behavioral|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
75895614|NCT03658941|Procedure|No dural tenting techniques|Not applying dural tenting sutures during closure of a craniotomy
75895615|NCT03658941|Procedure|Dural tenting techniques|Applying at least 3 dural tenting sutures during closure of a craniotomy
75601199|NCT04916249|Drug|Tibetree Pain Relieving Plaster|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
75895616|NCT02283164|Behavioral|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
75895617|NCT02095314|Biological|Pentavalen|Batch 5010613
75895618|NCT00517868|Drug|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
75895619|NCT00517868|Drug|Placebo|Liquid formulation without active URG101 drug components
75895620|NCT02098980|Dietary Supplement|Vitamin D|
75895621|NCT00381602|Drug|GHRP-1/AG 70 mg depot in ESRD|
75895622|NCT00381602|Other|Placebo|
76063404|NCT04127500|Drug|dexmedetomidine|dexmedetomidine
75616588|NCT00895414|Drug|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
75745320|NCT00419757|Drug|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
76063405|NCT04127344|Behavioral|Music Therapy Intervention|Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
76063406|NCT03017326|Drug|Cisplatin|Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
76063407|NCT03017326|Drug|Doxorubicin|Arms C, D and E used in combination
76063408|NCT03017326|Drug|Carboplatin|Arms C and D used in combination
75450102|NCT01702675|Drug|ACH15 - 2000mg|ACH15 500mg capsule (four 500mg capsules in one dose)
75450103|NCT01702675|Drug|ACH15 - 500mg|ACH15 - 500mg twice a day for 7 days
75450104|NCT01702675|Drug|Placebo 250 mg|Capsule manufactured to mimic ACH15 250 mg capsule
75450105|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule
75450106|NCT01702675|Drug|Placebo 1000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
75745321|NCT00419757|Drug|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
75745322|NCT00874913|Device|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
75450107|NCT01702675|Drug|Placebo 2000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
75450108|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
75895623|NCT05228938|Procedure|VNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
76063409|NCT03017326|Drug|5Fluorouracil|Arm C used alone
76063410|NCT03017326|Drug|Vincristine|Arms C and D used in combination
76063411|NCT03017326|Drug|Etoposide|Arm D used in combination
76063412|NCT03017326|Drug|Irinotecan|Arm D used in combination
75450109|NCT01702688|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
75450110|NCT01702688|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
75450111|NCT01702701|Drug|Montelukast|montelukast 10mg po pill q day for 12 weeks
75450112|NCT01702701|Drug|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
75450113|NCT01702714|Drug|RO5083945|multiple ascending doses
75450114|NCT01702714|Drug|carboplatin|up to 6 cycles
75450115|NCT01702714|Drug|cisplatin|up to 6 cycles
75450116|NCT01702714|Drug|gemcitabine|up to 6 cycles
75450117|NCT01702714|Drug|paclitaxel|up to 6 cycles
75450118|NCT01702727|Device|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
75895624|NCT05228938|Procedure|laparoscopic|laparoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
75895625|NCT03658239|Other|Inversion|Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
75895626|NCT00517790|Drug|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
75895627|NCT00517790|Drug|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
75895628|NCT03772392|Procedure|HPB resection|:Liver and Pancreas surgery - Compliance with ERAS protocol
75895629|NCT02095392|Dietary Supplement|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate [1g phosphorus/d]
75895630|NCT02095392|Dietary Supplement|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [0,5 g calcium]
75895631|NCT02095392|Dietary Supplement|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [1 g calcium]
75895632|NCT02095392|Dietary Supplement|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
75895633|NCT00123968|Biological|VRC-HIVDNA016-00-VP|1x10^11 per unit vaccine administered intramuscularly via Bioinjector
75895634|NCT00123968|Biological|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
75450119|NCT01702727|Device|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
75895635|NCT00123968|Biological|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
75895636|NCT00123968|Biological|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
75450120|NCT01702727|Device|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
75450121|NCT01702740|Drug|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
75450122|NCT01702740|Drug|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
75450123|NCT01702740|Drug|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
75450124|NCT01702740|Drug|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
75601200|NCT04916249|Other|Placebo|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
75601201|NCT04908215|Drug|INM-755 (cannabinol) cream|topical cream containing cannabinol for dermal application
75745323|NCT00878111|Drug|NGR-hTNF|"First cohort: iv q3W 60 mcg/sqm over 120 min*~Second cohort: iv q3W 80 mcg/sqm over 120 min*~Third cohort: iv q3W 100 mcg/sqm over 120 min*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min*~* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period."
75745324|NCT00867971|Other|Measuring intraoccular pressure|Measurement of intraoccular pressure by tonometry
75745325|NCT00434109|Drug|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
75745326|NCT00434109|Procedure|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
75895637|NCT03556254|Drug|GGT|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
75895638|NCT03556254|Drug|SGT|In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
76063413|NCT03017326|Drug|Gemcitabine|Arm F used in combination
75601202|NCT04908215|Drug|Vehicle Cream|topical cream base for dermal application containing no active agent
75601203|NCT04867785|Drug|LY3437943|Administered SC
75895639|NCT04350658|Procedure|Transcatheter aortic valve implantation required for symptomatic aortic stenosis|The procedure is performed via transfemoral or transcarotid access; Patients were confirmed to be eligible for TAVR by a multidisciplinary heart team including at least an interventional cardiologist, a cardiothoracic surgeon and an anesthetist. All TAVR implantation procedures were performed with the Edwards SAPIEN 3 THV or the MEDTRONIC CoreValve EVOLUT . For all patients, both vascular access and aortic valve were evaluated before the procedure by multislice computerized tomographic angiography (MSCT) of the entire aorta using vascular windows settings. The prosthesis and the vascular access were left to the discretion of the operating team. Transfemoral access was the first choice when possible. All TAVR procedures were performed in the same hybrid room (in Montpellier University Hospital), Most TAVR were performed under sedation or general anesthesia using mild low profile 14-16 French delivery systems and using percutaneous or surgical vascular access.
75895640|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895641|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895642|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895643|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895644|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895645|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895646|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895647|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895648|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895649|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895650|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
75895651|NCT05228782|Other|HOW R U? Intervention|HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
75895652|NCT02095470|Device|video laryngoscope|newly developed innovatory device
76063414|NCT03017326|Drug|Oxaliplatin|Arm F used in combination
76063415|NCT03017326|Drug|Sorafenib|Arm used in combination
75601204|NCT04867785|Drug|Dulaglutide|Administered SC
75601205|NCT04867785|Drug|Placebo|Administered SC
75601206|NCT04867317|Drug|Somatropin|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
75450125|NCT01702753|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
75616589|NCT00895414|Drug|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
75745327|NCT00875069|Other|Ethanol|Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
75745328|NCT01029639|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
75745329|NCT00875147|Drug|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
75895653|NCT02095470|Device|traditional laryngoscope|traditional way for intubation
75895654|NCT04088656|Other|Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization|The Systems Analysis and Improvement Approach to Optimize the Hypertension Care Cascade for People Living with HIV (SAIA-HTN) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by study nurses and district managers in intervention facilities. Components of the intervention include joint care cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally improve hypertension screening, diagnosis, treatment and care in the HIV+ population at intervention health facilities.
75895655|NCT03556176|Behavioral|Exercise|Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
75450126|NCT01702766|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
75450127|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
75450128|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
75450129|NCT01702792|Biological|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
75895656|NCT03556176|Behavioral|Quiet rest|Quiet rest during 30 min
75895657|NCT00372944|Drug|AZD6244|oral capsule
75895658|NCT00372944|Drug|capecitabine|oral tablet
75895659|NCT05228704|Behavioral|activities in the Botanical Garden or in urban|activities in the Taipei Botanical Garden or in Urban
75895660|NCT02099136|Procedure|UV Light Therapy|Undergo UV-irradiation
75895661|NCT02099136|Other|Placebo|Given PO
75895662|NCT02099136|Drug|Celecoxib|Given PO
75895663|NCT02099136|Procedure|Biopsy|Undergo skin biopsy
75895664|NCT02099136|Other|Imaging Biomarker Analysis|Correlative studies
76063416|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Active|"Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
75895665|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
76063417|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Sham|Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
75895666|NCT00117650|Biological|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
75450130|NCT01702857|Biological|Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant|
75895667|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
75450131|NCT01702857|Biological|Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant|
75745330|NCT01566513|Behavioral|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
75895668|NCT00117650|Other|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
75895669|NCT02099214|Device|3Tesla cardiac MRI|
75895670|NCT02099214|Device|Electrocardiogram (EKG)|
75601207|NCT04867317|Other|Placebo|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
75601208|NCT04853550|Device|Strattice Mesh|Subjects will be restrospectively identified has having undergone ventral hernia repair with Strattice mesh reinforcement. Once identified long term follow-up data will be collected.
75450132|NCT01702857|Other|Phosphate buffered saline|
75601209|NCT04850573|Other|equine assisted activities|Participants interact with the horse and learn how to safely handle the horse.
75601210|NCT04829110|Other|ETOH|Participants will consume Vodka
75601211|NCT04829110|Other|Sucrose|Participants will consume sucrose in solution with water
75745331|NCT01566513|Behavioral|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
75745332|NCT01566513|Behavioral|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
75745333|NCT05226845|Other|prescribed exercise|the therapist chooses the five exercises to do
75745334|NCT05226845|Other|chosen exercise|the patient chooses the five exercises to perform among fifteen possibilities
75450133|NCT01702857|Biological|1 µg TDENV-PIV with Alum adjuvant|
75450134|NCT01702857|Biological|1 µg TDENV-PIV with AS01E adjuvant|
75450135|NCT01702870|Procedure|Magnetic Resonance Imaging|
75450136|NCT01702974|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
75895671|NCT02099214|Biological|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
75895672|NCT02099214|Biological|Pregnancy test|Beta-hCG
75895673|NCT02099214|Device|Echocardiography at rest|Transthoracic echocardiograph
75895674|NCT02099214|Biological|Urinary pregnancy test|
75895675|NCT02099214|Device|3Tesla abdominal MRI|
75895676|NCT03324958|Device|Virtual reality Helmet|The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
75895677|NCT03324958|Other|No Virtual Reality Helmet|The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
75895678|NCT02095548|Drug|SM04690, 0.03mg/2mL|
75895679|NCT02095548|Drug|SM04690, 0.07mg/2mL|
75895680|NCT02095548|Drug|SM04690, 0.23mg/2mL|
75895681|NCT02095548|Drug|Placebo|
75450137|NCT01702974|Drug|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
75895682|NCT00113438|Drug|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
75601212|NCT04812912|Diagnostic Test|Hormone biomarker analysis|For female patients, hormone biomarker analysis will be performed to measure: anti-Mullerian hormone (AMH), estradiol and FSH in the blood. In male patients, hormone biomarkers of testicular function and spermatogenesis will be monitored: testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH. Sperm analysis will also be performed in male patients to monitor changes in sperm count.
75895683|NCT04087408|Drug|Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~Trigger will be done using HCG followed by OPU 36 h later.~Retrieved oocytes will be fertilized by ICSI.~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~Quantative BHCG will be performed 14 days after OPU."
75895684|NCT02099292|Drug|Rituximab and DexaBEAM|combination treatment
75601213|NCT04812912|Behavioral|QoL Questionnaires|All participants will respond to protocol questionnaires, which will include both validated questionnaires as well as non-validated ones. This design will allow for basic demographic, psychosocial and sexual-health-related data to be obtained.
75601214|NCT04806958|Other|PulsePoint notification|"The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator."
75601215|NCT04774224|Drug|Baricitinib|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
75601216|NCT04774224|Drug|Placebo|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
75616590|NCT02843464|Other|reported remote ischemic preconditioning (RIPC)|Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
75745335|NCT00875225|Behavioral|DVD|Control group will receive usual care DVD from health professionals
75745336|NCT00875225|Behavioral|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
75745337|NCT01034943|Procedure|External fixation|Operation with external fixation and optional addition of k-wire
75745338|NCT01034943|Procedure|Volar plate|Operation with a Synthes volar two column plate (TCP)
75745339|NCT00433329|Drug|Bosentan|Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
75745340|NCT00433329|Drug|Sildenafil|Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
75745341|NCT01035021|Drug|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
75745342|NCT01029951|Procedure|manipulation|
75745343|NCT01029951|Procedure|Mobilisation|
75745344|NCT01029951|Device|Activator instrument|
75450138|NCT01703052|Drug|CHF 6001 SD or placebo|Dry Powder Inhaler
75450139|NCT01703052|Drug|CHF 6001 MD or placebo|Dry Powder Inhaler
75450140|NCT01703078|Drug|Ingenol once daily for two consecutive days|
75450141|NCT01702116|Procedure|extralevator APR|"Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
75450142|NCT01702116|Procedure|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
75745345|NCT00616421|Biological|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
75895685|NCT02283242|Drug|Galantamine|Oral use for 12 weeks
75895686|NCT02283242|Drug|Placebo (for galantamine)|Oral use for 12 weeks
75895687|NCT02283320|Drug|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
75895688|NCT05228392|Other|listening to music|listening to lullaby or other music types
75895689|NCT05228236|Dietary Supplement|Plant based protein|A single dose of ~30 g of a plant-based protein blend was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
75895690|NCT05228236|Dietary Supplement|Whey protein|A single dose of ~30 g of whey protein was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
75895691|NCT03556098|Drug|glucose-dependent insulinotropic peptide|Infusion of GIP
75895692|NCT03556098|Drug|Glucose-Dependent Insulin-Releasing Hormone[3-30]|Infusion of GIP antagonist GIP[3-30]
75616591|NCT02843620|Dietary Supplement|b-2Cool|b-2Cool® is native type II collagen extracted from chicken sternums
75616592|NCT02843620|Other|Placebo|Excipients only
75745346|NCT00616421|Biological|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
75745347|NCT00616421|Biological|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
75895693|NCT03556098|Drug|Saline Solution|Infusion of Saline
75895694|NCT02096640|Procedure|Type of surgical teqnique for tracheostomy|
75895695|NCT02286986|Drug|Cannabidiol|
75895696|NCT04995874|Dietary Supplement|KOKOPlus protein and micronutrient powder|KokoPlus, a complementary food supplement was formulated by using linear programming methodology to improve the protein quality as well as the micronutrient and macronutrient content of commonly consumed traditional complementary (baby) foods in Ghana . It contains soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix. It complies with WHO's complementary feeding guidelines, FAO/WHO recommended micronutrient intake (RNI) and the WHO's guidelines for protein and essential amino acid intake for children in the age group of 6 to 24 months. A daily supply of KokoPlus achieves 30% of the total recommended energy, 60% of total protein and 40% of total fat requirements from complementary foods. It also meets 35-55% of minimum intake of essential amino acids and 50-150% RNI based on the total daily requirements.
75745348|NCT00875303|Behavioral|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
75895697|NCT02095626|Drug|AP-301|orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
75895698|NCT02095626|Drug|saline solution|placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
75616593|NCT05334394|Other|Mulligan Technique|Mulligan suggested that injuries or sprains can cause a minor positional error in a joint, thereby causing limitations in physiological movement. Unique to this concept is mobilization of the spine while weight bearing and directing the mobilization parallel to the spinal facet planes. Although it includes various mobilization techniques, one of the most important techniques, motion co-mobilization, is the SNAG's technique, which includes the application of accessory passive gliding to the lumbar vertebra while the patient performs active movement simultaneously.
75745349|NCT00875303|Behavioral|Control|Routine primary care.
75895699|NCT02287064|Drug|Intravenous Immune Globulin (IVIG)|"IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion"
75895700|NCT02095704|Drug|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
75895701|NCT02095704|Drug|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
75450143|NCT01703104|Drug|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
75450144|NCT01703104|Dietary Supplement|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
75450145|NCT01703130|Procedure|Dose of of ropivacaine 0.75% used in block procedure|
75450146|NCT01703143|Procedure|Laser ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
75450147|NCT01703156|Procedure|Stress Test|
75450148|NCT01703156|Procedure|No Stress Test|
75745350|NCT05226767|Dietary Supplement|NLC-V|NLC-V
75745351|NCT00878267|Behavioral|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
75745352|NCT00878345|Drug|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
75745353|NCT00878345|Drug|pentobarbital sedation protocol|"Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation."
75745354|NCT00433017|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of the infusion.
75895702|NCT02287142|Procedure|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
75895703|NCT02102412|Biological|screening colonoscopy|performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
75895704|NCT04820140|Procedure|Lymphatic drainage|Lymphatic drainage
75895705|NCT02287220|Device|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
75895706|NCT01675492|Device|LASIK|Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
75895707|NCT02250690|Device|experimental group - tDCS|
75895708|NCT02250690|Device|Control group (tDCS sham)|
75895709|NCT00095030|Drug|muraglitazar|
75895710|NCT02099604|Drug|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
75895711|NCT03075046|Device|Blue LED 405 nm|It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
75895712|NCT03075046|Other|Questionnaire of anamnesis|The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
75895713|NCT02099760|Device|STD testing (GC/Ct/trich)|
75895714|NCT04751110|Other|ultrasound guided rhomboid intercostal block|A linear ultrasound probe was medially placed in the sagittal plane on the medial border of the scapula at the T5-T7 level. We inserted a 22-gauge needle into the fascial plane between the rhomboid major and intercostal muscles in a craniocaudal direction and injected 15 ml mixture of 0.25% bupivacaine with 8 mg of dexamethasone into the fascial plane.
75895715|NCT02099916|Drug|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
75450149|NCT01703195|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
75450150|NCT01703195|Procedure|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
75601217|NCT04761302|Other|Use of non-steroid anti-inflammatory drugs (NSAIDS) as an alternative for post-operative pain management after a femur and tibia fracture|This is a randomized controlled, single blind, parallel groups, opioid control trial of all patients (total of 150 patients) who suffered tibial and femoral shaft fractures and were treated with intramedullary nailing. Patients will be aleatory assigned to two study groups: Group-1 will receive non-opioid medications, and Group-2 will receive opioid medications. During the inpatient postoperative period, patients will undergo subjective evaluation of pain utilizing a previously validated questionnaire, the Visual Analogue Score (VAS). The first questionnaire will be completed twelve hours after surgery and during subsequent twelve-hour intervals until discharge. Secondary outcomes will include efficiency such as time to gastrointestinal motility, time to weight bearing of affected limb, resumption of ambulation, and length of hospital stay. The evaluation will take approximately 15 minutes to complete each time, we the entire participation time to be 60 minutes.
75745355|NCT00433017|Drug|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
75745356|NCT00433017|Drug|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
75745357|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLE494
75745358|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLF497
75745359|NCT01035411|Drug|AZD9668|2 x 30 mg tablet variant 1
75450151|NCT01703234|Drug|Ramipril|ramipril 10 mg/day during 3 months
75450152|NCT01703247|Procedure|Pulmonary vein isolation|
75601218|NCT04717557|Drug|Hyperbaric Oxygen|Hyperbaric oxygen (HBO2) 1-2 times daily for up to 10 times after amputation
75601219|NCT04706507|Drug|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
75616594|NCT05334394|Other|Exercise Therapy|Exercise is recommended by physical therapists for most chronic low back pain patients.
75745360|NCT03726671|Other|25% Cho diet|Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
75745361|NCT03726671|Other|50% Cho diet|Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
75895716|NCT02099916|Drug|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
75895717|NCT02102646|Drug|Triptorelin|Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
75895718|NCT02102646|Procedure|Orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
75895719|NCT00366704|Drug|bifeprunox|.25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
75895720|NCT00366704|Drug|risperidone|4mg, QD, 8 week treatment
75895721|NCT03924622|Device|Mepilex|Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.
75895722|NCT03924622|Device|LiquiCell|LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.
75450153|NCT01703247|Procedure|Ganglionated plexi ablation|
75450154|NCT01703247|Procedure|Linear Lesion Ablation|
75895723|NCT02099994|Biological|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10^10 vp or saline placebo
75745362|NCT03726671|Other|100% Cho diet|Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
75745363|NCT01030029|Device|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point [2]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
75895724|NCT02099994|Biological|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10^8 pfu or saline placebo
75895725|NCT02099994|Biological|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
75895726|NCT02099994|Biological|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
75895727|NCT02097186|Procedure|Remote ischaemic preconditioning|Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
75601220|NCT04702373|Other|passive range of motion exercise therapy|Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
75895728|NCT05725850|Other|EG (Experimental A. Oleracea extract gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the EG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
75450155|NCT01703273|Behavioral|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
75895729|NCT05725850|Other|GP (Gel placebo)|Prior to bleaching treatment with 35% hydrogen peroxide, the GP group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
75616595|NCT01822288|Drug|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
75616596|NCT01822288|Drug|Estradiol & medroxyprogesterone acetate|Estradiol & medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
75895730|NCT02097264|Drug|NNC0109-0012|Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
75895731|NCT02097264|Drug|Adalimumab|Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
75895732|NCT02097264|Drug|placebo|"Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks)."
75895733|NCT03530618|Device|Flexible tip straight guidewire|Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization
75895734|NCT03530618|Device|J-tip|Use a J tip straight guidewire for ultrasound-guided central venous catheterization
75895735|NCT02097342|Drug|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
75895736|NCT02097342|Drug|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
75895737|NCT02097342|Drug|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
75450156|NCT01703273|Behavioral|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
75450157|NCT01703312|Drug|QGE031|Drug administered by subcutaneous injection
75450158|NCT01703312|Drug|omalizumab|Drug administered by subcutaneous injection
75450159|NCT01703312|Drug|placebo|Drug administered by subcutaneous injection
75616597|NCT02843542|Device|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
76063418|NCT04126954|Other|Serum PTH concentrations results|To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
76063419|NCT04126876|Drug|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
76063420|NCT04126876|Drug|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
76063421|NCT04126564|Behavioral|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations & yoga.
76063422|NCT04126564|Behavioral|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
75450160|NCT01703325|Drug|0.1% triamcinolone , 0.05% clobetasol propionate ointment|"Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~Group C: Controlled group"
75450161|NCT01703351|Drug|0.5% ropivacaine|(n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
76063423|NCT04126330|Dietary Supplement|Probiotic, Omega-3, Vitamin D supplement|"The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards)."
76063424|NCT04126330|Dietary Supplement|Placebo|Placebo generated for probiotic and omega-3/vitamin D supplements
76063425|NCT04126720|Dietary Supplement|topical corticosteroids and vitamin E suplements|
76063426|NCT04126720|Drug|Topical corticosteroid and placebo capsules|
75450162|NCT01703351|Drug|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|(n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
75450163|NCT01703364|Drug|Lenalidomide|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
75450164|NCT01703390|Drug|FOLFIRI + Cetuximab|
75895738|NCT03530540|Device|low-intensity extracorporeal shockwave therapy|Active shockwaves
76063427|NCT04126252|Drug|Sildenafil Citrate 50Mg Tab|The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.
76063428|NCT04126252|Behavioral|Cognitive Behavioral Psychotherapy|The Group B received cognitive behavior psychotherapy for a period of max 3 months.
76063429|NCT04126252|Combination Product|Combined or Integrated Therapy|The Group C received the combined therapeutic approach for a period of max 3 months.
75601221|NCT04695717|Biological|IVACFLU-S|"The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019)."
75895739|NCT03530540|Device|Placebo LI-ESWT|Placebo shockwaves
76063430|NCT04126252|Other|Placebo|The Group D received no treatment or placebo for a period of max 3 months.
76063431|NCT04125940|Dietary Supplement|Resync|The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.
76063432|NCT04125940|Dietary Supplement|Resync + Collagen|17g Collagen + 2g Resync + 1g Carbohydrate
76063433|NCT04125940|Other|Placebo|12oz water + food coloring
76063434|NCT04125628|Behavioral|Exercise with cooling|The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
75450165|NCT01703390|Drug|modifiedFOLFOX6 + Cetuximab|
75895740|NCT03530540|Device|Penile pump|both groups will be treated with a penile pump
76063435|NCT04125628|Behavioral|Exercise without cooling|The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
75895741|NCT04294498|Drug|Durvalumab|Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
75895742|NCT02260518|Behavioral|Lifestyle Intervention|During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
75895743|NCT02260518|Behavioral|Standard Care|Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
75895744|NCT04288648|Diagnostic Test|ultrasound examination|ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.
75895745|NCT02102958|Behavioral|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
75895746|NCT02102958|Behavioral|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
76063436|NCT04393480|Other|Robotic therapy|ReoGo™ - Motorika robotic therapy - upper extremity robotic rehabilitation system
75450166|NCT01703468|Drug|Oxcarbazepine|
75450167|NCT01703481|Drug|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
75601222|NCT04691375|Drug|PY314|Dose of PY314 as a single agent given in a standard 3+3 design.
75895747|NCT00366080|Drug|GSK189254|
75601223|NCT04691375|Drug|Combination Therapy: PY314 + Pembrolizumab|Dose of PY314 alone and given in combination with pembrolizumab
75895748|NCT02097498|Other|Directed feedback|Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
75745364|NCT01030029|Device|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
75745365|NCT00868127|Drug|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
75745366|NCT00868127|Drug|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
75450168|NCT01703481|Drug|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
75450169|NCT01703481|Drug|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
75601224|NCT04687033|Device|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
75601225|NCT04669899|Drug|JTX-8064|Specified dose on specified days
76063437|NCT04393480|Other|Conventional therapy|Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment
75895749|NCT02097498|Other|Basic Videolaryngoscopy Videos|Group will watch a series of educational videos related to common airway management errors.
75895750|NCT02097576|Other|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
75895751|NCT02097576|Other|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
75895752|NCT00359450|Drug|BMS-275183 (oral taxane)|
75895753|NCT02097654|Other|SENATOR software generated pharmacotherapy advice report.|
75745367|NCT00868205|Dietary Supplement|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
75745368|NCT00878423|Drug|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
75745369|NCT00878423|Drug|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
75745370|NCT05202197|Other|Smart cupboard|Development of a memory task with the help of a smart cupboard
75895754|NCT03530462|Drug|rituximab|375 mg/m2 weekly for 4 weeks
75895755|NCT03530462|Drug|cyclophosphamide|750 mg/m2 monthly for 4-6 cycles depending on the response
75450170|NCT01703481|Drug|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
75601226|NCT04669899|Drug|pimivalimab|Specified dose on specified days
75601227|NCT04630158|Other|SAF312 Placebo|Topical ocular, suspension eye drops,
75601228|NCT04630158|Drug|SAF312|Topical ocular, suspension eye drops
75895756|NCT03530462|Drug|Steroids|500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
75895757|NCT03530462|Drug|Intravenous immunoglobulin|intravenous immunoglobulin (IVIG) with or without plasmapheresis
75895758|NCT02250456|Procedure|Echo doppler|vascular ultrasound explorations
75895759|NCT04044664|Drug|Placebo oral capsule|Matching placebo capsules.
75895760|NCT04044664|Drug|NYX-783|NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
75895761|NCT03555474|Procedure|Theta burst stimulation|Patients were given intermittent TBS to the affected hemisphere and continuous TBS to the unaffected hemisphere for 4 weeks along with physiotherapy.
75895762|NCT03555474|Procedure|Functional Electrical Stimulation|Patients were given functional electrical stimulation of affected upper extremity for four weeks along with physiotherapy.
75895763|NCT03555474|Procedure|Physiotherapy|Patients received active and passive physiotherapy of the affected extremity for four weeks.
75450171|NCT01703494|Biological|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
75601229|NCT04618185|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI to study gut function and transit without the risk of exposure to ionising radiation.
75601230|NCT04549025|Drug|JTX-4014|Specified dose on specified days
75601231|NCT04549025|Drug|Vopratelimab|Specified dose on specified days
75601232|NCT04541004|Biological|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
75745371|NCT05200949|Procedure|Kidney transplant|Transplant surgery of Kidney
75745372|NCT05195879|Diagnostic Test|XTR004|Single dose intravenous injection of XTR004. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
75745373|NCT00868361|Drug|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
75745374|NCT04039373|Drug|BMS-986256|specified dose on specified days
75745375|NCT04039373|Drug|Mycophenolate Mofetil|specified dose on specified days
75745376|NCT00875537|Other|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
75745377|NCT00875537|Other|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
75895764|NCT02100306|Behavioral|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
75895765|NCT02100306|Behavioral|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
75895766|NCT05202184|Procedure|Percutaneous thermal ablation|All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance
76063438|NCT04393402|Procedure|lung ultrasound (LUS)|Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
76063439|NCT03007732|Drug|Pembrolizumab|200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
75895767|NCT02103036|Procedure|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
75895768|NCT02103036|Procedure|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
75895769|NCT02103036|Device|TENS|"Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes."
75895770|NCT02103036|Device|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
75895771|NCT02100384|Procedure|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
75895772|NCT03922126|Other|Peer counseling|Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
75895773|NCT03922126|Diagnostic Test|HIV/STI self-testing kits|Kits to self-test for HIV/STIs
75895774|NCT02103192|Other|Anti-Oxidant Drink|
75895775|NCT03555864|Device|infrared transluminescent device|use of infra red for venous access for second intravenous access
75895776|NCT02097810|Drug|Entrectinib|
75895777|NCT04153552|Dietary Supplement|HLNatural, Inc. Upset Stomach Relief|Supplement to take with mild to moderate indigestion. The degree of your indigestion pre and post will be recorded
76063440|NCT03007732|Drug|SD-101|5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-5 weeks prior to Cycle 1, Day 1) and and 1-3 weeks after Cycle 1 Day 1
76063441|NCT03007732|Drug|Leuprolide acetate|22.5 mg will be given intramuscularly (IM). First injection 3 months prior to Cycle 1 Day 1. Intermittent androgen deprivation therapy will be given every 3 months starting Cycle 1, Day 1 for 3 additional doses.
76063442|NCT03007732|Drug|Abiraterone Acetate|1000 mg oral dosage will be given daily for 3 months prior to Cycle 1, Day 1 and daily for 9 months starting Cycle 1, Day 1.
76063443|NCT03007732|Drug|Prednisone|5 mg oral dosage will be given daily for 3 months prior to Cycle 1 Day 1 and daily for 9 months starting Cycle 1, Day 1.
75450172|NCT01703494|Biological|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
75450173|NCT01703546|Procedure|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band & Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
75450174|NCT01703559|Drug|Phentolamine Mesylate Ophthalmic Solution 1.0%|Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
76063444|NCT03007732|Radiation|Stereotactic Body Radiation Therapy|7 Gy x 5 fractions (35 Gy total) 1-2 weeks after fiducial marker placement and simulation over 10-14 days.
75450175|NCT01703559|Drug|Phentolamine Mesylate Ophthalmic Solution 0.5%|Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
76063445|NCT03007420|Drug|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
76072163|NCT02983357|Other|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
75450176|NCT01703559|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
75450177|NCT01703572|Drug|OMP-52M51|
75450178|NCT01703611|Other|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
75745378|NCT00875693|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
75745379|NCT00878579|Device|PDS System|Percutaneous Dynamic Stabilization System
75745380|NCT00878579|Device|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
75745381|NCT00875771|Drug|Capecitabine+Irinotecan+Bevacizumab|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity."
75745382|NCT00875849|Biological|cetuximab|
75745383|NCT00875849|Drug|cisplatin|
75745384|NCT00875849|Radiation|radiation therapy|
75895778|NCT01918930|Biological|MGA271|MGA271 anti-B7-H3 monoclonal antibody
75895779|NCT03555162|Other|fMRI|Imaging examination
75895780|NCT05179798|Device|mobile app|Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
75745385|NCT00868595|Biological|BPX-101|Vaccine
75745386|NCT00868595|Drug|AP1903|Activating agent, infusion
75895781|NCT03555786|Other|minimum effective volume|"The determination of MEV90 and its 95% confidence interval (CI) will be based on a biased coin up-and-down sequential design"
75895782|NCT02100462|Drug|Chlorthalidone 12.5 mg|
75895783|NCT02100462|Drug|Hydrochlorothiazide 25 mg|
75895784|NCT02100462|Drug|Aspirin 81 mg|
75895785|NCT00150176|Drug|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
75450179|NCT01703611|Other|Usual Nutrition Care|Usual nutrition care in India
75745387|NCT00875927|Other|no scraping microcapsules|1, 4 grams isomalt candy containing no scraping microcapsules
75745388|NCT00875927|Other|scraping microcapsules containing inert TCP microcapsules|1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
75745389|NCT00875927|Other|scraping microcapsules containing Propolis|1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
75745390|NCT00875927|Other|scraping microcapsules containing and Zinc|1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
75745391|NCT00875927|Other|scraping microcapsules containing Propolis and Zinc|1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
75745392|NCT00878657|Drug|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
75745393|NCT00878657|Radiation|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
75745394|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
75895786|NCT00150176|Drug|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
75895787|NCT00150176|Drug|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
75895788|NCT02100540|Drug|I placebo capsule|I placebo capsule
75895789|NCT02100540|Drug|II RDC 0.3mg capsule|II RDC 0.3mg capsule
75895790|NCT02100540|Drug|III RDC 0.6mg capsule|III RDC 0.6mg capsule
76063446|NCT03007420|Drug|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
76063447|NCT04125706|Drug|Minocycline Topical|Minocycline will be delivered locally in the periodontal pocket
76063448|NCT04125706|Drug|Metronidazole Topical Gel|Metronidazole will be delivered locally in the periodontal pocket
75895795|NCT02100618|Procedure|Blood sampling|Blood samples will be collected from all subjects at Year 6.5
75895796|NCT05201768|Other|balance tests,questionnaire|Individuals will be tested and recorded.
75895797|NCT04435912|Drug|Hydrocortisone 200mg IV|single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine
75450180|NCT01703624|Drug|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
75450181|NCT01703637|Drug|Sitagliptin|"before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
75745395|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
75745396|NCT00868673|Dietary Supplement|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
75895798|NCT02287298|Procedure|TRIPLE COMBINATION THERAPY|TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
75895799|NCT00321958|Device|CSA System (CryoSpray AblationTM System)|10 second spray times
75895800|NCT00321958|Device|CryoSpray Ablation|10 second spray times
75895801|NCT02100852|Drug|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
75895802|NCT00057980|Drug|celecoxib|
75895803|NCT00057980|Drug|epirubicin hydrochloride|
75895804|NCT02985879|Drug|Placebo|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
75895805|NCT02985879|Drug|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr. For participants in Cohort 2, ABBV-8E12 doses may have been decreased after the evaluation by the Data Monitoring Committee of available safety, tolerability and pharmacokinetic data.
75895806|NCT02103426|Drug|ASP0113|intramuscular injection
75895807|NCT02103426|Drug|Placebo|intramuscular injection
75895808|NCT05039320|Dietary Supplement|Bactoblis|dissolve the tablets in the mouth once a day for 4 weeks
75895809|NCT05039320|Dietary Supplement|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
75745397|NCT00868673|Dietary Supplement|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
75895810|NCT05718518|Drug|ASC11 tablets|"Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)"
75895811|NCT05718518|Drug|Placebo|Part 1 and 2: Subjects will be randomized to receive placebo.
75895812|NCT05718518|Drug|RTV tablets|"Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)"
75895813|NCT02103504|Device|DePuy Attune posterior stabilized fixed bearing total knee replacement|
75895814|NCT04253782|Other|Team Intervention|"The Team will meet with participants (remotely/electronically and/or by phone) and will ask that they select one of three options that may help with opioid addiction:~treatment with buprenorphine/naloxone (BUP),~inpatient, 12-step, or methadone regimens, or~education only (materials provided by the CT Community for Addiction Recovery (CCAR)).~Throughout the study, participants may switch to any other option."
75895815|NCT02287454|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
75895816|NCT02097966|Drug|Daclatasvir|
75895817|NCT02097966|Drug|Sofosbuvir|
75895818|NCT02097966|Drug|Ribavirin|
75450182|NCT01703637|Drug|Vildagliptin|"before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
75895819|NCT05716958|Radiation|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) is a type of 3D mammography that creates detailed images of the breast tissue. It uses X-rays to take multiple images at different angles and combines them to create a clear, layered view of the breast tissue. DBT is used for breast cancer screening and diagnosis and provides a more accurate view of the breast tissue compared to traditional 2D mammography.
76063449|NCT04125394|Device|hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose|Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
75450183|NCT01703637|Drug|Saxagliptin|"before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
75450184|NCT01703650|Drug|iopromide|"iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight[BW] <50kg) or 35 mL (50kg ≤BW <70kg) or 40 mL (70 kg≤BW <90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~Injection rate is as follows; 6.0mL/sec if BW is <50kg, 7.0 mL/sec if BW is 50kg≤and <70kg, 8.0 mL/sec if BW is 70≤and<90kg and 9.0mL/sec if BW is 90kg≤."
75601233|NCT04513041|Procedure|Pinhole surgical technique and tunnel technique in a split mouth design|Each subject will have the each surgical procedure which are both considered routine minimally invasive clinical care for gingival recession. Gum recession on one side will receive Pinhole surgical technique (test procedure). The other side will receive Tunnel technique (control procedure), Research component involved is the capture of digital impression using intra-oral scanner in the baseline (preoperative) and the final visit (6 months postoperative).
75616598|NCT02843542|Device|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
76063450|NCT04125004|Device|Samsung Virtual Reality Headset|Patients will pick a game or feature from the virtual reality headset to use during their procedure
75616599|NCT02811952|Other|without intervention|without intervention
75616600|NCT02686606|Dietary Supplement|Vital 1.5|Oral nutritional supplement
75616601|NCT02686606|Dietary Supplement|Ensure Plus|Oral nutritional supplement
75745398|NCT00879593|Device|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
75895820|NCT05716178|Behavioral|Maternal health education|The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion.
75895821|NCT02103582|Other|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
75895822|NCT00052598|Biological|therapeutic allogeneic lymphocytes|Given IV
75895823|NCT00052598|Biological|aldesleukin|Given SC
75895824|NCT00052598|Other|laboratory biomarker analysis|Correlative studies
75895825|NCT00052598|Other|flow cytometry|Correlative studies
75745399|NCT00879671|Dietary Supplement|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
75895826|NCT05037994|Procedure|Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine|"The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap."
75895827|NCT03555084|Device|Extension of Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
75895828|NCT03555084|Device|Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
75895829|NCT03658161|Behavioral|Communicating About Sexual Concerns and Dysfunction Effectively|The coaching intervention will include two parts: 1) initial coaching session, and 2) follow-up appointment to check in on use of the intervention strategies.
75745400|NCT00879671|Dietary Supplement|placebo|Placebo capsules identical in taste and appearance
75616602|NCT01328626|Drug|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
75745401|NCT00868829|Device|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
75745402|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
75895830|NCT00052520|Biological|therapeutic allogeneic lymphocytes|Given IV
75895831|NCT00052520|Biological|aldesleukin|Given SC
75895832|NCT00052520|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
75895833|NCT00052520|Procedure|allogeneic bone marrow transplantation|Undergo transplantation
75895834|NCT00052520|Other|laboratory biomarker analysis|Correlative studies
75745403|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
75745404|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
75745405|NCT00868985|Drug|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
75745406|NCT00868985|Drug|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
75745407|NCT00869063|Drug|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
75895835|NCT00052520|Genetic|gene expression analysis|Correlative studies
75616603|NCT02842918|Procedure|Spinal Manual Therapy|
75616604|NCT02842918|Procedure|Spinal Range of Motion|
75745408|NCT00869063|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
75616605|NCT02840812|Drug|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
75745409|NCT00869219|Drug|Nevanac|1 drop of NEVANAC at random eye
75745410|NCT00869219|Drug|Acular LS|One drop of Acular LS
75616606|NCT01212770|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
75895836|NCT00052520|Other|immunologic technique|Correlative studies
75895837|NCT00052520|Other|flow cytometry|Correlative studies
75895838|NCT00052520|Genetic|polymerase chain reaction|Correlative studies
75745411|NCT00878735|Behavioral|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
75895839|NCT00052520|Genetic|cytogenetic analysis|Correlative studies
75895840|NCT00052520|Other|staining method|Correlative studies
75895841|NCT05041816|Device|Focal vibration therapy|Myovolt delivers vibration with a frequency between 60-300 Hz, and acceleration force between 1.8g to 19.1g peak to peak. Myovolt intensity will be set to ~up to 2X the participant's initial Myovolt perception threshold (however, the maximum intensity will be limited to 19.1g which is the maximum intensity the device can deliver). If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
75895842|NCT05036434|Drug|Pembrolizumab / Lenvatinib|Pembrolizumab Plus Lenvatinib administration.
75895843|NCT00051038|Drug|Entecavir|
75895844|NCT05035186|Drug|Amoxicillin|Anti-H. pylori regimens
75895845|NCT01067469|Drug|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
75895846|NCT01067469|Drug|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
75895847|NCT01067469|Drug|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
75616607|NCT01212770|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
75895848|NCT02098200|Device|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
75895849|NCT00050102|Drug|MDX-010 (CTLA-4)|
75745412|NCT00878813|Procedure|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
75745413|NCT00878813|Procedure|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
75745414|NCT00878891|Device|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
75745415|NCT00418665|Biological|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
75745416|NCT00418665|Drug|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
75745417|NCT03994965|Drug|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
75895850|NCT04873336|Device|Intellivent ASV|A closed loop mechanical ventilation mode that adjusts oxygenization and ventilation automatically
75895851|NCT02287532|Device|DIABEO software|DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
75895852|NCT02103660|Drug|Depo-Medroxyprogesterone Acetate|150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
75895853|NCT02103660|Drug|Progestin Contraceptive (Jadelle)|2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
75895854|NCT03658005|Other|Blood sample|3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and >6h, between two doses of ticagrelor (taken at 0 and 12 hours).
75616608|NCT01212770|Drug|Placebo|
75616609|NCT05334316|Drug|Dexamethasone|Administered intravenously or orally based on daily CRP values and CRP corticosteriod dosing algorithm
75895855|NCT04704232|Drug|ACD440|Double blind, parallel within subject comparison
75895856|NCT04704232|Drug|PLAC|Double blind, parallel within subject comparison
75895857|NCT02098356|Other|Low Bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
75895858|NCT03363256|Behavioral|TES-NAV|Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
75616610|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
75895859|NCT03363256|Behavioral|TAU|Standard outpatient addiction treatment
75616611|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
75895860|NCT02101086|Other|Blood transfusion|Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
75895861|NCT00358982|Drug|MGCD0103|MGCD0103 administered orally three times per wek
75895862|NCT02101164|Biological|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
75895863|NCT02101164|Drug|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
75895864|NCT00036608|Drug|Entecavir|
75895865|NCT03657927|Device|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
75895866|NCT03657927|Device|McGrath MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
75895867|NCT02098434|Behavioral|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
75895868|NCT03223480|Device|EUS-guided gastrojejunstomy|As listed in the arms description
75895869|NCT02103738|Other|0.5 mg Ranibizumab intravitreal injections|All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
75895870|NCT02985021|Drug|Carboplatin|Chemotherapy
75895871|NCT02985021|Drug|Docetaxel|Chemotherapy
75745418|NCT04648059|Diagnostic Test|Blood sampling|Blood sampling will be performed to allow analyses of epigenetic markers
75745419|NCT01952067|Procedure|line-to-line reaming and cementing technique|
75895872|NCT03902704|Device|Cleverscope|the device is used in patients without difficult airways predictors
75450185|NCT01703650|Procedure|CT|"Perfusion CT will be performed by using a 320 channel MDCT~Patients are requested for fasting for at least 8 hours before CT scan.~Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose."
75450186|NCT01703689|Behavioral|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
75745420|NCT01952067|Procedure|standard over-reaming with 2 broach sizes|
75745421|NCT00432237|Drug|MK0974 50 mg|
75745422|NCT00432237|Drug|MK0974 150 mg|
75745423|NCT00432237|Drug|MK0974 300 mg|
75745424|NCT00432237|Drug|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
75745425|NCT00531284|Drug|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
75745426|NCT00531284|Drug|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
75745427|NCT01005446|Device|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
75745428|NCT00531206|Drug|Tipranavir|
75745429|NCT00531206|Drug|Ritonavir|low dose
75745430|NCT00994994|Drug|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
75745431|NCT04000022|Device|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
75895873|NCT03902704|Device|Laryngoscope / Videolaryngoscope C-MAC® Storz|the device is used in patients with difficult airways predictors
75895874|NCT05714540|Drug|Ketamine Hydrochloride ,Magnesium sulphate and saline 0.9%|The Effect of Oropharyngeal Pack Soaked with Ketamine or Magnesium Sulphate on Post Operative Sore Throat after Nasal Surgeries
75895875|NCT04385667|Device|levonorgestrel intrauterine system (LNG-IUD)|progestin delivery for regression of atypical endometrial hyperplasia
75895876|NCT04385667|Drug|Oral Megesterol 160 mg daily|progestin delivery for regression of atypical endometrial hyperplasia
75895877|NCT02103894|Drug|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an [18F]MNI-777 PET imaging visit. For individuals with AD or CTE, [18F]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by [18F]florbetapir imaging) and tau protein uptake (measured by [18F]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, [123I]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
75895878|NCT04441346|Radiation|Echocardiography|test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
75895879|NCT03657615|Device|hearing aid fitting|All patients were fitted bilaterally with hearing aids for hearing loss compensation. . Apart from different HAs used, device selection followed strict criteria to fit hearing loss demands, patient profile, resources and algorithms recommended for tinnitus patients.
75895880|NCT04413136|Behavioral|Web-ORLA|
75895881|NCT04413136|Behavioral|Control|
75895882|NCT02101320|Device|TRECAM|using the camera during the surgery
76072164|NCT02983357|Other|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
75745432|NCT00999674|Other|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
75745433|NCT00999752|Drug|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure <140/90
75745434|NCT00999752|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
75745435|NCT00530816|Drug|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
75745436|NCT01005758|Drug|cyclophosphamide|
75450187|NCT01703689|Behavioral|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
75895883|NCT04441424|Biological|Convalescent plasma|400 ml of convalescent plasma (plasma taken 2 weeks from the recovered COVID-19 patients) and was transfused over 1-2 hours to the recipients by blood donation set.
75895884|NCT04441424|Drug|Hydroxychloroquin with Azithromycin|The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
75616612|NCT00598273|Drug|Darbepoetin alfa|As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
75616613|NCT05334238|Drug|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
75895885|NCT03657537|Drug|Ketone infusion|β-hydroxybutyrate is infused intravenously.
75895886|NCT03657537|Drug|Saline infusion|saline is infused intravenously.
75895887|NCT02103972|Dietary Supplement|GM080|
75895888|NCT02103972|Dietary Supplement|Maltodextrin|
75895889|NCT04470362|Device|Isokinetic dynamometer|an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.
75895890|NCT04607356|Device|Blood Flow Restriction (BFR)|The Delphi Personalized Tourniquet System (PTS) will be utilized for the BFR exercises. The external constriction device will be applied to the proximal aspect of an individual's limb to restrict the flow of blood into and out of the extremity at 50% of usual flow. Subjects will perform a 30-15-15-15 repetition progression of 1-3 exercises as selected by the therapist. The Delphi PTS cuff is inflated at the start of the exercise and remains inflated throughout the exercise. Once the participant has completed an exercise, the cuff is deflated for 1 minute and the same cycle is performed for each subsequent exercise.
75895891|NCT04607356|Other|Evidence-informed care|Evidence-based resistive exercises, stretches, soft tissue mobilization and patient education for lateral epicondylalgia.
75895892|NCT03530228|Drug|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment A
75895893|NCT03530228|Drug|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment B
76063451|NCT04125082|Drug|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
76063452|NCT04125160|Device|Continuous glucose monitoring|Continuous glucose monitoring over 16 days
76063453|NCT04125160|Diagnostic Test|Glycaemic markers|Measurement of HbA1c, glycated albumin and fructosamine.
76063454|NCT04393246|Drug|EDP1815|EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
75450188|NCT01703715|Device|The Hydrant|"The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant."
75616614|NCT02842840|Behavioral|Patient-based intervention|
75616615|NCT02842840|Behavioral|Family based intervention|
75450189|NCT01703728|Other|Highly purified menotropin (HP- hMG) treatment|No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
75450190|NCT01703754|Genetic|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
75450191|NCT01703754|Drug|Palifosfamide|Small molecule chemotherapy, IV administration
75616616|NCT02842840|Other|Routine counseling|
75745437|NCT01005758|Drug|cytarabine|
75745438|NCT01005758|Drug|dexamethasone|
75745439|NCT01005758|Drug|doxorubicin hydrochloride|
75745440|NCT01005758|Drug|etoposide phosphate|
75745441|NCT01005758|Drug|hydrocortisone sodium succinate|
75745442|NCT01005758|Drug|imatinib mesylate|
75745443|NCT01005758|Drug|mercaptopurine|
75745444|NCT01005758|Drug|methotrexate|
75745445|NCT01005758|Drug|methylprednisolone|
75745446|NCT01005758|Drug|pegaspargase|
75745447|NCT01005758|Drug|prednisolone|
75745448|NCT01005758|Drug|prednisone|
75745449|NCT01005758|Drug|vincristine sulfate|
75601234|NCT04478240|Behavioral|PeerLearning.net|"PeerLearning.net is a software package that supports teachers in designing and delivering peer learning lessons, either in-person or remotely while students are learning at home.~Peer learning is an instructional technique that puts students in groups under conditions of positive interdependence, where they are incentivized to work together and promote the success of one another. Peer Learning lessons also ensure individual accountability and explicitly observe for and reward specific group social skills (e.g., encouraging participation, checking for understanding). Peer Learning also includes group processing after the lesson is completed so that the students in the groups have an opportunity to discuss what they did well and what could use improvement; they also have the opportunity to provide positive reinforcement to one another for contributing to the success of the group."
75895894|NCT03530228|Drug|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
75895895|NCT03530228|Drug|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 1
75895896|NCT03530228|Drug|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 2
75895897|NCT03530228|Drug|Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days. Group 3
75895898|NCT03530228|Drug|Tegoprazan (C3)|Tegoprazan QD, oral administration
75895899|NCT03554928|Diagnostic Test|magnetic resonance imaging|Participants will receive a 60 minute magnetic resonance imaging assessment
75895900|NCT01066923|Drug|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
75895901|NCT01066923|Other|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
75895902|NCT01066923|Drug|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
75895903|NCT01066923|Other|Passive cooling|Removing protective garments for passive cooling following exercise
75450192|NCT01703767|Behavioral|Provider Education Workshop|Educational resources for physicians regarding the needs of GW1V patients.
75450193|NCT01703793|Drug|Test Product 49778|
75450194|NCT01703793|Drug|Test Product 10156|
75601235|NCT04466917|Drug|ABP 215|ABP 215 will be administered at a dose of 15 mg/kg IV
75895904|NCT01066923|Drug|Daily placebo|Placebo comparator for daily aspirin therapy
75895905|NCT01066923|Drug|Acute placebo|Placebo comparator for acute aspirin therapy
75895906|NCT03530150|Drug|Pirfenidone Oral Product|A pill containing 600 mg of pirfenidone
75895907|NCT02098590|Biological|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
75895908|NCT02098590|Biological|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
75895909|NCT02098590|Biological|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
75450195|NCT01703793|Drug|Vehicle (placebo)|
75450196|NCT01703884|Drug|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
75450197|NCT01703897|Device|Manometry and Impedance analysis|
75450198|NCT01703910|Drug|Arm A chemotherapy|
75450199|NCT01703910|Drug|arm B chemotherapy|
75450200|NCT01703936|Other|Agricultural and life skills training program|
75895910|NCT02098590|Biological|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
75895911|NCT02098590|Drug|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
75895912|NCT04216264|Behavioral|Standard response|Parents pick from a menu of behavior changes
75895913|NCT04216264|Behavioral|Targeted response|Stepped up phone interaction with parents based on menu of behavior changes
75895914|NCT03657381|Drug|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|Biological: F520 single-dose:0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 200mg/times, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 200mg/times, 10mg/kg, treat every 2 weeks; multiple dosing: 3mg/kg, 200mg/times, treat every 3 weeks.
75895915|NCT00005918|Drug|Efavirenz|
75895916|NCT00005918|Drug|Lamivudine|
75895917|NCT00005918|Drug|Stavudine|
75895918|NCT02250846|Drug|EGFR-TKI|egfr-TKI treatment
75895919|NCT02656797|Drug|Topical Amphotericin-B 0.4% liposomal gel|Topical Amphotericin-B 0.4% liposomal gel
75895920|NCT02101398|Device|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
75895921|NCT02101398|Device|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
75895922|NCT02101398|Device|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
75895923|NCT02101398|Device|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
75895924|NCT02101398|Device|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
75895925|NCT04443244|Drug|Botulinum Toxin Type A Injection (Botulax®) 24Units|Experimental: Botulax® 24Units
75895926|NCT04443244|Drug|Botulinum Toxin Type A Injection (Botulax®) 48Units|Experimental: Botulax® 48Units
75895927|NCT04443244|Drug|Botulinum Toxin Type A Injection (Botulax®) 72Units|Experimental: Botulax® 72Units
75895928|NCT04443244|Drug|Botulinum Toxin Type A Injection (Botulax®) 96Units|Experimental: Botulax® 96Units
75895929|NCT04443244|Other|Normal Saline|Placebo Comparator: Normal Saline
75895930|NCT04383327|Behavioral|ParentCorps-Professional Development (PD)|Multi-component school-based intervention that promotes early childhood mental health and development. Teachers and PTAs (pre-primary to 4th grade) will participate in a 3-day ParentCorps-PD training before the 1st school term. They will also receive 8 sessions (12 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
75895931|NCT04383327|Behavioral|T-Wellness|A brief teacher stress management psychoeducation package, adapted from EBIs including a half-day workshop for common stress management and a half-day for burnout management, and three follow-up group support sessions (3 additional monthly 1-hr wellness sessions for teachers as a group in each school, a total 15 hours of coaching).
75895932|NCT02101476|Drug|Percocet|10mg/650mg
75895933|NCT02101476|Drug|Xartemis|15mg/650mg
75895934|NCT00005606|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
75895935|NCT00005606|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
75895936|NCT02104128|Drug|Bupropion|Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
75895937|NCT00004916|Drug|ifosfamide|
76063455|NCT04393246|Drug|Dapagliflozin|Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
76063456|NCT04393246|Drug|Ambrisentan|Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
76063457|NCT04393246|Other|Standard of care|Regular standard of care for COVID-19 patients
75450201|NCT01703975|Other|Training in pairs (Dyad training)|
75450202|NCT01704001|Drug|ART-123|380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
75450203|NCT01704027|Radiation|Simultaneous integrated boost intensity-modulated arctherapy|"Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :~Pelvis : 55,5 Gy (1,85 Gy/fr)~Seminal vesicles : 66 Gy (2,2 Gy/fr)~Prostate : 72 Gy (2,4 Gy/fr)"
75601236|NCT04466917|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg IV
75601237|NCT04466917|Drug|Paclitaxel|Paclitaxel will be administered 175 mg/m2 IV
75601238|NCT04466917|Drug|Carboplatin|Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
75601239|NCT04462471|Diagnostic Test|I-124 PET/CT lesion dosimetry|I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)
76063458|NCT01923181|Drug|semaglutide|Once-daily oral administration as tablets.
76063459|NCT01923181|Drug|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
76063460|NCT01923181|Drug|oral placebo|Once-daily oral administration as tablets.
76072165|NCT02973789|Device|NovoTTF-200T|"Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel"
76072166|NCT02973789|Drug|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
75450204|NCT01704027|Drug|Androgen deprivation|Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
75450205|NCT01704040|Drug|CNTO 3157 (healthy participants)|CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
75601240|NCT04462471|Drug|Vemurafenib|Dose level 1 & 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid
75601241|NCT04462471|Drug|Copanlisib|Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
75895938|NCT00004916|Drug|paclitaxel|
75895939|NCT00004916|Drug|teniposide|
75895940|NCT00004916|Procedure|peripheral blood stem cell transplantation|
75895941|NCT02919267|Device|Double lumen tube|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.
75895942|NCT02919267|Device|Bronchial blocker|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
75601242|NCT04444076|Device|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a reconstituted bovine origin type I collagen mesh with a proprietary high porosity system that is commercialized sterile, dehydrated and desiccated in two sizes (20x26mm and 25x31mm). It will be implanted following supraspinatus tendon repair.
75895943|NCT04809610|Behavioral|Internet attachment-based compassion therapy (iABCT).|The iABCT is a self-applied program based on the attachment theory and the use of compassion meditations. It is composed of 8 modules that have been reformulated to be completely self-applied and include text, images, illustrations, videos, audio with guided meditations, exercises and homework. Downloadable PDF files will be made available so that users can review them offline. Each module has been optimized to have a duration of 60 and 90 minutes approximately. The entire intervention is estimated to be completed in eight weeks.
75895944|NCT03555318|Other|Ambulatory visit|All patients will have an ambulatory visit with the cardiologist.
75450206|NCT01704040|Drug|Placebo (healthy participants)|Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
75601243|NCT04432493|Device|Active repetitive transcranial magnetic stimulation (rTMS)|rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
75895945|NCT03555318|Other|Combined ambulatory visit|Both the geriatrician and cardiologist will evaluate the patient and cardiac treatment will be agreed on between both specialists.
75895946|NCT03555318|Other|Geriatric intervention|After the geriatric assessment, measures to improve frailty will be started.
75895947|NCT04778566|Diagnostic Test|Cologuard test|Cologuard is a stool-DNA screening test for detecting colon cancer
75895948|NCT02101632|Dietary Supplement|Bee Venom Ointment|2 weeks
75745450|NCT01005758|Other|laboratory biomarker analysis|
75745451|NCT01005758|Radiation|radiation therapy|
75450207|NCT01704040|Drug|CNTO 3157 (asthmatic patients)|CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
75745452|NCT01005836|Behavioral|Cognitive behavioral therapy for youth anxiety|
75745453|NCT01005836|Other|Usual clinic care|
75895949|NCT02101632|Other|Vaseline Ointment|2 weeks
75895950|NCT00004910|Procedure|bowel obstruction management|
75895951|NCT00004910|Procedure|quality-of-life assessment|
75895952|NCT04434274|Drug|Micronized Purified Flavonoid Fraction|Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
75450208|NCT01704040|Drug|Placebo (asthmatic patients)|Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
75601244|NCT04432493|Device|Sham repetitive transcranial magnetic stimulation (rTMS)|Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
75745454|NCT01005836|Behavioral|Cognitive behavioral treatment for youth depression|
75745455|NCT01005992|Procedure|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
75745456|NCT01005992|Procedure|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
75895953|NCT02101710|Drug|Elantan SR 60 mg|"Trade Name: Elantan~Active Substance: Isosorbide 5-mononitrate~Pharmaceutical form: Tablet~Concentration: 60 mg~Route of Administration: Oral administration"
75895954|NCT02101710|Drug|Imdur SR 60 mg|"Trade Name: Elantan~Active Substance: Isosorbide 5-mononitrate~Pharmaceutical form: Tablet~Concentration: 60 mg~Route of Administration: Oral administration"
75895955|NCT02098668|Other|Fertility treatment|Fertility treatment
75895956|NCT03529994|Other|Enrollment|All infants enrolled will have work of breathing assessed.
75895957|NCT03878368|Dietary Supplement|Sulforaphane|Intervention soup with dietary sulforaphane
75895958|NCT03878368|Dietary Supplement|Placebo|Control soup without dietary sulforaphane
75745457|NCT01008800|Behavioral|Social Communication|The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey & Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
75895959|NCT03529916|Other|isolation of endothelial cells precursors in blood|Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
75895960|NCT01368900|Device|Ulthera® System treatment|Focused ultrasound energy delivered below the surface of the skin.
75745458|NCT01008800|Behavioral|Social communication|Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy & Grusec, 2001).
75895961|NCT04383808|Diagnostic Test|Injected radiotracer with PET Insert|"Informed consent will be obtained before beginning any study procedures.~Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
75895962|NCT04383808|Diagnostic Test|Pre-injected group with PET insert|"Informed consent will be obtained before beginning any study procedures.~Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
75895963|NCT05696912|Genetic|Ex-vivo approach concerning 25 patients|Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis
75895964|NCT05696912|Genetic|In-vitro approach concerning 25 patients|In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay
75895965|NCT02910063|Drug|Blinatumomab|Blinatumomab monotherapy
75895966|NCT03554694|Dietary Supplement|Prebiotics|Galactooligosaccharides (GOS) (prebiotics) will be consumed by the participants for 4-6 weeks
75895967|NCT03554694|Dietary Supplement|Maltodextrin (placebo)|Maltodextrin (placebo) will be consumed by the participants for 4-6 weeks
75895968|NCT04441762|Drug|Intravenous Ketorolac Tromethamine|30 mg ketorolac single dose
75895969|NCT04441762|Drug|Intranasal Ketorolac Tromethamine|30 mg ketorolac single dose
75895970|NCT02104284|Procedure|methacholine and mannitol bronchial challenge tests|"Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis."
75895971|NCT00337532|Drug|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
76063461|NCT04124224|Other|Unidos|The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
76063462|NCT04124302|Drug|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
76063463|NCT04124302|Drug|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
76063464|NCT04124302|Drug|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
75601245|NCT04422730|Behavioral|Psychological evaluation|Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
75601246|NCT04370483|Drug|Leflunomide|Gievn PO
75601247|NCT04370483|Other|Quality-of-Life Assessment|Ancillary studies
75745459|NCT01006070|Procedure|kyphoplasty|surgical kyphoplasty
75745460|NCT05092802|Drug|HLX208|450mg bid po
75895972|NCT00337532|Drug|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
76063465|NCT04123990|Diagnostic Test|Iron status testing|Iron status testing
75745461|NCT00615017|Drug|AZD9773 (CytoFab)|intravenous infusions
75745462|NCT00615017|Other|Placebo|Placebo
75745463|NCT05236244|Other|İntervention group|Diaphragmatic Breathing Exercises
76063466|NCT04124068|Other|Hydrogen peroxide teeth whitening gel|Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
76063467|NCT04124068|Device|GLO Brilliant Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
75601248|NCT04283656|Drug|Doravirine/Lamivudine/Tenofovir|100mg/300mg/300mg orally for one dose, daily
75601249|NCT04283656|Drug|Spironolactone 100mg|200mg orally for two doses, twice-daily
75601250|NCT04283656|Drug|Estradiol 2mg|4mg orally for two doses, twice-daily
75601251|NCT04283656|Other|Placebo|Placebo for one dose, daily
76063468|NCT04124068|Device|GLO Lit Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
76063469|NCT04124068|Device|GLO Science Professional Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
76063470|NCT04411069|Drug|Droperidol|Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
76072167|NCT02906007|Drug|Bedaquiline|100 mg oral tablets. In Cohorts 2 and 3 only under protocol Version 2.0, 20 mg oral dispersible tablet may alternatively be used. Doses will vary based on the participant's age and weight.
76072168|NCT02903667|Device|Bone grafting|
75895973|NCT02106234|Other|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
76063471|NCT04123912|Behavioral|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
76063472|NCT04123912|Behavioral|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
76063473|NCT04124146|Radiation|MRI for some patients according functionnal tests results|Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.
76063474|NCT01896271|Drug|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
75601252|NCT04274374|Dietary Supplement|Gluten-Free Diet|Dietary supplement without gluten
75745464|NCT01006148|Biological|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
76063475|NCT01896271|Radiation|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
75450209|NCT01704040|Other|HRV-16|Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
75745465|NCT01008878|Behavioral|interdisciplinary intervention|
76063476|NCT04123600|Device|Origin Stem and Logical Cup|The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.
75450210|NCT01704066|Other|Training and education|
75450211|NCT01704092|Drug|Dexmedetomidine|
75745466|NCT01006226|Drug|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
75745467|NCT00879047|Drug|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
75745468|NCT00879047|Drug|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
76063477|NCT01884571|Drug|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
76063478|NCT01884571|Drug|Methylprednisolone|125 mg, IV (in the vein) on day 1.
76063479|NCT01884571|Drug|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
76063480|NCT01884571|Drug|Tacrolimus|1-5 mg PO, twice a day (BID) days 2-180.
75450212|NCT01704105|Behavioral|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
75601253|NCT04274374|Dietary Supplement|Gluten Diet|Dietary supplement with gluten
76063481|NCT01884571|Drug|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
76063482|NCT04123678|Device|Deep Ensemble for the Recognition of Malignancy (DERM)|AI-based decision support tool
75450213|NCT01704105|Behavioral|Sanitation|"Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound."
75745469|NCT01008956|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
75745470|NCT01006304|Drug|JNJ-39439335, Placebo|
75745471|NCT03742700|Behavioral|Cigarette smoking|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
75745472|NCT03742700|Behavioral|E-cigarette use|E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
75745473|NCT03742700|Behavioral|Simulation of the use of e-cigarette|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
75745474|NCT00879749|Biological|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
75745475|NCT00879749|Biological|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
75895974|NCT04433260|Other|Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
75895975|NCT04433260|Other|Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
75895976|NCT04433260|Other|Informed consent|Participants will need to give their consent to participate to the survey after reading PIS
75895977|NCT04453683|Device|Air-Q. ILA insertion of proper size|Success of fiberoptic guided intubation throuhgh Air Q supraglottic airway device
75895978|NCT04453683|Device|ILMA insertion of proper size|Success of fiberoptic guided intubation throuhgh ILMA supraglottic airway device
75450214|NCT01704105|Behavioral|Handwashing|"Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces."
75895979|NCT02101866|Drug|Vapendavir 300 mg tablet|tablet - single dose
75895980|NCT02101866|Drug|Vapendavir 132 mg capsules|2 capsules - single dose
75745476|NCT00879749|Biological|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
75745477|NCT00879749|Biological|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
75745478|NCT00879749|Biological|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
75745479|NCT00879749|Other|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
75745480|NCT00869297|Other|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
75745481|NCT00869297|Other|Control|Fluids titrated at discretion of anesthesiologist.
75745482|NCT00999986|Drug|cyclophosphamide|50 mg oral per day for 7 days
75745483|NCT05226611|Other|Counterstrain|Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
75745484|NCT05178758|Device|Virtual Reality (VR)|Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.
75895981|NCT02625441|Drug|Pertuzumab|Pertuzumab 420 mg i.v. 3-weekly for 3 cycles
75895982|NCT02625441|Drug|Trastuzumab|Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
75895983|NCT02104362|Radiation|exclusive single-fraction irradiation|
75895984|NCT04303468|Dietary Supplement|GABA|The dietary supplement GABA will be taken orally 3 times daily, before each main meal
75895985|NCT04303468|Other|Placebo|Gelatin capsule containing powdered cellulose
75895986|NCT03555240|Other|Biobank creation and Pharmacogenetic analysis|Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
75895987|NCT04209868|Drug|Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection|As per arm description
75895988|NCT04209868|Drug|0.9% Sodium Chloride 20mL Injection|As per arm description
75895989|NCT03657225|Device|Utilization of the mini CPB circuit|Comparison of the mini CPB circuit to conventional circuit
75895990|NCT03657225|Drug|Utilization of the conventional circuit|Comparison of the mini CPB circuit to conventional circuit
75895991|NCT03554538|Behavioral|Web app exercises program|Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence
75895992|NCT03554538|Behavioral|Exercise program|Exercise on an evidence based program for shoulder pain
75895993|NCT04469738|Device|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
75895994|NCT04469738|Device|SCS is switched on|Spinal cord stimulator is functioning
75895995|NCT04281004|Biological|Amniotic Fluid (AFED)|One drop (0.25 mL) of Amniotic Fluid Eye Drops (AFED) in each eye four times daily for seven days
75895996|NCT04281004|Other|Saline Solution|One drop (0.25 mL) of Saline Solution in each eye four times daily for seven days
75895997|NCT03656991|Other|Bicycle intervention|
76063483|NCT04123522|Procedure|anterior approach|anterior approach
76063484|NCT04123522|Procedure|posterior appraoch|posteiror appraoch
76063485|NCT01884337|Drug|Apixaban|
76063486|NCT02996890|Biological|MV-ZIKA|MV-Zika vaccine
76063487|NCT02996890|Other|Placebo|physiological saline
76063488|NCT04123288|Drug|ACT-709478|1 film-coated minitablet contains 2 mg of ACT-709478
75895998|NCT02106312|Radiation|dose reduction of preoperative radiotherapy in MLS|A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
75895999|NCT04469816|Behavioral|Family Check-Up 4 Health|A parent-training intervention to improve child health, school readiness and manage obesity.
76063489|NCT04123288|Drug|ACT-709478|1 hard capsule contains 10 mg of ACT-709478.
75896000|NCT04469816|Other|Services as Usual|Services/Treatment as usual.
75896001|NCT03841864|Other|IV placement using ultrasound guidance vs traditional method|Ultrasound guided IV placement
75896002|NCT02361801|Drug|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
76063490|NCT04392934|Procedure|a conservative physiotherapy protocol|5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
75896003|NCT02361801|Drug|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output < 2 mL/Kg/h despite adequate fluid replacement.
75896004|NCT02104440|Biological|"Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro"|
76063491|NCT04123210|Dietary Supplement|Vitamin A supplement|
76063492|NCT04123210|Dietary Supplement|Placebo|
76063493|NCT02994550|Drug|FSH/LH|
76063494|NCT04123132|Other|Kinesiophobia|The presence of kinesiofobia in patients with metabolic syndrome
76063495|NCT01922089|Drug|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
76063496|NCT04122664|Device|RayOne® Hydrophobic lens 800C|Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C
75745485|NCT01009112|Behavioral|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
76063497|NCT04122664|Device|RayOne® Hydrophilic lens 600C|Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
75745486|NCT01009112|Behavioral|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
76063498|NCT04122430|Other|Review of Health Information|
76063499|NCT04122586|Drug|Tongxieyaofang(granule)|Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
76063500|NCT04122820|Diagnostic Test|Diagnostic of specific learning disabilities or of Developmental Coordination Disorder|Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
76063501|NCT04121884|Behavioral|Accelerated Resolution Therapy|"The ART protocol first uses the technique of imaginal exposure to elicit physiological reactions associated with patient recall from beginning to end (verbally or non-verbally) of a traumatic/distressing experience. As physiological reactions emerge, the participant is directed to focus their attention on the specific body-centric reactions while laterally performing smooth pursuit eye movements which are achieved by tracking the clinician's hand which oscillates from left-to-right at a short distance from the participant's eyes. Then the participant is directed to imagine a positive way in which they prefer to recall their experience(s), including emphasis on replacing negative images in the brain with positive images. This technique is based on the process of memory reconsolidation, which allows for adding of positive material to the recall of negative, highly emotional past experiences."
76063502|NCT01884025|Behavioral|Get Moving and Get Well|Walking Class
76063503|NCT01884025|Behavioral|Health and Humor Class|Class about the role of humor in health
76063504|NCT04121494|Biological|ChadOx1 85A - aerosol|Aerosol administration through the Omron MicroAIR NE-U22 nebuliser
76063505|NCT04121494|Biological|ChadOx1 85A - IM|Intramuscular administration
75745487|NCT01000142|Procedure|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
75896005|NCT04469972|Other|Breathing Exercises|Breathing exercise is defined as therapeutic intervention to create a particular form of breathing.The application of the breathing exercise program is as follows; I. Pursed Lip Breathing Exercise (Total 10 minutes) II. Diaphragmatic breathing exercise (10 minutes in total), III. Cough exercise (Total 10 minutes)
75896006|NCT03965728|Drug|BAY1830839|Tablet, oral.
75896007|NCT03965728|Drug|Placebo|Tablet, oral.
75896008|NCT03965728|Drug|Midazolam|For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
75896009|NCT03965728|Drug|Methotrexate|Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
75896010|NCT00337454|Drug|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
75896011|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
75896012|NCT00337454|Drug|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
76063506|NCT04121416|Drug|Oxycodone 10mg|induction with 0.3mg/kg of oxycodone in general anesthesia
76063507|NCT04121416|Drug|Sufentanil|induction with 0.3 µg/kg of Sufentanil in general anesthesia
75896013|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
75896014|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
75896015|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
75896016|NCT02909907|Drug|Botulinum toxin|Botulinum injections into dominant upper extremity using protocol outlined above.
75450215|NCT01704105|Dietary Supplement|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
76063508|NCT02983864|Behavioral|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
76063509|NCT02983864|Behavioral|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
76063510|NCT02983864|Behavioral|Relaxation|A one session intervention focused on increasing relaxation skills
76063511|NCT02983864|Behavioral|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
76072169|NCT02901821|Genetic|salivary RNA collection|collection of saliva for microRNA (small noncoding RNA) processing
75450216|NCT01704118|Device|I-gel|Supraglottic airway device
75450217|NCT01704118|Device|ProSeal Laryngeal mask|Supraglottic airway device
75450218|NCT01704170|Device|Kona Externally Focused Ultrasound Therapy|
75450219|NCT01704235|Other|Demographic Form and Semi-Structured Interview Guide|"The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.~A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team."
75450220|NCT01704248|Device|Eye Drop Guide technique|"Wash the hands.~Shake and then uncap the bottle.~Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~Then place the upper lip down to cover the whole orbital rim area.~Tilt the head back if seated or standing.~Insert the bottle in the device all the way. Hold the bottle gently.~Look upward.~Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward."
75450221|NCT01704248|Behavioral|Routine self-instillation technique|"Wash the hands.~Shake and then uncap the bottle.~Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~Lie down or tilt the head back if seated or standing.~Using the other hand, pull the lower lid down.~Hold the bottle over the eye and look up.~Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye."
75450222|NCT01704313|Procedure|Interrupted|Interrupted suturing technique used aroudn the heel of the vascular anastomosis
75450223|NCT01704313|Procedure|Continuous|Continuous suturing technique used for the anastomosis
75450224|NCT01704339|Drug|QUTENZA|Single treatment with topical capsaicin 8%
75450225|NCT01704352|Behavioral|Cognitive behavioral therapy for insomnia|CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
75745488|NCT01000142|Procedure|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
75745489|NCT01000220|Drug|Omeprazole|
75745490|NCT01000220|Drug|Placebo|
75745491|NCT01006460|Drug|Rhodiola rosea, L|3 Capsules twice a day
75745492|NCT01006460|Drug|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
75745493|NCT01006460|Drug|Panax ginseng|3 capsules twice a day
75745494|NCT01006460|Drug|Placebo - dark brown sugar|3 capsules twice a day
75745495|NCT01006694|Other|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
75745496|NCT01006694|Drug|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
75745497|NCT01006772|Other|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
75896017|NCT02909907|Other|Placebo|Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above
75896018|NCT03962842|Other|Pilates method|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
75896019|NCT02104596|Device|Xylitol|
75896020|NCT00004898|Biological|filgrastim|
75896021|NCT00004898|Drug|cyclophosphamide|
75896022|NCT00004898|Drug|etoposide|
75896023|NCT00004898|Procedure|peripheral blood stem cell transplantation|
75896024|NCT00004898|Radiation|radiation therapy|
75896025|NCT02106468|Drug|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
75896026|NCT02106468|Drug|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
75896027|NCT03956446|Drug|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
75896028|NCT03956446|Drug|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
75896029|NCT03956446|Other|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
75896030|NCT03529682|Other|exercise|10 minutes warm-up exercises and stretching exercises, 40 mınutes consecutive exercises (strengthening exercises for trunk and lower extremities) and 10 mınutes cooling down exercises and stretching exercises will be applied.
75896031|NCT03529682|Other|control group|60 mınutes in a day and 3 times in a week traditional physiotherapy program will be applied
75896032|NCT02106624|Other|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
75896033|NCT02250768|Biological|GM-CSF|2ng/ml of GM-CSF supplemented into culture media
75896034|NCT00325364|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months
75896035|NCT00325364|Drug|Injectable insulin|patient specific dose, injectable, before meals, 24 months
75896036|NCT02102178|Other|Tapestry|"A gauze screen, wool thread appropriate for tapestry and a large needle were used.~The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges."
75896037|NCT02102178|Other|Regular occupation therapy|All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
76072170|NCT02897973|Other|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
75450226|NCT01704378|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
75450227|NCT01704417|Drug|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
75450228|NCT01704417|Drug|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
75450229|NCT01704430|Dietary Supplement|Glutamine|Enteric L-Glutamine
75450230|NCT01704430|Dietary Supplement|Maltodextrin|Enteric Maltodextrin
75745498|NCT04000100|Procedure|ultrasound- guided supraclavicular brachial plexus block|"Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure"
75745499|NCT01000298|Drug|Placebo|liquid placebo medication given twice per day for 7 days
76025115|NCT03158831|Drug|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
76025116|NCT03165877|Other|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (<55%),consisting of salad, main course and dessert, respectively.
76025117|NCT03165877|Other|Control|Subjects ate standard lunches and dinners (>60%),consisting of salad, main course and dessert, respectively.
76025118|NCT03115099|Drug|LY3325656|Administered orally
76025119|NCT03115099|Drug|Placebo|Administered orally
76025120|NCT03115099|Drug|Liraglutide|Administered subcutaneously
76025121|NCT03115099|Drug|Sitagliptin|Administered orally
76025122|NCT05746117|Device|Aktiia Device|The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.
76025123|NCT05746117|Device|Upper arm cuff|A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
75745500|NCT01000298|Drug|Amoxicillin|liquid amoxicillin given twice per day for 7 days
75896038|NCT02102178|Other|Weaving a scarf on a nail frame|"Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.~Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length."
75896039|NCT02102178|Other|Domino game|"Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became blocked, i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand."
75896040|NCT02651194|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
75896041|NCT02104674|Drug|lebrikizumab|Given SC on Days 1, 29, and 57
75896042|NCT02104674|Drug|montelukast [Singulair]|10 mg given orally once daily for 12 weeks
75896043|NCT02104674|Other|placebo|SC injection given on Days 1, 29, and 57
75450231|NCT01704443|Behavioral|Group Psychoeducational Treatment|"The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.~Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)"
75896044|NCT03529604|Other|Saliva sampling|Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
75896045|NCT03529604|Diagnostic Test|ELISA|Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
75896046|NCT03529604|Diagnostic Test|HPLC|High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
75896047|NCT01917604|Procedure|open exposure|the open surgical methods of exposing the canine is compared with control
75896048|NCT01917604|Procedure|closed exposure|closed exposure is compared with control
75896049|NCT01903330|Drug|ERC1671|Given intradermally
75896050|NCT01903330|Drug|GM-CSF|Given intradermally
75896051|NCT01903330|Drug|Cyclophosphamide|Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
75896052|NCT01903330|Drug|Oral Control (Sucrose pill)|Given PO
75896053|NCT01903330|Drug|Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Given IV
75450232|NCT01704443|Other|Waitlist control|No treatment will be provided during the 8 week Waitlist control period
75896054|NCT01903330|Drug|Bevacizumab/Bevacizumab Biosimilar|Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
75896055|NCT03529526|Drug|KN046|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg."
75896056|NCT02102256|Device|Auditory Brainstem Implant|
75896057|NCT03529370|Radiation|optic nerve ultrasound|sonograhy of the optic nerve sheath diameter
75896058|NCT02106702|Behavioral|Navigator enhanced case-management|Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
75450233|NCT01704469|Procedure|The local anesthetic injection|
75745501|NCT01000298|Drug|Cefdinir|liquid cefdinir given twice per day for 7 days
75745502|NCT00614939|Drug|Saxagliptin|2.5 mg once daily oral dose
75896059|NCT02106702|Behavioral|Forensic AIDS Project|The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
75896060|NCT03675620|Device|BFR|Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
75745503|NCT00614939|Drug|Placebo|Placebo
75745504|NCT01009268|Procedure|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
75745505|NCT01006928|Other|Questionaire|Questionaire to mothers
75896061|NCT03675620|Other|Standard Rehabilitation|The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
75896062|NCT03869632|Drug|YL-13027|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
75896063|NCT02104908|Procedure|paravertebral nerve|a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).
75896064|NCT02104908|Procedure|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
75896065|NCT03674372|Device|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E < 25%; O/E LHR < 30 %) and right CDH (O/E LHR < 45%).
75896066|NCT04366648|Drug|JK-1201I|malignant solid tumor that has been confirmed by histopathology and/or cytology
75896067|NCT02106780|Drug|14C-labeled ASP1707|oral
75896068|NCT02907177|Drug|Ponesimod|One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).
75896069|NCT02907177|Other|Placebo|One tablet of matching placebo administered orally once daily in the morning
75745506|NCT00869453|Other|test meal|Mixed meal containing bread, butter, beef
75896070|NCT00004172|Biological|filgrastim|
75745507|NCT00869453|Other|glucose|administration of a glucose meal
75745508|NCT00869453|Other|fat|administration of a lipid meal
75745509|NCT00869453|Other|protein|administration of a protein meal
75745510|NCT00869453|Other|control|no meal
75896071|NCT00004172|Drug|carboplatin|
75896072|NCT00004172|Drug|cyclophosphamide|
76063512|NCT04121338|Procedure|Celiac ganglion block|The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home
76063513|NCT04121338|Drug|Liposomal bupivacaine|Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
76063514|NCT01896193|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
76063515|NCT01896193|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76063516|NCT04121104|Other|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
75745511|NCT01007006|Device|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
75745512|NCT00879827|Biological|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
75745513|NCT00879827|Biological|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
75896073|NCT00004172|Drug|ifosfamide|
75896074|NCT00004172|Drug|thiotepa|
75896075|NCT00004172|Procedure|peripheral blood stem cell transplantation|
75896076|NCT00004172|Radiation|radiation therapy|
75896077|NCT04353310|Drug|Curcumin|Curcumin 1500mg PO BID
75896078|NCT04353310|Other|Placebo|identical in appearance to curcumin
75896079|NCT00004166|Drug|amifostine trihydrate|
75896080|NCT00004166|Procedure|quality-of-life assessment|
75896081|NCT00004106|Drug|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
75896082|NCT02105064|Device|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
75896083|NCT02105064|Device|SHAM rTMS|Sham rTMS, without brain stimulation
76063517|NCT04121104|Other|SCS is switched on|Spinal cord stimulator is on
76063518|NCT04120792|Behavioral|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
76063519|NCT04120792|Behavioral|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
75745514|NCT05734352|Other|Questionnaire|Completion of the patient reported experience measurements (PREMs) questionnaire
75896084|NCT00002246|Drug|Stavudine|
75896085|NCT02652442|Behavioral|Centrifugation Distance|To determine optimal distance off-axis, participants were rotated in a darkened rotary chair booth with 1 ear positioned 3.5 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period. Following a 2-week washout period, participants were rotated in a darkened rotary chair booth with 1 ear positioned 7.0 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period.
75896086|NCT02652442|Behavioral|Centrifugation Duration|To determine optimal duration, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes. Participants received 5 sessions in a 1-week period.
75745515|NCT01007084|Drug|Propranolol|40 mg
75896087|NCT02652442|Behavioral|Centrifugation Schedule|To determine optimal schedule, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes (determined to be optimal in Exp 2). Participants received biweekly sessions for a total of 5 sessions.
76063520|NCT04120792|Behavioral|Cognitive Training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
75896088|NCT03554460|Device|dual-limb NIV|dual-limb NIV was served with servo i ventilator
75896089|NCT00002240|Drug|Atazanavir|
75896090|NCT00002240|Drug|Nelfinavir mesylate|
76063521|NCT04120792|Behavioral|Neutral video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
76063522|NCT04393012|Other|Provide alternative nurse call and communication device|Evaluate impact of providing access to the nurse call system and a speech generating device.
76063523|NCT04121026|Other|External validation of the PAANTHER TB treatment decision algorithm|"The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:~history of contact~suggestive TB symptoms~tachycardia~chest radiography~abdominal ultrasound~Xpert MTB/RIF Ultra. A score of >100 is highly predictive of TB. In children with a score >100, anti-TB treatment will be initiated immediately. In children with a score of <100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up."
76063524|NCT01922011|Drug|Daptomycin|IV daptomycin Infusion A in 12 to <18 years old (7 mg/kg); in 7 to < 12 year olds (9 mg/kg); in 24 months to <7 year olds (12 mg/kg); in 12 to <24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
76063525|NCT01922011|Drug|Vancomycin (or equivalent)|IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
76063526|NCT01922011|Drug|Nafcillin (or equivalent)|IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
76063527|NCT04120090|Drug|low dose ruxolitinib|The dose for adult patients(Age>=14 years) is generally 10 mg twice daily. For children(Age<14 years ,weight >=25kg),the dose was generally 5mg twice daily. For children(Age<14 years, weight <25kg), the dose was generally 2.5mg twice daily.
75745516|NCT01007084|Drug|Propranolol ER|120 mg twice per day
75745517|NCT01007084|Drug|Sugar pills|sugar pill
75745518|NCT01000532|Device|SIELLO JT/T|Implantation of SIELLO and BPPU pacemaker leads
75745519|NCT01000532|Device|Pacemaker therapy|Pacemaker therapy
75745520|NCT01000532|Device|BPPU JT/T|Implantation of SIELLO and BPPU pacemaker leads
75745521|NCT00879281|Behavioral|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
75450234|NCT01704482|Drug|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
75450235|NCT01704482|Drug|placebo|
75745522|NCT04040309|Biological|PRGF injection|Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
75745523|NCT04040309|Drug|Lidocaine injection|1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
75450236|NCT01704508|Drug|Artemether-lumefantrine|
75745524|NCT00869531|Other|wholegrain|wholegrain wheat vs. refined wheat products
75745525|NCT00869531|Other|refined wheat|refined wheat products
75745526|NCT01000688|Drug|vildagliptin + acarbose|4 week treatment
75745527|NCT01000688|Drug|acarbose + vildagliptin|4 week treatment
75896091|NCT00002240|Drug|Stavudine|
75896092|NCT00002240|Drug|Didanosine|
75896093|NCT02105142|Behavioral|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
75896094|NCT02105142|Behavioral|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
75896095|NCT02105142|Behavioral|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
75896096|NCT03803566|Other|Pegboard practice|Practice of the grooved pegboard test
75896097|NCT03803566|Other|Force control practice|Practice performing steady muscle contractions
75896098|NCT02250924|Dietary Supplement|Caffeine|caffeinated gum
75896099|NCT02250924|Other|Gum|Chewing gum
75450237|NCT01704508|Drug|Dihydroartemisinin-piperaquine|
75745528|NCT00879905|Drug|HSP990|
75745529|NCT01007240|Device|polyethylenimine (PEI) nanoparticles.|
75896100|NCT02250924|Behavioral|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
75896101|NCT03645148|Biological|iNeo-Vac-P01|Neoantigen peptides
75896102|NCT03645148|Other|GM-CSF|immune adjuvant
75896103|NCT04142164|Other|MacInfo presentation|Presentation about intravitreal drug injection
75896104|NCT04142164|Other|Placebo presentation|Placebo presentation
76063528|NCT04120090|Drug|high dose ruxolitinib|The dose for adult patients(Age>=14 years) is generally 20mg twice daily. For children(Age<14 years ,weight >=25kg),the dose was generally 10mg twice daily. For children(Age<14 years, weight <25kg), the dose was generally 5mg twice daily
75450238|NCT01704534|Drug|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
75601254|NCT04270630|Behavioral|Shared Decision Aid|The decision aid was developed by this study group based on the International Patient Decision Aid Standards Collaboration's minimum standards for quality, and the Ottawa Framework (a process by which patients' and clinicians' decision determinants are assessed, a decision aid is developed that is tailored to these needs, and the quality of the decision-making process with the aid is evaluated). The aid then underwent an iterative feedback process with a patient advisory panel. Adjustments to format, length, and readability were made. A final feedback session occurred with three patients over the age of 70, after which point the paper decision aid was digitalized. The intervention will be delivered in-person by one of the co-investigators of the study. The intervention will occur once, prior to the patient making a final decision regarding undergoing left heart catheterization as treatment for NSTEMI. The approximate duration of the intervention is 30 minutes.
75601255|NCT04238624|Drug|Dabrafenib|Participants will receive dabrafenib 150 mg orally twice a day
75601256|NCT04238624|Drug|Trametinib|Participants will receive trametinib 2 mg orally once a day
75745530|NCT00879983|Drug|azithromycin (Zithromax)|"a single dose of azithromycin ER 2g~3-day regimen of azithromycin tablet 500mg"
75745531|NCT00879983|Drug|azithromycin (Zithromax)|"3-day regimen of azithromycin tablet 500mg~a single dose of azithromycin ER 2g"
75745532|NCT01007318|Procedure|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
75745533|NCT01007318|Procedure|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
75745534|NCT00880061|Drug|IL13-PE38QQR|
75745535|NCT00869687|Device|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
75896105|NCT05725538|Device|COVIDReApp Group|"The COVIDReApp group will be required to complete an exercise program guided by an m-health system for three times per week during 24 weeks. A 60-minute program, following the recommendations of the American College of Sports Medicine. The daily session will be divided into:~Warm-up: 5 min. walking so that the patient can hold a conversation , monopodial balance exercise, core exercise and other respiratory and joint mobility exercises.~Aerobic training: Walking for 10 to 20 min. so that the patient can maintain a conversation, but having to stop to breathe from time to time.~Strengthening: It will focus on 7 exercises. a) squats, b) dead weight with stiff legs, c) lateral pull-ups, d) inverted flies, e) flies, f) unilateral rowing and g) lateral raises.~Cool down: It will consist of stretching exercises. a) shoulders, b) triceps, c) chest, d) quadriceps, e) hamstrings, and f) back."
75896106|NCT05725538|Other|Control Group|Participants will receive the same intervention in the traditional way, they will receive the exercise program in paper format. They will receive a document with photos and descriptions of the exercises to be performed. Their doctors will determine if the patients will be able to exercise regularly and they will perform them for 24 weeks.
75896107|NCT04082728|Drug|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
75896108|NCT04082728|Drug|Placebo oral tablet|Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
76063529|NCT01883635|Behavioral|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
76063530|NCT01883635|Behavioral|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
76063531|NCT02983786|Drug|Indocyanine Green|ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
76063532|NCT04127968|Drug|Vitamin A|Children in intervention group will receive 50,000 IU vitamin A after being randomized.
75745536|NCT00869765|Drug|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
75896109|NCT02906709|Drug|Omarigliptin|Omarigliptin, 25 mg orally once weekly
75896110|NCT02906709|Drug|Placebo|Placebo to omarigliptin orally once weekly
75896111|NCT02906709|Biological|Insulin|Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
75896112|NCT00321308|Drug|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
75601257|NCT04233385|Other|Myofascial Massage|The myofascial protocol outlines techniques, areas of the body, as well as time to be spent for each technique for a total of 25 minutes. The remaining 5 minutes of the massage are for the massage therapist to tailor myofascial massage to the needs and circumstances of each participant. In order to provide some level of customization, the therapist will determine the impact of massage on the participant's pre-existing pain and/or mobility limitations. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will use effleurage and petrissage techniques to gently massage the identified locations to soften and release the tissues. Techniques used will include deep friction of muscles, sustained compression, and fascial stretch.
75896113|NCT00321308|Drug|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
75896114|NCT02110056|Device|tDCS|transcranial direct current stimulation (tDCS)
75896115|NCT02110056|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
75745537|NCT00869765|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
75896116|NCT03943732|Diagnostic Test|FilmArray Pneumonia|FilmArray Pneumonia testing of tracheal sample
75896117|NCT02110134|Device|Revlite Laser System with hydroquinone skin care regimen|Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma
75896118|NCT02110134|Other|Hydroquinone skin care regimen|Hydroquinone skin care regimen for the Treatment of Melasma
75896119|NCT03532646|Procedure|upper endoscopy|endoscopy of the gastrointestinal tract
75896120|NCT04108546|Device|Electroacupuncture device|The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% & low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.
75896121|NCT04108546|Drug|Epidural analgesia|Ropivacaine (Naropeine) 0.2%, 5-7% ml, and Fentanyl 25mcg
75745538|NCT00530504|Device|PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device|Carotid artery stenting with distal embolic protection.
75896122|NCT03529214|Behavioral|Exposed study site|The study sites will pilot the Team Birth Project designed to improve team communication (between providers, as well as providers and patients). The project includes three key implementation steps that involve: preparing local sites for the implementation of the project; training and coaching on the use of the tools; and sustainment through peer coaching and data feedback. A mixed methods approach will be used to assess acceptability and feasibility, including: (1) clinician surveys and interviews, (2) implementation team focus groups, and (3) patient surveys.
75745539|NCT00869843|Procedure|RF Ablation|
75745540|NCT00880139|Procedure|Blood sampling|Determination of cytokine plasma levels (ELISA)
75896123|NCT02105220|Other|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
75896124|NCT03877822|Behavioral|Habitual activity|Two days of habitual physical activity, under normal free-living conditions
75896125|NCT03877822|Behavioral|Bed rest|Two days of bed rest, to induce whole-body physical inactivity
75896126|NCT02110446|Drug|SS-1|"The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.~SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day."
75896127|NCT02110446|Drug|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
75896128|NCT03847168|Drug|KN026|Patient will be intravenously administrated with one dose of KN026 every week or every other week.
75745541|NCT00880139|Procedure|Noninvasive measurement of systemic hemodynamics|performed once
75745542|NCT00880139|Procedure|Visual acuity assessment|ETDRS charts
75745543|NCT00880139|Device|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
75745544|NCT00880139|Procedure|Ophthalmic examination and fundus photography|7 + 1 standard fields
75601258|NCT04233385|Other|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed light touch protocol for each of the 16 sessions. In addition, the therapist will inquire about the participant's response to the previous light touch treatment. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will place both hands on the participant for 3 minutes at each identified location. Pressure will be very light and consistent, with no side-to-side movement.
75745545|NCT00880139|Device|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
76063533|NCT04127968|Drug|Oil|Children in control group will receive equal volume of oil.
75896129|NCT00318656|Drug|rosiglitazone-metformin fixed dose combination|
75601259|NCT04219709|Other|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
75745546|NCT00880139|Device|High resolution optical coherence tomography (OCT)|performed once
75450239|NCT01704560|Other|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
75745547|NCT03999632|Other|Dietary modification with introduction of Mankai|Substituting the standard high protein, low carbohydrate preoperative shake during the preoperative liquid diet with Wolffia Globosa (Mankai) shake consisting of 16 oz of skim milk + 1 frozen cube of Wolffia Globosa (Mankai) +/- sugar substitute.
75745548|NCT01007474|Device|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
75745549|NCT01007474|Device|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
75896130|NCT00318656|Drug|metformin + glimepiride|
75896131|NCT02110524|Device|Percutaneous Transluminal Angioplasty|
75896132|NCT02908347|Drug|MP1032|hard gelatine capsules containing 50 mg MP1032 as active ingredient
75896133|NCT02908347|Drug|Placebo|hard gelatine capsules without active ingredient
75896134|NCT02110602|Other|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
75896135|NCT02110602|Other|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
75896136|NCT00317486|Drug|bosentan|
75896137|NCT02107170|Drug|Sevoflurane|sevoflurane-based general anesthesia
75896138|NCT02107170|Drug|Propofol|total intravenous anesthesia
75896139|NCT02107170|Drug|Remifentanil|
75896140|NCT03622281|Other|quality improvement intervention using artificial intelligence|Colonoscopists received performance measure monitoring and feedback
75896141|NCT00313196|Drug|bosentan|Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
76025124|NCT03165097|Drug|ACT-709478|Hard gelatine capsules for oral administration
76025125|NCT03165097|Drug|Placebo|Placebo capsules matching ACT-709478 capsules
76025126|NCT03165097|Drug|Midazolam|Midazolam oral solution (2 mg/mL) applied with a syringe
76025127|NCT03165097|Drug|ACT-709478 combined with midazolam|Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
76025128|NCT03165799|Behavioral|Mindfulness Education|Mindfulness Education
76025129|NCT03165643|Diagnostic Test|OGTT|75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
75601260|NCT04219709|Other|Standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
75896142|NCT02107248|Behavioral|Sleep position: no restrictions|during the first eight weeks after total hip replacement following a posterolateral surgical approach
75896143|NCT02107248|Behavioral|Sleep position: supine|during the first eight weeks after total hip replacement following a posterolateral surgical approach
75896144|NCT02983305|Device|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
75896145|NCT02110680|Device|Sports TENS 2|transcutaneous electric stimulation
75896146|NCT03532568|Other|skin biopsy|4mm punch skin biopsy
75896147|NCT03532568|Radiation|narrowband ultraviolet B|narrowband ultraviolet B for CKD-aP patients
75896148|NCT03656679|Procedure|Pectoralis Blockade (PECs)|Ten milliliters of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited between the pectoralis major and minor (PECs I) and 20 cc of 0.25% bupivacaine with 2.5mcg/ml epinephrine deposited between the pectoralis minor and serratus anterior muscle.
75896149|NCT03656679|Procedure|Paravertebral Blockade|10cc of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited at two levels (T3 and T5) per side while in the sitting position.
75896150|NCT02110836|Dietary Supplement|Glucose ingestion|Glucose ingestion during exercise at 1.8 g/min
75896151|NCT02110836|Dietary Supplement|Sucrose ingestion|Sucrose ingestion during exercise at 1.8 g/min
75601261|NCT04200391|Other|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
75896152|NCT02110914|Behavioral|Coaching|"Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months."
75896153|NCT03532334|Diagnostic Test|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
75896154|NCT02107326|Device|Webdia Software|
75896155|NCT03663166|Radiation|Thoracic Radiotherapy|2 Gy in 30 fractions directed at all sites of suspected disease
75896156|NCT03663166|Drug|Platinum Based Chemotherapy|Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).
75896157|NCT03663166|Drug|ipilimumab|ipilimumab 1mg/kg delivered concurrently with initiation of chemoradiotherapy and in week 4 of chemoradiotherapy
75896158|NCT03663166|Drug|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) at least 7 days but no more than 21 days after completion of radiation and chemotherapy every 4 weeks for up to 12 cycles.
75896159|NCT02107404|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
75896160|NCT03524404|Behavioral|6 Week Intervention|Weekly interactive webinars based on the DPP curriculum at senior center.
75896161|NCT03529136|Biological|UC-MSC|Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
75601262|NCT04199689|Biological|9vHPV Vaccine|9-valent human papillomavirus vaccine (9vHPV) is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles (VLPs) of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
75896162|NCT03554304|Drug|WCK 5222|FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
75896163|NCT03554304|Drug|IV placebo matched to WCK 5222 / Moxifloxacin IV solution|"Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet"
75896164|NCT03554304|Drug|Moxifloxacin 400-mg|Moxifloxacin 400-mg positive control (overencapsulated tablet)
75896165|NCT02107716|Procedure|Lidocaine injection with bicarbonate|bicarbonate added to change pH
75601263|NCT04199689|Other|Placebo (Saline for Injection)|0.9% sodium chloride given as a 0.5-mL intramuscular injection
75896166|NCT02107716|Procedure|lidocaine injection|Lidocaine injection with pH unchanged
75896167|NCT02110992|Drug|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
75896168|NCT02110992|Radiation|Stereotactic Radiation|SBRT will be given over 5 fractions separated by > 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
75896169|NCT03306394|Drug|Trifluridine/Tipiracil hydrochloride (S95005)|
75896170|NCT02287844|Other|XOS|5 g of XOS everyday for 4 weeks.
75896171|NCT02287844|Other|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
75601264|NCT04114422|Other|Seven-day preoperative exercise training program|The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
75601265|NCT04106414|Drug|Nivolumab|Nivolumab 480 mg every 4 weeks.
75745550|NCT01007474|Device|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
75896172|NCT02287844|Other|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
76063534|NCT01921387|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
76063535|NCT01921387|Drug|Carmustine|Given IV
75601266|NCT04106414|Drug|BMS- 986205|BMS-986205 100 mg every 4 weeks.
75601267|NCT04091646|Drug|Roflumilast Foam 0.3%|Roflumilast foam for topical application.
75601268|NCT04091646|Drug|Vehicle foam|Vehicle foam for topical application.
75601269|NCT04090957|Drug|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
75601270|NCT04090957|Drug|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
75601271|NCT04086550|Device|LIQOSEAL|Adjunctive bioresorbable patch
75601272|NCT04086550|Device|DuraSeal, Adherus|synthetic absorbable sealants
75601273|NCT04081298|Behavioral|Health Education|Attend nutrition and PA classes, and cooking sessions
75601274|NCT04081298|Other|Physical Activity|Participate in physical activities
75601275|NCT04081298|Other|Health Promotion and Education: Text Messages|Receive motivational text messages
75601276|NCT04081298|Other|Health Promotion and Education: Web Site|Given access to nutrition website
75601277|NCT04081298|Other|Quality-of-Life Assessment|Ancillary studies
75601278|NCT04081298|Other|Questionnaire Administration|Ancillary studies
75601279|NCT04063267|Device|E cigarettes|Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms
75601280|NCT04063267|Other|Nicotine Replacement Therapy|Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
75896173|NCT02105376|Device|Trigeminal Nerve Stimulation (TNS)|Trigeminal Nerve Stimulation (TNS)
75601281|NCT04063241|Other|Health Literacy-Informed Discharge Instructions|Web-based disease-specific instruction sheets that will be printed with the research team's help. Providers will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
75601282|NCT04063241|Other|Provider Training|20-minute long provider training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data.
75745551|NCT01007474|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
75745552|NCT01007474|Device|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
75745553|NCT00880295|Procedure|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
75745554|NCT00880295|Procedure|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
75745555|NCT00880373|Drug|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
75745556|NCT00880373|Drug|Placebo|Matching placebo three times daily for 4 days
75745557|NCT00880373|Drug|Diamorphine or Morphine|Diamorphine or Morphine by PCA
75896174|NCT02111070|Biological|IL-YANG FLU Vaccine|0.5mL
75896175|NCT02983227|Drug|GDC-0853|GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
75896176|NCT02107794|Other|Decision Aid|Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
75896177|NCT00311090|Drug|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
75896178|NCT00311090|Drug|Idraparinux sodium|"0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection"
75896179|NCT00311090|Drug|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
75896180|NCT00311090|Drug|Placebo (for Avidin)|"Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes"
76063536|NCT01921387|Drug|Cytarabine|Given IV
76063537|NCT01921387|Drug|Etoposide|Given IV
76063538|NCT01921387|Other|Laboratory Biomarker Analysis|Correlative studies
76063539|NCT01921387|Drug|Melphalan|Given IV
76063540|NCT01921387|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
75896181|NCT02105532|Other|Restrictive transfusion policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
75896182|NCT02105532|Other|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
75896183|NCT05622188|Other|Elevated ambient heat|Temporary exposure to increased ambient temperature +10°C (the effect of the intervention is fully and spontaneously reversible)
75896184|NCT05622188|Other|Elevated relative humidity|Temporary exposure to increased ambient relative humidity +40% (max. 90%) (the effect of the intervention is fully and spontaneously reversible)
75896185|NCT05622188|Other|Exertion|Temporary exertion on an ergometer (1W/kg body weight) (the effect of the intervention is fully and spontaneously reversible)
75896186|NCT03554070|Procedure|Thulium Fiber Laser Enucleation of the Prostate|Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.
75896187|NCT03554070|Device|"Thulium Fiber Laser Urolase"|"Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm."
75745558|NCT01007630|Drug|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
75896188|NCT03553992|Behavioral|POP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch"
75896189|NCT03553992|Behavioral|TSP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch"
75896190|NCT03815734|Procedure|motor imagery|motor imagery during the postoperative immobilization period
75896191|NCT02105610|Drug|desflurane, isoflurane, sevoflurane|
75896192|NCT02105610|Drug|total intravenous anesthetics|
75896193|NCT00301262|Drug|Viagra (Sildenafil citrate)|
75896194|NCT02254941|Drug|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
75896195|NCT02254941|Biological|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
75896196|NCT03713476|Other|Motor task training|motor task specific training
75896197|NCT02107872|Drug|REGN1500|
75896198|NCT02107872|Drug|placebo|
75896199|NCT02111148|Procedure|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
75896200|NCT02111148|Procedure|Nitrazine|Nitrazine detection in vaginal wash
75896201|NCT02111148|Drug|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
75896202|NCT02111226|Other|SMS text messaging|short message service
75896203|NCT02905149|Procedure|Serrato|Serratus plane block.
75896204|NCT02905149|Procedure|Control|Standard anesthesia
75896205|NCT03553680|Behavioral|Emotion-Focused CBT|10 CBT Sessions to improve emotional regulation and emotional intelligence.
75896206|NCT03656913|Diagnostic Test|Extremely low dose CT|Patients undergoing clinically indicated CT will also receive the extremely low dose CT
75896207|NCT02790606|Device|Covera(TM) Vascular Covered Stent|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
75896208|NCT03656523|Other|Acute coronary syndrome and PCI and AF|Patient with ACS and ACS treated with PCI
75896209|NCT02105922|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 3 months.
75745559|NCT01007630|Drug|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
75745560|NCT05883384|Other|stool analysis , CBC, specific IgE FOR Cow milk protein allergy|apply CoMiSS and food challenge test on patient whom suspected to have cow milk protein allergy.
75745561|NCT05883345|Diagnostic Test|Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin levels|Endoscopic biopsy
75745562|NCT05883332|Drug|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-50%)
75745563|NCT05883332|Other|Oxygen|100% oxygen at 10 Liters/minute
75745564|NCT05883306|Drug|[14C]LXI-15028|[14C]LXI-15028
75896210|NCT02105922|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 3 months.
75896211|NCT02105922|Procedure|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
75896212|NCT03077620|Drug|Suvorexant|Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
76063541|NCT01921387|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
75601283|NCT04053335|Behavioral|Multicomponent Physician Performance Peer-Comparison Feedback Intervention|"The intervention will consist of 5 components delivered simultaneously~Clinical Leadership Team: Each site will develop a Clinical Leadership Team (CLT), typically consisting of quality officers, clinician champions, etc. to implement and monitor the intervention~Speaker Series: VCHI will offer the CLTs access to national experts via a CME-approved speaker series and office hours to support the intervention.~Education Materials: The CLTs will distribute clinician and consumer education throughout the health systems calling to avoid 9 low-value services.~Clinician Report Cards: VCHI will distribute quarterly customized clinician performance report cards to the CLTs teams using the Milliman Health Waste Calculator and Virginia APCD~Quality improvement training: The intervention will provide the CLTs with in-person quality improvement and clinician performance feedback training, using principles of self-determination theory, and will include monthly check-in calls"
75745565|NCT05883293|Drug|Cell Free Fat Extract(CEFFE)|The subjects inhaled 2ml of CEFFE each time in a nebulized inhalation method, inhaling every 3 days, for a total of 7 inhalations
75745566|NCT05883280|Other|Binaural beats|The binaural beat audio file consists of pure tones with a frequency of 432 Hz in the left ear and 420 Hz in the right ear. It is played through headphones starting 30 minutes before the end of the surgery.
75450240|NCT01704573|Drug|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|"The study will be performed using an Investigational New Drug (IND) Application for the 2-[18F]FA radioligand. The 2-[18F]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-[18F]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-[18F]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-[18F]FA from the FDA."
75450241|NCT01704586|Radiation|Radioiodine I-131|Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.
75601284|NCT04051541|Other|Agitated saline push|Push of agitated saline to simulate adenosine used for supraventricular tachycardia
75745567|NCT05883254|Diagnostic Test|RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR|"Quantatative Real -Time PCR for quantification of PUM1;~The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~The method of total RNA extraction: TRIzol and TRIzol LS.~The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels"
75896213|NCT03077620|Drug|Placebo|Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
75896214|NCT03656445|Drug|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
75896215|NCT03656445|Drug|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
75896216|NCT03656445|Drug|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel
75896217|NCT02111304|Drug|iOWH032|
76063542|NCT04129996|Drug|camrelizumab in combination with nab-paclitaxel and famitinib|camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
76063543|NCT03179644|Other|Measurement of oesophageal pressure and pleural pressure|Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
75896218|NCT01903486|Drug|Apo-Prednisone Cordorol, Detasone - Prednisone|Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
75896219|NCT03656289|Drug|Etonogestrel 68Mg Implant|Participants will have an etonogestral contraceptive implant (NEXPLANON) placed sub-dermally just under the skin at the inner side of the non-dominant upper arm.
75896220|NCT02106000|Device|Inhalation profile recorder|Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
75896221|NCT02106078|Behavioral|Moderated Discussion Board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).~The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
75896222|NCT02106078|Behavioral|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~What is bipolar disorder? - Content about symptoms and diagnosis~Stress and triggers of illness~Medication and the biological basis of bipolar disorder~Depression - Symptoms, early detection and helpful strategies~Mania and hypomania - Symptoms, early detection and helpful strategies"
76025130|NCT04436003|Behavioral|Muscle and articulation chains GDS method|"A physiotherapy method adapting treatment to patient's terrain, or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement."
75450242|NCT01704586|Radiation|I-124|I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
75450243|NCT01704612|Drug|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
75450244|NCT01704625|Procedure|Osteopathic Manipulative Treatment|The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
75450245|NCT01704625|Procedure|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments.
75450246|NCT01704638|Drug|fluvoxamine|
75745568|NCT05883215|Other|Pain catastrophizing scale|"The pain catastrophizing scale is a self-report questionnaire used to assess an individual's tendency to engage in catastrophic thinking when experiencing pain. It measures the extent to which a person magnifies, feels helpless, and feels unable to cope with pain. The scale typically consists of several items that ask individuals to rate the degree to which they experience specific thoughts or emotions related to pain catastrophizing, such as I worry all the time about whether the pain will end or I feel like I can't stand it anymore. Participants provide responses on a Likert scale indicating the intensity or frequency of their agreement with each statement. The scale helps researchers and healthcare professionals gain insights into an individual's cognitive and emotional responses to pain, which can have implications for pain management strategies and overall well-being."
75745569|NCT05883215|Other|Beck Anxiety Inventory|"Beck Anxiety Inventory (BAI), which is designed to measure the severity of anxiety symptoms in individuals. The BAI is a self-report questionnaire consisting of 21 items that assess various symptoms of anxiety, such as nervousness, fear, and physiological manifestations of anxiety. Participants rate the intensity of their symptoms over the past week on a scale ranging from 0 (not at all) to 3 (severely). The scores obtained on the BAI can help clinicians and researchers evaluate the presence and severity of anxiety symptoms, monitor changes over time, and guide treatment decisions. It is important to note that the BAI is not a diagnostic tool but rather a measure of self-reported anxiety symptoms."
75745570|NCT05883215|Other|Social Media Use Integration Scale|The Social Media Use Integration Scale (SMUIS) is a self-report measure that assesses the degree to which individuals integrate social media into their daily lives. It aims to capture the extent to which individuals incorporate social media use into various aspects of their routines, behaviors, and identity. The scale typically consists of items that assess factors such as the frequency and duration of social media use, the importance and impact of social media on personal relationships, the integration of social media into daily activities, and the emotional connection to social media.
75745571|NCT05883215|Other|Fibromyalgia Impact Questionnaire|"The Fibromyalgia Impact Questionnaire (FIQ) is a widely used self-report measure specifically designed to assess the impact of fibromyalgia on various aspects of a person's life. It is a multidimensional questionnaire that evaluates the physical functioning, social functioning, and overall well-being of individuals with fibromyalgia.~The FIQ typically consists of items that ask individuals to rate the impact of fibromyalgia on their ability to perform daily activities, such as work, household chores, and recreational activities. It also assesses the severity of fibromyalgia symptoms, including pain, fatigue, sleep disturbances, and cognitive difficulties. Additionally, the questionnaire may include items related to emotional well-being, social support, and overall quality of life."
75745572|NCT05883189|Diagnostic Test|Draw blood|Draw blood from human body and make into serum to test
75745573|NCT05883176|Drug|Bevacizumab Biosimilar QL 1101|TACE + Bevacizumab (15mg/kg, intra-arterial infusion, Q3W) for 4 cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
76063544|NCT04129216|Drug|Tamoxifen Citrate|10mg administered daily. Patients take this drug for 2-6 weeks
76063545|NCT04129216|Drug|Letrozole|2.5mg is administered daily. Patients take this drug for 2-6 weeks
75450247|NCT01704638|Drug|Digoxin|
75450248|NCT01704664|Dietary Supplement|Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
75601285|NCT04047914|Device|Antimicrobial Photodynamic therapy|"Application 0.01% methylene blue with sterile swabs in each nostril with a 10-minute pre-irradiation~• Light-emitting diode (λ = 660 nm), for 300 seconds, with an irradiance of 400 mW / cm2"
75601286|NCT04047914|Drug|Mupirocin ointment|Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
75601287|NCT04042753|Drug|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks,
75745574|NCT05883124|Drug|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
75745575|NCT05883124|Drug|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
75745576|NCT05883111|Diagnostic Test|HPV DNA methylation assay|HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
75745577|NCT05883098|Procedure|Wound debridement|The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.
75745578|NCT05883098|Device|Wound closure matrix application|After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.
75745579|NCT05883085|Drug|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
75745580|NCT05883059|Device|Lower limb robot assisted walking training|The participants in the robot group received lower limb robot assisted walking training combined with routine rehabilitation therapy. Lower limb robot assisted walking training for 30 minutes each time, once a day, 5 times a week, for 4 consecutive weeks; Routine rehabilitation treatment includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabilitation treatment once a day, five times a week, for four consecutive weeks.
75745581|NCT05883059|Other|routine rehabilitation|The control group participants received routine rehabilitation, including lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabil
75745582|NCT05883046|Other|Performance-Enhancing Substances|All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
75745583|NCT05883046|Other|Placebo|20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
75745584|NCT05883046|Other|Baseline (Control)|No supplement conditions
75896223|NCT02106078|Behavioral|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
75896224|NCT01883817|Drug|DHA Omega-3|Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
75896225|NCT01883817|Drug|Placebo|corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
75601288|NCT04042753|Drug|Nivolumab|Nivolumab 1 mg/kg every 3 weeks for 4 cycles
75601289|NCT04042753|Drug|Nivolumab|Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first
75601290|NCT04040933|Device|Marketed Adhesive Bandage #1|On the randomized wound site, a marketed adhesive bandage will be applied.
75601291|NCT04040933|Device|Marketed Bandage #2|On the randomized wound site, a marketed adhesive bandage will be applied.
75601292|NCT04040933|Device|Non-Marketed Bandage #1|On the randomized wound site, a non-marketed adhesive bandage will be applied.
75601293|NCT04040933|Device|Non-Marketed Bandage #2|On the randomized wound site, a non-marketed adhesive bandage will be applied.
75601294|NCT04040933|Device|Non-Marketed Adhesive Bandage #3|On the randomized wound site, a non-marketed adhesive bandage will be applied.
75745585|NCT05883033|Device|VAC|Vacuum Assisted Closure device
75745586|NCT05883020|Other|Experimental Interventions|One session per week of rSWT will be applied using the BMI-1120 SHOCK MED device (BIO-MED-INC- ITALY). The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.
75745587|NCT05883020|Other|Standard physical therapy program|Regular rehabilitation procedures consist of strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait and balance training, and advice to parents. The duration of each session will be 1 hour, 3 times per week for 4 weeks
75896226|NCT00599170|Drug|Rituximab|375 mg/m2 IV
75896227|NCT05128240|Dietary Supplement|Placebo|1g corn oil capsules
75896228|NCT05128240|Dietary Supplement|Ceto 10|1g capsules containing oil broad spectrum marine oil from north atlantic fish
75896229|NCT03656211|Other|Telephone interview|"Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview."
75896230|NCT04256434|Drug|Dinalbuphine sebacate|150 mg Dinalbuphine sebacate
75896231|NCT04256434|Drug|Nalbuphine HCl|20 mg Nalbuphine
75896232|NCT03553602|Radiation|HDR Brachytherapy + EBRT + STAD|"HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen[until end of radiotherapy])"
75896233|NCT04234126|Procedure|ERCP|Routine ERCP for CBD stone with the gallbladder in situ, the chronic gallbladder status was defined as gallbladder wall thickness≥4mm, chronic cholecystitis, polyps,crudely or calculus .
75896234|NCT03655977|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 will be administered before external beam radiation therapy (EBRT).
75896235|NCT03655977|Device|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.
75896236|NCT03655977|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 will be administered before brachytherapy (BT).
75896237|NCT03655977|Device|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
75896238|NCT03769584|Other|Follow-up questionnaire|Online- Questionnaire investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
75896239|NCT03769584|Other|Follow- up interview|Semi- structured Interview investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
75896240|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 1|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
75896241|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 2|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
75745588|NCT05882994|Behavioral|rom exercise|At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks. Evaluation will be done. At the end of the study, rom exercises will be applied to the patients in the control group.
75896242|NCT02113722|Procedure|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation via a video
75896243|NCT02113722|Procedure|Standard of Care|Medical therapy
75896244|NCT03655509|Procedure|Dynamic test ACTH stimulation|
75896245|NCT02111460|Radiation|Loco-regional Radiotherapy|with or without Loco-regional Radiotherapy
75896246|NCT02111538|Other|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
76063546|NCT04129216|Drug|Exemestane|25mg is administered daily. Patients take this drug for 2-6 weeks.
75601295|NCT04040933|Device|Non-Marketed Adhesive Bandage #4|On the randomized wound site, a non-marketed adhesive bandage will be applied.
75601296|NCT04040933|Device|Non-Marketed Adhesive Bandage #5|On the randomized wound site, a non-marketed adhesive bandage will be applied.
75601297|NCT04030338|Drug|18F-DCFPyL-iPSMA|Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
75601298|NCT04030338|Drug|68Ga-HBED-iPSMA|Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
75601299|NCT04030338|Diagnostic Test|PET/CT scan|The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
75896247|NCT02982213|Other|Companion Present|A companion will be present during the epidural catheter placement.
75896248|NCT05403424|Other|Evaluation of pain|The severity of pelvic girdle pain will be evaluated with the Visual Analog Scale (VAS).
75896249|NCT05403424|Diagnostic Test|Application of pelvic girdle diagnostic tests|Pelvic girdle pain diagnostic tests will be applied.
75896250|NCT05403424|Other|Evaluation of biomechanics and viscoelastic properties of thoracolumbar fascia|The biomechanical and viscoelastic properties of the thoracolumbar fascia will be measured in the prone position and measurements will be taken from three different points
75896251|NCT05403424|Other|Evaluation of activity limitation|Pelvic Girdle Questionnaire will be filled
76063547|NCT04129216|Diagnostic Test|Blueprint|studies the genomics of the tumor and tumor behavior
76063548|NCT04129216|Diagnostic Test|Mammaprint|studies the genomics of the tumor
75896252|NCT02111616|Behavioral|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
75896253|NCT02111616|Behavioral|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
75896254|NCT03655431|Other|Telerehabilitation|Participants complete a standard physical therapy evaluation in-person. They are then provided telerehabilitation equipment for the telerehabilitation intervention. This intervention utilizes an Xbox Kinect sensor and tablet-based exercise software called Jintronix. The Jintronix exercise library includes an array of exercise activity options for varying functional levels. Exercise activities could be completed in sitting or standing postures and includes activities which focused on active range of motion, strength, balance, or calisthenic movements. Each activity requires the participant to complete a goal-directed game or replicate movements of an on-screen avatar. The therapist will adjust and progress the home exercise program using information provided by the Jintronix and the participant's verbal reports during clinical video teleconferencing. At the end of the intervention, the therapist will complete in-person discharge assessments.
75896255|NCT03655431|Other|Standard treatment|Participants complete standard in-person physical therapy evaluation, follow-up, and treatment. Therapeutic exercise and activities will be prescribed to participants to perform at home between standard follow-up treatment appointments. At the end of the intervention, the physical therapist will complete in-person discharge assessments.
75896256|NCT02111694|Behavioral|Bottle Type|Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
75601300|NCT04026490|Behavioral|Immediate Intervention|The Interventionist will use motivational interviewing skills, assess ethnic and racial microaggressions, and provide support, screen for posttraumatic stress, and, if appropriate, link student to advanced care. The student may meet with the Interventionist several times during the remainder of the school year. These meetings will be approximately 10-30 minutes in length and occur during the school day in a private location determined by the Interventionist. The student may be referred to additional resources as a result of the meetings. The meetings will be documented by the Interventionist using a case management system (in RedCap).
75601301|NCT04026490|Behavioral|Waitlist Intervention|In order to compare outcomes contemporaneously, students from waitlisted schools will be asked to complete baseline and follow-up surveys, which will be collected at approximately the same time as in the immediate intervention schools. The data will be captured for analysis at the end of the study. Students will complete intervention following the waitlist period.
75601302|NCT04026477|Behavioral|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop
75601303|NCT04026477|Behavioral|Waitlisted Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop following waitlist period
75601304|NCT04024956|Device|Sealing Device|The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
75601305|NCT03995355|Device|9618X investigational lipid eye drops|Test Eye Drops
75745589|NCT05882968|Diagnostic Test|kidney function tests|using GFR test according to kdigo guide lines
75745590|NCT05882955|Behavioral|Recipes consumption|Participants will eat one or two recipes a day for 17 weeks
75745591|NCT05882955|Behavioral|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
75745592|NCT05882942|Dietary Supplement|Matcha green tea|This is the condition with the Matcha green tea
75745593|NCT05882942|Dietary Supplement|Placebo|This is the condition with the placebo
75745594|NCT05882890|Other|cranio sacral therapy|Manual treatment of 5 grams on the whole airwaysystem, the throat, the neck, the meninges, the craniel , nerve sleeves, the visceral cranium, the soft tissue in the mouth
75745595|NCT05882864|Drug|6-Gingerol|6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
75745596|NCT05882864|Drug|Triamcinolone Acetonide 0.1% Oromucosal Paste|Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
75745597|NCT05882851|Behavioral|determination of the current nutritional status of patients|No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
75745598|NCT05882838|Other|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
75896257|NCT03655353|Diagnostic Test|ABY-PET|Diagnostic PET for HER2 expression
76063549|NCT04122274|Behavioral|NCAA education sheet|A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
75601306|NCT03995355|Device|Blink® Tears|Control Eye Drops
75601307|NCT03995212|Drug|CR845 1.0 mg|Oral CR845 1.0 mg administered twice daily
75601308|NCT03995212|Drug|Placebo|Oral Placebo administered twice daily
75601309|NCT03946618|Device|Medtronic Summit System, Olympus|Electrical brain stimulation with an implantable pulse generator
75601310|NCT03942211|Drug|Selexipag|Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
75745599|NCT05882825|Other|Dry Needling Therapy Knowledge and Awareness Questionnaire|Dry Needling Therapy Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
75896258|NCT02649634|Behavioral|Motivational Interviewing|The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
75896259|NCT02649634|Behavioral|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
75896260|NCT02107950|Biological|DCVAC/OvCa in parallel with chemotherapy|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
75896261|NCT02107950|Drug|Standard of Care|Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
76063550|NCT04122274|Behavioral|Sham Intervention|An approximately 7-minute video that includes information about basic sports nutrition facts.
76063551|NCT04122274|Behavioral|Decision-based interactive concussive education platform|A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
76063552|NCT04120558|Other|Qualitative interviews and focus groups|"Semi-structured interviews will be undertaken with at least 24 and up to as many as 36 through knee and above knee amputees. A topic guide will be used to interview participants about perceived functional ability, body image, adapting post amputation and overall quality of life. A sampling frame will be used to ensure a range of views are sought (e.g. both men and women with through and above knee amputations; and with different mobility levels). Thematic analysis will be used to analyse the data. Focus group discussions will be informed by the findings of the interviews.~The themes that emerge from the semi-structured interviews will be further explored using focus groups and allow for comparison of the experiences between through knee and above knee amputees."
76063553|NCT04120558|Other|Functional mobility tests and questionnaires|"Function in sitting and sit-and-reach will be assessed in non-ambulatory (wheelchair users) individuals. An overall score for each sitting activity will be recorded and the distance reached will be calculated.~Walking, timed-up-and-go, L-test, balance in sitting and standing, seated activities will be assessed in ambulatory (prosthetic using) individuals. The time taken, distance walked, distance reached, and the overall scores for each activity will be compared between the two groups. Fear of falls and confidence levels when performing tasks will be investigated using two questionnaires.~The EQ-5D-5L and SF-36 will be issued to the non-ambulatory and ambulatory participants to complete when attending the testing session.~The Locomotor Capability Index - 5 (LCI-5), Activities-specific Balance Confidence Scale (ABC-UK) and Houghton scale of prosthetic use in people with lower-extremity amputations"
75601311|NCT03942211|Drug|Placebo|Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
75896262|NCT03655275|Biological|PRP prolotherapy|PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.
75745600|NCT05882799|Procedure|Ultrasound-guided dry needling|Ultrasound-guided dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle while monitoring the needle's progress with real-time ultrasound imaging. In this technique, a trained practitioner visualizes the piriformis muscle and the surrounding structures using an ultrasound machine, and then inserts the needle through the skin and into the muscle tissue, guided by the ultrasound image.
75745601|NCT05882799|Procedure|Blinded dry needling|Blinded dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle without using real-time imaging guidance. In this technique, the practitioner relies solely on their palpation skills to locate the trigger points of the piriformis muscle and inserts the needle through the skin and into the muscle tissue.
75745602|NCT05882786|Procedure|Corticosteroid injection|Subacromial injection of 40mg triamcinolone acetonide.
75745603|NCT05882786|Procedure|Dry Needling|Dry needling treatment to the supraspinatus, infraspinatus, and subscapularis muscles tendons.
75601312|NCT03933397|Other|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.
75745604|NCT05882630|Drug|Surufatinib,Serplulimab,Etoposide,Carboplatin|"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."
75745605|NCT05882591|Procedure|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
75896263|NCT03655275|Biological|Saline prolotherapy|Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
75745606|NCT05882578|Other|Oncological physical exercise intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
75745607|NCT05882578|Other|Active Physical Activities intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
75896264|NCT02108106|Drug|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
75745608|NCT05882539|Device|endotracheal tube material,Bite block Material|Exposure factors associated with tracheal intubation in patients that may influence the occurrence of oral mucosa pressure injurie, such as the material and fixation of the tracheal tube, the patient's own nutrition, the level of tissue perfusion and relevant treatment factors.
75896265|NCT02108106|Drug|Placebo|
75896266|NCT03655041|Dietary Supplement|Beta-alanine|Beta-alanine in sustained-release tablets to increase muscle carnosine content
75896267|NCT03655041|Dietary Supplement|Placebo|Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine
75896268|NCT02108184|Drug|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
75896269|NCT02108184|Drug|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
75896270|NCT02108184|Drug|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
75896271|NCT02108184|Drug|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
75896272|NCT03654963|Procedure|Medication reconciliation|Medication reconciliation is the systematic process described above.
75896273|NCT02113800|Drug|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
75896274|NCT03622203|Device|Biofreedom|Use of Biofreedom in real life patients
75896275|NCT02108340|Procedure|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
75896276|NCT05405062|Device|Carboxytherapy, short pulsed 1064 Nd Yag laser and subcision|Carboxytherapy is involves the injection of carbon dioxide into the subcutaneous tissue, with the goal of affecting the adipose tissue and circulation. Its mechanism of action is through an increase in capillary blood flow induced by hypercapnia and a decrease in cutaneous oxygen consumption (Pianez et al., 2016).
75896277|NCT01066143|Drug|Seroquel XR|Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
75896278|NCT02108418|Drug|TG-2349 as the original formulation|single oral dose under fed condition
75745609|NCT05882526|Device|BURSTONE T-LOOP|Split mouth study one side using elastomeric power chain and other side using T loops
75745610|NCT05882513|Drug|Serplulimab and neoadjuvant therapy|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."
75745611|NCT05882513|Procedure|surgical resection of lung cancer|radical resection of lung cancer
75745612|NCT05882500|Other|No intervention, observation|
75745613|NCT05882487|Genetic|KL002 injection solution|Neurosurgical delivery of KL002 to the brain
75745614|NCT05882474|Device|PaCO2|Level of partial pressure of carbon dioxide
75745615|NCT05882461|Behavioral|90Second Caregiver health letter|Participant receives the weekly health letter via email
75745616|NCT05882448|Procedure|laparotomy|Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion
75896279|NCT02108418|Drug|TG-2349 as a new capsule formulation|single oral dose under fed condition
75896280|NCT05404984|Other|Dry cupping with core stabilization exercises|12 patients will receive dry cupping technique for 10 minutes followed by 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
75896281|NCT05404984|Other|Core stabilization exercises|A total of 12 patients will perform 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
75896282|NCT03654339|Procedure|root coverage|"Group A: After administration of local anaesthesia using ophthalmic microsurgical knives a V-shaped incision was made in the gingival recession area. the gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then secured with 6-0 absorbable sling suture without tension. the surgical procedure was done with seilar microscope 40X magnification.~Group B: After administration of local anaesthesia using 15 no blade a V-shaped incision was made in the gingival recession area . gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then carefully secured with 4-0 absorbable sling suture"
75896283|NCT02251470|Other|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
75896284|NCT02251470|Other|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
75896285|NCT05404828|Other|Polysomnography|Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI
75896286|NCT05404828|Other|Questionnaires|STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36
75896287|NCT05404828|Other|Blood and urine sample|Na, K, Creat, Osm, Urea
76025131|NCT04436159|Procedure|Addition of 360 fundoplication after crural closure|A total fundoplication was constructed in which the right and left part of the wrap was brought together in front of, and slightly to the right of the esophagus, and sutured with three interrupted stitches of 2-0 unabsorbable sutures from the GEJ and cranially to attain a length between the top and bottom sutures of at the most 2 cm. At least one wrap suture included the esophageal muscle-wall.
75601313|NCT03933397|Other|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.
75601314|NCT03933397|Drug|Morphine|4 mg for participants weighing <50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
75745617|NCT05882448|Procedure|Laparoscopy|laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.
75601315|NCT03933397|Drug|Hydromorphone|1 mg for participants weighing <60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
75601316|NCT03925090|Drug|Cisplatin+Toripalimab|chemotherapy and monoclonal antibody
75601317|NCT03925090|Drug|Cisplatin+placebo|chemotherapy
75745618|NCT05882435|Other|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
75745619|NCT05882409|Behavioral|Education|Education covers women's education on violence, conflict and awareness.
75745620|NCT05882396|Other|Rood's approach|Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.
75745621|NCT05882396|Other|Traditional physical therapy program|Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
75601318|NCT03919266|Procedure|Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the realization of a nasopharyngeal swab in the two strategies, and the PCT assay at D1, D3 and D7 in the pathogen-directed strategy
75745622|NCT05882344|Procedure|Device Implantation- Boston Scientific, VERCISE GENUS™ system|Participants will be implanted with DBS leads bilaterally, targeting the Nucleus Basalis of Meynert. The study team will record Local Field Potentials with and without stimulation, intraoperatively. These results will help the team determine at the end of the study whether LFP desynchronization (decrease in 5-15 Hz power), or other physiological signature, can be used to predict the location that provides the most effective intervention. Finally, the team will also ascertain the safety of the procedure and NB stimulation itself.
75896288|NCT03654495|Other|Exergame training|"Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (~1 min) for game change."
76025132|NCT04436159|Procedure|Addition of 180 posterior fundoplication after crural closure|"The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively."
76025133|NCT03165409|Biological|Nivolumab|Melanoma intervention
76025134|NCT03165409|Biological|Ipilimumab|Melanoma intervention
76063554|NCT04393168|Combination Product|Lymphatic clearance measurement|The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
76063555|NCT02983708|Biological|Peripheral blood mononuclear cells (mPBMC)|
76063556|NCT02983708|Drug|G-CSF|
75745623|NCT05882344|Device|DBS Stimulation - Boston Scientific, VERCISE GENUS™ system|Daily intermittent stimulation (60 Hz x 20s/min)
76063557|NCT02983708|Drug|Placebo|
76063558|NCT02979496|Dietary Supplement|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
76063559|NCT02979496|Dietary Supplement|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
75601319|NCT03919266|Procedure|Control: usual antibiotic treatment|usual antibiotic treatment
75601320|NCT03913273|Procedure|AMI transtibial amputation|Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.
76025135|NCT05403125|Device|silver diamine fluoride, 38%|Topical application to all surfaces of the teeth
76063560|NCT02979496|Dietary Supplement|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
76063561|NCT02979496|Dietary Supplement|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
76063562|NCT03824080|Drug|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
76063563|NCT01895335|Drug|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
75745624|NCT05882331|Procedure|Extracorporeal photopheresis|ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes ~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.
76063564|NCT03829696|Drug|Mifeprex® (Mifepristone 200 mg)|Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
75896289|NCT03654495|Other|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
76063565|NCT03829696|Drug|Misoprostol 800 mcg|Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
76063566|NCT03829696|Drug|ella® (ulipristal acetate emergency contraception 30 mg)|Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
76063567|NCT03829696|Diagnostic Test|AccuHome® Pregnancy OTC Test|Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
75601321|NCT03913273|Procedure|Standard transtibial amputation|A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
75601322|NCT03899753|Device|2-Octyl Cyanoacrylate and Mesh|2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
75601323|NCT03899753|Device|2-Octyl Cyanoacrylate|Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
75601324|NCT03896672|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be applied three times daily during 7 consecutive days, if the physiotherapist follow the previous training. Each application should during 30 minutes. Pressure should be adjusted in 15 centimeters of water.
75601325|NCT03829436|Drug|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
75601326|NCT03829436|Drug|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily
75601327|NCT03829436|Drug|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
75601328|NCT03829436|Drug|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
75745625|NCT05882292|Drug|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal [should be within 1 hour post-meal (fed state)] at approximately the same time each day in a 21-day cycle.
75745626|NCT05882266|Dietary Supplement|Plant Omega|A commercial plant-based omega-3 beverage consumed once daily during breakfast
75745627|NCT05882266|Other|Dietary therapy only|Standard dietary therapy
75745628|NCT05882240|Other|choice of initial position|current practice of correct application and interpretation of the PLR in critical care patients
75896290|NCT02108574|Device|Placebo Filter|
75896291|NCT02108574|Device|Rhinix Nasal Filter|
75896292|NCT03654183|Diagnostic Test|Indocynine green clearance test|Indocyanine green clearance was determined by non-invasive pulse spectrophotometry (NIHON KOHDEN™; Pulse Dye Densito-Graph Analyzer, Japan).
75896293|NCT02111928|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
75896294|NCT02112006|Procedure|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
75896295|NCT02112006|Procedure|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
75896296|NCT02521324|Device|DGB2|DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
75896297|NCT02980107|Other|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
75896298|NCT02980107|Other|PLS|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
75896299|NCT02108730|Procedure|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
75896300|NCT02114112|Other|NCPAP cycling|
75896301|NCT02114112|Other|NCPAP continuous|
75896302|NCT02251158|Drug|Tipranavir oral solution|
76063568|NCT03829774|Device|Primary Relief v 2.0|The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
76063569|NCT03829774|Drug|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
76063570|NCT02974738|Drug|Belzutifan|Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
75896303|NCT02251158|Drug|Tipranavir capsules|
75896304|NCT02251158|Drug|Ritonavir oral solution|
76063571|NCT02972398|Drug|N-acetylcysteine|Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
75450249|NCT01704664|Drug|glutamine|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
75896305|NCT02251158|Drug|Ritonavir soft gel capsules|
75896306|NCT02251158|Other|High fat breakfast|
75896307|NCT02652130|Biological|Remestemcel-L|No intervention was given in Study MSB-GVHD002 (NCT02652130). It was a safety follow-up trial of remestemcel-L-treated participants from Study MSB-GVHD001.
75896308|NCT03553914|Drug|PLM60|PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.
75896309|NCT02114190|Behavioral|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
75896310|NCT02114190|Behavioral|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
75896311|NCT05404750|Behavioral|Harm Reduction|Harm reduction aims to reduce negative effects of risky health behaviors without necessarily terminating the behaviors completely.Though often thought of as structural approaches (e.g., policy or syringe services), Harm reduction is also a relational approach to care focusing on non-punitive patient-provider interactions to promote autonomy. The degree to which harm reduction care is offered in study settings and is associated with clinical outcomes is the focus of this study.
75896312|NCT02112084|Behavioral|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
75896313|NCT05404516|Drug|Sorafenib|"Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year."
75896314|NCT05404516|Drug|Idarubicin|"Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3."
75896315|NCT05404516|Drug|Cytarabine|"Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3."
75896316|NCT02114346|Drug|Atorvastatin|
75896317|NCT02114346|Drug|Placebo|
76063572|NCT02972398|Drug|placebo comparator of N-acetylcysteine|Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
75896318|NCT02114346|Drug|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
75896319|NCT02112162|Radiation|fludeoxyglucose F 18|Undergo FDG PET/MRI
75896320|NCT02112162|Device|positron emission tomography|Undergo FDG PET/MRI
75896321|NCT02112162|Device|magnetic resonance imaging|Undergo FDG PET/MRI
75896322|NCT02112162|Other|laboratory biomarker analysis|Correlative studies
75896323|NCT02108808|Drug|Ticagrelor|
75896324|NCT02108808|Drug|Prasugrel or Clopidogrel|
75896325|NCT02108886|Drug|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
75896326|NCT02108886|Drug|Placebo|empty capsule filled with sugar
75896327|NCT02108886|Other|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
75896328|NCT05392816|Other|Single meal non-heme iron absorption|Two study groups, each designed as cross-over single-blinded iron isotope trials in apparent healthy Swedish women of the ages 18-45 years. Each participant serves as their own control. Meals are tagged with radiolabeled non-heme iron 55Fe and 59Fe.
75896329|NCT02114424|Device|Positional vibrator belt|Belt with vibarator to avoid sleep supine
75601329|NCT03827187|Other|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
75896330|NCT02114502|Drug|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
75896331|NCT02114502|Drug|SAHA|1,000 mg by mouth on Days -8 to -3.
75896332|NCT02114502|Drug|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
75896333|NCT02114502|Drug|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
75896334|NCT02114502|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
75896335|NCT02114502|Procedure|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
75896336|NCT02114502|Drug|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
75896337|NCT02114502|Drug|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
75896338|NCT02114502|Drug|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
75896339|NCT02114502|Drug|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
75896340|NCT02114502|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
75896341|NCT02979639|Biological|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
75896342|NCT02109120|Procedure|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
75896343|NCT02114580|Other|physical training|"Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on one on one basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the talk test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).~Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises."
75896344|NCT01674634|Biological|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent [0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride])
75896345|NCT02109198|Device|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
75896346|NCT02109198|Device|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
75896347|NCT03654027|Drug|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
75896348|NCT03654027|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1)
75896349|NCT03005964|Drug|AM001 Cream, 7.5%|Active Cream
75896350|NCT03005964|Drug|Vehicle Cream|Placebo
75896351|NCT02112240|Other|Intraoperative Mobile Gamma Camera imaging|Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
75601330|NCT03825965|Drug|MPL-001 (CBD: THC 25:1)|25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use
75896352|NCT02112240|Drug|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
75896353|NCT02112240|Other|Endoscopic injections of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
75896354|NCT02112240|Procedure|Preoperative flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
75896355|NCT02112240|Radiation|SPECT/CT|Preoperative imaging to identify lymph nodes in rectum.
75896356|NCT03455842|Biological|BCD-089, 162 mg, s/c, qw|Subcutaneous injections of anti-IL6R every week
75896357|NCT03455842|Biological|BCD-089, 162 mg, s/c, q2w|Subcutaneous injections of anti-IL6R every other week
75601331|NCT03825965|Drug|Placebo oil for oral use|Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.
75601332|NCT03808662|Radiation|Sterotactic Body Radiotherapy/SBRT|In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x [1 + d/(α/β)] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
75896358|NCT03455842|Drug|placebo|Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
75896359|NCT02979249|Drug|Oral Iron|for one year
75896360|NCT05404438|Other|Oral Appliances|A pre-experimental, single-group pretest-posttest design was performed. At stage one, each participant underwent a 2-day general sleeping test and a 2-day sleeping test with mouth tape. At stage two, participants underwent conventional impressions for TPD and TED appliances and were then randomly assigned to wear the TPD or TED; together for two days of sleeping test with their mouth taped. After a 2-day break (washout), with the same procedure, participants wore the other appliance for another 2-day sleeping test and decided accordingly the optimal appliance that had reduced their ODI scores more. At stage three, participants wore their optimal appliance mouth-taped during sleep for 6 weeks. At the end of the intervention, all participants underwent few days sleeping test for final results.
75896361|NCT02112396|Behavioral|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
75896362|NCT02114658|Drug|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
75896363|NCT05126602|Dietary Supplement|Vitamin D3 10000 IU|Tablet of 5000 IU of vitamin D3 given twice daily
75896364|NCT05126602|Dietary Supplement|Vitamin D3 1000 IU|Tablet of 1000 IU of vitamin D3 given once daily
75896365|NCT02114736|Procedure|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
75896366|NCT02114736|Drug|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
75896367|NCT02109276|Device|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
75896368|NCT02109276|Device|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
75896369|NCT04689373|Diagnostic Test|VAS Score|"The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain and worst pain.~The Mini-Mental State Exam (MMSE) is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills."
75896370|NCT02114970|Other|Randomized- paper consent|
75896371|NCT02114970|Other|Randomized- Tablet-delivered consent|
75896372|NCT02114970|Other|Focus Group- paper and tablet consent|
75601333|NCT03808662|Drug|Standard of care|Standard of care per physician discretion
75896373|NCT05126368|Other|Cataract surgery|During cataract surgery the Eyhance toric II intraocular lens will be implanted in one eye of the patient
75896374|NCT02251392|Other|Chamomila recutita Gel|Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve
75896375|NCT02251392|Other|Chamomila recutita Infuse|chamomila infuse in a concentration of 2,5% already determined in a dose response curve
75896376|NCT02251392|Drug|Urea cream based|Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
75896377|NCT05126212|Other|User experience|User experience is assessed by validated scale
76063573|NCT02971072|Procedure|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
76063574|NCT02971072|Other|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
76063575|NCT04392778|Biological|MSC Treatment|"Protocol length: 1 week~Doses:~Application: 3 million cells/kg IV-------------------------------------------------0 day~Application: 3 million cells/kg IV ------------------------------------------------3rd day~Application: 3 million cells/kg IV -------------------------------------------------6th day~will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation."
76063576|NCT04392778|Biological|Saline Control|Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.
75896378|NCT02112474|Device|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
76063577|NCT01617655|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
75601334|NCT03808337|Radiation|Stereotactic Body Radiotherapy/SBRT|Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.
75896379|NCT02112474|Device|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
75896380|NCT02112474|Device|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
75896381|NCT02112552|Drug|Paclitaxel|Given IV
75896382|NCT02112552|Drug|Carboplatin|Given IP
75896383|NCT02112552|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
75896384|NCT02112552|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75601335|NCT03808337|Drug|Systemic Therapy/Standard of Care|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
75601336|NCT03790488|Drug|JTX-4014|Specified dose on specified days
75601337|NCT03788434|Drug|VE303|VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under Good Manufacturing Practices (GMP) conditions.
75601338|NCT03788434|Drug|Placebo|Placebo capsules contained microcrystalline cellulose and were visually identical to VE303 capsules. Placebo capsules did not contain any VE303 Drug Product.
75745629|NCT05882227|Behavioral|video|The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.
75745630|NCT05882227|Behavioral|Traditional information|"Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group."
75896385|NCT02112552|Other|Quality-of-Life Assessment|Ancillary studies
75896386|NCT02112552|Other|Laboratory Biomarker Analysis|Correlative studies
75896387|NCT02976519|Drug|BI 443651|twice daily
75896388|NCT02976519|Drug|Placebo|twice daily
76063578|NCT01617655|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
75745631|NCT05882201|Procedure|Fascia Iliaca compartment block group|"Group FICB Fascia: with the patient supine, the skin was prepped and draped with alcohol solution 70%,~. A 22-G needle will be visualized entering the fascia Lata and the FI. bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40 ml will be injected after aspiration beneath the fascia Lata."
75896389|NCT05124028|Drug|Orelabrutinib|50mg po qd 6 weeks
75896390|NCT02109354|Biological|ALVAC-HIV|Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of >1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
75896391|NCT02109354|Biological|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
75896392|NCT02109354|Biological|Placebo for ALVAC-HIV|A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
75896393|NCT02109354|Biological|Placebo for AIDSVAX B/E|Sodium Chloride for Injection, 0.9% administered IM.
75896394|NCT02109354|Biological|Hepatitis B vaccine|Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
75896395|NCT02109354|Biological|Tetanus toxoid vaccine|The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
75896396|NCT02109354|Biological|Placebo for hepatitis B vaccine|Sodium Chloride for Injection, 0.9% administered IM.
75896397|NCT02109354|Biological|Placebo for tetanus vaccine|Sodium Chloride for Injection, 0.9% administered IM.
75896398|NCT04412746|Drug|MANAGEMENT OF COVID-19|"MANAGEMENT OF COVID-19 Oxygen therapy to maintain SpO2 target more than 94%. Low molecular weight heparin (LMWH) at preventive doses. Empirical antibiotic treatment.~Specific treatment for COVID-19 (approved by Algerian Ministry of Health) First line: Hydroxychloroquin: 200 mg oral three times a day for 10 days, with association of Azithromycin 250 mg oral : 500 mg the first day and 250 mg once a day for 4 days. Sulfate de Zinc : 220 mg once a day for 5 days. Second line: Lopinavir/ritonavir capsule 200 mg/50 mg, oral 2 capsules each times, twice a day during 5 to 7 days.~IF AGGRAVATION OR CRITICAL ILL CONDITION AT PRESENTATION Increase oxygenation flow. Consider Glucocorticoids. 3. Consider the diagnosis of pulmonary embolism and treat with LMWH at therapeutic doses.~MANAGEMENT OF DIABETES Discontinue metformin. Start or adjust insulin doses according to personalized glycemic target of patient."
75896399|NCT04565353|Behavioral|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
76063579|NCT01617655|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
75896400|NCT02975973|Device|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
75896401|NCT02109510|Drug|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
75745632|NCT05882201|Procedure|Femoral nerve block group|✓ Group FNB; With the patient supine, the skin will be prepped and draped with alcohol solution 70% The nerve in the crosssection is a triangular white structure lateral to the femoral artery. Ultrasoundallows direct visualization of the needle and nerve as well as real-time monitoring of the injection of local anesthetic. An in-plane approach will be used to direct needle placement to the femoral nerve and inject after aspiration with bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40ml.
75745633|NCT05882201|Procedure|General care|using ordinary technique
75896402|NCT02109510|Drug|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
75896403|NCT02109510|Procedure|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
75896404|NCT02109588|Behavioral|A supervised physical exercise program|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
75896405|NCT05404126|Other|exercise|• Static exercises and dynamic exercises to group 2; Hearing impaired children in group 3 will be given motor-motor double-task and motor-cognitive double-task exercises in addition to conventional balance exercises.
75450250|NCT01704664|Dietary Supplement|oral diet enriched with arginine (Cubitan)|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
75450251|NCT01704664|Drug|Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)|Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
75450252|NCT01704677|Procedure|Lumbar total disc replacement|The surgical intervention consisted of replacement of the degenerative intervertebral lumbar disc with a artificial lumbar disc device in one or two of the lover lumbal levels (L4/L5 or/and L5/S1). The ProDisc consists of three pieces, two metal endplates and a polyethylene core that is fixed to the inferior endplate when the device is implanted, and is implanted through a retroperitoneal (or transperitoneal) access.
75745634|NCT05882123|Other|cerebral microbleeds|Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
75745635|NCT05882019|Device|Breast Exam with Bexa|Breast exam with Bexa uses pressure elastography to produce a map of the breast tissue's elasticity.
75745636|NCT05881980|Drug|Terbinafine Tablets|Terbinafine 250 mg/day
75745637|NCT05881980|Drug|Itraconazole|Itraconazole 200 mg/day
75745638|NCT05881967|Diagnostic Test|Diagnostic biomarker|Diagnostic gene for uterine sarcoma
75745639|NCT05881954|Procedure|Groin infection|Femoral artery reconstruction with tubulized pericardium patch
75745640|NCT05881941|Device|using a soundproof nebulizer with a music and a funny mask added|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
75745641|NCT05881941|Device|using a silent nebulizer with no extra attachments|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
75896406|NCT04470895|Diagnostic Test|Failure Track patients analysis|"The nurse coordinator of the Fracture Track first comes to give the patient a written information note. She answers the patient's questions and obtains his or her non-opposition. The patient must be given sufficient time for reflection to make his decision in order to participate in the study. His non opposition will be traced in the computerized medical record. Each enrolling patient in the study can simultaneously participate in another research. There is no exclusion period in the protocol.~Once the patient is included, a semi-directed interview is conducted. The name of the patient's usual pharmacy will be collected. Data from the computerised medical record concerning the patient's stay are also analysed.~The patient's usual pharmacy or the nurse in charge of the patient will then be questioned in order to carry out a drug reconciliation interview."
75745642|NCT05881941|Device|using a routinely employed nebulizer|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
75896407|NCT03553368|Diagnostic Test|HF-NIV-MR|MRI data will be acquired with the use of HF-NIV.
75896408|NCT03553368|Diagnostic Test|HF-NIV-PET|PET data will be acquired with the use of HF-NIV.
75896409|NCT03553368|Diagnostic Test|MR|MRI data will be acquired without the use of any device as a reference.
76063580|NCT04758910|Device|High Flow Oxygen Therapy|A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.
75450253|NCT01704677|Behavioral|Multidisciplinary rehabilitation|The intervention is based on a treatment model described by Brox et al (Spine 2003;28:1913-1921) and is also described in details by Hellum et al (BMJ, May 2011). It consisted of a cognitive approach and supervised physical exercise and was delivered by a team of physiotherapists and specialists in physical medicine and rehabilitation. The rehabilitation programme lasted for about 60 hours over three to five weeks.
75896410|NCT03553368|Diagnostic Test|PET/CT breath hold|PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.
75896411|NCT03553368|Diagnostic Test|CPAP-MR|MRI data will be acquired with the use of CPAP.
75896412|NCT02818972|Device|RelayPro|Endovascular treatment with investigational device.
75896413|NCT04466995|Device|manometer|cuff pressure to be measured with manometer
75896414|NCT02115126|Biological|LMP2A-loaded conventional DC vaccine|"Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be > 1.5.~Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be > 1.5.~Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination."
76063581|NCT04758910|Device|T-piece|A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
76063582|NCT03829072|Other|Cooking Education|cooking Education and adapted physical activity on patients after allo stem cell transplantation
75745643|NCT05881902|Behavioral|HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|"A total of 4 home visits and 2 phone calls will be made by giving awareness training based on the Health Belief Model to the participants in the Intervention 1 group in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made"
75896415|NCT02115126|Biological|DUK-CPG-001|"On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.~DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.~Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination."
75896416|NCT03627793|Other|resistance training|Moving muscles against loads with the purpose of increasing strength.
75896417|NCT02109666|Drug|Abatacept|
75896418|NCT02865928|Drug|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivicaine
75896419|NCT02865928|Drug|Normal Saline|Same injection technique as intervention arm with normal saline
75450254|NCT01704690|Drug|S-1 and Paclitaxel|S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
75450255|NCT01704690|Drug|Paclitaxel and Cisplatin|The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
75896420|NCT03208855|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
75896421|NCT03167281|Combination Product|early tPA and DNase|Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
76025136|NCT05403125|Device|Sodium fluoride gel, 5000 PPM|Gel applied after application of silver diamine fluoride and dispensed for home use
76025137|NCT05701423|Drug|Natalizumab|Administered as specified in the treatment arm.
75450256|NCT01704690|Drug|5-FU and Cisplatin|The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
75450257|NCT01704703|Drug|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
75450258|NCT01704703|Drug|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
75450259|NCT01704716|Drug|Vincristine|given during Rapid COJEC and modified N7 therapy
75450260|NCT01704716|Drug|Aldesleukin|Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
75745644|NCT05881902|Behavioral|STANDART CANCER EDUCATİON|The participants in the intervention 2 group will be given the standard training applied by the Ministry of Health in KETEM for women's cancers during home visits, and a total of 4 home visits and 2 SMS reminders will be made.
76025138|NCT02795351|Drug|Sildenafil|Single oral administration of active or placebo one week apart
76025139|NCT02795351|Drug|Placebo|
76025140|NCT05403047|Drug|Fumarate, Tenofovir Disoproxil|all participants receive the intervention
76025141|NCT04626713|Device|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
76025142|NCT05399303|Procedure|obturation|obturation using different types of sealers
76025143|NCT03927443|Drug|SDP-133|one drop
76025144|NCT03927443|Drug|Lumigan|one drop
76025145|NCT02872493|Procedure|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
75601339|NCT03767257|Drug|Colesevelam Pill|For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
75450261|NCT01704716|Drug|ch14.18/CHO|ch14.18/CHO antibody is given during MRD treatment
75450262|NCT01704716|Drug|Carboplatin|Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
75896422|NCT02760004|Behavioral|PRogram In Support of Moms (PRISM)|"PRogram In Support of Moms Toolkit with Stepped Care Algorithms~Support clinic specific implementation using the Addressing Problems Through Organizational Change (APTOC) platform~Customization of depression screening for each practice~Proactively engage and track all women who screen +ve on the Edinburgh Postnatal Depression Scale(EPDS)~Employ psychoeducation and Motivational Interviewing to engage patients with depression~medical assistant champion and psychiatrist contact bi-weekly to review cases~Stepped care treatment to depression screening/assessment"
75896423|NCT02760004|Behavioral|Enhanced Usual Care group (Access to MCPAP for Moms)|"30-60 minute presentation on perinatal depression~Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns~Access to Ob/Gyn provider assessment and treatment recommendations via one-time face-face MCPAP for Moms psychiatrist patient evaluation~Access to assessment and treatment protocols in Provider Toolkit~Resource provision/referrals"
75896424|NCT02109900|Other|Serum Progesterone Levels|
75896425|NCT04408417|Device|Prototype child safety seat with tension indicator lights|The prototype child safety seat is a convertible rear-facing seat with a harness system that includes tension indicator lights.
75896426|NCT04408417|Device|Control child safety seat|The control child safety seat is a convertible rear-facing seat without tension indicator lights.
75896427|NCT02112630|Drug|P-IFN alfa 2a|P-IFN alfa 2b 0.75 mcg/kg/week
75896428|NCT02112630|Drug|P-IFN alfa 2b|P-IFN alfa 2a 135 mcg/kg/week
75896429|NCT02112630|Drug|Ribavirin|200 mg PO once daily or 200 mg PO three times a week
76063583|NCT03829072|Other|adapted physical activity|cooking Education and adapted physical activity on patients after allo stem cell transplantation
75450263|NCT01704716|Drug|Etoposide|Etoposide is given during Induction Treatment (both R3 randomisation arms)
75601340|NCT03758261|Drug|Paravertebral nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
75745645|NCT05881889|Device|low-frequency repetitive transcranial magnetic stimulation|For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses).
75896430|NCT02112630|Drug|Boceprevir|800 mg PO three times daily starting at week 4
75896431|NCT02654470|Device|Watchman FLX|Patients who are receiving the Watchman FLX device
75896432|NCT04873375|Drug|Cemiplimab|After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
75896433|NCT02112708|Other|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
75896434|NCT02112708|Other|Control Group usual care|In the control group the depression is treated as usual with the conventional treatment.
75450264|NCT01704716|Drug|Cisplatin|Cisplatin is given during Induction Treatment (both R3 randomisation arms)
75745646|NCT05881889|Device|sham low-frequency repetitive transcranial magnetic stimulation|sham low-frequency repetitive transcranial magnetic stimulation
75745647|NCT05881824|Behavioral|MDG intervention|6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet
75896435|NCT05125666|Other|Dual Task Training (Motor + Cognitive)|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the traditional physical therapy program three times weekly for 8 successive weeks.
76063584|NCT03828916|Other|NuShield|SOC surgery with the addition of NuShield
76063585|NCT02965768|Drug|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
75450265|NCT01704716|Drug|Cyclophosphamide|Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
75450266|NCT01704716|Drug|Doxorubicin|Doxorubicin is given during Induction Treatment (R3 arm modified N7)
75450267|NCT01704716|Drug|G-CSF|G-CSF is given during Induction Treatment
75450268|NCT01704716|Drug|Busulfan|In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
76063586|NCT01895101|Drug|2 gr tranexamic acid|This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
76063587|NCT01895101|Drug|Saline|This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
76063588|NCT03828682|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|Tacrolimus Extended Release Oral Tablet [Envarsus]
75450269|NCT01704716|Drug|Melphalan|Melphalan is given during MAT treatment
75450270|NCT01704729|Procedure|group1|Non-cycloplegic self-refraction +conventional glasses
75450271|NCT01704729|Procedure|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
75745648|NCT05881785|Biological|GR1501 low dose|3×low dose GR1501 every 2 weeks,then low dose GR1501 monthly
75745649|NCT05881785|Biological|GR1501 high dose|3×high dose GR1501 every 2 weeks,then high dose GR1501 monthly
75745650|NCT05881785|Biological|placebo|"Core treatment period:placebo~Maintenance treatment period: GR1501 injection"
75896436|NCT05125666|Other|Traditional Regular Exercise|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
75601341|NCT03758261|Drug|Erector Spinae nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
75601342|NCT03713268|Device|Microscope integrated optical coherence tomography|This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
76063589|NCT03828682|Drug|Mycophenolate Mofetil|Mycophenolate mofetil capsules or tablets
76063590|NCT03828682|Drug|Mycophenolic Acid Oral Product|mycophenolic acid tablets
76063591|NCT03828682|Drug|Tacrolimus|Twice daily tacrolimus
76063592|NCT03828682|Drug|Methylprednisolone|Methylprednisolone taper
75896437|NCT02112786|Device|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
76063593|NCT03828682|Drug|Prednisone|Prednisone taper
76063594|NCT03828682|Drug|Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]|Rabbit Anti-Human T-Lymphocyte Globulin
76063595|NCT03483649|Drug|HLX04|HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
76063596|NCT03483649|Drug|US-Avastin®|US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
76063597|NCT03483649|Drug|EU-Avastin®|EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
76063598|NCT03483649|Drug|CN-Avastin®|CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
76063599|NCT04392388|Biological|Non applicable|to collect data from questionnaires and to collect serological samples
75745651|NCT05881746|Procedure|anatomical liver resection|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
75745652|NCT05881746|Procedure|nonanatomical liver resection|Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
75450272|NCT01704729|Procedure|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
75450273|NCT01704729|Procedure|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
75601343|NCT03710928|Other|very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein."
75745653|NCT05881733|Device|POLARx FIT cryoballoon|Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
75896438|NCT05125588|Drug|"Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
75745654|NCT05881655|Device|Airdoc Red Lighting Device|A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.
75745655|NCT05881655|Device|Special Spectacles to Control Myopia|Customer designed power and fitting to each subject for all the study periods.
75896439|NCT05125588|Drug|"Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
76063600|NCT03822208|Biological|AL003|"Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort"
76063601|NCT03822208|Other|Saline Solution|Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
76063602|NCT03822520|Drug|Celecoxib|Celecoxib 400mg capsule
76063603|NCT03822520|Drug|Moxifloxacin|Moxifloxacin 400mg tablet
76063604|NCT03822520|Other|Water|Pure water 150ml
76063605|NCT03822364|Drug|009-1|Inhaled apomorphine via Staccato aerosol, Dose 1
76063606|NCT03822364|Drug|active comparator|commercially available apomorphine injector
76063607|NCT03822364|Drug|009-0|Inhaled placebo via Staccato device
76063608|NCT03822364|Drug|009-2|Inhaled apomorphine via Staccato aerosol, Dose 2
76063609|NCT03822364|Drug|009-3|Inhaled apomorphine via Staccato aerosol, Dose 3
76063610|NCT03822364|Drug|009-4|Inhaled apomorphine via Staccato aerosol, Dose 4
76063611|NCT03822364|Drug|009-5|Inhaled apomorphine via Staccato aerosol, Dose 5
76063612|NCT03822130|Drug|Arterial catheter infusion chemotherapy|Arterial catheter infusion chemotherapy
75601344|NCT03710928|Other|standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
75601345|NCT03689634|Device|Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group|Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
75601346|NCT03672019|Behavioral|FACT-Hep|Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
75601347|NCT03668977|Dietary Supplement|Fortified balanced protein-energy.|The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.
75601348|NCT03642327|Behavioral|Experimental: Maintenance of Certification (MOC)|MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.
75896440|NCT02115204|Drug|Epirubicin|
75896441|NCT02115204|Drug|Cyclophosphamide|
75601349|NCT03642327|Other|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
75601350|NCT03624881|Device|Catheter ablation with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
75601351|NCT03611335|Behavioral|CATCH Interviews|Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
75450274|NCT01704768|Behavioral|COPE/Healthy Lifestyles TEEN Program.|The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
75601352|NCT03594487|Drug|FMP30 Donor Stool|FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.
75601353|NCT03594487|Procedure|Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.
75745656|NCT05881642|Procedure|Prostate and seminal-sparing Cystectomy|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
75896442|NCT02115204|Drug|Docetaxel|
75896443|NCT02115204|Drug|Methotrexate|
75601354|NCT03594487|Other|Observational Control|Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
75601355|NCT03588975|Biological|MACI|autologous cultured chondrocytes on porcine collagen membrane
75601356|NCT03588975|Procedure|microfracture|Arthroscopic microfracture treatment
75745657|NCT05881642|Procedure|Conventional Radical Cystoprostatectomy|According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles
75745658|NCT05881629|Behavioral|Maternal position change to side-lying lateral with peanut ball|Participants will be assisted into a position lying on their side, specifically the same side as the fetal spine diagnosed by ultrasound. An inflated peanut ball will be positioned between the legs to open the pelvis. They will be asked to maintain the position for 60 minutes.
75745659|NCT05881629|Behavioral|Free maternal position|Participants will be asked to adopt any position of their choosing and to maintain it for 60 minutes. They will be asked to not use a peanut ball during the 60 minute study period.
75745660|NCT05881577|Other|Observational|Impact of AR on educational outcomes
75896444|NCT02115204|Drug|5-fluorouracil|
75896445|NCT02115360|Drug|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
76025146|NCT05124353|Drug|Cerebrolysin|Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
76025147|NCT02222831|Procedure|Day 0 denudation and time lapse culture on IVF-oocytes.|
76025148|NCT05124197|Other|prone position|extension of prone position duration
76025149|NCT03805841|Drug|tarloxotinib bromide|weekly intravenous infusion
76025150|NCT02815943|Procedure|biliopancreatic diversion with duodenal switch|
76025151|NCT02815943|Procedure|sleeve gastrectomy|
76025152|NCT02815943|Other|liquid meal|will be consumed over 30 minutes with [U-13C]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
75896446|NCT02115360|Drug|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
75896447|NCT01362322|Biological|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
75896448|NCT01362322|Biological|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
75896449|NCT02112942|Drug|IDX21459|
75896450|NCT02112942|Drug|Matching Placebo|
75601357|NCT03576690|Biological|REGN3470-3471-3479|
75601358|NCT03573947|Drug|Nivolumab|360 mg intravenously every 3 weeks
75745661|NCT05881525|Biological|TC-N201 cells|T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.
75745662|NCT05881525|Drug|IL-2|Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
75745663|NCT05881525|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
75745664|NCT05881525|Drug|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
75896451|NCT02113020|Drug|TAK-233|Oral administration of TAK-233
75896452|NCT02113020|Drug|Placebo|Oral admininstration of Placebo
75745665|NCT05881525|Drug|Nab-paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
75896453|NCT03553290|Device|A.R.C. FOX Laser-FOX Q-810nm|805-810 nm dichotomous laser, 12 Watt within the power of sensitive parts of the affected teeth
75896454|NCT03553290|Procedure|Control|Mechanical debridement alone
75896455|NCT02432404|Drug|NuvaRing|
75896456|NCT02115516|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
75896457|NCT02115516|Biological|0.9% Sodium Chloride (Placebo)|
75896458|NCT02192788|Radiation|Stereotactic Body Radiation Therapy for Oligometastases|
75601359|NCT03573947|Drug|Ipilimumab|1 mg/kg intravenously over 30 minutes
75601360|NCT03573947|Drug|Paclitaxel|80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
75601361|NCT03569449|Behavioral|Usual care|Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.
75601362|NCT03569449|Behavioral|Clinic-based visits|Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
75601363|NCT03569449|Behavioral|Standard pediatric surveillance|Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
75601364|NCT03569449|Behavioral|Structured, schedule-based visits|Family Partners will utilize a predetermined schedule of contacts with families
75745666|NCT05881512|Device|Transcutaneous Upper Airway Stimulation Device|Multiple frequency stimulation of the hypoglossal nerve
75745667|NCT05881434|Other|Emergency Department Visit Expectations Questionnaire|Patients presented with novel questionnaire designed to illicit patient's self-reported expectations across four domains (overall purpose of visit, medication intervention, imaging intervention and disposition) during check-in when arriving at the emergency department. Patients instructed to present the completed questionnaire to the treating provider.
75745668|NCT05881330|Device|ArtiAid Intra-articular Injection|Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
75745669|NCT05881317|Device|ArtiAid® Plus Intra-articular Injection|Inject ArtiAid® Plus in the affected joint at weekly interval for 3 weeks
75896459|NCT02113098|Other|Treadmill, ankle load|The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
75896460|NCT02113098|Other|Treadmill|The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
75896461|NCT02113176|Drug|Minocycline|
75896462|NCT01831570|Other|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
76025153|NCT02815943|Radiation|PET/scan|a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
75601365|NCT03569449|Behavioral|Enhanced pediatric surveillance|"In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team"
75601366|NCT03569449|Behavioral|Technology enhanced care coordination|Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
75896463|NCT02113254|Other|Corn zeaxanthin|The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
75896464|NCT01755208|Procedure|light-scattering spectroscopy|Undergo light-scattering spectroscopy
75896465|NCT02118870|Drug|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
75896466|NCT02118870|Drug|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
75450275|NCT01704768|Behavioral|Healthy Teens Attention Control Program|The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
75745670|NCT05881304|Device|Standardized research e-cigarette (SREC)|Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
75896467|NCT05125432|Device|Acupuncture group|Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
75896468|NCT05123638|Device|Virtual reality cycling exercise|Daily voluntary cycling for up to 30 minutes with the virtual reality technology
75601367|NCT03569449|Behavioral|:Individually-tailored visits|Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
75601368|NCT03569449|Behavioral|Clinic-based visits and community visits|In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
75601369|NCT03567642|Drug|Osimertinib|Osimertinib 80mg daily
75896469|NCT05123638|Behavioral|Unsupervised stationary cycling exercise|Daily voluntary cycling for up to 30 minutes (WITHOUT the virtual reality technology)
75601370|NCT03567642|Drug|Platinum|Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4
75896470|NCT02118948|Behavioral|Abuse-focused intervention|
75896471|NCT02118948|Behavioral|Sexual behavior-focused intervention|
76063613|NCT03822130|Drug|Sodium Bicarbonate|Arterial catheter infusion Sodium Bicarbonate
75601371|NCT03567642|Drug|Etoposide|Etoposide 100mg/m2 or Etoposide 80mg/m2
75896472|NCT05125120|Other|COGNİTİVE ORİENTATİTON DAİLY OCCUPATİONAL PERFORMANCE APPROACH|Polatajko et al. (2001) developed the CO-OP approach, which is an occupation-oriented problem-solving approach that combines cognitive strategies to help children acquire motor abilities throughout daily tasks (9, 29). The CO-OP approach of therapy focuses on the goal or task at hand rather than the acquisition of functions in occupational performance. CO-OP is a 'deductive' or 'occupational performance-oriented' approach that focuses on the activity target selected throughout the therapy, as opposed to 'inductive' or 'impairment-focused' alternatives (13). As a verbal approach, CO-OP focuses on skill acquisition at the activity level and strives to provide children with global problem-solving skills. Necessary performance strategies specific to the child and the activity are determined with a customised programme (12, 30). Skill acquisition, cognitive strategy development, and adapting and transferring these acquired skills to daily life are the three key goals of the approach.
75601372|NCT03557697|Behavioral|Standard of Care|At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS
75601373|NCT03557697|Behavioral|SMS Intervention|Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content. In addition, participants will receive biweekly phone calls from study community health workers to review the video content and clarify questions, set goals, and problem-solve barriers to achieving the goals.
76063614|NCT03822130|Drug|Systemic Chemotherapy|Systemic Chemotherapy
75745671|NCT05881239|Device|AROMHA Brain Health Test|The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.
75896473|NCT03552666|Dietary Supplement|vitamin D3|
75896474|NCT05123404|Diagnostic Test|multi parametric MRI|In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.
75745672|NCT05881187|Drug|Riboflavin|topical application of riboflavin followed by cross linking
76063615|NCT03822130|Drug|Oral Chemotherapy|Oral Chemotherapy
76063616|NCT04274062|Procedure|Integrated Nursing care of placenta previa|"Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)"
75896475|NCT05123404|Procedure|transurethral resection of bladder tumor|detection of degree of invasion to test accuracy of ViRADS score
75450276|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
75450277|NCT01704794|Drug|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
75450278|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
75450279|NCT01704807|Device|foot orthotics|Experimental wore experimental orthotics throughout the study period as much of the day as possible.
75450280|NCT01704807|Device|Sham foot orthotic|Control group wore sham insoles as much of the time as possible for the duration of the study period.
75450281|NCT01704820|Procedure|Retroflexion in the right colon|
75450282|NCT01704833|Behavioral|Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)|The PFCBT is a 15-week Program that includes weekly group and individual sessions.
75450283|NCT01704872|Drug|ch14.18/CHO|
75450284|NCT01704885|Behavioral|Play Intervention|
75450285|NCT01704885|Other|Questionnaires|
75601374|NCT03532880|Drug|Olaparib Pill 50 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
75896476|NCT02115594|Drug|Fulvestrant|
75601375|NCT03532880|Drug|Olaparib Pill 100 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
75896477|NCT02115594|Drug|Entinostat|
75896478|NCT02115594|Drug|Placebo|
75601376|NCT03532880|Drug|Olaparib Pill 150 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
75745673|NCT05881187|Drug|Antibotice.g vigamox ED Antifungal e.g Dflucan|topical application of antimicropial therapy
75745674|NCT05881187|Device|pack cross linking|TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
75896479|NCT05125042|Procedure|Amiodarone hydrochloride tablet + acupoint catgut embedding|Patients with persistent AF after undergoing catheter ablation take receive acupoint catgut embedding in Neiguan and Zusanli twice after and one month after surgery combined with amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
75896480|NCT05125042|Drug|Amiodarone hydrochloride tablet|Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
75896481|NCT02115672|Drug|BL-8040|BL-8040 will be added to imatinib to improve CML response.
75896482|NCT05124964|Other|PedsQL 4.0 Scale|The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. PedsQL 4.0 will be evaluated at baseline, yearly through 3 years post-enrollment.
75896483|NCT05124964|Other|Short Form-36|Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH). Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year. The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL. Physical component score (PCS) and mental component score (MCS) were also calculated. SF-36 will be evaluated at baseline, yearly through 3 years post-enrollment.
75896484|NCT05124964|Other|Chinese Wechsler Intelligence Scale for Children|The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University. The C-WISC consists of 11 individual tests that include six verbal tests [Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)] and five performance tests [Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)]. Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained. Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively . C-WISC will be evaluated at baseline, yearly through 3 years post-enrollment.
75450286|NCT01704898|Drug|Efavirenz 600 Test-Stocrin 600 Reference|
75450287|NCT01704898|Drug|Stocrin 600 Reference-Efavirenz 600 Test|
75450288|NCT01704911|Procedure|Transradial Coronary Intervention|
75450289|NCT01704911|Procedure|Transfemoral Coronary Intervention|
75450290|NCT01704911|Device|Coronary Stent System|Any kind of coronary stent system
75450291|NCT01704924|Device|Prevena|Device will be applied at end of procedure over closed incision
75450292|NCT01704924|Procedure|Standard of Care Dressing|Dressing applied as Standard of Care
75450293|NCT01704937|Drug|Fecal Microbiota Transplant (FMT)|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube"
75450294|NCT01704989|Procedure|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
75601377|NCT03532880|Drug|Olaparib Pill 200 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
75896485|NCT02119182|Behavioral|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
75896486|NCT02119182|Behavioral|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
75601378|NCT03532880|Drug|Olaparib Pill 250 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
75601379|NCT03532880|Drug|Olaparib Pill 300 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
75601380|NCT03532880|Radiation|Radiotherapy|The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
75745675|NCT05881122|Behavioral|Mad Dog Dietary Consultation|The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
75896487|NCT02119182|Procedure|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
75896488|NCT02119182|Procedure|Blood Draw for Plasma, DNA, Serum, RNA|Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).
75896489|NCT01341574|Procedure|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
75745676|NCT05881109|Drug|Caspogunfin|No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
75896490|NCT01341574|Procedure|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
75896491|NCT03622125|Diagnostic Test|Vital signs|Axillary temperature sampling, at the site of the scorpion sting and the contralateral site with infrared thermometer, and heart rate, respiratory rate and blood pressure on admission, 30 minutes after applying the vial and the medical discharge
75896492|NCT02113332|Drug|Liraglutide|
75896493|NCT02113332|Drug|Placebo|
75896494|NCT03653949|Other|Educational intervention|It will be an interactive lecture, 60 minutes long. The class will cover physiopathology, complications, treatment and prevention of exacerbations. Audiovisual resources and practical demonstrations of usual care will be used. Individual questions will be answered during the class.
75896495|NCT03653949|Other|Aerobic exercise|The aerobic exercise program will be performed at home, on a cycle ergometer for lower limbs between 24 and 35 minutes: 5 minutes of warm-up, 14 to 25 minutes of high-intensity interval exercise and 5 minutes of cool down.
75601381|NCT03531957|Drug|ASN002|Daily dose of ASN002 for 12 weeks
75601382|NCT03531957|Drug|Placebo Oral Tablet|Placebo of ASN002 for 12 weeks
75601383|NCT03531255|Drug|Pegcetacoplan|Complement (C3) Inhibitor
75601384|NCT03473795|Behavioral|Questionnaire forms|The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
75601385|NCT03473795|Other|Bio-specimen samples|Samples can include tissue, blood, urine, saliva, hair and nail clipping.
75601386|NCT03450824|Other|No intervention|The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
75601387|NCT03446079|Other|Topical Anti Aging Cream|Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
75896496|NCT05130112|Device|high flow nasal cannula and nasal cannula|"HFNC was administered using the MyAIRVO 2 device (Fisher & Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher & Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min."
75896497|NCT02115906|Other|1H/31P Magnetic Resonance Spectroscopy|The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
75601388|NCT03435042|Behavioral|Self care + Hypnosis group|Our groupal intervention is divided into 6 monthly 2-hour sessions in which some self-hypnosis exercises are proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
75601389|NCT03428997|Device|Lotion|Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
75450295|NCT01704989|Drug|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (>35 mmHg) or advanced damage at presentation.
75896498|NCT02115906|Other|oral glucose tolerance testing|"In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling."
75896499|NCT02115906|Other|Thyroid sonography|In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
75896500|NCT05129956|Device|"Covidien Emprint Ablation System with Thermosphere Technology"|The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
75896501|NCT02119338|Drug|5-ala|dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
75896502|NCT02918877|Drug|Sevoflurane|Volatile Anesthetic
75896503|NCT02918877|Drug|Propofol|Intravenous Anesthetic
75896504|NCT02116062|Device|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
75896505|NCT02116062|Device|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
75450296|NCT01705002|Drug|Promitil|2 mg/kg dose IV
75745677|NCT05881070|Behavioral|Mobile-health self management|Mobile-health self management
75450297|NCT01705002|Drug|Capecitabine|1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
75450298|NCT01705002|Drug|Bevacizumab|for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
75601390|NCT03428997|Other|Negative Control|Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
75745678|NCT05881044|Other|Psychiatric interview|"Psychiatric interview which include personal identification, present history, past history and family history~Complete physical and Neurological Examination.~Mini Neuropsychiatric Interview scale. (MINI): to diagnosis psychiatric disorders~Symptom checklist 90(SCL 90)~Quality of life questionnaire.~Hamilton Depression scale.~Hamilton Anxiety scale.~Socioeconomic scale (A.El.Gilany,A.El.Wehady,and M.EL.Wasify)"
75745679|NCT05881018|Dietary Supplement|Low glycaemic index|Diet will be supplemented with a drink containing a low glycaemic index carbohydrate
75896506|NCT02116062|Device|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
75896507|NCT05123014|Other|relex smile|In OCT, firstly, the thickness of the adenoviral subepithelial infiltration in the cornea is calculated in microns, and extraction is performed accordingly with Small Incision Lenticule Extraction( SMILE )and fresh lenticule implanted stromal in the same volume.
75896508|NCT03653871|Behavioral|Performing Arts Instruction|Professionally delivered performing arts curriculum
75896509|NCT05129800|Other|Platelet-rich plasma|"PRP preparation involved, withdrawal 8-10ml from each patient into a tube containg either 3,8 % sodium citrate and either enoxaparin gel or thixotropic cell-separation gel. The tubes were centrifuged at either 3900 rpm for 10 minutes or at 1500g for 5 minutes, resulting in four layers: a cell-rich layer at the bottom of the tube covered by the separating gel, a PRP layer on top of the gel, and a platelet-poor plasma (PPP) layer at the top. The tube was gently agitated in order to mix the PPP with the PRP. The solution, cca 4-5ml, was withdrawn with a needle and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or an injector. According to the protocol of our hospital, the injections to the scalp were spaced 0.5-1cm apart.~PRP was applied once every month for 3 months. Macroscopic and digital phototrichographic photos were taken before the beginning of treatment, 1 month after the last injection, and 3 months after the end of treatmert."
75745680|NCT05881018|Dietary Supplement|High glycaemic index|Diet will be supplemented with a drink containing a high glycaemic index carbohydrate
75745681|NCT05881018|Behavioral|Physical activity|Participants will include physical activity units
75745682|NCT05880979|Behavioral|Engaging Together for Healthy Relationships|A comprehensive parent-adolescent dating violence prevention intervention designed to be provider delivered within the context of a pediatric well-child visit
75745683|NCT05880979|Behavioral|Regular well child care|Participants will receive their regularly scheduled well-child care
76025154|NCT02815943|Other|[7,7,8,8-2H]-palmitate|i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to 360 min.
76063617|NCT03821974|Procedure|wet suction technique|"For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
76063618|NCT03821974|Procedure|dry suction technique|"For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
76063619|NCT03821662|Behavioral|OT Diabetes Self-Management Intervention|Occupational therapy chronic disease self-management intervention.
76063620|NCT01894477|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
76025155|NCT02815943|Device|indirect calorimetry|will be performed every hour throughout the protocol along with exhaled breath collection
76025156|NCT04440995|Procedure|pectoral nerve block|Patients received standardized general anesthesia. PECS block were applied under vision using blunted tip cannula(27G, 30mm) after surgical resection of breast by operator. 0.25% ropivacaine 10ml was injected into fascia between pectoralis major and minor muscles. 0.25% ropivacaine 20ml was injected into fascia between pectoralis minor and serratus anterior muscles at the level of the third rib. Breast reconstruction is performed after PECS block
76063621|NCT01894477|Drug|Fludarabine Phosphate|Intravenously administered Fludarabine Phosphate
76063622|NCT01894477|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
75745684|NCT05880927|Drug|Pyrotinib|Patients receive pyrotinib 400mg/day for half or one year
75745685|NCT05880745|Diagnostic Test|Nine-Hole Peg Test (NHPT)|Ataxia Rating and Rating Scale (SARA) for coordination Nine-Hole Peg Test (NHPT) and Dexterity Questionnaire-24 (DextQ-24) for manuel dexterity Beck Depression Inventory (BDI) for depression level The Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS) for general fatigue level Static and dynamic fatigue levels for hand fatigability
76063623|NCT01894477|Radiation|Total-Body Irradiation|Undergo TBI
75745686|NCT05880732|Drug|Magnesium Sulfate|Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
76025157|NCT03563651|Procedure|Biopsy|Undergo biopsy
76063624|NCT01894477|Drug|Treosulfan|Intravenously administered Treosulfan
76063625|NCT01894477|Other|Laboratory Biomarker Analysis|Correlative Studies
75450299|NCT01705015|Behavioral|direct feedback about exercise|
75450300|NCT01705015|Behavioral|PLacebo|UCFit plus encouraged exercise
75450301|NCT01705041|Device|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
75450302|NCT01705093|Dietary Supplement|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
75450303|NCT01705093|Dietary Supplement|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
76025158|NCT03563651|Procedure|Biospecimen Collection|Undergo collection of blood, urine, and stool
76025159|NCT03563651|Other|Laboratory Biomarker Analysis|Correlative studies
76063626|NCT03821428|Procedure|Acupuncture|Needling of P6 and CV24 points
76063627|NCT03821428|Procedure|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
75896510|NCT05129800|Other|Mesotherapy|"For mesotherapy, usually around 5ml of saline solution was withdrawn using a needle and released to the selected ampule containing adipose tissue stem-cell conditioned media and mixture of recombinant growth factors, in a powder form. We used preparations from two different companies, differing in the combination and concentration of ingredients. After the injection of normal saline, the ampule was gently agitated in order to disperse the powder and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or a gun injector. The injections were spaced 0.5-1cm apart.~Mesotherapy was repeated every 1-2 weeks for 6-7 times according to the protocol recommended for each preparation. Macroscopic and phototrichographic photos were taken before the beginning of treatment, a month after the last injection and 3 months after the end of treatment."
75896511|NCT03653793|Other|Natural Health Product: LivRelief Varicose Veins Cream|This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
75896512|NCT05129488|Device|Biotrue ONEday lenses with an alternate packaging solution (EPG03)|Biotrue ONEday lenses with an alternate packaging solution (EPG03)
75896513|NCT05129488|Device|Biotrue ONEday lenses|Commercially available Biotrue ONEday lenses
75896514|NCT03652857|Drug|Apatinib Combined With Vinorelbine|Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
75896515|NCT05129410|Drug|Mycophenolate Mofetil|"Prednisone 0.5-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~MMF1.5g-2.0g/d"
76063628|NCT03821350|Other|Information leaflet|The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
75896516|NCT02113566|Drug|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
75896517|NCT03652779|Drug|Tecarfarin 10mg|Tecarfarin 10mg tablets
75896518|NCT03652779|Drug|Tecarfarin 20mg|two tecarfarin 10mg tablets
75896519|NCT03652779|Drug|Tecarfarin 30mg|three tecarfarin 10mg tablets
75896520|NCT03652779|Drug|Tecarfarin 40mg|four tecarfarin 10mg tablets
75450304|NCT01705197|Drug|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
75896521|NCT02113644|Other|Lifestyle intervention|
75745687|NCT05880732|Drug|normal saline isotonic solution|only 250 ml of normal saline isotonic solution 30 minutes before induction,
75896522|NCT05124730|Drug|Metformin 500mg prolonged release tablets (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
75896523|NCT05124730|Drug|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of Reference (R) Product was administered orally with 240 mL of water.
75896524|NCT02251626|Dietary Supplement|coenzyme Q10|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
75896525|NCT02251626|Dietary Supplement|Placebo|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
75896526|NCT02116218|Procedure|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
75896527|NCT02116218|Procedure|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
75896528|NCT02119572|Behavioral|peer support|
75896529|NCT02119572|Other|usual education lectures|
75450305|NCT01705223|Biological|DNA vaccine|4mg/dose, three doses at week 0,4,8
75450306|NCT01705223|Biological|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
75450307|NCT01705223|Biological|rTV boost|at week 16
75450308|NCT01705223|Biological|rTV boost|at week 24
75450309|NCT01705223|Biological|rTV boost|at week 32
75745688|NCT05880719|Other|Computer-assisted Music remediation|"These sessions of computer-assisted music remediation last 1h and are each divide in 4 parts :~15 minutes of music improvisation~20 minutes of harmony and rythm exercices~20 minutes of Lesson about the software and musical interfaces~5 minutes of debrief."
75745689|NCT05880693|Drug|Dexmedetomidine|Group 1 received dexmedetomidine
75745690|NCT05880693|Drug|Magnesium sulfate|the group 2 received magnesium sulfate
76025160|NCT03563651|Other|Questionnaire Administration|Ancillary studies
76025161|NCT03560765|Device|MED|Training in the use of mainstream electronic devices with accessibility options
76025162|NCT03560765|Other|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
76025163|NCT04207073|Device|Mobilization of median nerve|Neural mobilization
76025164|NCT04435847|Biological|HST 001|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of active treatment (HST 001).
76025165|NCT04435847|Other|Phosphate Buffered Saline|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of placebo control (Phosphate Buffered Saline).
76025166|NCT03057743|Device|Positron emission tomography (PET/CT) imaging|
76025167|NCT03057743|Device|radiotracer [18F]ISO-1|
75450310|NCT01705249|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
75896530|NCT02122926|Other|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~Inpatient protocol for adjusting the discharge diabetes regimen;~Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~Visiting nurse intervention after discharge;~Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~Follow-up with PCP or endocrinologist within 1 week of discharge."
76063629|NCT03820648|Device|Alexis|The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
76063630|NCT03820648|Device|Standard 3M™ Steri-Drape 2|Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
75601391|NCT03420508|Drug|Ensartinib|Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
76063631|NCT03821194|Other|Gua sha|Scrape the skin around the knee joint
76063632|NCT03821194|Other|hot pack|hot pack
75450311|NCT01705275|Drug|ONO-8539|ONO-8539
75450312|NCT01705275|Other|Placebo|Identical to ONO-8539 tablet but without active ingedient
75450313|NCT01705301|Device|WINCS|The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
75896531|NCT02123004|Drug|Ticagrelor|180mg loading dose for one day ,and then 90mg per day for 4 weeks
75601392|NCT03420508|Diagnostic Test|ALKATI by Customized Nanostring Assay|a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
75745691|NCT05880680|Device|SEAL Device|Using standard interventional endovascular techniques, the device is navigated via the push wire delivery system through compatible neurovascular microcatheters to the aneurysm lumen or target site. The device is positioned into its target aneurysm lumen and is electrically detached by the operator with a hand-held, battery-powered detachment handle designed specifically for the SEAL Embolization System.
75896532|NCT02123004|Drug|Clopidogrel|300mg loading dose for one day ,and then 75mg per day for 4 weeks
75745692|NCT05880654|Procedure|Scaling & root planning|Non Surgical periodontal therapy
75745693|NCT05880589|Dietary Supplement|Milk secretory supplement group|Take 2 tablet 2 times per day for 14 days
75745694|NCT05880589|Dietary Supplement|Placebo group|Take 2 tablet 2 times per day for 14 days
75450314|NCT01704963|Drug|PCI-32765|PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
75745695|NCT05880563|Drug|[18F]-RoSMA-18-d6|[18F]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
75745696|NCT05880550|Other|ultrasound cavitation in addition to aerobic ex|"Ultrasonic cavitation was turned on, the program of cavitation 40 kHz was chosen, the time was adjusted at 30 minutes. The cavitational head was moved very slowly on each abdominal segment in a small circular movement for 5 minutes. After finishing the focused ultrasound of the 6 segments of the abdomen, the skin was cleaned with cotton.~in addition to that the patients will receive aerobic exercises for 40 minutes."
75745697|NCT05880550|Other|aerobic exercises.|the patients will do aerobic training for 40 minutes on a bicycle ergometer.
75896533|NCT02116296|Behavioral|ToyBox-intervention|
75896534|NCT02123082|Device|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
75896535|NCT02123082|Device|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
75601393|NCT03410875|Drug|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.
75896536|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
75601394|NCT03410875|Drug|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment.
75450315|NCT01705314|Dietary Supplement|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
75450316|NCT01705314|Dietary Supplement|placebo|7mls of placebo drops per week for 8 months.
75450317|NCT01705340|Drug|Akt inhibitor MK2206|Given PO
75745698|NCT05880511|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires ~ 11.5 minutes in total.
75745699|NCT05880511|Device|Augmented Reality Sensorimotor Training|Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
75745700|NCT05880511|Device|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires ~ 11.5 minutes in total.
75745701|NCT05880498|Behavioral|Mindfulness Intervention|Self-guided mindfulness training using a customized version of the Healthy Minds app
75745702|NCT05880472|Device|Intratumoral|Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.
75896537|NCT01674712|Drug|Simvastatin 20 mg|Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
75896538|NCT01674712|Drug|Fenofibrate 145 mg|Fenofibrate, tablet, 145 mg, once daily, 12 weeks
75896539|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
75450318|NCT01705340|Biological|trastuzumab|Given IV
75896540|NCT01674712|Drug|Simvastatin 40 mg|simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
75896541|NCT02119728|Drug|HPPH|Undergo photodynamic therapy with HPPH
75896542|NCT02119728|Device|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
75450319|NCT01705340|Drug|lapatinib ditosylate|Given PO
75896543|NCT02119728|Procedure|therapeutic conventional surgery|Undergo standard of care surgery
75896544|NCT01368432|Drug|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
75896545|NCT01368432|Drug|Placebo|Sugar pill placebo
75450320|NCT01705340|Other|laboratory biomarker analysis|Optional correlative studies
75450321|NCT01705366|Procedure|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
75450322|NCT01705366|Procedure|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
75450323|NCT01705366|Procedure|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
75601395|NCT03313999|Device|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
75896546|NCT05122858|Procedure|EUS guided biliary drainage|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.
75896547|NCT05122858|Procedure|ERCP|A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
76063633|NCT03820570|Procedure|hernia repair|inguinal hernia repair
76063634|NCT03820414|Biological|CRV 101|(Different formulations)
76063635|NCT03820414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
76063636|NCT03820336|Dietary Supplement|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
75896548|NCT05122780|Procedure|Coronary angiography|coronary angiography will be performed via the transradial or transfemoral approach with the use of a 6F sheath. Coronary angiography will be performed within 90 minutes from hospital admission in patients presenting with persistent ST-segment elevation, and within 48 hours in patients presenting with non-ST-segment elevation. Unfractionated heparin (initial weight-adjusted intravenous bolus of 60 IU/Kg, with repeat boluses to achieve an activated clotting time of 250 to 300 seconds) was administered in all patients. If evidence of plaque rupture
75896549|NCT05122780|Diagnostic Test|OCT imaging|"OCT imaging will be performed in the culprit artery in all patients randomized to the precision medicine approach. A 0.014-inch guidewire will be placed distally in the target vessel and an intracoronary injection of 200 µg of nitroglycerine will be performed. Frequency domain OCT (FD-OCT) images are acquired by a commercially available system (C7 System, LightLab Imaging Inc/ St Jude Medical, Westford, MA) connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/ St Jude Medical, Westford, MA), which was advanced to the culprit lesion. The FD-OCT run will be performed using the integrated automated pullback device at 20 mm/s. During image acquisition, coronary blood flow will be replaced by continuous flushing of contrast media directly from the guiding catheter at a rate of 4 ml/s with a power injector in order to create a virtually blood-free environment."
75896550|NCT05122780|Procedure|Percutaneous coronary intervention (PCI):|PCI with stent implantation will be considered in selected cases with evidences of plaque rupture
75896551|NCT05122780|Diagnostic Test|Acetylcholine provocative test|ACh will be administered in a stepwise manner into the left coronary artery (LCA) (20-200 μg) or into the right coronary artery (RCA) (20-50 μg) over a period of 3 min with a 2-3 min interval between injections. Coronary angiography will be performed 1 min after each injection of these agents and/or when chest pain and/or ischaemic ECG shifts were observed. The decision of testing with provocative test LCA or RCA as first will be left to the discretion of the physicians; both LCA and RCA will be tested if the first test was negative. Angiographic responses during the provocative test will be assessed in multiple orthogonal views in order to detect the most severe narrowing and/or analysed by using computerized quantitative coronary angiography (QCA-CMS, Version 6.0, Medis-Software, Leiden, The Netherlands).
75896552|NCT05122780|Diagnostic Test|TT-Echocardiography|TT-Echo will be used to calculate left and right ventricular and atrial dimensions, left and right ventricular systolic function, transmitral flow Doppler spectra, mitral and tricuspidal valve annulus tissue Doppler spectra, ejection time and stroke volume, inferior vena cava, aorta and pulmonary artery diameters and Doppler spectra, according to the recommendations of the American Society of Echocardiography.
75896553|NCT05122780|Diagnostic Test|TE/contrast echocardiography|In patients with angiographic evidence or suspicion of distal microembolization, TE-Echo consisting of an echocardiographic probe inserted in to the oesophagus will be used to detect a hidden cardioembolic source (i.e. left atrial thrombus); in patients with suspected left ventricular source of cardioembolism, contrast echocardiography consisting of a 0.3ml solution of SONOVUE will be used.
75896554|NCT05122780|Diagnostic Test|Cardiac magnetic resonance|CMR will be performed during hospital stay on a 1.5-T system equipped with a 32-channel cardiac coil. Patients underwent conventional CMR including cine, T2-weighted, first pass perfusion, and conventional breath-held late gadolinium enhancement (LGE).
75896555|NCT05122780|Diagnostic Test|Circulating biomarkers|Blood sampling for circulating biomarkers and miRNA expression profile at the time or within 12 hours of coronary angiography. Blood sampling will be processed and analysed in the research laboratory of the Department of Cardiovascular Science. Biological aliquots will be preserved at XBiogem Biobank at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (see section 33).
75896556|NCT05122780|Drug|Antiplatelet Drug|acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily).
75450324|NCT01705366|Device|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
75896557|NCT05122780|Drug|Statin|i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
75896558|NCT05122780|Drug|Beta blocker|i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
75896559|NCT05122780|Drug|ACEi/ARB|i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
75896560|NCT05122780|Drug|CCB|i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate
75896561|NCT05122780|Drug|Nitrates|i.e. nitroglycerine; dosages titrated on blood pressure, ECG, heart rate
75896562|NCT05122780|Drug|Anticoagulant|i.e. warfarin; the selection of the anticoagulant agent will be based on the clinical scenario, contraindications etc
75896563|NCT01063881|Drug|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
75896564|NCT02116374|Other|Physiopathology study|
75896565|NCT02116452|Dietary Supplement|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
75896566|NCT02119806|Drug|Benzodiazepine|Receive as premedication in the Benzodiazepine group.
75450325|NCT01705366|Device|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
75601396|NCT03252431|Drug|F-627|single dose pre-filled syringe
75601397|NCT03252431|Drug|Neulasta|single dose pre-filled syringe
75601398|NCT03234595|Drug|Cerebraca wafer|Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
75601399|NCT03216486|Drug|BPS804|IV administration of BPS804 in 5% Dextrose solution
75896567|NCT02119806|Drug|Fentanyl|Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
75745703|NCT05880433|Device|NIRS(INVOS 5100; Covidien Somanetics, Troy, MI|NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
75745704|NCT05880407|Procedure|SERI osteotomy|Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
75896568|NCT02119806|Drug|Propofol|Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
75896569|NCT05124496|Device|Screening Device|Screening device comparing Rt-PCR positive and negative results to HyperDetector results
75896570|NCT04054245|Drug|LOXL2 Inhibitor PAT-1251|Given PO
75896571|NCT04054245|Other|Quality-of-Life Assessment|Ancillary studies
75896572|NCT04054245|Other|Questionnaire Administration|Ancillary studies
75896573|NCT02119884|Drug|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
75896574|NCT02119884|Drug|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
76063637|NCT03820336|Dietary Supplement|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
76063638|NCT04391998|Drug|Iron Supplement|oral tablet twice daily after meals
75896575|NCT03653559|Behavioral|Home meals|"Adult participants with overweight or obesity are asked to consume home meals during 12 weeks."
75896576|NCT03653559|Behavioral|Healthy meals|"Adult participants with overweight or obesity are asked to consume healthy meals during 12 weeks."
75896577|NCT05109910|Procedure|Pelvic lymph node dissection|Bilateral extended pelvic lymph node dissection
75896578|NCT02123160|Behavioral|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
75896579|NCT02123160|Behavioral|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
75896580|NCT05104918|Drug|Vortioxetine|10 mg tablets
75896581|NCT05104918|Drug|Venlafaxine|75 mg tablets
75896582|NCT02123238|Other|bed positioning|
75896583|NCT03653403|Drug|IDP-126 Gel|Component A
75896584|NCT03653403|Drug|Control Gel|gel
76063639|NCT04391998|Drug|Metronidazole Oral|500 mg oral twice daily
75601400|NCT03207945|Drug|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
75896585|NCT05089942|Drug|Recombinant Human Insulin Patch ZJSRM2021|health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
75896586|NCT05089942|Drug|Placebo|health subjects receive placebo patch
75896587|NCT04055181|Device|rTMS in schizophrenia Controls|"all procedures were identical to rTMS in schizophrenia patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
75896588|NCT04055181|Device|rTMS in schizophrenia patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
75896589|NCT04055181|Device|rTMS in major depressive disorders controls|"all procedures were identical to rTMS in major depressive disorders patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
76063640|NCT04391998|Drug|Albendazole|200 mg oral single dose
76063641|NCT03828604|Behavioral|Stress; Trier Social Stress Task|Standardized acute psychosocial stressor
76063642|NCT03828604|Behavioral|Placebo Trier Social Stress Task|Active control version of the TSST
76063643|NCT03824782|Device|Phototherapy Mask|A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
75601401|NCT03207945|Other|Placebo|Placebo
75745705|NCT05880407|Procedure|percutaneous osteotomy according to Chevron|Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
75745706|NCT05880381|Device|Virtual Reality Group|Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
75601402|NCT03149757|Behavioral|YouTHrive|"The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring."
75601403|NCT03149757|Behavioral|Information-only Control|Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
75745707|NCT05880381|Other|Control Group|The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
75745708|NCT05880342|Drug|Reboxetine Pill|8 mg
75745709|NCT05880342|Drug|Methylphenidate Oral Product|20 mg
75896590|NCT04055181|Device|rTMS in major depressive disorders patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
75601404|NCT03134703|Drug|Methadone|Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
75745710|NCT05880316|Behavioral|Intermittent Fasting|3:4 regime
75745711|NCT05880290|Procedure|gynaecological examination in lateral decubitus|Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful
76063644|NCT03822598|Behavioral|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
75601405|NCT03134703|Drug|Morphine|Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
75601406|NCT03126851|Other|Label|Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
75601407|NCT03118674|Drug|Harvoni|One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
75601408|NCT03085056|Drug|Trametinib|trametinib orally 2mg daily during each 4 week cycle
75601409|NCT03085056|Drug|Paclitaxel|paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks
75745712|NCT05880277|Diagnostic Test|POCUS|Point of Care Ultrasound
75745713|NCT05880186|Dietary Supplement|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women.
76063645|NCT03792880|Behavioral|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
76063646|NCT03792880|Behavioral|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
76063647|NCT03774160|Behavioral|Generacion Actual|See description in arm description.
75601410|NCT03069352|Drug|Placebo|tablet
75601411|NCT03069352|Drug|Venetoclax|tablet
75601412|NCT03069352|Drug|Cytarabine|Subcutaneous injection
75601413|NCT03037437|Drug|Sorafenib (SOR)|Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
75601414|NCT03037437|Drug|Hydroxychloroquine (HCQ)|400mg by mouth daily
75601415|NCT03036488|Biological|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
75601416|NCT03036488|Drug|Carboplatin|On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
75745714|NCT05880173|Diagnostic Test|FIB4|"Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography"
75745715|NCT05880121|Diagnostic Test|MRI|brain MRI
75745716|NCT05880082|Drug|Tislelizumab|Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
75745717|NCT05880069|Other|Pathogen resistant phenotype|Drug resistant phenotype of the target pathogen under study
75745718|NCT05880056|Drug|Nerkardou 5 mg & Nerkardou 10 mg|"(Nerkardou 5 mg) Bisoprolol oral dissolved film ODF: equivalent to 5 mg of bisoprolol fumarate.~(Nerkardou 10 mg) Bisoprolol oral dissolved film ODF: equivalent to 10 mg of bisoprolol fumarate."
75745719|NCT05880030|Drug|Cholecalciferol|cholecalciferol 10000 UI
75745720|NCT05880030|Other|placebo|sunflower oil
75769195|NCT03972540|Behavioral|Mindful eating intervention|A Mindful Eating Workshop™ workbook was used for standardization and reproducibility of these sessions. The group sessions were focused on teaching applied strategies to consume food with intention and attention and aimed at improving emotional relationships with food. Intervention sessions were held once a week in the evening for 2 hours per session over 8 weeks. The intervention was delivered in a large conference room on the University of Georgia campus. Participants were required to attend seven out of eight sessions. If participants missed a session, they met with the instructor 30 minutes before the beginning of the following week's session to receive individual instruction on content of the missed session.
75769196|NCT01250470|Other|Laboratory Biomarker Analysis|Correlative studies
75601417|NCT03036488|Drug|Paclitaxel|On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
75601418|NCT03036488|Drug|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
75601419|NCT03036488|Drug|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
75896591|NCT04055259|Behavioral|mobile Health and Wellness Coaching|Participants in the mobile health and wellness coaching (mHWC) group received text-based mHWC messages and did not return to the clinic until the end of the 6 month intervention. Messages were sent at least weekly and focused on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. Participants could respond via text at any time. The Nudge platform was used for all messaging.
75601420|NCT03036488|Drug|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
75601421|NCT03036488|Drug|Placebo|normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
75896592|NCT04055259|Behavioral|Usual Care|Participants in the usual care (UC) group met in-person once a month with either a pharmacist or dietician for the duration of the 6-month intervention. The focus of these sessions was on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. These participants were set up on the Nudge app, but they did not use the mHWC (texting) feature.
75896593|NCT04941508|Behavioral|the mother's recorded voice|Children will be assigned to listen to the mother's recorded voice at 2 times (in the holding area 3 minutes before induction of anesthesia till induction of anesthesia is ended) and (during emergence from anesthesia till complete recovery).
75896594|NCT04941508|Drug|Dexmedetomidine|Children will be given a single bolus of dexmedetomidine 0.2 µ/kg IV at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
75896595|NCT04941508|Other|saline 0.9% placebo|Children will be given the same volume of saline at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
75896596|NCT03552510|Procedure|Oro-pharyngeal Administration of Mother's Milk|Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)
76063648|NCT03822286|Other|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
76063649|NCT03822286|Other|Support group|A counseling master mix 8~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40~60 minutes each time.
75896597|NCT04934254|Other|Attitude Scale|26-item related to scale will construct and apply to nurses for creating scale
75896598|NCT01062555|Drug|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
76063650|NCT03822286|Other|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
76063651|NCT03820180|Drug|Test Product|2 inhalations of Test and Reference product in each study period
76063652|NCT03820180|Drug|Reference Product|2 inhalations of Test and Reference product in each study period
76063653|NCT01894243|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
76063654|NCT03822832|Drug|BI 655130|Solution for infusion
76063655|NCT03822832|Drug|Placebo|Solution for infusion
76063656|NCT04758364|Other|measurement of gait speed|Cross sectional, cohort
75601422|NCT03036488|Biological|Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim|For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
75601423|NCT03033927|Diagnostic Test|CTC isolocation and analysis|Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
75601424|NCT03006315|Device|Garmin Vivofit device|Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
75601425|NCT03006315|Behavioral|Mobile Health quality of life assessements|
75601426|NCT02993523|Drug|Azacitidine|Solution for subcutaneous or intravenous administration.
75601427|NCT02993523|Drug|Venetoclax|Tablet
75601428|NCT02993523|Drug|Placebo|Matching placebo tablet
75601429|NCT02989584|Drug|Atezolizumab|
75601430|NCT02989584|Drug|Gemcitabine|
75601431|NCT02989584|Drug|Cisplatin|
75601432|NCT02957058|Procedure|SCAR technique|Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
75769197|NCT01250470|Drug|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
75769198|NCT01250470|Biological|Sargramostim|Given SC
75769199|NCT01148368|Drug|fimasartan|single administration of fimasartan 120mg
75769200|NCT03912688|Device|acupoint stimulation|
75769201|NCT03912688|Device|single acupoint|
75769202|NCT03912688|Device|dual acupoints|
75769203|NCT01250548|Biological|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
75769204|NCT01250548|Other|Placebo|
75769205|NCT03906838|Drug|Ropivacaine injection|Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
76063657|NCT04613713|Other|Somatocognitive physiotherapy|"The main intervention areas include:~education about the PVD, healthy vulvo-vaginal and sexual behaviors, nature of chronic pain and factors influencing pain intensity~bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension and respiration pattern in different situations~techniques to cope with emotions and thoughts related to bodily experiences and to PVD~structured homework assignments promoting application of the learned techniques in daily situations and gradual exposure of the patient to activities associated with pain.~Participants will be offered maximally 15 treatment sessions. No minimal number of sessions is set. Treatment will be conducted by female physiotherapists experienced in treating long-standing pain conditions."
75601433|NCT02905617|Device|Sientra 207 Silicone Gel Breast Implant|The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
75601434|NCT02884219|Drug|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
75601435|NCT02884219|Other|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
75745721|NCT05880017|Procedure|Modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; modified ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify longissimus (LG) and intercostalis muscles. After identifying the muscles and decontamination of the skin, the modified TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 15ºangle from the skin in-plane in a medial to lateral direction injecting the anesthetic locally between the longissimus and intercostalis muscles, which are easy to define using ultrasonography. After negative aspiration, injection will be in each side bilaterally in the interface between the LG and intercostalis muscles.
76063658|NCT04613713|Other|Treatment as usual|The participants will follow the current treatment advice as recommended by the Vulva Clinic at OUH, a tertiary health care center specialized in treatment of vulvar disorders. Advice include guidance about the management of PVD as a condition, use of medication, physiotherapy, sexologist and psychological counseling, usage of internet resources (vulva.no) and others. Participants will be free to pursue treatment options of their choice. The type of treatment, number of treatments and medication usage will be monitored by bi-weekly electronic forms during the whole study period.
75769206|NCT01251484|Drug|BIBF1120|Tablet 200 mg twice daily until progression
76063659|NCT03762694|Device|Acupuncture|Electroacupuncture (EA) and Auricular Acupuncture (AA)
75769207|NCT03912610|Diagnostic Test|Functional magnetic resonance examination|Functional magnetic resonance examination by a Ultra high field magnetic resonance instrument named MAGNATOM 7T.
75896599|NCT01062555|Drug|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
75896600|NCT01062555|Drug|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
75896601|NCT01062555|Drug|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
75896602|NCT02119962|Behavioral|Working memory training|
75896603|NCT02119962|Behavioral|Placebo training|
75896604|NCT05128864|Procedure|High Tibial Osteotomy|Surgery procedure - High Tibial Osteotomy
75896605|NCT03652701|Other|Hair Up|Herbal topical
76063660|NCT01450150|Device|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
75601436|NCT02884219|Drug|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
75896606|NCT03652701|Other|Placebo|Placebo
75896607|NCT05128708|Procedure|combined medial and caudal approach right hemicolectomy open and laparoscopic|resection of right colon cancer by this radical approach
75601437|NCT02795429|Drug|Spartalizumab|Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)
75601438|NCT02795429|Drug|Capmatinib|Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule
75601439|NCT02792114|Drug|Cyclophosphamide|
75601440|NCT02792114|Biological|Mesothelin-targeted T cells|
75601441|NCT02792114|Drug|AP1903|
75601442|NCT02783625|Drug|Romidepsin|
75601443|NCT02783625|Drug|Bortezomib|
75601444|NCT02783625|Drug|duvelisib|
75601445|NCT02652949|Device|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
75601446|NCT02632344|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
75601447|NCT02625324|Device|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
76063661|NCT01450150|Device|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
76063662|NCT01450228|Drug|KI1001|Prolonged release melatonin 2mg
75601448|NCT02605486|Drug|Palbociclib|
75601449|NCT02605486|Drug|Bicalutamide|
75896608|NCT03622047|Drug|Dexmedetomidine ropivacaine|Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
75896609|NCT03622047|Drug|No analgesia labor|No analgesia labor control group
75601450|NCT02552186|Other|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
75896610|NCT05128552|Device|Lung volume recruitment technique|A self inflating Ambu bag with one way valve , augmentation volume of air within 3 to 4 successive breaths and holding few seconds then coughing
75601451|NCT02538198|Drug|Lenalidomide|
75601452|NCT02507141|Device|Reflectance Confocal Microscopy|Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
75601453|NCT02484287|Device|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
75896611|NCT05128552|Other|Traditional chest physiotherapy|Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
75896613|NCT05073562|Dietary Supplement|Iron and folic acid (IFA) supplementation|Weekly IFA supplementation for duration of the study.
75896614|NCT05073562|Behavioral|Targeted nutrition education|Structured nutrition education package delivered at household level by trained Community Health Assistants (CHAs)
75896615|NCT05073562|Drug|Mebendazole Pill|One-time deworming treatment with mebendazole.
75896616|NCT05073562|Other|Standard nutrition services|Basic nutrition services currently provided at the health facility and at community level in Liberia
75896617|NCT01064817|Drug|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
75896618|NCT01064817|Drug|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
75896619|NCT01368276|Biological|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
75896620|NCT01368276|Drug|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|125 µg/m² subcutaneous injection
75896621|NCT05009524|Device|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
75896622|NCT05009524|Device|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
75896623|NCT01064739|Dietary Supplement|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
75896624|NCT01064739|Other|Fixed Sodium Diet|Fixed sodium low monoamine diet
75896625|NCT02116686|Device|ventilatory polygraphic recordings|Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
75896626|NCT02116842|Drug|0.1% bupivacaine|Epidural block in early labour.
75896627|NCT02116842|Drug|0.075% bupivacaine|Epidural block in early labour.
75896628|NCT02116842|Drug|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
75896629|NCT03652623|Drug|TDF/FTC|In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
76063663|NCT01450228|Drug|Placebo KI1001|Placebo KI1001 tablets
76063664|NCT01450384|Drug|sorafenib tosylate|Given PO
76063665|NCT01450384|Drug|pemetrexed disodium|Given IV
76063666|NCT01450384|Other|laboratory biomarker analysis|Correlative studies
76063667|NCT01450384|Procedure|biopsy|Optional correlative studies
76063668|NCT01450462|Dietary Supplement|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
75601454|NCT02484287|Device|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
75601455|NCT02484287|Device|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
75601456|NCT02375841|Behavioral|psychometric tests, questionnaires and neurocognitive assessments|
75896630|NCT02120118|Radiation|Radiation|2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.
75896631|NCT02120118|Other|Hyperthermia|42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
75896632|NCT02120118|Drug|Cisplatin|30mg/m2
76063669|NCT01450462|Dietary Supplement|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
76063670|NCT02643238|Device|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
76063671|NCT01450774|Drug|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
76063672|NCT01450774|Drug|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
75601457|NCT02341144|Procedure|Pre-op percutaneous rectus sheath block|After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
75601458|NCT02341144|Procedure|Intra-operative rectus sheath block|After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
75601459|NCT02341144|Drug|Ropivacaine|
76063673|NCT01450852|Behavioral|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
75601460|NCT02213328|Drug|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
75896633|NCT02120118|Drug|Taxotere|20mg/m2
75601461|NCT02204241|Drug|Carfilzomib|
75601462|NCT02204241|Drug|Cyclophosphamide|
75601463|NCT02204241|Drug|Dexamethasone|
75601464|NCT02198729|Procedure|Endoscopic Submucosal Dissection|
75601465|NCT02198729|Procedure|Endoscopic Mucosal Resection|
75745722|NCT05880017|Procedure|Conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; conventional ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. After identifying the muscles and decontamination of the skin, the TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 30ºangle from the skin in-plane lateral to the medial direction through the belly of the LG toward the MF muscle. After negative aspiration, injection will be done in each side bilaterally in the interface between the MF and LG muscles.
75769208|NCT03914638|Drug|Salbutamol 4Mg Tablet|Salbutamol 4 mg, three times daily
75896634|NCT04054089|Drug|Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy]|Biktarvy OD
75896635|NCT04054089|Drug|dolutegravir 50 mg / lamivudine 300 mg|DTG +3TC (Dovato OD)
75601466|NCT02185820|Drug|Carfilzomib|
75896636|NCT02120196|Drug|Rifaximin|rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
75896637|NCT02120196|Drug|Norfloxacin|FDA approved:400mg once daily
75896638|NCT05001802|Procedure|transverse scan, in-plane, posterior- anterior quadratus lumborum block|transverse scan, in-plane, posterior- anterior quadratus lumborum block The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
75896639|NCT05001802|Procedure|paramedian sagittal longitudinal scan, in-plane, caudal-cranial quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
75896640|NCT04242771|Behavioral|Mindfulness|Subjects practice mindfulness before bedtime
75896641|NCT02120274|Drug|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
75896642|NCT02120274|Drug|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
75601467|NCT02185820|Drug|Pomalidomide|
75601468|NCT02185820|Drug|Dexamethasone|
75601469|NCT02150967|Drug|BGJ398 (infigratinib)|Capsule for oral use
75601470|NCT02137603|Other|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
75601471|NCT02127398|Biological|fecal microbiota|fecal microbiota in capsule form
75601472|NCT02085408|Drug|Daunorubicin|Given IV
75601473|NCT02085408|Drug|Cytarabine|Given IV
75896643|NCT02402842|Drug|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
75896644|NCT02123316|Biological|Pangramin Plus D. pteronyssinus|Subcutaneous immunotherapy with Dermatophagoides pteronyssinus
75896645|NCT02123316|Biological|Placebo|Placebo for subcutaneous injection
75896646|NCT03652935|Behavioral|Mindfulness Based Stress Reduction|
75896647|NCT03652935|Other|Health Education Series|This is an active comparator condition that consists of 8 weekly classes related to health.
75896648|NCT02123394|Other|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
75896649|NCT02123394|Other|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
75896650|NCT04054479|Drug|Penehyclidine|Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
75896651|NCT04054479|Drug|normal saline|Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
75896652|NCT03553134|Diagnostic Test|transcranial doppler ultrasound scan|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 10 minutes)
75896653|NCT03553134|Diagnostic Test|ultrasound scan centered on the arterial canal|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 5 minutes)
75896654|NCT01061775|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
75601474|NCT02085408|Drug|Clofarabine|Given IV
75601475|NCT02085408|Drug|Decitabine|Given IV
75601476|NCT02085408|Other|Observation|Undergo clinical observation
75601477|NCT02085408|Procedure|Allogeneic hematopoietic stem cell transplantation|Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
75896655|NCT02123628|Drug|duration of the antibiotic therapy|
75896656|NCT02651116|Drug|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
75601478|NCT02004782|Drug|Prednisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
75601479|NCT02004782|Drug|Placebo Oral Tablet|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
76063674|NCT01450930|Drug|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
75745723|NCT05880017|Drug|Morphine for peritoperative analgesia (control group).|Morphine based analgesia, after emergence they will receive 5mg morphine IV as a start and the rest of the first 24 hours they will receive incremental dose of intravenous morphine according to pain score.
75896657|NCT02651116|Drug|Placebo|10 mL Placebo
76063675|NCT01450930|Drug|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
76063676|NCT01451008|Device|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
76063677|NCT01451086|Biological|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
75601480|NCT01969786|Other|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
75601481|NCT01908777|Other|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
75745724|NCT05880017|Drug|Bupivacain|As a local anesthetic will be injected in modified and conventional groups 20ml in each side.
75745725|NCT05879900|Other|Functional physical exercises|Functional physical exercises lasting approximately 15 minutes, for 12 weeks or 24 sessions. The exercises take place during physical education classes taught by the physical education teachers in charge of the classes. The place of intervention takes place in full-time schools in the rural area.
75745726|NCT05879900|Other|Physical Education classes|Physical Education classes according their previously planned contents.
75769209|NCT03914638|Drug|Placebo oral capsule|Placebo, three times daily
75896658|NCT02651116|Device|Cough recording device|FDA approved device validated for use in adults and children
76063678|NCT01451086|Biological|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
76063679|NCT01451242|Other|no intervention is made|no intervention is made
76063680|NCT01451710|Drug|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
76063681|NCT01451788|Device|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
76063682|NCT01451866|Other|resistance training|hypertrophic resistance training
76063683|NCT01451866|Other|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
76063684|NCT01451944|Behavioral|education|home asthma case management and education
75601482|NCT01892397|Device|Optune (NovoTTF-100A)|
75601483|NCT01873326|Drug|Paclitaxel|
75601484|NCT01873326|Drug|Ifosfamide|
75896659|NCT03552042|Behavioral|Counterclockwise program|A group of older adults (aged 75+) will take part of a residential role-play game, in which they will relive their previous self, acting as if they were in the year 1989. The whole residential program, which will last one week, is designed to enhance this perception, including a retrofitted environment and social activities that will prime participants to relive that period.
75601485|NCT01873326|Drug|Cisplatin|
75601486|NCT01873326|Drug|Mesna|
76063685|NCT01452022|Device|Inductigraft|Synthetic bone graft
75601487|NCT01873326|Drug|Bleomycin|
75745727|NCT05879848|Other|VR|virtual reality scenario synchronized with the uterine contractions
76063686|NCT01452100|Drug|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
76063687|NCT01452100|Other|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
76063688|NCT01452334|Biological|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
76063689|NCT01452490|Device|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
76063690|NCT01452568|Drug|Aspirin|150mg/daily for three months, starting day after surgery
76063691|NCT01452568|Drug|Warfarin|Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
75601488|NCT01873326|Drug|Etoposide|
75601489|NCT01862315|Drug|Floxuridine (FUDR)|
75601490|NCT01862315|Drug|dexamethasone|
75601491|NCT01862315|Drug|Gemcitabine|
75601492|NCT01862315|Drug|Oxaliplatin|
75601493|NCT01862315|Other|MRI|
75601494|NCT01862315|Other|Research blood draws|These are optional
75601495|NCT01854151|Other|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
75601496|NCT01806558|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
75601497|NCT01745588|Drug|Pomalidomide|
75601498|NCT01745588|Procedure|stem cell|
75601499|NCT01745588|Drug|Dexamethasone|
75601500|NCT01745588|Drug|Clarithromycin|
75601501|NCT01737567|Other|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
75745728|NCT05879809|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.
75745729|NCT05879809|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.
75745730|NCT05879809|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
75601502|NCT01737567|Other|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
75601503|NCT01475786|Biological|Low Dose: 16 mg Engensis (VM202)|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
75601504|NCT01475786|Biological|High Dose: 32 mg Engensis (VM202)|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
76063692|NCT01452646|Other|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
76063693|NCT01452724|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
75450326|NCT01705366|Device|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
75450327|NCT01705379|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
75450328|NCT01705392|Drug|Bevacizumab|Bevacizumab 10 mg/kg q3w
75450329|NCT01705392|Drug|Propranolol|Propranolol 80 mg x 1
75450330|NCT01705392|Drug|Enalapril|Enalapril 5 mg x 1
75450331|NCT01705392|Drug|Dacarbazine|dacarbazine 1000 mg/m2 q3w
75601505|NCT01475786|Other|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
75601506|NCT01372696|Other|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
75601507|NCT01369316|Procedure|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
75601508|NCT01369316|Procedure|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
75601509|NCT01368289|Procedure|Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of large sessile colonic polyps.
75745731|NCT05879796|Drug|cis-platinum|chemotherapeutics
75450332|NCT01705405|Device|Software for acquiring ultrasound and endoscopic images|Use of a medical device to acquire ultrasound and endoscopic images
75450333|NCT01705431|Behavioral|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
75450334|NCT01705444|Device|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
75450335|NCT01705457|Drug|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
75601510|NCT01290692|Biological|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
75601511|NCT00996866|Drug|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
75601512|NCT00996866|Drug|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
75769210|NCT01148446|Drug|Cyclophosphamide|750 mg/mq IV, day 1
75769211|NCT01148446|Drug|Cyclophosphamide|50 mg/mq IV, day 1
75769212|NCT01148446|Drug|Doxorubicin|50 mg/mq IV, day1
75769213|NCT01148446|Drug|Vincristine|1,4 mg/mq (max 2 mg)IV, day 1
75769214|NCT01148446|Drug|Prednisone|75 mg/mq IV, days 1-5
75769215|NCT01148446|Drug|Prednisone|60 mg/mq IV/PO, days 1-5
75769216|NCT01148446|Drug|Epirubicin|50 mg/mq IV, day 1
75769217|NCT01148446|Drug|Vinblastine|5 mg/mq IV, day 1
75769218|NCT01148446|Drug|Rituximab|375 mg/mq IV, day 1
75896660|NCT03552042|Behavioral|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
76063694|NCT01452724|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
75896661|NCT02120430|Other|Video|"The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children."
75896662|NCT01061385|Device|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
75745732|NCT05879796|Radiation|radiation|"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
75896663|NCT01061385|Other|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
75745733|NCT05879796|Drug|Envafolimab Injection|PD-L1 antibody
75745734|NCT05879796|Drug|Recombinant Human Endostatin Injection|angiogenesis inhibitors
76063695|NCT01452724|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
76063696|NCT01452724|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
76063697|NCT01452880|Drug|Remifentanil|Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
76063698|NCT01452880|Drug|Remifentanil|GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
76063699|NCT01513239|Biological|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
75450336|NCT01705457|Drug|placebo|
75601513|NCT00876993|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
75601514|NCT00876993|Drug|Irinotecan|Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
75601515|NCT00876993|Drug|Temozolomide|For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)
75745735|NCT05879783|Diagnostic Test|Confocal laser endomicroscopy|After intravenous injection of fluorescein sodium, pCLE-based optical biopsy will be performed.
75745736|NCT05879770|Other|suture material|Some patients have had a shouldice repair with wire in the past and others with Prolene.
75896664|NCT03652467|Drug|Conventional TACE|Conventional chemoembolization drugs are injected through hepatic artery.
75896665|NCT03652467|Drug|Deferoxamine and conventional TACE|Deferoxamine is injected before conventional transarterial chemoembolization.
75896666|NCT00292292|Device|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
76063700|NCT01513239|Biological|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
76063701|NCT01513239|Biological|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
76063702|NCT01513239|Drug|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
76063703|NCT01453114|Behavioral|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
75450337|NCT01705470|Drug|furosemide|
75450338|NCT01705470|Drug|placebo normal saline|
75450339|NCT01705483|Drug|ASP9853|oral
75450340|NCT01705483|Drug|Docetaxel|intravenous (IV)
75450341|NCT01705483|Drug|Paclitaxel|Taxol
75450342|NCT01705535|Behavioral|Individual supervised pelvic floor muscle exercises|Six individual treatments of 45 minutes by a physiotherapist specialized in pelvic floor disorders. Preparation of an individual adapted training program for the pelvic floor muscles. Encouragement to perform the pelvic floor muscle training program on a daily basis
75450343|NCT01705535|Other|Massage of the neck and back|six individual treatments of 30 minutes by a physiotherapist. The participants will get no instructions of pelvic floor muscle exercises.
75450344|NCT01705535|Behavioral|Standard information and guidance|Advice about diet and fiber supplements. Information about optimizing bowel emptying including use of medicine. Advice about use of antidiarrheal medication if appropriate.
75601516|NCT00700882|Drug|dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
75450345|NCT01705600|Behavioral|Pain Verbalization Repression Rules|The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
75896667|NCT00292292|Device|Charite Artificial Disc|Insertion of the Charite
75896668|NCT02120508|Device|rTMS|To test the efficacy of this specific setting.
75896669|NCT05403814|Other|observational screening procedure (no intervention)|observational screening procedure (no intervention)
76063704|NCT01453192|Drug|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
76063705|NCT01453270|Device|NICOM|Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
75601517|NCT00673309|Procedure|Stable Isotope Infusion study|Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
75601518|NCT00673309|Drug|Insulin High Dose|Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.
75450346|NCT01705639|Drug|Melatonin|All subjects receive the same dose of melatonin
75896670|NCT02120586|Other|Inspiratory Muscle Training (IMT).|"Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10."
75896671|NCT02120586|Other|Peripheral muscle training|"The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10."
75450347|NCT01705678|Dietary Supplement|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
75601519|NCT00673309|Drug|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
75601520|NCT00673309|Drug|Propranolol|Propranolol to be given daily throughout hospitalization until 95% wound healing.
75896672|NCT05725148|Device|CART-I plus|CART-I plus is a ring-type medical device that continuously monitors Atrial Fibrillation, heart rate, oxygen saturation, and blood pressure using PPG and ECG signals.
75601521|NCT00673309|Drug|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
75896673|NCT02117154|Device|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
75896674|NCT03528824|Other|Fenugreek wrap|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
75896675|NCT03528824|Drug|Diclofenac Gel|Daily application of diclofenac gel, 4 weeks application
75896676|NCT03553056|Other|NZ Step Away app|Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)
75896677|NCT03553056|Other|Modified NZ Step Away app|Access to 2 modules of the app (namely: drinkers profile and goals setting)
75896678|NCT00289640|Drug|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
75896679|NCT00289640|Drug|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
76063706|NCT01453270|Other|Usual care|Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
76063707|NCT01453426|Drug|BG00012 Dose 1|
76063708|NCT01453426|Drug|BG00012 Dose 2|
75450348|NCT01705678|Dietary Supplement|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
75450349|NCT01705743|Drug|Sevoflurane+Nitrous oxide|60% nitrous oxide +40% oxygen+ Sevoflurane
75450350|NCT01705743|Drug|Sevoflurane|100% oxygen+ Sevoflurane
75450351|NCT01705756|Drug|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
75601522|NCT00673309|Drug|Insulin Low Dose|Insulin administered IV until 95% wound healing
75601523|NCT00673309|Drug|IGF-1/IGFBP-3|Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing
75601524|NCT00673309|Drug|Itraconazole|Itraconazole administered until 95% wound healing
75896680|NCT00289640|Drug|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
75896681|NCT05039086|Drug|PDE5 inhibitor|PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.
75601525|NCT00673309|Drug|Growth Hormone and Propranolol|Growth Hormone and Propranolol given until 95% wound healing
75601526|NCT00673309|Drug|Oxandrolone and Propranolol|Oxandrolone and Propranolol
75896682|NCT05039086|Drug|Endothelin Receptor Antagonists|Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.
75896683|NCT03552432|Drug|Alirocumab|the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
75896684|NCT05006170|Drug|DTG DT 20 mg|Give 2 tabs of MYLTEGA DT (10mg) PO once daily
75896685|NCT05006170|Drug|DTG DT 25 mg|Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
75896686|NCT02117232|Device|Visualization balloon|"The Visualization Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the Visualization Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The Visualization Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The Visualization Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon."
75896687|NCT02117232|Device|Traditional CO2 insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
75896688|NCT03765632|Genetic|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|Autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
75896689|NCT03765632|Drug|Busulfan|Busulfan is used for non-myeloablative conditioning
75896690|NCT03765632|Drug|Peg-Ada|Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
75896691|NCT02973477|Drug|Dapagliflozin|Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
75896692|NCT02973477|Drug|Glimepiride|Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
75450352|NCT01705769|Other|Ready to Use Therapeutic Food-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company.
75450353|NCT01705769|Other|Ready to Use Therapeutic Food-Locally produced|Ready to Use Therapeutic Food prepared by the study team
75450354|NCT01705769|Other|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
75450355|NCT01705782|Biological|E. coli endotoxin, US standard|
75896693|NCT04558450|Diagnostic Test|carotid-femoral pulse-wave velocity|early vascular aging tests
75896694|NCT02117388|Behavioral|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
75896695|NCT02117388|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
75896696|NCT02117388|Behavioral|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
75896697|NCT03528746|Other|Isotonic Exercise|Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.
75896698|NCT03528746|Other|Isometric exercise|Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
75896699|NCT03552354|Drug|Argatroban plus dual antiplatelet|A continuous argatroban infusion of 1.0 ug/kg per minute for 2-5 days adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%). For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day
75896700|NCT03531944|Other|Community pharmacist-involved collaborative care|Community pharmacist-involved collaborative care in the management of individuals with type 2 diabetes mellitus
75450356|NCT01705795|Drug|Mepolizumab (a-IL-5 antibody)|750mg mepolizumab four times over four months
75601527|NCT00673309|Drug|Placebo or Control|Administration of Placebo or Control until 95% wound healing
75450357|NCT01705795|Drug|Placebo|Nacl four times over four months
75896701|NCT03531944|Other|Usual care|Usual care with physician and as needed visit to the nurse
75896702|NCT04154631|Behavioral|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
76063709|NCT01544127|Behavioral|MI-SI+TAU|MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
76063710|NCT01544127|Behavioral|MI-SI-R+TAU|MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
75896703|NCT04154631|Behavioral|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
75896704|NCT04154631|Other|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
75896705|NCT04847362|Behavioral|Experimental|education group
75896706|NCT02288000|Drug|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
75896707|NCT02288000|Drug|Placebo|the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
75896708|NCT02788656|Device|Implantable Hemodynamic Monitor|The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.
76063711|NCT01544127|Other|TAU Alone|Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.
76063712|NCT01453504|Drug|DHAP|Dexamethasone, Cytarabine, Cisplatin
76063713|NCT01453504|Drug|Everolimus|
76063714|NCT01453582|Drug|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
75450358|NCT01705808|Drug|Protein C concentrate|
75450359|NCT01705821|Device|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
75896709|NCT02788656|Drug|Angiotensin-Converting Enzyme Inhibitor|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
76063715|NCT01453582|Drug|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
75601528|NCT00666835|Drug|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
75450360|NCT01705821|Procedure|Removal of pituitary tumor using modified curette|
76063716|NCT01512693|Drug|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
76063717|NCT02588482|Device|high-density electroencephalography|Auditory stimulations during electroencephalography recording
76063718|NCT02588482|Device|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
76063719|NCT01453738|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
76063720|NCT01453738|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
76063721|NCT01454908|Device|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
76063722|NCT04272892|Behavioral|Digital cognitive behavioural therapy for insomnia|6 weeks of cognitive behavioural therapy for insomnia (Sleepio) delivered online
76063723|NCT04272892|Behavioral|Sleep hygiene information|A leaflet detailing advice to improve sleep through changes in sleep hygiene
76063724|NCT04273204|Diagnostic Test|one leg standing test, gross motor function measurement, pedobarographic measurement|OLST:During the OLST,the participants were asked to shoes off,place both hands on their hips and look at a point on the wall at eye level.A recording stopwatch was used to assess their standing duration on one leg while keeping the other leg in 90 degrees of knee flexion.The test was stopped when the contralateral foot touched the ground or when the participant broke 90 degrees of knee flexion.The OLST was repeated three times for each leg.GMFM:To assess standing and walking,running and jumping functions of the UCP group,the D and E dimensions of GMFM were utilized by a certificated physiotherapist.Each item was tested by three trials and the best trial was used.Pedobarography:The participants' plantar pressure was analyzed using pedobarography.For each participant, the pedobarography was calibrated before the assessment.During the pedobarographic analysis, the participants walked barefoot in 90 BPM cadence. Three steps were analyzed for each side.
75450361|NCT01705847|Drug|GS-9820|GS-9820 tablets containing 200 mg of GS-9820 administered orally
75450362|NCT01705860|Biological|Santyl|
75601529|NCT00666835|Drug|ERYPO®, Janssen-Cilag|Solution for i.v. injection
75601530|NCT00588068|Other|Tumor and Marrow Markers|Tumor and Marrow Markers
75601531|NCT00551759|Drug|5-Fluorouracil|given IV
75601532|NCT00551759|Drug|Oxaliplatin|given IV
76063725|NCT01458340|Drug|TD-9855|Once daily
76063726|NCT01458340|Drug|TD-9855|Once daily
76063727|NCT01458340|Drug|Placebo|Once daily
76063728|NCT04847752|Procedure|carotid artery stenting|common treatments for carotid artery stenosis
76063729|NCT04847752|Procedure|carotid endarterectomy|common treatments for carotid artery stenosis
76063730|NCT04847752|Drug|Aspirin|the dosage and duration
76063731|NCT04847752|Drug|Clopidogrel|the dosage and duration
76063732|NCT04847752|Drug|Anticoagulant|the dosage and duration
76063733|NCT04847752|Drug|Statin|the dosage and duration
75601533|NCT00551759|Drug|Cetuximab|given IV
75745737|NCT05879705|Other|Parent intervention|Family centered, strength-based, Occupational therapy intervention program
75745738|NCT05879627|Drug|BAT8007 for injection|Intravenous infusion: once every two weeks (Q2W). The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30~120 minutes.
76063734|NCT04847752|Drug|PCSK9 inhibitor|the dosage and duration
75745739|NCT05879601|Other|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding.
75601534|NCT00551759|Drug|Docetaxel|given IV
75601535|NCT00551759|Procedure|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
75745740|NCT05879601|Other|delayed orthodontic retainer delivery.|post orthodontic treatment patients will be given orthodontic retainer after 24 hours of debonding.
75745741|NCT05879588|Other|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
76063735|NCT04844554|Other|Active HD-tDCS 3mA|This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.
76063736|NCT04844554|Other|Sham HD-tDCS|This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
76063737|NCT04846270|Device|TENA SmartCare Change Indicator|Each participating subject will be provided with TENA SmartCare Change Indicator and incontinence products for the duration of the investigation. Each participating subject will be allocated to the incontinence type(s) that are considered most suitable.
76063738|NCT04845568|Behavioral|Virtual Reality Experience|"The virtual reality experience includes psychoeducation content about healthy eating and consideration of future consequences. It includes a game where participants are in a go kart and pick up healthy or unhealthy foods on the road. Participants play in the present and in the future."
75601536|NCT00551759|Radiation|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
75601537|NCT00335140|Biological|Rituximab|Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.
75601538|NCT00335140|Drug|Cytarabine|3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
75601539|NCT00335140|Drug|Dexamethasone|16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
75601540|NCT00335140|Drug|Leucovorin|25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
75745742|NCT05879588|Other|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 3 days of debonding
75745743|NCT05879562|Diagnostic Test|MoCA-Xpresso|MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.
75745744|NCT05879536|Drug|Tramadol-ondansetron continuous infusion|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
75745745|NCT05879536|Drug|Ropivacaine via epidural catheter|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
75769219|NCT01148446|Drug|G-CSF|300 µg tot., SC; days 7-11
76063739|NCT04847206|Drug|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
76063740|NCT04847206|Drug|3,4-methylenedioxyamphetamine|A moderate dose of 93.9 mg MDA will be administered.
76063741|NCT04847206|Drug|lysine-3,4-methylenedioxymethamphetamine|A moderate dose of 171.7 mg lysine-MDMA will be administered.
76063742|NCT04847206|Drug|lysine-3,4-methylenedioxyamphetamine|A moderate dose of 165.6 mg lysine-MDA will be administered.
76063743|NCT04847206|Other|Placebo|Placebo (Mannitol)
76063744|NCT04844008|Dietary Supplement|Nanobubble drink|Commercially available sports drink
75896710|NCT02788656|Drug|Angiotensin II Type 1 Receptor Blocker|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients
75896711|NCT02788656|Drug|sacubitril/valsartan|Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
75769220|NCT00228384|Device|GORE VIABAHN Endoprosthesis|Implantation
75896712|NCT03531866|Behavioral|DigiKnowIt News|DigiKnowIt News is an online, interactive, multimedia web-based resource designed to educate youth about participating in clinical trials. Youth will learn general information about clinical trials, their rights in a clinical trial, the good and not so good of participating in clinical trials, communication with others during a clinical trial, and specific types of procedures used in clinical trials (i.e., needles, scans). DigiKnowIt News is web-based and youth can complete it at home, on their own time.
75896713|NCT03652311|Device|ThermoNeuroModulation TNM Device|Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
75896714|NCT00284804|Drug|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
75450363|NCT01705912|Other|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
75601541|NCT00335140|Drug|Methotrexate|"3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture"
75601542|NCT00335140|Drug|Procarbazine|100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
75601543|NCT00335140|Drug|Vincristine|1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
75450364|NCT01705912|Other|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
75896715|NCT05258110|Drug|midazolam|midazolam
75769221|NCT00228384|Device|Bare Nitinol Stent|Implantation
75769222|NCT03914404|Drug|γ-linoleic acid and placebo(Thioctic Acid)|"γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
75769223|NCT03914404|Drug|Thioctic Acid and placebo(γ-linoleic acid)|"Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
76063745|NCT02868190|Device|Two trabecular micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
76063746|NCT02864914|Drug|Empagliflozin|drug
76063747|NCT02864914|Drug|DPP-4 inhibitors|drug
76063748|NCT04272814|Other|Compression therapy|Compression application
75601544|NCT00304239|Combination Product|Metvix-PDT|Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
75601545|NCT00304239|Combination Product|Vehicle-PDT|Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 J/cm². All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
76063749|NCT04272814|Diagnostic Test|initial clinical assessment|Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
76063750|NCT04272580|Drug|Control group|No preload was given before spinal anesthesia.
76063751|NCT04272580|Drug|4 ml/kg group.|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
76063752|NCT04272580|Drug|8 ml/kg group.|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
76063753|NCT04272580|Drug|12 ml/kg group.|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
76063754|NCT04390438|Procedure|Percutaneous Electrolysis|Needle emplacement with a galvanic electrical current
76063755|NCT04390438|Procedure|Dry needling|Needle emplacement without electrical current nor substance
75450365|NCT01705938|Drug|SP-333|
75450366|NCT01705951|Other|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
75450367|NCT01705951|Biological|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
75450368|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
75601546|NCT00101283|Drug|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
75896716|NCT05258110|Drug|BI 425809|BI 425809
75896717|NCT03652233|Drug|Nivolumab|Given by vein every 14 days for up to 12 months
75896718|NCT03652233|Drug|Afatinib|Taken by mouth daily for up to 12 months
76063756|NCT04843852|Drug|Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]|one 0.5ml intramuscular injection on day 0 and week 4.
76063757|NCT04390516|Device|COViage|The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
76063758|NCT02849470|Procedure|Intradermal Injection in hair loss|Comparative Injection of Control (PRP & Acel) in hair loss; 2) Intradermal Injection in hair loss
75601547|NCT00101283|Drug|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
75601548|NCT00101283|Drug|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
75601549|NCT01302041|Drug|Enzalutamide|Oral
75601550|NCT04327895|Behavioral|evaluation of the need for training|analyse of results of survey
75601551|NCT01301729|Drug|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
76063759|NCT02849470|Procedure|Platelet Rich Plasma|Growth factors and cytokines to promote healing and vascular supply
76063760|NCT02849470|Procedure|Adipose Derived Stem/Stromal Cells|Harvesting Adipose Lipoaspirate with Microcannula System
76063761|NCT02849470|Procedure|Stem/Stromal Cellular Isolation (Digestive)|Cell isolation and concentration add back to AD-stem/stromal cells utilizing Centricyte 1000 Protocol
76063762|NCT02849470|Procedure|MatriStem Matrix (ACell) - Current Standard of Care|
76063763|NCT02849470|Procedure|HD-PRP (High Density Platelet Rich Plasma)|
75601552|NCT01301729|Drug|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
76063764|NCT02849470|Procedure|Emulsified AD-tSVF|
76063765|NCT02849470|Procedure|Emulsified AD-cSVF|Stem/Stromal Cellular Isolate Added Back to Emulsified AD-tSVF
75450369|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
75450370|NCT01705990|Biological|Ad35-GRIN (0.5mL)|(1x10^10 vp) Delivered intramuscularly by standard syringe and needle injection
75601553|NCT01301729|Drug|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
75601554|NCT05643677|Drug|Fruquintinib|4 mg PO, QD (3 weeks on, 1 week off)
75601555|NCT05643677|Drug|Irinotecan|participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks
75601556|NCT01187043|Drug|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
75601557|NCT02890589|Device|SYNERGY stent|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
76063766|NCT02846974|Device|Pulse oximeter|A pulse oximeter will be used for calibration
76063767|NCT05025358|Drug|LP-118 tablet|Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
76063768|NCT05026528|Other|Digital diabetes self management education and support system|Digital diabetes self management and support system
76063769|NCT05024188|Drug|Antibiotics|Ciprofloxacin, 500 mg 2/day & Metronidazole (Flagyl), 500 mg 3/day.
75450371|NCT01706016|Procedure|Thermic destruction of tissue by Laser using the Novilase device|
75450372|NCT01706042|Other|legume meal|
75601558|NCT02890589|Device|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
75601559|NCT05357001|Other|Connective tissue manipulation|to remove muscle spasticity
75601560|NCT05357001|Other|stretching exercises|to remove muscle spasticity
76063770|NCT05024188|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation is the process of transferring stool from a healthy donor to another.
75450373|NCT01706042|Other|white bread|
75450374|NCT01706055|Biological|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
75601561|NCT05643521|Other|Dietary composition of macronutrients and calories|Carbohydrate restriction
75601562|NCT05643443|Other|Gradual increase of force|steady force
76063771|NCT05024188|Other|Cellules Pills|7 days of cellules placebo pills.
76063772|NCT05024188|Other|Agarose Capsules|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
76063773|NCT05023876|Other|IASTM+respiratory Exercise|Instrument assisted soft tissue mobilization
76063774|NCT05023876|Other|Respiratory Exercise|Respiratory Exercise
76063775|NCT04390594|Drug|Nafamostat Mesilate|"Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant"
76063776|NCT02843386|Drug|Adjuvant chemotherapy by Fotemustin|"Fotemustin is given for 6 cycles :~One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21."
76063777|NCT02843386|Other|Intensive surveillance|"Intensive surveillance~Total duration: 3 years.~liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months."
75745746|NCT05879406|Dietary Supplement|VitaMedica® Clear Skin Formula capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Vitamin A (from Betatene® Carotenoid Blend) (7,500 IU/2,250 mcg RAE) Vitamin A (from Retinyl Palmitate) (5,000 IU/1,500 mcg RAE) Vitamin C (as Ascorbic Acid) (60 mg) Vitamin E (from d-alpha-Tocopheryl Acid Succinate) (30 IU/20 mg) Zinc (from Zinc Bisglycinate Chelate) (24 mg) Selenium (from Selenium Glycinate) (48 mcg) Chromium (from Chromium Nicotinate Glycinate Chelate) (150 mcg) MSM (Methylsulfonylmethane) (200 mg) Bromelain (200 mg) Burdock (Arctium lappa) root (50 mg) Oregon Grape (Mahonia aquifolium) root (25 mg) Dandelion (Taraxacum officinale) root (50 mg) Yellow Dock Extract (Rumex crispus) root (50 mg) Hypromellose Microcrystalline cellulose Magnesium Stearate Silicon Dioxide"
75745747|NCT05879406|Other|Placebo Capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Magnesium Stearate (VEG) (NON-GMO) Silica (As Silicon Dioxide) Micro Cellulose (MCG) (NON-GMO)"
75601563|NCT01186809|Biological|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
75601564|NCT05367713|Other|patients having had an osteitis of the cranial flap after craniectomy|description of management and failure of cranial flap after craniectomy
75601565|NCT05643053|Other|thomas fixation|Use of the thomas tube holder for endotracheal tube fixation in patients operated in the prone position
75745748|NCT05879380|Diagnostic Test|MRPA|patients will receive an extra MRPA, on top of the standard CTPA
75745749|NCT05879380|Diagnostic Test|CPTA|patients will receive an extra MRPA, on top of the standard CTPA
75745750|NCT05879354|Other|Active Cycle of Breathing Techniques|Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
75745751|NCT05879341|Other|High intensitiy interval training|The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.
75745752|NCT05879328|Procedure|Liver Transplantation|Liver transplantation (LT) is an accepted surgical therapy for hepatocellular carcinoma (HCC) in patients who achieve effective and sustained tumor downstaging; in this study liver transplantation will be performed in patients undergoing a successful hepatocellular carcinoma (HCC) downstaging with the combination of atezolizumab and bevacizumab.
75745753|NCT05879315|Other|Fall risk prevention in hospital|All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
75745754|NCT05879302|Behavioral|Kidney Offer Shared Decision Making|The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
75745755|NCT05879289|Dietary Supplement|A power supplement|A dietary supplement containing vitamins and collagen
75745756|NCT05879276|Drug|Empagliflozin 10 MG|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.
75745757|NCT05879263|Other|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
75745758|NCT05879263|Other|CONTINUOS ENTERAL NUTRITITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
75601566|NCT05643053|Other|elastic band|Use of the elastic band for endotracheal tube fixation in patients operated in the prone position
75601567|NCT05643053|Other|normal fixation adhesive tape|Use of the adhesive tape for endotracheal tube fixation in patients operated in the prone position
75601568|NCT05643053|Other|reinforced adhesive tape fixation|Use of the reinforced adhesive tape fixation for endotracheal tube fixation in patients operated in the prone position
76063778|NCT05022082|Other|Chest Physiotherapy- Aspiration- Inhaler drugs group|In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.
75601569|NCT01186419|Drug|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
75601570|NCT01301027|Drug|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
75601571|NCT01301027|Drug|Placebo|1 pill a day for 26 weeks
76063779|NCT05024422|Drug|Cabergoline|Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
76063780|NCT05024422|Drug|Pyridoxine|Administration of Pyridoxine (200 mg X 3 per day for a week)
76063781|NCT04272502|Drug|CKD-348 F1, CKD-348 F2, CKD-828, D326, D337|Each arm has a different order for taking IP
75601572|NCT01185639|Radiation|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
75601573|NCT04207385|Diagnostic Test|pharmacogenomics|pharmacogenomics
76063782|NCT04758130|Other|Zamplo Digital Health Platform|This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
75601574|NCT04207385|Diagnostic Test|pharmacogenomics & therapeutic drug monitoring|pharmacogenomics & therapeutic drug monitoring
75601575|NCT04207385|Drug|Venlafaxine|Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
75601576|NCT01185561|Behavioral|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
75745759|NCT05879237|Drug|Vitamin D3|Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus triple therapy
75745760|NCT05879237|Drug|Helicobacter pylori triple therapy|"Triple therapy which is: amoxcillin on 50 mg/kg/day for 2 weeks, Clarithromycin 20mg/kg/day for 2 weeks and proton pump inhibitor~3.ppi 1mg/kg/day for 1month"
75745761|NCT05879211|Behavioral|Feedback|Providers will receive detailed feedback about the timing, quality, and frequency of their goals of care communication with patients
75601577|NCT02887209|Behavioral|CBT-I|"Cognitive behavioural therapy for insomnia (CBT-I; Edinger & Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered."
75745762|NCT05879172|Device|electric tubular anastomotic device|"The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment."
75745763|NCT05879172|Device|traditional anastomotic device|Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
75745764|NCT05879133|Behavioral|Questionnaires|Survey
75745765|NCT05879133|Other|Fit Bit|measures physical activity
75745766|NCT05879068|Drug|PM8002|IV infusion
75745767|NCT05879068|Drug|Paclitaxel|IV infusion
75745768|NCT05879055|Drug|PM8002|IV infusion
75745769|NCT05879055|Drug|FOLFIRI|IV infusion
76063783|NCT01890070|Dietary Supplement|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
76063784|NCT01890070|Dietary Supplement|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
76063785|NCT01890070|Dietary Supplement|Red wine|Italian Organic Red Wine
76063786|NCT01890070|Dietary Supplement|Olive Oil|Italian Organic Olive Oil
76063787|NCT01890070|Dietary Supplement|Wild mixed greens|Italian organic wild mixed greens
76063788|NCT01890070|Dietary Supplement|Chestnut|Italian Organic Chestnut
76063789|NCT01890070|Other|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
76063790|NCT02819596|Drug|Savolitinib|
75601578|NCT05367557|Procedure|laparoscopic cholecystectomy|removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg
75601579|NCT01185249|Procedure|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
75601580|NCT05641961|Behavioral|Survivorship mobile application|Mobile phone application
76063791|NCT02819596|Drug|MEDI4736|
76063792|NCT02819596|Drug|Tremelimumab|
75896719|NCT03652155|Procedure|Orthognathic surgery|Patient's pre and post operative hard and soft tissues will be evaluated retrospectively through the use of con-beam computed tomography imaging for hard tissue evaluation and 3DMd three dimensional photography for soft tissue imaging.
75896720|NCT03621969|Other|Physical exam and medical history|This will be completed by a medical doctor on the research team
75896721|NCT03621969|Diagnostic Test|Assessments|One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)
75896722|NCT03621969|Device|Patient Instruction and use of Device (RePlay)|"providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~improving assessment and evaluation of patients involved in future interventional studies,~producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home."
75896723|NCT02117466|Drug|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
75450375|NCT01706094|Other|Head Position|"Head position during the first 48 hours from admission of patients with acute ischemic stroke.~This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients."
75601581|NCT05641961|Other|Questionnaires|Questionnaires assessing cancer knowledge and system usability will be delivered to participants via Survivorship App
75896724|NCT02117466|Drug|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
75896725|NCT04766320|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10^9-3x10^11 autologous TILs to patients i.v. in 30-120 minutes.
75896726|NCT02123940|Device|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
75601582|NCT05641883|Combination Product|CardiaMend with antiarrhythmic|Pericardial patch with antiarrhythmic drug (amiodarone) topically applied
75601583|NCT02886897|Biological|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5*10^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
75601584|NCT04324697|Procedure|Horizontal alveolar bone augmentation|Horizontal augmentation in anterior maxilla using allograft shell and autogenous chips with no need for a second surgical site
75601585|NCT05619497|Other|Clinic-wide Trainings|The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.
75601586|NCT05619497|Other|Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST)|"The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.~The DST is founded on principles of decision-science and will address barriers to PrEP delivery. The DST will present HIV prevention information through a tablet in the clinical setting. The tool provides information about vulnerabilities to HIV and core characteristics of different HIV prevention methods, and the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The tool emphasizes the highly variable and individual nature of baseline risk."
75745770|NCT05879003|Behavioral|neuromuscular electrical stimulation|The symptomatic rotator cuff tear subjects had NMES on the two adductors.
75896727|NCT02117622|Drug|insulin degludec|Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
75896728|NCT04529902|Drug|Tumor Necrosis Factor Inhibitors|TNFi claim is used as the reference group.
75745771|NCT05878977|Drug|Immune checkpoint inhibitor|Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
75745772|NCT05878964|Other|EQ-5D-5L questionnaire|Quality of life evaluation questionnaire
75745773|NCT05878964|Other|FACT-G (Functional Assessment of Cancer Therapy - General)|Quality of life evaluation questionnaire
75896729|NCT04529902|Drug|Abatacept|Abatacept claim is used as the exposure group.
75896730|NCT02117778|Procedure|Continuous Nerve Block|
75896731|NCT04696900|Procedure|Exercise training|exercise training in an approved rehabilitation program
75896732|NCT02120742|Behavioral|SMS message reminder|SMS texts will be delivered to study participants over a 6-week period.
75896733|NCT03528668|Device|Virtual Reality Exposure|Exposure to Virtual Reality program for up to 30 minutes
76063793|NCT02818894|Drug|Lidocaine|Spinal anesthesia administered prior to participant's THA
76063794|NCT02818894|Drug|Bupivacaine|Spinal anesthesia administered prior to participant's THA
75745774|NCT05878964|Other|FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)|Self reported evaluation of cutaneous toxicity questionnaire.
75896734|NCT02120820|Behavioral|Multisensory environment (MSE)|Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
75601587|NCT05619497|Other|Standard Care with the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma informed care. These participants will view the decision support tool. These participants were recruited in Aim 1 of this study.
76063795|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
75896735|NCT02120820|Behavioral|Massage therapy (MT)|A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
75601588|NCT01184859|Drug|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
75601589|NCT01184859|Drug|Placebo|Placebo melt tablet for sublingual administration
75601590|NCT00623675|Dietary Supplement|Mineralox C|Mineralox C 2 capsules three times a day.
75601591|NCT02890511|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
75601592|NCT05609981|Other|Clinical medication review focused on deprescribing|"A pharmacist-led intervention consisting of a clinical medication review with the focus on deprescribing in older patients using multidose drug dispensing (MDD) systems.~Pharmacist are trained in deprescribing and a developed toolbox to support the intervention is provided"
75896736|NCT02120820|Other|Control group|Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
75745775|NCT05878834|Dietary Supplement|Beta-glucan supplement group|Take 1 capsule 1 time per day for 12 weeks.
75745776|NCT05878834|Dietary Supplement|Placebo group|Take 1 capsule 1 time per day for 12 weeks.
75896737|NCT02120820|Behavioral|Massage therapy in multisensory environment (MT-MSE)|Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
76063796|NCT01893736|Other|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
75745777|NCT05878756|Other|Functional Strength Training|In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
75745778|NCT05878535|Drug|Metformin|Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
75745779|NCT05878535|Drug|Placebo|Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
75450376|NCT01706133|Other|Factors associated with the use of emergency departments|Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
75601593|NCT02887287|Drug|EEN|
75601594|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
75896738|NCT02288078|Other|General condition|Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
75896739|NCT02288078|Other|Blood pressure|systolic blood pressure (SBP)/diastolic blood pressure (DBP)
75896740|NCT02288078|Other|Patient Reported Outcome|Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
75601595|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
75601596|NCT04316403|Procedure|Er:YAG laser|This application was made before the onset of canine retraction in one side of the mouth
75601597|NCT05340699|Device|Defocus Distributed Multi-point lens|Wear DDM lens
75450377|NCT01706172|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
75450378|NCT01706172|Other|Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
75450379|NCT01706185|Other|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
75450380|NCT01706211|Drug|BRL 49653C|BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
75601598|NCT05340699|Device|Single vision lens|Wear single vision lens
75601599|NCT04316325|Drug|Medical abortion|Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
75896741|NCT02288078|Other|Clinical findings|"Blood and lymphatic system disorders: febrile neutropenia~Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting~General disorders and administration site conditions: fatigue and malaise~Immune system disorders: allergic reaction~Metabolism and nutrition disorders: anorexia~Nervous system disorders: dysgeusia and peripheral sensory neuropathy~Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)~Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome~Vascular disorders: hypertension~Symptomatic pancreatitis"
75896742|NCT02288078|Other|Hematology/blood chemistry|White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
75896743|NCT02288078|Other|Coagulation and fibrinolysis system|international normalized ratio (INR)
75896744|NCT02288078|Other|Urinalysis|Proteinuria (qualitative)
75896745|NCT02288078|Other|Medication check|Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
75896746|NCT02288078|Other|Adverse event|CTCAE ver.4.0
75896747|NCT02288078|Other|Thyroid function test|Thyroid-stimulating hormone (TSH), T4, and T3
75896748|NCT02288078|Other|Contrast-enhanced torso CT|It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
75896749|NCT02288078|Other|Brain MRI|If any symptom of brain metastasis is suspected
75896750|NCT02288078|Drug|Dexamethasone|Capsule filled with dexamethasone and lactose
75896751|NCT02288078|Drug|Regorafenib|Film-coating tablet contains 40 mg of regorafenib
75896752|NCT02288078|Drug|Placebo|Capsule filled with lactose
75896753|NCT02288078|Drug|Proton pump inhibitor|PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
75896754|NCT02117856|Procedure|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
75450381|NCT01706211|Drug|Placebo|
75450382|NCT01706224|Procedure|Blood sample|Samples will be tested to determine the presence of anti-pertussis antibodies.
75450383|NCT01706224|Other|Data collection|Electronic Case Report Forms (eCRF)
75601600|NCT05333289|Biological|mRNA-1030|Sterile liquid for injection
75601601|NCT05333289|Biological|mRNA-1020|Sterile liquid for injection
75601602|NCT05333289|Biological|mRNA-1010|Sterile liquid for injection
75896755|NCT02117856|Procedure|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
75745780|NCT05877833|Other|Vibrancy Assessment|Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
75745781|NCT05877651|Biological|MASCT-I injection|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
75745782|NCT05877443|Procedure|Open system|Oxygen delivered on open system, for example high flow nasal cannula or low flow oxygen by nasal cannula or face mask
75896756|NCT02117856|Procedure|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
75896757|NCT02117856|Device|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
75896758|NCT02117856|Device|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
75896759|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
75896760|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
75896761|NCT03531554|Dietary Supplement|ketone ester drink|395 mg of ketone ester/kg
75896762|NCT03531554|Behavioral|exercise|35 min cycling test on an upright bicycle, followed by 10 minutes of supine cycling inside a MR scanner.
75450384|NCT01706224|Other|Data collection|Questionnaires, active questioning.
75450385|NCT01706237|Device|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
75450386|NCT01706302|Other|Data collection|The previous study has used four primary data sources: the General Practice Research Data (GPRD [recently re-named Clinical Practice Research Datalink (CPRD)], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
75450387|NCT01706315|Drug|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
75601603|NCT05333289|Biological|Active Comparator|Sterile liquid for injection
75601604|NCT01190865|Biological|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
75450388|NCT01706315|Drug|Placebo|Matching placebo will be available
75601605|NCT01190475|Drug|Active treatment with a high dose of BGS649|
75601606|NCT01190475|Drug|Active treatment with a low dose of BGS649|
75601607|NCT01190475|Drug|Placebo treatment to blind study|
75601608|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
75601609|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
75601610|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
75601611|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
75745783|NCT05877443|Procedure|Non-invasive mechanical ventilation|Respiratory support by for example continues or bilevel positive airway pressure
75745784|NCT05877443|Procedure|Invasive mechanical ventilation|Respiratory support delivered through endotracheal tube or tracheostomy
75745785|NCT05876247|Other|Electromagnetic Articulography|Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
75745786|NCT05876104|Behavioral|Behavioral therapy|Behavioral and supportive therapy
75745787|NCT05875506|Drug|Ozone gel|(Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
75896763|NCT03531554|Procedure|muscle biopsy|biopsy from the quadriceps muscle prior to and immediately after upright bicycling
75896764|NCT03531554|Diagnostic Test|Magnetic Resonance Imaging|1H MR images and 31P MR spectra were acquired from the upper leg prior to-, during and after exercise
75896765|NCT02120976|Drug|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
75896766|NCT02120976|Drug|JTT-252|Subjects will receive JTT-252
75896767|NCT04346524|Other|sampling of microbiome|women will sample from vagina, feces, and saliva during pregnancy
75896768|NCT02288234|Drug|Vibativ|This is an observational study for patients who were already prescribed Vibativ.
75896769|NCT03531398|Other|Metabolic test meal challenge|Metabolic test meal challenge
75896770|NCT04654312|Drug|Hydrochlorothiazide|Please see arm descriptions
75896771|NCT04654312|Drug|Placebo|Please see arm descriptions
76063797|NCT01893736|Other|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
75896772|NCT02973087|Biological|von Willebrand factor (Recombinant)|OD participants will receive intravenous (IV) rVWF:RCo at an initial prophylactic dose of 50 +/- 10 International Unit per Kilogram (IU/kg) twice (two infusions) a week for at least 12 months up to 15 months and may be increased up to 80 IU/kg. pdVWF switch cohort participants will receive rVWF:RCo equivalent (± 10%) to the weekly VWF dose received during prophylactic treatment with pdVWF.
75450389|NCT01706341|Drug|administer acetate Ringer's solution|During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
75745788|NCT05875506|Drug|doxycycline hyclate saturated chitosan dressing|doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
75745789|NCT05875350|Procedure|Intraligamental local anesthetic injection|The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
76063798|NCT02672644|Device|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
75601612|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
75601613|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
75896773|NCT02973087|Biological|Antihemophilic Factor (Recombinant)|During prophylaxis period any bleeding episodes requiring substitution therapy with VWF concentrate to control bleeding will be treated with rVWF with or without ADVATE. Participants will receive rFVIII IV if necessary for OD treatment of breakthrough bleeds or for peri-operative. The dose will be according to the bleeding type and severity and it will be adjusted to the clinical response.
75896774|NCT05284656|Drug|combination of Pentoxifylline 400 MG and Folic Acid|drugs used to delay progression of chronic kidney disease
76063799|NCT02672644|Device|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
76063800|NCT05586646|Dietary Supplement|alanyl-glutamine|Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
76063801|NCT05586568|Drug|XZP-3621 tablet and itraconazole oral liquid (for Arm1)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.
75450390|NCT01706341|Drug|acetate Ringer's solution containing no glucose|
75450391|NCT01706341|Drug|acetate Ringer's solution containing 1% glucose|
75450392|NCT01706354|Procedure|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
75601614|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
75601615|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
75601616|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
75601617|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
75601618|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
75601619|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
75601620|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
75601621|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
75601622|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
75601623|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
75601624|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
75601625|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
75601626|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
75601627|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
75601628|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
75601629|NCT01289990|Drug|Sitagliptin 100mg|Sitagliptin once daily
75601630|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
75601631|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
75601632|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
75601633|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
75745790|NCT05874947|Device|linear measurement|Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
75745791|NCT05872269|Drug|Saroglitazar|4 Mg Oral Tablet
75745792|NCT05871086|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 soft gelatin capsules daily for 3 months
75745793|NCT05871086|Other|Placebo|Placebo Capsules
75896775|NCT05284656|Drug|folic acid|drugs used to delay progression of chronic kidney disease
75896776|NCT05284656|Drug|Pentoxifylline 400 MG|drugs used to delay progression of chronic kidney disease
75896777|NCT04287088|Diagnostic Test|A shared decision making|Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
75896778|NCT02288390|Procedure|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
75896779|NCT02124174|Drug|Vidaza and Valproic Acid|"Days 1-5: 5-Azacytidine 40 mg/m^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily~*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days."
75896780|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
75896781|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
75896782|NCT00277238|Drug|Control|Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks
75896783|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
75896784|NCT02124252|Behavioral|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
75896785|NCT02124252|Behavioral|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
75601634|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
75769224|NCT01147198|Dietary Supplement|Ready to Use Supplementary Food|Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
75896786|NCT03956368|Drug|Atorvastatin 20mg|20mg (every evening orally) for 8 weeks.
75896787|NCT03956368|Drug|Placebos|20mg (every evening orally) for 8 weeks.
75896788|NCT02124330|Dietary Supplement|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
75896789|NCT02124330|Dietary Supplement|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
75896790|NCT02124330|Dietary Supplement|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
75896791|NCT02118090|Drug|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
75896792|NCT02118090|Drug|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
75896793|NCT04539184|Other|Motion Style Acupuncture Treatment (MSAT)|MSAT required a part of the patient's body to move passively or actively while acupuncture needles are retained.
75896794|NCT04539184|Other|Acupuncture|General acupuncture
75896795|NCT03551808|Drug|using of Ketorolac Tromethamine Eye Drop|using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
75896796|NCT04053543|Drug|CXA-10|(10-nitro-9(E)-octadec-9enoic acid)
75896797|NCT04229914|Other|stroke patinets|3-m backwards walk test, timed up and go test, 10 m walk test, Berg BalanceTest, Functional Reach Test
75601635|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
75769225|NCT01147198|Dietary Supplement|Premix CSB-oil treatment|Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
75769226|NCT01073280|Procedure|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
75769227|NCT03905980|Procedure|vaginal delivery|pregnancy ended by vaginal delivery
75769228|NCT03905980|Procedure|Cesarean section|pregnancy ended by cesarean delivery
75896798|NCT05724758|Procedure|Breast-conserving surgery|"Following oncoplastic surgeries are performed at the Brust-Zentrum in Zurich:~Oncoplastic reconstruction with round-block technique~Oncoplastic reconstruction using J-Plastic~Oncoplastic reconstruction using V-Plastic~Oncoplastic reconstruction using Grisotti~Oncoplastic reconstruction using Batwing~Oncoplastic reconstruction using Mammareductionplasty (Wise Pattern, Vertical)~Oncoplastic perforator flap surgery"
76063802|NCT05586568|Drug|XZP-3621 tablet and Rifampicin capsules (For Arm 2)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.
76063803|NCT05586568|Drug|XZP-3621 tablet and esomeprazole tablet (For Arm3)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
75896799|NCT02124408|Behavioral|Personalized Behavioral Intervention|
75896800|NCT04202458|Drug|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
75896801|NCT00273650|Drug|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
75896802|NCT00273650|Other|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
75896803|NCT04053777|Device|non-invasive ventilation|Noninvasive positive pressure ventilation used assist/control mode to treat chronic respiratory disease.
75896804|NCT02121288|Drug|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
75896805|NCT02121288|Drug|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
75896806|NCT03552900|Behavioral|7cups Mobile App|Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.
75896807|NCT03552900|Behavioral|Bliss|Participants who receive the Bliss app will get access to an app that that provides access to important community, health, wellness, academic, and support resources.
75896808|NCT04501042|Procedure|Bariatric surgery|Bariatric surgery
75896809|NCT05724680|Other|cognitive behavior therapy|Psycho-therapeutic intervention
76025168|NCT05123651|Biological|Lactobacillus rhamnosus X253|Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
76025169|NCT02811887|Behavioral|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
76063804|NCT01893814|Dietary Supplement|Probiotics|
76063805|NCT01893814|Dietary Supplement|Control|
76063806|NCT02660320|Device|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
76063807|NCT02660320|Device|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
76063808|NCT02655406|Other|Class 2 compression stockings|
75896810|NCT01525329|Drug|5-Fluorouracil|All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting ~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
75896811|NCT02121366|Procedure|EUS-guided ethanol ablation|Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethanol is administrated according to the size of lesion.
75896812|NCT03914014|Other|connective tissue manipulation|From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.
75896813|NCT03914014|Other|placebo ultrasound|From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
75896814|NCT04382313|Procedure|the adequate hydration group guided by Vigileo|If the patient is mechanically ventilated, the following scheme is adopted: if SVV≤10%, then adjust the rehydration speed to 1 ml/kg/h; if 10%<SVV<15%, then adjust the rehydration speed to 2 ml/kg/h; if SVV≥15%, then adjust the rehydration speed to 3 ml/kg/h. The hydration lasts 24 hours after operation, and the rehydration speed is changed according to the SVV. If the patient does not use mechanical ventilation, the following scheme is adopted: 250ml normal saline is administered within 10 minutes after direct PCI, and the rehydration volume changes to 125ml in patients with mild-to-moderate congestive heart failure. If the increment of SV≥15%, then adjust the rehydration speed to 3 ml/kg/h; if 10%≤the increment of SV<15%, then adjust the rehydration speed to 2 ml/kg/h; if the increment of SV<10%, then adjust the rehydration speed to 1 ml/kg/h. Reassessed every 1 hour until SV is stable，and the hydration also lasts 24 hours after operation.
75896815|NCT03133754|Procedure|DP-PEEP|PEEP titration trial for the lowest DP after the alveolar recruitment maneuver
75896816|NCT03133754|Procedure|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
75896817|NCT02121444|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|
76072171|NCT02890940|Behavioral|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
75896818|NCT02121444|Device|BETACONNECT auto-injector.|
75896819|NCT04413526|Procedure|radiofrequency|radiofrequency combined with liver resection
75896820|NCT04413526|Procedure|TACE|only TACE treatment
75896821|NCT04413526|Procedure|TACE+radiofrequency|TACE followed by radiofrequency
75896822|NCT05278416|Device|Lumoral treatment -device and Lumorinse tablets|Subjects will use Lumoral treatment -device and Lumorinse tablets daily as per protocol.
75896823|NCT00271544|Device|Pacing Lead|implant and follow-up of study device
75896824|NCT04383028|Procedure|MELD algorithm use to aid in the planning of SEEG electrode trajectories|"During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations."
75896825|NCT02124486|Procedure|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
75896826|NCT02124486|Behavioral|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
75896827|NCT03665506|Drug|Trifluridin/Tipiracil|QoL assessment
75896828|NCT02118168|Other|No intervention|No intervention is foreseen in this Observational Study
75896829|NCT03868540|Drug|BI 1291583|tablet
75896830|NCT03868540|Drug|Placebo|tablet
75896831|NCT03318874|Device|Blephasteam|Steam delivery goggles, once daily
75896832|NCT03318874|Device|THERA°PEARL Eye Mask|Heat delivery device, delivering heat to the eyelids, once daily
75896833|NCT03318874|Drug|Hylo-comod|Tear substitute containing hyaluronic acid, four times daily
75896834|NCT03551652|Drug|Pharmacokinetics of rocuronium induced neuromuscular block|Measurement of rocuronium induced neuromuscular block comparing patients aged > 80 years with patients aged 18 to 50 years
75601636|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
75896835|NCT05724524|Other|Stool sample collection|50mg stool sample taken for protein extraction
75896836|NCT05724524|Other|Blood sample collection|Venous blood sample taken for analysis of serum and plasma
75601637|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
75896837|NCT03615976|Procedure|high tibial osteotomy with or without arthroscopic circumpatellar denervation with or without arthroscopic circumpatellar denervation|"Arthroscopy will be done in all cases before osteotomy to assess lat. Comp and grade of patellofemoral O.A Arthroscopic patellar denervation with vaper or diathermy will be done plus open wedge high tibial osteotomy in one group and other group OWHTO only will be done comparing the rustles of two groups to assess the efficacy of this procedure~followed by an average follow up to 12 months. And follow up( 6th weeks ,3rd month ,6th month , 12th month)~By clinical examinationan and x-ray and knee scores~Scoring of patellofemoral disorders( Kujala) score~Knee Injury and Osteoarthritis Outcome Score (KOOS)"
75896838|NCT02118246|Device|Dry Needling|Dry needling was performed for one week, three times a week.
75450393|NCT01706354|Procedure|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
75450394|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
75601638|NCT04206345|Other|exercise with blood flow restriction|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
75601639|NCT04206345|Other|exercise|Elbow bending exercises
75896839|NCT02118246|Device|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
75896840|NCT00263042|Drug|Rimonabant|Tablet, oral administration
75896841|NCT00263042|Drug|Placebo (for Rimonabant)|Tablet, oral administration
75745794|NCT05871086|Drug|Standard Regimen|"Patients may be receiving any of these commonly used JIA treatments including:~Ibuprofen - 30 to 40 mg/kg/day in 3 to 4 divided doses~Diclofenac - 2 to 3 mg/kg/day in divided doses 2 to 3 times daily~Methotrexate - Initial: 10 to 15 mg/m2 once weekly; adjust gradually up to 20 to 30 mg/m2 once weekly~Leflunomide - Weight based, 10-20 mg once daily~Sulfasalazine - 30 to 50 mg/kg/day in 2 divided doses~Etanercept - 0.8 mg/kg/dose once weekly~Adalimumab - Weight based, 10-40 mg every other week"
75896842|NCT05055934|Drug|SHR-1314 injection|SHR-1314 injection
75896843|NCT05055934|Drug|placebo|placebo
75896844|NCT02251782|Device|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
75896845|NCT02251782|Device|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
75896846|NCT03218410|Procedure|surgical pulmonary embolectomy|
75896847|NCT03218410|Combination Product|catheter-directed thrombolysis|
75896848|NCT03528590|Device|size 3 i-gel supraglottic airway device|Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
75601640|NCT02886975|Behavioral|low protein diet plus α-keto acid|0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
75601641|NCT01190007|Drug|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
75601642|NCT01189461|Drug|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
75450395|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
75450396|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
75450397|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
75450398|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
75450399|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
75601643|NCT01189227|Procedure|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
75601644|NCT01189227|Procedure|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
75450400|NCT01706380|Behavioral|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
75450401|NCT01706380|Behavioral|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
75601645|NCT01300247|Drug|Fludarabine|Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
75745795|NCT05870215|Other|Visit 1: Clinical exam and questionnaires|Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.
75601646|NCT01300247|Drug|Obinutuzumab|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
75601647|NCT01300247|Drug|Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
75601648|NCT01300247|Drug|Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
75745796|NCT05870215|Other|Visit 1: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
75745797|NCT05870215|Other|Visit 1: Inflammometry|Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray
75896849|NCT03528590|Device|size 4 i-gel supraglottic airway device|Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
75601649|NCT02890277|Device|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
75896850|NCT03552744|Other|Mailed training intervention|"PCPs from the intervention group will be mailed an intervention package that includes:~2-page structured evidence summary on CRC screening and information about Colonoscopy & FIT (Decision box)~patient decision aid (20-page booklet) on CRC screening for distribution to patients (Decision Aid)~video example for the PCP, which illustrates a participatory approach to discussing CRC screening with a patient~4-page abridged version of the booklet to support PCPs when they discuss CRC screening with patients during a clinical visit (Decision Board)~individualized 1-page summary of PCP screening practices comparing their individual prescription patterns to group patterns, based on the data collected in 2017 (Performance card)~2-page document that encourages PCPs still using the inferior guaiac-based FOBT to switch to FIT and includes list of laboratories from which they can order FIT~sample FIT for PCPs who may not be familiar with its contents and use"
75896851|NCT05002192|Drug|Eucalyptol, Limonene and Pinene Enteric Soft Capsule|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
75896852|NCT05002192|Drug|Ambroxol injection|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort
75896853|NCT05002192|Drug|Other oral mucolytic drugs|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
75896854|NCT03528434|Dietary Supplement|Zinc|10mg dispersible zinc sulfate tablet
75896855|NCT03528434|Other|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
75601650|NCT02890277|Drug|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
75745798|NCT05870215|Other|Visit 2: Clinical exam and questionnaires|Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
75896856|NCT02121600|Other|[F-18]-FCH|Before the PET/MRI or PET/CT scan, patients will receive an [F-18]-Fluorocholine injection in the arm.
75896857|NCT02121600|Radiation|PET scan|A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
76072172|NCT02883049|Drug|Clofarabine|Given IV
76072173|NCT02883049|Drug|Cyclophosphamide|Given IV
75450402|NCT01706393|Dietary Supplement|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
75450403|NCT01706393|Dietary Supplement|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
75450404|NCT01706406|Behavioral|Brief psychoeducational intervention for female sexual arousal disorder|four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
75450405|NCT01706419|Dietary Supplement|Fortified rice cold extruded kernel|
75450406|NCT01706419|Dietary Supplement|fortified rice warm extruded kernel|
75450407|NCT01706419|Dietary Supplement|fortiified rice hot extruded kernel|
75450408|NCT01706445|Other|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
75745799|NCT05870215|Other|Visit 2: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
75745800|NCT05870215|Other|Visit 2: Inflammometry|SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)
75896858|NCT02121600|Radiation|MRI scan|Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
75896859|NCT02288468|Device|Vercise™ Deep Brain Stimulation System|"The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.~The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit."
76063809|NCT02649166|Device|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
76063810|NCT02649166|Device|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
76063811|NCT02624908|Drug|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
76063812|NCT02624908|Drug|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
76063813|NCT02616406|Device|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
76063814|NCT02597374|Device|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
76063815|NCT05586412|Device|vagus nerve stimulation|Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.
76063816|NCT02587000|Drug|Ulipristal acetate|
75601651|NCT01289678|Drug|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
75601652|NCT02886741|Other|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
75601653|NCT02886819|Other|vibration|Whole body vibration
75601654|NCT01289210|Drug|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
75601655|NCT01183221|Drug|Syntocinon|One dose of 24 IU (3 sprays/nostril)
75601656|NCT01183221|Drug|Placebo|Intranasal Placebo
75745801|NCT05870215|Other|Visit 3: e-mail|ACQ-5, peak flow measurement, and questions about the patient's asthma management.
75745802|NCT05866549|Other|Mindfulness-based Childbirth and Parenting Program|Mindfulness-based childbirth and parenting program will be applied to individuals in this group. The program consists of nine sessions, eight of which will take place during pregnancy. Sessions planned during pregnancy will be held once a week, lasting 8 weeks.
75745803|NCT05864755|Drug|HAIC+Durvalumab+Tremelimumab+Bevacizumab|Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
75896860|NCT04988698|Other|none intervention|none intervention
76063817|NCT02587000|Drug|Placebo|
76063818|NCT04757818|Other|0.07% cetylpyridinium chloride (CPC) in mouthwash|A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.
76072174|NCT02883049|Drug|Cytarabine|Given IT, IV, or SC
76072175|NCT02883049|Drug|Dasatinib|Given PO
76063819|NCT04757818|Other|Distilled water with the same colorant as the experimental product|A mouthwash and gargles with 15 ml of distilled water for 1 minute
76063820|NCT04758052|Other|Timing of placement|Simultaneous placement of tracheostomy and gastrostomy
76063821|NCT02563678|Drug|Hyperbaric Oxygen|Hyperbaric oxygen therapy
75601657|NCT01183143|Drug|GONAL-f®|GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
75745804|NCT05864404|Drug|remimazolam-remifentanil|In the case of remimazolam, the bolus is prepared in a 30cc syringe by mixing 0.075mg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Remimazolam is then infused at 0.5 to 1 mg/kg/hr to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
76063822|NCT02563678|Other|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
75896861|NCT02121678|Other|Resistance training|"Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~Week 0-4: 70-80 % of 1-RM~Week 5-8: 75-86 % of 1-RM~Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~CIDP patients train knee (flexion/extension) and elbow (flexion/extension)"
76063823|NCT02563678|Other|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
76063824|NCT02562430|Drug|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
76063825|NCT02562430|Drug|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
76063826|NCT02556424|Drug|Dexamethasone|Intravitreal implant at D0
76063827|NCT02556424|Drug|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
76063828|NCT02549638|Genetic|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
76063829|NCT02543944|Drug|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
76063830|NCT02543944|Drug|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
76063831|NCT02543944|Drug|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
76063832|NCT02543944|Drug|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
76063833|NCT02543944|Drug|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
76063834|NCT02543944|Drug|Placebo|Microcrystalline cellulose
76063835|NCT02531308|Drug|Metformin|Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
76063836|NCT02531308|Drug|Rituximab|monoclonal antibody against protein CD20 primarily found on the surface of B-cells
75450409|NCT01706471|Drug|Everolimus + Low dose CsA +PD|Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up >3 ng/mL. Steroid dose follows local protocol.
76063837|NCT02531308|Drug|Cyclophosphamide|Interferes with DNA replication
76063838|NCT02531308|Drug|Doxorubicin|anthracycline antitumor antibiotic
76063839|NCT02531308|Drug|Vincristine|Inhibits cell mitosis causing cell death.
76063840|NCT02531308|Drug|Prednisone|a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
76063841|NCT02531308|Drug|pegfilgrastim|stimulates the level of white blood cells (neutrophils).
76063842|NCT02523976|Drug|Dasatinib|Second-generation tyrosine kinase inhibitor
75450410|NCT01706471|Drug|Myfortic+ Standard CsA + PD|Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
75450411|NCT01706484|Drug|BNO 1016|comparison of different dosages of drug and placebo
76063843|NCT02523976|Drug|prednisone|
76063844|NCT02523976|Drug|cyclophosphamide|
76063845|NCT02523976|Drug|daunorubicin|
76063846|NCT02523976|Drug|vincristine|
76063847|NCT02523976|Drug|cytarabine|
76063848|NCT02523976|Drug|mercaptopurine|
76063849|NCT02523976|Drug|methotrexate|
76063850|NCT02523976|Drug|dexamethasone|
75896862|NCT02121678|Other|Aerobic training|"Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data."
75896863|NCT04973020|Drug|SHR6390、efavirenz|SHR6390 tablet single dose；Efavirenz single dose.
75896864|NCT02118324|Behavioral|Exergaming Program|Participants will exercise through exergaming play.
75601658|NCT01183065|Drug|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
75601659|NCT01182441|Device|WATCHMAN Device|WATCHMAN Left Atrial Appendage Closure Technology
75896865|NCT05724446|Drug|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).
76063851|NCT02523976|Drug|mitoxantrone|
75450412|NCT01706510|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
76063852|NCT02523976|Drug|etoposide|
75450413|NCT01706510|Drug|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
75450414|NCT01706523|Drug|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
75450415|NCT01706562|Drug|Itraconazole|Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
75450416|NCT01706627|Drug|10 mg Melatonin|Active Comparator: Drug: Melatonin 10 mg
75450417|NCT01706627|Drug|20 mg Melatonin|Active Comparator: Drug: Melatonin 20 mg
75601660|NCT01182441|Drug|Warfarin|Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
75601661|NCT02886507|Dietary Supplement|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
75745805|NCT05864404|Drug|dexmedetomidine-remifentanil|In the case of dexmedetomidine, the bolus is prepared in a 30cc syringe by mixing 1.0mcg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Dexmedetomidine is then infused at 0.4 to 0.8 mcg/kg/h to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
75896866|NCT05724446|Drug|Prednisolone acetate ophthalmic suspension, 1%|Microfine sterile ophthalmic suspension of dense and whitish appearance.
76063853|NCT02523976|Procedure|allogeneic hematopoietic stem cell transplantation|
76063854|NCT02523976|Procedure|autologous hematopoietic stem cell transplantation|
75450418|NCT01706627|Drug|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
75450419|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
75450420|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - medium|
75450421|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
75601662|NCT02886507|Dietary Supplement|Placebo|The placebo capsules contain microcrystalline cellulose.
75745806|NCT05863637|Other|Intensive Short-Term Dynamic Psychotherapy|A dynamic and intensive psychotherapy with eight therapeutic sessions
75745807|NCT05862454|Drug|Magnesium|Magnesium injection therapy
75896867|NCT03177772|Behavioral|Pre-loss group therapy|The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
75896868|NCT02124642|Dietary Supplement|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
76063855|NCT02507986|Device|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
75896869|NCT02124642|Dietary Supplement|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
75896870|NCT00262106|Drug|PRO 2000/5|Gel
75896871|NCT00262106|Drug|Placebo|Placebo
75896872|NCT03094234|Device|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
75896873|NCT03094234|Procedure|endoscopic variceal ligation (EVL)|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
75896874|NCT03094234|Drug|Propranolol|Appropriate dose of propranolol was administered to the patients.
75896875|NCT02118402|Dietary Supplement|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
75450422|NCT01706653|Dietary Supplement|Very low polyphenol fruit based drink (control)|
75450423|NCT01706679|Drug|ATX-101 (10 mg/ml)|
75450424|NCT01706679|Drug|ATX-101 (20 mg/ml)|
75450425|NCT01706679|Drug|Moxifloxacin (400 mg)|
75896876|NCT00260156|Drug|vildagliptin|
75896877|NCT00260156|Drug|placebo|
75450426|NCT01706679|Drug|Placebo vehicle (PBS)|
75450427|NCT01706718|Dietary Supplement|Bread|
75896878|NCT04367103|Drug|Norepinephrine|prophylaxis for hypotension
75896879|NCT04367103|Drug|Phenylephrine|standerd prophylaxis for hypotension
75896880|NCT01950130|Procedure|Preoperative IABC|IABP-Insertion upon inclusion into the trial and admission to the ICU
75896881|NCT02118480|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
75896882|NCT02118480|Other|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
75896883|NCT00260078|Drug|Atazanavir|200 mg to 400 mg orally daily
75896884|NCT00260078|Drug|Darunavir|300 mg or 600 mg orally twice daily
75896885|NCT00260078|Drug|Efavirenz|Dosage dependent on participant
75896886|NCT00260078|Drug|Nevirapine|Dosage dependent on participant
75450428|NCT01706731|Behavioral|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
75450429|NCT01706731|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
75450430|NCT01706744|Other|Intermediate care unit|
75450431|NCT01706744|Other|Local health care 1|
75450432|NCT01706744|Other|Local health care 2|
75450433|NCT01706757|Device|go-cart|conducts exercises with the help of a go-cart
75896887|NCT00260078|Drug|Ritonavir|50 mg or 100 mg orally twice daily
75896888|NCT00260078|Drug|Tenofovir disoproxil fumarate|300 mg orally daily
75896889|NCT00260078|Procedure|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
75896890|NCT03034564|Drug|Northera|
75896891|NCT03034564|Drug|Placebo Oral Tablet|
75745808|NCT05859243|Behavioral|Traditional concurrent training|The subjects will perform two sessions per week of traditional concurrent training, consisting of strength training followed by aerobic exercise over 12 weeks, with progressive intensities and training volumes. Each traditional concurrent training session will consist of specific warm-up performed on equipment for upper and lower limbs with a load of less than 30% of the training load. Then the bench press, low row, leg press, extension and knee flexion exercises will be performed. Participants will be instructed to perform the concentric phase of the movement in one second and the eccentric phase in two seconds. After strength training, aerobic training (walking outdoors or on a treadmill) will be performed with intensity based on the adapted BORG effort perception scale (ranged to 0 = minimum effort, to 10 = maximal effort).
75745809|NCT05859243|Behavioral|Concurrent training consisting of strength training combined with dance classes|Each concurrent training session associated with dance classes will consist of the same strength training as the traditional concurrent training group, but the traditional aerobic training will be replaced by a dance class. Each dance class will consist of a 5-minute general warm-up with joint mobility exercises and dynamic stretching. Then the main part will be performed with the elaboration of choreography, lasting approximately 20 minutes. Finally, there will be a 5-minute cool-down with stretching exercises. Classes will be held in four different dance modalities, divided into four modules.
75745810|NCT05856981|Drug|ADU-1805|anti-SIRPα monoclonal antibody
75745811|NCT05856981|Drug|Pembrolizumab|Keytruda
75896892|NCT03651921|Behavioral|CTS-BC-CH|"CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants.~Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making."
75896893|NCT05342532|Drug|Amoxicillin|1 g
75896894|NCT05342532|Drug|Omeprazole|40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.
75896895|NCT05342532|Drug|Clarithromycin|500 mg twice daily
75450434|NCT01706783|Drug|somapacitan|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 (somapacitan) in an escalating order
75896896|NCT03651843|Other|Questionnaire|Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
75896897|NCT04469114|Drug|Tofacitinib 10 mg|Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge
75896898|NCT04469114|Drug|Placebo|Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
75450435|NCT01706783|Drug|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
75450436|NCT01706796|Drug|PF-06273340|Oral solution, single dose, fasted
75450437|NCT01706796|Drug|PF-06273340|Immediate Release Tablet, single dose, fasted
75450438|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
75450439|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
75450440|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
75450441|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
75896899|NCT02118558|Device|Negative Pressure Wound Therapy (NPWT)|
75896900|NCT02118558|Drug|standard prophylactic therapy|administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
75896901|NCT02400567|Drug|Fluorouracile|
75896902|NCT02400567|Drug|Epirubicin|
75896903|NCT02400567|Drug|Cyclophosphamide|
75896904|NCT02400567|Drug|Letrozole|
75896905|NCT02400567|Drug|Palbociclib|
75896906|NCT02124720|Behavioral|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
75896907|NCT04966624|Procedure|"LUVS ventilatory strategy composed of a bundle of measures"|Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization
75896908|NCT04966624|Procedure|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
75896909|NCT05724368|Diagnostic Test|Fecal Calprotectin ELISA kit|"Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions."
75896910|NCT02868112|Other|Usual Oncology Care|Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
75896911|NCT02868112|Other|Transdisciplinary Intervention|Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
76063856|NCT02507986|Device|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
76072176|NCT02883049|Drug|Daunorubicin Hydrochloride|Given IV
75896912|NCT03531242|Biological|0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1|"administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
75450442|NCT01706809|Other|blood sampels from vena rectalis superior and vena cubiti|
75601663|NCT01182285|Drug|Valproic Acid|"Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
75745812|NCT05856357|Drug|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
75450443|NCT01706848|Other|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
75450444|NCT01706848|Other|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
75745813|NCT05850572|Drug|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
75745814|NCT05850572|Other|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
75896913|NCT04937920|Biological|DBI-002 probiotic gel|Topical application on skin affected with tinea versicolor
75450445|NCT01706861|Device|Celotres|Celotres following surgical removal of earlobe keloid.
75745815|NCT05849532|Device|Functional Electrical Stimulation|12-weeks of training sessions that include initial screening and clinical assessment (Week 1-2), onsite training sessions (Week 3-4), home training sessions (Week 4-8). There will also be pre (Week 1), mid (Week 7) and post-training (Week 12) assessment. Each session will consist of a 10-minute warm-up session with 5-6 stretching exercises. Warm-up will be followed by a 30 minute training session comprising of mobility, balance and walking exercises with FES. This will be followed by a cool down session for 10-minutes comprising of 5-6 muscle stretches. The participant will first watch video of the each exercise on the android tablet and then perform the exercises.
75896914|NCT04937920|Biological|Aqueous gel|Topical application on skin affected with tinea versicolor
75896915|NCT04936360|Other|questionnaires for clinical assessments|questionnaires for clinical assessments
75896916|NCT04468646|Drug|NK-1R antagonist|NK-1R antagonist, 80 mg daily once for 3-5 days along with dexamethasone 6 mg daily for 5 days
75896917|NCT00962884|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
75896918|NCT00962884|Device|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
75896919|NCT02802124|Radiation|carbon-ion radiotherapy for tumor away from GI|
76063857|NCT05586256|Radiation|ultra-hypofractionated whole breast irradiation|"All enrolled patients will be treated with an ultra-ipofractionated whole breast irradiation schedule (26 Gy delivered in 5 consecutive fractions, single dose 5.2 Gy), according to FAST-Forward trial. Whole bresat irradiation should be followed or not by a tumor bed boost (sequential: 7.6 Gy in 2 consecutive fractions, single dose 3.8 Gy or simultaneous intergrated boost: 30 Gy in 5 consecutive fractions, single dose 6 Gy). Either three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) or helicoildal techniques are allowed. Breath control techniques may be used at the discretion of each partecipating centre.~Main exclusion critereria are mastectomy and regional nodal irradiation. Neoadjuvant and/or adjuvant systemic therapies are allowed."
75450446|NCT01706874|Other|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
75450447|NCT01706887|Other|Diet Amiloride|only arm of the trial
75601664|NCT01182285|Drug|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
75601665|NCT04315935|Drug|Butorphanol and Propofol|The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia
75601666|NCT04315935|Drug|Fentanyl and Propofol|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
75745816|NCT05849103|Other|Blood Pressure Control Targets|This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90
75896920|NCT02802124|Radiation|carbon-ion radiotherapy for tumor adjacent to GI|
75896921|NCT00228176|Drug|Rimonabant|Tablet, oral administration
75896922|NCT00228176|Drug|Placebo (for Rimonabant)|Tablet, oral administration
75601667|NCT04316091|Drug|neoadjuvant chemotherapy+SPIONs/SMF|Intratumoral injection of SPIONs, followed by SMF, combined with conventional neoadjuvant chemotherapy
75745817|NCT05849103|Other|Hypertension Management|This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.
75745818|NCT05847985|Device|transcranial direct current stimulation (tDCS)|tDCS using electric currents to modulate underlying neurons
75896923|NCT02984943|Device|Hyperbaric Oxygen|30 treatments of Hyperbaric Oxygen.
75896924|NCT02091232|Biological|T Regulatory Cell Infusion|After blood is collected from the donor and recipient, the facility will sort out one particular kind of immune cell called a regulatory T cell which is strongly influenced by tolerance induction to minimize (suppress) responses to the donor cells. In this study, these regulatory T cells are the cells which will be given back to the recipient on Day 7 (+3 days) post-transplant.
75896925|NCT03528356|Behavioral|Regular diet|Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.
75896926|NCT05131984|Drug|Ocrelizumab|At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
75896927|NCT05724290|Genetic|EGR2|We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
75896928|NCT04874662|Dietary Supplement|NAM/B6|Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.
75896929|NCT03133442|Device|Somnomat V4|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
75896930|NCT01308190|Drug|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
75896931|NCT01308190|Radiation|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
75896932|NCT01308190|Procedure|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
75896933|NCT01308190|Procedure|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
75896934|NCT02787408|Device|EW Tricuspid Transcatheter Repair System|Treatment with the EW Tricuspid Transcatheter Repair System
75745819|NCT05847790|Device|Invu monitoring belt|INVU monitoring belt used for remote NSTs
75745820|NCT05847790|Other|Standard of care|In-clinic NSTs - standard of care
75896935|NCT00226772|Drug|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
76063858|NCT02505958|Other|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing ~ 6000 Kcal/24 h.
76063859|NCT02505958|Other|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (~333 calories each) totaling ~ 1,000 calories/24 hours.
75745821|NCT05846906|Drug|Sildenafil Citrate|oral sildenafil (Respatio® 20mg )
75896936|NCT00226772|Drug|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
75896937|NCT01210768|Drug|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
75896938|NCT01210768|Drug|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
76072177|NCT02883049|Drug|Dexamethasone|PO or IV
75450448|NCT01706900|Other|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
75601668|NCT04316091|Drug|neoadjuvant chemotherapy|Conventional neoadjuvant chemotherapy only
75601669|NCT04188015|Biological|2.5mg ANX007|A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
75601670|NCT04188015|Biological|5.0mg ANX007|A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
75601671|NCT04188015|Other|Sham Procedure|The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.
75601672|NCT01182207|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
75601673|NCT01182207|Drug|YAZ®|3 mg/0.02 mg Tablets
75601674|NCT01181895|Drug|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
75601675|NCT01181895|Drug|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
75745822|NCT05846906|Drug|Clomiphene Citrate 50mg|used for ovionulation induct
75745823|NCT05846074|Diagnostic Test|sweat samples and used face mask will be collected|Collection of sweat samples and used face mask will take approximately 15 minutes before or after collection for the SARS-Cov PCR test
75745824|NCT05845320|Other|ICIQ-UI SF questionnaire|validated arabic short form of ICIQ on urinary incontinence
75745825|NCT05844462|Drug|Tadalafil|Oral Tadalafil
75745826|NCT05844462|Drug|Placebo|Oral Placebo
75745827|NCT05844111|Drug|[14C]-BGB-11417|A single oral dose of liquid formulation
75745828|NCT05841719|Other|Screening test|Capillary blood sampling by finger-prick devices and second confirmatory venous sampling when needed.
75745829|NCT05839210|Behavioral|LIFE-L Mediterranean Diet|Mediterranean Diet will include goals of: 4+ vegetable servings (2-4 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week. Limit or avoid highly processed foods, sugar-sweetened beverages and foods, processed meats, red meat, and alcohol.
75745830|NCT05839210|Behavioral|LIFE-L Home-Based Exercise Program|The Home-Based Exercise Program will include goals of: 150+ minutes moderate or 75+ minutes vigorous exercise per week, completed in sessions of at least 10-minute duration, including daily aerobic exercise plus two resistance-based exercise sessions per week.
75896939|NCT02971605|Drug|Psilocybin|25 mg/70 kg Psilocybin
75896940|NCT02288624|Dietary Supplement|Processed orange juice|3 different formulation of edible orange drinks
76063860|NCT02493322|Drug|Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg|1 tablet a day
76063861|NCT02493322|Drug|Olmesartan medoxomil 20mg + Chlortalidone 25mg|1 tablet a day
75896941|NCT04410874|Biological|Imvamune|Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10^7, 1x10^8, or 4x10^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
75896942|NCT03651999|Other|"participation in a workshop: dream workshop animated by a nurse anesthesist"|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; the nurse anesthetist will take care to explain to them the progress of the hospitalization and help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...) ; he can customize his mask and choose the blanket he wants to take; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
75896943|NCT03054337|Drug|Vadadustat|
75896944|NCT03054337|Drug|Placebo|
76063862|NCT02493322|Drug|Olmesartan 20mg + hydrochlorothiazide 12,5mg|1 tablet a day
76063863|NCT01893892|Dietary Supplement|levocarnitine|Given PO
76063864|NCT01893892|Other|placebo|Given PO
76063865|NCT01893892|Other|questionnaire administration|Ancillary studies
76063866|NCT04757974|Drug|Fostemsavir 600 mg|Fostemsavir tablets will be administered via oral route.
76063867|NCT04757974|Drug|Fostemsavir 200 mg|Fostemsavir tablets will be administered via oral route.
76063868|NCT04757506|Drug|Naltrexone|opioid receptor antagonist
76063869|NCT04757506|Drug|Placebo|
76063870|NCT02484820|Device|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
75450449|NCT01706900|Other|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
75896945|NCT05134324|Other|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed contralateral abductor pollicis brevis (APB).The patient received robotic therapy for upper extremity just after each active TMS sessions.
75896946|NCT05134324|Other|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for upper extremity just after each sham TMS sessions.
76063871|NCT02477644|Drug|Olaparib|Tablets, per os, 300 mg twice daily;
76063872|NCT02477644|Drug|Placebo|Tablets, per os, 300 mg twice daily.
75450450|NCT01706991|Device|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
75450451|NCT01707017|Other|Strength training|
76063873|NCT02472028|Other|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
76063874|NCT02472028|Other|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
76063875|NCT02466334|Drug|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
76063876|NCT02466334|Drug|Placebo|40 ml of normal saline over 20 mins
76063877|NCT02460874|Drug|Glyburide|1.25mg, twice a day
76063878|NCT02460874|Other|Placebo|1.25mg, twice a day
76063879|NCT02451436|Behavioral|Sleep and Media Use Intervention|
75450452|NCT01707056|Other|Black Coffee|Taking Synthroid with 12 ounces of black coffee for 6 weeks.
75450453|NCT01707056|Other|Coffee with Milk|Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
75450454|NCT01707056|Other|Black Tea|Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
75450455|NCT01707056|Other|Water|Taking Synthroid with water for a period of 6 weeks.
75450456|NCT01707069|Biological|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."
75450457|NCT01707082|Drug|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
75450458|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
75450459|NCT01707082|Drug|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
75450460|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
75450461|NCT01707082|Drug|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
75450462|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
75450463|NCT01707082|Drug|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
75450464|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
75896947|NCT05134324|Other|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the C3/C4 (International 10/20 Electroencephalogram System) area, corresponding to the location of the affected hemisphere primary motor cortex (M1), and cathodal to the contralateral supraorbital region. The patient received robotic therapy for upper extremity just after each active tDCS sessions.
75896948|NCT05134324|Other|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
75896949|NCT02124954|Drug|TA-8995|
75896950|NCT02124954|Drug|Midazolam|
75601676|NCT01181895|Drug|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
75601677|NCT01181895|Drug|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
75601678|NCT04187781|Device|external microphone|External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.
75601679|NCT01181271|Drug|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
75896951|NCT02124954|Drug|Digoxin|
75896952|NCT04440800|Device|Wearable activity tracker - FitBit|Participants will be given a wearable activity tracker and their daily step count recorded. If there is a reduction from baseline of over 1000 steps, the participant will be contacted and an ambulatory review organised if the reduction is not due to a device compliance issue
75896953|NCT04928794|Procedure|Erector Spinae Plane Block|Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles
75896954|NCT04928794|Procedure|Paravertebral Block|Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
75896955|NCT04441112|Drug|Ketorolac Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
75896956|NCT04441112|Drug|Triamcinolone Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
75896957|NCT05131906|Device|gait task and activity of daily living task|use of lasers on shoes to potentially minimize freezing of gait
75896958|NCT02125032|Device|Transcranial low voltage pulsed electromagnetic fields (T-PEMF)|
75896959|NCT02125032|Device|Placebo Transcranial low voltage electromagnetic fields|
75896960|NCT04440878|Behavioral|Static stretching|Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 15 seconds of rest with 10 repetitions, and the individuals will be asked to participate in the exercise actively.
75896961|NCT04440878|Behavioral|Mulligan TSLR technique|Mulligan TSLR will be applied by a physiotherapist in 3 repetitions with the patient in the supine position.
75896962|NCT05134168|Procedure|bone marrow mononuclear cell injection|bone marrow mononuclear cells were injected in the intersphincteric space and around the internal opening after ligation and division of the tract
75896963|NCT05134168|Procedure|LIFT|The fistula tract is ligated in the intersphincteric space
75896964|NCT04440956|Drug|64Cu-SARTATE|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms."
75896965|NCT03528278|Behavioral|Motivational interviewing and environmental interventions|"Revision of ward routines towards facilitating physical activity in patients and motivational work by staff~Education of staff with certified MI-expert organized as an intensive course and follow-up guidance. The first course held shortly before start of interventions, the rest arranged within a month~Training equipment~Motivational Interviewing (MI) techniques applied by staff~Weekly treatment plans including physical activity which may consist of any continuous physical exercise."
75896966|NCT02121990|Drug|Paclitaxel,|
75896967|NCT02121990|Drug|Bevacizumab|
75896968|NCT02121990|Drug|Cisplatin|
75896969|NCT02121990|Drug|Olaparib|
75896970|NCT05724056|Device|Idroflog®|"The study intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
75896971|NCT05724056|Device|Sodium Hyaluronate 0.18% (Vismed®)|"The control intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
75896972|NCT05131360|Behavioral|Introduction Only|This is the placebo condition in which participants engage in one day of introductory mindfulness activities.
76063880|NCT02451436|Behavioral|Study Skills Control Group|
76063881|NCT02443324|Drug|Ramucirumab|Administered IV
75450465|NCT01707082|Drug|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
75450466|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
75450467|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
75450468|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
75450469|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
75601680|NCT01181271|Drug|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
75601681|NCT01181271|Drug|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
76063882|NCT02443324|Drug|Pembrolizumab|Administered IV
75601682|NCT01181271|Drug|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
76063883|NCT01893970|Behavioral|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
76063884|NCT01893970|Behavioral|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
76063885|NCT01894048|Drug|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
75601683|NCT01181271|Other|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
75601684|NCT01181271|Drug|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
76063886|NCT02427178|Biological|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
76063887|NCT02420314|Drug|Paclitaxel|"Administered intravenously (IV)~Prescribed at 200 mg/m2 (standard dose)~Given once every 21 days (i.e., one cycle)~Up to 4 cycles are administered depending on disease response"
76063888|NCT02420314|Drug|Carboplatin|"Administered intravenously (IV)~Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~Given once every 21 days (i.e., one cycle)~Up to 4 cycles are administered depending on disease response"
75450470|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
75601685|NCT01181271|Drug|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
75601686|NCT01181271|Drug|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
75601687|NCT01181271|Other|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10^6/kg of recipient's actual body weight
75601688|NCT01181271|Drug|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
75601689|NCT01181271|Drug|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
75745831|NCT05839210|Behavioral|Supportive Materials|"Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week."
76063889|NCT02420314|Drug|Ascorbic Acid|"Administered intravenously (IV)~75g per infusion~Two infusions per week~1 cycle is 3 weeks~given up to 4 cycles~may be given while chemotherapy if delayed due to low counts"
76063890|NCT02418832|Procedure|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
76063891|NCT02404012|Dietary Supplement|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
76063892|NCT01539291|Drug|Idelalisib|Idelalisib tablet(s) administered orally twice daily
76063893|NCT04746040|Drug|Test|2 inhalations of Test and Reference product in each study period
76063894|NCT04746040|Drug|Reference|2 inhalations of Test and Reference product in each study period
76063895|NCT02400814|Drug|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
76063896|NCT02400814|Radiation|Stereotactic Body Radiation Therapy|Undergo SAR
76063897|NCT02398240|Drug|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
75450471|NCT01707134|Drug|insulin aspart|Injected subcutaneously (s.c, under the skin) as meal time insulin
76063898|NCT02398240|Drug|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
76063899|NCT02398240|Drug|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
76063900|NCT02398240|Drug|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
75450472|NCT01707134|Drug|human soluble insulin|Injected subcutaneously (s.c, under the skin) as meal time insulin
75896973|NCT05131360|Behavioral|Purpose Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of purpose-based mindfulness techniques.
76063901|NCT02022280|Drug|Lansoprazole|
76063902|NCT02022280|Drug|Placebo|Vitamin pill
76063903|NCT02372734|Other|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
76063904|NCT02364310|Device|Baroreceptor stimulation with Barostim Neo TM|
76072178|NCT02883049|Drug|Doxorubicin Hydrochloride|Given IV
76072179|NCT02883049|Drug|Etoposide|Given IV
76072180|NCT02883049|Drug|Hydrocortisone Sodium Succinate|Given IT
75450473|NCT01707134|Drug|insulin NPH|Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
75450474|NCT01707160|Drug|biphasic insulin aspart 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
75745832|NCT05838807|Device|Thermal Ultrasound|Participants in this group will receive thermal ultrasound treatment using a gel-coupled ultrasound probe that delivers continuous ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 5 minutes per session, three times per week, for four weeks. The intensity of the ultrasound wave will be set at 1.0 W/cm2 applied for 5 minutes. The treatment will be administered three times per week, for four weeks.
75745833|NCT05838807|Device|Pulsed Ultrasound|Participants in this group will receive pulsed ultrasound treatment using a gel-coupled ultrasound probe that delivers pulsed ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 15 minutes with 25% duty cycle and intensity of 1.0 W/cm2.The treatment will be administered three times per week, for four weeks.
75896974|NCT05131360|Behavioral|Connection Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection-based mindfulness techniques.
75450475|NCT01707160|Drug|biphasic human insulin 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
76063905|NCT01538199|Device|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
76063906|NCT01538199|Device|Sham device|The sham device does not emit near-infrared radiation.
76063907|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
75601690|NCT01181271|Drug|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
75896975|NCT05131360|Behavioral|Connection and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection and purpose-based mindfulness techniques.
76063908|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
76063909|NCT01511055|Drug|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
76063910|NCT02344186|Drug|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
75601691|NCT00624741|Drug|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
75601692|NCT01180647|Drug|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
75896976|NCT05131360|Behavioral|Awareness Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness-based mindfulness techniques.
75896977|NCT05131360|Behavioral|Awareness and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and purpose-based mindfulness techniques.
75896978|NCT05131360|Behavioral|Awareness, Purpose, and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness, connection, and purpose-based mindfulness techniques
76063911|NCT04757428|Procedure|Endocrown|Endocrown
75450476|NCT01707173|Behavioral|Tailored education|Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information
75450477|NCT01707173|Behavioral|Standard Education|Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices
75896979|NCT05131360|Behavioral|Awareness and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and connection-based mindfulness techniques.
75601693|NCT01180647|Behavioral|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
75601694|NCT02886663|Other|stimulation of the blind visual field|
75896980|NCT02126904|Drug|IVA group|
75896981|NCT02609737|Device|PET/CT Imaging|
75896982|NCT02609737|Radiation|68Ga-DOTA-JR11|
75896983|NCT02609737|Radiation|177Lu-DOTA-JR11|
75896984|NCT05723978|Procedure|Selective extended dissection of pancreaticoduodenectomy|An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
76063912|NCT01537887|Drug|LY2484595|Administered orally once daily for 10 days.
76063913|NCT01537887|Drug|Placebo|Administered orally once daily for 10 days.
75896985|NCT01060059|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
75745834|NCT05838807|Device|Combined Ultrasound|Participants in this group will receive a combination of thermal and pulsed ultrasound treatments. The thermal ultrasound treatment will be administered first for 5 minutes, followed by the pulsed ultrasound treatment for another 15 minutes. The same parameters as described above will be used for each treatment modality. The combination treatment will be administered three times per week, for four weeks.
76063914|NCT01537887|Drug|Moxifloxacin|Single dose administered orally.
76063915|NCT04757350|Other|Observational research, not applicable|Observational research, not applicable
75450478|NCT01707199|Drug|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
75450479|NCT01707212|Behavioral|Pain management education|Education about pain management during infant immunization
75450480|NCT01707212|Behavioral|No pain management education|Control - no education about pain management during infant immunization
75450481|NCT01707251|Drug|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
75450482|NCT01707251|Drug|Saline|Placebo control
75450483|NCT01707277|Other|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
75745835|NCT05838807|Device|Placebo Ultrasound|Participants in this group will receive a placebo ultrasound treatment that looks and feels identical to the active ultrasound treatments, but does not deliver any therapeutic effects. The placebo treatment will be administered using the same gel-coupled ultrasound probe for 15 minutes per session, three times per week, for four weeks, with the intensity set at 0 W/cm² and the temperature maintained at room temperature.
75745836|NCT05837234|Device|ULF SCS|Ultra low frequency spinal cord stimulation
75745837|NCT05835245|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
75745838|NCT05835245|Drug|Sintilimab|a PD-1 immune check inhibitor
75896986|NCT01060059|Drug|basal insulin|subcutaneous injection, dosing according to physician's clinical judgment
75896987|NCT02122068|Behavioral|Mentalizing Imagery Therapy|4 week long meditation and mindfulness intervention
75896988|NCT02122068|Behavioral|Relaxation cd|
75896989|NCT04329481|Dietary Supplement|Mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder"
75896990|NCT02252094|Device|Prismalung|Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
76063916|NCT02305264|Drug|18F-DPA-714 and 18F-FDG|"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."
76063917|NCT05585944|Diagnostic Test|Genotyping of rs1883832C/T related single-nucleotide polymorphism|Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
76072181|NCT02883049|Other|Laboratory Biomarker Analysis|Correlative studies
75745839|NCT05835245|Drug|Lenvatinib|Lenvatinib capsules
75745840|NCT05832255|Drug|Psilocybin, 1.5 mg|Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
75450484|NCT01707277|Other|Usual care|Usual pahramacological treatment
75450485|NCT01707303|Other|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
75450486|NCT01707303|Other|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
76072182|NCT02883049|Drug|Leucovorin Calcium|Given PO or IV
75896991|NCT02252094|Other|Ultra-protective ventilation|Ventilation with </= 3ml/kg predicted body weight
75896992|NCT02252094|Other|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
75450487|NCT01707316|Drug|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
75450488|NCT01707316|Drug|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
75601695|NCT00969553|Drug|BI 6727|Dose level 1
75896993|NCT04846816|Combination Product|SQIN-01|The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
75896994|NCT05134090|Device|Ovaian tissue explant|Ovarian tissue explant for cryopreservation of ovarian tissue
75896995|NCT04318015|Drug|Hydroxychloroquine|All treatment will be administered orally.
75896996|NCT04318015|Drug|Placebo oral tablet|All placebo will be administered orally
75896997|NCT02127060|Drug|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
75896998|NCT02127060|Drug|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
75896999|NCT05133934|Other|Observational|A cohort study will be used to collect patient data, analyze the clinical characteristics, TCM syndromes, and treatment of knee osteoarthritis in China
75897000|NCT04307797|Drug|0.9% Sodium-chloride|Part A - 0.9% saline infusion during cardiac PET-MRI scan
75601696|NCT04285957|Other|Questionnaire administration pre test|"Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);"
75897001|NCT04307797|Drug|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part A - exenatide and glucagon infusion during cardiac PET-MRI scan
76072183|NCT02883049|Drug|Mercaptopurine|Given PO
75897002|NCT04307797|Drug|Glucagon 12.5ng/kg/min and 0.9% saline|Part A - Glucagon and 0.9% saline infusion during PET-MRI scan
75897003|NCT04307797|Drug|0.9% Sodium-chloride|Part B - 0.9% saline infusion during 7T 31P MRS scan
75897004|NCT04307797|Drug|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part B - exenatide and glucagon infusion during 7T 31P MRS scan
75897005|NCT04307797|Drug|Glucagon 12.5ng/kg/min|Part B - Glucagon infusion during 7T 31P MRS scan
75897006|NCT02288858|Dietary Supplement|Viviscal Oral Supplement Tablets|Tablet (512 mg)
75897007|NCT00790803|Drug|Pegaptanib|Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
75897008|NCT02125188|Drug|Desmopressin|Desmopressin 3ug/kg ivdrip before surgery
75897009|NCT02125188|Drug|saline|saline 100ml ivdrip before surgery
75897010|NCT05131126|Procedure|Latarjet method|This operation consists of fixing a bone graft
75897011|NCT05131126|Other|Different arms exercices|"Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~Perform 5 circumduction movements with the right and left arms~Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation."
75897012|NCT02288936|Drug|Enzalutamide|Enzalutamide 160 mg/day
75897013|NCT05131048|Other|conventional group|this group will perform conventional therapy
75897014|NCT05131048|Other|experimental group|this group will perform home based exercises
75897015|NCT02125344|Drug|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
75450489|NCT01707316|Other|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
75450490|NCT01707329|Drug|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
75450491|NCT01707329|Drug|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
75450492|NCT01707342|Drug|Simeprevir (TMC435)|Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
75897016|NCT02125344|Drug|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
75897017|NCT02125344|Drug|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
75897018|NCT02125344|Drug|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
75897019|NCT02125344|Drug|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
75601697|NCT04285957|Other|Questionnaire administration - validation|Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
75601698|NCT01179477|Device|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
75601699|NCT02863159|Device|Tecnis Multifocal 1-Piece IOL|+2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
75601700|NCT01179399|Drug|TAK-960|TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
75745841|NCT05827276|Other|Life story questionnaire|Participant will receive physical therapy treatment as usual using information from Life Story Questionnaire.
75897020|NCT02125344|Drug|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
75897021|NCT02125344|Drug|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
75897022|NCT02125344|Drug|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is <70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is <50 kg, both dosages will be reduced to 500 mg each.
75450493|NCT01707355|Behavioral|intervention - poster|
75450494|NCT01707394|Drug|Apixaban|Specified dose on specified days
75601701|NCT01178853|Drug|Warfarin|Warfarin 5 mg once daily
75601702|NCT01178853|Drug|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
75601703|NCT01178853|Drug|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
75601704|NCT02863393|Other|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
75745842|NCT05826327|Drug|Esketamine|The drug esketamine will be added to the experimental group as opposed to the control group.
75745843|NCT05826327|Drug|Sufentanil|Sufentanil for labour analgesia in the control group
75897023|NCT03651609|Procedure|Simple decompression of the ulnar nerve|Surgical HUA release 2-3 cm distal to medial epicondyle with minimal-incision technique .
75897024|NCT03651609|Behavioral|Conservative treatment|Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
75897025|NCT05468840|Drug|Ketamine Hydrochloride|see study arm description
75897026|NCT05468840|Drug|Normal saline|see study arm description
75897027|NCT03651375|Drug|Sequential chemotherapy - 3 courses of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
75450495|NCT01707407|Drug|Pomalidomide|4 mg pomalidomide capsule administered orally once in the morning
75897028|NCT03651375|Radiation|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
75450496|NCT01707407|Drug|Ketoconazole|200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
75450497|NCT01707407|Drug|Fluvoxamine|50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
75450498|NCT01707407|Drug|Carbamazepine|"100 mg Carbamazepine tablet administered orally once in the evening on Day 1~100 mg Carbamazepine tablet administered orally twice daily on Days 2-3~200 mg Carbamazepine tablet administered orally twice daily on Days 4-11"
75450499|NCT01707433|Other|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
75745844|NCT05823116|Drug|Vancomycin Continuous Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The total daily dose is infused over a period of 24 hours.
75745845|NCT05823116|Drug|Vancomycin Intermittent Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The dose is infused at rates of 1 gram per hour in every 8, -12, or -24 hour intervals.
75897029|NCT02122224|Other|High fiber breakfast|Breakfast will contain 10-11g fiber.
75897030|NCT02122224|Other|High Protein Breakfast|Breakfast will contain 19-20g of protein.
75897031|NCT02122224|Other|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
75897032|NCT05723900|Drug|Castor oil|"Procedure :pulpotomy procedure and histological evaluation. A sample of sixty two primary teeth from thirty healthy cooperative children of both sexes who were between 7-9 years and referred to Pediatric Dentistry Department. Two sound teeth without pulpotomy procedure were extracted and subjected to histological procedures to examine the normal pulp tissue and tissue organization (Negative control). The pulpotomy procedure was performed in sixty primary teeth (by split mouth design).~group I treated with castor oil"
75897033|NCT05723900|Drug|Formocresol|Group II treated with formocresol
75745846|NCT05817721|Drug|Proton pump inhibitor|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not
75745847|NCT05817721|Device|LAMS-implantation|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis
75897034|NCT03970291|Device|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
75897035|NCT03651297|Other|Balance training with Fall-Arrest harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
75897036|NCT03651297|Other|Balance training with Adjustable harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
75745848|NCT05814991|Drug|Nitroglycerin solution|Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.
75897037|NCT02122302|Device|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
75897038|NCT02127138|Device|Sirolimus eluting Drug stent|Use the Sirolimus-eluting Drug stents has been approved by the CFDA，But does not allow use taxol-eluting Drug stents and Drug-eluting stent without Polymer.
75897039|NCT03651531|Drug|Insulin|Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.
75897040|NCT03651531|Drug|Metformin|Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
75745849|NCT05814991|Device|monitoring of cerebral oxygen saturation|NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
75897041|NCT02648932|Biological|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
75897042|NCT02648932|Procedure|Matched Unrelated Donor Transplant|
75745850|NCT05814367|Drug|Blink® Tears eye drops in a multidose bottle|Control
75450500|NCT01707446|Device|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
75745851|NCT05814367|Drug|Preservative-free investigational lubricating eye drops in a Novelia® eyedropper|Test
76072184|NCT02883049|Drug|Methotrexate|Given IT and IV
76072185|NCT02883049|Drug|Pegaspargase|Given IV
75450501|NCT01707446|Other|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of < 75% from baseline is reached for > 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
75745852|NCT05812248|Diagnostic Test|Perioperative cardiac biomarker measurement|High-sensitivity cardiac troponin T is measured within 7 days prior to surgery and at day 1 and day 2 after surgery. N-terminal pro-B-type natriuretic peptide is measured within 7 days before surgery.
75897043|NCT03627637|Dietary Supplement|Soy nuts|Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.
75897044|NCT02127216|Behavioral|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
75897045|NCT03133520|Device|High flow oxygen therapy|High-flow nasal oxygen [HFNO] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
75897046|NCT05130736|Device|Robot rehabilitation|Effectiveness of using a rehabilitation robot in post-COVID-19 rehabilitation
76063918|NCT01489527|Biological|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
75897047|NCT02122458|Device|mild-gain hearing aids with high-frequency emphasis over 6-months|open-fit hearing aids with mild amplification in the high frequencies.
76063919|NCT01489527|Other|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
75897048|NCT04468724|Behavioral|MAKASI|"The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~Listening and building trust~Active referral to structures that answers sanitary and social needs~Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons."
75897049|NCT02903511|Drug|Metformin|Monitoring of safety and tolerability
76063920|NCT02315170|Device|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
76063921|NCT02315170|Device|standard lid speculum|standard wire lid speculum
76063922|NCT01487577|Drug|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
76063923|NCT02290366|Radiation|Focal prostate brachytherapy with Cesium-131|
76063924|NCT01928056|Drug|Torrent's Montelukast Sodium Tablets 10 mg|
76063925|NCT05585866|Drug|Anesthesia Agent|The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
76063926|NCT01992952|Drug|AZD5363|Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
76063927|NCT01992952|Drug|Placebo|Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
76063928|NCT01992952|Drug|Fulvestrant|2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
76063929|NCT01928134|Dietary Supplement|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
76063930|NCT01928134|Dietary Supplement|Vit K2+CaCO3|
76063931|NCT01894438|Behavioral|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
76063932|NCT01894438|Behavioral|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
75450502|NCT01707498|Procedure|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
75450503|NCT01707498|Procedure|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
75450504|NCT01707524|Procedure|Randomized left versus right radial artery approach|Randomized left versus right radial artery approach
75897050|NCT02903511|Drug|Placebo|Monitoring of safety and tolerability
75897051|NCT05133778|Dietary Supplement|Sweet orange and pomegranate extract|From the daily 650mg total supplementation of the investigational product, 250 mg will be of pomegranate extract containing 100mg of punicalagin. The remaining 400 mg will consist of sweet orange peel extract containing 360 mg of hesperidin.
75897052|NCT05133778|Other|Maltodextrin control|Supplementation with 760 mg maltodextrin
75897053|NCT05325528|Drug|Tislelizumab in Combination with Oxaliplatin and Tegafur|6 cycles of Tislelizumab plus SOX regimen every 21 days
75897054|NCT00147290|Device|Implantable Cardiac Defibrillator|Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
76063933|NCT01928212|Device|Optical coherence tomography|
76063934|NCT01894594|Drug|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: *~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: *~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
76063935|NCT01928368|Drug|AMG 282|Single dose either subcutaneously or intravenously on day 1.
76063936|NCT01928368|Drug|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
76063937|NCT01970254|Other|Hepatitis B Screening|Undergo 3 HBV screening tests (HbsAg, anti-HBc, and anti-HBs)
76063938|NCT01970254|Other|Survey Administration|Ancillary studies
76072186|NCT02883049|Drug|Prednisone|Given PO or IV
76072187|NCT02883049|Radiation|Radiation Therapy|Undergo radiation therapy
76072188|NCT02883049|Drug|Thioguanine|Given PO
76072189|NCT02883049|Drug|Vincristine Sulfate|Given IV
75897055|NCT05441696|Device|ezCVP measurement|"Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP.~Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US).~Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan)."
75897056|NCT02125422|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
75897057|NCT05130580|Other|Enhanced Consultation|Attend an enhanced consultation with decision aid
75897058|NCT05130580|Other|Standard of Care Consultation|Attend standard of care consultation
75897059|NCT05130580|Procedure|Conventional Imaging|Undergo 2D and 3D torso imaging
75897060|NCT05130580|Other|Educational Intervention|Receive educational materials
75897061|NCT05130580|Other|Questionnaire Administration|Ancillary studies
75897062|NCT02125500|Drug|Sofosbuvir/Ledipasvir fixed dose|SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
75897063|NCT05130502|Other|Foam roller|The investigators use Foam roller to 3 muscle groups per leg then conduct a dynamic warm up program and conduct performance tests
75745853|NCT05800730|Other|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
75745854|NCT05800730|Other|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 5, Day 6, Day 9, Day 11. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
75745855|NCT05800730|Other|energy-restricted diet|After completing the baseline data and biological sample collection, the ERD group volunteers underwent a 10-day dietary intervention from day 3 to day 12. During this period, a standard breakfast was provided to all volunteers daily by the research staff through the school cafeteria. The ERD group volunteers still had their lunch and dinner provided by the research staff through the school cafeteria to ensure their daily energy intake was controlled between 1200-1500 kcal.
75745856|NCT05800730|Other|time-restricted diet|After completing the baseline data and biological sample collection, the volunteers in the TRD group will undergo a 10-day dietary intervention from day 3 to day 12. The TRD group needs to adjust their breakfast eating time to after 10:00 am daily, and they are free to choose their own lunch and dinner according to their dietary habits but must finish their meals before 4:00 pm. During this time window, no other energy-providing foods should be consumed.
75745857|NCT05800145|Behavioral|Resource information Supplemental Nutrition Assistance Program (SNAP)|Participants randomized to the resource referral arm will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address FI (e.g. SNAP).
75897064|NCT05130502|Other|Kinesiotape|The investigators use Kinesiotape to 3 muscle groups per leg, wait 45 minutes for bring out the effects then conduct a dynamic warm up program and conduct performance tests
75897065|NCT02125578|Drug|BIIB017 (PEGylated Interferon Beta-1a)|Each participant will receive BIIB017 every other week or every 4 weeks.
75897066|NCT02125578|Drug|Placebo|Each participant will receive placebo every other week or every 4 weeks.
75897067|NCT05723744|Device|ECG Holter and investigational device recordings for the purpose of developing Continuous Measurement of Heart Arrythmias|"For Candidates for pacemaker implantation: ECG Holter and investigational device recordings (of PPG, ECG, and motion sensors tracings non-invasively) will be recorded before procedure, during patient's hospitalization at cardiology division. Blood pressure values that are collected by an automated cuff will be collected including any notes attached to the values.~All collected data will be analyzed offline"
75897068|NCT05723666|Other|Group watching virtual reality glasses|A nature video will be watched with virtual reality glasses.
75897069|NCT05130424|Drug|Herombopag|Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication
76072190|NCT02870699|Device|Evonail|film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
75450505|NCT01707537|Biological|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
75450506|NCT01707563|Procedure|skin punch biopsy and molecular biology|
76072191|NCT02870699|Device|Placebo excipient|film forming excipient solution
76072192|NCT02864251|Biological|Nivolumab|Specified dose on specified days
76072193|NCT02864251|Biological|Ipilimumab|Specified dose on specified days
76072194|NCT02864251|Drug|Pemetrexed|Specified dose on specified days
76072195|NCT02864251|Drug|Cisplatin|Specified dose on specified days
75450507|NCT01707563|Other|fibroblast culture and molecular biology|
75450508|NCT01707576|Behavioral|consultation 10 days later|new depression screening
75450509|NCT01707589|Device|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
75601705|NCT01178385|Behavioral|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
75601706|NCT01178385|Behavioral|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
75601707|NCT02863315|Device|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
75601708|NCT04286035|Drug|Bupivacaine Injection|Femoral nerve block with 20 ml %0.375 bupivacaine
75601709|NCT04286035|Drug|Bupivacaine Injection|Adductor canal block with 20 ml %0.375 bupivacaine
75601710|NCT02865889|Procedure|Laparoscopy in Gynecologic Oncologic Indications|
75601711|NCT02865889|Procedure|Conventional surgery (abdominal radical surgery)|
75601712|NCT04286815|Device|Lentiviral Vector Gene Therapy|Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells
75601713|NCT02865967|Other|Usual care + a-GPS|Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.
75745858|NCT05800145|Behavioral|community health worker (CHW)|Participants randomized to the CHW intervention will have an initial baseline visit scheduled at a mutually convenient location.
75897070|NCT02122536|Drug|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
75897071|NCT02122536|Drug|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
75897072|NCT03835039|Device|NIRS|Monitoring cerebral and perirenal perfusion using NIRS
75745859|NCT05800145|Behavioral|medically tailored meals|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
75897073|NCT00144014|Drug|V10153|Single acute intravenous bolus dose up to 10 mg/kg
75897074|NCT04573114|Procedure|Verticalization|Progressive levels of verticalization
75450510|NCT01707602|Biological|INTANZA® 15|intradermal vaccination
75450511|NCT01707602|Biological|Vaxigrip®|Intramuscular vaccination
75450512|NCT01707602|Biological|INTANZA® 15 T|transcutaneous vaccination
75450513|NCT01707615|Drug|GSPE|GSPE 240 mg/day (120mg bid)
75450514|NCT01707615|Other|lifestyle intervention|dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
75450515|NCT01707628|Biological|influenza vaccination with influenza vaccine|
75601714|NCT02865967|Other|Usual care|The subjects will be treat for their asthma by their physicians according to usual care.
75745860|NCT05796479|Drug|Amlitelimab DP1|"Injection solution 1~Subcutaneous"
75745861|NCT05796479|Drug|Amlitelimab DP2|"Injection solution 2~Subcutaneous"
75745862|NCT05794399|Drug|Rivaroxaban|"Intervention Group:~The patients in the intervention group will be treated with Rivaroxaban 20 mg once daily with the evening meal in patients with a CrCl >50 mL/min OR 15 mg in cases of moderate-to-severe renal impairment dose with the dosing of once daily with the evening meal in patients with a CrCl ≤50 mL/min. The patient in the intervention group will be requested for follow-up after 3 months of commencing the treatment or whenever the signs and symptoms of bleeding events are noted."
75897075|NCT03551184|Biological|Endotoxin|Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
75897076|NCT03551184|Biological|Placebo|Saline administered intravenously
75897077|NCT05606965|Biological|mRNA-1010|Sterile liquid for injection
76072196|NCT02864251|Drug|Carboplatin|Specified dose on specified days
75450516|NCT01707641|Dietary Supplement|CD#2|patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
75450517|NCT01707641|Other|bicarbonate sodium mouthwash|Patients will be asked to wash their mouth with bicarbonate sodium several times per day
75450518|NCT01707680|Other|SOC|Patient are given standard of care
75745863|NCT05794399|Drug|Warfarin|"Control Group:~The patients in the control group will be treated with Warfarin. The dose will be started with 5 mg and will be titrated based on the International Normalized Ratio (INR) which will be targeted at the range of 2.0 to 3.0. The dual antiplatelet duration will be based on the latest guidelines. The patients will be asked for frequent INR monitoring on an OPD basis until the INR is within the therapeutic range, after which patients will be asked for monthly follow-up INR reports. The patients in the control group will not be treated with heparin or low molecular weight heparin before the INR is maintained in the therapeutic range."
75745864|NCT05790473|Diagnostic Test|Artificial Intelligence|Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy
75745865|NCT05789563|Other|Hypoxia and Smartwatch model|Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.
75745866|NCT05789433|Behavioral|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
75745867|NCT05789433|Behavioral|Progressive stretching|Statistic stretching of eight major muscle groups
75897078|NCT05606965|Biological|Egg-based Quadrivalent Influenza Vaccine|Sterile suspension for injection
75897079|NCT05606965|Biological|Adjuvanted Quadrivalent Influenza Vaccine|Sterile injectable emulsion
75897080|NCT05606965|Biological|Inactivated Influenza Vaccine|Sterile suspension for injection
75897081|NCT03528200|Other|Contrast|"The scan requires that the patient lie still on a hard surface for about 5-10 minutes. Before the scan, they will have a special fluid called contrast dye injected through the IV in their arm. This contrast dye helps to see the blood in the arteries using x-ray pictures.~After the IV dyna CBV is completed, they will have their routine conventional angiography to evaluate the lesion for embolizable arteries as part of routine clinical care. If the patient undergoes embolization of the lesion (as part of the standard of care), a post embolization Dyna CBV will be performed."
75897082|NCT02125656|Other|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
75897083|NCT03830359|Other|T2769|At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days
75897084|NCT04551820|Procedure|Regular Hours|The regular hours cohort includes cholecystectomies performed during the day shift at the Institution during Monday through Friday, not inclusive of national holidays.
75897085|NCT04551820|Procedure|After Hours|The after hours cohort includes cholecystectomies performed outside of the day shift at the Institution during Monday through Friday, on the weekend, or during a national holiday.
76072197|NCT02841540|Drug|H3B-8800 (RVT-2001)|H3B-8800 (RVT-2001) orally at specified doses and schedules.
75450519|NCT01707706|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
75450520|NCT01707732|Drug|Enoxaparin|Administration of Enoxaparin
75450521|NCT01707745|Procedure|Intravitreal Bevacizumab|
75450522|NCT01707771|Procedure|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
75450523|NCT01707771|Behavioral|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
75745868|NCT05788510|Other|Pneumococcal vaccine|Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
75745869|NCT05786846|Drug|Iodinated contrast agents|Patients who use iodinated contrast agents clinically
75745870|NCT05783973|Diagnostic Test|Next generation sequencing|Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.
75745871|NCT05780203|Behavioral|One session exposure treatment|One session exposure treatment during which patients will be confronted with a height-related situation.
75745872|NCT05780203|Behavioral|Sham Cognitive Bias Modification training|Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.
76072198|NCT02838836|Procedure|Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
75601715|NCT04289857|Other|Neurodynamic training|Starting from a sitting position on a stretcher, with dorsolumbar flexion, it is required to maintain that posture throughout the exercise. Sliding with the straight leg sitting consists of performing alternate movements. First, knee extension and dorsal ankle flexion will be performed, increasing neural tension, combined with cervical extension (to decrease neural tension) in the first instance. Subsequently, knee flexion and plantar ankle flexion (decreasing neural tension) combined with cervical flexion (increasing neural tension) will be performed. The dosage of the technique will be: two seconds for each movement, with 10 repetitions of each one. All sessions will be led by one of the group's researchers.
75897086|NCT04551820|Device|Robotic-assisted Cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
75897087|NCT00141284|Drug|nelfinavir 1,250 mg twice daily|
75897088|NCT00141284|Drug|Zidovudine 300 mg twice daily|
75897089|NCT00141284|Drug|Lamivudine 150 mg twice daily|
75745873|NCT05780203|Behavioral|Active Cognitive Bias Modification training|Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
75897090|NCT02127294|Device|transcatheter patent foreman ovale closure|
75601716|NCT01288976|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
75897091|NCT04328506|Drug|CM082 tablet (test product)|Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals
76063939|NCT04756882|Drug|AbobotulinumtoxinA 500 UNT|"Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes"
76063940|NCT04756492|Drug|sandimmun|follow up for treatment response
76072199|NCT02822092|Drug|Risperidone or Aripiprazole (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
75601717|NCT01288976|Drug|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
75745874|NCT05769322|Device|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
75745875|NCT05765669|Procedure|Percutaneous transiliac - transsacral screw fixation|Surgical intervention in the form of percutaneous transiliac - transsacral screw fixation
75745876|NCT05765669|Other|Pain management and physical therapy|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
75745877|NCT05764395|Drug|Rigosertib|Given by mouth
75745878|NCT05764395|Biological|Pembrolizumab|Given by IV
75897092|NCT04328506|Drug|CM082 tablet (reference product)|Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
75897093|NCT03530930|Drug|Comarum Palustre|Comarum Palustre tablets 500 mg BID, 1 month
75897094|NCT02125812|Other|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
75897095|NCT02125812|Other|scaling and root planing|scaling and root planing
75897096|NCT01473199|Device|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
75897097|NCT02125890|Drug|Tranexamic Acid|two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
75897098|NCT03530774|Dietary Supplement|powdered egg white protein supplement|consumption of egg white protein supplement daily for 6 months
76063941|NCT02271256|Device|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
76063942|NCT01894126|Behavioral|Two-way SMS Dialogue|
76063943|NCT01894126|Behavioral|One-way SMS Messaging|
75745879|NCT05764395|Procedure|Magnetic Resonance Imaging|Undergo MRI
75897099|NCT03530774|Dietary Supplement|maltodextrin supplement|consumption of maltodextrin supplement daily for 6 months
75601718|NCT01288976|Procedure|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
76063944|NCT02267512|Drug|ATG-F|Intravenous (IV)
75450524|NCT01707810|Procedure|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
75601719|NCT05187169|Drug|VS-6766|Dual RAF/MEK inhibitor
75601720|NCT02863081|Other|Survey|Administered to healthcare providers
75897100|NCT05132764|Procedure|Microosteoperforations|2 inter radicular bone microosteoperforations using temporary anchorage device tip.
75897101|NCT03551418|Behavioral|Watching a video|Watching a video of an adult with DS washing his hands
75897102|NCT05287984|Drug|Zanubrutinib, Fludarabine, cyclophosphamide and rituximab|Patients aged 65 years or younger who can tolerate FCR.
75897103|NCT05287984|Drug|Zanubrutinib, bendamustine, rituximab|For patients older than 65 years or who cannot tolerate FCR regimens.
75897104|NCT05132608|Other|Social media-based Health education program|The social media-based health education program consist of 16 minute PNC video in Nepali language guided by Health Belief Model. The video provided general information on postnatal care including frequency, timing, and place providing postnatal care; danger signs of mother and newborn; different services provided at each PNC visit, and the importance of PNC visit. The researcher sent PNC videos through instant messaging (IM) software applications such as Viber, What's App, and Facebook messenger to the intervention group.
75450525|NCT01707810|Procedure|conventional method|
75450526|NCT01707823|Drug|acetylsalicylic acid|Given PO
75450527|NCT01707823|Other|laboratory biomarker analysis|Correlative studies
75450528|NCT01707849|Drug|EVL arm|Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.
75450529|NCT01707849|Drug|MMF arm|Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
75450530|NCT01707875|Other|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
75601721|NCT02863081|Other|interview|Administered to patients and LAR (i.e., interviews)
75745880|NCT05764395|Procedure|Biospecimen Collection|Undergo blood sample collection
75745881|NCT05764395|Procedure|Biopsy|Undergo tissue biopsy
75745882|NCT05763888|Other|No drug will given|No intervention will be given to the subject
75745883|NCT05763186|Other|Sampling|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
75897105|NCT00134264|Drug|torcetrapib/atorvastatin|
75897106|NCT00134264|Drug|atorvastatin|
75897107|NCT02122614|Behavioral|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
75897108|NCT02122614|Behavioral|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
75897109|NCT05285800|Drug|0.5% Hyperbaric Bupivacaine|In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
76072200|NCT02816021|Drug|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
75450531|NCT01707888|Procedure|Thoracoscopy/VATS|Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
75450532|NCT01707901|Drug|ONO-8539|Treatment
75745884|NCT05763186|Other|Sampling and rinsing|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
75745885|NCT05758571|Drug|EGCG|EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
75745886|NCT05756842|Dietary Supplement|Honey-based gel supplementation|70 g/day of a honey-based gel divided into 2 equal doses of 35 gr (in the morning and evening) for a total duration of 14 days
75745887|NCT05755113|Drug|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
75897110|NCT02122692|Drug|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
75745888|NCT05753462|Drug|Phase 1, SQY51|SQY51 is administered by intravenous infusion.
75897111|NCT02122692|Drug|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
75450533|NCT01707901|Other|Placebo|Placebo
75897112|NCT02122692|Drug|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
75897113|NCT03627247|Behavioral|Cognitive Behavioral Stress Management|Interactive activities (e.g., role-playing, use of physical props to introduce concepts related to coping and stress) were designed for each class to optimize participant engagement and understanding of the course material while tailoring class content to the stressors commonly reported by participants. Each week, participants were given coping and relaxation skills to practice at home (e.g., cognitive reappraisal, diaphragmatic breathing) and were asked to record their experiences on an activity log that was collected and discussed in class the following week. Course content was taught from a detailed training manual (Urizar & Kofman, 2012).
75897114|NCT05285722|Behavioral|Cognitive Behavioral Therapy form for dental anxiety|Message to Dentist form
75897115|NCT02122848|Device|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
75897116|NCT05707039|Other|Open kinetic chain exercises|In open chain exercises extremities are free to move and there is no weight bearing.
75897117|NCT05707039|Other|Closed kinetic chain exercises|In closed kinetic chain exercises extremities are fixed and weight bearing is done.
75897118|NCT04270786|Procedure|Early de-escalation|In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.
75897119|NCT04270786|Procedure|Standard|In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.
75897120|NCT05132530|Behavioral|yoga|yoga practice will be done two days a week for 10 weeks.
75897121|NCT02126046|Genetic|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
75745889|NCT05753462|Drug|Phase 2a, SQY51 (cohort 1)|SQY51 is administered by intravenous infusion at dose 1
75745890|NCT05753462|Drug|Phase 2a, SQY51 (cohort 2)|SQY51 is administered by intravenous infusion at dose 2.
75897122|NCT05132452|Diagnostic Test|The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)|Participants swallowed one cracker for the TOMASS. They swallowed 150 mL of water for the TWST.
75450534|NCT01707914|Dietary Supplement|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
75450535|NCT01707914|Dietary Supplement|placebo|
75745891|NCT05753462|Drug|Phase 2a, SQY51 (cohort 3)|SQY51 is administered by intravenous infusion at dose 3.
75745892|NCT05735262|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
75745893|NCT05735262|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
75897123|NCT02127606|Device|Vibration with tilt-table standing|
75897124|NCT05284630|Other|Exercise follow up with mobile application|Exercises will be followed by mobile application. Electrotherapy will be performed.
75450536|NCT01707940|Drug|Ketoconazole|Ketoconazole 400 mg / day
75450537|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
75450538|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
75450539|NCT01707953|Drug|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
75450540|NCT01707953|Drug|Placebo|Placebo capsule to mimic midodrine
75450541|NCT01707966|Drug|Orteronel|
75450542|NCT01707966|Drug|Placebo|
75745894|NCT05735171|Procedure|GTR surgery|Gross total resection of the enhancing tumor volume
75745895|NCT05735171|Procedure|AI-guided surgery|Supramarginal resection including high-risk areas of recurrence
75745896|NCT05733273|Other|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
75745897|NCT05733273|Other|Single leg bridge exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
75745898|NCT05733273|Other|Hamstring razor curl|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
75745899|NCT05727371|Combination Product|Regen Matrix-PRP-XLHA|Single intra-articular injection at Day 0
75897125|NCT05284630|Other|Home-Based Exercise Program followed by paper booklet|Exercise will be followed by paper booklet. Electrotherapy will be performed.
75897126|NCT05284630|Procedure|Electrotherapy|Electrotherapy will be performed.
75897127|NCT00131924|Biological|esterified estrogens|
75897128|NCT02126124|Device|Sham Treatment|In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
75897129|NCT02126124|Device|Active dTMS Treatment|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
75897130|NCT05284474|Diagnostic Test|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF)|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF) will be incorporated to the management of early-onset small fetuses (estimated fetal weight ≤10th percentile)
75897131|NCT05223361|Drug|Six percent hydroxy ethyl starch 130/0.4|6% HES 130/0.4 additive to ringer lactate as prime solution
75897132|NCT05223361|Drug|Ringer lactate|Ringer lactate as prime solution
75897133|NCT05223283|Other||
75450543|NCT01708005|Drug|Lecitone®Se-Vitamin D3|"Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study."
75450544|NCT01708005|Drug|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
75601722|NCT02862925|Procedure|Fetal Scalp Stimulation|"During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention."
75601723|NCT00629473|Drug|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
75897134|NCT05132218|Drug|Ensatinib|Prospective, exploratory, single-arm, multi-center, real-world research
75897135|NCT05405816|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy for obesity
75745900|NCT05727371|Device|Hylan G-F 20|Single intra-articular injection at Day 0
75745901|NCT05727371|Drug|Placebo|Single intra-articular injection at Day 0
75897136|NCT05609695|Drug|Immune checkpoint inhibitor|After signing the written informed consent form, patients begin to receive single or combined therapy with immune checkpoint inhibitor. The use of immune checkpoint inhibitors takes 3 weeks as a cycle, and the treatment dose for each cycle is carried out in accordance with the latest international authoritative guidelines.
75897137|NCT05624515|Device|dry needling|Active trigger point puncture of the angularis scapulae muscle
75745902|NCT05727293|Other|noting|Non intervention
75769229|NCT01251562|Drug|Sterile Compound C31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
75897138|NCT05624515|Other|Ischaemic compression|Ischaemic compression at the active trigger point of the angularis scapulae muscle
75897139|NCT05609539|Device|Endovascular Aortic Repair (EVAR)|"Techniques for delivery and deployment of the standard device have been well described by different papers, but for the prototype some attention is required.~Once the device was advanced at the level of the lowest RA the C-Arm has been moved to correct the parallax effect and positioned orthogonally to the origin of the artery. This procedure permits perfectly matching the scallop with the artery takeoff.~A selective angiogram was performed to assure the patency of the lower RA. After the deployment of the main body proper iliac extensions were delivered to completely exclude the aneurysm as standard practice."
75897140|NCT04246060|Drug|Cysteamine Bitartrate|ERT
76072201|NCT02816021|Drug|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
75897141|NCT05599633|Dietary Supplement|Sago starch drink|Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
75601724|NCT00629473|Drug|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
75450545|NCT01708018|Procedure|WATSU|"WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.~The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.~During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4)."
75601725|NCT00629473|Drug|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
75601726|NCT04286503|Drug|Carrimycin|Carrimycin
75745903|NCT05715255|Behavioral|Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)|Participants randomized to the adaptive intervention are telephoned weekly and asked to enter by pin-pad or voice the severity of the PRO-CTCAE items on a 0-4 scale, with 0 being none and 4 being very severe. Participants are mailed the Symptom Management and Survivorship Handbook in their preferred language (English or Spanish). Survivors who rated any item at moderate or higher (2-4) will be referred by the ATSM to read the corresponding chapters in the Handbook and given a call back in 24 hours to inquire about the severity of the reported symptom, whether it has improved or worsened, and whether the participant reported it to their HCP, or the HCP has contacted the survivor. Participants that report elevated symptoms for two consecutive weeks are rerandomized to continue the ATSM alone or continue the ATSM with TIP-C added for 8 weeks. TIP-C is delivered by a masters prepared counselor with cancer expertise via weekly 30-minute phone calls using interpersonal techniques.
75745904|NCT05715255|Behavioral|Active control comparator|Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe.
75601727|NCT04286503|Drug|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
75745905|NCT05714306|Biological|PEP-DC1|PEP-DC1 vaccine comprises autologous dendritic cells pulsed with personalized peptides detected or predicted a priori (using our current integrated antigen identification methodologies).
75745906|NCT05714306|Biological|OC-DC|OC-DC vaccine is an autologous dendritic cell vaccine loaded with autologous oxidized tumor lysate.
75601728|NCT04286503|Drug|basic treatment|basic treatment
75601729|NCT00970489|Drug|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
75745907|NCT05714306|Biological|PEP-DC2|PEP-DC2 comprises autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC.
75745908|NCT05714306|Drug|Low dose cyclophosphamide|Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
75745909|NCT05706259|Dietary Supplement|Soft gelatin 200000 IU vitamin D3 capsule|Weekly single dose for 3-weeks
75897142|NCT05599633|Dietary Supplement|Corn starch drink|Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
76072202|NCT02789956|Device|Internal vs. external cad cam co/cr framework|
75450546|NCT01708031|Other|physiological signals|
75745910|NCT05706259|Dietary Supplement|Orodispersible (sachet) 200000 IU vitamin D3|Weekly single dose for 3-weeks
76072203|NCT02779751|Drug|Abemaciclib|Administered orally
75450547|NCT01708044|Drug|Pramlintide acetate|
75450548|NCT01708044|Other|Placebo|Placebo Comparator
75601730|NCT00970489|Drug|Placebo|Olive Oil capsules
75601731|NCT00968617|Drug|MK2578|MK2578 1.0 mcg/kg/month
75601732|NCT00968617|Drug|MK2578|MK2578 2.0 mcg/kg/month
75601733|NCT00968617|Drug|MK2578|MK2578 3.6 mcg/kg/month
75601734|NCT00968617|Drug|Comparator: darbepoetin alfa|darbepoetin alfa
75601735|NCT00968539|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
75601736|NCT00968539|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
75601737|NCT00976573|Biological|bevacizumab|Given IV
75601738|NCT00976573|Drug|carboplatin|Given IV
75897143|NCT05132062|Procedure|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention is a catheter based technique widely used to restore coronary vessel patency. It is performed by fluoroscopic guidance and it requires the use of iodinated contrast medium. The use of iodinated contrast media has been historically linked to AKI occurring within days after their administration and typically referred to as CA-AKI. Furthermore, CA-AKI has been associated with long-term impairment of kidney function, need for renal replacement therapy, and subsequent all-cause mortality.
75897144|NCT04141852|Device|Implantation of VasQ device|"The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow."
75897145|NCT05656261|Genetic|Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys|On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.
75897146|NCT05283460|Behavioral|mandala|The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
75897147|NCT05129176|Drug|Levofloxacin|levofloxacin-tetracycline-containing quadruple regimens
75897148|NCT05129176|Drug|Metronidazole|Metronidazole-tetracycline-containing quadruple regimens
76063945|NCT01928602|Behavioral|TherAppy Language App|Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, & adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
75450549|NCT01708070|Behavioral|Asthma self-management|Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
76063946|NCT01928602|Behavioral|Mind-Games|A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
75745911|NCT05704374|Diagnostic Test|sympathetic stimulation maneuver (mental arithmetic test, cold pressure test)|Mental arithmetic calculation and cold pressure increase sympathetic tone. For the mental arithmetic task, the subject is asked to mentally subtract a two-digit number from a four-digit number and respond within 5 seconds. This arithmetic calculation is repeated for different numbers. This test is continued for three minutes. For the cold pressure test, subjects are asked to immerse their right hand in 2-4 degrees cold water up to the elbow and hold it in the water for three minutes. The mental arithmetic task and cold stress test will be applied simultaneously.
75745912|NCT05704374|Drug|Pregabalin 150mg|In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to FMS patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes.
75897149|NCT02127684|Drug|ranibizumab|ranibizumab 0.3mg intravitreally monthly
76063947|NCT01536951|Drug|LY3009104|administered orally
75897150|NCT02127684|Drug|ranibizumab|ranibizumab given every 2 weeks for 8 weeks then monthly as needed
75450550|NCT01708096|Dietary Supplement|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
75450551|NCT01708096|Dietary Supplement|Normal diet|normal diet 2 weeks before gastric by-pass
75601739|NCT00976573|Drug|everolimus|Given orally
75601740|NCT00976573|Drug|paclitaxel|Given IV
75897151|NCT05091658|Device|LH Urine Test|Test for qualitative detection of LH in urine
75897152|NCT05706571|Other|control group (skill laboratory), experimental group 1 (Banner model) and experimental group2 (augmented reality mobile application)|In the research, the control group will form the control group of both experiment one and experiment two. In the creation of quantitative and qualitative data, it will be formed in three groups, two of which are the experimental group and one is the control group. While forming the experimental and control groups of the research, it is planned to ensure homogeneity between the groups by making random and unbiased selection. It is planned to do a pre-test before applying the child patient end-of-life care module of nursing students of teaching with augmented reality and Benner model to the experimental and control groups.
75897153|NCT02126202|Procedure|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
75897154|NCT04066816|Other|Walnuts|Participants will consume 2 ounces of walnuts for 21 days
75897155|NCT02126280|Other|In vitro estimation of individual reactivity of monocytes|Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
75897156|NCT02127762|Behavioral|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
75897157|NCT02126358|Drug|Gemigliptin and/or Rosuvastatin|
75897158|NCT05088382|Device|LH Urine Test|Test for the qualitative measurement of LH in urine
76063948|NCT01536951|Drug|Placebo|Administered orally
75897159|NCT02127840|Drug|Synacthen infusion during adrenal venous sampling|Adrenal venous sampling during Synacthen infusion
75450552|NCT01708109|Other|no measures taken to clear bile ductus|biliary calculus remain
75450553|NCT01708109|Procedure|clearance of bile ductus|biliary calculus removed at surgery
75450554|NCT01708135|Behavioral|Use of smartphone app|
75450555|NCT01708148|Dietary Supplement|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
75897160|NCT05066074|Procedure|Distal Radial Vascular Access|Distal Radial Vascular Access
75897161|NCT02126436|Other|Acupuncture|"Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:~using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks."
75897162|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
75897163|NCT02131116|Behavioral|Integrated Metacognitive Therapy|Integrated Metacognitive Therapy
75450556|NCT01708148|Other|Placebo|control group would receive a oral lactose placebo
75450557|NCT01708200|Other|Memory Intervention|A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
75601741|NCT00629863|Drug|cisplatin|
75601742|NCT00629863|Drug|fluorouracil|
76063949|NCT01536951|Drug|moxifloxacin|Administered orally
76063950|NCT02259322|Behavioral|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
76063951|NCT02259322|Behavioral|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
76063952|NCT02259322|Behavioral|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
75601743|NCT00629863|Other|questionnaire administration|
75601744|NCT00629863|Procedure|diagnostic endoscopic procedure|
75601745|NCT00629863|Procedure|neoadjuvant therapy|
75601746|NCT00629863|Procedure|quality-of-life assessment|
75601747|NCT00629863|Procedure|therapeutic conventional surgery|
75601748|NCT00629863|Procedure|therapeutic endoscopic surgery|
75601749|NCT00629863|Procedure|ultrasound imaging|
75601750|NCT00629863|Radiation|radiation therapy|
75601751|NCT00629863|Radiation|radioisotope therapy|
75601752|NCT02865733|Drug|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
75897164|NCT02131116|Behavioral|Treatment as Usual|Treatment as Usual
75745913|NCT05704192|Procedure|TACE ± Systemic therapy|TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
75745914|NCT05704166|Drug|Pirfenidone/Placebo|Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
75745915|NCT05703750|Procedure|TACE ± Systemic therapy|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); Systemic therapy: PD-1/PD-L1 inhibitors, VEGF-TKI/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
75897165|NCT05031442|Device|RH1 (low waist)|Investigational product variant 1 low waist
75897166|NCT05031442|Device|Reference variant 1 (low waist)|Reference product variant 1
75897167|NCT05031442|Device|RC2 (high waist)|Investigational product variant 2 high waist
75897168|NCT05031442|Device|Reference variant 2 (high waist)|Reference product variant 2
75897169|NCT03527888|Drug|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
75745916|NCT05703724|Device|AI algorithm for the detection of glaucoma|The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
75897170|NCT02131194|Dietary Supplement|Lenstatin|Dietary Supplement Lenstatin
75897171|NCT02131194|Drug|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
75897172|NCT04820920|Behavioral|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postnatal mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
75745917|NCT05701709|Drug|SHR-A2102|SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.
75897173|NCT04820920|Behavioral|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
75897174|NCT04820920|Behavioral|Psychoeducation|This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions.
75897175|NCT02127918|Drug|ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
75897176|NCT00127634|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months, up to 36 months
75897177|NCT00127634|Drug|Injectable Insulin|patient specific dose, injectable, before meals, 24 months, up to 36 months.
75897178|NCT00127634|Drug|Insulin Glargine|patient specific dose, injectable, as needed, 24 months up to 36 months
75745918|NCT05696171|Procedure|Cochlear implant manual insertion|Manual insertion of the cochlear implant into the round window during the surgery
75897179|NCT03550638|Device|Coil system(Ton-bridgeMT)|1. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
75897180|NCT03550638|Device|Axium Detachable Coil(Medtronic)|2. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
75745919|NCT05696171|Procedure|Cochlear implant robotized insertion|Robotic insertion of the cochlear implant into the round window during the surgery
75745920|NCT05690256|Behavioral|Resilience Clinic|A psychoeducational caregiver-child intervention based in primary care, designed to mitigate toxic stress and promote child resilience. Participants engage in 6 weekly visits in primary care using an interactive curriculum based in the evidence-based Circle of Security Parenting along with mindfulness principles.
75745921|NCT05690256|Behavioral|Enhanced primary care|In addition to usual pediatric primary care, enhanced primary care (the control condition for this study) provides navigational services to link to community resources based on screening for unmet social needs (e.g., food insecurity, housing, financial strain).
75897181|NCT04730050|Drug|TT-01025-CL|Oral tablet
75897182|NCT03550560|Procedure|EUS-Guided drainage|Drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses.
75897183|NCT03528122|Procedure|Recurrent opened macular hole|pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
75897184|NCT02126514|Drug|AZD3293|7 subjects will receive AZD3293
75897185|NCT04720222|Device|TENA-PROTO1|Each volunteer will test the TENA-PROTO1 according to a standardized protocol in multiple postural positions to evaluate the detectability of the bladder by help of the investigational device
75897186|NCT05060926|Procedure|Awake prone positioning|Awake prone position as long as possible according to the patients' tolerance
75601753|NCT02865733|Drug|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
75745922|NCT05685472|Biological|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
75745923|NCT05683483|Other|WEsleep Interventions|1) Postponing morning nursing rounds to avoid waking patients early and daily assessment of sleep quality by the nurse during morning rounds; 2) Implementing sleep promoting interventions, including optimization of medication and iv fluid timing; 3) Education for health care professionals on sleep; 4) Implementing sleep rounds and change department infrastructure; including 'sleep menu' where patients can choose from earplugs, eye masks, and warm socks. Implement blackout curtains depending on baseline light intensity.
75897187|NCT02127996|Drug|GLP-1|GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
75897188|NCT02127996|Drug|placebo|Normal saline
75897189|NCT03551106|Other|Web based learning module|Web based learning module available on a especially designed website
75897190|NCT00126776|Behavioral|case management|case/self management for COPD vs usual care
75897191|NCT00126776|Behavioral|usual care|usual care for COPD
75897192|NCT02131350|Procedure|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
75601754|NCT00976495|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
75745924|NCT05680558|Drug|UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis|Extracorporeal Photopheresis (ECP)
75745925|NCT05680558|Device|THERAKOS® CELLEX photopheresis system|THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
75745926|NCT05679180|Device|micropulse laser|treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
75897193|NCT02131350|Drug|Ranibizumab|
76063953|NCT01536795|Drug|WR279,396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
76063954|NCT01536795|Drug|WR 279,396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
75897194|NCT02128308|Drug|Levofloxacin and Streptomycin added|
75897195|NCT02128308|Drug|Moxifloxacin and Kanamycin added|
75897196|NCT02131506|Drug|Lapatinib, Caelyx|Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq & Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq & Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq & Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq & Lapatinib 1500 mg die
75897197|NCT01674010|Drug|ELND005|
75897198|NCT01674010|Drug|Lamotrigine|
75897199|NCT01674010|Drug|Valproic acid|
76072204|NCT02779751|Drug|Pembrolizumab|Administered IV
76072205|NCT02779751|Drug|Anastrozole|Administered orally
76072206|NCT02774746|Other|35-week delivery|Induction at 35 weeks gestational age
76072207|NCT02774746|Other|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
76072208|NCT02774148|Drug|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
75601755|NCT00976495|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
75601756|NCT00976495|Drug|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
75601757|NCT00630019|Drug|1.5% levofloxacin ophthalmic solution|Topical application
75601758|NCT00630019|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
75601759|NCT01288430|Drug|DS-2248|Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
75897200|NCT01674010|Drug|Placebo|
75897201|NCT02131740|Other|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest & eye rubbing for a further 1 minute.
75897202|NCT02131740|Other|No eye rubbing|This eye will not be rubbed
75897203|NCT03551340|Diagnostic Test|Gastro-intestinal panel by PCR|The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
75897204|NCT02252328|Drug|Simvastatin|Simvastatin 80mg once daily
75897205|NCT02252328|Drug|Placebo|Placebo tablets once daily
76063955|NCT04767633|Drug|split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing|The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
76063956|NCT01894750|Behavioral|group-based skill building self-care program|
75450558|NCT01708226|Behavioral|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
75450559|NCT01708239|Other|Left rule, D-dimer measurement and complete ultrasonography in pregnant women.|Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
75450560|NCT01708252|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75745927|NCT05678127|Procedure|Skin biopsy|"Two 3mm skin biopsies from the abdominal wall will be taken. One at the triggerpoint of the pain, the second one at the contralateral, non-affected side of the abdominal wall.~Lidocaine will be used for local anaesthesia of the skin, before the biopsies will be taken."
75897206|NCT05392400|Device|Steri3X|This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the Steri3X wound dressing will have the liquid polymer applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s).
75897207|NCT05392400|Other|Control|"Device: Steri3X~This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the control wound dressing will have the current standard of care dressing applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s)."
75897208|NCT05388968|Biological|Metatranscriptomic|Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling
75897209|NCT05388968|Diagnostic Test|Specific microbiologic diagnosis|If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
75897210|NCT02135952|Procedure|SRP|SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.
75897211|NCT02135952|Other|Placebo|Administration of placebo for 14 days started immediately after the first session of SRP.
75897212|NCT02135952|Drug|MTZ+AMX|Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
76063957|NCT01894828|Dietary Supplement|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
76072209|NCT02774148|Drug|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
75450561|NCT01708265|Other|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
75450562|NCT01708265|Procedure|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
75601760|NCT02889848|Other|Saline|Saline injection
75601761|NCT02889848|Drug|EN3835|Comparison of maximum marketed dose and multiple doses EN3835
75897213|NCT05387096|Other|Definitive multi-faceted intervention consisting of several components|The definitive intervention will consist of the following components: structured history of medication (SHiM), Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) screening for PIMs and PPOs, drug-drug and drug-disease interactions screening, face-to-face consultation with attending hospital physicians to discuss PIMs, PPOs, interactions and other issues, pre-discharge medication review and adjustment, detailed medication adjustment discharge report to patients' general practitioners (GPs), post-discharge follow-up contact with patients' GPs and community pharmacists at 1 week, 1 month and 6 months post -discharge. The interventions will be applied by a trained physician or pharmacist.
75897214|NCT05387096|Other|Sham Intervention|Sham intervention in the form of the modified Medication Adherence Rating Scale (MARS) questionnaire in addition to standard care.
75897215|NCT04656964|Drug|remimazolam tosilate group|Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).
75897216|NCT04656964|Drug|Midazolam group|Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
75897217|NCT02136030|Drug|Liposomal amphotericin B|4mg/kg/day, IV infusion
75450563|NCT01708304|Behavioral|RDAD|Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.
75450564|NCT01708330|Drug|Lidocaine|2% Lidocaine gel
75450565|NCT01708330|Drug|Placebo gel|odorless, colorless gel will be used as a placebo
75450566|NCT01708343|Procedure|DIMMST|
75601762|NCT01287416|Behavioral|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
76063958|NCT05585554|Radiation|MRIdian|Stereotactic MRI-guided On-table Adaptive Radiation Therapy delivered on MRIdian linac
75450567|NCT01708356|Behavioral|Cycling on a residential route|
75450568|NCT01708369|Drug|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
75450569|NCT01708369|Drug|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
75450570|NCT01708369|Drug|Oseltamivir|Oseltamivir 150 mg orally
75450571|NCT01708369|Drug|Aspirin|Aspirin 650 mg orally will be given
75450572|NCT01708382|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75601763|NCT01287416|Behavioral|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
75601764|NCT05660252|Other|Collaborative request|The relative is approached by the clinical team and an organ procurement coordinator together.
75601765|NCT00998296|Drug|BIBW 2992|EGFR inhibitor
75897218|NCT02136030|Drug|Amphotericin B-deoxycholate|1mg/kg/day, IV infusion
75897219|NCT04468178|Device|Total joint arthroplasty of the glenohumeral joint|The arthroplasty of the glenohumeral joint will be performed as an anatomical reconstruction after primary or post-traumatic osteoarthritis.
75897220|NCT02136108|Other|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
75897221|NCT02136108|Other|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
76063959|NCT05583760|Procedure|Experimental: Osteopathic manipulation TUG for scaphoid bone|The sequence of execution of the scaphoid TUG technique shall be applied as follows. Patient in the supine position. The inner hand of the intervener makes contact with the pisiform through the hypothenar eminence and ulnar border of the hand over the scaphoid tubercle, the outer hand reinforces the contact. The thumbs are directed to the sole of the patient's foot. The parameters are sought by bringing the sole of the foot into eversion, thus bringing the scaphoid into internal rotation (the direction of correction). In order to reduce the slack, the operator drops his body weight backwards while increasing the internal rotation parameter of the scaphoid. The manipulation is performed by associating a rapid traction movement with an increase of the correction parameter towards the internal rotation of the scaphoid.
76072210|NCT02771197|Drug|Fludarabine|
76072211|NCT02771197|Drug|Melphalan|
76072212|NCT02771197|Drug|Pembrolizumab|
75450573|NCT01708434|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin
75450574|NCT01708447|Drug|L.M.X.4.® cream|A lidocaine topical anesthetic cream
75450575|NCT01708447|Other|A placebo cream|Placebo cream containing no anesthetic properties.
75601766|NCT00998296|Drug|BIBF 1120|VEGF inhibitor
75601767|NCT01178073|Drug|ambrisentan|ambrisentan (target dose: 10mg)
75601768|NCT01178073|Drug|tadalafil|tadalafil (target dose: 40mg)
75601769|NCT00997984|Drug|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
75601770|NCT00997984|Drug|placebo|dosed in the AM or PM
75601771|NCT00997984|Drug|extended-release guanfacine hydrochloride|Dosed in the PM
75601772|NCT04206111|Procedure|Preoxygenation|preoxygenation with high flow nasal cannula at 40l/min for 5min
75601773|NCT01177293|Drug|Amlodipine - reference|Amlodipine capsule, 10 mg, single dose, with water
75897222|NCT02131818|Drug|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
75897223|NCT02131818|Drug|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
75601774|NCT01177293|Drug|Amlodipine ODT - test|Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
75897224|NCT05171920|Drug|Auxora|All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA
75897225|NCT05171920|Drug|Placebo|Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
75897226|NCT04467398|Procedure|trigeminal nerve block|Trigeminal nerve or branch block using 22 gauge Quincke or Tuohy needle under fluoroscopic guidance.
75897227|NCT02131896|Other|Interventional arm-Mediterranean diet|
75897228|NCT02131896|Other|Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines|
75897229|NCT04636138|Other|Exercise|Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.
75897230|NCT03525626|Behavioral|Online Mindfulness-based Tic Reduction|8-week online group mindfulness-based intervention for tics
75897231|NCT04605796|Combination Product|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
75450576|NCT01708447|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75450577|NCT01708460|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
75601775|NCT01177137|Device|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
75601776|NCT01177137|Device|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
75450578|NCT01708473|Drug|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
75450579|NCT01708473|Drug|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
75450580|NCT01708473|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75450581|NCT01708499|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75450582|NCT01708512|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75745928|NCT05668728|Other|Group 1: Peppering|Before injection we will palpate the muscles of trapezius, m. rhomboideus, m. levator scapula for finding painful trigger points, and we will mark the point. the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. The needle will be inserted and removed until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
75769230|NCT01251640|Drug|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
75769231|NCT00257166|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
75897232|NCT02252640|Biological|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
75897233|NCT02252640|Biological|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
75897234|NCT02252640|Biological|ChAd63 ME-TRAP (5 x 10^10 vp)|
75897235|NCT02252640|Biological|MVA ME-TRAP (2 x 10^8 pfu)|
75897236|NCT04534660|Device|SMI-01|SMI-01 is a device consisting of silk particles in a hydrogel carrier.
75897237|NCT01345669|Drug|Placebo|Once daily
75897238|NCT01345669|Drug|Afatinib|Once daily
75897239|NCT05334212|Device|Surgical Theater|The surgical theater platform uses data from MRI and CT scans, creating a 3d image that can be seen by the patient.
75897240|NCT02136186|Device|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
75450583|NCT01708564|Biological|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
75450584|NCT01708577|Device|Validation of the IPANEMA - measurement system|Control of the body conditions under real life conditions during a sportive activity.
75450585|NCT01708616|Drug|RO5285119|multiple doses
75450586|NCT01708616|Drug|RO5285119 placebo|multiple doses
75450587|NCT01708616|Drug|risperidone|single dose
75450588|NCT01708616|Drug|risperidone placebo|single dose
75450589|NCT01708642|Drug|Adrenaline|Adrenaline infusion 0.05 microgram / kg / minute
75601777|NCT01177137|Behavioral|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
75745929|NCT05668728|Other|group 2: spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapula will be identified and marked by palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the dry needle is inserted at each point found, it will be spinned counterclockwise and left. Waiting time for each patient will be limited to 15 minutes. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
75897241|NCT05144464|Biological|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
75897242|NCT02128464|Procedure|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
75897243|NCT02128464|Procedure|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
75897244|NCT04313608|Drug|Glofitamab|Participants will receive intravenous (IV) glofitamab in combination with gemcitabine and oxaliplatin for up to 8 cycles, followed by up to 4 cycles of glofitamab monotherapy.
75897245|NCT04313608|Drug|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
75897246|NCT04313608|Drug|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
75897247|NCT04313608|Drug|Mosunetuzumab|Participants will receive IV mosunetuzumab in combination with gemcitabine and oxaliplatin for up to 8 cycles.
75897248|NCT04313608|Drug|Obinutuzumab|Participants will receive a single dose of IV obinutuzumab 7 days prior to the first administration of glofitamab.
75897249|NCT04313608|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
75897250|NCT05314088|Behavioral|RISE+|The intervention includes psychoeducational videos and written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience.
75897251|NCT05314088|Behavioral|Stress Reduction Control|Placebo Comparator: Stress Reduction Control Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games.
75897252|NCT02136264|Other|PCFA interventional dietary counselling|
75897253|NCT02136264|Other|conventional DASH diet counselling|
75897254|NCT04466774|Diagnostic Test|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures six urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
75897255|NCT04466774|Device|Urine analysis predicate device for professional user|Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user.
75897256|NCT03767166|Device|Biodegradable biliary and pancreatic stents placement|Biodegradable biliary and pancreatic stents placement
75897257|NCT04552418|Drug|Potato starch|Starting 5-7 days before treatment with dual-ICI, participant will consume 20g of potato starch (Bob's Red Mill®) once a day for 3 days, then increase to 20g twice a day, continuing throughout dual-ICI treatment (total duration approximately 13 weeks).
75897258|NCT02136342|Drug|chlorogenic acid|
75450590|NCT01708642|Drug|Placebo|Intraoperative isotonic saline infusion as placebo for adrenaline.
75450591|NCT01708655|Other|Sweat Evaporimeter measurement|"The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.~intracutaneous injection of 0.2 ml of atropine~Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:~Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.~intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion~intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .~The procedure would take about 45 minutes."
75450592|NCT01708668|Procedure|Epidural analgesia|
75450593|NCT01708668|Procedure|Combined spinal-epidural analgesia|
75450594|NCT01708668|Procedure|Continuous epidural infusion|
75450595|NCT01708668|Procedure|Intermittent epidural bolus|
75897259|NCT04502264|Device|Hand of Hope|A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
75897260|NCT04502264|Drug|Botulinum toxin type A injection|A safe agent representing the gold standard treatment for focal spasticity.
75897261|NCT05222503|Device|Knee Brace + OPUM Digital Knee|Knee Brace + OPUM Digital Knee
76072213|NCT02722421|Drug|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
75450596|NCT01708681|Dietary Supplement|Lean seafood|
75450597|NCT01708681|Dietary Supplement|Meat, egg, milk|
75897262|NCT05222503|Device|Knee Brace|Knee Brace without OPUM Digital Knee
75897263|NCT05222347|Dietary Supplement|Olive Leaf Tea|Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently [22, 23]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects [24, 25]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .
75897264|NCT02128620|Behavioral|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
75601778|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
75745930|NCT05668728|Other|group 3: Peppering and spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapul will be identified and marked with palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the needle is inserted and removed, it will be spinned counterclockwise for 15 minutes in each patient until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program. With this method, dry needling will be applied to the patient 4 times a week, once a week.
75745931|NCT05668221|Behavioral|Prehabilitation|Prehabilitation includes exercise prescription, cognitive function assessment and training, nutritional optimisation at least 4 weeks prior to surgery
75745932|NCT05667324|Drug|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)
75897265|NCT05530603|Behavioral|Educational mobile app|7 day educational course to educate American Indian women to receive regular mammogram.
75897266|NCT05521867|Device|Endoscopic balloon dilation|EBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them.
76072214|NCT02722421|Drug|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
75450598|NCT01708694|Dietary Supplement|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
75450599|NCT01708694|Dietary Supplement|Amylopectin|"The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months."
75450600|NCT01708707|Drug|Buprenorphine|"The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days."
75745933|NCT05667324|Drug|Dexamethasone|Plus 4 mg dexamethasone
75601779|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
75601780|NCT02886429|Drug|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
75745934|NCT05667324|Drug|Placebo|A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)
75745935|NCT05663242|Drug|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
75745936|NCT05663242|Drug|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
75745937|NCT05661851|Drug|Investigational Lubricating Eye Drop in a Novelia® bottle|Investigational Product
76025170|NCT02811887|Other|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
76072215|NCT02693184|Other|Full length Block 2014 Food Frequency Questionnaire|The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
75450601|NCT01708707|Drug|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
75601781|NCT02886429|Drug|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
75745938|NCT05661851|Drug|Blink® Tears eye Drops|Control Product
75745939|NCT05656521|Drug|101-PGC-005|'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
75745940|NCT05656521|Drug|Dexamethasone|Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
75745941|NCT05650086|Device|Thermalytix|One-time Thermal imaging is performed for this cohort.
75745942|NCT05646511|Radiation|SCRT|5x5 Gy: 25 Gy
75745943|NCT05646511|Drug|CAPOX|Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
75745944|NCT05646511|Drug|CAPOXIRI|Six cycles of CAPOX capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 200 mg/m2 intravenously on day 1, every 3 weeks)
75745945|NCT05644184|Biological|Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)|Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.
75450602|NCT01708720|Drug|IPV|
75450603|NCT01708720|Drug|Sabin-IPV|
75601782|NCT01177059|Genetic|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
75601783|NCT04315779|Procedure|Salpingectomy|Patients will undergo removal of the affected tube
75745946|NCT05644184|Biological|Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
75745947|NCT05644041|Drug|Gemcitabine|Gemcitabine will be administered intravesically at a dose of 2000 mg.
75745948|NCT05641207|Device|RheOx™ with the RheOx™ Catheter treated in the trial|"Eligible patients will be assigned to two sessions of treatments with RheOx~Treatment 1 is scheduled at right lung at the first treatment.~And then approximately one month later, treatment 2 is delivered to left lung at the second treatment."
75745949|NCT05633992|Biological|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
75745950|NCT05633992|Biological|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
75745951|NCT05630430|Procedure|The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures|Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
75450604|NCT01708720|Drug|Adjuvanted Sabin-IPV|
75450605|NCT01708733|Drug|KSY|Chinese herbal formula
75450606|NCT01708785|Behavioral|Single food Cue Exposure Treatment|Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
75450607|NCT01708785|Behavioral|Multiple food Cue Exposure Treatment|Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
75450608|NCT01708785|Behavioral|Partial Reinforcement - Enhanced Cue Exposure Treatment|Subjects will take random additional tastes of the food during cue exposure treatment.
75450609|NCT01708785|Behavioral|Partial Reinforcement -Consistent Cue Exposure Treatment|Subjects will consistently take the same tastes of the food during cue exposure treatment.
75450610|NCT01708798|Drug|Eplerenone|
75450611|NCT01708798|Drug|Placebo|
75450612|NCT01708824|Behavioral|Dietary|"Dietary intervention to meet the target of~<5 servings of red/processed meat weekly; <2 servings would be processed meat~2 servings of refined grains daily"
75601784|NCT01176513|Drug|GE-148 (18F)|All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
75601785|NCT01299389|Drug|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
75897267|NCT05521867|Device|Endoscopic stricturotomy with or without stricturoplasty|Endoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist.
75897268|NCT03550482|Dietary Supplement|ONCOXIN®|Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI <20 and serum albumin levels <30 g/l received nutritional support.
75897269|NCT03527732|Drug|Albendazole|Monotherapy of albendazole (400 mg)
75897270|NCT03527732|Drug|Albendazole and Ivermectin|Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
75897273|NCT03550326|Procedure|airway management|patients will be intubated or will be placed an airway device
75897274|NCT01673854|Drug|Ipilimumab|
75897275|NCT01673854|Biological|Vemurafenib|
76063960|NCT05583760|Procedure|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|The intervention will be performed in the same way as the intervention group, without actually performing the TUG manipulation on the scaphoid bone, only placing it in tension.
76063961|NCT01928914|Drug|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
76063962|NCT01928914|Drug|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
76063963|NCT01928914|Drug|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
76063964|NCT01928914|Drug|moxifloxacin|moxifloxacine given on Day 3 only
76063965|NCT01928914|Drug|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
75450613|NCT01708824|Behavioral|Physical activity|"Physical activity intervention with the following targets:~General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
75450614|NCT01708837|Drug|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
75450615|NCT01708850|Drug|Rivaroxaban|All specified in arm description. One arm study.
75450616|NCT01708876|Drug|Artesunate-mefloquine|
75450617|NCT01708876|Drug|Chloroquine|
75450618|NCT01708876|Drug|Primaquine|Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
76063966|NCT01928914|Drug|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
76063967|NCT02249104|Drug|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Topical AV therapy
75745952|NCT05628623|Drug|Cytarabine|Arm A: CBF-Cytarabine 3000 mg/m2 or 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3
75601786|NCT01299389|Drug|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
75745953|NCT05628623|Drug|Venetoclax|Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28
75745954|NCT05628623|Drug|CPX-351|Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3
75745955|NCT05628623|Drug|Azacitidine|Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference)
75450619|NCT01708889|Biological|BMS-914143 (Peginterferon Lambda-1a)|
75601787|NCT02886351|Drug|Nitrous Oxide|Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
75745956|NCT05622006|Behavioral|Sedentary breaks|Interrupting sitting with different frequencies of walking/jogging at moderate intensity.
75745957|NCT05616923|Drug|Trametinib|Topical cream containing 0.1 mg/g trametinib
75745958|NCT05614921|Other|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side
75745959|NCT05614921|Other|Wound infiltration|5 ml local anesthetic for each trocar side
75745960|NCT05612932|Other|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
75745961|NCT05612932|Other|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
75450620|NCT01708928|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75450621|NCT01708980|Other|Six different strength training exercises|"Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.~The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for."
75601788|NCT02890667|Other|Incident cancer|The number of incident cancer cases
75745962|NCT05608200|Drug|Lenvatinib, sintilimab plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
75601789|NCT01298999|Drug|YF476|25 mg: one capsule to be taken by mouth once daily for 12 weeks.
75601790|NCT01298999|Drug|Placebo|Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
75601791|NCT04324541|Diagnostic Test|PET scan of the brain with Flortaucipir|PET scan of the brain with non FDA approved Radio tracer.
75601792|NCT01007032|Biological|Cixutumumab|Cixutumumab intravenously
75601793|NCT00976027|Biological|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
75601794|NCT00976027|Biological|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
75601795|NCT01298765|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
75601796|NCT04296214|Drug|5-azacitidine|Cycles of 28 days
75745963|NCT05608200|Drug|Lenvatinib plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
76063968|NCT02249104|Other|Cetaphil Acne Regimen|Cleanse, Moisturize, and Protect
75897276|NCT05514301|Diagnostic Test|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|"Both diagnostic interventions will be performed in all patients~High definition colonoscopy performed by high experienced endoscopists blinded to Polydeep.~Polydeep: a CADe and CADx system. The gold standard will be the histological diagnosis of the lesion."
75745964|NCT05606692|Drug|Propofol 1%|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
75745965|NCT05606692|Drug|Sevoflurane/Ultane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
75897277|NCT03550248|Behavioral|Healthy Together|The Healthy Together (HT) program is designed to reduce overweight and obesity among children and youth in priority populations such as Indigenous, immigrant and refugee, and low income families.The HT program consists of 30 sessions, each of which includes cooking and eating together, physical activity and a learning activity covering topics that promote healthy weights. The HT program is delivered by trained facilitators who are provided with a program manual and resources. Trained facilitators in participating community organizations offer the HT program by integrating it within core programming.
75897278|NCT02136654|Behavioral|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
75897279|NCT03525470|Biological|Water|150 mil of water was drunk on two occasions
76063969|NCT01928992|Device|3D|subjects that underwent 3D mammography
75601797|NCT04296370|Drug|Fluzoparib; Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily
75601798|NCT04296370|Drug|Fluzoparib|Fluzoparib Orally twice daily
75601799|NCT04296370|Drug|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine Vinorelbine"
75745966|NCT05606614|Genetic|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
75745967|NCT05602688|Dietary Supplement|Lemon Balm Supplement|Oral 200 mg Lemon Balm supplement tablet Twice a day for three-weeks
75745968|NCT05602688|Dietary Supplement|Matched Placebo|Matched placebo tablet Twice a day for three-weeks
75745969|NCT05601336|Drug|Dapagliflozin 5 MG|SGLT2 inhibitor
75897280|NCT03525470|Other|No drink|Although body weight lost no drink consumed
75897281|NCT02804152|Behavioral|CBT for Chronic Pain in Pregnancy|"The content will be included in 8 weekly sessions, i.e., sessions 1-3 (Education on chronic pain, Theories of pain and diaphragmatic breathing and Progressive muscle relaxation and visual imagery), sessions 4 and 5 (Automatic thoughts and pain and Cognitive restructuring), sessions 7, 8 and 10 (Pleasant activity scheduling, Time-based pacing and Sleep hygiene), sessions 6 and 9 (Stress management and Anger management). Following this content, 1-2 sessions will be dedicated to review and reinforcement of key concepts or addressing any stuck points as well as cover content in session 11 (Relapse Prevention). The last session of therapy would include a review of achievements and commitment to continued application of CBT for chronic pain in participants daily lives."
75897282|NCT03549702|Drug|Povidone iodine 1% solution|irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
76063970|NCT01928992|Device|2D|those subjects that underwent 2D mammography
75450622|NCT01709006|Radiation|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
75450623|NCT01709019|Biological|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
75450624|NCT01709019|Biological|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
75450625|NCT01709019|Biological|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
75450626|NCT01709019|Biological|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
75601800|NCT02870296|Behavioral|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
75745970|NCT05601336|Drug|Metformin Hydrochloride 1000 MG|metformin
75745971|NCT05601336|Drug|Dapagliflozin/Metformin|SGLT2 inhibitor and metformin HCl extended-release
75769232|NCT00257166|Drug|placebo oral capsules|Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
75769233|NCT03912142|Diagnostic Test|three dimensional Transperineal Ultrasound Scan|Diagnostic test: three dimensional transperineal ultrasound scan
76063971|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
76063972|NCT01929538|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
75450627|NCT01709019|Biological|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
75897283|NCT02136732|Other|Active self-management intervention|Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.
75450628|NCT01709058|Drug|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
75450629|NCT01709058|Other|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
75897284|NCT02136732|Other|Attention control phone calls|Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
75601801|NCT04204720|Device|needle (Chiba)|intravascular injection using chiba needle during caudal epidural block
75897285|NCT03550950|Drug|JNJ-64232025 IV|JNJ-64232025 will be administered as IV infusion.
75897286|NCT03550950|Drug|JNJ-64232025 SC|JNJ-64232025 will be administered as SC injection.
75897287|NCT03550950|Drug|Placebo|Matching placebo will be administered as IV infusion or SC injection.
76063973|NCT01929538|Device|covered self-expanding biliary metal stent, 12mm in diameter|
75450630|NCT01709071|Drug|IPV|
75450631|NCT01709071|Drug|Low dose Sabin-IPV|
75450632|NCT01709071|Drug|Low dose adjuvanted Sabin-IPV|
75897288|NCT01343407|Drug|MK-1029 10 mg|Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
75897289|NCT01343407|Drug|MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
75450633|NCT01709071|Drug|Middle dose Sabin-IPV|
75450634|NCT01709071|Drug|Middle dose adjuvanted Sabin-IPV|
75450635|NCT01709071|Drug|High dose Sabin-IPV|
75450636|NCT01709071|Drug|High dose adjuvanted Sabin-IPV|
75601802|NCT04204720|Device|needle (Whitacre)|intravascular injection using whitacre needle during caudal epidural block
75897290|NCT01343407|Drug|Placebo for MK-1029 10 mg|"Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design."
75897291|NCT01343407|Drug|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
75897292|NCT02529904|Biological|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
76063974|NCT01929538|Device|covered self-expanding biliary metal stent, 10mm in diameter|
76063975|NCT04389736|Behavioral|Sitting|Participants sat in a chair with back, arms and legs supported.
76063976|NCT04389736|Behavioral|Standing|Participants were asked to stand with arms supported and feet spaced approximately 15 cm apart. If needed, adjustment of standing posture was allowed during standing trial to prevent orthostatic hypotension.
76072216|NCT02693184|Other|Revised Calcium, Vitamin D and Protein Screener|The food list includes 29 food items and 5 supplements
76072217|NCT02676349|Drug|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
75897293|NCT01367886|Drug|fesoterodine|Fesoterodine 4 mg. tablet by mouth daily for six weeks
75601803|NCT04285333|Procedure|fascia iliaca block|ultrasound guided block with 20 mL lidocaine 1.5%
75450637|NCT01709175|Behavioral|Strength Training|This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
75601804|NCT04285333|Procedure|percapsular nerve group block|ultrasound guided block with 20 mL lidocaine 1.5%
75601805|NCT00997438|Dietary Supplement|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
75745972|NCT05599672|Behavioral|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment. ABI-MTM includes 5 core elements. A common duration for medication counseling in outpatient pharmacies a single 30-45 minute session. These include a medication review, a personal medication record, a medication action plan, a brief motivational intervention, and documentation and follow up.
75897294|NCT04442594|Procedure|virtual reality session|"The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation."
75897295|NCT05706415|Diagnostic Test|Clinicians will review the suggestions of a hypothetical AI|There is no intervention. Clinicians will review the suggestions of a hypothetical AI
75897296|NCT02128698|Dietary Supplement|Protein|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
75897297|NCT02128698|Dietary Supplement|Placebo|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
75897298|NCT02128698|Behavioral|Computer-assisted exercise|Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.
75450638|NCT01709188|Behavioral|Musical Dual Task Training|
75450639|NCT01709188|Behavioral|Walking and Talking|
75450640|NCT01709201|Behavioral|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
75450641|NCT01709240|Device|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
75601806|NCT00997126|Drug|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
75601807|NCT00997126|Drug|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
75601808|NCT01000636|Procedure|Metvix PDT|"Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.~The target field will then be exposed to red light using Aktilite 128 lamp."
75601809|NCT00965419|Drug|Edivoxetine|0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
75745973|NCT05599672|Behavioral|Standard medication counseling|Standard Medication Counseling (SMC) will be the treatment as usual condition in this study and was chosen/developed following Gold et al.'s guide for selecting control conditions in behavioral intervention studies. For the first component, all SMC participants will receive a single 5-10 minute medication information/counseling session delivered by a pharmacist, other than the study pharmacist, that possesses a similar level of education and professional licensing. The content of this session follows federal and state pharmacy requirements requiring pharmacists to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids.
75745974|NCT05599243|Drug|Dutasteride|The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).
75745975|NCT05599243|Other|Placebo|Vehicle excipient
75769234|NCT03914092|Drug|triamcinolone acetonide injection|,1 mm percutaneous intralesional injection
75601810|NCT04433494|Drug|TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg|TY-302 is taken orally. Tamoxifen is taken orally.
75601811|NCT01000480|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
75601812|NCT01000480|Drug|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
75745976|NCT05597228|Behavioral|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
75745977|NCT05594576|Procedure|GI GENIUS™ artificial intelligence system|Device used during coloscopy for detection of colonic adenoma
75745978|NCT05594576|Procedure|ENDOCUFF VISION® endoscopic cap|Device used during coloscopy for detection of colonic adenoma
75745979|NCT05594264|Behavioral|HBPStories|A 6-week web-based study. Systolic blood pressure, diastolic blood pressure, and medication adherence will be measured at baseline and 6-weeks.
75450642|NCT01709253|Radiation|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
75450643|NCT01709266|Dietary Supplement|Probiotics|
75450644|NCT01709266|Dietary Supplement|Placebo|
75450645|NCT01709279|Biological|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
75450646|NCT01709344|Behavioral|PS-OT|
75769235|NCT03914092|Behavioral|Smith Accent method of voice therapy|regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
75450647|NCT01709344|Other|Usual care|Supportive and rehabilitation services available at DHMC
75450648|NCT01709357|Other|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
75601813|NCT01000480|Radiation|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
76063977|NCT04389736|Behavioral|Self-selected maximal intensity of neuromuscular electrical stimulation|Small electrodes placed (5*5 cm) on the lower limb of both legs. The instruction for NMES intensity was that the maximal intensity participants were be able to withstand for 2 hours whilst imagining sitting at home watching TV without feeling discomfort.
76063978|NCT04395040|Other|Semi-structured interview|Semi-structured interview
75601814|NCT02862691|Drug|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
75601815|NCT02862691|Drug|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
75450649|NCT01709357|Other|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
75897299|NCT02128698|Behavioral|Usual exercise|Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
75601816|NCT02871388|Behavioral|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
75601817|NCT00965341|Drug|Testosterone|Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
75601818|NCT00965341|Drug|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
75601819|NCT01175811|Drug|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
75601820|NCT01175811|Drug|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
75745980|NCT05592210|Other|Questionnaires|Participants will be asked to fill out the the Demographic Information Sheet, Karitane parenting confidence scale, Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU) and Dyadic Coping Inventory.
75745981|NCT05587855|Other|E-group|Participants with Hypertension will be assigned to eCulinary medicine
75601821|NCT01175811|Drug|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
75601822|NCT04293952|Other|Balance, Resistance, Aerobic, Cognition Exercises (BRACE)|BRACE is a combination of different exercises including Balance, Resistance, Aerobic, Cognition for fall risk reduction and to mobility in the elderly.
75745982|NCT05580666|Drug|Azithromycin Oral Tablet|Antimicrobial therapy
75897300|NCT04060420|Other|Comprehensive sexual and reproductive health services|The intervention includes community-based and peer-led delivery of comprehensive sexual and reproductive health services and a Yathu Yathu prevention points card, which is a card that adolescents and young people can use to gain points for accessing services and use these points to redeem rewards.
75601823|NCT04293952|Other|Balance Resistance Exercise (BRE)|this is the simple conventional treatment for the elderly in balance problems including warm-up, resistance exercises and cool-down exercises.
75897301|NCT05706337|Drug|Propofol|Propofol 1-2mg / kg was for anesthesia induction. Propofol is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus.
75601824|NCT00965263|Biological|Cocaine vaccine (TA-CD)|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
75601825|NCT02869594|Other|Data collection|
75601826|NCT03642691|Biological|Ryplazim|Plasminogen IV replacement therapy
75745983|NCT05580666|Drug|Placebo oral tablet|Inert ingredients
75769236|NCT03905824|Biological|Allogenic stromal mesenchymal cells derived from the umbilical cord|Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus
75769237|NCT03905824|Procedure|Debridement and microfracture|Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
76063979|NCT01929070|Drug|HCP1007|
76063980|NCT01929070|Drug|Omarco and Crestor|
76063981|NCT01536561|Biological|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
76063982|NCT02243020|Device|Vagus Nerve Stimulation (VNS)|
76072218|NCT02676349|Radiation|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
76063983|NCT01929148|Procedure|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
75897302|NCT05706337|Drug|Ciprofol|Ciprofol 0.2～0.5mg/kg was for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid return of consciousness, minimal residual effects on the central nervous system and less injection pain.
75769238|NCT03913936|Other|YES portal|The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician
75769239|NCT03913858|Procedure|Obesity Surgery with Low-Flow Anesthesia|Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.
75769240|NCT03913858|Procedure|Obesity Surgery with High-Flow Anesthesia|Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.
75897303|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
75897304|NCT01613560|Drug|AI+chemotherapy adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
75897305|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
75897306|NCT05222113|Drug|Remdesivir|The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.
75897307|NCT03854578|Drug|BI 1358894|Film-coated tablet
75897308|NCT03854578|Drug|Placebo matching BI 1358894|Film-coated tablet
75897309|NCT03854578|Drug|Citalopram|Film-coated tablet
75897310|NCT03550014|Procedure|Low Back Only|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
75897311|NCT03550014|Procedure|Low Back+Hip|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
75897312|NCT03627325|Other|Patients who are scheduled for any surgical procedure|looking for correlation for estimating the complications between the anesthesiologists and the computerized method.
75897313|NCT03038594|Drug|Somatropin|
76063984|NCT01929148|Procedure|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
76063985|NCT02236312|Drug|Botulinum Toxin Type A|
75450650|NCT01709357|Other|Ischemic compression technique|"The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds."
75769241|NCT01148602|Other|LED stopwatch-clock timers|"We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation."
75897314|NCT03038594|Drug|0.09% Saline Solution|
75897315|NCT05138302|Other|Observation|This study is an observe research
75897316|NCT05222035|Drug|Camrelizumab|PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
75897317|NCT05222035|Drug|G-CSF|G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
75897318|NCT02136888|Drug|Ponesimod Placebo|
75897319|NCT02136888|Drug|Moxifloxacin Placebo|
76063986|NCT02236312|Drug|Placebo|
76063987|NCT01916278|Device|Emervel Lips Lidocaine|
75769242|NCT01254682|Device|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
75897320|NCT02136888|Drug|Ponesimod 10 mg|
75769243|NCT01254682|Procedure|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
75897321|NCT02136888|Drug|Ponesimod 20 mg|
76063988|NCT01916278|Device|Juvéderma Volbella with Lidocaine|
76063989|NCT03084640|Drug|CMP-001|CMP-001 will be administered SC as per the dose and schedule specified in the respective arms.
76063990|NCT03084640|Drug|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
76063991|NCT03084640|Drug|CMP-001|CMP-001 will be administered IT as per the dose and schedule specified in the respective arms.
76063992|NCT01536405|Biological|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
76063993|NCT01536405|Biological|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
76063994|NCT01892410|Other|Cetaphil Restoraderm Skin Restoring Body Wash|Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
76063995|NCT04409691|Drug|prednison and Sirolimus|If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
75769244|NCT05570188|Biological|anti-CD19 UCAR-NK cells|"Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells:~Dose level one: 5-10×10^6/kg; Dose level two:1-2×10^7/kg; Dose level three:2-5×10^7/kg."
76063996|NCT04409691|Drug|prednison|Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.
76063997|NCT01887808|Other|Cetaphil DermaControl Oil Control Moisturizer SPF 30|
75897322|NCT02136888|Drug|Ponesimod 40 mg|
75897323|NCT02136888|Drug|Ponesimod 60 mg|
76063998|NCT04096989|Other|Traditional Chinese medicine regimen-based lifestyle mobile health APP|The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.
76063999|NCT04096989|Other|Lifestyle mobile health APP|Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
76064000|NCT02219776|Drug|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
76064001|NCT02219776|Other|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
76072219|NCT02676349|Procedure|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
75450651|NCT01709357|Other|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
75450652|NCT01709370|Drug|Letrozole, PD 0332991|
75450653|NCT01709396|Radiation|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
75450654|NCT01709487|Procedure|HIPEC|HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
75450655|NCT01709526|Behavioral|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
75897324|NCT02136888|Drug|Ponesimod 80 mg|
75897325|NCT02136888|Drug|Ponesimod 100 mg|
75897326|NCT02136888|Drug|Moxifloxacin 400 mg|
75897327|NCT04465994|Procedure|gastrocnemius turn-down flaps|We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
75897328|NCT05488951|Other|Otago Exercise Program|The Otago Exercise Program will be led by a physical therapist in a group setting (5-7 participants/exercise class). The exercise will be 20 min of walking and 30 min of strength and balance exercises (i.e., 50 min exercise class) 3x/week for 6 months. The physical therapist will select suitable exercises for each participant, such that the exercise is individualized and progressive.
75897329|NCT02128776|Other|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
75897330|NCT02128776|Other|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
75897331|NCT02132286|Drug|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
75897332|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
75450656|NCT01709552|Behavioral|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
75897333|NCT03627169|Device|MATRx plus|The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
75897334|NCT01673698|Device|ReShape Duo balloon|
75897335|NCT01673698|Other|Diet counseling|
75897336|NCT01673698|Other|Exercise counseling|
75897337|NCT05706103|Behavioral|Specific skilled motor training|Participants allocated to the skilled motor training group will receive sensorimotor training of the intrinsic muscles of the lumbopelvic region, namely the multifidus, transversus abdominis, and pelvic floor muscles.
75897338|NCT05706103|Behavioral|General extension training|Participants allocated to the general extension training group will receive general training exercises using the David Back equipment from the Back Unit at Ghent University Hospital
76064002|NCT04756960|Drug|CHF6001|4 inhalations of CHF6001 800µg/20mg NEXThaler® DPI (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5kBq)) of [14C]-labelled CHF6001
76072220|NCT02676349|Drug|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
75450657|NCT01709552|Behavioral|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
75450658|NCT01709591|Behavioral|Prenatal education|
75450659|NCT01709604|Procedure|CVVH|Ultrafiltration at 35ml/h/Kg
75450660|NCT01709604|Procedure|Standardized therapy regimens|"Standardized therapy regimens included the followings:~Remove all contaminated clothing~Gastric lavage~Receive activated charcoal as quickly as possible~Hemoperfusion with activated charcoal(160g)~Immunosuppression with methylprednisolone~Antioxidants (glutathione,1.2 gram iv twice a day)~Supportive care"
75897339|NCT02136966|Other|MNP + IYCN counseling + cooking demonstrations|Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
75897340|NCT05225090|Other|Smartphone App|"Medisafe is a Med_App that is free and has been used in several studies evaluating medication adherence. Patients will receive individualized instruction and be followed for 12 weeks. The researcher will show the patients how to input current medication list, set up medication reminders and track if daily doses have been taken using the App (20 minute training session). After the participant has input their medication information into the app, the researcher will assist the participant in adding an optional Medifriend who will be alerted if the participant misses a dose as an option. The participant will also be provided with written instructions about the Medisafe app to take home for reference. At each office visit (4, 8, and 12 weeks) participants will complete a medication checklist and reconciliation form with the research staff. Participants will also be asked to send a medication status report through the Medisafe app."
75897341|NCT02128854|Behavioral|Tablets Intervention|The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
75897342|NCT03522818|Behavioral|Manual Trigger|Will use the alarm as provided by the manufacture but parent has to manual trigger the alarm 1-2 hours after the child falls asleep.
75897343|NCT03522818|Behavioral|Normal|Will use the alarm as provided by the manufacture.
75897344|NCT05706025|Device|EnteroTracker|The EnteroTracker® is a capsule device that includes an absorbent string.
75450661|NCT01709617|Dietary Supplement|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
75897345|NCT05039008|Other|Blood flow restriction|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, at the same time. The intervention will last 4 weeks, with a periodicity of 3 weekly sessions. In total there will be 12 sessions that will last between 15 and 30 minutes depending on the number of joints affected.
75897346|NCT03525236|Other|Tasting of flavours|"Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
75897347|NCT02137044|Behavioral|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
75897348|NCT05032846|Procedure|Ultrasound guided laparoscopic ovarian cystectomy|Laparoscopic ovarian cystectomy to be performed under intra-operative ultrasound guidance.
75897349|NCT05032846|Other|Laparoscopic Ovarian Cystectomy|Laparoscopic Ovarian Cystectomy will be performed as standard clinical practice.
75601827|NCT04206189|Dietary Supplement|carbohydrate group - carbohydrate (400ml)|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery according to the standard protocol.
75897350|NCT03548246|Drug|Abiraterone acetate|Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.
75897351|NCT03548246|Drug|Placebo|Daily placebo for 2 years.
75897352|NCT03548246|Drug|Hydrocortisone|Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
75897353|NCT03548246|Drug|Fludrocortisone|Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.
75897354|NCT05705869|Diagnostic Test|NT-proBNP|NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
75897355|NCT02132442|Dietary Supplement|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
76064003|NCT01487265|Drug|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
76064004|NCT01516606|Drug|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
75450662|NCT01709630|Drug|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
75450663|NCT01709643|Dietary Supplement|High fat breakfast|"The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands)."
75450664|NCT01709643|Dietary Supplement|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
75450665|NCT01709656|Biological|MSC|"human mesenchymal stem cells,1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up."
75450666|NCT01709656|Drug|"celecoxib, Celebrex®"|"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"
75897356|NCT03522662|Drug|GSK1070806|Single 10mg/kg infusion on Day 0
75897357|NCT05010148|Drug|Lidocaine IV|Intravenous lidocaine will be given at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery
75897358|NCT05010148|Drug|Placebo|D5 water given at an equivalent ml/hr as intravenous lidocaine (treatment arm) for 48 hours following major spinal surgery
75601828|NCT04283695|Drug|GX-I7 or [14C] GX-I7|IM GX-I7 or IV/IM microdose of GX-I7
75450667|NCT01709682|Drug|Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)|propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
75450668|NCT01709682|Procedure|re-ablation procedure|Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
75450669|NCT01709682|Procedure|ILR implantation|"The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events."
75450670|NCT01709760|Drug|Methotrexate|Methotrexate 15-25 mg/week
75450671|NCT01709760|Drug|ENIA11|ENIA11 25 mg, sc twice weekly
75745984|NCT05560737|Behavioral|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consists of:~Automated digital counselling resources (educational pages, videos, tools, and trackers)~Chatrooms available 24/7~Weekly 30-minute presentations and discussions led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4 and 8, and study completion (up to 16 months)."
75745985|NCT05556889|Procedure|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
76064005|NCT04389970|Behavioral|Time Restricted Feeding|Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
76064006|NCT01485627|Behavioral|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
75450672|NCT01709760|Drug|Placebo|Placebo, sc twice weekly
76064007|NCT02209636|Drug|Lanthanum carbonate|Non-calcium containing phosphorus binder
75450673|NCT01709773|Procedure|Focal treatment|Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
75450674|NCT01709812|Other|individualized patient support program|individualized patient support with compliance supporting tools
75450675|NCT01709812|Other|Standard care|
75450676|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium Bifidum|Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
75450677|NCT01709825|Dietary Supplement|Sugar Pill|Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
75450678|NCT01709825|Dietary Supplement|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
75450679|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
75450680|NCT01709851|Device|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
75450681|NCT01709851|Device|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
75450682|NCT01709877|Procedure|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
75450683|NCT01709890|Device|YO2(R) catheter|
75450684|NCT01709929|Drug|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
75601829|NCT02886195|Drug|pemetrexed|500mg/m2 ivgtt d1, per three weeks
75601830|NCT02886195|Drug|cisplatin|80mg/m2 ivgtt d1, per three weeks
75601831|NCT02886195|Drug|Erlotinib|150mg po. every day
75601832|NCT04267783|Diagnostic Test|Shear wave elastography|Investigate the feasibility of use of shear-wave elastography of the uterus during the third stage of labour and following placental delivery in order to predict uterine atony .
76064008|NCT02209636|Drug|placebo|Table identical to lanthanum carbonate but with no active ingredient
76064009|NCT02209636|Drug|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
76064010|NCT02209636|Drug|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
75897359|NCT03550872|Behavioral|Physical Training|Participants will perform physical training three times a week on a stationary bicycle. The exercise intensity will be controlled between 14 and 16 by the Borg Scale for 40 minutes
76064011|NCT02209636|Procedure|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
76064012|NCT02209636|Procedure|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
76064013|NCT02209636|Procedure|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
76064014|NCT01515904|Behavioral|STOMP Clinic|"A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions."
76064015|NCT01508325|Drug|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was >=90 mmHg measured every 4 weeks.
75450685|NCT01709942|Drug|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
75601833|NCT05331963|Other|Kinesio Taping|Kinesio tape is designed in a specific way that it mimics the human skin nature. It more or less has the same width as the epidermis layer and can be stretched upto 40% of its resting length.Clinically, kinesio tape (KT) is used both alone and with other physiotherapeutic interventions, mainly for the pain control, to reduce inflammation, and to improve functional activity in patients with shoulder pain
75450686|NCT01709942|Drug|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were >300pg/ml
75601834|NCT02862769|Drug|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
75601835|NCT02862769|Drug|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
75601836|NCT00965185|Drug|atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
75450687|NCT01709955|Dietary Supplement|Glucomannan|750 MG of Glucomannan in capsule form
75601837|NCT00965185|Drug|Placebo|Placebo
75601838|NCT01174563|Drug|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
75601839|NCT02861599|Other|proprioceptive therapy|
75450688|NCT01709955|Other|Placebo|750 mg of Cellulose powder in a capsule form
75450689|NCT01709968|Drug|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
75450690|NCT01709968|Drug|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
75450691|NCT01709994|Drug|Aspirin|100 mg/day of aspirin
75450692|NCT01710059|Behavioral|Asthma Supervision|Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
75450693|NCT01710059|Behavioral|Mobile Phone|Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
75450694|NCT01710059|Behavioral|Inhaled Corticosteroid Mobile Phone Application|The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
75601840|NCT02861599|Other|speech therapy|
75601841|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
75601842|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
75601843|NCT01298531|Drug|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
76064016|NCT01508325|Drug|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was >=140 mmHg and/or DBP was >=90 mmHg measured every 4 weeks.
76064017|NCT01514344|Drug|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
75450695|NCT01710059|Behavioral|Beta2-adrenergic agonist Mobile Phone Application|The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
75450696|NCT01710072|Drug|aspirin|
75450697|NCT01710085|Device|Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011|Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
75450698|NCT01710098|Drug|Degarelix|subcutaneous injection
75601844|NCT02862145|Drug|MRX34|Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
75745986|NCT05556889|Procedure|Traditional auriculotemporal nerve blockade|Traditional auriculotemporal nerve blockade
75897360|NCT03525158|Behavioral|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
75897361|NCT05007028|Drug|EMONO|Exposure to 1 hour of EMONO via facial mask
75897362|NCT05007028|Drug|Medical Air|Exposure to 1 hour of Medical Air via facial mask
76064018|NCT01514344|Biological|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
76064019|NCT01508169|Device|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
76064020|NCT01536171|Other|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
76064021|NCT01536093|Other|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
76064022|NCT01536093|Other|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
76064023|NCT02191930|Drug|B-CAP|
75450699|NCT01710111|Device|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
75450700|NCT01710124|Other|Financial incentives|
75601845|NCT02862145|Drug|Dexamethasone|Premedication during the week of treatment
76064024|NCT02191930|Drug|Brentuximab Vedotin|
76064025|NCT01536015|Drug|Rotigotine|"Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours~Dosage and Frequency: One patch every 24 hours~Duration: 10 weeks"
75601846|NCT04284709|Other|cognitive-physical training|combined physical and cognitive training
76064026|NCT01536015|Drug|Placebo|"Frequency: One patch applied every 24 hours~Duration: 10 weeks"
75450701|NCT01710150|Procedure|CTI ablation alone|
75745987|NCT05545501|Dietary Supplement|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
76064027|NCT04725825|Other|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
75601847|NCT01174173|Drug|Ranolazine|ranolazine 1000 mg PO BID for 3 months
75601848|NCT02862379|Behavioral|home-based program|The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
75601849|NCT04315623|Procedure|Regional citrate anticoagulation CRRT|Regional citrate anticoagulation Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
75601850|NCT04315623|Procedure|No-anticoagulation CRRT|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
75745988|NCT05545501|Dietary Supplement|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
75897363|NCT03549936|Other|Low lactose or regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B."
75450702|NCT01710150|Procedure|CTI ablation and Pulmonary vein isolation (PVI)|
75450703|NCT01710163|Drug|Lithium|Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
75450704|NCT01710163|Drug|Aripiprazole|Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
76064028|NCT04725825|Other|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
75897364|NCT05381935|Drug|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
75450705|NCT01710189|Drug|TicoVac|Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
75450706|NCT01710202|Drug|Hydrocortisone|Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
75897365|NCT05381935|Drug|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
75601851|NCT05281653|Behavioral|Neuromuscular exercise Training|Progressive neuromuscular exercise training
75897366|NCT04467632|Other|Validation of the mobility assessment by IMU wearable sensors|"The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3.~It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale.~The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4."
75897367|NCT04467632|Other|Testing in real-life conditions at patients' home in a small group of subjects|"Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines.~B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity)."
76064029|NCT03028077|Dietary Supplement|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
75450707|NCT01710215|Other|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
75601852|NCT05281653|Behavioral|Routine training sessions|Routine training sessions
75601853|NCT05661071|Other|Modified Mini Mental Test:|To assess the cognitive function of children
75601854|NCT05661071|Other|The Controlled Oral Word Association Test|To assess the cognitive function of children
75601855|NCT05661071|Other|The Central Nervous System Vital Signs|To assess the cognitive function of children
75601856|NCT05661071|Other|Conners' Parent Rating Scale-48 (Parent Report)|To assess attention-deficit/hyperactivity disorder
76064030|NCT03028077|Dietary Supplement|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
76064031|NCT03028077|Dietary Supplement|Placebo|Placebo 1 g/day
76064032|NCT01863940|Device|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
76064033|NCT01484691|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
76064034|NCT01464034|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
75450708|NCT01710215|Other|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
75450709|NCT01710228|Drug|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
75897368|NCT04467632|Other|Testing in real-life conditions at patients' home in a small group of subjects|"Intervention phase~Phase A (11 days): subjects will receive one hour of morning and afternoon light exposure twice a day:~Day #1: baseline assessment of outcome measures;~Days #2 to #6: bright light in the morning (active treatment) + dim light in the afternoon (placebo), to progressively advance circadian phase of 30' per day (phase advance of 2.5 hours obtained at day 6);~Days #7 to #11: dim light in the morning + bright light in the afternoon to revert the circadian phase to the baseline of 30' per day.~Washout: 6 days. No intervention during this phase, to stabilise the reverted circadian rhythm to baseline, for phase B to be held at the same conditions as phase A.~Phase B (11 days): similar as in phase A:~Day #1: similar as in phase A;~Days #2 to #6: reverted conditions compared to phase A.~Days #7 to #11: reverted conditions compared to phase A."
75897369|NCT05138146|Drug|609A|"609A 200mg,IV, Day 1of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first.~Every 3 weeks a treatment cycle."
75897370|NCT05138146|Drug|doxorubicin hydrochloride|60mg/m2 or 75mg/m2, IV, Day1of the1-6th treatment cycles only. Every 3 weeks a treatment cycle.
75897371|NCT02252952|Other|Beverage Consumption|
75601857|NCT05661071|Other|Child Behavior Checklist 6-18 ages (Parent Report)|To assesses both child adaptive behaviors and problem behaviors.
75897372|NCT05221957|Drug|Iron(III)isomaltoside|Individual weight and hemoglobin dependent dosage
76064035|NCT01464034|Drug|Pomalidomide|PO daily on Days 1-21, every 28 Days
76064036|NCT01464034|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
75897373|NCT05221879|Other|Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a|We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.
75450710|NCT01710280|Dietary Supplement|High-fat meal containing native palm olein|
75450711|NCT01710280|Dietary Supplement|High-fat meal containing interesterified palm olein|
75450712|NCT01710293|Behavioral|Communication of Patients Lost to Follow-up to Providers|"The investigators will query the VA's database weekly to identify possible lost to follow-up events for a random sample of about half of the providers at our study sites. The queries will use the trigger criteria developed in our previous work for colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, and bladder cancer. The list of trigger positive patients will be transmitted to a facility-level recipient who will either disseminate the information to existing facility individual cancer care coordinators/trackers or will review the charts of the triggered patients in order to determine whether these patients have been truly lost to follow-up or not. If patients are found to be lost to follow-up, the Facility Recipient or cancer care coordinator/tracker will communicate the need for follow-up to the PACT or primary care provider, using secure emails, phone calls, or in person, depending on which method of communication they deem most appropriate and effective."
75450713|NCT01710319|Other|blood draw|a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
75450714|NCT01710371|Drug|18F-AV-133|296 MBq (8 mCi)
75601858|NCT05661071|Other|Strengths and Difficulties Questionnaire (Self-Reported)|It is a brief emotional and behavioural screening questionnaire for children and young people.
75601859|NCT05661071|Other|Brooke Lower Extremity Functional Classification|To determine the functional status of the lower extremity
75601860|NCT05661071|Other|Motor Function Measurement-32 Items|To assessment of motor function and progression of weakness in neuromuscular disorders
75897374|NCT03450772|Drug|Creon® 25000|Experimental drug
75897375|NCT03450772|Drug|Creon® 10000|Active comparator
76064037|NCT01860898|Other|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
76064038|NCT01458730|Drug|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
75450715|NCT01710371|Drug|10% Arginine Hydrochloride-R-Gene 10|
75450716|NCT01710384|Drug|betamethasone|
75450717|NCT01710397|Other|Rapid ART initiation|Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
75601861|NCT05661071|Other|Four Square Step Test|A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
75601862|NCT05661071|Other|Six Minutes Walk Test|It evaluates the walking function and physical capacity of children at the submaximal level.
75601863|NCT05661071|Other|Timed Performance Test|10 meters Walk& Run Test, Gower's(from a supine to a standing position), Right& Left Leg Standing, Ascent/Descent of 4 Steps
75601864|NCT00964795|Drug|Intravitreal Aflibercept Injection 2mg|
76064039|NCT01535235|Drug|Lisinopril|Lisinopril 20mg QD x 24 weeks
76064040|NCT01535235|Drug|Placebo|Placebo QD x24wks
76064041|NCT02985723|Device|AT LISA tri toric 939MP|
76072221|NCT02669810|Drug|PROTHERACYTES|ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
76072222|NCT02669810|Drug|Standard Treatment for CHF post AMI|
76064042|NCT04748211|Procedure|Infraclavicular Block|USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
75601865|NCT01173471|Drug|AZD4017|tablet, oral, one tablet once daily, 28 days
75601866|NCT01173471|Drug|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
75745989|NCT05545501|Dietary Supplement|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
75897376|NCT04083196|Biological|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
75601867|NCT01173471|Drug|AZD4017|tablet, oral 2 tablets twice daily, 28 days
75745993|NCT05541471|Drug|VX-548|Tablets for oral administration.
75897377|NCT04083196|Biological|Placebo|Placebo
75897378|NCT02129088|Drug|Esketamine|Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
75897379|NCT02129088|Drug|Placebo|Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
75450718|NCT01710410|Device|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
75450719|NCT01710410|Device|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
75601868|NCT01173471|Drug|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
75601869|NCT01172847|Drug|oseltamivir [Tamiflu]|multiple oral doses
75601870|NCT01172847|Drug|rimantadine|multiple oral doses
75897380|NCT05280080|Other|Resistance exercise|Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
75897381|NCT05221801|Behavioral|angle of inclination|The measurement would be done in seat inclination angles of 5,15,30,45 degrees.
75897382|NCT05221801|Other|food type|the swallowing was tested with 3 food types
75897383|NCT05137756|Other|no intervention|no intervention
75897384|NCT02137200|Procedure|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
76064043|NCT04748211|Procedure|Interscalen Block|USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
75601871|NCT04285645|Other|Warmup|The intervention through exercises will consist in the application of the protocol described by Waldén et al. The objective of the application of this exercise protocol is to produce an improvement in the stability of the knee and the strength of the quadriceps. Before carrying out the exercises, a continuous race will be carried out for 5 minutes, once this first step is finished we will proceed to the realization of the exercises that will be, squats with both legs placing the hands on the hips, feet placed at the width of the shoulders, lowering with a straight back and without raising the heels of the floor, 3 series of 15 repetitions, squats on one leg with the hands on the hips and leg not supported extended forward, 3 sets of 10 repetitions with each leg and jump forward with one leg with the hands on the hips and jump back to return to the starting position, 3 sets of 10 repetitions with each leg
75601872|NCT00966355|Drug|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
75601873|NCT00966355|Drug|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
75601874|NCT00966355|Drug|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
75745994|NCT05541471|Drug|Midazolam|Syrup for oral administration.
75745995|NCT05541471|Drug|Digoxin|Tablets for oral administration.
75745996|NCT05540405|Dietary Supplement|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
75745997|NCT05540405|Dietary Supplement|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
75745998|NCT05540405|Dietary Supplement|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
75745999|NCT05530772|Device|Endoscopic necrosectomy|Initially, a tract is created between the stomach or duodenum with the walled-off pancreatic necrotic collection through placement of a stent. Then, the endosocpe is entered the necrotic cavity with CO2 insufflation, and the necrotic materials are removed with snare, grasper, or suctioning.
75746000|NCT05525312|Procedure|"Open-lung protective ventilation strategy"|"In the open-lung group, the positive end-tidal pressure (PEEP) is titrated to match the best lung compliance. During a PEEP decrement trial, PEEP is decreased from 20 cmH2O to 4 cmH2O by steps of 2 cmH2O/minute, and the driving the transpulmonary pressure (PTP) is calculated at each level of PEEP. In the open-lung group, the targeted PEEP corresponds to the lowest driving PTP during the PEEP decrement trial, meaning the best lung compliance. Thereafter, the PEEP is set at this level and maintained until extubation."
75746001|NCT05525312|Procedure|"Standard protective ventilation strategy"|"In the standard group, the positive end-tidal pressure (PEEP) is arbitrarily set at 5 cmH2O, since this is the currently recommended level of PEEP, commonly used in control groups of previous clinical trials."
75746002|NCT05504278|Drug|pemetrexed|500mg/m^2, Q3W, day1, i.v.
75746003|NCT05504278|Drug|cis-platinum|75mg/m^2, Q3W, day1, i.v.
76064044|NCT04095429|Behavioral|Expect Respect|Expect Respect is a 24 session curriculum designed to support middle school students to increase skills in emotion regulation, relationship skills, communication, and positive bystander intervention behaviors.
76064045|NCT04095429|Behavioral|Enhanced Usual Care|Participants will be connected via a warm referral to available individual behavioral health supports and resources in their community that can support them.
76064046|NCT02168686|Genetic|ADVM-043|Gene transfer vector administration
76064047|NCT04756336|Drug|LTX-109 gel, 3% w/w|The drug is applied to affected lesions according to treatment regimen
76064048|NCT01456390|Device|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
76064049|NCT02317744|Drug|Naltrexone and bupropion combination|
75450720|NCT01710423|Behavioral|Peer mentoring intervention ('Cooking with Friends')|"'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children."
75450721|NCT01710449|Drug|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
75897385|NCT02137200|Procedure|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
75897386|NCT05705791|Device|QuiremSpheres|166Holmium selective internal intra-arterial radiation therapy at C1D15 of the Atezolizumab and Bevacizumab therapy
75450722|NCT01710462|Drug|Pantoprazole + Domperidone|
75450723|NCT01710462|Drug|Pantozol®|
75601875|NCT02861209|Other|Implementation of a care pathway|The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
75601876|NCT02862301|Biological|blood sample|
75601877|NCT04283305|Other|Virtual reality approach avoidance training|In the VR-based AAT, patients are situated in a bar environment where drinks appear on a bar table in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a controller, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
75746004|NCT05504278|Drug|Sintilimab|200mg, Q3W, day1, i.v.
75746005|NCT05504278|Drug|IBI351|recommended dose, po
75746006|NCT05504278|Drug|carboplatin|AUC=5, Q3W, day1, i.v.
75746007|NCT05500963|Device|Transcutaneous electrical nerve stimulation|Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
75746008|NCT05498792|Drug|CBL0137|Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
75746009|NCT05498792|Drug|Ipilimumab|Patient will be on Ipilimumab (1 mg/kg)
75746010|NCT05498792|Drug|Nivolumab|Patient will be on Nivolumab (3 mg/kg)
75746011|NCT05492214|Procedure|Delayed cord clamping (30s)|The same as that stated in arm descriptions.
76064050|NCT02317744|Other|Pill Placebo|
76064051|NCT02150902|Procedure|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF >10g, FTI > 500 g-sec and minimum ablation duration >10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
76072223|NCT02659241|Drug|Adavosertib|Given PO
75746012|NCT05492214|Procedure|Delayed cord clamping (60s)|The same as that stated in arm descriptions.
75746013|NCT05492214|Procedure|Delayed cord clamping (90s)|The same as that stated in arm descriptions.
75746014|NCT05490134|Drug|Naloxone|A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
76072224|NCT02659241|Other|Laboratory Biomarker Analysis|Correlative studies
76072225|NCT02647385|Drug|Block with lidocaine for SAM and PEC I block|"Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption."
75746015|NCT05490134|Drug|Saline|0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
75746016|NCT05486260|Dietary Supplement|DMB lowest dose|Intake of 150 mg of DMB
75897387|NCT03404362|Procedure|Bone Metastases Pain treatment|Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
76064052|NCT02150902|Procedure|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
75450724|NCT01710488|Drug|Levofloxacin 1 tablet 500 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
75746017|NCT05486260|Dietary Supplement|DMB highest dose|Intake of 300 mg of DMB
75746018|NCT05486260|Dietary Supplement|Strawberry lyophilisate|Intake of 300 mg of strawberry lyophilisate
75746019|NCT05483270|Biological|the timing of embryo transfer in freeze-all cycles|"Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval."
75746020|NCT05476458|Radiation|White Light Imaging|white light imaging is often the preferred option for poem surgery due to its effective results. However, it also comes with some drawbacks that make it difficult to identify areas of bleeding, unlike RDI, WLI cannot enhance the visibility of deep vessels This can lead to longer haemostasis time as the physician must wait for a longer period before stopping the bleeding. This can make it challenging as it may lead to excessive bleeding. This makes RDI a potential solution for those seeking a more accurate approach to treatment.
75746021|NCT05476458|Radiation|Red Light Imaging|Red dichromatic imaging (RDI) is a next-generation image enhancement technique which works by employing green, amber and red wavelengths. Greenlight(520-550nm) can visualize small blood vessels in superficial tissue without extending deep into the mucosa. Amber(595-610nm) and red light (620-640nm) can penetrate deep into the tissue owing to low scattering property. The blood vessels in the deeper tissues absorb the amber light because of strong affinity with hemoglobin. Even though red light can penetrate deep into the tissue, it is weakly absorbed by hemoglobin. Hence the reflected light contains red light and amber light without attenuation.
75897388|NCT05274932|Other|BFR resistance exercise|4 sets (30, 15, 15, 15 reps).
76064053|NCT05577442|Drug|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
75746022|NCT05475613|Procedure|Downstaging procedures containing immunotherapy|Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
75746023|NCT05475613|Procedure|Liver transplantation|Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
75897389|NCT02786004|Device|Full Field Digital Mammography|
75897390|NCT02786004|Device|Digital Breast Tomosynthesis|
75897391|NCT05137522|Drug|Chidamide combines with VP-16 and methylprednisolone|Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
76064054|NCT01895764|Drug|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
76064055|NCT01895764|Drug|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
75450725|NCT01710488|Drug|Prulifloxacin 1 tablet 600 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
75450726|NCT01710540|Other|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
75746024|NCT05463198|Device|CM-1600|Subjects undergoing blood donation will be connected to the CM-1600 device.
75897392|NCT05271890|Procedure|Immediate non-surgical periodontal treatment and oral hygiene instructions|
75897393|NCT02129166|Drug|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
75601878|NCT04283305|Other|Computer-based approach avoidance training|In the computer-based AAT, patients are situated in front of a computer where drinks appear on the screen in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a joystick, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
75897394|NCT02129166|Drug|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
76064056|NCT04756102|Other|Observation of their fetomaternal outcome|observe the fetal outcome and maternal outcome
75746025|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule|10 cc of blood is collected at one time point, which is prior to biopsy procedure
76064057|NCT01895140|Device|Renal denervation device|
75450727|NCT01710540|Other|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
75746026|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection|10 cc of blood is collected at three time points: 1) before surgery; 2) 4-6 weeks post surgery; and 3) 6 months post surgery
75450728|NCT01710553|Other|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
75450729|NCT01710553|Other|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
75746027|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer|10 cc of blood is collected at one time point
76064058|NCT01894360|Drug|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
76064059|NCT01483599|Drug|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
75746028|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease|30 cc of blood is collected at one time point
75746029|NCT05449340|Device|BEAUTIFY application|Interview with the coordinating nurse in the postoperative period to install the BEAUTIFY application on the patient's smartphone and to train her to record any Patients will monitor their symptoms weekly. In case of toxicity grade > 2, the nurse will contact the patient for further information.
76064060|NCT01483599|Drug|CNTO 1959 (15 mg)|SC injections
76064061|NCT01483599|Drug|CNTO 1959 (50 mg)|SC injections
75450730|NCT01710566|Drug|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
75450731|NCT01710566|Drug|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
75601879|NCT01172535|Drug|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
75601880|NCT05160493|Drug|S-ketamine and pregabalin|"S-ketamine and pregabalin~Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
76064062|NCT01483599|Drug|CNTO 1959 (100 mg)|SC injections
75601881|NCT05160493|Drug|Normal saline and placebo capsule|Normal saline and placebo capsule
75746030|NCT05440201|Other|Amount of anticoagulant Clexane|Change (increase/decrease) the amount of Clexane administered at the dialysis start.
75897395|NCT02858830|Other|High fat mixed meal|
75897396|NCT02137278|Drug|Vasoactive drug therapies|Continue current vasoactive therapy
75897397|NCT02137278|Other|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
76064063|NCT01483599|Drug|CNTO 1959 (200 mg)|SC injections
76064064|NCT01483599|Drug|Adalimumab|SC injections
76064065|NCT01483599|Drug|Placebo|SC injections
76064066|NCT01407562|Drug|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
76064067|NCT01407562|Drug|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
76064068|NCT01407562|Drug|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
76064069|NCT01406548|Drug|BPS804 20mg/Kg|
75746031|NCT05426785|Device|1:1 ratio for Treatment Group and Control Group|Randomization also will be performed at latest 10 days after ICD implantation, and the specified device programming settings for the allocated group will be set after successful implantation of the investigational devices.
75450732|NCT01710579|Procedure|Anorectal 3D-high resolution manometry|Anorectal probe is used with a single-use protective sheath with an inflation balloon Control of balloon deflation Patient in left lateral decubitus position with hips flexed to 90° (this position is the most commonly use and the most convenient) Transanal insertion 2 minutes resting period: resting anal pressure will be evaluated the second minute of rest Sustained voluntary maximal squeeze for at least 30 seconds; the maneuver will be repeated once Valsalva Bear down maneuver; the maneuver will be repeated once Anorectal reflexes evaluation with 20-, 40- and 60-ml intra-rectal balloon inflation Probe removal
76064070|NCT01406548|Drug|Placebo to 20mg/Kg BPS804|
75601884|NCT00966277|Drug|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
75601885|NCT03625063|Other|Exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day at patient's room. Inspiratory muscle training (threshold loading device (Threshold®- Inspiratory Muscle Trainer) at 20-30% of maximal inspiratory pressure (MIP)), upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) will be performed in the treatment group during acute hematopoietic stem cell transplantation process.
75601886|NCT03625063|Other|Control training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day in patient's room.Upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) except inspiratory muscle training will be performed in the control group during acute hematopoietic stem cell transplantation process.
75601887|NCT02862223|Dietary Supplement|Neoprinol|
75601888|NCT01298141|Biological|agalsidase alfa|"Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly"
75601889|NCT01171989|Biological|GSK2202083A vaccine|Intramuscular, one dose.
76064071|NCT01798810|Procedure|Supplemental Perioperative Oxygen|Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
76064072|NCT01393522|Drug|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
76064073|NCT01393522|Drug|Placebo|Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down
75601890|NCT01171989|Biological|Infanrix hexa™|Intramuscular, one dose.
75601891|NCT01171989|Biological|Menjugate™|Intramuscular, one dose.
75601892|NCT01171989|Biological|NeisVac-C™|Intramuscular, one dose.
75601893|NCT01171989|Biological|Synflorix™|Intramuscular, one dose.
75746032|NCT05418049|Drug|Baclofen|30mg - Supplied as 10mg and 20mg tablets
75746033|NCT05418049|Drug|Memantine|two 10 mg tablets
75746034|NCT05418049|Drug|Roflumilast|250 mcg capsule
75746035|NCT05418049|Drug|Placebo|Placebo pill
76064074|NCT02086786|Drug|Risperidone ISM|"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."
76064075|NCT02120482|Device|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
76064076|NCT02318992|Biological|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
76064077|NCT04389814|Diagnostic Test|Biochemical markers|Multiple biomarkers of myocaridial ishemia will be obtained serially to calculate thier time of their release according to their release kinetics
75897398|NCT05137444|Biological|LYB001|The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.
75897399|NCT05137444|Biological|Placebo|Aluminum hydroxide
75897400|NCT05705635|Drug|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
75897401|NCT05705635|Drug|Taxotere|Taxotere, by intravenous infusion, every 3 weeks.
75601894|NCT01297517|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
75601895|NCT01297517|Drug|Brinzolamide ophthalmic suspension, 1%|
75601896|NCT01297517|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
75601897|NCT01171677|Behavioral|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
75746036|NCT05414019|Other|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
75746037|NCT05414019|Other|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
75746038|NCT05414019|Other|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
75746039|NCT05409534|Other|Backward Walking (Exercise group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of backward walking training and 10 minutes of cooling-off exercise. The maximum time to do backward walking training will be 30 minutes. In the backward walking exercise, 1 set will take 5 minutes. The maximum number of sets that can be made will be 6 sets. No more than 6 sets will be made.
75746040|NCT05409534|Other|Forward Walking (Control Group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of forward walking training and 10 minutes of cooling-off exercise as the home exercise programme.
75746041|NCT05409378|Device|The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)|Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
75746042|NCT05406193|Other|Patient-centred complex intervention in complicated multimorbidity (CIM2)|CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity
75746043|NCT05404529|Drug|Tavapadon|Oral tablets
75746044|NCT05403554|Biological|NI-1801|All treatments will be administered in 28-day cycles. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given once weekly (QW) in Cycles 1 and 2 (e.g., Days 1, 8, 15, and 22), and once every two weeks (Q2W) in Cycles 3 through 6 (e.g., Days 1 and 15). NI-1801 treatment can extend beyond 6 cycles for those patients who do not have disease progression.
75601898|NCT01171521|Device|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
75601899|NCT01296347|Drug|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
75601900|NCT01296035|Biological|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
75746045|NCT05398237|Other|Solar Simulated Light (SSL)|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
75897402|NCT03527030|Other|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
75897403|NCT03527030|Other|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
75897404|NCT05204550|Drug|unfractionated heparin|intranasal
75897405|NCT05204550|Drug|0.9%sodium chloride|intranasal
75897406|NCT04467320|Behavioral|Teaching Recovery Techniques|Teaching Recovery Techniques is a 7-session group programme, with 5-sessions for the young person and 2-sessions for the carer. All sessions will be held online. The carer sessions are focused on psychoeducation around trauma and PTSD, as well as skills for supporting a young person through the intervention and with PTSD symptoms more broadly. The young person sessions are primarily focused on skill building and include: psychoeducation and understanding intrusive memories; intrusive images, worries and dreams; arousal, emotions, relaxation and coping; avoidance and triggers; and, memories.
76064078|NCT01776736|Device|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
76064079|NCT02108158|Drug|Azzalure|
76064080|NCT01774630|Drug|Nilotinib|300 mg/twice a day
76064081|NCT01895920|Other|Blood sample|
75746046|NCT05395442|Diagnostic Test|Training on web-based diabetic foot care based on the Health Belief Model|Training on web-based diabetic foot care based on the Health Belief Model will be implemented.Four materials will be used in the research, namely the Introductory Information Form, the Foot Care Behavior Scale, the Diabetic Foot Care Self-Efficacy Scale.
75601901|NCT01294787|Drug|indacaterol and glycopyrronium bromide (QVA149)|
75897407|NCT04467320|Behavioral|Care as usual|In the care as usual arm, social workers will follow their standard care protocol for young people experiencing psychological distress. A typical response may include a referral to either the specialist local CAMHS or general CAMHS.
75897408|NCT00085774|Drug|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
75601902|NCT01294787|Drug|placebo|
75601903|NCT01294787|Drug|tiotropium|
75746047|NCT05393986|Drug|CT048 Autologous Injection (CT048)|up to 3 times CT048 Autologous Injection infusion
75897409|NCT00085774|Drug|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
75897410|NCT00085774|Drug|placebo aerosol by HFA|placebo HFA
76064082|NCT01895218|Drug|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
75746048|NCT05393518|Behavioral|Anxiety-induced task|Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
75897413|NCT05193968|Other|Sympathoexcitatory stressors|Muscle sympathetic nerve activity will be measured continuously at baseline and in response to sympathoexcitatory stressors, including a Valsalva maneuver, isometric handgrip exercise, a cold pressor test, and stepped hypercapnia.
75897414|NCT05193968|Drug|Sodium Nitroprusside|Sodium nitroprusside, used to test endothelium-independent vasodilation, will be infused through a brachial artery catheter at 0.25, 0.5, 1.0 and 2.0 ug/100ml tissue/min.
75897415|NCT05193968|Drug|Acetylcholine|Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
75450733|NCT01710579|Procedure|Anorectal radial endosonography (rotative 360° probe)|Patient in left lateral decubitus position with hips flexed to 90° Transanal probe insertion Evaluation of internal and external anal sphincter integrity and puborectalis muscle at rest
75450734|NCT01710579|Procedure|Dynamic anorectal endosonography (sagittal and radial)|Patient in left lateral decubitus position with hips flexed to 90° Rectum is filled with 50-ml water Probe is covered with a water-filled balloon to maintain the acoustic window for the ultrasound wave Transanal probe insertion Slow and manual rotation of the linear probe through 360° to identify the various layers constituting the anal wall (mucosa, IAS, EAS), the layer forming the rectal wall and the perirectal tissues (puborectalis muscle, bladder, and vagina or prostate) After the initial examination, the patient will be asked to make a defecation effort with the probe left in the same position
75897416|NCT05193968|Drug|Terbutaline|Terbutaline, a β2-Adrenergic selective agonist, will be infused through a brachial artery catheter at 0.1, 0.5, 1.0, and 2.0 μg/100ml tissue/min.
75897417|NCT05193968|Drug|Norepinephrine|Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
75897418|NCT02137356|Radiation|standard dose pelvic radiation therapy|"radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy"
75450735|NCT01710592|Drug|Epirubicin|
75897419|NCT02137356|Drug|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
75450736|NCT01710592|Drug|Oxaliplatin|
75450737|NCT01710592|Drug|Capecitabine|
75450738|NCT01710592|Drug|Docetaxel|
75450739|NCT01710605|Biological|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
75450740|NCT01710631|Drug|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
75450741|NCT01710631|Drug|placebo|placebo
75601904|NCT04207463|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
75897420|NCT02137356|Drug|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
75897421|NCT05137288|Drug|Ondansetron , atropine and bupivacaine|"Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) ."
75601905|NCT04207463|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
75601906|NCT01294553|Drug|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
75601907|NCT04326023|Drug|PARP Inhibitors|olaparib, rucaparib, niraparib, talazoparib, veliparib
75601908|NCT01294397|Drug|Etanercept|Administered by subcutaneous injection once a week
75601909|NCT01294397|Drug|Denosumab|Administered by subcutaneous injection
75601910|NCT01293695|Behavioral|Hypnosis|Hypnosis relaxation in five weekly sessions
75897422|NCT04467476|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
75746049|NCT05393518|Behavioral|Neuropsychiatric assessment|Screening for depression and anxiety
75746050|NCT05391477|Device|GI-Genius artificial intelligence|The software allows for the real-time characterization of framed polyps during a colonoscopy classifying them on adenoma or non-adenoma.
75746051|NCT05387707|Drug|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablets administered twice daily
75746052|NCT05387707|Drug|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablets administered twice daily
75746053|NCT05387707|Drug|TCS Cream|TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
75746054|NCT05387707|Drug|Placebo|Oral Placebo tablets administered twice daily
75746055|NCT05387707|Drug|Vehicle Cream|Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
75746056|NCT05380076|Other|Mindfulness meditation|6 minutes of watching a video tape made for the study that inspire mindfulness like meditation just before entering the examination circuit.
75746057|NCT05380076|Other|Mobilization of inner resources|6 minutes of watching a video tape made for the study that provide psychological stimulation just before entering the examination circuit
75746058|NCT05380076|Other|Biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.
75746059|NCT05376241|Behavioral|Survey|Identify the prevalence and predictors of negative and positive reactions to evidence about mammography benefits and harms, and consequences for decision-making and trust.
75746060|NCT05369676|Drug|SSD8432 dose 1/Ritonavir|Cohort 1:SSD8432/ritonavir or placebo, on day 1 ~day5，BID；
75746061|NCT05369676|Drug|SSD8432 dose 2/Ritonavir|Cohort 2:SSD8432/ritonavir or placebo, on day 1 ~day5，BID；
75746062|NCT05364372|Behavioral|Symptom assessment only|Dyads will receive 12 weekly phone calls to assess symptom management.
75897423|NCT03767868|Other|color change in nail polish|The determination of color change in nail polish will be based on differences in skin temperature before and after the block.
75601911|NCT01293695|Other|Structured attention|Meets with therapist for five weekly sessions and receives structured attention/supportive counseling, but receives no hypnotic relaxation therapy
75746063|NCT05364372|Behavioral|Symptom management and lifestyle intervention|Survivor and caregiver dyads will work together with a coach to establish diet and physical activity change SMART goals. Motivational interviewing based weekly coaching sessions will review symptom management and goal attainment and then enact strategies to modify goals to be more relevant and achievable.
75746064|NCT05363176|Behavioral|Cognitive-Behavioral Therapy for Treatment Seeking|CBT delivered over the course of 1, ~45 minute sessions delivered via telehealth.
75746065|NCT05363176|Behavioral|Pain treatment education|Pain treatment education describes a variety of pain treatments offered in the VA. It is delivered over the course of 1, ~45 minute session delivered via telehealth
75746066|NCT05360498|Behavioral|Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C)|This group will get weekly calls for 16 weeks and two follow-up assessments. Participants will be asked to rate their symptoms on a 0-10 scale at each call. This group will receive the SMSH, a printed evidence-based self-care management handbook with specific modules, that will be directed to use for symptoms rated 4 or higher on a 0-10 scale. For symptoms ≥7, participants will be asked to report the symptom to their provider. At each weekly call, participants will be asked: if they tried symptom self-management strategies and, if yes, which strategies were used. These calls will take 10-15 minutes. If during 8 weeks of SMSH, either the survivor or caregiver have distress (symptoms 4 or greater on a 0-10 scale) for any two consecutive weeks during weeks 2-8, TIP-C will be added for the dyad for 8 weeks. The addition of TIP-C can start between weeks 4 and 9. Dyads will continue the SMSH in addition to the TIPC. TIP-C calls will take 35-45 minutes.
75897424|NCT05135182|Drug|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
75601912|NCT01293539|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle."
75601913|NCT01292837|Drug|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
75897425|NCT05135182|Drug|Metronidazole|metronidazole-tetracycline-containing quadruple regimens
75601914|NCT00965731|Drug|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
75897426|NCT02137434|Other|Dietary calcium|Dietary calcium from skimmed milk
75897427|NCT02137434|Dietary Supplement|Supplementary calcium|Supplementary calcium from calcium carbonate
75897428|NCT02137590|Dietary Supplement|Spanish Black Radish product|
75897429|NCT03051607|Drug|Tozadenant|1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
75601915|NCT00965731|Drug|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
75601916|NCT00965731|Drug|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
75897430|NCT02137668|Drug|Oral Vancomycin|Oral Vancomycin is given to PSC or BA participants
75897431|NCT02137746|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
75601917|NCT03252847|Genetic|AAV2/5-RPGR|Single, subretinal administration of AAV2/5-RPGR
75601918|NCT02862067|Other|Assessment of cardiorespiratory fitness|Assessment of cardiorespiratory fitness
75601919|NCT02861989|Other|qualitative study|
75601920|NCT00630175|Drug|zolpidem-MR (modified release)|
75601921|NCT00630175|Drug|zolpidem (SL800750)|
75601922|NCT00630175|Drug|placebo|
75601923|NCT02861911|Other|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
75601924|NCT02861911|Device|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
75601925|NCT00965575|Drug|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
75746067|NCT05360498|Behavioral|NCI Brochure|The attention control arm will receive an NCI brochure: Facing Forward: Life After Cancer Treatment. This group will also get weekly calls for 16 weeks and complete two exit interviews. The NCI brochure will not be address, the purpose of these calls will only be to record participant's symptoms throughout the study. These calls will take about 10 minutes or less.
75746068|NCT06014970|Behavioral|Health and Wellness Curriculum|The curriculum includes instructions, activities, and lessons on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition.
75746069|NCT06014931|Behavioral|Telemedicine ICU Recovery Clinic Visit|Multidisciplinary clinic visit that encompasses a medical examination, medication management, neuropsychological exam with focused psychotherapy, case management, and patient-centered consultation.
75897432|NCT04962568|Diagnostic Test|DTEE|endexpiratory diaphragm thickness in mm
75601926|NCT00965575|Drug|Placebos|Placebo. Taken 30 minutes prior to bedtime for four weeks.
75601927|NCT04282837|Diagnostic Test|AI classification of patients with obesity|Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.
75601928|NCT04285177|Procedure|Strabismus surgery|Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
75897433|NCT04962568|Diagnostic Test|DTEI|endinspiratory diaphragm thickness in mm
75450742|NCT01710670|Drug|Brivaracetam|"Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1."
75601929|NCT02862847|Other|stool samples|
75601930|NCT04285099|Device|Application of dual system in frequency A|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
75601931|NCT04285099|Device|Application of dual system in frequency B|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
75601932|NCT02862613|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
75601933|NCT02862613|Biological|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
75601934|NCT00965497|Drug|escitalopram|After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
75746070|NCT06014892|Device|Snoo smart bassinet|Participants in the intervention arm will be shipped a Snoo bassinet during their third trimester. The bassinet must be returned to the company at 6 months
75746071|NCT06014892|Device|Willow wearable breast pump|Participants in the intervention arm will be shipped a Willow wearable breast pump and milk storage bags during the third trimester, which participants may keep
75897434|NCT04962568|Diagnostic Test|DEx|diaphragm excursion during rest and diaphragmatic excursion during maximal inspiration in mm
75897435|NCT05291767|Other|Diet|participants will consume a high fat (intervention) or high carbohydrate (control) meal.
75897436|NCT05291767|Behavioral|Exercise|participants will exercise with medium intensity under supervision for 30 minutes (intervention) or rest (control) after consuming the meal.
75897437|NCT04956406|Behavioral|Motivational Interviewing for Adult Kidney Transplant Recipients|Motivational interviewing with individual sessions are planned to be conducted 3 times. Planned motivational interviews will be implemented the intervention group who are within 3th month, 4th month, 5th month and 6th month. Motivational interviewing will planned last 15-30 minutes with an interval of 10 days. The first interview will be performed face-to-face at the transplant outpatient clinic and the second and third ones will be phone interviews
75897438|NCT04956406|Other|Routine care|The control group will be provided with routine care( face-to-face care standard training) by the nurse educator at the transplant outpatient clinic.
75897439|NCT03522428|Dietary Supplement|vitamin b12|Vitamin B12 has been added to the experimental group of pregnant women, at a dose of 5 μg / 100 days
75897440|NCT05575999|Drug|Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination|The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg [3 mg/mL], Ketorolac Tromethamine 24 mg [1.2mg/mL], Ketamine HCl 24 mg [1.2 mg/mL]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg [5mg/ml]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
76064083|NCT01895218|Other|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
75450743|NCT01710670|Other|Ethanol|"Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L."
75450744|NCT01710670|Other|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
75450745|NCT01710670|Other|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
75450746|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid
75897441|NCT02132988|Biological|OPT-822/OPT-821|
75897442|NCT04449484|Drug|MEDI1341|Intravenous infusion over 60 minutes
75897443|NCT04449484|Other|Placebo|Intravenous infusion over 60 minutes
75897444|NCT01062399|Drug|concurrent RAD001 10 mg/day|During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
75897445|NCT01062399|Drug|concurrent temozolomide|During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
75897446|NCT01062399|Radiation|Radiation therapy|Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
76064084|NCT01895998|Drug|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
75450747|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid.
75450748|NCT01710696|Drug|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
75601935|NCT02859805|Other|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
75601936|NCT00963937|Drug|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
75601937|NCT00963937|Drug|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
75746072|NCT06014892|Behavioral|Maven Clinic on-demand perinatal consultation|Participants in the intervention arm will receive immediate access to Maven Clinic for 24/7 on-demand consultation with perinatal specialists.
75897447|NCT01062399|Drug|concurrent RAD001 2.5 mg/day|During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
75450749|NCT01710696|Drug|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
75450750|NCT01710722|Drug|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
75450751|NCT01710722|Drug|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
75450752|NCT01710722|Drug|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
75601938|NCT00963937|Drug|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
75601939|NCT03375697|Drug|JNJ-63733657|Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
75601940|NCT03375697|Drug|Placebo|Subjects will receive matching placebo intravenously.
75746073|NCT06014892|Behavioral|Faculty mentor|After enrollment, participants in the intervention arm will be paired with a faculty mentor who is also a mother to discuss issues related to work-family integration during pregnancy and early infancy.
75746074|NCT06014879|Behavioral|Teen Videos|All participants in the Teen Videos will create videos about living well with diabetes, which will be used in the upcoming clinical trial of a new behavioral intervention.
75601941|NCT04284241|Behavioral|Parents'Health-Education Handbook|We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
75601942|NCT01170663|Biological|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
75897448|NCT01062399|Drug|concurrent RAD001 5 mg/day|During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
75601943|NCT01170663|Drug|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
75601944|NCT01170663|Drug|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
75601945|NCT04315155|Drug|Belinostat|"Doublet Regimen Dose levels for Part 1:~Belinostat Dose Level 1 (starting dose) 500 mg/m2 Dose Level 2 750 mg/m2 Dose Level 3 1000 mg/m2"
75601946|NCT04315155|Drug|nivolumab|Doublet Regimen Dose levels for Part 1 Nivolumab Dose Level 1 (starting dose) 360 mg Dose Level 2 360 mg Dose Level 3 360 mg
75601947|NCT04315155|Drug|ipilimumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Ipilimumab Doublet Dose n/a Triplet Dose 1 mg/kg
75601948|NCT04315155|Drug|nivolumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Nivolumab Doublet Dose 360 mg IV Triplet Dose 3 mg/kg
75601949|NCT04315155|Drug|Belinostat|Triplet and Doublet Regimen Dose Levels for Phase 2 Belinostat Doublet Dose RP2D Triplet Dose RP2D
75601950|NCT01170273|Dietary Supplement|vitamin D|cholecalciferol
75897449|NCT01062399|Drug|post-radiation RAD001 10 mg/day|Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
75897450|NCT01062399|Drug|post-radiation temozolomide|Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
75897451|NCT02133144|Behavioral|overeating fat|
75897452|NCT02133144|Behavioral|overeating carbohydrate|
75897453|NCT05136508|Drug|Propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
75450753|NCT01710735|Procedure|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
75601951|NCT01170273|Dietary Supplement|placebo|placebo tablet
75601952|NCT04315077|Dietary Supplement|Oceanix®|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
75601953|NCT04315077|Other|Resistance Training|5 days of supervised and programmed whole-body resistance training.
75450754|NCT01710748|Device|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
75746075|NCT06014853|Drug|SOL-804-F|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
75897454|NCT05136508|Drug|Sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration [Ce] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
75897455|NCT02133222|Procedure|blood sample|
75897456|NCT05221567|Behavioral|Psychotherapy|Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)
75450755|NCT01710748|Device|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
75897457|NCT05132140|Device|adaptive optics system|the system consists of a wavefront sensor and a deformable mirror that measure and correct (or modify) the eye's optical imperfections (aberrations).
76064085|NCT02086708|Device|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
76064086|NCT02065882|Biological|BT524 (fibrinogen concentrate from human plasma)|single intravenous infusion
75450756|NCT01710774|Procedure|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
75450757|NCT01710813|Biological|alglucosidase alfa|Alglucosidase alfa IV infusion of 20 mg/kg; qow
75450758|NCT01710826|Biological|Genz-682452|Capsules for oral administration.
75450759|NCT01710826|Biological|Placebo|Placebo capsules matching the Genz-682452 capsules.
75450760|NCT01710852|Drug|ISIS CRP Rx|
75450761|NCT01710852|Drug|Placebo|
75450762|NCT01710865|Other|Ultraseal Sealant|This is a newly developed hydrophilic sealant material.
75746076|NCT06014853|Drug|Zytiga|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
75746077|NCT06014840|Other|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
75746078|NCT06014827|Procedure|Biospecimen Collection|Undergo blood sample collection
75897458|NCT02129322|Drug|Sorafenib|
75897459|NCT02129322|Drug|S-1|
75897460|NCT02129322|Drug|Oxaliplatin|
75450763|NCT01710865|Other|Ultraseal Sealant|This is a previously existing hydrophobic sealant material.
75601954|NCT01170039|Drug|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
75601955|NCT01170039|Drug|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
75746079|NCT06014827|Procedure|Computed Tomography|Undergo CT or PET/CT scan
75746080|NCT06014827|Drug|Osimertinib|Given PO
75746081|NCT06014827|Procedure|Positron Emission Tomography|Undergo PET/CT
75897461|NCT05221489|Other|listening to lullabies or self-selected music|listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group
75450764|NCT01710878|Device|Intergard Synergy Graft|
75450765|NCT01710904|Drug|Targinact® (oxycodone/naloxone)|
75746082|NCT06014827|Radiation|Stereotactic Body Radiation Therapy|Undergo BgRT/SBRT
76064087|NCT01507545|Drug|MORAb-004|MORAb-004 8mg per kg IV once a week
76064088|NCT01507545|Drug|Placebo|Placebo - normal saline IV once a week
75450766|NCT01710917|Drug|Targinact® (oxycodon/naloxon)|
76064089|NCT01507545|Other|Best supportive care|Best supportive care to improve quality of life
75450767|NCT01710930|Other|Study of predictive factors|"Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9)."
75450768|NCT01710943|Behavioral|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
75450769|NCT01710956|Radiation|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
75450770|NCT01710969|Behavioral|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
75450771|NCT01710969|Behavioral|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
75450772|NCT01710982|Drug|TZP-101|
75450773|NCT01710982|Other|Placebo|
75450774|NCT01710995|Drug|Zegerid|
75450775|NCT01710995|Drug|Losec|
75601956|NCT01169649|Drug|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
75601957|NCT01169493|Device|VVI-40|Pacing mode set to VVI-40, RV only pacing
75601958|NCT01169493|Device|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
75601959|NCT01169493|Device|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
75601960|NCT01287104|Biological|Natural Killer (NK) Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
75746083|NCT06014827|Other|Survey Administration|Ancillary study
75746084|NCT06014749|Procedure|undergo|regional anesthesia
75746085|NCT06014749|Device|ultrasound|ultrasound guided
75746086|NCT06014749|Drug|Local anesthetic|local anesthetic
75746087|NCT06014736|Drug|XJ101 for Injection|XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.
75746088|NCT06014736|Drug|Placebo|Placebo contains only excipients.
75746089|NCT06014710|Other|Swallowing evaluation|"For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.~For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)"
76064090|NCT04409535|Other|WHOQOL-BREF survey|Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency
76064091|NCT01482819|Device|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
76064092|NCT01482819|Device|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
76064093|NCT01482819|Device|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
76064094|NCT01482819|Device|polymacon|contact lenses worn bilaterally for 8-12 hours
76064095|NCT01482819|Other|spectacles|habitual spectacles owned by subject, non-specific manufacturer
76064096|NCT01534533|Dietary Supplement|Placebo|one gelatine capsule containing starch per day, for 12 months
76064097|NCT01534533|Dietary Supplement|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
76064098|NCT01534533|Dietary Supplement|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
76064099|NCT01534533|Dietary Supplement|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
76064100|NCT02986035|Other|ECA cream|
75746090|NCT06014684|Behavioral|Timing of exercise|High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
76064101|NCT02061358|Drug|UV-4B 3 mg|Oral solution, single dose
76064102|NCT02061358|Drug|UV-4B 10 mg|Oral solution, single dose
76064103|NCT02061358|Drug|UV-4B 30 mg|Oral solution, single dose
76064104|NCT02061358|Drug|UV-4B 90 mg|Oral solution, single dose
75601961|NCT01287104|Biological|Stem Cell Infusion|Transplant Day 0: >4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) >5000/microliters x2
75746091|NCT06014671|Behavioral|Interpersonal Psychotherapy|Intervention Group were took interpersonal psychotherapy
76064105|NCT02061358|Drug|UV-4B 180 mg|Oral solution, single dose
76064106|NCT02061358|Drug|UV-4B 360 mg|Oral solution, single dose
76064107|NCT02061358|Drug|UV-4B 720 mg|Oral solution, single dose
76064108|NCT02061358|Drug|UV-4B 1000 mg|Oral solution, single dose
76064109|NCT02061358|Drug|Placebo|Oral solution, single dose
76064110|NCT01758796|Procedure|Non-operative treatment|Below-the-knee cast for six weeks.
75601962|NCT05593562|Drug|SPH3127|Oral 100 mg [14 c] SPH3127 mixed suspension
75746092|NCT06014645|Other|Rehabilitation|The study group will be given a core stabilization program in addition to education.
75601963|NCT01286558|Drug|40 mg telmisartan|once daily
75746093|NCT06014645|Other|Control|The control group will receive post-operative cognitive training and will be encouraged to move.
76064111|NCT01758796|Procedure|Surgery|Open reduction and internal fixation with 1/3 semi-tubular plate and screws.
76064112|NCT01746160|Drug|C1 Implant|Patients treated with dental implants.
76064113|NCT01895296|Drug|Pasireotide|somatostatin analogue pasireotide
75601964|NCT01286558|Drug|5 mg amlodipine|once daily
75601965|NCT01286558|Drug|5 mg amlodipine|once daily
75601966|NCT01286558|Drug|80 mg telmisartan|once daily
75601967|NCT01169103|Drug|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
75601968|NCT01169103|Drug|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
75746094|NCT06014632|Other|Rehabilitation|The study group will be given motor control exercises in addition to the program given to the control group.
75746095|NCT06014632|Other|Control|The control group will receive stretching, strengthening, core stabilization and educational content as usual care.
75746096|NCT06014619|Procedure|Mohs surgery|Treatment of a skin disease by Mohs micrographic surgery technique (frozen sections).
75746097|NCT06014619|Procedure|Slow Mohs surgery|Treatment of a skin disease by Slow Mohs technique (formalin fixation and paraffin-embedded sections).
75746098|NCT06014606|Drug|placebo|oral formulation
75746099|NCT06014606|Drug|haloperidol 2mg|oral formulation
75746100|NCT06014606|Drug|propranolol 40mg|oral formulation
75746101|NCT06014593|Device|expirogram|Recovery of heart failure data (left ventricular ejection fraction LVEF on cardiac echography (in mL), VO²max during, maximal cardio-pulmonary exercise test, plethysmographic spirometry, carbon monoxide transfer, NT-ProBNP assay,), clinical examination and finally expirogram with the device measuring the 4 exhaled biomarkers (CO/NO/Acetone/Isoprene).
75746102|NCT06014554|Other|Low-risk subgroup|Self-managed exercise programme.
75746103|NCT06014554|Other|Medium-risk subgroup|Education, goal-orientated mobility programme, and enhanced discharge planning.
75746104|NCT06014554|Other|High-risk subgroup|Education, enhanced assessment, orientation, and goal-orientated activities of daily living training programme.
76064114|NCT01895296|Drug|Placebo|placebo s.c.
76064115|NCT04272190|Other|clinical routine treatments|The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
76064116|NCT04389502|Device|CaPtyVa app|The apps stores all the current local Clinical practice guidelines information related to CRC screening and surveillance and through its decision algorithms assist physicians in the screening process. In the screening function, CaPtyVa helps the physicians to classify patient´s according to their individual CRC risk and to determine how and when to start with screening tests. In the surveillance, function the app assist the physician in determining when to repeat the next colonoscopy according to guideline recommendation
75746105|NCT06014554|Other|Control group|Usual care entails physiotherapy and occupational therapy from the day after surgery to the point of discharge, with a focus on discharge planning and sufficient recovery of activities of daily living and mobility for safe return to prefracture residence.
75746106|NCT06014528|Drug|IN10018|100mg QD orally (PO)
75746107|NCT06014528|Drug|Placebo of IN10018|100mg QD orally (PO)
75601969|NCT01286480|Behavioral|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
75746108|NCT06014528|Drug|Pegylated Liposomal Doxorubicin|40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
75746109|NCT06014476|Other|questionnaires|Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
75746110|NCT06014450|Radiation|Prophylactic Cranial Irradiation for experiment arm|Prophylactic Cranial Irradiation DT30Gy/10f
75746111|NCT06014437|Drug|PLCL/Fg group|Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
75746112|NCT06014437|Drug|control group|Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds
75746113|NCT06014398|Diagnostic Test|Dynamic testing of Pituitary Function|"Pituitary Function Assessment:~Baseline assessment of pituitary function by measuring ACTH, cortisol, FSH, LH, oestrogen (in females), testosterone (in males), sex hormone binding globulin, thyroid function tests, prolactin and IGF-1].~Dynamic testing of pituitary function:~Patients will undergo dynamic testing of the ACTH and growth hormone axes using a glucagon stimulation test (GST).~Patients whose GST identifies cortisol deficiency will undergo a short synacthen test to confirm adrenal insufficiency as the GST has a false positive rate of approximately 20% for ACTH deficiency."
75746114|NCT06014281|Behavioral|SOS Meditation|"Focused-attention meditation technique will be used to train participants, specifically the SOS meditation technique. The SOS meditation technique is an easy-to-learn approach where participants are instructed to dissociate their attention from physical awareness, thoughts, and emotions by mentally slowly repeating a calming word or phrase (chosen by the participant themselves).~SOS Meditation Instructions:~Close your eyes very gently, in a relaxed way, as you do when we go to sleep~Your attention should be fully alert. Try not to put any strain on your eyes or try to look up.~Focus your eyes about eight to ten inches into the field of darkness in front of you on the horizontal plane~Mentally repeat the (chosen) calming word~Sit lovingly and calmly to see what comes up, as if you were watching a movie screen and waiting to see what appears on it."
75897462|NCT03767712|Diagnostic Test|Comparison of the levels of antinuclear antibodies (ANA) by indirect immunofluorescence on a Hep-2 cell line.|To analyse whether patients with pertrochanteric femoral fracture with consecutive gamma-nailing develop any laboratory signs of transient autoimmunity (comparison of the levels of ANA; in order to overcome the problem of subjective semiquantitative evaluation, the novel method of automated digital fluorescence microscopy will be used)
76064117|NCT04389502|Other|Control group|current physician knowledge on local current CRC screening and surveillance guidelines
75450776|NCT01711008|Dietary Supplement|Cereal|
75450777|NCT01711008|Dietary Supplement|No breakfast|
75450778|NCT01711034|Drug|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
75450779|NCT01711047|Procedure|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
75450780|NCT01711047|Procedure|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
75601970|NCT01286168|Device|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
75746115|NCT06014268|Other|electronic clinical decision support system|"eCDSS will alert clinicians if patients with documented atrial fibrillation are admitted to the hospital under their care.~The eCDSS will consist of prompts appearing on patients' electronic health records asking clinicians to clinically assess the risk of stroke (using CHAD2AD2-VASc tool) and the risk of bleeding (using the ORBIT tool) and record the scores on ePJS. Recommendations include reviewing the stroke and bleeding scores in specific cases, referral to an anticoagulation clinic to reduce AF related stroke risk (a referral template and emails/ telephone of the OAC clinics will be provided) and managing modifiable bleeding risk factors."
75746116|NCT06014216|Other|Flavoured ice lollies (popsicles)|Blackcurrant flavoured ice popsicles, 105ml volume.
76064118|NCT01895374|Procedure|laser treatments|
76064119|NCT01895374|Other|amniotic membrane application|
76064120|NCT01895374|Device|hydrocolloid application|
76064121|NCT02056756|Drug|Carfilzomib|
76064122|NCT01299532|Device|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
75450781|NCT01711060|Drug|oxytocin|
75450782|NCT01711060|Procedure|balloon catheter|
75601971|NCT01286168|Device|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
75601972|NCT01286168|Procedure|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
75746117|NCT06014216|Other|Water|Water from tap, one cup given by recovery nurses.
75746118|NCT06014203|Diagnostic Test|Edema measurement|"Subcutaneous fluid measurements will be made 3 times in total, before the surgery, immediately after the surgery and 24 hours after the surgery. Measurements will be made with the MoistureMeterD Compact local edema measuring device.~Points to be measured:~Midpoint of the upper trapezius muscle~5 cm distal to anterior acromion~5cm distal to lateral acromion~5cm distal to posterior acromion~3cm medial to the axilla~Anterior cubital fossa~Carpal tunnel"
75746119|NCT06014190|Drug|HS-20089|All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
75450783|NCT01711073|Drug|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
75897463|NCT05136274|Drug|Medical treatment|The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
76064123|NCT01276600|Drug|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
76064124|NCT04756180|Drug|Omega-3-acid ethyl ester or Placebo|Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week
76064125|NCT04745806|Device|ActiGraft|Whole blood clot (WBC) gel
75450784|NCT01711086|Device|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
75450785|NCT01711086|Device|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
75450786|NCT01711099|Device|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
75450787|NCT01711112|Drug|Docetaxel|Treatment will be continued until progression, unacceptable toxicity, or refusal
75450788|NCT01711125|Drug|Baclofen 30mg/day|30mg/day 10 mg t.i.d
75450789|NCT01711125|Drug|Baclofen 75mg/day|75mg/day 25 mg t.i.d
75601973|NCT01286168|Device|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
76064126|NCT04755868|Drug|Talazoparib|The Arm A (Experimental arm) Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
76064127|NCT04755868|Drug|Placebo|The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
76064128|NCT04772638|Behavioral|PLAY|This intervention focuses on promoting physical activity in preschoolers and the adults (parents and teachers) in their lives. It consists of 1) Teacher training 2) Activity trackers for children, teachers and parents and 3) text messaging with content and individualized goal setting.
76064129|NCT04772638|Other|Wait list control|not an active intervention
76064130|NCT05567926|Dietary Supplement|Beetroot juice concentrate (140 ml)|A beetroot juice concentrate (140 ml) will be administered to participants in experimental conditions.
75601974|NCT01286012|Drug|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
75601975|NCT01286012|Drug|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
75450790|NCT01711125|Drug|Placebo|Placebo 3 matched tabs/day
75746120|NCT06014151|Other|questionnaires|we will use a quantitative and a qualitative approach. For the first one, a psychosocial approach on a large number (500 women and 500 men) of candidates to donation. Of course, gender and parenthood will be considered in the analyses, as in the previous study. We will use two questionnaires for this study: 1) the one that was validated for the previous study, including socio-demographic data, donors' motivations and representations, 2) the second exploring personality, the NEO-PR inventory, which was also used for the previous study.
75746121|NCT06014138|Drug|Propofol|Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
75746122|NCT06014138|Drug|Isoflurane|Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
75746123|NCT06014034|Other|Programmed Weaning From Noninvasive Mechanical Ventilation|Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.
75746124|NCT06013956|Device|Neurostimulation|Electrical stimulation delivered via deep brain stimulation electrodes based on measurements of brain activity.
75746125|NCT06013956|Drug|Carbidopa 25/Levodopa 100Mg Tab|Anti-parkinsonian medication.
75746126|NCT06013904|Procedure|Difficult PIV placement personnel|Patients randomized to this group will have their difficult PIV placed following the usual protocol for pediatric ED patients.
75746127|NCT06013904|Procedure|US-trained PEM Fellows|US-trained PEM Fellows
75897464|NCT05221411|Drug|Mycophenolate Mofetil|Mycophenolate mofetil will be started at a dose 500mg twice daily. When tolerated and an AUC within range, patients will be titrated to 1000mg twice daily at week two.
75897465|NCT05221411|Drug|Tacrolimus|Meltdose tacrolimus will be started at a dose of 0.07 mg/kg/day. The drug will be taken orally once-daily in the morning. Dose will be adjusted to reach target AUC and trough levels.
75897466|NCT02133300|Other|electrical stimulation|
75450791|NCT01711190|Procedure|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
75450792|NCT01711203|Other|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
75450793|NCT01711203|Other|General Strengthening|General abdominal and lower quarter musculature strengthening
75450794|NCT01711229|Drug|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
75450795|NCT01711229|Drug|oral acetaminophen|oral acetaminophen will be given preoperatively
75450796|NCT01711281|Device|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
75450797|NCT01711307|Procedure|operative|
75450798|NCT01711307|Procedure|non-operative|casting within 48 hrs
75450799|NCT01711320|Drug|Placebo|
75450800|NCT01711320|Drug|Omeprazole|
75601976|NCT01286012|Drug|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
75601977|NCT01286012|Drug|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
75601978|NCT02889692|Drug|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
75746128|NCT06013787|Behavioral|"Nuestras Historias"|"Nuestras Historias is a digital story curriculum that is displayed on a small solar-powered tablet. The curriculum is a collection of 7 digital stories used to discuss health issues during pregnancy that the community identified as important. The digital stories are short videos that combine local photos and local voices sharing real-life narratives about experiences during pregnancy. The videos were made in collaboration with community health workers and local mothers."
75746129|NCT06013774|Device|IXSI|Hybrid imaging with IXSI will be performed during the radioembolization pre-treatment procedure
75897467|NCT05306002|Combination Product|Antioxidant therapy|Antioxidant therapy based in the following dietary components: Zinc, Selenium, Magnesium, carotenoids, indole-3-carbinol, curcumin, epigalactocatechin, caffeine, resveratrol, lycopene, genistein, phytoestrogens
75601979|NCT02889692|Drug|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
75601980|NCT02889692|Drug|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
75601981|NCT02889692|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
75601982|NCT02889692|Drug|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
75601983|NCT02889692|Drug|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
75601984|NCT02889692|Drug|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
75601985|NCT05569382|Drug|Verapamil|"1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
75897468|NCT03650517|Procedure|Extracorporeal Anastomosis|Anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
76064131|NCT05567926|Dietary Supplement|Blackcurrant juice (placebo)|140 ml of blackcurrant juice with added appropriate amount of sugar to equalize the carbohydrate value and lemon juice fort the taste.
76064132|NCT05560204|Device|Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO)|"Pulsed-field ablation (PFA) is a non-thermal ablation technology that uses high amplitude pulsed electrical fields to ablate tissues through the mechanism of irreversible electroporation~Percutaneous LAA Occlusion (LAAO) has been emerged as an alternative to oral anticoagulants for stroke prophylaxis in patients who refused or contraindicated to OAC"
75746130|NCT06013761|Other|IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm|12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.
75746131|NCT06013735|Drug|sodium fluoride solution|sodium fluoride solution mouth rinse (0.2%).
75746132|NCT06013735|Drug|guava leaves aqueous extract|guava leaves aqueous extract mouth rinse (0.5%)
75746133|NCT06013735|Drug|pomegranate peel aqueous extrac|pomegranate peel aqueous extract mouth rinse (0.5%).
75746134|NCT06013735|Other|Distilled water|placebo distilled water
75746135|NCT06013709|Device|PRESAE CARE|"PRESAGE CARE is a medical device CE marked based on artificial intelligence to prevent and reduce emergency department visits and unplanned hospitalization among frail older adults living at home.~These device is based on the use of a short questionnaire focused on functional and clinical autonomy (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with the home care aides (HAs)or their surroundings. This questionnaire is composed of very simple and easy-to-understand questions, giving a global view of the person's condition. For each of the 27 questions, a yes/no answer was requested. Data recorded by HAs were sent in real time to a secure server to be analyzed by our machine learning algorithm, which predicted the risk level on emergency hospitalization risk and some health clinical situations and displayed it on a web-based secure medical device."
75746136|NCT06013696|Other|Adding household bleach to urine sample|Adding household bleach to urine sample
75746137|NCT06013670|Procedure|Endoscopy+NSBBs|Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure>90mmHg and heart rate>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
76072226|NCT02643043|Other|Biospecimen Collection|Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
75601986|NCT05569382|Drug|Bisoprolol|"1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
75601987|NCT05569382|Drug|Placebo|"1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
75601988|NCT02889770|Other|PEEP titration|Exposure to different PEEP levels
75746138|NCT06013670|Procedure|Transjugular intrahepatic portosystemic shunt|TIPS group: All TIPS procedures are completed by a professional liver disease intervention treatment team.
75601989|NCT00623792|Behavioral|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
76064133|NCT01896076|Other|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
75601990|NCT00963547|Drug|MK-2206|[Part 1]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. [Part 2] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
75601991|NCT00963547|Biological|Trastuzumab|Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
75601992|NCT00963547|Drug|Lapatinib|Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
75746139|NCT06013657|Procedure|Liver Resection|Resection of a part of the liver afflicted by hepatocellular carcinoma
75746140|NCT06013644|Device|Acupuncture needle|a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2
75746141|NCT06013644|Device|Dry needle|a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes
75746142|NCT06013644|Drug|Botox Injectable Product|each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
75746143|NCT06013631|Other|Prosthesis Training|Training for prostheses at the appropriate amputation level will be provided. Conventional gait training protocols include Tandem walk, within parallel bar, controlled environment, full length Mirror on one side, weight shifting, shifting onto the Prosthetic Side, Pelvic 22 rotation, Stepping on multiple heights and positions, Tandem walk, within parallel bar, and weight shifting. Gait training will last six weeks in total.
75746144|NCT06013631|Other|Phantom Exercises|The phantom exercises involved visualizing and then trying to perform the movements of the phantom limb.
75897469|NCT03650517|Procedure|Intracorporeal Anastomosis|Anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique
75897470|NCT03650517|Procedure|Robotic Surgery|Procedure is performed using robotic instruments
75897471|NCT03650517|Procedure|Laparoscopic Surgery|Procedure is performed using standard laparoscopic instruments
76064134|NCT01252888|Device|iStents|Implantation of two iStents through a small temporal clear corneal incision
75601993|NCT01285310|Drug|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
75601994|NCT01285310|Drug|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
75601995|NCT01285310|Drug|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
75746145|NCT06013605|Behavioral|Walking Exercise and Leg Straightening|Participants performed the exercise on the day agreed upon with the researcher. Respondents did walking exercises 3 times per week for 4 weeks with a duration of 10 minutes of warm-up, 30 minutes of walking exercises, and 10 minutes of cooling down. Respondents also did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
75746146|NCT06013605|Behavioral|Leg Straightening|Respondents did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
75746147|NCT06013566|Device|SSVEP|Non-invasive, non-interventional SSVEP EEG device
75746148|NCT06013553|Other|Control Group|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
75897472|NCT05705557|Device|ABSOLOK™ Clip System|Use of ABSOLOK™ Clip System during parenchymal transection for open liver resection
75897473|NCT05305846|Device|TENA-PROTO2|During urodynamics, the TENA-PROTO2 will be positioned onto the lower abdomen of patients to collect raw data for the continuous development of the future ultrasound bladder sensor.
75746149|NCT06013553|Other|Aerobic Exercises group|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given"
75746150|NCT06013540|Combination Product|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)
75746151|NCT06013540|Combination Product|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
75746152|NCT06013527|Other|Supervised Training|"Two different classes over alternate weeks twice per week :~60-minute step aerobics class (Given week 1,3,5,7)~60 minutes circuit training class (Given week 2,4,6,8)~Each class will include warm-up and cool-down periods both lasting 10-15 min. The exercise period of 30 minutes the maximum target RPE would be set at 14-16 on a 20-point BORG scale, a level of exercise that feels somewhat hard or hard and coincides with about 86-92% of maximal heart rate, 76-85% of maximal VO 2 and 5-7 metabolic equivalents (METs) ideal for improving the related domains of QoL and Cardiovascular endurance (12). During the first 3 weeks, the participants would exercise at a lower level of RPE (approximately 11-13), to adapt to the training and so that newly recruited participants could also join the group without difficulty."
75897474|NCT02137902|Behavioral|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
75746153|NCT06013527|Other|Individually tailored home program|The type of home training would mainly consist of endurance training such as walking, Nordic walking, or aerobic training, but it would also include jumps and leaps like step aerobics to promote bone health. The Participants will be asked to perform these thrice per week.
75897475|NCT02137902|Behavioral|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
75897476|NCT05135962|Device|orthodontic - rapid maxillary expansion|Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.
75897477|NCT05135962|Device|orthodontic - slow maxillary expansion with leaf expander|Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.
75601996|NCT01254630|Biological|V212|V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
75601997|NCT01254630|Biological|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
75897478|NCT05135962|Device|orthodontic - slow maxillary expansion with self leaf expander|Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
75897479|NCT05221333|Device|Sorrel Wearable Injector|Use of Sorrel Wearable Injector in pilot study
75897480|NCT02970045|Procedure|Biospecimen Collection|Undergo collection of blood, tissue, and other biological samples
75897481|NCT02970045|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
75897482|NCT02970045|Other|Medical Chart Review|Review of medical chart
75897483|NCT02970045|Other|Quality-of-Life Assessment|Ancillary studies
75897484|NCT02970045|Other|Questionnaire Administration|Ancillary studies
75601998|NCT01284140|Behavioral|Sleep and circadian rhythm promotion|This multifaceted intervention attempts to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. The intervention began the morning after enrollment and enforced a specific period of enhanced light exposure from 9:00 a.m. to noon. The initial target of 5,000 lux administered by light box (Sunsation, SunBox Co.) was reduced to 400-700 lux after the first 10 subjects were enrolled in the study.
75601999|NCT01284140|Behavioral|Usual care|Usual care.
75602000|NCT01254318|Other|Standard Care|Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
75897485|NCT05565703|Other|PARO Robotic Seal Intervention|PARO is a therapeutic robot used to comfort PWD exhibiting agitation and restlessness (www.parorobots.com). Participants are brought out to the activity are on the ACE Unit and provided with an isolation gown to wear during their interaction with the seal. The robot is then placed on their laps for them to hold on their laps, pet, rock and pick up. The participants can also brush the robot and/or give it a bath with baby wipes. The researcher encourages participant engagement with the robot. If the participant does not want the robot on their lap it is placed on a bedside table for them to interact with.
75897486|NCT05565703|Other|Attention Control|The participants are randomly assigned and receive a one hour visit by the researcher or research assistant
75897487|NCT04346914|Biological|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide|ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w
75897488|NCT02129400|Drug|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
75897489|NCT02129400|Drug|Aer medicinalis Linde 100%|
75897490|NCT05135884|Behavioral|Standard inpatient stroke rehabilitation|According to Swiss national guidelines and local protocols
75897491|NCT05704465|Behavioral|Reiki Therapy|Reiki therapy involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. In this technique, energy is guided by therapist's hands placed near patient's body to activate the ability of the body to heal and restore its balance. 1st session for explanation of aim and objectives of program. 2nd one focused on knowledge about negative emotional state. 3rd one discussed Reiki technique and its concept, mode of action, and process. The 4th through 7th sessions were practical. During these sessions, a Reiki practitioner moves his/her hands close to the patient's body in a set of positions. Each hand position focuses on a different part of the body. The hands are held in position for 3 to 10 min., depending on patient's needs. By the end of the session, the patient and therapist reflect on their experience and the emotions with the technique. The eighth session was a recapitulation of the program and ended with evaluation or post-testing.
75450801|NCT01711385|Behavioral|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
75450802|NCT01711398|Drug|Drug|
75746154|NCT06013514|Device|PERLE Sterile Smooth Opaque gel filled mammary implants|Sterile smooth opaque gel filled mammary implants will be implanted in adult women having breast surgery for either augmentation, reconstruction or revision surgery. Different ranges of implants will be used to suit patient needs
75746155|NCT06013501|Behavioral|puppet show|puppet show to the child before and during subcutaneous application
75746156|NCT06013488|Behavioral|Character Strengths Based Coaching Support|Residential (five day) workshop and remote (weekly) telephonic support for 8 to 10 weeks
75897492|NCT05704465|Behavioral|Qi-gong Therapy|Qi-gong involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. It involves coordination of breathing and physical movement with mental energy to promote cognitive performance. Both 1st and 2nd sessions were similar to Reiki technique group. The 3rd one addressed the concept of Qi-gong therapy. The 4th through 7th sessions involved patients' doing simple movements and breathing techniques. The practitioner is at about a one-foot distance from the patient's body, to guide and manipulate movements. Breathing patterns are like yoga, with Qigong movements in a mindful link to inspiration and expiration, with incorporation of deep diaphragmatic breathing. The 8th session was similarly for program recapitulation and post-testing.
75897493|NCT05305768|Drug|IncobotulinumtoxinA|Injection of glabellar rhytids
75897494|NCT05245981|Device|BRI.MAG 2|Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.
75897495|NCT02133378|Device|Hemopatch|Baxter Hemopatch
75897496|NCT02133378|Behavioral|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
75746157|NCT06013488|Behavioral|Routine Supervision|Weekly face-to-face supervision by supervisor in groups of ~20 (1 supervisor for ~20 health workers)
75746158|NCT06013436|Drug|Autologous serum tears combined with 0.05% cyclosporin eye drop|All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
75746159|NCT06013410|Diagnostic Test|colonoscopy|colonoscopy
75450803|NCT01711411|Device|PrePex device for male circumcision|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
75450804|NCT01711437|Device|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
75450805|NCT01711437|Device|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
75450806|NCT01711437|Device|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
76064135|NCT01642342|Other|laboratory biomarker analysis|Correlative studies
76064136|NCT01642342|Other|pharmacological study|Correlative studies
76064137|NCT01642342|Biological|recombinant albumin fusion protein sEphB4-HSA|Given IV
76064138|NCT04755556|Other|home based intensive bimanual training|Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
75450807|NCT01711437|Device|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
75450808|NCT01711450|Procedure|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
75450809|NCT01711450|Procedure|Control sham procedure|Injection of Normal saline into the paravertebral space
75450810|NCT01711463|Drug|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
75450811|NCT01711463|Drug|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
75450812|NCT01711476|Behavioral|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
75450813|NCT01711476|Other|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
75450814|NCT01711489|Drug|isavuconazole|oral
75602001|NCT04319796|Other|Data set as defined by the ERN Research Workgroup of the European Commission|"The ERN-RND registry will be restricted to the minimum data set as defined by the ERN Research Workgroup of the European Commission. This includes the following data:~Name of specialist center~Pseudonym:~Date of birth: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of birth~Sex~Date of death: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of death~Age of onset~Orphacode for specific rare disease: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=DE~Online Mendelian Inheritance in Man (OMIM) code as defined for genetic diseases: https://www.omim.org/~Human Phenotype Ontology (HPO) terms for key features: https://hpo.jax.org/app/~Agreement to be contacted for research purposes: Yes/No~Biological samples (Yes / No)~Link to a biobank (Link / No)~Classification of disability (Disease group specific score)"
75746160|NCT06013397|Dietary Supplement|Ketogenic diet|"Ketogenic diet (KD) is a high-fat, low-carbohydrate and moderate protein diet pattern, suitable for refractory epilepsy, glucose carrier protein 1 deficiency, pyruvate dehydrogenase deficiency, tumors and some genetic metabolic diseases. The ketogenic diet has been used to treat epilepsy for nearly 100 years, and its safety has been recognized by the medical community. In 2015, the ketogenic diet was included in the Clinical Diagnosis and Treatment Guidelines - Epilepsy Volume and became a commonly used treatment for refractory epilepsy."
75450815|NCT01711489|Drug|Mycophenolate mofetil|oral
75746161|NCT06013371|Drug|PF-07038124|topical PDE4 inhibitor
75450816|NCT01711515|Drug|Cisplatin|Given IV
75450817|NCT01711515|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
75450818|NCT01711515|Radiation|Internal Radiation Therapy|Undergo intracavitary brachytherapy
75450819|NCT01711515|Biological|Ipilimumab|Given IV
75746162|NCT06013371|Drug|Placebo Ointment|matching placebo
75897497|NCT05135416|Procedure|chewing gum Group|control of consciousness chewing gum listening to bowel sounds assessment of pain
76064139|NCT04755556|Other|Routine Physical Therapy|Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
76072227|NCT02597504|Other|Pen and paper neuropsychological test|Will be administered for Construct Validity to determine agreement with Quick Test
75450820|NCT01711515|Other|Laboratory Biomarker Analysis|Correlative studies
75450821|NCT01711528|Drug|Bortezomib|Given SC
75450822|NCT01711528|Drug|Dexamethasone|Given PO
75450823|NCT01711528|Drug|Dinaciclib|Given IV
75897498|NCT05135416|Procedure|Control group|control of consciousness listening to bowel sounds assessment of pain
76072228|NCT02597504|Device|Quick Test|Quick Test, computerized test will be administered to all subjects.
75450824|NCT01711528|Other|Laboratory Biomarker Analysis|Correlative studies
75602002|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
75746163|NCT06013358|Genetic|AlloSeq cfDNA|An in vitro diagnostic medical device is employed for predicting damage to and rejection of transplanted organs (kidney, heart, liver, lung) by measuring the ratio of Donor-Derived Cell-Free DNA (dd-cfDNA) to total Cell-Free DNA (cfDNA) extracted from the plasma of patients who have undergone solid organ transplantation. This measurement is carried out using next-generation sequencing methods.
75746164|NCT06013332|Device|PBF PLLA microsphere (injectable poly-L-lactic acid)|Poly-L-lactic acid (PLLA) is a collagen stimulator, helps restore the deep, underlying structure of the skin to diminish facial wrinkles. PLLA microparticles are absorbable for human body, and it works with human body within the deep dermis to help revitalize collagen production and help restore human skin's inner structure and volume. PLLA can rebuilt collagen strands begin gradually helping to restore facial volume and the look of fullness to wrinkles and folds.
75746165|NCT06013332|Device|Sculptra®|Sculptra®
75746166|NCT06013293|Procedure|Zinc oxide eugeonal based sealer|Zinc oxide-eugenol (ZOE)- based preparations, which have been used in root canal obturation (RCO) for over a hundered years and are known for their antimicrobial activities.slight microleakage and zinc oxide-eugenol's superior antibacterial property,slight microleakage and concerning the lower cytotoxicity, the zinc oxide-eugenol (ZOE) sealer can be used for root canal obturation as an endodontic sealer.After root canal prepartion , the root canal will be dried with paper points and obturated using gutta-percha cones and zinc oxide eugenol sealer.
75746167|NCT06013293|Procedure|Resin Based Sealer|resin-based sealer used frequently as a gold standard for endodontic sealers, due to its good physicochemical properties and provide satisfactory adhesion interface with dentin radicular surface.After root canal preparation, the root canal will be dried with paper points and obturated using gutta-percha cones and Resin based sealer
75746168|NCT06013215|Other|Cochlear implant (Oticon) stimulation parameter optimization|The pulse amplitude and/or the pulse phase duration will be optimize to improve the intensity resolution of the cochlear implant which may benefit speech perception
75746169|NCT06013189|Other|Gas Flow Adjustment|Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
75746170|NCT06013150|Drug|Epinephrine|"Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.~Participants in the Part 2 of the study will receive multiple doses of the Epinephrine based on MTD of Part 1 of the study."
75450825|NCT01711567|Drug|tenofovir|tenofovir 300 mg qd
75746171|NCT06013150|Drug|Placebo|Participant in Part 1 of the study will receive matching doses of placebo
75897499|NCT03550716|Procedure|mTESE|mTESE is performed according to the initial description by Schlegel (4). General anesthesia is used. Midline incision of the scrotum is made and carried down to the level of the tunica vaginalis, which is opened to deliver the testis. Equatorial incision is made and the testis bivalved. The operating microscope is used to identify plump-appearing seminiferous tubules, and biopsies are taken from these areas. These samples are examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24G angiocatheter. The procedure is stopped if spermatozoa are found. If no plump tubules are found, random biopsies targeting every area of the testis are taken. If necessary the procedure is carried out on the contralateral testis. Hemostasis is obtained with careful bipolar cautery, and the tunica albuginea and the tunica vaginalis are closed with a running 4-0 Vicryl. Standard scrotal closure is performed and gentle pressure dressing is applied.
76064140|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
75450826|NCT01711567|Drug|entecavir|entecavir 0.5 mg qd
76072229|NCT02588677|Drug|Masitinib (4.5)|4.5 mg/kg/day
75602003|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
75450827|NCT01711580|Other|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
75602004|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
75602005|NCT01284062|Other|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
75602006|NCT01253304|Drug|LY2189265|Subcutaneous (SC) injection
75602007|NCT04319484|Drug|lenvatinib|1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mg (body weight < 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight < 60 kg) or 12 mg orally once a day.
75746172|NCT06013124|Other|Work environment, well-being, customer satisfaction|Evaluation hospital work environment, staff well-being features and patients/caregivers satisfaction and perceived quality of care
76072230|NCT02588677|Drug|Riluzole|
76072231|NCT02588677|Drug|Placebo|
76072232|NCT02588677|Drug|Masitinib (3.0)|3 mg/kg/day
75602008|NCT04319484|Drug|Placebo|1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight < 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight < 60 kg) or 12 mg orally once a day.
75450828|NCT01711580|Other|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
76064141|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
76064142|NCT01220752|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
75450829|NCT01711580|Other|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
75450830|NCT01711580|Other|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
75450831|NCT01711580|Other|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
75602009|NCT01253226|Drug|LY2127399 (Tabalumab)|Administered subcutaneously
75602010|NCT01253226|Drug|Placebo|Administered subcutaneously
75746173|NCT06013111|Biological|Intravenous infusion anti-CEA-CAR-T cell|Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10^7 CAR-T cells/kg, 1×10^7 CAR-T cells/kg, and 3×10^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
75746174|NCT06013098|Drug|30%Oxygen|60%FiO2 in one lung ventilation and 30% FIO2 in both lungs ventilation
75746175|NCT06013098|Drug|60%Oxygen|100%FiO2 in one lung ventilation and 60% FIO2 in both lungs ventilation
75602011|NCT01252290|Drug|Lovaza™|4 capsules daily for 6 months
75450832|NCT01711580|Other|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
75450833|NCT01711580|Other|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
75450834|NCT01711580|Other|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
75602012|NCT02888418|Biological|Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)|Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle
75602013|NCT02888418|Biological|placebo|
75602014|NCT02888340|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
75602015|NCT01252134|Device|Biotrue multipurpose solution|Contact lens care solution
75602016|NCT01252134|Device|Sauflon Synergi multipurpose solution|Contact lens care solution
75602017|NCT01252134|Device|OTE Elements multipurpose solution|Contact lens care solution
75602018|NCT01252134|Device|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
75602019|NCT01251744|Procedure|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
75746176|NCT06013085|Behavioral|cognitive behavioral therapy|6 weeks cognitive behavioral therapy
76064143|NCT01615510|Drug|Tapentadol immediate release|100 mg, single administration
76064144|NCT01615510|Drug|placebo|placebo, single administration
76064145|NCT00530062|Drug|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
76064146|NCT00530062|Drug|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
76064147|NCT01209364|Device|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
76064148|NCT05080192|Drug|Fenofibrate|145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
75602020|NCT01251744|Procedure|Cord blood sample|Cord blood sample taken at the time of delivery.
75897500|NCT03550716|Procedure|TESA|In general anesthesia an 18 gauge needle is introduced into each testis, and negative pressure applied with a 10 ml syringe. Multiple passes throughout the entire testis, numbering 50-100 passes, are made through a single percutaneous/tunical entry and continued until tissue is visible in the hub of the needle. This is removed by brisk extraction of the needle and pressure held to tamponade bleeding. The aspirated tissue is examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24 gauge angiocatheter.
75602021|NCT01251744|Procedure|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
75746177|NCT06013046|Behavioral|Intensity-controlled physical activity training (IPAT)|The IPAT group will receive 40 (90 minute) one-on-one, intensity-controlled, exercise sessions by trained staff over 14 weeks. The initial 2-week period will include dedicated education on topics including physical activity guidelines and the benefits of achieving them, the feeling of moderate-to-vigorous physical activity intensity levels, and the appropriate exercises for achieving desired intensity levels. Tailored sessions will be created for each participant based on their physical fitness, goals, preferred exercise equipment and results from their baseline assessment. Each session can include vitals, pain assessment, warm-up, aerobic training, strength exercises and a cool-down. The participants will be monitored to ensure they are achieving at least 150 minutes of moderate-to-vigorous intensity physical activity weekly. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. The overall goal is to improve cardiorespiratory fitness.
75602022|NCT01251744|Procedure|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
75897501|NCT05305690|Other|No intervention|This study did is a retrospective case series and does not involve an intervention. Investigators will compare patients managed operatively vs nonoperatively, focused on nonoperative therapy.
75897502|NCT03525080|Diagnostic Test|PET imagery|Every patients will have a PET imagery in addition to standard MRI
76064149|NCT05080192|Drug|Placebo|Matching placebo (once/day) for 10 days
76064150|NCT00474370|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
76064151|NCT00474370|Drug|Placebo|One tablet of placebo once daily.
76064152|NCT00472966|Drug|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
75602023|NCT01251744|Procedure|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
76064153|NCT01896154|Dietary Supplement|NPS|Comparison of multiple dietary non-digestible polysaccharides
76064154|NCT01573780|Drug|Smac mimetic TL32711|Given IV
76064155|NCT01573780|Drug|gemcitabine hydrochloride|Given IV
76064156|NCT01573780|Other|laboratory biomarker analysis|Correlative studies
76064157|NCT01573780|Other|pharmacological study|Correlative studies
76064158|NCT01573780|Procedure|biopsy|Optional correlative studies
75602024|NCT00624312|Drug|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit"
75602025|NCT00624312|Drug|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo"
75602026|NCT01251354|Drug|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
75602027|NCT01251276|Biological|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
75602028|NCT01251120|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
75897503|NCT05305378|Device|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded intraoperatively in each patient before, during, and after ICGA in the same surgical field of view to guarantee comparability of the methods.
76064159|NCT01186276|Dietary Supplement|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
76064160|NCT01186276|Dietary Supplement|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
76072233|NCT02587897|Other|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
75769245|NCT03905278|Behavioral|Parental guidance|A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.
75897504|NCT04171622|Drug|Lenvatinib|Given PO
75897505|NCT04171622|Biological|Pembrolizumab|Given IV
75897506|NCT05234580|Drug|PA9159 nasal spray solution, 10 μg once daily for 14 days|PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
75897507|NCT05234580|Drug|PA9159 nasal spray solution, 20 μg once daily for 14 days|PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
75897508|NCT05234580|Drug|PA9159 nasal spray solution, 40 μg once daily for 14 days|PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
75897509|NCT05234580|Drug|Placebo nasal spray solution without PA9159, once daily for 14 days|Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
75897510|NCT05305222|Drug|Risankizumab|Intravenous (IV) Infusion
75897511|NCT05305222|Drug|Placebo|Intravenous (IV) Infusion
75897512|NCT03522272|Device|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride
75897513|NCT03522272|Device|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water
75897514|NCT03522272|Other|Conventional denture hygiene|Mechanical cleaning of denture with a soft toothbrush and liquid detergent
75897515|NCT02138058|Drug|Topiramate|
76072234|NCT02587897|Other|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
75602029|NCT01251120|Drug|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
75897516|NCT02138058|Behavioral|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
75602030|NCT01250418|Drug|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
75602031|NCT04319562|Procedure|needle-embedding therapy|"First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan)."
75897517|NCT05187403|Drug|Laquinimod|Eye-drops
75897518|NCT05187403|Drug|Placebo|Eye-drops
75897519|NCT05069168|Diagnostic Test|Echocardiography before and after TAVR|"Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR.~cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume.~Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)"
75897520|NCT02129634|Device|CB-PTA|
75897521|NCT02129634|Device|DEB-PTA|
76072235|NCT02570113|Device|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
75897522|NCT05174455|Drug|Niraparib Tosylate Monohydrate|Given PO
75897523|NCT04142606|Other|fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)
75897524|NCT04335604|Drug|JPI-547|The dose levels will be escalated following a 3+3 dose escalation scheme.
75897525|NCT05063084|Procedure|Optiflow - HFNO|Pre-oxygenation: HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2 Oxygenation: during the tracheal intubation, HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2
75897526|NCT05063084|Procedure|Classic|Pre-oxygenation: with facemask during 2 min with 100% FiO2, flow 6 to 8L/min. No oxygenation during the tracheal intubation
75897527|NCT02138292|Drug|Trametinib (2mg)/Digoxin (.25mg)|"Trametinib (2mg) will be administered orally on a daily basis.~Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."
75897528|NCT04468100|Biological|Tigerase®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
75897529|NCT04468100|Biological|Pulmozyme®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
76072236|NCT02565914|Drug|TEZ/IVA|Fixed dose tablet for oral administration.
75746178|NCT06013046|Behavioral|Education and Access (EA)|The EA group will receive an initial 60 minute educational session, during which they will receive information on the adapted exercise equipment in the Orthwein Center, education on the physical activity guidelines and the health benefits of achieving them, and access to the Orthwein Center accessible gym. They will then complete a 14-week independent workout program with the goal of meeting physical activities guidelines. They will have access to Orthwein Center staff to help with minimal setup and guidance, but sessions will be self-directed. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. Participants will be asked to complete a log for each session to report pain, details of the activities they completed during their workout, the RPE for each activity, and how long each activity lasted.
75746179|NCT06013007|Procedure|ICI-guided JINS approach|OCT- or IVUS-guided JINS approach in DES implantation (DES types including Healing-Targeted SUPREME/Infinity Sirolimus-Eluting Stent, GuReater™ Sirolimus-Eluting Stent, XIENCE Alpine Everolimus-Eluting Stent, Promus PREMIER™ Everolimus-Eluting Stent, Resolute Integrity™ Zotarolimus-Eluting Stent, Firebird 2™ Sirolimus-Eluting Stent, Firekingfisher™ Sirolimus-Eluting Stent).
75746180|NCT06012955|Device|Target-controlled infusion (TCI) systems|Target-controlled infusion (TCI) with propofol and remifentanil was used for anesthesia induction and maintenance
75746181|NCT06012916|Drug|Esketamine nasal spray|This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.
75746182|NCT06012903|Other|Questionnaire Welbevinden|A validated questionnaire recommended by the Flemish inspection of education to measure well-being in primary school children of the 4th, 5th and 6th grade.
75746183|NCT06012903|Other|Questionnaire Vancouver symptom score for dysfunctional elimination syndrome|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016.
75746184|NCT06012903|Other|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning.
76025171|NCT02811887|Behavioral|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
76064161|NCT01141426|Behavioral|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
76072237|NCT02565914|Drug|IVA|Tablet for oral administration.
75602032|NCT04319562|Device|shame needle-embedding therapy|The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
75602033|NCT05490810|Other|Trunk stabilization|"Trunk stabilization exercises with~Static back: A roll of towel was pressed against the back and the position was held for 10 secs and then released~Static gluteus: The gluts were pressed inside and hold for 10 secs and then released.~Abdominal bracing: Brace your abdomen by contracting your entire abdomen. From here Perform different exercises such as raising your arms and then raising your legs.~Pelvic bridging: In crook lying, engage your gluts and trunk lift your hips towards the ceiling. Hold the position for 10 secs and then release.~SLR with-hold at 30 and 45 degrees: Ask the supine patient to raise the leg up-to 45 degrees and hold for 10 secs. Then raise the leg up-to 30 degrees then hold for 10 secs."
75602034|NCT05490810|Other|Activation exercises|"Activation exercises with~Upper rectus abdominis (URA) and lower rectus abdominis (LRA): body supine with hips and knees flexed 90°, with feet locked. Participants flexed the trunk (i.e. crunch execution) against resistance at the level of the shoulders..~External oblique (EO) and internal oblique (IO): side-lying with the hip at the edge of the bench and feet locked by a second operator. Participants performed side-bend exercise against resistance at the level of the shoulder.~Lower erector spinae (LES) and upper erector spinae (UES): prone position with ASIS at the edge of the bench and feet locked by a second operator. Participants performed a back extension against resistance at the level of the shoulders."
75602035|NCT01292603|Drug|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
75602036|NCT01292603|Drug|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
75602037|NCT01292603|Drug|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
76064162|NCT01141426|Behavioral|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
75897530|NCT01317277|Behavioral|individualized Texting for Adherence Building (iTAB)|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.~Behavioral: individualized Texting for Adherence Building (iTAB)~Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group."
75897531|NCT01317277|Behavioral|Psychoeducation|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence."
75897532|NCT04467788|Other|Computer-aided sessions|Changing participants' KAP of ergonomics in dentistry
75897533|NCT04467788|Other|Clinical simulation sessions|Changing participants' KAP of ergonomics in dentistry
75897534|NCT03526952|Other|Internet-Delivered Intervention for Sexual Re-Adjustment|Couples will meet with a therapist via video-conferencing for two 1.5-hr sessions. The therapist will facilitate couples' communication about their sexual and intimate relationship while providing psychoeducation about couple coping and sexuality after cancer and with an ostomy. Discussion will focus on current concerns, motivations for sex, relational strengths, and intimacy and sensual pleasure. Couples will also be encouraged to practice a sensate focusing exercise between sessions.
76064163|NCT01895530|Dietary Supplement|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
76064164|NCT01547260|Drug|Gemzar|Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
76072238|NCT02565524|Other|genetic and phenotypic profile|Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
75450835|NCT01711593|Biological|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
75602038|NCT01292603|Drug|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
75602039|NCT01292603|Drug|rituximab [MabThera]|6 cycles of intravenous MabThera
75602040|NCT01292057|Drug|Aripiprazole|Aripiprazole(up to 15 mg/day) for 8 days
75746185|NCT06012903|Other|Questionnaire concerning LUTS, NDDs and treatment perceptions|Unvalidated, complementary questions including the presence of LUTS, earlier diagnosis of bladder and/or boweldysfunction and neurodevelopmental disorders and perception concerning treatment characteristics.
75602041|NCT01292057|Drug|Placebo|Placebo to match active drug Aripiprazole for 8 days
75602042|NCT01291277|Device|Endoscopic Variceal Ligation|Ligation of esophageal varices
75746186|NCT06012903|Other|Questionnaire about policies and practices regarding children's toilet use and drinking habits in the classroom|These unvalidated questionnaire was based on the questionnaire developed by Ko et al. (2016) about the school's policies and practices regarding children's toilet use and drinking habits in the classroom, covering students in grades one through six. Epidemiological questions related to LUTS were added to complement the questionnaire.
75746187|NCT06012890|Other|Automation of cardiac MRI acquisition|The intervention will consist of the automation of the cMRI examination.
75602043|NCT01290887|Drug|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
75897535|NCT03526952|Other|Written Educational Material|Couples will receive written educational material for patients coping with changes in intimacy and sexuality when living with a permanent ostomy. This educational material is published by the United Ostomy Associations of America, Inc. and is available for free download from their website. Couples will have two weeks to read this material.
75746188|NCT06012877|Behavioral|Health Friendly Program|"The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021)."
75602044|NCT01290731|Drug|TMC435|100-mg capsule once daily for 12 weeks
75602045|NCT01290731|Drug|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
75602046|NCT01290731|Drug|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
75602047|NCT01290341|Drug|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
75602048|NCT01290341|Drug|Placebo|Topical; applied once daily for two weeks.
75602049|NCT01290263|Drug|Amgen 386|"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
75602050|NCT01290263|Drug|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
75602051|NCT01290029|Drug|Cinacalcet|Single, oral dose of 0.25 mg/kg cinacalcet
75746189|NCT06012864|Procedure|PNL|percutaneous extraction of the stones in the kidney
75746190|NCT06012838|Behavioral|Cause classification of OHCA protocol|training program with cause classification of OHCA protocol
75746191|NCT06012708|Drug|KN510 60mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
75897536|NCT03626935|Device|3D-printed customized guide plate|3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
76064165|NCT01547260|Drug|Revlimid|Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
76064166|NCT02317042|Device|Juno|Juno device set to ST mode with participant's current therapy settings.
76064167|NCT02317042|Device|Juno|Juno device set to AutoEPAP iVAPS mode.
75602052|NCT02890199|Drug|Bupivacaine liposomal|
75602053|NCT02890199|Drug|Lidocaine|
75602054|NCT04324073|Drug|Sarilumab|(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1
75602055|NCT01289639|Drug|fenofibrate|micronized fenofibrate 200 mg 1 po qd
75602056|NCT01289639|Drug|pioglitazone|pioglitazone 30 mg po qd
75746192|NCT06012708|Drug|KN510 120mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
75746193|NCT06012708|Drug|KN510 120mg/day + KN713 90mg/day|Once daily with 28 days (4 weeks) as one cycle.
75746194|NCT06012708|Drug|KN510 120mg/day + KN713 120mg/day|Once daily with 28 days (4 weeks) as one cycle.
75746195|NCT06010472|Drug|anti-CD19 CAR NK cells (KN5501)|"Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Doses of 3×10^8, 6×10^8, 1.2×10^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
75769246|NCT03905590|Procedure|Periapical surgery with amniotic membrane|periapical surgery will be done followed by amniotic membrane placement over the defect
75602057|NCT01289639|Drug|placebo|placebo 1 capsule po qd
75602058|NCT01289015|Drug|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
75602059|NCT01289015|Drug|Placebo|Topical; applied once daily for two weeks
75602060|NCT01288937|Drug|Milnacipran|"Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)"
75746196|NCT06009172|Other|Auricular point acupressure (APA)|Auricular point acupressure (APA) is a method derived from Traditional Chinese Medicine. PCOS women in the APA group began to apply pressure on the first day of enrollment. Patients were instructed to press each acupuncture point 3 times a day for 30 times. The PCOS woman is then trained to go to the outpatient clinic every 5-7 days to change the auricular acupressure sticker. The intervention period was 4 weeks.
75602061|NCT01288937|Drug|Placebo|Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
75746197|NCT06009133|Procedure|Conservative treatment|"Micronized purified flavonoid fraction, which is routinely used within indications in hemorrhoidal disease and recommended in ESCP and ASCRS guidelines, and licensed for use in hemorrhoidal disease by the Ministry of Health in our country, was given 2 g/day for one month.~Also, Conservative methods (fiber foods, warm shower, regulation of toilet habits, laxatives and nonsteroidal anti-inflammatory drugs) were recommended."
75602062|NCT01288469|Drug|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
75746198|NCT06009133|Procedure|Surgical Treatment|While the patient was in the Jack-knife position, both hips were pulled laterally with tapes, appropriate visualization was obtained, the external thrombosed pack was excised under local anesthesia, and the wound was left to heal with secondary intention.Conservative methods were recommended in the surgical group as well as in the medical group.
75602063|NCT01288469|Drug|Placebo (for alirocumab)|One SC injection in the abdomen only.
75746199|NCT06008210|Behavioral|Decision Support Intervention|The participants will receive two 60-minute consultation sessions delivered by a trained nurse in four weeks at home. Participant's family members will be encouraged to attend the sessions. In the first session, the nurse will explore the participant's understanding of the current health condition, introduce the concept of advance care planning and discuss their decisional needs for end-of-life care decision-making. In the second session, the nurse will ask the participants to complete a value clarification exercise individually.
75746200|NCT06008210|Behavioral|Health Coaching|The participants will receive two 60-minute health coaching sessions delivered by a trained nurse in four weeks at home. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes.
75602064|NCT01288469|Drug|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
75602065|NCT01288469|Drug|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
75602066|NCT02890043|Procedure|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
75602067|NCT02890043|Procedure|free-hand surgery|traditional free-hand surgery
75602068|NCT02890043|Device|TiRobot system|a robot-assisted spine surgery system
75746201|NCT06007612|Behavioral|Context Sensitivity in Emotion Regulation|Context Sensitivity of affective intensities and its association to Emotion Regulation Flexibility Selection
75746202|NCT06006676|Other|Near Apnoeic ventilation|Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation
75746203|NCT06006676|Other|Crossover standardised ECMO weaning trials|"When all patients are eligible for a trial of ECMO weaning, they will have standardised ECMO weaning trials lasting up to 1 hour with 0 sweep gas flow. 1) One-stage weaning- sweep gas flow rate sequentially decreased to zero 2) Two-stage weaning- fraction of oxygen of sweep gas flow decreased to 0.21 sequentially. Then the sweep gas flow rate decreased to 0 sequentially"
75746204|NCT05997316|Behavioral|Time restricted eating|Participants will work with a psychologist towards achieving a 16 hour fasting period, 2-3 days per week. The intervention will last 12 weeks, with different intervention materials gradually introduced over the course of the 12 weeks.
75746205|NCT05997004|Drug|Normal Saline|After surgical creation of umbilical port Control group received injection normal saline 1ml.
75746206|NCT05997004|Drug|Glycopyrrolate|After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
75602069|NCT01288079|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
75602070|NCT01288079|Drug|Duloxetine|Capsule, oral, once daily
75602071|NCT01288079|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
75602072|NCT00623753|Biological|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
75602073|NCT01287221|Drug|Rifampicin|300 mg, 2 times daily
75602074|NCT01287221|Drug|placebo|placebo
75746207|NCT05995301|Drug|Ropivacaine in Transversus abdominis plane|This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery
75746208|NCT05995301|Drug|Ropivacaine in Local infiltration at port site|This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery
75746209|NCT05993832|Other|input cue|The object is labelled with 1) gaze only; 2) novel label only; or 3) conflicting gaze and novel label
75769247|NCT03905590|Procedure|periapical surgery without amniotic membrane|periapical surgery will be done without placement of membrane over the defect.
75897537|NCT05134870|Behavioral|Mimic- game and groove- Telerehabilitation|Participants will mimic the exergaming-based animation videos shown to them by the health coach. They will also wear a wearable device that will measure the heart rate and physical activity during the training. The intervention will have 12 sessions for 4 weeks, each session for 1.5 hours, including warm-ups and cool-down. Warm-up and cool down are for 20 minutes. Additionally, Participants are provided with a set of balance exercises which includes non-interactive balance games (stepping forward, backward, sideways), Tai-Chi, Weight shifting (to right leg, left leg and practice distributing equal weights on both the legs), Aerobic (stepping in place), dance, strength, and stretching
75450836|NCT01711593|Procedure|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
75450837|NCT01711671|Drug|DKN-01 300 mg|300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
75450838|NCT01711671|Drug|DKN-01 600 mg|600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
75450839|NCT01711671|Drug|Standard of Care|Current approved standard of care
75769248|NCT00227370|Drug|valganciclovir|valgan 900mg QD x 9 months post lung transplant
76064168|NCT02317042|Device|Juno|Juno device set to Fixed EPAP iVAPS mode.
76064169|NCT01896388|Drug|Ifenprodil Tartrate|
75450840|NCT01711684|Drug|Diphenylcyclopropenone (DPCP)|Topical application of study drug
75450841|NCT01711697|Radiation|stereotactic body radiation therapy|Undergo SBRT
75450842|NCT01711697|Drug|carboplatin|
75450843|NCT01711697|Drug|paclitaxel|
75450844|NCT01711697|Radiation|radiation therapy|Undergo radiation therapy
75450845|NCT01711723|Drug|Darapladib 160 mg|Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
75450846|NCT01711749|Drug|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
75450847|NCT01711749|Drug|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
75769249|NCT00227370|Other|Placebo|
75450848|NCT01711762|Drug|GDC-0973|Single oral dose of [14C]-GDC-0973
75450849|NCT01711775|Drug|aleglitazar|Single oral dose Day 1, repeated oral dose once daily Days 5-14
75769250|NCT03905122|Device|bioreactans tool|It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
76064170|NCT01896388|Drug|Placebo|
76064171|NCT01125436|Dietary Supplement|Cholecalciferol|50,000 units of oral vitamin D3(cholecalciferol) weekly plus 800 calcium daily
76064172|NCT01125436|Dietary Supplement|Cholecalciferol|Weekly placebo plus 800 calcium alone
76072239|NCT02543320|Other|LORETA Neurofeedback Training|Undergo LORETA neurofeedback training
75450850|NCT01711788|Procedure|Intrabone infusion of umbilical cord blood stem cells|
75450851|NCT01711801|Drug|Placebo|Single ascending dose
75450852|NCT01711801|Drug|RO5545965|Single ascending dose
75450853|NCT01711801|Drug|RO5545965|Single dose, in fed and fasted state
75450854|NCT01711814|Drug|peficitinib|oral
75602075|NCT01168401|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)"
75602076|NCT01168401|Biological|Saline|Two doses 28 days apart
75602077|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
75602078|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
75602079|NCT01287065|Drug|Placebo AM|Inhalation powder
75602080|NCT01287065|Drug|Placebo PM|Inhalation powder
75602081|NCT04314999|Diagnostic Test|Examination of stool samples|Tests for diagnosis of parasitic diseases
75602082|NCT01167153|Drug|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
75769251|NCT03969030|Other|PEBRA model|"The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~ART Refill~SMS notifications~Support"
75897538|NCT02133612|Drug|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
75450855|NCT01711827|Drug|Isavuconazole|oral
75602083|NCT01167153|Drug|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
75602084|NCT02886273|Other|Group 1|Observation
75602085|NCT02886273|Other|Group 2|Observation
75602086|NCT02886273|Other|Group 3|Observation
75602087|NCT02886273|Other|Group 4|Observation
75602088|NCT01166763|Drug|vitamin D3|oral capsules, 10,000 IU per week for 6 months
75897539|NCT03522194|Drug|Sevoflurane|Anesthesia maintenance with Sevoflurane
75897540|NCT03522194|Drug|Propofol|Anesthesia maintenance with Propofol
76025172|NCT03995303|Other|NCP and home-delivered meals|The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.
75602089|NCT02886039|Other|Electroencephalogram|Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest
75602090|NCT02885961|Drug|Dabigatran|Anti-coagulant
75450856|NCT01711827|Drug|Prednisone|oral
75450857|NCT01711892|Behavioral|Soccer training|
75450858|NCT01711905|Dietary Supplement|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
75450859|NCT01711931|Device|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
75450860|NCT01711931|Device|Implantation of everolimus-eluting stents|
75450861|NCT01711931|Device|Implantation of biolimus-eluting stents|
75450862|NCT01711944|Behavioral|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
75450863|NCT01711957|Procedure|Liver transplantation|Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
75450864|NCT01711970|Drug|Paclitaxel|
75450865|NCT01712048|Procedure|Submucosal Injection EMR|"Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare."
75450866|NCT01712048|Procedure|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
75450867|NCT01712087|Device|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
75602091|NCT02885961|Radiation|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
75450868|NCT01712100|Drug|Irbesartan|
75450869|NCT01712100|Drug|Avapro|
75450870|NCT01712113|Drug|Irbesartan|
75450871|NCT01712113|Drug|Avapro|
75450872|NCT01712126|Drug|Irbesartan and Hydrochlorothiazide|
75450873|NCT01712126|Drug|Avalide|
75602092|NCT02885727|Drug|Durvalumab|Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
75602093|NCT02885727|Radiation|Radiation Therapy|The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
75602094|NCT01166373|Behavioral|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
75602095|NCT01166373|Procedure|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
75602096|NCT01166373|Procedure|ULS|uterosacral ligament suspension to suspend the vaginal apex
75602097|NCT01166373|Behavioral|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
75602098|NCT01166373|Other|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
75602099|NCT04314765|Procedure|lower third molar extraction|the extraction is performed with one of the two type of flap based non randomization.
75602100|NCT00963235|Biological|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
75602101|NCT00963235|Procedure|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
75602102|NCT02861833|Other|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
75602103|NCT04284163|Behavioral|Gamification|Teaching through gamification
75602104|NCT04284163|Behavioral|Traditional teaching|Teaching through master lesson methodology
75602105|NCT00630097|Drug|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
75602106|NCT04284085|Other|Psychoeducational intervention|Psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
75769252|NCT03905200|Diagnostic Test|3D-speckle tracking imaging|The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
75450874|NCT01712139|Drug|Irbesartan and Hydrochlorothiazide|
75450875|NCT01712139|Drug|Avalide|
75450876|NCT01712165|Dietary Supplement|ANMUM Materna|
75450877|NCT01712165|Dietary Supplement|Control (milk powder)|
75450878|NCT01712243|Other|Light|
75602107|NCT01165281|Drug|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
75602108|NCT01165281|Drug|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
75602109|NCT04283929|Other|Experimental: Intervention 1 (Int1)|This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
75602110|NCT04283929|Other|Experimental: Intervention 2 (Int2)|The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.
75602111|NCT04283929|Other|Experimental: Intervention 3 (Int3)|The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows > 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
75602112|NCT02861053|Other|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
75602113|NCT02861053|Other|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
75450879|NCT01712269|Procedure|Weight-loss (bariatric) surgery|Subjects will undergo bariatric surgery which will assist weight loss
75450880|NCT01712282|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulse reserve increase of 50%
75450881|NCT01712295|Drug|17% Salicylate with ethyl pyruvate|
75450882|NCT01712295|Drug|Salicylates|
75450883|NCT01712321|Drug|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
75450884|NCT01712321|Drug|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
75602114|NCT02860897|Drug|Premarin|Vaginal estrogen cream
75602115|NCT02860897|Drug|Vagifem|Vaginal estrogen tablet
75602116|NCT04314609|Device|Ultrasonography, fluoroscopy|success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
75602117|NCT02860819|Drug|Veliparib|Veliparib 250mg BID, continuously
75602118|NCT02860819|Drug|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
75769253|NCT01251796|Drug|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
75769254|NCT01251874|Drug|Carboplatin|Given IV
75746210|NCT05981131|Drug|N803 plus Bacillus Calmette-Guerin (BCG)|QUILT-2.005 phase 1b (NCT02138734) was an open-label, dose-escalation, multicenter study of intravesical Bacillus Calmette-Guerin (BCG) plus N-803 in BCG-naïve non muscle invasive bladder cancer (NMIBC). A modified 3 + 3 design was used. Three subjects were enrolled at each dose level starting at 100 μg/instillation of N-803 and subsequently increasing to 200 μg/instillation and 400 μg/instillation. A standard dose of BCG, 50 mg, was employed. The primary endpoints of the study were: determination of the maximum tolerated dose (MTD) and designation of the recommended dose (RD) of N-803 in combination with BCG in subjects who have BCG-naïve NMIBC; safety profile of N-803 plus BCG in treated subjects; and disease response rate in treated subjects. A total of 9 subjects with high-risk, high-grade, BCG-naïve, NMIBC were enrolled into 3 cohorts and treated by intravesical administration of N-803 plus BCG.
75897541|NCT05304988|Other|Testing of the EFT|A research committee which composes of a paediatric oncologist, a ward manager, an assistant professor and a research assistant will be set up. The committee will develop specific questions in EFT and design and implement the clinical Then, subject will be invited to fill in a set of questionnaires covering demographic characteristics, EFT items and a numerical rating scale for pain scores. The oncologist will rate the subject with the most appropriate level of physical activity on a 4-point scale.
75602119|NCT02860819|Drug|Carboplatin|Carboplatin AUC = 4, day 1
75602120|NCT05367453|Dietary Supplement|Tropical juice with probiotics (B.coagulans)|Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
75746211|NCT05978492|Drug|TXN10128|Participants receive TXN10128 capsules orally once daily
75769255|NCT01251874|Other|Fluorothymidine F-18|Correlative studies
75897542|NCT05098483|Procedure|Regeneration in primary molars by using MTA|Regenerative endodontic procedure in nonvital primary molars using MTA capping material
75897543|NCT05098483|Procedure|Regeneration in primary molars by using biodentine|Regenerative endodontic treatment in primary molars with biodentine as capping material
75897544|NCT05098483|Procedure|Conventional Root canal treatment in primary molars|Removal of pulp tissue from the canals of primary molars
75602121|NCT05367453|Other|a Tropical juice with no probiotics|Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
75897545|NCT02260752|Procedure|hysterectomy|surgical removal of the uterus
75897546|NCT02260752|Procedure|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
75897547|NCT02260752|Procedure|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
75897548|NCT02260752|Drug|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
75897549|NCT02260752|Procedure|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
75897550|NCT02260752|Procedure|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
75897551|NCT02260752|Procedure|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
75897552|NCT04820764|Device|CardioMech MVRS|CardioMech MVRS
75897553|NCT04820686|Drug|VBR|VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
76072240|NCT02543320|Other|Questionnaire Administration|Ancillary studies
75602122|NCT05367453|Other|lactase tablet|lactase tablet
75602123|NCT05367453|Other|placebo tablet (cornstarch)|placebo tablet (cornstarch)
75602124|NCT04284007|Drug|Perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
75602125|NCT04284007|Drug|Perineural dexamethasone in addition to levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
75746212|NCT05953363|Device|BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes|Insertion of a BD NRFit™ spinal needle and optional BD NRFit™ Spinal Introducer Needle using a BD NRFit™ Syringe to perform the neuraxial procedure.
75746213|NCT05876299|Other|95.1% Lean Pork|This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.
75897554|NCT04820686|Drug|AB-729|AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
75897555|NCT04820686|Drug|SOC NrtI|Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
75746214|NCT05876299|Other|81.16% Lean Pork|This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.
75897556|NCT02260830|Drug|Lu AF11167|
75897557|NCT02260908|Drug|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
75897558|NCT02260908|Other|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
75897559|NCT02969655|Drug|Daprodustat small|Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
75897560|NCT02969655|Drug|Daprodustat small placebo|Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
75450885|NCT01712347|Drug|Bevacizumab|Bevacizumab will be administered as per approved label.
75897561|NCT02969655|Drug|Daprodustat large|Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
75897562|NCT02969655|Drug|Daprodustat large placebo|Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
75450886|NCT01712347|Drug|Chemotherapy|The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
75602126|NCT04284007|Drug|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
75897563|NCT02969655|Drug|Darbepoetin alfa|Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
75897564|NCT02969655|Drug|Darbepoetin alfa placebo|Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
75897565|NCT02129712|Behavioral|Cognitive training|
75450887|NCT01712373|Drug|Ginseng|it is kind of drug
75450888|NCT01712373|Drug|Placebo|it is placebo
75450889|NCT01712386|Dietary Supplement|Beetroot|
75602127|NCT02861677|Other|pharmaceutical care|
75450890|NCT01712386|Dietary Supplement|Beetroot placebo|
75450891|NCT01712425|Biological|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
75450892|NCT01712425|Biological|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
75450893|NCT01712464|Drug|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
75450894|NCT01712477|Drug|Intravenous sedation using propofol|Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
75602128|NCT02861287|Other|Economic evaluation|
75602129|NCT01165203|Biological|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
75602130|NCT01165203|Biological|Placebo|intramuscular injection
75602131|NCT00960661|Drug|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
75602132|NCT00960661|Drug|insulin lispro|titrated based on pre-meal glucose level; three times a day
75602133|NCT00960661|Drug|Metformin|
75602134|NCT00960661|Drug|Insulin/ Glargine|
75602135|NCT04119193|Device|Novel smartphone application for blood pressure measurement|Continuous blood pressure measurements will be compared between the new application and the reference method (invasive radial arterial line) during 5 minutes of recordings.
75602136|NCT04282993|Device|Wearable devices for identifying and measuring risk factors for ischemic stroke|Identifying and monitoring cerebrovascular risk factors using wearable devices
75602137|NCT04282993|Other|Standard of care monitoring|Periodical medical examinations
75746215|NCT05876299|Other|Carbohydrate Beverage|This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.
75746216|NCT05871762|Other|Registry study, no specific intervention|Registry study, no specific intervention
75746217|NCT05868044|Device|PRIMUS|Peripheral Nerve Stimulator System
75746218|NCT05858632|Drug|Guselkumab|Guselkumab treatment for ~ 9 months
75746219|NCT05843890|Behavioral|Structured and tailored PainGuide|"Participants will receive specific instruction to complete one module a week over the first 4 weeks. Participants will then receive tailored messaging using scores from the assessments completed during T1(baseline visit) from the PROMIS 29+2.~Participants will be asked to complete surveys over 24 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
75769256|NCT01251874|Other|Laboratory Biomarker Analysis|Correlative studies
75769257|NCT01251874|Other|Pharmacological Study|Correlative studies
75602138|NCT00960193|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
75602139|NCT00960193|Other|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
75602140|NCT00960115|Biological|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram [mcg]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
75602141|NCT00960115|Drug|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg/m^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
75602142|NCT00960115|Biological|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
75746220|NCT05843890|Behavioral|Standard PainGuide|"Participants in the control group will not receive any messaging once enrolled. Participants will be asked to complete surveys over 24 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
75897566|NCT04489420|Biological|CYNK001-IV|Planned Starting dose dor IV 1.2x10^9 cells/dose
75897567|NCT04489420|Biological|CYNK001-IT|Planned starting dose for IT 200 x10^6 +/- 50 x10^6 cells dose
75897568|NCT02138526|Drug|pazopanib|pazopanib 800mg OD without food
76064173|NCT01113658|Device|SNaP Wound Care System|"The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician."
75746221|NCT05814783|Behavioral|supported digital CBTI|in session support for adherence to and engagement with digital CBTI
75746222|NCT05814783|Device|digital CBTI|CBTI app
75897569|NCT02138526|Other|continental breakfast|pazopanib 600mg OD with food
75897570|NCT03526796|Procedure|Hyperbaric oxygen therapy|Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
75897571|NCT04488874|Drug|Sodium Lactate|"Sodium lactate is administered at 2.5mL/kg during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.~Sodium Lactate and Mannitol 20% are used at an equimolar dose"
75897572|NCT04488874|Drug|Mannitol 20% Infusion|Mannitol 20% is administered intravenously at a dose of 5mL/kg, so 1g/kg, during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.
76064174|NCT04755478|Procedure|Thoracotomy|Participants will undergo lobectomy via open thoracotomy at the discretion of the surgical team.
76064175|NCT04755478|Procedure|VATS|Participants will undergo lobectomy via VATS at the discretion of the surgical team.
76064176|NCT04755400|Other|isotonic saline 9%|1 Liter of Isotonic saline administered I.V.
75602143|NCT00960115|Other|Saline|A single dose of saline (sodium chloride, 9 grams per liter [g/L]) will be administered intravenously, 3 days prior to the start of placebo.
75602144|NCT02859883|Device|gastroscope FUSE™|All patients undergoing a diagnostic gastroscopy are eligible. Using the FUSE endoscope with side screen, the duodenal and accessory papilla are monitored. Data are collected by each operator. Clinical examination of patients is performed before they leave the centre.
75602145|NCT04281355|Procedure|Omission of axillary lymph node dissection|Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B
75602146|NCT04281355|Radiation|Omission of regional irradiation|Regional irradiation will be omitted in the interventional arm of Randomisation A.
75602147|NCT04281277|Device|increase of mean arterial pressure at 80-85 mmHg.|increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
75602148|NCT04281277|Device|increase of mean arterial pressure at 65-70 mmHg.|increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
75769258|NCT01251874|Procedure|Positron Emission Tomography|Correlative studies
75769259|NCT01251874|Drug|Veliparib|Given PO
75769260|NCT03911674|Other|Oral manual stimulation of feeding in preterm infants|Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
75769261|NCT03903250|Dietary Supplement|A-GPC|Taken orally in liquid form
75769262|NCT03903250|Dietary Supplement|Sugar|Taken orally in liquid form
76064177|NCT04755400|Dietary Supplement|Potassium nitrate|24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.
75746223|NCT05786794|Behavioral|Patient Navigation Program for Hearing Health Care|Patients presenting for routine office visits will be invited to participate in the study and informed consent procedures and study enrollment will be conducted by a research assistant. Participants will then undergo baseline assessment. Following baseline measures, participants who screen positive for hearing loss will be contacted by the Patient Navigator (PN) to begin the intervention. The navigator will contact participants every 2 weeks to focus on addressing key aspects of Hearing Health Care (HHC): education, screening, diagnosis, and treatment. PNs will assist the patient to undergo a formal audiogram with the 12 months following enrollment. Each PN session will likely last between 10-30 minutes. Post-intervention data collection also administered by a trained interviewer, will occur following a diagnostic audiogram with an audiologist or at 12 months following enrollment.
75746224|NCT05785637|Procedure|Polygraphy diagnostic at home|Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
75602149|NCT04281121|Dietary Supplement|omega 3 fatty acids|: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
75602150|NCT00959647|Drug|Vismodegib|Vismodegib was supplied in capsules.
75602151|NCT00959647|Drug|FOLFOX|FOLFOX (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and oxaliplatin [OX]) was supplied as solutions for intravenous administration.
75602152|NCT00959647|Drug|FOLFIRI|FOLFIRI (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and irinotecan [IRI]) was supplied as solutions for intravenous administration.
75602153|NCT00959647|Drug|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
75602154|NCT02859493|Device|Saccharomyces cerevisiae|
75746225|NCT05785546|Other|usual care|For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.
75746226|NCT05774600|Behavioral|SSW Works|SSW Works is a behavioral, culturally tailored online intervention for skin cancer prevention amongst outdoor workers in the United States.
75450895|NCT01712477|Drug|Intravenous sedation with midazolam|patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
75450896|NCT01712503|Device|Phacoemulsfication cataract surgery and intra-ocular lens implant|
75450897|NCT01710761|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
75602155|NCT02859493|Device|Placebo|
75602156|NCT02859649|Behavioral|neuropsychological test|neuropsychological test
75602157|NCT02861443|Behavioral|practice of colonic irrigation|
75602158|NCT02808403|Other|No intervention|No intervention; observation of routine medical care
75746227|NCT05774600|Behavioral|Minimal Information Control|Provision of online materials for skin cancer prevention.
75450898|NCT01710761|Dietary Supplement|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
75450899|NCT01712529|Behavioral|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
75450900|NCT01712555|Procedure|autologous fat grafting with PRP to anophthalmic orbits|
75450901|NCT01712568|Drug|Test Product (Ropinirole)|"one Tablet at 0 hour"
75450902|NCT01712568|Drug|Reference Product (REQUIP )|"one Tablet at 0 hour"
75450903|NCT01712581|Other|Magnetic Resonance Imaging|
75450904|NCT01712594|Device|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
75450905|NCT01712607|Other|Preoperative Warm-Up training|Preoperative Warm-Up training
75450906|NCT01712646|Drug|Intranasal Oxytocin|
75450907|NCT01712724|Other|combined resistance and aerobic training|For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
75450908|NCT01712737|Other|Dietary intervention|
75602159|NCT00957931|Procedure|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
75602160|NCT00957931|Biological|Mesenchymal Stromal Cells|
75602161|NCT00957853|Drug|Cetuximab|First dose of 400 mg/m^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m^2 on week 2 and 3 (if applicable) given over 1 hour.
75746228|NCT05759442|Drug|Metformin Hydrochloride (HCL)|Tab Metformin HCL 500mg twice per day aimed at improving glycemic indices in Prediabetics
75746229|NCT05759442|Dietary Supplement|Apple cider vinegar|Apple cider vinegar aimed at improving glycemic indices in Prediabetics
75746230|NCT05755984|Diagnostic Test|3D printed model|scan
75746231|NCT05730218|Drug|ONL1204 Ophthalmic Solution|ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
75746232|NCT05730218|Drug|Sham treatment|Sham injection is performed by touching the eye surface with a syringe without a needle
75746233|NCT05728346|Drug|Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers|stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers
75769263|NCT01147978|Behavioral|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
75769264|NCT01252030|Device|physical activity monitors|physical activity monitors
75602162|NCT00957853|Drug|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
75602163|NCT00957853|Procedure|Surgical tumor resection|Surgical tumor resection on Day 10.
75602164|NCT02858167|Device|FDG-PET|FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
75450909|NCT01712802|Other|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
75450910|NCT01712802|Other|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
75450911|NCT01712802|Other|Saline|work as control for Denture Adhesives: Cream and Powder
75450912|NCT01712828|Drug|Lenalidomide|25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
75602165|NCT02858245|Other|No intervention - registry|
75450913|NCT01712828|Drug|Quinidine|300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
75602166|NCT00957229|Drug|GDC-0449|capsule, 150 mg, one pill daily, 18 months
76064178|NCT04755400|Dietary Supplement|Potassium chloride|24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
75450914|NCT01712828|Drug|Temsirolimus|25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
75450915|NCT01712828|Drug|Diphenhydramine|Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
75450916|NCT01712867|Other|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
75450917|NCT01712867|Other|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
75450918|NCT01712880|Procedure|open debridement with modular exchange|
75450919|NCT01712880|Procedure|one stage exchange|
75602167|NCT02604511|Drug|Ibrutinib|
75602168|NCT02858011|Other|Cash distribution during first 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
75602169|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
75602170|NCT02858011|Dietary Supplement|Preventive Nutrition Packages during last 12 months|Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)
76025173|NCT03957707|Procedure|stereotactic surgery plus thrombolysis|stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
76025174|NCT02739659|Device|carbon-ion radiotherapy|
75450920|NCT01712893|Drug|Zoladex|Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
75450921|NCT01712412|Drug|IW-9179|
75450922|NCT01712412|Drug|Placebo|
75450923|NCT01712919|Radiation|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
75602171|NCT02858011|Other|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
75602172|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
75602173|NCT02859571|Drug|Oxytocin|
75602174|NCT04282369|Device|HHHFNC|noninvasive ventilation modality
75602175|NCT04282369|Device|NCPAP|noninvasive ventilation modality
75602176|NCT04282369|Device|NIPPV|noninvasive ventilation modality
75602177|NCT04282369|Device|NHFO|noninvasive ventilation modality
75746234|NCT05728138|Behavioral|CMAP Plus CBT|Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
75746235|NCT05720832|Other|WINGS-IP1 Smartphone Application|"The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content."
75746236|NCT05701670|Behavioral|Purrble+SSI|"Purrble intervention as described above.~Single Session Intervention (SSI) (~30mins) combining the theories of ER with the experiences from students involved in previous studies, and follows a traditional SSI structure (Schleider et al 2020). Specific content has been co-produced with students and experts."
75746237|NCT05694052|Behavioral|Multifaceted Intervention of environment control|Dynamic light therapy, auditory masking, and rationalization of ICU nocturnal patient activities.
75746238|NCT05682352|Drug|LEO 158968|IV infusion or SC injection
75602178|NCT04280809|Device|GaAlAs laser|GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
75602179|NCT02857933|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
75450924|NCT01712919|Drug|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
75746239|NCT05682352|Drug|Placebo|IV infusion or SC injection
75746240|NCT05682352|Drug|LEO 158968|SC injection
75450925|NCT01712919|Biological|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
75746241|NCT05682352|Drug|Placebo|SC injection
75769265|NCT01252030|Other|No physical activity monitors|No physical activity monitors
75769266|NCT01252108|Drug|SQ109|300 mg SQ109 daily for 14 days
76072241|NCT02535078|Drug|Tebentafusp (IMCgp100)|soluble gp100-specific T cell receptor with anti-CD3 scFV
75450926|NCT01712945|Drug|Palifermin|Palifermin (Kepivance®) administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose.
75450927|NCT01712945|Drug|Alemtuzumab|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
75450928|NCT01712997|Drug|Iloprost|
75450929|NCT01712997|Drug|Bosentan|
75602180|NCT00956839|Drug|Vitamin D3 (Cholecalciferol)|"Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months"
76072242|NCT02535078|Drug|durvalumab|anti-PD-L1 monoclonal antibody
75746242|NCT05661721|Other|Sweet licorice|Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.
75746243|NCT05661721|Other|Salty licorice|A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.
75746244|NCT05654753|Drug|active FMT|MaaT033®, a lyophilized full-ecosystem intestinal microbiota delayed release oral capsule containing native, donor-derived (pooled from 4-6 donors) microbiome product manufactured by MaaT Pharma® will be delivered orally. Patients will receive 20 Maat033 capsules, each containing approximatively 0.42 g of microbiome product at once at day 0, then 3 capsules/day from day 1 through day 20.
75746245|NCT05654753|Drug|Placebo|Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
75746246|NCT05654597|Other|CAPTURE tool|CAPTURE 5-item questionnaire and a selected use of peak expiratory flow measurement.
76025175|NCT05123261|Behavioral|the mindfulness-based elder care (MBEC) therapy|According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
75450930|NCT01713010|Other|Predictive indexes of weaning from mechanical ventilation|
75450931|NCT01713023|Dietary Supplement|Glucose|The same described in Arm description
75602181|NCT00956293|Drug|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
75602182|NCT00956293|Drug|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
75602183|NCT00956293|Drug|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
75602184|NCT00956293|Drug|Cyclosporin A (CsA)|Dosage was based according to blood level
75746247|NCT05654597|Other|Spirometry|Spirometry performed with a portable device, used for comparison with the CAPTURE tool.
76025176|NCT05123105|Other|1) cupping therapy|The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.
76025177|NCT05123105|Other|2) control test (no intervention)|The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.
75450932|NCT01713023|Dietary Supplement|Fructose|The same described in Arm description
75450933|NCT01713049|Drug|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
75450934|NCT01713088|Other|Multisystemic therapy|
75450935|NCT01713088|Other|YOT (usual services)|
75602185|NCT00956293|Drug|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
75746248|NCT05639088|Behavioral|Transition preparation program|"AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach."
75746249|NCT05639088|Other|Educational materials|AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
75746250|NCT05635643|Drug|SRF114|SRF114
75746251|NCT05632497|Biological|Stool sample|Stool sample
75746252|NCT05631899|Biological|KRAS-EphA-2-CAR-DC|5~10 × 10^6 CAR-DCs per dose will be administered by intravenous injection.
75746253|NCT05631899|Drug|Abraxane|Intravenous abraxane 125 mg/m^2/day on day-5.
75746254|NCT05631899|Drug|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m^2/day on day -4.
75746255|NCT05631899|Drug|Anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
75746256|NCT05631899|Drug|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
75602186|NCT04204369|Other|Ultrasound education curriculum|"Participants were enrolled in a musculoskeletal ultrasound course including 2 components:~An online course (1-2 hours) to be done before the practical session. The videos were made available one (1) month prior to the practical course. This component reviewed the basics of ultrasonography, as well as the normal and abnormal appearance of relevant musculoskeletal structures (bone, tendon, ligaments, muscles, bursas, and nerves), and the ultrasound anatomy of high yield regions of the musculoskeletal system (shoulder, elbow, knee, ankle)~A practical session (4-6 hours) done during one of the usual academic days of the orthopedic residency program. This session covered the use of the ultrasound; the examination of the shoulder, elbow, knee, and ankle; ultrasound-guided musculoskeletal injections and aspirations; and ultrasound-guided distal radius fracture reductions. Ample practice time was given to the residents using means such as phantom models, cadavers, and real patients."
75897573|NCT02129790|Behavioral|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
75746257|NCT05631886|Biological|TP53-EphA-2-CAR-DC|5~10 × 10^6 CAR DCs per dose will be administered by intravenous injection.
75746258|NCT05631886|Drug|Abraxane|Intravenous abraxane 125 mg/m^2/day on day-5.
75746259|NCT05631886|Drug|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m^2/day on day -4.
75746260|NCT05631886|Drug|anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
75746261|NCT05631886|Drug|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
76064179|NCT04777942|Procedure|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
75897574|NCT05304754|Biological|NK cells stimulated ex vivo with IL-15|When patient and donor are KIR-HLA match, the patient submits all HLA class I molecules, or in the absence of any, your donor does not have this molecule, or having it lacks the corresponding KIR receiver. For more information detailed information on the product under investigation, reference is made to the Dossier of the Research Product (IMPD): PEI 09-008
75897575|NCT05304754|Biological|Alloreactive NK cells|When the patient lacks the HLA class I molecule and his donor has this molecule and also the donor NK cells have the KIR receptor that recognizes the absence of the corresponding HLA class I ligand
75897576|NCT01317199|Drug|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
75897577|NCT01317199|Drug|Low-dose MPX|Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
76064180|NCT04777942|Procedure|Surgery alone|hepatic resection remove the liver tumors
76064181|NCT00436540|Drug|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
76064182|NCT00436540|Drug|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
76064183|NCT00425230|Drug|Duloxetine|
75746264|NCT05601752|Genetic|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1
75746265|NCT05601752|Combination Product|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks
76064184|NCT04778098|Other|Received SMS reminder|telenursing
76064185|NCT03793738|Procedure|Anterior component separation|
76064186|NCT03793738|Procedure|Posterior component separation|
76064187|NCT03783052|Device|SmartPill in fasted state|SmartPill administration in fasted state
76064188|NCT03783052|Device|SmartPill in fed state|SmartPill administration in fed state
76064189|NCT03783052|Other|Aspiration|Aspiration of gastrointestinal samples in fasted and fed state
75450936|NCT01713101|Drug|Early intravenous tranexamic acid administration|Initial history taking and physical examination --> enrollment --> 1g bolus over 10 minutes followed slow infusion over 8 hours.
75450937|NCT01713101|Drug|placebo|
75450938|NCT01713114|Other|Acute measures of satiety and food intake at next meal|
75450939|NCT01713127|Drug|remifentanil infusion|
75450940|NCT01713127|Drug|Placebo|
75746266|NCT05600621|Behavioral|Financial Literacy Training (FLT) Workshops|Participants will be assigned to receive FLT workshops which are implemented by community-level agencies in collaboration with the financial institutions. FLT comprises six workshops delivered over 6 weeks. Topics include: a) an introduction to the notion of asset-building; b) coverage of asset-building strategies in detail, e.g., saving; c) coverage of specific topics related to saving, e.g., the importance of saving and how to save, d) an introduction of banking services to participants and e) coverage of basics of borrowing and debt management. Participants from the same location, in this case, clinics are assigned to the same group. Workshops occur on weekends to accommodate participants week-day schedules, including school and/or gardening.
76064190|NCT03783052|Other|Gastric emptying scintigraphy|Gastric emptying scintigraphy in fed state
76072243|NCT02535078|Drug|tremelimumab|anti-CTLA-4 monoclonal antibody
76072244|NCT02520791|Biological|Anti-ICOS Monoclonal Antibody MEDI-570|Given IV
75602187|NCT04282291|Procedure|fascial block as postoperative analgesia|The tissue damage induced by the surgery generates a nociceptive pain which is accompanied by inflammatory mechanism (somatic pain), visceral and neuropathic pain, and why the treatment must be adapted to each surgical procedure. As the innervation of the upper abdominal wall depends mainly on the last intercostal nerves, the block of these nerves should be considered a good analgesic strategy to avoid the somatic pain. The placement of the local anesthetic in the serratus intercostal plane at the eighth rib (serratus intercostal plane block, SIPB) in the middle axillary line, managed to block the lateral and anterior cutaneous branches of the last intercostal nerves (T7-11). The results were satisfactory in the postoperative pain control of the patients with open cholecystectomy.
75602188|NCT04282291|Drug|Morphine|The continuous (basal) dose
75897578|NCT01317199|Drug|High-dose MPX|Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
76064191|NCT04634578|Drug|Bevacizumab|"All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution."
76064192|NCT04778254|Other|PEEK attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
75602189|NCT04282291|Device|PCA CADD Smith Medical pumps|perfusion
75897579|NCT01317199|Drug|Placebo oral capsule|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
75897580|NCT03650439|Diagnostic Test|culture on Sabouraud's Dextrose Agar (SDA)|• Clinical samples will be cultured onto Sabouraud's Dextrose Agar (SDA) plates supplemented with chloramphenicol. the culture was incubated at 25 C° and at 37° C (for yeasts and moulds isolation )
76064193|NCT04778254|Other|metalic attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
76064194|NCT04778254|Other|conventional obturator|clasp retained obturator for management of hemi maxillectomy
75450941|NCT01713140|Other|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
75450942|NCT01713153|Drug|Misoprostol|600 mcg misoprostol oral
75450943|NCT01713153|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
76064195|NCT01066858|Drug|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
76064196|NCT04777552|Other|diazepam (or equivalence if other benzodiazepine)|
76064197|NCT04777318|Other|Conventional physiotherapy|A total of 12 sessions of conventional physiotherapy program for 4 weeks were applied 3 days a week. The conventional physiotherapy program included 20 min hotpack , 10 min ultrasound, 20 min conventional (Transcutaneous electrical nerve stimulation) TENS application.
75450944|NCT01713166|Drug|plasmalyte solution|plasmalyte solution
76064198|NCT04777318|Other|Conventional physiotherapy and Muscle Energy Technique|In addition to conventional therapy, the muscle energy technique was applied to the individuals in the second group at the same frequency. Muscle energy technique was applied to the upper trapezius, sternocleidomastoideus , scalene (anterior-medius-posterior) and levator scapula muscles. According to the MET post-isometric relaxation method, each muscle was applied as one set (each set includes three repetitions). The patient was asked to perform a 7-second isometric contraction corresponding to 20% of the maximum isometric contraction force in the area where the restriction was felt. After the application, the patient was asked to breathe and relax, and the neck was brought back to the barrier point and the technique was repeated.
75450945|NCT01713166|Drug|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
75450946|NCT01713179|Drug|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
75450947|NCT01713218|Drug|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
75602190|NCT00955825|Drug|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
75602191|NCT00955825|Drug|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
75897581|NCT02138682|Drug|l-123 Ioflupane|5 millicuries of Ioflupane
75897582|NCT03651219|Drug|Apatinib|Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)
76064199|NCT04777318|Other|Conventional physiotherapy and Cervical Mobilization Techniques|Cervical mobilization techniques were also applied to the individuals in the third group in addition to conventional physiotherapy at the same frequency. In the first few sessions, bridging and manual traction techniques were applied in 3-5 repetitions. In the next sessions, in addition to these techniques, rotation with 3-5 repetitions of manual traction, anteroposterior sliding with traction and cervical lateral shift techniques were applied. Vertebrobasilar InsufficiencyTest was applied to all participants to determine the appropriateness of cervical mobilization. Before mobilization, a deep friction massage was applied on painful spasmic nuchal muscles for 3-4 minutes in order to increase blood circulation and relax tense tissues.
75746267|NCT05600621|Behavioral|Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)|"ALHIV will receive a YSA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate.~As part of YSA, ALHIV are also trained on investing in income-generating activities (IGA) and are normally allowed to use up to 30% of their matched savings to invest in an IGA to benefit their family. The IGA portion helps promote economic stability for families and enable the ALHIV to afford medical expenses."
75746268|NCT05600621|Behavioral|A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon).|Participants assigned to this component will participate together with her/his caregiving family, in attending sixteen 60 minute sessions hosted within the community over 16 weeks. Each session involves 6-10 families. Participants will learn from the Suubi Cartoon curriculum about their HIV diagnosis and treatment needs, while coping with family loss, stigma, peer relationships, identity, and family functioning.
75746269|NCT05600621|Behavioral|Engagement with HIV treatment-experienced role models who share lived experiences of HIV|Participants will be assigned to small groups with an average of 3-4 peers from the same health clinic, and each ALHIV stays in the same group -- for 9 sessions - with the same role model. This is intended to build trust and rapport not only between the role model and mentee, but also between all group members. The 9 sessions, to be conducted over a 6-month period, include activities, videos, scenarios, and role-playing to facilitate discussion and learning. This is intended to promote their self-esteem, improve their HIV care engagement, reduce stigma and stress, encourage hopefulness, build stronger communication skills with their caregivers and/or family members, enhance safe sexual decision-making, and decrease sexual risk-taking behavior.
75746270|NCT05600621|Other|Standard of Care (SOC)|SOC consisting of pediatric ART initiation and monitoring outlined by Uganda's Ministry of Health.
75746271|NCT05576454|Drug|Mepolizumab Injection (BAT2606 Injection)|In this group, each subject will receive single subcutaneous injection of 100 mg BAT2606 Injection.
75746272|NCT05576454|Drug|Mepolizumab Injection (EU-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).
75746273|NCT05576454|Drug|Mepolizumab Injection (US-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).
75746274|NCT05565794|Drug|Pemigatinib|Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
75746275|NCT05557747|Other|cervicothoracic junction mobilization in form of Maitland mobilization|Group A: will receive cervicothoracic junction mobilization mobilization in form of Maitland mobilization to the C7-T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions (unilateral PA glide) for 3 sessions/week over 4 weeks periods.
75746276|NCT05557747|Other|autogenic muscle Energy Technique|"the technique will applied to neck muscles that are prone to get short including anterior, middle and posterior Scaleni, Sternocleidomastoid, Levator Scapulae and upper fibers of the Trapezius muscle.~The AI MET group will given 3-5 repetitions of post isometric relaxation (PIR) (30-50% isometric contraction of the muscle to be stretched for 7-10 seconds, followed by rest period of 5 seconds and then a stretch of 10-60 seconds hold"
76064200|NCT01506609|Drug|Placebo|
75746277|NCT05557747|Other|conventional physical therapy|conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods
76064201|NCT01506609|Drug|Veliparib|
76064202|NCT01506609|Drug|Carboplatin|
76064203|NCT01506609|Drug|Temozolomide|
76064204|NCT01506609|Drug|Paclitaxel|
76064205|NCT04777162|Drug|Tislelizumab|For included participants, tislelizumab would be administrated 200mg q3w iv.
75602192|NCT02859181|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
75602193|NCT02859103|Drug|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
75602194|NCT04282135|Diagnostic Test|MCC IMS|Diagnosis by MCC IMS
75602195|NCT02859025|Biological|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
75602196|NCT02859025|Biological|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
75602197|NCT02859025|Biological|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
75602198|NCT02869009|Drug|clopidogrel|
75602199|NCT02869009|Drug|Aspirin|
75602200|NCT01164579|Drug|Tasocitinib plus Methotrexate|Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
75602201|NCT01164579|Drug|Tofacitinib plus placebo methotrexate|Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
76064206|NCT04777162|Drug|Anlotinib|Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
75746279|NCT05532813|Drug|Treatment taken|Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
75602202|NCT01164579|Drug|Placebo tofacitinib plus Methotrexate|Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
75602203|NCT02859259|Drug|BMS-663068 (1 tablet at 600 mg)|BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
75602204|NCT02859259|Drug|BMS-663068 (4 tablets at 150 mg each tablet)|BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
75746280|NCT05528835|Procedure|Frozen embryo transfer|All women in both groups will receive oral estradiol valerate 8 mg/ day from the second day of the menstrual cycle. Endometrial thickness will be assessed by vaginal ultrasonography at the tenth day of treatment. When endometrial thickness reached ≥ 7 mm all subjects, in addition to estrogen, they will receive progesterone vaginal suppositories 400 mg twice daily and 100 mg of progesterone intramuscularly daily. Frozen thawed embryo transfer will be at day 6 of progesterone. Estrogen and progesterone will be continued until 9-10 weeks of gestation
75746281|NCT05526521|Drug|Dupilumab|Injection solution Subcutaneous
75746282|NCT05521399|Diagnostic Test|MRI Sequencing|MRI test-retest (select healthy volunteers) for development of MRI sequence.
75746283|NCT05521399|Diagnostic Test|MRI Testing (pediatric)|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.
75897583|NCT03651219|Drug|Irinotecan|Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
75897584|NCT02648698|Drug|Antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
75897585|NCT05032417|Other|implementation of evidence-based nutrition practice guidelines|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
75897586|NCT02133690|Biological|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
75897587|NCT02133690|Other|Placebo|Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
75450948|NCT01713218|Drug|Vismodegib|150 mg capsule, oral, once daily
75450949|NCT01713218|Procedure|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
75450950|NCT01713231|Dietary Supplement|standard-dose vitamin D (400IU per day)|
75450951|NCT01713231|Dietary Supplement|high-dose vitamin D (2000 IU per day)|
75746284|NCT05521399|Diagnostic Test|MRI Testing|Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction
75897588|NCT03627559|Procedure|Pancreaticoduodenectomy microdialysis catheter analyses|A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
76025178|NCT05123105|Other|3) ischemic compression|The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
75450952|NCT01713244|Procedure|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
75450953|NCT01713244|Procedure|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
75450954|NCT01713257|Dietary Supplement|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
75450955|NCT01713257|Dietary Supplement|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
75602205|NCT04280731|Dietary Supplement|fermented quinoa|Quinoa drink fermented with lactic acid bacteria isolated from food
75602206|NCT02858947|Procedure|Aelite Flo|Microhybrid flowable composite
75602207|NCT02858947|Procedure|x-tra base|Bulk-fill flowable composite
75602208|NCT00958789|Device|Triathlon TS Knee System|Total knee replacement for revision cases
75602209|NCT02857777|Drug|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
75602210|NCT02858635|Other|Clinical and neuropsychological assessment, Blood and saliva samples|Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
75746285|NCT05501847|Radiation|Patient with no ventricular hypertrophy|"Patients without LVH ≥ 12 mm will routinely receive a bone scan as part of the study.~In case of cardiac fixation on bone scan, the patient will be managed as part of routine care according to a standardized care protocol that follows Guillmor's algorithm: monoclonal abnormality testing on biological blood samples +/- genotyping, in order to specify the senile or mutated character of TTR cardiac amyloidosis and to give the genotype."
75746286|NCT05470751|Device|Intermittent self-catheterisation|Self-catheterising with GC Air Male with Feelclean technology
75746287|NCT05463237|Diagnostic Test|oral glucose tolerance test|oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation
75602211|NCT05367375|Procedure|removing osteophyte at patellofemoral joint|to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
75746288|NCT05463237|Diagnostic Test|Blood sample|Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes
75746289|NCT05453864|Behavioral|CMAP Plus TFCBT|This will include 8 individual sessions of CMAP Plus TFCBT delivered by a trained therapist over a period of 12 weeks. Each session will last between 45 to 60 minutes.
75450956|NCT01713270|Procedure|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
75450957|NCT01713270|Drug|drug|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
75450958|NCT01713270|Procedure|Direct-Current Cardioversion|After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
75602212|NCT00630643|Biological|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
75746290|NCT05447546|Drug|HT-6184|Oral capsule
75746291|NCT05447546|Drug|HT-6184 Placebo|Oral capsule
75897589|NCT02129868|Device|Closed-loop (Android Closed-Loop platform)|"The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes."
75897590|NCT03524846|Drug|Ascorbic Acid 300 MG|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
75897591|NCT03524846|Drug|Ascorbic Acid 600 MG|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
75897592|NCT03524846|Drug|Normal saline|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
75897593|NCT04087772|Behavioral|Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH)|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
76072245|NCT02520791|Other|Laboratory Biomarker Analysis|Correlative studies
76072246|NCT02520791|Other|Pharmacological Study|Correlative studies
75602213|NCT00630643|Drug|Placebo|Placebo
75602214|NCT03202849|Dietary Supplement|Vitamin D and A|A single dose of Vitamin A and Vitamin D will be given.
75602215|NCT03202849|Dietary Supplement|Vitamin D and Placebo|A single dose of Vitamin D plus a placebo will be given.
75602216|NCT04277533|Diagnostic Test|Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)|GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.
75602217|NCT04277221|Biological|Autologous Dendritic Cell/Tumor Antigen, ADCTA|ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.
75602218|NCT02445391|Drug|Capecitabine|Given PO
75602219|NCT02445391|Drug|Carboplatin|Given IV
75602220|NCT02445391|Drug|Cisplatin|Given IV
75602221|NCT01246986|Drug|LY2157299|Administered orally
75602222|NCT01246986|Drug|Sorafenib|Administered orally
75602223|NCT01246986|Drug|Ramucirumab|Administered IV
75602224|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
75602225|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
75602226|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
75602227|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
75769267|NCT01148680|Biological|Islet Graft|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
75769268|NCT05560048|Dietary Supplement|rice protein RP-80N|rice protein RP-80NY were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
75602228|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
75602229|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
75602230|NCT05322291|Behavioral|Mobil Application|The mobile application developed will be installed on the phones of hemodialysis patients
75746292|NCT05431374|Drug|Measurement Based Care (MBC)|"Patients in both groups will receive either open-label paroxetine (20-50mg/day) or open-label mirtazapine (15-45mg/day), within the therapeutic dosage range recommended by the US Food and Drug Authority (Paxil -Highlights of Prescribing Medication, 2022; Remeron -Highlights of Prescribing Medication, 2022). Paroxetine, a selective serotonin reuptake inhibitor, is chosen because it has been one of the most commonly prescribed antidepressants, and mirtazapine, an alpha-2 antagonist, is chosen because it has a different mechanism of action. The treating psychiatrists will decide which of the antidepressants and dosages to prescribe, as long as they were within the study's recommended dosage ranges.~patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient."
75746293|NCT05431374|Drug|Control/Standard-care|Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
75746294|NCT05422040|Other|Dry needling|Invasive treatment will be performed on the most symptomatic lumbar iliocostalis muscle.
75746295|NCT05422040|Other|Tecartherapy treatment|Treatment will be carried out with deep thermotherapy in the lumbar region.
75746296|NCT05415683|Diagnostic Test|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
75450959|NCT01713296|Drug|Pazopanib|
75450960|NCT01713309|Drug|Filgrastim|Filgrastim 300 ug daily for 7 days, subcutaneously.
75602231|NCT04276831|Device|Laryngoscope McCoy|Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
75602232|NCT04276831|Device|Laryngoscope Macintosh|Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
75602233|NCT04282057|Device|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
75602234|NCT04282057|Device|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
75602235|NCT04282057|Device|Shock wave therapy|The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
75602236|NCT04319640|Behavioral|Cognitive behaviour therapy for insomnia|CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.
75602237|NCT04319640|Behavioral|psychoeducation for ASD|psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
75746297|NCT05411029|Diagnostic Test|24 hour blood pressure (BP) monitoring|24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
75769269|NCT05560048|Dietary Supplement|placebo|placebo were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
75450961|NCT01713322|Behavioral|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
75450962|NCT01713322|Behavioral|No pain management education|Control - parents receive general information about childhood immunization.
75450963|NCT01713361|Drug|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
75450964|NCT01713361|Drug|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
75450965|NCT01713361|Drug|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). [Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.]
75602238|NCT04275271|Behavioral|Educational intervention|Skill centered Protocol Training based on IMB model
75602239|NCT00958711|Device|Unite Biomatrix|Collagen based, decellularized equine pericardial dressing for skin surface wounds
75746298|NCT05411029|Diagnostic Test|Polysomnography|Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
75450966|NCT01713374|Procedure|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
75602240|NCT00958711|Other|Saline and Gauze|gauze moistened with sterile saline
75746299|NCT05407194|Dietary Supplement|Collagen + vitamin C|Participants take the supplement (or placebo) every day for 24 weeks. On three days per week they perform tendon loading exercises.
75602241|NCT01163721|Drug|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
75602242|NCT01163721|Drug|Placebo|Placebo to match ranolazine administered orally twice daily
75602243|NCT03178981|Other|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
75602244|NCT02885493|Behavioral|tests|
75602245|NCT04314453|Other|percutaneous endoscopic lumbar discectomy|Resection of the hypertrophied faceted joints, osteophyte formation and ligamentum flavum (LF) hypertrophy, with or without disc protrusion for degenerative spinal stenosis.
75602246|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
75602247|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
75602248|NCT00958243|Biological|Placebo|Placebo
75602249|NCT01241760|Drug|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
75746300|NCT05405374|Other|OSTEOAMP|OSTEOAMP SELECT Fibers (derived from human bone allograft) rehydrated with bone marrow aspirate (BMA) and combined with local autogenous graft for use in lumbar interbody fusion of the lumbar spine.
75746301|NCT05405374|Device|Infuse|The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2, known as dibotermin alfa) placed on an absorbable collagen sponge (ACS). rhBMP-2 is the active agent in the Infuse Bone Graft component. The ACS is a soft, white, pliable, absorbent implantable matrix for rhBMP-2.
75746302|NCT05400564|Behavioral|Family Check-Up|This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
75746303|NCT05396443|Behavioral|Black Girls for Wellness|Weekly for 12 weeks, adolescent participants will attend 1) a live stream group Wellness session (90 min/wk), 2) a home cooking experience using ingredients sent to participants' home (60 min/wk), and 3) one live stream group dance classes via Zoom (60 min/wk); participants will also be encouraged to attend 2 other dance classes during the week at their own convenience. Enrolled caregivers and others in the home (e.g., siblings) will be encouraged to participate in activities.
76064207|NCT02087956|Behavioral|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
75746304|NCT05396443|Behavioral|Black Girls for Wellness Caregivers|Caregivers of adolescents participating in Black Girls for Wellness will be encouraged to participate in the program's activities with their child. For example, they may help adolescent cook, or participate in the dance classes along with their child.
75746305|NCT05368207|Drug|Pembrolizumab|Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
75746306|NCT05363020|Drug|S-Adenosyl-L-Methionine (Sam-E)|400 mg capsule
75450967|NCT01713374|Other|no intervention|control visit
75450968|NCT01713374|Procedure|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
75450969|NCT01713374|Procedure|Cold pressure test|A hand will be placed in ice-cold water.
75450970|NCT01713387|Drug|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
75450971|NCT01713413|Device|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
75450972|NCT01713413|Device|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
75450973|NCT01713426|Drug|Qutenza|Cutaneous patch
75450974|NCT01713426|Drug|Pregabalin|Oral capsule
75602250|NCT01241760|Drug|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
75602251|NCT01241760|Drug|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
75602252|NCT01241760|Drug|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
75602253|NCT04280263|Drug|Caffeine|caffeine tables containing 150mg caffeine will be provided to patients with instructions to take twice per day
75746307|NCT05363020|Drug|Placebo|400 mg identically appearing placebo
76064208|NCT02087956|Behavioral|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
76064209|NCT03027219|Drug|Alprostadil|Vasodilator for anastomosis-site of free flap
75450975|NCT01713452|Procedure|Purse string closure|"An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~Diameter of the skin defect should then be measured.~A postoperative photo will then be taken."
75746308|NCT05346796|Behavioral|Survivorship Care Plan-Personal Health Record (SCP-PHR)|The SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
75602254|NCT04280263|Drug|Placebo oral tablet|oral placebo tablets matching the caffeine tablets and will be provided to patients with instructions to take twice per day
75602255|NCT02858557|Behavioral|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
75746309|NCT05341115|Drug|Leuprorelin Acetate Depot 3M|Leuprorelin Acetate Depot 3M SC injections.
75746310|NCT05332600|Other|drop-jump test|The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.
75746311|NCT05327543|Behavioral|Iyengar Yoga|Iyengar Yoga focuses on the correct alignment of the body while practicing the physical exercises of yoga. Props are used to support the body in finding the right alignment. Relaxation is also part of this intervention. Participiants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
75746312|NCT05327543|Behavioral|Meditative Yoga|Meditative Yoga in the context of this study means practicing the physical exercises of yoga as well as meditation. Additionally, each week one of the yamas/niyamas, which are ethical principles to live by in the Yoga philosophy, will be presented at the beginning of each class and will form the theme of the class. Participants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
75746313|NCT05306912|Biological|Blood samples|Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.
75769270|NCT03903328|Other|Sarcopenia assessment|Sarcopenia assessment by measurement of Skeletal Muscle mass index, hand grip strength and usual gait speed for 5 meter distance, as per the guidelines of Asia Working group for Sarcopenia study, was carried out.
75450976|NCT01713452|Procedure|Primary closure|"An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (<1.5cm). No subcutaneous drains will be placed.~Length of the incision should be measured in centimeters.~A postoperative photo will then be taken."
75602256|NCT02858557|Behavioral|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
75602257|NCT00958165|Device|CardioFocus EAS-AC|PVI for PAF
76025179|NCT05122949|Device|3D Printed Ankle-Foot Orthosis|3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material
75450977|NCT01713465|Other|Computer based Metabolic Syndrome educational program|Individuals in the intervention group will receive metabolic syndrome related education using a touch screen interactive and bilingual multimedia enabled educational program
75602258|NCT04280185|Procedure|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is a way of intraperitoneal chemotherapy
75602259|NCT02858479|Other|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
75602260|NCT02858479|Other|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
75602261|NCT02858479|Radiation|MRI scan|"2 sessions for 10 minutes :~11 controls stimulations for 6 s each spaced 20 s without stimulation.~11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
76025180|NCT05122949|Device|Thermoformed Ankle-Foot Orthosis|Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
76025181|NCT02684617|Biological|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
76025182|NCT02684617|Drug|dinaciclib|dinaciclib 7 mg/m^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
76025183|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
75746314|NCT05298878|Other|Intervention Group: Virtual home-based rehabilitation plus usual outpatient care|"14 supervised exercise virtual sessions with Kinesiologist and 10 independent exercise sessions. Each session lasts 40 minutes. The exercises consist of aerobic training; functional lower and upper body strengthening; balance; and flexibility exercises. During the first 10 minutes of the first session of each week, there is an educational session.~Week 1-2: three supervised virtual sessions Week 3-4: two supervised virtual sessions and one independent session. Week 5-8: one supervised virtual session and two independent sessions."
75746315|NCT05262855|Drug|[68Ga]FAPI-46|[68Ga]-FAPI-46 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma (PDAC).
75746316|NCT05238324|Biological|Genetic HMI-203|HMI-203 delivered intravenously
75746317|NCT05233228|Drug|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
75602262|NCT00958009|Device|Rebidose®|The device is a ready to use single use auto injector containing Rebif® 44 mcg in a 0.5 mL prefilled syringe for sc injection
75450978|NCT01713478|Other|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
75602263|NCT02857075|Other|Blood donation|Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
75746318|NCT05233228|Behavioral|Self-help materials (to support smoking cessation|"The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit."
75746319|NCT05233228|Behavioral|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 26-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
75602264|NCT00953407|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
75746320|NCT05220371|Dietary Supplement|Collagen|Participants ingest 15 grams of either specific collagen peptides or Placebo daily
75746321|NCT05220371|Other|Concurrent training|Both arms undergo a 12-week trainingintervention 3x/week
75450979|NCT01713504|Biological|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
76025184|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
76025185|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
75450980|NCT01713517|Other|Indoor residual insecticide spraying (IRS)|Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
75450981|NCT01713517|Device|Long Lasting Insecticidal Nets (LLIN)|Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
75450982|NCT01713543|Other|physical therapy|Tailored physical therapy sessions to modify impairments in balance and/or gait and to transition high-risk participants to an evidence-based group exercise program.
75450983|NCT01713556|Drug|Propranolol|
75450984|NCT01713556|Other|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
75450985|NCT01713556|Drug|placebo|
75450986|NCT01713569|Device|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
75450987|NCT01713595|Drug|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
75450988|NCT01713634|Other|Preflight|4-d controlled diet sessions will occur twice before flight.
75450989|NCT01713634|Other|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
75450990|NCT01713647|Drug|Amlodipin, losartan, HCTZ|
75450991|NCT01713673|Drug|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75450992|NCT01713673|Drug|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
75602265|NCT00953407|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
75602266|NCT00953407|Device|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
75746322|NCT05209438|Device|Cereset Research|Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
75746323|NCT05193916|Drug|chiglitazar sodium tablets|the drugs will be given orally once a day
75746324|NCT05193916|Drug|Placebo|no active drug contained
75746325|NCT05136053|Drug|Lu AG22515|sterile solution for infusion
75746326|NCT05136053|Drug|Placebo|sterile solution for infusion
75746327|NCT05136053|Drug|Immune System Activator|sterile powder for injection
75746328|NCT05131672|Procedure|open reduction and internal fixation (ORIF)|open reduction and internal fixation with pin or screw fixation
75746329|NCT05131672|Procedure|cast immobilization|immobilization in a cast without reduction
76064210|NCT04776772|Dietary Supplement|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
76064211|NCT04776772|Dietary Supplement|Placebo|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo)."
75450993|NCT01713699|Procedure|lumbar puncture|
75602267|NCT00953407|Device|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
75602268|NCT00953407|Device|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
75602269|NCT00953329|Drug|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
75746330|NCT05127057|Other|PRIME Parkinson Care|A novel model of care
75746331|NCT05127057|Other|Usual Care|Usual NHS Care
75746332|NCT05119712|Drug|Terbinafine Tablets|500mg oral terbinafine or placebo daily
75746333|NCT05119712|Diagnostic Test|Laboratory Testing|Laboratory testing at screening, baseline, week 8, 16, 24 and 32.
75897594|NCT04087772|Behavioral|Racial/Ethnic Discrimination Interventions (RED)|Racial/Ethnic Discrimination Interventions are a set of components to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
76064212|NCT01506453|Drug|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
76064213|NCT01506453|Drug|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
76064214|NCT00218686|Behavioral|psychoeducational|psychoeducational
75746334|NCT05119712|Diagnostic Test|Laboratory Testing|Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.
75450994|NCT01713712|Behavioral|Nutritional Counseling|Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
75450995|NCT01713725|Biological|Omalizumab|"Two injections will be administered the first two weeks~The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
75450996|NCT01713725|Biological|Placebo|"Two injections will be administered the first two weeks~The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
75746335|NCT05119582|Device|TOOsonix System ONE-M|Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.
75746336|NCT05104047|Other|Moxibustion - Traditional (Active)|Traditional Moxibustion (Moxa) is a technique in which the herb, artemisia, in a cigar shape (pole moxa) is lit (burned) and applied over specific acupuncture points which follows a specific protocol aimed at reducing neuropathic lower limb pain/discomfort.
75746337|NCT05104047|Other|Moxibustion - Smokeless - (Active)|Smokeless Moxibustion uses the same technique as traditional moxa however, the moxa is smokeless. Smokeless moxa allows for use in a broad range of treatment settings. The protocol is aimed at reducing neuropathic lower limb pain/discomfort.
75746338|NCT05104047|Other|Placebo Moxibustion|Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not active.
75746339|NCT05101629|Drug|Pembrolizumab|Pembrolizumab 200 mg, IV, over 30 minutes every 3 weeks
75746340|NCT05101629|Drug|Lenvatinib Capsules|Lenvatinib 8 mg for BW < 60 kg / 12 mg for BW ≥ 60 kg oral, once daily for 3 weeks
75746341|NCT05080179|Behavioral|Self-Benefit/Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
75746342|NCT05080179|Behavioral|Self-Benefit/No Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app."
75746343|NCT05080179|Behavioral|Other Benefit/Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
75746344|NCT05080179|Behavioral|Other Benefit/No Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app."
75746345|NCT05067075|Device|Blinded CGM|CGM that records blood glucose but is not visible to patient or provider in real-time
75746346|NCT05042609|Drug|TRS01|TRS01 eye drops Dosed four times a day (QID)
75746347|NCT05042609|Drug|FDA approved steroid eye drop (masked)|FDA approved steroid eye drop Dosed four times a day (QID)
75746348|NCT05036720|Behavioral|LTP+Dads|"LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
75897595|NCT02138760|Procedure|MRI UroNav fusion biopsy|
75897596|NCT05134558|Radiation|Xenon-enhanced Ventilation CT-guided Radiotherapy|Xenon-enhanced Ventilation CT-guided Radiotherapy for functional protection of the lung
75897597|NCT05220553|Device|PROLIMB Prosthesis|Participants will be given the PROLIMB prosthesis to test in the lab and to use in their daily lives
75897598|NCT02129946|Other|Resistant Starch|In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
75897599|NCT04916236|Drug|RMC-4630|"SHP2-inhibitor~Powder in capsule~Administered on day 1 and day 2 of every week"
75897600|NCT04916236|Drug|LY3214996|"ERK inhibitor~Powder in capsule~Administered every day"
75897601|NCT02970669|Drug|sacubitril/valsartan (LCZ696)|sacubitril/valsartan tablet taken orally.
75897602|NCT02970669|Drug|enalapril|Enalapril tablet taken orally.
75897603|NCT02970669|Drug|matching placebo sacubitril/valsartan (LCZ696)|matching placebo sacubitril/valsartan tablet taken orally
75746349|NCT05036720|Behavioral|LTP+ Optional mother component|LTP+ is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP+ is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
75897604|NCT02970669|Drug|matching placebo enalapril|matching placebo enalapril tablet taken orally
75897605|NCT05220085|Drug|Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution|Intravitreal injection
75897606|NCT02133846|Drug|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
75897607|NCT02133846|Drug|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
75897608|NCT02133846|Drug|Placebo|500mL 0.9% sodium chloride
75897609|NCT02133846|Drug|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
76025186|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
76025187|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
75746350|NCT05036122|Device|LabClasp|Non-invasive device that estimates blood [lactate] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood [lactate] and return a value to the subject via an accompanying tablet within 20 seconds.
75746351|NCT05025345|Device|Tecnis Eyhance|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
75746352|NCT05025345|Device|Tecnis 1 piece IOL|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
75746353|NCT04985344|Drug|Propranolol Oral Product|Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.
75746354|NCT04985344|Drug|Placebo|Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
75746355|NCT04985344|Other|memory reactivation|90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
75746356|NCT04979312|Device|LabClasp|participants will be randomized to LabClasp + standard care or just standard care
75746357|NCT04974970|Drug|Peanut Immunotherapy|Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
75746358|NCT04946370|Drug|225Ac-J591|Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
75746359|NCT04946370|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
75746360|NCT04946370|Drug|Androgen receptor pathway inhibitor|Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.
75746361|NCT04946370|Diagnostic Test|68Ga-PSMA-11|[185 ±74 MBq or 5 ±2 mCi] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
75746362|NCT04941001|Device|ReferID|The ReferID tool is a digital tool which can be used to facilitate a review of asthma in primary care
75602270|NCT02857153|Drug|Urapidil|If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
75602271|NCT02857153|Drug|Phenylephrine|If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
75602272|NCT02857153|Procedure|Low-level MAP|MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
75746363|NCT04925128|Other|Moderate Physical Activity + Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain Moderate physical activity on treadmill, brisk walk was performed 5 days a week for 30 minutes at 4 mph speed (3-6 METs) with warm up for a 5 minutes at low speed and then at the end speed was also decreased for a 5 minutes"
75746364|NCT04925128|Other|Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain"
75602273|NCT02857153|Procedure|High-level MAP|MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
75602274|NCT02856997|Drug|Chidamide with ICE regimen|Chidamide and ICE regimen, dosage described in arm description
75602275|NCT00953017|Drug|Miralax (PEG 3350)|Miralax 255gm bottle
75602276|NCT00953017|Drug|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
75602277|NCT00953017|Drug|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
76025188|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
76025189|NCT04055389|Drug|Antithrombin III|"Patients with reversal of flow or sluggish flow in the main portal vein (<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life ~4 days) at a weight-based dosage according to the following formula:~[Desired level of AT (100%) - Subject level of AT (%)] * subject weight (kg) 1.4~or placebo for 24 weeks of therapy."
75746365|NCT04924569|Device|Intermittent Catheter|Flexible tubular device used to drain urine from the bladder via the urethra by male, female, and pediatrics.
75602278|NCT00953017|Drug|Golytely (polyethylene glycol)|Golytely 1 gallon
75602279|NCT00952705|Biological|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
75602280|NCT00952705|Biological|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
75602281|NCT00952705|Biological|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
75602282|NCT00955357|Drug|Lacosamide|"Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week"
75746366|NCT04920695|Drug|Nitric Oxide|Pulmonary vasodilator (gas).
75746367|NCT04920695|Drug|Placebo|medical grade normoxic gas (FiO2 = 0.21)
76025190|NCT04055389|Other|Placebo|No study drug
75602283|NCT00955279|Drug|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
75746368|NCT04918290|Device|Tegaderm Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
75746369|NCT04918290|Device|Transpore Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
75746370|NCT04902417|Other|Dairy Foods (Yoghurt, Cheese, Milk)|Participants will be provided with a combination of dairy products (Yoghurt, Cheese, Milk) to be consumed daily, for a total of 3 servings per day
75450997|NCT01713738|Drug|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
75602284|NCT00955279|Drug|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
75602285|NCT00955279|Drug|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
75602286|NCT00954733|Other|Arterial blood draw|One arterial blood draw
75450998|NCT01713751|Other|Interrupted suturing|Skin is closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
75450999|NCT01713751|Other|Subcuticular suturing|Skin is closed with subcuticular stitches using non-absorbable polypropylene [Prolene®]
75451000|NCT01713764|Behavioral|Low Carbohydrate Diet|
75451001|NCT01713764|Behavioral|American Diabetes Association Diet|
75451002|NCT01713764|Behavioral|Mindfulness and Positive Affect Skills|
75451003|NCT01713777|Drug|"Lamotrigine Generic A"|
75602287|NCT00630721|Other|IFNbeta-1b|no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
75602288|NCT00954421|Device|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
75602289|NCT02857309|Device|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
75746371|NCT04885569|Behavioral|Motivational interviewing with CBT (MICBT)|The culturally adapted MICBT will include approaches of motivational interviewing and offer ways of managing difficulties from a cognitive behavioural formulation.
75746372|NCT04885569|Behavioral|Mindfulness based Relapse Prevention (MBRP)|MBRP will incorporate cognitive-behavioural skills (i.e., effective coping skills, self-efficacy, and recognizing common antecedents of relapse) with mindfulness-based practices to decrease the probability of relapse by increasing awareness and flexible responding in the presence of substance use triggers.
75746373|NCT04885569|Behavioral|CAMIAB|This will be integrated CBT based motivational interviewing plus mindfulness based relapse prevention intervention group.
76025191|NCT03106207|Procedure|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
75451004|NCT01713777|Drug|"Lamotrigine generic B"|
75451005|NCT01713790|Device|Stochastic resonance whole-body vibration|Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.
75451006|NCT01713790|Device|Exergame|training program over 10 weeks, three times a week.
75451007|NCT01713790|Device|Leg press|training program over 10 weeks, three times a week.
75451008|NCT01713803|Drug|Buprenorphine and naloxone|
75451009|NCT01713829|Other|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
75451010|NCT01713829|Other|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
75451011|NCT01713842|Drug|TCZ|Tocilizumab at week 0, 4 and 8.
75451012|NCT01713855|Biological|Inactivated Trivalent Influenza vaccine|
75451013|NCT01713894|Other|Decision Aid|
75451014|NCT01713894|Other|Standard|
75451015|NCT01713907|Device|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
75451016|NCT01713920|Drug|SEVIKAR|
75451017|NCT01713959|Device|Ulthera System treatment|Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
75451018|NCT01713959|Device|Sham treatment|Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
75451019|NCT01713972|Drug|dabrafenib|Given PO
75451020|NCT01713972|Drug|pazopanib hydrochloride|Given PO
75451021|NCT01713972|Other|Correlative studies|"Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~Tumor genotyping: Archival tumor blocks or unstained slides~BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
75451022|NCT01713985|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
75451023|NCT01713985|Device|Thermage|Radiofrequency treatment focusing radiofrequency energy
75602290|NCT02857309|Drug|Optimal medical therapy|OMT using standard heart failure (HF) drugs
75602291|NCT04261231|Procedure|Surgery and anesthesia|Elective surgery in adults
75602292|NCT02857465|Drug|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
76025192|NCT05697055|Drug|Azvudine|5mg orally, once a day, for no more than 14 days
76064215|NCT00218686|Behavioral|control|VTC
75746374|NCT04820400|Other|Immersive VR Video|"The VR-360 video will be custom-made for the burn patient population. Through a review of current evidence for video scenarios/patients surveys, the study team will define and implement the key components appropriate for acute procedural pain such as type, duration and severity in this patient population. Next, patients will be asked about preferred pain relief elements (e.g. individual colours, geographical locations, sounds, etc.) that would help to design a video scenario. Finally, using a Likert pain scale, patients will be asked to rate each individual descriptor that exacerbates or alleviates pain. For instance, the colour red may be associated with 'flames', 'heat' and 'burns', and thus elevated pain, the colour blue may have the opposite effect, representing 'cooling' or 'cold'.~Combined, this information will be used to create a VR-360 video geared towards alleviating acute procedural pain in patients with burn injuries undergoing dressing changes after skin graft."
75746375|NCT04814147|Procedure|Sleeve gastrectomy|Measure of NLRP3 inflammasome preoperative activation level by the expression of NLRP3, IL-1β, IL18 and caspase-1 mRNAs in subcutaneous and visceral adipose tissue. of the epiploon;
75897610|NCT05220007|Diagnostic Test|Humphrey visual field testing|Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.
75602293|NCT02857465|Drug|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
75602294|NCT02857465|Drug|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
75602295|NCT02857465|Drug|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
75746376|NCT04809207|Other|CF Wellness Program Sessions|The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.
75746377|NCT04785066|Drug|Administration of dornase alfa|Patient treated for a cerebral thrombectomy will be administred dornase alfa treatment by intravenous
75451024|NCT01714011|Drug|Ziprasidone|"Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours."
75451025|NCT01714011|Drug|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
75897611|NCT02252484|Other|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
75897612|NCT02252484|Other|Standard of Care|Standard of Care for this patient population.
75897613|NCT05113108|Device|CUS|All neonates undergoing CUS at nursery unit at assiut university hospital. Cranial ultrasound is performed with basic grayscale imaging. For optimal resolution and good overview, a multifrequency (5-10 MHz) linear or convex sector transducer is used. Imaging is obtained through the anterior fontanel in the coronal and sagittal planes.{12,13} Typically, six to eight coronal images are obtained beginning at the frontal lobes just anterior to the frontal horns and extending to the occipital lobes posterior to the lateral ventricle trigones.{14} The transducer is then rotated 90°, and approximately five images are obtained, including a midline sagittal view of the corpus callosum and cerebellar vermis in addition to bilateral parasagittal images beginning in the midline and progressing laterally through the peripheral cortex.Doppler ultrasound may be added to assess ischemic areas.{13-15}
75897614|NCT03651453|Behavioral|Decision aid|Participants in the experimental arm will receive the PrEP decision aid.
75897615|NCT03651453|Behavioral|Standard care|Standard harm reduction information
75602296|NCT02857387|Biological|blood sample withdrawn|
75602297|NCT04273009|Device|Renew VS PTNS|These will be prescribed and applied as described above.
75602298|NCT04260139|Procedure|Calculation of metric variables on the colectomy specimens.|"Calculation of metric variables on the colectomy specimens including Lengths as mm~Proximal colon,~Ileum in cases with right hemicolectomy only,~Proximal border,~Tumor,~Distal border,~Total specimen,~Vascular pedicle, the longitudinal distance between the nearest bowel wall and the end of ligated major vascular pedicle depending on the tumor's localization, 2. Colonic mesenteric area as mm2."
75602299|NCT01241448|Drug|LY2409021|Administered Orally
75746378|NCT04778579|Drug|ARI-0001 cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
75746379|NCT04776356|Device|QuickFix Small Staple (Arthrex)|The Arthrex QuickFix Small Staple enables the surgeon to perform a wedge osteotomy of the first phalanx (Akin). The device is made of stainless steel and designed with barbed leg tips. The staple sizes are 8 and 10 mm wide with a 1 mm diameter.
75746380|NCT04751435|Other|Cognitive interview|Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
75746381|NCT04744402|Drug|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm^3 defect
75746382|NCT04737629|Behavioral|Expectancy and Water|In the expectancy and water condition, participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script for this condition will inform them of research that has shown water to decrease appetite by up to 50% (attempting to create an expectancy).
75746383|NCT04737629|Behavioral|No Expectancy and Water|Participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script will inform them of research that has shown water to decrease appetite by up to 50%. In this condition, however, the research team will also inform them that this herb is expected to counteract the effects of water on appetite because it decreases water retention, causing water to pass through the stomach and intestines at a faster than normal rate (attempting to create no water expectancy or nullify any pre-existing expectancy).
75602300|NCT01241448|Drug|Placebo|Administered Orally
75746384|NCT04737629|Behavioral|No Water|Participants will be instructed to consume the mint herb and 50mL of water before the start of the taste test. Participants will be given 100mL of water during the taste test to aid in their ability to taste and consume food, and to avoid acute thirst interfering with food consumption. Access to fluids during a taste test has been used in control conditions in similar studies. The script for this condition will inform participants of research that has shown water to decrease appetite by up to 50% but acknowledge that they will not be receiving water (thus, they should not expect an effect on appetite).
75746385|NCT04725721|Behavioral|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
75746386|NCT04725721|Behavioral|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
75897616|NCT05219773|Device|NuvoAir Air Next spirometer|"The collection of medical history and demographic data~Spirometry testing in both the clinic and home setting.~The measurement of height and weight.~The evaluation of the perception of home spirometry via a survey."
75897617|NCT02134002|Drug|Disulfiram|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
75897618|NCT02134002|Drug|Placebo|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
75897619|NCT03650361|Drug|Adapalene Gel 0.3%|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
75897620|NCT03650361|Drug|Differin 0.3% Topical Gel|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
75897621|NCT03650361|Drug|Adapalene Gel 0.3% Vehicle Placebo|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
75897622|NCT02138994|Device|Next Science Wound Gel|
75451026|NCT01714037|Drug|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
75602301|NCT04319406|Procedure|Prolotherapy|Test group will be administered 12.5% Dextrose mainly into superior joint space according to symptoms of patient at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
75451027|NCT01714037|Drug|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
75451028|NCT01714037|Drug|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
75451029|NCT01714037|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
75451030|NCT01714037|Drug|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
75451031|NCT01714076|Other|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
75451032|NCT01714089|Drug|RNS60 125 ml|
75451033|NCT01714089|Drug|RNS60 250 ml|
75451034|NCT01714089|Drug|Interferon beta 1a|
75451035|NCT01714102|Dietary Supplement|Placebo|Placebo manufactured to mimic resveratrol tablet
75602302|NCT04319406|Procedure|Dry needling|Only dry needling will be performed at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
75746387|NCT04720664|Drug|SM-88|"SM-88, Two 230 mg capsules taken orally twice daily (920 mg daily).~Methoxsalen, One 10 mg capsule taken orally once daily.~Phenytoin, One 50 mg tablet taken orally once daily.~Sirolimus, One 0.5 mg tablet taken orally once daily."
75746388|NCT04718168|Device|Gore ENFORM Biomaterial (Preperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
75746389|NCT04718168|Device|Gore ENFORM Biomaterial (Intraperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
75746390|NCT04711343|Drug|BAT2306|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
75746391|NCT04711343|Drug|Cosentyx (US-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
75746392|NCT04711343|Drug|Cosentyx (EU-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
75746393|NCT04683653|Radiation|Hypofractionated Radiation|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
75897623|NCT02138994|Drug|Triple Antibiotic Ointment Neosporin|"Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~Subject may continue the application of Neosporin until wound closure or~Subject may cross over to the treatment group for 3 months"
75897624|NCT05219461|Drug|Single dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
75897625|NCT05219461|Drug|Single dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
75897626|NCT05219461|Drug|Single dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
75897627|NCT05219461|Drug|Multiple dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
75451036|NCT01714102|Dietary Supplement|Resveratrol|Resveratrol PO BID for 30 days
75897628|NCT05219461|Drug|Multiple dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
75897629|NCT05219461|Drug|Multiple dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
75897630|NCT04771234|Behavioral|Digital self-guided CBT-i|A brief version of CBT-i consisting of brief psychoeducation, and the core components sleep restricion and stimulus control, where sleep restriction is based on a simplified sleep diary.
75897631|NCT03549546|Biological|Blood samples|"Blood samples will be collected in patients undergoing lung cancer surgery:~before lung cancer surgery,~the next day lung cancer surgery,~3 days after lung cancer surgery. They will be treated in flow cytometry."
75897632|NCT04761796|Other|Sleeping condition self-questionnaire|Professional flight members will answer a self questionnaire related to their sleeping conditions
75897633|NCT02130102|Device|The ModuLAAr Ambient Assisted Living System|"The system consists of the following modules which will be provided to the volunteers according to their needs:~tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies"
75897634|NCT02253186|Device|Auto-Adjustable MOBIDERM Armsleeve|
75897635|NCT05303818|Drug|Rivaroxaban 10 MG|Patients in post-operative colonic cancer will receive rivaroxaban 10mg/daily for 28 days after surgery
75897636|NCT05024149|Other|infrared thermography (IRT)|The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
75897637|NCT02134080|Drug|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
75897638|NCT02134080|Drug|Placebo|Placebo will be administered orally at 4mg daily for four weeks.
75897639|NCT05303740|Drug|Anlotinib|This is an observational study.
76025193|NCT05697055|Drug|Nirmatrelvir-Ritonavir|Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR < 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
75451037|NCT01714115|Drug|Aflibercept|2.0 mg Intravitreal Injection, every 2 to 4 weeks
75451038|NCT01714128|Drug|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
75451039|NCT01714141|Behavioral|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
75451040|NCT01714141|Behavioral|Asthma education active control|
75602303|NCT01240356|Device|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
75451041|NCT01714154|Drug|danoprevir|100 mg orally every 12 hours
75451042|NCT01714154|Drug|ritonavir|100 mg orally every 12 hours
75451043|NCT01714154|Drug|setrobuvir|200 mg orally every 12 hours
75602304|NCT01240356|Device|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
75602305|NCT04206618|Drug|Teriparatide|1 subcutaneous injection daily for 12 months
75602306|NCT04206618|Drug|Denosumab|1 subcutaneous injection every 6 months for 12 months
75602307|NCT01239732|Drug|Paclitaxel|175 mg/m^2 on Day 1 every 3 weeks or at a dose of 80 mg/m^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
75602308|NCT01239732|Drug|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
75602309|NCT01239732|Drug|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
75602310|NCT02227147|Drug|rhNGF 20µg/ml|
75602311|NCT02227147|Other|Placebo|Formulation containing antioxidant
75602312|NCT02856919|Drug|brimonidine tartrate|Mirvaso® gel (5 mg/g brimonidine tartrate)
75602313|NCT02854735|Other|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
75746394|NCT04683653|Other|Clinical Follow-Up and Assessments|"At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the EPIC questionnaire) during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer."
75746395|NCT04654949|Other|Horticultural Therapy|The horticultural therapy sessions are conducted by the occupational therapists or therapy assistants using the mobile horticultural kits. The horticultural activities are designed to stimulate the senses through interaction with specific tasks and the environment, promote social interaction, mobility and also promote a sense of self-worth through various horticultural activities such as planting seeds, transplanting plants, trimming and watering plants.
75746396|NCT04646707|Drug|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
75746397|NCT04646707|Drug|Erector Spinae (ESP) Block with placebo|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
75746398|NCT04646694|Drug|Ketamine|The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
75746399|NCT04646694|Other|Placebo|A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
75746400|NCT04636879|Other|Positive expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding message.
75746401|NCT04636879|Other|Neutral expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
75746402|NCT04636879|Other|Negative expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
75746403|NCT04629950|Drug|Rimegepant|Active Agent
75746404|NCT04629950|Drug|Placebo|Placebo Comparator
75746405|NCT04614155|Other|Educational Intervention|Take part in health education session
75746406|NCT04614155|Procedure|HPV Self-Collection|Receive HPV self-collection kit
75746407|NCT04614155|Other|Questionnaire Administration|Complete questionnaires
75746408|NCT04612400|Other|Oral amino acid tracer|Whole body protein metabolism response to a dose of the supplement will be measured using a continuous oral sip-feeding (every 10 minutes) method of stable isotope tracer.
75746409|NCT04611087|Behavioral|Discussion|Attend focus groups
75746410|NCT04611087|Other|Interview|Attend interviews
75746411|NCT04611087|Other|Survey Administration|Ancillary studies
75897640|NCT04998019|Behavioral|PositiveLinks|"The PositiveLinks (PL) patient mobile app delivers appointment reminders, daily queries (check-ins) of mood, stress and medication adherence, tailored educational resources, access to the PL team for individualized assistance, and the opportunity to interact with other users on a secure, anonymous community message board (CMB)."
75746412|NCT04595370|Drug|AZD9977|Participants will receive AZD9977 as per the arms they are randomized.
75746413|NCT04595370|Drug|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized.
75746414|NCT04554966|Drug|ABBV-382|Intravenous (IV) infusion
75897641|NCT02139072|Device|CoaguChek XS|CoaguChek XS will be used to measure INR in patients with APL
75746415|NCT04554966|Drug|ABBV-382|Subcutaneous (SC) injection
75746416|NCT04554966|Drug|Placebo for ABBV-382|Intravenous (IV) infusion
75897642|NCT02139072|Procedure|Standard Lab Draw|Patients on warfarin for any indication other than APL will measure INR by venous lab draw
75897643|NCT02139150|Radiation|[18F] FLT|
75451044|NCT01714167|Genetic|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
75897644|NCT02139150|Device|PET/CT scans|
75897645|NCT02130336|Behavioral|Aerobic interval training|
75746417|NCT04543942|Drug|Alcohol|Alcohol will be administered by IV infusion (60mg%). Brain activation during response inhibition (BARI) will be assessed using fMRI during performance of the stop signal task.
75746418|NCT04523714|Behavioral|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
75746419|NCT04523714|Behavioral|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
75746420|NCT04516122|Procedure|Biospecimen Collection|Undergo collection of blood samples
75746421|NCT04516122|Procedure|Dual X-ray Absorptiometry|Undergo DXA scan
75746422|NCT04511455|Drug|Cabozantinib|Cabozantinib 60 mg/day peroral
75746423|NCT04506567|Drug|225Ac-J591|Single cycle of fractionated dose of 225Ac-J591
75746424|NCT04506567|Diagnostic Test|68Ga-PSMA-HBED-CC injection|68Ga-PSMA-HBED-CC PET/CT before and after treatment
75602314|NCT00948025|Device|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
75602315|NCT00948025|Other|Processed Human Nerve Tissue|Implantation of appropriate length of processed human nerve tissue at time of surgery.
75602316|NCT02854579|Biological|neural progenitor cell|Neural progenitor cells are derived from the same aborted human fetal forebrain.
75897646|NCT02130336|Behavioral|Continuous moderate-intensity exercise|
75897647|NCT02902965|Drug|Ibrutinib|Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
75897648|NCT02902965|Drug|Bortezomib|Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
75451045|NCT01714193|Drug|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
75602317|NCT02854579|Biological|Paracrine factors|The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
75602318|NCT02854579|Biological|progenitor cell and paracrine factors|Neural progenitor cells will be received after paracrine factors therapy
75451046|NCT01714193|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
75451047|NCT01714206|Drug|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
75451048|NCT01714206|Drug|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
75451049|NCT01714206|Drug|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
75602319|NCT02854423|Device|percutaneous coronary interventions|Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
75602320|NCT00947011|Drug|Placebo|1 tablet 100 mg once a day
76025194|NCT04053361|Procedure|Catheter ablation|Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
76025195|NCT03162367|Biological|Autologous epidermal cell suspension|First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
75451050|NCT01714219|Procedure|Posterior reconstruction|
75451051|NCT01714258|Procedure|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
75451052|NCT01714284|Behavioral|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
75451053|NCT01714284|Behavioral|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
75602321|NCT00947011|Drug|Januvia|1 tablet 100 mg once a day
75602322|NCT02856685|Drug|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
75602323|NCT02860663|Dietary Supplement|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
75602324|NCT02860663|Dietary Supplement|Vitamin D2|10 ug/d of vitamin D3 for 6 weeks
75602325|NCT02860663|Dietary Supplement|25OHD|10 ug/d of vitamin D3 for 6 weeks
75746425|NCT04506567|Drug|225Ac-J591|Single dose of 225Ac-J591 every 6 weeks x 4
75746426|NCT04467866|Behavioral|A Ride-on Car with a Standing Posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
75746427|NCT04467866|Behavioral|Regular Therapy Program|The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
75746428|NCT04456478|Procedure|pH at 7.38 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
75602326|NCT04270513|Other|Endovascular treatment by Flying Intervention Team|After telemedicine-assisted decision for endovascular treatment, the Flying Intervention Team is transferred via helicopter to the primary stroke center and performs endovascular treatment in the local angiography suite.
75746429|NCT04456478|Procedure|pH at 7.22 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
75746430|NCT04427228|Radiation|Radiosurgery Single Treatment|Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) < 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
75602327|NCT02854189|Device|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
75746431|NCT04427228|Radiation|Radiosurgery Three Treatments|Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
75602328|NCT02854345|Device|Tomoscintigraphic parathyroid imaging on a CZT camera|
75746432|NCT04406818|Drug|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
75746433|NCT04404660|Biological|AUTO1|Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a total target dose of 410E+6 of CD19-positive CAR T cells as a split dose on Day 1 and on Day 10 (±2 days).
75746434|NCT04393623|Behavioral|Cognitive Reappraisal|This cognitive reappraisal microintervention lasts 45-60 minutes.
75746435|NCT04393623|Behavioral|Psychoeducation|This psychoeducational microintervention lasts 45-60 minutes.
75746436|NCT04371198|Other|Biopsy|Tissue biopsy
75746437|NCT04361708|Drug|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
75602329|NCT04281823|Diagnostic Test|Cardiovascular Magnetic Resonance|Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
76025196|NCT03162367|Drug|Silver sulfadiazine ointment|the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
76025197|NCT01999894|Drug|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
76025198|NCT03165565|Behavioral|Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)|Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
75602330|NCT02853877|Behavioral|Weekly Incentive|The tailored incentives intervention aims to assess the impact of tailored messaging and financial incentives on weight loss among obese employees.
75602331|NCT02854111|Other|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
75602332|NCT02854111|Other|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
75602333|NCT01239342|Drug|Akt Inhibitor MK2206|Given PO
75602334|NCT01239342|Drug|Everolimus|Given PO
75602335|NCT01239342|Other|Laboratory Biomarker Analysis|Optional correlative studies
75746438|NCT04361708|Drug|Docetaxel|Docetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
75602336|NCT04319250|Other|ischemic compression|ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.
75746439|NCT04361708|Drug|Leucovorin|Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
75746440|NCT04361708|Drug|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
75746441|NCT04361708|Drug|5-Fluorouracil|5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.
75746442|NCT04345146|Combination Product|FSRT combined with Bevacizumab|"Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases."
75602337|NCT04319250|Other|IASTM|"In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way."
75746443|NCT04339543|Other|Cognitive dual-task walking|• The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
75602338|NCT04319250|Other|Rehabilitation Program|A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
75602339|NCT00946309|Drug|High Sulforaphane Extract (Broccoli Sprout Extract)|100 umol sulforaphane, every other day for 5 weeks
75746444|NCT04336098|Drug|SRF617|SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.
75746445|NCT04336098|Drug|Gemcitabine|Gemcitabine as an intravenous (IV) infusion
75746446|NCT04336098|Drug|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel as an IV infusion
75746447|NCT04336098|Drug|Pembrolizumab|Pembrolizumab as an IV infusion .
75746448|NCT04316494|Drug|Hydroxychloroquine|"White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900"
75897649|NCT02902965|Drug|Dexamethasone|"Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects >75 years of age.~Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter."
75897650|NCT02134158|Device|anodal tDCS and sham tDCS stimulations|"Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.~All the investigations will associate with clinical, functional and 3D motion analysis assessments."
75897651|NCT02130414|Drug|Sandimmun® IV|2 mg/kg IV
75746449|NCT04316494|Drug|Placebo|"Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate"
75897652|NCT02130414|Drug|CyCol® capsules|37.5 mg CyCol® capsules
75897653|NCT03651141|Other|Neurodynamic Sliding|Subjects in the neurodynamic sliding group perform 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets. A metronome will be set at 30 beats per minute for 15 full slides per minute to standardize the amount of slides per session.
75897654|NCT03651141|Other|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
75746450|NCT04309981|Biological|Adult differentiated autologous T-cells with anti-BCMA specificity|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.
75746451|NCT04288154|Device|EMS Device On|The EMS Device will turned on during exercise as opposed to it being turned off for control group.
75602340|NCT00946309|Drug|Microcrystalline Cellulose NF (placebo)|250 mg every other day for 6 weeks
75602341|NCT04269499|Device|QuiremSpheres®|Radioembolization with QuiremSpheres® under MR imaging
75746452|NCT04288154|Other|EMS Device Off|The EMS Device will turned off during exercise as opposed to it being turned off for control group.
75746453|NCT04287569|Device|Record during endoscopy of video-endoscopy sequences and reflectance|Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
75746454|NCT04286594|Drug|CBD|Participants will receive CBD solution during the open-label phase of the trial.
75746455|NCT04286373|Device|active stimulation then placebo stimulation|"The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The two stimulation periods will be separated by a 4 weeks wash-out period."
75897655|NCT03651141|Other|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
75897656|NCT03650283|Other|monitoring|The bispectral index (BIS) and skin conductance (SC) monitors will be connected when patient will be positioned on the operating table. A BIS value greater than 60 will be considered an indicator of light anaesthesia. The SC monitoring will be achieved using the MEDSTORM AS 2005 monitor. Number of fluctuations in mean skin conductance (NFSC) of >0.1 s-1 in a period of 15 s might be counted as a significant change and indicates an increase in the sympathetic outflow. General anaesthesia will be performed and laryngeal mask will be inserted. Blood pressure, heart rate, BIS, SC, and PRST (pressure, rate, sweating, tears) score will be recorded.
75897657|NCT02130648|Other|A sampling of blood|A sampling of blood de 14 ml
75897658|NCT02139462|Other|Standard FBT training|Therapists will receive standard training in Family Based Treatment (FBT)
75897659|NCT02139462|Other|Novel FBT training|Therapists will receive a novel training in Family Based Treatment (FBT)
75897660|NCT02902809|Biological|Tralokinumab open-label|Subcutaneous injection; fixed dose; 300 mg
75451054|NCT01714297|Drug|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
75451055|NCT01714375|Device|QuietDose Device|"The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss."
75451056|NCT01714388|Drug|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
75451057|NCT01714401|Drug|Salbutamol 2,5 mg|20 min nebulization of 2.5 mg of salbutamol
75451058|NCT01714401|Drug|Salbutamol 5mg|20 min nebulization of 5 mg of salbutamol
75897661|NCT01362244|Drug|Mepolizumab|750 mg of mepolizumab by IV infusion
75897662|NCT01362244|Drug|Placebo|Placebo by IV infusion
75897663|NCT01362244|Drug|Run In Medication|subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
76064216|NCT04389580|Drug|Drug: Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen"
76064217|NCT04389580|Drug|Aerosolized Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen"
75451059|NCT01714414|Drug|FZD|
75746456|NCT04286373|Device|placebo stimulation then active stimulation|"VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~The two stimulation periods will be separated by a 4 weeks wash-out period."
75451060|NCT01714414|Drug|3TC|
75451061|NCT01714414|Drug|EFV|
75746457|NCT04280497|Drug|Administration procedures|"Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off."
75451062|NCT01714414|Drug|AZT|
76064218|NCT01482429|Other|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
75602342|NCT02853799|Other|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"Placement of feeding tube stomach (oral- or naso-gastric tube)~Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~There will be five blood glucose checks in each data collection period.~If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated."
75746458|NCT04258579|Behavioral|PROTECT with Technology Augmentation|PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.
75746459|NCT04231734|Other|Ketogenic Diet|Prepared ketogenic meals, 3 per day for up to 12 weeks (Day 1 through Day 84)
75746460|NCT04230967|Behavioral|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals
75746461|NCT04230967|Behavioral|Routine Care|No encouragement to ambulate will be provided to subjects. Their movement will be recorded
75746462|NCT04203381|Device|GnRH Agonist|Forty participants who are transgender and who have been prescribed a gonadotropin-releasing hormone (GnRH) agonist by their physician will undergo magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) scans at baseline, at 12 months and at 24 months after initiation of the GnRH agonist therapy. This longitudinal observational study of two cohorts seeks to identify significant changes in bone marrow adiposity and bone density over 24 months. The same assessments will be obtained in 40 healthy control subjects matched for age, race/ethnicity and body mass index, all factors that are known to influence skeletal outcomes. The evaluations of bone marrow adiposity will be correlated with bone density measurements and the assessments of mood (validated anxiety and depression scales) and health-related quality of life, before and after pubertal blockade.
75746463|NCT04178434|Behavioral|Internet-based CBT intervention|A nine step intervention including internet-based feedback by psychologists
75746464|NCT04138277|Drug|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
75746465|NCT04138277|Biological|ATB200|Enzyme Replacement Therapy via intravenous infusion
75746466|NCT04133909|Drug|Placebo|Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.
75746467|NCT04133909|Biological|Mepolizumab|Mepolizumab is a sterile liquid formulation. It will be administered as a SC injection (100 mg/mL) delivered once every 4 weeks using a pre-filled safety syringe.
75746468|NCT04069052|Drug|Nitric Oxide|Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
75746469|NCT04069052|Drug|Placebo|Room air (placebo) flowed into a mask and breathed in.
75746470|NCT04045470|Device|Microdevices|The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.
75451063|NCT01714427|Drug|Dexamethasone|Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
75451064|NCT01714427|Drug|Sterile isotonic saline|two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
75746471|NCT04045470|Other|Standard of care therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
75746472|NCT04045470|Other|Standard of care systemic therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
75746473|NCT04013256|Other|Cigarette Smoke|Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
75451065|NCT01714466|Drug|NER1006|
75451066|NCT01714466|Drug|MOVIPREP|
75451067|NCT01714479|Other|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
75451068|NCT01714479|Other|Placebo|
75451069|NCT01714531|Behavioral|Telephone-Based Goal Management Training|
75746474|NCT04013256|Other|Clean Air and Clean Clothing/Sham exposure|"Clean air, created by high-efficiency particulate air (HEPA) and charcoal filtration and temperature and humidity control.~Clean cotton clothing."
75746475|NCT04000776|Diagnostic Test|FDG Positron emission tomography (PET) scan|"Patients will undergo 18F-FDG and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).~The patient will be measured and weighed before the exam in order to calculate a personalized dose. An intravenous catheter will be put in place in peripheral vein to allow injection of the tracer."
75451070|NCT01714531|Behavioral|Telephone-Based Attention-Control|
75451071|NCT01714557|Drug|Piperacillin|4.0g q8h 3-5 days
75451072|NCT01714557|Drug|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
75746476|NCT04000776|Diagnostic Test|PSMA Positron emission tomography (PET) scan|Patients will sequentially undergo 68Ga-PSMA and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).
75746477|NCT04000776|Diagnostic Test|OCTREOTATE Positron emission tomography (PET) scan|"In the case a patient would present at least one PSMA-negative/FDG-positive lesion, he will be referred to undertake a whole-body 68Ga-OCTREOTATE PET/CT within 10 days of the first PET/CT. The delay between this third PET scan and the last one should be minimal (not least than 18 hours, not more than 10 days).~Images and data will be reviewed centrally within 4 days by the Imaging Corelab, which will produce a final report confirming patient's eligibility to Radioligand therapy (RLT)."
75746478|NCT04000776|Other|Optional Bone or soft-tissue biopsies|Patients presenting FDG-positive/PSMA-negative or Octreotate-positive lesions on imaging will be asked to undergo a biopsy of these lesions (optional) for research purposes. Bone or soft-tissue biopsies will be collected by an interventional radiologist according to site's standard-of-care procedure and sent to the local pathology department for preparation (formalin-fixed and paraffin-embedded); the blocks being sent to the Pathology Corelab.
75746479|NCT03974620|Behavioral|Individual Placement and Support|Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.
75746480|NCT03974620|Behavioral|Cognitive Remediation Therapy|This is an evidence based intervention that aims to improve cognitive functioning.
75746481|NCT03970343|Device|OPTIMIZER Smart System|"Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:~Optimizer Smart or Optimizer Smart Mini~Vesta Charger or Guardio Charger~Two commercially available intravascular leads"
75746482|NCT03963414|Combination Product|Durvalumab + Tremelimumab in combination with carboplatin and etoposide|1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.
75746483|NCT03963414|Combination Product|Durvalumab in combination with carboplatin and etoposide|1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
75897664|NCT02134470|Drug|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
75897665|NCT05285631|Device|Speckle tracking echocardiography (STE)|"Two-dimensional (2D) and 3D STE are based on the quantitative analysis of spatial dislocation (tracking) of acoustic markers (speckles) generated by the interaction between the ultrasound beam and myocardial fibers during the cardiac cycle."
75897666|NCT02130726|Procedure|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
76064219|NCT03856437|Behavioral|HPV vaccination messages|Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
75451073|NCT01714570|Drug|Piperacillin-tazobactam combination product|4.5g q6h, 5-10 days
75451074|NCT01714570|Drug|Imipenem|0.5g q6h, 5-10 days
75602343|NCT02853799|Dietary Supplement|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
75602344|NCT02888496|Drug|tocilizumab|3 monthly IV infusions in PMR patients
75602345|NCT01236534|Drug|Lubiprostone|24 mcg twice daily for 21 days.
75602346|NCT01236534|Drug|Placebo|matching placebo twice daily for 21 days.
75602347|NCT01235598|Other|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
75897667|NCT02130726|Procedure|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
76064220|NCT04409067|Diagnostic Test|electromyography|Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).
76064221|NCT00199108|Drug|Depocyt|
75602348|NCT01235598|Biological|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
76064222|NCT00199108|Drug|Dexamethasone|
76064223|NCT04776538|Biological|Stem cells|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
75451075|NCT01714596|Other|PO versus IV antibiotics Route of administration evaluation|This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
75602349|NCT01235598|Biological|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
75746484|NCT03955666|Biological|PRV-3279 or placebo|bi-specific antibody-based molecule
75746485|NCT03952520|Other|Standard Approach (SA)|The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.
75746486|NCT03952520|Other|Tailored Approach (TA)|The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.
75746487|NCT03945214|Behavioral|Meditation|10 minute per day, 8 week digital meditation
75746488|NCT03945214|Behavioral|Healthy Eating|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
75746489|NCT03945214|Behavioral|Meditation + healthy eating|10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
75746490|NCT03931538|Diagnostic Test|Guidance 4.0 PCR test|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
75746491|NCT03931538|Diagnostic Test|Urine Culture|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
75746492|NCT03929159|Procedure|Biospecimen Collection|Undergo blood biospecimen collection
75746493|NCT03922646|Behavioral|Neurocognitive Empowerment for Addiction Treatment (NEAT)|NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).
75746494|NCT03922646|Behavioral|Active Control|The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
75746495|NCT03890679|Diagnostic Test|rapid whole genomic sequencing (rWGS)|rWGS and NewbornDx are genomic sequencing platforms
75602350|NCT01235442|Drug|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
75746496|NCT03867955|Other|Collection of datas|Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
75746497|NCT03861390|Drug|60 mg Prednisone|Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
75746498|NCT03861390|Drug|Placebo|Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
75746499|NCT03829683|Drug|Vitamin C|200mg/kg/24hours
75746500|NCT03829683|Drug|Dextrose 5% in water|50mL intravenously every 6 hours
75746501|NCT03810456|Behavioral|Intensive Cognitive Behavior Therapy (iCBT)|Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
75897668|NCT04076319|Behavioral|CAPABLE: Community Aging in Place-Advancing Better Living for Elders|"CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations."
75897669|NCT05202067|Behavioral|pharmaceutical education|The patients who were assigned to the intervention group will receive a didactic talk from the research pharmacist. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
75897670|NCT03649737|Behavioral|Exercise Intervention|Attend supervised and unsupervised exercise sessions
75897671|NCT03649737|Other|Survey Administration|Ancillary studies
75897672|NCT03649737|Other|Quality-of-Life Assessment|Ancillary studies
75602351|NCT01235442|Drug|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
75602352|NCT01163253|Drug|CP-690,550|5 mg oral BID
75602353|NCT01163253|Drug|CP-690,550|10 mg oral BID
75602354|NCT01162863|Drug|Lubiprostone|lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
75602355|NCT01162863|Drug|Placebo|taken orally for 28 days
75746502|NCT03810456|Behavioral|Standard Cognitive Behavior Therapy (sCBT)|Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
75746503|NCT03737331|Behavioral|Fractal visual cueing|Walking to an external visual fractal (i.e., pink noise) stimulus.
75602356|NCT01162863|Other|Smartpill wireless motility capsule|Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
75746504|NCT03737331|Behavioral|Periodic visual cueing|Walking to an external visual periodic (i.e., invariant) stimulus.
76064224|NCT04776538|Biological|Placebo|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
75602357|NCT02885805|Drug|BAY987516|2.00 mg/cm2 ± 0.04 mg/cm2
75602358|NCT02885805|Drug|SPF 15 Control|2.00 mg/cm2 ± 0.04 mg/cm2
76064225|NCT01504971|Other|symptom questionaire|GerdQ questionaire
75746505|NCT03737331|Behavioral|Random visual cueing|Walking to an external visual random (i.e., white noise) stimulus.
75746506|NCT03715179|Device|Ostomy Pouching System|An ostomy pouching system is a medical device that provides a means for the collection of effluent from a surgically diverted biological system (colon, ileum, bladder), specifically from a stoma. No intervention is administered during the course of this study.
75746507|NCT03696797|Procedure|Blood Donation|Participants in the TREATMENT GROUP will have a Unit of blood (two cups, the same amount you would donate at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure blood count to be sure participants are not anemic, and blood pressure to be sure there is no dehydration. During or after donation, participants will be given a sports drink to replace the fluid loss. Participants in the CONTROL GROUP will not donate blood, but will have a needle inserted into a vein in your arm. Neither group will not know to which they have been assigned, all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so they will not know whether blood was actually removed.
75746508|NCT03696797|Procedure|Sham Blood Donation|Participants will have a needle inserted their arm, however, no blood will be drawn.
75746509|NCT03530696|Drug|Palbociclib|Palbociclib is to be taken orally on days 5-18 (14 days) of each cycle (each cycle length is 21 days). The starting dose will be 125mg.
75746510|NCT03530696|Drug|T-DM1|The recommended dose of T-DM1 is 3.6 mg/kg and is given as an intravenous infusion on Day 1 of every cycle (every 21 days).
75746511|NCT03522961|Drug|Nitrofurantoin Prophylaxis/Placebo|Drug: Nitrofurantoin Drug: Placebo
75746512|NCT03522961|Drug|Cranberry capsules|Drug: TheraCran® One Cranberry capsules
75746513|NCT03520686|Drug|N-803 + Pembrolizumab|"The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~Pembrolizumab (200 mg intravenous infusion [IV])~N-803 (15 μg/kg subcutaneously [SC])"
76064226|NCT01504971|Procedure|pH monitoring|24-hour pH monitoring
76064227|NCT01504971|Procedure|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
76064228|NCT01504971|Drug|rabeprazole|10mg, bid, p.o.
75451076|NCT01714622|Procedure|subtotal gastrectomy with gastroduodenostomy|
75451077|NCT01714622|Procedure|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
75451078|NCT01714622|Procedure|total gastrectomy with Rou-en-Y esophagojejunostomy|
75451079|NCT01714648|Drug|Triptorelin 0.2 mg|A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
75451080|NCT01714661|Drug|EVP-6124|Arms 1, 2
75451081|NCT01714661|Drug|Placebo|Arm 3
75451082|NCT01714674|Dietary Supplement|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
75451083|NCT01714674|Dietary Supplement|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
76064229|NCT04776616|Device|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
76064230|NCT04776616|Device|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
76072247|NCT02464644|Other|Questionnaire|To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
75746514|NCT03520686|Drug|N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|"The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~Carboplatin (up to 900mg IV)~Nab-paclitaxel (100mg/m² IV)~Pembrolizumab (200mg IV)~N-803 (15 μg/kg SC)~Day 8:~Nab-paclitaxel (100mg/m² IV)~Day 15:~Nab-paclitaxel (100mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~Pembrolizumab (200mg IV)~N-803 (15 μg/kg SC)"
75746515|NCT03520686|Drug|N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~Pembrolizumab (200mg IV)~Pemetrexed (500mg/m² IV)~N-803 (15 μg/kg SC)~Maintenance:~Day 1, every 3 weeks:~Pembrolizumab (200mg IV)~N-803 (15 μg/kg SC)"
75746516|NCT03520686|Drug|Pembrolizumab|"Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)"
75746517|NCT03520686|Drug|Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|"The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~Carboplatin (up to 900mg IV)~Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)~Pembrolizumab (200mg IV)~Day 8:~Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Day 15:~Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Maintenance:~Day 1, every 3 weeks:~Pembrolizumab (200mg IV)"
75897673|NCT02134626|Drug|Simvastatin|40mg / pill, one pill orally once a day for three months
75897674|NCT02134626|Drug|Placebo pill|
75897675|NCT05199883|Other|TI.VA algorithm: decision support system|TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.
75897676|NCT02134704|Other|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
75451084|NCT01714700|Behavioral|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
75602367|NCT01162473|Dietary Supplement|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
75602368|NCT01162473|Drug|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
75602369|NCT01162473|Other|Food Challenge|
75602370|NCT04314921|Other|Yoga trainings|10-week yoga sessions, 2 times per week, 90 min per session.
75897677|NCT02969187|Drug|Exparel|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.
75897678|NCT02969187|Drug|Bupivacain|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
75897679|NCT02969187|Drug|Saline|
75897680|NCT05220475|Device|fully covered self-expandable metal stent with an anchoring external plastic stent|Extrahepatic malignant biliary obstruction treated with fully covered self-expandable metal stent with an anchoring plastic stent
75897681|NCT05220475|Device|uncovered self-expandable metal stent|Extrahepatic malignant biliary obstruction treated with uncovered self-expandable metal stent without an anchoring plastic stent
75897682|NCT02134860|Other|Bed rest|8 days of full bed rest
75897683|NCT02134860|Other|OGTT|Oral glucose tolerance test with 75 g of glucose before and after bed rest
75897684|NCT02134860|Other|IVGTT|Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
75897685|NCT02134860|Other|Cognitive testing|Daily testing of memory and concentration using standardized tests
75897686|NCT02134860|Other|Muscle and fat biopsies|Biopsies will be obtained before and after bed rest
75897687|NCT02134860|Other|Dual-energy X-ray Absorptiometry (DXA) scan|DXA scan to evaluate fat and muscle distribution before and after bed rest
75602371|NCT02885649|Drug|Enzalutamide|Given PO
75602372|NCT02885649|Other|Laboratory Biomarker Analysis|Correlative studies
75602373|NCT02885649|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
75602374|NCT02885883|Device|MRI 3T|
75602375|NCT01162239|Drug|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.
75602376|NCT01162239|Behavioral|Initial Individual counseling|Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.
75602377|NCT01162239|Behavioral|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
75746518|NCT03520686|Drug|Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~Pembrolizumab (200mg IV)~Pemetrexed (500mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~Pembrolizumab (200mg IV)"
75746519|NCT03514888|Procedure|HIPEC|40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
75746520|NCT03450057|Drug|Daratumumab with dexamethasone|"Daratumumab:~Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs).~Dexamethasone:~Dexamethasone was administered at 40 mg (20 mg for patients >75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle."
75746521|NCT03360396|Device|Endobronchial Coils|Endobronchial Coil implants
75746522|NCT03353415|Device|Dexcom CGM masked|"The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
75746523|NCT03353415|Device|Dexcom CGM unmasked|"During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
75746524|NCT03270059|Drug|Ferumoxytol|Given IV
76064231|NCT01479777|Device|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
76064232|NCT03027063|Behavioral|10,000 steps|Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
76064233|NCT03027063|Behavioral|Usual Care|Participants will receive the ACC/AHA exercise guidelines
76072248|NCT02440295|Procedure|Lower Extremity Amputation|
75602378|NCT01162239|Behavioral|Extended Individual Counseling - Health Model|Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.
75602379|NCT01162239|Behavioral|Extended Individual Counseling - Relapse Prevention Model|Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.
75602380|NCT01161537|Drug|VX-770|Tablet.
75602381|NCT01161537|Drug|Placebo|Tablet.
75602382|NCT04314297|Drug|Anlotinib In Combination With Durvalumab|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
75602383|NCT02885571|Device|SomnoDent Flex with DentiTrac|
75602384|NCT04314063|Other|nasal swap|nasal swap to detect prevalence of staph aureus in food handlers
75602385|NCT04124133|Device|dressing with hyaluronic acid|Application of ialuset cream or gauzepad (hyaluronic acid)
75746525|NCT03270059|Drug|Gadolinium|Given IV
75746526|NCT03270059|Procedure|Magnetic Resonance Imaging|Undergo MRI
75746527|NCT03198351|Drug|Teriflunomide (HMR1726)|"Pharmaceutical form: tablet~Route of administration: oral"
75746528|NCT03160040|Drug|Minocycline IV|This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
75746529|NCT03144583|Biological|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
75746530|NCT03107182|Drug|nab-paclitaxel|All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
75746531|NCT03107182|Drug|Carboplatin|All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
75746532|NCT03107182|Drug|Nivolumab|"All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses."
75897688|NCT02134860|Other|MRI|Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
75897689|NCT03650985|Procedure|Fetoscope technique|Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
75897690|NCT02139618|Drug|Methyl Aminolevulinate (MAL)|
75451085|NCT01714700|Behavioral|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
75451086|NCT01714713|Drug|EVP-6124|Arm 1, 2
75897691|NCT02139618|Drug|Placebo|
75897692|NCT04850287|Behavioral|Digital Sensors for Population Awareness about Health Issues using Social Media|A clustered randomized control trial will be conducted and ZIP Codes from each demographic environment will be randomly assigned to control and intervention arms. Digital educational materials about organ donation will be exposed to online users in social media belonging to ZIP Codes assigned to the intervention arm
75451087|NCT01714752|Procedure|measure of left ventricular and diastolic pressure at exercise|
75897693|NCT05285085|Drug|Statin|Statin use
75897694|NCT02139696|Radiation|PET and MRI|Patients will be imaged using PET and MRI at baseline, and twice during treatment
75451088|NCT01714765|Drug|Dovitinib|Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg
75602386|NCT01233258|Biological|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
75602387|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
75602388|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
75602389|NCT01232868|Biological|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
75602390|NCT01232790|Dietary Supplement|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
75602391|NCT01232790|Drug|Placebo|Placebo
75451089|NCT01714765|Drug|Everolimus|Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
75451090|NCT01714778|Other|e-Cigarette|
75602392|NCT01232556|Drug|Inotuzumab ozogamicin|1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
75746533|NCT03107182|Drug|Cisplatin|Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
75746534|NCT03107182|Drug|Hydroxyurea|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
75746535|NCT03107182|Drug|5-FU|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
76025199|NCT03165565|Behavioral|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
76025200|NCT02679235|Drug|POST Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
76025201|NCT01976806|Drug|Aspirin|
75451091|NCT01714791|Other|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
76025202|NCT01976806|Drug|Docosahexaenoic acid|
76025203|NCT01976806|Drug|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
76025204|NCT02679079|Drug|NBI-98854|
76025205|NCT02679079|Drug|Placebo|
76025206|NCT02678923|Drug|MDCO-216|
75746536|NCT03107182|Drug|Dexamethasone|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
75746537|NCT03107182|Drug|Famotidine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
75746538|NCT03107182|Drug|Diphenhydramine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
75746539|NCT03107182|Drug|Paclitaxel|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
75746540|NCT03107182|Procedure|Transoral robotic surgery (TORS)|Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
75746541|NCT03107182|Radiation|Adjuvant RT|Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
75746542|NCT03107182|Radiation|Chemoradiotherapy|"Patients who have low risk disease with <50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and <30% reduction of tumor, patients who have high risk disease and <50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
75746543|NCT02982070|Behavioral|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
75746544|NCT02879318|Drug|Gemcitabine|
75746545|NCT02879318|Drug|Nab-paclitaxel|
75746546|NCT02879318|Drug|Durvalumab|
75746547|NCT02879318|Drug|Tremelimumab|
75746548|NCT02833701|Dietary Supplement|Ascorbic Acid|Given IV
75746549|NCT02833701|Biological|Bevacizumab|Given intravenously (IV)
75746550|NCT02833701|Other|Laboratory Biomarker Analysis|Correlative studies
76025207|NCT02678923|Drug|Placebo|
75746551|NCT02833701|Other|Quality-of-Life Assessment|Ancillary studies
75746552|NCT02767999|Drug|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
75746553|NCT02767999|Drug|Placebo|cellulose placebo per day from D0 to D90
75746554|NCT02767999|Radiation|fMRI|functional resting state MRI
75746555|NCT02675465|Drug|ATB200|
75746556|NCT02675465|Drug|AT2221|
75746557|NCT02670707|Drug|Cytarabine|Cytarabine 100 mg/m^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
75746558|NCT02670707|Drug|Vinblastine/prednisone|"Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
75746559|NCT02658890|Drug|BMS-986205|
75746560|NCT02658890|Drug|Nivolumab|
75746561|NCT02658890|Drug|Ipilimumab|
76025208|NCT01976728|Drug|Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump|
75746562|NCT02597062|Drug|Carfilzomib|
75746563|NCT02597062|Drug|Cyclophosphamide|
75746564|NCT02597062|Drug|Dexamethasone|
75746565|NCT02567292|Other|Human Milk|Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants <37 weeks PMA and/or or weight <2,200g or PBCLN-002 for infants >37 weeks PMA and/or weight >2,200g)
75746566|NCT02484417|Biological|RSV A2|Intranasal inoculation of healthy volunteers with 10^5 or 10^6.3 plaque forming units (PFU) of RSV A2.
75746567|NCT02458014|Biological|Blinatumomab|Given IV
75746568|NCT02458014|Other|Laboratory Biomarker Analysis|Correlative studies
76025209|NCT01976728|Drug|Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump|
76025210|NCT01976728|Drug|Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump|
76025211|NCT01976728|Drug|Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)|
76025212|NCT02689219|Drug|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
76025213|NCT03162133|Other|Baduanjin exercise|
75602393|NCT01232556|Drug|Rituximab|375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
75602394|NCT01232556|Drug|rituximab + gemcitabine|rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
75451092|NCT01714791|Other|Osteopathic treatment|"Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~Structural High Velocity Low Amplitude-techniques.~Muscle Energy Techniques.~General osteopathic mobilisations.~Functional techniques (Sutherland-, Jones-techniques,…) including inhibition techniques.~Fascia techniques.~Soft tissue- and connective tissue techniques.~Neurovisceral and neurolymphatic reflex techniques.~Fluidal techniques (lymphatic manipulative techniques,...).~Visceral manipulations.~Neurocranial and viscerocranial techniques."
75451093|NCT01714817|Biological|BMS-188667|
75746569|NCT02451982|Drug|Cyclophosphamide|200 mg/m2 IV
75746570|NCT02451982|Biological|GVAX pancreatic cancer|5x10^8 cells intradermal injection
75746571|NCT02451982|Drug|Nivolumab|480 mg IV
75746572|NCT02451982|Drug|Urelumab|8 mg IV
76064234|NCT04776304|Behavioral|Art Therapy|"This is a pilot study in which every participant receives the art therapy intervention arm. There are no waitlist or control arms. Art therapy is one promising intervention that helps service members (SMs) develop a visual voice, using imagery, symbolism, and metaphor to externalize emotions and experiences that they may not be able to express in words. The standardized, integrative mental health and human services approach of the art therapy program at the NICoE utilizes a mask-making directive to explore thoughts, feelings, and experiences of combat and self-understanding. This process is especially relevant to SMs with PTS symptoms who often remember their trauma as an incoherent, fragmented memory that is often predominantly sensory in nature. NICoE researchers have provided preliminary evidence suggesting associations between recurring art themes represented within the masks and individual BH symptoms."
76064235|NCT04753918|Drug|Porfimer sodium|Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
75746573|NCT02451982|Drug|BMS-986253|2400 mg IV
75746574|NCT02444741|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
75746575|NCT02444741|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75451094|NCT01714817|Drug|Mycophenolate mofetil|
75451095|NCT01714817|Drug|Prednisone|
75451096|NCT01714817|Biological|Placebo matching with BMS-188667|
75746576|NCT02444741|Other|Laboratory Biomarker Analysis|Correlative studies
75897695|NCT05057416|Behavioral|Exercise Adherence|Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.
75897696|NCT04850209|Other|oral and written education|oral and written education
75451097|NCT01714830|Device|standars electromagnetic DUOLITH SD1|In the first group patients will be treated by ESWT once a week for 4 weeks. (Each time 3000 impulses, with 0.25 mJouls/M2 and 3 Hertz of frequency. After each 500 pulses, the probe position will be corrected, using trans-perineal ultrasound.
75451098|NCT01714830|Device|turn off standars electromagnetic DUOLITH SD1|In the control group, the same protocol is applied but with the probe being turned off.
75602395|NCT01232556|Drug|rituximab +bendamustine|rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
75602396|NCT00946153|Drug|Lenvatinib|In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
75897697|NCT04850209|Other|Wechat group|Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional
75897698|NCT02139774|Behavioral|Walk with Ease|A six week walking program by the Arthritis Foundation
75897699|NCT03650205|Drug|Ivabradine|Ivabradine capsule
75897700|NCT03650205|Drug|Placebo|Placebo oral capsule.
75897701|NCT05698459|Biological|OH2 injection|OH2 injection administered by transcatheter Intraarterial infusion
75897702|NCT02139930|Behavioral|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
75746577|NCT02444741|Biological|Pembrolizumab|Given IV
75746578|NCT02444741|Radiation|Proton Beam Radiation Therapy|Undergo PBRT
75746579|NCT02444741|Radiation|Radiation Therapy|Undergo low dose radiation therapy
75746580|NCT02444741|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75746581|NCT02361671|Other|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
75602397|NCT04258891|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2004 in European, North American and South American centers, who have estimated glomerular filtration rate and proteinuria follow-up and data from protocol and for cause biopsies for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow-up, clinical, biological and histological data.
76064236|NCT04753918|Drug|Ethiodized oil|In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.
75602398|NCT01914367|Biological|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
75451099|NCT01714843|Drug|linaclotide|oral
75451100|NCT01714843|Drug|placebo|oral
75746582|NCT02235623|Procedure|Single-stage Fowler-Stephens orchidopexy (FSO)|
75746583|NCT02235623|Procedure|Two-stage Fowler-Stephens orchidopexy (FSO)|
75897703|NCT02139930|Behavioral|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
75746584|NCT02122185|Drug|metformin hydrochloride|Given PO
75746585|NCT02122185|Drug|placebo|Given PO
75746586|NCT02122185|Drug|Chemotherapy|Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
75897704|NCT02139930|Behavioral|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
75451101|NCT01714856|Drug|Ropinirole hydrochloride CR 2mg Tablets|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
75451102|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
75451103|NCT01714882|Behavioral|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
75746587|NCT02041663|Biological|BNP|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
75897705|NCT05285163|Behavioral|palliative care educatiom|The patients in the intervention group were presented palliative care training in addition to their usual care
75897706|NCT04494490|Behavioral|Clinical Practice Guidelines and Psychologically Informed Physical Therapy training/audit/feedback|The aim of the active training strategy is to improve the knowledge and skills of physical therapists with regard to evidence-based physical therapy with an emphasis on active treatments and PIPT for the treatment of patients with low back pain and to encourage increased adherence with CPGs. This Continuing Education (CE) training session will be offered to all therapists regardless of study participation. During the CE training session, focus will be placed on interventions that have been shown to be effective, such as interactive education and discussion, feedback, and reminders.
75897707|NCT02140008|Device|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
75897708|NCT02140008|Device|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
76064237|NCT04753918|Procedure|Novel light delivery methods of photodynamic therapy|Using high-refraction index contrast medium: lipiodol as a light diffusor to enhance the range of photodynamic therapy
76064238|NCT04753918|Device|Fiber optic|A cylindrical laser fiber was then inserted through the guide sheath to the tumor region then illuminate light to complete the photodynamic therapy.
75451104|NCT01714882|Behavioral|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
75897709|NCT04590118|Drug|it-hMSC|Single intravenous infusion of it-hMSC for ischemic stroke patients
75897710|NCT04590118|Drug|Placebo|Single intravenous infusion of 1 ml/kg placebo
76064239|NCT04161664|Drug|Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
76064240|NCT00936832|Drug|FOLFIRI regimen|
76064241|NCT00936832|Drug|fluorouracil|
76064242|NCT00936832|Drug|irinotecan hydrochloride|
75602399|NCT01914367|Biological|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
75746588|NCT01830621|Drug|BBI608|
75746589|NCT01830621|Drug|Placebo|
75746590|NCT01830621|Other|Best Supportive Care|
76064243|NCT00936832|Drug|leucovorin calcium|
76064244|NCT00936832|Drug|sunitinib malate|
76064245|NCT00936832|Other|laboratory biomarker analysis|
75746591|NCT01629498|Radiation|Image Guided Radiation Therapy|Undergo image-guided IMRT
75746592|NCT01629498|Radiation|Image Guided Radiation Therapy|Undergo image-guided IMPT
75746593|NCT01629498|Radiation|Intensity-Modulated Radiation Therapy|Undergo image-guided IMRT
75746594|NCT01629498|Radiation|Intensity-Modulated Radiation Therapy|Undergo image-guided IMPT
75746595|NCT01629498|Other|Laboratory Biomarker Analysis|Optional correlative studies
75746596|NCT01629498|Radiation|Photon Beam Radiation Therapy|Undergo image-guided IMRT
75746597|NCT01629498|Radiation|Proton Beam Radiation Therapy|Undergo image-guided IMPT
75746598|NCT01629498|Other|Questionnaire Administration|Ancillary studies
75746599|NCT01528852|Drug|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
75746600|NCT01528852|Drug|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
75746601|NCT01528852|Other|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
75746602|NCT01248585|Drug|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
75746603|NCT01248585|Drug|Placebo|2 placebo tablets taken once daily for 5 days
75746604|NCT00993655|Drug|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
76064246|NCT00936832|Other|pharmacogenomic studies|
76064247|NCT00936832|Other|pharmacological study|
76064248|NCT04753606|Drug|Obicetrapib|tablets
76064249|NCT04755946|Drug|Roflumilast|adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management
75602400|NCT02856529|Other|Training|The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
75897711|NCT04810351|Other|observational study|There is no intervention. It is an observational study
75746605|NCT00993655|Drug|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
75746606|NCT00993655|Drug|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
75746607|NCT00338702|Procedure|Autologous Platelet Gel|
75746608|NCT00251251|Device|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
75746609|NCT00251251|Device|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
75897712|NCT03549390|Behavioral|Physical activity|Light-moderate intensity physical activities
75897713|NCT05303506|Diagnostic Test|serum ferritin and AST|observiational study
75897714|NCT03650907|Behavioral|Group exercise program|"Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks."
75897715|NCT03650907|Behavioral|Self exercise program|Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
75897716|NCT02130804|Drug|Salsalate (4 g/day)|Given orally twice daily
75897717|NCT02130804|Drug|Placebo (4 g/day)|Given orally twice daily
75897718|NCT03650751|Other|Nursing observation indexes|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
75897719|NCT05303272|Drug|Abatacept Prefilled Syringe|Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd
75897720|NCT05303272|Drug|Mycophenolate Mofetil 500Mg Tab|MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
75897721|NCT02131038|Other|Medica device, drug-like|Ectoin (R) Allergy Nasal Spray
75451105|NCT01714895|Other|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
75451106|NCT01714895|Other|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
75602401|NCT02856529|Other|General session|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
75602402|NCT02856373|Procedure|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
75746610|NCT00168701|Drug|BG00012|
75746611|NCT05350800|Drug|BMS-986369|Specified dose on specified days
75746612|NCT05346653|Drug|SGLT2i|dapagliflozin (10 mg daily)
75746613|NCT05346653|Other|No SGLT2i|No SGLT2i
75746614|NCT05335889|Device|eButton|The eButton is a wearable camera that takes pictures every 6 seconds of whatever is in front of participants. The recorded data are processed by algorithms to determine food names, volumes, and nutrient value of the consumed food (e.g., grams of carbohydrates). The eButton is a wearable device containing a multicore microprocessor, a rechargeable battery capable of 10-15 hours of continuous operation (upon a flexible choice of battery capacity), a miniSD card for data storage.
75746615|NCT05335889|Device|Continuous Glucose Monitoring (CGM)|The use of this device provides ambulatory glucose profiles, giving graphic and quantitative information on 24-hour glucose patterns. It does not require finger-prick testing for calibration. The system consists of a reader and a sensor (35 mm x 5 mm). The sensor is applied to the back of a person's arm. The sensor automatically measures interstitial glucose at 15-minute intervals during daily activities like work, sleep, eating, and exercise. It is able to store blocks of glucose data for 14 days.
75746616|NCT05335863|Dietary Supplement|Oral Nutritional Supplement|Participants must consume 416 mL of ONS FontActiv® DiaBest HP / HC vanilla flavor. A maximum time of 10 min will be given to consume the entire product.
75746617|NCT05335863|Dietary Supplement|Glucose|Participants must consume a 50 g glucose solution in 10 min to obtain the ares under the curve (AUC) data from glucose consumption
75746618|NCT05331105|Drug|HL-085|"IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen."
75746619|NCT05328323|Other|questionnaire application|"Participants will be asked to fill in the Physical Activity and Social Support Scale (PASSS) adapted into Turkish. Evaluations of the participants will be made in the form of an online survey via Google Forms. Multidimensional Scale of Perceived Social Support and International Physical Activity Questionnaire will be used for construct validity of the scale, and SF-12 physical and mental component summary scores will be used for convergent and divergent validity. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
75746620|NCT05328180|Other|Sodium bicarbonate|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5% is buffered with 7.5% sodium bicarbonate in 1:10.
75602403|NCT02856607|Other|determine the prognosis of threated patients according to the clinical care pathway.|
75746621|NCT05328180|Other|Control arm|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5%.
75746622|NCT05324826|Device|Butterfly Network handheld ultrasound|Patients would be examined with a handheld US machine which would allow for dynamic imaging chairside and could easily be integrated into both hospital-based and private clinical practices. This would allow the patient to benefit from realtime imaging and a faster preliminary diagnosis with virtually no additional risks.
75746623|NCT05316493|Behavioral|Intensive Lifestyle Intervention (ILI)|dietary guidance, exercise guidance, lifestyle intervention
75746624|NCT05316493|Drug|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
75746625|NCT05316493|Drug|Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg|enrolled patients will be treated with LNG-IUS.
75746626|NCT05316467|Behavioral|Intensive Lifestyle Intervention (ILI)|"dietary guidance~exercise guidance~lifestyle intervention"
75602404|NCT01160289|Drug|LY2452473|Administered orally, once daily for 12 weeks
75602405|NCT01160289|Drug|tadalafil|Administered orally, once daily for 12 weeks
75746627|NCT05316467|Drug|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
75746628|NCT05310539|Other|assessment of the early recovery after wedge resection surgery|To assess the early recovery will be used 1 minute sit to stand, Numeric Rating scale to assess pain, incentive spirometer to assess vital capacity, Borg modified scale to assess dyspnea.
75746629|NCT05308459|Behavioral|Data-driven health promotion at Vocational Education and Training schools (Data Health VET)|"The intervention consists of the following steps:~A local health profile is conducted among all students~Results are shortly hereafter presented and discussed with all student and staff, and the school decide what health problem they will work with during the next year~A participatory group model process based on a dynamic systems approach is conducted to develop sustainable and system changing activities to address the chosen health problem~The activities are implemented~A new health profile is conducted to a) evaluate the effects of the implemented activities and to b) determine if a new health problem warrant focus and new activities are needed (the process repeats itself)."
75746630|NCT05306652|Other|Supervised physical activity|patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
75746631|NCT05306652|Other|Unsupervised physical activity|patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
75746632|NCT05305677|Dietary Supplement|NMN intervention|NMN capsules (total of 600mg/day) for 8 weeks
75746633|NCT05305677|Other|Placebo|NMN-free placebo capsules for 8 weeks
75746634|NCT05304949|Other|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription will be enrolled.
75746635|NCT05294341|Drug|Norethindrone Acetate 5 MG|As specified in arm design
75746636|NCT05294341|Drug|Norethindrone 0.35 MG|As specified in arm design
75746637|NCT05293964|Drug|SIM0270|SIM0270 is an oral, selective estrogen receptor degrader (SERD)
76064250|NCT04755946|Drug|Placebo|Placebo
75451107|NCT01714908|Other|Erlotinib w Concurrent Radiotherapy|
75451108|NCT01714908|Other|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
75451109|NCT01714960|Drug|MRZ-99030 eye drops 5mg/mL|
75451110|NCT01714960|Drug|MRZ-99030 eye drops 20mg/mL|
75451111|NCT01714960|Drug|Placebo to MRZ-99030 eye drops|
75451112|NCT01714973|Biological|ST266|Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
75451113|NCT01714986|Behavioral|Affect School|
75451114|NCT01714986|Behavioral|Body Awareness Therapy|
75451115|NCT01714999|Procedure|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
75451116|NCT01714999|Procedure|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
75602406|NCT01160289|Drug|placebo (tadalafil)|Administered orally, once daily for 12 weeks
75602407|NCT01160289|Drug|placebo (LY2452473)|Administered orally, once daily for 12 weeks
75602408|NCT02885415|Procedure|Gastrointestinal surgery|Major resectional gastrointestinal surgery (define as resection of part of gastrointestinal tract during esophageal, Gastric or colorectal surgeries)
75602409|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
75602410|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
75602411|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
75746638|NCT05293964|Drug|Palbociclib|palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
75746639|NCT05293964|Drug|everolimus|Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
75746640|NCT05293743|Device|Foot abduction bracing for clubfoot with novel dynamic bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares the standard straight bar in a foot abduction brace to our novel dynamic bar. This group uses the novel bar.
75897722|NCT02140086|Behavioral|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
75897723|NCT03549312|Drug|Genvoya|"Switching to Genvoya for 48 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA < 50 copies/mL at weeks 4, 12, 24, 36 and 48."
75897724|NCT03549312|Drug|Epclusa|"HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.~Plasma HCV RNA viral load at weeks 12, 24, 36, 48, 72 and 96."
75897725|NCT03549312|Drug|Biktarvy|"Switching to Biktarvy for 48 weeks in patients with HIV previously treated with Genvoya, stably supressed HIV RNA, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA < 50 copies/mL at weeks 52, 60, 72, 84 and 96."
75897726|NCT04573036|Drug|HRS4800 tablets|single oral administration
76064251|NCT01896466|Device|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
76064252|NCT01896466|Behavioral|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
76064253|NCT01479621|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
75451117|NCT01715025|Drug|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
75451118|NCT01715038|Dietary Supplement|LNS-PLW|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)~Daily dose of LNS-PLW will be 20 g, packaged in one sachet"
75451119|NCT01715038|Dietary Supplement|LNS-Child|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets"
75451120|NCT01715038|Dietary Supplement|MNP|"Dietary supplement: Micronutrient powder~Micronutrient powder for infants and young children (MNP)~The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet."
75451121|NCT01715038|Dietary Supplement|IFA|"Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid"
75451122|NCT01715051|Drug|D-serine|The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
75451123|NCT01715051|Behavioral|Cognitive Behavioral Therapy|CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
75451124|NCT01715051|Drug|Placebo|The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
75451125|NCT01715077|Drug|Ipilimumab at 3 mg/kg dose|
75451126|NCT01715090|Device|Web-based insulin titration|
75602412|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
75602413|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
75602414|NCT01159431|Device|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
75602415|NCT04314141|Procedure|Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty|"Send a questionnaire to patients to collect informations about:~Sexual quality of life before and after the surgery~Satisfaction after surgery~Data collection in medical file :~Surgery outcomes~Functional outcomes"
75602416|NCT02885259|Drug|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
75451127|NCT01715103|Procedure|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
75602417|NCT01158261|Biological|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
75602418|NCT02885103|Device|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
75746641|NCT05293743|Device|Foot abduction bracing for clubfoot with standard straight bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares the standard straight bar in a foot abduction brace to our novel dynamic bar. This group uses the standard bar.
75746642|NCT05292144|Device|Xperience Pro|Patients in whom treatment with (Xperience Pro) has been attempted
75746643|NCT05290207|Diagnostic Test|The hyperinsulinaemic hypoglycaemic clamp|Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
75746644|NCT05278624|Drug|Roflumilast Cream|Topical Cream
75897727|NCT04573036|Drug|Placebo tablets|single oral administration
75746645|NCT05271240|Drug|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation|Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.
75746646|NCT05271240|Drug|Temozolomide and Radiation Alone|Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
75746647|NCT05268042|Other|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
75746648|NCT05268042|Other|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
75451128|NCT01715116|Device|Enhanced ICD programming|"VT monitor: > 166/min~fVT: > 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~VF: > 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~SVT/VT discrimination is turned on, high rate time out is OFF~SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~T wave-oversensing and lead noise discrimination is turned on in all devices."
75451129|NCT01715142|Drug|Gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
75451130|NCT01715142|Drug|Abraxane|Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
75451131|NCT01715168|Drug|DOXIL/CAELYX|
75451132|NCT01715168|Drug|ATI-0918|
75451133|NCT01715181|Other|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
75451134|NCT01715194|Device|Telemedicine intervention|Patients undergoing telemedicine intervention
75602419|NCT02885103|Device|Nebulizer|Inhalation will be done will Nebulizer and via mouth
75602420|NCT04313829|Behavioral|Pharmacist Counseling Intervention|We used the counseling module (in the form of a guide book) for pharmacist-based counseling that had been validated regarding constructive content by an endocrinologist and a pharmacist expert in diabetes drug counseling. The module explained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed doses. The pharmacists should explain all the content within the module in 15 minutes to each patient of the intervention group each month for 6 months. As an ethical consideration, the control group patients were given the same explanation module through pharmacist counseling after the study finished.
75451135|NCT01715220|Drug|sublingual nitroglycerine|A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
75451136|NCT01715246|Other|Infant Formula|
75451137|NCT01715259|Drug|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
75451138|NCT01715259|Drug|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
75451139|NCT01715272|Device|TF037|
75746649|NCT05264883|Drug|Venetoclax-Decitabine/Azacitidine-Aclarubicin Association|Treatment with Venetoclax+Decitabine/Azacitidine+Aclarubicin
75746650|NCT05264883|Drug|Venetoclax-Decitabine/Azacitidine Association|Treatment with Venetoclax+Decitabine/Azacitidine
75746651|NCT05263453|Drug|HL-085|HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle
75746652|NCT05263453|Drug|Vemurafenib|Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle
75746653|NCT05257629|Combination Product|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Varenicline and nicotine e-cigarettes plus counseling
75746654|NCT05257629|Other|Varenicline Plus Counseling|Varenicline plus counseling
75746655|NCT05257343|Dietary Supplement|Liquid Placebo Supplementation|8-weeks of supplementing with a visually identical liquid placebo supplement.
75746656|NCT05257343|Dietary Supplement|Liquid Iron Supplement (Blood Builder ®)|8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
75746657|NCT05249400|Procedure|Off-site assistance|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.
75746658|NCT05245669|Biological|ENZ215|healthy volunteers receive ENZ215 (60mg) once
75746659|NCT05245669|Biological|EU Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
75746660|NCT05245669|Biological|US Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
75746661|NCT05243316|Procedure|Clamping|There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.
75746662|NCT05243316|Procedure|Non Clampling|There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.
75746663|NCT05233332|Drug|HL-085|12mg BID HL-085
75746664|NCT05233332|Drug|Vemurafenib|720mg BID Vemurafenib
75746665|NCT05232084|Drug|Bupivacaine + Fentanyl|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
75746666|NCT05229783|Procedure|Electronic chromoendoscopy|Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
75746667|NCT05229783|Procedure|White light endoscopy with Seattle protocol|Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
75746668|NCT05224622|Diagnostic Test|VOX|Breath exhalation into the mouthpiece of the VOX breath diagnostic device.
75746669|NCT05220709|Diagnostic Test|bio impedance spectroscopy by means of the Body Composition Monitor (Name of the device is BCM from Fresenius Medical Care D GmbH)|The Body Composition Monitor provides information about the hydration status by a bioimpedance spectroscopy measurement of the body composition from which the level of overhydration can be derived. Four electrodes are used per measurement. All subjects get electrodes attached, following the wrist-ankle approach, in a tetrapolar arrangement. Two electrodes are placed on the hand: one on the wrist, and the second on the dorsal side of the metacarpalia, close to the phalanges. The other two electrodes are placed on the foot: one on the ankle, and the second on the dorsal side of the metatarsals, close to the phalanges of the toes. Age, gender, height, weight and blood pressure are registered in the device before starting the measurement. If the quality calculated by BCM is < 60%, the measurement will be repeated again. Measurements are taken under supervision of a trained technician or nurse.
75451140|NCT01715272|Drug|Fleet enema|
75451141|NCT01715311|Drug|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
75746670|NCT05218863|Other|No intervention|No intervention
75746671|NCT05217303|Drug|HL-085|HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
75746672|NCT05204537|Procedure|Lung parenchyma resection|Lung parenchyma removal
75746673|NCT05204537|Procedure|Empyemectomy|Intrapleural cavity effusion removal, parietal pleura removal.
75746674|NCT05195619|Biological|Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)|"Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier."
76025214|NCT05673733|Other|scapular stabilization exercises with exergaming training|Group A will receive scapular stabilization exercises with exergaming training
76025215|NCT05673733|Other|exergaming training|Group B will receive only exergaming training
76025216|NCT05673421|Other|Exergaming Training|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks
76025217|NCT05673421|Other|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb.Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
76025218|NCT03165253|Drug|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
76025219|NCT03165253|Drug|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
76025220|NCT03165253|Drug|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
76025221|NCT03165253|Drug|Omeprazole|1 mg/kg/day
75746675|NCT05195619|Drug|Low dose cyclophosphamide|Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
75746676|NCT05181475|Drug|Sodium Oligomannate Capsules (GV-971)|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
75746677|NCT05180669|Other|OARSCM Software Application|Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
75746678|NCT05180669|Other|MyMAT Software Application|Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
75746679|NCT05164406|Procedure|Blood salvage therapy|In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
75746680|NCT05159362|Other|Software Application|Access is granted to participants for 4 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
75746681|NCT05158517|Drug|Subcutaneous vedolizumab|Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
75746682|NCT05152459|Drug|Tazemetostat|Given PO
75746683|NCT05152459|Biological|Ublituximab|Given IV
75746684|NCT05152459|Drug|Umbralisib|Given PO
75746685|NCT05151887|Other|Muscle protein synthesis|The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
75746686|NCT05151315|Device|Total Knee Arthroplasty with Evolution® NitrX™ Knee System|Patients will receive cemented Evolution knee system with NitrX coating for their total knee arthroplasty.
75451142|NCT01715311|Drug|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
75602421|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
75602422|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
75602423|NCT04313907|Combination Product|low level laser therapy plus topical clonazepam|combination of treatment, low level laser therapy (15 joules, 6 sesions, 14 days) plus topical clonazepam (1 mg,3 times per day, 14 days)
75746687|NCT05151315|Device|Total Knee Arthroplasty with Evolution Knee System|Patients will receive cemented Evolution knee system without NitrX coating for their total knee arthroplasty.
75897728|NCT03524768|Diagnostic Test|skin laser speckle contrast imaging and video-capillaroscopy|Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
75451143|NCT01715311|Drug|Tiotropium|Tiotropium capsules for inhalation once daily
75897729|NCT03649269|Dietary Supplement|PC-300 tea.|Patients had to drink one cup of the tea half an hour before breakfast, main meal and dinner.
75897730|NCT03649269|Drug|Bezafibrate|Patients were prescribed 200 mg/day at night.
76025222|NCT05543317|Diagnostic Test|18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
75451144|NCT01715311|Drug|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
75451145|NCT01715337|Other|pulmonary rehabilitation|3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
75451146|NCT01715350|Drug|PM012|"The drug will be taken with water within 30 minutes after breakfast and supper.~650mg/1 tablet, PO, 12weeks"
75451147|NCT01715350|Drug|Placebo|"The drug will be taken with water within 30 minutes after breakfast and supper.~650mg/1 tablet, PO, 12weeks"
75451148|NCT01715363|Drug|Oxaliplatin|
75451149|NCT01715363|Drug|Folinic Acid|
75451150|NCT01715363|Drug|Fluorouracile|
75602424|NCT04313907|Drug|Sham laser plus topical clonazepam|Sham laser therapy (0 joules, 6 sesions, 14 days) plus topical clonazepam(1 mg,3 times per day, 14 days)
75602425|NCT04313907|Radiation|Active laser plus placebo of topical clonazepam|low level laser therapy (15 joules, 6 sesions, 14 days) plus placebo topical clonazepam(lactose,3 times per day, 14 days)
75602426|NCT01231620|Drug|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
75746688|NCT05143372|Device|Vibrolung|Vibroacoustic respiratory therapy
75746689|NCT05142618|Other|Supervised Physical Therapy|The twice-per-week 8-week course of supervised physical therapy begins 2 weeks after surgery. It targets abdominal core function through progressive muscle retraining and strengthening, and patient-specific posture and body mechanics education.
75746690|NCT05142618|Other|Post-operative Precautions|This intervention includes standard of care post-operative instructions typically given to patients undergoing ventral hernia repair across the world. These include limiting strenuous physical activity and a lifting restriction of no more than 10 pounds for 6 weeks. Binder use is also encouraged for 4-6 weeks after the operation.
75746691|NCT05139914|Drug|Dapagliflozin|10 mg/day (in capsule form) of dapagliflozin for 6 weeks
75746692|NCT05139914|Other|Placebo|Placebo capsule for 6 weeks
75746693|NCT05138835|Drug|Botox Cosmetic|"BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults."
75746694|NCT05132231|Biological|Brodalumab|Brodalumab
75746695|NCT05132231|Biological|Matched cohort|Matched cohort
75746696|NCT05130853|Behavioral|Social Skills and Neurocognitive Individualized Training (SoCIAL)|"SoCIAL is composed of two modules:~Social Cognition Training The Emotions recognition training will train the subject's ability in discriminating between different emotional states through photos and videos. The Theory of Mind (ToM) training will help subjects discriminate between emotional expressions in social contexts and understand other people's mental state with videos that display actors expressing several emotional states. More details in Palumbo et al., 2017.~Narrative Enhancement Training The narrative enhancement training consists in story-telling exercises focused on improving the subject's capacity to comprehend his/her emotional experience."
75746697|NCT05130853|Other|Treatmment-as-usual|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
75746698|NCT05127252|Diagnostic Test|Vaginal and rectal microbiome and metabolome|Vaginal- and rectal sampling as a self-kit will be taken by the pat when ceasing the contraception at the midwife clinic when confirmed a clinical pregnancy and if a miscarriage occurs. If a miscarriage occurs additionally to the self-kit an endometrial biopsy will be taken.
75746699|NCT05121545|Radiation|Pro-GRID|Study participants will receive a single treatment of Pro-GRID therapy. After which, the participants would be able to resume standard therapy (after one week) and receive additional radiotherapy one month after Pro-GRID therapy, if recommended. Participants will be in the study for one year. Follow-up appointments will be scheduled at 1, 3, 6 and 12 months posttreatment, and may include a history and physical exam, labs and/or a CT scan and toxicity assessments.
75746700|NCT05112497|Other|No intervention procedure|No intervention procedure
75897731|NCT04758520|Device|FLOAT upper limb exoskeleton|The FLOAT device is composed by a wearable exoskeleton assembled on a poly-articulated arm that, in turn, is mounted on a support base with unlockable wheels. The exoskeleton includes 5 motors arranged in a way that, when generating movement, ensures the optimal involvement of all the articulations of the shoulder complex, particularly the glenohumeral and the scapulothoracic joints. According to the chosen modality of use of the exoskeleton, the device allows patient's passive or active-assisted mobilization. The poly-articulated arm supporting the exoskeleton is capable to compensate exoskeleton weight in every configuration and, if configured appropriately, permits exoskeleton use both in seated and standing positions. The support base of the device has unlockable wheels that, if unlocked, permit the free movement of the patient in the workspace, enabling the performance of more complex functional activities while assisted by the exoskeleton.
75451151|NCT01715389|Other|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
75451152|NCT01715402|Procedure|liver surgery|this intervention type includes hepatectomies; wedge; segmentectomies etc...
75746701|NCT05100056|Other|No Intervention|This is a non-interventional study.
75897732|NCT02134938|Dietary Supplement|Konjac Glucomannan|Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
75451153|NCT01715441|Drug|Sorafenib and irinotecan combination|
75746702|NCT05099107|Drug|Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet|taken 3 times daily for 6 months
75746703|NCT05099107|Drug|Salbutamol Only Product in Oral Dose Form|taken 3 times daily for 6 months
75746704|NCT05093634|Drug|Setmelanotide|Subcutaneous Injection
75746705|NCT05093634|Drug|Placebo|Subcutaneous Injection
75746706|NCT05091645|Other|GFI|Two trained raters who will be blinded and will have no access to each other's evaluation, will administer the GFI questionnaire within 24 hours of patients' hospital admission.
75746707|NCT05077423|Drug|CD33*CD3 BsAb|CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
75746708|NCT05077371|Behavioral|Peer support program|The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.
75746709|NCT05062772|Diagnostic Test|Ultrasound|Intraoperative ultrasound imaging
75746710|NCT05058040|Drug|Sodium Oligomannate Capsules|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
75451154|NCT01715441|Drug|Sorafenib monotherapy|
75746711|NCT05057923|Biological|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
75602427|NCT01231620|Drug|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
75746712|NCT05043649|Drug|Camsirubicin|The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
75746713|NCT05035810|Behavioral|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
75746714|NCT05035810|Drug|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
75746715|NCT05035810|Behavioral|No Social Incentive applied|No social incentive will be applied
75746716|NCT05035810|Drug|Procedure: Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
75746717|NCT05030090|Behavioral|Nutritional consultant|The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.
75897733|NCT04750408|Device|Standard oxygen|COT describes the application of low-flow oxygen in any way (Hudson mask, nasal prongs,...).
75897734|NCT04750408|Device|Nasal high-flow|F is combination of room air supplemented with oxygen can be better patients. This gas mixture will be provided to the patient with a specialized nasal prong.
75897735|NCT03649893|Device|Active Office|Active Office intervention includes sit-to-stand desk, bike desk, seddle chair, and active breaks.
75451155|NCT01715441|Drug|Irinotecan monotherapy|
75602428|NCT01231620|Drug|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
75602429|NCT01231620|Drug|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
75602430|NCT05511558|Drug|[14C]-Fosgonimeton|Carbon-14 Radiolabeled Fosgonimeton
75602431|NCT01231464|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
75746718|NCT05030090|Dietary Supplement|Nutritional consultant + High-calorie, high-protein liquid nutrition supplement|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group A to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein).
75897736|NCT05185609|Other|Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
75897737|NCT05185609|Other|Exposure 2: Changes in anorectal motor function or compliance.|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
75897738|NCT02135172|Behavioral|Sitting|
75897739|NCT02135172|Behavioral|Standing|
75897740|NCT02135172|Behavioral|Walking|
75897741|NCT04549558|Diagnostic Test|Multimodal Ultrasound|Multimodal Ultrasound (Strain Ultrasound Elastography, Conventional Grey-Scale Ultrasound, Color-Doppler Ultrasound, and Ultrasound Guided Fine Needle Aspirate) on Axillary Lymph Nodes
75451156|NCT01715480|Dietary Supplement|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
75451157|NCT01715493|Drug|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
75451158|NCT01715493|Drug|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
75602432|NCT01231464|Drug|placebo|placebo
75746719|NCT05030090|Combination Product|Nutritional consultant + Liquid supplement + Powdered supplement 1 and 2|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group B to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein). Meanwhile, nutrition care plan group B will be given powdered supplement 1 (containing β-glucan and gamma-aminobutyric acid) and nutritional products and powdered supplement 2 (contains water-soluble dietary fiber and probiotics).
75897742|NCT03649191|Other|The BABEL Approach to Advance Care Planning in Nursing Homes|In intervention nursing homes, eligible residents will: (i) receive The BABEL Approach to Advance Care Planning (ACP), (ii) after these ACP discussions occur, the resident's primary care physician will be notified of the residents' ACP wishes, (iii) a brightly colored document will be placed in a standard location of the NH chart that identifies the resident's ACP wishes, (iv) paramedics will be educated to know about these sheets and where to find them, and that they should be taken with any resident transferred to another care setting.
75897743|NCT03649191|Other|Control group Advance Care Planning|Eligible residents in each control nursing homes will receive the prevalent approach to Advance Care Planning in that nursing home. No elements of The BABEL Approach to Advance Care Planning will be introduced in the control homes.
75897744|NCT02135250|Drug|Xinkeshu tablets|4 Xinkeshu tablets are given three times per day
75897745|NCT02135250|Other|placebo|the placebo is not drug.
75897746|NCT05182723|Procedure|renal replacement therapy|Extracorporeal Methods for Removing Mediators of Systemic Inflammation
75897747|NCT05373446|Drug|SSD8432 300mg|SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID
75451159|NCT01715506|Behavioral|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
75746720|NCT05003726|Procedure|non-pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
75746721|NCT05003726|Procedure|pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
75746722|NCT05002868|Drug|RP12146|starting dose of 100 mg QD
75746723|NCT04998786|Drug|Ixazomib|Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
75746724|NCT04998786|Drug|Iberdomide|Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
75746725|NCT04998786|Drug|Dexamethasone Oral|Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
75897748|NCT05373446|Drug|SSD8432 750mg|SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
75897749|NCT05373446|Drug|SSD8432Placebo|SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
76064254|NCT01479621|Drug|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
75451160|NCT01715519|Drug|Treatment (Viibryd)|
75451161|NCT01715532|Drug|Huachansu|
75451162|NCT01715532|Other|TACE|
75451163|NCT01715584|Other|Sevoflurane/oxygen/air/nitrous oxide|Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
75451164|NCT01715597|Drug|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
75451165|NCT01715597|Drug|Normal saline|normal saline 500ml IV
75602433|NCT01156311|Drug|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
75602434|NCT02888028|Procedure|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
75602435|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
75602436|NCT01230060|Device|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
75602437|NCT02853955|Device|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
75746726|NCT04998500|Biological|Growth hormone, saline and GH receptor blockade (Pegvisomant)|This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
75451166|NCT01715610|Drug|Clavulin|Patients will be randomized to the antibiotic or placebo arm via a random number generator.
75602438|NCT04281745|Biological|CORETOX Inj|Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.
75602439|NCT02853721|Other|iPTH|iPTH assay six hours after surgery
75602440|NCT02853721|Other|no dosage of iPTH|Ca and P on postoperative day 1 and 2
75602441|NCT02860429|Drug|Cinobufacini injection|cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
75602442|NCT02860429|Drug|chemotherapy|Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
75602443|NCT01155531|Drug|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
75746727|NCT04992624|Drug|Placebo|"Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
75746728|NCT04992624|Drug|Cannabidiol (CBD)|"Epidiolex doses will be 0.37 milliliter (mL) for seven days of treatment and then 0.75 mL two times a day (b.i.d) for the remaining days of this treatment.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
75746729|NCT04992624|Drug|Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)|"Dronabinol Capsules doses will be 2.5 mg b.i.d. for seven days of treatment and then 5 mg b.i.d. for the remaining days of this treatment.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
75897750|NCT03649113|Procedure|sclerotherapy arm|The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
75897751|NCT03649035|Device|HTP treatment|Elegible patients will undergo HTP treatment, followed by standard of care Chemo therapy and SBRT protocol.
75897752|NCT04734028|Drug|Clopidogrel Tablets|DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily
75897753|NCT02135328|Behavioral|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
75897754|NCT02135328|Behavioral|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
75897755|NCT05285397|Drug|Liraglutide Pen Injector [Saxenda]|Subcutaneous injection of GLP-1 agonist
75451167|NCT01715610|Drug|Randomization to Placebo|Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
75451168|NCT01715610|Drug|Clindamycin|Patients will be randomized to the antibiotic or placebo arm via a random number generator
75897756|NCT05302960|Device|Fitbit|The use of Fitbit sensors to see if activity levels can be improved to track recovery from COVID
75897757|NCT05302882|Behavioral|Myofascial release|The physiotherapist placed both palms on the two right and left ribs at the T12 level and applied continuous stretching to the superior for 2 minutes. After this application, the physiotherapist placed one hand on the sacrum with the other hand on T12 with his hands crossed, and applied rhythmically 2 seconds of stretching and 2 seconds of relaxation for a total of 2 minutes. Then, myofascial release was terminated by applying deep compression to the paraspinal muscles with palms for 2 minutes on the right and 2 minutes on the left side, respectively.
75451169|NCT01715623|Biological|a blood sample|Dosage of Ig
75451170|NCT01715636|Drug|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
75451171|NCT01715649|Behavioral|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
75451172|NCT01715662|Device|Wii.n.Walk|Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
75746730|NCT04988399|Other|Reiki|Reiki is a wellness practice of energy healing that began in Japan and is now practiced throughout the world. The principle of Reiki is that everything in the universe consists of energy including the human body, and deviations of this energy can lead to disease (Doğan 2018). Reiki does not have a religious doctrine and is accepted by people of all backgrounds and belief systems (McManus, 2017, p. 1056). Reiki is considered by practitioners to be a great tool for stress reduction and relaxation (International Association of Reiki Practitioners). Many people use Reiki for wellness. Reiki is not a cure for a disease or illness, but it may assist the body in creating an environment to facilitate healing. According to the Center for Reiki Research, Reiki is an effective approach for reducing pain, depression, and anxiety. Tinnitus is a pain percept, and it is likely Reiki may reduce pain and anxiety in patients with tinnitus.
75746731|NCT04983225|Drug|Human Dental Pulp Stem Cells|Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
75451173|NCT01715662|Device|Wii Big Brain|Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
75602444|NCT02856061|Behavioral|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
75746732|NCT04983225|Other|Saline solution|Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
75746733|NCT04976569|Device|STN-DBS stimulation pattern change|Deep brain stimulation (DBS) is an elective surgical procedure in which electrodes are implanted into certain brain areas.We use specific STN-DBS stimulation pattern to regulate sleep architecture.
75746734|NCT04975191|Behavioral|Resources|Participants will be provided a list of resources available at VCU that are intended to support student success
75746735|NCT04975191|Behavioral|Personalized Feedback Program (PFP)|Participants will complete an interactive online program that explores their personality-related traits to provide personalized recommendations for success
75897758|NCT05302882|Behavioral|Classical massage|Classical massage was applied to the lumbar region for 9 minutes. Classical massage was applied with the patient in the prone position. A small amount of solid vaseline was taken and a gentle stroke was applied for 1 minute to spread it sufficiently to the lumbar region. Then, superficial stroking was applied to the right paraspinal region for 1 minute from distal to proximal by the physiotherapist. After the same procedure was performed on the right paraspinal region for 1 minute. Then, both hands were placed on the right and left paraspinal region and friction was applied for 2 minutes. Afterwards, the patient's right paraspinal region was kneeding for 1 minute and then the same procedure was applied to the left paraspinal region for 1 minute. As the last procedure, the fingertips of both hands were placed on the right and left paraspinal region and the classical massage was completed by performing 2 minutes of deep euphlorage from the L5-S1 level to the T12 level.
75897759|NCT03526640|Device|The BioSentry Tract Sealant System|The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
75897760|NCT03050359|Drug|TAK-438|TAK-438 tablets
75602445|NCT01138579|Drug|FBTA05|
75746736|NCT04975191|Behavioral|Substance Use Feedback Program (BMI)|Participants will complete an online program based on brief motivational intervention (BMI) content/principles that explores their current substance use patterns to make personalized recommendations for success
75746737|NCT04972487|Drug|Tofersen|Administered as intrathecal bolus injection
75746738|NCT04964089|Drug|KSI-301|Intravitreal Injection
75746739|NCT04964089|Drug|Aflibercept|Intravitreal Injection
75746740|NCT04964089|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
75746741|NCT04963075|Device|multisensory rehabilitation paradigm|"In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed."
75746742|NCT04961957|Device|Waterproof padding|Apply waterproof padding to allow for normal bathing and water activities
75451174|NCT01715675|Dietary Supplement|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
75451175|NCT01715675|Dietary Supplement|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
75451176|NCT01715688|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
75451177|NCT01715688|Drug|Saline|Administration of saline in the endotracheal tube cuff
75451178|NCT01715701|Procedure|Paravertebral nerve blockade|Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
75451179|NCT01715701|Procedure|Intercostal nerve blockade|Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
75451180|NCT01715701|Procedure|Patient Controlled Analgesia|Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
75746743|NCT04961957|Device|Non-waterproof padding|Apply standard padding that does not allow for normal bathing and water activities
75897761|NCT03050359|Drug|Lansoprazole|Lansoprazole capsules
75602446|NCT04313595|Device|RespirHó|"The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject ."
75746744|NCT04959383|Other|Low complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.
75897762|NCT03050359|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets.
75897763|NCT03050359|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
75897764|NCT03050359|Drug|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
75451181|NCT01715740|Drug|Chinese Herbal Medicine (CHM)|Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
75897765|NCT03648957|Behavioral|Lifestyle counselling|First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.
75451182|NCT01715740|Drug|Placebo|Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
75451183|NCT01715753|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
75451184|NCT01715753|Behavioral|Diet counseling and group education lessons|Individual and group diet counseling to achieve a >10% weight loss
75451185|NCT01715779|Drug|Eltrombopag|Eltrombopag exposure
75451186|NCT01715792|Other|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
75602447|NCT02860195|Other|oral dose of alcohol|
75746745|NCT04959383|Other|Moderate complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.
75897766|NCT03648957|Behavioral|Usual care|Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.
75897767|NCT03648957|Device|Activity tracker|Participants are encouraged to wear a activity tracker to monitor their physical activity
75897768|NCT05302726|Drug|Estrogen|Transdermal and oral estrogen both as substitution therapy
75897769|NCT05012072|Behavioral|The Mastery Lifestyle Intervention|Combination cognitive behavioral intervention of phase 3 CBT using ACT and PST
75897770|NCT04721236|Other|hyperimmune plasma|plasma collected from convalescent Covid-19 donors with titre 1:80 or more
75897771|NCT02135406|Biological|CART-19 T cells|
75897772|NCT03648411|Genetic|Drug resistance molecular markers|Proportion of the drug resistance molecular markers will be found-out and compared.
75897773|NCT04549402|Other|Mirror Therapy group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
75897774|NCT04549402|Other|Video group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
75897775|NCT02253264|Drug|Rituximab|
75897776|NCT03648333|Drug|Exforge tab. 10/160mg|
75897777|NCT03648333|Drug|Lodivixx tab. 5/160mg|
75897778|NCT03626779|Other|Prf|Take 10cc blood from patient and gain prf blug
75897779|NCT02252796|Radiation|Hypofractionated Stereotactic Boost|An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
75897780|NCT02252796|Drug|Carboplatin|Given during chemo-radiation phase and optional consolidative phase.
75897781|NCT02252796|Drug|Paclitaxel|Given during chemo-radiation phase and optional consolidative phase.
75897782|NCT02252796|Radiation|Image-guided IMRT|Given during chemo-radiation phase
75746746|NCT04959383|Other|High complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.
75746747|NCT04959383|Other|Control Group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
75746748|NCT04943432|Behavioral|Behavioral Activation|8 sessions of harm reduction-focused Behavioral Activation for Substance Use
75746749|NCT04943094|Other|Urodynamic examination|A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.
75746750|NCT04941807|Device|Platelet-rich plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
75746751|NCT04941807|Device|Platelet-poor plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
75746752|NCT04941274|Drug|Abemaciclib|An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.
75746753|NCT04937504|Behavioral|STAIR-PC Group|Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) is a face-to-face, individual, brief (5 session) therapy adapted from the STAIR program. STAIR-PC is an appropriate treatment for individuals who have experienced traumatic stressors, and addresses symptom targets by teaching skills to improve coping with emotions and strengthen interpersonal relationships.
75746754|NCT04937504|Behavioral|WebSTAIR Group|WebSTAIR is a web-based self-help program adapted from the STAIR program for individuals who have experienced traumatic stressors. WebSTAIR contains 10 self-guided interactive modules that teach skills to improve coping with emotions and strengthen interpersonal relationships.
75451187|NCT01715818|Drug|Placebo|matching aleglitazar placebo tablet orally daily
75897783|NCT05285007|Other|Mobilization with Movement|Participants will be lunging on a box with posterior ankle glide of 10 seconds times 5 sets. They will have 30 seconds rest between trials. Participant will have their ankle taped and then walk on a treadmill at a self-selected pace for 5 minutes.
75897784|NCT05285007|Other|No mobilization with movement and education|Participants ankle will not be taped and they will walk on the treadmill for 5 minutes and receive education.
75897785|NCT03524690|Dietary Supplement|Energy Balance|Energy Balance Sufficient food provided to maintain energy balance.
75897786|NCT03524690|Dietary Supplement|Negative Energy Balance|Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
75897787|NCT04721197|Other|Egg vouchers|30-day egg vouchers will be provided monthly, in addition to standard of care.
75602448|NCT02860195|Device|alcotest|
75451188|NCT01715818|Drug|aleglitazar|150 mcg orally daily
75451189|NCT01715844|Dietary Supplement|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
75602449|NCT02860195|Biological|blood samples|
75602450|NCT02860195|Device|Transdermal monitor|
75897788|NCT04721197|Other|Standard of Care|Participants will continue to receive the standard of care. No egg vouchers.
76025223|NCT03114241|Behavioral|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
75451190|NCT01715870|Behavioral|Life style and food habits questionnaire|
75451191|NCT01715909|Drug|Oseltamivir|Participants will receive standard dose (30 to 75 milligrams [mg]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for </= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
75451192|NCT01715922|Drug|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
75451193|NCT01715922|Drug|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
75451194|NCT01715922|Procedure|lumbar punctures|lumbar punctures to control intracranial pressure
75602451|NCT01155219|Drug|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
75602452|NCT01155219|Drug|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
75602453|NCT01229436|Drug|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
75602454|NCT01155141|Drug|H.P. Acthar Gel|Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
75602455|NCT00631033|Drug|Placebo|
75602456|NCT00631033|Drug|Diazoxide|
75602457|NCT00631033|Drug|Metformin + Diazoxide|
75602458|NCT04262323|Device|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the mobile phone application and the non-invasive reference method (upper arm cuff).
75746755|NCT04931355|Other|Acupuncture|The Acupuncture intervention（Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.） will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.
75897789|NCT04712422|Other|Healthy subjects|"Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised, their hand dominance by means of the Edinburgh inventory, and their eyedness Coren's Lateral Preference Inventory.~Participants will perform a cervical repositioning test. They will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order. The whole sequence will be repeated by another second operator. Both the tests will be repeated after two weeks.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant."
75897790|NCT04712422|Other|Pathologic group|"Clinical evaluation of the participants will be performed by means of the Myotonic Dystrophy Health Index (MDHI), the Rivermead Mobility Index (RMI), the Fall Events Questionnaire, and the Dizziness Handicap Inventory- short form (DHIsf).~Participants will perform a cervical repositioning test. Participants will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.~Participants will then perform test of balance in standing, using the EquiTest platform. Individuals will be requested to perform three different tasks: sensory organization test, adaptation test-upward tilt, and adaptation test-downward tilt."
76064255|NCT01479621|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
76064256|NCT01479621|Drug|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
76064257|NCT00918892|Genetic|gene expression analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
76064258|NCT00918892|Other|immunohistochemistry staining method|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
76064259|NCT00918892|Other|laboratory biomarker analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
75451195|NCT01715935|Drug|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
75451196|NCT01715961|Procedure|anthropometric measurement|To attest the muscular strength: hand grip test, balance test, up and go test
75451197|NCT01715987|Drug|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
75451198|NCT01715987|Drug|Entecavir|0.5mg oral daily for two years.
75451199|NCT01716000|Other|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
75451200|NCT01716000|Behavioral|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
75451201|NCT01716091|Procedure|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
75451202|NCT01716143|Procedure|radiofrequency catheter ablation|
75746756|NCT04931355|Other|Western medicine|Western medicine
75746757|NCT04924374|Dietary Supplement|Microbiota Transplant plus anti PD1 therapy|"Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (>30g/day).~anti PD1 therapy every 2-3 weeks"
75746758|NCT04924374|Drug|anti PD1 therapy|anti PD1 therapy every 2-3 weeks
75746759|NCT04918147|Drug|elotuzumab|Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
75746760|NCT04918147|Drug|placebo for elotuzumab|The placebo for elotuzumab is 0.9% sterile normal saline for injection.
75746761|NCT04918147|Drug|methylprednisolone|Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
75897791|NCT03648177|Behavioral|IPGT|Behavioral Intervention for Patients with Chronic Pain
75897792|NCT03648177|Behavioral|Treatment as Usual|Standard Care
75897793|NCT02785770|Drug|PF-04447943|Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
75746762|NCT04918147|Drug|diphenhydramine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
75897794|NCT02785770|Drug|Placebo|Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
75897795|NCT02785770|Drug|Moxifloxacin|Single oral dose of moxifloxacin administered as tablet
76064260|NCT04776226|Drug|Citalopram|Antidepressant use in patients with depression
76064261|NCT02319304|Drug|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
76064262|NCT02319304|Radiation|Low dose fractionated radiation therapy (LDFRT)|see arm description
76064263|NCT00910312|Device|Ice-Sense|Ice-Sense Cryoprobe
76064264|NCT00899782|Other|cytology specimen collection procedure|correlative studies
76064265|NCT00885664|Drug|Truvada (tenofovir/emtricitabine)|Tenofovir/emtricitabine fixed dose combination once daily
76064266|NCT00885664|Drug|Kaletra (lopinavir/ritonavir)|Lopinavir/ritonavir 400/100 mg twice daily
76064267|NCT04775992|Other|gabapentoids|Preemptive analgesia
75746763|NCT04918147|Drug|acetaminophen|Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
75746764|NCT04918147|Drug|famotidine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
75746765|NCT04918147|Drug|prednisone|Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
75602459|NCT01155063|Other|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
75602460|NCT04313517|Other|Yoga|Each yoga session included warm-up practices (for the large joints, spine, and extremities), Simple postures (Asana), breathing exercises (pranayama) and meditation/relaxation. All the yoga participants were given handouts to practice everyday at work as its feasible
75746769|NCT04914182|Radiation|LASER|Laser will be applied in specific points for perineal lacerations.
75746770|NCT04914182|Radiation|CONTROL|"A control group of sham laser will create for the patients the impression that laser is being played, with the lights of the instrument of on mode turned on, without biological effects."
75746771|NCT04912531|Device|Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG|The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.
75897796|NCT03650595|Device|"The TRANBERGCLS|Thermal Therapy"|"MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS|Thermal Therapy"
75897797|NCT05302648|Drug|Human Derived anti-BCMA CAR-T Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
75897798|NCT03648099|Behavioral|Labor dance|The dance group which involved pregnant women who performed the labor dance
75897799|NCT03648099|Behavioral|Music|The music group involving pregnant women who were exposed to music.
76025224|NCT03161977|Other|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
75451203|NCT01716247|Other|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
75451204|NCT01716273|Other|Granulated Sugar|30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
75451205|NCT01716273|Other|Debridement Dressing|1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
75602461|NCT04313673|Diagnostic Test|second trimester ultrasonography|Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
75602462|NCT01154673|Drug|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
76025225|NCT02683525|Drug|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
76025226|NCT01976338|Drug|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
76025227|NCT01976338|Other|Sham injection|Sham intravitreal injection
76025228|NCT02674633|Device|AKL-T01|Videogame-like digital therapy
76025229|NCT02674633|Device|AKL-T09|Videogame-like digital therapy
76025230|NCT02651987|Drug|Lanreotide autogel 120 mg|
75746772|NCT04912531|Device|Essence Olfactory Necklace|The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, >97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.
75746773|NCT04912531|Device|Bedside Olfaction Device|The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
75746774|NCT04905914|Drug|ATRN-119|ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
75746775|NCT04902625|Drug|Naltrexone-Bupropion Combination|Naltrexone-bupropion will be added to the BOT module in the interventional arm.
75897800|NCT05302258|Diagnostic Test|Attenuation imaging in ultrasonography|Attenuation imaging in ultrasonography
75897801|NCT04522492|Behavioral|Internet-based Cognitive Behavioral Therapy|2 booster sessions of cognitive behavioral therapy (CBT) delivered thru internet to patients previously treated with CBT. First session focus on understanding the symptoms of skin picking and training techniques to reverse the habit. Second session focus on comorbid symptoms of anxiety and depression, training strategies to improve it.
75451206|NCT01716286|Dietary Supplement|low fat vs. essence yoghurt|
75451207|NCT01716299|Other|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
75897802|NCT04522492|Other|Quality of life promotion|2 videos about quality of life promotion will be send to patients in the active control arm. In the first week, the videos will consist in: social support techniques and sleep hygiene. After one week, 2 another videos will be send, consisting in: guide about healthy diet and about physical exercise.
75451208|NCT01716299|Other|application of a confirmation test|use of rapid confirmation test
75451209|NCT01716338|Drug|Glyburide|
75602463|NCT01154673|Drug|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
75602464|NCT01154673|Drug|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
75451210|NCT01716338|Drug|Placebo|
75451211|NCT01716351|Behavioral|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
75451212|NCT01716364|Biological|Anti-LeY- scFv-CD28-ζ vector,.|
75451213|NCT01716377|Drug|Venlafaxine|Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
75451214|NCT01716390|Dietary Supplement|Drink that contains plant stanols|
75451215|NCT01716390|Dietary Supplement|Placebo drink|
75602465|NCT01154673|Drug|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
75602466|NCT02884869|Device|Intubating Laryngeal Mask|Direct laryngoscopy
75602467|NCT01154283|Device|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
75602468|NCT00944125|Device|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
75602469|NCT00944125|Device|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
75746776|NCT04888117|Procedure|Laparoscopic cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the cholecystectomy according to the surgeon's standard practice.
75897803|NCT05284929|Genetic|A single blood sample for HLA typing|Extracting of DNA from the blood sample using PCR-reaction
75897804|NCT04660123|Drug|Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication|"Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d."
75897805|NCT04530136|Drug|Ruconest|Patients will be randomized to Ruconest or Standard of Care
75897806|NCT03526406|Dietary Supplement|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
75602470|NCT02884713|Drug|Levofloxacin|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
75897807|NCT03526406|Dietary Supplement|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
75451216|NCT01716403|Biological|Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition|
75451217|NCT01716416|Drug|Pazopanib|
75451218|NCT01716416|Drug|Cetuximab|
75451219|NCT01716429|Behavioral|Vegan diet|Vegan dietary approaches for weight loss
75451220|NCT01716429|Behavioral|Low calorie diet|Reduced calorie diet for weight loss
75602471|NCT02884713|Drug|Doxycycline|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
75602472|NCT02884713|Drug|Esomeprazole|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
75602473|NCT00912223|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~Rituxan 375 mg/m^2 on Day -13~Rituxan 1000 mg/m^2 on Days -6, +1, and +8~Fludarabine 30 mg/m^2 on Days -5 to -3~Cyclophosphamide 750 mg/m^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~Methotrexate 5 mg/m^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11."
75897808|NCT02965833|Device|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix|For cleaning, disinfection and overnight storage of contact lenses
75602474|NCT04313439|Other|Online cognitive therapy (I-CT)|"The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual The treatment of Obsessions by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform."
75897809|NCT02965833|Device|Habitual Multi-Purpose Contact Lens Solution|
76064268|NCT04775758|Behavioral|Self-evaluating questionnaires|Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
75451221|NCT01716442|Drug|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
75602475|NCT01154127|Drug|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
75602476|NCT01154127|Drug|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
75897810|NCT02965833|Device|Habitual Contact Lenses|Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
75451222|NCT01716442|Drug|Placebo|
75451223|NCT01716481|Other|Mesenchymal stem cell|intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
75451224|NCT01716507|Procedure|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
75451225|NCT01716546|Drug|Pazopanib|
75451226|NCT01716572|Drug|Erythromycin|Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
75451227|NCT01716572|Procedure|gastric lavage|gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
75451228|NCT01716598|Device|IPS System|TLD Therapy will be achieved bronchoscopically.
75746777|NCT04888117|Procedure|Robotic-assisted cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
75451229|NCT01716611|Drug|Tolvaptan|15 - 60 mg/day for 28 days
75746778|NCT04885985|Device|DEB catheter|"Trade name of DEB catheter: AcoArt Tulip (0.018) or AcoArt Litos (0.014)"
75746779|NCT04884737|Other|Mepilex Border Flex® (MBF) dressing|A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
75746780|NCT04892303|Combination Product|Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)|To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
75897811|NCT04647019|Dietary Supplement|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder consumed daily with 250 ml water. The powder is sealed in sachets and stored at -24 °C, except when transported. Participants are asked to store the sachets in a freezer until consumption.
75897812|NCT04647019|Dietary Supplement|Placebo powder|22 g placebo powder matched for macronutrients, color, and flavor consumed daily with 250 ml water. The powder is sealed in sachets and participants are asked to store the sachets in a freezer until consumption.
75451230|NCT01716611|Drug|placebo|
76025231|NCT05676307|Behavioral|Vestibular Rehabilitation|Cawthorne Cooksey Based Vestibular Rehabilitation Exercises (Oculomotor exercise, Vestibulo-ocular Exercise, posture exercise, balance training, etc)
75602477|NCT01228734|Drug|Cetuximab|Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
75602478|NCT01228734|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
75602479|NCT01228734|Drug|Folinic Acid|FA 200 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
75602480|NCT01228734|Drug|5Fluorouracil|5-FU as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
75602481|NCT01227954|Radiation|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
75602482|NCT01153971|Drug|rituximab|1
75602483|NCT01153893|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
75602484|NCT01153893|Biological|InfanrixTM|Intramuscular injection, 1dose
75602485|NCT00951379|Drug|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
75451231|NCT01716624|Drug|Oxybutynin|standard oral therapy
75451232|NCT01716624|Drug|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
75451233|NCT01716637|Biological|Etanercept|
75451234|NCT01716637|Dietary Supplement|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
75451235|NCT01716676|Other|Telemedicine CPAP monitoring (webpage and televisit)|
75451236|NCT01716676|Other|Standard CPAP monitoring|
75451237|NCT01716689|Drug|oral cyclophosphamide|50mg daily
75602486|NCT00951379|Other|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
75602487|NCT00951379|Other|laboratory biomarker analysis|Correlative studies
75602488|NCT02855749|Procedure|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
76025232|NCT05115773|Procedure|Intraligamentary anaesthesia|one tooth anaesthesia by 2 or 4 points intraligamentary injection
76025233|NCT05115773|Procedure|Mandibular anaesthesia|Inferior alveolar nerve block by direct standart method
76025234|NCT05108285|Diagnostic Test|Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)|OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
75746781|NCT04879537|Other|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
75746782|NCT04861077|Drug|[18F]FMISO-PET with contrast-enhanced MRI|Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
75746783|NCT04848792|Dietary Supplement|Sulforaphane|Myrosinase-active whole broccoli sprout material
75746784|NCT04848792|Dietary Supplement|Placebo capsules|Placebo capsules
75746785|NCT04843306|Behavioral|Biofeedback|Relaxation coaching will be used in this study.
75746786|NCT04843306|Behavioral|Active Breathing Control Technique|Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
75746787|NCT04833075|Other|blood sampling|A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
75746788|NCT04808206|Device|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
75746789|NCT04805775|Drug|Desflurane Inhalation|Subjects were randomized in a 1:1 ratio to undergo breast surgery under maintenance of anesthesia with the classical intravenous anesthetic drug propofol (reference group) or the inhaled anesthetic drug desflurane (test group).
75746790|NCT04800744|Other|Lavender peppermint elequil aromatab|Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
75746791|NCT04800744|Other|Sweet almond oil elequil aromatab|Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
75451238|NCT01716702|Behavioral|Couples Prostate Cancer Support Group|"The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
75451239|NCT01716728|Other|enzyme analysis|
75451240|NCT01716741|Other|Enzyme analysis|
75451241|NCT01716767|Other|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
75451242|NCT01716767|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
75451243|NCT01716780|Other|Intervention|"Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care"
75451244|NCT01716793|Drug|Ara-C|"Intermediate dose during induction phase to remission.~High-dose during consolidation phase in patients with favorable cytogenetics."
75451245|NCT01716793|Other|Autologous transplantation|"In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~In patients with other cytogenetics without HLA-Identical sibling."
75451246|NCT01716793|Other|Allogeneic HLA-identical sibling transplantation|"Patients without favorable or normal karyotype(and one course to CR).~Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics."
75602489|NCT01153815|Drug|GSK1358820(Botulinum toxin type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
75602490|NCT01153815|Drug|placebo|placebo
75602491|NCT02855983|Procedure|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
76025235|NCT02677987|Device|Intervention systematic light exposure|Bright light using Litebook device.
76025236|NCT02677987|Device|Comparison systematic light exposure|Dim light using modified Litebook device.
76025237|NCT02463773|Device|Ultrasound|Diaphragmatic excursion ultrasound assessment
76025238|NCT05676151|Behavioral|Music Therapy|20-minute music-therapy-informed interventions (musical bingo, songwriting, lyric scramble) guided by a music therapist
76025239|NCT04701853|Other|Specific abdominal muscle training|Specific abdominal muscle training
76025240|NCT04701853|Other|Usual care|Care according to each center.
75451247|NCT01716793|Other|CD34+ selection|In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
75451248|NCT01716819|Other|Urine sample|dosages on one spot and 24h collection
76025241|NCT03049397|Other|Communication Intervention|Complete Enhancing Connections program
75451249|NCT01716819|Other|Blood sample|dosages
75451250|NCT01716819|Other|Assessment of sleep apnea syndrome|
75451251|NCT01716819|Other|Electrocardiogram|
75451252|NCT01716819|Other|Glucose tolerance test|
75602492|NCT01153425|Other|Virtual Bone Biopsy|MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
75451253|NCT01716819|Other|Echocardiography|
75602493|NCT01153425|Drug|Teriparatide|Participants are clinically indicated for treatment.
75602494|NCT01153425|Drug|Zoledronic Acid|Participants are clinically indicated for treatment.
75746792|NCT04798534|Behavioral|Service decentralization facilitation intervention|The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
75746793|NCT04795817|Device|Transoral Robotic Surgery|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA. Concomitant non-robotic surgical procedures may also be performed as part of the subject's treatment for OSA, and can include one or more of the following: uvulopalatopharyngoplasty (UPPP), lateral pharyngoplasty, expansion sphincter pharyngoplasty, palatine tonsillectomy, or a modified uvulopalatoplasty. Nasal surgery such as septoplasty or turbinoplasty can be combined if it is needed.
75746794|NCT04758702|Biological|L-PRF (Leucocyte- platelet rich fibrin)|Leucocyte-Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly. Patient's own blood is centrifuged using (Intra-spin) FDA approved centrifuge on 45 degrees angle on 2700 rpm for 12 minutes.
75746795|NCT04758702|Biological|H-PRF (Horizontal -platelet rich fibrin)|Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly.Horizontally centrifuged platelet rich fibrin using (Bio-prf) centrifuge on 700 g force for 8 minutes. On a horizontal centrifugation, the cells separate much more efficiently throughout the entire membrane. This leads to better layer separation and also favors cells that are evenly distributed throughout the PRF clot.
75746796|NCT04758702|Device|Surgical stent|An essix surgical stent will be obtained using a high vacuum suction and used to protect the denuded donor site after suturing the wound. (Biostar® Scan/Biostar®V) will be used to make the stent.
75451254|NCT01716819|Other|cardiac and abdominal magnetic resonance imaging|
75602495|NCT01153347|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
75602496|NCT01153347|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
75602497|NCT02884557|Other|collection of gut biopsies collection of blood samples|Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
75602498|NCT01153269|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
75602499|NCT02884635|Drug|ASP1707|Oral
75451255|NCT01716819|Other|Ambulatory blood pressure monitoring|
75451256|NCT01716819|Other|Echotracking|
75451257|NCT01716819|Other|Pulse wave velocity|
75451258|NCT01716819|Other|Composition of body mass by Dual x-ray absorptiometry|
75451259|NCT01716832|Behavioral|Mindfulness Walking|Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
75451260|NCT01716858|Dietary Supplement|Sulforaphane-rich Broccoli Sprout Extract|
75451261|NCT01716871|Device|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
75602500|NCT02884635|Drug|Placebo|Oral
75746797|NCT04755647|Drug|Nitric Oxide-Releasing Solution|Active antimicrobial
75746798|NCT04755647|Drug|Saline solution, hypotonic|Placebo
76025242|NCT03049397|Other|Questionnaire Administration|Ancillary studies
76025243|NCT04657939|Drug|Liraglutide|Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks.
75451262|NCT01716871|Device|cryotherapy with Cold pack® or ice-cubes pack|"Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group."
75602501|NCT02884635|Drug|Methotrexate|Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
75602502|NCT02884479|Drug|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
75602503|NCT02884479|Drug|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
75602504|NCT01152021|Drug|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
75602505|NCT01152021|Drug|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
75602506|NCT00637221|Drug|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
75897813|NCT05302024|Drug|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
75897814|NCT04252339|Drug|RLY-1971|RLY-1971 is an oral inhibitor of SHP2.
75451263|NCT01716897|Drug|E2609|
75451264|NCT01716910|Dietary Supplement|Combination of Lactobacillus acidophilus NCFM and cellobiose|
75451265|NCT01716923|Biological|S-303 Red Blood Cells (RBCs) - Test|
75897815|NCT04467944|Other|Pre-existing degenerative factors at adjacent segment|Pre-existing degenerative factors at adjacent segment, including disc factors and canal stenosis factors
75897816|NCT03647631|Procedure|sentinel lymph node biopsy|Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.
75897817|NCT03900442|Drug|PTX-100|Doses of 500 to 2000 mg/m2 will be administered.
75897818|NCT04225351|Procedure|MCAF+CM|CAF procedure + collagen matrix
75451266|NCT01716923|Biological|Conventional, untreated red blood cells (RBCs) - Control|
75602507|NCT00624975|Biological|Peru-15 Vaccine|up to 1 x 10^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
75602508|NCT00624975|Biological|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
75746799|NCT04739423|Drug|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
75746800|NCT04730557|Behavioral|Weight Loss|Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine [29]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Weekly intervention sessions and activities will be delivered virtually using Microsoft Teams, Duke ZOOM or Duke Webex and led by Registered Dietitians.
75746801|NCT04715438|Biological|mRNA-1273 SARS-CoV-2 vaccine from Moderna|All participants will receive two vaccinations against COVID-19 according to standard of care.
75897819|NCT04225351|Procedure|MCAT+CM|Tunnel procedure + collagen matrix
75897820|NCT05579418|Drug|Evolocumab|Evolocumab is an injection for management of dyslipidemia
75897821|NCT05301868|Behavioral|Multidomain intervention|For 24 weeks, participants will receive cognitive training twice a week, exercise 3 times a week, nutrition education 12 times, and education about vascular risk factor management every 2 weeks using the tablet PC application.
76064269|NCT04775758|Behavioral|iMotions analysis platform|While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
75451267|NCT01716949|Radiation|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
75451268|NCT01716949|Procedure|Hyperthermia|10 sessions, therapeutic time 60 min
75451269|NCT01716949|Drug|5-Fluorouracil|250 mg/m^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
75451270|NCT01716949|Drug|Capecitabine|1650 mg/m^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
75746802|NCT04704570|Other|Exercise|Spinal stabilization exercise
76064270|NCT04775602|Drug|18F-PSMA|18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
75746803|NCT04704570|Other|Remotely and face to face evaluation of Functional Capacity Level|Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
75746804|NCT04699123|Drug|NC318 800 mg|NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.
75746805|NCT04699123|Drug|NC318 400 mg|NC318 will be given intravenously (IV) every 2 weeks.
75746806|NCT04699123|Drug|Pembrolizumab|Pembrolizumab 200 mg will be given IV every 3 weeks
75746807|NCT04698356|Behavioral|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed in order to train each individual at their own level and to make the task challenging. A short-term memory component was also added to the original training paradigm, to enhance the cognitive skills of our participants. To provide maximal speech-in-noise benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate this in young, normal-hearing adults (18-30 years) by studying our outcome measure (speech reception threshold) for the different sentence-scenarios and test-retest sessions.
75746808|NCT04697264|Diagnostic Test|Blood and tissue sample collection from patients with endometrial cancer|Blood and tissue sample collection from patients undergoing surgery for endometrial cancer and blood sample collection only from patients undergoing chemotherapy for endometrial cancer
75746809|NCT04696432|Biological|Prizloncabtagene autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
75746810|NCT04678856|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
75746811|NCT04678856|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
75746812|NCT04661748|Device|real time alarm of deviating vital signs|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds
75746813|NCT04661501|Device|AlloDerm|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
75897822|NCT02968173|Drug|Palivizumab|Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.
75897823|NCT02785458|Behavioral|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
75746814|NCT04661501|Device|AlloMax|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
75746815|NCT04661501|Device|DermACELL|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
75746816|NCT04661501|Device|Flex HD|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
75746817|NCT04652609|Other|PRESIONA|Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
75746818|NCT04648046|Drug|Cyclophosphamide|Non-ablative conditioning with cyclophosphamide.
75746819|NCT04648046|Biological|LVgp120duoCAR-T cells, low dose|A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused.
75746820|NCT04648046|Biological|LVgp120duoCAR-T cells, high dose|A single dose of 1 x 10^6 cells/kg LVgp120duoCAR-T cells will be infused.
75746821|NCT04648046|Other|Analytic Treatment Interruption|HIV antiretroviral therapy medications will be paused.
75746822|NCT04648020|Drug|Clonidine HCl Mucoadhesive Buccal Tablet|100 μg of clonidine per tablet
75897824|NCT05301790|Device|MRI|use of MRI modality of imaging in evaluation of pathologic response in patients with breast cancer
75897825|NCT04053231|Other|liver resection|all type of liver surgical procedures
75746823|NCT04648020|Drug|Placebo Mucoadhesive Buccal Tablet|Placebo
75746824|NCT04637113|Other|This is a non-interventional study|This is a non-interventional study.
75746825|NCT04623398|Drug|Lithium Carbonate|The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.
75602509|NCT01151085|Drug|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
75746826|NCT04623398|Drug|Placebo|Placebo
75746827|NCT04617756|Drug|Patients receiving neoadjuvant therapy before radical nephrectomy|Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
75602510|NCT01149681|Drug|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
75746828|NCT04615650|Procedure|Surgical treatment|Surgical treatment of suprasyndesmotic ankle fractures
75746829|NCT04615650|Device|Ankle orthosis|Non-surgical treatment of suprasyndesmotic ankle fractures
75746830|NCT04614194|Drug|Letrozole|Oral. Tablets should be taken at the same times every day, with or without food.
75746831|NCT04614194|Drug|Abemaciclib|Oral. Tablets should be taken at the same times every day, with or without food.
75897826|NCT02140320|Drug|RV1729 single dose|Safety and tolerability of single dose
75451271|NCT01716949|Drug|Oxaliplatin|50 mg/m^2/d as 2-hour bolus infusion on d2, 9, 23, 30
75746832|NCT04604431|Other|iREACH CDS Tool|Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
75746833|NCT04603313|Other|tele-advice system|The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
75746834|NCT04602962|Procedure|fertility preservation, several methods|fertility preservation using assisted reproductive techniques or not
75897827|NCT02140320|Drug|RV1729 matching placebo single dose|Safety and tolerability of single dose
75897828|NCT02140320|Drug|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
75897829|NCT02140320|Drug|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
75451272|NCT01716962|Other|Infusion of 6% tetrastarch for a total of 500 ml|
75451273|NCT01716975|Drug|EVP-6124|Arms 1, 2
75451274|NCT01716975|Drug|Placebo|Arm 3
75451275|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
75451276|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
75746835|NCT04594824|Other|No Intervention|no intervention
75451277|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
75746836|NCT04593654|Drug|Dose of tinzaparin or dalteparin|The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
75451278|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
75451279|NCT01717066|Drug|the ginsenoside Rg3|
75451280|NCT01717066|Drug|Placebo|
75746837|NCT04591210|Drug|Angiotensin converting enzyme inhibitor|The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
75897830|NCT02140320|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
75897831|NCT02140320|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
75897832|NCT04867694|Behavioral|BCC|Behavior change communication on Nutrition, Health & Hygiene, including (but not limited to) awareness of dietary diversification from 6 months of age and adequate complementary feeding; and raising awareness of good water and hygiene practices.
75897833|NCT04867694|Dietary Supplement|Preventive supplement|Monthly delivery of a nutritional supplement: enriched flour (CSB++), at a dose of 3 kg/month/beneficiary child. The nutritional supplement is limited to [6-11] months old children diagnosed as non-wasted (green MUAC); or children [12-59] months old for 6 months after discharge from a CMAM treatment or consolidation program.
76025244|NCT04657939|Drug|Pioglitazone|Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.
75746838|NCT04591210|Drug|Angiotensin II Receptor Blockers|The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
75746839|NCT04585893|Drug|Rituximab|375 mg/m^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.
75746840|NCT04585893|Drug|Etoposide|Subjects with high-risk disease will receive 100 mg/m^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
75746841|NCT04583124|Other|ATENTO-B|Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.
75602511|NCT04313127|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
75746842|NCT04583124|Other|ATENTO-T|Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
75746843|NCT04581603|Behavioral|Cognitive Behavioral Therapy for Insomnia|CBT-I is conducted weekly for eight sessions during which the subjects meet individual with the study clinician for 45 minutes on the first session and for 30 minutes for sessions 2-8. Session 1 serves as an orientation and the onset of Sleep Restriction Therapy. Sessions 2 & 3 deliver the three main components that include, Sleep Restriction Therapy, Stimulus control, and Sleep Hygiene. All the sessions excluding the last two sessions are dedicated to the titration of total sleep time and to ensure patient adherence. The fifth session is used to deliver a specific form of cognitive therapy. The final session is used to engage the patient in a relapse-prevention didactic (i.e., to review how insomnia becomes chronic and strategies that abort an extended episode of insomnia). The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
75746844|NCT04581603|Behavioral|Sleep Hygiene Education|This non-active control arm of behavioral sleep intervention consists of psychoeducation on sleep hygiene, sleep-related disturbances, and the effects of stress on sleep that will be delivered weekly for 8 weeks, for a time duration that is identical to the CBT-I sessions. The effect of stress on sleep is a commonly used control condition in insomnia clinical trials. SHE is preferred to a monitor-only condition as it will control for contact with the therapist and elapsed time during sessions. The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
75602512|NCT02883933|Other|Data collection|
75602513|NCT01149369|Drug|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
75602514|NCT01149369|Drug|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
75602515|NCT02853487|Device|Actigraphy|An actigraph from Philips
75746845|NCT04573517|Procedure|Amniotomy|Artificial rupture of amniotic membranes
75746846|NCT04573517|Device|Foley balloon|The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.
75746847|NCT04565535|Behavioral|Novel donor lifestyle optimisation protocol|Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
75746848|NCT04558346|Drug|Ghrelin (OXE-103)|40ug/kg twice daily by self-injection
75602516|NCT02853487|Other|Diary|Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
75746849|NCT04558346|Drug|Placebo|40ug/kg twice daily by self-injection
75746850|NCT04557436|Drug|PBLTT52CAR19|gene therapy
75746851|NCT04547946|Drug|dabrafenib + trametinib|There was no treatment allocation. Patients administered adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) by prescription that had started before inclusion of the patient into the study could be enrolled.
75746852|NCT04542889|Diagnostic Test|Absolute coronary flow and resistance measurements|Thermodilution-based measurements of absolute coronary resistances using the FFR pressure guide (PressureWire® Certus® from St Jude Medical Abbott) and the Rayflow® microcatheter (Hexacath, Paris, France).
75746853|NCT04542889|Diagnostic Test|IMR measurement|IMR measurement by thermodilution using the St Jude pressure guide.
75602517|NCT00879931|Drug|Methylprednisolone|Methylprednisolone
75602518|NCT00879931|Drug|Placebo|Placebo (NaCl 0.9%)
75602519|NCT01149057|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
75746854|NCT04535700|Drug|Pioglitazone 30 mg|Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital
75746855|NCT04535700|Other|standard of care|Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
75746856|NCT04531215|Drug|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
75602520|NCT04281589|Other|if the ventilation parameter caused desaturation or hypercapnia we will change the parameter|we will increased fi02
75602521|NCT01227564|Biological|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
75602522|NCT01227564|Biological|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
75602523|NCT01227564|Other|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
75746857|NCT04531215|Drug|ultrasound guided Erector Spinae Plane|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
75746858|NCT04515498|Device|CloudCath Monitoring System|The CloudCath Monitoring System will analyze effluent dialysate for changes associated with peritonitis.
75746859|NCT04492020|Drug|Ubrogepant 100 mg|For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
75602524|NCT00739141|Drug|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
75746860|NCT04492020|Drug|Placebo|For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
75746861|NCT04491591|Other|Breast Reconstruction Education and Support Tool (BREASTChoice)|The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
75746862|NCT04491591|Other|Attention Control Website|-(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
75897834|NCT04867694|Dietary Supplement|MNP|Delivery of micronutrient powders to [12-23] months old children (30 sachets per month for 2 months, every 6 months, according to international recommendations).
75897835|NCT04867694|Other|Water purification input|Monthly delivery of a water purification input: bleach or flocculant/decontamination sachets for the potabilization of the water of the whole household. The water treatment input is limited to households with [6-11] months old children, or children [12-59] months old enrolled in a CMAM treatment program and for 6 months after discharge.
76025245|NCT01999114|Drug|Buprenorphine transdermal patch|Buprenorphine patch applied transdermally
75451281|NCT01717079|Procedure|Sham rTMS|120 pulses 0.2Hz
75451282|NCT01717079|Procedure|rTMS|120 pulses 0.2Hz
75602525|NCT01148979|Drug|Lisdexamfetamine Dimesylate (Vyvanse)|Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
75602526|NCT01148979|Drug|Placebo|Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
76025246|NCT01999114|Drug|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
76025247|NCT01999114|Drug|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
75602527|NCT04281433|Other|Activa Bioactive|Before cavity preparation and restoration, masticatory muscles activity will be evaluated by using electromyography. An electromyography detects the electrical potential generated by muscle cells. A total of 40 posterior teeth will be selected for this study and grouped into 2 main groups (20 for each group)) according to presence of caries in one or both side in patient (unilateral or bilateral). Split mouth technique will be used. The affected teeth will be treated by removing the caries and restored tooth with bulk fill composite material, after restoring the affected teeth. Masticatory muscles activity will be evaluated by using electromyography to detect any changes in masticatory muscles activity before and after restoration.
75746863|NCT04491591|Other|Clinician Survey|-Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
75451283|NCT01717118|Biological|Bivalent Vaccines|
75451284|NCT01717118|Biological|Tetravalent Vaccine|
75451285|NCT01717144|Behavioral|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
75451286|NCT01717157|Drug|Treatment A: DUROGESIC (8.4 mg fentanyl)|One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
75451287|NCT01717157|Drug|Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)|One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
75451288|NCT01717157|Drug|Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)|One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
75746864|NCT04479943|Other|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
75746865|NCT04479735|Device|Virtual Reality Goggles|Virtual reality goggles will placed at least 2 min prior to venipuncture to deteremine if it mitigates perceived anxiety or perceived pain scores.
75746866|NCT04449328|Device|Computerized Mirror Therapy (CMT)|"Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand."
75746867|NCT04449328|Device|Tendon vibration|Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.
75746868|NCT04445597|Other|Sampling of tissue|In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed
75602528|NCT01735825|Device|paclitaxel-coated balloon catheter with Iopromide coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
75451289|NCT01717157|Drug|Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)|One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
75602529|NCT01735825|Device|drug eluting stent with everolimus|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
75602530|NCT01735825|Device|seal-wing paclitaxel-eluting balloon catheter|Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
75746869|NCT04439669|Device|Sham nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2."
75746870|NCT04439669|Device|Active nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2."
75746871|NCT04437225|Dietary Supplement|Low oxalate controlled Diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
75602531|NCT02855905|Other|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
75451290|NCT01717157|Drug|Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)|One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
75602532|NCT01148511|Drug|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
75746872|NCT04437225|Other|Primed, continuous intravenous infusion of 13C2-Glycolate|Participants will receive a continuous intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, over the course of several hours until steady-state is achieved, using an IV catheter.
75746873|NCT04437225|Other|Bolus intravenous infusion of 13C2-Glycolate|Participants will receive a bolus intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, using an IV catheter.
75602533|NCT02860117|Device|Ketamine continuous infusion|Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
75602534|NCT02860117|Drug|Placebo|Placebo continuous infusion (0,2 ml/kg/h)
75602535|NCT02853253|Dietary Supplement|SMOFlipid®|"SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
75451291|NCT01717170|Drug|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
75602536|NCT02853253|Dietary Supplement|Medialipide®|"Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
75746874|NCT04437225|Other|Oral bolus administration of 13C2-Glycolate|Participants will orally ingest a single dose of carbon-13 glycolate, a naturally occurring form of glycolate.
75897836|NCT04867694|Behavioral|Family MUAC|"One-time delivery of a mid-upper arm circumference (MUAC) measuring tape and training of families in its use, and actions to be taken based on the results. This will involve distributing Shakir bands to all households with [6-59] months old children and training mothers/guardians, or any other family members who express an interest, in screening for wasting using the MUAC criteria, and explaining the procedure to follow if the child tests positive in the family.~Formative supervision of MUAC measurement in families. The training will be carried out by the members of the care groups and at each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary."
76025248|NCT01999114|Drug|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
75602537|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT)- 45 Gy|Dose of SBRT - 45 Gray (Gy) in five fractions
75602538|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT) - 47.5 Gy|Dose of SBRT - 47.5 Gray (Gy) in five fractions
75746875|NCT04429555|Drug|Ibudilast|Ibudilast orally administered, 50 mg twice daily for 7 days.
76025249|NCT02968355|Other|Observational study|Observational study
75451292|NCT01717183|Device|Urgo 310 3113|URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
75451293|NCT01717183|Device|Placebo URGO 310 3113 dressing|
75451294|NCT01717196|Other|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
75451295|NCT01717222|Drug|Intraperitoneal Lignocaine|Patients will receive 100 ml of 0.2% lignocaine
75451296|NCT01717222|Drug|Intravenous Lignocaine|Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
75746876|NCT04429555|Drug|Placebo|Placebo orally administered, 50 mg twice daily for 7 days.
75746877|NCT04419597|Device|HEMOPATCH|The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
75746878|NCT04419597|Device|Standard of care|Usual clinical practice techniques for reinforcing primary dural closure.
75746879|NCT04409444|Diagnostic Test|Lung Cancer Screening|The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)
75602539|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)|
75746880|NCT04409444|Diagnostic Test|Biomarkers|This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
75746881|NCT04408131|Biological|Blood sample|virological test
75746882|NCT04408131|Biological|Blood sample|serological test
75897837|NCT04867694|Behavioral|Screening by care group|"Monthly screening by the care group volunteers of the children they follow, using the MUAC.~Referral to the health center of [6-59] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled"
75451297|NCT01717235|Drug|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
75746883|NCT04400474|Drug|Cabozantinib 40 mg|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
75746884|NCT04398238|Combination Product|evaluation by transfusion medicine specialist|screening for anemia causes and treatment: iron/folate/vitamin B12 supplementation, Erythropoietin administration if indicated
75746885|NCT04387318|Device|Multimodal training|"IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
75746886|NCT04387318|Device|IMT + Pulmonary Rehabilitation|"IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
75746887|NCT04387318|Device|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
75746888|NCT04387318|Device|Pulmonary Rehabilitation|Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
75746889|NCT04383158|Other|PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)|ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
75746890|NCT04382911|Drug|18F-fluoroestradiol|Patients will receive the FES tracer during a PET/MRI scan
76025250|NCT03161743|Procedure|venipuncture|blood draw for the purpose of determining the platelet concentration in PRP
76025251|NCT02783105|Other|Musical intervention|
76025252|NCT02783105|Other|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
75451298|NCT01717248|Drug|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
75451299|NCT01717274|Procedure|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
75451300|NCT01717300|Drug|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
75602540|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)|
75602541|NCT04269187|Drug|Theophylline|Theophylline oral 200 mg daily for 12 days
75602542|NCT02853565|Drug|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
75746891|NCT04376229|Other|Registry|Registry of cancer patients who receive proton radiation therapy
75746892|NCT04374812|Other|Exposure to registered nurses|Change in outcomes associated with a one hour per patient day increase in exposure to registered nurses
75746893|NCT04374812|Other|Exposure to nursing assistants|Change in outcomes associated with a one hour per patient day increase in exposure to nursing assistants
75746894|NCT04372238|Behavioral|RAPIDS Intervention|RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.
75746895|NCT04372238|Behavioral|Standard OEND|In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
75602543|NCT02856217|Procedure|tunneling|In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
75746896|NCT04364386|Device|InPress Device|Treatment with InPress Device for Postpartum Hemorrhage
75746897|NCT04362618|Other|Muscle Strengthening Training|Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.
75746898|NCT04362618|Behavioral|Behavioral graded activity|Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).
75602544|NCT02856217|Procedure|non-tunneling|In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
75746899|NCT04360564|Other|Recurrent pregnancy loss|As described before.
75746900|NCT04336527|Behavioral|Home Treatment with Peer Support|After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.
75746901|NCT04336527|Behavioral|Home Treatment without Peer Support|After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).
75746902|NCT04327284|Device|Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
75746903|NCT04327284|Device|Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
76064271|NCT04784104|Drug|Bupivacaine HCl 0.5% Injectable Solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
76064272|NCT04784104|Drug|Prilocaine HCl 2% Injectable solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
76064273|NCT04784104|Drug|Adrenaline amp. 0.5 mg|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
75451301|NCT01717300|Drug|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
75451302|NCT01717300|Drug|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
75746904|NCT04327115|Procedure|"Control strategy"|"Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams."
75746905|NCT04327115|Procedure|"Intervention strategy"|"Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~High falling risk : out of bed exercise (on a chair for at least 30 min)~Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)"
75746906|NCT04319627|Drug|Rosuvastatin Calcium|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
75746907|NCT04319627|Drug|Placebo Oral Tablet|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
75746908|NCT04308395|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
75746909|NCT04305613|Other|Chemoradiation|Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
75602545|NCT04269109|Other|Multi-modal Opioid Sparing Pain Management Protocol|Incorporating multimodal opioid sparing ERAS techniques for cardiac surgery patients should show a decrease in the amount of opioids received, reduction in incidence of chronic pain, ileus, delirium, and potential for opioid addiction post-operatively. Between the dates of November 2018 through February 2019, a multi-modal, opioid sparing pain management protocol was evolving and a protocol was put into place. This study will compare outcomes before and after implementation of the protocol between the dates of September 1, 2018 - October 31, 2018 and March 1, 2019 - April 30, 2019.
75746910|NCT04305496|Drug|Fulvestrant|Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
75746911|NCT04305496|Drug|Capivasertib|400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
75746912|NCT04305496|Drug|Placebo|Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
75746913|NCT04301934|Device|Mona Lisa Touch|Fractional CO2 LASER
75746914|NCT04301934|Drug|Conjugated estrogen|Current standard treatment for recurrent UTIs in postmenopausal women
75746915|NCT04301934|Drug|Estradiol|Current standard treatment for recurrent UTIs in postmenopausal women
75451303|NCT01717300|Drug|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
75451304|NCT01717339|Other|Sleep Study|
75451305|NCT01717352|Behavioral|Weight Loss Education|
75451306|NCT01717352|Behavioral|Sleep and Eating Routine|
75451307|NCT01717404|Drug|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
76064274|NCT04784104|Procedure|Ultrasound guided supraclavicular block with coronal oblique method|The blocks will be performed by an experienced anesthesiologist with a USG guidence.
76064275|NCT04784104|Procedure|Ultrasound guided lateral sagittal infraclavicular block|The blocks will be performed by an experienced anesthesiologist with USG guidence.
75451308|NCT01717417|Device|miniscrew|
75451309|NCT01717417|Device|TPA|
75451310|NCT01717469|Device|Left ventricular pacing through coronary sinus tributaries (Attain StarFix)|Left ventricular pacing in patients with bradycardia
75451311|NCT01717469|Device|Right ventricular pacing (Medtronic)|Conventional right ventricular pacing in patients with bradycardia.
75451312|NCT01717508|Behavioral|Cognitive Behavioral Therapy|12 sessions of cognitive behavioral therapy
75451313|NCT01717534|Dietary Supplement|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
75451314|NCT01717547|Behavioral|Yoga-based treatment|
75451315|NCT01717560|Other|Collaborative, multidisciplinary, integrated care|"Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management."
75451316|NCT01717573|Procedure|Deferred stenting|
75451317|NCT01717573|Procedure|Conventional treatment|
75451318|NCT01717599|Drug|Diclofenac|Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
75451319|NCT01717599|Drug|normal saline|normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
75602546|NCT04268953|Drug|Tricaprilin|Tricaprilin formulated as AC-SD-03 mixed in 300mL water
75602547|NCT01227252|Drug|LY2886721|5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
75602548|NCT01227252|Drug|Placebo|Administered orally as capsules, daily for 14 days
75746916|NCT04287192|Other|Digital Bridge:Tool Intervention|Our Digital Bridge is an integration of the Care Connector and ePRO technologies that will support care transitions by: 1) inviting PCPs to access Care Connector while the patient is in hospital, allowing for asynchronous communication via the messaging feature for proactive discharge planning, 2) facilitating the inclusion of inter-professional recommendations in the discharge module (e.g. diet and mobility) typically missing from traditional physician generated discharge summaries, 3) electronic generation of PODS for use in patient-centred discharge teaching, 4) providing patients electronic access to PODS post discharge to facilitate use of information at home, 5) adoption of digital enabled goal-oriented process to engage patients and families in discharge process, and 6) providing ongoing self-management support for patients using ePRO for the vulnerable period 6 months post discharge.
75746917|NCT04281017|Drug|TIVA|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)
75746918|NCT04281017|Drug|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg
75746919|NCT04280003|Other|Alogenic adipose tissue-derived stem cells|Concentration of the cells: 10 million cells / ml
75746920|NCT04280003|Drug|Placebo solution|Placebo intravenous solution, same appearance stem cells solution
75746921|NCT04275791|Other|Triage|Experimental : Trauma patient orientation in a structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
75746922|NCT04267185|Behavioral|Physical Activity Together for PwMS and their CGs (PAT-MS)|A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
75897838|NCT04867694|Behavioral|CMAM compliance|"Weekly follow-up of [6-59] months old children under treatment and for 6 months after discharge from the national treatment and consolidation program : care group volunteers follow children under treatment until they recover and for the whole duration of their consolidation (for children cured of severe emaciation) through weekly home visits.~They monitor treatment adherence (i.e., families follow the planned schedule of visits and receive inputs for treatment or consolidation) and treatment compliance (i.e., the malnourished or consolidating child receives the planned dose of therapeutic or supplementary food each day)."
75897839|NCT04329598|Other|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
75897840|NCT04329598|Other|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
75897841|NCT02135562|Dietary Supplement|Dietary Intervention|Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
75897842|NCT02135562|Other|Informational Material|Receive carbohydrate reintroduction handout
75897843|NCT02135562|Other|Dietary Education|Receive education on nutrition label reading for carbohydrates
75451320|NCT01717612|Drug|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
75451321|NCT01717612|Drug|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
75451322|NCT01717625|Drug|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
75451323|NCT01717664|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
75451324|NCT01717677|Procedure|radical prostatectomy|
75451325|NCT01717677|Radiation|percutaneous radiation therapy|
75451326|NCT01717677|Radiation|permanent seed implantation|
75602549|NCT02855671|Device|Infrared thermal imaging|Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
75602550|NCT01227018|Drug|STA-9090|Given IV
75602551|NCT01227018|Radiation|Radiologic imaging|radiologic modalities used to evaluate response to treatment
75451327|NCT01717677|Procedure|Active Surveillance|
75451328|NCT01717690|Drug|CHG antiseptic body cleanser|The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
75451329|NCT01717703|Dietary Supplement|Water|
75451330|NCT01717703|Dietary Supplement|Fruit drink|
75451331|NCT01717703|Dietary Supplement|Cola|
75451332|NCT01717703|Dietary Supplement|1% chocolate milk|
75451333|NCT01717716|Dietary Supplement|water with Sucralose|
75451334|NCT01717716|Dietary Supplement|water with HFCS|
75451335|NCT01717716|Dietary Supplement|water with glucose|
75451336|NCT01717716|Dietary Supplement|water with sucrose|
75602552|NCT01227018|Procedure|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
75602553|NCT01659541|Device|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
75602554|NCT01659541|Procedure|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
75746923|NCT04265768|Procedure|Soft tissue augmentation surgery with CTG|"An epithelial-connective tissue graft of approximately 2-3 mm of thickness and adequate length will be taken from the palate or retromolar region of the patient and de-epithelialized with a scalpel (ideally a thickness of 1.5-2.0mm).~The connective tissue graft (CTG) obtained will then be positioned buccally to the dental implant and sutured to the internal side of the flap so to provide soft tissue bulk at the level of the neck of the implant and simulate a root prominence for the missing tooth."
75897844|NCT02135562|Dietary Supplement|Weight Maintenance|weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
76064276|NCT00880594|Drug|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
76064277|NCT04783870|Drug|Dapagliflozin|Dapagliflozin 10 mg PO QD
75451337|NCT01717729|Procedure|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
75602555|NCT01226472|Biological|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
75897845|NCT02135562|Other|Average score of Obesity and Weight-Loss Quality of Life Questionnaire|Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
75897846|NCT04854746|Biological|VXA-GI.1.NN|GI.1 oral vaccine tablet
75897847|NCT04854746|Biological|Placebo Tablet|Tablets matching in number and appearance to active vaccine tablets
75897848|NCT03647865|Procedure|Osseous Genioplasty|Surgical Procedure that cuts the chin and reposition it in the correct place
75897849|NCT05118841|Drug|ZX-4081|Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
75897850|NCT04255342|Device|Atlantis Abutment|A gold-hue titanium Atlantis abutment will be connected and secured to the implant fixture, and a provisional screwmentable PMMA crown seated to verify marginal adaptation, proximal contact intensity, and occlusion. Upon any necessary modifications and adjustments to the provisional crown, the abutment and crown will be cemented extraorally, disinfected ultrasonically in 0.12% chlorohexidine gluconate, and torqued to 25N/cm2, and screw-access channel obturated with polytetrafluorethylene (PTFE) tape and resin composite.
75897851|NCT04255342|Procedure|Intra-oral photographs|Intra-oral photographs of the sites of interest will be obtained
76064278|NCT04783870|Drug|Placebo|Placebo
76064279|NCT01896310|Device|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
76064280|NCT04783636|Drug|leuprorelin acetate 3.75mg|PT105, PT105R
76064281|NCT04784026|Other|Gait assessment (single)|The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.
76064282|NCT04784026|Other|Dual task gait assessment (motor+motor)|The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.
76064283|NCT04784026|Other|Dual tak gait assessment (motor+cognitive)|The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.
76064284|NCT00820846|Biological|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
76064285|NCT00820846|Biological|Placebo|1 mL of sodium chloride for injection
76064286|NCT00820846|Biological|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
76064287|NCT03371368|Procedure|Roux-en-Y Gastric Bypass (RYGBP)|This is a standard RYGBP procedure that would be performed clinically and is not research-specific.
76064288|NCT03371368|Procedure|Sleeve Gastrectomy (SG)|This is a standard SG procedure that would be performed clinically and is not research-specific.
76064289|NCT03371368|Behavioral|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian
76064290|NCT03364348|Drug|Utomilumab|Given IV
76064291|NCT03364348|Drug|Trastuzumab|Given IV
76064292|NCT03364348|Drug|Ado-Trastuzumab Emtansine|Given IV
76064293|NCT04775290|Behavioral|Yoga lessons|2 weekly yoga classes during the 5 weeks of radiotherapy
76064294|NCT04782622|Drug|Apatinib+Camrelizumab|Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
76064295|NCT04775212|Drug|Desﬂurane|compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.
76064296|NCT04775212|Drug|Sevoflurane|Sevoflurane
75451338|NCT01717729|Radiation|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
75602556|NCT04268563|Drug|placebo|Oral rehydration solution
75602557|NCT04268563|Drug|metformin|metformin tablet
75602558|NCT04268563|Drug|Sitagliptin|Sitagliptin tablet
75602559|NCT04268563|Drug|Sitagliptin/metformin|Sitagliptin/metformin tablet
75602560|NCT04319016|Other|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
75602561|NCT04206462|Other|Questionnaire of eating habits|frequency and type of aliments
75602562|NCT01225146|Drug|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
76064297|NCT03355066|Drug|SM08502|SM08502 tablets to be administered orally.
75602563|NCT01223196|Drug|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
75451339|NCT01717755|Other|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
75746924|NCT04265768|Procedure|Soft tissue augmentation surgery with Fibro-Gide|Fibro-Gide will be used to obtain buccal soft tissue augmentation. Fibro-Gide will be trimmed with a scalpel and adjusted in size and thickness to better adapt to the area buccal to the implant. In particular, the graft will be shaped in order to obtain a graft of approximately 2-3 mm of thickness and adequate length. Fibro-Gide will then be sutured to the inner side of the buccal flap, before repositioning the flap and suturing it in a tension-free way.
75602564|NCT01223196|Drug|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
75602565|NCT01222416|Radiation|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
75602566|NCT01222416|Radiation|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
75897852|NCT04255342|Device|provisional crown (te + 12 weeks)|modifications and adjustments to the provisional crown, the abutment and crown will be cemented extraorally, disinfected ultrasonically in 0.12% chlorohexidine gluconate, and torqued to 25N/cm2, and screw-access channel obturated with polytetrafluorethylene (PTFE) tape and resin composite.
75897853|NCT04255342|Other|medical history|medical history updated to medical record
75897854|NCT04255342|Other|dental history|dental history updated to medical record
76064298|NCT04774900|Procedure|Administration of oxygen|Administration of high-flow oxygen via face mask to a high fidelity mannequin.
75602567|NCT01221948|Device|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
75602568|NCT01221090|Behavioral|PDA|Technological assistance
75602569|NCT01221090|Behavioral|CDSMP|6-week classes
75602570|NCT01221090|Behavioral|PDA/CDSMP|Combined technology and education
75602571|NCT00950911|Drug|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
75746925|NCT04265768|Procedure|No soft tissue augmentation|During implant placement surgery, no soft tissue augmentation will be performed
75746926|NCT04261036|Drug|Ascorbic Acid 1000 mg|1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
75746927|NCT04261036|Other|Placebo|Placebo pills for 14 days post-op after an elective gynecological surgery.
75897855|NCT04255342|Procedure|suture removal|sutures will be removed
75897856|NCT04255342|Procedure|intra-oral digital scan|An intra-oral digital scan of the arch will be obtained using an intra-oral scanner
76064299|NCT04774900|Procedure|Administration of drug in a nebulizer|Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.
75746928|NCT04255407|Device|I-ONE® therapy|I-ONE® therapy will be used in patients with bone bruise on the knee after anterior cruciate ligament (ACL) injury 15 days before and 60 days after ACL reconstruction surgery for 4 hours a day compared to a control group (no-treatment).
75897857|NCT04255342|Diagnostic Test|wound healing index|Visual assessment of the healing status will be made using a wound healing index (WHI)
75897858|NCT04255342|Other|pain|Participants will be asked to report pain in terms of function, comfort and esthetics (PROMs).
75897859|NCT04255342|Other|level of satisfaction|Participants will be asked to report level of satisfaction in terms of function, comfort and esthetics (PROMs).
75897860|NCT04255342|Procedure|debridement|wound will be debrided
76064300|NCT04774900|Procedure|Securing intravenous line|Securing an intravenous line at the forearm of high fidelity mannequin.
76064301|NCT04774900|Procedure|Administration of IV drug|Administration of bronchodilator via IV line to a high fidelity mannequin.
75451340|NCT01717781|Procedure|Thunderbeat technology|
75897861|NCT04255342|Other|oral hygiene|oral hygiene instructions will be given
76064302|NCT04774900|Procedure|Needle decompression of tension pneumothorax|Needle decompression of tension pneumothorax on a high fidelity mannequin.
76064303|NCT04774978|Device|TTE|Transthoracic echocardiography
76064304|NCT04774822|Procedure|Color Fundus Photography|Stereoscopic Fundus photography
76064305|NCT04774822|Drug|Mydriatics Agent|Eye dilating agent
76064306|NCT04774822|Procedure|Optical Coherence Tomography (OCT)|Optical Tomographic imaging of retina
75602572|NCT02855515|Procedure|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
75602573|NCT01220856|Drug|Reparixin|Reparixin + immunosuppression
75602574|NCT04206228|Drug|Intravenous iron isomaltoside|"The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min)."
75602575|NCT04206228|Drug|Placebo|The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
75602576|NCT01218594|Drug|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
75451341|NCT01717781|Procedure|Standard bipolar electrosurgery|
75746929|NCT04255407|Drug|Anti-inflammatory drug|Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
75746930|NCT04254861|Procedure|Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)|"A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured."
75602577|NCT01610557|Drug|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
75897862|NCT04255342|Other|Shade selection|definitive shade selection will occur at this appointment, and a final monolithic screwmentable all-ceramic zirconium-oxide crown will be fabricated from the original Atlantis CoreFile
75897863|NCT04255342|Other|photographs|Intra-oral photographs will be obtained using a dSLR camera
75451342|NCT01716260|Drug|Chloroquine|
75602578|NCT01610557|Drug|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
75602579|NCT00943735|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
75602580|NCT00943735|Behavioral|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
75602581|NCT02853097|Other|Cytology Specimen Collection Procedure|Undergo blood collection
75451343|NCT01716260|Drug|Primaquine|
75451344|NCT01716325|Other|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
75602582|NCT02853097|Other|Laboratory Biomarker Analysis|Correlative studies
75602583|NCT00943579|Drug|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
75602584|NCT04204213|Behavioral|Tai Chi Exercise|8 Section Brocade (Baduanjin) sitting Tai Chi classes + Healthcare Education seminars
75602585|NCT02852707|Behavioral|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
75746931|NCT04254861|Procedure|Simplified Papilla Preservation Flap (SPPF) and GTR|A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
75897864|NCT04255342|Procedure|plaque removal|removal of plaque on crown and surrounding teeth
75897865|NCT04255342|Other|probing depth|probing depths will be measured
75897866|NCT04255342|Other|Bleeding on probing|bleeding on probing will be recorded
75897867|NCT04255342|Other|recession|recession respective to the incisal/occlusal plane
75602586|NCT02852707|Behavioral|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
75897868|NCT04255342|Other|keratinized mucosa height|keratinized mucosa height
75897869|NCT04255342|Other|plaque index|plaque index
75897870|NCT04255342|Other|gingival index|gingival index
76025253|NCT03161665|Other|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
76025254|NCT02666339|Other|Usual care|Usual care : drug therapy, nurse and physician consultations.
76025255|NCT02666339|Behavioral|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
75451345|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
75451346|NCT01717794|Procedure|Thunderbeat technology|
75451347|NCT01717794|Procedure|Standard bipolar electrosurgery|
75451348|NCT01717807|Other|C11-Erlotinib PET/CT|
75451349|NCT01717820|Dietary Supplement|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
75451350|NCT01717833|Procedure|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
75451351|NCT01717833|Procedure|Sham|Sham sessions of neuromuscular electrical stimulation
75451352|NCT01717846|Drug|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
75746932|NCT04247451|Diagnostic Test|Metabolic profile and nutritional goals in diabetic foot surgery patients|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using Bio electrical Impedance Analysis BIA (Nutrilab Akern) and Resting Energy Expenditure REE using indirect calorimetry (Cosmed Q NRG) will be analysed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
75746933|NCT04244929|Procedure|Total knee arthroplasty|Total knee arthroplasty using standard anterior approach.
75602587|NCT02852707|Behavioral|Not exposed|People not engaged in regular sports competition/exercise training.
75746934|NCT04244929|Device|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament retaining|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be retained
75746935|NCT04244929|Device|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament sacrifice|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be sacrificed
75602588|NCT02852551|Drug|PAT-1251|
75746936|NCT04219956|Other|Polyamine Deficient Diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
75746937|NCT04155190|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
75602589|NCT02852551|Drug|Placebo|
75746938|NCT04155190|Drug|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
75746939|NCT04129164|Drug|VIB4920|Intravenous Dose 1.
76064307|NCT04782934|Device|The YANG SENSOR is an active implantable device, for Real Time Continuous Glucose, Lactate and Ketone Measurement|The YANG SENSOR is an active implantable device, that is intended to be implanted in the subcutaneous abdominal tissue, approximately 10mm below the skin. The SENSOR is battery powered. The battery is wirelessly recharged through the skin by the YANGEXD, using a charging coil ('Donut') applied to the skin with an adhesive patch at the level of the SENSOR. The 'Donut' also receives data from the sensor.
75897871|NCT04255342|Device|provisional crown (te + 24 weeks)|modifications and adjustments to the provisional crown, the abutment and crown will be cemented extraorally, disinfected ultrasonically in 0.12% chlorohexidine gluconate, and torqued to 25N/cm2, and screw-access channel obturated with polytetrafluorethylene (PTFE) tape and resin composite.
76064308|NCT04782388|Drug|Alprazolam|Study participants will receive Staccato alprazolam at prespecified time-point.
76064309|NCT04782388|Other|Placebo|Study participants will receive Staccato placebo at prespecified time-point.
76064310|NCT04782076|Drug|Dabigatran|Administered orally.
75451353|NCT01717846|Other|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
75451354|NCT01717911|Drug|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
75602590|NCT01147809|Drug|Eltrombopag olamine|thrombopoietin receptor agonist
75602591|NCT01147809|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
75746940|NCT04129164|Drug|Placebo|Intravenous dose matched to VIB4920.
75746941|NCT04095832|Procedure|Epidural anesthesia|Epidural anesthesia using standardized technique
75746942|NCT04087629|Device|StrataCTX® gel|Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
75746943|NCT04083365|Drug|Capecitabine|chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks
75746944|NCT04083365|Drug|Radiotherapy|5040 cGy radiotherapy for 5 days per week for 5 weeks
75746945|NCT04083365|Drug|Durvalumab|One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations
76064311|NCT04782076|Drug|Selpercatinib|Administered orally.
75746946|NCT04072575|Drug|PP6M injection Dose 1|Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
75746947|NCT04072575|Drug|PP6M injection Dose 2|Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
75746948|NCT04072068|Drug|Edoxaban|Every patient will receive every day edoxaban orally once a day. Edoxaban therapy will start after at least 5 days of lead-in with low-molecular-weight heparin, as per clinical practice. Edoxaban will be administered at dosage of 60 mg/day. In case of patients with body weight ≤60kg or with renal failure (creatinine clearance between 15 and 50 ml/min) or that are treated with P-gp inhibitors (cyclosporine, dronedarone, erythomycin, ketoconazole), dosage will be 30 mg/day. Patients will be treated for 6 up to 12 months with edoxaban, as per medical decision.
76064312|NCT04782310|Drug|Pregabalin|Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
76064313|NCT04782310|Drug|Duloxetine|Duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
76064314|NCT04781764|Procedure|surgery|surgery
76064315|NCT04774432|Other|GM-CSF group|GM-CSF added to CAPA and maturation medium
76064316|NCT04774432|Other|Control group|GM-CSF will not be added to CAPA and maturation medium
75746949|NCT04071847|Device|Deep Brain Stimulation (DBS)|Deep brain stimulation therapy involves the delivery of electrical signals to targeted structures in the brain to modulate neural circuit activity, and has been used successfully for the treatment of various types of movement disorders, including Parkinson's disease (PD), disabling or essential tremor, and dystonia
75746950|NCT04037358|Drug|Radium-223|Radium-223 plus SABR will be within two weeks.
75746951|NCT04037358|Radiation|stereotactic ablative radiotherapy (SABR)|SABR 1-5 fractions
75746952|NCT04030130|Behavioral|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months).
76064317|NCT04774588|Other|VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.|1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
75451355|NCT01717911|Drug|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
75451356|NCT01717911|Drug|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
75451357|NCT01717937|Procedure|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
75602592|NCT00943111|Drug|Eliglustat tartrate|"Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (<) 5 nanogram per milliliter [ng/mL] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively.~Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6."
75746953|NCT04019327|Drug|Talazoparib|"Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6"
75746954|NCT04019327|Drug|Temozolomide|"Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 & 4 - 100 mg/m2 QD Days 2-8 Level 5 & 6 - 125 mg/m2 QD Days 2-8"
75746955|NCT04014413|Procedure|Fecal Microbiota Transplantation|Fecal microbiota transplantation
75746956|NCT03991052|Device|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically by the closed-loop system
75451358|NCT01717950|Biological|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
75451359|NCT01717950|Biological|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
75451360|NCT01717963|Drug|Naltrexone intramuscular suspension|A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
75746957|NCT03991052|Device|Control group|This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
75746958|NCT03985046|Drug|Sintilimab plus Chemotherapy|Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
75746959|NCT03983369|Device|Low-Level Laser Therapy|The LLL used is the K-Laser Cube 3. The LLL is an athermal laser beam of low power, equipped with a placebo function (dummy imitating beam laser light, emitted by the same device but without physiological effect).
75746960|NCT03983369|Other|Placebo|Placebo
75746961|NCT03973151|Drug|HL-085|HL-085 is one MEK inhibitor.
75746962|NCT03970655|Drug|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1|Group 1 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the LEFT pterygopalatine fossa
75746963|NCT03970655|Drug|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2|Group 2 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the RIGHT pterygopalatine fossa
75746964|NCT03963388|Other|Speech therapy|Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
75746965|NCT03962868|Procedure|Experimental procedure : ESD|ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (<1.5%)
75746966|NCT03962868|Procedure|Comparison procedure: WF-piece meal EMR|WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
75746967|NCT03952351|Radiation|CT Coronary Angiography (CTCA)|CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
75451361|NCT01717963|Drug|Buprenorphine-naloxone|Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
75451362|NCT01718002|Behavioral|Educational video|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
75451363|NCT01718054|Dietary Supplement|Vascular ready-to-use supplementary food|Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
75451364|NCT01718054|Dietary Supplement|Regular Ready-to-use supplementary food|Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
75451365|NCT01718054|Drug|Chloroquine|
75451366|NCT01718067|Device|VAKÜM system|15 minutes, twice a day.
75746968|NCT03949920|Drug|Migalastat|Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.
75897872|NCT04255342|Device|provisional crown (te + 36 weeks)|modifications and adjustments to the provisional crown, the abutment and crown will be cemented extraorally, disinfected ultrasonically in 0.12% chlorohexidine gluconate, and torqued to 25N/cm2, and screw-access channel obturated with polytetrafluorethylene (PTFE) tape and resin composite.
75897873|NCT03646929|Diagnostic Test|MEP using standard facilitation technique|measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology
76064318|NCT04774510|Other|Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography|Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
76064319|NCT04774042|Dietary Supplement|Infloran probiotic|Infloran
76064320|NCT04774042|Dietary Supplement|HAC probiotic|HAc probiotic
76064321|NCT04774042|Dietary Supplement|Infloran placebo|Infloran placebo
76064322|NCT04774042|Dietary Supplement|HAC placebo|HAC placebo
76064323|NCT03300544|Drug|Capecitabine|Given PO
76064324|NCT03300544|Drug|Fluorouracil|Given IV
76064325|NCT03300544|Drug|Leucovorin|Given IV
76064326|NCT03300544|Drug|Oxaliplatin|Given IV
76064327|NCT03300544|Radiation|Radiation Therapy|Undergo chemoradiation
76064328|NCT03300544|Biological|Talimogene Laherparepvec|Given intralesionally
75746969|NCT03944538|Behavioral|Lifestyle Physical Activity|The intervention consists of two primary components: a dedicated Internet website and one-on-one video chats with a behavioral coach via Zoom. The intervention focuses on the skills, techniques, resources and strategies for becoming and staying physically active with MS, but does not provide a prescription for exercise or physical activity itself.
75897874|NCT03646929|Diagnostic Test|MEP using modified facilitation technique|measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
75897875|NCT04052919|Other|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
75897876|NCT02135640|Drug|denosumab 60mg|solution
75602593|NCT00943111|Drug|Imiglucerase|"PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.~LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was <5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was >=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively."
75602594|NCT04268719|Diagnostic Test|wireless pH capsule recording|wireless pH capsule recording for up to 96 hours
75602595|NCT01147497|Drug|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
75602596|NCT01147497|Drug|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
75746970|NCT03944538|Behavioral|General Wellness|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
75451367|NCT01718067|Other|conventional manual ELTGOL technique|20 minutes twice a day
75451368|NCT01718093|Drug|Sitagliptin|up to 50 mg twice a day
75451369|NCT01718093|Drug|Metformin|up to 1000 mg twice a day
75746971|NCT03927066|Other|Assigned Interventions|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
75897877|NCT02135640|Drug|denosumab 120 mg|solution
75897878|NCT02135640|Drug|placebo|solution
75897879|NCT03647787|Other|observational study|This study is a longitudinal observational study
75451370|NCT01718093|Drug|Sitagliptin + Metformin|up to 50/1000 mg twice a day
75451371|NCT01718106|Device|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
75746972|NCT03916627|Drug|cemiplimab|Administered intravenous (IV)
75746973|NCT03916627|Drug|Platinum Doublet|Administered intravenous (IV)
75746974|NCT03916627|Drug|fianlimab|Administered IV
75746975|NCT03912064|Drug|Ipilimumab|Ipilimumab is an antibody that acts against CTLA-4
75897880|NCT02784834|Drug|dimethyl fumarate|
75451372|NCT01718119|Drug|r-hCG|r-hCG(250mcg) injection subcutaneously
75451373|NCT01718184|Procedure|toric intraocular lens implantation|piggyback Sulcolflex toric intraocular lens implantation
75746976|NCT03912064|Biological|CD25hi Treg depleted DLI|Donor lymphocyte product
75746977|NCT03911869|Drug|encorafenib|taken orally
75746978|NCT03911869|Drug|binimetinib|taken orally
75746979|NCT03911453|Drug|Rucaparib|Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
75602597|NCT01147341|Drug|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
75602598|NCT01147341|Drug|Placebo|prefilled saline syringe
75602599|NCT00950755|Biological|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
75897881|NCT03862274|Other|CLN2 Treatment|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
75746980|NCT03897088|Drug|PART 1: Double-blind Placebo-controlled|all eligible subjects will receive either tildrakizumab or placebo
75897882|NCT04564495|Behavioral|Seated exercise|Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
75897883|NCT02140398|Procedure|Endometrial Currettage|Only Laparoscopic ovarian drilling without endometrial currettage will be performed
75897884|NCT04467710|Procedure|Laparoscopic common bile duct exploration.|"Laparoscopic common bile duct exploration. ERCP (Endoscopic Retrograde Cholangiopancreatography) with sphincterotomy : : removal of common bile duct stones trought the cystic duct (transcystically) with a Dormia or a choledoscope, or throught the common bile duct with a choledoscope introduced throught an incision of the common bile duct.~ERCP with sphincterotomy: removal of common bile duct stones throught the duodenal papilla, and a sphincterotomy of the oddi sphincter during the same time."
75897885|NCT05284695|Procedure|Bariatric surgery|Patients undergoing elective bariatric surgery
75602600|NCT01147107|Drug|Raltegravir|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
75746981|NCT03897088|Drug|PART 2: Double-blind Active Treatment Extension|subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
75746982|NCT03896464|Procedure|Soft tissue hamstring autograft|Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
75602601|NCT01147107|Drug|Efavirenz|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
75746983|NCT03896464|Procedure|Quadriceps tendon autograft|Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
75769271|NCT03904810|Behavioral|Exercise intervention|HIIT groups performed 30-meter shuttle runs on a rooftop covered field whereas MICT group ran on a footpath with an overall flat and non-slippery road surface. All training sessions were preceded by a 5-minute self-pace warm-up jogging and ended with a 5-minute self-pace jogging or walking cool-down. Each session of MICT consisted of 30 minutes of continuous exercise at an intensity of 60% of heart rate reserve (HRR); [i.e., (maximal HR - resting HR) × intensity + resting HR]. For each HIIT session, the intensity was set at 90% HRR for high-intensity bouts, interspersed with active recovery at 70% HRR. All exercise sessions were supervised by qualified athletic coach or strength and conditioning coach.
75451374|NCT01718184|Procedure|Sulcoflex intraocular lens implantation|
75451375|NCT01718210|Drug|GM-CSF medium|incubation of IVF embryos with a specific medium containing GM-CSF
75451376|NCT01718210|Drug|CONTROL|group of controls treated with a standard IVF medium
75451377|NCT01718223|Drug|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
75451378|NCT01718223|Procedure|therapeutic conventional surgery|Undergo surgical resection
75451379|NCT01718223|Other|laboratory biomarker analysis|Correlative studies
75451380|NCT01718223|Drug|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
75602602|NCT02852473|Other|Continuous Positive Airway Pressure|CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
75602603|NCT02852863|Other|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
75602604|NCT00942409|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
75602605|NCT01146951|Drug|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) >= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
75602606|NCT01146951|Drug|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
75746984|NCT03873272|Device|Cryotherapy|Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.
76064329|NCT03249844|Drug|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),"
76064330|NCT04755166|Procedure|Lateral ridge augmentation|
76064331|NCT04755010|Device|Linq II implantable cardiac monitor|Implantation of Linq II implantable cardiac monitor
75602607|NCT01146873|Drug|Efavirenz (EFV)|Children are assigned to begin a EFV-based antiretroviral based regimen.
76064332|NCT04781608|Behavioral|English: In It Together (IIT)|Digital intervention program that consists of 4 modules, to be completed 1 week apart. The modules consist of psychoeducation, as well as acceptance and commitment therapy-inspired activities.
76064333|NCT00637624|Drug|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
76064334|NCT00637624|Drug|Placebo|Placebo once every 3 weeks intravenous saline fluid
75451381|NCT01718236|Drug|Rocuronium + sugammadex|Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
75602608|NCT01146873|Drug|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.
76064335|NCT04754620|Other|real time online video visit|Participants have received an online visit by a smartphone application
76064336|NCT04773964|Drug|MET642|MET642 active treatment
76064337|NCT04773964|Drug|Placebo|Placebo comparator
76064338|NCT01479465|Biological|Simtuzumab|SIM administered via intravenous infusion over 30 minutes
76064339|NCT01479465|Drug|Placebo to match SIM|Placebo to match SIM administered via intravenous infusion over 30 minutes
76064340|NCT01479465|Drug|Leucovorin|l-Leucovorin 200 mg/m^2 or dl-leucovorin 400 mg/m^2 administered via intravenous infusion over 2 hours
76064341|NCT01479465|Drug|Irinotecan|Irinotecan 180 mg/m^2 administered via intravenous infusion over 90 minutes
76064342|NCT01479465|Drug|Fluorouracil|Fluorouracil 400 mg/m^2 administered via intravenous bolus and 2400 mg/m^2 via intravenous infusion over 46 hours
75746985|NCT03873272|Device|Compression Therapy|Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
75746986|NCT03873272|Device|Loose glove/sock|Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
75746987|NCT03865290|Drug|Ondansetron 8mg|Oral Ondansetron 8 mg
75746988|NCT03865290|Drug|Placebo|Oral matched placebo
75746989|NCT03851237|Drug|64Cu-DOTA-ECLIi|-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
75451382|NCT01718236|Drug|Succinylcholine + Neostigmine|1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
75602609|NCT01146873|Drug|Stavudine (D4T)|Children are assigned to stay on their current antiretroviral regimen which includes D4T.
75602610|NCT01146873|Drug|Abacavir (ABC)|Children stop taking D4T and switch to ABC.
75602611|NCT01146795|Drug|Carboplatin|Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
75602612|NCT01146795|Drug|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
75602613|NCT01146795|Drug|Bevacizumab|Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
75602614|NCT00625053|Procedure|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
75746990|NCT03851237|Device|PET/CT|-Standard of care
75746991|NCT03843242|Device|Pacemaker with Fixed long AV delay|Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
75769272|NCT03904966|Device|Kinesio tape|Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy
76064343|NCT04773574|Device|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA)|"Ocular investigations were performed in each trimesters and at 6 weeks after childbirth.~st trimester : gestational age 8-12 weeks~nd trimester : gestational age 24-28 weeks~rd trimester : gestational age 34-38 weeks"
75451383|NCT01718249|Other|Implantable neurostimulation system|
75451384|NCT01718288|Drug|iloprost|"The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).~For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.~The 4 groups:~1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment~B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment~A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment~2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment"
75746992|NCT03843242|Device|Pacemaker with VpS® algorithm on|"After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
75451385|NCT01718288|Drug|Standard Treatment (aspirin.....),|"The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
75746993|NCT03843242|Device|Pacemaker with IRSplus algorithm on|"After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
75746994|NCT03840291|Drug|Edoxaban|Edoxaban will be used for resolution of left atrial appendage thrombi
75746995|NCT03837626|Drug|Placebo - Cap|6 months of 1 pill a day
75746996|NCT03837626|Drug|Amiloride Pill|Max dose of 5 mg a day for 6 months
75451386|NCT01718301|Drug|boceprevir|
75451387|NCT01718301|Drug|Ribavirin|
75451388|NCT01718301|Drug|Peginterferon alfa-2a|
75451389|NCT01718301|Drug|Peginterferon alfa-2b|
75602615|NCT00625053|Procedure|Open midline incisional hernia repair|"Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
75602616|NCT01146561|Biological|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
75602617|NCT01146561|Other|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
75602618|NCT00942175|Drug|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
75602619|NCT00942175|Drug|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
75602620|NCT00942175|Drug|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
75746997|NCT03787966|Other|ATOPE-B|Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
75746998|NCT03787966|Other|ATOPE-I|Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
75746999|NCT03781219|Drug|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
75451390|NCT01718314|Drug|Sublingual Misoprostol|
75451391|NCT01718314|Drug|Lidocaine pump spray|
75451392|NCT01718314|Drug|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
75451393|NCT01718314|Drug|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
75451394|NCT01718327|Drug|Sunitinib|sunitinib dose :37.5mg/day
75451395|NCT01718340|Drug|Metformin|metformin tablet 500mg three time per day
75602621|NCT00942175|Drug|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
75602622|NCT00942175|Drug|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
75602623|NCT01145625|Drug|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
75602624|NCT01145625|Drug|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
75602625|NCT02852941|Device|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
75602626|NCT02852941|Device|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
75602627|NCT02852083|Drug|Pioglitazone|Pioglitazone 25 mg once daily, p.o.
75747000|NCT03781219|Drug|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
75747001|NCT03773237|Dietary Supplement|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
75747002|NCT03773237|Dietary Supplement|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
75747003|NCT03731715|Drug|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
75769273|NCT03904966|Device|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
75747004|NCT03700684|Behavioral|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
75747005|NCT03700684|Device|SpeechVive|Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
75747006|NCT03700684|Behavioral|Control|Persons assigned to the non-treatment control group will not participate in voice treatment.
75747007|NCT03694808|Drug|Fluad Vaccine|single adjuvanted dose (AD) intramuscular injection
75747008|NCT03694808|Drug|Fluzone HD Vaccine|single high dose (HD) intramuscular injection
75451396|NCT01718366|Drug|Deferasirox, Vitamin D and Azacitidine|association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
75602628|NCT02852083|Drug|nivolumab|3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
75602629|NCT02852083|Drug|Treosulfan|Treosulfan 250 mg twice daily, p.o.
75602630|NCT02852083|Drug|Clarithromycin|Clarithromycin 250 mg twice daily p.o.
75602631|NCT02852395|Drug|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
75602632|NCT02852395|Drug|Placebo|Oral dose; appearance matched to JNJ-48816274
75602633|NCT02852629|Other|observational study|
75747009|NCT03691792|Behavioral|Cognitive-Behavioral Therapy (CBT-SAD)|12 group sessions over 6 weeks
75747010|NCT03691792|Other|Light Therapy|10,000-lux initiated at 30 min upon waking and adjusted per treatment algorithm, continuing for 6 weeks
75747011|NCT03690206|Drug|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
75747012|NCT03690206|Drug|Placebo|Placebo for glepaglutide
75747013|NCT03659539|Drug|PROPOFOL|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
75747014|NCT03659539|Drug|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
75747015|NCT03659136|Drug|Xentuzumab|Intravenous infusion
75451397|NCT01718379|Drug|Lenalidomide|Lenalidomide:10 mg per day during 21 days
75747016|NCT03659136|Drug|Placebo|Intravenous infusion
76064344|NCT04773496|Diagnostic Test|instrumental description of the subject's center of gravity (COG) sway|qualitative and quantitative analysis of the balance function through the description of the center of gravity (COG) sway
76064345|NCT04773886|Drug|Mineral trioxide aggregate|Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
76064346|NCT04773886|Drug|Biodentine|Vital Pulpotomy will be done using Biodentine as pulp capping agent
76064347|NCT04773886|Biological|Platelet rich fibrin|"10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~Acellular platelet plasma- top most layer~Platelet rich fibrin -middle layer~Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece"
75602634|NCT00602407|Drug|Cilostazol|
75602635|NCT01144377|Drug|LY2541546|Administered subcutaneously
75602636|NCT01144377|Drug|Placebo|Administered subcutaneously
75602637|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
75602638|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
75451398|NCT01718379|Drug|Epoetin beta|Epoetin beta: 60,000 Units/week.
75451399|NCT01718392|Behavioral|Training|
75451400|NCT01718405|Other|Cognitive function after exercise test|The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
75451401|NCT01718405|Genetic|Blood sample analysis|In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
75451402|NCT01718418|Other|test meal|
75451403|NCT01718418|Other|reference|
75451404|NCT01718431|Other|test meal|
75451405|NCT01718431|Other|reference meal|
75451406|NCT01718457|Device|Endobarrier|
75602639|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
75747017|NCT03659136|Drug|Everolimus|Tablet
75747018|NCT03659136|Drug|Exemestane|Tablet
75747019|NCT03629418|Drug|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
75747020|NCT03629418|Drug|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
75602640|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
75747021|NCT03615469|Device|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
75747022|NCT03615469|Device|Neuromuscular electrical stimulation|When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
75747023|NCT03607474|Other|Questionnaires of life quality for patients|"the WhoQoL~a specific scale of Cushing's syndrome~The Beck II scale~HAD scale~Rosenberg questionnaire~Stunkard, Sorensen and Schlusinger (1983) figurines~Brief Cope scale"
75747024|NCT03607474|Other|Questionnaires of life quality for caregivers|"the WhoQoL~The Beck II scale~HAD scale"
75747025|NCT03606213|Biological|PENNVAX-GP|PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.
75747026|NCT03606213|Biological|INO-6145|INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.
75747027|NCT03606213|Biological|INO-9012|The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
75747028|NCT03606213|Device|CELLECTRA® 2000|Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
75451407|NCT01718470|Procedure|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
75602641|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
75747029|NCT03603002|Diagnostic Test|Post-SABR Biopsy|Post-SABR Biopsy
75769274|NCT03905044|Other|eyes with congenital cataracts|observation
76064348|NCT04781686|Drug|Camrelizumab|Camrelizumab (200mg) will be given i.v. on day 1 of each 3-week cycle
76064349|NCT04781686|Drug|Apatinib Mesylate|Apatinib (250mg) will be administered orally once a day .
75451408|NCT01718470|Procedure|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
75602642|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
75602643|NCT00950599|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
75602644|NCT01144299|Biological|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
75602645|NCT04313205|Drug|JKB-122 in capsule or tablet form|JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
75602646|NCT02883621|Procedure|cap assisted upper endoscopy|A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.
75602647|NCT02883621|Procedure|standard upper endoscopy|standard examination without using a cap
75602648|NCT02883699|Behavioral|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
75602649|NCT02883699|Behavioral|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
75602650|NCT02883699|Behavioral|Standard resistance training|Machine based hypertrophy training 2 x per week
75602651|NCT02883699|Behavioral|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
75747030|NCT03596476|Procedure|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
75747031|NCT03596476|Procedure|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
75747032|NCT03596476|Procedure|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
75451409|NCT01718496|Drug|Morphine|patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
75451410|NCT01718496|Drug|Placebo|patients with advanced COPD on the other study arm will randomly receive Placebo
75451411|NCT01718548|Dietary Supplement|Cordyceps Sinensis (CS) and Lingzhi|
75451412|NCT01718548|Dietary Supplement|Tea and Flour|Placebo
75451413|NCT01718561|Procedure|SARI|The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
75451414|NCT01718574|Other|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
75451415|NCT01718587|Procedure|stem cell transplantation through interventional procedure|interventional procedure once
75602652|NCT04313049|Device|JACO2|Performing tasks using joystick control
75602653|NCT04313049|Device|VOCAL CONTROL|Performing tasks using vocal control
75602654|NCT05201235|Device|MAEVAD|"MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into le Royaume d'Adelia, a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character."
75602655|NCT05201235|Device|DeCaLigne|"DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the royaume d'Adelia in order to control the motivational effect of the serious game."
75747033|NCT03596476|Procedure|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
75747034|NCT03586739|Procedure|endovascular angioplasty using covered stents|Primary endovascular angioplasty using one or several covered stents
75747035|NCT03586739|Procedure|endovascular angioplasty using bare metal stents|Primary endovascular angioplasty using one or several bare metal stents
75451416|NCT01718587|Drug|antiviral therapy (lamivudine, other antiviral drugs)|lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
75451417|NCT01718613|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
75451418|NCT01718613|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
75451419|NCT01718626|Drug|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
75451420|NCT01718626|Drug|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
75602656|NCT01143207|Drug|Medroxyprogesterone acetate|Injectable hormonal contraceptive
75602657|NCT04312893|Other|Acupuncture (Press Tack Needle)|Press Tack Needle (PYONEX made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles.
75602658|NCT04312893|Other|press tack placebo|press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element.
75897886|NCT04468022|Procedure|Toric Trifocal IOL|Interventions are performed using a standard technique of sutureless phacoemulsification. In all cases, topical anesthesia was administered and pharmacologic mydriasis was induced using a combination of tropicamide and phenylephrine (10.0%). A mean clear corneal microincision of 2.2 mm was made with a knife according to position of the preop highest K value of the patient. A paracentesis was made 60 degree to 80 degree, clockwise from the main incision, and the anterior chamber was filled with an ophthalmic viscoelastic (OVD) after phacoemulsification/lensectomy and removal of clear lens. The IOL was subsequently implanted through the main incision using the BLUEMIXS 180 injector (Carl Zeiss meditec, Jena, Germany) for trifocal IOL , VISCOJECTTM BIO injector for toric trifocal IOL and then the OVD was removed. Postoperative pharmacologic treatment is performed with the combination of antibiotic and steroidal anti-inflammatory drops
75451421|NCT01718639|Device|IQP-LH-101 tablet|Oral medical device in the form of a chewable tablet
75451422|NCT01718639|Device|IQP-LH-101 liquid|Oral medical device in the form of a liquid
75451423|NCT01718639|Other|Placebo|
75451424|NCT01718652|Drug|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
75451425|NCT01718652|Drug|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
75451426|NCT01718678|Drug|Melatonin|it is kind of drug
75602659|NCT01143051|Drug|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
75602660|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
75602661|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
75602662|NCT02883543|Drug|icotinib|Icotinib is orally administered three times per day.
75602663|NCT02883543|Drug|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
75602664|NCT02883543|Radiation|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
75602665|NCT05199597|Drug|0.01% atropine|0.01%, room temp, Lab A
75602666|NCT05199597|Drug|0.05% atropine|0.05%, room temp, Lab A
75747036|NCT03586739|Device|Duplex-scan|a Duplex-scan will be performed during patient follow up.
75747037|NCT03586739|Device|computerized tomography scan (CT-scan)|"a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up."
75747038|NCT03586739|Device|digital angiography|In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
75747039|NCT03586739|Other|Short Form-36 (SF-36) questionnaire|The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
75747040|NCT03556501|Diagnostic Test|Endoscopy|Purpose of this study is to create a prospective registry of patients with pancreatic collections and their imaging studies
75769275|NCT03911440|Drug|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
75769276|NCT03911440|Drug|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
75769277|NCT01254838|Biological|HLA-A02 restricted HIG2|
75451427|NCT01718678|Drug|Placebo|It is Placebo
75451428|NCT01718704|Device|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
75451429|NCT01718717|Other|Thoracic Epidural Analgesia (TEA)|
75451430|NCT01718717|Other|TEA followed by Intravenous morphine|
75602667|NCT05199597|Drug|0.05% atropine|0.05%, refrigerated, Lab A
75602668|NCT05199597|Drug|0.05% atropine|0.05%, room temperature, Lab B
75769278|NCT00191100|Drug|Gemcitabine|
75602669|NCT01142661|Drug|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
75747041|NCT03555669|Other|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
75747042|NCT03553212|Radiation|tomotherapy|20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
75747043|NCT03514108|Drug|Hydralazine Isosorbide Dinitrate|Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
75897887|NCT02140476|Device|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
75897888|NCT02140476|Procedure|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
75897889|NCT03133364|Other|Sensory optimized meals|19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
76064350|NCT04781686|Drug|S1|S1 (BSA<1.25 40mg, BSA >=1.25-<1.5 50mg, BSA >=1.5 60mg) will be administered orally twice daily on days 1-7 of each 3-week cycle
75602670|NCT01142193|Drug|USL255|
76064351|NCT04781686|Drug|Docetaxel injection|Docetaxel (75mg/m2 IV.drop) will be administered on day 1 of each 3-week cycle, for six cycles.
76064352|NCT04781920|Other|datas collection|data collection in history medical : operative report, clinical examination, questionnaires, imaging, isokinetic tests
75747044|NCT03514108|Drug|Placebo Oral Tablet|2 tablets x 3 daily
75747045|NCT03514108|Drug|Metformin Hydrochloride|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
75747046|NCT03514108|Drug|Placebo Oral Tablet|2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
75747047|NCT03482791|Radiation|Proton beam therapy|"The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~The Mevion S-250 Proton Radiation Beam Therapy System will be used."
75747048|NCT03482791|Other|Patient-Reported Outcome Measures|-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation
76064353|NCT05605132|Other|Proprioceptive Training Exercise|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~head relocation~gaze stability~eye follow~saccadic eye movement~head and eye coordination"
75451431|NCT01718730|Device|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
75451432|NCT01718730|Device|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
75451433|NCT01718756|Drug|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
75451434|NCT01718756|Drug|Continuous infusion|"The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery"
75602671|NCT01142193|Drug|Placebo|
75602672|NCT01142115|Device|Intermittent catheter CP063CC|intermittent catheterisation
75602673|NCT01142115|Device|SpeediCath|intermittent catheterisation
75602674|NCT01140477|Device|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
75769279|NCT00191100|Drug|Cisplatin|
75769280|NCT00191100|Radiation|Brachytherapy|Brachytherapy, 30-35 Gy over 1 week
75769281|NCT00191100|Radiation|Pelvic radiation|Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
75897890|NCT02966223|Radiation|MRI and HIDA scan|Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
75602675|NCT01140477|Device|Accommodating Lens|Accommodating lens implanted after cataract extraction
75602676|NCT01139775|Drug|Pemetrexed|Administered intravenously as a continuous 10-minute infusion
75602677|NCT01139775|Drug|Cisplatin|Administered intravenously as a continuous 1-hour infusion
75602678|NCT01139775|Drug|LY2603618|Administered intravenously as a continuous 1-hour infusion
75747049|NCT03479541|Behavioral|Rehabilitation|"Participants will see a physiotherapist one-on-one twice per week for 2 weeks and once per week for 4 weeks for a total of 6 weeks. These sessions will consist of cardio, cervical flexion exercises and vestibule-ocular exercises for one hour. Participants will also have similar daily home exercises to complete for approximately 30 minutes. Both the one-on-one physiotherapy and home exercises will be individualized and progressive in the sense that each exercise can increase in the level of difficulty at the discretion of the physiotherapist depending on the performance of the participant.~For the group allocated to home monitoring, they will perform the vestibular exercises while wearing one wireless sensor on the head and one on the sternum. When the participant brings the sensors in to the physiotherapy session each week, the physiotherapist will examine the home data and likely make a more informed decision as to whether or not to increase the level of difficulty of the task."
75747050|NCT03469362|Procedure|Extracorporeal Urinary Diversion|Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
75747051|NCT03469362|Procedure|Intracorporal Urinary Diversion|Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
75747052|NCT03469362|Device|Da Vinci Robot|Da Vinci Robotic Surgical System
75747053|NCT03419325|Genetic|CYP2C19 test|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
75747054|NCT03419325|Diagnostic Test|P2RY12 assay|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
75747055|NCT03418792|Other|Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography|Head & neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
76064354|NCT05605132|Other|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
75451435|NCT01718756|Drug|Scheduled|"The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia."
75602679|NCT05224557|Other|No intervention|No intervention
75602680|NCT02883777|Behavioral|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
75602681|NCT02883777|Behavioral|Conventional Diet|Conventional diet over 1 year after transplantation.
75602682|NCT02883465|Procedure|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
75602683|NCT04312425|Procedure|Modified rapid sequence induction|Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.
75769282|NCT03911518|Procedure|Loop drainage|Loop drainage will occur via 2 small incisions, approximately 2 cm, with the cuff from the base of a sterile glove pulled through and then tied off.
75451436|NCT01718769|Other|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
75451437|NCT01718782|Device|laryngeal mask Ambu AuraOnce|airway management and mechanical ventilation with laryngeal mask
75451438|NCT01718782|Device|laryngeal mask LMA Supreme|airway management and mechanical ventilation with laryngeal mask
75602684|NCT04312425|Procedure|Classic rapid sequence induction|In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
75602685|NCT01283516|Drug|LDK378|LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
75602686|NCT04205721|Behavioral|School-based sexuality and HIV prevention scripted lesson plans|The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.
75602687|NCT01137435|Biological|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
75602688|NCT02883309|Other|intradialytic physical training program|Nine patients participated in the experimental group in a combined training program, which lasted 12 weeks with a frequency of 3 times a week, the training sessions were carried out within each dialysis session during the first 2 hours of the dialysis treatment, the working session involved a warm up period, aerobic exercise with pedals, or strength exercises based on free weight depending on the training stage. The Borg scale and the heart rate reserve were used to control the training intensity. The disability level was evaluated at the beginning and the end of the study through the World Health Organization Disability Assessment Schedule II, the aerobic capacity was evaluated through the six minute walk and the limbs strength was evaluated through a dynamometer.
75602689|NCT02883231|Other|taking peripheral blood|taking peripheral blood of no more than 3ml
75602690|NCT01283282|Drug|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
75602691|NCT01283282|Drug|Placebo|Placebo PO qday for 6 weeks
75602692|NCT01282814|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
75747056|NCT03411408|Device|HBO|"Hyperbaric oxygen is administrated in a multiplace hyperbaric chamber according to the following schedule:~Ten minutes of compression with a Fraction of inspired oxygen (FiO2) more than 90% from 152 to 253 kilopascal, 60 minutes of Fraction of inspired oxygen (FiO2) more than 90% at 253 kilopascal (three breathing cycles in oxygen for 22 minutes each, with two intervals breathing air for 2 minutes each) and 10 minutes of decompression with a Fraction of inspired oxygen (FiO2) more than 90% from 253 to 152 kilopascal."
75747057|NCT03411408|Radiation|RT|tomotherapy (within 60 minutes from completion of decompression of hyperbaric chamber) with 3-5 consecutive sessions- one fraction per day, 5 Gy / die .
75602693|NCT01282814|Drug|Effexor® XR|150 mg Extended-Release Capsule
75602694|NCT00941863|Drug|Sorafenib 100 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
75747058|NCT03406741|Behavioral|psychometric evaluation|Wechsler type composite scales (WISC)
75747059|NCT03406741|Behavioral|neuropsychological evaluation|Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
75747060|NCT03390036|Combination Product|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
75747061|NCT03390036|Device|Monovisc|Hyaluronic Acid
75897891|NCT04157179|Other|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
75897892|NCT02253342|Drug|WCK-2349|Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
75897893|NCT03844022|Diagnostic Test|MRI|magnetic resonance imaging
75897894|NCT02252874|Behavioral|Slow-paced action video game|20 hours slow-paced action video games
75897895|NCT02252874|Behavioral|Fast-paced action video game|20 hours fast-paced action video games
76064355|NCT05605132|Other|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
76064356|NCT04780906|Other|Wrist taping|Wrist taping as used as standard in CrossFit practice
76064357|NCT03996460|Drug|Placebo|"Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food."
75897896|NCT02252874|Behavioral|Control|20 hours leisure activities
75451439|NCT01718795|Device|Bag-valve mask or laryngeal tube ventilation|"Interventions are either Bag-valve mask (BVM) or Laryngeal tube (LT) ventilation during CPR"
75451440|NCT01718808|Drug|Cetuximab|Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
75897897|NCT05284461|Device|dental implant with transepithelial abutments manufactured by Galimplant Dental System (Spain)|Dental implants with transepithelial abutments with distinct morphology
75451441|NCT01718808|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
75451442|NCT01718834|Biological|prophylactic peptide vaccine|synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
75451443|NCT01718834|Biological|therapeutic peptide vaccine|therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
75897898|NCT04802096|Other|inspiratory muscle training|Intensity of inspiratory muscle training will be set at 30% of maximal inspiratory pressure. Subjects in intervention experimental group will perform 15 breaths per set, 6 sets per day on daily basis. The intervention will be last for 8 weeks.
75897899|NCT04802096|Other|pulmonary rehabilitation|Pulmonary rehabilitation consists of aerobic exercise training, strength training, and education related to airway clearance and drug utilization. All of subjects will receive 8-week pulmonary rehabilitation.
75897900|NCT00495508|Drug|Quinine|
75897901|NCT00495508|Drug|artemether / lumefantrine|
75602695|NCT00941863|Drug|Sorafenib 200 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
75747062|NCT03390036|Drug|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
76064358|NCT03996460|Drug|192 mg powder of K0706|Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
76064359|NCT03996460|Drug|384 mg powder of K0706|Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
75451444|NCT01718847|Drug|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
75451445|NCT01718860|Procedure|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
75451446|NCT01718886|Device|Obalon Gastric Balloon|
75451447|NCT01718899|Biological|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
75451448|NCT01718912|Drug|metronidazole-nystatin oral rinse|
75451449|NCT01718951|Drug|golimumab|golimumab
75451450|NCT01718951|Drug|Pamidronate|pamidronate
75451451|NCT01718964|Drug|Cortisol 20 mg|
75747063|NCT03389685|Biological|Platelet Rich Plasma|Pure PRPII®, leukocyte-poor, platelet rich plasma
75747064|NCT03389685|Other|Saline Placebo|saline solution
75747065|NCT03386383|Behavioral|Intervention|Individual session, physical activity tracker, online intervention
75747066|NCT03385798|Procedure|Endowrist|Anastomosis made by Endowrist
75747067|NCT03385798|Procedure|Endo-GIA|Anastomosis made by Endo-GIA
75451452|NCT01718964|Drug|Mannitol|Mannitol used as placebo
75451453|NCT01718977|Other|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
75451454|NCT01718977|Other|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
75602696|NCT00941863|Drug|Sorafenib 400 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
75602697|NCT00941863|Drug|Sorafenib 400 mg (200-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
75602698|NCT00941863|Drug|Sorafenib 400 mg (Expansion)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
75602699|NCT00602485|Other|Action Control Education|30 minute educational intervnetion
75747068|NCT03379506|Drug|EBR/GZR FDC Tablet|Participants who are 12 to <18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
75602700|NCT00602173|Drug|Cilostazol|
75602701|NCT02854969|Behavioral|Device: Anapphylaxis|
75602702|NCT02852239|Drug|dabrafenib|Single dose dabrafenib 100 mg
75747069|NCT03379506|Drug|Placebo|Placebo tablet matched to EBR/GZR FDC tablet.
75747070|NCT03379506|Drug|Grazoprevir Oral Granules|Participants 3 to <12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
75747071|NCT03379506|Drug|Elbasvir Oral Granules|Participants 3 to <12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
75747072|NCT03377517|Radiation|radiosurgical hypophysectomy|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
75747073|NCT03375788|Drug|Tesamorelin|Tesamorelin F4 formulation 1.4mg daily
76064360|NCT04780594|Procedure|The study evaluates all surgical patients operated, both elective scheduled and emergent cases|Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
75451455|NCT01719029|Other|Low-Carbohydrate/Higher Fat Diet|
75897902|NCT02135718|Device|ELLIPTA inhaler|ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)
75897903|NCT02135718|Device|Placebo Inhalation Aerosol (MDI)|Placebo inhaler MDI will be supplied containing aerosol propellant
75451456|NCT01719029|Other|High Carbohydrate/Low fat diet|
75451457|NCT01719042|Drug|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
75451458|NCT01719042|Dietary Supplement|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
75602703|NCT01282424|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
75602704|NCT02852785|Behavioral|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
75602705|NCT02852785|Behavioral|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
75747074|NCT03375788|Drug|Identical Placebo|Placebo injection daily
75897904|NCT03646851|Diagnostic Test|Questionnaries|patients will have to do a sputum and to complete some questionnaries
75897905|NCT04793828|Behavioral|Velibra|Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.
75897906|NCT03549156|Dietary Supplement|C-RUSF|-RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier
76064361|NCT04780750|Drug|Docetaxel|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\m2) and cisplatin (80mg\m2 every 3 weeks)
75451459|NCT01719081|Procedure|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
75451460|NCT01719107|Dietary Supplement|L. reuteri DSM 17938 chewable tablets|2 chewable tablets with breakfast for 4 weeks
75451461|NCT01719107|Dietary Supplement|Placebo chewable tablets|2 chewable tablets with breakfast for 4 weeks
75451462|NCT01719120|Behavioral|Cognitive-Behavioral Therapy|CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
75451463|NCT01719133|Drug|placebo|saline solution
75451464|NCT01719133|Drug|Histamine|positive control
75451465|NCT01719133|Drug|AllerT1|synthetic peptide T1
75451466|NCT01719133|Drug|AllerT2|synthetic peptide T2
75602706|NCT02852785|Behavioral|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
75602707|NCT02852785|Behavioral|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
75602708|NCT00602251|Drug|Terbinafine|
75602709|NCT01281956|Drug|PRX-00023|PRX-00023 (Selective 5HT1A agonist)
75602710|NCT01281956|Drug|Placebo|Placebo
75602711|NCT02889536|Other|Focus group interviews|Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
75602712|NCT02889614|Other|Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)|LDL-C dosage.
75747075|NCT03368079|Device|Negative Pressure Suction Catheter|The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
75747076|NCT03360539|Behavioral|Nurse-Family Partnership|
75747077|NCT03341949|Biological|Recurring blood sample|An additional tube will be collected for the assay of CD146s as part of the research
75747078|NCT03341936|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
75451467|NCT01719133|Drug|AllerT3|synthetic peptide T3
75451468|NCT01719133|Drug|AllerT4|synthetic peptide T4
75451469|NCT01719133|Drug|AllerT5|synthetic peptide T5
75451470|NCT01719133|Drug|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
75451471|NCT01719133|Drug|mix of AllerT4-T5|mix T4-T5
75602713|NCT00623870|Drug|RO5045337|Multiple ascending doses
75747079|NCT03341936|Drug|Lirilumab|Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
75747080|NCT03328702|Device|Continuous Positive Airway Pressure|Apex XT Fit CPAP Machine
75747081|NCT03311412|Drug|Sym021|Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
75747082|NCT03311412|Drug|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
75747083|NCT03311412|Drug|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
75747084|NCT03310528|Behavioral|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
75747085|NCT03310528|Procedure|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
75747086|NCT03306446|Drug|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
75747087|NCT03292133|Drug|EGF816|EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
75451472|NCT01719159|Drug|Rituximab|25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
75451473|NCT01719185|Drug|Phentermine and B12|
75451474|NCT01719185|Drug|Phentermine|
75451475|NCT01719250|Drug|Buparlisib|Given PO
75602714|NCT04323410|Procedure|Cast immobilization|Cast immobilisation is done using finger trap traction. The fractured forearm is splinted above elbow with dorsal cast without attempted reduction.
75602715|NCT04323410|Procedure|Percutaneus pinning|Reduction under fluoroscopic guidance and fixation using two crossing 1.6mm K-wires.
75602716|NCT05561270|Device|White LED light|Exposure to white LED light for 1-2 hours/day x 10 weeks
75602717|NCT05561270|Device|Green LED light|Exposure to green LED light for 1-2 hours/day x 10 weeks
75602718|NCT00949975|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
75602719|NCT00949975|Drug|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
75602720|NCT00949975|Drug|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
75747088|NCT03292133|Drug|Gefitinib|Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
75747089|NCT03289728|Other|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with < moderate ischemia will receive medical treatment only (MT)."
75451476|NCT01719250|Other|Laboratory Biomarker Analysis|Correlative studies
75451477|NCT01719250|Other|Questionnaire Administration|Ancillary studies
75602721|NCT00949975|Drug|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
75747090|NCT03289728|Procedure|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
75747091|NCT03284203|Device|SpiroPD|At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
75747092|NCT03275740|Drug|PF-06755347 intravenous healthy participant|Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
75747093|NCT03275740|Drug|Placebo intravenous healthy participant|Placebo comparator
75747094|NCT03275740|Drug|PF-06755347 subcutaneous healthy participant|single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
75747095|NCT03275740|Drug|Placebo subcutaneous healthy participant|placebo comparator
75747096|NCT03275740|Drug|PF-06755347 subcutaneous ITP|single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
75747097|NCT03275415|Drug|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
75747098|NCT03275415|Drug|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
75747099|NCT03269227|Radiation|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
75747100|NCT03233724|Drug|Decitabine (DAC)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
75747101|NCT03233724|Drug|Tetrahydrouridine (THU)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
75897907|NCT03549156|Dietary Supplement|HIPRO RUSF|HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate
75747102|NCT03233724|Drug|Pembrolizumab|200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.
75897908|NCT04052451|Biological|MET-2|Subjects will take study medication once daily for the duration of the study
76064362|NCT04780672|Drug|Molixan|The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
75747103|NCT03230734|Drug|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
75747104|NCT03230734|Drug|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
75747105|NCT03229408|Drug|Salsalate|Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
75747106|NCT03229408|Other|Placebo|Appears identical to experimental drug
75747107|NCT03223922|Radiation|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
75747108|NCT03209050|Device|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
75747109|NCT03183570|Drug|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) [18F]FP-R01-MG-F2 will be administered
75451478|NCT01719263|Device|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
75451479|NCT01719263|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
75747110|NCT03176420|Procedure|angioplasty and stenting of occluded cervical ICA|The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
75897909|NCT03526328|Other|EMR and RFA effect on stem cell marker expression in BE/EAC|Observation of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
75897910|NCT03549078|Behavioral|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
75897911|NCT05284851|Biological|Live Attenuated Influenza Vaccine(non freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
75897912|NCT05284851|Biological|Live Attenuated Influenza Vaccine(freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
75897913|NCT05284851|Biological|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
75602722|NCT00939055|Device|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
75602723|NCT00939055|Procedure|Sham procedure|False procedure
75602724|NCT00602563|Behavioral|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
75602725|NCT00602563|Behavioral|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
75897914|NCT03764904|Radiation|Airway Ultrasound|Laryngeal US will be performed with a 12 megahertz (MHz) linear probe attached to the ultrasound device. With the probe placed transversely on the midline of the anterior neck over the cricothyroid membrane.
75897915|NCT03783884|Device|Lungpacer Diaphragm Pacing Therapy|Transvenous phrenic nerve stimulation to induce diaphragm contraction.
75451480|NCT01719276|Other|Graded Activity|The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
75451481|NCT01719276|Other|Supervised Exercises|The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
75451482|NCT01719289|Behavioral|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
75451483|NCT01719302|Drug|Gemcitabine|1500 mg/m^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
75451484|NCT01719302|Drug|Docetaxel|50 mg/m^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
75451485|NCT01719302|Drug|Pazopanib|Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
75451486|NCT01719315|Other|Acoustical slow wave induction|Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
75451487|NCT01719328|Behavioral|Vinyasa yoga|
75451488|NCT01719354|Other|Community Health center|Observation of the functioning and coordination of health care before discharge to own home.
75602726|NCT00602563|Behavioral|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
75769283|NCT03911518|Procedure|Incision and drainage|The wound will be incised with a #11 blade scalpel along the point of maximal fluctuance, approximately 2-3 cm, and then all loculations bluntly dissected with a set of Kelly clamps. After drainage of pus, the wound will be loosely packed with gauze.
75769284|NCT03911362|Behavioral|Lumbopelvic Stabilisation Exercises Group|Lumbopelvic stabilisation exercises will be taught the basic movement, starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction.
75769285|NCT03911362|Behavioral|Pelvic Floor Exercises Group|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres, and for slowly contracting muscle fibres, slow contraction by counting to ten, hold for a count of ten, then gradually relax by counting to ten
75451489|NCT01719354|Other|Control|standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
75451490|NCT01719406|Behavioral|Intervention, behavioral lifestyle education|Twenty interactive weekly sessions that are scripted curriculum and peer led.
75451491|NCT01719419|Drug|Placebo|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
75769286|NCT01148758|Drug|RO5323441|cohorts receiving multiple doses iv
75747111|NCT03157713|Behavioral|Goal-Directed Financial Incentives|Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
75747112|NCT03157713|Behavioral|Enhanced Usual Care|Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
75747113|NCT03157713|Behavioral|Outcome-based Financial Incentives|Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to <2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to <5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to <5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
75747114|NCT03146962|Drug|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
75897916|NCT03049735|Drug|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
75897917|NCT03049735|Drug|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
75602727|NCT00602563|Behavioral|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
76064363|NCT04780672|Drug|Placebo|Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
76064364|NCT04780984|Drug|Tiotropium bromide inhalation solution|Tiotropium bromide inhalation solution
76064365|NCT04780984|Drug|Placebo|Placebo comparator
76064366|NCT04773340|Behavioral|Dialectical Behavior Therapy|Behaviorally-focused intervention for individuals with personality disorder and a history of significant behavioral problems.
76064367|NCT02090374|Other|Poly ICLC|Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug
76064368|NCT02090374|Other|Poly I:C|Single dose: 500ug
76064369|NCT02090374|Other|R848|High dose: 10ug Low dose: 1-2ug
76064370|NCT02090374|Other|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
76064371|NCT02090374|Other|Vitamin D|4000U orally
76064372|NCT02090374|Other|Tuberculin|Tuberculin PPD
76064373|NCT04772716|Procedure|operation|The intervention was not decided by the investigator but studied following emergency or elective surgeries undergoing in the system
76064374|NCT04772794|Other|fraction of inspired oxygen|after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
76064375|NCT04773028|Other|matrix metalloproteinase enzymes 2 and 9|concentration of matrix metalloproteinase 2 and 9 enzymes
76064376|NCT04772872|Other|Assessment by Brazelton neonatal behavior for group A,Band C|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
76064377|NCT02222740|Drug|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
76064378|NCT02222740|Drug|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
75747115|NCT03125564|Procedure|Fecal Microbiota Transplantation|Fecal microbiota transplantation
75747116|NCT03125564|Procedure|Sham|Infusion of sham
75747117|NCT03125564|Procedure|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
76064379|NCT04752982|Behavioral|c-SIGHT intervention|The c-SIGHT active intervention involves grasping, lifting and balancing wooden rods using the unaffected hand. C-SIGHT uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
75451492|NCT01719419|Drug|Orlistat|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.
75602728|NCT04268017|Device|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
75602729|NCT00604357|Drug|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
75602730|NCT05381701|Procedure|Lung Ultrasound Score|Measuring the atelectasis area by ultrasound guidance from 12 different regions of the lung
75602731|NCT04269733|Device|Right ventricular pacing|Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
75747118|NCT03085810|Drug|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
75747119|NCT03078452|Device|Power drill|Undergo bone marrow biopsy using power drill
76064380|NCT04752982|Behavioral|c-SIGHT attentional control|The c-SIGHT attentional control exercises involves grasping and lifting wooden rods from one end using the unaffected hand. Identical to the intervention group, the c-SIGHT attentional control version uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
75747120|NCT03078452|Device|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
75747121|NCT03077451|Other|Laboratory Biomarker Analysis|Correlative studies
75747122|NCT03077451|Drug|Nelfinavir Mesylate|Given PO
75747123|NCT03065725|Procedure|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
75747124|NCT03043794|Radiation|Stereotactic Body Radiation SBRT|Stereotactic Body Radiation to the breast to 21 Gy
75747125|NCT03026283|Device|HeartFLow CT-FFR|Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
75747126|NCT02998268|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
75747127|NCT02998268|Drug|Taxol|Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
75747128|NCT02998268|Drug|Carboplatin|Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
75747129|NCT02993900|Device|Image-Guided Brachytherapy|Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
75747130|NCT02948452|Other|fMRI|fMRI: reward task, anxiety provocation
75769287|NCT01254448|Drug|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
76064381|NCT04780360|Procedure|Cayanoacrylate tissue adhesives|Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains
75602732|NCT02854891|Other|autorefractometer, A-scan ultrasound|A measurement of refraction will be made by the Autorefractometer. A measurement of the eyes' biometer data will be made by A-scan ultrasound.
75602733|NCT00602719|Drug|Zolpidem|
75451493|NCT01719510|Other|Samples|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For both groups:~one swab for GBS detection by real-time PCR~the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.~For all women included will be achieved in the delivery room:~To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.~A sampling of umbilical cord blood.~Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.~For mothers, the collection of 3-5 ml of milk when breastfeeding."
75602734|NCT02854657|Behavioral|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
75897918|NCT03049735|Drug|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
75451494|NCT01719523|Drug|EPI-743|
75451495|NCT01719536|Drug|Icotinib|Icotinib: 125 mg is administered orally three times per day.
75602735|NCT00604435|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
75602736|NCT00604435|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
75602737|NCT01136967|Drug|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
75602738|NCT01218516|Biological|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
75602739|NCT01218516|Other|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
75897919|NCT03049735|Drug|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
75897920|NCT05579028|Dietary Supplement|Nutridrink ONS 200 ml|Nutridrink is a high-protein, high-calorie formula for the specialized nutrition of patients with or at risk of malnutrition. The product can be used as an additional or sole source of nutrition
76064382|NCT04780360|Procedure|Silk suture|Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
75602740|NCT01218516|Drug|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL^min [AUC5-6].
75747138|NCT02915367|Behavioral|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
75747139|NCT02871882|Radiation|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA [diethylenetriaminepentaacetic acid] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
75747140|NCT02871882|Other|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
75747141|NCT02871882|Drug|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
75747142|NCT02871882|Other|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
75747143|NCT02838680|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
75897921|NCT03957447|Other|thermotherapy (application of heat): This part of the trial is on hold due to the Covid19-pandemia|Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
75747144|NCT02824276|Drug|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
75747145|NCT02824276|Drug|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
75747146|NCT02813135|Drug|Ribociclib|
75747147|NCT02813135|Drug|Topotecan|
75897922|NCT02135796|Other|Echocardiography|
75897923|NCT03646695|Procedure|ILM flap transposition|during ILM flap Transposition, an ILM flap is placed on the macular hole
75897924|NCT03646695|Procedure|ILM peeling|during ILM Peeling the ILM is removed around the macular hole
75451496|NCT01719536|Drug|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
75897925|NCT03522116|Other|No intervention|No intervention
75897926|NCT03548844|Procedure|local excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
75897927|NCT03548844|Procedure|total mesorectal excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
75897928|NCT04785638|Combination Product|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
76064383|NCT04780438|Drug|Dapagliflozin|Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
75451497|NCT01719549|Drug|Dovitinib|"Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~Study drug: TKI258 capsule~Dose: 500mg p.o. qd~Every 3 weeks"
75451498|NCT01719575|Drug|Motilitone|
75451499|NCT01719575|Drug|Placebo|
75602741|NCT01218516|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 will be administered intravenously.
75602742|NCT01218516|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously.
75602743|NCT01218516|Drug|Cisplatin|Cisplatin 75 mg/m^2 will be administered intravenously.
75602744|NCT00938431|Drug|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
75747148|NCT02813135|Drug|Temozolomide|
75451500|NCT01719588|Drug|No intervention|This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
75602745|NCT02851927|Procedure|Mini Thoracoscopy|Pleural biopsy using rigid mini thoracoscope
75747149|NCT02813135|Drug|Everolimus|
75747150|NCT02813135|Drug|Adavosertib|
75747151|NCT02813135|Drug|Carboplatin|
75747152|NCT02813135|Drug|Olaparib|
75747153|NCT02813135|Drug|Irinotecan|
75602746|NCT02851927|Procedure|SemiRigid Thoracoscopy|Pleural biopsy using semirigid thoracoscope
75602747|NCT05381545|Behavioral|laser puncture, energy expenditure programming, and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet .This research group will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34&28, ST25&36&40, SP6, and CV4&9&12.
75747154|NCT02813135|Drug|Vistusertib|
75747155|NCT02813135|Drug|Nivolumab|
75747156|NCT02813135|Drug|Cyclophosphamide|
75747157|NCT02813135|Drug|Selumetinib|
75747158|NCT02813135|Drug|Enasidenib|
75747159|NCT02813135|Drug|Lirilumab|
75747160|NCT02813135|Drug|Fadraciclib|
75747161|NCT02813135|Drug|Cytarabine|
75747162|NCT02813135|Drug|Dexamethasone|
75747163|NCT02813135|Drug|Ceralasertib|
75747164|NCT02813135|Drug|Futibatinib|
75747165|NCT02813135|Drug|Capmatinib|
75747166|NCT02812537|Other|patients with conduct disorders|interview with a specialist
75747167|NCT02809196|Behavioral|1: Tailored SMS program implicating friend and mother|
75897929|NCT05578794|Other|Straining types|Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
75897930|NCT04762472|Drug|Montelukast Oral Tablet|i) Montelukast 10mg daily (tablet) orally x 26 weeks
76064384|NCT04780438|Drug|Placebo|Patients rendomized in this arm will receive placebo.
76064385|NCT04780126|Other|Sarcopenia diagnosis|History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
76064386|NCT04779892|Drug|Infliximab|100mg/vial
76064387|NCT02844868|Device|Active tDCS|During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
76064388|NCT02844868|Device|Sham tDCS|During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
75747168|NCT02809196|Behavioral|2: Standardized SMS program implicating friend and mother|
76064389|NCT04389268|Diagnostic Test|Visual Event-Related Potentials|Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
75747169|NCT02809196|Behavioral|3: Tailored SMS program implicating friend, not mother|
75747170|NCT02809196|Behavioral|4: Standardized SMS program implicating friend, not mother|
75602748|NCT05381545|Behavioral|energy expenditure programming and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet.
75602749|NCT04312815|Drug|SM03|SM03: 600 mg intravenous (IV)
75602750|NCT04312815|Drug|Placebo|Placebo: 600 mg intravenous (IV)
75602751|NCT04312815|Drug|MTX|Methotrexate: 7.5-20 mg/wk oral
75602752|NCT05381389|Drug|Bupivacaine Hydrochloride in-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues
75602753|NCT05381389|Drug|Bupivacaine Hydrochloride out of-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
75602754|NCT01136811|Device|Computer assisted surgery|"use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure"
75602755|NCT00949117|Dietary Supplement|Ensure|Given orally
75602756|NCT00949117|Dietary Supplement|PediaSure|Given orally
75602757|NCT00949117|Drug|cyproheptadine hydrochloride|Given orally
75602758|NCT04312347|Drug|Tamoxifen dose adjustment|Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
75747171|NCT02809196|Behavioral|5: Tailored SMS program implicating mother, not friend|
75747172|NCT02809196|Behavioral|6: Standardized SMS program implicating mother, not friend|
75747173|NCT02809196|Behavioral|7: Tailored SMS program not implicating mother or friend|
75747174|NCT02809196|Behavioral|8: Standardized SMS program not implicating mother or friend|
75747175|NCT02809196|Behavioral|9: No SMS program|
75747176|NCT02800512|Procedure|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
75747177|NCT02800512|Procedure|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
75747178|NCT02799823|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
75747179|NCT02732288|Dietary Supplement|melatonin|After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
75747180|NCT02712515|Procedure|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
75747181|NCT02712515|Device|Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips|Ad-Tech Medical Instrumentation Corp. electrodes are intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
75769288|NCT01254448|Drug|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
75897931|NCT04762472|Drug|Montelukast Placebo Oral Tablet|i) Placebo (Montelukast identical) tablet 1 daily orally x 26weeks
75897932|NCT03647397|Device|Photo Electrochemical Oxidation (PECO) for Air Purification|PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
76064390|NCT04771702|Device|Edmon|Exhaled air will be analyzed for propofol
76064391|NCT04771546|Device|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
76064392|NCT04389424|Drug|Tamoxifen|Use of tamoxifen for breast cancer recurrence prevention
76064393|NCT04389424|Drug|Exemestane|Use of exemestane for breast cancer recurrence prevention
76064394|NCT04389424|Drug|Anastrozole|Use of anastrozole for breast cancer recurrence prevention
76064395|NCT04389424|Diagnostic Test|Basal|Initial diagnosis of breast cacner by biopsy or mastectomy
75602759|NCT00631267|Procedure|Manual Manipulation|The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
75747182|NCT02712515|Device|FHC Guideline 4000+ system and/or Medtronic RC+S|Brain signals will be recorded using the clinical Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
75747183|NCT02687958|Drug|Everolimus|Maintenance therapy
75747184|NCT02657863|Procedure|Urine collection and blood draw|
75747185|NCT02623712|Other|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
75747186|NCT02623712|Other|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
75897933|NCT01295944|Drug|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
76064396|NCT04389424|Diagnostic Test|Recurrence|Breast cancer recurrence under endocrine therapy
76064397|NCT04389346|Procedure|Periapical surgery using autologous platelet aggregate|PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning
75747187|NCT02593565|Other|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
76064398|NCT04389346|Procedure|Periapical surgery without autologous platelet aggregate|Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
76064399|NCT04771390|Drug|Selitrectinib (BAY2731954) Adult tablet|Tablet, oral administration
76064400|NCT04771390|Drug|Selitrectinib (BAY2731954) Pediatric tablet|Tablet, oral administration
76064401|NCT04771390|Drug|Selitrectinib (BAY2731954) Oral solution|Oral solution after reconstitution
75602760|NCT00631267|Procedure|Finger Trap Traction|Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
75747188|NCT02586090|Behavioral|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
75747189|NCT02586090|Behavioral|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
75747190|NCT02567669|Radiation|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
75747191|NCT02503228|Procedure|Standard of care osteochondral and or meniscal allograft transplantation|Standard of care osteochondral and or meniscal allograft transplantation
75747192|NCT02487524|Other|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
75747193|NCT02487524|Other|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
75602761|NCT00938041|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
75747194|NCT02487524|Other|QST|Quantitative sensory testing.
75747195|NCT02478710|Drug|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
75897934|NCT01295944|Drug|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
76064402|NCT04771390|Drug|Selitrectinib (BAY2731954) Oral suspension|Oral suspension after reconstitution
75451501|NCT01719601|Drug|No intervention|This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
75602762|NCT00604513|Other|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun & Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
75602763|NCT00604513|Other|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
75747196|NCT02478710|Drug|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
75747197|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
75747198|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
75747199|NCT02455505|Behavioral|background questionnaire|
76064403|NCT04771468|Device|MOSTCAREup Monitoring|The patients will be equipped with mini-invasive hemodynamic monitoring (the MOSTACAREup system). The MOSTCAREup obtains the hemodynamic data from either the same arterial femoral line used by the neuro-radiologist to perform the treatment or from a dedicated radial artery, as decided by the attending anesthetist to monitor and optimize arterial pressure (the decision to use the arterial line is at discretion of the attending anesthetist for clinical reasons and does not delay the procedure, which starts using always the femoral access).
75451502|NCT01719614|Drug|Metformin|Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
75451503|NCT01719614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
75451504|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 300mg
75451505|NCT01719627|Drug|TVD 300/200 QD|TVD 300/200 QD during 7 days
75451506|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 600mg
75747200|NCT02455505|Behavioral|bereavement risk screening tool|
75897935|NCT03647319|Device|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
75451507|NCT01719679|Behavioral|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
75602764|NCT05381233|Other|Gross motor function classification System (GMFCS)|assessment
75602765|NCT05381233|Other|Arabic Version of Zarit burden Inventory measure|assessment
75451508|NCT01719692|Drug|Rituximab|
75451509|NCT01719705|Drug|Placebo|Ninety minutes before surgery, the parturients receive two identical placebo capsules
75602766|NCT05381233|Other|Arabic Version of Chalder Fatigue Scale (CFQ version 11)|assessment
75602767|NCT04266691|Other|nonIntervention|nonIntervention
75602768|NCT02851693|Device|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
75602769|NCT02851693|Device|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
75602770|NCT05379283|Drug|Lidocaine|effect of lidocaine on sweat production during exercise in the heat
75747201|NCT02432482|Behavioral|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
75747202|NCT02432482|Behavioral|Standard care|Brief advice to quit (<5 minutes) Self-help brochure Offer of nicotine patches
75747203|NCT02425865|Drug|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
76064404|NCT04771468|Device|Ecocardiography|Echocardiography will be performed 1) soon after the end of the treatment (whenever possible, avoiding delays, before od during the treatment in the angiography room); 2) at day 1 after the procedure; 3) at day 3 after the procedure.
76064405|NCT04779502|Other|oregawash|mouthwash containing oregano essential oil
76064406|NCT04779502|Other|corsodyl|0.2% chlorhexidine mouthwash
76064407|NCT04779502|Other|placebo|distilled water
75602771|NCT05379283|Other|control|one arm will be pretreated with topical lidocaine, the other arm will not
76064408|NCT05480956|Behavioral|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
75602772|NCT02851849|Drug|LGD-6972-5 mg|5 mg LGD-6972 QD
75602773|NCT02851849|Drug|LGD-6972-10 mg|10 mg LGD-6972 QD
75602774|NCT02851849|Drug|LGD-6972-15 mg|15 mg LGD-6972 QD
75602775|NCT02851849|Other|Placebo|Placebo QD
75747204|NCT02425852|Drug|Azathioprine|Azathioprine alone versus Azathioprine and IFX
75747205|NCT02425852|Drug|Infliximab|
75747206|NCT02425852|Drug|Prednisolone|
75897936|NCT03647319|Device|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
76064409|NCT05480956|Behavioral|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
76064410|NCT05480956|Behavioral|SIRI Checklist + Enhanced Peer Recovery Coach|A standardized checklist of clinical items to review by the attending hospitalist with participants. Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
76064411|NCT05411380|Drug|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
76064412|NCT05411380|Drug|Capecitabine|500mg orally three times a day (continuously)
76064413|NCT05411380|Drug|Endocrine Therapy|Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily or fulvestrant 500 mg each time, intramuscularly, injected on the 1st day and 15th day of the 1st cycle, and on the 1st day for subsequent cycle( 4 weeks for one cycle)
76064414|NCT04779580|Procedure|Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
76064415|NCT04779580|Procedure|Subcostal Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
75451510|NCT01719705|Drug|Pregabalin 300 mg group|Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg
75451511|NCT01719705|Drug|Pregabalin 150 mg group|Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule
75602776|NCT01218438|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
75747207|NCT02425852|Drug|Hydrocortisone|
75747208|NCT02333188|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
75451512|NCT01719731|Behavioral|Education|This group will receive the psychoeducation
75451513|NCT01719731|Behavioral|Non-Education|This group will not receive the psychoeducation
75451514|NCT01719770|Drug|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
75451515|NCT01719770|Other|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
75747209|NCT02333188|Drug|Leucovorin Calcium|Given IV
75747210|NCT02333188|Drug|Irinotecan Hydrochloride|Given IV
75747211|NCT02333188|Drug|Fluorouracil|Given IV
75747212|NCT02333188|Other|Laboratory Biomarker Analysis|Correlative studies
75451516|NCT01719796|Procedure|Regional analgesia infusion|
75602777|NCT01218438|Drug|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
75602778|NCT05381077|Other|MRI|Whole body MRI (ZTE sequence)
75602779|NCT00604591|Drug|Tolcapone|200 mg by mouth three times a day
75602780|NCT00604591|Drug|Placebo|200 mg by mouth three times a day
75747213|NCT02330601|Procedure|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
75897937|NCT03647319|Device|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
75897938|NCT04742348|Drug|Carbidopa Levodopa|Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
75602781|NCT04204291|Procedure|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
75747214|NCT02296528|Device|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
75451517|NCT01719822|Device|Yamax Digi-Walker CW-700|A pedometer with a daily step count target set by a physiotherapist.
75602782|NCT05380999|Diagnostic Test|Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)|Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
75602783|NCT00606073|Other|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
76064416|NCT04771312|Behavioral|Mobile app information-only intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.
75451518|NCT01719835|Drug|Cyclophosphamide|750mg/m2 IV every 21 days
75451519|NCT01719835|Drug|Gemcitabine|1000mg/m2 IV Days 1, 8, 15 every 28 days
75451520|NCT01719835|Drug|Doxorubicin|50mg/m2 IV every 21 days
75451521|NCT01719835|Drug|Vincristine|1.4mg/m2 (max 2mg) IV every 21 days
75451522|NCT01719835|Drug|Prednisolone|100mg PO Days 1-5 every 21 days
75451523|NCT01719835|Drug|methylprednisolone|1000mg oral or IV Days 1-5 every 28 days
75602784|NCT02691156|Diagnostic Test|Bilirubin Binding Capacity|Research laboratory assay of bilirubin binding capacity
75451524|NCT01719835|Drug|Cisplatin|100mg/m2 IV Day 15 every 28 days
75451525|NCT01719848|Other|Measurements of parameters related with physical examinations for difficult airway prediction|
75451526|NCT01719874|Biological|TCN-032|
75451527|NCT01719874|Biological|Placebo (saline)|
75451528|NCT01719913|Other|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
75451529|NCT01719913|Other|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
75451530|NCT01719926|Drug|Indomethacin|3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
75602785|NCT02691156|Diagnostic Test|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
75602786|NCT02691156|Diagnostic Test|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
75747215|NCT02282358|Drug|Mocetinostat|
75747216|NCT02259413|Behavioral|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
75747217|NCT02242760|Drug|SB204 2%|Applied topically twice daily
75747218|NCT02242760|Drug|SB204 4%|Applied topically daily
75747219|NCT02242760|Drug|Vehicle Gel|Applied topically twice and once daily
75747220|NCT02203695|Drug|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
75747221|NCT02203695|Radiation|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
75747222|NCT02177578|Drug|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
75747223|NCT02177578|Radiation|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
75747224|NCT02177578|Radiation|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
75747225|NCT02177227|Device|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
75769289|NCT03902548|Drug|[18F]P16-129|Injection of < 10 mCi [18F]P16-129 followed by PET/CT scanning
75769290|NCT03904576|Drug|BI 1358894|Film-coated tablet
75769291|NCT03904576|Drug|Placebo|Film-coated tablet
75897939|NCT04742348|Drug|Placebo|Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
75897940|NCT03548766|Biological|Homologous Blood Transfusion|Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
75897941|NCT03548766|Biological|Autologous Blood Transfusion|Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
75897942|NCT05284773|Other|Caretaker MUAC screening - training by health workers|Study personnel will train caregivers to conduct weekly AM screening using the color-coded MUAC tape. AM screening will involve identifying the midpoint of the child's right arm, wrapping the tape around the mid-point, inserting one end of the tape through the slit at the other end, pulling the tape secure, and reading the measurement based on the color bands. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be provided with a referral slip to do so. Caregivers will be informed of the signs, symptoms, and consequences of malnutrition as well as the available nutritional programs. Study personnel will conduct monthly supervision visits including brief refresher trainings. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
75897943|NCT05284773|Other|Caretaker MUAC screening - training by caregivers|Study personnel will train a group of caregivers to perform AM training of all caregivers living in their communities. they will instruct caregivers to conduct weekly AM screening. Training will include the same information as the communities receiving training by Health workers: MUAC training and how to interpret MUAC as well as key concepts of malnutrition. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
76064417|NCT04771312|Behavioral|Mobile app social support network intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
76064418|NCT04770688|Drug|Osimertinib|Osimertinib, 80mg, QD, p.o.
75451531|NCT01719952|Drug|Carbetocin|"IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group."
75451532|NCT01719952|Drug|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
75897944|NCT03522038|Procedure|percutaneous coronary intervention|PCI was performed using standard techniques. Antiplatelet and antithrombotic agents were prescribed according to current PCI guidelines. A procedure was considered successful when achieving TIMI flow grade 3 with <30% angiographic residual stenosis in the CTO vessel. All patients received drug-eluting stents and were discharged on dual antiplatelet therapy with duration of at least on year.
75897945|NCT05495178|Procedure|laparoscopic restorative proctocolectomy|laparoscopic restorative proctocolectomy
75897946|NCT04731584|Biological|Blood sample|Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke
75897947|NCT02140632|Procedure|Local methylprednisolone acetate and lidnocaine injection|
75897948|NCT02140632|Device|wrist splinting|
76064419|NCT04770688|Drug|Anlotinib|"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."
76064420|NCT05390476|Drug|Capecitabine|500mg orally three times a day (continuously)
75451533|NCT01719965|Other|Interviews and Focus Group Discussions|
75602787|NCT00603031|Other|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
75602788|NCT00603031|Other|NaCl|infusion with NaCl for 120 minutes as placebo-arm
75602789|NCT00603031|Other|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
75769292|NCT03902626|Other|Physiotherapy students|
75769293|NCT03902626|Other|Medical students|
75769294|NCT01149226|Drug|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
75769295|NCT01252342|Drug|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
75769296|NCT01252342|Drug|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
75769297|NCT03902470|Procedure|Thoracic epidural anaesthesia video assisted thoracoscopic surgery|Patients in (TEA) group will pre-medicated using midazolam 3-4 mg (IV)and fentanyl 50 mcg (IV). Then An epidural catheter will be inserted between T3-T4 and T4-T5 . A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5%.
75769298|NCT03911050|Dietary Supplement|Apple consumption|Apple blends (600 g) One single dose
75769299|NCT03911050|Dietary Supplement|Control group|Breakfast without any apple-related products
75747226|NCT02138448|Behavioral|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
75897949|NCT05536375|Other|Exhaled breath condensate collection and blood draw|"Venepuncture- 10mls of blood to be collected~and~Exhaled breath condensate (EBC) collection method- this involved breathing in and out through a disposable device (akin to breathing onto cold glass to produce condensate) with an external cooler device. The R Tube starter kit is a complete disposable EBC collection kit and It has been used in many research clinical investigations."
75747227|NCT01994954|Other|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
75747228|NCT01973881|Procedure|T1 Weighted MRI (magnetic resonance imaging)|"Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations."
75897950|NCT02965599|Drug|GSK3117391|GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
76064421|NCT05390476|Drug|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
76064422|NCT04770298|Other|Halliwick Concept|Halliwick Concept: Water intervention Bobath Concept: Neurodevelopmental Treatment
76064423|NCT05379088|Behavioral|Phone/zoom calls|Participants will complete weekly follow-up phone/zoom calls with a member of the research team. The phone/zoom calls will typically last 30-60 minutes. Participants will discuss barriers to activity and goals for upcoming weeks.
75451534|NCT01719978|Drug|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
76064424|NCT01503021|Drug|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
76064425|NCT01503021|Other|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
75747229|NCT01958840|Behavioral|Behavioral Activation for Depression Treatment|
76064426|NCT04779034|Other|Measurement of heart rate variability|Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
75747230|NCT01958840|Behavioral|Supportive Counseling|
76064427|NCT04778956|Drug|Toripalimab|Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
76064428|NCT04778956|Procedure|salvage surgery|Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.
76064429|NCT04778800|Drug|almonertinib|Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.
76064430|NCT04778800|Drug|LM-first line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
76064431|NCT04778800|Drug|LM-second line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
76064432|NCT01531725|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
76064433|NCT05324332|Drug|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
75747231|NCT01892709|Drug|Hydromorphone|
75897951|NCT02965599|Drug|Placebo|Placebo is a white, opaque, gelatin capsule.
75451535|NCT01719978|Procedure|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
75602790|NCT04268329|Other|Educational website|A website is used to educate patients and family members about head and neck cancer.
75602791|NCT00935701|Device|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
75602792|NCT02851537|Other|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
75602793|NCT05379049|Biological|Infliximab: Adalimumab; Etanercept;|Therapeutic drug monitoring, evaluation of clinical outcomes and laboratory analysis of biomarkers
75602794|NCT04266613|Diagnostic Test|TruGraf® Testing|5 mL collection PAXgene blood sample
75602795|NCT00604747|Other|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
75897952|NCT03524456|Other|Home blood pressure monitoring|Participants would use a blood pressure device at home, that sends the readings automatically to the health center via SMS. The physicians would use this tool for medication management or rescheduling visits.
76064434|NCT05324332|Drug|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
76064435|NCT04778878|Device|Mediracer® NCS|A point-of-care, hand-held nerve conduction device
76064436|NCT04769908|Drug|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
76064437|NCT04769908|Drug|Lenvatinib|Lenvatinib, 8mg or 12mg, po, QD
75451536|NCT01719978|Drug|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
75451537|NCT01719978|Drug|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
75602796|NCT04268095|Other|Dressing protocol|Patients are assigned with different postoperative dressing protocols.
75602797|NCT02851459|Behavioral|Baseline Survey|The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
75602798|NCT02851459|Behavioral|Pre-intervention Survey|Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
75602799|NCT02851459|Behavioral|Morally Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.~Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized."
75747232|NCT01873755|Behavioral|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
75451538|NCT01719991|Other|Nurse case management and self-management support|"Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.~Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease."
75451539|NCT01720199|Other|Diario della Salute (DDS)|"DDS is composed by~tools for children and their parents on health and social and emotional well-being issues:~a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers."
75451540|NCT01720459|Dietary Supplement|Micronized trans-resveratrol|
75451541|NCT01720459|Dietary Supplement|Placebo|
75451542|NCT01720537|Biological|PF-05335810 Dose A|Single SC Injection
75451543|NCT01720537|Biological|PF-05335810 Dose B|Single Subcutaneous Injection(s)
75451544|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
75451545|NCT01720537|Biological|PF-05335810 Dose B|Single Intravenous Infusion
75451546|NCT01720537|Biological|Placebo|Single Intravenous Infusion
75451547|NCT01720537|Biological|PF-04950615 Dose A|Single Subcutaneous Injection(s)
75451548|NCT01720537|Biological|PF-04950615 Dose A|Single Intravenous Infusion
75602800|NCT02851459|Behavioral|Morally Non-Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.~Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized."
75769300|NCT00189540|Genetic|HGF plasmid|Intramuscular injections into the index leg on days 0, 14, and 28
75769301|NCT00189540|Genetic|Placebo|Intramuscular injections into the index leg on days 0, 14, and 28
75769302|NCT03904654|Behavioral|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
75769303|NCT01254994|Drug|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
76064438|NCT04769908|Drug|Sintilimab|Sintilimab, IV, 200mg, q3w
75602801|NCT02851459|Behavioral|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
75602802|NCT02851459|Behavioral|Post-Intervention Survey|Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
75602803|NCT05378815|Procedure|PRP injection|3 weekly intra-articular injections of 5mL PRP under ultrasound guidance
75602804|NCT05378815|Procedure|Placebo injection|3 weekly intra-articular injections of 5mL NaCL under ultrasound guidance
75747233|NCT01858597|Diagnostic Test|biachemical detection|"Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed."
75747234|NCT01806571|Drug|Cytarabine|Given IV
75747235|NCT01806571|Drug|Daunorubicin Hydrochloride|Given IV
75747236|NCT01806571|Other|Laboratory Biomarker Analysis|Correlative studies
75897953|NCT05517577|Behavioral|Behaviour Change Communication and Male involvement intervention|For the integration of the intervention, it is planned to deliver both service at the same time a by the same means to the women and the men. Pregnant women who fail to take one of the intevetion will not be considered as the participant who received integrated intervention. The intervention will be provided through Women Developmental army (WDA) leaders imparted through gatherings and home visits whereas the Broadcast will be used to strengthen and as a frequent remidinng of the conveyed messages.
75897954|NCT04631848|Device|ULTRASCORE™ Focused Force PTA Balloon|The device will be used for percutaneous transluminal angioplasty (PTA) to dilatate calcified stenoses in below the knee vessels
75897955|NCT05578404|Drug|Cholecalciferol|Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
75451549|NCT01720537|Biological|PF-05335810 Dose C|Single Subcutaneous Injection(s)
75451550|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
75451551|NCT01720537|Biological|PF-05335810 Dose C|Single Intravenous Infusion
75451552|NCT01720537|Biological|Placebo|Single Intravenous Infusion
75451553|NCT01720537|Biological|PF-04950615|Single Subcutaneous Injection(s)
75451554|NCT01720537|Biological|PF-05335810 Dose D|Single Subcutaneous Injection(s)
75451555|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
75451556|NCT01720537|Biological|PF-05335810 Dose E|Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
75451557|NCT01720537|Biological|PF-05335810 Dose D|Single Intravenous Infusion
75602805|NCT00603343|Drug|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
75602806|NCT00603343|Drug|placebo|placebo corresponding to body weight
75747237|NCT01806571|Drug|Nilotinib|Given PO
75747238|NCT01806571|Other|Pharmacological Study|Correlative studies
75747239|NCT01741311|Behavioral|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
75897956|NCT05578404|Drug|Placebo|matching placebo to Vit D
75602807|NCT04266535|Device|Target controlled infusion|Target controlled infusion vs manually controlled infusion
75897957|NCT03646539|Behavioral|Use of smartphone application (app)|Use of a CBT-based automated conversational agent available as a mobile device smartphone application for the management of mood.
75451558|NCT01720537|Biological|Placebo|Single Intravenous Infusion
75451559|NCT01720719|Drug|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
75451560|NCT01720719|Drug|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
75451561|NCT01721005|Other|Subject education to pulse palpation|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
75451562|NCT01721213|Drug|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
75451563|NCT01721551|Other|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
75451564|NCT01721551|Other|Usual Treatment|The CON group received no intervention but the usual treatment
75451565|NCT01721785|Drug|GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
75602808|NCT00606385|Procedure|Liver resection|Laparoscopic or Open hepatectomy
75747240|NCT01741311|Behavioral|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
75897958|NCT03646539|Other|Treatment as usual|Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
75897959|NCT03521960|Drug|Buspirone oral capsule|15 milligrams, three times daily
75602809|NCT05378659|Behavioral|Montreal Cognitive Assessment|Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place
75602810|NCT05378659|Behavioral|Stroop Test|Evaluates Processing Speed and Executive Control
75602811|NCT05378659|Diagnostic Test|4AT Delirium|Screening tool to test for delirium post surgery
75602812|NCT05378659|Behavioral|Grooved Pegboard|Evaluation testing for dominant and non dominant sensory-motor speed
75451566|NCT01721824|Behavioral|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
75451567|NCT01721928|Device|Continuous venovenous hemodialysis|Continuous venovenous hemodialysis
75747241|NCT01705899|Drug|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
75897960|NCT03521960|Drug|Placebo oral capsule|0 milligrams (placebo), three times daily
75897961|NCT03548922|Other|Tanner stage|a scale of pubertal development in children, adolescents
75897962|NCT03548922|Other|Risser stage|a measure showing the growth left in the spine
75897963|NCT03548922|Other|Pressure of correction|an indirect parameter of the chest wall's flexibility. It is defined as the pressure applied to the patient, in the most protruding area of the chest, needed to accomplish a proper shape of the thorax.
75897964|NCT03548922|Other|Pectus carinatum protrusion|distance from the point of maximum protrusion to the estimated normal level of chest wall
75897965|NCT04616170|Other|Hip extension|Hips extended at the time of vaginal delivery
75602813|NCT05378659|Behavioral|NACC Cognitive Battery|A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.
75897966|NCT04616170|Other|Usual Care|"Hips positioned in the usual care position per provider preference at the time of vaginal delivery"
75897967|NCT03524300|Procedure|Robotic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted total gastrectomy will be performed in the experimental group.
75897968|NCT03524300|Procedure|Laparoscopic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted total gastrectomy will be performed in the experimental group.
75897969|NCT02898597|Behavioral|Cognitive Behavioral Therapy|Received 8 weekly individualized counseling sessions of cognitive behavioral therapy
75602814|NCT05378659|Diagnostic Test|ERP Testing|An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
75451568|NCT01722214|Biological|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
75747242|NCT01701154|Other|respiratory muscle strength training|
75747243|NCT01642641|Procedure|Non-surgical Subgingival Debridement (SD)|SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
75897970|NCT05479578|Drug|Cyclophosphamide|Given PO
75602815|NCT05378659|Diagnostic Test|Blood Plasma and Serum sampling|Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.
75602816|NCT05378659|Diagnostic Test|Cerebral Spinal Fluid Sample|At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
75897971|NCT05479578|Drug|Dexamethasone|Given PO
75451569|NCT01722214|Other|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
75602817|NCT01277510|Drug|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
75897972|NCT04482088|Behavioral|Occupational Therapy in an Equine Environment|10 weeks of occupational therapy in an equine environment aimed at improving individual goals related to self-regulation, social communication, and play
75897973|NCT04482088|Behavioral|Occupational Therapy in a Clinic (OTC)|10 weeks of occupational therapy in a clinic aimed at improving individual goals related to self-regulation, social communication, and play
75602818|NCT01277510|Drug|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
75602819|NCT01277510|Drug|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
75602820|NCT04323332|Drug|Traditional Chinese Medicine Prescription|Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
75602821|NCT00937495|Drug|vorinostat|400 mg given PO
75602822|NCT00937495|Drug|bortezomib|1.3 mg/m^2 given IV
75602823|NCT04323488|Behavioral|Lindamood-Bell Seeing Stars|Seeing Stars in a curriculum developed by Lindamood-Bell. It is published and openly available. It involves systematic training in the building blocks of skilled reading.
75602824|NCT00603421|Other|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
75897974|NCT02899377|Radiation|18F-FDG PET/CT Imaging|pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG
75897975|NCT02899377|Radiation|11C-MET PET/CT Imaging|"Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET"
75451570|NCT01722344|Behavioral|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
75451571|NCT01722344|Behavioral|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
75451572|NCT01722422|Drug|oxygen and saline|
75451573|NCT01722474|Device|ASI Device|
75602825|NCT00603421|Other|treatment as usual|Treatment as usual
75602826|NCT05378581|Device|Virtual reality mask|virtual reality mask Deepsen® with age-appropriate software Birdy®
75747244|NCT01642641|Procedure|Simplified Papilla Preservation Flap|The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.
75747245|NCT01642641|Procedure|Resective Periodontal Flap with Osseous Recontouring (RPFO)|RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
75747246|NCT01639196|Other|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
75897976|NCT02899377|Procedure|MRI Imaging with intravenous contrast with gadoterate meglumine|Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.
75897977|NCT02899377|Procedure|Minor Salivary gland (labial) biopsy|A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
76064439|NCT01478373|Drug|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
75602827|NCT05378581|Other|control arm|usual process
76064440|NCT04778488|Device|Near-Infrared-Spectroscopy (NIRS)|Placement of 2 NIRS optodes on the patients' forehead, measurement of NIRS during cardiac arrest and up to 72h post return of spontaneous circulation
75602828|NCT02851381|Drug|FG-3019|"The FG-3019 treatment will be administered over a 28-day cycle:~Dose: 35 mg/kg~Route: IV over one hour following completion of gemcitabine infusion~Schedule:~Days 1, 8, and 15~Please note that Day 8 infusion will on be completed during the first treatment cycle"
75602829|NCT01268306|Device|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch & Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
75602830|NCT04265833|Other|Biodentine|Biodentine has been shown to cause increased calcium ion release and this increase has been associated with the presence of pure tricalcium silicate and calcium chloride and the increased Ca(OH)2 formation
75897978|NCT05578248|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Non-invasive imaging technology that produces three-dimensional detailed anatomical images
75897979|NCT05578248|Procedure|ACL reconstruction|Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee
75897980|NCT04052217|Device|Penile Ring|Penile Ring at base of penis
75897981|NCT04467164|Device|exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)|Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
75602831|NCT04265833|Other|TheraCal LC|TheraCal LC (Bisco Inc, IL, USA) is a light-cured, resin-modified, calcium silicate-based material designed as a direct/indirect pulp-capping material. This agent has been shown to increase the pH on the pulpal surface thereby stimulating regenerative processes in the pulp, and ultimately contributing to the formation of dentin bridge
75897982|NCT04467164|Device|Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)|Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
75897983|NCT04853628|Behavioral|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different tailored text messages. Moreover, several gamification strategies are used (i.e. offering a challenge, giving different stories and the use of avatars in these stories that take place in three different scenarios: at home, at celebrations and in public places).
75897984|NCT04853628|Behavioral|Alerta Alcohol 2.0|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different animated videos. Moreover, new gamification strategies are added (i.e. giving rewards and allocating points that can be accumulated and shown in a progress ranking) to those already used in Alerta Alcohol.
75897985|NCT04052763|Diagnostic Test|FFR-CT|FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
75451574|NCT01722526|Drug|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
75451575|NCT01722578|Drug|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
75451576|NCT01722578|Drug|Placebo|Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
75451577|NCT01723007|Other|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
75451578|NCT01723280|Drug|Oxygen|During and 2 hrs after surgery
75602832|NCT04265833|Other|Calcium hydroxide|Calcium hydroxide (Ca[OH]2) is a successful pulp-capping agent activating the repair mechanism by stimulating the dentin-pulp complex. Ca(OH)2, with its bactericidal effects, protects the complex from bacterial effects and also has a stimulating effect on dentin remineralization
75451579|NCT01723475|Biological|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
75451580|NCT01723475|Biological|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
75451581|NCT01723852|Dietary Supplement|Vitamin D at 30 ug/day|
75451582|NCT01723852|Dietary Supplement|Vitamin D at 10 ug/day|
75451583|NCT01724229|Drug|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
75602833|NCT05380297|Device|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
75602834|NCT00604903|Device|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
75747247|NCT01639196|Other|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
75747248|NCT01633177|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
75747249|NCT01633177|Drug|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
75747250|NCT01633177|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
75747251|NCT01633177|Drug|Fish oil placebo|Fish oil placebo
75747252|NCT01607008|Other|MRI imaging|"3 total MRI imaging studies:~pre standard radiation treatment~during standard radiation treatment~post standard radiation treatment"
75747253|NCT01517451|Radiation|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
75451584|NCT01724450|Drug|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
75451585|NCT01724450|Drug|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
75602835|NCT00606541|Drug|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
75602836|NCT00606541|Drug|Placebo|Placebo
75602837|NCT04266067|Other|PNF exercise|Proprioceptive neuromuscular facilitation (PNF) is a form of neuromuscular retraining type containing the stimulation of sensory receptors to provide information about the body position and movement to facilitate the intended movement
75602838|NCT04266067|Other|Frenkel exercise|The Frenkel exercises consist of a series of slow, repetitive movements performed in different positions while lying, sitting and standing.
75602839|NCT02851225|Other|telemedicine transmission of biological results|telemedicine transmission of biological informations
75747254|NCT01517451|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
75747255|NCT01415817|Other|Training session|Series of two training sessions after the first phase of study followed by monthly feedback.
75747256|NCT01290835|Radiation|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
75747257|NCT01290835|Radiation|stereotactic radiotherapy|
75451586|NCT01724463|Other|Severe Sepsis Management Bundle|"Management Bundle includes:~Securing Intravenous Access~Obtaining Blood Culture~Antibiotic Administration~Goal Directed Fluid Bolus Therapy~Oxygen Administration~Measuring Serum Lactate Levels"
75451587|NCT01724567|Other|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
75451588|NCT01724567|Other|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
75602840|NCT00604981|Behavioral|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
75747258|NCT01204216|Biological|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
75747259|NCT01204216|Biological|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
75897986|NCT04052763|Diagnostic Test|FFRangio™|Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
75897987|NCT03521726|Drug|Amoxicillin|Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.
75897988|NCT03521726|Drug|Rabeprazole, Amoxicillin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
75897989|NCT04833348|Other|Motor function measurement using inertial sensors|"Measurement of motor skills at M0: start of the administration of the innovative therapy and then 1 month, 3 months, 6 months, 1 year and then 2 years later:~Free motor skills in the supine position~Motricity in the supine position stimulated by a play frame~Measurement of the proximal and distal activity of the upper limbs in motor skills stimulated by the play gantry~Measurement of activity in a supported sitting position Longitudinal study, the subject is his own control"
75897990|NCT03647241|Device|Self-Ligating Brackets|These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.
75897991|NCT03647241|Device|Traditionally-Ligated Brackets|These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.
75897992|NCT03647241|Procedure|Corticotomy|Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
75897993|NCT03524222|Other|Home Hospitalization|See above
75451589|NCT01724684|Other|Telehealth program|
75602841|NCT00604981|Behavioral|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
75602842|NCT00605059|Drug|[123I]AV94|Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
75602843|NCT00936715|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
75747260|NCT01204216|Behavioral|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
75747261|NCT01202305|Procedure|Lymph node biopsy|Inguinal lymph node biopsy
75769304|NCT01254994|Drug|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
75769305|NCT01148914|Other|Inflammatory biomarkers|tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
75897994|NCT03548610|Other|Nanofat-seeded biological scaffold on surgical defect|Nanofat-seeded biological scaffold in healing larger surgical defects (>1.5cm) involving the lower limbs
75602844|NCT05378503|Drug|Qsymia 3.75Mg-23Mg Extended Release Capsule|From W0 to W2, once a daily.
75451590|NCT01724684|Other|Usual care|
75451591|NCT01724723|Drug|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
75451592|NCT01724762|Other|Nursing Orientation|"Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath"
75451593|NCT01724892|Drug|Dexamethasone|
75451594|NCT01724892|Drug|Loteprednol etabonate|
75451595|NCT01725139|Drug|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
75747262|NCT01196312|Behavioral|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
75451596|NCT01725139|Drug|Placebo|Matching placebo will be available
75747263|NCT01161199|Procedure|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
75897995|NCT03621579|Procedure|cataract surgery|To measure the RNFLT and CMT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
75451597|NCT01725256|Drug|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
75897996|NCT04781946|Procedure|Endoscopic pneumatic balloon dilation|Using endoscopy, pneumatic balloon dilation may be used to treat stenosis of the gastric sleeve.
76064441|NCT01502709|Device|Caloric Vestibular Neurostimulation|1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
76064442|NCT01502709|Device|placebo|Matching placebo device
75602845|NCT05378503|Drug|Qsymia 7.5Mg-46Mg Extended Release Capsule|"From W2 to W14, once a daily.~At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily."
75602846|NCT05378503|Drug|Qsymia 11.25Mg-69Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
75602847|NCT05378503|Drug|Qsymia 15Mg-92Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
75602848|NCT05378503|Drug|Placebo|From W0(Randomisation) to W56(the End of visit) once a daily.
75897997|NCT04781946|Procedure|Gastric peroral endoscopic myotomy (G-POEM)|Gastric per-oral endoscopic myotomy (G-POEM) is a recent innovation offering a minimally invasive endoscopic approach. G-POEM allows for the creation of a tunnel and subsequent myotomy from the gastric cardia to the gastric pylorus.
75897998|NCT04781946|Procedure|Roux-en-Y gastric bypass (RYGB)|The Roux-en-Y gastric bypass is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine.
75897999|NCT04302064|Drug|Eplontersen|Eplontersen administered SC
75898000|NCT04302064|Drug|Placebo|Eplontersen-matching placebo administered SC
76064443|NCT03843268|Device|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
75451598|NCT01725269|Drug|AIR001|All doses specified are the amount loaded into the I-neb AAD System nebulizer.
75451599|NCT01725438|Other|sample blood|
75451600|NCT01725828|Device|Ultrasound|Using the Ultrasound to determine the location of the CTM.
75451601|NCT01725828|Other|External Palpation|Using External Palpation to identify cricothyoid membrane
75451602|NCT01726660|Device|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
75451603|NCT01726751|Device|Spinal Cord Stimultion (SCS)|Electric stimulation of the spinal cord
75451604|NCT01726751|Device|Spinal cord nerve stimulation|
75451605|NCT01727245|Other|Obese|gastric bypass
75451606|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
75602849|NCT00606619|Other|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
75602850|NCT00606619|Other|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
75602851|NCT05378191|Drug|COMIRNATY|One dose of COMIRNATY
75602852|NCT00605137|Drug|insulin detemir|
75602853|NCT00605137|Drug|insulin NPH|
75602854|NCT00603499|Dietary Supplement|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
75602855|NCT00603499|Other|Placebo|Subjects in the control group received inert placebo once per day during 4 months
75898001|NCT03645993|Genetic|Genetic Testing|A one time blood sample will be taken.
75898002|NCT03524144|Other|gastroscopy|Two endoscopists performed upper gastrointestinal endoscopy and biopsy on all patients; and histological review was performed by two pathologists. From each patient, 10 specimens were taken from 6 areas in the upper gastrointestinal tract and basic informations was collected.
76064444|NCT03843268|Device|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
76064445|NCT02931058|Other|Two knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
75747264|NCT01107015|Device|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
75747265|NCT01107015|Device|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
75898003|NCT03548376|Other|Hippotherapy|Hippotherapy is a therapeutic intervention that is typically conducted by a physical or occupational therapist and is aimed at improving impaired body function. Hippotherapy has been proposed as a technique to decrease the energy requirements and improve walking in patients with cerebral palsy. It is thought that the natural swaying motion of the horse induces a pelvic movement in the rider that simulates human ambulation. In addition, variations in the horse's movements can also prompt natural equilibrium movements in the rider.
75898004|NCT04291690|Other|Physical Component of the Intervention|We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
76064446|NCT02931058|Other|Four knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
76064447|NCT02931058|Other|Six knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
76064448|NCT01477749|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
75451607|NCT01727362|Other|Usual care + acupuncture|Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
75451608|NCT01727362|Other|Usual care|Patients of this group receive usual care only
75451609|NCT01727427|Drug|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
75451610|NCT01727609|Dietary Supplement|Milk feed (breast milk or formula milk)|
75451611|NCT01727661|Behavioral|exercise testing with near-infrared spectroscopy|subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
75451612|NCT01727661|Behavioral|lung function testing|"spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds."
75451613|NCT01727661|Behavioral|quality of life|assessing quality of life using short-forum 36 (questionnaire)
75451614|NCT01727778|Biological|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
75451615|NCT01728025|Drug|Ranolazine|
76025256|NCT02382497|Device|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
76064449|NCT05606458|Behavioral|İntervention Group|Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
76064450|NCT05297734|Other|Receive technology-based supportive cancer care|All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.
76064451|NCT05297734|Behavioral|Receive redesigned team-based supportive cancer care|Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.
75747266|NCT01107015|Device|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
76064452|NCT04094259|Behavioral|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
75747267|NCT01104350|Other|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
76064453|NCT00054028|Drug|suramin|Given IV
76064454|NCT00054028|Drug|paclitaxel|Given IV
76064455|NCT00054028|Other|pharmacological study|Correlative studies
76064456|NCT04753060|Procedure|Waxing|Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.
76064457|NCT05274334|Other|Assessment of de novo lipogenesis non-invasively in exhaled breath|"Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~Participants execute several exhalation sets over time.~Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~Participants execute several exhalation sets over time.~After around 4.5hours with regular exhalation sets taking place, the trial is concluded."
75451616|NCT01728207|Drug|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
75451617|NCT01728389|Procedure|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
76025257|NCT02382497|Device|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
76064458|NCT00058240|Drug|alvocidib|Given IV
75451618|NCT01728415|Other|exercise|Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
75451619|NCT01728675|Other|Exercise|Participants will perform two isokinetic eccentric exercise bouts
75451620|NCT01728870|Other|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
75451621|NCT01728870|Other|Exclusive Enteral Nutrition (Modulen)|
75451622|NCT01729195|Procedure|A ciprofloxacin containing bioabsorbable PLGA bone screw|The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
75451623|NCT01729741|Procedure|drain was inserted after thyroid surgery|insertion of drain after thyroid surgery
75451624|NCT01729780|Device|EEG-NF|
75451625|NCT01729910|Behavioral|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
75747268|NCT01100892|Drug|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
76064459|NCT05606068|Device|Paxman Limb Cryocompression System (PLCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours."
76064460|NCT05605990|Device|Innovative tourniquet (Acusense Nonpneumatic tourniquet)|To use this innovative tourniquet before collecting blood samples, and setting IV catheter. We also use this innovative tourniquet to occlude the flow of blood.
75451626|NCT01729910|Behavioral|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
75451627|NCT01729936|Behavioral|Sitting time Change Intervention|Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
75451628|NCT01730001|Procedure|Early Intubation|
75451629|NCT01730001|Procedure|Late intubation|
75451630|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
75451631|NCT01730014|Drug|placebo|In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
75451632|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
75602856|NCT04267627|Behavioral|Comprehensive Assistance: Rural Interventions, Nursing, and Guidance (CARING)|Cancer-related distress will be assessed using the NCCN Distress Thermometer amended to include HNC-specific areas of distress. For those participants experiencing high rates of distress, the nurse will provide targeted distress education. Education for participants exhibiting successful distress self-management, or with distress that has already resolved will focus on reinforcing surveillance and health promotion information contained in the Survivorship Care Plan. When indicated, the nurse will discuss potential referrals to support services with the patient, and they will decide jointly which referrals will be beneficial. Following the visits, the nurse will make agreed upon referrals using existing cancer center pathways, documenting these in the medical record. The nurse will follow-up with the patient via telephone 6 weeks following the telemedicine visit to determine uptake of the referral, documenting all referral information in the electronic medical record.
75602857|NCT00606775|Drug|Carvedilol|2.5-5mg/day
75602858|NCT04265989|Device|Single BMS|Single bare metal stent covered the coronary artery aneurysm
75602859|NCT04265989|Device|Single or Double BMS|Single or double layer bare metal stents covered the coronary artery aneurysm
75451633|NCT01730014|Drug|placebo|In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
75602860|NCT04265989|Device|Single or Double BMS|Treated with single or double layer bare metal stents
75602861|NCT04265989|Device|BMS+DES|Treated with bare metal stent combined with drug eluting stent
75747269|NCT01025089|Drug|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
75747270|NCT00999037|Drug|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
75747271|NCT00999037|Other|Placebo|1 inert tablet tid x 12 weeks
75747272|NCT00921856|Other|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
75747273|NCT00900471|Other|biologic sample preservation procedure|
75747274|NCT00900471|Other|medical chart review|
75747275|NCT00833664|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
75747276|NCT00833664|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
75747277|NCT00745355|Behavioral|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
75747278|NCT00696111|Drug|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
75747279|NCT00696111|Drug|Depot Lupron followed by progesterone plus placebo.|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of progesterone (200mg) plus placebo for six weeks.
75747280|NCT00696111|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for six weeks.
76064461|NCT01502631|Drug|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
75747281|NCT00380367|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
76025258|NCT02382497|Device|BED Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
76064462|NCT01502631|Drug|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
75451634|NCT01730014|Drug|insulin glargine|In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
75451635|NCT01730014|Drug|sodium chloride 0.9% w/v|In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
76064463|NCT03027999|Other|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP > 2.7"
75451636|NCT01730066|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|"Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups"
75451637|NCT01730157|Biological|ipilimumab|Given IV
75451638|NCT01730157|Radiation|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
75451639|NCT01730157|Other|laboratory biomarker analysis|Correlative studies
75451640|NCT01730183|Other|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
75451641|NCT01730196|Behavioral|Fit Body and Soul|
75451642|NCT01730196|Behavioral|Wellness Education|
75451643|NCT01730209|Drug|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
75451644|NCT01730209|Drug|Placebo|
75451645|NCT01730222|Drug|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
76064464|NCT03027921|Other|elastography|
76064465|NCT05262946|Behavioral|sensorimotor training based on Feldenkrais method|8 weeks of balance and sensorimotor training twice a week
76064466|NCT05262946|Behavioral|foot care education|Recommendations for preventing foot ulcers
75451646|NCT01730222|Drug|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
75451647|NCT01730222|Drug|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
75451648|NCT01730222|Drug|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
75451649|NCT01730235|Other|MyMediHealth access|Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
75451650|NCT01730248|Drug|INC424|5 mg tablets administered orally twice daily
75451651|NCT01730248|Drug|BKM120|10 mg and 50 mg hard gelatin capsules administered orally once daily
75747282|NCT00224393|Drug|Enbrel|
75747283|NCT00199862|Drug|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
75747284|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Psycho-educational group
75747285|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Spiritual-Existential Group
75747286|NCT00179348|Procedure|Quality-of-Life Assessment|Ancillary studies
75747287|NCT00179348|Procedure|Yoga|Undergo a yoga-based rehabilitation program
75747288|NCT00128310|Drug|Vinorelbine|
75747289|NCT00128310|Drug|Gemcitabine|
75747290|NCT00870077|Dietary Supplement|ProWHEY 94 CFM, SponserR|3 times 20g per day
75747291|NCT04782401|Other|Ultrasound guided genicular nerve block + exercise treatment|This method was used to inject a total of 6 mL of lidocaine plus 40 mg of triamcinolone (TA) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves plus exercise treatment
76064467|NCT05262946|Combination Product|usual care|drugs and diet usual care
76064468|NCT03026907|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
75747292|NCT04782401|Device|Physical therapy + exercise treatment|Ten sessions of hotpack as a surface warmer, TENS as a analgezic current, ultrasound therapy as a deep warmer and exercise treatment.
75747293|NCT01007708|Drug|IDP-108|Topical application once a day for 48 weeks
75747294|NCT01007708|Drug|Vehicle|Topical application once a day for 48 weeks
75747295|NCT00885443|Drug|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
76064469|NCT03026907|Drug|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
76064470|NCT00060424|Drug|Cyclosporine|Given PO
76064471|NCT00060424|Drug|Fludarabine Phosphate|Given IV
76064472|NCT00060424|Procedure|Hematopoietic Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
76064473|NCT00060424|Other|Laboratory Biomarker Analysis|Correlative studies
76064474|NCT00060424|Drug|Mycophenolate Mofetil|Given PO
76064475|NCT00060424|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
76064476|NCT00060424|Radiation|Total-Body Irradiation|Undergo TBI
76064477|NCT03026751|Procedure|Bone Marrow Aspirate|Bone marrow aspirate
76064478|NCT05253040|Other|KEEP Intervention|Educational intervention
76064479|NCT05253040|Other|control|booklet from Parkinson's UK
76064480|NCT05215522|Device|The BCI-FES Intervention|To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
75451652|NCT01730261|Behavioral|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
75747296|NCT00885443|Drug|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
75747297|NCT00882869|Drug|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
76064481|NCT00062764|Drug|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
75747298|NCT00882869|Drug|Sorafenib|Sorafenib will be administered at 400 mg BID every day
75747299|NCT01001000|Procedure|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
75747300|NCT00882947|Drug|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
75747301|NCT00531050|Drug|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
75747302|NCT00531050|Drug|Placebo|Single dose indacaterol matching placebo via Concept 1 device
76064482|NCT00063232|Drug|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
76064483|NCT00063622|Drug|Pioglitazone|30 mg daily
76064484|NCT00063622|Dietary Supplement|Vitamin E|800 IU daily
76064485|NCT00063622|Drug|Matching placebo|Daily
75602862|NCT04267471|Behavioral|Tai Chi|Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
75602863|NCT04267471|Behavioral|Walking|Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.
75747303|NCT00531050|Drug|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
75747304|NCT05231018|Other|Psychotherapy|8-sessions psychotherapy
76064486|NCT05185726|Behavioral|Lidcombe Program|"The LP consists of Stage 1 and Stage 2. Stage 1 aims at reducing the stuttering of the PCWS to (near) zero levels of stuttering. During stage 1, parents learn to provide verbal contingencies during daily, 10-minute practice sessions with their PCWS.~During Stage 1, treatment sessions are scheduled weekly. When the child has typical scores of 0 and 1 on the SR-scale with more 0s than 1s per week for three consecutive weeks, and the stuttering is rated as 0 or 1 during the treatment session, the child can proceed to stage 2.~The maintenance phase starts when the stuttering is reduced to (near) zero stuttering and parents are able to implement the practice sessions when it is necessary (when stuttering relapses). Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks."
76064487|NCT05185726|Behavioral|Mini-KIDS|Mini-KIDS for 4-6-year old PCWS consists of four stages: Stage 1 = desensitization, Stage 2 = identification, Stage 3 = modification and Stage 4 = generalization. The program for 2-4-year old child does not include stage 2. SLT and parent(s) are the speech model for the child. They add normal disfluencies and pseudo-stuttering to their speech at first to make sure the child dares to stutter and the child as well as the parent(s) are desensitized for it. Later on in treatment and if necessary, child learn to recognise and alter their stuttering moments. The maintenance phase starts when the child and parent(s) achieved the goals of Stage 4. Usually the stuttering is reduced to (near) zero stuttering. Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks.
75451653|NCT01730287|Drug|Control|The teeth in this group restored only by filling material,without liner application.
75451654|NCT01730287|Drug|Calcium Hydroxide|Calcium Hydroxide paste applied.
75747305|NCT00530348|Biological|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
75451655|NCT01730287|Drug|Mineral Trioxide Aggregate(MTA)|MTA applied .
75451656|NCT01730287|Drug|CEM cement|CEM cement applied .
75451657|NCT01730326|Drug|Paracetamol|1000 mg
75451658|NCT01730326|Drug|Dexketoprofen|50 mg
75602864|NCT00605371|Drug|Lamotrigine tablet|Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
75602865|NCT00605371|Drug|Lamotrigine caplet|Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
75747306|NCT00530348|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
75451659|NCT01730352|Drug|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
75451660|NCT01730365|Procedure|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
75451661|NCT01730391|Other|Data collection|Collection of demographic data and vaccination history
75451662|NCT01730391|Other|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
75747307|NCT01001156|Other|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
75747308|NCT01001312|Other|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
75747309|NCT01001312|Other|Clinical volume status assessment|Volume assessment based on history and physical examination
76064488|NCT05185726|Behavioral|Social Cognitive Behavioural Therapy|"A parent training is organised for parents with children who stutters who receive SCBT.~The parent training exists of 10 one-hour group evening sessions for parents to discuss and offer education topics about what stuttering is, how stuttering looks like, ...~The program is delivered in 5 phases and each phase takes as long as is necessary for the PCWS (variable): (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training.~The maintenance phase starts when the child and parent(s) achieved the goals of the 5 phases. During the maintenance sessions, the SLT asks the parent(s) to report about the child and observes the speech of the child."
75602866|NCT04265677|Other|Telemedicine FCR|Parents/guardians will be able to join family centered rounds using telemedicine (audio and visual)
75747310|NCT03886220|Drug|Elagolix|Oral; Tablet
75747311|NCT03886220|Drug|Placebo|Oral; Tablet
76064489|NCT00153166|Drug|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
75898005|NCT04291690|Other|Cognitive Component of the Intervention|We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
76064490|NCT00153166|Drug|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
75451663|NCT01730404|Drug|CHF6001 DPI|
75451664|NCT01730404|Drug|Roflumilast|
75451665|NCT01730404|Drug|Placebo|
75451666|NCT01730417|Drug|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
75451667|NCT01730456|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
75451668|NCT01730469|Drug|AT1001 150 mg|AT1001 150mg is available as a capsule
76064491|NCT00153166|Drug|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
76064492|NCT00153166|Drug|placebo/placebo|placebo orally three times daily
76064493|NCT00156910|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
76064494|NCT00156910|Other|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
75602867|NCT04265677|Other|Standard of care|Parents/guardians will not be able to join family centered rounds using telemedicine (audio and visual)
75747312|NCT01007864|Drug|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
75747313|NCT01007864|Drug|pramipexole or ropinirole|continuation of pre-study treatment regimen
75747314|NCT05111366|Drug|TQB2450 injection|TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
76064495|NCT01475721|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
76064496|NCT01475721|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
76064497|NCT01475721|Drug|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
76064498|NCT01475721|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
75451669|NCT01730482|Drug|[14C] AT1001|150 mg of [14C] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
75451670|NCT01730495|Drug|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
75451671|NCT01730508|Drug|Pegylated Interferon Alfa (Peginterferon Alfa)|Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
75451672|NCT01730521|Behavioral|Exercise (Running)|the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
75602868|NCT01267994|Drug|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
75602869|NCT00606853|Behavioral|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
75602870|NCT02850757|Device|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
75747315|NCT05111366|Drug|Anlotinib hydrochloride capsules|Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
75747316|NCT01008020|Dietary Supplement|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
75747317|NCT01008098|Drug|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
75747318|NCT01008176|Behavioral|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
75747319|NCT00530270|Drug|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
75898006|NCT04291690|Other|Nutritional Component of the Intervention|We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
75898007|NCT04291690|Other|Iron-Deficiency Anemia (IDA) Component of the Intervention|We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin <130g/L in men or <120g/L in women with (ii) a Ferritin <100μg/L or a Ferritin <300μg/L with a Saturation <20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
76064499|NCT01475721|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
75898008|NCT04466696|Behavioral|ERAS protocol|items of ERAS protocol applied
75898009|NCT03546426|Drug|Pembrolizumab|200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years
75898010|NCT03546426|Biological|Autologous dendritic cells|Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses
75898011|NCT03546426|Drug|Interleukin-2|3 MU s.c. from day +2 to day +6 after each DC administration
75898012|NCT03525938|Procedure|TAP block|Whilst the patient is in the supine position, a high frequency ultrasound probe (10 MH) is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Upon reaching the plane, 2 ml of saline is injected to confirm correct needle position after which 20 ml of levobupivacaine, 25% plus triamcinolone, 80 mg solution is injected for TAP group and 20 ml of saline only is injected for SHAM group.. The transversus abdominis plane is visualized expanding with the injection ( appears as a hypoechoic space)
75898013|NCT01316887|Drug|125/25 mcg once-daily GSK573719/GW642444|GSK573719/GW642444
75602871|NCT02850757|Device|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
75602872|NCT05379751|Procedure|Fixation free Spigelian hernia repair with tentacle mesh|Spigelian hernias are repaired through the fixation free placement of a tentacle mesh in preperitoneal sublay thanks the friction exerted by the tentacle straps delivered by a proprietary needle passer crossing trouh the abdominal wall from the preperitoneal space until the subutaneous layer. This procedural approach should also grant a broad overlap of the implant over the hernial defect
75602873|NCT02850913|Drug|Doxycycline|"115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~Treatment will be initiated in hospital but will be continued at home.~Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety"
75747320|NCT00530270|Drug|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
75747321|NCT01008254|Behavioral|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
75898014|NCT01316887|Drug|125mcg once-daily GSK573719|GSK573719
75898015|NCT01316887|Drug|Placebo once-daily|inactive
75898016|NCT02897349|Drug|placebo|
75898017|NCT02897349|Drug|linagliptin|
75898018|NCT02897349|Drug|background therapy|insulin with or without metformin
76064500|NCT01475721|Drug|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
75602874|NCT02850913|Other|Placebo|- Placebo (matching capsules containing no active ingredients)
75602875|NCT00603655|Other|Low glycemic load diet|Low glycemic load diet
75602876|NCT00603655|Other|High glycemic load diet|High glycemic load diet
75602877|NCT05371561|Device|reusable respirators|Dentist wearing reusable respirator will examin the patient
75747322|NCT01008254|Behavioral|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
75747323|NCT01008254|Other|No musical prompt|No intervention.
75898019|NCT03749044|Other|Patient Educational Tool|This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
75898020|NCT03525782|Biological|CAR-T Cells|Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
75898021|NCT03525782|Combination Product|CAR-T combining PD-1 Knockout|Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
75898022|NCT03525782|Biological|PD-1 knockout|Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients
75602878|NCT02850835|Other|Video Decision Aid|A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
75898023|NCT03525782|Drug|PD-1 mAb|Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1
75602879|NCT00934843|Drug|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
75898024|NCT03525782|Other|Sham control|Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.
75898025|NCT03103048|Diagnostic Test|Without bandages|All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
75602880|NCT00934843|Drug|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
75602881|NCT04268251|Diagnostic Test|MRI with deep learning based denoising|1-mm coronal contrast-enhanced T1 weighted image with deep learning based denoising
75602882|NCT00607009|Behavioral|ALIVE|ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
75602883|NCT04265521|Device|Biocool Footcare|BioCool Footcare is a footbath containing granulate of sodium percarbonate that will in this study be used for treatment of foot fungus, heel cracks, calluses and/or dry feet.
75602884|NCT00605605|Drug|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
75747324|NCT01008332|Biological|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
75747325|NCT01008332|Biological|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
75747326|NCT01008488|Drug|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
75747327|NCT01001468|Drug|VB-201|Single daily dose of oral VB-201 20 mg
75747328|NCT01001468|Drug|VB-201|Single daily dose or oral VB-201 80 mg
75747329|NCT01001468|Other|Placebo|Single daily dose of oral placebo
75747330|NCT01001624|Other|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
75747331|NCT01001624|Other|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
75747332|NCT01001780|Drug|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
75898026|NCT03103048|Diagnostic Test|With placebo|All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
75747333|NCT01001858|Other|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
75747334|NCT01008566|Biological|Cixutumumab|Given IV
75747335|NCT01008566|Other|Laboratory Biomarker Analysis|Correlative studies
75747336|NCT01008566|Drug|Sorafenib Tosylate|Given orally
75747337|NCT01008644|Other|Water|The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
75602885|NCT04256395|Other|mobile internet survey on self-test|1. make a questionnaire, the content of which refers to the new coronavirus diagnosis and treatment guidelines released by the National Health Commission; 2. develop the mobile applet and carry out internet propagation; 3. background data could be identified according to computer technology, de duplication and de privacy; 4. once registered, the applet can automatically remind the self-test twice a day, and encourage to adhere to 14 days; 5. automatically compare with the standards and highly suspected population could be given medical guidance and encouraged to go to the fever clinic of the designated hospital for definite diagnosis.
75898027|NCT03103048|Diagnostic Test|With bandage|All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
75898028|NCT03103048|Diagnostic Test|With tensioned bandage|All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
75451673|NCT01730560|Other|Treatment A|"The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~two visits in pre-tests evaluation (V1 and V2),~one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~two visits after treatment (V4 at one week and V5 at one month)."
75602886|NCT04267237|Drug|Atezolizumab|Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
75602887|NCT04267237|Drug|RO7198457|RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
75602888|NCT05379517|Device|Pulsed ectromagnetid field therapy|Pulsed electromagnetic field therapy is an innovative therapy. The technology is based on a high intensity electromagnetic field, which positively influences human tissue. It is a form of non-invasive treatment, with good tolerance by patients. High-intensity electromagnetic fields excite neural and muscle cells, which stimulates the human body.
75602889|NCT05379517|Other|Pulmonary rehabilitation program (PRP)|This type of physiotherapy program includes: respiratory muscle training, coughing exercises, diaphragmatic training, aerobic training and strength training.
75602890|NCT00605995|Drug|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
75747338|NCT01008644|Other|Saline 3%|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
75747339|NCT05733494|Other|Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)|the CADN will be administrated to each patient at the enrolment
75747340|NCT05601128|Drug|CAB + RPV|At Day 1 all participants will initiate oral CAB 30 mg + RPV 25 mg once daily for at least 28 days during the Oral Phase. Participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections at month 1 visit followed by CAB LA 400 mg + RPV LA 600 mg IM injections monthly at M2, M3, M4 and M5 visits. Then, starting at month 6 visit, participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections every 2 months at M6, M8, M10 and M12.
75747341|NCT05593406|Device|Vibration Group|Whole body vibration for 15 minutes in squat and lunge position.
75747342|NCT05593406|Other|Control Group|NDT treatment 2 sessions per week
75747343|NCT01001936|Drug|SKI-606|
75747344|NCT03885596|Drug|CA-008|Drug: CA-008 4.2 mg reconstituted in saline
75747345|NCT03885596|Drug|Ketorolac|30 mg IV at the onset of anesthesia
75747346|NCT03885596|Drug|Acetaminophen IV|1 g at the onset of anesthesia
75747347|NCT03885596|Drug|Fentanyl|100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
75747348|NCT03885596|Drug|Bupivacaine Hydrochloride|0.25% 30 mL (75 mg) prior to surgery
75898029|NCT01003262|Other|Emergency Department Observation Protocol|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
75898030|NCT01003262|Other|Unstructured, inpatient evaluation|This is unstructured management by an inpatient medical team.
75747349|NCT03885596|Drug|Lidocaine HCl|1.5% 12 mL at the end of surgery
75747350|NCT03885596|Drug|Celecoxib|200 mg PO bid each day postoperative
75747351|NCT03885596|Drug|Acetaminophen Oral|1 g postoperative
75747352|NCT03885596|Drug|Lidocaine Hydrochloride|2% 15 mL at the end of surgery
75747353|NCT03885596|Drug|Exparel|Bupivacaine liposome injection suspension
76064501|NCT00065806|Drug|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
75602891|NCT05383105|Procedure|Virtual bronchoscopic navigation|Virtual bronchoscopy navigation (VBN) calculates the access to a solitary pulmonary nodule via a trans-parenchymal route. In contrast to the gold Standard transthoracic approach, with this technique also very small lesions (7 mm diameter), and lesions which cannot be reached via the transthoracic route - located in the inner two thirds of the lung - can be approached.
75747354|NCT05733338|Other|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 5 days.
75747355|NCT05733338|Other|Sham Intermittent Hypoxia|The sham intermittent hypoxia protocol refers to 55 minutes normoxia inhaling, which is performed twice a day (at least 6 hours apart) in 5 days.
75898031|NCT04282408|Device|Scoliosis back brace|The patients will use the traditional brace, if not already in use, for 2 weeks and then they will wear a 3D printed back brace for the following 2 weeks. Both the braces will be worn for the amount of hours per day prescribed by the physician.
75747356|NCT01002092|Drug|Chemotherapy|Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
75451674|NCT01730560|Other|Treatment B|"Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~two visits in pre-tests evaluation (V1 and V2),~one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~two visits after treatment (V4 at one week and V5 at one month)."
75451675|NCT01730573|Procedure|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
75451676|NCT01730573|Procedure|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
75451677|NCT01730599|Other|neurological exam|motor and cognitive functions
75602892|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
75602893|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
75602894|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
75602895|NCT05379361|Behavioral|Emotional Intelligence Development Program|It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.
75747357|NCT01002092|Drug|Endostar|In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
75747358|NCT05567510|Drug|BMS-986369|Specified dose on specified days
75747359|NCT03999866|Device|airtraq|airtraq videolaryngoscope
75747360|NCT03999866|Device|mcgrath mac x-blade|mcgarth mac videolaryngoscope
75747361|NCT03999866|Device|storz c-mac|storz c-mac videolaryngoscope
75747362|NCT03999866|Device|storz d-blade|storz d-blade video laryngoscope
75747363|NCT01002326|Behavioral|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
75747364|NCT05733182|Device|3000K Reading lamp|Reading lamp with custom-made circuitry to emit light of 3000K colour temperature
75747365|NCT05733182|Device|4500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 4500K colour temperature
75747366|NCT05733182|Device|6500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 6500K colour temperature
75898032|NCT04465604|Other|Wearing surgical face mask sprayed with hypertonic saline|The inner surface of a standard surgical face mask will sprayed by 10 to 15 ml of HTS (6% w/v Saline solution prepared by adding 6 gram NaCl to 100 ml of water if not commercially available) and allowed to air dry. The participant will wear the face mask for 20-30 minutes every 6 hours until discharge, intubation for mechanical ventilation or death. A new HTS sprayed mask will be worn by the participant every 24 hours. The data items will be collected on daily basis
75898033|NCT03645915|Other|Immunohistochemistry|Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor.
76064502|NCT00065806|Drug|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
76064503|NCT02091466|Device|pre-warming|warming patients 30 minutes prior to anesthesia
76064504|NCT01530087|Device|CASTLE barrier|Prototype barrier to be used in place of current two piece device
75602896|NCT05379361|Behavioral|Plasebo Training Group|It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
75602897|NCT01266902|Drug|Rilpivirine|25 mg once daily
75602898|NCT04266847|Device|monofocal IOL,bifocal IOL,or trifocal IOL|phacoemulsification and implantation of IOL.IOL may be monofocal IOL,bifocal IOL,or trifocal IOL
75602899|NCT00605761|Drug|SB656933|50 mg treatment
75451678|NCT01726400|Drug|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
75451679|NCT01726400|Drug|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
75451680|NCT01730612|Drug|TF2 - 68 Ga-IMP-288:|ImmunoTEP
75602900|NCT00605761|Drug|SB656933|150 mg treatment
75602901|NCT05365867|Behavioral|iCAN Group|See description in iCAN study arm.
75602902|NCT05363995|Behavioral|i-Sleep & BioClock Intervention|"The 'i-Sleep & BioClock' intervention aims at improving sleep and the biological clock among university students. It is incorporates evidence-based techniques such as cognitive behavioural therapy for insomnia (CBTi). The intervention has a duration of 5 weeks and consists of five modules:~psychoeducation on insomnia, sleep hygiene and the biological clock,~stimulus control and sleep restriction therapy,~worrying and relaxation exercises,~cognitive therapy to change dysfunctional thoughts about sleep, and~summary module, relapse prevention, and plan for the future.~The intervention is supported by e-coaches who give personalized written feedback. Students will fill in a sleep & light exposure diary daily."
75602903|NCT01266824|Drug|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
75602904|NCT05383027|Behavioral|Music Listening Control (MLC)|MLC participants will engage in assigned music listening in the presence of their loved one with ADRD via a selected online platform (pandora or Spotify) for 10 minutes a day 5-7 days a week.
75747367|NCT01002404|Procedure|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
75747368|NCT00529100|Drug|Pemetrexed Phase 1|300 mg/m^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m^2 IV; then 500 mg/m^2 IV, repeated every 21 days (q 21 days) x 2 cycles
75747369|NCT00529100|Drug|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m^2 IV, Days 1-3 and 22-24 then 75 mg/m^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles."
75451681|NCT01730625|Behavioral|Cognitive behavioral therapy for anxiety|
75451682|NCT01730625|Behavioral|Attention Bias Modification Treatment|
75451683|NCT01730651|Radiation|Tomotherapy|"IMRT boost of gross LNs~Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
75451684|NCT01730664|Drug|ertapenem|single dose of 2000mg ertapenem IV
75451685|NCT01730677|Drug|Lapatinib|lapatinib 1000mg, once daily
75747370|NCT00529100|Procedure|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
75747371|NCT00529100|Drug|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22.
75747372|NCT00529100|Drug|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles.
76064505|NCT00068770|Radiation|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
75451686|NCT01730677|Drug|Vinorelbine|Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
75451687|NCT01730716|Device|Human spinal cord stem cell implantation|Human spinal cord stem cell implantation in ALS patients.
75451688|NCT01730742|Behavioral|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
75451689|NCT01730742|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
75602905|NCT05383027|Behavioral|Heart Focused Breathing|Heart-focused breathing participants will engage in heart-focused breathing using the inner balance device (shipped to their home), they will be asked to do this in the presence of their loved one with ADRD for 10 minutes a day 5-7 days per week.
76064506|NCT00068770|Drug|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
75602906|NCT04266769|Device|LightForce Orthodontic System|The LightForce Orthodontic System is a a digital treatment planning platform and patient-specific 3D printed polycrystalline alumina brackets for the treatment of malocclusion
75898034|NCT03362710|Diagnostic Test|simplified tools|"Skin temperature on the back of the foot with infra-red thermometry~Toe saturometry~ABI with an automatic sphygmomanometry~Skin Recoloration time at the foot"
75747373|NCT05467280|Other|Online HIIT Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars and challenges.
76064507|NCT01475487|Procedure|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
76064508|NCT04102527|Other|Questionnaires|"Patients have to complete the study questionnaires every 2 months :~Digestive Functional Score of Neurological Patients~Bowel Function Index~Severity score for constipation~Bristol Scale~Constipation assessment scale~Estimate scale of risk of constipation"
75898035|NCT03645291|Diagnostic Test|Local insect allergen extracts skin test|Every patient received both local and commercial insect allergen extracts but in blinded methods
75898036|NCT03761082|Other|NA(observation study)|NA(observation study)
76064509|NCT01475331|Drug|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
76064510|NCT01475331|Drug|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
76064511|NCT01475331|Drug|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
76064512|NCT01500213|Drug|Rolapitant|200 mg PO
76064513|NCT01500213|Drug|Granisetron|10 mcg/kg IV
76064514|NCT01500213|Drug|Dexamethasone|20 mg PO and 8 mg PO
76064515|NCT01500213|Drug|Placebo|(4 X 0 mg capsules) o mg PO
76064516|NCT00069160|Drug|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
75451690|NCT01730742|Procedure|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
76064517|NCT00069160|Drug|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
75451691|NCT01730755|Drug|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
75451692|NCT01730794|Other|NAVA ventilation|Neurally adjusted ventilatory assist
75451693|NCT01730794|Other|Conventional Lung Protective Ventilation|conventional protective mechanical ventilation
75451694|NCT01730807|Device|IntellaTip MiFi XP Catheter|Temperature controlled ablation catheter
75451695|NCT01730859|Other|Balance exercise and ankle taping|"Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.~Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week."
75747374|NCT04976660|Drug|TT-4|TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
75747375|NCT01002638|Other|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
75747376|NCT01002638|Procedure|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
75451696|NCT01730885|Other|Comparison of different Blood Glucose Meters|
75451697|NCT01730898|Other|Study product containing lutein|delivered in capsule form
75747377|NCT03878108|Dietary Supplement|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
75747378|NCT03878108|Dietary Supplement|LFHC diet|low-fat, high-carbohydrate (LFHC) diet
75747379|NCT01002716|Biological|Agrippal S1 (Influenza vaccination)|Single dose of vaccine
75747380|NCT01002794|Procedure|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital.
75747381|NCT01002794|Other|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training.
75747382|NCT05732714|Behavioral|Healthy lifestyle behaviors around the time of surgery|Healthy lifestyle choices, such as improving diet and beginning to exercise around the time of surgery and it's influence on an individual's long term risk of developing cardiovascular disease.
75898037|NCT03134378|Drug|Rabeprazole Sodium 20mg|Twice daily
75898038|NCT03134378|Drug|Clarithromycin 500mg|Twice daily
75898039|NCT03134378|Drug|Amoxicillin 500 Mg|Twice daily
75898040|NCT03645837|Other|Compression clamp release|Standard compression clamp is used and will be released at different times according to randomization
75898041|NCT05434104|Other|Vaginal lactoferrin|Lactoferrin vaginal pessaries to insert nightly for seven nights
76064518|NCT00069160|Other|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
76064519|NCT00071890|Drug|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
76064520|NCT00071890|Drug|HAART|HAART from week 0 to week 24
76064521|NCT00071890|Drug|Treatment interruption|HAART is interrupted from week 24 in both arms
76064522|NCT01475253|Drug|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
76064523|NCT01475253|Other|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
76064524|NCT01475253|Procedure|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
76064525|NCT00072514|Drug|gemcitabine hydrochloride|Given IV
76064526|NCT00072514|Drug|carboplatin|Given IV
75898042|NCT05434104|Drug|Usual care|Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
76064527|NCT00072514|Drug|dexamethasone|Given PO
76064528|NCT00072514|Biological|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
76064529|NCT00074308|Drug|imatinib mesylate|Given orally
75747383|NCT05388812|Other|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
76064530|NCT00074308|Biological|bevacizumab|Given IV
76064531|NCT00074308|Other|pharmacological study|Correlative studies
76064532|NCT00074308|Other|laboratory biomarker analysis|Correlative studies
76064533|NCT00159250|Drug|AVI-4658 (PMO)|morpholino antisense oligonucleotide
76064534|NCT00165958|Procedure|Excisional surgery of epidermal cyst|Traditional extirpation of cyst en toto
76064535|NCT00165958|Procedure|Punch incision of epidermal cyst|removal of cyst first with incisional effort with a punch biopsy tool
76064536|NCT01898026|Dietary Supplement|Bread|Samples of white bread, with or without the addition of PGX fibre blend
76064537|NCT01898026|Dietary Supplement|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
76064538|NCT01898026|Dietary Supplement|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
76064539|NCT01898026|Dietary Supplement|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
76064540|NCT00166036|Drug|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
76064541|NCT00166036|Drug|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
76064542|NCT01500135|Drug|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
76064543|NCT01500135|Drug|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
76064544|NCT00167206|Procedure|Hematopoietic Stem Cell Transplant|Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
75451698|NCT01730898|Other|Study product containing lutein|delivered in capsule form
75451699|NCT01730911|Other|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
75451700|NCT01730924|Procedure|Pulmonary vein isolation using contact force sensing catheter|
75898043|NCT03699748|Behavioral|Lay Health Worker Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice). The intervention is provided along with usual care as provided by Unite Here Health and local oncologists.
75898044|NCT03699748|Other|Usual Care|Usual care as provided by Unite Here Health and local oncologists
76064545|NCT00167206|Procedure|Thymic Shielding During Radiation|protecting the thymus during total body radiation (450 cGy administered)
76064546|NCT00167206|Procedure|Total Body Irradiation|Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
76064547|NCT00167206|Drug|Cyclophosphamide, Fludarabine|Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
76064548|NCT01475097|Drug|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
76064549|NCT01475097|Drug|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
76064550|NCT04779190|Device|Low-level laser therapy|Gallium-aluminum-arsenide diode laser device
76064551|NCT04779190|Device|Therapeutic ultrasound|Therapeutic pulsed ultrasound with a frequency of 1 MHz
76064552|NCT04779190|Other|Home-based exercise|Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
76064553|NCT01529385|Device|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
76064554|NCT01529385|Device|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
76064555|NCT01474551|Drug|vemurafenib|All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
76064556|NCT02094586|Biological|PXVX0200 Lot A|Lot P700-1CA03
76064557|NCT02094586|Biological|PXVX0200 Lot B|Lot P700-3CA03
76064558|NCT02094586|Biological|PXVX0200 Lot C|Lot P700-6BA03
76064559|NCT02094586|Biological|Placebo|Placebo
76064560|NCT02985645|Procedure|maxillary sinus augmentation with CGF|Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system
76064561|NCT02985645|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply the CGF to the maxillary sinus.
76064562|NCT01500057|Device|Greenlight XPS Laser|Treatment of BPH with Greenlight XPS laser
76064563|NCT01500057|Device|BiVAP Saline Vaporization of the prostate|treatment of BPH with BiVAP Saline Vaporization
76064564|NCT02094664|Device|Heated and humidified oxygen|
76064565|NCT01499667|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
76064566|NCT01499667|Drug|Placebo|Matching placebo in capsules for oral administration once daily.
75898045|NCT03524066|Drug|Inhalation|Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
75898046|NCT03524066|Drug|Systemic|Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
75451701|NCT01730976|Dietary Supplement|Vitamin D 2,000 I.U.|
75451702|NCT01730989|Dietary Supplement|Estromineral Serena Plus|
75451703|NCT01730989|Dietary Supplement|Estromineral|
75602907|NCT04253119|Drug|Antiretroviral/Anti HIV|NNRTI plus two NRTIs or PI boosted by ritonavir with 2 NRTIs per the usual standard of care of the investigator in AIDS clinics of Russia
75602908|NCT01266590|Drug|LY2216684|Administered orally
75747384|NCT05388812|Other|Individual Placement and Support (IPS)|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
75747385|NCT03999398|Procedure|Percutaneous coronary intervention (PCI)|Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
75747386|NCT00529958|Procedure|Patellar Tendon|Patellar Tendon autograft
75898047|NCT03524066|Other|Bronchoscopy|Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
75898048|NCT03903861|Other|Glucose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
76064567|NCT00168298|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
76064568|NCT00168298|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
76064569|NCT00168298|Other|Sham Injection|Sham injection on Day 0.
76064570|NCT01474317|Device|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
76064571|NCT00075088|Device|Electrocardiogram (ECG) Intervention|"Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED."
76064572|NCT00075088|Other|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
76064573|NCT00076258|Behavioral|SSRI + LD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
76064574|NCT00076258|Behavioral|SSRI + PHD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
76064575|NCT00078286|Drug|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
76064576|NCT00078286|Drug|Placebo|Dosage ranging from 50 mg to 200 mg once a day
76064577|NCT00078754|Drug|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
76064578|NCT00078754|Drug|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
76064579|NCT00078754|Drug|Placebo|Placebo capsules by mouth, up to 8 capsules daily
75898049|NCT03903861|Other|Galactose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
76064580|NCT00080470|Device|bion|battery powered microstimulator
76064581|NCT00081328|Drug|Metformin|capsule, 1000 mg bid
76064582|NCT00081328|Drug|Rosiglitazone|capsule, 4 mg bid
76064583|NCT00081328|Behavioral|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
76064584|NCT00082342|Device|Phoressor II (IOMED)|sham stimulation
75451704|NCT01731015|Drug|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience ~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
75451705|NCT01731028|Drug|Somatropin|Somatropin powder and solvent for solution for injection
75451706|NCT01731067|Drug|Cocktail probe drugs|
76064585|NCT00082342|Device|Phoressor II (IOMED)|real tDCS stimulation
76064586|NCT01499355|Biological|BIIB023|
75451707|NCT01731093|Drug|AT-001|
75602909|NCT01266590|Drug|Digoxin|Administered orally
75602910|NCT01266122|Behavioral|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
75747387|NCT00529958|Procedure|Hamstring Tendon|Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
76064587|NCT01499355|Biological|Placebo|
76064588|NCT01499355|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
76064589|NCT01499355|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
76064590|NCT00083122|Drug|cisplatin|Given IV
75451708|NCT01731093|Drug|Placebo|
75451709|NCT01731132|Drug|Levonorgestrel IUD or Copper IUD|Women who initiate the use of an IUD at the time of the study.
75451710|NCT01731145|Device|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
75451711|NCT01731158|Drug|Avastin in combination with Roferon-A|
75451712|NCT01731158|Drug|Afinitor|
75451713|NCT01731158|Drug|TKI: Sutent, Nexavar or Votrient|TKI
75451714|NCT01731184|Drug|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
75451715|NCT01731197|Dietary Supplement|Dry-Blended Beverage|
75451716|NCT01731210|Device|implantation of the new LV lead: NANO system.|
75602911|NCT00607555|Device|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
75602912|NCT04252027|Other|Sample collection|Plasma and urine sample collection
75602913|NCT04264975|Procedure|fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit
75747388|NCT00529958|Procedure|Double-Bundle|Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
75747389|NCT00529802|Drug|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
75747390|NCT03742622|Behavioral|CON . control condition without exercise / rest condition|CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75747391|NCT03742622|Behavioral|EX. Condition with an acute exercise set in the middle of the morning|EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals
76064591|NCT00083122|Drug|alvocidib|Given IV
76064592|NCT00083122|Drug|cisplatin/flavopiridol|Given IV
76064593|NCT01474239|Drug|bevacizumab [Avastin]|10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
76064594|NCT01474239|Drug|fotemustine|75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
76064595|NCT03026829|Device|CART sound therapy|"The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART"
76064596|NCT01473381|Drug|Vilazodone|Vilazodone was supplied as film-coated tablets.
76064597|NCT01473381|Drug|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
76064598|NCT01473381|Drug|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
76064599|NCT01473381|Drug|Citalopram|Citalopram was supplied as encapsulated tablets.
76064600|NCT00168454|Biological|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
75898050|NCT03903861|Other|Glucose and galactose|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
75898051|NCT05063305|Dietary Supplement|Probiotic|The probiotic to be used in the study is in capsule form and consists of 12 bacterial strains and 10-billion colony forming unit (CFU). The product consists of the following bacterial strains and species: Bifidobacterium infantis ATCC SD 6720, Bifidobacterium bifidum ATCC SD 6576, Bifidobacterium breve ATCC SD 5206, Bifidobacterium lactis ATCC SD 5220, Bifidobacterium longum ATCC SD 5588, Lactobacillus acidophilus DSM 32754, Lactobacillus casei ATCC SD5213, Lactobacillus paracasei ATCC SD 5275, Lactobacillus plantarum ATCC SD 5209, Lactobacillus reuteri ATCC SD 6689, Lactobacillus rhamnosus ATCC 53103, Lactobacillus salivarius ATCC SD 5208) in combination with the prebiotic, xylooligosacharide (XOS).
75898052|NCT05063305|Dietary Supplement|Placebo|A placebo, that will be indistinguishable in appearance to the probiotic, will be provided to half of all study participants for the length of the trial. It will contain the following ingredients: Microcrystalline cellulose, magnesium stearate, a vegetarian capsule, and silicon dioxide. The probiotic will be manufactured by MeriCal.
75898053|NCT04052529|Other|Dietary self-monitoring|Participants use a popular smartphone application to track their food and drink intake for one month.
75898054|NCT03446794|Other|Non Intervention|To assess the procedural safety and efficacy on stroke and bleeding prevention of LAAC in patients with NVAF and ESCKD on HD
76025259|NCT02382497|Device|BED Sham tDCS|The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
76064601|NCT00168454|Drug|Placebo|Placebo (normal saline) injected into detrusor on Day 1
76064602|NCT00175006|Other|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
76064603|NCT04737772|Behavioral|Behavioral: Quitline treatment as usual|TAU is state quitline treatment that may include coaching sessions, text messaging and access to the web-based program plus cessation medications and unlimited calls to the QL for support between sessions.
75602914|NCT00603811|Biological|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
75747392|NCT03742622|Behavioral|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75747393|NCT01003340|Behavioral|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
75747394|NCT04928456|Other|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) involves a number of hands-on techniques that are meant to address somatic dysfunction in the body as a part of the osteopathic approach to treating patients. There will be five techniques in total used in the study treatment plan.
75747395|NCT00528866|Drug|bicalutamide|50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
76025260|NCT04503161|Device|Duragen with Collagen Hydrodel and ASCs|Duragen combined with collagen hydrogel and patient's stem cells
75602915|NCT00603811|Biological|Placebo|Placebo
75602916|NCT05089435|Device|EZYPRO® ECG Recorder|EZYPRO is an ECG monitoring patch designed to enhance the arrhythmia detection rate by applying 14 days in a home setting environment.
75602917|NCT01265498|Drug|obeticholic acid|25 mg daily for 72 weeks
75602918|NCT01265498|Drug|placebo|placebo capsule, 25 mg daily for 72 weeks
75602919|NCT00603967|Procedure|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
75602920|NCT00603967|Procedure|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
76064604|NCT04737772|Behavioral|QL Marijuana Check-Up intervention (QL-MJCU)|QL Marijuana Check-Up intervention (QL-MJCU) was developed for non-treatment seeking MJ users and is based on Motivational Enhancement Therapy. Includes TAU (see standard quitline arm) with a trained coach plus a MJ assessment and Personalized Feedback Report (PFR).
76064605|NCT01499277|Drug|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
76064606|NCT01499277|Drug|Vancomycin|IV vancomycin 15mg/kg every 12 hours
76064607|NCT01499277|Drug|Aztreonam|IV aztreonam 1 g every 8 hours
75602921|NCT00603967|Behavioral|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline"
75747396|NCT00528866|Drug|docetaxel|75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
76064608|NCT00176800|Drug|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
76064609|NCT00176800|Procedure|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
75602922|NCT00607711|Drug|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
75602923|NCT01265420|Biological|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
76064610|NCT00176800|Procedure|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
75898055|NCT04515121|Device|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
75451717|NCT01731223|Behavioral|Group treatment for insomnia|Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
75451718|NCT01731249|Biological|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
75451719|NCT01731249|Biological|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
75451720|NCT01731275|Drug|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
75451721|NCT01731275|Drug|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
75451722|NCT01731301|Drug|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
75451723|NCT01731301|Drug|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
75602924|NCT04324658|Device|Lactiplus|capsules containing L. gasseri LA806
75602925|NCT05545826|Device|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with early stage Parkinson's disease
75602926|NCT04323644|Procedure|Surgery|Emergency or elective surgery
75602927|NCT01264718|Behavioral|Parent Mentors|After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
75747397|NCT00528866|Drug|flutamide|250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
75747398|NCT00528866|Drug|LHRH agonist|LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
75747399|NCT00528866|Radiation|3-dimensional conformal radiation therapy|
75747400|NCT00528866|Radiation|radiation therapy|66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
76064611|NCT00176878|Procedure|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10^9/kg.
76064612|NCT00176878|Drug|Fludarabine monophosphate|fludarabine 175 mg/m^2 (total) on Days -6 through -3.
76064613|NCT00176878|Procedure|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
75747401|NCT03999008|Drug|Budesonide Oral|"The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance."
75747402|NCT03999008|Drug|Placebos|Apple Sauce 5 mL+ 1 mL saline
75747403|NCT05140148|Drug|Amantadine|Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
75602928|NCT01264016|Device|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
75602929|NCT01263782|Drug|Carboplatin|AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
75747404|NCT05140148|Drug|Placebo|placebo pills
75747405|NCT01003574|Behavioral|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
75747406|NCT01003574|Behavioral|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
75747407|NCT01003652|Procedure|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
75898056|NCT04515121|Device|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
75898057|NCT04515121|Other|Lower limb rehabilitation|Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
75898058|NCT03523910|Device|Magnetic Resonance Imaging (MRI) with exercise|MRI scan with a novel exercise device.
75898059|NCT03525704|Device|Saline Solution Enriched|Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution
75451724|NCT01731301|Drug|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
75451725|NCT01731314|Behavioral|Learning and Memory of Pain|
75451726|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
75451727|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
75602930|NCT01263782|Drug|Pemetrexed|500 mg/m2 by vein on day 1 of each 21 day cycle.
75602931|NCT01263782|Drug|Bevacizumab|15 mg/kg by vein on day 1 of each 21 day cycle.
75602932|NCT01263782|Drug|Cixutumumab|20 mg/kg by vein on day 1 of each 21 day cycle.
75451728|NCT01731340|Dietary Supplement|Calcium Citrate|750mg
75451729|NCT01731340|Other|Low Dietary Calcium|450 mg
75451730|NCT01731340|Other|High Dietary Calcium|1200 mg
75602933|NCT01263704|Drug|Cyclophosphamide|150 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
75602934|NCT01263704|Drug|Fludarabine|12.5 mg/m^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
75602935|NCT01263704|Drug|Rituximab|375 mg/m^2 IV Day 0 of Cycle 1, 500 mg/m^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
75602936|NCT01263470|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
75602937|NCT01263470|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
75747408|NCT01003730|Other|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
75747409|NCT04000490|Other|SCARE Score|Predictive Score of acute coronary syndrome during the medical assessment of chest pain
75898060|NCT03525704|Device|Saline Rinse Solution|sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i
75747410|NCT01003808|Biological|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
75898061|NCT03047551|Procedure|Transabdominal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
75451731|NCT01731366|Other|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
75451732|NCT01731366|Other|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
75451733|NCT01731379|Procedure|Surgical resection|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
75451734|NCT01731392|Dietary Supplement|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
75451735|NCT01731392|Dietary Supplement|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
75451736|NCT01731392|Dietary Supplement|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
75898062|NCT03047551|Procedure|Transvaginal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
75898063|NCT02964741|Device|Active Comparator|non-invasive brain stimulation (active protocol)
75898064|NCT02964741|Device|Sham Comparator|non-invasive brain stimulation (sham protocol)
75451737|NCT01731418|Behavioral|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, & Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.
75451738|NCT01731418|Other|Treatment-as-usual|"Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling.~Regarding supportive counselling, the sessions included:~Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills"
75451739|NCT01731431|Other|Insulin|
75451740|NCT01731431|Drug|Glyburide|
75451741|NCT01731457|Drug|etanercept|adding appropriate dose of etanercept to the perfusion fluid
75451742|NCT01731496|Other|Telephone reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a telephone reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
75451743|NCT01731496|Other|Text Message reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a text message reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
75451744|NCT01731509|Other|Fetal endoscopic tracheal occlusion|FETO will be performed by placing a detachable balloon inside fetal trachea
75451745|NCT01731548|Radiation|hyperfractionated radiation therapy for both arms|1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
75602938|NCT01263470|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
75602939|NCT01263470|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
76064614|NCT00176878|Drug|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
75602940|NCT01263470|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
76064615|NCT00176878|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
75602941|NCT01263470|Drug|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
75602942|NCT04322942|Diagnostic Test|Monocyte Distribution Width|Monocyte Distribution Width as part of the CBC result.
75602943|NCT04322630|Other|Change in Soluble MER Concentration|Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
75602944|NCT04322786|Drug|ACE inhibitor|Any prescription of ACE inhibitor
75602945|NCT04322240|Drug|Alpha lipoic acid|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
75602946|NCT01262456|Drug|Desmopressin|
75602947|NCT01262456|Drug|Placebo|
76064616|NCT01898182|Other|Kinetin, N6-furfuryladenine, 0.1%|
75451746|NCT01731561|Drug|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are > to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
75602948|NCT02889380|Drug|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
75747411|NCT04932746|Drug|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine or placebo) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~It begins with infusion of 4 ml within 10 minutes and then continues infusion, depending on the child's weight, at 1.6 ml / kg / h.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
75747412|NCT04932746|Drug|Placebo|The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
75747413|NCT00614393|Biological|dalotuzumab|IV infusion
75898065|NCT05577780|Procedure|internal fixation|Patients with femoral neck fractures are treated with pinning or hip arthroplasty, depending on the age of the patient and the presence and degree of displacement
75898066|NCT03523832|Drug|Celecoxib and Pregabaline|Single dose versus repetition dose
76064617|NCT02338336|Drug|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
75451747|NCT01731561|Drug|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
75451748|NCT01731574|Drug|dapivirine|
75602949|NCT02889302|Drug|KPS-0373|24 weeks
75602950|NCT02889302|Drug|Placebo|24 weeks
75602951|NCT04321694|Drug|KHK2455|
75602952|NCT04321850|Drug|Zinc Sulfate 50 Mg Tab|The tablets were manufactured specifically for this study.
75602953|NCT04321850|Drug|Placebo oral tablet|The tablets were manufactured specifically for this study.
75602954|NCT04321616|Drug|Hydroxychloroquine|Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
75602955|NCT04321616|Drug|Remdesivir|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
75602956|NCT04321616|Other|(Standard of Care) SoC|The standard of care will be supplied to all patients not receiving a drug intervention.
75602957|NCT04321772|Other|High Intensity Interval Resistance Training|Subjects trained one leg with HIIRT
75602958|NCT04321772|Other|Traditional Resistance Training|Subjects trained the other leg with HIIRT
76064618|NCT02338336|Drug|Placebo|Matching placebo liquid for topic administration.
75747414|NCT00614393|Drug|irinotecan hydrochloride|IV infusion
75747415|NCT00614393|Biological|cetuximab|IV infusion
75747416|NCT00614393|Drug|placebo|IV infusion
75451749|NCT01731574|Drug|miconazole|
75602959|NCT04207658|Behavioral|Valsalva's Style Pushing|The second stage of labour is defined as the time passed after the cervical dilatation reaches 10cm. The expulsion stage is the time between the sight of baby's head in the vulva and the end of labour. the participants are given information about the study after self introduction of each gravid is done for completing baseline obstetric data forms by midwives. Also, blood samples for pre and postpartum haemoglobin level changes are collected. The perineal area is examined for postpartum tears through pad checks. Vital findings (respiration, pulse and TA) are evaluated prior to their transfer to the delivery room. Just after the birth, mothers are tested for pH, pO2, pCO2 and lactate levels in blood while the newborns are tested for pH, pO2 (mmHg) and pCO2 levels through umbilical artery along with 1st min and 5 min APGAR analysis. The visual scale is utilized for determination of first 24-hour fatigue and they are recorded in follow-up forms.
75602960|NCT00623948|Device|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
75602961|NCT04321304|Device|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
75747417|NCT00885521|Other|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
75898067|NCT03523832|Other|Placebo|Placebo
75898068|NCT05577624|Drug|AMG 510|Oral tablet
75898069|NCT05577624|Drug|Rifampin|Oral capsule
75898070|NCT03294694|Drug|Ribociclib|Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
75898071|NCT03294694|Drug|PDR001|Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
75898072|NCT03294694|Drug|Fulvestrant|Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
76064619|NCT04672174|Diagnostic Test|Questionnaire: DemTect|Questionnaire is handed out to subjects
76064620|NCT01499199|Drug|Dolutegravir|50mg Once Daily
76064621|NCT01499043|Drug|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
76064622|NCT00087022|Biological|girentuximab|Given IV
76064623|NCT00087022|Other|placebo|Given IV
76064624|NCT00179998|Drug|Recombinant Human DNase (Pulmozyme)|2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
76064625|NCT00179998|Drug|Placebos|2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
76064626|NCT00181168|Drug|Euthyroid Group|Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
76064627|NCT02151526|Drug|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
76064628|NCT00089752|Device|Continuous Positive Airway Pressure (CPAP) Treatment|CPAP device used at night
76064629|NCT00089752|Device|Sham CPAP device - CPAP device with pressure delivered <1 cm H20|Sham CPAP device used at night
75451750|NCT01731587|Other|Biological: MUC1 peptide specific immunotherapy|Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
76064630|NCT00090844|Drug|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
75747418|NCT00880529|Device|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
75747419|NCT00880529|Drug|IV opioid administration|Patient controlled analgesia with IV narcotics
76064631|NCT01897012|Drug|Alisertib|Given PO
75898073|NCT03523754|Drug|Isosorbide Mononitrate 40 MG to study group|Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening & induction of labor in study group
76064632|NCT01897012|Other|Laboratory Biomarker Analysis|Correlative studies
76064633|NCT01897012|Drug|Romidepsin|Given IV
75747420|NCT00880841|Drug|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
75898074|NCT04727034|Drug|Remimazolam tosylate|Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.
76064634|NCT01498887|Drug|Fingolimod (FTY720)|Hard gelatin capsules containing 0.5 mg of fingolimod.
76064635|NCT01498653|Drug|GW685698/GW642444|ICS/LABA
75451751|NCT01731587|Drug|Cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
75451752|NCT01731613|Dietary Supplement|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
75451753|NCT01731639|Other|MSOME|The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form > 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
76064636|NCT01498653|Drug|CCI18781|ICS
76064637|NCT01498575|Behavioral|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
76064638|NCT01498185|Drug|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
75451754|NCT01731652|Drug|TMX-101|
75451755|NCT01731704|Radiation|Stereotactic radiosurgery (SRS)|
75451756|NCT01731704|Radiation|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
75451757|NCT01731717|Behavioral|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
75451758|NCT01731717|Behavioral|Bibliotherapy|"Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision."
75451759|NCT01731717|Behavioral|Online self-help|"Patient works with online self-help program Deprexis under general physician's supervision."
75451760|NCT01731717|Behavioral|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
75747421|NCT04503863|Drug|NPC-22|Single administration of middle dose NPC-22
75747422|NCT04503863|Drug|NPC-22|Single administration of high dose NPC-22
75747423|NCT04503863|Drug|NPC-22 Placebo|Single administration of NPC-22 Placebo
75747424|NCT00883259|Drug|Metformin|850 mg twice daily
75747425|NCT00883259|Other|Placebo|Microcristallyne cellulose 1 table twice daily
76064639|NCT01498185|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
76064640|NCT01528605|Dietary Supplement|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
76064641|NCT01528605|Dietary Supplement|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
76064642|NCT01528605|Dietary Supplement|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
76064643|NCT01528605|Dietary Supplement|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
76064644|NCT01528605|Dietary Supplement|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
76064645|NCT01528605|Dietary Supplement|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
76064646|NCT01528215|Device|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
76064647|NCT01528215|Device|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
76064648|NCT01527357|Biological|Fibrocaps|Human fibrinogen and thrombin powder, for topical administration.
76064649|NCT01527357|Biological|Gelatin sponge|Absorbable gelatin sponge for topical administration.
76064650|NCT00093964|Drug|Cilengitide 500 mg|Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
76064651|NCT00093964|Drug|Cilengitide 2000 mg|Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
75747426|NCT00885599|Drug|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
75747427|NCT00885599|Drug|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
75747428|NCT00885599|Drug|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
76064652|NCT01526889|Drug|LFG316|LFG316 administered intravitreally (IVT)
76064653|NCT01526889|Drug|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
75602962|NCT04321304|Device|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
75451761|NCT01731717|Procedure|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
75451762|NCT01731717|Behavioral|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
75451763|NCT01731717|Other|Control group: treatment as usual|treatment as usual
75451764|NCT01731743|Device|AT LISA tri 839MP|
75451765|NCT01731756|Other|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
75451766|NCT01731756|Drug|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
75451767|NCT01731756|Other|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
75602963|NCT04321304|Device|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
75602964|NCT00932893|Drug|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
75602965|NCT00932893|Drug|Pemetrexed|Pemetrexed, 500 mg/m^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
75451768|NCT01731769|Procedure|vacuum assisted closure in experimental arm|
75602966|NCT00932893|Drug|Docetaxel|Docetaxel, 75 mg/m^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
75747429|NCT00885599|Drug|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
75747430|NCT00881075|Drug|SeeMore(TM)|single dose intravenous injectable
75747431|NCT04366115|Drug|AVM0703|Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
75898075|NCT04727034|Drug|Propofol|Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.
75898076|NCT05283759|Other|No intervention because it is a patient registry|
75898077|NCT03523676|Diagnostic Test|Red Cell Distribution Width|
75898078|NCT03644511|Drug|Regorafenib (Stivarga, BAY73-4506)|Prescribed by physician.
75898079|NCT03644511|Drug|Sorafenib (Nexavar, BAY43-9006)|Prescribed by physician.
75451769|NCT01731769|Procedure|Axillary dissection|
75602967|NCT04321070|Drug|Clindamycin Phosphate|A thin film of investigation product will be applied to the affected areas of the face once daily
75602968|NCT04321070|Drug|Clindamycin Phosphate RLD|A thin film of investigation product will be applied to the affected areas of the face once daily
75602969|NCT04321070|Drug|Placebos|A thin film of investigation product will be applied to the affected areas of the face once daily
75747432|NCT04366115|Drug|Placebo|Single IV infusion in normal saline over 1 hour to patients.
75747433|NCT04712747|Procedure|Ophthalmological examinations|"OCT (Optical Coherence Tomography): posterior pole OCT B scan , optic nerve and posterior pole OCT Angiography~Adaptive optics (AO) : Image acquisition on the vessels at the exit of the optic nerve before the first upper temporal bifurcation OD or OG and evaluation of the photoreceptor mosaic. Adaptive optics may require dilatation of the pupil with a drop of tropicamide in the eye examined a few minutes before the examination.~Color retinophotography~Measurement of intraocular pressure~Patients with stroke : At the inclusion visit and 3 months after their stroke Control group : At the inclusion visit."
75747434|NCT04712747|Procedure|Blood pressure measurement at rest|At the inclusion visit
75747435|NCT04038125|Drug|Ozurdex Drug Implant Product|Intravitreal Ozurdex injection
75747436|NCT00881153|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
75747437|NCT00881153|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
75898080|NCT03290560|Drug|Recombinant human tissue kallikrein|Recombinant human tissue kallikrein
75898081|NCT03290560|Other|Placebo|Placebo Comparator: Phosphate buffered saline
76025261|NCT02214407|Drug|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
76025262|NCT02214407|Drug|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
76025263|NCT02682823|Device|AI-1000 G2|Tocilizumab will be administered using the AI-1000 G2.
75747438|NCT00885833|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
76064654|NCT00181714|Drug|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
76064655|NCT04643626|Device|artificial intelligence dietary android mobile application|subjects use artificial intelligence dietary mobile application to monitor dietary intake
76064656|NCT01472835|Drug|Midazolam|Used for anxiolysis
76064657|NCT01472835|Drug|Fentanyl|Used for analgesia and as a sedative
76064658|NCT00185692|Procedure|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
76064659|NCT00185692|Drug|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
76064660|NCT00185692|Drug|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
76064661|NCT00185692|Drug|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
76064662|NCT00185692|Drug|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
76064663|NCT00185692|Drug|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
75451770|NCT01731795|Drug|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
76064664|NCT00185692|Drug|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
76064665|NCT00185692|Drug|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
75451771|NCT01731808|Behavioral|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
75451772|NCT01731821|Procedure|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
75451773|NCT01731834|Other|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
75451774|NCT01731847|Procedure|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
75451775|NCT01731860|Device|Additional PET Scan|Additional PET Scan with no additional radiopharmaceutical administration.
75451776|NCT01731899|Drug|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
75451777|NCT01731925|Drug|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
75602970|NCT04321226|Device|Femtosecond Laser guided Arcuate Keratotomy|Astigmatism will be reduced in cataract surgery using a low energy Femtosecond Laser device
75451778|NCT01731925|Drug|Placebo (for sunitinib)|
75451779|NCT01731925|Drug|Sunitinib|Sunitinib 37.5 mg daily
75451780|NCT01731964|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
75602971|NCT02889224|Other|Obese|
75602972|NCT02889224|Procedure|Hypercortisolism|
75602973|NCT02889224|Other|Hydrocortisone|
75602974|NCT02889224|Other|Control|
75602975|NCT02889146|Other|Conventional Physical Therapy|Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.
75747439|NCT00612677|Drug|Oxaliplatin|Dose Regimen: 120 mg/m^2 on Days 1 every 21 days
75747440|NCT00612677|Drug|Pemetrexed|Dose Regimen: 500 mg/m^2 on Days 1 every 21 days
75747441|NCT04038749|Drug|Bromocriptine|Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
75747442|NCT04038749|Drug|Cabergoline|Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
75747443|NCT04038749|Other|Natural methods|milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
75451781|NCT01731964|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
75602976|NCT02889146|Other|Early and progressive mobilization program|Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.
75602977|NCT02889146|Other|Respiratory therapy|Respiratory therapy according to the service routine.
75747444|NCT00883571|Procedure|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
75602978|NCT01260896|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
75747445|NCT00883571|Procedure|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
75451782|NCT01731977|Behavioral|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
75451783|NCT01732003|Dietary Supplement|Omega-3 Complete|
75451784|NCT01732003|Dietary Supplement|Placebo Pill|
75451785|NCT01732016|Other|Normobaric hypoxia chamber|
75602979|NCT01260896|Drug|Effexor® XR|150 mg Extended-Release Capsule
75602980|NCT00932737|Drug|Placebo|1-5 tablets per episode
75602981|NCT00932737|Drug|HBB 20 mg|Active drug, one to five tablets per episode
75602982|NCT00607399|Drug|SGX523 Capsules|This is a dose escalation study
75747446|NCT00883571|Procedure|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
75747447|NCT00881231|Drug|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
75747448|NCT00881231|Drug|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
75747449|NCT00613925|Device|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
75747450|NCT00613925|Device|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
75747451|NCT00881309|Drug|Tripterygium|TW 90mg/d
75747452|NCT00883649|Dietary Supplement|Hydroeye|2 Capsules BID
75747453|NCT00883649|Other|Inactive Capsule|2 Capsules BID
75747454|NCT00883727|Drug|Stem cell|IV infusion of stem cells
75747455|NCT00883727|Drug|Plasmalyte A|IV infusion
75747456|NCT00883805|Biological|Blood draw|Subjects will give blood for analysis of metal ion concentrations
75747457|NCT00883805|Radiation|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
75747458|NCT00881387|Biological|rituximab|Given IV
76064666|NCT00185692|Drug|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
76064667|NCT01526733|Drug|Sham Injection|
76064668|NCT01526733|Drug|Recombinant human hyaluronidase PH20|
75451786|NCT01732029|Other|Normobaric hypoxia chamber|
75451787|NCT01732055|Behavioral|Partner-Assisted Interpersonal Psychotherapy|
75602983|NCT00939523|Drug|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
75602984|NCT04264741|Device|repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
75747459|NCT00881387|Drug|gemcitabine hydrochloride|Given IV
75747460|NCT00881387|Drug|vinorelbine ditartrate|Given IV
76064669|NCT01526733|Drug|Insulin aspart|
76064670|NCT01526733|Drug|Insulin lispro|
75747461|NCT00883883|Drug|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
75898082|NCT03523598|Other|Placebo gel + Normal Toothpaste|"15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin.~A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
75898083|NCT03523598|Other|Placebo Gel + Potassium Nitrate Toothpaste|"15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin.~A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
75898084|NCT03523598|Other|Potassium Nitrate Gel + Normal Toothpaste|"15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin.~A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
75898085|NCT01316419|Drug|Telmisartan|Telmisartan 40mg or 80mg
76064671|NCT00094900|Drug|IL-1 Trap|
75898086|NCT01316419|Drug|amlodipine|amlodipine 5mg or 10mg
75898087|NCT03262324|Other|VAS-FA Turkish version|Self-reported outcome questionnaires
76064672|NCT00096460|Drug|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
76064673|NCT00096460|Drug|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
76064674|NCT00096460|Radiation|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of < 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC > 500/mm3 x 3 days."
76064675|NCT00096460|Drug|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
76064676|NCT00096460|Procedure|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
76064677|NCT00096460|Procedure|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
75451788|NCT01732055|Other|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
75451789|NCT01732068|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
75451790|NCT01732068|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
75451791|NCT01732068|Drug|hpHMG|300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
75451792|NCT01732094|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
75451793|NCT01732094|Drug|Corifollitropin alfa 150μg|Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
75602985|NCT04264741|Device|sham repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped sham Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
75747462|NCT00883883|Drug|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
75747463|NCT00883961|Other|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
75747464|NCT00885989|Drug|SLV338|5 - 1000 mg IV
75747465|NCT00885989|Drug|Placebo|Placebo
75747466|NCT00886067|Drug|AZD1446|Solution, oral, single dose
75451794|NCT01732094|Drug|hpHMG|hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
75451795|NCT01732133|Device|Nexfin|
75747467|NCT00886067|Radiation|2-[18F]-F-A85380|iv, single dose
75747468|NCT00881543|Drug|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
75898088|NCT03547362|Dietary Supplement|Casein|See arm description
75898089|NCT03547362|Dietary Supplement|Dairy protein blend 1|See arm description
75898090|NCT03547362|Dietary Supplement|Whey protein|See arm description
76064678|NCT00096460|Drug|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
76064679|NCT00096460|Drug|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
76064680|NCT00006178|Drug|Sirolimus|
76064681|NCT00006178|Drug|Thymoglobulin|
76064682|NCT00097708|Drug|experimental anti-anxiety drug|
76064683|NCT00098956|Drug|topotecan hydrochloride|Given IV
76064684|NCT00098956|Drug|7-hydroxystaurosporine|Given IV
76064685|NCT01472757|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
75451796|NCT01732146|Drug|erythropoietin Beta|erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
75451797|NCT01732146|Drug|Placebo|
75602986|NCT05382247|Device|ultrasonography|"Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone."
75747469|NCT00881699|Behavioral|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
76064686|NCT01472757|Drug|Placebo|Placebo delivered via a new dry powder inhaler
76064687|NCT02197156|Drug|10 mg HC-ER|Single dose
76064688|NCT02197156|Drug|20 mg HC-ER|Single dose
76064689|NCT02197156|Drug|30 mg HC-ER|Single dose
76064690|NCT02197156|Drug|40 mg HC-ER|Single dose
75451798|NCT01732159|Other|Checklist|he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
76064691|NCT02197156|Drug|10 mg HC / 325 mg APAP|Single dose
75602987|NCT04264429|Device|Infrapatellar strap|Orthotic device which is positioned over the patellar tendon
75602988|NCT04264429|Other|Elastic band|Orthotic device which is positioned over the patellar tendon
75602989|NCT01260584|Drug|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
76064692|NCT02197156|Drug|Matching Placebo|Single dose
76064693|NCT00187720|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
76064694|NCT01472289|Other|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
76064695|NCT00006244|Drug|melphalan|Given IV
76064696|NCT00006244|Biological|recombinant interferon alfa|Given SC
76064697|NCT00006244|Biological|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
76064698|NCT00006244|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
76064699|NCT00187876|Procedure|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
76064700|NCT00187876|Procedure|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
76064701|NCT01525875|Drug|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
76064702|NCT01525875|Drug|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
76064703|NCT01898260|Device|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
75451799|NCT01732172|Other|Sperm sample|Sperm sample
75451800|NCT01732185|Genetic|Patient|Blood and histological samples will be done at day of the inclusion.
75451801|NCT01732198|Biological|NU300|
75451802|NCT01732198|Biological|ActHIB|
75451803|NCT01732198|Biological|Prevnar 13|
75451804|NCT01732224|Drug|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
75602990|NCT01260584|Drug|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
75602991|NCT05176327|Device|Exoskeleton training with Ekso NR|Walking exercise with Ekso NR
76064704|NCT01898260|Device|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
76064705|NCT04409379|Diagnostic Test|Relative telomere length|Relative telomere length in peripheral blood cell
75602992|NCT05331313|Genetic|DNA sequencing|The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.
75602993|NCT00609349|Device|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
75747470|NCT00881699|Behavioral|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
76064706|NCT04409613|Other|Education and counseling|All patients or their caregivers will receive twenty minutes educational sessions for the first three visits according to patient ability to understand. At subsequent visits along the study duration, we will briefly review our educational material to refresh the patient's information. This will include: The objectives of treatment, disease progression process, risk factors, common symptoms of bleeding/thrombotic events and how to deal with this. Lifestyle modifications, including smoking cessation, blood pressure and diabetes control. Drug information: drug action, dose, indication, possible side effects, how to deal with the side effects, actions to take when missing the dose, storage conditions and when and how to administer. Possible interactions including drug-drug and drug-food interactions. Target INR and INR monitoring
76064707|NCT01525641|Drug|Mirapex LA|Pramipexole Hydrochloride Hydrate
75602994|NCT04262635|Drug|Cetuximab, Capecitabine|Maintenance treatment ( ArmA )
75602995|NCT04262635|Drug|Cetuximab|Maintenance treatment ( ArmB )
75602996|NCT00608101|Drug|Fludrocortisone|Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
75602997|NCT00608101|Drug|Dexamethasone|Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
75747471|NCT04638569|Procedure|obturator nerve block|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.
75898091|NCT03547362|Dietary Supplement|Dairy protein blend 2|See arm description
75898092|NCT03547362|Dietary Supplement|Dairy protein blend 3|See arm description
75898093|NCT03547362|Dietary Supplement|Dairy protein blend 4|See arm description
76064708|NCT03026985|Other|Observational cohort|Ultrasound assessment of quadriceps, muscle strength testing, highest mobility level
76064709|NCT00006400|Drug|Hydroxyurea|Participants will receive hydroxyurea.
76064710|NCT00006400|Drug|Placebo|Participants will receive placebo.
76064711|NCT01496469|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
75602998|NCT04264039|Biological|anti-CD19 UCAR-T cells|Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg
75602999|NCT04264039|Drug|Fludarabine|30mg/m^2 per day for 6 days
75603000|NCT04264039|Drug|Cytoxan|300mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline
75603001|NCT04264039|Drug|Melphalan|50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
75603002|NCT00608179|Drug|Glimepiride|Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.
76064712|NCT01496469|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
76064713|NCT00189436|Drug|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
76064714|NCT00189436|Drug|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
75898094|NCT04465682|Device|Experimental: Dip Home-Based Dipstick Analyzer|Dip Home-Based Dipstick Analyzer The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
75898095|NCT02290262|Other|Comprehensive phase one rehabilitation|"Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse."
75898096|NCT03763968|Other|treatment and outcome|
76064715|NCT04091607|Other|Music Therapy|Subject will listen to Music using provided ear buds or headphones.
76064716|NCT01471353|Drug|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
76064717|NCT01525407|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
76064718|NCT01525407|Drug|Atorvastatin Calcium|Given PO
76064719|NCT01525407|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
76064720|NCT01471197|Biological|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
76064721|NCT01471197|Biological|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
76064722|NCT04408989|Drug|MB02-SP|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
76064723|NCT04408989|Drug|MB02-DM|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
76064724|NCT04408989|Drug|US licenced Avastin®|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
76064725|NCT00011986|Drug|Paclitaxel|Given IV
76064726|NCT00011986|Drug|Carboplatin|Given IV
76064727|NCT00011986|Drug|Gemcitabine Hydrochloride|Given IV
76064728|NCT00011986|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|
76064729|NCT00011986|Drug|Topotecan Hydrochloride|Given IV
76064730|NCT00011986|Procedure|Therapeutic Conventional Surgery|Undergo surgery
76064731|NCT01898416|Drug|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|"60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given."
75451805|NCT01732224|Drug|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
75747472|NCT04124861|Drug|Drug free, IS monotherapy and GC combined with IS|Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
75747473|NCT00881777|Procedure|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
75747474|NCT00881777|Procedure|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
75898097|NCT04258150|Drug|Nivolumab|6 mg/kg IV q4w
76064732|NCT01524783|Drug|Everolimus|Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
76064733|NCT01524783|Drug|Placebo|Participants were treated with two tablets of matching placebo once daily orally taken.
76064734|NCT01524783|Other|Best suportive care (BSC)|Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
76064735|NCT01494987|Drug|Ranolazine|Ranolazine tablet(s) administered orally
76064736|NCT01494987|Drug|Placebo|Placebo to match ranolazine for the duration of the study
76064737|NCT01494987|Drug|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
76064738|NCT01494987|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
76064739|NCT01494987|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
76064740|NCT04409769|Other|Description of use of ceftaroline and ceftobiprole|Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
76064741|NCT01524627|Drug|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
76064742|NCT01524627|Drug|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
75451806|NCT01732237|Drug|JNJ-42396302|A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
75451807|NCT01732237|Drug|JNJ-42692507|A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
75451808|NCT01732237|Drug|JNJ-53773187|A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
75451809|NCT01732250|Drug|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
75451810|NCT01732250|Drug|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
75451811|NCT01732276|Drug|gefitinib|
75898098|NCT04258150|Drug|Ipilimumab|1 mg/kg IV twice q6w
75898099|NCT04258150|Drug|Tocilizumab|8 mg/kg IV q4w
75603003|NCT00608179|Drug|glyburide|Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.
75747475|NCT02542475|Device|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (< 100x) than those used in ECT and rTMS.
75747476|NCT00881855|Drug|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
75747477|NCT00881855|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
75747478|NCT04015115|Behavioral|Youth Opioid Recovery Support service model|see arm 1 description
75747479|NCT00881933|Other|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, & -2) (if body weight < 10 kg or if age < 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, & -8) total body irradiation (3G on days -1)
75747480|NCT03940547|Other|Provision of flour|Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months
75747481|NCT03940547|Other|Promotion of flour|Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months
75747482|NCT03929237|Other|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
75747483|NCT00882011|Other|Latest generation chemotherapies for T-LBL + transplant|"Standard doses of one of the following chemotherapies:~Holzer~LSA2-L2 modified~Stanford regimen~Hyper CVAD~Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
75747484|NCT00884195|Behavioral|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
75747485|NCT00884195|Behavioral|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
75747486|NCT02543957|Procedure|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
75747487|NCT00886223|Procedure|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
75747488|NCT00882089|Device|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
75747489|NCT02543645|Drug|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg."
75898100|NCT04258150|Radiation|SBRT|"A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~PTV should be covered by 95% isodose (PTV D99% > 95%)."
75898101|NCT03546348|Other|no intervention|only measurement of the carrying angle
75898102|NCT02964039|Behavioral|Error reduction|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
75898103|NCT02964039|Behavioral|Error augmentation|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
75603004|NCT00608179|Other|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes
75603005|NCT00608179|Other|glucose clamp|hypoglycemic glucose clamp procedure -120 minutes
75898104|NCT02964039|Behavioral|Activity matched control|During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
75603006|NCT00608335|Drug|Micafungin|IV
75603007|NCT00927589|Drug|carboplatin|Intravenous repeating dose
75603008|NCT00927589|Drug|docetaxel|Intravenous repeating dose
75603009|NCT00927589|Drug|trastuzumab|Intravenous repeating dose
75603010|NCT04264117|Procedure|FlexAbility (Mesh-like irrigated tip catheter) group|"AF catheter ablation (PV isolation and linear ablations)~30 sec ablation in each point~35W in anterior LA, 30 W in posterior LA~Irrigation flow rate 13mL/min~Measuring procedure time, Ablation time~Rhythm follow-up based on guidelines"
76064743|NCT01469637|Drug|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
76064744|NCT01469637|Drug|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
76064745|NCT04409223|Drug|Famitinib capsules|Oral KIT/PDGFRA kinase inhibitor
75603011|NCT04264117|Procedure|TactiCath (Contract force monitoring catheter) group|"AF catheter ablation (PV isolation and linear ablations)~contact force >10g, target force-time integral 400 in each point~35W in anterior LA, 30 W in posterior LA~Irrigation flow rate 15mL/min at 30W ablation, 30mL/min at 35W ablation~Measuring procedure time, Ablation time~Rhythm follow-up based on guidelines"
75603012|NCT05145517|Device|Open repair|Open repair of the aorta and peripheral arteries
75747490|NCT02543411|Drug|Lidocaine 1%|"Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol"
75747491|NCT02543411|Drug|Normal saline|"Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol"
75747492|NCT02543489|Device|Flex IM rod|
75747493|NCT00882167|Other|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
75747494|NCT00882245|Other|Vehicle ointment|Topical vehicle cream
76064746|NCT04409223|Drug|Sunitinib Capsules|Oral receptor tyrosine kinase (RTK) inhibitor
75898105|NCT03217708|Device|Jawbone UP4|Wrist worn wearable technology will be utilized to study HR, temperature, sleep, activity changes before and after surgery.
75898106|NCT02290418|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
75898107|NCT02290418|Procedure|Omega-Loop Gastric Bypass|Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
75451812|NCT01732289|Genetic|genes|Draw blood for genetic screening
75451813|NCT01732302|Other|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
75603013|NCT04262557|Diagnostic Test|Sunrise® solution|Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.
75747495|NCT00882245|Drug|Ointment|SRD441 Ointment
75898108|NCT04227730|Diagnostic Test|culture and PCR for group B streptococcus|all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
75898109|NCT02290496|Behavioral|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
76064747|NCT04748367|Device|Virtual Reality Headset|Virtual Reality Headset running SILVER software
76064748|NCT00012298|Biological|rituximab|Given IV
76064749|NCT00012298|Biological|yttrium Y 90 ibritumomab tiuxetan|Given IV
75603014|NCT04262557|Diagnostic Test|Polysomnography|Gold standard method to diagnose SAS used as comparator
75603015|NCT04262245|Procedure|Traditional Irrigation|irrigation with syringe
75603016|NCT04262245|Device|Xp-endo Finisher (XPF)|irrigation activation file
75747496|NCT02541929|Dietary Supplement|Docosahexaenoic acid|
75747497|NCT00882323|Drug|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
75747498|NCT00884429|Procedure|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
76064750|NCT00012298|Biological|indium In 111 ibritumomab tiuxetan|Given IV
76064751|NCT00012298|Biological|oprelvekin|Given subcutaneously
75747499|NCT00884429|Procedure|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
76064752|NCT00012298|Biological|filgrastim|Given subcutaneously
75747500|NCT00884429|Procedure|3-Airway suction|Airway suction
75747501|NCT00882401|Drug|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
75898110|NCT02290496|Behavioral|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
75898111|NCT03548298|Procedure|ARAT|After confirmation of GERD, participants will undergo to ablation with Hybrid-APC (ARAT). Participant will be admitted to hospital 24 hrs before procedure. Technique consist in ablation with hybrid-APC, submucosal injection of saline solution with methylene blue at 3-4 cm from 60-70% cardias and 1 cm esophageal. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic, esophageal manometry and pHmetry up to 1 year after procedure.
75898112|NCT03644433|Procedure|Single layer closure|Uterine incision will be approximated with continuous unlocked suture avoiding the inclusion endometrium and without trimming incision edges.
75898113|NCT03644433|Procedure|Double layer closure after resection uterine scar|Uterine incision will be trimmed and old scar tissue will be removed. Then first, endometrium will be approximated by continuous unlocked suture mimicking subcuticular suture avoiding the inclusion of endometrium and second, upper part of myometrium will be approximated by a continuous unlocked suture.
75451814|NCT01732315|Behavioral|Email Notification|This study will use a targeted email reminder/recall intervention that addresses specific aspects of adolescent under-immunization.
75451815|NCT01732328|Dietary Supplement|Calcium plus vitamin D|
75451816|NCT01732341|Device|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
75451817|NCT01732341|Device|VISION balloon-expandable stent|"STEMI treatment with a VISION balloon-expandable stent~--------------------------------------------------------------------------------"
75451818|NCT01732367|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
75603017|NCT04262245|Device|Passive Ultrasonic Irrigation|irrigation activation method
75603018|NCT04262245|Device|EndoActivator|irrigation activation method
75747502|NCT00882401|Drug|Placebo|Matching placebo at same dose schedule as ergocalciferol
75747503|NCT00886457|Drug|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
75747504|NCT04038671|Device|Activated Carbon Cloth Dressing|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
75747505|NCT04038671|Device|Knitted Cellulose Acetate Mesh|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
75747506|NCT04038671|Device|Antimicrobial Alginate Dressing with Silver|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
75898114|NCT02289014|Other|online stress Management program|Active treatment group
75898115|NCT05577078|Procedure|Transcatheter edge-to-edge repair (TEER)|Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation
75603019|NCT00932425|Device|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
75603020|NCT04260061|Device|training systems|Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
75747507|NCT02543177|Procedure|coronary angiography|
75451819|NCT01732367|Drug|Tenofovir|Tenofovir 300mg QD for 96 weeks
75451820|NCT01732380|Drug|Raltitrexed|
75451821|NCT01732380|Drug|Oxaliplatin|
75451822|NCT01732380|Radiation|Radiotherapy|
76064753|NCT00193258|Drug|Bevacizumab|10mg/kg IV infusion every 2 weeks
75603021|NCT05938816|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|MBSR consists of weekly two-hour sessions for eight weeks, and a 7.5 hour retreat between weeks 6 and 7. The MBSR intervention will be facilitated by an experienced and certified MBSR teacher. MBSR curriculum strongly encourages completion of home practice assignments (~30 minutes daily) to help integration of concepts into daily life. Participants will receive audio CDs and a DVD to help guide home practice.
75603022|NCT05938816|Behavioral|Health and Wellness Education (HWE)|HWE is a didactic-based group intervention designed as an active comparator for randomized-controlled trials of MBSR. HWE provides instruction to participants regarding improving their emotional and physical health. In contrast to MBSR, there are no attempts to train participants' breathing, movement, or meditation habits or practices. HWE is administered in 8 weekly 2.5-hour classes with home practice to be completed between sessions (matched to MBSR for amount and effort). HWE also features one extended 7.5-hour retreat, similar to MBSR.84 Dr. Autumn Gallegos (consultant) has conducted trials of MBSR among veterans with PTSD using a HWE control group, and will provide mentorship to the PI in administering the HWE intervention. Dr. Kaplan and a trained RA will facilitate HWE.
75603023|NCT05938764|Behavioral|MICRA|see earlier description
75603024|NCT05938764|Behavioral|TAU|see earlier description
75747508|NCT02543177|Procedure|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
75898116|NCT02289170|Device|Heating and cooling combination therapy|The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
75603025|NCT05938751|Behavioral|TEAm_YOUNG ADULTS program|The TEAm_YOUNG ADULTS program is an intervention to develop self-determination in young adults with autism. It consists of 20 1.5h weekly sessions. The intervention is conducted by two facilitators with expertise in autism and self-determination promotion. Groups are formed by 4 to 6 participants. The program can be applied online or in person. The first five sessions address specific characteristics and support needs of people with autism. The next ten sessions are focused on the development of self-determination. The last five sessions are focused on working with others and the closure of the group. The individual goals of every participant are considered in the beginning of the group and a weekly follow-up of goals is conducted.
75747509|NCT02543177|Procedure|prior kidney irrigation|
75747510|NCT02543099|Drug|policosanol|Patients will receive policosanol 20mg Qd
75747511|NCT02543099|Drug|placebo|Patients will receive placebo 20mg Qd;
75898117|NCT02289170|Device|Sham heating and cooling therapy|The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
75898118|NCT02854696|Procedure|Islet graft|Patients will be transplanted with pancreatic islet cells
75898119|NCT02854696|Drug|best medical care|Patients will continue their insulin treatment
75898120|NCT02289248|Drug|Ketamine|Subjects will undergo a twice weekly two week course of IV infusions of ketamine
75451823|NCT01732393|Drug|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
75898121|NCT02289248|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects will undergo twice weekly CBT for a total of 8 weeks
75898122|NCT05348304|Dietary Supplement|EUDIAMET|A combination of myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
75451824|NCT01732393|Drug|Placebo|
76064754|NCT00193258|Drug|Erlotinib|150 mg po daily
76064755|NCT00193258|Drug|Imatinib|400-600mg daily
76064756|NCT00029536|Biological|Progesterone Lozenges|200mg Progesterone Lozenges
76064757|NCT00029536|Other|Matched Placebo Lozenges|Matched Placebo Lozenges
76064758|NCT00193492|Drug|Bevacizumab|
76064759|NCT00193492|Drug|Rituximab|
76064760|NCT00194116|Drug|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
75451825|NCT01732497|Device|miraDry Treatment|Application of electromagnetic energy to heat the lower dermis.
75451826|NCT01732562|Other|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
75603026|NCT05938738|Device|PEP-buddy|PEP-buddy
76064761|NCT00194116|Drug|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
76064762|NCT02096458|Drug|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
76064763|NCT02096692|Device|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
75451827|NCT01732575|Behavioral|Enrichment with meaning-generating activities|Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
75603027|NCT05938686|Other|Home_Based Digital Mindful Dance Program|Home_Based Digital Mindful Dance Program including warm up, dance and cool down for 60 minute with 12 weeks.
75603028|NCT05938673|Other|Active stimulation- intermittent theta-burst (iTBS) stimulation|During active stimulation, patients will receive intermittent theta-burst (iTBS) stimulation in T2-T3 toracic region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.Each participant will receive a total of 1,200 rTsMS pulses at 120% of resting motor threshold, determined by abdominal muscle contractions. In 3 minutes and 58 seconds, 20 trains with 20 bursts and each burst with 3 pulses at 50 Hz repeated at 5Hz with an intertrain interval of 8 seconds will be applied.Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
76064764|NCT02096692|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
75603029|NCT05938673|Other|Sham stimulation|During sham stimulation, a circular magnetic coil will be positioned in the T2-T3 toracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus. To create a sensation of muscle contraction and impression of active stimulation, the group will be submitted to the sensory effect of transcutaneous electrical neurostimulation (TENS) for 5 minutes, with surface electrodes placed in parallel at the T2-T3, with the parameters (80Hz,150ms, 60 mA).Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
75603030|NCT05938660|Other|acupressure at Sanyinjiao point|When pressing Sanyinjiao point, the subject should be in a comfortable sitting position. Press the acupoints with the thumb until the subject feels soreness, then press and knead in a circle according to the strength acceptable to the subject. Press and knead once a second, and rest for 1 second every 5 seconds are one cycle, the speed is 10 cycles/minute, and it lasts for five minutes.
75603031|NCT05938569|Device|Hair restoration|The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
75603032|NCT05938504|Other|ONS_320275|Subjects will consume two packs (165ml/pack) of placebo ONS (ONS_320275) orally daily at any time of day.
76064765|NCT00194896|Drug|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
76064766|NCT00194896|Drug|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
75451828|NCT01732601|Behavioral|Intensive Outpatient CBT|Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.
76064767|NCT00197392|Device|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
75451829|NCT01732601|Behavioral|Standard Care|Treatment at step-down facilities
76064768|NCT00197392|Device|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
76064769|NCT04348474|Drug|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
75451830|NCT01732614|Procedure|Topcon Endpoint Management laser|
76064770|NCT04348474|Drug|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
75451831|NCT01732653|Other|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
75451832|NCT01732653|Other|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
75451833|NCT01732666|Drug|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
75451834|NCT01732666|Drug|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
75451835|NCT01732666|Drug|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
75451836|NCT01732679|Other|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
75747512|NCT00882635|Drug|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance < 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
75603033|NCT05938504|Other|ONS_211567|Subjects will consume two packs (165ml/pack) of test ONS (ONS_211567) orally daily at any time of day.
75603034|NCT05938491|Diagnostic Test|OCT and OCT-A|OCT and OCT angiography for the macula
75603035|NCT05938478|Drug|Tralokinumab|This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.
75747513|NCT00882635|Drug|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
75747514|NCT02543021|Device|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
75747515|NCT02543021|Procedure|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
76064771|NCT04318834|Other|Tumour and germline molecular profiling|Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
76064772|NCT04290364|Other|Palliative care|The patients in the prospective part of the study are seen on home-visits and offered standard palliative care within three weeks of diagnosis.
76064773|NCT04290286|Other|i2TransHealth|i2TransHealth: online intervention for TGD people
76064774|NCT00107536|Drug|lapatinib ditosylate|
75747516|NCT02541539|Dietary Supplement|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
75747517|NCT02541539|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
75747518|NCT00886847|Procedure|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
75747519|NCT00888641|Procedure|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
75747520|NCT00609947|Device|Endeavor Zotarolimus-Eluting Coronary Stent|
76064775|NCT00107536|Other|laboratory biomarker analysis|Correlative studies
75747521|NCT00609869|Drug|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
75747522|NCT00609869|Drug|Rituximab|Rituximab was administered at 375 mg/m^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
75747523|NCT00529568|Drug|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
75451837|NCT01732705|Behavioral|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
75451838|NCT01732731|Other|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
75747524|NCT00529568|Drug|placebo|double-blind matched placebo control daily oral administration
75747525|NCT00888719|Drug|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
75747526|NCT00888719|Drug|placebo|"Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks"
75747527|NCT00888719|Drug|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
76064776|NCT04389190|Other|Fluoroscopy settings for image acquisition|X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
76064777|NCT00108550|Drug|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
76064778|NCT00108550|Drug|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
75603036|NCT05938426|Device|ET-101|Patients have training sessions twice a day. Each training session takes about 10~25 minutes. Cognitive training programs include meditation, cognitive training, and cognitive testing.
75603037|NCT05938426|Device|Sham Device|Sham device has only cognitive function test excluding training programs.
75603038|NCT05938400|Device|Polyvinylsiloxane impression with different techniques|One step impression technique will be compared with the standard two step technique
75603039|NCT05938374|Drug|Fluzoparib|One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week).
76064779|NCT00109876|Procedure|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
76064780|NCT02093962|Drug|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
76064781|NCT02093962|Drug|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
76064782|NCT02094118|Biological|Point-of-care washed red blood cell transfusion.|
75603040|NCT05938374|Radiation|Preoperative moderately fractionated radiotherapay|Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr).
76064783|NCT02094118|Biological|Standard of care red blood cell transfusion.|
76064784|NCT01897636|Procedure|EUS-guided fine-needle injection of DCs vaccinations|
76064785|NCT00200902|Drug|Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
76064786|NCT00200902|Other|Placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
76064787|NCT00200902|Behavioral|Interpersonal Clinical Interaction (ICI)|Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
75603041|NCT05938361|Other|Psoriasis clinical assessments|Global evaluation of psoriasis and specific evaluation by areas
75603042|NCT05938361|Other|Quality of life evaluation|DLQI questionnaire at each visit
75603043|NCT05938361|Other|Satisfaction assessment|Visual analogic scale at W16, W28, W52
76064788|NCT00201448|Biological|Hepatitis A Vaccine|Single dose give IM
75603044|NCT05938361|Other|Pruritus evaluation|Visual analogic scale at each visit
75603045|NCT05938348|Behavioral|angiopuncture|we conducted acupuncture on perforators by using acupuncture needles.
75603046|NCT05938335|Genetic|sequencing of a panel of 14 genes in leptin melanocortin pathway|sequencing (NGS) of a panel of 14 genes in leptin melanocortin pathway in french children with severe obesity
76064789|NCT00201448|Biological|Towne CMV Vaccine|Single dose given subcutaneously
76064790|NCT00201760|Drug|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
76064791|NCT00201760|Drug|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
76064792|NCT00201760|Drug|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
76064793|NCT00201838|Drug|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
76064794|NCT00201838|Drug|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
76064795|NCT00040846|Biological|alemtuzumab|Given IV
76064796|NCT00040846|Drug|fludarabine phosphate|Given IV
76064797|NCT00040846|Radiation|total-body irradiation|Undergo TBI
76064798|NCT00040846|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
76064799|NCT00040846|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
76064800|NCT00040846|Drug|mycophenolate mofetil|Given PO
75603047|NCT05938322|Other|Ketogenic Diet|"In the group of intervention is prescribed a ketogenic diet plan characterized by the following composition: carbohydrates < 30g/day, 1.2g-1.5g protein/kg/day and lipids > 65%.~This diet will be followed during the period of treatment with chemo-radiotherapy (5 weeks)"
75603048|NCT05938322|Other|Standard Diet|The control group (SD) will follow the Mediterranean diet pattern based on ESPEN guidelines (carbohydrates 45-55%, protein 15-20% and lipids 30-35%).
75603049|NCT05938257|Procedure|TMJ discopexy|Arthroscopic versus open TMJ discopexy
75603050|NCT05938231|Device|Gastric Bypass Stent System|Subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy. Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months.
75603051|NCT05938231|Behavioral|Dietary Intervention|The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.
75603052|NCT05938218|Device|Intervention|Virtual Reality assisted information Patients in the intervention group receive a VR instructional application lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures.
75603053|NCT05938205|Dietary Supplement|AA-1|low dose aminoacids
75603054|NCT05938205|Dietary Supplement|AA-2|high dose aminoacids
75603055|NCT05938205|Behavioral|Placebo|Nutritional Placebo
75603056|NCT05938205|Behavioral|Exe-H|high intensity physical exercise
75603057|NCT05938192|Procedure|LASER surgery|Patients will have laser surgery for managing HPV-related lesions
76064801|NCT00040846|Drug|cyclosporine|Given IV or PO
76064802|NCT00041938|Drug|aspirin|325 mg per day
76064803|NCT00041938|Drug|Warfarin|INR 2.5-3.0; target INR 2.75
76064804|NCT00202930|Drug|anti-CD20 (Rituximab)|4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
76064805|NCT00044044|Drug|Lurasidone 20 mg|Lurasidone 20mg/day tablets
76064806|NCT00044044|Drug|Lurasidone 40mg|Lurasidone 40mg/day tablets
75451839|NCT01732744|Other|Physiological solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
76064807|NCT00044044|Drug|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
76064808|NCT00044044|Drug|Haloperidol 10mg|Haloperidol 10mg/day tablets
76064809|NCT00044044|Drug|Placebo|Matching Placebo to Lurasdione and Haloperidol
76064810|NCT00112918|Biological|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
76064811|NCT00112918|Drug|Capecitabine|Film-coated tablets
76064812|NCT00112918|Drug|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
76064813|NCT00112918|Drug|Leucovorin calcium|Administered as a 200 mg/m^2 infusion over 2 hours.
76064814|NCT00112918|Drug|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
76064815|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
76064816|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
76064817|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
75451840|NCT01732744|Other|Sodium hypochlorite|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
75451841|NCT01732744|Other|Alkaline Peroxide|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
75603058|NCT05938153|Other|observational physical tests|"Geriatric Locomotive Function Scale:~This scale consists of a questionnaire of 25 items that can be easily understood by the elderly and each item is graded between 0 and 4 points. The total score is the result of the sum of all items ranging from 0 to 100; the higher the score, the higher the physical impairment of the elderly, with a score of 16 being the cut-off point for locomotive syndrome. The GLFS-25 includes 4 questions about pain, 16 questions about activities of daily living, 3 questions about social performance and 2 questions about mental health status to assess geriatric individuals. Turkish validity and reliability of the questionnaire was conducted by Sadikoglu."
75603059|NCT05938140|Drug|Nirmatrelvir/ritonavir|Paxlovid is an oral drug for the treatment of COVID-19. It is suitable for adults with mild to moderate COVID-19 patients with high risk factors for progression to severe disease.
75603060|NCT05937997|Procedure|high intensity physiotherapy|high intensity exercises for 3 weeks inpatient rehabilitation
75603061|NCT05937997|Procedure|moderate intensity physiotherapy|moderate intensity exercises for 3 weeks inpatient rehabilitation
75603062|NCT05937997|Procedure|low intensity physiotherapy|low intensity exercises for 3 weeks inpatient rehabilitation
76064818|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
76064819|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
76064820|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
76064821|NCT00205504|Drug|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
76064822|NCT00205660|Other|Stayers|Participants remain on their current antipsychotic.
76064823|NCT00205660|Other|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
76064824|NCT00113230|Drug|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
76064825|NCT00113230|Drug|Capecitabine|900 mg/m^2 by mouth twice a day during days of radiation for all five weeks of therapy.
76064826|NCT00113230|Radiation|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
76064827|NCT00049036|Biological|rituximab|Given IV
76064828|NCT00049036|Drug|etoposide|Given IV
76064829|NCT00049036|Drug|doxorubicin hydrochloride|Given IV
76064830|NCT00049036|Drug|vincristine sulfate|Given IV
76064831|NCT00049036|Drug|prednisone|Given orally
76064832|NCT00049036|Drug|cyclophosphamide|Given IV
76064833|NCT00049036|Other|laboratory biomarker analysis|Correlative studies
76064834|NCT00212446|Device|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
76064835|NCT00049504|Drug|cyclophosphamide|Given IV
75603063|NCT05937984|Device|Active Controlled Transcranial Magnetic Stimulation (cTMS)|cTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of cTMS requires 9 minutes in total.
75603064|NCT05937984|Device|Sham Controlled Transcranial Magnetic Stimulation (cTMS)|A sham coil will be utilized for the sham cTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham cTMS will be identical to Active cTMS.
75747528|NCT04037111|Device|Transcutaneous electrical vagus nerve stimulation|The patient received active VNS and escitalopram oxalate tablets for 2 months.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
75747529|NCT04037111|Device|Sham vagus nerve stimulation|The patient received sham VNS.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
75747530|NCT04037111|Drug|drug treatment|Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg
75747531|NCT00886925|Drug|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
75898123|NCT02253420|Drug|Copanlisib (BAY80-6946)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 60mg (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose 60mg (based on Part 1 data)~Part 1 & Part 2~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
75898124|NCT02253420|Drug|Itraconazole|Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning
75898125|NCT02253420|Drug|Rifampin|Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning
75898126|NCT02253420|Drug|Copanlisib (BAY80-6946)|"Cycle 1 Day 1: Single i.v. dose 60mg Cycle 1 Day 15: Single i.v. dose 60mg~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
76064836|NCT00049504|Drug|fludarabine phosphate|Given IV
76064837|NCT00049504|Drug|tacrolimus|Given IV or orally
76064838|NCT00049504|Drug|mycophenolate mofetil|Given orally
76064839|NCT00049504|Genetic|polymerase chain reaction|Correlative studies
76064840|NCT00049504|Genetic|fluorescence in situ hybridization|Correlative studies
76064841|NCT00049504|Genetic|polymorphism analysis|Correlative studies
76064842|NCT00049504|Genetic|gene expression analysis|Correlative studies
76064843|NCT00049504|Radiation|total-body irradiation|Undergo total-body irradiation
76064844|NCT00049504|Procedure|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
76064845|NCT00049504|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
76064846|NCT00050986|Drug|Temozolomide|Starting Dose Level: 100 mg/m^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
76064847|NCT00050986|Drug|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
76064848|NCT00214786|Biological|Islet cell transplantation|Allogenic islet transplantation
75451842|NCT01732744|Other|Castor bean solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
75451843|NCT01732848|Drug|BMS-986094/INX-08189|
75451844|NCT01732848|Drug|Placebo matching BMS-986094/INX-08189|
75451845|NCT01732861|Drug|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
75451846|NCT01732861|Drug|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
75451847|NCT01732887|Other|Cognitive fitness training|"Computer-based training of basic cognitive functions. It has activities under two headings,~General training applications~Memory training applications~Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval."
75451848|NCT01732900|Other|Morphology|Embryos selected for transfer will be based upon morphology alone.
75451849|NCT01732900|Other|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
75603065|NCT05937919|Drug|Intravenous injection of 68Ga-PMD22|68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
76064849|NCT00118144|Drug|bortezomib|Given IV
75603066|NCT05937906|Drug|Phase I - Mirdametinib - Level 1|Mirdametinib 4 mg twice/day for 7 days per cycle
75603067|NCT05937906|Drug|Phase II - Mirdametinib|For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm
75747532|NCT00886925|Drug|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
75747533|NCT02542709|Device|Active repetitive Transcranial Magnetic Stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
75603068|NCT05937906|Drug|Phase I - Mirdametinib - Level 2|Mirdametinib 4 mg twice/day for 14 days per cycle
75603069|NCT05937906|Drug|Phase I - Mirdametinib - Level 3|Mirdametinib 6 mg twice/day for 7 days per cycle
75603070|NCT05937906|Drug|Phase I - Mirdametinib - Level 4|Mirdametinib 6 mg twice/day for 14 days per cycle
75603071|NCT05937880|Drug|Leflunomide|When patients appeared with rashes and treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rashes do not subside or fresh rash still appears, and it frequently repeats more than 3 times during hospitalization. Leflunomide would be administered
75747534|NCT02542709|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
75898127|NCT03523364|Device|dental restorations|partial or complete ceramic restorations bonded to dental tissues after WAB and total etching or after total etching
75451850|NCT01732965|Other|Phototherapy|
75451851|NCT01732965|Other|Phototherapy and Photochemotherapy|
76064850|NCT00118378|Drug|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
76064851|NCT00118378|Drug|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
75451852|NCT01732978|Behavioral|Crying record|"Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.~Listening tests:~Tests will be conducted playbacks with the father and mother separately, and with a staff"
75603072|NCT05937867|Drug|HS-10353 Capsules 30 mg, Oral, QN for 14 days|HS-10353 Capsules 30 mg
75603073|NCT05937867|Drug|HS-10353 Capsules 50 mg, Oral, QN for 14 days|HS-10353 Capsules 50 mg
75451853|NCT01732991|Device|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
75451854|NCT01733004|Drug|MM-141|
75451855|NCT01733017|Behavioral|Sodium reduction|Teaching and skill building to reduce dietary sodium
75603074|NCT05937867|Drug|HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.|Placebo
75603075|NCT05937867|Drug|HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days|Placebo
75747535|NCT00888797|Drug|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
75747536|NCT00888875|Device|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
75603076|NCT05937841|Drug|Compound 21|"AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response~Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response"
75603077|NCT05937828|Other|data collection|description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.
75603078|NCT05937815|Procedure|Sample collection|collection of sputum, stool and blood samples at baseline, 6 months and 1 year after baseline
75747537|NCT00888875|Device|ILMA|Insertion after Induction. Insertion of tracheal tube over device
75747538|NCT00884663|Drug|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
75747539|NCT00884663|Drug|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
75747540|NCT00884663|Drug|placebo|placebo tablets and capsules
75747541|NCT02542553|Procedure|Bilateral BAL|
75747542|NCT00887003|Drug|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
75898128|NCT04483180|Other|Comparison of sweetener blends in liquid form (cross-over study)|The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast
75898129|NCT01566396|Device|A3F|A3F fractional RF treatments for facial wrinkles
75898130|NCT02289404|Drug|NVP-1203|Oral
75898131|NCT02289404|Drug|NVP-1203|Oral
76064852|NCT00217438|Drug|melphalan|Given IV
76064853|NCT00217438|Drug|amifostine trihydrate|Given IV
76064854|NCT00217438|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
76064855|NCT00217438|Genetic|fluorescence in situ hybridization|Correlative study
76064856|NCT00217438|Procedure|bone marrow ablation with stem cell support|Undergo transplant
76064857|NCT04480450|Drug|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.
76064858|NCT00217594|Drug|Alemtuzumab (Campath)|
76064859|NCT00118534|Behavioral|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
76064860|NCT00118534|Behavioral|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
76064861|NCT00052078|Drug|Sertraline (SRT)|Participants were treated with sertraline.
75451856|NCT01733017|Dietary Supplement|omega 3 and lycopene supplements|omega-3 fatty acid supplements and juices containing lycopene
75451857|NCT01733017|Dietary Supplement|rice bran oil capsules|placebo capsules
75451858|NCT01733017|Behavioral|Generic dietary feedback from|Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
75451859|NCT01733030|Drug|Seromycin|250 mg versus 500 mg versus placebo effects on conditioned fear generalization
75451860|NCT01733030|Drug|Seromycin|
75603079|NCT05937802|Dietary Supplement|Osmotin|Oral administration for 6 months of 7 capsules per day (4 in the morning and 3 in the evening) for a daily dosage of 5 grams.
75603080|NCT05937789|Dietary Supplement|Vitamin D|1ampoule (72000IU) Q3H on ICU day 3 Number of Cycles: until progression or subject develops severe diarrhea (greater than 1000 grams) associated with vitamin D supplementation for two consecutive days.
75603081|NCT05937789|Dietary Supplement|Medium Chain Triglycerides|1ampoule Q3H on ICU day 3 Number of Cycles: until progression or subject develops severe diarrhea (greater than 1000 grams) associated with vitamin D supplementation for two consecutive days.
75603082|NCT05937763|Other|Staffing model|Staffing the hospitals emergency department offload zone with a PCP or RN or current workflow.
75603083|NCT05937711|Other|Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG|"PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes~Duloxetine 30 mg p.o 1X1 (daily)"
75603084|NCT05937711|Drug|Duloxetine 30 MG|Duloxetine 30 mg p.o 1X1 (daily)
75747543|NCT00887003|Drug|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
75747544|NCT00887003|Drug|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
75747545|NCT00887003|Drug|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
75747546|NCT00887003|Drug|Depo-Medrol|80mg Depo-Medrol
75747547|NCT00887081|Drug|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
75747548|NCT03998696|Drug|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
75747549|NCT03998696|Drug|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
75747550|NCT00888953|Other|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
75747551|NCT00888953|Other|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
75747552|NCT04867460|Procedure|Ultrasound guided venous access|Access of the axillary vein using ultrasound guidance.
75747553|NCT00889031|Other|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
76064862|NCT00052078|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants received CBT.
76064863|NCT00052078|Drug|Placebo|Participants were treated with a placebo pill.
76064864|NCT05820646|Other|Boswellia Sacra|"Boswellia Sacra used as an intracanal medicament for 3 days~Boswellia Sacra used as an intracanal medicament for 7 days"
75451861|NCT01733043|Drug|Dexmedetomidine|
75451862|NCT01733043|Drug|Placebo|
75451863|NCT01733095|Drug|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
75451864|NCT01733108|Drug|Glyburide|One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.
75451865|NCT01733108|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
76064865|NCT05820633|Radiation|Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)|Assess early and late genito-urinary (GU) toxicities induced assessed via the International Prostate Symptom Score (I-PSS) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
75451866|NCT01733134|Drug|Tolvaptan|Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
75451867|NCT01733134|Drug|placebo|Patient in the placebo group will receive tolvaptan in addition to standard therapy
75451868|NCT01733173|Procedure|MRI with DTI and fMRI|When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
75451869|NCT01733199|Other|questionnaires|Summons of patients and filling questionnaire.
75603085|NCT05937633|Other|Transformational Education Programme|"An evidence based targeted transformational leadership programme is designed to provide charge nurses an opportunity to develop transformational leadership knowledge and skill.~The programme includes a 2-day activity based educational training. A prereading booklet will be given prior to the educational activity aimed at enhancing the engagement of the participants. The educational programme comprises of the following contents: Concept of leadership and work engagement, transactional and transformational leadership styles, advantages, and disadvantages of transformational leaders. qualities of transformational leaders, 5- Practices of exemplary leadership practice, the 10 commitments of transformational leadership and developing transformational leadership skills."
75898132|NCT05576766|Procedure|Routine care|"Routine information provided before surgery.~No nutritional therapy.~No aerobic exercise.~No pelvic floor muscle training.~No psychiatrist intervention.~Bowel preparation with oral cathartic agent.~Fasting for over 8 hours; no oral carbohydrate solution (OCS) loading before surgery.~Hypothermia prevention not emphasized.~General anesthesia; regional block not emphasized.~Routine blood pressure management.~Mobilization from postoperative day 1.~Start oral feeding from postoperative day 1.~Patient-controlled analgesia with opioids.~Thromboembolism prophylaxis with low-molecular-weight heparin (LMWH).~Routine pelvic drainage tube removal (usually at postoperative day 4).~Routine urinary catheterization removal (usually at postoperative day 14)."
75898133|NCT05576766|Procedure|ERAS management pathway|"Patient consultation and education before surgery.~Nutritional intervention for patients whose BMI<18.5 or BMI>24 kg/m2.~Aerobic exercise for 2 weeks before surgery.~Pelvic floor muscle training for 2 weeks before surgery.~Psychiatrist intervention for patients with severe depression and anxiety.~No bowel preparation before surgery.~Provide oral carbohydrate solution 2 hours before surgery.~Hypothermia prevention.~General anesthesia combined with regional block.~Goal-directed fluid infusion and targeted blood pressure management.~Early mobilization.~Early oral feeding.~Multimodal analgesia, including opioids and non-steroid anti-inflammatory drugs.~Thromboembolism prophylaxis with low-molecular-weight heparin; rivaroxaban for high-risk patients.~Early pelvic drainage tube removal (at postoperative day 2) unless contraindicated.~Early urinary catheterization removal (at postoperative day 7) unless contraindicated."
75451870|NCT01733290|Drug|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
75898134|NCT04171804|Device|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
75747554|NCT05710952|Device|Review by Modjaw|A review by Modjaw's will be done before the braces treatment and after.
75898135|NCT03521648|Procedure|PAE|Prostatic artery embolization
75898136|NCT03521648|Procedure|TURP|Transurethral resection of the prostate
75898137|NCT03521648|Procedure|Other|Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
75747555|NCT04017923|Diagnostic Test|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
75898138|NCT02253732|Behavioral|3 months exercise intervention program|3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength & aerobic exercises
75898139|NCT02028364|Drug|Everolimus|10mg orally daily
75898140|NCT02028364|Drug|Exemestane|25mg orally daily
75898141|NCT03547284|Drug|sugarless gum|81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours
76025264|NCT02682823|Drug|Tocilizumab|Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
75451871|NCT01733290|Drug|Normal saline instillation|Normal saline instillation
75451872|NCT01733303|Behavioral|personalized core muscle training program|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
75451873|NCT01733342|Device|Celsite chemoport implantation|Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
75451874|NCT01733342|Procedure|local anesthesia|chemoport implantation will be done under local anesthesia using lidocaine.
75451875|NCT01733342|Device|Humanport chemoport implantation|Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
75747556|NCT02542787|Drug|VSN16R|Small molecule
75747557|NCT02542787|Other|Placebo|dummy tablet
75747558|NCT04847882|Behavioral|Questionnaire|Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
75747559|NCT05120648|Behavioral|Biofeedback|We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
76064866|NCT05820633|Radiation|"Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite (EPIC-26):"|Assess early and late genito-urinary (GU) and gastro-intestinal (GI) toxicities induced and quality of life assessed via expanded prostate cancer index composite (EPIC-26) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
76064867|NCT05820633|Radiation|Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM)|Assess early and late sexual health in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
75603086|NCT05937607|Behavioral|Hand massage|It is reported in the literature that the application should last 5-10 minutes on average to reduce acute pain, state anxiety, and provide physiological positive changes and relaxation in individuals during the procedure
76064868|NCT05820633|Radiation|Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE)|Assess early and late toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
75603087|NCT05937594|Genetic|Buccal swab saliva for further genetic testing|Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
76064869|NCT05820633|Radiation|Report and compare the biochemical disease free survival (bDFS)|Assess the 5 and 10 years biochemical disease-free survival (bDFS) in the UHF group and compare them for non-inferiority to those of the control group.
76064870|NCT05820633|Radiation|Report and compare the disease free survival (DFS)|Assess the 5 and 10 years disease-free survival (DFS) in the UHF group and compare them for non-inferiority to those of the control group.
75603088|NCT05937568|Drug|Imetelstat|Participants will receive imetelstat, intravenously (IV) by infusion every 4 weeks.
75603089|NCT05937529|Other|Cream containing madecassoside and 5 % panthenol|Immediately after daylight PDT, Cicaplast is administrated as post treatment. The patients are instructed to apply the cream twice daily for 14 days.
75603090|NCT05937529|Other|Daylight PDT|Daylight PDT performed with 2 hours of artifical indoor light.
75747560|NCT03999086|Procedure|Intervention|We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
75747561|NCT03999086|Other|Control Group|Laboratory analysis to guide transfusion
75747562|NCT00611975|Drug|Fluoxetine|Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
76064871|NCT05820633|Radiation|Report and compare the metastase free survival (MFS)|Assess the 5 and 10 years metastasis-free survival (MFS) in the UHF group and compare them for non-inferiority to those of the control group.
75451876|NCT01733355|Radiation|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
75451877|NCT01733394|Drug|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
75747563|NCT00611975|Drug|Bupropion|Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
75747564|NCT05695352|Drug|Levonorgestrel 1.5mg|oral synthetic progesterone agonist
76064872|NCT05820633|Radiation|Report and compare the overall survival (OS)|Assess the 5 and 10 years overall survival (OS) in the UHF group and compare them for non-inferiority to those of the control group.
75451878|NCT01733394|Drug|lamotrigine|
75451879|NCT01733446|Other|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
75603091|NCT05937516|Device|Nasotracheal intubation with conventionally|Nasotracheal intubation will be applied conventionally to patients in this group.
76064873|NCT05820607|Biological|Microbiome, metabolome, transcriptome, genome|Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome
76064874|NCT05820542|Other|miller laryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
75603092|NCT05937516|Device|Nasotracheal intubation with angled ETT using guidewire|a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
75603093|NCT05937490|Drug|Enantone|administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle.
75898142|NCT02290652|Other|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.~Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.~Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
75603094|NCT05937490|Drug|Dienogest 2 MG (milligram)|Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle).
75747565|NCT05695352|Drug|Meloxicam 15 mg|Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
75747566|NCT05695352|Other|Placebo|Each tablet contains Calcium Carbonate 1000 mg
75747567|NCT00889109|Other|Three dimensional unrestricted arm movements|The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
75747568|NCT04895306|Drug|Testosterone Cypionate|Weekly intramuscular administration of testosterone at a dose of 3 mg
75451880|NCT01733459|Drug|DLBS3233|1 DLBS3233 capsule 100 mg once daily for 6 months
75603095|NCT05937490|Drug|Enantone|COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).
75747569|NCT04895306|Drug|Placebo|Weekly intramuscular administration of Placebo
75747570|NCT02542241|Drug|Sodium Chloride [3%]|Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
75747571|NCT02542241|Drug|Sodium Chloride [0.9%]|Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
76064875|NCT05820542|Other|McGrath MAC videolaryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
76064876|NCT05820529|Procedure|adenotonsillectomy|removal of adenoid,tonsil in one session
76064877|NCT05820529|Procedure|adenoidectomy|removal of adenoid
75451881|NCT01733459|Drug|Metformin XR|1 Metformin XR caplet 750 mg twice daily for 6 months
76064878|NCT05820529|Procedure|tonsillectomy|removal of tonsil
76064879|NCT05820516|Device|TricValve implantation|TricValve implantation
75451882|NCT01733459|Drug|Placebo caplet of Metformin XR|1 placebo caplet of Metformin XR twice daily for 6 months
75451883|NCT01733459|Drug|Placebo capsule of DLBS3233|1 placebo capsule of DLBS3233 once daily for 6 months
75451884|NCT01733485|Drug|Aspirin|500 mg/8 h for 5 days
75451885|NCT01733485|Drug|Indomethacin|25 mg/8 h for 5 days
75451886|NCT01733524|Behavioral|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
75451887|NCT01733524|Behavioral|Picture of a fish|Participants will receive a picture of a betta fish.
75451888|NCT01733537|Other|Free reflective, fluorescent vest|Motorcycle taxi drivers in the intervention arm will receive a free reflective, fluorescent vest
75451889|NCT01733537|Behavioral|Education|Both arms will receive brief, basic education about recommended measures to increase their visibility
75898143|NCT02290652|Other|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.~Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).~Maximum retrospective collection of data 12 months."
75451890|NCT01733550|Device|Home iCare (study nurse)|the intraocular pressure is measured by iCare performed by the study nurse
75898144|NCT02897115|Biological|Adalimumab|Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
75898145|NCT02897115|Other|Non-steroidal Anti-inflammatory Drugs (NSAIDs)|ASAS recommended NSAID doses to treat axial spondyloarthritis.
75898146|NCT05576688|Other|Balance|Balance was evaluated with Berg Balance Scale (BBS), Functional Reach Test (FRT), One Leg Stance Test (OLST) and Five-Repeat Sit-and-Stand Test (5STS). BBS consists of 14 functional tasks of increasing difficulty, each scored on a scale ranging from 0 to 4. The maximum possible score is 56, indicating no identifiable balance difficulties. FRT measures the maximum distance that participants can reach forward with their dominant arm raised to 90 degrees without moving their feet, which were positioned 10 cm apart. OLST measures the time one is able to stand on one lower limb without support. The test was repeated for both sides. 5STS assesses the time it takes to get up and sit from the chair five times. Measurements were repeated 3 times and the average duration was calculated as a patient score.
75898147|NCT05576688|Other|Trunk control|Trunk control was evaluated with Trunk Impairment Scale (TIS).TIS evaluates static sitting balance, dynamic sitting balance, and trunk coordination on a scale from 0 to 23 points, a higher score indicating a better performance.
75451891|NCT01733550|Device|goldmann applanation tonometry|the intraocular pressure is measured by goldmann applanation tonometry
75451892|NCT01733550|Device|home iCare (by patient)|the intraocular pressure is measured by the iCare performed by the patient him self
75603096|NCT05937490|Drug|long GnRH agonist or flexible GnRH antagonist protocol.|During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
75451893|NCT01733563|Procedure|Soft drink consumption|
75603097|NCT05937464|Other|Exoskeleton ExoAthlet group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with exoskeleton ExoAthlet (ExoAtlet 1 model/2019, Russia). Participants were assessed at baseline and post-intervention.
75603098|NCT05937464|Other|Lokomat Free-D group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
75603099|NCT05937438|Drug|Immune Checkpoint Inhibitors|Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
75603100|NCT05937425|Other|LungCaNN|The needs of the patients included in the study will be determined with the supportive care needs scale. A training booklet will be given to the patients in the intervention group and they will be informed about the existing or newly formed unsupported care needs, the evaluation of their frequency and severity, and the ability of the patients to call the navigator nurse 24/7 or send an SMS. For interventions that can be applied in line with evidence-based guidelines for unsupported care needs with patients included in the intervention group every week for 12 weeks, a face-to-face navigation will be made by the navigator nurse over the phone and once a month.
75603101|NCT05937412|Other|Alcohol sterilization|Sterilizing skin using alcohol
75451894|NCT01733576|Device|HD-tDCS|
75451895|NCT01733589|Drug|Recombinant human endostatin|Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
75603102|NCT05937412|Other|Honey sterilization|Sterilizing skin using honey
75451896|NCT01733589|Drug|Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles|
75451897|NCT01733589|Drug|cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles|
75451898|NCT01733589|Other|laboratory biomarker analysis|
75451899|NCT01733589|Other|CT perfusion imaging|
75451900|NCT01733602|Device|transcranial direct current stimulation|
75603103|NCT05937360|Other|cross-sectional community based study|Participants (women between the ages of 18 and 45 years) are selected randomly throughout various regions of Trinidad. Every 10th house from the selected regions would be assessed.
75603104|NCT05937347|Behavioral|TAU + UP4H|Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).
75603105|NCT05937347|Behavioral|TAU + M4H|Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).
75603106|NCT05937347|Behavioral|TAU + CT|Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).
75747572|NCT04037891|Drug|rVA576|"19 Patients with moderate to severe AKC. the study includes two parts: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.~Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial."
75898148|NCT05576688|Other|Gait|Gait was evaluated with Dynamic Gait Index (DGI). DGI has 8 items: walking, walking while changing speed, walking while turning the head horizontally and vertically, walking with pivot turn, walking over and around obstacles, and stair climbing. The scoring of the DGI is based on a 4-point scale ranging from 0 to 3, with 0 indicating severe impairment and 3 indicating normal ability. The best performance total score is 24. A low composite DGI score indicates greater impairment in gait.
75898149|NCT05576688|Other|Functional mobility|Functional mobility was evaluated with Timed Up and Go Test (TUG). TUG is a test of the time required for an individual to stand up from a chair with armrests, walk 3 m, turn, walk back to the chair, and sit down. The stopwatch timing started when the participant's bottom left the chair and ended when the bottom made contact with the chair after the walk.
75898150|NCT05576688|Other|Fear of falling|Fear of falling was evaluated with the Falls Efficacy Scale-International (FES-I). FES-I was used to assess the level of concern about falls during 16 activities of daily living, ranging from basic to more demanding activities including social activities that may contribute to quality of life. It was administered as a self-report questionnaire.
75603107|NCT05937347|Other|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to children with ADHD.
75898151|NCT02290730|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
75451901|NCT01733654|Biological|RO4995819|The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
75898152|NCT03062878|Other|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
75898153|NCT03062878|Other|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
75898154|NCT03062878|Other|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
75603108|NCT05937334|Diagnostic Test|Diagnostic Test: lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma|lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma were performed. All interventions was made according to routine diagnosis and treatment.
75603109|NCT05937243|Behavioral|Base self-help CBT program|"The self-help app will deliver 12 modules that will be based on Chris Fairburn's Overcoming Binge Eating self-help book, the most widely used self-help resource for binge eating over 12 weeks. Treatment modules will aim to 1) provide psychoeducation on maintenance factors for binge eating, 2) teach CBT skills designed to interrupt these maintenance factors, and 3) coach participant to set personalized goals each week. Modules will be completed in succession over the course of 12-weeks and a new module will be made open each week. In addition, participants will track their eating and eating disorder behaviors using the self-help app."
75747573|NCT04037891|Other|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
75747574|NCT00887237|Device|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
75747575|NCT00887237|Device|Conventional cardiac resynchronization|Conventional cardiac resynchronization
75747576|NCT05007158|Other|procalcitonin blood test|blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
75898155|NCT03062878|Other|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
75451902|NCT01733667|Device|MediENT|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
75451903|NCT01733667|Device|MeroPack|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
76064880|NCT05820438|Device|Electromyography|"Disposable bipolar surface electrodes will be used.~The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres.Doing so the position of the electrodes results as follows:~Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient."
75603110|NCT05937243|Behavioral|Just-in-time, adaptive intervention (JITAIs) system|When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.
75451904|NCT01733706|Device|No nicotine electronic cigarette|"The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine."
75451905|NCT01733706|Other|Standard counseling|standard counseling
75747577|NCT02541695|Biological|E. coli strain E1392-75-2A|"At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
75747578|NCT00889343|Drug|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
75747579|NCT00889343|Drug|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
75747580|NCT00889343|Drug|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
75747581|NCT00889343|Drug|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
75898156|NCT03548142|Behavioral|provision of relevant information|caregivers are provided with brochure that informs about end-of-life issues for persons with advanced dementia
75898157|NCT02290808|Behavioral|Theory-based group|Workbooks and mini-counselling sessions will be provided to participants in this group.
75898158|NCT03818373|Procedure|polysomnography|Sleep examination strictly non-invasive with skin sensors. This exploration would allow for the detection of respiratory sleep disorders and consider of appropriate management for patients.
75898159|NCT01452802|Device|HM II (HeartMate II LVAD)|The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
75898160|NCT01452802|Drug|OMM (Optimal Medical Management)|Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
75898161|NCT02289482|Drug|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
75898162|NCT02289482|Drug|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
75451906|NCT01733719|Procedure|ER plus RFA|
75451907|NCT01733719|Procedure|ER plus APC|2 litres/minute, 70 watts
75451908|NCT01733771|Other|CAM treatments|CAM treatments last 10-30 minutes
75451909|NCT01733784|Other|Induced central apneas|
75451910|NCT01733797|Device|Wooden spatula|Lollipop sticks placed between incisors
75451911|NCT01733797|Device|Therabite|Hand held device placed in mouth that exercises the jaw
75747582|NCT00889343|Drug|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
75898163|NCT02289482|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
75898164|NCT02289482|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
76064881|NCT05820412|Other|Intensive interdisciplinary therapy|Intensive interdisciplinary therapy includes an intense burst of physical, occupational, and/or speech therapy with high intensity and frequency in a duration (e.g. 3-6 hours/day, 3-5 days/week for 4 weeks)
75451912|NCT01733810|Other|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
75451913|NCT01733823|Radiation|76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole|
75451914|NCT01733836|Drug|Metformin|
75451915|NCT01733836|Drug|placebo|
75451916|NCT01733849|Other|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
75898165|NCT03645213|Device|Virtual Reality Box|Virtual Reality box, a head-mounted display with stereo earphones transmits the cartoon image onto screens in front of the child's eyes. It was showed on Samsung Galaxy Note5 phone and Samsung Gear VR box /SM-R323N.
75451917|NCT01733849|Other|Data collection|Log books
75451918|NCT01733862|Other|Data collection|"Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016."
75451919|NCT01733875|Drug|CC-220 0.03 mg|A single dose of CC-220 0.03 mg will be administered orally once a day.
75451920|NCT01733875|Drug|CC-220 0.1 mg|A single dose of CC-220 0.1 mg will be administered orally once a day.
75747583|NCT00884819|Drug|Fenofibrate|fenofibrate 200 mg daily for 6-months
75898166|NCT03645213|Device|Tablet Computer|The tablet computer is a device that children watch on a 7-inch screen.
76064882|NCT05820399|Dietary Supplement|Organic Guayusa Extract|Supplementation: Participants will supplement daily with organic guayusa extract, which is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (~20% caffeine, 30% chlorogenic acids, 5% catechins) during 6 weeks of high intensity exercise training. Investigators and participants will be blinded to condition.
75451921|NCT01733875|Drug|CC-220 0.3 mg|A single dose of CC-220 0.3 mg will be administered orally once a day.
75451922|NCT01733875|Drug|CC-220 1 mg|A single dose of CC-220 1 mg will be administered orally once a day.
75451923|NCT01733875|Drug|CC-220 2 mg|A single dose of CC-220 2 mg will be administered orally once a day.
75451924|NCT01733875|Drug|Placebo|A single dose of placebo will be administered orally once a day.
75451925|NCT01733875|Drug|CC-220|CC-220 4 mg will be administered orally once a day
75451926|NCT01733875|Drug|CC-220|CC-220 6 mg will be administered orally once a day
75451927|NCT01733875|Drug|CC-220|CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
75451928|NCT01733901|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
75747584|NCT00884819|Other|Placebo|Placebo match for 6 months
75769306|NCT03902236|Other|Reaction Time and Postural Control|Reaction Time and Postural Control: With ''Fitlight TrainerTM'', 6 light emitting diode (LED) lights placed at certain points on the wall are randomly lit and expected to deactivate them as fast as possible. In the protocol, the leds will be placed according to the physical structure of the person, and the scores of 29 LED's will be kept in seconds. The scores will be compared cystic fibrosis, bronchiectasis and healthy groups.
75769307|NCT03902236|Other|Muscle oxygenation|Muscle oxygenation will be assessed with wearable lactate threshold predicting device in cystic fibrosis, bronchiectasis and healthy groups.
75898167|NCT03594422|Drug|HQP1351|HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
75898168|NCT03645135|Other|Goal elicitation|Patients will be asked to list 2 goals for their visit
75898169|NCT02921230|Device|Peripheral stenting|stent implantation during the index procedure
75898170|NCT04600128|Other|Dairy-based greek yogurt|Plain Greek yogurt (2% M.F; Danone, Boucherville, Quebec, Canada)
76064883|NCT05820399|Dietary Supplement|Placebo|Participants will supplement daily with placebo (maltodextrin). Investigators and participants will be blinded to condition.
75451929|NCT01733901|Procedure|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
75451930|NCT01733914|Procedure|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
75747585|NCT05229302|Behavioral|Reframet IT|The online intervention comprises 8 modules of cognitive behavioral therapy (CBT) delivered at schools by psychologists over 10 weeks. Contents: engagement and problem identification, emotional recognition and distress tolerance, identification of negative automatic thinking, help seeking and activity scheduling, problem solving, and cognitive restructuring, and a wrap up session. Two activities per module. Using a message board, the participant could communicate with research therapists who also check completed activities and respond with personalized messages. The face-to-face intervention comprises 4 CBT-based sessions to help the students in three aspects: i) close support and monitoring in case of an increase of symptomatology; ii) motivation to persist with the CBT; and iii) support the interaction between the students and CBT. Additionally, participants will be referred to a primary care clinic to receive treatment as usual.
75898171|NCT04600128|Other|Dairy-based cheddar cheese|Mild cheddar cheese (31% M.F. ; Armstrong, Saputo Dairy Products, Saint-Laurent, Quebec, Canada)
75898172|NCT04600128|Other|Plant-based yogurt|Plain Greek yogurt alternative (Daiya, Rupert Street, Vancouver, Canada)
75898173|NCT04600128|Other|Plant-based cheese|Medium cheddar style block (Daiya, Rupert Street, Vancouver, Canada)
75451931|NCT01733914|Other|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
75898174|NCT02289638|Device|Intubrite|Video-Laryngoscopy
75898175|NCT02289638|Device|MIL|Direct-Laryngoscopy
75451932|NCT01733927|Device|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
75451933|NCT01733940|Device|Application of a dressing with clorhexidine gluconate in intravascular catheters.|
76064884|NCT05820386|Procedure|Skin-to-skin Contact (SSC)|For the Skin-to-skin Contact (SSC) transfer, the bare-chested father will seat in a wheelchair. Newborns who will wear only a diaper and a cotton cap or noninvasive ventilation headgear will be placed in the kangaroo position against the father's chest to ensure direct contact with the father's skin. Preterm infants with gestational age less than 33 weeks will be wrapped with their father using plastic bags plus warmed cotton towels. More gestationally mature infants will be wrapped with only warmed cotton wraps. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
76064885|NCT05820386|Procedure|Incubator|In the incubator group, infants will be transferred after resuscitation in an incubator with air temperature set to 36°C. The newborn will be laid on his/her back in a polyethylene bag with a cap. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
75747586|NCT05229302|Behavioral|Usual care|Treatment as usual consists of identification and assisted referral to a primary care clinic where trained psychologists will assess the symptomatology and propose a course of actions, from initiation of psychotherapy to referral to a General practitioner to initiate medication if needed. Psychoterapy in primary care clinics consists of a range of 4-8 sessions twice a month. Most of the content of the psychotherapy are based on Cognitive-Behavioral Model. When needed, general practioners may suggest using medication, which normally are SSRI anditepressant (e.g., Fluoxetine, Sertraline). Medical check-up is conducted every month or every two months.
75898176|NCT05575986|Drug|Hetrombopag Olamine|Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.
75898177|NCT02896569|Other|Topical combination therapy|
75898178|NCT02290964|Procedure|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
75898179|NCT04599036|Device|MARK|EMG controlled arm orthosis
76064886|NCT05820373|Behavioral|Yoga therapy|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.
76064887|NCT05820373|Behavioral|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.
75747587|NCT04846946|Behavioral|Hey, Friend|"Intervention in development. However, we will use intervention mapping and the designing for dissemination approach, informed by self-reported qualitative data, to develop the Hey, Friend modules. The mHealth intervention will include three modules that include multiple sub-topics (e.g., What is HIV?; How do I protect myself from HIV?; What is PrEP?, etc.), deliver culturally appropriate counseling content in community settings, juvenile court system, clinics, and schools; will include Motivational Interviewing components that are effective in evoking behavior change while being acceptable to adolescents and parents, and will include ongoing support through a text reminder to maximize the likelihood of initiating HIV prevention through testing and PrEP."
75747588|NCT00573131|Drug|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
75747589|NCT00573131|Drug|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
75747590|NCT00573131|Drug|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
75898180|NCT04066270|Diagnostic Test|video nystagmography|routine test battery applied to all cochlear implant candidates
75898181|NCT03445988|Behavioral|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
75898182|NCT03445988|Behavioral|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session
75898183|NCT03445988|Other|Usual Care|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
75898184|NCT04030195|Genetic|PBCAR20A|"Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied."
75898185|NCT04030195|Drug|Fludarabine|Fludarabine is used for lymphodepletion (30 mg/m^2/day, Days -5 to -3).
75603111|NCT05937243|Behavioral|Advanced Digital Data Sharing (ADDS) with Coaches|When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
75898186|NCT04030195|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion (500 mg/m^2/day, Days -5 to -3).
75603112|NCT05937191|Drug|Leflunomide|Leflunomide+Glucocorticoids treatment Group
75603113|NCT05937191|Drug|Steroid Drug|Steroid Treatment
75898187|NCT02253966|Drug|Methylprednisoloneacetate|
75898188|NCT02253966|Drug|Lidocaine|
75898189|NCT02253966|Other|sodium chloride|
75898190|NCT03644979|Other|Skydiving|Tandem skydiving (with an experienced instructor)
75898191|NCT02291042|Drug|B+O Suppository|
75898192|NCT01673620|Drug|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
75747591|NCT00573131|Radiation|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
75747592|NCT00573131|Procedure|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
75603114|NCT05937178|Drug|ETV/TAF/TDF/TMF/IFN|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
75603115|NCT05937178|Drug|ETV/TAF/TDF/TMF|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
76064888|NCT05820373|Behavioral|Passive control group|The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
76064889|NCT05820282|Behavioral|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions
75603116|NCT05937139|Other|Breastfeeding education|Breastfeeding education will be given to fathers.
75603117|NCT05937126|Diagnostic Test|FilmArray Pneumonia Panel|FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.
76064890|NCT05820282|Other|Control condition|Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
75451934|NCT01733940|Device|Application of a dressing without clorhexidine gluconate|
75603118|NCT05937126|Diagnostic Test|Culture and antimicrobial susceptibility testing|Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.
75603119|NCT05937100|Drug|Formocresol|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute
75603120|NCT05937100|Drug|Biodentine|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
75603121|NCT05937100|Drug|Hyaluronic acid gel|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes.
75747593|NCT01565018|Drug|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
75451935|NCT01733966|Drug|Secnidazole, ciprofloxacine|"2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)"
75747594|NCT01565018|Drug|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
75747595|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
75747596|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
75898193|NCT01673620|Drug|Placebo|Matching placebo tablet administered once daily
76064891|NCT05820269|Behavioral|parents-child psychotherapy|filling out questionnaires during psychotherapy consultations
75747597|NCT01565096|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
75747598|NCT01565096|Drug|Glimepiride|Glimepiride at individual dose
75747599|NCT00887393|Other|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (< 15% of total kcaloric intake)
76064892|NCT05820165|Radiation|high-resolution 3D-T1|Subjects undergo a high-resolution 3D-T1 imaging to obtain structural images
75898194|NCT03547206|Drug|RPh201 Cohort A|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
76064893|NCT05820165|Radiation|diffusion tensor imaging (DTI)|Subjects undergo a DTI imaging to obtain images of white matter lesions
75898195|NCT03547206|Other|Placebo Cohort A|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene [BHT]).
75451936|NCT01733966|Drug|Amoxicillin-Clavulanic Acid|3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
75451937|NCT01733979|Dietary Supplement|Heme-Iron Polypeptide|Heme-Iron Polypeptide (1g/day)
75451938|NCT01733979|Dietary Supplement|Placebo|Placebo (1g/day)
75451939|NCT01733979|Dietary Supplement|Heme-Iron|Heme-Iron (1g/day)
75451940|NCT01733979|Dietary Supplement|Organic Iron|Organic Iron (1g/day)
75451941|NCT01733992|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
75451942|NCT01733992|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
75451943|NCT01733992|Drug|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
75898196|NCT03547206|Drug|RPh201 Cohort B|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
76064894|NCT05820165|Radiation|resting-state functional magnetic resonance imaging (rs-fMRI)|Subjects undergo rs-fMRI to investigate the differences in intra-regional brain activity and inter-regional functional connectivity
75451944|NCT01733992|Drug|Placebo|Placebo, single and multiple ascending dose
75451945|NCT01734005|Dietary Supplement|Red Ginseng|Red Ginseng (1.4g/day)
75451946|NCT01734005|Dietary Supplement|Placebo|Placebo (1.4g/day)
75603122|NCT05937061|Biological|Blood sample analysis|Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.
75603123|NCT05937061|Other|Anthropometrics measurement - at inclusion to the study (all groups).|Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.
75603124|NCT05937061|Radiation|Bone mineral density measurement (DXA)|Analysis of bone mineral density with DXA in patients with milk allegy. Analysis ordered by medical doctor.
76064895|NCT05820165|Radiation|arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)|Subjects undergo arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) to clarify the difference of cerebral blood flow (CBF) perfusion in certain regions
76064896|NCT05820165|Radiation|susceptibility-weighted images (SWIs)|Subjects undergo susceptibility-weighted images (SWIs) to segment the vein network
76064897|NCT05820113|Device|Deep learning based reconstruction of T2-TSE sequence|A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.
75603125|NCT05937061|Other|Influence of food allergy on growth (intervention groups)|Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.
75603126|NCT05937048|Biological|Albumin|20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
75603127|NCT05937048|Other|Standard of Care|Standard treatment that the patient would receive had they not been included in the trial.
75747600|NCT00887393|Other|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
76064898|NCT05820074|Diagnostic Test|Neural Activity Recording|Neural Activity is measured using EEG in all groups. Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.
76064899|NCT05820074|Diagnostic Test|Movement Parameter Recording|Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.
75451947|NCT01734044|Drug|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
75451948|NCT01734044|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
75451949|NCT01734057|Drug|recombinant human thrombopoietin (rhTPO); rituximab|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day)
75747601|NCT00889499|Drug|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
75747602|NCT00889499|Drug|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
75747603|NCT00889499|Drug|Placebo|NHCL 0,9%
75747604|NCT00889655|Drug|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
75747605|NCT00889655|Drug|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
75747606|NCT05002946|Drug|SP-104|single oral dose
75747607|NCT05002946|Drug|Naltrexone Hydrochloride 50Mg Oral Tablet|single oral dose
75747608|NCT04635098|Drug|dexmedetomidine|All participants will be randomly assigned to receive either dexmedetomidine or saline
75747609|NCT04635098|Drug|saline|All participants will be randomly assigned to receive either dexmedetomidine or saline
75747610|NCT00521144|Drug|obatoclax mesylate|Given IV
75747611|NCT00521144|Drug|topotecan hydrochloride|Given IV
75747612|NCT00521144|Other|laboratory biomarker analysis|Correlative studies
76064900|NCT05820074|Other|Neuromodulation|Neural signals are recorded with the electrodes of the deep brain stimulation device. Parkinson's patients are asked to modulate their neural activity by observing the streamed neural activity and applying mental strategies.
76064901|NCT05820061|Diagnostic Test|upper endoscopy|data will be collected from the enoscopy archive files in Department of Tropical Medicine and Gastroenterology,Sohag University Hospital
75603128|NCT05937035|Procedure|Customized allogenic bone block surgery|After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
75898197|NCT03547206|Other|Placebo Cohort B|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene [BHT]).
75898198|NCT02291120|Procedure|Pulpotomy|
75603129|NCT05936931|Behavioral|Changes in CRC screening awareness and intentions|Using a single arm, open-label, pre-test post-test design (n=15 adult child/parent dyads), assess the impact of a young adult-mediated intervention to increase CRC screening among a paired age-eligible family member (e.g., parent/grandparent). The focus of the intervention will be on changes in CRC screening awareness and intentions among the age-eligible adult, but we hypothesize that the young adult could benefit as well. Thus, in addition to assessing feasibility and acceptability, we will assess changes in 1) CRC screening intentions among the age-eligible adults and 2) CRC health literacy and awareness of screening guidelines among the younger adult participant.
75898199|NCT05284149|Dietary Supplement|Hirsutella Sinensis Nutrient Supplements|"This randomized control study will be conducted in 2 years. We expect to recruit 50 participants with age ≥ 50 years old. Enrolled participants will be recruited into Hirsutella Sinensis nutrient supplement group (50 patients H.S. suppl.) . The medication will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving Hirsutella Sinensis nutrient supplement."
75451950|NCT01734057|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
75747613|NCT00520676|Drug|pemetrexed|500 mg/m^2, IV, q 21 days x 6 cycles maximum
75747614|NCT00520676|Drug|docetaxel|75 mg/m^2, IV, q 21 days x 6 cycles maximum
75747615|NCT00520676|Drug|carboplatin|AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum
75747616|NCT03998852|Drug|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with [18F]-FDOPA
75747617|NCT03998852|Drug|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with [18F]-FEOBV
75747618|NCT03998852|Device|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the [18F]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
75747619|NCT03998852|Other|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
75898200|NCT05284149|Dietary Supplement|Placebo|"We expect to recruit 50 placebo participants with age ≥ 50 years old. This randomized control study will be conducted in 2 years. The placebo will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving placebo."
75898201|NCT04037956|Procedure|Tubeless NOSES|The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).
75898202|NCT04037956|Procedure|traditional laparoscopic radical resection|The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
75898203|NCT04671355|Drug|Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg|Pressurized metered dose inhaler
75898204|NCT04671355|Drug|Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg|Dry powder inhaler
75898205|NCT03644901|Procedure|nonsurgical periodontal treatment|patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.
75451951|NCT01734070|Other|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
75451952|NCT01734083|Device|Whole body vibration exercise|The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
76064902|NCT05820048|Drug|Lansoprazole 15 mg|"Short-term treatment of active duodenal ulcer~Short-term treatment of active benign gastric ulcers~Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~Maintain duodenal ulcer after treatmentLaw~Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~Short-term treatment of gastroesophageal reflux disease~Short-term treatment of erosive reflux esophagitis~Post-treatment maintenance therapy for erosive reflux esophagitis~Pathological hyperdivision, including Zolinger Ellison syndrome"
76064903|NCT05819996|Behavioral|Environmental educational campaign|Educational campaign will be conducted to promote participation in indoor air testing.
76064904|NCT05819983|Drug|Ivermectin Tablets|Ivermectin 200µg/kg BW
76064905|NCT05819983|Drug|Permethrin Cream|Permethrin cream 5%
76064906|NCT05819970|Drug|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament
76064907|NCT05819970|Drug|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament
75603130|NCT05936918|Other|Transcutaneous electrical acupoint stimulatios|Percutaneous electrical stimulation technology of acupuncture points is a technology that uses a trace current close to human bioelectricity on the surface of acupuncture points to prevent and treat diseases guided by meridian theory, and is a new treatment of percutaneous nerve electrical stimulation combined with acupuncture points. As one of the related techniques of acupuncture, it is a safe, non-invasive, simple and new acupoint stimulation method
75603131|NCT05936918|Other|Bilateral transverse abdominal plane block|Transverse abdominis plane block is a technique in which a local anesthetic is injected into the transverse abdominis plane to block sensory nerves passing through this plane to achieve analgesic effect
75603132|NCT05936905|Other|Acupuncture|Acupuncture 1 time per month
75603133|NCT05936905|Other|Chiropractic|Chiropractic 1 time per month
75603134|NCT05936892|Other|upper extremity aerobic training|upper extremity aerobic training & baseline treatment will be given. Overall session time will be 40-45 minutes
75603135|NCT05936892|Other|upper extremity resistance training|upper extremity resistance training Overall session time will be 40-45 minutes
75603136|NCT05936879|Other|Inspiratory muscle training|Group A: Intervention group will be treated with Inspiratory muscle training and early ambulation and routine physical therapy including ankle pumps,hand pumps isometrics of upper and lower limbs after surgery
75603137|NCT05936879|Other|physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.|Group B: Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs
75603138|NCT05936853|Other|Intravenous approach to anaesthetic maintenance|Anaesthetic agents given directly into the bloodstream via a cannula.
75603139|NCT05936853|Other|Inhalational approach to anaesthetic maintenance|Volatile-based anaesthetic drugs are breathed in and then absorbed into the bloodstream through the lungs.
75603140|NCT05936840|Device|Mira Monitor tracking|Using the Mira monitor to track the menstrual cycle
75603141|NCT05936827|Diagnostic Test|Ergometry|"Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion.~The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine.~ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams & Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)"
75603142|NCT05936827|Diagnostic Test|Ergospirometry|"VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion.~Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)"
75747620|NCT04063748|Behavioral|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
75747621|NCT04063748|Behavioral|Placebo Rehabilitation|CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
75747622|NCT04063748|Behavioral|Passive Control|No intervention in the passive control group for HA-users.
75747623|NCT00610649|Drug|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
76064908|NCT05819905|Diagnostic Test|PET/CT|Pre treatment staging 18F-FDG PET/CT
76064909|NCT05819736|Other|Monitoring|Monitoring
76064910|NCT05819723|Other|CAM score|"The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present."
76064911|NCT05819645|Behavioral|Fluid intake not as per standard guidlines|The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
76064912|NCT05819632|Other|curcumin gel 2%|curcumin gel 2%
76064913|NCT05819606|Other|Immunohistochemistry (IHC) analysis|Setting of the percentage amount of PSMA expression on the primary tumor cell surface on post-surgical samples by the Immunohistochemistry method (IHC)
76064914|NCT05819567|Device|Newly Developed Ankle Brace|The ankle brace is made of gripping tissue and includes two straps and one latex wedge. The purpose of this brace is to lift up the plantar arch.
76064915|NCT05819554|Procedure|Trans-sphenoidal surgery|Surgical removal of pituitary tumor by trans-sphenoidal approach
75603143|NCT05936801|Other|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs."
75603144|NCT05936801|Other|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
75898206|NCT04034212|Other|Singing for Lung Health group attendance|Singing for Lung Health is a group singing intervention designed for people with chronic lung diseases. Participants would attend weekly sessions lasting 1 hour.
75898207|NCT03521492|Diagnostic Test|serum vitamin D , calcium , parathyroid hormone and albumin level|measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
75747624|NCT00610649|Drug|Placebo|Orally administered matching placebo capsules.
75898208|NCT03765879|Other|Verum VGAIT (Video-Guided Acupuncture Imagery Treatment)|In VGAIT treatment sessions, participants will re-watch the video of themselves receiving acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
75898209|NCT03765879|Other|Sham VGAIT (Video-Guided Acupuncture Imagery Treatment)|In sham VGAIT treatment sessions, participants will re-watch this video of themselves receiving the sham acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
75747625|NCT02542085|Procedure|Laparoscopic repair|operative method
75747626|NCT02542085|Procedure|Hybrid repair|operative method
75747627|NCT00885053|Dietary Supplement|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
75747628|NCT00885053|Dietary Supplement|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
75747629|NCT00889733|Drug|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
75747630|NCT00887627|Drug|conivaptan hydrochloride|intravenous
75898210|NCT04644991|Other|Kinesiology taping|Y-type kinesiology tape will be applied to the thoracolumbar fascia in experimental gruoup.
75898211|NCT04644991|Other|Six minutes walking test|Participants will be asked to walk as fast as they can for 6 minutes.
75898212|NCT04644991|Other|Shame Kinesiology Tape|Sham kinesiology tape will be applied to the thoracolumbar fascia in sham gruoup.
75898213|NCT03521414|Device|Bispectral index (BIS) monitoring|When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug
75898214|NCT03521414|Drug|Sevoflurane|we used sevoflurane drug at inoperative
75898215|NCT00432094|Drug|carboplatin|Days -6, -5, -4: 500mg/m2^/day intravenously (IV) over 60 minutes
75898216|NCT00432094|Drug|etoposide|600mg/m^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
75898217|NCT00432094|Drug|ifosfamide|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
75898218|NCT00432094|Drug|paclitaxel|225 mg/m^2 intravenous over 3 hours on Day -7.
75898219|NCT00432094|Drug|thiotepa|150mg/m^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
75898220|NCT00432094|Procedure|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (< 4 x 10^6 CD34+ cells/kg)
75898221|NCT00432094|Drug|Mesna|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
75898222|NCT00432094|Biological|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
75898223|NCT04562779|Drug|Naltrexone 380 MG|XR naltrexone to be given once prior to hospital discharge
75451953|NCT01734083|Behavioral|Conventional exercise|The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
75898224|NCT04562779|Drug|Ketamine Hydrochloride|IV ketamine infusion to be given once prior to hospital discharge
75451954|NCT01734096|Other|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
75451955|NCT01734096|Drug|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
75451956|NCT01734109|Device|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
75747631|NCT04037579|Other|Survey|Non-randomised survey
75898225|NCT04562779|Behavioral|Enhanced linkage|Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up
75898226|NCT02291198|Device|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
76064916|NCT05819489|Diagnostic Test|Dynamic Vision Testing|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
76064917|NCT05819437|Other|Balneotherapy program|"Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C."
76064918|NCT05819411|Behavioral|Project iSTRIVE|This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
75603145|NCT05936788|Other|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
75603146|NCT05936788|Other|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
76064919|NCT05819411|Behavioral|incentivized Directly Observed Therapy (iDOT)|Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
75603147|NCT05936775|Other|nano-hydroxy apatite coated titanium implants|titanium implants with surface treatment of nano-hydroxy apatite
75603148|NCT05936775|Other|sandblasted large acid itched coated titanium implant|titanium implants with SLA surface treatment
75603149|NCT05936762|Device|Neoial HC|Patients with severe knee osteoarthritis were enrolled in the clinical study and treated with 3 injections of 40 mg NEOIAL HC (HA sodium salt at 2% with two molecular weights 20% with pm at 400 kD and 80% between 1200 and 1500 kD t + collagen) at a distance of 1 week from each other, followed by a fourth infiltration of the same product at a distance of 1 month from the third.Patients were followed up with baseline clinical evaluation, reporting of adverse events after each single infiltration and subsequently at the end of treatment, 3, 6 months follow-up.
76064920|NCT05819333|Other|Exercise Program + Respiratory Strength Training|Strength, Flexibility, Cardiovascular exercise + respiratory strength training
75603150|NCT05936749|Genetic|Pre-implantation genetic testing|
75603151|NCT05936723|Behavioral|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
75603152|NCT05936723|Behavioral|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
75603153|NCT05936697|Device|fNIRS|For fNIRS to be recorded by the wearable OctaMon+ system (Artinis Medical Systems, The Netherlands), two sources, each surrounded by four detectors positioned approximately 3 cm apart, will be placed on the scalp such that the two channels near the fissure on each side of the head are surrounded F3 and F4. Data will be sampled at 50 Hz.
75603154|NCT05936697|Device|EEG|For EEG to be recorded by the ANT eego rt8 amplifier (ANT Neuro, Hengelo, The Netherlands), electrodes will be placed at Fp1, F3, F4, Fz, Fpz, Cz, GND (ground), lower VEOG, and on the two earlobes (references). Data will be collected at 2,048 Hz.
75747632|NCT00889811|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
75747633|NCT00887705|Behavioral|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
75747634|NCT00890123|Dietary Supplement|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
75747635|NCT00885287|Drug|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
75747636|NCT00923429|Procedure|Stay-active care|No other treatment than the stay-active care
75747637|NCT00923429|Procedure|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
75898227|NCT05218200|Other|deep breathing and coughing exercises with triflo|patients will be given triflo. A video of the application of deep breathing and coughing exercises with triflo prepared by the researchers will be prepared. The video will be sent to the patients' phones. It will be ensured that the patients do the exercises every hour by watching the video and they will be followed.
75898228|NCT03751761|Drug|durvalumab, tremelimumab, paclitaxel|Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
75603155|NCT05936697|Other|Baseline Training|In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity within and across sessions.
75603156|NCT05936658|Drug|[F-18]Florastamin|A single dose of [F-18]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then [F-18]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).
75603157|NCT05935059|Drug|Pregabalin|Pregabalin 50Mg Oral Capsule. Pre-operative administration of Pregabalin for prevention of Post mastectomy Pain Syndrome (PMPS)
75603158|NCT05935059|Drug|Tianeptine|Tianeptine 12.5Mg Capsules. Prevention of Post Mastectomy Pain Syndrome
75898229|NCT03523130|Diagnostic Test|Imaging|Macrophage-specific inflammation
76064921|NCT05819333|Other|Exercise Program + Respiratory Relaxation Training|Strength, Flexibility, Cardiovascular exercise + respiratory relaxation training
75603159|NCT05933746|Behavioral|Sleep Hygiene Intervention|This 1-hour on-line intervention presents three sleep hygiene modules, selected randomly from among these six: establishing a bedtime routine, optimizing sleep environment, implementing a sleep schedule, bedtime relaxation, nutrition choices, and exercise habits.
75747638|NCT00923429|Procedure|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
75747639|NCT00923429|Procedure|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
75747640|NCT02542007|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
75747641|NCT02542007|Device|sirolimus-eluting stent system|
75747642|NCT00887861|Drug|Investigational new drug, company code: BGG492|
75898230|NCT03044197|Device|MRI/ultrasound transperineal prostate biopsy|3-6 targeted biopsy cores from each prostate region of interest
75747643|NCT00887861|Drug|Placebo|
75747644|NCT04037267|Procedure|endoscopic intraventricular evacuation surgery|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
75747645|NCT00892541|Drug|ER OROS paliperidone|
75747646|NCT02541617|Procedure|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
75898231|NCT03044197|Device|transrectal ultrasound-guided prostate biopsy|12 systematic biopsy cores
75898232|NCT05202990|Drug|Fecal Microbiota Transplantation by Stool capsules|"After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces)."
75898233|NCT05202990|Drug|Fecal Microbiota Transplantation by Intra-rectal enemas|"After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas."
76064922|NCT05819307|Device|OCT/FLIM|OCT/FLIM imaging of the retina
76064923|NCT05819281|Dietary Supplement|Probiotic blend|(Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 1010 CFU/day).
76064924|NCT05819281|Dietary Supplement|PLACEBO|Maltodextrin
76064925|NCT05819229|Drug|Oral antibiotic therapy|"Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days."
75747647|NCT02541617|Procedure|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
75898234|NCT02291354|Drug|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
75898235|NCT02291354|Other|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
75898236|NCT02291354|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
75898237|NCT03644823|Drug|Atezolizumab|PDL1- inhibitor
76064926|NCT05819216|Device|Treadmill|Gait training on treadmill training
75603160|NCT05933746|Behavioral|Non-behavioral Sleep Education|1-hour on-line set of three modules that cover non-skill (non-hygiene) educational topics (sleep research, sleep stages, dreams). This control condition equates for engagement rationale.
75603161|NCT05933707|Behavioral|People with Metabolically Unhealthy Obesity - Low Calorie Diet|Consumption of a low-calorie diet with caloric intake reduced by ~25% to achieve ~10% weight loss in about 4 to 5 months.
75603162|NCT05932719|Other|COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.|"The following items will be collected~Diagnostic date~Diagnostic stage~Date of surgery~Date of surgery appointment~First antineoplastic treatment date~Last antineoplastic treatment date~Number of treatment cycles recommanded by MDTM"
75603163|NCT05932654|Drug|BSI-045B|Patients in monotherapy cohorts will be treated with BSI-045B.
75603164|NCT05932654|Drug|Dupilumab|Patients in add-on cohorts will be treated with BSI-045B and dupilumab.
75603165|NCT05931523|Behavioral|Stress First Aid|The focus of the model is ongoing monitoring of stress in personnel, wide spread training to help personnel recognize peers or subordinates who may need additional assistance, a spectrum of one-on-one interventions, and the ability to provide personnel higher levels of care when indicated.
75603166|NCT05929534|Device|active intermittent Theta Burst Stimulation|Each patient will receive two 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
75747648|NCT00890279|Drug|Cilnidipine|Cilnidipine up to 20 mg
75747649|NCT00890279|Drug|Imidapril|Imidapril up to 10 mg per day
75747650|NCT00892619|Procedure|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
75898238|NCT03644823|Radiation|Radiotherapy|6 Gy x 3
75898239|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
76064927|NCT05819177|Other|Rehabilitation program|This group of patients underwent standard rehabilitation programs set by national guidelines.
75603167|NCT05929534|Device|sham intermittent Theta Burst Stimulation|Each patient will receive two sham 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
75603168|NCT05929391|Procedure|Recycling orthodontic brackets|"T0: The adhesive removal will be performed by high-speed hand piece with tungsten carbide bur. the bur will be changed every five attachments. T1: Control group of T0. T2: The adhesive removal will be performed by sandblasting via Micro-etcher.~T3: Control group of T2."
75747651|NCT00892619|Procedure|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
75747652|NCT00608543|Drug|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
75747653|NCT00890435|Other|questionnaire administration|
75747654|NCT00890435|Procedure|psychosocial assessment and care|
75747655|NCT02541383|Drug|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
75747656|NCT02541383|Drug|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
76064928|NCT05819164|Device|Masimo oximeter|During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
76064929|NCT05819164|Device|Nellcor oximeter|During this period, the Nellcor oximeter N-600 was used for SpO2 reading
76064930|NCT05819164|Device|Nonin oximeter|During this period, the Nonin oximeter was used for SpO2 reading
76064931|NCT05819151|Diagnostic Test|HbA1c Test|HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.
76064932|NCT05819086|Behavioral|Rate Emotional Response|Participants will view their assigned video package, and will be asked to rate their emotional response to the message
76064933|NCT05819086|Behavioral|Rate Impact of Message|Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.
76064934|NCT05819060|Drug|Fuzuloparib Combination with Bevacizumab|For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.
75603169|NCT05928962|Drug|Recombinant Human Adenovirus Type 5 Injection|"Recombinant Human Type 5 Adenovirus Injection:~This is expected to be administered prior to immunotherapy, i.e. scheduled for injection at C1D1 (C2D1, C3D1, C4D1). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles.~PD1 monoclonal antibody (Tremelimumab):~Administered intravenously within 48h of recombinant human adenovirus type 5 injection, scheduled at C1D2 (C2D2, C3D2, C4D2). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles."
75603170|NCT05927285|Diagnostic Test|Vexus|The VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0.
75603171|NCT05927285|Other|Control group|The control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested
75603172|NCT05924997|Drug|adebrelimab, camrelizumab plus apatinib|adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
75603173|NCT05920746|Other|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 10-20 Hz, type of impulse: bipolar, rectangular pulse
75898240|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
75898241|NCT03644745|Behavioral|VM @ Home Usability|Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
75898242|NCT03546114|Other|Gender Questionnaire|13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
75898243|NCT02289794|Biological|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
75898244|NCT02289794|Biological|Placebo|Single dose, intramuscular injection (0.5 mL)
76064935|NCT05819034|Other|Scoliosis-Specific Exercise Program|"Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour."
76064936|NCT05819034|Other|Soft orthoses with external strapping.|Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
75747657|NCT02541383|Drug|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
75747658|NCT04036643|Radiation|PET-MRI|Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
75747659|NCT04036487|Drug|Desflurane|Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.
75747660|NCT04036487|Drug|Propofol|Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
75747661|NCT04036565|Behavioral|sunlight therapy|Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
75747662|NCT02541149|Procedure|blood sample|
75898245|NCT03644355|Behavioral|Lifestyle counseling|Inter-disciplinary, interactive, family based behavioral intervention for overweight children
75747663|NCT05278793|Drug|Ferrous fumarate|Ferrous fumarate 200mg oral
75747664|NCT00892853|Procedure|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
75747665|NCT00890669|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1),~control condition (conventional physical therapy group) (B). and~treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
75747666|NCT00892931|Drug|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
75451957|NCT01734135|Other|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
75898246|NCT03521336|Drug|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
75898247|NCT03521336|Drug|Placebo|Saline，Sham operation
75898248|NCT03104920|Procedure|ERAS Program|An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.
75898249|NCT03104920|Procedure|Traditional treatment|A traditional perioperative management for HCC.
75898250|NCT03645447|Diagnostic Test|Taste test|A device is used to present a pseudo-randomised series of taste solutions to the participant for identification, in order to establish taste thresholds.
75898251|NCT02289872|Device|Macintosh Laryngoscope|Direct-Laryngoscopy
75898252|NCT02289872|Device|TruView PCD Video laryngoscope|Video-Laryngoscopy
75747667|NCT05278325|Other|Telephone intervention|Two planned phone call between clinical controls
75898253|NCT03104998|Drug|Coenzyme Q10|200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
75898254|NCT04572984|Procedure|EBUS-TBMCB|endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy was performed in experimental arm following EBUS-TBNA
75898255|NCT04545138|Other|cognitive training combine treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10~12 points (slight), and ensures that patients can be cognitively trained at the same time. The cognitive training tasks will be projected on the screen and the participant have to answer the task orders during treadmill training simultaneously.
75898256|NCT04545138|Other|Treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10~12 points (slight).
75603174|NCT05919914|Other|Exercise with Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric) with BFR. BFR involves the reduction of blood flow to working skeletal muscle by applying a flexible cuff to the most proximal portions of a person's arms or legs that results in decreased arterial flow to the exercising muscle and occluded venous return back to the central circulation.
75898257|NCT03522974|Dietary Supplement|Strawberry powder|Freeze dried strawberry powder
75898258|NCT03522974|Dietary Supplement|Placebo powder|40 g/d placebo powder matched for taste and appearance
75603175|NCT05919914|Other|Exercise without Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric)
75747668|NCT04037657|Drug|HSK3486|HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
75747669|NCT04037657|Drug|Propofol|Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.
75898259|NCT04543032|Other|sensorimotor training|Sensorimotor exercises progressed from stable surfaces to unstable surfaces, training gait in a line (tandem walk or walking straight) followed by gait including change in directions, gait without obstacles to gait with obstacles, change in the support base (feet apart and then together), physical exercises with eyes opened and closed, always respecting the functional capacity of each patient and progressively increasing the difficulty of each exercise. To help the training, cones, balance board, bars, mats and a mini-trampoline will be used. According to the patient progress, the exercises will be combined, generating circuits
75898260|NCT03990766|Drug|Theophylline|Theophylline delivered via high-volume, low-pressure nasal saline irrigation
75747670|NCT04037345|Biological|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL)
75747671|NCT04037345|Biological|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL)
75603176|NCT05917327|Device|Low-volume continuous veno-venous haemodialysis|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. One treatment will last 4 hours. For non-hospitalized patients, the treatment is performed on an outpatient basis.
75603177|NCT05912894|Procedure|Videolaparoscopic cholecystectomy|Evaluation of Rouvière's Sulcus Anatomical Variation.
75603178|NCT05910190|Drug|Use of buprenorphine with FAO > 30 OME|Patients will receive buprenorphine with concurrent FAO >30 OME and be assessed for withdrawal, pain, and other symptoms.
75747672|NCT04037345|Biological|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10^7 cells/2mL)
76064937|NCT05818995|Drug|angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker|Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: <standard dose, standard dose, >standard dose Frequency of administration: once a day, twice a day, three times a day.
75603179|NCT05910190|Behavioral|CPM Rx application use|The CPM Rx application is used on smart phones to allow patients to input time-stamped data about medication type, dosage, and pain score. This will allow analysis of trends in self-reported pain and optimal dosing patterns. Usage over three months will be assessed.
75603180|NCT05908435|Behavioral|Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors|The study intervention is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
76064938|NCT05818982|Drug|Afatinib|Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.
75603181|NCT05905861|Procedure|Skin incision with scalpel.|"A Pfannenstiel skin incision will be performed using a scalpel, extending through the subcutaneous tissue and rectus sheath. After separation of rectus muscles, peritoneum will be visualized and opened. Optimal hemostasis will be achieved by applying pressure to skin blood vessels and ligating any subcutaneous bleeding.~Group A: skin incision with a scalpel."
76064939|NCT05818982|Drug|Irinotecan|Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
76064940|NCT05818969|Behavioral|Hypnosis Therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calming ocean scene to be played at least once daily for 7 days preoperatively.
75603182|NCT05905861|Procedure|Skin incision with a diathermy.|"A Pfannenstiel skin incision will be made using a scalpel. Subsequently, a diathermy pen electrode will be employed for the dissection of deeper tissues.~Optimal hemostasis will be achieved by using the same blade pen electrode, set to coagulation mode.~Group B: skin incision with diathermy."
75603183|NCT05902910|Device|LUNA-EMG Robot|During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.
76064941|NCT05818917|Drug|FHND5071|"The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data."
76064942|NCT05818813|Device|Renal denervation|Renal denervation (ReCor Medical)
76064943|NCT05818748|Device|virtual reality|virtual reality distraction
76064944|NCT05818670|Drug|Tamsulosin|long term follow up
76064945|NCT05818670|Drug|Tadalafil|long term follow up
76064946|NCT05818657|Biological|levels of CKD markers, Oral health status, apical periodontitis|To observe levels of CKD markers :Levels of serum keratinise ,urea, eGFR, and assessment of Oral health status, apical periodontitis
75603184|NCT05898919|Other|Acupuncture|Acupuncture is a technique that inserts a needle into the acupuncture point to treat a condition. In this trial, we will use acupuncture to treat postoperative urinary retention.
75603185|NCT05898919|Other|Sham acupuncture|Participants will receive sham acupuncture at sham points.
75603186|NCT05898919|Drug|Neostigmine Injectable Product|Neostigmine was injected once after postoperative urinary retention.
75747673|NCT00893009|Drug|Theophylline|100 mg twice a day
75747674|NCT00893009|Drug|Placebo|Placebo
75747675|NCT00888095|Procedure|deep brain stimulation|electrode implantation in either STN or cZI
76064947|NCT05818657|Biological|systemic inflammatory marker, Oral health status, apical periodontitis|estimation of hs-CRP levels, and assessment of Oral health status, apical periodontitis
76064948|NCT05818605|Behavioral|Moderate Intensity Exercise Program|Subjects randomized to the EXER arm will undergo 24 weeks of Moderate Intensity Exercise Training (MIET). Patients will be signed up for 60-minute exercise sessions, 3 times a week
76064949|NCT05818592|Other|Self-Pulse Monitoring|Participants will manually monitor pulse for irregularities.
75451958|NCT01734148|Behavioral|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
75747676|NCT00890747|Drug|sunitinib malate|Given PO
75451959|NCT01734174|Procedure|transesophageal echocardiography (TEE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
75603187|NCT05881291|Drug|ciprofol|"induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1."
75603188|NCT05881291|Drug|propofol|"induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1."
75603189|NCT05871125|Behavioral|Reimbursement|Patients will be dosed in cohorts of 5, with a maximum available sample size of 30. The first cohort of 5 patients will be enrolled at the first reimbursement dose level of $1000 per month for 4 months ($4000 per patient in total). At the end of the 4-month period, reimbursement dose suitability will be determined as suitable by a cumulative negative financial toxicity screen and reimbursement dose deemed acceptable and appropriate in at least 4 patients. If the reimbursement dose is found suitable, we will de-escalate the reimbursement dose for the next cohort of 5 patients. If the reimbursement dose is found unsuitable, the next cohort of 5 patients will be enrolled at the same reimbursement amount ($1000 per month for 4 months).
75603190|NCT05870280|Behavioral|nurse coaching|Group coaching will be applied to individuals with diabetes, 5-8 people.
75603191|NCT05867563|Drug|TQB2103 for injection|TQB2103 for injection is an antibody-drug conjugate targeting CLDN18.2. The drug structure mainly includes anti-humanized CLDN 18.2 antibody, linker and cytotoxic DDDXD, with Drug antibody Ratio (DAR) of 8.
75603192|NCT05867342|Drug|Epinephrin|Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
75603193|NCT05867342|Drug|1% lidocaine with epinephrin 1:100,000|4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)
75603194|NCT05867342|Drug|Saline|4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)
76064950|NCT05818579|Other|Virtual reality experience|The VR experience is launched on the participants using all-in-one VR head-mount devices. Tablet computers are used to optimize the settings by the intervention facilitators. Each session lasts for approximately one hour with 10 minutes spent on the briefing, 20 minutes spent on the VR experience, and 30 minutes spent on the post-VR group discussion. There are two sessions per week. The whole course lasts for six weeks and there are a total of 12 sessions.
75603195|NCT05866952|Diagnostic Test|Computed Tomography of the Chest|Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
75603196|NCT05855733|Device|radiofrequency treatment|patient undergoing radiofrequency using the Fistura procedure for treatment of a infected pilonidal sinus
75898261|NCT03990766|Drug|Saline Nasal|Lactose delivered via high-volume, low-pressure nasal saline irrigation
75898262|NCT02294162|Drug|Ketamine i.v|
76064951|NCT05817552|Diagnostic Test|Geomagic Control X|3D Surface matching and compare
76064952|NCT05817383|Other|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
76064953|NCT05817383|Other|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
75451960|NCT01734174|Procedure|thermodilution|A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
75451961|NCT01734174|Procedure|transthoracic echocardiography (TTE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
75747677|NCT00890747|Other|pharmacological study|Correlative studies
75747678|NCT00890747|Other|laboratory biomarker analysis|Correlative studies
75747679|NCT00888251|Other|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
75747680|NCT00893087|Device|Triggering mode of the ventilator|10 min of each triggering mode
75747681|NCT00893087|Device|Triggering method of the ventilator|Flow triggering
75747682|NCT00893087|Device|Triggering method of the ventilator|Pressure triggering
76064954|NCT05816681|Drug|DWJ1230|Daewoong Pharmaceutical
76064955|NCT05816681|Drug|DWB2001|Daewoong Bio
76064956|NCT05816512|Drug|Gold Nano particle from Pelargonium Graveolens Mouthwash|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
75451962|NCT01734187|Dietary Supplement|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
75451963|NCT01734187|Dietary Supplement|Placebo|Placebo (30g/day)
75747683|NCT00893087|Device|Triggering method of the ventilator|NAVA triggering
75898263|NCT05176158|Drug|Dexketoprofen 25 MG|Pill at morning
75898264|NCT05176158|Drug|Dexketoprofen 25 MG|Pill at night
75898265|NCT03522896|Other|control|balancing sugars and organic acids
75898266|NCT03522896|Other|test meal 1|orange juice plus hesperidin low dose
76064957|NCT05816512|Drug|Chlorhexidine gluconate mouthwash .|Chlorhexidine gluconate mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
75747684|NCT04017845|Diagnostic Test|FIT|Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
75747685|NCT04017845|Procedure|Precolonoscopy cleansing regimen|Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
75747686|NCT04017845|Procedure|Conventional Colonoscopy|With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions <25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
75898267|NCT03522896|Other|test meal 2|orange juice plus hesperidin higher dose
76064958|NCT05816499|Drug|Cadonilimab|Given IV, 10mg/kg Q3W
75898268|NCT03522896|Other|test meal 3|diluted orange juice plus hesperidin low dose
75898269|NCT03104764|Device|Scalpel|Labial frenulum removed by scalpel
75898270|NCT03104764|Device|Er:YAG laser|Labial frenulum removed by Er:YAG laser
75898271|NCT05575050|Procedure|Oral Procedure|Interventions included 2 variants of oral hygienic procedures. One was extended of teeth brushing.
75898272|NCT04323163|Behavioral|Physical Activity|3 sessions per week, 60 minutes per session for 6 months
75898273|NCT02294240|Dietary Supplement|Energy dense biscuits|Energy dense biscuits will be provided
75898274|NCT02294240|Other|Wheat Flour, oil, iron & Folic acid|Wheat flour, oil, iron and folic acid will be provided
76064959|NCT05816499|Drug|Anlotinib|oral，6mg/8mg/10mg qd 2W/3W
76064960|NCT05816499|Drug|Docetaxel|Given IV, 60-75mg/m2 Q3W
76064961|NCT05816486|Diagnostic Test|Immunobiogram|This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
76064962|NCT05816434|Behavioral|Sleep extension|>1 hour additional time in bed per night for 1 week.
75451964|NCT01734200|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
75451965|NCT01734200|Dietary Supplement|Placebo|Placebo (1.5g/day)
75451966|NCT01734213|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
75451967|NCT01734213|Dietary Supplement|Placebo|Placebo (1.5g/day)
75898275|NCT05574738|Other|Observational|
75898276|NCT04481724|Dietary Supplement|gamma-linolenic acid|3 capsules per day of GLA for 24 months
75898277|NCT04481724|Dietary Supplement|placebo|3 capsules per day of placebo for 24 months
75898278|NCT02298218|Drug|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
75898279|NCT03547830|Drug|Plerixafor|Plerixafor for Conditioning before HSCT.
75898280|NCT03547830|Drug|Gcsf|GCSF for Conditioning before HSCT.
75451968|NCT01734226|Dietary Supplement|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
75898281|NCT02920216|Drug|indocyanine green|intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
75898282|NCT03132662|Dietary Supplement|Omega-3|3 gr/day of Omega-3
75898283|NCT03132662|Dietary Supplement|Very Low Calorie Diet|4 servings/day Optifast
75747687|NCT04017845|Diagnostic Test|Histopathological examinations of screen-detected lesions|Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: >10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
75747688|NCT04017845|Drug|Tribenoside 400 mg + lidocaine 40 mg suppositories|Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
75747689|NCT04017845|Drug|Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment|Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
75747690|NCT00893165|Behavioral|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
75898284|NCT05431933|Biological|Eupolio|Inactivated Polio vaccine (Sabin strains)
75898285|NCT03132818|Other|To evaluate the prevalence of sexual disorders in patients receiving AMP|To evaluate the prevalence of sexual disorders in patients receiving AMP
75898286|NCT05692765|Behavioral|smartphone application to enhance fruit and vegetables intake among adolescents|"This randomized intervention study was conducted in an urban area of Jeddah, Saudi Arabia. We included 104 adolescents aged 13-18 years, who were randomized into intervention (n=55) or control (n=49) arms. We examined the effects of a smartphone application (My Plate) on fruit and vegetable intake over 6 weeks in the intervention group. Pre- and postintervention questionnaires were used in the intervention and control groups."
75451969|NCT01734226|Dietary Supplement|Placebo|Placebo (3.94g/day)
75898287|NCT03547752|Other|observed action and motor imaginery|Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.
75451970|NCT01734252|Drug|Argatroban|Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
75451971|NCT01734265|Drug|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|
75747691|NCT02541773|Device|Cardiac Resynchronisation Therapy|Routine implantation of CRT - part of standard of care
75898288|NCT04390945|Drug|Camrelizumab|Camrelizumab combined with concurrent radiotherapy and chemotherapy
75747692|NCT00891137|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
75747693|NCT00520130|Biological|Rituximab|Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
75747694|NCT00520130|Drug|Cyclosporine|Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
75898289|NCT02291588|Drug|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
75898290|NCT02291588|Drug|Placebo|contains no active drug
75898291|NCT03521258|Device|Dehydrated Human Amnion/Chorion Membrane|
75451972|NCT01734265|Drug|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|
75451973|NCT01734278|Other|No intervention|This is a non-interventional study.
75747695|NCT00520130|Drug|Allogenic stem cell transplant (ASCT)|Allogenic stem cell transplant
75747696|NCT00520130|Drug|Conditioning Chemotherapy|"Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3"
75747697|NCT00520130|Drug|TMS|Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
75898292|NCT03521258|Procedure|Flap-Based Reconstructive Surgery|Standard of Care surgical intervention
75898293|NCT03102814|Behavioral|Current rehabilitation|The control group will receive the rehabilitation currently offered at each of the participating centers.
75898294|NCT03102814|Behavioral|The BRIDGE program|The experimental group will additionally receive the BRIDGE program, which comprises motivational interviewing, structured goal-setting, tailored follow-up, plans for self-management, and individualised written feedback that participants can use to monitor their progress and share with important care givers.
75898295|NCT03734809|Drug|Pembrolizumab|200mg every 3 weeks infusion
75451974|NCT01734291|Behavioral|Family psychoeducation|Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
75451975|NCT01734304|Biological|DC vaccination for postremission therapy in AML|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
75451976|NCT01734330|Behavioral|Cognitive behavioral therapy in group|
75451977|NCT01734330|Drug|Nicotine replacement|
75451978|NCT01734343|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
75898296|NCT04465890|Drug|ASC22|200mg/1ml/1bottle
75898297|NCT04465890|Drug|sodium chloride|90mg/10ml/1 bottle
75747698|NCT00520130|Drug|FLAG|Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
75747699|NCT00520130|Drug|EPOCH-F|Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
75603197|NCT05854368|Procedure|Additional blood collection as part of routine care|Collection of an additional blood volume (10mL) as part of a blood sampling performed during routine care
75603198|NCT05854368|Procedure|Blood collection|Blood sample collection (10 mL)
75603199|NCT05853757|Drug|Zzowin Nutra Tablet|1 Tablet daily half an hour before going to bed
75603200|NCT05843448|Biological|PD-L1/IDO Peptide Vaccine|Given SC
75747700|NCT00520130|Biological|Alemtuzumab|Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
75747701|NCT00519896|Drug|sunitinib malate|Given PO
75747702|NCT03998384|Procedure|retrobulbar injection of autoserum|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.
75451979|NCT01734343|Device|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
75898298|NCT03625843|Behavioral|Mindfulness exercises|
75451980|NCT01734356|Other|Skin biopsies|
75451981|NCT01734408|Biological|alum-adjuvant 160U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
75603201|NCT05843448|Biological|Pembrolizumab|Given IV
75603202|NCT05836051|Other|Flavor|E-liquid flavor chemicals
75747703|NCT03998384|Procedure|retrobulbar injection of placebo|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison
75769308|NCT03902236|Other|Exercise capacity|Exercise capacity will be assessed with incremental shuttle walk test in cystic fibrosis, bronchiectasis and healthy groups.The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases.The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends The number of shuttles is recorded. Each shuttle represents a distance of ten metres
75451982|NCT01734408|Biological|alum-adjuvant 320U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
75451983|NCT01734408|Biological|alum-adjuvant 640U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
75451984|NCT01734408|Biological|adjuvant-free 640U /0.5ml|inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
75451985|NCT01734408|Biological|0/0.5ml placebo|0/0.5ml placebo
75451986|NCT01734421|Other|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
75451987|NCT01734421|Device|Cell phone Aplication for Smarth Phone|
75451988|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
75451989|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
75451990|NCT01734447|Drug|somatropin|2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
75451991|NCT01734473|Dietary Supplement|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
75603203|NCT05829759|Behavioral|Tele-B6|Participants will be part of the Tele-B6 intervention that includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group (first phase) will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
75603204|NCT05829759|Behavioral|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (preintervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
75603205|NCT05828602|Other|Conventional treatment|Conventional treatment
75603206|NCT05828602|Other|TeleRehabilitation|TeleRehabilitation
75603207|NCT05821322|Other|Physical activity trial intervention|60 minutes aerobic ergocyle exercice at 60% VO2 Peak
75603208|NCT05820022|Other|Research Barriers Scale|This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
75603209|NCT05818319|Other|12 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting 12 hours.
75603210|NCT05818319|Other|36 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 36 hours.
75603211|NCT05818319|Other|60 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 60 hours.
75603212|NCT05812651|Other|Inspiratory muscle fatigue|"Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation."
75451992|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
75747704|NCT03941600|Behavioral|Community-based Exercise Intervention group (CBE)|The CBEI group will receive 36 (60-90 minute) one-on-one, formally directed exercise sessions by trained staff over 12 weeks. By the end the goal is to have the participants guiding their own regimens. Personalized sessions will be created for each participant based on their fitness goal(s) and preferences. Each session will include vitals, pain assessment, warm-up, stretching, cardiovascular, and strength exercises and cool-down. The participants will be monitored to ensure they are achieving at least 30 minutes of moderate-to-vigorous exercise 3 times a week. Activity monitors will also be worn to capture intensity data. At the end of each session, participants will describe their likes and dislike as well as what they gained and what they suggest for improvement. At the end of each session, the trainer will rate the participant's perceived participation during the session (1-6) using the Pittsburgh Rehabilitation Participation Scale.
75747705|NCT03941600|Behavioral|Exercise Education Control group (EEG)|The EEG group will complete an intervention that consists of a one-on-one, hour-long educational session orienting participants to an online resource center, the National Center on Health, Physical Activity, and Disability (NCHPAD). NCHPAD promotes health and well-being for PwD through resources such as adapted exercise videos, information on accessible fitness equipment, personalized exercise videos tailored to PwD, and an individualized 14-week exercise program. Participants will be given an overview of NCHPAD and asked to identify resources of interest on the website. Each participant will be asked to use resources on NCHPAD to engage in physical activity for 12 weeks. Each participant will receive a weekly phone call to inquire about their physical activity, exercises engaged in, RPE during exercise, and whether any resources were used.
75747706|NCT00527618|Drug|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
75747707|NCT00527618|Drug|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
75898299|NCT03102502|Device|EECP|Enhanced external counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. EECP enhances the aortic diastolic blood flow and coronary perfusion, leading to increased arterial wall shear stress in a pulsatile manner.
75898300|NCT03102502|Drug|Medical therapy|Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
75898301|NCT02291666|Drug|CRCHUM-MT cocktail|
75898302|NCT03102658|Drug|Micafungin|Administration of study drug
75747708|NCT04622072|Drug|XZP-5809-TT1 Tablet|Single tartrate of XZP-5809
75898303|NCT03546036|Device|Weighted metal chain blanket|Use of a weighted metal chain blanket of 8 kg
75898304|NCT03546036|Device|Control plastic chain blanket|A blanket with light plastic chains
75898305|NCT02291744|Procedure|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
75898306|NCT02291744|Drug|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
75451993|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
75898307|NCT02646748|Drug|Pembrolizumab|Pembrolizumab 200 mg IV Q3W.
75898308|NCT02646748|Drug|itacitinib|Itacitinib tablets administered orally once daily.
75898309|NCT02646748|Drug|INCB050465|INCB050465 tablets administered orally once daily.
75898310|NCT03547674|Other|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
75898311|NCT03547674|Other|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
75451994|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
75451995|NCT01734473|Dietary Supplement|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
75451996|NCT01734486|Drug|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
75451997|NCT01734486|Drug|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
75603213|NCT05810480|Diagnostic Test|polyreactive immunoglobulin G|Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
76064963|NCT05816291|Dietary Supplement|Time to Exhaustion at velocity at VO2max|During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.
76064964|NCT05816239|Procedure|Dual Energy CT|Patient will receive Dual Energy CT
75898312|NCT03547674|Other|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
75747709|NCT00527072|Biological|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
76064965|NCT05816213|Device|Portable low-field MRI|"Three FDA-approved low-field (LF) portable MRI commercialized by Hyperfine Research Inc. (www.hyperfine.io) will be employed. Patients will undergo LF-MRI in the CT suite during the downtime of preparation which usually occurs after urgent imaging in the CT suite (mean time, as calculated basing on the current door to imaging time: ~20-25 minutes), thus not delaying the conventional diagnostic processes and treatment administration. LF-MRI will be also repeated by the study staff at predefined time-points: 24 h, 72 h, at the discharge and 4 weeks after the event.~A prespecified acquisition of Fast-Spin Echo (Fast-SE) essential stroke sequences will be performed, starting with diffusion weighted imaging (DWI) + apparent diffusion coefficient (ADC) mapping and fluid attenuated inversion recovery (FLAIR)."
76064966|NCT05816200|Device|Low-Level Light Therapy|Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.
76064967|NCT05816200|Device|Transcutaneous Electric Nerve Stimulation|Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
76064968|NCT05816161|Diagnostic Test|Integrated Neuromuscular Inhibition Technique|Exercises
76064969|NCT05816161|Diagnostic Test|Myofascial Release|Exercises
76064970|NCT05816109|Diagnostic Test|superficial cervical block|After anesthesia and surgical procedures, bilateral superficial cervical plexus block will be applied to the lower border of the sternocleidomastoid muscle, accompanied by ultrasonography. After cleaning the area with povidone iodine before the block, the sternocleidomastoid muscle and carotid artery and other vascular structures are determined using a linear ultrasound probe. Local anesthetic will be administered between the lower border of the sternocleidomastoid muscle and the upper border of the prevertebral fascia with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection method with saline before local anesthesia is given. After the location of the needle is confirmed, 2 ml of saline will be injected, followed by 10 ml of 0.5% bupivacaine. The deep cervical fascia of the superficial lamina will appear to open.
76064971|NCT05816109|Diagnostic Test|without superficial cervical block|patients who underwent anterior cervical surgery and did not undergo superficial cervical block
75747710|NCT00526994|Other|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
75747711|NCT00526994|Behavioral|universal education|receives referral information
75747712|NCT04743128|Behavioral|Exercise|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
75898313|NCT03547674|Other|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
75898314|NCT03624985|Drug|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
75898315|NCT03624985|Drug|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
75603214|NCT05802836|Other|no interventions|no intervention, only 3 different patients groups
75603215|NCT05798533|Biological|Neo-T|Patients will receive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
75603216|NCT05798533|Combination Product|Toripalimab|"3mg/kg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 2 weeks.~Toripalimab is recommended for patients with Melanoma."
75603217|NCT05798533|Combination Product|Tislelizumab|"200mg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 3 weeks.~Tislelizumab is recommended for patients with NSCLC or other tumor types."
75747713|NCT00519428|Drug|escitalopram|10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
76064972|NCT05816096|Combination Product|Hall technique|The child will be placed to them SSC on one of their HSPM affected teeth. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
75451998|NCT01734499|Behavioral|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
75747714|NCT00519428|Drug|bupropion extra long (XL)|150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
76064973|NCT05816096|Combination Product|ART|The child will be restored to them one of their HSPM affected teeth by GIC. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
75747715|NCT00519428|Drug|escitalopram + bupropion|same dosing schedule as for monotherapy
76064974|NCT05815979|Behavioral|virtual reality|Presentation of the virtual reality glasses and an information meeting will be held for all students in the experimental group, and the working procedure of the virtual reality glasses will be introduced. Afterwards, students will monitor the practice skill at least once using virtual reality glasses. After the completed follow-up, the students will be asked to practice their nasogastric tube application skill on a simple simulation mannequin/model with low reality in the laboratory environment.
76064975|NCT05815966|Behavioral|The effect of emotion recognition and empathy focused education program|"Emotion recognition and empathy-oriented education program is a group-based, interactive program that includes techniques such as vision development, brainstorming, painting and drawing, recital, role-playing, gamification and information notes, which requires the active participation of children. Within the program; There are trainings aimed at establishing bilateral relations, gaining in-group commitment, expressing emotions comfortably, feeling that they are not alone, and learning new resources that will make them feel good when they feel bad.~The aims of education; children,"
75747716|NCT00432159|Device|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
75747717|NCT00432159|Device|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
75747718|NCT00519194|Device|Epicor LP Cardiac Ablation System|Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
75747719|NCT00519194|Procedure|Surgical ablation of permanent AF|Concomitant AF ablation during mitral valve surgery
75747720|NCT02363660|Biological|GINI|
75747721|NCT00431847|Procedure|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
75747722|NCT00431847|Procedure|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
75747723|NCT00431067|Drug|BIBW 2992|
76064976|NCT05815953|Device|Polarstem|Stem used in total hip replacement. Manufacturer: Smith & Nephew Orthopaedics AG, Baar, Switzerland.
76064977|NCT05815953|Device|Corail|Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.
75747724|NCT01030107|Behavioral|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
75747725|NCT01030107|Behavioral|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
75747726|NCT01030185|Device|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
75747727|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
75747728|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
75747729|NCT01030263|Other|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
76064978|NCT05815940|Behavioral|Mobile Application|a mobile application was developed that can be used by children with urinary incontinence and their parents.
76064979|NCT05815927|Drug|Pembrolizumab|Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).
76064980|NCT05815927|Radiation|stereotattic ablation radiotherapy (SABR)|Total dose and number of fractions will depend on the site of the disease. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
76064981|NCT05815914|Other|app|The app will include a nutritional education programme through the APP throughout the study. At 2, 4, 6 and 8 months data will be collected through a telematics questionnaire
76064982|NCT05815914|Other|control group|Routine nutritional and dietary recommendations will be given.
76064983|NCT05815901|Drug|Epaminurad 6 mg|Epaminurad 6 mg tablet
76064984|NCT05815901|Drug|Epaminurad 9 mg|Epaminurad 9 mg tablet
75451999|NCT01734499|Behavioral|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
75452000|NCT01734499|Behavioral|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
75747730|NCT01030263|Other|Random four-quadrant biopsies.|Random four-quadrant biopsies.
76064985|NCT05815901|Drug|Febuxostat 40 mg|Febuxostat 40 mg tablet
76064986|NCT05815901|Drug|Febuxostat 80 mg|Febuxostat 80 mg tablet
75452001|NCT01734538|Dietary Supplement|Omega-3 Complete|
75452002|NCT01734538|Dietary Supplement|Placebo capsule|
75747731|NCT01035567|Procedure|Hybrid revascularization|First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
75747732|NCT01035567|Procedure|Coronary Artery Bypass Grafting|Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
75747733|NCT00430989|Other|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
75747734|NCT00430989|Other|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
76064987|NCT05815901|Drug|Epaminurad 6 mg placebo|Placebo tablet
76064988|NCT05815901|Drug|Epaminurad 9 mg placebo|Placebo tablet
76064989|NCT05815901|Drug|Febuxostat 40 mg placebo|Placebo tablet
76064990|NCT05815901|Drug|Febuxostat 80 mg placebo|Placebo tablet
76064991|NCT05815862|Drug|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor.
76064992|NCT05815849|Dietary Supplement|Olive oil|0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group
76064993|NCT05815823|Other|robotic exercise therapy|Functional exercise programs such as collecting rain in a glass, grating vegetables, goalkeeper, cleaning the stove, watering flowers, wiping windows, catching fish, and exploring landscapes were applied by robotic games to the patients
76064994|NCT05815823|Other|conventional therapy|streching, range of motion, strengthening, balance and walking exercise
76064995|NCT05815797|Drug|SDD formula|SDD formula consists of 23 herbal medicines
76064996|NCT05815797|Drug|Placebo|Placebo
76064997|NCT05815784|Drug|Atropine|0.05% atropine. One drop per eye per day for 2 years.
76064998|NCT05815784|Device|MiSight contact lenses|Daily wear for 2 years.
75603218|NCT05793632|Drug|Quetiapine|The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
75452003|NCT01734564|Biological|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
75603219|NCT05791643|Behavioral|Personalized internal and external coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies and external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
75452004|NCT01734564|Radiation|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
75452005|NCT01734577|Procedure|Dry needling|Sterile monofilament needles
75452006|NCT01734577|Procedure|Sham needling|Applicator tubes from the sterile monofilament needles
75452007|NCT01734590|Dietary Supplement|Carbohydrate based food mix 1|Carbohydrate based food
75603220|NCT05791643|Behavioral|Personalized internal coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies from the participant's personalized safety plan.
75603221|NCT05791643|Behavioral|Personalized external coping strategies|A series of interactive, automated messages will recommend use of the external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
75452008|NCT01734590|Dietary Supplement|Carbohydrate based food mix 2|Carbohydrate based food
75452009|NCT01734590|Dietary Supplement|Control carbohydrate based food|Carbohydrate based food
75452010|NCT01734603|Procedure|experimental rehabilitation program|"Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.~Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.~Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .~Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% ."
75603222|NCT05791643|Behavioral|General internal and external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal and external coping strategies for suicidal thoughts.
75603223|NCT05791643|Behavioral|General internal coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal coping strategies for suicidal thoughts.
75603224|NCT05791643|Behavioral|General external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) external coping strategies (i.e., sources of social support/distraction) for suicidal thoughts.
75603225|NCT05791643|Behavioral|General internal coping strategies, relaxation|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, relaxation-based) coping strategies for suicidal thoughts.
75603226|NCT05791643|Behavioral|General internal coping strategies, distraction|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, distraction-based) coping strategies for suicidal thoughts.
75603227|NCT05791643|Behavioral|General internal coping strategies, physical activity|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, physical activity-based) coping strategies for suicidal thoughts.
75603228|NCT05789277|Other|Conventional training program|"Conventional training program:~5-10 Repetitions ( 0.5-to 1-min rest);~Vertical jumps~Multiple forward jumps~Running exercises~Sprints alternating with slow jogging"
75603229|NCT05789277|Other|Eccentric hamstring training|Functional training along with specific eccentric hamstrings exercises i.e., prone hamstring curl, exercise ball (or glider) bridge with curl, Nordic hamstring curl, single leg deadlift. The exercise program comprises 3 sets of 15 repetitions once to twice per day for at least 12 weeks.
75603230|NCT05789251|Diagnostic Test|Standardized breakfast|Standardized breakfast to replace in fine oral induced hyperglycemia test
75603231|NCT05787782|Device|Masimo INVSENSOR00063|Masimo INVSENSOR00063 will be used to measure temperature
75769309|NCT03902236|Other|Balance|Balance will be assessed with functional reach test in cystic fibrosis, bronchiectasis and healthy groups Functional Reach measures the maximum distance a person can reach forward, the distance of the person standing at the edge of the wall with a 90-degree shoulder flexion and the maximum distance to the front of the thumb will be noted.
75769310|NCT03904732|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
75769311|NCT01252420|Drug|Enoxaparin|1.5mg/kg daily for 2 weeks
76064999|NCT05815771|Procedure|Micro fragmented adipose tissue mixed with bone marrow stem cells|mixture of stem cells
76065000|NCT05815771|Procedure|Bone Marrow stem cells aspirate|stem cells
75603232|NCT05768191|Drug|premix insulin human isophane suspension and insulin human|Sequence (Premix first, then Humulin N + Humulin R): Subjects randomized to this sequence will receive premix insulin, twice per day for 16 weeks. After the first 16 weeks, subjects will cross over to the Humulin N plus Humulin R sequence for a further treatment of 16 weeks
75747735|NCT01035645|Drug|GSK1070806|"The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation."
76065001|NCT05815732|Other|Physical exercise|Personalized exercise program, with defined modalities, intensity, duration, frequency and progression of the exercise.
75603233|NCT05768191|Drug|Humulin N plus Humulin R|Sequence (Humulin N + Humulin R first, then Premix): Subjects randomized to this sequence will receive basal bolus insulin scheme with Humulin N (twice daily) and Humulin R (before meals) for 16 weeks. After the first 16 weeks, subjects will cross over to the Premix sequence for a further treatment of 16 weeks
75747736|NCT00430755|Device|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
75747737|NCT00430755|Procedure|physician taken history|Convential history taking by physicians
75747738|NCT00430755|Other|Computer-assisted history taking|
75747739|NCT00518882|Drug|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
75747740|NCT00518882|Drug|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
75747741|NCT00518336|Procedure|Blood sampling|Blood sampling at Visit 3, 5 and 7.
75747742|NCT00518336|Procedure|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
75747743|NCT00518336|Biological|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
75747744|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
75747745|NCT00518180|Biological|Tdap Vaccine|One dose of vaccine administered intramuscularly
75747746|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
75747747|NCT02352116|Other|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
75747748|NCT02352116|Other|Standard of care management|Current standard of care at a major U.S. teaching hospital.
75747749|NCT00525902|Drug|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
75747750|NCT00525824|Drug|Rosuvastatin (Crestor)|10mg and 20 mg
75747751|NCT00525824|Drug|Ezetimibe|10 mg
75747752|NCT00525824|Drug|Simvastatin|40mg and 80 mg
75747753|NCT02260778|Behavioral|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
75747754|NCT00525590|Drug|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
75747755|NCT00430677|Drug|Corticosteroids (prednisone or prednisolone)|tablets, oral, 0.5-0.8 mg/kg, daily
76065002|NCT05815719|Drug|Corifollitropin Alfa|150 micrograms per dose
76065003|NCT05815719|Drug|Follitropin Alfa|Variable dose.
75603234|NCT05762666|Device|nociception level index monitor|The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
75603235|NCT05759481|Drug|Propofol|Propofol is administered starting at surgery induction and ending at skin closure
76065004|NCT05815719|Drug|Follitropin Alfa Biosimilar|Variable dose.
76065005|NCT05815719|Drug|Urinary Human follicle stimulating hormone|Variable dose.
76065006|NCT05815706|Device|MEDELA Supplemental nursing system|The experimental group participants were fed based on the MEDELA Supplemental Nursing System, which consists of a syringe/container and a feeding catheter. One end of the feeding probe is in the syringe/container, while the other is fixed to the mother's nipple through a plaster. MEDELA SNS is a sterile product with an adjustable breast milk flow system and neck strap. It is bisphenol A (BPA) free. All its parts are in direct contact with breast milk. This system allows the baby to both suck and feed (MEDELA Supplemental Nursing System, 2018).
76065007|NCT05815667|Behavioral|Individualised Active Communication Education (I-ACE)|The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
76065008|NCT05815654|Device|Warm Palace Analgesic Point Sticker|The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
75898316|NCT03521024|Other|poly ether ketone ketone|Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials
75452011|NCT01734603|Procedure|conventional rehabilitation program|"Duration of the training 40 minutes (time excluding rest and warm up)~Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.~Increase :~Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible."
75747756|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 30 mg/kg, every 28 days
75898317|NCT03521024|Other|lithium disilicate|well documented in the literatures as successful restoration modality.
75452012|NCT01734616|Behavioral|Old Exercise|
75452013|NCT01734616|Dietary Supplement|Old Acute Cocoa|
75452014|NCT01734616|Dietary Supplement|Old 7 Day Cocoa|
75452015|NCT01734668|Device|In Vitro Diagnostic device to aid in diagnosis|
75452016|NCT01734681|Drug|G-202|
75747757|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
75747758|NCT00430677|Drug|Mycophenolate mofetil (MMF)|tablets, oral, 1.5 to 2 g, daily
75898318|NCT05178108|Other|Real-time MRI of swallowing|"The examination recording a total of 9 sequences of less than 30 seconds will be performed, in transverse section (passing through the epiglottis), frontal section, in the plane of the posterior pharyngeal wall, and in median sagittal section.~Each bolus of 20 ml will be administered in full, in one go, using a syringe. It is kept in the mouth for a few seconds and swallowed on demand.~The semi-liquid bolus of 20 ml comes from the mixture of 198 ml of pineapple juice to 10 gr of Nutilis Powder (NUTRICIA), food thickener containing neither gluten, nor lactose.~Ingredients: Dextrin-maltose, thickeners (modified starch (corn), tara gum, xanthan gum, guar gum).~3 sequences with no food~3 sequences with ingestion of a liquid bolus of 20 ml (pineapple juice) mouth closed~3 sequences with ingestion of a semi-liquid bolus of 20 ml (pineapple juice + Nutilis Powder) mouth closed"
75898319|NCT05431465|Other|Vita Ambria|onlay restoration will be fabricated from Zirconia reinforced lithium disilicate glass ceramic(vita ambria)
75898320|NCT05431465|Other|IPs emax onaly|onlay restoration will be fabricated from lithium disilicate glass ceramic(IPS emax)
75898321|NCT02294552|Drug|Cyclophosphamide|
75898322|NCT02294552|Drug|Busulfan|
76065009|NCT05815641|Dietary Supplement|food (breakfast)|The breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
76065010|NCT05815615|Device|Plasmapheresis|Plasma donation at different frequencies
76065011|NCT05815589|Other|screw retained prosthesis group|hybrid prosthesis screwed on four mandibular intra-foraminal implants
75452017|NCT01734707|Dietary Supplement|Allicor|
75452018|NCT01734707|Drug|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
75452019|NCT01734733|Other|NTCELL|
75603236|NCT05759481|Other|Placebo|Placebo is administered starting at surgery induction and ending at skin closure
75603237|NCT05758987|Behavioral|Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
75603238|NCT05758987|Behavioral|Prolonged exposure|A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.
75603239|NCT05751083|Other|brisk walk+ low intensity aerobic exercises|"Brisk Walking Protocol General flexibility Exercises Protocol Chair Sitting~Extending leg up then down~Raising up then down on toes later heels~Marching in place~Bringing leg to sideway then back towards middle~Bringing leg towards chair then forward~Bend arms up towards shoulders then back down again.~Pushing arms away from chest then back~Pushing arm up from shoulders then back down~Raising shoulders towards ears then back down~Rolling shoulders forward and backward~Raising arm at shoulder levels and extend forearm upward towards ceiling then back down~Bringing elbows inwards and outwards from chest Standing Balance Exercises"
75747759|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
75769312|NCT03911206|Behavioral|Inspiratory muscle training (IMT)|IMT exercises at home will gradually ramp up
75769313|NCT03911206|Behavioral|Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
75769314|NCT03911206|Behavioral|IMT and Exercise|Combining IMT training and exercise
76065012|NCT05815576|Behavioral|Intrinsic foot muscle fatigue|"Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction)."
76065013|NCT05815550|Drug|PPI|Use of PPI defined as PPI mentioned in the safety report
76065014|NCT05815524|Other|Physical activity training|training on treadmill
76065015|NCT05815511|Dietary Supplement|Probiotic mixture|Oral capsule consumption once a day for 12 weeks
76065016|NCT05815511|Dietary Supplement|Placebo|Oral capsule consumption once a day for 12 weeks
76065017|NCT05815472|Device|Fitbit charge|Internet of Things Technologies Device
75747760|NCT02631759|Drug|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
75898323|NCT02294552|Drug|Fludarabine monophosphate|
76065018|NCT05815407|Other|No intervention|No intervention
76065019|NCT05815394|Drug|177Lu-labeled NY108|Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.
76065020|NCT05815381|Other|Questionnaires, quantitative sensory testing, blood sampling, skin biopsies, functional magnetic resonance imaging, magnetic resonance spectroscopy|se arm/group descriptions
76065021|NCT05815368|Device|REMO|REMO training will consist of sEMG-biofeedback exercises provided by REMO device. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
76065022|NCT05815368|Other|Task-Oriented Training|Task-Oriented training will consist of task-specific functional exercises. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
76065023|NCT05815355|Dietary Supplement|exclusive enteral nutrition treatment group|
76065024|NCT05815329|Other|cognitive training|After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered to half of the outpatients included in this research by means of technological devices (Neurotablet). A neuropsychologist will supervise the cognitive training offline (about 30 minutes per 5 days, 8 weeks) and through a face-to-face 1 hour-session each week per each outpatient.
75747761|NCT02631759|Drug|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
76065025|NCT05815316|Drug|18F-PSMA-1007|(3S, 10S, 14S)-1-[4-[[(2S)-4-carboxy-3-[(2S)-4-carboxy-2-(6-[18F]fluoropyridin-3- amido)butanamido]butanamido]methyl]phenyl]-3- [(naphtalen-2-yl)methyl]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
76065026|NCT05815303|Drug|Cadonilimab|10mg/kg iv on day 1, every 21 day
76065027|NCT05815303|Drug|Oxaliplatin|130mg/m2 iv on day 1, every 21 day
76065028|NCT05815303|Drug|Capecitabine|1000mg/m2 po bid on day 1 to 14, every 21 day
76065029|NCT05815290|Drug|Cadonilimab|Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
76065030|NCT05815134|Biological|blood sample|10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
76065031|NCT05815121|Other|Acupressing|Acupuncture with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.
76065032|NCT05815121|Other|Control|with stickers only on the points, and the points should not be massaged.
76065033|NCT05815108|Other|NO INTERVENTION|NO INTERVENTION
76065034|NCT05815082|Procedure|Colorectal cancer resection combined with liver metastasis resection.|The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
76065035|NCT05815082|Drug|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
75603240|NCT05751083|Other|Brisk walk|"Brisk Walking Protocol~The brisk walking protocol will consist of :~10 min: warming up of the knees, hips and back by flexibility exercises~30 min of walking~5 min of cool down."
75747762|NCT01035801|Drug|IN-105|Prandial Oral Insulin
75747763|NCT01035801|Drug|Insulin Lispro Injection|Insulin Lispro Injection
75898324|NCT02294552|Drug|Tacrolimus|
75898325|NCT02294552|Drug|Mycophenolate mofetil|
75898326|NCT02294552|Procedure|Allogeneic hematopoietic stem cell transplantation|
75898327|NCT03514706|Diagnostic Test|volume controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
75603241|NCT05738733|Device|MsChief Classic Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
75603242|NCT05738733|Device|MsChief Ylang Ylang Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
75603243|NCT05738733|Device|MsChief Vanilla & Citrus Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
76065036|NCT05815056|Device|Sedakit (R) using hypnosis induced by the virtual reality device|we use the virtual reality device and no medication during the surgery
76065037|NCT05815056|Drug|drug intervention|using sufentanyl 5mg intravenously during the surgery
75603244|NCT05738733|Device|MsChief Tea & Peach Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
75747764|NCT00525512|Drug|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
75747765|NCT00525512|Drug|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
75747766|NCT03998306|Dietary Supplement|Experimental: Probiotics|"the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions"
75747767|NCT03998306|Other|No intervention|No intervention
75747768|NCT04501406|Drug|Pioglitazone|An insulin-sensitizer FDA-approved to treat hyperglycemia caused by type 2 diabetes.
75747769|NCT04501406|Other|Placebo|Placebo looks just like pioglitazone and is given in the same way but has no active drug in it.
76065038|NCT05815043|Behavioral|Low-sodium intake|Participants will consume less than or equal to 720 milligrams of sodium per day for 3 days.
76065039|NCT05815043|Dietary Supplement|High-sodium intake|Participants will supplement their existing diets with 10 salt tablets daily for 3 days.
75747770|NCT00517634|Drug|FP|Fluticasone Propionate 100 mcg BD
75747771|NCT00517634|Drug|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
75747772|NCT00517634|Drug|Placebo|Matching Placebo
75747773|NCT02167490|Procedure|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
75747774|NCT03683576|Drug|GB001|film-coated oral tablet
75747775|NCT03683576|Drug|Placebo|film-coated oral tablet
75747776|NCT03863834|Device|InModeRF|InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
75747777|NCT03998150|Procedure|Holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)
75747778|NCT03998150|Procedure|Bipolar plasma kinetic enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
75747779|NCT03656666|Drug|Apremilast|Apremilast oral tablets
75747780|NCT03656666|Drug|Placebo|Placebo oral tablets
75747781|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
75747782|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
75747783|NCT01036035|Drug|Tolterodine|Comparison of different dosages of drug
76065040|NCT05814978|Other|Experimental Scapular Therapeutic Exercise Group|"All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions."
75747784|NCT01036035|Drug|Pilocarpine|Comparison of different dosages of drug
75747785|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
75603245|NCT05735808|Behavioral|Physician based education|Regular education provided by physician
75603246|NCT05735808|Behavioral|VR based education|VR based education
75603247|NCT05731284|Procedure|Platelet rich plasma (PRP) Injection|Randomly picked (like the flip of a coin) by a computer to receive either platelet-rich plasma (PRP) or normal saline. This is a double-blind study. During vaginal prolapse surgery, the surgeon will inject PRP into the vaginal tissue at the surgical site.
75603248|NCT05731284|Procedure|Placebo|Normal saline Injection
75603249|NCT05719610|Other|Cawthorne Cooksey Exercises for Balance Training|Group of Exercises used to Increase balance
75603250|NCT05719610|Other|Swiss Ball Exercises|Swiss Ball Exercises
75603251|NCT05706961|Other|Power Walking|"For 1- 2 Week 60% of the target heart rate with 5,000 to 7,500 steps/day Total 30 min Session The exercise intensity was set at 60% of the target heart rate during the first 2 weeks.~For 3- 4 week 70 % of the target heart rate with 7,500 to 10,000 steps/day Total 30 min Session B) Progressive increase walk according to 6MWD as improved Low intensity"
75747786|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
75747787|NCT01036035|Drug|placebo capsule|Comparison of different dosages of drug
75747788|NCT01323699|Behavioral|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
75747789|NCT01036659|Drug|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
76065041|NCT05814965|Procedure|endodontic treatment in the form of root canal treatment|Patients will receive endodontic treatment, and inflammatory markers will be assessed
75747790|NCT01033149|Drug|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
75898328|NCT03514706|Diagnostic Test|pressure controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
76065042|NCT05814965|Procedure|endodontic treatment|Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment
76065043|NCT05814965|Diagnostic Test|assessment of inflammatory marker|assessment of inflammatory markers
76065044|NCT05814965|Diagnostic Test|inflammatory markers will be assessed along with metabolic markers assessment|inflammatory markers will be assessed along with metabolic markers assessment
76065045|NCT05814952|Genetic|LX103 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
76065046|NCT05814926|Drug|GP681|GP681, tablet, oral
76065047|NCT05814874|Dietary Supplement|selenium supplement|Selenium supplement containing 55 µg of sodium selenate
76065048|NCT05814874|Dietary Supplement|Brazil nut|Brazil nut butter; consumption corresponds to a selenium intake of 55 µg/d
76065049|NCT05814874|Other|Placebo|Placebo pill
76065050|NCT05814861|Diagnostic Test|culture and PCR|"Stool samples will be cultured inTwo media :~A-Locke egg serum medium (LE) B- Jones' medium Then Molecular identification of Blastocystis hominis using polymerase chain reaction (PCR)."
76065051|NCT05814770|Drug|Finerenone|The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP < 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP > 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
75747791|NCT00429663|Device|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
75747792|NCT00429663|Device|locking periarticular plate|Standard of care device for femur fractures
75603252|NCT05706961|Other|Standardized Outpatient Cardiac Rehabilitation|"For 1- 2 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 60 % of of target heart rate, resistive ex with 1- 3 kg of weight for 20 min and 10 min of cool down)~For 3 - 4 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 70 % of target heart rate, resistive ex with 2- 3 kg of weight for 20 min and 10 min of cool down)"
75603253|NCT05706948|Other|High Intensity Interval Training (With Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with Face mask
75603254|NCT05706948|Other|High Intensity Interval Training (Without Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with out Face mask
75747793|NCT00429585|Device|reamed, interlocking intramedullary nail|Standard of care device for tibia fracture repair; Randomized Treatment - Nail
75747794|NCT00429585|Device|locking periarticular plate|Standard of care device for tibia fracture repair; Randomized Treatment - Plate
75898329|NCT03940924|Other|Training program|High Intensity Interval Training + Resistance Training (HIIT + RT)
76065052|NCT05814770|Drug|Spironolactone|The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP < 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP > 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
76065053|NCT05814731|Drug|MA-BUCY2|Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
76065054|NCT05814731|Drug|BUCY2|Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
76065055|NCT05814718|Drug|modified BEAM|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
76065056|NCT05814718|Drug|BEAM|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
75769315|NCT03902158|Device|Glasses|The patient will wear virtual reality glasses during anesthesia
76065057|NCT05814679|Other|Relaxation with virtual reality|In this research, a virtual reality relaxation video will be used in which the natural wonders are presented to the audience in an immersive environment.
76065058|NCT05814679|Other|Attention match|kidney function instruction
76065059|NCT05814601|Drug|norepinephrine|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
76065060|NCT05814562|Behavioral|Remote Intervention|The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
75747795|NCT06051383|Other|Self management|"patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes~Session 1 :~Introduction to the concept of self-management.~Education/reassurance~Managing fluid intake.~Caffeine abstinence~Alcohol advice~Session 2 :~Adjusting medications~Constipation advice.~Strategies for dribbling. pelvic floor exercise.~Double-voiding.~Bladder re-training.~Session 3:~• Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months"
75898330|NCT05692531|Behavioral|A Story Within A Story|"The intervention is the screening via Zoom of A Story Within A Story, two dramatized scenarios. The first depicts a reinforcing feedback loop connecting internalized, anticipated and enacted HIV stigma and serosorting within the Black SGL/MSM community. Set during the COVID-19 pandemic, it depicts a Zoom call among three generations of Black SGL/MSM, a chosen family. In this scene, the oldest member of the family, not knowing that the youngest has just tested positive for HIV, describes how they would never partner with someone who was living with HIV because of what they saw at the beginning of the HIV epidemic. The middle-aged member attempts to mitigate the damage done by this, while the youngest member describes what kind of support he needs. The second scenario depicts a Telehealth visit between a young Black gay man and his sexual health provider; his older lover joins the call at one point and the focus is on sexual communication and PrEP use."
75898331|NCT03517982|Drug|Mycophenolate Mofetil|Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil
76065061|NCT05813548|Other|FASTer Way Intervention|6-weeks of exercise, building healthy nutritional habits such as intermittent fasting and carb-cycling
76065062|NCT05813548|Other|Control Group Intervention|6-weeks of following general exercise and nutrition guidelines from American Heart Association (AHA) and United States Department of Agriculture (USDA), respectively.
75898332|NCT02298374|Other|Homecare reablement|
76065063|NCT05812391|Procedure|test|the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement
76065064|NCT05812391|Procedure|conventional|the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
76065065|NCT05812235|Procedure|esophagectomy|esophagectomy
75452020|NCT01734759|Drug|Taste Test|"Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg"
76065066|NCT05812105|Other|Healthy Buddy Program|The Healthy Buddy Program is a community-based initiative that pairs college students with transportation disadvantaged, community- dwelling older adults age 65 and older. The Spanish-language Healthy Buddy Program was developed to measure the transportation and health challenges of Hispanic/Latino older adults and determine the efficacy of the adapted HB program model.
76065067|NCT05812014|Biological|SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
76065068|NCT05812014|Drug|0.9% sodium chloride solution|One dose was administered by intramuscular injection, 1.0ml/dose
76065069|NCT05812001|Behavioral|Exergames-acceptance and commitment therapy (e-ACT)|In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.
75452021|NCT01734798|Radiation|Radiation|
75769316|NCT03902158|Behavioral|Distraction techniques|The patient will undergo distraction techniques
75898333|NCT02298374|Other|usual care|
76065070|NCT05812001|Behavioral|Acceptance and commitment therapy (ACT)|As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
76065071|NCT05810974|Dietary Supplement|Concentrated beetroot juice|Subjects will consume 70ml shot (Beet-it Sport nitrate 400 shot, James White Drinks) and this drink contains 0.4g inorganic nitrate
76065072|NCT05810974|Dietary Supplement|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|Nitrate-depleted beetroot juice (70ml) and 0.4g KNO3- will be mixed. (Same appearance and taste with Beet-it sport shot)
76065073|NCT05810974|Dietary Supplement|Nitrate depleted beetroot juice|Subjects will consume 70ml of (Beet-it Placebo shot, James White Drinks). This drink is the same as the Beet-it Sport nitrate shot but has the nitrate removed.
75452022|NCT01734798|Drug|gemcitabine and cisplatin|
75452023|NCT01734798|Other|Radiotherapy and Drug|
75452024|NCT01734824|Drug|Denosumab|sc RANKL-inhibitor
75452025|NCT01734824|Drug|Teriparatide|daily subcutaneous injection of teriparatide
75452026|NCT01734824|Drug|Placebo Denosumab|one subcutaneous injection denosumab placebo
75452027|NCT01734824|Drug|Placebo Teriparatide|daily subcutaneous placebo injection
75898334|NCT03869944|Drug|Lamivudine Oral Solution|"During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight <8 kg; and 50 mg twice a day if weight >8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART."
75747796|NCT06051344|Drug|Zoledronic acid|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
75898335|NCT02291822|Drug|Gadobenate Dimeglumine|gadolinium contrast agent
75898336|NCT05105178|Other|Giving orientation with headphones|During emergence, recorded voice of an investigator giving Information of orientation (time, place, patient's own name) is repeatedly played from noise-cancelling headphones
76065074|NCT05810545|Other|Per- and polyfluoroalkyl substances (PFAS)|Assess the association between exposure to per- and polyfluoroalkyl substances (PFAS) via drinking water in pregnancy and birth outcomes (i.e. growth retardation, premature birth, and congenital developmental defects) and maternal morbidity (gestational hypertension, diabetes and preeclampsia) in a prospective population-wide register based cohort.
76065075|NCT05810519|Behavioral|Active break with the proposed lumbar and hip extension exercises|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting. In the experimental intervention, the exercise program include exercises and will be based on patient education. The participants will also explain the importance of regular training and receive a booklet with photographed and described exercises.
76065076|NCT05810519|Behavioral|Self-care recommendations|Participants assigned to the control group will receive an educational self-care book containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. The control group will perform their regular baseline activities.
76065077|NCT05808426|Device|Bonus Winner Mahjong|Bonus Winner Mahjong developed by Bonus Winner Online Entertainment Co., Ltd. The participants in experimental group played three times a week, each time requiring at least lasting 30 minutes, for half of a year.
76065078|NCT05807451|Procedure|High Tibial Osteotomy (Uniplanar and Biplanar )|High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques
76065079|NCT05804643|Procedure|Diffusion magnetic resonance imaging|Free water elimination diffusion MRI and diffusion kurtosis MRI techniques
76065080|NCT05804136|Device|Duramesh|Laparotomy closure with Duramesh
75452028|NCT01734837|Device|DS-Ligature Clip|
75452029|NCT01734863|Radiation|External Beam Radiotherapy|
75603255|NCT05696327|Other|Tyler Twist Exercises|Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.
75747797|NCT06051331|Behavioral|simulation-based breast health education|The intervention group will receive simulation-based breast health education once a week for eight weeks. The simulation- based breast health education program will compose two part. The first part, it will theoretical education and second part will continue as practical education. On the plan date, a 60-min lecture will give about breast cancer, its risk factors, interventions to reduce the risk of breast cancer, the value of early diagnosis and cancer screening. After a 10-min break, course attendees watched a 20-min video, after which the course attendees' questions will answer.
75452030|NCT01734876|Behavioral|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
75452031|NCT01734876|Behavioral|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
75452032|NCT01734915|Device|Circulating tumor cell chip|three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
75452033|NCT01734941|Drug|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
75452034|NCT01734941|Drug|Placebo|
75603256|NCT05696327|Other|conventional physical therapy|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
75603257|NCT05665855|Dietary Supplement|Ketone monoester|A commercial liquid ketone monoester supplement.
75603258|NCT05665855|Other|Placebo|A liquid placebo that is taste-matched to the ketone monoester supplement.
75603259|NCT05665426|Other|acupuncture|Patients allocated to the acupuncture group will be punctured at the pre-specified acupoints. According to the theory of traditional Chinese medicine and clinical experience, we will use the Bilateral Weizhong point (BL 40). Because of the similar anatomy, the Chize point (LU 5) was chosen as a control. Sterile disposable stainless steel acupuncture needles (length: 40 mm, diameter: 0.25 mm; Hwato, Suzhou, China) will be used.
76065081|NCT05804136|Device|Polydioxanone suture|Laparotomy closure with standard PDS
76065082|NCT05803759|Dietary Supplement|Allicor|Each capsule contains 150 mg dried garlic powder
76065083|NCT05803759|Drug|Placebo|Capsules manufactured to mimic Allicor 150 mg capsules
76065084|NCT05801861|Device|Active 10-Hz TMS to the parietal cortex|The active 10-Hz TMS group will receive 10hz TMS stimulation in the first TMS session, and single pulse TMS in the second TMS session. Participants in the active stimulation group will receive 10-Hz TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
76065085|NCT05801861|Device|Active single pulse TMS to the parietal cortex|The active single pulse TMS group will receive single pulse TMS stimulation in the first and second TMS session. Participants in the active stimulation group will receive single pulse TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
76065086|NCT05801861|Device|Sham 10-Hz TMS to the right parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
75452035|NCT01734954|Procedure|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
75603260|NCT05665426|Other|moxibustion|Moxibustion Participants in the moxibustion group will receive moxibustion treatment via portable Moxibustion (Aikeshu, Bozhou, China); the moxibustion is composed of The inner tube (containing the moxa pillar) and the outer tube. To use, pull out the inner tube and light the moxa pillar, then insert the outer tube and fix the moxibustion on the acupuncture points. Two Moxibustion devices will be sequentially applied at two acupoints Weizhong (BL 40) and Chize (LU 5), for 30 minutes.
75603261|NCT05635110|Drug|VX-548|Tablets for oral administration.
75603262|NCT05635110|Drug|Omeprazole|Tablets for oral administration.
75452036|NCT01734954|Procedure|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
75452037|NCT01734954|Drug|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
75452038|NCT01734954|Device|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
75452039|NCT01734954|Device|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
75452040|NCT01734954|Drug|supplemental oxygen|supplemental oxygen during the block and/or during surgery
75603263|NCT05635110|Drug|Rifampin|Capsules for oral administration.
75603264|NCT05630807|Drug|Bepirovirsen|Bepirovirsen will be administered.
75603265|NCT05630807|Other|Placebo|Matching placebo will be administered.
75603266|NCT05619367|Drug|Odronextamab|
75603267|NCT05616702|Other|Pressure Biofeedback Therapy + Progressive Muscles Relaxation + thermotherapy|"Pressure Biofeedback Therapy~prone position, abdominal drawing in for 10 sec. (PBU inflated to 70 mmHg)~Supine position with flexed knees, abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Progress to leg loading in supine abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Exercising dosage:~Duration: 15 mins~Frequency: 3 sessions/ week~Repetitions: 3 sets of 15 reps~Progressive Muscles Relaxation Technique~Tense => five seconds and,~release => ten seconds (Each group of muscle)~2 circuits daily~Exercising dosage:~Duration: 15 mins~Frequency: weekly 3 sessions; for 6 weeks~Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
75603268|NCT05616702|Other|Progressive Muscles Relaxation + thermotherapy|"Progressive Muscles Relaxation Technique~Tense => five seconds and,~release => ten seconds (Each group of muscle)~2 circuits daily~Exercising dosage:~Duration: 15 mins~Frequency: weekly 3 sessions; for 6 weeks~Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
76065087|NCT05801861|Device|Sham single-pulse rTMS the rigt parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
75898337|NCT05105178|Other|Emergence as usual with headphones|During emergence, recorded voice of an investigator calling the patient's name is repeatedly played from noise-cancelling headphones
76065088|NCT05797662|Drug|Propranolol|Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks
76065089|NCT05795257|Procedure|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
76065090|NCT05786378|Biological|Platelet Rich Plasma|"Sample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use.~Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~PRP activation prior to injection. PRP can be activated exogenously by calcium chloride."
75898338|NCT02291900|Procedure|core decompression|retrograd drilling of the avascular talar necrosis, followed by osseous autograft
75898339|NCT05429905|Biological|Phase I|"Dose level 0: CAR+CD3+ 0.4 x 10e6/kg (de-escalation dose)~Dose level 1: CAR+CD3+ 1 x 10e6/kg (starting dose)~Dose level 2: CAR+CD3+ 2.5 x 10e6/kg.~Dose-escalations for adults and paediatrics will be performed in 2 independent strata for determination of RP2D."
75898340|NCT05429905|Biological|Phase II|RP2D will be determined in Phase I
76065091|NCT05786378|Drug|local anesthesia in external auditory canal|local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
76065092|NCT05786378|Procedure|Intratympanic Injection|0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.
76065093|NCT05785845|Radiation|Computed tomography-guided stereotactic adaptive radiotherapy|Fractions will be delivered on consecutive business days.
76065094|NCT05785845|Device|ETHOS|ETHOS is a unique ring-gantry CT-guided linear accelerator notable for having an on-board cone beam CT (CBCT) imaging unit with improved definition and resolution to enable target and organ-at-risk contouring. It also has a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
76065095|NCT05782738|Procedure|Percutaneous Coronary Intervention|Use dedicated two stents technique for treatment of coronary bifurcation stenosis
76065096|NCT05781880|Other|Oxygen 100%|NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)
76065097|NCT05779241|Drug|LYN-005|Risperidone long-acting oral capsule
76065098|NCT05779241|Drug|Risperidone|Risperidone immediate release (IR) oral tablets
76065099|NCT05778344|Behavioral|Teletechnology-assisted home-based pulmonary rehabilitation|The accuracy and safety of home-based pulmonary rehabilitation will be checked regularly through technology devices such as smart watch and via videotelephony (or telephone calls if indicated).
76065100|NCT05772572|Other|Questionnaires|"Questionnaires are completed only once and assess:~recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~psychiatric questionnaires for parents and patients on anxiety and depression~behavior questionnaires for the parents and the patient: assessment of attachment~questionnaires for the parents and the patient concerning the family context, the quality of life"
76065101|NCT05770596|Drug|vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
75603269|NCT05615025|Drug|Sevoflurane|Anesthesia will be maintained by sevoflurane.
75603270|NCT05615025|Drug|Propofol|Anesthesia will be maintained by propofol.
75747798|NCT06051292|Other|Fast method|Fast decremental catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
76065102|NCT05770596|Other|placebo group|patients in this group will receive placebo tablets with the same manner; orally 1 hour before surgery and for 50 days starting from the 2nd postoperative day.
75452041|NCT01734954|Drug|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
75747799|NCT06051292|Other|Conventional method|Conventional catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
75769317|NCT01149304|Drug|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
76065103|NCT05768100|Dietary Supplement|1,3-Butanediol|1,3-Butanediol
76065104|NCT05768100|Dietary Supplement|Placebo|Isovolumic placebo
76065105|NCT05766358|Behavioral|Intensive lifestyle change therapy|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
76065106|NCT05766358|Drug|Tirzepatide|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
75452042|NCT01734954|Drug|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
75452043|NCT01734954|Procedure|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
75452044|NCT01734967|Device|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis."
75603271|NCT05608018|Other|Intervention Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with all features turned on.
75603272|NCT05608018|Other|Intervention non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with all features turned on.
75603273|NCT05608018|Other|Control Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with some features turned off.
75603274|NCT05608018|Other|Control non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with some features turned off.
76065107|NCT05762926|Other|Transcranial pulse stimulation (TPS)|Clinical treatment consists in ten sessions of neuronavigation system guided halocranial application of 6000 focused sound wave pulses, with energy flux density of 0.25 mJ/mm2, depth of focus of 5 cm and useful energy between 4 to 6 cm, frequency of 4 Hz, total energy applied will be 50 Joules, for it will be used the Storz Neurolith™ equipment.
76065108|NCT05762614|Other|Dyspnea assessment|Dyspnea assessment, respiratory variability, Spirometry, Electromyography
76065109|NCT05757557|Drug|Sham treatment|Sham treatment: Oxygen-air mixture without NO after intubation, during CPB, and for six hours after surgery.
76065110|NCT05757557|Drug|80-ppm NO|NO will be supplemented at 80-ppm concentration to cardiac surgery patients perioperatively after trachea intubation, during CPB, and for six hours after surgery.
76065111|NCT05751317|Diagnostic Test|Culture|"Samples will be transported to Medical Microbiology and Immunology Laboratory and will be inoculated on MacConkey medium.~Pink colonies will be inoculated on bile esculin agar medium.~Enterococci produce blackening of the agar"
76065112|NCT05751317|Diagnostic Test|Staining:|The growing colonies on bile esculin agar medium will be examined microscopically after staining by Gram stain.
76065113|NCT05751317|Diagnostic Test|Biochemical reactions:|"Catalase test.~Salt tolerance test"
76065114|NCT05751317|Diagnostic Test|VITEK|Automated identification of Enterococci will be done with VITEK2 system.
76065115|NCT05751317|Diagnostic Test|Antibiotic sensitivity test|Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on Mueller-Hinton Agar.
76065116|NCT05751317|Diagnostic Test|nanoparticles effect|The effect of nanoparticles on Enterococci antimicrobial resistance pattern
76065117|NCT05751317|Diagnostic Test|The biofilm formation activity|The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique
76065118|NCT05751317|Diagnostic Test|molecular diagnosis|Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR
76065119|NCT05750082|Device|CCTA CT-FR CAG OCT|Per the protocol, patients will have a CCTA (coronary computed tomography angiography), CT-FFR (fractional flow reserve derived from CTA), ICA (invasive coronary angiography), OCT (optical coherence tomography).
76065120|NCT05748470|Other|SkinCeuticals A.G.E|Ultrasound therapy combined with SkinCeuticals A.G.E + conventional moisturizing and sunscreen.
76065121|NCT05748470|Other|standard cream|Ultrasound therapy combined with standard cream + conventional moisturizing and sunscreen
76065122|NCT05746182|Diagnostic Test|Hereditary Cancer Panel|UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
76065123|NCT05745909|Procedure|Laparoscopic or open low-anterior resection of the rectum with TME and created loop transverse colostomy|The loop transverse colostomy is matured without torsion using a plastic retainer. The stoma protrudes 2-3 cm. The loop of the transverse colon is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
76065124|NCT05745909|Procedure|Laparoscopic or open low-anterior resection of the rectum with TME and created loop ileostomy|The loop ileostomy is matured 25-30 cm from the ileocecal angle without torsion and without a retainer, so that stoma protrudes 2-3 cm. The loop of the ileum is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
76065125|NCT05742113|Device|Masimo Radical-7|perfusion index measuring device
76065126|NCT05740228|Device|Anodal tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
75898341|NCT05692219|Behavioral|Lifestyle medicine|6 weeks booklet-delivered multicomponent lifestyle medicine intervention
75898342|NCT05692219|Behavioral|Cognitive behavioral therapy|6 weeks booklet-delivered self-help cognitive behavioral therapy
75898343|NCT03547596|Other|questionnaire passation|Questionnaires to evaluate lower urinary tract symptoms and erectile dysfunction.
76065127|NCT05740228|Device|Anodal High-Definition (HD) tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
76065128|NCT05740228|Device|Sham stimulation - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
75747800|NCT06051266|Device|Dynamic navigation|Dynamic navigation eliminates the need for a laboratory fabrication process and allows for direct visualisation of the operative area during implant placement. Moreover, it can avoid interfering with water cooling. Navigation-assisted surgery makes it possible to modify the implant system, length, diameter or position in real time, both in the perioperative period and during surgery.
75747801|NCT06051266|Device|Static template|In most clinical situations, a static template can be used to assist in guiding the placement of implants precisely. The static guide has some limitations in that it requires additional fabrication time, has insufficient cooling in the surgical field and is not suitable for simultaneous grafting procedures.
75898344|NCT03514628|Other|Standard Care|The Valsalva strain will be produced using Standard Care techniques
75898345|NCT03514628|Device|Valsalva Assist Device (VAD)|Use of Valsalva Assist Device (VAD) to generate VM
75603275|NCT05602181|Behavioral|ALL Phonics Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech.
75603276|NCT05602181|Behavioral|ALL Sight Word Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech. This group will only use the sight word lessons, as well as the library for sight word books. No phonics instruction will be provided through the app.
75898346|NCT04435522|Drug|Maraviroc|Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
75898347|NCT03843970|Drug|Levobupivacaine Hydrochloride 0.5%|The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
75603277|NCT05583461|Procedure|Positive end-expiratory pressure titration|Positive end-expiratory pressure level
75603278|NCT05578963|Other|Schaeffer's Test for palmaris tendon|After demographics, Schaeffer's Test will be used to check the presence or absence of palmaris longus muscle. In this test, students will maintain the forearm at 90 degrees first followed by moving the thumb in opposition towards the little finger with the wrist partially flexed. If the tendon bulges out, it will reflect presence of palmaris longus and vice versa. This finding will be recorded. After that, students will perform Phalen's test. In this test, researcher will ask them to press the backs of their hands and fingers together with their wrists flexed and fingers pointed down. they'll stay that way for a minute or two. If fingers tingle or get numb, it will indicate carpal tunnel syndrome. The reading will be recorded.
75898348|NCT03843970|Drug|Isobaric bupivacaine 0.5%|The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
75898349|NCT02298452|Device|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
75747802|NCT06051240|Drug|Lithium|Lithium sulphate, 42 mg (6 mmol lithium)
75747803|NCT06051240|Drug|Placebo|White round tablet, 10 mm. Identical to experimental drug (lithium)
75747804|NCT06051214|Biological|thrombogram|blood sampling every month for 12 months
75747805|NCT06051201|Other|ReceptIVFity test (vaginal microbiome swab)|"A vaginal self-swab for determination of the vaginal microbiome is performed by the patient.~For women of European origin randomization in one of the following groups:~SDM group: Using Shared-Decision-Making according to the ReceptIVFity microbiome profile with its predicted chance of achieving a pregnancy in the current cycle.~Physician decision group: Postponing treatment until a switch to a favorable ReceptIVFity microbiome profile"
75898350|NCT03645369|Device|ShotBlocker|ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
75898351|NCT03645369|Device|Ice pack|Ice pack containing gel
75898352|NCT02294708|Behavioral|postoperative postures|two postoperative postures: supine and temporal-lateral
75898353|NCT04367298|Behavioral|Chronoprevention|Preventive measures will be focused on organizational, educational and behavioural elements related to older people and healthcare professionals
75898354|NCT02291978|Device|ExAblate 2100|The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
75747806|NCT06051175|Other|Bitter taste perception|"Participants will perform a bitter taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
75747807|NCT06051175|Other|Salty taste perception|"Participants will perform a salty taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
75452045|NCT01734967|Procedure|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
75747808|NCT06051175|Other|Sweet taste perception|"Participants will perform a sweet taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
75898355|NCT02807350|Device|Overminus treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
76065129|NCT05737667|Behavioral|Youth Readiness Intervention (YRI)|The YRI is a culturally adapted group intervention that integrates common practice elements of cognitive behavioral and interpersonal therapies. The YRI's core treatment elements target improving emotion regulation skills, interpersonal functioning, and problem-solving skills. The YRI has 12 session that last about 90 minutes. The YRI will be delivered in schools by teachers receiving either mobile-based supervision or standard, in-person supervision.
76065130|NCT05737004|Diagnostic Test|functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II|fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
76065131|NCT05733013|Other|Surveillance Visit|Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
76065132|NCT05723107|Drug|Chemotherapy|Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
75452046|NCT01734980|Procedure|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
75452047|NCT01735006|Biological|HPV Vaccine|3 doses at month 0,1 and 6
75452048|NCT01735006|Biological|HEV vaccine|3 doses at month 0,1 and 6
75452049|NCT01735019|Drug|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
75452050|NCT01735045|Device|Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens|Daily Wear
75452051|NCT01735045|Device|Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens|
75747809|NCT06051175|Other|Acid taste perception|"Participants will perform a acid taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
75747810|NCT06051175|Other|Umami taste perception|"Participants will perform a umami taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
75747811|NCT06051136|Behavioral|Pulmonary rehabilitation|"The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise.~The exercise program is individualized and can be delivered in telerehabilitation."
75747812|NCT06051110|Device|Combined risk score|Prehospital risk stratification by the use of a combined clinical risk score including POC-troponin
75898356|NCT02807350|Device|Non-overminus treatment|spectacles with full cycloplegic refraction without overminus
75898357|NCT04465526|Diagnostic Test|computed tomography perfusion imaging|The new-generation dual-source computed tomography scanner Somatom® Force will be used for all CTP studies. Myocardial perfusion will be evaluated in a stress dynamic CT protocol. The scan range will be determined based on a low-dose non-contrast scan. Subsequently, regadenoson will be administered intravenously at a single dose of 0.4 mg, and followed after 50 seconds delay by 35 mL of the iodinated contrast agent (iohexol, concentration 350 mg I/mL) injected at the flow rate of 5 mL/s. Finally, low-dose non-contrast dual-energy CT scan will be performed 5-6 min after the dynamic scan to assess late enhancement of the myocardium.
75898358|NCT03043651|Drug|Oral treprostinil|Sustained-release oral tablets for TID administration
76065133|NCT05723107|Device|Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)|"EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes."
76065134|NCT05723029|Other|Bowen Technique|A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.
76065135|NCT05723029|Other|Post Isometric Relaxation|Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
76065136|NCT05720377|Device|continuous glucose monitor (Freestyle Libre|15 minute phone interview by health care provider to assess health goals set at clinic visits.
76065137|NCT05720299|Drug|Treatment with Akkermansia muciniphila|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
75452052|NCT01735058|Drug|Sodium Hyaluronate|Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
75452053|NCT01735058|Drug|Normal saline|Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
75452054|NCT01735071|Drug|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
75898359|NCT04353024|Drug|Dimethyltryptamine (DMT)|Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min
75898360|NCT04353024|Drug|Saline|Intravenous saline bolus and/or saline maintenance perfusion over 90 min
75898361|NCT04465292|Drug|Tildrakizumab Prefilled Syringe|Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
75898362|NCT03638817|Drug|Eltrombopag|"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is < 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"
76065138|NCT05720299|Other|Treatment with placebo|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
75452055|NCT01735071|Drug|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
76065139|NCT05719701|Drug|ICP-490|The initial dose of ICP-490 is 0.1 mg, five dose groups are planned for the dose exploration (0.1 mg to 1.5 mg).
75452056|NCT01735084|Biological|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg)."
75452057|NCT01735084|Biological|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
75452058|NCT01735097|Dietary Supplement|Vitamin E|Vitamin E (200 mg, soft capsule)
75747813|NCT06051110|Other|Usual care|Prehospital risk stratification by EMS protocols
75747814|NCT06051110|Device|point-of-care troponin|Prehospital risk stratification by the use of a POC-troponin
75747815|NCT06051097|Diagnostic Test|sleep study|over-night polysomnography
75747816|NCT06051084|Behavioral|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
75747817|NCT06051084|Behavioral|App-Delivered Coloring|An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
75747818|NCT06051071|Device|Transcranial Direct Current Stimulation (tDCS)|In tDCS, surface electrodes (anode and cathode) inject low-intensity direct current through the skull to modulate brain activity and cortical excitability
76065140|NCT05716984|Drug|recombinant human brain natriuretic peptide|rhBNP 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
76065141|NCT05716984|Drug|Placebo|placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
76065142|NCT05715177|Other|Cura Kinesio-taping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length will be applied on origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
76065143|NCT05715177|Other|Placebo kinesio-taping|Placebo kinesiotaping
76065144|NCT05715034|Behavioral|Compassionate Care|Single-session web-based program
76065145|NCT05715034|Behavioral|Relaxing with Nature|Single-session web-based program
76065146|NCT05713448|Other|No intervention|No intervention
75452059|NCT01735097|Dietary Supplement|Nigella sativa|Nigella sativa (200 mg, soft capsule)
75452060|NCT01735097|Dietary Supplement|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
75452061|NCT01735110|Procedure|transfemoral intervention (TFI)|
75452062|NCT01735110|Procedure|Transradial intervention|
75452063|NCT01735123|Dietary Supplement|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
75769318|NCT01149304|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
75452064|NCT01735136|Dietary Supplement|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
75452065|NCT01735136|Dietary Supplement|Placebo|Placebo (10g/day)
75452066|NCT01735149|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
75452067|NCT01735149|Dietary Supplement|Placebo|Placebo (34.5g/day)
75898363|NCT02298530|Other|Combination of caffeine and theanine|Beverage containing caffeine and theanine
75747819|NCT06051032|Device|Balloon thrombectomy|A specialized catheter with an inflatable balloon at the tip is inserted over a guidewire, previously inserted through the sheath, and advanced to the location of the clot within the blood vessel. The catheter is positioned precisely using fluoroscopic guidance or other imaging modalities. Once positioned, the balloon is inflated, creating pressure against the clot and effectively removing or dislodging it from the vessel walls.
75769319|NCT01149304|Drug|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
75898364|NCT02298530|Other|Caffeine|Beverage containing caffeine
75898365|NCT04218877|Other||There will be no intervention, only observation
75898366|NCT03634215|Diagnostic Test|fibrinogen plasma concentration, coagulation factor XIII activity|blood sampling for a routine coagulation test
75898367|NCT02294864|Device|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
75898368|NCT02294864|Procedure|Physical Therapy|
76065147|NCT05713305|Procedure|Online-based self-help psychological intervention|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists
76065148|NCT05713305|Procedure|Provide online mental health knowledge|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news
76065149|NCT05707390|Drug|Mezigdomide|Specified dose on specified days
75603279|NCT05549414|Device|Proton Radiation|Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios
75603280|NCT05541627|Genetic|AB-1001 Gene Therapy|One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
75603281|NCT05521256|Drug|NNC0113-6856|Participants will receive NN0113-6856 orally or intravenously.
75603282|NCT05521256|Drug|Placebo|Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.
75769320|NCT01254526|Drug|GDC-0980|Oral repeating dose
75769321|NCT01254526|Drug|bevacizumab|Intravenous repeating dose
75898369|NCT04084522|Dietary Supplement|Saturated Fat- Desi Ghee (Clarified Butter)|Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.
75898370|NCT04084522|Dietary Supplement|Soyabean Oil|Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
75452068|NCT01735227|Drug|omeprazole|all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
75452069|NCT01735227|Drug|Pantoprazole|On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
75898371|NCT03644589|Biological|Pembrolizumab|200mg,Given intravenous (IV) infusion, every 21 days
75603283|NCT05519644|Other|Sleep Deprivation|The sleeping protocol will be monitored by investigators and personnel with experience in sleep medicine. Participants will be required to reduce sleep by 50% of normal, for 4 consecutive nights, to observe potential deficits in physical and cognitive performance
75898372|NCT03644589|Drug|Cisplatin|75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
75898373|NCT02298608|Device|Nano Knife|Percutaneous, CT guided, ablation of renal mass
75898374|NCT03621423|Procedure|ultrasound guided injection|"Patient will be positioned lying on side with the hemiplegic side up. The shoulder will be placed in a flexion and external rotation/abduction position, as possible by the patient, to give the ultrasound probe access to the posterior axillary fold.~As previously described in the literature, a line of best fit was calculated by bisection of hypothetical line connecting the inferior spine and the acromial tip, an 18-gauge, 10-cm needle will be inserted under direct ultrasound guidance and by a nerve stimulation . After placing the needle tip in the target point's 100 units of botulinum toxin will be injected."
75898375|NCT03536143|Biological|Topical beremagene geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
75898376|NCT03536143|Biological|Placebo gel|Placebo gel
75898377|NCT03514550|Drug|Propofol|Propofol will be used for anesthesia during surgery
75898378|NCT03514550|Drug|Sevoflurane|Sevoflurane will be used for anesthesia during surgery
75603284|NCT05519644|Other|Heart Rate|HR will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets. Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
75603285|NCT05519644|Other|Sleep Monitoring|Sleep will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets.Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
75898379|NCT03514550|Procedure|Epidural block|Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
75898380|NCT04173988|Genetic|alloCART-19|"AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10^6 CAR+ cells/kg~For children with body weight > 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10^8 CAR+ cells."
76065150|NCT05701163|Other|Abstinence followed by semen sample collection.|Abstinence is the intervention. Semen samples will be collected after abstinence periods.
76065151|NCT05689879|Drug|STOP arm|TNF-alpha antagonists withdrawal
75452070|NCT01735240|Drug|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
75452071|NCT01735240|Drug|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
75452072|NCT01735253|Procedure|laparoscopic roux en Y gastric bypass / open duodenojejunal bypass|routine GBP with 80cm roux and biliopancreatic limb
75452073|NCT01735266|Other|Air colonoscopy|Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
75452074|NCT01735266|Other|Water exchange colonoscopy|Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
75747820|NCT06051032|Device|Thromboaspiration system|The thromboaspiration catheter is carefully guided to the site of the clot within the blood vessel. Once positioned, the suction mechanism is activated, creating a vacuum effect. The catheter gently aspirates or suctions the clot, gradually removing it from the vessel walls. The procedure is performed under fluoroscopic guidance or other imaging modalities to ensure accurate placement of the catheter and successful clot aspiration.
75747821|NCT06051019|Other|Aerobic training|Aerobic training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Sessions will be performed with the assistance or supervision of a physical therapist and will consist of the following steps: 1) warm up with a stationary bike (no load, 10 min, 60 cycles/min); 2) upper and lower limb stretching (10 min); 3) 10 min rest in a sitting position; 4) first exercise bout: stationary bike, 15 min, 60 cycles/min (the load will be modulated so that the participant's heart rate is between 60 and 70% of the estimated maximum heart rate, and the patient perceives moderate fatigue on the Borg Rating of Perceived Exertion; 5) upper and lower limb stretching (10 min); 6) 10 min rest in a sitting position; 7) second exercise bout (same parameters as the first exercise bout); 8) upper and lower limb stretching (10 min).
75769322|NCT01254526|Drug|paclitaxel|Intravenous repeating dose
75452075|NCT01735292|Device|Automatic Respiration Transfer System- Timer|
75452076|NCT01735318|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
75452077|NCT01735318|Drug|Lisinopril|40 mg tablet once a day
75769323|NCT01148992|Drug|Lofexidine|0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
75769324|NCT01148992|Drug|Placebo|0mg
75769325|NCT03910582|Procedure|personalized frozen-thawed embryo transfer|The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
75769326|NCT03910582|Procedure|routine frozen-thawed embryo transfer|The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
75898381|NCT04173988|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
75603286|NCT05519644|Other|Diet|Diet will be included and the same meals will be available for all subjects while controlling for caffeine. Participants will be given food during each intervention week.
75898382|NCT04173988|Drug|Fludarabine|Chemotherapy for lymphodepletion
75452078|NCT01735344|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
75452079|NCT01735344|Drug|Lisinopril|40 mg tablet once a day
75898383|NCT02294942|Drug|RANCAD|Extended-Release RANCAD
75898384|NCT01344759|Drug|Dexmedetomidine|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
75898385|NCT01344759|Drug|Propofol|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
75898386|NCT05692141|Device|ultrasound|For each lesion, ultrasound Elastography would be performed using a Linear probe ;
76065152|NCT05688904|Drug|Imipramine|Topical 4% Imipramine
76065153|NCT05688904|Other|Vehicle|Vehicle
76065154|NCT05687357|Drug|Tislelizumab|IV infusion
75452080|NCT01735357|Dietary Supplement|EPA-rich triacylglycerol oil|
76065155|NCT05687357|Drug|S-1|Oral tablets
75452081|NCT01735357|Dietary Supplement|Placebo - olive oil (BP specification)|
75747822|NCT06051019|Other|Balance training|Balance training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Treatments will be performed with a physical therapist and will consist of the following exercises: 1) standing with feet together, 2) standing with closed eyes, 3) standing on unstable surfaces, 4) standing while performing upper limbs movements; 5) standing while performing head rotations; 6) walking on a treadmill at alternating speeds; 7) leg press and chest press exercises for training trunk balance during ballistic movements of the upper and lower limbs. These constituents of balance training can be combined in the same task according to the participant's ability.
76065156|NCT05687357|Drug|Oxaliplatin|IV infusion
75898387|NCT03520868|Diagnostic Test|Monitoring Anti Factor Xa level|Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
75898388|NCT05885386|Drug|Temozolomide|TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
75898389|NCT05885360|Drug|Istradefylline Pill|"Istradefylline targets adenosine A2A receptors in the basal ganglia, by inhibiting the indirect pathway It is an adjunctive treatment to carbidopa-levodopa indicated to improve on time and decrease off time."
75898390|NCT05885347|Other|360 videos|Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.
75898391|NCT05885347|Other|VR|Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.
76065157|NCT05687357|Drug|Nab paclitaxel|IV infusion
76065158|NCT05687357|Radiation|Radiation|TOMO/VMAT
76065159|NCT05683457|Biological|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).
76065160|NCT05683457|Biological|Placebo|0.9% sodium chloride (normal saline) injection
76065161|NCT05682144|Biological|Autologous Plasmablasts (B cells)|Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
76065162|NCT05675943|Biological|Anti-COVID-19 Antibody SA55 for Injection|After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
76065163|NCT05673330|Other|Spinal Mobilizations|"Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks"
76065164|NCT05673330|Other|Myofascial Release Technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
75452082|NCT01735357|Dietary Supplement|DHA-rich triacylglycerol oil|
75452083|NCT01735370|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
75898392|NCT05885347|Other|AR|Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
75898393|NCT05885347|Other|Control group|Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
75603287|NCT05519644|Other|Exercise Performance|Since weight training is now a crucial part of any warfighter's physical preparation, we will have subjects perform weight training workouts emphasizing all major muscle groups on Days 2, 3 and 4
75603288|NCT05519644|Behavioral|Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index|These will be administered on Days 1 and 5 of each intervention trial to assess different behavioral outcomes.
75452084|NCT01735370|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
75452085|NCT01735383|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
75452086|NCT01735383|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
75452087|NCT01735409|Drug|ABX + DDP|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
75452088|NCT01735409|Drug|ABX + DDP|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
76065165|NCT05662800|Diagnostic Test|Assessment of peanut, tree nuts and sesame allergy|"Children will undergo skin prick testing with the following allergens: commercial extracts for peanut, hazelnut, almond, cashew, pistachio, walnut, macadamia, sesame, Timothy grass, and birch pollen; positive and negative control; peanut butter and tahini (sesame) paste.~Specific IgE levels will be quantified to all the above-listed tree nuts, peanuts, sesame seed and peanut components (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, Ara h 9).~Children will undertake cumulative or incremental oral food challenge with peanut, sesame and tree nuts, depending on the risk assessment based on patient's medical history and results of diagnostic tests."
76065166|NCT05657769|Device|Medwell Preventive Care Application|Regular diabetes treatment with additional Medwell application and wearable device.
76065167|NCT05657769|Device|Manual Records|Regular diabetes treatment only with a diary card to record daily activities manually.
76065168|NCT05656924|Device|digital prosthetic interface technology|Individuals randomized to this group will receive a socket and liner that are manufactured using a novel technique meant to achieve a better distribution of pressure on the residuum. The study is based on the hypothesis that an improvement in pressure distribution on the residuum will enable high adherence to an exercise program meant to improve health status in dysvascular amputees.
76065169|NCT05653934|Behavioral|Pre-operative use of virtual reality headset|Patient use the virtual reality headset the day before and / or the day of the surgery
76065170|NCT05653934|Procedure|Standard surgery|Patient are operated as needed for treatment of colorectal cancer (usual care)
76065171|NCT05653934|Behavioral|Post-operative use of virtual reality headset|Patient use the virtual reality headset as many time as they want after the surgery during a maximum of 30 days
76065172|NCT05653570|Diagnostic Test|Electrical stimulation|Electrical stimulation will be used to confirm needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
75603289|NCT05519644|Other|Cognitive performance|Automated Neuropsychological Assessment Metrics (ANAM), Cambridge Neuropsychological Test Automated Battery. (CANTAB),Gradual-onset Continuous Performance Task (GRAD-CPT),Face-Name Task will be used to assess cognitive function and performance.
76065173|NCT05653570|Diagnostic Test|Ultrasound|Ultrasound guidance will be used to visualize needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
76065174|NCT05648539|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
75452089|NCT01735409|Drug|ABX + DDP|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
75452090|NCT01735422|Drug|r-hFSH|Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
75603290|NCT05519644|Other|Marksmanship Performance|The Virtual Training Simulator (VirTra V-100) system (VirTra Corporate HQ, Tempe, AZ) is used by both military and law enforcement agencies to provide training. The V-100 and associated compatible weapons are equipped with recoil kits for unsurpassed live-fire simulation, at distances up to 2,000-m, authoring capabilities for the creation of customized scenarios on 4 individual firing lanes. Multiple metrics of marksmanship (total number of shots fired/silhouette target presentation, percentage of targets successfully hit/min, the radial distance of a shot from the center on target, shot group tightness, and time from target presentation to trigger pull) will be collected during each visit.
75747823|NCT06050993|Other|Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.|During the preoperative procedure scheduled at the Paul Brousse hospital, 3 additional blood tubes (total volume 12 ml) will be withdrawn in addition of samplings already done for the patient's standard of care.
75747824|NCT06050980|Drug|HSK40118|Oral administration, QD
75747825|NCT06050967|Combination Product|Enzyme replacement therapy for Gaucher disease in combination with altus care application|In coordination with the patient's treating physician and the home treating nurse, an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks enzyme replacement therapy dosages and timing frames for its administration. Per protocol, the patient's monthly dose was not changed, but each dose and the timing of administration was changed randomly using the app.
75747826|NCT06050941|Drug|idarubicin|Idarubicin 6mg/m2 d5-7
75747827|NCT06050941|Drug|Cytarabine|Cytarabine 60mg/m2 d5-9
75769327|NCT03901846|Device|ColdZyme|ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin
75898394|NCT05885308|Behavioral|Otago|Group training is compared with training performed at participants' homes, using an online film
75898395|NCT05885295|Diagnostic Test|MRI brain, Blood tests, cognitive assessments|observational study examining cognition post stroke using behavioural tests, MRI brain and blood tests
75898396|NCT05885269|Drug|Group A applied topical Clobetasol Propionate|Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months
75898397|NCT05885269|Drug|Group B applied topical Tacrolimus|Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
76065175|NCT05646654|Procedure|Erector spinae plane block|Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected
76065176|NCT05646654|Procedure|Interscalene brachial plexus block|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
76065177|NCT05645159|Other|Blended learning in heart disease|The intervention included face-to-face classes and online resources (Moodle, online syllabus, videos, websites, podcasts, activities, apps, forums, emails, tutoring).
76065178|NCT05643482|Device|Hyperbaric Oxygen Treatment|Pressurization at 2.0 ATA with 100% oxygen
76065179|NCT05643482|Other|Placebo gas|Pressurization at 2.0 ATA with 10.5% oxygen to mimic normal air
76065180|NCT05636280|Other|schroth exercise|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
76065181|NCT05636280|Other|traditional scoliosis exercise|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
76065182|NCT05634161|Other|Cognitive improvement software|Cognitive improvement software
76065183|NCT05633693|Behavioral|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
75898398|NCT05885256|Diagnostic Test|Amending current standard trauma order set|Blood draw happens as part of routine clinical care for all trauma activations. As part of the study, we will use existing blood that is drawn as part of routine clinical care, or when necessary, draw additional blood to obtain samples at 0, 3, 6, 12, 18, and 24 hours assessing ionized calcium, serum calcium, and magnesium. We will strive to have draws occur within +/- 1 hour of the goal times. However, given that the blood draws will be performed by way of the clinical team and the unpredictable nature of trauma care, missed draws or draws out of the goal time frame will not be considered protocol violations
75898399|NCT05885243|Device|ESWT|will be given once a week, total 5 sessions ofESWT+ home exercises program
75898400|NCT05885243|Device|customized insoles|Will be given customized insoles+ home exercise program. Insoles will be used for 12 weeks.
75898401|NCT05885243|Combination Product|combined ESWT and custtomized insoles|Will be given once a week, total 5 sessions of ESWT+ home exercise program. Also, simultaneous insoles will be provided. Insoles will be used for 12 weeks.
75452091|NCT01735422|Drug|r-hLH|Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
76065184|NCT05633693|Behavioral|Baseline Stand|Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
75898402|NCT05885204|Procedure|Robot-assisted radical cystectomy|Robot-assisted laparoscopic radical cystectomy
75898403|NCT05885204|Procedure|Conventional laparoscopic radical cystectomy|Conventional laparoscopic radical cystectomy
76065185|NCT05633446|Biological|PepGNP-COVID19 (One vaccination)|One dose with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
76065186|NCT05633446|Other|Water for injection (One vaccination)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
76065187|NCT05633446|Biological|PepGNP-COVID19 (Two vaccinations)|Two vaccinations with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
75452092|NCT01735422|Drug|u-hCG|Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
75898404|NCT05885178|Procedure|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
75898405|NCT05885165|Behavioral|Supervised team-based exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each.
75898406|NCT05885165|Behavioral|Unsupervised exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each. First two weeks are supervised, the following 10 weeks are unsupervised.
75898409|NCT05885126|Other|MANDALA TECHNIQUE|The ambient light and the position of the laptop table were adjusted appropriately during the intervention to help the participants move freely and eliminate the environmental stimulus. In addition, there was no communication between the patient and the practitioner during the application.
75452093|NCT01735435|Other|Indirect Calorimetry|"The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes."
75603291|NCT05519644|Other|Quick Board|Upper body and lower body reaction tests will be assess using Quick Board Analysis on days 1 and 5 of the sleep restriction intervention.
75603292|NCT05519644|Other|Advanced Medical Technologies Inc, Jump Test|Whole body power will be assessed with a repetitive jump test. Power (peak, average, curve functions) will be assessed using an AMTI force plate with Accupower 2.0 software (Advanced Mechanical Technology Inc, Watertown, MA).
76065188|NCT05633446|Other|Water for injection (Two vaccinations)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
76065189|NCT05618938|Other|Rocabado's approach|"Group A will be treated with Rocabado's approach. Rocabado' approach will be comprised of six exercises.~Rest position of the tongue~Control of TMJ rotation~Rhythmic stabilization technique~Axial extension of the neck The patients will receive Rocabado's approach consisting 6 repetitions six times a day thrice per week for four weeks"
76065190|NCT05618938|Other|Kraus exercises|"Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~Tongue position at rest~Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~Nasal-diaphragmatic breathing~Tongue up and wiggle~Strengthening~Touch and bite: Proprioceptive re-education: Lateral deviation The patients will receive Kraus exercises with the frequency of 2 sets and 10 repetitions twice a day three times per week for four weeks"
76065191|NCT05616065|Other|Blinding to academic performance of candidate|Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.
76065192|NCT05616065|Other|Usual Interview methodology|Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
76065193|NCT05612139|Device|JTIN implantation surgery|The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.
75603293|NCT05519644|Other|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at ~2- week intervals during the study. The sensor will be removed at the end of the final test day.
75603294|NCT05519644|Biological|Blood Draw|Blood samples will be collected according to the schedule in Figure 1.
76065194|NCT05604222|Drug|Mirabegron 50 MG|Medication to treat overactive bladder
76065195|NCT05604222|Behavioral|Brief Behavioral Treatment for Insomnia|A behavioral intervention for insomnia
76065196|NCT05654610|Device|Halova|Halova is a class I medical device formulated as vaginal ovules and intended for intravaginal administration in order to promote and/or accelerate the hydration, healing, re-epithelialization and/or soothing of injured, atrophic or irritated vaginal mucosa. The ovules melt evenly in the vaginal mucosa forming a cream with a moisturizing and calming effect that support the restoration of the vaginal epithelium.
76065197|NCT05589350|Other|saturated fat intake|Intake of saturated fat from yogurt and animal butter daily for 4-week period
76065198|NCT05586152|Drug|INV-102|INV-102 Ophthalmic Solution
76065199|NCT05586152|Drug|Vehicle|Vehicle Ophthalmic Solution
76065200|NCT05565222|Drug|Piperacillin/tazobactam or temocillin|"Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)"
76065201|NCT05565222|Drug|Meropenem|2 g every 8 hours by intravenous route (adjusted in case of renal failure)
76065202|NCT05562427|Behavioral|Gold-Standard Online Behavioral Obesity Treatment|Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
75603295|NCT05519644|Dietary Supplement|Ketone Supplement|Participants will take a diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) during one of the trial interventions
75603296|NCT05501002|Device|eShunt® Implant|The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.
75603297|NCT05485441|Other|Digital Educational Intervention|"The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)"
75603298|NCT05456815|Other|Standardized diet|During 9 weeks all food products will be standardized and provided by the Research Unit. The standardized diet is based on the average food composition in the Netherlands.
75898410|NCT05885100|Drug|Eleveld Model|Target plasma propofol
75898411|NCT05885087|Device|Foley or balloon catheter|Three Foley balloon catheters attached side by side were inflated with 60mls each and a gentle traction of 250mls water applied.
75898412|NCT05885048|Diagnostic Test|Blood samples for analysis|Test hormone levels in blood
75898413|NCT05885048|Diagnostic Test|Sperm samples for analysis|Spermiogram
75898414|NCT05885048|Other|Satisfaction evaluation|Participant satisfaction assessment
75898415|NCT05885048|Other|Quality of Life questionnaire|Short-Form 12-items health survey (SF-12)
75898416|NCT05885035|Drug|Calcium Hydroxyapatite|Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
76065203|NCT05552820|Device|Verum Electroacupuncture|Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.
76065204|NCT05552820|Device|Sham Electroacupuncture|Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23)，SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.
76065205|NCT05547932|Procedure|RIB+SAP blocks|RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
75603299|NCT05453071|Other|Cognitive Exercise Therapy Approach (BETY)|BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
75747828|NCT06050902|Device|Subclavian venipuncture for catheter placement using the needle-steering device|"Navigation software is implemented in an ultrasound machine.~A linear ultrasound probe (similar in appearance to a standard ultrasound probe) is used~Magnetization of the puncture needle after short introduction of the needle in a dedicated device.~Real time needle guidance on the ultrasound screen during the puncture."
75898417|NCT05885009|Genetic|Liquid Biopsy|Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy
75898418|NCT05885009|Genetic|Archival Tumor DNA sequencing|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
75898419|NCT05884983|Procedure|participants will undergo dual-energy CT and endoscopy|Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy
76065206|NCT05546502|Biological|SARS-CoV-2 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
76065207|NCT05546502|Biological|Active Comparator|Covovax
76065208|NCT05537233|Drug|Semaglutide|Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
75603300|NCT05429372|Genetic|PF-06939926|All participants will receive a single dose of PF-06939926 on Day 1.
75603301|NCT05427292|Other|serratus anterior block and PECs II block combination|The pre-surgery block will be applied. Sensorial block will be evaluated at the surgical incision site with the pinpirick test at 30 minutes after the block, and if the block is successful, surgery will begin.
75603302|NCT05423925|Procedure|Bipolar hysteroscopic myomectomy|Bipolar hysteroscopic myomectomy.
75603303|NCT05423925|Procedure|Monopolar hysteroscopic myomectomy|Monopolar hysteroscopic myomectomy
75747829|NCT06050876|Procedure|Laparoscopic cholecystectomy for gallbladder volvulus|Laparoscopic cholecystectomy for volvulus of gallbladder
75747830|NCT06050863|Biological|silk fibroin|silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films
75747831|NCT06050863|Drug|Chlorhexidin|chlorhexidine is used
75898420|NCT05884970|Drug|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
76065209|NCT05537233|Drug|Placebo|Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
75747832|NCT06050863|Biological|combination of silk fibroin and chlorhexidine|combination of silk fibroin and chlorhexidine is used
75747833|NCT06050837|Other|No intervention|No intervention
76065210|NCT05532865|Other|Blood samples|80 ml of blood samples collected at inclusion and at 18 months
76065211|NCT05532865|Other|Stool samples|A stool sample for collection of digestive microbiota at inclusion
76065212|NCT05532865|Other|Skin swab samples|A skin swab sample for collection of skin microbiota at inclusion and at 18 months
76065213|NCT05532865|Other|Questionnaires on quality of life, pain and disability|At inclusion and each year for 5 years
76065214|NCT05524623|Other|percutaneous microelectrolysis in myofascial trigger points of the trapezius|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
76065215|NCT05506345|Behavioral|Creative Drama Workshop|"The host introduces the theme and stressor scene of this workshop~Nursing students group discussion~Nursing student group performance practice ④Nursing group formal performance ⑤Nursing student group discussion ⑥The representative of the nursing student group made a speech ⑦ The host summarizes the positive coping methods of nursing students in stressor events"
76065216|NCT05497635|Drug|STSA-1002 Injection|Intravenous injection
76065217|NCT05497635|Drug|Placebo|Intravenous injection
75898421|NCT05884970|Drug|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
76065218|NCT05486962|Behavioral|Remote Patient Monitoring|Patients undergoing elective abdominal surgery will be asked to use a wearable activity tracker, vivosmart®HR by Garmin, pre and post-operatively to help remotely monitor health metrics. Data collected through the Garmin device will be reviewed to assess compliance and improvement in activity. Aggregate data will be analyzed to assess feasibility and effectiveness of this device in improving patient recovery.
76065219|NCT05482789|Drug|Exenatide|10 microgram injected sub-cutaneously once
76065220|NCT05476211|Device|BTL-785F|Radiofrequency
76065221|NCT05474950|Drug|minocycline|minocycline capsule (100mg) per day orally
76065222|NCT05465096|Procedure|Micro-fragmented adipose tissue injection|Intra-articular ultrasound-guided injection of MF-AT
75747834|NCT06050785|Drug|Vancomycin|ACL graft will be soaked in vancomycin versus gentamycin
75747835|NCT06050772|Behavioral|Immersive Virtual Reality Reminiscence|a computer-generated environment using head-mounted displays (HMDs) that provide a fully immersive, completely engaging, and realistic experience so that users feel like they are a part of the virtual world
76065223|NCT05462509|Device|bCPAP with blenders|The intervention device is a low-cost bCPAP kit which includes two fixed-ratio oxygen blenders that do not require a source of pressurized air. These simple and inexpensive devices sit in-line from the oxygen source and dilute the flowing stream of oxygen with room air, obviating the need for a pressurized source of air. The oxygen may be supplied from either high-pressure sources or low-pressure sources such as oxygen concentrators. Each of the two blenders are single plastic parts, injection moulded from a biocompatible, medical-grade polyethylene resin. No electricity is required for the blenders to provide a stable and constant mix of air and oxygen over the full range of clinically relevant pressure and flows for newborns.
75747836|NCT06050772|Behavioral|Traditional Reminiscence Therapy|RT is a technique that encourages older adults' positive emotions and coping mechanisms by using the recall of earlier memories and the sharing of life experiences.
75603304|NCT05413603|Procedure|ultrasonic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by ultrasound (US) to fully focus the shock waves on the stone
75603305|NCT05413603|Procedure|fluoroscopic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by fluoroscope (FS) to fully focus the shock waves on the stone
75603306|NCT05410938|Drug|Chemotherapy|Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
75747837|NCT06050759|Diagnostic Test|CRP and Albumin level in blood sample|CRP and Albumin levels will be measured from blood samples of the patients to determine CRP/Albumin Ratio
75747838|NCT06050746|Other|Systematic screening|Included children will be followed prospectively during five years through clinical visits and medical records, where need for additional treatment (casting, braces and/or surgery) is the primary endpoint.
75898422|NCT05884970|Drug|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
75898423|NCT05884970|Drug|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
76065224|NCT05461404|Other|Topical Emollient Therapy|Application of high-linoleate (>60% linoleic acid) SSO to the epidermis.
76065225|NCT05458557|Diagnostic Test|Rapid Antigen Testing|Community testing for SARS-COV-2 using rapid Antigen test
76065226|NCT05457413|Procedure|Sleeve gastrectomy|Bariatric surgery
76065227|NCT05452213|Drug|Ribociclib|"All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion."
76065228|NCT05447689|Behavioral|Integrative-Mind-Body Skills Group|Integrative-Mind-Body Skills Group (I-MBS-G) is an 8-week group that teaches skills to build inner resources for effective mood management. This group incorporates a holistic approach to wellness through meditation and mindfulness practices, guided imagery, breath and body awareness, relaxation techniques, self-reflection, and mindfulness-based cognitive-behavioral skills. Mind-body approaches have demonstrated effectiveness in reducing stress mood symptoms and improving quality of life.
75603307|NCT05408065|Drug|Triamcinolone Hexacetonide and hyaluronic acid|infiltration under fluoroscopy
75603308|NCT05408065|Drug|Triamcinolone Hexacetonide|infiltration under fluoroscopy
76065229|NCT05445076|Biological|anti-TRBV9 monoclonal antibody, low dose|infusion
76065230|NCT05445076|Biological|anti-TRBV9 monoclonal antibody, high dose|infusion
76065231|NCT05445076|Other|placebo|infusion
76065232|NCT05436912|Drug|Selpercatinib|Administered orally.
75898424|NCT05884944|Procedure|Sham- Light touch, not reaching restrictive barrier|Sham- Light touch, not reaching restrictive barrier For the control group, the subjects hip, knee, and ankle joints will be moved bilaterally 3 times into each plane to mimic the OMM muscle energy treatment. The joint will be moved in each plane of motion without reaching the joint barrier. The hip joint will be moved into adduction, extension, and flexion, the knee joint will be moved into extension and flexion, and the ankle will be moved into plantarflexion and dorsiflexion 3 times in each direction without reaching the barrier passively.
76025265|NCT01634711|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
75603309|NCT05395520|Other|Retrospective chart review|Retrospective chart review to be conducted at Methodist Charlton Medical Center (MCMC) in Dallas, TX. Adult patients who received vancomycin while inpatient at MCMC with at least one corresponding vancomycin trough level taken at steady state will be included. All vancomycin orders by providers are entered as pharmacy to dose; thus dosing and routine monitoring is conducted by pharmacists.
75747839|NCT06050720|Device|Apne-Scan DC1 device|The primary objective of this exploratory study is to assess Apnea-Tech's UKCA Class I Apne-Scan DC1 sleep apnoea screening device in assisting a clinical diagnosis of sleep apnoea in comparison to standard sleep apnoea test devices (ResMed NOX T3 and Phillips Alice Night One).
76025266|NCT05008601|Device|Wrist-word optical heart rate and ECG measurement device|Aino ECG: wrist-word optical heart rate and ECG measurement device
76025267|NCT01478555|Drug|ISV 101|Bromfenac in DuraSite
76065233|NCT05413928|Behavioral|Time Restrictive Eating- late|Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.
75603310|NCT05393193|Diagnostic Test|Point-of-Care Cepheid Xpert HIV-1|Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.
75603311|NCT05393193|Drug|DTG/ABC/3TC|Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
75603312|NCT05385718|Other|Magnetic Resonance Imaging|Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.
75603313|NCT05381753|Drug|Avapritinib|Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.
75603314|NCT05381753|Drug|Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )|Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
75747840|NCT06050694|Drug|glofitamab|Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
75747841|NCT06050681|Behavioral|Mindfulness Training|Participants will be asked to complete 21 mindfulness sessions within the Calm app on their own time and at a location of their choosing. They will be instructed to complete the '7 Days of Calm' program within the first two weeks of the intervention, the '7 Days of Managing Stress' program during weeks 3 & 4 of the intervention, and the 'Letting Go of Anxiety' program during the final two weeks of the intervention. The sessions have a mean run time of 11.76 minutes. Each 7-day program will be completed within a 2-week period, which equates to about one session every other day, but can be completed at any interval within those 2 weeks. All 21 sessions will be completed within a 6-week period.
75747842|NCT06050655|Device|Lingual aligners|orthodontic treatment with lingual aligners
76025268|NCT02261285|Drug|ONO-4538|
76025269|NCT01422083|Procedure|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
76025270|NCT01288625|Drug|Amifostine|500 mg sc, qod, 3 times per week
76025271|NCT01288625|Radiation|Amifostine|500mg rinsing wash, qod, 3 times per week
76025272|NCT05041829|Other|Dietary sodium|Low sodium diet with sodium of <2.3 g/day (<100 mmol/day) and high sodium diet with sodium of ≥4 - <6 g/day (≥174 - <261 mmo/day)
76025273|NCT05129813|Behavioral|Recovery Guide Counseling|Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
76065234|NCT05413928|Behavioral|Time Restrictive Eating- early|Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.
76065235|NCT05413928|Behavioral|Time Restrictive Eating- early with early caloric intake|Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.
76065236|NCT05413928|Other|Macronutrient-controlled meals|Meals with a determined amount of protein, carbohydrates, and fat.
76065237|NCT05413837|Diagnostic Test|anotomy and variation of venous sinus|Contrast enhanced-magnatic resonance venography（CE-MRV）and other magnetic resonance imaging methods are used to estimate the anatomy of cerebral venous sinus.
76065238|NCT05413837|Diagnostic Test|the level of biomarker in bood|Elisa or omics analysis is used to test the level of biomarker in blood.
76065239|NCT05408520|Procedure|Targeted Muscle Reinnervation|When a nerve is severed or injured, it attempts to regenerate. The TMR procedure will transfer the transected nerves to adjacent muscle nerves in efforts to encourage the nerve to regenerate in an organized fashion.
75452094|NCT01735448|Other|Focus group|"Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research."
76065240|NCT05407779|Biological|BCD-180, dose 1|anti-TRBV9 monoclonal antibody single infusion at dose 1
76065241|NCT05407779|Biological|BCD-180, dose 2|anti-TRBV9 monoclonal antibody, single infusion at dose 2
75603315|NCT05350813|Procedure|Measurement of the PCT plasma levels|antibiotic treatment duration will be based on PCT plasma levels
76065242|NCT05407779|Biological|BCD-180, dose 3|anti-TRBV9 monoclonal antibody, single infusion at dose 3
76065243|NCT05407779|Biological|BCD-180, dose 4|anti-TRBV9 monoclonal antibody, single infusion at dose 4
76065244|NCT05407779|Biological|BCD-180, dose 5|anti-TRBV9 monoclonal antibody, single infusion at dose 5
76065245|NCT05407779|Biological|BCD-180, dose 6|anti-TRBV9 monoclonal antibody, single infusion at dose 6
76065246|NCT05407779|Biological|BCD-180, dose 7|anti-TRBV9 monoclonal antibody, single infusion at dose 7
76065247|NCT05406219|Drug|BAY2395840|Immediate release (IR) tablet, oral administration
76065248|NCT05393973|Other|Core stability exercises along with conventional physical therapy|"Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions"
76065249|NCT05393973|Other|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
76065250|NCT05389722|Drug|CC-92480|Specified dose on specified days
75898425|NCT05884944|Procedure|Experimental: Interventional Group- OMM- Muscle energy|The interventional group will received Osteopathic Manipulative Medicine, specifically Muscle energy treatment. An osteopathic manipulative treatment protocol will be applied to the lower extremity joints bilaterally. Muscle energy technique (MET) will be applied to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated. Muscle energy is a direct active treatment asking the subject to move their joint in a direction against a counterforce by the treatment provider for 3 times for 3 seconds and repeating the procedure 3 times and afterwards a passive stretch to the joint is applied by the provider.
75898426|NCT05884905|Procedure|short hydration|NSS infusion prior to and following cisplatin administration within 6 hours
75898427|NCT05884905|Procedure|conventional hydration|NSS infusion prior to and following cisplatin administration over 24 hours
76065251|NCT05389722|Drug|Rifampin|Specified dose on specified days
76065252|NCT05389722|Drug|Itraconazole|Specified dose on specified days
75603316|NCT05350813|Procedure|Usual practice based on guidelines|antibiotic therapy duration will be determined by the type of infection, microbiological results and clinical, biological and/or radiological evolution, according to the usual practice based on guidelines.
75603317|NCT05350267|Behavioral|HALO|"Health and Lifestyle Behaviors in Offspring, or HALO is designed for mothers who recently had bariatric surgery who have a school-aged child. HALO focuses on providing each mother with education and parenting strategies to improve her child's healthy lifestyle behaviors, such as her child's eating and physical activity, while she is engaged in her own lifestyle behavior change after bariatric surgery."
75747843|NCT06050642|Other|enhanced care model provided by Timkl, a home support provider|A new type of care provided by timkl, a home support provider, involving nurses and the dispensing pharmacist. This approach combines the current tasks of the service provider's nurses with closer monitoring by the pharmacist, thanks to more frequent contacts and a holistic view of the patient.
76065253|NCT05389722|Drug|Digoxin|Specified dose on specified days
76065254|NCT05389722|Drug|Rosuvastatin|Specified dose on specified days
76065255|NCT05373680|Drug|Metformin|Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
76065256|NCT05373680|Drug|Empagliflozin|Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
76065257|NCT05373680|Other|Control|Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
76065258|NCT05372718|Drug|Recombinant non-immunogenic staphylokinase (Fortelyzin®)|lyophilisate for preparation a solution
76065259|NCT05372718|Procedure|surgical methods of treatment|Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
75603318|NCT05350267|Behavioral|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
75603319|NCT05349123|Behavioral|Mindful Breathing|Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.
75898428|NCT05884879|Behavioral|Tinnitus simulation|The control group will perform speech perception tests and listening effort tests in the absence and presence of a simulated tinnitus percept using a bone vibrator.
76065260|NCT05364970|Combination Product|VR_Training_1PP|Immersive VR scenario of physical training with avatar embodiment
75603320|NCT05349123|Behavioral|Home-Based Pulmonary Rehabilitation|Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
75898429|NCT05884827|Device|EMG|Measure the electrical activity of the muscle and nerve
76065261|NCT05364970|Combination Product|VR_Training_3PP|Immersive VR scenario of physical training without avatar embodiment
76065262|NCT05362682|Other|Sinopharm Vaccine|Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign
76065263|NCT05361122|Dietary Supplement|Maternal Use of Xylitol Chewing Gum During Pregnancy|There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at <20 weeks gestation).
75452095|NCT01735448|Other|One-on-one interviews|One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
75603321|NCT05333107|Drug|NNC0385-0434 G|Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
75898430|NCT05884775|Other|Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool|Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.
76065264|NCT05361122|Dietary Supplement|No Maternal Xylitol Chewing Gum Use During Pregnancy|There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group
76065265|NCT05359640|Other|quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
76065266|NCT05353348|Drug|Iron Sucrose, recombinant human erythropoietin, ascorbic acid|During the 1 week period following admission, 3 consecutive dosing regimens were administered, 200 mg of iron sucrose by intravenous infusion at 8am daily in combination with 150 IU/kg of recombinant human erythropoietin by subcutaneous injection and 2 g of ascorbic acid by intravenous infusion.
75603322|NCT05333107|Drug|NNC0385-0434 F|Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
75603323|NCT05333107|Drug|NNC0385-0434 B|Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
75603324|NCT05318352|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that modulates cortical activity. tDCS has been conducted to improve wide range of neurological impairments including sleep.
76065267|NCT05353348|Drug|Iron sucrose|Within 1 week of admission, 3 consecutive combination regimens of 200mg of iron sucrose and saline combined with subcutaneous saline infusions at 8am daily
76065268|NCT05338281|Device|Negative Pressure Wound Therapy|The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.
76065269|NCT05334836|Diagnostic Test|MRI for pancreatic fat and liver fat quantitation|MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.
76065270|NCT05331820|Other|weekly mobile reminder|a weekly reminder will be sent to participants in the intervention group via mobile internet applications
76065271|NCT05326256|Other|Exercise training- PSSE|Barcelona Scoliosis Physical Therapy School (BSPTS) method exercises
76065272|NCT05326256|Other|Exercise training- PSSE with vestibular exercises|Vestibular exercises added to Barcelona Scoliosis Physical Therapy School (BSPTS) exercises
76065273|NCT05320419|Other|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
76065274|NCT05320419|Other|Physiotherapy (PT group)|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
76065275|NCT05314543|Other|Hypoxia|Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
75603325|NCT05305963|Radiation|Mammogram|mammogram
75603326|NCT05295420|Procedure|platelet rich plasma|Injection of Platelet Rich Plasma in the female conditions that suffer from SUI
75603327|NCT05295004|Behavioral|Mindfulness Meditation Training|Patient will watch a 10 minute video on how to use mindfulness meditation to help with sleep after a total joint replacement procedure.
75603328|NCT05278312|Other|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
75747844|NCT06050603|Device|TMS|"The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3."
75452096|NCT01735448|Other|Survey|A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
75747845|NCT06050590|Device|NeuroGlove|Study participant with PTSD will undergo daily at home treatment using the NeuroGlove.
75898431|NCT05884749|Behavioral|Peer to Community (P2C) Model|The P2C model is an outreach model including peer support, occupational therapy and social work aimed at facilitating community integration through relationship building and meaningful activity engagement for individuals living with concurrent disorders following homelessness.
75747846|NCT06050577|Drug|oral Semaglutide/Rybelsus|Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.
76065276|NCT05313022|Biological|ZR-202-CoV|Adjuvanted Recombinant SARS-CoV-2 S-protein Subunit Vaccine
75747847|NCT06050577|Drug|Placebo|Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
76065277|NCT05313022|Other|Placebo|Normal saline solution
76065278|NCT05304520|Drug|Natalizumab|Administered as specified in the treatment arm.
76065279|NCT05294263|Drug|Varenicline|Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
76065280|NCT05294263|Drug|Placebo|Matching, inactive medication
76065281|NCT05294068|Other|standard of care for patients with cognitive impairments|clinical examination, radiological, biological and physiological examinations.
76065282|NCT05294068|Other|standard of care for patients with neuromotor impairments|clinical examination, radiological, biological and physiological examinations.
76065283|NCT05294068|Other|standard of care for patients with sensory impairments|clinical examination, radiological, biological and physiological examinations.
76065284|NCT05292625|Biological|UC-MSC infusion via intravenous route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intravenous (IV) route with a 3-month intervening interval
75747848|NCT06050564|Other|Treatment recommendations will be based on video documented PBS-Score|Therapeutic recommendations from orthopedic surgeons, will be summarized and described
75898432|NCT05884749|Behavioral|Care as Usual (UC)|Participants in this group will receive care available typically in the community
75898433|NCT05884723|Dietary Supplement|Ketogenic Diet|4-week preoperative well-formulated very low carbohydrate isocaloric diet consisting of 50g net daily carbohydrates and 1.5g/kg protein with the remaining energy needs consisting of primarily mono- and polyunsaturated fats
75898434|NCT05884697|Other|K-Talk Intervention (Storytelling and K-Bot)|The K-Talk intervention group receives a combination of a storytelling intervention and an artificial intelligence chatbot (K-Bot) education.
76065285|NCT05292625|Biological|UC-MSC infusion via intrathecal route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intrathecal route with a 3-month intervening interval
76065286|NCT05292625|Other|standard stroke treatment and rehabilitation therapy|Each patient can receive up to 30 days of rehabilitation therapy
76065287|NCT05285579|Biological|Blood collection|Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer
76065288|NCT05285579|Other|Tumour samples|reuse of tumour tissue collect in usual patient care
76065289|NCT05281757|Device|posterior stabilization for the cervical spine|The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.
76065290|NCT05280886|Procedure|therapeutic drug monitoring(TDM)|Based on this data, population pharmacokinetic models of antibiotics drugs that can be applicable to TDM will be developed.
76065291|NCT05271981|Other|Retrospective data collection|Data collection from the medical file of the patients
76065292|NCT05271981|Other|Phone interview|Call for collecting fertility data and obstetrical issues of the patients
76065293|NCT05271916|Drug|Dacomitinib+Anlotinib|The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.
76065294|NCT05271916|Drug|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.
76065295|NCT05271656|Device|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake of fiber pills 5 days, and contrast agent 48 hours prior to scheduled C-Scan capsule ingestion. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan Track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
76065296|NCT05261594|Dietary Supplement|Caffeine|Caffeine capsule 150 mg, oral intake
76065297|NCT05261594|Drug|Placebo|Placebo capsule, oral intake
76065298|NCT05254431|Behavioral|Exercise|"Novel Moderate Intensity Interval Exercise~The Experimental Design is a randomized trial of moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls"
76065299|NCT05247567|Biological|serum punction|A blood sample inclusion and at the end of study visit
76065300|NCT05247567|Biological|skin swab in elbow folds|passage of a cotton swab in the crease of the elbow at the inclusion
76065301|NCT05245617|Device|JuniOrtho™ Plating System™|The patient underwent surgery for the application of JPS for treatment of deformity or traumatic fracture.
75898435|NCT05884697|Other|Storytelling Intervention|The storytelling intervention features 12 authentic stories from young Korean immigrants and Americans. Each video is about 3 minutes long and includes stories from 1st, 1.5, and 2nd generation young Korean individuals, highlighting their perceptions of HPV and HPV vaccines, and their experiences with HPV vaccination.
75747849|NCT06050551|Procedure|uniportal VATS|"elective uniportal VATS lung resection, pleural tumor removal or mediastinal lymph node biopsy, etc.~(exclude the bil. operation, extended wound length over 5 cm, conversion to thoracotomy or multiportal VATS procedure, surgeon's decision for exclusion during operation.)~thoracoscopic internal costal nerve block with 10 mL of 1% Ropivacaine at the end of the operation,~routinely prescribed with oral Tramadol 37.5mg and Acetaminophen 325mg four times a day postoperatively and intravenous morphine as extra dose if need."
75898436|NCT05884697|Other|K-Bot Intervention|The K-Bot intervention is a conversational and button-based artificial intelligence Chatbot that is available in both English and Korean.
75898437|NCT05884697|Other|Written Information|The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.
75898438|NCT05884645|Procedure|Video-directed endotracheal intubation|There will be no intervention in this prospective observational cohort study. Endotracheal intubation is already used to secure the airway by placing an endotracheal tube into the trachea via the oral or nasal route. Indications include the need for airway control during general anaesthesia, mechanical ventilation, resuscitation, and various forms of acute respiratory distress.
75747850|NCT06050538|Procedure|Transabdominal preperitoneal (TAPP) using polyprolene mesh|Transabdominal preperitoneal (TAPP) approach for recurrent inguinal hernia using polyprolene mesh
76065302|NCT05238103|Combination Product|Corrie Virtual Cardiac Rehabilitation Program|The Corrie Virtual Cardiac Rehabilitation Program is multi dimensional intervention. It consists of the Corrie smartphone app for cardiovascular health optimization which is paired with wristband device (Apple Watch or Fitbit), Bluetooth-enabled Omron blood pressure monitor and exercise resistance bands. The program also includes individualized treatment plan development, setting health goals and communication with trained Corrie Health Coach. Furthermore, the intervention includes motivational text messages sent to participants throughout the study to aid with risk factor modification.
76065303|NCT05236179|Other|Integrative therapies|Integrative therapy methods used at the Filderklinik, such as music therapy, therapeutic painting, therapeutic sculptural forming, speech therapy, eurythmy therapy, rhythmical massage, external applications, coloured light therapy
75898439|NCT05884632|Radiation|Daily Adaptive RadioTherapy|Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
75747851|NCT06050538|Procedure|Total extraperitoneal (TEP) hernioplasty using polyprolene mesh|Total extraperitoneal (TEP) approach for recurrent inguinal hernia using polyprolene mesh
75898440|NCT05884606|Device|Allurion Digital Behaviour Change Intervention|The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
75898441|NCT05884567|Other|Isometric exercises|These exercises are used to increase muscle endurance, power and ROM
75898442|NCT05884567|Other|Mobilization|These exercises are used to increase ROM and used for pain reduction
75898443|NCT05884502|Drug|combination of high-dose rosuvastatin and ezetimibe|combination of rosuvastatin 20mg and ezetimibe 10mg
75898444|NCT05884502|Drug|high-dose rosuvastatin single administration|rosuvastatin 20mg monotherapy
75898445|NCT05884489|Behavioral|A gamified smartphone app-based eating behaviour intervention|All patients gained access to the healthy nutrition application and were encouraged to make full use of its feature, and they were also required to maintain a logbook through the application at home to follow-up on their diet. The intervention last for six weeks.
75898446|NCT05884463|Drug|18F-FAPI|Intravenous injection of one dosage of 18F-FAPI.
75898447|NCT05884463|Drug|18F-FDG|Intravenous injection of one dosage of 18F-FDG.
75898448|NCT05884450|Other|Acupressure|Acupressure is an integrated method of applying physical pressure to acupuncture points on the body surface with hands, elbows or various tools. With good counseling, patients can apply this method, which is non-invasive, easy to apply and safe, on their own.
75898449|NCT05884411|Device|Left bundle branch area pacing|A cardiac pacing electrode is inserted into the left bundle branch area of the myocardium via a transvenous approach.
75898450|NCT05884411|Diagnostic Test|Cardiac MRI|A diagnostic imaging test using magnetic resonance imaging to evaluate cardiac function.
76065304|NCT05235815|Procedure|Retro SCTL compartment block|"For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4)."
76065305|NCT05234515|Diagnostic Test|Microbiology swab|Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery. Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021. Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
76065306|NCT05234515|Other|Questionnaire|Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days. These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
76065307|NCT05234437|Drug|tigilanol tiglate|"Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
76065308|NCT05220748|Combination Product|RM-1995|RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts
75898451|NCT05884385|Other|Simulated exercises|as detailed in arm description
75769328|NCT03904186|Behavioral|QUIT|QUIT is a transdiagnostic Cognitive Behavioral Therapy-based smoking cessation protocol designed to address distress intolerance, anxiety sensitivity, and anhedonia in people living with HIV who smoke. QUIT is delivered in 9 60-minute individual weekly sessions over a 10-week period. Sessions are active, with treatment components practiced within and outside of the session. Participants will also receive the transdermal nicotine patch for 8 weeks, starting when they attempt to quit smoking during week 7 of the study.
75898452|NCT05884385|Other|Mental Visualisation|as detailed in arm description
75898453|NCT05884281|Drug|Roflumilast|0.5 mg once daily for treatment period
75898454|NCT05884281|Drug|Placebo|Placebo for treatment period
75898455|NCT05884268|Drug|Venlafaxine|Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery
75898456|NCT05884268|Drug|Placebo|Patients scheduled for elective LC will receive placebo venlafaxine before surgery
75898457|NCT05884255|Drug|Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide|Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
75898458|NCT05884255|Drug|long-acting Octreotide.|High-dose long-acting Octreotide.
75898459|NCT05884229|Other|Intra-operative analgesia guided by SPI|In the SPI-guided group, when SPI is higher than 50 for the first time and for more than 3 minutes, we will administer 1,0 μg/kg of fentanyl LBW. When SPI is again higher than 50 and for more than 5 minutes, we will re-administer 1,0 μg/kg of fentanyl LBW. We will repeat until SPI is between 20-50.
75603329|NCT05278013|Other|Dermabond|High viscosity Dermabond is a sterile, liquid topical skin adhesive containing monomeric (2-OCA) formulation and the colorant D & C Violet # 2. The product has a syrup-like in viscosity and polymerizes within minutes when applied to the skin. 2-OCA is an effective barrier against microbial penetration by Gram-positive (inc. methicillin-resistant Staphylococcus aureus) and Gram-negative motile and nonmotile species as long the as the film is intact (11-13). The high viscosity of Dermabond is intended to reduce the risk of unintended placement of the adhesive during the application process to other body parts, patient's clothing or in between the skin layers in the wound, which can result in delayed wound healing.
75747852|NCT06050486|Behavioral|Mentalization-based treatment for children (MBT-C)|MBT-C is a time-limited intervention designed to resolve the child's emotional or behavioral problems and to promote resilience, by promoting the child's and parent's mentalizing capacities. It is composed by 1) an assessment phase, composed of 3 to 4 sessions, with the family, the child and the parent(s), 2) an intervention phase, composed of a minimum block of 12 individual sessions with the child and parallel sessions for the parent(s), that can be repeated up to three times (i.e., maximum of 36 sessions), and 3) a booster session 3 to 12 months after the last session. In this clinical trial, MBT-C will be composed of: 3 assessment sessions; 12 individual sessions with the child, plus 6 parallel individual sessions with the parent with BPD; 1 booster family session, 3 months after the last session.
75747853|NCT06180772|Behavioral|FIT FIRST|High intensity sports drills and games
75898460|NCT05884164|Procedure|Thoracic erector spinae plane block|After induction of general Anaesthesia,a high frequency ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinal muscle and the transverse processes are identified, spinal needle will be inserted after standard skin disinfection in a caudal to cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep to the erector spinal muscle. After hydrolocalization with ml normal saline, this plane will be opened and 20 ml of 0.25 %bupivacaine will be administered for block performance
75898461|NCT05884164|Procedure|Thoracic paravertebral plane block|After induction of general Anaesthesia ,with the probe in the longitudinal paramedian position, it is then moved from medial to lateral direction to appreciate the saw tooth appearance of the facet joints close to the midline which changes to long finger-like shadow of the transverse process as the probe is moved slightly laterally. Repositioning the probe over the transverse process ensuring the space of interest is in the middle of the probe once again one should appreciate the intercostal muscles and the dense bright white line of the pleura in between the shadows of the transverse processes. The needle is then introduced at the caudal end of the probe in plane in a caudal to cranial direction aiming for the angle between the bottom of the transverse process and the pleura. Once position is confirmed, 20 ml of 0.25% bupivacaine will be administered for the block performance.
75898462|NCT05884151|Drug|Tranexamic acid|Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
75898463|NCT05884151|Drug|Platelets rich plasma|Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
76065309|NCT05220748|Biological|Pembrolizumab|Pembrolizumab (200 mg) will be administered by intravenous (IV) infusion one week before the first RM-1995 PIT treatment and the second dose three weeks later for patients in the combination arm. Once the DLT window is complete, pembrolizumab dosage will be maintained at either 200 mg Q3w, or shift to 400 mg Q6w, per investigator discretion.
76065310|NCT05217420|Behavioral|Moving Well|Experimental arm
76065311|NCT05217420|Behavioral|Staying Well|Active comparator arm
76065312|NCT05209230|Procedure|Continuous renal replacement therapy|Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter
76065313|NCT05209230|Other|Control group|Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
75747854|NCT06180759|Drug|Intravenous infusion of DMT|A dose rate of 1.2 mg/min will be administered
76065314|NCT05199610|Drug|aumolertinib|A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.
75603330|NCT05276206|Drug|NSAID , NALUFIN , local anesthetic andTAP Block|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared"
75747855|NCT06180759|Drug|Intravenous infusion of ketamine|A dose rate of 1.0 mg/min will be administered
75747856|NCT06180759|Drug|Intravenous infusion of placebo|A Placebo (saline infusion) will be administered.
75747857|NCT06180746|Behavioral|Knowledge mobilization to facilitate the structuring of health mediation|"The ECEMSo intervention involves knowledge mobilization to facilitate the structuring of health mediation throughout French territory, and the development of a co-designed effective action plan to facilitate cancer screening uptake by people living in informal housing.~The action plan will, consider territorial specificities at the regional level. The ECEMSo project team will organize a seminar and three workshops. The aim of the seminar and workshops is to mobilize knowledge to facilitate i) the structuring of health mediation in the regions, and ii) the development of an action plan with health mediators and other stakeholders to foster organized cancer screenings uptake by underserved people. This action plan must match with the needs of people living in informal housing, and must be coordinated, suitable and feasible to implement, in terms of knowledge about people living in informal housing specificities and specific local collaborations"
75747858|NCT06180733|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.
75747859|NCT06180720|Drug|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
75747860|NCT06180720|Drug|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
75747861|NCT06180707|Drug|pregabalin gel|10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
75747862|NCT06180707|Drug|gel with 5% potassium nitrate and 2% sodium fluoride|gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
75747863|NCT06180707|Other|Placebo gel|placebo gel (carbopol-based gel 1%) for topical application to teeth before bleaching with hydrogen peroxide
75452097|NCT01735474|Other|Manual technique|"A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles."
75603331|NCT05274178|Device|"Audeo P hearing aid labeled as Prescriptive"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as prescriptive in view of the participant."
75603332|NCT05274178|Device|"Audeo P hearing aid labeled as OTC"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as OTC in view of the participant."
75603333|NCT05265689|Behavioral|Bike Club|"Administration of a bicycle safety education program to children ages 9-12 based on Let's Go NC!. Let's Go NC! includes observational skill checklists for instructors to track participant progress throughout the program, on-bicycle skills practice, hazard anticipation and avoidance, and traffic law importance and consequences. Additionally, participants will go on a capstone ride to practice their skills across varying transportation and recreation infrastructure and settings. The program will be administered at various sites across Iowa City."
75603334|NCT05265689|Behavioral|Bike Club Plus|Same as Bike Club, with the addition of a parent training component. Parents from these dyads will receive a training session on bicycling safety best practices, tips for practicing with their children at home, and feedback on how their child performed in the program (including areas in need of improvement).
75898464|NCT05884112|Device|"MAGSTIM reprtitive Transcranial Magnetic Stimulator (rTMS) System"|iTBS is a new treatment method for depression. It uses the principle of magnetoelectricity to intermittently stimulate local brain nerves. In recent years, domestic and foreign studies have confirmed its efficacy and safety for depression. In addition, research has also It shows that iTBS has better therapeutic effect and efficiency than the previous regular rTMS.
75898465|NCT05884112|Device|sham control|sham control
75898466|NCT05884086|Other||no intervention is necessary. Clinical observation and clinical examination only.
76025274|NCT05129579|Behavioral|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
76025275|NCT05129579|Other|no intervention|No intervention will be made in the control group.
76025276|NCT05129267|Other|Group B|Scaling and Root debridement + iPRF
76025277|NCT05129267|Other|Group C|Scaling and Root debridement + iPRF together with vitamin C
75452098|NCT01735474|Other|Placebo|Usual care
75452099|NCT01735487|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
75452100|NCT01735487|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
76025278|NCT01374451|Drug|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
75452101|NCT01735487|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
76065315|NCT05194332|Device|LIFUP sonication to the amygdala|LIFUP sonication to amygdala will be performed.
75452102|NCT01735487|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
75603335|NCT05262062|Other|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~2. Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.~3. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.~4. Once the position of ease was identified, it was held for 20 to 30 seconds."
75452103|NCT01735487|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
75452104|NCT01735513|Device|Intra-aortic embolic protection management system; Embol-X|"The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream."
75747864|NCT06180681|Behavioral|Team-Enhanced Collaborative Life Skills Program|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
75603336|NCT05262062|Other|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~2. Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
75452105|NCT01735539|Dietary Supplement|15g EAA bolus|Oral; in aqueous solution
75747865|NCT06180681|Behavioral|Standard Collaborative Life Skills Program|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
75747866|NCT06180668|Procedure|Trauma Laparotomy|Emergency abdominal surgery through midline incision to access abdominal and / or pelvic organs, to access identified injuries or exploratory diagnostic reasons
75603337|NCT05262062|Other|Integrated Neuromuscular Inhibition Technique|"Group c will receive Combination of exercise (strain counter strain , muscle energy & ischemic compression. In ischemic compression patient will receive compression,~After MTrPs identification,~Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright"
75603338|NCT05250505|Device|eShunt Implant|The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.
75747867|NCT06180655|Behavioral|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
75747868|NCT06180642|Other|Assessment of soft tissue properties|Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
75747869|NCT06180642|Other|Retest assessment of soft tissue properties|Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
76065316|NCT05193786|Procedure|Different level of PEEP|Different level of PEEP (low versus high) was applied in noninvasive ventilation.
75898467|NCT05884073|Behavioral|Circuit-based Resistance Training|Participants will engage in a 12-week, twice weekly circuit-based resistance training program. Each supervised session will last about 25 minutes and will consist of 5 resistance exercises. Each exercise will be completed for 1 minute for a total of 5 minutes followed by a 1-minute rest. The circuit will then repeated 3 additional times (total of 4 circuits). All resistance sessions will be supervised by a certified fitness professionals.
75898468|NCT05884073|Behavioral|Circuit-based Resistance Training + Home-based Walking|"Participants will engage in a 12-week, twice weekly circuit-based resistance training program. Each supervised session will last about 25 minutes and will consist of 5 resistance exercises. Each exercise will be completed for 1 minute for a total of 5 minutes followed by a 1-minute rest. The circuit will then repeated 3 additional times (total of 4 circuits). All resistance sessions will be supervised by a certified fitness professionals.~Participants will also be asked to engage in 25 minutes of brisk power walking or light jogging at home (unsupervised) 3 days/week for 25 minutes on days when they have not engaged in resistance training."
75898469|NCT05884073|Behavioral|Home-based Walking|Participants will be asked to engage in 25 minutes of self-paced walking at home (unsupervised) 3 days/week.
76065317|NCT05187364|Behavioral|COPE|The COPE therapy is a talk-therapy in which individuals are asked about their trauma, alcohol use, mood, and behavior. The therapy occurs over 12 sessions and will be paired with a telehealth technology system to determine if it enhances the COPE therapy. The telehealth system is worn on the arm and hand during the out-of-office COPE homework assignments. It consists of a small camera (about the size of a pencil eraser), Bluetooth earpiece with microphone, monitors to measure and record heart rate and skin conductance, and a breathalyzer to assess blood alcohol content. The device will connect to an application on password protected cell phone that will monitor and record the above listed information as well as reported subjective units of distress and craving. A study coach will virtually guide participants through one out-of-office assignment per week using this technology. Interviews and surveys will be collected at study baseline and weekly during treatment.
75452106|NCT01735539|Dietary Supplement|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
76065318|NCT05180357|Other|FASENRA(benralizumab)|This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
76065319|NCT05180253|Diagnostic Test|Esophageal studies|Healthy subjects will undergo esophageal and blood testing.
76065320|NCT05166694|Other|Drug-Drug Interaction Profile|A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.
76065321|NCT05166694|Other|Drug-Gene Interaction Profile|A profile based on genetic testing that shows information about how the participant's genes interact with/respond to certain medications they are taking.
75603339|NCT05249829|Biological|mRNA-1273.529|Sterile liquid for injection
76065322|NCT05166694|Other|Standard of Care|The standard treatment and prescribing for the participant's specific type of cancer.
76065323|NCT05164744|Diagnostic Test|Cardiac MRI|Patients participate in an NIH funded cardiac MRI to assess their symptoms.
76065324|NCT05164744|Diagnostic Test|Echocardiogram|Patients participate in an NIH funded cardiac echocardiogram to assess their symptoms.
76065325|NCT05164744|Diagnostic Test|6-minute walk test|Patients participate in a 6-minute walk test to assess their symptoms.
76065326|NCT05164744|Diagnostic Test|Questionnaire|Patients answer a survey-based questionnaire to assess their symptoms.
75452107|NCT01735539|Dietary Supplement|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
75452108|NCT01735591|Dietary Supplement|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
75452109|NCT01735591|Dietary Supplement|Probiotic|Capsules with 3x10^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
76065327|NCT05158907|Other|Patient reported Adverse event scale|Participants will be given a patient reported AE scale with numbers from 0 to 10 before start of each chemotherapy cycle. The PRAE scale will be like a Visual Analogue Scale and the patients will be given instructions how to record AEs that they experience after each chemotherapy cycle, until the first radiological assessment is done (palliative settings) or after 4 cycles of chemotherapy in adjuvant settings. Participants will take scale home to record the adverse effects and give it a number. Only the most severe will be analyzed. When patient reports for the next cycle of chemotherapy they will be asked to deposit the scale before meeting the physician. The physician will ask patient about the AEs experienced with the chemotherapy and record them using CTCAE grade. The study participants, at the start of chemotherapy cycle, will be informed, as a standard practice, to report to the emergency or contact nearest local clinic/hospital if the AE is severe or can't be managed at home.
75452110|NCT01735604|Biological|anti-CD20-CAR vector-transduced autologous T cells|anti-CD20-CAR vector-transduced autologous T cells
75452111|NCT01735604|Other|genetically engineered lymphocyte therapy|genetically engineered lymphocyte therapy
75452112|NCT01735643|Device|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
75452113|NCT01735643|Other|waiting|waiting for 12 weeks
75452114|NCT01735669|Drug|Remifentanil|
75452115|NCT01735669|Drug|Nitrous Oxide|
75452116|NCT01735682|Device|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
75603340|NCT05249829|Biological|mRNA-1273|Sterile liquid for injection
75603341|NCT05249829|Biological|mRNA-1273.214|Sterile liquid for injection
75603342|NCT05246111|Drug|[14C]M6620|Participants will receive single intravenous infusion of [14C]M6620 on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
75603343|NCT05246111|Drug|M6620|Participants will receive intravenous infusion of M6620 on Day 2 and Day 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation are met.
76025279|NCT01374451|Drug|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
75603344|NCT05246111|Drug|Topotecan|Participants will receive intravenous infusion of topotecan on Day 1 through Day 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation are met.
75603345|NCT05243303|Device|Active taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated. Subjects self-administer the stimulation on a daily basis for 3 months.
76065328|NCT05157477|Behavioral|CBT-based VR exporsure program|This project seeks to establish a 8-week CBT-based VR exposure program to tackle sensory problems in ASD according to the theory of exposure and desensitization (both social and non-social scenarios) as well as identifying dysfunctional thought and searching for alternative thinking. In brief, this program aims to build up the core competence of the ASD individuals in facing the sensory environment, including (1) Relaxation skills (2) Ranking the fearful sensory situations (3) Anxiety coping strategy (3) Graded exposure (4) Cognitive appraisal and restructuring: identifying the dysfunctional thought when facing the social situations and figuring out alternative thinking.
76065329|NCT05152485|Drug|BIIB104 Reference Formulation|Administered as specified in the treatment arm
75452117|NCT01735682|Behavioral|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
75452118|NCT01735682|Behavioral|Control|The control treatment involves exercises of the upper limbs.
75603346|NCT05243303|Device|Sham taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted. Subjects self-administer the sham taVNS on a daily basis for 3 months.
75603347|NCT05228015|Drug|IK-930|tablets for oral administration
75452119|NCT01735708|Behavioral|HIVPASS|
75452120|NCT01735708|Other|Health Education|
75603348|NCT05211466|Other|Digital healthcare platform|In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.
75747870|NCT06180629|Behavioral|Music conset|The music modes to be used (Rast and Hüseyni), classical music, nature music, and listening time of 20-30 minutes were determined by taking expert opinion from a faculty member from the Conservatory department and by reviewing the literature. The researcher asked the patients to choose the music genres. After each patient decided on the music they wanted to listen to, the researcher recorded the selected music genres on their smartphones. The music playback application was played to the patients in the experimental group for 20-25 minutes in each session for 4 sessions, i.e. 4 times in total, once a week for a month, until the end of one course. During each session, the patients listened to the music genre they had chosen each week.
75747871|NCT06180629|Other|normal treatment routine|normal treatment routine
75747872|NCT06180590|Drug|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Evaluate the efficacy of Vosevi in DAAs-experienced patients
76025280|NCT02674477|Device|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
76025281|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
76065330|NCT05152485|Drug|BIIB104 Test Formulation|Administered as specified in the treatment arm
75452121|NCT01735721|Procedure|Open Sinus Lift|"A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).~The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material."
75452122|NCT01735734|Device|Air cooling to CM site|
75452123|NCT01735747|Radiation|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
75452124|NCT01735747|Drug|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
75452125|NCT01735747|Drug|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
75747873|NCT06180577|Device|Nerivio|Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine
75747874|NCT06180564|Other|Intra-operative Infra-red thermography|. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature >3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
75747875|NCT06180551|Diagnostic Test|DKK-3|DKK-3-Urine measurement
75747876|NCT06180512|Dietary Supplement|Beta Alanine high dose|4 intakes of 5 g of beta alanine every 1 hour and 15 minutes.
75747877|NCT06180512|Dietary Supplement|Beta Alanine low dose|4 intakes of 2.5 g of beta alanine every 1 hour and 15 minutes.
75747878|NCT06180512|Dietary Supplement|Control group|4 intakes of 2.5 g of wheat semolina every 1 hour and 15 minutes.
75747879|NCT06180473|Other|questionnaire|PPQ, TTAQ PTCS
75452126|NCT01735747|Drug|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
75452127|NCT01735786|Device|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
75452128|NCT01735851|Drug|Thoracic epidural analgesia|
75452129|NCT01735851|Procedure|Bilateral Paravertebral block|
75452130|NCT01735864|Drug|Indirubin 200μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment containing 200 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
75452131|NCT01735864|Drug|Indirubin 100 μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment contains 100 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
75603349|NCT05207436|Drug|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.
75603350|NCT05207436|Behavioral|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
75747880|NCT06180447|Biological|Hepatitis B vaccine, rabies vaccine, HPV vaccine, influenza vaccine|Exposure was defined as use of the vaccine 90 days before the last menstrual period and during pregnancy.
75747881|NCT06180408|Other|manual therapy and exercise for the big toe|Maitland mobilization (Grade 3,4), Mulligan mobilization with movement techniques, muscle energy techniques, manual therapy for plantar fascia, strengthening exercises and self-stretching exercises was performed
75747882|NCT06180408|Other|lumbar stabilization exercise|core training and myofascial release therapy
75747883|NCT06180395|Other|Group 1|"consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
75747884|NCT06180395|Other|Group 2|"consisted of 38 children with CP classified to level IV and V according to GMFCS. then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
75747885|NCT06180382|Drug|Adalimumab|Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.
75747886|NCT06180382|Drug|Vedolizumab|Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.
75747887|NCT06180369|Other|GC Fuji Triage ® GC America Inc., Alsip, Illinois )|Fissur Sealent application
75747888|NCT06180369|Other|BeutiSealant (Shofu, Kyoto, Japonya)|Fissur Sealent application
75747889|NCT06180317|Other|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI and VAS just before the endometrial biopsy procedure, VAS during the procedure and again with STAI and VAS after the procedure.
75747890|NCT06180304|Other|Exercise training|The indoor physical exercise program was carried out in a gym with weight machines. The physical exercise program was divided into four parts. Part I: playful game or shuttle run (5 to 7 minutes). Part II: aerobic training (treadmill; 10 minutes; 40% to 80% of Heart Rate Reserve; between 12 to 17 according to the Borg Rating Of Perceived Exertion Scale; between 5 to 8 according to the Borg Category-Ratio 10 Scale. Part III: strength training (more or less 25 minutes; Leg Press + Chest Press + Leg Extension + Lat Pull Down + Leg Curl + Shoulder Press; 40-80% of 3 maximum repetitions; 10-15 reps; 2-3 sets). Part IV: 4 static stretches (30 to 60 seconds each).
75603351|NCT05206331|Device|contrast enhanced mammography|Dual-energy contrast images; low-energy CEM images will be obtained with a kilovoltage below 35 kVp while the high-energy images will be obtained with 45-49 kVp.The average glandular dose of the CEM procedure is approximately 2.44 mGy per view
75603352|NCT05206331|Drug|Iodinated Contrast Media (ICM)|standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
75603353|NCT05206123|Other|Interview|Patients will be interviewed with a semi-structured qualitative interview in order to know how they lived their first sexual experiences and their sex lives during their adolescence
75747891|NCT06180291|Other|PRECOP program|"PRECOP program is the first program combining early detection of cerebral palsy with implementation of early interventions following the latest international recommendations (multidisciplinary program at home, with the possibility of intensive courses, coaching parental, in the first 2 years of life).~This comprehensive monitoring is implemented as soon as the infant arrives at home, by a multidisciplinary team and continues during the child's first 2 years. It includes:~Follow-up organized primarily at home~Monitoring of psychomotor development~Screening for possible cerebral palsy~Comprehensive support for the child's development: weight, diet, sleep...~Reeducation, implementation of SMART type objectives (Specific, Measurable, Achievable, Achievable, Timely defined) determined with parents~Creation of equipment if necessary: early seating installation in particular~Parental support and guidance for optimizing early care~Parental psychological support."
75747892|NCT06180278|Other|Blood tests|Participants will have blood tests done at each scheduled visit (approximately every 6 months).
75747893|NCT06180278|Drug|Inebilizumab|Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment at the discretion of their treating physician will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
75747894|NCT06180265|Diagnostic Test|presepsin, procalciton, endotoxin|measurement of presepsin, procalciton, endotoxin plasmatic levels
75747895|NCT06180252|Diagnostic Test|PET with 11C MP4|Each subject will undergo a PET exam using 11C MP4 as a tracer. This is a specific ligand for the acetyl-choline esterase enzyme already used abroad both in healthy volunteers and in various patient groups.
75747896|NCT06180226|Diagnostic Test|PET CT with 18 FDG .|Impact exerted by the use of 18FDG PET in the process of functional monitoring of the patient undergoing radiotherapy treatment.
75747897|NCT06180213|Diagnostic Test|FDG PET|Distribution pattern of the FDG tracer in patients with neurodegenerative diseases and identify the regions of altered brain function specific for each clinical condition.
76065331|NCT05149950|Behavioral|Active internet treatment|The patient gets access to the internet treatment via a secure login to 1177 The care guide e-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
76065332|NCT05144035|Drug|PEG-rhGH|the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
76065333|NCT05141708|Drug|Talazoparib|Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
76065334|NCT05141565|Other|No intervention|No intervention
75452132|NCT01735864|Drug|Indirubin 50 μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment contains 50 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
75452133|NCT01735864|Drug|Indirubin 10 μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment contains 10 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
75452134|NCT01735890|Drug|CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg|single dose
75452135|NCT01735903|Procedure|Arm A - Non-Diabetic, Gait and Balance|"Arm A will enroll patients WITHOUT diabetes, but with peripheral neuropathy and lower limb pain, paresthesia, gait disturbances, or motor weakness and will follow the same protocol except the subject will NOT participate in blood flow testing performed at Colorado State University, and therefore do not include the inclusion/exclusion criterion that are specifically related to the blood flow assessment.~Subjects may have any combination of lower limb nerve decompression surgery of the listed surgical sites with or without the addition of Soleal Sling Decompression. Soleal Sling Decompression surgical procedure will require the use of a thigh tourniquet."
75603354|NCT05165927|Device|BFR|BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
75603355|NCT05163301|Behavioral|Relapse Prevention Intervention|2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
75603356|NCT05145738|Behavioral|C-Raven with avatar|Computer delivered intervention with the investigators' avatar; with linkage to community health worker.
75603357|NCT05145738|Behavioral|C-Raven without avatar|Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
75747898|NCT06180200|Diagnostic Test|PET for the analysis of mu opioid receptor expression.|PET for the analysis of the expression of mu opioid receptors and to directly measure the distribution of the receptors and enzyme reuptake sites at the brain level.
75452136|NCT01735968|Drug|ST571 + BYL719|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
75452137|NCT01736007|Device|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
75452138|NCT01736007|Device|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
75452139|NCT01736020|Drug|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
75747899|NCT06180187|Device|Electrical mallet|elevation of the Schneiderian membrane of maxillary sinus using electrical mallet and place bone graft material to augment the residual alveolar ridge and then place dental implant .
75747900|NCT06180187|Device|Osseo-densification burs|elevation of the Schneiderian membrane of maxillary sinus using osseodensification burs and place bone graft material to augment the residual alveolar ridge and then place dental implant .
75452140|NCT01736020|Drug|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
75747901|NCT06180148|Device|Mechanical insufflator-exsufflator|"In the active comparator group a mechanical insufflator-exsufflator will be used in the postoperative period 6 and 24 hours after extubation as follows (coughing maneuver): application of inspiratory pressure of 40-70 cm of water (the minimum value to achieve a peak cough flow of 300 l/min) for 2 seconds with the subsequent creation of an expiratory vacuum of -40 cm of water within 2 seconds. During inhalation and exhalation, the patient will apply oscillations with a frequency of 10 Hz and an amplitude of 10 cm of water. A series of 10 such maneuvers will be used, with a pause of a few seconds to ensure patient comfort. The coughing maneuver will be performed through an oronasal mask tightly pressed to the face."
75452141|NCT01736020|Drug|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
75452142|NCT01736020|Drug|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
75452143|NCT01736020|Drug|Placebo|Placebo
75452144|NCT01736033|Drug|Tamsulosin|1 tablet(0.2mg) orally q.d.
75452145|NCT01736033|Drug|Finasteride|1 tablet(5mg) orally q.d.
75452146|NCT01736033|Drug|Placebo|1 tablet(0.2mg) orally q.d.
75452147|NCT01736046|Radiation|CT Enterography|"Diagnostic CT Enterography Scan (CTE)~Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease."
75747902|NCT06180135|Other|TURKISH COFFEE DRINK|TURKISH COFFEE DRINK
75747903|NCT06180135|Other|FENNEL TEA DRINK|FENNEL TEA DRINK
75747904|NCT06180122|Diagnostic Test|Duplex ultrasound|Vascular ultrasound scan of the left common iliac vein
76065335|NCT05137925|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT is an 8-week group-based treatment modality designed specifically to prevent recurrence of depressive symptoms. MBCT combines principles of cognitive behavioral therapy and mindfulness meditation to help participants change the way in which they relate to automatic negative thinking patterns that trigger symptom recurrence. Through awareness and acceptance of negative thoughts and emotions, participants learn how to dismiss negative thoughts and to tolerate distress and uncertainty.
75603358|NCT05141305|Drug|rhTNK-tPA ( 0.25 mg/kg, Max 25 mg )|rhTNK-tPA (0.25 mg/kg) is being used.
75603359|NCT05141305|Drug|standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.
75452148|NCT01736098|Other|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
75452149|NCT01736111|Behavioral|one way text|
75603360|NCT05139498|Procedure|Conservative management for placenta accreta spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
75603361|NCT05139498|Procedure|Cesarean hysterectomy for placenta accreta spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
75452150|NCT01736111|Behavioral|Personal feedback|
75603362|NCT05129969|Other|Physician's choice according to patient's needs.|Routine care as per site standard.
75603363|NCT05103618|Drug|[F-18] Fluorodopa Positron Emission Tomography|Subjects will receive FDOPA imaging at baseline and 2-3 months after practicing the OM Meditation for evaluation of the dopamine function, [F-18] Fluorodopa (FDOPA), dose (5-10 mCi, ± 20%) will be injected intravenously into an antecubital vein. In accordance with the standard imaging protocol for FDOPA; subjects will be pre-medicated with 200 mg of carbidopa orally approximately one hour prior to injection.
75747905|NCT06180109|Drug|Empagliflozin film coated tablets|1 film coated tablet of 25 mg Empagliflozin
75747906|NCT06180109|Drug|Jardiance film-coated tablets|1 film coated tablet of 25 mg Empagliflozin
75452151|NCT01736137|Other|Six minute walk test|If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
75452152|NCT01736150|Drug|Placebo|"Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals."
75452153|NCT01736150|Drug|Sevelamer carbonate|"Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals."
75452154|NCT01736163|Drug|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
75452155|NCT01736163|Drug|131I|28 mCi or ≥ 1.036 GBq.
75452156|NCT01736163|Other|Thyroid Hormone Withdrawal|Stop taking hormone therapy
75603364|NCT05103618|Behavioral|OM Meditation|Couple pairs will engage in OM Meditation together approximately 3-4 times a week approximately 2-3 months.
75603365|NCT05082181|Behavioral|UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is an 8-week program that combines cognitive behavioral therapy (CBT) and mindfulness techniques and is delivered to small groups of participants by phone. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home practice assignment. CBT-related skills include thought monitoring, identifying cognitive distortions, problem identification, goal setting, and identifying supports. Relaxation exercises are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to breath, sights and sounds and other meditations. Audio guides are provided for home practice of mindfulness exercises.
75603366|NCT05082181|Behavioral|BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program delivered in 8 weekly group sessions. Each weekly session is 1 hour long and is comprised of a check-in period, introduction of the week's topic, and group discussion. Weekly BOOST session topics include: (1) personal experience of epilepsy; (2) personal experience of mood problems (depression, anxiety, stress); (3) seizure triggers; (4) concerns related to epilepsy treatment (e.g., medication adherence, side effects); (5) changes in seizures over time; (6) the impact of behavior (e.g., sleep, substance use) on seizures; (7) social relationships and epilepsy; and (8) review of the BOOST experience.
75747907|NCT06180070|Drug|Ibuprofen/ Paracetamol tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
75747908|NCT06180070|Drug|Nuromol® tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
75747909|NCT06180031|Drug|Pericapsular nerve group block using bupivicaine and magnesium sulphate|This technique involves the deposition of the local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus
76065336|NCT05137925|Behavioral|Treatment as Usual (TAU)|TAU (the control group) provides participants with information about the benefits of mindfulness in pregnancy and offers referrals for psychotherapy in the community. Participants in TAU are contacted monthly via phone or videoconference call to maintain engagement.
76065337|NCT05137119|Drug|Cefazolin|Cefazolin
75747910|NCT06180018|Other|interrupted sutures|Using interrupted sutures in repair of hypospadias by Snodgrass TIP repair
75747911|NCT06179979|Diagnostic Test|PET/CT with 11C-PiB|Subjects considered suitable will undergo a clinical and neuropsychological evaluation and a PET/CT study with intravenous administration of 11C-PIB.
75747912|NCT06179953|Other|NAO intervention|"The protocol is divided into 4 stages:~EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The robot provides instructions and if the child requests it, it elects prompts."
75603367|NCT05057221|Drug|Uproleselan|Uproleselan 20 mg/kg BID up to maximum dose of 2500 mg, infused IV over 20 minutes on days 1-7 or until hospital discharge. It should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.
75603368|NCT05054842|Drug|Retagliptin phosphate tablets、metformin sustained-release tablets|Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication
75747913|NCT06179953|Other|Traditional intervention|"The protocol is divided into 4 stages:~EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The therapist provides instructions, and if the child has difficulty responding, he or she may ask the operator for prompts."
75747914|NCT06179940|Other|Pairwise food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The experimental group will conduct the protocol activity in pairs.
75747915|NCT06179940|Other|Individual food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The control group will conduct the activity individually.
75603369|NCT05054842|Drug|Retagliptin phosphate placebo tablets、metformin sustained-release tablets|Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication
76025282|NCT03164863|Diagnostic Test|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
76025283|NCT03164941|Procedure|Selective Laser Trabeculoplasty|Laser treatment for glaucoma.
76025284|NCT03164707|Diagnostic Test|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
76025285|NCT01352845|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
76025286|NCT01352845|Other|Placebo|0.5 mL dose, given at 0, 2 and 6 months
76065338|NCT05137119|Drug|Penicillin|benzylpenicillin
76065339|NCT05137119|Drug|Clindamycin|Clindamycin
76065340|NCT05137119|Drug|Vancomycin|Vancomycin or Daptomycin
75603370|NCT05040477|Other|Muscle energy Technique|"Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I & II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy."
75603371|NCT05039528|Behavioral|Personalized OSA messages|Participants will receive personalized OSA messages designed to nudge and navigate them toward evaluation and treatment for OSA. Participants will complete questionnaires at baseline and at study follow-up.
76025287|NCT02674399|Drug|JointStem|
76065341|NCT05137119|Other|Effectiveness of early switch to oral antibiotics|This involves testing a strategy rather than individual antibiotic agents
76065342|NCT05128006|Other|New patient teledermatology visit|new patient teledermatology visits
75747916|NCT06179927|Other|QT voice|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes made via tablet. In the scenario, the depictions will be presented in color. They, guided by QT Robot's narrator voice, will have to choose from two or three alternatives the one that represents the appropriate mental state by selecting it on the tablet. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
75747917|NCT06179927|Other|Image stimuli|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the control group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes on paper. They, guided by the narrator's voice of the operator will have to choose from two or three alternatives the one that represents the appropriate mental state by indicating it on the paper. Consequently, feedback will be provided by the operator to return information to the subject on the accuracy of the response.
75747918|NCT06179901|Procedure|Integrative Korean Medicine Treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine, cupping, moxibustion.
75747919|NCT06179901|Procedure|lower limb motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
75747920|NCT06179888|Procedure|Biospecimen Collection|Undergo collection of blood samples
75747921|NCT06179888|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
75747922|NCT06179888|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75898470|NCT05884047|Device|Virtual Glasses|"In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel & Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel & Relax is a Paris-Notre Dame museum tour video."
75898471|NCT05884034|Other|Telerehabilitation|Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.
76025288|NCT02674399|Drug|Synvisc-One|
76025289|NCT05675839|Other|Film (Wit) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life)|Film (Wit) (https://www.youtube.com/watch?v=2s4ozvI_hzY&t=160s) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life) (https://www.youtube.com/watch?v=XsabHOiF0CY&t=284s)
76025290|NCT03161509|Drug|Paracetamol|single dose of 1 gr paracetamol
75603372|NCT05039528|Other|Control|Participants will complete questionnaires at baseline and at study follow-up. At the end of the study period, participants will receive the OSA message intervention.
75452157|NCT01736228|Device|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
75452158|NCT01736280|Other|Standard of Care|Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
75452159|NCT01736332|Drug|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
75452160|NCT01736332|Other|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
75603373|NCT05024916|Dietary Supplement|Intervention|26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.
75603374|NCT05024916|Dietary Supplement|Control|26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
75603375|NCT05022927|Drug|ERY974|ERY974 vial
75603376|NCT05022927|Drug|Tocilicumab|Tocilizumab vial
75603377|NCT05022927|Drug|Atezolizumab|Atezolizumab vial
75603378|NCT05022927|Drug|Bevacizumab|Bevacizumab vial
75603379|NCT05022485|Device|ZNN Bactiguard tibia|Tibia fracture fixation
75603380|NCT05015478|Device|Tailored Rhythmic Lighting Intervention|40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.
75603381|NCT05015478|Device|Placebo Rhythmic Lighting Intervention|Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered with a random interval determined by a Poisson process with an average interval of 40 hertz (Hz). The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
75603382|NCT04976530|Device|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
75603383|NCT04976530|Device|Sham comparator|Sham comparator in similar position to the investigative device, but NOT integrated into the cardiopulmonary (CPB) circuit
75898472|NCT05884034|Other|Education|Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.
75747923|NCT06179888|Procedure|Computed Tomography|Undergo PET/CT and/or CT
75898473|NCT05884021|Other|Postoperative analgesia|In patients who used intravenous PCA after surgery
75898474|NCT05883995|Other|Phage therapy requests|Quantification of phage therapy requests received at the Hospices Civils de Lyon from 2015 to 2028
75898475|NCT05883982|Procedure|I-PRF injection|Intra-articular I-PRF injection to temporomandibular joint cavity
75898476|NCT05883969|Behavioral|GO-PLAY|The intervention is family-centered, individualized, goal-directed, intensive, and carried out within the home environment. The GO-PLAY intervention will last for six months and consists of a home visit once a month and a virtual meeting by telephone or video once a month. The intervention will be family centered. Experienced physiotherapists and occupational therapists will be the primary therapists providing the intervention to ensure uniformity. The motor learning element of the intervention is based on the principles of motor learning and dynamic systems theory. Emphasis is on children's self-initiated actions, which are stimulated by meaningful and motivating activities and toys. The child's play preferences to elicit self-generated motor activity will be the underlying basis of the training. Minimal manual guidance is provided when needed and withdrawn when the child demonstrates self-generated ability to complete part of the task.
76065343|NCT05127109|Combination Product|Nutrition Ecosystem pathway|"parenteral nutrition initiated within 72 hours of operative intervention~Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~Philips Lumify L12-4 broadband linear array transducer ultrasound~expedited delivery of oral nutrition supplements and~a team-based approach on proper documentation of nutrition delivery and intake"
76065344|NCT05127109|Other|Comparator|retrospective cohort of 300 historical matched control subjects
75603384|NCT04957745|Behavioral|Binocular visual confusion (unilateral opaque)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the binocular visual confusion condition, the non-transparent (opaque) peripheral target will be displayed on only one eye (unilateral opaque display)."
75603385|NCT04957745|Behavioral|Unilateral monocular visual confusion (unilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the unilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on only one eye (unilateral see-through display)."
76065345|NCT05085808|Drug|Trazodone|Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.
76065346|NCT05085808|Drug|Quetiapine|Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.
75452161|NCT01736371|Drug|1% Sevoflurane|In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
75452162|NCT01736371|Drug|Propofol|In this group the maintenance of anesthesia is maintained by only propofol infusion.
75603386|NCT04957745|Behavioral|Bilateral monocular visual confusion (bilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For bilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on both eyes (bilateral see-through display)."
75603387|NCT04950166|Drug|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
75747924|NCT06179888|Drug|Iberdomide|Given PO
75747925|NCT06179888|Procedure|Magnetic Resonance Imaging|Undergo MRI
75747926|NCT06179888|Procedure|Patient Monitoring|Undergo disease monitoring
75747927|NCT06179888|Procedure|Positron Emission Tomography|Undergo PET/CT
75452163|NCT01736371|Drug|Sevoflurane|In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
75452164|NCT01736384|Procedure|Gastric bypass or cholecystectomy|
75747928|NCT06179888|Procedure|Skeletal Survey X-Ray|Undergo skeletal survey x-ray
75747929|NCT06179875|Drug|Intervention/Treatment|VRDN-001 10 mg/kg (5 infusions of VRDN-001 10 mg/kg)
75747930|NCT06179810|Other|Baduanjin exercise|Baduanjin exercise
75747931|NCT06179797|Device|remote ischemic conditioning|suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.
75747932|NCT06179784|Behavioral|Cognitive Behaviour Therapy including third-wave|All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behaviour Therapy including methods from the third wave like Acceptance and Commitment Therapy or Mindful Selfcompassion.
75898477|NCT05883969|Behavioral|Usual care|Children will receive referral for rehabilitation in the municipality as usual. Standard care consists of the additional follow up assessments in CP-EDIT as well as rehabilitation offered by their local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied according to the center's protocol and not possible to standardize.
75898478|NCT05883943|Device|Cook® Venous Valve System|The Cook® Venous Valve is a permanent prosthetic, bicuspid, one-way flow valve designed to be percutaneously implanted into the peripheral deep venous system. The Cook® Venous Valve Delivery System is used to percutaneously deliver the Cook® Venous Valve into the deep venous system.
76065347|NCT05085808|Drug|Placebo|Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
76065348|NCT05084625|Other|Digitized support|Access to information about the disease, treatment, side effects and self-care
75603388|NCT04945655|Other|Adolescents and parents' education and motivation at school (component 1)|"The component 1 includes first an information group session (duration: 1h30) on HPV infection and vaccination for parents. This session starts with a webconference delivered by two medical experts on HPV, using a standardized presentation. Then, a discussion is open for parents' questions and/or comments.~Second, adolescents participate during the school time to two educational group sessions on HPV infections and vaccination, using a pedagogy based on active learning. These sessions (duration: 2h each) are delivered by the school staff (e.g., nurse, teacher in life sciences) using an educational package comprising: a guide that describes activities that should be implemented during each session; one video and a fact sheet developed by health students; a serious video game that promotes HPV vaccination and accessible on an internet website. Before the sessions, the school staff is encouraged to attend an e-learning training course (duration: 1 hour)."
75452165|NCT01736410|Drug|Trastuzumab, TS ONE, Cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
75747933|NCT06179771|Device|HA 380|HA380 hemoperfusion cartridge is filled with neutral macroporous resin, mainly adsorbing molecules from 10 to 60 kDa. Because of the accurate 3D macroporous structure and over 54000 m2 adsorption surface area of the resin. The cartridge is attached to the extracorporeal circuit in series with the oxygenator/ filter of the extracorporeal circuit.
75898479|NCT05883917|Procedure|robot assisted gait training|Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.
75898480|NCT05883904|Drug|Fedratinib|Fedratinib administered after AIFA reimbusement approval
76065349|NCT05079750|Biological|ChAdOx1 biEBOV|ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
76065350|NCT05078944|Device|Active acupuncture|Acupoints: Principal: GV20, EX-HN1, GV24 and bilateral PC6, HT7, ST36, KI3, SP6. Additional: CV6 and bilateral GB39, ST40, SP10 Sterile stainless steel disposable acupuncture needles (size 0.30 × 50 mm, Hwato brand, China) are used. After sterilization, a small plastic ring will be fixed over the acupuncture point with plaster to facilitate maintenance of blinding for the participant, and then the needle will be inserted through the plaster inside the ring. The electric stimulator (SDZ-Ⅲ electroacupuncture apparatus, Hwato brand, China) is applied to GV20, GV24, bilateral PC6 and HT7, dilatational wave, 10/50 Hz and tolerable electric current. Needles placed in other acupoints will be manually stimulated by rotation every 15 minutes. Each session lasts for 45 min.
76065351|NCT05078944|Device|Sham acupuncture|"Sham acupoints: SA1 (5 cun lateral to GV5), SA2 (5 cun lateral to GV4), SA3 (1 cun lateral to BL56).~After sterilization, pragmatic placebo needles with blunt tip (size 0.30 × 50 mm, Hwato brand, China) are used. When their tips are pressed against the skin through plastic rings, participants will feel a pricking sensation. The electric stimulator is applied to bilateral SA1 and SA2 with no current output. The mental wire has been cut off with a same outlook as the electroacupuncture group. Needles placed in SA3 will be manually rotated every 15 minutes. Each session lasts for 45 min."
75452166|NCT01736423|Drug|YM060|oral
75452167|NCT01736436|Drug|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
75452168|NCT01736436|Procedure|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
75747934|NCT06179758|Device|icompanion app|use of the icompanion app as a digital telemonitoring solution
75452169|NCT01736436|Procedure|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
75452170|NCT01736449|Drug|Bevacizumab|
75452171|NCT01736462|Drug|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
75452172|NCT01736488|Drug|Fimasartan|Fimasartan 60mg
75452173|NCT01736488|Drug|Atenolol|Atenolol 50mg
75452174|NCT01736501|Other|Genetics education at baseline|
75452175|NCT01736501|Other|Hypothetical genomic scenarios at follow-up|
75747935|NCT06179745|Combination Product|EEG-based brain-computer interface|EEG-based brain-computer interface detecting the patient's EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient.
75747936|NCT06179745|Combination Product|Sham EEG-based brain-computer interface|Fake (Sham) EEG-based brain-computer interface which outputs a decision at random about whether EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient are currently detected.
75898481|NCT05883891|Diagnostic Test|prothrombin time|Prothrombin time at value at diagnosis was used to assess the presence of a correlation with Lille score at day 7 and therefore wether it could predict response to medical treatment.
75452176|NCT01736514|Drug|febuxostat|oral
75452177|NCT01736514|Drug|Allopurinol|oral
75452178|NCT01736605|Procedure|Massage|Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.
75452179|NCT01736605|Procedure|Massage combined with meditation|Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
75452180|NCT01736644|Device|Electrocautery|Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
75452181|NCT01736644|Device|Bipolar sealer Aquamantys|Aquamantys use in tourniquet and tourniquetless total knee replacement.
75452182|NCT01736670|Drug|Triamcinolone Acetonide spray|
75898482|NCT05883878|Genetic|PRS|genetic test for the evaluation of PRS cardiovascular risk
75898483|NCT05883878|Device|Digital app and wearable device|a wearable device connected with its app
75452183|NCT01736670|Drug|Triamcinolone acetonide cream|
75452184|NCT01736670|Drug|Alcohol spray|
75452185|NCT01736709|Biological|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
75452186|NCT01736722|Device|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
75452187|NCT01736735|Drug|CLP|
75452188|NCT01736735|Drug|placebo|
75603389|NCT04945655|Other|General practitioners' training (component 2)|The component 2 consists of an individual e-learning training session for general practitioners (GPs) that is accessible on computer and smartphone. Lasting 3 hours, GPs are able to access to the training whenever they want and then to progress at their own pace. The training includes three main parts: up-dated information on HPV infection and vaccination; an introduction to the use of motivational interviewing techniques in the field of vaccination; and a presentation of the decision aid tool developed as part of the intervention and explanation of how to use it during consultations. GPs may ask questions to the consortium team by using a dedicated chat.
75603390|NCT04945655|Other|Access to vaccination at school (component 3)|The component 3 aims at enhancing access to HPV vaccination for adolescents by offering them the first free-of-charge injection at school, without any medical prescription. For each concerned school, we organise a vaccination day inside the school premises where health professionals (one physician and one nurse) from the local vaccination centre initiate HPV vaccination with Gardasil-9® (in accordance with the French recommendations) for all eligible adolescents.
75603391|NCT04945642|Radiation|High-Dose Rate Brachytherapy|Undergo HDR-BT
75603392|NCT04945642|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75603393|NCT04915508|Drug|Hormone Therapy|Receive hormonal therapy
75603394|NCT04915508|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75603395|NCT04867525|Other|Physician's choice according to patient's needs.|Routine care as per site standard.
75898484|NCT05883865|Drug|Fenofibrate|Fenofibrate is orally administrated daily with food for at least 1 week during pregnancy
75898485|NCT05883839|Other|Student Group|"Sexual Healthcare Questionnaire will be applied to nursing students to adapt it to Turkish."
76025291|NCT03161509|Drug|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
75452189|NCT01736761|Drug|Darunavir, Ritonavir and Rilpivirine|
75452190|NCT01736774|Other|Usual care intervention|The usual care intervention will include appropriate primary care as required including medication
75452191|NCT01736774|Other|Physiotherapy treatment|Exercise and manipulative therapy treatment for 10 weeks:The treatment intervention consists of two visits per week for the first four weeks (8 treatments) and one visit per week for the last six weeks (6 treatments)
76025292|NCT04587193|Device|Robotic-assist gait training device|PD participants will walk while wearing a robotic-assist gait training device
75452192|NCT01736787|Dietary Supplement|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
75452193|NCT01736787|Dietary Supplement|Placebo|Placebo (1g/day)
75452194|NCT01736800|Drug|Topotecan|Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
75452195|NCT01736800|Drug|Temozolomide|Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
75452196|NCT01736813|Drug|Maraviroc|Twelve patients with 300 mg/bid
76025293|NCT02676895|Biological|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
76025294|NCT02676895|Biological|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
75603396|NCT04866004|Behavioral|Contingency Management - Cannabis|Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.
75747937|NCT06179745|Device|Functional Electrical Stimulation|Neuromuscular stimulation of several upper limb muscles (elbow extensors, hand extensors/flexors) to effectuate reach, grasp and release movements of the affected upper limb.
75898486|NCT05883813|Procedure|sustained natural apophyseal glides (SNAGS)|SNAGS will be given with patient in sitting position and the therapist will be standing behind the patient. The therapist will place the thumb on the spinous process of the vertebra. Move spinous process upward towards the eyeball direction & maintain the glide and ask the patient to turn (rotation) his head slowly in painful direction, sustain the mobilization until head turn to the midline. Three repetitions of each glide will be given and each glide will be maintained for 10 seconds at end range.
75898487|NCT05883813|Procedure|suboccipital muscle release|Sub-occipital muscle release will be applied with the patient in the supine position with the eyes closed and the physiotherapist's hands placed under the patient's head, in contact with the sub-occipital muscles. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.
76065352|NCT05078944|Drug|Donepezil Hydrochloride|Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily.
76065353|NCT05076019|Drug|Atorvastatin 80mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
76065354|NCT05076019|Drug|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
76065355|NCT05073913|Diagnostic Test|Vascular remodeling characterization|Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol
76065356|NCT05069922|Other|Fresh Frozen Plasma|Fresh Frozen Plasma
76065357|NCT05065333|Other|Septic Shock Clinical Decision Support|The intervention will be activating a septic shock clinical decision support tool (CDS) in the Electronic Health Record at the site, making it available to trigger and alert Emergency Department providers during clinical care. Patients will be identified when providers suspect sepsis and initiate a sepsis evaluation, using the institutional, clinically-standard, sepsis pathway/orderset. After the CDS is triggered, it will use available Electronic Health Record data to calculate the risk of septic shock, using previously-published predictive models [Ref 1, 2]. The CDS will notify providers if the patient is at elevated risk of septic shock and prompt them to follow institutional standard care for septic shock (including close monitoring, complete laboratory evaluation for organ dysfunction, and immediate clinical involvement of an attending Pediatric Emergency Physician). All clinical care decisions will be determined by the providers.
76065358|NCT05065333|Other|Clinical Diagnosis Only|Emergency Department sites in this arm will not have Clinical Decision Support for septic shock visible in the Electronic Health Record for providers at the site. Providers will follow usual institutional standards of sepsis care.
75452197|NCT01736826|Biological|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
75452198|NCT01736826|Biological|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 & 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
75603397|NCT04864028|Other|physical activity|15min sitting, 15min standing, 15min sitting, 15 min low intensity cycling
75603398|NCT04820998|Other|Families|Families's interviews about their precarious situation of living and the consequences on their autistic child care
75603399|NCT04820998|Other|professionals|Interviews so as to know how the specifics of precarious situations are identified and taken into account by the professionals
75603400|NCT04818008|Other|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
75603401|NCT04793867|Diagnostic Test|Xenon|"Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time <10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose."
75747938|NCT06179745|Device|Active hand orthosis|Active hand orthosis effectuating reach, grasp and release movements of the affected uppe r limb.
75898488|NCT05883813|Procedure|Supplemental therapy|General warm-up exercises, TENS, hot pack, trapezius stretching
75898489|NCT05883787|Other|Exploration of a database|extraction of data
75898490|NCT05883722|Procedure|Catheter ablation|The ablation approach includes: pulmonary vein isolation, left side linear ablation, left side driver ablation and right atrial driver ablation
75747939|NCT06179732|Combination Product|Mesh - spatial repellent impregnated with transfluthrin (2500mg)|"Mesh is one of the first spatial repellent tools to provide long-lasting protection to users, with predicted efficacy of 6-months. The active ingredient of Mesh is transfluthrin, a fast-acting volatile pyrethroid with low persistency, which can act either by killing or via sublethal toxicity that causes deviation (repellency) in host attraction, reducing host-contact and risk of infectious bites. The chemical passively releases into the air and interacts with vector odour receptors causing irritation. The design of Mesh is simple with a transfluthrin-infused sheet protected by plastic mesh and encased in a plastic frame.~Mesh will be distributed to the intervention arm only."
75747940|NCT06179732|Behavioral|Information and Education Campaigns (IEC)|IEC campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home) using leaflets and word of mouth. IEC will be conducted in both arms.
75747941|NCT06179732|Diagnostic Test|test and treat malaria cases|All children in the cohort (both arms) will be tested by rapid diagnostic testing (RDT) monthly. If any children test positive, they will be treated with a course of 3-day artemisinin combination therapy (ACT) according to standard protocol and local guidelines. All children in the cohort will receive ACT to provide clearance of any malaria parasites during the baseline of the study.
75747942|NCT06179719|Drug|Propofol|Anesthesia will be induced intravenously using the hypnotic drug propofol. The drug is used regularly in everyday clinical practice to carry out general anesthesia, and the intended concentrations are within the usual clinical dosage range. Propofol will be applied via target-controlled infusion (TCI) with a perfusor using TCI set to effect mode as described by Schnider (Schnider et al., 2016). Starting at low concentrations, the effect site concentration will be increased stepwise to achieve the target level of sedation as measured by the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale. We aim for three different levels of sedation: low (MOAA/S=5-4), mid (MOAA/S=3-2) and high (MOAA/S=1).
75747943|NCT06179719|Behavioral|visual flickering stimulation at the alpha frequency|Participants will receive visual stimulation as a flickering light during the different sedation levels, including wakefulness pre- and post-anesthesia. Stimulation will be done with eyes closed in all conditions.
76025295|NCT02676895|Biological|Menveo|One injection of Menveo was administered in subjects in the Control Group.
75452199|NCT01736826|Biological|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
75452200|NCT01736878|Drug|Sorafenib|
75452201|NCT01736891|Drug|Rasagiline|Tablets, qd
75452202|NCT01736891|Drug|Placebo|Tablets, qd
75603402|NCT04790526|Other|Eccentric Exercises Dose|Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance
75603403|NCT04758611|Device|eShunt™ Implant|The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.
75603404|NCT04752462|Behavioral|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
75603405|NCT04749433|Drug|[11C]CPPC Injection|A single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
75452203|NCT01736904|Drug|wXELIRI regimen|irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
75603406|NCT04700800|Other|Exercise|Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake
75747944|NCT06179706|Diagnostic Test|11C-choline PET/CT|In our study we evaluated the efficacy of high-dose RT guided by 11C-Choline PET/CT on bone metastases in prostate cancer patients with a limited number of metastases.
75747945|NCT06179693|Diagnostic Test|Diagnostic accuracy|As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.
75747946|NCT06179680|Diagnostic Test|Magnetic Resonance Imaging|"MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition."
75898491|NCT05883709|Drug|Tafasitamab Injection|The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
75898492|NCT05883696|Other|Swedish Palliative Care Guide (S-PCG)|"S-PCG is a care guide that aim to inform best practice and to meet palliative care needs of patients and their families throughout all the time with palliative care needs. The S-PCG support palliative care for adult patients regardless of diagnosis, place of care and if it is early och late palliative care.~The S-PCG includes three parts~Assements of palliative care needs~Initiating palliative care 2D. End of life care.~After death. In this study only the first part of the S-PCG will be used."
76025296|NCT02676895|Biological|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
76025297|NCT05235451|Other|Human-Animal Interactions|Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
76065359|NCT05063097|Other|urine test|The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol [THC]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
76065360|NCT05063097|Other|Fagerström questionnaire|Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
76065361|NCT05063097|Other|Exhaled carbon monoxide (CO) measurement|Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of > 3 parts per million (ppm) signifying active smoking.
76065362|NCT05062239|Drug|Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative|Discontinuance of prior statin therapy
76065363|NCT05062239|Drug|No-intervention.|Continuance of prior statin therapy
75603407|NCT04700800|Other|Infusion of Amino Acids|Intravenous infusion of mixture of amino acids
75603408|NCT04698018|Drug|Faster Aspart|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
75603409|NCT04698018|Drug|Novo Rapid|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
75603410|NCT04678310|Other|Support from the hospital palliative and end of life care volunteer service (developed for this study).|Hospital palliative and end of life care volunteer service: a volunteer service to provide support to patients dying in the hospital and their families. The volunteer service has been designed to provide presence and companionship to dying patients at the end of life, and their families.
75452204|NCT01736904|Drug|FOLFIRI regimen|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
75452205|NCT01736969|Device|RD047-023|Experimental hydrogel
75452206|NCT01736969|Device|Predicate Device|
75452207|NCT01736982|Behavioral|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
75452208|NCT01736982|Other|Standard of Care|Standard smoking cessation counseling
75452209|NCT01736982|Other|Standard of Care|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)]
75452210|NCT01736982|Other|Standard of Care|Breath sample monitoring
75452211|NCT01736995|Behavioral|Functional Family Therapy|
75603411|NCT04657367|Other|Observational study - registry|Observational study - registry
75603412|NCT04634591|Procedure|Bariatric surgery|Bariatric surgery (Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy) for the treatment of morbid obesity
75603413|NCT04577729|Procedure|Allogenic Fecal Microbiota Transplantation|Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
76025298|NCT05675683|Drug|Capmatinib|Patients receiving Capmatinib
75747947|NCT06179667|Behavioral|Mobile Application|"It is aimed to develop the mobile application to address the problems and training needs of informal caregivers regarding the caregiving process. In this context, in order to determine the needs of caregivers, face-to-face in-depth interviews will be held with caregivers using the Semi-Structured Questionnaire for Qualitative Interviews at the University of Health Sciences GTRH Geriatrics Department. The content of the mobile application will be created according to the topics determined as a result of qualitative research. Technical development of the application will be carried out by the web application designer."
75747948|NCT06179654|Behavioral|Preoperative pelvic floor physical therapy|Pelvic floor physical therapy to start before prostate surgery rather than after surgery.
75747949|NCT06179628|Drug|Low and standard concentrations and volumes|Compare low and standard concentrations and volumes of bupivacaine boluses for continuous adductor block
75898493|NCT05883683|Other|Molecular Profiling & drug testing in tumor organoids and PDXs|Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.
75898494|NCT05883670|Drug|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
75898495|NCT05883657|Device|Condition 1 : Prototypes (816-v1) every weeks|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75898496|NCT05883657|Device|Condition 2 : Prototypes (816-v1) every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75452212|NCT01736995|Behavioral|Motivational Enhancement Tx/Cognitive Behavioral Tx|
75452213|NCT01736995|Behavioral|Contingency Management|
75452214|NCT01737008|Drug|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
75603414|NCT04577729|Procedure|Autologous Fecal Microbiota Transplantation|Patients receiving their own stool in terms of sham FMT.
75603415|NCT04566159|Behavioral|CBI-CHW|2 sessions of computer delivered counseling + nicotine replacement therapy and CHW follow up post hospitalization up to twice weekly for up to 8 weeks
75603416|NCT04566159|Other|Standard Care|Standard tobacco treatment care offered by the inpatient care
75452215|NCT01737008|Radiation|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
75452216|NCT01737008|Drug|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
75603417|NCT04561453|Diagnostic Test|Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring|All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
75747950|NCT06179615|Other|surface hardness test for denture teeth|surface hardness test of denture teeth at insertion then after 6 months of use
75747951|NCT06179615|Other|wear resistance of denture teeth measurement|2D, Vertical wear, 3D Volumetric wear were measured for denture teeth
75747952|NCT06179589|Dietary Supplement|VS002A|Amino acid based, glucose free ORS
75898497|NCT05883618|Other|Exposure|Human Development Index of Country
75898498|NCT05883605|Device|Measuring blood pressure|Measuring blood pressure using electronic device and using a mercury sphygmomanometer
75747953|NCT06179576|Behavioral|Connect to Baby|"To engage both fathers and mothers, CTB recruits parents at the time of birth, capitalizing on the magic moment of delivery, and uses father-inclusive digital media content to engage men. A key innovation lies in the introduction and rehearsal of four interaction skills -- Noticing, Following, Talking, and Encouraging (NiFTE, pronounced Nifty) -- to foster serve-and-return interactions with infants as well as supportive, cooperative coparenting interactions between mothers and fathers. To maximize program uptake, CTB is situated within an early education program parents already trust and attend. Additionally, the study will test hybrid program delivery with both in-person and remote sessions using video-enabled tablets to reduce scheduling and logistical barriers and thereby enhance retention."
75747954|NCT06179563|Other|On-Demand Telemonitoring|Patients assigned to the on-demand intervention group do not have to use the app at set time intervals but will be asked to use the app at their own discretion, in case of symptoms. This implies that patients have full control over their monitoring activities. Patients have the option to reach out to the hospital whenever they feel the need.
75452217|NCT01737034|Other|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
75898499|NCT05883592|Device|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
75898500|NCT05883579|Procedure|percutaneous coronary intervention|doing percutaneous revascularization of chronic coronary total occlusion.
75898501|NCT05883553|Device|Usability and added value of device within sexual activity|Participants and there partners will be asked to use the device over the course of 4 months, during which both will provide answers to questionnaires on quality of relation and sexual life, and detailed questions on the usability and the added value of the used device during sexual activity along with overall satisfaction with the device.
75452218|NCT01737073|Behavioral|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
75452219|NCT01737073|Behavioral|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
75898502|NCT05883527|Other|Not applicable as not an intervention - PLwD and family/carers|Exploring the safeguarding process through interviews.
75603418|NCT04526860|Other|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 2 standard deviations of normal WHO weight standards, in order to prevent infant obesity and subsequent childhood obesity.
75747957|NCT06179537|Drug|BLU-5937|Single and multiple doses assessment
75898503|NCT05883527|Other|Not applicable as not an intervention - HCP's|Exploring the safeguarding process through interviews and a focus group.
75452220|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tip and usual clinical care
75898504|NCT05883514|Behavioral|Motivational interviewing|According to the Miller and Rollnick principles, the framework of the motivational interviewing group's sessions was taken from the workbook of the intervention's six sessions of motivational interviewing. A researcher recruited participants in groups of 7 patients for six sessions of 60-90 minutes each (two sessions per week). The training sessions covered topics like stress alleviation, appropriate drug usage, quitting smoking, regular physical activity, healthy eating habits, and regular physical activity. Patients in the control group got standard treatment for PPM, including education on proper medication usage, nutrition, and exercise, as well as regular checking.
75603419|NCT04520490|Behavioral|Family Based Behavioral Treatment|Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.
75603420|NCT04520490|Drug|Exenatide 2 mg [Bydureon]|Weekly injections of active drug.
75603421|NCT04520490|Drug|Placebo|Weekly placebo injections
75747958|NCT06179524|Biological|CAR-T-19 cell injection|The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
76065364|NCT05061277|Drug|Recifercept|A lyophilized powder for solution for injection
75898505|NCT05883501|Behavioral|Self-affirmation versus back massage|"Self-affirmation is non-pharmacological intervention which represents structured sentences to convey to the subconscious mind to help in reprogramming negative thoughts into positive ones.~Massage is defined as systematic touch of soft tissues for therapeutic purposes, such as pain relief, increased comfort and patient's relaxation"
76025299|NCT04691999|Behavioral|Intermittent Fasting|16-18 hour fasting period four times per week
76025300|NCT01680809|Device|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
76065365|NCT05056740|Biological|Data analysis|Analysis of the data from routine care at the end of the diagnostic work-up
75452221|NCT01737086|Dietary Supplement|Lactobacillus reuteri DSM 17938 and zinc sulphate|
75452222|NCT01737086|Dietary Supplement|placebo|
75452223|NCT01737099|Dietary Supplement|DHA-O|
75452224|NCT01737099|Dietary Supplement|Fish oil|
75452225|NCT01737099|Dietary Supplement|Placebo|
75452226|NCT01737112|Drug|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
75452227|NCT01737125|Radiation|Magnetic Resonance Imaging (MRI)|"spatial high-resolution MRI multiplanar acquisition in T1 and T2 anatomical sequences~MRI acquisition in movements with dynamic sequences BEAT-IRT ( dynamic TrueFISP)"
75603422|NCT04483778|Biological|second generation 4-1BBζ B7H3-EGFRt-DHFR|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR
75747960|NCT06179498|Behavioral|Partner Navigation Intervention|A two-session, disclosure counselor-led, behavioral intervention to enable the injecting partner to support and navigate the adult PWID to start HCV treatment.
75747961|NCT06179485|Drug|Ketamine|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
75747962|NCT06179485|Drug|Etomidate|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
75747963|NCT06178276|Diagnostic Test|behavior|behavioral measurements will be performed during the oral comprehension testing
76025301|NCT01680809|Device|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
76025302|NCT04440085|Drug|Midodrine Hydrochloride|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
76025303|NCT04440085|Drug|Placebo|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
76025304|NCT05129033|Drug|Prednisone tablet|Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.
76025305|NCT05129033|Drug|itraconazole|Anti-fungal medication to reduce fugal load.
76025306|NCT05129033|Biological|Omalizumab|Anti-IgE monoclonal antibody, used for high IgE allergic disease.
76025307|NCT04780399|Drug|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
76025308|NCT04780399|Drug|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
75603423|NCT04483778|Biological|second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
75747964|NCT06178276|Diagnostic Test|physiology|physiologic (autonomic) measurements will be performed during the oral comprehension testing
75747965|NCT06178276|Diagnostic Test|imaging|central (brain) measurements will be performed during the oral comprehension testing
75603424|NCT04483778|Drug|Pembrolizumab|SCRI-CARB7H3(s)x19 plus pembrolizumab
75747966|NCT06176612|Procedure|total hip arthroplasty|Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent hip replacement
75747967|NCT06176066|Procedure|CEST PH MRI based resection of glioblastoma|Using pre-operative amine chemical exchange saturation transfer pH weighted MRI, regions of interest that correspond to infiltrating glioblastoma will be identified and via intraoperative neuronavigation, guide resection of glioblastoma
75747968|NCT06175494|Biological|Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
75747969|NCT06175494|Biological|Recombinant COVID-19 Variant Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
75747970|NCT06175494|Biological|Placebo|boost with saline
76025309|NCT04780399|Drug|Placebo|72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
76065366|NCT05036005|Drug|Ontruzant|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
75452228|NCT01737138|Procedure|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
75452229|NCT01737138|Drug|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
75452230|NCT01737151|Radiation|stereotactic body radiation therapy|Undergo SBRT
75452231|NCT01737151|Radiation|four fraction split-course SBRT|four fraction split-course SBRT
76065367|NCT05036005|Drug|Chemotherapy|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
75452232|NCT01737164|Behavioral|Aerobic Exercise|
75603425|NCT04482309|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
75603426|NCT04480554|Drug|Methadone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
75747971|NCT06174519|Device|Medical device simulation|For the subjects included, investigators used the iAST® tool to predict which antibiotics would have been recommended as the top three choices both for empiric and semi-targeted therapy and recorded this data with the percentage of coverage predicted (the first three antibiotics in the iAST® ranking that have been tested in the antibiogram of the center where the study was carried were chosen). Investigators checked the final microbiological reports and logged if the recovered bacteria were susceptible to the drug prescribed by doctors and simulated by the iAST® tool according to the final antibiogram results.
75747972|NCT06174168|Other|Modified Frailty Index -11|MFI-11: the parameter included in the score is history of congestive heart failure, presence of diabetes mellitus, history of chronic obstructive pulmonary disease or pneumonia, functional health status/dependence, history of hypertension, history of myocardial infarction, cardiac problems, cognitive impairment, history of transient ischemic attack or cerebrovascular accident, history of peripheral vascular disease is questioned. Patients will be monitored according to standard non-operating room anesthesia procedures.
75747973|NCT06173661|Drug|Fremanezumab|The intervention will be active medication.
76025310|NCT05404997|Device|Shockwave Therapy|"Subjects in Group A will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes. After the conventional therapy, this group will be given shockwave therapy treatment twice a week for four weeks.~After exposing and cleaning the treated area with alcohol, adequate amount of gel will be placed on the lower back region, and the machine will be adjusted at (2000 shock per session, 8 sessions 2 per week for 4 weeks, energy flux density 0,18mJ per mm square, 2 bars of pressure, frequency 10hz), with using 20mm D-Actor head."
75747974|NCT06173661|Other|Placebo|The intervention will be placebo injection.
75603427|NCT04480554|Drug|Buprenorphine/naloxone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
75898506|NCT05883475|Other|Disabilities of the Arm, Shoulder, and Hand Questionnaire|Upper limb function was assessed with the Turkish version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). The questionnaire DASH is a self-report instrument with 30 items. The total score ranges from 0 to 100, with higher scores indicating a worse upper limb function.
75898507|NCT05883475|Other|Arm Motor Ability Test|The test assesses hemiparetic upper extremity functional tasks.The increase in the scores of both subparameters of the scale, which is composed of the parameters of functional ability and quality of movement, indicates an improvement in the motor functions of the upper limbs.
75898508|NCT05883475|Other|Nine Hole Peg Test|Fine motor skills of the upper extremities were assessed.The patient was asked to insert the nine sticks in the box on the table into the holes in the other box as quickly as possible and then remove them immediately. As time increases, fine motor skills of the upper extremities decrease
75898509|NCT05883475|Other|Pittsburg Sleep Quality Index|"Sleep quality was assessed using the this test.This scale, which provides a quantitative measure of sleep quality, is a 19-item self-report scale. The total score greater than 5 indicates poor sleep quality."
75452233|NCT01737177|Drug|Bendamustine, Lenalidomide, Rituximab|"INDUCTION PHASE (COURSE 1-4)~Bendamustine: 70 mg/m2 on day 2 and 3 every 28~Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days"
75603428|NCT04480554|Drug|XR-Naltrexone|Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
75898510|NCT05883475|Other|Functional Independence Measure|This test assessed functional capacity in activities of daily living.The higher a person's score, the higher the level of independence.
75898511|NCT05883436|Device|DEXA-C Cervical Interbody System|The Dexa-C Cervical Interbody System is intended for use on patients who require anterior cervical discectomy and fusion surgery. The system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate
75603429|NCT04477889|Other|Treatment for COVID-19|Patients treated for COVID-19
75603430|NCT04472000|Drug|Vitamin C|Study participants in the verum group receive one capsule of Burgerstein Vitamin C retard 500mg b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
75603431|NCT04472000|Drug|Placebo|The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
75747975|NCT06173219|Combination Product|Radiotherapy combined with immunotherapy|(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
75747976|NCT06172790|Other|Training|A protocol has been established for the progression of the strengthening and balance training components of the Otago Exercise Program, increasing every two weeks in a four-stage manner. The exercise intensity will be gradually increased based on patient tolerance, ensuring that the perceived difficulty level remains in the range of 4-6 on the Borg dyspnea scale throughout the 8-week period. Supervised walking training is planned to be conducted on a treadmill to ensure standardization. The initial treadmill walking speed for patients will be determined based on the submaximal walking speed in the 6-minute walking test. The progression of the walking program will be carried out every two weeks, similar to the other exercise components of the program, with a 10% increase in walking speed each time.
75747977|NCT06169280|Biological|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.
75747978|NCT06169280|Dietary Supplement|N-acetylcysteine amide (NACA)|N-acetylcysteine amide (NACA) 600 mg oral, is taken daily from registration to just prior to dose 2 of NSC-CRAd-S-pk7.
75747979|NCT06167694|Drug|HRS-8080; Dalpiciclib Isethionate Tablets|HRS-8080 combined with Dalpiciclib Isethionate Tablets
75898512|NCT05883423|Other|FPCMP-Old Age|"Exercise program：The main purpose of the exercise program is to improve cardiorespiratory endurance, upper and lower limb muscle strength and endurance, body flexibility, sense of balance and coordination. The exercise program is carried out with a suspension training system, which can improve core muscle strength, improve physical fitness, activate more core and stabilizing muscle groups, increase joint stability, and strengthen ligaments.~Health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities involved)"
75898513|NCT05883410|Other|Exercise|It is important for the therapist to organize a home exercise program to provide edema and pain control. The exercise program should be specific and clear to the patient. The exercise program will be taught to the patient and given as a home program
75898514|NCT05883410|Other|PNF Technique|While the limb is in the agonist pattern, the patient is instructed to perform isometric contractions for 5-8 seconds against maximum resistance without movement at the limiting point. After maximum isometric contraction, the patient is instructed to actively relax.Participants in the second group will be applied 10 repetitions of isometric contractions for 8 seconds at the limitation points of the movement with the PNF techniques, the hold and relax active movement technique in the direction of wrist flexion and extension.
75898515|NCT05883410|Other|Mulligan Mobilization|In thw Mobilization with movement technique; the patient is expected to perform painless ROM. After obtaining painless movement in the patients participating in the study, this application will be applied to the patient with the painless active movement technique in 10 repetitions and 2-3 sets. Rest time between sets will be 15-20 seconds. Patients will be taught self-mobilization to ensure the continuity of painless movement. Self-mobilization will be applied by the patient at home with 10 repetitions every two hours (29).
75898516|NCT05883397|Other|HBOT|Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.
75898517|NCT05883397|Other|Hippocampal training|Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session.
76065368|NCT05036005|Drug|Pertuzumab|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
75452234|NCT01737190|Other|PEEP guided by Esophageal pressure + Recruitment maneuver|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
75452235|NCT01737203|Drug|Viagra|50 mg tablet on Day 1 of each period
75452236|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
75603432|NCT04463446|Behavioral|Use of the CHD app|Use of the CHD app
75452237|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
75603433|NCT04463446|Behavioral|Nurse-led intervention|Teaching session with clinic nurse
76065369|NCT05035823|Device|Motor Neuroprosthesis (MNP)|Type of implantable brain computer interface
76065370|NCT05033769|Drug|Eribulin Injection [Halaven]|on days 1 and 8 q21d
76065371|NCT05033769|Drug|Paclitaxel injection|on days 1, 8, and 15 q21d
75452238|NCT01737216|Drug|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
75603434|NCT04433117|Biological|Shefabone|Silica-calcium phosphate composite.
75603435|NCT04433117|Biological|Bio-Oss|Xenograft Bone substitute. Bone from animals.
75603436|NCT04427930|Biological|JOINTSTEM|Autologous Adipose Tissue derived MSCs
75603437|NCT04398394|Device|Cellularis version 1 imaging|Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).
75747980|NCT06167668|Other|the routine chronic disease management mode|indoor temperature and humidity adjustment, regular ventilation and hygiene of ward and clinic environment, promotion of patients' health awareness by distributing disease brochures, regular inspection of wards, and home nursing and health guidance based on disease knowledge when discharged
75747981|NCT06167668|Other|the family-centered family enabling health management mode|The specific measures were as follows :(1) intervention group construction. (2) Online knowledge promotion. (3) Disease assessment.(4) Medication guidance reminder.(5) Enabling psychological counseling.
75747982|NCT06166719|Other|No intervention|No intervention
75747983|NCT06166290|Procedure|CO2 LASER Vaporisation|The CO2 LASER vaporization procedure is described as follows. Patient positioning will be done, and patient will be anesthetized. Local infiltration with 2% lidocaine, nerve block or general anesthesia will be given. The surgical field will be disinfected and draped. The perianal and anal area will be investigated for lesion. CO2 LASER from 20 cm distance in a continuous wave mode and 20 W power will be applied. After warts melts, necrotic tissue will be removed. After the operation was completed, residual debris will be wiped away with a piece of moist gauze. Bacitracin cream applied over the treated areas. Upon discharge acetaminophen 1-gram q8 and Ibuprofen 600 q8 for pain.
75898518|NCT05881720|Drug|Sacubitril / Valsartan Oral Tablet|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
75603438|NCT04378452|Behavioral|COM-COVID anonimous survey|Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
75898519|NCT05881720|Drug|Valsartan 80 mg|group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
75898520|NCT05881564|Other|blood use for priming cardiopulmonary bypass circuit|one arm will have the cardiopulmonary bypass circuit primed with blood
75898521|NCT05881564|Other|clear prime for cardiopulmonary bypass|this arm will not have bypass circuit primed with blood
75898522|NCT05881174|Procedure|acupuncture|acupuncture
75898523|NCT05881096|Other|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
75898524|NCT05881096|Other|Sham Control|Practice of movement task without START
75898525|NCT05879016|Other|Functional Correction Technique|A single I strip will be used for this technique. Taping will be done by applying moderate (25-35%) degree of stretching to the middle 1/3 of the tape, with the stretched area centered on the trigger point. The ends of the tape will be adhered without stretching.
75898526|NCT05879016|Other|Fascia Correction Technique|Y tape will be applied to prevent fascia adhesions. In the Y tape application, first the tail strips of the Y will be adhered with maximum tension so that the muscle fiber is transverse. Then it will be glued so that its base is in front of the pain point. No tension will be applied to the ends of the tape. The application will be applied when the patient is in a resting position and his joints are in a tense position.
75452239|NCT01737216|Drug|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
75898527|NCT05879016|Other|Star Taping Technique|4 I tapes of the same length between 15 cm and 20 cm will be glued on top of each other. After the first I tape is adhered, the 2nd I tape will be adhered at 90 degrees, then the 3rd and 4th I tapes will be adhered at 45 degrees to obtain a star appearance. There will be no tension at the ends of the tapes
75898528|NCT05879016|Other|Sham Comparator|I shape tape will be adhered for sham purpose without applying any tension.
75898529|NCT05876884|Device|Celsi Warmer Mattress|The hypothermic neonate will be placed on the Celsi Warmer mattress and a temperature probe will be placed on the neonate to monitor the temperature of the neonate for up to 24 hours of intervention time
75898530|NCT05873725|Drug|Follitropin delta|Evaluation of the IVF cycle using the prescribed medication
75452240|NCT01737229|Device|Application of Biodentine™ (RD94), dentin substitute|
75452241|NCT01737294|Drug|Qutenza exposure|Cutaneous patch
75452242|NCT01737307|Drug|Fluoride varnish|Fluoride Varnish (NaF 5%)
75452243|NCT01737307|Other|Oral Hygiene|Oral hygiene followed.
75898531|NCT05873166|Other|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
75452244|NCT01737307|Drug|CPP-ACP|CPP-ACP paste was applied by patient, once daily.
75603439|NCT04371861|Device|Peripheral Artery Treatment|Peripheral lesions may be treated by any standard of care methods of treatment.
75603440|NCT04340362|Drug|VX-147|Tablets for oral administration.
75603441|NCT04308759|Other|Experimental Smoking Cessation Program|Participate in Quitbot experimental cessation program
75603442|NCT04308759|Other|Control Smoking Cessation Program|Participate in Quitbot control cessation program
75603443|NCT04290806|Other|Routine care as per site standard|Physician's choice according to patient's needs. Routine care as per site standard.
75747984|NCT06166290|Procedure|Electrosurgical Fulguration|The procedure is described as follows. Patient will be administered regional or general anesthesia, placed in prone jack-knife position. Prepping and draping will be done. The perianal and anal area will be investigated for lesion. The lesions will be excised, and the bases will be fulgurated. Electrosurgery device will be used in monopolar setting (30 Cut mode, 30 Coag mode). After procedure local analgesics total MERCAINE/EPI 0.25% 20 ml on both sides of the lesion. Bacitracin cream applied over the treated areas. Upon discharge 1000 mg of Tylenol every 8 hours along with 600 mg of ibuprofen every 8 hours.
75747985|NCT06164847|Behavioral|AERO Program|HEP, identification of barriers for exercise using the COM-B model. Interventions for these barriers: Review of HEP, review of method of delivery, cues, reminders, discussion of barriers and problem solving, motivational interviewing, decision balance sheets, behavioural contract, goal setting reviews, monitoring calls (detailed description in the link below).
75747986|NCT06164847|Other|Standard Care|home exercise programs, mobilisations, soft tissue techniques, or training with gym equipment
75747987|NCT06164821|Drug|luspatercept|Adult patients with TD thalassemia were given luspatercept subcutaneous injection.
75747988|NCT06164145|Other|Usual care|The training program used in this study is the stroke rehabilitation program focusing on health education for stroke and a routine exercise program based on the National Strategic Plan for Stroke Rehabilitation in Myanmar.
75747989|NCT06162806|Procedure|ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl|injection of local anesthetic mixture(Bupivacaine +Fentanyl ) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
75898532|NCT05873166|Other|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
75603444|NCT04272216|Device|Treatment with HydroPearl via radial access|This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
76065372|NCT05030142|Procedure|Mechanical Thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
75603445|NCT04269031|Drug|AZD2373 subcutaneous injection|Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
76065373|NCT05030142|Drug|Best medical treatment alone|Best medical treatment alone (usual care)
76065374|NCT05019846|Drug|Triptorelin Embonate|single administration before SRT starting
75452245|NCT01737320|Drug|short-course antibiotic treatment|"On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~Intervention group - antibiotic treatment stopped on day 7~Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines."
75452246|NCT01737320|Drug|accepted prolonged antibiotic treatment|
75603446|NCT04269031|Drug|Placebo|Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
75452247|NCT01737346|Drug|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
75603447|NCT04268498|Drug|Bortezomib|1.3 mg/m2 administered Subcutaneous (SC) or intravenous (IV) on days 1, 4, 8 and 11 of a 21 day treatment cycle for participants randomized to Arm A.
75747990|NCT06162806|Procedure|ultrasound guided caudal epidural block using 50 mg of Magnesium sulfate added to(1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl)|injection of local anesthetic mixture(Bupivacaine +Fentanyl +magnesium sulfate) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
75747991|NCT06158841|Drug|ABBV-383|Intravenous (IV) Infusion
75747992|NCT06158841|Drug|Carfilzomib|IV Infusion
75747993|NCT06158841|Drug|Pomalidomide|Oral Capsule
75747994|NCT06158841|Drug|Elotuzumab|IV Infusion
75747995|NCT06158841|Drug|Selinexor|Oral Tablet
75747996|NCT06158841|Drug|Bortezomib|Subcutaneous or IV Injection
75898533|NCT05872061|Other|Acceptability of food-to-food fortified (FtFF) instant porridge flours|This study will evaluate the market potential of a food-to-food fortified (FtFF) flour.
76065375|NCT05019846|Drug|Bicalutamide 50 mg|1 dose each day, 7 days before LHRH until 10 days after LHRH administration
75452248|NCT01737359|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
75747997|NCT06158841|Drug|Dexamethasone|Oral Tablet or IV Infusion
76065376|NCT05017298|Biological|Allogeneic adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
76065377|NCT05014971|Behavioral|Tele-neurohub|Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.
76065378|NCT05014256|Behavioral|STEPS Health System Outreach intervention|STEPS Transplant Social Worker Education and Outreach, STEPS Transplant Coordinator Outreach
76065379|NCT05011578|Radiation|Radiographic assessment|Radiographic assessment after at least 10 years after radiocapitellar surgical treatment
76065380|NCT05004233|Biological|Blood collection before antiplatelet treatment|Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment
76065381|NCT05004233|Biological|Blood collection after antiplatelet treatment|"A follow-up will be carried out 5 to 8 days after the initiation of the treatment.~A blood test will be taken in the NeuroVascular Unit"
76065382|NCT05004025|Device|Novocure Optune|Novacure Optune with Opdivo and Yervoy
75603448|NCT04268498|Drug|Dexamethasone|"20 mg or 40 mg per dose administered by mouth (PO) or IV.~Participants randomized in Arm A:~20 mg/dose on days 1, 4, 8 and 11 on a 21 day treatment cycle;~Participants randomized in Arm B:~Cycles 1 through 8 - 40mg/dose on days 1, 8 and 15 on a 28-day cycle~Participants randomized in Arm C:~Cycle 1-2 - 40 mg/dose on days 1, 8, 15 and 22 on a 28-day cycle; Cycles 3-8 - 40mg/dose on Days 1, 8, 15 on a 28-day cycle;"
75603449|NCT04268498|Drug|Lenalidomide|"10 or 25 mg/day capsules administered PO.~Participants randomized in Arm A:~25 mg/day capsules on Days 1 through 14 of a 21 day cycle.;~Participants randomized in Arm B:~Cycles 1 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Participants randomized in Arm C:~Cycles 1 - 25 mg/day capsules on Days 2 through 21 of a 28 day cycle; Cycles 2 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Maintenance Therapy:~10 mg capsules on Days 1 through 21 on a 28 days cycle."
76065383|NCT05004025|Drug|Opdivo|Novacure Optune with Opdivo and Yervoy
75603450|NCT04268498|Drug|Acetaminophen|"650 mg administered PO.~Participants randomized to Arm C:~Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15."
76065384|NCT05004025|Drug|Yervoy|Novacure Optune with Opdivo and Yervoy
75603451|NCT04268498|Drug|Diphenhydramine|"25 mg administered via IV~Participants randomized to Arm C:~Cycles 1 through 8 - 25 mg administered on Days 1, 8 and 15."
75603452|NCT04268498|Drug|Montelukast|10 mg administered PO to participants randomized to Arm C prior to the first 4 doses of Daratumumab.
75603453|NCT04268498|Drug|Carfilzomib|"20 mg or 56 mg/m2 per dose administered via IV.~Participants randomized to Arm B:~Cycle 1 - 20 mg/m2 per dose on Day 1 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle;~Participants randomized to Arm C:~Cycle 1 - 20 mg/m2 per dose on Day 2 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle"
76065385|NCT04998240|Biological|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration:~Intramuscular~Storage Conditions: 2°C to 8°C"
76065386|NCT04998240|Biological|Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|"Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein), manufactured by Johnson and Johnson in the United States of America.~Dose formulation: One dose (0.5 ml) contains contains 5 x 10 10 virus particles~Mode of administration: Intramuscular~Storage Conditions: 2°C to 8°C"
76065387|NCT04998240|Biological|Placebo - Normal saline (0.9% sodium chloride solution)|"Placebo - Normal saline (0.9% sodium chloride solution)~Dose formulation: Not Applicable~Mode of administration: Intramuscular~Storage conditions: 15°C to 30°C"
76065388|NCT04997824|Procedure|Artificial Intelligence-based atrial fibrillation catheter ablation|"Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~AI-guided prediction for poor responder of AFCA in the outpatient clinic~Sharing information on the AI prediction with the patient and family member~AFCA after consent to the procedure~Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~Monitoring esophageal temperature~Evaluation of Procedure and ablation time, and complication afer procedure~Post-procedure rhythm follow-up is carried out according to the study design above."
76065389|NCT04997824|Procedure|Medical Therapy|"Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~Decision for AFCA based on clinical guidelines and the experience of the attending physician~AFCA after consent to the procedure~Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~Monitoring esophageal temperature~Evaluation of Procedure and ablation time, and complication afer procedure"
76065390|NCT04997200|Behavioral|One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
75452249|NCT01737359|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
76065391|NCT04995341|Device|Investigational ultracompact OCT and OCTA system|Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece
75603454|NCT04268498|Drug|Daratumumab|"16 mg/kg administered via IV or 1800 mg SC, per treating physician discretion.~Participants randomized to Arm C:~Cycles 1 though 2 - 16 mg/kg IV or 1800 mg SC on days 1, 8, 15, and 22 of a 28 day cycle; Cycles 3 through 6- 16 mg/kg IV or 1800 mg SC on days 1 and 15 of a 28 day cycle; Cycles 7 through 8 - 16 mg/kg IV or 1800 mg SC on day 1 of a 28 day cycle"
75603455|NCT04268498|Biological|Autologous Stem Cell Transplant (ASCT)|Participants who are MRD positive at the conclusion of 8 cycles of study treatment, and were able to have their stem cells that were extracted, will receive ASCT from participants' bone marrow samples.
75747998|NCT06158620|Drug|intra-nasal ketorolac|Experimental group receiving intra-nasal ketorolac for management of post-operative pain following ureteroscopy for kidney stone, and associated ureter stent discomfort.
76065392|NCT04995341|Device|retinal photographs|retinal photographs with a commercial portable bedside widefield fundus camera system
75452250|NCT01737359|Drug|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
75452251|NCT01737385|Procedure|Measurement with O2C|Measurement of microcirculation using O2C light probes.
75452252|NCT01737411|Drug|solifenacin|
75452253|NCT01737411|Procedure|cesa/vasa|surgical repair of USL
75452254|NCT01737424|Drug|LC28-0126|LC28-0126
75452255|NCT01737424|Drug|Placebo|Placebo
75452256|NCT01737437|Drug|group C|0.9% normal saline was applied to trachea and laryngoscope blade
75452257|NCT01737437|Drug|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
75452258|NCT01737437|Drug|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
75452259|NCT01737437|Drug|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
75452260|NCT01737450|Drug|BKM120|
75747999|NCT06158620|Drug|oral diclofenac|Control group to receive oral diclofenac, which is a comparable medication to intra-nasal ketorolac.
75898534|NCT05871398|Drug|Tegoprazan|Novel, potent, and highly selective potassium-competitive acid blocker which was developed in Korea
76065393|NCT04992611|Behavioral|Sleep Extension (Early)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping rise time the same as the sleep restriction period, but extending sleep by going to bed earlier. This produces a sleep extension that is aligned for Morning Larks and misaligned for Night Owls.
75452261|NCT01737463|Procedure|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
75452262|NCT01737476|Procedure|Transcranial Magnetic Stimulation. PFC|
75603456|NCT04264819|Drug|RTH258/Brolucizumab|Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.
75748000|NCT06157944|Other|GPT-4|OpenAI's GPT-4 large language model with chat interface.
75748001|NCT06153758|Drug|Formulation A|Danuglipron IR PF-06882961-82 40 mg Oval White to Off-White Tablet
75748002|NCT06153758|Drug|Formulation B|Danuglipron MR, Danuglipron 80 mgA (500 mgW) Oval MR Tablet (Long Release)
75748003|NCT06153758|Drug|Formulation C|Danuglipron MR, Danuglipron 80 mgA (1000 mgW) Oval MR Tablet (Long Release)
75898535|NCT05871398|Drug|Placebo|Placebo
75898536|NCT05869929|Dietary Supplement|Vegetables|4-5 servings of vegetables daily, per USDA guidelines.
75898537|NCT05864469|Other|12-week psychosocial dyadic intervention|Comprising six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
75452263|NCT01737489|Behavioral|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
75452264|NCT01737489|Behavioral|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
75452265|NCT01737515|Other|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
75452266|NCT01737541|Drug|Fluoxetine|
75452267|NCT01737541|Drug|Placebo|
75603457|NCT04220931|Drug|botulinum toxin injection|injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
75748004|NCT06153758|Drug|Formulation D|Danuglipron MR Danuglipron 80 mgA (500 mgW) Oval MR Tablet (Short Release)
75748005|NCT06150170|Other|Proprioceptive training|Proprioceptive exercises were applied to both groups. In addition to these exercises, balance, coordination and strengthening exercises will also be applied to both groups.
75898538|NCT05860530|Drug|The test olaparib tablet (T)|The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours
75748006|NCT06143670|Drug|Stannous fluoride toothpaste|0.454% w/w SnF2
75748007|NCT06143670|Drug|Sodium fluoride toothpaste|0.243% w/w Sodium fluoride
75748008|NCT06133010|Biological|mRNA-1647|Sterile liquid for injection
75748009|NCT06133010|Biological|Placebo|Sterile liquid for injection
75748010|NCT06131593|Drug|TAPB with dexamethasone as an adjuvant to local anesthetics|patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics
75748011|NCT06131593|Drug|TAPB with methylprednisolone as an adjuvant to local anesthetics|patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
75748013|NCT06127368|Drug|GB-5001A|Depending on the cohort, volume will be varied to administer, and the dosage and route of administration may be varied.
75748014|NCT06127368|Drug|GB-5001D|Depending on the cohort, volume will be varied to administer.
75748015|NCT06127368|Drug|Oral cohort|Single dose of Aricept tablet.
75748016|NCT06126926|Behavioral|group therapy|32 weeks of group therapy
75898539|NCT05860530|Drug|The reference olaparib tablet (R)|The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours
75748017|NCT06126926|Other|Treatment as usual|Control participants remain in their current placement and may be eligible for a number of services offered to inmates to facilitate rehabilitation and planning for release to the community, including sexual offender treatment. MnDOC's sexual offender treatment is a two to three year program, thus most of our control subjects will not have enough time remaining on their sentences to complete such treatment. However, a number of them may participate in MnDOC's current program.
75748018|NCT06124508|Behavioral|Lung Cancer Screening Education|Tailored lung cancer screening education will consist of an annual, in-person 60 minute visit of lung cancer screening education in the participant's native language with material in layman's terms about the importance of lung cancer screening, tobacco cessation, and the risk of developing a second primary lung cancer.
75748019|NCT06124508|Behavioral|Semi-Structured Interview|Participants will undergo an annual, in-person or virtual, semi-structured interviews to understand barriers and perception towards screening and cultural competencies to increase adherence to lung cancer screening. The interviews will last approximately 30 minutes at each visit.
75898540|NCT05859451|Device|Tobacco Heating System (THS)|Participant who are not willing to quit cigarette smoking during the study duration will switch from cigarettes to using THS
75898541|NCT05859451|Other|Smoking abstinence|Participant who are willing to quit cigarette smoking and will not use any electronic nicotine delivery system during the study duration
75452268|NCT01737554|Other|Catheter Resistance Monitoring|Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
75452269|NCT01737580|Drug|resiquimod|
75898542|NCT05858450|Biological|Comirnaty|COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
75898543|NCT05858450|Biological|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines
75898544|NCT05849272|Drug|toludesvenlafaxine hydrochloride sustained-release tablets|orally once a day
75898545|NCT05839340|Device|Neurally Adjusted Ventilatory Assist|NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.
76065394|NCT04992611|Behavioral|Sleep Extension (Late)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping bedtime the same as the sleep restriction period, but extending sleep by rising later. This produces a sleep extension that is misaligned for Morning Larks and aligned for Night Owls.
76065395|NCT04991506|Drug|ES102|The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
75898546|NCT05839340|Device|Assist Control Ventilation|ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.
76065396|NCT04991506|Drug|JS001|JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
76065397|NCT04990544|Biological|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
76065398|NCT04990544|Biological|202-CoV low antigen dose|low dose of 202-CoV with CpG / alum adjuvant
75898547|NCT05836675|Other|Intradialytic exercise|The exercise program will be carried out during dialysis time. Participants will be asked to carry out cycling for 15-20 minutes, resistance exercises, and Kegel exercises during the first 2 hours of their regular routine hemodialysis session. Exercise can be done with rest periods as necessary.
76065399|NCT04990544|Biological|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
76065400|NCT04990544|Biological|Placebo|Normal saline solution
75452270|NCT01737580|Drug|placebo gel|
75452271|NCT01737606|Device|Fast Cerebral Pulsatility Imaging|Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
75452272|NCT01737632|Behavioral|Multidimensional Family Therapy (MDFT)|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
76065401|NCT04990427|Drug|CLBS201|1 x 10^6 to 300 x 10^6 autologous CD34+ cells
75452273|NCT01737632|Behavioral|Adolescent Residential Treatment|The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
75452274|NCT01737658|Other|Exercise Program|Exercise Program for Obese Adolescents
75748020|NCT06124508|Behavioral|Standard of Care Lung Cancer Screening Program|Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.
76065402|NCT04987502|Other|Virtual Reality|8 sessions of virtual reality with 3D audio and visual rendering
75603458|NCT04198688|Behavioral|Intensive Smoking Cessation Intervention|The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.
75603459|NCT04194775|Drug|Nofazinlimab (CS1003)+Lenvatinib|Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily
75603460|NCT04194775|Drug|Nofazinlimab (CS1003) Placebo+Lenvatinib|Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
75748021|NCT06117202|Other|music therapy|The research is a thesis study aimed at determining the stress and anxiety levels of patients seeking in vitro fertilization, investigating influencing factors, and revealing the impact of pre-procedural music listening on these stress and anxiety levels.
75748022|NCT06107738|Drug|Iberdomide|Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.
75748023|NCT06107738|Drug|Daratumumab/rHuPH20 Co-formulation|"Daratumumab/rHuPH20 will be dosed as follows:~Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)"
75898548|NCT05835687|Drug|B7-H3-CAR T cells|Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells). Six (6) infusions of B7-H3-CAR T cells will be locoregionally administered via CNS reservoir catheter.
75603461|NCT04146545|Behavioral|"Community Rx-Dementia CRxD Caregiver Resources"|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
75603462|NCT04104217|Behavioral|Music therapy|Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.
75748024|NCT06106191|Behavioral|Mindfulness meditation|Ordinary activities like breathing, eating, and walking are turned into a meditation by creating greater awareness of the moment-to-moment sensations, emotions, thoughts and behaviors that arise during these activities.
75748025|NCT06106191|Other|Perspectives on pain|Understanding pain from a mind-body perspective and viewing pain as a stressor on physical sensations, thoughts, emotions, and behavior.
75748026|NCT06106191|Other|Discussion|Discussion on patients' use of mindfulness to work with pain and pain-themed meditations.
75748027|NCT06104605|Other|Institutional interventions|Intervention will include, but not be limited to, the following: adding a referral option to chiropractic care in the electronic health record (EHR), optimizing referral option, e.g., creating a list of preferred providers. Additional strategies may be added depending on community health center staff engagement prior to implementation.
75748028|NCT06104605|Other|PCPs interventions|"Two one-hour interactive grand rounds/lunch seminars that allow for inter-professional learning for PCPs with optional continuing education credits for PCPs.~Short teaching cases involving clinical vignettes developed with local DCs, information about DCs (e.g., evidence-base for treatments), and logistics of the referral process (e.g., geographic location of community-based DCs who accept Medicaid) sent to participating providers unable to attend the seminars. Additional strategies may be added depending on primary care provider engagement prior to implementation."
75898549|NCT05831241|Dietary Supplement|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
75898550|NCT05831241|Other|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
75603463|NCT04104217|Behavioral|Interviews|Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
76065403|NCT04987502|Behavioral|Standard treatment|counselling, relaxation techniques, sound enrichment
76065404|NCT04984759|Drug|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
76065405|NCT04984759|Drug|Tafenoquine|Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
76065406|NCT04982068|Biological|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
76065407|NCT04982068|Biological|202-CoV low antigen dose|low dose 202-CoV with CpG / alum adjuvant
75898551|NCT05830799|Drug|Drug Drug Interaction|The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated
75898552|NCT05827523|Drug|Cisplatin|Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery
75603464|NCT04098432|Drug|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
75603465|NCT04098432|Radiation|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
75748029|NCT06104605|Other|Patient interventions|Printed and electronic educational materials (e.g., brochures) written at a sixth grade reading level in English and Spanish that present chiropractic as a safe and effective evidence-based treatment for LBP. These materials will be written, reviewed, and revised by the researchers with CHC patient input. Additional strategies may be added depending on patient engagement prior to implementation.
75898553|NCT05826470|Device|"TRANBERG®|Thermal Therapy System"|Focal laser ablation.
75898554|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
75898555|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions BID over 14 days
75898556|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions daily (QD) over 14 days
75898557|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
75452275|NCT01737671|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain.
75452276|NCT01737671|Drug|Methotrexate|2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
75452277|NCT01737671|Drug|Leucovorin|5 mg/square meter per dose administered every 6 hours by vein or mouth.
75452278|NCT01737723|Device|Neurokeeper stroke detector|Monitoring stroke patients
75452279|NCT01737736|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
75452280|NCT01737749|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
75452281|NCT01737775|Procedure|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
75452282|NCT01737788|Procedure|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
75452283|NCT01737801|Procedure|Lung function test|Lung function test.
75452284|NCT01737814|Drug|Saline|
75452285|NCT01737814|Drug|MST-188|
75452286|NCT01737853|Drug|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
75452287|NCT01737853|Drug|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
75452288|NCT01737866|Drug|AMG 423|omecamtiv mecarbil
75452289|NCT01737918|Procedure|TOT|
75452290|NCT01737918|Drug|solifenacin|
75898558|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every QD over 14 days
75898559|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
75898560|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
75452291|NCT01737957|Device|Low-fluence PRP with 532nm green LASER|To administer low-fluence PRP in a single session for PDR
75898561|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
75898562|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
75452292|NCT01737957|Device|Full-Fluence PRP with 532nm LASER|To administer full-fluence PRP in two sessions for PDR
75603466|NCT04083534|Drug|REGN5459|Administered by intravenous (IV) infusion
75603467|NCT04073628|Device|Lighting Intervention|Lighting Intervention consisting of a cool or warm light source.
75603468|NCT04069702|Behavioral|VR Blue|VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
75603469|NCT04048356|Drug|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
75603470|NCT03996850|Procedure|Computed Tomography|Undergo SPECT/CT
76065408|NCT04982068|Biological|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
75748030|NCT06098482|Device|the Mobile Research App|"The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the keypad on the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.~Speech material used will be determined by the country/local language and the sub-investigation. For example, sub-investigation A, will use CNC monosyllabic words."
75898563|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
75898564|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
75898565|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
76065409|NCT04982068|Other|Placebo|Normal saline solution
76065410|NCT04978480|Other|no intervention|There is no intervention. We are only collecting standard of care data.
76065411|NCT04971044|Behavioral|COACH|Multi-Level Behavioral Intervention
75452293|NCT01737983|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10^10 colony-forming units) for 6 months.
75452294|NCT01737983|Dietary Supplement|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
75452295|NCT01738022|Other|Administration of gas mixtures|
75452296|NCT01738035|Drug|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
75603471|NCT03996850|Other|Questionnaire Administration|Ancillary studies
75603472|NCT03996850|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
75603473|NCT03996850|Radiation|Technetium Tc-99m Sestamibi|Given IV
75748031|NCT06098482|Device|SOC/validated delivery of the speech perception test material|Speech material used will be determined by the country/local language and the sub-investigation. For example, sub-investigation A, will use CNC monosyllabic words.
75748032|NCT06098144|Drug|Nicoderm C-Q Gum|"Participants will receive an 8-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition."
75898566|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
75898567|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
75898568|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
75898569|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
75898570|NCT05807490|Drug|PF-07328948|Single doses of PF-07328948 will be administered as oral tablet (single dose) and oral suspension (single dose) under fed and fasted condition
75898571|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
75898572|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
75898573|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
75898574|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
76065412|NCT04971044|Behavioral|School Readiness Intervention|Multi-Level Language and School Readiness Intervention (Control Group)
76065413|NCT04967729|Device|Device: Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
75748033|NCT06098144|Behavioral|Tobacco Quit-line|The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.
75748034|NCT06098144|Behavioral|Brief Behavioral Counseling|"The counseling session will discuss preparing to quit, coping with job-related stress, getting social support, the 5A's for preventing relapse (Avoid, Alter, Alternatives, Anticipate, and Active), proper use of NRT, and last approximately 30 minutes."
75898575|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
75898576|NCT05803928|Drug|Ronvatinib + sindillimab|A RFA treatment group B RFA+ Ronvatinib + sindillimab treatment group
76065414|NCT04956159|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of depression and anxiety.
75452297|NCT01738035|Other|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
75452298|NCT01738048|Procedure|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
75452299|NCT01738061|Behavioral|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
75748035|NCT06098144|Behavioral|Intensive Behavioral Counseling|Participants will receive four weekly counseling sessions which include information about how to quit, challenges, and short and long-term relapse prevention. Each session will last approximately 20 minutes.
75603474|NCT03985761|Behavioral|Home Telerehabilitation using HoVRS|The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
75603475|NCT03980808|Behavioral|American Sign Language-Accessible Diabetes Education|Video-based ASL interpreted diabetes educational intervention (ASL-ADE), the content of which will be derived from diabetes health information regarding symptoms and risk factors that are published by the U.S. Centers for Diseases Control and Prevention (CDC) and the National Institute for Health (NIH) National Diabetes Education Program.
75603476|NCT03980808|Behavioral|Control Intervention|Non-health related video approximately the same length as ASL-ADE.
75748036|NCT06096714|Drug|Nicotine|Nicotine will be infused using a pump.
75748037|NCT06096714|Other|Saline|Saline with be used to compare Nicotine, Saline will be infused using a pump
75748038|NCT06095973|Drug|GB-6002|Depending on the cohort, volume will be varied to administer.
75748039|NCT06095973|Drug|Placebo|Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.
75898577|NCT05803928|Procedure|radiofrequency ablation|radiofrequency ablation
76065415|NCT04956159|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
75452300|NCT01738074|Biological|trivalent rotavirus genetic reassortment vaccine|
75452301|NCT01738074|Biological|Placebo|
75452302|NCT01738087|Drug|NEXThaler 100/6 mcg DPI|
75452303|NCT01738087|Drug|Flixotide Accuhaler 500 mcg|Active comparator
75452304|NCT01738087|Drug|NEXThaler 200/6 mcg DPI|
75452305|NCT01738087|Drug|NEXThaler placebo|Placebo comparator
75452306|NCT01738100|Drug|Ticagrelor|
75452307|NCT01738100|Drug|Clopidogrel|
75452308|NCT01738100|Drug|Morphine Sulfate|
75452309|NCT01738100|Drug|Saline|
75452310|NCT01738113|Other|Open Kinetic Chain exercise|"Hamstrings strengthening exercise~Quadriceps strengthening exercise~Hamstrings stretch~Hip extensors and abductors strengthening~Calf-muscles stretching~Strength exercise of ankle dorsiflexors & plantar flexors"
75748040|NCT06095973|Drug|Naropin injection|Single dose of Naropin s.c. injection.
75748041|NCT06091007|Dietary Supplement|Magnesium|Magnesium citrate of either 200mg or 400 mg will be taken by the participant with food in the morning.
75748042|NCT06086093|Dietary Supplement|RespireAid TM/placebo|"Direction: Take 1 sachet(5g) 4 times daily~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
75748043|NCT06085664|Drug|REGN5678|Given by IV (vein)
75898578|NCT05799911|Dietary Supplement|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
75898579|NCT05799911|Dietary Supplement|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
75898580|NCT05798091|Behavioral|Supportive-expressive group therapy|The intervention is based on the evidence-based supportive-expressive (SEGT) approach and was designed by an interprofessional team from psychiatry, social work, physiatry and occupational therapy, along with patient advisors. The SEGT approach fosters mutual support, promotes openness and emotional expression. It has been shown to yield improvements in anxiety, psychosocial functioning, health literacy, and social support in breast cancer survivors. This SEGT approach has been modified, in both content and process, to specifically address the needs of limb loss inpatients.
75748044|NCT06085664|Drug|Piflufolastat F18|Given by IV (vein)
75748045|NCT06083571|Drug|Ketorolac|Non-inferiority
76065416|NCT04955990|Drug|PAH Therapies|PAH therapies will be administered in a routine clinical setting and data will be collected from participants who newly initiate any PAH therapy(ies), or have already been receiving macitentan 10 mg for at least 3 months prior to the index date. Participants will receive PAH therapies such as Macitentan, Ambrisentan, Bosentan, Tadalafil, Sildenafil, Riociguat, Selexipag, Epoprostenol, Iloprost, Treprostinil, and Beraprost.
75452311|NCT01738113|Other|Closed kinetic chain exercise|"Foot sliding from sitting~Seated Toe Raises~Hamstrings and quadriceps co-contraction from sitting~Bridging exercise~Sitting-to-standing~Side-to side, forward and backwards weight shifting~Lunge exercise~Squatting exercise~Standing Toe Raises~Standing Hamstrings Stretch"
75603477|NCT03976219|Other|ECAPS Closed Loop SCS|The purpose of this study is to determine the feasibility of recording evoked compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs) from the spinal cord (SC) and Dorsal root ganglions (DRG), and their suitability as feedback signals.
75452312|NCT01738152|Other|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
75452313|NCT01738152|Behavioral|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
75452314|NCT01738178|Drug|Caffeine|
75452315|NCT01738178|Drug|Placebo|
75452316|NCT01738217|Procedure|Fluobeam|
75452317|NCT01738243|Drug|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
75603478|NCT03972215|Drug|Berberine Chloride|Traditional Chinese Medicine
75603479|NCT03972215|Drug|Placebo|Placebo Control
75603480|NCT03956238|Behavioral|Alcohol intoxication|Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
75603481|NCT03956238|Behavioral|Objectification|Women assigned to objectifying gazes condition or eye contact control condition
75748046|NCT06083571|Drug|Prochlorperazine|Adjunct
75748047|NCT06083571|Drug|Diphenhydramine|Adjunct
75748048|NCT06077695|Other|therapeutic education|The themes covered concern head trauma in the chronic phase.
75748049|NCT06077695|Other|tDCS|The constant electric current will be delivered at an intensity of 2 mA for 20 minutes.The anode will be placed opposite the dorsolateral prefrontal area on the right. The cathode (or reference electrode) will be positioned opposite the supraorbital area on the left. This methodology is based on the general directions and results from scientific studies which aimed to improve the efficiency of neural networks engaged in attentional processes and working memory.
75898581|NCT05798091|Other|Treatment as usual|All patients may be referred to social work and/or a psychiatrist to address their mental health needs. As well, members of the interprofessional team provide psycho-social supports where needed. The types of psycho-social supports provided to patients in the TAU condition will be documented (e.g., referral to psychiatrist, social worker, etc.).
75748050|NCT06077695|Other|cognitive remediation|"Personalized sessions combining 2 approaches:•Retraining deficit components of working memory.exercise the strengthening of metacognition and the learning of reorganization-facilitation strategies. At the end of each exercise, the participant will be asked to analyze their performance and will benefit from feedback from the rehabilitator as well as a discussion on the use of the strategies. Finally, all of the proposed tasks will be made up of several levels of complexity; moving to a more complex stage will require more than 90% success in the exercise.•More ecological exercises will also be carried out in order to get as close as possible to the difficulties encountered by the patient on a daily basis. The examiner will guide the rehabilitation and propose tasks imitating his daily life."
75898582|NCT05787054|Other|Third trimester ultrasound|Third Trimester U/S on indication (TT-Indication) vs Late Third Trimester Protocol (Late-TT)(Trial n°2).
75898583|NCT05776368|Other|Syntactic comprehension battery (BCS)|"The BCS is a battery for assessing syntactic skills. In this study, only one part of the BCS will be performed, namely task C2.~It consists in assessing the ability to assign thematic roles. To do this, the participant selects the image corresponding to the sentence he/she hears on a board of 2 images.~Task C2 consists of 50 tests of 2 images. A total score is given out of 50 points. The higher the score, the more successful the test."
75452318|NCT01738243|Drug|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
75603482|NCT03955055|Device|Video Capsule Endoscopy|Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
76065417|NCT04952324|Other|Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP|Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
76065418|NCT04951726|Drug|Neostigmine|cholinesterase inhibitor
75748053|NCT06068933|Behavioral|K-HEARS Intervention|Tailored aural rehabilitation for participant and care partner
75452319|NCT01738256|Behavioral|Wellbeing intervention (ACT)|The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.
75603483|NCT03953157|Dietary Supplement|Dietary Intervention|Receive dietary intervention
75603484|NCT03953157|Behavioral|Exercise Intervention|Receive exercise intervention
75603485|NCT03953157|Other|Questionnaire Administration|Ancillary studies
75748054|NCT06068933|Device|K-HEARS Sound Amplifier Intervention|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
75748055|NCT06064968|Other|Intermittent bladder catheterization|Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
75898584|NCT05776368|Other|Montreal Cognitive Assessment (MOCA)|"The MOCA is a short 30-question test that assesses several cognitive domains and allows for early detection of cognitive disorders. The MOCA test takes about 10-15 minutes to administer and consists of several sections, the first of which is an assessment of orientation in time and space. Then there are tasks that assess memory, concentration and reasoning ability, as well as language and visuospatial ability tasks.~The MOCA score can range from 0 to 30 points, with a score of 26 points or more considered normal."
76065419|NCT04948892|Other|Prescence of the father during cesarean section in general anesthesia|The father is now present in the OR during cesarean section category 1, instead of waiting outside
76065420|NCT04937478|Other|Observation|Only observational study, no intervention.
76065421|NCT04936919|Device|BroadBand Light|Treatment arm will receive Broadband light treatment
76065422|NCT04931212|Procedure|FETO with Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
76065423|NCT04926792|Device|Leadless Pacemaker|Leadless pacemaker implantation
76065424|NCT04926571|Drug|Dexamethasone Oral|New users of Dexamethasone
75452320|NCT01738256|Behavioral|Wellbeing intervention (Internet)|The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).
76065425|NCT04924127|Diagnostic Test|Detection of IDH and TERT mutation|Detection of IDH and TERT mutation using frozen glioma tissues
75603486|NCT03943953|Behavioral|Information and Therapy Guides|"We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~Facial palsy: Coping with the early stages.~Facial palsy: Coping with comments, questions and staring.~Facial palsy: Communicating with confidence.~Facial palsy: Managing anxiety.~Facial palsy: Managing your mood.~Facial palsy: Building your self-esteem.~Facial palsy: Advice for friends, family and partners."
76065426|NCT04919135|Biological|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
76065427|NCT04919135|Drug|standard frailty treatment and supplementary medication|Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
76065428|NCT04918823|Drug|Restasis|Subject will use one drop of Restasis in the lens before insertion
75452321|NCT01738256|Behavioral|No intervention|No intervention
75603487|NCT03927573|Drug|GEM3PSCA|Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
76065429|NCT04909073|Drug|Afatinib|Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.
76065430|NCT04894656|Diagnostic Test|Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy|Tests to assess intestinal permeability
76065431|NCT04893772|Dietary Supplement|Intermittent fasting|"Three fasting days a week, whereby participants consume 600-800 kcal/day from 4 meal replacement products: breakfast, lunch, a snack and dinner. During the other 4 non-fasting smart days each week, participants are instructed to consume 2 x 300 kcal meals and 2 x 100 kcal snacks, from a selection of recipes, plus one meal of their own choosing."
76065432|NCT04887519|Other|No Intervention|This is a non-interventional study.
75452322|NCT01738282|Drug|Baclofen|
75603488|NCT03920007|Drug|SAR439483|Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
75603489|NCT03920007|Drug|SAR439483 Diluent Solution|Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
75748056|NCT06061536|Drug|Lipovirtide 10mg|Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
75748057|NCT06061536|Drug|Lipovirtide 40mg|Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
76065433|NCT04885166|Other|Web-based placebo presentation|This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.
76065434|NCT04885166|Behavioral|Web-based simulation active intervention|This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
75452323|NCT01738282|Drug|Placebo (for baclofen)|
75452324|NCT01738295|Drug|Donepezil administration|
75452325|NCT01738295|Drug|Placebo administration|
75603490|NCT03920007|Drug|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
75603491|NCT03920007|Drug|Triamcinalone Acetonide|Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
75603492|NCT03920007|Drug|1% Prednisolone|Pharmaceutical form:Suspension Route of administration: Drops
75603493|NCT03920007|Drug|Trimethoprim/polymyxin B|Pharmaceutical form:Solution Route of administration: Topical
75748058|NCT06061536|Drug|Lipovirtide 60mg|Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
75748059|NCT06061536|Drug|DTG|DTG +3TC + TDF（once daily）.
75748060|NCT06060587|Drug|Docetaxel|75 mg/m2 via IV
75748061|NCT06060587|Drug|ADT|Prior to randomization as part of standard of care.
75748062|NCT06060587|Drug|Abiraterone|1000 mg by mouth
75748063|NCT06055959|Drug|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants.
75748064|NCT06055075|Drug|Forimtamig|Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
75748065|NCT06055075|Drug|Carfilzomib|Carfilzomib will be administered via IV infusion in combination with forimtamig.
75898585|NCT05776368|Other|Purdue Pegboard Test|"The Purdue Pegboard Test is a test of fine motor skills and hand-eye coordination. The test consists of a perforated board with holes into which participants must insert pegs or counters.~The assessment consists of four subtests, each repeated 3 times:~Right hand (30 seconds): The total number of pins placed in the right column with the right hand in 30 seconds.~Left hand (30 seconds): The total number of rods placed in the left column with the left hand in 30 seconds.~Two hands (30 seconds): The total number of pairs of rods placed in both columns using both hands simultaneously, in 30 seconds.~Assembly (60 seconds): The total number of rods, washers and clamps assembled in the allotted time, using both hands."
75898586|NCT05776368|Other|The Box and Block Test (BBT)|"The Box and Block Test (BBT) is a standardised test of manual dexterity used to assess motor function and hand-eye coordination in people of all ages.~The subject must move, one by one, a maximum number of cubes from one compartment of the box to another of equal size for 60 seconds. He starts with the healthy upper limb or, if not, with the dominant side. A 15 second trial period is allowed at the beginning of each side."
75898587|NCT05776368|Other|Motor training with a tool|"The patient will do around 30 minutes of motor training with a tool (pliers). They have to put most pieces as possible in the board with the pliers. Patients hold the pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder).~For E1 Arm1 and E1 Arm 4: the participant will do the motor training with a tool one time in this study.~For E3 Arm 1: the participant will do the motor training with a tool During 4 weeks (3 to 5 training sessions of 30 minutes)"
75898588|NCT05776368|Other|Motor training with a hand|The patient will do around 30 minutes of motor training with the hand. They have to put most pieces as possible in the board with the right hand (dominant hand) or with the left one if not possible (motor disorder).
75898589|NCT05776368|Other|on/off effect of tool motor training|"During 4 weeks, patients switch between tool training weeks (on) and control weeks (off) during which they don't practice motor training.~During on weeks they do 3 to 5 tool motor training sessions of 30 minutes. They use pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder) and have to put most pieces as possible in the board.~During off weeks they do 3 to 5 control sessions where they only do the two linguistic tasks separated between a 30-minutes break."
75452326|NCT01738308|Procedure|Healing Touch|"When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
75452327|NCT01738308|Procedure|Healing Touch Sham Treatment|"The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside"
75452328|NCT01738334|Behavioral|Active comparator (meditation) with healthy subjects|"The control group with healthy subjects that was participate in meditation (active control group)"
75452329|NCT01738334|Behavioral|Meditation|"In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1."
75898590|NCT05776368|Other|linguistic tasks|"The linguistic tasks consists in the presentation of correct sentences at the center of a computer screen. The sentence can be a coordinated one ( The policeman stopped the woman and asked the question ), or a subject relative (i.e.,  The policeman who stopped the woman asked the question ), or an object relative ( The policeman who the woman stopped asked the question ). After the sentence an affirmation test is proposed of the kind  the policeman stopped the woman , and the participant has to respond ads quick as possible whether it is true or false."
75452330|NCT01738347|Drug|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
75603494|NCT03906136|Biological|Secukinumab/Adalimumab-Biosimilar|Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab-Biosimilar, s.c.
75603495|NCT03906136|Other|Standard-of-care|Patients will receive treatment according to local practice standards by their treating physician following the current treatment recommendations.
75748066|NCT06055075|Drug|Daratumumab|Daratumumab will be administered via SC injection in combination with forimtamig.
75898591|NCT05769062|Procedure|Single digit pelvic exam|The exam takes approximately 5 minutes and uses a single digit to palpate the pelvic floor muscles, during which patients will rate pain on a scale of 0-10 at 5 paired locations.
75898592|NCT05762692|Device|High-flow nasal oxygenation device|The patients included will be oxygenated by HFNO device during the operation
75748067|NCT06053710|Device|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
75748068|NCT06053684|Device|Standard Non-Invasive Mechanical Servo Ventilation|The active comparator arm will utilize a standard non-invasive mode to provide ventilation support
75452331|NCT01738360|Drug|Arsenic trioxide|"The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~Pre-inclusion between D-35 and D-15~Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~A telephone contact between D32 and D34~A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180"
75748069|NCT06053684|Device|Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation|The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
75748070|NCT06041373|Device|Verily Watch Cardio|The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.
75748071|NCT06041373|Device|iRhythm Zio monitor|The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.
75748072|NCT06041373|Device|Schiller CARDIOVIT FT-1|The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.
75452332|NCT01738373|Drug|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
75452333|NCT01738399|Dietary Supplement|Coffee|
75748073|NCT06040502|Behavioral|The DICE Approach|Systematic guidance for care partners through assessment and management of the behavioral and psychological symptoms of dementia
75748074|NCT06037863|Other|Best Practice|Undergo bladder filling prior to CT
75452334|NCT01738399|Dietary Supplement|Placebo|
75748075|NCT06037863|Procedure|Computed Tomography|Undergo CT
75748076|NCT06037863|Other|Electronic Health Record Review|Ancillary studies
75898593|NCT05748873|Drug|SPVN06|AAV-RdCVF-RdCVFL
75452335|NCT01738412|Device|Neurokeeper stroke detector|Monitoring stroke patients
75452336|NCT01738425|Drug|GIC-1001; 125 mg oral tablets|"Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days"
75452337|NCT01738425|Drug|GIC-1001 matching placebo|"Single ascending doses (SAD) [equivalent to active arm, 125 mg to 1000 mg]~Multiple ascending doses, TID over 7 successive days [equivalent to the active arm, 125 mg to 500 mg]"
75748077|NCT06037863|Procedure|Imaging Technique|Undergo bladder emptying prior to CT
75748078|NCT06037863|Other|Questionnaire Administration|Ancillary studies
75898594|NCT05733208|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning will consist of four cycles of 5-minute inflation of an blood pressure cuff on the upper arm to 200 mmHg followed by 5-minute deflation. RIPC will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
75898595|NCT05733208|Procedure|Sham-remote ischemic preconditioning|The identical looking cuff will be placed around the upper arm but not actually inflated for 40 minutes. The control device's components and external appearance are identical to that of the RIPC. However, as compared to the RIPC, the blood pressure cuff's line of inflation is disconnected such that the cuff cannot be inflated. Control treatment will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
75898596|NCT05731843|Drug|Cohort 1 BEM + Ruzasvir|Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions
75898597|NCT05731843|Drug|Cohort 2 Ruzasvir + BEM|Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions
75452338|NCT01738451|Drug|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
75452339|NCT01738451|Drug|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
75603496|NCT03902600|Radiation|Moderately Hypofractionated RT|Patients will be treated with moderately hypofractionated radiation treatment
75603497|NCT03896529|Behavioral|Anticipatory psychological stress|Unpredictable delivery of low-level electrical stimulation to left ankle periodically throughout psychology tasks (virtual navigation). Established procedure for inducing anticipatory stress.
75452340|NCT01738490|Device|Bone anchored hearing implant|
75603498|NCT03876301|Drug|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
75748079|NCT06037863|Radiation|Radiation Therapy|Undergo radiation therapy
75748080|NCT06032338|Other|CRC screening invitation not including the screening test.|The invitation to CRC-PBOSP will only contain informations on how to get the screening test.
75748081|NCT06032338|Other|Mailing of FIT with invitation|The invitation to CRC-PBOSP will contain the CRC screening test.
75748082|NCT06032338|Other|Information letter before invitation|An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.
75748083|NCT06027229|Biological|NVX-CoV2372|Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5
75748084|NCT06026033|Drug|Desflurane induction|Following tracheal intubation, the fresh gas flow will be set to 1 liters/minute, desflurane vaporizer will be set to maximum.
75748085|NCT06023953|Device|Nerivio device|REN treatment with Nerivio device
75748086|NCT06020846|Other|Soleus Pushup Exercise|"Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time"
75748087|NCT06020846|Other|treadmill walk group 2|The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
75748088|NCT06019819|Other|strengthening exercise|Perform general physical training activities conducted in schools including upper limb forward elevation, lateral elevation, touching toes in standing and cervical range of motion, strengthening exercise will be performed for 3days a week for 4 weeks.
75748089|NCT06019819|Other|Postural correction exercises|Chin Tuck, Strengthening shoulder retractors, Stretching sternocleidomastoiD, Pectorals stretch For strengthening exercises 3 sets of 10 repetitions were performed with 6 seconds rest period between each set and a hold of 6 seconds. Stretching exercises will be performed in 3 sets of 10 repetitions ,30 seconds hold and 30 seconds rest period between each exercise. The exercises were performed 3days a week for 4 weeks.
75748090|NCT06017297|Drug|Durvalumab|Durvalumab 1500 mg via intravenous (IV) infusion every 3 weeks for up to 8 cycles
75748091|NCT06017297|Drug|Tremelimumab|A single dose of tremelimumab at 300mg IV is given on C1.
75748092|NCT06017297|Drug|Gemcitabine|Gemcitabine is dosed at 1000 mg/m2 IV on day (D)1 and D8 of each cycle.
75748093|NCT06017297|Drug|Cisplatin|Cisplatin is dosed at 25mg/m2 on D1 and D8 of each cycle.
75748094|NCT06017297|Procedure|Surgical Resection|If the tumor is evaluated to be resectable (as defined as successfully treated stage II (tumor shrink away from vessels), stage IIIA (tumor shrink away from visceral peritoneum), stage IIIB (N1 disease no longer pathologically enlarged) after C4 or C8, then the patient may proceed with surgical tumor resection.
75748095|NCT06016764|Device|Continuous Theta Burst in Transcranial Magnetic Stimulation|This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia and social-emotional impairment in autism
75748096|NCT06016582|Device|Use of virtual reality hypnosis headset during frozen embryo transfer|"The virtual reality hypnosis headset will be used before, during, and after the FET procedure:~The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.~The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).~The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.~Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary state anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study."
75748097|NCT06015672|Device|Transcranial Magnetic Stimulation (TMS)|Participants will experience three accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
75748098|NCT06015646|Behavioral|Personalized lifestyle coaching and educational handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study. Participants will also receive a 30-minute focused, personalized lifestyle coaching within a week of the initial overnight shift. The lifestyle coach will be in close contact during the night shifts.
75748099|NCT06015646|Behavioral|Handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
75898598|NCT05730387|Other|Observational only|This is a non-interventional study
75898599|NCT05720949|Drug|Genicular Nerve Block with bupivacaine and preservative free dexamethasone|"A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid"
75452341|NCT01738529|Device|CLE ileocolonoscopy|The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
75452342|NCT01738542|Drug|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
75452343|NCT01738542|Drug|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
75452344|NCT01738542|Drug|Statins|
75452345|NCT01738542|Drug|Antihypertensive therapy|
75452346|NCT01738555|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
75452347|NCT01738555|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
75452348|NCT01738568|Behavioral|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at ~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
75452349|NCT01738568|Behavioral|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
75452350|NCT01738620|Behavioral|psychological counseling|
75452351|NCT01738620|Behavioral|prevention of sleep disorders in ICU|
75452352|NCT01738633|Behavioral|nutritional counseling|
75452353|NCT01738633|Behavioral|respirology counseling|
75452354|NCT01738659|Dietary Supplement|normal sodium diet|normal sodium diet (120 mmol/daily) for 1 year
75452355|NCT01738685|Behavioral|Behavioral Intervention.|
75452356|NCT01738685|Other|Nutritional Education.|
75452357|NCT01738711|Behavioral|Cognitive behavioural therapy|Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
75452358|NCT01738724|Drug|Dienogest|Dienogest 2mg pills daily during 6 months
75748100|NCT06009081|Behavioral|postural exercise|The exercises consisted of 4-way neck isometric exercises and stretching exercises for the activation of deep cervical flexors (chin tuck exercise) and combined with this exercise. This protocol consisted of protocols studied in similar studies.
75748101|NCT06009081|Behavioral|aerobic exercise|The walking program was carried out daily on a flat surface with a target of 7000 steps. This goal is based on the American College of Sports Medicine reports on the minimum recommended levels of physical activity required to achieve health benefits, which includes several design elements.
75748102|NCT06009068|Other|Surgimap soft ware|20 healthy subjects will be recruited in the study, the q angle will be measured using goniometer and surgimap soft ware, 3 examiners will measure the q angles for the same individuals to check the inter rater reliability, and the test will be repeated after 2 days by the same examiners to check the intra rater reliability
75898600|NCT05699915|Procedure|Cardiology consultation|"Electrocardiogram (ECG).~Echocardiogram: A comprehensive evaluation of systolic and diastolic function, ventricular and atrial geometry will be performed. Special attention will be given to acquire a 3D measurement of left ventricular ejection fraction (LVEF) and to perform deformation imaging of left ventricle (global longitudinal strain (GLS)). The right ventricular function will be evaluated by tricuspid annular plane systolic excursion (TAPSE) and peak systolic velocity S' derived from color coded tissue Doppler imaging (TDI). Diastolic dysfunction will be based on average E/e' ratio > 15 and left atrial (LA) area > 30 cm2."
75898601|NCT05699915|Diagnostic Test|Chest Computed Tomography (CT) without contrast|Calcium score. This will be performed at baseline, 12 and 24 months. The scans at 12 and 24 months will be combined, if possible, with standard of care scans for cancer treatment.
76065435|NCT04884607|Other|subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes|"Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart."
76065436|NCT04876651|Other|177Lu-DOTA-rosopatamb|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC
76065437|NCT04869683|Other|description of MDS pzatient cohort|description of MDS patient cohort
75748103|NCT06006507|Other|control|no exercise will be given
75748104|NCT06006507|Other|exercise|In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
75748105|NCT06006494|Other|aerobic|"We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week."
75452359|NCT01738724|Drug|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
75748106|NCT06006494|Other|resistant|Resistance exercises are the whole of the exercises in which effort is made against the weight and the weight is lifted. Exercises with therabands, dumbbells or body weight will be given. The exercises will be done 2 days a week for an average of 30-40 minutes.
75452360|NCT01738724|Drug|Desogestrel|Desogestrel 75mcg pills daily during six months
75452361|NCT01738763|Dietary Supplement|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
75898602|NCT05699915|Procedure|Non-invasive endothelial function tests|"FMD~PAT~This aspect of the study will only be performed in the patients included by the Antwerp University Hospital due to organizational/practical issues."
75898603|NCT05699915|Procedure|Electrocardiogram|An ECG will be taken prior to each ICI cycle during the first three months of treatment.
75898604|NCT05699915|Diagnostic Test|Extra serum sample (7.5 mL)|An extra serum sample will be taken at baseline, 3, 6, 12, 24 months and in case of sudden cardiac problems. This will subsequently be analysed to determine high-sensitivity troponin I, high-sensitivity troponin T and NT-proBNP.
75452362|NCT01738802|Dietary Supplement|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
76065438|NCT04869514|Procedure|spinal manipulation|intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
76065439|NCT04863599|Other|Questionnaire|Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
75452363|NCT01738802|Drug|Placebo|This group will take a placebo.
75452364|NCT01738815|Drug|Valproic Acid|500 mg orally, once daily for up to 30 days
75898605|NCT05683405|Procedure|Non-surgical treatment of peri-implantitis with mechanical debridement|Non-surgical treatment of peri-implantitis with mechanical debridement .
75898606|NCT05683405|Procedure|Non-surgical treatment of peri-implantitis with air polishing|Non-surgical treatment of peri-implantitis with air polishing
76065440|NCT04861766|Device|STYLAGE® L|Injection in both NLFs
75452365|NCT01738841|Biological|Priorix-Tetra™|Single dose, subcutaneous injection
75452366|NCT01738841|Other|Safety data collection|Recording of adverse events, using diary cards
76065441|NCT04861766|Device|Active Comparator|Injection in both NLFs
76065442|NCT04857996|Drug|UBX1325|Patients will be administered a single 50 μL UBX1325 IVT injection
76065443|NCT04857996|Other|Sham|Sham procedure
75452367|NCT01738854|Procedure|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
75603499|NCT03875820|Drug|VS-6766|"VS-6766 will be supplied as 0.8mg hypromellose (HPMC) capsules for oral administration. The capsule fill consists of VS-6766 and the inactive ingredients mannitol and magnesium stearate.~VS-6766 will be administered on a twice weekly (Monday and Thursday or Tuesday and Friday) schedule for 3 weeks followed by 1 week off in every 4 week cycle, under fasting conditions (approximately 1 hour prior or 2 hours after a meal). The starting dose, based on the previous Phase I trial will be 3.2 mg given orally as a single daily dose. This can be escalated to a maximum of 4mg (as per dose escalation rules in the protocol)."
76065444|NCT04857814|Device|ADAMM- RSM Device|All participants will wear the ADAMM- RSM device for a 6 month period
76065445|NCT04848961|Behavioral|LungTalk|MSK developed LungTalk, a novel computer-tailored health communication and decision support tool to (1) increase awareness and knowledge about lung screening; (2) decrease perceived barriers to screening based upon misinformation; and (3) increase screening rates.
75603500|NCT03875820|Drug|Defactinib|"Defactinib is formulated as a white to off-white oval tablet for oral administration and supplied in single unit dose strength of 200 mg in 120 cc (HDPE) bottles. In addition to Defactinib, formulation components include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate.~Patients will receive Defactinib orally immediately after a meal twice daily (approximately every 12 hours) for 3 weeks followed by 1 week off in every 4 week cycle. The starting dose will be 200mg. This can be escalated to a maximum of 400mg (as per dose escalation rules in the protocol)."
75603501|NCT03860935|Drug|acoramidis|TTR stabilizer administered orally twice daily (BID)
75603502|NCT03860935|Drug|Placebo Oral Tablet|Non-active control administered orally twice daily (BID)
75603503|NCT03818243|Behavioral|Diary (for reporting all impulse control disorders especially compulsive eating disorders)|During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.
75748107|NCT06006494|Other|yoga|Yoga is basically breathing exercises, warm-up exercises, relaxation, It is a session consisting of movements and relaxation exercises.movements are performed by standing in a fixed posture for 15 seconds to 2 minutes in a certain posture, they are postures for both strengthening, stretching and balance. Yoga practice will be done 2 days a week for an average of 40 minutes.
75748108|NCT06006351|Other|Physiotherapy|manual therapy stretching exercises strengthening exercises electrotherapy applications
75748109|NCT06006351|Other|Hypervolt Device|The painful area will be applied with a massage tool, and the frequency and mode of the tool will be adjusted in a way that does not disturb the patient.
75898607|NCT05676411|Drug|Benzoyl Peroxide Topical|Topical benzoyl peroxide cream will be applied to the shoulder skin twice a day for 2 days leading up to and in the morning of surgery.
75898608|NCT05676411|Procedure|Electrocautery surgical skin incision|The skin incision will be made entirely using electrocautery at the beginning of shoulder replacement.
75898609|NCT05647369|Dietary Supplement|Mastic mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
76065446|NCT04842747|Drug|VERU-111|Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
76065447|NCT04839458|Device|Dental Prescale II|"The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end."
76065448|NCT04810481|Device|BIS Complete Monitoring System|The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
75452368|NCT01738867|Drug|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
75452369|NCT01738867|Drug|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
75452370|NCT01738867|Drug|Placebo|Matching placebo capsules to GSK1521498 or NTX
75452371|NCT01738880|Drug|SVV|During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
75748110|NCT06004427|Other|Diet program|A diet program will be prepared with the help of a dietitian at the beginning of 12 weeks for all participants who agree to participate in the study, and this program will be controlled by a dietitian once a month and completed at the end of 12 weeks.
75748111|NCT06004427|Other|Exercise training protocols|calisthenic exercises exercises with lower and upper extremity theraband exercises with light dumbbells
75748112|NCT06003894|Other|kegel exercises|Kegel exercises; It is done by squeezing your pelvic floor muscles for 3 to 5 seconds and relaxing them. Participants are expected to do this exercise in the form of hold-relax 10-15 times each set. Participants are expected to practice Kegel exercises, 2 sets a day, 3 days a week for 8 weeks.
75748113|NCT06003894|Other|360 degree expanded diaphragmatic breathing training|360-degree expanded diaphragm breathing is the delivery of air taken during inspiration to the postero-lateral wall of the abdomen. Breathing in this way ensures that the pressure in the abdomen is distributed equally in all directions. Practices for using this breathing pattern will be done 2 sets per day, each set for 10 minutes.
75748114|NCT06003868|Other|traditional physiotherapy|Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises
75748115|NCT06003868|Other|hippotherapy-assisted physiotherapy|"The patients will be placed on the simulator and the starting position will be taught. your simulator before the application and in order to maintain the starting position throughout their movements.~they will be warned during the applications.. Hippotherapy simulator is almost like walking.~pattern and will be run in the 1st stage of the 3-stage speed level."
75748116|NCT06002633|Other|Alcohol|Participants will consume beverages containing alcohol.
75748117|NCT06002633|Other|Placebo|Participants will consume beverages containing a very low dose of alcohol (placebo condition).
75748118|NCT05998057|Other|exercise|"Exercises:~Lunge to Hamstrings Stretch 3 sets of 30 seconds~Standing Hip Out 3 sets of 30sec~90-90 Hip Stretch 3 sets of 30 seconds~World's Greatest Stretch 3 sets of 30 seconds~Star Excursion 3 sets of 5 reps~Side Jumps+ Balance 3 sets of 10 reps~Forward Hops + Balance 3 sets of 10 reps~Squat 3 sets of 10 reps~Squat Jump 3 sets of 10 reps~Jumping Spider Push-up 3 sets of 10 reps~Double Leg Vertical Jump 3 sets of 10 reps~Broad Jumps 3 sets of 10 reps~Lateral Box Shuffles 3 sets of 10 reps~Plank 3 sets of 30 seconds~Side Plank 3 sets of 30 seconds~Bird Dog 3 sets of 10 reps~Glute Bridge 3 sets of 10 reps~Single Leg Glute Bridge 3 sets of 10 reps~Single Toe Raises 3 sets of 30sec~Nordic Hamstrings 3 sets of 10 reps~Monster Walk 3 sets of 10 reps"
76065449|NCT04806724|Behavioral|Opening the Conversation|The intervention includes 5 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on reproductive and sexual health distress.
75452372|NCT01738880|Drug|CVP|Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
75452373|NCT01738893|Drug|Gabapentin 300 mg|Test product
75603504|NCT03800524|Drug|Tauroursodeoxycholic Acid|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
75603505|NCT03800524|Drug|Placebo|"Placebo 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
75452374|NCT01738893|Drug|Gabapentin 300 mg|Reference product
75452375|NCT01738906|Other|Orange juice|
75452376|NCT01738906|Other|maltodextrin|
75452377|NCT01738906|Other|Vodka|
75452378|NCT01738906|Other|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
75452379|NCT01738906|Other|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
75452380|NCT01738945|Drug|Amlodipine|10 mg/day for 12 weeks
75452381|NCT01738958|Biological|L. retueri|two tablets a day for 6 weeks
75452382|NCT01738958|Biological|Placebo|
75452383|NCT01738997|Device|Dilation 10 sec|
75452384|NCT01738997|Device|Dilation 2 min|
75603506|NCT03742076|Dietary Supplement|High-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
75452385|NCT01739023|Biological|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
75603507|NCT03742076|Dietary Supplement|Low-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
75603508|NCT03742076|Dietary Supplement|Placebo|Powder fiber supplement, yellowish-white in color, that is dissolvable.
75748119|NCT05998057|Other|control|The control group was asked to continue the standard (routine) classical training training (5 days/12 weeks).
75748120|NCT05996731|Procedure|Skin biopsy|A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
75748121|NCT05985122|Diagnostic Test|C3NEF assay|This assay will consist of a dual test, detecting C3 convertase binding C3NEF autoantibodies and measuring the functional consequence by complement alternative pathway (AP) activity using two distinct ELISA designs: C3NEF detection assay and AP activity assay.
75748122|NCT05980507|Drug|ICI201|ICI201 CAR-T cell injection
75748123|NCT05977842|Device|CTO PCI using DCB-only strategy|Successful CTO recanalization treated with DCB at the occlusion site
75748124|NCT05976230|Drug|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
75748125|NCT05974722|Device|OviTex Mesh|Patient will receive Ovitex Mesh (TELA Bio)
75748126|NCT05974722|Other|Pledgeted sutures|Patient will receive pledgeted sutures
75748127|NCT05969223|Drug|Risankizumab|Subcutaneous injection
75748128|NCT05969223|Drug|Placebo for Risankizumab|Subcutaneous injection
75452386|NCT01739036|Biological|ChAd63 CS/ME-TRAP|Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
75603509|NCT03733028|Behavioral|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
75748129|NCT05968326|Drug|Autogene cevumeran|Autogene cevumeran will be administered intravenously (IV) at a recommended dose at specified timepoints.
75748130|NCT05968326|Drug|Atezolizumab|Atezolizumab will be administered IV at a dose of 1680 milligrams (mg) at specified timepoints.
75898610|NCT05647369|Dietary Supplement|Placebo mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
75898611|NCT05633563|Drug|Trimetazidine|Oral intake of capsules
75452387|NCT01739036|Biological|MVA CS/ME-TRAP|Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
75452388|NCT01739036|Biological|ChAd63 CS/ME-TRAP/AMA1|Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
75452389|NCT01739036|Biological|MVA CS/ME-TRAP/AMA1|Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
75603510|NCT03733028|Behavioral|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
75898612|NCT05633563|Drug|Placebo|Oral intake of capsules
75898613|NCT05627271|Other|ocrelizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
75898614|NCT05627271|Other|natalizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
76065450|NCT04806724|Behavioral|Side by Side|The intervention includes 4 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on general cancer-related distress.
76065451|NCT04800913|Diagnostic Test|Multimodal imaging|Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
76065452|NCT04800913|Diagnostic Test|Standard imaging|Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
75452390|NCT01739036|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately three weeks post MVA dosing.
75452391|NCT01739049|Drug|Liraglutide|liraglutide
75452392|NCT01739049|Behavioral|Diet and Exercise|diet and exercise
75603511|NCT03695744|Drug|Daratumumab|Daratumumab
75603512|NCT03695744|Drug|Bortezomib|Bortezomib
75603513|NCT03695744|Drug|Dexamethasone|Dexamethasone
75603514|NCT03690869|Drug|cemiplimab (monotherapy)|To be administered intravenously as monotherapy in Phase 1
75748131|NCT05968326|Drug|mFOLFIRINOX|mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.
75748132|NCT05966584|Drug|Benralizumab|Benralizumab 30mg subcutaneously on day -1.
75748133|NCT05966584|Drug|fulvestrant or AIs) and PI3K inhibition (alpelisib)|SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)
75748134|NCT05966272|Drug|HRS9531 injection|single dose
75748135|NCT05966272|Drug|HRS9531 injection Placebo|single dose
76065453|NCT04785651|Drug|Tibial osteotomy with Tranexamic acid|"Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure."
75603515|NCT03690869|Drug|cemiplimab (maintenance)|To be administered intravenously in combination with radiation and then used as maintenance therapy
75603516|NCT03690869|Radiation|Conventional or hypofractionated|Combined with cemiplimab IV administration
75603517|NCT03690869|Radiation|Re-irradiation|Combined with cemiplimab IV administration
75603518|NCT03670628|Device|Shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
76065454|NCT04785651|Procedure|Tibial osteotomy without Tranexamic acid|Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
76065455|NCT04781114|Drug|JS002|JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
76065456|NCT04781114|Drug|Placebo|JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
75452393|NCT01739088|Other|Remote ischemic pre-conditioning stimulus.|Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.
75452394|NCT01739088|Other|Sham Ischemic Pre-conditioning|In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
75603519|NCT03670628|Other|Sham shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver sham shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
75603520|NCT03637764|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75603521|NCT03637764|Drug|Atezolizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75603522|NCT03636022|Other|VR System|Use of virtual reality to deliver exposure therapy
75603523|NCT03636022|Other|Control|Use of conventional delivery of exposure therapy
75748136|NCT05964868|Drug|Liposomal Bupivacaine|Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.
75748137|NCT05964868|Drug|0.25% bupivacaine with 1:200,000 epinephrine|Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.
75898615|NCT05627271|Other|ofatumumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
75898616|NCT05614960|Other|Dried purple laver (Nori)|Dried purple laver (Nori) that has been test to have bioactivity vitamin B12 will be given for intervention groups.
75898617|NCT05611866|Procedure|Fecal Microbiota Transplantation|FMT at Week 0
75452395|NCT01739101|Behavioral|Reproductive Life Plan|A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
75603524|NCT03594266|Device|Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy A stimulation patterns
75603525|NCT03594266|Device|Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy B stimulation patterns
75603526|NCT03591965|Drug|ATG-008|Approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg/QD and another 20 subjects will receive oral ATG-008 at an initial dose of 20mg/BID for 28 days each cycle.
75603527|NCT03589794|Other|AP10-602|Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
75748138|NCT05964868|Other|Placebo - Saline solution|This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
75748139|NCT05964504|Procedure|Blood Specimen|Blood will be drawn via venipuncture
75748140|NCT05962164|Behavioral|Passive Heat Therapy|The intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
75748141|NCT05962164|Behavioral|Sham Immersion|The sham intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
76065457|NCT04780204|Drug|Treatment|Tenofovir Alafenamide 25 mg oral once daily
76065458|NCT04770480|Behavioral|Standard Care (SC)|No attempt will be made to change usual care practice after surgery
76065459|NCT04770480|Behavioral|Enriched Pain Management Pathway (EPM)|Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
75748142|NCT05960604|Diagnostic Test|Passive leg raising|"All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes."
75603528|NCT03589794|Other|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
75603529|NCT03589794|Biological|rCSP|The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
75603530|NCT03498495|Behavioral|Self-Monitoring Activity-restriction and Relaxation Training (SMART)|SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
75603531|NCT03483116|Biological|RV3-BB|Oral administration
75603532|NCT03483116|Biological|Placebo|Oral administration
75603533|NCT03481569|Other|Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use|Blood and cerebrospinal fluid pharmacocinetic samples at different time point
75452396|NCT01739114|Procedure|"IPPV group"|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
75452397|NCT01739114|Procedure|SI group|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided"
75603534|NCT03443791|Diagnostic Test|Women Enrolled|Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.
75603535|NCT03443791|Diagnostic Test|Newborns of Female Study Participants|Newborns will be tested after birth as soon as possible for CMV positivity.
75603536|NCT03401853|Other|Laboratory Biomarker Analysis|Correlative studies
75898618|NCT05595681|Drug|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The investigational product is a C2C_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).~C2C_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The exipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
75603537|NCT03401853|Biological|Pembrolizumab|Given IV
75603538|NCT03401853|Biological|Rituximab|Given IV
75603539|NCT03401853|Biological|Obinutuzumab|Given IV
75603540|NCT03393546|Behavioral|Auricular Point Acupressure|It includes 4 weekly auricular point acupressure treatments.
75603541|NCT03320577|Behavioral|Class instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
75603542|NCT03320577|Behavioral|DVD instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
75603543|NCT03320577|Behavioral|Control|Log dinner times
75898619|NCT05584176|Device|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
75898620|NCT05584176|Device|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
75603544|NCT03286387|Other|Functional brain imaging without any contrast agent|"During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
75603545|NCT03222076|Biological|Ipilimumab|Given IV
75898621|NCT05576337|Other|16 weeks of strength training protocol|16 weeks of strength training protocol
75603546|NCT03222076|Biological|Nivolumab|Given IV
75603547|NCT02970747|Drug|Carfilzomib|In accordance with SmPC.
75603548|NCT02936843|Drug|Salsalate|1 gram, 3 times daily by mouth (total of 3 grams daily)
75603549|NCT02936843|Drug|PLACEBO|Placebo for Salsalate; 2 Tabets, 3 times daily by mouth (total of 3 grams daily)
76065460|NCT04762719|Drug|PET/CT Scan with 11C-ER176|Subjects will have a low-dose, non-gated, non-contrast-enhanced, free-breathing CT from the orbits to upper thigh for attenuation correction (CTAC) and anatomic co-localization. Immediately following the start of the PET scan, 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi) of 11C-ER 176 will be administered intravenously followed by a saline flush. A whole-body PET scan from the orbits to upper thigh will then be acquired.
75603550|NCT02828202|Other|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
75748143|NCT05954143|Drug|BDC-1001|BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.
75748144|NCT05954143|Drug|Pertuzumab|Pertuzumab is a monoclonal antibody that targets HER2 and prevents dimerization of HER2 with other members of the HER family (HER1, HER3, and HER4), thereby blocking ligand-activated downstream signaling.
75748145|NCT05952167|Other|Intensive cervical traction protocol|2x/day over 5 weekdays without public holidays
75748146|NCT05952167|Other|Intensive cervical traction protocol - placebo|2x/day over 5 weekdays without public holidays
75748147|NCT05950256|Device|N95 mask and surgical mask|Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
75748148|NCT05947084|Other|Infant Formula|Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period
75898622|NCT05571514|Dietary Supplement|Mother-of-pearl|"The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone.~The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation."
75452398|NCT01739127|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
75452399|NCT01739127|Drug|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
75452400|NCT01739140|Behavioral|Yoga|
75452401|NCT01739153|Other|Dietary intervention: CHEESE (High cheese intake)|
75452402|NCT01739153|Other|Dietary intervention: MEAT (High Meat intake)|
75452403|NCT01739153|Other|Dietary intervention: CARB (High Carbohydrate intake)|
75452404|NCT01739166|Other|Practice-tailored intervention to increase rates of targeted services|"Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.~During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed."
75452405|NCT01739179|Procedure|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
75452406|NCT01739179|Procedure|VP Shunt Surgery for open insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted openly
75452407|NCT01739192|Drug|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
75603551|NCT02828202|Other|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
75748149|NCT05946213|Radiation|External Beam Radiation Therapy|Undergo EBRT
75748150|NCT05946213|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75769329|NCT03904186|Behavioral|Time-Matched Control (TM)|Participants will receive a standard smoking cessation treatment, based on the clinical practice guidelines from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence. Treatment will be delivered in nine, 60-minute sessions over a ten-week period. The treatment is based on a treatment protocol developed and used previously by Dr. Zvolensky. Because clinical guidelines recommend that all smokers attempting to quit smoking receive pharmacotherapy, participants will also receive the transdermal nicotine patch for 8 weeks.
75603552|NCT02828202|Other|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
75603553|NCT02816879|Procedure|Cytology Specimen Collection Procedure|Undergo anal cytology collection
75603554|NCT02816879|Other|Laboratory Biomarker Analysis|Correlative studies
75748151|NCT05945615|Drug|Oxymetazoline 0.1% (Pf) Oph Soln Ud|"Oxymetazoline was initially developed in 1961. It is a direct sympathomimetic, binding directly to alpha-1 and alpha-2 receptors. Currently, it is used as a nasal decongestant, in the treatment of epistaxis, and as a topical treatment for rosacea. Previously, an ophthalmic formulation was used to treat eye redness and irritation as it is FDA approved for the treatment of acquired blepharoptosis. However, this product line was discontinued when in July of 2020, oxymetazoline received Food and Drug Administration approval for treatment of cosmetic blepharoptosis.~In the treatment of blepharoptosis, oxymetazoline acts on the superior tarsal muscle, Müller's muscle, to elevate the eyelid. The superior tarsal muscle is a sympathetically innervated muscle that is partially responsible for elevating the eyelid. Previous cosmetic studies have shown oxymetazoline can serve as an adjunct to botulinum toxin in patients with acquired blepharoptosis."
75748152|NCT05945615|Other|Preservative free lubricating drops|Over the counter ophthalmic lubricating drop.
75748153|NCT05940974|Other|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the surgery and after the surgery (on 4 dates over a 1-year period); the DASH and ASES questionnaires to measure their functional outcomes before the surgery and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the surgery and after the surgery (on 4 dates over a 1-year period).
75748154|NCT05933824|Drug|LP-98 injection|Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
75748155|NCT05926960|Drug|encorafenib|encorafenib
75603555|NCT02811861|Drug|Lenvatinib|
75748156|NCT05926960|Drug|binimetinib|binimetinib
76065461|NCT04762719|Diagnostic Test|Core biopsy of gastric muscle|The echoendoscope (Aloka Arietta 850; Olympus, Center Valley, PA) will be advanced into the gastric lumen and a site targeted for EUS-guided core biopsies based on findings of the PET scan. Fine needle biopsy of the gastric wall will be performed.
76065462|NCT04755231|Device|AcrySof IQ PanOptix Presbyopia Correcting IOL|UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
75603556|NCT02811861|Drug|Everolimus|
75603557|NCT02811861|Drug|Pembrolizumab|
75603558|NCT02811861|Drug|Sunitinib|
75603559|NCT02700451|Drug|Ketorolac|"Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed."
75603560|NCT02700451|Drug|Acetaminophen|Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
75603561|NCT02700451|Drug|Placebo|Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
75603562|NCT02697344|Drug|Dexamethasone|Given PO
75603563|NCT02697344|Other|Laboratory Biomarker Analysis|Correlative studies
75603564|NCT02697344|Drug|Lenalidomide|Given PO
75603565|NCT02697344|Other|Pharmacological Study|Correlative studies
75603566|NCT02697344|Drug|R-(-)-Gossypol Acetic Acid|Given PO
75603567|NCT02696343|Device|NTrainer|pulsed orocutaneous stimulation paired with tube feedings
75603568|NCT02696343|Device|SHAM blind pacifier|regular green Soothie pacifier paired with tube feedings
75603569|NCT02667418|Drug|Fidaxomicin|200 mg PO twice daily for 10 days
75603570|NCT02667418|Drug|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
75603571|NCT02667418|Drug|Vancomycin|125 mg PO for times daily for 10 days
75748157|NCT05926960|Drug|pembrolizumab|pembrolizumab
75748158|NCT05926960|Drug|ipilimumab|ipilimumab
75748159|NCT05926960|Drug|nivolumab|nivolumab
75748160|NCT05921981|Behavioral|Multisensorial Stimulation|Multisensory stimulation in newborns involves the deliberate and simultaneous activation of multiple sensory modalities to provide sensory experiences that promote development and enhance learning. Newborns are naturally inclined to explore and make sense of their environment through their senses, including touch, sight, sound, taste, and smell.
75748161|NCT05921981|Behavioral|White Noise|White Noise
75769330|NCT01255072|Procedure|Transcranial Magnetic Stimulation|20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
75452408|NCT01739205|Behavioral|CALM-D Intervention|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
75603572|NCT02623426|Drug|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
75603573|NCT02623426|Drug|Intravitreal Methotrexate 400 µg|Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
75603574|NCT02623426|Drug|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
76065463|NCT04755231|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
75898623|NCT05571514|Dietary Supplement|Calcium Carbonate|Calcium carbonate is a source of calcium.
75898624|NCT05559372|Dietary Supplement|Acute energy drink or placebo consumption|Participants consumed either 16 oz of Nutrabolt C4 Energy Carbonated, Monster Energy Original, or Placebo in randomized order in three separate visits separated by 7±3 days.
75898625|NCT05556720|Biological|Pfizer Bivalent COVID-19 Vaccine|One or Two doses three months apart, per manufacturer's recommendations.
75603575|NCT02580058|Biological|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
75452409|NCT01739218|Drug|Carboplatin|Carboplatin will be administered at a dose calculated according to the Calvert formula ([participant's glomerular filtration rate + 25] multiplied by the target area under the concentration-time curve [AUC] of 5 milligrams per milliliter per minute [mg/mL/min]), as intravenous [IV] infusion over 30-60 minutes [min] every 3 weeks).
75603576|NCT02580058|Drug|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
75898626|NCT05556720|Biological|Moderna Bivalent mRNA vaccine|One or Two doses three months apart, per manufacturer's recommendations.
75898627|NCT05555485|Device|transcutaneous Auricular neurostimulation - Active|Active auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved
75603577|NCT02539394|Drug|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
75603578|NCT02539394|Other|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
75603579|NCT02530437|Drug|Carboplatin|Given IV
75603580|NCT02530437|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
75603581|NCT02530437|Other|Laboratory Biomarker Analysis|Correlative studies
75603582|NCT02530437|Drug|Paclitaxel|Given IV
75898628|NCT05555485|Device|transcutaneous auricular neurostimulation - Sham|Sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX) but will not deliver prolonged stimulation.
75898629|NCT05552378|Device|Multi-Gyn FloraFem|Vaginal gel packed in 5 single use plastic tubes.
75898630|NCT05509309|Behavioral|APERS-based model|APERS-assessments followed by in-service training, APERS-feedback and on-site coaching to improve primary school classroom quality for students with ASD/SCC
75898631|NCT05498389|Drug|EMB-01|EMB-01 is a bispecific antibody against epidermal growth factor receptor (EGFR) and the receptor tyrosine kinase Met (cMET).
75898632|NCT05498389|Drug|Osimertinib|Osimertinib is an approved, third-generation EGFR tyrosine kinase inhibitor
75898633|NCT05467085|Device|BX Pulsar 1002|Imaging-Guided Low Intensity Focused Ultrasound Pulsation (LIFU) device
76065464|NCT04753853|Procedure|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
75898634|NCT05462782|Device|Transcranial Magnetic Stimulation (TMS) Cone Coil|The cone coil Cool-DB80 (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). TMS interventions will involve the following parameters: 1. Hippocampal directed stimulation at ISI 0ms, 2. Hippocampal directed stimulation at ISI 200ms, 3. Motor cortex stimulation at ISI 0ms, and 4. Motor cortex stimulation at ISI 200ms.
75452410|NCT01739218|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 milligrams per meter-squared [mg/m^2] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
75452411|NCT01739218|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram [mg/kg] as IV infusion over 30-90 min every 3 weeks.
75748162|NCT05921253|Device|PARASYM neuromodulation device|Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
75748163|NCT05921253|Device|PARASYM neuromodulation device|"Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study."
75748164|NCT05908786|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
75748165|NCT05908786|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.
75748166|NCT05908786|Drug|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.
75898635|NCT05462782|Device|Transcranial Magnetic Stimulation (TMS) Sham Coil|The sham coil Cool B65 A/P (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). The different TMS interventions will be involve the following parameters: 1. Sham stimulation at ISI 0ms, and 2. Sham stimulation at ISI 200ms.
76065465|NCT04748588|Drug|Anti-SARS-CoV-2 mAb|"Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used."
76065466|NCT04735510|Drug|cyclosporine ophthalmic emulsion 0.05%|All subjects will receive restasis
76065467|NCT04734015|Behavioral|Together Overcoming Diabetes (TOD)|Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
76065468|NCT04696523|Drug|Xenon|Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care
75452412|NCT01739244|Drug|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
76065469|NCT04696523|Drug|air/oxygen|Control group will be treated with air/oxygen
75603583|NCT02530437|Drug|Taladegib|Given PO
76065470|NCT04664400|Behavioral|Symbolic conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) through symbolic conditioning (no actual heat stimuli, only pictures of thermometers)
75603584|NCT02412670|Drug|Methotrexate|Given IV
75898636|NCT05459363|Other|I-THINC|Improved Training Happens with Integrated Neuromuscular and Cognitive Challenge (I-THINC) is an injury prevention program. It will be used to integrate cognitive tasks with traditional sports injury prevention approaches that focus on balance, agility, and neuromuscular control.
75898637|NCT05458531|Other|Questionnaire|A single questionnaire
75898638|NCT05458531|Other|Semi-structured interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
75898639|NCT05438771|Combination Product|Ankaferd Blood Stopper|mouth wash
75898640|NCT05438771|Other|Bicarbonate|mouth wash
75898641|NCT05437458|Other|Delirium (exposure)|No interventions.
76065471|NCT04664400|Behavioral|Conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from experience (with actual heat stimuli).
76065472|NCT04664400|Behavioral|Instructions|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from verbal instructions.
75452413|NCT01739244|Drug|Placebo|Ocular topical administration of placebo for 14 consecutive days
75452414|NCT01739257|Behavioral|Medical Lecture|
75452415|NCT01739257|Behavioral|Dramatic Reading|
75452416|NCT01739270|Procedure|supraclavicular brachial plexus block|
75452417|NCT01739283|Other|GIP|
75452418|NCT01739283|Other|GLP-1|
75603585|NCT02412670|Drug|Vinblastine|Given IV
75603586|NCT02412670|Drug|Doxorubicin|Given IV
75603587|NCT02412670|Drug|Cisplatin|Given IV
75452419|NCT01739283|Other|Saline|
75452420|NCT01739296|Other|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
75452421|NCT01739296|Other|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
75603588|NCT02412670|Drug|Gemcitabine|Given IV
75603589|NCT02412670|Drug|Carboplatin|Given IV
75603590|NCT02412670|Drug|Pegfilgrastim|Administered subcutaneously
75603591|NCT02412670|Procedure|Nephroureterectomy|Undergo nephroureterectomy and lymph node dissection
75603592|NCT02405208|Device|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
75603593|NCT02206360|Procedure|Endoscopic Ultrasound|
75603594|NCT02206360|Procedure|Magnetic Resonance Imaging (MRI)|
75748167|NCT05908786|Drug|Tobemstomig|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
75748168|NCT05904886|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
75452422|NCT01739322|Biological|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
75452423|NCT01739374|Other|reduced mesh implants|mesh for pelvic floor reinforcement
75898642|NCT05434871|Other|Yoga training|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
76065473|NCT04664400|Behavioral|Counterfactual|Thermal stimuli will be either the better outcome or the worse outcome out of two possible outcomes.
76065474|NCT04657770|Device|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned remote-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system. During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
76065475|NCT04655222|Drug|Interferon Beta Therapy|Administered as specified in the treatment arm.
75452424|NCT01739387|Device|Flutiform® pMDI and Breath Actuated Inhaler (BAI)|Both devices contain placebo
76065476|NCT04653194|Drug|Biktarvy|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
76065477|NCT04653194|Drug|Symtuza|Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg
76065478|NCT04652440|Drug|PD-1 monoclonal antibody|The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and 21(±7) days, 42(+7) and 63(+7) after ablation.
76065479|NCT04652440|Procedure|Radiofequencey or microwave ablation|The enrolled patients received primary radiofrequency or microwave ablation on the day after the first dose of PD-1 antibody treatment.
76065480|NCT04650867|Device|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
76065481|NCT04643951|Behavioral|Interview|Interview study using Grounded theory, to investigate dental professionals' and students' perception of child patient's experience and need for treatment regarding procedural and postoperative pain.
75452425|NCT01739413|Procedure|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
75748169|NCT05904886|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
76065482|NCT04614389|Other|Contrast-enhanced ultrasound|Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio
76065483|NCT04614389|Other|Shear Wave Elastography|Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.
76065484|NCT04614389|Device|Sequoia System|UltraSound System Cleared by FDA 510 (k) K180067
76065485|NCT04612725|Biological|Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
76065486|NCT04612725|Biological|Placebo and Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
76065487|NCT04612192|Device|Active luminette|receive an active blue-enriched light-glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period
76065488|NCT04612192|Device|Placebo luminette|receive a dim red-light placebo light (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group
75748170|NCT05904886|Drug|Tiragolumab|Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
75452426|NCT01739426|Device|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
75452427|NCT01739439|Drug|gemcitabine hydrochloride|Given IV
75452428|NCT01739439|Radiation|hyperfractionated radiation therapy|Undergo hyperfractionated IMRT
75748171|NCT05904886|Other|Placebo|Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
75769331|NCT01255072|Procedure|Repetitive Transcranial Magnetic Stimulation|20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
75769332|NCT03904342|Behavioral|Sophie CBT System|The Sophie CBT system is a tablet-based system that delivers self-paced cognitive behavioral therapy educational curriculum in the format of 6 discrete modules.
75769333|NCT03904342|Behavioral|iHope CBT|Licensed therapists will use the iHope HIPAA-compliant telemedicine platform to deliver cognitive behavioral therapy to patients via telephone, videoconferencing, and/or text chat.
75769334|NCT03903952|Dietary Supplement|Vitamin B12 and folate|Vitamin B12 and folate levels in blood
76065489|NCT04607967|Device|High Flow Nasal Oxygen|"Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation."
75769335|NCT03910348|Device|Whole-body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA).
75452429|NCT01739439|Radiation|intensity-modulated radiation therapy|Undergo hyperfractionated IMRT
75603595|NCT01973153|Behavioral|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
75603596|NCT01973153|Behavioral|Brief Motivational Counseling Plus Phone Calls (BMC + Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
75603597|NCT01973153|Behavioral|Brief Motivational Counseling Plus Home Visits (BMC + Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
75603598|NCT01889199|Drug|Flutamide|Flutamide 125 mg orally each 28 day cycle for 6 cycles
75603599|NCT01889199|Other|Placebo|Placebo orally each 28 day cycle for 6 cycles
75603600|NCT01816152|Other|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
75603601|NCT01816152|Other|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
75603602|NCT01737502|Drug|Auranofin|Given PO
75603603|NCT01737502|Drug|Sirolimus|Given PO
75603604|NCT01737502|Other|Laboratory Biomarker Analysis|Correlative studies
75603605|NCT01737502|Other|Pharmacological Study|Correlative studies
75603606|NCT01666080|Drug|Busulfan|0.4 mg/kg (0.5 mg/kg if <4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
75769336|NCT03910348|Other|High-impact exercise|In the high-impact exercise program, the patients were asked to jump using a jump-rope at the beginning of each session
75898643|NCT05434871|Other|Physiotherapy|The standard physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
75898644|NCT05417568|Dietary Supplement|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
75898645|NCT05417568|Dietary Supplement|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
75898646|NCT05401461|Other|Evening mobilisation|Evening mobilisation delivered between (19.00 and 21.00) according to standardised procedures and established safety criteria. The intervention will begin on day 1 of admission or the first evening following recruitment. Mobilisation will be defined as a score of ≥ 2 on the Manchester mobility score (sit on the edge of the bed or higher), with actual mobilisation level achieved and duration of intervention based on clinical decision of the mobilisation therapists. Patients will also be offered the opportunity to engage in activities which may be part of their normal evening routines (e.g. brushing teeth, reading or watching television). The intervention will be carried out for up to seven consecutive evenings. The evening mobilisation will be delivered in addition to any input from the MDT during normal daily working hours and will not replace any standard therapy.
76065490|NCT04605159|Biological|RSV MAT|One dose of RSV MAT vaccine reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.
75452430|NCT01739439|Radiation|radiosurgery|Undergo radiosurgery boost
75452431|NCT01739439|Procedure|diffusion-weighted magnetic resonance imaging|Correlative studies
75452432|NCT01739465|Procedure|Self expanding metallic stent (SEMS)|Self expanding metallic stent
75452433|NCT01739465|Procedure|Endoscopic radiofrequency ablation (ERFA)|Endoscopic radiofrequency ablation
75452434|NCT01739465|Procedure|Photodynamic therapy (PDT)|Photodynamic therapy
75603607|NCT01666080|Drug|Fludarabine|40 mg/m^2 intravenously (IV) over 1 hour on days -6 through -2.
75603608|NCT01666080|Radiation|Total body irradiation|200 cGy on Day -1
75603609|NCT01666080|Biological|Stem cell transplant|stem cell infusion on day 0
75603610|NCT01666080|Drug|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
75769337|NCT00257010|Drug|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
75769338|NCT03901768|Drug|Dexamethasone|a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.
75769339|NCT03901768|Drug|Triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
75898647|NCT05400291|Diagnostic Test|Chondroitin Sulfate Staining|Staining of histopathological slides
75452435|NCT01739478|Other|Packing of abscess cavity|
75452436|NCT01739478|Other|External dressing|Application of external dressing whilst abscess cavity heals
75452437|NCT01739491|Drug|No intervention|This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
75748172|NCT05900479|Other|PTSD Service Dog|According to the Americans with Disabilities Act (ADA), a service dog is a dog that is trained to perform specific tasks to mitigate a disability. For PTSD service dogs, examples include detecting and alerting to physical signs of distress to interrupt anxiety and panic attacks, waking up Veterans from nightmares, and retrieving medication. In addition to trained tasks, service dogs live with the Veterans to provide emotional value as a source of comfort and companionship. Under the ADA guidance, PTSD service dogs have pubic access and are legally allowed to accompany their person in public places such as grocery stores, workplaces, and schools. In the proposed study, service dogs will be sourced from two Assistance Dog International (ADI) accredited providers, including K9s For Warriors and Canine Companions for Independence. Both providers have an established track record of training and providing PTSD service dogs, as well as collaborating with the investigative team in research.
75748173|NCT05896748|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
75769340|NCT03901768|Drug|Placebos|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
75603611|NCT01494103|Biological|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
75452438|NCT01739504|Procedure|Liposuction with Local Anesthesia|Liposuction under tumescent anesthesia for adipose tissue harvesting.
75452439|NCT01739504|Biological|Intra articular infusion of AD-SVF|"Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.~AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.~Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing."
75603612|NCT01494103|Drug|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
75769341|NCT03903718|Drug|Oseltamivir|75 mg capsules orally twice a day from Day 2 to Day 7
75769342|NCT03903718|Biological|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.
76065491|NCT04605159|Drug|Placebo|One dose of lyophilized sucrose reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.
75769343|NCT03903718|Drug|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
75898648|NCT05384379|Drug|Inhaled BZ371B|Intubated patients suffering from ARDS will receive BZ371B in a dose of 12 mg. This will be divided into 2 nebulizations, each with 10 ml. The first nebulization is at a dose of 3 mg and the second at a dose of 9 mg.
75898649|NCT05382962|Behavioral|iCanCope Post Op Application|The iCanCope program is designed to enhance pain self-management and self-efficacy, defined as perception of one's ability to successfully produce a desired effect in a task or behavior affecting their life. The intervention will be delivered on the iOS or Android smartphone platform depending on the participant's device. Usage of app features will be centrally tracked by the research team using Analytics Platform to Evaluate Effective Engagement (APEEE), developed at the Centre for Global eHealth Innovation. Participants will receive alerts through iCanCope to complete a pain diary check-in once per week preoperatively, twice per day over the initial 2-week postoperative period, and once per day for the subsequent 2-week period.
76065492|NCT04604067|Drug|Acalabrutinib|"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
76065493|NCT04603443|Dietary Supplement|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine
76065494|NCT04603443|Dietary Supplement|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 20 g BID x 12 weeks
76065495|NCT04603443|Dietary Supplement|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 30 g BID x 12 weeks
76065496|NCT04603443|Dietary Supplement|Protein Control|Protein placebo control - all amino acids except for BCAA, 30 g BID x 12 weeks
75603613|NCT01263379|Biological|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
75603614|NCT00992238|Drug|Flavoxate Hydrochloride Tablets, 100mg|
75603615|NCT00992238|Drug|Urispas® Tablets, 100mg|
75603616|NCT00858897|Other|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-[3,3-2H2]cysteine
75603617|NCT00858897|Drug|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
75603618|NCT05940922|Other|No intervention. Retrospective observation only.|No intervention. Retrospective observation only.
75603619|NCT05940909|Drug|Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet|"Perindopril/Indapamide/Amlodipine is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril erbumine, 2.5 mg of indapamide and 10 mg of amlodipine.~Triplixam® is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine, 2.5 mg of indapamide and 10 mg of amlodipine."
75603620|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
75603621|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
75748174|NCT05896748|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
75748175|NCT05894122|Diagnostic Test|DM-DIV MITRA®|Comparison of phenylalanine concentrations in the new device with those in the current device (blotter).
75748176|NCT05888532|Drug|Copper-64 labeled Granzyme B (64Cu-GRIP B)|Given IV prior to imaging
75748177|NCT05888532|Procedure|Positron Emission Tomography (PET)|Imaging procedure
75603622|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.
75603623|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.
75748178|NCT05877885|Behavioral|Targeted Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
75603624|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.
75748179|NCT05877885|Behavioral|General Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
75603625|NCT05940883|Drug|Placebo|Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.
75748180|NCT05876767|Drug|SAR444336|Single or repeated dose subcutaneous injection
75748181|NCT05876767|Drug|Placebo|Single or repeated dose subcutaneous injection
75748182|NCT05870098|Diagnostic Test|All participants|"Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine."
75452440|NCT01739517|Drug|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
75452441|NCT01739530|Biological|Repaircell|allogenic differentiated adipocyte
75452442|NCT01739543|Device|Hem-Avert|Application of Hem-Avert
75452443|NCT01739556|Drug|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
75452444|NCT01739582|Drug|Androxal|
75452445|NCT01739608|Other|Invitation to screening|Invitation to screening
75452446|NCT01739621|Drug|Proellex 12 mg|
75898650|NCT05380284|Other|Senior Driving Simulation Training|The experimental group (Senior Driving Simulation Training: 30-mins training session two times per week for 5 weeks, with a total of 10 sessions) .
75603626|NCT05940844|Drug|OB-002|The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
75603627|NCT05940831|Behavioral|Support-Moms|Scheduled SMS-audio messages from the final messaging prototype (SM), plus social supporter engagement through SMS (SS).
75603628|NCT05940831|Behavioral|Control|Routine care/ information giving
75603629|NCT05940818|Behavioral|the intensive oral care|the intensive oral care
75898651|NCT05380284|Other|Waiting list control|The control group is waiting list control. They will also receive the (Senior Driving Simulation Training) after all research is done.
75898652|NCT05375604|Drug|CDK-004|ASO-STAT6 exosome administered Intravenously
75452447|NCT01739621|Drug|Proellex 24 mg|
75452448|NCT01739634|Drug|CASAD|CASAD is provided in 500mg capsules.
75452449|NCT01739647|Drug|AZD3293|Oral solution
75748183|NCT05868525|Drug|Aspirin 325Mg Tab, Aspirin 81Mg Tab|Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
75748184|NCT05864534|Drug|Balstilimab|Balstilimab 450 mg IV over 30 minutes every 3 weeks
75748185|NCT05864534|Drug|Botensilimab|Botensilimab1mg/kg mg IV over 30 minutes every 6 weeks
75748186|NCT05864534|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks
75748187|NCT05864534|Device|Sonocloud-9 (SC-9)|Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks
75748188|NCT05859698|Drug|Valbenazine|Valbenazine capsules for oral administration
75748189|NCT05856695|Drug|Carboplatin + Paclitaxel + Durvalumab|Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
75748190|NCT05850663|Other|Ecologic Momentary Assessment (EMA)|"EMA enables measurement of phenomena in real-time, natural settings.~EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.~The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.~The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone."
75748191|NCT05844982|Drug|Faricimab|6.0 mg intravitreal injection at randomization and every 3 months
75748192|NCT05844982|Drug|fluocinolone acetonide|0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
75748193|NCT05840354|Device|repetitive transcranial magnetic stimulation|"1-4 weeks after administration of the SJI, participants will attend their first rTMS session. rTMS will be delivered using a biphasic stimulator (DuoMag) and a figure-of-eight coil to the corticomotor representation of the first dorsal interosseous muscle contralateral to the side of worst pain. Recording electrodes will be positioned in a belly-tendon montage over the FDI for electromyography recording. The hotspot and resting motor threshold (rMT) of the FDI will be determined and saved using a Brainsight Neuronavigation system to ensure accurate coil repositioning within and between sessions.~The hotspot and rMT will be confirmed and adjusted if needed at each intervention session. Each rTMS session will consist of 40 trains of 5s delivered at 10Hz, at an intensity of 85% of the resting motor threshold for the FDI muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session)."
75748194|NCT05840354|Device|sham repetitive transcranial magnetic stimulation|Sham intervention will follow same protocol as active rTMS using a sham coil that does not deliver actual magnetic stimulation.
75748195|NCT05840354|Drug|Steroid Joint Injection|The steroid joint injection will be given 1-4 weeks ahead of active rTMS and sham rTMS commencement. A dose of 0.5mL of 40mg/mL triamcinolone and 0.5mL of 2% lidocaine will be given per joint via spinal needle. The treatment team will determine how many joints will be injected based on their standard clinical assessment. Usually, about 2-4 joints are injected depending on a person's pain presentation. Standard practice is to place the needle in the region of the facet joint opening, resulting in a peri- +/- intra-articular infusion of the injectate. This project will utilize standard clinical practice without modification.
75748196|NCT05838781|Diagnostic Test|Risk prediction model|A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
75748197|NCT05838781|Diagnostic Test|14-days continuous ECG monitoring|14-days continuous ECG monitoring with an ECG patch.
75452450|NCT01739647|Drug|Placebo|Oral solution
75452451|NCT01739660|Drug|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
75452452|NCT01739673|Other|Ultraviolet-A and riboflavin|
75898653|NCT05375201|Other|VR skateboarding training|The virtual reality skateboard training (VR-skate) is used treadmill-based training. Virtual reality system is integrated into the split-belt treadmill for VR-skate. Participants slide the swing leg (sliding leg) along with the moving treadmill belt at a comfortable speed (same as walking speed).
75603630|NCT05940805|Procedure|Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|"Low-frequency transcranial electrical stimulation (2/100 Hz) applied through 0.3-mm-diameter and 40-mm-long needles placed subcutaneously on the scalp at the projection of Penfield's motor homunculus and sensory and frontal supplementary motor associative areas.~Paraspinous block at the levels of the C5, C6 and C7 vertebrae concordant with spasticity laterality.~Dry needling of spastic upper limb muscles, as identified through a thorough physical examination, using 0.3-mm-diameter and 40-mm-long needles.~Muscular functional electrical stimulation (FES) in the antagonists of the upper limb muscles with spasticity with the following parameters: 20-Hz frequency, 300-µs pulse width, zero-second ramp time, 5-second stimulation time, and 5-second resting time."
75769344|NCT03910504|Drug|Rocuronium 0.3 mg*kg|Patients randomized to the control group will receive rocuronium at 0.3 mg*kg ev bolus at the induction of anesthesia.
75898654|NCT05368038|Diagnostic Test|Confirmatory Testing|All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.
75452453|NCT01739686|Other|CASA Intervention|"CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
75748198|NCT05836688|Behavioral|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
75748199|NCT05836688|Behavioral|Individual Supportive Listening|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
75452454|NCT01739712|Behavioral|Sleep extension|There will be a consultation with families to help youth to be successful in extending their sleep.
75452455|NCT01739712|Behavioral|Fixed Sleep Duration|There will be a consultation with families to instruct youth to maintain the same average nightly sleep duration during the modification week. The purpose is to control for time and attention.
75452456|NCT01739725|Device|Stent insertion|The patient will receive the helical stent
75452457|NCT01739738|Device|Ureteral Stent|patients who need to receive stent as per standard of care
75452458|NCT01739751|Device|pedometers|portable device that estimate the number of steps walked daily
75452459|NCT01739777|Biological|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
75452460|NCT01739777|Other|Controls|Autologous Serum will administrated as placebo
75452461|NCT01739816|Behavioral|Medication review|"Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
75452462|NCT01739829|Device|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
75452463|NCT01739829|Device|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
75452464|NCT01739842|Dietary Supplement|Kudzu extract|
75452465|NCT01739855|Drug|Calciferol, calcium carbonate|
75452466|NCT01739868|Other|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:~1 visit the first year (inclusion visit)~1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes~1 intermediary visit (in 3 years) or activated by the following conditions:~Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)~Normalization of the glycemia (fasting blood glucose < 1 g/l)"
75452467|NCT01739881|Device|Olympus Ultrathin Bronchofibervideoscope (XP260F)|The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.
75452468|NCT01739894|Drug|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
75452469|NCT01739907|Other|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
75452470|NCT01739920|Other|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
75452471|NCT01739920|Other|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
75452472|NCT01739972|Drug|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
76065497|NCT04594109|Behavioral|Tailored behavioral counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
76065498|NCT04594109|Behavioral|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
76065499|NCT04593069|Behavioral|Neurocognitive assessment|6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
76065500|NCT04586712|Drug|High dose CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 1000mg/30mL (high).
75452473|NCT01739972|Drug|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
75452474|NCT01739985|Drug|Dexamethasone + ondansetron + Placebo|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
75452475|NCT01739985|Drug|Dexamethasone + ondansetron + Droperidol|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
75603631|NCT05940805|Procedure|SHAM Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used.
75748200|NCT05830409|Behavioral|Multisensorial Stimulation|Strategies such as touching, calling, making sense of smell, entering the eye area, and activating the sense of taste will be applied to activate the five senses of the newborn.
75452476|NCT01739998|Dietary Supplement|functional oil|
75452477|NCT01739998|Dietary Supplement|Placebo|
75452478|NCT01740011|Procedure|Laparoscopic surgery|
75452479|NCT01740024|Biological|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
75603632|NCT05940792|Other|Nonelastic taping|Non-elastic taping was placed on the ankle of the affected side with a plaster band starting from the middle of the sole of the foot and extending from the lateral side of the foot to the level below the knee to provide eversion support.
75748203|NCT05822921|Behavioral|In-person Psychoeducation (IP)|Parents will attend two 60-minute (i.e. one day per week, for the next two weeks), in-person psychoeducation sessions on the MAC, in or near their hometown. During these sessions, a clinician will discuss a series of psychoeducation topics supplemented with PowerPoint slides. Across the two sessions, the following topics will be covered: (1) signs/symptoms and epidemiology of ASD, (2) risk factors associated with developing ASD (e.g., genetics, neurobiology, environment, social motivation), (3) navigating the IEP process, and (4) evidence-based best practices recommended for their child's profile of ASD symptoms and co-occurring conditions. This delivery method will allow parents to ask questions and receive immediate, live, and detailed answers from an expert clinician, to focus on specific examples relevant to their child, and to foster ASD knowledge and efficacy in helping their child.
75748204|NCT05822921|Behavioral|Telehealth Psychoeducation (TH)|Parents in this group will attend two 60-minute sessions, remotely via a live video chat platform, rather than in-person. Otherwise, it will follow the same format and PowerPoint materials as the IP Group. Sessions will still be facilitated by a clinician, thus maintaining the option to ask questions, discuss personalized examples, etc. For families without computer and internet access, the family will be assisted with to connecting to internet access at a private and convenient location (e.g., a church, library, or local community services agency). In the event that this is not possible, the family will be randomized to one of the other two groups.
75769345|NCT03910504|Drug|No Rocuronium|Patients randomized to the interventional group will not receive neuromuscular blockade at the induction of anesthesia.
75769346|NCT03901690|Drug|Betaglucin soluble gel 0.2%|With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
76065501|NCT04586712|Drug|Low Dose CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD oil at concentrations of 500mg/30mL (low)
76065502|NCT04586712|Drug|Vehicle Control Group|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
76065503|NCT04585711|Drug|Etanercept Optimal dosing|Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
76065504|NCT04566484|Drug|BBV87 Chikungunya vaccine|BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.
76065505|NCT04566484|Drug|Normal Saline|Normal saline is the placebo
76065506|NCT04559334|Device|Tetrasodium EDTA Catheter Lock Solution|KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.
76065507|NCT04551495|Drug|Entrectinib|Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles
76065508|NCT04551495|Drug|Letrozole|Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles
76065509|NCT04551495|Drug|Goserelin|Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
76065510|NCT04548778|Diagnostic Test|BÜHLMANN fPELA assay|BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
76065511|NCT04536779|Other|Training in the local departments of TT and cycling trips with CUA|in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
75452480|NCT01740037|Other|Specialized outpatient AF Clinic|
75452481|NCT01740037|Other|Usual Care|
75452482|NCT01740050|Dietary Supplement|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
75452483|NCT01740050|Procedure|RYGB|
75452484|NCT01740050|Procedure|LAGB|
75748205|NCT05822921|Behavioral|Psychoeducation as Usual (PAU)|Parents in this group will receive basic paper psychoeducation resources, distributed at their feedback session. It will be up to each parent how frequently and diligently these resources are reviewed. This should be akin to what a family might have access to at their pediatric or primary care office. To be consistent across study groups, the materials produced for these parents will be comprehensive and will include the same span of content as the PowerPoint slides used in the other two groups, but without structured sessions facilitated by a clinician. Upon distribution of materials, parents will be provided with our contact information and encouraged to reach out if any questions occur. Parents in the paper informational materials group will have the option to complete two in-person or video conference psychoeducation sessions after the end of the study, if preferred (i.e., 6 months later).
75603633|NCT05940792|Other|Conservative physiotherapy|The conventional physiotherapy programme included range of motion exercises, balance and gait training and neuromuscular electrical stimulation.
75748206|NCT05817656|Drug|Sucralfate|3g of sucralfate powder through colonoscopy will be sprayed precisely on the polypectomy wound in the intervention group
75748207|NCT05817539|Procedure|Fluid balance negativation|"During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .~When the patient's baseline body weight is reached the UF net will be settled to maintain it.~In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it~In case of hemodynamic intolerance (NADN > 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN < 0,5 µg/kg/min and without tissue hypoperfusion."
75748208|NCT05817539|Procedure|Body weight Stabilization|"During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.~In case of weight stabilisation failure ( variation >5%), the UF net can be increased to 1,5 ml/kg/h.~In case of hemodynamic intolerance (NADN > 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN < 0,5 µg/kg/min."
75748209|NCT05808764|Drug|Risdiplam|Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
75603634|NCT05940779|Other|Therapeutic exercise program|The intervention is a therapeutic program composed of self-resisted strength exercises, balance training and exercises to improve posture.
75603635|NCT05940766|Other|Automated fever alerts|Fever alerts are automated sent to participants if fever is detected
75748210|NCT05806814|Biological|Sipuleucel-T|Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.
75769347|NCT03901690|Drug|Imiquimod 5% cream|With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
75769348|NCT03901378|Drug|Pembrolizumab|Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:
75898655|NCT05357742|Behavioral|Individualized basic need navigation and lifestyle coaching and skills training|During each session participants will receive the manualized study intervention which includes 1) DKD education, 2) Individualized basic needs navigation, and 3) Lifestyle coaching and skills training. Participants will be provided a FORA 2-in-1 device with glucose test strips to allow testing at least once a day. The device automatically uploads blood pressure and glucose readings to a secure server in real time and the health educator will have access to this secure server. Readings will be used to guide lifestyle coaching and skills training.
75898656|NCT05357742|Behavioral|Enhanced usual care|During each session participants will receive DKD education only.
75452485|NCT01740063|Drug|DAS181-F02 formulation|
75452486|NCT01740063|Drug|DAS181-F04 formulation|
75452487|NCT01740063|Drug|Placebo|
75452488|NCT01740076|Other|soy nuts|
75452489|NCT01740102|Procedure|RIPC|The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
75452490|NCT01740141|Procedure|Plexus brachialis block|
75452491|NCT01740167|Behavioral|health promotion lifestyle program|Individual counseling, once a month, total 3 times.
75452492|NCT01740180|Other|Data entry|"This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.~These data are extracted from patient records by each participating center and collected in an e-CRF."
75452493|NCT01740193|Procedure|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
75603636|NCT05940753|Other|Survey about travel willingness regarding cancer treatment and follow-up|No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
75603637|NCT05940740|Other|Colorectal-Mobile application|The use of Colorectal-Mobile application by the patients on a daily basis by the researcher will be monitored remotely via the management platform of the usage status of the mobile health application.
75603638|NCT05940727|Other|Habitual macroalgae consumption|The participant have a habitual macroalgae consumption at baseline.
75898657|NCT05357118|Behavioral|Suppress Stigma, Support Services|Women living with HIV/AIDS (WLHA) will attend an initial group preparation session in Month 1 to form a network with peers and prepare for the following online support groups. During Month 2-4, study investigators will teach cognitive, emotional, and behavioral strategies to cope with stigma and utilize social support to seek healthcare services through online group activities. During Month 4-6, WLHA will self-administer the online support groups without the intervention of study investigators
75748211|NCT05802914|Device|Back Exosuit|The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
75748212|NCT05799599|Behavioral|Stay-Play-Talk Basic|Stay-Play-Talk (SPT) Basic and SGD with augmented peer input in which peers are taught to model verbal responses while simultaneously selecting screen icons with spoken peer input only (i.e., peers taught to model language)
76065512|NCT04533659|Behavioral|ADA-based nutrition education with digital self-monitoring|Diabetes nutrition education developed by the American Diabetes Association with digital self-monitoring for diet and physical activity
76065513|NCT04533659|Behavioral|Personalized Behavioral Nutrition (PBN) intervention group|Personalized behavioral nutrition intervention consisting of digital self-monitoring for diet and physical activity, personalized nutrition change goal and recommendation, and diabetes nutrition education developed by ADA
75452494|NCT01740193|Procedure|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
75452495|NCT01740219|Behavioral|Capacity Enhancement|Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
75452496|NCT01740219|Behavioral|Standard Dissemination|Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
75452497|NCT01740232|Procedure|trephination|Artroscopic meniskal repair with trephination.
75452498|NCT01740232|Procedure|Normal meniscal repair|Artroscopic meniskal repair without trephination.
75452499|NCT01740245|Device|Chlorhexidine vaginal suppositories|
75603639|NCT05940727|Other|No macroalgae consumption|The participants exclude any macroalgae products from their diet
75603640|NCT05940714|Behavioral|Video participants|Showing a video of oral hygiene intructions
75603641|NCT05940701|Combination Product|Curasept Biosmalto Mousse and toothpaste|at each visit a Curasept Biosmalto Mousse will be applied on the facial surface of the maxillary and mandibular anterior teeth using a tray.
75748213|NCT05799599|Behavioral|Stay-Play-Talk Plus|SPT Plus with augmented SGD peer input (i.e., peers taught to use verbal language models concurrently while selecting SGD icons).
75898658|NCT05338463|Drug|Fespixon Cream|"Name : Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (not exceeding 2 mm in thickness)~Dosing schedule: Apply twice a day~Duration: up to 20 weeks"
76065514|NCT04523558|Device|Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes|Extended depth of field intraocular lens made form hydrophobic material
76065515|NCT04520087|Procedure|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
75452500|NCT01740245|Device|Polyhexamethylene biguanide vaginal suppositories|
75452501|NCT01740271|Drug|Epirubicin|
75452502|NCT01740284|Drug|Grazax + Aerius|
75452503|NCT01740284|Drug|Grazax + placebo|
75603642|NCT05940701|Other|Colgate toothpaste|The control group will receive a fluoridated toothpaste (Colgate toothpaste)
75603643|NCT05940662|Procedure|Immediate Implant Placement|"The extraction of the failing tooth will be carried out. Subsequently, immediate implant placement and bone grafting of the intra-alveolar space by the means of a well-documented xenogeneic bone substitute will be carried out, will be conducted all in one single surgical intervention.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
75748214|NCT05799599|Behavioral|Stay-Play-Talk Advanced|SPT Advanced adds direct instruction strategies for the children with ASD (i.e., adult prompts, reinforcers, and embedded teaching trials) to increase peer-directed communication.
75748215|NCT05796518|Other|PREVENT Cardiovascular Health Assessment Tool|Participants will access a heart health information visualization tool online using a personal device or a study tablet computer using their e-mail address to log-in. Investigators will review participant lab results specifically related to their cardiovascular health (e.g. blood pressure, cholesterol) in order to personalize the heart health tool for participants. A brief survey before and after use of the tool will also be completed by participants.
75748216|NCT05796518|Other|Survey|A brief survey before and after use of the tool will also be completed by participants.
75748217|NCT05796518|Other|Interview Regarding Heart Health|Participants will be asked questions related to their heart health.
75603644|NCT05940662|Procedure|Early Implant Placement|"The extraction of the failing tooth will be carried out. Within a healing period of 4-16 weeks, the extraction socket will be completely covered by soft tissues.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
75603645|NCT05940662|Procedure|Late Implant Placement|"The extraction of the failing tooth and a socket grafting procedure using a well-documented xenogeneic bone substitute will be carried out. Within a healing period of at least 16 weeks, the extraction socket will be completely covered by soft tissues and complete bone healing is anticipated.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
75603646|NCT05940597|Device|Pulse field ablation|ablation of paroxysmal atrial fibrillation by Pulse field ablation
75603647|NCT05940597|Device|Cryoballoon pulmonary vein isolation|ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation
75603648|NCT05940571|Drug|MBF-362|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
75603649|NCT05940558|Drug|MBF-018 oral capsules|MBF-018 oral capsules PPAR gamma receptor partial agonist
75603650|NCT05940532|Drug|Sugemalimab and Chemotherapy|"Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years."
75603651|NCT05940480|Behavioral|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
75603652|NCT05940480|Behavioral|Health education|Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.
75748218|NCT05794191|Biological|Vaccine Administration|PCV13 administration
75748219|NCT05785754|Drug|DCSZ11|A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
75748220|NCT05785754|Drug|Pembrolizumab|Pembrolizumab injection
75748221|NCT05785611|Drug|Filgotinib|Tablets administered orally once daily
75748222|NCT05785611|Drug|Placebo|Tablets administered orally once daily
75898659|NCT05334056|Drug|Cocaine Nasal|2 ml of 4% cocaine given as a nasal spray immediately prior to nasal intubation
75898660|NCT05328414|Drug|Prednisolone|intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
75603653|NCT05940454|Procedure|Pericapsular nerve group block|"The patient's arm is externally rotated and abducted at 45 degrees. A longitudinal linear ultrasound probe is placed between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle on it, a 50 mm needle is inserted with the in-plane technique. When the needle passes through the deltoid muscle and touches the subscapularis tendon, a hard bone-like tissue is felt and the needle is not advanced any further. It is noteworthy that the subscapularis tendon is very rigid and resistant to needle penetration when performing the pericapsular nerve group block. The needle tip is placed between the deltoid muscle and the subscapularis tendon and a local anesthetic drug (20 ml, %0.5 bupivacain hydrochlorur) is injected"
75603654|NCT05940441|Drug|Capecitabine 500Mg Oral Tablet|650 mg/m² body surface area twice daily for 1 year
75603655|NCT05940415|Behavioral|active surveillance|active surveillance without prostate biopsy
75603656|NCT05940389|Device|Naso Alveolar Mold|The NAM appliance is constructed according to the Grayson technique [8] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed.
75748225|NCT05776628|Device|Plenum® Tissue ortho membrane (polydioxanone membrane)|Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
76065516|NCT04515316|Device|OPM sensors|Optically-pumped magnetometers (OPM) sensors, which are based on optical probing of alkali atoms in the vapor phase at (or slightly above) room temperature, have recently demonstrated sensitivity levels comparable with SQUID magnetometers in the laboratory. These sensors require no cooling and can potentially be fabricated at much lower cost than SQUIDs. Beginning in the late 1990s, optically-pumped magnetometers began to be used for biomagnetic applications, first for measurement of heart magnetic fields and more recently for measurement of brain fields by several groups around the world.
76065517|NCT04515316|Device|SQUID sensors|Magnetic sensors based on superconducting quantum interference devices (SQUIDs) have been the dominant sensor in the field of magnetoencephalography since its birth in the early 1970s. SQUIDs have exceptional sensitivity to enable the detection of these very weak signals. Current FDA-approved MEG devices contain liquid helium gas in a big container that is mounted over the head of the subject
76065518|NCT04513132|Device|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
75898661|NCT05316181|Procedure|HIPEC|HIPEC perfusion, doxorubicin 35mg/m2 & mitomycin 15 mg/m2, 41.5'C, 90 min.
75452504|NCT01740310|Behavioral|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
75603657|NCT05940389|Device|Taping with nasal elevator:|For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.
76065519|NCT04513132|Device|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
76065520|NCT04508478|Behavioral|Aerobic training|Aerobic training
76065521|NCT04508478|Behavioral|Resistance training|Resistance training
75748232|NCT05766839|Drug|Patiromer|Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split
75748233|NCT05766709|Drug|NNC0194-0499|NNC0194-0499 will be administered subcutaneously once weekly.
75748234|NCT05766709|Drug|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
75748235|NCT05766709|Drug|NNC0194-0499/Semaglutide A (40/3.20 mg/mL)|NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.
75748236|NCT05766709|Drug|NNC0194-0499/Semaglutide A (40/0.33mg/mL)|NNC0194-0499/Semaglutide A (40/0.33mg/mL) will be administered subcutaneously once weekly.
75748240|NCT05763875|Drug|Inclisiran|284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
75748241|NCT05763875|Drug|Ezetimibe|10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
75748242|NCT05763875|Drug|Matching Placebo for Inclisiran|0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
75898662|NCT05298085|Drug|Oxytocin nasal spray|Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study
76065522|NCT04508478|Behavioral|Control physical exercise|Control physical exercise
75452505|NCT01740336|Drug|GDC-0941|GDC-0941 will be administered QD orally for 5 consecutive days each week.
75452506|NCT01740336|Drug|Placebo|Placebo matching to GDC-0941
75748243|NCT05763875|Drug|Matching Placebo for Ezetimibe|0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
75452507|NCT01740336|Drug|Paclitaxel|Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
75748244|NCT05763576|Drug|RO7565020|RO7565020 will be administered by subcutaneous injection or intravenous infusion.
75748245|NCT05763576|Other|Placebo|Matching placebo will be administered by subcutaneous injection or intravenous infusion.
75748246|NCT05763576|Drug|Nucleos(t)ide analogue (NUC) treatment|NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
76065523|NCT04501718|Drug|Apatinib Combined With Temozolomide and Etoposide Capsules|"Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator."
76065524|NCT04501705|Drug|Apatinib Mesylate|"Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator."
76065525|NCT04496453|Other|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
76065526|NCT04483791|Combination Product|DynamX Novolimus Eluting Coronary Bioadaptor System|up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System
75452508|NCT01740375|Procedure|esophagectomy|esophagectomy
75452509|NCT01740453|Drug|ropivacaine 2 mg/ml|single
75452510|NCT01740479|Procedure|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
75748247|NCT05763407|Device|FIRE1 System|FIRE1 System
75898663|NCT05298085|Drug|Placebo|Study treatment will be administered intranasally daily for 12 weeks.
75898664|NCT05295693|Device|Correlation of the Quantra with the TEG|"The purpose of this study is to evaluate the efficacy/reliability/validity of the Quantra device in patients with congenital heart disease for cardiac surgery on CPB.~The study if of investigational interest only. No clinical decisions will be made based on the results obtained by the Quantra device."
76065527|NCT04463394|Drug|Vasopressin|Vasopressin administered intravenously
76065528|NCT04461691|Procedure|Cryoballoon Pulmonary Vein Isolation|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
75452511|NCT01740505|Behavioral|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
75452512|NCT01740505|Behavioral|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
75452513|NCT01740505|Behavioral|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
75452514|NCT01740518|Drug|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
75452515|NCT01740531|Biological|S-303 Treated Red Blood Cells (RBCs)|
75452516|NCT01740531|Biological|Conventional, untreated Red Blood Cells|
75603658|NCT05940376|Drug|rapid acting insulin|Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2°C) and, was provided by the cornea specialist and was self-administered by patients at a dosage of 1 eye drop 4 times daily. Treatment continued until NK healed and then tapered accordingly. Patients would discontinue topical insulin if the condition did not improve or worsen within 4 weeks. Patients were followed up daily and slit-lamp photographs were captured with and without fluorescein corneal staining.
75603659|NCT05940363|Combination Product|Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies|To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
75748248|NCT05761158|Other|questionnaire|patients are asked to complete a questionnaire
75748249|NCT05757817|Procedure|Oropharyngeal or oral cavity reconstruction|"Oropharyngeal or oral cavity reconstruction will be performed using a free super thin external pudendal artery flap (STEPA flap).~Post-operative follow-up and adjuvant treatment: Post-operative follow-up of patients will be performed according to the standards of the participating centers."
75748250|NCT05756179|Drug|Diosmin and Hesperidin Combination|Diosmin 450 mg and Hesperidin 50 mg Combination
75748251|NCT05755139|Device|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
75898665|NCT05291598|Drug|Institution specific joint replacement pain protocol|"Participants will be treated with a standard orthopaedic joint replacement protocol which includes:~Dexamethasone~Tylenol~Lyrica~Celebrex~Meloxicam~Oxycodone"
75898666|NCT05291598|Drug|IV meloxicam|Participants will be administered meloxicam 30 mg IV push pre-operatively.
75898667|NCT05291598|Drug|Ketorolac|Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.
75452517|NCT01740544|Other|Cathodal tDCS|Cathodal tDCS applied over the right PPC
75452518|NCT01740544|Other|Sham tDCS|Sham tDCS applied over the right PPC
75452519|NCT01740570|Drug|Cabazitaxel|"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I."
76065529|NCT04459104|Other|Low glycemic load|Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
76065530|NCT04459104|Other|High glycemic load|Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
76065531|NCT04454905|Drug|Camrelizumab|Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
76065532|NCT04454905|Drug|Apatinib|Apatinib is a novel angiogenesis inhibitor vascular endothelial growth factor 2.
75452520|NCT01740583|Device|percutaneous annuloplasty|plication of the mitral valve annulus
75603660|NCT05940298|Drug|Intravenous injection of [99mTc]Tc-DB8|One single intravenous injection of [99mTc]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
75603661|NCT05940272|Behavioral|Hematolo-GIST Training|Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
75603662|NCT05940272|Behavioral|Participants Appointment|Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
75603663|NCT05940259|Drug|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
75452521|NCT01740609|Drug|Placebo|Placebo
75452522|NCT01740609|Biological|PF-06342674 Dose A|Single SC Dose
75452523|NCT01740609|Biological|PF-06342674 Dose B|Single SC Dose
75452524|NCT01740609|Biological|PF-06342674 Dose C|Single SC Dose
75452525|NCT01740609|Biological|PF-06342674 Dose D|Single SC Dose
75452526|NCT01740609|Biological|PF-06342674 Dose E|Single SC Dose
75452527|NCT01740609|Biological|PF-06342674 Dose F|Single IV Dose
75452528|NCT01740609|Biological|PF-06342674 Dose G|Single SC Dose
75452529|NCT01740609|Biological|PF-06342674 Dose H|Single IV Dose
75452530|NCT01740609|Biological|PF-06342674 Dose I|Single SC Dose
75452531|NCT01740609|Biological|PF-06342674 Dose J|Single IV Dose
75452532|NCT01740622|Other|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
75748252|NCT05752201|Biological|Gamma Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
75748253|NCT05752201|Biological|Omicron Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
75748254|NCT05752201|Biological|Bivalent RBD-based ARVAC-CG vaccine|Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
75748255|NCT05752201|Other|Placebo (Alum)|Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
75748256|NCT05749393|Drug|Heparin sodium|Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
75748257|NCT05736835|Biological|CVXGA|CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
75898668|NCT05277779|Diagnostic Test|cardiac magnetic resonance(CMR)|CMR was performed to assess myocardial tissue characteristics in the study population
75898669|NCT05272709|Drug|TT-702|TT-702 will be administered orally, once daily, for up to 12 months.
75898670|NCT05267678|Other|No intervention|This is an observational study without any intervention
75898671|NCT05253261|Diagnostic Test|Preoperative Cone Beam Computed Tomography (CBCT) scan|CBCT scans (Green X, Vatech, Hwaseong, Korea) are carried out prior to cystostomies. The scanning conditions are constant at 200 µm isotropic voxel size with 360° rotation, 94 kV tube voltage, 7.2 mA tube current and 9 s exposure time with a 15 × 8 cm field of view field of view (FOV).
76065533|NCT04448106|Biological|Celltex- AdMSCs|Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
76065534|NCT04440163|Biological|MenABCWY|N meningitidis groups A, B, C, W, and Y vaccine
75748258|NCT05735119|Device|Tapestry Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
75748259|NCT05733390|Drug|JZP541|Oral suspension
75898672|NCT05253261|Procedure|tooth removal and cystostomy|Surgical interventions are carried out in local anaesthesia. If it is deemed that a tooth or teeth included in the odontogenic cyst is of hopeless prognosis, it is removed at the time of cystostomy procedure. During cystostomy a bony window is created to accessthe cyst. The lining of the cyst is opened to accomodate the tube of the decompression appliance. A sample from the lining of the cyst is sent for histologic evaluation to confirm the diagnosis of odontogenic cyst.
75898673|NCT05253261|Procedure|Decompression|The decompression appliances is delivered in the same sitting as the cystostomy. Patients are instructed on how to wear and clean their decompression device and are recalled for clinical examinations.
75898674|NCT05253261|Diagnostic Test|Postoperative Cone Beam Computed Tomography (CBCT) scan|Postoperative CBCT examination is performed six months into the decompression period using the same scanning conditions as those used for the preoperative CBCT scan.
75452533|NCT01740635|Device|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
75603664|NCT05940246|Behavioral|Motivational Interviewing|"MI was introduced by William Miller in 1983 as a strategy to promote behavioral changes that would make people drink less. It is well established that MI can be successfully applied to many areas across the medical disciplines. Although the aim of MI is behavioral changes toward a specific goal it is necessary to understand the essence of MI with the four key interrelated elements of the spirits of MI. These are partnership, acceptance, compassion, and evocation. Together they form an equal and respectful collaboration between the MI practitioner and the patient wherein empathy and acknowledgment are important pillars. Moreover, an important message derived from the spirit of MI is the belief that patients in themselves have and know what is needed and get support from the MI practitioner to find it."
75603665|NCT05940233|Drug|Letrozole|In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
75603666|NCT05940207|Device|e-Bandages|A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.
75748260|NCT05733390|Other|Placebo|Oral suspension
75748261|NCT05722015|Biological|Pembrolizumab coformulated with hyaluronidase|MK3475A SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
75748262|NCT05722015|Drug|Pemetrexed|Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
75898675|NCT05253261|Procedure|Cyst Enucleation|Following the decompression period enucleation of the remaining cyst is carried out in local anaesthesia.
75898676|NCT05248100|Behavioral|Conditional Cash Transfer|The intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
75898677|NCT05245409|Other|Chiropractic adjustment using an activator|Chiropractic adjustment using an activator
75898678|NCT05239026|Behavioral|Advanced treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
75898679|NCT05239026|Behavioral|Traditional treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
75898680|NCT05225480|Behavioral|Illness perception conversation|A conversation based on the indvidual's knee pain related illness perceptions
75898681|NCT05225480|Behavioral|research motivation conversation|A conversation based on the indvidual's motivation for participating in research
75898682|NCT05202379|Drug|CC-42344|CC-42344 capsules
76065535|NCT04440163|Biological|Saline|Placebo
76065536|NCT04440163|Biological|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
76065537|NCT04440163|Biological|MenACWY-CRM|Meningococcal group A, C, W-135, and Y conjugate vaccine
76065538|NCT04436601|Drug|Polyethylene Glycols|Polyethylene glycol will be administered to half of the study patients, and their response recorded and compared with that of the Lactulose arm.
75748263|NCT05722015|Drug|Cisplatin|Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
75748264|NCT05722015|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
75748265|NCT05722015|Drug|Paclitaxel|Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
76065539|NCT04436601|Drug|Lactulose|Lactulose (standard of care) will be administered to half of the study patients and their response recorded.
76065540|NCT04428801|Biological|autologous adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
76065541|NCT04417036|Drug|BAY1097761 Active Dose 1|Participants will receive a lower dose ADM by inhalation
75748266|NCT05722015|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
76065542|NCT04417036|Other|Placebo to BAY1097761|Participants will receive Placebo to BAY1097761 by inhalation
76065543|NCT04417036|Drug|BAY1097761 Active Dose 2|Participants will receive a higher dose ADM by inhalation
75748267|NCT05722015|Biological|Pembrolizumab|Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
75748268|NCT05717738|Procedure|TACE|Procedure of TACE is standardized.
75748269|NCT05717738|Drug|Lenvatinib|8mg; p.o.; q.d.
75748270|NCT05717738|Drug|Anti-PD-1 monoclonal antibody|Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
76065544|NCT04416243|Behavioral|Recumbent Stepping, High-Intensity Interval Training|"The intervention will involve 12 weeks of supervised, progressive (i.e., intensity increases after midpoint testing based on reassessment of aerobic fitness) HIIT sessions two to three times per week. HIIT exercise sessions will be manualized and led by exercise leaders. Secondary outcomes testing will occur at baseline (week 0), midpoint (following week 6 of training), and post-intervention (following week 12 of training).~The individual HIIT sessions will involve 10 cycles of 60s intervals at the wattage associated with 90% VO2peak followed by 60s of active recovery intervals at 15 watts, totaling 20 min in length. All exercise sessions will begin and end with a 5-minute warm-up and cool-down, respectively. Required power output for each interval of the exercise session will be individualized and completely automated. VO2peak from baseline and midpoint testing will be used to determine exercise intensity for weeks 1-6 and weeks 7-12, respectively."
75603667|NCT05940181|Biological|XH001+ sintilimab|During treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).
75603668|NCT05940168|Behavioral|I-Navigator ACT|The intervention is an internet-delivered ten module Acceptance and Commitment Therapy treatment program for stressed and distressed parents of children with disabilities. The contents of the program is mostly text based, but also includes videos, mindfulness exercises and written exercises, as well as homework between modules.
75603669|NCT05940168|Behavioral|Navigator ACT group|The intervention is a five session Acceptance and Commitment Therapy group treatment for stressed and distressed parents of children with disabilities. All five sessions have different themes and are held by two group leaders. Sessions are around two and a half hours long. Homework is given between sessions.
75748271|NCT05717738|Drug|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
75748272|NCT05717738|Drug|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
75748273|NCT05717738|Drug|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
75748274|NCT05717738|Drug|Sorafenib|400mg; p.o. bid
76065545|NCT04402151|Drug|PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
76065546|NCT04402151|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive standard of care radiation therapy (SBRT)
75452534|NCT01740661|Other|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
75603670|NCT05940155|Diagnostic Test|RT PCR test of COVID 19|diagnostic test by naso-pharyngel swab to confirm the diagnosis of covid-19 at moderate and severe cases.
75748275|NCT05717738|Drug|Donafenib|200mg; p.o. bid
75748276|NCT05717738|Drug|Regorafenib|160 mg; p.o.; q.d.
75748277|NCT05715086|Procedure|Ureteroscopy|Upfront ureteroscopy
75748278|NCT05713994|Procedure|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
75748279|NCT05713994|Drug|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
75748280|NCT05713994|Drug|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
75748281|NCT05713994|Drug|Lenvatinib|8mg; p.o.; q.d.
75452535|NCT01740661|Other|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
75452536|NCT01740674|Other|Electronic data collection|
75452537|NCT01740700|Device|p-Branch®|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
75452538|NCT01740752|Behavioral|UCAN+CBT|weekly manualized couple therapy plus weekly manualized individual CBT
75748282|NCT05713994|Drug|Sorafenib|400mg; p.o. bid
75748283|NCT05713994|Drug|Donafenib|200mg; p.o. bid
75748284|NCT05713994|Drug|Regorafenib|160 mg; p.o.; q.d.
75748285|NCT05713994|Drug|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
75898683|NCT05202379|Drug|Placebo|Placebo capsules
75898684|NCT05202340|Other|No intervention|No intervention
75603671|NCT05940064|Drug|Zanubrutinib, Polatuzumab Vedotin, Rituximab|Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m^2 ivgtt D1
75603672|NCT05940051|Drug|Zanubrutinib, Polatuzumab vedotin and Rituximab|Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1
75748286|NCT05713994|Drug|Anti-PD-1 monoclonal antibody|HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
75748287|NCT05709860|Behavioral|EMC2 PrEP Educational Tool|Patients will receive an interactive PrEP Educational Tool. This interactive tool will be securely sent via the patient portal. After logging into their portal, patients will have the opportunity to review the information on their own time.
75748288|NCT05709860|Behavioral|Discrete Scheduling of a Dedicated PrEP Visit|Within the interactive PrEP Educational Tool, patients who choose to will have the opportunity to discretely schedule a dedicated PrEP visit with a primary care clinician trained on PrEP delivery. The clinician will have time reserved to allow for 'rapid' scheduling.
75748289|NCT05703399|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
75748290|NCT05703399|Other|Questionnaire Administration|Complete questionnaire
75748291|NCT05702138|Other|Physical therapy|The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
75748292|NCT05695573|Diagnostic Test|ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile|Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis
76065547|NCT04373785|Radiation|Intensity-modulated radiation therapy|Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
76065548|NCT04373785|Drug|Temozolomide|"Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles."
76065549|NCT04373785|Drug|NG101m|Oral NG101m capsule continuously twice daily.
75603673|NCT05939986|Behavioral|Virtual reality-based exposure treatment with multimodal feedback (VRET-M)|The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.
75603674|NCT05939986|Behavioral|Virtual reality-based exposure treatment with bimodal feedback (VRET-B)|The VRET-B group will experience visual and auditive cues in the exposure sessions.
75603675|NCT05939986|Behavioral|Imagery exposure treatment (IET)|The IET group will experience its own subjective imagined environment without any external stimulation.
75748293|NCT05683977|Drug|durvalumab|Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
75748294|NCT05682326|Drug|Daprodustat|Daprodustat will be administered up to Week 52.
75748295|NCT05674487|Device|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
75748296|NCT05674487|Drug|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
75748297|NCT05672511|Behavioral|Simulation Teaching Method|Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory. The control group will not receive any simulation training. Both groups will be given a knowledge test after teaching with simulation. Students in both groups will fill out a form evaluating their skills in performing the steps of vaginal examination before each vaginal examination is performed on women in the clinic.
76065550|NCT04367571|Other|Osteopathic Manipulative treatment (OMT)|"OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
76065551|NCT04367571|Other|Manual Placebo (MP)|"The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
76065552|NCT04366310|Device|capillary refill index|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
75452539|NCT01740752|Behavioral|CBT|"weekly manualized higher dose of individual CBT"
75452540|NCT01740765|Other|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
75452541|NCT01740830|Device|Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)|The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
75452542|NCT01740843|Device|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
75748298|NCT05667649|Biological|RB-ADSC|Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)
75603676|NCT05939973|Device|g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|The intent is to evaluate the safety and preliminary efficacy of a new Snowshoe suture placement pattern, POSE2.0 (sutures placed in the mid + distal body without fundus), with a moderate intensity diet and exercise program.
75603677|NCT05939960|Diagnostic Test|CGT test|GCT、PRP-CT、PPP-CT monitor
75603678|NCT05939934|Device|Mandibular advancement device treatment|a titratable thermoplastic mandibular advancement device will be proposed to patient in the experimental group during the 2 weeks of CPAP withdrawal.
75603679|NCT05939908|Other|Using Jamar Dynamometer for Grip Strength.|Hand grip strength as a marker by using JAMAR hand grip dynamometer in patients with T2DM.
75603680|NCT05939882|Drug|low concentration atropine (0.01%)|low concentration atropine (0.01%)
75603681|NCT05939882|Drug|low concentration atropine (0.02%)|low concentration atropine (0.02%)
76065553|NCT04366310|Procedure|rewarming|warming fingertip skin temperature using an instant hot pack
76065554|NCT04359563|Behavioral|Mindfulness-Based Intervention|"The MBI consists of four 2h online group sessions spread over eight weeks. In between sessions, online support will be offered to assist participants in their practice. Each session consists of guided mindfulness exercises (e.g., focus on the breath, body scan, breathing space, mindful yoga, insight meditation, walk meditation), sharing of experiences of these exercises, reflections in small groups, psycho-education (e.g., stress, depression, self-care), and review of home practices. An overview of core elements is given in Van der Gucht et al. (2017b).~The MBI is supported by homework assignments and audio material. Groups will include 5 participants, yielding 6 groups in total. The MBI will be delivered by highly qualified certified trainers with more than 10 years of experience in mindfulness meditation and extensive experience working with adolescents. Trainers will attend inter- and supervision moments on a regular basis to check treatment fidelity and trainer adherence."
76065555|NCT04357574|Other|Telehealth|patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
75603682|NCT05939882|Drug|low concentration atropine (0.04%)|low concentration atropine (0.04%)
75603683|NCT05939882|Drug|Placebo|Placebo eye drop
75603684|NCT05939843|Behavioral|Pain Coping Information|A three minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery)
75603685|NCT05939843|Behavioral|Mindfulness Practice (alone)|A 3-minute audio-guided mindfulness practice.
75603686|NCT05939843|Behavioral|Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to the practice of mindfulness followed by a 2-minute audio-guided mindfulness practice
75748299|NCT05660330|Behavioral|Holistic semi-tailormade well-being intervention|The holistic well-being intervention consists of a mandatory basic package that will take 2 half days and 1 full day to complete. In the first half day, the conclusion of the baseline measurement will be discussed, as well as the specific outline of the well-being thay. On the well-being day, three trained professionals from an HR service company, called Liantis, will guide these interventions (consisting of training and workshops) in the workplace. Only a small proportion of the company employees, called the ambassadors, will attend the well-being day. In the second half day, the ambassadors will be coached to disseminate the obtained information to the entire workplace. This information will be personalized according to the problems, needs and context of each company. Besides the basic package, an optional expertise package will be offered during this second half day. In the period afterwards, the ambassadors are followed every 2 months by means of a semi-structured interview.
75748300|NCT05656508|Biological|ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)|2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection
75748301|NCT05653219|Biological|Ianalumab|Concentrate for solution for infusion for intravenous use
75748302|NCT05653219|Drug|Eltrombopag|Film-coated tablet for oral use
75748303|NCT05653219|Drug|Placebo|Concentrate for solution for infusion for intravenous use.
75748304|NCT05651594|Procedure|Biopsy|Undergo tissue collection
75748305|NCT05651594|Procedure|Biospecimen Collection|Undergo collection of blood samples
75748306|NCT05651594|Procedure|Computed Tomography|Undergo CT scans
75603687|NCT05939843|Behavioral|Pain Introduction + Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to pain, followed by a 1-minute audio-recorded introduction the practice of mindfulness, followed by a 1-minute audio-guided mindfulness practice
75603688|NCT05939817|Biological|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
75603689|NCT05939817|Biological|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
75603690|NCT05939817|Drug|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
75748307|NCT05651594|Drug|Fluorouracil|Given IV
75748308|NCT05651594|Drug|Leucovorin|Given IV
75748309|NCT05651594|Drug|Oxaliplatin|Given IV
75748310|NCT05651594|Biological|Pembrolizumab|Given IV
75748311|NCT05651594|Drug|Propranolol Hydrochloride|Given PO
75748312|NCT05651594|Other|Questionnaire Administration|Perceived Stress Scale
75748313|NCT05650632|Drug|ABBV-383|Intravenous Infusion
75748314|NCT05649748|Drug|Treprostinil Palmitil|Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
76065556|NCT04317755|Behavioral|AdhaFULL body image comics|The comics were co-created with the expertise of four stakeholders: the investigators, UNICEF, BBC Media Action, and the Dove Self-Esteem Project. There are six different comics, which target issues relating to gender stereotypes and appearance concerns amongst adolescents in rural India. Based on 'Dove Confident Me', each comic tells a story which targets a specific established risk factor for body dissatisfaction. Specifically, they focus on gender prejudice (Comic 1), societal appearance ideals (Comic 2), media literacy (Comic 3), appearance comparisons (Comic 4), appearance-related conversations and teasing (Comic 5), and promoting 'body activism' (Comic 6). In each session, students will read the respective comic as a class. At the end of each comic, the teacher will facilitate one or two activities with the students based on the key learnings from the comics. These activities will encourage students to think critically about what they have read and consolidate their learning.
76065557|NCT04315545|Diagnostic Test|meal tolerance test|In addition to the standard oral glucose tolerance (which is normally performed between 24-28 weeks of pregnancy), is used to test the metabolic resilience capacity of glucose, we will provide our participants with a different diagnostic tool named 'meal tolerance test' in an earlier stage of pregnancy (12-16 weeks), mid pregnancy (24-28 weeks) and 3 months postpartum.
75603691|NCT05939778|Biological|TH-SC01(Umbilical cord mesenchymal stem cells)|"5+7 principle:~1. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject.~If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group.~If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step.~2. 7 subjects were included in the second step."
76065558|NCT04312997|Drug|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
75603692|NCT05939661|Radiation|Radiation|Neoadjuvant radiation therapy : 5Gyx5
75603693|NCT05939661|Drug|Chemotherapy|CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles
75603694|NCT05939661|Procedure|Surgery|Operation: Total methorectum excision wiht radical lymph node dissection
75603695|NCT05939583|Other|Shock Wave Therapy|Receiving Shock wave therapy + US, TENS, IR and exercises.
75603696|NCT05939583|Other|US, TENS, IR and exercises.|Receiving US, TENS, IR and exercises only.
75603697|NCT05939557|Procedure|Jones technique|is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)
75603698|NCT05939557|Device|Kinesiotape|KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
75603699|NCT05939466|Drug|Bedrocan®-type cannabis (22% THC, <1% CBD)|Decoction with 100 mg of Bedrocan®-type cannabis (22% THC, <1% CBD)
75748315|NCT05649748|Drug|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
76065559|NCT04312997|Drug|Placebo|Sterile saline for inhalation
75603700|NCT05939440|Other|Proactive Cost of Care (P-COC) intervention|As in Arm description
75603701|NCT05939440|Other|Usual Care|As in Arm description
75603702|NCT05939375|Behavioral|FCC educational training|An educational training, grounded in six weeks of nurse-centered interactions, was implemented.
75603703|NCT05939284|Drug|Injection of Cetrorelix|Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.
75603704|NCT05939284|Drug|Oral insertion of dydrogeserone|Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day
75603705|NCT05939271|Procedure|lower extremity amputation|"persons are defined as having a lower extremity amputation when an operation with removal of an extremity below the hips took place.~To identify those people with diabetes who underwent amputation, the following DBC's claims were extracted from the system: 038590; amputation upper leg, 038690; amputation lower leg, 038691; exarticulation of the lower leg, 038790; amputation of the tarsus, 038791; amputation or exarticulation of a toe, 038793; exarticulation of the foot, 038794; Chopart exarticulation, Lisfranc, respectively trans metatarsal amputation. Amputations were categorized into minor (038790, 038791, 038793, 038794) and major (038590, 038690,038691) amputations"
75603706|NCT05939206|Procedure|rTARUP|robotic assisted transabdominal retromuscular umbilical prosthetic repair
75603707|NCT05939180|Drug|Venetoclax Oral Tablet|VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.
75603708|NCT05939180|Drug|Daunorubicin|DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.
75748316|NCT05645432|Drug|Brexanolone|Brexanolone IV infusion
75748317|NCT05642988|Device|LifeSignals 1AX Biosensor|Biosensor worn by patients for 30-days after intra-abdominal or pelvic surgery on discharge from hospital
75898685|NCT05198375|Diagnostic Test|Lung ultrasound score (LUS)|LU score (LUS) will be performed between 1 and 3 hours of life. LUS will be calculated by performing longitudinal scans of the chest in the anterior (midclavicular line), lateral (anterior axillary line) and posterior (posterior axillary line) area bilaterally using high-frequency linear or micro linear (hockey stick) probe. A score from 0 to 3 will be assigned to each area based on the ultrasound detected pattern.
75748318|NCT05641987|Behavioral|Healthy Workplace Participatory Program|The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.
75748319|NCT05641324|Drug|ANV419|ANV419 administered by intravenous (IV) infusion
75603709|NCT05939141|Device|Genio System|"All participants have previously been implanted with a Genio® system implantable stimulator. This research is observational in nature (long term safety follow-up) and participants will not be exposed to additional procedures.~The Genio System comprises of a bilateral Implantable Stimulator (IS), which is implanted via a minimally invasive surgery procedure and positioned over the genioglossus muscle with its electrodes positioned over both the left and right hypoglossal nerve branches. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway. The Implantable Stimulator receives energy pulses transmitted via the DP placed under the patient's chin and connected to the Activation Chip (AC), which contains the patient's stimulation parameters and contain a battery that provides energy."
75603710|NCT05939115|Device|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
75748320|NCT05641324|Drug|Lenalidomide with low-dose dexamethasone|Lenalidomide and dexamethasone administered orally
75898686|NCT05190432|Dietary Supplement|Taxifolin|A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
75603711|NCT05939102|Combination Product|v-prep combined with RMGIC for bracket bonding|prepare the tooth surface with the V-prep, then bond a bracket with the RMGIC
75748321|NCT05641324|Drug|Daratumumab|Daratumumab administered by subcutaneous injection
75898687|NCT05190432|Dietary Supplement|Ergothioneine|An amino acid found in mushrooms, oats and some bean varieties.
75898688|NCT05190432|Dietary Supplement|Control|Microcrystalline cellulose.
75898689|NCT05167318|Other|frequent standardized oral care|Standardized oral care will be provided every 3-4 hours
75898690|NCT05161377|Procedure|Surgical management|Surgical clipping will be performed following randomization according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
75898691|NCT05161377|Procedure|Endovascular management|Endovascular treatment will also be performed following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents, flow-diverters, ISFD/WEBs or other innovative devices, as well as post- treatment medical management issues, will be left up to the physician performing the endovascular treatment and initial strategies determined prior to randomization.
75898692|NCT05149326|Drug|KN046|KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
75603712|NCT05939102|Combination Product|Conventional bracket bonding technique|prepare the tooth with acid-etch, then bond a bracket using resin composite
75603713|NCT05939089|Diagnostic Test|ECG, Echocardiography, cTnI, NT-ProBNP|All pediatric cancer survivors are evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.
75603714|NCT05939076|Device|Pulmonary vein isolation|Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation
75603715|NCT05939076|Drug|dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™|Antiarrhythmic drugs
75603716|NCT05939050|Device|Powered toothbrush|Oral-B Powered toothbrush
75748322|NCT05636124|Device|Kaneka i-ED coil|The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
75748323|NCT05634811|Biological|VLA15|6-valent OspA-based Lyme disease vaccine
75748324|NCT05634811|Other|Normal Saline|0.9% sodium chloride solution for injection
75748325|NCT05631041|Drug|Silymarin|participants in silymarin group will receive silymarin 140 mg once daily.
75898693|NCT05149326|Drug|placebo|placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
75898694|NCT05141760|Diagnostic Test|PSMA-1007 Positron Emission Tomography (PET) scan and 3T Magnetic Resonance Imaging (MRI)|Additional staging PET and MRI scan prior to prostatectomy and lymph node dissection
75748326|NCT05630690|Device|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
75748327|NCT05616221|Biological|AP-PA02|Bacteriophage administered via inhalation
75748328|NCT05616221|Other|Placebo|Inactive Placebo administered via inhalation
75898695|NCT05123131|Drug|Isatuximab|Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.
75898696|NCT05123131|Drug|Bortezomib|Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32.
75898697|NCT05123131|Drug|Lenalidomide|Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance [CrCl] ≥30 to <60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.
75748329|NCT05612490|Drug|Furosemide stress test|The FST corresponds to the intravenous single-dose administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. In the 12 hours following the first RRT liberation, a FST will be performed. The test will be considered positive if urinary output is ≥200 mL in the two hours following furosemide administration.
75603717|NCT05939037|Drug|Zanubrutinib Oral Product|Treatment will consist of Rituximab administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22 only (4 total infusions). The experimental part of the treatment will consist of Zanubrutinib, given once daily 320 mg (4 x 80 mg capsules). Although Zanubrutinib is taken continuously, therapy cycles are calculated per 28 days. Participants will be treated for a minimum of 6 cycles per protocol. Participants who still use Zanubrutinib at the end of study can continue indefinitely until registration and reimbursement in the Netherlands.
75603718|NCT05938998|Behavioral|Yoga; Support Group|BEHAVIORAL: Group Exercise Sessions- Yoga. BEHAVIORAL: Social Support Sessions
75603719|NCT05938985|Diagnostic Test|Questionnaires and dry eye tests|Ocular Surface Disease Index (OSDI), National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), best visual acuity (BCVA) measuring, intraocular pressure, corneal fluorescein staining, lissamine green staining, Schirmer test type I and II, tear breakup time (TBUT) and noninvasive tear breakup time (NIBUT).
75603720|NCT05938972|Biological|Mepolizumab|Monoclonal antibodies
75603721|NCT05938881|Procedure|self-cut mesh procedure|transvaginal mesh procedure using self-cut mesh
75603722|NCT05938881|Procedure|mesh-kit procedure|transvaginal mesh procedure using mesh-kit
75748330|NCT05610735|Drug|DOXIL|DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes first to a maximum of 10 cycles.
75748331|NCT05610735|Drug|Withaferin A|Ashwagandha in the form of tablets will be administered orally on daily basis.
75748332|NCT05610735|Drug|Ashwagandha|Administered orally on daily basis twice a day
75748333|NCT05610735|Drug|Combination of ASWD and DOXIL|DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
75748334|NCT05600777|Drug|BLU-5937|Oral administration of BLU-5937 Tablets
75748335|NCT05600777|Drug|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
76065560|NCT04309552|Drug|18F-FMISO PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
76065561|NCT04309552|Drug|18F-FLT PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
75603723|NCT05938868|Device|Low intensity pulsed ultrasound (LIPUS)|LIPUS will be delivered intra-orally using a probe applied on the buccal aspect of the implant site. The probe is in contact with the buccal attached gingiva with a thin film of intra oral gel intervening between them, acting as a transmitting medium. It will be applied twice a week for 20 minutes each session that commenced after surgery on the second day and continued for 10 weeks. The intensity of ultrasound therapy used was 30 mW/cm2 with a frequency of 1.5 MHz and temporal average power of 20 Mw
75603724|NCT05938868|Device|low level diode laser therapy|The patients will be irradiated with low level diode laser therapy (GaAs) (Chattanooga, model 27841, USA) .Patient will be irradiated with low level diode laser therapy with parameters: wavelength 850 nm and power of 200 mw in continuous mode will be applied in six points in non-contact method 10 mm away from the peri-implant soft tissue after suturing. The laser irradiations will be administered at six sites that included mesiobuccally, distobuccal, midbuccal, midlingual, mesial, and distal areas around implant for a duration of 10 seconds for each site. The total energy delivered was 6 J per session. And is based on a previous study by Gulati et al., 2020
75748336|NCT05599945|Drug|NNC0581-0001|Participants will receive up to four single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.
75748337|NCT05599945|Drug|Placebo|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.
75748338|NCT05599191|Drug|BLU-5937|Oral administration of BLU-5937 Tablets
75748339|NCT05599191|Drug|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
75748340|NCT05597917|Drug|Trabectedin|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
75748341|NCT05597917|Biological|tTF-NGR|Patients will receive standard trabectedin according to arm 1 plus the safe dose according to safety run-in part of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following days, q d 22 x until disease progression or contraindications against further application.
75748342|NCT05595577|Other|Exercise with Trainerize application|1-2 sessions per week consisting of slow 15 minute aerobic warm, 20 minutes of strength training, 15 minutes progressive intensity aerobic exercise and 10 minute cool down (stretching/toning) with elastic bands.
75748343|NCT05595577|Diagnostic Test|Cardiopulmonary exercise testing|Maximal peak VO2 (to monitor the body's oxygen consumption) and 6-minute exercise walking test.
75748344|NCT05595577|Diagnostic Test|MRI scan|Images of the heart will be taken.
75603725|NCT05938868|Other|Standard Care|Patients in all three groups will receive the standard care which includes: (1) Extra-oral ice packs during the first 2 days every two hour; (2) maintain daily routine oral hygiene after surgery; (3) Patients will be instructed to eat a soft diet for one weeks; (4) Broad spectrum oral antibiotics in a dose of one capsule every twelve hours for a week; (5) Non-steroidal anti-inflammatory drugs at a dose of one tablet every 8 hours for four days; (6) Warm chlorhexidine gluconate solution as a mouthwash for a period of 2 weeks to enhance plaque control.
75748345|NCT05595577|Behavioral|Quality of Life Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
75748346|NCT05595577|Behavioral|Cognitive and Brain Function Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
75748347|NCT05595577|Other|Blood draws|Approximately 2 teaspoons of blood withdrawn from either a vein in your arm or a currently placed central line port-a-cath. A portion of blood from each visit will be used to collect information about blood cell count.
75748348|NCT05592743|Drug|Vorasidenib|Oral therapy
75748349|NCT05592002|Device|Genio System|The Genio® IS electrode placement does not require an extensive surgical manipulation of the hypoglossal nerve, it requires only a single incision site and does not require battery replacements as those are external components. Whereas UPPP surgery and other similar upper airway enlargement surgeries are much more extensive, are irreversible and tend to have more complications and modest long-term results in reducing OSA severity and symptoms. In summary, the solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
75898698|NCT05123131|Drug|Dexamethasone (IV)|Dexamethasone (IV on the days of Isatuximab and PO on other days): 20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33. If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32.
76065562|NCT04309461|Behavioral|Stress Management Control|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
76065563|NCT04309461|Behavioral|Adapted MBC2 Program|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
75603726|NCT05938855|Device|Electrical stimulation and biofeedback group|10 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.
75603727|NCT05938842|Behavioral|Online DBT-Mindfulness Intervention|"The whole intervention exists of 10 sessions, one session a week for at least one hour and a half. The session 1 is tailored to address specific issues to people with MS, whereas the sessions 2 to 7 are based on DBT and mindfulness contents, and in sessions 7 to 10 introduced some contents of ACT. The program is based in teaching two different sets what and how (Linehan, 1993). The first skill what, teaches patients to simply observe; in a second level, to describe, which implies the ability to put the name to what one has observed; and in the third, what skill patients learn to fully participate in their actions in the current moment and without self-consciousness (Soler et al., 2012). In the other hand, the skills of how are related to how observe, how to describe and how to participate. Moreover, some mindfulness skills such as Observing the breath, Half-smiling, Awareness are practice introduced as homework tasks."
75748350|NCT05590078|Device|Virtual reality session|The 20-minute virtual reality session, in the outpatient department before surgery, immerses the patient in calm environments combined with music therapy and breathing exercises to relax and reduce anxiety.
75452543|NCT01740856|Other|Rest three hours|Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
75452544|NCT01740856|Other|Rest five hours|Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
75748351|NCT05590078|Other|State Trait Anxiety Inventory|"The State Trait Anxiety Inventory (State anxiety) is a questionnaire given to adults that shows how strong a person's feelings of anxiety are right now, just now. The score is measured on arrival in the outpatient department and just before going into the intervention room (= after the virtual reality session for the experimental group)"
75748352|NCT05590078|Other|Virtual Reality Satisfaction Score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding virtual reality session
75748353|NCT05590078|Other|Perioperative care satisfaction score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding perioperative care
75748354|NCT05589610|Drug|EQ101|EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses
75748355|NCT05583227|Biological|Tezepelumab|Tezepelumab subcutaneous injection
75748356|NCT05583227|Biological|Tezepelumab|Tezepelumab subcutaneous injection
75748357|NCT05583227|Other|Placebo|Placebo subcutaneous injection
75748358|NCT05581121|Other|Standard treatment: Control arm|Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations.
76065564|NCT04304508|Drug|BAY2433334|Tablet, taken orally once a day.
76065565|NCT04304508|Other|BAY2433334 matching placebo|Tablet, taken orally once a day.
75452545|NCT01740869|Other|Stem cells|
75452546|NCT01740908|Other|Hyperbaric Oxygen Treatment|"Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle.~All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days."
75748359|NCT05581121|Procedure|Experimental arm|Pre-therapeutic para-aortic lymphadenectomy followed by tailored chemo-radiotherapy and brachytherapy.
76065566|NCT04292145|Behavioral|Relaxation Application|The use of an application for relaxation.
76065567|NCT04292145|Behavioral|Relaxation Only|The individual's personal method to relax.
76065568|NCT04291560|Behavioral|Stretching Exercise Intervention|Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
76065569|NCT04291300|Drug|Lutetium-177-PSMA-I&T|4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
75452547|NCT01740921|Drug|Liraglutide|Administered once daily
75452548|NCT01740921|Other|diet|reduction of caloric intake to promote weight loss
75452549|NCT01740921|Drug|Aspirin|300mg of Aspirin per day
75452550|NCT01740934|Other|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
75452551|NCT01740934|Other|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
75452552|NCT01740947|Drug|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
75452553|NCT01740960|Drug|delta-9-tetrahydrocannabinol|During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
75452554|NCT01740960|Drug|Placebo|On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
75452555|NCT01740986|Drug|SA09012 Low dose|Tablet, b.i.d
75452556|NCT01740986|Drug|SA09012 High dose|Tablet, b.i.d
75748360|NCT05580991|Drug|CAN1012|CAN1012 IT injection (once every 4 weeks)
75748361|NCT05578872|Drug|ANV419|ANV419 administered by intravenous (IV) infusion
75748362|NCT05578872|Drug|Pembrolizumab|Pembrolizumab administered by intravenous (IV) infusion
75898699|NCT05108090|Procedure|sentinel lymph node biopsy (SLNB)|"Preoperative Lymphoscintigraphy: A standard injection of 2 mCi of 99m-Technetium sulfur colloid. Sequential immediate and delayed images will be obtained using SPECT/CT using a gamma probe. Ten-second counts will be done in areas of high activity to identify location of sentinel lymph node (SLN). After removal of the lymph node, a 10-second count will be done of the lymph node ex-vivo followed by 10-second count of the lymph node resection bed to ensure removal of SLN (less than 10% activity of LN).~Surgical resection: Mohs micrographic surgery followed by SLNB. Intraoperative margins around the tumor will be confirmed through frozen section analysis. Patients with planned free flap reconstruction, will undergo SLNB with intraoperative, frozen section analysis. If lymph node is positive, immediate completion neck dissection will occur."
75898700|NCT05101187|Drug|Olorofim|Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
76065570|NCT04288856|Drug|BIIB078|Administered as specified in the treatment arm.
75452557|NCT01740986|Drug|Placebo|Tablet, b.i.d
75452558|NCT01741025|Device|iFuse Implant System|Placement of iFuse implant system via surgery
76065571|NCT04275180|Drug|Argatroban|Argatroban plus standard medical treatment
76065572|NCT04271332|Drug|Arbaclofen|Arbaclofen tablet
76065573|NCT04271332|Drug|Placebo oral tablet|Manufactured to match Arbaclofen in size, shape, color and taste
76065574|NCT04268875|Device|Optical Coherence Tomography (OCT)|"The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same."
75452559|NCT01741025|Other|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
75452560|NCT01741038|Biological|AlloStim®|AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
75452561|NCT01741038|Procedure|cryoablation|percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
75748363|NCT05578872|Drug|Ipilimumab|Ipilimumab administered by intravenous (IV) infusion
75748364|NCT05571488|Other|Electronic surveys|Online questionnaires will be used to collect data, at recruitment and follow-up once a year
75748365|NCT05571488|Other|Qualitative Interviews|Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
75748366|NCT05570565|Procedure|Erector spinae plane block|ultrasound guided injection of local anesthestics drugs (mixture of lidocaine and bupivacaine) in the Erector spinae plane which lies between the Erector spinae muscle and lumbar transverse process
75748367|NCT05570565|Procedure|local field block|infiltration of local anesthestic drugs( mixture of lidocaine and bupivacaine) in the surgical field before surgical incision
75603728|NCT05938842|Behavioral|Online psychoeducational intervention|The active control group intervention will be based on a psycho-educational framework and will involve MS-related topics (Oz & Oz, 2020). The psychoeducational intervention will be conducted by a psychologist with experience in working with pwMS through group videoconference and will follow similar format as the DBT-Mindfulness intervention, except for the homework tasks. The participants will receive information about different aspects related to the disease (e.g., disease progression, disease-symptoms, stress management, nutrition, sleep hygiene, physical activity, social relationships). The content of the sessions of the psychoeducation program was created based on the current literature about MS. Similar psychoeducational programs were used in other studies before (Oz & Oz, 2020; Dowd et al., 2015).
75748368|NCT05567796|Drug|Cagrilintide|Cagrilintide will be administered subcutaneously.
75748369|NCT05567796|Drug|Semaglutide|Participants will recieve semaglutide subcutaneously.
75748370|NCT05567796|Drug|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide.
75748371|NCT05567796|Drug|Placebo semaglutide|Participants will receive placebo matched to semaglutide.
75748372|NCT05566756|Other|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
75748373|NCT05553353|Device|repetitive transcranial magnetic stimulation--Active|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
75748374|NCT05553353|Device|repetitive transcranial magnetic stimulation--Sham|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.
75898701|NCT05101187|Drug|AmBisome®|Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
75452562|NCT01741038|Other|Physician's Choice (PC)|Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
75452563|NCT01741051|Device|HEPA Filter|
75452564|NCT01741077|Dietary Supplement|folic acid|subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
75898702|NCT05073978|Other|No intervention|This is an observational study without any intervention
75603729|NCT05938829|Other|Ultrasound following the SMFM guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery. This information will be captured in our ultrasound reporting software, Viewpoint.
75452565|NCT01741090|Biological|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
75452566|NCT01741116|Drug|TKI258|Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
75452567|NCT01741129|Device|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
75452568|NCT01741129|Device|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
75452569|NCT01741142|Drug|ABT-436|Subjects receiving ABT-436
75748375|NCT05553223|Behavioral|Microdoses of activity|Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
75748376|NCT05548907|Behavioral|sleep restriction treatment|"Treatment consists of sleep restriction treatment for insomnia. In this treatment, participants limit their bedtimes to the time they actually sleep. If they sleep most of the time in bed again then bedtimes are slowly built up again. This treatment technique has already been studied in several trials and found to be effective.~Mode of delivery is an online booklet, online exercises and weekly telephone support"
75898703|NCT05065502|Behavioral|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better.[practice]."
75452570|NCT01741142|Drug|Escitalopram|Subjects receiving escitalopram
75452571|NCT01741142|Drug|Placebo|Subject receiving placebo
75452572|NCT01741168|Other|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
75748377|NCT05548907|Behavioral|sleep diary monitoring|As an active control condition people monitor their sleep with a sleep diary (also included in the sleep restriction intervention)
75748378|NCT05546645|Other|Questionnaire|Hypersecretion questionnaire
75452573|NCT01741168|Other|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
75452574|NCT01741181|Drug|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
75452575|NCT01741181|Drug|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
75452576|NCT01741207|Drug|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
75452577|NCT01741233|Genetic|VitDgen|
75452578|NCT01741285|Drug|Beclomethasone (QVAR)|Small particle treatment
75748381|NCT05533112|Other|Binaural Beat Stimulation|During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz
75748382|NCT05527379|Device|Virtual reality|"When the patient is ready to have the CIP procedure the tablet will be presented to him so that he can view and choose the immersive film that suits him best.~Before fitting the virtual reality helmet and the start of the film, the patient's anxiety will be evaluated by ENS on a scale of 0 to 10 . The patient's anxiety will also be evaluated at the end of the procedure.~The patient will be contacted by telephone by an investigator between D+1 and D+5 in order to reassess and remotely from the pose, his memorization of the gesture and to look for adverse events."
75748383|NCT05524883|Drug|DYNE-251|Administered by IV infusion, every 4 weeks
75748384|NCT05524883|Drug|Placebo|Administered by IV infusion, every 4 weeks
75748385|NCT05517044|Other|Nitrogen tent preacclimatization to high altitude|The participants assigned to the preacclimatization group spend a minimum of six hours during sleep, throughout the acclimatization period (four weeks preceding the expedition) in a nitrogen concentration tent (Hypoxico OHG, Traunstein, Germany) set to an environmental PO2 corresponding to an altitude of 2500 masl, with a progression to 5500 masl within 28 days in steps of 1000 m every seven days. Respiratory Polygraphy is used to detect periodic breathing, SpO2, and heart rate continuously during sleep and is performed before and after the designated preacclimatization period, and repetitively when increasing normobaric hypoxia in the group with nitrogen concentration tent preacclimatization.
75603730|NCT05938829|Other|Ultrasound following the ISUOG guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery, middle cerebral artery, and ductus venosus. This information will be captured in our ultrasound reporting software, Viewpoint.
75603731|NCT05938179|Drug|HS-10353 30mg oral capsules|HS-10353 30mg oral capsules
75603732|NCT05938179|Drug|HS-10353 50mg oral capsules|HS-10353 50mg oral capsules
75748386|NCT05516563|Other|EDucation and eXercise intervention|"The exercise programme includes 3 key streams:~Low-load isometric abduction~Functional loading~Abductor loading: Graduated abductor loading, designed to improve load tolerance by applying progressively higher loads across the abductor muscles. Daily exercise will be completed three days a week at a 'hard' to 'very hard' level, alternating with three 'light' days and one rest day. The clinic day will constitute one of the 'hard' days.~Education will be delivered via a 20 minute video which focusses on understanding and managing lateral hip pain ( ie pain associated with gluteal tendinopathy). Education will also be tailored to each patient on attendance with the physiotherapist at the 6 clinic visits"
75748387|NCT05516498|Drug|Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
75748388|NCT05516498|Drug|Part A: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
75748389|NCT05516498|Drug|Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
75748390|NCT05516498|Drug|Part B: placebo (matching zibotentan capsule) + dapagliflozin|"placebo capsule (matching zibotentan capsule)~dapagliflozin tablet"
75603733|NCT05938179|Drug|Placebo for HS-10353 30mg capsules|Placebo for HS-10353 30mg capsules
76065575|NCT04267978|Drug|recombinant human endostatin,temozolomide,irinotecan|"Temozolomide was given orally 200mg/m2 for 5 days in each cycle. Day 1 TMZ was administered 3-6 hours prior to irinotecan.~Irinotecan was administrated 125mg/m2 on day 1 and day 15. Recombinant human endostatin was administrated 15mg/d, daily for 14 days. One treatment cycle was defined as 28 days (4 weeks), even if treatment is held mid-cycle for toxicity.~Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.~The maximum number of treatment cycles was 12. After 12 cycles of treatment, if the investigator judges that the subject may continue to benefit from the regimen, the duration of treatment may be extended with the subject's consent."
75603734|NCT05938179|Drug|Placebo for HS-10353 50mg capsules|Placebo for HS-10353 50mg capsules
75603735|NCT05938166|Device|oral care augmented reality (AR)|Augmented reality (AR) is an extension of perceptible reality, whereby additional information, such as texts or virtual objects, can be displayed in the user's field of vision.The oral care augmented reality (AR) simulation training can train foreign care workers by switching languages (Indonesian) and therefore reduce language-related learning barriers.
75748391|NCT05516498|Drug|Part B: zibotentan (dose A) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
75898704|NCT05065502|Behavioral|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
76065576|NCT04250233|Device|Respiratory Monitor|All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.
76065577|NCT04230252|Drug|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
76065578|NCT04206332|Drug|VRC-MALMAB0100-00-AB|VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
75603736|NCT05938049|Device|IVC ultrasound & Carotid doppler|"bed side ultrasonographic assessement of inferior vena cava maximum and minimum diameters 2 to 5 cm caudal to its junction with the right atrium over a single respiratory cycle , inferior vena cava collapsibility index (IVC-CI) will calculated as (IVC max - IVC min)/IVC max).~carotid doppler assessment (2-3 cm proximal to the carotid bulb in the longitudinal plane) of corrected carotid flow time(systole time/√cycle time) ,carotid artery peak velocity variation calculated as ([PV max- PV min]/PV mean) × 100, where PV mean = (PV max + PV min)/2. during three consecutive respiratory cycles. as part of their routine care and assessment"
75603737|NCT05937737|Behavioral|Type 2 Diabetes Diet Modification|A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.
75603738|NCT05937282|Drug|Dexmedetomidine|Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.
75603739|NCT05937282|Drug|Propofol|Patients will receive propofol infusion in the dose of 3 mg/kg/hr. 25 ml propofol 1% (10 mg /ml) in 50 ml syringe pump.
75603740|NCT05937282|Drug|Lidocain|Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr.25 ml lidocaine 1% (10 mg/ml) in 50 ml syringe pump.
76065579|NCT04206332|Other|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
75603741|NCT05937282|Drug|normal saline|Patients will receive infusion of 25 ml normal saline in 50ml syringe pump (control group).
75603742|NCT05936814|Procedure|total knee arthroplasty|cemented bicondylar PCL substituting total knee replacement
75603743|NCT05936268|Drug|Genakumab for injection|150 mg/1ml/bottle
75603744|NCT05936268|Drug|Colchicine|0.5mg/table
75603745|NCT05935787|Drug|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 15 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 25 days
75603746|NCT05935787|Drug|Placebo|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 15 days + Placebo, 2 tablets 2 times a day, for 25 days
75603747|NCT05933642|Drug|Aminophylline|aminophylline 150mg
75603748|NCT05933642|Drug|Frusemide|frusemide 120mg
75603749|NCT05933226|Behavioral|Khanya|"Khanya is a peer-delivered, behavioral intervention to improve HIV medication adherence and reduce problematic SUD symptoms. Participants will either receive Khanya Step 1 or if they continue to struggle with ART adherence, they will be stepped up to the more intensive intervention, Khanya Step 2."
75603750|NCT05933109|Behavioral|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound S1 is associated with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, the investigators want to accelerate the remission of traumatic nightmares and PTSD symptomatology.
75748392|NCT05516498|Drug|Part B: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
75748393|NCT05516498|Drug|Part B: zibotentan (dose C) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
75748394|NCT05513534|Other|Yoga|A standard yoga program will be provided using Hatha poses.
75748395|NCT05513534|Other|High-speed Resistance Training|Each session will consist of three sets of 10 repetitions each with 1.5 to 2-minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds
75748396|NCT05513261|Diagnostic Test|High definition colonoscopy (standard colonoscopy) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply the standard colonoscopy without computer-aided colonoscopy (polyDeep)
76065580|NCT04189263|Other|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day)
76065581|NCT04189263|Drug|standard of care aromatase inhibitors|standard of care aromatase inhibitors
76065582|NCT04174157|Other|Prospective observational registry|This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
76065583|NCT04174157|Drug|Zolgensma|Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
76065584|NCT04170426|Biological|autologous adipose derived stem cells|Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
75452579|NCT01741285|Drug|Beclomethasone (Clenil)|Course particle beclomethasone
75452580|NCT01741285|Drug|Fluticasone|Course particle treatment
75603751|NCT05933109|Behavioral|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without association with the sound S1.
75748397|NCT05513261|Diagnostic Test|PolyDeep assisted high definition colonoscopy (CAD system) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply polyDeep assisted high definition colonoscopy (CAD system).
75898705|NCT05051501|Dietary Supplement|Probiotics C2P|Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.
75898706|NCT05027451|Drug|IXT-m200|Anti-methamphetamine chimeric monoclonal antibody (mAb)
75898707|NCT05027451|Other|Placebo|Normal saline
75452581|NCT01741298|Behavioral|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
75452582|NCT01741324|Dietary Supplement|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
75452583|NCT01741324|Dietary Supplement|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
75452584|NCT01741324|Dietary Supplement|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
75452585|NCT01741337|Procedure|Adaptive servo-ventilation post-operative treatment for 6 months|
75452586|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-day sampling|Collect two stool samples in two separate days
75603752|NCT05932251|Drug|Metformin|All patients are diagnosed with gestational diabetes and treated with metformin (per routine clinical practice
75452587|NCT01741363|Other|FIT(Eiken OC-Sensor) One-year interval|Screening with one-year interval
75603753|NCT05932173|Biological|Anti-CD19 Autologous CAR-T Cell Infusion|Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform
75603754|NCT05932108|Behavioral|Education in TERMA|"Education of staff in TERMA. The primary aim of TERMA is to prevent aggression and violence through a system of low-effective treatment that is divided into escalating levels based on the patient's aggression level, risk of violence, and acts of violence . The TERMA model focuses on treatment, communication, and management of compassionate healthcare in forensic psychiatric settings . The levels of the TERMA model are in a cascading order, whereby if the treatment and management of one level are ineffective, the next level is initiated, and so on. The primary level involves the daily behavior and health status of the patient. The secondary level involves risk assessment and violence management, with a focus on creating an understanding of the situation for both the patient and healthcare workers. The tertiary level is utilized when violence cannot be avoided . Each level corresponds to a specific response according to the demands of the situation and environment."
75898708|NCT05024045|Drug|LOXO-338|Oral
75898709|NCT05024045|Drug|Pirtobrutinib|Oral
75898710|NCT05019339|Behavioral|Healthy HomeStyles|Comparison of 2 educational interventions
75898711|NCT05019339|Behavioral|Eat Healthy Be Active|Comparison of 2 educational interventions
75452588|NCT01741363|Other|FIT(Eiken OC-Sensor) One-day sampling|One-day sampling
75452589|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-year interval|Screening with two-year interval
75603755|NCT05932108|Other|Changed work routines based on TERMA|NO planned intervention but staff work routines and behavior may change after their education in TERMA. Patients are exposed to these changes.
75898712|NCT05001958|Behavioral|Action observation|Participants will view a video of a task performed by a non-disabled actor and then the participants perform the task from the video with their weaker arm & hand.
75898713|NCT05000047|Device|3D ear scanner|A commercially-available ear scanning device used according to standard of care. A hand-held device is used and is considered less invasive than conventional earmold impressions.
75898714|NCT05000047|Other|Conventional silicon ear impressions|A two part silicon impression material that is used to fill the ear and produce a physical cast of the ear canal. The procedure is standard of care.
75898715|NCT04996420|Device|Clearsight non invasive hemodynamic monitoring|Goal directed fluid therapy fuided by Clearsight monitoring
76065585|NCT04159194|Other|Control Diet|Players during the control trial will be instructed to maintain their normal food intake (~55% CHO) and the type and amount of ingested food will be recorded.
76065586|NCT04159194|Other|Experimental Diet|The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
76065587|NCT04157192|Other|Real acupuncture|The patient will be treated for migraine with real acupuncture.
75603756|NCT05928520|Drug|Tramadol 5%|Topical tramadol 5%
75603757|NCT05928520|Drug|Lidocaine 2%|Topical Lidocaine 2%
75748398|NCT05505214|Drug|Bacterial decolonization|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
75748399|NCT05505214|Drug|Mometasone furoate 0.1% cream|Mometasone furoate 0.1% cream to be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
75748400|NCT05505214|Drug|Bacterial decolonization and Mometasone furoate 0.1% cream|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT. Also, mometasone furoate 0.1% cream will be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
75748401|NCT05496595|Drug|DCBY02|A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
75748402|NCT05495386|Device|Hyposafe hypoglycaemia notification device (H02)|"The H02 device consists of two parts:~An implantable part which records the EEG signal and transmits the signal wirelessly to the external device.~The external device receiving signals and storing data from the implant."
75748403|NCT05493566|Biological|Aldesleukin|Given SC
75748404|NCT05493566|Biological|Pembrolizumab|Given IV
75748405|NCT05492513|Behavioral|Grade 1 CI Therapy +Sensory Components|All participants will receive Grade 1 CI Therapy + Sensory Components over a two-week period of time. The treatment intervention will include all CI Therapy treatment strategies including: 1) supervised motor training in the form of shaping with repeated trials and task practice for 3.5 hours per day for 5 weekdays for 2 weeks 2) a behavioral Transfer Package (TP) will be employed to aid carry-over of skills gained by the participant in the laboratory to the life situation 3) each participant will wear a mitt on the less-affected hand for most of their waking hours to encourage use of the more-affected hand 4) participants will be given home assignments to be carried out for at least 30 minutes each day. Sensory component strategies will be added to stimulate sensory input through the more-affected arm and hand as well as to train sensory discrimination skills.
75748406|NCT05488678|Drug|VNRX-7145|single oral dose
75748407|NCT05488678|Drug|Ceftibuten|single oral dose
75898716|NCT04974047|Drug|Tislelizumab|Administered intravenously as specified in the treatment arm.
75898717|NCT04920942|Drug|Ivermectin 0.4mg/kg/day for 5 days|Ivermectin 0.4mg/kg/day for 5 days with standard-of-care
75898718|NCT04911530|Other|no intervention|no intervention
75898719|NCT04875169|Drug|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
75898720|NCT04875169|Drug|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
75452590|NCT01741363|Other|HpSA (Firstep Helicobacter pylori Antigen Rapid Test)|HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
75452591|NCT01741376|Drug|Progesterone|Progesterone 200 mg twice daily
75452592|NCT01741376|Drug|Placebo|
75452593|NCT01741389|Drug|"Melatonin (Circadin)"|
75452594|NCT01741402|Device|Virtual Reality Training|The participants of the study trained 10 balance games during 14 sessions
75452595|NCT01741402|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
75603758|NCT05927441|Device|DragonFly Transcatheter Mitral Valve Repair System|Edge-to-edge repair with DragonFly System
75452596|NCT01741415|Behavioral|SIDI|
75603759|NCT05927324|Behavioral|CAVEAT|Brief psychotherapy with mothers of infants and young children, to which infants and young children attend many but not all sessions with mother
75603760|NCT05924048|Other|Reducing the Oxygen Concentration From 5% to 2%|Effect of Reducing the Oxygen Concentration From 5% to 2% in arm 1.
75603761|NCT05923411|Drug|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
75603762|NCT05923411|Drug|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
75603763|NCT05923411|Drug|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level
76065588|NCT04157192|Other|Sham acupuncture (placebo group)|Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine. In this study, the subjects will not know whether they are getting true acupuncture or not. In the placebo group, the acupuncture needles will not actually be inserted into the skin. Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin). The patient should not be able to feel the difference between real acupuncture and sham acupuncture.
76065589|NCT04155398|Procedure|EUS elastography|A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
76065590|NCT04152343|Device|RFA Physics Library -- a Planning and Guidance Platform (PGP)|Research software used to support liver RFA of HCC lesions >2cm
75452597|NCT01741415|Behavioral|SC|
75603764|NCT05923411|Drug|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
75603765|NCT05923411|Drug|Single dose of PF-07220060 as a Tablet Formulation|A single dose of PF-07220060 as a tablet formulation administered under fed conditions
75748408|NCT05487248|Other|Blood Sample Collection|"For subjects receiving treatments with a 2- or 4-weekly schedule, blood samples for ctDNA testing will be collected at the following timepoints:~Before treatment start (day 1)~2 weeks after treatment start (day 15)~4 weeks after treatment start (day 29)~8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e., at the same time of each imaging tumour assessment)~For subjects receiving treatments with a 3-weekly schedule, blood samples for ctDNA testing will be collected at the following timepoints:~Before treatment start (day 1)~3 weeks after treatment start (day 22)~6 weeks after treatment start (day 43)~8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e., at the same time of each imaging tumour assessment)"
75603766|NCT05923411|Drug|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|Single dose of PF-07220060 tablets under fasting conditions and under Proton Pump Inhibitor (PPI) administration (following a 7 day oral rabeprazole tablets daily administration).
75603767|NCT05923411|Drug|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|Single dose of PF-07220060 tablets given with high-fat, high-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)
75603768|NCT05923190|Drug|Enfortumab vedotin|EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
75748409|NCT05482802|Behavioral|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
75748410|NCT05482802|Behavioral|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
75603769|NCT05923190|Drug|Pembrolizumab|Pembrolizumab will be administered on day 1 of a 21-day cycle
75603770|NCT05922657|Device|Cerene|Real world use of Cerene.
75603771|NCT05919173|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution|Bupivacaine Hydrochloride 0.25% Injection Dose: 1mL/kg (milliliter per kilogram body weight)
75603772|NCT05919173|Drug|Bupivacaine Hydrochloride 0.25% Injection plus Dexmedetomidine 1 microgram/kg body weight|Bupivacaine HCL 0.25% Injection plus Dexmedetomidine 1micro/kg Dose: 1 mL/kg (milliliter per kilogram body weight)
75603773|NCT05911776|Drug|Nasal packing Dexmedetomidine|patients will receive nasal packing Dexmedetomidine (1.5 mg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
75603774|NCT05911776|Drug|Intravenous Dexmedetomidine|patients will receive 0.5 mg/kg bolus over 10 min then 0.1- 0.4 mg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
75603775|NCT05910580|Behavioral|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|See SBIRT arm description.
75748411|NCT05481879|Drug|DYNE-101|Administered by IV infusion
75748412|NCT05481879|Drug|Placebo|Administered by IV infusion
75748413|NCT05471128|Procedure|Standard of Care Biopsy|Patients will be evaluated with multiparametric MRI prostate followed by ExactVu micro-ultrasound to identify target lesions all of which will be biopsied by the examiner
75603776|NCT05908747|Drug|surufatinib + gemcitabine + nab-paclitaxel|surufatinib: 250mg, QD po; nab-paclitaxel: 125mg/m2, I.V., D1/8/15, Q4W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1/8/15, Q4W
75452598|NCT01741428|Behavioral|Intervention (INT1)|"The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)"
75452599|NCT01741441|Procedure|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
75748414|NCT05469945|Device|Compressive garments class II|Daily wearing of compressive garments, especially during prolonged standing upright or strenuous activities.
75748415|NCT05468359|Drug|Atezolizumab|Atezolizumab intravenously, every 3 weeks, Day 1
75748416|NCT05468359|Drug|Sorafenib|Sorafenib by mouth every 12 hours, Days 1-21
75748417|NCT05468359|Drug|Bevacizumab|Bevacizumab intravenously, every 3 weeks, Day 1
75603777|NCT05908240|Other|Care Coordinator Model|A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
75452600|NCT01741467|Behavioral|RT-CGM|Dexcom Seven+
75452601|NCT01741493|Drug|ABT-494|Oral administration of ABT-494 capsules
75603778|NCT05904808|Drug|IV Furosemide|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus
75452602|NCT01741493|Drug|Placebo|Oral administration of placebo capsules
75452603|NCT01741493|Drug|Tofacitinib|Oral administration
75452604|NCT01741506|Drug|Dalteparin (Fragmin®)|
75603779|NCT05904808|Drug|IV Furosemide and PO Metolazone|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus +5mg PO Metolazone
75898721|NCT04875169|Drug|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
75898722|NCT04875169|Drug|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
75898723|NCT04875169|Drug|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
76065591|NCT04152239|Procedure|Motorized spiral enteroscopy (MSE)|Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
75452605|NCT01741519|Drug|LDLL600|Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
75748418|NCT05468359|Drug|Cyclophosphamide|Low-dose cyclophosphamide by mouth once daily, Days 1-21
75452606|NCT01741519|Drug|Brevibloc|Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
75452607|NCT01741558|Drug|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
75603780|NCT05904808|Drug|IV Furosemide and IV Acetazolamide|"Furosemide would be given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus.~500mg IV Acetazolamide would be given in 100cc of saline over half an hour"
75603781|NCT05899426|Other|motor learning based clinical pilates|The exercises will be created as function and goal. At least one stimulus will be given during each exercise (visual, tactile, auditory or vestibular). 3 different levels were determined for 3 months of treatment, according to the months. As the level increased, the intensity of the exercise increased. In general, the exercise intensity was increased according to the against gravity and the decreasing in the support area.
75603782|NCT05899426|Other|Conventional Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
75603783|NCT05897931|Other|Connective tissue massage|Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
75603784|NCT05897931|Other|Kinesio Tape Application|"Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib."
75898724|NCT04873505|Dietary Supplement|troches|Take one troche after each meal.
75898725|NCT04866342|Device|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA). By means of a modified closed-loop algorithm, the devise uses MasimoSET or Nellcor pulse oximetry to target a user-set SpO2 value.~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
75898726|NCT04844034|Dietary Supplement|High-EPA multinutrient supplement.|"Three capsules with the largest meal of the day providing:~1,125 mg EPA~441 mg DHA~330 mg Magnesium~7.5 mg a-tocopherol"
75898727|NCT04844034|Other|Placebo|"Three capsules with the largest meal of the day providing:~3,060 mg sunflower seed oil~60 mg lecithin~300 mg glyceryl monostearate~465 mg EPA/DHA (18%/12% respectively for blinding)"
75452608|NCT01741558|Drug|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
75603785|NCT05897502|Behavioral|multimedia education|"The experimental group use multimedia education, 20 minute nutrition education courses each time, a total of 8 courses.~The control group use routine education."
75748422|NCT05467150|Dietary Supplement|Probiotic Supplement|The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
75748423|NCT05462613|Other|quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
75452609|NCT01741571|Device|EBUS guided FNA with and without suction|"Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied."
75452610|NCT01741584|Behavioral|stationary bike exercise|
75452611|NCT01741584|Behavioral|aerobic|
75452612|NCT01741597|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
75452613|NCT01741597|Other|pharmacological study|Correlative studies
75452614|NCT01741597|Biological|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
75452615|NCT01741610|Biological|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
75452616|NCT01741623|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
75748424|NCT05462613|Procedure|Blood sample|Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
75748425|NCT05462613|Drug|Regorafenib|"- Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
75748426|NCT05462613|Drug|Metronomic chemotherapies|"Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~Cyclophosphamide: 50 mg per os, daily, for two months"
75748427|NCT05462613|Drug|Aspirin|75 mg orally and daily during two months
75748428|NCT05462613|Drug|Bevacizumab|5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
75452617|NCT01741623|Drug|Bisoprolol|10 mg tablet once a day
75748429|NCT05462613|Drug|FOLFIRI or FOLFOX|every 2 weeks according to investigator practice
75452618|NCT01741636|Other|educational intervention|Undergo Survivorship Care Planning
76025311|NCT05404997|Other|Maitland's lumbar mobilizations|"Subjects in Group B will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes.~After the conventional treatment, Group B will be given Maitland's lumbar postero-anterior glide mobilizations initiating from Grade 1, with 3-4 sets of oscillations of 40 counts in each set, 2 sets of oscillations will be given below and above the affected joint level.This whole mobilization treatment will also be given twice a week for 10 minutes."
75603786|NCT05896280|Procedure|EST|Stones are taken by cutting the papillary sphincter
75748430|NCT05452668|Device|Laser Therapy|- Laser will be applied with the specified wave length using a diode laser device over 4 consecutive days.
75748431|NCT05452668|Device|Sham procedure|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current Protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
75748432|NCT05451004|Other|Lymphatic Mapping with SPECT-CT|Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
75748433|NCT05451004|Radiation|Ipsilateral and Contralateral Neck|Radiotherapy
75603787|NCT05896280|Procedure|ECPP|During ERCP, a generous biliary sphincterotomy (>1 cm) will be performed to facilitate large stone extraction by use of a lithotripsy basket and a stone extraction balloon. After all stone fragments were cleared from the bile duct, this group will undergo ECPP after EST. A single-pigtail biliary stent will be placed (suspended overlength biliary stent, 7F × 20 cm). Then the rotatable repeatable opening and closing of soft tissue clamps (referred to as harmony clips, Mico-Tech, ROCC-D-26-195) should be applied to extend the bile duct axially, linear clamp the incised duodenal papilla, taking care to avoid clamping the bile duct stent, and removing the bile duct stent 3 weeks after ECPP.
75603788|NCT05895721|Other|Virtual Reality|Virtual Reality as adjunct treatment
75748434|NCT05444257|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
75748435|NCT05438407|Drug|Leniolisib|The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
75748436|NCT05407363|Procedure|ABB and ATG with simultaneous implant placement|Ridge augmentation using ABB and ATG as a graft material with simultaneous implant placement
75748437|NCT05407363|Procedure|XBB and ATG with simultaneous implant placement|Ridge augmentation using XBB and ATG as a graft material with simultaneous implant placement
75748438|NCT05407363|Procedure|ABB and ABG with simultaneous implant placement|Ridge augmentation using ABB and ABG as a graft material with simultaneous implant placement
75748439|NCT05402293|Diagnostic Test|Blood samples to measure lidocaine levels|Blood sampling is the only intervention Plasma samples will then be analyzed for lidocaine concentration
75748440|NCT05392946|Drug|Bortezomib|Given SC
75452619|NCT01741636|Other|questionnaire administration|Ancillary studies
75452620|NCT01741636|Procedure|quality-of-life assessment|Ancillary studies
75452621|NCT01741649|Procedure|Clorhexidine|Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
75452622|NCT01741649|Procedure|Povidone|Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
75452623|NCT01741662|Other|neuropsychological evaluation|
75452624|NCT01741675|Behavioral|Questionnaire and monetary incentive|
75452625|NCT01741675|Behavioral|Questionnaire only|
75452626|NCT01741714|Other|Sham chiropractic manipulative therapy|Sham manipulation
75748441|NCT05392946|Biological|Daratumumab|Given SC
75748442|NCT05392946|Drug|Dexamethasone|Given PO
75748443|NCT05392946|Drug|Iberdomide|Given PO
75748444|NCT05384626|Drug|NVL-655|Oral Tablet of NVL-655
75748445|NCT05382299|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
75748446|NCT05382299|Drug|Paclitaxel|Administered intravenously
75748447|NCT05382299|Drug|nab-Paclitaxel|Administered intravenously
75748448|NCT05382299|Drug|Gemcitabine|Administered intravenously
75748449|NCT05382299|Drug|Carboplatin|Administered intravenously
75452627|NCT01741714|Other|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
75603789|NCT05891782|Behavioral|HAPA-based multicomponent fall intervention|"According to the HAPA and the conceptual model of IC, this intervention consists of 3 phases: pre-intention phase → intention phase → action phase.~The pre-intention phase: Group lectures will be used, and the intervention is conducted from week 1 to week 3, with a frequency of 2 times per week and a duration of 30-45 minutes per intervention.~The intention phase: Individualized plans will be used, and the intervention is week 4, with an intervention length of 20-30 minutes. By designing action goals and plans in exercise, daily habits, and external improvements, the intention of the study subjects to manage fall risk is clarified.~The action phase: face-to-face interviews will be used, and the intervention keep from week 5 to week 16. It is supplemented with the text tool Tumbler: A Falls Risk Management Manual for Older Adults in Nursing Homes to assist participants in removing barriers to action and increasing their subjective motivation to change health behaviors."
75748450|NCT05378737|Drug|BAT8006 for Injection|Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30~120 minutes.
75748451|NCT05372497|Other|Intervention group (IG)|"Participants randomized to this treatment will receive a central nervous system-focused intervention consisting of a 20-session treatment program delivered in 30-45-minute sessions scheduled 5 days a week over a 4-week period and standard physical therapy will be continued.~Chronic pain training will be given according to the needs of the person and 5-10 minutes will be allocated every day for the first week and chronic pain education will be divided into modules.~Right / Left Discrimination Training~Localization Training Level 1- Level 2 Training~Visual imagination Training~Visual Imagery Training~Mirror Therapy~Isometric and functional exercises"
75748452|NCT05372497|Other|Control group (CG)|"The control group will receive only conventional physiotherapy. Conventional physiotherapy will be 5 days a week.~The conventional physiotherapy treatment session will take place as follows.~Electrotherapy~Scapular mobilization~Passive stretches~Stick Exercises~Pendulum Exercises~Shoulder flexion, extension, internal rotation, external rotation, horizontal abduction/ adduction strengthening exercises~Conventional physiotherapy intervention is planned for 45-60 minutes a day, five days a week for both groups."
75748453|NCT05370391|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|The CBIT (or CBIT-JR) intervention consists of a minimum of 6 sessions of 50-minutes each week in an individual or group setting.
75748454|NCT05368402|Drug|Ladarixin|The two daily oral doses of ladarixin (400 mg each dose) will be administered at about a 12-hour interval (morning and evening; ideally between 6:30/11:30 and 18:30/23:30). At each administration, 2 capsules will be swallowed with a glass of water, at least 2 hours apart from breakfast or dinner
75748455|NCT05368402|Other|Placebo|Placebo will be administered with the same ladarixin schedule.
75748456|NCT05362903|Other|Inclisiran|Prospective observational cohort study. There is no treatment allocation. Patients administered Inclisiran by prescription will be enrolled.
75748457|NCT05360329|Procedure|Transarterial geniculate artery embolization|The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
75748458|NCT05354544|Biological|Autologous adipose derived SVF|A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.
75898728|NCT04840134|Behavioral|From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk|"The intervention will be delivered in two consecutive phases:~Intensive Intervention Phase (week 1-9), including 9 weekly peer-led group sessions (90min) and four one-on-one coaching sessions (60min); and~Follow-up Intervention Phase (weeks 10-24),consisting of 3 monthly group sessions (90min) and bi-weekly phone check-ins to provide ongoing support (15-20min).~Key intervention components:~Peer-led group sessions include personal stories of financial empowerment; practical information about available financial supports; basic financial coaching and mutual support/ accountability (e.g., goal/action check-ins);~One-on-one peer coaching sessions (throughout 24 weeks) to help participants identify their personal financial stressors and facilitate a personalized Financial Wellness Action Plan.~Support to navigate and access financial supports in the community (e.g., financial counseling, free tax prep, housing eviction prevention, debt relief)."
75898729|NCT04821687|Drug|Ongentys 50mg|Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI
75898730|NCT04821687|Drug|Madopar Tab. 125 or Perkin Tab. 25-100mg|Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
75748459|NCT05350930|Other|Assessment of patient satisfaction regarding tele-consultation|Questionnaire completed following the teleconsultation, if applicable.
75748460|NCT05350930|Other|Literacy questionnaire|Questionnaire completed during hospitalization for the first chemotherapy cycle
75748461|NCT05350930|Other|Collection of socio-demographic characteristics|Questionnaire completed during patient hospitalization for the first chemotherapy cycle
75748462|NCT05350930|Other|Assessment of patient knowledge on chemotherapy side effects and support medications|Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
75748463|NCT05350930|Other|Assessment of patient satisfaction on pharmaceutical follow-up|Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
75748464|NCT05344469|Other|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.
75452628|NCT01741727|Drug|ABT-414|ABT-414 will be administered by intravenous infusion.
75452629|NCT01741753|Drug|BKM120|Orally, every morning
75452630|NCT01741753|Drug|Abiraterone|Orally, 1000 mg, every morning
75452631|NCT01741753|Drug|Prednisone|Orally, 5 mg, every morning
75452632|NCT01741766|Other|Stretching Training|The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
75748465|NCT05344469|Other|glatiramer acetate|There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.
75748466|NCT05344469|Other|interferon β1|There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.
75748467|NCT05337696|Procedure|Vertebral Implant PEEK Procedure|Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure. Two VIP devices are implanted in each to be treated vertebra. A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall. A part of the implant is embedded into the pedicle, thus providing posterior support. The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate. The combination of the implant and the cement allows the treatment of vertebral fractures.
75452633|NCT01741779|Other|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
75452634|NCT01741779|Other|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
75452635|NCT01741779|Other|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
75452636|NCT01741805|Other|Severe Asthma|Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
75748468|NCT05337696|Device|Vertebral Implant PEEK (VIP) implant|The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5. It is intended to be used in combination with PMMA bone cement.
75452637|NCT01741818|Other|Measuring IVC collapsibility index by bedside ultrasonography|
75603790|NCT05891782|Behavioral|Regular health education lectures|Conduct regular health education lectures and distribute relevant materials in paper or electronic form. At the same time, follow-up visits is conducted once a month by phone, WeChat or face-to-face, with each visit lasting at least 25-30 minutes. We will understand the questions and needs of the study participants in multiple ways, and provide answers and support. Weekly bulletin board with information about falls.
75748469|NCT05331300|Drug|LASN01|Escalating doses of LASN01 will be given in different cohorts of Parts A, B, C and D.
75748470|NCT05331300|Drug|Placebo|Escalating doses of matching placebo will be given in different cohorts of Parts A, B, C and D.
75748471|NCT05320445|Behavioral|Supportive Expressive Group Therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
75748472|NCT05314400|Diagnostic Test|Full Gadoxetate-enhanced liver MRI|Standard pulse sequences
75748473|NCT05314400|Diagnostic Test|Shortened Gadoxetate-enhanced liver MRI|Fewer pulse sequences
75748474|NCT05309655|Drug|Adenosine Stress Cardiac Magnetic Resonance Imaging|Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.
75898731|NCT04810247|Behavioral|Body Project|The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised for use among adult women with weight/shape concern and higher body weight.
75452638|NCT01741831|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
75748475|NCT05309655|Diagnostic Test|Electrocardiogram|A 12-lead electrocardiogram will be done when at the start of the study and at the participant's 2 year stress test to look at the electrical signals of your heart.
75748476|NCT05309655|Diagnostic Test|Computed Tomography Angiogram|Contrasted coronary CT angiography will be performed for visual and quantitative analysis of coronary artery plaque burdens.
75748477|NCT05309655|Other|Laboratory Testing|10 teaspoons of blood will be withdrawn at every visit that participants receive a stress test. Participants may have up to six blood draws associated with each imaging visit.
75748478|NCT05309655|Behavioral|Quality of Life Survey|A general health status survey with 10 questions and should take about 5-10 minutes to finish. This survey is related to research.
75603791|NCT05891184|Device|color doppler ultrasound, transient elastography, upper endoscopy|"Abdominal US: for detecting the portal hypertension, splenomegaly and portosystemic abdominal collaterals .~Doppler US: detecting the diameter and mean blood flow velocity, blood flow volume, perfusion pressure gradient, congestion index, resistive index, pulsatility index of hepatic artery and platelet count-to-spleen diameter ratio will be performed using logic 10 with a 3.5-MHz duplex convex transducer, in supine position after overnight fasting, with holding their breath in maximal expiration in order to minimize the effect of respiration, body position and postprandial changes on the portal flow Endoscopy : Using Sarin classification ( The presence of esophageal varices, their number, exact location, shape, size and cherry-red spots ) Fibroscan: using the standard-probe, and on a fasting (4 h) patient lying flat on his/her back, with the right arm tucked behind the head to facilitate access to the right upper quadrant."
75603792|NCT05888350|Drug|Beclometasone Dipropionate and Formoterol Inhalation Aerosol|Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks
75603793|NCT05888350|Drug|Placebo|Inhaled Placebo, 1puff, BID, 4weeks
75603794|NCT05881083|Behavioral|1-week nicotine replacement therapy sampling|Participants will be given an 1-week sample of nicotine replacement therapy (patch or gum) with brief instructions on how to use the product
75748479|NCT05305794|Drug|Insulin + semaglutide treatment|Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
75748480|NCT05305794|Drug|Usual insulin treatment|Usual insulin treatment
75748481|NCT05305794|Biological|Biological check-up|at D0, D90 and D180
75748482|NCT05300724|Other|No intervention|No intervention will be administered in this study.
75452639|NCT01741844|Drug|No intervention|This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
75748483|NCT05300152|Procedure|pulpotomy procedure and Histological evaluation|Sixty primary teeth in thirty children aged 7-9 years selected from Outpatient dental clinic Pedodontic and Endodontic Departments, Suez Canal University. divided into group I includes 30 teeth treated with ACTIVA BioACTIVE Base/Liner and group II includes 30 teeth treated by MTA with standard pulpotomy procedure Patients will be recalled after 15 and 30-days . 15 teeth from group I and 15 teeth from group II will be extracted after 15 days then subjected to decalcification then15 teeth from group I and 15 teeth from group II will be extracted after 30 days & subjected to decalcification procedure in 20% EDTA at 4 °C for approximately 5 weeks then embedded in paraffin. Serial sections will be cut at 5 µm thickness. Deparaffinize the sections by 2 changes of xylene for 10 minutes each. Stain in Harris hematoxylin solution for 8 minutes. mount with xylene based mounting medium for conventional histological assessment using light microscope
75748484|NCT05300152|Diagnostic Test|Immunohistochemistry Protocol for Fibronectin Antibody|"Deparaffinization/Rehydration~Slides heated in an oven at 65C for 1 hour.~De-paraffinization~Antigen Retrieval~Immersion of slides into staining dish containing Antigen Retrieval Solution.~Placing the staining dish into rice cooker.~When turned to warm, unplug cooker~Allow to cool down for 20 min~Staining~Wash slides with TBST for 5 min on a shaker.~Inactivate endogenous peroxidase by 3% hydrogen peroxide for 10 min.~Block slides with blocking solution for 1 hour.~Dilute primary antibody in blocking buffer~Apply primary antibody to each section and incubate overnight in humidified chamber~Wash slides three times with TBST"
75748485|NCT05300152|Diagnostic Test|Immunohistochemistry Protocol for Osteopontin Antibody|will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.
75452640|NCT01741857|Biological|human umbilical cord derived MSC transplantation for SLE|
75452641|NCT01741870|Dietary Supplement|Nutritional supplement|Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
75748486|NCT05296668|Device|Cuffed ETT (Microcuff®, Halyard Health Inc., Atlanta, GA, USA)|(group C) to receive a cuffed ETT for airway management.
76065592|NCT04121650|Behavioral|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
76065593|NCT04117178|Drug|Donepezil|Adjustment of treatment with donepezil according to serum level.
75748487|NCT05296668|Device|Uncuffed ETT group|(group U) to receive an uncuffed ETT for airway management.
75898732|NCT04809402|Other|remote monitoring after cataract surgery|remote monitoring after cataract surgery
76065594|NCT04117178|Drug|Memantine|Adjustment of treatment with memantine according to serum level.
76065595|NCT04117178|Diagnostic Test|Measurement of serum level of anti-dementia drug|"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."
76065596|NCT04115826|Procedure|Per-oral Pancreatoscopy-guided Lithotripsy|Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.
75603795|NCT05881083|Behavioral|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
75452642|NCT01741883|Behavioral|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
76065597|NCT04115826|Procedure|Extracorporeal Shock-Wave Lithotripsy|ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
76065598|NCT04109820|Dietary Supplement|MitoQ|Oral; 20mg once a day for 14 days
75603796|NCT05874271|Combination Product|Revised case management package|"Point-of-care quantitative G6PD testing using G6PD STANDARD (SD Biosensor) prior to use of primaquine (Day 0)~Prescription of short course primaquine (7 mg/kg total) (Day 0):~PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~PQ14 (0.5 mg/kg/day for 14 days) if G6PD activity is 30-70 percent~PQ8w (0.75 mg/kg/week for 8 weeks) if G6DP activity less than 30 percent~Participant counselling at the health facility (Day 0):~Supervision of first dose of primaquine~Education regarding importance and risks of primaquine therapy and necessity to take primaquine with food~Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
75603797|NCT05872100|Behavioral|MINDFULNESS BASED APPLICATION|"The effectiveness of mindfulness practices in the field of health~Breathing exercise~Discussing and sharing about exercise~Introduction of informal and formal mindfulness practices~Communication exercise with conscious awareness~Sounds and thoughts meditation~The concept of compassion~Biological foundations of compassion~Self-compassion~Barriers to compassion~Coping with compelling emotions~Coping with the intensity of compassion~Compassionate mindfulness attitudes~Admission stages and improving acceptance~Compassion Meditation~Courtesy Meditation~My partner activity~Body Scan~Mindfulness Sitting Meditation~Receiving feedback on the development of mindfulness skills and the content of the training program~Integration of conscious awareness exercises in daily life for the future"
75748488|NCT05292131|Drug|bimekizumab|Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.
75452643|NCT01741883|Behavioral|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
75898733|NCT04764344|Drug|Haloperidol|2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
75452644|NCT01741896|Procedure|Remote ischaemic preconditioning|The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
75452645|NCT01741909|Behavioral|education|after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
75748489|NCT05287126|Drug|Etrasimod|Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
75748490|NCT05285891|Drug|Ocrelizumab|Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
75748491|NCT05285891|Drug|Placebo for Ocrelizumab|Placebo infusions every 6 months from Month 18 through Month 48.
75748492|NCT05281718|Drug|Factor IX|Factor IX is on of the substrates of emicizumab.
75898734|NCT04764344|Drug|Ondansetron|Ondansetron
76065599|NCT04094961|Drug|Ixazomib|Oral, administered four times per cycle
76065600|NCT04094961|Drug|Pomalidomide|Oral, administered 14 times per cycle
76065601|NCT04094961|Drug|Dexamethasone|Oral, fixed dose administered 8 times per cycle
76065602|NCT04070040|Drug|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
76065603|NCT04054817|Device|Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix|Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
76065604|NCT04053946|Device|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
76065605|NCT04046406|Device|MR neurography-guided cryoanalgesia|Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
75603798|NCT05871983|Device|MUNICH TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM|"The replacement valve consists of a self-expanding, tri-leaflet, dry bovine -pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The key characteristics of Munich valve are:~Nitinol stent frame~Bovine pericardium~Polyester skirt~Anchoring system allows anchoring the frame to the annulus~Hooks are used to reduce the mobility of the native leaflets and decrease risk of embolization.~The Munich TMVR system design proposed for this clinical investigation represents a significant evolution from previous TMVR designs:~Transfemoral / transseptal access~Self-expanding~Dry pericardium (can be pre-loaded)~No anchors~27 Fr delivery catheter (~Sizes: 40/48/55mm~Height 30 mm The valve is available in 3 sizes with a 30mm profile and has been designed to reduce the complexity of implantation in comparison to other TMVR systems."
75748493|NCT05281601|Drug|AZD7442|"IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion."
75748494|NCT05280548|Drug|Venglustat (GZ402671)|Tablet; Oral
75603799|NCT05870683|Drug|Tegoprazan|Included in dual eradication medication.
75603800|NCT05870683|Drug|Amoxicillin|Included in dual eradication medication.
75603801|NCT05870683|Drug|Esomeprazole|Included in dual eradication medication.
75748495|NCT05280548|Drug|Agalsidase alfa|Concentrate for solution for infusion; IV infusion
75748496|NCT05280548|Drug|Agalsidase beta (GZ419828)|Powder for concentrate for solution for infusion; IV infusion
76065606|NCT04056013|Device|Vicryl Rapide absorbable suture|"In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own."
76065607|NCT04044248|Device|TIPS-obliteration|Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
75748497|NCT05280548|Drug|Migalastat|Hard capsules; Oral
75603802|NCT05870293|Behavioral|nurse coaching|2 sessions of nurse coaching including the Walt Disney method will be applied to the participants.
75898736|NCT04738981|Drug|UC-MSC|UC-MSC, iv, 1×10^6 cells/kg, once a week, for 4 weeks.
76065608|NCT04040413|Procedure|bariatric surgery|All bariatric procedures
76065609|NCT04039633|Procedure|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
76065610|NCT04039633|Procedure|Sham spinal cord stimulation|A pulse generator is implanted, but no spinal cord stimulation is provided
76065611|NCT04033614|Device|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
75603803|NCT05862675|Diagnostic Test|RNA sequencing of blood samples|Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
75603804|NCT05860400|Behavioral|Healthy life style|Healthy diet, regular exercise, and quitting smoking
75748498|NCT05265546|Drug|Psilocybin|The effects of different doses of psilocybin (0 - 14 mg) will be compared.
75748499|NCT05251285|Procedure|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
75748500|NCT05245487|Diagnostic Test|DNA repair gene mutation analysis|Prospective monitoring of patients with next-generation sequencing for blood mutations
75748501|NCT05233891|Procedure|Breast reconstruction|Breast reconstruction after breast cancer.
75748502|NCT05233891|Procedure|Breast reduction|Breast reduction due to breast hypertrophy.
75748503|NCT05232929|Drug|Risdiplam|Participants will receive risdiplam orally.
75748504|NCT05216224|Drug|ATI-450|Oral, small molecule MK2 inhibitor
75748505|NCT05216224|Drug|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
75748506|NCT05203510|Drug|Parenteral Treprostinil|Parenteral treprostinil will be administered per schedule specified in the arm description.
75748507|NCT05203510|Drug|Oral Treprostinil|Oral treprostinil will be administered per schedule specified in the arm description.
75748508|NCT05191238|Other|IUD self-removal education|Two part educational intervention (watching IUD self-removal video and practicing IUD removal on two simulation models)
75898737|NCT04738981|Drug|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
75898738|NCT04709185|Drug|Dexamethasone 1 MG Oral Tablet|oral 1 mg dexamethasone at 23:00-24:00 the night before AVS
76065612|NCT04030676|Procedure|Biopsies|Two more biopsies in inflammatory zone will be collected.
76065613|NCT04030676|Biological|Blood samples|Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
76065614|NCT04014205|Drug|Orelabrutinib (ICP-022)|ICP-022 The drug product is a white, round, uncoated tablet
76065615|NCT04010422|Diagnostic Test|no intervention|no intervention
76065616|NCT04010409|Other|no intervention|no intervention
75603805|NCT05860400|Drug|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
75748509|NCT05160025|Other|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
75748510|NCT05155423|Other|mask for immobilization|mask for immobilization
75748511|NCT05155423|Other|Elekta BodyFix|Elekta BodyFix
75452646|NCT01741922|Drug|ASA evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
75748512|NCT05151744|Drug|Vamikibart|Vamikibart will be administered by IVT injection in the study eye.
75748513|NCT05151744|Drug|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
75748514|NCT05151744|Other|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
75898739|NCT04709185|Drug|Placebo|oral placebo at 23:00-24:00 the night before AVS
75898740|NCT04693156|Procedure|unilateral ultrasound-guided oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. The rectus abdominis and underlying transversus abdominis muscles will be identified. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
75603806|NCT05860400|Drug|Immunosuppressive therapy|Glucocorticoids and/or immunosuppressive agents
75603807|NCT05860400|Procedure|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
75603808|NCT05860400|Drug|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
75748515|NCT05151731|Drug|Vamikibart|Vamikibart will be administered by IVT injection as specified in each treatment arm.
75748516|NCT05151731|Drug|Ranibizumab|Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
75748517|NCT05151731|Other|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
75603809|NCT05856747|Drug|TBP-PI-HBr|TBP-PI-HBr tablets.
75748518|NCT05141721|Drug|GRT-C901|A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10^12 viral particles 2 times over the course of the first year.
75748519|NCT05141721|Drug|GRT-R902|A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
75748520|NCT05141721|Drug|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
75898741|NCT04693156|Procedure|unilateral ultrasound-guided oblique subcostal TAP block with %0.9 NaCl 30ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. %0.9 NaCl 30ml will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
75603810|NCT05850052|Other|Conventional direct laryngoscopy using a Macintosh blade|Examine a patient's airway to aid placement of tracheal tube with ease.
75603811|NCT05850052|Device|McGrath videolaryngoscope for rapid sequence endotracheal intubation|Visualize a patient's airway to aid placement of tracheal tube with ease.
75603812|NCT05847452|Drug|Benralizumab|30mcg ever month for 3 months
75603813|NCT05842499|Procedure|Line Set Strategy|Substrate-guided ablation procedure of atypical atrial flutter
75603814|NCT05842499|Procedure|Conventional strategy|Electrical activation-guided ablation
75748521|NCT05141721|Drug|Ipilimumab|Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
75748522|NCT05141721|Drug|Fluoropyrimidine plus leucovorin|Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
75748523|NCT05141721|Drug|Bevacizumab|Bevacizumab administered as maintenance therapy per standard of care.
75748524|NCT05138068|Drug|MDMA|Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.
75748525|NCT05138068|Behavioral|Psychotherapy|Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
75748526|NCT05126901|Drug|Ferric Maltol|"Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to < 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID."
76065617|NCT04009447|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week CBT-I therapy to help improve sleep quality
75452647|NCT01741922|Drug|Acetylsalicylic morning|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
75452648|NCT01741922|Drug|Placebos morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
75452649|NCT01741922|Drug|Placebo evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
75748527|NCT05126901|Drug|Ferrous sulfate|"Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID."
75748528|NCT05119569|Drug|Fenebrutinib|Fenebrutinib will be administered orally.
75748529|NCT05119569|Drug|Placebo|Placebo will be administered orally.
76065618|NCT04005651|Device|POD L GF IOL|Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag
75748530|NCT05116761|Biological|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
75748531|NCT05116761|Other|Saline|Placebo Saline
75748532|NCT05110157|Drug|Placebo|Oral capsules
75748533|NCT05110157|Drug|Valbenazine|Oral capsules
75748534|NCT05096728|Drug|Nifedipine XL|"Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~Once daily Nifedipine XL 60mg Vs.~Twice daily Nifedipine XL 30mg"
76065619|NCT04005651|Device|Symfony® IOL|Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag
76065620|NCT04005651|Device|AcrySof® IOL|Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
76065621|NCT03991936|Drug|Placebos|Normal saline intralesional injection
76065622|NCT03991936|Drug|Triamcinolone Acetonide 2.5 mg/mL|2.5 mg/mL intralesional injection
75748535|NCT05094154|Drug|anti-pseudomonal cephalosporin|Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
75748536|NCT05094154|Drug|anti-pseudomonal penicillin|Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
75748537|NCT05094141|Other|Virtual reality|Virtual reality game
76065623|NCT03991936|Drug|Triamcinolone Acetonide 5.0 mg/mL|5.0 mg/mL intralesional injection
75898742|NCT04693156|Procedure|unilateral ultrasound-guided posterior TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound (Esaote MyLab5) probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration.
76065624|NCT03991936|Drug|Triamcinolone Acetonide 7.5 mg/mL|7.5 mg/mL intralesional injection
75452650|NCT01741948|Drug|Hormonal contraceptive|"The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy."
75603815|NCT05837507|Other|Telerehabilitation solution (m-Rehab)|"Patients in the experimental group will have access to a multimodal digital platform (m-Rehab®). The solution includes a website and an application available on smart phones for the patient and caregivers. Patients and caregivers will have access to educational content about the condition and its treatments, NIV compliance data, digital group educational workshops, secure messaging and video conferencing.~All the professionals forming the patient's circle of care will be able to have access to the solution, after the patient's authorization. The circle of care, in a non-exhaustive way, includes specialist doctors, the general practitioner, the staff of the reference center of the Montpellier University Hospital, the physiotherapist, the speech therapist, the dietician and the psychologist."
75748540|NCT05076149|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
75748541|NCT05076149|Drug|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
75748542|NCT05076149|Drug|IVA|Tablet for oral administration.
76065625|NCT03991936|Drug|Triamcinolone Acetonide 10 mg/mL|10 mg/mL intralesional injection
75603816|NCT05837507|Other|Usual management including NIV.|Usual management including NIV.
75603817|NCT05834387|Procedure|EICU Transfer Routine Care|EICU Transfer Routine Care
75748543|NCT05076149|Drug|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
75748544|NCT05076149|Drug|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
75748545|NCT05076149|Drug|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
75748546|NCT05069610|Biological|AD17002|A recombinant protein
75748547|NCT05069610|Biological|Placebo (Formulation buffer)|Formulation buffer
75748548|NCT05067790|Drug|Nusinersen|Administered as specified in the treatment arm
75748549|NCT05066880|Other|Exercise training|Exercise training for 8 weeks
75748550|NCT05059522|Drug|Avelumab|oral
75748551|NCT05059522|Drug|Lorlatanib|oral
75748552|NCT05059522|Drug|Talazoparib|oral
75748553|NCT05059522|Drug|Pemetrexed|IV (intravenous) infusion
75748554|NCT05059522|Drug|Axitinib|oral
75748555|NCT05059522|Drug|CMP 001|IT (intratumoral) or SC (subcutaneous)
75748556|NCT05059522|Drug|Utomilumab|IV infusion
75748557|NCT05059522|Drug|PF04518600|IV infusion
75748558|NCT05056857|Procedure|Biospecimen Collection|Undergo collection of blood sample
75748559|NCT05056857|Other|Electronic Health Record Review|Medical charts are reviewed
75748560|NCT05048953|Diagnostic Test|Muscle ultrasound measurements (the index test)|"The following parameters will be measured by muscle ultrasound~Muscle thickness~Muscle echogenicity~Muscle fasciculations"
75603818|NCT05834387|Procedure|Implementing interventions based on a 'health care-family-environment' linkage|"Nursing interventions in the experimental group The interventions were based on the health care-family-environment linkage"
75748561|NCT05041803|Drug|CTP-543|Twice daily dosing
75748562|NCT05036096|Device|CBBCT Imaging|Both breasts will be scanned by CBBCT. Only one breast will be scanned if the patient had mastectomy.
75452651|NCT01741961|Procedure|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
75748563|NCT05036096|Device|Digital Mammography|Both breasts will take digital mammography standard views (CC, MLO) Only one breast will take digital mammography standard views if the patient had mastectomy.
75748564|NCT05035368|Drug|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).
75748565|NCT05035368|Other|Placebo|Placebo is administered with the same schedule of Ladarixin.
75898743|NCT04693156|Procedure|unilateral ultrasound-guided posterior TAP block with %0.9 NaCl 30ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. %0.9 NaCl 30ml will be injected after negative aspiration.
75452652|NCT01741974|Dietary Supplement|Karinat|
75452653|NCT01741974|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
75452654|NCT01741987|Other|Optive ®|instilation of 1 drop each eye 4 times per day
75452655|NCT01741987|Other|Fresh Tears ®|instilation of eye drop 4 times a day (qid)
75452656|NCT01742000|Dietary Supplement|Karinat|
75452657|NCT01742000|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
75452658|NCT01742013|Drug|GCJBP Laennec Inj.|Test drug
75452659|NCT01742013|Drug|Placebo|Comparator
75452660|NCT01742052|Drug|MT-1303-Low|
75603819|NCT05833776|Procedure|spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)|group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
75452661|NCT01742052|Drug|MT-1303-Middle|
75452662|NCT01742052|Drug|MT-1303-High|
75452663|NCT01742052|Drug|Placebo|
75452664|NCT01742130|Drug|sodium bicarbonate solution|
75452665|NCT01742130|Drug|Isotonic saline|
75452666|NCT01742169|Behavioral|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
75452667|NCT01742182|Other|Light exposure|
75452668|NCT01742195|Procedure|Oral EBUS insertion|
75452669|NCT01742195|Procedure|Nasal EBUS insertion|
75748566|NCT05030766|Drug|Nicotine Replacement Therapy|6 weeks of Nicotine replacement patches
75748567|NCT05030766|Behavioral|Mindfulness Training Smoking Cessation Intervention|Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.
75748568|NCT05030766|Behavioral|Contingency Management Smoking Cessation Intervention|Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.
75748569|NCT05010785|Procedure|Immediate implant placement and alveolar ridge splitting with GBR and i-PRF|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with i-PRF
75748570|NCT05010785|Procedure|Immediate implant placement and alveolar ridge splitting with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
75748571|NCT05002777|Drug|rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
75748572|NCT04998721|Behavioral|Promoting First Relationships-Brief|A brief version of the evidence based Promoting First Relationships (PFR) parenting intervention in which a parent is supported in appropriate interpretation of infant cues and in developing skills to effectively parent an infant. Sessions consist of reflective content (observing and reflecting back to the mother on patterns of dyadic interaction) and informational handouts. Reflective content will be delivered in person, and text messaging protocol will deliver informational content at developmentally appropriate times. PFR-B sessions are delivered in primary care settings beginning in the third trimester and continuing postpartum.
75748573|NCT04998721|Behavioral|Perinatal Collaborative Care|Collaborative Care (CC) is an integrated care model that is effective in the treatment of perinatal depression. CC provides team driven, population focused, measurement guided and evidence based care to improve access and outcomes, control costs, and increase patient satisfaction.
76065626|NCT03979599|Procedure|ultra-sound guided transversus abdominis plan block|comparing ultrasound guided transversus abdominis plan block using combination of magnisum sulphate and levobupivacaine versus levobupivacaine
75748574|NCT04992793|Combination Product|Congenital heart surgery|Paediatric congenital heart surgery
75748575|NCT04991116|Drug|TILD sub-cutaneous (SC) injection|1 mL injection of study medication
75748576|NCT04989803|Drug|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
76065627|NCT03979599|Drug|magnesium sulphate& levobupivacaine|magnesium sulphate& levobupivacaine
76065628|NCT03979599|Drug|Levobupivacaine|levobupivacaine
76065629|NCT03974230|Other|Collection of datas|Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
76065630|NCT03974230|Biological|blood sample|Blood sample will be performed (genetic analyses).
76065631|NCT03974230|Other|slit lamp examination|Slit lamp examination will be performed.
76065632|NCT03969693|Radiation|Standard treatment protocol with combined chemoradiation|As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
76065633|NCT03956784|Device|E-assessed clinical and biological follow up|"Clinical questionnaire: self-evaluation of pain (0 to 10), resumption of transit, bleeding, fever, pulse. In case of no filling, the patient is contacted.~An automatic alert system is defined and divide the patient according to three situations:~Normal situation~Situation requiring the nurse to call back the patient and contact the surgeon if the assessment requires medical advice~Disturbing situation requiring contact of the first-line surgeon if a potentially serious event is suspected. Each speaker's place is described for each item in the detailed protocols~Biological questionnaire:~Biological monitoring (blood count, Ionogram, C-Reactive Protein, urea, creatinine) is performed on D1, D3 and D7.~All information is accessible in real time by the surgeon who receives notifications by email and on his smartphone in case of clinical or biological abnormality on patient monitoring."
75452670|NCT01742221|Biological|HemaMax|single subcutaneous 12 microgram dose of HemaMax
75452671|NCT01742221|Drug|Placebo|single subcutaneous dose
75452672|NCT01742234|Procedure|Organ Donation|People in this study will donate either a lung or kidney
75452673|NCT01742247|Other|Physiogel|Application of moisturizer on laser-treated area
75603820|NCT05832957|Behavioral|Drive fun|"The Drive Fun intervention program aims to promote the development of adaptive self-awareness and facilitate the acquisition of management strategies that foster safe and confident driving among participants. The program utilizes a driving simulator to provide a guided learning experience, which incorporates various sources of information, as well as games and thinking tasks. Additionally, participants will engage in reflective exercises that draw upon their occupational experiences and their driving performance within the simulator. Parental involvement is also incorporated to ensure ongoing support for the continued practice of learned skills."
75748577|NCT04989803|Drug|Fludarabine|Lymphodepleting chemotherapy administered intravenously
75748578|NCT04989803|Biological|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
75452674|NCT01742247|Other|Moisturizer|Application of moisturizer on laser-treated area
75452675|NCT01740999|Procedure|silicone arthroplasty|silicone arthroplasty
75452676|NCT01740999|Procedure|arthrodesis|arthrodesis
75452677|NCT01742260|Procedure|Repair of cranial defects by tissue engineering|Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
75452678|NCT01742273|Drug|Vitamin K1|Vitamin K1 to slow vascular calcification
75452679|NCT01742312|Radiation|DEXA scan|all patients will undertake a full body DEXA scan before and after chemotherapy
75452680|NCT01742312|Procedure|Muscle biopsy|All patients will have a muscle biopsy before and after chemotherapy
75748579|NCT04989803|Biological|KITE-753|A single infusion of CAR-transduced autologous T cells administered intravenously
75748580|NCT04987112|Drug|CAN1012|CAN1012 IT injection (once every 4 weeks)
75748581|NCT04975555|Drug|Siltuximab|Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.
75748582|NCT04933227|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously (IV) on Day 1 of each 21-day cycle.
75748583|NCT04933227|Drug|Tiragolumab|Tiragolumab 600 mg will be administered IV on Day 1 of each 21-day cycle.
75748584|NCT04933227|Drug|Oxaliplatin|Oxaliplatin 130 mg/m^2 will be administered IV on Day 1 of each 21-day cycle during Cycles 1-4.
75748585|NCT04933227|Drug|Capecitabine|Capecitabine 1000 mg/m^2/d will be administered orally (PO) twice daily (bid) on Days 1-14 during Cycles 1-4.
75748586|NCT04931342|Drug|Ipatasertib|Ipatasertib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)
75748587|NCT04931342|Drug|Cobimetinib|Cobimetinib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length=28 days)
75748588|NCT04931342|Drug|Trastuzumab Emtansine|Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
75748589|NCT04931342|Drug|Atezolizumab|Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
75748590|NCT04931342|Drug|Bevacizumab|Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
75748591|NCT04931342|Drug|Paclitaxel|Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)
75748592|NCT04931342|Drug|Giredestrant|Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)
75898744|NCT04677556|Other|Esogastric pressures measurement|"Catheter placement : at least 2 hours after and within 24 hours following the initial ventilation support establishment (CPAP or NiPPV according to usual practice and clinical conditions). 2 periods of measurements : with the initial and with the 2nd ventilation support using a cross-over for each patient. For each period, the first serie of measurements will be carried out without modifying the settings of the support ( clinical setting), and the second one using esogastric pressures by adjusting the settings of the ventilation support in order to obtain an optimal normalization or reduction of the amplitude of the Pes and Pdi deltas (physiological setting). 5 minutes of spontaneous breathing with/without oxygen between period 1 and 2 (depending on the patient's conditions). All measurements will be performed for 5 minutes after a 15 minutes quiet breathing. After measurements, the optimal respiratory support will be continued."
75898745|NCT04670237|Device|Liberty677MTY Multifocal Toric IOL|multifocal, toric intraocular lens (IOL)
75898746|NCT04647682|Other|physical activity program|"30 second chair test,~balance with joint-feet and semi-tandem stance~4 meters comfortable walking test were evaluated"
75898747|NCT04645979|Other|Online survey|Participants will be invited to complete an online questionnaire about their experience of product use.
76065634|NCT03956784|Other|Usual at home follow up|"An information sheet on the clinical parameters to be monitored will be given to patients and will include the following information:~Immediate complications and warning signs:~Tachycardia> 120 bpm~Dyspnea~Rectorragies and / or melena~Vomiting with or without presence of blood~Major abdominal pain (visual analogue scale> 6/10)~Fever> 38~Management to deal with complications: call the service and / or the surgeon~Actions to be performed by the patient after the exit:passage of the nurse during 10 days for anticoagulant morning and evening (identical in both study groups)~Each patient will be given a prescription to perform a C-Reactive Protein assay on D1, D3 and D7, similarly."
76065635|NCT03948698|Other|Innovative approached to pediatric TB care|Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers
75898748|NCT04617496|Behavioral|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features
76065636|NCT03946514|Drug|losartan/hydrochlorothiazide|losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination
75452681|NCT01742312|Other|cardio-pulmonary exercise testing (CPEX)|patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
75452682|NCT01742325|Behavioral|walking|two 20-minute sessions of walking around the nurse's station daily, five days a cycle
75898749|NCT04617496|Behavioral|Health education|Provision of general information about a variety of topics
75452683|NCT01742338|Drug|Low Dose Corticosteroids|
75452684|NCT01742338|Drug|High Dose Corticosteroids|
75452685|NCT01742351|Behavioral|Guided internet-based cognitive behavior therapy|
75452686|NCT01742377|Procedure|Patients with GerdQ positive|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
75748593|NCT04931342|Drug|Abemaciclib|Abemaciclib will be administered by mouth twice a day during each 28-day cycle
75748594|NCT04931342|Drug|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle
75748595|NCT04931342|Drug|Palbociclib|Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle
75748596|NCT04931342|Drug|Letrozole|Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle
75748597|NCT04931342|Drug|Olaparib|Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle
75748598|NCT04931342|Drug|Luteinizing Hormone-Releasing Hormone (LHRH) Agonists|LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.
75748599|NCT04931342|Drug|Cyclophosphamide|Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
75748600|NCT04931342|Drug|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle
75748601|NCT04925479|Drug|Asciminib Pediatric formulation group|"Asciminib Pediatric formulation group: Mini-tablets will be supplied as size 0 capsules containing 1 mg mini-tablets, taken orally:~10 mg (10x 1 mg tablets in capsule) 15 mg (15x 1 mg tablets in capsule) 20 mg (20x 1 mg tablets in capsule) 30 mg (30x 1 mg tablets in capsule)"
76065637|NCT03946514|Drug|amlodipine/hydrochlorothiazide|amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
76065638|NCT03945279|Drug|BIIB100|Administered as specified in the treatment arm.
76065639|NCT03945279|Drug|Placebo|Administered as specified in the treatment arm.
76065640|NCT03935958|Dietary Supplement|Curcumin|Patients will receive curcumin 2000 mg a day, for 12 months
75452687|NCT01742377|Procedure|Patients with GerdQ negative|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
75452688|NCT01742377|Procedure|Normal volunteers|Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
75452689|NCT01742390|Drug|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
75748602|NCT04925479|Drug|Asciminib Adult formulation group|"Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally."
75898750|NCT04614558|Drug|Isatuximab|"Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.~Isatuximab (SAR) is monoclonal antibody (mAb)."
76065641|NCT03935958|Other|Placebo|Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
75452690|NCT01742390|Drug|risperidone or paliperidone|
75452691|NCT01742416|Procedure|Ultrasound|Arterial cannulation facilitated by ultrasound.
75452692|NCT01742416|Procedure|Palpation Method|Arterial cannulation by palpation method.
75452693|NCT01742429|Drug|Proton pump inhibitor|
76065642|NCT03935295|Drug|AbobotulinumtoxinA|Paraspinal abobotulinumtoxinA injections (compared to placebo)
76065643|NCT03935295|Drug|Placebos|Placebo prepared by Ipsen for use as control
76065644|NCT03935295|Device|Custom Thoracolumbosacral Orthosis|Non-operative external bracing for scoliosis curves
75452694|NCT01742429|Drug|Bismuth subsalicylate|
75452695|NCT01742429|Drug|Metronidazole|antibiotic
75452696|NCT01742429|Drug|Tetracycline|antibiotic
75452697|NCT01742429|Drug|Amoxicillin|antibiotic
75452698|NCT01742429|Drug|Levofloxacin|antibiotic
75452699|NCT01742468|Dietary Supplement|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
75452700|NCT01742468|Dietary Supplement|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
75452701|NCT01742481|Behavioral|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
75452702|NCT01742494|Procedure|Water-jet POEM|Water-jet assisted POEM procedure was performed
75452703|NCT01742494|Procedure|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
75452704|NCT01742507|Device|Resolute Integrity Stent|Resolute Integrity Stent
75452705|NCT01742507|Device|Biomatrix stent|Biomatrix stent
75452706|NCT01742520|Drug|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
75603821|NCT05832957|Behavioral|educational intervention|7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
75603822|NCT05832957|Other|No intervention|one-time short guidance on safe driving at the end of the study.
75603823|NCT05830981|Other|Educational intervention|3 months of educational intervention (Lectures, information bulletin, handbook and hardcopy presentation slides) among professionals and patients.
75603824|NCT05823441|Drug|Oxytocin nasal spray|Volunteers inhale 24 units of oxytocin spray
75603825|NCT05823441|Drug|Placebo|Volunteers inhale 24 units of placebo spray
75603826|NCT05823441|Behavioral|Stranger|Volunteers watch a video of a pain test and attach a photo of a stranger
75748603|NCT04915950|Drug|Temanogrel|Participants will receive a single oral dose of temanogrel during the treatment visit.
75748604|NCT04915950|Drug|Placebo|Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
75748605|NCT04899310|Biological|mRNA-3705|A sterile liquid for injection
76065645|NCT03927651|Drug|ICG|Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
76065646|NCT03919214|Other|Automated Messaging|This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg.
75748606|NCT04899271|Drug|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
75748607|NCT04899271|Other|Placebo|Placebo will be administered orally with the same scheme of administration of LDX to preserve blinding
75748608|NCT04897347|Device|Robotic Trunk-Support-Trainer (TruST)|"This will involve tailoring the level of postural assistance via force fields and systematically introduce postural task-progression across training sessions. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)"
75748609|NCT04897347|Device|Static Trunk Support|"This will involve static support for the trunk via a trained therapist. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)"
76065647|NCT03915444|Drug|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
76065648|NCT03911986|Device|R Test 4 External Loop Recorder|The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.
76065649|NCT03894631|Procedure|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
76065650|NCT03894631|Procedure|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
76065651|NCT03892785|Drug|Prednisone treatment|tapering prednisone regimen
76065652|NCT03892785|Drug|Tocilizumab treatment|Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)
76065653|NCT03892785|Drug|Methotrexate treatment|"Methotrexate subcutaneous from W0 to W51 (52 administrations).~W0: 7.5 mg/week~W1: 0.2 mg/Kg/week~W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51"
76065654|NCT03892785|Other|Questionnaires|HAQ, SF-36, FACIT-fatigue
75452707|NCT01742520|Drug|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
75452708|NCT01742533|Biological|human umbilical cord mesenchymal stem cells|
76065655|NCT03892785|Biological|Blood samples|Additionnal blood samples for immunomonitoring
76065656|NCT03888287|Device|Watch Rx system|The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
76065657|NCT03888287|Other|Parkinson's Disease Inpatient Clinical Knowledge and Management Program|Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
76065658|NCT03880058|Drug|SLI-F06|Active treatment
75748614|NCT04895436|Drug|Venetoclax|Oral tablet
76065659|NCT03880058|Drug|Formulation buffer|Placebo treatment
76065660|NCT03876795|Biological|Bone Marrow Concentrate|Bone Marrow Concentrate injection
75452709|NCT01742533|Biological|hUCMSCs and hCBMNCs|
75452710|NCT01742533|Biological|human cord blood mononuclear cells|
75748615|NCT04895436|Drug|Obinutuzumab|Intravenous (IV) infusion
75748616|NCT04894370|Biological|Sample collection|"PBMC collection at baseline, after radiotherapy 8 Gy (gray), at 6 months and at 12 months from inclusion: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell [PBMC] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection at baseline, after radiotherapy 8 Gy, at 6 months and at 12 months from inclusion: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection at baseline, at 2, 6 and 12 months from inclusion: two EDTA tube of 4 ml should be frozen in each investigation center for ctDNA collection."
75748617|NCT04891029|Diagnostic Test|DOvEEgene test|Women participating in the study will undergo a genomic uterine pap test, DOvEEgene test, for the screening of ovarian and endometrial cancers
75748618|NCT04889872|Device|SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA|Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve
75748619|NCT04889469|Procedure|Breast reduction|Procedure to remove excess fat, tissue and skin from the breasts.
75748620|NCT04884750|Behavioral|ECA-ACE Vaccination Promotion Intervention|A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
75748621|NCT04882241|Biological|Pembrolizumab|IV infusion
75748622|NCT04882241|Drug|Placebo|IV infusion
75748623|NCT04882241|Drug|Cisplatin|IV infusion
75748624|NCT04882241|Drug|Capecitabine|Oral tablets
75748625|NCT04882241|Drug|5-fluorouracil|IV infusion
75748626|NCT04882241|Drug|Docetaxel|IV infusion
75748627|NCT04882241|Drug|Oxaliplatin|IV infusion
75748628|NCT04882241|Drug|Leucovorin|IV infusion
75748629|NCT04873869|Drug|NBI-921352|Administered orally
76065661|NCT03869034|Combination Product|HAIC+PD1|Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.
76065662|NCT03869034|Drug|HAIC|FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
75603827|NCT05823441|Behavioral|Acquaintance|Volunteers watch a video of a pain test and attach a photo of an acquaintance
75748630|NCT04873869|Drug|Placebo|Administered orally
76065663|NCT03861975|Other|Breast Cancer-Related Lymphedema Measurements|All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
76065664|NCT03861351|Device|Mini WELL Toric Ready intraocular lens|The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
76065665|NCT03858608|Dietary Supplement|Counterweight Plus|Total diet replacement followed by food reintroduction and weight maintenance.
75452711|NCT01742533|Drug|Hormone Replacement Therapy|
75748631|NCT04871321|Drug|nab-paclitaxel plus gemcitabine-cisplatin|- gemcitabine 800mg/m2 + cisplatin 25 mg/m2 + nab-paclitaxel 100mg/m2 on day 1 and day 8, every 21 days
76065666|NCT03858608|Other|Usual asthma care|Usual asthma management
76065667|NCT03849638|Other|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~5 minutes of heating at a comfortable speed for the patient~Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
75452712|NCT01742546|Device|Therapeutic ultrasound combine TENS|"Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius)."
75603828|NCT05822869|Procedure|EIT-guided mechanical ventilation strategy|During prone ventilation, the PEEP level is adjusted based on EIT monitoring. The optimal PEEP is the lowest sum of collapse and overdistension percentages
75603829|NCT05822869|Procedure|Lung protective ventilation group|Lung-protective ventilation strategy during prone positioning that continues the supine position.
75603830|NCT05821244|Behavioral|Exercise Timing Groups|Individualized resistance training program, consisting of twice weekly training sessions supervised via telehealth with a cancer exercise trainer.
75748632|NCT04870034|Drug|Binimetinib|Given PO
75748633|NCT04870034|Drug|Palbociclib|Given PO
75748634|NCT04870034|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75748635|NCT04862689|Device|Ringer Perfusion Balloon Catheter|Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
75748636|NCT04849169|Device|Experimental|Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.
75748637|NCT04845945|Biological|PCV15|Blood draw after the vaccination
75748638|NCT04845178|Drug|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
75748639|NCT04845178|Drug|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/PhEur
75748640|NCT04837248|Other|Active Comparator: Group 1. Conventional treatment|"Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital.~The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment."
76065668|NCT03842475|Procedure|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
75603831|NCT05816616|Diagnostic Test|Functional imaging of the lungs using MagniXene (hyperpolarized xenon-129) MRI|Patients for this observational study will be selected on a voluntarily basis from the ongoing Airflow-3 interventional clinical trial at Temple University Hospital. For this observational sub-study, patients will have their lung function measured using hyperpolarized xenon-129 MRI prior to TLD treatment, and 90 days post-treatment for a better understanding of treatment effects. This sub-study does not influence in any way the patient treatment or the outcomes for the main Airflow-3 TLD clinical trial.
75603832|NCT05809349|Device|transcranial magnetic stimulation|The stimulation intensity will be 80% resting motor threshold (RMT). The theta burst stimulation (cTBS) with a frequency at 50Hz, repeated at 5Hz, are delivered in a duration of 33.2s with the number of stimulation pulses of 600. Two groups of stimulation will be repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. The treatment will last for 2 weeks, with 5 times per week.
75603833|NCT05805475|Other|Endotracheal suctioning with expiratory pause|Perform closed endotracheal suctioning with an expiratory pause of 5 seconds
76065669|NCT03841097|Drug|Extended Release Tacrolimus Tablets|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
75603834|NCT05805475|Other|Endotracheal suctioning without expiratory pause|Perform closed endotracheal suctioning without expiratory pause
75603835|NCT05804825|Behavioral|Argument inoculation messages|Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
75603836|NCT05804825|Behavioral|Simple forewarning message|Participants will be presented with a simple forewarning message.
75603837|NCT05798572|Drug|Sildosin group|Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.
75748641|NCT04837248|Other|Experimental: Group 2. Experimental treatment.|"A digitally supported physiotherapy programme including:~Group session: expectations, interests, experiences with regard to their health problem and the consequences on their life, joint exercise and discussion with subsequent debate will be held.~Exercise session: each week, patients will find different exercise videos on the platform according to the phase of recovery in which each one of them is, having been previously evaluated in the group session.~Relaxation session: this will be carried out by means of audio that will be posted on the platform and that the patient will be able to perform simultaneously.~Empowerment session: audio sessions that will deal with those needs that frequently arise after breast surgery in their daily lives, focusing on limiting beliefs (e.g. fear of moving), positive thoughts and information extracted from the motivational interview that should be developed."
75748642|NCT04817241|Procedure|Biospecimen Collection|Undergo collection of blood samples
75898751|NCT04606030|Device|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
75898752|NCT04606030|Procedure|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
76065670|NCT03841097|Drug|Immediate Release Tacrolimus Capsule|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
75603838|NCT05798572|Procedure|Placebo/control group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
75603839|NCT05795140|Drug|Iptcaopan 200 mg|Open label, participant specific kits, hard gelatin capsules to be taken twice a day
75603840|NCT05792189|Other|Timed Up and Go Test on subjects with ORIF of distal femur fractures|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
76065671|NCT03831776|Drug|Bosutinib|Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (> 300 mg/d > 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.
75603841|NCT05792189|Other|Koos Jr assesment on subjects with ORIF of distal femur fractures|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
75748643|NCT04817241|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
75748644|NCT04817241|Drug|Cytarabine|Given IV
75748645|NCT04817241|Drug|Daunorubicin|Given IV
75748646|NCT04817241|Drug|Decitabine and Cedazuridine|Given PO
75748647|NCT04817241|Drug|Venetoclax|Given PO
75748648|NCT04806347|Biological|TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft|After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.
75748649|NCT04806347|Device|CliniMACS® System|The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.
76065672|NCT03831776|Drug|Ropeginterferon|Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens. RoPegIFN will be given in an open-label fashion. Patients assigned to RoPegIFN will start with 50 μg injected subcutaneously every 14 days, in combination with Bosutinib.
75452713|NCT01742559|Procedure|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman & Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
75452714|NCT01742559|Procedure|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
75452715|NCT01742572|Behavioral|Diet|Change in dietary intake
75452716|NCT01742585|Drug|ASP1585|oral
75452717|NCT01742585|Drug|placebo|oral
75452718|NCT01742598|Device|Portico Transapical Aortic Valve System|
75452719|NCT01742611|Drug|ASP1585|oral
75452720|NCT01742624|Drug|Advagraf|oral
75452721|NCT01742624|Drug|Prograf|oral
75452722|NCT01742624|Drug|Corticosteroid|oral
75452723|NCT01742624|Drug|Mycophenolate mofetil|oral
75452724|NCT01742637|Drug|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
75452725|NCT01742637|Drug|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
75452726|NCT01742637|Drug|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
75748650|NCT04792385|Drug|E4/DRSP 15/3 mg combined tablet|One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
75748651|NCT04791579|Drug|Ciprofloxacin|Fluoroquinolone antibiotic
75748652|NCT04791579|Drug|Placebo|Placebo pill
75748653|NCT04781530|Device|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus): Nasopharyngeal swab
75748654|NCT04768972|Drug|ION363|ION363 will be administered by IT bolus injection.
75748655|NCT04768972|Drug|Placebo|Placebo will be administered by IT bolus injection.
75898753|NCT04589273|Dietary Supplement|Alginate|Volunteers will be asked to consume the alginate capsules with each of their three main meals per day.
75898754|NCT04589273|Other|Placebo|Volunteers will be asked to consume the placebo capsules with each of their three main meals per day.
75898755|NCT04578210|Biological|T memory cells and NK cells|Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).
76065673|NCT03831425|Dietary Supplement|Coenzyme Q10|6 week trial of either treatment with CoenzymeQ.
76065674|NCT03831425|Other|Placebo|6 week trial of either treatment with Placebo
76065675|NCT03804944|Radiation|Focal Radiation therapy|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
75603842|NCT05792189|Other|Timed Up and Go Test on subjects with DFR of distal femur fracture|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
75748656|NCT04768777|Behavioral|Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and one-on-one video chats with a behavioral coach. The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory. Each course consists of an introduction, the primary content, and a take home message.The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries. The chats are conducted face-to-face through an online videoconferencing platform. There are a total of 12 chats over 16 weeks. Chats occur on weeks 1-8, 10-11, 13 and16.
75748657|NCT04762953|Drug|Paclitaxel|Intraperitoneal Paclitaxel
75748658|NCT04762953|Drug|Paclitaxel|IV Paclitaxel
75748659|NCT04762953|Drug|Leucovorin|IV Leucovorin
75748660|NCT04762953|Drug|Fluorouracil|IV 5-FU
75898756|NCT04553341|Device|Navigated repetitive transcranial magnetic stimulation|In these patients we will apply the following protocol: after the initial nTMS mapping of the according function, patients will be stimulated on 20 consecutive days by a series of rTMS pulses. The frequencies (1-20 Hz), number of pulses (100-1,000), and stimulation intensities (50-130% resting motor threshold = rMT = individual lowest stimulation intensity that evokes positive muscle responses) will be applied in dependency of the individual patients comfort and the evoked effect. Stimulations will be applied to the eloquent brain region, which is infiltrated by the tumor.
75898757|NCT04549454|Behavioral|FITSTART+ PBI|Personalized normative feedback on other parents behaviors + alcohol-specific parenting advice + general parenting advice
75452727|NCT01742650|Procedure|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
75898758|NCT04549454|Behavioral|General Parenting Advice|General parenting advice
75452728|NCT01742650|Procedure|TightRope|TightRope transfixation of syndesmosis
75452729|NCT01742663|Drug|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
75898759|NCT04546451|Behavioral|Music practice|Patients will be trained to play a simple instrument (tongue-drum) in a group setting using different musical styles.
75898760|NCT04546451|Behavioral|Psychomotor therapy|Patients will be trained in body awareness and a wide range of of movement activities.
75452730|NCT01742663|Drug|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
75452731|NCT01742663|Drug|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
75748661|NCT04742595|Biological|SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes|Given IV
75898761|NCT04510532|Diagnostic Test|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment
75898762|NCT04504331|Drug|Infigratinib|Oral dose
75898763|NCT04504331|Drug|Tamoxifen|Oral Dose
75898764|NCT04504331|Drug|Omnipaque 350|IV contrast agent
75898765|NCT04504331|Drug|Iopamidol|IV contrast agent
75452732|NCT01742676|Drug|ADVAGRAF|oral
75452733|NCT01742676|Drug|PROGRAF|oral
75452734|NCT01742689|Drug|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
75452735|NCT01742689|Drug|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
75748662|NCT04735978|Biological|RP3|Genetically modified HSV-1
75748663|NCT04735978|Biological|Nivolumab|anti-PD1 monoclonal antibody
75898766|NCT04504331|Diagnostic Test|Computed tomography (CT)|Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.
75898767|NCT04457102|Device|MANIV|mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac
75898768|NCT04457102|Other|Spontaneous DIBH|performed on Varian® Halcyon LINAC and Infinity Elekta® linac
75898769|NCT04447911|Drug|Empagliflozin 25 MG|Empagliflozin 25mg per os once daily for 30 days
75898770|NCT04447911|Drug|Placebo|Placebo per os once daily for 30 days
76065676|NCT03804944|Drug|Pembrolizumab (200mg IV for 30 minutes|Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
76065677|NCT03804944|Biological|CDX-301|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
75603843|NCT05792189|Other|Koos Jr assesment on subjects with DFR of distal femur fracture|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
75748664|NCT04719988|Biological|Blood sample collection|"A total of 9 EDTA (ethylenediaminetetraacetic acid) tubes will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell [PBMC] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: Two 4 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
75603844|NCT05781906|Drug|HMPL-523|D1-D7: HMPL-523 Tablet 300 mg QD
75603845|NCT05781906|Drug|150 µCi [14C]HMPL-523|D8: [14C] HMPL-523 Suspension 300 mg/150 μCi Single dose
75603846|NCT05777005|Behavioral|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
76065678|NCT03790111|Drug|telotristat ethyl|XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study
76065679|NCT03780543|Drug|standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)|Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
76065680|NCT03772314|Drug|Modafinil|Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.
76065681|NCT03772314|Drug|Amphetamine-Dextroamphetamine|Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.
76065682|NCT03760575|Drug|Pembrolizumab|Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
76065683|NCT03760575|Procedure|Indocyanine Green (ICG) Image-Guided Surgery|Standard surgery with image guided resection.
76065684|NCT03760575|Drug|Cisplatin|75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
75452736|NCT01742689|Drug|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
76065685|NCT03760575|Drug|Pemetrexed|500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
75452737|NCT01742702|Drug|Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
75452738|NCT01742702|Drug|Salbutamol 400 µg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
75452739|NCT01742702|Drug|L-arginine (10 min infusion, no longer given since January 2017)|From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).
75452740|NCT01742702|Dietary Supplement|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).
75452741|NCT01742702|Dietary Supplement|Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).
75452742|NCT01742702|Drug|Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).
75603847|NCT05777005|Other|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
75603848|NCT05777005|Other|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
75603849|NCT05777005|Behavioral|Counselor-led individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
75603850|NCT05777005|Behavioral|Chatbot-led group support|Participants will receive three months of chatbot-led group support via WeChat.
75748665|NCT04719988|Procedure|Biopsy|A tumor biopsy will be performed at 2 months after enrollment.
75748666|NCT04700072|Biological|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
75748667|NCT04700072|Biological|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
75748668|NCT04700072|Drug|Lenvatinib|Administered via oral capsule at a specified dose on specified days
75748669|NCT04696653|Other|Comprehensive Unit Based Safety Program (CUSP)|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
75748670|NCT04678154|Drug|Standard of care|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
75748671|NCT04678154|Drug|Vancomycin and Tobramycin|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
75748672|NCT04665856|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
75748673|NCT04665856|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
75748674|NCT04665856|Drug|Carboplatin|Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
75748675|NCT04665856|Drug|Etoposide|Etoposide 100 mg/m^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
75748676|NCT04665856|Drug|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
75748677|NCT04628481|Drug|Ladarixin|Oral ladarixin twice a day for 13 cycles
75748678|NCT04628481|Drug|Placebo|Oral placebo twice a day for 13 cycles
75748679|NCT04622228|Drug|Atezolizumab|Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
75748680|NCT04622228|Drug|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
75748681|NCT04622228|Drug|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
75748682|NCT04622228|Drug|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
75452743|NCT01742715|Other|PEEP by Best oxygenation|"Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
75452744|NCT01742715|Other|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
75748683|NCT04622228|Radiation|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
75748684|NCT04619472|Device|Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter|The conjunction of the pulmonary RFA system with the disposable pulmonary RFA catheter developed by Hangzhou Broncus Medical Co., Ltd. is aim to specifically target lung tumors. The ablation catheter is designed to reach the tumor through the bronchial pathway.
75748685|NCT04597008|Drug|Treatment group|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed immediately before wound closure.
75748686|NCT04597008|Drug|Control group|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed immediately before wound closure.
75748687|NCT04591392|Device|reSept ASD Occluder|Transcatheter closure of secundum ASD using a permanent implant
75748688|NCT04586010|Drug|Fenebrutinib|Participants will receive fenebrutinib.
75748689|NCT04586010|Drug|Teriflunomide|Participants will receive teriflunomide.
75748690|NCT04586010|Drug|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
75603851|NCT05771389|Diagnostic Test|serum raftlin-1 protein levels|Lipid raft linker 1 (Raftlin-1) is a protein which enables double-stranded RNA binding activity. It is involved in T cell receptor signaling pathway; membrane raft assembly; and positive regulation of growth rate. It acts upstream of or within dsRNA transport; response to exogenous dsRNA; and toll-like receptor signaling pathway. Located in endosome; membrane raft; and plasma membrane.
75748691|NCT04584502|Behavioral|Mindful Moms Yoga Mindfulness Intervention|MMORE is an 8-session yoga-mindfulness intervention protocol, offered over the course of 10 consecutive weeks at the partner maternity care practice or a nearby location. Each session will last approximately 60 minutes (8 - 10 participants per group). Intervention participants will also be asked to use a mobile companion app at least once each week of the intervention period.
76065686|NCT03750981|Behavioral|12 week pilot intervention study.|Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
75603852|NCT05760261|Drug|Midazolam|Midazolam will be administered.
75603853|NCT05760261|Drug|GSK3882347|GSK3882347 will be administered.
75603854|NCT05759832|Device|Modified HFNC oxygen therapy|In the modified HFNC group, high-flow devices (AIRVOTM 2; Fisher & Paykel Healthcare, Auckland, New Zealand) were utilized for respiratory support. The nasal cannula used was a modified single nasal cannula.
75603855|NCT05759832|Device|Face mask|In the face mask group, oxygen was delivered via a face mask during bronchoscopy. The oxygen flow was set to achieve a saturation of pulse oxygen > 90%.
75603856|NCT05756192|Other|Educational video|Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
75603857|NCT05751915|Device|CardioFlux|CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.
75452745|NCT01742715|Other|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
75452746|NCT01742741|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
75452747|NCT01742754|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
75452748|NCT01742767|Drug|Cisplatinum|
75452749|NCT01742767|Drug|Pemetrexed|
75452750|NCT01742780|Procedure|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
75603858|NCT05748730|Behavioral|iCHART|"The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
75769349|NCT03909958|Other|Electroacupuncture+Routine rehabilitation training Group|"Electroacupuncture： Major acupoints: Jiaji points. With urinary and stool dysfunction:+Shenshu (BL23) ,Huiyang(BL35).~Localization:Jiaji points of the upper 1 and the lower 1 segment of the Spinal cord injury plane, a total of 4 points.~Operation: Insert Jiaji points By using Hwato-brand disposable acupuncture needles(0.30mm*50mm), with 0.5 inch from the median line and a depth of 50 to 60mm with perpendicular insertion.Then, participants will receive electroacupuncture treatment by connecting Han's pain irritant instrument (HANS100A) for 30min with the stimulation frequency of 2 /100 Hz and intensity of 1-2mA. Once a day, 5 days a week and rest 2 days, a week is one course and the duration need 12 courses.~Routine rehabilitation training:~Same as Routine rehabilitation training Group."
75452751|NCT01742793|Drug|lenalidomide (Revlimid) and romidepsin (Istodax)|
75748692|NCT04581681|Behavioral|Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA)|"The 6-session group CBT intervention for perinatal anxiety has been formalized with session guides for the facilitators and a workbook, Overcoming Anxiety in Pregnancy and Postpartum (Furer & Reynolds, 2015), developed by members of our Anxiety Disorders Clinic. There are 6 core modules covered over the 6 treatment sessions, including: (1) Understanding anxiety during pregnancy and postpartum, (2) self-care, (3) setting goals and facing fears, (4) nurturing the developing relationship with baby, (5) coping with negative thoughts and worries, and (6) relapse prevention. Content is based on general principles of CBT for anxiety but specific themes and examples are geared towards the pregnancy and postpartum periods. Distorted cognitions are also explored, with an additional focus on beliefs about motherhood and perfectionism. Due to the COVID-19 pandemic, the intervention will be conducted via a hospital-approved video-conferencing platform."
75603859|NCT05748730|Behavioral|Treatment As Usual|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
75748693|NCT04581681|Other|No treatment (waitlist control)|Patients in this condition are randomly assigned to a waitlist control condition before receiving treatment.
75748694|NCT04578444|Drug|Zanidatamab|Administered intravenously
75603860|NCT05746377|Drug|Metoclopramide 10mg|IV Metoclopramide
75748695|NCT04568902|Drug|H3B-6545|H3B-6545 oral tablets.
75748696|NCT04568902|Drug|Antihistamine|Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
75452752|NCT01742806|Device|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
75452753|NCT01742845|Other|Ultrasound-guided administration of ropivacaine 4.75 mg/ml|
75452754|NCT01742845|Other|landmark based superfical ropivacaine 4.75 mg/ml injection|
75603861|NCT05746377|Drug|Saline|Placebo
75603862|NCT05744180|Other|Interventional|The FitScore is a machine learning algorithm embedded within the electronic health record that identifies patients most likely to benefit from remote patient monitoring.
75603863|NCT05725798|Drug|Sitagliptin|Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.
75603864|NCT05725525|Behavioral|Remote PCIT augmented with wearable devices|Participants will be enrolled in remote PCIT and be asked to wear a Garmin watch throughout the course of the study in order to measure biometric fluctuations
75748697|NCT04550923|Combination Product|Z-Brace interbody fusion device|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
75748698|NCT04550923|Combination Product|PEEK interbody fusion device|Use rigid (PEEK) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
75748699|NCT04550442|Drug|Azacitidine|Given IV or SC
75748700|NCT04550442|Drug|Venetoclax|Given PO
75452755|NCT01742884|Other|Thealoz|Instillation of 1 drop of Thealoz
75452756|NCT01742884|Other|Vehicle|1 drop of the vehicle will be instillated in the eye
75452757|NCT01742910|Procedure|intraocular lens implantation|
75452758|NCT01742923|Behavioral|Complex tailored intervention|
75452759|NCT01742923|Behavioral|Usual care|
75452760|NCT01742962|Procedure|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
75452761|NCT01742975|Device|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
75452762|NCT01742988|Drug|fimepinostat|
75452763|NCT01742988|Drug|Rituximab|
75452764|NCT01742988|Drug|venetoclax|
75603865|NCT05721157|Other|AI-enabled Chest X-ray-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
75603866|NCT05704296|Procedure|Y-composite grafting|Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting
75603867|NCT05704296|Procedure|Aortocoronary grafting|Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting
75748701|NCT04548999|Drug|Ocrelizumab|The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (participants's body weight <75 kg) or 1800 mg (participant's body weight >/=75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion every 24 weeks.
75748702|NCT04548999|Drug|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 milligram (mg) every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
75748703|NCT04548999|Drug|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
75748704|NCT04548999|Drug|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
75748705|NCT04547907|Drug|Albumin binding paclitaxel+ trastuzumab+ patuzumab|Albumin binding paclitaxel 125 mg / m2 (1, 8, 15 days) + trastuzumab (8 mg / kg for the first loading dose and 6 mg / kg for the sequential maintenance dose) + patuzumab (840mg for the first loading dose and 420mg for the sequential maintenance dose) ，every 21 days for 6 cycles.
75898771|NCT04443452|Diagnostic Test|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
75452765|NCT01743014|Drug|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
75452766|NCT01743014|Drug|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
75452767|NCT01743053|Device|Standard Care plus ReCell|
75452768|NCT01743053|Other|Standard Care|
75452769|NCT01743066|Dietary Supplement|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
75452770|NCT01743079|Drug|Telbivudine|LdT 600mg QD
75452771|NCT01743079|Drug|Lamivudine|LAM 100mg QD
75452772|NCT01743105|Procedure|Diaphragm excursion measures 1|A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
75452773|NCT01743105|Procedure|Diaphragm excursion measures 2|A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
75452774|NCT01743118|Drug|SPS4251 Ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
75452775|NCT01743118|Drug|Placebo|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
75452776|NCT01743118|Drug|Daivonex® ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
75603868|NCT05699252|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT intervention will be used to help participants learn about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
75748706|NCT04547907|Drug|Docetaxel+ carboplatin+ trastuzumab + patuzumab|Docetaxel 75 mg/m2 + carboplatin (AUC = 6) + trastuzumab(8 mg / kg for the first loading dose and 6 mg / kg for the sequential maintenance dose) + patuzumab (840mg for the first loading dose and 420mg for the sequential maintenance dose) ，every 21 days for 6 cycles.
75748707|NCT04534218|Drug|Regorafenib|"For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle."
75748708|NCT04534218|Drug|Cyclophosphamide|50 mg per os, daily, for 6 months
75748709|NCT04534218|Drug|Capecitabine|625mg/m²/orally twice daily continuously for 6 months
75748710|NCT04534218|Drug|Aspirin|75 mg orally and daily until progression
75748711|NCT04533763|Behavioral|Technology-based Mindful Living program|The program is delivered using web-based group conferencing. During each session, participants are taught new stress management and coping techniques. Each week there is opportunity to apply techniques to real world situations for practice. Participants have a group orientation session, and then meet for 10 weeks. Group sessions last 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post- randomization. Program includes training in mindfulness, cognitive behavioral stress management, relaxation, imagery, prioritizing meaningful activities, communication, and coping strategies. Content is geared toward concerns of cancer survivors.
75748712|NCT04533763|Behavioral|Technology-based Healthy Lifestyles program|The program is delivered using web-based group conferencing. Sessions include content from the National Cancer Institute, American Cancer Society, and health care providers with expertise in oncology. All content is geared to promoting healthy living among ovarian cancer survivors. Participants have a group orientation session, and then meet for 10 weeks, with group sessions lasting 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post-randomization. Healthy Lifestyle sessions include topics such as nutrition, exercise, sleep, quality of life, survivorship, and cognitive function with content geared toward concerns of cancer survivors.
75748713|NCT04530448|Drug|Sodium bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
75748714|NCT04530448|Other|Standard of Care|Standard of Care treatment
75748715|NCT04511078|Drug|Panitumumab-IRDye800|single dose infusion of panitumumab-IRDye800CW
75909542|NCT03475082|Device|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is utilized clinically by a variety of health care professionals for the reduction of pain. The mechanisms by which TENS produces analgesia or reduces pain are only recently being elucidated. TENS is a non-invasive modality that is inexpensive, safe and easy to use with relatively few contraindications. Frequency of stimulation is broadly classified as high frequency (>50Hz), low frequency (<10Hz) TENS. Intensity is determined by the response of the patient as either sensory level (low-intensity) TENS strong but comfortable. With sensory level TENS, the voltage (i.e. amplitude) is increased only until the patient feels a comfortable tingling (perceived with high frequency) or tapping (perceived with low frequency) sensation without motor contraction. With strong but comfortable TENS the intensity is increased to a strong but comfortable level which may include muscle contraction.
75452777|NCT01743144|Drug|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
75452778|NCT01743144|Drug|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
75452779|NCT01743157|Drug|Biochemo + bevacizumab then ipilimumab|Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, & 4)
75452780|NCT01743170|Other|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
75748716|NCT04495452|Drug|Fentanyl Drug Administration|Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
75748717|NCT04476030|Drug|SAGE-217|Oral capsules
75748718|NCT04476030|Drug|Matching Placebo|Oral capsules
75748719|NCT04476030|Drug|Sertraline|Oral tablets
75603869|NCT05699252|Behavioral|Hypnotic Cognitive Therapy (HYP-CT)|The HYP-CT intervention will be used to help participants learn about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
75898772|NCT04443452|Radiation|Radiographic Evaluation|Tibiofemoral and patellofemoral radiographs of the most painful knee will be taken using a standardised protocol (standing posterior-anterior (PA) and skyline views) and will be scored by a single experienced observer in order to generate data for correlation analyses with the primary and secondary outcomes. A Perspex Rosenberg template with lead beads is used for the standing PA view to standardising the degree of knee flexion, foot rotation and magnification. PA radiographs are taken with the participant facing the x-ray tube while standing on the Rosenberg jig and leaning forwards with their thighs touching the anterior aspect of the jig, the x-ray beams passing from the posterior aspect through to the anterior aspect of the knee. Variable jigs are used for the skyline view to obtaining 300 of knee flexion with the participant lying in a reclined supine position on a couch. Grading of radiographs for changes of OA will be based on the Kellgren and Lawrence (K/L) score.
75748720|NCT04476030|Drug|Escitalopram|Oral tablets
75452781|NCT01743183|Device|Threshold|The load adjustment was done weekly by a single examiner.
75748721|NCT04476030|Drug|Citalopram|Oral tablets
75748722|NCT04476030|Drug|Duloxetine|Oral capsules
75748723|NCT04476030|Drug|Desvenlafaxine|Oral tablets
75748724|NCT04462042|Radiation|Proton radiotherapy|Proton radiotherapy
75909543|NCT02694068|Other|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
75452782|NCT01743222|Genetic|eASC|"First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells."
75452783|NCT01743222|Drug|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node"
75452784|NCT01743235|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
75452785|NCT01743235|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
75452786|NCT01743235|Drug|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
75452787|NCT01743261|Other|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
75452788|NCT01743261|Other|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
75748725|NCT04462042|Radiation|Photon radiotherapy|Conventional photon radiotherapy
75748726|NCT04458831|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75748727|NCT04458831|Drug|Pomalidomide|Pharmaceutical form: oral
75748728|NCT04458831|Drug|Dexamethasone|Pharmaceutical form: oral
75748729|NCT04458831|Drug|Carfilzomib|Pharmaceutical form: solution for infusion
75748730|NCT04450316|Drug|Naltrexone|4.5mg tab (low-dose) nightly
75748731|NCT04450316|Drug|Placebo|1 tab nightly
75748732|NCT04447820|Drug|K-877-ER (Dose A)|Dose A Oral Administration
75748733|NCT04447820|Drug|K-877-ER (Dose B)|Dose B Oral Administration
75748734|NCT04447820|Drug|K-877-IR|K-877-IR Oral Administration
75748735|NCT04443062|Drug|177Lu-PSMA-617|PSMA radioligand therapy
75748736|NCT04438213|Drug|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
75748737|NCT04438213|Drug|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
75748738|NCT04438213|Drug|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
75748739|NCT04431453|Drug|Remdesivir|Administered as an intravenous infusion
75909544|NCT02694068|Other|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
75748740|NCT04424407|Behavioral|Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist once a week for six weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
75748741|NCT04402957|Drug|LSALT peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
75748742|NCT04402957|Drug|Placebo|0.9% saline solution
75748743|NCT04395989|Drug|A1: Pyrotinib with nab-paclitaxel|A1: pyrotinib(EGFR-TKI) 400mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
75748744|NCT04395989|Drug|A2: nab-paclitaxel|A2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
75748745|NCT04395989|Drug|B1: everolimus with nab-paclitaxel|B1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
75748746|NCT04395989|Drug|B2: nab-paclitaxel|B2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
75748747|NCT04395989|Drug|C1: PD-1 with nab-paclitaxel and famitinib|C1: PD-1 antibody SHR1210 200mg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt + famitinib 20mg po qd, 4 weeks as a cycle
75748748|NCT04395989|Drug|C2: nab-paclitaxel|C2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
75898773|NCT04443452|Procedure|Ultrasound-guided Aspiration|Ultrasound scanning will be conducted on the most painful knee to identify synovial effusion. During the ultrasound scan, the supra-patellar pouch, medial and lateral recess of the knees will be assessed for synovial thickening, synovial fluid/effusion and for positive power Doppler. An ultrasonic probe will be used to direct ultrasonic waves onto the knee joint during sonography, and a computer converts the signals received so that they can be presented on the screen. During skin application, a sterile probe cover and sterile acoustic gel will be used. Once the best aspiration location is identified and the location of the needle insertion marked, the skin will be prepared with a cleansing agent such as iodine or chlorhexidine. The needle may be introduced into the skin either parallel to the probe or perpendicular to the probe. Once the aspiration is completed, the needle will be removed, the skin cleansed, and a bandage will be applied.
75452789|NCT01743274|Procedure|OCT|"Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.~OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution."
75452790|NCT01743287|Drug|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
75452791|NCT01743287|Drug|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
75452792|NCT01743300|Drug|Sunitinib|All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
75603870|NCT05699252|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will be used to help participants learn about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
75603871|NCT05688683|Other|use of a theremin-type musical instrument|The patient will perform the task of reproducing sounds by manipulating an object. The settings of the object will be changed and the patient will have to reproduce the sounds a second time by manipulating the object.
75452793|NCT01743300|Drug|Midazolam|All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
75603872|NCT05683964|Drug|Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]|per standard care
76065687|NCT03747393|Behavioral|DoD/VA CPG Core Set + PT|Participants randomized to receive the core set management class and physical therapy will be scheduled for their initial physical therapy evaluation approximately 1 week from their enrollment date. The purpose of the evaluation will be to identify relevant impairments that can be addressed during the physical therapy treatments. After this initial evaluation, the goal is for the patient to receive approximately 4 weeks of physical therapy (about 8-10 sessions in the clinic 2-3 times per week). Consistent with a pragmatic study we will not use placebos to blind patients or attempt to balance provider contact.
76065688|NCT03747393|Behavioral|DoD/VA CPG Core Set|The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.
75603873|NCT05683964|Diagnostic Test|Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan|Per standard care
76065689|NCT03745820|Drug|BIIB104|Administered as specified in the treatment arm
76065690|NCT03745820|Other|Placebo|Administered as specified in the treatment arm
76065691|NCT03720522|Procedure|Short cardiovascular MRI (CMR)|A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
76065692|NCT03720522|Procedure|Adenosine-perfusion cardiovascular MRI (CMR)|An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
75452794|NCT01743300|Other|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
75452795|NCT01743300|Other|Grapefruit juice|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
75603874|NCT05678998|Drug|WTX-330|Investigation Product
75603875|NCT05638802|Drug|DS-7011a|20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
75603876|NCT05638802|Drug|Placebo|Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
75603877|NCT05637762|Other|- EEG video recording or extension of an EEG video recording planned as part of the care - Wearing a connected heart rate and motion recording patch|The study consists of creating a database to develop an algorithm using machine learning methods.
75603878|NCT05633888|Device|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
76065693|NCT03720522|Procedure|Blood draw|"The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months."
75452796|NCT01743326|Procedure|Radio Frequency Denervation|
75452797|NCT01743326|Procedure|Local Anesthesia|
75452798|NCT01743339|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
75603879|NCT05627869|Procedure|Transversus thoracic plane block|TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.
75603880|NCT05627869|Procedure|Pecto intercostal fascial block|PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
75748749|NCT04395989|Drug|D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
75748750|NCT04395989|Drug|D2: nab-paclitaxel, with maintenance of capecitabine|D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
75748751|NCT04395989|Drug|E1: everolimus with nab-paclitaxel|E1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
75748752|NCT04395989|Drug|E2: nab-paclitaxel|E2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
75748753|NCT04382612|Device|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
76065694|NCT03720522|Procedure|Urine (collection over 24h)|"The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months"
75603881|NCT05625594|Procedure|Aspiration|Undergo CSF aspiration
75603882|NCT05625594|Procedure|Biospecimen Collection|Undergo blood sample collection
75603883|NCT05625594|Procedure|Catheterization|Undergo catheterization
75603884|NCT05625594|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given ICV
75603885|NCT05625594|Procedure|Computed Tomography|Undergo CT
75603886|NCT05625594|Drug|Cyclophosphamide|Given IV
75603887|NCT05625594|Drug|Fludarabine|Given IV
76065695|NCT03706664|Other|Machine learning algorithm|Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.
76065696|NCT03704922|Biological|Transfusion|Red cell units for transfusion
75452799|NCT01743339|Behavioral|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
75603888|NCT05625594|Procedure|Leukapheresis|Undergo leukapheresis
75603889|NCT05625594|Procedure|Lumbar Puncture|Undergo lumbar puncture
75748754|NCT04360941|Drug|Palbociclib|Highly selective oral inhibitor of CDK4 and CDK6.
75748755|NCT04360941|Drug|Avelumab|Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
75748756|NCT04357275|Other|ICU treatment|ICU treatment according to standard of care
75748757|NCT04336618|Device|Liver MultiScan|The LiverMultiscan is a quick 15 minute, contrast free, non-invasive MRI scan that provides 3 liver metrics
76065697|NCT03699631|Drug|Tacrolimus|Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
76065698|NCT03699631|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
75452800|NCT01743365|Drug|Cisplatin-5FU-Afatinib|
75603890|NCT05625594|Procedure|Magnetic Resonance Imaging|Undergo MRI
75603891|NCT05625594|Procedure|Positron Emission Tomography|Undergo PET
75603892|NCT05622565|Diagnostic Test|Various modalities of ocular fundus imaging|Through various modalities of ocular fundus imaging, combining with clinical data and the experience of clinicians to diagnose different fundus diseases.
75603893|NCT05618301|Drug|Motixafortide|Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
75603894|NCT05618301|Drug|Natalizumab|Natalizumab will be administered as an IV infusion at a flat dose of 300 mg
75748758|NCT04303858|Drug|Eciskafusp Alfa|Participants will be administered eciskafusp alfa in different schedules.
75748759|NCT04303858|Drug|Atezolizumab|Participants will be administered 1200 mg of atezolizumab once every 3 weeks.
76065699|NCT03699631|Drug|Tocilizumab|Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
75452801|NCT01743378|Procedure|TAP Block Ropivacaine 0,75 %|
75603895|NCT05618301|Procedure|Leukapheresis|Leukapheresis consisting of a 1 Blood Volume procedure
75603896|NCT05618158|Behavioral|4 Corners Rural Health Cancer Prevention|Participants, aged 18-26, will join a private Facebook group to participate in the intervention. The group is not viewable to the public, including other Facebook users. Content that focuses on cancer prevention behaviors will be posted twice per day for up to 12 months. Each group will be hosted by a moderator who is responsible for managing the intervention goals and participants' engagement.
75748760|NCT04294810|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
75748761|NCT04294810|Drug|Tiragolumab|Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
75748762|NCT04294810|Drug|Matching Placebo|Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
75748763|NCT04282785|Diagnostic Test|Concentration monitoring of antibiotics in plasma|Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.
75748764|NCT04273555|Drug|[18F]-FDG|[18F]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.
76065700|NCT03686150|Dietary Supplement|Vitamin D3 oral regimen|Vitamin D3 oral regimens supplementation
75452802|NCT01743378|Procedure|TAP Block Saline 0,9 %|
75452803|NCT01743404|Dietary Supplement|Inflaminat|
75452804|NCT01743404|Drug|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
75748765|NCT04258722|Other|Resuscitation Personnel|Type of resuscitation team
75748766|NCT04239794|Drug|Propofol|General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
75748767|NCT04239794|Drug|Sevoflurane|General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
75603897|NCT05596695|Other|Minimizing blood pressure variability|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anaesthesia.
75603898|NCT05590975|Behavioral|PACT Intervention|PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.
75603899|NCT05576636|Behavioral|Simulation training|"Expectations regarding the scenario were explained to the participants before the implementation. They were given information about the standard patient. Roles were distributed, and the implementation time of the scenario was announced. Written permission was obtained from students involved in the scenario. The intervention group was given scenario-based education appropriate for the approach to a standard patient with COVID-19. During the implementation of the scenario, the instructor did not interfere with students, and after the feedback, the show-do method was used to improve the incorrect skill steps. Two instructors evaluated students' performance on the standard patient simulation as achieved-failed and the application was recorded as a pre-test."
75603900|NCT05576636|Other|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
75603901|NCT05549778|Drug|Polaprezinc group|Abiraterone plus Polaprezinc for 6 months
75603902|NCT05549778|Drug|Control group|Abiraterone, radio- or chemotherapy
75603903|NCT05541796|Device|Intraocular lens|"Tecnis Symfony Optiblue (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus IOL that provides a continuous range of clear vision at far and intermediate.~Tecnis Synergy™ IOL (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles."
75603904|NCT05535933|Drug|HMPL-523(300mg PO QD)|No more than two doses will be explored
75603905|NCT05535933|Drug|Placebo|Placebo
75603906|NCT05513924|Drug|Latanoprost 0.005% Ophthalmic Solution|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~The LT solution will be applied immediately to vitiligo patch one drop (contains 1.5 μg of LT) for every 2.5 cm.~This procedure will be repeated every two weeks for six months."
75748768|NCT04225455|Device|Glucose monitoring|"To compare the glucose monitoring CGMS Dexcom G6® with their usual self-glucose monitoring in pilots by way of assessing times achieved in safe Green flying range, in Amber flying range and in Red flying range as defined by the ARA.MED.330 diabetes protocol.~[Green: 5-15 mmol/L; Amber: 4 to <5mmol/L and >15 to 20mmol/L; Red: <4mmol/L and >20mmol/L]"
75748769|NCT04222556|Behavioral|Thiwáhe Gluwáš'akapi|Thiwáhe Gluwáš'akapi (TG, sacred home in which family is made strong) is a cultural adaptation of the Strengthening Families Program for Parents and Youth 10-14 (SFP 10-14). TG, like SFP 10-14, is a 7-week family-based prevention program with separate youth and adult sessions followed by family sessions. Videos teach content and spark discussion; games and activities foster interaction and provide opportunities to practice skills. Four key adaptations were made to create TG: (1) cultural kinship teachings and tribal language kinship words were embedded throughout; (2) a parent session on coping with stress was enhanced to teach recognizing and responding to trauma reactions in youth; (3) a session on listening was moved earlier in the curriculum, given cultural oral tradition; (4) session videos were remade with local actors and adapted scenarios. A multiphase optimization strategy design was used to test potential adaptations, resulting in the optimized TG program.
75748770|NCT04222556|Behavioral|Woyute Waśte|Woyute Waśte (WW) was adapted from the Colorado School of Public Health's Integrated Nutrition Education Program (INEP) for the culture and context of the reservation. Families will meet for 1 session to participate in hands-on activities - preparing healthy meals, family physical activity, and sugary drinks. They will discuss setting healthy goals and tracking progress, receive recipes and water bottles, and for 6 weeks after the session, will get text messages with additional program content.
75748771|NCT04220229|Drug|Cabozantinib S-malate|Given PO
75748772|NCT04220229|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
75748773|NCT04200911|Drug|Rapamune|Sirolimus 1mg capsules
75452805|NCT01743417|Behavioral|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
75452806|NCT01743430|Other|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
75452807|NCT01743443|Other|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
75452808|NCT01743456|Other|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
75748774|NCT04164472|Behavioral|Friend to Friend (F2F) with Coaching|Friend to Friend (F2F) with Coaching has 14 small group sessions and 8 classroom sessions as led by school staff with coaching from the Children's Hospital of Philadelphia (CHOP) research team. The program aims to improve problem solving and prosocial behaviors, and decrease aggressive behaviors.
75748775|NCT04158687|Drug|CTP-692|Administered as powder for oral solution.
75452809|NCT01743482|Drug|Pazopanib|
75603907|NCT05513924|Drug|5Fluorouracil|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~Topical application of 5-fluorouracil 5% solution will be rubbed over the affected area for about 2 minutes. Occlusive dressing for hours.~This procedure will be repeated every two weeks for six months."
75603908|NCT05502562|Drug|Oral semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
75452810|NCT01743495|Behavioral|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
75452811|NCT01743508|Procedure|Misoprostol treatment by midwife|Misoprostol treatment by midwife
75603909|NCT05496062|Device|F&P Toffee Nasal and Toffee Nasal Pillows Masks|F&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
75603910|NCT05470205|Drug|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
75603911|NCT05470205|Drug|SHAPE measurement (Definity ultrasoud contrast agent)|Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
75748776|NCT04158687|Drug|Placebo|Administered as powder for oral solution.
75748777|NCT04155125|Drug|efepoetin alfa|The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.
75748778|NCT04155125|Drug|Mircera|The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.
75748779|NCT04153864|Behavioral|Brief Behavioral Activation Treatment|A manualized 6-8 session BA treatment delivered individually to each participant.
75898774|NCT04443452|Diagnostic Test|Muscle Strength Assessment|Isometric testing will be done at 30 and 60 degrees of flexion as done in the previous study and the participant will be in sitting position with hips and knees strapped to keep the position standardised.
75452812|NCT01743547|Other|Yoga|Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
75452813|NCT01743573|Other|yoga|
75452814|NCT01743586|Other|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
75452815|NCT01743612|Procedure|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
75452816|NCT01743612|Procedure|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
75452817|NCT01743638|Procedure|MR-Guided Laser Ablation|
75452818|NCT01743664|Behavioral|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
75748780|NCT04127032|Behavioral|PSP Wellbeing Course|A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
75748781|NCT04123418|Biological|WVT078|WVT078 will be administered IV (intravenously) in a dose escalation schedule
76065701|NCT03680781|Device|Intermittent theta-burst stimulation (iTBS)|"Participants will receive iTBS to the left DLPFC or bilateral DLPFC, to the right and left DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device."
76065702|NCT03678233|Drug|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
76065703|NCT03663218|Radiation|Dose escalation|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
76065704|NCT03657771|Other|DED|DED: Diet eliminating dairy
76065705|NCT03657771|Other|FREE|FREE: Diet eliminating dairy and food additives
76065706|NCT03650478|Device|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
76065707|NCT03650478|Device|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
76065708|NCT03632616|Other|PANQOLI (quality of life instrument)|A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, and 6 months post-intervention.
75452819|NCT01743664|Behavioral|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
75452820|NCT01743690|Biological|Probiotic lactobacilli reuteri|
75452821|NCT01743690|Drug|Nystatin|
75452822|NCT01743690|Drug|fluocinolone|
75603912|NCT05463835|Dietary Supplement|RubusElite|Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.
75603913|NCT05463835|Dietary Supplement|'Protein rich' dairy beverage|This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.
75748782|NCT04123418|Drug|WHG626|WHG626 will be administered orally in a dose escalation schedule
75452823|NCT01743755|Drug|Dexamethasone|Dexamethasone tablet 6 mg, once daily for four consecutive days
75452824|NCT01743755|Drug|Placebo|Placebo tablet, once daily for four consecutive days
75452825|NCT01743781|Behavioral|video|view a 10-minute informational video about comprehensive eye examination
75452826|NCT01743794|Drug|Ropivacaine|wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
75452827|NCT01743794|Drug|Saline solution 0.9%|wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
75603914|NCT05463835|Dietary Supplement|'Low Protein' dairy beverage|This product also contains no polyphenols and negligible protein.
75603915|NCT05451979|Device|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
75603916|NCT05447416|Device|Hyperbaric Oxygen Therapy - HBOT|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
75603917|NCT05447416|Device|Intermittent Hypoxic Training - IHT|Each session lasts 60 minutes of 15.2% oxygen at 1.0 ATA. Subjects will be training according to individualized training protocol.
75603918|NCT05444777|Drug|Ketamine Hydrochloride|Ketamine was given prior to wound closure.
75603919|NCT05433961|Drug|MagniXene Hyperpolarized Xenon MRI|Magnetic Resonance Imaging of lung function using Hyperpolarized Xenon as a contrast agent.
75603920|NCT05429411|Other|Silicone gel|At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach >21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
75748783|NCT04098276|Behavioral|WeWomen Plus technology based intervention|The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
75748784|NCT04094818|Diagnostic Test|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
75898775|NCT04443452|Diagnostic Test|Function Assessment (A)|"The participant will start in a seated position. The participant will stand up upon therapist's command, walk 3 meters, turn around, walk back to the chair and sit down. The time will stop when the participant is seated. The subject can use an assistive device. If the assistive device is used, it will be documented.~Important Note: A practice trial will be completed before the timed trial."
75898776|NCT04443452|Diagnostic Test|Function Assessment (B)|The 30-Second Chair Test is administered using a chair. The participant is seated in the middle of the chair with arms crossed at the wrists and held against the chest. The participant will practice a repetition or 2 before completing the test. If a participant must use their arms to complete the test, they are scored 0. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand. While monitoring the participant's performance to ensure proper form, the tester silently counts the completion of each correct stand. The score is the total number of stands within 30 seconds (more than halfway up at the end of 30 seconds counts as a full stand). Incorrectly executed stands are not counted. The 30-second chair stand involves recording the number of stands a person can complete in 30 seconds rather than the amount of time it takes to complete a pre-determined number of repetitions.
75898777|NCT04443452|Diagnostic Test|Balance Assessment|Static balance and postural sway either in the medial-lateral or antero-posterior direction will be assessed using the RS Scan force plate. The participant will be asked to stand on the plate looking straight forward for 30 seconds in two conditions: first with their eyes open and then with eyes closed. Medial-lateral, antero-posterior and total sway will be recorded.
76065709|NCT03617718|Drug|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
75898778|NCT04384835|Biological|Blood sample collection (one tube)|Collection of one tube of 7.5 ml blood in addition to a blood sample made in clinical practice
75898779|NCT04384835|Biological|Blood sample collection (five tubes)|Collection of five tubes of 7.5 ml blood in addition to a blood sample made in clinical practice
75898780|NCT04336215|Other|Non-Interventional|This non-interventional study poses no additional risks to people with pre-existing conditions.
76065710|NCT03610061|Drug|Durvalumab|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
76065711|NCT03610061|Radiation|Radiotherapy|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
76065712|NCT03610061|Radiation|Radiotherapy (cohort 6 only)|"Cohort 6 patients (only) will receive:~Day 8-Day 10: External Beam Radiotherapy to target site(s)- daily (ie. 5 further fractions to a total of 10 fractions)"
75452828|NCT01743807|Drug|GNKG168|GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.
75452829|NCT01743820|Drug|dihydroartemisinin-piperaquine|
75452830|NCT01743820|Drug|0.125 mg/kg Primaquine|
75452831|NCT01743820|Drug|0.5 mg/kg Primaquine|
75452832|NCT01743820|Drug|0.25 mg/kg Primaquine|
75452833|NCT01743820|Drug|0.0625 mg/kg Primaquine|
75452834|NCT01743833|Other|Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)|
75452835|NCT01743833|Other|Scapular High Velocity, Low Amplitude Thrust Maneuver|
75748785|NCT04090749|Behavioral|Caregiver-Support|intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
76065713|NCT03606642|Drug|Dual Antiplatelet (DAPT) Therapy|"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."
75748786|NCT04090424|Device|NovoSorb BTM|NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
75603921|NCT05423613|Procedure|Microneedling|A 5% lidocaine anesthetic cream will be applied to the scar to be treated and will be wrapped with an occlusive dressing (saran wrap) for 30 minutes prior to the procedure. The same scar will be subjected to the ACS-Pen treatment at a depth of 1.5 mm or less depending on the results of the thickness measurement performed prior to treatment. Within 5 minutes after the microneedling treatment, a thin layer of triamcinolone acetonide and 2% xylocaine (1:3 ratio) suspension will be spread over the scar. The physician will then gently massage the product into the microneedling columns. The same amount will be used for each subsequent treatment. The patient will also be given a small amount of hydrocortisone 2.5% (low potency corticosteroid) to be applied to the treated site at 12 hours and 24 hours post-treatment.
75748787|NCT04090424|Procedure|Standard of Care|Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.
75748788|NCT04076059|Drug|Enzalutamide|Oral
76065714|NCT03606642|Device|The Synergy® stent|IVUS guided stent
76065715|NCT03604172|Behavioral|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
75748789|NCT04076059|Drug|Placebo|Oral
76065716|NCT03604172|Behavioral|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
76065717|NCT03591263|Other|Pulmonary rehabilitation|Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
76065718|NCT03572322|Other|Focus Group|Focus Group
76065719|NCT03572322|Other|Interviews|Interviews
76065720|NCT03561012|Behavioral|Team-Based Goals and Incentives|The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).
76065721|NCT03561012|Other|Control Condition|Standard of care
75603922|NCT05421130|Device|Selective Cerebral Perfusion Catheter|This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
75603923|NCT05410821|Drug|177Lu-DOTA-EB-FAPI 1 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 60 mCi (2.22 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
75603924|NCT05410821|Drug|177Lu-DOTA-EB-FAPI 2 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.33 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
75748790|NCT04076059|Drug|Androgen deprivation therapy (ADT)|All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
75748791|NCT04047420|Drug|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
75748792|NCT04026516|Device|CAVA Device|The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
76065722|NCT03527043|Drug|Escitalopram|10mg by mouth daily for 6 weeks
76065723|NCT03527043|Other|Placebo|matched placebo control by mouth for 6 weeks
76065724|NCT03503032|Procedure|Extracardiac Fontan|Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery [applied to both arms]
76065725|NCT03503032|Procedure|Fontan fenestration|Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium [Fenestrated arm]
76065726|NCT03496207|Drug|Placebo|Placebo
76065727|NCT03496207|Drug|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
75748793|NCT04006457|Drug|PF-06651600|50 mg oral tablets/capsules
75748794|NCT04006457|Biological|Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
75748795|NCT04006457|Biological|Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
75748796|NCT04003636|Biological|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
75748797|NCT04003636|Drug|Gemcitabine|Gemcitabine by IV infusion
75748798|NCT04003636|Drug|Cisplatin|Cisplatin by IV infusion
75748799|NCT04003636|Drug|Placebo|Placebo to pembrolizumab
75748800|NCT03973814|Device|Thermax Blood Warmer|Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
75603925|NCT05410821|Drug|177Lu-DOTA-EB-FAPI 3 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 135 mCi (4.99 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
75603926|NCT05410743|Drug|177Lu-LNC1010 1|The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
75452836|NCT01743885|Drug|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
75603927|NCT05410743|Drug|177Lu-LNC1010 2|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
75603928|NCT05410743|Drug|177Lu-LNC1010 3|The patients were intravenously injected with single dose 5.18GBq (140 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
75603931|NCT05408546|Drug|TS23|Monoclonal antibody to a2-antiplasmin
75603932|NCT05408546|Drug|Placebo|Placebo
75603933|NCT05402579|Genetic|Genomic analysis|Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)
75748801|NCT03966651|Drug|PRRT with 177Lu-DOTATATE|Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
75748802|NCT03958045|Combination Product|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
75748803|NCT03954067|Biological|ASP9801|Administered by intratumoral injection
75452837|NCT01743885|Drug|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
75452838|NCT01743898|Drug|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
75452839|NCT01743898|Other|no anticoagulation|
75452840|NCT01743911|Other|sugar pill|Sugar pills: 20mg orally, once a day for 2 weeks
75452841|NCT01743911|Drug|Tadalafil|Tadalafil pills: 20mg orally, once a day for 2 weeks.
75452842|NCT01743924|Other|raw broccoli|To eat this plant material
75748804|NCT03954067|Combination Product|Pembrolizumab|Administered by Intravenous Infusion
75748805|NCT03952065|Drug|PD1/PDL1/CTLA4 inhibitors|Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.
75748806|NCT03911271|Drug|0.1% atropine and 0.01% atropine|0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months
75748807|NCT03911271|Drug|0.01% atropine|0.01% atropine for 24 months
75748808|NCT03911271|Drug|0.9% Sodium-chloride|Placebo for 24 months
75452843|NCT01743937|Procedure|Coronary occlusion with balloon inflation|
75452844|NCT01744002|Other|Shoulder treatment and neck mobilization|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
75748809|NCT03904134|Other|Donor Search Prognosis Score|Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
75748810|NCT03898479|Drug|CTP-543|Twice daily dosing
75452845|NCT01744002|Other|Control|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
75452846|NCT01744015|Behavioral|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
75603934|NCT05388526|Other|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
76065728|NCT03496207|Other|SOC|SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
75603937|NCT05384431|Dietary Supplement|Muscle5 and TRIM7|Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks
75603938|NCT05384431|Other|Mixed exercise|Mixed exercise (aerobic and resistance) three days per week for 12 weeks
76065729|NCT03494868|Dietary Supplement|Carbohydrate Drink|2 - 12 oz drinks
75748811|NCT03885024|Other|Retention Video|Participants assigned to the retention training arm will watch a brief training video that will include information on how to retain peers in clinical trials.
75748812|NCT03868475|Procedure|Vacuum-assisted percutaneous excision|The intervention group will undergo the vacuum assisted percutaneous excision (VAPE). All VAPE procedures will be performed on a digital supine table using the ATEC© Breast Biopsy System hand piece (Hologic) with a 9-gauge needle and a 10 or 20 mm aperture providing 6-mmHg of suction strength to completely excise the breast lesion.
75603939|NCT05370469|Other|Sensus Smartwatch Application|Sensus is capable of administering ecological momentary assessments (EMAs) on a schedule, randomly, or using sensor-triggers. In this way, Sensus will capture both active (patient-initiated) and passive data streams from native smartphone sensors. Passive streams may include, but are not limited to, GPS, accelerometer, gyroscope, and pedometer data. Participants will be able to log data such as their activity, symptoms and medication adherence via user-initiated surveys within the Sensus app. Sensus will also prompt users to record their medication adherence, symptoms, or activity. This will be done either at fixed intervals (e.g., three times daily) or whenever the onboard sensors detect potential changes in a user's physiological state (e.g., shaking / moving around).
75603940|NCT05370469|Device|RX Cap|The RXCap medication event monitoring device will be used to collect data on participant adherence to their TKI medication. A small computer chip is included in the top of a pill bottle. When the cap is taken off of the pill bottle by turning it or unscrewing it, the cap records the time and date that it was removed.
75898781|NCT04313985|Device|Tennant Biomodulator-Pro™ Device|Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
75898782|NCT04305782|Device|Release/Relock Socket - In Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, in lab, following a structured protocol. Tests will determine if the order of the re-lock mechanisms influences changes in limb volume.
75898783|NCT04305782|Device|Release/Relock Socket - Out of Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine if the order of the re-lock mechanisms changes participant experience.
75603941|NCT05370469|Device|Fitbit Sense|The Fitbit Sense smartwatch will be used to collect data including steps, calories burned, total distance travelled, sleep (e.g. time spent sleeping and quality of sleep), flights of stairs climbed, active minutes, exercise (e.g. minutes spent exercising at various intensities), and average heart rate.
75603942|NCT05370469|Other|Surveys|Electronic and paper surveys will be administered throughout the study.
75748813|NCT03868475|Procedure|Open surgical excision|The control group will undergo standard open surgical excision of the breast lesion. This will be done in the operating room using preoperative image-guided localization with radioactive seed (I-125) or in the procedure room of the Breast Care Centre if appropriate (i.e. lesion is palpable and localization is not required).
75748814|NCT03847766|Behavioral|PRO-based follow-up|Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic
75898784|NCT04305782|Device|Release/Relock Socket & Control|The participants will operate the test socket in one of two test conditions: (1) release/relock mechanisms enabled and (2) release/relock mechanisms disabled. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine how the novel release/relock mechanisms compare against traditional socket release methods.
75898785|NCT04283578|Drug|OT|One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
75898786|NCT04283578|Drug|Placebo comparator|One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.
75898787|NCT04274998|Drug|[18F]NOS|Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer [18F]NOS.
76065730|NCT03481985|Other|Fenestration status|The exposure variable will be status of the Fontan fenestration
76065731|NCT03458221|Drug|Letrozole Oral Product|Letrozole 2.5mg tablet - 2.5mg once dailty until progression of disease.
76065732|NCT03458221|Drug|Bicalutamide Oral Product|Bicalutatmide 150mg tablet - 150mg once daily until progression of disease.
76065733|NCT03458221|Drug|Everolimus Oral Product|Everolimus 10mg tablet - 10mg once daily until progression of disease.
76065734|NCT03458221|Drug|Itraconazole Oral Product|Itraconazole 100mg capsule - 300mg twice daily until progression of disease.
76065735|NCT03451487|Drug|Panadol®|Acetaminophen 500mg Tablet
76065736|NCT03451487|Drug|SafeTynadol®|Acetaminophen 500mg Tablet
76065737|NCT03444870|Drug|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
76065738|NCT03444870|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
75748815|NCT03847766|Behavioral|PRO-based telephone consultation|diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation
75748816|NCT03844048|Drug|Venetoclax|oral; film-coated tablets or tablets for oral suspension
75748817|NCT03833167|Biological|Pembrolizumab 400 mg|Administered by IV infusion on Day 1 of each 42-day cycle
75748818|NCT03833167|Drug|Placebo|Administered by IV infusion on Day 1 of each 42-day cycle
75748819|NCT03808584|Other|Physiotherapy|4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
75748820|NCT03806179|Drug|10 MBq/kg Betalutin|10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
75748821|NCT03806179|Drug|15 MBq/kg Betalutin|15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
75748822|NCT03789084|Behavioral|Brief Cognitive-Behavioral Therapy for Health Anxiety|4-session in-person 45-minute psychotherapy sessions focused on building motivation for change, psychoeducation, cognitive restructuring, and situational and interoceptive exposure to health-related fear stimuli.
75748823|NCT03789084|Behavioral|Referral to mental health provider|Provider makes a referral to a mental health provider in the outpatient psychiatry clinic or a community provider of the participant's choice.
75748824|NCT03788213|Radiation|3 week RT|40 Gy in 15 fractions over 3 weeks to the whole breast or chest wall. Patients undergoing breast conservation therapy will receive additional boost radiotherapy to the tumor bed. The supraclavicular fossa will be treated in patient with node positive disease or those receiving neoadjuvant chemotherapy. IMC and Axillary radiotherapy will be given as per the institutional policy. Boost Dose schedule for BCS patients will be 8 Gy delivered in 15 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
75898788|NCT04274998|Drug|[11C]PBR28|Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer [11C]PBR28 in comparison to [18F]NOS.
76065739|NCT03429322|Behavioral|Medical Care and Resource Facilitation|The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
76065740|NCT03429322|Other|Usual Care|Participants will receive and provide usual and customary care in their communities.
76065741|NCT03410030|Drug|Ascorbic Acid|combination therapy
75452847|NCT01744015|Other|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
75452848|NCT01744028|Device|Remote Patient Monitoring|Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
75452849|NCT01744028|Other|Usual care|Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
75452850|NCT01744054|Device|PET/MR|
75452851|NCT01744054|Device|PET/CT|
76065742|NCT03410030|Drug|Paclitaxel protein-bound|combination therapy
76065743|NCT03410030|Drug|Cisplatin|combination therapy
75603943|NCT05370274|Procedure|Strength training intervention|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb (the wrist extensors and the elbow and shoulder flexors). In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Training will start at 50% of 1RM and progress by 10% each week to reach 80% of 1RM by week 4. The same gradation of intensity will be applied to the grip muscles. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
75898789|NCT04271371|Other|Not yet developed|A prototype intervention will be developed over Phase 1 & 2 and piloted in Phase 3 of this study.
75898790|NCT04267302|Other|Baby Bouncer|Fischer Price baby bouncer.
75603944|NCT05370274|Procedure|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each strength training session, the CN-NINM will be applied, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants for 20 minutes. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 μsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
75603945|NCT05355168|Procedure|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
75603946|NCT05352542|Biological|LCAR-H93T Cells|before treatment with LCAR-H93T cells, subjects will receive a conditioning regimen
75603947|NCT05342337|Other|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management.~Telerehabilitation group participate in the sessions that last for one and a half hours, 3 days a week for 12 weeks, video conference over the Zoom program. The investigator, who provides supervision during the sessions, also participates in the exercises simultaneously."
76065744|NCT03410030|Drug|Gemcitabine|combination therapy
75603948|NCT05342337|Other|Control group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
75603949|NCT05340868|Drug|Semaglutide Pill|Oral semaglutide treatment
76065745|NCT03406221|Behavioral|Information Communication Technology Continuum of Care Service|Mobile phones were made available to community health workers in the intervention arms that integrated a comprehensive set of functions to assist them in their duties, including registration and tracking of beneficiaries, automated scheduling of home visits, provision of health information through videos, guided protocols for conducting home visits through checklists, a feature to track child immunizations, and supervisory tools.
75603950|NCT05330130|Drug|Follitropin beta injection 150 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
75748825|NCT03788213|Radiation|1 week RT|26 Gy in 5 fractions over 1 week to the whole breast or chest wall. Treatment volumes will be same as the control arm. Additional boost will be delivered to patients who have undergone breast conservation. Boost Dose schedule for BCS patients will be 6 Gy delivered in 5 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
75452852|NCT01744067|Drug|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
75452853|NCT01744067|Drug|Placebo|Placebo capsules 3 times a day (oral administration)
75748826|NCT03783624|Behavioral|Hypnosis|A 6 session course of individual hypnosis therapy will be offered.
75748827|NCT03783624|Behavioral|Open label placebo|Ritual intake of 2 placebo capsules twice a day
75748828|NCT03768440|Procedure|continuous erector spinae block (ESB)|Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
75769350|NCT03909958|Behavioral|Routine rehabilitation training Group|"Routine rehabilitation training:~Participants with good spinal stability will receive sitting training as early as possible, and will carry out standing training if participants had no adverse reactions (postural hypotension, etc.) after sitting training. Muscle strength training will be performed in recovery phase, and functional movement training will be selected according to participants' conditions. Functional movement training and transfer training will be performed for 20min each time and once a day;Standing and walking training, 2 times a day, 30min each time."
75898791|NCT04267302|Other|Infant t-shirts with Language Environment Analysis (LENA) audio recorders|Infant t-shirts with wearable LENA audio recorders for 2-8 hours of recordings of vocal interaction, crying and turn-taking.
76065746|NCT03406221|Other|Control Condition|Standard of care
75452854|NCT01744080|Other|Regular Wait Time|Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.
75452855|NCT01744080|Other|Early Surgery|Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
75452856|NCT01744106|Drug|pseudoephedrine hydrochloride 30 mg tablets|
75452857|NCT01744106|Drug|Placebo tablets|
75452858|NCT01744119|Device|Vascutek Anaconda™ Stent Graft System|
75452859|NCT01744132|Behavioral|Aim 3: Contract|
75898792|NCT04267302|Other|Baby Carrier|Ergobaby Baby carrier.
75603951|NCT05330130|Drug|Follitropin beta injection 300 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
75603952|NCT05326711|Behavioral|Telerehabilitation-based motor imagery training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies."
75603953|NCT05323981|Drug|HS627(210mg/7ml)|Intravenous drip of 420mg HS627
75603954|NCT05323981|Drug|HS627(420mg/14ml)|Intravenous drip of 420mg HS627
75603955|NCT05323981|Drug|Perjeta|Intravenous drip of 420mg PERJETA
75603956|NCT05319860|Drug|Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)|Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
75603957|NCT05319860|Drug|Aromatherapy Care|An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
75603958|NCT05311475|Drug|Mometasone|Mometasone furoate nasal spray (50 mcg per actuation)
75603959|NCT05311475|Drug|Azelastine|Azelastine hydrochloride nasal spray (140 mcg per actuation)
75603960|NCT05311475|Drug|Placebo|Placebo nasal spray
75603961|NCT05311176|Biological|IMU-131|IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
75603962|NCT05311176|Drug|Ramucirumab plus Paclitaxel|Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
75603963|NCT05311176|Biological|Pembrolizumab|Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
75603964|NCT05309226|Other|Cannabis use in pregnancy or cannabis exposure in utero|Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).
75603965|NCT05294549|Other|Caring Contact|The Caring Contact intervention is an email with messages of hope, support and resource information sent to patients post-discharge from psychiatric hospitalization.
75769351|NCT02527876|Behavioral|High Intensity Interval Training|High Intensity Interval Training
76065747|NCT03400553|Diagnostic Test|Blood analysis|The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
75769352|NCT02527876|Behavioral|Moderate Intensity|Moderate Intensity Training
75769353|NCT02527876|Behavioral|Delayed Control|Delayed Control
75769354|NCT02527876|Device|FitBit Flex|Use to measure increase in Physical Activity
75898793|NCT04220255|Device|Liberty677MY Multifocal IOL|multifocal intraocular lens (IOL)
75452860|NCT01744158|Other|No intervention applicable|"Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:~differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)~measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording~measurement of severity of spasticity using the modified Ashworth score~description of presence of chorea or athetosis~classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)~classification of fine motor abilities using the manual ability classification system (MACS)~collection of demographic data and associated medical history"
75452861|NCT01744184|Drug|Entonox|Entonox arm
75452862|NCT01744184|Drug|Midazolam|up to 5mg midazolam as appropriate
75452863|NCT01744236|Drug|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
75898794|NCT04160130|Procedure|Transcatheter aortic valve replacement|Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.
76065748|NCT03397017|Other|Transfusion|
76065749|NCT03382301|Drug|Ciclosporin A preconditioning before renal artery stenosis dilation|Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
76065750|NCT03382301|Drug|NaCl preconditioning before renal artery stenosis dilation|NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
75603966|NCT05292781|Other|CHOICES|An innovative web application to provide interactive information about reproductive health options for people with SCD or SCT. CHOICES is a multimedia intervention that provides targeted and tailored information for participants to become informed ns about their reproductive health options. Targeted to their sex and tailored to their SC reproductive health knowledge, reproductive health behavior during the previous 6 mo, and parenting plan (e.g., intention to have child with SCD or not), CHOICES presents information about options to help the participant achieve their parenting plan through reproductive partner selection based on sickle cell status, prenatal testing, ovum and sperm donation, advanced reproductive technologies, and options to avoid pregnancy or adopt. The website will be housed on secure University of Florida (UF) servers and accessible via computers or mobile devices (e.g., tablets, smart phones); device capture will inform plans for long-term dissemination.
75748829|NCT03768440|Procedure|continuous paravertebral block (PVB)|The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
75748830|NCT03768440|Drug|Ropivacaine|Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
75748831|NCT03768063|Drug|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
75748832|NCT03768063|Drug|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
75748833|NCT03768063|Drug|Alectinib|Alectinib will be administered as directed per the parent study.
75748834|NCT03768063|Drug|Cobimetinib|Cobimetinib will be administered as directed per the parent study.
75748835|NCT03768063|Drug|Vemurafenib|Vemurafenib will be administered as directed per the parent study.
75748836|NCT03768063|Drug|FAP IL2V|FAP IL2V will be administered as directed per the parent study.
75748837|NCT03768063|Drug|Venetoclax|Venetoclax will be administered as directed per the parent study.
75748838|NCT03768063|Drug|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
75748839|NCT03768063|Drug|Pembrolizumab|Pembrolizumab will be administered as directed per the parent study.
75748840|NCT03768063|Drug|Sunitinib|Sunitinib will be administered as directed per the parent study.
75748841|NCT03768063|Drug|Niraparib|Niraparib will be administered as directed per the parent study.
75452864|NCT01744236|Drug|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
75748842|NCT03768063|Drug|Cabozantinib|Cabozantinib will be administered as directed per the parent study.
75748843|NCT03768063|Drug|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
75748844|NCT03768063|Drug|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
75748845|NCT03768063|Drug|Emactuzumab|Emactuzumab will be administered as directed per the parent study.
75748846|NCT03768063|Drug|Rucaparib|Rucaparib will be administered as directed per the parent study.
75748847|NCT03759587|Drug|Niraparib|Niraparib capsule
75748848|NCT03752684|Other|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate
75748849|NCT03752684|Other|Moderately high oxalate/low calcium diet|Subjects will be instructed to ingest a controlled diet moderately high in oxalate
75748850|NCT03752684|Other|Oxalobacter formigenes|Subjects will ingest live preparation of O. formigenes
76065751|NCT03379870|Device|Electric Acoustic Speech Processor: EAS fitting|Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
75452865|NCT01744236|Drug|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
75452866|NCT01744236|Drug|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
75452867|NCT01744236|Drug|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
75748851|NCT03748953|Drug|Ixazomib|Ixazomib Capsules
75748852|NCT03746431|Drug|[111In]-FPI-1547 Injection|[111In]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive [111In]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
76065752|NCT03379870|Device|Electric Acoustic Speech Processor: Electric only fitting|Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
76065753|NCT03290391|Other|Rapid ART initiation|The infectionist will streamline the approval with the ultimate goal of starting participants on ART while they are still hospitalized at the City Addiction Hospital.
76065754|NCT03290391|Drug|Pharmacotherapy for opioid use disorder|Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
76065755|NCT03290391|Behavioral|Strengths-based HIV case management|Strengths-based case management: 10 sessions over 12 months in which a trained case manager (CM) meets individually with patients to motivate them to engage in HIV medical care by supporting the recognition of their own strengths to make positive changes in their lives and ultimately improve their HIV outcomes.
76065756|NCT03280030|Drug|Midostaurin|Midostaurin 50 mg [two 25 mg capsules] will be administered twice per day by mouth on day 8-21 during induction and consolidation phase; then continuously during continuation phase
75452868|NCT01744236|Drug|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
75748853|NCT03746431|Drug|[225Ac]-FPI-1434 Injection multi-dose|[225Ac]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of [225Ac]-FPI-1434 Injection. Dose is per cohort assignment.
75748854|NCT03746431|Biological|FPI-1175 Infusion|FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.
75748855|NCT03746431|Drug|[225Ac]-FPI-1434 Injection single-dose|[225Ac]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of [225]-FPI-1434 Injection. Dose is per cohort assignment.
75748856|NCT03737851|Drug|elezanumab|solution for infusion
75748857|NCT03737851|Drug|placebo|solution for infusion
75748858|NCT03737149|Other|mymobility with Apple Watch|The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
75748859|NCT03735121|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in arm or cohort.
75898795|NCT04157062|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in memory and thinking.
75898796|NCT04152772|Device|transcranial direct current stimulation|Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
75898797|NCT04143126|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
76065757|NCT03280030|Drug|Placebo|Placebo two capsules will be administered twice per day by mouth on day 8-21 during induction and consolidation phase ; then continuously during continuation phase.
75603967|NCT05292781|Other|eBook|e-Book contains information typically shared in clinical SCD care, including stick figure representation of inheritance because the investigator considers it unethical to withhold this basic information. It does not include other information related to the SCKnowIQ knowledge items or any of the behaviors needed to implement a parenting plan. Although not as long as CHOICES, the e-Book is sufficiently long, attractive, and engaging to retain participants randomized to the usual care control group; key factors for an adequate control condition. Interestingly, during the study and in interviews after the study, many e-Book participants commented that they were pleased to be assigned to the intervention group (they had not), which indicates that the control condition is sufficient for its intent--2-yr longitudinal retention of the sample. Also, human contact is the same for both groups, and the time-on-task on the computer is unlikely to influence study knowledge and behavior endpoints.
75748860|NCT03735121|Drug|rHuPH20|rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
75748861|NCT03730194|Dietary Supplement|Melatonin|Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime
75748862|NCT03730194|Behavioral|Bedtime Bank|The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
75748863|NCT03723551|Drug|Afabicin|Administered intravenously and orally.
75898798|NCT04143126|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
76065758|NCT03260842|Diagnostic Test|Bio-Specimen Collection|Collection of bio-specimens and observation over time.
76065759|NCT03235219|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
76065760|NCT03235219|Drug|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
75748864|NCT03723551|Drug|Standard of Care|Administered with SOC in accordance with local practice and applicable treatment guidelines.
76065761|NCT03224624|Other|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
76065762|NCT03194867|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
76065763|NCT03194867|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75748865|NCT03689699|Drug|Nivolumab|A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
75748866|NCT03689699|Drug|Degarelix|Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
75748867|NCT03689699|Drug|BMS-986253|BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
75748868|NCT03669497|Radiation|Hypo fractionated whole breast radiotherapy|Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
75748869|NCT03655886|Procedure|radical prostatectomy|can be performed either open, laparoscopic or robot-assisted, which is chosen by the discretion and expertise of the performing surgeon
76065764|NCT03143647|Other|Collect a study-specific blood sample of healthy subjects|One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
75452869|NCT01744236|Drug|L-NMMA|
75452870|NCT01744249|Drug|Axitinib|Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
75452871|NCT01744249|Drug|Sandostatin LAR|Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
75452872|NCT01744249|Drug|Placebo|orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
75452873|NCT01744275|Dietary Supplement|Omega 3 fatty acids|
75452874|NCT01744275|Dietary Supplement|corn oil|Placebo
75452875|NCT01744288|Drug|Ticagrelor|Oral single loading dose 180ng
75452876|NCT01744288|Drug|Clopidogrel|Oral single loading dose 600mg
75452877|NCT01744288|Drug|ASA|81mg once daily from day -2 up to platelet transfusion
75452878|NCT01744301|Drug|Risk of seizure|Patients newly prescribed PPI and H2RA, respectively
75603968|NCT05292599|Other|Experimental|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
75748870|NCT03655886|Radiation|Whole pelvis radiotherapy|radiation of prostate bed and pelvis
75748871|NCT03655678|Biological|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan
75748872|NCT03653507|Drug|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
75748873|NCT03653507|Drug|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
75748874|NCT03653507|Drug|capecitabine|Capecitabine will be administered orally twice daily (bid).
75452879|NCT01744314|Drug|Indomethacin and Pantoprazole|
75452880|NCT01744314|Drug|microcrystalline cellulose powder tablets|
75452881|NCT01744366|Drug|Degarelix|
75452882|NCT01744366|Drug|Goserelin|
75452883|NCT01744379|Drug|Lesinurad|
75452884|NCT01744379|Drug|Placebo|
75452885|NCT01744444|Drug|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
75452886|NCT01744444|Drug|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
75452887|NCT01744457|Device|Measurement of tear film osmolarity with the TearLab® instrument|
75452888|NCT01744457|Other|Schirmer I test|
75452889|NCT01744457|Other|Tear break up time|
75452890|NCT01744457|Device|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
75452891|NCT01744457|Other|Ocular Surface Disease Index|
75748875|NCT03653507|Drug|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
75748876|NCT03581318|Device|MRI|MRI for up to two hours, some without- and some with- administration of intravenous gadolinium based contrast agents (GBCAs), as well as some without and some with pharmacologic or physical stress.
75748877|NCT03568890|Drug|Rivaroxaban, dabigatran, apixaban, or edoxaban|Duration of treatment: 60 days
75748878|NCT03568890|Drug|Clopidogrel -75 mg/day|Duration of treatment: 60 days
75748879|NCT03568890|Drug|Low dose aspirin -80 to 125 mg/day-|Duration of treatment: 60 days
75748880|NCT03562364|Other|AlterG anti-gravity treadmill|The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
75603969|NCT05292599|Other|Control|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
75603970|NCT05289492|Drug|EOS884448|EOS884448 will be administered in arm A,B and C
75603971|NCT05289492|Drug|Iberdomide|Iberdomide will be administered in arm B and C
75748881|NCT03559400|Drug|local gentamicin injection|Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
75748882|NCT03559400|Drug|placebo saline injection|Treatment includes debridement and administration of the local antibiotic which will consist of 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
75898799|NCT04132544|Other|standardized gerontological evaluation (EGS)|Evaluation (EGS): initially, the patient benefits from a complete EGS and a complete fall balance realized by a Gerontological Assessment Nurse (initial visit V0) in the 7 working days following the intervention of the SAMU for fall. This assessment is based on the EGS and the assessment of risk factors for falls (HAS, INPES).
75748883|NCT03530683|Drug|Maplirpacept (PF-07901801)|maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
75748884|NCT03530683|Drug|Azacitidine|intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks
75898800|NCT04132544|Other|Proposal for a personalized intervention plan (PIP)|"A PIP containing personalized recommendations to improve the patient's state of health, treatment and environment as well as risk factors for falls is proposed during the multi-professional consultation and discussed by telephone with the attending physician (pre-arranged telephone appointment). with the latter).~The PIP validated by the attending physician is delivered and explained to the patient by the Gerontological Assessment Nurse in the week following the Multidisciplinary Team Meeting (MDTM) during the V1 visit to the patient's home."
75898801|NCT04132544|Other|Follow-up|"Four follow-up visits at 6, 12, 18 and 24 months (V2, V3, V4, V5) are performed at the patient's home. During these visits, the Gerontological Assessment Nurse reassesses the person from the gerontological point of view and from the point of view of risk factors for falls.~A mail containing the elements of interest is sent to the attending physician after each visit. The patient is also contacted by telephone by the Gerontological Assessment Nurse at 2, 4, 9, 15 and 21 months of follow-up to maintain a link, identify possible difficulties and encourage him / her to apply the PIP recommendations."
75452892|NCT01744470|Drug|Tacrolimus targeted half-dose|
75452893|NCT01744470|Drug|Tacrolimus targeted plain dose|
75452894|NCT01744509|Device|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
75452895|NCT01744522|Procedure|Leech therapy|Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
75603972|NCT05289492|Drug|Dexamethasone|Dexamethasone will be administered in arm C
75603975|NCT05255666|Drug|Pembrolizumab|400 mg intravenously
75603976|NCT05255666|Drug|Liposomal Irinotecan|Starting at 50 mg/m^2. The dose may be increased to 70 mg/m^2 if tolerated or dose reduced to 35 mg/m^ if treatment-emergent severe adverse event (TESAE) occurs.
75603977|NCT05255146|Device|Atricure Inc. Nitrous oxide Cryoprobe|Cryoanalgesia will be given by applying a nitrous oxide-cooled probe (AtriCure, Inc. 2000) locally to intercostal nerves in the 4th, 5th, and 6th rib spaces after completion of the surgical repair and before surgical closure. The probe will be cooled to -60°C and held on each location for 60 sec.
75603978|NCT05247541|Drug|Definity|Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
75603979|NCT05199259|Diagnostic Test|Multi-analyte Blood Test|A clinical diagnostic test based upon the detection and quantification of DNA methylation markers in cell-free DNA (cfDNA) isolated from plasma and of tumor-specific proteins isolated from serum.
76072249|NCT02440295|Device|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
75603980|NCT05198609|Procedure|FOLFOX-HAIC|Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times
75603981|NCT05198609|Drug|Camrelizumab|Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.
75452896|NCT01744535|Behavioral|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users receive instant nutritional feedback and feedback via text message."
75452897|NCT01744535|Behavioral|Paper food diary|"The paper food diary is provided by a commerical slimming organisation called Weight Loss Resources. The diary allows the user to record daily food and drink consumed. It is accompanied by a book which provides a database of the nutritional content of 40,000 food and drinks. The diary also encourages participants to record their physical activity."
75603982|NCT05198609|Drug|Apatinib|Apatinib was administered orally 250mg once per day
75603983|NCT05191004|Drug|NUV-422|NUV-422 is an investigational drug for oral dosing.
75603984|NCT05191004|Drug|Fulvestrant|Fulvestrant
75452898|NCT01744535|Behavioral|Online food diary|"The online food diary is provided by a commerical slimming organisation called Weight Loss Resources. The electronic diary allows the user to record daily food and drink consumed. System users are also encouraged to record their physical activity."
75452899|NCT01744548|Behavioral|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
75603985|NCT05190926|Behavioral|Smart-Treatment for Anorexia Nervosa Recovery (STAR)|"Adolescents will use their smartphone to access short 5-10 minute modules that teach them about the function of emotions, ways to regulate challenging emotions, and strategies to improve negative thinking, mood, and reduce eating-disorder symptoms. Module content will include text, images, videos, and interactive questions and quizzes."
75603986|NCT05190926|Behavioral|Present-focused Anorexia Nervosa Coping Treatment (PACT)|Adolescents will use their smartphone to access two brief psychoeducational modules that teach about the common symptoms of AN, common reactions and problems associated with AN, and goals for treatment. Starting in Week 3, adolescents will complete a Daily Diary that will ask them to record life stressors, challenges, and problems, which will serve as a launching point for discussion with their outpatient therapist.
75603987|NCT05181826|Diagnostic Test|Multi-analyte Blood Test|Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer
75603988|NCT05176457|Other|communication tool PICT'REA|"The pictograms communication tool PICT'REA will be available to patients with invasive ventilation systems preventing them from speaking"
75603989|NCT05144347|Drug|XL114|Tablets of XL114
75748885|NCT03530683|Drug|Venetoclax|orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole
75748886|NCT03530683|Drug|Carfilzomib|Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.
75748887|NCT03530683|Drug|Dexamethasone|starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles
75748888|NCT03530683|Drug|Anti-CD20 Targeting agent|Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
75769355|NCT05619016|Diagnostic Test|[68Ga]Ga-ABY-025 PET|[68Ga]Ga-ABY-025 PET: Each patient in Cohort 1 will be imaged with a PET/CT twice using the radiolabeled investigational product ABY-025 as a tracer. At the time of injection, a 45-minutes long dynamic scan will take place over a pre specified region of interest. Three hours after injection a full body PET scan followed by a CT scan will be performed.
75748889|NCT03530683|Drug|Isatuximab|"F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1."
75748890|NCT03518853|Radiation|Short-course Hypofractionated Once-weekly Radiation Therapy|Eligible patients will be treated with a radiation regimen of 35 Gy in 5 fractions delivered at one fraction per week at 7 day intervals. The dose of radiotherapy is based on the consensus alpha beta ratio of 1.5.
75748891|NCT03513484|Drug|Azacitidine|Given IV or SC
75748892|NCT03513484|Other|Laboratory Biomarker Analysis|Correlative studies
75748893|NCT03513484|Drug|Nintedanib|Given PO
75748894|NCT03500315|Other|HIV D+/R+|Kidney from an HIV-infected deceased donor
75748895|NCT03495674|Behavioral|Exercise Intervention|Complete cycling classes
75748896|NCT03495674|Other|Informational Intervention|Receive information about exercise guidelines
75748897|NCT03495674|Device|Monitoring Device|Wear Fitbit
75748898|NCT03495674|Other|Questionnaire Administration|Complete questionnaire
75748899|NCT03483012|Drug|Atezolizumab|Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway
75898802|NCT04132544|Other|Usual care|"The patients included in the control group will benefit from the usual care as well as documentation on general recommendations to be put in place to prevent falls and to age in good health [series of brochures published by INPES for the elderly. They are informed by telephone of their home group by the Gerontological Assessment Nurse. The documents are sent by mail to the patient's home address."
75898803|NCT04123873|Drug|Paracetamol|1g x 4 p.o.
75748900|NCT03483012|Procedure|Stereotactic radiosurgery (SRS)|Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
75898804|NCT04123873|Drug|Ibuprofen|400mg x 4 p.o.
75898805|NCT04123873|Drug|Dexamethasone|24mg IV x 1 after induction om anaesthesia
76072250|NCT02440295|Drug|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
75748901|NCT03474965|Drug|Crizanlizumab|Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
75748902|NCT03455673|Diagnostic Test|ATE score|"The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (> 270 ng/ml) = 1"
75748903|NCT03440970|Drug|Lysine Chloride|Patients will receive the study drug twice a day for 5 days.
75748904|NCT03440970|Other|Placebo|Patients will receive the placebo twice a day for 5 days.
75898806|NCT04123873|Drug|Placebo oral capsules|p.o. x 4
75898807|NCT04123873|Drug|Placebo IV|IV x 1
75898808|NCT04121585|Device|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
75898809|NCT04117620|Other|Pediatric Vestibular Symptom Questionnaire|Subjects respond to the translated questionnaire twice with 15 days interval
75898810|NCT04116203|Drug|Metformin|Manufacturer's standard 500 mg. Submission Control No.:128147
75748905|NCT03424005|Drug|Capecitabine|Capecitabine will be administered 1250 mg/m^2 orally twice daily on Days 1-14, of each 21 day cycle.
75748906|NCT03424005|Drug|Atezolizumab|"For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle."
75748907|NCT03424005|Drug|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
75748908|NCT03424005|Drug|SGN-LIV1A|SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
75748909|NCT03424005|Drug|Bevacizumab|Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
75748910|NCT03424005|Drug|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.~Or~Eribulin will be administered by IV, 1.4 mg/m^2 on days 1 and 8 of each 21 day cycle."
75748911|NCT03424005|Drug|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
75748912|NCT03424005|Drug|Tocilizumab|Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
75748913|NCT03424005|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered by IV, 100 mg/m^2, on Days 1, 8, and 15 of each 28-day cycle.
75898811|NCT04116203|Combination Product|Fish Oil and Metformin|Combo of 2 other arms
75898812|NCT04116203|Dietary Supplement|Fish Oil|NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral
75898813|NCT04110795|Other|No Intervention|No Intervention
75603990|NCT05132881|Other|Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS)|The intervention administered is the TaVNS program and the fMRI scans to evaluate changes in the brain. The TaVNS program consists of placing ear buds from the device into each ear. They are initially sprayed once with a small amount of saline that is also provided as part of the TaVNS materials. Once the ear buds are placed in each ear, the test subject will start a preprogramed session of vibrations that will stimulate the vagus nerve. The session will last for 15 minutes and then the subject will take the ear buds out and clean them. They will use the TaVNS program once a day for 3 months.
75603991|NCT05132881|Other|Waitlist Control|Baseline imaging and follow up imaging for comparison to the TaVNS health device group at approximately 3 months. The TaVNS intervention is offered after completion of the imaging.
75748914|NCT03424005|Drug|Sacituzumab Govitecan|Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
75748915|NCT03424005|Drug|Abemaciclib|Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
75748916|NCT03424005|Drug|Fulvestrant|Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
75748917|NCT03424005|Drug|Ribociclib|Ribociclib tablets of 400 mg will be administered by mouth on Days 1-21 of each 28-day cycle.
75452900|NCT01744561|Behavioral|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
75452901|NCT01744587|Other|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
75452902|NCT01744587|Dietary Supplement|Placebo|Placebo qd (2# bid) for 3 years
75452903|NCT01744600|Behavioral|Music Therapy|The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
75452904|NCT01744639|Behavioral|HCC under treatment with radioablation|The evaluation will take place over a period of 30 days.
75603992|NCT05132881|Other|Healthy Controls: Substudy Group III|fMRI Imaging to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
75603993|NCT05132881|Other|Distressed Workers: Subgroup II|Subgroup II of 10 subjects with distress(all receiving TaVNS) will undergo fMRI scans with the TaVNS system being turned on and off while in the scanner to observe for any immediate effects and to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
75603994|NCT05128461|Other|Exercise|M-CIMT-based telerehabilitation will be implemented.
75748918|NCT03424005|Drug|Inavolisib|Inavolisib tablets will be administered at a dose of 9 mg by mouth on Days 1-28 of each cycle (cycle = 28 days).
75452905|NCT01744678|Behavioral|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
75452906|NCT01744678|Behavioral|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
75748919|NCT03424005|Drug|Inavolisib (9 mg)|Inavolisib tablets will be administered at a dose of 9 mg by mouth on Days 1-21 of each cycle (cycle = 21 days).
75748920|NCT03424005|Drug|Inavolisib (6 mg)|Inavolisib tablets will be administered at a dose of 6 mg by mouth on Days 1-21 of each cycle (cycle = 21 days).
75748921|NCT03424005|Drug|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
75748922|NCT03420833|Device|Cardiac resynchronization therapy pacemaker (CRT-P)|A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
75898814|NCT04106362|Biological|Cetuximab|Given IV
75898815|NCT04106362|Drug|Cisplatin|Given IV
75898816|NCT04106362|Other|Quality-of-Life Assessment|Ancillary studies
75603995|NCT05128461|Other|Home program|Lower and upper extremity exercises and gait training exercises selected according to the Bobath approach will be given as a home program consisting of 10 same exercises.
75748923|NCT03379649|Combination Product|Platelet rich plasma|Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
75748924|NCT03379649|Combination Product|Placebo|Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
75748925|NCT03368950|Other|Online Mindfulness Course|An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.
75748926|NCT03363893|Drug|CT7001|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
75748927|NCT03363893|Drug|Fulvestrant|Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
75748928|NCT03339128|Drug|Eluxadoline|Oral tablets
75748929|NCT03339128|Drug|Placebo|Oral tablets
75748930|NCT03325088|Procedure|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
75898817|NCT04106362|Other|Questionnaire Administration|Ancillary studies
75898818|NCT04106362|Radiation|Radiation Therapy|Undergo radiation therapy
75898819|NCT04101188|Other|Moderate Potassium/Low Sodium Diet|Consumption of 10 days of a diet moderate in potassium and low in sodium.
75898820|NCT04101188|Other|Moderate Potassium/High Sodium Diet|Consumption of 10 days of a diet moderate in potassium and high in sodium.
75898821|NCT04101188|Other|High Potassium/High Sodium Diet|Consumption of 10 days of a diet high in potassium and high in sodium.
75452907|NCT01744717|Other|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~TURNING / POSITIONING (moving side to side or up or down in bed)~ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
75452908|NCT01744262|Drug|Total intravenous anesthesia|Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5~4 µg/mL and remifentanil effect site concentration 2~5 ng/mL.
75452909|NCT01744262|Drug|Inhalation Anesthesia|Anesthesia induction with intravenous propofol bolus of 1.5~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5~2.0 % and remifentanil effect site concentration 2~5 ng/mL.
75748931|NCT03325088|Procedure|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
75748932|NCT03325088|Procedure|Bronchial alveolar enema|For participants who had signed ancillary research consent
75748933|NCT03251599|Drug|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
75748934|NCT03251599|Drug|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
75748935|NCT03241056|Behavioral|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
75748936|NCT03241056|Other|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
75748937|NCT03231709|Drug|Trelagliptin|Trelagliptin tablets
75748938|NCT03231709|Drug|Alogliptin|Alogliptin tablets
75898822|NCT04100733|Diagnostic Test|Xpert Bladder Cancer Monitor|Xpert Bladder Cancer Monitor detects mRNA fragments from 5 genes frequently overexpressed in non-muscle invasive bladder cancer.
75898823|NCT04100733|Diagnostic Test|Flexible cystoscopy (WL/NBI) and urinary cytology|Adhering to current danish guidelines for follow-up of non-muscle invasive bladder cancer.
75452910|NCT01744743|Procedure|levothyroxine|Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
75452911|NCT01744756|Drug|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
75603996|NCT05111145|Drug|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
75603997|NCT05111145|Drug|IVA|Tablets for oral administration.
75603998|NCT05101824|Radiation|SABR|Two fractionation regimes are available (37.5 Gy in 3 fractions and 30.0 Gy in 3 fractions)
75898824|NCT04095117|Procedure|Epidural block|"Epidural catheter will be inserted at the L3-L4 or L4-L5 interspace in obese subjects scheduled for surgery on the lower extremities under epidural anesthesia.~The sagittal abdominal diameter, BMI and skin to epidural space distance will be recorded."
75898825|NCT04079088|Drug|Placebo|Administered as specified in the treatment arm.
75603999|NCT05095272|Biological|HMPBS02-Pv|The blood-stage P. vivax master cell bank HMPBS02-Pv was also produced using blood collected from a consenting patient with naturally acquired malaria infection. The malaria infection was confirmed to be P. vivax by species-specific PCR at Pathology Queensland (accredited by the Australian National Association of Testing Authorities) and further confirmed by deep sequencing at the Sanger Institute. The clinical response to antimalarial chemotherapy was also demonstrated with this donor, who was successfully cured with artemether/lumefantrine.
75748939|NCT03206645|Drug|Unesbulin|Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
75748940|NCT03199651|Other|Best Practice|Receive usual care
75748941|NCT03199651|Procedure|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
75748942|NCT03199651|Procedure|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
75898826|NCT04079088|Drug|BIIB061|Administered as specified in the treatment arm.
75898827|NCT04079088|Biological|Interferon-beta1|Stable dose as prescribed by the physician.
75452912|NCT01744795|Other|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the TEE and thermodilution technique.
75748943|NCT03199651|Other|Laboratory Biomarker Analysis|Correlative studies
75898828|NCT04079088|Drug|Glatiramer acetate|Stable dose as prescribed by the physician.
75898829|NCT04060030|Drug|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
75898830|NCT04060030|Other|Placebo|Placebo
75452913|NCT01744808|Drug|EB-1020 IR|Immediate release
75452914|NCT01744808|Drug|EB-1020 SR1|sustained release
75452915|NCT01744808|Drug|EB-1020 SR2|Sustained release
75452916|NCT01744808|Drug|EB-1020 SR3|Sustained release
75452917|NCT01744808|Other|Placebo|Placebo formulation
75452918|NCT01744847|Device|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
75452919|NCT01744873|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
75748944|NCT03199651|Other|Medical Chart Review|Undergo medical record abstraction
75748945|NCT03199651|Other|Quality-of-Life Assessment|Ancillary studies
75452920|NCT01744873|Drug|Bisoprolol|10 mg tablet once a day
75748946|NCT03199651|Other|Questionnaire Administration|Ancillary studies
75748947|NCT03199651|Behavioral|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
75748948|NCT03199469|Genetic|AT132|AT132 is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
75748949|NCT03180502|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|Undergo IMRT
75748950|NCT03180502|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
75748951|NCT03180502|Drug|Temozolomide|Chemotherapy drug
75748952|NCT03180268|Other|Clinical Observation|Undergo observation
75898831|NCT04036071|Device|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ MIA cement free hip stem
75898832|NCT04033861|Drug|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
75898833|NCT04033861|Drug|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
75898834|NCT04012944|Device|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System comprises seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor~Cordella Delivery System~myCordella Patient Reader~Reader Dock~Cordella Calibration Equipment (CalEQ)~myCordella Hub~Cordella Data Analysis Platform (CDAP)."
75604000|NCT05064826|Other|Observation|"Emergency Department Observation Units (EDOU) would allow the highest risk patients - those presenting for nonfatal overdose - to receive their first dose of BUP before leaving the ED.~Operationally defined to include placement in an observation unit and/or placement under observation status with care provided by Emergency Medicine and/or other services (e.g., Internal medicine, Psychiatry)"
75748953|NCT03180268|Radiation|Radiation Therapy|Undergo radiation therapy
75604001|NCT05050864|Procedure|venous sinus stenting|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid
75452921|NCT01744886|Procedure|maintain oxygenation during one lung ventilation|"All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.~If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung."
75748954|NCT03167203|Biological|Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells|Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
75748955|NCT03143374|Drug|18F-AV-1451|"The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain.~Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit.~The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."
75748956|NCT03138863|Device|BALT GoldbBAL2 Detachable Balloon|Latex balloon, with radio-opaque inclusion
75898837|NCT03990870|Other|dCBGT + WASABI|Participants in the experimental treatment group will complete daily Ecological Momentary Assessments (EMAs), 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week, and weekly cognitive biases assessments and self-reports for 16 weeks. Participants assigned to this intervention will also have daily access to 1:1 and group chat Instant Messaging (IM) and will have weekly electronic check-ins with study staff (as needed).
75452922|NCT01744899|Other|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
75748957|NCT03138863|Device|Catheter System|100 cm tapered micro-catheter
75748958|NCT03121248|Radiation|WBI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
75898838|NCT03990870|Other|dCBGT Only|Participants in the active comparator group will be asked to attend 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week for 16 weeks and weekly electronic check-ins with study staff (as needed).
75898839|NCT03986411|Other|Phase 1: Qualitative interviews: Health care professionals|Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community
75898840|NCT03986411|Other|Phase 2: Physiotherapy for urinary incontinence|Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence
75898841|NCT03986411|Other|Phase 3: Qualitative Interviews: Participants|Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
75898842|NCT03948893|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
75748959|NCT03121248|Radiation|WBI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
75748960|NCT03121248|Radiation|LNI 5 fractions|External beam radiotherapy in 5 fractions of 5,4Gy
75898843|NCT03948893|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
75452923|NCT01744925|Drug|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
75452924|NCT01744925|Drug|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
75452925|NCT01744938|Procedure|preoperative biliary drainage|percutaneous preoperative biliary drainage guided by CT
75452926|NCT01744626|Drug|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
75452927|NCT01744626|Drug|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
75604002|NCT05050864|Procedure|Neurosurgical internal ventricular shunt|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
75604003|NCT05032755|Other|SPECTRUM NRC 102/103 investigational cigarettes|Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
75604004|NCT05032755|Other|SPECTRUM NRC 600/601 investigational cigarettes|Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
75604005|NCT05023980|Drug|Pirtobrutinib|Oral
75604006|NCT05023980|Drug|Bendamustine|IV
75604007|NCT05023980|Drug|Rituximab|IV
75748961|NCT03121248|Radiation|LNI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
75748962|NCT03121248|Radiation|SIB 5 fractions if needed|Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed
75748963|NCT03121248|Radiation|SIB 15 fractions if needed|Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed
75748964|NCT03121248|Radiation|TWI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
75452928|NCT01744951|Behavioral|ADAPT|"ADAPT consists of the following modules/sessions:~Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)"
75452929|NCT01744964|Drug|Apomorphine|1.5 mg Apomorphine
75452930|NCT01744990|Other|Oral food challenges to multiple nuts|
75604008|NCT05019521|Drug|Danicopan|Oral tablet.
75604009|NCT05019521|Drug|Placebo|Oral tablet.
75604010|NCT05009004|Behavioral|text messages to support medication adherence|text messages to support medication adherence
75748965|NCT03121248|Radiation|TWI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
75748966|NCT03117972|Drug|FOLFOXIRI|12 cycles
75748967|NCT03117972|Drug|FOLFOX|12 cycles
75748968|NCT03117972|Drug|FOLFIRI|12 cycles
75748969|NCT03117972|Drug|Bevacizumab|12 cycles
75748970|NCT03117972|Drug|LV5FU2|Maintenance chemotherapy
75898845|NCT03924037|Behavioral|Intergenerational Knowledge Sharing group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the Intergenerational Knowledge Sharing group will attend 12 weekly groups taught by tribal elders that focuses on sharing knowledge about the tribe.
75748971|NCT03117972|Drug|Capecitabine|Maintenance chemotherapy
75898846|NCT03924037|Behavioral|Support group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the support group will attend 12 weekly support groups led by a behavioral health specialist that focuses on social support of the youth.
75898847|NCT03921333|Dietary Supplement|Low dose response efficacy of plant extracts|300mg
75898848|NCT03921333|Dietary Supplement|Middle dose response efficacy of plant extracts|500mg
75898849|NCT03921333|Dietary Supplement|High Dose response efficacy of plant extracts|700mg
75898850|NCT03921333|Dietary Supplement|Placebo|Cellulose microcrystalline
75898851|NCT03913819|Drug|First line treatment: oral NSAID and anticholinergic agents|oral NSAID and anticholinergic agents
75898852|NCT03913819|Drug|Second line treatment: additional treatment for pain control|Gabapentin, tramadol, Lyrica
75452931|NCT01745003|Procedure|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes-anode and cathode. We will be using this device to investigate fibromyalgia.
75452932|NCT01745016|Dietary Supplement|Placebo|
75452933|NCT01745016|Dietary Supplement|Beta-alanine|
75898853|NCT03913819|Drug|Third line treatment: A course of intravesical hyaluronate will be given.|A course of intravesical hyaluronate will be given.
75898854|NCT03913819|Procedure|Fourth line treatment: surgical intervention|Consideration of hydrodistention and augmentation cystoplasty
75452934|NCT01745029|Device|Motilis-3D-transit|
75604011|NCT05007522|Drug|Ketotifen/Indomethacin|2 mg tablet, 75 mg SR tablet
75604012|NCT05007522|Drug|Placebo|Matching placebo tablet
75604013|NCT05004012|Device|Magnetically Controlled Capsule Endoscopy|This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
75604014|NCT05003349|Other|Occlusal Splint (OS).|OS will be made of heat-cured acrylic by the same specialized dentist. These intraoral devices will be flate, rigid, will cover the entire dental arch, and will have the lowest possible height. The perimeter of the splint will have at least 11 dental contacts, light, symmetrical and pinpoint as possible. The patients will be instructed to use the splint every night during the study Two supervisions will be carried out 30 and 60 days after the use of the OS, in order to stabilize the contact points.
75604015|NCT05003349|Other|Pain Neuroscience Education (PNE).|"A power point presentation with metaphors and animated videos will be used. The PNE will be held in 10 sessions of 20 minutes each. The intervention will be developed using content according to the book Explain Pain and the web page www.retrainpain.org."
75748972|NCT03108066|Drug|PT2385 Tablets|PT2385 inhibits HIF-2α and is a novel approach to treatment of VHL disease-associated ccRCC.
75898855|NCT03900273|Other|No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS)|Novel measures of Cognitive and Everyday function
75898856|NCT03900273|Other|Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)|Established measures of Cognitive and Everyday Function
75898857|NCT03865472|Other|Questionnaire Administration|Ancillary studies
75898858|NCT03865472|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
75898859|NCT03865472|Procedure|Sham Intervention|Undergo sham rTMS
75898860|NCT03819465|Drug|Durvalumab|Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
75452935|NCT01743768|Drug|SB010|Treatment group (n=19), receiving the active drug substance.
75452936|NCT01743768|Drug|Placebo|Treatment group (n=19), receiving placebo.
75452937|NCT01745042|Other|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
75452938|NCT01745068|Other|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
75452939|NCT01745081|Drug|20% mannitol bolus administration|
75452940|NCT01745081|Drug|Hypertonic saline 3% bolus administration|
75452941|NCT01745107|Radiation|Prophylactic postoperative radiation therapy|Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
75452942|NCT01745159|Drug|tacrolimus|
75452943|NCT01745172|Procedure|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
75452944|NCT01745224|Device|Revlite Q switched Nd:YAG|Revlite Q switched Nd:YAG 1064nm
75604016|NCT05003349|Other|Motor Imagery (MI).|"The participants will have to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The procedure will begin with a familiarization test with the Basic level followed by a laterality discrimination task. It will be performed using 20 images, with 5 seconds for each image, beginning with the Vanilla program and progressively increasing the difficulty using the Context and Abstract programs. The estimated time to complete the task will be about 10 minutes per session."
75604017|NCT05003349|Other|Action Observation (AO).|The patients will see videos showing the jaw and cervical exercises with the same series and repetitions that they will actively perform in the session. Therefore, the training of the action observation will be carried out dynamically. The patient will be asked to think and visualize the movement that he/she will have to perform later. It is estimated 10 minutes per session for the AO.
75604018|NCT05003349|Other|Jaw and Neck Exercises (JNE)|A jaw and neck exercise program will be carried out in 3 series of 10 repetitions per session will be planned with 1minute rest between exercise. The exercises will be executed with a total time per session of 20 minutes, initially in the clinic and later at home. In the clinic, verbal and tactile instructions will be provided for the correct execution of the exercises and later they will be sent through WhatsApp and / or mail to perform them at home.
75604019|NCT05003349|Other|Counselling.|Counselling include education about the anatomical, biomechanical and psychosocial factors relationed with temporomandibular disorders, guidance regarding the parafunction jaw activities for eg will be taught the resting postural position of the mandible (teeth apart, lips slightly touching and tongue not pushing against the teeth).
75748978|NCT03054896|Drug|Venetoclax|Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor
75748979|NCT03054896|Other|DA-EPOCH-R|Intensive chemotherapy regiment
75748980|NCT03054896|Other|R-CHOP|Intensive chemotherapy regiment
75748981|NCT03053193|Diagnostic Test|MammaPrint, BluePrint, and Full-Genome Testing|Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
75748982|NCT03043573|Behavioral|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
75748983|NCT03043573|Behavioral|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
75898861|NCT03819465|Drug|Danvatirsen|Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
75898862|NCT03819465|Drug|Oleclumab|Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
75898863|NCT03819465|Drug|MEDI5752|MEDI5752 IV Every 3 weeks (q3w)
75898864|NCT03819465|Drug|Pemetrexed|Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
75452945|NCT01745224|Device|Trivantage Q switched Nd: YAG|Trivantage Q switched Nd: YAG 1064nm
75452946|NCT01745263|Drug|Vitamin D3|2000 IU/d
75604020|NCT04971278|Behavioral|Supportive care program|Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.
75898865|NCT03819465|Drug|Carboplatin|Carboplatin IV Day 1 of each 21-day cycle
75898866|NCT03819465|Drug|Gemcitabine|Gemcitabine IV Days 1 and 8 of each 21-day cycle
75452947|NCT01745263|Drug|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2~1 g/d"
75898867|NCT03819465|Drug|Cisplatin|Cisplatin IV Day 1 of each 21-day cycle
75898868|NCT03819465|Drug|Nab-paclitaxel|Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
75898869|NCT03819465|Drug|AZD2936|AZD2936 IV
75748984|NCT03032172|Drug|Risdiplam|Risdiplam will be administered orally once daily.
75748985|NCT03028337|Radiation|Spine Radiosurgery|"Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction)."
75748986|NCT03028337|Behavioral|Questionnaires|"Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up."
75748987|NCT03014479|Drug|Trelagliptin|Trelagliptin 100 mg or 50 mg
75748988|NCT03014479|Drug|Daily DPP-4 inhibitor|Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
75748989|NCT02974582|Behavioral|Exposure to smoking advertising with coupon|Direct mail marketing of smoking advertising with discount coupon
75748990|NCT02974582|Behavioral|Exposure to smoking advertising without coupons|Direct mail marketing of smoking advertising without discount coupon
75748991|NCT02974582|Behavioral|Exposure to non health related images|Control group
75748992|NCT02937818|Drug|Durvalumab and Tremelimumab|Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
75748993|NCT02937818|Drug|AZD1775 and carboplatin (CBPT)|AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
75748994|NCT02937818|Drug|AZD6738 and olaparib|AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
75748995|NCT02927691|Device|EMST|
75748996|NCT02927691|Behavioral|smTAP|
75898870|NCT03806764|Diagnostic Test|Blood sampling|Blood sampling from prospective study participants will be taken for immune functions measurements
75898871|NCT03705286|Device|EVAC-PU-ETT|Placement of a EVAC-PU-ETT in the setting of emergent intubation.
75452948|NCT01745263|Procedure|Strength Home Exercise|
75452949|NCT01745263|Procedure|Flexibility Home Exercise|
75748997|NCT02916511|Drug|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw*5
75748998|NCT02916511|Drug|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw*5
75748999|NCT02916511|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
75452950|NCT01745276|Device|Biphosfonate|External pins coated by biphosfonate.
75749000|NCT02872805|Other|PEPFAR Enhanced Standard of Care (PESCA)|Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
75749001|NCT02872805|Behavioral|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
75749002|NCT02864394|Biological|Pembrolizumab|Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).
75749003|NCT02864394|Drug|Docetaxel|Docetaxel administered IV at 75 mg/m^2 on Day 1 of each 21-day cycle as per the approved product label.
75749004|NCT02836418|Drug|ATYR1940|Concentrate for solution for infusion
75898872|NCT03705286|Device|PVC-ETT|Placement of a PVC-ETT in the setting of emergent intubation.
75898873|NCT03679117|Behavioral|Mindfulness Training|Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
75898874|NCT03641677|Device|Centralized Lung Evaluation System|Assessment of allograft lung for transplant suitability
75452951|NCT01745276|Device|Hydroxylapatit|External pins coated by Hydroxylapatit.
75452952|NCT01745302|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
75452953|NCT01745302|Drug|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
75749005|NCT02823860|Other|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
75749006|NCT02773849|Biological|ADSTILADRIN|
75749007|NCT02727270|Other|No Intervention - Observational Study|No Intervention - Observational Study
75604021|NCT04957537|Behavioral|semantic therapy and semantic re-education|"Patients will be followed over two periods Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks).~Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.~Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.~In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes)."
75749008|NCT02684006|Drug|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
75749009|NCT02684006|Drug|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
75749010|NCT02684006|Drug|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
75749011|NCT02654990|Drug|panobinostat capsules|20mg, 10mg or 15mg (for dose reductions only)
75749012|NCT02654990|Drug|bortezomib injection|1.3mg/m^2 sub-cutaneous administration; Cycle 1-4: 2 weeks on/1 week off twice a week for patients ≤ 75 years at time of screening; once a week for patient > 75 years Cycle 5+: once a week for all patients
75898875|NCT03641677|Procedure|Lung Transplant|Orthotopic single or double lung transplantation.
75898876|NCT03637803|Drug|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
75898877|NCT03637803|Drug|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
75898878|NCT03630289|Procedure|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
75909545|NCT04458896|Behavioral|Stand When You Can|"Intervention strategies can be customized to different environments based on consultation with management. Some strategies will be mandatory:~Education session: group information session during the first week of the intervention (30min) to discuss sedentary time (ST), health risks, strategies to reduce ST, goal setting, & the identification of barriers and motivators to reducing ST. Group discussion will be encouraged to increase self-motivation and self-efficacy. An information workbook will be given to each attendee for their personal use and goal setting.~Point of decision prompts (ie: signs that encourage standing; see attachments) will be placed in common areas of the facility, and/or given as pamphlets to residents.~An intervention package will be provided to the Activity Coordinator and Manager of the facility. This package will provide an introductory letter along with materials to promote reduced sedentary time in the facility"
75749013|NCT02654990|Drug|dexamethasone tablets|pre and 24h after BTZ administration; patients ≤ 75 years at time of screening: 20mg/dose patients > 75 years: 10mg/dose
75749014|NCT02606422|Device|Active HD-tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
75749015|NCT02606422|Device|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
75452954|NCT01745315|Device|Advanced bipolar devices|
75452955|NCT01745328|Drug|LVX-AMX|Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
75749016|NCT02583672|Drug|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
75452956|NCT01745328|Drug|TCM|Subject is treated with TCM for 4 weeks.
75452957|NCT01745328|Drug|LVX-AMX|treatment with placebo from 2 to 4 weeks.
75452958|NCT01745354|Drug|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
75452959|NCT01745354|Radiation|Local Radiation|
75452960|NCT01745432|Device|ADBLOCK|Laparoscopic surgery
75749017|NCT02542839|Device|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
75749018|NCT02542839|Device|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
75749019|NCT02542839|Other|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
75749020|NCT02542839|Other|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
75604022|NCT04952779|Drug|Xultophy® (insulin degludec/liraglutide)|"Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study."
75604023|NCT04941573|Combination Product|Hyperpolarized 129-Xenon (MagniXene) MRI of the lung|Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.
75898879|NCT03567720|Biological|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks
75604024|NCT04936776|Behavioral|Text messaging|Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
75604025|NCT04934995|Other|Blood Pressure Cuff|"After obtaining consent and confirming eligibility, Blood Pressure cuffs will be used as specified below:~Cuff size: large BP cuffs will be the default size for both arm and ankle measurements, but can be changed as clinically indicated based on circumferences of limbs Cuff location: BP cuffs will be placed on the contralateral arm to the main peripheral IV following standard procedures. Left ankle cuff will be placed underneath intermittent pneumatic compression cuffs Ankle blood pressure monitor screen will be covered. Thus, anesthesia providers will not be able to make any clinical decisions based on ankle blood pressures but arm blood pressure (standard) instead."
75749021|NCT02542839|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
75749022|NCT02542839|Procedure|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
75749023|NCT02516241|Drug|MEDI4736 (Durvalumab)|IV infusion
75749024|NCT02516241|Drug|Tremelimumab|IV infusion
75749025|NCT02516241|Drug|Cisplatin|IV infusion
75749026|NCT02516241|Drug|Carboplatin|IV infusion
75898880|NCT03567720|Biological|Pembrolizumab|Intravenous 3 weekly treatments
75749027|NCT02516241|Drug|Gemcitabine|IV infusion
75749028|NCT02491528|Biological|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
75749029|NCT02491528|Biological|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
75898881|NCT03567720|Device|Immunopulse|Device that administers electroporation
75749030|NCT02464878|Drug|Alpha 1-Antitrypsin|Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
75749031|NCT02464878|Procedure|Islet Transplantation|
75749032|NCT02464878|Drug|Thymoglobulin|Patients will receive a total of 5 doses between Day -2 and Day +2
75749033|NCT02464878|Drug|Basiliximab|Basiliximab will be used for subsequent transplants.
75898882|NCT03567720|Drug|nab paclitaxel|intravenous on days 1, 8 and 15 of each 28 day cycle
75898883|NCT03567720|Drug|gemcitabine plus carboplatin|intravenous on days 1 and 8 of every 21 days
75898884|NCT03519906|Drug|Metoprolol|Patients are tested for their normal prescription metaprolol medication
75898885|NCT03519893|Drug|Losartan|Patients are tested for their normal prescription losartan medication
75898886|NCT03519256|Biological|Nivolumab|Specified dose on specified days
75898887|NCT03519256|Biological|BCG|Specified dose on specified days
75898888|NCT03519256|Drug|BMS-986205|Specified dose on specified days
75898889|NCT03507608|Drug|Flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
75898890|NCT03507608|Other|Placebo|placebo prior to brachytherapy and prostatic biopsy
75898891|NCT03465579|Diagnostic Test|pelvic MRI|multi-parametric pelvic MRI
75898892|NCT03465579|Diagnostic Test|68Ga-PSMA PET/CT|68Ga-PSMA PET/CT
75604026|NCT04900623|Device|NavDx HPV ctDNA Testing|Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.
75604027|NCT04900623|Radiation|Radiotherapy|Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
75604028|NCT04900623|Drug|Chemotherapy drug|"Chemotherapy and radiation therapy are both considered standard treatments~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy."
75898893|NCT03458000|Device|PillCam UGI|An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
76065765|NCT03143504|Diagnostic Test|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
75604029|NCT04899180|Drug|99mTc-PYP|Radioisotope used by SPECT/CT imaging
75604030|NCT04899050|Drug|Cannabidiol (Epidiolex)|Use of Epidiolex to control absence seizures.
75604031|NCT04874441|Diagnostic Test|Diagnosis strategy based on C. glabrata / krusei PCR|For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
75604032|NCT04870099|Behavioral|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
75604033|NCT04868994|Diagnostic Test|Whole Body MRI and ENMG|Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
75604034|NCT04859335|Radiation|gammaknife radiosurgery|Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
75604035|NCT04829071|Behavioral|Explicit motor learning|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
75604036|NCT04829071|Behavioral|Implicit motor learning|Participants will walk on a treadmill that drives their right and left legs to move at two different speeds.
75604037|NCT04828551|Device|Ultrasound based shear wave speed and fat quantification methods|Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system
75749034|NCT02464878|Drug|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
75749035|NCT02399995|Behavioral|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~Baseline sociodemographic and clinical variable data sheet (RSA)~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Post surgical follow up disease status and treatment assessment questionnaire~At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
75898894|NCT03458000|Other|Standard of Care|Patient was admitted to hospital for care and received in-patient EGD.
75749036|NCT02372097|Drug|SYR-472|SYR-472 25mg, 50mg
75749037|NCT02309151|Procedure|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
75749038|NCT02212860|Radiation|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
75749039|NCT02162810|Drug|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
75749040|NCT02162810|Drug|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
75898895|NCT03453528|Drug|68Ga-PSMA|68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
75898896|NCT03390413|Procedure|Robot|Renal cancer treated with robotic surgery
75898897|NCT03390413|Procedure|Cryoablation|Renal cancer treated with cryoablation
75898898|NCT03375710|Device|Cordella™ Heart Failure System|"The Cordella™ Heart Failure System collects, records, and transmits physiologic data and communications from the patient at home to clinicians for assessment, patient communication, and patient-centered heart failure management. The system consists of the following components:~myCordella™ Patient Management Portal~myCordella™ Hub~myCordella™ Peripherals, including the Cordella™ Pulmonary Artery Sensor System (CorPASS)"
75898899|NCT03215927|Drug|Abatacept|Abatacept 125mg subcutaneous weekly
76065766|NCT03138720|Drug|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
75749041|NCT02040857|Drug|Palbociclib|CDK 4/6 inhibitor
75749042|NCT02040857|Drug|Aromatase Inhibitor|Endocrine Therapy
75749043|NCT02000089|Drug|Secretin|inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
75749044|NCT02000089|Diagnostic Test|MRI|MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
75898900|NCT03215927|Other|Placebo|Placebo
75898901|NCT03076034|Device|Reference Point Indentation|"The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of ~375 µm."
76065767|NCT03131726|Drug|Simvastatin 40mg|see arm description
76065768|NCT03112590|Biological|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
75604038|NCT04828551|Diagnostic Test|Blood collection|"Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes.~Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed"
75604039|NCT04828551|Other|Physical measurements|Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.
75604040|NCT04828551|Other|Clinical history and medication reviews|"The following questionnaires will be administered at Screening:~Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire~The following questionnaires will be administered at Visit 1 and Visit 2:~Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire"
75604041|NCT04825717|Other|Nutrition and fluid plans prepared using calorimetry-based measurements.|Nutrition and fluid plans prepared using calorimetry-based measurements.
75749045|NCT02000089|Other|Tumor marker gene test with CA19-9|A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
75749046|NCT01709435|Drug|Cabozantinib S-malate|Given PO
75749047|NCT01709435|Other|Laboratory Biomarker Analysis|Correlative studies
75749048|NCT01709435|Other|Pharmacological Study|Correlative studies
75749049|NCT01585480|Behavioral|Weight Gain Prevention Intervention|"Behavioral Approaches~Distribution of pedometers~Traffic light labeling in worksite cafeteria and vending machines~Informational & Persuasive Messages~Stair use prompts~Posters, pamphlets, table toppers~Website~Social Approaches~a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~Environmental Changes~Traffic light labeling~1/2 portions at 1/2 price~Walking routes~Introduction of healthier foods~Rearrangement of foods in the cafeteria~Adjusting serving spoon size"
75898902|NCT03009110|Device|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
75898903|NCT03009110|Device|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
76065769|NCT03112590|Drug|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m^2/week, for 12 weeks.
76065770|NCT03112590|Drug|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
75452961|NCT01745445|Other|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
75452962|NCT01745458|Drug|SB-659032|
75452963|NCT01745458|Drug|Placebo|Matched placebo
75604042|NCT04823754|Other|Hospitalized patient with advanced hepatocellular carcinoma receiving systemic therapy.|"Administation of two surveys to included patients, about the perception of the disease and the expectations related to the treatment.~The physician will be asked to complete a survey on his or her perception of the prognosis and information received by the patient."
75604043|NCT04823130|Drug|Dupilumab (SAR231893)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
75604044|NCT04822129|Behavioral|Treatment as Usual|Treatment as usual will provide participants with basic information that is readily available as well as the encouragement to develop a brain health program that may be available from medical professionals.
75749050|NCT01571895|Drug|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 [CXCL8; formerly interleukin (IL)-8] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
75749051|NCT01358877|Drug|5-Fluorouracil|5-Fluorouracil will be administered as per the schedule specified in the respective arm.
75898904|NCT02999230|Other|Caries Free 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
76065771|NCT03112590|Other|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
76065772|NCT03112590|Procedure|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
75749052|NCT01358877|Drug|Carboplatin|Carboplatin will be administered as per the schedule specified in the respective arm.
75749053|NCT01358877|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
75749054|NCT01358877|Drug|Docetaxel|Docetaxel will be administered as per the schedule specified in the respective arm.
75749055|NCT01358877|Drug|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
75898905|NCT02999230|Other|Caries Free Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
75898906|NCT02999230|Other|Caries Active 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
75898907|NCT02999230|Other|Caries Active- Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
75898908|NCT02941315|Drug|etiologic treatment,anti-myocardial remodeling|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
75898909|NCT02941315|Drug|anti-myocardial remodeling|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
75898910|NCT02941315|Drug|anti-myocardial remodeling,anti-acute heart failure|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
75898911|NCT02941315|Drug|Etiological, anti-remodeling and symptom treatment|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
75898912|NCT02920229|Drug|68Ga- PSMA|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
75898913|NCT02918721|Device|Restylane Lidocaine|Intradermal injection
75898914|NCT02918721|Device|Restylane|Intradermal injection
75898915|NCT02884180|Drug|Dexamethasone|A dose of 24 mg dexamethasone given after start of anaesthesia
75604045|NCT04822129|Behavioral|Cogtrastim Model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model.
75604046|NCT04820595|Diagnostic Test|RASS|Richmond Agitation-Sedation Scale
75604047|NCT04820595|Diagnostic Test|CAM-ICU|Confusion Assessment Method for the ICU
75604048|NCT04817644|Drug|Oral semaglutide|Oral semaglutide once daily for a total of 10 days
75604049|NCT04808622|Drug|Trans-Sodium Crocetinate|TSC given as a one-time IV bolus injection
75604050|NCT04808622|Drug|Placebo|Placebo normal saline given as a one-time 7 mL one-time IV bolus injection
75604051|NCT04802603|Radiation|Spine stereotactic body radiotherapy|"Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions."
75604052|NCT04783675|Drug|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
75898916|NCT02884180|Drug|Saline isotonic|A dose of 6 ml of isotonic saline given after start of anaesthesia
75898917|NCT02879682|Procedure|nTMS data available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will be available for the surgeon
75898918|NCT02879682|Procedure|nTMS data not available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will not be available for the surgeon
75898919|NCT02799602|Drug|BAY1841788 / darolutamide (ODM-201)|600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
75898920|NCT02799602|Drug|Standard ADT (androgen deprivation therapy)|As prescribed by the treating physician.
75898921|NCT02799602|Drug|Docetaxel|As prescribed by the treating physician.
75604053|NCT04782856|Drug|Levothyroxine|levothyroxine sodium tablet for oral use
75604054|NCT04782856|Drug|Liothyronine|Liothyronine sodium tablets for oral use treatment of hypothyroidism
75604055|NCT04782856|Drug|Placebo|inert sugar tablets for oral use blinding for treatment of hypothyroidism
75604056|NCT04781374|Drug|Neratinib|Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
75749056|NCT01358877|Drug|Epirubicin|Epirubicin will be administered as per the schedule specified in the respective arm.
75749057|NCT01358877|Drug|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
75749058|NCT01358877|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
75749059|NCT01358877|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
75749060|NCT01358877|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
75749061|NCT01149083|Procedure|Biopsy|Undergo biopsy
75749062|NCT01149083|Procedure|Biospecimen Collection|Undergo blood sample collection
75749063|NCT01149083|Drug|Carboplatin|Given IV
75749064|NCT01149083|Procedure|Computed Tomography|Undergo CT
75749065|NCT01149083|Procedure|Magnetic Resonance Imaging|Undergo MRI
75749066|NCT01149083|Drug|Veliparib|Given PO
75749067|NCT00694850|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
75749068|NCT00670358|Biological|pegfilgrastim|
75749069|NCT00670358|Biological|rituximab|
75898922|NCT02799602|Drug|Placebo|Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone [LHRH] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
75898923|NCT02792166|Procedure|BPD-DS|Biliopancreatic Diversion with Duodenal Switch
75749070|NCT00670358|Drug|cyclophosphamide|
75898924|NCT02792166|Procedure|SADI-S|Single Anastomosis Duodeno-ileal Bypass with Sleeve Gastrectomy
75452964|NCT01745484|Other|SPECT-based treatment plan|"SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.~The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated"
75898925|NCT02788903|Other|Weight Counseling|This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
75898926|NCT02770040|Drug|Infliximab|INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
75898927|NCT02754297|Drug|177Lu-Octreotate|"The induction course will consist in 4 cycles at 8-10 weeks intervals.~Concomitant amino acids will be administered for renal protection.~Intra-arterial LuTate administration will be allowed in suitable cases.~Dosimetry will be based on quantitative SPECT/CT imaging.~In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."
75604057|NCT04767009|Drug|PD-1 Blockade|Patients will receive PD-1 blockade for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1 blockade will be administrated as an intravenous(IV) infusion.
75898928|NCT02747459|Behavioral|Sensory Supported Swimming|A swimming and water safety program for children with autism spectrum disorders. Individualized instruction utilizing evidence-based teaching methods and sensory modifications.
75898929|NCT02663609|Other|No intervention|No treatment (intervention) was administered.
75604058|NCT04767009|Radiation|SBRT|Patients with oligo-residual or oligoprogressive NSCLC after treatment with PD-1 inhibitors will be treated with curative-intent SBRT of progressing lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1 blockade will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
75604059|NCT04746170|Other|Labor Dance|Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
75604060|NCT04736316|Behavioral|Early CCLAD|Community-based client led antiretroviral therapy delivery groups.
75749071|NCT00670358|Drug|doxorubicin hydrochloride|
75749072|NCT00670358|Drug|lenalidomide|
75749073|NCT00670358|Drug|prednisone|
75749074|NCT00670358|Drug|vincristine sulfate|
75749075|NCT00670358|Genetic|polymorphism analysis|
75898930|NCT02472015|Procedure|telemedicine|psycho-behavioural care by telemedicine
75749076|NCT00670358|Other|laboratory biomarker analysis|
75749077|NCT00643279|Device|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
75898931|NCT02291705|Procedure|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
75898932|NCT02291705|Drug|Tramadol|tramadol 1 mg/kg iv
75898933|NCT02243709|Drug|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
75898934|NCT02192931|Drug|Creatine monohydrate|
75749078|NCT00643279|Other|Standard of Care|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
75898935|NCT02012153|Biological|Mesenchymal Stromal Cells|
75604061|NCT04720456|Drug|SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
75749079|NCT00633087|Drug|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
76065773|NCT03085394|Drug|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
75898936|NCT01896011|Biological|Teriparatide 20 mcg|Teriparatide 20 mcg injection pen
75898937|NCT01896011|Other|Placebo|Placebo 20 mcg injection pen
75898938|NCT01891396|Device|Hyaluronic Acid and TH (Cingal®)|Injection into knee
75898939|NCT01891396|Device|Hyaluronic Acid (Monovisc®)|Injection into knee
76065774|NCT03085394|Drug|Placebo|Preoperative intravenous administration of 10 ml saline
75898940|NCT01891396|Device|Saline|Saline placebo packaged to look identical to comparator syringes. Injection into knee.
75898941|NCT01747304|Device|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
75452965|NCT01745510|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid from algae source
75452966|NCT01745510|Dietary Supplement|Placebo|Placebo was designed to mimic the color and consistence of the oil that contains DHA
75452967|NCT01745523|Procedure|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
75452968|NCT01745523|Procedure|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
75749080|NCT00182728|Procedure|surgery|conventional
75749081|NCT00182728|Procedure|therapy|neoadjuvant
75749082|NCT00182728|Radiation|radiation therapy|intraoperative radiation therapy
75749083|NCT00176631|Dietary Supplement|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
75452969|NCT01745536|Procedure|Oocytes are vitrified/stored using a closed device|Vitrification will be carried out using a modification of the current device (Cryotop®), thus providing air tight sealing. Closed systems are devices that are hermetically sealed before vitrification and remain sealed during storage.
75604062|NCT04720456|Drug|SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
75749084|NCT00176631|Drug|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
75749085|NCT00002965|Biological|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
75749086|NCT06050473|Procedure|Nerve-sacrificing procedure|Surgical fixation of the clavicle fracture will be performed through a horizontal incision over the clavicle. During the incision and soft tissue dissection, the surgeon will not attempt to identify the supraclavicular nerve branches. Instead, the surgeon will cut the nerve branches during the dissection.
75749087|NCT06050473|Procedure|Nerve preserving procedure|Surgical fixation of the clavicle fracture will be performed through the same horizontal incision over the clavicle. The surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
75749088|NCT06050460|Drug|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
75898942|NCT01746225|Drug|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
75452970|NCT01745536|Procedure|Oocytes are vitrified/stored using an open device|The vitrification process takes place through direct contact with liquid nitrogen. The system has an external straw to protect the samples during storage, but the device is not hermetically sealed.
75898943|NCT01730547|Biological|Autologous mesenchymal stem cells|
75898944|NCT01716806|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
75898945|NCT01716806|Drug|bendamustine|70 mg/m^2 by IV infusion on Days 1 and 2 of 3-week cycle
76065775|NCT03065621|Drug|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
76065776|NCT03060629|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
76065777|NCT03060629|Biological|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
76065778|NCT03060629|Biological|Placebo|Participants will receive matching placebo.
76065779|NCT03060434|Drug|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
76065780|NCT03060434|Drug|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
76065781|NCT03617354|Procedure|Total Laparoscopic Hysterectomy|The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
75452971|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge|
75452972|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge|
75452973|NCT01745562|Drug|Alprazolam 0.5 mg|Reference product
75452974|NCT01745562|Drug|Alprazolam 0.5 mg|Test product
75749089|NCT06050460|Other|Placebo for SA55 injection|Placebo for Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
75898946|NCT01716806|Drug|dacarbazine|375 mg/m^2 every 3 weeks by IV infusion
76065782|NCT03021486|Drug|Chlorpromazine|Given IV
76065783|NCT03021486|Drug|Haloperidol|Given IV
75604063|NCT04709653|Other|Occupation-based nursing program|"First Session (Rug Weaving Activity): The child and the caregiver will be informed about the purpose and process of the research. The researcher will show in detail how to use rug weaving materials. Rug weaving activity will be started with the child. At the end of the 30-minute practice, the second session with the child will be planned and the session will be ended.~Second Session (Rug Weaving Event Continues). Third Session (Rug Weaving Activity Continues): Rug weaving activity will be completed and the session will be ended by planning the fourth session with the child.~Fourth Session (Origami Activity): A figure will be made with origami with the child. The child will be given support to make another figure. The fifth session hour will be planned with the child and the session will be ended.~Fifth Session (Shape Making Activity with Chenille): A shape will be created with the child with chenille."
75604064|NCT04709653|Other|Control Group|Routine nursing care
76065784|NCT03021486|Other|Quality-of-Life Assessment|Ancillary studies
76065785|NCT03021486|Other|Questionnaire Administration|Ancillary studies
76065786|NCT02999789|Device|SmartInhaler with reminder function turned on|The SmartInhaler is a medication monitoring system that functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
76065787|NCT02999789|Device|SmartInhaler|The SmartInhaler is a medication monitoring system manufactured by Adherium that also functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
76065788|NCT02970331|Drug|pefcalcitol ointment, 0.005%|pefcalcitol ointment, 0.005%
75749090|NCT06050447|Procedure|Right hemicolectomy|Resection of the caecum and ascending colon is appropriate for patients with tumors located anywhere from caecum to the transverse colon
75749091|NCT06050447|Procedure|Left hemicolectomy|Resection of the sigmoid colon is appropriate for patients with tumors located anywhere from the distal transverse colon to the rectosigmoid junction.
75452975|NCT01745575|Drug|Alprazolam 2mg tablets|Reference product
75452976|NCT01745575|Drug|Alprazolam 2 mg tablets|Test product
75749092|NCT06050447|Procedure|Sigmoid colon resection|Resection of the sigmoid colon is appropriate for patients with tumors located in the sigmoid colon
75749093|NCT06050447|Procedure|Anterior resection of the rectum|AR is appropriate for tumors located in rectosigmoid junction and in the proximal rectum
75898947|NCT01716806|Drug|nivolumab|3 mg/kg every 3 weeks by IV infusion
75898948|NCT01650545|Drug|Liposomal aerosol cyclosporine|inhaled form of immune suppression
75898949|NCT01650545|Other|standard immune suppression, oral|"conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin"
76065789|NCT02949128|Biological|Ravulizumab|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: ≥ 40 to < 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; ≥ 60 to < 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; ≥ 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.
76065790|NCT02945631|Radiation|PTV56|total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.
76065791|NCT02945631|Radiation|PTV50.4|total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
76065792|NCT02944682|Other|Liquefied petroleum gas (LPG) cookstove|The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
76065793|NCT02944617|Other|Laboratory Biomarker Analysis|Correlative studies
76065794|NCT02944617|Dietary Supplement|Micronutrient-Fortified Probiotic Yogurt|Receive Activia yogurt
76065795|NCT02944617|Drug|VEGF-TKI|Must be received as standard of care chemotherapy
76065796|NCT02935556|Other|no intervention|database and epigenetic study
75452977|NCT01745601|Drug|escitalopram 10 mg|Reference product
75452978|NCT01745601|Drug|escitalopram 10 mg|Test product
75452979|NCT01745614|Drug|Nimesulide 100 mg tablets|Reference product
75452980|NCT01745614|Drug|Nimesulide 100 mg tablets|Test product
75452981|NCT01745640|Drug|POMALIDOMIDE|hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
75452982|NCT01745640|Drug|Dexamethasone|40mg (if patient <75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
75452983|NCT01745653|Device|Low level laser therapy|
75452984|NCT01745653|Procedure|sham procedure|
75452985|NCT01745666|Other|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
75452986|NCT01745666|Other|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
75604065|NCT04695080|Drug|Cladribine (MAVENCLAD®)|"Cladribine (MAVENCLAD®) 3.5mg/kg, administered as weight-adjusted 10mg tablets in two treatment courses (12 months apart) lasting 8- 10 days each.~Cladribine (MAVENCLAD®) 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
75604066|NCT04695080|Drug|Placebo|"Placebo administered as weight adjusted tablets in two treatment courses (12 months apart) lasting 8-10 days each.~Placebo 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
75604067|NCT04648124|Device|IRMf-r (séquence resting state)|Functional MRI of functional brain networks
75604068|NCT04624932|Behavioral|RR Digital Tool|This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.
75604069|NCT04624932|Behavioral|Position Statement on Active Outdoor Play|This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
76065797|NCT02923115|Drug|DS-1040b|Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
75604070|NCT04609319|Drug|Dacomitinib|This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC
75749094|NCT06050447|Procedure|Low anterior resection of the rectum|LAR is appropriate for tumors located in the middle and low rectum
75749095|NCT06050447|Procedure|Abdominoperineal resection|APR is appropriate for distal rectal cancers that invade the external sphincter or the levator muscles
75749096|NCT06050447|Procedure|Total Colectomy|Total abdominal colectomy may be indicated for patients with primary multiple cancer tumors
75898950|NCT01528189|Other|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
75898951|NCT01528189|Other|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
75898952|NCT01471522|Procedure|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
75898953|NCT01471522|Procedure|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
75898954|NCT01471522|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
75898955|NCT01471522|Behavioral|Lifestyle|diet, physical activity, smoking cessation
75898956|NCT01471522|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
75898957|NCT01191008|Drug|Latanoprost-timolol maleate fixed combination ophthalmic solution|"Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. One drop should be applied to the affected eye(s) once daily."
76065798|NCT02923115|Drug|Placebo|Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
75749097|NCT06050421|Behavioral|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.
75749098|NCT06050421|Other|Treatment As Usual|he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
75749099|NCT06050421|Other|No intervention|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
75898958|NCT01155232|Drug|Teriparatide|Forteo (teriparatide)pen daily for 24 months
75898959|NCT01060371|Genetic|All Participants|If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
75898960|NCT00821587|Drug|Cyclosporine|Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
76065799|NCT02923115|Drug|Enoxaparin|Subcutaneous injection 1 mg/kg twice daily
76065800|NCT02910583|Drug|ibrutinib|ibrutinib administered orally once daily (three 140 mg capsules)
76065801|NCT02910583|Drug|venetoclax|venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
76065802|NCT02910583|Drug|Placebo|placebo capsules to match ibrutinib administered orally once daily
75452987|NCT01745679|Drug|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
75452988|NCT01745692|Device|Mechanical thrombectomy|
75452989|NCT01745692|Drug|Intravenous rtPA|All patients receive IV alteplase
75452990|NCT01745705|Other|Cervical Spine Manipulation|
75452991|NCT01745705|Other|Manual Contact|
75452992|NCT01745718|Other|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
75749100|NCT06050408|Device|1hz repetitive transcranial magnetic stimulation|1hz rTMS applied over P3 EEG 10-20 location. Total of 1200 pulses administered. Figure of eight coil used to stimulate, held tangential to the scalp.
75898961|NCT00821587|Drug|Tacrolimus|Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
75898962|NCT00751829|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
75604071|NCT04605484|Biological|Posoleucel (formerly known as ALVR105) cells|Infusion
75604072|NCT04605484|Biological|Placebo (visually identical to Posoleucel)|Infusion
75604073|NCT04594473|Behavioral|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|[see arm/group descriptions]
75604074|NCT04592588|Behavioral|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 45-60 minutes.
75749101|NCT06050382|Other|PROGRESSIVE RELAXATION TRAINING|"Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling."
75749102|NCT06050343|Drug|Humulin® Regular|subcutaneous injection at a dose of 0.3 IU / kg
75604075|NCT04592588|Behavioral|Wait-list control|Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
75604076|NCT04591353|Drug|PENG Block|The pericapsular nerve group (PENG) block is a novel regional anesthesia technique for providing analgesia after hip fractures and hip arthroplasties.
75604077|NCT04591353|Drug|Lidocaine|2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected.
75898963|NCT00751829|Drug|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
75898964|NCT00645801|Drug|lubiprostone (Amitiza)|24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total
75452993|NCT01745731|Other|Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.|Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
75898965|NCT00645801|Drug|Placebo|Amitiza Placebo
75604078|NCT04580914|Device|Treatment with IntellaNav StablePoint Ablation Catheter|Patients will be treated with an ablation catheter
75604079|NCT04556123|Other|Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes."
75604080|NCT04556123|Other|Measurement of the hydration state and decongestive treatment according to clinical judgement alone|Clinical judgement will be performed in each center by a reference physician or nurse
75749103|NCT06050343|Drug|Rinsulin® R|subcutaneous injection at a dose of 0.3 IU / kg
75452994|NCT01745744|Other|Mesenchymal stem cells from adipose tissue|- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
75452995|NCT01745770|Drug|Mesalazine - TID 1000 mg|
75452996|NCT01745770|Drug|Mesalazine - TID 2x 500 mg|
75604081|NCT04502758|Device|MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.
75749104|NCT06050330|Diagnostic Test|skin biopsy|Paraffin sections,5 Um thick will be prepared from the skin samples and will be analyzed for light microscopy
75749105|NCT06050317|Drug|Sintilimab Plus mFFN and Radiation|Sintilimab Plus mFFN and Radiation
75749106|NCT06050304|Behavioral|Observation of behavior and search of biomarkers with 3 blood tests.3 weeks wearing an actimeter|In the form of a small watch, which collects the level of motor activity throughout the day and night. Patients will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. We want to know if certain uses lead to more behavioral problems (especially after periods of cessation).
75898966|NCT00424099|Drug|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
75898967|NCT00424099|Behavioral|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
75898968|NCT00424099|Drug|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
75898969|NCT00424099|Behavioral|Non NTI|Non NTI are calls from research staff 3 times weekly.
75898970|NCT00382213|Drug|Olmesartan medoxomil|
75898971|NCT00382213|Drug|Placebo|
75898972|NCT00176267|Radiation|Radiotherapy|50 cGy on days 1, 2, 8, 15, 22, 23, 29 & 36 of chemotherapy
75898973|NCT00176267|Drug|Paclitaxel|75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
75604082|NCT04502758|Device|Sham MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.
75604083|NCT04499950|Drug|Contrave|Initiate Contrave at 1 tab in morning (AM) for Week 9; then 1 tab in AM and 1 tab in evening (PM) for Week 10; then 2 tab in AM and 1 tab in PM for Week 11; then 2 tab in AM and 2 tab in PM for week 12; then constant dose for months 4-6.
75604084|NCT04499950|Behavioral|Behavioral Weight Loss|6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.
75898974|NCT00176267|Drug|Carboplatin|AUC of 6 on Days 1 & 22
76065803|NCT02896348|Device|SynPhNe platform|SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.
75452997|NCT01745809|Procedure|Bronchoscopy|Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
75452998|NCT01745835|Drug|2L Coolprep®|* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
75452999|NCT01745835|Drug|1L Coolprep® and Bisacodyl|"Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) * composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg"
75453000|NCT01745861|Dietary Supplement|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
75453001|NCT01745861|Dietary Supplement|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
75453002|NCT01745887|Drug|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
75453003|NCT01745926|Device|MECHANICAL CHEST COMPRESSION|
75453004|NCT01745939|Other|Lumbar Manipulation|Manual therapy intervention
75453005|NCT01745939|Other|Sham manipulation|Manual therapy intervention
75453006|NCT01745978|Procedure|Precut papillotomy|
75453007|NCT01745991|Device|CoSeal spray|
75604085|NCT04488055|Behavioral|Crisis Line Facilitation (CLF)|CLF is a motivational interviewing-based intervention
75604086|NCT04488055|Behavioral|Enhanced Usual Care (EUC)|In addition to receiving the brochure, EUC condition participants will meet with a therapist (in-person or remotely) for approximately 15 minutes for a descriptive overview of the brochure.
75604087|NCT04461626|Device|Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)|
75604088|NCT04448613|Other|MRI|"Patients with optic disc swelling diagnosed by a fundus and included in the study will have a brain MRI and visual pathways lasting 30 minutes.~Two additional 10-minute sequences will be added to the standard protocol."
75604089|NCT04427254|Drug|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
75604090|NCT04411303|Behavioral|Step length biofeedback|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
75604091|NCT04411303|Behavioral|Propulsive force biofeedback|Participants will be provided with real-time visual feedback of anterior-posterior ground reaction forces of the paretic limb during stance phase on a screen in front of a treadmill.
75604092|NCT04411303|Behavioral|Interlimb asymmetry biofeedback|Participants will be provided with visual feedback of stride-by-stride values of their interlimb asymmetry on a screen in front of a treadmill.
75604093|NCT04411303|Behavioral|Aerobic intensity-based walking|Participants will walk at three different aerobic intensities. Aerobic intensity will be set based on target heart rate zones calculated with the Karvonen Formula. For low intensity, participants will walk at 30-40% intensity. In moderate intensity conditions, participants will walk at a 50-60% intensity level. In vigorous intensity conditions, participants will walk at an 70-80% intensity level. Aerobic intensity will be manipulated by changing walking speed.
75604094|NCT04402385|Drug|Aspirin 81 mg|Participants randomized to 81 mg of Aspirin daily
75604095|NCT04402385|Drug|Placebo|Participants randomized to placebo daily
75604096|NCT04399031|Drug|E-cigarette e-liquid|Participants will self-administer an experimenter-provided e-cigarette.
75749107|NCT06050304|Biological|3 blood tests|We will try to identify biomarkers of BS: blood proteins, genetic markers passed on by your parents, or the expression of proteins in particular situations
75604097|NCT04396730|Drug|Cannabidiol Oil|400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
75604098|NCT04396730|Drug|Placebo|Placebo will be administered daily along with oral contraceptives daily for 24 days.
75604099|NCT04396730|Drug|Combined oral contraceptive pill|All participants will receive oral contraceptives
75749108|NCT06050239|Drug|177Lu-PSMA-0057|The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
75453008|NCT01746004|Drug|[^14C]-LY2157299|[^14C]-LY2157299 monohydrate administered as oral solution
75604100|NCT04378868|Drug|Antibiotics, cefuroxime and metronidazole|Patient receives antibiotics while waiting appendectomy
75898975|NCT03102346|Other|home-based cardiac rehabilitation|The exercise training includes aerobic exercise (fast walking or cycling ,30-40 minutes per day,5-6 times a week), stretching exercise (15 minutes every time, 5-6 times a week), and resistance and balance training (each of 15 minutes every time, twice to 3 times a week).
75749109|NCT06050226|Drug|MY008211A tablets|The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.
75749110|NCT06050213|Device|Maxillary implant overdenture|maxillary overdenture retained by different number of implants
75749111|NCT06050200|Procedure|PVE|The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. Embolization is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). After filling the entire volume of the branch of the portal vein, all catheters, guidewires and the vascular sheaths are removed. A dressing is left over the access site and removed the next day. After treatment the patient is given analgesics and antipyretics if necessary.
75769356|NCT05619016|Diagnostic Test|Biopsy and analysis of HER2 expression|Biopsy: Within 3 days after the first ABY-025-PET a tissue sample from at least one metastasis >10 mm available for biopsy, preferably shallow lymph nodes, will be analyzed for HER2 expression through immunohistochemistry- (IHC) and in situ hybridization- (ISH) analysis in patients with GEAC and HER2low mBC.
75769357|NCT03901222|Device|tDCS|20 minutes of anodal tDCS (C3 & C4/FPZ) 2mA or sham
75898976|NCT02298764|Other|Standard back pain treatment|Standard back pain treatment
75898977|NCT02298764|Other|Standard back pain treatment + 10 psychotherapeutic sessions|"Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method somatic experiencing."
75898978|NCT05428501|Other|no treatment given|People / Person Living with Obesity (PLwO) Health Care Professionals (HCPs)
75898979|NCT03102112|Other|MRI examination|A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
75898980|NCT02292056|Behavioral|1-on-1 counseling|"Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling"
75898981|NCT03643731|Device|HeatTens (HV-F311-E)|Patients need to apply the device during 30 minutes.
75453009|NCT01746069|Behavioral|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
75453010|NCT01746069|Behavioral|health advice|routine clinical practice
75453011|NCT01746121|Genetic|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
75453012|NCT01746147|Other|No intervention and study treatment|
75604101|NCT04378868|Drug|No antibiotics|No antibiotics are given while waiting surgery.
75604102|NCT04378868|Other|urgent schedule|Patients can wait up to 8 hours for surgery.
75453013|NCT01746199|Drug|cotrimoxazole daily prophylaxis|
75453014|NCT01746199|Drug|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
75604103|NCT04378868|Other|less urgent schedule|Patients can wait up to 24 hours for surgery.
75604104|NCT04347135|Drug|F-18 FES|F-18 FES PET/MRI for detection of endometriosis.
75604105|NCT04305769|Drug|Alanyl-glutamine|The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
75604106|NCT04301206|Behavioral|Intervention Group|Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
75769358|NCT03900676|Drug|VB-1953 - 2%|Topical Gel
75453015|NCT01746212|Procedure|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
75453016|NCT01746212|Biological|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
75453017|NCT01746212|Device|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
75453018|NCT01746251|Drug|Afatinib|
75453019|NCT01746277|Drug|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
75604107|NCT04285125|Other|cerebral MRI|Patients who agree to participate in the study will perform an MRI with ultra high resolution sequences added by the research MRI of control will be done at one year and two years
75769359|NCT03900676|Drug|VB-1953 - 0% (Vehicle)|Topical Gel
75604108|NCT04278417|Biological|Brolucizumab 6 mg|3 x q6w loading injections, followed by q12w maintenance through Week 90
75604109|NCT04278417|Procedure|Panretinal photocoagulation laser|initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
75604110|NCT04254185|Procedure|Simple decompression|Surgical technique
75604111|NCT04254185|Procedure|Subcutaneous anterior transposition|Surgical technique
75898982|NCT05425459|Device|Corvia Atrial Shunt System / IASD System II|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
76065804|NCT02896348|Other|Conventional therapy|Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.
76065805|NCT02866461|Other|No treatment|Observation
76065806|NCT02863172|Behavioral|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
75453020|NCT01746277|Drug|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
75453021|NCT01746290|Other|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
75453022|NCT01746303|Dietary Supplement|Omega-3 fatty acid|A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
75453023|NCT01746303|Dietary Supplement|Blueberry powder|Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
75453024|NCT01746303|Other|Placebo oil|Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
75453025|NCT01746303|Other|Placebo powder|Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
75604112|NCT04253379|Diagnostic Test|Neuropsychological evaluation , Evaluation of theory of mind, Evaluation of executive functions, Evaluation of verbal skills|Several tests will be used: Raven's Advanced Progressive Matrices, auditory attention subtest of the NEPSY II, Peabody Picture Vocabulary test, specific comprehension test The cognitive TOM will be evaluated with questions about 4 stories of false beliefs. The affective TOM will be evaluated with a specific emotion inference task 4 adapted subtests from several validated scales will be used to investigate inhibition, cognitive flexibility and working memory The semantic and pragmatic competences will be evaluated with 4 comprehension tasks.
75453026|NCT01746329|Other|Tea|Oral intake of tea containing 75 grams of glucose
75453027|NCT01746329|Other|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
75604113|NCT04221269|Behavioral|Enhanced Treatment as Usual|Routine community care plus assessment feedback reports to clinicians.
75453028|NCT01746329|Other|Placebo|Oral intake of 75 grams of glucose in water
75604114|NCT04221269|Behavioral|Coping Long-term with Active Suicide Program for Schizophrenia|Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
75898983|NCT05425459|Other|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
75453029|NCT01746342|Device|Effective continuous positive airway pressure (CPAP)|
75453030|NCT01746342|Device|Sham continuous positive airway pressure (CPAP)|
75604115|NCT04218357|Drug|Probenecid|safety
75604116|NCT04218357|Drug|Matching placebo|Placebo
75604117|NCT04204330|Device|CardioQvark cardiac monitor and software, single-lead ECG|"Registration certificate for the medical device No. РЗН 2019/8124 dated February 15, 2019.~Product form: phone case.~Way of applying:~Download the CardioQVARK mobile application; create a profile.~Fill out the questionnaire:~age;~date of birth;~sex;~weight;~height;~blood type;~eye color;~hair color;~occupation;~town;~alcohol consumption;~tobacco use;~overeating;~insufficient sleep;~hypertension;~type 2 diabetes;~pacemaker;~the 10th revision of the International Classification of Diseases (ICD-10) code;~medicines.~Place index fingers on sensors that are on the case's backside and record 1-lead ECG of up to 3 minutes duration.~Recorded parameters:~time parameters of the ECG intervals (RR, P, PR, QRS, QT, QTc);~abnormal rhythms;~heart rate variability;~additional function - blood pressure and blood sugar diary. All recorded and calculated parameters are passed to the server."
75604118|NCT04203550|Procedure|Intraoperative irrigation|Operation with irrigation
75604119|NCT04203550|Procedure|No irrigation|Operation without irrigation
75604120|NCT04166877|Drug|Magnesium Sulfate in Parenteral Dosage Form|IV bolus followed by continuous infusion for 24 hours
75604121|NCT04166877|Drug|Normal saline placebo|IV bolus followed by continuous infusion for 24 hours
75604122|NCT04164979|Drug|Cabozantinib|Given PO
75604123|NCT04164979|Drug|Pembrolizumab|Given IV
75604124|NCT04153643|Procedure|Arthroscopic Partial Meniscectomy|Surgical treatment for meniscus tear
75604125|NCT04135846|Drug|Doxazosin|16 mg or maximum tolerated dose (MTD)
75604126|NCT04135846|Drug|Placebo|Matching placebo
75898984|NCT05431894|Behavioral|Laguna Coach Intervention Group|Behavioral and mental support was delivered through personal interactions with Laguna Coaches via phone, video, or web chat. Behavioral and mental support was individualized to best match each patient's needs and strengths. Support was provided to participants through human interactions over approximately 30 days.
76065807|NCT02863172|Procedure|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
76065808|NCT02821299|Other|Laryngeal transplantation|Laryngeal transplantation
75453031|NCT01746355|Procedure|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
75453032|NCT01746381|Device|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
75453033|NCT01746394|Behavioral|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
75453034|NCT01746394|Behavioral|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
75604127|NCT04117893|Drug|Duloxetine|Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
75604128|NCT04117893|Drug|intra-articular injection of corticosteroid and hyaluronic acid|Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
75604129|NCT04113395|Other|sequences T1 FE|T1 TSE and T1 TFE sequences with a duration of 6 minutes are added to the imaging protocol.
75769360|NCT00256854|Drug|Ropinirole IR 1 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance.
75604130|NCT04103190|Device|cerebral MRI|"Patients who agree to participate in the study will perform a 3T multi-parametric MRI with advanced spectroscopic imaging techniques and standard protocol.~A neurological consultation will take place during the inclusion visit as well as a questionnaire and a control MRI at 1 year and 2 years +/- 1 month."
75604131|NCT04098003|Drug|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
75604132|NCT04098003|Drug|Placebo|Matched placebo control
76065809|NCT02820857|Drug|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
76065810|NCT02820857|Drug|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
76065811|NCT02797457|Procedure|Bilateral allograft of the hands and forearms.|Bilateral allograft of the hands and forearms.
76065812|NCT02797457|Procedure|Prosthetic forehands|Prosthetic forehands
76065813|NCT02797314|Other|Bone biopsies|Bone biopsies
76065814|NCT02790710|Drug|Propanolol|Active treatment
75604133|NCT04054414|Drug|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
75604134|NCT04054414|Drug|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
75604135|NCT04049851|Drug|Moxidectin 2 MG Oral Tablet|One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.
76065815|NCT02790710|Drug|Placebo|
75453035|NCT01746433|Other|Sitting up|"The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient."
75453036|NCT01746446|Other|Care team|Provides additional support to patients, family, and friends.
76065816|NCT02762318|Other|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:~Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.~A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.~For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
75453037|NCT01746459|Other|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
76065817|NCT02680015|Behavioral|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
76065818|NCT02650843|Other|DAT SPECT imaging|
75453038|NCT01746459|Other|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
76065819|NCT02648477|Drug|Anastrozole|Given PO
76065820|NCT02648477|Drug|Doxorubicin Hydrochloride|Given IV
76065821|NCT02648477|Drug|Exemestane|Given PO
76065822|NCT02648477|Other|Laboratory Biomarker Analysis|Correlative studies
75453039|NCT01746472|Behavioral|Facebook app - condition t|Application components hypothesized to increase the duration (t, time) that a participant spends using the application.
75453040|NCT01746472|Behavioral|Facebook app - condition z|Application components hypothesized to increase the number of friends that a user has that are eligible to install the application.
75453041|NCT01746472|Behavioral|Facebook app - condition B-active|Application components hypothesized to increase the contagiousness of the app by increasing a users ability and desire to proactively contact others.
75453042|NCT01746472|Behavioral|Facebook app - condition B-passive|Application components hypothesized to increase the contagiousness of the app by increasing the passive diffusion of information from the user to their friends.
75453043|NCT01746485|Drug|UT-15C|
75453044|NCT01746498|Procedure|Direct current stimulation using Anodal electrode|11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
75453045|NCT01746498|Procedure|direct current stimulation using cathodal electrode|11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
75453046|NCT01746498|Procedure|Sham direct current stimulation|11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
75453047|NCT01746524|Device|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
75604136|NCT04049851|Drug|Ivermectin 3Mg Tab|3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.
75604137|NCT04049851|Drug|Placebo oral tablet|Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
75604138|NCT04042025|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
75604139|NCT03970954|Drug|low-dose IL-2|Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.
75769361|NCT00256854|Drug|Ropinirole IR 2 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.
76065823|NCT02648477|Drug|Letrozole|Given PO
76065824|NCT02648477|Biological|Pembrolizumab|Given IV
76065825|NCT02613377|Other|Blood transfusion|
76065826|NCT02604732|Procedure|Laparoscopic inguinal hernia repair with perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
76065827|NCT02604732|Procedure|Laparoscopic inguinal hernia repair without perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
76065828|NCT02603640|Device|MRI scanning|
76065829|NCT02498847|Behavioral|ENGAGE|"Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~What is Osteoarthritis?~Information about treatments~Exercise~Sleep hygiene~Relaxation~Pleasant Activity Scheduling~Goal setting~Problem Solving~Pacing~Communication"
76065830|NCT02487394|Procedure|Exhaled Breath Condensate (EBC)|Collection of EBC condensate
76065831|NCT02481648|Other|Exercise|
75604140|NCT03963375|Drug|Cladribine|All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
75453048|NCT01746550|Device|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
75453049|NCT01746563|Drug|Ranibizumab|Intravitreal injection
75453050|NCT01746563|Procedure|Laser therapy|Laser therapy
75604141|NCT03936361|Drug|Statins|Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
75604142|NCT03907644|Device|Transcranial Alternating Current Stimulation (tACS)|The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
75604143|NCT03886909|Behavioral|Exercise|The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
75749112|NCT06050200|Procedure|LVD|"The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. A similar puncture of the hepatic vein or veins is then performed; sometimes with access via the internal jugular vein. Embolization of the portal branch is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). Embolization of the right hepatic vein or veins begins with the insertion of a vascular plug (Amplatzer) approx. 2 cm from the confluence of the vein(s). The remaining part of the hepatic vein(s) is then filled with a homogeneous mixture of histacryl glue and Lipiodol (volume ratio 1:1).~A dressing is left over the access site and removed the next day; patient is given analgesics and antipyretics if necessary."
75749113|NCT06050200|Procedure|ALPPS|"The ALPPS procedure will be performed in the operating theatre, under general anesthesia, preferably using a minimally invasive (laparoscopic) technique.~The procedure consists of surgical ligation or clipping of the branch of the portal vein with a vascular clip and in partial transection of the parenchyma at the plane of the future resection planned in the second stage (partial transection, approx. 75% of the transection plane)."
75898985|NCT02298920|Drug|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
75898986|NCT05007366|Behavioral|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
75604144|NCT03886909|Behavioral|Prehabilitation Education|Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
75453051|NCT01746576|Other|Use of impedance threshold device during spontaneous ventilation|
75604145|NCT03880162|Other|Low carbohydrate diet|A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)
75604146|NCT03880162|Other|Energy-matched standard diet|Energy-matched (30% deficit) standard diet (50% of carbohydrates)
75604147|NCT03860805|Procedure|Laparoscopic tubal ligation|Laparoscopic tubal ligation
75604148|NCT03860805|Procedure|Laparoscopic bilateral salpingectomy|Laparoscopic bilateral salpingectomy
75604149|NCT03837847|Behavioral|Health Coaching Calls|12 weekly health coaching calls
75604150|NCT03837847|Behavioral|Wait list control|after being 12 week in the usual care arm , patient will compassionately be offered the health coaching intervention
75604151|NCT03827031|Other|Mutlidisciplinary medication Review (MMR)|The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
75453052|NCT01746589|Device|bilateral myopic LASIK|200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
75453053|NCT01746602|Drug|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
75453054|NCT01746602|Drug|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
75453055|NCT01746602|Device|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
75453056|NCT01746602|Device|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
75453057|NCT01746602|Device|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
75453058|NCT01746628|Procedure|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
75453059|NCT01746641|Drug|Remifentanil|
75453060|NCT01746641|Drug|Propofol|
75453061|NCT01746654|Drug|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
75453062|NCT01746654|Drug|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
75453063|NCT01746654|Drug|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
76065832|NCT02444429|Drug|Corticosteroid boluses Methylprednisolone|"Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered"
75749114|NCT06050174|Drug|Azadirachta Indica|"Azadirachtaindica L. is a multipurpose medicinal tree of family Meliaceae.Is also named Nimba, holy tree, Vembu, Arishtha, Indian neem tree, Indian lilac, wonder tree. It occurs in tropical and semitropical regions of the world. Almost all parts of this incredible tree have been used as phytomedicines for more than 4,000 years.~Various pharmacological attributes such as antifungal, antiviral, antibacterial, anti-inflammatory, sterilant, antiscabic, antiallergenic and analgesic are attributed to various parts of the tree."
76065833|NCT02444429|Other|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
76065834|NCT02444429|Other|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
76065835|NCT02318342|Drug|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
76065836|NCT02296216|Device|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
76065837|NCT02258165|Device|PET/CT|"PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By freezing this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images."
76065838|NCT02154516|Device|ODH Hip System|
76065839|NCT02134184|Biological|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
76065840|NCT02029846|Drug|Standard Treatment|traditional drugs only
76065841|NCT02029846|Drug|Incretin-Based Treatment|incretin-based drugs
76065842|NCT06018649|Combination Product|Balneotherapy plus complex|The three groups of study (SAB, LAB, LIB) will get same balneotherapy intervention with the difference in duration and mode (outpatient/inpatient). Balneotherapy plus complex procedures: swimming pool with light exercises- 20 min (29-31°C), rest 15 min, wrapping/bath with peloids (peat mud, sapropel)- 20 min (38-40°C), rest 20 min, mineral water bath- 20 min (36-38°C), salt therapy- 25 min (humidity 35%, temperature about 22°).
76065843|NCT06018649|Combination Product|Combined nature resources treatment|"The participants of CNT group will be given combined treatment: nature therapy procedure (45 min) and balneotherapy plus complex intervention procedures.~The nature therapy procedure was created by researchers by combining the principles of nature therapy, mindfulness, wild nature therapy, kinesiology selecting actions suitable for the season. A procedure instructions with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest)."
76065844|NCT06018649|Other|Nature therapy procedure|The participants of NT group will be given nature therapy procedure (45 min) created by researchers by combining the principles of nature therapy, kinesiology, mindfulness, wild nature therapy, selecting actions suitable for the season. A procedure instruction with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest).
75749115|NCT06050174|Procedure|Non Surgical Periodontal Therapy|The patients will receive full mouth one stage debridement using ultrasonic scalers, manual scalers and curettes with oral hygiene instructions and education.
75749116|NCT06050161|Device|Articulating laparoscopic instrument|The Artisential articulating laparoscopic instrument will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
75749117|NCT06050161|Device|Conventional laparoscopic instrument|Conventional laparoscopic instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
75453064|NCT01746654|Drug|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
75453065|NCT01746667|Behavioral|Exposure in vivo|
75453066|NCT01746667|Behavioral|Virtual Reality Exposure Therapy|
75453067|NCT01746680|Drug|Tacrolimus with Methotrexate|Tacrolimus 1 mg for 0~week4, 2mg for week4~week8, 3mg for week8~week24 with MTX ≤20mg/week
75453068|NCT01746706|Device|PET amyloid tracer (Florbetapir F18 AV45 F18|
75898987|NCT05007366|Behavioral|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
75749118|NCT06050161|Device|Robotic surgical instrument|Robotic surgical instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
75898988|NCT05691907|Device|THE therapy|"THE therapy consisting of:~Heating Pad~Interferential Therapy"
75898989|NCT05691907|Procedure|Directional Preference Exercises|Directional Preference Exercises consisting of Mckenzie's extension protocol
75898990|NCT05691907|Procedure|Motor Control Exercises|Motor Control Exercises consisting of External limb loading extension protocol
75898991|NCT03517748|Device|DM05 eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
75898992|NCT03517748|Device|Optive™ eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
75898993|NCT03104686|Other|Short pasta (dry)|50g available carbohydrate of penne pasta
75453069|NCT01746719|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
75453070|NCT01746719|Drug|Etodolac|500 mg tablet once a day
75453071|NCT01746758|Behavioral|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
75453072|NCT01746771|Drug|HM781-36B(Poziotinib)|QD*2weeks/3weeks
75749119|NCT06050148|Biological|Feacal microbial transplantation (FMT)|Feacal microbial transplantation (FMT)
75749120|NCT06050148|Other|Placebo transplantation (PT)|Transplantation with coloured 0,9% NaCl-solution
75749121|NCT06050122|Drug|Patidegib Topical Gel|Patidegib Gel 2% is a smooth, clear, colorless-to-yellow, viscous, hydro-alcoholic gel for topical administration.
75749122|NCT06050122|Drug|Patidegib Topical Gel with no active patidegib|Vehicle Gel consists of the excipients of Patidegib Gel with no active patidegib. It is a smooth viscous gel for topical administration.
75898994|NCT03104686|Other|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
75898995|NCT03104686|Other|Bread|50g available carbohydrate of bread
75453073|NCT01746771|Drug|Paclitaxel|175mg/m2
75453074|NCT01746771|Drug|Trastuzumab|8mg/kg
75453075|NCT01746810|Radiation|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
75453076|NCT01746823|Drug|Cyclosporins|
75453077|NCT01746875|Drug|Aflibercept|2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
75898996|NCT03104686|Other|Glucose|50g available carbohydrate of glucose monohydrate
75898997|NCT02253498|Device|deep brain stimulation (DBS)|
75898998|NCT02298998|Other|Intervention|Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
75898999|NCT02298998|Other|Control|Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
75453078|NCT01746875|Drug|Verteporfin|given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
75453079|NCT01746927|Other|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
75453080|NCT01746992|Drug|Cyclophosphamide 750mg/m2|day 1 in both arms
75453081|NCT01746992|Drug|Vincristine 1.4mg/m2|day 1
75453082|NCT01746992|Drug|Doxorubicin 50mg/m2|day 1
75453083|NCT01746992|Drug|prednisone 60mg/m2|day1-day5
75749123|NCT06050096|Procedure|PCI|CTO patients treated by DCB
75749124|NCT06050044|Drug|Group A (hyperbaric bupivacaine)|Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution
75749125|NCT06050044|Drug|Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)|Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution
75749126|NCT06050031|Dietary Supplement|Intake of antioxidant supplement|All participants will supplent oral antioxidants (individual or combined which can be obtained without prescription, and which are not regulated as a pharmaceutical drug) over three months.
75749127|NCT06050018|Other|YesMilkdiet|In the YesMilkdiet the participants will consume Milk and dairy products
75899000|NCT03104608|Other|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.
75453084|NCT01746992|Drug|ifosfamide 2000mg/m2|day 22-day 24
75604152|NCT03827031|Other|Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up|"Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted."
75899001|NCT03104608|Other|Treatment as Usual|Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
75899002|NCT03517670|Other|Rhythmic tolerance|Rhythmic intolerance is defined by the occurrence of arrhythmia prompting the initiation of an antiarrhythmic medication and the need to decrease or even to stop the infusion of milrinone
75899003|NCT03517670|Other|Hematological tolerance|Hematological tolerance will be considered good if milrinone infusion was not interrupted owing to the occurrence of thrombocytopenia
75899004|NCT03517670|Other|Milrinone efficiency on cerebral vasospasm|It will be assessed using ultrasound measurements of middle cerebral arteries velocities. A decrease of at least 20% of the mean velocity or of the Lindegaard index will be considered as a significant positive effect of the treatment (including milrinone).
75749128|NCT06050018|Other|NoMilkdiet|In the NoMilkdiet the participants will not consume milk or dairy products only another sources of proteins
75749129|NCT06050005|Diagnostic Test|Diagnostic test through functional tests and comparison of scales applied to participants in the pre-surgical and post-surgical period.|The protocol is based on the ligamentization stages, since the bibliography relates the ligamentization process with rehabilitation. These stages are necrosis, revascularization, cellular priorities and collagen formation, and different care is required for each stage. Taking these aspects into account, the authors developed recommendations to establish a protocol divided by the evaluation phases of the present work. Users should only move on to the next phase if they achieve the expected results, or that makes the total duration of each protocol vary from user to user. tests and scales will be evaluated before surgery, after 6 weeks of surgery and at the end of treatment.
75749130|NCT06049992|Device|Pacemaker implantation with conduction system pacing using Lumenless leads|Pacemaker implantation for conduction system pacing will be done using leads without internal lumen (Lumenless; Medtronic Selectsecure 3830, Minneapolis, USA).
75749131|NCT06049992|Device|Pacemaker implantation with conduction system pacing using Stylet-driven leads|Pacemaker implantation for conduction system pacing will be done using leads with internal lumen and retractable helix (Tendril STS 2088TC, Abbott, Inc., USA; Solia S60, Biotronik, SE & Co., KG, Germany; Ingevity +, Boston Scientific, Marlborough, MA, USA)
75453085|NCT01746992|Drug|pirarubicin 50mg/m2|day 1
75453086|NCT01746992|Drug|pirarubicin 25mg/m2|day 22
75899005|NCT03517670|Other|Milrinone efficiency using the modified Rankin scale|Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to perform all usual activities, despite certain symptoms, 2= Slight disability. Able to take care of his own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderate severe disability. Unable to meet their own physical needs without help and unable to walk without help, 5 Severe disability. Needs constant care and attention, bedridden, incontinent, 6 = Death.
75899006|NCT03626155|Behavioral|Walking|Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline
75899007|NCT03626155|Behavioral|Seated Control|Participants will be asked to sit quietly and read during a 50 minute control period
75453087|NCT01746992|Drug|Etoposide phosphate 100mg/m2|day 22-day 24
75453088|NCT01746992|Drug|methotrexate 1500mg/m2|day 43
75604153|NCT03810105|Drug|Olaparib|Olaparib 300mg twice daily (600mg total daily dose)
76025312|NCT03114007|Behavioral|Preventure program|Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
75453089|NCT01747018|Biological|Platelet-rich Plasma|
75453090|NCT01747031|Device|PressureWire™ Certus(St. Jude Medical Systems, Sweden)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
75453091|NCT01747044|Drug|Milnacipran|100mg/day
75604154|NCT03810105|Drug|Durvalumab|Durvalumab 1500mg IV monthly
75749132|NCT06049979|Other|Acute gastrointestinal injury|AGIUS score>2
75749133|NCT06049966|Drug|Atezolizumab|TECENTRIQ C/S.SOL.IN 1200MG/VIAL (20ML) 1 VIAL x 20ML
75749134|NCT06049966|Drug|Carboplatin|SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML
75749135|NCT06049966|Drug|Etoposide|ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML
75749136|NCT06049914|Behavioral|Experimental group|"Exercise interventions~Measuring blood pressure and weight: before starting exercise~Flexibility exercises: 5-10 minutes of stretching~Strength exercises: Consists of 4 upper body exercises (Biceps Curl, Dips, Front raise, Chest press) and 5 lower body exercises (Leg lateral rotation, Leg extension, Hip abduction, Squat, Heel raise). The intensity of the band starts according to the subject's muscle strength.~Aerobic exercise: 5 times a week, home-based, 30 minutes or more each time~Nutritional interventions~Well nourished: Overall diet check and correction~at risk: Correction of diet and intake of up to 2 packs of supplemental protein products per day~Malnourished: Correction of diet and intake of up to 3 packs of supplemental protein products per day~Nutrition counseling is provided at the beginning of the intervention and high-protein diet composition education is provided~Confirm compliance and provide feedback once every 2 weeks"
75749137|NCT06049901|Drug|Nitazoxanide|Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.
75909546|NCT03473054|Other|Web-based Mindfulness Course|"The intervention is a therapist led, web-based MBI course, delivered asynchronously via a series of online videos. The Be Mindful course is a four-week mindfulness course based on the Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy courses. The course has been positively evaluated and shown to reduce stress, anxiety, and depression for participants.~Participants complete ten online interactive videos (30 minutes each), twelve daily practice assignments (with supportive emails), five audio downloads, and online tools for reviewing progress. The minimum time to complete the course is four weeks, but people can take longer if they wish and will still have access to the resources."
75909547|NCT02541188|Genetic|Genetic analysis|
76065845|NCT06018623|Other|It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients|"It is an observational study and no non-routine procedures will be performed on patients.~Routine anesthesia procedure will be applied to the patients"
76065846|NCT06018610|Other|Rehabilitation|In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group.
76065847|NCT06018610|Other|Control|Conventional rehabilitation will be applied to the control group.
75453092|NCT01747044|Drug|Placebo|
75453093|NCT01747057|Behavioral|Dynamic-parameters-guided fluid management|"● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation* and with sinus rhythm.~PPV >12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ [(PPmax+PPmin)/2] x100 (during 5 respiratory cycles)~SVV > 12% (15). SVV: Stroke volume variation~A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.~Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV < 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP>12).~● Non-preload responsive patients (defined as PPV or SVV < 12%) will resume the same protocol as responders when fluid response parameters are negative."
75453094|NCT01747057|Behavioral|Standard-guided-fluid management|Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (> 65mmHg) or CVP > 12mmHg. If CVP reaches > 12 mmHg and MAP remains < 65mmHg, norepinephrine should be started to reach MAP > 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output < 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
75604155|NCT03785210|Drug|nivolumab|480 mg intravenous (IV) every 4 weeks
75604156|NCT03785210|Drug|tadalafil|10 mg by mouth (PO) daily
75604157|NCT03785210|Drug|oral vancomycin|125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
75604158|NCT03757689|Drug|Pembrolizumab|Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.
75604159|NCT03757689|Procedure|Wide Excision and Sentinel Lymph Node (SLN) Biopsy|Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
75604160|NCT03750968|Drug|Carotenoid Group|Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
75604161|NCT03750968|Dietary Supplement|Control Group|Placebo ingredients: Safflower oil
75604162|NCT03742817|Other|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
75604163|NCT03741335|Other|Resistance Training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
75604164|NCT03741335|Other|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session
75604165|NCT03741335|Other|Tai Chi|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
75604166|NCT03722498|Drug|HAIC of FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
75604167|NCT03722498|Drug|Sorafenib|administration of Sorafenib
75604168|NCT03710824|Drug|Nintedanib|diagnosed IPF patients initiating treatment with nintedanib
75604169|NCT03699826|Device|TMS for tinnitus|Targeted stimulation to decrease tinnitus symptom severity.
75749138|NCT06049888|Behavioral|Restricted Social Media|Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.
75604170|NCT03690388|Drug|Cabozantinib|Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
75749139|NCT06049862|Behavioral|MaRiTensi App|"MaRiTensi is a mobile health-based hypertension self-management application used on Android smartphones.~MariTensi provides facilities for recording blood pressure, BMI, activity, examination results, education about hypertension, consultations, reminders and community chat."
75749140|NCT06049849|Device|Biophoton Energizing Brain and Whole Body|The patient is to be energized within a strong biophoton field which is constantly generated by active biophoton generators.
75749141|NCT06049836|Other|Holograms|Clinical decision making based on visualising liver 3D holographic augmented reality liver models
75604171|NCT03690388|Drug|Placebo|Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
75604172|NCT03665922|Dietary Supplement|BroccoMax®|Nutraceutical neoadjuvant
75604173|NCT03665922|Other|Placebo|control
75604174|NCT03648892|Drug|[c11] raclopride|The present study will attempt to resolve the controversy by measuring D2BP using both [18F]fallypride and [11C]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from [18F]fallypride and [11C]raclopride.
75604175|NCT03648892|Drug|[18F]fallypride|The present study will attempt to resolve the controversy by measuring D2BP using both [18F]fallypride and [11C]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from [18F]fallypride and [11C]raclopride.
75604176|NCT03626831|Drug|Evolocumab Prefilled Syringe|Injection of study drug
76065848|NCT06018597|Drug|Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL|No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
75604177|NCT03626831|Drug|Placebos|Injection of placebo
76065849|NCT06018584|Other|Tooth extraction|Tooth extractions were performed by a single physician. Topical anesthesia (Xylo-caine, Astra, Södertalje, Switzerland) was applied to the dried mucosa in the area to be lo-calized with the help of an ear stick for 1 minute. Posterior-superior-alveolar nerve block anesthesia and palatal anesthesia were applied for the upper primary molars; Inferi-or-alveolar nerve block anesthesia and lingual anesthesia (Ultracain, Aventis Pharma, Is-tanbul, Turkey) were applied for the lower primary molars. After anesthesia control was achieved, a randomly selected tooth was extracted. Tooth extraction on the other side was performed two weeks later. During the shootings, attention was paid to the traumatic ap-proach. After the control of bleeding was achieved, data were recorded for each group.
75604178|NCT03619213|Drug|Dapagliflozin|10 mg tablets given once daily, per oral use.
75749142|NCT06049836|Other|PDF|Clinical decision making based on visualisation of 3D liver rendering on computer monitors on a PDF file
75749143|NCT06049823|Procedure|Alveolar ridge preservation|Different grafting strategy of alveolar ridge preservation with different sealing materials
76065850|NCT06018532|Device|PRESAGE CARE|PRESAGE Care informations from the application will be processed by the PRESAGE Care algorithm in real time, and may generate alerts indicating an increased risk of hospitalization or emergency department visits within 7 to 14 days. These alerts will be transmitted to a Care Manager platform, who will analyse the situation, initiate the healthcare intervention and coordinate its implementation. In practice, a care manager (coordinating nurse) will process the alert and carry out an initial assessment of the beneficiary's situation, using the information feedback platform, then by telephone, contacting the older adults beneficiary and the relative. The care manager may or may not implement preventive measures. If necessary, the patient may be offered an outpatient medical consultation, a home visit, a consultation with his or her GP and/or social or paramedical interventions.
75453095|NCT01747070|Other|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
75453096|NCT01747070|Other|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
75453097|NCT01747070|Other|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
75453098|NCT01747070|Other|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
75453099|NCT01747083|Drug|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
75604179|NCT03619213|Drug|Placebo|Placebo matching dapagliflozin 10 mg
75604180|NCT03570515|Behavioral|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
75604181|NCT03570515|Behavioral|Educational film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
76065851|NCT06018519|Other|Clinical endpoints|"Number of epileptic seizures~Change in antiepileptic treatment (increase or decrease)~Visual analogical scale on a target symptom defined with the parents,~CGI,~Actimetry data over 24 hours,~Podometry data over 24 hours,~6 minutes' walk test,~Clinical examination~Feasibility of performing an MRI without any anesthesia on a mock scanner"
75453100|NCT01747109|Device|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
75453101|NCT01747109|Procedure|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)"
75453102|NCT01747122|Device|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
75453103|NCT01747122|Device|Epidural|
75453104|NCT01747135|Drug|VTS-270|
75453105|NCT01747148|Drug|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
75453106|NCT01747161|Drug|Botulin toxin|50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
75453107|NCT01747161|Drug|physiological water|3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
75453108|NCT01747174|Drug|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
75453109|NCT01747174|Drug|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
75453110|NCT01747174|Procedure|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
75453111|NCT01747200|Procedure|Sham rTMS|
75453112|NCT01747200|Procedure|Bilateral rTMS at same frequency and in phase|
75453113|NCT01747200|Procedure|Bilateral rTMS at different frequencies|
75453114|NCT01747200|Procedure|Bilateral rTMSat same frequency and out of phase|
75453115|NCT01747200|Procedure|rTMS over TP8|
75453116|NCT01747200|Procedure|rTMS over TP7|
75453117|NCT01747226|Other|Fluoride rinse|rinse with 15 ml for 1 minute
75604182|NCT03527992|Device|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
75604183|NCT03527992|Device|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
75749144|NCT06049784|Device|Visual Biofeedback using self operated home ultrasound device|participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home. Session records will be sent electronically to the sonographer for assessment and feedback.
75749145|NCT06049784|Device|Visual Biofeedback using ultrasound at hospital|A single ultrasound biofeedback session using Transperineal Ultrasound will guide maternal pushing.
75453118|NCT01747226|Other|Halita|rinsing with 15 ml for 1 minute
75453119|NCT01747226|Other|Meridol Halitosis|rinsing with 15 ml for 1 minute
75453120|NCT01747226|Other|Water|rinsing with 15ml for 1 minute
75453121|NCT01747239|Drug|Cabazitaxel|25 mg/m2 IV every three weeks
75453122|NCT01747252|Dietary Supplement|RGC|
75453123|NCT01747252|Dietary Supplement|RGC|
75453124|NCT01747252|Dietary Supplement|Resveratrol|The equivalent of 150 mg resveratrol
75749146|NCT06049771|Other|Collect blood sample|Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose
75749147|NCT06049758|Procedure|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
75453125|NCT01747278|Drug|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
75453126|NCT01747317|Device|FFR (PressureWire)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden;ComboWire, Volcano Corporation, San Diego, California) will be advanced past the stenosis.
75453127|NCT01747356|Device|Resolute stent treatment|A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
75453128|NCT01747382|Procedure|Renal denervation|
75453129|NCT01747395|Other|Exercise training|The heart failure patients are subjected to differents protocols of physical training
75749148|NCT06049758|Drug|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation
75909548|NCT03474926|Procedure|Routine Template-based lymphadenectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
75453130|NCT01747408|Drug|Human Albumin|"25% human albumin given in four escalating doses:~Group 1: .625g/kg infused over 3hrs daily X 7day~Group 2: 1.25g/kg infused over 3hrs daily X 7day~Group 3: 1.875g/kg infused over 3hrs daily X 7day~Group 4: 2.5g/kg infused over 3hrs daily X 7day"
75909549|NCT03474926|Procedure|LND only for lymph nodes enlargement found in preoperative image or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (e.g. CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery
75453131|NCT01747512|Drug|C-PERT|Patients with thyroid and Head and Neck cancer
75453132|NCT01747512|Drug|G-PERT|Patients with thyroid and Head and Neck cancer
75604184|NCT03481049|Behavioral|Usual CM|Behavioral reinforcement for alcohol abstinence
75749149|NCT06049758|Drug|Levofloxacin 500mg|Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.
75749150|NCT06049758|Procedure|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
75749151|NCT06049745|Drug|Misoprostol 400 Microgram Oral Tablet|S.L misoprostol 400 mcg
75749152|NCT06049719|Other|NIH Task Force's Recommended Multidimensional Minimal Dataset|Questionnaire
75749153|NCT06049706|Device|Active Priming|"It will be applied an active priming stimulation in the supplementary motor area previously to the main stimulation to analyse if that will enhance the response to TMSr, compared to inactive priming.~To apply intervention, it will be used Repetitive Transcranial Magnetic Stimulation Model MagPro R20 (MagVenture Brazil, country Brazil) and the butterfly coil MCF-B70 (MagVenture Brazil, country Brazil).~Each session will last around 20 minutes, and it will be used a 1 Hz frequency, 1200 pulses/day, with 100% of Motor Threshold, once a day, 5 days a week, for two consecutive weeks.~Active Priming group participants will be previously stimulated for 10 minutes (20 trains of 5 seconds with intertrain interval of 25 seconds), with 6Hz frequency over Supplementary Motor Area, receiving 80% of Motor Threshold, with a total of 600 stimulations."
75453133|NCT01747525|Device|NIRS/IVUS of coronary artery|Evaluation of coronary plaque by NIRS/IVUS.
75453134|NCT01747538|Drug|Placebo|Solution for subcutaneous injection
75453135|NCT01747538|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
75453136|NCT01747538|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
75453137|NCT01747564|Drug|YM178 (mirabegron)|oral
75453138|NCT01747590|Drug|Zolpidem|
75453139|NCT01747590|Drug|Alprazolam|
75453140|NCT01747590|Drug|Caffeine|
75453141|NCT01747590|Other|Placebo|
75453142|NCT01747603|Other|Specialized LPTB clinic|50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
75453143|NCT01747616|Device|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
75604185|NCT03481049|Behavioral|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
75604186|NCT03481049|Behavioral|Shaping CM|Behavioral reinforcement for alcohol abstinence
75604187|NCT03445949|Drug|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device
75604188|NCT03445949|Drug|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device
75604189|NCT03445949|Drug|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
75749154|NCT06049706|Device|Sham Priming|Sham Priming group participants will receive a placebo stimulation for ten minutes, with the same parameters and target area as the active group, they will hear the equipament noise and might feel any sensation in the scalp, but there won't be effective stimulation.
75453144|NCT01747616|Other|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
75453145|NCT01747642|Dietary Supplement|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
75453146|NCT01747642|Drug|Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
75604190|NCT03445949|Drug|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
75453147|NCT01747668|Dietary Supplement|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
75453148|NCT01747668|Dietary Supplement|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
75453149|NCT01747681|Procedure|Microfracture|
75453150|NCT01747694|Behavioral|Multi-respiratory muscle training|Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
75899008|NCT04988880|Other|Multiple Sclerosis Expert Patient Program of Catalonia|It is intended to constitute 12 groups of patients (6 with relapsing and 6 for progressive MS; one of each type per unit). The study will be conducted virtually due to the current pandemic situation. Throughout 9 sessions (1 per week for 9 sessions), participants in the group will share knowledge and lived experiences on all aspects related to MS and their self-management. In each session there is a theoretical part to focus on the topic, conducted by the EP. Immediately afterwards, the EP will encourage interaction, facilitating the expression of doubts, questions or experiences about the contents. Its resolution will be sought among the group, resulting in empowerment and control over the health situation. The knowledge acquired will be based on the information provided by the EP and on the knowledge resulting from the life experiences regarding MS of all the people involved. In all sessions, a healthcare professional will act as an observer, providing help and support to the EP.
75899009|NCT02295098|Other|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
75899010|NCT02295098|Other|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
75453151|NCT01747707|Drug|Docetaxel|
75453152|NCT01747707|Drug|Cisplatin|
75453153|NCT01747707|Drug|S-1|
75453154|NCT01747720|Dietary Supplement|Vitamin D3|Given orally
75453155|NCT01747720|Dietary Supplement|Placebo|
75453156|NCT01747733|Device|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
75453157|NCT01747746|Drug|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
75749155|NCT06049680|Drug|SMOFlipid® (lipid injectable emulsion)|"SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated."
75749156|NCT06049667|Drug|NTQ2494 tablet|"Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle)."
75453158|NCT01747746|Drug|Warfarin and Enoxaparin|Historical Control
75453159|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|
75453160|NCT01747785|Other|Cardiac rehabilitation|Aerobic cardiac exercise training will be provided over the 12 week study duration.
75604191|NCT03421977|Biological|Onasemnogene Abeparvovec-xioi|Patients received treatment with onasemnogene abeparvovec-xioi in the parent study, AVXS-101-CL-101
75604192|NCT03342690|Drug|Eplerenone|"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."
75453161|NCT01747785|Other|Myocardial deformation imaging|A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
75453162|NCT01747785|Other|Cardiopulmonary exercise test|The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
75453163|NCT01747798|Drug|auranofin|Given PO
75749157|NCT06049628|Behavioral|FIFA 11+ exercise program|FIFA 11+ program; It consists of simple, easily remembered, and time-consuming, sport-specific exercises underlying fair play. The F 11+ consisted of 3 parts: the first part consisted of running exercises (part 1); the second part included six exercises, which were made up of three levels of difficulty and aimed at enhancing balance, strength, muscle control, and core stability (part 2). The final and the third part covered advanced running exercises (part 3) .
75749158|NCT06049628|Behavioral|routine program|This program consists of jogging, and stretching exercises.
75769362|NCT00256854|Drug|Ropinirole IR 1 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg.
75769363|NCT00256854|Drug|Ropinirole IR 2 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
75604193|NCT03333616|Drug|Ipilimumab|is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.
75899011|NCT03316573|Drug|Pembrolizumab|The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
75899012|NCT05431504|Drug|Dalpiciclib in combination with endocrine therapy by Physicians choice|"Dalpiciclib 150 mg orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses"
75899013|NCT02292134|Device|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
75899014|NCT03104296|Diagnostic Test|Griffiths Mental Development Scales|"Griffiths Mental Development Scales investigate 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand coordination, performance), providing a general developmental quotient (DQ) of infant's abilities and five sub-scale quotients (SQ) for each developmental area.~The assessments are performed individually in a quiet room, over a 45-min period, by the same professional trained psychologist for the whole study period and are implemented in the presence of the infant's parent. The obtained results are adjusted for corrected age, in order to consider the neurobiological maturation of the enrolled infants."
75899015|NCT03626077|Other|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip.Children were trained for 60 minutes per session, three times a week for three consecutive months.
75453164|NCT01747798|Other|laboratory biomarker analysis|Correlative studies
76065852|NCT06018519|Other|Parental questionnaires|"10- Adaptive assessment with Vineland Adaptive Behavior scale II,~11- Mac Arthur questionnaire regarding language,~12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),~13- Dunn sensory profile,~14- Aberrant Behavior Checklist,~15- Nisonger Child Behavior Rating form,~16- Social Responsiveness Scale 2,~17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)"
75453165|NCT01747863|Other|Neurologic examination|Neurologic examination includes: (1) neurologic examination using modify Sarnat score at </= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
76065853|NCT06018519|Other|Quality of life scale|18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
75453166|NCT01747889|Device|electronic chest drainage system|"Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.~On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients"
75604194|NCT03333616|Drug|Nivolumab|Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
75604195|NCT03331601|Drug|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
75604196|NCT03313817|Device|Additional MRI sequences|"Patients will be hospitalized for suspicion of CRAO. An optimized MRI will be performed with specific sequences: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; 3D PD T1 after injection. A consultation of ophthalmology and a control MRI will be carried out one month after the CRAO. Again, specific sequences will be added: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; DTI (Diffusion Tensor Imaging); 3D PD T1 after injection."
75604197|NCT03310879|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
75604198|NCT03267459|Device|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.
75769364|NCT00256854|Drug|Ropinirole CR 2 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance.
75899016|NCT03626077|Device|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months.
75899017|NCT03626077|Combination Product|physical therapy program and E-Link Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months.
75899018|NCT03520634|Other|PD-L1 PET imaging|PD-L1 PET imaging
75899019|NCT03104530|Other|Brown crabmeat|Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
75899020|NCT03514472|Dietary Supplement|Dried Moringa oleifera leaves|
75899021|NCT00109668|Drug|beclomethasone dipropionate (QVAR)|
75899022|NCT03104140|Drug|Ketamine|After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
75899023|NCT03104140|Drug|Thiopental|After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
75453167|NCT01747902|Procedure|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
75453168|NCT01747902|Procedure|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
75453169|NCT01747941|Drug|PF-06305591|single dose, solution
75899024|NCT05472883|Procedure|blood samples|- Research blood sample: 2 additional tubes compared to the classic sample for the analysis of the 9 research molecules.
75604199|NCT03262662|Drug|Varenicline|oral varenicline tablets
75604200|NCT03262662|Behavioral|Brief smoking cessation counseling|~10-minute individual counseling at each of 6 clinic visits
75604201|NCT03257267|Drug|Cemiplimab|Intravenous (IV) administration every 3 weeks (Q3W)
75899025|NCT05472883|Procedure|collection of body tissues|removal of intra-abdominal fat and muscle tissue
75899026|NCT05472883|Procedure|routine care procedure|"Routine care blood sample: Full vitamin panel, CBC, liver panel, urea, creatinine, blood ionogram, blood calcium, phosphorus, magnesium at all visits, except the morning of surgery when only ß HCG (for women of childbearing age), HbA1c.~clinical examination : weight, height, waist measurement, cardiovascular examination, digestive system examination.~dosage of ß HCG for womens."
75899027|NCT03514316|Procedure|Scalpel Gingivectomy|The patients were anesthetized in the area around the teeth which were to undergo the procedure with local anesthesia (Drug: 2% lidocaine and 1:80,000 adrenaline). Initially, the Periodontal Probing Depth was measured and when sufficient anesthesia was achieved, biologic width calculation was done by the trans-gingival probing method. Once the amount of gingival tissue to be excised was demarcated, an external bevel incision was performed by using a scalpel blade (Device: scalpel blade No.15) and the gingival tissue was excised. Left out tissue tags and any beads of granulations tissue were removed to attain a smooth surface.
75453170|NCT01747941|Drug|Placebo|matching placebo
75453171|NCT01747941|Drug|PF-06305591|single dose, solution
75453172|NCT01747941|Drug|Placebo|matching placebo
75453173|NCT01747941|Drug|PF-06305591|single dose, solution
75453174|NCT01747941|Drug|Placebo|matching placebo
75453175|NCT01747954|Other|Bag Squeezing|To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.
75604202|NCT03257267|Drug|Investigator Choice (IC) Chemotherapy|"IC chemotherapy options include:~Antifolate: Pemetrexed~Topoisomerase 1 inhibitor: Topotecan or Irinotecan~Nucleoside analogue: Gemcitabine~Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above."
75769365|NCT00256854|Drug|Ropinirole CR 3 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.
75769366|NCT00256854|Drug|Ropinirole CR 2 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
75453176|NCT01747954|Other|Thoracic vibrocompression|To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
75604203|NCT03245645|Other|Dietary Intervention|Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
75749159|NCT06049615|Device|CLAAS® System|The CLAAS® System delivers a plug to the ostia of the Left Atrial Appendage (LAA) and is designed to occlude the appendage to eliminate blood flow. It is designed to conform to the geometry of the LAA. The implant is designed to permanently seal off the LAA from the LA with an endothelial layer that forms across the LA face of the implant. The implant is available in two different sizes; Regular (27mm) and Large (35mm) to accommodate patient anatomy. Angiography and/or echocardiography may be used to determine the LAA ostium diameter to properly select the Implant size. The implant has an inner, cylindrical, Nitinol endoskeleton that provides the mechanical base structure. The Nitinol endoskeleton contains 10 face struts and 20 anchors (Regular) and 12 struts and 24 anchors (Large) facing proximally to engage the tissue to resist movement. The endoskeleton also provides the conformable structure to enable the foam cylinder to compress against the LAA tissue to facilitate sealing.
75749160|NCT06049589|Dietary Supplement|Coconut Oil|Coconut oil rinsing
75749161|NCT06049589|Drug|Chlorhexidine mouthwash|Chlorhexidine rinsing
75899028|NCT03514316|Procedure|Laser Gingivectomy|In the Laser Gingivectomy group, the procedure was performed by using a 810 nm diode laser (Device: 810 nm FOX III diode laser) . Though a local anesthetic gel is sufficient considering that the procedure is minimally invasive, the area was adequately anesthetized with 2% lidocaine and 1:80,000 adrenaline. The laser unit, comprising of a 300 μm disposable tip, was used in a contact mode with a setting of 1 to 1.5 watts in continuous mode along the demarcated area with a paint brush like strokes progressing slowly to remove the gingival tissue and expose adequate amount of tooth structure. High-volume suction was used to evacuate the laser plume and charred odor
75899029|NCT03514316|Procedure|Nonsurgical periodontal treatment|In all subjects of the Control Group a full-mouth periodontal debridement was performed at baseline, 1 and 3 months with an ultrasonic scaler. Chlorhexidine prophylaxis (0.05% chlorhexidine gluconate) was also administered twice a day for 2 weeks after the periodontal treatment. Oral-hygiene instructions were reinforced again.
75604204|NCT03190668|Drug|Bolus dose of Cefazolin|Mode of Cefazolin administration will be a intermittent bolus
75453177|NCT01747967|Other|Meal Test|Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
75453178|NCT01747980|Drug|PRX-112|Single dose level, four doses per cohort
75453179|NCT01747993|Drug|Tamsulosin (0.4 mg/j)|(1 tablet / day for 6 days)
75604205|NCT03190668|Drug|Continuous Cefazolin drip|Mode of Cefazolin administration will be a continuous drip
75749162|NCT06049589|Other|Water mouthwash|Control with water rinsing
75749163|NCT06049563|Diagnostic Test|Diagnostic MRI|MRI scan of the upper abdomen performed with the low-field 0.4T MRI system.
75749164|NCT06049550|Other|no intervention|no intervention
75453180|NCT01747993|Drug|Placebo|(1 tablet / day for 6 days)
75453181|NCT01748006|Other|Standard of care therapy for severe decompensated heart failure|
75453182|NCT01748019|Drug|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
75604206|NCT03190668|Device|Paraspinal muscle microdialysis catheters|Two dialysis probes will be inserted into a paraspinal muscle
75769367|NCT00256854|Drug|Ropinirole CR 3 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg.
75769368|NCT01256242|Device|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
75604207|NCT03190668|Device|Subcutaneous microdialysis catheters|Two dialysis probes will be inserted into a paraspinal subcutaneous region
75749165|NCT06049511|Behavioral|oral self care protocol|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.
75749166|NCT06049511|Behavioral|standard care|the patients received standard nursing care provided at the clinic to prevent oral mucositis.
75604208|NCT03162653|Drug|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
75749167|NCT06049498|Drug|Mongolian Medicine ZhenBao Pills|Mongolian Medicine ZhenBao Pills, orally, 15 pills each time, twice a day.
75749168|NCT06049498|Drug|Mongolian Medicine ZhenBao Pills Placebo|Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
75749169|NCT06049446|Device|Pintuition|Magnetic seed localization
75749170|NCT06049433|Behavioral|Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
75749171|NCT06049433|Behavioral|On-Demand + Discussion board (DB)|Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. a discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
76065854|NCT06018519|Other|Cognitive assessments|"19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible~20- CPM-BF~21- Simple reasoning task on tablet (match-to-sample task)~22- Implicit rules learning (modified Brixton),~23- 4 sub-tests from the WPPSI-IV (zoo location to assess spatial memory, block design to assess visuo-constructive abilities, bug search , cancellation),~24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),~25- Elementary visuo-spatial perception (on tablets)"
75749172|NCT06049433|Behavioral|Arm 2|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. On-demand multi-media MBCT content (digital audio-video files and downloadable content)
75749173|NCT06049433|Behavioral|On Demand (OD) + Video Conference (VC)|on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. A discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
75769369|NCT01256242|Procedure|Standard Suture Repair|standard suture repair
75453183|NCT01748032|Behavioral|Cognitive training|20 minutes/day for 5 sequential working days
75453184|NCT01748058|Behavioral|Exercise based on active video gaming|
75453185|NCT01748084|Drug|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
75453186|NCT01748084|Drug|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
75453187|NCT01748097|Drug|sodium bicarbonate 4.2%|
75453188|NCT01748110|Behavioral|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.
75453189|NCT01748110|Behavioral|TRIMM|text message intervention.
75453190|NCT01748123|Drug|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
75453191|NCT01748123|Drug|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
75604209|NCT03162653|Drug|Mannitol|Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
75604210|NCT03144206|Drug|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
75453192|NCT01748136|Device|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
75604211|NCT03098004|Other|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
75604212|NCT03025789|Drug|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (1 tablet) for 6 days (with food)
75604213|NCT02999932|Other|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
75453193|NCT01748188|Procedure|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
75749174|NCT06049433|Behavioral|Arm 3|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings.
75453194|NCT01748188|Procedure|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
75749175|NCT06049433|Behavioral|On Demand (OD) + Video Conference (VC)|Access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC)
75899030|NCT02114242|Other|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
75453195|NCT01748188|Procedure|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
75749176|NCT06049407|Behavioral|Participation in a socio-emotional competence program through a technological platform (EMOWELL)|(1) Participants who meet the inclusion criteria will be contacted. (2) Participants will answer the questionnaire battery (T1) (3) Participants will participate in the intervention by remotely playing the EMOWELL desktop serious game and the EMOWELL app. (4) They will answer the T2 questionnaires. (5) They will answer the follow-up (T3) questionnaires.
75749177|NCT06049368|Drug|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
75749178|NCT06049355|Other|Exercise Intervention|Undergo Exercise Together exercise program
75899031|NCT02114242|Other|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
75899032|NCT02253576|Other|inhaled 7% hypertonic saline|Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
75899033|NCT02253576|Other|inhaled nebulized normal saline|Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
75899034|NCT03520478|Drug|SHR3680|Tablet. Specifications of 80 mg; orally, once a day
75899035|NCT03520478|Drug|Bicalutamide|Tablet. Specifications of 50 mg; orally, once a day
75453196|NCT01748188|Procedure|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
75453197|NCT01748188|Procedure|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
75453198|NCT01748201|Procedure|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
75604214|NCT02991456|Drug|Rolapitant|single 180 mg dose by mouth
75604215|NCT02991456|Drug|Ondansetron|8 mg by mouth daily
75604216|NCT02876640|Procedure|Biospecimen Collection|Undergo blood and urine sample collection
75604217|NCT02876640|Drug|Retinoid 9cUAB30|Given PO
75604218|NCT02876640|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection surgery
75604219|NCT02848586|Other|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
75899036|NCT04412590|Other|Vermont Family Based Approach|Comprehensive and individualized program to promote emotional health and wellbeing in families using evidence-based health promotion, prevention and intervention.
75899037|NCT04412590|Other|Treatment as Usual|Pediatric care as usual.
75899038|NCT05544864|Device|Drug eluting stent (DES)|DES-implantation with an everolimus-eluting stent (Xience, Abbott Vascular)
75749179|NCT06049355|Procedure|Biospecimen Collection|Undergo collection of blood samples
75749180|NCT06049355|Other|Educational Intervention|Receive educational materials
75769370|NCT01256320|Other|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
75769371|NCT01256320|Other|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
75899039|NCT05544864|Device|Drug coated ballloon (DCB)|DCB angioplasty with a paclitaxel-coated balloon (Agent, Boston Scientific)
75899040|NCT05691673|Other|No intervention|Observational during 16 weeks
75899041|NCT05430880|Diagnostic Test|impact of fluid challenge on the cardiac index and CO2 respiratory parameters analysis (VCO2, EtCO2)|"Preliminary daily data will record: demographic, ventilatory (tidal volume, FiO2, positive expiratory pressure, compliance, respiratory rate, I/E ratio) and biological parameters (fibrinogen, CRP, leukocytes count, PaO2, PvO2, PaCO2, PvCO2, CO2gap, arterial lactate, ScvO2, platelets count)~st step CO2 record (between Time-6minutes and T0; T0 corresponding to fluid challenge) VCO2 and EtCO2 (End-tidal CO2) automated measurement by Hamilton module. Average VCO2 obtained before fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli.~nd step: Crystalloid (ringer lactate) filling 500mL in 5 minutes~rd step CO2 record (between T+5min and Time+11minutes): VCO2 and EtCO2: automated measurement by Hamilton module. Average VCO2 obtained after fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli"
75899042|NCT00102648|Drug|Lonafarnib|Given PO
75899043|NCT00102648|Drug|Temozolomide|Given PO
75453199|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
75769372|NCT03898492|Other|Physical training|Training two times/week for an hour each time in 8 weeks. The training included strength training, aerobic training, balance training and flexibility training. The training was modified to the participants and initiated by the staff at the center.
76065855|NCT06018519|Other|Language assessments|"26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),~27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),~28- Automatic language analysis (during a 10 minutes interaction, play)."
76065856|NCT06018519|Other|Motor assessments|"29- Kinematic task (specifically designed),~30- Purdue-Pegboard test,~31- Renzi test"
76065857|NCT06018519|Other|Social assessments|"32- Eye-tracking analysis of social visual scenes and social preference index (movies),~33- theory of mind assessment,~34- ADOS scale (Autism Spectrum Disorder),~35- sensitivity to inequality,~36- pro-social behaviors (help of the psychologist)"
76065858|NCT06018519|Other|3T MRI|37- Structural, metabolic and functional data
76065859|NCT06018519|Other|Cardiac assessments|"38- ECG~39- Ultrasound"
76065860|NCT06018519|Other|Biological collection|"40- Blood sample~41- Urinary sample~42- Superficial skin biopsy"
76065861|NCT06018506|Drug|BR108 injection|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
75453200|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
75453201|NCT01748266|Other|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
76065862|NCT06018454|Other|Handout on PGT-A|Educational handout on PGT-A
76065863|NCT06018454|Other|Handout on PGT-A and genetic counseling|Handout on PGT-A and genetic counseling session with a genetic counselor on PGT-A
76065864|NCT06018363|Biological|Allogenic B7H3 CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10^7 cells) , dose 2 (3 × 10^7 cells), dose 3 (1× 10^8 cells); Phase 2 : dose of RP2D.
76065865|NCT06018285|Behavioral|Stepped Approach to Reducing Risk of Suicide in Primary Care|Intervention consists of implementation of clinical pathway for youth suicide risk
76065866|NCT06018259|Procedure|healthy volunteers blood sampling|One blood sample will be taken from healthy volunteers in order to isolate PBMC and to assess the effect of the lipid of interest on them PBMC will be activated in vitro (e.g. using LPS or PHA) in the presence or absence of the lipid of interest.
76065867|NCT06018246|Dietary Supplement|Malnutrition five-step treatment model + conventional nutritional intervention|"Before operation：Same as arm description.~After operation:Same as control group.~Out-of-hospital: Same as before operation.~Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day, gradually increase the patient's muscle endurance and improve the body resistance."
75769373|NCT00189462|Drug|Montelukast|
75769374|NCT00189462|Drug|Placebo|
76065868|NCT06018246|Other|Conventional nutritional intervention|Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
75899044|NCT04216446|Behavioral|Mobile Health Intervention|A mobile based application will be developed that will function on android as well as the iPhone operating system. The application will be provided to eligible pregnant women randomized to the intervention group. The dietary, supplement use and physical activity coaching will be provided over the period of 6 months through the application.
75899045|NCT05691361|Drug|ADX-324|siRNA duplex oligonucleotide
75899046|NCT05691361|Drug|Placebo|saline
75899047|NCT03517514|Other|Physical Therapy service|routine physical therapy care
75899048|NCT01894282|Procedure|Manual Therapy|Manual Therapy Arm
76065869|NCT06018207|Drug|Midazolam oral solution|"The ED50 dose of midazolam oral solution for hypnosis is studied using an up-and-down sequential allocation while waiting for surgery and general anesthesia in preoperative room.~The starting dose is 6 mg and the step size is 1 mg. The interval sequential dose is varied by 1 mg based on the hypnosis response of the previous patient after one hour.~Definition of successful hypnosis by taking midazolam oral solution:~The polysomnograph (PSG) not only shows stage N2 within 30 minutes, but also shows stage N3 within an hour; or else, definition of unsuccessful hypnosis.~The procedure is as follows: (1) The first subject is given 6mg of midazolam oral solution; (2) If succeed, the second subject takes 4mg; (3) If not succeed, the second subject takes 8mg; (4) Until seven sequence reversal inflection points."
76065870|NCT06018194|Device|ElucidVivo|Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
75899049|NCT01894282|Procedure|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
75899050|NCT03545958|Behavioral|High-intensity Interval Training (HIT)|Following the mind-motor training component, participants in the experimental group will then continue in the 45-minute HIT intervention, which will be composed by a 10-minute warm-up, a 25-minute core activity, and a 10-minute cool down. The 25-minute core activity will be carried out based on a 4 x 4 minutes aerobic interval training model. The intensity in each cycle will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
75453202|NCT01748279|Drug|Atorvastatin|
75453203|NCT01748279|Drug|Formoterol|12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
75453204|NCT01748279|Drug|Lactose tablet|One lactose tablet taken once a day as add-on treatment to Formoterol therapy
75769375|NCT03898258|Other|Qualiveen full version|Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
75769376|NCT03898258|Other|Qualiveen short-form|Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
75453205|NCT01748305|Behavioral|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
75453206|NCT01748318|Drug|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
75604220|NCT02848586|Behavioral|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
75604221|NCT02848586|Other|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
75769377|NCT01150318|Drug|Administration of 131 iodine|100 mCi 131 iodine irradiation
75769378|NCT03910114|Drug|Magnevist|GBCA enhancement
75453207|NCT01748318|Drug|Bactrim DS|Bactrim DS
75604222|NCT02842827|Drug|bomedemstat|oral administration
75453208|NCT01748331|Other|Fluid restriction|Patients will be randomized to strict fluid restriction < 1 L/day versus moderate fluid restriction < 2.5 L/day
75769379|NCT03910114|Drug|Dotarem|GBCA enhancement
75899051|NCT03545958|Behavioral|Moderate-intensity Continuous Training (MCT)|After the mind-motor training component, participants in the comparison/control group will then continue in the 45-min MCT intervention, which will be composed by a 10-minute warm-up a 25-minute moderate-intensity continuous aerobic exercise training, and a 10-minute cool down. The exercise intensity will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
75453209|NCT01748344|Drug|Cetirizine|10mg tablets
75453210|NCT01748344|Drug|High dose ONO-4053|Experimental
75453211|NCT01748344|Drug|Low dose ONO-4053|Experimental
75899052|NCT01827904|Device|Transcranial ExAblate|
75453212|NCT01748344|Drug|Placebo|None active
75899053|NCT01827904|Device|Sham Transcranial ExAblate|
75453213|NCT01748370|Drug|Vitamin D supplementation in hypogonadal men|
75453214|NCT01748370|Drug|Vitamin D supplementation in eugonadal men|
75453215|NCT01748370|Drug|Placebo hypogonadal|
75453216|NCT01748370|Drug|Placebo eugonadal|
75453217|NCT01748383|Procedure|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
75453218|NCT01748383|Procedure|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
75604223|NCT02842827|Drug|tretinoin|oral administration
75604224|NCT02778750|Procedure|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
75604225|NCT02666378|Other|Cardiac Magnetic Resonance Imaging (CMR)|Subjects will be recruited for observational cardiac magnetic resonance imaging.
75769380|NCT03910114|Drug|Gadovist|GBCA enhancement
75769381|NCT01255228|Other|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
75769382|NCT03900364|Procedure|partial nephrectomy|Partial nephrectomy is the standard technique for organ-sparing resection of renal tumors. The EAU Guidelines recommend partial nephrectomy to all patients with T1 tumours and can be performed either with an open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.
75453219|NCT01748383|Procedure|stenting of IRA|The only stent implantation
75453220|NCT01748396|Drug|Calcitriol|
75769383|NCT03910192|Behavioral|Mindfulness-based coaching|16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.
75769384|NCT03910192|Behavioral|Dietary cardiovascular risk reduction coaching|Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
75769385|NCT02528110|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
75899054|NCT03290287|Drug|Aclidinium bromide|Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
75899055|NCT03290287|Drug|Other COPD medication|"Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol"
76065871|NCT06018181|Drug|Shuxuetong Injection|According to clinical real treatment records
75453221|NCT01748396|Drug|Calcium Carbonate|
75453222|NCT01748409|Other|Biopsies of peripheral autonomic nervous system|
75453223|NCT01748409|Other|Autonomic dysfunction questionnaires|
75899056|NCT02295176|Dietary Supplement|Armolipid Plus|
75899057|NCT02295176|Dietary Supplement|Placebo|
75899058|NCT04211142|Procedure|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)|Laparoscopic inguinal hernia repair
75899059|NCT04211142|Procedure|Open Inguinal Hernia Repair (Lichtenstein repair)|Open Inguinal Hernia Repair
75899060|NCT03104218|Other|tDCS group|Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
75453224|NCT01748409|Other|Electrophysiological tests|
75453225|NCT01748422|Drug|Qutenza|Transdermal patch
75604226|NCT02666378|Other|Echocardiogram (ECHO)|Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.
75604227|NCT02503774|Drug|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arms' description.
75604228|NCT02503774|Drug|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arms' description.
75604229|NCT02476734|Other|There is no intervention|Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.
75604230|NCT02432274|Drug|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
76065872|NCT06018168|Other|Skincare Routine|"Morning:~1. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~VITAMINSCRUB - Wet your face with lukewarm water & apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face"
75453226|NCT01748435|Drug|Qutenza|Single treatment with Qutenza
75453227|NCT01748461|Behavioral|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
75453228|NCT01748461|Behavioral|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
75453229|NCT01748474|Procedure|Supplemental oxygen via a mask|
75453230|NCT01748487|Drug|dexamethasone intravitreal implant (OZURDEX)|intravitreal implant
75453231|NCT01748500|Drug|Pantoprazole|
75769386|NCT02528110|Procedure|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
75899061|NCT03104218|Other|Placebo group|"Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition."
75769387|NCT02528110|Other|SOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
75769388|NCT02528110|Other|XELOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
76065873|NCT06018168|Dietary Supplement|MINDBODYSKIN Supplement|Participants will take 3 capsules daily with a meal. The MINDBODYSKIN acne supplement contains Vitamin A (6,100mcg per serving of 3 capsules), Vitamin B12, Vitamin B-5, 5-Hydroxytryptophan (5-HTP), 3,3'-Diindolymethane (DIM), a proprietary liver blend of milk thistle, dandelion extract and L-glutathione, turmeric root extract, a proprietary digestive blend of protease and betaine hydrochloride, and silicon dioxide.
76065874|NCT06018090|Other|The presence and rate of MES measured by TCD monitoring|TCD monitoring within 24 hours from the last known well time. Bilateral M1 segments of middle cerebral artery were insonated at a single depth with 2-MHz transducers secured by a probe-holder.
75453232|NCT01748513|Other|preoperative venous return optimizing|Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
76065875|NCT06018077|Behavioral|Dietary İntake, Biochemical parameters, Antropometric measuruments|Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.
76065876|NCT06018025|Drug|CGRP antibody|treatment with CGRP antibody for 4 months
76065877|NCT06017986|Other|Ultra-processed food - Picture Set Meal|A meal containing ultra-processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
75899062|NCT02253888|Drug|TPV - Room condition|
75899063|NCT02253888|Drug|TPV - Refrigerated conditions|
75899064|NCT02253888|Drug|Ritonavir (RTV)|
75453233|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
75453234|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
75899065|NCT03520244|Behavioral|Exercise + Holistic Education|The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
76065878|NCT06017986|Other|Ultra-processed food - Additives Meal|A meal containing ultra-processed foods that very on degree of additives.
76065879|NCT06017986|Other|Ultra-processed food - Ingredients Meal|a meal containing ultra-processed foods that very on degree of processing but not ingredients.
76065880|NCT06017986|Other|Minimally Processed Food - Picture Set Meal|a meal containing minimally processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
75453235|NCT01748539|Drug|KHK4827|
75453236|NCT01748539|Drug|Placebo|
75453237|NCT01748578|Drug|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
76065881|NCT06017986|Other|Minimally Processed Food - Additives Meal|A meal containing minimally processed foods that very on degree of additives.
75453238|NCT01748578|Drug|EBI-005-1 Placebo|
75453239|NCT01748604|Other|Manual Lymphatic Drainage (MLD)|MLD with Földi's technique by an expert therapist during 45 minutes
75453240|NCT01748604|Device|Generic intermittent pneumatic compression Device (IPC)|Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
75453241|NCT01748604|Other|multilayer, multicomponent bandages (MB)|multilayer, multicomponent bandages (MB) until next day.
76065882|NCT06017986|Other|Minimally Processed Food - Ingredients Meal|A meal containing minimally processed foods that very on degree of processing but not ingredients.
76065883|NCT06017921|Drug|Eszopiclone 3 mg|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
76065884|NCT06017921|Drug|Placebo|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
75453242|NCT01748604|Device|Lymphapress-Plus(TM) device (LPD)|Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
75453243|NCT01748617|Other|Controlled diet|1 week of controlled diet
75909550|NCT03474848|Other|HABIT|Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
75453244|NCT01748630|Drug|dexmedetomidine|
75453245|NCT01748630|Drug|Midazolam|
75453246|NCT01748630|Drug|fentanyl|
75453247|NCT01748656|Device|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
75453248|NCT01748656|Device|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
75453249|NCT01748669|Dietary Supplement|Garlic oil|Oral administration
75453250|NCT01748682|Other|A very low calorie diet of two different consistencies|Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
75909551|NCT03474848|Other|Conventional Occupational Therapy (OT)|Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
76065885|NCT06017908|Device|Optokinetic stimulation through Virtual Reality|The experiment will be conducted in two phases. In the first experiment the patients will be passively watch the visual images while seated. An optokinetic stimulus will be delivered through the VR headset by displaying rotating visual patterns. In the second trial they will have to perform the enhanced rod and disc test.
76065886|NCT06017856|Other|Life style intervention program|Life style intervention program for the obese/overweight subjects conducted regardless of this study at the child sport and health center at Meir medical center
76065887|NCT06017830|Device|Physical treatment agents|Physical treatment agents such as TENS (transcutaneous electric nerve stimulation), hot pack and ultrasound will be applied to patients with low back pain. Sexual function will be assessed before, just after and 3 months later physical therapy.
75453251|NCT01748708|Device|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
75453252|NCT01748708|Device|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
75453253|NCT01748721|Biological|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
75453254|NCT01748721|Other|pharmacological study|Correlative studies
75453255|NCT01748721|Other|laboratory biomarker analysis|Optional correlative studies
75453256|NCT01748734|Procedure|quality-of-life assessment|Ancillary studies
75453257|NCT01748734|Other|questionnaire administration|Ancillary studies
75604231|NCT02432274|Drug|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
75453258|NCT01748734|Other|counseling intervention|Undergo cognitive behavioral therapy
75604232|NCT02432274|Drug|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
75604233|NCT02432274|Drug|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose). Lenvatinib dose can be escalated to the RD from Cohort 1 or de-escalated to 40 and 60% lower than the RD from Cohort 1.
75604234|NCT02432274|Drug|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
75899066|NCT05690737|Behavioral|Tai Chi training|The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.
75909552|NCT00308516|Drug|5-Fluorouracil|"Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15"
75453259|NCT01748734|Behavioral|behavioral intervention|Undergo cognitive behavioral therapy
75453260|NCT01748747|Drug|Montanide ISA 51 VG|Given SC
75453261|NCT01748747|Biological|MART-1 antigen|Given SC
75453262|NCT01748747|Other|laboratory biomarker analysis|Correlative studies
75453263|NCT01748747|Biological|Gag:267-274 peptide vaccine|Given SC
75453264|NCT01748747|Drug|resiquimod|Applied topically
75453265|NCT01748773|Drug|Oxaliplatin|Participants will receive oxaliplatin 100 mg/m^2 IV on Day 1 of Cycles 1-3.
75453266|NCT01748773|Radiation|Radiation|Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
75604235|NCT02432274|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Ifosfamide dose can be de-escalated to 2400 mg/m2/day and 1800 mg/m2/day.
75604236|NCT02432274|Drug|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Etoposide dose can be de-escalated to 80 mg/m2/day and 60 mg/m2/day.
75453267|NCT01748773|Drug|Capecitabine|Participants will receive capecitabine 850 mg/m^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
75604237|NCT02432274|Drug|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
75604238|NCT02432274|Drug|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
75604239|NCT02424955|Drug|perflutren lipid microspheres|
75453268|NCT01748773|Drug|Trastuzumab|Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
75453269|NCT01748786|Behavioral|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
75453270|NCT01748786|Other|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
75453271|NCT01748812|Drug|Osteomalacia|
75453272|NCT01748838|Drug|CTX-4430|Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
75604240|NCT02424955|Diagnostic Test|3D ultrasound|
75453273|NCT01748838|Other|Mannitol|excipient blended with CTX-4430 in capsules
76065888|NCT06017778|Device|whole body vibration|patients will receive WBV training in addition to traditional training will be performed on a tri-planar (mostly vertical, Z axis) oscillating vibration platform (Power PlateR pro5™; Power Plate North America, Inc., Northbrook, IL,USA) for 20-30 minutes per session. WBV training will be supervised and performed in a clinic three days a week with at least one day between each session for four weeks (total of 12 sessions).
76065889|NCT06017778|Other|traditional exercise group|10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.
76065890|NCT06017765|Behavioral|Meditation Training|"The Meditation Training consists of 8 weekly sessions of Mindfulness Training and is adapted from the group-based Stress Management and Resiliency Training - Relaxation Response Resiliency Program, SMART-3RP. This training is structured around the following four goals:~Education about stress response~Elicitation of the Relaxation Response through Mindfulness Training~Creating adaptive perspectives~Coping strategiest."
76065891|NCT06017765|Behavioral|Waitlist|The waitlist consists of a waiting time of 12 weeks during which participants will nog receive any type of intervention.
76065892|NCT06017752|Behavioral|STAC Teacher Module|"The STAC Teacher Module is a 30-minute presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies teachers can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
75604241|NCT02393859|Drug|Blinatumomab|15 μg/m^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
76065893|NCT06017726|Other|treatment of insulin resistance with appropriate modality according to each patient|insulin resistance will be treated with either diet alone or combined diet and appropriate pharmacological treatment with the net result of normalization of HOMA IR index
76065894|NCT06017700|Behavioral|Interpersonal Psychotherapy Group|IPT is a psychological intervention that focuses on four common problems that trigger depression: grief, disputes, role transitions and social isolation. Using techniques and strategies such as linking mood to event and event to mood, role play and skill-building, IPT encourages the individual to analyse and improve their interpersonal relationships context. IPT was developed in the USA to treat depressed adults but it has also been used to treat other mental disorders and among different age groups.
76065895|NCT06017700|Behavioral|Enhanced Usual Care|Participants attending schools in the control arm will receive enhanced usual care. In intervention and control arms, we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package (mhGAP). Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Adolescents in the control cluster reporting a current suicide plan (i.e. in the past 2 weeks) or suicide attempt in the past three months will be assessed by a psychosocial counsellor employed through the project and offered counselling or referral to other services as per need.
75453274|NCT01748838|Drug|Placebo|Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
75453275|NCT01748838|Drug|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
75453276|NCT01748838|Drug|Placebo|Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
75453277|NCT01748838|Other|Mannitol|excipient blended with CTX-4430
75453278|NCT01748851|Drug|XELOX|capecitabine 1000mg/m2 bid po D1-D14
75453279|NCT01748851|Drug|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
75453280|NCT01748864|Drug|Etarfolatide (EC20)|
75453281|NCT01748877|Drug|NXN-462|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
75453282|NCT01748877|Drug|Placebo|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
75453283|NCT01748903|Device|Target 360°, 2D Coils, Nano Coils|
75453284|NCT01748929|Drug|Albendazole|
75453285|NCT01748929|Drug|Placebo|
75604242|NCT02393859|Drug|Dexamethasone|10 mg/m^2/day intravenous (IV) on Days 1-6
75604243|NCT02393859|Drug|Vincrisitne|1.5 mg/m^2/day IV on Days 1 and 6
75604244|NCT02393859|Drug|Daunorubicin|30 mg/m^2 IV over 24 hours on Day 5
75604245|NCT02393859|Drug|Methotrexate|1 g/m^2 IV over 36 hours on Day 1
75604246|NCT02393859|Drug|Ifosfamide|800 mg/m^2 IV for 1 hour on Days 2-4
75604247|NCT02393859|Drug|PEG-asparaginase|1000 U/m^2 IV for 2 hours or intramuscularly (IM) on Day 6
75604248|NCT02393859|Drug|Erwinia-asparaginase|In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
75604249|NCT02369393|Behavioral|Behavioral Activation|Behavioral Activation intervention promotes the involvement in meaningful activities close to personal values.
75453286|NCT01748981|Other|Physical training|"Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls"
75453287|NCT01748981|Other|As usual|Controls, not training
75453288|NCT01749020|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks
75749191|NCT06049225|Behavioral|High-Tech|Access to technological platform and weekly health coaching
75749192|NCT06049225|Behavioral|Low-Tech|Weekly email with educational content and weekly health coaching
75604250|NCT02369393|Behavioral|Physical Activity|Physical Activity intervention promotes the gradual increase of the frequency and intensity of PA levels, with special attention to motivational strategies.
76065896|NCT06017674|Procedure|Intra-articular Pulsed Radiofrequency|A 22-gauge 10 cm radiofrequency cannula with a 10-mm active tip was advanced to the mid-tibiofemoral joint under fluoroscopic guidance. After needle insertion, paresthesia-pain and motor stimulation tests were performed using sensory (50 Hz) and motor (2 Hz, 1 V) stimulation to confirm the absence of stimulation. Intra-articular Pulsed Radiofrequency (IAPRF) was applied at 45 V voltage for 20 ms pulse width for 360 s, followed by a 480 ms silent phase. The tissue temperature was adjusted to not exceed 42°C.
76065897|NCT06017674|Drug|Steroid Injection|8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.
75604251|NCT02096588|Drug|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
76065898|NCT06017661|Dietary Supplement|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|2 times a day
76065899|NCT06017661|Dietary Supplement|Nutridrink Skin Repair|2 times a day
75453289|NCT01749020|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
75604252|NCT02096588|Drug|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
75604253|NCT02095288|Procedure|Blood draw|This is a single blood donation, no drugs or devices administered
75604254|NCT01827098|Procedure|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
75453290|NCT01749046|Drug|Remegal|Remegal 1500 mg for 12 weeks
75453291|NCT01749072|Drug|Gefitinib group|Gefitinib 250mg once per day until the progression disease or intolerant side effects
75453292|NCT01749072|Drug|Vinorelbine, Ifosfamide, Mesna|Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
75749193|NCT06049225|Behavioral|Attention Control|No technology access or health coaching
75909553|NCT00308516|Drug|Bevacizumab|"Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15"
75909554|NCT00308516|Procedure|Radiation Therapy|radiation 1.8 Gy/day or 28 fractions weeks 1-6
75909555|NCT00308516|Drug|Oxaliplatin|"Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15"
75909556|NCT00308516|Drug|Leucovorin|"Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15"
75909557|NCT03471494|Other|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
75909558|NCT02523404|Procedure|interventional therapy|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
75604255|NCT01622335|Drug|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
75899067|NCT05690737|Drug|Standard prophylactic medication|Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
76065900|NCT06017648|Device|Non Invasive Ultrasound (FUBA5200)|the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd
76065901|NCT06017648|Device|Non Invasive Ultrasound (Contour I V3)|the Focused Ultrasound Fat Reduction device (Contour I V3) is manufactured by Syneron Medical Ltd.
76065902|NCT06017635|Other|Exposure factors|"General information Name, gender, age, weight (kg), major diseases~Clinical data:~Non-contrast CT scan results of cranial CT on the first day of admission, serum SUR1, trpm4 and MMP-9 expression on the 1st, 4th, 7th and 14th days of admission, S100-β and NSE values on the 1st, 4th, 7th, and 14th days of admission, disturbance coefficient on the 1st, 4th, 7th, and 14th days of admission, Glasgow coma score on the 1st, 4th, 7th, and 14th days of admission, GOS-E score and Merriam-Webster Intelligence Scale score at 3 months of discharge."
76065903|NCT06017609|Drug|JTT-861 Capsules|Active drug capsules containing JTT-861
76065904|NCT06017609|Drug|Placebo Capsules|Placebo capsules matching in appearance to the active drug capsules
76065905|NCT06017596|Device|PEEK framework|All-on-4 implants with PEEK framework of fixed detachable prosthesis
76065906|NCT06017492|Behavioral|video assisted discharge teaching|Patients will be educated using the video assisted discharge teaching. The educational content will be in English and will focus on the following topics: surgical process, medication use complication after surgery, pain management, wound care, nutrition, self-care after, surgery, home care after surgery and situations to refer to a physician.
75453293|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
75453294|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
75453295|NCT01749098|Drug|PF-04958242|PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
75453296|NCT01749098|Drug|Ketamine|At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
75604256|NCT01622335|Other|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
75604257|NCT01359592|Biological|rituximab|
75604258|NCT01359592|Drug|cyclophosphamide|
75749194|NCT06049186|Behavioral|CRD|During the initial 8 weeks of the trial, polycystic ovary syndrome (PCOS) patients are instructed to follow a diet of 1200 to 1500 kcal per day supervised by dietitians. The CRD includes a combination of 40 to 55% of calories from carbohydrates, 15 to 20% from protein, and 20 to 30% from fat; this regimen represented approximately 75% of the participants' daily caloric intake at baseline. All the participants receive dietary counseling daily during the trial.
75749195|NCT06049186|Drug|Metformin|After randomization, patients entering the metformin group will be given 1500 mg daily (bid/tid) metformin and regular diets as control. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.
75899068|NCT05430802|Drug|Furmonertinib+cisplating/pemetrexed|Furmonertinib 80mg/d for 9 weeks and cisplating75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv in 21-day cycles for 3 cycles
75899069|NCT05524038|Drug|Bupivacaine Hydrochloride|20mg of Bupivacaine hydrochloride as local anesthetic will be used in (QL) group and (ESB) group
75899070|NCT05524038|Device|Ultrasound device|high-frequency linear probe covered with sterile sheath Active Array L12-4 (8-13MHz) of an ultrasound machine (Philips clear vue350, Philips Healthcare, Andover MA01810, USA) for performing the blocks .
75453297|NCT01749098|Drug|Placebo|Placebo capsule orally administered on Days 1 - 5
75604259|NCT01359592|Drug|doxorubicin hydrochloride|
75604260|NCT01359592|Drug|prednisone|
75604261|NCT01359592|Drug|vincristine sulfate|
75604262|NCT01359592|Other|R-CHOP regimen|
75604263|NCT01359592|Other|laboratory biomarker analysis|
75604264|NCT01359592|Radiation|fludeoxyglucose F 18|
75604265|NCT01359592|Radiation|selective external radiation therapy|
75604266|NCT01359592|Radiation|yttrium Y 90 ibritumomab tiuxetan|
75749196|NCT06049173|Other|novel recruitment maneuver therapy|The use of abdominal compression cardiopulmonary resuscitation apparatus for new recruitment maneuver therapy: the use of autonomous ventilation mode (PSV or CPAP) during mechanical ventilation, followed by abdominal compression recruitment maneuver therapy, the number of times of each compression is 5-10, each time the duration of 30 to 40s, and then adjust to the previous breathing pattern.
75899071|NCT05524038|Drug|Dexamethasone|injection of 4mg dexamethasone in each block
75749197|NCT06049082|Drug|KB408 (Nebulization)|Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
76065907|NCT06017466|Diagnostic Test|Visual Vertigo Analogue Scale (VVAS)|The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.
76065908|NCT06017375|Other|Questionnaire based intervention|Three validated questionnaires amended from hepatitis B to D (Chronic liver disease questionnaire, self-stigma scale and HBV virus knowledge scale) will be used.
75453298|NCT01749098|Drug|Ketamine|At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
75453299|NCT01749111|Drug|ARM A Cyclophosphamide|Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation
75604267|NCT01331018|Procedure|Bone Marrow Aspiration|Undergo bone marrow harvest
75749198|NCT06048874|Procedure|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
75749199|NCT06048874|Drug|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
75453300|NCT01749111|Drug|ARM B Calcineurin inhibitor and methotrexate|Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
75604268|NCT01331018|Biological|Filgrastim|Given SC
75749200|NCT06048874|Drug|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
75749201|NCT06048848|Procedure|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
75749202|NCT06048848|Drug|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
75749203|NCT06048848|Drug|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
75749204|NCT06048640|Dietary Supplement|Dynamine (methylliberine)|Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.
75899072|NCT05524038|Device|echogenic needle|22- gauge, 50 mm echogenic needle (Stimuplex D; B Braun, Germany) for performing the blocks .
75604269|NCT01331018|Biological|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
75604270|NCT01331018|Other|Laboratory Biomarker Analysis|Correlative studies
75604271|NCT01331018|Procedure|Leukapheresis|Undergo leukapheresis
75604272|NCT01331018|Drug|Methylprednisolone|Given IV
75899073|NCT04046731|Diagnostic Test|Skin Testing|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
75604273|NCT01331018|Drug|Plerixafor|Given SC
75604274|NCT01331018|Drug|Prednisone|Given PO
75604275|NCT01091857|Behavioral|STRIDE|
75604276|NCT00930111|Other|2-week rotation|Attending physician is assigned to a 2-week rotation.
75604277|NCT00930111|Other|4-week rotation|Attending physician is assigned to a 4-week rotation.
75604278|NCT00840853|Genetic|CD19CAR/virus specific T cells|CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
75899074|NCT02295254|Other|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
75899075|NCT03249727|Diagnostic Test|IVDD for NK cell activity in whole blood|Once subject has been scheduled for a colonoscopy by the institution (up to 4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.
76065909|NCT06017349|Device|Non-invasive glucose meter|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
75604279|NCT00840853|Drug|Benadryl and Tylenol|Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
75604280|NCT00710892|Biological|Allodepleted T Cells|"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."
76065910|NCT06017349|Device|EKF analyzer|Blood glucose levels were measured while fasting, after breakfast, and after lunch，After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
76065911|NCT06017349|Device|Accu-Chek Guide|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
75749205|NCT06048614|Procedure|Saline Enema (SE)|"infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds~Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm"
75604281|NCT00699816|Biological|Immuncell-LC|Activated T lymphocyte
75604282|NCT00697073|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
75604283|NCT00656331|Drug|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
75604284|NCT00653432|Device|Monovisc®|Intra-articular injection
75604285|NCT00653432|Other|Saline|0.9% Sterile Saline
75604286|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients > 45 kg/99 lbs: idebenone 900 mg/day
75604287|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
75604288|NCT00537680|Drug|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
76065912|NCT06017310|Diagnostic Test|Evaluate the performance of IFN I/III|Evaluate the response in diagnosing non-respiratory viral infection.
76065913|NCT06017271|Diagnostic Test|CTPA (computed tomography pulmonary angiography)|The CTPA diagnosis suggest or did not suggest pulmonary embolism.
76065914|NCT06017232|Other|Hybrid telerehabilitation program|"The telerehabilitation program lasts 12 week (3 per week). The program includes aerobic, strength, coordination, balance, flexibility, and breathing exercises, in addition to educational components focused on disease management.~This hybrid program incorporates both supervised and unsupervised sessions. A progressive approach from synchronous (supervised) to asynchronous (unsupervised) sessions is adopted.~Each session is structured into 4 components: Warm-up; Muscle strengthening, coordination, and balance; Flexibility; and Breathing exercises.~Participants are asked to maintain a log of their aerobic activity, recording details such as the type of activity, duration, and intensity. The aim is to align with the recommended aerobic physical activity guidelines (150 min/week). Weekly assessments are conducted to provide personalized guidance based on individual progress.~Also, participants engage in weekly educational videos that cover a diverse range of PD-related topics."
76065915|NCT06017219|Dietary Supplement|spermidine|spermidine
75899076|NCT04953312|Biological|Blood samples|blood
76065916|NCT06017167|Drug|Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .|compare antiemetic effects between dexmedetomidine and ondansetron in the first group versus dexamethasone and ondansetron in the second group
76065917|NCT06017167|Drug|Ondansetron 4mg + dexamethasone 8mg + normal saline.|Group II: Ondansetron 4mg + dexamethasone 8mg + normal saline.
75453301|NCT01749124|Device|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
75453302|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
75453303|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
75453304|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
75749206|NCT06048614|Drug|Glycerin Suppository|"Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned."
75749207|NCT06048341|Procedure|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
75749208|NCT06048341|Drug|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
75749209|NCT06048341|Drug|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
75749210|NCT06047639|Device|Bone-anchored hearing implants|surgically placed hearing device
75749211|NCT06046092|Biological|H7HLAII|DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules
75749212|NCT06045884|Procedure|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
75749213|NCT06045884|Drug|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
75899077|NCT02299154|Behavioral|Psychological questionnaires|Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
76065918|NCT06017154|Other|Motor-Cognitive Training Program|The training will incorporate cognitive tasks which focus on reaction time, processing speed, working memory, cognitive flexibility, and inhibitory control using visual stimuli on a screen or through sensors which illuminate using LED lights. These cognitive tasks will be performed while also executing physical performance tasks that challenge static and dynamic postural stability, lateral movement, agility, and other movement patterns. The training session will last approximately 30 minutes and participants will complete up to 5 exercises
76065919|NCT06017141|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
76065920|NCT06017141|Other|Electronic Health Record Review|Ancillary studies
75749214|NCT06045884|Drug|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
75749215|NCT06045442|Behavioral|Intradialytic exercise training|The patients in the intervention group will receive 3 months of endurance training, 2x/week for 30 min. 5 min of this should be a warm-up, 20 min of exertion and 5 min of cool down. The warm-up and cool-down should be equivalent to a very light load (Borg scale 9), whereas the exertion phase should be exhausting for the patients (Borg scale 14-15).
75749216|NCT06045442|Behavioral|Control|Usual care
75749217|NCT06044805|Drug|Chloroquine|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
75749218|NCT06044805|Drug|Primaquine|Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
76065921|NCT06017141|Drug|Fentanyl Citrate|Given via injection
76065922|NCT06017141|Drug|Propofol|Given IV
76065923|NCT06017141|Other|Questionnaire Administration|Ancillary studies
75453305|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
75453306|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
75453307|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
75749219|NCT06044779|Procedure|Transversus Abdominis Plane Block using 0.25% Bupivacaine|TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
75453308|NCT01749163|Biological|Saline|
75453309|NCT01749163|Biological|GIP|
75749220|NCT06044779|Procedure|Erector Spinae Plane Block using 0.25% Bupivacaine|Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
76065924|NCT06017141|Drug|Sevoflurane|Given via inhalation
75453310|NCT01749163|Biological|GLP-1|
75453311|NCT01749176|Behavioral|SMS texting intervention|
75453312|NCT01749176|Behavioral|Control-Usual Care|
75453313|NCT01749189|Dietary Supplement|Blend|22 grams of protein/day
75453314|NCT01749189|Dietary Supplement|Whey|22 grams of protein/day
75453315|NCT01749189|Dietary Supplement|Placebo|22 grams of carbohydrate/day
75453316|NCT01749202|Dietary Supplement|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
75453317|NCT01749202|Dietary Supplement|EPA softgels|3 x 500 mg softgel capsules/day
75453318|NCT01749202|Other|Sunflower Oil Food|3 servings/day
76065925|NCT06017141|Procedure|Surgical Procedure|Undergo SOC surgery
76065926|NCT06017076|Other|Oral energy drinks|Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.
75453319|NCT01749202|Other|SDA soybean Oil Food|3 servings/day
75453320|NCT01749228|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
75453321|NCT01749228|Drug|Etodolac|500 mg tablet once a day
75453322|NCT01749241|Drug|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
75749221|NCT06043895|Device|EpiFaith CV|The conducting physician will localize the central vein using EpiFaith CV and assess if there is arterial puncture.
75749222|NCT06043895|Device|Conventional|The conducting physician will localize the central vein using Raulerson syringe and assess if there is arterial puncture.
75749223|NCT06043882|Procedure|flexible bronchoscopy|fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination
75749224|NCT06043609|Other|This is an observational cohort study|This is an observational cohort study
75749225|NCT06043362|Other|0 mg nicotine pouch|Oral nicotine pouches that contain 0 mg of nicotine
76065927|NCT06017076|Device|Warming matress|From the end of anesthesia, warming matriss at 40 ℃ was used to keep warm until the end of surgery.
76065928|NCT06017063|Other|Psychological intervention|The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
76065929|NCT06017050|Behavioral|BullyDown|BullyDown is an 8 week, text messaging-based prevention program aimed to prevent bullying behaviors among middle school-aged youth. Message content is based upon the social-emotional learning model.
76065930|NCT06017050|Behavioral|Attention-matched control|The attention-matched control will receive the messages for the same number of days as the intervention. Content will talk about 'healthy lifestyle' topics, such as fitness and healthy social media use.
76065931|NCT06017037|Drug|Citalopram 20mg|Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days
76065932|NCT06017037|Drug|Placebo|Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days
76065933|NCT06017024|Device|microprocessor-controlled knee (MPK) assessment|The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
76065934|NCT06016985|Dietary Supplement|caffeine gum|This study investigated the effects of chewing 3 mg/kg of caffeinated gum on basketball free throw accuracy and basketball -specific performance.
76065935|NCT06016933|Drug|spirulina gel|Patient were received spirulina gel in diseased sites. The process will be repeated at 7, 14, 21 days.
75453323|NCT01749241|Drug|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
76065936|NCT06016933|Procedure|SRP of all teeth|Patients received oral hygiene instructions and SRP of all teeth.
76065937|NCT06016894|Procedure|coronally advanced flap|coronally advanced flap operation
75453324|NCT01749267|Procedure|partial caries removal only at enamel dentin junction.|Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
76065938|NCT06016894|Other|Nanocrystalline hydroxyapatite loaded in PRF|Nanocrystalline hydroxyapatite loaded in PRF
75749226|NCT06043362|Other|3 mg nicotine pouch|Oral nicotine pouches that contain 3 mg of nicotine
75749227|NCT06043362|Other|6 mg nicotine pouch|Oral nicotine pouches that contain 6 mg of nicotine
76065939|NCT06016894|Other|Nanocrystalline tricalcium phosphate loaded in PRF|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF
76065940|NCT06016868|Procedure|Tumor tissue|Each newly diagnosed patient with LACC who meets the inclusion criteria will undergo cervical cancer biopsy either during the outpatient clinical examination or during examination during anesthetic. Part of the biopsy will be sent for histopathological analysis, while the remaining tissue will be embedded in OCT compound and immediately frozen at -80°C prior to transfer to biobank for subsequent analysis.
75453325|NCT01749306|Biological|ABH001|ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
76065941|NCT06016868|Procedure|Blood sample|Every patient will undergo a peripheral venous blood sample which will be processed to analyze the presence of the proteins codified by three RNA species (ANXA2-NDRG1-STAT1). This blood sample will be performed before starting the treatment with exclusive CTRT.
76065942|NCT06016855|Procedure|Tumor Debulking|Undergo surgical debulking
76065943|NCT06016855|Drug|Lutetium Lu 177 Dotatate|Given by IV
76065944|NCT06016855|Procedure|Computed Tomography|Undergo Computed Tomography
76065945|NCT06016855|Procedure|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
76065946|NCT06016855|Drug|Copper Cu 64 Dotatate|Given by IV
75453326|NCT01749306|Other|Control wound treatment|Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
75453327|NCT01749319|Drug|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
75453328|NCT01749319|Drug|Intervenous baclofen|
75453329|NCT01749332|Other|Perihepatic Phlebotomy|
75453330|NCT01749358|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
75749228|NCT06043362|Other|Smooth nicotine pouch|Non-flavored nicotine pouches that are characterized as smooth.
75749229|NCT06043362|Other|Wintergreen nicotine pouch|Menthol flavored nicotine pouches that are characterized as wintergreen.
76065947|NCT06016855|Procedure|Positron Emission Tomography|Undergo Positron Emission Tomography
76065948|NCT06016803|Device|Cicatryl (RL3010A - DP0378)|Tested product is applied twice a day. The maximum duration of application is 7 days.
76065949|NCT06016712|Device|SENSIMED Triggerfish Eye Lenses|Contact lenses used for measuring intraocular pressure.
75749230|NCT06043128|Other|Patients With Stroke With Different Trunk Impact Levels|"Before the study, written and verbal Informed Consent Form will be obtained from all participants who meet the inclusion criteria.Trunk Impairment Scale (TRS) will be used to measure trunk control, which is our independent variable. Scores close to 23 points on the TIS will constitute the group with high trunk control, and those with scores close to 0 will constitute the group with low trunk control. Spasticity of the participants, Modified Tardiue Scale (MTS), cervical proprioceptive awareness cervical joint error test, lower extremity proprioceptive awareness Proprioception test in Technobody Prokin 252 Isokinetic Balance Platform, balance skills Dynamic and static balance in Tecnobody Prokin 252 Isonkinetic Balance Platform will be evaluated by tests. The patients' quality of life will be evaluated with the stroke-specific quality of life scale. All data obtained will be noted on a prepared evaluation form."
75749231|NCT06042127|Procedure|POEM-F|POEM-F would be performed as described in the arms section
76065950|NCT06016699|Other|blood draws|Blood draws to collect PBMCs at baseline (week 0), during (chemo)radiation treatment (end of week 3 and/or before delivery of cycle 4 of cisplatin) and after conclusion of (chemo)radiation (week 9, week 12, week 20, week 34 and week 60, respectively 1 week, 5 weeks, 3 months, 6 months and 12 months after completion of (chemo)radiation) in order to compare immunological function upon treatment with either protons or photons
75749232|NCT06042127|Procedure|Conventional POEM|Anterior POEM performed as described in the arms section
75899078|NCT05686525|Procedure|Transurethral Microwave Thermotherapy|TUMT is performed by a urologist and/or a trained urological nurse. In TUMT a specially designed instrument that sends out microwave energy is inserted inside the prostate through the urethra. Cooling fluid circulates the instrument to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate a temperature sensor is inserted into the patient's rectum and at the penoscrotal angle. If the temperature reaches the safety limit the microwave generator's output will be shut off automatically. Microwave is then used to heat the prostate (preferably to 50-60 degrees Celsius) and destroy hyperplastic prostate tissue. As the prostate heals it will shrink and reduce the blockage of urine flow and the symptoms of BPH.
76065951|NCT06016660|Other|Physiotherapy|Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation
75453331|NCT01749358|Behavioral|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
75453332|NCT01749371|Drug|Vitamin E|1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
75453333|NCT01749384|Biological|Bevacizumab|Given IV
75453334|NCT01749384|Other|Laboratory Biomarker Analysis|Correlative studies
75899079|NCT05686525|Procedure|Prostate Artery Embolisation|In PAE an interventional radiologist will insert a small catheter into the vessels that supply blood to the prostate. An arteriogram is done to map the blood vessels feeding the prostate. Tiny embolization particles are injected through the catheter and into the blood vessels to reduce the blood supply to the prostate. This procedure is intended bilaterally at both sides of the prostate. Following the procedure, the prostate will begin to shrink reducing the symptoms of BPH.
75899080|NCT03520166|Other|Medium frequency electrotherapy (interferential currents)|Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.
75453335|NCT01749384|Other|Pharmacological Study|Correlative studies
75899081|NCT03520166|Other|No treatment|No treatment
75899082|NCT03240835|Drug|cisplatin and docetaxel|"NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles."
75899083|NCT03240835|Radiation|IMRT|intensity modulation radiation therapy
75899084|NCT03545880|Other|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
76065952|NCT06016647|Other|Musculoskeletal-specific WSIB programs of care|Clinicians within this network provide care under a standardized framework that limits confounding from different interventions and the researchers will not manipulate treatment decisions.
75899085|NCT03545880|Other|Placebo|Individuals will not perform any action after the application of trigger point dry needling
76065953|NCT06016257|Other|Use of VirtuaCare™ for home program|Use of VirtuaCare™ system for the Home Program.
75453336|NCT01749384|Drug|Tivantinib|Given PO
75453337|NCT01749397|Drug|Floxuridine|Given IP
75453338|NCT01749397|Other|Laboratory Biomarker Analysis|Correlative studies
75453339|NCT01749397|Other|Pharmacological Study|Correlative studies
75453340|NCT01749397|Drug|Veliparib|Given IV
75453341|NCT01749423|Biological|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
75453342|NCT01749436|Other|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
75453343|NCT01749449|Other|protein and meal frequency|comparison of different levels of protein intake and meal frequency on body composition in obese adults
75453344|NCT01749475|Drug|Midazolam|The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.
75453345|NCT01749475|Other|hypnotherapy|A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.
75749233|NCT06041776|Drug|Befotertinib + Icotinib placebo|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis)."
75749234|NCT06041776|Drug|Icotinib + Befotertinib placebo|"Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis."
75899086|NCT03517358|Other|Service of care|Subjects will be receiving care from case management or clinical pharmacy.
75899087|NCT04067310|Other|Spray skin protector|Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
75899088|NCT04067310|Other|moisturizer Dnativ Revita derm|Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
75899089|NCT03514238|Behavioral|High Intensity Interval Aerobic Exercise (HIIT)|"Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min)."
75899090|NCT03514238|Behavioral|Continuous Moderate Aerobic Exercise (MOD)|35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
75899091|NCT03514238|Behavioral|Control Sitting Condition (C)|Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
75899092|NCT03216109|Behavioral|Weekly telephone symptom assessment|Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
75899093|NCT03133052|Behavioral|internet-based adaptive cognitive control training program|The cognitive training will be an internet-based adaptive cognitive control training program, specific training paradigms include Flanker, 1-back, 2-back. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.
75899094|NCT03133052|Behavioral|placebo program|For the control group, a fixed, primary difficulty level program for all participants is set.
76065954|NCT06015620|Procedure|Mini gastric bypass surgery|Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.
76065955|NCT06015581|Behavioral|Workforce Development: Tailored Motivational Interviewing and Technical Assistance|TMI training includes an initial 12 hour virtual workshop, standard patient interaction with feedback, group coaching, and a final standard patient interaction and feedback. TMI relies on experiential activities developed by the network while minimizing didactic presentations. Stigma-reducing communication is emphasized by practicing autonomy supportive and empathic statements and improving cultural humility practices. Role plays map on to the Mystery Shopper domains focusing on risk reduction counseling and PrEP referral. TA addresses factors in the EPIS framework.
76065956|NCT06015581|Behavioral|Quality Management, Mystery Shopper Feedback|Mystery shoppers visit each agency two times per quarter to systematically examine testing clinics' environmental characteristics and their experiences with clinic staff (e.g., quality of testing session, safer sex discussions, perceived provider competency, PrEP discussions and referral). The investigator team meets with each agency once per quarter to review the data and provide technical assistance.
75604289|NCT00446043|Drug|Adapalene/Benzoyl Peroxide|Adapalene 0.1 percent (%) [weight by weight (W/W)] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.
75604290|NCT00400725|Drug|Clobex® Shampoo|Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.
75604291|NCT00400725|Drug|Clobex® Vehicle Shampoo|Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
75604292|NCT00400725|Drug|Clobex® Shampoo|Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
75604293|NCT00316342|Device|Back supports|
75604294|NCT04264195|Other|Constraint-induced movement therapy: PEPS-MIT|"All participants of control and experimental groups received standard stroke rehabilitation. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~• Specific for the experimental group was that patients performed all manipulation tasks with forced use of the paretic hand/arm by wearing a soft-padded mitten at the non-paretic hand, preventing manipulation with that hand. Patients were encouraged to wear the mitten also for 3 hours/day at home, while performing ADL and learned exercises. Behavioural strategies included a treatment contract and daily use of the home activity checklist which was checked by patient's caregiver and signed by both patient and caregiver. Each treatment day the activity checklist was submitted to the therapist who gives feedback."
75749235|NCT06040060|Drug|Ketamine|The intervention was prepared by the research team (anesthesia resident) in the form of ketamine which had been diluted to a dosage of 10 mg/cc, taken according to the required dose based on actual body weight then diluted with 0.9% NaCl to 10 cc. Then the two solutions were given to researchers without knowing the contents of the drugs that had been prepared by the resident who assisted in this research.
75749236|NCT06040060|Other|Placebo|While the 0.9% NaCl solution was used as placebo was prepared in a 10 cc syringe
75749237|NCT06040034|Drug|Lidocaine IV|Lidocaine given as bolus or continuous infusion.
75899095|NCT05671783|Other|Hemodynamic observation of the patients.|"For the purposes of this study, we defined intraoperative hypotension as a decrease in mean blood pressure of 30% from baseline for a minimum of 5 minutes, including induction and maintenance of anesthesia. The measuring blood pressure method (noninvasive or invasive) depended on the surgical intervention's invasiveness and the patient's cardiac performance.~As soon as the patients entered the PACU, the responsible nurses started the standard monitoring. Anesthesiologists constantly oversee all actions based on the patient's condition. Clinical observation for respiratory and gastrointestinal problems and all disorders were monitored. When in room air SO2 was <94, we started oxygen treatment with a 4 liter/minute nasal cannula, and in cases of nausea antiemetic was administered. The Modified Aldrete Score was used to discharge the patent."
75604295|NCT04264195|Other|Bimanual manipulation exercises (PEPS-Bimanual)|"All participants of control and experimental groups received standard stroke. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~Specific for the control group was that patients performed all manipulation tasks bimanually, as they used to do in occupational therapy activities. Patients were also asked to document their 'at home' activities in an activity checklist that was regularly checked by the therapists."
75899096|NCT03133130|Drug|BMT101|BMT101 is administered to 6 subjects in each of 4 groups.
75899097|NCT03133130|Drug|Placebo|Placebo is administered to 2 subjects in each of 4 groups.
75899098|NCT04172454|Biological|AK104|AK104, 6mg/kg, Q2W
75899099|NCT03514160|Behavioral|Group exercise|Group exercise based on the American College of Sports Medicine guidelines.
75899100|NCT03545802|Behavioral|Home-HIT|Participants completed 6 weeks of home-based high-intensity interval training 3 times per week
75899101|NCT03132974|Drug|Sogyeonghwalhyeol-tang granule|Sogyeonghwalhyeol-tang herbal extract granule
75899102|NCT03132974|Other|Sogyeonghwalhyeol-tang granule with manipulation procedure|Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
75453346|NCT01749488|Other|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
75749238|NCT06038981|Drug|Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced|"The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)"
75749239|NCT06038435|Behavioral|Cognitive Orientation Approach|Cognitive training will be given for the selected occupation
75749240|NCT06038435|Behavioral|Ayres Sensory Integration Therapy|Sensory integration therapy will be applied.
75899103|NCT03132974|Other|Placebo with manipulation procedure|Placebo granule with manipulation procedure
75899104|NCT02295332|Drug|Placebo|Matching oral placebo capsules to RG7625, according to treatment schedule
75899105|NCT02295332|Drug|RG7625|oral administration, capsules, single ascending dose according to treatment schedule
75899106|NCT04118868|Combination Product|Pembrolizumab administered using the Sofusa® DoseConnect™|pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
75899107|NCT03514082|Device|Rigid Thermoplastic Spinal Brace|Custom made rigid thermoplastic brace with 23 hours daily wearing time.
75453347|NCT01749514|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
75453348|NCT01749527|Behavioral|minimal activity|Pad test with minimal activity
75453349|NCT01749540|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
75453350|NCT01749553|Other|Sleeper Stretch|Posterior shoulder stretch technique
75453351|NCT01749566|Drug|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
75453352|NCT01749579|Drug|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
75453353|NCT01749579|Drug|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
75453354|NCT01749579|Drug|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
75453355|NCT01749592|Device|cochlear implant|Surgical implantation of a cochlear implant device
75604296|NCT04263883|Device|Study or Experimental Group|3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
75604297|NCT00932113|Drug|Methotrexate|"2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study."
75604298|NCT00932113|Drug|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
75604299|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
75604300|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
75604301|NCT00931801|Drug|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
75604302|NCT04263805|Other|Vignette with emphasis on research climate|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
75604303|NCT00931723|Drug|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
75604304|NCT00931723|Drug|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
75604305|NCT00931723|Drug|Placebo|Oral treatment twice daily.
75604306|NCT05026021|Biological|Blood sample|For each patient blood (17 ml of whole blood) will be collected during a peripheral venous blood sample carried out in the the standard care at inclusion visit, M3 visit (3 months after inclusion) and M6 visit ( (6 months after inclusion)
75604307|NCT05025397|Drug|Danavorexton|Danavorexton intravenous infusion.
75899108|NCT03514004|Behavioral|ICT-based intervention|"The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members."
75899109|NCT03545178|Behavioral|glucose control (Substudy A)|Comparison of glucose values during days 0 - 3 with days 4 - 28 and 0 - 7 with days 8 - 28 before a medical consultation at the diabetes clinic in patients suffering from diabetes and wearing a continuous glucose monitoring and/or flash glucose monitoring device
75899110|NCT03545178|Diagnostic Test|hypoglycemia prediction (Substudy B)|Use of CGM/FGM data to develop and evaluate a neural network based hypoglycemia prediction model
75899111|NCT03520088|Procedure|Inferior mesenteric Vein dissection|Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision
75453356|NCT01749618|Behavioral|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
75453357|NCT01749722|Device|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
75453358|NCT01749748|Procedure|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
75604308|NCT05025397|Drug|Danavorexton Placebo|Danavorexton placebo-matching intravenous infusion.
75604309|NCT05025397|Drug|Propofol|Propofol intravenous bolus.
75604310|NCT05025397|Drug|Sevoflurane|Sevoflurane inhalation.
75604311|NCT05025397|Drug|Propofol|Propofol intravenous infusion.
75604312|NCT00608803|Drug|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
75604313|NCT05234359|Diagnostic Test|Serology Testing|A simple home sampling kit containing volumetric absorption microsampling devices (Mitra(R) cartidge device, Neoteryx LLC) will be used by the participants to collect a finger stick blood sample (10 ul; a few drops). Kits will be delivered to participants' homes and returned by mail. An instructional video will be provided.
76065957|NCT06014918|Device|A new smart device application (Smart APS)|The application sends alarms to patients to enter their pain intensity and opioid-related side effects at the times set by the researcher. Additional entries for severe pain or opioid side effects are also available at any other time. Researchers can monitor the results in real-time via an integrated web program. If a red flag sign is observed during regular office hours, an anesthesiologist participating in the research will visit the patient for assessment and intervention. In addition, patients can watch pre-made perioperative pain-related educational videos through the smart APS.
76065958|NCT06014372|Drug|Envafolimab|Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
76065959|NCT06014372|Drug|CAPEOX|The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
75899112|NCT03520088|Procedure|Inferior mesenteric Artery dissection|Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
75899113|NCT03546504|Behavioral|Procedure alteration and occupational therapy|Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
76065960|NCT06013254|Dietary Supplement|sour liquid|applying lemon juice
76065961|NCT06012253|Other|Home Based Walking Program|"The intervention group will be applied to Home Based Walking Program. It was aimed that the patients should do at least 150 minutes of moderate-intensity physical exercise per week for up to 8 weeks. The content of the program includes a walking information booklet (information notes, activity chart and obstacle avoidance form), exercise diary, face-to-face-telephone counseling, sending text messages, prepared in line with international guides. It was planned to give weekly counseling to the patients included in the intervention group for an 8-week period."
76065962|NCT06012227|Dietary Supplement|kent'erbas cheese study|"Nutritional intervention with kent'erbas pecorino from extensive farming with crossover and industrial pecorino from intensive farming"
76065963|NCT06011330|Drug|Fruquintinib combined with anti-PD-1 antibodies|Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).
75604314|NCT05234359|Diagnostic Test|Stool sample|Stool samples collected for genetic, microbial and viral analysis.
75899114|NCT03513926|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
75899115|NCT04900350|Drug|AK117|Subjects receive AK117 intravenously.
76065964|NCT06011213|Behavioral|Information notification based on the health warning system for heat waves and cold spells|Whenever a health risk warning for a heat waves or cold spells is issued, only the elderly in the intervention group will be alerted to the early warning information through the Wechat Mini Programme.
76065965|NCT06011213|Device|The electrocardiography(ECG) and blood pressure monitoring|The electrocardiography (ECG) and blood pressure indicators will be monitored every day during the study period in the intervention group and monitoring group, respectively.
76065966|NCT06011018|Other|Mirror Therapy|"Sitting, mirror place at the midline between the legs. Unaffected leg is placed in front of the mirror and perform ankle dorsiflexion exercises.~Duration: 5 seconds, Rest: 5 seconds"
76065967|NCT06011018|Other|Mirror Therapy + Electrical Stimulation|Same as the mirror therapy protocol. Affected leg: electrical stimulation on tibialis anterior muscle. Frequency: 35 Hz, Pulse width: 250µs, Duration: 5 seconds, Rest: 5 seconds.
76065968|NCT06011018|Other|Mirror Therapy + Binaural Beat|Same as the mirror therapy protocol. Listen to music (mozart's clarinex concerto in A major K622), with Alpha (8Hz) binaural beat stimulation
76065969|NCT06010589|Drug|DWJ1558|DWJ1558
76065970|NCT06010589|Drug|DWC202310 and DWC202311|Co-administration of DWC202310 and DWC202311
76065971|NCT06007391|Drug|Nicotinamide|nicotinamide 3g per day
76065972|NCT06006403|Biological|CD123 targeted CAR-NK cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
76065973|NCT06002945|Other|Blood sample|Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
76065974|NCT05997563|Drug|Micronized progesterone|Vaginal micronized progesterone effervescent once daily until delivery
76065975|NCT05995548|Other|Interview|The interview will take place face-to-face. It will take place in a quiet room, with the door and windows closed. Only the participant and the investigator will be present. It will be recorded using a dedicated to this research. At the end of the interview, so as not to influence the participant's discourse, the participant will be asked to fill in the self-questionnaire 'EAI' (Exercise Addiction Inventory), which will confirm or refute the diagnosis, thus exploring a possible discrepancy between the participant's feelings and the diagnosis.
76065976|NCT05990452|Drug|9MW2921|All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.
75453359|NCT01749761|Other|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
75453360|NCT01749761|Other|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
75453361|NCT01749774|Behavioral|Physical activity counseling|
75453362|NCT01749787|Drug|PRTX-100 at 1.5 mcg/kg|
75453363|NCT01749787|Drug|PRTX-100 at 3.0 mcg/kg|
75453364|NCT01749787|Drug|PRTX-100 at 6.0 mcg/kg|
75899116|NCT04900350|Drug|Azacitidine|Subjects receive Azacitidine subcutaneously.
76065977|NCT05980572|Drug|Glenohumeral joint and subacromial space triamcinolone injections|"All patients will receive both glenohumeral joint and subacromial space injections. The injections will consist of a solution containing 1 ml of 40 mg/ml triamcinolone acetonide and 1 ml of 1% lidocaine in each site. The glenohumeral joint injection will be performed blindly using an anterior approach. The needle will be inserted medially to the head of the humerus, located approximately 1 cm lateral to the coracoid process, and directed posteriorly at a slight superior and lateral angle.~Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds."
75899117|NCT03982550|Behavioral|Periodized Resistance Training|Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
76065978|NCT05980572|Device|App-assisted exercise|Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds. Then the APP group will suggest performing the exercise from APP education The APP intervention group will be guided through the exercises using the mobile app, while the conventional group will be provided with a printed pamphlet illustrating the exercises.. Each set exercise will have 10 repetitions and investigators recommend 4 sessions per day.
76065979|NCT05980572|Drug|Nonsteroidal anti-inflammatory drugs (aceclofenac)|All patients will be prescribed two weeks of nonsteroidal anti-inflammatory drugs (aceclofenac) .
75453365|NCT01749787|Drug|PRTX-100 at 12.0 mcg/kg|
76065980|NCT05980182|Behavioral|mHealth Application|Self-directed application (app) that is downloaded to the participant's personal device. The app contains five informational videos, that provide an orientation to the content on the app, and discuss what colorectal cancer is, and the type of CRC screening tests that are available as well as a video with a personal history. There is a a National Cancer Institute (NCI) risk calculation tool, and a family history infographic. Once the videos have been viewed participants have the option to indicate if they wish to receive a call from the healthcare clinic to discuss scheduling an appointment for screening.
75453366|NCT01749787|Drug|PRTX-100 at 240 mcg|
75604315|NCT00931411|Other|Formulation 609580 20|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
75899118|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
75899119|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
75453367|NCT01749787|Drug|Placebo|Placebo administered via infusion once per week for 5 weeks
75453368|NCT01749787|Drug|PRTX-100 at 420 mcg|
75453369|NCT01749852|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks
75453370|NCT01749852|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
75453371|NCT01749865|Biological|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
75453372|NCT01749878|Drug|REGN1500|
75453373|NCT01749878|Drug|placebo|
75453374|NCT01749891|Drug|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
75453375|NCT01749917|Other|Exercise program|Exercise program An brief exercise session including proprioceptive and dexterity activities
75453376|NCT01749917|Other|Control intervention|Active upper limb range of movement exercises for 15 minutes.
75453377|NCT01750008|Procedure|Global Fibroid Ablation|
75604316|NCT00931411|Other|Formulation 609209 (Lipikar Baume)|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
75604317|NCT04250935|Diagnostic Test|Patients with cognitive dysfunction|Mini Mental Test Those with a score below 21 points
75604318|NCT00931255|Drug|Tacrolimus|3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
75604319|NCT00931255|Drug|Sirolimus|5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
75899120|NCT02292290|Drug|Sulfonylurea or Pioglitazone|Addition to Metformin
75453378|NCT01750008|Procedure|Myomectomy|
75453379|NCT01750021|Dietary Supplement|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
75899121|NCT02292290|Drug|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
75899122|NCT02295410|Behavioral|CPT|
76065981|NCT05978570|Other|A personally tailored exercise program|A personally tailored exercise program will be offered to the participants after Physical Therapy assessment, before the surgery.
76065982|NCT05975515|Procedure|Connective tissue graft /Bone graft/ Customized HA|Soft tissue management and augmentation
75899123|NCT03943849|Other|Particulate bone graft|Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
75899124|NCT03943849|Other|Autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket.
76065983|NCT05967585|Device|Behavioral: Quitting Program (TIQ)|"Implementation processes developed in Phase 1 to develop assessment of vaping behaviors and referral to an evidence-based program for vaping cessation (TIQ) will be tested in Phase 2.~TIQ program is a mHealth, text messaging based intervention. Users who enroll in this program will receive 1 to 2 messages per day with 3 messages sent on their quit date. Messages are tailored to users' age, enrollment date or quit date, and the vape product they use.~Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for up to 6 weeks preceding the date and up to 8 weeks after that include encouragement, support, skill- and efficacy- building exercises, coping strategies, etc. Keywords such as COPE, STRESS, SLIP, and MORE can be used to request on-demand support."
76065984|NCT05964673|Device|bioptron light therapy|patients will receive patient education program and bioptron light therapy for four weeks
75453380|NCT01750021|Dietary Supplement|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
76065985|NCT05964153|Diagnostic Test|Liquid Biopsy|Analysis of the circulating free DNA in blood patients affected by gliomas
75453381|NCT01750034|Procedure|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
75453382|NCT01750034|Procedure|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
75453383|NCT01750060|Drug|Fentanyl|
75453384|NCT01750060|Drug|Naltrexone|
75453385|NCT01750099|Procedure|Combined Spinal-epidural|See arm description
75453386|NCT01750099|Procedure|Continuous Lumbar epidural|See arm description
75604320|NCT05204485|Procedure|Fibular intramedullary nail|The standard manufacturers approved technique will be performed including the use of 2 distal interlocking screws and the use of a minimum of 1 fibula pro tibia fixation screw depending on the patients' anatomical characteristics.
75604321|NCT05204485|Procedure|Open reduction and internal fixation|An open approach (direct lateral or posterolateral incision) will be carried out. The reduction will be performed using standard techniques of clamping and traction. Fixation will be performed after reduction of the fracture with a plate and screw construct. The surgeon will then proceed to perform surgical fixation of other associated fractures or ligament injuries as indicated. This will most often include open reduction and internal fixation of the medial malleolus with screws through a separate medial incision.
75899125|NCT03943849|Other|Resorbable collagen membrane|After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured.
75899126|NCT03943849|Other|Suture|Resorbable or non-resorbable suture material
75899127|NCT03545724|Device|Neofitoroid®|NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
75899128|NCT02299232|Drug|Dexmedetomidine|Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
75899129|NCT03517124|Other|Ceramic tooth restoration|Dental restorations
75899130|NCT03517046|Drug|CartiLife|Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
75899131|NCT02963493|Drug|Melphalan flufenamide (Melflufen)|
76065986|NCT05962996|Device|Pupillometry|Measurement of pain levels by pupillometry during the insertion of a deep venous catheter
76065987|NCT05961046|Device|Vivity IOL|Vivity IOL
76065988|NCT05954988|Drug|LTI-03|Caveolin-1-Scaffolding-Protein-Derived Peptide
76065989|NCT05954988|Drug|Placebo|Matching placebo
76065990|NCT05947136|Behavioral|Interpretation of the results from the detection visit|"- An interpretation of the results of the detection tests concerning~the 7 complications of interest assessed at T1, T2, T3 and T4 ;~the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;"
75749241|NCT06022185|Diagnostic Test|Web Based Training on E-health Literacy, Digital Literacy and Healthy Lifestyle Behaviors.|"In the trainings planned for elderly individuals, digital literacy and e-health literacy levels will be improved, knowledge and awareness levels of elderly individuals will be increased and they will be provided with information in this direction. healthy lifestyle behaviors.~Personal information form, E-Health Literacy Scale, Acquisition and Confirmation of Health Information in Digital Environment Scale, Healthy Lifestyle Behaviors Scale-II will be used in the research."
75749242|NCT06022172|Diagnostic Test|MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.|"Motivational interview based on Calgary family intervention model in parents of children with cerebral palsy.~Introductory information form, caregiving burden, parent self-efficacy and stress coping styles scale will be used."
75749243|NCT06021795|Device|Sound Treatment|Customized sound audio track delivered via standard commercially available bone conduction headset
75899132|NCT02963493|Drug|Dexamethasone|IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
75899133|NCT02299310|Drug|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
75453387|NCT01749657|Device|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
76065991|NCT05947136|Behavioral|Explaining detection results and referrals to the patient|"Explanation of results and directions to the patient using plain language;The aims of this call are as follows:~Clearly explain the results of the detection visit and the action to be taken for each referral;~Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;~Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications."
75453388|NCT06176599|Drug|Shenxiao Yuning decoction|Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
75453389|NCT06176599|Drug|Symptomatic treatment|(i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure &gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
75604322|NCT04263103|Other|SJ-RS-WL2015 visual training program software|It is a software with perceptual learning methods for binocular functions
75604323|NCT00609193|Drug|lithium|standard clinical care
75604324|NCT00609193|Drug|quetiapine|standard clinical care
75749244|NCT06015737|Combination Product|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
75749245|NCT06015737|Other|Placebo|Matching placebo solution for injection in aPFS.
75899134|NCT02299310|Drug|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
75899135|NCT03516890|Procedure|Partial hepatectomy|Partial hepatectomy was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
75899136|NCT05657899|Procedure|Cerclage fixation|The intervention is by surgical open reduction and internal fixation of the fracture using two 1.0mm cerclage.
75899137|NCT05657899|Procedure|Tension band wiring|The intervention is by surgical open reduction and internal fixation of the fracture using a 1.0mm cerclage and two 1.6 mm k-wires as described in AO-guidelines.
75899138|NCT03644199|Other|Oral Glucose Tolerance Test (OGTT) assessment arm|Hormonal and motility responses to a standard OGTT evaluation arm
75899139|NCT03644199|Other|Mixed meal test evaluation test arm|Evaluate the hormonal and motility responses to a standard mixed meal test through the day
75604325|NCT00930553|Biological|alemtuzumab|Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
75604326|NCT00609427|Behavioral|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
75604327|NCT00609427|Behavioral|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
75604328|NCT00609505|Other|Telemedicine|Telemedicine genetic counseling
75604329|NCT00609505|Other|Face-to-Face|Face-to-face genetic counseling
75749246|NCT06015087|Other|fasting diet|A total of 50 patients with breast cancer will be randomly devided in intervention and control group. Intervention group will follow a 60 hours fasting diet (36h prior and 24h after chemotherapy infusion), low in calories, mainly plant based, and the Mediterranean Diet in the meantime between chemotherapy cycles. Control group will receive only standard of care. Nutritional counseling and dietary records will be performed by registered dietitian. Adherence to the Mediterranean Diet will be estimated with MedDietScore. Grade of toxicity will be estimated by using the National Cancer Institute Common Terminology Criteria for Adverse Events. All participants will be encourange to continue usual physical activity.
75899140|NCT02292524|Other|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
75899141|NCT04051489|Other|Mobile health App - Test|"Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants with knee osteoarthritis (KOA).~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
76065992|NCT05947136|Behavioral|Early medical care through the network|Early, proactive medical care through a network of dedicated healthcare professionals.
75453390|NCT06176586|Other|Mat Pilates Exercises|The intervention will consist of mat Pilates exercises performed twice a week over a duration of 12 weeks, as an adjunct to the routine medical treatment for the patients, under the guidance of a qualified physiotherapist. Each exercise session will last for approximately 60 minutes. The treatment protocol will encompass targeted mobility exercises for the thoracic and lumbar regions, along with strengthening exercises focusing on core activation. The exercise program will be progressed in every four weeks.
75453391|NCT06176573|Procedure|Chlorhexidine|Pre-operative and post-operative vaginal cleansing.
75453392|NCT06176560|Drug|Mesalazine|Oral Formulation
75604330|NCT04262011|Procedure|immediate treatment|Patients allocated to the immediate treatment group will receive full mouth treatment, and will use 0.12% chlorhexidine mouthwash, every 12 hours for a week, and will receive oral hygiene instructions throughout the follow-up period. Patients will be evaluated at the beginning, at 3 and 6 months.
75899142|NCT03513692|Device|Fill-Up composite resin|2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
75899143|NCT03513536|Other|Citrus-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
75453393|NCT06176534|Drug|Experimental: chemotheyapy|nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14
75453394|NCT06176534|Drug|Active Comparator: endocrine therapy|palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
75604331|NCT04262011|Procedure|postponed treatment|Patients allocated to the late treatment group will be assessed at baseline, 3 and 6 months. After the end of the follow-up period, they will receive non-surgical periodontal treatment performed in four sessions.
75604332|NCT04261933|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
76065993|NCT05947136|Behavioral|Transmission of results from each detection visit to the referring onco-haematologists - Control Group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.
75749247|NCT06010823|Device|PlaXtreme|"A robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the patients hand movement.~The device consists of a controller and specifically designed games projected on a screen requiring 3D active reaching movements. During the treatment sessions, the device will be operated by a trained occupational therapist."
75749248|NCT06004700|Other|Mobile Application|The current app contains a disease activity questionnaire, a mood scale, a sleep scale, a pain scale, and a functional status scale. The app triggers a brief set of questions each day and allows patients to answer them within 24 hours.
75899144|NCT03513536|Other|Mint-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
75604333|NCT00609817|Drug|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
75604334|NCT00609817|Drug|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
76065994|NCT05946161|Behavioral|e-Health intervention to promote mental and sexual health of prostate cancer survivors|An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
75899145|NCT03513536|Other|Spice-Scented Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
75899146|NCT03513536|Other|Control|This control is a blend of plant derived oils which have been expressed from crude plant matter.
75899147|NCT03641391|Procedure|Intraoperative direct cortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate cortex, was performed using a 5-mm wide bipolar electrode with a pulse frequency of 60 Hz and an amplitude of 1.5 to 6 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
75899148|NCT03641391|Procedure|Intraoperative direct subcortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate subcortical pathways, was performed using a biphasic square-wave pulse delivered at 60 Hz with a current amplitude ranging from 1.5 to 10 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
76065995|NCT05936645|Procedure|A temporary sub-placental Uterine Tourniquet in management of Placenta Accreta Spectrum disorder by a retrograde cesarean hysterectomy (Bladder Last)|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
76065996|NCT05936645|Procedure|Retrograde cesarean hysterectomy (Bladder Last) for management of Placenta Accreta Spectrum disorder|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
76065997|NCT05936606|Drug|Clopidogrel monotherapy|Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.
75604335|NCT00929695|Drug|prednisone|immunosuppressive drug
75604336|NCT00929695|Drug|methylprednisolone|immunosuppressive drug
75604337|NCT00929695|Other|questionnaire administration|Ancillary studies
75453395|NCT06176521|Procedure|Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh|Comparison of pre and postoperative POP-Q values of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy SurgeriesWithout Using Mesh Comparison of pre and postoperative PISQ-12 scores of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Without Using Mesh
75604338|NCT00609895|Drug|INSULIN GLARGINE|
75453396|NCT06176508|Drug|HS-10374|Administered orally QD for 16 weeks
75604339|NCT04261465|Drug|Olaparib|PARP INHIBITOR
75604340|NCT04261465|Drug|Paclitaxel|Chemotherapy
75604341|NCT04261465|Drug|Carboplatin|Chemotherapy
75604342|NCT05115643|Behavioral|Immobilization|Immobilization of left arm using a brace and sling.
75604343|NCT05095519|Drug|18F-DCFPyL|18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection
75604344|NCT04260919|Procedure|Chest physiotherapy|
75453397|NCT06176508|Drug|HS-10374-matched placebo tablets|Administered orally QD for 16 weeks
75453398|NCT06176508|Drug|Tofacitinib 5Mg Tab,Oral|Administered orally BID for 16 weeks
76065998|NCT05936606|Drug|Tailored anti-platelet therapy|In the tailored therapy arm, non-HPR (PRU<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
76065999|NCT05936086|Drug|Cytoxan|Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);
75604345|NCT04260997|Dietary Supplement|Lactobacillus gasseri BNR17™ capsule|Once per day (QD), 12 weeks
75749249|NCT05998005|Behavioral|First Face Training Program|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
75604346|NCT04260997|Other|Placebo capsule|Once per day (QD), 12 weeks
75899149|NCT03519776|Diagnostic Test|Progesterone variation|The potential gain for medical caretakers and patients would be a certainty if the progesterone level is affected by variations during daytime
75453399|NCT06176482|Device|Magnetic markers implantation|Surgical implantation of magnetic markers in the upper limb stump to allow the management of an external hand prosthesis
75749250|NCT05990400|Drug|Finasteride|finasteride topical 0,1%
75899150|NCT03641235|Biological|Sputum collection|Analysis of Sputum collection
75899151|NCT02988661|Behavioral|Chronic Disease Self-Management Program (CDSMP)|The CDSMP consist of 6 weekly classes of two and a half hours each one, for six weeks. A group of 10-16 people with different chronic conditions attend the classes together. Classes are facilitated by two certified leaders, one or both of whom are non-health professionals with chronic diseases. The workshop covers topics such as: 1) how to deal with frustration, fatigue, pain and isolation, 2) exercise for maintaining and improving strength, flexibility, and endurance, 3) communicating effectively with family, friends, and health professionals, 4) nutrition, 5) decision making, 6) appropriate use of medications and how to evaluate new treatments. Participants receive a companion book, Living a Healthy Life with Chronic Conditions, and an audio relaxation CD, Relaxation for Mind and Body.
75604347|NCT04260763|Behavioral|Social Cognition Group|Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
75453401|NCT06176456|Diagnostic Test|rTMS|Active regiment
75749251|NCT05990400|Drug|Minoxidil|minoxidil topical 5%
75749252|NCT05987605|Drug|1A46 Drug Substance|Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
75749253|NCT05985200|Drug|BI 3032950|BI 3032950
75453402|NCT06176456|Other|Placebo|Tactile artefacts without magnetic pulses
75453403|NCT06176417|Procedure|horizontal ridge augmentation by decompression technique.|Instead of a cover screw, a 2-mm healing abutment was used after implant insertion
75453404|NCT06176417|Procedure|horizontal ridge augmentation by ridge splitting technique using piezosurgery.|horizontal ridge augmentation was done using piezosurgery tips and bone expanders
75453405|NCT06176391|Device|Spinal Cord Stimulation|Single lead placement in the posterior thoracic epidural space (T1-T4) connected to a subcutaneous battery
75749254|NCT05985200|Drug|Placebo matching BI 3032950|Placebo matching BI 3032950
75749255|NCT05983302|Drug|Platelet-Rich Plasma-Fibrin Glue|The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
75749256|NCT05983302|Drug|Repairing Gel|The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
75749257|NCT05983302|Drug|Repairing Gel and Platelet-Rich Plasma-Fibrin Glue|The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
75749258|NCT05983302|Other|Classical wound irrigation (control)|For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
75749259|NCT05976711|Device|Magnetic resonance imaging (with PROUD software)|Philips Ingenia 3.0T MR system with in-house developed PROUD software
75749260|NCT05973669|Device|MED-EL Remote Care|Remote cochlear implant support
75749261|NCT05970731|Drug|Beclomethasone|84 mcg of Beclomethasone administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
76066000|NCT05936086|Drug|Etoposide|etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.
76066001|NCT05936086|Drug|Dexamethasone|Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
76066002|NCT05936086|Drug|Cyclosporine (CSA)|Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
76066003|NCT05932511|Drug|30% ascorbic acid in DMSO|see above
76066004|NCT05927792|Device|repeated transcranial magnetic stimulation (continuous theta-burst stimulation)|Participants in intervention group will receive cTBS over the left M1for 5 consecutive days. The detailed parameters as follows: 80% of resting motor threshold (RMT), 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with no intertrain interval (i.e. triplet standard cTBS, 1800 pulses, 120s). Stimulation sessions were delivered hourly, 10 sessions were applied per day (18,000 pulses/day).
76066005|NCT05927792|Device|sham repeated transcranial magnetic stimulation|The sham group will be stimulated with a pseudo-stimulation coil, which emitted sounds with the same intensity, rhythm and vibratory sensation as the real stimulation, and the intervention target, duration and frequency are the same as the real intervention group.
75604348|NCT04260763|Device|Novel Mobile App|"The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking."
75604349|NCT05080465|Biological|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
75604350|NCT00610285|Other|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
75604351|NCT04260841|Device|bed in 45 degrees for passive leg raising test|fluid responsiveness is tested by the passive leg raising test
75604352|NCT00610519|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
75604353|NCT00610519|Dietary Supplement|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
75604354|NCT05063617|Device|SCI Step Together|The 8-week program features weekly blocks of content. Each week builds from the previous week and targets specific components related to the three basic psychological needs (autonomy, relatedness, competence). The overall cadence of each weekly block is maintained throughout. For example, each week contains: 1) education modules 2) a worksheet or guided practice to apply the strategies in their own goals for that week along with embedded questions to discuss with their community coach 3) behavioural support from the community coach and 4) peer support from the discussion group.
75604355|NCT05062213|Other|Moisturizer Body Lotion|Moisturizer Body Lotion
76066006|NCT05925101|Behavioral|Extinction-only condition|In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).
76066007|NCT05925101|Behavioral|Rate-drop condition|In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.
76066008|NCT05925101|Behavioral|Rate-hold condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline.
75453406|NCT06176352|Drug|Faricimab|Faricimab 6 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
75453407|NCT06176352|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
75453408|NCT06176352|Procedure|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Participants will undergo the sham procedure at study visits where no study drug is to be administered, in order to maintain masking.
75453409|NCT06176339|Drug|Pentoxifylline Oral Tablet|Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.
75453410|NCT06176339|Drug|Placebo|Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
75749262|NCT05970731|Other|Placebo|Placebo (0.9% sodium chloride) administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
75899152|NCT02292602|Behavioral|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
76066009|NCT05925101|Behavioral|Magnitude-drop condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR according to a VI 1.5-s schedule, but we will deliver the reinforcer for just 6 s each time. This change from delivering 60 s of access to the functional reinforcer following destructive behavior in baseline to delivering 6 s of reinforcer access for the FCR during FCT will produce a large reduction in the magnitude of reinforcement relative to baseline.
76066010|NCT05925101|Behavioral|Magnitude-hold condition|This condition will be identical to the magnitude-drop condition except that we will deliver 60 s of access to the functional reinforcer contingent on the FCR, so that the magnitude of reinforcement will equal that delivered in baseline for destructive behavior. To ensure that the magnitude of reinforcement does not drop in the magnitude-hold condition, we will yoke the rate and timing of reinforcer deliveries for the FCR during FCT to the rate and timing of reinforcer deliveries for destructive behavior in baseline.
75453411|NCT06176326|Other|Ethics Education Program in Nursing|In the 7-session training program, each session, lasting 2 hours, presented to students the topic headings determined through the needs analysis of the program development study. This education program consists of sessions on the Introduction to Ethics-Bioethics, Principles of Beneficence and Non-maleficence, Autonomy and Responsibility, Informed Consent and Those Lacking Capacity for Consent, Respect for Human Vulnerability and Individual Integrity, Respect for Private Life and Ensuring Confidentiality, Discrimination, Stigmatization, and Cultural Diversity.
75453412|NCT06176313|Other|Mandala Group|"The Mandala activity lasts approximately 60 minutes.~• A calm environment is provided during the Mandala activity, and participants are ensured not to be disturbed by external stimuli or individuals unless they request assistance.~Each student's last menstrual date is recorded in an Excel table.~Two days before the intervention day, students will be contacted and invited to participate in the study.~Monitoring each student's menstrual cycle, the Mandala activity intervention is scheduled during the late luteal phase of each student's menstrual cycle. The intervention is planned within the 5 days before the expected start of menstrual bleeding on days and hours convenient for the student's class schedule.~After each session, on the 4th day of the expected menstrual bleeding, students are subjected to PMSÖ.~On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
75604356|NCT04875325|Other|Standardized surveillance|Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.
76066011|NCT05925101|Behavioral|Quality-drop condition|In this condition, we will place destructive behavior on extinction and deliver the reinforcer from the paired-choice assessment that the participant chooses approximately 1/12th as often as the highest preference stimulus from that assessment. This change from the most preferred stimulus from the paired-choice assessment to one chosen 1/12th as often will constitute a large drop in the quality of reinforcement during FCT relative to baseline.
76066012|NCT05925101|Behavioral|Quality-hold condition|We will place destructive behavior on extinction and deliver the most preferred reinforcer from the paired-choice assessment on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline in this condition.
75604357|NCT00927355|Drug|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
75604358|NCT00927355|Drug|Placebo|"The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
75604359|NCT00923845|Drug|Pentostatin|Pentostatin: 2- 4mg/m^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
75604360|NCT00923845|Drug|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
75604361|NCT00923845|Drug|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
75604362|NCT00923845|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
75749263|NCT05970731|Device|Microsponge|Drug delivery using chitosan-based biocompatible microsponge
75604363|NCT00923845|Procedure|Th2 rapa cells|Th2 rapa cell Transplantation
75604364|NCT00923845|Procedure|Donor Lymphocyte Harvest|Apheresis
75604365|NCT00923845|Procedure|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
75604366|NCT00923845|Procedure|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
75899153|NCT05262933|Other|coffee|It will be given to patients brewed coffee to drink and evaluated to hypotension and post spinal puncture headache
75453413|NCT06176313|Other|Coping with Premenstrual Symptoms Education Group|"The education will be conducted through face-to-face interviews in the master's course classroom at the Faculty of Health Sciences at Bilecik Şeyh Edebali University. The education was conducted using PowerPoint presentations projected onto a white smartboard.~One month after the completion of the education, a 1st Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~One month after the 1st Reminder training, a 2nd Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
75453414|NCT06176313|Other|Control Group|"No intervention will be applied to the control group throughout the research. However, students in this group who cope with premenstrual syndrome using medication or non-medication methods will be monitored during the three-month menstrual cycle.~Each student's menstrual cycle in the control group has been recorded in the Excel table. The estimated end of menstruation for each student has been noted.~At the estimated end of menstruation, the researcher contacts the students in the control group to inquire whether they have used any medication or non-medication methods to cope with premenstrual syndrome.~Those who use medication or non-medication methods to reduce premenstrual symptoms are excluded from the study.~On the 4th day of the 4th menstrual period bleeding, the post-test with PMSÖ will be applied to the students."
75453415|NCT06176300|Behavioral|PAR - the SEED Method|The SEED Method is an evidence-based Participatory Action Research (PAR) approach that engages youth and adult stakeholders in collective decision-making and action in supporting PYD opportunities in their communities.
75453416|NCT06176300|Behavioral|PAR-Youth Voices|Youth Voices is a developmentally appropriate and culturally responsive PAR approach designed for African American adolescents. The curriculum relies on frameworks including sociopolitical development (e.g., civic engagement and social justice), racial socialization, and racial identity development. Youth Voices will be implemented in high schools serving the intervention communities.
75453417|NCT06176300|Behavioral|Emerging Leaders hospital-based intervention|Emerging Leaders is a violence prevention strategy that provides evidence-based intervention and resources for high-risk youth and their families in the youth's home and community. Emerging Leaders consists of four core components to prevent violence: (1) brief hospital-based violence intervention, (2) 3-months of community case management, (3) an in-home firearm safety counseling program, and (4) an 8-week youth positive development workshop series.
75453418|NCT06176287|Procedure|Dental Implantation with high torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with high insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
75453419|NCT06176287|Procedure|Dental Implantation with low torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with low insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
75453420|NCT06176274|Other|Prehabilition program|this program includes nutrition, physical activity, medical optimization and psychological support interventions.As a practice, the prehabilitation program (according to the surgery program) is planned in the preoperative period between 2-4 weeks Dec. it will be applied for 4 weeks before surgery. the first meeting is scheduled for 40 minutes. the program compliance process will be monitored by phone weekly. postoperative recovery and functional capacity measurements will be performed.
75453421|NCT06176261|Drug|Datopotamab Deruxtecan|Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.
75453422|NCT06176248|Drug|Triamcinolone Acetonide|1 injection of local anaesthetic (5 ml levobupivacaine 2.5 mg/mL) opposite the subscapular nerve, under ultrasound control, in a lateral decubitus or sitting position. Subsequently, they underwent Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.
75453423|NCT06176248|Drug|saline solution|intramuscular injection of 1 ml saline under ultrasound control under the same conditions as the experimental group. Subsequently, they will undergo Xray-controlled arthrodistension under the same conditions as the experimental group
75453424|NCT06176222|Drug|PRECEDEX INJ★ 2ML|patient received PRECEDEX INJ★ 2ML 0.1~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
75453425|NCT06176222|Drug|Normal saline|patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
75453426|NCT06176209|Diagnostic Test|screening tool with biomarkers for prediction of chronic post traumatic neck pain|Diagnostic screening with biomarkers for prediction of chronic post traumatic neck pain
75453427|NCT06176157|Dietary Supplement|vitamin D2, vitamin D3|comparing parentral D2, D3, to oral D2, D3
75604367|NCT00923845|Procedure|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
75749264|NCT05964218|Behavioral|Food-Body-Mind Intervention|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
75769389|NCT03910036|Biological|platelet rich plasma|Thirty ml of venous blood was taken from every patient and collected in sodium citrated sterile tubes. Platelet concentrates obtained by adjusting centrifuge at 1800 rpm for 15 min to separate erythrocytes, then at 3500 rpm for 10 min to concentrate the platelets. The preparation was done by a single laboratory technician. Thus 5 ml of PRP were obtained, 0.2 mL of 10% calcium chloride was added to the final product to activate the platelets and injected immediately without storage.
75899154|NCT05262933|Other|Water|It will be given to patients water to drink and evaluated to hypotension and post spinal puncture headache
75899155|NCT03641157|Other|Easy Intubation|
75899156|NCT02295488|Procedure|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
75899157|NCT02295488|Biological|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
75453428|NCT06176144|Drug|Desflurane|Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled desflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), and sufentanil (administered by intermittent injection).Towards the end of surgery, desflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Desflurane inhalation will be stopped at the end of surgery.
75604368|NCT05329597|Genetic|Genotyping|Genotyping is performed using the subjects' blood cells
75604369|NCT05329519|Behavioral|Listening music|Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
75604370|NCT04256239|Behavioral|Dignity Therapy|Intervention aimed at enhancing patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress
75899158|NCT02295566|Drug|Nitric Oxide|Not required
75899159|NCT02295566|Drug|Control|Not required
75899160|NCT05283681|Drug|Risankizumab|Subcutaneous Injection via Prefilled Syringe (PFS)
75899161|NCT05283681|Drug|Risankizumab|Subcutaneous Injection via Auto-Injector (AI)
75899162|NCT03513458|Biological|Anakinra|A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
76066013|NCT05925101|Behavioral|Rate-drop/quality-increase condition|In this condition, we will program the same large drop in reinforcement by delivering reinforcement on a VI 15-s schedule, but we also will increase reinforcement quality by simultaneously delivering the highest quality reinforcer identified during a competing stimulus assessment. We will use the competing stimulus assessment in Ex 4 because it directly assesses the quality of alternative reinforcement relative to the quality of the reinforcer for destructive behavior, whereas the paired-choice assessment could not guarantee that the selected stimulus would be of a higher quality than the reinforcer for destructive behavior.
75749265|NCT05960812|Procedure|skillful neglect Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear conservative treatment which is considered the standard technique.~Semisetting position under GA.~Standard shoulder arthroscopy with standard portals for RC repair.~Inspection of articular surface of rotator cuff and biceps tendon.~Bursectomy, visualization of all rotators.~Mobilization is done for associated rotator tears by shaver and radiofrequency device.~Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~Skillful neglect to the tear.~Rotator repair technique by RC anchors~Biceps Tenotomy will be done in all cases by cutting of LHBT."
75899163|NCT03513458|Other|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
75899164|NCT03513458|Drug|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
75899165|NCT03641079|Drug|Brinjal peel extract containing cream|Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
75899166|NCT03760471|Other|Evidenced-based symptom management and coping intervention|The intervention visits will focus on coping and the following symptoms prevalent during CRT: (1) pain and mucositis, (2) nausea, (3) constipation, (4) fatigue, (5) sleep disturbances, (6) xerostomia, (7) thick mucus, and (8) depression
75899167|NCT03643419|Procedure|Laminectomy|According to the standard procedure of laminectomy for acute spinal cord injury
76066014|NCT05924919|Procedure|Whole-body Passive Heat Therapy (HT)|The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.
76066015|NCT05924919|Procedure|Thermoneutral Control (CON)|Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
76066016|NCT05919238|Combination Product|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
76066017|NCT05911204|Other|Questionnaire about intense noises exposure during pregnancy|Response to questionnaire given within 3 days after delivery about noise exposure
76066018|NCT05896709|Other|MK-RS|The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
76066019|NCT05888974|Diagnostic Test|Cardiac ultrasonography|During the inclusion visit, the patient will receive 3 cardiac ultrasonography. The first one will be performed at the time of the initiation of the 500mL vascular filling (T0), without delaying and the second one after the end of the filling (Tfin). These first two ultrasound are part of standard practice. A third will be performed 20 minutes after the end of the vascular filling (Tfin+20).
76066020|NCT05882903|Drug|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
75899168|NCT03643419|Device|Spinal nerve laser therapeutic apparatus（Composed of 808-band fully automatic control laser device and implantable 360° scattering medical fiber）|According to the standard procedure of decompression of laminectomy for acute spinal cord injury, the patient in the Near Infrared Light Irradiation Group placed the implantable 360° scattering fiber laterally above the operation area at the end of the operation. Near infrared light irradiation is applied by spinal nerve laser therapeutic apparatus every day from the day after surgery, once a day for 60 minutes each time.
75899169|NCT03747835|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.
75899170|NCT03747835|Behavioral|Motivational Interviewing|"Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions."
75899171|NCT03516734|Dietary Supplement|Iron fortified lentils|Lentils will be iron-fortified using NaFeEDTA iron fortificants
76066021|NCT05882903|Device|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
75899172|NCT03516734|Other|Non Iron-fortified lentils|Non-fortified lentils will be provided
75453429|NCT06176144|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection).Towards the end of surgery, sevoflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
76066022|NCT05875116|Behavioral|Virtual reality|The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.
75453430|NCT06176118|Dietary Supplement|2-HOBA|2-HOBA supplement take three times daily for 12-weeks
75453431|NCT06176079|Drug|Hyperpolarized (HP) 13C|A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
75604371|NCT04260451|Other|ventilation|"Driving Pressure Limited Ventilation~Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 10 to 2 cmH2O during one-lung ventilation.~1. Lung recruitment: stepwise increase of positive end expiratory pressure 5,10,15 cmH2O with tidal volume 5mL/kg, inspiratory:expiratory 1:1, respiratory rate 10. and driving pressure up to 20 cmH2O. Then decremental PEEP titration is performed using a volume-controlled ventilation until the lowest driving pressure (plateau pressure minus PEEP) is found. This individualized PEEP is adjusted during one-lung ventilation."
75453432|NCT06176079|Drug|Hyperpolarized 13C-Urea|Given intravenously (IV)
75453433|NCT06176079|Procedure|Magnetic Resonance Imaging|Imaging procedure
75453434|NCT06176079|Procedure|Saline Flush|A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C
75604372|NCT04260373|Drug|[14C]SHR4640|Patients will receive single dose of orally [14C]SHR4640 on Day 1.
76066023|NCT05875116|Behavioral|Modified constraint-induced movement therapy|"Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day."
75453435|NCT06176053|Other|Homebased stretching exercise and app supervision|The intervention group will perform a self-administered, home-based stretching program (a total of 6 minutes per day) and maintain their daily activities as identified at baseline. Exercises are to be performed daily for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
75453436|NCT06176040|Drug|TAVO101|TAVO101 IV Infusion.
75604373|NCT05052541|Drug|THC/CBD|Oral solution containing 5mg THC and 50 mg CBD per 1 ml
75453438|NCT06176014|Procedure|implant placement|5 implant were placed in intraforaminal area using surgical guide
75453439|NCT06176001|Other|psychoeducation in groups|Group-based psychoeducation for relatives. Group size: 20-40 relatives. Duration of intervention: six sessions, each two hours long with a 15 minutes break, over a period of 6-10 weeks. The sessions are held by experienced clinicians from the Copenhagen Affective Disorder Clinic, one chief physician and one nurse. Each session focuses on a specific topic, which the clinicians present and discuss using a presentation viewer. The sessions are interactive, and the participants are encouraged to ask questions during the presentations. During each session the participants will have some discussions in smaller groups to reflect on a topics and issues raised during the session.
75604374|NCT05052541|Drug|THC|Oral solution containing 5mg THC per 1 ml
75899173|NCT03516734|Other|Usual Intake|No lentils will be provided.
75899174|NCT05260905|Behavioral|REHIT|REHIt involves 10 minutes of unloaded cycling on a stationary bike, interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
75453440|NCT06175988|Other|Visceral adiposity|Visceral adiposity assess by the visceral adiposity index
75453441|NCT06175975|Other|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
75453442|NCT06175949|Drug|HRS-7085 Tablets|HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
75453443|NCT06175949|Drug|HRS-7085 simulant|PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
75604375|NCT05052541|Drug|Placebo|Oral solution containing no active drug
75604376|NCT04260685|Drug|Lidocaine|IV bolus of 1.5mg/kg lidocaine 1% followed by continuous infusion of 1.5mg/kg/h
75899175|NCT02915575|Other|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
75899176|NCT02915575|Other|Usual Care|Participants will be discharged as per usual ward discharge protocols.
75453444|NCT06175936|Other|Laugther Yoga|Laughter yoga will be applied to the intervention group in 6 sessions (45 minutes each session).
75453445|NCT06175910|Procedure|percutaneous nephrolithotomy|"A 7 Fr ureteric catheter was placed into the ipsilateral ureteric orifice. The patients were then placed in the prone position. Opacification of the pelvicalyceal system was performed. The puncture was done by a 22-guage puncture needle was advanced into the posterior lower calyx under fluoroscopic guidance. After successful access is established, a 0.035-inch curved guide wire was advanced through the puncture needle into the kidney. The central Alkane Rod was passed over the guide wire. Under fluoroscopic guidance serial Amplatz dilators up to 30 Fr were advanced over central Alkane rod and guide wire. Then 30 Fr long Amplatz sheath was advanced over the last dilator.~26 Fr rigid long nephroscope used for stone fragmentation and retrieval. Stone fragmentation was done by pneumatic Swiss Lithoclast. Fragments removal was done using toothed peanut stone retrieval forceps."
76066024|NCT05875116|Behavioral|Usual Physical and Occupational Therapy|The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
75604377|NCT04260685|Drug|Esmolol|IV bolus of esmolol 0.5 mg/kg followed by continuous infusion of 100-300 ug/kg/min
75604378|NCT04259593|Other|exercise training|
75604379|NCT05052151|Other|Low dialysate temperature|35°C
75453446|NCT06175910|Procedure|retrograde intrarenal surgery|"urethrocystoscopy was carried out then inserting of a 7F open ended ureteral catheter over the 0.035-inch straight floppy tip guide wire in the working channel of the 22Fr cystoscope under fluoroscopic guidance, access to the ureter was made.~Teflon ureteric dilators are used to dilate the distal ureter till 14 FR. ureteral access sheath placement 12 or 14 Fr. OTU, a disposable digital flexible ureteroscope, is then used then the tip of a 272 m holmium laser fiber is placed on the surface of the stone for fragmentation.~Intra renal lithotripsy was carried out using a 30 W Holmium: YAG laser (Sphinx Jr.) via a 272 m silica quartz laser fiber. 1.9 Fr tipless nitinol baskets were finally used to remove the large fragments. A Double-J (6 Fr) stent is generally applied at the end of the procedure, and a urethral catheter was applied."
75604380|NCT05052151|Other|High dialysate temperature|37°C
75604381|NCT05052151|Other|Low dialysate bicarbonate concentration|30 mmol/L
76066025|NCT05873712|Procedure|Biospecimen Collection|Undergo collection of blood samples
75769390|NCT05667298|Drug|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~Standard of Care Arm (CROSS):~Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
75604382|NCT05052151|Other|High dialysate bicarbonate concentration|38 mmol/L
75604383|NCT05013853|Procedure|Restoration teeth|Remove caries and restore with resin composite
75604384|NCT00610831|Device|DIRECTVIEW CR Mammography|4 views screening mammogram
75604385|NCT05013463|Drug|Hydroxychloroquine Pill|Oral Hydroxychloroquine, 200mg BID
75604386|NCT05013463|Drug|Indapamide Pill|Oral Indapamide, 2.5 mg OD
75604387|NCT05011591|Other|Swimming economy|Detailed in arm's section
75899177|NCT03519698|Other|Warm water|Footbaths were prepared with 12 liters of warm water (40 °C)
75899178|NCT03519698|Other|Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour (Sinapis nigrea semen plv.)
76066026|NCT05873712|Procedure|Bone Marrow Biopsy|Undergo BM biopsy
75604388|NCT00922987|Drug|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
75604389|NCT00610909|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
76066027|NCT05873712|Procedure|Computed Tomography|Undergo CT and/or PET/CT
76066028|NCT05873712|Drug|Cyclophosphamide|Given IV
76066029|NCT05873712|Drug|Fludarabine|Given IV
75604390|NCT00610909|Drug|Placebo|Placebo
75604391|NCT05331079|Other|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
76066030|NCT05873712|Procedure|Leukapheresis|Given IV
76066031|NCT05873712|Biological|Lisocabtagene Maraleucel|Given IV
76066032|NCT05873712|Procedure|Lymph Node Biopsy|Undergo lymph node biopsy
76066033|NCT05873712|Procedure|Positron Emission Tomography|Undergo PET/CT
76066034|NCT05873712|Drug|Zanubrutinib|Given PO
76066035|NCT05872737|Behavioral|Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)|The Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB) is a 12-week self-help parenting program that integrates Acceptance and Commitment Therapy (ACT) principles with web-based modules and group-based sessions. The program includes a self-help workbook/manual and ACT protocols that cover various self-help exercises such as guided imagery, grounding, mindfulness, and values clarifications. To make the programme more relatable to Hong Kong parents caring for children with NDD, storytelling vignettes and therapeutic narratives will be included. Parents will work on each module at their own pace within 2-3 weeks and meet with trained facilitators in a video-conferencing format after completing each module to review their progress and learn positive parenting techniques.
76066036|NCT05872737|Behavioral|General Parenting Education and Advice|Both the FAB group and the Control Group will receive routine family support services from collaborating NGOs, including education on managing the emotional and behavioral symptoms of children with NDD. To control for the interaction/social effect present in the FAB group, the Control Group will also receive four video-conferencing sessions guided by a trained research assistant over 12 weeks. These sessions will facilitate parents to discuss their parenting challenges, identify parenting traps, and provide general parenting advice as recommended by the Child Assessment Services, Department of Health under the HKSAR government.
75899179|NCT03519698|Other|Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour (Zingiberis rhizoma plv.)
75899180|NCT03513380|Behavioral|Exergaming|free access to the exergame PedalTanks during 6 months
75899181|NCT03516578|Other|Cardiac magnetic resonance imaging|
75899182|NCT02299544|Device|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
76066037|NCT05872451|Drug|Rocuronium Bromide|After measuring the initial current intensity, quantitative neuromuscular blockade monitoring is applied, and rocuronium (0.6 mg/kg) is administered.
76066038|NCT05872451|Diagnostic Test|Nerve stimulator|Measuring the minimum current intensity for the stimulation of the obturator nerve to show the contraction of the adductor longus muscle.
75453447|NCT06175897|Procedure|Deep Brain Stimulation|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.~Device: STN-DBS devices DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
75453448|NCT06175897|Procedure|non-Deep Brain Stimulation|Patients with PD were given their original drug dose and did not receive DBS.
75604392|NCT05046691|Behavioral|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
75604393|NCT00928135|Drug|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
75453449|NCT06175871|Other|OTAGO exercises|Exercices for improvement postural control and mobility and decrease falls risks
75453450|NCT06175871|Other|Conventional therapy|Exercice and education from physical therapy practice conventional from Hospital.
75899183|NCT03738397|Biological|Upadacitinib|Extended release tablet
75899184|NCT03738397|Biological|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection
75453451|NCT06175858|Diagnostic Test|CMR|We will use cmr and bone scintigraphy to detect cardiac amyloidosis due t the high accuracy and reliability
75604394|NCT00928135|Drug|Hypertonic saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
75604395|NCT04259827|Other|Neuronation|Online cognitive training app, with exercises created for patients with mild cognitive impairment
75604396|NCT04259827|Other|Aspecific online games|Online gaming without cognitive training
75604397|NCT00928057|Device|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
75899185|NCT03738397|Drug|Placebo to dupilumab|Placebo administered as a subcutaneous injection
75899186|NCT03738397|Drug|Placebo to upadacitinib|Tablet
75899187|NCT02295800|Other|Standard of care|
75899188|NCT02295800|Other|Semi-structured interviews|
75899189|NCT02292836|Other|Questionnaire testing|Questionnaire testing on rosacea and non-rosacea dermatology outpatients
75899190|NCT02960217|Drug|UX007|liquid for oral (PO) administration
75899191|NCT02960217|Drug|Placebo|liquid safflower oil for PO administration
76066039|NCT05868278|Other|Training method intervention|Traditional learning method will be used in the control group. In the experimental group, interactive learning method will be used.
75769391|NCT05667298|Drug|Adjuvant chemoradiotherapy|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~Standard of Care Arm (CROSS):~Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
75453452|NCT06175845|Procedure|Intraductal biliary radiofrequency ablation|Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
75453453|NCT06175819|Other|Manuka honey( MgO 850, UMF+20) loaded nano-formulation|Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris
75453454|NCT06175806|Drug|Ondansetron Oral Film|5-hydroxytryptamine (5-HT) receptor antagonist
75453455|NCT06175806|Drug|Granisetron Oral Liquid Product|5-hydroxytryptamine (5-HT) receptor antagonist
75453456|NCT06175793|Behavioral|ASPIRE Intervention|In addition to usual care and a free blood pressure cuff, participants in the intervention arm will receive the ASPIRE components: (1) ASPIRE Tool Kit, (2) ASPIRE Coach, (3) SMBP EHR Documentation, and (4) screening and addressing SDOHs.
75453457|NCT06175767|Drug|MT101-5|Tablet
75453458|NCT06175754|Procedure|Laser ablation|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser
75453459|NCT06175754|Procedure|Laser with Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser plus sclerotherapy
75453460|NCT06175754|Procedure|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy
75453461|NCT06175741|Procedure|erector spinae plane block|The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in three levels (T3,T4 and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
75453462|NCT06175728|Device|S-Press|Leg Strengthening Device that can be used in supine and seated positions
75453463|NCT06175715|Procedure|carotid endarterectomy|carotid endarterectomy under local or general anethesia
75453464|NCT06175702|Drug|Vincristine|dose 1.5 mg/m2 at days 1, 8, 15 and 22
75453465|NCT06175702|Drug|Dexamethasone|40 mg on days 1-2, 8-9,15-16 and 22-23
75453466|NCT06175702|Drug|Imatinib|600 mg per day from 1 to up to 5 years
75453467|NCT06175702|Drug|Cytarabine|1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion
75899192|NCT02292914|Procedure|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
76066040|NCT05862987|Dietary Supplement|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
76066041|NCT05862987|Dietary Supplement|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
76066042|NCT05862623|Drug|AER-01|AER-01 solution for inhalation delivered via nebulizer
75453468|NCT06175702|Drug|Mercaptopurine|50 mg/m2 on days 1 to 28 of maintenance
75453469|NCT06175702|Drug|Methotrexate|1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance
75453470|NCT06175702|Drug|Ponatinib|15 mg per day from consolidation start up to 5 years
75453471|NCT06175702|Procedure|allogeneic stem cell transplantation|Allogeneic stem cell transplantation from hematpoietic stem cells progenitors of familiar or not familiar origin. Cord blood transplantation can also be done.
75453472|NCT06175702|Procedure|Total body irradiation|Fractionated dose with total dose of 12 Gy between days -4 and -1 of allogeneic stem cell transplantation (alloSCT)
75453473|NCT06175702|Drug|Cyclophosphamide|60 mg/kg on days -6 and -5 before alloSCT
75453474|NCT06175702|Drug|Fludarabine|30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
75453475|NCT06175676|Drug|Hydroxybutyl chitosan|Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
75453476|NCT06175676|Drug|5-Fluorouracil|Inject 0.3ml of 5-FU solution (25mg/ml) into the nasal mucosa around the anastomosis, and apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
75453477|NCT06175676|Drug|Gelatin Sponge Sheet|Apply gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment to the anastomosis of nasal mucosal flap and dacryocyst mucosal flap
76066043|NCT05862623|Drug|Placebo|Placebo for solution for inhalation delivered via nebulizer
76066044|NCT05861921|Other|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.
75604398|NCT00928057|Device|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
75749266|NCT05960812|Procedure|arthroscopic repair Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear repair which is considered the standard technique.~Semisetting position under GA.~Standard shoulder arthroscopy with standard portals for RC repair.~Inspection of articular surface of rotator cuff and biceps tendon.~Bursectomy, visualization of all rotators.~Mobilization is done for associated rotator tears by shaver and radiofrequency device.~Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~Skillful neglect to the tear.~Rotator repair technique by RC anchors~Biceps Tenotomy will be done in all cases by cutting of LHBT."
75769392|NCT01256554|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
75899193|NCT02292914|Procedure|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
75899194|NCT02292992|Device|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
75453478|NCT06175663|Drug|Antihypertensive medication withdrawal|To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs are known to interfere with this ratio, patients often have to discontinue drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine). Drugs have to be stopped for at least four weeks (for mineralocorticoid receptor antagonists) or two weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly and blood pressure levels drop again.
75604399|NCT00928057|Device|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
75604400|NCT05331547|Device|BioFreedom BA9 (SS) Ultra DCS|BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
75453479|NCT06175650|Procedure|Cardiac surgery|Cardiac surgery of all types
76066045|NCT05858437|Dietary Supplement|Sodium propionate|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
75453480|NCT06175624|Other|Clinically Helathy|"Our study will include 25 people with clinically healthy patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
75604401|NCT00927901|Drug|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
75899195|NCT02295878|Dietary Supplement|Treatment capsule containing seaweed extract (treatment)|400mg capsule containing seaweed extract (treatment)
75899196|NCT02295878|Dietary Supplement|Placebo|
75899197|NCT02293070|Other|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
75899198|NCT02293070|Procedure|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
75899199|NCT02299622|Genetic|Genetic test|Next-generation sequencing (AmpliSeq) & fusion analysis
75899200|NCT03643497|Drug|anti-infective drugs|According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
75899201|NCT03519620|Other|SWWSV|Behaviours to prevent child obesity
75749267|NCT05951660|Behavioral|Educational intervention|"Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~What is sexuality?~How psychopharmacology influences sexuality~What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences."
75604402|NCT00927901|Drug|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
75749268|NCT05951179|Biological|TARA-002|"Cohort A: All subjects will receive 6 weekly instillations of TARA-002 at the established recommended Phase 2 dose (RP2D). Subjects who are eligible for reinduction will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period.~Cohort B: All subjects will receive 6 weekly instillations of TARA-002 at the established RP2D. Subjects who are eligible for reinduction will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Subjects confirmed to have a complete response will receive 3 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. All eligible subjects will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18."
75899202|NCT03643341|Behavioral|Family Healthy Living|Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
75899203|NCT02299700|Other|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
75899204|NCT02299778|Dietary Supplement|13C6-p-aminobenzoic acid|
75899205|NCT05252169|Other|Proprioceptive training|"Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip."
76066046|NCT05858437|Other|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
76066047|NCT05854953|Device|Hawley retainers in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
76066048|NCT05854953|Device|Hawley retainers in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
76066049|NCT05854953|Device|VFRs in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
76066050|NCT05854953|Device|VFRs in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
76066051|NCT05854953|Device|Baseline characteristics|Hawley retainers and VFRs that are newly constructed will be used as baseline samples. The samples will be taken for microbial, physical and mechanical tests.
75453481|NCT06175624|Other|Gingivitis|"Our study will include 25 people with gingivitis patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
75604403|NCT00927901|Drug|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
75604404|NCT00927901|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
75604405|NCT04255771|Drug|Gemcitabine|Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
75604406|NCT04255771|Drug|Placebos|Use a placebo as a comparison
75604407|NCT05329363|Diagnostic Test|PEPITS Programme|"The programme has three main phases:~Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and stepping stone phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery."
75604408|NCT05329363|Other|Usual care|Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.
75453482|NCT06175624|Other|Periodontitis|"Our study will include 25 people with periodontitis patients.~Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study."
75453483|NCT06175585|Other|narrative nursing|"The narrative nursing process is based on the practice of two-line system proposed by Jiang, which is carried out in a separate classroom, office or ward with sufficient space and good lighting. The environment is set to the right temperature and humidity for comfortable face-to-face conversation. This process is done in stages, depending on how often the patient is dialysis three or more times a week.~Each session lasts about 30 minutes and the whole process lasts four weeks. Adjust to the specific needs of each patient ."
75749269|NCT05941247|Drug|Hemay005 60 mg|"The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition.~On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9."
75899206|NCT05252169|Other|Routine Physical therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~Passive stretching exercises~Weight bearing exercises~Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
75899207|NCT03519542|Drug|Sunitinib|Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
75899208|NCT03643029|Device|Video-laryngoscopy following SAD insertion|Following insertion of a supraglottic airway device (SAD), the placement and performance tests are carried out. If the tests are successful, a video-laryngoscopy will be performed to confirm the placement of the SAD in the hypopharynx.
75453484|NCT06175585|Other|traditional nursing|Patients undergoing MHD received traditional nursing interventions, encompassing various aspects such as dietary advice, instructions on medication usage, health education, emphasis on precautions during dialysis, and guidelines for vascular access care. Additionally, the nurses proactively inquired about patients' emotional well-being during the nursing shift change, actively engaged and uplifted patients experiencing low spirits, and encouraged family members to provide emotional support.
75749270|NCT05941052|Diagnostic Test|Tongue swab-based molecular assays|The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
75453485|NCT06175572|Device|coronary physiological indices|coronary physiological indices
75453486|NCT06175559|Combination Product|Healing Town: Embedded Narrative in Interactive Game Design|"The game-based medication intervention game Wanping Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game"
75899209|NCT02295956|Behavioral|Questionnaires|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
75749271|NCT05940090|Device|SkinIO|The device is simply an application that photographs skin lesions and identifies lesions that may require further examination
75899210|NCT02295956|Other|Exercise|Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
75899211|NCT02295956|Other|Nutrition Counseling|Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
76066052|NCT05854498|Drug|Liposomal irinotecan|60mg/m2 IV on days 1 and 15
75453487|NCT06175546|Device|Compression socks|Wearing of compression sock in prescribed regimen
75749272|NCT05934240|Other|Manual therapy group|Manual therapy will be applied to the diaphragm and thoracic region.
75749273|NCT05934240|Other|Sham-manual therapy|Sham-manual therapy will be applied to the diaphragm and thoracic region.
76066053|NCT05854498|Drug|TAS102|35mg/m2 PO BID on days 1-5 and 15-19
75749274|NCT05932368|Other|evaluation|examining files and taking records
75899212|NCT02295956|Behavioral|Phone Calls|Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
75899213|NCT02295956|Other|Booklet|Exercise instructional booklet given to all participants describing all exercises.
75899214|NCT03642561|Device|radiotherapy ablation|We using Cool Tip system or RITA system to perform RFA
75899215|NCT03642561|Device|transarterial chemoembolization(TACE)|TACE treatment is a first line treatment for BCLC stage B HCC
75899216|NCT03516500|Drug|Iron Sucrose Injection|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) into the segmental bronchus.
75899217|NCT03642405|Diagnostic Test|Electrocardiogram examination|12-lead ECG monitored by Holter
76066054|NCT05854498|Drug|Bevacizumab|5mg/kg IV on days 1 and 15
75453488|NCT06175533|Procedure|ultrasound guided 60 degree CRF for plantar fasciitis|ultrasound guided plantar fascia CRF for chronic conditions not responding to treatment
75604409|NCT01218204|Drug|10mg atorvastatin|10mg
75604410|NCT01218204|Drug|80mg atorvastatin|80mg
75604411|NCT01218204|Drug|GSK1292263 Placebo|Placebo
75604412|NCT01218204|Drug|100mg GSK1292263|100mg
75604413|NCT01218204|Drug|300mg GSK1292263|300mg
75604414|NCT01218204|Drug|800mg GSK1292263|800mg
75604415|NCT01218204|Drug|10mg ezetimibe|10mg
76066055|NCT05853211|Combination Product|Aligner and inter-arch elastics|Correction of class II malocclusion by class II elastics on clear aligners
76066056|NCT05844852|Device|P200TE|The P200TE provides OCT imaging including retinatopography and ONH (optic nerve head) scans.
76066057|NCT05841472|Drug|Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin|"200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles."
76066058|NCT05831449|Drug|Local anesthetic injection of CPL-01|Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
76066059|NCT05831449|Drug|Naropin, 0.5% Injectable Solution|Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
76066060|NCT05831449|Drug|Placebo|Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
76066061|NCT05825014|Other|No intervention|No intervention
76066062|NCT05822011|Procedure|Rhomboid intercostal subserratus plane block|Fascial plane block
76066063|NCT05822011|Procedure|Erector spinae plane block|Fascial plane block
76066064|NCT05822011|Procedure|Thoraccic Epidural analgesia|Neuroaxial block
76066065|NCT05821725|Device|Hyaluronic acid|Hyaluronic acid and hemostatic sponge
76066066|NCT05821725|Device|Control|Hemostatic sponge
76066067|NCT05819450|Procedure|Volumetric rejuvenation|Volumetric Rejuvenation with FDA-approved fillers on the skin of the dorsal hands
76066068|NCT05818358|Dietary Supplement|black beans|¾ cup of cooked black beans
76066069|NCT05818358|Dietary Supplement|wheat berries|¾ cup of cooked whole wheat grain
75463243|NCT05855551|Other|Food basket|"The monthly food basket will provide 10 kg micronutrient fortified rice , 3.5 kg of lentils, and 1000 ml of oil, valued at 800 BDT . Assuming a the ration is split equally among the 5 members of an average-sized household in rural Bangladesh and using food composition data for Bangladesh, the food basket is estimated to provide 354 kcal and 11 g of protein per person per day. The food basket will be provided once every month.~The individually packaged foods will be distributed at the Union parishad office, community clinic, or another government facility in the first week of each month. The UDW will inform the beneficiaries of the place and time of the food distribution. Recipients will only receive the food when they present their food card. The card will also be used to record receipt of each ration. If beneficiaries cannot attend the food distribution themselves, a designated nominee can pick up the ration on their behalf."
75604416|NCT01218204|Other|Washout|No interventions - washout period
75604417|NCT00926575|Drug|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
75604418|NCT00926575|Drug|Placebo|Two tablets QID for 50 days
75604419|NCT01218126|Drug|losmapimod|comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg
75604420|NCT01218126|Drug|placebo|placebo comparison with active
75604421|NCT05456412|Other|JAK inhibitor treatment|Standard care
76066070|NCT05818358|Dietary Supplement|white rice|¾ cup of cooked white rice
76066071|NCT05818124|Drug|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
75604422|NCT01217892|Drug|dapagliflozin|2.5 mg tablet, taken orally, twice daily
75604423|NCT01217892|Drug|dapagliflozin|5 mg tablet taken orally, twice daily
75604424|NCT01217892|Drug|dapagliflozin|10 mg tablet taken orally, once daily
75604425|NCT01217892|Drug|metformin|>/= 1500 mg total daily dose, tablets taken orally, twice daily
75604426|NCT01217892|Drug|placebo|placebo
75604427|NCT01217814|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75604428|NCT01217814|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75604429|NCT01217814|Drug|Golimumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75604430|NCT01217814|Drug|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
75604431|NCT01217814|Drug|Folic/folinic acid|"Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard."
75604432|NCT01217190|Drug|Ondansetron (ODFS)|Test Article
75604433|NCT01217190|Drug|Zofran (ODT)|Comparator
75604434|NCT01136733|Drug|Lenvatinib|taken orally, once a day
75604435|NCT01136733|Drug|Everolimus|taken orally, once a day
75604436|NCT05178693|Drug|ASTX727|Cedazuridine 100mg + 35mg decitabine
75604437|NCT05178693|Radiation|Lutathera|Peptide receptor radionuclide therapy (PRRT)
76066072|NCT05818124|Drug|Placebo molnupiravir|Four placebo capsules matched to molnupiravir taken twice daily by mouth.
76066073|NCT05818124|Drug|Placebo oseltamivir|Placebo capsule matched to oseltamivir taken twice daily by mouth.
76066074|NCT05818124|Drug|Oseltamivir|One capsule of oseltamivir 75 mg taken twice daily by mouth.
75604438|NCT01136655|Drug|80/2.25 μg Symbicort pMDI|inhalation
75604439|NCT01136655|Drug|80/4.5 μg Symbicort pMDI|inhalation
75604440|NCT01136655|Drug|Foradil Aerolizer 12 μg|inhalation
75604441|NCT01136655|Drug|40 μg budesonide HFA pMDI|inhalation
75899218|NCT03642405|Diagnostic Test|Echocardiography|Echocardiography in accordance to Danish Society of Cardiology
75604442|NCT01136655|Drug|placebo HFA pMDI|inhalation
75604443|NCT04312581|Device|Extracorporeal shock wave therapy|3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.
75899219|NCT03642405|Procedure|Blood Samples|Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
76066075|NCT05818124|Biological|Influenza A Virus|Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
75604444|NCT04312581|Other|Conventional rehabilitation|physical & occupational therapy
75604445|NCT01135017|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
75604446|NCT01135017|Drug|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
75604447|NCT02883153|Drug|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
75604448|NCT01134783|Behavioral|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
75604449|NCT01134705|Drug|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
75899220|NCT03642405|Behavioral|Questionnaire|Questionnaire regarding patients quality of life
75899221|NCT02299856|Other|Cardiac magnetic resonance scan|
75899222|NCT05283603|Diagnostic Test|ECG, Echocardiogram, Magnetic resonance|Clinical and instrumental follow-up
76066076|NCT05818046|Diagnostic Test|transcutaneous oxygen pressure|External proxe fixed to the skin and ultrasound examination.
75453489|NCT06175520|Behavioral|Preconception care (PCC)|The investigators will introduce PCC through the existing public health system. At the community level facility, healthcare providers will screen the women for some specific health problems and provide necessary supplements. Healthcare providers will screen for health problems such as- infectious diseases (e.g., Tuberculosis), Hypertension, Anaemia, Diabetes Mellitus, Thyroid problems, Sexually Transmitted Infection/Reproductive Tract Infection/Urinary Tract Infection, Nutritional status (e.g., Body mass index), Thalassemia symptoms, Thyroid symptoms, severe Dysmenorrhea, Immunization status, and Symptoms of acute Hepatitis B Virus infection, etc. The provider will also consider age, menstrual history, and reproductive history during preconception screening. If the provider finds any abnormality from the screening test which is a risk for a woman to become pregnant and for her newborn; the woman will be provided proper counseling, treatment, and referral to the appropriate facility.
75453490|NCT06175507|Drug|Naltrexon|Naltrexone 50mg orally once daily will give for 12 weeks
75453491|NCT06175507|Drug|Baclofen|Baclofen 10mg orally thrice daily will give for 12 weeks
75453492|NCT06175481|Other|Popliteal Vein Compliance|Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).
75604450|NCT01134705|Drug|Placebo Nasal Aerosol|HFA Vehicle Aerosol
75604451|NCT00927823|Drug|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
75769393|NCT01256554|Behavioral|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
75769394|NCT01256632|Drug|Ranibizumab|All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
75769395|NCT00256698|Drug|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
75769396|NCT00256698|Drug|Anastrozole|1 mg oral tablet
75769397|NCT01150630|Drug|capecitabine|1250 mg/mq/day per os for 14 days every 14 days for 6 months
75769398|NCT01150630|Drug|cisplatin|30 mg/mq every 14 days for 6 months
75769399|NCT01150630|Drug|epirubicin|30 mg/mq every 14 days for 6 months
75769400|NCT01150630|Drug|gemcitabine|ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
75604452|NCT01134627|Drug|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
76066077|NCT05818046|Procedure|Supervised Exercise therapy|Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.
75604453|NCT01134627|Drug|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
75604454|NCT04992715|Diagnostic Test|[99mTc]-NM01 SPECT/CT|Technetium-99m radiolabelled anti-PD-L1 single-domain antibody (NM01) single-photon emission computed tomography (SPECT)/computed tomography (CT)
75604455|NCT01134393|Drug|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
75604456|NCT05331469|Drug|NPH basal insulin titration|Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
75604457|NCT00610753|Behavioral|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
75604458|NCT00610753|Behavioral|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
75604459|NCT04246957|Behavioral|general quality of life questionary|Every patient will have to fill out a general quality of life questionary : DLQI (Dermatology Life Quality Index)
75749275|NCT05928078|Behavioral|intervention|Participants will be required to use the MOVI-ageing platform 3 times a week for 12 weeks. The platform will include videos of cognitively demanding physical activities designed and guided by health professionals, who will also be able to check compliance with the intervention.
75899223|NCT03513224|Other|eDosette|The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
76066078|NCT05813847|Drug|local anaesthetic injection|Local infiltration of study drug
76066079|NCT05813743|Diagnostic Test|3 dimensional ultrasound|Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
76066080|NCT05813730|Other|urinary creatinine excretion measurement|Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
75604460|NCT04246957|Behavioral|specific quality of life questionary|Every patient will have to fill out a specific quality of life questionary : Hair Specific Skindex 29.
75604461|NCT00922441|Drug|Fimasartan 60 mg group|Fimasartan 60 mg
75604462|NCT00922441|Drug|Fimasartan 120 mg group|Fimasartan 120 mg
75604463|NCT00922441|Drug|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
75604464|NCT01217112|Drug|GWP42003|100 mg capsules, PO, BD, 91 days
75899224|NCT03644043|Device|EEG scan|WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
75604465|NCT01217112|Drug|GWP42003|5 mg capsules, PO, BD, 91 days
75899225|NCT05283525|Dietary Supplement|Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches|0 - 90 Days of Treatment
75604466|NCT01217112|Drug|GWP42004|5 mg capsules, PO, BD, 91 days
75604467|NCT01217112|Drug|Placebo|0 mg capsules, QDS, PO, 91 days
75604468|NCT01216332|Drug|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
75749276|NCT05926505|Drug|Placebo|Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
75604469|NCT01216332|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
75604470|NCT00922207|Drug|Adefovir|From week -4 to week 2
75604471|NCT00922207|Drug|Entecavir|From week -4 to week 2
75604472|NCT00922207|Drug|Placebo|From week -4 to week 2
75749277|NCT05926505|Drug|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
75749278|NCT05926193|Dietary Supplement|Tailor Food Bags|The treatment group will participate in 6 nutrition workshops over the course of 6 months as well as receive weekly food bags that have been tailored for a DASH diet.
75604473|NCT00922207|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
75899226|NCT05283525|Dietary Supplement|Oxygen Saturation|0 - 90 Days of Treatment
76066081|NCT05810467|Other|Active Surveillance|"Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA <10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, >50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa."
75604474|NCT05316103|Device|Probe-based confocal laser endomicroscopy targeted optical biopsy|After intravenous injection of fluorescein sodium, pCLE-based targeted optical biopsy will be performed.
76066082|NCT05810233|Dietary Supplement|Ascorbic acid 1000mg|Health supplement
76066083|NCT05810233|Other|Placebo|Glucose chewable tablet without any ascorbic acid
76066084|NCT05805891|Drug|bortezomib|bortezomib 2mg/week subcutaneous injection
76066085|NCT05805358|Drug|Hyperpolarized 13C-Pyruvate injection|DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
75604475|NCT04255459|Other|Moist Snuff|Moist Snuff product
75604476|NCT04255459|Other|Camel Snus|Camel Snus product
75604477|NCT04255459|Other|Cigarettes|Cigarette product
75604478|NCT04255459|Other|No tobacco usage|No tobacco usage
75749279|NCT05925322|Behavioral|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
75453493|NCT06175468|Drug|Formosa 1-Breath Free (NRICM101)|After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
75453494|NCT06175468|Drug|Placebo control drug|After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
75453495|NCT06174883|Dietary Supplement|Folic acid fortified iodized salt|addition of folic acid to iodized salt to be consumed daily and assess rise in serum folate levels.
75453496|NCT06174051|Behavioral|Flashforward EMDR|The Flashforward procedure in EMDR-treatment aims to reduce fear evoked by images of imagined future adverse events.
75453497|NCT06174051|Behavioral|Flashback EMDR|The Flashback procedure in EMDR-treatment aims to successfuly process the memories of traumatic events that happened in the past.
75453498|NCT06170840|Drug|QY101Placebo/QY101 ointment|External use for BID
75453499|NCT06170619|Device|Obsidio™ Conformable Embolic|Embolization with Obsidio™ Conformable Embolic.
75453500|NCT06169800|Device|MPFL repair with Biobrace augmentation|MPFL repair with Biobrace augmentation
75453501|NCT06169761|Other|Assessment of motor skills of the tongue and others muscles, see below) and risk for sleep apnea|"The following items will be assessed:~Risk for sleep apnea, through the STOP-BANG Questionnaire.~Anthropometric data: Height, weight, neck circumference, maximal mouth opening and maximal mouth opening with tongue to palate (with the Quick Tongue-Tie Assessment tool).~Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb in kPa) during 3 sec. of tongue protrusion and elevation.~Tongue endurance (i.e., the time to task failure in maintaining a pressure equal to a fixed percentage of Pmax against the IOPI bulb) during tongue protrusion and elevation~Tongue mobility restriction measured with the Quick Tongue-Tie Assessment Tool~Maximum inspiratory and expiratory pressures measured with MicroRPM in cmH2O~Handgrip strength (measured with a JAMAR dynamometer in kg)~Tongue skills measurements will be repeated 2 to 4 weeks after baseline to assess the reliability of these measurements."
75453502|NCT06168617|Diagnostic Test|Performance tasks in daily life|Evaluation of performance tests executed by patients in real-life situations.
75604479|NCT01134315|Drug|Paricalcitol|
75604480|NCT01134315|Drug|Calcitriol|
75604481|NCT04253431|Device|Droplet lancing device (HTL-Strefa S.A.)|
75604482|NCT04253431|Device|Microlet 2 lancing device (Bayer)|
75604483|NCT04253431|Device|OneTouch Delicia lancing device (LifeScan)|
75604484|NCT04253431|Device|ReliOn lancing device (ReliOn)|
75604485|NCT04253431|Device|Accu-Chek Softclix lancing device (Roche)|
75749280|NCT05925322|Behavioral|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
75749281|NCT05922618|Device|I-One|"I-ONE® is a medical device certified by the Ministry of Health as a Medical Device (risk class II A) for the treatment of inflammatory and degenerative tissue pathologies. The device consists of a signal generator and an applicator, called a solenoid. The solenoid will be placed on the joint, not necessarily in direct contact with the skin. The device works with a rechargeable battery and is equipped with an hour counter to assess patient compliance.~Treatment with I-ONE® therapy will start within 3-7 days of recruitment, will last 6 hours a day and will be maintained for 60 days. The treatment will be carried out at home and the device will be delivered directly to the patient's home by courier."
75899227|NCT05283525|Dietary Supplement|Total Blood Chemistry|0 and 90 Days of Treatment
75899228|NCT05283525|Dietary Supplement|Adverse Event Monitoring|Adverse Event Monitoring Throughout the Study
76066086|NCT05805124|Diagnostic Test|Preop evaluation|"All preop evaluations prescribed in the preadmission clinic will be recorded, especially:~renal function tests~hematologic tests~coagulation tests~hepatic function tests~ECG~cardiac function tests~pulmonary function tests~endocrine function tests"
76066087|NCT06133790|Genetic|PCR - Immunohistochemistry - Immunolabelling|Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
76066088|NCT06133764|Procedure|Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+CS + PO)|The enucleation procedures, which were meticulously carried out in order to remove the odontogenic keratocyst in one piece without breaking its lining or leaving any epithelial remnants.The peripheral ostectomy treatment will be carried out with a large spherical bur and plenty of irrigation.After filling the bone cavity with more sterile gauze, the Carnoy's solution was slowly injected into it with a plastic syringe. The gauze was continuously injected with CS until it was fully saturated without leaking too much into the surrounding tissues. The CS was held in place for 3 minutes.
76066089|NCT06133764|Procedure|Decompression/ marsupialization (D/M)|A surgical window will be created in the cyst wall to drain the contents while retaining continuity between the cyst and the oral cavity
76066090|NCT06133764|Procedure|Enucleation (E)|The enucleation will be accomplished in the same manner that it will be performed in the group of Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
76066091|NCT06133764|Procedure|Enucleation+Carnoy's solution (E+CS)|Both enucleation and Carnoy's solution will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
76066092|NCT06133764|Procedure|Enucleation+ Peripheral Ostectomy (E+ PO)|Both enucleation and peripheral ostectomy will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+ Carnoy's solution chemical cauterization (E+ PO+ CS).
76066093|NCT06133751|Drug|black chokeberry (Aronia melanocarpa)|Black chokeberry capsules standardized for anthocyanin compounds
76066094|NCT06133751|Drug|Placebo|Chokeberry fiber placebo capsules
76066095|NCT06133738|Other|Standardized Exercise Program|"Participants will be asked to attend to the department for 8 supervised physiotherapy sessions designed to strengthen lower limb muscles. Eight sessions were chosen as this number should be able to achieve improvements in pain and function. Standardized exercises sessions will be held once weekly in the health center and will be supervised by the researcher. In addition, participants will be requested to perform the prescribed exercises 3 times per week at home, with 1-2 days rest interval between the exercise's sessions.~The program is comprised of a minimum of 4 and a maximum of 6 individualized lower limb exercises to be performed 4 times per week (once in the health center and 3 times at home). All exercise programs will include at least 2 knee extensor strengthening exercises, 1 hip abductor strengthening exercise, 1 hamstring strengthening exercise, 1 calf strengthening exercise, and 1 other exercise will be chosen based on assessment findings."
76066096|NCT06133738|Other|Internet based Cognitive Behavioral Therapy|"This intervention will be given to participants in intervention group. This is a link to access pre-recorded online sessions of CBT.~The iCBT link contained eight 35- to 45-minute sessions, designed to be completed weekly, each provided an explanation of a cognitive or behavioural pain coping skill. Session 1 provided an overview, including a therapeutic rationale of CBT, followed by training in progressive muscle relaxation. Sessions 2 through 7 taught brief relaxation skills, activity-rest cycling, pleasant activity scheduling, cognitive restructuring, pleasant imagery, and problem-solving. Session 8 consolidated the learnt and taught strategies for long-term skill use. Each session has to be completed within the same week where the physiotherapy session is given.~The researcher has developed a website that contained all the CBT materials."
76066097|NCT06133738|Other|Educational Materials|All participants will receive a link to access online educational material about chronic knee pain. This is a YouTube link that consists of 5 sessions, with each lasting for 5-7 minutes, and is comprised of general information about the following: healthy eating, osteoarthritis and X-Ray, physical activity, the full pain experience, and proper footwear. Participants will be encouraged to access the educational material at their own leisure and pace.
75453503|NCT06168240|Other|Manual lymphatic drainage. will be applied three days per week for four weeks.|Training will applied 3 days a week, for a total of 4 weeks.
75453504|NCT06168214|Drug|Rabeprazloe+bismuth+amoxicillin+clarithromycin|PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
75453505|NCT06168214|Drug|Vonoprazan+amoxicillin+clarithromycin 14 days|VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
75453506|NCT06168214|Drug|Vonoprazan+amoxicillin+clarithromycin 7 days|VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
75749282|NCT05897983|Other|Rocabado exercises plus TENS device|Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
75749283|NCT05897658|Drug|Levetiracetam|Tablets
75899229|NCT05283525|Dietary Supplement|Body Weight Monitoring|0 - 90 Days of Treatment
75899230|NCT05283525|Dietary Supplement|Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health|0 - 90 Days of Treatment
75899231|NCT03516422|Procedure|ULTRASOUND DEBRIDEMENT|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
75749284|NCT05897658|Other|Placebo|Tablets
75899232|NCT03516422|Other|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
75899233|NCT02293148|Drug|GSK1278863 75 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
76066098|NCT06133725|Procedure|erector spinae plane block|The experimental group received ultrasound-guided erector spinae plane block, and bilateral erector spinae plane block was performed at T7 segment with 20ml 0.375% ropivacaine on each side.While the control group received ultrasound-guided transversus abdominis plane block combined with rectus sheath block, which will be performed under the costal margin with 10ml 0.375% ropivacaine for bilateral transversus abdominis plane block and 10ml 0.375% ropivacaine for bilateral rectus sheath block.
76066099|NCT06133686|Drug|Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)|Group A will receive oral TDF-FTC PrEP (using either event-driven or daily) for 9-months. After 9-months, participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP
76066100|NCT06133686|Drug|Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)|Group B will receive CAB-LA for 9-months. After 9-months participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP.
76066101|NCT06133660|Procedure|pars plana vitrectomy|pars plana vitrectomy and Silicone oil removal to distinguish subjects
76066102|NCT06133634|Dietary Supplement|Fisetin|Fisetin dietary supplement
76066103|NCT06133634|Other|Placebo|Placebo capsules identical in appearance to fisetin capsules
76066104|NCT06133608|Other|MOBILIZATION TRAINING|"Things to consider in the hospital in the early period after surgery: The first day in the hospital after surgery, the importance of the abduction pillow and early mobilization,~Exercises performed in bed in the early period after surgery: Exercises such as ankle pump, ankle rotation, bed-supported knee bending, hip contraction, opening exercise, thigh exercise, straight leg raise,~Early standing up: Activities such as sitting in bed or on a chair, standing up with the help of a walker, walking,~Exercises performed while standing: Exercises such as lifting the knee, opening the leg to the side,~Daily living activities: It will provide information on regulating ADLs such as bathing, dressing, using the toilet, getting into and driving the car, going up and down stairs, eating, sleeping, doing housework, sexual life, and information about the safety precautions that should be taken at home."
76066105|NCT06133595|Behavioral|Behavioral: MiBridge|A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
76066106|NCT06133569|Behavioral|ReDirection|Self help program based on principles for cognitive behavioral therapy
75453507|NCT06168214|Drug|Vonoprazan+tetracycline+furazolidone 14 days|VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
75453508|NCT06168214|Drug|Vonoprazan+tetracycline+furazolidone 7 days|VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
75604486|NCT04253431|Device|BGStar lancing device (Sanofi Aventis)|
75604487|NCT04253431|Device|Ultra-Fine 33G lancets (BD)|
75604488|NCT04253431|Device|Droplet 33G lancets (HTL-Strefa S.A.)|
75604489|NCT04253431|Device|OneTouch Delicia Extra Fine 33G lancets (LifeScan)|
75604490|NCT04253431|Device|HaemoFine 33G lancets (HTL-Strefa S.A.)|
75604491|NCT04253431|Device|Softclix 28 G lancets (Roche)|
75604492|NCT04253431|Device|ReliOn Ultra-Thin Plus 33G lancets (ReliOn)|
75604493|NCT04253431|Device|GlucoJect Dual S lancing device (Menarini)|
75604494|NCT04253431|Device|Microlet 28G lancets (Bayer)|
75604495|NCT04253431|Device|BGStar Ultra-Thin 33G lancets (Sanofi Aventis)|
75604496|NCT01216176|Drug|Anastrozole|
75604497|NCT01216176|Drug|AZD0530 (saracatinib)|
75604498|NCT01216176|Drug|Placebo|
75604499|NCT05330845|Biological|IL6 assessment|Blood IL6 will be assessed during trial
75749285|NCT05892081|Biological|Colloidal oatmeal|The colloid oatmeal had the following component: Colloidal Oat (5gm), stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
75749286|NCT05892081|Biological|Cold cream|It is composed of stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
75749287|NCT05891860|Other|Participation in virtual rounds|Virtual participation in daily ICU team rounds
75749288|NCT05885737|Drug|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
75749289|NCT05885737|Drug|Placebo Injection|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
75749290|NCT05876611|Device|New type of self stabilizing atlantoaxial fusion cage|Using the above-mentioned new fusion cage for the treatment of atlantoaxial dislocation
75749291|NCT05875636|Other|Esophagogastroduodenoscopy|All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.
75749292|NCT05869721|Other|Yoga|The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
75749293|NCT05861856|Other|Manual therapy|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
75899234|NCT02293148|Drug|GSK1278863 500 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
75749294|NCT05861856|Other|Virtual reality|Virtual reality supported core stabilization exercises will be performed.
75749295|NCT05859100|Other|≥ 2 eggs in addition to usual diet for 8 weeks|Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.
75453509|NCT06168214|Drug|Vonoprazan+amoxicillin+furazolidone 7 days|hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.
75749296|NCT05859100|Other|≥ 2 eggs in addition to usual diet for 4 weeks|Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
75749297|NCT05855577|Drug|Terazosin|Treatment of Terazosine vs placebo and Lisosan-G vs placebo in cross-over double-blind, double-dummy
75749298|NCT05832177|Behavioral|Cancer CientoUno (101) program|The Spanish version of Cancer 101 consists of several modules that address cancer control and prevention, risk factors, early detection and screening guidelines, cancer diagnosis and stages, cancer treatment, cancer and genetics, cancer and chronic disease, patient and caregiver support, HPV, biobanking, and clinical trials. All modules contain a written summary with learning objectives, a PowerPoint presentation, pre- and post-module evaluations with an answer sheet, a glossary, references, and supplemental resources. This program will occur on an ongoing basis.
75749299|NCT05832177|Behavioral|Latinos y el cáncer/Hablemos de cáncer (Translation in English: Latinos and Cancer/Let's Talk About Cancer)|This is a biennial cancer symposium focused on cancer topics important to Hispanic/Latinos. This day-long event includes a plenary session and concurrent sessions where healthcare professionals present educational information about cancer, cancer prevention, early detection methods, and other related topics.
75749300|NCT05832177|Behavioral|¡Salud! Serie de Charlas (Translation in English: Health! Talk Series)|This is an educational and community outreach effort comprised of local charlas (talks) led by Hispanic/Latino healthcare professionals (e.g., the partnership Community Health Educator [CHE], topic experts) who provide education and answer questions about specific cancer topics. The charlas may be conducted in multiple modalities (in person, virtual, hybrid) and may be conducted in English and/or Spanish. At least three events will be held each year in the partnership locations.
75749301|NCT05832177|Behavioral|Community/Researcher Forum: El Puente (Translation in English: The Bridge).|The main goal of the El Puente annual event is to generate dialogue between community members and researchers about cancer treatment and cancer-focused research topics. During El Puente's presentations, researchers present their projects and data results to community members, allowing community members to react to the research, make suggestions, and express concerns.
75899235|NCT02293148|Drug|Moxifloxacin 400 mg|Oblong, dull red, film-coated, convex tablets with M400 on one side
76066107|NCT06133556|Drug|MCBC regimen|using MCBC as conditioning regimen, Mel 60mg/ m2 -9~-8d, Cladribine 5 mg/m2 -9~-5d, Bu3.2mg/kg -5~-3d； Cy 30mg/kg -2~-1 d
76066108|NCT06133556|Drug|Bu/Cy regimen|control group, the standard conditioning regimen Busulfan/Cyclophosphamide
75453510|NCT06168214|Drug|Vonoprazan+amoxicillin+tetracycline 14 days|hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.
75453511|NCT06168214|Drug|Vonoprazan+amoxicillin 7 days|hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
75453512|NCT06168214|Drug|Vonoprazan+amoxicillin 14 days|hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
75899236|NCT02293148|Drug|Placebo matching GSK1278863|A round, biconvex, white film coated tablet as matching placebo for GSK1278863
75899237|NCT02293148|Drug|Placebo matching Moxifloxacin|Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
75899238|NCT05283447|Other|Osteopathic Medicine|The clinical protocol subject to analysis for the intervention group consists of manual approach techniques for the myofascial and viscerofascial structures of the anterior face of the neck, maneuvers for the mediastinal region, techniques for normalizing the tone of the thoracic diaphragm and its pillars, on the peritoneal ligaments, and caudal traction of the stomach for manual correction of hiatal hernia.
75899239|NCT05283447|Other|Control|The physiotherapeutic treatment on the control group consists of an approach to the lumbopelvic joint restrictions and a massage on the inframesocolic abdominal region with minimal pressure, which does not affect the activity and position of the stomach.
75899240|NCT02300090|Device|Test Group|Patients receive a mobile phone with the Me & My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.
75899241|NCT02300090|Other|Control Group|Patients in the control group receive only standard care; there are no interventions within this group of patients
75899242|NCT03643887|Drug|FMT Capsule DE|30 capsule one-time oral dose
75899243|NCT03643887|Drug|Placebo oral capsule|30 capsule one-time oral dose
75453513|NCT06167876|Radiation|Stereotactic Body Radiotherapy (SBRT) Treatment|The intervention in this study utilizes Stereotactic Body Radiotherapy (SBRT) for treating Hypertrophic Obstructive Cardiomyopathy (HOCM). The process begins with precise localization and planning, employing CT scans, Cardiac MRI (CMR), and echocardiography to accurately identify the target area in the interventricular septum, while avoiding critical structures like the aortic valve, His bundle, and left ventricular papillary muscles. Pre-treatment preparation involves using customized fixation devices to limit patient movement and breathing, coupled with cone-beam CT scans for accurate alignment with the Treatment Planning System (TPS). The treatment itself is delivered using image-guided linear accelerators, administering a single, focused dose of 25 Gy to the targeted area. This approach ensures precise radiation delivery, maximizing treatment efficacy while minimizing risks to surrounding cardiac tissues.
75453514|NCT06167876|Other|Sham Procedure|The sham procedure in this study is designed to closely mimic the actual Stereotactic Body Radiotherapy (SBRT) process without delivering any radiation. Participants in this arm are subjected to the same initial steps as those in the SBRT group, including precise alignment with the linear accelerator using CT scans and the application of customized fixation devices to limit movement and breathing. However, in this sham intervention, the linear accelerator is activated but does not emit any radiation. The procedure replicates the environmental aspects of the actual treatment, such as the equipment's sounds and lighting, to maintain the study's single-blind nature. This method ensures that participants in the sham group experience a procedure identical in appearance and feel to the SBRT treatment, without receiving any therapeutic dose, thereby serving as an effective control for evaluating the true impact of SBRT in treating HOCM.
75604500|NCT05330845|Biological|CRP and PCT assessment|Blood CRP and PCT will be assessed during trial
75604501|NCT01133847|Drug|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
75604502|NCT01133847|Behavioral|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
75604503|NCT01133847|Behavioral|Parent Training|Nine sessions on parenting a child with ADHD
75604504|NCT01133847|Drug|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
75604505|NCT01133847|Drug|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
75604506|NCT01133847|Drug|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
75899244|NCT03640923|Other|a swab of mucous membrane|a swab of mucous membrane in oredre to analyse the genome
75899245|NCT03519152|Drug|low dose diclofenac|it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
75899246|NCT03516344|Procedure|Liver pumping and Spinal manipulation|Interventions are described in group descriptions
75899247|NCT02300168|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
75899248|NCT02959983|Drug|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
75899249|NCT02959983|Drug|Placebo|Placebo matching eluxadoline oral tablets BID with food.
75899250|NCT02293226|Device|CoopDech|Video-laryngoscopy 1
75899251|NCT02293226|Device|CoPilot|video-laryngoscopy 2
75899252|NCT02293226|Device|Intubrite|Video-laryngoscopy 3
75899253|NCT02293226|Device|Vividtrack|video-laryngoscopy 4
75749302|NCT05832177|Behavioral|Lunch and Learn Updated Recommendations Series.|This is a virtual podcast that will discuss cancer-related recommendations and guidelines from the United States Preventive Services Task Force (USPSTF). The podcasts are pre-recorded, 30 minute long, and will be in English and/or Spanish. This podcast will be hosted by the Outreach Core (OC) CHE, and feature experts who will explain the updated recommendations and active steps that community members and providers can take to facilitate adherence. This activity will begin according to the project timeline
75604507|NCT05000125|Diagnostic Test|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
75604508|NCT02887950|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
75604509|NCT02887950|Dietary Supplement|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
75604510|NCT02887950|Dietary Supplement|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
75749303|NCT05832177|Behavioral|Community Engagement (CE) Training Program for U54 Partnership Investigators|This is a series of 2 1/2-day CE workshops designed and delivered up to 20 partnership researchers (including faculty and junior investigators) delivered across four sessions per year (6 to 10 researchers per year). Each session includes two hours of lectures (didactic material) and one hour of practice activities (practical application of the theoretical content). Session topics will include CE: concepts and principles, theoretical roots, levels, and ethics. The OC team will provide educational materials and additional references in each session.
75453515|NCT06166914|Drug|Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml)|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml).
75453516|NCT06166914|Drug|Placebo|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
75453517|NCT06166407|Other|no intervention|no intervention
75453518|NCT06166355|Behavioral|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
75453519|NCT06166355|Behavioral|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
75604511|NCT02883075|Other|Supine position|Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration
75604512|NCT02883075|Other|Right lateral position|Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration
75604513|NCT02883075|Other|Left lateral position|Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
75604514|NCT04984525|Drug|SYNB1934|SYNB1934 is formulated as a nonsterile solution intended for oral administration
75604515|NCT04984525|Drug|SYNB1618|SYNB1618 is formulated as a nonsterile solution intended for oral administration
75604516|NCT01133379|Device|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
75604517|NCT01133379|Device|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
75899254|NCT03513146|Procedure|Oropharyngeal Administration of Mother's Milk (OPAMM)|0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol
75899255|NCT03518996|Device|rTMS/iTBS/tACS|Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
75604518|NCT01133379|Device|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
75604519|NCT04259437|Other|High Protein, Energy Dense Nutritional Supplement|Ready to drink oral supplement
75604520|NCT04259515|Drug|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
75604521|NCT04259515|Drug|Buckberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
76066109|NCT06133543|Procedure|Robot-assisted ICG-guided sentinel lymph node biopsy|The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
75604522|NCT04259671|Device|My Autism Passport (MAP) Application|Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. MAP is a mobile alternative to the paper version, and offers additional benefits such as the ability to set reminders, see regional developmental service agencies and other resources on a map, and directs the caregiver to information so that they may further their understanding about how to support their child.
75604523|NCT01132755|Procedure|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
75604524|NCT04312035|Procedure|end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of increasing extensibility of the periarticular tissues
76066110|NCT06133530|Dietary Supplement|Human milk oligosaccharides|Prebiotic
75453520|NCT06166355|Behavioral|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
75453521|NCT06165978|Behavioral|Self-monitoring|pedometer/activity band provided to each participant
75604525|NCT04312035|Procedure|Non end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of alleviating pain
75604526|NCT04312035|Procedure|Control|hands-on cutaneous technique
76066111|NCT06133530|Dietary Supplement|Maltose|Control
76066112|NCT06133517|Drug|Sacituzumab govitecan|Sacituzumab govitecan is administered at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle.
76066113|NCT06133517|Drug|Zimberelimab|ZIM is administered at 360 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
76066114|NCT06133517|Drug|Domvanalimab|DOM is administered at 1200 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
75453522|NCT06165978|Behavioral|Goal setting and review|Goal setting and review (weekly: +15% of the previous week's average daily steps or walking time, or +1000 steps/day or +10 minutes walking - to be specified)
75453523|NCT06165978|Behavioral|Education|Educational sessions (face-to-face: providing a manual/explanatory brochure of the intervention; remote: addressing symptom pathophysiology, symptom management, among other topics)
75453524|NCT06165978|Behavioral|Feedback|Daily or weekly feedback for patients (emotional/social support)
75453525|NCT06165978|Behavioral|Contact|Contact with patients (face-to-face: for assessments; on remote: 1 -messages: for therapists' daily/weekly feedback or patient reports; 2 - calls: to adjust weekly goals or address doubts or issues)
75453526|NCT06165978|Behavioral|Exercise|Exercise based on patient preference, explaining how to identify moderate intensity (HRmax=64-76%, Borg 3-6) or vigorous intensity (HRmax=77-95%; Borg 7-8) and monitoring safety parameters (StO2>88%, HRmax<96%, Borg<9)
75604527|NCT04311957|Drug|Continuation of boosted PI|"Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs"
75604528|NCT04311957|Drug|B/F/TAF|Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
75604529|NCT02882997|Behavioral|an interactive computer game|Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
75604530|NCT02882997|Behavioral|standard activities|For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
75604531|NCT00637455|Drug|fexofenadine HCl|
75749304|NCT05832177|Behavioral|Community Advisory Panels (CAP)|These CAPs work closely with the (CHE) to oversee the identification, development, and coordination of the outreach activities; provide advice on the development and implementation of community needs and assessments; provide guidance for recruitment and retention of research participants; and assist in the recruitment for educational events and research and vetting community educational materials and the content of protocols for research projects.
75453527|NCT06165978|Behavioral|Report|Daily or weekly reporting for therapists (messages)
75453528|NCT06165978|Behavioral|Social support|Support meetings (in-person), parallel to educational sessions
75604532|NCT00919711|Drug|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
75604533|NCT00919711|Drug|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
75749305|NCT05832177|Behavioral|Research Corner|The goal is to provide bidirectional communication between the community and researchers to increase CE strategies into cancer disparities research through periodic meetings between community members and researchers to discuss CE strategies, research recruitment strategies, dissemination strategies, among others.
75604534|NCT01131585|Procedure|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
75749306|NCT05832177|Behavioral|Community-based Training Program (CBTP) for Community Leaders and Stakeholders.|The CBTP provides the opportunity to acquire knowledge to impart cancer prevention education (Cancer 101) and skills necessary to disseminate educational information (hands-on experiences through OC educational activities). This training will be provided in-person and remotely to increase participation. This activity will begin according to the project timeline.
76066115|NCT06133491|Biological|Daxibotulinumtonix A|SQ injections of 10u per site will be given over standard landmarks (18 sites) to patients who consent and are found eligible.
76066116|NCT06133426|Device|"Connected scale Body Comp Pro from Withings"|Use once a day from inclusion to week 7.
75453529|NCT06165978|Behavioral|Group activities|Group activities (e.g., walking on familiar routes - parks, monumental areas, etc.)
75604535|NCT01131585|Drug|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
75604536|NCT01131585|Drug|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
75749307|NCT05832177|Behavioral|Integrate Cancer 101 into the Stakeholders Programs|This program will offer stakeholders a no-cost workshop of three credit hours to increase cancer prevention education among Hispanic/Latinos. CMEs will be provided virtually to increase participation. This activity will begin according to the project timeline.
76066117|NCT06133413|Device|Body Comp Pro connected scale (Withings manufacturer)|Use once a week
76066118|NCT06133413|Other|Alert generation by remote plateform|Alert will be generated from weight regain > 5% of baseline weight
75453530|NCT06165978|Behavioral|World Health Organization recommendations for being physically active|World Health Organization's recommendations to maintain physical activity levels (i.e., 150-300 minutes/week of moderate to vigorous intensity physical activity; a weekly average of 10,000 steps/day or 100-120 minutes walking, which implies maintaining a pace of 100 steps/minute - corresponding to the average cadence across different age and gender groups).
75604537|NCT01131507|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
75604538|NCT01131351|Drug|Delamanid|OPC-67683 film-coated tablets
75749308|NCT05832177|Behavioral|Community Engagement (CE) Training Program for Lay Community Members|A series of two-day CE workshops designed and delivered to 30 lay community members over a four-year period (6 to 10 participants per year). The proposed CE workshops includes: 1) CE principles, 2) cancer prevention education principles, and 3) community-based promotion strategies for cancer prevention. This activity will begin according to the project timeline.
75749309|NCT05832112|Procedure|VATS/RATS lobectomy|"Consenting patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, aside from the ports that will be placed in the subcostal plane. The characteristics of both the patient and the case, will determine the number of incisions from 1-4.~The Davinci Xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. Once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. A 24 Fr soft chest tube will be left in place, as in the standard VATS/RATS lobectomy procedure. The incision closure will be done in a standard manner."
75749310|NCT05829564|Other|virtual reality|The individuals participating in the study will experience virtual reality.
75749311|NCT05829564|Other|cervical mobilization|The individuals participating in the study will be applied cervical mobilization techniques.
75453531|NCT06163690|Combination Product|Endourage Targeted Wellness Formula C™, a full hemp flower extract|A hemp-derived formulation designed as a daily use adjunctive therapy to help improve Long COVID symptoms. Endourage Targeted Wellness Formula C™ are used as sublingual drops held under the tongue for 60 to 90 seconds.
75749312|NCT05829564|Other|exercise|The individuals participating in the study will performed neck-specific exercises.
75749313|NCT05829330|Other|Outpatient|Outpatient Initiation of noninvasive mechanical ventilation
75749314|NCT05829330|Other|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
75749315|NCT05816031|Dietary Supplement|Ketogenic diet|Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy
75749316|NCT05809752|Biological|Dendritic Cell Vaccine|"Intrathecal (IT) dendritic cell vaccine (DCV) will be administered once every week. As per standard procedures of IT chemotherapy or antibody administration it is administered over 5 -10 minutes or at 1 ml/minute while monitoring the patient under sterile conditions. In general, to assure delivery of the DCVs into the ventricular space and compensate for dead space in the Ommaya, the delivery of IT DCV cells is followed by the administration of 2.5 mls of saline. In general there is a maximum volume of 10 mls of DCVs."
75749317|NCT05809453|Drug|Cocaine|Cocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
75749318|NCT05809453|Drug|Lidocaine|Lidocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
75749319|NCT05809219|Other|1 hour combined intervention ( Exercise and nutrition)|Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.
75749320|NCT05809219|Other|3 hours combined intervention ( Exercise and nutrition)|"All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them."
75749321|NCT05809219|Dietary Supplement|Nutrition intervention|"Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
75899256|NCT03518996|Device|Sham TMS/tACS|Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
75899257|NCT01344447|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
75453532|NCT06162637|Device|femoral neck locking plate|femoral neck fractures fixation by femoral neck locking plate
75453533|NCT06162637|Device|multiple cannulated cancellous screws|femoral neck fractures fixation by multiple cannulated cancellous screws
75453534|NCT06162611|Drug|Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg|Single pill of oral levonorgestrel 1.5mg X 1 dose (e.g. Plan B) same day as contraceptive implant insertion
75604539|NCT01131351|Drug|Optimized Background Regimen (OBR)|OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
75604540|NCT04311879|Device|Soft tissue Diode laser application|post-operative soft tissue diode laser application
75604541|NCT04311879|Other|Placebo|mock diode laser application
75604542|NCT00919633|Drug|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
75604543|NCT00919633|Drug|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
75604544|NCT00919633|Drug|ribavirin, USP|All patients will receive oral ribavirin
75453535|NCT06162611|Device|Etonogestrel implant with oral placebo|Single pill of placebo same day as contraceptive implant insertion
75604545|NCT00919633|Device|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
75604546|NCT04311801|Diagnostic Test|Optical Coherence Tomography|Every patient underwent OCT examination before and after surgery.
75604547|NCT05143905|Drug|AZD7503|Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
75749322|NCT05808530|Behavioral|Cognitive Stimulation Therapy|"CST involves the use of standard tasks that focus on cognitive functions, designed to meet varying levels of difficulty in accordance with the individual's ability and rehabilitation. A detailed guide for CST is available for a range of health and care professionals, including care workers, occupational therapists, psychologists, and nurses (https://www.ucl.ac.uk/international-cognitive-stimulation-therapy/) publications/cst-manuals). The CST application consists of 14 sessions of 45-50 minutes, 2 days a week.~Intervention Group Week 1=Getting acquainted and applying pre-tests Week 2=Physical games and Sounds Week 3=Childhood and Food Week 4=Current events and Faces / Scenes Week 5=Word association and Creativity Week 6=Categorizing Objects and Orientation Week 7= Money usage and Games Week 8=Word Games and Team Competition Week 9=Closing and post-test application"
75453536|NCT06161181|Device|Decision Support System|"TREAT (TREatment Adherence SupporT) is a web-based DSS that comprises four sections:~i) Metastatic Breast Cancer: contains information about MBC and its physical and psychological consequences;~ii) Adherence to Cancer Therapies: contains information about adherence in the cancer population;~iii) Promoting Adherence: contains information about resources, barriers, and available interventions used to foster adherence;~iv) My Adherence Diary."
75769401|NCT03909880|Device|kinesio tape|Kinesio taping(kinesio taping;kinesio holding corporation,USA) is given between the pretest and the posttest. The taping is operated by a physical therapist who is the co-host of this experiment in 614 room, Research Building, National Yang-Ming University. Posttest will be started immediately after taping. After posttest, kinesio tape will be removed. There are 3 types of taping conditions. Kinesio tape is pulled from 5 cm distal wrist joint line to medial epicondyle and 5 cm at both ends of the head and tail without tension .All participants will receive all conditions of taping. They will be randomly assigned to any taping conditions. In order to wash out the effect of taping, the interval of any condition is at least 7 days.
76066119|NCT06133387|Device|ELS System|The intended endoluminal resection procedures of the ELS System are partial thickness local excision procedures (resection of a lesion without removing a large colon segment or the entire colon).
76066120|NCT06133361|Biological|PRP injection|The PRP will be prepared according to a well-established technique and then injected into the palatal mucosa of the upper anterior teeth before retraction.
75453537|NCT06157749|Other|Gait analysis|It will be carried out on a 10-meter flat surface, with the participant walking at normal walking speed.
75453538|NCT06157697|Behavioral|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Based on the monthly minimum wage in Brazil and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately 100 USD would fairly subsidize women's breastfeeding efforts. Therefore, all social transfer options equate to approximately 100 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
75453539|NCT06157502|Drug|Shuxuening Injection|Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
75453540|NCT06157502|Other|Placebo|Receiving 20 ml placebo Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days.
75453541|NCT06156722|Procedure|Sperm selection by IMSI|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI)
75604548|NCT05143905|Drug|Placebo|Randomised participants will receive placebo by SC injection
75604549|NCT04859647|Other|Method of Levels Therapy|MOL is a flexible, client-led psychological therapy that allows people to talk freely about important problems and life goals.
75604550|NCT04255225|Behavioral|Walking for 10 minutes|Participants will walk on a treadmill for 10 minutes at a moderate intensity.
75604551|NCT04255225|Behavioral|Walking for 20 minutes|Participants will walk on a treadmill for 20 minutes at a moderate intensity.
75604552|NCT04255225|Behavioral|Walking for 30 minutes|Participants will walk on a treadmill for 30 minutes at a moderate intensity.
75604553|NCT00926029|Drug|Fluoride|Brush twice daily
75604554|NCT00926029|Drug|Triclosan, fluoride|Brush twice daily
75604555|NCT00926029|Other|Metal salt|Brush twice daily
75604556|NCT04254835|Drug|Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein|Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
75604557|NCT04254835|Drug|Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein|Conventional Fluoride varnish
75604558|NCT04254991|Diagnostic Test|ImmunoXpert™|The ImmunoXpert™ technology employs a biochemical assay that measures a proprietary combination of three biomarkers of the immune system coupled with pattern recognition algorithms that classify the source of an infection as bacterial or viral
75453542|NCT06156722|Procedure|Sperm selection by IMSI and spermslow|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI) + spermslow
75453543|NCT06155656|Other|Pea protein concentrate|Ingestion of a soup containing 25 g of protein from pea protein concentrate
75453544|NCT06155656|Other|Pea protein isolate|Ingestion of a soup containing 25 g of protein from pea protein isolate
75453545|NCT06155656|Other|Pea protein extrudate|Ingestion of a soup containing 25 g of protein from pea protein extrudate
75453546|NCT06155656|Other|Whey protein|Ingestion of a soup containing 25 g of protein from whey protein
75453547|NCT06152172|Drug|KYV-101|The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
75453548|NCT06152172|Drug|Cyclophosphamide|Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2 and fludarabine (FLU) 30 mg/m2 intravenously (IV)
75453549|NCT06152172|Drug|Fludarabine|Fludarabine (FLU) 30 mg/m2 intravenously (IV)
75453550|NCT06148662|Other|No intervention (negative control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds."
75453551|NCT06148662|Other|Water (positive control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds. Then, participants will to rinse their mouth with tap water 60 seconds."
75453552|NCT06148662|Drug|"Dental foam Biorepair PERIBIOMA"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
75604559|NCT04980547|Device|ACUMED® Scapholunate Repair System Group|To address the technical difficulties associated with the RASL procedure, Dr. Mel Rosenwasser developed an external over-the-top jig that in theory enables accurate and easy scapholunate-axis screw placement. The Acumed Scapholunate Repair System was designed treat patients with acute or chronic, static or dynamic scapholunate instability in the absence of significant capitolunate osteoarthritis, scapholunate ligament repair, scapholunate reduction, lunotriquetral ligament repair, lunotriquetral reduction, and carpal instability. This new Scapholunate Repair System features a targeting guide designed to enable the surgeon to reproducibly place the implant in optimal position. The implant allows physiologic intercarpal scapholunate rotation by means of a free rotation design. The procedure can forestall progressive osteoarthritis and the need for secondary salvage procedures.
75604560|NCT04254757|Procedure|Two different treatment|One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery
75749323|NCT05803889|Other|Cardiac evaluation|In order to obtain information on the body composition of the patients, a body composition measurement will be performed. A resting cardiac echocardiography will be performed to record myocardial deformations in a non-vulnerable way. A non-invasive evaluation of arterial function will be performed by ultrasound on the femoral artery during a standardized passive movement of the leg. An assessment of myocardial deformations will also be performed under submaximal exercise conditions (at a target heart rate of 120 beats per minute, low to moderate exercise intensity). All of these measurements will be performed during evaluation 1 and reproduced in the same way during the 4 other sessions planned during (evaluation 2, 3 and 4) and after the treatment (evaluation 5).
75749324|NCT05803889|Other|Cardiac evaluation|The same measurements as the EC + Tax group will be performed but only once, at the end of the treatment.
75749325|NCT05778448|Device|Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality|A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).
75749326|NCT05773703|Drug|PSMA-Targeted [In-111]-Labeled Trillium Compound|Radiotracer
75453553|NCT06148662|Drug|"Dental foam WATER:DENT"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam WATER:DENT to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
75453554|NCT06148662|Drug|"Dental spray BUCCOTHERM"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
75453555|NCT06145789|Other|standing powered wheelchair evaluation|standing powered wheelchair evaluation
75453556|NCT06144294|Other|Whole-Body Hyperthermia|The Clearlight dome sauna is portable infrared sauna consisting of two lightweight domes and an infrared heating pad. The sauna will be used to deliver the intervention to the participant and the sauna session will end as soon as (1) an internal body temperature of 38.5 C (101.3 F) is reached for two consecutive minutes or, (2) 140 minutes have passed.
75604561|NCT01130493|Drug|IPX066|experimental product
75604562|NCT01130493|Drug|CLE|active comparator
75453557|NCT06144294|Diagnostic Test|fMRI|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain.
75604563|NCT04255069|Drug|Placebo|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
75604564|NCT04255069|Drug|Dose 1 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
75749327|NCT05773703|Drug|PTI-122|Cytoprotective agent
75749328|NCT05772520|Drug|TLL018 tablets|oral tablets administered BID for 12weeks
75749329|NCT05771545|Other|Telepsychiatry|Instead of coming to the hospital physically, the attending psychiatrist will evaluate the patient via a video-link.
76066121|NCT06133361|Procedure|En-masse retraction of upper anterior teeth|The anterior teeth will be moved backward in an en-masse retraction way using a frictionless method. The anterior teeth will be manipulated as one block. Coil springs will be stretched between the power arms (in the anterior area) to the miniscrews placed in the posterior area bilaterally.
75453558|NCT06144281|Behavioral|Nudge for PHPC NP Referral|The attending and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for home palliative care services upon hospital discharge will be asked to refer their patient for these services.
75453559|NCT06138054|Behavioral|MI-CBTech|"Three in-person MI sessions focused on identifying goals for community integration (in the areas of vocational, recreational, social, or independent living activities) and unhelpful thinking that tends to get in the way of those goals, building motivation for goals, introducing participants to the CBT model and its potential benefits, and downloading and orienting them to the mobile phone application.~Six weeks of mobile phone application use to guide participants through CBT. Weekly content will be provided to learn and practice CBT skills to address unhelpful thinking and problem solving to address obstacles to goal attainment. There will be brief content pages worksheets to guide participants through practice. The worksheets will be tailored to each participant, framing the skills around their pre-identified goals and unhelpful thinking patterns. The application will also include access to crisis resources."
75604565|NCT04255069|Drug|Dose 2 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
75604566|NCT04253275|Genetic|blood samples|"Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls."
75604567|NCT04253275|Diagnostic Test|MRI without injection|MRI at inclusion for controls
75749330|NCT05768789|Dietary Supplement|Buoy Electrolyte|Buoy intervention amount is 4% of total body weight given in 16 divided doses over 4 hours.
75604568|NCT04252651|Other|Blood Draw|This study will involve blood draws to test for specific cytokines
75604569|NCT01130337|Drug|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
75604570|NCT01130337|Drug|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
75604571|NCT01130337|Drug|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
75604572|NCT04901689|Drug|Leronlimab|Leronlimab 700 mg
75604573|NCT04901689|Drug|Placebo|Placebo
75604574|NCT04252963|Drug|MUCOLASE tablet (streptokinase • streptodornase)|streptokinase • streptodornase 5mg
75604575|NCT04252963|Drug|Placebo|Placebo of MUCOLASE tablet
75604576|NCT04258657|Drug|paclitaxel-albumin and S-1|neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
75749331|NCT05768789|Dietary Supplement|Nuun|Nuun intervention given as 1L bolus and then free water in divided doses for a total of 4% total body weight.
75749332|NCT05768789|Other|Water|Water serves as a control
75749333|NCT05763589|Other|No intervention is involved|No intervention is involved
75749334|NCT05760742|Dietary Supplement|MicAlgae|2 months of supplementation with an innovative microalgae based ingredient
75749335|NCT05760742|Dietary Supplement|Placebo|2 months of supplementation with a placebo (Maltodextrin)
75749336|NCT05756686|Behavioral|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
75749337|NCT05756686|Behavioral|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
75769402|NCT03909568|Procedure|Third molar surgery|Comparing complete removal of third molar with removal of crown only on contralateral side
75769403|NCT03969342|Device|Point of care ultrasound training|Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
75899258|NCT03516188|Drug|Alginate-antacid group|Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)
75453560|NCT06138054|Behavioral|Mindfulness control|"Three in-person supportive therapy sessions focused on empathic listening during client-led discussions of presenting concerns, introducing participants to mindfulness (defined as noticing and paying attention to the present moment without judgment), and downloading and orienting them to the mobile phone application. Participants will be informed of potential benefits of mindfulness, including stress reduction and increased self-awareness.~Six weeks of mindfulness training mobile application use to help participants learn to practice mindfulness through a gradual, self-guided training program. The application offers a library of information about mindfulness, 12 different audio-guided mindfulness exercises, goal-setting and tracking, customizable reminders, and access to crisis resources."
76066122|NCT06133335|Other|Periodontal examination|"Periodontal examination is performed using PCP UNC15 periodontal probe (common diagnostic method not added by research).~Gingival smear from various points in the oral cavity. This intervention consists in a smear of gingival area with an absorbent paper point into the space between the gum and the tooth (Jourdain et al. 2018). The objective of this technique is to remove the various elements of the periodontal pocket and in particular the desquamated cells."
75604577|NCT04252729|Procedure|Psychotherapy|Psychotherapy sessions based on Psychoanalytic Psychosomatics
75604578|NCT01130103|Drug|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
75604579|NCT01130103|Behavioral|Prolonged Exposure Therapy|Weekly for 10 weeks
75604580|NCT04254523|Device|Programmed intermittent epidural bolus (PIEB) of bupicavaine|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
75604581|NCT04254523|Device|Continuous epidural infusion (CEI) of bupivacaine|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
75604582|NCT04254523|Device|Continuous epidural infusion (CEI) of morphine|A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.
75604583|NCT02882919|Behavioral|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
75899259|NCT03516188|Drug|Non antacid alginate group|Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
76066123|NCT06133322|Behavioral|Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension
75453561|NCT06135714|Drug|Systemic therapy for 12 weeks after primary registration|"Luminal BC~Denovo stage IV~Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~Postmenopausal(POST): AI + CDK~Recurrence after completion of postoperative endocrine therapy~PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~POST: AI + CDK, or FUL + CDK~Recurrence during postoperative endocrine therapy~PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~POST: FUL + CDK~HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~PD-L1 negative - following a) or b)~Taxane (naive for taxane)~S-1 or Capecitabine or Eriblin (previously treated with taxane)~PD-L1 positive - following a) or b)~Pembrolizumab + Gemcitabine + Carboplatin~Atezolizumab + Nab-paclitaxel~BRCA-mutation positive Olaparib"
75453562|NCT06135714|Procedure|Radiation therapy (SBRT/conventional RT)|Brain: 18-24Gy/1Fr. or 27Gy/3Fr. or 30Gy/5Fr. Lung: 42Gy/4Fr.(peripheral) or 50Gy/8Fr.(central) or 60Gy/25Fr.(ultra central) Liver/Adrenal: 40Gy/5Fr. Bone: 35Gy/5Fr. Distant lymph node: 45/10Fr. or 60Gy/25Fr.
75604584|NCT04258501|Other|Mulberry fruit|
75604585|NCT04258501|Other|Mulberry leaf|
75604586|NCT04258501|Other|White bean|
75604587|NCT04258501|Other|Apple|
75604588|NCT04258501|Other|Elderberry|
75604589|NCT04258501|Other|Turmeric|
75604590|NCT04258501|Other|Rice porridge|
75604591|NCT00625209|Drug|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
75899260|NCT03513068|Device|Portable Oxygen Concentrator (POC)|COPD patients prescribed with LTOT will be randomized to receive a portable oxygen concentrator (POC)
75899261|NCT03516110|Other|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.
75899262|NCT02293304|Other|Self-etch approach|The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
75899263|NCT02293304|Other|Etch-and-rinse approach|After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
75453563|NCT06135714|Procedure|Surgery|Surgery for the oligometastases
75604592|NCT00625209|Drug|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
75453564|NCT06135714|Drug|Same systemic therapy after secondary registration|"Luminal BC~Denovo stage IV~Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~Postmenopausal(POST): AI + CDK~Recurrence after completion of postoperative endocrine therapy~PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~POST: AI + CDK, or FUL + CDK~Recurrence during postoperative endocrine therapy~PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~POST: FUL + CDK~HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~PD-L1 negative - following a) or b)~Taxane (naive for taxane)~S-1 or Capecitabine or Eriblin (previously treated with taxane)~PD-L1 positive - following a) or b)~Pembrolizumab + Gemcitabine + Carboplatin~Atezolizumab + Nab-paclitaxel~BRCA-mutation positive Olaparib"
75604593|NCT00625209|Drug|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
75604594|NCT00625209|Drug|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
75604595|NCT04254445|Other|Personalized training video|Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
75604596|NCT02882841|Other|Biopsies, stool and blood collection|
75604597|NCT04254601|Device|Narrow band ultraviolet B.|NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
75604598|NCT04254601|Drug|topical erythromycin cream 2% (Akne-Mycin- Egypt)|"two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves"
75604599|NCT01129557|Drug|Aliskiren|
75604600|NCT01129557|Drug|Valsartan|
75604601|NCT04976413|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy|Experimental arm will receive eight phase EMDR treatment using manualized standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12-14 weeks.
75604602|NCT04976413|Behavioral|Counselling as usual|Control arm will receive counseling as usual for 12-14 weeks
75604603|NCT04831567|Radiation|MIBG-I131|Radiopharmaceutical
75604604|NCT04884295|Drug|XVR011|Single dose of XVR011 via intravenous (IV) infusion
75604605|NCT04254679|Drug|Opioid analgesics|"Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
75604606|NCT04254679|Drug|Non-opioid analgesics|"Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
75453565|NCT06135493|Drug|Losartan|Using losartan to prevent paclitaxel-induced peripheral neuropathy
75453566|NCT06127342|Behavioral|Moderate Intensity Exercise|Participants will wear a heartrate monitor and walk on a treadmill at a slow speed for 5 minutes, then slowly jog on a treadmill for 30 minutes, then walk on the treadmill at a slow speed for 5 minutes.
75604607|NCT05330533|Radiation|scrotal duplex|Scrotal colour doppler ultrasonography
75604608|NCT01129011|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
75604609|NCT01129011|Drug|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
75604610|NCT04254211|Other|NLR|neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
75749338|NCT05749094|Diagnostic Test|Optic nerve ultrasound|The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.
75749339|NCT05737082|Drug|HCP2201|Take 2 tablets once per period
75749340|NCT05737082|Drug|RLD2205|Take 2 tablets once per period
75749341|NCT05737082|Drug|RLD2206|Take 1 tablet once per period
75749342|NCT05731934|Drug|HX301|At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
75899264|NCT03621267|Other|Interactive Stepping Exercise|Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment
75899265|NCT03621267|Other|Home exercise program|Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
75453567|NCT06127342|Behavioral|Low Intensity Exercise|Participants will wear a heartrate monitor and walk on a treadmill at a slow speed for 40 minutes.
75899266|NCT03512990|Procedure|Bupivacaine - Superior Trunk Block|It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
75604611|NCT04253041|Behavioral|Effects of Instagram Exposure on Lifestyle Satisfaction|Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
75604612|NCT02882607|Behavioral|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
75453568|NCT06123988|Behavioral|Prolonged Overnight Fasting|"Participants will undergo a 12-week program of prolonged overnight fasting (POF) during which they will abstain from consuming food or drink after 8pm, and wait 12 to 14 hours before resuming eating the next day. Participants will fast overnight for six nights each week, with one night off, and log their fasting start and stop times and timing of food intake daily via text messaging, or via study-provided app accessible by web browser or smart phone, or via paper journal returned by mail at the end of each month.~Participants will also complete one weekly session with a health coach to review their fasting log and any barriers to and/or facilitators of meeting the POF goals. Sessions may be delivered in-person, by telephone, or by video call based on participant preference. Sessions will last 15 to 30 minutes each, for a total of 12 sessions.~Participants will be provided with a notebook with information and support to encourage meeting the POF goals."
75453569|NCT06123988|Behavioral|Moderate-Intensity Exercise|"Participants will undergo a 12-week program consisting of three weekly sessions of moderate-to-vigorous aerobic and resistance exercises, under the supervision of a health coach. Sessions may be delivered either in-person or virtually via telehealth. Sessions will be tailored to the individual participant based on fitness level and symptoms at study entry, and limited to daylight hours as much as possible. Each session will last 30 to 50 minutes, as tolerated by the participant, for a total of 36 sessions.~Participants will receive a Fitbit device to track their activity, and to provide heart rate monitoring during each session. Participants without access to wi-fi will be loaned cellular-enabled tablets to allow them to participate in telehealth sessions. Participants will also receive a notebook with information and support to encourage exercise."
75453570|NCT06123988|Behavioral|General Health Education Sessions|Participants will receive a general health education resource manual at study entry, followed by six bi-weekly sessions with a health coach to review the information. Six topics, one topic for each session, will be selected based on topics of potential interest to a population living with advanced breast cancer, focusing on general nutrition, healthy lifestyle, and quality of life, with no discussion of prolonged overnight fasting or exercise. Each session, administered via telephone or video call, will last about 15 to 30 minutes, and have a specific topic and call script for the health coach to follow to minimize any intervention drift and/or contamination. Participants will receive a Fitbit activity monitoring device and additional study materials at the end of their participation in the study.
75604613|NCT04203589|Behavioral|The Explorer Baby Early Intervention Program|Centered based intervention, once or twice a month, 6 months follow up
75604614|NCT04203589|Other|Neurodevelopmental Therapy|Centered based intervention, once or twice a month, 6 months follow up
75604615|NCT02882763|Other|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
75453571|NCT06123000|Procedure|Modified Widman Flap (MWF)|At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.
75604616|NCT02882373|Dietary Supplement|Arginine|Given PO
75604617|NCT02882373|Drug|Placebo|Given PO
75749343|NCT05730972|Device|Transcutaneous electrical acupoint stimulation|The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.
75749344|NCT05730972|Device|Sham transcutaneous electrical acupoint stimulation|The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, but could not output current normally.
75749345|NCT05730972|Drug|Routine palliative treatment|The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
76066124|NCT06133296|Other|Conventional fixed treatment|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment
75453572|NCT06123000|Procedure|Fiber Retention Osseous Resective Surgery (FibReORS)|At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed.
75453573|NCT06122194|Drug|Drug: PF-07817883|PF-07817883 tablet
75453574|NCT06120985|Device|Countertop pitcher water filter|Point-of-use drinking water filter
75604618|NCT04824781|Other|Qualitative interview|Participants will be interviewed about their experiences of recovery from paranoia.
75604619|NCT04258735|Diagnostic Test|Genomic analysis|WES, RNASeq, ctDNA, Exosome
75899267|NCT05212935|Biological|Rotavirus Vaccine|administration of the 3 doses of Rotavirus human bovine pentavalent reassortant vaccine
76066125|NCT06133296|Other|Clear aligner treatment|After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
76066126|NCT06133283|Behavioral|High intensity endurance exercise|High intensity interval exercise on a recumbent stepper for 30 minutes, 3 days per week.
76066127|NCT06133283|Behavioral|Stretching exercise|Stretches of face, neck, upper extremity, trunk and lower extremity muscles including whole body stretches for 30 minutes, 3 days per week.
75899268|NCT03642093|Combination Product|Nutritional Intervention|Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
75453575|NCT06118359|Behavioral|Intervention to Support Interhospital Transfer Decisions (SITe)|The SITe intervention and implementation toolkit was developed in Aim 1 through stakeholder activities. SITe, an intervention to support interhospital transfer decisions regarding older EGS patients, includes a checklist and script to be utilized by accepting providers during their conversations with referring providers. The investigators and stakeholders also developed a toolkit for implementation with resources to reduce barriers to and support facilitators of utilizing the tools. The toolkit includes: (1) the checklist and script; (2) methods to train accepting providers on the tools including a PowerPoint presentation and demonstration video; and (3) resources to familiarize other parties (transfer center nurses, referring providers, referring hospitals) with the SITe intervention.
75453576|NCT06111742|Device|Bedside Entertainment and Relaxation Theater (BERT)|BERT is a Nebula Capsule Max portable projector that creates a familiar theater experience designed for children to divert attention away from procedures. It is fitted with a remote control that can be utilized to manage on-screen activities. BERT can be used with any wall, ceiling, or projector screen to create the theater experience with a large screen. It can also be used with assist devices, such as steering wheel and noise-canceling headphones.
75604620|NCT04873765|Biological|Pegfilgastrim Megalabs|Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
75604621|NCT04873765|Biological|Pegfilgastim Amgen|Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
75604622|NCT04254055|Other|exercises|Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
75604623|NCT04245241|Other|High-flow nasal cannula (HFNC)|24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).
75604624|NCT04252885|Drug|Lopinavir and Ritonavir Tablets|As indicated in arm/group descriptions
75604625|NCT04252885|Drug|Arbidol|As indicated in arm/group descriptions
76066128|NCT06133283|Behavioral|Virtual reality (VR)-based gaming|VR games will involve games that challenge balance such as reaching different targets during activities such as sit to stand, dodging obstacles etc. Participants will play approximately 6 games for 30 minutes, 3 days a week.
76066129|NCT06133270|Drug|NNC0560-0004|NNC0560-0004, Oral administration (taken through the mouth)
76066130|NCT06133270|Drug|Placebo (NNC0560-0004)|Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
75899269|NCT03642093|Behavioral|Physical Activity Intervention|Walking and Inspiratory Muscle Training
76066131|NCT06133257|Procedure|Goal-Directed Fluid Therapy guided by Inferior Vena Cava Collapsibility Index|Measuring Inferior vena cava(IVC) diameter using ultrasound then calculation Inferior vena cava(IVC) collapsibility index and administer fluid accordingly.
76066132|NCT06133257|Procedure|standard fluid management|standard fluid management
76066133|NCT06133231|Dietary Supplement|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|Participants will take 2-3 capsules of EMP+ two to three times per day for eight weeks.
76066134|NCT06133218|Other|Mepitel Film|A safetac-based barrier film with a clinically insignificant bolus effect to protect the skin during radiotherapy.
75604626|NCT04258345|Other|ASB Feeding Study|Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
76066135|NCT06133205|Other|Catgut Embedding at acupoints|Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
75453577|NCT06111079|Drug|aspirin discontinuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
76066136|NCT06133192|Drug|Uvadex|Uvadex use for ECP
76066137|NCT06133192|Drug|Steroids|steroids 2 mg/kg/d
76066138|NCT06133179|Procedure|Transtemporal ultrasound with contrast product (Sonovue)|"During their hospitalization and in the 7 days following their stroke, all patients will perform a transtemporal ultrasound including the use of Sonovue contrast product.~The examination will last 1 hour and will be carried out on the opposite side of the stroke then on the side of the stroke"
76066139|NCT06133153|Device|THIODERM ELATE|Thiomer-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
75453578|NCT06111079|Drug|aspirin continuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
75899270|NCT02296268|Behavioral|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
75899271|NCT03512912|Device|transcutaneous electrical calf muscle stimulation + supervised walking therapy|transcutaneous electrical calf muscle stimulation + supervised walking therapy
75899272|NCT03512834|Drug|Avelumab|Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity
75899273|NCT03512834|Drug|Paclitaxel|Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.
76066140|NCT06133153|Device|Juvéderm Ultra 3|BDDE-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
76066141|NCT06133127|Other|Frailty assessment|Assessments for all patients : isometric quadriceps strength, malnutrition by RFH-NPT and MNA questionnaires, body composition by circumference and triceps skinfold, frailty by LFI and SPPB, muscle cramps by Cramp questionnaire.
76066142|NCT06133101|Drug|Standard Soy Milk|Consumption of commercially available soy milk
76066143|NCT06133101|Drug|2% Fat Cow's Milk|Consumption of commercially available 2% cow's milk
76066144|NCT06133088|Drug|dalpiciclib; fluvestrant; compound gossypol acetate tablets|"Darcilie: 150mg orally for three weeks and stop for one week. Fluvestrant: 500mg every four weeks. A further 500mg dose two weeks after the first dose.~Compound gossyrol acetate tablet: 20mg daily."
76066145|NCT06133049|Drug|Ozanimod|Women with MS who were exposed to ozanimod during pregnancy
76066146|NCT06133049|Drug|Select DMTs other than ozanimod|Women with MS exposed to select DMTs other than ozanimod during pregnancy
76066147|NCT06133049|Drug|No DMTs|Women with MS not exposed to any DMTs during pregnancy
75453579|NCT06109402|Drug|TQB2450|Specified dose on specified days
75453580|NCT06109402|Drug|Carboplatin|Specified dose on specified days
75453581|NCT06109402|Drug|Pemetrexed|Specified dose on specified days
75453582|NCT06109402|Drug|Nab-paclitaxel|Specified dose on specified days
75453583|NCT06109402|Procedure|Surgery|Surgery for II-IIIB (N2) non-small cell lung cancer
75604627|NCT04252417|Drug|MD1003|Single oral dose administration of MD1003 at Day 1
75604628|NCT02887872|Other|Electrical stimulation-dynamic hand orthosis|Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
75604629|NCT04939207|Diagnostic Test|CT-FFR|CT-images will be processed by an algorithm to calculate FFR-values of the full coronary tree
75453584|NCT06108999|Device|Connettivina BIO cream and gauze|Connettivina Bio cream and gauze-pad efficacy and tolerability will be evaluated in the management of acute or chronic wounds of different etiology, according to instruction for use. Only one wound per patient will be considered for the treatment according to the study protocol. The schedule treatment will consist on a daily medication changes, according to the instruction for use and the clinical practice, for a maximum of 7 Visits.
75604630|NCT04939207|Diagnostic Test|Angiography-derived FFR|FFR-values are calculated during coronary angiography based on the acquired images of the coronary arteries
75749346|NCT05726825|Device|Therapeutic Plasma Exchange (TPE)|"The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure.~Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication.~To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid."
75749347|NCT05724511|Drug|MIYAIRI 588|In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
75749348|NCT05723549|Drug|HCP1803-3|Take it once per period
75749349|NCT05723549|Drug|RLD2002|Take it once per period
75749350|NCT05723549|Drug|HCP1904-1|Take it once per period
75749351|NCT05714930|Other|Treat-to-target as a new treatment concept|After trial initiation, the study personnel in the intervention centers will receive a training on T2T and shared decision making (SDM). Patients in the intervention centers will receive 6-weekly visits for at least 24 weeks with therapeutic adjustments to achieve remission. In case of stable remission for 6 weeks at week 24, the patients switch to 12-weekly visits until the end of the trial at week 120. In case of flare, the patient switches to 6-weekly visits for 24 consecutive weeks. Pharmaceutical treatment decisions will be guided by current treatment standards and will be taken in accordance with SDM between patients and treating physicians.
75453585|NCT06100432|Drug|DLBS5055 200mg|1x1 caplet
75453586|NCT06100432|Drug|Placebo DLBS5055|1x1 caplet
75453587|NCT06100432|Drug|Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)|1x2 caplets
75453588|NCT06100432|Drug|Placebo Multivitamin|1x2 caplets
75453589|NCT06095297|Behavioral|Speed of Processing Training|"Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. In the first level of difficulty, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. This intervention aims to improve the mental processing speed of participants. Trainees receive immediate feedback at the end of each trial, and rest will be provided after trials if necessary. These games will be implemented during training, and participants are also encouraged to practice at home."
75453590|NCT06095297|Behavioral|In-lab Instrumental Activities of Daily Living Training|Participant will receive shaping on IADLS. Participants will receive training on everyday tasks with important cognitive components, in which the difficulty is increased in small steps over the course of treatment.
75604631|NCT04939207|Diagnostic Test|Angiography with invasive FFR-measurements|during coronary angiography, a specialized pressure wire is passed through the coronary stenosis to calculate FFR based on the difference between the actual pressure and the expected pressure in the hypothetical healthy coronary artery.
75604632|NCT04253743|Other|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households with children under age 5 incomes below 75% of the federal poverty level living in Clark County, Nevada received $40 in extra SNAP benefits per eligible child, and access to case management and nutrition education.
75604633|NCT04258189|Drug|JNJ-64417184|Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
75749352|NCT05707702|Biological|Probiotic oral lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
75749353|NCT05707702|Other|Standard of care for oral dysplasia|Oral dysplasia standard of care includes clinical surveillance and risk factor reduction (such as smoking cessation).
75749354|NCT05706610|Behavioral|Tailored Program|Participants in the tailored program will participate in 4 sessions with a coach, 1 every other week. During these sessions, the AYA will work with their coach to identify a barrier to adherence to target and create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text including a reminder about the action plan and a calendar of the AYA's eCAP adherence data.
75749355|NCT05706610|Behavioral|Feedback Program|Participants in the Feedback Program will receive weekly text messages including: a calendar depicting their weekly adherence (per eCAP data) and guidance for requesting additional support as desired.
75899274|NCT03642015|Behavioral|Music listening|listening the music 15 min
75899275|NCT03516032|Behavioral|exercises|
75749356|NCT05706168|Device|treadmill exercise|Treadmill exercise is a form of aerobic exercise training that involves the use of a treadmill machine in a structured exercise programs.
75749357|NCT05706168|Device|Cycle ergometer exercise|Cycle ergometer exercise is a form of aerobic exercise training that involves the use of a stationery recumbent bike in a structured exercise programs.
75749358|NCT05703763|Diagnostic Test|Applanation tonometry|"Applanation tonometry will be used to measure arterial stiffness in these segments, bilaterally:~Superficial temporal artery to frontal temporal artery~Superficial temporal artery to parietal temporal artery~Common carotid artery to frontal temporal artery~Common carotid artery to parietal temporal artery~Common carotid artery to femoral artery"
75749359|NCT05694819|Drug|Darolutamide|Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
75899276|NCT03641781|Other|isometric strength training and isokinetic strength training|"Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps."
75899277|NCT03518762|Procedure|Sustained lung inflation (SLI)|SLI was given using a peak pressure of 20 cm H₂O sustained for 15 seconds,using a T-piece resuscitator, Neopuff device
76066148|NCT06133023|Procedure|Plastic stent|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed."
76066149|NCT06133023|Procedure|LAMS|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed."
76066150|NCT06132997|Procedure|Thoracoscopy procedure|is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.
76066151|NCT06132997|Procedure|Chest tube thoracostomy|Insert chest intercostal tube without thoracoscopy
76066152|NCT06132971|Behavioral|New Beginnings Program|
76066153|NCT06132945|Drug|Cabozantinib|Cabozantinib (40 mg PO daily)
76066154|NCT06132945|Device|Nivolumab|Nivolumab (240 mg IV Day 1 and Day 15)
76066155|NCT06132945|Radiation|Stereotactic Radiosurgery (SRS)|Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.
76066156|NCT06132932|Drug|WX390|Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
75604634|NCT04962841|Other|Nutraceuticals|To observe the effect on cognitive and physical impairment.
75604635|NCT04253197|Device|Ultrasound|Pregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.
75749360|NCT05694819|Drug|Goserelin|Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
75749361|NCT05677425|Other|Temperature measurement|Temperature measurement in the renal pelvis during ureteroscopic laser activation.
75604636|NCT00919867|Drug|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
75749362|NCT05668988|Drug|DZD9008|orally, 300 mg, once daily until a treatment discontinuation criterion is met.
75749363|NCT05668988|Drug|Pemetrexed+carboplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
75749364|NCT05662982|Device|Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS)|A custom-made prosthetic socket for transfemoral amputation that consists of proximal trimlines that do not interact with the pelvis.
75749365|NCT05647213|Biological|iPSC-CL|Autologous IPSCL
75749366|NCT05644600|Drug|Nintedanib|The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
75749367|NCT05644600|Drug|AZD5055|The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
75749368|NCT05643105|Procedure|Any kind of colectomy|This is a registry of surgical patients with colon cancer that are managed following current clinical practice in each participating center. The aim of this research is studying anastomotic leak rates and posible risk factors.
75749369|NCT05639036|Device|Image Guided External Ventricular Drain Placement Using the NAV3 System|Nav3 image guidance system used to assist with external ventricular drain placement
75899278|NCT03518762|Procedure|Continuous positive airway pressure (CPAP)|CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
75899279|NCT03641625|Device|Muscular tissue oxygen saturation guided care|Muscular tissue oxygen saturation monitored at flank and arm will be maintained > 70% (absolute measurement) and > baseline throughout the entire procedure.
76066157|NCT06132906|Procedure|Orthognathic surgery (lefort1)|"All patients will be treated under general anesthesia.~The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~External reference marking~Incision and subperiosteal dissection~Maxillary osteotomy~Pterygomaxillary disjunction,~Septal, vomerine, and lateral nasal osteotomies~Down fracture~Mobilization of the maxilla~Application of stent in one group and the locating guide in the other group.~Maxillary fixation~Occlusal evaluation~Wound debridement and closure"
76066158|NCT06132815|Device|Laser troughing|Laser troughing will be carried out by passing laser optic fiber in contact mode along the gingival sulcus. Laser energy will be delivered with a wavelength of 980nm and power of 0.8W, in continuous mode. Laser tip will be inserted 1mm into the gingival sulcus, to facilitate an accurate recording of finish line
76066159|NCT06132815|Other|Retraction cord and astringent|Partial isolation of the tooth with cotton rolls and saliva ejector will be performed. Appropriate size of retraction cord will be soaked in astringent for 5 mins. Then packing of the cord will be started from the mesial interproximal area by gently packing into the sulcus with the gingival cord packer instrument using the single cord technique. Retraction cord will be kept in place for 5 minutes. Cord will be removed immediately before the start of the intraoral scan
76066160|NCT06132815|Other|Cordless retraction paste with astringent|The cordless paste with astringent will be injected gently into the sulcus, leaning on the tooth at the point of the cervical limit and not on the gingiva, the cannula will remain parallel to the axis of the tooth to exert optimal pressure. Then it will removed after 5 mins with copiously irrigated water until no traces of the materials left.
76066161|NCT06132815|Other|Cordless retraction paste without astringent|The cordless paste without astringent 10 will be injected into the sulcus of the gingiva. The suitable size of Comprecap will be held on the abutment to push the material deep into the sulcus of the gingiva, and the participants will be informed to bite over it for a period of 3 to 5 minutes. After 5 minutes, the comprecap with the set retraction material attached to it, will be removed from the patient mouth.
75604637|NCT00919867|Drug|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
75453591|NCT06095297|Behavioral|In-lab Brain Health Training|Participants will receive training on healthy eating, sleeping, and relaxation techniques that have been shown to improve brain health.
75453592|NCT06095297|Behavioral|Transfer Package|"The Transfer Package was designed to try and bridge the gap between what is trained in the lab and what the participant does outside of the treatment setting. This components includes negotiation of a behavioral contract with participants at the outset of treatment regarding the responsibilities of the participant, family caregivers, if available, and the treatment team, self-monitoring, assignment of homework, review of homework by the trainer, and support of problem-solving by the participant."
75453593|NCT06095297|Behavioral|Follow Up Phone Calls|After completing training, participants will receive four follow up phone calls in the first month of training. Each call will separated by about a week. The focus of the calls will incorporating the lessons learnt during treatment into daily life.
75453594|NCT06095297|Behavioral|Vocational Rehabilitation|In partnership with the Alabama Department of Rehabilitation Services (ADRS), participants who are eligible may receive vocational rehabilitation. Participants will receive typical services offered by the ADRS. These could include career counseling, guidance regarding job retention or return-to-work, and guidance regarding workplace accommodations.
75604638|NCT00919867|Drug|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
75453595|NCT06095297|Behavioral|Peer Mentoring|Participants who are eligible for vocational rehabilitation, and agree will also have a peer mentor, a co-worker that will be trained by our team, to reinforce strategies the participant learned during training, and to help the participant problem solve issues that may arise on the job during the first month after treatment. Peer mentors will meet with trainers during the month after treatment to make sure procedures are being followed and address any issues that may arise.
75604639|NCT04252261|Drug|sulforaphane|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
75899280|NCT03518684|Drug|Natalis|"A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping"
75604640|NCT04252261|Drug|placedo|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
76066162|NCT06132802|Procedure|Patients who received treatment involving ARS and arthrocentesis only|A 5mm acrylic anterior repositioning splint (ARS) with maxillary coverage was crafted from alginate impressions. After arthrocentesis, the ARS was worn incrementally over six months, starting at two hours and reaching 14 hours daily. In the second week, wear time was continuous, increasing to 24 hours daily (excluding meals) until the sixth month. The ramp was removed in the seventh week. Follow-ups involved grinding the splint by 1mm every four weeks. Arthrocentesis included anesthesia, betadine prep, and using two 18-gauge needles to inject Ringer's lactate solution (100-200 cc) for joint lavage, freeing the disc by moving the lower jaw in various orientations.
76066163|NCT06132802|Procedure|Patients who received treatment involving ARS, arthrocentesis, and an I-PRF injection|"A 5mm acrylic anterior repositioning splint (ARS) was crafted from alginate impressions, secured with Adam's clasps on upper first molars. After arthrocentesis, patients wore the splint incrementally over six months, starting at two hours and reaching 24 hours daily (excluding meals). The ramp was removed in the seventh week, and follow-ups included grinding the splint by 1mm every four weeks until it reached 3mm, guided by articulating paper.~Arthrocentesis involved administering anesthesia, prepping the area with betadine, and using two 18-gauge needles to inject 2-3 ml of Ringer's lactate solution for joint lavage. The lower jaw was moved to free the disc and release fibrous tissue. I-PRF preparation included centrifuging collected blood for 3 minutes at 700 rpm, and the resulting I-PRF was injected into the superior joint space of the lavaged joints."
76066164|NCT06132776|Device|HiToP 191 PNP|High tone therapy
76066165|NCT06132776|Device|Placebo device|Placebo therapy
75453596|NCT06093893|Drug|Dexmedetomidine|1 mcg/kg will be administered intravenously over 10 minutes; followed by maintenance infusion of 0.2 to 1 mcg/kg/hour.
75604641|NCT01215942|Drug|LY2127399|Administered Subcutaneously
75604642|NCT04251871|Drug|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days."
75604643|NCT04251871|Drug|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
75604644|NCT04253353|Drug|tafamidis|61 mg capsule
75604645|NCT04253353|Drug|rosuvastatin|10 mg tablet
76066166|NCT06132750|Other|No intervention|No intervention
76066167|NCT06132711|Other|APRIL-BAFF-Bicephali CAR-T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
76066168|NCT06132646|Other|Proprioceptive exercises|Specific proprioceptive exercises for the wrist that the patient has to do currently with standard rehabilitation.
76066169|NCT06132633|Device|Neospot vitals measurement|Vitals of participants in the intervention group will be measured using neospot alongside standard of care measurement.
75453597|NCT06093893|Drug|Nicardipine|1 mg will be administered intravenously and increase by 0.5-1 mg if the initial dose is ineffective, to a maximum of 15 mg / hour or
75453598|NCT06093893|Drug|Labetalol|20 - 80 mg will be administered intravenously at 10-minute intervals to maximum of 300 mg;
75604646|NCT04924543|Other|Online self-learning training module|Training module in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
75604647|NCT04924543|Other|Refresher training|Brief refresher training in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
75604648|NCT01128621|Drug|GSK1292263|Tablet
75604649|NCT01128621|Drug|GSK1292263 matching placebo|Tablet
75899281|NCT05164640|Other|not required|This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms
75899282|NCT05201690|Drug|VV116 200 mg Group|Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;
75453599|NCT06093386|Other|Intensive Transition Support|Participants assigned to the intervention arm will transfer their transition support leadership to a transition team composed of a transition navigator (an advance practice nurse), a nurse navigator (a registered nurse) and a social worker over 2 years to support them through the multiple phases of CMC transitions including guidance, monitoring, planning, care transfer and transfer completion. CMC and their caregivers will be offered support in care planning, receiving funding, and connecting with a primary care provider and adult subspecialists.
75453600|NCT06090864|Drug|Chemotherapy|Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.
75604650|NCT01128621|Drug|Sitagliptin|Tablet
75604651|NCT00918463|Drug|dasatinib|100 mg daily dosing
75604652|NCT04251793|Other|Observation|Soft tissue implant measurements and radiographs
75604653|NCT04811989|Behavioral|Instructive video on diabetic foot care|In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
75899283|NCT05201690|Drug|VV116 400mg Group|Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;
75899284|NCT05201690|Drug|VV116 600mg Group|Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;
75899285|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 25 µg/h during 48 hours
75899286|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 10 µg/h during 48 hours
75899287|NCT01067859|Drug|Placebo|Infusion of placebo during 48 hours
75453601|NCT06090864|Biological|Cell infusion|ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.
75749370|NCT05639036|Procedure|Free Hand External Ventricular Drain Placement|External ventricular drain will be placed with the standard free-hand technique
75749371|NCT05635591|Biological|Autologous monocyte - derived DCs pulsed with EBV antigen|Patients will receive approximately （5-10）x10^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
75604654|NCT04811989|Behavioral|Informative leaflet with real-time guided reading|The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.
75899288|NCT02296658|Radiation|intensity-modulated radiotherapy|A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
75604655|NCT04811989|Behavioral|Informative leaflet to read at home|Patients receive a leaflet about diabetic foot care to read at home.
75604656|NCT04811989|Behavioral|Face-to-face teaching|Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
75749372|NCT05628883|Biological|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
75604657|NCT04251637|Other|Cardiac output monitoring with Starling SV.|Intraoperative monitoring of cardiac output by esophageal Doppler, NICOM Starling SV and collection of values for each patient at at least 7 predefined intraoperative times.
75749373|NCT05628883|Drug|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL over approximately 1 hour per day for 2 days.
75749374|NCT05628883|Drug|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 15 to 30 minutes for 5 days, prior to T-Cell infusion
75749375|NCT05628883|Drug|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously every 8 to 12 hours beginning within 24 hours after T-cell infusion.
75899289|NCT02296658|Drug|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
75899290|NCT03640689|Device|Endovenous ablation + iliac US +/- iliac stenting|Concomitant Ablation of the GSV with endovenous therapy with associated iliac vein interrogation and stenting if required
75899291|NCT03640689|Device|Endovenous ablation of Great Saphenous Vein|Ablation of the Great Saphenous Vein and subsequent Graduated Compression
75899292|NCT02300246|Procedure|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
75453602|NCT06085495|Procedure|mechanical thrombectomy (PMT)|After the establishment of the pathway, Angiojet (Boco, USA) was used to infuse urokinase into the blood vessels of the thrombotic segment. After waiting for 15 minutes, mechanical thrombectomy was performed. After thrombectomy, the effectiveness of thrombectomy was evaluated through angiography. For residual thrombi, repeated thrombectomy was performed, with a maximum thrombectomy volume of 480ml. After thrombectomy, antegrade angiography of the dorsal vein of the foot was performed again. If iliac vein stenosis was found to be greater than 50%, Then, Mustang balloons (Boko, USA) that match the normal blood vessel diameter are used for dilation. If the residual stenosis after dilation is greater than 30%, Wallsten stents that match the normal blood vessel diameter are inserted (Boko, USA). After all operations are completed, a dorsalis pedis venography is performed again to evaluate the thrombus burden and calculate the immediate thrombus clearance rate and thrombus clearance level.
75453603|NCT06083064|Diagnostic Test|Abdominal imaging|Abdominal ultrasound and/or abdominal CT
75453604|NCT06083064|Other|Score based selective abdominal imaging|Abdominal imaging is done selectively based on Adult Appendicitis Score
75453605|NCT06083064|Other|Score based selective observation combined with selective abdominal imaging|Observation based on Appendicitis Severity Score combined Adult Appendicitis Score based selective abdominal imaging
75604658|NCT04251559|Other|oral glucose loading test|oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
75604659|NCT05048641|Other|Whatsapp reminder|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
75749376|NCT05623137|Device|Acu-TENS|A dual-channel TENS stimulator will be used (ECS300A; Neurotrac, Verity Medical LTD, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
75899293|NCT03619239|Drug|GX-I7|During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.
75899294|NCT02296736|Radiation|Computerised tomography (CT) scan|Retrospective review of CT scans
75899295|NCT03515954|Procedure|Treatment of diffuse ocular surface squamous neoplasia|Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.
75899296|NCT02293616|Dietary Supplement|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
75899297|NCT02293616|Dietary Supplement|Placebo|
76066170|NCT06132620|Drug|Femoston|"Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment."
76066171|NCT06132620|Drug|Qingxin Zishen Decoction|Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
76066172|NCT06132607|Device|Preoperative 3D lung reconstruction created with open-source software|Preoperative 3D lung reconstruction created with open-source software 3D Slicer
75899298|NCT03640221|Drug|Ertugliflozin|The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
75604660|NCT05330065|Drug|bevacizumab and camrelizumab|"Stage 1 was classical 3+3 dose escalation with pts assigned to one of the following 3 cohorts, Cohort A:Avastin 5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort B:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort C:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 200mg once every 2 weeks.DLT was observed for 28 days."
75749377|NCT05623137|Device|Sham Acu-TENS|A dual-channel TENS stimulator will be used (ITO Physiotherapy & Rehabilitation, Co, Ltd, Tokyo, Japan). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
75749378|NCT05623137|Other|SHP|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
75604662|NCT01128543|Drug|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
75604663|NCT01128387|Drug|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
75604664|NCT01214850|Biological|Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)|
75899299|NCT03640221|Drug|Hydrochlorothiazide 12.5mg|comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
75899300|NCT03640221|Device|Microneurography|"Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are <10% and < 5%, respectively."
75899301|NCT03640221|Other|SKNA recordings|SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
75453606|NCT06080529|Other|Sandbag exercise|Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
75749379|NCT05616247|Behavioral|ECALC|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention
75749380|NCT05616247|Behavioral|ECALC Plus Weekly Boosters|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention Plus Weekly Booster Content Delivered by Mobile Device
75749381|NCT05607043|Device|Testing for SARS CoV2 RNA|Device: Testing for SARS CoV2 RNA- lab-based RNA RT-PCR testing
75453607|NCT06080516|Other|Kettlebell exercise|Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch
75749382|NCT05591833|Procedure|SASI|Single-Anastomosis Sleeve ileal (SASI) Bypass
75453608|NCT06072183|Drug|Ritlecitinib|100mg Capsule
75453609|NCT06072183|Drug|Ritlecitinib|50mg Capsule
75453610|NCT06072183|Drug|Placebo|Matching capsule
75453611|NCT06069778|Drug|BNT321 Dose Level 1|Intravenous infusion
75604665|NCT01214850|Biological|MenACWY-CRM conjugate vaccine|
75749383|NCT05591833|Procedure|SAS-J|Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
75604666|NCT01214850|Biological|Japanese Encephalitis vaccine|
75604667|NCT01128153|Drug|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
75604668|NCT01128153|Drug|Placebo|tablet once daily for 24 weeks to be taken orally
75604669|NCT04318782|Device|Pharmacodynamic thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
75604670|NCT00925015|Biological|Dalotuzumab 10 mg/kg|Dalotuzumab at 10 mg/kg was intravenously administered once weekly
75604671|NCT00925015|Biological|Cetuximab|Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m^2, followed by subsequent once weekly intravenous infusions of 250 mg/m^2
75604672|NCT00925015|Drug|Irinotecan|Irinotecan was administered with an intravenous infusion of 150 mg/m^2, once every other week for 42 days
75604673|NCT00925015|Biological|Dalotuzumab 15/7.5 mg/kg|Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
75749384|NCT05590455|Drug|Adalimumab Injection|one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids
75899302|NCT03640221|Other|Static Handgrip|Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
75749385|NCT05589116|Other|Online Compassionate Imagery Intervention|The intervention comprises 14 pre-recorded, 10-15 minute videos. Participants will be asked to watch one video per day over a two-week period. The videos initially focus on providing psychoeducation about what self-compassion is, before delivering a series of guided Compassion Focused Therapy (CFT) informed exercises to cultivate self-compassion. The first week of the intervention will teach key compassion skills, with the second week focusing on skill consolidation.
75749386|NCT05582876|Radiation|Radiopharmaceutical 68Ga-PSMA-11 PET/CT|The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.
75899303|NCT03640221|Other|Post-handgrip forearm vascular occlusion|This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
75604674|NCT01127763|Drug|RAD001|
75604675|NCT01127763|Drug|Carboplatin|
75604676|NCT04251403|Diagnostic Test|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
75604677|NCT04251325|Other|Basic Life Support Courses|4 hours basic life support courses for laypersons
75453612|NCT06069778|Drug|BNT321 Dose Level 2|Intravenous infusion
75453613|NCT06069778|Drug|mFOLFIRINOX|Intravenous infusion
75453614|NCT06069778|Drug|BNT321 RP2D|Intravenous infusion
75453615|NCT06068270|Procedure|Micro-ostoperforations (MOPs)|3 MOPs will be performed in the bone next to the root of the experimental tooth. MOPs will be performed using the Excellerator® (Propel Orthodontics, Denstply, Sirona)
75604678|NCT04257409|Other|Physical intervention by exercise|12 week lasting exercise intervention
75604679|NCT04250779|Device|CapMedic smart inhaler device|The CapMedic device provides active coaching to promote correct and regular use of MDI.
75604680|NCT04250779|Behavioral|Video-based guidance|Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.
75749387|NCT05580003|Drug|PF-07817883|Oral suspension or solid oral formulation(s)
75749388|NCT05580003|Drug|Placebo|Placebo suspension
75749389|NCT05580003|Drug|Midazolam|midazolam oral solution
75453616|NCT06066151|Dietary Supplement|Minayo Yeast Drink Product|Participants need to drink one piece of the products each day, for 4 consecutive weeks.
75453617|NCT06060847|Procedure|Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome|Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.
75453618|NCT06060847|Procedure|Liver resection for HCC induced by metabolic syndrome|Patients in the active comparator arm will undergo liver resection for HCC
75604681|NCT05252299|Other|Rolling Fresher Group|The use of telemedicine to provide remote CSS installation instruction via audio and visual input by a Certified child passenger safety technician (CPST)
75604682|NCT01127607|Drug|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
75749390|NCT05580003|Drug|Moxifloxacin|Moxifloxacin 400 mg tablet
75604683|NCT00924781|Drug|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
75604684|NCT00924781|Drug|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
75604685|NCT00924781|Drug|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
75604686|NCT05252065|Other|Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging|Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
75604687|NCT05251987|Biological|PD1+ T Cell Expression|The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
75604688|NCT01127451|Drug|Denileukin diftitox|Denileukin diftitox intravenous infusion over 30-60 minutes.
75749391|NCT05578742|Procedure|PEEP increase|Positive End Expiratory Pressure (PEEP) will be increased from 5 to 15 cmH2O.
75749392|NCT05578742|Procedure|PEEP decrease|Positive End Expiratory Pressure (PEEP) will be decreased from 15 to 5 cmH2O.
75749393|NCT05574790|Other|annual follow up|Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality
75899304|NCT03640221|Other|Testing of the Arterial Baroreflex Function|We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
75453619|NCT06054659|Device|Real Time Continuous Glucose Monitoring (rt-CGM)|Participants randomized to rt-CGM will have CGM placed prior to hospital discharge. They will also receive teaching from the research team on the proper use of their CGM sensor and reader. The study team will CGM devices but subjects may use their own glucometer for FBG testing as needed including for CGM calibration.
75453620|NCT06054659|Other|Fingerstick blood glucose (FBG) monitoring|Participants will use their own glucometer for FBG testing as advised by their treating provider (usually primary care or diabetes doctor).
75749394|NCT05572229|Drug|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
75453621|NCT06054659|Behavioral|Diabetes Education|Participants will receive standard-of-care diabetes education with a certified diabetes educator (CDE) prior to discharge (with the approval of the treating inpatient team).
75453622|NCT06051864|Device|Modius Mood Active Device|Battery powered non-invasive neurostimulation device
75453623|NCT06051864|Device|Sham Device|Placebo comparator sham device (no active stimulation)
75453624|NCT06037148|Biological|DM-101PX|subcutaneous injection of DM-101PX
75604689|NCT04759651|Other|Functional Outcome of Sleep Questionnaire Turkish version (FOSQ-TR)|Sleep related quality of life questionnaire.
75604690|NCT04759651|Other|Epworth Sleepiness Scale (ESS)|Subjective level of daytime sleepiness.
75604691|NCT04759651|Other|Berlin Questionnaire|Evaluation of high-risk for Obstructive Sleep Apnea.
75604692|NCT04759651|Other|Stop-Bang Questionnaire|Evaluation of high-risk Obstructive Sleep Apnea.
75604693|NCT04759651|Other|Insomnia Questionnaire|Subjective evaluation of insomnia.
75749395|NCT05572229|Drug|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
75749396|NCT05572229|Drug|Lenalidomide|Lenalidomide will be administered orally
75749397|NCT05570825|Procedure|Biopsy|Undergo biopsy
75749398|NCT05570825|Procedure|Biospecimen Collection|Undergo collection of blood samples
75749399|NCT05570825|Procedure|Computed Tomography|Undergo PET/CT or CT
75749400|NCT05570825|Drug|CXCR1/2 Inhibitor SX-682|Given PO
75749401|NCT05570825|Procedure|Magnetic Resonance Imaging|Undergo MRI
75749402|NCT05570825|Biological|Pembrolizumab|Given IV
75899305|NCT03640143|Other|venous blood lead|data about ve,nous blood lead
75899306|NCT02300324|Dietary Supplement|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
75453625|NCT06037148|Biological|Placebo to Match DM-101PX|Placebo to match DM-101PX administered subcutaneously
75453626|NCT06028464|Drug|BI 1810631|BI 1810631
75453627|NCT06028464|Drug|Carbamazepine|Carbamazepine
75604694|NCT04759651|Other|Restless Leg Syndrome Questionnaire|Subjective evaluation of Restless Leg Syndrome.
75604695|NCT04759651|Other|Zung Self-rating Depression Scale (SDS)|Subjective test for evaluation of depressive mood.
75604696|NCT04759651|Other|Beck Anxiety Inventory|Subjective test for evaluation of anxiety.
75749403|NCT05570825|Procedure|Positron Emission Tomography|Undergo PET/CT
75749404|NCT05569408|Drug|EVUSHELD|Tixagevimab (AZD8895) and cilgavimab (AZD1061)
75749405|NCT05567679|Drug|Tazverik|Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
75749406|NCT05563818|Other|WinterLight Mobile Phone Speech Analysis|N/A- observational study
75749407|NCT05558410|Drug|VX-548|Tablets for oral administration.
75899307|NCT02300324|Dietary Supplement|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
75899308|NCT02300324|Dietary Supplement|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
75899309|NCT03640767|Behavioral|Message-based lifestyle intervention|Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
75899310|NCT02300480|Procedure|CTB group|CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
75453628|NCT06026540|Behavioral|Pilates Exercise|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
75604697|NCT01127373|Radiation|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
75604698|NCT01127373|Behavioral|BreastQ questionnaire-|MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
75604699|NCT01214616|Drug|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
75604700|NCT01214616|Drug|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
75604701|NCT01214616|Drug|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
75604702|NCT01213836|Drug|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
75604703|NCT01213836|Drug|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
75749408|NCT05558410|Drug|HB/APAP|Capsules for oral administration.
75749409|NCT05558410|Drug|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
75749410|NCT05558410|Drug|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
75749411|NCT05557032|Procedure|cardiopulmonary resuscitation|pulse checks during cardiopulmonary resuscitation
75749412|NCT05555576|Dietary Supplement|Vitamin C|1000 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
75749413|NCT05555576|Other|Placebo|Placebo taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
76066173|NCT06132594|Procedure|Conventional arthrocentesis followed by I-PRF injection|An auriculotemporal nerve block using Mebacaine 0.5% was administered near the mandible's neck. The patient sat at a 45° angle with their head turned. The posterior entry point was 10 mm from the midtragus and 2 mm below the line, while the anterior entry point was marked 20 mm from the midtragus and 10 mm below the line. A biting block kept the mouth open. 2-3 ml of Ringer lactate was injected with an 18-gauge needle to enlarge the joint space. A second needle allowed the solution to flow freely. After lavaging the joint, 1 ml of I-PRF was injected into the upper joint space. Jaw manipulation was done to address adhesions and improve disc mobility.
75749414|NCT05552781|Drug|H002 capsule|Small molecule, Capsule
76066174|NCT06132594|Procedure|3d surgical guided Arthrocentesis followed by I-PRF injection|Patients underwent arthrocentesis with Ringer lactate, followed by I-PRF injection in the TMJ's superior space using a CT-planned 3D-printed guide. Positioned at a 45° angle, patients were comfortably seated, and disinfection was performed. The patient-specific guide, fitting over maxillary teeth and the face, was employed unilaterally or bilaterally with a biting block for mouth opening maintenance. An 18-gauge needle administered 2-3 ml of Ringer lactate, widening the joint space, followed by a second needle allowing free solution flow (80-90 ml) to flush the superior joint space. Post-arthrocentesis, 1 ml of I-PRF was injected. To enhance joint mobility and free the disc, gentle manipulation of the lower jaw was performed after removing the needles and guide.
75453629|NCT06026306|Behavioral|Problem Management Plus (PM+)|PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session
75453630|NCT06018272|Behavioral|Mentalization-Based Treatment (MBT)|Patients in MBT will receive a maximum of 58 sessions in total. Of those, 30 are weekly individual sessions. 28 sessions are weekly group sessions conducted by two therapists, and consisting of 8 introductory sessions of group psychoeducation followed by 20 group therapy sessions. The duration of MBT is 12 months. MBT is manualized and relies on validating the emotional experience of patients that aims to promote mentalizing. The proposed mechanism of change in MBT is to stabilize mentalizing in certain focus areas in order to create a psychic buffer between affect and behaviour to foster affect regulation, reduce impulsivity and promote functional supportive relationships.
75604704|NCT01213836|Drug|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
75604705|NCT01213836|Drug|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
75749415|NCT05548543|Drug|HCP2202|Take it once per period.
75749416|NCT05548543|Drug|RLD2202|Take it once per period.
75749417|NCT05548543|Drug|RLD2203|Take it once per period.
75749418|NCT05548387|Drug|HCP2202|Take it once per period.
75604706|NCT01127061|Behavioral|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
75604707|NCT00924703|Drug|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
75749419|NCT05548387|Drug|RLD2202|Take it once per period.
75604708|NCT01213524|Behavioral|sensorimotor replacement|denicotinized cigarettes
75604709|NCT01213524|Drug|42 mg transdermal nicotine replacement|2 21-mg nicotine patches
75749420|NCT05548387|Drug|RLD2203|Take it once per period.
75749421|NCT05534646|Drug|Apalutamide|Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
75749422|NCT05534646|Drug|Carotuximab|"Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose."
75749423|NCT05522569|Drug|Allogeneic human mesenchymal stem cells (Allo-hMSCs)|Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.
75749424|NCT05512234|Dietary Supplement|L. reuteri|Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
75899311|NCT02300480|Procedure|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
75749425|NCT05512234|Dietary Supplement|Placebo|Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
75899312|NCT03518528|Drug|Estradiol 2 MG|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
75899313|NCT03518528|Drug|Estradiol 100 µg|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
75769404|NCT03900052|Device|Haptic cane|• A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.
75604710|NCT01213524|Drug|Placebo transdermal nicotine|2 placebo patches matched to 21-mg nicotine patches
75769405|NCT03900052|Device|typical cane|Typical training cane loading training
75899314|NCT03518450|Procedure|Apex Femoral Triangle Block|Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.
75453631|NCT06018272|Behavioral|Bona-Fide Treatment in Germany (BFT)|Patients in BFT will receive one to two weekly sessions of Bona-Fide-Treatment (Psychodynamic Therapy, PT, or Cognitive Behavioural Therapy, CBT) conducted by community experts delivered as short-term psychotherapy (<24 sessions) or long-term psychotherapy (>24 sessions). BFT can be delivered as individual, group or a combination of individual and group treatment as stated in the German psychotherapy regulations.
75453632|NCT06018233|Other|New proposal for regime creation|Interviews and building of proposals in the light of the information obtained and desk based research
75604711|NCT01213524|Other|usual brand smoking|participant smokes usual brand of cigarette
75453633|NCT06016335|Diagnostic Test|CT scan|Participants receive a CT scan of the head as part of their regular care. A larger part of the head will be scanned than for standard care.
75453634|NCT06016335|Diagnostic Test|MRI scan|Participants receive an MRI scan, specifically for the purpose of the study.
75453635|NCT06016335|Other|Synthetic CT scan|Synthetic CT scans will be generated from MRI scans, using the trained machine learning algorithm.
75604712|NCT01212744|Drug|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
75604713|NCT01212588|Drug|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
75604714|NCT01212588|Drug|Placebo|3 tablets once daily for seven days
75604715|NCT00918385|Drug|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
75604716|NCT00918385|Drug|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
75604717|NCT05253235|Behavioral|SAAF|A 7 session online intervention designed to augment protective processes associated with deterrence of substance use
75604718|NCT05253235|Other|Receipt of parenting book|Parents will receive a copy of the book, Parenting for Liberation: A Guide for Raising Black Children
75749426|NCT05508152|Drug|Wound irrigation with amoxicillin-clavulanate in saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes."
75749427|NCT05508152|Drug|Wound irrigation with a saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes."
75749428|NCT05500378|Other|Head extension and rotation movement|Active exercise of the head
75453636|NCT06015529|Diagnostic Test|4PEPS strategy|"Physicians of the participating centers in the intervention group will have the recommendation to apply the 4PEPS strategy. Using 12 variables, 4PEPS defines four levels of CP that rule out a PE, namely~based only on clinical data (very low CP: PEPS < 0),~based on a D-dimer level < 1000 μg/L (low CP: PEPS ≥ 0 and < 5),~based on a D-dimer level with an age-adjusted cut-off value (moderate CP: PEPS ≥ 5 and <12), or~the diagnosis cannot reliably be ruled out based on a D-dimer test (high CP: PEPS ≥ 12)"
75749429|NCT05492565|Drug|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
75899315|NCT03518450|Procedure|Femoral Nerve Block|Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).
75899316|NCT03518450|Procedure|Adductor Canal Block|Interfascial block that targets mainly the saphenous nerve.
75899317|NCT01348425|Device|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
75899318|NCT01348425|Device|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
75899319|NCT02296814|Drug|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
75453637|NCT06011629|Device|Aquacel dressing|Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
75453638|NCT06011603|Device|Prineo dressing|Prineo dressing is a common dressing option used in Joint Arthroplasty surgery. It is an adhesive dressing growing in popularity that is thought to lead to reinforced tension across the wound while also decreasing the skin edge ischemia.
75453639|NCT06010693|Drug|Daridorexant|Participants will receive one Daridorexant 50mg tablet, orally, once daily for about 28 consecutive night on each night approximately 30mintues before participants intends to try to sleep.
75453640|NCT06010693|Drug|Placebo|Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.
75899320|NCT02296814|Drug|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
75899321|NCT03515798|Drug|Pembrolizumab Injection|Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
75899322|NCT03515798|Drug|neoadjuvant EC-paclitaxel chemotherapy|The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
75749430|NCT05486104|Drug|Hemay005 tablets|Hemay005 tablets (15mg/tablet）will be orally administered twice daily.
75899323|NCT03512600|Dietary Supplement|Intervention 0|Without nutritional intervention, it will consist of normal food intake without food derived from cocoa or coffee for a period of 1 day in the group of 20 patients during meals. ( That day the patient can not consume cocoa derivates nor coffe or coffe derivates).
75453641|NCT06008301|Other|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.
75453642|NCT06007053|Behavioral|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning.
75453643|NCT06007053|Behavioral|Supportive Therapy|The supportive therapy treatment consists of 12 sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
75604719|NCT05253157|Other|Virtual Reality Augmented remote rehabilitation|XRHealth offers remote skilled therapy treatments such as education, exercise, and VR-augmented activities. The platform consists of the VRHealth portal with multiple immersive applications for measurement, motor-cognitive training, and mindfulness/cognitive behavioral applications for symptom relief, the external control application, and the XR Health data portal with real-time analytics for evaluating performance. Contraindications for VR use are assessed. Treatment sessions are 60 min long. Duration and frequency are based on clinical judgement. VR interventions used are; VR motor-cognitive: ReAct, Color Match, Memorize, Rotate, and Balloon Blast; VR Reliever: Relax 8, Luna, and Mindset. An external VR portal and mirroring software allows the clinician to view patient activities in real time. Additionally, the clinician can remotely monitor patient performance via the external portal and adjust parameters accordingly.
75604720|NCT04727281|Other|Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form and Malnutrition-Inflammation Score|"Data about nutritional status using the Malnutrition-Inflammation Score, and Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form. Dialysis related data, The time needed for the patient to recover from a dialysis session (in minutes), Detailed history taking, Thorough physical examination, Laboratory Investigations:~• Hemoglobin , Serum sodium and potassium , Serum creatinine and blood urea , Serum phosphorus, serum calcium , Serum PTH level , Serum albumin ,CRP ,Total iron-binding capacity ."
75604721|NCT05251831|Drug|Intradermal injection|Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.
75749431|NCT05486104|Drug|Hemay005 placebo tablets|Hemay005 placebo tablets will be orally administered twice daily.
75749432|NCT05485168|Other|Sequential Variety|3 different foods served in 3 successive courses
75749433|NCT05485168|Other|Single-Food|1 food served in 3 successive courses
75749434|NCT05485168|Other|Small Portion|Small meal portion size
75749435|NCT05485168|Other|Large Portion|Large meal portion size
75749436|NCT05481411|Drug|Olpasiran|Subcutaneous injection
75604722|NCT04761679|Behavioral|Applying the Mepilex foam|Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
75749437|NCT05481307|Drug|RLD2202|Take it once a day per period
75749438|NCT05481307|Drug|RLD2203|Take it once a day per period
75604723|NCT04899037|Other|No intervention|This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
75604724|NCT04257643|Other|aquatic based exercise.|exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
75604725|NCT04257643|Other|land-based exercise.|land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles [14]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
75749439|NCT05454514|Device|HiDO medication adherence platform|The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.
75899324|NCT03512600|Dietary Supplement|Intervention 1|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa that will be provided to the paient (Food based on soluble cocoa) during one 1 day period in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
75453644|NCT06002204|Other|Observational Study|No Treatment or Intervention Provided
75453645|NCT05996133|Drug|Bupivacain|30 mL of 0.25% bupivacaine
75453646|NCT05996133|Drug|Dexamethasone|0.5 mL (5 mg) preservative-free dexamethasone
75453647|NCT05996133|Drug|Epinephrine|0.1 mL epinephrine 1:400,000.
75453648|NCT05996133|Drug|Normal saline|3 mL normal saline
75453649|NCT05993507|Behavioral|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, scalable intervention that is developed by World Health Organization for communities exposed to adversity. PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session 5. Facilitators will receive weekly supervisions by PM+ supervisors.
75749440|NCT05454514|Device|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
75749441|NCT05454514|Other|Time on Task|"Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score."
75749442|NCT05452174|Drug|Mirtazapine|Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
75749443|NCT05448547|Radiation|Radiotherapy or surgery|see arm/ group description
75453650|NCT05991934|Behavioral|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
75453651|NCT05988229|Other|Toolkit to improve discharge equity|Linguistically appropriate discharge teaching aids: a medication calendar, pictographics added to the after visit summary (AVS), and an audio recording of the discharge teaching.
75453652|NCT05982730|Behavioral|Sensory-Augmented Postural Training|To examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control and to assess the effectiveness of postural training using Segway
75453653|NCT05980416|Drug|EO-3021|Anti-Claudin 18.2 antibody drug conjugate
75749444|NCT05448547|Other|initial observation|see arm/ group description
75749445|NCT05448547|Drug|Hormone therapy|androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
75749446|NCT05446779|Diagnostic Test|Adrenal aldosterone synthase (CYP11B2) staining|Immunoshistochemical diagnosis of primary aldosteronism
76066175|NCT06132555|Other|Online questionnaire survey|"The investigators have made an electronic questionnaire through the questionnaire star, and send the link or two-dimensional code of the electronic questionnaire to the subjects through WeChat or SMS to remind them to fill in the answer on the mobile phone or computer.~The questionnaire consisted of four parts: (1) basic information of the interviewees, (2) drug abuse of the interviewees, (3) drug treatment interventions received by the interviewees, and (4) problems encountered by the interviewees when they return to society."
75749447|NCT05446779|Diagnostic Test|Adrenal cortisol synthase (CYP11B1) staining|Immunoshistochemical diagnosis of adrenal hypercortisolism
75604726|NCT04703725|Behavioral|Psychosocial Care|"First Follow-Up: One of the implementation of the module~Second Follow-up: Implementation of the second module; Breathing Exercises and EFT~Third Follow-up: Emotional preparation about egg pick up process, individual application of coping methods~Fourth Follow-up: Implementation of the second module; Briefing about Breathing Exercises and EFT embryo transfer process~Fifth Follow-up: Implementation of the second module; Breathing Exercises and EFT~Sixth Follow-up: Individual application of coping methods until the learning process of pregnancy test result~Seventh Follow-up: Providing information about the first periods of pregnancy after treatment resulting in pregnancy and providing information about the psychosocial problems that may be encountered. Identifying psychosocial problems that may be encountered after unsuccessful treatment and individual application of coping methods to help cope."
75453654|NCT05977816|Device|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
75749448|NCT05446779|Diagnostic Test|Histopathological analysis|Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
75749449|NCT05434702|Behavioral|Digital Diet Diary|Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.
75453655|NCT05977816|Other|Standard wound dressing|Application of a standard wound dressing to the wound post laparotomy
75453656|NCT05975307|Drug|Toripalimab|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the induction and concurrent phases, respectively."
75453657|NCT05975307|Drug|Gemcitabine|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles."
75453658|NCT05975307|Drug|Cisplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
75604727|NCT00637819|Drug|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
75749450|NCT05434702|Behavioral|NHANES Food Frequency Questionnaire (FFQ)|Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.
75749451|NCT05434702|Behavioral|Fitbit data collection|Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.
75749452|NCT05434702|Behavioral|Quality of Life questionnaire|The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.
75749453|NCT05434702|Behavioral|Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire|The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
75899325|NCT03512600|Dietary Supplement|Intervention 2|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cacao (Food based on black chocolate) during a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
75899326|NCT03512600|Dietary Supplement|Intervention 3|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa (Food based on chocolate with milk) for a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
75899327|NCT03041701|Drug|Dasatinib|Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
75604728|NCT05253079|Other|subcostal transversus plane block|Patient in TAP block group will receive oblique subcostal TAP while in supine position using a linear 6-13 MHz ultrasound transducer. The operator will place the ultrasound probe obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The landmarks, which included the rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin and xyphoid. The probe will be then moved laterally until the aponeurosis of the external, internal oblique, and transversus abdominis are seen, and then the probe will be moved further laterally until the transversus abdominis muscle is identified. The operator will direct the needle toward the transversus abdominis, and the local anesthetic solution will be injected after negative aspiration between the rectus abdominis and transversus abdominis muscles along the subcostal line (in-plane superomedial to inferolateral)
75899328|NCT03041701|Drug|Dasatinib|Twice daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
75453659|NCT05975307|Drug|Carboplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate < 40 ml/min, area under curve = 2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
75899329|NCT03041701|Drug|Ganitumab|Once every 2 weeks beginning on day 0.
75453660|NCT05975307|Radiation|Intensity-modulated radiation therapy|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions."
75453661|NCT05974267|Drug|M5717 60 mg|Participants will receive single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition
75453662|NCT05974267|Drug|Pyronaridine|Participants will receive Pyronaridine tablets orally single dose of 720 (Participants >= 65 kg) and 540 mg (Participants >= 45 to < 65 kg) on Study Day 1 under fasting condition
75749454|NCT05434702|Behavioral|Godin Exercise Leisure-Time questionnaire|The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).
75899330|NCT02296970|Procedure|Deep shave removal using a blue surgical blade|Removal of a skin lesion with 2mm margins and an adequate amount of tissue deeper than the clinical appearance of the lesion using a blue surgical blade
75899331|NCT04465058|Other|COVID19|viral infection
75899332|NCT03512522|Behavioral|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in an online format.
75453663|NCT05974267|Drug|Atovaquone-Proguanil|Participants will Receive Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.
75899333|NCT03512522|Behavioral|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in a printed (workbook) format.
75453664|NCT05974267|Drug|M5717 200 mg|Participants will receive single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition
75453665|NCT05974267|Drug|M5717 660mg|Participants will receive single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition
75899334|NCT04464902|Device|brace1|The brace1 can provide resistance when patients want to extend their knee.
75899335|NCT04464902|Device|brace2|The brace1 can't provide resistance when patients want to extend their knee.
75899336|NCT04464902|Other|No Intervention|Control Group don't have any brace.
75899337|NCT04464824|Other|no intervention|no intervention
75899338|NCT02293694|Drug|Sayana Press|Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
75899339|NCT02297048|Dietary Supplement|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
75899340|NCT02297126|Other|Pharmacogenetic Intervention Arm (pharmacogenetic testing)|In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
75899341|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
75453666|NCT05971173|Drug|Juven|Nutritional supplements
75453667|NCT05971173|Drug|Centrum Silver 50+|Over the counter nutritional supplement
75899342|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
75899343|NCT02300636|Other|Training|Standard ACL rehabilitation
75749455|NCT05434702|Behavioral|Zoom interviews|A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
75899344|NCT02293772|Other|Hypoxic ambulatory|21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
75749456|NCT05431166|Behavioral|Virtual Yoga at First 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the first 8 weeks of the study
75749457|NCT05431166|Behavioral|Virtual Yoga at Second 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the second 8 weeks of the study
75749458|NCT05423197|Drug|89Zr-panitumumab IV|Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
75749459|NCT05423197|Drug|Panitumumab|Panitumumab 30mg will be given orally
75749460|NCT05411471|Biological|COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain|The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
75899345|NCT02293772|Other|Hypoxic Bedrest|21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
75453668|NCT05970042|Behavioral|GameDay Ready|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. The GameDay Ready program promotes increasing physical activity, reducing sedentary time, and improving dietary habits through education, behavioral self-monitoring, and goal setting. Each 60-minute intervention session includes a brief educational component followed by a group discussion of weekly progress. Following a short warmup walk, participants engage in group-based competitive physical activities and then a short cooldown walk. Participants then set individual and group-based goals for the upcoming week and discuss strategies for overcoming barriers to achieving goals. The program is sensitive to intersectional influences of gender, race, and rurality on health; and strategies to enhance motivation are threaded throughout the program.
75453669|NCT05970042|Behavioral|Walking and General Health Education|Participants receiving the comparison program will complete a 12-week walking and general health education program. Group sessions meet once per week at a publicly accessible walking track, and each 60-minute session consists of a brief educational component on a health topic followed by walking and socializing during the remainder of the session.
76066176|NCT06132555|Other|In-depth personal interview|The in-depth personal interview was conducted in a semi-structured way. The outline of the interview was formulated from seven aspects: drug use history, drug abstinence history, relapse situation, living conditions, physical and mental health status, return to society status, and active drug abstinence willingness of the drug abstinence personnel. The aim was to understand the needs of drug addicts in terms of family relationship, peer relationship, history of drug use, history of drug withdrawal, employment, economy, social support network, psychology, and assistance.
75899346|NCT02293772|Other|Normoxic Bedrest|21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
75749461|NCT05399693|Procedure|platelet transfusion|platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
75749462|NCT05399498|Drug|Psilocybin|Psilocybin 25mg capsule
75749463|NCT05389826|Device|mHealth App|We will compare the degree of improvement in phosphate control with respect to baseline values and report any adverse event. Nephrologist will use a web management system to provide results of phosphorus levels and medical recommendations to the patient, mediated by a cloud IT environment. In addition, patients will receive alerts, suggestions, and general information. They will also be able to communicate with nephrologists and interact with their corresponding group of fellow patients.
75749464|NCT05377008|Behavioral|OPTIMAL-SSI|The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
75749465|NCT05371860|Other|Omit breast radiation|Omit breast radiation for 3 years after surgery
75749466|NCT05349591|Biological|cePolytreg|The treatment group will receive cePolyTregs 2 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
75899347|NCT03512444|Device|Negative Pressure System|Negative Pressure System is a non-invasive system that applies sub-atmospheric(Negative) pressure, through a foam and an air-tight film dressing which is connected by suction tubes to a controller unit by which the primary negative pressure can be adjusted.
75899348|NCT02956629|Drug|Uprifosbuvir|Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
75604729|NCT05253079|Other|erector spinae plane block|Patients in ESPB group will be turned to the lateral position and receive ESPB at the level of the 7th thoracic (T7) transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T7) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution will be injected below the muscle. the procedure will be repeated on the other side
75749467|NCT05342441|Procedure|QT graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
75769406|NCT03909802|Behavioral|Self-and family management of diabetic foot ulcers programs|The intervention combines self-management and family management focusing on behavioral changes in patients with diabetic foot ulcers. Self-management focuses on intensive health education of physical activities, diet, medication, foot care, and blood glucose control. Family management focuses on problem-solving, establishing roles, and effective involvement in providing care amid individuals suffering DFU.
75899349|NCT02956629|Drug|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
75769407|NCT03909802|Other|Usual care|Usual care
75899350|NCT02956629|Drug|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
75453674|NCT05956730|Other|Physical Activity (AUD)|Home training of patients with severe low vision managed through audio-guides (AUD).
75453675|NCT05956730|Other|Physical Activity (SUP)|Training of patients with severe low vision in a gym supervised by a personal trainer (SUP).
75453676|NCT05948176|Other|The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition|It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years
75453677|NCT05932992|Other|Mother education on how to perform MUAC assessment|Mothers will be trained to perform MUAC weekly on their children
75453678|NCT05924971|Drug|Aspirin 81Mg Ec Tab|Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
75453679|NCT05924815|Drug|Aficamten|Oral Tablet
75453680|NCT05924815|Drug|Aficamten-matching Placebo|Oral Tablet
75453681|NCT05924815|Drug|Moxifloxacin|Oral Tablet
75453682|NCT05924412|Drug|Intravenous study drug|40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión
75899351|NCT02297204|Procedure|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
75899352|NCT02297204|Drug|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
75899353|NCT02300714|Procedure|oblique view approach|
75899354|NCT03515642|Behavioral|HIIT group|Physical Training
75899355|NCT02293850|Biological|OBP-301|A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
76066177|NCT06132555|Other|Colloquia|"The colloquia were carried out in the form of group interviews, 1-2 people from each different institution were selected to participate, and the number of people in each colloquium was controlled to be between 6 and 12.~The colloquia mainly focused on: ① The status quo of the implementation of the local drug drug treatment policy, ② the status quo of the compulsory isolation drug treatment work, ③ the status quo of the work of social workers for drug drug treatment, ④ the status quo of the work of community health centers, ⑤ the operation of various mechanisms in the work of various units, and ⑥ what content in the drug control work needs assistance from other departments and what external resources are needed."
76066178|NCT06132542|Biological|stem cell therapy|The fat derived stem cell will be transplanted by a reproductive gynecologist who does routine ovarian puncture.
76066179|NCT06132529|Diagnostic Test|Brain Magnetic Resonance Imaging (MRI) Scan|Imaging of the brain
76066180|NCT06132529|Other|Speech Sample|Recorded reading aloud of pre-written words and sentences
75899356|NCT02300792|Dietary Supplement|honey|Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
75604730|NCT04758715|Other|Food provided from a commercial meal service provider for a week|Meals from a commercial meal service provider provide for a week to participant
76066181|NCT06132529|Other|Electronic Daily Headache Diary|Headache diary to provide information about headaches experience that day.
76066182|NCT06132516|Other|HIIT|High Intensity Interval Training On semi-recumbent ergocyclometer, after a symptom-limited graded exercise Test
76066183|NCT06132516|Other|LIGT|Low Intensity Group Training Group gymnastics, mainly with short static stretching/strengthening tasks.
76066184|NCT06132490|Device|Conventional Insufflator with 12 mmHg intra-abdominal pressure|In this group conventional insufflators, which have been in clinical practice for a long time, will be used under low intra-abdominal pressure throughout the surgery.
76066185|NCT06132490|Device|Valveless Insufflator with 12 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under low intra-abdominal pressure throughout the surgery.
76066186|NCT06132490|Device|Valveless Insufflator with 8 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under ultra-low intra-abdominal pressure throughout the surgery.
76066187|NCT06132464|Behavioral|Expanding Communication and Language Generated in Conversation Treatment|ECoLoGiC Treatment is a behavioral therapy developed to improve language abilities in everyday conversation for people with aphasia. It is delivered through therapeutic use of spontaneous conversational interactions between a speech-language pathologist and a person with aphasia. ECoLoGiC Treatment is based on theories of conversational interaction in adults without communication disorders, as well as on theories of neuroplasticity, rehabilitation, and learning. The therapy consists of two components: a) Therapeutic Conversation, during which the pair discuss any topic of interest to the person with aphasia, while the speech-language pathologist uses techniques to promote social interaction; and b) Therapeutic Repair, used when communication breakdown occurs. At this time, the speech-language pathologist implements the intervention's 7-step least-to-most hierarchy, supporting the person's independence and learning in communicative problem-solving to communicate the desired idea.
76066188|NCT06132451|Other|Postponement of antihypertensive treatment|Hypertensive blood pressure values in medical in-patients will not be treated during hospitalisation until confirmed by ABPM 4 weeks after hospital discharge
75453683|NCT05924412|Other|Intravenous saline solution|Saline solution (same volume as the study drug) will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incision
75463244|NCT05855551|Other|Top-up cash|"The monthly top-up cash of 1,000 BDT will be added to the base amount that is part of the standard program. For the top-up cash transfer, a person-to-person payment system is used. WFP will contract with one popular mobile banking service (either bKash or Rockets) for the monthly top-up cash transfers. About two weeks after receiving the base cash transfer, women will receive the top-up cash through a mobile account (which can also be used to receive the base cash transfer). A text message will be sent to the beneficiary to inform her that the top-up transfer has been made into her account."
75769408|NCT00189306|Drug|Imiquimod 5% cream|Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
75769409|NCT03898102|Drug|Regorafenib|regorafenib plus zinc gluconate
75769410|NCT03898102|Dietary Supplement|Zinc gluconate supplement|Zinc gluconate supplement
75899357|NCT02300792|Dietary Supplement|molasses|Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
76066189|NCT06132438|Drug|PEP-CMV vaccine|The PEP-CMV vaccine is a long synthetic peptide (PEP) made up of 26 amino acids that is derived from the human cytomegalovirus (CMV) matrix protein pp65 and has both MHC class I and II epitopes. A vaccine platform that initially consists of TMZ-induced lymphopenia and Td pre-conditioning will be used, with serial vaccinations of up to 12 times (maximum 20) being applied. To ensure the effectiveness of the future Td pre-conditioning, which is given right before the initial PEP-CMV vaccine, a Td booster is required at enrollment.
75749468|NCT05342441|Procedure|ST/Gr graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus and gracilis muscles.~The ST/Gr graft is harvested through a 4-5 cm incision at the pes anserinus. Both the semitendinosus and the gracilis tendon is identified and harvested. The tendons are prepared and folded to a four-stranded graft with a total diameter of 7-10 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
75749469|NCT05342441|Procedure|BPTB graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the patella tendon with bone block (bone-patellar-tendon-bone).~The BPTB graft is harvested through two 4-5 cm incisions, one on the tibial tuberosity and one on the patella. The middle 10 mm of the patella tendon plus 20-30 mm bone plugs at each end from corresponding tibia and patella is harvested.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus. The BPTB graft is fixed both proximally and distally with a Milagro skrew (DePuy Synthes) or similar."
76066190|NCT06132425|Behavioral|Exposure|All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.
75453684|NCT05923437|Other|Feeding model group with a chronobiological approach|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiologic approach simultaneously with the provision from the mother, and the newborn will be ensured to receive breast milk in accordance with the day cycle. Within the scope of the study, firstly, mothers and nurses in the NICU will be informed about the study. Mothers will be asked to put the milk mothers express between 06:00-17:59 in the daytime breast milk storage bag and the milk mothers express between 18:00-05:59 in the nighttime breast milk storage bag and bring them to the unit. The brought breast milk will be prepared by the nurses by matching day and night milk according to the dates, with the first milk brought in priority, and the newborns will be fed by using the time of day factor (cycle so that the milk collected during the day will be given during the day and the milk expressed at night will be given at night)."
76066191|NCT06132425|Behavioral|Rehearsal|After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.
76066192|NCT06132412|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
76066193|NCT06132412|Other|physical therapy|Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
76066194|NCT06132399|Device|VIRTUAL REALITY GLASSES|The RESET virtual reality software will be integrated into the PICO virtual reality glasses (Pico Interactive, San Francisco, US) by DYNAMICS. Virtual reality consists of simulated interactions with environments and events that are presented to the individual through technology. The virtual environments may mirror real world situations or represent controlled environments away from the real world.
76066195|NCT06132386|Other|biopsy|colorectal biopsy for tissue acquisition
75453685|NCT05922930|Drug|TROP2-CAR-NK|Given by IV (vein)
75453686|NCT05922930|Drug|Cyclophosphamide|Given by IV (vein)
75453687|NCT05922930|Drug|Fludarabine|Given by IV (vein)
75453688|NCT05921903|Biological|RSVPreF3 OA Investigational Vaccine|The investigational vaccine will be administered intramuscularly as 1 dose to RSV_IC_1 and RSV_HA groups, and 2 doses to RSV_IC_2 group).
75453689|NCT05911516|Dietary Supplement|Pennisetum purpureum|300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks
75453690|NCT05911516|Dietary Supplement|Placebo|Placebo
75453691|NCT05911165|Other|No surgical coaching|During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study
75453692|NCT05911165|Other|Surgical coaching|Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
75463245|NCT05855512|Other|Nursing Educational Intervention|Nursing Educational Intervention
76066196|NCT06132373|Behavioral|Peer delivered problem solving therapy|PST uses a straightforward approach amenable to use in new settings given its focus on idiographic problems, therefore session content is driven by the adolescent's presenting problem causing the most distress or impairment. We will use the standardized, core steps of PST and existing manualized protocols including from the Friendship Bench study and the WHO protocol for Problem Management Plus. The peers will deliver PST through 5 structured counseling sessions of 30-60 minutes over a 4-6 week period. There are 5 core components of PST which including problem listing and identification, problem exploration, developing an action plan, implementation, and follow up. The components will be introduced in the first session and be reviewed in an iterative process across the session to help participants use this model for different problems.
76066197|NCT06132321|Behavioral|Quality of life questionnaires|Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction
76066198|NCT06132308|Procedure|PENG Block with 0.25% bupivacaine|Peng block was performed.
75749470|NCT05342428|Drug|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
75453693|NCT05898724|Procedure|Blank group|include six orthodontic patients, which have a surgical procedure to install two orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed orthodontic titanium miniscrews.
75453694|NCT05898724|Procedure|Silver hydroxyapatite|include six orthodontic patients, which have a surgical procedure to install two silver hydroxyapatite nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed silver hydroxyapatite nano-coated orthodontic titanium miniscrews.
75453695|NCT05898724|Procedure|Zinc oxide|include six orthodontic patients, which have a surgical procedure to install two zinc oxide nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed zinc oxide nano-coated orthodontic titanium miniscrews.
75453696|NCT05897073|Behavioral|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
75453697|NCT05897073|Behavioral|Exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion >7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at >85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
75463246|NCT05855499|Device|CPtcube, CPTpatch|This study investigates the effectiveness of a system for reproducible application of cold plasma on larger areas and observes the effect of a 4-week additional plasma treatment on wound healing of large chronic wounds.
75463247|NCT05855486|Device|Saline eye drops|Ocular drops used to facilitate the removal of ocular secretions in pediatric subjects
75749471|NCT05335083|Device|CPAP withdrawal|A negative CPAP intervention
75749472|NCT05323812|Drug|TW001|daily dose of 100 mg TW001/placebo
75749473|NCT05323812|Drug|Placebo|daily dose of 100 mg TW001/placebo
75749474|NCT05323110|Drug|CBS001|Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
75749475|NCT05323110|Drug|Placebo|CBS001 matched placebo
75749476|NCT05301062|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Treatment with Radium-223 should follow the approved local product information according to National Medical Products Administration (NMPA) approved label
75749477|NCT05294159|Other|The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)|The Feasibility and Acceptability of Intervention Measure (FIM and AIM) are used to evaluate the feasibilit and acceptability of our implementation strategies. The FIM and AIM is a validated implementation outcome measure where higher scores indicate greater feasibility and acceptability
75899358|NCT02297282|Behavioral|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
76066199|NCT06132295|Other|Nursing care|"Consistent Schedule for the Replacement of Positioning Line Pens~Tailored Educational Content~Hypoallergenic Adhesive Patches~Enriched Treatment Care Platform~Participants with BMI > 25 and an education level of high school or below, without specific caregivers, were identified by placing a red dot on the treatment record and on the patient's happiness card. Patients with BMI < 25 and an education level of high school or above, with specific caregivers, were identified by placing a green dot on their records.~Individual interventions, educational pamphlets prepared in-house were added, to assess the maintenance status of the positioning marks."
76066200|NCT06132217|Drug|Simmitinib|Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
76066201|NCT06132217|Drug|SG001|Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
76066202|NCT06132204|Drug|HRS-7535 Tablets|HRS-7535 Tablets
76066203|NCT06132191|Drug|Cemiplimab|
76066204|NCT06132165|Drug|Deoxycholic Acid|Injection into the cutaneous Neurofibromas lesion.
75749478|NCT05271630|Other|Autologous Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT
76066205|NCT06132165|Drug|Polidocanol|Injection into the cutaneous Neurofibromas lesion.
76066206|NCT06132165|Device|1064nm Nd:YAG laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion.
76066207|NCT06132165|Device|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
75453698|NCT05897073|Behavioral|Time-restricted eating plus exercise intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion >7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at >85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
75749479|NCT05271630|Drug|Immunomodulatory Agent|ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
75749480|NCT05271630|Drug|Proteasome Inhibitor|ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
75749481|NCT05269303|Device|Live With Wearable Monitoring Device program|The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
76066208|NCT06132152|Procedure|Open hemorrhoidectomy with 'cold' scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.
76066209|NCT06132152|Procedure|Open hemorrhoidectomy with electrosurgical scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
76066210|NCT06132100|Device|digitalized incentive spirometry|digitalized incentive spirometry
76066211|NCT06132100|Device|traditional incentive spirometry|traditional incentive spirometry
76066212|NCT06132061|Other|universal prevention|Health education related to depression to strengthen the participants' self-care skills to reduce sub-health risk factors.
76066213|NCT06132061|Other|selective prevention|Psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) aimed at risk factors to prevent more severe depressive symptoms.
75453699|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 1 for 32 weeks、level 2 for 20 weeks
75453700|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 2
76066214|NCT06132061|Other|targeted prevention|Therapeutic psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) to reduce patients' depressive symptoms.
76066215|NCT06132061|Other|Waiting treatment.|Waiting treatment.
75453701|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 3
75604731|NCT04256863|Behavioral|Breakfast / Lunch|Participants in the BFL group will participate in 16 weekly, group based sessions weekly sessions in which they will be exposed to standard behavioral therapy (SBT) for weight control. Each 90-minute session will cover one weight control topic (self-monitoring, modifying the home food environment, physical activity, goal setting, stimulus control, stress-related eating, motivation, problem solving, healthy eating on a budget, social influences and weight loss maintenance) and an experiential learning activity. These hands-on activities will help teens build skills to adhere to 1) their calorie goal (1,400 - 1,600 calories/day) and 2) the prescribed timing for consumption (>50% of their energy needs consumed before 3PM every day of the week. Sample meal plans will be provided to help with adherence. .
76066216|NCT06132048|Device|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
76066217|NCT06132035|Drug|CG-P5 peptide|Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye [self-administered] using the single use tear-off disposable packaging
76066218|NCT06132035|Drug|Placebo|Patient will instill daily 1 package of Placebo eye drops in the study eye [self-administered] using the single use tear-off disposable packaging
76066219|NCT06132035|Drug|Aflibercept Injection [Eylea]|Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month
76066220|NCT06132022|Other|Mandala|Mandala work is one of the non-pharmacological approaches and is used to support patients and caregivers in various diseases. Mandala is a method that anyone can apply based on coloring a circular shape.
75453702|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 4
75453703|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks、HRS9531 injection level 2 for 20 weeks
76066221|NCT06132022|Other|Routine care|The clinic's routine information will be given to the caregivers of the control group.
75453704|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks、HRS9531 injection level 2 for 20 weeks
75453705|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks、HRS9531 injection level 2 for 20 weeks
75453706|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks、HRS9531 injection level 2 for 20 weeks
75453707|NCT05881213|Drug|CKD-378 (low-dose)|Quaque day (QD), PO
75769411|NCT03898336|Other|broad-spectrum micronutrient|daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
76066222|NCT06132009|Procedure|Surgery of endometriosis|Cystectomy or unilateral oophorectomy due to endometriosis
76066223|NCT06131996|Other|Volar supported splint|participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
76066224|NCT06131996|Other|elastic splint|participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week
76066225|NCT06131983|Drug|ARO-DUX4 for Injection|single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
75453708|NCT05880199|Device|Body surface gastric mapping device|A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.
75453709|NCT05856890|Biological|HepB mAb19|"HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg)."
75453710|NCT05856890|Other|Sterile Saline|Placebo will be normal sterile saline (NaCl 0.9%).
75453711|NCT05854628|Procedure|skin biopsy|Skin biopsies will be obtained at different time points.
75453712|NCT05851625|Device|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
75453713|NCT05851625|Device|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
75463248|NCT05855473|Other|Auricular acupuncture|The NADA protocol used in this study uses five specific points on the ear: Shen men, sympathetic autonomic, lung, liver, and kidney. Using this protocol, semi-permanent needles and seeds were placed unilaterally at five specific points in the ear by a specialist physician certified in acupuncture.
76066226|NCT06131983|Drug|Placebo|calculated volume to match active treatment by IV infusion
75604732|NCT04256863|Behavioral|Dinner (DIN)|Participants randomized to the Dinner (DIN) group will participate in the same 16-week intervention as those in the BFL group; however, the topics covered in the experiential learning session will pertain to skills needed to adhere to prescribed calorie goals NOT to timing. They will be instructed to consume >50% of their energy needs after 3PM daily.; however, given that most teens consume the bulk of their calories after 5PM, the focus will be on general calorie goals vs. timing., Teens in this group will also be provided sample meal plans that outline how to spread out their calorie intake across breakfast (200), lunch (300), after school snack (200 calories), Dinner (700 calories), after dinner snack (200 calories for 1,600 calorie diet only).
75604733|NCT00631501|Drug|Placebo|
75604734|NCT00631501|Drug|Doxycycline|
75604735|NCT04746547|Drug|Dolutegravir 50 MG|Twice daily dolutegravir with rifampicin containing TB treatment
75604736|NCT04782037|Drug|L-Methylfolate Calcium|Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
75749482|NCT05267444|Procedure|Individualized motion-based interactive game program|The participants will receive a 12-session, 4.5 months home visit service that is provided by the young adults, and supervised by an occupational therapist. Young adults will follow the individualized exercise plan with the older adults, facilitate their use of interactive games, provide psychological and technological support to help older adults cope with their fear of using technologies to perform physical activity.
75749483|NCT05261009|Drug|Peri-capsular Nerve Group (PENG)|PENG block for postoperative pain management
75749484|NCT05261009|Other|Lumbar Plexus Block (LPB)|LPB for postoperative pain management
75453714|NCT05849441|Behavioral|Aware Program|The program includes interactive, multimedia lessons for adolescent participants to learn, practice, and apply different mindfulness skills. Parent-adolescent pairs will have the option to subscribe to a mobile messaging service that includes progress reminders, encouragement, and practice content. Parent participants also have access to online resources to support and monitor their teen's use of the program.
75453715|NCT05847712|Other|Simulated work in the heat|Participants perform a continuous moderate-intensity work bout (metabolic rate of ~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of ~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
75453716|NCT05846789|Drug|Carboplatin|Carboplatin will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
75453717|NCT05846789|Drug|Tocilizumab|Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
75453718|NCT05840900|Behavioral|Digital Mindfulness Training|Once daily, 5-10 minute mindfulness exercises for 8 week intervention period using the existing perinatal mindfulness application Expectful
75453719|NCT05835219|Drug|REBYOTA™|REBYOTA™ is administered in the rectum
75463249|NCT05855460|Diagnostic Test|Skin biopsy|biochemical assessment for measurement IL35 by ELISA (Enzyme linked immunosorbent assay) technique in tissue and serum samples of all thirty patients and healthy controls.
75463250|NCT05855434|Diagnostic Test|Magnetic Resonance Imaging|Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy
75604737|NCT04257019|Other|Lavender oil|Inhalation of Lavender oil
75749485|NCT05259059|Other|No intervention is involved|No intervention is involved
75749486|NCT05257928|Behavioral|CARE-CITE Gait|The CARE-CITE intervention content modified to address gait rehabilitation, and test 4-weeks of CARE-CITE-Gait in 15 CP/SS dyads.It will occur in the dyad's home.CP will complete 6 online CARE-CITE modules. Modules will include demonstration videos and instructive content covering the following areas:principles of functional task practice, the adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity. Examples are provided to address potential SS frustration and improve adherence.Underpinning the content is the concept of autonomy support,with examples of fostering empathy, problem-solving, instruction in the use of non-controlling language with role-playing situations and the importance of creating choice in activities. During the two home therapy sessions, the physical therapist will work with the CP and stroke survivor to collaboratively develop goals and an exercise program to improve mobility, gait and balance.
75604738|NCT04257019|Other|Almond oil|Inhalation of Almond oil
75749487|NCT05254236|Biological|COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
75749488|NCT05254236|Biological|COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
75909559|NCT04331366|Device|GO2 PEEP MOUTHPIECE|The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.
75604739|NCT04257019|Other|Water|Inhalation of water
75749489|NCT05247216|Drug|Hemay007 800 mg QD group|daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
75604740|NCT01211262|Drug|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
75604741|NCT01211184|Dietary Supplement|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
75749490|NCT05247216|Drug|Hemay007 1200 mg QD group|daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
75899359|NCT02297360|Dietary Supplement|Viviscal Extra-Strength Supplement|The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
75604742|NCT01211184|Dietary Supplement|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
75604743|NCT01211184|Behavioral|Fasting.|The patient is fasting from midnight before the surgery.
75899360|NCT02297360|Other|Placebo tablet|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
75899361|NCT02293928|Procedure|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
75453720|NCT05829070|Behavioral|CHAT-S|The CHAT-S intervention will include 4 videoconference sessions over a 2-month time period that is delivered by a patient navigator. Session 1 will include content to educate participants about survivorship care and common types of follow-up care required for their specific cancer, as well as, basic insurance terms and concepts. Session 2 will teach participants about their own insurance plan (e.g., coverage, benefits, breakdown of bills, and explanation of benefits) so they can better navigate both the medical and insurance systems. Session 3 reviews health insurance laws (e.g., ACA, FMLA, No Surprises Act) and how to proceed with an appeals process. Session 4 explains how to manage the costs through budgeting and cost-of-care conversations with their medical providers.
75463251|NCT05855356|Procedure|Rehabilitation|respiratory physiotherapy, personalized aerobic and strength training
75604744|NCT00924469|Drug|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
75604745|NCT00924469|Drug|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
75604746|NCT00924469|Drug|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
75604747|NCT00631579|Drug|Rasburicase (SR29142)|
75749491|NCT05247216|Drug|Hemay007 600 mg QD group|daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
75749492|NCT05247216|Drug|Hemay007 placebo group|daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
75749493|NCT05245071|Drug|Tusamitamab ravtansine|Pharmaceutical Form: Concentrate for solution Route of Administration: Intravenous infusion
75749494|NCT05243810|Device|EPC Silver Wound Gel|Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
75749495|NCT05242042|Drug|JT001|JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
75749496|NCT05242042|Drug|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
75749497|NCT05232942|Other|Headache calendar completion|The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
75749498|NCT05221125|Behavioral|Psychologically-Informed Physical Therapy (PIPT)|The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
75749499|NCT05217147|Other|Obtaining blood samples|Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
75749500|NCT05216081|Behavioral|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
75749501|NCT05199129|Drug|HCP1904-3|Take once daily for 8 weeks orally
75749502|NCT05199129|Drug|RLD2001-1|Take once daily for 8 weeks orally
75453721|NCT05829070|Behavioral|Usual Care|Usual care will consist of a resource list that describes organizational and community resources available on insurance, financial burden, and survivorship care. Further, we will track whether participants were referred or engaged in services using the follow-up surveys and via the EHR/claims data.
75453722|NCT05821777|Drug|LB101|Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101
75453723|NCT05819047|Device|Functional test with a haptic device|Volunteers will complete two tests based on the Nine Hole Peg Test with a haptic device.
75453724|NCT05814510|Behavioral|Asthma CHAMPS full program|Full program includes (1) education for staff, students, and caregivers (2) environmental education and intervention (3) asthma care coordination (4) resources
75604748|NCT04256551|Other|Heali mobile application + Registered Dietitian|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. RDs employed by Heali provide real-time messaging to users. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
75604749|NCT04256551|Other|Heali mobile application|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
75604750|NCT04256551|Other|Standard Dietary Education|An educational guide to the implementation of the elimination and reintroduction phases of the diet, a suitable/unsuitable food guide, 19 substitutes for unsuitable foods, a guide of example meals (i.e., breakfast-6 recipes, lunch-8 recipes, dinner-12 recipes, and snacks/beverages-13 recipes), and tips for reading labels and eating a balanced diet while following the LFD. The website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System.
75604751|NCT00924313|Drug|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
75749503|NCT05194202|Behavioral|ED-HEART|Behavioral intervention that assesses 1) healthy and unhealthy relationship behaviors, 2) conversation with partners around boundaries within relationships, 3) harm reduction strategies, and 4) resources for Adolescent Relationship Abuse (ARA) and related concerns, including Point of Care (POC) Reproductive and Sexual Health (RSH) harm reduction resources.
75749504|NCT05189457|Drug|Luteinizing Hormone Releasing Hormone|During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
75749505|NCT05189457|Drug|New Hormonal Agent|During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
75749506|NCT05189457|Drug|Docetaxel|"During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel."
75749507|NCT05189457|Drug|Tislelizumab|During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
75749508|NCT05181917|Behavioral|STUDIA app|STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
75749509|NCT05179616|Procedure|Transcatheter edge-to-edge tricuspid valve repair|Percutaneous edge to edge repair of tricuspid valve using the TriClip system
75769412|NCT03898336|Other|placebo|daily intake of capsules
75604752|NCT01209780|Biological|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
75604753|NCT01209780|Biological|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
75604754|NCT01209780|Biological|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children <4 years.
75604755|NCT00916357|Drug|Humalog|
75749510|NCT05175014|Biological|PCV10 full dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a full dose.
75604756|NCT00916357|Drug|Humulin-R|
75604757|NCT00916357|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
75749511|NCT05175014|Biological|PCV10 fractional dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a fractional dose.
75749512|NCT05165823|Behavioral|Sodium restriction|Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.
75749513|NCT05159245|Drug|Alectinib|ALK
75749514|NCT05159245|Drug|Cobimetinib|MEK1, MEK2
75749515|NCT05159245|Drug|Vismodegib|Hedgehog
75749516|NCT05159245|Drug|Trastuzumab+Pertuzumab|HER2
75749517|NCT05159245|Drug|Entrectinib|NTRK/ ROS1, ALK
75749518|NCT05159245|Drug|Atezolizumab|PD-L1
75749519|NCT05159245|Drug|Vemurafenib|BRAF V600
75749520|NCT05159245|Drug|Regorafenib|KIT/BRAF, RET
75749521|NCT05159245|Drug|Apalutamide|AR
75749522|NCT05159245|Drug|Abemaciclib|CDK4/6
75749523|NCT05159245|Drug|Selpercatinib|RET
75749524|NCT05159245|Drug|Dabrafenib|RAF
75749525|NCT05159245|Drug|Trametinib|MEK1, MEK2
75749526|NCT05159245|Drug|Dabrafenib+Trametinib|RAF, MEK1, MEK2
75749527|NCT05159245|Drug|Pralsetinib|RET
75749528|NCT05155995|Drug|HCP2001|Take it once per period.
75899362|NCT02294006|Drug|Everolimus plus Octreotide LAR plus Metformin|Everolimus plus Octreotide LAR plus Metformin
75899363|NCT01348347|Drug|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
75899364|NCT01348347|Drug|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
75899365|NCT01348347|Drug|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
75899366|NCT02294084|Drug|Sitagliptin|Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.
75453725|NCT05814510|Behavioral|Asthma CHAMPS Wait List Control|Stepped wedge design
75453726|NCT05810038|Drug|Rimegepant|Rimegepant
75453727|NCT05810038|Drug|Placebo|matching placebo
75604758|NCT00916279|Device|Lutonix Paclitaxel-Coated Balloon|PTCA
75604759|NCT05329753|Device|Mobile health application|Health intervention through a smartphone application that favors the process of learning
75604760|NCT04849897|Device|Experimental: Virtual Reality Guided Imagery|Platform and VR Goggles
75604761|NCT04849897|Other|Active Comparator: Audio Only Guided Imagery|Audio Recordings of Guided Imagery via an iPAD
75604762|NCT00631345|Behavioral|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
75749529|NCT05155995|Drug|RLD2007|Take it once per period.
75749530|NCT05155995|Drug|RLD2008|Take it once per period.
75749531|NCT05155995|Drug|RLD2102|Take it once per period.
75749532|NCT05142371|Other|Best Practice|Continue current activities of daily living
75749533|NCT05142371|Other|Exercise Intervention|Participate in exercise intervention
75453728|NCT05806515|Procedure|Biospecimen Collection|Undergo collection of blood samples
75453729|NCT05806515|Drug|Carboplatin|Given IV
75453730|NCT05806515|Procedure|Chest Radiography|Undergo chest X-ray
75453731|NCT05806515|Procedure|Computed Tomography|Undergo CT
75453732|NCT05806515|Procedure|Magnetic Resonance Imaging|Undergo MRI
75453733|NCT05806515|Procedure|PSMA PET Scan|Undergo PSMA PET
75749534|NCT05142371|Other|Quality-of-Life Assessment|Ancillary studies
75749535|NCT05142371|Other|Questionnaire Administration|Complete questionnaires
75749536|NCT05120830|Biological|Biological NTLA-2002|CRISPR/Cas9 gene editing system delivered by LNP for IV administration
75749537|NCT05120830|Other|Normal Saline IV Administration|The administration of IV normal saline
75749538|NCT05116995|Drug|Rivaroxaban|rivaroxaban 2.5 mg twice a day for 7 days
75749539|NCT05116995|Drug|Ticagrelor|Ticagrelor 60 mg twice a day for 7 days
75749540|NCT05116917|Drug|Nivolumab|3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle
75749541|NCT05116917|Drug|Ipilimumab|1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks
75749542|NCT05116917|Biological|Influenza vaccine|Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days)
75899367|NCT02294084|Drug|placebo|Each subject will receive a placebo (once a day) for 12 weeks.
75899368|NCT03640533|Behavioral|Nanit-Insights|Nanit-Insights is an app-based intervention that provides personalized sleep tips to parents.
76066227|NCT06131957|Combination Product|Fluoride varnish with SBGC|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA) mixed with 7.5% SBGC (Dencare (Chongqing) Oral Care Co., Ltd).
76066228|NCT06131957|Drug|Fluoride varnish|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA)
76066229|NCT06131931|Other|CLP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Connecting Latinxs en Pareja (CLP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
76066230|NCT06131931|Other|WP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Wellness Promotion (WP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
75453734|NCT05806515|Procedure|Surgical Procedure|Undergo surgery
75604763|NCT00631345|Other|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
75604764|NCT00631345|Behavioral|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
75749543|NCT05116917|Radiation|SBRT|"A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~PTV should be covered by 95% isodose (PTV D99% > 95%)."
75749544|NCT05105776|Device|Galvanic stimulation|Galvanic stimulation during physiotherapy sessions
75749545|NCT05097885|Other|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
75749546|NCT05097222|Device|BioFlex Dualport System|The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.
75749547|NCT05097222|Device|Sham device|Control
75749548|NCT05095857|Drug|S-ketamine|S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
75769413|NCT03972462|Drug|NPC-12G Gel 0.2%|Period 1
75453735|NCT05799313|Other|At home removal|Removal of PNE lead at home
75453736|NCT05799313|Other|In office removal|Removal of PNE lead in the office
75453737|NCT05793957|Other|Questionnaire Administration|Ancillary studies
75453738|NCT05793957|Behavioral|Telephone-Based Intervention|Use smartphone
75453739|NCT05793957|Other|Virtual Technology Intervention|Use VR headset
75769414|NCT03972462|Drug|Rapamune® 2 mg tablet|Period 2
75463252|NCT05855356|Procedure|Standard of Care|Behavioural and Medical management
75749549|NCT05095857|Other|Isotonic saline (placebo)|Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
75749550|NCT05094817|Other|Brain Health Assessment|BHA is a free, self-administered online cognitive screening test developed in Toronto at Baycrest (www.cogniciti.com). BHA has been validated against a gold standard neuropsychological assessment for detecting amnestic MCI (aMCI) - the most common type of MCI - in community dwelling older adults. BHA has high sensitivity (.78), specificity (.78), PPV (.82), NPV (.74), and was better than MoCA for identifying aMCI. ROC curves showed an AUC of 0.75 for detecting aMCI from normal subjects. BHA measures memory and executive attention processes sensitive to subtle cognitive changes associated with normal aging and MCI. BHA can be completed from a patient's home or can be self-administered in hospital.
75749551|NCT05094817|Other|Demographics questionnaire|To compare the sociodemographic characteristics of patients completing Cogniciti's BHA vs. those who are not able to complete the BHA.
75749552|NCT05094817|Other|PHQ-2|PHQ-2 is a shortened version of PHQ-9 which is originally a component of the longer Patient Health Questionnaire. The tool incorporates DSM-IV depression criteria and other leading major depressive symptoms into brief self-reported instruments. PHQ-2 inquires about the degree to which an individual experiences depression and anhedonia (inability to feel pleasure) over the past two weeks. The tool is not for final diagnosis of depression or monitoring its severity but only for the purpose of screening for the condition.The questionnaire comprises of the first two questions from PHQ-9, each item is scored 0-3. Therefore, the PHQ-2 score ranges from 0-6.
75769415|NCT01150786|Dietary Supplement|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
75769416|NCT01150786|Other|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
75769417|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
75899369|NCT04464746|Other|implementation of a specific program to improve therapeutic adherence|"Discussion of risks associated with high BP;aims,healthy lifestyle options.~Individualized educational intervention:verbal, written,audiovisual information. Evaluation of knowledge of prescribed drugs.~Behavioral counseling.training patients to participate in their own care, while positively modifying their skills or routines (i.e. pill boxes,calendars,specific measures to remind the patient taking drugs,adapt the regimen to atient's daily routine).~Socio-psycho-affective interventions.~Reminder systems: phone,email,alarm on the mobile phone.~Simplification as far as possible of therapeutic scheme.~Explanation of prescribed medications (name&dosage), correct intake.~Explanation of possible side effects and what to do if they happen. Facilitate a contact.~Advise and training on home blood pressure self-measurement.~Verbal, written and/or audiovisual information and the online patients'section of scientific societies addresses will be provided."
75899370|NCT03640065|Drug|freeze-dried probiotic sachets|"The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~This procedure will be repeated once daily for the following 4 weeks.~4 weeks supply will be given to the participants."
75899371|NCT03640065|Dietary Supplement|fermented dairy product ( yogurt)|"The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home"
75453742|NCT05782075|Other|Remote biological monitoring by a heart failure nurse|Review of biological results by a nurse (IDE) trained in heart failure monitoring, alongside the cardiologist, at S1, S2, M1, M2 and M3.
75453743|NCT05781620|Dietary Supplement|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks. If the serum 25(OH)D concentration exceeds 48 ng/mL, the intervention remains the same. However, if the serum 25(OH)D concentration is under 48 ng/mL, the dosage would increase by 2,500 IU. The principle remains the same at week 6.
75453744|NCT05781620|Dietary Supplement|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily.
76066231|NCT06131515|Device|extra corporeal shock wave therapy device|"Patients were seated in a relaxed position with their forearm and finger placed on the table. The median nerve was identified at the pisiform level of the proximal carpal tunnel, with the palm facing upwards. rESWT was delivered with the Physio Shock Wave Therapy system .The rESWT probe was located and oriented perpendicularly on the median nerve, and treatment comprised graduated shots at a bar pressure of 4 and a pulse repetition frequency of 5Hz for each patient ( The treated area was parallel to the median nerve from the pisiform level to 2 cm proximal to the inlet of the carpal tunnel with equal diffusion of 800, 900, 1000, 1100 shots from first to fourth session respectively. The procedure was painless, and there was no need for additional anesthesia or analgesia.~In the control group, sham rESWT just made the same sound without energy emission"
76066232|NCT06130215|Other|Simple meal management|"Regular meal: Total Carbs per Day x 0.6 / 3~Large meal: Total Carbs per Day x 0.6 / 3 x 1.5~Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5"
76066233|NCT06130215|Other|Precise meal management|precise carbohydrate counting for each meal
75453745|NCT05769881|Procedure|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
75453746|NCT05769881|Procedure|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
76066234|NCT06130020|Behavioral|Expressive Writing: Self|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing to themselves.
75604765|NCT00631345|Behavioral|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
75604766|NCT05252455|Behavioral|pelvic and abdominal mechanics exercise|"starting from 24 weeks of pregnancy, participate in the pelvic and abdominal mechanics exercises offered by the Good Pregnancy College of Shanghai Tongren Hospital once a week. Each class lasts one hour until the 38th week of pregnancy (attend at least 10 times)"
75604767|NCT04698421|Biological|Blood collection on admission and longitudinally|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).
75453747|NCT05765500|Drug|Relugolix|Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
75604768|NCT05217823|Device|Er:YAG laser|
75604769|NCT05217823|Other|hand instruments|
75604770|NCT01209078|Drug|GSK1322322|GSK1322322 1500mg BID
75604771|NCT01209078|Drug|Linezolid|Linezolid 600mg
75604772|NCT01209078|Drug|GSK1322322 placebo|Placebo
75604773|NCT01209078|Drug|Linezolid placebo|placebo
75453748|NCT05765500|Drug|Leuprolide|Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
75453749|NCT05760781|Drug|STSG-0002 Injection|Intravenous infusion
75453750|NCT05760703|Drug|STSG-0002 Injection|Intravenous infusion
75604774|NCT04708561|Behavioral|Speech and language therapy|"The intervention focuses on understanding the thoughts of the characters. Twenty written stories will be used, which end with statements that can be interpreted literally, ironically, as a lie, a request or a faux-pas (maladroitness). At the end of each story, the participant should explain what the characters want to mean by their statement.~To help the participant in his understanding of the character's intention, he will be asked:~1) To mention as many intentions as possible that can be associated with the target statement presented out of context (eg: it's hot here that can be interpreted literally, ironically, as a lie or a request) and to imagine contexts in connection with interpretation; 2. Analyze the relevant elements of the context (environment, the relationship between the characters, knowledge of the characters); 3. To judge the probability of the possible interpretations (pt 1) by justifying using the elements of the context analyzed previously (pt 2)."
75749553|NCT05094817|Other|AFT|AFT is a free, rapid cognitive assessment commonly used to assess semantic language ability. Language is one of the earliest functions affected by AD and naming and semantical knowledge seems to be particularly affected. The identification of language deficits may pick up signs of neurological decline preceding the appearance of clinical symptoms. Milder forms of cognitive impairment such as MCI may also show language deficits if language is one of the domains affected.
75453751|NCT05758337|Device|Vibropneumostimulation|New vibrators and techniques of vibropneumostimulation of periimplant tissues have been developed, which will allow us to develop a new concept of the relationship of bone remodulation processes around implants of various designs.
75453752|NCT05758194|Other|Standardized RV Management|Standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
75453753|NCT05758194|Other|Usual Care RV Management|No standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
75453754|NCT05757466|Drug|Prolgolimab|Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
75453755|NCT05757466|Drug|Combination with prolgolimab and bendamustine|Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
75453756|NCT05754216|Device|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired pharyngeal musculature in a therapeutic manner.
75453757|NCT05753189|Drug|Aceclidine+Brimonidine combination ophthalmic solution|Combination ophthalmic solution of Aceclidine and Brimonidine
75604775|NCT04849585|Other|semi-directed entretien|semi-directed entretien
75604776|NCT04672135|Drug|REM0046127|Oral solution: 100 mg/mL REM0046127
75604777|NCT04672135|Drug|Placebo|Oral solution with 0 mg/mL REM0046127
75604778|NCT04584385|Diagnostic Test|EEG|EEG monitoring
75604779|NCT05212909|Behavioral|General Anxiety Disorder-7 scale|The General Anxiety Disorder-7 scale was used to evaluate the level of anxiety in anesthesiology providers.
75604780|NCT04318470|Diagnostic Test|mNGS|Metagenomic next generation sequencing for microbial DNA
75604781|NCT04318158|Drug|Bupivacaine|single shot US guided TAP block using 20 ml bupivacaine 0.25%.
75604782|NCT04318158|Drug|Dexmedetomidine|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
75604783|NCT04318158|Drug|Fentanyl|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
75769418|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
75769419|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
75769420|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
75769421|NCT03897790|Other|Transcranial Doppler (DTC)|Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
75749554|NCT05094817|Other|GAI-SF|GAI-SF is a 5-item questionnaire derived from the original 20-item Geriatric Anxiety Inventory (GAI).In the population of community dwelling older women GAI-SF was developed in, a cut-off score of 3 yields a specificity of 87% and sensitivity of 75%. This highly accessible questionnaire is suitable for everyday use in a range of health-care settings. It has been employed amongst older adults in primary care settings, nursing homes, geriatric psychiatry patients and amongst clinical geriatric participants with co-morbid anxiety and unipolar mood disorder and their controls.
75604784|NCT05418426|Device|IVR Dose 1|Estradiol 80 ug/progesterone 4 mg
75604785|NCT05418426|Device|IVR Dose 2|Estradiol 160ug/progesterone 8 mg
75453758|NCT05753189|Drug|Placebo|Placebo: Proprietary Vehicle Solution
75749555|NCT05094817|Other|pain VAS|The VAS is a unidimensional measure of pain intensity. The VAS tries to measure a continuous characteristic or attitude signifying the intensity or frequency of symptoms. The scale ranges from 0-10, with 0 = no pain to 10 = worst pain.
76066235|NCT06130020|Behavioral|Expressive Writing: Other|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing/talking to someone they're close to.
75604786|NCT05418426|Drug|Oral Reference|estradiol 1mg/progesterone 100 mg
75604787|NCT05416710|Diagnostic Test|Invitae's 84 gene multi-cancer panel.|Invitae's Multi-Cancer panel analyzes 84 genes associated with hereditary cancers across major organ systems.
76066236|NCT06130020|Behavioral|Factual Writing|This intervention consists of a daily factual writing exercise carried out for 14 consecutive days, for 15 minutes each day. Participants are asked to give a factual description of their day. This is a standard control for Expressive writing studies. Participants in this condition will be asked to direct their writing to themselves.
75749556|NCT05094817|Other|IADL|Instrumental activities such as preparing meals or managing finances allow individuals to maintain their health while living on their own. The IADL measures the ability of older adults to manage their daily activities, as well as the impact, if any, cognitive decline would have on these activities. Scores range from 0-5 for men, and 0-8 for women, with higher sores being more independent and higher functioning.
76066237|NCT06129747|Radiation|Radiation Therapy|"Weeks 1, 2 and 3~Weeks 1, 2 and 3 will include 5 days of treatment.~One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes."
76066238|NCT06129526|Dietary Supplement|EPAVasc|EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol
76066239|NCT06129526|Dietary Supplement|Corn Oil|Corn Oil
75453759|NCT05753189|Drug|Aceclidine Ophthalmic Solution|Aceclidine
75453760|NCT05746208|Drug|Lenvatinib|Given orally
75604788|NCT01207596|Drug|Hydromorphone|Oral hydromorphone extended release, once daily
75604789|NCT00915343|Drug|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
75453761|NCT05746208|Drug|Pembrolizumab|Given IV
75453762|NCT05746208|Drug|Hyperpolarized 13C-Pyruvate|Given IV
75453763|NCT05744167|Behavioral|BFRT|Following a warm-up of 10 min, subjects in the experimental group will undergo BFRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). BFRT will be at 40% of 1 repetition maximum (1RM); The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
75463253|NCT05855291|Diagnostic Test|PET/MRI|The participants receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
75463254|NCT05855278|Diagnostic Test|PET/MRI|The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
75604790|NCT00915343|Drug|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
75604791|NCT04667533|Drug|Desidustat|"A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~Cohort I: Single-dose 100 mg~Cohort II: Single-dose 150 mg~Cohort III: Single-dose 200 mg"
75604792|NCT04578301|Other|No Intervention|No Intervention
75749557|NCT05094817|Other|FAM CAM|FAM-CAM was derived from the CAM instrument in order to screen for delirium by interviewing family members or caregivers of the patient. They are asked specific questions about any new or sudden changes in the patient's activity, behavioural or cognitive status. FAM-CAM showed good sensitivity and specificity in the original study where caregivers of elderly patients with pre-existing cognitive impairment were interviewed.
75749558|NCT05094817|Other|4AT|The 4AT is a rapid tool for delirium detection that has previously been used in a surgical setting. The 4Ats test for the patient's alertness, mental state, attention, and signs of acute change. Across 17 studies, the pooled sensitivity and specificity of 4AT was 0.86 and 0.89. The 4AT will be administered after the patient has completed surgery, prior to discharge.
75749559|NCT05094817|Other|BHA Usability Survey|The survey aims to assess system usability and acceptability based on standard questions adapted from the validated System Usability Scale. The questions evaluate satisfaction, experience with technology, and comfort level, as well as questions targeting usability concerns typically experienced by older adults, such as typeface and font size, consistent navigation, and writing style.
75749560|NCT05094817|Other|Clinical Frailty Scale|CFS is a 9-item scale that uses clinical descriptors and pictographs and is an easily applicable tool to stratify older adults according to level of vulnerability. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). It is easy to use and may readily be administered in a clinical setting, an advantage over the tools previously developed. The scale helps in objective early identification of older adults with frailty in acute care units and helps to target interventions to prevent complications and to implement effective discharge planning.
75749561|NCT05086380|Behavioral|Mindfulness-based stress reduction therapy|MBSR Therapy is a structured 8-week program that employs mindfulness meditation to alleviate suffering associated with physical, psychosomatic and psychiatric disorders. The program is based upon a systematic procedure to develop enhanced awareness of moment-to-moment experience of perceptible mental processes.
75749562|NCT05086380|Device|Inhibitory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using cTBS stimulation protocol for transcranial magnetic stimulation
75749563|NCT05086380|Behavioral|Psychoeducation|Participants will learn about the symptoms and how to cope with the symptoms
75749564|NCT05086380|Device|TMS sham|The device will be used to neuromodulate the right TPJ of participants' brain using transcranial magnetic stimulation over the vertex
75749565|NCT05086380|Device|Excitatory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using iTBS stimulation protocol for transcranial magnetic stimulation
75749566|NCT05086380|Device|Virtual Reality|The device will be used to manipulate the perception of symptoms of patients while they are playing a game in virtual/augmented reality.
75749567|NCT05086380|Behavioral|Neurofeedback|Neurofeedback training will be applied in patients while laying in an MRI scanner. Patients will play a game, which targets the sense of agency, and will receive a real-time feedback about their performance and brain activity. They will learn to self-regulate their performance on the game in order to increase brain activity relevant for the sense of agency.
75749568|NCT05078398|Behavioral|POINT Protocol|Patients will receive counseling on risks and benefits of opioids for pain control, asked to choose whether they need opioid prescription when ready for discharge.
75749569|NCT05078398|Behavioral|Usual care|Will prescribe standardized amount of opioid for postoperative pain without patient input
75749570|NCT05056623|Behavioral|Dyadic pain management program|"Face-to-face part: The DPM will start with 20-30 minutes of physical exercise supervised by research assistant, followed by 20-minutes of pain management education. Communication skills regarding the practice of various pain management techniques by the participants and their caregivers will be taught. At the end of the session, the caregiver and research assistant will help the older adults to make portfolio entries on the activities of the day, to help them recall the various pain-relief methods learned in each class.~Home-based part: An exercise book will be given to guide them in performing exercises at home. It is recommended to perform 30 minutes of exercise, 3 times a week, at home and the more frequent the exercise time, the better.~All participants will join a WhatsApp group to receive teaching materials and videos of the physical exercises learned, for practice at home. The team will produce compact disc (CD) with the exercise video clips to the dyads for revision."
75749571|NCT05056623|Other|Usual care and pain management pamphlet|Usual care and pain management pamphlet
75749572|NCT05053113|Device|Activity Monitor|Monitor physical activity with FitBit
75899372|NCT03515486|Other|Post stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations
75899373|NCT03512366|Procedure|Desarda's technique|It will be performed by separating a strip from the upper leaf of the external oblique aponeurosis in continuity with the muscle and suturing it with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence.
76066240|NCT06129448|Diagnostic Test|transthoracic echocardiography|All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.
75453764|NCT05744167|Behavioral|MDRT|Following a warm-up of 10 min, subjects in the experimental group will undergo MDRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). The exercise will be at 80% of 1RM concentric-only or 120% of 1RM eccentric-only in a 3:1 ratio. The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
75749573|NCT05053113|Device|Activity Monitor|Wear accelerometer
75749574|NCT05053113|Other|Educational Intervention|Receive educational newsletter
75749575|NCT05053113|Other|Survey Administration|Ancillary studies
75749576|NCT05053113|Behavioral|Telephone-Based Intervention|Receive phone call from health coach
75749577|NCT05041842|Drug|Tucatinib|300 mg orally twice daily
75604793|NCT05220865|Procedure|Hall Technique|"Only food scraps or debris will be removed from the caries cavity.~The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~The child will be asked to bite firmly until the crown is pushed down over the tooth.~If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~The child will continue to bite on a cotton roll until the cement hardens~Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
75604794|NCT05220865|Procedure|Modified Hall Technique|"Food scraps or debris will be cleaned from the caries cavity and infected soft carious dentin tissue will be excavated with hand instruments.~The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~The child will be asked to bite firmly until the crown is pushed down over the tooth.~If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~The child will continue to bite on a cotton roll until the cement hardens~Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
75749578|NCT05041842|Drug|Pertuzumab|Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
75749579|NCT05041842|Drug|Trastuzumab|"Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly"
75899374|NCT03512366|Procedure|Lichtenstein's technique|A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring.
76066241|NCT06129188|Drug|Remimazolam|Remimazolam is an ultra-short acting benzodiazepine medication. Benzodiazepines are a class of drug that directly interact with gamma-aminobutyric acid (GABA) and modifiable chloride channels through polysynaptic pathway inhibition. The anxiolytic properties of benzodiazepines make them useful as sedatives.
76066242|NCT06129188|Drug|Propofol|Standard of care usage of the intravenous anesthetic agent propofol to achieve adequate sedation conditions for the procedure.
75453765|NCT05735067|Other|Blood sample collection|5 ml of blood samples were withdrawn from RRMS patients
75749580|NCT05041842|Drug|Hormone therapy|Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
75749581|NCT05041842|Drug|Pertuzumab/ Trastuzumab|"Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly"
75749582|NCT05039541|Device|Alio Device|Subjects will wear the Alio device over their vasculature.
75749583|NCT05022459|Drug|Emicizumab|Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A
75749584|NCT05022459|Drug|FVIII|Patients in this group will be on standard of care FVIII prophylaxis for Hemophilia A
75749585|NCT05018728|Drug|Voxelotor|Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
75899375|NCT02959671|Device|Lower Anterior EXD-952 Self-ligating Brackets|Placement of EXD-952 Self-ligating Brackets on mandibular incisors
76066243|NCT06128447|Drug|ZP5-9676 600 mg dose|oral, chewable tablet formulation of flubendazole
75453766|NCT05733975|Other|Decision Making Guide|The tool will be used by parent(s) to help guide them in discussion with their infant's clinicians.
75453767|NCT05728944|Drug|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine + Brimonidine combination ophthalmic solution
75453768|NCT05728944|Drug|Aceclidine|Aceclidine ophthalmic solution
75453769|NCT05728944|Drug|Vehicle|Proprietary vehicle ophthalmic solution
75453770|NCT05724095|Other|high frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 10/50 Hz is given
75453771|NCT05724095|Other|low frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 2/10 Hz is given
76066244|NCT06128447|Drug|Placebo|Matching placebo
76066245|NCT06128330|Drug|Tranexamic acid bolus 20 mg/kg|Bolus of tranexamic acid in the standard dose group
76066246|NCT06128330|Drug|Tranexamic acid bolus 10 mg/kg|Bolus of tranexamic acid in the low dose group
76066247|NCT06128330|Drug|Tranexamic acid bolus 1 mg/kg|Bolus of tranexamic acid in the low dose group (to add into the CPB prime)
76066248|NCT06128330|Drug|Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group|Tranexamic acid continuous infusion during the procedure
75749586|NCT05014412|Drug|Elranatamab|BCMA-CD3 bispecific antibody
75749587|NCT05014412|Drug|Elranatamab+ dexamethasone|BCMA-CD3 bispecific antibody + corticosteroids (dexamethasone)
75749588|NCT04998422|Drug|HG381|HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
75749589|NCT04996004|Drug|Ontorpacept (TTI-621)|Ontorpacept (TTI-621) will be administered by intravenous infusion.
75749590|NCT04996004|Drug|Doxorubicin|75 mg/m^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
75749591|NCT04995913|Other|Online cognitive behavioral therapy|The intervention includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy. Participants will learn and practice a variety of the cognitive behavioral skills to cope with their social anxiety. The functions of the EASE Online Program include animation briefing and debriefing, case demonstration videos, assignment and feedback, forum, internal messaging, reminder, online assessment, online booking and progress checking. The duration of the intervention is 14 weeks.
75749592|NCT04995835|Drug|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
75899376|NCT03515408|Device|rTMS|The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
75899377|NCT01597258|Drug|Crizotinib (Xalkori)|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
75899378|NCT02958267|Biological|BMAC injection|60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician.
75899379|NCT02958267|Biological|PRP injection|60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician.
75749593|NCT04983511|Diagnostic Test|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
75899380|NCT02958267|Device|Gel-One® hyaluronate injection|Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution [10 mg/mL], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance.
75899381|NCT02302352|Other|Probiotic|Probiotic 1g once a day by mouth for 8 weeks
75899382|NCT02302352|Other|Placebo|Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
75899383|NCT02302430|Drug|Oxytocin|20 International Units Intranasal Oxytocin
75899384|NCT02302430|Other|Placebo comparator|Saline nasal spray
76066249|NCT06127862|Other|Education group|Students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals.
76066250|NCT06127862|Other|No training was given|No training was given
75453772|NCT05724095|Other|electrodes attached|electrodes are attached to area of acupoints
75453773|NCT05723614|Behavioral|TRUE HAVEN|The two components of the TRUE HAVEN intervention are: housing support for recently incarcerated people as well as family members of currently incarcerated people, and mental wellness training for neighborhood residents to participate in trauma-informed care training sessions.
75749594|NCT04979104|Procedure|Hip arthroplasty with SL Cementless|Total or partial hip arthroplasty with implant of SL cementless femoral stem.
75749595|NCT04977167|Drug|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
75749596|NCT04977167|Drug|PD-(L)1 antibody|PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
75749597|NCT04973683|Drug|AL101|Given IV
75749598|NCT04973683|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
75749599|NCT04962594|Other|Experimental formulas (EF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
75749600|NCT04962594|Other|Control formulas (CF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
76066251|NCT06126757|Device|PelviSense-assisted pelvic floor muscle training|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays the electrical activity of the PFMs on the user's mobile device. The re-usable sensor can be attached to the user's perineal region, and when positioned correctly, the width of the sensor is oriented along the medial-lateral axis, and the length is oriented along the anterior-posterior axis of the perineal region. The sensor detects PFM activity as the voltage between the two surface electrodes and transmits this activity to the data acquisition unit, which processes the signal and conveys it to a smartphone via a Wi-Fi connection. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts.
76066252|NCT06126757|Other|Active Comparator|Pelvic Floor Muscle Training Exercise will be performed without the assistance of the PelviSense Device.
76066253|NCT06126549|Behavioral|Building Better Caregivers|Peer-led, group intervention for caregivers focused on problem-solving
76066254|NCT06126549|Behavioral|Problem Solving Training|Clinician-led, one-to-one intervention for caregivers focused on problem-solving
76066255|NCT06126549|Behavioral|Usual Care|Usual discharge training and support offered to family caregivers of ABI patients
76066256|NCT06126393|Diagnostic Test|next generation sequencing AND Immunohistochemical examination|First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.
76066257|NCT06125067|Procedure|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
76066258|NCT06125067|Procedure|Fascia Iliaca Compartment Block|Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.
76066259|NCT06125067|Procedure|iPACK Block|During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
76066260|NCT06124625|Procedure|Rehabilitation combined to a digital maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week maintenance program (2 sessions per week à 90 minutes, digital and live). The multimodal programs consist of physiotherapy, training therapy, medical support, cognitive training, education and psychological support.
75604795|NCT04651621|Device|continuous theta burst stimulation over the SMA|Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.
75604796|NCT04651621|Device|sham continuous theta burst stimulation over the SMA|The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation
75604797|NCT00632047|Other|active surveillance|
76066261|NCT06124625|Procedure|Rehabilitation without maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week usual care period.
75604798|NCT00632047|Other|educational intervention|
75604799|NCT00632047|Procedure|examination|
76066262|NCT06124287|Diagnostic Test|MR Enterography (MRE)|MRI scan
76066263|NCT06124131|Behavioral|Financial incentive for colorectal cancer screening|$50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment
76066264|NCT06124131|Behavioral|Financial incentive for flu shot|$50 incentive paid to participant for completion of flu shot within 2 months of enrollment
76066265|NCT06124131|Behavioral|Financial incentive for COVID-19 shot|$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
76066266|NCT06124001|Drug|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
76066267|NCT06124001|Drug|camrelizumab for Injection|Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
76066268|NCT06121505|Radiation|low-dose radiation therapy and stereotactic body radiation therapy|Patients will receive radiation therapy.
75604800|NCT00632047|Procedure|long-term screening|
75604801|NCT04203043|Drug|Pycnogenol Oral Product|pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
75604802|NCT04203043|Other|Placebo|Placebo
75604803|NCT04435015|Drug|Camostat Mesylate|Participants will be given Camostat mesylate three times daily.
75604804|NCT04435015|Drug|Microcrystalline Cellulose, NF|Participants will be given Microcrystalline Cellulose (placebo) three times daily.
76066269|NCT06121505|Drug|chemotherapy|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
75604805|NCT04235725|Other|Harmonized Depression Outcome Measures|This is an observational study where retrospective data on previous disease status and patient characteristics will be collected and combined with longitudinal data from these data sources on outcomes during the study timeframe.
76066270|NCT06121505|Drug|Sintilimab|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
76066271|NCT06119035|Other|Single dose of 75 grams glucose in 200ml water|Consume single dose of 75 grams glucose in 200ml water
75899385|NCT04485208|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
76066272|NCT06116656|Diagnostic Test|blood leucocyte transcriptomics|the analysis of the RNA transcripts produced by the genotype at a given time that provides a link between the genome, the proteome, and the cellular phenotype.
75453774|NCT05720741|Behavioral|Project THINK|Project THINK is a 30-minute self-guided digital intervention designed to teach children and adolescents how to change the way that they think. Specifically, Project THINK is based on the principles of cognitive restructuring, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project THINK uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for assessing the presence of unhelpful thoughts and replacing them with more helpful ones. Although never formally tested in a randomized trial, Project Think has been used by hundreds of students, and feedback has been very positive.
75604806|NCT04170361|Other|Conventional Chest Physiotherapy|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
75604807|NCT04170361|Other|Conventional Chest Physiotherapy+Incentive Spirometry|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals.
75899386|NCT03640299|Procedure|ERAS procedure|Optimized preoperative, intraoperative and postoperative procedures.
75909560|NCT05155592|Biological|reduction or discontinuation of Adalimumab|For patients with non-infectious uveitis whose inflammation stabilizes after treated with Adalimumab, extended dosing intervals to once a month, during which inflammatory status is monitored. If there was no recurrence within 6 months, Adalimumab was discontinued, and whether inflammation recurred after withdrawal was observed.
75909561|NCT03474614|Drug|Propranolol|The medication will be administered so that patient receives a minimum of 7- days and maximum of 10-days of treatment with propranolol prior to planned surgical resection of CCM (routine care)
76066273|NCT06115577|Diagnostic Test|endometrial tissue and peripheral blood mononuclear cells receptivity|Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.
75604808|NCT04817293|Other|Questionnaire|Questionnaire SSD-12 and EQ5D5L
76066274|NCT06114147|Device|trans thoracic echocardiography measure|The trans thoracic echography would be carried out with cardiac classic sections to ensure the structural cardiac and valvular normality and then sections repeated 3 times over 10 minutes will be carried out to calculate the cardiac output.
76066275|NCT06114147|Device|ICON measure|The ICON will be placed at the beginning of the consultation and the measurements will be taken at the same time as the trans thoracic ultrasound in the left lateral decubitus position.
76066276|NCT06114147|Device|USCOM|Afterwards, measurements will be made with USCOM in left lateral position and 3 of the best spectra archived according to the Fremantle score.
76066277|NCT06111898|Other|No Intervention|No intervention
76066278|NCT06107634|Procedure|Gastropexy|"In the intervention group, the following three additional attachment points between the stomach and surrounding anatomical structures will be completed with non-absorbable suture material:~The left lateral part of the fundus flap is adapted to the diaphragm at its flat tendinous part of the diaphragm lateral to the hiatus, with a 2-3 cm long continuous non-absorbable suture (left postero-lateral gastropexy).~The anterior stomach wall is attached to the abdominal wall with a 2-3 cm long continuous non-absorbable suture (anterior gastropexy).~The posterior fundus is adapted to the right crus with a 2-3 cm long non-absorbable suture (right-posterior gastropexy)."
76066279|NCT06107452|Other|training strategy with adaptation of training strategies to the ANS|a training strategy for subjects whose PFVP is in favour of strength or speed with training load adjusted according to SNA
76066280|NCT06107452|Other|training strategy (standard practice)|a training strategy for subjects whose PFVP is in favour of strength or speed
76066281|NCT06105567|Behavioral|Training given according to the health promotion model by applying the Philips 66 technique|The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress
76066282|NCT06099964|Behavioral|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
76066283|NCT06099964|Behavioral|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
75749601|NCT04962594|Other|Breast feeding (BF)|Exclusive breast feeding up to 4 months
75749602|NCT04949750|Other|Paper - based cognitive training|Cognitive training
75604809|NCT04817293|Other|medical consultation|Medical consultation during the visit with data collection
75749603|NCT04949243|Behavioral|Behavioral questionaires|Behavioral surveys and questionaires
76066284|NCT06099509|Other|Self-administered oral glucose tolerance test|Participants will be asked to self-administer the postpartum 75-gram oral glucose tolerance test. They will be provided the glucose solution and instructions. A 4 week virtual visit will be arranged where the test results will be reported to the provider and appropriate follow up arranged based on the results of their screen.
76066285|NCT06099275|Diagnostic Test|Transthoracic Echocardiography|Cardiac output measured by transthoracic echocardiography (TTE)
76066286|NCT06096428|Device|Pulsed-field ablation|Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.
76066287|NCT06096428|Device|Radiofrequency ablation|Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).
76066288|NCT06095349|Other|inhalatory treatment with sulfureous aerosol|osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
76066289|NCT06094855|Other|20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest|2 bouts of 20 minutes of pedaling on a stationary recumbent bicycle, 1-2 weeks apart. Subjects will be cooled for one of the bouts and uncooled for the other.
75604810|NCT04408651|Behavioral|LIIT.CI ACT|4-week online self-management intervention based on Acceptance and Commitment Therapy and adapted to people with chronic medical conditions
75604811|NCT04408651|Behavioral|LIIT.CI CFT|4-week online self-management intervention based on Compassion-Focused Therapy and adapted to people with chronic medical conditions
75749604|NCT04929275|Procedure|Enhanced recovery program|12 items of program (preoperative, peroperative postoperative) according to the enhanced recovery after surgery society
75749605|NCT04929184|Behavioral|Speech and non-speech tasks|Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.
75749606|NCT04922034|Drug|Amoxicillin|Outcome of patients with negative oral challenge to amoxicillin
75749607|NCT04918121|Drug|Yutiq 0.18 MG Drug Implant|a sustained-release steroid insert (Yutiq)
75769422|NCT01586182|Radiation|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
76066290|NCT06094322|Other|MR prostate exam|Subjects will lie in supine position. The systematic use of a headset will reduce the acoustic noise inherent to the machine. We are going to carry out the standard MR prostate protocol which patients usually benefit from in clinical routine. This protocol consists of morphological sequences (T2 weighting with spin echo readout), Diffusion MR and dynamic contrast-enhanced sequences. We will then perform an additional faster enhanced T2-weighting SE and DWI sequences combined with Deep Learning reconstruction
76066291|NCT06094049|Other|Preference test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using flour fortified with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food.
76066292|NCT06094049|Other|Triangle test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using unfortified flour and fortified-flour with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food and who will be blinded to the flour type.
75453775|NCT05720741|Behavioral|Project SHARE|Intervention delivered in a web browser that focuses on encouraging feelings disclosure to trusted others using facts about the brain, testimonials from peers, and writing exercises (also referred to as Sharing Feelings Intervention; Schleider et al., 2021).
75453776|NCT05717114|Procedure|Pecs block|(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.
75453777|NCT05715814|Drug|Empagliflozin 25 MG|PO once daily
75453778|NCT05711758|Procedure|PSAM Treatment Patients|PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
75453779|NCT05705271|Drug|Finerenone (Kerendia, BAY94-8862)|Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
76066293|NCT06089668|Other|Observational Study|None, this is a non-interventional trial
76066294|NCT06081335|Device|EdgeEndo x7 continuous rotation files|endodontic files operating in continuous rotation
76066295|NCT06081335|Device|EdgeOne Fire reciprocating files|endodontic files operating in reciprocating motion
76066296|NCT06079567|Diagnostic Test|Validation of new COMs for FSHD2 patients|Monitoring of commonly used and new COMs in FSHD2 patients
76066297|NCT06075615|Drug|dacomitnib|patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
76066298|NCT06073626|Behavioral|Relational agent (RA) / Chatbot|Consists of clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among Black cancer survivors.
76066299|NCT06073626|Behavioral|Enhanced Usual Care (EUC)|Consists of clinical letter and recommendation for genetic testing for hereditary cancer risk among Black cancer survivors.
75453780|NCT05704868|Behavioral|UniVRse + TAU|"UniVRse uses well-established evidence-basedcognitive behavioural therapy (CBT) techniques - specifically graded exposure - to reduce fear and worries about social situations. People work towards overcoming their anxiety in a step-by-step fashion, building up to the most feared situation. In the context of UniVRse, students will be presented with four university-based scenarios that our coproduction team identified as being the most anxiety-induing for students:~Attending a lecture;~Group work in a seminar;~Delivering a presentation;~Contributing to an online seminar.~The UniVRse programme has been designed with our co-production team comprised of tirst-generation students with social anxiety, CBT therapists, and a VR design company."
75453781|NCT05701527|Drug|EBC-129|EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-90-minute intravenous (IV) fusion.
76066300|NCT06072378|Behavioral|Value-manipulation|During the decision-making task, different choices are assigned different values probabilistically.
76066301|NCT06064136|Procedure|Psoas tenotomy under ultrasound|Tenotomy of the ilio-psoas tendon under ultrasound is performed using an ultrasound machine, a 3 mm Acufex hook blade and a specific kit usually used for guided vertebroplasty and which allows the introduction of the Acufex hook blade atraumatically (foam end). The patient, under general anesthesia, is placed in supine position with the hip extending from 15 to 20°.
76066302|NCT06055946|Device|robotic assisted radical prostatectomy|Adult male patients undergoing elective robotic assisted radical prostatectomy.will be included in the study
76066303|NCT06052592|Other|Milk|Newborns will be fed with breast milk, formula milk or postbiotic formula milk
76066304|NCT06048419|Behavioral|Home Program|Home program for 6 weeks (1 hr and 15 minutes per week)
76066305|NCT06045611|Dietary Supplement|Isolated Pea Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
76066306|NCT06045611|Dietary Supplement|Isolated Whey Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
75749608|NCT04903717|Behavioral|Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
75749609|NCT04894084|Device|CP321|The primary objective is to evaluate the system performance of the test product. This is done by asking subjects to answer questions throughout the study
75749610|NCT04893330|Dietary Supplement|pepticate syneo|follow up of pepticate syneo for one month
75749611|NCT04884685|Biological|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
75453782|NCT05701527|Drug|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
75604812|NCT04576429|Procedure|venous puncture|"Venous punctures will be performed:~for patients of cohort A and B1:~before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~each 3 months up to 12 months.~for patients of cohort B2:~before the radiotherapy;~within the 6 weeks after the end of radiotherapy;~at the 2 following evaluations (every 3 months)."
75604813|NCT04576429|Procedure|tumoral biopsy|Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
75604814|NCT04203277|Other|IVY|a combination of practice education and quality improvement interventions
75604815|NCT00631813|Drug|Prucalopride|0.5 mg bid
75604816|NCT00631813|Drug|Prucalopride|1 mg bid
75604817|NCT00631813|Drug|Prucalopride|2 mg bid
75749612|NCT04884685|Biological|Placebo|aluminium hydroxide solution only
75749613|NCT04881812|Device|Drug-Coated Balloons|Percutaneous coronary intervention of residual disease adjacent to a chronic total occlusion with a paclitaxel drug-coated balloon (minimal stenting strategy).
75749614|NCT04881812|Device|Drug-Eluting-Stent|Percutaneous coronary intervention of the chronic total occlusion and residual coronary artery disease with an everolimus-eluting platinum chromium coronary stent (complete stenting strategy).
75453783|NCT05696613|Drug|SNP-ACTH (1-39) Gel|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
75453784|NCT05696613|Drug|Rituximab|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
75453785|NCT05685511|Behavioral|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
75453786|NCT05685511|Other|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
75604818|NCT00631813|Drug|Placebo|bid
75604819|NCT04404049|Biological|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
75604820|NCT04404049|Biological|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
75604821|NCT00911989|Device|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
75749615|NCT04881526|Dietary Supplement|D-beta-hydroxybutyrate|Drink containing D-beta-hydroxybutyrate administered at a dose of 395 mg/kg.
75749616|NCT04881526|Dietary Supplement|Placebo|Isocaloric flavored water with medium-chain triglyceride oil.
75749617|NCT04880226|Device|Magnetic Resonance Imaging (MRI)|Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.
75749618|NCT04857944|Behavioral|IDEA program (Improving depressive symptoms through personalised exercise and activation)|The program will consist of six 90-minute group sessions composed of four to six participants. These short intervention sessions will be distributed in one month, with a frequency of once or twice a week depending on the week of the program. Of the six sessions, two will be exercise-oriented and will include on-site practice. The remaining four sessions will include definitions of depressive symptomatology, the relationship between depression and having an active lifestyle, motivation and barriers towards exercise, and maintenance strategies.
75769423|NCT03900130|Dietary Supplement|Preload|"In the 2 x 2 factorial design we vary two factors:~caloric load of the preload such that it is either high calorie or low.~protein to carbohydrate ratio of the preload such that it is either high or low"
75604822|NCT04635163|Other|None intervention|None intervention
75604823|NCT04911517|Combination Product|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
76066307|NCT06045611|Dietary Supplement|Isolated Faba Bean Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
76066308|NCT06045611|Dietary Supplement|Placebo|Participants will consume the placebo in an opaque mug wearing a nose clip.
76066309|NCT06042257|Drug|Guanfacine Hydrochloride Immediate Release|0.5 mg capsules
75604824|NCT04617379|Behavioral|Stretching|One-year stretching program for 15 minutes every day
75604825|NCT04503655|Other|Training|"Training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
75604826|NCT04853563|Other|PEEP|High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
75604827|NCT03880279|Biological|TAC01-CD19|Dose-escalating cohorts plus expansion groups
75604828|NCT00637897|Drug|docetaxel|
75604829|NCT00637897|Drug|ixabepilone|
75604830|NCT00637897|Drug|paclitaxel|
75604831|NCT00637897|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
75604832|NCT00637897|Drug|paricalcitol|
75604833|NCT03992443|Drug|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
75604834|NCT04334707|Procedure|Kidney Biopsy|A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.
75604835|NCT03926689|Behavioral|SMS messages|A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.
75604836|NCT03926689|Behavioral|Standard SII SBCC|Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
75604837|NCT03915535|Dietary Supplement|Eicosapentaenoic acid + Docosahexaenoic acid|Monoglyceride Omega-3 fish oils
75453787|NCT05677594|Diagnostic Test|Whole Body Magnetic Resonance Imaging|Magnetic resonance imaging of the entire body from skull base through distal thighs/knees without contrast material
75453788|NCT05674175|Biological|Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)|CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
75604838|NCT03915535|Dietary Supplement|Eicosapentaenoic acid|Monoglyceride Omega-3 fish oil
75604839|NCT04816513|Drug|Ustekinumab|Ustekinumab will be administered as SC injection.
75749619|NCT04857944|Device|IDEApp|An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.
75749620|NCT04843917|Diagnostic Test|Immunoglobulin G detection|Detection of immunoglobulin G against Spike Receptor Binding Domain against severe acute respiratory syndrome coronavirus 2
75749621|NCT04831918|Device|Mueller cemented cups|Patients undergo total hip arthroplasty with the implant of Mueller cemented cups
75749622|NCT04830449|Drug|HCP1904-2|Take it once daily for 8 weeks orally.
75749623|NCT04830449|Drug|RLD2001-2|Take it once daily for 8 weeks orally.
75453789|NCT05674175|Biological|Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)|HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
75453790|NCT05674149|Device|camera|photographs using multi-spectral camera
75604840|NCT03858283|Behavioral|Mindfulness Based Health Care (MBHC) Program|Mindfulness Based Health Care (MBHC) Program for Caregivers of Alzheimer's Disease Patients. The duration of this group was 8 weeks. The program included one session per week, with each session lasting 1 hour and 30 minutes
75604841|NCT04203511|Drug|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to12 cycles.
75604842|NCT04203511|Drug|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
76066310|NCT06042257|Drug|Placebo|Matching placebo capsule
75749624|NCT04820907|Drug|HCP1904-1|Take it once daily for 8 weeks orally.
76066311|NCT06039774|Drug|α-Mangostin Hydrogel Film With Chitosan Alginate Base|Patients will apply α-Mangostin Hydrogel Film With Chitosan Alginate Base once a day for 7 days
76066312|NCT06039774|Drug|Placebo|Placebo
76066313|NCT06037980|Drug|Gemcitabine|◦ Gemcitabine 800 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
76066314|NCT06037980|Drug|Nab paclitaxel|◦ Nab-paclitaxel 100 mg/mq, day 1 and 8 of 21-day cycles, for 3 cycles
76066315|NCT06037980|Drug|Cisplatin|◦ Cisplatin 25 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
76066316|NCT06037980|Procedure|Curative Surgery|Curative surgery on primary tumor
76066317|NCT06037980|Drug|Capecitabine|1250 mg/m2 given orally twice daily on days 1 to 14 of a 3 weekly cycle for a total of 8 cycles
75749625|NCT04820907|Drug|RLD2001-1|Take it once daily for 8 weeks orally.
75899387|NCT02300948|Drug|PregVit® contains 1.1 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
75604843|NCT04203511|Drug|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle with either carboplatin or cisplatin (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
75604844|NCT04203511|Drug|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle with either etoposide or pemetrexed (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
75453791|NCT05671302|Behavioral|Walk Together|Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.
75604845|NCT04203511|Drug|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle with either pemetrexed (nonsquamous NSCLC only) or paclitaxel for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
75604846|NCT04203511|Drug|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle with carboplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
75749626|NCT04801446|Device|Soterix Medical 1X1 tDCS stimulator (active C-tDCS)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
75749627|NCT04801446|Device|Soterix Medical 1X1 tDCS stimulator (sham stimulation)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
75749628|NCT04798339|Drug|Canakinumab Injection|Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose
75749629|NCT04798339|Drug|Darbepoetin Alfa|Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle
75749630|NCT04791514|Drug|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
75909562|NCT03474614|Genetic|DNA and RNA Analysis|During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
76066318|NCT06026371|Drug|Fecal Microbiota Transplantation Capsule|Given PO
75604847|NCT04203511|Drug|Etoposide|Etoposide administered intravenously every 3 weeks on Days 1-3 of each cycle with cisplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
75604848|NCT04203511|Radiation|Radiotherapy|Total dose of 60 Gy ± 10% (54 to 66 Gy) in 2 Gy daily fractions.
75604849|NCT04203121|Radiation|low dose whole brain radiation to treat Alzheimer disease|"subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions"
75604850|NCT04299685|Other|Interview|Qualitative family interviews of 20 family units, or more until data saturation, of at least one parent and one adolescent (aged 10-19 year old) will be conducted based on deductive thematic approach. Each interview will last for about an hour, be conducted in Cantonese, and audio-taped for transcription in verbatim in Chinese.
75604851|NCT04297891|Other|Clinical rating scale to measure Ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
75604852|NCT04297891|Other|Clinical rating scale to measure spastic paraplegia disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
75749631|NCT04789096|Drug|Tucatinib|Oral tablet
75749632|NCT04789096|Drug|Pembrolizumab|Intravenous
75749633|NCT04789096|Drug|Trastuzumab|Intravenous
75749634|NCT04789096|Drug|Capecitabine|Oral tablet
75749635|NCT04782986|Diagnostic Test|Pan-intestinal capsule endoscopy|Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation
76066319|NCT06026371|Drug|Placebo|Given PO
76066320|NCT06023602|Drug|Generic cetrorelix acetate|Generic cetrorelix acetate (0.25 mg SC)
75453792|NCT05661461|Drug|nab-sirolimus|This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
75749636|NCT04780503|Diagnostic Test|Rapid Shallow Breathing Index|The RSBI is defined as the ratio of respiratory frequency to tidal volume.
75749637|NCT04776239|Drug|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
75749638|NCT04776239|Other|Placebo|Placebo delivered via peripheral intravenous infusion
75749639|NCT04769037|Dietary Supplement|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
75749640|NCT04769037|Dietary Supplement|Placebo|Lactose identical in appearance and taste to the active supplement
75749641|NCT04768127|Other|early aftercare|This group begins the aftercare program immediately after their bariatric surgery.
75899388|NCT02300948|Drug|PregVit-folic 5® contains 5 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
76066321|NCT06023602|Drug|Reference cetrorelix acetate|reference cetrorelix acetate (0.25 mg SC)
76066322|NCT06014385|Drug|Scopolamine|TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
76066323|NCT06014385|Radiation|[11C]EMO ([11C]LSN3172176)|A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of [11C]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.
75453793|NCT05656105|Drug|DPA-714 PET/MRI|DPA-714 PET/MRI
75453794|NCT05656027|Drug|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
75453795|NCT05656027|Drug|Aceclidine|LNZ100 Aceclidine ophthalmic solution
75453796|NCT05656027|Drug|Brimonidine|Brimonidine ophthalmic solution
75453797|NCT05651802|Radiation|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
75453798|NCT05651802|Radiation|Thoracic radiotherapy|Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
75453799|NCT05651802|Drug|Chemotherapy|Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
75463255|NCT05855265|Device|photon therapy face mask|"In this study the patients were randomly assigned into two equal groups after agreeing to participate through signing an informed consent.,Out of 70 identified Nasopharyngeal tumor receiving radiotherapy, only 60 subjects completed the full requirements of the study,Participant's age ranged from 30-60 yearsThe subjects in control group (CG) were treated with their medical treatment in addition to routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent. 0.9% normal saline cotton balls will be used to gently clean the wound and remove necrotic tissue, and the wound was dried with sterile gauze.~The subjects in study group (SG) were received photon therapy during radiotherapy treatment. In addition to medical treatment and routine methods of nursing,"
75749642|NCT04768127|Other|mid-term to late aftercare|This group begins the aftercare program 18 months post surgery.
75749643|NCT04745559|Biological|Pneumococcal conjugate vaccine (PCV13)|Licensed heptavalent pneumococcal conjugate vaccine (PCV13, Pneumococcal 13-valent conjugate vaccine
75604853|NCT04297891|Other|Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)|"The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity."
75463256|NCT05855252|Other|No intervention|No intervention
75899389|NCT03103828|Behavioral|Computer-Tailored Intervention|CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.
75899390|NCT03103828|Behavioral|Motivational Interviewing|MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.
75909563|NCT05155514|Procedure|Mobil-O-Graph PWA|After resting in a quiet room preoperatively, blood pressure was measured on the right arm using an oscillometric method.
75463257|NCT05855213|Device|High Velocity Nasal Insufflation|A relatively new respiratory support modality which delivers very high velocity flows. This improves ventilatory efficiency via washing out carbon dioxide occupying the anatomical dead space of the upper airways.
75749644|NCT04745559|Biological|CD19 targeted CAR T Cell Therapy|This is a personalized therapeutic approach that entails removal of T cells from patient's peripheral blood, genetic modification, activation and expansion in vitro to retarget cells against CD19 protein on the surface of B cells, and infusion of the genetically engineered cells back into the patient. CD19 is a surface protein that is expressed on B cells starting from early pre-B cells to mature fully differentiated B cells. Therefore, CD19-targeted CAR T cell therapy can effectively treat refractory B cell lymphomas.
75463258|NCT05855213|Device|Non-invasive positive pressure ventilation|An established non-invasive ventilation method via delivery of an expiratory positive airway pressure and inspiratory positive airway pressure.
75463259|NCT05855187|Drug|Bravamax 200 mg (Modafinil)|Test drug
75463260|NCT05855187|Drug|Vigil 200 mg (Modafinil)|Reference drug
75463261|NCT05855148|Procedure|Enlistment For Lung Transplant|All included patients are enlisted for lung transplantation
75604854|NCT04297891|Diagnostic Test|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
75604855|NCT03690037|Drug|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
75604856|NCT03690037|Drug|Tranexamic Acid 500 MG|Tranexamic Acid: Tranexamic Acid 500mg Tablets
75604857|NCT00910273|Drug|etanercept|etanercept 50 mg/week
75604858|NCT04202653|Drug|ETV|entecavir 0.5 mg qd
75604859|NCT04202653|Drug|TQ-A3334|TQ-A3334 po qw
75604860|NCT04202653|Drug|TQ-B2450|TQ-B2450 q3w iv
75749645|NCT04741997|Drug|Encorafenib Pill|Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles
75749646|NCT04741997|Drug|Binimetinib Pill|Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles
75749647|NCT04741997|Drug|Nivolumab|Nivolumab will be administered at a dose of 480 mg IV infusion over 30 minutes every 4 weeks.
75749648|NCT04720755|Device|Low-Intensity Extracorporeal Shock Wave Therapy|Twice-weekly treatments for 6 weeks, of 0.2mL/mm^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
75749649|NCT04709705|Biological|Human platelets|Platelets given to control bleeding
75749650|NCT04697004|Device|Investigational Arm: SMR Stemless Reverse|The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function.
75749651|NCT04697004|Device|Control Arm: SMR Reverse Shoulder System|Conventional stemmed shoulder prostheses are commonly used in the clinical practice.
76066324|NCT06014112|Device|Freestyle Libre Pro iQ|"Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed."
75749652|NCT04684524|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
75899391|NCT03103828|Behavioral|Motivational Enhancement Therapy|Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
75899392|NCT02302508|Drug|Clopidogrel, Prasugrel, Ticagrelor|PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
76066325|NCT06013813|Procedure|Radial Artery approach on percutaneous coronary intervention (PCI)|"Randomized patients with a right patent radial artery.~The outcomes of the distal radial approach will be compared with those of the conventional radial approach.~Technique and devices (introducer and compression devices) are the same in both approaches."
76066326|NCT06007781|Biological|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
76066327|NCT06007781|Biological|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
75463262|NCT05855070|Drug|Intralesional treatment with Hyaluronic acid|Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid16 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
75749653|NCT04684524|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
76066328|NCT06007482|Drug|ES009|ES009 is administered via intravenous infusion, once every 21 days.
76066329|NCT06006702|Drug|TYRA-300-B01|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
76066330|NCT06006286|Drug|Atezolizumab|Given by IV (vein)
75604861|NCT00910039|Drug|sunitinib malate|Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
75749654|NCT04668781|Procedure|Analgesia via epidural catheter|Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
75749655|NCT04668781|Procedure|Analgesia via wound catheter|Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
75909564|NCT05155202|Drug|Antihypertensive Agents|Administration of intravenous Nicardipine or Urapidil
76066331|NCT06006286|Drug|Bevacizumab|Given by IV (vein)
76066332|NCT06006286|Drug|ADI-PEG 20|Given by Injection (inj)
75909565|NCT05154812|Drug|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
75749656|NCT04656730|Drug|Iberogast® and Iberogast® N|Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
75769424|NCT01150864|Device|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
75909566|NCT05154812|Drug|Routine medical care|Routine medical care
75909567|NCT03474380|Behavioral|iHI-FIVES|Implementation of iHI-FIVES caregiver skills training
75463263|NCT05855070|Drug|Intralesional treatment with Verapamil|Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.
75909568|NCT03215342|Behavioral|Pediatric Goal Management Training|7 GMT modules will be administered in 7x2 hours sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving. Homework assignments between sessions.
75899393|NCT03103984|Other|Weight loss diet|Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.
75749657|NCT04649034|Diagnostic Test|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
75899394|NCT02297594|Drug|AK0529|AK0529 capsule for oral administration
75899395|NCT02297594|Drug|Placebo|Sugar placebo capsule for oral administration
75899396|NCT04484584|Other|complex decongestive therapy|Manual lymphatic drainage Manuel lymphatic drainage therapeutic technique is used for reducing edema and symptoms related with edema by accelerating lymphatic drainage. The aim of massage along the extremity is to provide fluid drainage.Manuel lymphatic drainage stimulates the internal contraction of lymphatic channels. If interstitial space concentration of protein is reduced, it provides drainage of obstructed lymph fluid from local lymph nodes.
76066333|NCT06004973|Device|STAR Particles|A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand) and 100 mg of aloe vera will be applied to the control site on one of the forearms. Two rubbing cycles (20 and 30 cycles at 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated.
76066334|NCT06004115|Drug|Lorazepam|1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form
75899397|NCT02301026|Drug|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
75899398|NCT01742026|Procedure|Aspergillus PCR technique|Aspergillus DNA PCR technique
75453800|NCT05651659|Other|TIME model in the prevention and treatment of crises in frail community-dwelling people|TIME is a manual-based, multicomponent programme that will include a rigorous assessment of the crises, one or more interdisciplinary case conferences and the testing and evaluation of customised treatment measures.This multicomponent interdisciplinary model consisting of three overlapping phases. First the assessment phase where the care staff and the physician collaborate in a comprehensive bio-psychosocial assessment. The second phase is the reflection phase with interdisciplinary case conferences based on principles from cognitive behavioural therapy and abc-method, where a customized treatment plan is developed. The abc-method from cognitive behavioural therapy is used as an analytic tool for the analyses of the complex challenges in the case conferences. In the third phase the treatment plan is implemented and evaluated systematically.
75453801|NCT05650710|Device|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired infrahyoid musculature in a therapeutic manner.
75453802|NCT05646784|Drug|Cerebiome|Evaluate the effect of oral intake of a probiotic agent, on clinical and plasma inflammatory markers, in a subgroup of target patients versus a subgroup treated with placebo, in combination with conventional treatment, during the patient's stay in the hospital, and after his discharge, for a total duration of 12 weeks
75453803|NCT05646784|Drug|Placebo|Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment, during the patient's stay in the hospital, and after his discharge, for a total duration of 12 weeks
75453804|NCT05646095|Behavioral|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|We will adapt CBT for insomnia for children in foster care using a trauma-informed approach that considers the child's individual history, unique family environment, and child welfare policies regarding safe sleep practices.
75899399|NCT01742026|Procedure|Aspergillus AGA technique|Aspergillus AGA technique
75899400|NCT02297750|Procedure|double-wire technique in patients undergoing ERCP with biliary cannulation|
76066335|NCT06004115|Other|Placebo|placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form
76066336|NCT06003751|Drug|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
76066337|NCT06003751|Drug|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
76066338|NCT06003751|Drug|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
75899401|NCT02297750|Procedure|single-wire technique in patients undergoing ERCP with biliary cannulation|
75749658|NCT04649034|Diagnostic Test|Cardiac magnetic resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
75899402|NCT01682278|Device|Removal of dental amalgam restorations|"Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient."
75899403|NCT01952574|Drug|Erenumab|Administered by study site staff once a month (QM) as a subcutaneous injection
75453806|NCT05641077|Other|Virtual Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via a virtual visit using videoconference technology at 6 weeks after the anticipated date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
75453807|NCT05641077|Other|Office Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via an in-office visit at 6 weeks after the planned date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
75604862|NCT00910039|Other|cognitive assessment|The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
75604863|NCT00632437|Procedure|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
75604864|NCT00909181|Drug|Oxybutynin|"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
75749659|NCT04649034|Diagnostic Test|Brain magnetic resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
75749660|NCT04649034|Diagnostic Test|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
75749661|NCT04649034|Diagnostic Test|Holter monitoring|At inclusion all patients will carry a Holter device for 24 hours to ensure absence of atrial fibrillation
75749662|NCT04626466|Other|Biological investigations|(complete blood count, platelet count, renal function evaluation)
75749663|NCT04616495|Procedure|Liver transplantation|Chemotherapy and liver transplantation
75749664|NCT04614129|Diagnostic Test|Low Dose CT|All participants will have a low dose chest CT either within one year of enrollment or after enrollment
75899404|NCT01952574|Drug|Placebo|Administered by study site staff once a month (QM) as a subcutaneous injection
75899405|NCT01952574|Drug|Erenumab PFS|Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy
75899406|NCT01952574|Drug|Erenumab AI/Pen|Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy
75749665|NCT04611867|Other|Supportive application with integrated weekly PRO|Patients will fill in a web-based application PRO-CTCAE with integrated preparation questionnaire every week. If their weekly reported symptoms exceed a predefined threshold of severity, this results in a notification on the staff application interface and a nurse will contact a patient for verification of symptoms. Nurse will review patient recent treatment and PRO reports and advise patient according to the local practice for symptom management and reinforce reporting. Nurse will consult with or refers to (if possible) treating physician if patient will require medical intervention and/or physician assistance.
75749666|NCT04598451|Biological|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
75749667|NCT04598451|Other|Placebo|Subcutaneous injection of placebo
75749668|NCT04598451|Drug|prednisone|Oral prednisone tablets
75749669|NCT04596410|Radiation|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
75749670|NCT04596410|Radiation|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily
75749671|NCT04589611|Drug|amobarbital/Gel-One (one dose)|One dose of amobarbital/Gel-One during the initial surgical intervention
75749672|NCT04589611|Drug|Placebo (single dose)|One dose of placebo during the initial surgical intervention
75749673|NCT04589611|Drug|amobarbital/Gel-One (two doses)|One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
75749674|NCT04589611|Drug|Placebo (two doses)|One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
75899407|NCT02302586|Drug|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
75453808|NCT05636514|Drug|Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET|Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
75453809|NCT05636514|Drug|Defactinib|"Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily"
75453810|NCT05634369|Biological|GEM/DOX + TGFBi expanded NK cells|"8 cycles consisting of gemcitabine, docetaxel, supportive dexamethasone and pegfilagrastim, and universal donor, TGFBi ex vivo expanded NK cells~Each cycle will be repeated every 21 days based upon disease response and toxicity criteria~Tumor response assessed after Cycles 2, 4, 6, and 8~Gemcitabine 675mg/m2/dose IV on Days 1 and 8~Docetaxel 75mg/m2/dose IV on Day 8~Dexamethasone 3mg/m2/dose (max 8 mg/dose) PO BID on Days 7, 8, and 9~Pegfilgrastim (Peg-GCSF) 0.1mg/kg/dose (max 6 mg/dose) SQ on Day 9~NK cells 1 x 10e8 cells/kg/dose IV on Day 12 (+ 1-2 days)"
75453811|NCT05630170|Device|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.
75453812|NCT05627713|Other|Blood sample collection|Blood sample collection between inclusion and 12 months after inclusion
75453813|NCT05627713|Other|urine sample collection|urine sample collection at inclusion
75604865|NCT00909181|Drug|Placebo|"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
75604866|NCT02691169|Drug|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
75604867|NCT03944161|Dietary Supplement|Oral nutrition supplement|Hypercaloric and high protein supplement
75604868|NCT03944161|Other|Nutritional advice|Advice given by the clinician
75604869|NCT04268797|Device|HR rTMS|high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days
75604870|NCT04268797|Device|sham|SHAM HF rTMS coil once daily x 20 days
75749675|NCT04565041|Behavioral|Social Support|Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
75453814|NCT05620186|Other|PROSPECT|PROficiency Based StePwise Endovascular Curricular Training
75453815|NCT05615636|Drug|Mosunetuzumab|Given by IV (vein)
75453816|NCT05615636|Drug|Polatuzumab vedotin|Given by IV (vein)
75453817|NCT05615636|Drug|Tafasitamab|Given by IV (vein)
75453818|NCT05615636|Drug|Lenalidomide|Given by PO
75453819|NCT05612347|Diagnostic Test|FIT|Annual FIT
75453820|NCT05612347|Diagnostic Test|Colonoscopy|One time surveillance colonoscopy
75604871|NCT01286987|Drug|Talazoparib|Oral capsule with multiple dosage forms given once daily
75604872|NCT05598671|Procedure|PCNL without reverse insertion of a ureteral catheter|The ureteral catheter was not retrograde inserted during PCNL
75604873|NCT01286753|Drug|Vemurafenib|Vemurafenib 960 mg orally twice daily.
75604874|NCT01286129|Procedure|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
75604875|NCT05590013|Drug|Pectointercostal and ESP block|Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
75769425|NCT03909724|Drug|Sunitinib Malate|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
75604876|NCT05566925|Other|Direct access to physiotherapist for assessment, diagnosis and treatment.|Patients with knee osteoarthritis will be interviewed about their experience of being assessed, diagnosed and treated by a physiotherapist first in primary care.
75604877|NCT01285349|Behavioral|Couple HIV/STI prevention intervention|
75604878|NCT01285349|Behavioral|Couple-based HIV/STI prevention|
75604879|NCT01285349|Behavioral|Individual HIV/STI prevention|
75604880|NCT01285349|Behavioral|Couple Wellness Promotion|
75604881|NCT01284959|Drug|risperidone|risperidone 3mg, PO, 3 times
75604882|NCT01284959|Drug|paliperidone ER|paliperidone ER 6mg, PO,3 times
75749676|NCT04564976|Behavioral|Social support image|An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
75749677|NCT04561466|Drug|Béfizal|600 mf befizal a day for one year
75899408|NCT02302586|Drug|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
76066339|NCT05999695|Other|self-management|"The experimental group received the SelfManagement Program for Acute Coronary Syndrome:~the research subjects completed the first data collection within one week of hospitalization. Guide the research subjects to browse this manual and watch the Acute Coronary Self-Care Video, and explain what they do not understand, hoping to stimulate the research subjects to discuss nursing issues, and jointly formulate self-management goals, and This handbook was given to study subjects to take home. Telephone interviews every 2 weeks in the first month after discharge, and then again after two and three months after discharge. Each call is about 10 minutes to track the completion of goals and self-management,including usual medication, regular exercise, balance Food and spiritual support and encouragement, etc.,and clarify any doubts."
75453821|NCT05610033|Device|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
75453822|NCT05604560|Drug|Tislelizumab|Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
75749678|NCT04553523|Device|Hydrus Microstent|Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
75749679|NCT04553523|Procedure|Cataract surgery|Cataract surgery performed using standard anesthesia and phacoemulsification techniques
75453823|NCT05604560|Drug|SX-682|Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
75749680|NCT04553523|Device|Monofocal IOL|Commercially available monofocal intraocular lens as determined by the investigator
75909569|NCT03215342|Behavioral|Pediatric Brain Health Workshop|7 pBHW modules will be administered in 7x2 hours sessions (ten groups). Psychoeducation; brain (dys)function, plasticity, memory, executive function, and attention. Stress, physical exercise, sleep, nutrition, and energy management. Homework assignments between sessions
75909570|NCT03088202|Other|Educational program|E-learning lectures, group exercises, skills training
75909571|NCT03088202|Other|Standardized care pathways|Pathways for systematic follow-up
75909572|NCT03088202|Other|Early palliative care|Compulsory referral to palliative care at inclusion
75453824|NCT05604287|Drug|ID119031166M|The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.
75453825|NCT05604287|Drug|Placebo|The participant will receive a oral dose of Placebo.
75453826|NCT05602649|Drug|Cannabis|Cannabis will be orally ingested
75453827|NCT05602649|Drug|Placebo|Placebo will be orally ingested
75604883|NCT01284959|Drug|placebo|lactose PO, 3times
75604884|NCT01284491|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
75604885|NCT01284491|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
75604886|NCT01283009|Drug|Inactive Substance|Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
75604887|NCT01283009|Drug|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
75749681|NCT04553263|Drug|Contrave 8Mg-90Mg Extended-Release Tablet|Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
75749682|NCT04553263|Drug|Bupropion|Bupropion is FDA-approved and marketed both as an antidepressant agent (Wellbutrin®) and treatment for smoking cessation (Zyban®) and has shown efficacy in reducing symptoms of depression and drug craving in stimulant users. it is also a promising candidate to improve cognition function.
75749683|NCT04550962|Drug|Dupilumab SAR231893|"Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:"
75453828|NCT05601180|Other|Respicure®|Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.
75453829|NCT05601180|Other|Standard of care|standard treatment is prescribed by the treating physician.
76066340|NCT05999695|Other|regular care|"gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text."
76066341|NCT05999032|Behavioral|CASE in person version (High Intensity Package)|Controlling Asthma in Schools Effectively (CASE) is a multi-level school-based asthma management program delivered by a Community Health Worker (CHW) that includes 1) staff training involving education on asthma management in school, 2) child-based asthma management education with an emphasis on control of symptoms in the school setting provided in a group setting during the school day, 3) caregiver education after school involving supporting children's asthma control in the school setting, 4), and provision of an Asthma Action Plan (AAP) to the school for child enrollees.
76066342|NCT05999032|Behavioral|CASE-V remote version (Low Intensity Package)|CASE-V, the low intensity version of CASE, includes similar child and caregiver-based asthma management education that is provided in a remote format with adaptation to integrate technological feature of Zoom. All CASE-V components (for staff, children, and parents) have been adapted to promote engagement (e.g., use of chat and polling function).
75453830|NCT05594992|Drug|JR-141|IV infusion, 2.0 mg/kg/week
75453831|NCT05590377|Drug|Modakafusp Alfa|Modakafusp alfa intravenous infusion
75604888|NCT05659277|Other|Workplace Stress and Irregular shift hours|The physiological, psychological, and cognitive impacts that workplace stress and irregular shift hours have on first responders.
75604889|NCT01282463|Drug|Docetaxel|Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
75604890|NCT01282463|Biological|Ramucirumab DP|Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
75453832|NCT05590377|Drug|Daratumumab|Daratumumab SC injection
75453833|NCT05588193|Behavioral|PVO|post-visit outreach
75453834|NCT05588193|Behavioral|TS|tele-sexual health visit during the ED visit
75453835|NCT05584644|Drug|Palbociclib plus hormonal treatment - first line treatment|Palbociclib plus hormonal treatment
75453836|NCT05584644|Drug|Palbociclib plus hormonal treatment - second line treatment|Palbociclib plus hormonal treatment
75604891|NCT01282463|Biological|Icrucumab|12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
75604892|NCT01282229|Device|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
75604893|NCT01281917|Drug|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
75604894|NCT01281917|Drug|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
75604895|NCT01281839|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
75604896|NCT01281839|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
75604897|NCT01281839|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
75749684|NCT04550221|Behavioral|Shauriana|The components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions. The four in-person health education and coaching sessions will be delivered once per week, by trained peer facilitators who identify as GBMSM. These sessions will focus on the following topics: sexual health basics (understanding how HIV and STIs are transmitted, prevented, and diagnosed/treated), relationships (types of relationships we have, characteristics of healthy relationships, communication skills), stress and coping (understanding mental health challenges, adaptive and maladaptive coping strategies), and healthy sexuality and empowerment (understanding sexual orientation and gender identity, challenging stereotypes about GBMSM, making sexual choices).
75749685|NCT04549688|Procedure|high-intensity focused ultrasound, HIFU|see above
75749686|NCT04542707|Procedure|joint manipulation|Thrust manipulation to the spine, hand, and foot
75749687|NCT04542707|Procedure|Exercise|Strength training, bike aerobic training, and yoga exercise
75749688|NCT04542707|Device|Soft tissue massage|Graston tool
75749689|NCT04535076|Procedure|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation
75604898|NCT01281839|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
75604899|NCT01281137|Genetic|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
75604900|NCT01281137|Other|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
75604901|NCT01281137|Procedure|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
75604902|NCT01280981|Drug|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
75604903|NCT01280903|Behavioral|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
75604904|NCT01280903|Behavioral|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
75604905|NCT04323605|Other|"Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse"|"Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)"
75604906|NCT01280591|Drug|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
75749690|NCT04535076|Procedure|Surgical Aortic Valve Replacement|Surgical Aortic Valve Replacement
75749691|NCT04534738|Behavioral|Mediterranean Diet|The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
76066343|NCT05999032|Behavioral|CASE and HARP in person (High Intensity package)|"Children with poorly controlled asthma will receive both the CASE and HARP programs. HARP is a home-visiting program that includes individualized asthma management education and strategies and supplies for environmental remediation. All 3 visits can be conducted by a CHW. The first includes a walk-through to identify triggers. Asthma education and self-management strategies are provided using a structured protocol and low-literacy flip-book (English or Spanish). Referrals and advocacy are offered to address asthma management barriers (e.g., communication with landlord/housing re: code violation). The 2nd and 3rd visits include delivery of supplies (e.g., HEPA vacuum, pest gels, mattress covers), instruction for use, review of AAP, and follow-up on environmental control recommendations provided during the 1st visit."
75453837|NCT05574101|Drug|Cemiplimab|Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.
75453838|NCT05574101|Radiation|Radiotherapy|Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
75453839|NCT05563103|Other|Daily acute intermittent hypoxia|Each participant will be exposed to 8 sessions of daily acute intermittent hypoxia via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
75604907|NCT01280591|Drug|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
75749692|NCT04525365|Procedure|Pleural aspiration|Pleural aspiration
75749693|NCT04525157|Drug|Afamelanotide|
75749694|NCT04525157|Drug|Placebo|
75749695|NCT04515004|Drug|leucoselect phytosome|A standardized grape seed procyanidin extract complexed with soy phospholipid.
75749696|NCT04514107|Other|Brazilian National Dengue Control Program|This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.
75453840|NCT05563103|Other|Room air (SHAM)|Each participant will be exposed to 8 sessions of daily room air via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).
75453841|NCT05563103|Other|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
75453842|NCT05563103|Other|Walking + Sham transcutaneous spinal stimulation (tSHAM)|Individuals will participate in 45 minutes of gait training while having SHAM transcutaneous spinal cord stimulation. The stimulation will briefly increase to 80% involuntary motor threshold and then brought down to 0 within 30 seconds.
75453843|NCT05560659|Drug|177Lu-PSMA|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Numerous retrospective series initially demonstrated high clinical activity and limited normal tissue toxicity using PSMA-617 and PSMA-I&T, which are the most advanced small molecule inhibitors of PSMA, radiolabelled with 177Lu
75453844|NCT05559853|Diagnostic Test|CEST-MRF|CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
75453845|NCT05558358|Device|Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation|6 months of active stimulation -- > 6 months of sham stimulation
75604908|NCT01280591|Drug|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
75604909|NCT01280591|Drug|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
75604910|NCT04323683|Genetic|Microarray|High throughput technique for determining global gene expression of the condition of interest
75604911|NCT01280357|Device|Monica AN24 (K101081)|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
75604912|NCT01280357|Device|Philips 50XM|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
75604913|NCT04323917|Diagnostic Test|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
75604914|NCT04323761|Drug|Remdesivir|Intravenous infusion administered over a 30 to 120 minute period
75604915|NCT05566223|Drug|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
75604916|NCT05566223|Drug|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
75604917|NCT05566223|Biological|CISH Inactivated TIL|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
75604918|NCT05566223|Drug|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
75749697|NCT04514107|Other|Wolbachia-infected Aedes aegypti|Brazilian strain of Aedes aegypti infected with Wolbachia pipientis released into geographic clusters.
75749698|NCT04509011|Device|Fluobeam® LX|Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
75749699|NCT04503694|Drug|Nivolumab 10 MG/ML Intravenous Solution|"Nivolumab will be given at a dose of 240 mg during the pre-operative phase only as indicated below:~On day 1 and 15, during the Induction treatment~On day 29, 43 and 57, during the Consolidation treatment"
75749700|NCT04503694|Drug|Regorafenib 40 MG Oral Tablet|"Regorafenib will be administered orally once a day at a dose of 80 mg/day (2 tablets of 40 mg), during the pre-operative phase only as indicated below:~From day 1 to 14, during the Induction treatment~From day 29 to 49, during the Consolidation treatment"
75749701|NCT04503694|Radiation|Radiotherapy|All study subjects will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy. Radiotherapy is to start on day 22 and to finish on day 26.
75909573|NCT03063164|Device|Intralase IFS150|Intralase flap creation
75909574|NCT03063164|Device|Visumax|Visumax flap creation
75909575|NCT02737358|Drug|N-acetylcysteine (NAC)|NAC or matched placebo will be given to study participants for 8 weeks.
75909576|NCT02737358|Other|Placebo|Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
75604919|NCT05566223|Drug|Pembrolizumab|Administered as maintenance therapy in some patients starting at first follow-up (400 mg/dose starting Day 28 /Week 4 then every 6 weeks thereafter until disease progression, unacceptable toxicity, or up to 24 months)
75604920|NCT01274351|Drug|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
75604921|NCT01271933|Drug|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
75604922|NCT01271933|Drug|placebo|matching placebo tablet; given once daily
75604923|NCT01269125|Drug|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
75749702|NCT04503694|Procedure|Surgery|Subject will undergo surgical resection of the primary tumour in the rectum between day 74 and 87. Surgery must be performed according to the principles of total mesorectal excision as described by Heald et al. The type of surgical approach (low anterior resection or abdominoperineal resection, etc.) will be left to the discretion of the treating surgeon.
75899409|NCT03512054|Procedure|Standardized 5-step weaning procedure|"Weaning process in 5 steps (0-4), by a multi-professional team (neurosurgeon, physiotherapist, nurse, caregiver…) Stability criteria are defined for each person, after validation pass the next step. Stability criteria degradation return to the previous step. Weaning process can take back after stability criteria renormalization.~Step 0: cuff deflate. Step 1: occlusion test. Steps 0 and 1 can assess the freedom and protect capacity airway. In failure process, we can propose a nasofibroscopy.~Step 2: Phonatory Valve. Respiratory rehabilitation/ swallowing, limiting breathing effort. The valve ought to stay 12 hours before going to the step 3.~Step 3: Plug. Finish the Respiratory rehabilitation/ swallowing. The plug ought to stay 24hours minimum before going to the step 4.~Step 4: Decannulation"
75899410|NCT05430646|Device|Covered metal ureteral stents|The CMUS is a fully covered, self-expanding, large caliber metal stent. The stent is made of super-elastic nickel-titanium alloy, which maintain lumen patency via providing long-term direct wall support.
75453846|NCT05558358|Device|Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation|6 months of sham stimulation -- > 6 months of active stimulation
75453847|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
75453848|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
75604924|NCT01269125|Procedure|IVF|Assisted Reproduction Technique.
75453849|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
75453850|NCT05543616|Biological|Variant-adapted BNT162b2 (Omicron XBB.1.5) Substudy A Ph 2/3 Selected Dose|Injection in the muscle
75453851|NCT05543616|Biological|Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose|Injection in the muscle
75899411|NCT05430646|Device|Tandem DJ stents|Tandem DJ stents represents for two stents side-by-side, which improves the urine flow by better withstanding the compressive tumoral forces and allowing urine to flow between the stents.
75899412|NCT02302664|Procedure|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
75453852|NCT05543616|Biological|Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose|Injection in the muscle
75453853|NCT05543616|Biological|Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose|injection in the muscle
75453854|NCT05543382|Device|Axonics System|The Axonics System will be implanted as standard care
75453855|NCT05541510|Biological|AD17002 + Formulation buffer|Intranasal innate immune modulator
75453856|NCT05541510|Biological|Placebo|Formulation buffer
75604925|NCT01268891|Drug|Placebo|Once daily; tablet; orally; 18 weeks
75604926|NCT01268891|Drug|Azilect®|1 mg daily; tablet; orally; 18 weeks
75453857|NCT05538663|Drug|Gemcitabine|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
75453858|NCT05538663|Drug|Docetaxel|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
75604927|NCT01268501|Device|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
75769426|NCT03909724|Drug|TAS 102|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
75899413|NCT02302664|Procedure|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
75899414|NCT01551472|Device|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
75899415|NCT03104062|Diagnostic Test|Microbubble Contrasted Echocardiography|Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography
75899416|NCT03104062|Diagnostic Test|Platelet Aggregability|Obtained using Multiplate Analyzer
75899417|NCT03104062|Diagnostic Test|Laboratory|it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.
75899418|NCT03515330|Other|mHealth Intervention|The mHealth application will allow liver transplant recipients to see their medication regimen, record a video of themselves taking every dose, report side effects or symptoms, visualize their treatment progress, and access educational content. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
75453859|NCT05538663|Drug|Bacillus Calmette Guerin|intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
75453860|NCT05533892|Drug|Nocardia rubra cell wall skeleton|Nocardia rubra cell wall skeleton (N-CWS) 400μg hypodermic injected every 1 week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected every 4 weeks (Q4W)
75453861|NCT05533892|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
75453862|NCT05533892|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
75453863|NCT05533892|Drug|Tislelizumab|200mg intravenously every 3 weeks
75453864|NCT05533502|Dietary Supplement|Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement|Ingestion of the Test Product at 07.00am - Fava-bean protein concentrate dosed at 0.33 g/kg body mass and Aquamin F dosed at 800mg in 500 ml water volume. Supplied by Marigot Limited, Strand Farm Currabinny, Co. Cork, Ireland
75453865|NCT05533502|Dietary Supplement|Placebo Control|Ingestion of the Control Product at 07.00am - 500ml water volume.
75453866|NCT05525598|Behavioral|"One step at a time"|[see 'arms' section for full description]
75453867|NCT05525598|Behavioral|"Get started"|[see 'arms' section for full description]
75453868|NCT05520788|Genetic|precise medicine|During screening stage, all patients should accept next-generation sequencing (NGS) test.
75604928|NCT04323527|Drug|Chloroquine diphosphate|150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
75604929|NCT01268267|Device|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
75453869|NCT05515406|Drug|ONO-7018|ONO-7018 tablet(s) are administered orally
75453870|NCT05515406|Drug|ONO-7018|ONO-7018 tablet(s) are administered orally
75453871|NCT05511272|Biological|blood test|four blood samples will be withdrawn from the participants during the day of their frozen embryo transfer cycle
75453872|NCT05501665|Procedure|Biospecimen Collection|Correlative studies
75453873|NCT05501665|Drug|Carboplatin|Given carboplatin
75453874|NCT05501665|Procedure|Computed Tomography|Undergo PET/CT
75453875|NCT05501665|Other|Fludeoxyglucose F-18|Given IV
75604930|NCT01267253|Drug|Brivanib Alaninate|Given PO
75604931|NCT01267253|Other|Laboratory Biomarker Analysis|Correlative studies
75899419|NCT03103672|Procedure|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
75899420|NCT03511898|Drug|THR-149 dose level 1|single intravitreal injection of THR-149 dose level 1
75899421|NCT03511898|Drug|THR-149 dose level 2|single intravitreal injection of THR-149 dose level 2
75453876|NCT05501665|Drug|Nab-paclitaxel|Given nab-paclitaxel
75453877|NCT05501665|Biological|Pembrolizumab|Given pembrolizumab
75453878|NCT05501665|Drug|Pemetrexed|Given pemetrexed
75604932|NCT04378777|Procedure|Biological sample collection|During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study [GWAS]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
75899422|NCT03511898|Drug|THR-149 dose level 3|single intravitreal injection of THR-149 dose level 3
75899423|NCT02254044|Drug|bivatuzumab mertansine|
75899424|NCT03103594|Drug|DMSO|DMSO will be instilled intravesically.
75899425|NCT03103594|Drug|Botox|Botox will be instilled intravesically with DMSO.
75604933|NCT04378777|Procedure|Data Collection: Clinical Care Assessments|Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
75899426|NCT03515252|Biological|Immune Killer Cells (IKC)|
75453879|NCT05501665|Procedure|Positron Emission Tomography|Undergo PET/CT
75899427|NCT02143284|Device|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
75899428|NCT05430568|Procedure|robot-assisted surgery|"traditional sternotomy for coronary bypass graft or valvular replacement~robot-assisted surgery for coronary bypass graft or valvular replacement"
75453880|NCT05501665|Radiation|Radiation Therapy|Undergo radiation therapy
75453881|NCT05501665|Other|[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|Undergo PET scan
75453882|NCT05501665|Biological|Ipilimumab|Given Ipilimumab
75604934|NCT02889419|Device|Evaluation of underwear Selfia®|Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
75604935|NCT02889497|Biological|the first batch vaccine|
75604936|NCT02889497|Biological|the second batch vaccine|
75604937|NCT02889497|Biological|the third batch vaccine|
75604938|NCT01266317|Drug|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
75604939|NCT01266161|Drug|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
75749703|NCT04503694|Procedure|Non-operative Management|"Subjects who achieve cCR after pre-operative treatment can, after discussion with the local investigator, decline surgery and opt for a non-operative management. cCR will need to be confirmed between day 67 and 74 by the following procedures per local practise:~Digital rectal examination~Rectal endoscopy~Rectal MRI Subjects who achieve near cCR at the first assessment time point after pre-operative treatment, can be re-assessed 6 to 8 weeks later with the same procedures. If cCR is diagnosed, they can opt for watch & wait, otherwise they would need to undergo surgical resection.~Subjects who opt for a non-operative management will be followed for tumour recurrence and survival for 5 years after end of treatment visit. Follow-up for these subjects will be more intensive than that for subjects undergoing surgery"
75749704|NCT04493996|Behavioral|Cognitive training|The cognitive training involves a standardized, paper-and-pencil-based cognitive training that will be performed by the patients at home for approximately 40 minutes per day over a preoperative period of 2-3 weeks
75749705|NCT04493151|Drug|Imipenem, Cilastatin and Relebactam|After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
75899429|NCT02302820|Other|Advance Care Planning Intervention|"ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids."
75604940|NCT01266161|Drug|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
75604941|NCT01265849|Biological|LI|LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
75749706|NCT04468165|Drug|Dimethyl Fumarate (DMF)|Gastro-resistant Hard Capsules. Each capsule contains 240mg or 120mg Dimethyl Fumarate
75749707|NCT04463992|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
75899430|NCT02301104|Drug|TAS-102|
75899431|NCT02302898|Behavioral|Eating Behavior Evaluation|Scores will be measured on binge eating behaviors and an increased craving for sweets.
75899432|NCT02302898|Other|Measurement of Functional gastric volume|The functional gastric volume is the amount of food or liquid that can be consumed to a feeling of comfortably full in one meal.
75899433|NCT02302898|Other|Measurement of gastric pouch and GJ size|Anatomical dimensions of the gastric pouch and GJ will be determined by using an articulated measuring tool during upper GI tract endoscopy.
75899434|NCT02959437|Drug|Azacitidine|Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
75453883|NCT05501665|Biological|Nivolumab|Given Nivolumab
75453884|NCT05501301|Other|IS weaning off|IS weaning off will be conducted in recipients with chronic virus infection or side effects of IS
75909577|NCT03474302|Behavioral|Physical Activity|Aerobic, strength training, balance, flexibility
75749708|NCT04463992|Other|Usual Care|Usual care as provided by local oncologists
75749709|NCT04454476|Drug|Trametinib treatment|1 mg taken by mouth once a day for 14 days
75899435|NCT02959437|Drug|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
75899436|NCT02959437|Drug|Epacadostat|Epacadostat tablets will be administered orally twice daily.
75899437|NCT02959437|Drug|INCB057643|INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
75453885|NCT05501236|Device|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. During the DISE and second sleep study, fine-wire electrodes will be placed into the hypoglossal nerve or genioglossus muscle. Two more electrodes are placed transcutaneously, proximate to the bilateral branches of the cervicalis innervating the sternothyroid muscle in the anterior neck.
75749710|NCT04454476|Procedure|Endoscopy|A tiny camera on the end of a long, flexible tube will be used to examine the stomach and take biopsies.
75899438|NCT02959437|Drug|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
75453886|NCT05496205|Drug|iN1011-N17|"This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached."
75453887|NCT05496205|Drug|Placebo|Matching Placebo for each formulations
75749711|NCT04452461|Drug|mFOLFIRINOX|mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
75749712|NCT04452461|Drug|Gemcitabine / Nab-paclitaxel|Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
75899439|NCT02959437|Drug|Epacadostat|Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
75899440|NCT02959437|Drug|INCB059872|INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
75899441|NCT05179304|Procedure|Oncoplastic technique with a droplet-shaped glandular flap|"A droplet-shaped glandular flap (DSG) is in a shape of a water drop, with the pedicle at the top of the defect and the base underlying nipple-areolar complex (NAC). It runs from the outer upper quadrant to the center along a line parallel to the radial line. We harvest a DSG flap by dissociating the supplement mammary gland from the lateral of the defect after resection, developing deep to the pectoralis fascia, from the cusp at the defect and the round pore underlying nipple-areolar complex (NAC). The DSG flap was rotated inwards around the cusp, reaching the top of the defect. This tailored redistribution allowed the defects to be plugged with the lateral glandular flaps."
75453888|NCT05483010|Drug|Atorvastatin|Atorvastatin is commercially available.
75453889|NCT05483010|Drug|Rosuvastatin|Rosuvastatin is commercially available.
75453890|NCT05481827|Genetic|GT005|GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study.
75749713|NCT04448249|Behavioral|APN intervention|"APN intervention is divided into five main steps:~clinical and paraclinical examinations,~appraisal of patient's knowledge,~health education on hypertension and treatments,~setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary,~decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
75749714|NCT04424667|Other|donor milk|pasteurized donor milk
75749715|NCT04417829|Device|Biological prosthesis in the aortic valve|Transcatheter aortic valve implantation of bioprosthesis in patients with severe symptomatic aortic stenosis (clinically indicated)
75749716|NCT04401020|Drug|SAR442257|Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
75749717|NCT04389242|Other|REST Online（Reduce Stress Tour Online）|Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.
75899442|NCT03102424|Device|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
75899443|NCT03102424|Device|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
75899444|NCT02297906|Drug|Ketorolac|Non-steroidal anti-inflammatory drug
75749718|NCT04388800|Other|Confront and Navigate Depression Online (CANDO)|This study adopts a blended mode of service delivery, which included both online and offline intervention. The online intervention includes 8 weekly online model, animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, reminder, online assessment, session review and online booking system. The offline intervention includes two face-to-face sessions and two telephone follow-ups.
75453891|NCT05480449|Biological|Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)|The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
75453892|NCT05473767|Behavioral|Family Check Up Heart|Family Check-Up Heart consists of the Family Check up with an added heart health component. The Family Check-Up Heart assessment will include evaluations of maternal cardiovascular health; specifically, measurement of maternal blood pressure, body mass index, diet quality, exercise, and smoking, which will be included in the feedback session. After the Feedback Session participants will also receive information about healthy eating and weight loss, stress management, and smoking and to monitor weight and blood pressure.
75749719|NCT04382963|Other|High Risk - intensive coaching|"The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.~Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis."
75749720|NCT04382963|Other|High Risk - standard care|The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.
75749721|NCT04382963|Other|Low Risk - control|Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
75749722|NCT04378335|Other|completion of questionnaire|parents have to complete 2 questionnaires: demographic questionnaire and Montréal questionnaire when they come on allergy consultation.
75749723|NCT04373902|Procedure|Physiological-based cord clamping|See 'Arm'
75749724|NCT04373278|Other|failure of reconstruction of the mandibule by free fibula flap|description of failure of reconstruction of the mandibule by free fibula flap:delay, type of bacteria involved in the failure, treatment, outcome
75899445|NCT03619161|Other|Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap)
75899446|NCT03619161|Other|Bleach and Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap).
75899447|NCT03511820|Drug|Lipo-AB® (amphotericin B) liposome|"Name: Lipo-AB® (amphotericin B) liposome for injection~Dosage form: Lyophilized powder 50 mg/vial~Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision."
75899448|NCT02957331|Drug|Propranolol|
75899449|NCT03791008|Other|Risk based screening|Breast cancer risk measurement, screening recommendations and shared decision making
75899450|NCT03510806|Dietary Supplement|Supplement|dietary supplement contain protein from milk and fruit extract
75899451|NCT03510806|Other|Placebo|color, taste, and calorie-matched placebo
75909578|NCT03474302|Other|Successful Aging|Healthy aging education
75909579|NCT05052710|Drug|AZD4831|Subjects will receive oral doses once daily from Days 2-11.
75909580|NCT05052710|Drug|Midazolam|Subjects will receive oral single doses on Day 1 and Day 11.
75909581|NCT02866838|Drug|Tranexamic acid|intravenous
75909582|NCT02866838|Drug|Saline 0.9%|intravenous
75604942|NCT01265849|Drug|Cyclophosphamide|Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
75604943|NCT01265849|Drug|Indomethacin|One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
75899452|NCT02298062|Drug|Infliximab|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
75899453|NCT02298062|Drug|IVIG|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
75899454|NCT03510728|Behavioral|college drinker's check up|The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.
75899455|NCT03510728|Behavioral|Protective Behavioral Strategies Intervention|This intervention component focuses on educating and promoting PBS activities in future college drinking situations
75604944|NCT01265849|Dietary Supplement|Zinc|One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
75899456|NCT03510728|Behavioral|Ecological Momentary Intervention|This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.
75899457|NCT03101956|Procedure|Lumbar Spine Manipulation|• The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position the subject's superior thigh in flexion and rotate the subject's upper trunk to the opposite side. The therapist will place his cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
75604945|NCT01265849|Procedure|Surgery|Excise tumor and nodes
75604946|NCT01265849|Drug|Cisplatin|Cisplatin was administered 100mg/m^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
75604947|NCT01265849|Radiation|Radiotherapy|Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
75604948|NCT01265615|Drug|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
75604949|NCT01265615|Drug|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
75604950|NCT01265615|Drug|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
75604951|NCT01265615|Dietary Supplement|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
75604952|NCT05545865|Other|Low Flavanol Cocoa Powder|Measure the response 2 and 6 hours post low flavanol cocoa intake
75899458|NCT03101956|Procedure|Lumbar Spine Manipulation Placebo|The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position both hips and knees in approximately 45° of flexion. The therapist will place his or her cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
75453893|NCT05473767|Behavioral|Family Check-Up|"The Family Check-Up typically takes place over the course of 3-5 sessions, each about an hour long. First, a trained Family Check-Up family coach will conduct an Initial Interview. Second is an assessment of that includes questionnaires and videotaped interaction tasks. Third, during the Feedback Session, the family coach discusses with the participant strengths and challenges for their child and family as a whole. They then set goals for their family to support and maintain strengths, and to address any areas of concern. After the Feedback Session families have the option to continue meeting with their family coach to support the child's development and improve parental well-being."
75453894|NCT05469139|Diagnostic Test|Portable MRI acquisition|Patients on ECMO will undergo a portable MRI of the brain
75453895|NCT05466448|Drug|RZL-012|concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
75453896|NCT05464719|Drug|Loncastuximab Tesirine|Given by IV
75453897|NCT05456555|Procedure|Flapless with Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.
75604953|NCT05545865|Other|High Flavanol Cocoa Powder|Measure the response 2 and 6 hours post high flavanol cocoa intake
75604954|NCT05545865|Other|Vine to Bar Chocolate - 2 servings|Measure the response 2 and 6 hours post chocolate intake
75604955|NCT05545865|Other|Vine to Bar Chocolate - 1 serving|Measure the response 2 and 6 hours post chocolate intake
75604956|NCT05545865|Other|Vine to Bar Chocolate covered almonds|Measure the response 2 and 6 hours post chocolate covered almond intake
75604957|NCT01264835|Device|Slotted Anoscope|SA411
75604958|NCT00623909|Device|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
75604959|NCT01264679|Drug|Ferumoxytol|IV Ferumoxytol
75604960|NCT02889341|Dietary Supplement|DHA|
75604961|NCT02889341|Other|Placebo|
75604962|NCT05542043|Other|Data collection|"The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction.~Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode.~Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode.~Data on peripartal and postpartum surgical measures."
75604963|NCT01263665|Device|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
75749725|NCT04353297|Other|EEG-based BCI system for (hand) Motor Imagery training|The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
75899459|NCT03511508|Behavioral|ChroPreg + standard care|"Ongoing update of individual maternity care plan.~Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~Possibility for psychologist consultation.~Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth."
75749726|NCT04353297|Other|Motor Imagery training|Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
75899460|NCT02303054|Procedure|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
75899461|NCT02303132|Other|Ussing experiment|fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
75899462|NCT03515018|Drug|hydroxyurea|pulse therapy
75749727|NCT04343365|Other|Evolutionary Tumor Board (ETB)|The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
75899463|NCT03515018|Drug|Imatinib|400mg qd PO per day
75899464|NCT03748966|Drug|Calcitriol|Adults and children (age 3-17) with X-linked hypophosphatemia will be treated with calcitriol therapy without phosphate supplementation. Doses of calcitriol will be escalated and optimized in the first three months of the study. Calcitriol is an oral medication taken once a day.
75453898|NCT05456555|Procedure|Flapless without Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
75453899|NCT05453136|Drug|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
75749728|NCT04301323|Drug|BHVI1 eye drops|Including 35 children enrolled to receive BHVI1 eye-drops once nightly
75749729|NCT04301323|Drug|BHVI2 eye drops|Including 35 children enrolled to receive BHVI2 eye-drops once nightly
75749730|NCT04301323|Drug|BHVI3 eye drops|Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
75749731|NCT04296123|Behavioral|Step training|A 12-week step training consisting of two 30-minute training session per week. The participants will be instructed to stand upright and step on different targets on a plastic mat repeatedly.
75749732|NCT04280575|Procedure|Percutaneous coronary intervention|Coronary artery stenting for stable angina
75899467|NCT05891418|Behavioral|Two informational emails with plan information|Informational emails about the benefits of Cost-Sharing Reduction Silver plans.
75899468|NCT05891418|Behavioral|Standard notice of eligibility determination|No extra outreach during intervention period.
75899469|NCT05891405|Procedure|Cardiac surgery|Operations for congenital heart diseases
75899470|NCT05891366|Drug|WAL0921|Investigational product WAL0921
75899471|NCT05891366|Drug|Placebo|Placebo product
75453900|NCT05453136|Drug|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
75453901|NCT05453136|Drug|Placebo to TS-142|Participants received repeated doses of placebo to TS-142 (oral tablet)
75604964|NCT04323371|Diagnostic Test|ELISA|Blood and derived fluids will be collected from 26 ADHF CS patients admitted to intensive care at Niguarda Hospital and locally stored.Stocked samples will be shipped to the Central Laboratories at Milano Uni and MilaIFC-CNR for the metabolomic and biomarkers analysis,respectively.To evaluate interleukin-6 (marker of systemic inflammation),angiopoietin-2 (marker of endothelial permeability), syndecan-1 and heparan sulfate (markers of endothelial glycocalyx),2 aliquotes of serum samples will be used by IFC CNR.The biomarkers will be assessed through ELISA analytical techniques, based on the interactions inside a microplate between a primary pre-coated antibody and the specific protein contained in serum samples.A secondary antibody, link to a horseradish peroxidase (HRP) detection system, is able to recognize and bind the antigen, and to produce a colorimetric reaction after the addition of enzyme substrate which is proportional to the amount of the target protein bound
75604965|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
75604966|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
75749733|NCT04280471|Drug|Fecal Microbiota Transplantation Capsule|Receive OpenBiome FMT Capsule DE PO
75604967|NCT01263197|Drug|LY2216684|administered orally
75604968|NCT01263197|Drug|albuterol|administered orally
75604969|NCT01263197|Drug|propranolol|administered orally
75604970|NCT01263197|Drug|placebo for LY2216684|administered orally
75604971|NCT01263197|Drug|placebo for albuterol|administered orally
75604972|NCT01263197|Drug|placebo for propranolol|administered orally
75749734|NCT04278404|Drug|The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:|The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
75749735|NCT04275999|Drug|ivermectin|Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.
75453908|NCT05445336|Behavioral|PREVENT Program|PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
75453909|NCT05431699|Diagnostic Test|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
75453910|NCT05431699|Diagnostic Test|careHPV test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
75453911|NCT05431699|Procedure|Colposcopy and biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
75604973|NCT01263119|Drug|Warfarin|10-mg warfarin oral dose
75604974|NCT01263119|Drug|LY2216684|18-mg LY2216684 oral dose
75604975|NCT05537597|Procedure|active M1-rTMS|"Magnetic stimulation will be carried out using a MagPro X100 machine with a MCF-B70 figure-of-eight coil (Magventure, Farum). All rTMS sessions will be assisted by a neuronavigation system (TMS Navigator，Localite GmbH), maintaining the M1 target and the orientation of coil stable during stimulation sessions. The M1 target was defined as the hand knob region, which corresponds to the motor cortical representation of the hand, regardless of the location of pain.~Stimulation paradigm consists of 20 trains of pulses with an intra-train frequency of 20 Hz, resulting in 2000 pulses for a total duration of 20 minutes.~The stimulation intensity will be 80% of RMT, defined as the lowest stimulation intensity necessary to induce a visible muscle twitch of the hand contralateral to the stimulated hemisphere.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
75604976|NCT05537597|Procedure|sham rTMS|"The sham protocol was similar to the rTMS protocol. Sham stimulations will be performed with a MCF-P-B65 figure-of-eight coil (Magventure) to M1, assisted by a neuronavigation system.~The following stimulation parameters will be used: stimulus frequency 20 Hz; stimulus intensity 80 % of RMT; total stimulation pulses 2,000; total stimulation time 20 min.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
75604977|NCT01262651|Drug|Nabiximols|
75899472|NCT02297828|Device|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
75453912|NCT05431699|Procedure|Gas-based cryotherapy|"Cryotherapy is performed to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, a metal probe is inserted into the vagina and the tip is pressed against the cervix. Compressed carbon dioxide or nitrous oxide gas at a temperature of approximately -50ºC/-58ºF freezes the tip and creates an ice ball on the cervix. The ice ball ablates or destroys the abnormal cells."
75453913|NCT05431699|Procedure|Thermal ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
75453914|NCT05427383|Drug|KN026/Placbo Injection|IV KN026/Placebo at 30 mg/kg on D1, Q3W
75604978|NCT01262651|Drug|Placebo (GA-0034)|
75604979|NCT01262573|Procedure|Closure of vaginal cuff|Closure of the vaginal cuff
75604980|NCT04323059|Dietary Supplement|Standardized milk-based formulation|Nutritional formulations prepared from locally available food stuffs for reversing childhood malnutrition
75453915|NCT05427383|Drug|Paclitaxel Injection|IV Paclitaxel at 175 mg/m² on D1, Q3W
75604981|NCT04323215|Device|Support system|A support system named Provement will be used to provide behavioral treatment.
75453916|NCT05427383|Drug|Docetaxel Injection|IV Docetaxel at 75 mg/m² on D1, Q3W
75604982|NCT04322903|Behavioral|Passport to Freedom (P2F)|During the P2F sessions, the women learn to understand and process the impact of multiple traumas on women's lives and health and learn specific strategies to overcome the symptoms of trauma and everyday stress. Each session will begin and end with a mindfulness exercise to provide different strategies the women can use when these women are in a stressful situation. At the end of each session, the participants will complete a session evaluation. The women will also have a home visit or telephone call with a community health navigator who will conduct a social determinant of health screenings assessment to determine what identified social barriers these women may have. The community health navigator will help with linking the participant to a community agency that addresses the identified problem. Four weeks after the completion of the program, the women will be contacted for a follow-up interview to learn the effectiveness of the program sessions.
75604983|NCT04322045|Diagnostic Test|multi-parametric MRI|Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
75604984|NCT04322201|Device|continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care
75604985|NCT04322201|Procedure|Ultrasound-guided intermittent large-volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
75604986|NCT02889185|Device|RTX1 IMAGIN EYE retinal camera|In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
75604987|NCT01262027|Drug|Dovitinib|500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
75604988|NCT01261793|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
75604989|NCT01261793|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
75604990|NCT01261793|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
75604991|NCT04321967|Drug|Nitroglycerin Paste|1g of 2% Nitroglycerin paste topical application
75604992|NCT04321967|Drug|Dermabond|Topical skin adhesive
75604993|NCT04321655|Other|High Intensity LASER Therapy (HILT)|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~Initial phase (710 and 810 mJ (millijoule)/cm2 for a total of 500 J)~Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J"
75604994|NCT04321655|Other|Ibuprofen Gel Phonophoresis (IGP)|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. (8 min/ one session each day for 3 days/week for 8 weeks).
75749736|NCT04275999|Behavioral|digital interaction|Subjects will receive weekly digital interaction; an electronic survey asking about their use of the ivermectin which will have the electronic monitoring device attached. Subjects will be instructed to use the ivermectin once daily. They will have a 3 month return appointment for end of study visit.
75899473|NCT02297828|Device|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
75453917|NCT05427383|Drug|Irinotecan Injection|IV Irinotecan at 125 mg/m² on D1, D8, Q3W
75453918|NCT05427045|Other|home - exercise program|Home exercise program
75453919|NCT05426252|Drug|Abatacept|Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.
75604995|NCT04321655|Other|Transcranial Direct Current Stimulation (tDCS)|Anode electrode -C3/C4 (contralateral side of the most affected knee), Cathode electrode- contralateral supraorbital area. (2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
75749737|NCT04275999|Device|GPSkin|Subjects in the GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin with the electronic monitoring device once daily. They will be scheduled for a 3 month end of study visit.
76066344|NCT05999032|Behavioral|CASE-V and HARP-V remote version (Low Intensity package)|"HARP-V replicates the content delivered in HARP in a remote format. The first session includes a virtual walk-through in which the educator uses a structured script and checklist to guide the caregiver through the home and show specific components of the environment (e.g., carpeting, area under the kitchen sink, exhaust fan in bathroom) to identify asthma triggers. Asthma education and self-management strategies are provided using a structured protocol and slide overview based on the HARP flip-book. Supplies for environmental remediation are delivered prior to the 2nd visit. The 2nd and 3rd visit include instruction for use of supplies, review of AAP, and follow-up on recommendations and referrals."
75749738|NCT04243759|Behavioral|Control App Version|"The control version is a smartphone-compatible CGNG. The cued go/no-go (CGNG) tests ability to respond fast to go targets (activation) while withholding response to no-go targets (inhibition)."
75749739|NCT04243759|Behavioral|Standard App Version|The standard version is the same as the control version with the exception that information about performance (correct or incorrect) is displayed along with RT in ms for a correct response during each inter-trial interval.
75453920|NCT05426252|Drug|Sirolimus|Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.
75453921|NCT05420207|Other|No intervention|No intervention included
75453922|NCT05410574|Behavioral|Family-based Behavioral Weight Loss Treatment|The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts
75453923|NCT05396807|Device|AI|The aim of using AI software to support physicians in choosing the most effective treatment.
75604996|NCT04321655|Other|Conventional Physiotherapy (CPT)|"Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~Heel raise ( 3sets X10 Reps X 3 min rest in between)~One leg balance ( 3sets X10 Reps X 3 min rest in between)~Step ups ( 3sets X10 Reps X 3 min rest in between)~Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
75604997|NCT04207541|Behavioral|Brief motivational interview|Client (who has suboptimal diabetic control with oral anti-diabetic agent) will be advised for insulin initiation with brief motivational interviewing in one session of individual education.
75604998|NCT05532605|Other|cardiac rehabilitation phase I protocols|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own.
75749740|NCT04243759|Behavioral|Experimental, Feedback App Version|The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.
75749741|NCT04193176|Drug|Gefapixant|Administered twice daily as an oral tablet of 45 mg
75749742|NCT04193176|Drug|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
75749743|NCT04190485|Other|Placebo|Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.
75749744|NCT04190485|Other|GMNL-143 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-143 probiotic toothpastes toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
75749745|NCT04190485|Other|GMNL-464 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-464 probiotic toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
75749746|NCT04174703|Other|Self-compassionate letter-writing intervention|Participants in this condition will be asked to engage in an online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks.
75899474|NCT05891340|Other|Respiratory muscle exercise|respiratory muscle exercise with inspiratory muscle trainer (two times a day)
75749747|NCT04166071|Drug|Naltrexone|Half of the participants will be randomly assigned to take one dose of naltrexone (50mg, capsule form) during the experimental session
75749748|NCT04166071|Drug|Placebo|Half of the participants will be randomly assigned to take a placebo capsule during the experimental session
75604999|NCT05532605|Other|Cardiac rehab phase I protocols + Mindfullness base therapy|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own. Plus Mindfullness base therapy
75605000|NCT04321499|Genetic|lung cancer|PCR for SHOX2 and PTGER4
76066345|NCT05995847|Behavioral|Harmonica playing program plus basic PR care with routine follow-up|The intervention will last for a total of six months. During this period, patients are expected to play the harmonica daily for 30 minutes, five days a week. Additionally, patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months.
76066346|NCT05995847|Behavioral|Basic PR care with routine follow-up|These patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months
76066347|NCT05992662|Behavioral|Mindfulness-Based Training Programme in Bariatric Surgey Patients|"ACTION Conducting mindfulness-based 4-session training program Focus group discussion after the training Within the scope of mindfulness-based training: Mindful Eating practices; qigong exercises; meditation exercises; breathing exercises; training specific to the bariatric surgery process was given.~FOLLOW-UP PHASE (3rd MONTH/6.MONTH POSTOPERATIVE)~Reminder of weekly practices~Recording changes in mindful eating in participant experience diaries during the follow-up"
76066348|NCT05988138|Behavioral|Family Promoting Positive Emotions|An 8-week dyadic intervention using cognitive and behavioral skills to up-regulate positive emotions in children and mothers
75605001|NCT04321577|Procedure|Radical surgery|Radical surgery is proposed to participants with pT1b, pT2 or pT3 tumors in the cholecystectomy specimen without evidence of disseminated disease with staging imaging techniques. A resection of the gallbladder bed or an anatomic resection of the hepatic segments IVb/V is performed. A lymphadenectomy of the hepatic hilum is associated in all cases. Common bile duct resection is performed in patients with involvement of the cystic margin.
75749749|NCT04164277|Behavioral|Caregiver Component.|Facebook-based program including four new habit-formation tasks/week. Three face-to-face or virtual caregiver meetings: Meeting 1: Study orientation and healthy cooking education will be offered, and each family will receive a small bag of groceries to facilitate preparation of a recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: Study interveners will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: Study interveners will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource booklet.
75749750|NCT04164277|Behavioral|Caregiver-Preschooler Learning.|Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger on two weekdays. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
75899475|NCT05891340|Other|Endurance exercise|walking exercise 5000 steps/day
75899476|NCT05891288|Other|BioCoat® by Premier®|Bioactive pits and fissure sealant
75899477|NCT05891288|Other|3M™ Clinpro™ Sealant.|Fluoride releasing pits and fissure sealant
76066349|NCT05988138|Behavioral|Psychoeducation|An 8-week comparison condition that offers education in mental health, depression prevention, and accessing mental health resources
75453924|NCT05393128|Procedure|Control group (Supine Position)|"In this group the patients will be given supine position.~Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~The patient will be given supine position.~The arms and the hands will be elevated and supported, the legs will be elevated and supported.~The patient will be covered.~The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
75605002|NCT04321889|Device|defurocumarinized bergamot loaded in a nanotechnological essential oil release system|Patients will be treated either with placebo cream or with defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of cream 2 times a day for 4 weeks. The subject will be monitored throughout the treatment and for at least 4 weeks after the end of the treatment.
75605003|NCT04321889|Other|Placebo|nanotechnological system loaded with placebo cream
75605004|NCT04321421|Other|hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
75749751|NCT04164277|Behavioral|Center-based Preschooler Component.|"Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat & Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity."
75749752|NCT04142619|Biological|UCARTCS1A|Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
75749753|NCT06083285|Other|Implement the CRRT specialist nursing group management program on the basis of routine care|Training the department nurses on CRRT related theoretical knowledge and operation skills; guiding the process of CRRT different treatment modes, solving CRRT nursing problems, evidence-based nursing guidance; consulting CRRT treatment and nursing related treatment, timely understanding the new progress; responsible for CRRT nursing quality control, etc.
75749754|NCT06083155|Diagnostic Test|Coronary Function Test|All participants are referred for a clinically indicated coronary function test
75899478|NCT05891223|Other|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
76066350|NCT05984706|Other|Focus groups and Delphi Questionnaire|1. Focus groups to identify relevant domains of PTSD-related functional impairment in trauma-exposed children and adolescents to ensure content validity. 2. Delphi Questionnaire evaluation of a list of domains of PTSD-related functional impairment in trauma-exposed children and adolescents (previously selected from based on a literature review and focus groups) on a Likert scale of 1 to 5 for their relevance
76066351|NCT05983575|Device|LIPUS-Brain|Transcranial low-power pulsed-wave ultrasound device
76066352|NCT05983575|Device|Placebo|Placebo
76066353|NCT05978661|Drug|FKC288|Administration of FKC288 Four dose groups of 0.1×10^6 CAR-T/kg, 0.3×10^6 CAR-T/kg, 1.0×10^6 CAR-T/kg, and 3.0×10^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
75605005|NCT02889107|Other|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
76066354|NCT05977439|Device|fMRI-EEG-TMS|Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
76066355|NCT05976724|Other|TENS, exercise|"TENS: The patients were sat in a chair positioned next to a treatment table. The hand to be treated was placed on the treatment table with the forearm in the supine position. Electrodes were then placed on the transverse carpal ligament and palmar surface of the hand. Conventional TENS was applied, with the current transition time set to 50-100 µs, and performed at a frequency of 100 Hz for a period of 20 minutes at an amplitude that did not cause muscle contraction or any feeling of numbness or tingling.~The supervised exercises were performed by the patients in a seated position. Strengthening exercises were performed with both hands by means of Digi-Flex hand exerciser (IMC Products Corp, Hicksville, New York), modeling mass and elastics. The patients were tasked with performing these exercises 10 times in each session and three times daily."
75605006|NCT04320875|Other|Transcranial direct current stimulation|Anode electrode -C3/C4 (International 10-20 electroencephalogram system), contralateral side of the most affected knee) Cathode electrode- contralateral supraorbital area. 2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
75605007|NCT04320875|Other|Conventional Physiotherapy|"Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~Heel raise ( 3sets X10 Reps X 3 min rest in between)~One leg balance ( 3sets X10 Reps X 3 min rest in between)~Step ups ( 3sets X10 Reps X 3 min rest in between)~Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
75605008|NCT01261325|Drug|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
75605009|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
75605010|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
75749755|NCT06083155|Other|Patient questionnaires|All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent
75749756|NCT06083142|Biological|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules
75749757|NCT06083129|Drug|Grafalon|10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)
75749758|NCT06083129|Drug|Thymoglobulin|2.5 mg/Kg/day IV for 2 consecutive days (day-3 and -2 before transplantation)
75749759|NCT06083116|Drug|Hydrochlorothiazide、Henagliflozin Proline|Hydrochlorothiazide and Henagliflozin Proline
75899479|NCT05891223|Other|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
76066356|NCT05976724|Other|Mulligan mobilisation|Each participant was tested with sustained manual glides in each of the possible directions during active wrist flexion and extension from the seated position. For the lateral glide, the therapist stabilises the lateral aspect of the distal radius using the first web-space. And glides the proximal row of carpal bones laterally (towards the thumb) using the first web-space of the other hand, following the joint line. For the medial glide, the therapist stabilises the medial aspect of the distal ulna using the first web-space. And glides the proximal row of carpal bones medially (away from the thumb) using the first web-space of the other hand, following the joint line.
75749760|NCT06083103|Diagnostic Test|18-FDG PET-MRI|For this trial, 18-FDG PET-MRI will be conducted directly after PET-CT using a single dose of radiotracer
75749761|NCT06083090|Procedure|Yogatherapy|The experimental arm will benefit from support by a physiotherapist trained in yoga, in a group for ten weeks with two weekly sessions of approximately 1 hour each. A new yoga program adapted for the axSPA will be implemented.
75899480|NCT05891223|Other|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application."
76066357|NCT05968924|Device|PodimetricsSmart Mat|receive training on stepping on SmartMat each day for 6 months; and step on the mat every day for 6 months; monthly phone calls will be conducted to assess foot health and mat.
75749762|NCT06083090|Procedure|Physiotherapy|The comparator arm will benefit from support by a physiotherapist, in groups for ten weeks at the rate of two weekly sessions of approximately 1 hour each. An already existing program adapted for the axSPA will be implemented.
76066358|NCT05968690|Drug|Propranolol|Propranolol will be administered to patients in all cohorts.
76066359|NCT05968690|Drug|Naltrexone|Naltrexone will be administered to patients in cohorts 2, 3, and 4.
76066360|NCT05966168|Device|Medtronic Micra AV Device|Participants will already be planned to have a Micra AV 2.0 device implanted. Participants will then undergo treadmill exercise testing and wear a Holter monitor to determine the effectiveness of the Micra AV 2.0 device during exercise or elevated heart rates.
76066361|NCT05963048|Drug|Rituximab|IV infusion 1000 mg
75453925|NCT05393128|Procedure|Experimental Group (Right Lateral position)|"In this group the patients will be given right lateral position.~Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~The patient will be positioned supine and the bed will be straightened.~Lines, probes will be taken to the right side of the patient and the patient will be turned with 60-90 degrees right lateral and the back will be supported with a pillow along the neck and sacrum.~Between the legs will be supported with pillows.~The patient's head will be elevated with 45-60 degrees.~The patient will be covered :~The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
75453926|NCT05393128|Procedure|Experimental Group (Left Lateral position)|"In this group the patients will be given left lateral position.~Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~The patient will be positioned supine and the bed will be straightened.~Lines, probes will be taken to the left side of the patient and the patient will be turned with 60-90 degrees left lateral and the back will be supported with a pillow along the neck and sacrum.~Between the legs will be supported with pillows.~The patient's head will be elevated with 45-60 degrees.~The patient will be covered :~The patient's vital findings, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
76066362|NCT05963048|Drug|IL6 inhibitor|6 mg/kg I V infusion monthly
75605011|NCT01261325|Drug|Antiepileptic drugs with market authorization available per country|
75605012|NCT01260701|Drug|Akt Inhibitor MK2206|Given PO
75605013|NCT01260467|Drug|memantine|10 milligrams orally twice a day
75605014|NCT01260311|Drug|Fesoterodine|Any dose of Fesoterodine
75605015|NCT00623987|Drug|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
75605016|NCT01259375|Drug|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
75749763|NCT06083077|Other|Chest wall strapping|An elastic band (6 cm wide) is placed around the lower part of the chest wall (at the junction of the chest and abdomen) to tighten the chest wall for 10 min at PEEP 7 cmH2O and 10 min without PEEP
75749764|NCT06083025|Device|CleaRing|The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate. The device is implanted into the capsular bag after the extraction of the crystalline lens and prior to implantation of the IOL. The device is manufactured by Hanita Lenses from a hydrophilic acrylic co-polymer which is being used for the production of Intra-ocular lenses.
75899481|NCT05891223|Other|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
75749765|NCT06082973|Device|Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID dHmG system, and microdoses of glucagon (GlucaGen®) will be subcutaneously administered based on automatic recommendations for hypoglycemia mitigation. The subcutaneous administration of reconstituted glucagon will be conducted using a 0.5 mL insulin syringe with needle, allowing for precise doses as small as 0.01mg/0.01 mL.
75749766|NCT06082973|Device|Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID sHC system, along with automatic rescue carbohydrate recommendations for hypoglycemia mitigation. As per the carbohydrate recommendation, participants will received the suggested amount of carbohydrates using an oral glucose gel containing 15g of carbohydrates per unit.
75749767|NCT06082934|Drug|Olverembatinib plus venetoclax and dexamethasone|Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
75749768|NCT06082869|Drug|Protegera™ toothpaste (NaF)|Plaque Reduction
75749769|NCT06082869|Drug|Crest™ Cavity Protection toothpaste (NaF)|Plaque Reduction
75749770|NCT06082739|Other|Exercises|Stretching exercises with and without a bolster, ball, or foam roller.
75749771|NCT06082700|Diagnostic Test|imaging|clinical examination to see missing posterior teeth & vertical measurements by lateral cephalometric x-ray
75749772|NCT06082674|Device|Vayu bCPAP|The Vayu bCPAP uses a constant flow of dry oxygen from the source with an adjustable flow meter. Oxygen is blended by Venturi blender with ambient air to create a source of oxygen-enriched air of adjustable concentration.
75749773|NCT06082674|Device|Mechanical Ventilator Driven CPAP|Mechanical Ventilator Driven CPAP
75899482|NCT05891223|Other|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. Courtesy meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
76066363|NCT05959356|Drug|Cetuximab + Envafolimab + mFOLFOXIRI|Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
76066364|NCT05959356|Drug|Cetuximab + mFOLFOX6/FOLFIRI|Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
76066365|NCT05948059|Drug|SHR-2106 injection or placebo|starting dose from 50 mg
76066366|NCT05948059|Drug|SHR-2106 injection or placebo|starting dose from 300 mg
75453927|NCT05386797|Procedure|Geniculate Artery Embolization|The GAE procedure involves the use of an embolization agent to block blood flow to specific areas of the knee. Under sedo-analgesia, access to the target vessels is gained through the femoral or radial artery. GAE is performed with angiography to visualize blood vessels to assess the affected knee joint and ensure successful treatment.
75453928|NCT05366777|Drug|acetaminophen/ibuprofen fixed-dose combination|Intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (total 100 ml)
75453929|NCT05366777|Drug|Saline|100 ml of normal saline
75453930|NCT05363605|Drug|[225Ac]-FPI-1966|[225Ac]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
75453931|NCT05363605|Drug|[111In]-FPI-1967|[111In]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide. Participants will receive [111In]-FPI-1967 Injection of 185 MBq for imaging.
75749774|NCT06082648|Device|Transcranial magnetic stimulation|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla.Stimulation group: Intermittentpulse transcranial magnetic stimulation (iTBS) will be performed with : the cluster consists of 3 pulses, the intra-cluster frequency is 50Hz, the intercluster frequency is 5Hz, the interval is 8.2s for every stimulus. There are 20 cycles and a total of 600 pulses. Each intervention time is 3min11s, and the stimulation intensity is set as 80% resting state motion threshold. The intervention will be performed once a day for 2 weeks.
75605017|NCT05487053|Procedure|Continuous adductor canal block|Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed in the region of the middle third of the adductor canal. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
75749775|NCT06082648|Device|Sham Transcranial magnetic stimulationt|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla. Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
75749776|NCT06082635|Drug|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
75749777|NCT06082635|Drug|Crizotinib|Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
75749778|NCT06082622|Combination Product|laxatives|triple therapy of drugs, behaviour and mental axis
75749779|NCT06082609|Procedure|Removable partial denture|All patients will receive Removable partial denture by two different impression techniques
75749780|NCT06082596|Drug|BEBT-908 for injection|"Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle."
75749781|NCT06082583|Device|Remote Ischemic Conditioning|Remote ischemic conditioning conducted by an electric auto-control device will be performed twice a day for 14 days, each session including 5-min ischemia and 5-min reperfusion.
75749782|NCT06082583|Drug|Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)|Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
75749783|NCT06082570|Drug|c610 injection|Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptors. The obtained c610 is used for one-time intravenous infusion.
75749784|NCT06082557|Drug|T60c injection|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion."
75749785|NCT06082531|Drug|Sodium hyaluronate injection|The control group was injected into the joint cavity with sodium hyaluronate injection..
76066367|NCT05935800|Behavioral|COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC|This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
75453932|NCT05363605|Biological|vofatamab|Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
75453933|NCT05357781|Diagnostic Test|Laboratory test|Frequency of fatigue (defined as Fatigue Scala for Motor and Cognitive Function (FSMC) total ≥ 43 points) in MS patients with IgG-deficiency
75453934|NCT05356260|Device|URincontrol4men|The intervention is built as an app
75453935|NCT05356260|Other|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
75605018|NCT05487053|Procedure|Continuous femoral nerve block|Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
76066368|NCT05935579|Drug|Durvalumab|Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.
75605019|NCT05468021|Other|Educational intervention|Randomized Clinical Trial (study design) to evaluate the effectiveness of an educational intervention to increase vaccine uptake among socioeconomically disadvantaged adults. The intervention will consist of a health promoter with an educational toolkit addressing misinformation, distrust, and hesitancy regarding the COVID-19 vaccine. An educational website with videos addressing COVID-19 vaccine will be available to study participants to boost information provided in the educational toolkit.
76066369|NCT05935579|Drug|Lenvatinib Oral Product|The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of <60 kg, taken once daily.
76066370|NCT05935579|Drug|Chemotherapy|GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
76066371|NCT05924334|Other|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
76066372|NCT05924334|Other|placebo|placebo
75605020|NCT02888873|Other|Charisma|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
75605021|NCT02888873|Other|Charisma Classic|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
75605022|NCT00624143|Drug|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC >1000/MM3 or development of fungal infection
75605023|NCT05284799|Biological|OVX836 480µg|One single administration intramuscularly at Day 1
75605024|NCT05284799|Biological|Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)|One single administration intramuscularly at Day 1
75605025|NCT05284799|Biological|Placebo|One single administration intramuscularly at Day 1
75605026|NCT05245253|Radiation|Positron Emission tomography|Patients will be tested with PET-examination at 3 weeks, 3 months and 1 year after the trauma
75605027|NCT05154695|Device|LASER|The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
75605028|NCT05154695|Device|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
75605029|NCT05154695|Drug|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
75605030|NCT02889029|Device|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
75605031|NCT05116787|Drug|BCX9930 monotherapy|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
75749787|NCT06082453|Diagnostic Test|Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum|A quantitative polymerase chain reaction (qPCR) assay detects and quantifies DNA in a sample, and the qPCR assay used in this study targets the polA gene of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. qPCR data will only be used to determine testing performance and will not be used in clinical management of study participants.
76066373|NCT05922085|Other|Ultrasound|performed within 3 hours prior to extubation
76066374|NCT05922085|Other|nasofibroscopie|performed within 24 to 36 hours after extubation
75605032|NCT05116787|Drug|Placebo|Administered orally twice daily
75605033|NCT04913129|Other|Exercise Training|8 week home-based exercise therapy 4-5 times/week
75605034|NCT04323995|Other|Sprint Interval Training|Sprint interval training of 2 weeks and more.
75749788|NCT06082453|Diagnostic Test|Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum|The Aptima transcription-mediated amplification (TMA) assay used in this study will target RNA of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. TMA data will only be used to determine testing performance and will not be used in clinical management of study participants.
75749789|NCT06082453|Other|Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis|Using the Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines, new born syphilis infection is categorized by clinical providers at birth as follows: confirmed proven/highly probably, possible congenital syphilis (CS), CS less likely, or CS unlikely. These CS categories are determined using neonatal nontreponemal test results, physical exam of the infant, placental pathology, and maternal serologies and treatment history, and comparison of maternal and neonatal nontreponemal tiers. These data will be collected as part of standard clinical care.
75749790|NCT06082427|Device|Virtual reality hypnosis|VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system based on hypnosis induction and suggestions (relaxation, comfort, and safety). The complete intervention lasted 17 minutes.
75749791|NCT06082414|Other|no interventions|no interventions because of an observational study
75749792|NCT06082401|Device|hemodiafiltration (HDF)|Hemodiafiltration (HDF) is a variation of conventional HD. By the addition of a substitution solution, convection forces are significantly increased. This substitution solution is added to the blood and is completely removed again in the dialyzer. This increases the negative pressure on the dialysate side and the removal of toxins through convection. The substitution solution can be added in a pre-dilution (before the dialyzer) or post-dilution (after the dialyzer) manner. Pre-dilution is associated with longer run times, less filter clotting, but is also less effective in removing toxins. Post-dilution offers a better toxin clearance capacity, but is associated with an increased risk of filter clotting. Several studies have shown that HDF provides higher clearance rates for both small and middle molecule solutes. Moreover, effective cytokine removal has been shown in HDF both in acute and chronic renal disease patients.
75749793|NCT06082401|Device|Ex vivo lung perfusion (EVLP)|"Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. One of the major obstacles in the modern transplant era is the fact that the need for organs by far exceeds availability. This leads to growing waiting lists with mortality rates ranging between 10-30%. On the other hand, up to 80% of offered lungs from brain dead donors are rejected because they do not meet predefined donor selection criteria.~Recently, ex vivo lung perfusion (EVLP) has become available as a tool to expand the donor pool. Based on experimental work by Stig Steen, the Toronto lung transplant group developed an EVLP system with the purpose to evaluate lungs with uncertain quality. Consequently, Aigner et al. have expanded the indications for EVLP by showing that primarily unacceptable donor lungs can be reconditioned and then become suitable for transplantation. This concept of organ repair by EVLP has recently been highlighted by a number of publications."
75749794|NCT06082388|Drug|Comparison of atropine and isoprenaline|Comparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline
75749795|NCT06082375|Dietary Supplement|Vitamin D|Vitamin D3 in the form of cholecalciferol.
75749796|NCT06082375|Dietary Supplement|Placebo|Vegetable oil.
75749797|NCT06082362|Other|Collection of clinical and biological material|Collection of clinical and biological material (e.g., samples of semen, stool, urine, blood, buccal swab)
75749798|NCT06082336|Diagnostic Test|MagIA IBC test in capillary blood|After a finger prick, patients will be taken a drop of capillary drop. This drop will be used to perform the MagIA IBC test.
76066375|NCT05915299|Device|OCS Heart|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
76066376|NCT05910697|Other|MyProstateScore 2.0 Results|Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.
76066377|NCT05906251|Genetic|SRP-6004|Single IV infusion of SRP-6004
75605035|NCT04320641|Other|ACUPRESSURE|Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.
75605036|NCT02888795|Drug|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
76066378|NCT05902208|Drug|Antiviral treatment with conventional non-surgical treatment|Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
75605037|NCT04320095|Device|Bizact tonsillectomy device|Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.
75749799|NCT06082336|Diagnostic Test|MagIA IBC test in other matrices|Blood samples will be taken and used to perform the MagIA IBC in veinous blood, serum and plasma.
76066379|NCT05902208|Drug|Placebo with conventional non-surgical treatment|Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
76066380|NCT05901285|Drug|VAX014|Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
76066381|NCT05899868|Device|Time to Intubation using FASTER device|Time from fiberoptic placement onto airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
75749800|NCT06082323|Drug|LT-002-158/Placebo oral tablet(s)|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
76066382|NCT05890079|Other|Subcostal transversus abdominis plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure.
76066383|NCT05890079|Other|External oblique intercostal plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure. .
76066384|NCT05889039|Device|BEMER|Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.
76066385|NCT05889039|Procedure|OMT|Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.
76066386|NCT05889039|Procedure|Sham OMT + Sham BEMER|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
76066387|NCT05885113|Behavioral|NIDCAP Developmental Care|The intervention of Individualized Developmental Care (IDC) is designed to minimize the mismatch between the fragile infant brain's expectations and the experiences of stress and pain inherent in the hospital environment. An ICU that provides individualized, developmentally-supportive care includes a soothing environment, supports parents as their child's primary caregiver, providing continual adjustment of caregiving in support of the child's wellbeing by reading the infant's cues and providing interventions to calmness throughout caregiving, capitalizing on the infant's strengths, and providing supports toward healing, growth and learning. NIDCAP is the experimental intervention to be tested in the current study. NIDCAP is the only evidence-based, comprehensive, internationally recognized program of IDC.
76066388|NCT05878860|Biological|ATSN-201|AAV.SPR-hGRK1-hRS1syn
75453936|NCT05339477|Other|Accelerometer measurement|Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
75605038|NCT04232735|Other|Tool and training|"The Source tool aims to assist health care providers with giving evidence based information about treatment outcomes by providing visualizations of personalized predictions of treatment outcomes for different treatments of oesophageal and gastric cancer. These predictions result from recently designed and updated prediction models on the survival, toxicity, complications and health related quality of life of oesophageal and gastric cancer patients.~The training aims to teach participants to inform patients about outcomes of treatment. The training is placed in the context of shared decision making (SDM), following the 4-step model by Stiggelbout et al., 2015.8 The training is provided in small groups (3-6 participants) by an experienced trainer and supported by professional actors. The training aims to address knowledge, attitude and skills."
75749801|NCT06082297|Device|Chattanooga Physio, DJO, neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) was applied with a device called Chattanooga Physio (DJO), testing 10 different combinations of parameter-settings. The parameter-settings that were varied and combined were frequency (1Hz and 36Hz) and plateau times (0.5s, 1.5s, 3s, 5s, 7s). The NMES was applied to the calf of the participants via transversally placed textile electrodes (3x3 cm) integrated in a sock starting with very low current amplitude followed by gradual small increases in current amplitude until induction of ankle plantar flexion, at which time-point the outcomes where measured.
75453937|NCT05335915|Other|Nicotine|Nicotine pouches will be self-administered
75453938|NCT05335915|Other|Cigarette|Cigarette will be smoked
75453939|NCT05328037|Diagnostic Test|Blood sample collection|Blood sample collection for dosage of vitamin C
75453940|NCT05317533|Procedure|cardiac catheterization via distal radial artery|cardiac catheterization via distal radial artery
75605039|NCT04005287|Drug|WST-057 (4% pirenzepine) Lose Dose 2mL|Topical Solution
75605040|NCT04005287|Drug|WST-057 (4% pirenzepine) High Dose 4mL|Topical Solution
75605041|NCT04005287|Drug|Placebo Low Dose|Topical Solution
75605042|NCT04005287|Drug|Placebo High Dose|Topical Solution
75749804|NCT06082245|Procedure|TLIP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"Patients were placed in a prone position;~ultrasound-guided TLIP block: (1) The transducer was positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles. (2) The probe was moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. (3) the TLIP block was performed under real-time ultrasound guidance using an insulated 100-mm 22G echogenic needle which was inserted in-plane lateral to the medial direction. (4) After negative aspiration, 20-mL 0.25% ropivacaine was injected in each side bilaterally in the interface between the MF and LG muscles.~patients received general anesthesia"
75749805|NCT06082245|Procedure|ESP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"Patients were placed in a prone position;~ultrasound-guided ESP block: (1) The 12th rib was identified in the parasagittal plane, and with probe shifted caudad and medial, the L3 transverse process (TP) was identified. (2) Insulated 100-mm 22G echogenic needle was inserted from cranial to caudal direction. (3) The needle tip was identified between the L2 and L3, and 20 mL of 0.25% ropivacaine was injected in each side bilaterally in ESP.~patients received general anesthesia"
75605043|NCT03763799|Procedure|PCR-based microbiological diagnosis strategy|A multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
75749806|NCT06082245|Procedure|Lidocaine injection|"patients received general anesthesia~the expected incision was anesthetized with 15ml of 1% lidocaine mixed with 1/200,000 adrenaline on each side before surgery."
75605044|NCT03763799|Procedure|Standard microbiological diagnosis strategy|Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
75749807|NCT06082180|Procedure|prophylactic central neck dissection|prophylactic central neck dissection was performed for the ipsilateral lesion
75749808|NCT06082128|Behavioral|FOCUSau|"FOCUSau is a self-administered web-based intervention and completed autonomously via the internet by the dyad. Delivery encompasses the completion of four prescribed consecutive FOCUSau sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and family carer, together at a computer. The intervention sessions can be completed at any time within the 12-week timeframe. Participants receive tailored individual and dyadic messages according to the information provided at study enrollment and their responses to questions within the sessions. Dyads are also provided with an online personal workbook containing the results of interactive exercises completed during the internet sessions. Any information sheets that the dyad indicated as 'of interest to them' during the internet sessions are included as a hyperlink in their personal workbook which also contains evidence-based local advanced cancer related resources."
75749809|NCT06082115|Other|Selected Physical and Occupational Therapy Program|"The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L & L.L (U.L & L.L approximation, U.L & L.L weight bearing exercises), stretching exercises for U.L & L.L muscles, strengthening exercises for antispastic group of U.L & L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands."
75605045|NCT04319861|Procedure|Anal fistula plug procedure|A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
76066389|NCT05876377|Biological|Pfizer-BioNTech COVID-19 bivalent mRNA vaccine|Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is FDA authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.
75605046|NCT02888717|Procedure|'OSNA stadification during surgery'|"The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.~Slices A and C are sent OSNA analysis~Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.~After the analysis, the report indicates whether the node is:~Free (-): <250 copies~Micrometastatic (+): 250 ≤ - <5,000 copies,~Macrometastatic (++): ≥ 5000 copies."
76066390|NCT05873374|Biological|50 μg Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of 50 μg Baiya SARS-CoV-2 Vax 2
76066391|NCT05873374|Other|Placebo|Intramuscular injection in the deltoid region of 0.5 mL/dose of 0.9% Sodium Chloride
75605047|NCT03741569|Device|Transabdominal Fetal Heart Rate|"Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes"
75749810|NCT06082115|Other|Mirror Therapy|The mirror therapy program include tasks of manipulative and grasping skills that performed by the non-affected hand in-front of mirror while the affected hand behind the mirror. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
75899483|NCT05891223|Other|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
75453941|NCT05303883|Other|Pediatric Constrained Induced Movement Therapy|Constraint of the child's less-impaired upper extremity for first 17 days of treatment. Children wear a removable, lightweight constraint for the first 17 of 20 therapy sessions.
75605048|NCT03616379|Behavioral|Psychoeducational Control|The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
75605049|NCT03616379|Behavioral|Affect Regulation|In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
75453942|NCT05303194|Behavioral|Patient Priorities Care (PPC) Approach|First, identify patient priorities, and second align care received with those priorities.
75605050|NCT03616379|Behavioral|Affect Labelling|In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
75605051|NCT04320173|Drug|Lidocaine patch 1.8%|Three patches are applied to the subject's back for 12 hours.
75605052|NCT04320173|Drug|Lidocaine patch 5%|Three patches are applied to the subject's back for 12 hours.
75605053|NCT04320173|Drug|Lidocaine medicated plaster 5%|Three plasters are applied to the subject's back for 12 hours.
76066392|NCT05868096|Other|Structured holistic thinking course(2 hr)|The holistic thinking curriculum was designed as a structured program using mind maps, case-based discussions, and clinical observations to integrate physical, psychological, social, and spiritual aspects.
76066393|NCT05868096|Other|Clinical practice training|there is no holistic thinking curriculum.Using the holistic thinking case study form - introductory version self-study
75605054|NCT04321733|Drug|Amoxicillin Clavulanate|Intravenous drug intake of our drug.
75605055|NCT03002519|Biological|PLX-R18|Intramuscular (IM) administration of PLX-R18
75453943|NCT05303194|Behavioral|Adapted PPC|First, identify patient priorities, and second align care received with those priorities.
75453944|NCT05295784|Drug|Caffeine citrate|A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
75605056|NCT02915549|Other|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
75605057|NCT02915549|Other|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
75605058|NCT02914301|Device|Babyscripts Prenatal App|The use of a mobile digital app to facilitate certain aspects of standard prenatal care.
75749811|NCT06082115|Other|Task-Oriented Training|The task-oriented training program include tasks of manipulative and grasping skills that performed by the affected hand based on repetition practice. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
75605059|NCT02914301|Device|Placebo|No Mobile App, Usual care
75605060|NCT02693093|Drug|NI-03|
75605061|NCT02693093|Drug|Placebo|
75605062|NCT01613495|Drug|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
75749812|NCT06082089|Behavioral|Divorce Adjustment Program (DAP)|This is a brief group intervention program for divorced women. It consists of 6 sessions for participants with children and 5 sessions for participants without children. Each session lasts approximately 2.5-3 hours focusing on one of the difficulties experienced by women after divorce (i.e., self-perception, emotions and emotion regulation, social problems, family-related problems, problems with ex-spouse and children (for participants with children)). In this study, the DAP will be implemented in online format.
75749813|NCT06082076|Drug|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
75749814|NCT06082076|Drug|Ketamine|Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
75749815|NCT06082076|Drug|Meperidine|If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine
75749816|NCT06082063|Drug|Aspirin tablet|Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.
75749817|NCT06082063|Drug|Semaglutide|GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c >53 mmol/mol or BMI>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.
75749818|NCT06082063|Drug|Sotagliflozin|SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR >30 mg/g and eGFR < 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.
75749819|NCT06082063|Drug|Finerenone|Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (>30 mg/g) despite RAS blockade.
75899484|NCT05891223|Other|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
75453945|NCT05293925|Behavioral|announcement of cessation of treatment|"The first 40 outpatients for whom an announcement to stop anti-tumour treatments is made at the Institut Curie Paris, in a conventional oncology consultation or in Palliative Care Day Hospital.~Categorical variables will be described by numbers and percentages. Quantitative variables will be described by the mean, standard deviation, median of the distribution as well as the minimum, maximum and interquartile range and compared by a Student's t test or a Wilcoxon test according to the normality of the variables."
75453946|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
75453947|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
75453948|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|"Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~Methotrexate 15 mg, IT, Days 36, 56"
75453949|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
75749820|NCT06082050|Drug|YOLT-201|Infusion of YOLT-201 at Day 1。
75749821|NCT06082011|Device|da Vinci SP Surgical System|Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
75749822|NCT06081985|Device|Transcranial Magnetic Stimulation with double-cone coil|Deep Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with double-cone coil
75749823|NCT06081985|Device|Transcranial Magnetic Stimulation with sham coil|Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with sham coil
75749824|NCT06081959|Drug|SKB264|IV infusion on day 1 and Day 15 of each 28 day cycle
75749825|NCT06081959|Drug|Eribulin|1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
75749826|NCT06081959|Drug|Capecitabine|1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
75899485|NCT05891223|Other|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
75899486|NCT05891145|Drug|Remimazolam|Remimazolam is dispensed at 2 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
75749827|NCT06081959|Drug|Gemcitabine|1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
75899487|NCT05891145|Drug|midazolam|Midazolam is dispensed at 1 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
75749828|NCT06081959|Drug|Vinorelbine|25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
75749829|NCT06081933|Drug|intranasal dexmedetomidine|Patients will receive 1.5 micro g/kg intranasal dexmedetomidine diluted with saline + infusion saline
75749830|NCT06081933|Drug|intravenous dexmedetomidine|patients will receive 0.1- 0.4 micro g/kg intravenous infusion dexmedetomidine + intranasal saline.
75749831|NCT06081868|Behavioral|Use of toothbrush/toothpaste/fluoride varnish|Children receive information about the use of toothbrush/toothpaste/fluoride varnish.
75749832|NCT06081868|Behavioral|Education on nutrition/oral hygiene|Children receive education on nutrition/oral hygiene.
75749833|NCT06081855|Diagnostic Test|CT|Measuring aortic root diameter by CT
75749834|NCT06081842|Other|Contraceptive counseling strengthening intervention package|Development of contraceptive counseling strengthening intervention package that strengthens existing family planning services and is effective, safe, sustainable, scalable, and culturally appropriate.
75899488|NCT05891080|Drug|Toripalimab|Specified dose on specified days.
75899489|NCT05891080|Drug|JS004|Specified dose on specified days.
75749835|NCT06081816|Other|carie|Caries lesions were assessed by visual tactile examination and periodontal disease through two probing sites around third molar, considering the presence of periodontal pathology when at least one periodontal probing depth was greater than 4 mm, and both were evaluated by radiograph diagnostic methods. The assessment of oral health related quality of life by Oral Health impact Profile questionary (OHIP-14), applied as an interview. The evaluation of the position of the third molars was made by clinical and panoramic radiographs according to the classification of Pell and Gregory and Winter
75749836|NCT06081803|Drug|Repatha®|Repatha® 140mg x 3 pens subcutaneous injection
75749837|NCT06081764|Other|Exercise|Doing Otago Exercise Program, which lasting 3 days a week and an average of 30 minutes per day under the supervision of a physiotherapist. Also doing walking exercise for 30 minutes a day, 2 days a week for total of 12 weeks.
75749838|NCT06081751|Behavioral|Pretest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
75749839|NCT06081751|Behavioral|Posttest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
75899490|NCT05891080|Drug|Pemetrexed|Specified dose on specified days.
75899491|NCT05891080|Drug|Nab-paclitaxel|Specified dose on specified days.
75899492|NCT05891080|Drug|Carboplatin|Specified dose on specified days.
75899493|NCT05891080|Procedure|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
75899494|NCT05891067|Behavioral|SterkWerk|Classroom-based intervention program
75899495|NCT05891067|Behavioral|Treatment-as-usual|Active control group
75899496|NCT05891054|Behavioral|Active breaks|Two active breaks are taken daily in a predetermined time slot. The development of each break is done through access to a specific digital platform where students follow the instructions of an avatar, which is in charge of guiding the realization of the active break. Each active rest involves a total of 4 minutes of activity, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed, ending with a brief return to calm consisting of two deep breaths. The activities selected for each of the active breaks include aerobic and strengthening activities of moderate and vigorous intensity.
75605063|NCT01613495|Drug|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
75749840|NCT06081738|Drug|Neostigmine|a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium
75749841|NCT06081738|Drug|Sugammadex|2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium
75749842|NCT06081725|Behavioral|Playful interactions in an online format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom
76066394|NCT05866406|Behavioral|Time restricted eating|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
75453950|NCT05284435|Behavioral|Cognitive Behavioral Therapy-Email (iCBT-E)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently."
75453951|NCT05284435|Behavioral|Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed."
75605064|NCT01429493|Radiation|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
75605065|NCT01429493|Radiation|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
75605066|NCT01429493|Radiation|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
75605067|NCT00694733|Drug|Placebo injection|Normal saline injection IM monthly for 4 months
75749843|NCT06081725|Behavioral|An active control condition in a face-to-face format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.
75749844|NCT06081725|Behavioral|An active control condition in an online format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom
75749845|NCT06081725|Behavioral|Playful interactions in a face to face format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.
75749846|NCT06081712|Drug|TNP-2198|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
75605068|NCT00694733|Drug|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
75605069|NCT00694733|Drug|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
75749847|NCT06081712|Drug|TNP-2198 Placebo|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
75749848|NCT06081699|Drug|TNP-2198|Oral
75749849|NCT06081699|Drug|TNP-2198 Placebo|The placebo for TNP-2198 active drug
75749850|NCT06081686|Drug|Phase I:[177Lu]Lu-XT033 Injection|Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of [177Lu] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .
75899497|NCT05891054|Behavioral|Physically active learning|"The physically active learning is carried out once a week for 1 hour outside the classroom, where physical activity (through movement, jumping, strengthening exercises, throwing, etc.) is incorporated into academic mathematics classes.~The mathematics teachers (with the support of the research team) are in charge of teaching the physically active classes. Prior to the development of each class, the research team, together with the mathematics teachers involved, meet and design the class according to the contents to be addressed."
75453952|NCT05282225|Behavioral|MI- Safety Plan|"The MI-enhanced safety plan (MI-SP) component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy"
75605070|NCT00694733|Drug|placebo|Placebo Cream 1ml applied twice daily for four months
75605071|NCT00694733|Drug|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
75605072|NCT04320953|Device|Non-contact MCE system|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.
75605073|NCT00242021|Behavioral|Fatty acid composition of a margarine (spread)|
75605074|NCT01259297|Drug|Aliskiren|Aliskiren 150/300 mg once daily
75749851|NCT06081686|Drug|Phase II:[177Lu]Lu-XT033 Injection|Patients received [177Lu]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
75899498|NCT05891002|Device|Cirq® Robotic Alignment Module Cranial|Robotic navigation for cranial biopsy procedure
75605075|NCT01259297|Drug|Amlodipine|Amlodipine 5 mg
75605076|NCT01259297|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
75749852|NCT06081673|Drug|Penpulimab injection|Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
75749853|NCT06081673|Drug|cisplatin|Cisplatin :75mg/m2, D1, IV(21 days/cycle)
75749854|NCT06081673|Drug|albumin-paclitaxel|albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
75749855|NCT06081660|Behavioral|ACP-I Plan|ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
75749856|NCT06081647|Device|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
75605077|NCT01259297|Drug|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
75605078|NCT01259297|Drug|Placebo for Amlodipine|Placebo for Amlodipine
75749857|NCT06081647|Device|Regular Nasal Cannula|Using regular nasal cannula for oxygenation.
75605079|NCT01259297|Drug|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
75605080|NCT01126437|Drug|tiotropium 18 mcg|HandiHaler
75749858|NCT06081634|Behavioral|Enhancing cognitive reserve|Intervention in group format (6-8 patients) consisting of 12 weekly sessions, each lasting approximately 60 minutes. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Technological resources such as the use of the Internet and some telephone applications will also be used in some sessions. For those sessions in which the practice of mindfulness techniques will be promoted, a virtual reality device will be used per patient.
75749859|NCT06081634|Other|Treatment as Usual|The group will only receive the pharmacoloical treatment according to the based guidelines.
75899499|NCT05890989|Diagnostic Test|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT OF THE PARTICIPANTS WAS MADE.
75453953|NCT05282225|Behavioral|Texts messages|For participants randomized to receive supportive text messages (Texts), text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
75453954|NCT05282225|Behavioral|Monitoring|Adolescent participants will complete daily surveys for 4 weeks (including assessment of suicidal ideation, behavior, and other relevant risk and protective factors) and these will be monitored daily to identify presence of heightened suicidal ideation and presence of suicidal behavior. In addition, daily surveys will be used to determine if adolescents are sufficient responders to Phase 1 intervention.
75605081|NCT01126437|Drug|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
75605082|NCT01126437|Drug|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
75605083|NCT01258595|Biological|High-Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
75605084|NCT01258595|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
75605085|NCT05596799|Behavioral|Facing Eating Disorder Fears Condition|The first session consists of diagnosis and general psychoeducation on anorexia nervosa and treatment for anorexia nervosa. After psychoeducation and baseline questionnaires are complete, sessions 2-12 include exposure-based virtual treatment for common eating disorder fears (food, weight gain, body sensations, and social situations).
75749860|NCT06081621|Biological|REGEND001|REGEND001: 1-1.5×10^6 bronchial basal cells/kg administrated by bronchoscopy.
75749861|NCT06081621|Biological|Placebo|Placebo: Sodium chloride injection administrated by bronchoscopy.
75749862|NCT06081608|Diagnostic Test|kidney function test|blood sample for kidney function test
75749863|NCT06081595|Drug|Fluzoparib|Fluzoparib 100mg bid
75749864|NCT06081595|Drug|Apatinib|Apatinib 375mg qd
75899500|NCT05890937|Diagnostic Test|Oral and practical exam|Oral and practical exam that performed at the end of the semester
75899501|NCT05890911|Diagnostic Test|Polysomnography|Each of the patients will undergo polysomnography
75899502|NCT05890911|Diagnostic Test|Blood dopamine level measurement|In each of the patients blood dopamine level will be measured
75899503|NCT05890911|Diagnostic Test|Genetical test|Each of the patients will undergo genetical test focusing on selected single nucleotide polymorphisms within genes regulating the concentration of dopamine - the gene responsible for production of the enzyme catechol-O-methyltransferase (COMT) - rs4680 and rs6269 and genes encoding receptors dopamine (DRD1 - rs686, rs5327 and DRD2 - rs1800497).
75899504|NCT05890885|Procedure|Real left prefrontal tDCS - sham|Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
75749865|NCT06081582|Drug|Toripalimab|"This study was conducted on 30 patients with initially unresectable locally advanced head and neck squamous cell carcinoma who underwent two cycles of PD-1 antibody (trepril monoclonal antibody) combined with fluorouracil, cisplatin, and cetuximab conversion therapy. The feasibility of radical surgery should be evaluated before surgical treatment.Three patients were enrolled in the safe induction period before the study began.~The dosage of medication used is as follows:~Toripalimab: 240mg, Day1, Q3W~Cisplatin: 25mg/m2, Day1-3, Q3W（every 3 weeks）~5-FU: 1000mg/m2, Day1-3, Q3W~Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week"
75749866|NCT06081569|Diagnostic Test|gait video; speech video; facial expression video;|The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
75749867|NCT06081556|Diagnostic Test|ultrasonic testing|mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected
75899505|NCT05890885|Procedure|Sham - Real left prefrontal tDCS|Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
75899506|NCT05890859|Diagnostic Test|DXA scan|The patients will undergo 5 DXA scans fro pre- to post treatment
75899507|NCT05890859|Behavioral|Physical testing|The patients will undergo tests for maximal muscle strength and functional performance before and after treatment
75899508|NCT05890820|Other|Preoperative nutritional assessment|Preoperative nutritional assessment and postoperative pulmonary complications
76066395|NCT05866406|Behavioral|Extended eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
76066396|NCT05866406|Behavioral|Healthy diet|Participants will be provided nutrition education and counselling to follow a diet consistent with the existing guidelines for chronic disease prevention.
75453955|NCT05282225|Behavioral|Portal follow-up|This will be part of Phase 2. The portal follow-up will similarly address content offered in the booster call. For the adolescent, the focus will be on revisiting and adjusting the safety plan, addressing barriers to safety plan adherence, as well as enhancing motivation and self-efficacy to use healthy coping. For the parent, portal communication will focus on revisiting safety recommendations provided as part of MI-SP, addressing barriers in implementing safety recommendations and in supporting the adolescent's safety plan use, as well as enhancing parents' motivation and self-efficacy in these areas. The portal will enable additional asynchronous contacts up to 3 weeks to provide added support and problem solving, based on identified barriers and concerns, to promote post-discharge behavior change. Counselors will initiate approximately 6 contacts with adolescents and, separately, with parents over 3 weeks as soon as non-response is detected.
75605086|NCT01257737|Drug|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine [PAGN] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
75605087|NCT01126359|Drug|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
75899509|NCT05890781|Procedure|Skin biopsy|Skin biopsy
75899510|NCT05890781|Procedure|Fresh tumor sample|Fresh tumor sample
76066397|NCT05864859|Other|Simulation|In the simulation session, while 2 participants (1 midwife, 1 pregnant) performed the roles in accordance with the clinical scenario, the performance was recorded in the control room. A Wearable Pregnancy Simulator was worn by the student performing the pregnant role. During the simulation, the participants were able to interact with the facilitators when they had questions. The application time did not exceed 10 minutes.
76066398|NCT05863130|Drug|BI 764198 (C-14) (approach 1)|BI 764198 (C-14) (approach 1)
75605088|NCT01126359|Drug|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
75605089|NCT00637533|Procedure|Lumbar sympathetic block with Botulinum Toxin type A|
75605090|NCT01125813|Biological|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
75899511|NCT05890781|Biological|Blood sample|Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
75899512|NCT05890781|Procedure|Healthy tissue from the tumor|Healthy tissue from the tumor site whenever possible
76066399|NCT05863130|Drug|BI 764198 (C-14) (approach 2)|BI 764198 (C-14) (approach 2)
76066400|NCT05861245|Radiation|5-fraction hipofractionated protontheray|"The therapeutic schemes that will be proposed to patients based on clinical criteria such as tumor size and relationship of the tumor with adjacent critical organs are:~For chordomas: 37.5 Gy in 5 consecutive sessions of 7.5 Gy per fraction.~For chondrosarcomas: 35 Gy in 5 consecutive sessions of 7 Gy per fraction."
76066401|NCT05854914|Procedure|Use of hypnosis videos|Hypnosis on smartphone will be used to manage pain for emergent coelioscopy surgery of patients with acute and complicated appendicitis, with generalized peritonitis
75749868|NCT06081543|Dietary Supplement|Ketogenic diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
75749869|NCT06081543|Dietary Supplement|Low-fat Mixed diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
75749870|NCT06081517|Behavioral|Social Determinants of Health and toxicity questionnaires|Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.
75749871|NCT06081504|Other|Wii fit exercises program|Wii fit exercises for balance training and lower limb strengthening for 30 minutes. In addition to warming up and cooling down, 10 minutes each in the form of a range of motion exercises and stretching.
75453956|NCT05282225|Behavioral|Booster call|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, is to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
75749872|NCT06081504|Other|Pilates exercises program|Selected pilates exercises for balance training and lower limb strengthening: Articulating bridge, Spine stretch, Single leg stretch, Double leg stretch, Criss-cross, One leg kick, Side kick, Hip twist, and Standing footwork for 30 minutes, 10 repetitions each. In addition to the warming up and the cooling down exercises before and after the pilates exercises, 10 minutes each in the form of a range of motion exercises and stretching, and deep friction massage for scar management.
75749873|NCT06081504|Other|Standard physical therapy program|All patients will receive the standard physical therapy program consisting of 45 minutes per session of a supervised and individualized exercise program for three sessions per week for eight weeks which will include: Stretching exercises for lower limb muscles, each stretch will be maintained for 45 seconds, 3 repetitions, strengthening exercises for lower limb muscles starting from 50 to 60% of 1 repetition maximum and the intensity will be increased gradually until 80 to 85 % through the treatments weeks.
75749874|NCT06081491|Diagnostic Test|diagnosis|Pediatric patients within the inclusion criteria will be diagnosed for MIH by the primary investigator and the questionnaire will be filled with face to face interviews with their parents
75749875|NCT06081478|Drug|CD19/CD22-bispecific CAR-T cells|CD19/CD22-bispecific CAR-T cells were infused at the same day with 2×10e6/kg and 1×10e6/kg dosage, respectively.
75749876|NCT06081426|Other|Non-ketogenic Diet|Consuming a non-ketogenic diet
75749877|NCT06081426|Other|Ketogenic Diet|Consuming a ketogenic diet
75749878|NCT06081426|Other|No diet|Participants without Bipolar Disorder will not participate in the diet phases of the study
75749879|NCT06081413|Procedure|bariatric surgery|bariatric surgeries - sleeve gastrectomy, roux-en-Y gastric bypass, one anastomosis gastric bypass, adjustable gastric band
75749880|NCT06081400|Procedure|Cryoablation|Percutaneous imaging-guided cryoablation
75749881|NCT06081400|Drug|Chemotherapy drug|"Either :~methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months."
75749882|NCT06081387|Dietary Supplement|Vitamin D|Oral capsules containing 5,000 international units of vitamin D every two weeks for four months. The tablets will be taken with 250 ml of water at lunch.
75749883|NCT06081387|Other|Resistance training|Sarcoplasm stimulating training system. This program will run for 15 weeks and three sessions a week. This exercise plan is designed in three 5-week periods.
75749884|NCT06081387|Drug|placebo|Capsules made of paraffin oil, designed as a placebo. They will be indistinguishable in shape and colour from vitamin D capsules. The tablets will be taken with 250 ml of water at lunch.
75749885|NCT06081374|Device|simulation implication|Breastfeeding education is planned by dressing pregnant women with simulation models.
75749886|NCT06081322|Drug|PRRT with 177Lu-EB-FAPI|PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue
75749887|NCT06081296|Procedure|Control group|Control Group (Ctl): alveolus closure with total flap elevation and simple suture; and socket sealing with mixed free gingival tissue graft.
75749888|NCT06081296|Procedure|Mixed free gingival graft group|closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual's own palate, which will be properly sutured. This graft is a combination of epithelialized-subepithelial connective tissue graft, which will be taken from the hard palate of the regions.
75899513|NCT05890781|Procedure|Spinal cerebrospinal fluid (SCF)|Spinal cerebrospinal fluid (SCF) whenever possible
75899514|NCT05890768|Drug|Lumateperone|FDA approved antipsychotic drug
75899515|NCT05890768|Drug|Risperidone|FDA approved antipsychotic drug
75899516|NCT05890755|Other|Mechanical pertubation|Acceleration or deacceleration of one treadmill gait belt.
75453957|NCT05278962|Drug|SGLT2i|empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
75453958|NCT05278962|Other|No SGLT2i|No SGLT2i
75453959|NCT05278130|Other|Additional vaginal swabs|Every 2 weeks from 16 weeks gestational age to 34 weeks gestational age
75453960|NCT05275868|Drug|MGY825|investigational drug
75605091|NCT00996892|Drug|Cobimetinib|Repeated oral dosing.
75605092|NCT00996892|Drug|Pictilisib|Repeated oral dosing.
75605093|NCT04311645|Drug|Activated charcoal|Activated charcoal
75605094|NCT04311645|Dietary Supplement|Dry seeds|Dry seeds
75605095|NCT01257581|Drug|creatine|creatine monohydrate powder
75605096|NCT01257581|Drug|tamoxifen|Tamoxifen citrate capsules
75605097|NCT01257503|Drug|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
75605098|NCT01257503|Drug|placebo|liquid made to look like the active homeopathic remedy
75749889|NCT06081296|Procedure|Bone+ mixed free gingival graft group|closure of the socket without flap elevation, placement of a freeze-dried bone graft and sealing of the socket with a mixed free gingival tissue graft.
75749890|NCT06081296|Procedure|Bone + Titanium Seal group|socket closure without flap elevation, placement of lyophilized bone graft, socket sealing by installing a non-absorbable titanium membrane.
75749891|NCT06081270|Other|Liquid biopsy|Blood withdrawal for each patient is performed (i) at the time of treatment initiation with tyrosine kinase inhibitors (TKI); (ii) at the time of the first planned instrumental re-evaluation according to clinical practice regardless of the type of response to the TKI employed (9-12 weeks); (iii) at the time of radiological progression according to RECIST 1 criteria. 1 at computerized tomography scan with contrast or metabolic progression at 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose during TKI therapy; (iv) at the time of the change of therapeutic strategy decided by the investigator when used beyond progression and not coinciding with point iii. The ctDNA is extracted from plasma and analyzed with Illumina sequencing method.
75749892|NCT06081218|Other|activity test|Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
75749893|NCT06081205|Other|Admission in the Cardiac Intensive Care Unit (CICU)|all patients admitted in the CICU will be enrolled in the study provided they give their informed consent.
75749894|NCT06081192|Procedure|Implant placement surgery|Placement of six mini implants in the edentulous maxilla using a partially-guided protocol
75749895|NCT06081166|Drug|Obicetrapib|obicetrapib 10 mg daily
75749896|NCT06081166|Drug|Atorvastatin Calcium|Atorvastatin 80 mg
75749897|NCT06081166|Drug|Rosuvastatin Calcium|Rosuvastatin 40 mg
75749898|NCT06081140|Dietary Supplement|Standard Process Hemp Oil Complex|10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.
75749899|NCT06081127|Other|MOve-ABC|"The intervention is called Moving On After Breast Cancer (MOve-ABC) and includes:~Three in-person visits for clinical measurements~Enhanced usual care (EUC)~Pre-hab (pre-treatment PT evaluation and individualized home therapeutic exercise prescription with safe progressions).~Teach Back (HEP, post-op movement precautions)~Self-management education with reinforcement check-ins via text messaging and phone calls at regular intervals."
75899517|NCT05890742|Drug|IBI310|In arm 1，IBI310 will be used once
75899518|NCT05890742|Procedure|Radical surgery|Radical surgery after neoadjuvant therapy
75899519|NCT05890742|Drug|Sintilimab|In arm1&2，Sintilimab will be used twice ，q3w
75749900|NCT06081127|Other|Enhanced Usual Care|"All patients will receive EUC. However, half of our sample will have ONLY EUC consisting of~Three in-person visits for clinical measurements~Planned oncology treatment (surgery, chemotherapy, radiation)~Nursing education on surgical site and drain care, post-operative movement precautions, pain management~If needed, laboratory and radiological testing to rule out disorders that interfere with treatment outcomes~Monthly monitoring with PROMIS-PF surveys beginning at baseline with alerts from scores = or < 45 (indicating moderate or severe impairment) for physical therapy referral"
75749901|NCT06080672|Other|Experimental: Group 1 (dental examination-training-tooth brushing) Experimental: Group 2 (dental examination-training-plaque disclosing-tooth brushing)|All participants will be examined and their decay, filling and extracted teeth, plaque index and gingival index measurements will be recorded. Plaque disclosing will be applied to Group 2 after brushing training.
75749902|NCT06080360|Other|Patient-Reported Outcome Measures|Functional Independence Measurement-FIM, Barthel Index and European Quality of Life-5 Dimensions Questionnaire-EQ-5D, which are self-report based evaluation methods, were applied to patients who received routine treatment and met the inclusion criteria.To determine the patients' level of participation in the treatment, Hopkins was scored by the physiotherapist applying the treatment.
75749903|NCT06079840|Device|mindfulness-based stress reduction app|mobile application (app) for caregivers
75749904|NCT06079242|Device|Resin microspheres containing yttrium-90 (Y-90)|SIR-Spheres Y-90 resin microspheres are permanent implant and for single use only
75453961|NCT05268107|Drug|Dupilumab|"Patients will be treated with dupilumab for 4 months (standard FDA-approved dosing of 600 mg subcutaneously at baseline/week 0, followed by 300 mg every 2 weeks).~Skin biopsies will be assessed at baseline (lesional and non-lesional), week 2 (lesional), and week 16 (lesional). In addition, blood will be obtained at baseline and week 16."
75749905|NCT06078384|Drug|Pembrolizumab 25 mg/ml|"Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion."
75749906|NCT06078384|Drug|Paclitaxel injection|Injectable solution for IV administration. Dose of 80 mg/m² weekly.
75749907|NCT06078358|Other|Resistance exercise training|Traditional linear periodization resistance training.
75749908|NCT06078215|Combination Product|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysine in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset
75749909|NCT06077903|Biological|GT101|Autologous tumor infiltrating lymphocyte injection
75749910|NCT06077188|Other|Gum group|Group chewing gum with xylitol
75453962|NCT05259722|Drug|Delgocitinib|Cream for topical application 20 mg/g
75453963|NCT05259722|Drug|Toctino|1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
75453964|NCT05249959|Drug|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))|"Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~Rituximab 375 mg/m2 i.v. Day 1~Bendamustine 70 mg/m2, Days 2 and 3~Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
75749911|NCT06077175|Other|hand massage group|Each individual will receive a 10-minute hand massage, 5 minutes for each hand. Since the speed and number of repetitions of the massage movements should be at normal frequency, the massage will be performed at a speed that does not disturb the individual, is not stimulating and has a calming effect, and will not tire the practitioner. In the massage, effleurage (stroking) and friction (circular rubbing) movements will be used, which have a circulation-supporting and tissue-relaxing effect. Evaluations will be made within 30 minutes after the hand massage.
75749912|NCT06077149|Biological|RSV vaccine|"All participants will get either the Pfizer RSV vaccine (RSVpreF (ABRYSVO)) or the GSK RSV vaccine (RSVpreF (AREXVY)) at 120 ug of the RSV prefusion F antigen intramuscularly in the the non-dominant deltoid muscle.~Long-term care facility residents will get whichever vaccine is available at the facility as part of standard of care. Community cohort will be matched proportionally"
75909583|NCT03474146|Other|Ocimum sanctum|Ocimum sanctum (known as Tulsi, Holy basil) is natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is one of the best examples of Ayurveda's holistic lifestyle approach to health. It is also been well practiced in traditional medicine in India and south Asian region. Literature showed that Ocimum sanctum extract have significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
75605099|NCT04205032|Device|Test of the different devices integrated in cardiospace II|"The different devices included in CARDIOSPACE II will be tested~Electrocardiogram~Vascular Doppler~LaserDoppler and iontophoresis~Brachial blood pressure~Continuous blood pressure recorded at the finger level~Ultrasound~Ambulatory Electrocardiogram / SAO2 (arterial oxygen saturation)"
75605100|NCT02870452|Behavioral|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
75899520|NCT05890703|Drug|IMP2 (lidocaine-23%-tetracaine-7% gel)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
75453965|NCT05249959|Drug|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)|"Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~Rituximab 375 mg/m2 i.v. Day 1~Bendamustine 70 mg/m2, Days 2 and 3~Cytarabine 500 mg/m2, Day 2 and 3~or~Rituximab 375 mg/m2 i.v. Day 1~Bendamustine 100 mg, Days 2 and 3~Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
75453966|NCT05248594|Drug|HEMLIBRA|Emicizumab (Hemlibra, also known as ACE910 and RO5534262) is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.
75453967|NCT05247255|Drug|Active Comparator|QL block with 0.25% ropivacaine
75453968|NCT05247255|Drug|Placebo Comparator|QL block with saline
75453969|NCT05240638|Device|TD Drainage|Image-guided percutaneous cannulation of the TD and drainage with an endovascular catheter (microcatheter)
75605101|NCT02870452|Behavioral|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
75605102|NCT00995566|Drug|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
75605103|NCT01257425|Drug|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|"Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85."
75605104|NCT00995488|Drug|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
75605105|NCT04293172|Drug|Brilinta|"Patients in the open-label Run-in period (patients aged 6 to <24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight >9 to ≤12 kg) or 15 mg twice a day (body weight >12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
75605106|NCT04293172|Drug|Placebo|"Patients in the open-label Run-in period (patients aged 6 to <24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight >9 to ≤12 kg) or 15 mg twice a day (body weight >12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
75605107|NCT01256879|Drug|Drug: cimetidine|cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
75605108|NCT04293250|Procedure|Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group|Compare postoperative pain scores for the physical activity Vs non-physical activity group
75749913|NCT06076551|Diagnostic Test|Adenosine stress echocardiography|Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood ﬂow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel ﬂow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary ﬂow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.
75749914|NCT06076408|Other|SNAGS with Pilates|Patients will Receive Sustained Natural Apophyseal glides and Pilates Technique. Pilates Exercises focusses on five main areas (breath control, pelvic lumbar region, chest, shoulder positioning, head and neck positioning) a special session was organized for each patient
76066402|NCT05839470|Drug|cadonilimab|Cadonilimab (6mg/kg, iv, Q2W, Day1)
76066403|NCT05839470|Drug|irinotecan|irinotecan* 165 mg/m² iv continue for 1.5 hours, D1
75605109|NCT04292938|Dietary Supplement|Low carbohydrate ketogenic diet|Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
75605110|NCT04293718|Other|papillary gum biopsies|1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
75749915|NCT06076408|Other|SNAGS|Patients will Receive Sustained Natural Apophyseal glides
75749916|NCT06076356|Other|Foam Rolling|Foam Roller for 90 seconds over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
75749917|NCT06076356|Other|Kinesio Taping|Kinesio taping over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
76066404|NCT05839470|Drug|Oxaliplatin|oxaliplatin 85 mg/m² iv continue for 2 hours,
75605111|NCT02869672|Biological|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
75749918|NCT06076304|Drug|Amoxicillin/clavulanate|Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days
75749919|NCT06076304|Drug|Placebo antibiotic|Placebo antibiotic, oral, twice daily for 7 days
75749920|NCT06076304|Drug|Budesonide nasal spray|Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day
75605112|NCT02869672|Biological|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
75749921|NCT06076304|Other|C-reactive protein|Measurement of C-reactive protein level in capillary blood
75749922|NCT06076304|Other|Mid-turbinate swab (optional)|Optional collection of mid-turbinate nasal swab sample
75749923|NCT06072911|Behavioral|Pelvic floor exercise program|General exercises will be prescribed along with a specialized pelvic floor program
75749924|NCT06072911|Behavioral|General exercise|A general progressive resistance exercise program
75749925|NCT06072911|Behavioral|Physical Activity Counseling|Advice on increasing physical activity
76066405|NCT05839470|Drug|leucovorin or levoleucovorin|leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours
76066406|NCT05839470|Drug|5-FU|5-FU 2400 mg/m² cont. inf. 46h
75605113|NCT01125189|Drug|Daclatasvir|Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
75605114|NCT01125189|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
75605115|NCT01125189|Drug|Placebo|Tablets, oral, 0 mg, once daily, 24 weeks
75605116|NCT01125189|Drug|peg-interferon alfa-2a|Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
75749926|NCT06071702|Device|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloybased stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
75749927|NCT06071195|Diagnostic Test|Prostate Cancer Patients|see arm/group description
75749928|NCT06071065|Behavioral|Pharmacist counselling|Counselling session with Pharmacist about disease and medication therapy.
75749929|NCT06069973|Other|No intervention, observational study|No intervention
75749930|NCT06069076|Diagnostic Test|cathepsin S and chromogranin A|Diagnostic value of serum Cathepsin S and Chromogranin A
75749931|NCT06067269|Drug|Apalutamide|Given PO
75749932|NCT06067269|Procedure|Biospecimen Collection|Undergo collection of blood samples
75749933|NCT06067269|Procedure|Computed Tomography|Undergo PSMA-PET/CT
75749934|NCT06067269|Other|Gallium Ga 68 Gozetotide|Undergo PSMA-PET/CT
75749935|NCT06067269|Radiation|Guided Stereotactic Body Radiation Therapy|Undergo guided SBRT
75749936|NCT06067269|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
75749937|NCT06067269|Procedure|Positron Emission Tomography|Undergo PSMA-PET/CT
75453970|NCT05236699|Combination Product|DEB-TACE combined with Surufatinib and Camrelizumab|"All patients will be treated with standard DEB-TACE on the first day (D1).~After DEB-TACE, if the liver function is Child-PughA grade, they will be treated with Camrelizumab on the same day, 200mg/ times, intravenous injection, once every 3 weeks.~Surufatinib capsule will be given orally to 250mg within 1 hour after breakfast on the second day (D2) after the first DEB-TACE. The drug will be given continuously once a day and stopped on the same day of each DEB-TACE.~The combination of drugs for 3 weeks is a cycle.The treatment will continue until the patient developed the disease or met the other criteria for terminating the study."
75899521|NCT05890703|Drug|IMP1 (EMLA 5% cream)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
75899522|NCT05890664|Drug|Colchicine|"Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol[a]heptalen-7-yl) acetamide.~Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether."
75899523|NCT05890664|Drug|Placebo|Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.
75453971|NCT05231629|Drug|Dara-VRd intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
75749938|NCT06067269|Other|Questionnaire Administration|Ancillary studies
75749939|NCT06066411|Other|Massage Ball|The massage ball application will be applied to the patients by the researcher for 20 minutes every day for 3 days.
75749940|NCT06063941|Drug|1% Lugol's iodine solution|1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.
75749941|NCT06063941|Drug|5% Lugol's iodine solution|Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
75605117|NCT01125189|Drug|ribavirin|Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
75605118|NCT01256567|Biological|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
75605119|NCT01256567|Drug|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.
75605120|NCT00996736|Drug|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
75605121|NCT00996736|Drug|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
75605122|NCT00996658|Drug|Placebo|Placebo matching linagliptin tablets once daily
75605123|NCT00996658|Drug|Linagliptin|Linagliptin tablets once daily
75749942|NCT06056830|Drug|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
75749943|NCT06054984|Drug|TCR-T Cells Injection（GB3010 Cells Injection）|The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10^8±20%,5×10^9±20%,5×10^10±20%.
75749944|NCT06054464|Drug|PC14586|Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.
75749945|NCT06054464|Drug|Rabeprazole|Part 1: Daily oral dose of rabeprazole on days 11-14.
75749946|NCT06054464|Drug|Famotidine|Part 2: Twice daily oral dose of famotidine on days 11-13. Single, oral dose of famotidine on day 14.
75749947|NCT06054308|Other|MSLN CART|Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
75749948|NCT06052462|Drug|[14C]-LY3556050|Administered orally
75899524|NCT05890651|Diagnostic Test|ECG|Describe the electrocardiography (ECG) changes 24 hours,1,6,12 months after VSD transcatheter device closure in a pediatric population.
75899525|NCT05890521|Biological|Recombinant new coronavirus vaccine (CHO cell)|"Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person.~Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person."
75605124|NCT01124643|Biological|Replagal|0.2 mg/kg administered intravenously [IV] every other week
75899526|NCT05890508|Device|Acupuncture|Disposable acupuncture needles (0.20 mm in diameter) are are used in the study. The acupoints are GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). Electrical stimulation will be delivered with waves at 2-5 Hz from an electroacupuncture device. The needles will be retained in position for 30 minutes.
75605125|NCT04310631|Drug|Ranibizumab Injection|Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections
75899527|NCT05890508|Device|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
75899528|NCT05890495|Drug|Lidocaine topical|4% aqueous solution
75453972|NCT05231629|Drug|AHCT intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
75453973|NCT05231629|Drug|AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
75453974|NCT05231629|Drug|AHCT intensification, Dara-R consolidation, Dara-R maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
75605126|NCT04309851|Diagnostic Test|deep learning|the deep learning method is a field of study involving artificial neural networks and similar machine learning algorithms with many hidden layers.
75605127|NCT05108025|Drug|Topical Powder|Topical Powder mixed with diluent
75605128|NCT05108025|Drug|Placebo Topical Powder|Placebo Topical Powder mixed with diluent
75605129|NCT01256411|Drug|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
75749949|NCT06051669|Device|iLivTouch|The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.
75749950|NCT06051669|Device|FibroScan|The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.
75749951|NCT06047938|Radiation|ultrasound on carotid|CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children[11]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
75749952|NCT06047704|Other|No intervention|No intervention
75749953|NCT06045104|Dietary Supplement|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
75749954|NCT06045104|Dietary Supplement|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
75749955|NCT06042725|Procedure|Biospecimen Collection|Undergo optional collection of blood samples
75749956|NCT06042725|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
75749957|NCT06042725|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
76066407|NCT05836103|Behavioral|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
76066408|NCT05825729|Diagnostic Test|Dry suction technique (A)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~- Dry suction puncture: Once the lesion is located and punctured, the stylet will be completely removed, and a 10 mL syringe with a vacuum of 10 mL will be attached. In each pass, the needle will be advanced and retracted 20-30 times according to the standard technique. The suction will then be closed, and the needle will be removed. The fanning technique will be performed whenever possible."
76066409|NCT05825729|Diagnostic Test|Slow-pull technique (B)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms."
75605130|NCT01256411|Drug|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
75605131|NCT01256411|Drug|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
75453975|NCT05231629|Drug|Dara-VRd induction|Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
75453976|NCT05229263|Diagnostic Test|Non- contrast Enhanced Multiparametric Renal Magnetic Resonance|MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
75453977|NCT05180110|Diagnostic Test|Venepuncture|Venous blood draw
75453978|NCT05180110|Diagnostic Test|Fingerstick|Capillary blood draw
75453979|NCT05173298|Drug|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
75453980|NCT05165485|Drug|Revefenacin|Revefenacin DoseA
75453981|NCT05165485|Drug|Tiotropium|Tiotropium DoseB
75453982|NCT05165485|Drug|Revefenacin Placebo|Placebo for Revefenacin administered with Tiotropium
75453983|NCT05165485|Drug|Tiotropium Placebo|Placebo for Tiotropium administered with Revefenacin
75453984|NCT05165381|Device|Video PPG|Contactless vital signs and stress measurement using video PPG technology. An iPad will be used to record a video of the participant's, which can then be converted to vital signs using a specialized algorithm.
75453985|NCT05163964|Behavioral|Lifestyle Intervention|Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
75453986|NCT05159388|Drug|PRS-344/S095012|PRS-344/S095012 Monotherapy
75899529|NCT05890495|Device|Tampon|Tampon with plastic applicator provided
75605132|NCT00996580|Drug|DR-103|"One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE."
75605133|NCT01124175|Drug|Losartan|100 mg Tablets
75605134|NCT01124175|Drug|Cozaar®|100 mg Tablets
75605135|NCT04259554|Device|OFC rTMS|repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains á 60 pulses with 30s intertrain-interval)
75899530|NCT05890482|Behavioral|Islamic Trauma Healing|Manualized, lay-led psychosocial intervention
75899531|NCT05890456|Behavioral|Students with Involved Families and Teacher Program|The SWIFT Program is a 9-12 month intervention that includes four components: (a) behavioral progress monitoring, (b) clinical supervision of the intervention elements and coordination with the school, (c) parent support to promote parent engagement/collaboration with the school and study routines in the home, and (d) behavioral skills coaching for students.
75605136|NCT00625521|Drug|ASF 1096 0.5 % cream applied twice daily|
75899532|NCT05890456|Behavioral|Services As Usual|The SAU students and families will continue to receive any services that they were receiving prior to their entry into the study. These may include school-based interventions and supports and related services as required in the student's Individualized Education Program.
75899533|NCT05890443|Behavioral|Exercise|Before starting the research, self-management training in rehabilitation was given to both groups. While the exercise practices were carried out in the experimental group, encouraging reminders were made by following the background web page created in the experimental group.
75453987|NCT05150990|Behavioral|Virtual Reality|Older adults (residents of senior living communities) will engage in four 20-minute virtual reality activities (via the Rendever platform) with their adult child each week for 4 consecutive weeks. The 4 sessions will include immersive virtual adventures (e.g., bucket list travel) and reminiscence activities (e.g., virtual life story). Adult children will be participating remotely from their own homes.
75453988|NCT05150990|Behavioral|Video Chat|Older adults (residents of senior living communities) will engage in four 20-minute video chat sessions (via the Zoom platform) with their adult child each week for 4 consecutive weeks. Adult children will be participating remotely from their own homes.
75605137|NCT00625521|Drug|Cream vehicle for ASF 1096 cream applied twice daily|
75605138|NCT01256177|Drug|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
75899534|NCT05890391|Other|Time-Restricted Eating|They were fed ad libitum between 10.00 a.m-06.00 p.m and fasted between 06.00 p.m-10.00 a.m.
75605139|NCT01256177|Drug|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
75605140|NCT02882451|Dietary Supplement|pinaverium bromide|
75605141|NCT02882451|Dietary Supplement|Vitamin C|
75605142|NCT00999544|Drug|Aprepitant 0mg|Aprepitant 0mg, p.o. pretreatment
75605143|NCT00999544|Drug|Aprepitant 40mg|Aprepitant 40mg, p.o. pretreatment
75605144|NCT00999544|Drug|Aprepitant 200mg|Aprepitant 200mg, p.o. pretreatment
75605145|NCT00999544|Drug|Oxycodone 0mg, p.o.|Oxycodone 0mg, p.o.
75899535|NCT05890391|Other|Energy-Restricted Diet|The total energy expenditure (TEE) of individuals was determined using the 'Resting Energy Expenditure (REE) x Physical Activity Level (PAL) ' formulation. 'TEE-500 kcal' formulation was used for the diet to be given to individuals.
75899536|NCT05890339|Procedure|Laparoscopic Proximal Gastrectomy With Double-flap Technique|Patients in this group receive laparoscopic proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p and 11d). The double-flap technique is used for the esophagogastric reconstruction.
75605146|NCT00999544|Drug|Oxycodone 20mg, p.o.|Oxycodone 20mg, p.o.
75605147|NCT00999544|Drug|Oxycodone 40mg, p.o.|Oxycodone 40mg, p.o.
75605148|NCT00999544|Drug|Oxycodone 0mg, IN|Oxycodone 0mg, IN
75749958|NCT06042725|Procedure|Chest Radiography|Undergo chest x-ray
75749959|NCT06042725|Procedure|Computed Tomography|Undergo PET/CT
75899537|NCT05890339|Procedure|Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction|Patients in this group receive laparoscopic total gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p and 11d, 12a). The Roux-en-Y esophagojejunostomy method is used for the esophagojejunal reconstruction.
75453989|NCT05148078|Other|PROMISE (Pediatric Radiation Oncology with Movie Induced Sedation Effect)|Pediatric Radiation Oncology with Movie Induced Sedation Effect (PROMISE) is an interactive, incentive-based movie system that integrates with a video surveillance gating module (VisionRT) to help keep a child's attention and prevent him or her from moving during radiation treatment. This technology is being studied as an alternative sedation solution for pediatric patients needing radiation treatment. As part of the trial, patients will be attempted to have CT simulation scan and first radiation treatment(s) using PROMISE, with general anesthesia on standby should PROMISE be unsuccessful. If PROMISE is unsuccessful for a given patient, then standard of care general anesthesia will be used for that patient's radiation treatment and PROMISE will be reattempted at physician discretion with anesthesia on standby.
75453990|NCT05140525|Drug|Macitentan Tablets|10 mg oral once daily
75453991|NCT05140525|Drug|Riociguat|1 mg to 2.5mg oral three times daily
75605149|NCT00999544|Drug|Oxycodone 15mg, IN|Oxycodone 15mg, IN
75605150|NCT00999544|Drug|Oxycodone 30mg, IN|Oxycodone 30mg, IN
75605151|NCT02869984|Drug|Ramosetron|
75453992|NCT05140525|Device|balloon pulmonary angioplasty|on hemodynamics and RV function (including advanced assessments of RV-PA coupling
75605152|NCT01124097|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
75605153|NCT01124097|Drug|Placebo|Tablets will be used.
75605154|NCT02882529|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
75605155|NCT01123941|Biological|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
75605156|NCT01123941|Biological|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
75605157|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
75605158|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
75605159|NCT01255787|Drug|Vortioxetine|Vortioxetine tablets
75605160|NCT01255787|Drug|Placebo|Vortioxetine placebo-matching tablets
75605161|NCT01123161|Device|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
75605162|NCT01123161|Drug|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
75453993|NCT05136027|Other|Combined training|Low-intensity interval training and resistance exercise
75749960|NCT06042725|Biological|Daratumumab|Given SC
75749961|NCT06042725|Drug|Dexamethasone|Given PO
75749962|NCT06042725|Drug|Lenalidomide|Given PO
75749963|NCT06042725|Procedure|Low Dose Computed Tomography of the Whole Body|Undergo WBLDCT
75749964|NCT06042725|Procedure|Magnetic Resonance Imaging|Undergo MRI
75749965|NCT06042725|Procedure|Positron Emission Tomography|Undergo PET/CT
75749966|NCT06042725|Drug|Venetoclax|Given PO
75749967|NCT06042725|Procedure|X-Ray Imaging|Undergo x-rays
75749968|NCT06036082|Other|Conventional physical therapy|"Standing with feet together .~Step standing .~High step standing and trying to keep balanced.~Single leg stance unilateral standing with assistance.~Standing on a declined surface by using wedge.~Standing with manual locking of the knees.~Changing position.~Gait training.~Static and dynamic muscle contraction."
75749969|NCT06036069|Other|Conventional physical therapy|"Standing with feet together while the therapist was sitting behind and manually locking the child knees.~Step standing with the therapist behind the child.~High step standing and trying to keep balanced. The child stood on exercise mattress.~Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~Standing with manual locking of the knees.~Changing position.~Gait training.~Static and dynamic muscle contraction."
75749970|NCT06034288|Drug|Xeomin 100 UNT Injection|intravesical injection
75749971|NCT06034288|Drug|Botox 100 UNT Injection|intravesical injection
75749972|NCT06025565|Diagnostic Test|Pain Experience Measures|Patient reported outcomes measures, quantitative sensory testing, and physical examination measures.
75749973|NCT06012175|Dietary Supplement|Melatonin|One 3 mg melatonin tablet every night before bedtime for 12 weeks
75749974|NCT06012175|Dietary Supplement|Placebo|One placebo tablet, having an identical appearance to the melatonin tablet, every night before bedtime for 12 weeks
75749975|NCT06010680|Drug|[14C]SHR2554|Patients will receive single dose of orally [14C]SHR2554 on Day 1.
75605163|NCT01255631|Device|PEMF Device|"The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks."
75749976|NCT06008938|Genetic|HEMGENIX|HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.
75453994|NCT05130658|Device|Virtual reality treadmill training|C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
75749977|NCT06008938|Biological|Factor IX (FIX)|FIX prophylaxis therapy
75749978|NCT06003348|Dietary Supplement|OHCit- standard dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
75749979|NCT06003348|Drug|Potassium Citrate|10 mEq Extended-release tablets for oral use
75749980|NCT06003348|Drug|Placebo|Placebo
76066410|NCT05825729|Diagnostic Test|Wet suction technique (C)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~- Wet suction technique: Prior to puncture, the stylet should be removed and the needle should be flushed with 1-2 ml of physiological saline and a 10 ml vacuum syringe with 3-5 ml of saline should be attached. In each pass, the needle should be moved forward and backward 20-30 times. Aspiration should be opened as the needle advances and closed as it is withdrawn. Afterwards, the aspiration should be closed and the needle should be removed. The fanning technique should be performed whenever possible."
75749981|NCT06003348|Dietary Supplement|OHCit- low dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
75749982|NCT06000891|Drug|ZP7570|13 once-weekly subcutaneous injections
75749983|NCT06000891|Drug|Placebo|13 once-weekly subcutaneous injections
75749984|NCT05998070|Other|Training group|Hip strengthening exercises will be performed 3 times a week for 6 weeks in the training group. 3 exercises consisting of 2 sets and 10 repetitions will be performed every week. A rest interval will be given between sets.
75749985|NCT05998044|Other|Pilates Based Exercises|"The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively. Participants will be asked to open the video recording each time they exercise and follow them to do the exercises.~Exercise Program:~Arm Circles~Toe Touch~bridge~Shoulder Bridge~Chest Lift~Hundred~Roll Up~Leg Circles~Chris Cross~Side Kick~Side Leg Circles~one leg kick~double leg kick~Swan~Single leg Stretch~Double leg Stretch~saw~Spine Stretch"
75749986|NCT05998044|Other|control|They will be asked not to participate in any regular exercise for 8 weeks.
75453995|NCT05130658|Other|Treadmill Training|Conventional gait and balance training using treadmill.
75453996|NCT05129787|Procedure|Surgical resection|Resection of metastasis
75453997|NCT05129787|Procedure|Thermal ablation|Ablation of metastasis
75749987|NCT05994638|Dietary Supplement|Aerosol (Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3)|Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3
75749988|NCT05979233|Procedure|staged managment|staged management
75749989|NCT05979233|Procedure|one session ERCP then LC|one session ERCP then LC
75749990|NCT05979233|Procedure|one session LC then ERCP|one session LC then ERCP
75749991|NCT05975021|Drug|Istaroxime|IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 1.0 or 0.5 µg/kg/min for 18 hours, 0.5 µg/kg/min for 24 hours. Total duration 48 hours.
75749992|NCT05975021|Drug|Placebo|IV infusion via a syringe pump. Total duration 48 hours.
75454000|NCT05111613|Device|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
75454001|NCT05111613|Device|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
75605164|NCT01255631|Device|Sham PEMF Device|Inactive PEMF device, delivers no PMF
75749993|NCT05974735|Behavioral|Wellness trail|"Setting up wellness trails based on four distinct themes:~Food, Nutrition and Micronutrition~Physical activity~Sleep~Stress and well-being"
75749994|NCT05967520|Drug|JMKX000189|JMKX000189 will be administered orally once a day
75749995|NCT05967520|Drug|Placebo|Placebo will be administered orally once a day
75605165|NCT04540835|Drug|Calcium phosphate desensitizer|Calcium phosphate containing desensitizing agent that creates hydroxyappatite
76066411|NCT05824741|Behavioral|Infant Cardiovascular Health (CVH) Promotion|The pilot infant CVH intervention will be delivered by Nurse-Family Partnership (NFP) staff starting no later than 1 month postpartum and lasting up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long. This pilot study will include an enhanced version of the NFP standard care plan delivered by trained nurses to promote cardiovascular health by targeting soothing, feeding, sleep, and physical activity behaviors during infancy. The intervention delivered by trained visiting nurses will include behavior change strategies (e.g., goal setting, problem solving barriers). This pilot study will also examine the feasibility and acceptability of a digital device (infant foot worn actigraphy) during this same time period.
75605166|NCT00999466|Drug|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
75899538|NCT05890326|Behavioral|Pain neuroscience education (PNE)|Pain neuroscience education (PNE) is a health education intervention that aims to provide up-to-date information on neuroscience developments in the field of chronic pain. All patients were trained once a week for 12 weeks, in groups of 3-4 people, for a maximum of 6 sessions and a minimum of 60 minutes. During the intervention, psychological factors such as self-efficacy, pain intervention/injury, coping with pain, catastrophic thoughts, emotional response to pain, anxiety, frustration/anger, fear of harm, concerns about pain, and fear of pain were examined. and discussed with patients. The sessions aimed to provide patients with a better understanding of their chronic pain by addressing the multifactorial aspects of chronic pain, sensitization and the plasticity of the brain, thus involving patients in treatment.
76066412|NCT05822531|Behavioral|Maternal CVH Intervention|All participants will be enrolled into the intervention arm of this pilot study.
75605167|NCT00999466|Drug|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
75899539|NCT05890326|Behavioral|Motor imagery-based exercise protocol (MIEP)|"All patients performed sessions of maximum 60 minutes in groups of 3-4 people twice a week for 12 weeks. This study protocol was developed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The key standard was to practice simple and safe exercises that would encourage the patient to repeat the program at home. The exercises proposed in MIEP were selected according to the following principles: slowness, painlessness, arousing attention, easy to imagine. The main purpose of the motor imagery exercises was to bring the patient back to the state of feeling and self-perception of the execution of the movement. More important than the quantity of repetition was the painless quality of movement. It was performed in 3 phases: relaxation (3 minutes), MI (8.5 minutes per image) and refocus (3 minutes), which included both kinesthetic imagery (KI) and visual imagery (VI)."
75899540|NCT05890326|Behavioral|Combination Group|Subjects received 6 sessions of Pain neuroscience education (PNE) and 12 weeks (2 times a week) of Motor imagery-based exercise protocol (MIEP).
75605168|NCT01255163|Drug|Exendin-4 SC|Exenatide 5 mcg or 10 mcg SC twice daily
75605169|NCT01255163|Drug|Placebo SC|Placebo SC twice daily
75605170|NCT01123083|Biological|Otelixizumab|infusion
75605171|NCT01123083|Biological|Placebo|Infusion
75605172|NCT02870062|Other|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
75605173|NCT02870062|Other|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
75605174|NCT02869516|Other|Clinical data collection|
75605175|NCT02870140|Device|SUPRAFLEX|Percutaneous Coronary Intervention
75605176|NCT02870140|Device|XIENCE|Percutaneous Coronary Intervention
75605177|NCT01254305|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
75605178|NCT01254305|Drug|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
75749996|NCT05948644|Drug|TPN171H|TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
75749997|NCT05947162|Behavioral|extinction training (nicotine cues)|extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
75749998|NCT05947162|Behavioral|extinction training (neutral cues)|extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
75749999|NCT05947162|Behavioral|Time-restricted smoking cessation|Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
75605179|NCT01254305|Drug|Placebo|Matching placebo capsules, oral administration, once daily dosing
75605180|NCT01122927|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
75750000|NCT05947162|Behavioral|Time-restricted fasting|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.
75750001|NCT05947162|Behavioral|Time-restricted fasting with food supplemnet|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.
75750002|NCT05945680|Drug|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
76066413|NCT05814653|Behavioral|Family Based Treatment-Primary Care|Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.
75454002|NCT05110313|Biological|TILDRAKIZUMAB|"ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle."
75605181|NCT02869906|Other|FFR and iFR|The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
75750003|NCT05945680|Drug|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
75750004|NCT05943795|Drug|SI-B001|Administration by intravenous infusion
75750005|NCT05943795|Drug|Docetaxel|Administration by intravenous infusion
75750006|NCT05941728|Other|Avocado|The intervention treatment will contain avocado
75605182|NCT02869828|Device|Monitoring by arterial catheter and Spot-on|
75750007|NCT05941728|Other|Oil + Fiber|The active comparator will contain a snack with oils and fibers that mimic an avocado
75454003|NCT05107856|Drug|PRT1419|PRT1419 will be administered by intravenous infusion
75454004|NCT05107856|Drug|Azacitidine|Azacitidine will be administered by intravenous or subcutaneous
75605183|NCT02869828|Device|Monitoring by oesophagal probe and Spot-on|
75605184|NCT01254227|Drug|Deferasirox and Deferoxamine|
75605185|NCT04311333|Diagnostic Test|Endostomal three-dimensional ultrasonography|Examination with rectal probe enclosed by water-filled balloon. Rectal mode. Dynamic examination in different positions with and without increased intra-abdominal pressure.
75454005|NCT05107856|Drug|Venetoclax|Venetoclax will be administered orally
75605186|NCT04311333|Diagnostic Test|Computerized tomography of the abdomen|"Supine position, without increased intra-abdominal pressure. Experienced radiologist interprets the examination.~If adequate examination has already been performed within the last 10 months, these images will be used and the patient will thus not undergo computerized tomography within the study."
75750008|NCT05941728|Other|Average American Diet|The sham comparator will contain foods/beverages that mimic a standard American Diet
75750009|NCT05939739|Biological|Blood samples|Samples collected during blood sampling for array CGH (1 EDTA tube for index case and 2 biological relatives)
75454006|NCT05106296|Drug|Ibrutinib|Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
75454007|NCT05106296|Drug|Indoximod|Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
75454008|NCT05106296|Drug|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
75605187|NCT04311333|Diagnostic Test|Clinical examination|Patients will be clinically examined with inspection and palpation in supine and erect position with and without increased intra-abdominal pressure.
75605188|NCT04311333|Diagnostic Test|Evaluation at laparotomy/laparoscopy|During laparotomy or laparoscopy, inspection and/or palpation of the stoma at the abdominal wall orifice is performed.
75750010|NCT05939739|Other|Consultation for results delivery|at 4 months
75750011|NCT05939739|Other|Study Humanities and Social Sciences|Interview offered to 20 families with positive results and 10 families with negative results
75750012|NCT05939414|Drug|AAA617|Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
75750013|NCT05938959|Drug|Sham block|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% normal saline
75750014|NCT05938959|Drug|ESPB|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
75750015|NCT05937230|Device|Drug-coated balloon|Paclitaxel is a pharmacologically active substance for anti-neointima.
75750016|NCT05937230|Device|Drug-eluting stents|Drug-eluting stent is composed of a metal stent, primer, and drug coating.
75454009|NCT05106296|Drug|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
75750017|NCT05932615|Device|Navitor Transcatheter Aortic Valve Implantation (TAVI) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
75750018|NCT05932615|Device|Any Commercially Available Transcatheter Aortic Valve (CAV) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
75750019|NCT05932459|Drug|Deuremidevir Hydrobromide for Suspension 100mg|Take it with 240ml water in fasted condition.
75454010|NCT05106192|Device|Med-Jet Injector|The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue
75454011|NCT05106192|Drug|Triamcinolone Acetonide|The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).
75750020|NCT05932459|Drug|Deuremidevir Hydrobromide for Suspension 300mg|Take it with water in fasted condition or after taking infant formula.
75750021|NCT05932459|Drug|Deuremidevir Hydrobromide for Suspension 25mg|Take it with 240ml water on an empty stomach.
75750022|NCT05932459|Drug|Deuremidevir Hydrobromide tablets 100mg|Take it with 240ml water in fasted condition.
75750023|NCT05914649|Other|IV normal saline (1500mL infusion)|1500mL of IV normal saline will be infused intravenously
75750024|NCT05914649|Other|IV normal saline (50mL infusion)|50mL of IV normal saline will be infused intravenously as a placebo control.
75750025|NCT05914090|Procedure|ERAS|Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.
75750026|NCT05913869|Behavioral|Online Mindfulness Based Stress Reduction|Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
75750027|NCT05903209|Device|Chang Gung Pneumothorax Detection Software|"The Chang Gung Pneumothorax Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pneumothorax. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pneumothorax.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
75454012|NCT05106192|Drug|Bexarotene 1% Top Gel|Bexarotene can be applied up to four times daily according to patient tolerance directly to lesions. The gel is 1% bexarotene concentration.
75750028|NCT05899595|Other|Exercise protocol|"Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~Subjective fatigue (Rate of Fatigue scale)~Heart rate variability with a holter ECG~Muscle pain with a visual analogue scale~Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises."
75750029|NCT05894876|Other|No treatment is given|No treatment is provided to the participants as part of this study.
75750030|NCT05892835|Other|Educative|A 2-hour training workshop was held where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Manikin for CPR practices Little Anne QCPR). Laerdal and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
75605189|NCT00995410|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
75605190|NCT04311255|Procedure|regional anesthesia for the upper limb|pecs-II block and intercostal nerve block
75605191|NCT02691299|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
75899541|NCT05890300|Device|Use of an occupational passive back-exoskeleton|The experimental group will use an occupational passive back-exoskeleton (ShoulderX V3, Ottobock bionics) for a period of 24 weeks during working hours. The exoskeleton is designed to reduce the load of the lower back during manual materials handling. The first four weeks will serve as a familiarization period, where the workers will slowly progress in hours of exoskeleton-use, while they in the remaining twenty weeks will be free to use the exoskeleton as much as they like, with a minimum limit of 18 hours per week. The control group will carry on their normal work without any changes.
75454013|NCT05106192|Drug|Nitrogen Mustard|Nitrogen mustard is applied once daily as patient tolerates. It is sold in a concentration of 0.016% gel.
75454014|NCT05106192|Device|Conventional syringe|A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
75454015|NCT05103007|Procedure|DEB-TACE|It is suggested that the tumor feeding artery should be selected for the microcatheter. The mixed volume of pirarubicin 80mg + microsphere 2g is about 2ml, and the mixture of at least 10ml and contrast medium is slowly injected with 5-10min.
75454016|NCT05103007|Procedure|PVL/PVE+DEB-TACE|DEB-TACE will be performed after the liver function recovered within 7-10 days. After that, conventional transarterial chemoembolization（cTACE) was performed every 2 months, a total of 2-3 times of chemoembolization.
75605192|NCT02691299|Drug|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
75605193|NCT00995020|Procedure|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
75605194|NCT00995020|Procedure|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
75605195|NCT01122381|Drug|ethosuximide|ethosuximide (ESX)
75605196|NCT01122381|Other|placebo comparator|placebo
75750031|NCT05880849|Drug|Choline|Eight 275mg capsules taken orally twice daily (4 capsules with breakfast & 4 capsules with dinner) x 180 days
75750032|NCT05878015|Drug|Acetaminophen|1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
75899542|NCT05890287|Drug|Chidamide|Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
75899543|NCT05890274|Other|AF and EKG Interpretation Project ECHO|The AF and EKG Interpretation Project ECHO program is delivered via Zoom videoconferencing technology and includes 12, 1-hour long sessions that involve education on best practice management of AF for primary care providers. Each session includes an EKG challenge, case presentation by a participant, didactic presentation, and time for open Q&A. Supplementary materials are made available to all participants.
75899544|NCT05890261|Device|Cold water-perfused cooling garment|Two types of cooling garments will be used. One is a cooling vest and the other includes cooling pants.
76066414|NCT05814653|Behavioral|Family-Based Treatment|Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
75605197|NCT00996034|Biological|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
75899545|NCT05890235|Drug|Ningmitai Capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
75899546|NCT05890235|Drug|Tamsulosin Hydrochloride|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
75899547|NCT05890209|Device|Continuous Glucose Monitoring device|A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
76066415|NCT05812144|Other|Remote monitoring program|Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
76066416|NCT05810753|Behavioral|SPOONful|Participants will be asked to consume two ONS daily, in addition to their regular diet, for three weeks. Participants will be asked to consume one ONS with their breakfast, and one with lunch.
76066417|NCT05810181|Other|Interview|"The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication)."
76066418|NCT05793684|Drug|Period A|Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
76066419|NCT05793684|Drug|Period B|Week 1: AD816 low dose; Week 2: AD816 high dose
76066420|NCT05793684|Drug|Period C|Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
76066421|NCT05790967|Other|Sexual Education|Women in the experimental group will be given education on sexual life during pregnancy. Before the training, preliminary data will be collected and then the participants will be given two hours of individual and face-to-face training.
75605198|NCT00996034|Radiation|[123I]5-IA-85380|up to 10 mCi of [123I]5-IA-85380, I.V. on each of two SPECT Scan days
75605199|NCT00996034|Drug|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
75605200|NCT04311021|Other|No intervention|No intervention
75605201|NCT04278196|Other|AI-Box|AI-box is a system fixed adjacent to magnet controlled capsule endoscopy. Patients who accept the check of magnet controlled capsule endoscopywill be enrolled .
75605202|NCT01253447|Drug|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
75909584|NCT03474146|Other|Chlorhexidine Gluconate|Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. Chlorhexidine over a period of over 40 years has been thoroughly investigated and successfully used as plaque control agent in dental practice. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in variety of oral disorders in various formulations.
75909585|NCT03474146|Other|Propylene Glycol|Propylene glycol or 1,2-dihydroxypropane or 1,2-propanediol, is a clear, colourless, viscous, practically odourless liquid with a density of 1.038 g/cm³ at 20 °C and a molecular weight of 76.095. It is miscible with water, acetone and chloroform. It is miscible in water. Propylene glycol is commonly used as an excipient in a variety of drugs and it is also authorised in food products and cosmetics.
75909586|NCT04458350|Behavioral|Digital Promotions Group|Digital promotions on the Fresh EBT app and Facebook will run for 13 weeks, advertising a SNAP fruit and vegetable incentive at farmers' markets in New England. The intervention will be applied to zip codes randomized to the intervention arm.
75909587|NCT04458662|Procedure|Interval running protocol / eccentric-based resistance exercise protocol|
75750033|NCT05872477|Drug|Ruxolitinib Topical|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
75909588|NCT01090154|Drug|Cimzia|Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
75909589|NCT05159024|Diagnostic Test|CRP, PCT, and WBCs trajectories|the levels of CRP, PCT, and WBCs were assessed before surgery and after the onset of leak
75605203|NCT01253447|Other|laboratory biomarker analysis|Correlative studies
75454017|NCT05100966|Other|FitJoints Multi-modal Intervention|"Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization."
75454018|NCT05096611|Behavioral|Attachment and Biobehavioral Catch up|ABC is delivered by a trained parent coach. The parent coach provides information about parenting and child development. The focus is on providing support for parents of young children and improving the parent-child relationship.
75605204|NCT04230382|Diagnostic Test|Diagnosis of diabetes (OGTT)|Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
75750034|NCT05872477|Drug|Placebo|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
75605205|NCT01121991|Drug|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
75605206|NCT04277728|Diagnostic Test|hypoperfusion-hypodensity mismatch|hypoperfusion-hypodensity mismatch on computed tomography
75605207|NCT00994240|Procedure|Electrodessication & Curettage|Electrodessication & Curettage 1 or 3 cycles
75605208|NCT01253369|Drug|Pazopanib|
75750035|NCT05870930|Other|Carob beverage|Volunteers will consume 2 tablespoons of carob powder in 200mL drinking water.
75605209|NCT04292548|Diagnostic Test|taking saliva samples to determine TAS, TOS and LL-37|
75605210|NCT04292236|Dietary Supplement|Lauric Acid, Perilla Oil and Diindolylmethane|Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
75750036|NCT05870930|Other|Sucrose beverage|Volunteers will consume a beverage with sucrose equal to this contained in carob beverage (approx. 5g) prepared in 200mL drinking water.
75750037|NCT05867875|Other|Unblinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and both values will be provided to investigator
75909590|NCT05158868|Diagnostic Test|HiF-1 alpha measurement|HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology
75909591|NCT03473990|Other|High-intensity interval training|2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)
75909592|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
75909593|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
75605211|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
75750038|NCT05867875|Other|Blinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and only SpO2 values will be provided to investigator
75750039|NCT05854602|Behavioral|Component A|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component A focusses on making parents aware of the process of avoidance in children with anxiety, and helps them to identify situations in which they accommodate to the anxiety of their children. Subsequently, a first step that parents can take to reduce accommodation is discussed."
75750040|NCT05854602|Behavioral|Component B|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component B tries to increase parents empathetic reactions to their anxious child. This is done by teaching parents to label the emotion of their children, empathize with the emotion, and communicate confidence in the abilities of their child to face the situation."
75899548|NCT05890183|Behavioral|Cognitive training|This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.
76066422|NCT05790668|Behavioral|Traditional Schedule Thinning|During traditional schedule thinning during functional communication training with discriminative stimuli (e.g., multiple schedules, chained schedules), practitioners correlate a unique stimulus with reinforcement (e.g., a green card) and another for extinction (e.g., a red card). When the reinforcement and extinction stimuli are presented, the child's communication responses are honored or not honored, respectively. Behavior analysts begin with a brief period of extinction (e.g., 2 s) and gradually increase that duration as the child displays low levels of destructive behavior and high levels of discriminated communication responses (i.e., communication requests during reinforcement components only) until the child reaches a terminal schedule informed by caregiver/child preference (e.g., 2.5-min reinforcement, 10-min extinction). Typically, the starting extinction period is brief and arbitrarily selected and there are no competing stimuli programmed.
75909594|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
75454019|NCT05096611|Behavioral|Attachment and Biobehavioral Catch up Plus Depression Treatment|ABC+D offers the same 10-sessions of parenting support that is provided by ABC and additionally provides weekly short videos that help mothers develop skills for coping with stress and regulating mood.
75454020|NCT05094128|Drug|Upadacitinib|Tablet; Oral
75454021|NCT05093933|Drug|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
75454022|NCT05093933|Drug|Placebo|0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
75909595|NCT05019872|Behavioral|(Components of) pasta meal|Samples will be provided one by one in cups labeled with an unique code.
75909596|NCT05004272|Procedure|Massage|20-minute manual full-body massage
75909597|NCT05004272|Procedure|Gymnastics|20-minute moderate body workout
75454023|NCT05092880|Device|radioembolization|holmium-166 microspheres
75454024|NCT05092880|Drug|Standard of care first-line systemic therapy|Capecitabine plus anti-VEGF antibody
75454025|NCT05087030|Drug|RGB-14-P|Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
75454026|NCT05087030|Drug|Prolia®|Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
75605212|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
75605213|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
75605214|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
75605215|NCT00994162|Device|EZCare/V1STA Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
75605216|NCT04292158|Device|SomnoTouch|"The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis."
75605217|NCT04292158|Device|MOX|"The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis."
75605218|NCT04293640|Diagnostic Test|Parasternal electromyogram measurement|Three electrodes are applied to the chest (two to parasternal muscles, one reference electrode to clavicle). Measurements of EMG signals are recorded on appropriate software.
75769427|NCT03899974|Other|Test meal|"Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch."
75769428|NCT01253122|Drug|TRx0037|
75454027|NCT05081479|Drug|N-Acetylcysteine|N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients <45kg will be adjusted to weight based dosing.
75899549|NCT05890183|Behavioral|Aerobic Exercise Program|The Aerobic Exercise Program group sessions will be conducted by Zoom videoconferencing. The group exercise training sessions are a combination of moderate intensity aerobic conditioning (1-min intervals) and moderate to high intensity strength and callisthenic conditioning (1-min intervals). The exercise dosage goal is 150 minutes/week of moderate aerobic activity, over 4 days, including for the first 6 months two group sessions (45 min duration) and two individual sessions personalized to the patient's choice of exercise (30 min duration) in the target heart rate zone. After the first 6 months, the group exercise sessions are once a week but the goal remains 150 minutes/week of moderate exercise.
75899550|NCT05890183|Behavioral|Moderated Online Social Therapy (MOST)|MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT&E group, involvement in our exercise program.
75454028|NCT05071209|Drug|Elimusertib|Given PO
75454029|NCT05065216|Drug|Recombinant human tissue kallikrein|Treatment is completed by week 3 (Day 21). After dosing is complete, participants will be followed up by the investigator at approximately 30 and 90 days after their first dose.
75454030|NCT05062044|Dietary Supplement|Multivitamins (Elevit, BAY987808)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
75605219|NCT02868814|Drug|Pregabalin Release Tablets|
75605220|NCT02868814|Drug|Pregabalin Release Tablets|
75605221|NCT02868814|Drug|Placebo|
75605222|NCT04292314|Drug|Omega 3|Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months
75605223|NCT04292314|Drug|Nigella Sativa Oil|Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
75605224|NCT04292314|Drug|Hydroxyurea|hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
75605225|NCT04292314|Drug|Honey|Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
75605226|NCT04292314|Drug|Deferoxamine|deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
75605227|NCT04292314|Procedure|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
75605228|NCT00993928|Behavioral|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
75605229|NCT01253291|Drug|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
75899551|NCT05890183|Behavioral|Chorus Participatory Text Messaging Program|The Chorus text messaging program is a web-based application that allows clinicians to create a broad range of automated SMS text messages and interactive voice responses using a simple, accessible graphical user interface. It will target encouragement to exercise and social feedback on completed exercise in the CT&E group.
75605230|NCT04292002|Behavioral|Test@Work|Offer of a general health check including opt-in sexual health consultation and HIV testing, weight/height, Body Mass Index (BMI), blood pressure, mental health screen. Provision of tailored health advice and a resource pack with information and signposting.
75605231|NCT01121757|Drug|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
75605232|NCT01121757|Drug|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
75605233|NCT04319471|Drug|Capecitabine/S-1|Drug: Capecitabine/S-1
75605234|NCT04319471|Drug|Chemotherapy|Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
75605235|NCT04319471|Radiation|Head and neck radiotherapy|IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma；
76066423|NCT05790668|Behavioral|PIA-Informed Schedule Thinning|This intervention involves the same general components as Traditional Schedule Thinning. However, rather than starting with an arbitrary duration of the extinction component (e.g., 2 s), the behavior analyst empirically derives the starting point based on a progressive-interval assessment (PIA). The PIA involves rapidly increasing the duration of the extinction component within a single session to determine the leanest schedule of reinforcement that does not produce untoward effects. Behavior analysts will progress through the following extinction durations within a single session: 3 s, 11 s , 21 s, 34 s, 50 s, 70 s, 95 s, 126 s, 164 s, 213 s, and 270 s. For example, if the participant displays destructive behavior at 164 s consistently, but not at 126 s, the experimenters will start schedule thinning with a 126-s extinction component. There will be no competing stimuli programmed in this intervention.
75454031|NCT05062044|Dietary Supplement|Multivitamins (Elevit, BAY2906300)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
75454032|NCT05062044|Drug|Multivitamins (Elevit, BAY987386)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
75454033|NCT05062044|Dietary Supplement|Folic acid|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
75605236|NCT04319471|Other|Local Consolidative Therapy|radiotherapy，surgery or interventional therapy for all metastatic sites.
75605237|NCT02882217|Drug|XC8 (histamine glutarimide)|
75750041|NCT05854602|Behavioral|Component C|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component C consists of cognitive restructuring of parental maladaptive cognitions concerning their child's anxiety. Parents are taught to recognize their own cognitions about the anxiety of their child, challenge this thought and come up with an alternative, helpful thought."
75454034|NCT05050214|Drug|Obinutuzumab|Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
75454035|NCT05044273|Device|Synergy XD stent or Synergy Megatron™ Stent|Percutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent
75454036|NCT05043090|Drug|savolitinib|Tablets : 3 × 200 mg tablets once daily
75454037|NCT05043090|Drug|durvalumab|Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks
75454038|NCT05043090|Drug|sunitinib|Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off
75454039|NCT05042687|Drug|Tc99m sestamibi|Given by IV
75605238|NCT02882217|Drug|Placebo|
75605239|NCT01253135|Biological|Fibrin|Topical application of fibrinogen spray, followed by thrombin spray
75605240|NCT01253135|Other|White Petrolatum|Topical application
75750042|NCT05844657|Other|Case report form|Sociodemographic information (age, gender, height, body mass index, marital status, occupation, education level, contact information), frequency of smoking and alcohol use, frequency of caffeine consumption, frequency of salt consumption, dominant side, background, family history, medical and audiological information were recorded.
75899552|NCT05890183|Behavioral|Healthy Living Group (HLG)|The Healthy Living Group (HLG) meets two sessions/week to discuss wellness, nutrition, insight, recovery, independent living, social skills, and hobbies for the first 6 months and then one session/week for the next 6 months.
75899553|NCT05890170|Other|Patient Reported Outcomes Measures|Questionnaires and information extracted from the medical records would be collected.
75909598|NCT05004272|Other|Lecture|20-minute lecture on medicinal herbs
75605241|NCT02882061|Procedure|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
75454040|NCT05035173|Other|Survivorship Clinic Assessments|"Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit."
75750043|NCT05844657|Other|Tinnitus disability scale|Tinnitus disability scale was used to evaluate the tinnitus severity of Meniere's patients. It consists of 25 items in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Tinnitus level or severity is determined by calculating the total score of the answers given.
75454041|NCT05035173|Other|Survivorship Clinic Nurse Resource|"Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes."
75454042|NCT05035173|Other|Survivorship Clinic Dietitian Resource|"Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise."
75454043|NCT05031949|Combination Product|hyperbaric oxygen therapy plus Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
75454044|NCT05018806|Drug|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
75750044|NCT05844657|Other|A feeling of fullness and/or pressure in the ear|The feeling of fullness or pressure in the ear was evaluated verbally by receiving yes/no responses from the participants.
75454045|NCT05018806|Drug|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
75454046|NCT05013554|Drug|SAR443216 IV|Pharmaceutical form: Powder for solution; Route of administration: IV infusion
75750045|NCT05844657|Other|Dizziness intensity and frequency|In order to determine the frequency and severity of dizziness, the participants were asked to mark the appropriate score between 1-10 points.
75454047|NCT05013554|Drug|SAR443216 SC|Pharmaceutical form: Powder for solution; Route of administration: SC injection
75909599|NCT04940234|Behavioral|Exposure to a Photo|We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.
75605242|NCT02881905|Device|ball attachment|it is attachment part that connects the overdenture to the implant
75750046|NCT05844657|Other|Dizziness disability inventory|The dizziness disability inventory was used to determine the disability level of the individuals participating in our study. It consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'.
75750047|NCT05844657|Other|Vertigo symptom scale-short form|The short form of the vertigo symptom scale was used to determine the frequency and duration of vertigo in the individuals participating in our study. The vertigo symptom scale consisting of 8 questions consists of vertigo (VSS-V), and the vertigo symptom scale consisting of 7 questions consists of two subsections consisting of a total of 15 questions: anxiety (VSS-A). Each item; Never (0), Very rarely (1 point), Often (2 points), Often - every week (3 points), Very often - On average, at least twice a week (4 points). The total score ranges from 0 to 60.
75454048|NCT05003895|Drug|Cyclophosphamide|Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)
75454049|NCT05003895|Biological|CAR-T cell|Single infusion on Day 0
75454050|NCT05003895|Drug|Fludarabine|Daily x 2 doses on Day -2 and -1 30 mg/m2 IV infusion administered following cyclophosphamide
75454051|NCT05000138|Diagnostic Test|FDG PET/CT|Patients with suspected giant cell arteritis, of which FDG PET/CT is indicated for diagnosis of large vessel involvement, will have the small cranial arteries analyzed for involvement.
75454052|NCT04996966|Biological|human umbilical cord-derived mesenchymal stem cells|In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
75454053|NCT04996966|Other|saline|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
75454054|NCT04994522|Drug|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
75605243|NCT02881905|Device|cm loc attachment|It is a new attachment made of peek material
75605244|NCT00993616|Drug|belinostat|Given IV
75454055|NCT04987957|Other|Music Therapy|Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
75454056|NCT04971161|Biological|allo-APZ2-CVU|Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe.
75454057|NCT04971161|Drug|Placebo|One topical application with a syringe
75454060|NCT04966455|Dietary Supplement|Raisins|Daily supplementation of 50 g of rainsins for 3 months
75605245|NCT00993616|Drug|carboplatin|Given IV
75605246|NCT01120899|Drug|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
75605247|NCT01120275|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
75605248|NCT01120275|Other|laboratory biomarker analysis|Correlative studies
75605249|NCT00991510|Drug|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
75605250|NCT00991510|Drug|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
75899554|NCT05890157|Other|PRF|Split mouth randomized clinical trial will be the design of the study. 12 periodontitis patients with 24 opposite shallow periodontal pockets (4-6 mm in depth) will be selected. Randomization in this study will be achieved using toss of coin method in which periodontal pockets were designated either control site or test site. PRF will be used as an adjunct to scaling and root planing to treat the test sites. While control sites will be treated by scaling and root planing only. Clinal periodontal parameters will be recorded and GCF level of PDGF-BB will be measured at baseline and1- and 3- month follow-up visits to evaluate the healing response to the treatment.
75605251|NCT01119963|Drug|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
75605252|NCT01119963|Drug|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
75605253|NCT02868736|Device|Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test|
75605254|NCT01252667|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
75605255|NCT01252667|Drug|Clofarabine|Given IV
75454061|NCT04965155|Drug|Isatuximab-dexamethasone|Isatuximab 10 mg/kg IV: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3 Dexamethasone 40 mg OS: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3
75454062|NCT04958707|Other|Information including knowledge and skills related to dementia patient care|The intervention will be administered to the participants via a smartphone app (Zalo app). Weekly, the investigator will post one of the eight topics identified in Phase 1 in the chat room. After posting the topic, one investigator will call the participants to ensure they read and understand the contents.
75454063|NCT04958707|Other|Usual care|Caregivers will be introduce to the website www.alzheimer.org to search for eligible information
75750048|NCT05844657|Other|Hearing Impairment Scale|The Adult Hearing Impairment Scale was used to determine the effect of the current hearing impairment levels of the individuals participating in our study on their daily living activities. The scale consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Participants mark the most appropriate expression for them.
75899555|NCT05890144|Other|Big Canoe|The Big Canoe will involve an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. It is 10 modules long and takes 10 weeks to complete (1 hour of learning per week).
75899556|NCT05890144|Other|Little Canoe|The Little Canoe involves a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session
75454064|NCT04957147|Other|12 months of guideline-directed heart failure therapy|Standard guideline-directed heart failure drug +/- device therapy
75454065|NCT04946734|Device|PFO closure device|Device PFO closure.
75605256|NCT01252667|Drug|Cyclosporine|Given PO
75605257|NCT01252667|Other|Laboratory Biomarker Analysis|Correlative studies
75605258|NCT01252667|Drug|Mycophenolate Mofetil|Given PO
75605259|NCT01252667|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
75605260|NCT01252667|Other|Pharmacological Study|Optional correlative studies
75605261|NCT01252667|Radiation|Total-Body Irradiation|Undergo TBI
75605262|NCT04292626|Diagnostic Test|SPECT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
75605263|NCT02881827|Radiation|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
75899557|NCT05890144|Other|Control|The control is a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
75605264|NCT02881827|Other|Placebo|Simulation of treatment with the device switched off
75605265|NCT02881827|Other|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
75605266|NCT02868580|Drug|Triumeq|Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
75605267|NCT02868658|Biological|Blood sampling|
75899558|NCT05890092|Other|Observation|Observing for disease prevalence - actual and self-reported
75899559|NCT05890053|Drug|HSK16149 40mg BID|HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose.
75605268|NCT02868658|Other|Nasal swab|
75605269|NCT02881749|Radiation|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
75605270|NCT02881749|Drug|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
75605271|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
75605272|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
75605273|NCT00629044|Biological|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
75605274|NCT01119105|Drug|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
75454066|NCT04946734|Drug|Aspirin and clopidogrel|Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
75454067|NCT04946734|Drug|Triptans|If migraine recurred, Triptans would be administered during the acute phase.
75454068|NCT04944888|Drug|Eliglustat|Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
75454069|NCT04944888|Drug|Immune checkpoint inhibitor|immune checkpoint inhibitor (physician decided).
75454070|NCT04936035|Drug|Placebo|Placebo administered by SC injection
75605275|NCT01119105|Drug|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
75605276|NCT01119105|Drug|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
75605277|NCT01118949|Drug|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
75899560|NCT05890040|Other|questionnaire|assessment of anxiety
75899561|NCT05887687|Drug|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
75899562|NCT05887505|Other|Vitamin D|Oral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days
75899563|NCT05887505|Other|Placebo|Oral supplementation of placebo in 3 consecutive days.
75909600|NCT02736578|Drug|Cetuximab-IRDye800|Administered intravenously (IV) at 50 or 100 mg
75909601|NCT02736578|Drug|Cetuximab|Administered as a 100 mg IV loading dose
75454071|NCT04936035|Drug|ALN-AGT01|ALN-AGT01 administered by SC injection
75454072|NCT04934176|Other|Psychosocial scales/questionnaires|We will use three psychosocial scales/questionnaires for this patient population to gauge patients' perceptions of the impact of their paralysis and their recovery. The questionnaires will be completed by the patients at baseline, and 18 months after surgery. Moreover, we also will compare patient perceptions to the patient-related responses with clinical scoring made by the surgeons using the eFACE,6 Face-Gram/Emotrics12 software, and the 3D dynamic measures.
75909602|NCT05158400|Radiation|Ultrasound|Ultrasound examination on the hand
76066424|NCT05790668|Behavioral|PIA-Informed Schedule Thinning with Competing Stimuli|This intervention is identical to PIA-Informed Schedule Thinning except that behavior analysts will program competing activities (e.g., alternative activities like toys or therapist attention) during extinction components. The competing stimuli will be derived from a competing stimulus assessment in which destructive behavior is analyzed across various conditions in which only the activity is manipulated during the extinction period (e.g., a session with action figures during extinction, a session with tablet during extinction). The items that produce the highest levels of child engagement and lowest levels of destructive behavior are known as highly competing items.
76066425|NCT05790408|Device|Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG)|The Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb during transconjunctival needle revision of trabeculectomy bleb.
76066426|NCT05790408|Device|Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)|The Spectralis Anterior-segment OCT (AS-OCT) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb in the office.
76066427|NCT05779917|Biological|CAR-T cells|Transfer CAR-T cells into patients for anti-ancer therapy.
76066428|NCT05774301|Behavioral|simulation-based training|the training will include a theoretical & practical parts
76066429|NCT05767749|Drug|lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.
76066430|NCT05767749|Drug|Ropivacaine 0.5% Injectable Solution|0.5 ml Ropivacaine 0.5% Injectable Solution
75605278|NCT04310865|Drug|Yinhu Qingwen Granula|"Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days."
76066431|NCT05767749|Drug|Bupivacaine 0.5% Injectable Solution|0.5ml bupivacaine 0.5%
76066432|NCT05766774|Other|Low-added sugar, high-fat diet|Consist of <5% kcal from added sugars as recommended by the American Heart Association, and the glycemic index will be 45 or lower (25% lower than typical CF diet). The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
76066433|NCT05766774|Other|High-added sugar, high-fat CF diet|Consist of ≥13% kcal from added sugars and the glycemic index will be >60. The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
76066434|NCT05759728|Biological|CNA3103: 5 x 10^7 cells|CNA3103: 5 x 10^7 cells - intravenous infusion
75605279|NCT04310865|Drug|Yin Hu Qing Wen Granula(low does)|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
75605280|NCT04310865|Other|standard medical treatment|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
75605281|NCT01252355|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
75605282|NCT01252355|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
75605283|NCT01252355|Drug|Interferon-beta (IFN-beta)|"Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert."
75605284|NCT01118325|Drug|ticagrelor|Drug oral treatment
75605285|NCT01118325|Drug|clopidogrel|Drug oral treatment
76066435|NCT05759728|Biological|CNA3103: 1.5 x 10^8 cells|CNA3103: 1.5 x 10^8 cells - intravenous infusion
76066436|NCT05759728|Biological|CNA3103: 4.5 x 10^8 cells|CNA3103: 4.5 x 10^8 cells - intravenous infusion
75454073|NCT04934176|Other|3D Facial Measurements|3D dynamic (objective) facial movement data will be collected first (estimated time 1 hour), followed by static 3D photographic data (estimated time 15 minutes), and then video data of the different facial animations (estimated time 15 minutes).
75750049|NCT05844657|Other|Cervical Range of Motion (CROM 3) device|"Cervical Range of Motion (CROM) device was used to evaluate the sense of proprioception and range of motion (ROM) in the cervical region muscles. A total of six positions were performed: right cervical rotation, left cervical rotation, right cervical lateral flexion, left cervical lateral flexion, cervical extension and cervical flexion."
75750050|NCT05844657|Other|Temporomandibular joint range of motion assessment|In our study, the temporamandibular joint range of motion (ROM) was evaluated with a ruler specific to each participant in four positions, including mandibular depression, protraction, and right and left lateral deviation.
76066437|NCT05759728|Biological|CNA3103: 1.5 x 10^9 cells|CNA3103: 1.5 x 10^9 cells - intravenous infusion
76066438|NCT05759728|Biological|CNA3103: 2.5 x 10^7 cells|CNA3103: 2.5 x 10^7 cells - intravenous infusion
75750051|NCT05844657|Other|Posture evaluation with New York posture analysis|The New York Posture Evaluation method was used to obtain information about the general posture correctness of the participants. Posture changes that may occur in 13 different parts of the body, 7 from the side and 6 from the back, including the head, neck, shoulder, back, waist, hip and ankle, were examined in the anatomical position of the individuals. As a result of the observation, the posture of the individual was scored according to whether it was severely bad (1 point), moderately bad (3 points), and straight (5 points). The total score obtained varies between 13-65.
75899564|NCT05886686|Device|Validation of the accuracy of a combined oximeter, thermometer and heart rate measurement device|Validation of the combined device measurements compared with standard of care devices
75899565|NCT05886387|Other|High PEEP + Recruitment maneuvers|The use of a High PEEP (positive end-expiratory pressure) level after recruiting collapsed alveoli can protect from mechanical ventilation associated lung injury
75899566|NCT05886114|Behavioral|Structured Multi-domain Intervention|Structured Multi-domain Intervention (SMI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
75899567|NCT05886114|Behavioral|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
75899568|NCT05882162|Procedure|Coronectomy|Removal of crown part of the mandibular third molar
75899569|NCT05882162|Procedure|Pulp Capping with calcium silicate|Application of a pulp capping material (BiodentineTM, Septodont, St Maur-des-Fosses, France) on pulp tissue to preserve the vitality of the residual pulp and prevent inflammation
75899570|NCT05881486|Drug|Ondansetron 8mg|8 mg Ondansetron+100 ml normal saline
75899571|NCT05881486|Drug|Fosaprepitant 150 mg|150 mg fosaprepitant +100 ml normal saline
75454077|NCT04924101|Biological|Pembrolizumab|IV infusion
75454078|NCT04924101|Biological|MK-4830|IV infusion
75454079|NCT04924101|Biological|Boserolimab|IV infusion
75454080|NCT04924101|Drug|Lenvatinib|Oral capsule
75899572|NCT05879575|Behavioral|weight training|Pregnant women assigned to the intervention group will receive online weight training sessions twice a week, for 60 minutes per session, from the 16th to the 36th week of pregnancy. The Pelvic Girdle Questionnaire will be used to assess the condition of pelvic girdle pain during pregnancy, and to analyze whether weight training can improve this problem. Pelvic floor muscle structure will also be analyzed by pelvic ultrasound to determine whether it has been altered by weight training, leading to an improvement in pain.
75899573|NCT05869630|Other|Exercise Programme|All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.
75909603|NCT04366856|Behavioral|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
75909604|NCT04366856|Behavioral|2: No instruction regarding positioning|group with no instruction regarding positioning (control group)
75909605|NCT05157776|Drug|PD-1 and chemotherapy|Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP
75909606|NCT02479568|Dietary Supplement|Control|500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
75909607|NCT02479568|Dietary Supplement|100% Florida OJ|500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
75454081|NCT04924101|Drug|Etoposide|IV infusion
75454082|NCT04924101|Drug|Cisplatin|IV infusion
75454083|NCT04924101|Drug|Carboplatin|IV infusion
75454084|NCT04921943|Drug|Hypertonic saline|Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
75454085|NCT04921943|Drug|Azithromycin|Standard of care
75454086|NCT04921943|Drug|Ethambutol|Standard of care
75454087|NCT04921943|Drug|Rifampin|Standard of care
75454088|NCT04919382|Biological|Atezolizumab|Given IV
75454089|NCT04919382|Drug|Temozolomide|Given PO
75454090|NCT04907045|Behavioral|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
75899574|NCT05869630|Other|Experiments|The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.
75899575|NCT05869240|Drug|BPB-101|Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
75899576|NCT05869123|Radiation|Online adaptive radiotherapy|PTV with 5 margins covers CTV
75899577|NCT05866328|Other|Cognitive Rehabilitation and Individual Placement and Support|Cognitive Rehabilitation and Individual Placement and Support
75899578|NCT05858853|Drug|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
75454091|NCT04907045|Behavioral|Practice Facilitation|In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
75454092|NCT04907045|Behavioral|Standard Implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
75605286|NCT01117857|Drug|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
75605287|NCT02888405|Other|High-carbohydrate diet|
75605288|NCT02888405|Other|Low-carbohydrate diet|
75605289|NCT01251887|Dietary Supplement|Linoleic Acid|
75605290|NCT01251887|Dietary Supplement|Docosahexaenoic Acid|
75605291|NCT01251887|Dietary Supplement|Eicosapentaenoic Acid|
75605292|NCT00991276|Drug|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
75605293|NCT00991276|Drug|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
75605294|NCT00991276|Drug|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
75605295|NCT02869282|Other|Blood samples|Additional blood samples at baseline, 6, 12, 18 and 24 months.
75605296|NCT02869282|Other|Urine samples|Additional urine samples at baseline, 6, 12, 18 and 24 months.
75454093|NCT04905290|Device|Left ventricular coronary sinus configuration|For subjects with a pacemaker, pacing of the left ventricular coronary sinus only. For subjects with a defibrillator, biventricular pacing of the left ventricular coronary sinus and the right ventricle.
75750052|NCT05844657|Other|Evaluation of the anterior tilt angle of the head|Anterior tilt angles of the head of the participants were evaluated with photographs taken from the lateral (lateral) side. The anterior tilt angle was calculated as the angle between the line drawn between the C7 cervical spinous process and the tragus and the straight line drawn vertically from C7.
75750053|NCT05844657|Other|Evaluation of postural balance with the Freemed pressure platform|Postural sway and lower extremity weight transfer were evaluated with the Freemed baropodometric pressure platform (Rome, Italy) system, which has been shown to be valid and reliable.
75750054|NCT05844657|Other|Static balance assessment with tandem stance test|In our study, the tandem stance test was used for static evaluation. A total of four assessments were made on the participants, first with their right foot in front, eyes open and eyes closed, then left foot in front with eyes open and eyes closed.
75454094|NCT04905290|Device|Conduction system pacing-only configuration|Conduction system pacing (CSP) of the left bundle branch.
75605297|NCT02869204|Other|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
75605298|NCT02869204|Dietary Supplement|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
75605299|NCT02869204|Dietary Supplement|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
75899579|NCT05858853|Drug|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
75899580|NCT05858853|Drug|Human serum albumin|Control drug (human blood albumin injection) 10 g/ day for 14 days
75605300|NCT02869204|Dietary Supplement|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
75605301|NCT04291846|Drug|SHR1459 fasted in P1, high-fat diet in P2|SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
75605302|NCT04291846|Drug|SHR1459 high-fat diet in P1, fasted in P2|SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
75605303|NCT04291924|Diagnostic Test|Dynamometry|A test for maximal muscle strength and explosive power in the lower limbs
75605304|NCT02869126|Procedure|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~Stress conventional acquisition with D.SPECT camera 20 min after injection~60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~double isotope acquisition 5 min after thallium-201 injection~injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~rest conventional acquisition 20 min later"
75605305|NCT02869126|Drug|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
75899581|NCT05858853|Drug|Human serum albumin|Control drug (human blood albumin injection) 20 g/ day for 7 days
75899582|NCT05855096|Other|Google Form Questionnaire|Google form questionnaire is performed by responders.
75899583|NCT05852470|Device|Clareon Vivity/Vivity Toric Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
75899584|NCT05852470|Device|Clareon/Clareon Toric Aspheric IOL|Ultraviolet-absorbing and blue light-filtering intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
75899585|NCT05851612|Procedure|constant PEEP|Constant PEEP of 5 cm H2O will be applied and maintained throughout one-lung ventilation.
76066439|NCT05754359|Behavioral|I'm an Active Hero (IAAH) Intervention Program|"The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active."
76066440|NCT05752500|Behavioral|Cognitive Behavioral Intervention for Physical Activity|Interventionist will use cognitive and behavioral techniques to help the participant increase facilitators and decrease barriers to physical activity, particularly barriers such as lack of motivation, depression, and chronic pain. Meetings will occur every other week for 4 months.
75454095|NCT04905290|Device|Conduction System Pacing Optimized Therapy (CSPOT) configuration|A combination of left ventricle (LV) pacing and conduction system pacing (CSP) of the left bundle branch.
75899586|NCT05851612|Procedure|Driving pressure guided PEEP|PEEP titration will be started at 5 cmH2O and then increased in 1 cmH2O interval to 10 cmH2O. After 10 breath cycles will maintained, Driving pressure (ΔP) will be measured at each PEEP level at the last cycle. The PEEP indicating the lowest ΔP will be selected if multiple levels of PEEP showed the same lowest ΔP, the lowest PEEP will be selected. Driving pressure will be calculated as plateau pressure minus PEEP. Titration will stopped if peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension will be observed.
75899587|NCT05851612|Procedure|oxygenation method guided PEEP|PEEP titration will be started from 5 cmH2O and increase of 1 cmH2O every 4 min with fixed driving pressure that will result in delivery of a fixed tidal volume (TV) of 6ml/kg ideal body weight (IBW). Optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected.
75899588|NCT05837143|Biological|JV001|JV001 (AAV9/modTERT) will be delivered by a percutaneous method in the catheter laboratory. Dose: 2×10^11vg/kg，6×10^11vg/kg，or 2×10^12vg/kg.
75899589|NCT05826392|Other|Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention|Web-Based, 30-minute self-administered intervention for adolescents
75909608|NCT02479568|Dietary Supplement|100% Florida OJ-enriched|500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
75909609|NCT02479100|Diagnostic Test|Contrast Enhanced Spectral Mammogram|Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care
75909610|NCT03473834|Other|Modified exercise programme|The exercise will be modified from the standardized exercise program (Schenkman, 1998) includes a series of exercises based on the concept that muscle length and coordination.
75909611|NCT03473834|Behavioral|Medication|The control group will be received the normal medication from their doctor.
75454097|NCT04891640|Other|Standard TNFi Therapy|Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.
75605306|NCT02869126|Drug|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
75605307|NCT00990652|Drug|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
75605308|NCT00990652|Drug|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
75605309|NCT02867878|Drug|Adenosine|
75605310|NCT02867878|Drug|Saline solution|
75605311|NCT00990340|Device|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
75605312|NCT00990340|Procedure|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
75605313|NCT01207440|Drug|Ponatinib|Ponatinib tablets.
75605314|NCT00990184|Drug|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
75605315|NCT00990184|Other|placebo|tablet (s) orally given with evening meal
75605316|NCT00986830|Device|FinESS Sinus Treatment|
75899590|NCT05825716|Other|Ifaa Basic|"PSNP Systems: (1) Provision of food aid commodities (wheat, oil, and pulse) per the PSNP transfer schedule for 3-6 months; 2) Food System Taskforce (FSTF) capacity building, and 3) private sector engagement~Health and Nutrition: 1) Government of Ethiopia (GoE) basic health extension program; 2) GoE supportive supervision coaching; 3) GoE-led community social behavior change (SBC) sessions; and 4) Community Management of Acute Malnutrition (CMAM) Programming.~Water and Sanitation: 1) Water infrastructure development; 2) improved governance via water, sanitation and hygiene (WASH) committees; and 3) water source monitoring.~Natural Resource Management: 1) Public works projects; 2) community training in planning and sustaining community assets; 3) Implementation of the environment and social management framework; 4) enhance participation of watershed committees"
75909612|NCT03473678|Dietary Supplement|Nitrate-rich beetroot juice|concentrated beetroot juice
75909613|NCT03473678|Dietary Supplement|Nitrate-depleted beetroot juice|concentrated beetroot juice
75750055|NCT05844657|Other|Dynamic balance assessment with tandem gait test|In our study, the tandem gait test was used for dynamic evaluation. A straight line was created with a white tape attached to the floor, almost 2 feet away from the 10-foot-long wall. The participant was asked to walk along the line created by taping the heel of the forward foot to touch the toe of the back foot, at a comfortable pace in daily life and with eyes open.
75909614|NCT04312412|Procedure|Controlled active motion (CAM)|Rehabilitation, post-surgery protocol
75909615|NCT05157542|Drug|Durvalumab|Day 1 and 22, 1500mg
75909616|NCT05157542|Drug|nanoparticle albumin bound paclitaxel|Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5
75454098|NCT04891640|Other|TNFi fixed longer dosing intervals|"Participants randomly assigned to this arm will increase the time between TNFi medication doses.~Adalimumab- from every 2 to 3 weeks~Certolizumab- from every 2 to 4 weeks~Etanercept- from every 1 to 2 weeks~Golimumab- from every 4 to 6 weeks~Infliximab- from baseline to baseline + 2 weeks"
75454099|NCT04891640|Other|Stop TNFi treatment|Participants randomly assigned to this arm will stop TNFi medication.
75454100|NCT04891237|Biological|10,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
75454101|NCT04891237|Biological|30,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
75454102|NCT04891237|Other|Placebo|The same solution and presentation as the active treatment, but without active ingredients
75454103|NCT04889716|Drug|mosunetuzumab|1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.
75605317|NCT00990106|Drug|prazosin hydrochloride|"Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually."
75605318|NCT00990106|Drug|placebo|placebo
75899591|NCT05825716|Behavioral|Ifaa Enhanced|"PSNP Systems: 1) establishment and training of Community Technical Coordinating Forum; 2) Case management capacity building; and 3) private sector construction of infrastructure~Health and Nutrition:1) the Care Group Model approach; 2) home garden promotion; 3) the nutrition budget calculator; and 4) labor and time-saving technologies.~Community-level interventions are 1) adolescent nutrition school clubs; 2) religious leader mobilization and training vulnerable groups; 3) audio toolkit against harmful traditional practice; 4) enhanced SBC tools for health/nutrition promotion; 5) additional health extension programs~Water and Sanitation: 1) Community Led Total Sanitation and Hygiene; 2) WASH systems assessments and strengthening; 3) Ensuring water quality and safety via routine monitoring; 4) Private sector engagement of WASH-related businesses;"
76066441|NCT05752500|Behavioral|Social Support for Physical Activity|This component will leverage the social functionality of the Fitbit app, promoting social support and friendly competition via a moderated Facebook group.
76066442|NCT05752500|Behavioral|Physical Activity Coaching|The PA coach will meet with the participant to set goals for physical activity (steps) and encourage self-monitoring. Meetings will occur every other week for 4 months.
75605319|NCT02867566|Drug|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
75605320|NCT02867566|Drug|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
76066443|NCT05752500|Behavioral|Brief Advice and Self-Monitoring|Participants will receive a single session with brief advice about increasing physical activity, and instructions on how to use their study-provided FitBit.
75605321|NCT02868502|Device|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
75605322|NCT02868502|Device|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
75605323|NCT02868502|Device|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
75454104|NCT04889716|Drug|glofitamab|2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12
75454105|NCT04889716|Drug|obinutuzumab|1000 mg IV on Cycle 1 Day 1.
75454106|NCT04874714|Biological|MM09-MG01(30.000-30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
75454107|NCT04874714|Biological|MG01(30.000)|Grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
75454108|NCT04874714|Biological|MM09(30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
75454109|NCT04874714|Biological|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
75605324|NCT02868502|Device|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
75605325|NCT02868424|Drug|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
75605326|NCT02867722|Drug|aminolevulinic acid HCl|Drug will be administered to consented patients
75605327|NCT04291222|Device|Iron biocorrodable coronary scaffold system|Implantation of Iron biocorrodable coronary scaffold system
75605328|NCT02867800|Drug|Diphenhydramine|"(Standard of Care) Premedication~Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)"
75605329|NCT02867800|Drug|Acetaminophen|"(Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)"
76066444|NCT05752292|Behavioral|Standard Health Information|Standard health information about postpartum screening and lifestyle programs for diabetes prevention
76066445|NCT05752292|Behavioral|Values Affirmation (VA)|Interactive prompts to reflect on core personal values
75605330|NCT02867800|Drug|Methylprednisolone|"(Standard of Care) Premedication~Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours"
75454110|NCT04868656|Other|Implementation Strategy: Foundational Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We propose that low intensity implementation support that promotes adapting STRIDE for context and provides tools for ongoing STRIDE evaluation (defined as foundational support), will be sufficient for some but not all hospitals to successfully incorporate STRIDE into routine practice.
75605331|NCT02867800|Drug|Meperidine|"(Standard of Care) Premedication~Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)"
75605332|NCT02867800|Drug|Alemtuzumab|"(Standard of Care) Immunosuppression~Alemtuzumab:~A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third."
75750056|NCT05844657|Other|Headache, Temporomandibular pain and Craniocervical pain presence and severity assessment|Headache, temporomandibular pain and craniocervical pain were asked to mark the person from the photographs taken from the front, back and side in the form of a human figure. Pain severity was evaluated with the numerical rating scale (NRS).
75909617|NCT05157542|Radiation|low dose radiation therapy|10 Gy in 5 fractions, 20 Gy in 10 fractions, 30 Gy in 15 fractions respectively in our three groups from Day1
75454111|NCT04868656|Other|Implementation Strategy: Enhanced Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We posit that monitoring hospitals' progress and adding, for hospitals with low adoption, higher intensity strategies (defined as Enhanced Support) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
75454112|NCT04867603|Drug|[Ga-68]PSMA|The injectable activity will be a maximum of 210 MBq (6.0 mCi) [Ga-68]PSMA at the time of injection and is administered to subjects by intravenous injection.
75454113|NCT04867603|Device|PET/CT imaging|PET/CT imaging procedure
75605333|NCT02867800|Drug|Thymoglobulin|"(Standard of Care) Immunosuppression~Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed."
75605334|NCT02867800|Drug|Fludarabine|"(Standard Conditioning Regimen)~Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes."
75605335|NCT02867800|Drug|Melphalan|"(Standard Conditioning Regimen)~Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete."
75605336|NCT02867800|Drug|Thiotepa|"(Standard Conditioning Regimen)~Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour."
75605337|NCT02867800|Drug|Cyclosporine|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml."
75605338|NCT02867800|Drug|Tacrolimus|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml."
75909618|NCT03472976|Other|Aqueous Cream B.P.|Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
75909619|NCT03472976|Drug|Imiquimod|Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
75909620|NCT03472976|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04|Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
75909621|NCT04457726|Biological|SARS-CoV-2 Specific T Cells|Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.
75454114|NCT04856826|Device|ultrasound guidance and therapeutic communication|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
75454115|NCT04849884|Device|CORI™ KNEE TENSIONER|Robotic TKA procedure with the REAL INTELLIGENCE™ CORI™ Surgical System including the use of the CORI™ KNEE TENSIONER accessory.
75750057|NCT05844657|Other|Pain sensitivity assessment in the head, neck, shoulder girdle and upper back region|In our study, muscle tenderness was evaluated by manual pressure algometry and palpation. Muscle tenderness was assessed in the upper and lower regions of the masseter, temporalis, sternocleidomastoid, and upper trapezius muscles on both right and left sides.
75750058|NCT05844657|Other|International physical activity questionnaire-measurement of physical activity level with short|The short form of the international physical activity questionnaire was used to determine the physical activity level of the individuals participating in our study. The short form of the international physical activity questionnaire evaluates the last week and consists of a total of 4 sections and 7 questions. Duration of physical activity that requires intense physical effort, such as heavy lifting, soccer, or fast cycling; times of doing moderate physical activities that cause breathing slightly more often than usual; The total duration of walks at work, home, for sports, exercise and hobby, and the total sitting time spent in a day at work, at home or while resting are calculated.
75750059|NCT05844657|Other|Evaluation of sleep quality with the Pittsburgh sleep quality index|The Pittsburgh Sleep Quality Index (PUKI) was used to evaluate the sleep quality and disturbance of the individuals participating in our study in the last month. It consists of a total of 24 questions. The participant responds to each item according to the frequency between 0-3 points. The total score (0-21 points) from these components indicates whether the sleep quality is good or not.
76066446|NCT05752292|Behavioral|Tailored Risk Information (TRI)|Interactive prompts to provide tailored information on risk factors for type 2 diabetes
75605339|NCT02867800|Drug|Methotrexate|"(Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight."
75750060|NCT05844657|Other|Evaluation of fatigue with the fatigue severity scale|The Fatigue severity scale was used to evaluate the fatigue status of the individuals participating in our study. The scale uses a scoring system ranging from 1-7, which starts as I do not agree (1 point) and increases gradually towards I agree (7 point). It consists of 9 items in total and people mark the option that suits them.
75909622|NCT04457570|Other|mortality|To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
75909623|NCT04216394|Procedure|Emergency general surgery|multidisciplinary surgery performed for traumatic and non-traumatic acute conditions during the same admission in the hospital.
76066447|NCT05752292|Behavioral|Motivational Interviewing-based (MI)|Interactive prompts based on principles of motivational interviewing
76066448|NCT05752292|Behavioral|Action planning (AP)|Interactive prompts to problem solve challenges
76066449|NCT05736016|Device|medial wedge insoles ((corrective insoles are equipped with hard 10-degree medial wedge, while sham insoles are equipped with pliable 10-degree medial wedge)|All study participants will be instructed to use insoles for exercising, walking, and other everyday activities.
75454116|NCT04828304|Device|PLASOMA|Treatment with cold plasma device
75605340|NCT02867800|Drug|Abatacept|"(Investigational)~Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted."
75605341|NCT02867800|Procedure|Marrow infusion|"(Standard)~A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer"
75454117|NCT04826224|Biological|Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.|Bone marrow aspirate concentrate contains a median nucleated cell count of 121,700/uL, and platelets of 384,000/uL. This leads to a cellular dose of approximately 400 million cells.
75454118|NCT04817670|Drug|VIT-2763 120 mg|"Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
75605342|NCT02867800|Drug|Sirolimus|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
75454119|NCT04817670|Drug|VIT-2763 360 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally."
76066450|NCT05732142|Other|Postpartum Integration of Vaccines and Contraception Through Gender-Transformative Programming(PIVoT)|The PIVoT intervention is a 30-minute focused information exchange that supports shared contraceptive decision making. The program includes a gender-equity and family planning curriculum covering basic family planning information as well as gender norms and son preference and interactive family planning method index cards (detailing method characteristics, use, duration of action, efficacy, side effects, and contraindications for each method). The program is designed to support person-centered contraceptive choice and encourages women to consider joint family planning decision-making with male partners. If a contraceptive method is desired, it will be provided by nurses who are trained to provide comprehensive family planning care.
75750061|NCT05844657|Other|Evaluation of anxiety-depression status with hospital anxiety and depression scale|The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the anxiety and depression status of the individuals participating in our study. For each item, the participant answers with a four-point (0-3 points) response option. Therefore, the possible score probabilities in line with the answers given are minimum '0' and maximum '21'. The cut-off point for the anxiety subscale is 10 points, while the cut-off point for the depression subscale is 7 points.
76066451|NCT05725837|Drug|Paroxetine|Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
75454120|NCT04817670|Drug|VIT-2763 240 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
76066452|NCT05719935|Device|KinematX total wrist arthroplasty system|The KinematX total wrist implant is a joint metal/polymer semi-constrained cemented prosthesis that utilizes an articulation that mimics the midcarpal joint instead of the radiocarpal joint.
75605343|NCT02867800|Drug|Mycophenolate Mofetil|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
75750062|NCT05844657|Other|Evaluation of quality of life with short form-12 (SF-12)|The Short form SF-12 Questionnaire was used to evaluate the quality of life of the individuals participating in our study. The summary score of the physical and mental components varies between 0-100, and the higher the score in the components, the better the quality of life.
76066453|NCT05716516|Drug|Estradiol|Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
76066454|NCT05711667|Procedure|Biospecimen Collection|Undergo collection of blood samples
75454121|NCT04817670|Drug|Placebo BID|"Participants receive 2 capsules of placebo in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
75605344|NCT00983476|Behavioral|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
75605345|NCT00983476|Behavioral|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
75605346|NCT00629200|Drug|Sodium Stibogluconate|400 mg/m^2 IV daily on days 1-5.
75605347|NCT00629200|Drug|Interferon Alpha-2b|3x10^6 units subcutaneously three times weekly
75605348|NCT02867488|Other|Soybean oil in salad dressing|
75750063|NCT05844657|Other|the International Fall Efficiency Scale|The International Fall Activity Scale (UDES) was used to evaluate both the attack and the general fear of falling of the individuals participating in our study. It consists of 16 questions in total. The answer to each question is marked on a scale between 1 and 4 points. Expressions such as I never worry (1 point), I worry a little (2 point), I am very worried (3 point), I am very worried (4 point) are used as the level of anxiety increases as the score increases. The total score obtained ranges from 16 (no worries) to 64 (extremely worried).
75454122|NCT04817670|Drug|Placebo TID|"Participants receive 2 capsules of Placebo in the morning, in the afternoon and in the evening, for 8 weeks.~Capsules are to be taken orally."
75454123|NCT04816643|Biological|Biological/Vaccine: BNT162b2 10mcg|BNT162b2 Low/Mid-Dose (10mcg) level
75454124|NCT04816643|Biological|BNT162b2 20mcg|BNT162b2 Mid-Dose (20mcg) level
75454125|NCT04816643|Biological|BNT162b2 30mcg|BNT162b2 High-Dose (30mcg) level
75605349|NCT02867176|Drug|Gabapentin|The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
75605350|NCT02867176|Drug|Ketorolac|The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
75750064|NCT05844657|Other|assessment of muscle performance|In our study, the strength of cervical flexors, anterior and oblique trunk flexors, cervical extensor muscles, back extensor muscles, trapezius muscle, and rhomboid major-minor muscles were evaluated. In addition, the endurance of the deep cervical flexor muscles, cervical flexors and cervical extensor muscles were also evaluated.
76066455|NCT05711667|Drug|Letermovir|Given PO or IV
75454126|NCT04816643|Other|Placebo|Intramuscular injection
75454127|NCT04816643|Biological|Biological/Vaccine: BNT162b2 3mcg|BNT162b2 Low-Dose (3mcg) level
75605351|NCT02868034|Behavioral|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
75605352|NCT02868034|Behavioral|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
76066456|NCT05708066|Other|Lavender Aromatherapy|"Participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations.~After the lavender patch has been in place for 5 minutes, the same VAS anxiety questionnaire will be provided"
75750065|NCT05838755|Drug|GSK3858279|GSK3858279 will be administered
75750066|NCT05838755|Drug|Placebo|Placebo will be administered
76066457|NCT05708066|Other|Non-scented Tab|A non-scented tab will be placed on the participant's chest, according to manufacturer recommendations. Participants in this group will only receive the initial VAS anxiety questionnaire.
75454128|NCT04809467|Drug|tafasitamab|tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.
75454129|NCT04809467|Drug|parsaclisib|parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
75750067|NCT05838313|Behavioral|Elective Induction of Labor Decision Support Tool|Decision support tool for people having their first baby and planning vaginal delivery without a medical indication for induction of labor
75750068|NCT05827965|Behavioral|education and drug adjustement|education of the patients (lifestyle) and adjustement of glucocorticoid replacement schedule
75750069|NCT05821465|Device|HeartWatch|The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
75463264|NCT05855057|Procedure|Flank suspended supine position percutaneous nephrolithotomy|The patients will be placed in the supine position with the shoulder and the buttock will be raised by a 3-l bag of water suspending the flank of the affected side. The body contour will be aligned to the edge of the table. The operating table will be adjusted to the jack knife position, with the tip of the lower part of the table will be slightly lowered. The leg of the affected side of the patent will be straightened dorsally flexed and slightly inner rotated, with the knee of the other side will be flexed. The patients will be then immobilized at the chest and the pelvis with two adherent tapes which crossed each other at the abdomen to form a 'V' shape.
75750070|NCT05816226|Drug|Hydrocortisone 2.5%|Applied four times daily to TMJ with arthralgia
75750071|NCT05816226|Drug|Diclofenac 1% topical|Applied four times daily to TMJ with arthralgia
75750072|NCT05793801|Other|Dressing change|"The patient circuit corresponds to that of usual care.~Not part of usual patient management:~The rhythm of PICCline dressing changes, which differed between the two groups.~The collection of pain on a visual analog scale at each dressing change."
76066458|NCT05703061|Behavioral|10-hour Time in Bed|Participants will be asked to increase their time in bed to 10-hours per night for 7 consecutive days.
76066459|NCT05702424|Drug|IGM-7354|IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
76066460|NCT05695885|Behavioral|STEPS|behavioral counseling
76066461|NCT05695885|Behavioral|Services as usual (SAU)|behavioral counseling normally provided
76066462|NCT05691348|Procedure|Ambulatory appendectomy|Appendectomy will be performed in outpatient surgery unit. Patient will be discharge from the hospital the same day as surgery
75605353|NCT02868034|Behavioral|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
75605354|NCT02868034|Behavioral|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
75899592|NCT05825716|Other|Ifaa Enhanced + Livelihoods|"Additional resources provided to the groups, including 1) Engagement of Private Service Providers to enable access to sustainable credit and larger loans; 2) Financial Education using an expanded 'Smart Skills' curriculum focusing on savings, smart borrowing and effective financial management; and 3) Life Skills Training for Youth.~Additional supports include: 1) Seven Steps of Marketing Training; 2) Climate Smart Agriculture to reduce water needs and increase soil health and vegetation coverage; 3) Producers Groups and linkages to markets/suppliers/buyers; Selected financial institutions will be provided with a credit guarantee fund and capacity-building support to help facilitate loans. Private sector value chain assessment and financing. Additional private sector engagement and linkage facilitation."
75899593|NCT05805111|Device|endovascular intervention|Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) is a new, minimally invasive technique, for treating extensive and/or recurrent aorto-iliac occlusive disease. The technique rebuilds the diseased aortic bifurcation and iliac arteries through the use of stent-grafts introduced through the groin or arm arteries.
75605355|NCT00982228|Drug|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
75605356|NCT00982228|Drug|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
75899594|NCT05793307|Genetic|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
76066463|NCT05691348|Procedure|Conventional appendectomy|Appendectomy will be performed in digestive surgery department. Patient will be discharge from the hospital the day after surgery: he will spend a night under observation
75605357|NCT00982228|Drug|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
75454130|NCT04799834|Other|Questionnaire administration,blood sampling and genetic analyses.|"Adults (≥18 years) living in Bergamo and in all the towns of its territory shall be invited to voluntarily complete a questionnaire, with their personal data and information on SARS-CoV-2 clinical history (swab test and serologic test results, clinical symptoms, treatments, hospital care) and other previous conditions. Subjects considered fit for the genetic study will be asked to report to the Daccò Clinical Center for an interview, during which the data entered in the questionnaire will be reviewed and implemented, the informed consent for participation in the genetic investigations will be collected and blood sampling will be carried out.~Genetic: Exome sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing severe disease (cases), or infected with SARS-CoV-2 and showing mild disease or remaining asymptomatic, and in individuals without evidence of infection with SARS-CoV-2 (negative sierology)."
75454131|NCT04797780|Drug|Tamibarotene|Administered as specified in the treatment arm
75605358|NCT02867956|Drug|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
75605359|NCT02867956|Drug|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
75750073|NCT05792956|Behavioral|Using mobile app|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
75750074|NCT05787483|Behavioral|MindUP group|MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.
76072251|NCT02436213|Other|Cardiopulmonary exercise test|"On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down (within the hour on Day 1), they will fill in a short questionnaire describing how they feel."
75454132|NCT04797780|Drug|Placebo|Administered as specified in the treatment arm
75454133|NCT04797780|Drug|Azacitidine|Administered as specified in the treatment arm
75605360|NCT04290832|Behavioral|CO Intervention|"South Africa: Values clarification and attitude transformation (VCAT) workshop with conscientious objection content, debrief session(s) with termination of pregnancy (TOP) providers to give them an opportunity to share concerns/challenges, meeting(s) with facility mangers to facilitate continued support and provision of TOP care~Mexico: Training on abortion and conscientious objection law, posters on law, offer of legal assistance for abortion providers, scholarship to attend conference awarded on basis of quality of abortion care"
75605361|NCT04291066|Drug|N-Acetyl cysteine|Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
75750075|NCT05787483|Behavioral|active control group|business as usual; regular wellness or SEL classes
75605362|NCT04290910|Behavioral|Weight Loss Program|There are three components of the intervention, this includes: psychology, nutrition, and physical activity. For the psychological portion, a therapist will assess the participant at baseline to determine if there are barriers associated with making lifestyle changes. For nutrition, the dietitian will assess the participant and create a meal plan based on their nutritional needs and guide the participant to reaching their nutritional goals. The psychological and nutrition portion may be interchangeable depending on the participants needs. For physical activity, the personal trainer will assess the participant and create an exercise plan that consists of resistance training and weight bearing exercises suitable for the participant while also guiding the participant to reach their exercise goals.
76066464|NCT05687292|Device|Clinical decision support system (CDSS) for ventilator weaning|A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.
76066465|NCT05686499|Other|Didactic Lectures and demonstrations|"Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors."
75750076|NCT05771779|Biological|Oral Cholera Vaccine (OCV)|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
75750077|NCT05771779|Biological|Typhoid Conjugate Vaccine (TCV)|Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT
75750078|NCT05771779|Biological|Measles and Rubella (MR)|Live attenuated vaccine
75605363|NCT01260350|Drug|SOF|Sofosbuvir (SOF) tablets administered orally once daily
76066466|NCT05678439|Dietary Supplement|sesame extract|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
75463265|NCT05855057|Procedure|Supine percutaneous nephrolithotomy group|The patient will remain in the supine position, with the side of interest at the edge of the table, with a small cushion placed under the flank to elevate it 15-20°.
75605364|NCT01260350|Drug|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
75750079|NCT05763667|Drug|Liposomal bupivacaine|"Liposomal bupivacaine is FDA-approved for use single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
75899595|NCT05779137|Behavioral|MBCT|Patients will join a mindfulness-based cognitive therapy course at the Radboudumc Center for Mindfulness. The course consists of eight weekly sessions of 2.5-hour and one 6-hour silence day between the 6th and 7th session. The sessions include meditation exercises (body-scan, sitting meditation, gentle movement exercises, three-minute breathing space, daily activities with attention), psychoeducation and group discussion. Psychoeducation includes information on cognitive techniques, like monitoring and scheduling of events and identification of negative automatic thoughts. In addition, all participants will be encouraged to perform daily practice assignments at home for about 30-45 minutes per day, mainly consisting of meditation exercises.
75899596|NCT05772988|Dietary Supplement|Beta-alanine|Beta-alanine
75899597|NCT05772988|Dietary Supplement|Maltodextrin|Maltodextrin
75899598|NCT05772260|Procedure|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy will be performed under general anesthesia. Per-oral endoscopic myotomy will be performed according to the standard care.~General anesthesia will be conducted according to the standard care in our institution, and standardized as follows.~Monitoring: ECG, SpO2, noninvasive blood pressure, invasive blood pressure monitoring via radial artery cannulation, advanced hemodynamic monitoring (including cardiac output, cardiac index) uisng EV1000 clinical platform (Edwards Lifesciences, USA), anesthetic depth monitoring by SedLine Sedation monitor (Masimo corporation).~Anesthetic induction: Target controlled infusion (TCI) of Remifentanil (target 3.0 ng/mL), propofol 2 mg/kg IV, rocuronium 0.8 mg/kg IV~Anesthetic maintence: sevoflurane 0.9 age corrected MAC and remifentanil TCI (target range 1.0-4.0 ng/mL)"
75899599|NCT05771623|Device|Iontophoresis drug delivery device|"Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.~This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months)."
75463266|NCT05855057|Procedure|Prone percutaneous nephrolithotomy group|Prone percutaneous nephrolithotomy. The prone position (PRON) technique followed these classic steps: patients will be placed in a lithotomy position and a ureteral catheter will be inserted through a rigid cystoscope to perform a retrograde pyelogram. The ureteral catheter will be fixed to a Foley catheter, and then the patient will be repositioned to the prone position with pads under their shoulders.
75750080|NCT05763667|Drug|Bupivacain|"Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
75605365|NCT01260350|Drug|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
75750081|NCT05753670|Drug|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
75463267|NCT05855018|Drug|Atropine sulfate eye drops|One drop once daily
75605366|NCT01260350|Drug|LDV|Ledipasvir (LDV) tablets administered orally once daily
75605367|NCT01260350|Drug|GS-9669|GS-9669 tablets administered orally once daily
75605368|NCT01260350|Drug|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
75605369|NCT04150120|Device|e-health device with application|In this project we focus on eHealth solutions for patients and/or their families in situations where they could benefit from enhanced communication options with specialist staff. In this design space we use a model where a 4G-enabled tablet computer is lent to the families for the length of the study, thus avoiding economic requirements on the families and keeping the equipment uniform. The tablets run an application that enables multiple forms of direct and bi-directional communication in real-time with specialist staff at the hospital. For the staff, the technical situation is different; here we have in earlier demonstrators used web-based solutions accessed with existing computer equipment.
75605370|NCT04291378|Radiation|Proton versus photon radiation therapy|The intervention is proton radiation therapy versus photon radiation therapy
75750082|NCT05753670|Drug|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
75899600|NCT05771623|Behavioral|Traditional physical therapy|Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).
75899601|NCT05770297|Dietary Supplement|Propolis|intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group
75899602|NCT05770297|Other|placebo|intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group
75605371|NCT04273828|Procedure|Lumbar decompressive surgery|Patients with lumbar degenerative diseases and symptoms of nerve compression (radiculopathy or neurogenic claudication) who will undergo surgical treatment for neural decompression (discectomy, foraminotomy or laminectomy).
75605372|NCT01260194|Drug|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
75605373|NCT00629278|Biological|trastuzumab|
75605374|NCT00629278|Drug|aromatase inhibition therapy|
75605375|NCT00629278|Drug|cyclophosphamide|
75605376|NCT00629278|Drug|docetaxel|
75605377|NCT00629278|Drug|doxorubicin hydrochloride|
75605378|NCT00629278|Drug|epirubicin hydrochloride|
75605379|NCT00629278|Drug|fluorouracil|
75605380|NCT00629278|Drug|paclitaxel|
75605381|NCT00629278|Drug|releasing hormone agonist therapy|
75605382|NCT00629278|Drug|tamoxifen citrate|
75605383|NCT00629278|Procedure|adjuvant therapy|
75605384|NCT00629278|Radiation|radiation therapy|
75605385|NCT04320758|Other|conventional preparation design|chamfer finish line
75463268|NCT05854979|Diagnostic Test|Gastric Ultrasound|A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.
75463269|NCT05854940|Diagnostic Test|Serum Raman spectroscopy intelligent diagnostic system|Intelligent diagnostic system based on Raman spectrum of serum
75605386|NCT04320758|Other|biologically oriented preparation technique|shoulder less preparation design
75605387|NCT04207112|Drug|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
75605388|NCT04207112|Drug|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
75899603|NCT05760378|Drug|Famitinib|TKI
75899604|NCT05760378|Drug|Camrelizumab|PD1 inhibitor
75899605|NCT05760378|Drug|nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin|TPC
75899606|NCT05744635|Drug|Tacrolimus|Tacrolimus received as part of routine clinical care
75899607|NCT05736003|Procedure|Laparoscopic cholecystectomy|Removal of gallbladder laparoscopically
75899608|NCT05733689|Device|ctDNA Blood Test|Blood will be collected for ctDNA testing
76066467|NCT05678439|Other|placebo|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
76066468|NCT05676749|Biological|C-TIL051|C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab
75769429|NCT03909646|Drug|Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram|A layer of methylaminolevulinc acid 160 mg/g cream (about 1 mm thick) is applied to the lesion, with a clinical margin of 5-10 mm surrounding of normal skin and then covered by an occlusive dressing. After 3 hours the occlusive dressing will be removed and the area is illuminated with Omnilux or Actilite (Galderma). After PDT the treatment site is covered again with the above mentioned occlusive dressings during 48 hours. Treatment is performed by an authorized nurse in the hospital. Two sessions should be administered with an interval of one week between sessions.
75769430|NCT03909646|Drug|5Fluorouracil|5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.
75899609|NCT05733689|Combination Product|FLOT|"Oxaliplatin 85 mg/m2 IV on Day 1~Docetaxel 50 mg/m2 IV on Day 1~Leucovorin 200 mg/m2 IV on Day 1~Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1 Every 14 Days"
75899610|NCT05733689|Combination Product|FOLFOX|"Oxaliplatin 85 mg/m2 IV on Day 1~Leucovorin 400 mg/m2 IV on Day 1~Fluorouracil 400 mg/m2 IV Push on Day 1~Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
75899611|NCT05733689|Combination Product|FOLFIRI|"Irinotecan 180 mg/m2 IV on Day 1~Leucovorin 400 mg/m2 IV on Day 1~Fluorouracil 400 mg/m2 IV Push on Day 1~Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
76066469|NCT05667207|Diagnostic Test|Point-of-care microscopy and dipstick guided management|"GPs will be encouraged to apply the following diagnosis and treatment algorithm (figure 1) to consenting women, taking their preferences into account:~If POCTs are positive for bacteria by microscopy and/or for erythrocytes by dipsticks the GP issues, at his/her own clinical judgement, a delayed or immediate prescription for an antibiotic.10 In the MicUTI intervention, delayed prescription is defined as issuing an antibiotic prescription with the advice to take the medication only when symptoms do not improve or worsen in 48 hours.~If POCTs are negative for bacteria and erythrocytes, the GP advises for self-help remedies according to guidelines and to do without antibiotics Study specific training in point-of-care microscopy will be provided to intervention practices."
76066470|NCT05658484|Drug|Dimethyl fumarate|Administered as specified in the treatment arm.
75899612|NCT05733689|Combination Product|FOLFIRINOX|"Oxaliplatin 85 mg/m2 IV on Day 1~Irinotecan 150 mg/m2 IV on Day 1~Leucovorin 200 mg/m2 IV on Day 1~Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 days"
75899613|NCT05733689|Combination Product|PACLITAXEL with or without CARBOPLATIN|"Paclitaxel 200 mg/m2 IV on Day 1~Carboplatin AUC 5 IV on day 1 Every 21 Days~OR~- Paclitaxel 80mg/m2 IV on Days 1,8,15 Every 28 Days"
75899614|NCT05733689|Combination Product|DOCETAXEL and IRINOTECAN (alone or combined)|"Docetaxel 35 mg/m2 IV on Days 1 and 8~Irinotecan 50 mg/m2 IV on Days 1 and 8 Every 21 Days~Docetaxel 75 mg/m2 IV on Day 1 Every 21 Days~Docetaxel 150 mg/m2 IV on Day 1 Every 14 Days"
75605389|NCT04207112|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
75769431|NCT03909646|Other|Surgical excision|Local anesthesia with lidocain 1% (1-2ml) will be used before performing standard surgical excision with 5 mm safety margin followed by routine histological examination. The skin will be closed using cutaneous sutures, which will be removed after 1-2 weeks. The surgical excision will take place in the hospital by the treating physician
75899615|NCT05733689|Drug|NIVOLUMAB (alone or when added to a regimen above)|"240 mg IV on Day 1 every 14 days, or~360 mg IV on Day 1 every 21 days, or~480 mg IV on Day 1 every 28 days"
75899616|NCT05733689|Drug|PEMBROLIZUMAB (alone or when added to a regimen above)|"200 mg IV on Day 1 every 21 days, or~400 mg IV on Day 1 every 42 days"
75899617|NCT05733533|Drug|HRS-2261 oral tablet|HRS-2261 oral tablet, oral, BID
75899618|NCT05733533|Drug|Matching placebo to HRS-2261|Matching placebo to HRS-2261, oral, BID
75769432|NCT01256866|Drug|Dexmedetomidine|
75899619|NCT05723874|Drug|BI 425809|BI 425809
75899620|NCT05723874|Drug|bosentan|bosentan
75899621|NCT05718817|Drug|XEN1101|XEN1101 capsules
76066471|NCT05658198|Behavioral|Counseling|Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.
75463270|NCT05854901|Diagnostic Test|Procalcitonin|blood test, measuring the concentration of PCT in ug/L
75463271|NCT05854901|Other|Physician's decision|The physician's decided whether the patient will receive antibiotic treatment or not
75463272|NCT05854888|Procedure|Perineal Massage and Warm Compresses (PeMWaC)|Perineal Massage was performed in the II Hodge Plan, between maternal contractions and regardless of maternal position. Warm Compresses were applied by the midwife between Hodge plans III and IV, during pushing and regardless of maternal position.
75605390|NCT04207112|Drug|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
75769433|NCT01256866|Drug|Midazolam|
75769434|NCT03897946|Biological|Birth dose hepatitis B vaccine|Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
75899622|NCT05699200|Other|Arterial Tonometry|We will measure arterial stiffness using arterial tonometry.
76066472|NCT05653882|Biological|AB248|Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug
75605391|NCT04207112|Drug|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
75899623|NCT05699200|Diagnostic Test|Echocardiogram|We will collect limited ultrasound images of the heart.
75899624|NCT05699200|Diagnostic Test|Carotid Ultrasounds|We will perform ultrasound imaging of the carotid artery.
75899625|NCT05699200|Diagnostic Test|Elastography|We will measure the elastic properties of the arteries using elastography.
75899626|NCT05699200|Other|Ankle-Brachial Index|We will measure the ankle-brachial index to assess peripheral artery blood flow.
75605392|NCT04207112|Drug|Standard Drugs|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
75605393|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
75750083|NCT05746468|Behavioral|Ecological assessment and intervention|The MBI-EMI app will include five main parts, including virtual counselor, intervention library, weekly mindfulness practice, assessment bank and daily emotion log. In the eight weeks, the virtual counselor will initiate the conversation every day for three times (morning, afternoon and evening) to check the status of the participants. If the participants responded, the virtual counselor would invite the participants to rate their level of depression, stress and anxiety and then recommend appropriate mindfulness practice in the intervention library, such as 3-minute breathing space or mindful eating. The conversation between the virtual counselor and participants will be in the format of menu list and participants can easily choose from different options.
75750084|NCT05746468|Behavioral|Audio-based Mindfulness intervention|The control group will receive audio recordings of how to practice mindfulness at home.
75750085|NCT05744765|Other|breathing exercises|After the initial 5 minutes of relaxed breathing, the participants will perform diaphragmatic and costal breathing for 10 minutes. .5 diaphragmatic breathing will be done in 1 minute.
75750086|NCT05742698|Drug|Nabilone|Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
75750087|NCT05742698|Drug|Placebo|The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
75899627|NCT05699200|Other|Microneurography with sympathoexcitatory maneuvers|We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.
75899628|NCT05684315|Procedure|soft tissue flossing therapy|BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
76066473|NCT05653882|Biological|Pembrolizumab|Intravenous infusion of pembrolizumab
76066474|NCT05652868|Drug|MYTX-011|MYTX-011 will be administered as an intravenous infusion every 21 days for up to two years.
76066475|NCT05650476|Drug|Talazoparib|capsules
75454134|NCT04795999|Behavioral|Project With|There are 12 lessons in Project With, typically delivered in six weekly sessions, with each session having two one-hour long lessons and a meal with facilitators in between the two lessons. Each lesson includes a discussion of selected literary works, including poetry, short stories, and excerpts from films and other videos. The curriculum is intended to be delivered to groups of 8-12 youth. In ideal program delivery, participants also share a meal with each other and with the Youth Advocate. Shared mealtimes create group cohesion and allow Youth Advocates to connect with participants on a personal level, building trust. At the end of the Project With curriculum, youth will partake in an offsite day excursion to Camp Eaton, a wooded camp outside of Los Angeles. At Camp Eaton, Youth Advocates will lead a Project With session, lunch, bonding activities and games, and an opportunity to engage in an outdoor activity.
75454135|NCT04794517|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
75454136|NCT04794517|Other|Placebo|Placebo one tablet/die will be administered orally for six-weeks.
75454137|NCT04786548|Drug|Celecoxib|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
75605394|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
75605395|NCT01259726|Other|Placebo|10 mL placebo once daily for 14 days
75899629|NCT05683132|Behavioral|Trauma-Informed CBT-I|5 individual sessions incorporating behavioral and cognitive therapy components and trauma-informed adaptations with a trained instructor.
75899630|NCT05683132|Behavioral|PTSD Psychoeducation|5 individual sessions incorporating psychoeducation about PTSD symptoms with a trained instructor.
76066476|NCT05637840|Other|Urine sample|Collection of 36-84 urine samples over a 14 consecutive day period.
75605396|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 14 days
75605397|NCT05527730|Device|Comparison of PRO-FIT or SELF-FIT fitting|add
75605398|NCT01259492|Drug|Placebo|Placebo Comparator: Placebo
75605399|NCT01259492|Drug|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
75605400|NCT01259492|Drug|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
75605401|NCT04320446|Behavioral|Test in the morning|The exercise test was performed between 8 a.m and 11 a.m
75605402|NCT04320446|Behavioral|Test in the afternoon|The exercise test was performed between 5 p.m. and 8 p.m.a
75605403|NCT00624026|Drug|Memantine-HCl|20 mg per day (once daily)
76066477|NCT05637840|Other|Sleep restriction|Participants will be asked to limit their sleep to 4 hours within a 24-hour period for 2 days in a row.
76072252|NCT02436213|Procedure|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
76072253|NCT02408588|Other|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
75750088|NCT05731960|Drug|Dexamethasone|10 mg IV dexamethasone provided immediately after spinal anesthesia
75605404|NCT05512910|Drug|Minocycline|200 mg minocycline orally or via nasogastric tube prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting.
75750089|NCT05731960|Drug|Metoclopramide|10 mg IV metoclopramide provided immediately after spinal anesthesia
75454138|NCT04775914|Procedure|PCI + Ischemic conditioning|IPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.
75750090|NCT05726812|Behavioral|Plan My Life Together|A group training for adolescents with ADHD in which they learn to plan and organize. The training consists of 8 weekly sessions of 90 minutes for the adolescent and 2 parent sessions of 90 minutes.
75750091|NCT05723679|Combination Product|HeO2 gas mixture|Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.
75750092|NCT05723679|Combination Product|Room air gas mixture|Normal room air
75899631|NCT05681455|Device|Neuromodulation NESA NXSIGNAL® device|"Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®.~The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire.~The directional electrode will be placed in the cervical area at the superficial level between C6 and C7."
75899632|NCT05663957|Drug|Evusheld|EVUSHELD users
75605405|NCT02888990|Drug|Dasatinib|
75750093|NCT05714696|Behavioral|Weight discrimination experience|"In the experimental condition, participants will learn that their group members are biased against overweight people but not elderly or racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive negative feedback about their personal attributes by being labeled with negative weight-based stereotypes. Although some ratings will be positive (e.g., they will receive high ratings on being friendly and kind), participants will be rated poorly on attributes viewed as necessary to develop a strong marketing campaign (i.e., motivation to work hard, possessing self-discipline to persist at the task, and competence). After (ostensibly) assembling the group's preferences, the experimenter will inform participants that no one selected them to be their partner, thus they will perform the next few tasks alone. This manipulation has been shown to prompt feelings of social exclusion."
75750094|NCT05714696|Behavioral|Control experience|"In the control condition, participants will learn that their group members have positive attitudes toward people with higher body weight, as well as elderly and racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive positive feedback about their personal attributes, as indicated by the summary ratings averaged across the three members. Finally, participants in the control condition will be told that one of their group members had to leave unexpectedly for a family emergency, so pairs cannot be assembled as usual, thus they will perform the next few tasks alone. This manipulation should not prompt feelings of social exclusion."
75750095|NCT05705739|Procedure|retrolaminar block|curved probe will be placed 1-1.5 cm lateral to the target spinous process after identification of the lamina, the needle will be advanced caudally until it contacts the lamina
75899633|NCT05654181|Drug|PF-07328948|investigational drug administered orally
76072254|NCT02405169|Device|4 vs 6 implant treatment in the maxilla|
75454139|NCT04775914|Procedure|Stent with ultrasound|IVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.
75750096|NCT05705739|Procedure|ESPB|curved probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle.
75750097|NCT05701098|Device|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an ultrasound imaging system and a therapy probe driven by a high voltage generator. The probe will be placed on the patient's skin, the stone located via diagnostic ultrasound and up to 30 minutes of therapy will be delivered to the stone. The therapy probe accommodates coaxial alignment of an ultrasound imaging probe for treatment guidance.
75750098|NCT05688436|Drug|Diroximel Fumarate|Administered as specified in the treatment arm.
75750099|NCT05688436|Biological|Alemtuzumab|Administered as specified in the treatment arm.
75750100|NCT05688436|Drug|Fingolimod|Administered as specified in the treatment arm.
75750101|NCT05688436|Drug|Glatiramer acetate|Administered as specified in the treatment arm.
75899634|NCT05654181|Drug|Placebo|Placebo matching active drug administered orally
76072255|NCT02380092|Device|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
75605406|NCT05476016|Device|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs HbA1c
75605407|NCT05463302|Device|Active sleepgift blanket|Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.
75605408|NCT05463302|Device|Sham Sleepgift Blanket|Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.
75605409|NCT00624104|Dietary Supplement|Food (fat free meal)|Fat free meal (40% of REE)
75605410|NCT02889068|Other|Blood sample|
76066478|NCT05613985|Other|Usual Care alone|"Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) [If, during the study, PEDIS is < 2, the ulcer will be covered with nonadherent paraffin gauze].~Treatment 2 times a week (4 treatment weeks, 8 treatments)."
75899635|NCT05640557|Other|Physical Exercises|An original, noninvasive exercise program
75899636|NCT05638360|Drug|Ru Yi Jin Huang Powder|Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
75899637|NCT05638360|Drug|Placebo|Each patch contains 13g starch and 10c.c. water.
75750102|NCT05688436|Biological|Interferon beta|Administered as specified in the treatment arm.
75899638|NCT05634278|Behavioral|Preoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
76066479|NCT05613985|Device|System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|"System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®)."
76066480|NCT05613517|Other|Eye examination|"orthoptic assessment (visual acuity, refraction, stereopsis test, Cover-test, evaluation of the disparity of fixation and ocular dominance, measurement of the inter-pupillary distance~ocular biometry~corneal topography~monocular photographs in photopic condition"
76066481|NCT05609110|Device|Remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
76066482|NCT05609110|Device|Sham remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
75454140|NCT04757519|Behavioral|DPP-GLB Standard|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.
75750103|NCT05688436|Biological|Natalizumab|Administered as specified in the treatment arm.
75899639|NCT05634278|Behavioral|Postoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
76066483|NCT05598723|Drug|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
75899640|NCT05634278|Behavioral|Mind wandering|"A timed, seven-minute mind wandering period during which participants are instructed: For the next 7 minutes, allow your mind to wander."
75605411|NCT05273450|Behavioral|Quitline Information with Reinforcement|The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
75605412|NCT05252078|Drug|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
75750104|NCT05688436|Biological|Ocrelizumab|Administered as specified in the treatment arm.
76066484|NCT05598723|Drug|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
76066485|NCT05595382|Behavioral|Emotional Appeal|Participants will be presented with a short vignette about a child undergoing cancer treatment and needing a bone marrow transplant in order to survive cancer.
75899644|NCT05608837|Drug|OCS-01|One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
75899645|NCT05607680|Drug|Placebo|Placebo administered subcutaneously (SC) once a week.
75605413|NCT05252078|Drug|TQB2450|TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
75750105|NCT05688436|Biological|Ofatumumab|Administered as specified in the treatment arm.
75899646|NCT05607680|Drug|IBI362|IBI362 administered subcutaneously (SC) once a week.
75899647|NCT05593887|Procedure|Hip reconstruction surgery.|This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction, pelvic osteotomy and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur, internal fixation
75750106|NCT05688436|Drug|Ozanimod|Administered as specified in the treatment arm.
75750107|NCT05688436|Biological|Peginterferon beta-1a|Administered as specified in the treatment arm.
75750108|NCT05688436|Drug|Ponesimod|Administered as specified in the treatment arm.
75750109|NCT05688436|Drug|Siponimod|Administered as specified in the treatment arm.
75750110|NCT05685758|Other|FTP-based therapeutic mobile-app|Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
75750111|NCT05679622|Other|Fecal Microbiota Transplantation|In the induction stage of UC, FMT group received FMT and PEN intervention, and FMT group are given for at least one course of FMT treatment. If repeated FMTs are received, it is usually at a 2 month interval. All the participants received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention to help induce and maintain clinical remission.
75750112|NCT05676450|Diagnostic Test|cell-free DNA|Given by IV (vein)
75899648|NCT05593887|Procedure|Proximal femoral resection|Resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur
75899649|NCT05593887|Procedure|Proximal femoral valgus ostetomy|The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate
75454141|NCT04757519|Behavioral|DPP-GLB Enhanced|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.
75454142|NCT04755725|Device|Epidural catheter|epidural catheter inserted pre induction
75454143|NCT04755725|Device|rectus sheath catheter|The surgeon will place one hand inside the abdomen and with the other hand inserted the Tuohy needle through the skin and fascia. The surgeon will feel when the needle tip is just superfacial to interface between the peritoneum and muscle layer and avoid penetration of inferior epigastric artery. The procedure will be repeated on the contralateral
75605414|NCT05118386|Drug|RSM01|"Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 ≥ 300 mg - ≤ 600 mg IM"
75605415|NCT05118386|Other|Placebo|"Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM"
75605416|NCT05101928|Drug|Ozurdex 0.7mg Ophthalmic Implant|A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
75605417|NCT05101928|Drug|Prednisone|The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
75605418|NCT05069714|Drug|MTX-hold|Temporary discontinuation of methotrexate for 1 or 2 weeks
75750113|NCT05667012|Other|Educational videos|There will be a total of 6 videos, each of these videos will last between 8 and 10 minutes and will be accessed through a YouTube link to a private channel.
75750114|NCT05658575|Drug|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
75899650|NCT05580913|Behavioral|Resistance training|12 weeks of resistance-training performed two times per week
75899651|NCT05570435|Biological|Blood collection|Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
75899652|NCT05560685|Other|Outcomes4Me|Patient participants will use the outcomes4Me app to answer PROs over the first 12 weeks of endocrine therapy.
75899653|NCT05560685|Other|Semi-structured interview|Team member participants will complete a semi-structured interview.
75899654|NCT05542498|Behavioral|Mindfulness|Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.
75605419|NCT05048966|Behavioral|Group Wellness Class 1|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
75605420|NCT05048966|Behavioral|Group Wellness Class 2|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
75899655|NCT05542498|Behavioral|Relaxation|Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
75899656|NCT05532735|Biological|ANXV|ANXV (Human recombinant Annexin A5 protein)
75899657|NCT05505305|Behavioral|Time-restricted eating and high-intensity interval training|Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at > 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
75899658|NCT05498454|Behavioral|Breathworks Mindfulness (Health or Stress Arm)|As for previous descriptions
76066486|NCT05595382|Behavioral|Rational Appeal|Participants will be presented with data regarding the importance of considering race/ethnicity when looking for a bone marrow transplant donor and the likelihood of finding a match based on the patient's racial/ethnic background.
75605421|NCT04207034|Procedure|flap surgery with diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
75605422|NCT04207034|Procedure|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
75605423|NCT02888912|Other|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
75750115|NCT05658575|Other|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
75899659|NCT05497687|Other|Resistance exercise|The training schedule for supervised sessions (including community-based and home-based) will last for 60 minutes per session, two sessions per week. From Week 3 and 4, the exercise specialist will deliver supervised home-based training, with one in-person session via home visits and one session to be delivered remotely via an online platform (Zoom). Then the supervision will gradually tail off from Week 5 and onwards, from online supervised sessions, to unsupervised self-practice sessions. An in-person supervised home visit as a booster session will be given at Week 9, the beginning of the habituation phase. Telephone follow-ups will be arranged at Week 10 - 12 by the exercise specialist. All participants in the intervention group will be invited to take part in a qualitative interview to explore the feasibility and acceptability of the intervention.
75899660|NCT05490862|Behavioral|Lifestyle Modification|"An individualized low-calorie diet is characterized by sugars and starchy food intake restriction, 500 kcal daily energy deficit for 12 weeks (3 months).~Regular physical activity is represented by individualized 30 minutes trainings on an anti-gravity treadmill 3 workouts per week for 12 weeks with individual targets of stepping activity, which will be evaluated according to personal fitness monitoring data"
75899661|NCT05490862|Behavioral|Traditional Recommendations|The list of traditional diet and physical activity recommendations for patients with obesity
75899662|NCT05489887|Drug|Naxitamab|Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
75899663|NCT05489887|Drug|Ceritinib|Ceritinib is an inhibitor that selectively targets the ALK tyrosine kinase
75899664|NCT05487027|Behavioral|Goldilocks work principle|"Using the Goldilocks work principle we have tried to find the just right distribution of physical strain in the home care sector. This is an intervention to test if it possible to distribute the physical strain experienced in the home care sector in a way that may be more health promoting for the workers."
76066487|NCT05592158|Procedure|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.
76066488|NCT05591859|Device|Restoration Anatomic Acetabular Shell|Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
75454144|NCT04733547|Procedure|Placement of a central venous catheter|The right internal jugular vein is located at the first rib level under ultrasound-guidance. Using an out-of-plane technique, a needle is introduced into the lumen of the vessel. The aspiration of blood into the syringe connected to the hub of the needle confirms the placement of the needle tip in the lumen. After the syringe is detached from the needle, a guidewire is advanced into the vessel lumen through the needle. A dilator is introduced over the guidewire and subsequently is removed. Then, a central venous catheter is introduced over the guidewire into the vessel lumen through the pathway expanded by the dilator. The catheter tip is placed in the superior vena cava by inserting the catheter as far as the distance between the edge of the right transverse process of the first thoracic vertebra and the carina, which is preoperatively measured on a posteroanterior chest radiograph.
75750116|NCT05650606|Other|High Intensity Gait Training|Physical therapy intervention for improving gait in patients post Cerebral Vascular Accident.
75750117|NCT05650606|Other|Conventional Therapy|Standard inpatient rehabilitation physical therapy treatments for Cerebral Vascular Accident.
75454145|NCT04733547|Device|Monitoring of central venous pressure|Following the placement of a central venous catheter, a fluid-filled system for monitoring central venous pressure is connected to the proximal lumen of the catheter. The reference transducer is placed at the level of 4/5 of the anteroposterior diameter of the thorax.
75750118|NCT05637515|Biological|Humira 40 MG in Prefilled Syringe|Humira (40 mg every other week)
75605424|NCT02888912|Other|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
75899665|NCT05480904|Other|Neurocognitive (Thinking) Testing|"Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min."
75750119|NCT05637515|Biological|Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe|"• Subjects will receive Humira (initial dose of 80 mg [2 × 40 mg]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~Humira (40 mg every other week) at Week 16 and Week 18, and~Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
75750120|NCT05635162|Drug|Zanubrutinib|Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
75899666|NCT05480904|Diagnostic Test|CNS Vital Signs (Thinking) Testing|Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins
75899667|NCT05480904|Other|Health Questionnaires, Sleep Surveys & Sleep Diary|The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.
75454146|NCT04733547|Drug|Furosemide-induced hypovolemia before graft procurement|Patients fast from 10 pm the day before surgery. On the arrival at the operating room, an intravenous catheter for Plasmalyte infusion is placed into the right cephalic or basilic vein. The distal lumen of the central venous catheter is used for the infusion of 6% hydroxyethyl starch. Fluid requirements due to anesthesia, surgery, and no per os intake are not replaced by minimizing the administration of the fluids. Five minutes after the collection of the baseline data, 20 mg of furosemide is administered to promote diuresis for facilitating the venous outflow of the liver. An additional dose of furosemide 20 mg is given if the urine output is <1 ml/kg within 30 minutes after the first dose. Unless the second dose of furosemide produces >1 ml/kg of urine within 30 minutes, 40 mg of furosemide is administered. In the absence of effective diuresis (1 ml/kg within 30 minutes after each dose), the use of furosemide is abandoned and the patients are excluded from the study.
76072256|NCT02338518|Drug|oxaliplatin|"oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.~Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group."
75750121|NCT05635162|Drug|Rituximab|Rituximab 375 mg/m2 intravenous (IV)* on day 1 (+/-3 days) of each 28-day cycle
75454147|NCT04733547|Drug|Replacement of fluid loss after graft procurement|Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
75605425|NCT04320524|Device|Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention|3 weeks
75605426|NCT04795700|Behavioral|MSC intervention|Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
75605427|NCT04685720|Device|LungFit|LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
75899668|NCT05480904|Diagnostic Test|Echocardiography/EKG|All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography
76072257|NCT02338518|Drug|etoposide|etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
75899669|NCT05480904|Diagnostic Test|Pulmonary Function|PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).
75899670|NCT05480904|Device|Remote Polysomnography|The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.
75899671|NCT05480904|Diagnostic Test|Physical Function|This is a test of how your heart and lungs respond to exercise.
75605428|NCT04678544|Device|Scalp cooling system 2|The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.
75605429|NCT04654052|Drug|Clopidogrel|Clopidogrel during 11 months
75750122|NCT05620264|Diagnostic Test|Tear Sample Probe|Samples will be collected by conjunctival lavage of the affected eye without topical anesthesia. Sterile normal saline will be infused at room temperature into the lower conjunctival sac by gently pulling down the lower eyelid and with a needle-free insulin syringe. After few seconds, the lavage fluid will be aspirated back into the same syringe without the syringe touching the conjunctiva.
75454148|NCT04733547|Device|Monitoring of stroke volume variation|Following anesthesia induction, the right radial artery is catheterized. The catheter is connected to the EV1000 monitor (Edwards Lifesciences, Irvine, CA) through the FloTrac transducer (Edwards Lifesciences). The transducer is level with the one for central venous pressure monitoring. Using pulse contour analysis without external calibration, the stroke volume for each heartbeat is measured. At a 20-second interval, stroke volume variation is calculated as (maximum stroke volume - minimum stroke volume)/mean stroke volume.
75605430|NCT04654052|Drug|Previous treatment|non-intervention
75605431|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
75750123|NCT05614544|Drug|HSK3486|HSK3486 for induction of general anesthesia
75750124|NCT05614544|Drug|Propofol|Propofol for induction of general anesthesia
75750125|NCT05614544|Drug|Placebo|Intralipid
75750126|NCT05604443|Other|retrospective analyze|retrospective analyze of MS39 and Pentacam images
76072258|NCT02338518|Drug|pharmorubicin|pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
75454149|NCT04725604|Device|pH probe|"Patients who agree to take part will have a pH probe inserted into their injured limb. The pH probe will be attached to a pH monitor which will record pH data for up to a maximum of 72 hours (24 hours per probe). The surgical team will not have access to the pH data. During the time they are considered at risk for ACS, patients will be monitored in the routine way (using regular clinical assessment and pressure monitoring). If ACS is diagnosed in the routine way, then treatment (fasciotomy) will be offered as appropriate."
75605432|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
75750127|NCT05547412|Device|NovaGuide 2 Intelligent Ultrasound System|The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.
75750128|NCT05533372|Drug|IA-14069|IA-14069 for oral administration.
75750129|NCT05533372|Drug|Placebo|Placebo for oral administration.
75750130|NCT05533372|Drug|Methotrexate|Methotrexate for oral administration.
76072259|NCT02338518|Drug|S-1|80~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
75750131|NCT05527938|Other|web-based intervention|"Establishing management teams.~Establishment of a nursing intervention team.~Daily uploading of health intervention records~Regularly delivering related health knowledge.~Home visiting~Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing."
75454150|NCT04725071|Dietary Supplement|Impact Advanced Recovery|L-arginine and omega-3 rich supplement
75454151|NCT04725071|Dietary Supplement|Boost High Protein|conventional supplement
76066489|NCT05589194|Behavioral|Nursing Practices Based on Kolcaba's Comfort Theory|Nursing interventions planned to be carried out within the scope of the research will be based on Comfort Theory. Nursing interventions will be planned according to the needs in the physical comfort (diet practice, providing effective and correct pelvic floor muscle contraction, repetitive and regular yoga practice training), psychospiritual comfort (appreciation and encouragement, self-confidence, expressing the feeling of embarrassment, expressing fear, confidence, repetitive and regular practice of yoga practice, meditation), sociocultural comfort (to be informed, to develop effective interpersonal communication, to interact with other women with SUI) and environmental comfort (Informing about making the necessary arrangements to prevent possible situations such as sleep disruption and falling, bad smell, etc. and performing nursing practices by respecting privacy). The yoga practice will carry out with the participation of 60-minute group yoga classes twice a week for 6 weeks.
76066490|NCT05577403|Behavioral|Mulligan's mobilization with movement MWM added isometric strength training|"Mulligan's mobilization with movement added isometric exercise:~the participants in the experimental group will receive a Mulligan's mobilization with movement added isometric exercise.~Treatment will be given for the period of three weeks, for five days a week in both groups.~Data will be collected before intervention and after 2nd & 4th week of intervention."
75899672|NCT05466136|Behavioral|Mental fatigue condition|In mental fatigue condition, the mental fatigue manipulation will use a modified Stroop task with complete incongruent trials, which is wildly used to induce a mentally fatigued state in previous studies. The Stroop task included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), the color of the word will paint inconsistent with the semantic meaning of the word (e.g., red word printed in green). The task consisted of five 6-minute blocks and 1080 incongruent trials for each block. The total duration will be 30-min.
75605433|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
75899673|NCT05466136|Behavioral|Control condition|Similar to mental fatigue conditions, the modified Stroop task with complete congruent trials will be used, The Stroop task also included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), but the color of the word will paint consistent with the semantic meaning of the word (e.g., red word printed in red) in order to set up the match condition of relative less cognitive demanding for participants. Same with the mental fatigue condition, the task consisted of five 6-minute blocks and 1080 congruent trials for each block. The total duration will be 30-min.
76066491|NCT05577000|Biological|Manufactured Anti-BCMA CAR-T cells|Given IV
76066492|NCT05577000|Drug|Fludarabine|Given IV
76066493|NCT05577000|Drug|Cyclophosphamide|Given IV
76066494|NCT05572554|Other|Foot Bath Group|The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks.
75454152|NCT04723056|Device|Use of Zemedy Application|8 weeks of CBT via the Zemedy Application.
75454153|NCT04711005|Drug|(2R,6R)-Hydroxynorketamine hydrochloride|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.
75454154|NCT04711005|Drug|Placebo|Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
75454155|NCT04696406|Device|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
75454156|NCT04659954|Other|Application O'DIDE|The intervention is the use of an application that aimed to favorize contact between the patient and the care team between the consultations.
75454157|NCT04646733|Other|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.
75899674|NCT05453019|Device|Cochlear Implant|The surgeon will make a small cut (incision) behind patient's ear, and form a small hole in the portion of skull bone (mastoid) where the internal device rests. Then the surgeon create a small opening in the cochlea in order to thread the electrode of the internal cochlear implant device. The skin incision is stitched closed so that the internal device is under the skin.
75899675|NCT05446727|Drug|Ropivacaine injection|30ml of 0.375% ropivacaine
75899676|NCT05444114|Behavioral|Mental Exercise|Participants perform a 10 minute mental exercise
75750132|NCT05525507|Combination Product|Conditioning and Stem cell infusion|Patients will undergo a conditioning with TLI and ATG, followed by infusion of hematopoietic stem cells from the same HLA-identical donor that provided the original kidney
75605434|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
75605435|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
75750133|NCT05525078|Behavioral|e-cigarette|Participants will select a Target Switch on which they will stop smoking cigarettes and switch entirely to the e-cigarette product.
75750134|NCT05525078|Other|Nicotine patch, Nicotine lozenge|Participants will select a Target Quit Date on which they will stop smoking, using the patches and lozenges provided.
75750135|NCT05521854|Behavioral|DynamiCare app (app-based contingency management)|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
75750136|NCT05521854|Behavioral|Sham control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
75750137|NCT05519007|Other|No-Rinse Solution (NS)|The surgical site will be irrigated with NS prior to closure,
75750138|NCT05519007|Other|Saline irrigation|The surgical site will be irrigated with Saline
75750139|NCT05498038|Behavioral|Aerobic Exercise|Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
75750140|NCT05493657|Drug|Aspirin single antiplatelet therapy|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
75750141|NCT05493657|Drug|Clopidogrel single antiplatelet therapy|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
75750142|NCT05489575|Device|Active CPAP|Continuous positive airway pressure (CPAP) is applied at 8, 10, or 12 cm H20. The active CPAP level will be determined during a CPAP titration trial
75750143|NCT05489575|Device|Sham CPAP|Sham continuous positive airway pressure applied at <4 cm H2O
75750144|NCT05489575|Other|Sleeping in a head-up tilt (HUT) position|Sleeping with the whole bed tilted head-up by 10 degrees or with the head elevated by 13-14 inches.
75454158|NCT04646733|Other|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
75454159|NCT04636710|Procedure|Lymphoscintigraphy|An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
75750146|NCT05477602|Procedure|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients undergoing cardiac ablation for the treatment of persistent atrial fibrillation
75750147|NCT05476094|Drug|Polyene Phosphatidylcholine|AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
75750151|NCT05466916|Behavioral|Exercise and diet education and instruction|1:1 or small group sessions consisting of educational materials and exercise instruction.
75750152|NCT05444790|Diagnostic Test|Rapid Diagnostic Test|The performance of two index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
75899679|NCT05425511|Behavioral|sophrology / neurolinguistic programming intervention|"2 sessions will be offered per week at 2 different time and will last 1 hour. They can take place in a seated or standing position, without physical contact. The sessions will consist of breathing exercises, visualization, dynamic relaxation and concentration exercises. The program is standardized:~Dialogue between the sophrologist and the participants. It is possible to specify the objective(s) of the session. The sophrologist can ask more specific questions to adapt the session.~Presentation of the conduct of the session (possible variations) and instructions promoting autonomy~Guided by the sophrologist, the goal is to help free yourself from tensions, to play down a situation that worries and finally to realize that we can deal with. Exercises are adapted to the difficulties encountered by the participants.~Time for free expression after the practice to promote the integration of the technique while giving elements to the sophrologist to guide the future sessions."
75899680|NCT05418764|Other|Miyamodel Training|standardized training by performing five hysterectomies on the Miyamodel with a trainer who is a sub-PI at each institution
75454160|NCT04635228|Device|Biodesign Otologic Repair Graft|The Biodesign Otologic Repair Graft is intended for use as grafting material for tympanic membrane perforation closure.
75454161|NCT04632992|Drug|Entrectinib|Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
75454162|NCT04632992|Drug|Inavolisib|Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
75605436|NCT01117623|Drug|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
75899681|NCT05404139|Drug|Enzalutamide|Second-generation androgen pathway inhibitor (ARAT), oral tablet
75605437|NCT01117623|Drug|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
75899682|NCT05404139|Other|Standard of Care SBRT and ADT|Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
75899683|NCT05398315|Behavioral|Empathic Statements/Reflections|Presence of Empathic Statements
75899684|NCT05398315|Behavioral|Narrator Backstory|Presence of a narrator backstory
75454163|NCT04632992|Drug|Alectinib|Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
75750153|NCT05440058|Device|Bispectral Index (BIS) monitoring system|Left and right sensors to record EEG activity and muscle reaction to anesthesia utilized in the operating room by anesthesia providers to assess the depth of sedation in patients with anesthesia.
75750154|NCT05439902|Drug|Tamsulosin|One 0.4mg Tamsulosin capsule taken per day for 30 days
75750155|NCT05439902|Drug|Placebo|one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose
75899685|NCT05398315|Behavioral|Male Narrator|Presence of a male narrator
75899686|NCT05398315|Behavioral|Female Narrator|Presence of a female narrator
75454164|NCT04632992|Drug|Ipatasertib|Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
75454165|NCT04632992|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
75454166|NCT04632992|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
75454167|NCT04632992|Drug|Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
75899687|NCT05398315|Behavioral|MI Techniques|Presence of MI techniques
75899688|NCT05386992|Diagnostic Test|Anthropometric study|Once the 5 models of lasts have been produced in phase 1, certain shoe models will be designed and manufactured based on these lasts at random and at the free choice of the designers of a footwear company. These models will then be physically tested on children to analyze their effects on walking and walking.
75454168|NCT04632992|Drug|Tucatinib|Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
75454169|NCT04632992|Drug|Investigator's Choice of Chemotherapy|Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
75454170|NCT04632992|Drug|Paclitaxel|The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
75899689|NCT05376059|Behavioral|How Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.
75605438|NCT01117623|Drug|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
75605439|NCT05625308|Dietary Supplement|Epigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid|One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
75605440|NCT02888834|Other|Adverse drug reaction|
75605441|NCT04291664|Drug|Abiraterone Acetate|Abiraterone Acetate 1000mg will be administered orally once daily
75750156|NCT05439148|Drug|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
75750157|NCT05424757|Drug|PEG 3350|"Data and biospecimens will be collected from two groups of children:~Children who have taken PEG 3350 daily for at least 30 days.~Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study."
75605442|NCT04291664|Drug|Prednisone 5Mg Tab|"Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped"
75750158|NCT05422599|Dietary Supplement|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
75750159|NCT05422599|Dietary Supplement|Placebo|300mg Maltodextrin capsules
75750160|NCT05419427|Drug|Denosumab|Denosumab 60 MG/ML
75750161|NCT05419427|Drug|Denosumab-Ref|Denosumab 60 MG/ML
75605443|NCT04291664|Drug|DST-2970 (Abiraterone)|DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped
75605444|NCT04310553|Procedure|Irreversible electroporation|Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology will receive nano knife treatment if the target lesion is not suitable for surgical resection or the target lesion is suitable for surgical resection but patients give up surgery and choose nano knife combined with chemotherapy. Patients who have not previously received first-line chemotherapy will receive systemic chemotherapy for 4-6 cycles of treatment. Imaging evaluation will be performed every 6-8 weeks (± 7 days) during chemotherapy.
75750162|NCT05414305|Drug|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
75454171|NCT04632992|Drug|Tiragolumab|Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
75454172|NCT04632992|Drug|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
75750163|NCT05412290|Drug|Mosunetuzumab|"Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following."
75605447|NCT04187469|Drug|Moxifloxacin, Isoniazid, Rifampicin|"Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day > 50 kg 600 mg/day, Isoniazid 300 mg/day.~All treatment is taken daily, for a duration of up to 6 months depending on treatment arm."
75605448|NCT04187469|Drug|Rifampicin,Isoniazid,Pyrazinamide,Ethambutol|"Rifampicin ≤50 kg 450 mg/day, >50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, >50 kg 1000mg/day.~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
75605449|NCT04320212|Procedure|lumber epidural analgesia|the lumber epidural analgesia will be given after induction of general anesthesia.
75605450|NCT04320212|Procedure|erector spinae analgesia|the erector spinae analgesia will be given after induction of general anesthesia.
75605451|NCT01116687|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
75750164|NCT05384834|Behavioral|#HerHeart tool|An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
75899690|NCT05376059|Behavioral|How and Why Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.
75899691|NCT05376059|Behavioral|Incentive|Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
75899692|NCT05354102|Drug|BMC128|A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.
75750165|NCT05362929|Device|Sciton Halo|Laser treatment
75750166|NCT05358444|Behavioral|National Diabetes Prevention Program Lifestyle Intervention (DPP)|"The National Diabetes Prevention Program lifestyle intervention (DPP) is a 12-month long, group-based lifestyle intervention for adults at high-risk for type 2 diabetes. The DPP will be delivered by certified coaches from the Johns Hopkins Brancati Center. The program uses the CDC's Prevent T2 curriculum, with a total of 32-34 sessions delivered over a 12-month period. In the initial core period (first 6 months), there are at least 16 sessions delivered on a weekly basis. In the post-core period, additional (at least 6) sessions are offered over a 6 month period. Sessions are delivered either in-person or via a virtual synchronous platform (Zoom)."
75769435|NCT01257022|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
75899693|NCT05354102|Drug|Nivolumab|A human monoclonal antibody that blocks programmed-death-1 (PD-1). It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
75769436|NCT03902782|Procedure|ESP block|"ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline"
75454179|NCT04622319|Drug|DS-8201a|Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
75454180|NCT04622319|Drug|T-DM1|Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
75463273|NCT05854888|Procedure|Control Group (Hands-on)|"The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum."
75605452|NCT01116687|Other|laboratory biomarker analysis|Correlative studies
75605453|NCT04139486|Procedure|combined EMBOTRAP II or III and Contact Aspiration|refer to title
75769437|NCT03902782|Procedure|Intercostal block|"Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline"
75769438|NCT03902782|Procedure|Sham ESP block|As described earlier
75769439|NCT03902782|Procedure|Sham Intercostal block|As described earlier
75769440|NCT03902782|Drug|Bupivacaine-epinephrine|As described earlier
75899694|NCT05349890|Biological|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
75899695|NCT05349890|Drug|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
75899696|NCT05349890|Drug|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
75899697|NCT05335239|Other|Professional dental cleaning|The dental nurse will visit at home and delivers professional dental cleaning, a reminder to use the fluoridated toothpaste (> 4000 ppm ) and oral hygiene instruction to participants accompanied by home care aides, with manual toothbrush, fluoridated toothpaste (> 4000 ppm) and relevant interproximal aids.
75899698|NCT05313269|Other|ISAFE technique for adductor canal catheter insertion|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
75605454|NCT04139486|Procedure|Contact Aspiration alone|refer to title
75605455|NCT00625599|Other|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
75605456|NCT02867020|Drug|Apalutamide|APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
75605457|NCT02867020|Drug|Abiraterone|Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
75899699|NCT05313269|Other|Conventional technique for adductor canal catheter insertion|Adductor canal block catheter tip located lateral to the femoral artery.
75899700|NCT05310396|Other|Experimental formula|Cow's milk-based infant formula with a specific blend of nutrients at pre-defined levels
75899701|NCT05310396|Other|Control Formula|Cow's milk-based infant formula with standard nutritional composition
75899702|NCT05307055|Device|STN DBS - Theta Burst|200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device
75899703|NCT05307055|Device|STN DBS - Gamma|Standard of care gamma stimulation with an existing device
75899704|NCT05301517|Drug|SEPO®|SEPO® will be administered per dose and schedule specified in the arm description.
75899705|NCT05301517|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
75899706|NCT05296304|Drug|Bexarotene|Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.
75899707|NCT05296304|Radiation|Total Skin Electron Beam (TSEB)|At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).
75769441|NCT03902782|Drug|Dexamethasone injection|As described earlier
75769442|NCT03902782|Drug|Normal saline|As described earlier
75769443|NCT01150942|Biological|JE vaccine|3 times, IM
75769444|NCT03899740|Other|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
75750167|NCT05358444|Behavioral|Family Diabetes Prevention Program (Family DPP)|The Family DPP has been developed as an augmented version of the National Diabetes Prevention Program Lifestyle Intervention (DPP). It includes all elements of the 12-month, group-based DPP lifestyle intervention, led by a CDC certified-coach using a CDC-approved curriculum (involving around 32-34 sessions). The augmentations of the Family DPP supplement the DPP's sessions to additionally address barriers to adults' own lifestyle change efforts related to being a caregiver of children AND to introduce basic concepts regarding healthy child habits related to dietary intake, physical activity and screen time, and sleep. The Family DPP will involve thus additional sessions that will be delivered to the adult DPP participant, and in which children, ages 5 through 12, may also be engaged.
75750168|NCT05356897|Biological|Trastuzumab|Given IV
75750169|NCT05356897|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
75750170|NCT05356897|Drug|Tucatinib|Given PO
75750171|NCT05346757|Diagnostic Test|miRFec test|The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression
75750172|NCT05345847|Other|Active Surveillance|Close monitoring of liver enzymes with steroid rescue strategy (watch and wait approach)
75750173|NCT05345847|Other|Early initiation|Immediate start of high-dose steroids
75750174|NCT05345041|Behavioral|Keep it Movin'|Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.
75769445|NCT03899740|Other|Ranking - Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
75899708|NCT05280301|Device|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
75899709|NCT05274763|Other|Quality-of-Life Assessment|Ancillary studies
75463274|NCT05854875|Procedure|Laparoscopic Roux en Y gastric bypass|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb.
75463275|NCT05854875|Procedure|Laparoscopic Roux en Y gastric bypass with fundus resection|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb. Fundus resection is further applied in this arm.
75605458|NCT02867020|Drug|ADT|Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
75605459|NCT02867020|Drug|Prednisone|Subjects will receive prednisone 10mg/day.
75899710|NCT05274763|Other|Questionnaire Administration|Ancillary studies
75769446|NCT03899740|Other|Ranking - Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
75899711|NCT05274763|Procedure|Spiritual Therapy|Deliver or undergo CCSH session
75899712|NCT05272280|Other|External oblique intercostal (EOI) block|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
75463276|NCT05854849|Drug|Camrelizumab|200mg, D1, Q3W, iv drip.
75463277|NCT05854849|Drug|Gemcitabine|1000mg/m2, Day 1 and Day 8, Q3W, iv drip, maximum 6 cycles.
75463278|NCT05854849|Drug|Cisplatin|80 mg/m2, D1, Q3W, iv drip, maximum 6 cycles.
75463279|NCT05854849|Drug|Apatinib|250mg, PO, QD
75463280|NCT05854823|Radiation|dose-reduced radiotherapy|Patients receive 50Gy/25F, 2Gy/F QD, five days a week for 5 weeks
75605460|NCT05067855|Other|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
75605461|NCT04320056|Other|Standard administration of oxygen flow|"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode"
75750175|NCT05345041|Behavioral|Go 4 Life Self Guided Education|Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
75605462|NCT04320056|Device|Automated oxygen administration - FreeO2|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
75605463|NCT03834272|Combination Product|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device.
75750176|NCT05337930|Device|Happyr App|"The Happyr app offers three main areas:~(A) A mood diary in which a user can keep track of emotional wellbeing by answering three short questions.~(B) A pain diary in which a user and supporter can record headache attacks by answering a set of predefined questions whenever a user experiences or has experienced a headache attack.~(C) An overview section in which entries from the mood and pain diary are visualized for the user. In this section, a PDF document can also be exported with a summary of data from the symptom diary that can be taken to the clinician.~A standardized notification is sent to each user at 6pm local time to remind them about logging their mood and symptoms of a headache attack."
75750177|NCT05329935|Biological|Cultured Thymus Tissue|Product will be surgically administered into the quadriceps
75899713|NCT05272280|Other|Erector spinae plane block (ESPB)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of Local Anesthetic mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
75899714|NCT05271448|Other|Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan )|Randomized to continue on prescribed ACE1 or ARBs ( Enalapril 5, 10, 20 mg // Ramipril 2.5 , 5 mg // Valsartan 80 , 160 mg // Candesartan 8, 16 mg // Losartan 50 mg )
75899715|NCT05271448|Other|Hold ACEI or ARBs|"Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-72 hours post-catheterization (after creatinine measurement)~Other Name: Includes all ACEI inhibitors or ARBs"
75899716|NCT05268367|Behavioral|Written Exposure Therapy|A brief exposure-based psychotherapy for posttraumatic stress disorder
75899717|NCT05254405|Drug|Brexanolone Injection [Zulresso]|Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
75454181|NCT04622150|Behavioral|Customized Adherence Enhancement (CAE)|CAE is comprised of a series of up to four treatment modules whose inclusion is determined based upon an individuals reasons for nonadherence (adherence barriers).The standardized modules are Psychoeducation, Modified Motivational Interviewing, Communication with Providers, Medication Routines. CAE participants will have a core series of approximately four sessions spaced about one week apart over a period of 4-6 weeks, and one booster in-person session 4 weeks after the completion of the four core sessions (total of approximately 5 sessions). Sessions 2-4 will be delivered remotely by the study interventionist. All participants will have the first session in-person. The final booster session will be conducted at the sites and will review all previously introduced materials. There will be a follow-up phone call with the study interventionist that will occur in the four-week time period between completion of four CAE core sessions and prior to initiation of the booster CAE session.
75463281|NCT05854810|Procedure|fertilized embryo Insertion|insertion of single fertilized embryo through IVF
75463282|NCT05854810|Procedure|fertilized embryo Insertion|insertion of double fertilized embryo through IVF
75605464|NCT03817502|Drug|Cariprazine|Cariprazine capsules, oral administration, once daily.
75605465|NCT03817502|Drug|Placebo|Matching placebo capsules, oral administration, once daily.
75605468|NCT04319978|Drug|Dexamethasone injection|Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.
75750178|NCT05320887|Other|Normal Nicotine Content Vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
75750179|NCT05320887|Other|Normal nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
75750180|NCT05320887|Other|Low nicotine content vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
75750181|NCT05320887|Other|Low nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
75750182|NCT05312177|Other|Stanford Binet Intelligence Scales, Fifth Edition|The SB-5 is a comprehensive measure of cognitive and intellectual functioning for individuals from age two through 85 years of age. The SB-5 individually assess a child's functioning in five areas of cognitive functioning: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual Spatial, and Working Memory. The SB-5 is well established in the existing research literature as an assessment tool to evaluate developmental and intellectual abilities in children with ND disorders.
75750183|NCT05312177|Other|Vineland Adaptive Behavior Scales Third Edition|The VABS-3 are a parent report, interview style measure of adaptive behavior for individuals ages birth through 90 months. The VABS-3 assesses adaptive behavior in four broad domains of Communication, Daily Living Skills, Socialization, and Motor Skills, and includes a Maladaptive Behavior Domain that assesses problem behaviors.
75899718|NCT05252338|Biological|CVSQIV|Participants will receive an intramuscular injection by needle in the deltoid area.
75750184|NCT05312177|Other|Peabody Picture Vocabulary Test, Fifth Edition|The PPVT-5 is a norm-referenced language measure that evaluates single-word receptive vocabulary. The PPVT-5 provides standard scores for individuals ages 2.6 through 90 years.
75750185|NCT05312177|Other|Expressive Vocabulary Test, Third Edition|The EVT-3 is a norm-referenced language measure that evaluates single-word expressive vocabulary. The EVT-3 provides standard scores for individuals ages 2.6 through 90 years.
75750186|NCT05312177|Other|Leiter International Performance Scale, Third Edition|The Leiter-3 is a nonverbal measure of cognitive functioning and fluid reasoning skills in individuals ages 3 through 75 years. The Leiter-3 measures nonverbal IQ across four subscales, including Sequential Order (SO), Form Completion (FC), Classification and Analogies (CA), and Figure Ground (FG).
75750187|NCT05312177|Other|Social Communication Questionnaire, Current Form|The SCQ is a parent-report measure of social communication, social interactions, play, and behavior.
75750188|NCT05312177|Other|Aberrant Behavior Checklist|The ABC-2 is a parent report measure of problematic behavior at home and in the community. It measures behavior on five subscales (1) Irritability, (2) Social Withdrawal, (3) Stereotypic Behavior, (4) Hyperactivity/Noncompliance, and (5) Inappropriate Speech.
75750189|NCT05312177|Other|Repetitive Behavior Scale, Revised|The RBS-R is a parent report measure that comprehensively surveys for the presence of repetitive behaviors.
75454182|NCT04622150|Behavioral|Enhanced Treatment as Usual (eTAU)|eTAU participants will receive monthly text messages (or phone calls for participants who prefer not to receive texts) to refill medications, fill eCAPs and brief general adherence promotion messages during the follow-up period.
75605469|NCT01114737|Drug|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
75605470|NCT01114737|Drug|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
75750190|NCT05311956|Device|Active tDCS|The study intervention will be participants self-applying 40 tDCS active stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
75899719|NCT05252208|Other|Stretching exercise|Stretching (30-45 minutes, 5 days per week, 6 months)
75605471|NCT00624182|Biological|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
75899720|NCT05252208|Other|Walking exercise|Walking (30-45 minutes, 5 days per week, 6 months)
75750191|NCT05311956|Device|Sham tDCS|In this arm of the study participants will self-apply 40 sham tDCS stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
75899721|NCT05215106|Drug|Durvalumab|Following preparation of durvalumab, the entire contents of the IV bag should be administered as an IV infusion over approximately 60 minutes (±5 minutes), using a 0.2μm in-line filter (or add-on filter).
75899722|NCT05212883|Behavioral|Behavioral questionaires|Behavioral surveys and questionnaires
75899723|NCT05206253|Dietary Supplement|Whole egg powder|Nutritional supplementation during a 12 week resistance training program
75899724|NCT05206253|Dietary Supplement|Whey protein powder|Nutritional supplementation during a 12 week resistance training program
75899725|NCT05206253|Dietary Supplement|Maltodextrin placebo|Nutritional supplementation during a 12 week resistance training program
75899726|NCT05198713|Device|New hearing aid|Participants will complete testing while using a novel hearing aid which has been fit to compensate for their hearing loss.
75899727|NCT05185843|Drug|Olezarsen|Olezarsen will be administered by SC injection.
75899728|NCT05177731|Drug|Venetoclax|Orally by mouth
75454183|NCT04621188|Drug|Lorlatinib|100 mg once daily
75454184|NCT04579653|Device|transcutaneous electrical nerve stimulation devices|electrical stimulation through surface electrodes
75454185|NCT04574895|Other|Hematology Review|VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
75899729|NCT05177731|Drug|Decitabine for Injection|Intravenous infusion
75899730|NCT05177731|Drug|Cytarabine|Intravenous infusion
75899731|NCT05177731|Drug|Idarubicin|Intravenous infusion
75899732|NCT05177731|Drug|Gilteritinib|Orally by mouth
75605472|NCT00624182|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
75750192|NCT05307783|Device|EmboCube Embolization Gelatin|EmboCube is a uniformly cut gelatin foam pre-loaded into a syringe, indicated for use in embolization of blood vessels to occlude blood flow to control bleeding/hemorrhaging in the peripheral vasculature
75750193|NCT05304962|Drug|RGT-419B|oral capsules
75750194|NCT05304962|Drug|RGT-419B in combination with hormonal therapy|RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
75750195|NCT05298371|Behavioral|Corrected Sitting postures|Change after being in Corrected Sitting postures
75750196|NCT05298371|Behavioral|Natural / relaxed sitting postures|Change after being in relaxed sitting postures
75750197|NCT05298371|Behavioral|Corrected Standing posture|Change after being in Corrected Standing posture
75750198|NCT05298371|Behavioral|Natural / relaxed standing postures|Change after being in relaxed standing postures
75750199|NCT05294016|Device|BRA CONNECT device|skin thermal analysis for the detection of breast abnormalities
75750200|NCT05292794|Device|CereGate Software; BSN cDBS Programmer; BSN Burst Programmer|"CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD:~(i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced cueing stimulation-to mitigate FOG.~The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System."
75750201|NCT05287464|Drug|pembrolizumab plus axitinib|collect global experiences with the use of immuno-combinations in patients with metastatic RCC
75750202|NCT05275907|Drug|Amlodipine Besylate|10 mg capsule once daily for 6 weeks
75750203|NCT05275907|Drug|Chlorthalidone|25mg capsule once daily for 6 weeks
75899733|NCT05153811|Behavioral|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
75899734|NCT05153811|Behavioral|mHealth|Participants will engage with an application designed to gamify drinking reduction.
75899735|NCT05153811|Behavioral|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
75454186|NCT04571814|Behavioral|Psycho-social, computerized intervention targeting error sensitivity|"A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes."
75605473|NCT04322474|Device|Catheter-based left atrial appendage occlusion|Catheter-based implantation of left atrial appendage occluder
75605474|NCT02881983|Other|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
75899736|NCT05139290|Behavioral|Prototype Intervention|The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
75605475|NCT05131269|Drug|Dextrose 15 % in Water|A 15% dextrose solution is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
75605476|NCT05131269|Drug|Normal Saline 20 mL Injection|A Normal Saline 0.9% is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
75605477|NCT03292874|Diagnostic Test|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
75605478|NCT00625677|Biological|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
75605479|NCT00625677|Biological|Menjugate (Meningococcal C conjugate vaccine)|Dosage
75605480|NCT03258008|Drug|Utomilumab|Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
75750204|NCT05274048|Drug|Neratinib Pill|Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
75750205|NCT05274048|Drug|Fam-Trastuzumab Deruxtecan-Nxki (TDxD)|standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
75750206|NCT05269316|Drug|IMP9064|IMP9064 Monotherapy administered for 21 days
75750207|NCT05265429|Genetic|Data and Specimen Collection|"Provide research team access to relevant medical records~Answer two (2) short questionnaires at time of consent~Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample~Consider consenting to other optional parts of the research such as:~Providing additional blood or tissue samples in the future (optional)~Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)"
75769447|NCT03899740|Other|Ranking - Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
75769448|NCT03897400|Other|AMH levels in young women with crohn's disease will be considered.|Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.
75899737|NCT05127265|Other|Video Monitoring|continuous video monitoring
75899738|NCT05127265|Other|Accelerometer Monitoring|continuous accelerometer monitoring of patient movements
75899739|NCT05127265|Other|Noise Level Monitoring|continuous environmental noise monitoring
75899740|NCT05127265|Other|Light Level Monitoring|continuous environmental light monitoring
75899741|NCT05127265|Other|Air Quality Monitoring|continuous environmental air quality monitoring
75605481|NCT03258008|Biological|ISA101b|ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
75750210|NCT05250843|Procedure|TACE/HAIC|Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.
75750211|NCT05250843|Drug|Lenvatinib|Participants received lenvatinib capsules 8mg for patients weight <60kg, or 12mg for patients weight more than 60Kg.
75750212|NCT05250843|Drug|Sintilimab|Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.
75750213|NCT05250843|Procedure|liver resection|liver resection is feasible after evaluation by the liver cancer surgery expert group
75750214|NCT05230082|Other|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
75750215|NCT05230043|Other|Algometer test|The computerized pressure algometer, AlgoMed (Medoc, Ramat Yishai, Israel), will be used for mechanical pain stimulation to assess information about pain threshold and tolerance. A constant rate of pressure is delivered by the examiner, and the pressure is recorded in Kilopascal (kPa). The stimulation will be applied between the medial and distal joints of the phalanges of the dominant hand.
75899742|NCT05127265|Other|EKG Monitoring|continuous EKG monitoring
75454187|NCT04543591|Biological|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
75454188|NCT04543591|Other|Placebo|Matching placebo
75899743|NCT05127265|Other|Vitals Monitoring|continuous vitals monitoring (heart rate, oxygen saturation)
76066495|NCT05571228|Behavioral|Self-stigma intervention|Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) is a group-based intervention integrating cognitive behavioural therapy (CBT) and peer support to reduce or prevent the internalization of stigma in early psychosis. The BOOST group will last for 4 weeks and consists of two 1-hour sessions per week. Participants will be assessed prior to the first group, following the final group, six months after the group ends, and twelve months after the group ends.
75454189|NCT04543591|Other|Best supportive care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
75454190|NCT04535414|Device|Cellvizio (Registered trademark)Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes|Participants of both study arms will undergo confocal endomicroscopy of the gastric mucosa until sufficient data for statistically accurate and reliable application of machine learning (i.e., computer models), currently believed to total the first 50 enrolled participants.
75454191|NCT04535414|Device|Olympus GIF 190 endoscope|Participants will undergo white light endoscopy. The mucosa of the stomach may be thoroughly washed before examination, as medically indicated, and inspection will include repeated inflation and deflation to check distensibility and any abnormal appearing areas will additionally be biopsied. Nontargeted biopsies will be obtained as indicated per the assigned Arm.
75454192|NCT04521712|Diagnostic Test|2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor|All women enrolled in this study will have a 2-hour 75-g oral glucose tolerance test performed immediately postpartum (within 4 days of delivery), at 4-6 weeks postpartum, and at 6 months postpartum. Enrolled women will also wear a continuous glucose monitor for 10 days at each of these time periods. Both women and their infants will have skin fold thickness measured at each of these 3 study visits to estimate body fat composition. Additionally umbilical cord blood and placental biopsies will be collected at delivery and stored for future research.
75605482|NCT05116605|Other|Photobiomodulation (PBM)|Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
75454193|NCT04518306|Drug|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg|Oral tablets
75454194|NCT04518306|Drug|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Oral tablets
75605483|NCT01113879|Behavioral|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
75605484|NCT01113879|Behavioral|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
75605485|NCT00979576|Drug|BIBF 1120 M + Pemetrexed|BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m^2
75605486|NCT00979576|Drug|BIBF 1120 H + Pemetrexed|BIBF 1120 high dose bid+ Pemetrexed 500 mg/m^2
75605487|NCT00979576|Drug|BIBF 1120 RD + Pemetrexed|confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m^2
75605488|NCT00979576|Drug|BIBF 1120 L + Pemetrexed|BIBF 1120 low dose bid+ Pemetrexed 500 mg/m^2
75605489|NCT00979576|Drug|BIBF 1120 Placebo + Pemetrexed|placebo BIBF 1120 bid + Pemetrexed 500 mg/m^2
75605490|NCT02867332|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
75605491|NCT02867332|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
75605492|NCT02867332|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
75750216|NCT05230043|Other|functional MRI|"Two 8s sequences of spin echo field map with phase encoding AP and PA~A 12:00min bold sequence for resting-state~A 15:12min bold sequence for gambling task thickness=2mm, Matrix Size = 105×105, FOV=210×210mm2;~A 6:38min T1w MPR sequence~A 7:40min T1w MPR sequence~A 5:57min T2w SPC sequence~A 8:24min T2w SPC sequence~A 8:32min FLAIR T2w sequence~Two 8:26min Multi-echo GRE sequence~A 8:29min high resolution multi-echo GRE sequence~Two 6:46min multi-echo GRE sequence with and without magnetic transfer contrast~Two 6:03min diffusion weighted images with phase encoding AP and PA"
75750217|NCT05223829|Drug|Brexanolone|Brexanolone will be administered as a continuous IV infusion over 20 hours under medical observation
75750218|NCT05223725|Biological|AdKCNH2-G628S|adenovirus containing the transgene KCNH2-G628S
75750219|NCT05205343|Other|Standard of Care|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
76066496|NCT05566704|Device|Modulus ALIF System|The Modulus ALIF System is designed to address lumbar pathologies utilizing interbody placement through an anterior or anterolateral surgical approach. The Modulus ALIF System is an interfixated interbody system available in various shapes and sizes to suit the individual pathology and anatomical conditions of the patient.
75750220|NCT05205343|Other|Control Group|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
75750221|NCT05197842|Drug|BDB-001 injection|Intravenously administered
75750222|NCT05197842|Drug|Cyclophosphamide|Intravenously administered
75750223|NCT05197842|Drug|Glucocorticoids|Orally administered
75750224|NCT05176145|Device|VisioCyt®|"Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines.~Urine collection for conventional cytology and VisioCyt® test"
75899744|NCT05127265|Other|Biosample Collection|blood and urine samples collected once on Day 1 and once on Day 2
75454195|NCT04518306|Drug|Placebo|Placebo
75454196|NCT04515667|Behavioral|Mindfulness|Participants will view a brief mindfulness video
75454197|NCT04515667|Behavioral|Video|Participants will view a control video
75454198|NCT04512547|Drug|Hyperpolarized 129XeMRI|Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics
75899745|NCT05127265|Other|Delirium Motor Subtyping Scale 4 (DMSS-4)|done daily on delirious patients to subtype delirium
75454199|NCT04502043|Other|Exercise therapy|"Education~Hip-specific strengthening exercises~Functional lower limb strengthening exercises~Core stability exercises~Postural balance exercises"
75899746|NCT05120804|Behavioral|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
75605493|NCT02867410|Other|No intervention|
75605494|NCT02867098|Drug|XmAb5871|
75605495|NCT02702180|Drug|Molgramostim|300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
75605496|NCT02702180|Drug|Placebo|Placebo nebulizer solution for inhalation
75750225|NCT05152940|Drug|Ertugliflozin|Treatment with Ertugliflozin 5 mg oral once per day for one month
75750226|NCT05152940|Drug|Placebo|Treatment with matching placebo to ertugliflozin administered orally once daily for a period of one month
75750227|NCT05131087|Device|Cadence implant|CADENCE Glaucoma Drainage Device System is a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach
75750228|NCT05107219|Procedure|Biopsy|Undergo biopsy
75750229|NCT05107219|Procedure|Biospecimen Collection|Undergo collection of luminal fluid
75750230|NCT05107219|Procedure|Esophagogastroduodenoscopy|Undergo EGD
75750231|NCT05107219|Drug|Linaclotide|Given PO
75605497|NCT02702180|Device|PARI eFlow nebulizer system|PARI eFlow nebulizer system
75750232|NCT05107219|Drug|Plecanatide|Given PO
75750233|NCT05101486|Biological|Ad26.RSV.PreF-based Vaccine|Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.
75899747|NCT05120804|Behavioral|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus relationship skills training
75605498|NCT00980980|Drug|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
75750234|NCT05100706|Drug|Continuous adductor canal block (CACB)|Ropivacaine 0.2% infusion through adductor canal catheter
75750235|NCT05100706|Drug|Sham continuous adductor canal block (ShACB).|NaCl 0.9% infusion through adductor canal catheter
75750236|NCT05095727|Drug|mRNA-3745|Sterile frozen liquid dispersion for injection
75750237|NCT05091372|Drug|Belantamab mafodotin|"Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician."
75899748|NCT05112315|Device|Predigraft|The Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.
75899749|NCT05111288|Device|Pulsed electromagnetic field therapy (PEMF)|Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields.
75750238|NCT05091372|Drug|Lenalidomide|"Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment."
75750239|NCT05089474|Device|Streamline Surgical System|The Streamline System is a device that delivers viscoelastic into Schlemm's Canal.
75605499|NCT02888600|Behavioral|Mindfulness Training|Guided mindfulness meditation and stress management training
75605500|NCT02888600|Behavioral|Health Education|Guided health education and stress management training
75899750|NCT05111288|Device|Inactive Pulsed electromagnetic field therapy (PEMF)|PEMF device that turns on but does not provide any electromagnetic stimulation
75899751|NCT05110482|Drug|Syntocinon|uterotonic drugs
75899752|NCT05110482|Drug|Carbetocin|uterotonic drug
75605501|NCT02888522|Biological|immunomodulation|Immunomodulation depending on chimerism
75605502|NCT02866864|Other|Animal allergy +|Allergic symptom occurs when subject contact animal
75605503|NCT02866864|Other|Animal allergy -|Allergic symptom does not occur when subject contact animal
75605504|NCT00980200|Drug|Dose 4 QD|QD once daily
76066497|NCT05561595|Behavioral|Healing HEARTS|Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.
75899753|NCT05108623|Drug|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
76066498|NCT05561595|Behavioral|Peer Support|Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.
76066499|NCT05553327|Behavioral|Multimodal prehabilitation|"Physical state: individualised physical status will be evaluated by a physiotherapist. A specific training program and pelvic floor exercises sessions will be led by a physiotherapist.~Nutritional state: individual nutritional status will be evaluated by a nutritionist and intervention will be done if applicable. A nutrition group session will be held.~Mental health: mindfulness group sessions led by psychologists will be held."
76066500|NCT05543629|Biological|BMS-986442|Specified dose on specified days
75605505|NCT00980200|Drug|Dose 3 QD|QD once daily
75605506|NCT00980200|Drug|placebo|placebo
75605507|NCT00980200|Drug|Dose 2 QD|QD once daily
75605508|NCT00980200|Drug|Dose 1 BD|BD twice daily
75899754|NCT05108623|Drug|Approved ICIs|Nivolumab and pembrolizumab
75605509|NCT04116502|Drug|Ruxolitinib|10mg of ruxolitinib twice daily (bd)
75605510|NCT04116502|Drug|Hydroxycarbamide|Via standard hospital mechanisms
75605511|NCT04116502|Drug|Interferon-Alpha|Any formulation, via standard hospital mechanisms
75605512|NCT04290442|Procedure|adductor canal block|The block is performed in supine position under ultrasound guidance using 22 G Touhy needle advanced in plane and 15 cc of 0.5% Ropivacaine ( local anesthetic) with dexmedetomidine 20-30 mcg depending on the age of the patient is injected at midthigh level lateral to the femoral artery in adductor canal to provide sensory blockade to the anterior aspect of the knee.
75899755|NCT05087810|Behavioral|Psychological stress induction|Subjects will undergo acute psychological stress induction by performing mental arithmetic tasks.
75899756|NCT05087810|Other|Accelerated oral hydration|Participants will drink 2L of fluid in a short period of time to force diuresis and urine production.
75899757|NCT05044663|Other|No intervention|This is an observational study
76066501|NCT05543629|Biological|Nivolumab|Specified dose on specified days
76066502|NCT05543629|Drug|Docetaxel|Specified dose on specified days
75750240|NCT05087563|Device|Neurolens spectacle lens|spectacle lens
75750241|NCT05087563|Device|Placebo spectacle lens|spectacle lens for refractive correction
75750242|NCT05085301|Diagnostic Test|Rapid diagnostic test|The performance of three index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
75750243|NCT05083585|Biological|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.
75750244|NCT05081219|Drug|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
76066503|NCT05543629|Drug|Carboplatin|Specified dose on specified days
76066504|NCT05543629|Drug|Pemexetred|Specified dose on specified days
76066505|NCT05543629|Drug|Paclitaxel|Specified dose on specified days
75750245|NCT05081219|Drug|Empagliflozin 10 MG|Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.
76066506|NCT05531786|Drug|Pacritinib|Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.
76066507|NCT05517265|Drug|Calquence|acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
75605513|NCT04290442|Procedure|SPANK|SPANK: The block is performed in supine position, using 22 G Touhy needle, under ultrasound guidance, needle is advanced in plane to posteromedial shaft of femur taking care to avoid popliteal artery, and 0.5% ropivacaine 15 cc, dexmedetomidine 20-30mcg and dexamethasone 4 mg is injected into inner thigh above the knee provide sensory block to posterior aspect of the knee.
75605514|NCT04290442|Drug|Ropivacaine|ropivacaine 0.5% will be use in the block
75605515|NCT02866708|Device|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
75605516|NCT02866786|Drug|Metformin|
76066508|NCT05517265|Drug|Calquence|acalabrutinib according to Calquence® SmPC.
76066509|NCT05515978|Drug|Metformin|In this study, patients on the Metformin arm will be started on 850 mg daily for 2 weeks, then escalated to a final dose of 850 mg twice daily, which is lower than the maximum recommended dose of 2550 mg total daily.
75454200|NCT04477187|Device|Dermal Handpiece|Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
75454201|NCT04450758|Procedure|Bridge to Surgery (stent or stoma)|The study is an observational study and patients will not be randomized. Resection is defined as upfront surgical resection, Bridge to Surgery as a two stage procedure.
75454202|NCT04450212|Genetic|Phase I, Buccal Swab Collection for DNA Isolation|Buccal swab will be taken from study participants for DNA isolation.
75605517|NCT02866786|Drug|ethinyl estradiol and cyproterone acetate|Oral Contraceptive Pill
75605518|NCT00979654|Drug|Sifalimumab|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
75605519|NCT02866552|Drug|Stromal Vascular fraction|
75605520|NCT02866552|Drug|Ringer lactate|
75605521|NCT02866474|Dietary Supplement|population living at home with meals on wheels|
75605522|NCT02866474|Dietary Supplement|population living in an EHPAD|
75605523|NCT00978562|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
75605524|NCT00978562|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
75605525|NCT00978562|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
75605526|NCT00978562|Drug|Gadolinium|Given IV
75605527|NCT04289974|Drug|Palbociclib|Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)
75750246|NCT05081219|Device|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
75750247|NCT05081219|Drug|Placebo (Insulin Diluent)|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
75750248|NCT05081219|Drug|Placebo (Capsules)|Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
75750249|NCT05071313|Biological|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as single IM injection.
75750250|NCT05071313|Biological|Quadrivalent High-dose Influenza Vaccine|Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.
75750251|NCT05071313|Biological|Placebo|Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.
75750252|NCT05056077|Other|Counseling|Receive support person coaching
75899758|NCT05040841|Behavioral|M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result|"Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the Risk of Treatment Failure (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1."
75750253|NCT05056077|Other|Educational Intervention|Receive personal report and booklet on nutrition and physical activity for patients with colon or rectal cancer
75750254|NCT05056077|Behavioral|Health Education|Receive health coaching
75605528|NCT02866630|Biological|Blood samples|Six additional blood samples will be taken from in-situ catheters during heart surgery
75750255|NCT05056077|Other|Health Promotion and Education - Direct Text Messaging|Receive text messages
75899759|NCT05040841|Behavioral|M2/PRM: Immediate outreach to subject after a missed pharmacy refill|The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
75454203|NCT04450212|Dietary Supplement|Phase II, Vitamin K (Vitacost) Supplementation|1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
75605529|NCT02866162|Genetic|High-throughput exome sequencing|
75605530|NCT02865616|Drug|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
75899760|NCT05040841|Behavioral|M3/EAM: Immediate outreach to subject after EAM-identified missed doses|The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
75454204|NCT04447339|Procedure|Nipple Sparing Mastectomy|Prophylactic open NSM procedures
75454205|NCT04441307|Behavioral|Healthy Foundations|Healthy Foundations combines elements of a community-based parent education program with additional information about infant and child development, good parenting practices, parent health behavior, and couple support.
75605531|NCT02865616|Drug|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
75605532|NCT02865460|Drug|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
75605533|NCT02865460|Drug|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
75750256|NCT05056077|Other|Health Promotion and Education - Digital health tool kit|Receive digital health tool kit
75750257|NCT05056077|Other|Questionnaires|Quality of Life and Behavioral Questionnaires
75750258|NCT05048797|Drug|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan administered by intravenous infusion
75750259|NCT05048797|Drug|Cisplatin|Investigator's choice of platinum chemotherapy (cisplatin) administered by intravenous infusion
75454206|NCT04441307|Behavioral|Family Foundations|A modified version of Family Foundations, an evidence-based preventive intervention for couples during the transition to parenthood, will be implemented to address several aspects of parent and family adjustment, including parent health behavior, particularly alcohol use, and couple relationship dynamics, to promote a healthy parenting environment.
75454207|NCT04437264|Dietary Supplement|Intermittent feed participant|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
75605534|NCT01206816|Drug|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
75605535|NCT01206582|Biological|Hemin|10 iv infusions for 8 weeks
75605536|NCT01206582|Biological|Albumin|10 iv infusions for 8 weeks
75605537|NCT05409456|Other|mild aerobic exercise|mild aerobic exercise given to group A on treadmill
75605538|NCT05409456|Other|moderate aerobic exercise|moderate aerobic exercise given to group B on treadmill
75605539|NCT01259102|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
75750260|NCT05048797|Drug|Carboplatin|Investigator's choice of platinum chemotherapy (carboplatin) administered by intravenous infusion
75750261|NCT05048797|Drug|Pembrolizumab|Pembrolizumab administered by intravenous infusion
75750262|NCT05048797|Drug|Pemetrexed|Pemetrexed administered by intravenous infusion
75750263|NCT05039892|Drug|3D185|All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.
75750264|NCT05023434|Procedure|Intraoperative Brain Simulation - Alternate Stimulation Parameters|Additional stimulation parameters outside of standard of care during intraoperative brain stimulation to aid in motor mapping.
75750265|NCT05019729|Drug|VRC-MALMAB0114-00-AB|VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.
75750266|NCT05019729|Other|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum
75750267|NCT05007080|Biological|Ad26.COV2.S|Ad26.COV2.S will be administered as intramuscular (IM) injection.
75750268|NCT04975607|Behavioral|Music Therapy|The three live music therapy sessions will be provided after lung transplant. All three music therapy sessions will employ a variety of data-based interventions to address pain, anxiety, and improve relaxation. Music therapy interventions may include patient preferred live music, active music listening, singing or other active music-making, and guided breathing and relaxation.
75750269|NCT04927143|Device|App-Based Contingency Management|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
75899761|NCT05040841|Behavioral|S1/Text: Weekly check-in texts|"Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent."
75899762|NCT05040841|Behavioral|S2/Peer: Enhanced peer group support|"Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks."
75605540|NCT00978250|Drug|5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.
75605541|NCT01259024|Device|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
75750270|NCT04927143|Behavioral|Sham Control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
75605542|NCT04319900|Drug|favipiravir tablets+chloroquine phosphatetablets tablets|"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).~Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.~Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug."
75750271|NCT04906980|Drug|JNJ-64281802|JNJ-64281802 will be administered orally.
75750272|NCT04906980|Drug|Placebo|Matching placebo (PEG400) will be administered orally.
75750273|NCT04891406|Other|A|Use of product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes
75750274|NCT04891406|Other|B|Use of product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 minutes
75750275|NCT04891406|Other|C|Use of product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 minutes
75454208|NCT04437264|Dietary Supplement|Continuous feeds participant|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
75750276|NCT04891406|Other|D|Use of product D (Nicotine pouch, 10.6 mg/pouch) for 20 minutes
75750277|NCT04891406|Other|E|Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes
75750278|NCT04890236|Drug|Duvelisib|Given PO
75454209|NCT04433182|Drug|Copanlisib|"Induction phase: 6 cycles of Copa-RB every 28 days according to the following schedule~Copanlisib (Copa): 60 mg/day i.v. on days 1,8,15~Rituximab (R): 375 mg/sqm i.v. day 1*~Bendamustine (B): 90 mg/sqm i.v. days 1-2*~note: during cycle 1 rituximab can be administered on day 2: in this case bendamustine will be administered on days 2-3; in the case of a frail patient or a patient with high tumor burden copanlisib could be administered on day 1, rituximab on day 2 and bendamustine on days 3-4, at physician discretion.~Maintenance phase: patients who reach at least SD after induction will receive a maintenance with copanlisib in monotherapy according to the following schedule:~• Copanlisib: 60 mg/day i.v. on days 1 and 15 in 28-day cycles for 1 year"
75750279|NCT04890236|Biological|Tisagenlecleucel|Given via infusion
75750280|NCT04885998|Drug|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
75750281|NCT04885998|Drug|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
75750282|NCT04867954|Other|Ensure Plus®|In-between two MRI exams, patients will ingest a standardized meal of two cans (16oz) of Ensure Plus® (Abbott Laboratories), providing a 700cal meal (13g protein, 11g fat, 50g carbohydrates), proven to elicit a strong hyperemic splanchnic response.
75899763|NCT05029960|Drug|Brivaracetam|Dose of 50 mg twice daily for 6 months
75899764|NCT05027217|Other|No intervention|No intervention. Arms are subdivided based on patients' diagnostic status on admission to ICU.
75899765|NCT05021393|Other|Clinical Pharmacist Intervention|Medication review, patient education, counseling, and corresponding written recommendation will be performed by clinical pharmacists for all randomized patients.
75899766|NCT05005000|Biological|Micro-Fragmented Adipose Tissue (MFAT)|1ml of autologous micro-fragmented adipose tissue will be used.
75605543|NCT04319900|Drug|Favipiravir tablets|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
75605544|NCT04319900|Drug|Placebo|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
75605545|NCT01257698|Drug|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
75605546|NCT01257542|Drug|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
75605547|NCT01257542|Drug|Placebo|A single 10 mL dose of matching placebo syrup
75605548|NCT01257230|Drug|tiotropium Respimat low dose|IMP
75454211|NCT04408118|Drug|Atezolizumab|"Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes."
75605549|NCT01257230|Drug|placebo Respimat|placebo representing comparator
75605550|NCT01257230|Drug|tiotropium Respimat high dose|IMP
75750283|NCT04867954|Other|Pre-clinical validation contrast enhanced MRI|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
75899767|NCT05005000|Drug|Triamcinolone Acetonide 10mg/mL|The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.
75454212|NCT04408118|Drug|Paclitaxel|Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.
75454213|NCT04408118|Drug|Bevacizumab|Will be administered intravenously over 30-90 minutes on Days 1 and 15.
75454214|NCT04404595|Biological|CT041|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
75454215|NCT04385368|Drug|Durvalumab + SoC chemotherapy|Experimental Treatment
75454216|NCT04385368|Other|Placebo + SoC chemotherapy|Placebo Comparator
75454217|NCT04380636|Biological|Pembrolizumab|intravenous (IV) infusion
75454218|NCT04380636|Drug|Olaparib|oral tablets
75454219|NCT04380636|Drug|Placebo for olaparib|oral tablets
75605551|NCT01113801|Drug|LY2382770|Subcutaneous injection given monthly for 12 months
75605552|NCT01113801|Drug|Placebo|Subcutaneous injection given monthly for 12 months
75605553|NCT01256684|Drug|Placebo|Placebo vaginal suppository
75605554|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
75605555|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
75605556|NCT01204710|Biological|Olaratumab|15 milligrams per kilogram (mg/kg) intravenous (IV) Days 1 and 8
75899768|NCT04995055|Device|JJVC Investigational Multifocal Contact Lens TEST Lens|TEST Lens
75454220|NCT04380636|Drug|Etoposide|IV infusion
75454221|NCT04380636|Drug|Carboplatin|IV infusion
75454222|NCT04380636|Drug|Cisplatin|IV infusion
75454223|NCT04380636|Drug|Paclitaxel|IV infusion
75454224|NCT04380636|Drug|Pemetrexed|IV infusion
75454225|NCT04380636|Radiation|Thoracic Radiotherapy|external beam radiation
75454226|NCT04380636|Drug|Durvalumab|IV infusion
75463283|NCT05854797|Other|Normal Walking|"Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
75605557|NCT01204710|Drug|Mitoxantrone|"Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)"
75605558|NCT01204710|Drug|Prednisone|5 mg orally (PO) twice daily (BID) on each day
75605559|NCT02881359|Device|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
75605560|NCT00625755|Biological|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
75605561|NCT01256450|Drug|Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
75605562|NCT01256450|Drug|Placebo|buccal soluble film; applied to the buccal mucosa twice daily
75899769|NCT04995055|Device|ACUVUE® OASYS Multifocal|CONTROL Lens
75899770|NCT04987996|Drug|GR-MD-02|Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
75899771|NCT04987996|Drug|Placebo|Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
76066510|NCT05515978|Behavioral|Lifestyle Modification|"Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.~Here are some examples of the educational material from the American Diabetes Association website, and topics will be rotated on quarterly basis:~Healthy eating: https://www.diabetes.org/nutrition/healthy-food-choices-made-easy Prediabetes: https://www.diabetes.org/diabetes-risk/prediabetes Fitness: https://www.diabetes.org/fitness/get-and-stay-fit Weight loss: https://www.diabetes.org/fitness/weight-loss"
75605563|NCT01204398|Drug|telmisartan+amlodipine fixed dose combination|after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
75605564|NCT04306575|Other|Trans-venous lead extraction|Patients with a dysfunction or infection of a cardiac pacemaker or a defibrillator are indicated for extraction of these devices, so lead extraction is done transvenously to remove these leads
75899772|NCT04987996|Drug|Pembrolizumab|Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
76066511|NCT05508399|Other|DNA panel and RNA Sequencing|"Interventions include collecting samples, DNA panel test and full transcriptome sequencing.~Before collecting samples, obtaining written informed consent from patient in advance.~Blood cell samples;~Paraffin sample of residual tumor tissue of biopsy;~Paraffin sample of residual tumor tissue and paracancer tissue after gastrectomy."
76066512|NCT05499520|Other|Culturally Tailored Anti-Smoking Messages|Anti-smoking messages will be administered online via a Qualtrics survey.
76066513|NCT05499143|Other|Online questionnaire|Online questionnaire impact for DCD - Belgian version
76066514|NCT05487170|Drug|RNK05047|RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
76066515|NCT05480761|Biological|Sucraid (sacrosidase) Oral Solution 8500 IU/mL|Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
76066516|NCT05469165|Drug|Cyproheptadine 4 Mg Oral Tablet|Cyproheptadine treatment for 3 months
75899773|NCT04986670|Behavioral|Nutritional Counseling|Medical oncology providers will refer participants to oncology RDs for remotely delivered medical nutrition therapy counseling. For cohort 1, participants will receive nutrition counseling for 8 months. The counseling will be provided on a weekly basis during the first 6 months and every other week during the last 2 months (for cohort 1 only). For cohort 2, participants will receive nutrition counseling for 6 months. The ultimate frequency of nutrition counseling being provided to each participant will also be adjusted according to the participant's preference and needs.
75899774|NCT04986670|Other|Medically Tailored Meals (MTMs)|Medically tailored meals will be provided to participants in the intervention group for a total of 24 weeks for both cohorts. During the first 8 weeks of the intervention, 3 meals/day will be provided each week for a total of 168 meals per participant. It will be followed by less frequent meal provision during the subsequent 16 weeks following this schedule: 3 meals/day will be provided every other week for the next 8 weeks (a total of 84 meals per participant); and 3 meals/day will be provided every four weeks during the last 8 weeks (a total of 42 meals per participant). The number of meals provided to each participant may be adjusted according to participant's preference and needs.
75899775|NCT04986670|Behavioral|Nutrition Prescription|Oncology providers will advise participants with lung cancer to follow evidence-based nutrition recommendations using a Nutrition Prescription. The Nutrition Prescription aims to enhance providers' role in communicating basic nutrition advice to participants with lung cancer. It contains seven recommendations, adapted from the newly released Cancer Prevention Recommendations by WCRF/AICR with strong evidence-base.
75454227|NCT04372953|Procedure|Positive End-Expiratory Pressure (PEEP)|"PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV)."
75454228|NCT04370054|Biological|PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy|Single IV infusion
75454229|NCT04362826|Biological|Novel probiotic|Investigational novel probiotic
75454230|NCT04362826|Other|Placebo|Placebo for probiotic
75454231|NCT04349436|Biological|RP1, intra-tumoral injection, oncolytic virus|Genetically modified herpes simplex type 1 virus
75899776|NCT04986670|Other|Nutrition Assessment|Oncology care providers will assess the nutritional status of patients with lung cancer using PG-SGA Short Form (the Scored Patient-Generated Subjective Global Assessment). PG-SGA is an interdisciplinary patient assessment in oncology and other chronic catabolic conditions. The short form contains four patient generated historical components (weight history, food intake symptoms, and activities and function).
75899777|NCT04986670|Behavioral|Nutrition Toolkit|Patients will receive a printed copy of a Nutrition Toolkit from providers. Evidence-based nutrition recommendations have been compiled for cancer survivors from 4 sources into a Nutrition Toolkit. The sources include: (1) AmericanCancer Society (ACS) Nutrition and Physical Activity Guidelines for Cancer Survivors; (2)World Cancer Research Fund / American Institute for Cancer Research (WFRF/AICR) Cancer Nutrition Guide; (3) National Cancer Institute (NCI) Eating Hints; and (4) National Comprehensive Cancer Network (NCCN) Guidelines for Cancer Survivors. The Nutrition Toolkit outlines topics about the impact of cancer treatment on dietary intake patterns and quality, strategies to manage treatment-related eating issues, maintaining a healthy weight post treatment, and evidence-based recommendations and practical. Nutrition Toolkit strategies for improving diet quality and maintaining an optimal weight for cancer survivors.
75750284|NCT04867954|Other|Clinical validation MRI|"Participants will be screened for any previous reactions to Ferumoxytol or GBCAs and dosing will be consistent with standard of care.~Participants will then undergo a research MRI lasting approximately 1.5 hours.~All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which a 3/4 of the full dose of gadolinium based contrast agent (GBCA) or the total dose of Ferumoxytol will be administered.~The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing).~All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 minutes) during which, the remaining 1/4 dose of GBCA will be administered, if required."
75899778|NCT04986670|Behavioral|Monthly Emails|Monthly emails will be sent to participants to encourage the use of the toolkit with healthy recipes and general nutrition information.
75899779|NCT04924205|Device|FM2 Knee Brace|Participants in this group will use the FM2 Knee Brace for their post-TKA physical therapy.
75899780|NCT04924088|Behavioral|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
75750285|NCT04867954|Other|Pre-clinical validation contrast enhanced MRI + fasting|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1.5 hours. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
76066517|NCT05469165|Other|Placebo|Placebo administration for 3months
76066518|NCT05466578|Drug|abrocitinib|
76066519|NCT05462834|Other|Compressed Air|Participants will be instructed to use compressed air during sleep as a placebo control.
75899781|NCT04924088|Behavioral|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
75899782|NCT04916509|Drug|Palbociclib plus an aromatase inhibitor|Palbociclib plus an aromatase inhibitor therapy
75454232|NCT04341948|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
75750286|NCT04799171|Other|Isometric Contraction Exercise - Young Adults (Age group 18-39)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
75899783|NCT04916509|Drug|Palbociclib plus fulvestrant|Palbociclib plus fulvestrant
75899784|NCT04897581|Behavioral|Brief Behavioral Therapy for Insomnia, BBTI|BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.
75899785|NCT04897581|Behavioral|Physical Self-Regulation, PSR|PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
75454233|NCT04325607|Procedure|Excision of HS followed by NPWTi|The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
75454234|NCT04325607|Procedure|Excision of HS followed by NPWT|The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
75454235|NCT04323280|Drug|Dexamethasone therapy|Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
75454236|NCT04323280|Drug|NSAID therapy|NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
75454237|NCT04318548|Combination Product|Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)|rMenB+OMV will be administered intramuscularly as 1 dose each at day 1 and 61 to subjects in MenB+MenACWY group and MenB group and as 1 dose at day 91 to subjects in MenACWY group, to the deltoid region of the non-dominant arm.
75605565|NCT04318236|Behavioral|HERMES (Online Self-Help Intervention based on problem-solving therapy)|"The Online Self-Help Intervention is an online program based on the problem-solving therapy (an evidence based approach of psychotherapy). All participants will receive the exact same intervention.~However, what will be experimentally varied are the four listed interventions."
75605566|NCT01111851|Drug|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
75605567|NCT01111851|Drug|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
75605568|NCT01111851|Drug|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
75750287|NCT04799171|Other|Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
75899786|NCT04891380|Device|LUCAS 2 Active Decompression 2|Chest compression with active decompression of the chest. Measurement of physiological parameters.
75899787|NCT04891380|Other|Hypotension|measurement of physiological parameters
75899788|NCT04891380|Other|Intensive care transport|Measurement of physiological parameters
75899789|NCT04884048|Diagnostic Test|Radiographs|Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system
75899790|NCT04882774|Drug|Treprostinil Diolamine|Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID
75899791|NCT04878887|Procedure|IP-DRA vs IP- PRA|Catetherization approach in plane : distal radial artery VS proximal radial artery
75454238|NCT04318548|Biological|Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)|MenACWY will be administered intramuscularly as 1 dose at day 1 to subjects in MenB+MenACWY group, 1 dose at day 91 for MenB group and as 1 dose at day 1 to subjects in MenACWY group, to the deltoid region of the non-dominant arm.
75454239|NCT04318548|Combination Product|Placebo|Placebo will be administered intramuscularly as 1 dose at day 91 to subjects in MenB+MenACWY group, 1 dose at day 1 to subjects in MenB group and MenACWY group, to the deltoid region of the non-dominant arm.
75454240|NCT04307134|Drug|Inotuzumab ozogamicin|R/R ALL who treated with Inotuzumab ozogamicin
75454241|NCT04307004|Other|Unattended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
75899792|NCT04874558|Diagnostic Test|Ultra-low dose chest CT|A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.
75899793|NCT04866134|Drug|ERAS-007|ERAS-007 will be administered orally as specified in Arm description.
75899794|NCT04866134|Drug|ERAS-601|ERAS-601 will be administered orally as specified in Arm description.
75605569|NCT01111851|Drug|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
75454242|NCT04307004|Other|Attended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
76066520|NCT05462834|Other|Supplemental Oxygen|Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
75899795|NCT04860700|Drug|anlotinib hydrochloride|Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
75899796|NCT04846920|Drug|Belzutifan|40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.
76066521|NCT05459831|Device|QDot Micro Catheter|Atrial fibrillation radiofrequency ablation with 90W or 50W energy setting.
76066522|NCT05458102|Drug|Vesatolimod|Administered orally
76066523|NCT05458102|Drug|Cobicistat|Administered orally
76066524|NCT05458102|Drug|Voriconazole|Administered orally
76066525|NCT05458102|Drug|Rifabutin|Administered orally
76066526|NCT05453461|Diagnostic Test|Validation of new COMs for non ambulant FSHD patients|Monitoring of commonly used and news COMs in non ambulant patients with facioscapulohumeral muscular dystrophy
75454243|NCT04307004|Other|Ambulatory blood pressure monitoring|Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.
75454244|NCT04307004|Other|Home blood pressure monitoring|Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
75605570|NCT01111851|Drug|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
75750288|NCT04799171|Other|Isometric Contraction Exercise - Old Adults (Age group >60)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
76066527|NCT05450718|Drug|buprenorphine-naloxone|Low-dose initiation of buprenorphine-naloxone protocol
75750289|NCT04764799|Procedure|Rapid sequence induction|Rapid sequence induction starts with the administration of rapid acting intravenous narcotics, opioids and neuromuscular blockage and avoids whenever possible positive-pressure ventilation after induction of anesthesia.
75750290|NCT04747054|Drug|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
75750291|NCT04747054|Radiation|Loco-regional radiotherapy|The loco-regional radiotherapy will start at D8 after the first administration of pembrolizumab (D1) (if delayed, RT should be started no later than three weeks after the first administration of pembrolizumab, i.e. before the second administration of pembrolizumab if possible), with 54 Gy/18 fractions in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary.
75899797|NCT04785144|Biological|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the Wuhan-Hu-1 strain of SARS-CoV-2. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
75899798|NCT04785144|Biological|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
76066528|NCT05450718|Drug|buprenorphine-naloxone|Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
76066529|NCT05449067|Procedure|Group A and Group B|Group A: Participants receive APD for 12 weeks then switch to CAPD for another 12 weeks; Group B: Participants receive CAPD for 12 weeks and switch to APD for another 12 weeks.
76066530|NCT05440643|Biological|Peanut SLIT-tablet|Peanut extract
76066531|NCT05439980|Other|Knowledge questionnaire|Completion of a questionnaire at baseline
76066532|NCT05439980|Other|Focus groups|structured interviews
75750292|NCT04747054|Drug|Chemotherapy|If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will be composed of carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles
75454252|NCT04289870|Device|Trillium™|Trillium™ Stent Graft for Functional Tricuspid Valve Replacement
75454253|NCT04281498|Drug|Ruxolitinib|Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
75454254|NCT04281498|Drug|Enasidenib|50mg -100mg daily
75454255|NCT04276870|Biological|Murine CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment
75454256|NCT04263025|Biological|Cryopreserved Umbilical Cord Allograft|"CLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue [43]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a 361 human cell and tissue-based product (HCT/P) and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271."
75605571|NCT01111851|Drug|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
75605572|NCT01111851|Drug|MK0999|I.V. infusion of MK0999 containing ~100 MBq (~3 mCi) containing ≤ 5 ug of MK0999)
75605573|NCT01256294|Drug|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
75605574|NCT01256294|Drug|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
75605575|NCT04310241|Behavioral|Patching therapy, Glasses|Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
75750293|NCT04740515|Other|pharmacists involved PPMTM|This was an open labelled randomised study. Preterm Infants With iron supplementation were recruited and arbitrarily divided into the intervention group (usual care plus PPMTM) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
75605576|NCT01256060|Drug|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
75750294|NCT04731649|Behavioral|Families Talking Together Plus (FTT +)|FTT + consists of three online intervention sessions of approximately 60-90 minutes each, that cover content from nine modules designed to teach parents effective communication skills, build parent-adolescent relationships, help parents develop successful monitoring strategies, and teach adolescents assertiveness, refusal skills, and how to use a condom correctly and every time.
75750295|NCT04692181|Biological|SYN-004, Ribaxamase or Placebo|SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
75454257|NCT04263025|Procedure|Robot-Assisted Radical Prostatectomy|Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy
75454258|NCT04242667|Behavioral|e-Health (web-based) disclosure portal|Patient uses secure web-based portal to access genetic research results
75454259|NCT04242667|Behavioral|Provider mediated disclosure|Patient has disclosure of genetic research result by a provider (genetic counselor)
75750296|NCT04682834|Drug|Sulopenem Etzadroxil/Probenecid|Individual Patients
75899799|NCT04780542|Behavioral|Yo Puedo Sentirme Bien- Clinician-Guided version|Internet delivered Cognitive Behavioral Therapy- Guided version
75899800|NCT04780542|Behavioral|Yo Puedo Sentirme Bien- Self-Guided version|Internet delivered Cognitive Behavioral Therapy- Self-Guided version
75899801|NCT04774406|Drug|olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib|All patients treated at least with 1 PARPi (alone or in combination)
76066533|NCT05439421|Behavioral|Package/Advertisement With Claim|Waterpipe tobacco packages and digital marketing advertisement images with claim of interest as part of design
75454260|NCT04221438|Drug|Binimetinib|Given PO
75605577|NCT02880501|Device|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
75605578|NCT01255904|Drug|Chloral Hydrate|Oral chloral hydrate 50 mg/kg
75605579|NCT01255904|Drug|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg
75750297|NCT04661124|Device|SPECTRALIS|ophthalmic imaging device with head and chinrest
75750298|NCT04661124|Device|SPECTRALIS with Flex Module|ophthalmic imaging device on mobile instrumentation stand
75750299|NCT04643574|Biological|NeoTIL|Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)
75750300|NCT04643574|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
75750301|NCT04643574|Drug|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
75750302|NCT04643574|Drug|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.
75750303|NCT04643574|Radiation|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to tumor lesions once before NeoTIL infusion.
75899802|NCT04773730|Procedure|Posterior transversus abdominus plane block|Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side
75899803|NCT04773730|Procedure|Quadratus lumborum block type 2|Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side
75899804|NCT04768400|Drug|Arm I (MEP)|Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
75899805|NCT04754100|Drug|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
75899806|NCT04752813|Drug|BPM31510|Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.
75899807|NCT04752813|Other|Vitamin K1|Subjects will receive prophylactic Vitamin K1 at a recommended dose of 10 mg Intramuscularly prior to the beginning of each week of BPM31510 therapy.
76066534|NCT05439421|Behavioral|Package/Advertisement Without Claim|Waterpipe tobacco packages and digital marketing advertisements shown without claim of interest as part of design
76066535|NCT05431413|Drug|Control group: Fluoxetine and Placebo|Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
76066536|NCT05431413|Drug|Experimental group: Fluoxetine and ATP|Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
75454261|NCT04221438|Procedure|Computed Tomography|Undergo PET/CT
75454262|NCT04221438|Procedure|Conventional Surgery|Undergo surgery
75454263|NCT04221438|Drug|Encorafenib|Given PO
75454264|NCT04221438|Other|Fluorothymidine F-18|Given IV
75454265|NCT04221438|Procedure|Positron Emission Tomography|Undergo PET/CT
75454266|NCT04218370|Procedure|Dialysis|Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)
75454267|NCT04196218|Other|Driving simulator|Computer simulated driving assessment
75605580|NCT01255904|Other|Oral placebo|Oral saline administered
75605581|NCT01255904|Other|Intranasal placebo|Intranasal saline administered
75605582|NCT01255670|Drug|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
75605583|NCT01255592|Drug|AZD5069|Oral dose bid
75605584|NCT01255592|Drug|Placebo|Oral dose bid
75605585|NCT01255436|Other|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
76066537|NCT05431413|Drug|Control group: Fluoxetine and Phosphocreatine|Cap Fluoxetin 20mg OD for four weeks and injection Phosphocreatine 1g in NS BD for two weeks.
75899808|NCT04752813|Drug|Temozolomide (TMZ)|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment.
75899809|NCT04752813|Radiation|Radiation|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent standard RT for 42 days.
75454268|NCT04181749|Drug|aspirin and atorvastatin|Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
75454269|NCT04178551|Other|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
75454270|NCT04165317|Drug|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
75605586|NCT01255436|Other|Usual Care|Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
75605587|NCT01203930|Drug|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
75454271|NCT04165317|Drug|Bacillus Calmette-Guerin|Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
75605588|NCT01203930|Drug|Rituximab|Rituximab 375 mg/m^2 administered intravenously once weekly x 8 weeks
75605589|NCT01254890|Drug|Azacitidine|75 mg/m^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
75605590|NCT01254890|Drug|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
75605591|NCT01203852|Drug|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
75750304|NCT04642105|Device|Sensor-Dot and Plug 'n Patch system|We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
75750305|NCT04626791|Drug|Acalabrutinib|Given PO
75605592|NCT01203852|Drug|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
75605593|NCT01105533|Drug|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
75605594|NCT01105533|Drug|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
75750306|NCT04626791|Drug|Bortezomib|Given SC
75605595|NCT01105533|Drug|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
75605596|NCT01105533|Drug|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
75605597|NCT01105533|Drug|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
75605598|NCT01105533|Drug|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
75605599|NCT01105533|Drug|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
75899810|NCT04743635|Device|Avéli device|Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
75899811|NCT04735367|Drug|palbociclib plus letrozole|palbociclib plus letrozole
75605600|NCT01105533|Drug|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
75605601|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
75605602|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
75899812|NCT04715113|Other|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75605603|NCT01203072|Drug|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
75605604|NCT01203072|Drug|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
75750307|NCT04626791|Drug|Cyclophosphamide|Given IV
75750308|NCT04626791|Drug|Cytarabine|Given IV
75750309|NCT04626791|Drug|Doxorubicin Hydrochloride|Given IV
75750310|NCT04626791|Drug|Prednisone|Given PO
75750311|NCT04626791|Biological|Rituximab|Given IV
75750312|NCT04626791|Biological|Rituximab and Hyaluronidase Human|Given IV
75899813|NCT04715113|Other|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75899814|NCT04715113|Other|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
75899815|NCT04715113|Other|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
76066538|NCT05417334|Device|Resistive Capicitive Monopolar Radiofrequency|5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
75454272|NCT04163289|Drug|Fecal Microbiota Transplantation|Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
75899816|NCT04713657|Other|N-thymidine|15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
75899817|NCT04713657|Other|Urine Collection|Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
75899818|NCT04713657|Procedure|Echocardiogram|On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in ToF/PS and is non-invasive.
75750313|NCT04589663|Drug|Mometasone furoate|Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
75750314|NCT04589663|Drug|QMF149|Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
76066539|NCT05413590|Other|Questionnaires completion|Cognitive tests, completing questionnaires, balance test, measuring cardiac variability and post-ischemic hyperemia. Assessments of neuromuscular function on a semi-recumbent ergometric bicycle.
76066540|NCT05413590|Other|Isometric forces|Measurement of the maximum isometric forces of the knee flexors, the plantar flexors of the ankle and the grip strength of the hand.
75454273|NCT04161898|Drug|Upadacitinib|Upadacitinib will be administered as oral tablet
76066541|NCT05413590|Other|Energy cost|Measurement of feet pressure and measurement of the energy cost. Maximum test on an endocycle (classic) to determine VO2max.
76066542|NCT05408884|Other|Social Support|"Social support phone buddy program."
76066543|NCT05408884|Other|Basic income|$750 per month for 12 months
75605605|NCT01203072|Drug|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
75605606|NCT01203072|Drug|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
75750315|NCT04589663|Drug|Standard of Care (Soc)|Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
75750316|NCT04585295|Dietary Supplement|Betaine|50 mg/kg Betaine consumed twice daily for 7 days.
75750317|NCT04585295|Dietary Supplement|BCAA Big 6|1 level scoop (~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.
76066544|NCT05400330|Biological|LX1001|Gene therapy
75454274|NCT04161898|Drug|Placebo for Upadacitinib|Placebo for upadacitinib will be administered as oral tablet
75454275|NCT04161898|Drug|Prednisolone|Prednisolone will be administered as oral tablet
75454276|NCT04161755|Drug|Atezolizumab|Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
75454277|NCT04161755|Biological|RO7198457|RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
75454278|NCT04161755|Drug|mFOLFIRINOX|mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
75605607|NCT01203072|Drug|Placebo|Matching placebo oral tablets, once daily for 2 weeks
75605608|NCT01105377|Drug|entinostat|Given orally
75605609|NCT01105377|Drug|azacitidine|Given SC
75605610|NCT01105377|Other|laboratory biomarker analysis|Correlative studies
75605611|NCT04309071|Other|Dietary intervention|Salivary insulin responses to a standardized mixed meal
75605612|NCT01105065|Drug|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
75605613|NCT01111539|Drug|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
75605614|NCT01111539|Drug|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
75605615|NCT01111539|Drug|Blinded capsule|Blinded capsule administered orally, once daily.
75605616|NCT02880345|Drug|PEMBROLIZUMAB|
75605617|NCT02880345|Radiation|hypofractionated radiation|
75750318|NCT04585295|Dietary Supplement|Placebo|50 mg/kg Placebo consumed twice daily for 7 days.
76066545|NCT05395507|Drug|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
76066546|NCT05395507|Drug|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
76066547|NCT05391711|Behavioral|Culturally Smart Relationships|"Mentors assigned to the intervention will receive the following trainings and support:~Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~Culturally Smart Relationships Training (live, virtual)~JEDI enhanced monthly supervision from case managers~Monthly emails with activity suggestions for mentors and youth"
75454279|NCT04151563|Biological|nivolumab|Specified dose on Specified days
75454280|NCT04151563|Biological|ipilimumab|Specified dose on Specified days
75454281|NCT04151563|Drug|cabozantinib|Specified dose on Specified days
75454282|NCT04151563|Biological|docetaxel|Specified dose on Specified days
75454283|NCT04151563|Biological|ramucirumab|Specified dose on Specified days
75605618|NCT02880267|Device|CGM|Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.
75605619|NCT02879955|Other|Glucose + Fructose|Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
75454284|NCT04151563|Drug|lucitanib|Specified dose on Specified days
75454285|NCT04151368|Procedure|Robotic Nipple-Sparing Mastectomy (RNSM)|RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
75454286|NCT04142242|Biological|Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection; Route of administration: Intramuscular
75605620|NCT02879955|Other|Sucrose|Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
75605621|NCT02879955|Other|Isomaltulose|Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
75605622|NCT02879955|Other|Sucrose + Acarbose|Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
75605623|NCT02880033|Drug|deferiprone|to test the action of deferiprone on lymphocytes from patients and controls ex vivo
75605624|NCT02880033|Drug|placebo|to control the action of placebo on lymphocytes from patients and controls ex vivo
75750319|NCT04572815|Drug|Placebo Administration|Given IV and SC
75750320|NCT04572815|Other|Quality-of-Life Assessment|Ancillary studies
75454287|NCT04142242|Other|Blood sample|Blood sample for assessment of antibody persistence.
75750321|NCT04572815|Other|Questionnaire Administration|Ancillary studies
75750322|NCT04572815|Biological|Ustekinumab|Given IV and SC
75750323|NCT04562233|Behavioral|Online-delivered physical activity intervention.|Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.
75454288|NCT04129528|Drug|CFZ533|First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
75454289|NCT04129528|Other|Placebo|Placebo for active drug
75750324|NCT04562233|Behavioral|Printed, individualized resistance-based physical activity program.|Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
75605625|NCT04308993|Procedure|percutaneous transhepatic choledochoscopy|percutaneous transhepatic choledochoscopy
75605626|NCT05052645|Procedure|Auricular acupuncture|Placement of acupuncture needles in specific points on the ear in two consecutive treatments spaced 7 days apart.
75605627|NCT00625911|Drug|morphine|intravenous patient controlled analgesia, standard protocol
75454290|NCT04126018|Diagnostic Test|MRI with strain measurement|CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
75605628|NCT00625911|Drug|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
75750325|NCT04551560|Other|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
75750326|NCT04549662|Dietary Supplement|Active A|Powdered formula containing whey protein and arginine
75454291|NCT04126018|Diagnostic Test|Echocardiography|Doppler, PISA, VCA, volumetric method as performed during echocardiography
75454292|NCT04123535|Device|ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)|The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table
75454293|NCT04123366|Drug|Olaparib|Oral tablet
75454294|NCT04123366|Biological|Pembrolizumab|Intravenous infusion
75454295|NCT04109950|Drug|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
75605629|NCT04110496|Drug|RTX-134|RTX-134 is a cellular therapy containing AvPAL
75605630|NCT01111149|Other|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
75605631|NCT01111149|Drug|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
75605632|NCT01111149|Drug|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
75605633|NCT01254656|Drug|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
75605634|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
75605635|NCT01254656|Drug|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
75605636|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
75605637|NCT01254656|Drug|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
75605638|NCT01254656|Drug|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
75750327|NCT04549662|Dietary Supplement|Active B|Powdered formula containing whey protein
75750328|NCT04549662|Dietary Supplement|Lipid bolus|Omega-3 fatty acids
75750329|NCT04549662|Dietary Supplement|Placebo oil|Control placebo oil that does not contain omega-3 fatty acids
75750330|NCT04544475|Device|Revaree|Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.
75750331|NCT04544475|Drug|Estrace|Vaginal estrogen cream, estradiol: 100mcg
75750332|NCT04539964|Procedure|Implant Procedure|The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
75750333|NCT04539964|Drug|Conventional Synthetic DMARD|All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
75454296|NCT04097158|Other|Sample Collection|The investigators will be collecting blood, urine, and spinal fluid samples.
75750334|NCT04539964|Device|Active stimulation|Active stimulation for 1 min once per day
75605639|NCT05544188|Diagnostic Test|Differential diagnostic|Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
75454297|NCT04092634|Device|Dual mobility implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
75909624|NCT03471104|Other|PAID in clinical diabetes consultations|"The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician."
75750335|NCT04539964|Device|Non-active stimulation|Non-active stimulation for 1 min once per day
75750336|NCT04507438|Drug|Donepezil 5-10 Mg Oral Tablet|Donepezil 5mg or 10mg oral tablet administered daily for an 8 week period
75605640|NCT01110915|Device|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
75750337|NCT04507438|Drug|Placebo Oral Tablet|Placebo oral tablet administered daily for an 8 week period
75750338|NCT04459273|Procedure|Computed Tomography|Undergo PET/CT
75750339|NCT04459273|Drug|Gallium Ga 68 FAPi-46|Given IV
75454298|NCT04092634|Device|Traditional, Single-bearing hip implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
75454299|NCT04086589|Other|Observational study without intervention|Observational study without intervention
75750340|NCT04459273|Procedure|Positron Emission Tomography|Undergo PET/CT
75750341|NCT04459273|Radiation|18F-FDG|Given IV
75750342|NCT04457973|Device|Active tDCS|tDCS with a constant current intensity of 2 milliampere (mA) will be applied for 20 minutes per session daily for 5 days via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and 5x7 cm saline-soaked surface sponge electrodes.
75750343|NCT04457973|Device|Sham tDCS|The electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
75750344|NCT04457232|Procedure|Computed Tomography|Undergo PET/CT imaging
75750345|NCT04457232|Other|Gallium Ga 68 FAPi-46|Given IV
75454306|NCT04049669|Drug|Indoximod|Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.
75750346|NCT04457232|Procedure|Positron Emission Tomography|Undergo PET/CT imaging
75750347|NCT04441775|Other|AI-assisted RT modelling|Artificial Intelligence assisted Radiation Treatment
75750348|NCT04440358|Device|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system to deliver carboplatin
75750349|NCT04440358|Drug|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
75750350|NCT04417088|Drug|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
75750351|NCT04417088|Device|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
75750352|NCT04381897|Drug|N-acetyl cysteine|Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.
75750353|NCT04381897|Other|Placebo|NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.
75909625|NCT04608578|Behavioral|Silver|A serious game to improve mental health in youth
75909626|NCT03473600|Procedure|Cryotherapy|Liquid Nitrogen spray
75454307|NCT04049669|Radiation|Partial Radiation|Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).
75454308|NCT04049669|Radiation|Full-dose Radiation|Palliative full-dose radiation plan to all known sites of disease (>50 Gy to brain, >45 Gy to spine).
75454309|NCT04049669|Drug|Temozolomide|Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.
75454310|NCT04049669|Drug|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
75454311|NCT04049669|Drug|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
75454312|NCT04049669|Drug|Lomustine|Lomustine will be taken by mouth once daily, on day 1 of each chemo-immunotherapy treatment cycle.
75454313|NCT04041401|Other|PICU storybook|Narrative and developmentally appropriate intervention
75899819|NCT04713657|Procedure|Cardiac MRI|"A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this feed, swaddle, and sleep technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle."
75899820|NCT04713657|Drug|Propranolol Hydrochloride|For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
75899821|NCT04713657|Drug|Placebo|For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
75899822|NCT04713657|Procedure|Physical Exam|On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
75899823|NCT04713657|Other|Specimen Collection|On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
75605641|NCT01110915|Device|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
75605642|NCT01254344|Drug|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
75899824|NCT04712110|Biological|TAK-019|TAK-019 intramuscular injection
75899825|NCT04712110|Biological|Placebo|Placebo intramuscular injection
75899826|NCT04706546|Other|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
75605643|NCT01254344|Drug|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
75605644|NCT01254344|Drug|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
75454314|NCT04029454|Biological|birth dose vaccination against hepatitis B strategy|"Complex intervention targeting healthcare workers and involving:~training on hepatitis B awareness and management~training on EPI vaccination and cold chain~training on the modalities for the birth dose administration~the use of a monovalent unidose vaccine against Hepatitis B"
75454315|NCT04028674|Device|Laryngeal Pacing Device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
75454316|NCT04023331|Drug|67Cu-SARTATE|67Cu-labelled MeCOSar-Tyr3-octreotate
75454317|NCT04023331|Drug|64Cu-SARTATE|64Cu-labelled MeCOSar-Tyr3-octreotate
75454318|NCT04023305|Drug|Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts|Pharmacokinetic of inhaled sevoflurane used for sedation
75454319|NCT04014712|Drug|Tetrahydrobiopterin|Oral, Single dose
75454320|NCT04014712|Drug|Placebo oral tablet|Single dose
75899827|NCT04706546|Other|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75899828|NCT04704440|Other|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75899829|NCT04704440|Other|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75899830|NCT04704440|Other|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75899831|NCT04704440|Other|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75899832|NCT04697875|Other|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75454321|NCT03967158|Device|Xience Sierra stent|Percutaneous coronary intervention with Xience Sierra stent
75454322|NCT03915184|Biological|zevor-cel|A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
75605645|NCT01254344|Drug|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
75605646|NCT02879877|Drug|UCB7858|
75605647|NCT02879877|Drug|Placebo|
75454323|NCT03912259|Drug|Dupilumab|"Pharmaceutical form: solution,~Route of administration: SC"
75899833|NCT04697875|Other|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75899834|NCT04697862|Other|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
75899835|NCT04697862|Other|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
75605648|NCT05051007|Drug|fentanyl|patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
75605649|NCT05051007|Drug|Lidocaine IV|patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
75909627|NCT03473600|Drug|Triamcinolone acetonide injection|Intralesional Triamcinolone Acetonide injection
75909628|NCT03473522|Device|tDCS|Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
75454324|NCT03912259|Drug|Placebo|"Pharmaceutical form: solution,~Route of administration: SC"
75454325|NCT03912259|Drug|Emollient (moisturizer)|"Pharmaceutical form: cream,~Route of administration: topical use"
75454326|NCT03871829|Drug|Carfilzomib 20 mg/m^2|Carfilzomib 20 mg/m^2 will be administered intravenously (IV).
75454327|NCT03871829|Drug|Carfilzomib 70 mg/m^2|Carfilzomib 70 mg/m^2 will be administered IV.
75605650|NCT02881671|Genetic|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
75605651|NCT02879565|Other|Semi structured interviews + EEG exams|
75605652|NCT04310319|Dietary Supplement|Sodiumchloride|Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
75605653|NCT04310319|Dietary Supplement|Protein|Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
75605654|NCT04310319|Dietary Supplement|Placebo comparator (salt)|Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
75605655|NCT04310319|Dietary Supplement|Placebo comparator (protein)|Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
75605656|NCT01102803|Behavioral|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
75605657|NCT01102803|Drug|D-Cycloserine|D-Cycloserine
75454328|NCT03871829|Drug|Dexamethasone 40 mg|Dexamethasone 40 mg will be administered as IV infusion or orally.
75454329|NCT03871829|Drug|Dara-SC 1800 mg|Dara-SC 1800 mg will be administered by SC injection.
75454330|NCT03871829|Drug|Dexamethasone 20 mg|Dexamethasone 20 mg will be administered as IV infusion or orally.
75605658|NCT01102803|Drug|Placebo|Sugar Pill
75605659|NCT01254188|Drug|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
75605660|NCT01109979|Drug|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
75605661|NCT01109979|Drug|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
75750354|NCT04381689|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Teratect Prefilled Syringe Inj. 0.5mL
75750355|NCT04381689|Biological|Fluarix Tetra Pre-filled Syringe|Fluarix Tetra Pre-filled Syringe 0.5mL
75750356|NCT04379596|Drug|Fluorouracil (5-FU)|5-FU: administered as an IV infusion
75750357|NCT04379596|Drug|Capecitabine|Capecitabine: administered orally
75750358|NCT04379596|Biological|Durvalumab|Durvalumab: administered as an IV infusion
75750359|NCT04379596|Drug|Oxaliplatin|Oxaliplatin: administered as an IV infusion
75750360|NCT04379596|Biological|Trastuzumab|Trastuzumab: administered as an IV infusion
75750361|NCT04379596|Drug|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
75750362|NCT04379596|Drug|Cisplatin|Cisplatin: administered as an IV infusion
75750363|NCT04379596|Biological|Pembrolizumab|Pembrolizumab: administered as an IV infusion
75750364|NCT04379596|Biological|MEDI5752|MEDI5752: administered as an IV infusion
75750365|NCT04362501|Biological|dupilumab|300mg dupixent SC every two weeks for six months
75454331|NCT03862859|Drug|Warfarin|Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
75454332|NCT03845270|Drug|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
75605662|NCT01102491|Drug|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
75605663|NCT01102257|Drug|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA"
75605664|NCT01102257|Drug|Olive Oil|Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
75605665|NCT01253564|Drug|RO5185426|960 mg b.i.d. orally
75605666|NCT04309149|Dietary Supplement|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
75605667|NCT01108809|Drug|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
75605668|NCT01253408|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
75605669|NCT01253408|Drug|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
75750366|NCT04362501|Drug|placebo|placebo SC injection every two weeks for six months
75750367|NCT04360213|Device|Advanced multimodal wireless vital signs monitor|Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
75750368|NCT04350268|Device|Wearable sensor|Wireless sensor
75750369|NCT04330690|Drug|Artesunate|2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care
75750370|NCT04330690|Drug|Imatinib|400 mg enterally daily for 14 days plus standard of care
75605670|NCT02879799|Other|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
75605671|NCT02879643|Drug|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
75605672|NCT02879487|Device|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
75454333|NCT03831464|Drug|Metformin Hydrochloride|"The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment ."
75605673|NCT02879721|Drug|Candesartan|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for
75605674|NCT02879721|Drug|Enalapril|Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
75605675|NCT01253174|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
75454334|NCT03831464|Drug|Placebo Oral Tablet|The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
75750371|NCT04330690|Drug|Infliximab|5 mg/kg IV given one time, over 2 hours plus standard of care
75750372|NCT04330690|Drug|Dexamethasone|6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10
75750373|NCT04330690|Drug|LSALT Peptide|5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
75454335|NCT03799991|Behavioral|Vestibular physical therapy|Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
75454336|NCT03799991|Behavioral|Active control|Strength and flexibility exercises that do not involve head movements.
75454337|NCT03783936|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2
75454338|NCT03783936|Drug|Leucovorin|Leucovorin 400 mg/m2
75454339|NCT03783936|Drug|5 fluorouracil|5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
75750374|NCT04304872|Behavioral|Gamification|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
75750375|NCT04304872|Behavioral|Loss-Framed Financial Incentives|Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
75750376|NCT04280757|Procedure|Biopsied ICSI embryos (PGS)|Biopsied ICSI embryos (PGS)
75605676|NCT01253174|Drug|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
75605677|NCT01253174|Drug|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
75605678|NCT01108731|Drug|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
75605679|NCT01108731|Drug|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
75605680|NCT04308447|Device|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
75750377|NCT04276064|Device|Auditory closed-loop stimulation: slow oscillation boosting|Auditory-closed loop stimulation: slow oscillation boosting
75454340|NCT03783936|Drug|Trastuzumab|Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
75454341|NCT03783936|Drug|Avelumab|Avelumab 800 mg
75454342|NCT03755414|Procedure|Stem cell transplantation|Standard of care
75454343|NCT03755414|Drug|Itacitinib|Itacitinib may be taken without regard to food.
75454344|NCT03755414|Other|Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)|"Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
75605681|NCT01253018|Behavioral|Robot Therapy|Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
75605682|NCT01253018|Behavioral|Transition to Task Training|Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
75605683|NCT04308915|Behavioral|Game-based cognitive training|A suite of 5 games is presented to the participants for training working memory
75750378|NCT04276064|Device|Auditory closed-loop stimulation: slow oscillation disruption|Auditory closed-loop stimulation: slow oscillation disruption
75750379|NCT04276064|Device|Sham stimulation|Sham stimulation
75750380|NCT04268199|Drug|Bortezomib Injection|Subcutaneous injection
75750381|NCT04255303|Other|Integrated clinical prediction rule (iCPR) system (iCPR)|"The iCPR tool consists of an electronic calculator that can be used to determine whether the patient is at low, intermediate or high risk for having the diagnosis and a bundled order set (called a Smartset). The iCPR tool will be made available directly within the Electronic Health Record (EHR) for Registered Nurses (RNs) who are seeing patients fall into the study categories. The iCPR tool through the use of order sets will guide the RN in the patient's care. The order set for patients at low risk for these diseases will recommend supportive care including over the counter cold remedies and pain relievers. The order set for patients at intermediate or high risk of these disease will recommend diagnostic tests (rapid strep antigen or CXR) to help determine if they have the disease. Based on the results of the diagnostic tests new order sets will recommend antibiotics or supportive care"
75750382|NCT04252794|Procedure|Splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
75750383|NCT04252794|Other|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
75750384|NCT04223310|Drug|Virtual AAD TEST group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Preselect drug with optimal antiarrhythmic effects in the patient.~Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
75750385|NCT04223310|Drug|Empirical AAD group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
75750386|NCT04198116|Drug|Varenicline|Varenicline 2mg/day
75750387|NCT04198116|Drug|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
75454345|NCT03755414|Other|Human Activity Profile|"Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
75463284|NCT05854797|Other|Brisk Walking|"Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
75605684|NCT04308525|Behavioral|Early ambulation|Early ambulation will help prevent postoperative infections, especially pneumonia and urinary tract infections. Additionally it will prevent constipation by promotion of bowel-movement and function and prevent thromboembolic complications. Patients undergoing surgery with a free fibula flap are currently unable to ambulate for 6 to 7 days while a split-thickness skin-graft is healing. We will apply a pressure dressing to the wound which makes ambulation possible immediately after surgery (or after return from the ICU). Likewise, all other patient groups will be encouraged to fully ambulate on POD (post-operative day) 1 or POD 2.
75750388|NCT04172844|Drug|Azacitidine|75mg/m^2 Days 1-7 given IV
75750389|NCT04172844|Drug|Venetoclax|100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
75899836|NCT04696029|Drug|Difluoromethylornithine|"DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C)."
75899837|NCT04653597|Procedure|Close monitoring|surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS>8 or responds adequately to a simple order
75899838|NCT04653597|Procedure|Endotracheal intubation|invasive airway management in order to avoid risk of pulmonary aspiration
75899839|NCT04652544|Drug|Cholecalciferol (Vitamin D3)|Vi-De 3® Monthly Dose from Dr. Wild & Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.
75750390|NCT04172844|Drug|Pevonedistat|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
75750391|NCT04147494|Procedure|Computed Tomography|Undergo PET/CT scan
75899840|NCT04652544|Other|Placebo|A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
75750392|NCT04147494|Radiation|Gallium Ga 68 FAPi-46|Given IV
75750393|NCT04147494|Radiation|Gallium Ga 68-labeled PSMA-11|Given IV
75899841|NCT04642508|Procedure|Prepectoral reconstruction|Immediate prepectoral breast reconstruction in women requiring a mastectomy
75899842|NCT04635085|Behavioral|Empowerment-based Cognitive behavioral therapy for insomnia for MCI|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups. In total, six face-to-face sessions (90 minutes/session) will be conducted in a small group format with 6-8 participants in a group.
75899843|NCT04625699|Drug|Durvalumab|4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)
75899844|NCT04625699|Drug|Tremelimumab|2 doses of Tremelimumab 300 mg IV Day 1, q56 days
75899845|NCT04606927|Other|Natriuresis|Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.
75899846|NCT04562467|Drug|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|2 x 1g capsules BID as per REDUCE-IT
75899847|NCT04533698|Other|Assessment of reason for resternotomy|No intervention is performed. Reasons for resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
75899848|NCT04533698|Other|Assessment of reason for avoidance of resternotomy|No intervention is performed. Reasons for avoidance resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
75454346|NCT03754114|Other|ICP + PbtO2 guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
75454347|NCT03754114|Other|ICP guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
75454348|NCT03742986|Drug|Nivolumab 360mg|Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)
75454349|NCT03742986|Drug|Paclitaxel 80mg/m^2|Paclitaxel 80mg/m^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)
75454350|NCT03742986|Drug|Doxorubicin 60mg/m^2|Doxorubicin 60 mg/m^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
75454351|NCT03742986|Drug|Cyclophosphamide 600mg/m^2|Cyclophosphamide 600mg/m^2 on Day 1 of every 14 day cycle (Cycle 5-8)
75899849|NCT04510584|Drug|Atezolizumab|Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.
75899850|NCT04510584|Drug|Bevacizumab|Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
75899851|NCT04500847|Drug|Emtriva Capsule|200mg daily oral dose
75899852|NCT04500847|Drug|Placebo|200mg daily oral dose
75899853|NCT04484532|Biological|Trivalent Influenza Vaccine|Given IM
75454352|NCT03742986|Drug|Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2|Paclitaxel 80mg/m^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m^2 on Day 1 of every 21 day cycle (Cycle 1-4)
75454353|NCT03742986|Drug|Trastuzumab 8mg/kg and 6 mg/kg|Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4
75750394|NCT04147494|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75750395|NCT04147494|Radiation|18F-FDG|Given IV
75750396|NCT04144413|Drug|Open-label Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
75750397|NCT04144413|Drug|Masked Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
75750398|NCT04144413|Other|Vehicle Comparator: Masked Vehicle|Vehicle of IKERVIS® - sterile, ophthalmic cationic oil-in-water emulsion containing no active substance.
75750399|NCT04124939|Drug|OnabotulinumtoxinA 100 Units|"BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication."
75750400|NCT04124250|Other|Observational|Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years
75605685|NCT04308525|Behavioral|Early oral feeding|To monitor the patients' nutritional status, blood samples will be taken to identify risk of refeeding syndrome and patients will be evaluated according to the current guidelines from the ENT (ear-, nose-, throat-) department. We wil use the ESPEN guidelines for nutritional risk screening (NRS-2002), which have been validated for head and neck cancer patients to perform a risk assessment for malnutrition. A consultation with a clinical dietician will be arranged in order to calculate the required daily nutritional intake. Patients in risk of refeeding syndrome will be closely monitored in the outpatient clinic during the time from the MDT(Multi Disciplinary Team) conference to the day of surgery. Patients in need of additional nutritional support will be provided with supplementary energy/protein drinks. Some patients may need closer monitoring, guidance regarding extra meals and to have a nasogastric tube placed to get used to the tube and optimize pre-operative nutritional status.
75750401|NCT04078698|Device|Immunoadsorber GLOBAFFIN®|Documentation of the treatment with one of the immunoadsorber GLOBAFFIN® depending on the patient's underlying disease
75750402|NCT04047251|Drug|FF-10850 Topotecan Liposome Injection|FF-10850 to be diluted and infused over 60 minutes.
75750403|NCT04045613|Drug|Derazantinib 300 mg once daily monotherapy|Derazantinib was administered orally at a dose of 300 mg once daily
75899854|NCT04483583|Drug|Ticagrelor 60mg|Patients will be administered a 180 mg loading dose followed by a 60 mg bid for the duration of the study.
75899855|NCT04483583|Drug|Clopidogrel|Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.
75899856|NCT04477681|Other|Data collection|In particular, the patient's demographic data, medical history, previous and concomitant treatments, data on the treatment of interest (legal framework, ATU / off-label), dosage, start date, etc.), clinical data will be collected. biological (including molecular profiling of the tumor if available) and radiological follow-up, information on adverse effects. The data to be filled in is that of the CERFA pharmacovigilance form of the ANSM, but additional fields can be created if necessary.
75899857|NCT04447989|Drug|Sildenafil|Sildenafil citrate injection or powder for suspension
75899858|NCT04447989|Drug|Placebo|dextrose 5%
75899859|NCT04392960|Drug|[18F]Florbetaben|"Patients will undergo on the same day:~18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~standard assessment of clonal and organ disease;~echocardiography;~cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation."
76066548|NCT05388032|Behavioral|Sodium Reduction Intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to <2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
75454354|NCT03742986|Drug|Pertuzumab 840mg and 420mg|Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
75454355|NCT03736720|Drug|Fluorouracil|Given IV
76066549|NCT05374785|Drug|CPL409116|CPL409116 contained in the tablet called PG242 (60 mg)
76066550|NCT05374785|Other|Placebo|Tablets without CPL409116 as an active substance
75454356|NCT03736720|Drug|Leucovorin|Given IV
75454357|NCT03736720|Drug|Liposomal Irinotecan|Given IV
75750404|NCT04045613|Drug|Derazantinib 200 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
75750405|NCT04045613|Drug|Derazantinib 300 mg once daily+ atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
75750406|NCT04045613|Drug|Derazantinib 200 mg twice daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
75454358|NCT03736720|Procedure|Quality-of-Life Assessment|Correlative studies
75454360|NCT03708328|Drug|Lomvastomig|Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
75454361|NCT03703167|Drug|Ibrutinib|Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).
75454362|NCT03703167|Drug|Lenalidomide|Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 & 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).
75605686|NCT04308525|Other|Multimodal opioid-sparing analgesia|"On-label use of already approved drugs including perioperative dexamethasone, administered with the aim of reducing opioid intake.~Pre-operatively the patients are given 400 mg of Celebra. During surgery 24 mg of dexamethasone is administered. The post-operative regimen consists of 12 mg of Dexamethasone 48 and 96 hours post-operatively, 200 mg of Celebra morning and evening (maximum 14 days) and 1g of paracetamol times four times daily. Morphine will only be administered when assessed necessary with a dose of 10 mg p.n. maximum six times a day."
75605687|NCT04308525|Procedure|Goal-directed fluid therapy|Focus on avoidance of over-hydration. Aim for fluid-load after surgery: max: +1000-1500 ml
75605688|NCT04308525|Procedure|CAD/CAM system for reconstructive plates|Computer-assisted design and modelling (CAD/CAM) are a system for pre-operative planning and construction of reconstructive plates used for mandibular reconstruction. This will help reduce the operating-time, as the maxillofacial surgeon will bring a pre-bent reconstructive plate to the procedure instead of manually forming it during surgery. Already implemented for several procedures in the department.
75605689|NCT04308525|Other|Functional discharge criteria|Introduction of a number of functional discharge criteria to avoid prolonged postoperative hospitalisation
75605690|NCT04308525|Other|Standard/historical postoperative regimen|Non-formalised historical peri- and postoperative regimen.
75605691|NCT02881437|Drug|IgHy10|Sub Cutaneous IgHy10 administration
75605692|NCT01108341|Drug|Bendamustine hydrochloride|Bendamustine will be administered at 90 mg/m^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
75750407|NCT04045613|Drug|Derazantinib 300 mg once daily monotherapy (QD)|Derazantinib was administered orally at a dose of 300 mg once daily
75750408|NCT04045613|Drug|Derazantinib 300 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
75750409|NCT04045613|Drug|Derazantinib 200 mg twice daily monotherapy|Derazantinib was administered orally at a dose of 200 mg twice daily
75750410|NCT04042831|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
75750411|NCT04042831|Procedure|Computed Tomography|Undergo CT
75899860|NCT04385888|Behavioral|Low-calorie sweetener restriction|Participants will avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners for 12 weeks and will instead consume unsweetened alternatives, such as still or sparkling water
75899861|NCT04380155|Other|Exercise|Moderate intensity cycling trials of different duration (30, 60 and 120 min)
75454363|NCT03703167|Drug|Rituximab|Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
75454364|NCT03676465|Other|CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject & their parent had during the week about the participant's diabetes management.
75454365|NCT03676465|Other|Will not receive a CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject & their parent had during the week about the participant's diabetes management.
75454366|NCT03674528|Other|Magnetic Resonance Elastography (MRE)|The MRE scan will several breath holds and will take approximately 30 minutes to complete.
75605693|NCT01108341|Drug|Ofatumumab|Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
75605694|NCT01108263|Drug|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
75750412|NCT04042831|Procedure|Magnetic Resonance Imaging|Undergo MRI
75750413|NCT04042831|Drug|Olaparib|Given PO
75750414|NCT03964207|Drug|Tiotropium Respimat® (T1)|inhalation solution
75750415|NCT03964207|Drug|Tiotropium Handihaler® (T2)|Inhalation Powder
75750416|NCT03947255|Drug|brentuximab vedotin|1.8 mg/kg given intravenously (IV)
75750417|NCT03930147|Procedure|ASV ventilation|Ventilation on ASV mode
75750418|NCT03929757|Biological|Ad26.ZEBOV|Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.
75750419|NCT03929757|Biological|MVA-BN-Filo|Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.
75750420|NCT03929757|Biological|MenACWY|Participants will receive 0.5 mL IM injection of MenACWY.
75899862|NCT04378101|Other|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
75899863|NCT04375527|Drug|Binimetinib|Given PO
75899864|NCT04375527|Biological|Nivolumab|Given IV
75899865|NCT04375527|Other|Questionnaire Administration|Ancillary studies
75899866|NCT04356027|Procedure|ICA (Invasive Coronary Angiography)|Patients will undergo a Pre-PCI Angiography
75899867|NCT04356027|Procedure|OCT|OCT pullback images will be collected pre-PCI and (optional) post-PCI procedure
75899868|NCT04356027|Procedure|FFR|FFR will be measured
75899869|NCT04356027|Other|VFR Analysis|VFR will be calculated offline using the OCT pullback images
75605695|NCT01252940|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
75605696|NCT01252940|Drug|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
75605697|NCT01252940|Drug|RTV|Ritonavir (RTV) was administered according to prescribing information.
76066551|NCT05370183|Procedure|Hyperambulatory tenotomy|Using mini-optics a minimally invasive device, hypermabulatory tenotomy is performed in consultation, with a local anethesia
75605698|NCT01252940|Drug|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
75605699|NCT02879331|Procedure|10 coils in upper lobes|
75605700|NCT02879331|Procedure|15 coils in upper and lower lobes|
75605701|NCT02879331|Procedure|cycloergometry|
75605702|NCT04319744|Other|other|Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
75605703|NCT04206878|Diagnostic Test|Point-of-care birth test|Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
75605704|NCT01252238|Drug|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
75750421|NCT03919773|Drug|IVIG|"If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each."
75899870|NCT04351711|Other|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
76066552|NCT05370183|Procedure|Operating room tenotomy|Operating room tenotomy is performed according standard practice, with general anesthesia.
76066553|NCT05366712|Device|Stryker Trident® II HA coated cementless acetabula component|New acetabula component.
76066554|NCT05361668|Drug|Randomized: 40 mg Paltusotine|Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)
75454367|NCT03674528|Diagnostic Test|Liver biopsy|Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.
75454368|NCT03672630|Drug|Azithromycin|Azithromycin 500 MG Oral Tablet [ZITHROMAX]
75454369|NCT03672630|Drug|Ethambutol|Ethambutol 25 mg/kg [MYAMBUTOL]
75454370|NCT03672630|Drug|Rifampin|Rifampin 600 MG [RIFADIN]
75454371|NCT03659734|Behavioral|Motivational Interviewing and Guided Opioid Tapering Support|Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
75605705|NCT01252238|Drug|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
75605706|NCT01252238|Drug|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
75750422|NCT03919773|Drug|Albumin|This will be the matching placebo used in the study.
75750423|NCT03904147|Device|Tricuspid valve repair|Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
75750424|NCT03900429|Drug|MGL-3196|Tablet
75750425|NCT03900429|Drug|Placebo|Matching Tablets
75750426|NCT03877653|Device|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
75750427|NCT03845829|Procedure|In situ laser assisted fenestration|In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
75750428|NCT03789786|Diagnostic Test|Gait and Motion Analysis|Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
75899871|NCT04351711|Other|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
76066555|NCT05361668|Drug|Randomized: 80 mg Paltusotine|Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
75454372|NCT03659734|Behavioral|Enhanced Usual Care|Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
76066556|NCT05346627|Procedure|Personalized and mixed training program|Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
76066557|NCT05345899|Diagnostic Test|Evaluation of vitamin C level in plasma|A protocol-specific blood test wil assess the vitamin C level in plasma
75605707|NCT01101477|Procedure|TCI titration by different Cet.|"Induction:~After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.~If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.~Maintenance:~The Cet will be increased according to the assigned regimens if:~Patients become irritant and interfere procedures.~Patients open eyes or talk to express uncomfortable.~The Cet will be decreased if:~Systolic blood pressure is less than 90mmHg;~Mean arterial blood pressure is less than 65mmHg;~Oxyhemoglobin saturation is less than 90 %~with any duration."
75605708|NCT00624260|Other|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
75605709|NCT00624260|Other|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
75605710|NCT04308213|Device|Marrow Cellution System|The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
75605711|NCT01251770|Drug|0.45% NaCl/dextrose 5%|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 body surface.
75605712|NCT01251770|Drug|0.3% NaCl/dextrose 5%|Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 surface.
75605713|NCT01101321|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
75605714|NCT01101321|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
75605715|NCT04309929|Drug|Analgesics|All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
75605716|NCT01101165|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken without food
75605717|NCT01101165|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
75605718|NCT01100853|Drug|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
75605719|NCT02881281|Other|educational program for Development of problem-solving skills|
75605720|NCT02881281|Other|no education program|no education program
75454373|NCT03642028|Drug|Suvorexant|Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.
75454374|NCT03642028|Other|Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
75454375|NCT03639753|Behavioral|Parent-Teen Intervention|Parent health coaching and resources + teen on-road driver experience + safe driving eLearning Modules
75454376|NCT03639753|Other|Usual Practice|Standard care for teens who get licensed in the state of PA
75454377|NCT03636295|Drug|Warfarin|Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
75605721|NCT00626067|Device|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
75605722|NCT00626067|Device|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
75605723|NCT00626067|Device|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
75605724|NCT01100307|Drug|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
75605725|NCT01100307|Other|sham injection|sham injection every 6 weeks
75750429|NCT03789786|Diagnostic Test|Gross Motor Function Measure (GMFM)|Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
75750430|NCT03789786|Behavioral|Surveys|Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
75750431|NCT03786081|Drug|Tisotumab Vedotin|Given into the vein (IV)
75454378|NCT03630107|Other|WO 5101 Shampoo for Scalp and Hair|Wash the hair at least three times a week for a period of four weeks
75454379|NCT03609177|Other|Clinician Communication Skills Training|Communication skills training
75454380|NCT03609177|Other|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
75454381|NCT03609177|Other|Video Declarations (ViDec)|Recording of patient advance care planning videos
75750432|NCT03786081|Drug|Bevacizumab|Given via IV
76066558|NCT05345899|Other|Evaluation of quality of life|Several questionnaire will be completed by patients to evaluate quality of life: Analog and visual scale (EVA) pain, Neuropathic pain (DN) 4 questionnaire, EVA fatigue, Short Form (SF) 12 questionnaire and Hospital Anxiety and Depression scale (HAD questionnaire)
76066559|NCT05337566|Drug|Azithromycin Pill + Cefuroxime|Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
76066560|NCT05337566|Drug|Placebo + Cefuroxime|Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
76066561|NCT05333874|Drug|Neoadjuvant chemotherapy administered before surgical extraction of a tumor|SignateraTM is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera methodology is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor tissue. This maximizes accuracy for detecting the presence or absence of disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
76066562|NCT05333874|Other|Observational|In participants, undetectable ctDNA at fourteen days will be in the observation arm (observation defined as TNBC: No adjuvant chemotherapy. Participants may complete checkpoint inhibitor from neoadjuvant setting; HER2 positive BC: Completed one year of anti-HER2 therapy from the neoadjuvant setting). No investigational drugs will be used. Samples of ctDNA will be collected at time points described in the study arm.
76066563|NCT05332626|Dietary Supplement|Probiotic group|The probiotic gorup is focused on the treatment of postmenopause osteoporosis women with a capsule cointained 1x10^9 CFU of Lactobacillus acidophilus UALa-01™/day (30 people)
75454382|NCT03603210|Device|Drug coated balloon angioplasty|Drug coated balloons are semi compliant percutaneous coronary angioplasty balloons coated with a chemotherapeutic drug such as Paclitaxel used with an excipient which allows rapid absorption to vessel wall upon balloon expansion for 30-60s. This allows coronary angioplasty without any permanent or semi- permanent stent or scaffold provided there are no vessel threatening dissections or significant acute recoil.
76066564|NCT05332626|Dietary Supplement|Placebo group|The group is assigned on the treatment of postmenopause osteoporosis women without probiotic intervention (30 people)
75454383|NCT03589846|Device|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. Under anesthesia, fine-wire electrodes will be placed into the right genioglossus muscle (in the floor of the mouth) and the right palatoglossus muscle (in the anterior tonsillar pillar).
75454384|NCT03588481|Device|DESyne X2|Novolimus-eluting stent
75454385|NCT03586102|Dietary Supplement|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive > 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
75454386|NCT03586102|Dietary Supplement|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (< 4.5 g/kg/day of enteral protein)
75750433|NCT03786081|Drug|Pembrolizumab|Given via IV
75750434|NCT03786081|Drug|Carboplatin|Given via IV
75750435|NCT03770858|Drug|Crisaborole|Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
76066565|NCT05324293|Drug|HMI-115|Once Every 2 weeks, subcutaneously injection
76066566|NCT05321862|Drug|[68Ga]Ga-PentixaFor|Tomography by Emission of Positons (PET) with the radiopharmaceutic [68Ga]Ga-PentixaFor
75454387|NCT03562793|Behavioral|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
75454388|NCT03556826|Behavioral|Social Value Learning Training|For each child, two faces will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display.
75454389|NCT03551691|Drug|Omeprazole 40mg Capsule|Omeprazole 40mg daily for 28 days
75750436|NCT03770858|Device|Scratch sensor|advanced, flexible and wearable skin sensor
75454390|NCT03551691|Drug|Placebo oral capsule|Identically-appearing capsule to omeprazole for 28 days
75454391|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
75605726|NCT01099917|Drug|Maitake|"Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test."
75605727|NCT02879097|Biological|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
75899872|NCT04334343|Other|Additional Muscle Biopsy Collection|Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
75899873|NCT04322370|Procedure|Standard of Care Surgical Procedure|Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.
75899874|NCT04322370|Device|VersaWrap Treatment|is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue
75899875|NCT04296903|Device|MID-C System|Minimal invasive deformity correction system for the treatment of AIS
75454392|NCT03508518|Other|Shared care device in psychiatry (DSPP)|The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
75454393|NCT03508518|Other|Usual Care|psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
75899876|NCT04290520|Other|bioassay|Serum progesterone level (ng/ml)
75899877|NCT04271423|Procedure|Ridge Preservation|Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.
75454394|NCT03508427|Other|Daily self-monitoring|Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
75454395|NCT03501303|Procedure|No touch technique|Veins for CABG is harvested with the no touch technique
75454396|NCT03501303|Procedure|Control technique|Veins for CABG is harvested with the Control technique.
75454397|NCT03494881|Drug|Nucala|All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
75899878|NCT04223999|Procedure|Skullremodeling surgery|"Strategically placed cranial burrholes in order to improve the TTField dose focally in the tumor."
75899879|NCT04223999|Other|Control|Tumor treating fields combined with best medical treatment.
75899880|NCT04218799|Drug|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
75899881|NCT04189445|Drug|Futibatinib|Futibatinib tablets will be dosed orally every day on a continuous 28-day cycle
75899882|NCT04183920|Other|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
75899883|NCT04183920|Other|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
75899884|NCT04179032|Combination Product|Belimumab|Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.
75899885|NCT04148703|Other|Follow up post Pacemaker implantation in office|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up
75899886|NCT04148703|Other|Follow up post Pacemaker implantation by home monitoring|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
75899887|NCT04138953|Device|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation, also known as repetitive transcranial magnetic stimulation, is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction.~It will be used to create a 'virtual lesion,' disrupting neural activity in a specific brain region to identify whether it is causally involved in a specific behavioral process."
75899888|NCT04138953|Other|Sham TMS|Sham Transcranial Magnetic Stimulation (TMS) over premotor cortex
75454398|NCT03493425|Drug|Carboplatin|Given IV
75454399|NCT03493425|Drug|Cisplatin|Given IV
75454400|NCT03493425|Drug|Docetaxel|Given IV
75454401|NCT03493425|Radiation|Image Guided Radiation Therapy|Undergo image guided IMRT
75454402|NCT03493425|Radiation|Intensity-Modulated Radiation Therapy|Undergo image guided IMRT
75454403|NCT03493425|Other|Laboratory Biomarker Analysis|Correlative studies
75454404|NCT03493425|Other|Questionnaire Administration|Ancillary studies
75605728|NCT02879097|Biological|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
75750437|NCT03761641|Other|Neurotriage|NeuroTriage binocular handset monitors pupil dynamics & eye position with infrared cameras. Rubber non-allergenic ocular spacers contoured to eye sockets come in contact with the face &cushion between the skin & eyepiece. During pupil dilation tests, an LED briefly illuminates the pupil. The NeuroTriage system measures neurological pupil index, constriction velocity, & dilation velocity. Total pupil dilation testing time is < 1 minute. During saccade-tracking tests, patients direct their gaze towards dim LED targets selectable across the range of view. Visual targets involve center-out ocular motion or smooth pursuit following of illusory movement. The NeuroTriage system measures eye position & movement velocity during these tests. Total saccade-tracking testing takes < 3 minutes. Ocular measures are non-invasive, are done quickly and commonly used to measure neurological function.
75750438|NCT03754803|Other|HIV Symptom Distress Module Questionnaire|The Symptom Distress Module is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
75750439|NCT03754803|Other|HIV treatment satisfaction questionnaire|The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.
75454405|NCT03493425|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
75750440|NCT03748823|Combination Product|Ravulizumab OBDS|The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
75899889|NCT04125992|Procedure|distal radial artery access in coronary angiography and angioplasty|"The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis."
75899890|NCT04125992|Procedure|Forearm radial artery access in coronary angiography and angioplasty|"The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis."
75899891|NCT04100954|Device|Reinforced prosthesis|Implementation of a reinforced prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
75899892|NCT04100954|Device|Standard prosthesis|Implementation of a standard prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
75899893|NCT04093310|Device|Word Catheter|Use of the Word catheter to remove the Bartholin's abscess
76066567|NCT05320666|Behavioral|Yes You Can…Make Smart Choices! (YYC…MSC!) program|The YYC…MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.
76066568|NCT05308108|Procedure|(Adeno)tonsillectomy|registration of PORC in children with OSAS after (adeno)tonsillectomy
75605729|NCT02879097|Drug|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
75454406|NCT03490929|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|injection of Lumason (ultrasound contrast agent)
75454407|NCT03490929|Device|contrast-enhanced ultrasound|ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
75454408|NCT03477058|Other|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
75454409|NCT03468634|Diagnostic Test|endoscopy|Oesophageal endoscopy with biopsy
75454410|NCT03451123|Drug|FET PET/MRI|FET PET/MRI scan before and after surgery
75605730|NCT02879097|Drug|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
75750441|NCT03748823|Biological|Ravulizumab|Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
75454411|NCT03429582|Device|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
75454412|NCT03429582|Device|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
75454413|NCT03429582|Device|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
75899894|NCT04093310|Procedure|Incision-drainage|Incision-drainage to remove the Bartholin's abscess
75605731|NCT04307901|Device|Colon capsule endoscopy|Endoscopy performed using PillCam2 camera capsule for oral ingestion
75605732|NCT04307823|Other|Treadmill training|"3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms"
75605733|NCT04307823|Other|Treadmill protocol and Respiratory training|"Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks"
75605734|NCT02880969|Behavioral|answering questionnaires|
75605735|NCT01099215|Biological|PVS-10200|PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
75605736|NCT02878941|Procedure|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
75605737|NCT02879019|Other|Stretching exercise group|In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
75605738|NCT02879019|Other|Walking training group|Patients will perform two walking session per week, each consisting of 15*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
75605739|NCT05087745|Biological|Tumor Infiltrating Lymphocytes|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
75605740|NCT02878863|Drug|Paeoniflorin + phosphatidylcholine or silymarin|
75750442|NCT03741400|Device|Neofect RAPAEL Smart Glove|The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
76066569|NCT05305872|Drug|Gandouling|The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
76066570|NCT05304195|Diagnostic Test|Glucocerebrosidase|Blood sample (10ml) for GCase activity
75750443|NCT03716167|Device|Summus Laser|infrared laser treatment
75454414|NCT03382145|Other|No intervention|No intervention
75454415|NCT03373383|Drug|Padsevonil|Padsevonil in different dosages.
75454416|NCT03373383|Other|Placebo|Placebo will be provided matching Padsevonil.
75605741|NCT02878863|Drug|Phosphatidylcholine or silymarin|
75605742|NCT02881125|Drug|Nortriptyline Hydrochloride|Given PO
75605743|NCT02881125|Drug|Paclitaxel|Given IV
75605744|NCT02880657|Dietary Supplement|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
75605745|NCT02880657|Dietary Supplement|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
75750444|NCT03716167|Device|Summus Laser Sham|non-infrared light
75750445|NCT03690154|Drug|FN-1501|Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
75750446|NCT03665831|Device|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
75750447|NCT03622606|Diagnostic Test|Right Language screening test (R-LAST)|Validation of the Right Language screening test in acute and subacute phase of right stroke
75899895|NCT04090476|Other|Exercise|During each of the exercise sessions the LSVT Big daily exercises will be performed along with functional tasks and gait/balance tasks. The functional tasks and gait/balance tasks will change weekly to monthly and all activities will be modified to the participant's mobility level.
75899896|NCT04050293|Drug|SPN-538|Patients will receive SPN-538
75899897|NCT04050293|Drug|Placebo|Patients will receive Placebo
76066571|NCT05304195|Genetic|GBA gene|Blood sample (10ml) for variants or mutations of the GBA gene
76066572|NCT05279417|Drug|ATI-450 50mg oral tablet BID|Oral, small molecule MK2 inhibitor
76066573|NCT05279417|Drug|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
76066574|NCT05279417|Drug|Methotrexate|15 mg to 25 mg weekly
75454417|NCT03348566|Other|fish|fish intkae
75454418|NCT03332797|Drug|GDC-9545|GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
75454419|NCT03332797|Drug|Palbociclib|Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
75605746|NCT02880735|Device|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
75605747|NCT02880813|Other|Infusion|infusion of nutrients
75605748|NCT05354193|Other|vasoplegic syndrome|"In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure < 65 mmHg, cardiac index < 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock"
75605749|NCT01107405|Drug|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
75605750|NCT01107405|Drug|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
75605751|NCT01107405|Drug|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
75605752|NCT01107405|Drug|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
75605753|NCT01107405|Drug|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
75605754|NCT01097577|Drug|pregabalin|1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
75605755|NCT01097577|Drug|Placebo|1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
75605756|NCT01097421|Drug|Pramipexole Extended Release|
75899898|NCT04026776|Drug|Allopurinol|Study Part 2- Preterm group only: After Visit 5 preterm born participants will start allopurinol 200 mg daily PO for 6 weeks. The 1 week high and low salt diets and assessments will be repeated while on allopurinol.
75899899|NCT04026776|Other|Dietary Intervention|High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
75899900|NCT03978871|Behavioral|Growth Mindset|Growth emotion mindset induction
75899901|NCT03978871|Behavioral|Control|Brain education
75899902|NCT03975855|Device|NeoNavia® Biopsy System|Biopsy of axillary lymph node using the NeoNavia Biopsy System. The investigator shall obtain as many/large samples as judged adequate and sufficient for diagnosis.
75454420|NCT03332797|Drug|LHRH Agonist|The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
75454421|NCT03320018|Drug|Hydrogen|Hydrogen will be infused into bags of normal saline solution and administered intravenously, or hydrogen generating tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.
75454422|NCT03320018|Drug|Minocycline|"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."
75454423|NCT03320018|Other|Placebo Hydrogen|"Normal saline solution will be administered intravenously, in place of hydrogen solution.~Placebo tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days."
75454424|NCT03320018|Other|Placebo Minocycline|Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
75454425|NCT03306082|Other|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
75454426|NCT03276559|Behavioral|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
75454427|NCT03276559|Other|Enhanced Usual Care|Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
75605757|NCT02878629|Device|Mandibular Advancement Devices|
75605758|NCT02878395|Procedure|Ileocolic resection|
75605759|NCT04205877|Device|Transcatheter PDA Closure|Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.
75605760|NCT01251614|Biological|Adalimumab|Adalimumab by subcutaneous injection every other week (eow)
75605761|NCT01251614|Drug|Methotrexate|Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
75605762|NCT01251614|Biological|Placebo to Adalimumab|A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
75605763|NCT01251614|Drug|Placebo to Methotrexate|Orally once a week
75605764|NCT01106625|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
75605765|NCT01106625|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
75899903|NCT03946449|Drug|Fazirsiran Injection (TAK-999, ARO-AAT)|solution for subcutaneous (sc) injection
75899904|NCT03916939|Other|osteopathy|osteopathy treatment
75605766|NCT01106625|Drug|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
75454428|NCT03274492|Drug|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
75454429|NCT03274492|Drug|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
75454430|NCT03274492|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
75454431|NCT03274492|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
75899905|NCT03916939|Other|simulated osteopathy|simulated osteopathic sessions
75454432|NCT03274492|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
75454433|NCT03274492|Drug|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
75454434|NCT03274492|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
75454435|NCT03274492|Drug|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
75605767|NCT01106625|Drug|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
75605768|NCT01251380|Biological|Botulinum toxin type A|Intramuscular (IM) injection on day 1 of each treatment cycle.
75899906|NCT03913637|Behavioral|Strategy Training|Occupational therapists deliver Strategy Training to older adults virtually. Strategy training optimizes engagement in meaningful daily activities through generating self-selected goals, monitoring daily activities, scheduling activities, and problem-solving solutions to barriers experienced when engaging in activities.
75605769|NCT04307979|Dietary Supplement|High-fat coffee|A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.
75605770|NCT04307979|Dietary Supplement|Black coffee|A regular black coffee with no added caloric content.
75605771|NCT04309539|Procedure|Fascia iliaca block|"A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia."
75605772|NCT04309539|Procedure|combined LFCN block with PENG block|With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
75899907|NCT03913637|Other|Enhanced Usual Care|In this comparison condition, usual care will be enhanced by connecting older adults with MCI to resources available to meet their needs, and notify appropriate physicians when required. Enhanced Usual Care provides a usual care comparison while providing the participants with close monitoring of changes in symptoms.
75750448|NCT03617497|Diagnostic Test|scalp EEG and polysomnography|48 hour 22 channel EEG with polysomnography
75899908|NCT03909854|Procedure|mode of mechanical ventilation|Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.
75750449|NCT03617497|Diagnostic Test|scalp EEG with foramen ovale electrodes with polysomnography|long-term scalp EEG with additional foramen ovale electrodes with polysomnography
75750450|NCT03598699|Drug|AXR-159|AXR-159 Ophthalmic Solution
75750451|NCT03598699|Drug|Vehicle|AXR-159 Ophthalmic Solution Vehicle
75750452|NCT03588754|Drug|Propranolol|Propranolol Extended Release (160mg/day).
75750453|NCT03588754|Drug|Placebo|Placebo pill administered orally.
75750454|NCT03573089|Drug|Liberal phosphate target|All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
75454436|NCT03271034|Dietary Supplement|Weight loss|Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian and/or behaviorist weekly for ~4 months.
75454437|NCT03269136|Drug|PF-06863135 monotherapy IV or SC|PF-06863135 will be administered intravenously or subcutaneously.
75454438|NCT03269136|Drug|PF-06863135 + dexamethasone|PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.
75454439|NCT03269136|Drug|PF-06863135 + lenalidomide|PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally
75454440|NCT03269136|Drug|PF-06863135 + pomalidomide|PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
75454441|NCT03257384|Other|Black box recording of surgery|Time delays will be recorded from the moment the patient is draped and enters the operating room to the moment they exit the operating room.
75454442|NCT03255577|Procedure|Sentinel Lymph Node Biopsy (SLNB)|Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
75454443|NCT03250975|Drug|Budesonide and Azithromycin|Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
75454444|NCT03250975|Other|Placebo control of budesonide and azithromycin|placebos of the medications will be given for 14 days in patients randomized to the control group
75454445|NCT03230318|Drug|derazantinib|Derazantinib was administered orally at 300 mg once daily
75454446|NCT03193151|Procedure|liver biopsy|5 mm fragment of liver transplant biopsy taken for clinical indication
75454447|NCT03191162|Drug|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
75605773|NCT01251146|Drug|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
75605774|NCT01251146|Drug|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
75605775|NCT04309695|Device|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
75605776|NCT04307745|Other|Primary prevention|The primary prevention that the 4 groups put in place for the upper limp athletes
75605777|NCT02888678|Behavioral|Economic Strengthening (Impumelelo)|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
75605778|NCT02888678|Behavioral|HIV Prevention Education (Vhutshilo 2.2)|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
75605779|NCT00626145|Procedure|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
75605780|NCT00626145|Procedure|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
75605781|NCT02878707|Drug|Dexmedetomidine|Intraoperative dexmedetomidine infusion
75605782|NCT02878551|Other|Prehabilitation program|multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
75605783|NCT01096017|Drug|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
75899909|NCT03905668|Other|Video Monitoring|Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
75899910|NCT03905668|Other|Accelerometer Monitoring|Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
75899911|NCT03905668|Other|Electromyographic Monitoring|Patients may have electromyographic monitoring for up to seven days while in the ICU.
75605784|NCT01096017|Drug|Salbutamol pMDI|200 μg, inhalation, single dose
75605785|NCT01096017|Other|pMDI placebo pMDI|Placebo pMDI 2 inhalations
75605786|NCT01096017|Other|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
75605787|NCT00626223|Drug|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
75605788|NCT00626223|Drug|folic acid|5 mg per day of oral folic acid
75750455|NCT03573089|Drug|Intensive phosphate target|This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
75750456|NCT03565913|Drug|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
75899912|NCT03905668|Other|Noise Level Monitoring|Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
75899913|NCT03905668|Other|Light Level Monitoring|Patients may have light level monitoring for up to seven days while in the ICU.
75899914|NCT03877510|Drug|IPX203|IPX203 extended release capsules
75605789|NCT04908111|Biological|ChAdOx1-MAGEA3-NYESO|"Patients will commence their standard of care chemotherapy in combination with an immune checkpoint inhibitor in three weekly cycles. Patients will be screened during the first two cycles of standard of care treatment to confirm whether they are eligible to take part in the trial.~Patients who are to receive the trial vaccines (in the safety run in stage and in Arm A of the NSCLC randomisation cohort) will continue to receive their standard of care treatment plus:~First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of standard of care treatment.~First boost MVA-MAGEA3 vaccine 21 days later.~Only for patients who have not progressed: Second prime ChAdOx1-MAGEA3-NYESO vaccine 15 week following the first prime vaccine.~Second boost MVA-MAGEA3 vaccine 21 days following the second prime vaccine.~Patients in Arm B will continue to receive their standard of care treatment only throughout the trial (i.e. no trial vaccines)."
75454448|NCT03169972|Biological|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
75750457|NCT03565913|Other|CaAcS|CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
75454449|NCT03142958|Device|Integra Cadence Total Ankle System|Primary or revision on total ankle replacement
75454450|NCT03132337|Other|Serial Blood Draws|Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
75454451|NCT03090633|Device|Fetoscopy|Minimally invasive in-utero surgery
75454452|NCT03085316|Device|Investigational device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
75454453|NCT03084081|Device|CO2 standard therapy|Standard therapy using carbon dioxide for freezing of tissue
75454454|NCT03084081|Device|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
75454455|NCT03084081|Device|Thermocoagulator|Thermoablation
75454456|NCT03080883|Drug|Apixaban|Given PO
75750458|NCT03548558|Behavioral|Group sessions|Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 8 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send a short message service (SMS) mobile phone reminder of the session's topic, time and location to all participants.
75750459|NCT03548558|Behavioral|Group+Home sessions|Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV.
75750460|NCT03548558|Behavioral|Booster sessions|After the end of the 16 biweekly sessions (phase 1), we will re-randomize across the 40 intervention villages, stratified by Arms 1 and 2, and half of each of Arm 1 and Arm 2 villages will receive group booster visits every other month for the period between end-line and follow-up surveys. This will constitute Phase 2 of the study.
75454457|NCT03060291|Behavioral|FCU-Online, web/ mobile only|Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
75454458|NCT03060291|Behavioral|FCU-Online, web/ mobile + coach|"Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills."
75454459|NCT03058627|Procedure|PCI|FFR guided PCI
75454460|NCT03025035|Drug|Pembrolizumab|Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
75454461|NCT03025035|Drug|Olaparib|Olaparib administered orally twice a day
75454462|NCT02956291|Device|Magnetic Resonance Fingerprinting|Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes
75454463|NCT02953509|Drug|Magrolimab|Administered intravenously
75454464|NCT02953509|Drug|Rituximab|Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
75454465|NCT02953509|Drug|Gemcitabine|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
75454466|NCT02953509|Drug|Oxaliplatin|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
75454467|NCT02939872|Drug|aspirin and clopidogrel|at the discretion of investigator
75454468|NCT02939872|Drug|Clopidogrel only|at the discretion of investigator
75605790|NCT04908111|Biological|MVA-MAGEA3|"Patients will commence their standard of care chemotherapy in combination with an immune checkpoint inhibitor in three weekly cycles. Patients will be screened during the first two cycles of standard of care treatment to confirm whether they are eligible to take part in the trial.~Patients who are to receive the trial vaccines (in the safety run in stage and in Arm A of the NSCLC randomisation cohort) will continue to receive their standard of care treatment plus:~First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of standard of care treatment.~First boost MVA-MAGEA3 vaccine 21 days later.~Only for patients who have not progressed: Second prime ChAdOx1-MAGEA3-NYESO vaccine 15 week following the first prime vaccine.~Second boost MVA-MAGEA3 vaccine 21 days following the second prime vaccine.~Patients in Arm B will continue to receive their standard of care treatment only throughout the trial (i.e. no trial vaccines)."
75605791|NCT04908111|Combination Product|Standard of care treatment|Patients will continue to receive standard of care treatment (chemotherapy and checkpoint inhibitor).
75750461|NCT03548558|Behavioral|Fathers invited|During phase 1's 16 biweekly sessions, in half of Arm 1 and Arm 2 villages (20 total), fathers will additionally be invited to attend the 16 sessions. Separate father-only sessions will be held for 4 of the 16 sessions. This randomization will end after phase 1.
75750462|NCT03535883|Drug|Novel Oral Anti-Coagulants|Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
75750463|NCT03523156|Drug|Azithromycin mass treatment|Standard of care annual community-wide mass drug administration (MDA) will be provided at the normally scheduled time.
75750464|NCT03523156|Drug|Azithromycin targeted treatment|Two rounds of treatment targeted to all children aged 2 to 9 years old. The first targeted round will be 1-2 weeks after the community-wide MDA and the second round will occur another 1-2 weeks later.
75750465|NCT03517657|Behavioral|Bilateral Motor Priming + Task Specific Training (BMP + TST)|"Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement."
75750466|NCT03517657|Behavioral|Control Priming + TST (CP + TST)|The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
75750467|NCT03503058|Biological|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
75454469|NCT02887859|Biological|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
75454470|NCT02856438|Drug|Elotuzumab|Specified dose on specified days
75454471|NCT02856438|Drug|Lenalidomide|Specified dose on specified days
75750468|NCT03503058|Biological|PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|"Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
75454472|NCT02856438|Drug|Dexamethasone|Specified dose on specified days
75454473|NCT02850406|Drug|Voxelotor|"Part A: Voxelotor will be administered as oral capsules or tablets~Part B: Voxelotor will be administered as oral capsules or tablets~Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension"
75454474|NCT02803190|Behavioral|ICG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.
75750469|NCT03503058|Other|Normal Saline|0.9% Sodium chloride
75750470|NCT03503058|Drug|Chloroquine chemoprophylaxis alone|"Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS."
75750471|NCT03502993|Diagnostic Test|Validation of biomarker|
75899915|NCT03872778|Drug|[177Lu]-NeoB|[177Lu]-NeoB: peptide receptor radionuclide therapy
75605792|NCT02880423|Procedure|tubal ligation group II|"Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .~The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries"
75605793|NCT02880423|Procedure|salpingectomy group I|women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
75605794|NCT04123275|Other|No intervention wil be done. Patient characteristics and the standard care before and after withdrawal of life-sustaining treatment in all potential cDCD donors, will be studied. .|
75605795|NCT04307199|Procedure|Amniotic membrane sweep|Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.
75605796|NCT01106157|Drug|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
75750472|NCT03482349|Procedure|Total Knee Robotically-Assisted|The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
75605797|NCT01106157|Drug|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
75454475|NCT02803190|Behavioral|MTG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
75605798|NCT01106157|Drug|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
75750473|NCT03459534|Drug|Radotinib HCl|"Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~Storage conditions: Store in an airtight light proof container at room temperature."
75899916|NCT03872778|Drug|[68Ga]-NeoB|[68Ga]-NeoB radioactive diagnostic agent
75454476|NCT02764801|Drug|Ultrasound contrast agent (Contrast-enhanced ultrasound)|Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
75454477|NCT02764801|Device|Logiq E9 Scanner (Contrast-enhanced ultrasound)|Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
75899917|NCT03846427|Drug|Zanubrutinib|Zanubrutinib at a dose of 160 mg orally twice a day (BID)
75899918|NCT03831113|Drug|Buprenorphine: Magnitude Group|Dose reductions will continue until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
75899919|NCT03831113|Drug|Buprenorphine: Frequency Group|Dose reductions will continue until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
75899920|NCT03831113|Drug|Buprenorphine: Dosing Group|Dose reductions will continue until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
75454478|NCT02723929|Device|active low-intensity transcranial electrical stimulation/active transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes."
76066575|NCT05279417|Drug|ATI-450 20mg oral tablet BID|Oral, small molecule MK2 inhibitor
75454479|NCT02723929|Device|Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes."
75454480|NCT02709226|Radiation|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
75454481|NCT02670447|Procedure|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
75605799|NCT01094301|Device|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
75605800|NCT04835571|Other|Optimization of cardiovascular risk management|"Treatment goals were set according to current guidelines (Perk et al. Eur Guidelines on CVD prevention in clinical practice (2012). Eur heart J. 2012;33(13):1635-701):~blood pressure <140/90 mmHg~Tot cholesterol <5 mmol/l~LDL <1,8 mmol/l~Waist circumference: men <94 cm, women <80 cm~BMI <25 kg/m2~HbA1c without diabetes mellitus <42 mmol/mol, HbA1c with diabetes mellitus <52 mmol/mol~Antithrombotic treatment (or anticoagulants, if indicated)~Physical activity 30 min/day, 5 days/week, alternatively high-intensity training at least15 min/day, 5 days/week or a combination of the two.~Healthy diet, including low levels of saturated fats, high intake of vegetables, fruits, whole-grain and fish~Smoking cessation~Low alcohol consumption~Patients were encouraged to follow the above recommendations through support of the study physicians, who made individual assessments of all patients and adjusted ongoing medical treatment to reach treatment targets."
75605801|NCT04828005|Drug|Nalmefene hydrochloride|3mg Nasal spray
75605802|NCT04828005|Drug|Naloxone hydrochloride|4mg Nasal Spray
75899921|NCT03824561|Drug|Vedolizumab|Vedolizumab IV infusion
76066576|NCT05270694|Behavioral|Public Health Intervention Package|"The intervention package consists of two components:~At the time of study enrollment, participants will attend an in-person training on how to properly take an at-home COVID-19 test. Study staff will verbally walk through the steps of the test with the participant while the participant administers the test on themselves, with the opportunity to ask questions and receive corrective feedback, as needed.~To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits at the training and then every other month throughout the course of the year-long study for a total of 35 kits."
76066577|NCT05267652|Other|Preoxygenation with Non-Invasive Positive Pressure Ventilation|The delivery of oxygen and ventilation by non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
75605803|NCT04306887|Drug|TQ-B3101 capsule|Escalating doses starting at 200 mg bid.
75899922|NCT03821857|Drug|18-F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
75899923|NCT03818087|Behavioral|Observational cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessments over a period of five years from registration.
75899924|NCT04305236|Drug|Abemaciclib|Given PO
75899925|NCT04305236|Drug|Fulvestrant|Given Intramuscularly
75605804|NCT02877459|Device|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
76066578|NCT05267652|Other|Facemask Oxygen|The delivery of supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
76066579|NCT05251389|Other|Fecal microbiota transplantation|Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
76066580|NCT05233436|Drug|PF-07265028|PF-07265028 will be administered orally
75454482|NCT02670408|Procedure|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.
75454483|NCT02647099|Drug|Acetylsalicylic acid|
75454484|NCT02647099|Drug|Placebo|
75750474|NCT03456817|Drug|Treatment Arm - high dose ATG|Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 & -2, ATG will be infused after fludarabine & busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 & over at least 4 hrs on days -3, -2, -1 & 0. Dose is based on actual body wt, & rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in >5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 & 10 mg/m2 on days +3, +6 & +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.
75899926|NCT03761537|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
76066581|NCT05233436|Biological|Sasanlimab|Administered subcutaneously
76066582|NCT05233189|Other|MOOC|"Registrants will be offered a personalized e-education consisting of 3 to 11 modules adapted to the treatment received in childhood by each in the form of a MOOC entitled Cancer in childhood, living well after over a total duration of about 3 to 7 weeks of training."
75454485|NCT02626715|Drug|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
75454486|NCT02626715|Drug|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
75454487|NCT02593994|Device|Onyx Drug Eluting Stent group|
75605805|NCT04306497|Drug|TCM prescriptions|TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
75605806|NCT02878161|Drug|methotrexate(necessary)|Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
75454488|NCT02585622|Biological|Mesenchymal Stromal Cells|Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml
75454489|NCT02585622|Other|Placebo|Volume total of fluid infused: 40 ml
75605807|NCT02878161|Biological|infliximab|infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)
75605808|NCT02878161|Biological|etanercept|Etanercept :hypodermic injection,25mg/twice a week
75605809|NCT02878161|Biological|adalimumab|Adalimumab:hypodermic injection,40mg/twice a week
75750475|NCT03456817|Drug|Control Arm - standard of care|The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
75750476|NCT03435705|Behavioral|maintaining of occupational therapy|8 home sessions over a 4 months period with caregivers' education, occupational therapy and care coordination for post intervention
75750477|NCT03428633|Drug|Ropivacaine|Paravertebral block using ropivacaine preoperatively and postoperatively
75750478|NCT03428633|Drug|Morphine|Morphine intraoperatively and postoperatively
75605810|NCT02878161|Drug|leflunomide (permitted, not necessary)|LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
75899927|NCT03761537|Other|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
75899928|NCT03733678|Behavioral|Price discounts for SARCs|SARCs are offered free to the client
75750479|NCT03419832|Other|NEAT Form|The NEAT form consists of a clear and concise overview document containing information satisfying all elements of consent. This is made up of IRB-approved wording from the regular consent form. More detailed information, such as specific clinic measures are provided as additional material and are discussed during the consent process after the general overview has been provided with the NEAT form.
75750480|NCT03419832|Other|Standard Form|The regular IRB approved version.
75899929|NCT03733678|Behavioral|Price discounts for LARCs|LARCs are offered at lower prices to the client
75899930|NCT03733678|Behavioral|Sequential vs. simultaneous recommendations|Top ranked methods are presented to the client sequentially or simultaneously
75899931|NCT03706079|Biological|Tezepelumab|Tezepelumab subcutaneous injection
75899932|NCT03706079|Other|Placebo|Placebo subcutaneous injection
75899933|NCT03683030|Device|Multi-Electrode RF Balloon Catheter|Multi-Electrode RF Balloon Catheter will be inserted
75899934|NCT03657160|Drug|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion.
75899935|NCT03657160|Drug|Vedolizumab|Vedolizumab IV infusion.
75899936|NCT03635320|Device|TFNA|intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation
75899937|NCT03635320|Device|PFNA-II|intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
75454490|NCT02531854|Drug|ADXS11-001|ADXS11-001 is a live attenuated Listeria monocytogenes (Lm) bacteria bioengineered to secrete an antigen-adjuvant fusion protein (tLLO¬HPV-E7) consisting of a truncated fragment of the listeriolysin O (tLLO) fused to the full length E7 peptide of HPV-16.
75605811|NCT02878161|Drug|NSAIDs (permitted,not necessary)|NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
75605812|NCT02878161|Drug|Glucocorticoids (permitted,not necessary)|Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
75605813|NCT02877069|Device|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
75605814|NCT02877225|Drug|Ibrutinib|Ibrutinib (test treatment) 140 milligram (mg), tablet.
75605815|NCT02877225|Drug|IMBRUVICA|IMBRUVICA (reference treatment), 140-mg capsule
75605816|NCT01093755|Drug|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
75899938|NCT03623620|Behavioral|Digital Delivery of Mindfulness-Based Cognitive Therapy|12-week program that emphasizes mindfulness and cognitive behavioral skills
75454491|NCT02531854|Drug|Pemetrexed|Chemotherapy
75454492|NCT02530658|Other|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
75454493|NCT02530658|Other|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
75454494|NCT02530658|Other|Informed Consent Follow-Up Visit|Within 2-4 weeks following the Informed Consent Visit, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
75454495|NCT02530658|Other|Return of Results Conversation|Participants will complete the assessment questionnaires.
76066583|NCT05233189|Other|No intervention|Patients will be followed up until 18 months only
75899939|NCT03587870|Other|Enteral nutrition with Fresubin Intensive|Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
75899940|NCT03576274|Behavioral|Technology Enhanced Home Exercise (TEHE)|A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.
75750481|NCT03367247|Behavioral|BOLSTER|BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
75899941|NCT03576274|Behavioral|Auricular Point Acupressure (APA)|A non invasive complementary method to provide pressure on the ear points.
76066584|NCT05224258|Device|MiniMed 780G System|780G System used with Insulin Fiasp® (Insulin Aspart Injection)
76066585|NCT05215158|Drug|Dexmedetomidine|to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
76066586|NCT05206981|Device|IlluminOss Device|Patients may enroll in the registry if they have been implanted (retrospective) or will be implanted (prospective) with the IlluminOss device.
76066587|NCT05197569|Other|thyme oil|Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
75750482|NCT03367247|Other|Enhanced Discharge Planning (EDP)|EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
76066588|NCT05196841|Behavioral|Anastatica Hierochuntica|During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
75750483|NCT03364673|Other|Fitness Tracker|Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
75899942|NCT03576274|Behavioral|Mindfulness body scan (MBI)|The open, nonjudgmental attention to move one's attention calmly to the different part of the body
75899943|NCT03539068|Behavioral|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
75605817|NCT01093755|Drug|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
75605818|NCT01093599|Behavioral|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
75605819|NCT01093599|Behavioral|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
75605820|NCT01092663|Drug|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
75605821|NCT01092663|Drug|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
75750484|NCT03364673|Other|Social Incentive (Way to Health)|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
75750485|NCT03330405|Drug|Avelumab Phase 1b|Avelumab
75899944|NCT03508726|Drug|Ascorbate|"Phase 1 dose escalation:~75gm IV three times a week~Phase II portion:~75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV"
75899945|NCT03499964|Device|Optilume Drug Coated Balloon (DCB)|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
75899946|NCT03499964|Device|Control Treatment|A control subject may be dilated with either a rod, uncoated balloon or DVIU until the desired result is reached, based on standard of care for the clinical site and treating physician
75899947|NCT03437694|Other|Medication optimization intervention|Pharmacists will engage participants in medication therapy management either with access to the medical records (intervention) or without access (control).
75899948|NCT03404661|Drug|Synthetic Human Secretin|Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
75899949|NCT03370172|Drug|BAX 888|Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1, 2, 3 on Day 0.
76066589|NCT05195437|Other|QoLiSSY and PedsQL 4.0 questionnaires|"Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy."
75605822|NCT02877147|Other|SEBTC|SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
75454496|NCT02530658|Other|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 32±8 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
75605823|NCT01078623|Drug|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
75750486|NCT03330405|Drug|Talazoparib Phase 1b|Talazoparib
75750487|NCT03330405|Drug|Avelumab Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
75454497|NCT02530658|Procedure|Blood Sample|For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
75750488|NCT03330405|Drug|Talazoparib Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
75750489|NCT03222869|Diagnostic Test|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
75454498|NCT02530658|Procedure|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
75605824|NCT01078623|Drug|Placebo|Placebo control twice daily
75605825|NCT01078623|Drug|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
75605826|NCT01078623|Drug|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
75750490|NCT03207958|Drug|Belimumab|-Given over 1 hour
75750491|NCT03176927|Diagnostic Test|magnetogastrogram|
75899950|NCT03351803|Other|BFOR Digital Health solution/Web Portal|A digital health solution with Internet-based participant recruitment and ascertainment is a mechanism for distributing access to genetic testing to populations who might not otherwise have access. For this project, LifeLink will build a private web-portal designed by the PI's of the study as described in this protocol, including the wireframes that are in the appendices, that will enable secure contact between study participants and the participating commercial laboratory (Quest Diagnostics) and BFOR researchers, as well as facilitate contacts between study participants and their primary care providers and/or a list of BFOR study centers and BFOR providers.
75899951|NCT03328130|Biological|AAV2/5-hPDE6B|Subretinal administration in one eye
75899952|NCT03319537|Drug|pevonedistat|Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.
75899953|NCT03319537|Drug|Pemetrexed and cisplatin|Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
75899954|NCT03279692|Drug|Pembrolizumab|pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
76066590|NCT05188469|Drug|EG-COVID-003|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
75605827|NCT01078623|Drug|Aclidinium 200 μg / Formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
75605828|NCT04879251|Other|No intervention|No intervention
75750492|NCT03164928|Drug|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
75750493|NCT03164928|Other|Placebo|SC Q6M placebo
75750494|NCT03153280|Drug|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
76066591|NCT05188469|Drug|EG-COVID-001|"Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
75750495|NCT03153280|Drug|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
75750496|NCT03153280|Drug|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
75750497|NCT03150797|Drug|Melatonin|Melatonin
75899955|NCT03276702|Procedure|Re-biopsy|For those participants who agree, a biopsy of their tumor to obtain tissue for genetic analysis will be done at the time of relapse or disease progression.
75899956|NCT03276702|Other|Questionnaire|Parents or patients will be asked to complete a questionnaire to assess the impact and perception of an optional/research only biopsy. A second questionnaire will be administered approximately 4-8 weeks after biopsy to assess decisional regret.
75899957|NCT03152929|Drug|Paravertebral Block|20-30 mL 0.5% Ropivacaine
75899958|NCT03152929|Drug|Pectoral Nerve Block|20-30 mL 0.5% Ropivacaine
75899959|NCT03139266|Behavioral|UPLIFT|Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
75899960|NCT03139266|Behavioral|Treatment as usual|The control group will receive the recommendation to consider maintaining mental health services
76066592|NCT05188469|Drug|A: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"
76066593|NCT05188469|Drug|B: EG-COVID|"Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"
75605829|NCT01092507|Biological|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
75605830|NCT01092507|Biological|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
75605831|NCT05051397|Biological|HYPERCAPNIA|Controlled moderate hypercapnia PaCO2 50mmHg under general anesthesia with mechanical ventilation
75605832|NCT05051397|Biological|NORMOCAPNIA|Controlled normocapnia PaCO2 40mmHg under general anesthesia with mechanical ventilation
75750498|NCT03150797|Drug|Placebo oral capsule|Placebo
75750499|NCT03096418|Drug|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
75750500|NCT03074513|Drug|Atezolizumab|Given IV
75750501|NCT03074513|Biological|Bevacizumab|Given IV
75750502|NCT03074513|Other|Laboratory Biomarker Analysis|Correlative studies
75750503|NCT03074513|Other|Pharmacological Study|Correlative studies
75750504|NCT03070106|Dietary Supplement|Functional Medicine|Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
75899961|NCT03100786|Drug|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
75899962|NCT03100786|Other|Placebo|Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
75899963|NCT03047239|Device|SENSIMED Triggerfish|Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
75899964|NCT03043053|Drug|oxytocin nasal spray|oxytocin intranasal spray
75750505|NCT03054909|Biological|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
75750506|NCT03054909|Biological|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
75899965|NCT03043053|Drug|Placebo|Placebo nasal spray
75899966|NCT03011541|Procedure|Arm 1|"Procedure/ Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)"
75899967|NCT03001882|Biological|Nivolumab|Specified dose on specified days
75899968|NCT03001882|Biological|Ipilimumab|Specified dose on specified days
75899969|NCT02985151|Device|Syneron-Candela CO2RE Laser|This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
75899970|NCT02981966|Drug|Dapagliflozin|dapagliflozin, 10mg tablet
75899971|NCT02981966|Drug|Placebo|Placebo for dapagliflozin
75899972|NCT02932956|Genetic|GAP T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10^7/m2~DL2: 3x10^7/m2~DL3: 1x10^8/m2~DL4: 3x10^8/m2~DL5: 1x10^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
76066594|NCT05188469|Drug|C: EG-COVARo|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"
75454499|NCT02524834|Procedure|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
75454500|NCT02524834|Device|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
75454501|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
75750507|NCT03044392|Other|Next Bolus Interval|Next Bolus Interval 15, 30, or 45 minutes
75750508|NCT03014414|Behavioral|Fun First|Learn key enjoyable maintenance skills before losing weight
75899973|NCT02932956|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
75750509|NCT03014414|Behavioral|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
75750510|NCT02835443|Device|Deep Brain Stimulation|Electrical stimulation of the dentate nucleus area of the cerebellum.
75750511|NCT02817698|Drug|cannabis|All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
75750512|NCT02758717|Drug|Brentuximab Vedotin|Given IV
75750513|NCT02758717|Biological|Nivolumab|Given IV
75750514|NCT02756897|Drug|Ibrutinib|Given PO
75750515|NCT02756897|Other|Laboratory Biomarker Analysis|Correlative studies
75750516|NCT02756897|Drug|Venetoclax|Given PO
75899974|NCT02932956|Drug|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
75899975|NCT02891148|Drug|BI 690517|
75899976|NCT02843165|Drug|Checkpoint blockade immunotherapy|Approved Checkpoint blockade immunotherapy (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
75750517|NCT02754830|Drug|LY3303560 - IV|Administered IV
75750518|NCT02754830|Drug|Saline Solution - IV|Administered IV
75750519|NCT02754830|Drug|LY3303560 - SC|Administered SC
75750520|NCT02732171|Other|Research Blood Collection|Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
75750521|NCT02683239|Drug|Fasinumab|Participants will receive sub-cutaneous (SC) injections of fasinumab
75750522|NCT02683239|Drug|Placebo|Participants will receive sub-cutaneous (SC) injections of matching placebo
75899977|NCT02843165|Radiation|Checkpoint blockade immunotherapy plus SBRT|SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
75899978|NCT02807467|Drug|Dexmedetomidine|Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
76066595|NCT05180838|Device|BioSticker|The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring
76066596|NCT05178927|Device|HoloLens v2|The HoloLens v2 will be used to access the participant's hologram & set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.
76066597|NCT05175352|Drug|Cendakimab|Specified dose on specified days
75750523|NCT02608411|Drug|ARQ197|
75454502|NCT02487966|Behavioral|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
75454503|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
75605833|NCT02877381|Procedure|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
75605834|NCT02877381|Procedure|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
75750524|NCT02551237|Radiation|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
75750525|NCT02551237|Drug|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
75750526|NCT02551237|Radiation|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
75750527|NCT02437214|Other|Use of music for anxiety in children|"The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song."
75750528|NCT02407808|Drug|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
75899979|NCT02807467|Drug|Propofol|Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
75899980|NCT02795052|Procedure|Intravenous and Intranasal BMSC|Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
76066598|NCT05175352|Drug|CYP substrates|Specified dose on specified days
76066599|NCT05168813|Biological|Moderna mRNA-1273|COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).
76066600|NCT05168813|Biological|Vaccine 3 Dose|COVID-19 mRNA vaccine in 100 mcg dose given as IM injection into the deltoid muscle on Day 1, Day 29, and Day 169.
76066601|NCT05168813|Biological|Vaccine 2 Dose|COVID-19 mRNA vaccine is to be administered as IM injection into the deltoid muscle on Day 1 and Day 169.
75899981|NCT02794428|Drug|Eflornithine|Eflornithine*, 2 tablets, Oral, Daily for 18 months
75899982|NCT02794428|Other|Eflornithine placebo|Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
76066602|NCT05166265|Device|Active transcutaneous bone conduction hearing system|The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.
75454504|NCT02487966|Behavioral|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
75454505|NCT02471690|Drug|Oritavancin|IV - Single dose 1200 mg Oritavancin
75454506|NCT02471690|Drug|Dextrose|D5W 5% in Water
75454507|NCT02470702|Drug|Oritavancin|
75454508|NCT02470702|Drug|Placebo (D5W)|
75454509|NCT02407145|Other|24 month follow up of women with validated questionnaire|24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.
75454510|NCT02392442|Other|Saline|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
75454511|NCT02392442|Biological|Endotoxin|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
76066603|NCT05165225|Drug|Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment|Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m^2 d1 iv Q3W for 4 cycles
76066604|NCT05155332|Drug|BI 1831169|BI 1831169; Intratumoral (i.t.) and/or Intravenous (i.v.)
76066605|NCT05155332|Drug|ezabenlimab|ezabenlimab; Intravenous (i.v.)
76066606|NCT05145400|Drug|Isatuximab|Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab :10 mg/kg intravenous will be administered in cycle 1-24.
76066607|NCT05145400|Drug|Lenalidomide|"Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR > 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR < 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death."
76066608|NCT05145400|Drug|Dexamethasone|Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
75463285|NCT05854771|Other|Single bout of yoga before eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend before the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition maximum of each participant will be calculated first, and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
75605835|NCT02878239|Other|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
75605836|NCT02878239|Other|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
75605837|NCT01078545|Drug|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
75750529|NCT02407808|Drug|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
76066609|NCT05143177|Drug|Evogliptin|DA-1229 5mg, 1 tab
76066610|NCT05143177|Drug|Evogliptin|DA-1229 10 mg, 1 tab
76066611|NCT05143177|Drug|Placebo|DA-1229 Placebo, 1 tab
75605838|NCT01202760|Drug|LY2127399|
75605839|NCT01202760|Drug|Placebo|
75605840|NCT01091259|Drug|Irinotecan|
75605841|NCT01091259|Drug|Bevacizumab|
76066612|NCT05142709|Drug|Anti-PD-1 Immune Checkpoint Inhibitors|used as 1st line treatment for metastatic ESCC.
76066613|NCT05124977|Drug|Antimicrobial Stewardship|Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
76066614|NCT05124977|Drug|Standard management|Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
76066615|NCT05114941|Device|immunosorbent column|Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
75750530|NCT02299921|Other|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
75750531|NCT02228343|Other|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
76066616|NCT05114941|Drug|intravenous immunoglobulin|Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
75899983|NCT02741986|Other|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
75899984|NCT02740179|Drug|Eplerenone|Eplerenone 50mg by mouth twice daily
75899985|NCT02740179|Drug|Placebo|Placebo by mouth twice daily
76066617|NCT05111093|Device|ARC-IM Investigational System implantation|Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
75750532|NCT02097134|Drug|Melphalan|Given IA
75750533|NCT01961375|Drug|Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)|Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
75454512|NCT02373189|Device|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
75454513|NCT02357524|Drug|Oritavancin|
75750534|NCT01954992|Drug|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
75750535|NCT01954992|Drug|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
75454514|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
75750536|NCT01946854|Behavioral|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year."
75750537|NCT01927744|Drug|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
75750538|NCT01927744|Drug|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
75750539|NCT01927744|Other|Placebo|150 mg by mouth daily continuously until the day before surgery.
75750540|NCT01927744|Behavioral|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
75750541|NCT01927744|Behavioral|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
75750542|NCT01927744|Drug|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
75750543|NCT01891981|Drug|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
75750544|NCT01859130|Device|Zimmer Persona Total Knee System|
75750545|NCT01750892|Behavioral|REACH for Independence|REACH for Independence is a transition and self-care skill-building peer support group led by a social worker. It is comprised of two 2.5-hour group sessions where participants participate in activities designed to teach self-care, self-advocacy and improve transition to adulthood skills.
75750546|NCT01750892|Behavioral|Transition Consult|The transition consult is a 1-on-1 visit with an MD and social worker. At the consults, participants will receive individualized information related to their unique medical and psychosocial needs and support related to issues relevant to their gaining healthcare independence and finding an adult doctor, such as accommodations, transportation, insurance and finances. After the consult, this group will have access to a transition coordinator who can help with any transition-related problems that may occur.
75899986|NCT02740179|Behavioral|Lifestyle Modification|Counseling regarding diet and healthy activity
75899987|NCT02679144|Drug|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
75899988|NCT02650986|Drug|Cyclophosphamide|Given IV
75899989|NCT02650986|Drug|Decitabine|Given IV
75899990|NCT02650986|Other|Laboratory Biomarker Analysis|Correlative studies
75899991|NCT02650986|Procedure|Leukapheresis|Undergo leukapheresis
75899992|NCT02650986|Biological|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
76066618|NCT05108805|Procedure|Telemedicine Visit|A remote telemedicine visit with audio and video, using the internet with a nurse practitioner located elsewhere. The participant and NP will activate the telemedicine App in their electronic device. Family will obtain vital signs (BP, HR, RR, SPO2) and provide NP with the information. NP will also review the previous vital signs. Review of system questions are asked, and the answers given by subject recorded. Neurological assessment done, and ICE score calculated.
75750547|NCT01750892|Other|Study Materials|The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
75750548|NCT01696734|Drug|Domperidone|Given PO
75899993|NCT02619409|Drug|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
75899994|NCT02619409|Drug|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
76066619|NCT05108805|Procedure|Vital sign measurements|Participant and their family will record and measure vital signs using a wearable device and will place a call to the covering nurse practitioner to report the vital signs prior to reporting to the out patient visit.
76066620|NCT05108805|Procedure|Out-Patient Clinic Visit|Physical exam and review of all available data
76066621|NCT05108805|Procedure|Blood pressure and pulse oximeter|Participant and their family take their blood pressure and pulse oximeter
75750549|NCT01696734|Other|Questionnaire Administration|Ancillary studies
75454515|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
75454516|NCT02235610|Procedure|EVLP Group|"EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.~Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice."
76066622|NCT05094791|Device|Telescoping Lag Screw|Intertrochanteric fracture fixation using Arthrex Hip Nail with Telescoping Lag Screw
76066623|NCT05094791|Device|Standard lag Screw|Intertrochanteric fracture fixation using Zimmer Natural Nail Cephalomedullary Nail using standard lag screw
75454519|NCT02201589|Device|Endovascular repair with Valiant PS-IDE Stent Graft|Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
75750550|NCT01628536|Dietary Supplement|Black cohosh|Remifemin 20 mg tablet orally twice per day x 4 weeks
75750551|NCT01534299|Device|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
75750552|NCT01335308|Behavioral|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
75899995|NCT02619409|Drug|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
75899996|NCT02619409|Drug|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
75899997|NCT02619409|Drug|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
75899998|NCT02606045|Drug|recombinant von Willebrand factor|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
76066624|NCT05094791|Device|Standard lag screw with addition of worm screw|Intertrochanteric fracture fixation using Smith and Nephew TRIGEN INTERTAN with addition of worm screw
76066625|NCT05076370|Drug|CBD Day 1|CBD 400mg
76066626|NCT05076370|Drug|CBD Day 2|CBD 800mg
76066627|NCT05076370|Drug|CBD Day 3|CBD 1200mg
76066628|NCT05073159|Biological|Allocating head-of-bed position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
76066629|NCT05062707|Procedure|Blood sampling|Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).
76066630|NCT05062291|Device|Merit WRAPSODY Endovascular Stent Graft|Target Lesion Primary Patency (TLPP)
76066631|NCT05061238|Device|Vibrating Device|The vibrating device strapped to different parts of your leg. The device will be secured to your leg with a Velcro strap.
76066632|NCT05057312|Behavioral|Experimental arm 1|Video narrative persuasion
76066633|NCT05057312|Behavioral|Experimental arm 2|Written narrative Persuasion
76066634|NCT05057312|Other|Experimental arm 3|Enhanced Access to HPV vaccines
75605842|NCT05328375|Behavioral|Telehealth-enhanced Hybrid CR|Participants in this group attend a total of 24 CR sessions (5 clinic-based + 19 home-based) over a 12-week period. Clinic-based sessions occur during the first week of the program and at the end of each month. Home-based sessions take place remotely once or twice per week via telehealth, depending on the week of the program. Patients are provided with onboarding sessions, remote patient monitoring devices (tablet, pulse oximeter, blood pressure monitor and cuff) and home-based exercise equipment (e.g., stationary bike and weights). Each CR session (clinic and home) is 60 minutes in duration and includes aerobic and resistance exercise training. Patients will also be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
75605843|NCT05328375|Behavioral|Traditional CR|Participants in this group attend a total of 24 clinic-based CR sessions according to standard of care protocols over a 12-week period. Each CR session is 60 minutes in duration and includes aerobic and resistance exercise training. In addition to scheduled sessions, patients will be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
75750553|NCT01335308|Behavioral|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
76066635|NCT05057312|Other|Experimental arm 4|Video narrative persuasion; Enhanced Access to HPV vaccines
75750554|NCT01335308|Behavioral|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
75750555|NCT01174043|Drug|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
75750556|NCT00954226|Drug|Erlotinib Hydrochloride|Given PO
75750557|NCT00954226|Other|Laboratory Biomarker Analysis|Correlative studies
75750558|NCT00575549|Other|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
75750559|NCT00494728|Behavioral|Smoking Cessation Treatment|12 60-minute individual sessions of standard smoking cessation treatment.
75454520|NCT02153437|Drug|BMS-919373|
75454521|NCT02153437|Drug|Sotalol|
75454522|NCT02153437|Drug|Placebo for BMS-919373|
75454523|NCT02051088|Procedure|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
75454524|NCT02051088|Procedure|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
75750560|NCT00494728|Drug|Nicotine Replacement Therapy|21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
75454525|NCT02051088|Device|drug-coated balloons and/or drug-eluting stents|
75750561|NCT00494728|Behavioral|CBASP|Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
75750562|NCT00488072|Drug|Mirtazapine|15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.
75750563|NCT00488072|Drug|Placebo|One placebo tablet by mouth daily.
75750564|NCT00398034|Drug|Testosterone Gel|
76066636|NCT05057312|Other|Experimental arm 5|Written narrative Persuasion; Enhanced access to HPV vaccines
76066637|NCT05056168|Other|Dermatology-Specific Treatment Satisfaction Instrument|Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients' preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.
76066638|NCT05043207|Diagnostic Test|uAud|Patients will receive hearing aid treatment based on an audiometry obtained with an user-operated automated audiometry procedure
75454526|NCT01950520|Drug|Propranolol|Propanolol 160mg, oral, by mouth (Cohort 1 only)
75454527|NCT01950520|Drug|Pindolol|Pindolol 20mg, oral, by mouth (Cohort 1 only)
75454528|NCT01950520|Drug|Dantrolene|Dantrolene 100mg, oral, by mouth (Cohort 1 only)
75454529|NCT01950520|Drug|Magnesium Sulfate|Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)
75454530|NCT01950520|Drug|Caffeine|Caffeine 200mg, oral, by mouth (Cohort 2 only)
75454531|NCT01950520|Drug|Qysmia|Qysmia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)
75454532|NCT01950520|Drug|Topiramate|Topiramate 200mg, oral, by mouth (Cohort 2 only)
75605844|NCT05381844|Other|Blood sampling|30 ml blood sampling for virological research
75605845|NCT01091103|Drug|Enzalutamide|
75454533|NCT01950520|Behavioral|Phentermine|Phentermine 37.5mg, oral, by mouth (Cohort 2 only)
75454534|NCT01950520|Drug|Naltrexone|Naltrexone 100mg, oral, by mouth (Cohort 2 only)
75605846|NCT01078389|Drug|Febuxostat|Febuxostat capsules
75750565|NCT00389350|Drug|Extract of Green and Black Tea|
75750566|NCT00329043|Drug|LHRH Agonist|Intramuscular injection either monthly for 3 months or in a single 3-month dose.
75750567|NCT00329043|Drug|Sunitinib Malate|25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
75899999|NCT02606045|Drug|tranexamic acid|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
75900000|NCT02603432|Biological|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
75900001|NCT02603432|Other|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
75750568|NCT00329043|Procedure|Radical Prostatectomy|Radical prostatectomy after completion of Sunitinib and LHRH agonist.
75750569|NCT00254384|Drug|Cisplatin|Given IV
75900002|NCT02603432|Biological|Following the planned interim analysis for this study: Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
76066639|NCT05043207|Diagnostic Test|Traditional audiometry|Patients will receive hearing aid treatment based on an audiometry obtained with an traditional audiometry procedure
75750570|NCT00254384|Drug|Docetaxel|Given IV
75900003|NCT02582866|Drug|Lacosamide|"Pharmaceutical Form: Oral tablets~Concentration: 50 mg~Route of Administration: Oral administration"
76066640|NCT05025449|Diagnostic Test|Focused Assessment with Sonography for Trauma (FAST)|The Focused Assessment with Sonography for Trauma (FAST) exam is widely used and accepted as part of Advanced Trauma Life Support (ATLS) protocol. After consent, a baseline FAST exam will be performed and documented. This FAST will be distinct from the initial ATLS resuscitation FAST in order to avoid any interference in the trauma evaluation. The investigator will use a phased array or curvilinear transducer to record video of their baseline FAST exam.
75454535|NCT01950520|Drug|Mirabegron 50mg|Mirabegron 50mg, oral, by mouth (Cohort 3 only)
75454536|NCT01950520|Drug|Mirabegron 200mg|Mirabegron 200mg, oral, by mouth (Cohort 3 only)
75454537|NCT01950520|Drug|Placebo Cohort 1|Placebo, oral, by mouth (Cohort 1 only)
75454538|NCT01950520|Drug|Placebo Cohort 2|Placebo, oral, by mouth (Cohort 2 only)
75454539|NCT01950520|Drug|Placebo for Mirabegron|Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
75454540|NCT01901965|Behavioral|Neuromuscular electrical stimulation|
75750571|NCT00254384|Drug|Erlotinib|Given PO
75454541|NCT01901965|Behavioral|eccentric training|
75605847|NCT01078389|Drug|Placebo for Febuxostat|Febuxostat placebo-matching capsules
75605848|NCT01090323|Drug|ICL670|Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
75605849|NCT00626301|Drug|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
75605850|NCT02878005|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
75605851|NCT02878005|Device|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
75605852|NCT00626457|Behavioral|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
75750572|NCT00254384|Drug|Erlotinib Hydrochloride|Given PO
75750573|NCT00254384|Other|Laboratory Biomarker Analysis|Correlative studies
75750574|NCT00253318|Drug|Docetaxel|40 mg/m^2 IV over 1 hour on Day 1.
75750575|NCT00253318|Drug|RAD001|30 mg orally on Days 1 and 8.
75750576|NCT00253318|Drug|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
75750577|NCT00081874|Drug|RAD001|"Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I."
75605853|NCT02876991|Procedure|Sodium fluoride PET|"Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results."
75605854|NCT01201356|Drug|Fingolimod|0.5 mg/day
75605855|NCT04872153|Behavioral|Dividat Senso Exergames|"The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.~Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min)."
75605856|NCT00637611|Drug|Fexofenadine HCl|
75605857|NCT00626535|Drug|Esomeprazole|20mg Oral Once Daily
75605858|NCT00626535|Drug|Matching placebo|Oral Once Daily
75605859|NCT05400642|Device|THRIVE|Apneic ventilation
75605860|NCT05400642|Device|mechanical ventilation|mechanical ventilation in Positive Pressure
75605861|NCT01200810|Other|placebo|Given orally
75605862|NCT01200810|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
75605863|NCT01200810|Drug|bicalutamide|Given orally
75605864|NCT04317378|Device|Braun thermoscan /, IRT 6520|The temperature will be measured in both ears with an ear thermometer. Practically, we will measure the temperature twice when generel anaesthsia is established, and immidiately before and after the MRI scan.
75605865|NCT01200342|Drug|Genasense|900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
75605866|NCT01200342|Drug|Paclitaxel|175 mg/m^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
75750578|NCT04119674|Drug|Drug is Anlotinib.|Anlotinib 8 mg/day (Chia-tai Tianqing Pharmaceutical Co., Ltd.) was given orally on days 1 to 14 per 3-week cycle for 2 cycles during concomitant therapy and maximally 8 cycles during adjuvant chemotherapy. One week after discontinuation of adjuvant chemotherapy, anlotinib 8 mg/day was given for maintenance .
75750579|NCT04119674|Drug|Drug is Temozolomide Capsule.|Temozolomide 75 mg/m2/day was taken for maximally 49 days during concurrent chemoradiotherapy. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients received adjuvant temozolomide for 5 days every 28 days, first cycle 150 mg/m2/day and subsequent cycles 200 mg/m2/day for maximally 6 cycles .
75750580|NCT04119674|Radiation|Radiotherapy was initiated 4 to 6 weeks postoperatively.|Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
75750581|NCT04109365|Diagnostic Test|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
75900004|NCT02559778|Drug|Ceritinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
75900005|NCT02559778|Drug|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
75750582|NCT04089566|Drug|Nusinersen|Administered as specified in the treatment arm
75900006|NCT02559778|Drug|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
75900007|NCT02559778|Drug|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
75605867|NCT01200342|Drug|Carboplatin|"Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC)."
75605868|NCT01199016|Procedure|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
75900008|NCT02559778|Drug|DFMO|DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
75605869|NCT01199016|Procedure|Nose/throat swab|To be performed at every study visit
75605870|NCT01199016|Biological|Observational|Observational Study Only
75605871|NCT01198548|Drug|leucovorin calcium|Given IV
75605872|NCT01198548|Biological|bevacizumab|Given IV
75605873|NCT01198548|Dietary Supplement|cholecalciferol|Given PO
75605874|NCT01198548|Drug|fluorouracil|Given IV
75605875|NCT01198548|Drug|oxaliplatin|Given IV
75750583|NCT04086524|Other|Binocular cartoon treatment at home|see arm description.
75750584|NCT04086524|Other|Patching|see arm description
75605876|NCT01198548|Other|pharmacological study|Correlative studies
75750585|NCT04086524|Other|Binocular cartoon treatment in office|see arm description.
75750586|NCT04050982|Device|AF CARE|Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
75750587|NCT04050982|Behavioral|Usual Care|Participants will be given recommendations for CVRF reduction based on their initial American Heart Association Life Simple 7 (LS7) assessment and will be provided educational materials and be wait listed for digital app 3 months later
75454542|NCT01884038|Drug|treprostinil sodium|"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"
75454543|NCT01884038|Drug|Placebo|
75605877|NCT01198470|Device|TRIUMPH® Lumbar Artificial Disc|The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
75900009|NCT02512432|Device|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
75900010|NCT02491476|Device|intracerebral micro-macroelectrodes|All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
75454544|NCT01801072|Drug|Levetiracetam|Details covered in Arm Descriptions.
75454545|NCT01784536|Drug|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
75454546|NCT01718743|Drug|Ixazomib Citrate|Given PO
75454547|NCT01718743|Drug|Lenalidomide|Given PO
75454548|NCT01718743|Other|Questionnaire Administration|Ancillary studies
75454549|NCT01605084|Drug|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
75454550|NCT01605084|Drug|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
75454551|NCT01605084|Drug|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
75605878|NCT00977938|Drug|Placebo & Aspirin|
75605879|NCT00977938|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|
75605880|NCT02716675|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
75605881|NCT02716675|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
75605882|NCT04227925|Biological|Trichuris trichiura|Infective eggs from human whipworm, Trichuris trichiura
75605883|NCT00632515|Behavioral|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
75605884|NCT04259203|Behavioral|Erickson hypnosis|Erickson hypnosis sessions performed by an experienced hypnotherapist, according to a pre-established protocol : 5 sessions (1 per week). Between each session : exercise of auto-hypnosis by the patient himself, at home
75750588|NCT04047433|Genetic|screening for single nucleotide polymorphism|samples from both arms will be tested for a set of single nucleotide polymorphism
75750589|NCT04047433|Genetic|whole exome sequencing|samples from arm #1 (women with external anal sphincter) will be tested for identifying specific genetic mutation
75750590|NCT04042155|Drug|dabigatran, rivaroxaban, apixaban or edoxaban|Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.
75750591|NCT04032847|Biological|ATL001|ATL001 infusion
75750592|NCT04032847|Drug|Pembrolizumab|Checkpoint inhibitor
75750593|NCT04031430|Device|Telemonitoring|Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.
75900011|NCT02465307|Behavioral|Confusion Assessment Method|Confusion Assessment Method (CAM) score
75605885|NCT00977548|Drug|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
75605886|NCT04290208|Drug|Acetaminophen|IV Acetaminophen
75605887|NCT04290208|Drug|Acetaminophen|Acetaminophen liquid syrup
75605888|NCT04290208|Drug|Placebos|Flavored, non-medicated (placebo) liquid syrup
75750594|NCT04031430|Other|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
75750595|NCT04031430|Other|CV profiling before and after the start/switch of antihypertensive medication|CV profiling before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
75750596|NCT04013126|Diagnostic Test|• Endothelial function using ENDOPAT system|All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
75750597|NCT03990571|Drug|Avelumab|Given IV
75900012|NCT02465307|Device|Accelerometer|3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
75750598|NCT03990571|Drug|Axitinib|Given PO
75750599|NCT03948139|Device|Functional Brace|The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.
75900013|NCT02465307|Device|Commercially available camera|As part of facial recognition video system
75900014|NCT02465307|Device|Internet Pod (iPod)|Monitors noise levels in the room
75454552|NCT01605084|Drug|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~Didanosine + Stavudine~Zidovudine + Stavudine~Lamivudine + Emtricitabine"
75454553|NCT01514864|Drug|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
75454554|NCT01502917|Drug|Radioactive iodine-labeled monoclonal antibody omburtamab|Prior to treatment children will be pre-medicated with super-saturated potassium iodide & liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations & PET/CT or PET/MRI scans of the brain & other organs. Clinical observations, intensive care unit monitoring, routine blood & interval imaging studies (MRI & PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
75454555|NCT01502917|Radiation|External Beam Radiotherapy|Standard radiation therapy is given 4-6 weeks prior to study entry.
75454556|NCT01458366|Drug|Bendamustine|"Phase 1: Given via IV at the following dose levels:~Level 1: 70 mg/m2~Level -1: 50 mg/m2~Level 2: 90 mg/m2~Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."
75454557|NCT01458366|Drug|Ofatumumab|"Phase II~Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~Cycles 2 and 3: 1000 mg via IV on Day 1"
75454558|NCT01458366|Drug|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
75900015|NCT02465307|Diagnostic Test|Cortisol Swab|Cortisol level collected through self administered salivary swab
75605889|NCT04290208|Drug|Placebos|IV salt solution (non-medicated)
75605890|NCT03223597|Drug|Radium-223 dichloride|Registry of patients who receive Radium-223.
75605891|NCT02865382|Procedure|white light was used for colonoscopy withdrawal|
75605892|NCT02865382|Procedure|OE mode was used for colonoscopy withdrawal|
75605893|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
75750600|NCT03948139|Device|Hip Spica Cast|Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
75750601|NCT03944434|Drug|Ribociclib|ribociclib 600 mg/day orally
75900016|NCT02453373|Device|ThermoSuit Cooling Induction|Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
75750602|NCT03944434|Drug|Aromatase Inhibitors, non steroideal|letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally
75750603|NCT03944434|Drug|LHRH agonist|Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.
75750604|NCT03918096|Other|Questionnaire|Questionnaire to the parents after the hospital discharge
75750605|NCT03905265|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
75750606|NCT03901469|Drug|ZEN003694|PO QD
75900017|NCT02453373|Drug|Magnesium Sulfate|Magnesium sulfate will be administered intravenously as needed to control shivering
75605894|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
75750607|NCT03901469|Drug|Talazoparib|PO QD
75900018|NCT02453373|Drug|tPA|tPA will be administered intravenously if indicated
75900019|NCT02453373|Drug|Propofol|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
75900020|NCT02453373|Drug|Etomidate|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
75900021|NCT02453373|Procedure|Neurothrombectomy|If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
75900022|NCT02452008|Drug|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
75900023|NCT02452008|Drug|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
75454559|NCT01458366|Drug|Etoposide|Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
75750608|NCT03899350|Other|No intervention|No intervention
75750609|NCT03898596|Diagnostic Test|ECG|An ECG collects superficial readings of heart activity
75750610|NCT03869476|Diagnostic Test|Non-invasive diagnosis score|"spleen fibrosis by elastography~plasma cytokines levels~mutationnal landscape by NGS~CD34 circulating cells"
75454560|NCT01458366|Procedure|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
75454561|NCT01458366|Procedure|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
75454562|NCT01458366|Genetic|Stem Cell Transplant (STC)|"For potential transplant candidates:~Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"
75605895|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
75605896|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
75605897|NCT03206905|Procedure|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
75605898|NCT03206905|Behavioral|Diet and Exercise|nutritional/exercise counseling
75900024|NCT02450318|Other|Slow-paced walking|Subjects will walk on a treadmill at a slow pace for 47 minutes
75900025|NCT02447874|Drug|Arginine|"Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~Loading dose: 200 mg/kg once~Continuous IV: 300 mg/kg/24 hours"
75900026|NCT02447874|Drug|Arginine (Loading)|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 200 mg/kg once
75900027|NCT02447874|Drug|Arginine (Continuous)|Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
75900028|NCT02402582|Other|Family-centered empowerment model|FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.
75750611|NCT03859752|Biological|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
75750612|NCT03852784|Other|Bone and joint infection with Streptococcus peumoniae|description of the osteoarticular infection with Streptococcus peumoniae
75750613|NCT03850860|Other|empirical antibiotherapy|comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
75900029|NCT02402582|Other|Control|FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
75605899|NCT04257331|Behavioral|Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme|The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
75605900|NCT04300803|Biological|Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression|Expanded Access Program, Non-Interventional Study
75900030|NCT02365051|Behavioral|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
75454563|NCT01351545|Drug|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
75454565|NCT01126723|Other|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
75454566|NCT01126723|Other|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
75454567|NCT00968760|Procedure|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
75454568|NCT00968760|Procedure|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
75454569|NCT00968760|Procedure|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
75605901|NCT04242355|Behavioral|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
75605902|NCT02877615|Drug|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
75605903|NCT02877615|Drug|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
75750614|NCT03848845|Drug|belantamab mafodotin|belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
75750615|NCT03848845|Drug|Pembrolizumab|Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
75750616|NCT03827434|Device|Continuous glucose Monitoring Devices and Clarity Software|Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
75750617|NCT03827434|Other|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
75750618|NCT03807765|Drug|Nivolumab|480 mg intravenous Nivolumab administered every 4 weeks.
75900031|NCT02098161|Other|Laboratory Biomarker Analysis|Correlative studies
75900032|NCT02098161|Other|Questionnaire Administration|Ancillary studies
75900033|NCT02098161|Drug|Smac Mimetic LCL161|Given PO
75900034|NCT01734928|Drug|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
75900035|NCT01734928|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
75750619|NCT03807765|Radiation|Stereotactic Radiosurgery|"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."
75605904|NCT02877615|Drug|Placebo|Two sachets of placebo twice a day
75900036|NCT01734928|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [>75 years old] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
75605905|NCT02437279|Procedure|Surgery of the tumor|
75900037|NCT01682616|Drug|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
75605906|NCT02437279|Drug|Infusion with ipilimumab 3 mg/kg q3wks|
75900038|NCT01682616|Drug|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
75605907|NCT02437279|Drug|Infusion with nivolumab 1 mg/kg q3wks|
75605908|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
75750620|NCT03781440|Procedure|Bilateral ESP catheter with lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
75900039|NCT01644747|Device|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
75454570|NCT00968760|Drug|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10^6 U/m^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
75454571|NCT00968760|Drug|Carmustine|300 mg/m^2 IV over 1 hour on Day -6
75454572|NCT00968760|Drug|Etoposide|200 mg/m^2 IV over 3 hours every 12 hours on Days -5 to -2
75454573|NCT00968760|Drug|Cytarabine|200 mg/m^2 by vein over 1 hour every 12 hours on Days -5 to -2.
75454574|NCT00968760|Drug|Melphalan|140 mg/m^2 IV over 30 minutes on Day -1
75454575|NCT00967733|Dietary Supplement|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
75454576|NCT00967733|Dietary Supplement|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
75454577|NCT00967733|Dietary Supplement|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
75454578|NCT00967733|Dietary Supplement|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
75605909|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
75605910|NCT01251653|Drug|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
75605911|NCT01251653|Drug|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
75605912|NCT00910663|Drug|Mycophenolate Mofetil|250 mg Capsule
75605913|NCT00910663|Drug|CellCept®|250 mg Capsule
75605914|NCT04306185|Procedure|OVARIAN FRAGMENTATION|BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
75605915|NCT01077375|Drug|Placebo|"Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
75454579|NCT00769223|Other|medical chart review|
75454580|NCT00769223|Other|questionnaire administration|
75454581|NCT00769223|Procedure|quality-of-life assessment|
75454582|NCT00769223|Radiation|brachytherapy|
75454583|NCT00769223|Radiation|radiation therapy|
75454584|NCT00415233|Biological|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
75454585|NCT00415233|Radiation|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
75605916|NCT01077375|Drug|Milnacipran|"Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
75605917|NCT00624299|Drug|Botox|Botox injection (100 ius) per muscle
75750621|NCT03781440|Procedure|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
75750622|NCT03771989|Biological|autologous, micro-fragmented adipose tissue|"The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection."
75750623|NCT03771989|Other|Saline|The placebo is an injection with saline
75750624|NCT03762044|Other|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|"Health education / patient empowerment.~Neurodynamic activities oriented to ADL.~Proprioceptive neuromuscular facilitation exercises oriented to ADL.~Self-adherent self-adhesive antiedema of low compression."
75454586|NCT00364286|Drug|Dasatinib (BMS-354825)|50mg Orally twice daily
75900040|NCT01430572|Drug|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
75454587|NCT00328614|Drug|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
75750625|NCT03762044|Other|Complete Decongestive Therapy (CDT)|"Skin care.~Kinesitherapy~Manual lymphatic drainage (MLD)~Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments."
75750626|NCT03742037|Drug|Cenerimod 0.5 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
75605918|NCT00624299|Other|Saline|Saline injection
75750627|NCT03742037|Drug|Cenerimod 1 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
75750628|NCT03742037|Drug|Cenerimod 2 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
75750629|NCT03742037|Drug|Cenerimod 4 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
75750630|NCT03742037|Drug|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
75750631|NCT03742037|Drug|cenerimod 2 mg (ex-4 mg)|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
75900041|NCT01430572|Drug|Everolimus|"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."
75454588|NCT00328614|Drug|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
75454589|NCT00328614|Drug|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
75454590|NCT00328614|Device|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
75454591|NCT00217737|Biological|Bevacizumab|Given IV
75454592|NCT00217737|Drug|Fluorouracil|Given IV
75750632|NCT03714815|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
75900042|NCT01224288|Procedure|Perfusion CT scan|DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
75605919|NCT02877849|Device|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
75605920|NCT02877771|Device|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
75605921|NCT04306653|Drug|ACTH|patients with acute gout will receive 100 IU ACTH IM
75605922|NCT04306653|Drug|Betamethasone|patients with acute gout will receive 6 mg of betamethasone
75605923|NCT04306731|Dietary Supplement|Nanotechnology Structured water Magnalife|Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules
75750633|NCT03713229|Diagnostic Test|Screening for anal squamous intraepithelial lesions|digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
75750634|NCT03712943|Drug|Regorafenib|Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
75750635|NCT03712943|Drug|Nivolumab|Nivolumab 240 mg administered intravenously every 2 weeks.
75750636|NCT03710915|Drug|HG146|HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.
75750637|NCT03707938|Drug|Brigatinib|Given PO
75750638|NCT03707938|Procedure|Local Consolidation Therapy|Undergo local consolidative therapy
75900043|NCT00950430|Drug|Pittsburgh Compound B (C-11 PiB)|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
75454593|NCT00217737|Other|Laboratory Biomarker Analysis|Correlative studies
75605924|NCT04306731|Drug|Trimethoprim|Antibiotic
75605925|NCT04306731|Dietary Supplement|Ordinary bottled drinking water|Placebo
75605926|NCT02877537|Drug|Salbutamol|bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
75454594|NCT00217737|Drug|Leucovorin Calcium|Given IV
75454595|NCT00217737|Drug|Oxaliplatin|Given IV
75454596|NCT00098072|Procedure|Heart Catheterization|Heart Catheterization and collection of samples
75605927|NCT02877537|Procedure|Forced oscillation technique|before and after bronchodilation
75605928|NCT02877537|Procedure|Plethysmography|
75750639|NCT03686488|Drug|TAS 102|TAS 102 35 mg will be administered orally twice daily every 2 weeks.
75454600|NCT01750125|Device|measure ascending aortic blood flow with pulse wave Doppler|
75454601|NCT01750138|Drug|Glutamine|
75454602|NCT01750138|Drug|Dextrose powder|
75454603|NCT01750151|Dietary Supplement|Glucose Beverage|
75454604|NCT01750151|Behavioral|Video Game Playing|
75605929|NCT01250873|Drug|LY2216684|po administration
75605930|NCT01250873|Drug|Sertraline|po administration
75750640|NCT03686488|Drug|Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]|Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
75750641|NCT03646760|Behavioral|HYCR|"This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site."
75750642|NCT03646760|Behavioral|CBCR|This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
75750643|NCT03640312|Drug|QUARTET LDQT|Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
75750644|NCT03640312|Drug|Candesartan|Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
75750645|NCT03625388|Drug|Dasatinib|Film coated tablet contains dasatinib monohydrate
75750646|NCT03622879|Behavioral|MT|A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
75454605|NCT01750151|Dietary Supplement|Control Beverage|
75605931|NCT01250171|Biological|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
75605932|NCT01250171|Biological|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
75605933|NCT01250171|Biological|Placebo|The placebo solution for infusion contained 5% glucose.
75605934|NCT02888327|Drug|AL-794|
75750647|NCT03622879|Device|TENS|TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
75750648|NCT03622879|Behavioral|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
75454606|NCT01750177|Behavioral|Television Viewing before mealtime|
75454607|NCT01750177|Behavioral|Video Game Playing|
75605935|NCT02888327|Drug|Oseltamivir|
75605936|NCT02888327|Drug|Digoxin|
75605937|NCT02888327|Drug|Midazolam|
75605938|NCT02888327|Drug|Pitavastatin|
75900044|NCT00950430|Drug|F-18 FDG|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
75900045|NCT00950430|Drug|Tau (18-F-AV-1451)|"PIB PET scan, Tau PET scan and/or FDG PET scan~Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan."
75454608|NCT01750177|Behavioral|Computer Use|
75454609|NCT01750177|Behavioral|Sitting quietly|
75454610|NCT01750203|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
75605939|NCT02888327|Drug|JNJ-63623872|
75605940|NCT01077063|Procedure|paracentesis|surgical drainage of malignant ascites
75750649|NCT03614962|Device|Warmth + TENS|"A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.~A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius."
75454611|NCT01750307|Dietary Supplement|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
75454612|NCT01750307|Dietary Supplement|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
75454613|NCT01750320|Device|Koning Breast CT-guided Biopsy|The breast will be positioned and stabilized in the grid/compression device. Four KBCT scans will be taken to guide the vacuum-assisted biopsy procedure.
75454614|NCT01750359|Drug|curcumin|500 mg/day for 6 week
75454615|NCT01750385|Drug|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
75454616|NCT01750385|Drug|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
75454617|NCT01750424|Procedure|Autologous Fat Grafting|
75454618|NCT01750424|Other|No intervention|Subjects in this arm will only be followed up and have no procedure performed.
75454619|NCT01750437|Drug|YH1885L(Revaprazan)|
75454620|NCT01750437|Drug|Esomeprazole 20mg|
75605941|NCT01077063|Device|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
75605942|NCT01248065|Drug|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
75605943|NCT01248065|Drug|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
75605944|NCT01250756|Biological|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
75605945|NCT01250756|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
75605946|NCT01250756|Biological|DTaP|0.5 mL per dose, 4 doses
75605947|NCT01250054|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
75605948|NCT01250054|Device|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
75750650|NCT03614962|Device|Warmth + placebo-TENS|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. The TENS electrodes are presented in the cap but no output will be delivered via these electrodes.
75605949|NCT00977470|Drug|Erlotinib|150 mg taken orally once daily
75750651|NCT03614962|Device|TENS|A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.
75750652|NCT03614962|Device|Warmth only|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. No built-in TENS electrodes in the cap.
75750653|NCT03614962|Device|control|No warmth pad and TENS electrodes presented in the cap.
75900046|NCT00909051|Drug|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
75900047|NCT00667459|Device|PRESTIGE® LP Cervical Disc|The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
75900048|NCT00667459|Device|ATLANTIS Anterior Cervical Plate|Anterior cervical discectomy and fusion with ATLANTIS plate for control group
75750654|NCT03598309|Drug|Curcumin C3 complex®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
75900049|NCT00546429|Device|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
75454621|NCT01750437|Drug|placebo|
75900050|NCT00453544|Other|Enhanced Consent Procedure|This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
75900051|NCT00453544|Other|Routine Consent Procedure|This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
75605950|NCT00977470|Drug|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
75605951|NCT04319666|Device|Left main stenting with intravascular lithotripsy|Intravascular lithotripsy (IVL) will be used to modify coronary artery calcification prior to stent implantation in left main coronary disease. Intravascular ultrasound (IVUS) will be used pre and post IVL and post stenting.
75605952|NCT04289896|Other|Plyometric exercise|"The plyometric program to be followed by the subjects assigned to the experimental group during the four weeks includes: Squat jumps, alternate lunge, cyclic horizontal jump, horizontal left leg jump, horizontal right leg jump, vertical left leg jump, right leg vertical jump, squat box jumps, box jumps left leg, box jumps right leg, box to box squat jumps, box to box left leg, box to box right leg.~In all the exercises the subjects will be able to help themselves with the arms and a rest period of 120 seconds will be left between each series.~The intervention will be carried out prior to training, keeping a minimum of 48 hours of rest between sessions."
75900052|NCT00280657|Drug|Valette|1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
75900053|NCT00280657|Drug|Diane|1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
75900054|NCT00280657|Drug|Placebo|2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
75454622|NCT01750463|Other|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
75454623|NCT01750463|Other|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
75454624|NCT01750476|Drug|Mirena|
75454625|NCT01750476|Drug|Oral contraception|
75454626|NCT01750476|Drug|Depo-Provera|
75454627|NCT01750489|Device|non-invasive ventilation (NIV)|
75454628|NCT01750515|Device|Acupuncture|
75750655|NCT03598309|Drug|Lovaza®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
75750656|NCT03598309|Other|Placebo|Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
75750657|NCT03580213|Other|Hand therapy MCPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices.
75750658|NCT03580213|Other|Hand therapy PIPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices. Possible additional splint and exercises specifically for the PIPJ extension.
75750659|NCT03576417|Drug|Cisplatin|Intravenous
75900055|NCT03740698|Device|BiAP|The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.
76066641|NCT05025449|Drug|Bubble-Enhanced FAST (BEFAST)|Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. Contrast may be redosed if images are inadequate or incomplete. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by AAST criteria.
76066642|NCT05012371|Drug|Cabozantinib|Given PO
75900056|NCT03740698|Device|ABC4D|The Advanced Bolus Calculator for Diabetes (ABC4D) is a novel, adaptive decision support algorithm based on case-based reasoning (CBR) providing real-time insulin advice through a smartphone application.
75454629|NCT01750541|Drug|Haloperidol|
75605953|NCT01245374|Device|Norditropin NordiFlex®|Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
76066643|NCT05012371|Drug|Everolimus|Given PO
76066644|NCT05012371|Drug|Lenvatinib|Given PO
75605954|NCT02865304|Drug|endostar|
75750660|NCT03576417|Drug|Nivolumab|Intravenous
75900057|NCT03514940|Diagnostic Test|ultrasound|second trimester us scan will be made to pregnant women
76066645|NCT05012371|Other|Questionnaire Administration|Ancillary studies
76066646|NCT05011279|Other|Move Together app/Garmin Activity Tracker|"The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links.~Garmin activity tracker in this study is for participants to track their steps and sedentary time."
76066647|NCT05004935|Dietary Supplement|beetroot juice|single intake of beetroot juice containing 800mg nitrates
75750661|NCT03576417|Radiation|RT|IMRT 66 Gy / 6.5 weeks
75750662|NCT03570827|Drug|Androgen Suppression|Given androgen suppression therapy
75750663|NCT03570827|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75750664|NCT03570827|Other|Quality-of-Life Assessment|Ancillary studies
75750665|NCT03570827|Other|Questionnaire Administration|Ancillary studies
75900058|NCT05421520|Device|Artificial intelligence assisted system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
75900059|NCT03514862|Behavioral|Mindfulness Booster Training|Four additional mindfulness booster sessions after the 4-week MBI program.
76066648|NCT05004935|Other|nitrate|single intake of 800mg nitrates
76066649|NCT05002816|Drug|Elotuzumab|Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.
75454630|NCT01750541|Drug|Valproate|
75454631|NCT01750554|Other|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
75454632|NCT01750580|Drug|Lirilumab|
75454633|NCT01750580|Drug|Ipilimumab|
75454634|NCT01750593|Procedure|Radiofrequency ablation of the thyroid nodule|Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
75454635|NCT01750632|Procedure|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
75454636|NCT01750645|Drug|Intradetrusor Injection of Type-A Botulinum Toxin|
75605955|NCT04289272|Behavioral|Dove Confident Me|Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
75900060|NCT03514862|Behavioral|Mindfulness-Based Intervention (MBI)|MBI program is delivered once a week for 4 weeks, 90 minutes each preceded by a 90-minute orientation session. The training sessions will include discussion, and introduction and practice of mindfulness practices.
75900061|NCT03514862|Behavioral|Self-Practice|4 weeks of self-practice after the MBI training.
76066650|NCT05002816|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered via IV infusion. There will be 2 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be teste
76066651|NCT04999358|Behavioral|Protein education|The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.
76066652|NCT04999358|Behavioral|Standard education|Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.
76066653|NCT04999332|Drug|leucovorin, oxaliplatin, docetaxel, S-1|Perioperative chemotherapy with LOTS
75454637|NCT01750645|Other|Other interventions analyzed according to protocol|"Placebo~Different dosage of Type-A Botulinum Toxin injected~Anticholinergic drugs"
75605956|NCT04075474|Device|silver diamine fluoride|38% SDF on primary upper anterior teeth
75605957|NCT04075474|Device|sodium fluoride|5% NaF on primary upper anterior teeth
75605958|NCT00977314|Device|The Sonitus Bone Conduction Hearing System|Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
75900062|NCT03103516|Procedure|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
75900063|NCT03103516|Procedure|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
76066654|NCT04993885|Drug|Avatrombopag|The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10^9/L and 200×10^9/L. If the platelet count does not reach to 30×10^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
75605959|NCT00977314|Device|SoundBite|
75605960|NCT00977314|Device|SoundBite Hearing System|
76066655|NCT04987814|Other|HD-sEMG|high definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair lifts, depending on the patient's functional state.
76066656|NCT04987814|Other|- Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed.
75454638|NCT01750723|Drug|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
75454639|NCT01750736|Other|Augmented Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
75454640|NCT01750736|Other|General Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
75750666|NCT03552978|Behavioral|Tech-Facilitated IC Intervention|The Integrated Care (IC) treatment protocol for smoking cessation is a PTSD-informed intervention that has been adapted to be delivered over video or telephone and to incorporate technological components, including the Stay Quit Coach (SQC) smart phone application (app) which is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation. and the coVita Bedfont® Scientific Ltd iCO® Smokerlyzer® device and app which is a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The coVita mobile app is compatible with iOS &Android and used with the iCO® Smokerlyzer® to display CO readings. Content of sessions is consistent with that delivered in the IC treatment protocol for veteran smokers with post-traumatic stress disorder (PTSD).
75750667|NCT03552978|Behavioral|VA Quitline|The SFVAMC's standard of care referral service, known as the VA Quitline which involves weekly telephone sessions through the VA's proactive telephone Quitline, available to all veterans for up to 8 weeks.
75900064|NCT02298140|Other|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
76066657|NCT04987814|Other|IPAQ Physical Activity Questionnaire.|physical activity assessment questionnaire/adapted version for seniors
76066658|NCT04987476|Biological|analyzes in singles cells|genome expression analyzes in single cells
76066659|NCT04982952|Behavioral|Contingency Management - Increasing|Increasing incentive payment for abstinent participant
76066660|NCT04982952|Behavioral|Fixed payments|Fixed payments for attending study visits
75454641|NCT01750749|Biological|Autologous BMDC implantation at the venous ulcer|An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
75454642|NCT01750762|Drug|Lenalidomide|
75605961|NCT02866396|Drug|Pregabalin|Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
75605962|NCT02866396|Other|Naive patient|Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
75605963|NCT01087203|Biological|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
76066661|NCT04978506|Drug|BI 1569912|BI 1569912
76066662|NCT04978506|Drug|Placebo|Placebo
76066663|NCT04975880|Device|SC+ Hemodialysis System|Following the in-clinic training phase and one week transition, the intervention of self or care partner hemodialysis delivered in the home setting will occur for 8 weeks.
76066664|NCT04975399|Drug|CC-92328|CC-92328
75454643|NCT01750775|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
75454644|NCT01750775|Drug|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
75454645|NCT01750788|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
75605964|NCT01087203|Biological|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
76066665|NCT04964726|Behavioral|Real-time fMRI dyadic neurofeedback|Participants will attempt to regulate their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
76066666|NCT04949048|Device|Magneto PE Kit|All enrolled patients will be treated with Magneto PE Kit
75605965|NCT04289350|Diagnostic Test|fetal heart rate variability|An observational study. No intervention
75605966|NCT02865226|Other|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)|
75605967|NCT02865226|Other|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).|
75605968|NCT01246583|Drug|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
75605969|NCT01246583|Drug|Vehicle 1|Vehicle 1 twice daily for 4 weeks
75750668|NCT03543189|Drug|Nivolumab|Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
75750669|NCT03543189|Radiation|Brachytherapy|High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.
75750670|NCT03543189|Radiation|External Beam Radiation Therapy|External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.
75750671|NCT03543189|Drug|Androgen Deprivation Therapy|Standard of care.
75750672|NCT03529019|Drug|Ensure Surgery Immunonutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
75750673|NCT03529019|Drug|Ensure Enlive Advanced Nutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered 2 weeks prior to and 2 weeks post surgical procedure for a period of one week. .
75750674|NCT03404310|Dietary Supplement|Zinc Sulfate|Participant will take one 220mg tablet twice daily for three months.
75900065|NCT05089396|Other|Maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
75900066|NCT02303210|Device|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
75463286|NCT05854771|Other|Single bout of yoga after eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend after the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition of each participant will be calculated first and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
75605970|NCT01246583|Drug|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
75605971|NCT01246583|Drug|Vehicle 2|Vehicle 2 twice daily for 4 weeks
75605972|NCT01084239|Radiation|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
75605973|NCT01244906|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
75750675|NCT03404310|Other|Placebo (Gelatin Tablet)|Participant will take one tablet twice daily for three months.
75750676|NCT03399721|Device|Chordate S101|Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
75750677|NCT03399721|Device|Chordate S101 Placebo|Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
75750678|NCT03387553|Biological|Dendritic Cell Vaccine (DC1)|"Study Vaccine:~Lead In Phase - Weekly as outlined in each treatment Arm.~Expansion Phase - At the optimal schedule determined at the end of the Lead In Phase.~Pre-surgery - Booster Vaccine at week 25 prior to receiving surgery.~Post-surgery - Participants will receive a series of 3 booster intranodal study vaccines given once every 6 months."
75750679|NCT03387553|Drug|Neoadjuvant Chemotherapy|Upon completion of the 3 week series of vaccinations participants will then undergo neoadjuvant chemotherapy treatment with the TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen given intravenously once every 3 weeks for up to 6 cycles. The treating physician will have the discretion to delay, modify, or shorten the neoadjuvant chemotherapy as per routine practice guidelines and physician discretion.
75750680|NCT03387553|Procedure|Curative Surgery|Planned definitive curative surgery at 26 to 28 weeks.
75750681|NCT03367533|Drug|Ketamine|Intravenous ketamine
75750682|NCT03367533|Drug|Perampanel|Oral perampanel (6 mg)
75750683|NCT03367533|Drug|Placebo|Oral placebo
75750684|NCT03340896|Drug|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
75750685|NCT03340896|Drug|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
75750686|NCT03340896|Drug|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
75750687|NCT03340896|Radiation|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
75750688|NCT03299088|Biological|Pembrolizumab|Given IV
75750689|NCT03299088|Drug|Trametinib|Given PO
75750690|NCT03290079|Drug|Pembrolizumab|200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle.
75750691|NCT03290079|Drug|Lenvatinib|20 mg Lenvatinib by mouth every day of each 3 week cycle
75750692|NCT03272464|Drug|Trametinib|Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
75900067|NCT02303210|Device|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
75900068|NCT05076994|Other|Exercise therapy|A series of home exercise videos to improve patient adherence to exercise prescription
75454646|NCT01750801|Drug|Propolis|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
75750693|NCT03272464|Drug|Dabrafenib|Dabrafenib may work by stopping your cancer cells from duplicating.
75605974|NCT00626613|Drug|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
75750694|NCT03272464|Drug|INCB039110|Itacitinib may work by stopping your tumor cells from living and growing.
75750695|NCT03263481|Procedure|Intraductal secretin test (IDST)|If pancreatic duct entry incidentally occurs during the clinically scheduled ERCP and the pancreatic duct appears normal, an IDST will be performed for study purposes. An IDST consists of the administration of human secretin, after which pancreatic juice is collected intraductally. In this study, the fluid will be collected through continuous aspiration in 5 minute intervals for 30 minutes. Samples will be collected at 5, 10, 15, 20, 25, and 30 minutes after secretin administration (6 collections in total).
75750696|NCT03177291|Drug|Pirfenidone|"Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation."
75750697|NCT03177291|Drug|Carboplatin|Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
75750698|NCT03177291|Drug|Paclitaxel|200 mg/m^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
75750699|NCT03177291|Drug|Pemetrexed|500 mg/m^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
75900069|NCT05076994|Other|Standard Care|An exercise prescription and verbal instructions in clinic
75900070|NCT03510572|Drug|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
75900071|NCT03511274|Behavioral|Hygiene based educational film|Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
75900072|NCT05030896|Other|Invasive treatment and exercise therapy|The subjects of experimental group will perform therapeutic exercise program and they will be receive Percutaneous Electrolysis therapy and the subjects of experimental group will perform the same exercise program and they will be receive only needling puncture
75605975|NCT01080807|Drug|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
75900073|NCT03510494|Behavioral|Augmented physical education program|Augmented physical education program
75900074|NCT05015608|Drug|Savolitinib + Osimertinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
75750700|NCT03162536|Drug|Nemtabrutinib|Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
75900075|NCT05015608|Drug|Pemetrexed + Cisplatin /Carboplatin|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
75900076|NCT02301260|Behavioral|Speed of Processing Training (SPT)|
75750701|NCT03155737|Other|Self-acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
75900077|NCT02301260|Behavioral|Placebo Control|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
75900078|NCT05009836|Drug|Savolitinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
75900079|NCT05009836|Drug|Placebo|Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse
75900080|NCT03510416|Drug|Apatinib|apatinib is a kind of Inhibitor of VEGFR-2
75454647|NCT01750801|Drug|chlorhexidine|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
75900081|NCT03510416|Radiation|TACE|Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
75454648|NCT01750814|Biological|GC3102C|a single dose (0.5 mL) intramuscularly on the deltoid muscle
75454649|NCT01750814|Biological|GC FLU inj.|a single dose (0.5 mL) intramuscularly on the deltoid muscle
75900082|NCT02303288|Device|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
75900083|NCT03507920|Other|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
75900084|NCT03507920|Other|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
75900085|NCT02301338|Other|Usual care|
75454650|NCT01750827|Drug|SB659032|single dose
75454651|NCT01750853|Drug|LY3045697|Administered orally
75454652|NCT01750853|Drug|Placebo|Administered orally
75605976|NCT01080807|Drug|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
75750702|NCT03155737|Other|Knee health education|A course regarding knee health will be offered to the subjects in this group.
75750703|NCT03128151|Behavioral|Educational program for clinicians: implementation of a package of clinical prevention measures of NMB|Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
75750704|NCT03110224|Device|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the knee(Subchondroplasty (SCP) Procedure).
75900086|NCT02301338|Other|Phone Calls|
75900087|NCT03720262|Combination Product|Mesh reinforcement|Reinforcement of the abdominal wall with Ultrapro Advanced.
75900088|NCT03720262|Other|No reinforcement|Suturing the abdominal wall without mesh reinforcement
75900089|NCT02306486|Other|with 0,5% oxalic acid (Desenssiv SSWhite)|with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
75900090|NCT03103360|Device|videopupillometer|Measure of pupillary diameter and pupillary pain index via an infrared camera Each measure lasts approximately 20 seconds
75900091|NCT03103360|Procedure|skin incision|performed under general anesthesia by the surgeon, at the beginning of an elective or emergency surgery.
75900092|NCT03511040|Device|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
75454653|NCT01750866|Drug|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
75454654|NCT01750866|Drug|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
75900093|NCT03671122|Diagnostic Test|Cardiac imaging in the PREFERS and CABG PREFERS cohorts|performed at baseline and after 1 year
75900094|NCT03671122|Other|Biomarker analysis in the PREFERS and CABG PREFERS chorts|blood samples will be taken for biomarker analysis at baseline and after 1 year
75750705|NCT03082248|Other|Physical Therapy|Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.
75750706|NCT03082248|Procedure|Spinal Surgery|Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
75900095|NCT03671122|Procedure|Cardiac biopsies in the CABG PREFERS cohort|myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
75454655|NCT01750866|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
75454656|NCT01750905|Drug|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
75454657|NCT01750905|Drug|Placebo|Vehicle (D5W) SQ
75750707|NCT03079011|Drug|Palbociclib 125mg|Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle
75750708|NCT03079011|Drug|Aromatase Inhibitors|Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
75750709|NCT03079011|Drug|Fulvestrant Injectable Product|500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
75750710|NCT03071406|Drug|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
75900096|NCT03510962|Other|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.
75900097|NCT03510962|Other|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
75900098|NCT03510962|Drug|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
75900099|NCT03510962|Other|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
75454658|NCT01750944|Procedure|Ankle first|"Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~A 15 minute walking test (WT) is performed.~BBP-LR and BPA-LR are re-measured.~2 hours of rest.~BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~WT is reperformed.~BBP-LR and BPT-LR are re-measured."
75605977|NCT01079949|Drug|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
75750711|NCT03071406|Drug|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
75750712|NCT03071406|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
75900100|NCT03510962|Other|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention."
75750713|NCT03038828|Biological|Leukocyte Interleukin, Injection|Immunotherapy
75750714|NCT02991469|Drug|Sarilumab SAR153191 (REGN88)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
75750715|NCT02964624|Other|Rehabilitation|Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
75750716|NCT02866383|Drug|Nivolumab|3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
75900101|NCT03510962|Other|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
75900102|NCT02646124|Drug|Naproxen|Naproxen 500mg by mouth two times a day, #20
75900103|NCT02646124|Drug|Placebo|28 placebo capsules
75900104|NCT02646124|Drug|Diazepam|Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28
75750717|NCT02866383|Drug|Ipilimumab|1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
75750718|NCT02866383|Radiation|Radiotherapy|15 Gy x 1 fraction given on day 1
75750719|NCT02841215|Drug|Ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
75454659|NCT01750944|Procedure|Toe first|"Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~A 15 minute walking test (WT) is performed.~BBP-LR and BPT-LR are re-measured.~2 hours of rest.~BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~WT is reperformed.~BBP-LR and BPA-LR are re-measured."
75454660|NCT01750970|Other|Endoscopic resection under blue light (Hexvix®)|Endoscopic resection
75454661|NCT01750983|Drug|Ipilimumab|"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."
75454662|NCT01750983|Drug|Lenalidomide|"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."
75454663|NCT01750996|Behavioral|Strongest Families|Behavioural intervention
75454664|NCT01751009|Dietary Supplement|Vitamin A supplements|Sprinkles with Vitamin A
75454665|NCT01751009|Dietary Supplement|Sprinkles without Vitamin A|Active comparator
75750720|NCT02841215|Drug|Ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
75750721|NCT02807571|Procedure|Wide Awake Local Anesthesia No Tourniquet|Wide Awake Local Anesthesia No Tourniquet for office based hand surgery.
75750722|NCT02804542|Other|Observational|
75750723|NCT02804542|Other|Retrospective review|
75750724|NCT02798601|Other|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
75750725|NCT02793466|Drug|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
75750726|NCT02767557|Drug|Tocilizumab|Intravenous infusion
75750727|NCT02767557|Drug|Gemcitabine|Intravenous infusion
75750728|NCT02767557|Drug|nab-Paclitaxel|Intravenous infusion,
75750729|NCT02638090|Drug|Vorinostat|Administered per treatment arm guidelines.
75750730|NCT02638090|Drug|Pembrolizumab|Administered per treatment arm guidelines.
75900105|NCT02306564|Drug|Cabergoline|given to patients at high risk for OHSS
75900106|NCT02301494|Drug|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
75900107|NCT02301494|Drug|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
75900108|NCT03101800|Drug|Azathioprine and Allopurinol|Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
75900109|NCT03101800|Drug|Azathioprine|Standard weight based azathioprine dosage
75750731|NCT02594917|Procedure|Right Heart Catheterization|Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.
75750732|NCT02594917|Other|Blood draw|Test and control group will be asked to give 20 ml of blood samples
75454666|NCT01751035|Behavioral|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
75900110|NCT03507842|Drug|High dose Cytarabine|High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
75900111|NCT03507842|Drug|Cytarabine|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)
75900112|NCT03507842|Drug|Hign dose Daunorubicin|Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
75605978|NCT01079949|Drug|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
75605979|NCT01079949|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
75605980|NCT01079949|Drug|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (>=) 14 mm, and maintained until at least one follicle of >=18 mm and two additional follicles of >=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
75605981|NCT04306263|Dietary Supplement|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics
75750733|NCT02463708|Behavioral|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
75605982|NCT04306263|Dietary Supplement|Standard formula|Infants receiving a standard infant formula.
75605983|NCT04306263|Dietary Supplement|Breastfeeding arm|Infants exclusively or predominantly breastfed (>75%).
75605984|NCT00909727|Drug|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
75605985|NCT00909727|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
75605986|NCT00977080|Drug|Paricalcitol|Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
75605987|NCT00977080|Drug|Cinacalcet|On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
75900113|NCT04464044|Device|verofilcon A toric contact lenses|Daily disposable toric soft contact lenses
75900114|NCT04435132|Device|PCL under fluoroscopy with the aid of the robotic device|During the surgery, the robot was positioned over the estimated insertion point. It was aligned to be parallel to the fluoroscope imaging plane as much as possible. The needle is to be placed through the holder, and slightly penetrate the surface of the skin. An x-ray image is then taken to ensure that the whole device can be seen on the screen. Image calibration is then performed through the software GUI. After which, the clinician is also to perform needle tip selection. After which, needle alignment will then be performed. Once needle alignment is complete, the clinician will then advance the trocar needle into the patient's body, using the fluoroscopy to judge the penetration depth. Once the target has been reached, the needle style is to be extracted. The indication of leakage of fluid through the outer needle confirms the success of the procedure.
75900115|NCT03132584|Drug|Cyclophosphamide|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~- Via IV Day 3"
75900116|NCT03132584|Drug|Alemtuzumab|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~Alemtuzumab will be administered as follows:~IV Day 1~IV Day 2~Target dose IV on Day 3 and 4"
75750734|NCT02461368|Procedure|Glenohumeral triamcinolone injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
75750735|NCT02461368|Procedure|Glenohumeral triamcinolone injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
75900117|NCT03507764|Other|Use of the treadmill workstation at work|"During the randomized study phase, provision of the treadmill workstation with the recommendation to use it for at least one hour (continuous or split) during each of the working shifts.~After six months, all subjects will use treadmill without restrictions or conditions."
75900118|NCT02301650|Drug|Lamivudine|mothers use Lamivudine in late pregnancy
75750736|NCT02400190|Other|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
75750737|NCT02373072|Drug|PF-06649751|Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
75900119|NCT02301650|Drug|Telbivudine|mothers use Telbivudine in late pregnancy
75900120|NCT02301650|Drug|Tenofovir|mothers use Tenofovir in late pregnancy
75900121|NCT03600844|Behavioral|Community distribution of SP for IPTp|SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
75454667|NCT01751035|Behavioral|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
75454668|NCT01751048|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.
75605988|NCT04098055|Device|Custom-Made Foot Orthoses|The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
75605989|NCT04098055|Device|Placebo|The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
75605990|NCT05581381|Behavioral|empathy training program|Empathy training, a total of 8 weeks of training (1 time a week, 1 hour each time)
75900122|NCT03510338|Drug|Sublingual sildenafil|100 mg biphasic sildenafil tablet
75900123|NCT03510338|Drug|Oral sildenafil|50 mg oral sildenafil (Viagra)
75900124|NCT02301728|Other|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
75750738|NCT02373072|Drug|Trimethobenzamide Hydrochloride|300mg TID, Capsules. Optional in both Cohorts.
75750739|NCT02373072|Drug|Placebo|Subjects completing all three treatment periods will be receiving placebo once.
75900125|NCT03510260|Other|Study Group I|Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).
75900126|NCT03510260|Other|Study Group II|The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent
75900127|NCT03510260|Other|Control Group|Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
75900128|NCT02303366|Radiation|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
75900129|NCT02303366|Drug|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
75900130|NCT02301806|Other|dieting|
75900131|NCT02301806|Drug|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
75605991|NCT03873649|Other|Bronchoscopy with lavage|"Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response."
75605992|NCT00975676|Other|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
75605993|NCT03770221|Behavioral|CATCH|Brief, intensive case management service.
75605994|NCT03770221|Other|Financial Incentive|Financial incentive for maintaining contact with CATCH service providers.
75750740|NCT02303678|Drug|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
75750741|NCT02292004|Device|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
75750742|NCT02292004|Procedure|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
75750743|NCT02285140|Drug|Cefazolin|administration as outlined
75900132|NCT02301806|Drug|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
75900133|NCT03103204|Combination Product|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants."
75900134|NCT03507530|Other|Assessments|Falls related assessments, functional physical performance evaluations and quality of life assessments.
75750744|NCT02285140|Drug|Vancomycin|administration as outlined
75750745|NCT02254278|Drug|Cisplatin|40 mg/m2 IV (intravenously) weekly for 6 weeks
75750746|NCT02254278|Radiation|IMRT 6 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
75900135|NCT02301884|Biological|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
75900136|NCT04724512|Device|suture|a type of suture used in entropion surgery
75900137|NCT02301962|Drug|Panitumumab|Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
75900138|NCT04702438|Behavioral|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
75900139|NCT03507374|Drug|Alirocumab|Alirocumab is approved by the FDA as a secondary treatment for high cholesterol for adults whose cholesterol can not be controlled by diet and/or statin treatment. Additionally, Alirocumab works to inhibit the PCSK9 protein.
75900140|NCT03507374|Drug|Placebo|Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
75605995|NCT03766087|Procedure|decompressive craniectomy|decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
75900141|NCT05141890|Dietary Supplement|Lactobacillus Plantarum|Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.
75900142|NCT03510026|Device|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
75750747|NCT02254278|Radiation|IMRT 5 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
75750748|NCT02174549|Drug|Tirapazamine|Intra-arterial injection into the tumor feeding artery
75750749|NCT02174549|Procedure|Conventional Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
75750750|NCT02145000|Biological|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
75750751|NCT02145000|Biological|Placebo|
75750752|NCT02059499|Drug|imiquimod|Given intra-anally
75750753|NCT02059499|Drug|fluorouracil|Given intra-anally
75750754|NCT02059499|Other|questionnaire administration|Ancillary studies
75750755|NCT02059499|Other|laboratory biomarker analysis|Correlative studies
75750756|NCT01998841|Drug|Crenezumab|Crenezumab will be administered as per the schedule specified in the treatment arm.
75750757|NCT01998841|Drug|Placebo|Placebo will be administered as per the schedule specified in the treatment arm.
75750758|NCT01864850|Radiation|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
75900143|NCT02302040|Behavioral|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
75750759|NCT01864850|Radiation|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
75750760|NCT01607879|Drug|Standard of care ADT + (HMB + arginine + glutamine)|"1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months"
75750761|NCT01607879|Other|Standard of care ADT|Patient will receive standard of care androgen deprivation therapy (ADT) alone
75750762|NCT01561612|Behavioral|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
75750763|NCT01336933|Drug|prednisone|Given PO
75750764|NCT01336933|Drug|cyclophosphamide|Given IV
75900144|NCT02302040|Behavioral|Self-guided|Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
75900145|NCT02639650|Drug|Etoposide|etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle
75454669|NCT01751048|Biological|LEISH-F3|LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.
75454670|NCT01751048|Biological|MPL-SE|Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.
75454671|NCT01751048|Drug|SE|Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
75605996|NCT02866240|Device|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
75454672|NCT01751074|Drug|Rosuvastatin 10 mg|Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
75454673|NCT01751074|Drug|Darapladib 160 mg|Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
75605997|NCT02866318|Device|Echocardiography|
75605998|NCT00629356|Genetic|dengue fever|
75605999|NCT02865148|Behavioral|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
75606000|NCT00629434|Other|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
75606001|NCT00629434|Other|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
75606002|NCT04289194|Drug|HCR040 (Phase 1)|(Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)
75606003|NCT04289194|Drug|Placebo (Phase 2)|(Phase 2) Intravenous administration of vehicle solution
75606004|NCT04289194|Drug|HCR040 (Phase 2)|(Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)
75606005|NCT03935854|Other|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
75750765|NCT01336933|Drug|etoposide|Given PO or IV
75750766|NCT01336933|Drug|Vincristine|Given IV
75750767|NCT01336933|Drug|pralatrexate|Given IV
75750768|NCT01336933|Other|laboratory biomarker analysis|Correlative studies
75750769|NCT01336933|Genetic|comparative genomic hybridization|Correlative studies
75750770|NCT01336933|Genetic|gene expression analysis|Correlative studies
75750771|NCT01336933|Genetic|nucleic acid sequencing|Correlative studies
75900146|NCT02639650|Drug|actinomycin D|actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle
75750772|NCT01336933|Genetic|mutation analysis|Correlative studies
75750773|NCT01336933|Other|immunohistochemistry staining method|Correlative studies
75750774|NCT01336933|Genetic|microarray analysis|Correlative studies
75750775|NCT01336933|Genetic|RNA analysis|Correlative studies
75750776|NCT01107522|Drug|CTO|Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
75750777|NCT01107522|Drug|CTO and Temodar®|"Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.~Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.~Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle"
75900147|NCT02639650|Drug|methotrexate|methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
75606006|NCT04289584|Other|Strength and proprioception exercises|Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
75454674|NCT01751100|Behavioral|HIV Test Offer|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
75900148|NCT02639650|Drug|vincristine|vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle
75900149|NCT02639650|Drug|cyclophosphamide|cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
76066667|NCT04948476|Other|Standardized Dialysis and Structured Discontinuation (S2D2)|"Prescription to minimize dialysis-induced ischemia~Cool dialysate (35.0◦C)~Dialysate sodium of 145mmol/L~Dialysate calcium of 1.5mmol/L~Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)~Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.~Structured dialysis discontinuation (all criteria met)~Most recent pre-dialysis potassium <6mmo/L and bicarbonate >12mmol/L~Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis <1L/session~If available, timed urine collection with result for mean creatinine and/or urea clearance >12mL/min"
75454675|NCT01751100|Behavioral|General Health Screen Offer|A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
75454676|NCT01751204|Dietary Supplement|Calcium tablet|
75900150|NCT02639650|Drug|Paclitaxel|paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle
75900151|NCT02639650|Drug|Cisplatin|cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle
75900152|NCT02639650|Drug|Carboplatin|carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin
75900153|NCT03509870|Biological|mesenchymal stromal cells|mesenchymal stromal cells in a collagen scaffold
75900154|NCT03581734|Biological|Oral Polio Vaccine|OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
75900155|NCT03581734|Biological|Oral Cholera Vaccine|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
75900156|NCT02306798|Drug|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
75606007|NCT03857191|Dietary Supplement|Nutritional psychocomportemental rehabilitation|Nutritional psychocomportemental rehabilitation
75454677|NCT01751204|Dietary Supplement|Calcium ion water (250mg)|
75900157|NCT04980430|Device|Virtual Reality|Virtual Reality Demonstration
75454678|NCT01751204|Dietary Supplement|Calcium ion water (125mg)|
75900158|NCT02306876|Drug|PF-06412562 3mg BID|PF-06412562
75900159|NCT02306876|Drug|PF-06412562 15mg BID|PF-06412562
75900160|NCT02306876|Other|Placebo|Placebo
75454679|NCT01751217|Behavioral|Functional Family Tx|
75454680|NCT01751217|Behavioral|Services as Usual|
75454681|NCT01751243|Other|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
75454682|NCT01751243|Other|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
75454683|NCT01751256|Device|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
75454684|NCT01751269|Drug|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
75606008|NCT04289818|Other|Health Coaching|Health Coaching as face to face with a coach
75606009|NCT03812809|Drug|BPI-7711|BPI-7711: 180mg, QD, oral
75606010|NCT04083157|Biological|Intradermal hepatitis B vaccine with imiquimod|Intradermal hepatitis B vaccine with topical imiquimod pretreatment
75900161|NCT04347226|Drug|BMS-986253|BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).
75900162|NCT02302118|Procedure|Esophagogastrectomy|Esophagogastrectomy
75900163|NCT04962178|Procedure|Primary PCI|The patients assigned to early invasive strategy group will receive the primary PCI.
75900164|NCT04962178|Other|Optimal medical therapy with primary PCI not performed|The patients assigned to conservative strategy group will receive optimal medical therapy before primary endpoint accomplished.
76066668|NCT04948476|Other|Usual Care|Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.
76066669|NCT04944992|Drug|Efinopegdutide 20 mg/mL|Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
75750778|NCT01107522|Drug|CTO, Temodar®, Radiation therapy|Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
75750779|NCT01087619|Procedure|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
75750780|NCT00756379|Other|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
75454685|NCT01751269|Drug|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
75750781|NCT00352027|Drug|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
75750782|NCT00352027|Drug|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
75900165|NCT02302196|Procedure|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
75454686|NCT01751282|Genetic|Stem Cell|
75454687|NCT01751295|Drug|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
75454688|NCT01751321|Drug|Sitagliptin, placebo|sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
75454689|NCT01751334|Device|total knee arthroplasty|Mobile Bearing Total knee Arthroplasty
75454690|NCT01751334|Device|total knee arthroplasty|Fixed Total Knee Arthroplasty
75454691|NCT01751347|Drug|Bupivacaine|Local anesthetics
75454692|NCT01751347|Drug|Lidocaine|Local anesthetics
75606011|NCT04083157|Biological|Intramuscular hepatitis B vaccine with aqueous cream|Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
75606012|NCT05522101|Device|Mini-sized MCE|AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application
75606013|NCT05522101|Device|Normal-sized MCE|Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340*340, working time is not less than 8 hours.
75900166|NCT02302196|Other|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
75900167|NCT03509714|Dietary Supplement|Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)|2 Pills to be taken orally per day during their entire menstrual cycle
75900168|NCT03509714|Dietary Supplement|rice flour (Placebo)|250 mg rice flour (Placebo)
76066670|NCT04944992|Drug|Semaglutide 1.34 mg/mL|Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
76066671|NCT04920162|Other|Biospecimen into patients who had skin diseases|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
76066672|NCT04914507|Device|Anterior Vertebral Body Tethering|Subject will receive anterior vertebral body tethering surgery.
75454693|NCT01751373|Behavioral|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
75606014|NCT00975286|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
75606015|NCT00975286|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
75750783|NCT00352027|Drug|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
76066673|NCT04900506|Procedure|Posterior SPAIRE approach, anterior approach|Based on power calculation a sub-group analysis of 50 patients will be examined with DXA, all patients for biochemical and clinical muscle damage (CK, CRP, TUG-test, Trendelenburg, strenght test)
76066674|NCT04893824|Device|Grappler® Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
76066675|NCT04874194|Drug|Omacetaxine Mepesuccinate|Given SC
75454694|NCT01751373|Behavioral|Standard Therapy|
75606016|NCT00975286|Drug|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
75606017|NCT00975286|Device|Pen auto-injector|Lantus® SoloStar® OptiClik®
75606018|NCT00975286|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
76066676|NCT04874194|Drug|Venetoclax|Given PO
76066677|NCT04862455|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally/intranodally
76066678|NCT04862455|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
76066679|NCT04862455|Biological|Pembrolizumab|Given IV
76066680|NCT04862455|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
76066681|NCT04857788|Other|Pandah Application smartphone only|Patients will have an application on their smartphone to help them do their homework
76066682|NCT04851678|Other|None - observational study|None - observational study
76066683|NCT04843566|Procedure|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
76066684|NCT04843566|Procedure|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
75454695|NCT01751464|Behavioral|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
75606019|NCT00975286|Drug|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
75606020|NCT00907777|Biological|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
75606021|NCT00907777|Biological|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
75750784|NCT00352027|Drug|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
76066685|NCT04843566|Drug|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
76066686|NCT04842773|Diagnostic Test|Ultrasound measurement|Ultrasound measurement of sarcopenia in an elderly population
76066687|NCT04837209|Drug|Niraparib|Capsule, taken by mouth
76066688|NCT04837209|Drug|Dostarlimab|Intravenous infusion
76066689|NCT04837209|Radiation|Radiation therapy|Radio Therapy
75606022|NCT03741517|Radiation|18F-FDG-PET|Fludeoxyglucose F18
75606023|NCT03741517|Radiation|68Ga-DOTATOC-PET|DOTA-tyr3-Octreotide Ga68
75606024|NCT03741517|Radiation|Computed tomography|Computed tomography of thorax and abdomen with 3-phase contrast
75606025|NCT03741517|Other|Core needle biopsy|Core needle biopsy of metastatic lesions
75606026|NCT03741517|Other|Phlebotomy|Phlebotomy from peripheral vein
75606027|NCT04270396|Behavioral|Presence or absence of implant|We procedure to observed clinically the sample size, to be able to determine if the dental implant was present or no. If the implant was absent we recorded if it was early( prior to restoration) or late ( after prosthesis was delivered).
75750785|NCT00352027|Drug|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
75750786|NCT00352027|Drug|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
75750787|NCT00352027|Drug|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
75750788|NCT00352027|Drug|Prednisone|Given PO every other day of weeks 1-12.
75750789|NCT00352027|Biological|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
76066690|NCT04837092|Drug|FR104|FR104 treatment administration at day 0, day 14 then every 28 days until month 12
76066691|NCT04836897|Device|PrizValve® valve and transapical delivery system|Transcatheter aortic valve replacement system
76066692|NCT04820530|Drug|Iptacopan (LNP023)|Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
76066693|NCT04813627|Procedure|Regular blood sample collection for ctDNA assessment|Blood samples for in vitro testing of ctDNA status will be drawn at study visits every three months
76066694|NCT04812795|Other|Culturally tailored anti-smoking messages|Anti-smoking messages that are culturally tailored for sexual minority women.
75606028|NCT02866084|Device|Device|"The following parameters will be set for active treatments using the CVS Device:~A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies."
75606029|NCT00908011|Drug|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
75606030|NCT00908011|Drug|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
75606031|NCT02864836|Procedure|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
75454696|NCT01751503|Procedure|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
75606032|NCT00976456|Drug|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
75606033|NCT00976456|Drug|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
75900169|NCT02303522|Other|Other: not applicable - observational study|No intervention exists as this is a retrospective observational study
75900170|NCT03101878|Drug|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
75606034|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
75750790|NCT00352027|Procedure|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
75750791|NCT00285259|Biological|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
75750792|NCT00285259|Other|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
75900171|NCT03101878|Drug|Placebo|Saline .9%
75900172|NCT02302274|Drug|flecainide iv|infusion over 10 min
75606035|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
75606036|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
75606037|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
75750793|NCT00262470|Drug|Acetazolamide|250 mg PO x 1
75750794|NCT00262470|Drug|Atomoxetine|10-40 mg PO x 1 dose
75750795|NCT00262470|Other|NO Drug|No intervention - just monitoring
75750796|NCT00262470|Drug|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
75750797|NCT00262470|Drug|Entacapone|Entacapone 200-400 mg PO x 1 dose
75750798|NCT00262470|Drug|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
75750799|NCT00262470|Drug|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
75750800|NCT00262470|Drug|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
75900173|NCT05245318|Other|Standard Clinical care|The standard care treatment comprises 12 face-to-face individual physiotherapy sessions at a ratio of 1 session a week. Every patient in the control group will be treated in a tailored manner according to their results on the baseline measurements. The multimodal treatment program will consist of exercises to increase strength, endurance and coordination of the cervical spine and shoulder stabilising muscles, exercises to increase mobility and improve posture. In case of jaw complaints stretching exercises of the masticatory muscles are added to the program. In addition, manual mobilisations and manual techniques to decrease muscle tension in neck and jaw muscles can be added to the exercise program if necessary. Patients will receive counselling to learn about their neck/jaw complaints but no tinnitus counselling. Patients will be motivated to perform the exercise program at home on a daily basis. Patients will be evaluated weekly.
75454697|NCT01751503|Procedure|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
75454698|NCT01751529|Procedure|Contrast-enhanced Ultrasound|All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
75454699|NCT01751529|Drug|Perflutren lipid|All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
75454700|NCT01751542|Behavioral|Mindfulness + Residential Treatment|
75606038|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
75606039|NCT00629512|Drug|Esomeprazole|20mg oral daily
75606040|NCT00629512|Drug|Esomeprazole|40mg oral daily
75750801|NCT00262470|Drug|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
75750802|NCT00262470|Drug|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
75750803|NCT00262470|Dietary Supplement|Melatonin|melatonin 3 mg PO x 1 dose
75750804|NCT00262470|Drug|Midodrine|midodrine 2.5-10 mg PO x 1 dose
75750805|NCT00262470|Drug|Modafinil|modafinil 100-200 mg PO x 1 dose
75750806|NCT00262470|Drug|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
75750807|NCT00262470|Radiation|Placebo|lactose tablet x 1 pill
75750808|NCT00262470|Drug|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
75750809|NCT00262470|Drug|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
75750810|NCT00262470|Drug|Sertraline|sertraline 25-50 mg PO x 1 dose
75750811|NCT00262470|Procedure|IV Saline|1 liter IV over 2 hours
75750812|NCT00262470|Other|Drinking Water|16 fluid ounces
75750813|NCT00262470|Device|Breathing Device|Breathing through a dead space tube
75750814|NCT00262470|Drug|memantine|memantine 5-20 mg PO x 1 dose
76066695|NCT04812795|Other|Non-culturally tailored interventions|Anti-smoking messages that are not culturally tailored for sexual minority women.
76066696|NCT04807907|Behavioral|Infant Directed Speech (IDS) Video + IDS Wall Calendar|"IDS Video: The IDS video was developed by the research team. It is a simple animation with a voiceover describing the value of IDS and encouraging the viewer to speak to her babies and to tell family members to do so as well. The video has been translated into Dagbani and English (viewers select the language). They may choose to watch it twice.~Breastfeeding women are told by the surveyor following the video, For instance, you could talk to your baby in full sentences when your baby is breastfeeding.~Wall Calendar: The calendar contains images from the video of parents practicing IDS, and key facts about IDS in bullet points. The 12-month calendar contains an empty star next to each week that the respondent can fill in if they perform IDS at least once a day in that week. The calendar also provides a link to a Facebook page where the respondents can re-watch the video or show it to others (https://www.facebook.com/ghanababytalk/videos)."
76066697|NCT04800250|Procedure|Treatment of gingival recessions|Patients will have a surgery for their gingival recessions. They will be enrolled in the split mouth-study. They will have on one side mucogain matrix transplant, an on another side they will have the gold standard procedure
75454701|NCT01751542|Behavioral|Residential treatment alone|
75454702|NCT01751555|Drug|Regimen:TDF+3TC+EFV|TDF+3TC+EFV for HIV/HBV co-infection
75750815|NCT00262470|Device|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
75750816|NCT00082641|Biological|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
75750817|NCT00440271|Drug|tipranavir|
75750818|NCT00440271|Drug|ritonavir|
75750819|NCT00440271|Drug|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
75750820|NCT00346216|Drug|celecoxib|100 to 200 mg twice daily, taken by mouth
75750821|NCT00346216|Drug|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
75454703|NCT01751581|Behavioral|Short Sleep|Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
75454704|NCT01751581|Behavioral|Habitual sleep|Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
75606041|NCT00629512|Drug|Placebo|
75606042|NCT01711021|Drug|d-Amphetamine Transdermal Patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
75606043|NCT01711021|Drug|Placebo patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
75606044|NCT02864680|Other|Electroretinography|
75606045|NCT02864680|Other|Contrast sensitivity test during Electroencephalography|Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
75606046|NCT02864680|Other|Visual simultaneity test during Electroencephalography|Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
75750822|NCT00346216|Drug|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
75750823|NCT01030419|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
75750824|NCT01030419|Behavioral|Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
75750825|NCT01325116|Behavioral|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
76066698|NCT04797767|Drug|Cladribine|Given IV
75606047|NCT02864680|Other|Face perception test during Electroencephalography|Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
75606048|NCT02864680|Other|CAST (cannabis abuse screening test)|
75606049|NCT02864680|Other|PANSS (Positive And Negative Symptoms Scale) test|
75750826|NCT01051648|Drug|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy
75750827|NCT00417963|Device|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
75750828|NCT00429273|Drug|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
75750829|NCT00429273|Drug|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
75750830|NCT00359632|Drug|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
75750831|NCT00359632|Drug|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
75750832|NCT01324960|Drug|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
76066699|NCT04797767|Drug|Cytarabine|Given IV
75454705|NCT01751594|Behavioral|MOVE Intervention|MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
75454706|NCT01751594|Behavioral|H4L Comparison Intervention|Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
75750833|NCT01324960|Drug|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
75750834|NCT00417885|Drug|exemestane|25 mg, oral, daily dosing
75750835|NCT00417885|Drug|sunitinib malate|37.5 mg, oral, continuous dosing, daily
76066700|NCT04797767|Drug|Mitoxantrone|Given IV
76066701|NCT04797767|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
76066702|NCT04797767|Drug|Venetoclax|Given PO
76066703|NCT04794972|Drug|GNC-039|Administration by intravenous infusion.
75454707|NCT01751620|Behavioral|Project ACCEPT|The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
75606050|NCT02864680|Other|Delayed Matching to Sample (DMS) test|
75606051|NCT02864680|Other|Spatial Working Memory (SWM) test|
75606052|NCT02864680|Other|Rapid Visual Information Processing (RVP) test|
76066704|NCT04784715|Drug|Trastuzumab deruxtecan|Administered by intravenous infusion
75606053|NCT02864680|Other|Test for attentional performance (TAP) / Divided Attention|
75606054|NCT02864680|Other|Collection of saliva sample|In case of specific consent of participant to ancillary study, for ancillary study
75606055|NCT02864602|Drug|IV dexamethasone|An infusion of IV dexamethasone
76066705|NCT04784715|Drug|Placebo|Administered by intravenous infusion
76066706|NCT04784715|Drug|Taxane|Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
76066707|NCT04784715|Drug|Pertuzumab|Administered by intravenous infusion
76066708|NCT04784715|Drug|Trastuzumab|Administered by intravenous infusion
76066709|NCT04770207|Drug|Injection of drug-eluting microspheres with multiple drugs into solid tumors|Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
75606056|NCT03788083|Drug|Trimix|Intratumoral TriMix injection
75606057|NCT03788083|Drug|Placebo|Intratumoral placebo injection
75750836|NCT01056250|Procedure|SILS cholangiography|intraoperative
76066710|NCT04759105|Drug|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells
76066711|NCT04759105|Other|Sham Procedure|anaesthesia, no disc injection, no placebo injection
76066712|NCT04752163|Drug|DS-1594b|Given DS-1594b PO
76066713|NCT04752163|Drug|Azacitidine|Given IV or SC
76066714|NCT04752163|Drug|Cyclophosphamide|Given IV
76066715|NCT04752163|Drug|Cytarabine|Given IT
76066716|NCT04752163|Drug|Dexamethasone|Given PO or IV
76066717|NCT04752163|Biological|Filgrastim|Given SC
76066718|NCT04752163|Drug|Leucovorin|Given IV or PO
76066719|NCT04752163|Drug|Mesna|Given IV
76066720|NCT04752163|Drug|Methotrexate|Given IT
75750837|NCT03989596|Radiation|Hypofractionated radiotherapy|"Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.~Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks."
75750838|NCT03989596|Other|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
75606058|NCT04289506|Diagnostic Test|mRNA expression|The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
75606059|NCT00993148|Drug|maraviroc|150 mg tab by mouth once daily for 96 weeks
75606060|NCT00993148|Drug|darunavir|800 mg tab by mouth once daily for 96 weeks
75606061|NCT00993148|Drug|ritonavir|100 mg capsule by mouth once daily for 96 weeks
75606062|NCT03775369|Other|endurance training|physical activity and exercising (PAE)
75750839|NCT01036893|Drug|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
75900174|NCT05245318|Device|Blended physiotherapy program|The experimental group will receive a blended physiotherapy program consisting of six physiotherapy treatments over a period of 12 weeks, meaning one treatment session every two weeks. In addition, a smartphone application will offer the patients a daily exercise program, based upon the standard physiotherapy treatment, and psychological counselling. Before the start of the program, the exercises will be tailored to the area, type and degree of the patient's dysfunctions. During the six physiotherapy treatment sessions patients will (if needed), receive additional manual mobilisations to increase mobility of the neck and/or temporomandibular joints or manual techniques to decrease muscle tension in neck and jaw muscles. Additional counselling on knowledge about neck and jaw pain and advice about good posture and movement habits will also be provided by the physiotherapist during these six treatment sessions.
75750840|NCT01056406|Behavioral|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
75750841|NCT01856439|Drug|ProSavin|Long term follow up of patients who received ProSavin in a previous study
75750842|NCT01051726|Other|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
76066721|NCT04752163|Drug|Posaconazole|Given PO
76066722|NCT04752163|Drug|Prednisone|Given PO
76066723|NCT04752163|Biological|Rituximab|Given IV
75606063|NCT03775369|Other|social support and counseling|social support and counseling
75606064|NCT03775369|Other|resistance training|physical activity and exercising (PAE)
75606065|NCT03661177|Other|Sovereign nation diet|We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
75606066|NCT05505955|Drug|HRS-5965|Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
75606067|NCT05505955|Drug|Placebo|Subjects took Placebo in Part 1 and Part 2.
75606068|NCT04223947|Procedure|DIGESTIVE ENDOSCOPY|DIGESTIVE ENDOSCOPY
75606069|NCT00907621|Procedure|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
75606070|NCT04230811|Diagnostic Test|Corneal impression membrane (Millicell Cell Culture Insert, 12mm, hydrophilic PTFE 0.4µm (PICM01250))|Application of corneal membrane to the cornea for 3-5 seconds, after anaesthesia
75606071|NCT05332951|Other|Interpersonal Reactivity Index|Questionnaire to be completed by the patient
75750843|NCT01051726|Other|None essential oil|Baby oil
75750844|NCT04488770|Drug|GSK3882347|Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
75750845|NCT04488770|Drug|Placebo|Matching strength placebo capsules will be provided
75750846|NCT00525044|Drug|Ambroxol|
75750847|NCT00525044|Drug|Placebo|
76066724|NCT04752163|Drug|Venetoclax|Given PO
76066725|NCT04752163|Drug|Vincristine|Given IV
76066726|NCT04752163|Drug|Voriconazole|Given PO
76066727|NCT04751331|Biological|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113)
76066728|NCT04751331|Biological|Saline|0.9% saline administered as an intravenous bolus
76066729|NCT04750928|Drug|Abemaciclib|Abemaciclib is to be administered orally on Days 1 through 28 of each 28-day cycle
75606072|NCT03601117|Device|Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC.~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
76066730|NCT04749030|Other|Faecal microbiota transplantation (FMT) capsules|The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (~50 grams of original donor faeces).
75606073|NCT03601117|Device|Anterior Cingulate Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the anterior cingulate cortex (ACC).~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
76066731|NCT04749030|Other|Placebo capsules|The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
76066732|NCT04744428|Behavioral|Autism Parent Navigators|The Autism Parent Navigator program consists of six sessions delivered to parents in the home, supporting adjustment to ASD, accessing services, and coparenting support.
75606074|NCT03587233|Behavioral|Physical assessment|Besides the demographic features of the participants, the interventions on physical assessment will be performed including weight in kilogram and height in meter; and weight and height will be combined to report body mass index in kg/m2. The waist circumference will be measured to understand the central fattening from costal margins or above umbilicus in cm. If it is measured above 95cm for men and 80cm for women is considered as higher than normal; if higher than 110cm for men and 88cm for women is considered as having risks for obesity, diabetes, cardiovascular diseases etc. Hand and pinch grip power will be assessed. It the elbow is in extension upper extremity power, and if it is flexed at 90 degree and forearm is supported on the table handgrip power is to assess.
75606075|NCT03587233|Device|Analyses of body composition|The analyzes of body composition will be measured with bioelectrical impedance analysis method by a body composition analyzer.
75750848|NCT00355342|Drug|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
75750849|NCT00355342|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
75750850|NCT00355342|Device|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
75750851|NCT03573362|Device|ViziShot FLEX 19G needle|EBUS-TBNA using the ViziShot FLEX 19G needle
75750852|NCT03573362|Device|Vizishot 22G needle (standard)|EBUS-TBNA using the Vizishot 22G needle (standard)
75750853|NCT01051804|Other|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
75750854|NCT01051804|Other|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
75750855|NCT01051882|Biological|MSC-NTF cells transplantation (IM)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
75750856|NCT01051882|Biological|MSC-NTF cells transplantation (IT)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
75750857|NCT01573754|Drug|Hydroxychloroquine|100 mg by mouth twice weekly
75750858|NCT01573754|Procedure|Phlebotomy|450 mL every 2 weeks
75750859|NCT03989674|Dietary Supplement|Anthocyanin|25% w/w anthocyanin extract obtained from black rice
75900175|NCT02303600|Drug|Montelukast|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
75900176|NCT02303600|Other|Placebo|Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
75900177|NCT05245240|Procedure|Dietary and physical intervention|"Low-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences.~Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes."
75900178|NCT02307110|Other|cross-sectional observation|cross-sectional opthalmic examination
75900179|NCT05244928|Other|"The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®"|"Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A stepped wedge cluster randomized controlled trial provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total."
75900180|NCT03505034|Drug|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
75900181|NCT05244850|Other|Test|Measurements
75454708|NCT01751620|Behavioral|HEALTH|The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
75454709|NCT01751633|Procedure|Surgical|
75454710|NCT01751633|Procedure|Conservative treatment|
75454711|NCT01751698|Behavioral|JASP-EMT|JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
75454712|NCT01751698|Behavioral|DTT|CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
75454713|NCT01751737|Procedure|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
75454714|NCT01751750|Other|Grape|16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
75454715|NCT01751763|Drug|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator.
75454716|NCT01751776|Drug|BI 655064 medium dose|Medium dose
75454717|NCT01751776|Drug|BI 655064 high dose|High dose
75454718|NCT01751776|Drug|BI 655064 high dose|High dose
75454719|NCT01751776|Drug|Placebo|Placebo
75750860|NCT03986788|Other|Weightlessness|Volunteers will be studied during parabolic flight. Cerebral blood flow will be measured in different part of the brain during weightlessness ans compared to 1g and hypergravity measurements.
75750861|NCT03989830|Drug|second-line chemotherapy|choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
75750862|NCT03989830|Drug|Recombinant human endostatin|7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
75900182|NCT02817178|Other|Additional biological samples|blood and tumor tissue samples
75900183|NCT02303756|Device|Pillcam® COLON Capsule|colonoscopy
75900184|NCT04730986|Behavioral|ED GOAL Nursing|A brief (<7minutes) interview by an emergency department nurse to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
75900185|NCT04463342|Combination Product|Non Coated Glass Ionomer|KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.
75454720|NCT01751776|Drug|BI 655064 low dose|Low dose
75454721|NCT01751776|Drug|Placebo|Placebo
75454722|NCT01751776|Drug|BI 655064 medium dose|Medium dose
75900186|NCT04463342|Combination Product|Conventional Glass Ionomer with Coat|Conventional Glass Ionomer with Coat
76066733|NCT04744428|Behavioral|Peer mentoring|Six in-home or telephone sessions, depending on family uptake, providing non-manualized general support as usual from parent peer mentors regarding adjustment to ASD.
75900187|NCT05244772|Other|Remote monitoring|Remote monitoring with a smartphone application of pain and nausea after day care surgery
75900188|NCT02303834|Device|Continuous Positive Airway Pressure Ventilation (CPAP)|A mask worn over the nose that delivers air under slight pressure.
76066734|NCT04738877|Diagnostic Test|Body fat measurement|Body fat measurement using skinfolds
76066735|NCT04738877|Diagnostic Test|Cardiopulmonary exercise testing|Electrocardiographic exercise testing with ergospirometer on a treadmill
76066736|NCT04738877|Diagnostic Test|Echocardiography|Transthoracic echocardiography
75750863|NCT03989518|Behavioral|Fear acquisition|Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).
75750864|NCT03989518|Behavioral|Imaginal extinction|Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.
75750865|NCT03989518|Behavioral|Reinstatement|Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.
75750866|NCT03989284|Behavioral|Community-based depression interventions|We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
75750867|NCT00355264|Drug|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
75750868|NCT01054378|Procedure|M-mode ultrasonography|Evaluation of diaphragmatic movement using M-mode ultrasonography before and after stellate ganglion block with 1% lidocaine
76066737|NCT04738877|Diagnostic Test|Blood test|Blood test for measurement of haemoglobin, serum electrolytes, iron, ferritin and vitamins
75454723|NCT01751789|Behavioral|Linkage|
75454724|NCT01751789|Other|Treatment as Usual|
75454725|NCT01751815|Procedure|Acu-TENS|Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
75750869|NCT02533648|Drug|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
75750870|NCT02533648|Drug|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
75750871|NCT01056796|Device|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
75750872|NCT02533492|Device|vicryl|wound closure with vicryl suture
75750873|NCT02533492|Device|Vicryl plus|wound closure with vicryl plus suture
76066738|NCT04732598|Drug|Paclitaxel + bevacizumab therapy|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~[Paclitaxel] 90mg/m^2, day1,8,15, IV [Bevacizumab] 10mg/kg, day1,15, IV"
75454726|NCT01751815|Procedure|Placebo-TENS|Patients randomized to the control group will receive placebo-TENS at the same acupoints.
75454727|NCT01751828|Drug|Sertraline|
75454728|NCT01751854|Drug|SSRI|SSRI alone or with training
75454729|NCT01751854|Drug|Placebo|Placebo alone or with training
75454730|NCT01751880|Behavioral|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
75454731|NCT01751893|Drug|Henna|natural henna in the form of paste
75454732|NCT01751893|Drug|Placebo|placebo
75606076|NCT03587233|Behavioral|physical activity level assessment|The physical activity level will be assessed through the intervention titled with the Turkish version of the 'International Physical Activity Questionnaire-Short Form'. It consists of seven questions searching for the amount of walking and low, moderate and high intensity physical activities as total time in minutes per day and frequency in days per week. Sitting, as a sedentary behavior, will be evaluated separately. The scores will be achieved by the multiplication of the minutes, days and metabolic equivalent time values in a week, and over the last 7 days. Walking score and total weekly walking duration will be calculated as medium and vigorous; the physical activity level will be classified as low, moderate and high level activity.
75606077|NCT03581695|Other|Blood test|Blood test
75606078|NCT03517111|Behavioral|Nutrition/substance use prevention|Parenting program focusing on diet improvement and substance use prevention
75606079|NCT03517111|Behavioral|Substance use prevention only|Parenting program focusing only on substance use prevention
75606080|NCT03517111|Behavioral|Academic success program|Program focusing on academic success and college acceptance
75750874|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose
75750875|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
75750876|NCT01056874|Drug|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
75750877|NCT01056952|Procedure|O2stand|Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 > 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
75750878|NCT01056952|Procedure|CPAP|o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher & Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 > 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
75900189|NCT02303912|Drug|Nuc-1031 and Carboplatin|Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
75900190|NCT03507140|Other|Multiple sampling|"Bile, saliva, feces, urine et blood samples before and after liver transplantation in recipients.~Bile, saliva, feces, urine et blood samples during liver removal in donors."
75900191|NCT01597492|Biological|Belimumab plus Early Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
75454733|NCT01751919|Drug|Imatinib mesylate tablet 400 mg, 1 Tablet|
75606081|NCT04225429|Drug|Tazemetostat|800mg/dose taken orally twice every day.
75750879|NCT01056952|Procedure|Optiflow|High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 > 90%
76066739|NCT04732598|Drug|Paclitaxel + bevacizumab + atezolizumab|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~[Atezolizumab] 840 mg/body, day 1,15, IV [Paclitaxel] 90mg/m^2, day1,8,15, IV [Bevacizumab] 10mg/kg, day1,15, IV"
75750880|NCT00355030|Drug|somatropin|0.05 mg/kg/day
76066740|NCT04731467|Drug|CM-24 and Nivolumab - Dose Escalation|Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors
76066741|NCT04731467|Drug|CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion|Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
75606082|NCT00907153|Dietary Supplement|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
76066742|NCT04731467|Drug|CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion|Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
75750881|NCT00355030|Drug|leuprorelin|11.25 mg/3 months
75750882|NCT01057030|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
75750883|NCT01057030|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
76066743|NCT04731467|Drug|Nivolumab, Nab paclitaxel and Gemcitabine - Expansion|Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
76066744|NCT04731467|Drug|Nivolumab and Nal-IRI/5-FU/LV - Expansion|Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
76066745|NCT04726683|Procedure|Dry needling and placebo injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin.
75750884|NCT03991546|Behavioral|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot|Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
75900192|NCT01597492|Biological|Belimumab plus Late Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
75900193|NCT04483726|Procedure|minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)
76066746|NCT04726683|Procedure|Injection and placebo dry needling|Lidocaine injection applied in the myofascial trigger point of the masseter muscle. Lidocaine injection is combined with placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin
76066747|NCT04726683|Procedure|Dry needling and injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with lidocaine injection applied in the myofascial trigger point of the masseter muscle.
75454734|NCT01751919|Drug|Glivec film-coated tablet 100 mg, 4 Tablets|
75454735|NCT01751932|Device|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
75606083|NCT00907153|Drug|Placebo|Placebo by mouth once daily for 12 weeks
75606084|NCT03984799|Procedure|Bronchoscopy|Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
75606085|NCT00904033|Drug|Calcitriol|Calcitriol tablet taken once per week.
75606086|NCT00904033|Behavioral|Exercise|Exercise consisting of progressive walking and resistance band training
76066748|NCT04726683|Procedure|Placebo dry needling and placebo injection|Placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin. Placebo dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin
76066749|NCT04709978|Diagnostic Test|Videofluoroscopic Swallowing Study|Participants enrolled in supplemental study will swallow different barium containing liquid and food boluses types that are captured on fluoroscopic imaging in real time.
75606087|NCT00904033|Dietary Supplement|Multivitamin|
75606088|NCT05175625|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
75454736|NCT01751945|Behavioral|EmONC package|"The EmONC package consists of:~Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~Community mobilisation"
75454737|NCT01751958|Radiation|Epidural steroid injection|Epidural steroid injection
75606089|NCT05175625|Biological|Saline placebo|0.9% sodium chloride (1 mL); a single intramuscular injection into the deltoid muscle of the non-dominant arm
75606090|NCT02647177|Other|Pancreatic Cyst Aspiration|10 CC of pancreatic cyst aspiration
75606091|NCT00903877|Drug|T3|Patients receive T3 in a dose of 25mcg and 50mcg
75606092|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
75606093|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
75750885|NCT03986632|Behavioral|Tundra Gifts|Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.
75750886|NCT03989128|Other|Medical Chart Review|Undergo medical chart review
75750887|NCT03989128|Other|Survey Administration|Complete survey
75606094|NCT03353389|Other|No AKI|Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
75606095|NCT03353389|Other|CA-AKI|"CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
75454738|NCT01751997|Drug|Transplants from 8/8-matched Unrelated donors|"Myeloablative conditioning~Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~Reduced-intensity conditioning; older patients (age > 55 years) and/or patients with comorbidities~Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m^2)~Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~GVHD prophylaxis~Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11"
75606096|NCT03353389|Other|HA-AKI|"HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
75606097|NCT05332249|Procedure|Surgery|Patients who undergo spinal surgery for degenerative spinal disease
75606098|NCT01241591|Drug|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
75750888|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg BID
75750889|NCT01057108|Other|FOSTRAP Chewing Gum|40 mg BID
75750890|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
75750891|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
75750892|NCT01057108|Other|Placebo chewing gum|
75750893|NCT01057186|Dietary Supplement|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
75750894|NCT01057186|Drug|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
75750895|NCT03986476|Dietary Supplement|Probiotics|5x10^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
75750896|NCT03986476|Other|Placebo|Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
75750897|NCT01057264|Drug|HAI Abraxane|Starting dose: 120 mg/m^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
75750898|NCT01057264|Drug|Gemcitabine|Starting dose: 600 mg/m^2 by IV on Days 1 and 8 of 21 day cycle
75750899|NCT01057264|Drug|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
75750900|NCT01057264|Drug|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
76066750|NCT04709978|Diagnostic Test|Nuclear medicine pulmonary aspiration study|Participants enrolled in supplemental study will be administered radiotracer (Tc-99m-Sulfur Colloid) orally and static images of the chest will then be obtained at specified intervals over the next 2 hours to determine location of the radiotracer.
76066751|NCT04709978|Diagnostic Test|TOR-BSST and 3 oz Water Swallow|"The research specialist will conduct ten 1 tsp water swallows, one cup sip of water and a 3 ounce water swallow test with the patient. After each swallow, the participant is asked to say ah so that their voice quality can be assessed."
75750901|NCT03991312|Drug|itraconazole|Participants will receive an oral solution as described in the arm description.
75750902|NCT03991312|Drug|rifampin|Participants will receive oral capsule(s) as described in the arm description.
75750903|NCT03991312|Drug|mitapivat sulfate|Participants will receive an oral tablet as described in the arm description.
75750904|NCT03988972|Device|diathermy|In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?
75750905|NCT03988972|Device|scalpel|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
76066752|NCT04709978|Diagnostic Test|Sputum Culture|Patients will have sputum collected during stay (ED participants only)
75750906|NCT01057342|Drug|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
75750907|NCT01057342|Drug|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
75750908|NCT01057342|Drug|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
75750909|NCT01054534|Procedure|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
75750910|NCT01057420|Drug|oxygen inhalation|Inhalation of 80% oxygen via face mask
75606099|NCT01241591|Drug|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
75606100|NCT01241591|Biological|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
75606101|NCT01241591|Other|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
75606102|NCT05463679|Drug|Enzastaurin|500 mg QD orally in the form of four 125 mg tablets with background standard of care
75606103|NCT05463679|Drug|Placebo|Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
75750911|NCT01054612|Other|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
75606104|NCT02513251|Other|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
75606105|NCT05332171|Behavioral|Pyhsiohterapy and rehabilitation|Before starting the exercise program, 10 repetitive warm-up exercises will be given including the lower and upper extremities and distal joints. The exercises will be started with 5 repetitions in the first week. Depending on the patient's tolerance, the intensity of the exercise will be increased as 10 repetitions, 15 repetitions and 20 repetitions, and optional rest will be allowed between exercises. It is aimed that the patients reach 20 repetitions in the 6th week at the latest.
75750912|NCT01054690|Device|Bactiguard Infection Protection (BIP) Cathter.|
75750913|NCT01054690|Device|Silicone Urinary Catheter|
75750914|NCT01057498|Drug|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
75750915|NCT01057498|Drug|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
75750916|NCT03742258|Drug|Cyclophosphamide|Given IV
75750917|NCT03742258|Drug|Doxorubicin Hydrochloride|Given IV
75750918|NCT03742258|Drug|Prednisone|Given PO
76066753|NCT04709978|Diagnostic Test|MeMed BV®|A blood test to help determine if the infection is viral or bacterial (ED participants only)
76066754|NCT04709978|Diagnostic Test|Lung Ultrasound|To image the lungs (ED participants only)
75606106|NCT03315247|Behavioral|Telephone-Based CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
75606107|NCT04319705|Drug|Azithromycin|Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
75750919|NCT03742258|Biological|Rituximab|Given IV
75606108|NCT04319705|Drug|Placebo oral tablet|capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
75750920|NCT03742258|Drug|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
75750921|NCT03742258|Drug|Vincristine Sulfate|Given IV
75750922|NCT01057576|Dietary Supplement|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
75750923|NCT01057576|Other|Placebo|capsule, daily dosage
75750924|NCT00354172|Biological|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If < 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
76066755|NCT04709978|Diagnostic Test|Respiratory Function Tests|To measure respiratory pressures.
76066756|NCT04702854|Diagnostic Test|Ultrasound Biomicroscopy|Measure of cutaneous melanomas by ultrasound Biomicroscopy
76066757|NCT04694456|Other|cytokines dosage|Mesure of cytokines concentration in serum
75750925|NCT00354172|Biological|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
75750926|NCT00354172|Biological|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
75750927|NCT00354172|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
75750928|NCT00354172|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of >200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
75750929|NCT00354172|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
75900194|NCT04483726|Procedure|open distal pancreatectomy|open distal pancreatectomy
75900195|NCT03423602|Device|PerQseal®|Large hole closure system
76066758|NCT04694456|Procedure|test of walk|patient must walk during 6 minutes on a flat surface
76066759|NCT04694456|Procedure|Manual muscular test|test performed to evaluate the patient muscular weakness
76066760|NCT04694456|Procedure|Motrice fonction mesurement|scale allowing the evaluation of patient posture and upper body movements
76066761|NCT04667078|Drug|Cangrelor|administration of cangrolor by iv befor thrombectomy
76066762|NCT04667078|Other|best medical management|used yhe best medical management
76066763|NCT04657432|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
76066764|NCT04630808|Drug|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1%
76066765|NCT04630808|Drug|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005%
75606109|NCT04319393|Behavioral|Cognitive Behavioral Therapy|"The CBT intervention was carried out through six two-hour sessions over a month. The intervention group was divided into three subgroups of 18 to 19 nurses each. It was required for each subgroup to attend two CBT sessions to complete the intervention.~The CB therapist followed the same structure in the delivery of each CBT session. The CBT session was delivered in five modules: generating objectives and outcomes, enhancing self-esteem and interpersonal relationships, changing beliefs regarding symbolic mortality, and changing attitudes regarding death anxiety. The first session began with highlighting the objectives of the CBT. Then, a detailed presentation of the intervention modules was provided to the nurses with integration of CBT exercises, including cognitive restructuring, graded exposure, mindfulness meditation, interpersonal skills training, and activity scheduling"
75606110|NCT04319315|Other|survey|online survey
75606111|NCT00906373|Biological|IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
75606112|NCT00906373|Biological|IMC-A12 (cixutumumab) - 20 mg/kg|intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
75606113|NCT00906373|Drug|Sorafenib|400 milligrams (mg) twice per day orally
75606114|NCT02850445|Drug|Olanzapine|All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
75606115|NCT02850445|Other|Cognitive behavior therapy|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
75606116|NCT02850445|Other|Rehabilitation treatment|Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
75606117|NCT02850445|Other|Case management|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
75750930|NCT00354172|Drug|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
75750931|NCT00354172|Drug|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9 /L)."
75750932|NCT00354172|Procedure|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
75750933|NCT00354172|Radiation|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
75750934|NCT03986242|Device|rolling|use non- vibration rolling and the total time is 20 minutes.
75750935|NCT03986242|Device|Vibration rolling|use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
75606118|NCT04220203|Drug|Tucatinib|300 mg orally two times per day
76066766|NCT04617444|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75606119|NCT04220203|Drug|Capecitabine|1000 mg/m^2 orally two times per day on Days 1-14 of each 21-day cycle
75606120|NCT04220203|Drug|Trastuzumab|Loading dose of 8 mg/kg into the vein (IV; intravenously), followed by 6 mg/kg IV once per 21-day cycle
75606121|NCT02850211|Drug|Celecoxib|1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
76066767|NCT04617444|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75606122|NCT02850211|Drug|Ibuprofen|1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
75606123|NCT02850211|Drug|Tramadol|1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
75606124|NCT02850289|Drug|Pegylated interferon (PEG-INF) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
75606125|NCT02850289|Drug|Ribavirin|Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
75606126|NCT02393521|Device|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
75750936|NCT03986242|Other|static stretching|static stretching and the total time is 20 minutes.
75750937|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
75750938|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
75750939|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
75606127|NCT05176171|Procedure|Photorefractive Keratectomy with Corneal Cross-Linking|To our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (PRK) applying sequential and simultaneous corneal cross-linking (CXL) treatment for keratoconus. Considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.
75750940|NCT01052506|Drug|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
75606128|NCT04984057|Drug|PS is stopped when the pressure is equal between bPDA and aPDA.|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
75606129|NCT04984057|Drug|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
75750941|NCT01052506|Drug|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
75750942|NCT03988816|Drug|Roflumilast|500Mcg Tab, once daily
75750943|NCT03988816|Drug|Placebo oral tablet|once daily
75750944|NCT00353704|Drug|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
75750945|NCT00353704|Drug|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
75750946|NCT00353704|Drug|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
75750947|NCT03742180|Drug|intranasal dexmedetomidine|The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline
75900196|NCT04051645|Device|Breathing through a system with adjustable flow resistance|"The proband will breathe through the adjustable flow resistance within the experiment, to which a standard D-lite Flow sensor will be connected, and the airway pressure, flow, minute consumption, oxygen and carbon dioxide, tidal volume, oxygen saturation of peripheral blood and oxygen and carbon dioxide concentrations in both inspired and expired air will be recorded using the Datex-Ohmeda S/5 Patient Monitor vital signs monitor.~The proband will breathe through the flow resistors in a randomized order, and pre-defined three-minute pauses will be maintained between measurements with different flow resistance values. Each measurement will take approximately two minutes and will be measured on ten different flow resistances."
76066768|NCT04603352|Other|Hip Helpers home program|Home program: Infants will wear Hip Helpers 30 minutes, twice per day.
75750948|NCT03742180|Drug|sublingual ketorolac|The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
75750949|NCT00512252|Drug|AMD3100|
75750950|NCT00512252|Drug|Mitoxantrone|
75750951|NCT00512252|Drug|Etoposide|
75750952|NCT00512252|Drug|Cytarabine|
75750953|NCT03988894|Device|mDASHNa App|The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
75750954|NCT00516386|Drug|RhIGF-1|35-40 mcg/k/dose twice daily SC
76066769|NCT04581629|Drug|Encaleret|Tablets administered orally
76066770|NCT04568382|Other|CI-PVP (context-informed pre-visit planning)|may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
76066771|NCT04568382|Other|Standard PVP (pre-visit planning)|standard clinic staff chart review, email and/or phone call prior to diabetes office visit
75750955|NCT00524420|Device|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
75750956|NCT00524420|Device|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
75750957|NCT00512096|Drug|Ifosfamide|1200 mg/m^2 By Vein Over 2 Hours on Days 1-3
75750958|NCT00512096|Drug|Paclitaxel (Taxol)|175 mg/m^2 By Vein Over 3 Hours on Day 1
75900197|NCT04569994|Drug|NNC0363-0845|A single dose administered s.c. (subcutaneously, under the skin)
76066772|NCT04551391|Other|Blood and urine sampling|Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid
76066773|NCT04540406|Drug|NBT-NM108|Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
76066774|NCT04540406|Other|Usual Care Only|Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.
76066775|NCT04539808|Drug|Capecitabine|Given PO
75606130|NCT05331781|Procedure|Ultrasound-Guided Transversus Abdominis Plane Block|patient in the supine position, ultrasound will be used to identify the plane between the internal oblique and transversus abdominis muscle to inject 20 ml of local anesthetic for each side
75606131|NCT05331781|Drug|Morphine|intrathecal 150 microgram morphine in a 0.5 ml volume will be added to bupivacaine as an adjuvant to spinal anesthesia
75606132|NCT04202887|Drug|Low Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
75606133|NCT04202887|Drug|High Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
75750959|NCT00512096|Drug|Cisplatin|25 mg/m^2 By Vein Over 2 Hours on Days 1-3
75750960|NCT01565252|Dietary Supplement|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
75750961|NCT04462796|Dietary Supplement|Magnesium Citrate|Magnesium Citrate 200 mg daily
75750962|NCT00524030|Drug|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
75750963|NCT00524030|Drug|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
75750964|NCT00523718|Drug|riluzole|50 mg PO bid, 12 weeks
75750965|NCT00523718|Drug|placebo|placebo, 1 capsule PO bid, 12 weeks
75750966|NCT00523640|Drug|combination of gemcitabine, capecitabine, and bevacizumab|gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
75900198|NCT04569994|Drug|Placebo (NNC0363-0845)|A single dose administered s.c.
75606134|NCT04202887|Device|Gastric Ultrasonography|"The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF."
75606135|NCT05331703|Other|designed physical therapy program in addition to program of virtual reality.|physical therapy program in addition to program of virtual reality.
75750967|NCT00345358|Biological|Synflorix|1, 2, 3 or 4 Intramuscular injections, depending on age group
75750968|NCT00345358|Biological|Infanrix IPV/Hib|4 intramuscular injections
75750969|NCT03869684|Drug|MT-0814|Randomly assigned dose
75750970|NCT03869684|Drug|Placebo|Placebo manufactured to mimic MT-0814
75750971|NCT01058746|Other|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
75750972|NCT01058746|Other|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
75454739|NCT01751997|Drug|Transplants from family-mismatched/haploidentical donors|"Reduced-intensity conditioning~Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m^2)~Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~GVHD prophylaxis~Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11"
75454740|NCT01752010|Other|Traditional Chinese Acupuncture|"Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being blocked. Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic."
75454741|NCT01752010|Device|Tennant™ Biomodulator Treatment|An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
75606136|NCT05331703|Other|designed physical therapy program in addition to program of mirror therapy.|physical therapy program in addition to program of mirror therapy.
75750973|NCT00516074|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
75750974|NCT00516074|Drug|placebo|subcutaneous injection, volume equivalent to active, twice a day
75750975|NCT01057654|Drug|Pravastatin|Pravastatin 40 mg
75750976|NCT01057654|Drug|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
76066776|NCT04539808|Drug|Fluorouracil|Given IV
75750977|NCT00515294|Drug|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
75750978|NCT00515294|Other|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
75750979|NCT00515294|Drug|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
75750980|NCT00515294|Other|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
75750981|NCT00345046|Drug|Pred Forte|Four drops daily decreasing to once daily over four weeks.
75900199|NCT04569994|Drug|Insulin degludec|A single dose administered s.c.
75900200|NCT02307344|Dietary Supplement|Nigella Sativa|
76066777|NCT04539808|Drug|Irinotecan Hydrochloride|Given IV
75750982|NCT00345046|Drug|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
75900201|NCT02307344|Dietary Supplement|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
75900202|NCT05243992|Other|CTS-PAD device imaging|Participants in the CTS-PAD Study will undergo a conventional ABI (cABI) evaluation, followed by the non-contact imaging evaluation with the CTS-PAD device. The supplemental CTS-PAD testing will add approximately ten (10) minutes to the overall evaluation time.
76066778|NCT04539808|Drug|Leucovorin Calcium|Given IV
76066779|NCT04539808|Drug|Losartan Potassium|Given PO
76066780|NCT04539808|Drug|Oxaliplatin|Given IV
75454742|NCT01752010|Device|Transcutaneous electrical nerve stimulation (TENS) Treatment|An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
75606137|NCT02850367|Dietary Supplement|Nitrate|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
75606138|NCT02850367|Dietary Supplement|Nitrate and L-Arginine|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
75606139|NCT02850367|Dietary Supplement|Nitrate and L-Citrulline|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
75606140|NCT02850367|Dietary Supplement|Placebo|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.
75750983|NCT00345046|Drug|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
75750984|NCT01055002|Biological|Blood stage parasite (BSP) inoculum|Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
75606141|NCT02850367|Biological|Evaluation of post-ischemic vascular reactivity|After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.
75750985|NCT00515216|Drug|5-fluorouracil|
75750986|NCT00515216|Drug|Oxaliplatin|
75750987|NCT00515216|Drug|Leucovorin|
75900203|NCT05374096|Other|Patient-Chosen Music|Music played into headphones.
75900204|NCT05374096|Other|Placebo|Silence into headphones.
75900205|NCT02307422|Genetic|IL-1 Genotypes, other SNPs associated with CAD|Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
76066781|NCT04539808|Radiation|Radiation Therapy|Undergo short-course or long-course RT
76066782|NCT04539808|Procedure|Resection|Undergo surgical resection
76066783|NCT04539808|Procedure|Diagnostic Imaging|Undergo diagnostic imaging
76066784|NCT04539808|Procedure|Biospecimen Collection|Undergo blood sample collection
76066785|NCT04538716|Procedure|transconjunctival lower blepharoplasty|transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
76066786|NCT04530487|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
76066787|NCT04530487|Drug|Cyclosporine|Given IV and PO
75750988|NCT00522626|Device|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
75750989|NCT00440193|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
75750990|NCT00440193|Drug|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
76066788|NCT04530487|Drug|Etoposide|Given IV
76066789|NCT04530487|Drug|Fludarabine Phosphate|Given IV
76066790|NCT04530487|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
76066791|NCT04530487|Drug|Melphalan|Given IV
76066792|NCT04530487|Drug|Mycophenolate Mofetil|Given IV or PO
76066793|NCT04530487|Drug|Tacrolimus|Given IV and PO
76066794|NCT04530487|Drug|Thiotepa|Given IV
75750991|NCT00511472|Drug|MK-0941|"In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose [TD] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2."
76066795|NCT04528680|Device|Sonication for opening of blood-brain barrier|Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles
75750992|NCT00511472|Drug|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
75750993|NCT00511472|Drug|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
75454743|NCT01752075|Drug|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
75606142|NCT02850367|Biological|Neuromuscular evaluations|After the intake of the supplement. Measure the stretching force in the ankle (N)
75750994|NCT01033305|Drug|CyCol™|Orally, once per day for 4 weeks
75750995|NCT01033305|Drug|Placebo|Orally, once per day for 4 weeks
75750996|NCT01037049|Other|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
75900206|NCT03509480|Procedure|Surgical Curettage for benign bone lesion|Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
75900207|NCT04457206|Behavioral|SCI Group and one-on-one services through student led occupational therapy clinic|The Collaborative Community Clinic (CCC) students collaborate with Dr. Walker to conduct the spinal cord injury/disease (SCI/D) Health and Participation Program, which consists of a combination of groups and one-on-one OT sessions serving persons with spinal cord injury and disease who are un- or under-insured. The program includes a pre-assessment session, four groups, optional individual sessions and a post-survey. Group topics include bowel/bladder management, community mobility, advocacy, transportation, promoting intimacy, adaptive parenting and finding resources. Students are involved in recruiting participants, co-leading group sessions, treatment planning and implementation for individual sessions, and development of topic-specific materials.
75606143|NCT02850523|Other|Cognitive Behavioural Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
75750997|NCT00514904|Biological|Nimenrix|Single dose, intramuscular injection
75750998|NCT00514904|Biological|Mencevax|Single dose, subcutaneous injection
75750999|NCT03319082|Combination Product|Corneal Collagen Cross-linking|Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
75751000|NCT00440115|Behavioral|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
75751001|NCT00440115|Behavioral|Low intensity disease management|Health education mailings, one motivation interview/counseling
75751002|NCT00440115|Behavioral|Comparison group|Health education mailings
75751003|NCT00440115|Drug|Bupropion|Buproprion or Nicotine Replacement Therapy
75751004|NCT04384328|Other|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
75751005|NCT01037205|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
75751006|NCT01037205|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
75751007|NCT04378790|Other|Patching|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
75751008|NCT04378790|Other|Glasses|Eye Glasses are created and worn by patient to improve vision
75751009|NCT00440037|Biological|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
75751010|NCT01037283|Behavioral|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
75751011|NCT01033461|Dietary Supplement|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
76066796|NCT04528680|Drug|Chemotherapy, albumin-bound paclitaxel|Intravenous infusion of ABX over 30 minutes
76066797|NCT04528680|Drug|Chemotherapy, carboplatin|Intravenous infusion of carboplatin over 30 minutes
76066798|NCT04523324|Biological|Flublok™ Quadrivalent by Sanofi, Inc.|0.5 mL intramuscular dose of Flublok
75454744|NCT01752127|Procedure|percutaneous coronary intervention using drug eluting stent|"1. Intracoronary stenting~The procedure could be conducted via brachial, radial or femoral approaches.~There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~Direct stenting or bifurcation stenting is allowed.~Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator."
75454745|NCT01752140|Procedure|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
75454746|NCT01752140|Procedure|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
75454747|NCT01752153|Drug|Desferrioxamine, Legalon® (Silymarin)|Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
75454748|NCT01752153|Drug|Silymarin (Legalon)|
75454749|NCT01752179|Procedure|kinesio Tape : Width 5cm ,Length 35cm Y shape|"In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~puts the base of tape over the contralateral of sacrum with no tension.~attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application."
75606144|NCT05117203|Device|WB-EMS (Whole body electrostimulation)|Application of physical exercise and electrical stimulation on the abdominal muscles through the WB-EMS during 20 minutes training session with specific exercise (CORE)
75606145|NCT05117203|Device|EMS|Application of physical exercise and electrical stimulation on the abdominal muscles through the EMS during 20 minutes training session with specific exercise (CORE)
75606146|NCT05117203|Device|WB-EMS off|Application of physical exercise without electrical stimulation on the abdominal muscles through the WB-EMS off during a 20 minutes training session with specific exercise (CORE).
75606147|NCT05324215|Procedure|Transversalis fascia plane block and rectus sheath block|Transversalis fascia plane block and rectus sheath block will be administered after the surgery.
75606148|NCT05324215|Device|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
75606149|NCT05070559|Other|Active Release Technique|"Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone & wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~Hot pack for 15 minutes~TENS for 15 minutes~Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
75751012|NCT01033461|Dietary Supplement|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
75751013|NCT01033461|Other|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
75751014|NCT01033539|Other|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
75751015|NCT01037439|Device|Adaptive Servo-controlled Ventilation (ASV)|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
75751016|NCT01033617|Procedure|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
75900208|NCT03509402|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm)
75900209|NCT03509402|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal long implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
75900210|NCT05243758|Device|Group video fiberscope of experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopyvideo fiberscope( Karl Storz GmbH &Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
75900211|NCT05243758|Device|Group video laryngoscope of experienced practitioner|Intubation Pending Difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.
75900212|NCT05243758|Device|Group video fiberscope of less experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopy video fiberscope( Karl Storz GmbH &Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
75900213|NCT05243758|Device|Group video laryngoscope of less experienced practitioner|Entubation pending difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.Storz DCI Video Laryngoscope (Karl Storz GmbH &Co. KG, Tuttlingen, Germany)
75900214|NCT02311556|Device|dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging|
75900215|NCT04372030|Other|Online questionnaire|this is an online questionnaire collecting retrospective data on health care use and non-use
75909629|NCT03473522|Behavioral|Exercise Therapy|Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
75454750|NCT01752192|Device|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
75454751|NCT01752205|Drug|Paclitaxel|45mg/m2/w,total 6 weeks
75606150|NCT05070559|Other|Graston Technique Group|"Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~Hot pack for 15 minutes~TENS for 15 minutes~Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
75454752|NCT01752205|Drug|Erlotinib|150mg/d,days 1-42,total 6 weeks
75454753|NCT01752205|Radiation|Radiation therapy|
75454754|NCT01752218|Device|arcuate incision|
75454755|NCT01752244|Dietary Supplement|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
75454756|NCT01752244|Dietary Supplement|Alfacalcidol|Alfacalcidol
75454757|NCT01752257|Drug|EF5 Hypoxia|EF5 is a dye used to measure hypoxia
75606151|NCT02850133|Other|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
75751017|NCT02562963|Biological|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment.
75751018|NCT02561559|Radiation|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
75751019|NCT03055611|Drug|ELOCTA|Extended half-life factor VIII product
75751020|NCT03055611|Drug|ALPROLIX|Extended half-life factor IX product
75751021|NCT01030731|Drug|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
75751022|NCT00417027|Procedure|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
75751023|NCT00416949|Device|Patient-specific dosimetry|Patient-specific 3D-RD dosimetry was applied to the data collected
75751024|NCT03993483|Behavioral|Unilateral resistance exercise|The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
75751025|NCT00416715|Drug|letrozole|Given PO
75751026|NCT00416715|Dietary Supplement|calcium carbonate|Given PO
75751027|NCT00416715|Other|laboratory biomarker analysis|Optional correlative studies
75751028|NCT00416715|Dietary Supplement|calcium citrate|Given PO
75751029|NCT00416715|Dietary Supplement|calcium glucarate|Given PO
75751030|NCT00416715|Drug|calcium gluconate|Given PO
75751031|NCT00416715|Dietary Supplement|cholecalciferol|Given PO
75751032|NCT00416715|Procedure|assessment of therapy complications|Ancillary studies
75454758|NCT01752270|Drug|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
75454759|NCT01752270|Drug|Diane-35 pretreatment|
75454760|NCT01752283|Procedure|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
75454761|NCT01752283|Procedure|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
75454762|NCT01752322|Drug|Lidocaine 5% medicated plaster|
75454763|NCT01752322|Drug|Placebo plaster|
75751033|NCT00416715|Procedure|musculoskeletal complications management/prevention|Correlative studies
75751034|NCT01037517|Drug|Plerixafor|Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
75751035|NCT01037517|Other|Observation: Nonintervention|Nonintervention group, no drug will be given, observation only
75454764|NCT01752335|Other|Braquial ecography|At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
75751036|NCT01323933|Drug|AB0024|Comparison of different dosages of drug
75751037|NCT00406029|Drug|Preladenant|1 mg BID capsules
75751038|NCT00406029|Drug|Preladenant|2 mg BID capsules
75900216|NCT02311634|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
75454765|NCT01752348|Other|Endotoxin, US standard reference E.coli|
75454766|NCT01752361|Device|Motilis-3D transit|
75454767|NCT01752439|Device|Anodal transcranial direct current stimulation|
75751039|NCT00406029|Drug|Preladenant|5 mg BID capsules
75751040|NCT00406029|Drug|Preladenant|10 mg BID capsules
75751041|NCT00406029|Drug|Placebo|BID capsules
75454768|NCT01752439|Device|Sham transcranial direct current stimulation|
75454769|NCT01752465|Behavioral|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
75454770|NCT01752465|Behavioral|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
75751042|NCT00406029|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
75454771|NCT01752504|Behavioral|Community Mobilization|The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
75751043|NCT00406029|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
75751044|NCT00514514|Drug|Everolimus|Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
75751045|NCT00514514|Drug|Myfortic|"1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)"
75751046|NCT00514514|Drug|Sandimmun Optoral|1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
76066799|NCT04523324|Biological|VaxigripTetra™ by Sanofi, Inc.|0.5 mL intramuscular dose of Vaxigrip
75751047|NCT00514514|Drug|Simulect®|Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
75900217|NCT02311634|Device|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
75900218|NCT00109590|Drug|Didanosine, enteric-coated|once daily
75900219|NCT00109590|Drug|Lopinavir/ritonavir|twice daily
75900220|NCT00109590|Drug|Nevirapine|single-dose at the onset of labor
76066800|NCT04513808|Drug|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia, titrated to clinical need.
76066801|NCT04513808|Drug|Sevoflurane intravenous anesthesia|Sevoflurane intravenous anesthesia, titrated to clinical need.
75454772|NCT01752517|Drug|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
75454773|NCT01752530|Other|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
75900221|NCT00109590|Drug|Zidovudine|twice daily
76066802|NCT04494113|Procedure|Biopsy|Undergo biopsy
76066803|NCT04494113|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
76066804|NCT04494113|Procedure|Resection|Undergo surgical resection
76066805|NCT04494113|Drug|Triapine|Given IV
76066806|NCT04484935|Drug|Nirsevimab|Single fixed IM dose of nirsevimab 50 mg if body weight < 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
75454774|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
75454775|NCT01752543|Drug|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
75454776|NCT01752543|Drug|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
75454777|NCT01752556|Procedure|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
75454778|NCT01752556|Procedure|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
75606152|NCT04202419|Device|FRAX 1940 nm laser|A fractional 1940 nm solid-state diode laser will deliver linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin, in order to treat pigmented skin lesions.
75606153|NCT02849821|Other|hypobaric pressure chamber|hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
75606154|NCT02849821|Other|Sigmoidoscopy|To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H&E).
75606155|NCT04202575|Procedure|Tube clamping|Clamping of the tube between the additional and standard venous reservoir
75606156|NCT00905437|Drug|Placebo|Placebo as an adjunct to standard of care
75606157|NCT00905437|Drug|Pregabalin|75 mg BD for 14 days
75900222|NCT05243446|Drug|Losartan|losartan treatment
75900223|NCT02311712|Device|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
75909630|NCT02523326|Device|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
75909631|NCT04457882|Behavioral|Intraperitoneal Laparoscopic Radical Prostatectomy Without Drainage Tube|No place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
75909632|NCT04457882|Behavioral|Intraperitoneal Laparoscopic Radical Prostatectomy With Drainage Tube|Place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
76066807|NCT04478734|Drug|Moderate doses of Thiamine y Biotin|Thiamine 600 mg every day + Biotin 150mg every day
76066808|NCT04478734|Drug|High doses of Thiamine y Biotin|Thiamine 1200 mg every day + Biotin 300mg every day
76066809|NCT04478292|Drug|Sodium Thiosulfate Injection|Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight < 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.
76066810|NCT04478292|Procedure|Primary surgery resection|Resection of the primary tumor up-front
75751048|NCT00405639|Drug|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
75751049|NCT00405639|Drug|Placebo|Normal saline will be used for placebo.
76066811|NCT04478292|Drug|mono CDDP-Group A2|Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
76066812|NCT04478292|Drug|Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C|All the patients in Group C (2 arms) will receive 6 cycles chemotherapy in total. Cisplatin 100 mg/m2/dose Day 1; 5-Fluorouracil 600 mg/m2/dose Day 1; Vincristine 1.5 mg/m2/dose Day 1,8 and 15; Doxorubicin 30 mg/m2/dose Day 1 and 2; (Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)
75900224|NCT05234008|Other|High intensity training at home|"A HIT exercise intervention is performed. Four sessions are performed at REVAL Research Center to educate participants on the exercise protocol. Eight exercise sessions are performed at home with support of Physitrack (a mobile application for participants and a software platform for researchers).~In-center program (2 weeks, 4 sessions): Participants perform a concurrent exercise protocol of 1h-1.5h, as published by our research team previously, consisting of cardiorespiratory, general resistance, and core muscle training, all at high intensity.~Home sessions (4 weeks, 8 sessions): Researchers provide participants with a fitness bike, smartwatch, and training mat. Using Physitrack, researchers formulate a personalized HIT program to be performed at home for each participant by selecting from >3500 exercises or insert a new exercise to add to the library. This HIT program resembles the program performed in the rehabilitation center as much as possible."
75751050|NCT03993795|Other|A19010-W|A snus product
76066813|NCT04478292|Procedure|Biopsy|Tumors are deemed unresectable at diagnosis.
75751051|NCT03993795|Other|B19010-F|A snus product
75751052|NCT01030809|Other|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
75751053|NCT00439725|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
75454779|NCT01752569|Drug|Selumetinib|"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
75454780|NCT01752582|Device|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
75751054|NCT00439725|Drug|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
75751055|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
75751056|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
75751057|NCT00515502|Drug|GSK573719|250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
75751058|NCT00515502|Drug|Tiotropium|strips of five capsules, each containing 18 μg administered via dry powder inhaler
75751059|NCT03997734|Drug|AB001|single and repeated dosing
75751060|NCT03997734|Drug|oral capsule|single dose
75751061|NCT03997734|Drug|positive comparative patch|single and repeated dosing
75751062|NCT03997734|Drug|Placebos|single and repeated dosing
76066814|NCT04478292|Procedure|Resection or transplant|Ideal timing to resect of the primary tumors or transplant if if excellent response achieved at 1st or 2nd evaluation timepoint. But surgery timing is not mandated. Irrespective of the timing of surgery, patients should complete all planned protocol cycles of chemotherapy (including post transplantation). If surgical resection of the primary tumor is delayed until the end of therapy, no further post-operative chemotherapy should be given.
75751063|NCT03997890|Procedure|Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs|After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
75751064|NCT03997344|Behavioral|Group nature hikes|Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
75751065|NCT03997344|Behavioral|Group urban hikes|Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
75454781|NCT01752582|Device|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
75751066|NCT01010646|Drug|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
75751067|NCT01010646|Drug|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
75606158|NCT05081947|Behavioral|COMPASS|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
75606159|NCT04219111|Genetic|Clariom|Clariom S Assay
75751068|NCT01010646|Drug|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
75751069|NCT00439647|Drug|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
75751070|NCT00439647|Drug|Placebo|Placebo intravenous (i.v.) once a year
75751071|NCT00515112|Drug|AndroGel|Androgel 1%, 10g daily
75751072|NCT00515112|Drug|placebo|placebo
75751073|NCT03034785|Device|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
75751074|NCT01030887|Behavioral|Exercise programme|Moderate intensity exercise
75751075|NCT03742557|Drug|Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV|Ketamine 0.5 mg/kg IV
76066815|NCT04478292|Procedure|Resection of pulmonary nodules|Resection of pulmonary nodules should be considered in Group D2, patients at any cycle if continuing to respond to consolidation therapy.
75751076|NCT01324011|Behavioral|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
75751077|NCT01324089|Dietary Supplement|Resveratrol|Resveratrol 2.5 grams
75751078|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
75751079|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
75751080|NCT00404547|Drug|Ciclesonide|Asthma Care with Alvesco
75751081|NCT00404547|Drug|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
75751082|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
75751083|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
75751084|NCT00515034|Drug|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
75751085|NCT00515034|Drug|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
75751086|NCT01012518|Device|Standard PCT|The standard technique, performed without video guidance
75751087|NCT01012518|Device|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
75900225|NCT03506984|Device|Threshold Inspiration Muscle Training Device|Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.
75751088|NCT00404235|Drug|carboplatin|
75751089|NCT00404235|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
75900226|NCT03506984|Device|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
75751090|NCT00404079|Drug|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
75751091|NCT00404079|Drug|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
75751092|NCT00403845|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
75751093|NCT00403845|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
75751094|NCT00403845|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
75751095|NCT00509262|Drug|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
75751096|NCT00509262|Drug|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
75900227|NCT02143362|Drug|Anesthesia induction,propofol, remifentanil ,cisatracurium|"Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~Intermittent injection cisatracurium (0.15mg/kg).~A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60."
75606160|NCT05007691|Device|Occlusal splint|Occlusal splints are hard, made of polymer biocompatible material using digital additive technology.
75606161|NCT01238861|Biological|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
75606162|NCT01238861|Biological|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
75606163|NCT01238861|Biological|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
75751097|NCT00509262|Drug|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
75751098|NCT00509262|Drug|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
75751099|NCT00607997|Drug|vosaroxin|Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
75751100|NCT00509106|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
75751101|NCT00509106|Drug|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
75900228|NCT02143362|Drug|Anesthesia maintenance , propofol,remifentanil,cisatracurium|"Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~Target Controlled Infusion remifentanil , targeted plasma concentrations are 3~6ng/ml ,maintain heart rate to 60~100 beats per minute and mean blood pressure to 70~105 mmHg.~Intermittent injection cisatracurium (0.05mg/kg)."
76066816|NCT04478292|Drug|mono CDDP- Group B|Cisplatin 80 mg/m2/dose Day 1. All patients in Group B (2 arms) will receive 6 cycles of mono cisplatin chemotherapy. Each cycle lasts 2 weeks (14 days).
75606164|NCT01238861|Other|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
75751102|NCT00509106|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
75751103|NCT03997656|Behavioral|MyDiPP (Malaysia Diabetes Prevention Program)|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
75751104|NCT03997656|Other|usual care|standard health education from primary care providers in the clinic
75751105|NCT00607919|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
75751106|NCT00607919|Drug|Placebo|oral, daily, for 16 weeks
75751107|NCT00344968|Drug|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
75454782|NCT01752595|Behavioral|Preference Based Rhythmic Auditory Stimulation Music|"Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most."
75454783|NCT01752595|Other|Preference Based Music Intervention|
75454784|NCT01752608|Behavioral|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
75454785|NCT01752647|Procedure|Low dose computed tomography|Low dose computed tomography scan
75454786|NCT01752660|Behavioral|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
75454787|NCT01752660|Behavioral|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
75751108|NCT00344968|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
75751109|NCT00344968|Procedure|Standard of care laser photocoagulation|Laser photocoagulation
75751110|NCT02541461|Procedure|Laparoscopic gastrectomy|(1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
75900229|NCT02143362|Procedure|Awaken test|"Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~Patients will receive initial anesthesia after finish awaken test."
75900230|NCT03509324|Drug|Insulin LISPRO|receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved
75900231|NCT02304068|Other|Home monitoring|
75900232|NCT02304068|Other|Hospital assessment|
75900233|NCT02143440|Behavioral|The initial assessment of daily insulin dose.|
75900234|NCT04906564|Other|Identification of genetic variants|Identification of genetic variants
75900235|NCT02311790|Dietary Supplement|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
75900236|NCT02311790|Dietary Supplement|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
75454788|NCT01752673|Other|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
75751111|NCT00509028|Drug|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
75751112|NCT00509028|Drug|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
75751113|NCT01055080|Dietary Supplement|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
75751114|NCT00893321|Procedure|Inferior Oblique Muscle Recession and Myectomy|
75751115|NCT01012752|Biological|modified allergen extract|subcutaneous injections
75751116|NCT01012752|Biological|Placebo|subcutaneous injections
75751117|NCT00352846|Drug|Zoledronic Acid|4 mg/m^2 by vein over 30 Minutes at baseline and 6 months.
75751118|NCT00352846|Drug|Vitamin D|400 mg by mouth daily
75751119|NCT00352846|Drug|Calcium Carbonate|1200 mg by mouth daily
75751120|NCT00508872|Drug|5-Fluorouracil|400 mg/m^2 IV over 15 minutes, followed by 2400 mg/m^2 IV Over 46 Hours
75751121|NCT00508872|Drug|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
75751122|NCT00508872|Drug|Leucovorin|400 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
75751123|NCT00508872|Drug|Oxaliplatin|85 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
75751124|NCT00508482|Other|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks."
75751125|NCT00508482|Drug|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
75900237|NCT02143518|Biological|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
75900238|NCT02143518|Biological|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
75900239|NCT03504878|Procedure|Laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
75751126|NCT00508482|Other|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
75900240|NCT03504878|Procedure|Open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision.
75454789|NCT01752673|Other|Didactic review lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
75454790|NCT01752686|Drug|carboplatin|carboplatin as adjuvant chemotherapy
75454791|NCT01752699|Drug|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
75454792|NCT01752699|Drug|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
75454793|NCT01752725|Device|BiCision®|
75454794|NCT01752725|Device|Ultracision® Har-monic Scalpel(Ethicon)|
75454795|NCT01752764|Other|Test product: Salad with a high dosage fat|
75751127|NCT00344500|Behavioral|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~Be given a 7% weight loss goal~Be assisted in obtaining a 500 calorie reduction per day~Exercise for at least 30 min/day, at least 5 days a week~Maintain weekly food and exercise diaries~Be quizzed on their knowledge of healthy eating habits and nutrition"
75751128|NCT00344032|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
75751129|NCT00344032|Biological|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
75751130|NCT00607373|Drug|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
75751131|NCT00607373|Drug|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
75751132|NCT00508404|Drug|Panitumumab|Administered by intravenous infusion
75751133|NCT00508404|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
75900241|NCT02254590|Procedure|Irrigation Endoscopic Decompressive Laminotomy|2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
75900242|NCT03506906|Diagnostic Test|Sleep studies under noninvasive ventilation therapy|Polysomnography Transcutaneous capnography
75454796|NCT01752764|Other|Control product: Salad with low dosage fat|
75454797|NCT01752777|Behavioral|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
75454798|NCT01752777|Behavioral|General Health Improvement|Educational counseling to help link participants to social serves and health related strategies.
75454799|NCT01752790|Drug|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
75454800|NCT01752790|Drug|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
75454801|NCT01752803|Dietary Supplement|Probiotic|mix probiotic
75454802|NCT01752803|Dietary Supplement|Placebo|placebo
75454803|NCT01752816|Behavioral|exercise training|
75454804|NCT01752868|Dietary Supplement|Supplement|Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
75751134|NCT00888407|Behavioral|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
75751135|NCT00888407|Behavioral|Nutrition - Small group educational session|Small group session with diet & nutrition focused, topic related resources provided.
75751136|NCT00352690|Drug|Paclitaxel poliglumex|
75751137|NCT00352690|Drug|Carboplatin|
75751138|NCT00352690|Radiation|External beam radiation therapy|
75751139|NCT00888485|Behavioral|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
75751140|NCT03294408|Diagnostic Test|multimodal imaging|
75751141|NCT00895505|Drug|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
75751142|NCT00895505|Drug|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
75751143|NCT03988738|Other|Social Media Publications|Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
75751144|NCT03268824|Device|Electroencephalogram (EEG)|Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
75900243|NCT03506906|Diagnostic Test|Routine tests|Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
75900244|NCT03682770|Drug|Dupilumab|Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
75900245|NCT03682770|Drug|Placebo matching dupilumab|Placebo matching dupilumab is prepared in the same formulation without the addition of protein
75900246|NCT03682770|Drug|AR101|AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
75454805|NCT01752881|Biological|Influenza vaccine (split virion, inactivated)|"AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013~Dosage: 0.5mL/per syringe~Administration route: Intramuscular Injection, once"
75454806|NCT01752881|Biological|AdimFlu-S|
75900247|NCT03506828|Procedure|Surgical sympathectomy|thoracoscopic sympathectomy
75454807|NCT01752894|Device|Angio-guided PCI with EES or BES|Angio-guided intervention
75454808|NCT01752894|Device|OCT-guided PCI with EES or BES|OCT-guided intervention
75454809|NCT01752894|Device|PCI with BES under angio-guide or OCT guide|biolimus A9-eluting stent.
75454810|NCT01752894|Device|PCI with EES under angio-guide or OCT guide|everolimus eluting stent.
75454811|NCT01752894|Drug|Keep DAPT|maintain DAPT for 12 months according to level of uncovered strut (>6%) at 3months OCT follow up after stent implantation.
75454812|NCT01752894|Drug|Discontinue DAPT|discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
75454813|NCT01752959|Drug|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
75454814|NCT01752959|Drug|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
75454815|NCT01752972|Dietary Supplement|Spirulina|10 g/day orally for 12 weeks
75751145|NCT03268824|Device|Diffusion Tensor imaging|We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
75751146|NCT03268824|Other|Language assessment|The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
75751147|NCT03249012|Other|Empiric use of Calcium Carbonate and Calcitriol|Empiric calcium carbonate and calcitriol repletion
75751148|NCT03249012|Other|PTH based Calcium Carbonate and Calcitriol repletion|PTH based treatment
75900248|NCT03506828|Procedure|Radiofrequency ablation with phenol injection|All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
75454816|NCT01752998|Behavioral|Treating Opioid Patients' Pain and Sadness (TOPPS)|
75454817|NCT01752998|Behavioral|Health Education|
75454818|NCT01753024|Dietary Supplement|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
75454819|NCT01753037|Dietary Supplement|Dehydroepiandrosterone (DHEA)|DHEA 130 mg administered orally for 5 days.
75454820|NCT01753037|Other|Placebo|Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
75454821|NCT01753050|Device|Stroke volume monitoring|Pulse contour stroke volume monitoring
75454822|NCT01753063|Behavioral|Patient Expectations|Baseline Expectations survey (parent/guardian and adolescents 12 and older)
75751149|NCT01565460|Other|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
75900249|NCT00546598|Device|Total hip replacement/arthroplasty|Hip replacement
75909633|NCT04457804|Behavioral|Virtual ACT Workshop for Emotional Eating|"This is a brief online intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's 1-day ACT workshop for emotional eating intervention, which was derived from Forman and colleagues' Mind Your Health Program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
75606165|NCT02888561|Drug|Dobutamine|Dobutamine will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
75606166|NCT02888561|Drug|Nitrite|Nitrite will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
75606167|NCT04319549|Other|Ketorolac Tromethamine irrigant|Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.
75606168|NCT04319549|Other|sodium hypochlorite irrigant|NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
75606169|NCT00903409|Drug|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) [formerly known as Omacor]
75751150|NCT03194880|Device|AlereCOMBO and Alere q Detect|"The feasibility assessment will comprise of two components:~User's perspective: A questionnaire will be developed and used to assess the level of satisfaction among community health workers performing the two new tests, using a 5 point Likert scale. We will assess the training and manual, the use of the test, the user's confidence, troubleshooting and technical support components and resolving problems.~The laboratory component: For each test we will evaluate:~The percentage of assays completed~The percentage of assays incomplete (i.e. invalid result on two attempts)~Reasons for incomplete assays, e.g.~The sample could not be delivered to the strip or cartridge correctly~Invalid control~Results could not be interpreted~Others"
75900250|NCT02307734|Behavioral|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.
75909634|NCT04457648|Device|manuka honey 16% eye drops ( Optimel )|16% manuka honey eye drops, australian FDA approved
75751151|NCT00893477|Biological|rituximab|
75751152|NCT00893477|Biological|sargramostim|
75751153|NCT00893477|Genetic|gene expression analysis|
75751154|NCT00893477|Genetic|gene rearrangement analysis|
75751155|NCT00893477|Genetic|polymerase chain reaction|
75751156|NCT00893477|Genetic|polymorphism analysis|
75751157|NCT00893477|Other|laboratory biomarker analysis|
75454823|NCT01753063|Behavioral|Patient Expectations|3 month follow up survey (parent/guardian and adolescents 12 and older)
75454824|NCT01753102|Drug|Estradiol|one tablet will be inserted daily for 14 days
75454825|NCT01753128|Drug|imipramine|
75454826|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation|
75454827|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
75751158|NCT01010724|Drug|bIAP|
75751159|NCT01010724|Drug|Placebo|
75751160|NCT00609245|Drug|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
75751161|NCT00609245|Drug|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
75751162|NCT01010802|Drug|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
75751163|NCT04036253|Biological|Erythropoietin alfa|Prefilled syringes of erythropoietin
75751164|NCT00343642|Drug|Active fructo-oligosaccharide|2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
75909635|NCT04457648|Device|systane eye drops|systane lubricant eye drops
76066817|NCT04478292|Drug|Block 1 to 3 (Cisplatin, Doxorubicin) Group D|Block 1 and 2: Cisplatin 70 mg/m2/dose Day1, 8 and 15; Doxorubicin 30 mg/m2/dose, Day 8 and 9; (Dexrazoxane: 300 mg/m2/dose Day 1 and 2, where is available); Block 3: Cisplatin 70 mg/m2/dose Day1and 8; Doxorubicin 30 mg/m2/dose Day 8 and 9; (Dexrazoxane BSA ≥ 0.6 m2/dose: 300 mg/m2/dose Day 8 and 9, where is available) All patients in Group D will receive 3 blocks in induction, followed by consolidation therapy. Block 1 and 2 last 28 days. Block 3 is 21 cycles.
75606170|NCT02850055|Other|Conventional Physiotherapy|"Leaflet care and health habits of the temporomandibular joint.~Program of cranio-cervical and temporomandibular exercises.~Massage of the cervical muscles and self care document for home."
75606171|NCT02850055|Other|Specific Manual Therapy|"Leaflet care and health habits of the temporomandibular joint.~Program of cranio-cervical and temporomandibular exercises.~Massage of the cervical muscles and self care document for home.~Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
75606172|NCT02849665|Other|Kangaroo Position|
76066818|NCT04478292|Drug|Consolidation (Carboplatin, Doxorubicin) -Group D1|Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
75606173|NCT01237223|Drug|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
75606174|NCT01237223|Drug|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
75606175|NCT01237223|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
76066819|NCT04478292|Drug|Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2|"Following Block 1-3 of induction therapy, patients in Group D2, will receive 6 cycles of consolidation chemotherapy with Carboplatin + Doxorubicin in Cycles 1, 3, and 5 alternating with Vincristine + irinotecan in Cycles 2, 4, and 6. One cycle of therapy lasts 3 weeks (21 days). Cycle 1, 3 and 5: Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).~Cycle 2, 4 and 6: Vincristine 1.5 mg/m2/dose, Day 1 and 8; Irinotecan 50 mg/m2/dose, Day 1 to 5;"
76066820|NCT04474470|Drug|NT219|Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors
76066821|NCT04474470|Drug|NT219 and ERBITUX® - Dose Escalation|Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma
76066822|NCT04474470|Drug|NT219 and ERBITUX® - Expansion|Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
75606176|NCT01237223|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
75751165|NCT00343642|Drug|Placebo fructo-oligosaccharide|2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
75751166|NCT00343642|Dietary Supplement|Diet|A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)
76066823|NCT04466033|Device|Magneto Microcatheter|All patients will be treated with Magneto Microcatheter
76066824|NCT04464174|Drug|Ipatasertib|Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
76066825|NCT04464174|Drug|Capecitabine|Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
76066826|NCT04464174|Drug|Eribulin|Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle
75454828|NCT01753154|Drug|Solution B (balance PD solution)|balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
75454829|NCT01753154|Drug|Solution A (conventional PD solution)|Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
75454830|NCT01753180|Biological|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
75454831|NCT01753180|Drug|saline|Local intra-coronary administration of saline at or into the CTO
75454832|NCT01753219|Procedure|Onstep|
75454833|NCT01753219|Procedure|Lichtenstein|
75454834|NCT01753232|Device|DALI-adsorber|Recording of treatment data. No extra interventional treatment
75454835|NCT01753232|Device|MONET-Lipoprotein filter|Only treatment data recording. No extra interventional treatment
75454836|NCT01753271|Other|thoracic mobilization & shoulder mobilization & exercise|
75606177|NCT01237223|Drug|Placebo of Aliskiren|Aliskiren placebo tablet
75606178|NCT01237223|Drug|Placebo of Amlodipine|Amlodipine placebo capsule
75606179|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
75606180|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
75606181|NCT01236755|Device|single-vision glasses|Daily wear of glasses to correct vision in the first seven months of the study
75606182|NCT01236755|Device|ortho-k lenses|Nightly wear of lenses to correct vision in day time in the second seven months of the study
75606183|NCT01236365|Drug|Atorvastatin|10 or 20 mg daily
75751167|NCT00893555|Drug|voriconazole|TDM (through level of 2-5mg/L).
75751168|NCT00893555|Drug|voriconazole (dosing according to the SPC)|No serum concentrations are determined
75751169|NCT02541071|Behavioral|Stress Film|
76066827|NCT04464174|Drug|Carboplatin|Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle
76066828|NCT04464174|Drug|Gemcitabine|Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
75606184|NCT01236365|Drug|Atorvastatin Placebo|10 or 20 mg daily
75454837|NCT01753271|Other|shoulder mobilization & exercise|
75454838|NCT01753349|Biological|Botulinum toxin type A|Investigators were free to prescribe any BoNT A preparation, including Dysport, Botox and Xeomin.
75454839|NCT01753375|Dietary Supplement|Vitamin D3|Vitamin D3 given as 50000 IU orally on weekly basis
75606185|NCT01235975|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
75454840|NCT01753375|Dietary Supplement|Placebo|Placebo to be given orally on weekly basis
75454841|NCT01753388|Device|Liberty Stent|
75454842|NCT01753440|Procedure|Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).|Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
75751170|NCT02541071|Drug|Yohimbine|
75751171|NCT02541071|Drug|Clonidine|
75606186|NCT01235975|Biological|MencevaxACWY TM|Subcutaneous injection
75606187|NCT00903331|Drug|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
75606188|NCT00903331|Drug|Placebo|matching placebo, once daily
75751172|NCT02541071|Drug|placebo|
75751173|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
75751174|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
75454843|NCT01753453|Drug|Plerixafor|240mcg/kg, solution, subcutaneous injection
75606189|NCT02849431|Behavioral|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
75606190|NCT01235741|Drug|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
75606191|NCT01235741|Drug|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
75606192|NCT02849353|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
76066829|NCT04459117|Drug|Acetaminophen|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
75454844|NCT01753453|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
75454845|NCT01753466|Dietary Supplement|Hydration|
75606193|NCT02849353|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
75606194|NCT04206527|Behavioral|Training of AHSAs on PCC for FP|ASHAs provided with training on FP methods and counseling plus PCC for FP
75606195|NCT04206527|Behavioral|Enhanced FP training|Participation in an enhanced FP training including PCC
75751175|NCT00895739|Biological|alemtuzumab|
75751176|NCT00895739|Drug|cyclosporine|
75751177|NCT01325038|Procedure|Isometric exercise|Isometric exercise several times/week for three months
75751178|NCT03988660|Diagnostic Test|Circulating fibrocytes|Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
75751179|NCT03986320|Device|Keeogo™ Dermoskeleton|This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
75900251|NCT02307734|Behavioral|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
75900252|NCT04653454|Device|Continuous Glucose Monitor (CGM)|CGM data will be downloaded prior to discharge and it will be compared with hospital glucometer readings taken at the same time.
76066830|NCT04459117|Drug|NACL 0.9%|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
75606196|NCT04571827|Other|Dry Needling|"Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell & Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding."
76066831|NCT04428112|Behavioral|Building Better Caregivers Workshop|"Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times."
75454846|NCT01753479|Other|Spectroscopy device|Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
75454847|NCT01753492|Device|Ologen|
75454848|NCT01753505|Other|64-slice Multidetector coronary CT angiography|
75454849|NCT01753531|Device|Flu Symptoms|
75454850|NCT01753583|Device|Optical Coherence Tomography (OCT)|High-resolution OCT imaging of the cornea
75454851|NCT01753583|Other|Slit lamp biomicroscopy|Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
75606197|NCT01235507|Drug|methotrexate|stable dose as prescribed
75606198|NCT01235507|Drug|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
75606199|NCT04708015|Other|No Intervention|A retrospective chart review of medical records
75606200|NCT01933477|Other|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
76066832|NCT04428112|Behavioral|Attention Control|Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
75751180|NCT03986398|Other|Infection prophylaxis|Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
75751181|NCT03988348|Procedure|infraumbilical transverse incision|a 10 mm infraumbilical transverse incision will be done to allow trocar to be inserted without undue resistance from the skin so that the trocar will pass through the fascia and the peritoneum with ease
75454852|NCT01753596|Device|GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)|
75454853|NCT01753596|Other|Physiological Sodium Chloride solution (0,9%)|Placebo
75454854|NCT01753609|Device|Tulip capsule|swallowing Tulip capsule for up to 29 days
75454855|NCT01753622|Behavioral|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
75454856|NCT01753635|Device|supraglottic airway placement and use|
75751182|NCT03988348|Procedure|intraumbilical incision|right sided curved longitudinal intraumbilical incision will be performed for initial intraperitoneal access
75900253|NCT03506750|Drug|IVC|Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
75900254|NCT03506750|Procedure|Blood and aqueous humor at the time of IVC|Initial blood and aqueous humor will be harvested at the time of IVC.
75606201|NCT01868269|Drug|Dexamethasone acetate|"First step:~immunosuppressive treatment with dexamethasone"
75751183|NCT03988582|Biological|EBV-specific T-cells|During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
75751184|NCT01058902|Drug|Aspirin 75 mg|Aspirin 75 mg
75751185|NCT01058902|Other|no aspirin|nothing
75751186|NCT01055158|Behavioral|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
75751187|NCT01055158|Behavioral|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
75751188|NCT00609167|Drug|bortezomib|"First 33 patients: 1.3 mg/m^2 IV Days 1, 4, 8 & 11~Remaining 30 patients: 1.5 mg/m^2 IV Days 1, 8, 15 & 22"
75751189|NCT00609167|Drug|cyclophosphamide|300mg/m^2 PO days 1, 8, 15 & 22
75900255|NCT03506750|Procedure|Collect blood, aqueous humor, and initial vitreous at the time of surgery.|Blood, aqueous humor, and vitreous will be collected at the time of surgery.
75900256|NCT03506750|Procedure|IVC-sham|Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
75900257|NCT00054964|Drug|Albuterol HFA-BOI|Albuterol HFA breath operated inhaler, 90 mcg/sprau
75900258|NCT00054964|Drug|Albuterol HFA-MDI|Albuterol HFA multi-dose inhaler
75900259|NCT02781558|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
75900260|NCT02781558|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
75900261|NCT05073796|Device|Cochlea Implant|"examination and documentation of vital signs and concomitant medication~application of an cochlea implant loan processor (external body surface) with varying stimulus pattern for vestibular stimulation by means of basal, medial and apical electrodes~attraction of an special mask to determine the subjective visual vertical (SVV)~assessment of the vertical spatial axis with all electrodes turned off~assessment of the vertical spatial axis with all electrodes turned on~assessment of the vertical spatial axis while using basal (12-16) and medial (6-11) electrodes~assessment of the vertical spatial axis while using basal (12-16) and apical (1-5) electrodes~assessment of the vertical spatial axis while using medial (6-11) and apical (1-5) electrodes"
75900262|NCT05073640|Drug|Oxopurin|Subjects will receive two capsules per day.
75606202|NCT01868269|Drug|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
75454857|NCT01753661|Behavioral|Linguistic Feedback Report|Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings
75454858|NCT01753661|Behavioral|Multimedia Education Sessions|Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.
75454859|NCT01753661|Behavioral|EI-As-Usual|The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
75454860|NCT01753674|Dietary Supplement|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
75454861|NCT01753674|Dietary Supplement|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
75606203|NCT01868269|Drug|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
75606204|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
75751190|NCT00609167|Drug|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
75751191|NCT01055236|Drug|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
75751192|NCT04036955|Other|INFOSA-DEM|Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
75751193|NCT00895973|Other|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
75751194|NCT00896129|Other|HRQOL Survey Packet|Questionnaires
75454862|NCT01753687|Other|Ocular scattering of the tear film|
75454863|NCT01753687|Other|Optical Coherence Tomography (OCT)|Tear film thickness as measured with OCT
75606205|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily
75606206|NCT01234883|Drug|multiple electrolyte solution|IV multiple electrolyte solution dosed as clinically indicated for rehydration
75900263|NCT02304224|Other|eye masks|eye masks from 21:00 to 6:00 each night during admission
75900264|NCT02143596|Other|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
75900265|NCT05073094|Drug|Esmolol|Esmolol injected intravenously and added to cardioplegia solution
75900266|NCT05073094|Drug|Placebo|Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
75909636|NCT05004584|Other|Wheat home-based appetite assessment|Home-based appetite assessment with diet based on wheat cereal products.
75606207|NCT01234883|Drug|saline|IV solutions dosed as clinically indicated for rehydration
75606208|NCT01234649|Drug|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
75751195|NCT00606281|Drug|Aripiprazole|oral, 24mg/day
75751196|NCT00606281|Drug|placebo|oral, 0mg(4tablets)/day
75751197|NCT00506142|Drug|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
75751198|NCT01010880|Drug|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
75900267|NCT03509246|Drug|Pegylated liposomal doxorubicin plus Bortezomib|Pegylated liposomal doxorubicin 40mg/m2 subcutaneous for 60 - 90 minutes at day 4 plus Bortezomib 1.3mg/m2 subcutaneous injection at day 1,4,8,11 for 6 cycles
75606209|NCT01234649|Drug|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
75606210|NCT02876679|Drug|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
75606211|NCT02876679|Drug|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
75751199|NCT00891605|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
75751200|NCT00891605|Drug|paclitaxel|"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
75751201|NCT00891683|Drug|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
75900268|NCT03509168|Drug|Misoprostol Pfizer Brand|insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally
75900269|NCT03509168|Other|Non-insertion of Misoprostol Pfizer Brand|participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.
75900270|NCT04330534|Drug|BCX9930|BCX9930 capsules for oral administration
75454864|NCT01753687|Other|Measurement of tear film osmolarity|
75454865|NCT01753700|Dietary Supplement|UHT treated milk|
75454866|NCT01753726|Other|Diaphragm stretching.|A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.
75454867|NCT01753726|Other|Placebo.|Disconnected ultrasound was used for the 7 min as sham treatment
75454868|NCT01753752|Drug|Chitosan- N- Acetylcysteine eye drops|
75454869|NCT01753752|Drug|Placebo|
75454870|NCT01753778|Device|Cryo-Touch III Device|Treatment with Cryo-Touch III
75454871|NCT01753791|Drug|80 mg PF-06473871|80 mg of PF-06473871 or placebo
75454872|NCT01753791|Drug|160 mg PF-06473871|160 mg of PF-06473871 or placebo
75454873|NCT01753791|Drug|320 mg PF-06473871|320 mg of PF-06473871 or placebo
75606212|NCT02876679|Drug|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
75751202|NCT00893711|Other|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
75751203|NCT00893711|Other|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
75454874|NCT01753791|Drug|480 mg PF-06473871|480 mg of PF-06473871 or placebo
75454875|NCT01753804|Other|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
75454876|NCT01753843|Procedure|early cord clamping|early ( <20 seconds)
75454877|NCT01753843|Procedure|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
75751204|NCT00893711|Dietary Supplement|L.reuteri + Vit D|
75900271|NCT04330534|Drug|Placebo|placebo to match BCX9930 capsules for oral administration
75900272|NCT03509090|Procedure|erector spinae block|erector spinae block will be performed in this group as postoperative analgesia treatment.
76066833|NCT04408690|Procedure|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
76066834|NCT04408690|Other|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
76066835|NCT04408690|Procedure|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
75751205|NCT00893711|Dietary Supplement|Vit D placebo|
75606213|NCT01075815|Drug|Recombinant human luteinizing hormone (rhLH)|
75454878|NCT01753869|Procedure|Airways clearance and Hypertonic saline inhalation|
75454879|NCT01753882|Drug|Lexapro|Agent + training vs Placebo + training
75454880|NCT01753882|Drug|Placebo|Agent + training vs Placebo + training
75606214|NCT01075815|Drug|Recombinant follicle-stimulating hormone (rFSH)|
75751206|NCT00514020|Drug|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
75454881|NCT01753908|Drug|Broccoli Sprout Extract|Given PO
75454882|NCT01753908|Other|Laboratory Biomarker Analysis|Correlative studies
75454883|NCT01753908|Other|Pharmacological Study|Urinary ITCs and metabolites measured
75454884|NCT01753908|Other|Placebo|Given PO
75454885|NCT01753921|Other|this is not an intervention study|Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
75606215|NCT04306107|Device|Prone position during non-invasive respiratory support|HFNC and NIV application with patient on prone position
75606216|NCT00626691|Behavioral|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
75751207|NCT00514020|Drug|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
75751208|NCT00514020|Drug|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
75454886|NCT01753921|Other|this is not an intervention study|Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
75454887|NCT01753921|Device|MRI|MRI study of the brain will be performed at t=3months.
75454888|NCT01753947|Other|Deliberate Practice|
75454889|NCT01753986|Behavioral|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
75454890|NCT01753986|Behavioral|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
75454891|NCT01754012|Dietary Supplement|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
75454892|NCT01754051|Device|PC 400 coils|
75454893|NCT01754064|Device|Cardiac Rhythm Management device|
75606217|NCT00905359|Procedure|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
75606218|NCT00905359|Procedure|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
75606219|NCT01072149|Drug|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
75606220|NCT01072149|Device|placebo|placebo
75606221|NCT04413253|Drug|Lifitegrast 5% Ophthalmic Solution|To reduce signs and symptoms of dry eye disease
75751209|NCT00514020|Genetic|gene expression analysis|Blood collection
75751210|NCT00514020|Genetic|polymorphism analysis|Blood collection
75751211|NCT00514020|Genetic|protein expression analysis|Blood collection
75751212|NCT00514020|Other|pharmacological study|Blood collection
75751213|NCT03560531|Drug|ZN-c5|ZN-c5 is a study drug
75751214|NCT03560531|Drug|Palbociclib|Palbociclib (IBRANCE®) is an approved drug
75751215|NCT00513708|Behavioral|Motivation Enhancement Therapy (MET)|"Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification."
75751216|NCT00513708|Behavioral|Peer-Twelve Step Facilitation (P-TSF)|"In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs."
75751217|NCT00896207|Drug|Akt inhibitor SR13668|Given orally as a single dose
75751218|NCT00896285|Other|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
75900273|NCT03509090|Procedure|Control group|patients will receive only multimodal analgesic treatment including patient-controlled analgesia
75900274|NCT05072938|Drug|Mucotra SR Tablet 150mg|Rebamipide/Nizatidine Combination Therapy
75900275|NCT05072938|Drug|Axid Capsule 150mg|Nizatidine Monotherapy
75900276|NCT03041311|Drug|Trilaciclib|Trilaciclib IV
75900277|NCT03041311|Drug|Placebo|Placebo IV
75454894|NCT01754077|Behavioral|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
75454895|NCT01754077|Behavioral|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
75454896|NCT01754077|Behavioral|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
75606222|NCT04413253|Drug|Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution|To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
75606223|NCT01071915|Drug|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
75606224|NCT02876445|Other|ZARIT Burden Interview|ZARIT Burden Interview completed Day 0 and 1 year
75606225|NCT02849275|Other|Lactose Free 1% Milk|isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
75606226|NCT02849275|Other|Probiotic Treatment|Probiotic treatment, consumed once daily, over 4-5 weeks.
75751219|NCT00896285|Other|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
75900278|NCT03041311|Drug|Carboplatin|Carboplatin IV
75900279|NCT03041311|Drug|Etoposide|Etoposide IV
75900280|NCT03041311|Drug|Atezolizumab|Atezolizumab IV
75900281|NCT02311868|Dietary Supplement|SYNBIOTIC (Probinul neutro®)|Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
75454897|NCT01754090|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
75454898|NCT01754090|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
75751220|NCT00896285|Other|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
75751221|NCT00896285|Other|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
75751222|NCT00891761|Drug|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
75751223|NCT00891761|Drug|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
75751224|NCT00891761|Drug|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
75751225|NCT00891761|Drug|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
75900282|NCT02311868|Dietary Supplement|PLACEBO|Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
75900283|NCT05072860|Drug|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
75900284|NCT05072860|Other|: normal saline|temporary uterine packing with gauze of the dimensions soaked with placebo to 2 gm tranexamic diluted in 60ml saline acid
75900285|NCT02311946|Drug|Palbociclib Alone|In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
75606227|NCT02876133|Device|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
75606228|NCT02876133|Device|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
75454899|NCT01754090|Behavioral|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
75454900|NCT01754103|Other|Tactile Training|Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
75454901|NCT01754116|Drug|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
75454902|NCT01754116|Drug|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
75454903|NCT01754116|Drug|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
75454904|NCT01754116|Drug|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
75454905|NCT01754116|Drug|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
75606229|NCT01679119|Drug|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
75606230|NCT01679119|Drug|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
75606231|NCT01679119|Drug|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
75606232|NCT01679119|Drug|Rituximab|Rituximab 375mg/m2 IV given day 1
75606233|NCT01679119|Drug|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
75606234|NCT01679119|Drug|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
75751226|NCT00891761|Drug|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
75606235|NCT04778787|Drug|Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)|Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
75606236|NCT02876289|Drug|Perampanel|
75751227|NCT01012830|Drug|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
75751228|NCT04036175|Device|High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen|Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2>= 92%
75751229|NCT02540603|Device|F&P Jupiter Full Face Mask|Investigative F&P Jupiter full face mask to be used for OSA therapy
75751230|NCT00513474|Drug|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
75751231|NCT00513474|Drug|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
75606237|NCT04304391|Procedure|Resective Gingival Surgery|Gingivectomy and gingivoplasty:Resective gingival surgical procedured
75751232|NCT00513474|Drug|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
76066836|NCT04407754|Dietary Supplement|Inositol supplement|Inositol supplements given to inositol arm
75454906|NCT01754155|Radiation|RSA images|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
75454907|NCT01754181|Drug|Insulin|the intervention is applied only at the dose of insulin
75606238|NCT04304157|Drug|Dexmedetomidine|Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
75606239|NCT04305717|Device|ReDS-guided strategy|A discharge scheme based on specific target value given by the device
75606240|NCT02875587|Drug|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
75751233|NCT00513474|Drug|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
75751234|NCT00513474|Drug|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
76066837|NCT04407754|Dietary Supplement|Placebo supplement|Placebo supplement given to placebo arm
75900286|NCT02311946|Drug|Palbociclib + Rabeprazole|In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
75900287|NCT05072392|Device|Foley catheter|"Using a 16G Foley catheter to cover the tip of the endotracheal tube as it passes through the nose. This is done in comparison to the standard practice of directly passing an endotracheal tube through the nose without a cover.~Both groups use warmed endotracheal tubes and the use of topical vasoconstrictor (4 sprays of 0.1% xylometazoline to each nare)."
75606241|NCT02875587|Drug|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
75454908|NCT01754220|Drug|Montelukast|Montelukast is a leukotriene receptor antagonist
75751235|NCT00513474|Drug|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
75751236|NCT00513474|Drug|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
75454909|NCT01754233|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
75454910|NCT01754246|Device|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
75751237|NCT00513474|Drug|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
75751238|NCT00513474|Procedure|allogeneic hematopoietic stem cell transplantation|
75751239|NCT00513474|Procedure|peripheral blood stem cell transplantation|
75751240|NCT00513474|Radiation|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
75751241|NCT00513474|Drug|fludarabine|Fludarabine 40 mg/m^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
75751242|NCT00513474|Drug|allopurinol|Allopurinol per institutional guidelines
75751243|NCT00891917|Dietary Supplement|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
75751244|NCT00891917|Dietary Supplement|syrup (placebo)|syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
75751245|NCT00893867|Drug|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
75751246|NCT00893867|Drug|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
75900288|NCT02312024|Device|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
75900289|NCT04302766|Drug|Remdesivir|Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).
75900290|NCT02312102|Drug|Lenalidomide|Chemotherapy
75454911|NCT01754285|Drug|LF-PB and Placebo|
75454912|NCT01754285|Drug|Placebo|
75454913|NCT01754285|Drug|LF-PB|
75454914|NCT01754298|Procedure|Retro-articular drilling|"Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~Use a 0.045 K-wire for drilling.~Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
75454915|NCT01754298|Procedure|Trans-articular drilling|"Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~Use a 0.045 K-wire for drilling~A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
75751247|NCT01010958|Drug|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
75751248|NCT04036877|Other|Mood Disorder Assessment|Assess depression, anxiety, HRQOL, and financial toxicity in both bladder cancer patients and their caregivers via telephone survey
75751249|NCT00896519|Biological|rituximab|
75751250|NCT00896519|Biological|sargramostim|
75751251|NCT00896519|Drug|cyclophosphamide|
75751252|NCT00896519|Drug|doxorubicin hydrochloride|
75751253|NCT00896519|Drug|prednisone|
75751254|NCT00896519|Drug|vincristine sulfate|
75751255|NCT00896519|Genetic|gene expression analysis|
75751256|NCT00896519|Genetic|gene rearrangement analysis|
75751257|NCT00896519|Genetic|polymerase chain reaction|
75900291|NCT02312102|Drug|Velcade|Chemotherapy
75900292|NCT04287946|Device|Ablation|Ablation of a single-side of the greater splanchnic nerve
76066838|NCT04407364|Device|CoMatryx Surgical Bovine Collagen|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
75454916|NCT01754324|Drug|Methadone|The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
75454917|NCT01754337|Other|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
75454918|NCT01754415|Device|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
75454919|NCT01754454|Biological|Human Umbilical Cord Derived MSC|1×10^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
75454920|NCT01754506|Dietary Supplement|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
75900293|NCT02304536|Drug|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
75606242|NCT00904969|Device|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
75454921|NCT01754532|Biological|Hair Sample|Analysis of hair cortisol levels
75606243|NCT00904969|Device|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
75606244|NCT01070979|Drug|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
75606245|NCT01070979|Drug|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
75751258|NCT00896519|Other|R-CHOP regimen|
75751259|NCT00896519|Other|laboratory biomarker analysis|
75751260|NCT00896597|Drug|NRL972|2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
75900294|NCT02304536|Procedure|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
75900295|NCT05408221|Drug|Rulonilimab+Lenvatinib|Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
76066839|NCT04387305|Drug|Tranexamic acid injection|Active drug is provided to participants as described based on the TXA arm they are randomized to.
76066840|NCT04380649|Device|New headset prototype|creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.
76066841|NCT04377217|Other|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months, in order to evaluate the evolution of facial damage. Then algorithms will be developped to be able of differentiating FSHMD patients with facial damage from control subjects using video and audio recordings.
75606246|NCT01070979|Drug|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
75606247|NCT01234337|Drug|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
75751261|NCT00505752|Drug|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
75751262|NCT00505752|Drug|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
75751263|NCT00505752|Drug|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
76066842|NCT04374305|Drug|Brigatinib|Oral daily per predetermined dosage per protocol.
76066843|NCT04374305|Drug|Neratinib|Oral daily per predetermined dosage per protocol.
75751264|NCT00505752|Drug|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
75751265|NCT00505752|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to [>=] 18 millimeter [mm], two or more additional follicles with a diameter of >= 16 mm, and Estradiol [E2] levels will approximately 150 picogram per milliliter [pg/mL] per mature follicle).
75751266|NCT01011036|Drug|clobazam|test substance
75751267|NCT01011036|Drug|clonazepam|positive control
75751268|NCT01011036|Drug|tolterodine|active placebo
75900296|NCT05408221|Drug|Rulonilimab placebo +Lenvatinib|Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
75900297|NCT02644096|Other|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
75751269|NCT03601637|Drug|LUM|Fixed Dose Combination (FDC) granules (LUM/IVA).
75900298|NCT03504722|Behavioral|RESCUE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area SPCA facilities. The logistics of the training sessions will be facilitated by study staff, with SPCA animal behaviorists and professionals conducting the training program identical to the program that they use for their general volunteer training. During volunteer sessions, the veteran learns behavioral techniques for training non-aggressive dogs through didactic instruction followed by demonstration and supervised practice. The animal socialization component of the RESCUE volunteer sessions are comprised of the SPCAs current training program, which is designed developmentally such that early training focuses on general topics (safety, basic handling skills) and later training builds on previously learned skills through successive approximation within each individual's zone of proximal development.
75909637|NCT05004584|Other|Rye home-based appetite assessment|Home-based appetite assessment with diet based on rye cereal products.
75751270|NCT03601637|Drug|IVA|FDC granules (LUM/IVA).
75751271|NCT00896675|Other|proteomic profiles|blood samples analysis
76066844|NCT04374175|Biological|Blood sample|Blood sample will be performed
75454922|NCT01754545|Drug|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
75454923|NCT01754545|Drug|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
75454924|NCT01754558|Procedure|Ajust system|The use of Ajust system for stress incontinence
75454925|NCT01754558|Procedure|TVT/TVT-O|sling surgery
75454926|NCT01754571|Behavioral|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
75454927|NCT01754597|Drug|Peptide Natriurétique de type B|Peptide Natriurétique de type B
75454928|NCT01754636|Other|No intervention|
75751272|NCT00896675|Other|proteomic profiles|blood samples analysis
75751273|NCT00893945|Drug|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
75751274|NCT00893945|Drug|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
75751275|NCT00893945|Drug|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
75751276|NCT00894023|Drug|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
75751277|NCT00894023|Drug|IV abciximab|IV abciximab + infusion
75909638|NCT05004584|Other|Wheat clinic-based appetite assessment|Clinic-based appetite assessment with diet based on wheat cereal products.
75909639|NCT05004584|Other|Rye clinic-based appetite assessment|Clinic-based appetite assessment with diet based on rye cereal products.
75909640|NCT05004584|Other|Rye/Wheat clinic-based appetite assessment with blood sampling|Clinic-based appetite assessment with diet based on rye or wheat cereal products and continuous blood sampling.
76066845|NCT04351958|Behavioral|"Experimental: Augmented Reality (No Time Wasted)"|"No Time Wasted will be an innovative, immersive intervention using novel technology that will captivate the target audience with narrative and gaming elements to scaffold the educational message."
76066846|NCT04351555|Drug|Osimertinib|Oral
76066847|NCT04351555|Drug|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
75751278|NCT00892073|Drug|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
75900299|NCT03504722|Behavioral|Prolonged Exposure|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.
75900300|NCT05072002|Other|no intervention / observational study|no intervention / observational study
75606248|NCT01234337|Drug|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
75606249|NCT01234337|Drug|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily,
75606250|NCT02848963|Drug|Ketamine-propofol mixture|Ratio of Ketamine-propofol mixture will be compare for every groups.
75454929|NCT01754649|Drug|Misoprostol|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
75454930|NCT01754662|Dietary Supplement|Soy protein|2 bars daily for 8 weeks.
75454931|NCT01754662|Dietary Supplement|Isoflavones|2 bars daily for 8 weeks.
75454932|NCT01754662|Dietary Supplement|Cocoa|2 bars daily for 8 weeks.
75454933|NCT01754662|Dietary Supplement|Placebo|
75454934|NCT01754675|Behavioral|Soccer|Watching the soccer match at the time that the favorite team is playing
75454935|NCT01754675|Behavioral|Movie|Watching a movie at the time that the favorite team is playing
75454936|NCT01754701|Dietary Supplement|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
75454937|NCT01754701|Dietary Supplement|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
75606251|NCT01070043|Drug|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
75900301|NCT02304614|Other|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
76066848|NCT04351555|Drug|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
75751279|NCT00892073|Drug|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
75751280|NCT00894101|Drug|[F-18] FLT|10 mCi [F-18] FLT and 10 mCi [F-18] FDG will be used for PET imaging.
76066849|NCT04351555|Drug|Placebo|Oral
75900302|NCT02304614|Other|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
75900303|NCT02304614|Other|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
75900304|NCT02304614|Other|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
76066850|NCT04351555|Drug|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
76066851|NCT04317742|Device|Sleep Healthy Using the Internet (SHUTi) Intervention Group|"SHUTi is a fully automated, interactive and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is presented in six Cores, metered out over time."
76066852|NCT04317742|Device|Online Patient Education (PE) Control Group|The online PE program provides static information about: insomnia symptoms; the impact, prevalence, and causes of insomnia; when to see a doctor; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
75751281|NCT00896831|Drug|L-ornithine-L-aspartate|L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
75751282|NCT00896831|Drug|placebo|Placebo: 5 g (1 sachet) three times per day for 60 days
75751283|NCT00896909|Genetic|gene expression analysis|
75454938|NCT01754740|Drug|Uréia|"The subjects were randomly divided into two groups:~1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months."
75751284|NCT00896909|Genetic|mutation analysis|
75751285|NCT00896909|Genetic|polymerase chain reaction|
75454939|NCT01754740|Drug|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
75751286|NCT00896909|Other|diagnostic laboratory biomarker analysis|
75900305|NCT03625999|Behavioral|video game training exercise|"The game, called The Silent Service and developed by our collaborators, is an online game with an underwater theme, and is comprised of 5 distinct mini-games, each of which demands auditory attention. The mission is to navigate an underwater scene, listening and responding to 'sonar' (e.g., an oddball in a stream of sounds). For example, participants may have to respond to an oddball sound stream to protect their submarine from a looming sea monster, while successfully ignoring a distractor sound stream (responses to the distractor sound stream allow the sea monster to damage the submarine). The five games share the same underlying framework of detecting oddballs while ignoring distractors but have unique artwork and 'backstories' to keep players interested. There is a hierarchical reward structure for 'leveling up' across the game that helps players to stay engaged and interested while playing."
75454940|NCT01754805|Drug|peficitinib|oral
75454941|NCT01754805|Drug|methotrexate|oral
75900306|NCT04211194|Procedure|Upper GI Endoscopy|Patients with upper gastrointestinal bleeding undergoing endoscopic therapy. Information regarding the need for interventional radiology procedures or surgical interventions will also be collected in patients in whom endoscopic therapy is not successful.
75900307|NCT04196842|Device|Telemonitoring devices|Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
76066853|NCT04299906|Device|Solaris Vascular Stent Graft|Solaris Vascular Stent Graft for treatment of Iliac Lesions
76066854|NCT04297254|Drug|Lenvatinib|Lenvatinib capsules.
75751287|NCT02541227|Drug|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
75751288|NCT00896987|Drug|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
75751289|NCT00896987|Drug|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg~600 mg) and maintenance for 40 weeks (600 mg)
75751290|NCT00897065|Genetic|microarray analysis|
75751291|NCT00897065|Genetic|polymerase chain reaction|
75900308|NCT03508856|Drug|Ingenol Mebutate (Picato®) 0.015% gel|
75900309|NCT03132428|Drug|INOmax|Nitric oxide gas for inhalation provided via mechanical ventilation or non invasive ventilation
75900310|NCT02643628|Procedure|Microneedling|
75900311|NCT02643628|Device|Microneedling followed by Bellafill treatment|
75751292|NCT00897065|Genetic|protein expression analysis|
75751293|NCT00897065|Other|diagnostic laboratory biomarker analysis|
75751294|NCT00897065|Other|fluorescent antibody technique|
75751295|NCT00897065|Other|immunohistochemistry staining method|
75751296|NCT00897065|Other|immunologic technique|
75751297|NCT00897143|Genetic|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
75751298|NCT00897143|Genetic|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
75751299|NCT00897143|Other|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
75751300|NCT00897143|Other|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
75606252|NCT01070043|Drug|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
75900312|NCT03508778|Device|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
75454942|NCT01754818|Drug|Bendavia 10mg|
75454943|NCT01754818|Drug|Bendavia 50mg|
75454944|NCT01754818|Drug|Bendavia 100mg|
75606253|NCT02849119|Procedure|Laparoscopic or robotic partial nephrectomy|Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
75751301|NCT04035863|Device|Low level laser therapy|"For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light."
75454945|NCT01754818|Drug|Placebo|
75454946|NCT01754831|Device|Fluoride varnish|Topical application of fluoride varnish on present teeth
75454947|NCT01754844|Drug|AZD7624|Single dose inhaled IMP via a nebulizer
75454948|NCT01754844|Drug|Placebo to match|Single dose inhaled Placebo via a nebulizer
75454949|NCT01754870|Drug|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
75454950|NCT01754883|Drug|Lithium Carbonate|Oral Lithium carbonate to target serum levle of 0.6-0.8.
75751302|NCT00343252|Drug|teriparatide|20 ug/day, subcutaneous, 18 months
75751303|NCT00343252|Drug|risedronate|35 mg/once weekly, oral, 18 months
75454951|NCT01754896|Other|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
75606254|NCT04772391|Other|Exercise Sessions|Participant will complete up to 8 exercise sessions
75606255|NCT04718545|Procedure|Mucogingival surgery|The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
75751304|NCT00343252|Drug|placebo|once weekly, oral, 18 months
75751305|NCT00343252|Drug|placebo|daily, subcutaneous, 18 months
75751306|NCT00892229|Drug|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
75900313|NCT03508778|Device|AcrySof IQ PanOptix Trifocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
75900314|NCT03508778|Procedure|Cataract surgery|Cataract surgery per investigator's standard practice
75900315|NCT02643472|Behavioral|Parent Navigator|Parents will be contacted by the parent navigator within 2 business days after discharge to assess how the family is coping, answer questions, and provide necessary resources. Navigators will be in touch with families monthly and according to the parent's needs. They will assist the parent in making and keeping appointments, answer questions about insurance coverage, medical equipment and supplies, and serve as a liaison between parent and healthcare providers. However, the specific PN intervention for each family will be based on each family's needs and therefore may differ.
75606256|NCT02849197|Procedure|surgery for pilonidal sinus disease|surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
75606257|NCT01074255|Drug|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
75454952|NCT01754896|Other|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
75454953|NCT01754896|Other|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
75751307|NCT00892229|Drug|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
75751308|NCT00897221|Drug|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
75900316|NCT02643472|Behavioral|Care Notebook|A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.
75606258|NCT02848807|Dietary Supplement|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
75900317|NCT02738840|Procedure|MRI scan|MRI scan
75606259|NCT01073943|Drug|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
75900318|NCT03508700|Drug|TNX-102 SL 5.6 mg|cyclobenzaprine HCl sublingual tablets
75900319|NCT04038736|Device|C-Scan System|During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.
75900320|NCT02304692|Device|Bone anchored hearing aid|
75454954|NCT01754896|Other|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
75900321|NCT05071378|Behavioral|Our Family, Our Voices|Many Men, Many Voices (3MV) is a seven-session, group-level intervention developed to prevent HIV and sexually transmitted diseases (STDs) among black men who have sex with men (MSM) who may or may not identify themselves as gay. The intervention addresses factors that influence the behavior of black MSM: cultural, social, and religious norms; interactions between HIV and other STDs; sexual relationship dynamics; and the social influences that racism and homophobia have on HIV risk behaviors. Our Family, Our Voices seeks to create an adaptation of Many Men, Many Voices specifically tailored to young people who are members of the house ball community by incorporating elements of family support and resilience afforded to participants in the intervention.
75454955|NCT01754961|Drug|Vitamin D|Vitamin D 500,000 IU given orally on Day 1
75454956|NCT01754961|Drug|Placebo|Placebo given orally on Day 1
75454957|NCT01754974|Biological|Peginterferon Lambda-1a|
75454958|NCT01754974|Drug|Ribavirin|
75454959|NCT01754974|Biological|Peginterferon alfa-2a|
75454960|NCT01755000|Procedure|USCOM scan|
75454961|NCT01755000|Procedure|Fluid Bolus|
75454962|NCT01755013|Procedure|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
75454963|NCT01755078|Drug|Sevelamer HCl|Non-metal phosphate binder
75454964|NCT01755078|Drug|Calcium-based phosphate binder|
75454965|NCT01755104|Dietary Supplement|Stablor|
75454966|NCT01755104|Dietary Supplement|Placebo|
75454967|NCT01755117|Other|Sciatic, femoral, obturator nerve blocks|
75454968|NCT01755117|Other|Sciatic nerve block, posterior lumbar plexus block|
75454969|NCT01755130|Procedure|Photoacoustic Imaging|Undergo LOUISA 3D
75454970|NCT01755182|Drug|approved pharmacologic therapy|
75454971|NCT01755182|Procedure|TAE|after randomization, and after 3 months
75751309|NCT00897221|Drug|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
75751310|NCT02540525|Device|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
75900322|NCT02307968|Other|insulin injection site|insulin injected site between inner thigh and out thigh
75900323|NCT02312180|Biological|Plasminogen (Human) Intravenous|Plasma-derived purified plasminogen formulated for intravenous administration
75900324|NCT05070832|Procedure|Deep Hyperthermia|Hyperthermia is a type of treatment in which tumor is heated to as high as 40.5-43℃ to help damage and kill cancer cells with little or no harm to normal tissue.
75900325|NCT03504566|Drug|Linagliptin|Linagliptin
75900326|NCT03504566|Drug|Empagliflozin|Empagliflozin
75900327|NCT03504566|Drug|Telmisartan|Telmisartan
75751311|NCT02540525|Device|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
75751312|NCT00892307|Radiation|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
76066855|NCT04262882|Behavioral|Multilevel Family Planning Intervention|"The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community."
76066856|NCT04262882|Behavioral|Time and attention matched control|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda."
75454972|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|All subjects will have a pH probe placed at their initial clinic visit and will have the probe removed 24 hours later. They will start on PPI medication (as per the standard of care) after probe removal. Subjects will have a follow up clinic visit 8-12 weeks after the initial visit. At the follow up visit, all subjects will have the option of a second probe placement to assess the effects of PPI therapy on reflux events.
75454973|NCT01755247|Drug|Topical Gel Vehicle|
76066857|NCT04244981|Drug|Prothrombin Complex Concentrate, Human|A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
76066858|NCT04244981|Drug|Fresh Frozen Plasma|When APTT is prolonged (> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
75606260|NCT01073943|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
75900328|NCT03504566|Drug|Sulodexide|Sulodexide
75900329|NCT05070520|Drug|Artemether-lumefantrine|Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020
75606261|NCT01073943|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
75606262|NCT05273125|Behavioral|Gait disorders and falls risk assessment|Implementation of a standardized assessment of the fall risk and gait disorders in the memory clinic in addition to usual care.
76066859|NCT04244773|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75751313|NCT00897299|Genetic|microarray analysis|
75751314|NCT00897299|Genetic|protein expression analysis|
75751315|NCT00897299|Other|immunohistochemistry staining method|
75900330|NCT03508544|Procedure|Lumbar ESP block|Lumbar ESP block will be performed at the begining of surgery under ganeral anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 4-6 cm lateral to L4 spinous process. The erector spinae muscles will be identified superficial to the tip of L4 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
75909641|NCT04993976|Other|Resistant training (Prehabilitation)|Resistance training (10-15 repetitions: major muscle groups of upper and lower limbs [eg, shoulder overhead press, biceps curl, knee lift, and quadriceps extension in sitting and hamstrings curl exercises], one to three sets each) for 20-60 minutes five days a week.
75909642|NCT04993976|Other|Active Comparator: Control group|Conventional physiotherapy group followed basic pre-operative respiratory physiotherapy including deep breathing exercises, instructions in coughing techniques, mobilization, and active exercises of the upper limbs and thorax. Walk 30 m in the hospital ward.
75909643|NCT02622724|Drug|Interferon beta-1a|Investigational drug
75454974|NCT01755247|Drug|8% NVN1000 Topical Gel|
75454975|NCT01755247|Drug|8% NVN1000 Topical Gel and moisturizer|
75909644|NCT02622724|Drug|Placebo|Placebo for investigational drug
75751316|NCT00897299|Other|laboratory biomarker analysis|
75900331|NCT03508544|Procedure|QLB bLock|QLB block will be performed at the begining of surgery under ganeral anesthesia. The convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest.The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscles, transverse abdominis muscles, internal and external oblique muscles and the quadratus lumborum muscles will be identified. A 15cm 22G insulated needle will be inserted on the posterior corner of the convex probe. 40 ml of local anesthetic mixture(bupivacaine and lidocaine ) will be administered between the quadratus lumborum and psoas muscles into the fascial plane. We observed the local anesthetic pressing down on the psoas muscle in the ultrasound image.
76066860|NCT04244773|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
76066861|NCT04201184|Behavioral|Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules|Caregivers will receive 12 lessons, weekly, over a period of 12 weeks. Full curriculum contains: 4 lessons on cultural connection and traditions, 4 lessons on parenting adapted from Family Spirit intervention, and 4 lessons on stress and trauma adapted from CETA. modules
76066862|NCT04201184|Behavioral|Active nutrition control|The active control condition will receive nutrition information, weekly food boxes and recipes. Recipes will be developed based on seasonal foods and a shopping list for making future meals will be included.
76066863|NCT04198922|Drug|Acalabrutinib|Given PO
75900332|NCT03508544|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
75606263|NCT05254483|Behavioral|UNICEF kid power program immediately|"The intervention will be delivered via the UNICEF Kid Power website (https://www.unicefkidpower.org/) and any screened device such as a computer, smartphone, smart TV or an electronic tablet can be used to watch the videos and perform the assigned physical activity.~Participants will self-select activities 5 days a week. The participants will have the choice to undertake the physical activity in bouts and accumulate it over the course of the day.~To promote adherence to intervention, a weekly email with reminder to perform the physical activity will be sent to parents. In addition, research-based articles on the importance of physical activity and behavior change in children will also be emailed."
75606264|NCT05254483|Behavioral|UNICEF kid power program for waitlist control|The wait-list control group will perform physical activity as usual and will only receive a weekly email on the importance of healthy dietary habits in children. The intervention will last 12 weeks. At the end of the study, the wait-list control group will be offered the UNICEF Kid Power intervention for a duration of 12-weeks
75606265|NCT05254483|Device|ActiGraph Accelerometer|The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
75606266|NCT01073865|Drug|ZD9393 (Zoladex) 10.8 mg|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
75900333|NCT04435054|Diagnostic Test|Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.|"Non-invasive blood biological tests - NAFLD Fibrosis Score, FIB-4, Fibrotest, FibrometerNAFLD~Non-invasive imaging:~- Transient elastography (FibroScan), Shear Wave imaging, Magnetic resonance imaging (MRI-PDFF and MRE) in a subgroup of participants."
76066864|NCT04198922|Other|Questionnaire Administration|Ancillary studies
76066865|NCT04189991|Device|Free 02|"With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test."
76066866|NCT04182373|Drug|Antithrombin gamma|Intravenous infusion, once a day, 7 days
76066867|NCT04182373|Drug|physiological saline|Intravenous infusion, once a day, 7 days
76066868|NCT04180085|Drug|Belatacept Injection|9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
76066869|NCT04179175|Drug|secukinumab|secukinumab 300mg every 2 or every 4 weeks
75606267|NCT01073865|Drug|ZD9393 (Zoladex) 3.6 mg|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
75606268|NCT02900053|Device|tDCS|tDCS for transcranial Direct-Current Stimulation
75751317|NCT00342628|Biological|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
75751318|NCT00342628|Biological|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
75751319|NCT00342628|Biological|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
75751320|NCT00897377|Radiation|Radiation therapy|
75751321|NCT00897377|Drug|Temozolomide|
75606269|NCT02900053|Device|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
76066870|NCT04175977|Behavioral|Aliviado Dementia Care-Hospice Edition QAPI program|Multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
75606270|NCT04862065|Device|Alinity s Anti-HCV II|For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
75454976|NCT01755260|Other|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
75606271|NCT04714645|Device|VR neglect training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. The training consists of 5 different VR tasks specifically designed for neglect training.
75606272|NCT04714645|Device|VR control training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. This is a placebo training, where patients will also wear the HMD. Patients will be immersed in a virtual environment without a specific task.
75606273|NCT01064635|Drug|Letrozole|letrozole for 2-3 years after Tam
75606274|NCT01064635|Drug|Letrozole|Letrozole for 5 years after Tam
75606275|NCT00930007|Other|Blood sampling|Blood sampling for later hormone measurements
75606276|NCT04697485|Drug|Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg|"Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~Loop diuretic (bumetanide 0.5 mg)~Mineralocorticoid receptor antagonist (eplerenone 25 mg)~Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg"
75606277|NCT02768935|Procedure|blood sample|blodd sample at 12 months
75606278|NCT01073631|Drug|voriconazole tablet|200 mg PO bid (orally, twice a day)
75454977|NCT01755273|Procedure|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
75454978|NCT01755286|Drug|OTO-201|Single intra-operative injection
75606279|NCT00626769|Dietary Supplement|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
75606280|NCT00626769|Dietary Supplement|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
75606281|NCT04305171|Procedure|non-surgical periodontal treatment|scaling and root planing, home care instruction
75751322|NCT00505284|Drug|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
75751323|NCT00505284|Drug|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
75751324|NCT00505284|Drug|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
75454979|NCT01755286|Drug|Placebo|Single intratympanic injection
75454980|NCT01755286|Drug|Sham|Simulated single intratympanic injection
75454981|NCT01755299|Other|"Regular 5-hour Energy"|Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)
75454982|NCT01755299|Other|"Decaf 5-hour Energy"|"Commercially available 5-Hour Energy Decaf product in the amount that is packaged (1.93 fl. oz.)"
75454983|NCT01755299|Other|Compounded concentrated caffeine liquid|"Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular 5-hour Energy"
75454984|NCT01755299|Other|Flavored bottled water|Bottled water will be flavored and colored to serve as a placebo product for this trial.
75606282|NCT04294797|Diagnostic Test|Blood draw|One additional blood sample for study purpose from the day before surgery, postoperative 1, 3 and 8.
75606283|NCT02875743|Drug|Posaconazole|
75606284|NCT01073163|Drug|Bendamustine|Bendamustine at 90 mg/m^2 IV on Days 1 and 2 of a 28-day cycle.
75606285|NCT01073163|Drug|Rituximab|Rituximab at 375 mg/m^2 IV on Day 1 of a 28-day cycle.
75900334|NCT02304770|Drug|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
75606286|NCT04305483|Procedure|Laser Bleaching|Content; There are 35% hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative. The way of application; Gingival protection is applied. The gel is applied to the labial surfaces of the teeth with a thickness of 1-2 mm. The use of laser increases the effectiveness of the gel. Operator and patient use protective glasses during laser application. The gel shows its effectiveness in about eight minutes. Then the gel is removed with the help of saliva absorber. The procedure is repeated until the desired degree of whitening is achieved. Then it is checked with a color scale.
75606287|NCT04305483|Procedure|Chemical Bleaching|"Total Blanc Office Teeth Whitening System (H35) will be used as chemical whitening agent. Content; There are 35% hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water. Method of Application; Gingival protection is applied. A 1 mm thick layer of gel is applied to all of the labial surfaces of the tooth. The whitening agent remains on the tooth surface for 20 minutes. At the end of this period, the gel is removed with saliva absorber and the surface is cleaned with a moist gauze."
75900335|NCT03101410|Behavioral|Gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
75900336|NCT03101410|Behavioral|Gluten free|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
75900337|NCT03504332|Procedure|intracanal disinfection in revascularization|a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
75900338|NCT05070676|Diagnostic Test|newly developed mobile application|"The application will be developed in native Android, using Java (backend) and XML (front-end) as the programming language. The program of choice will be Android Studio®, YouTube® (video reproduction) and Firebase® (database) will be used as external APIs (Application Programming Interfaces).~The layout of the application will be developed using:~Adobe Illustrator® software. The logo, brand, objects, and shapes of the mobile application will be designed to enable to resize of the images without any loss of quality, due to the wide range of scales available in current smartphones"
75900339|NCT02304848|Other|DBS (Deep Brain Stimulation)|Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
75900340|NCT03919864|Behavioral|CONNECT Intervention|Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
75900341|NCT03919864|Behavioral|CONTROL Group|Participants will receive a generic printed list of hospital, community, and national supportive care resources.
75454985|NCT01755312|Device|Medication reminder|Medication reminder
75454986|NCT01755325|Drug|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
75454987|NCT01755325|Drug|placebo|
75454988|NCT01755338|Drug|Methylprednisolone|Methylprednisolone 15mg/kg
75900342|NCT05070598|Drug|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle
75900343|NCT05070208|Other|NOT PROVIDED|NOT PROVIDED
75900344|NCT02308436|Device|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries & acidic challenges
75909645|NCT03471026|Diagnostic Test|Advanced MRI sequences|Structural, diffusion and perfusion MRI sequences
75909646|NCT03710720|Behavioral|TIPS app|Psycho-educational electronic application
75454989|NCT01755338|Drug|Placebo|Placebo
75454990|NCT01755364|Biological|AdimFlu-V|
75606288|NCT04304859|Diagnostic Test|BASIC|Validation
75606289|NCT02875665|Device|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
75606290|NCT02875821|Drug|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
75454991|NCT01755377|Drug|Benznidazole|
75454992|NCT01755390|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
75454993|NCT01755403|Drug|Benznidazole|
75454994|NCT01755442|Other|Placebo|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
75454995|NCT01755442|Drug|AMG 151|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
75454996|NCT01755468|Drug|Intermittent insulin therapy|
75454997|NCT01755468|Drug|Continuous metformin|
75454998|NCT01755481|Other|Probiotic|
75454999|NCT01755481|Other|Whey protein concentrate|
75455000|NCT01755494|Drug|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
75455001|NCT01755494|Drug|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
75751325|NCT00505284|Drug|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
75900345|NCT02308514|Device|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
75455002|NCT01755494|Drug|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
75455003|NCT01755494|Drug|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
75455004|NCT01755494|Drug|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
75455005|NCT01755507|Drug|norUDCA|Comparison of different dosages of norUDCA acid administered orally.
75455006|NCT01755507|Drug|Placebo|
75455007|NCT01755520|Drug|Ticagrelor|90mg twice daily dose
75455008|NCT01755520|Drug|Aspirin|Aspirin 100mg once daily
75455009|NCT01755520|Drug|Placebo - Ticagrelor|Placebo
75455010|NCT01755520|Drug|Placebo - Aspirin|Placebo
76066871|NCT04175977|Behavioral|Usual Care|Usual care as provided by the hospice agency
76066872|NCT04168060|Procedure|Crura dissection|The diaphragmatic crura, one of two tendon structures below the diaphragm, will be removed during the laparoscopic sleeve gastrectomy.
75455011|NCT01755533|Other|Rural curriculum|Students in schools randomly assigned to this condition receive the rural version of the curriculum.
75455012|NCT01755533|Other|Classic curriculum|Students in schools randomly assigned to this condition receive the classic version of the curriculum.
75455013|NCT01755559|Drug|Artesunate-amodiaquine|antimalarial ACT
75455014|NCT01755559|Drug|Dihydroartemisinin-piperaquine|antimalarial ACT
75455015|NCT01755559|Drug|Artemether-lumefantrine|antimalarial ACT
75455016|NCT01755572|Drug|Liraglutide|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
75455017|NCT01755572|Drug|Placebo|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
75455018|NCT01755611|Drug|Minocycline 100mg|Test product
75455019|NCT01755611|Drug|Minocycline 100mg|Reference product
75606291|NCT02875821|Drug|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
75606292|NCT04721535|Drug|DWJ1248|Orally, 1 tablet of DWJ1248 TID, up to 14 days
75455020|NCT01755624|Device|NovoTTF-100A device|
75751326|NCT00505284|Drug|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
75751327|NCT00894569|Drug|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
75751328|NCT00894569|Drug|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
75751329|NCT00337168|Drug|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
75455021|NCT01755624|Other|Best Standard of Care|
75455022|NCT01755663|Drug|Ivabradine and Metoprolol|
75455023|NCT01754792|Dietary Supplement|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
75455024|NCT01755676|Drug|Orlistat 60 mg|1 tablet 3 times a day
75455025|NCT01755676|Other|Placebo|1 tablet 3 times a day
75455026|NCT01755689|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the right arm.
75455027|NCT01755689|Biological|Cervarix®|Three doses administered intramuscularly (IM) in the deltoid of the left arm.
75455028|NCT01755689|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the left arm.
75455029|NCT01755715|Procedure|Immediate IUD insertion|Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.
75455030|NCT01755728|Drug|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
75455031|NCT01755728|Drug|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
75606293|NCT04721535|Drug|Placebo|Orally, 1 tablet of placebo TID, up to 14 days
75900346|NCT02308514|Other|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
75900347|NCT03884452|Drug|Atorvastatin|Tablets taken orally once daily in the morning
75900348|NCT03884452|Drug|Simvastatin|Tablets taken orally once daily in the morning or evening
75900349|NCT03884452|Drug|Ezetimibe|Tablet taken orally once daily in the morning or evening
75900350|NCT03884452|Drug|Placebo for Ezetimibe|Tablets taken orally once daily in the morning or evening
75900351|NCT02308592|Behavioral|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
75900352|NCT02308592|Behavioral|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
75900353|NCT02305082|Other|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
75455032|NCT01755728|Procedure|Closure of PDA|Open surgery for closure of PDA
75900354|NCT03882892|Drug|Ezetimibe|Ezetimibe 10 mg tablets
75900355|NCT03882892|Drug|Atovastatin|Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
75455033|NCT01755741|Combination Product|Placebo Vaginal Ring|a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
75455034|NCT01755741|Device|Condom|Male condom
75606294|NCT02875119|Drug|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
75455035|NCT01755754|Combination Product|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
75455036|NCT01755754|Device|Female Condom|Female condom
75455037|NCT01755780|Other|Left interscalene block|
75455038|NCT01755780|Other|Right interscalene block|
75455039|NCT01755819|Device|Biocomposite interference screw|
75606295|NCT02875119|Drug|Placebo Gel|Placebo Gel
75606296|NCT04757415|Other|Traction straight leg raise technique for hamstring|traction straight leg raise technique is used along with gluteal exercises
75606297|NCT04757415|Other|Gluteal activation exercises,Hotpack|only gluteal activation exercises were performed without traction straight leg raise technique
75606298|NCT04304313|Drug|Sildenafil citrate tablets|0.1g/day for 14 days
75751330|NCT00337168|Drug|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
75455040|NCT01755819|Device|Extracortical ACL Tightrope fixation|
75455041|NCT01755832|Procedure|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
75455042|NCT01755845|Drug|paclitaxel|
75455043|NCT01755845|Drug|cisplatin|
75455044|NCT01755845|Radiation|radiotherapy|
75751331|NCT00892385|Drug|Methoxyamine|For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
75751332|NCT00892385|Drug|Temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
75751333|NCT00892463|Drug|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
75751334|NCT01011114|Drug|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
75751335|NCT01011114|Drug|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
75751336|NCT00606905|Biological|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
75751337|NCT00606905|Other|normal saline|equivalent volume of normal saline
75751338|NCT01055392|Drug|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
75751339|NCT01055392|Drug|Placebo|Identical placebo tablets were administered twice-a-day for two years.
75751340|NCT03063762|Drug|Atezolizumab|"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
75900356|NCT03882892|Drug|Placebo|Placebo tablets matched to ezetimibe
75900357|NCT02305160|Drug|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
75900358|NCT02305160|Drug|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
75455045|NCT01755871|Drug|Fingolimod|0,5mg Fingolimod once a day
75455046|NCT01755884|Dietary Supplement|Wheat oral immunotherapy|Cooked spaghetti
75455047|NCT01755910|Other|Left thoracic paravertebral block|
75900359|NCT03101332|Behavioral|Virtual Reality cognitive behavior therapy|"Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.~Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.~Interventions are delivered by a psychologist in face-to-face sessions."
75900360|NCT03504176|Other|Ventilation bundle|ventilation targets (pH, spO2, pCO2) tidal volume 3-6ml/kg peak pressures <28-32cmH2O PEEP-FiO2 titration tables
75900361|NCT05069506|Other|Glucose as reference food|Twelve subjects (male: 4 female: 8) consumed 25g glucose diluted in 150ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75900362|NCT05069506|Other|Goat milk as test food|Twelve subjects (male: 4 female: 8) consumed 617 g goat milk yogurt, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75900363|NCT05069506|Other|Goat milk and currants as test food|Twelve subjects (male: 4 female: 8) consumed 308 g goat milk yogurt and 19 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75900364|NCT05069506|Other|Currants as test food|Twelve subjects (male: 4 female: 8) consumed 37.8 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75900365|NCT05069506|Other|Sultanina raisins as test food|Twelve subjects (male: 4 female: 8) consumed 37.5 g sultanina raisins, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75900366|NCT05069506|Other|Goat milk yogurt as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g goat milk yogurt). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
75900367|NCT05069506|Other|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g milk with lactic acid). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
75900368|NCT02312336|Other|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
76066873|NCT04168060|Procedure|Sleeve gastrectomy|Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
76066874|NCT04168060|Procedure|Hiatal hernia repair|This involves tightening the opening in your diaphragm with stitches to keep your stomach from bulging upward through the opening in the muscle wall.
76066875|NCT04161235|Device|The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
76066876|NCT04159987|Other|Spinraza intrathecal injection|The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
76066877|NCT04140305|Drug|RPC-1063|Oral capsule
75455048|NCT01755910|Other|Right thoracic paravertebral block|
75751341|NCT03063762|Drug|Bevacizumab|"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
75751342|NCT03063762|Drug|RO6874281|"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
75751343|NCT00897455|Genetic|DNA analysis|
75900369|NCT02312336|Other|Cohort B - Cooled coronary perfusate|"Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees."
75900370|NCT03504098|Behavioral|nutrition consult|Post-lung cancer operation diet pattern
75900371|NCT04434742|Other|Complex interventions|An advanced practice nurse (APN) from a hospital discharge team visited them to familiarize him/herself with their condition and prepare a discharge plan. A face-to-face or telephone call handover between the APN and the project nurse case manager (NCM) was performed before the client was discharged. The past and current medical conditions, medical and nursing management, and follow-up appointments were discussed. After discharge home, the NCM, functioning as the leader of health-social care team, conducted the initial assessment in the first home visit to identify the client's health and social problems within one week of discharge. Community workers, supervised by both the nurse case manager and social worker, provided telephone follow-up and subsequent home visits to monitor the client's progress and provide support when necessary.
75900372|NCT04434742|Other|Usual care|Social call was given to this group.
75900373|NCT02312414|Drug|L-Canitine|Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
75900374|NCT05069272|Other|Bakuchiol and Ethyl Linoleate|A synergistic combination of Bakuchiol and Ethyl Linoleate
75900375|NCT05069272|Other|Vehicle|No actives
75900376|NCT02305394|Drug|ketamine and propofol|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
75751344|NCT00897455|Genetic|mutation analysis|
75751345|NCT00897455|Genetic|polymorphism analysis|
75900377|NCT02305394|Drug|propofol and normal saline|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.
75751346|NCT00897455|Other|laboratory biomarker analysis|
75751347|NCT00897455|Procedure|evaluation of cancer risk factors|
75751348|NCT03985228|Dietary Supplement|Fortified milk|Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose <0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
75900378|NCT02305472|Device|NeoVas BCS|Subjects receiving NeoVas BCS
75900379|NCT02305550|Device|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
75909647|NCT03710720|Behavioral|Trauma Focused-Cognitive Behavioral Therapy|Effective form of trauma therapy for adolescents
75909648|NCT03690596|Other|NRT + QuitBuddy|QuitBuddy treatment app and 1 month supply of 4 mg nicotine lozenge
75751349|NCT03985228|Dietary Supplement|Placebo milk|"Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose <0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a."
75909649|NCT03690596|Other|NRT + QuitBuddy-Recall|QuitBuddy-Recall treatment app and 1 month supply of 4 mg nicotine lozenge
75909650|NCT03690596|Other|Treatment as Usual|1 month supply of 4 mg nicotine lozenge
75751350|NCT01058980|Procedure|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
75751351|NCT01058980|Procedure|No additional ablation|Presence of dormant PV conduction, no additional ablation.
75751352|NCT01058980|Procedure|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
76066878|NCT04135859|Behavioral|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
75751353|NCT01058980|Procedure|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
75751354|NCT00894725|Procedure|laparoscopic left colonic resection|laparoscopic colonic resection
75751355|NCT00894725|Procedure|open left colonic resection|conventional open colonic resection
75751356|NCT05278637|Drug|Aspirin|Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
75751357|NCT05278637|Drug|Ticagrelor|Ticagrelor 90mg BID x 4 weeks
76066879|NCT04135859|Behavioral|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
75455049|NCT01755923|Drug|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
75751358|NCT00897533|Genetic|gene mapping|
75751359|NCT00897533|Genetic|polymorphism analysis|
75751360|NCT00897533|Other|diagnostic laboratory biomarker analysis|
75751361|NCT00897533|Other|immunohistochemistry staining method|
75751362|NCT00897611|Procedure|DNA methylation analysis|
75751363|NCT00897611|Procedure|polymerase chain reaction|
75751364|NCT00897611|Procedure|computed tomography|
75751365|NCT00897611|Procedure|magnetic resonance imaging|
75455050|NCT01755923|Drug|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
75455051|NCT01755936|Other|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
75455052|NCT01755936|Other|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
75751366|NCT00900965|Device|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
75751367|NCT00900965|Device|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
75751368|NCT00901043|Dietary Supplement|Walnut supplementation|Eight weeks of walnut supplementation
75751369|NCT00901043|Dietary Supplement|Ad lib diet|Eight weeks without walnut supplementation
75751370|NCT00901121|Device|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
75751371|NCT00901121|Device|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
75751372|NCT04017377|Drug|Drug: Cisplatin; nab-paclitaxel|Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)
75606299|NCT01072929|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
75606300|NCT01072929|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
76066880|NCT04133948|Drug|Domatinostat|"Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks)."
76066881|NCT04133948|Drug|Nivolumab|2 courses nivolumab 240 mg q3weeks
75455053|NCT01755936|Other|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
75900380|NCT03673852|Behavioral|WE Harambee|WE Harambee is a 6-month intervention, comprised of twice a week group meetings for 12 weeks, followed by a second 12 weeks of individual peer coaching/navigation. WE Harambee aims to enhance access to and engagement in primary care and behavioral health services, as well as improve overall health and well-being, including the 8 dimensions of wellness and social determinants of health.
75751373|NCT02539901|Behavioral|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
75751374|NCT02539901|Behavioral|Free hearing test categorization|Free hearing test categorization evaluation
75455054|NCT01755962|Other|Glycemic Load|
75751375|NCT02539901|Behavioral|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
75751376|NCT02539901|Behavioral|psychomotor infancy development scale|
76066882|NCT04133948|Drug|Ipilimumab|2 courses ipilimumab 80 mg q3weeks
75455055|NCT01755962|Other|Resistance Training|
75455056|NCT01755988|Other|Educational website (in addition to usual care).|
75455057|NCT01755988|Other|Website and interactive platform with telemonitoring.|
75455058|NCT01756001|Device|GlowCap|The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
75455059|NCT01756001|Behavioral|Daily email, text message, or phone call reminders|
76066883|NCT04126642|Behavioral|Assessment only group|Individuals randomized to this group will receive radiation therapy as usual plus baseline, follow-up, and EMA assessments.
76066884|NCT04126642|Behavioral|Intervention group|Individuals randomized to the intervention group will complete the same measures (in person and daily EMAs) as the assessment only group, but will additionally receive messaging that is tailored to patient responses on EMAs.
75455060|NCT01756001|Behavioral|Paid for adherence|
75455061|NCT01756027|Device|Ulthera System providing one treatment per cheek|Focused ultrasound energy delivered below the surface of the skin per cheek.
75455062|NCT01756027|Device|Ulthera System providing two treatments per cheek|Focused ultrasound energy delivered below the surface of the skin
75455063|NCT01756066|Behavioral|Different levels of cost sharing|
75606301|NCT02875197|Other|Running on a treadmill at 6 different speeds|All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
75606302|NCT04305015|Device|NOL Guided Analgesia|NOL values exceeding 25 will typically be treated with boluses of fentanyl 50 µg at roughly 5-minute intervals. The target will be maintained until surgery ends
75606303|NCT04305015|Other|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 50 µg can be given per clinical judgement
75606304|NCT04304937|Other|patient reported outcome measure|2 questionnaires are tested against each other
75606305|NCT01231607|Drug|1mg Finasteride active|1mg finasteride active, by mouth once daily
75606306|NCT01231607|Drug|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
75606307|NCT01231607|Drug|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
75606308|NCT01231607|Drug|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
75606309|NCT01231607|Drug|Finasteride placebo|finasteride placebo, by mouth once daily
75751377|NCT02539901|Behavioral|"NEPSY (two domains: memory and learning and attention and executive functions)."|NEPSY evaluation
75751378|NCT00897845|Genetic|RNA analysis|
75751379|NCT00897845|Genetic|microarray analysis|
75751380|NCT00897845|Other|immunohistochemistry staining method|
75606310|NCT01231607|Drug|Dutasteride placebo|dutasteride placebo, by mouth once daily
75900381|NCT03673852|Behavioral|Behavioral Health Home Enrollment|A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
75900382|NCT03506516|Dietary Supplement|Mixing alcohol|Alcoholic beverages, different types
75900383|NCT03506516|Dietary Supplement|Single type alcohol|Alcoholic beverages, different types
75900384|NCT02312492|Other|Oleic Diet|The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
75900385|NCT02312492|Other|Palmitic Diet|The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
75455064|NCT01756092|Procedure|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
75606311|NCT04304547|Drug|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2|"Subject of sequence A takes IP in the following order:~Each tablet of CKD-828 and D097 and D337 be taken at once~CKD-348 T1 1 tablet~CKD-348 T2 1 tabet"
75606312|NCT04304547|Drug|CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,|"Subject of sequence B takes IP in the following order:~CKD-348 T1 1 tablet~CKD-348 T2 1 tablet~Each tablet of CKD-828 and D097 and D337 be taken at once"
75606313|NCT04304547|Drug|CKD-348 T2, CKD-348 T1, CKD-828, D097, D337|"Subject of sequence C takes IP in the following order:~CKD-348 T2 1 tablet~Each tablet of CKD-828 and D097 and D337 be taken at once~CKD-348 T1 1 tablet"
75606314|NCT01231373|Drug|polidocanol injectable foam, 0.125%|active placebo for blinding
75606315|NCT01231373|Drug|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
75751381|NCT00897845|Other|laboratory biomarker analysis|
75751382|NCT00897923|Procedure|radionuclide imaging|
75751383|NCT00897923|Radiation|indium In 111-labeled autologous peripheral blood mononuclear cells|
75751384|NCT00897923|Radiation|indium In 111-labeled autologous polymorphonuclear leukocytes|
75455065|NCT01756105|Drug|Metformin|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
75606316|NCT01231373|Drug|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
75606317|NCT01231373|Drug|Vehicle|injection of vehicle comparator
75606318|NCT00975130|Biological|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
75606319|NCT00975130|Biological|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
75606320|NCT01230827|Drug|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
75606321|NCT01230827|Drug|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
75751385|NCT00894881|Procedure|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
75751386|NCT00901277|Behavioral|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
75606322|NCT01230827|Drug|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
75900386|NCT02312492|Other|Stearic Diet|The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
75900387|NCT02312570|Device|PRP Concepts Fibrin Bio-Matrix|Administration of PRP Concepts Fibrin Bio-Matrix to wound in addition to usual and customary care
75900388|NCT02312570|Other|Usual and Customary Practice|Ussual and customary care of non-healing pressure wounds
75455066|NCT01756105|Drug|Rapid acting analog insulin Intermediate acting NPH Insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
75606323|NCT01230749|Drug|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
75606324|NCT01230749|Drug|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
75606325|NCT01230749|Drug|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
75606326|NCT02865694|Other|Cascade|
75606327|NCT04292392|Other|preop ACB, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~Ropivacaine 5mg/ml (49.25ml)~Epinephrine 1mg/ml (0.5ml)~Ketorolac 30mg/ml (1ml)~Clonidine 0.1mg/ml (0.8ml)~Saline 48.45ml"
75606328|NCT04292392|Other|preop ACB+IPACK block|Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
75751387|NCT00901277|Behavioral|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
75751388|NCT04035785|Drug|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
75751389|NCT00898079|Other|Cytology Specimen Collection Procedure|Correlative studies
75751390|NCT04035707|Drug|Rocuronium|using rocuronium as a relaxants during general anaesthesia
75909651|NCT04933396|Diagnostic Test|ultrasound diagnostic criteria|evaluate using the recent consensus based definition for FGR using biometric and Doppler parameters to identify fetuses at risk of adverse perinatal outcomes compared to using solely biometric based parameter (EFW <10th percentile according to the Hadlock growth standard).
75751391|NCT04035707|Drug|general volatile anaesthesia|method of anaesthesia
75751392|NCT00901433|Device|Personal WheezoMeter|pulmonary sounds analyzer
75751393|NCT00898157|Other|laboratory biomarker analysis|
75751394|NCT02539745|Other|Vitamin D receptor polymorphic analysis|Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
75751395|NCT02539745|Other|Serum levels of 1a, 25-Dihydroxyvitamin D3|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
75751396|NCT00894959|Biological|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
75751397|NCT00894959|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
75751398|NCT04035395|Other|Peer-led Support Group|The Viviendo Saludable pláticas (or talks) connected Salud y Vida participants living with diabetes together. These talks served as a forum for Salud y Vida participants to share their knowledge and experiences, including some that many health workers, friends, or family do not have. Viviendo Saludable helped participants develop better strategies for managing their diabetes in their daily life. The Viviendo Saludable pláticas complement and enhance the other services by helping participants create a network of emotional, social, and practical support needed to manage diabetes and stay healthy over the long term. Classes met once a week for one hour at locations central to participants' homes.
75751399|NCT04035395|Other|Behavioral Health Consult|In a Behavioral Health consult, a participant meets with a counselor for one or more thorough meetings to talk about things that influence their health and well-being. A participant receiving a Behavioral Health consult receives support and is empowered with health coping skills that will allow for improved medication adherence and motivation to control their diabetes.
75455067|NCT01756131|Drug|GSK1265744 injectable suspension|200 milligram per milliliter sterile solution for injection
75455068|NCT01756131|Other|Placebo to match injectable suspension|placebo
75455069|NCT01756144|Device|rhBMP-2|
75455070|NCT01756170|Drug|paclitaxel|
75455071|NCT01756170|Drug|cisplatin|
75455072|NCT01756170|Radiation|Radiotherapy|
75455073|NCT01756183|Drug|S-1 + Paclitaxel Chemotherapy|"Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1"
75455074|NCT01756196|Drug|Spinal Steroid Injection|Steroid Injection
75455075|NCT01756261|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
75751400|NCT04035395|Other|Medication Therapy Management Consult|Medication Therapy Management helps participants and their doctors make sure that their medications are working to improve their health. In a Medication Therapy Management (MTM) consult, a pharmacist gives participants a comprehensive review of all their medications and speaks with them about 1) how well their medications are working, 2) whether their medications have side effects, 3) if there might be interactions between the drugs their taking, 4) whether costs can be lowered and 5) other problems participants are having. The participant will get a written summary of this discussion, including an action plan that recommends what can be done to make the best use of their medications.
75900389|NCT03670446|Other|Pharmacists' intervention|"Medication education: When the patient is enrolled in the intervention group, pharmacists issue an education manual to give a medical education which contains the reasons for using NOACs, the characteristics of the drug, the precautions, and how to monitor the efficacy. Pharmacists re-educate through telephone or clinic during follow-up.~Establish a medical record and remind their follow-up by message, phone every 2 weeks.~Follow-up in the 4th week and 8th week : Pharmacists recommend patients for drug therapy optimization after conducting a full pharmacotherapy review of each patient's medication regimen and remind them to test urinary occult blood every 1-3 months, detect hemoglobin and liver/kidney function every 3-6 months."
75900390|NCT02643394|Drug|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
75455076|NCT01756287|Other|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
75455077|NCT01756313|Procedure|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
75455078|NCT01756326|Drug|PREOB® Implantation|
75455079|NCT01756326|Procedure|Bone Autograft|
75455080|NCT01756378|Procedure|joint mobilization with movement|
75455081|NCT01756378|Procedure|traditional physical therapy program|I.R, stretching exercises, strengthen exercises
75751401|NCT04035395|Other|La Cocina Alegre/ The Happy Kitchen|The Happy Kitchen is a program where people come together to learn skills and self-sufficiency in preparing healthy, economical meals, laugh, cook, and enjoy food together. The cooking and nutrition program is an interactive 6-week series of classes, where the essential skills for healthy eating is taught and emphasis is placed on the selection and preparation of fresh, seasonal foods that are nutritious, economical, and delicious. Classes meet once a week for 1 ½ hours to cook, discuss, and learn together. All participants leave each class with recipes and groceries to practice new cooking skills.
75455082|NCT01756404|Drug|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
75455083|NCT01756404|Drug|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
75751402|NCT04035395|Other|Mind, Exercise, Nutrition, Do it!|MEND is a diet and exercise education program that helps families support their kids, ages 6-13, to reach a healthy weight. The program teaches adults and their children how to maintain energy and confidence throughout the day while learning how to cook healthy meals. Each program lasts 10 weeks and classes are 2 times per week. An adult must attend with the child.
75751403|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
75751404|NCT00901589|Dietary Supplement|thistle oil|four capsules a day
75751405|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
75751406|NCT00901589|Dietary Supplement|Thistle oil|Four capsules daily
75751407|NCT04035083|Device|Laser activated irrigation|Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
75751408|NCT04035083|Device|Passive ultrasonic irrigation|ultrasonic activation inside the canal for 1 min
75751409|NCT00895115|Dietary Supplement|vitamin E|Given once daily
75751410|NCT00895115|Procedure|sham intervention|No supplementation
75900391|NCT02643394|Drug|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
75455084|NCT01756417|Drug|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
75751411|NCT02540759|Dietary Supplement|Buglossoides oil|
75751412|NCT02540759|Dietary Supplement|High Oleic Sunflower Oil|
75751413|NCT00901745|Drug|Angiotensin II|Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
75751414|NCT00901745|Drug|Noradrenaline infusion|Infusion of up to 480 picomol/ml of noradrenaline will be infused.
75751415|NCT02540837|Drug|Bupivacaine|Obturator nerve block
75751416|NCT02540837|Drug|Saline|Obturator nerve block with saline(placebo)
75900392|NCT02143674|Other|Muscle stretching and Strength Training|"Each step of stretching on specific muscles was repeated three times by keeping the posture for 30 seconds, (Arnold and Kokkonen, 2007; Toraman A, Yildirim. 2010; Dai, Ware, Giuliani, 2012; Duque et al., 2013; Granacher et al., 2013). The Pectoral, Quadriceps, Paraspinal, Abdominal and Ischial tibial and sural triceps muscles were elongated.~Strength Training Muscle strengthening was performed using weights and dumbbells. The training load individually determined through the test of strength with 10 repetitions maximum. The load was reevaluated four weeks of training. The Abdominal, Paraspinal, Quadriceps and Posterior thigh muscles (hamstrings) were submitted to the intervention protocol."
75900393|NCT02143674|Other|Educated about physical exercises|
75900394|NCT02308904|Other|Blood Draw/Semen Exam|"Females:~1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older)."
75455085|NCT01756417|Drug|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
75751417|NCT00898391|Other|laboratory biomarker analysis|Correlative studies
75751418|NCT00898391|Genetic|polymerase chain reaction|Correlative studies
75751419|NCT00898391|Genetic|polyacrylamide gel electrophoresis|Correlative studies
75909652|NCT04932928|Device|FreeStyle Libre|Flash glucose monitoring + Education on lifestyle modification
75455086|NCT01756430|Drug|Carvedilol SR 32mg, QD|"Carvedilol SR 32mg QD for 4 weeks~With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
75455087|NCT01756430|Drug|Carvedilol SR 64mg, QD|"Carvedilol SR 64mg QD for 4 weeks~With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
75751420|NCT00898391|Genetic|DNA analysis|Correlative studies
75751421|NCT00901823|Drug|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
75751422|NCT00901823|Drug|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
75751423|NCT00898469|Genetic|polymorphism analysis|
75751424|NCT00606593|Drug|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75455088|NCT01756430|Drug|Carvedilol IR 25mg, QD|"Carvedilol IR 25mg QD for 4 weeks~With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks."
75455089|NCT01756430|Drug|Carvedilol IR 25mg, BID|"Carvedilol IR 25mg BID for 4 weeks~With the others investigation product placebo 2 capsules QD for 4 weeks."
75751425|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75751426|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75606329|NCT04292392|Other|preop ACB+IPACK block, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~Ropivacaine 5mg/ml (49.25ml)~Epinephrine 1mg/ml (0.5ml)~Ketorolac 30mg/ml (1ml)~Clonidine 0.1mg/ml (0.8ml)~Saline 48.45ml"
75751427|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75751428|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75751429|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75751430|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75751431|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75751432|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75909653|NCT04932928|Device|Blood glucose meter|Self monitoring of blood glucose + Education on lifestyle modification
75909654|NCT04932772|Other|Kinesiotaping|Technique: Include Rectus Abdominas Muscles (RAM), Oblique Abdominal Muscles (OAM). Tape will be applied on RAM using muscles technique from origin to insertion of muscle with a tension between15-35%. Band will be start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xyphoid process. Finally will perform on the right and left external oblique muscles the procedure will be start with no tension from bottom and of 6-12 ribs and then the hip will be place in flexion and rotation to opposite direction and the band will tape on pubic bone with tension between 15-35% (Kase et al., 2003).
75455090|NCT01756443|Drug|2% lidocaine/adrenaline and 0.5% bupivacaine|
75455091|NCT01756469|Behavioral|Behavioral Intervention for Alcohol Use|Behavioral Intervention for Alcohol Use
75455092|NCT01756495|Drug|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
75455093|NCT01756495|Drug|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
75455094|NCT01756495|Drug|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
75455095|NCT01756495|Drug|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
75606330|NCT00903175|Drug|everolimus|Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
75606331|NCT00903175|Drug|sunitinib|Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
75751433|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
75751434|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
75751435|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 3mcg
75751436|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 15mcg
75751437|NCT00902057|Drug|placebo|saline subcutaneous
75751438|NCT00895349|Procedure|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
75751439|NCT00895349|Procedure|CT Abdomen and Pelvis scan|Pre-treatment scan
75751440|NCT00898547|Other|immunoenzyme technique|
75455096|NCT01756508|Drug|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
75455097|NCT01756521|Drug|Moxifloxacin|
75455098|NCT01756534|Device|SURGICEL|Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
75606332|NCT01229735|Drug|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
75606333|NCT01229735|Drug|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
75751441|NCT00898547|Other|laboratory biomarker analysis|
75751442|NCT04035941|Behavioral|Cycle Nation Multicomponent Intervention|"This intervention group will receive 4 elements:~Practical skills programme: a workplace-based programme covering basic cycling skills, delivered by trained 'cycle champions' - HSBC staff members.~Cycle provision scheme: participants will have the opportunity to have their own bicycles serviced or obtain a loaned bike or e-bike from local bike shops before the start of the programme.~Cycle-friendly workplace culture: all offices taking part will have a minimum of secure bike parking facilities as part of an ongoing roll-out of cycle infrastructure across HSBC UK offices.~Our Cycle Hub app: an adapted version of an existing HSBC app including route planning, goal setting and practical skills videos, as well as supportive social interaction among participants."
75751443|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
75751444|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
75751445|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
75751446|NCT00898703|Other|flow cytometry|
75751447|NCT00898703|Other|immunoenzyme technique|
75606334|NCT03866200|Drug|resveratrol|125 mg/day or 5 ml once per day for 90 days
75606335|NCT03866200|Drug|Placebo|5 ml once per day for 90 days
76066885|NCT04107948|Other|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42), Haute-Loire (43) or Ardèche (07) for 2 months."
75606336|NCT02742493|Other|0.028 bonded to canines|lower fixed canine and canine retainer (0.028 stainless steel bonded to canines) and upper removable Hawley (Intervention A)
75606337|NCT02742493|Other|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer (7-strand Twistflex 0.027 bonded to all six anterior teeth) and upper removable Hawley (Intervention B)
76066886|NCT04107948|Other|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
75606338|NCT02742493|Other|removable Hawley-type|lower Hawley-type and upper Hawley removable retainer (Control)
76066887|NCT04103892|Drug|CLE-100|1 tablet of CLE-100 administered once daily
75606339|NCT02848495|Genetic|Non-Interventional|
76066888|NCT04103892|Drug|placebo|1 tablet of placebo administered once daily
75751448|NCT00898703|Other|laboratory biomarker analysis|
75751449|NCT02539589|Behavioral|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
75455099|NCT01756547|Drug|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
75455100|NCT01756547|Drug|Placebo|
75455101|NCT01756599|Biological|blood samples|
75455102|NCT01756612|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
75455103|NCT01756638|Drug|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
75455104|NCT01756638|Drug|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
75455105|NCT01756651|Drug|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
75455106|NCT01756664|Other|Sunscreen|
75606340|NCT02848183|Drug|Cytarabine|
75606341|NCT02848183|Drug|Idarubicin|
75606342|NCT02848183|Drug|Mitoxantrone|
75606343|NCT02848183|Drug|Etoposide|
75606344|NCT02848183|Procedure|Hematopoietic stem cell transplantation|
75606345|NCT00974974|Drug|IPX066|extended-release carbidopa-levodopa capsules
75606346|NCT00974974|Drug|IR CD-LD|immediate-release carbidopa-levodopa tablets
75606347|NCT02715583|Drug|11C-Acetate|
75606348|NCT02848417|Drug|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
75606349|NCT02848417|Drug|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
75606350|NCT02848417|Other|Placebo|"Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
76066889|NCT04082936|Drug|imvotamab|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
76066890|NCT04071756|Drug|Topical Tazarotene|This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin
76066891|NCT04071756|Other|Placebo|A substance that has no therapeutic effect, used as a control in testing new drugs
76066892|NCT04070183|Behavioral|POST Facilitation|Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
76066893|NCT04070183|Behavioral|Home Safety Evaluation|Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
76066894|NCT04068610|Drug|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
76066895|NCT04068610|Drug|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
76066896|NCT04068610|Drug|FOLFOX|Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
76066897|NCT04068610|Drug|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
76066898|NCT04057833|Drug|E-CEL UVEC|Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site
76066899|NCT04057040|Drug|PTG-300|Active
76066900|NCT04057040|Drug|Placebo|Placebo
76066901|NCT04038138|Diagnostic Test|Validation of new COA for FSHD patients|Monitoring of commonly used and news COA in patients with facioscapulohumeral muscular dystrophy
76066902|NCT04005690|Drug|Cobimetinib|Given PO
76066903|NCT04005690|Drug|Olaparib|Given PO
75751450|NCT02539589|Behavioral|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
75606351|NCT04221841|Other|descriptive|correlation
75751451|NCT00902213|Behavioral|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
75751452|NCT00902213|Behavioral|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
75751453|NCT02540369|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
75455107|NCT01756664|Other|Vaseline|
75606352|NCT04204642|Other|CAA patients data collection|Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
75455108|NCT01756703|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
75455109|NCT01756703|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
75455110|NCT01756703|Drug|Placebo|Placebo for 8 weeks
75751454|NCT00902369|Drug|AK106-001616|Part1: Dose escalation Part2: Dose expansion
75751455|NCT00902369|Drug|Placebo|
75455111|NCT01756716|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
75455112|NCT01756716|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
75606353|NCT02847403|Drug|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
75606354|NCT02847403|Other|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
75606355|NCT04801537|Other|normal body temperature and warm extremities|environmental temperature is set according to the standard method to keep normal body temperature and warm extremities
75606356|NCT04801537|Other|normal body temperature and cold extremities|environmental temperature is set according to the standard method to keep normal body temperature, but cold extremities
75751456|NCT00902369|Drug|Active comparator|
75751457|NCT02540135|Other|fluorescein|fluorescein and conventional neuro-navigation
75751458|NCT02540135|Other|intraoperative MRI|conventional neuro-navigation and iMRI
75751459|NCT00905879|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
76066904|NCT04005690|Drug|Onvansertib|Given PO
75455113|NCT01756716|Drug|Placebo|Placebo for 8 weeks
75455114|NCT01756729|Device|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
75455115|NCT01756742|Other|Respiratory physiotherapy|"The respiratory physiotherapy intervention included:~Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry."
75751460|NCT02539433|Procedure|F-18-F-DOPA|F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
75751461|NCT00605267|Drug|Tamoxifen|20 mg once daily oral dose
75751462|NCT00605267|Drug|Anastrazole (Arimidex)|1 mg once daily oral dose
75751463|NCT00605267|Drug|Goserelin acetate (Zoladex)|3.6mg/month depot injection
76066905|NCT04005690|Drug|Temuterkib|Given PO
76066906|NCT03997370|Procedure|Biospecimen Collection|Undergo collection of blood samples
75455116|NCT01756742|Other|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
75455117|NCT01756755|Device|PMX-20R Hemoperfusion|Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
75455118|NCT01756768|Radiation|[14C]-PD-0332991|A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of [14C]-PD-0332991.
75455119|NCT01756781|Drug|Midazolam|Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
75606357|NCT02863900|Other|cohort of BC of each subtypes|
75606358|NCT02848339|Drug|aspirin|aspirin desensitization
75606359|NCT04288492|Behavioral|Respiratory biofeedback|Repeat the inspiration and exhalation breaths for a fixed period of time using a biofeedback device (ResCalm)
75751464|NCT02539355|Other|Diet A|12-week diet
75751465|NCT02539355|Other|Diet B|12-week Diet
75751466|NCT00902525|Drug|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
75751467|NCT00902603|Drug|Commercial Ventavis® (iloprost)|Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
76066907|NCT03997370|Drug|Carboplatin|Given IV
76066908|NCT03997370|Drug|Iohexol|Given IV
76066909|NCT03981926|Other|Team-Based Connected Health (TCH)|TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
75606360|NCT04288180|Other|No intervention|There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
75606361|NCT02847481|Procedure|fecal microbiota transplantation|fecal microbiota transplantation
75606362|NCT02847481|Drug|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
75606363|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v1)|FMT with antibiotic pre-treatment (v1)
75455120|NCT01756781|Drug|PD-0332991|Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
75455121|NCT01756781|Drug|Midazolam|"Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone."
75455122|NCT01756781|Drug|PD-0332991|Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
75606364|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v2)|FMT with antibiotic pre-treatment (v2)
76066910|NCT03961971|Drug|MBG453|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
75751468|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
75751469|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
75900395|NCT02308904|Other|Retrospective data/Chart Review/Relevant Clinical Results|"1. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2* MRI. 4. Ferritin levels.~NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~1. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~1. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement."
76066911|NCT03938298|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standards of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
75455123|NCT01756794|Procedure|Liver transplantation|
75455124|NCT01756807|Device|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
75455125|NCT01756820|Procedure|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
75455126|NCT01756820|Procedure|Knifelight|A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
75455127|NCT01756859|Procedure|MRI Scan|
75455128|NCT01756872|Procedure|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
75455129|NCT01756911|Device|MFM|Implantation of the MFM
75606365|NCT04287634|Other|Segmental Mobilization|Hot fermentation =10 minutes Soft tissue mobilization =5 minutes Targeted segmental mobilization= 3 sets of 10 repetitions Home plan exercise= cervical muscles stretching, postural care.
75606366|NCT04287634|Other|Entire Spine Mobilization|Hot fermentation=10 minutes Soft tissue mobilization=5 minutes Entire spine mobilization =3 sets of 10 repetitions Home plan exercises=cervical muscles stretches, postural care.
75606367|NCT04795453|Other|score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
75751470|NCT00906113|Drug|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
75751471|NCT00906113|Drug|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
75751472|NCT00906191|Drug|SAM-531|
75751473|NCT00902759|Other|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
75751474|NCT04035317|Drug|Aesculus Hippocastanum / Horse Chestnut|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
76066912|NCT03938298|Other|Smoking cessation counseling|"Participants in the control group will receive standard of care only, i.e. i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
76066913|NCT03921827|Device|Enhance External Counterpulsation Therapy|EECP therapy would be administered to this group for 1-hour a day for a total of 35 sessions
76066914|NCT03919968|Behavioral|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
75455130|NCT01756937|Drug|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
75455131|NCT01756937|Drug|Placebo|1 capsule once daily for 24 weeks
75455132|NCT01756950|Biological|2 mg/kg CR8020|administered as a single 2-hour intravenous infusion
75455133|NCT01756950|Biological|5 mg/kg CR8020|administered as a single 2-hour intravenous infusion
75455134|NCT01756950|Biological|15 mg/kg CR8020|administered as a single 2-hour intravenous infusion
75606368|NCT04795453|Other|usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
75606369|NCT04287712|Diagnostic Test|Plasma lipids|Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
75606370|NCT04288102|Biological|UC-MSCs|3 does of UC-MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.
75606371|NCT04288102|Biological|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo（intravenously at Day 0, Day 3, Day 6）
75606372|NCT02848261|Behavioral|Developmental Demands|Education and training related to use of CGM in this age group
75455135|NCT01756950|Biological|30 mg/kg CR8020|administered as a single 2-hour intravenous infusion
75606373|NCT02848261|Behavioral|Distress Reduction|Education and training on reducing distress
75606374|NCT02848261|Behavioral|Remote Monitoring|Education and training on the use of remote monitoring
75606375|NCT02848261|Behavioral|Fear of Hypoglycemia|Education and training on reducing fear of hypoglycemia
75606376|NCT02848261|Behavioral|No intervention|No intervention - serves as the control group
75606377|NCT04287244|Device|Transcutaneous Spinal Direct Current Stimulation|tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
75751475|NCT04035317|Drug|Placebo|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
75751476|NCT00902837|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
75455136|NCT01756950|Biological|50 mg/kg CR8020|administered as a single 2-hour intravenous infusion
75751477|NCT00902837|Drug|oxycodone prolonged release tablet|
75751478|NCT00902837|Drug|oxycodone naloxone tablet|
75900396|NCT02308904|Other|Pituitary MRI|"MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted."
75900397|NCT03545646|Device|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
75455137|NCT01756950|Biological|Placebo|administered as a single 2-hour intravenous infusion
75455138|NCT01756989|Drug|Thalidomide, etoposide, celecoxib|"Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day."
75606378|NCT02848105|Drug|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
75455139|NCT01757002|Behavioral|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.|Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.
75455140|NCT01757002|Behavioral|Teens in the control group will receive generic, web-based asthma education.|Web-based, generic asthma management intervention delivered in 4 sessions.
75455141|NCT01757015|Drug|NVA237|NVA237 (50µg, o.d. via SDDPI) in the morning,
75455142|NCT01757015|Drug|Placebo to NVA237|Placebo to NVA237
75606379|NCT02864524|Other|Manipulative and Massage Therapy|
75606380|NCT02864524|Other|Exercise Program|
75606381|NCT02847871|Behavioral|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:~Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.~Perform a nutritional assessment by a dietician followed by appropriate care management.~Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.~At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;~Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
75606382|NCT04288024|Behavioral|Weight-shifting training|"Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time."
75751479|NCT00899015|Other|pharmacological study|
75751480|NCT00605813|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
75751481|NCT00899093|Other|Cytology Specimen Collection Procedure|Correlative studies
75751482|NCT00899093|Other|Laboratory Biomarker Analysis|Correlative studies
75751483|NCT00906269|Drug|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
75455143|NCT01757054|Dietary Supplement|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
75455144|NCT01757080|Other|Cardiorespiratory performance assessment with ergospirometry test|
75455145|NCT01757080|Other|Biochemical analysis|
75455146|NCT01757093|Device|Automatic Tube Compensation plus CPAP|SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
75455147|NCT01757093|Device|Continuous Positive Airway Pressure|SPONTANEOUS BREATHING TRIAL WITH CPAP
75455148|NCT01757106|Drug|Xenon|general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
75455149|NCT01757106|Drug|sevoflurane|general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
75455150|NCT01757132|Device|Implantable Miniature Telescope|Device - Implantable Miniature Telescope
76066915|NCT03919968|Behavioral|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
75900398|NCT03101644|Drug|Darunavir|The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
76066916|NCT03899649|Drug|SOC|Standard of Care treatment
75900399|NCT03115918|Device|Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm to have a PD stent placed.
75606383|NCT02847793|Behavioral|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
75455151|NCT01757145|Drug|Eltrombopag|"From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count >50,000/microliter will be reached again)."
75455152|NCT01757158|Radiation|Cs-131 brachytherapy seeds|Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
75455153|NCT01757223|Biological|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
75455154|NCT01757223|Biological|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
75900400|NCT03115918|Other|No Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm and not receive PD placement.
75900401|NCT03508466|Behavioral|hypersensitivity reaction|Previous hypersensitivity reaction
75900402|NCT03545100|Other|motor control therapy|scapular muscle progressive resistive exercise(PRE)
75900403|NCT03545100|Other|regular physical therapy|transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
75900404|NCT03132272|Device|Immunoadsorption with Globaffin|Immunoadsorption for treatment of persons with Alzheimer Dementia
75455155|NCT01757236|Drug|VANCOMYCIN|
75455156|NCT01757236|Drug|CEFTRIAXONE|
75455157|NCT01757236|Drug|CLINDAMYCIN|
75455158|NCT01757236|Drug|SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)|
75455159|NCT01757236|Drug|FLUOROQUINOLONE|
75900405|NCT03627234|Behavioral|Same Day Discharge|Patients will be randomized to same day discharge
75455160|NCT01757236|Drug|LINEZOLID|
75455161|NCT01757236|Drug|RIFAMPIN|
75455162|NCT01757249|Drug|Combined Oral Contraceptive Pill (Microgynon 30)|Pre-IVF treatment for 8 weeks
75455163|NCT01757262|Drug|90 mg Ticagrelor|Morning and Evening dose for 5 days
75606384|NCT02847793|Behavioral|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
75606385|NCT02847325|Drug|AC0058TA|50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
75606386|NCT02847325|Drug|Placebo capsules|Placebo capsules
75606387|NCT04216303|Diagnostic Test|hemoglobin A1c|The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.
75606388|NCT02847013|Drug|TAP block w Liposomal bupivacaine|TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
75900406|NCT03627234|Behavioral|Overnight Stay|Patients will be randomized to stay overnight
76066917|NCT03899649|Device|NanoKnife System|Irreversible Electroporation
76066918|NCT03882372|Device|Nasal high flow|See arm description.
76066919|NCT03879135|Biological|rVWF|Recombinant von Willebrand factor
76066920|NCT03879135|Biological|rFVIII|Recombinant Factor VIII
76066921|NCT03874936|Drug|Dexamethasone 24mg Solution for Injection|Administrated i.v.
76066922|NCT03874936|Drug|Saline Solution for Injection|administrated i.v.
76066923|NCT03870854|Procedure|PEFA VT ablation technique|Catheter ablation guided by PEFA technique
76066924|NCT03860844|Drug|Isatuximab|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
75751484|NCT00906269|Drug|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
75606389|NCT02847013|Procedure|TAP block w normal saline|TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
75751485|NCT02538653|Other|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
75900407|NCT02305706|Procedure|starting position in colonoscopy|
75900408|NCT02623309|Biological|Allogeneic (Allo) hematopoietic stem cell transplantation|
75900409|NCT05068804|Procedure|Cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
75455164|NCT01757262|Drug|75mg Clopidogrel|Morning dose for 5 days
75455165|NCT01757314|Behavioral|ultrasound technique|instruction in the ultrasound technique
75606390|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment|"Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
75900410|NCT05068804|Other|control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
76066925|NCT03860844|Drug|Dexamethasone or equivalent|Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
76066926|NCT03860844|Drug|Fludarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
75455166|NCT01757314|Other|palpation technique|placement of a line via palpation technique
75455167|NCT01757327|Drug|Erismodegib|
75455168|NCT01757327|Drug|Placebo|
75455169|NCT01757340|Behavioral|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
75455170|NCT01757340|Behavioral|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
75455171|NCT01757353|Behavioral|BASICS motivational interview|
75455172|NCT01757353|Behavioral|BASICS plus normative enhancement motivational interview|
75455173|NCT01757353|Behavioral|Self-directed: Information only|
75455174|NCT01757366|Drug|Ginsenoside Rg3 plus First-line Chemotherapy|"Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression"
75455175|NCT01757366|Drug|First-line Chemotherapy|XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
75751486|NCT02538653|Other|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
75751487|NCT00902915|Drug|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
75455176|NCT01757379|Dietary Supplement|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
75455177|NCT01757379|Dietary Supplement|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
75751488|NCT02538575|Other|6-minute walk test|a walk of 6 minutes repeated twice in an interval of 30 minutes
75751489|NCT02540057|Procedure|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
75751490|NCT02540057|Procedure|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
75751491|NCT00902993|Drug|AZD1446|Solution, oral single and multiple dose
75751492|NCT00902993|Drug|Placebo|Placebo
76066927|NCT03860844|Drug|Cytarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
76066928|NCT03860844|Drug|Liposomal daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
76066929|NCT03860844|Drug|Daunorubicin (nonliposomal)|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
75606391|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment and behavioural activation|"Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
75455178|NCT01757379|Dietary Supplement|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
75606392|NCT01233869|Drug|Bosutinib|Once daily oral dose of 200 mg of bosutinib
75751493|NCT00922493|Other|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.~An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
75751494|NCT00899171|Genetic|DNA analysis|
75751495|NCT00899171|Genetic|DNA methylation analysis|
75751496|NCT00899171|Genetic|RNA analysis|
75751497|NCT00899171|Genetic|gene expression analysis|
75751498|NCT00899171|Genetic|reverse transcriptase-polymerase chain reaction|
75751499|NCT00899171|Other|laboratory biomarker analysis|
75751500|NCT00604721|Drug|selumetinib|Given orally
75900411|NCT03545022|Procedure|Acupuncture|"The application of acupuncture was performed in four sessions, 30 minutes prior to surgery, 24, 48 and 72 hours following the surgery, before variables measurements. The points were manually stimulated and the needles were inserted up to 4mm. There were 11 points, applied bilaterally, two of them, point VG20 and Yintang, for anxiety control, only at the preoperative time and not bilateral. The points to reduce pain, edema, and trismus were IG4 (Hegu), F3 (Taichong) and E44 (Neiting), TA21 (Ermen), ID19 (Ting-Kong), E6 (Jiagle) and E7 (Towei) , point B60 (Kunlum) and VB34 (Yanglingquan). All patients received the same treatment in all sessions.~After the needle devices were inserted, the needles were re-stimulated manually once after 10 minutes and removed after more 10 minutes."
75606393|NCT01233869|Drug|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
75455179|NCT01757379|Dietary Supplement|Inulin|15 g of inulin dissolved in 200 ml of water
75455180|NCT01757431|Drug|Eculizumab|
75606394|NCT01233869|Drug|Placebo|Once daily oral dose of placebo
75606395|NCT02847091|Drug|Ipragliflozin|Oral administration, 50mg once daily
75606396|NCT02847091|Drug|Insulin|Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
75606397|NCT02846935|Drug|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested ~60 minutes after THU capsules.
75606398|NCT02846935|Drug|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
75606399|NCT02844751|Biological|[StroMed + platelet rich plasma (PRP)]|[Day 0] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
75455181|NCT01757444|Device|BiPAP - A40|Patients receiving BiPAP AVAPS - AE ventilatory mode at home
75455182|NCT01757444|Device|BiPAP - ST|Patients receiving BiPAP- ST mode at home.
75455183|NCT01757457|Drug|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
75455184|NCT01757457|Drug|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
75751501|NCT00604721|Other|pharmacological study|
75751502|NCT04034771|Drug|Melatonin 10 MG Oral Tablet|Melatonin tablets
75751503|NCT04034771|Drug|Propofol|propofol amp
75751504|NCT04034771|Drug|Placebo oral tablet|sugar pill manufactured to mimic melatonin tablets
75751505|NCT00906581|Behavioral|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
75751506|NCT00899327|Genetic|DNA methylation analysis|
75751507|NCT00899327|Genetic|RNA analysis|
75751508|NCT00899327|Genetic|cytogenetic analysis|
75751509|NCT00899327|Genetic|gene expression analysis|
75751510|NCT00899327|Genetic|mutation analysis|
75751511|NCT00899327|Genetic|polymerase chain reaction|
75751512|NCT00899327|Genetic|protein expression analysis|
75751513|NCT00899327|Other|laboratory biomarker analysis|
75751514|NCT00899483|Drug|Glucose potassium insulin solution|Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
75751515|NCT02539121|Device|Acupuncture|Acupuncture needles
75900412|NCT05068180|Drug|low-dose neuroleptanalgesia|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
75455185|NCT01757496|Device|Cough Assist|
75751516|NCT02539199|Drug|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
75751517|NCT02539199|Drug|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
76066930|NCT03860844|Drug|Idarubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
75751518|NCT00903227|Drug|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
75751519|NCT00903227|Drug|Placebo|1 puff of inhaled Placebo twice a day
75751520|NCT00903227|Drug|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
75606400|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
75900413|NCT05068180|Drug|Placebo|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
76066931|NCT03860844|Drug|Filgrastim or equivalent|Pharmaceutical form: Solution for injection Route of administration: Intravenous
75455186|NCT01757509|Other|Intervention group|"Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling."
75455187|NCT01757548|Procedure|open operation|high ligation of spermatic vein by open operation
75455188|NCT01757548|Procedure|microsurgery|high ligation of spermatic vein by microsurgery
75455189|NCT01757574|Drug|Alemtuzumab infusion|
76066932|NCT03860844|Drug|Mitoxantrone|Pharmaceutical form: Solution for injection Route of administration: Intravenous
76066933|NCT03860844|Drug|Doxorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
75606401|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
75455190|NCT01757587|Drug|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
75606402|NCT02844829|Other|Prostate MRI|MRI of the prostate prior to prostate biobsy
75455191|NCT01757587|Drug|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
75606403|NCT02844673|Drug|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
75606404|NCT02844673|Device|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
75751521|NCT00903227|Drug|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
75751522|NCT00903227|Drug|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
75751523|NCT00605657|Drug|Valproic Acid|Oral administration of valproic acid
75751524|NCT00605657|Procedure|CT Scan|CT scans were done before and after treating the patient with valproic acid
75751525|NCT00605657|Procedure|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
75900414|NCT02143908|Dietary Supplement|lysine supplementation|
75900415|NCT02143908|Dietary Supplement|Placebo|
75900416|NCT02847364|Dietary Supplement|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
76066934|NCT03860844|Drug|Vincristine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
76066935|NCT03860844|Drug|Pegaspargase (PEG) Asparaginase|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
75455192|NCT01757600|Other|Microperimetry|
75455193|NCT01757613|Drug|AK 3012|cutaneous use twice a day
75455194|NCT01757639|Biological|Ipilimumab|Given IV
75455195|NCT01757639|Other|Laboratory Biomarker Analysis|Correlative studies
75455196|NCT01757756|Drug|Pf-05175157|200-mg administered twice daily for 14 days
75455197|NCT01757756|Drug|placebo|placebo administered twice daily for 14 days
75455198|NCT01757756|Drug|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
75751526|NCT04034849|Radiation|Photobiomodulation|Photobiomodulation whit Low-Level Laser Therapy
75900417|NCT02308982|Drug|Immunoglobulins, Intravenous (Privigen)|
75900418|NCT02308982|Drug|Placebo|
75900419|NCT05515627|Drug|Atezolizumab|Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
76066936|NCT03860844|Drug|Cyclophosphamide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
76066937|NCT03860844|Drug|Etoposide|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
75606405|NCT02847247|Drug|CCRE|Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
75751527|NCT04034849|Radiation|Placebo|Device turned off
75751528|NCT00903305|Other|medical chart review|
75900420|NCT03503708|Drug|Livitol-70|Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
75900421|NCT02144064|Drug|Heparin|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
75900422|NCT02312648|Other|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
75900423|NCT02312648|Other|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
75455199|NCT01757769|Drug|Silodosin|8 mg daily for 24 weeks
75455200|NCT01757795|Drug|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
75455201|NCT01757795|Drug|Placebo|Placebo will be intravenously administered
75900424|NCT02090530|Other|Biospecimen collection|Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
75900425|NCT02144142|Biological|Moisturizer with each subject's own antimicrobial bacteria|
75455202|NCT01757808|Drug|Ranolazine|ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
75455203|NCT01757808|Drug|Placebo|placebo at a dose of 500mg for one month followed by a dose of 1000mg.
75455204|NCT01757834|Device|SWUS Elastography|
75455205|NCT01757860|Drug|CARD-024|Comparison of different dosages of drug
76066938|NCT03860844|Drug|Methotrexate|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
75455206|NCT01757860|Other|Drug Carrier|Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
75455207|NCT01757873|Drug|Z160|
75455208|NCT01757873|Drug|Placebo|
75455209|NCT01757886|Other|Biomarkers to analyze both intracoronary thrombi as blood|
75455210|NCT01757899|Drug|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
75455211|NCT01757899|Drug|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
75455212|NCT01757912|Procedure|cuff pressure|The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
75455213|NCT01757925|Behavioral|weight managment program|a comprehensive peditric weight management program consisting of 16 weekly group sessions
75455214|NCT01757925|Other|Active Gaming|partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
75751529|NCT00903305|Other|questionnaire administration|
75751530|NCT00903305|Procedure|fatigue assessment and management|
75751531|NCT00903305|Procedure|psychosocial assessment and care|
75751532|NCT00903305|Procedure|quality-of-life assessment|
75751533|NCT00899795|Genetic|cytogenetic analysis|
75751534|NCT00899795|Genetic|fluorescence in situ hybridization|
75751535|NCT00899795|Other|flow cytometry|
75751536|NCT00899795|Procedure|biopsy|
75751537|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
75751538|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
76066939|NCT03860844|Drug|L - Asparginase|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
75606406|NCT00992992|Biological|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
75751539|NCT00903461|Biological|EGFR Antisense DNA|"Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
75751540|NCT00604565|Drug|soluble ferric pyrophosphate (SFP)|"Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)"
75751541|NCT00604565|Other|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
75751542|NCT00903539|Device|SecurAcath Securement System|Subcutaneous catheter securement system
75751543|NCT00899873|Genetic|cytogenetic analysis|
75900426|NCT02309060|Behavioral|Storytelling Video Intervention (sTVi)|Narrative communication, video-based intervention for depressed primary care patients.
76066940|NCT03860844|Drug|Hydroxyurea|Pharmaceutical form: Solution for injection Route of administration: PO
76066941|NCT03860844|Drug|L - Asparaginase (Erwinase)|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
75455215|NCT01757938|Procedure|Shang Ring Guided Circumcision|
75455216|NCT01757938|Procedure|Forceps Guided Circumcision|
75455217|NCT01757951|Procedure|Unimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
75455218|NCT01757951|Procedure|Bimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
75455219|NCT01757119|Drug|Tardyferon 80 mg|Oral administration (2 tablets)
75455220|NCT01757977|Device|double lumen endotracheal tube placement and use|
75455221|NCT01757990|Dietary Supplement|Effect of Stevioside and Rebaudioside on plaque pH|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
75455222|NCT01758029|Drug|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
75751544|NCT00899873|Other|flow cytometry|
75455223|NCT01758055|Biological|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
75455224|NCT01758068|Procedure|Coconut Oil Application|Coconut oil - 4 ml
75751545|NCT00899873|Other|fluorescence activated cell sorting|
75751546|NCT00899873|Other|immunoenzyme technique|
75751547|NCT00899873|Other|laboratory biomarker analysis|
75751548|NCT00899951|Drug|fentanyl citrate|
75751549|NCT00899951|Other|pharmacological study|
75751550|NCT00900107|Procedure|Exercise|
75751551|NCT00900185|Genetic|mutation analysis|
75751552|NCT00900185|Genetic|polymerase chain reaction|
75751553|NCT00900185|Genetic|polymorphism analysis|
75751554|NCT00900263|Genetic|cytogenetic analysis|
75751555|NCT00900263|Genetic|microarray analysis|
75455225|NCT01758094|Drug|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
75900427|NCT03101098|Procedure|Retroperitoneal liagation of uterine artery|the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
75900428|NCT03101098|Procedure|Classical ligation of uterine artery|the site of ligation of uterine artery is the area alongside the cervix
75900429|NCT02447120|Device|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
75606407|NCT04201951|Drug|Tranexamic acid injection|Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
75606408|NCT04201951|Other|Glucose water 5%|Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
75455226|NCT01758107|Other|Withdraw cyclosporine|
75455227|NCT01758120|Drug|prednisone plus cyclophosphamide|"prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
75606409|NCT02847715|Device|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
75751556|NCT00900263|Other|biologic sample preservation procedure|
75751557|NCT00900263|Other|laboratory biomarker analysis|
75900430|NCT05067322|Device|Minecraft|A game played within the videogame Minecraft
75900431|NCT02254356|Device|Zilver Flex Bare Metal Stent|
75900432|NCT01405066|Behavioral|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
75900433|NCT01405066|Behavioral|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
75900434|NCT02309216|Other|Whol-Body MRI scan|
75900435|NCT04475770|Other|Real Sustained Natural Apophyseal Glides (SNAGS)|"Manual therapists use treatment modalities that include passive techniques such as mobilization and manipulation. Mobilization with movement (MWM) developed by Mulligan involves applying a sustained transverse glide to the spinous process of a vertebra while actively or passively performing. These techniques have gained the name Sustained Natural Apophyseal Glides (SNAGS) as it is maintained at the pain-free range and follows the plane of the apophyseal joints under treatment."
75900436|NCT04475770|Other|Sham Sustained Natural Apophyseal Glides (SNAGS)|The participants in the Sham SNAGs group will be positioned same as the SNAG group. Mulligan belt will be used, which included the patient's waist and physiotherapist's hip. The physiotherapist will place the hypothenar region of his hand on the spinous processes of the symptomatic lumbar spine levels and waited a few seconds without no glide will be performed. Sham SNAGs practice consisted of 3 sets of 6 repetitions and a 60-second rest period was given between the sets.
75900437|NCT03538158|Behavioral|Intervention Condition|Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.
75455228|NCT01758120|Drug|Prednisone alone|"prednisone alone: prednisone(0.5mg/kg/day*6 months);~supportive care,including ACE-I or ARBs and blood pressure control"
75455229|NCT01758133|Behavioral|Exposure to medical clown activities|
75455230|NCT01758146|Drug|Tamoxifen|20 mg once daily for 5 years
75606410|NCT00992836|Biological|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
75606411|NCT04753723|Combination Product|Gentamycin with Platform Wound Device|Treatment of wounds with gentamycin and covered with platform wound device.
75751558|NCT00900341|Genetic|DNA analysis|
75751559|NCT00900341|Genetic|gene expression analysis|
75751560|NCT00900341|Genetic|protein expression analysis|
75751561|NCT00900341|Genetic|reverse transcriptase-polymerase chain reaction|
75751562|NCT00900341|Genetic|western blotting|
75751563|NCT00900341|Other|immunohistochemistry staining method|
75751564|NCT00900341|Other|laboratory biomarker analysis|
75751565|NCT02539979|Drug|Paracetamol|
75751566|NCT02539979|Drug|Placebo - Normal Saline|Normal Saline 100cc
75751567|NCT00906737|Device|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
75751568|NCT00906737|Other|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
75751569|NCT00906893|Procedure|18F]-FMISO PET-CT|pretherapy([18F]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe [18F]-FMISO uptake will be used.
75900438|NCT03538158|Behavioral|Control Condition|Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
75900439|NCT02305862|Drug|Rosuvastatin 5mg|drug intervention
75606412|NCT04751851|Behavioral|Medium duration withdrawal programme with ACT|"10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
75455231|NCT01758146|Drug|Letrozole|Letroz, Femara, Letronat
75606413|NCT04751851|Behavioral|Long duration withdrawal programme with ACT|"10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
75606414|NCT04751851|Behavioral|Medium duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.
75751570|NCT00903773|Drug|telaprevir|
75751571|NCT05277701|Drug|Lazertinib|Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
75606415|NCT04751851|Behavioral|Long duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
75606416|NCT02844517|Device|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
75606417|NCT03901729|Drug|BAY 1753011|Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
75606418|NCT03901729|Other|Placebo BAY 1753011|Tablet; Once daily in the morning; Oral
75900440|NCT02305862|Drug|Rosuvastatin 20mg|drug intervention
75606419|NCT03901729|Drug|Furosemide|Tablet; 40mg unit; 80mg once daily in the morning; Oral
75606420|NCT03901729|Other|Placebo Furosemide|Tablet; Once daily in the morning; Oral
75751572|NCT00900653|Drug|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
75900441|NCT03101176|Drug|SonoVue|The ultrasound contrast agent used for the CEUS specific ultrasound mode
75900442|NCT02305940|Drug|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
75455232|NCT01758159|Dietary Supplement|Iron supplementation|
75606421|NCT04292782|Procedure|anterior Quadratus lumborum block|ultrasound anterior quadratum lumborum block with 1 ml/kg 0.2% ropivacaine
75606422|NCT04292782|Procedure|caudal block|ultrasound guided caudal block with 1 ml/kg 0.2% ropivacaine
75606423|NCT03834844|Behavioral|Meditation|Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
75606424|NCT03834844|Other|AF Education|6 weekly education modules on topics related to AF
75606425|NCT03834844|Other|Phone Calls|Weekly phone call to discuss patient concerns or questions
75751573|NCT00605345|Drug|Darbepoetin alfa|As prescribed
75751574|NCT00605345|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
75900443|NCT02305940|Drug|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
75900444|NCT03099460|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
75455233|NCT01758159|Other|CFR|Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
75455234|NCT01758172|Drug|6% hydroxyethyl starch 130/0.4|
75455235|NCT01758172|Drug|Albumin|
75455236|NCT01758185|Biological|recombinant hepatitis b vaccine|0.5ml intramuscular
75455237|NCT01758185|Biological|Aleph influenza vaccine|0.5ml intramuscular
75455238|NCT01758198|Biological|Abatacept|
75455239|NCT01758198|Drug|Placebo matching with Abatacept|
75455240|NCT01758198|Drug|Methotrexate|
75455241|NCT01758211|Procedure|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
75455242|NCT01758211|Procedure|conventional resection|conventional resection in AVM patients
75751575|NCT00903851|Drug|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
75751576|NCT00900887|Drug|Ketorolac|ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
75751577|NCT00900887|Drug|Nepafenac|topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
75606426|NCT02846857|Other|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
75751578|NCT00900887|Drug|Polietilenglicol 400, propilenglicol|"ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week"
75751579|NCT02539277|Drug|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
75751580|NCT02539277|Drug|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
75751581|NCT02539277|Drug|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
75900445|NCT03099460|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
76066942|NCT03856814|Device|ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
75751582|NCT02539277|Drug|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
75751583|NCT00904085|Drug|Oxymorphone IR|5 mg
75751584|NCT00908453|Drug|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
75751585|NCT02538497|Behavioral|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
75751586|NCT02538497|Behavioral|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
76066943|NCT03853304|Other|+ Folic acid|Salt fortified with folic acid
75751587|NCT04034537|Diagnostic Test|cPSTA|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
75751588|NCT00907127|Behavioral|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
75751589|NCT02538731|Procedure|dilation-assisted stone extraction|
75606427|NCT02846857|Other|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
75751590|NCT02538731|Device|Spyglass Guided Laser Lithotrips|
75751591|NCT00908531|Drug|letrozole (Femara)|tablet 2.5 mg daily
75751592|NCT02538263|Device|Volume-targeted noninvasive ventilation|
75900446|NCT03099460|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
75900447|NCT03544554|Behavioral|a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program|The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
75606428|NCT02846857|Other|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
75606429|NCT02846857|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
75606430|NCT02846857|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
75606431|NCT02846857|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
75751593|NCT00904319|Other|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
75751594|NCT00604175|Biological|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
75751595|NCT00605189|Device|Powered Suction Pump (VAC Freedom)|continuous foam based negative pressure wound therapy
75900448|NCT03099772|Behavioral|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
75606432|NCT02846857|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
75751596|NCT00605189|Device|Powered Suction Pump|continuous gauze based negative pressure wound therapy
75751597|NCT00605189|Device|MWT|moist wound therapy
75751598|NCT00904397|Drug|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
75751599|NCT00904397|Drug|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
75751600|NCT02538887|Device|Radio Frequency Surgical Detection|
75751601|NCT00907205|Drug|SF1126|Dose Escalating with 3+ patients in each cohort
75751602|NCT00908765|Behavioral|Exercise|"High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks"
75751603|NCT00903071|Behavioral|Real PPL|See above arm description
75751604|NCT00903071|Behavioral|Sim PPL|See above arm description
75751605|NCT00908843|Other|Intravenous hydration with bicarbonate|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
75900449|NCT02312804|Drug|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
75900450|NCT02312804|Drug|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
76066944|NCT03853304|Other|+ Vitamin B12|Salt fortified with vitamin B12
75900451|NCT02312804|Drug|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
75900452|NCT03100630|Drug|RO7239361|Specified dose on specified days
75606433|NCT04287322|Behavioral|Tactile-kinesthetic stimulation|"Tactile-kinesthetic stimulation involved three sessions per day; morning, afternoon, and evening for 10 days starting day 3 of life (initial contact). The stimulation included three phases; Phase 1: With neonates in prone position, moderate pressure was used to provide 12 strokes with palms of the hands, each stroke lasting 5 seconds. The strokes were provided in each area as follows: head, neck, shoulders and back.~Phase 2: In supine position, twelve moderate pressure strokes with palms of the hands, 5 seconds each, were provided in each area as follows:forehead,cheeks,chest, abdomen, upper limbs (each separately), lower limbs, palms and soles.~Phase 3: Kinesthetic stimulation was done for 5 minutes. The intervention comprised five passive flexion and extension movements of each large joint."
76066945|NCT03853304|Other|DFS|Salt fortified with iron and iodine
75751606|NCT00908843|Other|Oral hydration with Sodium solution|Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
75606434|NCT04287322|Behavioral|Recorded maternal voice|Following informed written consent from mothers,maternal voice was recorded (5 minutes talking to her baby and 10 minutes singing) using Philips Electronics, SA2RGA04KS, Netherlands. Recorded voice was played back inside the incubator or cot via micro audio system, which has been validated for safety and feasibility in previous studies (Doheny et al., 2012. Preterm neonate lay in supine/lateral position and recorded maternal voice was played for 15 minutes three times a day (morning, afternoon, evening) starting on day 3 of life up to day 12 of life (10 days).
75606435|NCT03833128|Drug|Low Dose REN001|Oral
75606436|NCT03833128|Drug|High Dose REN001|Oral
75606437|NCT02844205|Other|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
75751607|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
75751608|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
75606438|NCT04672525|Drug|Rifabutin|2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
75751609|NCT00908921|Drug|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
75900453|NCT02306018|Device|EV1000™/volumeView™|
75900454|NCT03099616|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
75900455|NCT03099616|Drug|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
75900456|NCT04463966|Drug|Tranexamic acid injection|1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
75900457|NCT00794248|Drug|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
75900458|NCT00794248|Drug|fexofenadine|Allegra 180 mg daily x 7 days
75900459|NCT04463732|Other|Loaded inspiratory muscle test and cardiopulmonary exercise test|This is an observational study. Loaded inspiratory muscle test is setting at 30% of maximal inspiratory pressure. Subjects will perform only 15 breaths under this intensity to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training. Cardiopulmonary exercise test is performed by using bicycle ergometer. These two tests will be performed at least 1 week separately.
76066946|NCT03841149|Other|Ultrasound Imaging|3D volume calculation using on-line and off-line softwares
76066947|NCT03808272|Device|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
76066948|NCT03787264|Drug|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
76066949|NCT03787264|Biological|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
76066950|NCT03787264|Biological|Acalabrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o."
76066951|NCT03787264|Biological|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
75606439|NCT04672525|Drug|Rifampicin|10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
75606440|NCT00992446|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
75900460|NCT05066542|Behavioral|NDPP + Basketball (BB)|DPP Hoops: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30- minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and biweekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
75751610|NCT00904631|Device|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
75751611|NCT00909077|Drug|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
75751612|NCT00909077|Drug|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
75900461|NCT05066542|Behavioral|NDPP Standard of Care SOC|DPP: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
75900462|NCT02309450|Drug|.Asunaprevir, Daclatasvir and BMS - 791325|All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
75900463|NCT04475224|Drug|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
76066952|NCT03786523|Behavioral|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
76066953|NCT03786523|Behavioral|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
76066954|NCT03777631|Procedure|Catheter ablation|CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
75455243|NCT01758224|Other|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
75455244|NCT01758224|Other|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
75606441|NCT00992446|Drug|Bortezomib|Given IV
75606442|NCT00992446|Drug|Carmustine|Given IV
75606443|NCT00992446|Drug|Cytarabine|Given IV
75606444|NCT00992446|Drug|Etoposide|Given IV
75606445|NCT00992446|Drug|Melphalan|Given IV
75606446|NCT00992446|Drug|Rituximab|Given IV
75606447|NCT00992446|Drug|Vorinostat|Given PO
75606448|NCT04452565|Drug|Drug: NA-831|NA-831 is a neuroprotective drug, available at 30 mg capsule
75606449|NCT04452565|Combination Product|NA-831 and Atazanavir|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet"
75606450|NCT04452565|Combination Product|NA-831and Dexamethasone|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg"
75900464|NCT05401201|Device|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
75900465|NCT05401201|Other|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self care.
75900466|NCT03506126|Other|Leucine|There are 8 different leucine test levels ranging from 20 to 120 mg of leucine per kilogram body weight per day (20-120 mg/kg/d)
75900467|NCT05066620|Drug|Chinese herbal medicine FYTF-919|Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
75900468|NCT02309528|Other|Educational computerized digital stories|computerized digital stories made by American Indians
75900469|NCT03498781|Other|Exercise-only|Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
75900470|NCT03498781|Other|Control|Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
75900471|NCT05066152|Dietary Supplement|Lactobacillus rhamnosus GG (ATCC 53103)|One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)
75900472|NCT05066152|Dietary Supplement|Placebo|Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
75900473|NCT02309606|Other|PET scan with 5-HT receptor ligands|Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.
75455245|NCT01758237|Device|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
75455246|NCT01758237|Procedure|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
75455247|NCT01758250|Other|Acoustic Radiation Force Impulse (ARFI)|
75455248|NCT01758250|Other|Laser Doppler Flowmetry (LDF)|
75455249|NCT01758250|Other|Laser Doppler Perfusion Imaging (LDI)|
75455250|NCT01758250|Other|Optical Coherence Tomography (OCT)|
75455251|NCT01758250|Other|Orthogonal Polarization Spectral Imaging (OPSI)|
75455252|NCT01758250|Other|Nail fold video capillaroscopy (NVC)|
75900474|NCT05066464|Other|Fluid Resuscitation|Fluid Resuscitation for Suspected Sepsis in Paediatric Emergency Departments
75900475|NCT05066386|Other|Modified RCRI risk stratification|"The objective of the study is to compare the predictive value of RCRI and substitution of the DM on insulin component with HH ratio for 30- and 90-day mortality, and postoperative acute myocardial injury(AMI) and acute kidney injury(AKI)."
75455253|NCT01758263|Drug|Metoprolol|Metoprolol, oral administration
75455254|NCT01758263|Drug|Nebivolol|Nebivolol, oral administration
76066955|NCT03745612|Behavioral|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
75455255|NCT01758302|Behavioral|Simple physical task|Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
75606451|NCT04452565|Combination Product|Atazanavir and Dexamethasone|Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg
75606452|NCT04615195|Other|cries 13 questionnaire|"Participant will be contacted by telephone by a clinical research assistant to answer the CRIES 13 questionnaire.~In large families, the CRIES-13 of the holder of parental authority and of the child will be applied for each of them whose age corresponds to the inclusion criteria."
75606453|NCT04285840|Other|Venous ACT|Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
75751613|NCT00904709|Drug|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
75751614|NCT05277389|Other|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
75606454|NCT04440319|Behavioral|Intervention group|Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
75606455|NCT00629668|Genetic|TNF-alpha and HBV genotype|
75751615|NCT05277389|Other|Sham Control|Practice of Movement task without START
75751616|NCT00340834|Drug|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
75900476|NCT03100708|Procedure|PIPAC|"Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.~Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.~The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system."
75900477|NCT05493085|Procedure|Quadratus lumborum block|Ultrasound-guided quadratus lumborum block
75900478|NCT05493085|Procedure|Caudal epidural injection|Single Caudal epidural injection
75900479|NCT02306252|Other|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
75900480|NCT02313116|Device|Interferometric Synthetic Aperture Microscopy|Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.
75900481|NCT05395585|Procedure|Manual placental separation|Manual separation of the placenta from uterus
76066956|NCT03745612|Behavioral|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without a restriction of feeding time.
75900482|NCT03508310|Other|Taking Care of Me Video|The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
76066957|NCT03739372|Other|Specialized tumor board recommendation|Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
75455256|NCT01758302|Behavioral|Complex physical task|Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
75606456|NCT00629668|Other|TNF-alpha and HBV genotypes|
75900483|NCT02306330|Device|Malditof|Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
75900484|NCT02306330|Other|Routine clinical microbiology|Pathogens will be identified by the routine clinical microbiology of the hospital.
75900485|NCT02643082|Drug|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
76066958|NCT03736512|Device|GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber|observational registry
76066959|NCT03732950|Biological|Pembrolizumab|Given IV
76066960|NCT03721068|Biological|iC9.GD2.CAR.IL-15 T-cells|Three dose levels are being evaluated: 0.5 x 10^6, 1.0 x 10^6, 1.5 x 10^6
75455257|NCT01758302|Other|Cookies|Participants are asked to taste test chocolate chip cookies
75606457|NCT02863120|Drug|liposomal bupivacaine|
75455258|NCT01758302|Other|Vegetables|Participants are asked to taste test raw celery or radishes
75455259|NCT01758302|Behavioral|No physical task|As a control, for 2 of the arms, participants are not asked to engage in a physical task
75606458|NCT02863120|Drug|bupivacaine HCl|
75606459|NCT02863120|Drug|Ropivacaine|
75606460|NCT02863120|Drug|Saline|
75606461|NCT04201795|Other|Laser|laser with no emision will applied
76066961|NCT03721068|Drug|Cyclophosphamide|500 mg/m^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
76066962|NCT03721068|Drug|Fludarabine|30 mg/m^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
76066963|NCT03710109|Other|EEG|non-invasive, non-interventional sensor
76066964|NCT03707951|Drug|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)
75455260|NCT01758315|Other|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
75455261|NCT01758341|Procedure|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
75455262|NCT01758341|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
75606462|NCT04201795|Other|pressure and traction tecnique|pressure and traction in plantar fascia with hands will be applied
76066965|NCT03707951|Drug|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
76066966|NCT03691493|Drug|Anastrozole|Given PO
76066967|NCT03691493|Drug|Exemestane|Given PO
76066968|NCT03691493|Drug|Fulvestrant|Given IM
75606463|NCT02846701|Drug|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
75606464|NCT04344301|Other|Audio recording|The investigators will audio record the visits of patients in the intervention group. An RA will enter the exam room and begin the recording with the patient's permission. The patient and clinician can choose to stop or start the recording at any time. Once the visit is complete, the RA will enter the room, turn off the recording, and bring the patient to a private room where the RA will follow standardized instructions demonstrating how to access recordings. Patient access to recordings will be possible via a secure web-based platform. Patients will also receive reminders to listen to their recordings.
76066969|NCT03691493|Drug|Letrozole|Given PO
75606465|NCT00970294|Behavioral|Health Promotion Program|10 week health promotion program 3-4 times per week
75455263|NCT01758341|Device|HabibTM EndoHPB catheter|"Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)"
75455264|NCT01758354|Other|Pompe disease newborn screening|DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
75455265|NCT01758367|Drug|Deciatbine(DAC)|
76066970|NCT03691493|Drug|Palbociclib|Given PO
76066971|NCT03691493|Radiation|Radiation Therapy|Undergo radiation therapy
75900486|NCT02643082|Drug|Placebo MDI|Comparator: Placebo MDI which contains no active ingredients
75900487|NCT00353496|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
75900488|NCT00353496|Drug|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
75900489|NCT03411746|Other|Subarachnoid haemorrhage|Data on the type of patients enrolled have been described already in other sections.
76066972|NCT03691493|Drug|Tamoxifen|Given PO
76066973|NCT03666533|Other|Active transcranial Direct Current Stimulation|Active tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
76066974|NCT03666533|Other|Sham transcranial Direct Current Stimulation|Sham tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
76066975|NCT03634007|Biological|LX1001|LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.
76066976|NCT03632421|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75455266|NCT01758380|Drug|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
75455267|NCT01758380|Drug|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
75455268|NCT01758380|Drug|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
75455269|NCT01758380|Drug|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
75455270|NCT01758380|Drug|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
75455271|NCT01758393|Drug|Prednisone|
75455272|NCT01758406|Biological|Intracoronary injection|stem cell transplantation
75606468|NCT04285918|Procedure|Percutaneous device closure|If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
75751617|NCT00340834|Drug|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
75751618|NCT00340834|Drug|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
75900490|NCT00389896|Drug|MK0733 / Duration of Treatment: 18 Weeks|
75900491|NCT00389896|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
75900492|NCT03508154|Other|Control Meal 1|carbohydrate test meal
75900493|NCT03508154|Other|Control Meal 2|carbohydrate test meal
75900494|NCT03508154|Other|Experimental Nutritional Product|ready to drink nutritional formulation
75900495|NCT05313373|Other|Virtual Reality|In addition to the routine procedure, virtual reality glasses will be applied to the women in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After being taken to the gynecological table for the HSG procedure, the women included in the experimental group will be made to watch a video lasting an average of 10 minutes with virtual reality glasses until the procedure is completed. While watching the video, the relaxing music of the video will be played.
75900496|NCT05065996|Diagnostic Test|Aortic MRI + 4D flow MRI|Together with routine aortic MRI specific 4D flow MRI sequence will be done.
75900497|NCT03478579|Other|observational|No intervention, it is observational study
75606469|NCT02844283|Drug|Ad-HGF|
75606470|NCT02844283|Other|0.9% NaCl|
75900500|NCT05065606|Diagnostic Test|Dual-energy computed tomography|Dual-energy scanner examinations stored in the PACS (medical imagery) at Lariboisière Hospital are to be analyzed retrospectively and prospectively
75900501|NCT05065138|Behavioral|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
75606471|NCT02844361|Other|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
75606472|NCT02844361|Other|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
75606473|NCT04286698|Other|Complex decongestive physiotherapy|MLD was administered 5 days a week for 4 weeks, with each session lasting 30 minutes [25]. Compression therapy was applied to the patients by wearing a compression mask (FM Velcro Fastener, LIPOELASTIC), made of polyamide, cotton, viscose, and elastane, that covered the submandibular region, the masseter region, and the neck. The compression mask is specifically designed for the healing and recovery of tissues after plastic and aesthetic surgeries. The patients were advised to wear the compression masks for at least 4-6 hours per day for 4 weeks and gradually increase wearing time according to their tolerance. The patients were asked to perform skin care by themselves. Skin care was applied using a low pH skin lotion to moisturize the skin. Neck, face/mimic, tongue, and posture exercises were performed by patients while the compression mask was worn and under the supervision of a physiotherapist, with 10 repetitions 5 times a week for 4 weeks.
75900502|NCT02309762|Drug|FB825|FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
75900503|NCT02309762|Drug|Placebo|Solution containing no active ingredients
75900504|NCT04463888|Other|occupational therapy|occupational therapy targeted to goals that are relevant to the functional needs of the patient
75900505|NCT03508076|Device|Vibrating Capsule|Patients in this group would be treated with Vibrating Capsule
75900506|NCT03508076|Device|Sham Capsule|Capsules can't vibrate but look the same as Vibrating Capsule
75751619|NCT03986554|Procedure|Videofluoroscopic swallow study|The Swallowing Systems Core laboratory is fully equipped to perform VFSS with a C-arm (OEC 9900) that is dedicated solely for research purposes. VFSS recordings will be kept to a minimum and only turned on during the execution of each swallow in all sequences. Video recording and images captured during the VFSS will be synced and saved to a secure server for data analysis. VFSS allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the hyolaryngeal complex during swallowing) cannot be visualized with any other technique. Patients will swallow only water. Aspiration (bolus into trachea) is not expected to occur during this study given that the individuals recruited will have no prior history of disease or disorder, and aspiration is uncommon in healthy individuals.
75900507|NCT03473977|Biological|Benralizumab|Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
75900508|NCT03473977|Biological|Placebo|Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.
75900509|NCT03503084|Behavioral|Classical Yang's TCC exercise|
75900510|NCT03507998|Drug|CGX1321|CGX1321 capsules for oral administration
75455273|NCT01758406|Biological|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
75455274|NCT01758419|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
75455275|NCT01758471|Drug|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
75455276|NCT01758471|Drug|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
75455277|NCT01758484|Other|palliative care|Undergo supportive care intervention
75455278|NCT01758484|Other|questionnaire administration|Ancillary studies
75455279|NCT01758484|Procedure|quality-of-life assessment|Ancillary studies
75455280|NCT01758497|Procedure|Fascia iliaca compartment block|30 ml 0.5% ropivacaine, beneath the fascia iliaca
75455281|NCT01758497|Procedure|Fascia Iliaca compartment block|30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
75455282|NCT01758510|Genetic|HYNR-CS-Allo|The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10^6 cells/kg, 0.5 X 10^6 cells/kg, 1 X 10^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10^6 cells/kg dose cohort.
75455283|NCT01758536|Drug|Huatuo Zaizao Pills|A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
75455284|NCT01758549|Other|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
75606474|NCT04286698|Other|Home program|Self-MLD and exercises (neck, face/mimic, tongue, and posture exercises) were shown to the patients in this group. Self-MLD included self-administered lymph drainage of the axillary, posterior, lateral, and anterior neck areas; the pre- and retro-auricular regions; the lateral and anterior regions of the face; and the lower jaw region. Then the order is reversed back to the starting point [3]. A video of self-MLD and a text including exercise descriptions were shared with patients and their relatives to ensure that the self-MLD and exercises were performed accurately and regularly at home. Self-MLD was recommended to be applied once a day, and the exercises were advised to be performed for 10 repetitions each, 10 times a day for 4 weeks. The patients were called by phone during the second week after their first evaluation as a control and to motivate the patient for performing self-MLD and home exercises properly.
75606475|NCT05337865|Other|Aerobic exercise test.|Aerobic exercise test at a treadmill.
75606476|NCT02864056|Other|Tai Chi|Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
75606477|NCT05242861|Radiation|Brachytherapy|Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
75606478|NCT02863822|Behavioral|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
75606479|NCT02863822|Behavioral|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
75900511|NCT01361464|Drug|Tipifarnib|Given PO
75900512|NCT01361464|Other|Laboratory Biomarker Analysis|Correlative studies
75900513|NCT03424213|Other|No interventions - retrospective data collection|No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
75606480|NCT05337787|Other|flipped classroom approach|All students in the experimental group were trained only according to the flipped classroom approach.
75900514|NCT03099226|Drug|Placebo|Placebo blue hard gelatine capsules
75900515|NCT03099226|Drug|BIA 5-453|Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
75900516|NCT03505970|Dietary Supplement|Sodium bicarbonate|Sodium bicarbonate in powder form ingested in gelatine capsules. This leads to an increase bicarbonate concentration in blood, increasing buffering capacity which may lead to improvements in exercise
75900517|NCT03505970|Dietary Supplement|Maltodextrin|Maltodextrin will be used as a placebo as it will not lead to any increases in circulating bicarbonate and, at this dose, will not likely have any physiological effect.
75900518|NCT03317743|Drug|NOV140101 (IDX-1197)|The dose levels will be escalated following a 3+3 dose escalation scheme.
75900519|NCT04078828|Procedure|Pelvic floor Reconstruction|Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.
75900520|NCT03505814|Device|High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)|High flow and humidified oxygen support for new borns and young infants for post-extubation care
76066977|NCT03632421|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75455285|NCT01758549|Other|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
76066978|NCT03631849|Procedure|peri implantitis sanitation surgery|"an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0."
75606481|NCT04292704|Radiation|the fractional CO2 laser|The fractional CO2 laser therapy mechine: the wavelength is 10.6 μ m, the output power is 40 w, the action time is 2000 μ s and the lattice spacing is 700 ~ 1000 μ m
76066979|NCT03631849|Other|Care|descaling and maintenance of implants
75751620|NCT03986554|Procedure|pharyngeal High Resolution Manometry|This procedure will only take place once during sequence 2 of the randomization B session. If desired, a small amount (< 0.5 mL) of topical 2% viscous lidocaine hydrochloride will be applied to the participant's nostril of choice prior to catheter insertion. The catheter will be placed through the nasal passage, oropharynx, and hypopharynx to the esophagus. Correct catheter placement will be verified with VFSS. With the catheter in place, the subject will perform 10 swallows of 10ml and is expected to take approximately 2.5 minutes. The catheter will then be removed and the subject will move on to sequence 3. Individuals have the option to decline this procedure if it is uncomfortable or difficult to tolerate.
75751621|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)|Single full strength dose capsule taken one time
75751622|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)|Single half strength dose capsule taken one time
75455286|NCT01758562|Device|Caphosol|
75455287|NCT01758601|Other|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
75455288|NCT01758601|Other|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
75606482|NCT04292704|Drug|Clotrimazole|Clotrimazole vaginal tablets
75751623|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)|Single, full strength dose tablet taken one time
75606483|NCT05242783|Drug|Terlipressin|intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.
75606484|NCT04181944|Other|Exercise Treatment Group|be specific
75606485|NCT05336305|Dietary Supplement|Polydextrose|Administration of 3g polydextrose per day, for 2 months
75751624|NCT01058044|Other|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
75751625|NCT01058122|Procedure|Collection of adverse drug events|
75751626|NCT00603941|Drug|CS-7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
75751627|NCT00603941|Drug|Paclitaxel|Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
75751628|NCT00340678|Drug|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
75751629|NCT00340678|Drug|Placebo|Treatment with placebo corresponding to each dose of losartan.
75606486|NCT04214743|Device|Incident dark field videomicroscope from Braedius|It allows to look at conjunctival microcirculation
75606487|NCT04214743|Device|Fundus camera from Optomed|It allows to monitor retinal microvasculature
75606488|NCT02846467|Other|Informed consent trough a portable video media|Information provided to patients using the mobile application (iURO app)
75606489|NCT02846467|Other|Written informed consent|Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
75751630|NCT01055470|Drug|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
76066980|NCT03623464|Other|Mobile health application and Fitbit + standard of care|Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
75751631|NCT01055470|Drug|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
75751632|NCT00904787|Drug|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
75900521|NCT03505814|Device|Conventional oxygen therapy|conventional oxygen support for new born and young infants in post-extubation care
75455289|NCT01758627|Drug|Peritoneal dialysis (PD)|PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
75455290|NCT01758640|Drug|Warfarin|Low dose warfarin of 5mg or less per day
75455291|NCT01758640|Drug|phenindione|Phenindione of 100mg or less per day
76066981|NCT03623464|Other|Standard of care|Post-operative standard of care information
76066982|NCT03621592|Device|Cutimed® Sorbact®|Dialkylcarbomoyl chloride based wound dressing
75455292|NCT01758666|Drug|Methotrexate,Calcium folinate|
75455293|NCT01758679|Biological|Licartin and CIK|Licartin and CIK
75455294|NCT01758718|Procedure|Eyelash line resection|Eyelash resection surgery was performed for entropion with Down's syndrome
75455295|NCT01758744|Drug|Inhaled Treprostinil Therapy|Treprostinil: Inhaled prostanoid therapy
75455296|NCT01758757|Procedure|Vitrectomy|
75455297|NCT01758783|Drug|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
75455298|NCT01758809|Procedure|Pre-emptive bupivacaine wound infiltration|Pre-emptive bupivacaine wound infiltration
75455299|NCT01758809|Procedure|intravenous patient controlled analgesia|postoperative pain control with intravenous patient controlled analgesia
75455300|NCT01758822|Other|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
75455301|NCT01758835|Other|Splint 3 weeks|A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.
75606490|NCT03987685|Drug|Oratopo|Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
75751633|NCT02533102|Drug|E7050|100 mg tablet administered orally
75751634|NCT00907361|Device|MRI with pacemaker or ICD|The aim of the present protocol is to prospectively determine the adverse event rate of non-thoracic MRI for patients with implanted cardiac devices by collecting pre- and post-MRI device interrogations in a multi-center registry.
75751635|NCT02533024|Other|Electromyography|All subjects will have an EMG before, during and immediately after surgery.
75751636|NCT05277311|Drug|LongShengZhi capsule|LongShengZhi capsules, orally, 5 capsules each time, three times a day.
75900522|NCT02012179|Other|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
75900523|NCT02309918|Drug|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
75900524|NCT03098914|Other|Cohort Study； pathogen； clinical features|Cohort Study； pathogen； clinical features
76066983|NCT03621592|Device|Acticoat®|Silver impregnated contact layer dressing
75751637|NCT05277311|Drug|LongShengZhi capsule placebo|LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
75606491|NCT00969436|Biological|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
75606492|NCT00969436|Biological|Priorix™|Subcutaneous injection
75606493|NCT00969436|Biological|Varilrix™|Subcutaneous injection
75751638|NCT03986008|Drug|Benaglutide|The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
75751639|NCT03986008|Drug|Liraglutide|The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
75751640|NCT00909233|Drug|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
75751641|NCT03985774|Procedure|Transcarotid revascularization|The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
75751642|NCT00904865|Procedure|SPA cholecystectomy|SPA cholecystectomy
75751643|NCT00904865|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
75751644|NCT03986086|Drug|MPH966|RP2D tablet
75751645|NCT03986086|Drug|Placebo|MPH966 placebo table
75751646|NCT03313895|Behavioral|ACT|ACT stands for combined aerobic exercise and cognitive training.
75455302|NCT01758835|Other|Cast 3 weeks|A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.
75455303|NCT01758835|Other|Cast 6 weeks|standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
75455304|NCT01758861|Drug|EPO group|
75455305|NCT01758861|Drug|Placebo|
75455306|NCT01758874|Procedure|phlebotomy|repeated phlebotomy for 4 weeks
75455307|NCT01758913|Drug|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
75455308|NCT01758965|Other|PPI|monotherapy of PPI
75751647|NCT03313895|Behavioral|Cycling Only|Cycling on a recumbent stationary cycle
75751648|NCT03313895|Behavioral|Cognitive Training Only|Engage in cognitive training on a computer
75751649|NCT03313895|Behavioral|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
75751650|NCT01058200|Device|iCup|new vacuum extractor: sterile disposable plastic cup
75751651|NCT01058200|Device|reference cup|reference cup of the obstetrical ward: metallic cup
75751652|NCT00909311|Drug|ABT-450|capsules, QD, 1 dose in each cross-over period
75751653|NCT00909311|Drug|ritonavir|capsule, QD, 1 dose in each cross-over period
75455309|NCT01758965|Other|H2RA and surgicel|combination therapy of H2RA and surgicel
75606494|NCT00900757|Drug|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
75606495|NCT05242393|Other|No intervention is planned|No intervention is planned
75606496|NCT02846311|Device|Flu Test|
75900525|NCT04051255|Drug|full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
75900526|NCT03538834|Dietary Supplement|Cod meal from residual material|Cod meal from residual material, 8 g protein daily for 8 weeks
75900527|NCT03538834|Dietary Supplement|Control|Placebo
75606497|NCT00969280|Device|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
75606498|NCT00969280|Device|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
75606499|NCT04136743|Device|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
75606500|NCT04136743|Drug|Dexamethasone|Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance.
75606501|NCT03931057|Drug|ADV6209 (=gamma-cyclodextrin-Midazolam)|30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)
75606502|NCT03931057|Drug|Midazolam|30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
75751654|NCT00907595|Drug|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
75751655|NCT00907595|Drug|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
75751656|NCT05277467|Other|no intervention|no intervention
75751657|NCT00907673|Device|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
75900528|NCT03920072|Drug|Burosumab|Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
75900529|NCT03534154|Diagnostic Test|MRI|Magnetic Resonance Imaging
75606503|NCT00969124|Device|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
75606504|NCT02846155|Other|clear water|the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination
75606505|NCT02846155|Drug|simethicone|the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination
75751658|NCT00907751|Drug|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
75900530|NCT03534154|Diagnostic Test|Blood Sampling|Sampling of serum
75606506|NCT02846155|Drug|simethicone combined with pronase|the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion)，pronase granules（Deyou；Beijing Tide Pharmaceutical Co，China,containing 20,000iu pronase），and clear water before Magnetic-controlled Capsule Endoscopy examination
75900531|NCT03534154|Diagnostic Test|Microdialysis|Monitoring of cerebral fluid protein levels
75900532|NCT03534154|Diagnostic Test|Neuropsychological tests|Battery of tests to assess cognitive function, patient outcomes
75900533|NCT03534154|Diagnostic Test|MRI (advanced)|Advanced MRI
75751659|NCT00909467|Other|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
75751660|NCT00905333|Drug|Candesartan (test)|16 mg oral tablet, single dose
75751661|NCT00905333|Drug|Felodipine (test)|5 mg oral extended release tablet, single dose
75751662|NCT00905333|Drug|Candesartan Cilexetil|16 mg oral tablet, single dose
75751663|NCT00905333|Drug|Felodipine|5 mg oral extended release tablet, single dose
75455310|NCT01758978|Drug|a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
75751664|NCT00907829|Drug|lidocaine|comparison of the effect of the drug to help improve finger function
75751665|NCT00907829|Device|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
75751666|NCT00905411|Behavioral|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study."
75751667|NCT00336544|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
75900534|NCT03502928|Other|Motor Control|Neck Motor Control
75900535|NCT03502928|Other|Manual Therapy|Massage + Joint Mobilizations
75900536|NCT03502928|Other|Dry Needling|Dry Needling in Neck Muscles
75606507|NCT02846077|Other|No intervention. Observation only|No intervention. Observation only
75900537|NCT03505736|Biological|Adenosine|Given IV
75455311|NCT01759004|Other|volume, muscle strength, physical condition, BMI|phys. condition, muscle strength, volumetry, BMI
75606508|NCT03825523|Other|iART|After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
75606509|NCT03825523|Other|cART|After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
75751668|NCT00336544|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
75751669|NCT01059058|Procedure|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
75751670|NCT01059058|Procedure|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
75900538|NCT03505736|Procedure|Magnetic Resonance Imaging|Undergo CMR imaging
75900539|NCT03505736|Drug|Regadenoson|Given IV
75900540|NCT03505736|Procedure|Stress Management Therapy|Undergo stress test
75455312|NCT01759030|Drug|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
75606510|NCT03744403|Drug|CS1001|In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.
75900541|NCT03532750|Device|Particle|"300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.~300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.~Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.~Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578."
75606511|NCT02845921|Other|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
75606512|NCT02845921|Other|leg wrapping|Esmarch bandage is used to wrap each lower limb
75606513|NCT02845921|Other|control|no intervention has been done
75900542|NCT03532750|Device|Coil|Ruby or Interlock detachable coils
75751671|NCT01059058|Procedure|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
75751672|NCT00605033|Drug|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
75751673|NCT00605033|Drug|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
75751674|NCT03988114|Drug|Abemaciclib|Administered orally
75751675|NCT03988114|Drug|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole administered orally or anastrozole administered orally (physician choice)
75455313|NCT01759043|Procedure|guiding catheter|using a single transradial guiding catheter for coronary angiography and intervention
75455314|NCT01759043|Procedure|diagnostic catheter|diagnostic for coronary angiography and guiding catheter selection for intervention
75751676|NCT00905723|Drug|estradiol|1 mg daily for 6 months
75751677|NCT00905723|Drug|isoflavone|150 mg isoflavone daily for 6 months
75751678|NCT00905723|Drug|Placebo|sugar pill daily for six months
75751679|NCT04034069|Device|Theta burst stimulation (TBS)|Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
75751680|NCT04034069|Behavioral|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
75751681|NCT03987646|Procedure|Non-staged vestibular fresh socket therapy|a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
75900543|NCT04027114|Behavioral|Individualized behavioural physical activity intervention|• The intervention involves a tailored physiotherapy (PT) intake that will serve as the foundation for the individualized approach. Participants' individual attributes and physical activity needs, including a general PT assessment will occur initially. Over the next 12 months, participants will receive individualized PT coaching and a physical activity plan plus access to educational literature that outlines methods and benefits of exercise. An estimated 15 hours of PT contact hours per participant is anticipated and the specifics of each encounter will be documented.
75455315|NCT01759056|Drug|AVX 470|active comparator
75455316|NCT01759056|Drug|Placebo|
75455317|NCT01759069|Procedure|Surgical treatment with microscope|
75751682|NCT00907985|Drug|Placebo|Single dose of placebo will be provided.
75751683|NCT00907985|Drug|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
75751684|NCT00907985|Drug|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
75751685|NCT03987880|Procedure|4.0 mm treatment|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
75751686|NCT03987880|Procedure|3.5 mm treatment|PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
75751687|NCT01325194|Drug|liposomal cytarabine|50 mg intrathecally three times
75455318|NCT01759095|Device|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
75455319|NCT01759108|Drug|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
75455320|NCT01759121|Radiation|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
75455321|NCT01759121|Radiation|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
75455322|NCT01759134|Other|Post discharge formula|Babies will be given either materna sensitive or similac neosure
75455323|NCT01759147|Procedure|Surgical treatment of acromioclavicular dislocation.|Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
75751688|NCT00908063|Drug|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
75900544|NCT02309996|Behavioral|Supervisor Training Program|
75900545|NCT03103126|Behavioral|Combined resistance exercise and walking|Combined resistance exercise and walking
75900546|NCT02313350|Device|Chemonucleolysis with Discogel|Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes, each for single use which is stored at room temperature. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia .
75900547|NCT02313350|Procedure|open discectomy|The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root.
75455324|NCT01759199|Procedure|Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test|
75751689|NCT00908063|Drug|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
75455325|NCT01759303|Drug|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
75455326|NCT01759316|Other|heliox|heliox or oxygen is used in the two groups respectively
75455327|NCT01759329|Dietary Supplement|test coffee|test coffee with higher alkyl pyridine content
75455328|NCT01759329|Dietary Supplement|control coffee|control coffee with regular alkyl pyridine content
75455329|NCT01759342|Behavioral|Aerobic exercise|
75455330|NCT01759342|Behavioral|Resistance exercise|
75455331|NCT01759342|Behavioral|Flexibility and postural exercise|
75455332|NCT01759342|Behavioral|Balance exercise|
75455333|NCT01759355|Procedure|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
75455334|NCT01759394|Drug|Avatrombopag maleate 40 mg|"Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:~Fed, Fed, Fasted; or~Fed, Fasted, Fed; or~Fasted, Fed, Fed~During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.~During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.~Randomization Phase consists of three single-dose treatment periods:~Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval."
75455335|NCT01759485|Drug|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
75455336|NCT01759485|Drug|placebo|
75455337|NCT01759498|Dietary Supplement|HYDRO|
75751690|NCT00909701|Dietary Supplement|PreOP Booster|1 serving of 400 ml per study arm
75751691|NCT00909701|Dietary Supplement|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
75751692|NCT01058278|Procedure|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
75900548|NCT05064748|Drug|Benvitimod|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
75900549|NCT02316626|Drug|Subcutaneous progesterone|25 mg daily for 14 days
75900550|NCT02316626|Drug|Vaginal progesterone|90 mg daily for 14 days
75900551|NCT05065060|Other|Observation|Observation
75900552|NCT03502850|Drug|ASK120067|patients take ASK120067 orally once per day at 40,80,160,240,320,480mg
75900553|NCT03100162|Dietary Supplement|Probiotic|
75455338|NCT01759498|Dietary Supplement|ACTIVE|
75455339|NCT01759498|Dietary Supplement|HYDRO 2|
75455340|NCT01759524|Drug|Bupivacaine|
75455341|NCT01759524|Drug|Lidocaine|
75900554|NCT03100162|Dietary Supplement|Placebo|
75900555|NCT03505658|Behavioral|Education and Behavior|Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
75751693|NCT00905801|Other|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
75751694|NCT00908219|Drug|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
75900556|NCT05063890|Procedure|Muscle Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at muscles of the neck prone to get short
75900557|NCT05063890|Procedure|Movement Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at specific movements of the cervical spine
75751695|NCT00927173|Device|Brainsway H-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
75455342|NCT01759563|Device|nasopharyngeal targeted brain cooling|
75751696|NCT00927173|Device|Brainsway H-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
75751697|NCT02538185|Device|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
75900558|NCT05063890|Procedure|unilateral postero-anterior glide|3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment
75900559|NCT05063890|Procedure|Heating and TENS|Heating and TENS for 10 minutes
75900560|NCT03502772|Other|Pilates exercises|Clinical Pilates training program will be given one session in a week for 8 weeks plus two days home exercise program. Group exercise sessions will be performed. The sessions will be supervised by a physiotherapist who is certified.
75900561|NCT03502772|Other|Home exercise program|written exercises that matched the aims of the Pilates exercises, 3 times per week for 8 weeks. These exercises reflect routine clinical practice (flexibility, strength, and balance exercises).
75455343|NCT01759576|Drug|Canagliflozin (JNJ-28431754)|Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
75455344|NCT01759589|Drug|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
75455345|NCT01759589|Drug|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
75455346|NCT01759589|Drug|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
75455347|NCT01759615|Other|Early Enteral feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
75455348|NCT01759615|Other|Late enteral feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
75455349|NCT01759628|Drug|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
75455350|NCT01759641|Device|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
75606514|NCT05336149|Procedure|Alveolar ridge preservation using whole-tooth dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft
75606515|NCT05336149|Procedure|Alveolar ridge preservation using particulate dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
75455351|NCT01759654|Biological|AdimFlu-V|
75455352|NCT01759667|Other|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
75455353|NCT01759680|Device|Vibrosphère device|Vertical Sinusoidal vibration
75455354|NCT01759693|Procedure|Blood sampling|Blood sampling
75606516|NCT02845843|Drug|Combination of Lopinavir /Ritonavir and Interferon beta-1b|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
75606517|NCT02845843|Drug|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
75751698|NCT02538185|Device|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
75751699|NCT02538185|Device|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
75751700|NCT02538185|Drug|Vaccin rabique Pasteur®|
75751701|NCT02538185|Drug|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
75900562|NCT03505502|Drug|IV tranexamic acid|in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
75751702|NCT00908297|Dietary Supplement|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).~Dose escalation:~300 mg for two weeks~600 mg for two weeks~1200 mg for two weeks~1800 mg for final two weeks"
75900563|NCT03977896|Procedure|11C-MET PET/MRI|"Except PET/MRI imaging, all the examinations will be done according to the patient's usual care.~PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging.~PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL)."
75900564|NCT03501758|Diagnostic Test|Ultrasound|Transabdominal ultrasound of the bowel for categorisation of disease activity
75455355|NCT01759706|Behavioral|Enhanced recovery after surgery protocol|ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
75455356|NCT01759706|Procedure|Standard perioperative care|Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
75900565|NCT03501758|Diagnostic Test|Analysis of prouroguanyline and uroguanyline in full blood|Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
75900566|NCT02316704|Device|THA with G7 PPS coted acetabular component|
75455357|NCT01759706|Drug|PONV prophylaxis with Ondansetron + Dexamethasone|Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
75606518|NCT02845999|Biological|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10^6 ; 8.10^6 and 12.10^6 cells/kg of recipient body weight
75606519|NCT02845999|Biological|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
75751703|NCT00927329|Biological|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
75751704|NCT00931541|Drug|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
75900567|NCT02316704|Device|THA with G7 OsseoTi coted acetabular component|
75900568|NCT03501680|Drug|Insulin|"Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump."
75900569|NCT03501680|Device|plasmapheresis|Triglyceridemia should be less than 5.65 mmol/l.
75900570|NCT03502694|Drug|Lumicitabine|Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.
75455358|NCT01759706|Other|Postoperative mobilization program|Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward
75455359|NCT01759706|Drug|Epidural analgesia with naropin + sufentanil|Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
75455360|NCT01759706|Drug|Pre-anesthetic medication with diazepam|Premedication before general anesthesia
75606520|NCT02845999|Drug|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
75606521|NCT02845999|Drug|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
75606522|NCT02845999|Drug|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
75606523|NCT00900601|Procedure|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
75751705|NCT00931541|Drug|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
75751706|NCT00927407|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
75900571|NCT03502694|Drug|Placebo|Participants will receive matching placebo tablets orally.
75900572|NCT05059756|Device|PTNS|PTNS and PFR
75900573|NCT05059756|Device|Sham PTNS|Sham PTNS and PFR
75900574|NCT03486912|Drug|BMS-986036|Specified dose on specified days.
75455361|NCT01759706|Behavioral|Preadmission counselling|Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.
75900575|NCT03486912|Other|Placebo|Specified dose on specified days.
75751707|NCT00927407|Drug|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
75751708|NCT00339040|Biological|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
75751709|NCT00339040|Other|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
75751710|NCT03743519|Dietary Supplement|Cherry juice|30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
75751711|NCT03743519|Dietary Supplement|Placebo|Identical in taste and colour to the Cherry juice, but with no anthocyanin content
75751712|NCT04015193|Procedure|Single-port thoracoscopic sympathicotomy (patient care)|Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
75751713|NCT00931697|Drug|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
75751714|NCT00931697|Drug|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
75751715|NCT00931697|Drug|Placebo|Over-encapsulated placebo to maintain blinding
75751716|NCT00927797|Drug|Cyclophosphamide, Pentostatin, Rituximab|
75751717|NCT00338962|Drug|paroxetine|paroxetine (40mg/day)
75900576|NCT02310074|Drug|Pulsatile Gonadotropin Releasing Hormone|
75751718|NCT00338962|Drug|desipramine|200 mg per day
75751719|NCT00338962|Drug|Naltrexone|50 mg per day
75751720|NCT00338962|Drug|Placebo|placebo
75751721|NCT00931775|Drug|Pindolol|Pill orally administered. 15 mg/day t.i.d.
75751722|NCT00927875|Drug|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
75900577|NCT02310074|Drug|Human chorionic gonadotropin|Human chorionic gonadotropin (hCG)
75900578|NCT02310074|Drug|Urinary Follicle-Stimulating Hormone|Urinary Follicle-Stimulating Hormone (uFSH)
75900579|NCT05059912|Biological|Humanized CD7 CAR-T cells|Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma
75900580|NCT05063968|Drug|XZP-6019 tablet|Tablet is administered orally once on Day 1 and Day 9, respectively
75455362|NCT01759706|Drug|Preoperative bowel preparation with sodium phosphate|Preoperative bowel preparation with oral assumption of sodium phosphate
75751723|NCT00927875|Drug|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
75751724|NCT00927875|Drug|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, & 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
75751725|NCT00924599|Behavioral|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
75751726|NCT00924599|Behavioral|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
75751727|NCT00924677|Procedure|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
75751728|NCT00924677|Procedure|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
75751729|NCT00568061|Drug|Nitric Oxide|Nitric oxide for inhalation
75751730|NCT00568061|Drug|Placebo|Nitrogen gas (placebo) for inhalation
75751731|NCT00931853|Drug|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
75751732|NCT00931931|Biological|HSV1716|
75751733|NCT03547427|Other|Basal insulin alone|A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
75900581|NCT05063968|Drug|Placebo|Tablet is administered orally once on Day 1 and Day 9, respectively
75900582|NCT05063968|Drug|XZP-6019 tablet|Tablet is administered fasted orally once on Day 1
75900583|NCT05063968|Drug|XZP-6019 tablet|Tablet is administered after a high-fat meal orally once on Day 9
75900584|NCT05063968|Drug|XZP-6019 tablet|Tablet is administered orally once daily for 14 Days continuously
75900585|NCT05063968|Drug|Placebo|Tablet is administered orally once daily for 14 Days continuously
75900586|NCT02313584|Drug|dabigatran|
75900587|NCT02313584|Drug|placebo|
75900588|NCT02310152|Behavioral|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
75900589|NCT02310152|Behavioral|CBT|Cognitive Behavioral Therapy
75606524|NCT03671239|Behavioral|Placebo rectal insert|Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
75751734|NCT03547427|Other|Basal pramlintide and reduced basal insulin|A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at ~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
76066984|NCT03612544|Other|ENDS (Vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75751735|NCT03547427|Other|CGM|Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
75751736|NCT03547427|Other|Acetaminophen test|Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
75751737|NCT03547427|Other|Insulin-induced hypoglycemia|During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
75900590|NCT05063578|Drug|Lidocaine 2% Injectable Solution|Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
75900591|NCT02310230|Device|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
75900592|NCT02667652|Procedure|short biliarypancreatic limb|biliarypancreatic limb:50cm;roux limb:150cm.
75900593|NCT02667652|Procedure|long biliarypancreatic limb|biliarypancreatic limb:100cm;roux limb:100cm.
75455363|NCT01759719|Device|coronary angioplasty with PtCr stent implantation|PCI with deployment of at least 1 PtCr stent
75900594|NCT02310308|Dietary Supplement|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
75900595|NCT04412434|Diagnostic Test|Electroencephalography (EEG)|"Electroencephalography (EEG) is a painless and harmless method to record the bioelectric activity of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp This method can be helpful in the diagnosis of many various brain diseases and pathological conditions.~For the examination, electrodes are placed on the head, using a special harmless gel, similar to gel, used in ultrasonographic studies."
75751738|NCT03547427|Other|Exercise-induced hypoglycemia|During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
75751739|NCT00932087|Procedure|Blood sample|Blood sample for lipidomic study
75751740|NCT00928109|Behavioral|CBCT|Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
75751741|NCT00928109|Behavioral|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
75455364|NCT01759732|Drug|Fludarabine|40mg/M2 once daily IV on days -7 to -4
75455365|NCT01759732|Drug|Cyclophosphamide|60 mg/kg IV on day-3 and -2
75455366|NCT01759732|Biological|anti-thymocyte globulin|
75455367|NCT01759732|Biological|filgrastim|
75455368|NCT01759732|Radiation|Total body irradiation|200 cGy per day on D-5 & -4
75455369|NCT01759732|Procedure|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
75455370|NCT01759758|Other|Plaster Ulnar Gutter Splint|Patients are placed in a plaster ulnar gutter splint, molded in the safe position.
75606525|NCT03671239|Behavioral|Placebo rectal suppository|Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
75900596|NCT02316782|Device|Blinded IVUS assessment|Only the angiogram is used for stent placement
75900597|NCT02316782|Device|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
75900598|NCT03545568|Other|Neu5Ac supplementation|Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
75900599|NCT03845374|Device|Hyper-CL™ lens|Use of the Hyper-CL™
75455371|NCT01759758|Other|Thermoplastic Splint|Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
75455372|NCT01759771|Drug|Vitamin D3|4,000 IU of VD3 for at least one year
75455373|NCT01759771|Drug|Placebo|Placebo for at least one year
75455374|NCT01759784|Biological|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
75606526|NCT03671239|Behavioral|Placebo rectal douche|Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
75751742|NCT00928265|Device|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.~Accomplishes this by providing coil support at the neck of the aneurysm"
75751743|NCT00928343|Drug|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
75751744|NCT00928343|Drug|Placebo|Matching subcutaneous or oral placebo
75900600|NCT02140710|Procedure|Osteopathic treatment|visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
75900601|NCT05063422|Drug|polymyxin b/trimethoprim ophthalmic, Carboxymethyl cellulose|3 forms of denture adhesives from each brands are used to compare the retentive strength on highly resorbed ridges
75455375|NCT01759797|Biological|intra venous injection of stem cell|Intra venous injection of mesenchymal stem cell
75455376|NCT01759810|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
75455377|NCT01759810|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
75751745|NCT00338884|Drug|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
75751746|NCT00338806|Behavioral|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
75455378|NCT01759823|Biological|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
75751747|NCT00338806|Behavioral|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
75751748|NCT03038100|Drug|Paclitaxel|Paclitaxel 175 milligrams per square meter (mg/m^2) IV infusion on Day 1 of each 21-day cycle
75751749|NCT03038100|Drug|Carboplatin|Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) on Day 1 of each 21-day cycle for a total of 6 cycles
75751750|NCT03038100|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
75751751|NCT03038100|Drug|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
75455379|NCT01759823|Other|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
75606527|NCT02845609|Drug|Sialic Acid-Extended Release|Oral drug of Sialic acid
75751752|NCT03038100|Drug|Atezolizumab Placebo|Placebo matching to atezolizumab on Day 1 of each 21-day cycle
75751753|NCT00338728|Drug|Imatinib Mesylate|Given PO
75751754|NCT00338728|Drug|Letrozole|Given PO
75606528|NCT05177185|Radiation|Hippocampal-sparing|Dose constraint placed on hippocampi to minimize dose to hippocampi, while maintaining target coverage (at least 98% of brain metastasis volume must receive 100% of prescription dose).
75606529|NCT05177185|Radiation|Stereotactic radiosurgery|Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
75606530|NCT05337085|Drug|Dexmedetomidine|Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery
75606531|NCT05337085|Drug|Midazolam|Midazolam
75606532|NCT02845765|Device|Dynamic Vessel Analyzer (DVA)|
75751755|NCT01059136|Drug|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
75751756|NCT01061242|Behavioral|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
75751757|NCT03985618|Procedure|Caesarean section|Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
75751758|NCT03985618|Procedure|Induction of Labour|Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
75751759|NCT03983278|Other|School Model|Free delivery of glasses at the school within two weeks after screening
75751760|NCT03983278|Other|Referral Model|After the primary screening children referred to nearby Vision Center/ secondary center for refraction and delivery of free glasses.
75606533|NCT02845765|Drug|Phosphodiesterase type 5 Inhibitor (PDE5I)|
75751761|NCT03983278|Other|Referral Model + Cost Recovery|"After the screening children referred to Vision Center for refraction and delivery of free glasses with the option to purchase upgrade glasses"
75900602|NCT03501602|Device|LMA protector|In this arm the LMA protector will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
75900603|NCT03501602|Device|I-gel LMA|In this arm the I-gel LMA will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
75751762|NCT00336856|Drug|Cetuximab|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
76066985|NCT03612544|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
76066986|NCT03612453|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
75606534|NCT05097937|Other|Sham intervention|The needle will be inserted into the right common extensor tendon of the epicondyle for 90 seconds without galvanic current.
75606535|NCT05097937|Other|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 0.3 mA for 90 seconds.
75606536|NCT05097937|Other|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 3 mA and a duration of 3 seconds each.
75751763|NCT00336856|Drug|Irinotecan|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
75751764|NCT02532868|Drug|MK-0457|
75751765|NCT01059370|Procedure|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
75751766|NCT00566501|Drug|Donepezil|Donepezil SR 23 mg once daily orally.
75606537|NCT01723579|Drug|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
75606538|NCT01723579|Drug|Estradiol (E2)|Daily release of 1.5 mg
75900604|NCT05063188|Other|Connective Tissue Massage|Connective tissue massage was started from lumbosacral region and continued lower thoracic, scapular, interscapular, and cervical regions, respectively.
75900605|NCT05063188|Other|clinical pilates exercises|Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
75900606|NCT02316860|Other|Passive tilt test|Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
75900607|NCT05063266|Other|Deep Breathing Exercise|control groups received deep breathing exercise 6 days a week for two weeks. Deep breathing exercises includes diaphragmatic breathing and pursed lip breathing.
75900608|NCT05063266|Other|Inspiratory muscle Training|Treatment group received inspiratory muscle training 20 minutes 6 days a week for two weeks.IMT was done by using pressure threshold device.
75900609|NCT03501524|Device|VATS evacuation|the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax
75900610|NCT03501524|Device|thoracostomy tube|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
75900611|NCT02313662|Device|NBI and PDD|
75900612|NCT03782350|Drug|Tranexamic Acid Dosage 1|Tranexamic Acid Dosage 1
75900613|NCT03782350|Drug|Tranexamic Acid Dosage 2|Tranexamic Acid Dosage 2
75900614|NCT02310386|Device|BEMER electromagnetic field therapy|To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
75900615|NCT02313740|Biological|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
75900616|NCT02310542|Device|MARS albumin dialysis system|
75900617|NCT02310542|Device|SPAD albumin dialysis system|
76066987|NCT03612453|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
75455380|NCT01759823|Biological|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
75455381|NCT01759849|Other|Allergen|Allergen extract is administered by inhalation.
75455382|NCT01759875|Drug|Ritonavir-boosted Atazanavir|Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
75751767|NCT00504894|Drug|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
75900618|NCT03098680|Drug|Albuterol Sulfate|see arm/group descriptions
75900619|NCT03098680|Drug|Nicardipine Hydrochloride|see arm/group descriptions
75900620|NCT03098680|Drug|Dobutamine Hydrochloride|see arm/group descriptions
75900621|NCT03098680|Drug|Phenylephrine Hydrochloride|see arm/group descriptions
75455383|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
75455384|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
75751768|NCT00504894|Drug|Propofol|A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
75751769|NCT00504894|Drug|Thiopental|A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
75751770|NCT03743441|Other|Low-level Laser Therapy|LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.
75900622|NCT03098680|Drug|Verapamil Hydrochloride|see arm/group descriptions
75900623|NCT03098680|Drug|Phentolamine Mesylate|see arm/group descriptions
75900624|NCT03098680|Drug|Placebo|see arm/group descriptions
75900625|NCT02317094|Other|Blood-flow restricted training|The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
75900626|NCT02317094|Drug|Care as usual|The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
75900627|NCT03098446|Behavioral|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
75751771|NCT03743441|Other|Sham Low-level Laser Therapy|Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
75455385|NCT01759888|Drug|18F-DTBZ|"Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
75900628|NCT03098446|Behavioral|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
75900629|NCT02313818|Behavioral|Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
75900630|NCT03098524|Procedure|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
75900631|NCT03098524|Procedure|No ventilation (noV arm)|During cardiopulmonary bypass, no mechanical ventilation is performed.
75900632|NCT03098524|Procedure|Lung recruitment manoeuver|"An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit)."
75900633|NCT02313896|Behavioral|Phone calls|Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
75900634|NCT03098368|Drug|Rotigotine|
75900635|NCT03098368|Drug|Placebo|Placebo of rotigotine patch
75900636|NCT02310854|Procedure|ACL Repair|augmented suture of acute ACL rupture (<3 weeks after injury)
75900637|NCT02310854|Procedure|ACL reconstruction|reconstruction hamstring autograft
75900638|NCT02313974|Procedure|Renal Biopsy|
75900639|NCT04434820|Device|External negative pressure dressing system (Yuwell 7E-A portable suction unit)|A portable suction unit that will deliver 125 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
75900640|NCT02310932|Behavioral|Healthy Living Intervention|"Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support."
75900641|NCT05062486|Drug|Resveratrol, Quercetin, Curcumin (RQC)|100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
75606539|NCT03648931|Behavioral|Focus Group Discussion (FGD)|"No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~Perceptions of HIV risk during pregnancy and breastfeeding~Perceived role of male partners during pregnancy and breastfeeding~Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding"
75900642|NCT05062486|Drug|Curcumin|1000 mg curcumin BID
75900643|NCT02317172|Other|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
75900644|NCT02314130|Dietary Supplement|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
75900645|NCT02314208|Drug|Xenbilox|
75751772|NCT03743441|Other|Exercise therapy|Concentric and eccentric exercises with a total duration of approximately 20 minutes.
75751773|NCT03743441|Other|Cryotherapy|Twenty minutes of cryotherapy applied to the Achilles tendon.
75900646|NCT02314208|Dietary Supplement|Resveratrol|
75900647|NCT02314208|Drug|Tahor|
75900648|NCT03098212|Other|Aromatherapy|On the day of admission for labor. Pregnant women select type of essential oil. Aroma diffuser is used during labor. Pain score was record during latent, early active and late active phase.
75455386|NCT01759914|Drug|Potent topical steroid|
75455387|NCT01759914|Drug|Superpotent topical steroid|
75751774|NCT00924755|Device|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
75751775|NCT01011348|Dietary Supplement|Coenzyme Q10|100mg/day for three months
75751776|NCT01011348|Dietary Supplement|Coenzyme Q10|300mg/day for three months
75751777|NCT01011348|Dietary Supplement|Placebo|Three month period
75751778|NCT00924911|Drug|GSK1322322|Four different formulations of 1000mg of GSK1322322
75751779|NCT00924911|Drug|GSK1322322|GSK1322322 1000mg
75751780|NCT00928655|Drug|acetazolamide|acetazolamide 250mg 1/0/2
75606540|NCT03648931|Behavioral|In-depth Interview (IDI)|"No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~Perceptions of HIV risk during pregnancy and breastfeeding~Perceived role of male partners during pregnancy and breastfeeding~Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women"
75606541|NCT01481935|Other|Enhanced cleaning of surfaces in ICU rooms|Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.
75751781|NCT00928655|Procedure|nocturnal continuous positive airway pressure|continuous positive airway pressure
75751782|NCT00928655|Drug|placebo|placebo capsules
75751783|NCT03743363|Other|Exergame 2/week|virtual training 2 times a week(8 week-long)
75751784|NCT03743363|Other|Exergaming 3/week|virtual training 3 times a week(8 week-long)
75751785|NCT03743363|Other|Healthy control / Exergaming 1/week|In the first 8 week-long only control group. For the next 8 weeks, the control group will do 1 workout per week.
75751786|NCT01011426|Drug|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
75751787|NCT01011426|Drug|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
75751788|NCT00925067|Procedure|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
75751789|NCT00925067|Device|lightweight TiMesh|
75751790|NCT00925067|Device|lightweight VyproII|
75900649|NCT02317250|Procedure|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
75751791|NCT00925067|Device|Heavyweight Marlex|
75751792|NCT02808156|Other|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
75751793|NCT02808156|Other|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
75751794|NCT00932555|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
75751795|NCT00928733|Device|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
75900650|NCT02317250|Procedure|FDG-PET|[F-18] FDG-PET brain scans are administered once to all arms.
75900651|NCT05059288|Device|Investigational Non Invasive Ventilation Mask|Oronasal non invasive ventilation mask
75900652|NCT03502538|Device|Curaprox 5460 Ultra Soft|The toothbrush Curaprox 5460 Ultra Soft will be the tested toothbrush model, in order to asses its efficacy in plaque removal. Therefore, the study participants should brush their teeth using this toothbrush model, following the instructions of the investigator. From the data collect related in plaque removal the results will be arrived at.
75900653|NCT03502538|Device|Oral-B Indicator Plus|Following the same method of the Curaprox group intervention, the participants should brush their teeth using the Oral-B Indicator Plus toothbrush and based on the data collect, the results will be compared with the first group of intervention.
75900654|NCT03100318|Drug|FYU-981|Oral daily dosing for 14 weeks
75751796|NCT01012908|Dietary Supplement|Norzyme - Bergamo|2 - 8 tablets per day.
75751797|NCT01012908|Dietary Supplement|Creon|2 - 8 tablets pet day
75751798|NCT00932711|Behavioral|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
75751799|NCT04014959|Combination Product|TMS/ fMRI Stimulation|"The study uses a modified repetitive TMS stimulation protocol. Participants receive active TMS on five separate days: a baseline TMS/ fMRI scan, three mini TMS sessions, and a final TMS/ fMRI scan.~Again, this level of stimulation is considered to be sub-threshold for that of a TMS treatment protocol."
75751800|NCT01012986|Other|Assessment of reading skills|
75751801|NCT00513240|Drug|Erythropoetin|Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
75751802|NCT00513240|Drug|Normal saline|"Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~."
75751803|NCT00925145|Procedure|Single Incision Laparoscopic Appendectomy|
75606542|NCT01481935|Other|Sham enhanced cleaning of surfaces in ICU rooms|While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
75606543|NCT00901927|Drug|Bendamustine|Starting dose 90 mg/m^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
75751804|NCT00928811|Drug|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
75751805|NCT00928811|Drug|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
75751806|NCT00932867|Drug|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
75751807|NCT00928967|Drug|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
75751808|NCT00932945|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
75751809|NCT00504426|Drug|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
75751810|NCT00933023|Drug|hydrocortisone|1%hydrocortisone topical once daily for 8 weeks
75751811|NCT00933023|Drug|Betamethasone|Betamethasone 0.1% topical once daily for 8weeks
75900655|NCT03100318|Drug|Benzbromarone|Oral daily dosing for 14 weeks
75900656|NCT04463420|Drug|PHR160 Spray|One puff spray per hour containing 300 mg of the drug will be given to patients. This treatment lasts up to 10 days.
75751812|NCT00933179|Drug|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
75751813|NCT00933179|Drug|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
75751814|NCT00504348|Drug|Tacrolimus|Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
75751815|NCT00929123|Procedure|neural mobilization|manual therapy technique known to directly stress the median nerve
75751816|NCT00929123|Procedure|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
75751817|NCT00929123|Other|healthy controls|People without carpal tunnel syndrome for comparison
75751818|NCT00507546|Drug|Ramelteon|8 mg nightly
75751819|NCT00507546|Drug|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
75751820|NCT00925457|Other|No Intervention|Neither current domperidone nor current PPI
75751821|NCT00925457|Drug|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
75751822|NCT00925457|Drug|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
75751823|NCT04522674|Biological|Autologous platelet rich plasma|0.5 mL autologous platelet rich plasma into a symptomatic osteoarthritic lumbar facet to treat back pain caused by lumbar facet syndrome
75900657|NCT04463420|Drug|Placebo|participants will receive a placebo spray every hour. This process will continue for 10 days.
75900658|NCT04463420|Drug|Standard treatment|: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days
75751824|NCT00933257|Drug|LACTIC ACID(ND)|Treatment duration 5 weeks
75751825|NCT04015271|Behavioral|Action Observation + Repetitive Task Practice|Observing a video of another person performing a functional task and physically repetitively performing the same task for upper extremity hemiparesis
75751826|NCT04015271|Behavioral|Placebo Video + Repetitive Task Practice|Observing a video of static images and physically repetitively performing functional task for upper extremity hemiparesis
75900659|NCT02311010|Drug|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
75751827|NCT00925613|Device|LMA Proseal|"Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube."
75900660|NCT02314286|Drug|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
75900661|NCT02314286|Drug|Placebo|
75900662|NCT02317406|Drug|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
75900663|NCT02317406|Drug|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
75900664|NCT05061784|Procedure|Routine thymectomy, which has been performed|There is no intervention
75900665|NCT03132194|Drug|DPSG 7.5%|topical gel
75900666|NCT03132194|Drug|Aczone|topical gel
75900667|NCT03132194|Drug|Placebo|topical gel
75900668|NCT05061628|Drug|JS006 as Monotherapy|"JS006 as Monotherapy dose-escalation: JS006, 18/ 60/ 180/ 600/ 1800mg, IV infusion, every 3 weeks (q3w).~JS006 as Monotherapy dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w)."
75900669|NCT05061628|Drug|JS006 in combination with Toripalimab|"JS006 in combination with Toripalimab dose-escalation: JS006, 2 or 3 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~JS006 in combination with Toripalimab dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~JS006 in combination with Toripalimab indications expansion: JS006, RP2D, IV infusion, every 3 weeks(q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w)."
75900670|NCT05010616|Device|Fixed orthodontic appliances|"Visual presentation of patient's predicted teeth alignment at the end of orthodontic treatment:~Presenting predicted teeth alignment after orthodontic treatment to patients before treatment starts, by using photos and videos of dental digital set-up.~Predicted teeth alignment can be described as: well-leveled and aligned patient's dental arches, well engaged posterior teeth and normal frontal teeth relationships."
75900671|NCT02314442|Drug|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
75900672|NCT02314442|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
75455388|NCT01759927|Behavioral|physical activity coaching|After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
75455389|NCT01759940|Drug|ropivacaine 0,375%|
75455390|NCT01759940|Drug|ropivacaine 0,75%|
75455391|NCT01759953|Other|Game|InsuOnline game, on the web, in the player´s own time and rhythm
75455392|NCT01759953|Other|Traditional CME|In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
75455393|NCT01759979|Procedure|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
75455394|NCT01759979|Procedure|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
75606544|NCT00901927|Drug|Mitoxantrone|10 mg/m^2 by vein over 15 minutes on Day 2 of each cycle.
75606545|NCT00901927|Drug|Rituximab|375 mg/m^2 by vein over several hours on Day 1 of each cycle.
75606546|NCT01400269|Behavioral|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
75606547|NCT02845141|Procedure|Actifuse|bone tunnel filled with Actifuse
75606548|NCT02845141|Procedure|bone graft|bone graft to fill bone tunnel
75606549|NCT04602871|Diagnostic Test|Breath Biopsy|Breath Biopsy sampling using the ReCIVA® Breath Sampler
75751828|NCT00925613|Device|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
75900673|NCT03614572|Behavioral|Group MI|refer to the arm description
75751829|NCT00929279|Drug|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
75751830|NCT00929279|Drug|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
75900674|NCT03501290|Dietary Supplement|Fortimel® Protein supplementation|"Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month."
75900675|NCT05058586|Other|The Effects of Aerobic Exercise Training on Cardiorespiratory Fitness, Functional Capacity, Balance and Ventricular Repolarization Indices in Stroke Patients|Seventy patients with history of stroke admitted to our center between July 2017 and January 2018. Subjects participated in the study were randomly assigned to anti-gravity treadmill training, underwater walking therapy and control group. We examined aerobic capacity of participants by using 6-minute walk test and cycle ergometer testing before starting the treatment along with one month follow up. Patient's balance examined by using the Berg Balance Scale (BBS).
75900676|NCT03505268|Behavioral|Telemedicine|Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
75900677|NCT03423862|Other|Mixed Meal Tolerance Test|"After a 10-hour overnight fast (not eating or drinking anything except water), participants will complete a mixed meal tolerance test (MMTT):~This involves participants drinking a Boost drink, like a milkshake, which will raise participants' blood sugar.~The amount of Boost will be based on participants body weight, up to a maximum of 360 mL or about 1 ½ cups, and should be consumed within 5 minutes.~An IV will be placed in participants arm and blood will be drawn from it. Blood will be drawn from the IV before and then 6 times over the next 2 hours after participants drink the Boost."
75900678|NCT02311088|Drug|Caffeine|
75900679|NCT02311088|Drug|Placebo|
75900680|NCT05058352|Drug|HS269|Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.
75900681|NCT02314676|Biological|PEG-somatropin|
75455395|NCT01759992|Device|Threshold® Inspiratory Muscle Trainer (treatment).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
75455396|NCT01760018|Drug|desflurane group|anesthesia is maintained with desflurane and remifentanil (Desflurane group)
75900682|NCT05060770|Genetic|transcriptomic analysis|transcriptomic analysis on preserved tumor tissue
75455397|NCT01760018|Drug|TIVA group|anesthesia is maintained with fresofol and remifentanil (TIVA group).
75455398|NCT01760031|Other|Ischemic preconditioning|Subjects received ischemic preconditioning previous to cardiac catheterization
75455399|NCT01760044|Device|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
75900683|NCT03501212|Drug|Topical Anesthetic|EMLA Cream 2.5 gr applied to both wrists
75900684|NCT03501212|Drug|Placebo|Placebo Cream 2.5gr applied to both wrist
75900685|NCT02317484|Drug|Ipragliflozin (SGLT2 inhibitor)|
75900686|NCT02140866|Other|Hand Exercise|
75900687|NCT02140866|Other|Compensatory Intervention Program (CIP)|
75900688|NCT03502460|Other|Operating Room Fluid Administration Lung Ultrasound|Use of lung ultrasound to limited fluid administration
75900689|NCT02141022|Other|plasticity-based computerized cognitive remediation program|
75900690|NCT02141022|Drug|Gileyna|
75900691|NCT02642614|Drug|BI 1026706|
75455400|NCT01760057|Behavioral|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging|
75455401|NCT01760057|Behavioral|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites|
75455402|NCT01760070|Device|Hybrid knife|Use Hybrid knife in ESD procedure
75455403|NCT01760070|Device|IT knife|Use IT knife in ESD procedure.
75455404|NCT01760083|Device|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
75455405|NCT01760096|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
75900692|NCT02642614|Drug|Placebo|
75900693|NCT02642614|Drug|Placebo|For blinding purposes
75900694|NCT03501134|Device|NovoTTF|We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
75900695|NCT02781324|Procedure|Posterior Spinal Fusion|
75900696|NCT02781324|Device|Ultrasonic Bone Scalpel|
75900697|NCT04435210|Drug|Hydralazine|Participants in this group will receive 10mg of hydralazine intravenously. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses.
75751831|NCT00567593|Drug|Rosiglitazone|8mg tablet once a day for 14 days
75751832|NCT00335764|Drug|sorafenib tosylate|given orally
75751833|NCT00335764|Drug|erlotinib hydrochloride|given orally
75751834|NCT00335764|Drug|tipifarnib|given orally
75751835|NCT00335764|Drug|temsirolimus|IV administration
75751836|NCT03743285|Device|AID System|AID system
75751837|NCT03743285|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
75751838|NCT00933413|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
75751839|NCT03981562|Drug|Vit D|Patients will take an oral vitamin D supplement once a day for 6 months.
75751840|NCT03981562|Drug|Placebo Oral Tablet|Patients will take a placebo oral tablet once a day for 6 months.
75751841|NCT03981484|Biological|Prothrombin Complex Concentrate|single dose of 25 IU/kg of 4-PCC at time of enrollment
75751842|NCT03981484|Biological|Whole Blood, Plasma, Packed Red Blood Cells|site's standard resuscitation protocol
75751843|NCT03983200|Device|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min, bid
75751844|NCT03983200|Drug|Mecobalamin|mecobalamine 0.5mg,tid
75751845|NCT00567359|Drug|Erlotinib|Oral drug taken daily around the same time. Starting dose is 150mg once daily.
75455406|NCT01760096|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
75751846|NCT01063582|Other|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
75751847|NCT01063582|Procedure|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
75751848|NCT04014725|Device|Myopia Intelligent Diagnostic System|An artificial intelligence to make diagnosis of myopia using ocular appearance images
75751849|NCT01063660|Drug|Treosulfan|14 g/m²/d day -6 to -4
75751850|NCT00933569|Drug|LACTIC ACID(ND)|treatment period: 21 consecutive days
75751851|NCT00925847|Drug|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
75751852|NCT00492726|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
75751853|NCT00492726|Drug|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
75455407|NCT01760096|Drug|Glucocorticoids|Glucocorticoids0.25mg/kg every day(prednisone)
75751854|NCT00925925|Other|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
75751855|NCT00933647|Dietary Supplement|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
75751856|NCT00933647|Dietary Supplement|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
75751857|NCT00933647|Dietary Supplement|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
75751858|NCT00933725|Other|TCM intervention|"Drug: Particle of compound Chinese herbs(produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~One tablet placebo of Tibolone (provided by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.~Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months."
75751859|NCT00933725|Other|Western intervention|"Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months."
75751860|NCT00309946|Drug|cediranib maleate|Given orally
75751861|NCT00492648|Procedure|Blood sampling for assay of persistence of immunogenicity|Two blood samples: 30 and 42 months after first vaccination
75751862|NCT00929591|Drug|cyclophosphamide|
75751863|NCT00929591|Drug|doxorubicin hydrochloride|
75751864|NCT00929591|Drug|endocrine therapy|
75751865|NCT00929591|Drug|endocrine-modulating drug therapy|
75751866|NCT00929591|Drug|fluorouracil|
75751867|NCT00929591|Drug|tamoxifen citrate|
75455408|NCT01760109|Drug|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
75455409|NCT01760122|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
75455410|NCT01760122|Drug|Pegasys|sc, qw, 48 weeks.
75455411|NCT01760135|Dietary Supplement|high caloric nutritional supplement|high caloric nutritional supplement (25kcal/kg)
75455412|NCT01760135|Dietary Supplement|low caloric nutritional supplement|low caloric nutritional supplement(15kcal/kg)
75455413|NCT01760148|Drug|interferon alpha 2b|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
75455414|NCT01760161|Drug|Ropivacaine|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
75606550|NCT05335837|Procedure|Regional Anesthesia and Sedation|Preoperative ilioinguinal/iliohypogastric nerve block and moderate to deep intraoperative sedation.
75606551|NCT05336929|Other|Roy adaptation model-based nursing education|
75606552|NCT00903721|Drug|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months"
75606553|NCT02844985|Other|No Intervention|
75606554|NCT04900987|Device|Steri-strips|Pneumatic TR band compression with use of steri-strips
75606555|NCT02845219|Drug|semaglutide|Oral administration once daily alone or together with oral contraceptive.
75751868|NCT00929591|Radiation|brachytherapy|
75751869|NCT00929591|Radiation|low-LET electron therapy|
75751870|NCT00929591|Radiation|low-LET photon therapy|
75751871|NCT00929591|Radiation|radiation therapy|
75751872|NCT01063738|Dietary Supplement|Amino acid supplement|Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
75900698|NCT04435210|Drug|Nifedipine|Participants in this arm will receive 20mg of nifedipine and the blood pressure will be measured 30 minutes after the dose. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses
75900699|NCT03501056|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
75900700|NCT03501056|Procedure|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
75900701|NCT03100084|Other|Blood sampling|Maternal blood sampling
75900702|NCT03502382|Diagnostic Test|x-ray|Radiological: standing antero-posterior full-length digital images of the lower extremities
75455415|NCT01760161|Drug|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
75455416|NCT01760174|Drug|Ropivacaine bolus in transversus abdominis plane catheter|"Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours."
75455417|NCT01760174|Drug|Bupivacain-infusion in epidural catheter|"Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours"
75606556|NCT02845219|Drug|SNAC|Oral administration once daily together with oral contraceptive.
75606557|NCT02845219|Drug|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
75606558|NCT00968968|Drug|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
75751873|NCT01063738|Other|PEPSE|Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
75751874|NCT01063738|Other|Intensive Care Unit (ICU) Recovery Manual|Standard self-directed 6 week rehabilitation package
75751875|NCT01063738|Dietary Supplement|Placebo nutritional supplement|Cherry flavoured low calorie and low protein placebo drink
75751876|NCT00929747|Device|Toric|Unilateral implantation of the AcrySof IQ Toric IOL
75751877|NCT00929747|Procedure|Limbal Relaxing Incision|Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
75751878|NCT03997500|Drug|normal saline|a bolus of normal saline was given followed by normal saline infusion
75751879|NCT03997500|Drug|Norepinephrine|a bolus of norepinephrine was given followed by norepinephrine infusion
75900703|NCT03292146|Drug|Denosumab 60 MG [Prolia]|Denosumab 60mg injection at baseline and 6 months
75900704|NCT03292146|Drug|Placebo Injection|Placebo Injection at baseline and 6 months
75900705|NCT03292146|Drug|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at Month 12 through 24 months.
75751880|NCT00933881|Other|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
75751881|NCT01013064|Drug|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
75751882|NCT00933959|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
75751883|NCT00933959|Behavioral|Sleep Hygiene|Treatment as usual
76066988|NCT03612375|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75455418|NCT01760213|Other|CBT delivered via Internet|
75606559|NCT00968968|Biological|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
75606560|NCT02842801|Other|Hip manipulation|High-amplitude and low-velocity thrust mobilization
75606561|NCT04819009|Other|the Enhanced Transtheoretical Model Intervention (ETMI)|"ETMI consists of a physical and functional examination, a discussion about the role of physical activity matched to the patient stage of change, and guided through motivational interviewing techniques, exposure to fast walking, and goal setting. The patient receives a postcard outlining the main messages about physical activity and four simple stretches.~The ETMI method consists of four parts:~Creating a therapeutic alliance (communication skills and reassurance)~Clear messages to the patient: Mandatory 3 sentences: (1. physical activity is the only thing that will help your back pain over time. 2. It's easy to reduce your pain now - but the important thing is to prevent the next episode, 3. Your body must be strong and flexible.)~Exposure to brisk walking (brisk walking in the corridor, hand by hand with the therapist) and graded activity.~Postcard with reminder messages on how to self manage the back."
75606562|NCT02862886|Other|myometrium biopsy|
75606563|NCT00973102|Drug|Premarin IV|One time dose of Premarin IV
75606564|NCT00973102|Drug|Placebo|One time dose of placebo.
75751884|NCT01011660|Drug|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
75751885|NCT04014881|Biological|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
75751886|NCT04015505|Behavioral|Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'|The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
75751887|NCT01015248|Drug|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
75751888|NCT00926081|Behavioral|Supervised exercise training|A standardized supervised exercise training program
75751889|NCT00929825|Device|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
75751890|NCT00929825|Procedure|TENS|transcutaneous electrical stimulation
75751891|NCT01013142|Drug|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
75751892|NCT01013142|Drug|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
75751893|NCT01013142|Drug|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
75751894|NCT00934037|Procedure|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
75751895|NCT00934037|Other|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
75606565|NCT04689061|Device|Arthrex FastThread Interference Screw|The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
75606566|NCT04622605|Device|Trabecular bypass and Schlemm's canal stent|ab interno Microstent placement after cataract surgery
75900706|NCT03132506|Other|patient-reported-outcomes|Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
75606567|NCT05205070|Biological|Rosnilimab|humanized monoclonal antibody
75606568|NCT05205070|Biological|Placebo|Placebo solution
75751896|NCT01013220|Other|Depression Product Detailing|"two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits~technical assistance in purchasing high quality depression management products"
75751897|NCT01013220|Other|Depression HEDIS detailing|"academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition~technical assistance"
75751898|NCT04014569|Device|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA Algorithm
75606569|NCT02863588|Biological|seropositive for Toxoplasma gondii|blood sample
75606570|NCT03691090|Drug|SHR-1210|SHR-1210 200mg
75606571|NCT03691090|Drug|Placebo|Placebo
75606572|NCT03691090|Drug|paclitaxel|paclitaxel 175mg/m2
75606573|NCT03691090|Drug|cisplatin|cisplatin 75mg/m2
75606574|NCT00783211|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
75606575|NCT00783211|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
75751899|NCT00506922|Drug|Pentostatin|"Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m^2~Group 3 - Pentostatin 1 mg/m^2~Group 4 - Pentostatin 1.5 mg/m^2~Group 5 - Pentostatin 2 mg/m^2"
75751900|NCT00506922|Drug|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
75751901|NCT00506922|Drug|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
75751902|NCT00929903|Drug|pazopanib hydrochloride|Given orally
75900707|NCT02144376|Dietary Supplement|Ispaghula|
75606576|NCT00783211|Drug|placebo|placebo, once daily for 15 days
75606577|NCT00779545|Drug|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
75606578|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
75751903|NCT00929903|Other|pharmacological study|Correlative studies
75751904|NCT01013298|Device|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
75900708|NCT02144376|Dietary Supplement|Maltodextrin|
75900709|NCT03249532|Device|standard hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
75900710|NCT03249532|Device|cool hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
75900711|NCT03249532|Device|low volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
75606579|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
75751905|NCT00934193|Drug|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
75751906|NCT00934193|Drug|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
75606580|NCT00779545|Drug|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
75606581|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
75751907|NCT01013376|Drug|MC-1101|MC-1101 1.0%
75606582|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
75751908|NCT01013376|Drug|Vehicle|Vehicle
75751909|NCT01011972|Drug|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
75751910|NCT04014491|Procedure|Scapula control exercise|To perform arm elevation in the scapular plane, subjects will be first asked to correct scapular resting posture in sitting with EMG biofeedback. Then the subjects will be instructed to do elevation in the scapular plane, side lying external rotation and dynamic hug plus with control of the scapula by EMG feedback and verbal cues
75751911|NCT04014491|Procedure|scapular strengthening exercise|The subjects in the scapular strengthening group will be asked to perform these three exercises the same as scapula control group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
75751912|NCT04014491|Other|No intervention|No intervention
75751913|NCT01012050|Device|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
75751914|NCT01012050|Other|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
75751915|NCT00930137|Other|isocaloric for week diet|"Consumption of the 2 experimental diets~a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)."
75455428|NCT01760252|Drug|Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)|Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
75606583|NCT00901459|Device|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
75606584|NCT00901459|Device|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
75751916|NCT01015404|Drug|Trafermin|Administered to the bone defect during flap operation
75751917|NCT00934271|Radiation|fractionated stereotactic radiotherapy|Audit of outcome
75751918|NCT00492024|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
75751919|NCT00492024|Drug|Placebo|Placebo - 380 mg Microcrystalline Cellulose
75751920|NCT00934427|Drug|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
75900712|NCT03249532|Device|high volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
75900713|NCT02254122|Drug|BEA 2180 BR|
75900714|NCT02254122|Drug|Placebo|
75606585|NCT00901459|Device|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
75900715|NCT02254122|Device|Respimat®|
75606586|NCT02842567|Drug|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
75900716|NCT02314754|Drug|Mifepristone followed by misoprostol 24-48 hours later|200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
75900717|NCT02144454|Dietary Supplement|Saturated fat|
75900718|NCT02144454|Dietary Supplement|Monounsaturated fat|
75900719|NCT02144454|Dietary Supplement|n-6 polyunsaturated fat|
75900720|NCT02317640|Drug|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
75900721|NCT02317640|Other|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
75900722|NCT02317640|Device|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
75606587|NCT02842567|Drug|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
75606588|NCT02842489|Procedure|left lateral tilt-down position|patients will be positioned on their left side and at an angle of 20 degree
75606589|NCT02842489|Procedure|left lateral horizontal position|patients will be horizontally positioned on their left side
75606590|NCT02133703|Behavioral|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
75606591|NCT02133703|Behavioral|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
75606592|NCT02133703|Behavioral|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
75606593|NCT02133703|Behavioral|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
75751921|NCT00934427|Drug|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
75751922|NCT00926315|Drug|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
75900723|NCT05060614|Procedure|Hip fracture surgery|Hip fracture surgery
75900724|NCT05058118|Drug|FL058|50mg、250mg、500mg、1000mg、1500mg、2000mg
75751923|NCT00926315|Drug|Calcitriol|calcitriol 0.25 mcg PO bid
75751924|NCT01013454|Drug|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload [drug amount loaded in each patch]) will be applied to the upper back over a single 24 hour period
75751925|NCT00930215|Drug|D961H|Oral gelatin capsule
75751926|NCT00930215|Drug|D961H|Oral HPMC capsule
75751927|NCT00926471|Behavioral|Cognitive Behavioral Therapy (CBT) Program|12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
75900725|NCT05058118|Drug|Placebo|empty bottle
75900726|NCT02144532|Device|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
75900727|NCT03500978|Behavioral|Peer CBT Intervention|Peer specialist delivery of cognitive behavioral therapy intervention over the phone.
75900728|NCT02716948|Other|Laboratory Biomarker Analysis|Correlative studies
75900729|NCT02716948|Biological|Nivolumab|Given IV
75900730|NCT02716948|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
75900731|NCT03500900|Drug|Vildagliptin 50 mg|Acute administration of Vildagliptin, 50 mg.
75900732|NCT03500900|Drug|Placebo Oral Tablet|Acute administration of placebo tablet
75900733|NCT02144688|Drug|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
75751928|NCT00491556|Procedure|Early Initiation of Highly Active Anti-Retroviral Therapy|Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
75751929|NCT00491556|Procedure|Standard Care|Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
75900734|NCT02320760|Behavioral|Physical activity on prescription|
75900735|NCT05046652|Biological|Convalescent Plasma Therapy|In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
75455429|NCT01760278|Drug|recombinant Follicle Stimulating Hormone (rFSH)|"There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study."
75455430|NCT01760317|Procedure|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
75455431|NCT01760330|Drug|IV acetaminophen|
75606594|NCT02133703|Behavioral|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
75606595|NCT00896233|Procedure|MRE|"Part 1: Participants will have a screening visit, followed ~1 month later by two imaging visits over ~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed ~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans."
75751930|NCT04015037|Combination Product|placebo or drug|Group A and B (medicated or placebo)
75751931|NCT00926549|Device|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
75751932|NCT00926627|Drug|bosentan|62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight < 40 kg/90 lb)
75751933|NCT00926627|Drug|placebo|identical preparation as the study drug, but without the active substance, administered b.i.d.
75900736|NCT04463186|Other|Muscle Static Stretching|Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
75900737|NCT02141100|Drug|6-thioguanine|"All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.~In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy."
75900738|NCT05057650|Dietary Supplement|Vegan diet|Provide
75455432|NCT01760330|Drug|Placebo|
75455433|NCT01760343|Biological|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
75455434|NCT01760343|Biological|CSL830|CSL830 is a formulation of Berinert.
75455435|NCT01760382|Device|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
75455436|NCT01760408|Other|all patients on Home Parenteral Nutrition|
75455437|NCT01760421|Drug|Hydroxychloroquine|Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
75455438|NCT01760434|Other|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
75455439|NCT01760460|Drug|Anacetrapib|
75455440|NCT01760460|Drug|Placebo for anacetrapib|
75455441|NCT01760486|Behavioral|Shape Up Rhode Island|
75455442|NCT01760486|Behavioral|Shape Up Rhode Island + Professional Coach + Incentives|
75455443|NCT01760486|Behavioral|Shape Up Rhode Island + Peer Coach + Incentives|
75606596|NCT00705211|Drug|Ezetimibe|Ezetimibe, 10-mg tablets,
75606597|NCT00705211|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
75606598|NCT02839993|Device|tDCS|
75606599|NCT02839993|Behavioral|training|
75606600|NCT02842255|Device|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
75900739|NCT04462718|Other|Radiofrecuency|EXPERIMENTAL GROUP: After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.
75900740|NCT04462718|Other|Therapeutic Exercise|CONTROL GROUP: will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated at the end of that period and six moths later in order to have at least three timepoints to evaluate.
75900741|NCT02141178|Drug|Bupivacaine|
75900742|NCT02141178|Drug|Exparel|
75900743|NCT05057338|Behavioral|CoreDISTparticipation|CoreDISTparticipation is a thorough intervention that contains coordination of services (physiotherapy, MS-nursing and work adaptations) between the MS-OP clinic and the municipality aiming to improve function, physical activity and employment in individuals with MS.
75606601|NCT02840071|Other|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
75900744|NCT05057338|Behavioral|Standard care|The standard care group will follow regular consultations at the MS-outpatient clinic including a session with the physiotherapist. Furthermore, this group will follow usual care in the municipality which might include other forms of physiotherapy or physical activity. These will be registered.
75900745|NCT02314832|Procedure|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
75606602|NCT02839837|Behavioral|Aerobic Exercise|Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.
75751934|NCT00934583|Behavioral|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
75900746|NCT02314832|Procedure|femoral nerve block|ultrasound guided femoral nerve block
75751935|NCT00934739|Drug|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
75751936|NCT00934739|Drug|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
75751937|NCT00930371|Other|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
75751938|NCT00930371|Other|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
75751939|NCT01015482|Drug|Remifentanil|Remifentanil Infusion
75751940|NCT01015482|Drug|Midazolam|Midazolam Infusion
75751941|NCT03760679|Device|Laryngeal mask Supreme evaluation|Device: Laryngeal mask Supreme evaluation
75900747|NCT02141256|Dietary Supplement|Protein enriched products|Newly developed products with extra protein. Specially developed for elderly.
75900748|NCT03500822|Procedure|Metronome-paced tachypnea|three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2
75900749|NCT03500822|Procedure|Expiratory-stenosis breathing|three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm
75900750|NCT02141412|Drug|dexmedetomidine 0.25 µg/kg IV|
75900751|NCT02141412|Drug|dexmedetomidine 0.5 µg/kg IV|
75900752|NCT02141412|Drug|dexmedetomidine 1 µg/kg IV|
75900753|NCT02141412|Drug|Placebo Comparator|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
75900754|NCT03098992|Device|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
75751942|NCT03760679|Device|i-gel evaluation|Device: i-gel evaluation
75900755|NCT03098992|Device|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
75900756|NCT04463264|Drug|Nitazoxanide|NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
75900757|NCT04463264|Drug|Placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
75900758|NCT03210558|Drug|Testosterone cream 1% (Andro-Feme® )|Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
75900759|NCT03210558|Drug|Placebo cream|Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
75900760|NCT05060224|Device|EasyLaser: Low Level Laser therapy|
75900761|NCT02317718|Other|monitor reproductive outcome|
75900762|NCT05046262|Drug|Calcium chloride|Calcium electroporation
75900763|NCT03502226|Behavioral|Tailored feedback|"Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing."
75606603|NCT02839837|Device|Paired Associative Stimulation|After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
75606604|NCT02839759|Other|TELLYHealth|Educational videos and questions.
75900764|NCT05036824|Drug|tinzaparin|Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
75900765|NCT03544476|Behavioral|Mobile phone TB treatment support app plus usual care|The behavioral intervention is delivered through a mobile phone TB support app. The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report. The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app. The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
75900766|NCT03544476|Other|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
75455444|NCT01760499|Drug|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
75606605|NCT02839525|Dietary Supplement|Omega 3|3000mg of n-3 oil (2000mg EPA e 1000mg DHA)
75751943|NCT00934817|Drug|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
75751944|NCT00934817|Drug|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
75751945|NCT01013532|Drug|Cilostazol|Cilostazol 100mg bid
75751946|NCT01013532|Drug|Probucol|Probucol 250mg bid
75751947|NCT01013532|Drug|Aspirin|Aspirin 100mg qd
75751948|NCT01013532|Drug|placebo of cilostazol|same shape and size of active cilostazol
75751949|NCT01013532|Drug|placebo of aspirin|same size and shape of active aspirin 100mg
75751950|NCT01013532|Device|ankle-brachial index (ABI)|measurement of ABI every years during follow up
75900767|NCT03500666|Device|Robot|Robot lateral neck lymph node dissection
75900768|NCT03500666|Device|Total endoscopic|Total endoscopic lateral cervical lymph node dissection
75900769|NCT04462250|Device|Prescription Opioid Management App|Smartphone application that provides education and reinforcement of safe opioid use, storage, and disposal
75455445|NCT01760499|Procedure|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
75455446|NCT01760512|Procedure|Gastric bypass|Gastric bypass
75455447|NCT01760525|Drug|CGM097|Patients treated with CGM097
75455448|NCT01760538|Behavioral|Exercise training|exercise training
75455449|NCT01760538|Behavioral|usual care|received usual medical care after heart transplantation
75606606|NCT02839525|Dietary Supplement|Isolate whey protein|23g of protein of whey protein
75606607|NCT02839525|Dietary Supplement|Omega 3 and Isolate whey protein|3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein
75606608|NCT02839525|Other|Eccentric exercise|100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
75606609|NCT02839213|Drug|Hyoscine Butyl bromide|
75606610|NCT02839213|Drug|Saline|
75751951|NCT01013532|Device|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
75751952|NCT01013532|Device|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
75751953|NCT01013532|Device|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
75751954|NCT01012206|Behavioral|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
75751955|NCT00926705|Drug|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
75606611|NCT02839447|Other|no intervention|
75751956|NCT00926705|Drug|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
75751957|NCT00930449|Other|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.~Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
75751958|NCT00930449|Other|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
75751959|NCT00930449|Other|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
75751960|NCT00506454|Drug|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
75751961|NCT00506454|Drug|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
75751962|NCT03415139|Drug|Oral Glucose Tolerance Test (OGTT)|A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
75751963|NCT03415139|Drug|2 OGTTs with and without GLP-1 analogue|A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with GLP-1 analogue.
75751964|NCT03415139|Drug|Hyperglycemic clamp procedure|During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
75751965|NCT01012284|Drug|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
75751966|NCT00930527|Dietary Supplement|Omega-3 Fatty Acid|4g per day for 3 weeks
75751967|NCT00934973|Drug|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
75751968|NCT00934973|Drug|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
75606612|NCT05334043|Drug|CuminUP30|7 capsules, 500 mg / capsule
75606613|NCT05334043|Drug|Curcumin capsules|5 capsules, 450 mg / capsule
75606614|NCT02839369|Other|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
75606615|NCT02839369|Other|walking under varies conditions|walking on electronic walkway under different conditions
75606616|NCT04250623|Other|Health care product (gel)|hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
75606617|NCT04250701|Other|Body Posture Assessment|Application of three evaluations above at a one time.
75606618|NCT02838823|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
75606619|NCT05333887|Behavioral|PFC+|Therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support. Emphasis throughout the program is placed on parents' connection and engagement with the material and therapist.
75606620|NCT03362749|Other|RFA, MWA, cryo and IRE|local tumor ablation
75751969|NCT00934973|Drug|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
75751970|NCT00934973|Behavioral|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
75751971|NCT00934973|Behavioral|No website|No CBT website
75751972|NCT00934973|Behavioral|CBT website with minimal support|
75751973|NCT00485472|Drug|lacosamide|50 or 100mg tablet, 400mg daily, for 12 weeks
75751974|NCT00485472|Other|Placebo|50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
75751975|NCT00930605|Drug|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
75751976|NCT00930605|Drug|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
75900770|NCT03095560|Device|NIRVANA|Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.
75900771|NCT02315222|Dietary Supplement|Regenium|
75900772|NCT02315222|Dietary Supplement|Placebo|
76066989|NCT03612375|Other|smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75900773|NCT02315222|Procedure|Full Mouth Disinfection|
76066990|NCT03612336|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75900774|NCT02144766|Drug|ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
75455450|NCT01760564|Drug|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
75455451|NCT01760577|Drug|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
75455452|NCT01760577|Drug|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
75751977|NCT01018836|Drug|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
75751978|NCT01018836|Radiation|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
75751979|NCT00935051|Other|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
75751980|NCT04015661|Drug|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
75751981|NCT00491400|Drug|Fenofibrate|140 mg/day for 8 weeks
75900775|NCT02144766|Drug|saline|caudal block with 1 ml/kg of saline
75900776|NCT05035966|Other|Plasma β-amyloid 40 and 42 concentration|Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).
75900777|NCT03502304|Behavioral|Endurance training plus resistant training|CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
75751982|NCT00491400|Drug|Atorvastatin|20 mg/day for 8 weeks
75751983|NCT04015583|Behavioral|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
75751984|NCT00491322|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
75751985|NCT00491322|Dietary Supplement|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
75751986|NCT00930683|Drug|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
75606621|NCT03340207|Device|Pneumaglide|The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
75606622|NCT04201717|Procedure|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
75606623|NCT04201717|Procedure|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, all surgical area was flushed and drainage tubes were left.
75751987|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
75751988|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
75606624|NCT00156091|Drug|Olanzapine|5- 20 mg QD
75751989|NCT00930683|Drug|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
75751990|NCT00930683|Drug|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
75751991|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
75751992|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
75751993|NCT00930683|Drug|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
75900778|NCT03498482|Behavioral|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)|FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.
75455453|NCT01760590|Procedure|Manual Manipulation|A grade 5 thrust to the thoracic spine
75455454|NCT01760590|Procedure|Mobilization|A grade 1-4 mobilization directed at thoracic spine
75455455|NCT01760603|Procedure|ISFF|Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
75455456|NCT01760616|Drug|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
75455457|NCT01760629|Device|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
75455458|NCT01760642|Drug|Midazolam|Midazolam 3 mg IV
75455459|NCT01760642|Drug|Ketoconazole|ketoconazole 400 mg PO
75455460|NCT01760642|Drug|Rifampicin|Rifampicin 600 mg PO
75606625|NCT00156091|Drug|Asenapine|5 or 10 mg BID
75606626|NCT00156091|Other|Placebo|
75455461|NCT01760681|Device|H- Coil DTMS|20 daily deep rTMS treatments
75606627|NCT00140959|Drug|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
75606628|NCT00140959|Drug|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
75751994|NCT00930683|Drug|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
75751995|NCT00926861|Device|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
75751996|NCT00926861|Device|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
75751997|NCT00935129|Device|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
75455462|NCT01760681|Device|Sham|
75606629|NCT00095017|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
75606630|NCT00092755|Drug|MK0663, etoricoxib|
75751998|NCT00935129|Device|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
75751999|NCT00930839|Drug|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
75606631|NCT00092755|Drug|Comparators: ibuprofen and placebo|
75606632|NCT00899431|Drug|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
75606633|NCT00899431|Drug|Fludarabine|30 mg/m^2 intravenously daily on days -5, -4, -3.
75606634|NCT00899431|Drug|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8.
75752000|NCT00935207|Other|Pediatric Pain Diary|Pain diary designed for pediatric patients
75752001|NCT01013610|Drug|LNK-754|Escalating dose
75752002|NCT01013610|Drug|Placebo|Escalating dose
75752003|NCT00926939|Behavioral|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
75752004|NCT00926939|Behavioral|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
75752005|NCT01015716|Behavioral|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
75752006|NCT01015716|Behavioral|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
75752007|NCT00927017|Other|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
75752008|NCT00927017|Other|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
75455463|NCT01760694|Other|Multi-Modality; IORT, Surgery, Radiation, Chemotherapy|
75455464|NCT01760707|Behavioral|exercise training|
75455465|NCT01760707|Behavioral|usual care|
75455466|NCT01760720|Behavioral|MMT CARE|
75752009|NCT03997032|Dietary Supplement|Ocufolin|Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
75752010|NCT00930917|Device|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
75752011|NCT00930917|Device|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
75606635|NCT00899431|Drug|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
75606636|NCT00899431|Procedure|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
75752012|NCT00930917|Other|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
75752013|NCT01015794|Drug|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
75752014|NCT01015794|Drug|ephedrine hydrochloride|single dose of 1 mg/kg body weight
75606637|NCT00899431|Drug|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
75606638|NCT00899431|Drug|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
75606639|NCT05335213|Diagnostic Test|16S rRNA gene sequencing|"DNA extraction and 16S rRNA gene sequencing DNA extraction, 16S rRNA gene amplification, and deep sequencing of the 16S rRNA amplicon performe.~The V4-V5 region of the 16S rRNA gene amplify with barcodes for multiplexing."
75752015|NCT01015872|Device|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
75752016|NCT00935363|Drug|glyburide|single oral dose
75752017|NCT00935363|Drug|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
75752018|NCT00935363|Drug|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
75752019|NCT00935363|Drug|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
75606640|NCT02843971|Device|Intraocular pressure measurement with the Sensimed triggerfish Device|
75606641|NCT00899353|Dietary Supplement|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
75752020|NCT00930995|Drug|Candesartan|16mg po daily
75752021|NCT00930995|Drug|Placebo|once daily
75752022|NCT00935441|Behavioral|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
75752023|NCT00935441|Behavioral|usual case management|telephone contact with a case manager
75752024|NCT01015950|Dietary Supplement|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
75752025|NCT01015950|Dietary Supplement|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
75752026|NCT01015950|Dietary Supplement|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
75752027|NCT01015950|Dietary Supplement|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
75752028|NCT00931073|Drug|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
75752029|NCT00931073|Drug|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
75752030|NCT00931073|Drug|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
75752031|NCT01016028|Behavioral|Questionnaire|3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
75752032|NCT01016028|Behavioral|Sensory Tests|Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
75752033|NCT01016028|Behavioral|Interview|First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
75752034|NCT00935597|Biological|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
75752035|NCT00931151|Dietary Supplement|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
75752036|NCT00936689|Procedure|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
75752037|NCT00936689|Procedure|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
75752038|NCT01018914|Drug|Prograf|oral
75606642|NCT02844127|Procedure|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
75606643|NCT02843893|Device|Measure the minimum intensity of a painful stimulation|With Neurolight device.
75752039|NCT01018914|Drug|Advagraf|oral
75752040|NCT01018914|Drug|Myfortic|oral
75752041|NCT01019070|Drug|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
75606644|NCT00898807|Drug|citalopram|target dose 30mg daily for 9 weeks
75606645|NCT00898807|Drug|placebo|daily for 9 weeks
75606646|NCT05335135|Other|TriageGO-MDW Clinical Decision Support|TriageGO-MDW is non-device clinical decision support that provides patient-level clinical risk estimates based on clinical data derived from the electronic health record
75752042|NCT00936767|Drug|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
75752043|NCT00936767|Drug|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
75900779|NCT05056636|Diagnostic Test|Plasma α-Gal A activity; Plasma Lyso-GB3; GLA genetic sequencing.|"Screening Visit 1:~Male patient will first screened by enzymatic assay (Cutoff: 1.3 μM /hr)~Female patient will first screened by lyso-GB3 (Cutoff: > 5ng/ml)~Screening Visit 2:~If both male and female who has deficient enzymatic level (Cutoff: 1.3 μM /hr) or lyso-GB3 level (Cutoff: > 5ng/ml) respectively, those patients will be confirmed whether they have carried Fabry Disease causing mutation by whom GLA genetic sequencing."
75900780|NCT02144844|Behavioral|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
75900781|NCT03498404|Radiation|Photodynamic Therapy|After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications.
75900782|NCT03498404|Other|scaling and root planing|Scaling and root planing, also known as conventional periodontal therapy, or deep cleaning, is a procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation. This helps to establish a periodontium that is in remission of periodontal disease. Periodontal scalers and periodontal curettes are some of the tools involved.
75752044|NCT00931229|Drug|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
75752045|NCT01013688|Procedure|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
75606647|NCT05335135|Other|Usual Care|Clinical care without decision support provided by TriageGo-MDW
76066991|NCT03612336|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75752046|NCT00936923|Drug|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
75752047|NCT01019382|Drug|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
75752048|NCT04014023|Drug|DWP16001|DWP16001 tablets
75752049|NCT04014023|Drug|Placebo|DWP16001 placebo-matching tablets
75752050|NCT03997188|Device|Hepilor|ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
75606648|NCT02842177|Procedure|Classic group|The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.
75606649|NCT02842177|Procedure|Uterine sounding sparing group|after bimanual examination, the same sonographer (Level II experience) performed transvaginal /US using a SonoAce X6 machine (Medison, Korea) with transvaginal probe (4-8 MHz frequency, using an average 6.5 MHz). Firstly, he evaluated the uterine position. Then, he measured the endometrial and cervical stripe lengths in the sagittal view of the uterus and summed to have the actual length of the uterus; by which the IUD tube was adjusted before insertion.The same speculum and vulsellum were used and the IUD was inserted directly into the uterine cavity.
75752051|NCT00935675|Drug|Escitalopram|Escitalopram 10 mg once a day
75752052|NCT01016184|Dietary Supplement|Vitamin D|Oral vitamin D 100,000 IU
75752053|NCT01016184|Dietary Supplement|Placebo|Placebo
75606650|NCT02842177|Radiation|Transvaginal ultrasound|
75606651|NCT02842177|Device|Cu-IUD|
75752054|NCT00502320|Drug|Ramelteon|one 8 mg tablet at bed for up to 4 months
75752055|NCT00502320|Drug|Placebo|one tablet at bedtime for up to 4 months
75606652|NCT01229267|Biological|V212|V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.
75606653|NCT01229267|Biological|Matching placebo|Vaccine stabilizer for V212 with no virus antigen
75606654|NCT02690779|Other|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
75752056|NCT02567825|Device|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used.
75752057|NCT02567825|Drug|Amoxicillin-Clavulanate and/or Ceftriaxone|Children randomized to nonsurgical management will receive stepwise therapy with amoxicillin-clavulanate (90/6.4 mg/kg in two divided doses for 10 days), and in the event of inadequate response, ceftriaxone (75 mg/kg intramuscularly, repeated in 48 hours), as recommended in the American Academy of Pediatrics guidelines.
75606655|NCT02690779|Other|Routine Care Instructions|patients will follow routine care and instructions
75606656|NCT00897715|Drug|Rilonacept|160 mg of rilonacept administered subcutaneously once a week for 12 weeks
75752058|NCT02567825|Drug|Ofloxacin Otic|Participants randomized to receive tympanostomy tubes will also be followed overtime for recurrences of AOM and treated with topical ofloxacin (Floxin® 0.3%, 5 mL) 5 drops into the affected ear twice daily for 10 days. Persistence of otorrhea after 7 days of treatment will be considered inadequate response, and children so affected will be prescribed empiric amoxicillin-clavulanate (90/6.4 mg/kg/day in two divided doses) followed by culture-directed therapy 48 hours later.
75752059|NCT00490776|Drug|Panobinostat|Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
75606657|NCT00897715|Drug|Placebo|160 mg of placebo administered subcutaneously once a week for 12 weeks
75752060|NCT00935753|Drug|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
75900783|NCT05056558|Drug|Baricitinib|Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
75900784|NCT05056558|Drug|Placebo|Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
75900785|NCT02317796|Drug|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
75900786|NCT05055700|Behavioral|Mobile app with prenatal genetic testing information|In the intervention group, participants will be asked to download, register, and review a mobile app on their own mobile phones before their appointment with maternal-fetal medicine specialists. This mobile app includes prenatal genetic testing information about amniocentesis, chorionic villus sampling, nuchal translucency screening, cell-free DNA, triple/quad/penta screening, anatomy ultrasound, and carrier screening.
75900787|NCT02317952|Other|Experimental Extensively Hydrolyzed Formula|
75900788|NCT02317952|Other|Active Comparator Formula|
75606658|NCT00633295|Drug|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
75900789|NCT05045248|Drug|Apraclonidine Hcl 0.5% Oph Soln|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
75900790|NCT02144922|Drug|Pitavastatin|statin
75900791|NCT02144922|Other|Control|Life style modification alone
75900792|NCT05055310|Diagnostic Test|MicRNAs test|plasma micRNAs concentration
75455467|NCT01760746|Other|Injection of Avastin / Lucentis, sampling aqueous humour|"Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.~On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .~Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays."
75455468|NCT01760759|Behavioral|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
75455469|NCT01760759|Behavioral|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
75455470|NCT01760772|Drug|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
75900793|NCT02315300|Device|medilog® DARWIN FD12|
75900794|NCT02315300|Device|Continuous Glucose Monitoring|
75900795|NCT02141568|Other|Medical and Psychological treatment|"Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist)."
75900796|NCT05036200|Device|pulsed dye laser|four pulsed dye laser sessions were administered every eight weeks in the 21 patients
75455471|NCT01760772|Drug|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
75455472|NCT01760772|Other|saline|Constant infusion
75455473|NCT01760798|Drug|Teriparatide|
75606659|NCT04205773|Device|CompuFlo|After priming with 5 mL saline, the catheter was connected to CompuFlo to record the occurrence of pulsatile waveforms and/or their disappearance during its removal
75606660|NCT02842099|Drug|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
75606661|NCT02842099|Drug|X|Capecitabine
75606662|NCT02842021|Drug|S2G6T-1|Twice a day topical cream
75606663|NCT02842021|Drug|S2G6T-2|Twice a day topical cream
75606664|NCT02842021|Drug|S2G6T-3|Twice a day topical cream
75606665|NCT02842021|Drug|S2G6T-4|Twice a day topical cream
75606666|NCT02839057|Procedure|Non-surgical treatment|Cervical collar immobilisation for 12 weeks.
75606667|NCT02839057|Procedure|Surgical treatment|Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
75606668|NCT01229111|Drug|cediranib maleate|Given PO
75900797|NCT02318108|Other|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
75752061|NCT01019460|Procedure|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
75752062|NCT00935831|Drug|GSK1278863A|50mg, 150mg
75752063|NCT00935831|Drug|Placebo|matching placebo
75752064|NCT01019538|Other|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
75606669|NCT01229111|Drug|oxaliplatin|Given IV
75752065|NCT00566735|Drug|Razadyne|The starting dose of study medication is 4 mg twice a day
75752066|NCT00566735|Drug|Placebo|4 mg, 2 times a day
75900798|NCT02318108|Other|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
75900799|NCT03095482|Device|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
75752067|NCT03653273|Other|DMT withdrawal|Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).
75752068|NCT03653273|Drug|DMT continuation|Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.
75752069|NCT00936143|Drug|infliximab|100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
75752070|NCT00937079|Other|111In-exendin-4 imaging|90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once
75900800|NCT03095482|Behavioral|In vivo exposure therapy|Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
75900801|NCT02261064|Drug|Telmisartan/Amlodipine low dose|
75606670|NCT01229111|Drug|leucovorin calcium|Given IV
75606671|NCT01229111|Drug|fluorouracil|Given IV
75606672|NCT00894361|Procedure|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
75606673|NCT00894361|Procedure|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
75606674|NCT02843815|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
75606675|NCT02843815|Biological|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
75606676|NCT01228175|Drug|Placebo|25mg look alike riboflavin tablets to match active study medication.
75752071|NCT04013633|Other|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
75900802|NCT02261064|Drug|Telmisartan/Amlodipine high dose|
75900803|NCT02261064|Other|Japanese meal|
75900804|NCT05044858|Procedure|Midpoint transverse process block group|After marking the level of the incision by surgeon (commonly T5- T6) The patient will be situated in the lateral position, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally 3 cm lateral to the spinous process at the level of skin incision. 100-mm short bevel echogenic needle (Contiplex, B.Braun, Germany) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura titrated bolus of 20 ml of 0.25% bupivacaine and dexamethazone 8 mg will be injected at the target site. At end of the surgery general anaesthesia will be stopped with reversal of muscle relaxation and awakening of patient
75455474|NCT01760811|Drug|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
75455475|NCT01760824|Drug|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
75455476|NCT01760824|Drug|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
75752072|NCT04013633|Other|Face-to-face training|Short face-to-face CPR training
75752073|NCT00566111|Drug|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
75752074|NCT00566111|Drug|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
75752075|NCT00937313|Other|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
75752076|NCT00514046|Drug|Vandetanib|once daily continuously (28 day cycles)
75455477|NCT01760837|Other|Baked milk products to cow's milk allergic patients|
75455478|NCT01760863|Other|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
75606677|NCT01228175|Drug|Varenicline|Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
75606678|NCT02843737|Other|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
75606679|NCT01228019|Drug|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
75606680|NCT02987959|Drug|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
75752077|NCT00937469|Behavioral|Social skills training, parental tr. and standard tr.|Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
75752078|NCT00937469|Other|Standard treatment|The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
75900805|NCT05044858|Procedure|Sham group|"General anesthesia will be induced with the same protocol and MTP block will be done but with injection of placebo (2 ml normal saline) instead of local anesthetic .~On arrival to the PACU postoperative Numerical Rating scale at rest and coughing will be recorded, analgesia will be maintained with intravenous paracetamol 1 g every 8 h and required additional rescue analgesia (morphine) at any time will be calculated."
75900806|NCT02320916|Procedure|23Gauge|Arterial puncture will be made using a 23Gauge needle
75900807|NCT02320916|Procedure|25Gauge|Arterial puncture will be made using a 25Gauge needle
75455479|NCT01760902|Behavioral|Diet and Physical Activity|The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
75455480|NCT01760967|Drug|Dexmedetomidine|intervention to administer dexmedetomidine or not
75455481|NCT01760980|Drug|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
75455482|NCT01760980|Drug|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
75455483|NCT01761006|Device|NIOX MINO®|
75455484|NCT01761032|Device|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
75455485|NCT01761045|Dietary Supplement|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
75455486|NCT01761045|Dietary Supplement|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
75455487|NCT01761045|Dietary Supplement|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
75455488|NCT01761071|Drug|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
75455489|NCT01761071|Drug|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
75455490|NCT01761097|Device|Endocuff attachment|Endocuff
75606681|NCT05335057|Behavioral|VR Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
75606682|NCT05335057|Behavioral|VR Alone|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone
75606683|NCT05335057|Behavioral|VR Stranger|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger
75606684|NCT05335057|Behavioral|Video Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
75606685|NCT02841631|Genetic|HPV status and typing of tissue|HPV status and typing of tissue
75606686|NCT01227707|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
75606687|NCT01227707|Drug|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
75606688|NCT01227707|Radiation|Radiation therapy|Total dose of 45 Gy over 38 days
75900808|NCT02955966|Device|imaging 18F-FDG-PET/CT|18F-FDG PET Scan at Day 0, W6 and W12
75900809|NCT02955966|Biological|Blood collection|Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
75455491|NCT01761110|Behavioral|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
75455492|NCT01761123|Biological|VXA-A1.1|
75455493|NCT01761136|Biological|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
75606689|NCT01227707|Procedure|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
75900810|NCT05035498|Drug|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
75900811|NCT05035498|Drug|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
75900812|NCT03498326|Drug|Gemcitabine|One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.
75900813|NCT03498326|Drug|Gemcitabine|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.
75455494|NCT01761136|Biological|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
75455495|NCT01761149|Drug|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
75455496|NCT01761188|Procedure|Ablation|electrophysiology substrate mapping is the critical difference between both groups
75606690|NCT01227707|Drug|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
75606691|NCT01227707|Drug|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
75752079|NCT00937625|Biological|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
75752080|NCT04014101|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
75752081|NCT04014101|Drug|apatinib|Apatinib is a selective VEGFR2 inhibitor.
75752082|NCT04014257|Drug|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
75900814|NCT02141724|Other|Positioning consultation|Assessment of pain,bedsores and postural troubles
75900815|NCT03498248|Drug|lenograstim|injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
75455497|NCT01761201|Drug|Levofloxacin|Levofloxacin
75455498|NCT01761201|Drug|Isoniazid|"300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months."
75455499|NCT01761214|Drug|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
75455500|NCT01761214|Drug|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
75606692|NCT01227707|Drug|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
75900816|NCT02141802|Behavioral|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
75900817|NCT02141802|Behavioral|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
76066992|NCT03603353|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling.~Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit."
76066993|NCT03603353|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
75606693|NCT00633373|Drug|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
75606694|NCT05334745|Other|Alvogyl|application of Alvogyl in the palatal wound with stent versus hyaluronic acid application
75606695|NCT04586179|Other|Aerobic (treadmill) Exercise|"Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. [3.2 mph] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90*[{208-(.7*age)}-resting HR]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5."
75752083|NCT00936533|Drug|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
75752084|NCT00936533|Drug|Placebo|Placebo preparation without active compound, administered as the active drug.
75752085|NCT04618250|Other|SOFIA model|A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
75900818|NCT01360996|Drug|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
75900819|NCT02254434|Drug|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
75455501|NCT01761227|Drug|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
75455502|NCT01761227|Drug|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
75455503|NCT01761240|Drug|MORAb-066|
75455504|NCT01761318|Drug|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
75900820|NCT03498170|Drug|BCT197|Single dose of BCT197
75900821|NCT03498170|Drug|Itraconazole 200 mg|Single dose of itraconazole
75606696|NCT04586179|Other|Dynamic (Agility) Exercise|"Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90*[{208-(.7*age)}-resting HR]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5."
75455505|NCT01761318|Drug|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
75455506|NCT01761331|Other|Acupuncture|"Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute."
75606697|NCT02821273|Other|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
75606698|NCT02821273|Other|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
75606699|NCT02838589|Drug|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
75606700|NCT02838589|Drug|Isotonic saline|Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
75606701|NCT02841475|Other|Charlson comorbidity index|Charlson comorbidity index
75606702|NCT02838511|Other|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
75606703|NCT02838511|Other|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
75606704|NCT02839135|Drug|Reformulated scopolamine patch|Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours
75606705|NCT02839135|Drug|Marketed scopolamine patch|Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
75752086|NCT04264052|Diagnostic Test|CBE & MRI|"The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used."
75752087|NCT00564629|Drug|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
75752088|NCT00564629|Drug|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
75752089|NCT00564629|Biological|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
75752090|NCT00564395|Drug|Insulin Detemir mixed with RAI injection|Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection
75900822|NCT03544944|Drug|TJP-008-1|Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
75900823|NCT03544944|Drug|TJP-008-2|Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
75900824|NCT03544944|Drug|Coolprep powder|Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
75606706|NCT00895843|Drug|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
75606707|NCT00895843|Drug|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
75606708|NCT00895843|Drug|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
75606709|NCT02838433|Other|biological samples|blood and tissue samples
75606710|NCT05333809|Drug|Pembrolizumab|an anti-PD-1 monoclonal antibody
75606711|NCT05333809|Drug|Disitamab vedotin|HER2-ADC
75900825|NCT05055544|Drug|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),
75900826|NCT05055544|Drug|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
75900827|NCT02315456|Procedure|capsulorhexis|
75900828|NCT03498092|Drug|Bupivacaine-Dexmedetomidine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg
75900829|NCT03498092|Drug|Bupivacaine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg
75752091|NCT00564395|Drug|Insulin Detemir and RAI injection|Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection
75752092|NCT00937703|Device|placebo|paper support for glycaemia face to face visit at T4mounths
75752093|NCT00937703|Device|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
75752094|NCT00937703|Device|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
75752095|NCT00937781|Genetic|RNA analysis|
75752096|NCT00937781|Genetic|gene expression analysis|
75752097|NCT00937781|Genetic|microarray analysis|
75752098|NCT00937781|Genetic|polymerase chain reaction|
75752099|NCT00937781|Other|immunohistochemistry staining method|
75752100|NCT00937781|Other|laboratory biomarker analysis|
75752101|NCT00939419|Other|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
75752102|NCT00939419|Other|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
75752103|NCT00939419|Other|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
76066994|NCT03603340|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
76066995|NCT03603340|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
76066996|NCT03587064|Device|Conventional 3-lead CRT defibrillator system implantation|Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation
75455507|NCT01761344|Other|Intraoperative cortisol measurement.|Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
75455508|NCT01761357|Other|answering to questionnaires of quality of live|
75455509|NCT01761370|Procedure|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
75455510|NCT01761370|Procedure|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
75455511|NCT01761383|Other|Nintendo Wii video console and Nintendo Wii Fit Plus games|The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
75455512|NCT01761396|Behavioral|CBT|
75455513|NCT01761396|Behavioral|UC|
75455514|NCT01761435|Biological|Influenza vaccine|"Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline."
75606712|NCT02838667|Procedure|Standard of Care plus Nephrology Care|
75606713|NCT05333731|Drug|Oxytocin|In the two groups, if spontaneous labor does not occur after PROM, they all receive the oxytocin for up to 24h.
75606714|NCT02838355|Device|Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.
75606715|NCT02838355|Other|Standard Non-invasive Respiratory Depression Monitoring|Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
75606716|NCT02843581|Device|Cryosurgery|Argon-helium cryosurgical system
75752104|NCT04013243|Drug|Magnesium Sulfate|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
75752105|NCT04013243|Drug|Placebo|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
75752106|NCT00940277|Behavioral|Group Counseling|Group counseling
75900830|NCT03498092|Drug|General anesthesia|Normal saline in a volume of 0.5 ml/kg
75900831|NCT05055388|Other|Multidrug-resistant bacteria|Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
75606717|NCT02843581|Biological|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
76066997|NCT03587064|Device|2-lead CRT defibrillator system implantation|2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation
76066998|NCT03575351|Drug|Standard of Care|Standard of Care
76066999|NCT03575351|Genetic|JCAR017|JCAR017
76067000|NCT03529422|Drug|Durvalumab|Durvalumab 1500mg IV every 3 weeks for 6 cycles
76067001|NCT03529422|Radiation|Intensity Modulated Radiotherapy Treatments|Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
76067002|NCT03501368|Drug|Ceritinib|Participants will take ceritinib by mouth (PO) once daily at a dose of up to 450 mg (3 capsules of 150 mg)
76067003|NCT03501368|Drug|Trametinib|Participants will take trametinib by mouth at a dose of 2 mg daily
76067004|NCT03493685|Drug|sparsentan|Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
75606718|NCT02843503|Device|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
75606719|NCT02843503|Device|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
75455515|NCT01761448|Device|Guide Exercise (GEx-)- Training|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
75455516|NCT01761448|Device|Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity|
75455517|NCT01761448|Device|Control group training without Guided Exercise system at home|
75900832|NCT02145234|Drug|BMS-986089|
75900833|NCT02145234|Drug|Placebo matching with BMS-986089|
75900834|NCT03501914|Behavioral|Mindfulness|A mindfulness program based on mindfulness-based principles developed by colleagues in Manchester will be adapted to be accessible for people with intellectual disabilities (ID) in Pakistan. This intervention will be translated into Urdu afterwards focus group will be conducted to get the views from people with ID, thei care takers and other stake holders to adapt and culturally modify the program. It will include some mindfulness based exercises i.e.welcome & introduction, exploring senses, its all in the mind, Mindful eating, breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking.
75900835|NCT05055154|Device|Very low calorie diet|In hospital patients will eat prepared diet with 567 kcal a day during 3 weeks
75900836|NCT03500588|Diagnostic Test|PCR|Polymerase chain reaction was used to diagnose gene polymorphism.
76067005|NCT03493685|Drug|Irbesartan|target dose of 300 mg daily
76067006|NCT03486197|Other|Laboratory Biomarker Analysis|Correlative studies
75900837|NCT03500588|Device|Doppler ultrasound|Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
75900838|NCT05044624|Procedure|retroperitoneal mass excision|retroperitoneal mass excision
76067007|NCT03486197|Biological|Pembrolizumab|Given IV
76067008|NCT03486197|Radiation|Radiation Therapy|Undergo neutron radiation therapy
75455518|NCT01761461|Drug|TS-1, oxaliplatin|
75455519|NCT01761487|Device|Gentamicin and polymyxin E|
75455520|NCT01761500|Other|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
75455521|NCT01761513|Drug|YH4808|"Group1~adminitration of YH4808 dose1, bid for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of YH4808 dose2, qd for 2weeks"
75455522|NCT01761513|Drug|YH4808|"Group2~adminitration of YH4808 dose2, qd for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of YH4808 dose1, bid for 2weeks"
76067009|NCT03459846|Drug|Durvalumab|Durvalumab 1500 mg IV q4w
76067010|NCT03459846|Drug|Olaparib|Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
76067011|NCT03459846|Drug|Placebo|Matching placebo for oral tablet BID
76067012|NCT03439683|Other|Survey about patient-ventilator asynchrony|Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
75606720|NCT02843503|Device|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
75606721|NCT02815813|Behavioral|PeerFIT|The 12-month PeerFIT intervention consists of a 6-month intensive phase including: (a) once weekly 60-minute group weight management and exercise session led by a lifestyle coach; (b) once weekly one-hour physical activity session delivered in community settings; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change. Participants then transition to a 6-month lower intensity phase in which the 90-minute weight management sessions are discontinued. The groups will be conducted as open groups with a minimum of 4 and maximum of 18 participants at any given time.
75606722|NCT02815813|Behavioral|BEAT|Participants in BEAT will receive monthly individual lifestyle sessions delivered by a lifestyle coach including education, guidance, and support for self-monitoring behaviors (i.e., daily self-weighing and tracking daily steps) during the first six months of the study, plus text message reminders and encouragement for self-monitoring weight loss behaviors during the entire 12-month study period. Participants will receive materials with tips and strategies for healthy eating and increasing physical activity. They will also be given a wearable activity tracker (i.e., Fitbit Zip) to use with instructions for using the device. The first session with the lifestyle coach will be in person and thereafter by phone.
75606723|NCT02690857|Drug|Docosahexaenoic acid|
75900839|NCT03501836|Device|Rapid Rhythm Handheld 8-lead ECG Device|"We want to explore whether using 6 electrodes on the chest (as in the Rapid Rhythm Handheld 8-lead ECG device) can give the same diagnostic result to the standard 10 electrode (12-lead) ECG, which uses 6 chest electrodes plus 4 electrodes on the arms and legs.~To do this we need to compare measurements taken with the 6 electrode (8 lead) study device to those taken with the gold-standard 10 electrode (12 lead) method.~We want to find out whether the new equipment can detect the same heart rhythms as the standard method, so that ECG measurements might be made more quickly and easily in the future."
76067013|NCT03417583|Other|Protocol Intervention Group|For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
75752107|NCT03160547|Other|Usual Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
75455523|NCT01761513|Drug|YH4808|"Group3~adminitration of YH4808 dose2, bid for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of Nexium tab 40mg, bid for 2weeks"
75752108|NCT03160547|Other|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
75752109|NCT00938093|Behavioral|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
75455524|NCT01761513|Drug|YH4808|"Group 4~adminitration of Nexium tab 40mg, bid for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of YH4808 dose2, bid for 2weeks"
75455525|NCT01761526|Drug|Rotigotine transdermal patch|Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
75752110|NCT00938093|Behavioral|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
75900840|NCT05055232|Drug|XZP-3621|tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
75900841|NCT02145312|Drug|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
75455526|NCT01761539|Other|Aggressive Hydration|Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
75455527|NCT01761539|Other|Moderate Hydration|Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
75455528|NCT01761552|Drug|Sugammadex Reversal|
75455529|NCT01761552|Drug|Atropine/Neostigmine|
75455530|NCT01761578|Device|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
75455531|NCT01761591|Device|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
75455532|NCT01761591|Device|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
75455533|NCT01761604|Device|Nasal ganglion block for TN|
75606724|NCT02690857|Drug|Sunflower Oil|
75606725|NCT02843269|Behavioral|Multi-component lifestyle intervention|The exact same intervention was given to the three Stepped-wedge groups - but each of the three groups were started up three months apart. The waiting groups served as control groups. Thus, the intervention were for all three groups a multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
75606726|NCT02843347|Procedure|Blood draw|Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
75606727|NCT02843113|Behavioral|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
75606728|NCT02841319|Other|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
75606729|NCT02841007|Device|geko neuromuscular electrostimulation device|
75606730|NCT02842957|Behavioral|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
75606731|NCT02615353|Behavioral|Intensive Lifestyle Intervention|6-months of lifestyle education
75606732|NCT02615353|Other|Usual Care Control|Medical visit and dietary counseling
75752111|NCT00938171|Procedure|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
75752112|NCT00938171|Procedure|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
75752113|NCT00938249|Dietary Supplement|Monascus Garlic Fermented Extract|
75752114|NCT00938249|Dietary Supplement|Placebo|
75752115|NCT00939497|Drug|Risperidone|
75752116|NCT00940355|Behavioral|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
75606733|NCT02842879|Other|Outpatient Foley cervix priming|Outpatient setting for cervix priming with Foley catheter
75606734|NCT05334667|Other|Routine management|Routine management
75752117|NCT00940433|Procedure|open properitoneal hernia repair|suprapubic retro-inguinal approach
75752118|NCT00940433|Procedure|Lechtestien hernia repair|onlay mesh repair
75606735|NCT05334667|Device|CRRT|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
75606736|NCT05334667|Device|PPH|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
75606737|NCT00895453|Drug|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
75606738|NCT00895453|Drug|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
75606739|NCT00895453|Drug|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
75606740|NCT00893971|Drug|PT001|Inhaled PT001, single dose
75606741|NCT00893971|Drug|PT005|Inhaled PT005, single dose
75606742|NCT00893971|Drug|PT003|Inhaled PT003, single dose
75606743|NCT00893971|Drug|PT001 + PT005|Inhaled PT001 + PT005, single dose
75606744|NCT00893737|Drug|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
75606745|NCT00893113|Drug|Placebo|Alfuzosin-matched One tablet once daily
75606746|NCT00893113|Drug|Alfuzosin|10 mg once daily
75752119|NCT00940433|Procedure|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
75752120|NCT00940433|Procedure|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
75752121|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (active)- oral - once per day
75752122|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
75752123|NCT00938405|Drug|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
75606747|NCT05333653|Other|Continouse supportive care|"Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic."
75606748|NCT05333653|Other|routine care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
75606749|NCT02838199|Device|SAPIEN 3|
75752124|NCT00938405|Drug|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
75455534|NCT01761617|Behavioral|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
75752125|NCT00938483|Other|Nutramigen Lipil (Infant formula)|
75752126|NCT00938561|Drug|Inulin|
75752127|NCT03045653|Drug|Tamoxifen Oral Product|Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
75900842|NCT03500432|Procedure|local anesthesia of trnasperineal prostate biopsy|three different block site with lidocaine
75455535|NCT01761617|Behavioral|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
75900843|NCT05035108|Biological|hiHep bioartificial liver therapy|HiHep cell bioartificial liver treatment was performed 24-48 hours after extensive hepatectomy. Temporary hemodialysis tube for large vein (jugular vein or femoral vein) is indwelled before treatment. Before treatment, prepare hiHeps-BAL in a biological safety cabinet that meets clinical standards, connect the corresponding tubing to the Jianfan DX-10 blood purification machine, and prefill with heparin saline. Half an hour before treatment, the patient was pre-heparinized (heparin about 600iu) and dexamethasone to prevent allergic reactions. The patient enters the ICU, the monitor is connected to the corresponding pipeline, the arterial pump 120-160ml/min, the slurry pump 30-40ml/min, the circulating pump 75-100ml/min, the duration is 6-9h.
75900844|NCT02318420|Other|The PartoMa intervention|WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
75455536|NCT01761656|Drug|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
75455537|NCT01761656|Drug|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
75455538|NCT01761669|Drug|Vitamin D|
75752128|NCT02991365|Other|nasal insulin|
75606750|NCT02838199|Procedure|SAVR|
75606751|NCT02840929|Procedure|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
75606752|NCT02840929|Drug|Esomeprazole|
75606753|NCT04201483|Other|DCE without RUSI feedback|Participants assigned to this group will perform an exercise known to selectively activate the semispinalis cervicis muscle
75752129|NCT02991365|Other|placebo spray|
75752130|NCT03972137|Behavioral|Cognitive-Behavioral Smoking Cessation|Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
75752131|NCT03972137|Behavioral|Heart Rate Variability Biofeedback (HRVB)|All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
75752132|NCT03972137|Drug|Transdermal Nicotine patch|All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
75752133|NCT00940511|Behavioral|Coordinated care|
75752134|NCT00490698|Drug|Zoledronate|4 mg IV Once Every 4 Weeks
75900845|NCT05044702|Other|Retro walking|Retro walking will be performed on treadmill for 15 min per day for 3 days per week for 4 weeks at self-paced speed.
75900846|NCT05044702|Other|conventional physical therapy|"hot pack for 10 mints and conventional exercise program Conventional physiotherapeutic exercise program which consist of exercises such as~prone leg extension~prone lying chest elevation~prone extension with alternate arm and leg lift~supine bridging, bridging with one leg lift Each exercise will be performed as 2 sets of 12 repetitions of each exercise, each exercise position maintained for 10 s, and a rest of 1 min between the sets will be perform. No external load/resistance will be provided for the exercises, and the participants will be perform the exercise within their available range of motion"
75455539|NCT01761682|Other|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
75455540|NCT01761695|Other|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
75455541|NCT01761708|Procedure|primary ventral hernia repair with mesh|
75455542|NCT01761734|Behavioral|text message|
75455543|NCT01761760|Behavioral|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
75606754|NCT04201483|Other|DCE + RUSI feedback about performance|Participants in this group will perform the same exercise as the DCE group to selectively activate the semispinalis cervicis muscle but receiving RUSI feedback about correct performance
75606755|NCT02837887|Behavioral|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
75606756|NCT02840617|Drug|Indocyanine Green (ICG)|
75752135|NCT00490698|Drug|Atorvastatin|20 mg PO Daily
75606757|NCT02838121|Drug|Aclasta|Aclasta once annually for 2 years
75752136|NCT02884271|Procedure|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
75752137|NCT04492254|Drug|Enoxaparin|The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
75752138|NCT01013766|Drug|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
75455544|NCT01761773|Drug|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
75752139|NCT01013766|Drug|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
75606758|NCT02838121|Drug|Placebo|No IV aclasta
75606759|NCT02837965|Drug|treatment with topical superpotent corticosteroid therapy|
75606760|NCT02837965|Drug|treatment with systemic therapy (methotrexate)|
75606761|NCT02837965|Drug|treatment systemic therapy (prednisone)|
75606762|NCT02837965|Drug|treatment with systemic therapy (prednisone)|
75606763|NCT02837965|Drug|treatment with systemic therapy (doxycycline)|
75752140|NCT03855228|Drug|Mometasone furoate nasal spray (MFNS)|Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
75752141|NCT03855228|Drug|Loratadine|Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
75752142|NCT03855228|Drug|Placebo nasal spray|Daily dose of placebo administered as a nasal spray for 15 days.
75752143|NCT03855228|Drug|Placebo tablet|Daily dose of placebo administered as an oral tablet for 15 days.
75752144|NCT04013165|Behavioral|Active control|Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
75900847|NCT03497858|Other|Coconut Water|participants will consume coconut water and complete a simulated basketball game
75900848|NCT03497858|Other|Placebo - water|participants will consume Placebo - water and complete a simulated basketball game
75900849|NCT03497858|Other|Sports drink|participants will consume a sports drink and complete a simulated basketball game
75606764|NCT04250389|Other|Hemodynamic assessment (micro and macrocirculatory)|"Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~Mean, systolic, diastolic arterial, heart rate (HR)~Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~Cutaneous and gingival refill time~Tissue oxygen saturation combined with vascular occlusion test (VOT)~Video microscopy measurements of the sublingual microcirculation~Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases."
75900850|NCT02321072|Drug|Oxygen|
75900851|NCT02315690|Drug|dihydroartemisinin-piperaquine (DHAp)|In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
75900852|NCT02315690|Procedure|reactive case detection|Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
75900853|NCT02639338|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
75900854|NCT02639338|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
75900855|NCT01754857|Drug|Bendamustine|Given IV
75900856|NCT01754857|Drug|Rituximab|Given IV
75900857|NCT01754857|Drug|Lenalidomide|Given PO
75455545|NCT01761786|Genetic|CYP2C19 genotyping|CYP2C19 genotyping will be performed in the intervention group. In patients with *1/*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (*2 or *3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
75455546|NCT01761799|Behavioral|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
75455547|NCT01761812|Other|MRI with gadofosveset and MR elastography|
75455548|NCT01761825|Drug|ivabradine|
75455549|NCT01761838|Other|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
75606765|NCT02838043|Dietary Supplement|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
75606766|NCT00892957|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
75606767|NCT00892957|Other|Surgical gauze pads|Manual compression with surgical gauze pads
75606768|NCT02834611|Drug|Ceramide NanoLiposome|Intravenous administration of Ceramide NanoLiposome
75606769|NCT02834689|Behavioral|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
75606770|NCT02834689|Behavioral|Seated Control|Sitting for 50 minutes
75606771|NCT05322733|Drug|Orelabrutinib|150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
75900858|NCT03497702|Drug|Doxorubicin|60mg/m2 IV every 3 weeks for 4 cycles
75900859|NCT03497702|Drug|Cyclophosphamide|600mg/m2 IV every 3 weeks for 4 cycles
75900860|NCT03497702|Drug|Docetaxel|75mg/m2 IV every 3 weeks for 4 cycles
75900861|NCT03497702|Drug|Letrozole|2.5 mg once daily preoperably
75900862|NCT03497702|Drug|leuprorelin|3.75 mg SC every 4 weeks for premenopausal patients
75900863|NCT02321150|Procedure|Cautery|"Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~Conjunctiva undermined at the recipient site.~Relaxing incisions placed at the corners of the recipient site.~Graft is slid into place~Graft / host interface is gently dried with a Qtip~Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~Power setting: 25.~Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~Cautery is applied at the 4 apices of the graft then in between these points."
75900864|NCT02321150|Procedure|Sutures|"Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~Conjunctiva undermined at the recipient site.~Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures"
75900865|NCT03097744|Device|Ceterix NovoStitch|The device allows the physician to place a circumferential compression stitch around meniscal tears. This stitch is placed by passing suture from the tibial side to the femoral side of the meniscus and across the tear. This allows compression across the entire tear surface.
75900866|NCT02900352|Drug|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
75900867|NCT02900352|Drug|Placebo|Placebo
75752145|NCT04013165|Behavioral|Village-based intervention|"Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults."
75752146|NCT04013477|Drug|DA-5207|DA-5207 Transdermal Delivery System
75752147|NCT04013477|Drug|Donepezil Hydrochloride|donepezil HCl 10mg QD
75455550|NCT01761838|Other|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
75455551|NCT01761838|Other|Low back pain participants without SMT|No treatment
75455552|NCT01761864|Behavioral|academic detailing intervention|
75455553|NCT01761916|Drug|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
75606772|NCT05322733|Drug|Obinutuzumab|1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
75606773|NCT05322733|Drug|Fludarabine|25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
75606774|NCT05322733|Drug|Cyclophosphamide|250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
75606775|NCT00968812|Drug|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
75606776|NCT00968812|Drug|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
75606777|NCT00968812|Drug|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
75606778|NCT02834767|Device|Genioglossis Strength Trainer|The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
75606779|NCT02834767|Device|Placebo Genioglossis Strength Trainer|The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
75752148|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
75752149|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
75752150|NCT00940667|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
75752151|NCT00940667|Drug|Amlodipine|amlodipine 5mg q.d.
75752152|NCT04013087|Dietary Supplement|Oral feeding of Feihe Stage 1 infant formula|Oral feeding of Feihe Stage 1 infant formula for 16 weeks
75455554|NCT01761916|Drug|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
75455555|NCT01761942|Dietary Supplement|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
75455556|NCT01761955|Other|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
75606780|NCT02834845|Drug|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
75606781|NCT02834845|Drug|Desflurane|Desflurane %6-8 for general anesthesia maintenance
75455557|NCT01761968|Drug|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
75752153|NCT04013087|Dietary Supplement|Oral feeding of control Stage 1 formula|Oral feeding of control Stage 1 formula for 16 weeks (A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used))
75900868|NCT02318498|Procedure|CMR|Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
75900869|NCT05034406|Drug|2% Lidocaine|6 mL of 2% lidocaine injected at the trocar insertion site.
75900870|NCT05034406|Drug|0.5% levobupivacaine|6 mL of 0.5% levobupivacaine injected at the trocar insertion site.
75900871|NCT02318576|Other|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
75455558|NCT01761994|Drug|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
75900872|NCT02254668|Other|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
75900873|NCT02254668|Other|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
75900874|NCT03097978|Device|Commercial system|Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
75900875|NCT03097978|Device|RIC arm system|Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
75900876|NCT03097978|Other|Direct Control|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
75900877|NCT03097978|Other|Pattern Recognition|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
75900878|NCT02315924|Other|simultaneous coronary and cerebral intervention|Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
76067014|NCT03370406|Drug|5-fluorouracil|Intralesional injections of 50mg/ml over a 3 week period.
76067015|NCT03370406|Drug|Imiquimod 5% cream|Topical application of 5% cream over a 3 week period.
76067016|NCT03362294|Drug|GA Depot 40mg once monthly|Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
76067017|NCT03362294|Drug|GA Depot 25mg once monthly|Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)
75455559|NCT01762020|Device|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
75455560|NCT01762020|Drug|Standard Preparation|standard creams
75455561|NCT01762033|Drug|ASONEP|Intravenous infusion
75606782|NCT02840851|Device|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
75606783|NCT02840851|Device|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
76067018|NCT03362060|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
75455562|NCT01762046|Drug|Glipizide|
75455563|NCT01762046|Drug|Metformin|
75455564|NCT01762046|Other|Oral Glucose Tolerance Test|
75455565|NCT01762072|Dietary Supplement|Fish oil|
75455566|NCT01762072|Dietary Supplement|vitaminB12|
75455567|NCT01762085|Procedure|nerve decompression|surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
75455568|NCT01762124|Device|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
75752154|NCT04013087|Dietary Supplement|Breast feeding|Breast feeding of human milk for 16 weeks
75900879|NCT02315924|Other|staged coronary and cerebral intervention|Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
75900880|NCT03040687|Biological|Anti CS6 BSIgG product (Lot PD1601105CS)|
75606784|NCT02834533|Device|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
75752155|NCT01019772|Biological|LBVH0101 (Hib vaccine)|
75606785|NCT02834143|Other|No intervention|The is no intervention. This study is a descriptive one
75752156|NCT01019772|Biological|Hiberix™ Vaccine|
75752157|NCT00940745|Device|Stereotactic Aspiration and Thrombolysis|"Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
75752158|NCT00940745|Drug|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
75900881|NCT03040687|Biological|Anti B7A BSIgG product (Lot PD1601132ET)|
75900882|NCT03040687|Biological|Bovine Immunoglobin Negative Control (Lot PD161071NC)|
75900883|NCT03040687|Biological|B7A- CS6-expressing ETEC challenge strain|
75900884|NCT03544398|Other|robot assisted gait training|we use two types of robot assisted gait training and we will compare two groups.
75900885|NCT03500276|Behavioral|Yoga program|Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
75900886|NCT03500276|Behavioral|Arthritis-education|Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
75900887|NCT03098134|Behavioral|Behavior Therapy|Virtual Reality and Video based Exposure Therapy
75455569|NCT01762137|Procedure|Flow Diversion|Endovascular flow diverter placement
75900888|NCT03098134|Other|Health Education|Video based health education covering common myths and false believes about dental surgeries
76067019|NCT03362060|Biological|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
76067020|NCT03354741|Other|laser therapy|stimulation of the acupuncture point P6 by laser therapy
75606786|NCT02834299|Behavioral|DBT Guided Self-Help|DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
75455570|NCT01762137|Procedure|Coiling|Endovascular coil placement
75455571|NCT01762150|Drug|Sorafenib|Sorafenib 400mg BID by oral until progressed;
75455572|NCT01762150|Drug|Gemcitabine|Gemcitabine: 1000mg/m2, administered by intravenous drip for 30~60min on Day 1 and 8,for 4 cycles;
75455573|NCT01762150|Drug|Cisplatin|Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
75455574|NCT01762163|Drug|Qizhitongluo Capsule|
75455575|NCT01762163|Drug|Naoxintong Capsule|
75455576|NCT01762163|Drug|Aspirin Enteric-coated Tablets|
75752159|NCT01014000|Device|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
75752160|NCT01014000|Device|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
75752161|NCT00513500|Drug|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
75752162|NCT00513500|Drug|Coartem|Give Coartem without RDT and refer fast breathing
75752163|NCT03969719|Drug|Placebo|Placebo
75752164|NCT03969719|Drug|PF-06835919|150 mg once daily
75752165|NCT03969719|Drug|PF-06835919|300 mg once daily
75752166|NCT03998072|Other|Five session cognitive analytic therapy (CAT) consultancy|Five session consultancy with patients and care coordinators using cognitive analytic therapy
75900889|NCT05270785|Other|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management (2-3 follow-up calls). The intervention will consist of an initial session with the youth focusing on accessing mental health care plus two case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to two months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
75900890|NCT05270785|Other|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate 1-2 supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 2 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 2 months.
75606787|NCT02834299|Behavioral|DBT Unguided Self-Help|DBT self-help manual without any therapy sessions for 12 weeks
75606788|NCT02834299|Behavioral|Self-Esteem-Focused Unguided Self-Help|Self-esteem focused self-help manual without any therapy sessions for 12 weeks
75752167|NCT00511004|Drug|Albendazole|Comparing 400 mg to 800 mg dose
75752168|NCT00511004|Drug|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
75752169|NCT02550197|Biological|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
75606789|NCT05333575|Behavioral|Lullaby|The mothers in this group were asked to sing a lullaby while their babies were fed with an orogastric tube. Mothers were released on lullabies. They were encouraged to sing the lullaby they knew or loved the most. The mother was given a sound decibel meter. Mothers were asked to do an application before going to the baby. It was taught that the number of sound decibels should not exceed 40 decibels while singing a lullaby. Later, the mother was taken to the baby's incubator at feeding time. She was seated in a chair. The working status of the decibel meter was checked and given to the mother. When the feeding started, the mother started singing lullabies and continued to sing until the feeding was finished. Attention was paid to aseptic techniques during all procedures. A single mother was asked to sing a lullaby at each feeding, and the baby of the mother who sang only a lullaby was included in the study.
75752170|NCT02550197|Biological|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
75455577|NCT01762163|Behavioral|the routine recovery training|
75455578|NCT01762163|Drug|placebo|
75455579|NCT01762189|Procedure|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
75455580|NCT01762202|Drug|Cyclophosphamide|
75455581|NCT01762202|Drug|Fludarabine|
75455582|NCT01762202|Drug|Ofatumumab|
75752171|NCT02959502|Other|Receive tDCS+CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
75752172|NCT02959502|Other|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
75752173|NCT01009424|Drug|R7103|escalating inhaled dose
75752174|NCT00938795|Other|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
75752175|NCT00938795|Other|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
75455583|NCT01762215|Behavioral|PatientsLikeMe.com|PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
75455584|NCT01762228|Device|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
75900891|NCT03097354|Other|no intervention/observational survey study design|no intervention/observational survey study design
75900892|NCT02321306|Drug|LUM001|LUM001 administered orally once each day.
75900893|NCT05034094|Other|VEMP recording|"Clinical evaluation: All participants will undergo detailed medical and neurological histories and examinations.~The severity of manifestations of PD will be assessed using the Movement Disorder Society (MDS)-sponsored new version of Unified PD Rating Scale (MDS-UPDRS)."
75455585|NCT01762228|Dietary Supplement|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
75455586|NCT01762241|Behavioral|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
75752176|NCT00939887|Drug|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
75752177|NCT00938873|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
75752178|NCT00939965|Drug|isotretinoin|
75900894|NCT02316080|Other|Dental bleaching|Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
75900895|NCT02316080|Other|Desensitizing therapy|Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
75900896|NCT03095404|Drug|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
75900897|NCT03095404|Drug|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
75900898|NCT02145546|Drug|Amiodarone|Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
75900899|NCT02145546|Drug|Propafenone|150mg per 8 hours, 3 times per day
75900900|NCT02145546|Drug|Sotalol|80mg twice per day.
75900901|NCT03039673|Drug|Riluzole|"All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS."
75752179|NCT00939965|Genetic|DNA analysis|
75752180|NCT00939965|Genetic|polymerase chain reaction|
75752181|NCT00939965|Other|laboratory biomarker analysis|
75900902|NCT03039673|Drug|IL-2|"The dose of IL-2 to be used in this study will be 2.0 million IU/day.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.~In case of intolerance, a flexible dose-reduction schedule is available."
75900903|NCT03039673|Drug|5% glucose water solution|"The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period."
75900904|NCT02316158|Other|Web-based support|Comparison between the efficacy between webb-based support and informational support
75900905|NCT03097432|Drug|ORALVAC COMPACT BÄUME|
75900906|NCT04461782|Dietary Supplement|Lactobacillus plantarum|Oral food supplement
75900907|NCT02145624|Drug|Repevax|vaccine
75900908|NCT02145624|Drug|Boostrix-IPV|vaccine
75752182|NCT00939965|Other|pharmacological study|
75752183|NCT04012541|Procedure|active dental procedure|scaling and root planing
75900909|NCT03042559|Device|Protonics Knee brace|The Protonics system has been introduced to physical therapists as a potential treatment for PFPS. The system includes a brace set to resist knee flexion and a set of specific exercises to perform daily. Through resistance to knee flexion, the system is advertised to decrease retropatellar contact pressure due to changes in pelvis inclination and available hip rotation. Specifically, resistance to knee flexion is purported to increase hamstring activity and inhibit the activity of the tensor fasciae latae and psoas muscles. The manufacturer asserts that prolonged use of the system results in greater hamstring activation, which leads to permanent structural changes through reciprocal inhibition at the hip and pelvis. The warm-up consisted of the subject wearing the ProtonicsTM knee brace set at a moderate resistance level and flexing the knees while sitting, standing, and reclining in the supine and prone positions.
75900910|NCT03042559|Device|Sports Cords|Subjects assigned to the sport cord group were asked to do the same warm-ups and exercises using the sport cord in the supine, standing, sitting, and prone positions. prone. The only difference is that subjects were asked to only walk backwards instead of forwards in order to avoid activation of the hip flexor muscle. The appropriate level of resistance for each subject was calculated by multiplying their weight in pounds by 0.3. Subjects were then given either light, medium, or heavy resistance cords according to the following classification scheme: light (pink color) with resistance 3 (R3), 0-30 lbs.; medium (orange color) with resistance 5 (R5) 0-50 lbs.; heavy (yellow color) with resistance 7 (R7) 0-70 lbs. All subjects completed three study visits, and a total of four measurements were taken at baseline, immediately following the first session, at two weeks, and at 4 weeks.
75455587|NCT01762254|Procedure|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
75455588|NCT01762254|Procedure|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
75455589|NCT01762267|Other|nutrition intervention|DASH diet control diet
75455590|NCT01762280|Drug|Famitinib Malate Capsule|
75606790|NCT05333575|Behavioral|Classic music|The babies in this group were given classical music recitals during feeding. The classical music piece Mozart-Baby Smart was preferred because it was seen to be used in the literature (Keidar 2014). Mozart-Baby Smart was loaded into the music player by the researcher before the feeding process. Before feeding, the decibel meter was disinfected by surface disinfectant and placed on sterile sponge in an incubator 10 cm away from the baby's head. The music player was turned on, not exceeding 40 decibels, by adjusting the decibel meter at the time of starting the feeding, and classical music was continued during the feeding. When the feeding was finished, the music player was turned off and the incubator was taken out. Attention was paid to acetic techniques during all procedures. Ambient sounds were tried to be controlled as much as possible so that the baby would not be affected by different sounds when listening to classical music.
75606791|NCT02837809|Radiation|Low dose CT|annual CT vs biennial CT
75606792|NCT00992056|Drug|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
75606793|NCT00992056|Drug|Metoprolol|Metoprolol 50 mg titrated to 100 mg
75606794|NCT02837653|Behavioral|Physical Activity Counselling|
75752184|NCT04012541|Drug|post-myocardial infarction management|aspirin, clopidogrel, ticagrelor
75752185|NCT04012541|Radiation|basic periodontal examinations|panorama radiograph : full mouth periapical radiograph
75752186|NCT02877134|Drug|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
75752187|NCT02877134|Drug|Placebo|Participants will receive placebo Subcutaneously.
75752188|NCT02877134|Drug|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
75752189|NCT00563381|Drug|Tiotropium bromide|18 mcg/daily
75455591|NCT01762293|Drug|Famitinib|Famitinib 25 mg p.o. qd
75455592|NCT01762293|Other|placebo|p.o. qd
75455593|NCT01762306|Drug|Diclofenac Potassium|
75455594|NCT01762306|Drug|Folic Acid|
75455595|NCT01762319|Drug|Misoprostol|
75455596|NCT01762319|Drug|Vitamin B6|
75606795|NCT02837653|Other|Therapeutic Exercise for LBP|
75606796|NCT02837653|Other|Superficial Thermotherapy|
75606797|NCT04249999|Behavioral|ActivOnline|Access to online physical activity platform (www.activonline.com.au)
75752190|NCT00563381|Drug|Salmeterol|100 mcg/daily
75752191|NCT00563381|Drug|Placebo Salmeterol|Placebo identical to Salmeterol device
75752192|NCT00563381|Drug|Placebo Tiotropium|Placebo identical to Tiotropium device
75752193|NCT00512798|Drug|PS-341 (VELCADE)|"Dose Levels PS-341 (day 1)~Level -1 0.7 mg/m2~Level 1 1.0 mg/m2~Level 2 1.0 mg/m2~Level 3 1.3 mg/m2~Level 4 1.5 mg/m2"
75752194|NCT00512798|Drug|temozolomide|"Temozolomide (day 8)~Level - 1 50 mg/m2~Level 1 50 mg/m2~Level 2 75/mg/m2~Level 3 75 mg/m2~Level 4 75 mg/m2"
75752195|NCT00512798|Other|immunoenzyme technique|Not noted
75752196|NCT00512798|Drug|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
75752197|NCT00512798|Drug|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
75752198|NCT03998930|Other|Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)|Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
75900911|NCT05033938|Procedure|Early Mobilization Protocol|Subjects will be placed in a bulky soft dressing immediately after surgery. They will be made non-weight bearing, but active and passive motion of digits, forearm, elbow, and shoulder will be allowed with light functional tasks permitted as tolerated. Wrist motion within the soft dressing will be permitted as tolerated by patient. On postoperative day 3, patients will be advised to remove the dressing at home and begin home hand/wrist therapy. They will use a removable Velcro wrist splint for nighttime wear and strenuous activity. This splint can be removed during normal activities of daily living and therapy.
75900912|NCT05033938|Procedure|Late Mobilization Protocol|Subjects will be placed in a plaster volar resting splint. They will be made non-weight bearing, with use of digits for light functional tasks permitted. They will be given home exercises for their fingers but will not yet resume wrist motion
75900913|NCT02321384|Drug|Placebo|Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
75900914|NCT02321384|Drug|RO6889678|RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
75900915|NCT02321384|Drug|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.
75900916|NCT02321384|Drug|Ritonavir|RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
75900917|NCT03095326|Dietary Supplement|Zinc|formula of ZnSO4, usually used to treat zinc deficiency.
75900918|NCT03095326|Drug|Sucrose|Placebo of sucrose syrup
75606798|NCT04286074|Other|50% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 50% of the maximum inspiratory pressure of each athlete
75455597|NCT01762332|Drug|Base level of remifentanil effect side concentration: 2ng/ml|constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
75455598|NCT01762332|Drug|Base level of remifentanil effect side concentration: 4ng/ml|constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
75752199|NCT03743207|Other|Room temperature|These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.
75752200|NCT03743207|Other|Warmer temperature|Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
75752201|NCT00940121|Drug|mirabegron|oral tablet
75900919|NCT03095326|Biological|PCV Vaccine|Pneumococcal conjugate vaccine
75900920|NCT03095326|Biological|PPV Vaccine|Pneumococcal polysaccharide vaccine
75900921|NCT02780856|Device|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black & white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
75900922|NCT03497624|Other|Biospecimens collection|Collection of tumor tissue when a participant is having a clinically-indicated biopsy or surgery for their ROS1-fusion cancer.
75900923|NCT03095092|Drug|BIA 6-512 400 mg|4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
75455599|NCT01762332|Other|chronic beta-blocker treatment|Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
75455600|NCT01762358|Other|Khalifa's therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin
75455601|NCT01762358|Other|Physiotherapy|Twelve times standardized Physiotherapy
75752202|NCT00940121|Drug|mirabegron|IV solution
75752203|NCT00565721|Drug|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
75455602|NCT01762371|Other|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
75455603|NCT01762384|Procedure|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
75752204|NCT00940979|Procedure|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
75752205|NCT00938951|Other|Systane® Ultra|Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
76067021|NCT03325985|Behavioral|Nurse-led telephonic case management|Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
75606799|NCT04286074|Other|10% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 10% of the maximum inspiratory pressure of each athlete
75606800|NCT02834221|Device|Real-time ultrasound-guided puncture|A 7 megahertz ultrasound linear probe will be used.
75606801|NCT02834221|Other|Anatomical landmark guided puncture|Anatomical landmark puncture
75606802|NCT00972322|Drug|MK-8245|MK-8245 50 mg twice daily for 28 days
75606803|NCT00972322|Drug|Comparator: placebo|matching placebo to MK-8245 twice daily for 28 days
75606804|NCT02840773|Other|Peri-implanter sulcus fluid sampling|PISF sampling was made twice
75752206|NCT04012619|Drug|Anlotinib Hydrochloride|Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.
75900924|NCT02318810|Drug|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
75455604|NCT01762384|Procedure|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
75455605|NCT01762384|Device|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
75455606|NCT01762397|Drug|PMK-S005|
75455607|NCT01762410|Drug|P7170|Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
75455608|NCT01762423|Device|Active Device (IVIVI SofPulse)|
75606805|NCT02840773|Other|Probing depth|The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
75606806|NCT02840773|Other|Crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
75752207|NCT00561977|Behavioral|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
75752208|NCT00561977|Behavioral|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
75752209|NCT00561977|Behavioral|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
75752210|NCT00941057|Drug|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
75752211|NCT00941057|Drug|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
75900925|NCT02318810|Drug|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
75900926|NCT02318810|Drug|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
76067022|NCT03325985|Behavioral|Facilitated,outpatient specialty palliative care|In-person palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
75455609|NCT01762423|Device|Sham Device|
75900927|NCT02318810|Drug|Placebo|Patients receive saline
75900928|NCT03766477|Diagnostic Test|Pittsburgh Sleep Quality Index (IQSP) and Johansson|All participants will to answer the Pittsburgh Sleep Quality Index (IQSP) and Johansson questionnaires before polysomnography examination and use of APP.
76067023|NCT03298984|Drug|Alvocidib|IV bolus followed by IV infusion
76067024|NCT03298984|Drug|Cytarabine|continuous infusion
75455610|NCT01762436|Drug|bisoprolol|
75455611|NCT01762436|Drug|atenolol|
76067025|NCT03298984|Drug|Daunorubicin|IV bolus
76067026|NCT03270358|Procedure|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session"
76067027|NCT03270358|Procedure|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
75606807|NCT02840773|Other|Presence of bleeding on probing|The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
76067028|NCT03248492|Drug|DS-8201a|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
75606808|NCT02840773|Other|Plaque index levels|The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
75752212|NCT00941057|Drug|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
75752213|NCT00561821|Drug|Esmirtazapine|one tablet daily
75752214|NCT00561821|Drug|Placebo|one tablet daily
75752215|NCT00558701|Device|Microcurrent stimulator|Microcurrent stimulation from 15-50 microamps
76067029|NCT03232164|Drug|18F-DCFPyL PET|18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
76067030|NCT03225560|Other|Bowel Preparation|Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
76067031|NCT03224468|Drug|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
76067032|NCT03219528|Drug|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
76067033|NCT03219528|Other|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
76067034|NCT03216252|Biological|samples|Blood samples, oral smear and urine
76067035|NCT03172195|Procedure|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
76067036|NCT03172195|Biological|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
76067037|NCT03172195|Biological|blood sample|Blood sample will be collected in more.
76067038|NCT03163511|Combination Product|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
75455612|NCT01762449|Other|Followup survey|
75455613|NCT01762462|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
75752216|NCT00558701|Device|Silverlon Wound Contact Dressing|Silver coated nylon dressing FDA approved for use on donor sites in burn patients
75752217|NCT03684044|Drug|Baloxavir Marboxil|Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
75455614|NCT01762475|Drug|Sildenafil|
75752218|NCT03684044|Other|Placebo|Participants will receive matching placebo on Days 1, 4 and 7.
75752219|NCT01009502|Drug|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
75752220|NCT00510692|Drug|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
75455615|NCT01762488|Procedure|Ablation of the renal arteries|Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
75752221|NCT00510692|Procedure|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
75752222|NCT00510692|Procedure|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
75752223|NCT00510692|Drug|Placebo|2 x 500mg placebo capsules twice daily for 6 months
75752224|NCT00335452|Drug|Clopidogrel|oral administration
75752225|NCT00335452|Drug|acetylsalicyclic acid (ASA)|oral administration
76067039|NCT03162016|Procedure|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
76067040|NCT03160430|Drug|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
76067041|NCT03160430|Drug|Placebos|matching placebo capsule
76067042|NCT03149003|Drug|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
76067043|NCT03149003|Drug|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
75455616|NCT01762488|Procedure|Renal angiography|Renal angiography by femoral access
75455617|NCT01762514|Drug|Amifostine every-other-day regimen|Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
76067044|NCT03148275|Other|Questionnaire Administration|Ancillary studies
76067045|NCT03148275|Drug|Trametinib|Given PO
75606809|NCT02863744|Procedure|coronally advanced flap with subepithelial connective tissue graft|"Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
75752226|NCT00522548|Drug|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
75752227|NCT00522548|Drug|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
75752228|NCT00522392|Drug|bortezomib|Given IV
75752229|NCT00522392|Drug|lenalidomide|Given PO
75752230|NCT00522392|Drug|dexamethasone|Given PO
75752231|NCT04346264|Diagnostic Test|NO intervention planned due to the observational study design only a diagnostic testing|Only a diagnostic test (serum blood and antibody measurement) is planned
75752232|NCT01061320|Drug|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
75752233|NCT01061320|Drug|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
75752234|NCT01061398|Procedure|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
76067046|NCT03103750|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
75606810|NCT02834377|Other|Treatment algorithm targeting individual cardiac output|
75752235|NCT01061398|Procedure|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
75752236|NCT01565408|Drug|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
75752237|NCT01565408|Drug|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
75752238|NCT03985306|Procedure|Inforatio technique|"We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment."
75752239|NCT01012544|Drug|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
75752240|NCT01012700|Drug|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
75752241|NCT01012778|Behavioral|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
75900929|NCT03766477|Diagnostic Test|Smartphone APP|All study participants will use a smartphone application (APP), which will be made available by the researchers, at the same time as the polysomnography exam.
75900930|NCT03766477|Diagnostic Test|Polysomnography|All participants slept for one night in a sleep laboratory for PSG recording. The data will be confirmed by an otorhinolaryngology certified by the Brazilian Association of Sleep Disorders
75900931|NCT03098056|Other|PROG2|"Nutritional Supplements to be administered:~Protein Shakes: one shake po twice daily~Phytosterol supplement: one capsule po twice daily~Cinnamon: one tablet twice daily~Fiber supplement; one shake twice daily~Antioxidant supplement: 2 capsules daily with dinner~Fish Oil supplement: 1 capsule twice daily with food~Probiotic supplement: 1 capsule twice daily with food"
76067047|NCT03103750|Drug|PHNO|Used as a tracer for in vivo imaging.
76067048|NCT03103750|Dietary Supplement|calcitriol|three 0.5 mcg capsules
75455618|NCT01762514|Drug|Amifostine everyday regimen|Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
76067049|NCT03103750|Drug|Placebo oral capsule|three 0.5 mcg capsules
76067050|NCT03103750|Procedure|high-resolution research tomography|A functional imaging technique that is used to observe metabolic processes in the body.
75455619|NCT01762527|Radiation|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
75455620|NCT01762540|Drug|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
75455621|NCT01762540|Drug|Calcium Supplement|Placebo
75606811|NCT02834455|Device|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
75606812|NCT02834455|Device|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
75752242|NCT01565486|Device|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
75752243|NCT01565486|Device|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
75752244|NCT01565720|Drug|Isavuconazole|oral
75900932|NCT03544788|Device|Cirvo™ Therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
75900933|NCT03500120|Diagnostic Test|Seated saline infusion test|"Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Fludrocortisone suppression test:Patients received 0.1 mg oral fludrocortisone every 6 h for 4 days, together with slow-release potassium chloride and sodium chloride supplements.~Captopril challenge test:Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 1 h. Blood samples were drawn at time zero and 2 h after the challenge."
75900934|NCT05054764|Device|Promus PREMIER BTK DES|Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients
75900935|NCT02141958|Drug|Fenretinide|Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
75455622|NCT01762553|Behavioral|The TEA intervention|TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
75900936|NCT02141958|Drug|Placebo|A matching placebo will be used to keep the study double-blind.
75900937|NCT03500042|Device|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
75900938|NCT02142036|Drug|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
75455623|NCT01762566|Dietary Supplement|wheat|wheat is administered blindly versus placebo in capsules once
75455624|NCT01762566|Dietary Supplement|xylose|placebo (xylose) will be administered blindly versus wheat in a capsule once
75455625|NCT01762592|Drug|Iodine (124I) Girentuximab|i.v.
75455626|NCT01762618|Behavioral|Cognitive Behavioral Therapy Group|Therapy Groups
75455627|NCT01762644|Drug|Oral Cyclosporine and Oral Omeprazole|
75455628|NCT01762644|Drug|Oral Omeprazole|
75606813|NCT02837575|Biological|VCL-HB01|Investigational Product
75606814|NCT02837575|Other|Phosphate-buffered saline|Placebo
75606815|NCT04209361|Other|Questionnaire|Data will be obtained through a printed questionnaire for assessment of knowledge, attitude and practice of dentists at military hospitals regarding child abuse and neglect. The collected data will be saved and tabulated on a computer and finally will be statistically analyzed.
75752245|NCT01565720|Drug|Placebo|oral
75752246|NCT01565720|Drug|Moxifloxacin|oral
75752247|NCT00309244|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
75752248|NCT00309244|Drug|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
75752249|NCT00483756|Drug|Cyclosporine|Standard of care
75752250|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
75752251|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
75752252|NCT00309166|Biological|Cervarix vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
75752253|NCT00309166|Biological|Engerix-B vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
75752254|NCT01063816|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
75606816|NCT04249765|Other|Assessing grasping force, pinch force,|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table."
75752255|NCT01063816|Drug|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
75752256|NCT01063816|Drug|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
75752257|NCT00501852|Drug|NVA237|single-dose dry-powder inhaler (SDDPI)
75752258|NCT00501852|Drug|Placebo|single-dose dry-powder inhaler (SDDPI)
75752259|NCT00501852|Drug|Tiotropium|Handihaler inhaler
75606817|NCT05334355|Other|Family history of hypertension|Presence or absence of a family history of hypertension in a cross sectional study design.
75752260|NCT03981250|Behavioral|12-week home-based resistance exercise programme|Participants will perform 6 exercises (press-ups, squats, squat jumps, plank, upright row and seated row) for one minute, aiming for the maximum number of repetitions. Participants will perform one exercise per day, for 6 days a week, for 12 weeks.
75752261|NCT00482274|Drug|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
75455629|NCT01762657|Drug|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
75455630|NCT01762657|Drug|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
75752262|NCT03985462|Biological|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
75752263|NCT03983122|Procedure|Laparoscopic sleeve gastrectomy|Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.
75752264|NCT00490542|Drug|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
75752265|NCT00490542|Drug|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
75900939|NCT05501743|Drug|Intra-articular injection of microfat and PRP|The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
75900940|NCT05501743|Procedure|Total denervation of the wrist|The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
75900941|NCT05053984|Procedure|Percutaneous Echoguided Neuromodulation|Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
75900942|NCT03494582|Procedure|Sacral Hysteropexy|Abdominal approach for uterine suspension
75455631|NCT01762670|Drug|GoldenCare|Copper intravaginal device to treat bacterial vaginosis.
75455632|NCT01762670|Drug|Metronidazole|500 mg twice daily for 7 days
75606818|NCT02840695|Drug|bDMARD treatment|Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
75606819|NCT02837497|Other|ICU-RESUS CPR Improvement Bundle|"Point-of-care CPR training~Post-cardiac arrest educational debriefings"
75606820|NCT00967798|Drug|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
75606821|NCT02837419|Behavioral|Health related Quality of life EQ-5D|Quality of Care
75606822|NCT04248361|Diagnostic Test|TEM-PCR URI Panel|Target Enriched Multiplex Polymerase Chain Reaction (TEM-PCR™) is a breakthrough molecular multiplex technology that allows rapid DNA/RNA identification of multiple pathogens (i.e., bacteria and viruses) in a single sample, typically within one day of specimen receipt.
75752266|NCT03982966|Dietary Supplement|Omega 3 fatty acids (fish oil) 1000 mg/day oral|Omega 3 fatty acids (fish oil) 1000 mg/day oral
75752267|NCT01016418|Dietary Supplement|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
75752268|NCT01059604|Drug|Sumatriptan|Sumatriptan
75752269|NCT01059604|Drug|Naratriptan|Naratriptan
75752270|NCT01059604|Drug|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
75752271|NCT02532634|Drug|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
75752272|NCT02532634|Drug|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
75752273|NCT03981172|Behavioral|Daily snack food intake|participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.
75752274|NCT00501540|Drug|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
75752275|NCT01014156|Drug|epoprostenol|titration up to 4 ng/kg/min
75752276|NCT00322348|Drug|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
75900943|NCT03494582|Procedure|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
75900944|NCT05053594|Drug|Neostigmine 10 mcg/kg|Once the third response to TOF is obtained, neostigmine 10 mcg/kg will be administered
75900945|NCT05053594|Drug|Neostigmine 20 mcg/kg|Once the third response to TOF is obtained, neostigmine 20 mcg/kg will be administered
75900946|NCT05053594|Drug|Neostigmine 30 mcg/kg|Once the third response to TOF is obtained, neostigmine 30 mcg/kg will be administered
75900947|NCT05053594|Other|Placebo|Once the third response to TOF is obtained, saline will be administered
75900948|NCT04462016|Other|Calamansi|250 ml of a commercially sourced calamansi drink
75900949|NCT04462016|Other|Glucose|75 g of glucose dissolved in 250 ml of drinking water
75900950|NCT02324426|Drug|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
75752277|NCT00322348|Drug|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
75752278|NCT01014234|Drug|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
75900951|NCT03097510|Behavioral|Transcendental meditation|The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
75900952|NCT02142114|Device|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
75900953|NCT05053516|Other|A standardized training program for social workers|A standardized training program for social workers who work with drug addicts / drug users based on industry needs
75900954|NCT02318888|Procedure|Surgery|
75900955|NCT02318888|Drug|Icodextrin|
75900956|NCT02142192|Drug|natalizumab|Administered as specified in the treatment arm
75900957|NCT05053906|Device|Endoscope|effect of FESS on eustachian tube function
75900958|NCT02145702|Other|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
75900959|NCT02145702|Procedure|Standard Care Dialysis|12 weeks of standard of care.
75900960|NCT05033860|Other|Read leaflets containing knowledge of COVID-19 and vaccination.|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and participants are asked to read the leaflets.
75900961|NCT02318966|Dietary Supplement|Medical Food - Glycosade|double blind randomised crossover of 2 starches - glycosade and UCCS
75900962|NCT02145780|Dietary Supplement|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
75900963|NCT02145780|Dietary Supplement|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
75900964|NCT02749045|Radiation|SPECT imaging|myocardial perfusion imaging
75752279|NCT01014234|Drug|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
75752280|NCT00501228|Drug|Filgrastim|5 mg/kg ID Once Daily x 1 Week
75900965|NCT02321540|Drug|Ibrutinib|"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."
75900966|NCT03544320|Device|Activity Monitoring-Wrist worn wearable|Participants wear an activity monitor on their wrist.
75900967|NCT03544320|Device|Activity Monitoring-Waist-worn wearable|Participants wear an activity monitor on their waist.
75900968|NCT02321618|Behavioral|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
75900969|NCT02321618|Behavioral|BP educational materials|Exposure to hypertension educational materials
76067051|NCT03103750|Drug|Dextro Amphetamine|Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
75752281|NCT00308620|Drug|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
75752282|NCT00308620|Drug|Placebo|Placebo once daily for 8 weeks
75752283|NCT01014312|Behavioral|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
75752284|NCT01014312|Behavioral|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
75900970|NCT02324582|Drug|Intravenous MK-3475/ Intravesical BCG|6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembrolizumab.
75900971|NCT01255891|Radiation|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
75900972|NCT02321696|Device|Acupuncture|
75900973|NCT02321696|Other|Physiotherapy and eccentric exercise|
75900974|NCT02321696|Other|Watchful waiting and eccentric exercise|
75900975|NCT02321696|Other|eccentric exercise|
75900976|NCT02777190|Drug|Misoprostol|Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
75900977|NCT03494426|Procedure|radiofrequency thoracic sympathectomy|"Under fluoroscopic guidance thoracic sympathectomy will be done as follow~antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient."
75752285|NCT01016496|Other|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
75752286|NCT01016496|Other|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
75900978|NCT03494426|Drug|pregabalin ,tramadol,and tricyclic antidepressants|patient will receive anti neuropathic medications
75900979|NCT03494270|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
75900980|NCT03494270|Drug|Monorova|Rosuvastatin 20mg
75900981|NCT02145858|Device|Blood drainage post cardiac surgery using PleuraFlow System|
75900982|NCT03497468|Other|Combined exercise training|Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
75900983|NCT03497468|Other|Task-oriented training|Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
75900984|NCT03497312|Procedure|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
75900985|NCT02319122|Other|High Intensity Interval Training|See arm description
75900986|NCT02319122|Other|Progressive Resistance Training|See arm description
75752287|NCT00492752|Drug|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
75752288|NCT00492752|Drug|Placebo|Matching placebo (orally) twice daily
75752289|NCT01016574|Device|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
75900987|NCT02432209|Other|Caloric Restriction|Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
75606823|NCT04248361|Other|SOC/Empiric Diagnosis|The SOC for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
75606824|NCT04248439|Biological|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
75752290|NCT01009658|Dietary Supplement|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
75752291|NCT01009658|Dietary Supplement|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
75752292|NCT00308308|Drug|Technosphere Insulin|Inhalation, 15U/30U
75752293|NCT00308308|Drug|Active comparator|sc injectable insulin
75752294|NCT00505934|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily).~Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
75752295|NCT02532790|Drug|Prednisone|1.5mg/kg/d
75752296|NCT02532790|Drug|ACEI|0.2-0.3mg/kg/d
75606825|NCT02863510|Device|Renal Sympathetic Denervation|Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
75606826|NCT04286464|Other|No intervention|No intervention
75606827|NCT04248205|Drug|Ketamine|Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
75606828|NCT02833831|Drug|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
75606829|NCT02833831|Drug|Placebo|Matching Placebo will be administered.
75606830|NCT02833831|Drug|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
75752297|NCT03981406|Behavioral|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
75752298|NCT03981406|Behavioral|Standard of Care|Control group will receive standard of care treatment for IPF.
75752299|NCT00505778|Drug|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
75752300|NCT00505778|Drug|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
75900988|NCT02432209|Drug|Orlistat|Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.
75455633|NCT01762683|Other|Myometrium biopsy and blood samples|"The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study."
75752301|NCT01061554|Dietary Supplement|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
75752302|NCT01061554|Dietary Supplement|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
75752303|NCT01063894|Other|breakfast cereal|breakfast cereal and milk
75752304|NCT01063894|Other|water|water
75606831|NCT02833987|Drug|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
75752305|NCT01064050|Device|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
75752306|NCT00308074|Drug|Aripiprazole|open-label, flexible-dosing
75455634|NCT01762696|Behavioral|MET|Motivational Enhancement Therapy only
75455635|NCT01762696|Behavioral|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
75606832|NCT02833987|Drug|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
75606833|NCT02833987|Drug|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
75606834|NCT02833987|Drug|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
75606835|NCT02833909|Other|surgery|
75752307|NCT01059838|Behavioral|sentence recognition|testing the ability for sentence recognition in quiet and in noise.
75752308|NCT03997058|Other|Auricular point pressure therapy|Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
75752309|NCT03997058|Drug|Oral estazolam medication|The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
75752310|NCT01061632|Procedure|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
75752311|NCT01061632|Procedure|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
75752312|NCT00500760|Drug|Cisplatin|Administered intravenously (IV; in a vein)
75752313|NCT00500760|Radiation|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
75752314|NCT00500760|Drug|Panitumumab|Administered intravenously
75752315|NCT00505622|Drug|Perampanel|
75752316|NCT01009736|Dietary Supplement|tomato-soy juice|
75752317|NCT01009736|Other|laboratory biomarker analysis|
75752318|NCT01009736|Other|pharmacological study|
75752319|NCT01009736|Procedure|therapeutic conventional surgery|
75752320|NCT03852576|Drug|KSP/QRH dimer|KSP-QRH-E3-IRDye800 (Peptide 919288G)
75900989|NCT02432209|Other|Moderate physical activity|All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
75900990|NCT00108732|Drug|Bicalutamide|Given orally
75900991|NCT00108732|Drug|Goserelin Acetate|Given SC
75900992|NCT00108732|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
75900993|NCT00108732|Biological|Recombinant Vaccinia-TRICOM Vaccine|Given SC
75900994|NCT00108732|Biological|Sargramostim|Given SC
75752321|NCT01012856|Behavioral|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
75752322|NCT01012856|Behavioral|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
75752323|NCT03851094|Behavioral|Wellth app|The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
75752324|NCT01016730|Drug|Bortezomib|Given IV
75752325|NCT01016730|Other|Laboratory Biomarker Analysis|Correlative studies
75900995|NCT02319200|Drug|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
75900996|NCT02319200|Drug|placebo tablet|4 tablets per day for 36 months
75900997|NCT02145936|Other|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
75900998|NCT02319278|Drug|Ferumoxytol|Infusion following between paired MRI scans
75752326|NCT01016730|Other|Questionnaire Administration|Ancillary studies
75752327|NCT00505076|Drug|MK-0777|MK-0777 GEM, 8 mg BID
75752328|NCT00505076|Drug|MK-0777|MK-0777 GEM, 3 mg BID
75752329|NCT00505076|Drug|placebo|2 tablets placebo BID
75900999|NCT02324738|Drug|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
75901000|NCT02324738|Other|Wash-out period|
75901001|NCT02324738|Drug|Mefloquine|2 tablets of Mefloquine single dose
75901002|NCT03497234|Diagnostic Test|Perilynx Analyzer to measure AF and VF fluid|Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
76067052|NCT03103581|Drug|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
75752330|NCT01012934|Drug|Alendronate Sodium Tablets, 70 mg|1 x 70 mg, single-dose fasting
75752331|NCT01012934|Drug|Fosamax Tablets, 70 mg|1 x 70 mg, single-dose fasting
75752332|NCT04334330|Drug|Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant|ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
75752333|NCT01015196|Drug|Zavedos|
75752334|NCT01015196|Drug|Cerubidine|
75752335|NCT01009892|Drug|Codeine Sulfate|Tablet
75752336|NCT00307684|Drug|double blind placebo|matching placebo tablets once daily for 4 weeks
75752337|NCT00307684|Drug|double blind PR OROS methylphenidate|18, 36, 54,72 or 90 mg/day once daily for 4 weeks
75752338|NCT00307684|Drug|open label PR OROS methylphenidate|Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
75752339|NCT00489918|Drug|teriparatide|Macroflux® patch applied to the abdomen for 30 minutes daily
75752340|NCT00489918|Drug|teriparatide|FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
75901003|NCT02146014|Other|Placebo|"Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.~In the placebo group the current will be off."
75606836|NCT02833519|Behavioral|group exercise|"Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~A weekly supportive email."
75606837|NCT02833441|Behavioral|Peer Support|
75752341|NCT01061788|Drug|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
75752342|NCT00307294|Drug|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
75752343|NCT00307294|Drug|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
75752344|NCT03981094|Drug|BMS-986278|suspension
75752345|NCT03981094|Drug|Pirfenidone|capsule
75752346|NCT01064128|Procedure|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
75752347|NCT01064128|Procedure|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
75752348|NCT03963401|Drug|PF-06700841|Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
75752349|NCT03963401|Other|Placebo|Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
75752350|NCT04410965|Drug|TERIFLUNOMIDE|Pharmaceutical form:tablet Route of administration: oral
75752351|NCT04012775|Biological|Insulin Humulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
75752352|NCT04012775|Biological|Insulin Rinsulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
75455636|NCT01762709|Procedure|The VT 4 ml/kg group|the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
75455637|NCT01762709|Procedure|The VT 6 ml/kg group|the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
75752353|NCT00944723|Dietary Supplement|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
75752354|NCT00944723|Dietary Supplement|Zinc supplement|Liquid supplement with zinc
75901004|NCT02146014|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
75901005|NCT02321852|Drug|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
75901006|NCT02321852|Drug|Placebo|Once daily oral administration of placebo mannitol for 7 days
75752355|NCT00944723|Dietary Supplement|Non-fortified bread|Daily consumption of non-fortified bread
75752356|NCT00944723|Dietary Supplement|Placebo supplement|Daily intake of placebo supplement
75752357|NCT00944801|Drug|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
75752358|NCT00334282|Drug|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
75901007|NCT02146092|Procedure|Incentive spirometry|
75901008|NCT02146092|Other|Physiotherapy|Standard of care exercise training and supervision
75752359|NCT00334282|Drug|placebo|matching placebo (800 mg tablet) once daily
75752360|NCT03982420|Procedure|Transcarotid Revascularization (TCAR)|Carotid revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
75752361|NCT01060228|Drug|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
76067053|NCT03093974|Drug|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d dosing).~The 1 MIU/mL CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (~10 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d (morning and evening) over a period of 12 months.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g., salbutamol /albuterol), supplied by the Sponsor, could be taken to improve tolerability."
75455638|NCT01762709|Procedure|The VT 8 ml/kg group|the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
75455639|NCT01762735|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
75455640|NCT01762735|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
75455641|NCT01762748|Drug|Saccharomyces boulardii|Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
75455642|NCT01762761|Drug|eltrombopag|TPO-R agonist
75455643|NCT01762761|Drug|placebo|placebo
75455644|NCT01762774|Drug|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
75455645|NCT01762774|Drug|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
75455646|NCT01762787|Drug|Cantharidin solution|5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
75455647|NCT01762787|Drug|Aspirin|300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
75455648|NCT01762787|Drug|Prednisolone|30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
75455649|NCT01762787|Drug|Placebo to aspirin|0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
75455650|NCT01762787|Drug|Placebo to prednisolone|0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
75455651|NCT01762813|Procedure|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
75606838|NCT04248049|Other|Platelet rich fibrin|The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
75606839|NCT04247893|Device|blood flow restriction|Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
75606840|NCT04247893|Device|Photobiomodulation|Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
75752362|NCT01060228|Drug|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
75752363|NCT00306670|Drug|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
75752364|NCT00306670|Drug|prednisone|<30 mg/day
75606841|NCT04247893|Device|Placebo photobiomodulation|Placebo photobiomodulation - photobiomodulation device turned off.
75606842|NCT02837341|Device|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
75752365|NCT00306592|Biological|BG00002 (natalizumab)|
75752366|NCT03982732|Biological|Boostrix-IPV|Receipt of Boostrix IPV at three different gestational time periods
75752367|NCT00321646|Drug|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
75752368|NCT00321646|Drug|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
75752369|NCT03982654|Device|Bloomlife|Women use the Bloomlife sensor to collect data throughout their pregnancy. The collected data is stored locally in the device, but it is not used to provide any feedback to the patients or to the clinical team. Therefore the use of the device doesn't have an impact on clinical decision making and patients' care.
75752370|NCT00403767|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
75455652|NCT01762826|Dietary Supplement|Myo-inositol|Dietary control plus Myo-inositol
75455653|NCT01762826|Dietary Supplement|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
75752371|NCT00403767|Drug|Warfarin|Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
75752372|NCT00403767|Drug|Matching placebo for Rivaroxaban arm (Warfarin placebo)|Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
75752373|NCT00403767|Drug|Matching placebo for Warfarin arm (Rivaroxaban placebo)|Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
75752374|NCT00492284|Drug|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
75752375|NCT00492284|Drug|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
75752376|NCT00492284|Drug|ranibizumab|0.5 mg intravitreal injection
75752377|NCT00492284|Drug|dexamethasone|0.5 mg intravitreal injection
75752378|NCT01013012|Drug|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
75752379|NCT01013012|Drug|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
75752380|NCT01009970|Drug|Rituximab|375 mg/m2 day 1
75752381|NCT01009970|Drug|Cyclophosphamide|750 mg/m2 day 2
75752382|NCT01009970|Drug|Vincristine|1,4 mg/m2 (max 2 mg) day 2
75752383|NCT01009970|Drug|Prednisone|40 mg/m2 day 2-6
75901009|NCT03499886|Drug|Ketamine Hydrochloride 50Mg/1mL Solution for Injection|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
76067054|NCT03093974|Other|Placebo|1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
76067055|NCT03089606|Diagnostic Test|FDG PET/CT scan|18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).
75752384|NCT01009970|Drug|Doxorubicin|50 mg/m2 day 2
75752385|NCT01013090|Drug|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
75455654|NCT01762826|Dietary Supplement|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
75455655|NCT01762826|Dietary Supplement|Placebo|Dietary control plus folic acid 400 mcg daily
75455656|NCT01762839|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin will be administered via two dedicated, peripheral venous lines one in each arm. The infusion will last approximately 3 hours.
75455657|NCT01762839|Drug|Placebo|IV placebo will be administered via two dedicated, peripheral venous lines one in each arm. The infusion will last approximately 3 hours.
75455658|NCT01762839|Drug|Moxifloxacin|Subjects randomized to the open label Moxifloxacin treatment arm will only receive a 400 mg moxifloxacin tablet and will not receive a placebo infusion.
75606843|NCT02837185|Procedure|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
75606844|NCT02837185|Other|Physiological measures|These include TMS and EMG measurements
75606845|NCT00965458|Biological|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
75606846|NCT00965458|Drug|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
75606847|NCT02837107|Dietary Supplement|Mind Master|80ml Mind Master / day for 8 weeks
75606848|NCT02837107|Dietary Supplement|Placebo|80ml a look-alike Placebo / day for 8 weeks
75606849|NCT04249531|Drug|Amikacin Inhalation Dry Powder|Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
75752386|NCT01013090|Drug|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
75752387|NCT01015352|Drug|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
75752388|NCT01015352|Drug|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections~NeoRecormon®"
75752389|NCT01043757|Behavioral|Financial incentives for increasing physical exercise|Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
75752390|NCT00510458|Device|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
75901010|NCT03499886|Drug|Ketamine Hcl 50Mg/Ml Inj|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
75752391|NCT03563157|Biological|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
75752392|NCT03563157|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1]
75752393|NCT03563157|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
75901011|NCT02319356|Dietary Supplement|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
75901012|NCT02319356|Dietary Supplement|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
75901013|NCT02324894|Procedure|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
75901014|NCT02142582|Dietary Supplement|WHO ORS|Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
75752394|NCT03563157|Biological|ETBX-021|Ad5 [E1-, E2b-]-[HER2]
75455659|NCT01762852|Drug|Belimumab 10 mg|Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
75455660|NCT01762852|Drug|Placebo|Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
75752395|NCT03563157|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
75752396|NCT03563157|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1]
75901015|NCT02142582|Dietary Supplement|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
75901016|NCT02319434|Device|Ostom-i Alert Sensor|Sensor on ostomy bag.
75455661|NCT01762878|Drug|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
75455662|NCT01762878|Drug|Placebo|Dry powder for oral inhalation once daily using DIKUS device
75455663|NCT01762891|Drug|Celecoxib|celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
75455664|NCT01762891|Drug|Acetaminophen|Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
75455665|NCT01762891|Drug|Rofecoxib|Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
75752397|NCT03563157|Biological|GI-4000|RAS yeast
75752398|NCT03563157|Biological|GI-6207|CEA yeast
75752399|NCT03563157|Biological|GI-6301|Brachyury yeast
75752400|NCT03563157|Biological|haNK|haNK™, NK-92 [CD16.158V, ER IL-2]
75752401|NCT03563157|Drug|Avelumab|BAVENCIO® injection
75752402|NCT03563157|Drug|Capecitabine|XELODA® tablets
75752403|NCT03563157|Drug|Cetuximab|ERBITUX® injection
75752404|NCT03563157|Drug|Cyclophosphamide|Cyclophosphamide Capsules
75752405|NCT03563157|Drug|5-Fluorouracil|5-FU; Fluorouracil Injection
75752406|NCT03563157|Drug|Leucovorin|Leucovorin Calcium
75752407|NCT03563157|Drug|Nab-paclitaxel|ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]
75752408|NCT03563157|Drug|Oxaliplatin|ELOXATIN® injection
75752409|NCT03563157|Drug|Regorafenib|STIVARGA® tablets
75752410|NCT03563157|Procedure|SBRT|Stereotactic body radiation therapy
75752411|NCT01010048|Drug|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
75752412|NCT01013168|Procedure|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
75752413|NCT01013246|Other|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
75752414|NCT00414765|Drug|Aldesleukin|
75752415|NCT03997292|Drug|Alteplase|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
75901017|NCT02142660|Procedure|ablation of gastric|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
75901018|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
75901019|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp).
75901020|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
75901021|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 1*10^11 viral particles (vp).
75901022|NCT02325050|Other|Placebo|One 0.5 mL IM injection of 0.9% saline.
75901023|NCT02687646|Drug|Adult Allogeneic Mesenchymal cells from adipose tissue.|"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"
75901024|NCT02319512|Other|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
75901025|NCT02319512|Other|Glucose|12ml glucose solution (13,6g) per day
75455666|NCT01762891|Drug|placebo|Placebo pills were given during 15 days by oral rout as one of the four interventions.
75455667|NCT01762930|Drug|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
75455668|NCT01762956|Other|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
75606850|NCT04249531|Drug|Amikacin Injectable Product|patient wil receive one dose of 400 mg amikacine intravenously in week 1
75606851|NCT02836951|Other|Withdrawal of blood|Withdrawal of blood
75606852|NCT02836639|Drug|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
75606853|NCT02836639|Drug|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
75606854|NCT02836639|Drug|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
75606855|NCT00972244|Drug|Dapagliflozin|once daily, 12 weeks
75606856|NCT00972244|Drug|Placebo|once daily, 12 weeks
75752416|NCT03997292|Drug|Urokinase|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
75752417|NCT01013402|Drug|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
75752418|NCT01013402|Drug|Human Insulin|0.1U/kg IV pulse.
75901026|NCT02142816|Device|Doppler|Fluid therapy guided by doppler
75901027|NCT02142816|Other|PVI'|Fluid therapy guided by PVI
75901028|NCT02442050|Other|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
75455669|NCT01762969|Other|Treatment modification based on molecular response at 3 months|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
75606857|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
75606858|NCT00892723|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
75606859|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
75606860|NCT04286854|Diagnostic Test|Stress echocardiography with semi-supine bicycle|"The patient is accelerating against a workload that gradually increases at a constant rate, during the exercise the images will be obtained by echocardiography.~The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms."
75901029|NCT02442050|Other|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
75606861|NCT03811912|Drug|CTP-543|CTP-543 administered as 8 mg tablet.
75606862|NCT03811912|Drug|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
75606863|NCT02836561|Other|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
75606864|NCT05333419|Drug|100ng/day PA5346 Latanoprost FA SR Ocular Implant|PA5346 ocular implant is a small, clear rod-shaped implant that is placed in the anterior (front) chamber of the eye, at a single timepoint, and slowly releases a drug called latanoprost free acid (100ng/day) over a period of approximately 30 weeks
75606865|NCT04285996|Procedure|PET Scan|
76067056|NCT03089606|Diagnostic Test|C11-AMT PET scan|11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).
76067057|NCT03089606|Drug|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
75606866|NCT02836795|Biological|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
75752419|NCT01013480|Drug|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
75752420|NCT00500682|Drug|Placebo|9g /day (3 times a day)
75752421|NCT00500682|Drug|AST-120|9g /day (3 times a day)
75752422|NCT00500370|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
75752423|NCT00500370|Drug|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
75752424|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
75901030|NCT03544710|Other|preoperative bathing with antiseptic|"Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
75606867|NCT04285762|Other|LVEEA|lymphaticovenous end-to-end
75455670|NCT01762995|Drug|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
75455671|NCT01762995|Drug|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
75455672|NCT01762995|Drug|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
75606868|NCT04285762|Other|LVESA|lymphaticovenous end-to-side
75606869|NCT04285762|Other|LVSEA|lymphaticovenous side-to-end
75606870|NCT02836483|Drug|LCB01-0371 800mg, QD|Oral administration
75606871|NCT02836483|Drug|LCB01-0371 400mg, BID|Oral administration
75606872|NCT02836483|Drug|LCB01-0371 800mg, BID|Oral administration
75606873|NCT02836483|Drug|Tubes 3~5Tablet, QD|Oral administration
75606874|NCT02836483|Drug|Zyvox 600mg, BID|Oral administration
75606875|NCT02836483|Drug|LCB01-0371 1200mg, QD|Oral administration
75752425|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
75901031|NCT02322008|Biological|infliximab and adalimumab|In this retrospective, observational study, no interventions were undertaken by the researchers.
75901032|NCT02647554|Drug|ulinastatin|ulinastatin 400,000 IU every 8 hours for 10 days
75901033|NCT02647554|Drug|Placebo|matching placebo every 8 hours for 10 days
76067058|NCT03089606|Diagnostic Test|CT scan|Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
75606876|NCT02836171|Drug|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
75606877|NCT02836171|Drug|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
75606878|NCT00971932|Drug|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.
75606879|NCT00971932|Drug|Cisplatin/Carboplatin|Subjects will receive 100 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 [AUC5]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
75752426|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
75752427|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
75752428|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
75606880|NCT00971932|Drug|5-Fluorouracil|Subjects will receive 1000 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
75606881|NCT02840305|Other|Evaluation of visual function|
75606882|NCT02840305|Other|Magnetic Resonance Imaging|
75606883|NCT00629746|Device|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
75901034|NCT02325128|Behavioral|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
75901035|NCT02322086|Drug|Topical Rose Bengal, 0.005%|Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
76067059|NCT03084510|Device|Lotus Edge™ Valve System|"• The Lotus Edge™ Valve System consisting of two main components:~a bioprosthetic bovine pericardial aortic valve, and~a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter."
76067060|NCT03055377|Drug|N-acetyl cysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
76067061|NCT03055377|Drug|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
76067062|NCT03029949|Behavioral|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
76067063|NCT03029949|Behavioral|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
76067064|NCT03029949|Other|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
75455673|NCT01763008|Drug|No intervention|This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
75455674|NCT01763021|Drug|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
75455675|NCT01763021|Drug|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
76067065|NCT03023332|Behavioral|Resourcefulness Training|A cognitive-behavioral intervention delivered through iPad technology that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
75606884|NCT04400929|Drug|Sargramostim|Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
75606885|NCT04400929|Other|Normal Saline 0.9%|IV normal saline 0.9% for 5 days
75606886|NCT05170672|Biological|Abatacept|
75455676|NCT01763034|Procedure|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
75455677|NCT01763060|Radiation|CT scan|
75455678|NCT01763060|Behavioral|Cognitive function|
75606887|NCT02836405|Device|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
75606888|NCT04285138|Other|phantom limb exercise|phantom limb exercises (that is, active imaginal efforts to move the phantom), under the assumption that the neural pathways involved in performing actual movements are activated when using one's imagination to move the phantom extremity
75455679|NCT01763060|Radiation|MRI|
75752429|NCT03996798|Other|Disability Case Manager|The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
75752430|NCT03996486|Drug|BAY1093884|Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
75752431|NCT01014468|Drug|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
75752432|NCT01014468|Drug|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
75752433|NCT03980782|Other|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
75752434|NCT00503984|Drug|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
75752435|NCT00503984|Drug|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
75752436|NCT00503984|Drug|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
75901036|NCT03499730|Drug|Midazolam injection|The dose of preoperative midazolam is the predictor variable and will be registered as a continuous variable in a single cohort.
75901037|NCT03499652|Diagnostic Test|neonatal bacterial meningitis risk score|In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
75901038|NCT02325206|Drug|dapagliflozin|one administration in the morning
75606889|NCT04285138|Other|conventional treatment|"Mirror therapy uses a flat mirror placed parasagittally in front of the patient's body with the reflective surface toward the sound limb so that the amputee sees the reflection of the sound limb in the mirror [Figure 1]. This reflection mimics the amputated limb, and with the movement of the intact limb, the mirror provides an optical illusion that the phantom limb is moving simultaneously.~Equipment:~Therapy mirror: A standing mirror (130 cm × 46 cm) with wooden frame and base (62 cm × 65 cm) Routine physiotherapy The general exercise programme consisted of strengthening, stretching, dynamic, and isometric exercises based on the level of amputation and their assessment results. Participants allocated to the control group were advised to continue rehabilitation at their respective physiotherapy out-patient departments as frequently as possible. Participants were given a diary and advised to record their activities, specifying the nature, frequency and duration of each activity"
75606890|NCT02862652|Other|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
75606891|NCT04284982|Behavioral|16-week supervised heavy resistance training program with weekly undulating periodization|Participants trained a whole-body program consisting of squat, bench press, deadlift and pendlay row two times per week for 16 weeks
75606892|NCT00970684|Biological|bevacizumab|15 mg/kg on day 1 of a 21-day cycle
75606893|NCT00970684|Drug|docetaxel|75 mg/m2 on day 1
75455680|NCT01763086|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
75455681|NCT01763099|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
75455682|NCT01763099|Biological|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
75752437|NCT00503984|Genetic|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
75455683|NCT01763112|Device|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
75455684|NCT01763138|Behavioral|oral health education|oral health education in the form of a pictorial pamphlet.
75455685|NCT01763138|Behavioral|reminder phone call|a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
75455686|NCT01763151|Device|toric IOL|implantation of an aspheric, toric, acrylic IOL during cataract surgery
75455687|NCT01763151|Procedure|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
75455688|NCT01763177|Other|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
75455689|NCT01763190|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
75901039|NCT02325206|Drug|Placebo|one administration in the morning
75901040|NCT03499574|Behavioral|Dysphagia therapy using surface EMG as biofeedback|10 x 45 minute sessions over 14 days
75606894|NCT00970684|Drug|gemcitabine hydrochloride|900 mg/m2 on days 1, and 8,
75606895|NCT00967330|Drug|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
75455690|NCT01763216|Other|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
75606896|NCT00967330|Drug|irinotecan|125mg/m2 iv every 2 weeks
75606897|NCT00967330|Drug|temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
75752438|NCT00503984|Drug|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
75752439|NCT00503984|Drug|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
75752440|NCT03981016|Other|Biological collection|"blood samples collected at different times : Before surgery and during the post-operative visit and~frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
75752441|NCT03996564|Device|Battlefield Acupuncture|1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.
75752442|NCT03996564|Drug|Acetaminophen|Acetaminophen 500mg-1000mg,
75752443|NCT03996564|Drug|Diclofenac|Diclofenac 50mg-75 mg orally
75752444|NCT03996564|Drug|Diazepam|Diazepam 5mg-10 mg intravenous or oral
75752445|NCT03996564|Drug|Hydrocodone|Hydrocodone 5mg/325mg-10mg/650mg mg
75752446|NCT03996564|Drug|Ketorolac|oral, or intramuscular Ketorolac 30mg-60 mg
75606898|NCT02863276|Procedure|Intensified insulin therapy|
75606899|NCT00967018|Drug|Degarelix|
75606900|NCT00965146|Device|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
75455691|NCT01763216|Other|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
75455692|NCT01763229|Procedure|transthoracic echocardiography|
75455693|NCT01763242|Other|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
75455694|NCT01763255|Biological|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
75752447|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
75752448|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
75752449|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
75752450|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
75752451|NCT00565409|Drug|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
75752452|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
75752453|NCT03980860|Other|Exercise Type|The implementation of 2 types of exercise programs to reduce body fat
75752454|NCT00394251|Drug|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m^2 intravenous, plus Cytoxan 600 mg/m^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
75752455|NCT00394251|Drug|ABI-007|260 mg/m^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
75752456|NCT00394251|Drug|Taxol|175 mg/m^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
75752457|NCT00394251|Drug|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
75752458|NCT00394251|Drug|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
75606901|NCT02863042|Procedure|Repair Deltoid Tendon|
75606902|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|Standard of care
75606903|NCT04286152|Drug|Mirabegron 50 MG|The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal
75606904|NCT04286152|Drug|Placebo oral tablet|A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
75606905|NCT00966940|Drug|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
75752459|NCT02532400|Drug|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d*7 plus exemestane: 25mg, po, qd*24w, or anastrozole: 1mg, po, qd*24w
75752460|NCT02532400|Drug|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w*6, Epirubicin 75mg/m2, d1, q3w*6 and Cyclophosphamide: 500mg/m2, d1, q3w*6
75752461|NCT03980704|Drug|IMPACT|Administration of oral immunostimulating oral supplement
75752462|NCT03980704|Drug|resource protein|Administration of oral high-protein oral supplement
75752463|NCT03980548|Procedure|CABG|Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
75606906|NCT00966940|Drug|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
75455695|NCT01763268|Biological|Trivivac vaccine|Trivalent MMR vaccine
75752464|NCT00394095|Drug|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
75752465|NCT00394095|Drug|Placebo|Matched placebo to Experimental arm
75901041|NCT03499574|Behavioral|Usual Care|Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
75901042|NCT03499496|Diagnostic Test|ultrasound guided detection of atherosclerotic plaques|screening by ultrasound of atherosclerotic plaques
75455696|NCT01763281|Drug|CRH|
75901043|NCT02325284|Device|Pressure Algometer Testing|
75606907|NCT00965848|Drug|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
75606908|NCT04284748|Other|Plyometric exercise with blood flow restriction|"Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)"
75455697|NCT01763281|Drug|Placebo|
75455698|NCT01763294|Device|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
75606909|NCT04284748|Other|Plyometric exercise|Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
75752466|NCT00503906|Drug|Avastin|
75752467|NCT00503906|Drug|Gemcitabine|
75752468|NCT00503906|Drug|Abraxane|
75752469|NCT00305110|Drug|2 mg IV hydromorphone|
75752470|NCT03984760|Drug|Ferric Citrate|Take the capsules with meals or immediately after meals.
75752471|NCT03984760|Drug|Sevelamer Carbonate|Take the tablets with meals.
75752472|NCT01060462|Drug|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
75752473|NCT00491894|Drug|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
75752474|NCT01060618|Other|Maraviroc + Trofile ESTA® (diagnose test)|The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
75752475|NCT03984604|Drug|CHI-921|a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
75752476|NCT03984604|Drug|Placebo|Placebo is a vehicle oil will match CHI-921
75752477|NCT00491504|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
75752478|NCT00491504|Other|Placebo|Placebo: 2 sprays in each nostril
75901044|NCT02322398|Drug|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
75752479|NCT04326452|Device|bidirectional oxygenation mouthpiece|Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
75455699|NCT01763294|Device|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
75606910|NCT04284748|Other|Routine physiotherapy program|Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
75752480|NCT01015508|Other|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
75606911|NCT03447574|Other|ethanol dilution|Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
75901045|NCT02322398|Drug|hMG|150-300 IU/d hMG
75606912|NCT04284826|Procedure|Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture|
75901046|NCT02325362|Drug|Miglustat ; placebo|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
75901047|NCT02325362|Drug|Placebo ; Miglustat|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
75901048|NCT03499340|Behavioral|text-only PWL|control condition (no image)
75901049|NCT03499340|Behavioral|low arousal graphic PWL|pictorial warning
75901050|NCT03499340|Behavioral|high arousal graphic PWL|pictorial warning
75901051|NCT03499340|Behavioral|absolute risk|Percentage risk information for smoking-related diseases for smokers
75901052|NCT03499340|Behavioral|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
75606913|NCT04284670|Other|EXERCISE|The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
75752481|NCT01015508|Other|Weight maintenance|10 months
75752482|NCT00500292|Drug|Vandetanib|once daily oral tablet two dose strengths
75752483|NCT00500292|Drug|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
75752484|NCT01013558|Drug|Remifentanil|0.15 microgram/kg/min continuous infusion.
75752485|NCT01013558|Drug|saline|continuous infusion
75752486|NCT01013636|Procedure|Blood sampling|"Anaplasma diagnosis test : serology and PCR~If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
75752487|NCT00499746|Drug|tramadol|oral dose, once per day
75752488|NCT00499746|Drug|placebo|oral dose, once per day
75901053|NCT02322476|Other|No intervention will be performed|No intervention will be performed
75901054|NCT03004664|Behavioral|Support Empowerment Model|The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.
75752489|NCT00499746|Drug|Hydromorphone|oral dose, once per day
75752490|NCT00499746|Drug|Methylphenidate|oral dose, once per day
75752491|NCT01010516|Drug|High-dose rosuvastatin|40 of rosuvastatin daily
75752492|NCT01010516|Drug|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
75901055|NCT03004664|Behavioral|The Chronic Care Model|the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
75901056|NCT02322554|Biological|Cellular and tissue based products|Procedure: Application of device or biological to wounds
75752493|NCT01010516|Drug|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
75752494|NCT01020162|Drug|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
75752495|NCT01020162|Procedure|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
75752496|NCT00489216|Biological|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
75901057|NCT03499262|Behavioral|Group Social ABCs|Social ABCs coach will facilitate the intervention to small groups of parents in a clinic setting, rather than the family's home. This new format allows the program to be completed in 6 weeks, versus the current 12-week model, and also offers the potential benefit of creating a parent support network within the program. Parents will still get live, one-on-one coaching for strategies to use with their child over the course of the program.
75901058|NCT04462094|Drug|Ketamine 0.3 mg/kg at end-of-surgery|Ketamine 0.3 mg/kg at end-of-surgery (intravenously)
75901059|NCT04462094|Drug|Ketamine 0.3 mg/kg at anesthesia induction|Ketamine 0.3 mg/kg at anesthesia induction (intravenously)
75901060|NCT02325440|Drug|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
75901061|NCT02325440|Drug|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
75901062|NCT02319746|Behavioral|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
75901063|NCT02319746|Behavioral|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
75901064|NCT03499184|Dietary Supplement|P Flor locally delivered|Locally delivered Lactobacillus reuteri 1.2 CFU per gram
75901065|NCT03499184|Dietary Supplement|P Flor systemically administered|Systemically administered Lactobacillus reuteri 1.2 CFU per gram
75901066|NCT03499184|Drug|Amoxil 500 mg Oral Capsule|Systemically administered Amoxil 500 mg thrice daily
75901067|NCT03499184|Drug|Flagyl 400 mg Tablet|Systemically administered Metronidazole 400 mg twice daily
75606914|NCT03442192|Other|PrEP Care Anywhere Services|"PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~HIV and Sexually Transmitted Infection (STI) at Home Self-Testing"
75901068|NCT03497078|Other|Bone scintigraphy|Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
75901069|NCT03497000|Procedure|OCTA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
75901070|NCT03497000|Procedure|ICGA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
75901071|NCT03494114|Drug|Ga-EC2115|Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
75606915|NCT04284904|Diagnostic Test|aGVHD biomarker|To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
75606916|NCT04284592|Procedure|Remote ischemic post-conditioning (RIP)|The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
75606917|NCT04204564|Device|pactlitaxel PAD device|Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.
75752497|NCT01016886|Drug|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
75752498|NCT00499590|Drug|bevasiranib|Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
75752499|NCT00499590|Drug|ranibizumab|Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
75752500|NCT00510146|Drug|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
75752501|NCT00510146|Drug|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
75901072|NCT02322632|Drug|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
75901073|NCT00107952|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
75901074|NCT00107952|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
75901075|NCT03499106|Drug|IW-1973|Oral Tablet
75901076|NCT03499106|Drug|Itraconazole|Oral Capsule
75901077|NCT02325596|Genetic|miRNA mimics or inhibitors|DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
75901078|NCT02146404|Other|hypoglycemia|Blood glucose levels will be kept at ~3.0 mmol/l
75901079|NCT02146404|Other|euglycemia|Blood glucose levels will be kept at ~5.0 mmol/l
75901080|NCT02319902|Device|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
75901081|NCT02319902|Device|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
75901082|NCT03494036|Dietary Supplement|Synbiotic|capsule
75901083|NCT03494036|Dietary Supplement|Placebo|capsule
75901084|NCT02146638|Drug|Morphine|
75901085|NCT02146638|Drug|Fentanyl|
75901086|NCT03498950|Other|laser therapy|laser irradiation on the taste papillae
75901087|NCT02146716|Other|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
75901088|NCT02322944|Behavioral|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
75606918|NCT04285528|Drug|General anesthetia Fentanyl and Propofol|Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
75606919|NCT04285528|Combination Product|PFK|A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
75606920|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
75901089|NCT02322944|Behavioral|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
75901090|NCT02550522|Device|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton|
75901091|NCT02325752|Other|Intervention|"A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~Post discharge surveillance of the patient to ensure adherence to care plans.~Coordination of follow-up visits with specialist care providers.~Patent education and care giver training.~Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge."
75901092|NCT02254200|Other|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
75901093|NCT02254200|Other|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of ~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
75901094|NCT03498872|Device|AMPfoot 4.0|The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.
75901095|NCT03498872|Other|No intervention|The control group included healthy subjects. Comparisons were made between amputees and able-bodied individuals.
75901096|NCT02354118|Other|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
75901097|NCT02354118|Other|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
75606921|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
75606922|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
75901098|NCT03498794|Procedure|Ureteral stent|"Patients will be randomized into 2 groups:~Group (A): 75 patients with the use of ureteral stent. Group (B): 75 patients with the use of PCN.~How the technique will be applied?~Technique of ureteral stent insertion:~The ureteral stent will be inserted retrograde by using flexible cystoscope.~Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively."
75901099|NCT03496688|Procedure|Sinus floor augmentation|
75901100|NCT03544164|Other|Manual Ventilation|Manual ventilation via endotracheal tube using adult manual resuscitation device
75455700|NCT01763294|Device|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
75455701|NCT01763294|Device|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
75455702|NCT01763294|Device|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
75606923|NCT04285216|Other|Dry Needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
75606924|NCT04285216|Other|Strain counter strain|Hot pack 10 mints, stretchings,Neck isometrics, Strain counterstrain(SCS)
75606925|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
75606926|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
75606927|NCT00961636|Drug|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
75606928|NCT00961636|Drug|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
75606929|NCT04285060|Device|Samsung GEMS-H|Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
75606930|NCT02862262|Device|ARIES Bordetella Assay|
75606931|NCT02862340|Genetic|Genetic test|
75606932|NCT04283422|Diagnostic Test|Biofire filmarray|"Identification of microorganisms including:~Isolation of microorganisms:~The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~Identification of the organism by Vitek2~Antibiotic sensitivity test of the organism by Vitek2~Identification of the organism by Biofire filmarray"
75606933|NCT00964678|Drug|Carvedilol|twice daily oral treatment in escalating dose
75606934|NCT00964366|Drug|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
75606935|NCT00964366|Drug|Dapsone gel|Twice-daily applications of dapsone gel
75606936|NCT02861326|Device|Gracey Curettes|
75606937|NCT02861404|Genetic|skin flakes collection|viral status assessment of skin flakes
75606938|NCT03523702|Drug|PembroRT|Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.
75606939|NCT03523702|Drug|ChemoRT|Patients whose tumors are found to have low (< 50%) PD-L1 expression will automatically be placed in the ChemoRT group. These patients will receive radiotherapy over a course of four to seven weeks. During radiotherapy, patients will also receive two standard chemotherapy agents (carboplatin and paclitaxel) once each week. Following completion of chemotherapy and radiotherapy, patients may receive additional treatments with chemotherapy or immunotherapy as part of routine care. These treatments are optional and are not required by this clinical trial.
75606940|NCT04284514|Drug|AKB-9778 Ophthalmic Solution|AKB-9778 Ophthalmic Solution
75455703|NCT01763307|Drug|RECONVAL CREAM|
75455704|NCT01763307|Drug|PLACEBO|
75455705|NCT01763385|Drug|Erlotinib|
75455706|NCT01763385|Radiation|concurrent brain radiotherapy|
75455707|NCT01763385|Radiation|secondary brain radiotherapy|
75455708|NCT01763437|Drug|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
75606941|NCT04284514|Drug|Placebo Ophthalmic Solution|Matched vehicle-control
75752502|NCT00480636|Drug|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
75752503|NCT01017198|Drug|BIIB021 and Food|Assessing the effect of food use on BIIB021
75752504|NCT01017198|Drug|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
75752505|NCT01013948|Other|Non-Interventional|Non-Investigational Product (Survey Study)
75752506|NCT00499122|Drug|Cyclophosphamide|
75752507|NCT00499122|Drug|Docetaxel|
75752508|NCT00499122|Drug|Doxorubicin|
75752509|NCT00499122|Drug|NOV 002|
75752510|NCT01017276|Drug|ASP1585|oral
75752511|NCT00393939|Drug|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
75752512|NCT00393939|Drug|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
75752513|NCT00488982|Drug|Docetaxel|Docetaxel 75mg/m2 every 21 days
75901101|NCT02325830|Device|CARILLON Mitral Contour System|Percutaneous mitral valve repair
75901102|NCT02146794|Device|Renal denervation|Renal denervation
75606942|NCT02861248|Procedure|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
75606943|NCT04283344|Other|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula
75606944|NCT02860078|Device|Ultrasound|Location and function of sacral epidural space with ultrasound
75606945|NCT02860078|Device|Radioscopy|Location and puncture of the sacral epidural space only with fluoroscopy
75606946|NCT02859922|Device|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
75606947|NCT02859922|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
75606948|NCT02860936|Drug|Lenvatinib|Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
75606949|NCT04283266|Dietary Supplement|Synbiotic|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of synbiotic (Bifidobaterium animalis lactis Vesalius 002 and Fructo-Oligosaccharrides) for 5 days, then they received daily 1 sachet for the next 25 days
75606950|NCT04283266|Dietary Supplement|Placebo|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of placebo (maltodextrin and sucrose) for 5 days, then they received daily 1 sachet for the next 25 days
75752514|NCT00488982|Drug|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
75752515|NCT00488826|Biological|7-valent pneumococcal conjugate vaccine|
75752516|NCT00488826|Biological|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
75752517|NCT01017354|Drug|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
75752518|NCT01017354|Dietary Supplement|ViDe3 (CH)|60000 vitamin D3 orally and once per month
75752519|NCT01017354|Dietary Supplement|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
75752520|NCT00393861|Drug|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
75901103|NCT03496532|Device|biphasic stimulation|Fixed 70Hz symmetrical biphasic pulses
75752521|NCT01020240|Behavioral|Avolition|- avolition for cesarean discomforts
75752522|NCT01020240|Behavioral|Orientation|"avolition of cesarean discomfort~physiotherapy orientation"
75752523|NCT01020240|Behavioral|Guide|"avolition of cesarean discomfort~physiotherapy orientation~guide orientation"
75752524|NCT03993639|Drug|Pegfilgrastim|Single dose of SC administration
75752525|NCT01040559|Drug|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
75901104|NCT03496532|Device|standard stimulation|Fixed 70Hz pseudo-monophasic pulses
75901105|NCT03496532|Device|Uniform distribution|Uniform distribution 70Hz Biphasic pulses
75752526|NCT03996954|Device|Alivecor recording|Alivecor recording and ECG recording from the same patient in very close temporal proximity
75752527|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
75752528|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
75606951|NCT04281550|Other|Think Drink|The Think Drink Guide that had three interacting components. The 'policy' component was directed at the governance of the care home, whereas 'practice' components were directed at hydration procedures and processes, and 'educational' components that provided learning resources for care home staff to develop knowledge and understanding of hydration care. Think Drink was implemented through a short awareness-raising educational programme and accompanying information booklet detailing a range of practices (including organisational, system and individual practice) designed to encourage hydration.
75901106|NCT03496532|Device|Poisson distribution|Poisson distribution 70Hz Biphasic pulses
75455709|NCT01763450|Drug|bevacizumab plus chemotherapy|"Bevacizumab:~7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
75455710|NCT01763463|Drug|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
75606952|NCT00630214|Dietary Supplement|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
75606953|NCT00630214|Dietary Supplement|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
75606954|NCT04204486|Behavioral|Exercise|Functional strength training, 1 hour, 3 times a week.
75606955|NCT04284358|Other|Technology integrated instruction neuromuscular training warm-up workshop|Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
75606956|NCT02859766|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
75752529|NCT01014702|Device|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
75752530|NCT01014702|Device|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
75752531|NCT00480324|Biological|Rotarix|Two-dose oral vaccination.
75752532|NCT00480324|Biological|Placebo|Two-dose oral administration.
75752533|NCT00488592|Biological|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
75901107|NCT03496532|Device|Recordings of LFP oscillations|"Two minutes of recordings of LFP oscillations will be performed from the contacts of the implanted electrode.~Recordings of the depth of anaesthesia (BIS) all along the measurements performed under general anaesthesia.The correlation between the depth of anaesthesia and the cerebral oscillations recorded at the site of subthalamic nucleus will be studied."
75901108|NCT03496454|Other|PfSPZ Challenge|The administration of an injection PfSPZ Challenge in Gambian adults
75901109|NCT02319980|Procedure|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
75901110|NCT02320370|Device|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
75901111|NCT02320448|Drug|PIPAC|
75752534|NCT00488592|Biological|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
75752535|NCT00488592|Drug|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
75752536|NCT00488592|Biological|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
75901112|NCT03496376|Other|Kinesio Taping|The material used for thoracic kinesio taping application was Kinesio® Tex Gold™ (Kinesio Holding. Patients were instructed to sit upright on an armless chair with no back support, with knees flexed to 90 degrees, feet on the floor and arms relaxed. Kinesio tape was applied anteriorly and posteriorly to facilitate respiratory muscles (primarily diaphragm) along the subcostal area. Additionally, two more kinesio tapes were applied to upper trapezius and scalene muscles' area which lies between neck and acromion at both sides (left and right).
75752537|NCT04244760|Behavioral|Pain assessment for verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.
75901113|NCT03496376|Other|Deep Breathing Exercises|Three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
75455711|NCT01763463|Drug|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
75455712|NCT01763476|Procedure|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
75752538|NCT04244760|Behavioral|Pain assessment for non-verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
75752539|NCT00488514|Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
75752540|NCT00320710|Drug|Zoledronic acid|4mg IV
75752541|NCT00320710|Drug|Placebo|Placebo to zoledronic acid
75752542|NCT00320398|Drug|Fondaparinux|
75901114|NCT02323022|Drug|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
75901115|NCT02323022|Drug|High-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
75901116|NCT02323022|Drug|Intermediate-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 10mg/msq/d (d1-3)
75901117|NCT03493724|Other|telemedecine|to evaluate the diagnostic performance of the photographs made by Smartphone, during requests for emergency dermatological advice
75901118|NCT03496142|Procedure|Transperineal prostate biopsy|Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
75455713|NCT01763476|Procedure|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
75455714|NCT01763489|Behavioral|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
75752543|NCT00498186|Drug|Rotigotine|"Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)"
75752544|NCT01017510|Device|Subcutaneous injection luer syringe|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
75752545|NCT01017510|Device|DERMOJET (a syringe without a needle)|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
75752546|NCT00333970|Behavioral|cognitive remediation|individual cognitive training
75901119|NCT03496142|Procedure|Transrectal prostate biopsy|Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
75901120|NCT03496064|Other|Successful reperfusion|Defined as modified Thrombolysis in Cerebral Infarction 2b/3
75606957|NCT04282798|Other|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
75752547|NCT01017588|Device|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
75752548|NCT03984526|Drug|normal saline|intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
75752549|NCT03984526|Drug|atropine 0.5mg|intravenous atropine 0.5mg pretreatment at the onset of dexmedetomidine infusion
76067066|NCT03023332|Behavioral|Biofeedback training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and continue to influence behavior."
75455715|NCT01763502|Other|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
75455716|NCT01763502|Other|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
75455717|NCT01763515|Procedure|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
75901121|NCT02320526|Behavioral|Control|
75901122|NCT02320526|Behavioral|Continuous walking|
75455718|NCT01763528|Other|nutrition intervention|high protein diet
75455719|NCT01763541|Drug|leuprolide acetate|Given to both arms to induce hypogonadism
75455720|NCT01763541|Drug|Anastrozole|Given to men to prevent conversion of administered testosterone to estradiol.
75455722|NCT01763619|Device|Freedom Cervical Disc|
75455723|NCT01763632|Device|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
75455724|NCT01763658|Drug|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
75455725|NCT01763658|Other|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
75455726|NCT01763697|Behavioral|taste acuity assessment|Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
75455727|NCT01763697|Behavioral|Recorded meal|
75455728|NCT01763710|Drug|Paclitaxel 80 mg/m2|Paclitaxel 80 mg/m2 days 1, 8 and 15
75455729|NCT01763710|Drug|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
75752550|NCT03984526|Drug|ephedrine 8mg|intravenous ephedrine 8mg pretreatment at the onset of dexmedetomidine infusion
75752551|NCT01017666|Drug|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
75752552|NCT01017666|Drug|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
75752553|NCT03984370|Drug|ZP4207|Abdominal SC administration
75901123|NCT02320526|Behavioral|Interval walking|
75606958|NCT02862028|Biological|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
75606959|NCT02860858|Biological|Intravitreous aflibercept injection|
75606960|NCT00960154|Device|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
75606961|NCT00960154|Procedure|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
75606962|NCT02861170|Behavioral|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
75606963|NCT00960076|Drug|Saxagliptin|5mg oral tablet once daily
75752554|NCT03984370|Other|Placebo (saline)|Abdominal SC administration
75752555|NCT01017744|Device|Anesthetic Conserving Device|"Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
75752556|NCT03984292|Procedure|Teaching of laparoscopic skills on a box simulator|The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
75752557|NCT01064596|Other|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
75752558|NCT03980392|Other|Multidomain intervention program|Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
75752559|NCT03980236|Device|Livongo-Insulia Study App|Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
75752560|NCT00477594|Drug|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
75752561|NCT00475722|Behavioral|1 Healthy Eating|6 months telephone counseling
75752562|NCT00475722|Behavioral|2 Mediterranean|6 months telephone counseling
75752563|NCT00304954|Drug|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
75752564|NCT00304954|Drug|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
75752565|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
75752566|NCT00304954|Drug|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
75752567|NCT00475176|Drug|Peginterferon alfa-2a|
75752568|NCT00475176|Drug|Ribavirin|
75752569|NCT00475176|Drug|S-adenosyl methionine for Chronic Liver Disease|
75606964|NCT00960076|Drug|Metformin XR|500mg oral tablet once daily
75752570|NCT01062022|Behavioral|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
75752571|NCT01062022|Behavioral|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
75606965|NCT00960076|Drug|Metformin XR|750mg, 2 tablets once daily
75606966|NCT02859688|Genetic|pyrosequencing|
75752572|NCT01064674|Other|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
75752573|NCT01062100|Device|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
75752574|NCT00414609|Drug|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
75901124|NCT02320604|Drug|Administration of study drug|i.v. administration of Ambisome in two different dossages
75901125|NCT03493568|Drug|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
75752575|NCT00414609|Drug|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
75606967|NCT02859688|Genetic|Methylome|
75606968|NCT04281082|Drug|ursofalk|To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
75752576|NCT00393705|Drug|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
75752577|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
75752578|NCT00393705|Drug|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
75752579|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
75752580|NCT00303628|Drug|oxaliplatin|Given IV
75752581|NCT00303628|Drug|fluorouracil|Given IV
75901126|NCT03493568|Drug|Dolutegravir 50 mg plus one RTI|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
75752582|NCT00303628|Drug|leucovorin calcium|Given IV
75901127|NCT01366638|Drug|TMC435|100 mg capsule taken by mouth once daily for 12 weeks
75455730|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
75455731|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1 and 15|Nab-paclitaxel 150 mg/m2 days 1 and 15
75901128|NCT01366638|Drug|Peginterferon alfa-2b (pegIFN alfa-2b)|PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
75901129|NCT01366638|Drug|Ribavirin (RBV)|The dose of RBV given will be based on body weight. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
75455732|NCT01763723|Device|IPL-home use device|A light based home use device for hair removal
75455733|NCT01763736|Behavioral|Music|playlist per patient preference
75455734|NCT01763749|Drug|Closone|Closone 75mg/100mg, 4weeks, PO
75455735|NCT01763749|Drug|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
75455736|NCT01763762|Behavioral|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
75455737|NCT01763762|Behavioral|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
75606969|NCT04284202|Drug|PD-1 plus Dasatinib|Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
75606970|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
75606971|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
75606972|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
75606973|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
75752583|NCT00303628|Drug|bevacizumab|Given IV
75901130|NCT02320682|Device|Surgery for Total Hip Arthroplasty (THA)|THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
75901131|NCT02147028|Radiation|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
75901132|NCT02147028|Radiation|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
75901133|NCT02323178|Drug|eltrombopag|initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
75901134|NCT02147808|Drug|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
75901135|NCT02147808|Drug|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup [2mg/mL]).
75901136|NCT02323256|Other|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
75901137|NCT02323256|Other|Speech-ABR|
75901138|NCT02323256|Other|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
75901139|NCT02323256|Other|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
75901140|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|Cabaletta for IV infusion once weekly
75901141|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|
75901142|NCT03543072|Drug|Bisphosphonates|a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
75901143|NCT02147964|Drug|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months [all subjects]
75901144|NCT02147964|Drug|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months [all subjects]
75901145|NCT02147964|Drug|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
75606974|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
75606975|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
75606976|NCT01227629|Drug|warfarin|comparator
75606977|NCT01227629|Drug|dabigatran without ASA|dose comparison
75606978|NCT01227629|Drug|dabigatran without ASA|dose comparison
75606979|NCT01227629|Drug|dabigatran without ASA|dose comparison
75606980|NCT00963820|Drug|Ixazomib citrate|Ixazomib citrate capsules
75901146|NCT02147964|Drug|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
75901147|NCT02147964|Drug|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
75901148|NCT02147964|Drug|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
75901149|NCT02147964|Drug|placebo ketoconazole|placebo ketoconazole daily for 4 months
75901150|NCT03491852|Behavioral|BOOST Intervention|A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
75901151|NCT03491852|Behavioral|Waitlist Control|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
75901152|NCT03493334|Other|Visual feedback|Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.
75901153|NCT03493334|Other|No visual feedback|Participants will be asked to perform active movements of their neck with the mirrors covered.
75901154|NCT02147106|Other|Videoconsultation|
75901155|NCT03495830|Procedure|Carotid endarterectomy|Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.
75901156|NCT02780700|Drug|Nintedanib|
75606981|NCT03241186|Drug|Ipilimumab|1mg/kg
75606982|NCT03241186|Drug|Nivolumab|3mg/kg
75606983|NCT03241186|Drug|Nivolumab|480mg
75606984|NCT01227395|Drug|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
75606985|NCT02859532|Radiation|elastography SWIRE|
75752584|NCT00414453|Drug|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
75901157|NCT02780700|Drug|Capecitabine|
75752585|NCT00414453|Drug|Extended-release oxycodone|extended-release oxycodone titrating schedule
75752586|NCT00414453|Drug|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
75752587|NCT00414453|Drug|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
75752588|NCT01040715|Biological|TNFa Kinoid|TNFa kinoid
75752589|NCT01040715|Biological|TNF kinoid|IM administration 2 or 3 injections within 28 days
75752590|NCT01037595|Drug|turmeric|turmeric 500 md tid orally for 8 weeks
75752591|NCT01037595|Drug|placebo|placebo 3 time orally for 8 weeks
75752592|NCT01037595|Drug|turmeric|500 mg tid orally for 8 weeks
75752593|NCT01037673|Procedure|Exercise program|A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
75752594|NCT01037673|Procedure|Movement exercises|A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
75901158|NCT03493256|Other|exposure to type 2 neurological complications|exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
75901159|NCT02151396|Behavioral|Working memory training|
76067067|NCT03023332|Behavioral|Bipolar Education|An educational program designed to teach family caregivers of about the types, causes, symptoms, episodes, warning signs, and treatments for individuals with bipolar disorder, as well as available resources for assisting a family member with bipolar disorder. The content to be presented within an audiovisual format using iPad technology follows the recommendations and guidelines developed through research and by the Depression and Bipolar Support Alliance and the National Institute of Mental Health.
75455738|NCT01763762|Behavioral|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
75606986|NCT04319003|Behavioral|Sugar-reduction intervention|The intervention consisted of a) installation of a water filter at the school. b) each participant received a metal water bottle. c) a registered dietitian gave a 30-minute presentation on sugar reduction for the purposes of type 2 diabetes prevention
75606987|NCT04281238|Other|Yoga group|Yoga training 3 days a week for 8 weeks. In addition to this, home exercises 5 days a week for 8 weeks
75606988|NCT04281238|Other|Control group|Home exercises 5 days a week for 8 weeks
75606989|NCT02859376|Dietary Supplement|sucrose 24%|Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
75752595|NCT01040949|Behavioral|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
75752596|NCT01040949|Behavioral|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
75752597|NCT00332488|Drug|Technosphere Insulin|Inhalation, 15U/30U, prandial
75752598|NCT00332488|Drug|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
75752599|NCT00332488|Drug|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
75752600|NCT00332332|Biological|etanercept|etanercept subcutaneous injection
75752601|NCT00392925|Drug|pramlintide acetate 360 mcg|subcutaneous injection, twice a day, 360mcg
75752602|NCT00392925|Drug|metreleptin|subcutaneous injection, twice a day, 5mg
75455739|NCT01763775|Device|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
75455740|NCT01763775|Device|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
75455741|NCT01763788|Drug|Necitumumab|Administered IV
75455742|NCT01763788|Drug|Gemcitabine|Administered IV
75455743|NCT01763788|Drug|Cisplatin|Administered IV
75752603|NCT00392925|Drug|placebo-pramlintide 600 uL|twice a day
75752604|NCT00392925|Drug|placebo-metreleptin 1 mL|twice a day
75752605|NCT00392925|Drug|Pramlintide acetate 180 mcg|subcutaneous injection twice a day, 180 mcg
75455744|NCT01763801|Device|P-Max|tip placement in correspondence to the P-Max on the ECG
75455745|NCT01763801|Device|P-Submax|tip placement in correspondence to the P-Submax on the ECG
75752606|NCT03979846|Other|Best Practice|Receive usual care
75752607|NCT03979846|Other|Computer Application|Use computer-based symptom reporting system
75901160|NCT02151396|Device|Functional magnetic resonance imaging (fMRI)|
75901161|NCT03495752|Other|Bruce Fatigue Protocol|Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
75901162|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 14 days|
75901163|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 28 days|
75901164|NCT02447276|Drug|REGN475|
75901165|NCT02447276|Drug|Placebo|
76067068|NCT03023085|Drug|BLI4700|BLI4700 bowel preparation
75606990|NCT04283032|Procedure|Multiparametric magnetic resonance|MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
75455746|NCT01763814|Procedure|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
75455747|NCT01763814|Procedure|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
75455748|NCT01763814|Procedure|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
75455749|NCT01763840|Drug|Contrast enhanced Ultrasound|Ultrasound, then contrast enhanced ultrasound.
75455750|NCT01763853|Drug|4% albumin|
75606991|NCT01226459|Drug|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
75606992|NCT01226459|Drug|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
75455751|NCT01763879|Other|The PCV-VCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
75606993|NCT01225991|Drug|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
75606994|NCT00959374|Device|V-Loc 180/90 Wound Closure Device|Barbed absorbable suture
75606995|NCT00959374|Device|3-0 Monocryl Absorbable Sutures|3-0 Monocryl Absorbable Suture (non-barbed)
75606996|NCT02859298|Device|Uterine Cervix Polarimetric Imaging|Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
75606997|NCT04283110|Drug|intrthecl midazolam|midazolm as as adjuvant in spinal anesthesia
75752608|NCT03979846|Other|Questionnaire Administration|Ancillary studies
75752609|NCT03979846|Other|Quality-of-Life Assessment|Ancillary studies
75455752|NCT01763879|Other|The VCV-PCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
75455753|NCT01763944|Behavioral|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
75455754|NCT01763957|Behavioral|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
75606998|NCT02859610|Other|research on interactions between portal hypertension and microparticles|
75606999|NCT02860780|Drug|prexasertib|Administered IV
75607000|NCT02860780|Drug|ralimetinib|Administered orally
75752610|NCT00474786|Drug|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
75752611|NCT00474786|Drug|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
75752612|NCT00392769|Drug|Cetuximab|Initial Dose = 400 mg/m^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m^2 IV Over 60 Minutes.
75752613|NCT03532893|Other|No intervention|This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.
75752614|NCT01041183|Drug|intravenous ramosetron|0.3 mg IV ramosetron (group I)
75752615|NCT01041183|Drug|oral ramosetron|0.1 mg oral ramosetron (group II)
75752616|NCT01041183|Drug|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
75752617|NCT01041261|Dietary Supplement|BariatrX Essentials 360 Treatment|Medical food
75752618|NCT03764943|Dietary Supplement|Impact Advanced Recovery|immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
75752619|NCT00319696|Drug|Bosentan 62.5 mg|Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
75752620|NCT00319696|Drug|Bosentan 125 mg|Bosentan 125-mg oral tablets administered b.i.d. (target dose)
75752621|NCT01037751|Behavioral|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
75752622|NCT01037751|Behavioral|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
75752623|NCT00474630|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
75752624|NCT00474630|Drug|Placebo|
75901166|NCT03544008|Other|The use of AXIOS in Endoscopic transmural drainage|
75901167|NCT02151552|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
75901168|NCT02151552|Drug|[18F](+/-)NOS|7 mCi of [18F](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
75901169|NCT03491774|Behavioral|Montessori Intervention|The Montessori method is a system of teaching developed by Maria Montessori based on principles to promote learning and independence in children. In the context of dementia care, this method has been tried in research settings in older people and was found to be effective in improving certain behavioral outcomes such as eating behaviors, agitation, and mood. The intervention is based on designing and offering activities that take into consideration the interests, needs, past experiences and preferences of participants. Importantly, participants demonstrating positive engagement with the intervention, suggesting that this may be a promising form of support to investigate and develop further for the care of people with dementia.
75901170|NCT05064644|Other|Product that contains plant stanol ester|Product with active ingredient
75455755|NCT01763957|Behavioral|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
75455756|NCT01763983|Behavioral|Cognitive Behavioural Therapy|"CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study."
75455757|NCT01763983|Behavioral|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
75607001|NCT01225835|Drug|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
75607002|NCT01225835|Drug|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
75752625|NCT00474630|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
75901171|NCT05064644|Other|Placebo product|Product without active ingredient
75901172|NCT04926272|Drug|18F-92|Intravenous injection of one dose of 0.10mCi/kg(±5%) 18F-92. Each subject receive a single intravenous injection of 18F-92, and undergo PET/CT imaging within the specificed time.
75901173|NCT03495518|Other|Symptom feedback to Health Care Provider|"These children will complete SPARK daily for 5 days in a row, daily symptom reports will be printed and provided in the patient chart. On days 1 and 3, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical"
75901174|NCT03495518|Other|Standard of care|A clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
75901175|NCT03495362|Dietary Supplement|Yeast Beta-glucan|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
75752626|NCT01043835|Procedure|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
75752627|NCT01043835|Procedure|Open gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
75752628|NCT01064752|Drug|Minocycline|100 mg po bid for 8 weeks
75455758|NCT01764009|Biological|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
75752629|NCT01043913|Drug|Guarana extract|Guarana extract 50mg q12 hours for 21 days
75752630|NCT00392379|Drug|Nicotine Lozenges|Nicotine lozenges, 4 mg
75752631|NCT00392379|Drug|Placebo lozenge|Placebo lozenge
75752632|NCT01037829|Other|Non-intervention observational study|Non-intervention observational study
75752633|NCT01020552|Other|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
75752634|NCT01038063|Drug|Artemether-lumefantrine combination|
75901176|NCT03495362|Other|Placebo|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
75901177|NCT03493100|Dietary Supplement|oral nutritional supplementation|The intervention group will receive optimized nutritional support, by ONS. While hospitalized each patient receives 2 portions of oral supplementation per day. For remaining days supplementation is calculated individually according to a sarcopenia/energy balance schema resulting in none or maximum 2 portions per day.
75901178|NCT03493100|Other|Usual care|The control group will receive treatment according to usual care.
75901179|NCT02323412|Drug|Amoxicillin (Amoksicillintrihydrat)|Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
75901180|NCT02323412|Drug|Placebo|Placebo tablets 1x3 for 100 days (oral intake).
75455759|NCT01764035|Behavioral|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
75455760|NCT01764035|Behavioral|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
75752635|NCT00497874|Behavioral|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
75752636|NCT01043991|Drug|Darbepoetin alfa|
75752637|NCT01043991|Drug|Placebo|
75752638|NCT01044147|Behavioral|VLM-S|Online program for weight loss - standard
75901181|NCT03493022|Other|Test Granola|50.5 Test Granola
75901182|NCT03493022|Other|Control Granola|54.3 Control Granola
76067069|NCT02993731|Drug|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
75752639|NCT01044147|Behavioral|VLM-M|Online program for weight loss - modulated
75752640|NCT01044147|Behavioral|OGR|Online program for weight loss - resources
75752641|NCT01020630|Drug|Sunitinib|Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
75752642|NCT01020630|Drug|Placebo|Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
75752643|NCT00403455|Drug|Paroxetine|SSRI
75752644|NCT04923282|Biological|single 1-hour IV infusion of 0.8 mg/kg recAP|Intravenous infusion
75752645|NCT04923282|Biological|single 1-hour IV infusion of 1.6 mg/kg recAP|Intravenous infusion
75752646|NCT04923282|Biological|single 1-hour IV infusion of 3.2 mg/kg recAP|Intravenous infusion
75752647|NCT04923282|Biological|1-hour infusions of 1.6 mg/kg recAP on Days 1, 2 and 3|Intravenous infusion
75752648|NCT04923282|Biological|Placebo|Intravenous infusion
75752649|NCT00318370|Drug|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
75752650|NCT00318370|Drug|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
75752651|NCT03996408|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
75752652|NCT03996408|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
75752653|NCT01064908|Device|OxyMask|Novel vortex oxygen delivery mask
75752654|NCT00510068|Drug|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
75752655|NCT00510068|Drug|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
75752656|NCT00509600|Drug|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
75607003|NCT01225835|Drug|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
75752657|NCT04485026|Radiation|Local consolidative radiation therapy|All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
75752658|NCT04485026|Drug|Standard of care radiation therapy|Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
75752659|NCT01014026|Other|Screening test|Two Vaginal self sampling devices and HPV test
75455761|NCT01764048|Drug|Fix protocol|Please see arm description
76067070|NCT02993731|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
75455762|NCT01764048|Drug|medications following demand protocol|Please see arm description
75455763|NCT01764074|Behavioral|Brief Sleep Intervention|Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
75455764|NCT01764087|Drug|KX2-391 and Paclitaxel|"A treatment cycle in phase I will consist of 28 days, according to the following schedule:~KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated~A treatment cycle in phase II will consist of 28 days, according to the following schedule:~KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle."
75455765|NCT01764100|Genetic|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
75455766|NCT01764113|Behavioral|Mindful Eating|Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
75607004|NCT01225835|Drug|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
75455767|NCT01764113|Behavioral|Standard dietary counselling|
75455768|NCT01764126|Drug|Pneumococcal protein vaccine|One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
75455769|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
75455770|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
75607005|NCT01225835|Drug|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
75607006|NCT00962650|Device|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
75752660|NCT01014104|Drug|Methylprednisolone|Administration of Methylprednisolone
75752661|NCT01014104|Drug|Control|Normal salin injection
75752662|NCT00402987|Drug|Celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
75752663|NCT00402987|Drug|Celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
75752664|NCT00402987|Drug|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
76067071|NCT02993731|Drug|Gemcitabine|Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
75607007|NCT04282252|Drug|I.V. SOLUTIONS|All i.v. fluids used in an Intensive Care Unit.
76067072|NCT02991703|Device|pOpmètre®|the pOpmètre® uses saturation sensors,
76067073|NCT02991703|Device|Sphygmocor|the Sphygmocor uses applanation tonometry
76067074|NCT02991573|Device|Prime & Bond Universal|Prime & Bond Universal
76067075|NCT02991573|Device|Ceram X|
76067076|NCT02991573|Device|Prime & Bond XP|Control
76067077|NCT02991573|Procedure|technique 1|
76067078|NCT02991573|Procedure|technique 2|
76067079|NCT02977052|Drug|Ipilimumab|
76067080|NCT02977052|Drug|Nivolumab|
76067081|NCT02977052|Procedure|Surgery|Surgery will be done at 6 weeks
76067082|NCT02977052|Procedure|Blood for PBMCs|Blood will be taken for translational research on PBMCs
76067083|NCT02977052|Procedure|Biopsies|Biopsies will be taken during screening and at relapse.
75607008|NCT04282096|Other|native and non native casein|selected participant will test the 3 treatments in a random order
75455771|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
75455772|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
75455773|NCT01764139|Procedure|Blood sampling|
75455774|NCT01764152|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
75607009|NCT04284046|Other|CT score|CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
75607010|NCT00630136|Behavioral|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
75607011|NCT04280614|Behavioral|Dialectical behaviour therapy (DBT)|DBT is based on the behavioural therapy principals focusing on four main modules: mindfulness, interpersonal effectiveness, emotional regulation and distress tolerance. The therapy is taught in a group and individual therapy model with coaching during periods of crisis. CBT is a standard model of therapy similar to DBT but is more direct in focusing clients on changing maladaptive behaviours or thoughts to effectively manage difficult emtions.
75607012|NCT04280770|Procedure|23 PARS PLANA VITRECTOMY|We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
75607013|NCT02899000|Drug|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
75455775|NCT01764165|Other|Oxygen|oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
75455776|NCT01764165|Other|High flow of room air|Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
75455777|NCT01764178|Drug|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
75455778|NCT01764178|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
75752665|NCT00402987|Drug|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
75752666|NCT01015664|Drug|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
75752667|NCT01015664|Drug|cisplatin|75 mg/m2 IV over 60 minutes on day 1
75752668|NCT01015664|Drug|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
76067084|NCT02945722|Drug|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
76067085|NCT02945722|Other|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
76067086|NCT02945579|Radiation|External Beam Radiation Therapy|Undergo EBRT
76067087|NCT02945579|Other|Laboratory Biomarker Analysis|Correlative studies
76067088|NCT02945579|Other|Quality-of-Life Assessment|Ancillary studies
76067089|NCT02945579|Other|Questionnaire Administration|Ancillary studies
76067090|NCT02945579|Radiation|Whole Breast Irradiation|Undergo whole breast irradiation
76067091|NCT02934529|Drug|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
76067092|NCT02934529|Drug|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
76067093|NCT02934529|Drug|5-FU|5-FU 400 mg/m² bolus day 1, q d15
76067094|NCT02934529|Drug|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
76067095|NCT02934529|Drug|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
76067096|NCT02934529|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
76067097|NCT02934529|Drug|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
76067098|NCT02934529|Drug|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
76067099|NCT02934529|Drug|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
76067100|NCT02934529|Drug|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
75752669|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
75752670|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment.
75752671|NCT01015742|Drug|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
75752672|NCT00501644|Drug|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
75752673|NCT00501644|Drug|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
75607014|NCT02899000|Drug|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets [50 mg], twice daily)
75607015|NCT02858986|Procedure|3D laparoscopy|
75607016|NCT02858986|Procedure|4K laparoscopy|
75607017|NCT02859220|Other|Determination of PTH following|"Determination of PTH following:~in group 1: intact PTH Elecsys Roche"
75607018|NCT02859220|Other|Determination of PTH following:|"PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used."
75607019|NCT04281862|Drug|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
75607020|NCT04281862|Drug|Topical Prednisolone|Standard of care topical drop treatment
75607021|NCT00958828|Device|Nelfilcon A contact lens|Spherical, soft contact lens for daily disposable wear
75752674|NCT00501644|Drug|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
75752675|NCT03997214|Device|inspiratory muscle strength training|The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
75752676|NCT01014260|Drug|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
75752677|NCT01014260|Drug|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
75752678|NCT01010672|Drug|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
75752679|NCT01014338|Drug|Fosinopril|10mg od
75752680|NCT01014338|Other|lactose|placebo
75752681|NCT01014416|Drug|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
75752682|NCT00497796|Drug|maribavir|100mg twice a day for 14 weeks.
75752683|NCT00497796|Drug|ganciclovir|1000mg three times per day for 14 weeks.
75752684|NCT01017822|Biological|conatumumab|
75752685|NCT01017822|Drug|capecitabine|
75752686|NCT01017822|Drug|gemcitabine hydrochloride|
75752687|NCT01017822|Radiation|3-dimensional conformal radiation therapy|
75752688|NCT04449822|Procedure|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
75752689|NCT04449822|Procedure|Colonic stenting|The colonic stent placement to relieve the colonic obstruction.
75752690|NCT00496782|Drug|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
75752691|NCT00496782|Procedure|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
75752692|NCT01017900|Procedure|local excision|surgical excision by orthopaedic surgeon under local anesthesia
75752693|NCT01020708|Drug|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
75752694|NCT01020708|Drug|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
75752695|NCT01020708|Drug|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
75752696|NCT01020864|Drug|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
75607022|NCT00958828|Device|Narafilcon A contact lens|Spherical, soft contact lens for daily disposable wear
75607023|NCT03122002|Drug|Drug Therapy|For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
75607024|NCT03122002|Diagnostic Test|Routine Blood Test and Image Scan|Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
75752697|NCT01020864|Drug|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
75752698|NCT01020864|Drug|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
75901183|NCT02323490|Procedure|with microfractures|following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
75901184|NCT02323490|Procedure|without microfractures|standard procedure meniscal repair without augmentation.
75607025|NCT03122002|Other|Intravascular therapy|Intravascular therapy including thrombectomy
75607026|NCT03122002|Other|Emergency Treatment|Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
75901185|NCT04960514|Diagnostic Test|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
75607027|NCT03122002|Other|Medical history|Medical history including hypertension, diabetes, hyperlipemia and ect.
75607028|NCT02858596|Dietary Supplement|Semi-solid feed (Terumo PG soft)|
75607029|NCT02858596|Dietary Supplement|Liquid feed (Meibalance)|
75607030|NCT02861482|Device|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
75607031|NCT02861482|Drug|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
75607032|NCT02861482|Drug|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
75901186|NCT02323568|Other|Gynecological consultation|
75901187|NCT04537910|Drug|LY3819253|Administered SC.
75901188|NCT04537910|Drug|Placebo|Administered SC.
75901189|NCT04821362|Device|Ultrasound group|In the ultrasound group, the nurses will insert the cannulas to the peripheral veins as horizontally and longitudinally with the linear probe.
75901190|NCT04821362|Device|Near Infrared Device Group|In the near infrared device group, the nurses will insert the cannulas to the peripheral veins with AccuVein AV 400.
75901191|NCT04692584|Behavioral|The Lullaby Group|"Approximately 15 seconds before the vaccination, each baby's mother began to sing a lullaby. Infant's mother continued to sing lullabies until all the vaccinations, which were given immediately after the BCG vaccination, were completed. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure. All the mothers sang the same lullaby, Sleep and Grow. Mothers were reminded of the words to the lullaby before vaccine administration."
75752699|NCT01020942|Procedure|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
75752700|NCT01020942|Procedure|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
75752701|NCT01017978|Procedure|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
75752702|NCT00402831|Biological|ProQuad®|Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
75607033|NCT02861482|Drug|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
75752703|NCT04428372|Drug|Mannitol|Hypertonic mannitol infusion
75752704|NCT04428372|Drug|0.9% saline|Normal saline 'placebo' arm
75752705|NCT03996642|Behavioral|Avatar Life Review|VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
75752706|NCT01038141|Procedure|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
75752707|NCT01014858|Drug|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
75752708|NCT00496626|Biological|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
75752709|NCT00496626|Biological|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
75607034|NCT02861482|Procedure|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
75607035|NCT02861482|Procedure|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
75607036|NCT02861482|Procedure|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
75752710|NCT01018212|Other|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
75752711|NCT01015014|Drug|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
75752712|NCT01015014|Drug|Placebo|0.9% sodium chloride for injection
75752713|NCT04052958|Device|IMT - inspiratory muscle training|respiratory strength or indurance training with respiratory therapy device
75752714|NCT00471276|Drug|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
75901192|NCT03109730|Drug|ABI-H0731|A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
75607037|NCT02861482|Procedure|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
75607038|NCT02861482|Procedure|Hysterectomy|Hysterectomy with all the above measures not working
75607039|NCT02861482|Drug|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
75752715|NCT00470262|Drug|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
75901193|NCT03109730|Drug|Placebo for ABI-H0731|Sugar pill manufactured to mimic the ABI-H0731 tablet
75901194|NCT03109730|Drug|Entecavir|An antiviral medication used in the treatment of hepatitis B virus infection
75901195|NCT03109730|Drug|Tenofovir Disoproxil Fumarate|An antiviral medication used in the treatment of hepatitis B virus infection
75752716|NCT00470262|Drug|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
75752717|NCT04034862|Drug|Treatment simplification (dolutegravir lamivudine)|Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen
75752718|NCT00496470|Drug|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
75752719|NCT00496470|Drug|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
75752720|NCT01021176|Other|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
75752721|NCT01021176|Drug|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
75901196|NCT03109730|Drug|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
75901197|NCT02323724|Genetic|BRAF V600E mutation by pyrosequencing technique|
75901198|NCT02323802|Behavioral|educational group intervention|
75752722|NCT00496080|Device|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
75752723|NCT01018368|Drug|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
75752724|NCT01018368|Drug|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
75752725|NCT00487578|Drug|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
75752726|NCT00495612|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
75752727|NCT00495612|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
75752728|NCT01021488|Drug|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
75752729|NCT01021488|Drug|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
75901199|NCT02323802|Behavioral|prescriptive diet|
75752730|NCT00487188|Drug|Enfuvirtide|90 mg subcutaneous injection twice a day
75752731|NCT00487188|Drug|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
75752732|NCT00509366|Drug|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
75752733|NCT00509366|Drug|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
75901200|NCT03495206|Drug|Y-2(Edaravone And Borneol) Sublingual Tablet|Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
75901201|NCT04230122|Drug|LY3478006 - IV|Administered IV
75752734|NCT00509366|Drug|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
75901202|NCT04230122|Drug|LY3478006 - SC|Administered SC
75752735|NCT00509366|Drug|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
75901203|NCT04230122|Drug|Placebo - IV|Administered IV
75901204|NCT04230122|Drug|Placebo - SC|Administered SC
75901205|NCT04223024|Drug|CCRT+Nimotuzumab|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
75752736|NCT01015898|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
75901206|NCT04223024|Drug|CCRT alone|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
75607040|NCT02861716|Drug|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
75901207|NCT04202354|Drug|ARO-HSD Injection|single or multiple doses of ARO-HSD by subcutaneous (sc) injections
75752737|NCT03997682|Other|Hands-Up Program|In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
75752738|NCT01016054|Biological|AGS-8M4|IV infusion
75901208|NCT04202354|Drug|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment, by sc injection
75901209|NCT03491696|Drug|Metyrapone|Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
75901210|NCT04077086|Device|Spectacles|Intervention group children in middle school Years 1 and 2 will receive spectacles at the beginning of the academic year (September 2021). Assuming that the relevant effects of treatment (glasses wear) on the main study outcome are complete once examinations determining high school attendance are finished at the end of Middle School Year 3, Intervention participants will have undergone either 22 months (September 2021 to July 2023 for those recruited in Year 2) or 34 months (September 2021 to July 2024 for those recruited in Year 1) of treatment by the endpoint of the trial.
75901211|NCT03492866|Drug|Gentamicin Sulfate|Topical treatment of 1 side of the scalp twice daily during 6 months
75901212|NCT03492788|Other|ECGI-optimized VV-offset|ECGI guided optimization of VV offset programming of CRT device
75901213|NCT03492788|Other|Zero VV-offset|Standard-of-care nominal (zero VV-offset) programming of CRT device
75455779|NCT01764204|Drug|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
75455780|NCT01764230|Drug|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
75455781|NCT01764243|Drug|MT-4666|low dose, high dose
75455782|NCT01764243|Drug|Placebo|
75752739|NCT01016054|Drug|Pegylated liposomal doxorubicin (PLD)|IV infusion
75752740|NCT01016054|Drug|gemcitabine|IV infusion
75752741|NCT01016054|Drug|carboplatin|IV infusion
75752742|NCT00500318|Drug|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
75752743|NCT00500318|Drug|Placebo|Dose matched placebo, once daily oral inhalation.
75752744|NCT00508820|Biological|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
75752745|NCT00499694|Biological|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
75752746|NCT00499694|Drug|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
75752747|NCT01014494|Device|Adaprev|Class III Medical Device
75455783|NCT01764269|Other|text message surveillance for fever|
75455784|NCT01764282|Behavioral|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
75455785|NCT01764295|Drug|DWJ1276|
75455786|NCT01764295|Drug|Olmesartan|
75455787|NCT01764295|Drug|Rosuvastatin|
75455788|NCT01764295|Drug|Placebo|
75752748|NCT00486954|Drug|Lapatinib|6 pills at 250 mg each once daily
75752749|NCT00486954|Drug|Paclitaxel|Infusion at 80 mg/m2 weekly
75752750|NCT00494676|Device|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
75752751|NCT00494676|Device|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
75901214|NCT03491618|Other|PAIN REDUCTION ON VAS/NRS|Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
75901215|NCT02323958|Other|acupoint stimulation|stimulation is given at acupoints
75901216|NCT02323958|Other|non-acupoint stimulation|stimulation is given at acupoints
75901217|NCT02323958|Other|electrode attached|electrodes are attached to skin
75901218|NCT02323958|Device|electrical stimulation|electrical stimulation is given through electrodes attached to th skin
75901219|NCT02324036|Device|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
75455789|NCT01764308|Dietary Supplement|Omega-3|1200mg twice a day for 24 weeks
75901220|NCT02324036|Behavioral|Coached Care|Community health worker provides participation training to patient
75607041|NCT02861716|Drug|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
75455790|NCT01764308|Dietary Supplement|Placebo|4 tablets twice a day for 24 weeks
75607042|NCT02861716|Drug|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
75607043|NCT04265092|Drug|Incobotulinum toxin A|Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.
75607044|NCT00960934|Drug|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
75607045|NCT00960934|Drug|Placebo|Dose-matched oral placebo to MK-5442
75607046|NCT00960934|Dietary Supplement|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
75607047|NCT00960934|Dietary Supplement|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
75607048|NCT00892177|Biological|bevacizumab|Given intravenously
75607049|NCT00892177|Drug|dasatinib|Given orally
75752752|NCT00486720|Drug|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
75752753|NCT00486720|Drug|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
75752754|NCT00486330|Drug|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
75752755|NCT04010682|Other|urine sample collection|no drug/devise intervention. sample collection study only
75752756|NCT01021566|Device|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
75752757|NCT01021566|Drug|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
75752758|NCT01021644|Behavioral|aerobic exercise-training|3 times per week for 6 months
75752759|NCT01021644|Behavioral|stretch exercise|3 times per week for 6 months
75752760|NCT01021722|Procedure|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
75752761|NCT00486252|Other|Observational|This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
75752762|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
76067101|NCT02934399|Other|27 hour subcutaneous fluid sampling|"One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours)."
76067102|NCT02922816|Biological|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
75752763|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
75752764|NCT01021800|Biological|MIS|Cell infusion
75752765|NCT03851016|Behavioral|Life Story Book|Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.
75752766|NCT03851016|Behavioral|Usual Care|Three weeks of Usual Care with no visits from research team
75752767|NCT00493974|Drug|Zileuton|Zyflo tablets, 600 mg, 4 times a day
75752768|NCT00493974|Drug|Placebo|Placebo 4 x daily
75752769|NCT01018446|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
75752770|NCT01018524|Procedure|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
75901221|NCT03492710|Biological|Immunoglobulin|Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
75901222|NCT02780388|Drug|VIB4920|Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
75901223|NCT02780388|Other|Placebo|Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
75901224|NCT02324114|Device|Hsp90|Detect plasma Hsp90α concentration
75901225|NCT03954938|Behavioral|Craving Manipulation|Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
75607050|NCT00892177|Other|placebo|Given orally
75607051|NCT00962104|Drug|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
75607052|NCT00962104|Drug|Placebo|Taken by mouth, once daily for 10 weeks.
75607053|NCT02821000|Biological|Pembrolizumab|Intravenous infusion
75752771|NCT01018602|Drug|vildagliptin|100 mg per day over 24 months
75752772|NCT01018602|Drug|inactive pill|1 pill per day over 24 months
75752773|NCT01018758|Drug|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
75752774|NCT00469092|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
75752775|NCT00469092|Drug|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
75901226|NCT03954938|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
75607054|NCT02836327|Other|Magnetic Resonance Imaging|Magnetic Resonance Imaging
75607055|NCT02860624|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
75607056|NCT02860624|Drug|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
75607057|NCT02831647|Dietary Supplement|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
75607058|NCT02860468|Other|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
75607059|NCT02860468|Other|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
75607060|NCT02858518|Other|questionnaires|scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
75607061|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given weekly
75607062|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given monthly
75607063|NCT00892099|Other|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
75607064|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
75607065|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
75752776|NCT00469092|Drug|metformin|Tablets, 2550 mcg. Administered once daily.
75752777|NCT00469092|Drug|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
75752778|NCT03997110|Radiation|Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
75901227|NCT03954938|Drug|Placebo|The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
75901228|NCT02148120|Drug|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
75901229|NCT02148120|Drug|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
75901230|NCT02148120|Drug|Placebo|
75901231|NCT03543930|Device|Postoperative preventive CPAP|Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2
75607066|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
75607067|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
75607068|NCT04248907|Other|0 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
75607069|NCT04248907|Other|2 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
75607070|NCT04248907|Other|4 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
75455791|NCT01764334|Device|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
75455792|NCT01764347|Procedure|therapeutic conventional surgery|Undergo robotic radical prostatectomy
75607071|NCT02835937|Other|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
75607072|NCT02835781|Other|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
75607073|NCT00958438|Drug|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
75607074|NCT00958438|Drug|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
75752779|NCT03997110|Radiation|Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
75901232|NCT03901820|Device|Medication Interaction System of Dr App (SIMDA)|A module for the electronic clinical records allowing detection of the potential drug interactions
75607075|NCT00958438|Drug|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
75607076|NCT02835859|Other|Dietary: saccharin|Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
75607077|NCT02835859|Other|Estimate glucose absorptions|Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
75607078|NCT02835703|Procedure|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
75607079|NCT02835469|Drug|Menotrophin|
75607080|NCT02858674|Other|Pop Up Interruption Alert|Traditional Pop Up Alert used in Epic
75607081|NCT02858674|Other|Side Bar Non Interruptive Provider Checklist|Noninterruptive alert that sits in the checklist
75607082|NCT02860390|Other|Denver Health Asthma Management Program|text message (SMS) support including educational, motivational, and resource content.
75607083|NCT02860390|Other|Person of Support|Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
75607084|NCT02832973|Drug|Spironolactone|Spironolactone 25 mg
75607085|NCT02832973|Drug|Furosemide,|Furosemide 20-40 mg
75607086|NCT02832973|Drug|Amiloride|Amiloride 5 mg
75901233|NCT02148198|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
75901234|NCT02148198|Dietary Supplement|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
75455793|NCT01764347|Procedure|ultrasound-guided prostate biopsy|Undergo MRI-TRUS fusion image-guided prostate biopsy
75455794|NCT01764347|Procedure|magnetic resonance imaging|Undergo MRI-TRUS fusion image-guided prostate biopsy
75607087|NCT02832973|Drug|Ramipril|Ramipril 5-10 mg
75607088|NCT02832973|Drug|Bisoprolol|Bisoprolol 5-10 mg
75607089|NCT02832739|Device|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==> www.senaca.ch
75607090|NCT00958360|Other|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
75752780|NCT00499616|Drug|carboplatin|Given IV
75752781|NCT00499616|Drug|cyclophosphamide|Given IV
75752782|NCT00499616|Drug|doxorubicin hydrochloride|Given IV
75752783|NCT00499616|Drug|etoposide|Given orally
75752784|NCT00499616|Drug|topotecan hydrochloride|Given IV
75752785|NCT00499616|Drug|Isotretinoin|Given orally
75752786|NCT00499616|Procedure|Surgery|With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
75752787|NCT00499616|Drug|Filgrastim|Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy & continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
75752788|NCT01016210|Drug|Leuveris|IV
75752789|NCT01016210|Drug|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
75752790|NCT00402597|Drug|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
75901235|NCT03495050|Device|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform
75901236|NCT03492632|Other|Hormone panel|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.
75901237|NCT02324192|Other|Ultrasonography|imaging findings
75455795|NCT01764373|Other|Aerobic Exercise|Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
75455796|NCT01764425|Drug|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
75455797|NCT01764438|Procedure|Primovist-enhanced MRI|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
75455798|NCT01764451|Drug|Simvastatin|
75752791|NCT00402597|Drug|Placebo|1 placebo tablet twice daily for 6 months.
75752792|NCT00402597|Drug|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
75752793|NCT00402363|Drug|omega-3-acid ethyl esters|
75752794|NCT00402363|Drug|Placebo|
75752795|NCT00469014|Drug|Clofarabine|Day -6 to Day -3 for Arm 1 = 10 mg/m^2 intravenous (IV) Daily; Arm 2 = 20 mg/m^2 IV Daily; Arm 3 = 30 mg/m^2 IV Daily; Arm 4 = 40 mg/m^2 IV Daily
75752796|NCT00469014|Drug|Busulfan|"Day -6 to Day -3 for Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily; Arm 4: 40 mg/m^2 IV Daily.~Test dose Day -8 32 mg/ m^2 IV over 45 min, rest on Day -7."
75752797|NCT00469014|Drug|Fludarabine|Day -6 to Day -3 for Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily
75752798|NCT00469014|Other|Stem Cell Infusion|Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
75752799|NCT00469014|Drug|Thymoglobulin (ATG)|Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
75752800|NCT00469014|Drug|Filgrastim|Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
75901238|NCT03491462|Drug|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
75901239|NCT03491462|Drug|Placebo|2 matched placebo capsules taken 3 times daily
75901240|NCT02147496|Other|Dietary Intervention|
76067103|NCT02922816|Procedure|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
76067104|NCT02922816|Procedure|Stool or perirectal swab sampling|Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
76067105|NCT02922816|Other|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
76067106|NCT02914951|Behavioral|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
75752801|NCT00493038|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
75752802|NCT00493038|Drug|Amoxicillin/Clavulanate|Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
75752803|NCT01024998|Biological|AAV2-sFLT01|2 x 10^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
75752804|NCT01024998|Biological|AAV2-sFLT01|2 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
75752805|NCT01024998|Biological|AAV2-sFLT01|6 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
75752806|NCT01024998|Biological|AAV2-sFLT01|2 x 10^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
75752807|NCT00392223|Drug|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
75752808|NCT00392223|Drug|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
75752809|NCT00392223|Drug|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
75901241|NCT02147574|Procedure|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
75455799|NCT01764477|Drug|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
75455800|NCT01764542|Procedure|Endoscopy and biopsy|Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
75607091|NCT00958360|Other|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
75607092|NCT02832895|Other|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
75607093|NCT02832817|Device|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
75607094|NCT02860312|Behavioral|Intradialytic exercise on stationary bicycles|Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
75607095|NCT02860312|Behavioral|Non-exercising group|Patients are having their usual physical activity
75607096|NCT02831491|Drug|Ramucirumab|Administered IV
75607097|NCT02831491|Drug|Docetaxel|Administered IV
75607098|NCT02860234|Drug|Oxaliplatin|
75607099|NCT02860234|Drug|Capecitabine|
75607100|NCT02860234|Radiation|intensity modulated radiotherapy|
75607101|NCT02860234|Procedure|DRE-Endoscopy-MRI-CEA|
75607102|NCT02860234|Procedure|Nonoperative Management|
75752810|NCT00392223|Drug|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
75752811|NCT00402285|Dietary Supplement|lycopene supplement|
75752812|NCT00402285|Dietary Supplement|fish oil supplement|
75752813|NCT00402285|Other|Placebo|placebos for lycopene and fish oil.
75752814|NCT01038375|Behavioral|lifestyle counseling, home blood pressure monitoring|monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
75752815|NCT01324479|Drug|INC280|
75752816|NCT00413283|Biological|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
75752817|NCT00413283|Drug|Placebo|Placebo subcutaneous injection.
75752818|NCT00413283|Drug|Gemcitabine|Intravenous infusion
75752819|NCT00413283|Drug|Carboplatin|Intravenous infusion
75901242|NCT02147652|Other|Personalized music|
75752820|NCT00413283|Drug|Cisplatin|Intravenous infusion
75752821|NCT00402051|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
75752822|NCT00402051|Drug|Cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
75752823|NCT00402051|Drug|Carboplatin|Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
75752824|NCT00468858|Other|Placebo|"Lyophilized, single dose vials and sterile water for~> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
75752825|NCT00468858|Biological|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
75752826|NCT00468858|Biological|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
75752827|NCT00401973|Drug|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
75752828|NCT00401973|Drug|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
75901243|NCT04584554|Behavioral|BETTER Transitional Care Intervention|Patient and family will receive pre- and post-discharge support and education from interventionist.
75752829|NCT00401973|Drug|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
75752830|NCT00401973|Drug|zonisamide|Zonisamide, 100-400mg, oral, daily.
75607103|NCT02860234|Procedure|Local Excision|
75607104|NCT02860234|Procedure|Total Mesorectal Excision|
75752831|NCT00401973|Behavioral|Wellness education|weight management
75752832|NCT01038453|Dietary Supplement|Cholecalciferol 35 µg per day|"Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
75752833|NCT01038453|Other|placebo tablet|placebo 2 tablet, once a day,
75752834|NCT01038453|Dietary Supplement|Cholecalciferol (Vitamin D3) 70 µg|"Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
75752835|NCT00401193|Drug|Tranexamic acid tablets|3900 mg/Day
75752836|NCT00401193|Drug|Tranexamic acid tablets|1950 mg/Day
75752837|NCT00401193|Drug|Placebo tablets|
75752838|NCT00400569|Drug|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
75752839|NCT03993015|Other|Help to diagnosis software|Help to diagnosis software
75752840|NCT01038531|Other|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
75752841|NCT01038531|Other|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
75901244|NCT02147730|Procedure|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
75752842|NCT00413049|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
75901245|NCT02147730|Procedure|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
76067107|NCT02914951|Other|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
76067108|NCT02903368|Drug|Apalutamide|
76067109|NCT02903368|Drug|Leuprolide|
76067110|NCT02903368|Drug|Prednisone|
75607105|NCT02860234|Behavioral|Quality of Life Questionnaires|
75607106|NCT02858752|Other|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
75607107|NCT02858752|Other|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, …). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
75607108|NCT02858752|Other|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
75752843|NCT00413049|Drug|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
75752844|NCT03732495|Drug|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
75752845|NCT01041729|Drug|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
75752846|NCT01041729|Drug|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment."
75752847|NCT01324245|Drug|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
75752848|NCT00454194|Drug|pemetrexed disodium|given IV
76067111|NCT02903368|Drug|Abiraterone Acetate|
75455801|NCT01763424|Drug|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
75607109|NCT02858752|Other|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
75752849|NCT00454194|Drug|sorafenib tosylate|given orally
75607110|NCT02858752|Other|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
75455802|NCT01763424|Drug|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
75607111|NCT02832583|Device|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
75607112|NCT04280380|Diagnostic Test|Real time PCR|At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with >500 copies/mL of plasma will be considered positive.
75607113|NCT04280146|Behavioral|daily energy intake|Investigate daily energy intake according to eating rate and food processing
75607114|NCT05263141|Procedure|retro-auricular single-site endoscopic thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
75607115|NCT05263141|Procedure|traditional open surgery thyroidectomy|The strap muscles were separated in the midline to expose the thyroid gland. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified， a lobe of thyroid specimen and central lymph nodes were dissected.
75607116|NCT00630370|Drug|Placebo|2 Placebo tablets, TID, orally, 58 days
75607117|NCT00630370|Drug|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
75752850|NCT00412971|Drug|Hexvix|Single installation, TURB
76067112|NCT02855554|Other|Cardiac Magnetic Resonance (CMR) imaging techniques|Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
75607118|NCT00630370|Drug|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
75607119|NCT00630370|Drug|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
75607120|NCT02832349|Other|Educational Actions|Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
75607121|NCT04280068|Behavioral|Clinician Guide (CG)|An evidence-based, intervention approach to reduce heavy drinking in primary care settings.
75752851|NCT00412971|Other|Standard white light cystoscopy|
75752852|NCT00303472|Drug|Romiplostim|
75752853|NCT00468546|Drug|MabThera/Rituxan|1
75752854|NCT00468546|Drug|Methotrexate|2
75752855|NCT00468546|Other|Placebo|3
75752856|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
75455803|NCT01764555|Drug|acetaminophen 2 g|
75752857|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
75752858|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (~5 minutes)
76067113|NCT02841839|Drug|Stannous Fluoride|
75901246|NCT03109808|Other|e-health strategy|"First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
76067114|NCT02826161|Drug|Napabucasin|Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
75901247|NCT03109808|Other|Traditional Oral Hygiene Education|traditional oral hygiene education
75901248|NCT02151630|Drug|Pyruvic acid|
76067115|NCT02826161|Drug|Paclitaxel|Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
76067116|NCT02799901|Biological|Nivolumab|Injection of nivolumab
75455804|NCT01764568|Behavioral|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz & Woodward 2007a; Moritz & Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8-module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
75901249|NCT02151630|Drug|Salicylic Acid|
75901250|NCT03494972|Drug|Tetracyclin ointment|During 3rd molar surgery
75901251|NCT02148354|Behavioral|Smiling is Fun|"Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else…?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress."
76067117|NCT02799901|Radiation|hypofractionned radiotherapy|radiation
75607122|NCT04280068|Behavioral|Clinician Guide plus HealthCall|HealthCall is a smartphone application designed to help participants keep track of their daily alcohol use, medication adherence and a few other health behaviors through brief daily use.
75607123|NCT02835547|Other|Data collection|Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
75901252|NCT03494894|Diagnostic Test|Middle meatus aspirations and sputum|Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.
75901253|NCT02224573|Drug|GWP42003-P|
76067118|NCT02796885|Other|no intervention - observational study|
76067119|NCT02766543|Device|MRI-guided Transurethral Ultrasound Ablation|Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
76067120|NCT02753127|Drug|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
76067121|NCT02753127|Drug|Fluorouracil|
76067122|NCT02753127|Drug|Leucovorin|
76067123|NCT02753127|Drug|Irinotecan|
76067124|NCT02753127|Drug|Bevacizumab|
75752859|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
75752860|NCT01064986|Biological|Placebo|Saline vehicle (placebo)
75752861|NCT01064986|Biological|Hydrocortisone|Hydrocortisone
75901254|NCT04520750|Drug|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita
75901255|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent [%] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
75901256|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
75901257|NCT01360840|Other|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
75901258|NCT01360840|Other|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
75752862|NCT00468312|Drug|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
75752863|NCT00468312|Drug|Placebo|Two sprays in each nostril in the morning
75752864|NCT03980002|Drug|FCR and Ibrutinib|"Induction treatment:~Patients <65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count <10×10^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~Ibrutinib:420mg/d"
75901259|NCT03529292|Device|AmeaCell|Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.
76067125|NCT02752685|Drug|Pembrolizumab|
75455805|NCT01764568|Behavioral|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
75607124|NCT02835391|Device|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
75607125|NCT02835391|Device|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
75607126|NCT02835391|Procedure|Electrocautery/Diatermy|Procedure for the control of bleeding
75607127|NCT02997826|Other|Infantil formula|
75607128|NCT02835001|Procedure|Bronchoscopy|Two sequences of 30 minutes are necessary by patient
75607129|NCT02835001|Device|Lung Volume Reduction Coil (HEAT-LVRC)|Bronchoscopy with Heat-LVRC
75607130|NCT02835235|Drug|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
75607131|NCT02835235|Drug|placebo|Administered daily subcutaneously (s.c., under the skin)
75607132|NCT02831101|Drug|Sufentanil|To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
75901260|NCT02151708|Drug|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
76067126|NCT02752685|Drug|Nab-Paclitaxel|
76067127|NCT02746796|Drug|ONO-4538|
76067128|NCT02746796|Drug|Oxaliplatin|
76067129|NCT02746796|Drug|Tegafur- Gimeracil-Oteracil potassium|
76067130|NCT02746796|Drug|Capecitabine|
76067131|NCT02746796|Drug|Placebo|
75752865|NCT03980002|Drug|BR and Ibrutinib|"Induction treatment:~Patients ≥65y and ≤75 y or <65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d"
75901261|NCT02151708|Drug|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
75607133|NCT02831101|Drug|Placebo|To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
75607134|NCT02834923|Behavioral|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
75607135|NCT02834923|Behavioral|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
75607136|NCT04247659|Drug|sodium aescinate|The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
75752866|NCT03980002|Drug|Ibrutinib and Thalidomide|"Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy."
75607137|NCT02831413|Behavioral|RS+|The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
75607138|NCT02831413|Behavioral|Codeacademy|a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
75752867|NCT03938220|Device|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
75752868|NCT00331864|Drug|Ranibizumab|
75752869|NCT03984136|Behavioral|COHIV with exchange mechanism|A WeChat-based mini program has been developed to send and receive Center for Disease Control and Prevention certified online HIV results (COHIV). WeChat is the ubiquitous communication and social networking tool in China. Participants in the intervention group will receive his friend's COHIV only when the participants share their own in exchange. If the participant already has the COHIV, the system will lead the user to send his COHIV to the friend. If the participant does not have the COHIV, the system will guide him to make online appointment at the testing clinic.
75752870|NCT03984136|Behavioral|COHIV without exchange mechanism|The participants in the control group will be able to receive the friend's Center for Disease Control and Prevention certified online HIV results (COHIV) entirely at the friend's discretion without the mandatory exchange requirement. The system will also guide users on how to get an HIV test by making appointments with the MSM friendly clinics in the mini program.
75901262|NCT03490058|Drug|Truvada|A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
75901263|NCT02148432|Drug|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
75607139|NCT04201327|Behavioral|Project Jumpstart|PrEP focused intervention to improve PrEP related health outcomes
75607140|NCT04245787|Drug|Self assembling peptide with fluoride|peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
75607141|NCT04201171|Device|CSII and CGM|use of CSII as insulin delivery or CGM as glucose monitoring
75607142|NCT02831803|Dietary Supplement|Walnuts|28 gm/day in single-serve package
75607143|NCT02831803|Dietary Supplement|Extra Virgin Olive Oil|32 gm/day provided in 3, 34 ounce bottles
75901264|NCT02148432|Drug|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
75901265|NCT01976455|Other|20% fewer calories|
75901266|NCT01976455|Other|40% fewer calories|
75752871|NCT00331630|Drug|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
75752872|NCT00331630|Drug|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
75901267|NCT03096964|Other|Free walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
75901268|NCT03096964|Other|Nordic walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
75901269|NCT02151864|Drug|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
75901270|NCT03350984|Drug|NPH insulin|NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose >180 mg/dL.
75455806|NCT01764581|Procedure|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
75455807|NCT01764594|Biological|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
76067132|NCT02735928|Device|Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin|After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 10.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 2.1 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
75455808|NCT01764594|Other|Placebo|Placebo comparator
75455809|NCT01764620|Other|Elastic taping applied with tension|
75455810|NCT01764620|Other|Elastic taping applied without tension|
75607144|NCT00633451|Other|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
75455811|NCT01764620|Other|Fatigue protocol|
75752873|NCT00331552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
76067133|NCT02717624|Drug|Acalabrutinib in combination with BR|
75455812|NCT01764646|Radiation|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
75607145|NCT00633451|Other|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
76067134|NCT02717624|Drug|Acalabrutinib in combination with VR|
75455813|NCT01764646|Radiation|Volumetric modulated arc therapy|Highly conformational dose distribution
75455814|NCT01764646|Radiation|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
76067135|NCT02657551|Drug|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
75455815|NCT01764672|Drug|Methylphenidate|Oral dose 40mg (2 x 20mg)
75455816|NCT01764672|Other|Placebo|Oral intake of 2 placebo tablets
75455817|NCT01764698|Behavioral|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
75455818|NCT01764698|Behavioral|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
75607146|NCT02828605|Device|Virtual Interactive Platform (VIP) Transplant|
75607147|NCT02831179|Drug|Capecitabine|Given PO
75607148|NCT02831179|Drug|Temozolomide|Given PI
75607149|NCT02831179|Drug|Veliparib|given PO
76067136|NCT02624271|Other|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
75607150|NCT02831179|Other|Pharmacological Study|Correlative studies
75607151|NCT02831179|Other|Laboratory Biomarker Analysis|Correlative studies
75607152|NCT04245553|Diagnostic Test|Abdominal Point of Care Ultrasound|Participants will be have their needle insertion site for a paracentesis land-marked using both the traditional anatomical method, and with a point of care ultrasound. Note that the current standard of care does not require the use of point of care ultrasound.
75752874|NCT00331552|Drug|cyclophosphamide|Given orally
75752875|NCT00331552|Biological|trastuzumab|Given IV
75752876|NCT01062178|Drug|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
75752877|NCT03983746|Device|core stability exercises and treadmill training exercises|Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
75752878|NCT03980080|Drug|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC"
75752879|NCT03980080|Drug|Placebo|Vehicle study drug
75752880|NCT03980080|Drug|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV"
75752881|NCT04320628|Device|AnaSept®|AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.
75752882|NCT04320628|Other|NSS|NSS
75752883|NCT01065064|Procedure|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
75752884|NCT03983902|Procedure|Delayed cord clamping|Delayed cord clamping will occur for up to 2 minutes.
75752885|NCT03983902|Procedure|Umbilical cord milking|Umbilical cord milking will occur milking of the 30 cm of the cord from placental site to baby, at a speed of 5 cm/second, 3 times in preterm newborns, 4 times in term newborns.
75752886|NCT03983902|Procedure|Immediate cord clamping|Immediate cord clamping will occur in 20 seconds after birth.
75901271|NCT03350984|Drug|Glargine and Lispro insulin|Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
75607153|NCT04245631|Diagnostic Test|Recombinase aided amplification (RAA) assay|We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.
75607154|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
75901272|NCT02148510|Device|Monobloc|Construction fitted to upper and lower jaw
75901273|NCT02148510|Device|Bibloc|Biblock construction
75455819|NCT01764724|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
75455820|NCT01764737|Drug|VX15/2503|single dose intravenous administration
75901274|NCT03504423|Drug|CPI 613, mFolfirinox|CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
75901275|NCT03504423|Drug|Folfirinox|Folfirinox
75901276|NCT05053048|Device|SL-PLUS-Stem for total hip arthroplasty|Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
75455821|NCT01764737|Drug|Placebo|single dose intravenous administration
75455822|NCT01764750|Drug|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
75455823|NCT01764750|Drug|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
75455824|NCT01764776|Drug|LDE225|LDE225
75901277|NCT04461548|Behavioral|Thinking, writing and imagining|All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.
75752887|NCT00317356|Drug|OPC-6535(Tetomilast)|
75752888|NCT00331006|Drug|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
75901278|NCT05176717|Drug|QR-421a|RNA antisense oligonucleotide for intravitreal injection
75901279|NCT05176717|Other|Sham-procedure|Sham-procedure (no experimental drug administered)
75901280|NCT03097198|Other|Plum-blossom Needle|"acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding."
75901281|NCT03097198|Drug|Tropicamide Eye Drops|Instill one drop in both eyes every night before bed.
75901282|NCT02324348|Procedure|Deferred coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
75901283|NCT02324348|Procedure|Immediate coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
75455825|NCT01764789|Other|questionnaire administration|Ancillary studies
75455826|NCT01764789|Procedure|quality-of-life assessment|Patients will participate in a quality life assessment.
75455827|NCT01764789|Procedure|psychosocial assessment and care|Participate in multi-component biobehavioral intervention
75455828|NCT01764789|Behavioral|behavioral intervention|Participate in multi-component biobehavioral intervention
75455829|NCT01764789|Other|cognitive intervention|A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
75455830|NCT01764789|Other|educational intervention|Participate in multi-component biobehavioral intervention
75455831|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in enhanced standard care
75752889|NCT00302458|Drug|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
75752890|NCT00302458|Drug|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
75752891|NCT00302458|Drug|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
75752892|NCT03982264|Procedure|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
75901284|NCT02770248|Drug|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
75455832|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in psychological intervention
75455833|NCT01764815|Device|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
75455834|NCT01764828|Drug|Refametinib (BAY86-9766)|
75455835|NCT01764828|Drug|Gemcitabine|
75455836|NCT01764867|Drug|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
75455837|NCT01764867|Drug|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
75455838|NCT01764867|Other|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
75455839|NCT01764867|Other|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
75455840|NCT01764867|Drug|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75455841|NCT01764867|Drug|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75455842|NCT01764867|Drug|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75455843|NCT01764867|Drug|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75455844|NCT01764867|Drug|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75752893|NCT03982264|Procedure|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
76067137|NCT02580604|Drug|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
75752894|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
75752895|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
75752896|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
75607155|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
75752897|NCT00391053|Biological|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
75752898|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg twice daily
75752899|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg once daily
75752900|NCT00317044|Drug|Placebo|Placebo twice daily
75752901|NCT00301834|Biological|alemtuzumab|
76067138|NCT02580604|Drug|Placebo|Saline Infusion
76067139|NCT02577406|Drug|AG-221|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
75455845|NCT01764867|Drug|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75607156|NCT02828527|Other|Observational|
75607157|NCT04245007|Behavioral|Fasting|Doing fasting 2 days a week within 8 weeks
75607158|NCT05097469|Device|Carbon dioxide laser|3 consecutive sessions of carbon dioxide laser treatment
75607159|NCT05097469|Device|Sham laser treatment|3 consecutive sessions of sham laser treatment
75607160|NCT02830789|Dietary Supplement|Calcium Carbonate|
76067140|NCT02577406|Other|BSC|Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
75607161|NCT02830789|Dietary Supplement|Calcium Citrate|
75752902|NCT00301834|Drug|busulfan|
75752903|NCT00301834|Drug|cyclosporine|
75752904|NCT00301834|Drug|fludarabine phosphate|
75752905|NCT00301834|Drug|methotrexate|
75752906|NCT00301834|Drug|methylprednisolone|
75752907|NCT00301834|Procedure|allogeneic bone marrow transplantation|
75752908|NCT00301834|Procedure|allogeneic hematopoietic stem cell transplantation|
75752909|NCT00301834|Procedure|peripheral blood stem cell transplantation|
75752910|NCT00301834|Procedure|umbilical cord blood transplantation|
75752911|NCT00301366|Drug|alpha-1 proteinase inhibitor (human)|60 mg/kg weekly for 20 weeks
75752912|NCT00330928|Device|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
76067141|NCT02577406|Drug|Azacitidine|continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
75455846|NCT01764867|Drug|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75455847|NCT01764867|Drug|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75455848|NCT01764867|Drug|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75607162|NCT02830789|Dietary Supplement|Placebo|Tablet manufactured to mimic a calcium carbonate tablet
75607163|NCT02830789|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
76067142|NCT02577406|Drug|Low-dose cytarabine (LDAC)|continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
76067143|NCT02577406|Drug|Intermediate-dose cytarabine (IDAC)|28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
76067144|NCT02531048|Device|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
76067145|NCT02531048|Device|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
76067146|NCT02531048|Device|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
76067147|NCT02531048|Device|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
76067148|NCT02527434|Biological|Tremelimumab monotherapy|IV infusion
76067149|NCT02527434|Biological|MEDI4736 monotherapy|IV infusion
76067150|NCT02527434|Biological|MEDI4736 + tremelimumab combination therapy|IV infusion
76067151|NCT02508038|Procedure|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.
76067152|NCT02508038|Drug|Zoledronate|Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
76067153|NCT02460835|Radiation|Adaptive Radiation Therapy|
76067154|NCT02432690|Drug|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
75455849|NCT01764867|Drug|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75455850|NCT01764867|Drug|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
75455851|NCT01764880|Drug|SST0001 (Roneparstat)|SST0001 once daily for 5 or 10 days in a cycle of 28 days.
75455852|NCT01764893|Other|PTNS plus solifenacin|12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.
75455853|NCT01764893|Other|Placebo|12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
76067155|NCT02422550|Device|MRI|Participants enrolled on this protocol may undergo multiple MRI examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
75455854|NCT01764906|Device|Novosis|
75455855|NCT01764906|Procedure|Iliac crest bone graft|
75455856|NCT01764932|Procedure|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
75455857|NCT01764971|Other|IQ assessment and visual- motor assessment|Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
75455858|NCT01764971|Other|EEG,brain imaging|For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
75455859|NCT01764984|Device|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
75901285|NCT02770248|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
75901286|NCT05053282|Other|endurance running exercise|regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
75455860|NCT01765010|Drug|Calcitriol|
75455861|NCT01765010|Drug|Alfacalcidol|
75455862|NCT01765010|Drug|Cholecalciferol|
75455863|NCT01765010|Drug|Placebo|
75455864|NCT01765023|Drug|Period I : atorvastatin, Period II : atorvastatin and metformin|
75455865|NCT01765023|Drug|Period I : metformin, Period II : atorvastatin and metformin|
75752913|NCT00330928|Device|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
75752914|NCT01062334|Procedure|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
75901287|NCT04459130|Behavioral|Child Obesity Program|"The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.~The topics of the sessions are as follows:~Session 1: Healthy lifestyles~Session 2: Self-esteem and positive thinking, Setting goals Session 3: Stress and Coping, Coping with Emotions in Healthy Ways Session 4: Personality and effective communication~Session 5: Activity: Time for action Session 6: Nutrition basics Session 7: Reading tags Session 8: Portion size, nutrition and healthy food choices in schools Session 9: Snacks can also be healthy: Healthy choices~Session 10: Together for a healthy life (Melnyk et al., 2006; 2007; 2009). Detailed information about the sessions is given in annex -3."
75901288|NCT05044390|Procedure|Lung transplantation (single, lobar or bilateral lung transplantation)|Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis
75901289|NCT03619005|Drug|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
75901290|NCT03619005|Drug|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
75901291|NCT02686346|Drug|Brentuximab Vedotin|"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
75901292|NCT02686346|Drug|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
76067156|NCT02358811|Device|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.~Before any examination, the manipulator will check the absence of contraindication to MRI.~During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~Throughout the examination, a physician will always be present."
75901293|NCT02686346|Drug|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
76067157|NCT02358811|Behavioral|Cognitive assessment|"This cognitive assessment will include the following executive tests :~test of Stroop~left Trail Making Test A and B~verbal fluence test~test of memory of figures direct and inverse in order~completion of matrices~Paced Auditory Serial Addition Test (PASAT)"
75901294|NCT02686346|Drug|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
75901295|NCT03618927|Behavioral|Daily physical activity intervention|
75901296|NCT03489044|Drug|Levetiracetam|To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
75901297|NCT03489044|Drug|Placebo Oral Tablet|To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
76067158|NCT02320292|Other|Quality-of-Life Assessment|Ancillary studies
76067159|NCT02320292|Biological|Rituximab|Given IV
76067160|NCT02320292|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
75752915|NCT00330616|Drug|323U66 SR|
75752916|NCT00466440|Drug|enzastaurin|1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years
75752917|NCT00466440|Drug|placebo|Loading dose, then po QD until unblinding
75752918|NCT00466440|Drug|docetaxel|75 mg/m^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
75752919|NCT00466440|Drug|prednisone|5 mg po BID, six 21-day cycles
75901298|NCT02630654|Other|This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.|
75901299|NCT01344369|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
75901300|NCT01344369|Drug|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
76067161|NCT02315534|Drug|BBI608|"In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
75607164|NCT04243993|Other|Calcium silicate cement|Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
75752920|NCT00465972|Drug|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
75752921|NCT00465972|Drug|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
76067162|NCT02315534|Drug|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m^2.
76067163|NCT02278887|Procedure|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
76067164|NCT02278887|Drug|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
75752922|NCT00465972|Drug|Placebo|Placebo capsule nightly for duration of study
76067165|NCT02278887|Drug|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
76067166|NCT02278887|Drug|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
75455866|NCT01765036|Drug|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
75455867|NCT01765088|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
75455868|NCT01765088|Drug|α-IFN|3mIU (3million) D1，3，5
75455869|NCT01765101|Other|customized insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
75607165|NCT04243603|Behavioral|Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)|Please see description of experimental arm (arm one)
75607166|NCT02828293|Other|Dynamic videofluoroscopic analysis|Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.
75752923|NCT03926754|Drug|Mirabegron|"Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days)."
76067167|NCT02278887|Drug|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
76067168|NCT02231749|Biological|Nivolumab|
76067169|NCT02231749|Biological|Ipilimumab|
76067170|NCT02231749|Drug|Sunitinib|
76067171|NCT02212886|Drug|GA Depot 80 mg|Recruitment completed
75752924|NCT00465894|Drug|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
75607167|NCT04245163|Behavioral|Educational program|The intervention program will include 3 phases. At phase 1 a presentation on Microsoft PowerPoint in order to increase the general knowledge about glaucoma. At phase 2 a video and a one on one teaching to develop skills of administering the eye drops in a correct and systematic way. At phase 3, a discussion in order to identify cues to action that can easily be adopted by the patient in his/her daily routine, (such as, how to remember to put in drops) will take place.
75901301|NCT03491306|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
76067172|NCT02212886|Drug|GA Depot 40 mg|Recruitment completed
76067173|NCT02188745|Drug|17B-estradiol|Anti-estrogen
76067174|NCT02188745|Drug|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
75455870|NCT01765101|Other|ready made insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
75607168|NCT04245319|Drug|Acitretin|The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
75607169|NCT04245319|Other|Narrow band ultraviolet B|Patients receive nbUVB session 3 times per week
75752925|NCT00465894|Drug|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
75752926|NCT00330460|Drug|Alendronate|ALN; 70 mg; oral; once weekly
75455871|NCT01765114|Drug|PEG-Formulation|
75455872|NCT01765166|Behavioral|SSGRIN-Parent Guide|All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
75607170|NCT02828449|Behavioral|therapeutic education program|
75607171|NCT02828371|Device|stepping verticalization|After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
75752927|NCT00330460|Drug|Denosumab|60 mg; SC; every 6 months
75752928|NCT03979768|Other|Diabetes risk assessment service in Norwegian community pharmacies|Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
75752929|NCT01062490|Drug|Treosulfan|14 g/m2/d, day -6 to -4
75752930|NCT00454116|Drug|Vandetanib|once daily oral tablet two doses
76067175|NCT02188745|Drug|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
76067176|NCT02188745|Drug|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
76067177|NCT02024607|Drug|BBI608|
76067178|NCT02024607|Drug|Fluorouracil|
75752931|NCT00454116|Drug|FOLFIRI|Intravenous infusion
75752932|NCT00465816|Biological|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
75752933|NCT00465816|Biological|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
75752934|NCT00465738|Drug|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
75752935|NCT00400179|Drug|S-1/Cisplatin|"In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin."
75752936|NCT00400179|Drug|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
75752937|NCT00465270|Device|AMPLATZER PFO Occluder|patent foramen ovale closure device
75455873|NCT01765205|Device|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
75455874|NCT01765231|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
75752938|NCT00465270|Other|Standard of Care - Medical Management|Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
75752939|NCT00464568|Drug|GSK256066|
75752940|NCT00464490|Drug|Dexmedetomidine|Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
75752941|NCT01022034|Procedure|sacral rectopexy with sutures or meshes|
75752942|NCT01022034|Procedure|full rectal mobilization from the sacrum without sacral rectopexy|
75752943|NCT03849300|Other|Aquatic walking exercise program group 1|12 week aquatic walking exercise program
75752944|NCT03849300|Other|Aquatic walking exercise program group 2|12 week aquatic walking exercise program
75752945|NCT03849300|Other|Land-based walking exercise group|12 week land-based walking exercise program
75752946|NCT00412893|Drug|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
75455875|NCT01765231|Drug|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
75455876|NCT01765244|Drug|Anterior lamellar nanostructured artificial human cornea.|Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold
75455877|NCT01765244|Other|Amniotic membrane transplantation|Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.
75455878|NCT01765257|Drug|AZILECT®|
75752947|NCT00412893|Drug|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
75752948|NCT00412737|Drug|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
75752949|NCT00412737|Drug|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
75752950|NCT00508742|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
75752951|NCT00508742|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
75752952|NCT01041885|Device|INSTRUCT|INSTRUCT PolyActive scaffold implantation
75752953|NCT01041963|Drug|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
75752954|NCT01041963|Drug|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
75752955|NCT01041963|Drug|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
75752956|NCT01044225|Drug|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
75752957|NCT01044225|Drug|Cilengitide EMD 121974|A dose of 2000 mg by IV administration 2 weekly.
75752958|NCT00848757|Behavioral|Intensive Lifestyle Intervention|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
76067179|NCT02024607|Drug|Oxaliplatin|
75455879|NCT01765257|Drug|Placebo|
75752959|NCT00508274|Drug|lapatinib|Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.
75752960|NCT00508274|Drug|capecitabine|Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
75901302|NCT03491306|Other|Breflex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
76067180|NCT02024607|Drug|Leucovorin|
75455880|NCT01765283|Biological|HepaStem|
75455881|NCT01765309|Procedure|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
75455882|NCT01765322|Device|ZILOS-TK IVOS Analyzer|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
75455883|NCT01765335|Device|NICaS system|NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
75455884|NCT01765348|Behavioral|Syntax treatment via sentence-combining method|"Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.~Treatments are conduced by school-speech therapist once two weeks for 8 sessions."
75607172|NCT02828371|Other|conventional mobilization|in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
75752962|NCT01038999|Biological|Peripheral blood biological tests|A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
75752963|NCT01042041|Drug|sorafenib tosylate|Given orally
75752964|NCT01042041|Drug|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
75752965|NCT01042041|Drug|cisplatin|Given via transarterial/hepatic chemoembolization
75752966|NCT01042041|Drug|mitomycin C|Given via transarterial/hepatic chemoembolization
75752967|NCT01042041|Procedure|transarterial chemoembolization|
75752968|NCT01042041|Procedure|hepatic artery embolization|
75752969|NCT00499460|Dietary Supplement|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
75752970|NCT00499460|Drug|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
75752971|NCT01010828|Procedure|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
75752972|NCT01010828|Procedure|Incision technique|Mini Mid-Vastus Approach
75752973|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 5 mg
76067181|NCT02024607|Drug|Irinotecan|
76067182|NCT02024607|Drug|Bevacizumab|
76067183|NCT02024607|Drug|Capecitabine|
75752974|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
75752975|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 10 mg
76067184|NCT02024607|Drug|Regorafenib|
76067185|NCT01966159|Device|SYNERGY Investigational Device|percutaneous coronary intervention
76067186|NCT01966159|Device|PE Plus Investigational Device|percutaneous coronary intervention
76067187|NCT01938248|Drug|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
76067188|NCT01938248|Drug|aspirin|aspirin 81 mg once daily
76067189|NCT01776307|Drug|BBI608|BBI608 is administered at 500 mg po bid continuously.
76067190|NCT01776307|Drug|Panitumumab|Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
76067191|NCT01776307|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
76067192|NCT01776307|Drug|Cetuximab|Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
76067193|NCT01622322|Drug|Nitrous Oxide|Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
76067194|NCT01622322|Other|oxygen|Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
76067195|NCT01531803|Drug|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin)."
75455885|NCT01765348|Behavioral|Syntax treatment managed by narrative-based treatment|Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
75607173|NCT02828215|Device|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.~The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
75752976|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
75901303|NCT03491072|Device|Transcutaneous electrical nerve stimulation|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
75901304|NCT03491072|Drug|Fentanyl|Patients will receive IV fentanyl
75607174|NCT05143099|Drug|TEC|tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
75607175|NCT02828059|Drug|Ropivacaine|Surgical wound Infiltration over 48 hours
75607176|NCT02827903|Drug|Metformin + Rosuvastatin|Group I: Metformin + Rosuvastatin,
75607177|NCT02827903|Drug|Metformin + placebo|Group II: Metformin + placebo,
75607178|NCT02827903|Drug|placebo + Rosuvastatin|Group III: placebo + Rosuvastatin
75752977|NCT01014650|Drug|GLYX-13|single IV or SC dose
75752978|NCT01014650|Drug|IV normal saline|Single IV dose of normal saline
75455886|NCT01765374|Device|ESAOTE MyLab60|US evaluation at different time points
75901305|NCT03503409|Drug|AG-120|500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
75901306|NCT03490994|Drug|Rivaroxaban|Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
76067196|NCT01531803|Drug|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
75752979|NCT00411645|Drug|maribavir|100 mg twice daily for up to 12 weeks
75752980|NCT00411645|Other|placebo|twice daily for up to 12 weeks
76067197|NCT01325441|Drug|BBI608|
76067198|NCT01325441|Drug|Paclitaxel|
76067199|NCT01073475|Other|There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.|"There is no intervention associated with the parent MNHR study~For the MNHR COVID sub-study, each woman will be asked to provide a blood specimen of approximately 3-5 cc at or near delivery (at delivery or 14 days after) to be tested for COVID-19 antibodies. The person collecting the specimen will be a trained member of the registry staff. The ZEUS ELISA SARS-CoV-2 IgG Test System will be used and run at each site. RTI International will provide central quality support of the analyses."
76067200|NCT00900419|Other|immunohistochemistry staining method|Laboratory test
75752981|NCT00490724|Drug|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
76067201|NCT00900419|Other|laboratory biomarker analysis|Laboratory Test
75455887|NCT01765374|Drug|Rituximab|
75455888|NCT01765387|Behavioral|Spa session|
75455889|NCT01765413|Biological|Varicella-zoster virus|
75455890|NCT01765413|Biological|Yellow Fever Vaccine|
75455891|NCT01765413|Biological|Placebo|
75455892|NCT01765452|Drug|Closone|75mg/100mg, 8weeks, PO
75455893|NCT01765452|Drug|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
75455894|NCT01765478|Drug|HM71224 single ascending dose|
75455895|NCT01765478|Drug|HM71224 food effect|
75455896|NCT01765478|Drug|HM71224 Multiple ascending dose|
75455897|NCT01765517|Dietary Supplement|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
75455898|NCT01765517|Dietary Supplement|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
75607179|NCT05135923|Dietary Supplement|Randomized, controlled trial (RCT) with parallel arms and double blinded|Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).
75607180|NCT02830945|Behavioral|Motivational Interviewing Intervention Arm|
75607181|NCT02830945|Other|Control Brochure Arm|
75901307|NCT03490994|Drug|Warfarin + LMWH|dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
75901308|NCT03179462|Dietary Supplement|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
75901309|NCT03179462|Dietary Supplement|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
75901310|NCT03179462|Dietary Supplement|Tofu intake|Each participant will consume 2 ounces of tofu.
76067202|NCT00900419|Other|sputum cytology|Laboratory Test
76067203|NCT00900419|Procedure|biopsy|Laboratory Test
75455899|NCT01765556|Drug|ketoconazole|multiple doses of ketoconazole in Period B and C
75752982|NCT00490724|Drug|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
75455900|NCT01765556|Drug|vemurafenib|single dose of vemurafenib in Period A and C
75607182|NCT04247113|Behavioral|Parent-based prevention following bariatric surgery|PBP-B is an adapted version of Parent-Based Prevention (PBP), an innovative approach with demonstrated efficacy in targeting the familial effects of parents with eating disorders on their young children's healthy behaviors. PBP-B addresses the parental cognitions and behaviors that putatively increase the risk for maladaptive outcomes in their children.
75607183|NCT00888433|Device|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
75607184|NCT01243424|Drug|linagliptin|linagliptin tablets 5mg QD
75607185|NCT01243424|Drug|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
75607186|NCT01243424|Drug|linagliptin placebo|linagliptin placebo
75752983|NCT00490724|Drug|Nesritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
75901311|NCT02031705|Procedure|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
75901312|NCT02031705|Procedure|control group|Control group was performed no additional cavotricuspid isthmus ablation.
75455901|NCT01765595|Other|DDI+|
75607187|NCT01243424|Drug|glimepiride placebo|glimepiride placebo
75607188|NCT02831023|Drug|Sulphadoxine-pyrimethamine|Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
75607189|NCT02831023|Drug|0.25 mg/kg primaquine|Primaquine will be administered in an aqueous solution according to weight-based dosing.
75607190|NCT02831023|Drug|Dihydroartemisinin-piperaquine|160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
75607191|NCT02831023|Drug|Methylene blue|Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
75607192|NCT02831023|Drug|Amodiaquine|Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
75455902|NCT01765608|Drug|Zonisamide|Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
75455903|NCT01765608|Drug|Placebo|
75455904|NCT01765608|Device|nCPAP|
75455905|NCT01765621|Other|DDI+ System and Pharmacogenetic Data|
75455906|NCT01765634|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) each week, four times for a cycle.
75752984|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
75607193|NCT02830711|Other|Positive and Negative Affect Scale for Children|A 36-item instrument, including the Mood and Anxiety Symptom Questionnaire (MASQ)16 developed by Chang and Yeh and the Positive and Negative Affect Scale for Children developed by Watson and Clark
75752985|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
76067204|NCT00815789|Behavioral|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
75607194|NCT02826967|Procedure|Colonic Irrigation|
75752986|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
76067205|NCT00742807|Drug|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
75455907|NCT01765634|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
75607195|NCT04244539|Device|high-intensity laser Device.|Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of ~0.1%.
75607196|NCT02827825|Other|No intervention|No intervention. It's a study on retrospective Data
76067206|NCT00742807|Drug|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
75607197|NCT02827669|Behavioral|One Drop Experts Program|
75752987|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
75752988|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
75455908|NCT01765660|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
75455909|NCT01765660|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
75455910|NCT01765686|Device|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
75455911|NCT01765686|Device|Ligasure Small Jaw (Covidien, USA)|
75455912|NCT01765699|Device|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
75752989|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
75752990|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
75752991|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
75752992|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
76067207|NCT00590850|Procedure|ORIF with Plate and Screws|ORIF with plate and screws
75455913|NCT01765725|Behavioral|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
75455914|NCT01765738|Device|PICC (Cook, Bard)|Comparison of antibiotic coated PICC vs. non-coated PICC
75455915|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"Dosing every 2 weeks~Intravenous injection"
75455916|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"Dosing weekly~Intravenous injection"
75455917|NCT01765816|Behavioral|high intensity interval training|
75455918|NCT01765816|Behavioral|moderate intensity training|
75607198|NCT02827669|Behavioral|One Drop Experts Program + Apple Watch|
75607199|NCT04244695|Drug|Dexamethasone Oral|To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
75607200|NCT00887809|Drug|gemcitabine|
75607201|NCT00887809|Drug|docetaxel|
75607202|NCT00887809|Drug|bevacizumab|
75607203|NCT02830399|Device|active rTMS-ECT|5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
75901313|NCT03618459|Other|Phone questionnaire|Patients were contacted by phone 6 months after surgery and, after oral consent, a standardized questionnaire was administered in order to inquiry about the length and nature of post-operative pain, the incidence of post-discharge pain, its characteristics, its impact on daily life, its treatment and its rate of chronicity
75901314|NCT02031783|Dietary Supplement|Mixture of glucose and fructose|
76067208|NCT00590850|Procedure|Pin Fixation|Clavicle fixation with clavicle pin
76067209|NCT00484770|Device|Brain Natriuretic Peptide Levels -- Diagnostic testing|
75455919|NCT01765829|Drug|Discontinuation antipsychotic treatment|Dose reduction until withdrawal
75455920|NCT01765829|Drug|Antipsychotic treatment|Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
76067210|NCT00484770|Other|clinical assessment|
76067211|NCT05805046|Device|Negative Pressure Wound Therapy System|The study device combines a sterile dressing comprising gelling fibre technology to absorb wound exudate with negative pressure applied to the wound via a vacuum pump.
76067212|NCT05803083|Dietary Supplement|Hyaluronic acid 75 mg/capsule|Take 2 capsules per day at any time.
75607204|NCT02830399|Device|sham rTMS-ECT|5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
75455921|NCT01765842|Biological|Rituximab|Only one cycle of rituximab will be administered in this arm.
75455922|NCT01765881|Drug|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
75455923|NCT01765881|Drug|Dinoprostone|administration of one sustained released pessary of 10 milligrams by intravaginal route
75455924|NCT01765894|Other|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
75455925|NCT01765907|Device|HIFU|
75455926|NCT01765933|Dietary Supplement|DMAA|no placebo
75455927|NCT01765946|Drug|Metformin|Metformin tablets 500 mg tris in die (tid)
75455928|NCT01765946|Drug|placebo|
75455929|NCT01765959|Other|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
75607205|NCT02826889|Device|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
75607206|NCT02826889|Device|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
75752993|NCT01039077|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
75752994|NCT01039155|Drug|Azacitidine|Given IV
75752995|NCT01039155|Other|Laboratory Biomarker Analysis|Correlative studies
75752996|NCT01039155|Drug|Oxaliplatin|Given IV
75752997|NCT01039155|Other|Pharmacological Study|Correlative studies
75752998|NCT03835221|Device|methafilcon A toric contact lenses|Bilateral daily wear of methafilcon A toric contact lenses
75752999|NCT03835221|Device|fanfilcon A toric contact lenses|Bilateral daily wear of fanfilcon A toric contact lenses
75753000|NCT01039233|Drug|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
75753001|NCT00398073|Biological|mouse gp100 plasmid DNA vaccine|
75753002|NCT00398073|Device|The Dermal PowderMed® devices|
75753003|NCT00398073|Other|intramuscularly (IM injection)|
75753004|NCT00490646|Drug|ixabepilone|"Ixabepilone 40 mg/m^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
75901315|NCT02031783|Dietary Supplement|glucose|
75901316|NCT01314703|Drug|ChloraPrep One-Step|10.5 ml applicator preoperative skin preparation
75901317|NCT01314703|Drug|70% isopropyl alcohol|10.5 ml applicator
76067213|NCT05803083|Dietary Supplement|Hyaluronic acid 50 mg/capsule|Take 2 capsules per day at any time.
76067214|NCT05803083|Dietary Supplement|Placebo|Take 2 capsules per day at any time.
76067215|NCT05795296|Drug|Fruquintinib|Fruquintinib: 5mg po, d1-d14, q3w
76067216|NCT05795296|Drug|Sintilimab|Sintilimab: 200mg ivgtt, d1, q3w
75753005|NCT00490646|Drug|docetaxel|Docetaxel 100 mg/m^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
75607207|NCT04244617|Behavioral|iCBT with addition of peer-support|Peer-supporters and participants, as well as psychologists and participants, interact in the treatment program via asynchronous secure messages. Peer-supporters are able to give support and feedback on exercises. A reconciliation call via telephone is entered into the middle of the treatment and a follow-up call after completion of treatment conducted by the peer-support. The interaction between peer-supporters and participants is tracked by the psychologist.
75753006|NCT00490646|Drug|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
75753007|NCT01039311|Device|Optical Coherence Tomography|Obtain OCT images.
75901318|NCT03618069|Diagnostic Test|CCI scanning (CTA, cardiac CT), and MRI scanning|Scanning
75753008|NCT01039389|Drug|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
75753009|NCT01039389|Drug|Placebo|bid placebo
75901319|NCT01360762|Drug|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
75901320|NCT04382924|Drug|NP-120 (Ifenprodil)|Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID
75901321|NCT05034016|Device|High Myopic Posterior Scleral Fixation System|Implant HM into the eye through posterior scleral reinforcement
75455930|NCT01765959|Other|cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future"
75901322|NCT05693233|Device|EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation|"- After filling out the consent form for 10 subjects who meet the selection criteria, a total of three evaluations are conducted: one pre-evaluation and one post-evaluation for the knee assist robot and hip assist robot.~Pre-evaluation: Evaluation simultaneously with walking on an inclined treadmill (Uphill_incline 10°) for 5 minutes without wearing knee and hip assist robots (speed 1.5 m/s)."
75607208|NCT02827747|Other|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
75607209|NCT02827747|Other|Placebo|Placebo pill
75607210|NCT02827747|Dietary Supplement|Centrum|Centrum
75607211|NCT02827747|Combination Product|Dietary Sources|From dietary sources of vitamins.
75607212|NCT02830633|Procedure|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
75753010|NCT04558827|Other|Low Carbohydrate Diet|Dietary choices are counseled to come primarily from lean meats, eggs, nuts, seeds, vegetables and berries.
75753011|NCT04558827|Other|Time Restricted Feeding|Participants will be asked to have 2 meals within an 8 hour period, preferably before 2pm.
75901323|NCT02816996|Procedure|Hand-holding|Subject will have their hand held.
75901324|NCT02816996|Procedure|Stress Ball|Subject will be given a stress ball to hold.
75901325|NCT05439343|Other|Pain scores (numerical rating scale at rest and motion)|As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
75901326|NCT05439343|Other|Secondary outcomes|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.
75901327|NCT03097042|Procedure|Embryo transfer any further manipulation|The catheter will be pulled back slowly and without rotation with the plunger still pushed forward
75607213|NCT02830633|Procedure|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
75901328|NCT03097042|Procedure|Embryo transfer with catheter Manipulation|catheter rotation during withdrawal
75901329|NCT00002601|Biological|filgrastim|5 ug/kg daily following stem cell reinfusion
75901330|NCT00002601|Drug|cisplatin|Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
75901331|NCT00002601|Drug|doxorubicin hydrochloride|Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
75901332|NCT00002601|Drug|ifosfamide|Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
75901333|NCT00002601|Drug|melphalan|Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
75901334|NCT00002601|Procedure|peripheral blood stem cell transplantation|Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
75753012|NCT00388947|Device|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
75607214|NCT04244851|Other|Malnourished patients|"Data of included patients will be recorded during hospitalization using medical charts.~Every patient will be contacted by phone 3 months after hospital discharge. A sample of patients and their caregivers will be interviewed to better understand their perception of malnutrition and what they need to better take care of malnutrition."
75901335|NCT05033704|Drug|5% human plasma protein fraction (PPF)|"Infusion of 5% human plasma protein fraction PPF. PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium)."
75901336|NCT03044431|Procedure|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
75901337|NCT03618303|Diagnostic Test|PET-MRI scan|Patients will undergo combined Positron Emission Tomography and Magnetic Resonance Imaging prior to a planned invasive angiogram (performed as standard of care). During the angiogram procedure, an additional imaging test (optical coherence tomography) will be performed.
75901338|NCT03492320|Other|Health Quality of Life Questionnaire Assessment|Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Self-Rated Questionnaire SF36 and Health Related Quality of Life (HRQoL) 15D questionnaire were used as outcome measurement for functionality and disability assessment.
75901339|NCT04335032|Drug|Eicosapentaenoic acid gastro-resistant capsules|same as in arm/group description
75901340|NCT04335032|Drug|Placebo|same as in arm/group description
75901341|NCT03094936|Procedure|APC|Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
75901342|NCT03094936|Device|Endoscopic Suture Technique (OverStitch TM)|OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
75901343|NCT03490526|Device|Root canal disinfection with XP-endo Finisher|The XP-Endo® finisher will be used next to the X-Smart Plus endodontic motor, with speed settings at 800rpm and torque at 1 N.cm. Irrigation with 17% EDTA and 2.5% NaOCl will be performed in three cycles of one minute each. In each cycle the XP-Endo will be used in the working length in continuous and slow movements of entrance and exit, with amplitude of 5mm, for a period of 1 minute, followed by new irrigation with 2.5ml of EDTA solution or hypochlorite of sodium 2,5%. Finally, the channel will be completely dry with absorbent paper tips
75901344|NCT03490526|Device|Root canal disinfection with passive ultrasonic irrigation|For cleaning using passive ultrasonic irrigation, the E1 Irrisonic tip (Helse Ultrasonic, Ribeirão Preto, SP), will be used with Jetlaxis Sonic BP LED (Schuster, Santa Maria, RS). The insert has a diameter equivalent to a manual file 20, with reduced taper (0.01). The power used will be 10%. With root canals flooded with 17% EDTA, the irrigation tips will be coupled to the ultrasound and 1mm shorter than the working length. These tips will be kept in the center of the canal avoiding contact with the dentin walls. The irrigation will be performed in three cycles, and in each cycle the irrigation tips will be activated for 1 minute followed by new irrigation with 2.5ml EDTA. The same procedure will be repeated with 2.5% NaoCl. Finally, the channel will be completely dry with absorbent paper tips.
75901345|NCT03095014|Procedure|Cesarean Myomectomy|Myomectomy was done during Cesarean section
75901346|NCT03095014|Procedure|Cesarean section|Cesarean delivery
75901347|NCT04247438|Other|12h and 36h Biofilm formation on PMMA (Palapress®) dentures and samples worn by participants and brushing cycles needed to remove it.|"Capturing the clinical data for biofilm formation on PMMA dentures and samples worn by participants and the number of brushing cycles required to remove this biofilm.~Development of artificial denture biofilm substitute with similar mechanical properties to real denture biofilm."
75901348|NCT02770170|Drug|BI 655064 dose 1|
75901349|NCT02770170|Drug|BI 655064 dose 2|
75607215|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
75607216|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
75901350|NCT02770170|Drug|BI 655064 dose 3|
75901351|NCT02770170|Drug|Placebo|
75901352|NCT03618615|Biological|artericitc surgery|biological sample (leg) from leg amputation surgery used for research
76067217|NCT05792631|Device|Near infra red imaging|"The iTero Element 5D is an intra-oral scanner that incorporates near-infrared illumination capabilities used to provide a near-infrared image of the teeth enabling the detection of both occlusal and proximal caries, at the various stages, ranging from initial enamel caries to established caries reaching the DEJ.~Near-infrared Imaging (NIRI) is a nonionizing imaging technology that leverages differences in scattering and absorption of near-infrared light depending on the degree of tooth mineralization."
76067218|NCT05792345|Procedure|Transversus Thoracic Muscle Plane Block|The transversus thoracic muscle plane block It is most commonly performed following cardiothoracic surgeries (or any surgeries requiring sternotomy) to provide analgesia to the anterior chest wall. he TTMPB, and thoracic fascial plane blocks, are increasingly being employed as part of enhanced recovery after surgery (ERAS) protocols for cardiothoracic procedures. They have been shown to significantly reduce both the time to extubation and the incidence of acute and chronic perioperative pain
76067219|NCT05792345|Procedure|Control|Infiltration by surgeon
75607217|NCT00958126|Biological|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
75607218|NCT02861560|Other|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
75753013|NCT03992937|Drug|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.
75753014|NCT03992937|Device|Levonorgestrel-Intrauterine System|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.
75607219|NCT04281394|Device|Robot assisted gait training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.
75607220|NCT04281394|Other|conventional gait training|even level gait training and range of motion exercises
75753015|NCT01039545|Drug|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
75753016|NCT01039545|Drug|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
75753017|NCT00490568|Drug|Rosiglitazone XR|Experimental drug
75753018|NCT00561353|Drug|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
75753019|NCT00561353|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
75753020|NCT00561353|Drug|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
75753021|NCT00561353|Drug|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
75753022|NCT03996746|Diagnostic Test|No intervention|No intervention
75753023|NCT04383587|Other|Serologic testing|COVID19 IgG antibody testing to be performed
75753024|NCT00944957|Drug|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
75901353|NCT03490448|Behavioral|aerobic exercise and appropriate caloric control|The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
75607221|NCT04281628|Drug|Ketamine group:|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
75607222|NCT04281628|Drug|Control group|where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
75607223|NCT02859844|Device|Transcutaneous Tibial Nerve Stimulation (TTNS)|
75607224|NCT04280302|Behavioral|Virtual Reality-based Rehabilitation|VR-based eye stabilization exercises and balance exercises
75607225|NCT04280302|Behavioral|Conventional Therapy|Conventional rehabilitation therapy based on eye stabilization exercises and balance exercises
75607226|NCT04279756|Other|Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch|Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
75607227|NCT02861638|Device|Experimental group|Video of the exercises
75607228|NCT02861638|Device|Control group|video of nature scenes
75607229|NCT02861638|Device|Conventional physiotherapy|Mobilization, exercises and transfer practice.
75607230|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
75753025|NCT00944957|Drug|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
75753026|NCT00944957|Drug|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
75753027|NCT00944957|Drug|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
75753028|NCT00945113|Behavioral|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
75753029|NCT00945347|Drug|Miglustat|Nasal instillation of miglustat
75753030|NCT00945347|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
75753031|NCT00945425|Drug|AZD7325|oral capsule, once or twice daily, 7 days
75753032|NCT00945425|Drug|Placebo|oral capsule, once or twice daily, 7 days
75753033|NCT00560885|Device|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
75753034|NCT00945503|Drug|GSK1018921|GSK1018921 is a GT1 recepor antagonist
75753035|NCT00945581|Other|Experimental Nutritional Powder Formula|Powder twice a day
75753036|NCT00945581|Other|Placebo comparator|Powder twice a day
75901354|NCT02031861|Drug|nifedipine CR tablets (Xin Ran)|
76067220|NCT05785013|Dietary Supplement|Zinc|Zinc Supplementation
76067221|NCT05783648|Drug|Use of tranexamic acid|Percentage of correct use according to POISE-3 criteria of tranexamic acid
76067222|NCT05783310|Behavioral|Psychoeducation Intervention|The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
76067223|NCT05783076|Drug|Stereotactic body radiation therapy|Details have been shown in arm descriptions.
76067224|NCT05783076|Drug|adoptive cell therapy with vNKT cells|Details have been shown in arm descriptions.
76067225|NCT05762432|Device|Wound Dressing|RTD Wound Dressing that is being investigated
75753037|NCT00941135|Other|Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab|"Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks~Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43"
75753038|NCT00397215|Biological|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
75753039|NCT00397215|Biological|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
75901355|NCT02031861|Drug|nifedipine CR tablets (Adalat)|
75455931|NCT01765985|Device|PSORIAMED|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
75753040|NCT01042353|Procedure|E test|At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
75753041|NCT01042353|Procedure|standard culture method|BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
75753042|NCT01039623|Biological|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
75753043|NCT01042431|Other|No Intervention|No intervention
75753044|NCT01042587|Other|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
75753045|NCT01042587|Other|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
75753046|NCT01039701|Drug|AZD1446|capsules, oral, 3 times daily
75753047|NCT01039701|Drug|Placebo|capsules, oral, 3 times daily, 4 weeks
75901356|NCT03617991|Other|Exercise Group|An 8-week home exercise program will be given to the participants. The program is designed to have four phases, progressed every two weeks. The participants will receive and email from study personnel every two weeks with new videos detailing the progression of exercises. The participants will be given all of the equipment to complete the exercises. The exercises will include balance and strength training exercises for the core and lower extremity.
75901357|NCT03938402|Other|Positive end-expiratory pressure|Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.
75455932|NCT01765985|Device|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
75455933|NCT01765998|Drug|Probiotic|Clinical evaluation according to the Crohn's activity scale
75455934|NCT01765998|Drug|Placebo|
75607231|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
75607232|NCT04279600|Dietary Supplement|Taurine|Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day
75607233|NCT04279600|Dietary Supplement|Placebo|Placebo supplementation in capsules of 1 gram of starch powder, total dosage: 3 grams/day
75607234|NCT04279600|Other|Exercise training|4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.
75607235|NCT02830321|Other|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
75607236|NCT04246645|Other|CORE STABILITY EXERCISES|SELECTED CORE EXERCISES
75607237|NCT00886795|Drug|abatacept (Orencia ®)|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
75607238|NCT02783482|Biological|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
75607239|NCT02827357|Other|No specific intervention|Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response
75607240|NCT00889681|Device|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
75753048|NCT03742401|Procedure|Surgery|Traditional open excisional surgery
75753049|NCT03742401|Device|HIFU (Echopulse)|High intensity focused ultrasound (HIFU) non invasive intervention
75455935|NCT01766011|Other|study pre-term formula|24 kcal/fl oz pre-term formula for in-hospital use
75455936|NCT01766063|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
75455937|NCT01766089|Drug|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
75901358|NCT05052424|Diagnostic Test|Analysis of cytokines and immun cell related markers|blood samples
75901359|NCT02645474|Procedure|PECS block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 30 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.
75607241|NCT05048095|Other|AI cancer detection system|The use of AI as a third reader and as a decision support system during consensus meeting
75607242|NCT00957658|Device|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
75607243|NCT00953680|Drug|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
75607244|NCT00953680|Drug|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
75753050|NCT00556439|Drug|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~Participants weighing less than 60kg will receive 500mg of abatacept.~Participants weighing 60 to 100kg will receive 750mg of abatacept.~Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
75753051|NCT00556439|Drug|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
75901360|NCT02645474|Procedure|Paravertebral block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.
75901361|NCT02645474|Drug|Ropivacaine|Amidic local anesthetic standardly used for nerve block and infiltration
75901362|NCT05052814|Other|root canal medicament-calcium hydroxide|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
75753052|NCT04012229|Genetic|BRCA mutation|The genetic testing was performed according interregional consensus (Manchester score > or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
75753053|NCT00945737|Dietary Supplement|Soy protein; 25 grams/day|Soy protein
75753054|NCT00945737|Dietary Supplement|Control protein|Milk protein
75753055|NCT04012307|Drug|Candesartan Cilexetil 32mg|Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
75753056|NCT04012307|Drug|Atacand® PROTECT|Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
75901363|NCT05052814|Other|root canal medicament-chlorhexidine gel|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
75455938|NCT01766089|Drug|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
75455939|NCT01766115|Drug|Telaprevir|HCV Protease Inhibitor
75901364|NCT05052814|Other|root canal medicament-calcuim hyroxide &chlorhexidine ge|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
75901365|NCT03615417|Device|High Flow Nasal Cannula (HFNC)|"Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
75455940|NCT01766141|Other|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
75455941|NCT01766154|Drug|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
75455942|NCT01766167|Drug|MP-424|Low
75455943|NCT01766167|Drug|MP-424|Middle
75455944|NCT01766167|Drug|MP-424|High
75455945|NCT01766167|Drug|MP-424|Multiple
75455946|NCT01766180|Drug|Fruitflow-II|150 mg/day for 3 months, orally
75455947|NCT01766180|Drug|resVida|150 mg/day for 3 months, orally
75455948|NCT01766193|Procedure|vaginal delivery|
75607245|NCT00953680|Drug|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
75607246|NCT00890929|Drug|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
75607247|NCT00890929|Drug|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
75753057|NCT00939263|Other|assessment of disease activity using the EEsAI|disease activity index
75753058|NCT00941213|Device|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
75753059|NCT00941213|Device|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
75901366|NCT03615417|Device|Standard anesthesia FaceMask (FM)|"Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
75901367|NCT03490370|Device|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4|In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
75455949|NCT01766193|Procedure|forceps extraction|vaginal delivery by forceps extraction
75455950|NCT01766193|Procedure|vacuum extraction|vaginal delivery by vacuum extraction
75607248|NCT04279366|Behavioral|Lifestyle intervention|The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
75607249|NCT04246567|Procedure|Mean Blood Pressure (MBP)|Mean blood pressure (MBP) for patients 50-65 mmHg
75753060|NCT00387465|Drug|Azacitidine 30mg/m2|Azacitidine 30mg/m2 subcutaneously (SQ)
75753061|NCT00387465|Drug|Entinostat|7mg by mouth (PO) on days 3 and 10 of each cycle
75753062|NCT00387465|Drug|Azacitidine 40mg/m2|Azacitidine 40mg/m2 SQ
75607250|NCT04246567|Drug|Add to 0.5 mcg / kg fentanyl.|When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.
75901368|NCT02155530|Drug|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
75901369|NCT02155530|Drug|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
75901370|NCT03617835|Drug|Spesolimab|single-dose
75901371|NCT03933254|Diagnostic Test|Intraocular pressure measurement via ocular tonometry|Intraocular pressure and optic nerve sheath diameter changes of the patients undergoing laparoscopic cholecystectomy will be measured throughout the surgery at different times using ocular tonometry and ultrasound, respectively.
75901372|NCT05043844|Device|abdominal binder|Wearing an abdominal binder postoperatively
75901373|NCT03845738|Device|OsseoSpeed EV implant|The investigational product (OsseoSpeed EV implant) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
75901374|NCT05051956|Drug|Palbociclib 125mg and Ribociclib 600 mg|Administration of Palbociclib or Ribociclib
75901375|NCT02769858|Device|Light therapy|Light therapy glasses
75901376|NCT03490214|Device|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
75455951|NCT01766193|Procedure|cesarean section|
75455952|NCT01766245|Drug|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
75455953|NCT01766258|Drug|ODM-101 65mg Carbidopa|
75455954|NCT01766258|Drug|ODM-101 105mg Carbidopa|
75455955|NCT01766258|Drug|Stalevo|
75753063|NCT00945971|Other|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
75753064|NCT01042665|Drug|latanoprost 0.005%|Active comparator
75753065|NCT01042665|Drug|Placebo|Placebo comparator
75753066|NCT03679221|Other|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
75753067|NCT00949949|Drug|everolimus|Given PO
75753068|NCT00949949|Drug|gemcitabine hydrochloride|Given IV
75901377|NCT05051488|Procedure|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
75901378|NCT05051488|Device|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
75901379|NCT02152020|Behavioral|Survey|
75455956|NCT01766271|Behavioral|Health Coaching|biweekly health coaching for 5 months
75455957|NCT01766271|Genetic|9p21|Genetic testing results of 9p21
75455958|NCT01766271|Other|Standard Risk Assessment|All 4 arms are assigned to receive standard assessment on coronary heart disease risk
75455959|NCT01766284|Device|NIRIS 1300e|Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
75455960|NCT01766323|Drug|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
75607251|NCT04271566|Behavioral|Education program|A mobile application plus short message service (SMS) program to deliver disease-related health education and reinforcement to experimental group patients and see its impact on their health related quality of life, physical activity and Body mass index
75753069|NCT00949949|Drug|cisplatin|Given IV
75753070|NCT00941369|Drug|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
75753071|NCT01042743|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
75753072|NCT01042743|Procedure|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
75753073|NCT00941447|Behavioral|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
75607252|NCT04243681|Combination Product|CD 34 and MSC infusion|Combination of stem cells
75607253|NCT04243681|Drug|Standard of care for Cirrhosis management|Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
75607254|NCT00886639|Other|6MWT with oxygen|2 liter per minute as continuous-flow
75901380|NCT05051800|Behavioral|Online Program to Support Coping and Communication in Families|Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.
75455961|NCT01766323|Drug|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
75455962|NCT01766349|Behavioral|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
75455963|NCT01766362|Procedure|PRPC using Pascal laser|
75455964|NCT01766375|Drug|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
75455965|NCT01766414|Drug|C1-esterase inhibitor|intravenously
75455966|NCT01766414|Drug|Endotoxin|intravenously
75455967|NCT01766453|Behavioral|Standard Exercise|Aerobic exercise with a progressive increase in intensity over 12 weeks.
75455968|NCT01766453|Behavioral|Bhangra dance exercise|Bhangra Dance classes taught by an instructor.
75455969|NCT01766479|Radiation|CT colonography|
75607255|NCT00886639|Other|6MWT with medical air|2 liters as continuous-flow
75607256|NCT04244383|Diagnostic Test|interleukin IL-1beta and interleukin IL-18|pro-inflammatory cytokines measured in the serum
75607257|NCT04244305|Other|Exercise Therapy|Endurance training in the form of treadmill/cycle-ergometry
75753074|NCT00941447|Behavioral|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
75753075|NCT00941447|Behavioral|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
75753076|NCT00946049|Device|Vicryl Plus|
75753077|NCT00946049|Device|Vicryl|
75901381|NCT05051410|Procedure|intracanal cryotherapy using needle irrigation and EndoVac system|a cold saline will be used as final irrigant in two groups but with different irrigation systems.
75901382|NCT02769624|Drug|Treprostinil|A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
75455970|NCT01766518|Drug|Mycophenolate mofetil|MY-REPT capsule 500~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation
75455971|NCT01766531|Device|body bioelectrical impedance|
75455972|NCT01766544|Other|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
75455973|NCT01766544|Other|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
75607258|NCT02830243|Drug|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
75607259|NCT02830243|Drug|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
75607260|NCT02830009|Other|Urines samples|24-hour urines will be collected
75607261|NCT02830009|Other|Blood sample|
75607262|NCT00889603|Drug|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
75607263|NCT04244071|Device|Bair Paws Blanket 81003 and FOC device 87500|This study is a randomized, pretest - posttest controlled experimental design.
75607264|NCT04244071|Other|routine hospital care|routine hospital care
75455974|NCT01766557|Other|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
75455975|NCT01766557|Other|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
75607265|NCT04244149|Other|Prolonged Exercise session|After a standardized warm-up of 10 minutes of continuous running on a treadmill at 60% of their maximum heart rate (HRmax), subjects will perform a maximum oxygen consumption test (VO2max) with a gas analyzer (UltimaTM Series, MGC Diagnostic Corporation, St. Paul, MN, USA. The protocol will start with a slope of 1% at a speed of 10 km/h, with increments of 0.3 km/h every 30 s until volitional exhaustion. Finally, ten minutes after the treadmill test, volunteers will run 1 kilometer (t1km) as fast as possible and the time needed to cover the distance will be recorded.
75753078|NCT00946127|Procedure|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
75607266|NCT04243135|Device|ESWT|Extracorporeal shock wave therapy
75607267|NCT02826577|Drug|Pregnenolone 175mg|Single Dose 175mg
75607268|NCT02826577|Drug|Pregnenolone 400mg|Single Dose 400mg
75607269|NCT02826577|Drug|Placebo|Single Dose
75607270|NCT00886483|Device|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
75607271|NCT00886483|Device|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
75753079|NCT00946127|Procedure|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
75753080|NCT00946205|Procedure|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
75753081|NCT00946205|Procedure|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
75753082|NCT00950027|Drug|povidone iodine|oropharyngeal decontamination every 4 hours
75901383|NCT02769624|Drug|Placebo|3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
75901384|NCT02228954|Procedure|Molecular imaging|
75901385|NCT05032924|Combination Product|PPR group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy) (3000 impulse, each point, 24 KV, 0.32 mJ/mm2) one week after PRP or HA injection
75901386|NCT05032924|Combination Product|PPR group without ESWT|PRP or HA injection only
75607272|NCT00886015|Device|TT Clamp|trichiasis surgery performed with TT clamp
75901387|NCT05032924|Combination Product|HA group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy)
75901388|NCT05032924|Combination Product|HA group without ESWT|PRP or HA injection only
75901389|NCT03446768|Other|Peer support|Access to educational and informational support by a trained peer coach
75607273|NCT00886015|Procedure|Standard BLTR Technique|bilamellar tarsal rotation procedure in trichiasis surgery
75753083|NCT00950027|Drug|Placebo|oropharyngeal decontamination every 4 hours
75901390|NCT03446768|Other|Online platform|An online platform that provides educational, informational and access to several therapeutic device metrics
75901391|NCT03446768|Other|Respiratory Therapist support|Limited medical support provided by trained Respiratory Therapists.
75901392|NCT03543774|Drug|Simvastatin 40mg|Simvastatin mono-therapy at the dose of 40 mg/day for 12 months
75901393|NCT03543774|Drug|Ezetimibe/simvastatin 10/20 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months
75901394|NCT03543774|Drug|Ezetimibe/simvastatin 10/40 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
75607274|NCT02829853|Genetic|Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING|Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo & HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
75753084|NCT00941525|Drug|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
75753085|NCT00456261|Drug|Pemetrexed|pemetrexed 500 mg/m2
75753086|NCT00456261|Drug|Gemcitabine|gemcitabine 1500 mg/m2
76067226|NCT05762432|Device|NHS Standard Dressing|This is the standard dressing used by NHS staff when currently dealing with a diabetic foot ulcer
75607275|NCT00890695|Dietary Supplement|Ready to use supplementary food (RUSF)|It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
75753087|NCT00456261|Drug|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
75901395|NCT05032768|Radiation|post-operative radiotherapy|Breast cancer patients who have received reconstructive surgery will receive post-operative radiotherapy.
76067227|NCT05761951|Drug|DKN-01|Given by IV (vein)
75607276|NCT02826655|Device|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
75607277|NCT02826499|Device|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
75753088|NCT00456261|Drug|Carboplatin|carboplatin AUC=5
75753089|NCT01042821|Procedure|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
75753090|NCT01042821|Procedure|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
75901396|NCT02152098|Procedure|Acute Early onset of rehabilitation|Early onset of rehabilitation
75901397|NCT02152098|Procedure|Acute Delayed onset of rehabilitation|Delayed onset of rehabilitation
75901398|NCT02152098|Procedure|Chronic Exercise|Exercise
75901399|NCT02152098|Procedure|Chronic Control|Control
76067228|NCT05761951|Drug|Pembrolizumab|Given by IV (vein)
76067229|NCT05761405|Combination Product|mannitol-enhanced aminoglycoside|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes."
76067230|NCT05761405|Drug|Ceftriaxon|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes."
76067231|NCT05761405|Drug|Amikacin|Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
76067232|NCT05752786|Behavioral|"Eat Less Meat Challenge"|Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
75607278|NCT02826499|Other|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
75753091|NCT01042899|Behavioral|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
75901400|NCT03096574|Other|Questionnaire|The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 5-10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
75901401|NCT02676284|Device|Durolane SJ|DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
75901402|NCT05032222|Other|Uroflowmetry|Diagnostic test
76067233|NCT05746884|Procedure|duodenal mucosectomy|Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
75463287|NCT05854758|Other|Core strengthening with conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform planks, side planks and superman exercises along with knee to chest, pelvic rotation, back extension, and bridge exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes."
75753092|NCT01042899|Behavioral|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
75901403|NCT02155686|Device|Biosensors|Device: Biometric sensors; Home automation; telecare
75901404|NCT02155686|Device|Home automation|
76067234|NCT05746884|Procedure|ampullectomy|Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
76067235|NCT05739474|Biological|Influenza vaccine [inactivated]|solution for intramuscular injection, 1 dose (0.5 mL)
76067236|NCT05739474|Biological|Influenza vaccine [inactivated]|suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
76067237|NCT05736562|Dietary Supplement|Ritual Epre Multimineral-Vitamin Supplement|The Ritual Epre supplement is a commercially available multivitamin-mineral supplement designed for pregnant and lactating women.
76067238|NCT05736562|Dietary Supplement|Placebo Control|This is a customarily designed blank placebo provided by Ritual.
76067239|NCT05736237|Genetic|Whole exome sequencing|With Next Generation Sequenzing
76067240|NCT05733169|Other|Frequency lowering intervention|Modified parametrization of the current frequency lowering parametrization.
76067241|NCT05733169|Other|Frequency lowering reference|Current frequency lowering parametrization
76072260|NCT02336672|Device|Cryothermal ablation|Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
75753093|NCT01042899|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
75753094|NCT03993405|Other|Ultrasonographic evaluation|Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
75753095|NCT00387153|Drug|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
76067242|NCT05726669|Other|Self-help materials for depression|Self-help materials for depression based on cognitive behavioural therapy have been created and tailored to those with PH by researchers involved in this project, using the evidence base and theory plus clinical experience. The Medical Research Council Frameworks for complex interventions (Craig et al., 2008; Skivington et al., 2021) have been followed as well as the quality appraisal tool for self-help interventions in depression (Cape, 2015). The self-help materials will be shared for feedback with a readership panel of people with PH and caregivers who are members of Pulmonary Hypertension Association UK (a charity for people with PH) prior to being given to participants. The self-help materials will be provided online or posted in paper form to the intervention group and will take four weeks for the person to complete at home (one booklet per week).
76067243|NCT05726084|Biological|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
75607279|NCT04242979|Behavioral|Questionnaire about albumin use in liver cirrhosis|"Permission to carry out the study will be obtained from the Faculty's Ethics Committee.~To achieve validity and reliability of the tool. It will be reviewed by two experts in the field of the study and necessary modification will be done.~A pilot study will be 10% done to test the clarity and feasibility of developed tool.~Each participant involved in the study will be assessed for his or her knowledge using (tool I).~Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians"
75607280|NCT02829541|Drug|BIIB068|Administered as specified in the treatment arm.
75607281|NCT02829541|Drug|Placebo|Administered as specified in the treatment arm
75607282|NCT02827123|Device|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
75607283|NCT02827123|Drug|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
75607284|NCT00633607|Other|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
75607285|NCT05041543|Drug|NTX-101|Eye drops, topical administration
75607286|NCT05041543|Drug|Placebo|Placebo as eye drops
75607287|NCT02826265|Device|multiple breath washout test (MBW)|
75607288|NCT02826265|Device|impulse oscillometry (IOS)|
75607289|NCT02826265|Device|body plethysmography (BP)|
75607290|NCT02826265|Device|quantitative computed tomography (qCT)|ultra-low-dose qCT
75753096|NCT00386607|Drug|Aliskiren|Aliskiren 300 mg
75753097|NCT00386607|Drug|Valsartan|Valsartan 320 mg
75753098|NCT00386607|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
75753099|NCT00410163|Drug|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
75753100|NCT00410163|Drug|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
75901405|NCT05032300|Device|Focused shockwave|Procedure: Focused shockwave therapy received shock wave therapy once a week: first locate, touch on the heel of the patient Tenderness points, take tenderness points as treatment points;Then ask the patient to take the lower limbs straight sitting or prone position, Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, Total of 3000 pulses; rest for 20 minutes after the treatment
75607291|NCT04246411|Behavioral|Ultrasound-guided determination of cuffless RAE tube depth|"Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
75901406|NCT05032300|Other|Home therapy|Stretching and ice massage
75901407|NCT02155764|Device|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
75901408|NCT02155764|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
75901409|NCT02155764|Device|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
75901410|NCT01829750|Genetic|Cardiac progenitor cell infusion|"(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1."
75901411|NCT05032456|Device|Oculus Quest All-in-one VR Gaming Headset (128 GB) VR system|The laboring women who enrolled in the VR group were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the screenshots of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance.
75901412|NCT02152176|Device|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
75901413|NCT03617055|Diagnostic Test|serum cystatin c|Blood sample for serum cystatin c will be taken on the first and third days of life for all neonates with clinical or laboratory signs of perinatal asphyxia who are admitted to NICU for early detection of AKI in the study group.
75607292|NCT04246411|Behavioral|Auscultation-guided determination of cuffless RAE tube depth|"Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
75607293|NCT02829385|Drug|Apatinib and XELOX combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
75607294|NCT02826109|Device|PeriAcryl®90 HV|
75607295|NCT02826343|Drug|Xenon129 MRI imaging|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
75607296|NCT02826343|Drug|Gadolinium MRI|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
75753101|NCT00410163|Drug|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
75607297|NCT02826343|Drug|Advair (250mcg/50mcg) one puff twice a day|subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
75607298|NCT04246255|Drug|Xylocaine 10% Oral|"50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
75753102|NCT00410163|Drug|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
75753103|NCT03617523|Biological|Fluzone Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75753104|NCT03617523|Biological|Flublok Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75901414|NCT02155842|Behavioral|High intensity endurance exercise|
75901415|NCT02155842|Behavioral|Moderate continuous endurance exercise|
76072261|NCT02286687|Other|Laboratory Biomarker Analysis|Correlative studies
75753105|NCT03617523|Biological|Fluzone High-Dose vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75753106|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Other Week dosing
75753107|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
75753108|NCT00300274|Drug|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
75753109|NCT00300274|Drug|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
75753110|NCT00300274|Drug|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
75607299|NCT04246255|Drug|Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul|"50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
75901416|NCT03094780|Behavioral|Quality of life counseling|Will receive quality of life counseling from PI, social workers, and physical therapists
75753111|NCT00300274|Drug|corticosteroids|Corticosteroids standard dose.
75753112|NCT01043211|Drug|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
75607300|NCT04246099|Other|Post-operative care|"Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients."
75901417|NCT03094780|Other|Video-conference quality of life counseling|Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
75607301|NCT02824861|Behavioral|Bemobile|
75607302|NCT02825953|Drug|surfactant|the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
75901418|NCT03488888|Drug|Normal Saline 0,9%|Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
75901419|NCT03488888|Drug|Bupivacaine|Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
75607303|NCT02825953|Device|nasal continuous positive airway pressure|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
75607304|NCT02825953|Device|non-invasive intermittent positive-pressure ventilation|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
75607305|NCT02825953|Device|Neopuff|Fisher and Paykel, Auckland, New Zealand
75607306|NCT02825953|Device|neonatal ventilator|GE Healthcare, Madison, USA
75607307|NCT02826187|Other|Early complications data|"Early complications of interest are :~New arthroplasty for any reason~Related to the implant :~Wrong position of the implant~Early displacement of the implant~Related to the intervention :~Hematoma~Dislocation (or not causing the resumption of joint replacement)~Deep vein thrombosis~Pulmonary embolism~Acute Infection"
75607308|NCT02826187|Other|Late stage complications data|"Late complications taken into account are:~New arthroplasty for any reason~Aseptic loosening~Delayed hypersensitivity reaction type IV~Solid Tumors~Recurrent dislocation (causing or not the resumption of joint replacement)~Allergic reactions of any kind~Chronic infection"
75607309|NCT02826187|Other|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
75607310|NCT02826187|Other|Efficacity|Efficacity as evaluated by Harris HIP score
75753113|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
75753114|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
75753115|NCT01043289|Other|Light therapy|During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
75753116|NCT01043367|Dietary Supplement|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
75753117|NCT01043367|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
75753118|NCT01043445|Dietary Supplement|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
75753119|NCT01043445|Dietary Supplement|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
75753120|NCT01043445|Dietary Supplement|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
75607311|NCT02826187|Other|Radiographic evaluation|Bone reaction visible in radiography
75607312|NCT05210725|Drug|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
75607313|NCT02826031|Drug|Sodium Hyaluronate Injection|
75753121|NCT00299728|Biological|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG
75607314|NCT02826031|Drug|DICL-SR|
75607315|NCT02829697|Drug|Ropivacaine|Perineural injection.
75753122|NCT03741946|Procedure|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
75607316|NCT04980469|Other|Vitex negundo + Zingiber officinale|200 mg/ Capsule
75607317|NCT04980469|Other|Placebo (MCC)|200 mg/ Capsule
75753123|NCT00396591|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
75753124|NCT00316264|Biological|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
75901420|NCT05031676|Other|opioid free anesthesia|Maintenance of anesthesia was done with halothane. The incision was allowed at 1.2 MAC of halothane. This halogen was administered according to the hemodynamic parameters and the habits of the anesthesia team. Before waking up, all the patients benefited from preventive analgesia with 1 g paracetamol combined with 20 mg nefopam by slow intravenous injection over approximately 15 minutes.
76067244|NCT05726084|Biological|Placebo|solution for intramuscular injection, 0.5 ml
75455976|NCT01766570|Other|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
75455977|NCT01766570|Other|Placebo|
75901421|NCT05149430|Other|Observational Quality of life and functional capacity|Observational Quality of life and functional capacity
75455978|NCT01766583|Drug|CC-292 + lenalidomide|CC-292 + lenalidomide
75753125|NCT00316264|Biological|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
75607318|NCT02829151|Drug|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
75901422|NCT03615339|Dietary Supplement|Molkosan|Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
76067245|NCT05721690|Device|UED-A Videolaryngoscopy|Tracheal Intubation with UED-A videolaryngoscope
75607319|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
75607320|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
75607321|NCT05207137|Behavioral|Telephone call about vaccination|Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
75607322|NCT02825719|Drug|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
75753126|NCT00316264|Biological|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
75753127|NCT02532946|Behavioral|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
75753128|NCT00385827|Drug|Mitoxantrone|Mitoxantrone 12 mg/m^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2)
75753129|NCT00385827|Drug|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
75753130|NCT00385827|Drug|Prednisone|Prednisone 5 mg orally twice daily
75753131|NCT00498602|Biological|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
75901423|NCT02769312|Device|Theta burst stimulation|Theta burst transcranial magnetic stimulation
75901424|NCT02769312|Device|Sham stimulation|Sham Theta burst transcranial magnetic stimulation
75455979|NCT01766596|Procedure|Optical Coherence Tomography|
75753132|NCT00498602|Biological|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
75455980|NCT01766609|Drug|Triamcinolone Acetonide|
75901425|NCT03616743|Behavioral|Psychoeducation|Psychoeducation about the links between smoking and chronic pain.
75901426|NCT03616743|Behavioral|Brief smoking control arm|Psychoeducation about the general adverse effects of smoking.
75901427|NCT03489902|Procedure|Transobturator Paravaginal Repair|Transobturator application of sutures to the white line in cases needing paravaginal repair
75901428|NCT03489902|Procedure|traditional transvaginal Paravaginal Repair|traditional transvaginal application of sutures to the white line
75901429|NCT03617757|Diagnostic Test|Oral Glucose Tolerance Test|Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.
76067246|NCT05721690|Device|Glidescope Videolaryngoscopy|Tracheal Intubation with Glidescope Titanium videolaryngoscope
76067247|NCT05716087|Drug|LP-168|Subjects to take LP-168 orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
76072262|NCT02286687|Other|Pharmacological Study|Correlative studies
76072263|NCT02286687|Drug|Talazoparib|Given PO
75455981|NCT01766622|Drug|[18F]-CP18|7mCi, IV (in the vein) at baseline
75455982|NCT01766622|Procedure|PET/ CT|At baseline, Within 3 days after the initial Birinapant dose, A third [18F]-CP18 PET/CT will be obtained within 3 days following cycle 2, day 15 Birinapant therapy
75455983|NCT01766661|Procedure|Hand-sewn coloanal anastomosis|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as hand-sewn coloanal anastomosis with protective loop ileostomy.
75455984|NCT01766661|Procedure|Two staged Turnbull-Cutait procedure|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as two staged Turnbull-Cutait procedure anastomosis without protective ileostomy.
75455985|NCT01766661|Procedure|Ultralow anterior rectal resection with total mesorectal excision|Standard ultralow anterior rectal resection with total mesorectal excision
75455986|NCT01766674|Behavioral|Kyphosis spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
76072264|NCT02270658|Device|CPAP|
75753133|NCT00498602|Other|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
75753134|NCT00498602|Biological|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
75901430|NCT03617757|Diagnostic Test|HbA1c|2mL blood will be taken for analysis of HbA1c.
75753135|NCT00507728|Drug|Bupropion|Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
75607323|NCT02825719|Other|Placebo pills|Placebo pills will be prescribed
75607324|NCT02825719|Drug|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
75455987|NCT01766687|Dietary Supplement|Hydration|
75455988|NCT01766700|Behavioral|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
75607325|NCT02825719|Drug|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
75753136|NCT00507728|Drug|Varenicline|Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
75753137|NCT00507728|Drug|Placebo|Placebo by mouth for 12 weeks.
75753138|NCT00507728|Behavioral|Smoking Cessation Counseling|Counseling over 8 months and telephone support calls.
75455989|NCT01766700|Behavioral|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
75607326|NCT04241653|Procedure|Pressure Support Ventilation|Ventilator will be adjusted to administer pressure at 10 cmH2O.
75753139|NCT00498368|Drug|Intravenous Rituximab|"Rituximab Therapy [27 Patients]~Rituximab 1 gm IV on Treatment Day 1~Rituximab 1 gm IV on Treatment Day 15~Rituximab 1 gm IV on Treatment Day 168~Rituximab 1 gm IV on Treatment Day 182"
75753140|NCT00498368|Drug|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of <130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
75901431|NCT03489824|Procedure|modified- WIM colonoscopy|Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
75901432|NCT03543696|Radiation|Single Dose Radiotherapy (SDRT)|
75901433|NCT03615261|Behavioral|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy & attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing & strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
75455990|NCT01766752|Device|GlucoTab System|Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
75607327|NCT04241653|Procedure|Unparalyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.
75607328|NCT04241653|Procedure|Paralyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.
75607329|NCT04241653|Device|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.
75607330|NCT04241653|Drug|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.
75753141|NCT00498368|Dietary Supplement|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
75753142|NCT04460066|Drug|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
75753143|NCT04460066|Drug|albumin bound paclitaxel|Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
75753144|NCT04460066|Drug|cisplatin|Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
75901434|NCT02148744|Biological|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
75901435|NCT02148744|Biological|Placebo|
75753145|NCT04460066|Drug|placebo|Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
75753146|NCT04460066|Procedure|radical resection of esophageal carcinoma|Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
75753147|NCT00385671|Drug|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
75753148|NCT00385671|Drug|pregabalin|Pregabalin (PGB) orally (PO)
75901436|NCT01632644|Other|Survey/Interview|Each group will be surveyed and interviewed.
75901437|NCT05034510|Device|Deep Brain Stimulation|modification in stimulation parameters
75901438|NCT03488810|Other|Radiation Therapy|Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
75901439|NCT03488810|Drug|Apalutamide|240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
75901440|NCT03488810|Drug|Luteinising Hormone Releasing Hormone analog agonist (LHRHa)|2 injections of a three-monthly LHRH agonist depot
75455991|NCT01766765|Procedure|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
75753149|NCT00385671|Drug|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
75901441|NCT03488810|Drug|Non-steroidal anti-androgen|Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
76067248|NCT05700331|Procedure|Fecal Microbiota Transplantation|"FMT performed at week 0, week-2 and week-4: FMT solution will be prepared using stool from a single donor or mixing of stool from multiple donors. Feces will be diluted with sterile saline (0.9%). This solution will be blended and strained with filter. The resulting supernatant will then be used directly as fresh FMT solution or stored as frozen FMT solution for future FMT.~Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.~2 study biopsies in total (from duodenum) will be obtained during FMT infusion via OGD."
75901442|NCT03615027|Behavioral|Dementia-specific advance care planning|see detailed description
75901443|NCT02254746|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
75901444|NCT03492242|Drug|Immune checkpoint inhibitor|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
75901445|NCT03572283|Drug|Bethanechol|Supplied as 50mg oral tablets. Take 2 tablets (total 100mg) twice daily from day 1 for a minimum of 1 week and a maximum of 4 weeks (or 2 days prior to scheduled surgery). Medication should be taken 1 hour before meals in the morning and the evening. Although bethanechol is FDA approved, in this study its use is experimental.
75901446|NCT02254824|Drug|Xuezhikang|Xuezhikang
76067249|NCT05700331|Procedure|Sigmoidoscopy|Optional sigmoidoscopy will be done at week 0 and week 4, during which 2 study biopsies in total (obtained via sigmoidoscopy) will be obtained from the rectum.
76067250|NCT05690698|Drug|Quatiapine|Atypical antipsychotic
76067251|NCT05690698|Drug|Haloperidol|Antipsychotic
75455992|NCT01766765|Other|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
75455993|NCT01766791|Other|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM
75455994|NCT01766791|Other|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - < 75 1RM
75455995|NCT01766791|Other|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM and Protein Supplementation
75455996|NCT01766791|Other|Control|control group, no intervention, maintenance of physical activity
75455997|NCT01766804|Dietary Supplement|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
75455998|NCT01766804|Dietary Supplement|placebo|
75607331|NCT05199961|Behavioral|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
75607332|NCT04241731|Drug|Raltitrexed|Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
75607333|NCT04241731|Drug|Cetuximab|Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
75901447|NCT02254824|Drug|Atorvastatin|Atorvastatin
75901448|NCT02254824|Behavioral|Lifestyle modification|Lifestyle modification
75901449|NCT03617601|Diagnostic Test|MET|Testing of the metabolic equivalent of task before aortic procedure
75901450|NCT01525316|Dietary Supplement|Bovine Lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
76067252|NCT05687695|Other|backward walking program|six weeks of backward walking program at self selected speed for 30 minutes 3 times per week
76067253|NCT05687695|Other|core training|six weeks of core training program including curl up, lateral plank on both sides, bird dog exercises done 3 times per week
76067254|NCT05686278|Device|Bipolar i and cemented stem (Océane+ or Meije)|Hip hemiarthroplasty is a surgical procedure that involves replacing half of the hip joint
75455999|NCT01766830|Device|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
75456000|NCT01766830|Device|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
75456001|NCT01766830|Device|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
75607334|NCT02829073|Device|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
75753150|NCT00497198|Drug|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
75753151|NCT00497198|Drug|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
75753152|NCT00496964|Drug|Botulinum toxin A + exercise|Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
75753153|NCT00496964|Drug|Placebo|Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
76067255|NCT05661695|Device|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
76067256|NCT05661123|Other|Complete decongestive therapy|"Education.~Skin care .~Pneumatic compression device .~Manual lymph draining .~Multilayer short stretch compression bandages.~Exercises."
75607335|NCT02829073|Device|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
75753154|NCT05076578|Device|Autologous Regeneration of Tissue (ARTTM) system|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
75753155|NCT01011062|Procedure|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
75607336|NCT02824159|Other|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
75607337|NCT02824159|Other|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
75753156|NCT01011062|Drug|Losartan|Acute administration of losartan 200mg total prior to clamp
75607338|NCT02824159|Other|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
75901451|NCT01525316|Dietary Supplement|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
75901452|NCT03616665|Other|CBASPersonalized|"In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.~Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented."
75607339|NCT02824159|Other|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
75607340|NCT02824159|Genetic|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
75901453|NCT03488732|Device|Transcatheter valvular repair or replacement|Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
75901454|NCT01673386|Drug|Tivozanib|
75901455|NCT01673386|Drug|Sunitinib|
75901456|NCT00103740|Drug|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
75901457|NCT00103740|Drug|placebo to zoledronic acid|5 mL of sterile water for infusion
75901458|NCT00103740|Drug|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
75901459|NCT00103740|Drug|Placebo to risedronate|oral capsules
75607341|NCT02824159|Genetic|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
75607342|NCT02824159|Other|Biological statement|"The following parameters will be assessed :~Complete blood count~Hemoglobin~Hepatic enzymes~Creatinine clearance~Lactate dehydrogenase rate~Total bilirubin rate~Cluster of differentiation 4 T lymphocytes rate~Total gamma-globulins rate"
75607343|NCT02824159|Other|Clinical examination|"The clinical examination are composed by :~Weigh, Height and body mass index measurement~Clinical state of patient during examination~Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~Presence of B symptomatology~Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
75607344|NCT04241887|Procedure|thoracic paravertebral blockade|Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.
75901460|NCT00103740|Drug|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
75901461|NCT03131804|Other|Intradialytic aerobic low intensity exercise|Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
75607345|NCT04241887|Procedure|local anaesthesia|Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
75753157|NCT01011062|Drug|Saline|Infusion of Saline as a volume control intervention
75753158|NCT01016366|Drug|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
75753159|NCT01016366|Drug|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
75753160|NCT03996980|Device|Custom-made foot orthoses Versus a flat insole|Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
75753161|NCT00490490|Drug|Bexxar (tositumomab)|Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.
75901462|NCT03616509|Drug|Growth hormone|12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
75901463|NCT03616509|Drug|Placebo|2 months on placebo, sodium chloride 0,9% injections
76067257|NCT05650749|Biological|GPC2 CAR T cells|The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.
75753162|NCT00490490|Procedure|External beam radiotherapy (XRT)|Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.
75607346|NCT05660005|Other|Muscle Stretching|Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.
75753163|NCT00490490|Drug|Potassium Iodide (KI)|"Potassium iodide (KI) will be administered as:~Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~Lugol's solution 20 drops orally 3-times-a-day, OR~KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab"
75753164|NCT04431830|Behavioral|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants manage pain so that they can engage with what gives them a sense of meaning, purpose, and significance in life.
75753165|NCT04420364|Other|Maintenance or reduction of immunosuppression|Maintenance versus reduction of immunosuppression
75753166|NCT01014884|Other|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
75901464|NCT03488654|Diagnostic Test|Cardiovascular magnetic resonance|CMR including cine, late gadolinium enhancement (LGE) and stress perfusion sequences
75753167|NCT01014884|Other|Multidisciplinary team bimonthly visits either in person or via telephone.|
75753168|NCT01014884|Other|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
75753169|NCT01011140|Behavioral|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
75901465|NCT03616353|Procedure|Perineural Hydrodissection|The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.
75901466|NCT03616353|Procedure|Corticosteroid Injection|The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.
76067258|NCT05640843|Other|Whole Foods Plant-based Diet|"The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing.~Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a health coach daily. Patients will also receive dietary education and counselling from a research dietitian every 4 weeks for the 12-week intervention period. They will have access to the team for questions and support as needed"
76067259|NCT05640843|Dietary Supplement|Algae omega 3|Algae omega 3 given twice daily.
76067260|NCT05640843|Other|Placebo supplements|Placebo supplements given twice daily.
75753170|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
75753171|NCT01014962|Drug|Placebo|Placebo oral once daily for 5 days
75753172|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
75753173|NCT01014962|Drug|Placebo|Placebo oral every 12 hours for 5 days
75753174|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
75753175|NCT01014962|Drug|Placebo|Placebo oral every 8 hours for 5 days
75753176|NCT05058248|Procedure|pudendal block|general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco
75753177|NCT05049980|Drug|Medical treatment with Mifégyne® and MisoOne®|When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
75753178|NCT05049980|Procedure|Endo-uterine aspiration|When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.
75753179|NCT01039779|Behavioral|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
75753180|NCT01016522|Dietary Supplement|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
75753181|NCT00385593|Drug|Symbicort (budesonide/formoterol) Turbuhaler|
75753182|NCT00385593|Drug|Conventional treatment|
75753183|NCT01015040|Drug|solifenacin succinate suspension|Oral
75901467|NCT03488576|Procedure|Complete Macular Peeling|A complete peeling of the internal limiting membrane was performed
75901468|NCT03488576|Procedure|Macular Peeling with Foveal Sparing|A partial peeling of the internal limiting membrane was performed, sparing the fovea.
75901469|NCT03094858|Device|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
75607347|NCT05660005|Other|Self Myofascial Release|The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).
75607348|NCT05660005|Other|home exercises|The exercise brochure consists of 5 different exercises that include isometric and isotonic strengthening of the hip and surrounding muscles. Isometric contraction of gluteus maximus, hip march, external/internal rotation of hips with theraband, 4 sided straight leg raises were the exercises and prescribed 5 days a week, 10 repetitions, 3 sets. All participants were advised to use analgesics determined by the physician in case of unbearable pain and to apply a hot pack for 10-20 minutes before sessions.
75607349|NCT04242745|Behavioral|Intervention group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.~A Beyid wristwatch was used. This spoke the time in Turkish, every hour on the hour. In this way, the old people were reminded to drink a glass of liquid each hour. The watch had an alarm capability, and could be taken on to sleep mode at night in order not to wake the old people."
75753184|NCT01015040|Drug|solifenacin succinate tablet|Oral
75901470|NCT03094858|Device|Wristband|Wristband will monitor activity of all participants
75901471|NCT03094858|Device|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
75901472|NCT03746730|Device|ultrasound|gray scale and doppler ultrasound
75901473|NCT01281644|Device|Diode Laser|810 nm diode laser
75901474|NCT02869893|Drug|Secretin|
75901475|NCT00202826|Procedure|Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage|
75901476|NCT03616275|Other|HRV biofeedback|HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
75607350|NCT04242745|Behavioral|Control group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes."
75607351|NCT02825875|Drug|18F DCFPyL- Radiopharmaceutica|
76067261|NCT05636189|Procedure|warming during induction of anesthesia|Warming group patients are applied air-forced warming device (bair-hugger 43'C) with blanket (warm touch, COVIDIEN, full body blanket) during induction of anesthesia in the operation room.
75753185|NCT04388618|Other|NHANES smell and taste tests|participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
75753186|NCT01039857|Behavioral|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy|
75753187|NCT01039857|Behavioral|Integrative Neuro-Psychotherapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
75753188|NCT00495794|Behavioral|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
75753189|NCT01011296|Drug|PF-04427429|Single 0.2mg dose of intravenous infusion
75753190|NCT01011296|Drug|PF-04427429|Single 1mg dose of intravenous infusion
75901477|NCT05119790|Drug|[14C] BIIB122 ([14C] DNL151)|Oral dose
75901478|NCT05050786|Device|Negative Wound Pressure Therapy (Prevena(TM))|After skin closure, NPWT in the form of Prevena™ (KCI/Acelity, San Antonia, TX, USA) is applied using the following technique: The sterile foam dressing is removed from the package and placed on the incision in the entire length, on top of which the sterile dressing is placed, ensuring air tightness. An appropriate hole in the dressing is cut at the center of the dressing and the tube for the interface pad is connected and a negative pressure of 125mmHg is applied. The Prevena™ system is removed on the morning of postoperative day 3.
75901479|NCT05050786|Other|Standard Wound Dressing|After skin closure, a standard operative dressing is applied in the entire length of the incision. This operative dressing is removed in the morning of postoperative day two. Only in the case of blood or serous fluid mandating changing of the dressing, will this be done prior to postoperative day 2.
75901480|NCT03614871|Other|Epidemiological study|
75901481|NCT02152332|Drug|JNJ-54861911-Therapeutic Dose|JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
75901482|NCT02152332|Drug|JNJ-54861911 - Supratherapeutic Dose|JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
75901483|NCT02152332|Drug|JNJ-54861911-Matched Placebo|JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
75901484|NCT02152332|Drug|Moxifloxacin|Moxifloxacin 400 mg on Day 7 in all treatment sequence.
75901485|NCT02152332|Drug|Moxifloxacin Matched Placebo|Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
76067262|NCT05636189|Procedure|Prewarmed intravenous fluid administration|Prewarmed intravenous fluid is connected.
76067263|NCT05635045|Drug|I 124-Evuzamitide|Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
76067264|NCT05629611|Device|Vi-Sealer|using Reusable device, Vi-Sealer
76067265|NCT05629611|Device|Ligasure|using Ligasure
75607352|NCT02828995|Other|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:~The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
75753191|NCT01011296|Drug|PF-04427429|Single 3 mg dose of intravenous infusion
75753192|NCT00495170|Drug|Carboplatin|2 area under curve (AUC) by vein Weekly
75753193|NCT00495170|Radiation|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
75753194|NCT00495170|Drug|Paclitaxel|50 mg/m^2 by vein Weekly
75607353|NCT02825485|Procedure|Voiding cystourethrogram|
75607354|NCT02825563|Drug|Anlotinib|in the fasting state
75901486|NCT03488498|Other|questionnaires|Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
75901487|NCT05050708|Other|Patient interview|Patient will be interviewed pre-operatively and at 24 hrs post-opartively
75901488|NCT03492086|Dietary Supplement|Dietary supplementation with capsules containing rosemary and alkylglycerol|
75901489|NCT03492086|Dietary Supplement|Dietary supplementation with control capsules|
75901490|NCT03616197|Procedure|free gingival graft|A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.
76067266|NCT05629611|Device|Other AHD|Using other AHDs such as Thunderbeat, Harmonic scalpel, Caiman®, Enseal, etc. except Ligasure
75607355|NCT02825563|Drug|Anlotinib|in the high fat diet
75607356|NCT02825797|Drug|3BNC117|Intravenous infusion of 3BNC117
75607357|NCT02825797|Drug|10-1074|Intravenous infusion of 10-1074
75607358|NCT02825797|Other|Analytical treatment interruption|Analytical treatment interruption
75607359|NCT02825797|Drug|Placebo|Intravenous infusion of placebo (sterile saline)
75753195|NCT03853148|Behavioral|Otago|Exercise program for strength and balance
75753196|NCT03853148|Behavioral|Gentle yogic breathing|yogic breathing
75607360|NCT04241497|Behavioral|Home-based rehabilitation|1 supervised exercise session at the hospital; 3 weeks of supervised home-based exercise training (3x/week); 9 weeks of unsupervised home-based exercise training (3x/week)
75607361|NCT02824315|Drug|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
75607362|NCT02824315|Drug|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
75607363|NCT02824315|Drug|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
75753197|NCT03853148|Behavioral|Behavioral Activation|Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
75753198|NCT03853148|Behavioral|Caregiver Gentle yogic breathing|yogic breathing
75753199|NCT01011374|Drug|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
75753200|NCT04369976|Device|ARTIFICIAL GRAVITY COMBINED WITH EXERCISE|The passive control group will abstain from any exercise. Recordings of the participant's will include cardiovascular functioning cardiac output (CO), stroke volume (SV) mean arterial pressure (MAP) diastolic blood pressure (DBP), systolic blood pressure (SBP), and heart rate (HR), Electroencephalography ( EEG) as well as dynamic force and stance and muscle oxygenation. More specifically, after 6 training sessions (2 weeks), the centrifugation load will be increased and will be combined with either aerobic exercise (through an ergometer) or resistance training through elastic training bands. Functional connectivity and cortical-network features will be used by deep learning algorithms in order to define the optimal centrifuge training .
75753201|NCT00385203|Drug|AZD2171|45 mg oral tablet once daily dose
75901491|NCT05050630|Drug|TR2-ICE|Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
75901492|NCT05118308|Procedure|Transjugular hepatic venous pressure gradient measurement with liver biopsy|This procedure will be performed by an experienced interventional radiologist who will be supported by a radiology technician and nurse. Transjugular hepatic venous pressure gradient measurement will be performed using standard procedure. Following this, a transjugular liver biopsy will be obtained using an 18-gauge transjugular liver biopsy needle.
76067267|NCT05627349|Device|wrist splinting|standard wrist splinting at night for 2 weeks
75607364|NCT00633529|Drug|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
75753202|NCT01043601|Drug|Inhaled PT005|inhaled, twice daily for 1 week duration
75607365|NCT02823613|Dietary Supplement|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
75901493|NCT05118308|Procedure|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy|A linear echoendoscope is inserted with the patient under conscious sedation. Using a through the scope 25-gauge needle connected to a digital manometer, portal and hepatic veins will be punctured under EUS guidance from a trans-gastric/hepatic approach. Following this, EUS-Liver biopsy is then performed immediately following EUS-PPG using a 19-gauge fine needle biopsy (FNB).
75607366|NCT02823613|Dietary Supplement|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
75901494|NCT03617289|Drug|Magnesium Sulfate|
75901495|NCT03617289|Drug|D5W|
75901496|NCT05050552|Device|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
75607367|NCT02824081|Biological|Blood sample|Blood sample in order to study inflammatory biomarkers and genetics purpose
75607368|NCT04242433|Drug|Direct Acting Antivirals|"All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent."
75901497|NCT02152410|Device|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
75901498|NCT02152410|Drug|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS> 30).
75901499|NCT02236845|Device|Lacrima Medical Device and sham comparator|
75901500|NCT05050396|Procedure|Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis|Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). [16, 17] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation [20]
75607369|NCT02825407|Dietary Supplement|Oral physiology|
75901501|NCT03615963|Diagnostic Test|echocardiography and coronary angiography|transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease
75607370|NCT04242511|Diagnostic Test|Measurement of tuberculosis medications level|Measurement of tuberculosis medication levels at 2 hours post-dose
75901502|NCT05043688|Drug|SHR-1210|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: immunotherapy combined with neoadjuvant chemotherapy, immunotherapy combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
75607371|NCT02825173|Device|Seal-G|"Intervention:~Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques"
75753203|NCT01043601|Drug|Inhaled Placebo|inhaled, twice daily for 1 week duration
75901503|NCT03615885|Dietary Supplement|Montmorency Tart Cherry Capsules|Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
75901504|NCT03615885|Dietary Supplement|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
75901505|NCT03615885|Dietary Supplement|Placebo|"130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
75901506|NCT03614715|Drug|Interferon Beta-1A|A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
76072265|NCT02248701|Drug|Testosterone Enanthate|Subjects receive testosterone (125 mg/week) by intramuscular injection
76072266|NCT02248701|Drug|Finasteride|Subjects receive finasteride (5 mg/day) orally
76072267|NCT02248701|Drug|Placebo injection|Subjects receive placebo (weekly) by intramuscular injection
75607372|NCT02825329|Device|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
75753204|NCT01043601|Drug|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
75753205|NCT01043679|Drug|Utapine|Efficacy and Safety of Utapine
75607373|NCT02823925|Drug|Pamidronate or Zoledronate|
75753206|NCT01043679|Drug|Seroquel|Efficacy and Safety of Seroquel
75753207|NCT00408993|Drug|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
75753208|NCT00408993|Drug|Placebo|Placebo every day (QD), by mouth (PO)
75753209|NCT00395967|Drug|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
75607374|NCT05659771|Behavioral|Food properties manipulation to alter eating behavior and food and energy intake|Food properties of commercially available food products
75607375|NCT04242589|Radiation|Radiotherapy|External beam radiation therapy is a type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays from outside the body into tumor
75901507|NCT05131802|Device|upper GIT endescopy|Gastric mucosa alterations as erythema, bile existence in the stomach, gastric folds thickening, erosions, and petechiae were also recorded (Olympus single-channel CLK-4). Multiple biopsies were taken from gastric mucosa for histopathological study. Via Triple Lumen ERCP Cannula, 5 mL of gastric fluid was aspirated through the suction channel of the endoscope and collected in a sterile trap placed in the suction line, to be sent for analysis. Quantitative determination of gastric aspirate total bilirubin level was performed (Gen.3® kit and Cobas 8000 analyzer). The pH monitoring of gastric aspirate was performed during the gastroscopy just after collection with a glass electrode pH meter (Adwa®).
75901508|NCT00363038|Drug|Petrolatum United States Pharmacopeia (USP)|Topical formation applied to bruise twice daily for 2 weeks.
75901509|NCT00363038|Drug|Vitamin K and retinol ointment|Topical formation applied to bruise twice daily for 2 weeks.
75901510|NCT00363038|Drug|Arnica ointment|Topical formation applied to bruise twice daily for 2 weeks.
75901511|NCT00363038|Drug|Vitamin K ointment|Topical formation applied to bruise twice daily for 2 weeks.
76072268|NCT02248701|Drug|Placebo pill|Subjects receive placebo pill (daily) orally
75607376|NCT04242589|Procedure|Vertebropladty|Vertebroplasty is a procedure for stabilizing compression fractures in the spine. Bone cement is injected into vertebrae that have cracked or broken. The cement hardens, stabilizing the fractures and supporting your spine.
75607377|NCT04201249|Drug|Piroxicam, lidocaine|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
75753210|NCT03993093|Other|CD4 cell count|CD4 cell count from treatment naive HIV patients
75753211|NCT00395733|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
75753212|NCT00395733|Drug|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
75753213|NCT00441987|Drug|GSI-953|
75456002|NCT01766830|Device|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
75753214|NCT00395343|Drug|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
75456003|NCT01766830|Device|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
75753215|NCT00395343|Drug|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
75753216|NCT00560573|Drug|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
75753217|NCT00560573|Drug|Cisplatin|"Cisplatin 75* mg/m2 or 80* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
75753218|NCT00560573|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
75753219|NCT00560573|Drug|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
75753220|NCT00950105|Drug|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
75901512|NCT03614637|Other|Cannabis use abstinence for 11 weeks|Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
76072269|NCT02224261|Other|Physical Therapy protocol|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords, and patient education."
76072270|NCT02224261|Other|Control|Control protocol includes standard progressive active and action-assisted arm exercises & patient education.
75456004|NCT01766830|Device|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
75753221|NCT00946283|Dietary Supplement|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
75753222|NCT00946361|Other|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
76072271|NCT02204982|Drug|Duvelisib|PI3K Inhibitor
75753223|NCT00946439|Device|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
75753224|NCT00941837|Dietary Supplement|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
75753225|NCT00946517|Other|Questionnaires|Parenting and behavioral questionnaires
75753226|NCT00950261|Radiation|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
75753227|NCT05280197|Procedure|TAP block|Transversus abdominis plane (TAP) nerve block with liposomal bupivacaine plus free bupivacaine
75753228|NCT05280197|Procedure|TAP block|Transversus abdominis plane (TAP) nerve block with normal saline
75901513|NCT04876352|Other|Upper limb/handwriting exercises in an immersive virtual reality setting (VR-training)|"Progressively difficult multimodal physiotherapy under the augmented visual feedback induced by the VR. Participants will wear a head-mounted display and their upper limb movements during the training will be captured by a motion tracker. Patients will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) under the augmented visual feedback provided by the use of VR in increasingly wide range of movement; active upper limb multi-joints movements under the augmented visual feedback provided by the use of VR (following trajectories designed in the virtual space - movement involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage in VR context on a tablet and a smartphone.~30 minutes of exercises, 2 times a week, for 8 weeks."
76072272|NCT02204982|Drug|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
76072273|NCT02204982|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
76072274|NCT02184663|Other|without APA program|Control Arm : chemotherapy alone
75607378|NCT04201249|Device|Mesotherapy without drug administration|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
75607379|NCT00633685|Drug|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
75607380|NCT00633685|Drug|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
76072275|NCT02184663|Other|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
75607381|NCT02823691|Drug|Lanreotide and Metformin|Lanreotide and Metformin
75607382|NCT04888195|Other|Questionnaire|Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
75607383|NCT02825095|Procedure|Talc Pleurodesis|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
75607384|NCT02825095|Procedure|Indwelling Pleural Catheter|Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
75607385|NCT02825095|Procedure|chest ultrasound|All insertion of a chest drain will be guided by ultrasound
75753229|NCT05280197|Drug|liposomal bupivacaine plus free bupivacaine|TAP block using liposomal bupivacaine plus free bupivacaine
75753230|NCT05280197|Drug|normal saline|TAP block using normal saline
75753231|NCT00946595|Drug|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
75753232|NCT00946595|Drug|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
75753233|NCT00942071|Biological|MVA-NP+M1|1. Intradermal injection at 5 x 10^7 pfu at day 0
75753234|NCT00942071|Biological|MVA-NP+M1|2.Intramuscular injection at 5 x 10^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10^8 pfu/ml at day 0
75753235|NCT00942071|Biological|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
75753236|NCT03961529|Drug|0.3% OPA-15406 ointment|Twice daily
75753237|NCT03961529|Drug|1% OPA-15406 ointment|Twice daily
75901514|NCT04876352|Other|Upper limb/handwriting exercises in a real setting (RS-training)|"Participants will perform progressively difficult multimodal physiotherapy in a real setting. Participants will be encouraged to perform their upper limb movements during the training in order to perform faster and ampler movements. They will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) in increasingly wide range of movement under the feedback provided by therapist; active upper limb multi-joints movements under the feedback provided by the therapist (following trajectories designed on a table or on a blackboard - movements involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage under the supervision of the therapist.~30 minutes of exercises, 2 times a week, for 8 weeks."
75901515|NCT04876352|Other|No intervention|Only baseline evaluations, without longitudinal assessment
76067268|NCT05627349|Device|FSN|FSN is a single-use disposable needle(Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.). The needle body is solid, and covered with a plastic tube. The needle penetrates the skin with insertion device. Under the guidance of ultrasound, the needle enter the loose subcutaneous layer obliquely without penetrating into the muscle. This is the difference from traditional acupuncture. The insertion point is midpoint of the anterior forearm. The needle tip is toward the carpal tunnel. After the needle is inserted, SM and RA are performed. The frequency of SM is 200 times in two minutes. The method of SM is to make a horizontal fan swaying with the base of the needle as the fulcrum. RA is performed while SM-slowly make a fist for 10 seconds and then relax for 5 seconds. Eight times of RA in two minutes. After the FNS treatment, the needle was withdrawn.
76067269|NCT05626998|Drug|Dexmedetomidine|The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward.
75901516|NCT03489668|Drug|MetFORMIN 500 Mg Oral Tablet|metformin administration 1500mg per day
75753238|NCT00494780|Drug|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
75753239|NCT00494780|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
75456005|NCT01766830|Device|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
75456006|NCT01766830|Device|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
75456007|NCT01766830|Device|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
75607386|NCT02825095|Drug|Local anesthesia|Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
75607387|NCT02825095|Procedure|Chest Tube|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
75607388|NCT04241263|Device|Wireless vital sign monitoring - comparative|Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.
75607389|NCT04241263|Device|Wireless vital sign monitoring - usability|Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
75753240|NCT00494780|Drug|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
76067270|NCT05626998|Drug|Gabapentin|The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
75456008|NCT01766830|Device|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
75456009|NCT01766843|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
75456010|NCT01766843|Drug|Seretide Diskus|2 inhalations as a single dose
75456011|NCT01766843|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
75456012|NCT01766843|Drug|SF Easyhaler|2 inhalations as a single dose
75456013|NCT01766856|Other|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
75753241|NCT00494780|Drug|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
75753242|NCT00494780|Drug|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
75753243|NCT01011452|Drug|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
75607390|NCT02823535|Behavioral|Iwin: Individual Well-Being Navigator|Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
75753244|NCT01011452|Drug|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
75753245|NCT00490022|Drug|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
75901517|NCT02872311|Biological|High Dose Influenza vaccine|Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
75901518|NCT02872311|Biological|Adjuvanted Influenza vaccine|Licensed and FDA approved FluAd vaccine to be administered to study participants
75901519|NCT02872311|Biological|Standard Dose Influenza vaccine|Licensed and FDA approved Fluvirin vaccine to be administered to study participants
75901520|NCT02872311|Biological|Recombinant Influenza vaccine|Licensed and FDA approved FluBlok vaccine to be administered to study participants
75901521|NCT04461470|Genetic|epigenetic longitudinal waves|force - inducing energies using electromagnetic field(s)
75901522|NCT05120336|Device|transcutaneous vagus nerve stimulation|Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
75901523|NCT05120336|Device|sham stimulation|Sham procedure for active transcutaneous vagus nerve stimulation
75607391|NCT02823379|Behavioral|Physical Activity|A Smartphone delivered physical activity program
75607392|NCT02823379|Behavioral|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
75607393|NCT02825017|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm*2 test application.(Formulation-SR15-79_Y73-161)
75607394|NCT02824939|Other|Transversus Abdominis Plane (TAP) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
75607395|NCT02824939|Other|Quadratus Lumborum (QL) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
75607396|NCT04195009|Procedure|major surgery under opioid free anesthesia without regional anesthesia|measuring nociception in every patient but blinded for attending anesthesiologist
75753246|NCT00490022|Drug|Placebo gel|Placebo gel for one month
75753247|NCT01011530|Drug|MLN4924|Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
75753248|NCT00493454|Drug|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
75753249|NCT00493454|Drug|Rituximab|250 mg/m^2 IV Over 6 to 8 Hours
75753250|NCT00493454|Drug|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
75753251|NCT00493220|Drug|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
75753252|NCT00493220|Drug|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
75901524|NCT03488342|Procedure|Repair for primary inguinal hernia|Repair for primary inguinal hernia
75901525|NCT03614403|Drug|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
75901526|NCT04461314|Behavioral|peer-led counselling|"About 50 university students will be trained as peer counsellors through a structured training programme. A pre and post and 6-month self-administered questionnaire will be conducted before, immediately and 6-month after the training programme to examine their changes of knowledge and attitudes. A satisfaction survey will also be conducted to measure participants' perception of the quality of the training programme.~Drug-abusing youth and young adults will receive telephone-based, Peer-led Brief Motivational Interviewing (BMI) counselling to rehabilitate from drug abuse. The peer counsellors will give referral advice if the youth and young adult needs appropriate treatment and rehabilitation services.~The drug abusers will be counselled and invited to complete the follow-up questionnaires at 1 week, 1 month, 3 months, 6 months, 9 months and 1 year. Self-reported quitters at 6-month and 1-year follow-ups will be invited to have a urine test to validate the drug abuse abstinence."
75607397|NCT05660083|Drug|L-NMMA|Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
75753253|NCT00493220|Drug|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
75753254|NCT00950339|Drug|omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
75753255|NCT00950339|Drug|famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
75901527|NCT02871375|Device|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
75901528|NCT02871375|Device|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
76067271|NCT05620225|Device|Axon Therapy and CMM|transcutaneous magnetic stimulation (TMS)
76067272|NCT05620225|Device|Sham and CMM|Sham and CMM
75456014|NCT01766882|Behavioral|Lower sodium intervention|"1. Lower sodium intervention:~Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately >180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants."
75607398|NCT02824549|Device|FreeStyle Libre Flash Glucose Monitoring|
76067273|NCT05607121|Device|intermittent theta burst stimulation|transcranial magnetic stimulation
76067274|NCT05607121|Device|continuous theta burst stimulation|transcranial magnetic stimulation
76067275|NCT05597839|Drug|DF9001|Immunotherapy agent targeting NK cells.
76067276|NCT05597839|Drug|Nivolumab|Anti-PD-1 immunotherapy agent
75901529|NCT04691414|Genetic|NGS|next-generation sequencing on preexisting samples
75901530|NCT02032017|Procedure|Ceramic on ceramic couple|All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
75901531|NCT02032017|Procedure|Percutaneous assisted approach|
75901532|NCT02032017|Procedure|Anterolateral approach|
75607399|NCT02824705|Procedure|Congenital Heart Disease Surgery|Stool and blood sample collected prior to surgical intervention for congenital heart disease; stool and blood samples then collected in days following cardiac intervention.
75607400|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
75901533|NCT02032017|Other|Usual care|Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
75901534|NCT03492008|Other|Conventional technique|Nasogastric tube insertion with patient's head in neutral position
75901535|NCT03492008|Other|Contralateral cricothyroid pressure|Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.
76067277|NCT05583292|Other|ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.
76067278|NCT05583292|Other|SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.
75753256|NCT00950339|Drug|pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
75607401|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
75753257|NCT00942227|Other|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
75901536|NCT03492008|Other|Ipsilateral head turning|Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
75901537|NCT03488186|Drug|Lansoprazole Capsules|24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
75901538|NCT05103644|Drug|Atorvastatin 80mg|patients received statin experimental group
75901539|NCT05103644|Other|placebo|patients received placebo control group
75901540|NCT03614325|Other|Virtual Reality Immersive Relaxation|The software developed by VRHealth allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
76067279|NCT05583292|Other|Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity
76067280|NCT05582174|Drug|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
76067281|NCT05582174|Drug|esomeprazole|A high dose PPI infusion (esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours), and frorm day 4-30 oral esomeprazole daily
75753258|NCT00942227|Other|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
75753259|NCT01011608|Other|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
75753260|NCT01011608|Other|standard hospital food|standard hospital diet ad. lib.
75753261|NCT00950417|Drug|Nimotuzumab|
75753262|NCT03996902|Behavioral|Tailored intervention|Brief motivational smoking intervention tailored to address smoking in the context of pain. Included a novel pain-smoking psycho education component, personalized feedback component, and elicitation of participant's pain-related goals to develop discrepancy between continued smoking and desired pain outcomes.
75901541|NCT03615651|Dietary Supplement|Probiotic|The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
75901542|NCT03615651|Other|Placebo|Placebo intervention.
75901543|NCT03491930|Device|VA MOVE! Coach app|The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.
75901544|NCT03491930|Behavioral|Telephone Coaching|Weekly Telephone Coaching
75753263|NCT03996902|Behavioral|Ask-Advise-Refer|The Ask-Advise-Refer intervention is commonly used in standard clinical practice.
75901545|NCT03491930|Behavioral|Standard of Care for weight loss.|"Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~Vioscreen food frequency assessment and bionutritionist consult.~Healthy eating nutritional pamphlets (during consult)~Decrease daily caloric intake by 500 cal/day~Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~Dietary counseling by Clinician (monthly)"
75753264|NCT00946673|Drug|Vorinostat|Orally up to 400 mg
75753265|NCT00946673|Procedure|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
75901546|NCT03614091|Procedure|Erector spinae plane block|20 ml Bupivacaine 0.5% below erector spinae muscle groups
75901547|NCT03614091|Procedure|Paravertebral plane block|20 ml Bupivacaine 0.5% between pleura and costotransverse ligament
75456015|NCT01766882|Other|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
75456016|NCT01766895|Other|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
75753266|NCT00394953|Drug|Darbepoetin alfa|As prescribed, iv.
75901548|NCT03887624|Drug|Ethosuximide|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
75901549|NCT03887624|Drug|Placebo|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
75901550|NCT03887624|Drug|Escitalopram|1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
75901551|NCT03614247|Procedure|Retrograde intrarenal surgery|The procedure was performed with the patient in the dorsal lithotomy position under general anesthesia. Firstly, diagnostic ureteroscopy was done with a 6/7.5 Fr semi-rigid ureteroscope (Richard Wolf, Knittlingen, Germany). A 0.035mm double-tipped sensor guidewire was placed to the renal pelvis. A 10/12 Fr ureteric access sheath (Cook Medical, Indiana, USA) was used. A 7.5 Fr flexible ureteroscope (Flex X2, Karl Storz, Tuttlingen, Germany) was used for the main procedure. The stones were fragmented using a Holmium:Yttrium Aluminum Garnet laser (272 microns). At the end of each procedure, a double-j ureteric catheter and urethral catheter were routinely placed.
76067282|NCT05578664|Drug|Pembrolizumab injection plus metastasis directed treatment (surgery or RT)|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
76067283|NCT05578664|Other|Tumor resection or RT|Tumor resection or RT will be applied within 42 days from randomization.
75456017|NCT01766908|Other|Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery|None to add
75753267|NCT00394953|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
75753268|NCT00946751|Drug|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
75753269|NCT00946751|Drug|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
75753270|NCT00485732|Biological|HPV-16/18 VLP/AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
75753271|NCT00485732|Biological|Placebo|Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
75753272|NCT00946829|Drug|telmisartan|
75753273|NCT00489554|Biological|Synflorix|Intramuscular injection, 3 doses.
75753274|NCT00489554|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
75753275|NCT00489554|Biological|Rotarix|Oral, 2 doses.
75753276|NCT00408681|Drug|lithium carbonate|Given orally
75753277|NCT00408681|Other|laboratory biomarker analysis|Correlative studies
75753278|NCT01040013|Procedure|Laparoscopy|Laparoscopic Left-Colectomy
75901552|NCT03614247|Procedure|Micro-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 4.8 Fr for micro PNL (PolyDiagnost, Pfaffenhofen, Germany). Stone fragmentation was carried out using laser in micro PNL. No nephrostomy was placed in any patient whom underwent micro PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
75901553|NCT03614247|Procedure|Ultra-mini PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 7.5 Fr for ultramini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using laser in ultramini PNL. No nephrostomy was placed in any patient whom underwent ultramini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
75901554|NCT03614247|Procedure|Mini-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 12 Fr for mini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in mini PNL. No nephrostomy was placed in any patient whom underwent mini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
75901555|NCT03614247|Procedure|Standard PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 24 Fr for standard PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in standard PNL. A nephrostomy was placed in all standard PNL patients at the end of the procedure
75901556|NCT03486002|Device|Cleansweep|The Cleansweep closed suction system
75456018|NCT01766947|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
75456019|NCT01766960|Other|High fat meal|A high fat breakfast will be administered to induce gall bladder emptying.
75456020|NCT01766960|Drug|Morphine|Five milligrams of intravenous morphine will be administered.
75456021|NCT01767012|Device|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
75456022|NCT01767012|Device|Polylens EC-Y10-PAL (uncoated)|
75456023|NCT01767025|Drug|Oxytocin|
75456024|NCT01767025|Drug|Sea water|
75456025|NCT01767038|Procedure|OCT Spectralis|
75753279|NCT01040013|Procedure|left colectomy by laparotomy|PatientS will be operated by laparotomy
75753280|NCT00560417|Drug|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
75753281|NCT00560417|Drug|Insulin Glargine|Administered subcutaneously once a day at bedtime
75753282|NCT01044927|Other|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
75753283|NCT01044927|Other|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
75901557|NCT03486002|Device|Halyard|Halyard Closed Suction System
75901558|NCT03489590|Drug|PFP|"Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
75901559|NCT02867709|Drug|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
75753284|NCT01040091|Drug|Emtricitabine (FTC)|200 mg once a day
75753285|NCT01040091|Drug|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
75901560|NCT02867709|Drug|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
75901561|NCT02446028|Drug|BIOD-531|
75901562|NCT02446028|Drug|Humalog® Mix 75/25|
75901563|NCT03485846|Drug|Narlaprevir|100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
75901564|NCT03485846|Drug|Ritonavir|100 mg, tablets, taken as 100 mg per os daily
75901565|NCT03485846|Drug|Daclatasvir|60 mg, tablets, taken as 60 mg per os daily
76067284|NCT05576493|Procedure|phaco+MP-TSCPC|The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
75456026|NCT01767038|Procedure|microperimetry|
75753286|NCT01040091|Drug|Efavirenz (EFV)|600 mg once a day
75753287|NCT01040091|Drug|Truvada|200 mg emtricitabine + 300 mg TDF once a day
75901566|NCT04461392|Diagnostic Test|Cardiorespiratory exercise test|"Cardiorespiratory exercise test to evaluate the exercise tolerance~Cardiac imaging for the assessment of the left atrium anatomy and function."
75901567|NCT04909671|Device|Gi Genius, Medtronic|GI geniusTM (Medtronic) is an artificial intelligence device designed and validated on a dataset of white-light endoscopy videos from high-quality randomized controlled trials for the detection of colorectal lesions during colonoscopy. Based on a deep learning system using convolutional neural networks, GI genius works in real-time side-to-side with the gastroenterologist during colonoscopy highlighting the presence of precancerous lesions with a visual marker (green box) in real time and designed to be integrated with the majority of colonoscopies.
75901568|NCT04909671|Other|White light standart colonoscopy|High definition white light endoscopy will be used during the scope withdrawal
75901569|NCT02032095|Drug|GB-0998|
75901570|NCT03614169|Procedure|Implantation of a HIS-pacing lead|This intervention is attempted first
75901571|NCT03614169|Procedure|Implantation of a LV-pacing lead|This intervention is attempted first
75901572|NCT03613857|Drug|Clopidogrel|8 tablets 75 mg clopidogrel loading dose before PCI
75456027|NCT01767077|Dietary Supplement|Butter oil|Daily intake of 40 g butter oil
75456028|NCT01767077|Dietary Supplement|Cream|Daily intake of 100 g cream (40%)
75456029|NCT01767090|Drug|ASP1707|Oral
75456030|NCT01767090|Drug|Placebo|Oral
75456031|NCT01767090|Drug|Leuprorelin acetate|subcutaneous
75456032|NCT01767168|Other|comprehensive preoperative testing for risk factors of persistent postoperative pain|nociceptive reflex threshold, pain threshold, CPM-effect of hot water bath, pain sensitivity questionnaire, STAI, BDI, fear of surgical consequences
75456033|NCT01767181|Other|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
75753288|NCT00950495|Device|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
75753289|NCT00950495|Device|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
75753290|NCT00950495|Device|placebo|as a placebo, a thin (< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
75753291|NCT00942461|Procedure|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
75901573|NCT03613857|Drug|Ticagrelor 90mg|2 tablets 90 mg brilique before PCI
75901574|NCT03613389|Dietary Supplement|oral topical vitamin E|Vitamin E is an antioxidant agent which may limit tissue damage from free oxygen radicals and, thus, may reduce the severity of mucositis during cancer treatments and protect cell membranes from radiation damage (Alterio et al., 2007). It has a very low toxicity and is generally well-tolerated (Geeraert et al., 2015).
75607402|NCT02824393|Biological|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
75753292|NCT00942461|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
75753293|NCT00946907|Drug|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
75753294|NCT00946907|Drug|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
75753295|NCT00942539|Drug|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
75901575|NCT03613779|Combination Product|LUS-guided therapy|Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment. If no congestion (less than 3 B-lines), low dose (0-40mg PO/day furosemide) will be prescribed until next follow up re-assessment
75901576|NCT03613779|Other|Standard of Care|Standard of care will be provided.
75901577|NCT03044353|Drug|GSK2315698 (CPHPC)|20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
75901578|NCT03044353|Biological|GSK2398852 (anti-SAP mAb)|Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
75901579|NCT03614013|Other|Immunotherapy responders/non-responders|paraffin samples will be collected retrospectively along with clinical data
75901580|NCT03613311|Diagnostic Test|Urodynamic study|Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile
75901581|NCT02032329|Device|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
75607403|NCT02823769|Device|SI-R21204 resin composite|Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
75901582|NCT02259777|Drug|Telmisartan/Amlodipine|Fixed dose combination tablet
75901583|NCT02259777|Other|high fat, high caloric meal|
75901584|NCT03613935|Other|Product 1|Comparison with products 2, 3, and 4
75901585|NCT03613935|Other|Product 2|Comparison with products 1, 3, and 4
75607404|NCT02823769|Device|Nanohybrid resin composite|One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
75607405|NCT02824003|Drug|ISIS-GCGRRx|once weekly dosing for 13 weeks
75607406|NCT02824003|Drug|Placebo|once weekly dosing for 13 weeks
75607407|NCT04240951|Other|Sweat patch|Flexible, epidermal, wearable skin patch to collect and analyze sweat
75607408|NCT04241107|Procedure|Laparoscopic repair of Uterine niche|Repair of uterine niche through Laparoscopic approach.
75753296|NCT00947063|Drug|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
75753297|NCT00947063|Drug|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
75753298|NCT00942617|Drug|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
75753299|NCT00345345|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
75753300|NCT03968159|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
75753301|NCT03968159|Drug|Placebo|Placebo (2×placebo tablets [size- and color-matched to pimavanserin]) administered orally as a single dose once daily
75753302|NCT01045005|Other|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
75753303|NCT01045005|Other|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
75901586|NCT03613935|Other|Product 3|Comparison with products 1, 2, and 4
75901587|NCT03613935|Other|Product 4|Comparison with products 1, 2, and 3
75901588|NCT03261375|Device|Renal Artery Radiofrequency Ablation System (Generator and Catheter )|A renal denervation system with a mesh 6-electrode radiofrequency ablation catheter and multi-channel radiofrequency generator
75901589|NCT03261375|Drug|Antihypertensive Agents|Calcium channel blocker, Diuretic
75607409|NCT04241107|Procedure|Transvaginal repair of Uterine niche|Repair of uterine niche through Transvaginal approach.
75753304|NCT00947141|Drug|ganciclovir (start when CMV PCR >200copies / ml x2)|"Group A: Start ganciclovir when CMV PCR >200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
75753305|NCT00947141|Other|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|"Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
75753306|NCT00947141|Drug|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
75753307|NCT00947141|Other|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
75753308|NCT03966911|Device|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter|Continuous Glucose Monitoring and frequent sample testing
75901590|NCT03261375|Device|Sham Procedure|Catheterization without renal denervation
75456034|NCT01767181|Other|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
75456035|NCT01767207|Other|mental disorders|mental disorders
75901591|NCT03613233|Procedure|Glaucoma surgery|phacoemulsification
75901592|NCT03613545|Procedure|fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
75901593|NCT03613545|Procedure|Infusion of sham|Infusion of sham
75901594|NCT03613545|Drug|probiotics, antibiotics or antidepressants|Drugs such as probiotics, antibiotics, antidepressants
76067285|NCT05576493|Procedure|phaco+TSCPC|The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
76067286|NCT05576493|Procedure|phaco+endocyclophotocoagulation|phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
76067287|NCT05576493|Procedure|phaco GSL|phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
76067288|NCT05569629|Procedure|Bronchial washing before endobronchial biopsy and brushing|Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
75456036|NCT01767207|Behavioral|screening for mental disorders|screening for mental disorders
76067289|NCT05568134|Diagnostic Test|Oral glucose tolerance test|"An oral glucose tolerance test will be completed. A fasting glucose will be measured.~Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours."
75456037|NCT01767220|Procedure|Strategy 1 - endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
75607410|NCT02822365|Procedure|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
75607411|NCT02822365|Device|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
75607412|NCT02822365|Procedure|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
75607413|NCT02823301|Behavioral|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
75607414|NCT04806607|Procedure|19G FNB|Biopsy specimen adequacy using the 19G FNB
75607415|NCT04806607|Procedure|22G FNB|Biopsy specimen adequacy using the 22G FNB.
75607416|NCT02822131|Dietary Supplement|sodium phosphate|
75607417|NCT02822131|Drug|sevelamer, sodium bicarbonate, sodium chloride|
75607418|NCT02820649|Other|Sleep deprivation|40 hours of continuous wakefullness
75607419|NCT04240873|Biological|Catholic MASTER cell|Injection of CATHOLIC MASTER cells 1 x 10^8 cells/DMEM 5cc into knee of patents with osteoarthritis
75607420|NCT04240873|Other|Saline|Injection of saline 5cc into knee of patents with osteoarthritis
75607421|NCT02820805|Other|Meal Skipping|No meal
75607422|NCT02820805|Other|French fries|50g of available carbohydrates meal
75607423|NCT02820805|Other|Mashed potatoes|50g of available carbohydrates meal
75607424|NCT02820805|Other|Hash browns|50g of available carbohydrates meal
75607425|NCT02820805|Other|Rice|50g of available carbohydrates meal
75607426|NCT02820805|Other|Beans|50g of available carbohydrates meal
75607427|NCT02821975|Other|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
75607428|NCT04239469|Drug|KL16-012|Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD
75607429|NCT04239469|Drug|Placebo|Placebo
75607430|NCT04240795|Dietary Supplement|Low lubricity (LL) hydrogels containing fibre-based beads|The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
75607431|NCT02821897|Procedure|Target-controlled intravenous anaesthesia|
75607432|NCT02821897|Procedure|Total anaesthesia|
75607433|NCT04239547|Procedure|Alveolar Recruitment maneuver (ARM) +PEEP|Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP
75607434|NCT04239547|Procedure|PEEP|Following anesthesia induction and intubation, only 5 mmHg PEEP
75901595|NCT01361308|Drug|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
75901596|NCT01361308|Drug|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
75607435|NCT02822209|Behavioral|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
75607436|NCT02822209|Behavioral|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
75607437|NCT02822209|Behavioral|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
75607438|NCT02822209|Behavioral|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
75901597|NCT03613467|Procedure|VATS lobectomy|Patients who received lobectomy by video-assisted thoracoscopic surgery
75607439|NCT02690623|Other|Pediatric hospitalist program|In-house hospitalists available at all hours
75607440|NCT02690623|Other|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
75607441|NCT02823067|Other|Blood sample|One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
75607442|NCT02820493|Drug|vedolizumab|
75901598|NCT03613467|Procedure|Thoracotomy lobectomy|Patients who received lobectomy by thoracotomy
75607443|NCT02820415|Other|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
75607444|NCT02822053|Procedure|US-guided laser ablation for refractory neoplasms|
75607445|NCT02822989|Device|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
75607446|NCT02822989|Device|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
75607447|NCT04239391|Drug|Triferic|Ferric Pyrophosphate Citrate
75607448|NCT02820259|Drug|Tacrolimus|
75607449|NCT02823223|Device|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
75607450|NCT02821663|Behavioral|vocal intervention|10 x 60 min. sessions of vocal intervention
75607451|NCT02822755|Other|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
75607452|NCT02821585|Behavioral|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
75456038|NCT01767220|Procedure|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
75607453|NCT02821351|Device|Radio frequency (RF) Cardiac ablation|Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
75753309|NCT03966365|Drug|PRO-122|"PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: topical ophthalmic."
75753310|NCT03966365|Drug|Krytantek Ofteno®|"- 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~- Route of administration: topical ophthalmic."
75753311|NCT02007239|Drug|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
75901599|NCT03613155|Other|Administration of MEOPA as part of the care|Patients should be managed by a SMUR team from Toulouse and benefit from MEOPA administration as part of their management, with a view to analgesia for a painful complaint or prevention of induced pain (for example during mobilization or venous route).
75901600|NCT02032251|Drug|oral administration of ginger|Oral administration of ginger in patients with infertility.
75901601|NCT02032251|Drug|Placebo|
75456039|NCT01767233|Procedure|ERCP and pancreatic stenting|
75456040|NCT01767246|Other|PFS Algorithm treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.
75456041|NCT01767246|Other|Multimodal treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
75456042|NCT01767259|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
75456043|NCT01767259|Drug|Valsartan|Valsartan alone
75753312|NCT00375219|Drug|Omacetaxine mepesuccinate|"Induction:~1.25 mg/m^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
75753313|NCT03965351|Drug|Probenecid|This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.
75753314|NCT03965351|Other|Placebo|placebo
75901602|NCT03612765|Behavioral|Push-Pull-Hold Program|Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
75901603|NCT03612999|Device|Dexcom continuous glucose monitor|Continuous glucose monitors (CGMs) record subjects glucose levels
75753315|NCT00947375|Drug|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
75901604|NCT03612999|Device|Fitbit activity tracker|Activity trackers will record subjects' physical activity, heart rate, and sleep.
75901605|NCT03612999|Behavioral|Subjects record daily activity|Subjects will record their daily activities, either on paper or on a secure texting app.
75901606|NCT03612999|Behavioral|Subjects record psychological state|Subjects will record their psychological state, either on paper or on a secure texting app.
75901607|NCT05043142|Diagnostic Test|ELISA test for the antibodies to COVID-2019.|Each subject will be assigned an individual number, which will be used for conduction of a rapid ELISA test for the antibodies to COVID-2019. Subjects will be notified of the test results.
75901608|NCT03612297|Diagnostic Test|Selective reporting of Antibiotic Susceptibility Tests|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
75901609|NCT02872935|Drug|Glycopyrrolate|.2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose
76067290|NCT05555901|Drug|Fruquintinib+ chemotherapy|"Second-line treatment : Fruquintinib+FOLFIRI Drug: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off, q4w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Fruquintinib+Capecitabine Drug: Fruquintinib 4mg, orally, once daily, 2 weeks on/ 1 week off, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
75753316|NCT00947375|Drug|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
75456044|NCT01767259|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
75456045|NCT01767272|Drug|fexofenadine|fexofenadine brand name
75456046|NCT01767298|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
75607454|NCT02820103|Behavioral|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
75607455|NCT02820103|Behavioral|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
75607456|NCT02820103|Behavioral|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
75607457|NCT05658991|Diagnostic Test|Retinal electrophysiology|Retinal electrophysiology to assess retinal function before and with fasting during ramadan in both groups.
75607458|NCT02822833|Procedure|Sentinel lymph node mapping|Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
75607459|NCT02819947|Other|This is an observational prospective study.|Investigators will get clinical information including gender, date of birth, height, weight, family history for systemic sclerosis, education, and symptoms of organ involvement of skin, lung, heart, gastrointestinal tract, kidney, musculoskeletal system and laboratory data. Investigators will evaluate nailbed capillary microscope, hand x-ray, 6 minute walk test, echocardiography, computed tomography of chest, pulmonary function test (FVC%, DLCO%), and electrocardiogram as baseline. Investigators permit replacement of previous results within one year from baseline. Participants in the cohort will be followed up annually and investigators will treat SSc patients according to their routine practice in the best interest of patents. Medications for other comorbid conditions are allowed.
75607460|NCT02821429|Other|Combined Thoracic Echography Record|This examination will be done to do the longitudinal follow-up of the patient
75607461|NCT00633763|Drug|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
75607462|NCT00633763|Drug|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
75607463|NCT02822911|Behavioral|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
75607464|NCT02822911|Procedure|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
75607465|NCT02822911|Procedure|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
75607466|NCT02822911|Procedure|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
75607467|NCT02820025|Drug|doxapram|
75607468|NCT02820025|Other|saline|
75607469|NCT02819869|Drug|Statin and Metformin use|
75607470|NCT02819713|Other|ultrasound gel|
75607471|NCT02819713|Other|Instillagel|
75753317|NCT00942695|Other|1.5PD|average American diet plus 1.5 oz per day pistachios
75753318|NCT00942695|Other|3.0PD|average American diet plus 3.0 oz per day pistachios
75753319|NCT00942695|Other|control|average American diet without pistachios
76067291|NCT05555901|Drug|Bevacizumab+ chemotherapy|"Second-line treatment : Bevacizumab+FOLFIRI Drug: Bevacizumab 5mg/kg on day 1, q2w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Bevacizumab+Capecitabine Drug: Bevacizumab 7.5mg/kg on day 1, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
75607472|NCT02821117|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
75456047|NCT01767298|Drug|Valsartan|Valsartan alone
75607473|NCT02820883|Biological|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
75607474|NCT02820883|Biological|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
75607475|NCT02820883|Biological|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
75607476|NCT00633841|Biological|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
75456048|NCT01767298|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
75456049|NCT01767324|Device|Injection to deltoid|Deliver 0.5 milliliters of saline intradermally
75456050|NCT01767324|Device|Injection to forearm|Deliver 0.5 milliliters of saline intradermally
75456051|NCT01767324|Device|Injection to thigh|Deliver 0.5 milliliters of saline intradermally
75456052|NCT01767337|Device|FLUGEN 101.2 device|
75456053|NCT01767350|Procedure|Blood withdrawal for DNA|"Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up."
75607477|NCT05659615|Other|Study will not have intervention|Study will not have intervention
75607478|NCT04811287|Device|Carpal Tunnel Release with Platelet-Rich Plasma|CTR is performed with adjuvant PRP placed intra-operatively.
75607479|NCT04811287|Procedure|Carpal Tunnel Release without Platelet-Rich Plasma|CTR is performed without adjuvant PRP placed intra-operatively.
75607480|NCT02819401|Other|pediatric formula|high-fiber enteral formula
75607481|NCT04200859|Other|Cold application|cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
75607482|NCT02819245|Procedure|posterior correction and fusion|
75607483|NCT04200703|Other|Adult and Child Survivor Centered Approach|Child welfare workers and supervisors, and community partners will be trained in the Adult and Child Survivor Centered Approach, and supervisors will receive ongoing coaching and training.
75607484|NCT02819089|Drug|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
75607485|NCT02819089|Other|NSS|NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
75607486|NCT02818699|Dietary Supplement|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
75456054|NCT01767363|Other|5-alpha reductase inhibitors|Use of 5-alpha reductase inhibitors over the course of the study period.
75607487|NCT02818699|Dietary Supplement|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
75607488|NCT02690311|Device|smartphone display|
75607489|NCT04191265|Diagnostic Test|serum tropinin, serum CKmb|early detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock
75607490|NCT04238923|Drug|Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)|Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
75607491|NCT02819167|Other|neurologic and neuropsychological evaluation|cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging
75607492|NCT04239001|Drug|PEG-rhG-CSF|24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
75607493|NCT04240015|Other|Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale|It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.
75607494|NCT02815657|Drug|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
75607495|NCT02815657|Drug|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
75607496|NCT04597333|Drug|Dinoprostone|Dinoprostone vaginal insert.
75607497|NCT04597333|Device|Cervical ripening balloon.|Double lumen cervical ripening balloon.
75753320|NCT00947453|Drug|montelukast|montelukast 10 mg once daily for 8 weeks
75901610|NCT02872935|Drug|Normal Saline|1ml of normal saline will be given intravenously with the administration of the spinal dose
75901611|NCT00103662|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
76067292|NCT05540028|Biological|IVT PCV-25|25 valent pneumococcal conjugate vaccine
76067293|NCT05540028|Biological|PCV 20|20 valent pneumococcal conjugate vaccine
76067294|NCT05531136|Other|Foot strengthening training|a 12-weeks exercise program consisting of foot strengthening exercises prescribed for 5 daily sessions a week, of which 1 supervised, 20 minutes per session on top of the regular exercise therapy to prevent falling
76067295|NCT05521828|Drug|Follitropin delta (Rekovelle)|12 mcg/day will be used for ovarian stimulation in both arms
76067296|NCT05521828|Drug|Duphaston|20 mg/day will be used for pituitary suppression in both arms
76067297|NCT05521828|Drug|GnRH agonist (Gonapeptyl)|(2 ampules:0.2 mg) will be used for ovulation triggering in both arms
76067298|NCT05515445|Drug|Chiglitazar|Oral single dose 48 mg
76067299|NCT05503082|Drug|Ubrogepant 50 MG [Ubrelvy]|Ubrogepant 50 MG [Ubrelvy]
76067300|NCT05503082|Drug|Ubrogepant 100 MG [Ubrelvy]|Ubrogepant 100 MG [Ubrelvy]
75753321|NCT00554801|Procedure|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
75753322|NCT00942773|Drug|Voriconazole|
75753323|NCT00947687|Drug|PUR003|Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
75607498|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
75607499|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
75607500|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
75607501|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
75753324|NCT00947687|Drug|Placebo|
75753325|NCT00943007|Device|Stealth Station|Neuronavigation based on preoperative MRI
75753326|NCT00943007|Device|PoleStar N20|Intraoperative MRI guided surgery
75753327|NCT00943085|Behavioral|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
75753328|NCT00943085|Behavioral|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
75753329|NCT04279769|Drug|CB-280|CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
75753330|NCT04279769|Drug|Placebos|Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
75753331|NCT00374907|Drug|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
75753332|NCT00374907|Drug|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
75753333|NCT00374907|Drug|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
75607502|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
75607503|NCT02817373|Other|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
75607504|NCT04279210|Device|Platelet-rich plasma|The RegenKit-THT (RegenLab SA, Switzerland) was used to separation of plasma and blood cells. 3mL PRP was extracted from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia.
75607505|NCT02817295|Other|clinical measurements|follow up on the number of complications, revisions, hospitalization and co-morbidities
75753334|NCT00374907|Drug|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
75753335|NCT00374127|Drug|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
75753336|NCT00374127|Drug|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
75753337|NCT01040247|Other|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
75753338|NCT01045083|Drug|RO4917523|Oral single dose
75607506|NCT00957424|Behavioral|telephone-based intervention|10-15 minute web-based survey on a computer
75607507|NCT00957424|Drug|nicotine replacement therapy|One week supply
75753339|NCT01045083|Drug|escitalopram|Oral single dose
75753340|NCT01045083|Drug|methylphenidate|Oral single dose
75753341|NCT01045083|Drug|placebo|Oral single dose
75753342|NCT01040325|Biological|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
75753343|NCT01040325|Biological|TD Vaccine System|TD Vaccine System Containing Placebo Product
75753344|NCT01045239|Device|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
75753345|NCT01045239|Device|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
75753346|NCT01045317|Drug|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
75607508|NCT00957424|Other|informational intervention|
75607509|NCT00957424|Other|internet-based intervention|
75607510|NCT00957424|Other|questionnaire administration|Given out week 2, 3 and 4.
75607511|NCT02817061|Device|Omnilux|The Omnilux LED array sources can be changed to emit different wavelength.
75753347|NCT01045863|Drug|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
75753348|NCT01045863|Drug|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
75753349|NCT01045863|Drug|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
75456055|NCT01767363|Other|Alpha-blockers|Use of alpha-blockers over the study period.
75456056|NCT01767389|Other|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
75456057|NCT01767389|Other|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
75456058|NCT01767389|Other|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
75607512|NCT02818855|Procedure|Coronally advanced flap (CAF)|"The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner."
75607513|NCT02818855|Drug|Collagen Matrix|A new collagen membrane
75456059|NCT01767402|Biological|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
75456060|NCT01767402|Biological|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
75456061|NCT01767402|Biological|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
75753350|NCT01045863|Drug|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
75753351|NCT01045863|Drug|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
75753352|NCT03081585|Behavioral|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
75753353|NCT00553787|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
75753354|NCT00553787|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
75753355|NCT00553787|Drug|VI-0521|placebo
75753356|NCT00947843|Drug|aspirin + pregrel (Clopidogrel resinate)|
75753357|NCT00947843|Drug|aspirin + placebo|
75456062|NCT01767428|Drug|Paracetamol|500 mg immediate release paracetamol formulations
75456063|NCT01767441|Procedure|Roux-en-Y-gastric bypass|Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
75456064|NCT01767441|Procedure|laparoscopic adjustable gastric banding|Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
75456065|NCT01767441|Procedure|laparoscopic sleeve gastrectomy|Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
75607514|NCT02818855|Procedure|Subepithelial connective tissue graft|Connective tissue graft
75753358|NCT00947843|Drug|aspirin + plavix (Clopidogrel bisulfate)|
75753359|NCT00943475|Procedure|circumcision|circumcision by plastbell
75753360|NCT00947921|Procedure|Plasty|Restrictive Annuloplasty
75753361|NCT00947921|Procedure|Prosthesis|Valve replacement
75753362|NCT00948077|Drug|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---> Treatment B (6th day) ; Treatment B (5th day) ---> Treatment A (6th day)"
75456066|NCT01767441|Other|diet treatment|Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
75607515|NCT04278976|Other|Implementation of CoBaTrICE|"The implemention of CoBaTrICE will include the three following essential elements:~Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process."
75607516|NCT02818621|Drug|Group Dex (dexmedetomidine)|1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
75607517|NCT04642651|Drug|Dexmedetomidine|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
75607518|NCT04642651|Drug|Placebo|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
75607519|NCT01061151|Drug|Zidovudine (ZDV)|300 mg twice daily
75607520|NCT01061151|Drug|Nevirapine (NVP): Antepartum Mothers|200 mg at onset of labor
75607521|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail|200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
75607522|NCT01061151|Drug|Lamivudine-Zidovudine (3TC-ZDV)|150 mg/300 mg twice daily
75607523|NCT01061151|Drug|Lopinavir-ritonavir (LPV-RTV)|400 mg/100 mg twice daily beginning at >= 14 weeks gestation; 600 mg/150 mg twice daily beginning at >= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
75456067|NCT01767454|Drug|Dabrafenib|Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
75753363|NCT00407745|Drug|placebo|Placebo
76067301|NCT05494671|Procedure|conjunctival limbal autologous transplant|"Patients with unilateral chemical ocular injury will be included in the study. All selected patients will receive a thorough explanation of the study design and aims and informed consent will be obtained in all patients. Eyes of all participants will be subjected to: Best corrected visual acuity, Slit lamp examination and ocular ultrasound if no fundus view.~Staging of degree of limbal stem cell deficiency is done by Roper Hall classification and then the patient will have conjunctival limbal autologous transplant (CLAU)"
76067302|NCT05490654|Procedure|Abdominal Massage|Abdominal Massage delivered by manual method or by Mowoot device
75607524|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|200 mg/300 mg
75607525|NCT01061151|Drug|Nevirapine (NVP): Infant short-course|Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
75607526|NCT01061151|Drug|Nevirapine (NVP): Infant extended|Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
75607527|NCT01061151|Other|No Intervention|"Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail."
75607528|NCT01061151|Other|Discontinue triple ARVs|ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
75753364|NCT00407745|Drug|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
75753365|NCT00948233|Behavioral|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
75753366|NCT00948233|Behavioral|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
75753367|NCT00948233|Behavioral|Surveys|Computer surveys taken at 4 points throughout the study.
75456068|NCT01767454|Drug|Trametinib|Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
75456069|NCT01767454|Drug|Ipilimumab|Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
75456070|NCT01767480|Device|RT|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
75753368|NCT00948467|Drug|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
75753369|NCT03958955|Drug|Delgocitinib cream|Cream for topical application.
75901612|NCT00103662|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
75753370|NCT03958955|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
75753371|NCT00951119|Device|Resperate|device-guided breathing exercises
75753372|NCT00951119|Device|Resperate|breathing device without slowing of breathing frequency
75753373|NCT00464334|Biological|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
75753374|NCT00464334|Biological|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
75753375|NCT00464334|Biological|Placebo to V950|
75607529|NCT01061151|Other|Continue triple ARVs|Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
75607530|NCT02818543|Drug|LYC-30937|
75753376|NCT00951197|Other|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
75753377|NCT00951431|Drug|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
75753378|NCT00951431|Drug|Placebo|Placebo in the form of study drug
75753379|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
75753380|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
75753381|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
75753382|NCT00299494|Drug|Rituximab|rituximab 375 mg/m^2 via IV infusion on Day 1
75753383|NCT00951587|Device|PillCam™ (Capsule Endoscopy)|Medical Device
75753384|NCT00943553|Drug|decitabine Induction Chemotherapy|Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day)
75607531|NCT02816047|Other|Registry|Observational study to describe WCD indications, event rates, inappropriate shock rates and follow up (including ICD rate, shock rate, morbidity and mortality) in all Austrian WCD patients
75753385|NCT00943553|Drug|Induction Chemotherapy|Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day only)
75753386|NCT04011917|Behavioral|Standard care|Treatment by an extended scope physiotherapist following Standard Operating Procedures.
75753387|NCT00453180|Drug|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
75456071|NCT01767480|Behavioral|Conventional rehabilitation (CR)|CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
75607532|NCT04472143|Drug|Granisetron Transdermal Delivery System|A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
75456072|NCT01767532|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
75456073|NCT01767532|Drug|Cephalexin 125 mg/5ml|Test product 20 ml
75753388|NCT00453180|Drug|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
75753389|NCT00943709|Biological|insulin glargine recombinant|Given subcutaneously
75753390|NCT00943709|Drug|therapeutic insulin|Given subcutaneously
75753391|NCT00948545|Other|Observational study - there is no intervention|Observational study - there is no intervention
75753392|NCT00951743|Drug|Adaptavir (monomeric DAPTA)|"Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day."
75456074|NCT01767545|Drug|Dexamethasone implant|
75753393|NCT01065142|Procedure|Therapeutic education|Improve therapeutic education efficiency on life quality of heart failure patients in general practice
75456075|NCT01767545|Drug|Bevacizumab|
75753394|NCT00464178|Drug|Bortezomib|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
75753395|NCT00560105|Device|Lung Flute|8 weeks home use, twice daily
75753396|NCT00560105|Device|Acapella|8 weeks home use, twice daily
75753397|NCT00467610|Drug|Panhematin|
75753398|NCT00316186|Drug|topotecan|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
75901613|NCT03612219|Drug|Apatinib mesylate tablet|Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.
75901614|NCT03612219|Radiation|Intensity-modulated radiation therapy (IMRT)|Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.
75901615|NCT03612219|Drug|Cisplatin|Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
75456076|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
75456077|NCT01767571|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
75901616|NCT03612843|Other|Observational dry needle|No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
75456078|NCT01767571|Drug|Cephalexin 250mg/5ml|Test product 10 ml
75456079|NCT01767584|Drug|Cephalexin 1g tablets|Reference product
75456080|NCT01767584|Drug|Cephalexin 1g tablets|Test product
75753399|NCT00316186|Drug|carboplatin|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
75901617|NCT05030116|Drug|Shenqu Xiaoshi oral liquid|Shenqu Xiaoshi oral liquid
75901618|NCT05030116|Drug|Domperidone suspension|Domperidone suspension
75901619|NCT03015129|Drug|Durvalumab|
75901620|NCT03015129|Drug|Tremelimumab|
75901621|NCT05049304|Other|Functional olive oil|Eleven adolescents will consume OA-enriched functional olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
75901622|NCT05049304|Other|Olive oil|Eleven adolescents will consume olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
75901623|NCT02255058|Other|No intervention|The study is a Prospective observational cohort study
75456081|NCT01767623|Drug|Vemurafenib|Vemurafenib orally BID 960 or 720 mg.
75607533|NCT04303923|Procedure|Ultrasonography|The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
75753400|NCT04011761|Other|expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
75753401|NCT00948623|Behavioral|physical activity counseling program|
75753402|NCT00948623|Behavioral|sham counseling program|
75753403|NCT01065220|Drug|Testolactone undecanoate|4ml i.m.
75753404|NCT01065220|Drug|Lynestrenol|2/day
75753405|NCT01065220|Drug|Cyproterone Acetate|50mg per day
75753406|NCT01065220|Drug|Estradiol|100 microgram TTS twice a week
75753407|NCT01065220|Drug|5-alpha reductase inhibitor|1mg daily
75753408|NCT00943865|Behavioral|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
75456082|NCT01767649|Other|Caesarean|Collection of tissues and blood
75456083|NCT01767649|Other|Vaginal delivery|Collection of tissues and blood
75456084|NCT01767662|Procedure|manipulation|home programme
75456085|NCT01767662|Procedure|No intervention|observation
75456086|NCT01767714|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
75456087|NCT01767714|Drug|Plerixafor|0.24 mg/kg/day subcutaneous injection
75607534|NCT00634075|Drug|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
75607535|NCT00634075|Drug|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
75607536|NCT01241552|Biological|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
75607537|NCT01241552|Biological|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
75456088|NCT01767714|Drug|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
75456089|NCT01767727|Procedure|Soft tissue coverage|The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
75607538|NCT01241552|Biological|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
75607539|NCT01241552|Biological|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
75607540|NCT01241552|Drug|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
75607541|NCT04748523|Drug|Mirtazapine|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
75607542|NCT04748523|Drug|Placebo Oral Tablet|arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
75607543|NCT02817217|Drug|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
75607544|NCT02817217|Drug|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
75753409|NCT00943865|Behavioral|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
75901624|NCT02148978|Drug|Saxagliptin|The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
75456090|NCT01767740|Device|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
75456091|NCT01767740|Device|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
75456092|NCT01767753|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
75456093|NCT01767766|Drug|TGR-1202|TGR-1202 Daily Oral Dose
75456094|NCT01767805|Procedure|Standard incubator|
75456095|NCT01767805|Procedure|Mini incubator|
75456096|NCT01767805|Procedure|5% oxygen|
75456097|NCT01767805|Procedure|20% oxygen|
75753410|NCT00943865|Behavioral|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
75901625|NCT04470154|Drug|Stage I:HSK21542 0.05 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
75901626|NCT04470154|Drug|Stage I:HSK21542 0.15 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
75901627|NCT04470154|Drug|Stage I:HSK21542 0.30 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
75901628|NCT04470154|Drug|Stage I:HSK21542 0.80 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
75901629|NCT04470154|Drug|Stage II:HSK21542 0.3 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
75607545|NCT00948922|Drug|Bortezomib|AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
75901630|NCT04470154|Drug|Stage II:HSK21542 0.6 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
75901631|NCT03612609|Biological|blood, urine and semen sample|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 15, 30, 60 and 90 days after. Dengue virus RNA being diagnosed with blood and/or urine sample positive for dengue virus RNA. Dengue virus RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
75456098|NCT01767831|Behavioral|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
76067303|NCT05489484|Device|MD-Shoulder Collagen Medical Device|"Only one experimental group is scheduled by the Investigation Plan to be treated with 2-mL volume ultrasound-guided infiltrations of MD-Shoulder Collagen Medical Device (GUNA, Milan-Italy).~Subjects will be treated with number one ultrasound-guided infiltration at the time of enrollment, 2 weeks after enrollment, and 4 weeks after enrollment.~Intra-articular infiltrations will be performed with 5cc syringes and 22-gauge needles.~MD-Shoulder Collagen Medical Device will be infiltrated within the scapulohumeral joint under conditions of complete asepsis."
75607546|NCT00948922|Drug|Melphalan|AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes.
75607547|NCT00948922|Procedure|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.
75607548|NCT00948922|Drug|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
75753411|NCT00943865|Behavioral|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
75901632|NCT05048914|Drug|Ibuprofen|treatment of acute migraine attack
75901633|NCT02255136|Other|Individualized homeopathic medicines|5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year
75901634|NCT02255136|Other|Placebo|Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
75901635|NCT04715529|Drug|FZJ-003|Subjects will receive FZJ-003 oral capsules in a dose escalation format.
75901636|NCT04715529|Drug|Placebo|Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
75901637|NCT03094624|Other|Neuropsychological and neurophysiological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
75607549|NCT00948922|Procedure|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients. Allogeneic donor stem cells may also be cryopreserved if they cannot be infused fresh.
75607550|NCT02817139|Device|TDCS|
75607551|NCT02858128|Other|IMAGING STUDY|Choline-PET/CT versus NMRscan comparative study
75607552|NCT04238065|Device|Caterna Virtual Reality|"Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone softwareWechat to upload vision acuity and choose 2 eyes' video output automaticly."
75456099|NCT01767844|Dietary Supplement|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
75607553|NCT04238065|Device|Spectacles(Best optical corrected distance vision)|Each eye has best corrected vision spectacles with best corrected optical lens.
75753412|NCT00943865|Behavioral|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
75901638|NCT03094624|Other|Experiment 1|Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
76067304|NCT05485181|Behavioral|Spiritual Intervention|The Intervention is a CBT- based psychotherapeutic process that occurs in a group setting with two cohorts of 8 subjects each. It will occur in an introductory 3-hour session followed by 9 weekly 1 ½ hour sessions. In this process, self-worth (self-confidence, self-esteem, self-competence) and dignity (reason, compassion, courage) as operationally defined are strengthened through an interpersonal, psychological process including mindful self-awareness training, attitude transformation with self-compassion, forgiveness, and self-acceptance, and opens to a new level of awareness. This awareness opens to spiritual / numinous features of connectedness, vitality, wholeness, meaning, and serenity that are predicted to be associated with greater well-being and relief of anxiety and depression symptoms.
76067305|NCT05479006|Device|Transcranial direct current stimulation (high- definition)|20 minutes, 2 mA stimulation.
76067306|NCT05469828|Drug|Crizanlizumab|patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).
76067307|NCT05469828|Other|control|Standard of care
75456100|NCT01767844|Dietary Supplement|Placebo|
75607554|NCT04238065|Device|Patch|2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
75753413|NCT02532712|Drug|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
75753414|NCT02532712|Drug|Placebo|Placebo with same shape and size
75753415|NCT00948701|Behavioral|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
75901639|NCT03094624|Other|Experiment 2|Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
75456101|NCT01767870|Procedure|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
75456102|NCT01767870|Procedure|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
75456103|NCT01767883|Other|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms~On-going mentoring and practice facilitation~Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference."
75456104|NCT01767883|Other|Clinical Decision Support Only|"CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms"
75456105|NCT01767896|Biological|ASP7374|subcutaneous (sc)
75456106|NCT01767896|Biological|approved egg-derived TIV|subcutaneous (sc)
75607555|NCT04237909|Biological|PRP injection into at least one ovary|The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
75607556|NCT04237831|Drug|BMS-986259|Specified Dose on Specified Days
75753416|NCT01065298|Biological|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of >40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
75901640|NCT03094624|Other|Experiment 3|Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
76072276|NCT02138734|Biological|BCG+N-803|"BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, & 18 months.~An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included."
75607557|NCT00634309|Drug|Candesartan|
75607558|NCT00634309|Drug|Placebo|
75607559|NCT01239992|Drug|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
75607560|NCT02816905|Drug|0.1 % Dexamethasone|20 eyes are randomized to receive topical 0.1% Dexamethasone four times per day for 2 weeks.
75753417|NCT00943943|Drug|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
75753418|NCT00943943|Drug|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
75753419|NCT00943943|Drug|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily."
75753420|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
75901641|NCT03094624|Other|Experiment 4|"Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners."
75901642|NCT03046017|Device|tDCS|Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
75901643|NCT03046017|Other|Lidocaine cream|Lidocaine cream will be applied to reduce pain sensitivity (analgesia).
75901644|NCT03046017|Other|Control cream|A neutral cream will be applied as a control.
75901645|NCT05383989|Behavioral|UniVenture Hopelessness manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Hopelessness (HOP) personality traits on the Substance Use Risk Profile Scale (SURPS).
75901646|NCT05383989|Behavioral|UniVenture Anxiety Sensitivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Anxiety Sensitivity (AS) personality traits on the Substance Use Risk Profile Scale (SURPS).
75901647|NCT05383989|Behavioral|UniVenture Sensation Seeking manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Sensation Seeking (SS) personality traits on the Substance Use Risk Profile Scale (SURPS)
75607561|NCT02816905|Drug|0.1% Fluorometholone|20 eyes are randomized to receive topical 0.1% Fluorometholone four times per day for 2 weeks.
75901648|NCT05383989|Behavioral|UniVenture Impulsivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Impulsivity (IMP) personality traits on the Substance Use Risk Profile Scale (SURPS).
75901649|NCT05383989|Behavioral|Service as usual provided by the University|It is the regular university-provided well-being services.
75901650|NCT03542370|Other|DASH dietary pattern|A dietary pattern that emphasizes intake of fruits and vegetables, low-fat or non-fat dairy, limiting saturated fat intake, and usually also recommends limiting sodium intake.
75901651|NCT03542292|Diagnostic Test|placental drainage|
75607562|NCT02816905|Drug|1% Rimexolone|40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks. 20 of these eyes were the contralateral eyes of the patients who received 0.1% Dexamethasone in their first eye. The other 20 eyes were the contralateral eyes of the patients who received 0.1% Fluorometholone in their first eye
75607563|NCT02816827|Dietary Supplement|AG-01|Product to increase mental alertness
75607564|NCT02816827|Dietary Supplement|AG-05|Product to increase mental alertness
75607565|NCT02816827|Dietary Supplement|AG-06|Product to increase mental alertness
75607566|NCT02816827|Dietary Supplement|AG-07|Product to increase mental alertness
75607567|NCT01239680|Drug|Glutamine|Intravenous 25 grams once over 6 hours
75607568|NCT01239680|Drug|Ringer's Lactate|Intravenous 1 liter once over 6 hours
75607569|NCT01239680|Drug|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
75607570|NCT02816749|Procedure|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
75607571|NCT02816749|Procedure|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
75607572|NCT04211857|Device|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.
75901652|NCT03736278|Other|No intervention|We group the patients according to the outcome (survival vs mortality)
75607573|NCT05515094|Behavioral|Empowerment Counseling Intervention|The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
76067308|NCT05467527|Behavioral|Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice|The PACT group will receive a combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks. The modules will cover real-life scenarios of daily parenting challenges in caring for a child with SHCN, followed by age-appropriate positive parenting advice based on the Centers for Disease Control and Prevention guidelines. After going through the scenarios, parents will be audio/visually guided to participate in ACT activities, including mindfulness exercises, ACT metaphors and experiential exercises, which will be used to increase psychological flexibility.
76067309|NCT05467527|Behavioral|Positive parenting advice|The Control Group will receive a total of 6 online modules and 4 group-based video conferencing sessions in a closed group of 6-8, 60 minutes per session guided by a trained facilitator via the mobile app across 12 weeks. The online modules will provide identical contents to those in the PACT group, but no guided ACT metaphors or experiential exercises. The interaction sessions serve to review and discuss the contents of online modules, but without the contents related to ACT/prosociality.
75607574|NCT05654077|Biological|CAR-T Cell Injection|intravenously once, and the dose group was 3.0 × 10^6cells/kg、9.0 × 10^6cells/kg、1.5 × 10^7cells/kg。
75607575|NCT05654077|Drug|Fludarabine|Fludarabine 25~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
75607576|NCT05654077|Drug|cyclophosphamide|250~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
75607577|NCT04303767|Drug|Casein phosphopeptide amorphous calcium phosphate|varnish containing calcium and phospate ions which act as a source for tooth remineralization
75607578|NCT04303767|Procedure|Atraumatic restorative treatment|excavation of dental caries and restoring with light cured Glass Ionomer Restoration
75753421|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
75753422|NCT00453102|Drug|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
75753423|NCT00453102|Drug|Ibritumomab Tiuxetan|"IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³"
75901653|NCT05043610|Biological|Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)|Cell Tech Pharmed Company (Tehran, Iran) will provide us with cGMP grade WJ-MSCs. 10^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.
75901654|NCT05043610|Other|Conventional Treatment|Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
76067310|NCT05460845|Behavioral|Low-Carbohydrate Diet|Using a meal delivery service and a list of prepared meals and recipes, foods/meals will be delivered to participants weekly to maintain daily net carbohydrate intake to less than 40 grams.
75901655|NCT02149056|Behavioral|observation|
75607579|NCT02816671|Device|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
75607580|NCT01238900|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
75901656|NCT02149056|Other|Impaired Glucose Tolerance|Impaired Glucose Tolerance
75901657|NCT02149134|Dietary Supplement|TeHF2013-01|
75901658|NCT05042752|Procedure|CLINICAL ULTRASOUND|The intervention group will receive the standard care of treatment in AHF and the performance of CU.
75901659|NCT02149212|Drug|Phlebotonic|Aminaftone -- 75 mg BID
75901660|NCT02149212|Device|Stent|Iliac Vein Stenting
75901661|NCT02149212|Procedure|Limb elastic compression support|CEAP 3-5 > 20-30 mmHg compression stockings CEAP 6 > elastic bandages
75901662|NCT02149212|Procedure|Unna boot dressing|CEAP 6 > Unna boot dressing
75607581|NCT04303299|Drug|Oral|Anti virus treatment
75607582|NCT02874963|Procedure|Surgical Periodontal Treatment|In the patient's with periodontal disease at least one tooth extraction will be performed.
75753424|NCT00944099|Behavioral|Behavioral weight loss intervention|both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
75753425|NCT00949013|Other|immunohistochemistry staining method|
75753426|NCT00949013|Other|laboratory biomarker analysis|
75901663|NCT04667013|Drug|Tetramethylpyrazine nitrone (TBN) tablet / Placebo|Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.
75901664|NCT03612063|Device|Fitbit Iconic HR and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
75901665|NCT03612063|Device|Fitbit Iconic HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
75456107|NCT01767922|Dietary Supplement|Extramel 10 mg - 140 UI SOD|"Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~visit V1, so-called inclusion visit (D0),~visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~visit V3 at 84 days, tolerance of +/- 3 days, (D84)."
75901666|NCT03612063|Device|Garmin Vivosmart HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
75901667|NCT03612063|Device|Fitbit Iconic HR and Apple Watch III|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
75901668|NCT03612063|Device|Apple Watch III and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
76067311|NCT05451524|Behavioral|Insomnia prevention program|Youths in the intervention group will receive 4 weekly insomnia prevention program. Each session will last for about 60-90 mins.
75456108|NCT01767922|Dietary Supplement|Placebo - Excipient only|
75456109|NCT01767948|Drug|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
75456110|NCT01767961|Procedure|diagnostic imaging|Undergo MBS
75456111|NCT01767961|Other|questionnaire administration|Correlative studies
75456112|NCT01767961|Procedure|quality-of-life assessment|Correlative studies
75456113|NCT01768039|Drug|Vitamin D|
75456114|NCT01768039|Drug|Placebo|
75456115|NCT01768052|Device|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
75753427|NCT00299182|Drug|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
75753428|NCT00299182|Drug|Rituximab|375 mg/m^2 by vein over 4-6 hour infusion day 1, each cycle.
75607583|NCT02874963|Device|Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.
75607584|NCT02874963|Drug|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
75607585|NCT02818465|Other|Vascular calcifications by Xray|
75753429|NCT00299182|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, & 5.
75753430|NCT00299182|Drug|Vincristine|1.4 mg/m^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,& 5.
75753431|NCT00299182|Drug|Doxorubicin|50 mg/m^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,& 5.
75753432|NCT00299182|Drug|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,& 5.
75901669|NCT03612063|Device|Apple Watch III and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
75901670|NCT05048290|Other|Communication Skills Training|Participate in communication workshops
76067312|NCT05451524|Behavioral|General health education|Youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group.
75456116|NCT01767610|Drug|micronized fenofibrate 160mg|
75456117|NCT01767610|Drug|pitavastatin Ca 2mg|
75456118|NCT01767610|Drug|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
75456119|NCT01768065|Device|Nasal Expiratory Positive Airway Pressure Device|assigned to Nasal Expiratory Positive Airway Pressure arm
75901671|NCT05048290|Other|Communication Skills Training|Participate in generic communication skills workshops
75901672|NCT05048290|Other|Educational Intervention|Develop a video
75901673|NCT05048290|Other|Survey Administration|Complete surveys
75607586|NCT02818465|Other|Vascular calcifications by tomodentimetry|
75901674|NCT03611985|Drug|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
75901675|NCT03611985|Drug|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
75901676|NCT05029804|Other|Education|This intervention will be applied to the patients in the experimental group. The education will be provided by the researcher and based on the transtheoritical model. Printed materials and PowerPoint presentations will be used for the education and the education will be conducted in a face-to-face session with each participant (10 weeks).
76072277|NCT02138734|Biological|BCG|"BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, & 18 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included."
75456120|NCT01768065|Device|placebo sham|
75456121|NCT01768078|Procedure|Intravitreal injection of Betamethasone + antibiotics|
75456122|NCT01768078|Procedure|Intravitreal injection of antibiotics|
75456123|NCT01768091|Procedure|POEM|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.~(Inoue H et al. POEM for esophageal achalasia… Endoscopy 2010; 42: 265-271)"
75456124|NCT01768091|Procedure|Pneumatic dilation|"A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.~(N Engl J Med 2011;364:1807-16.)"
75753433|NCT00299182|Drug|Methotrexate|200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours Day 2, Cycles 2, 4 & 6.
75753434|NCT00299182|Drug|Cytarabine|3 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4; OR,1 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4 for patients > 60 years and for patients with serum creatinine > 1.5 mg/dL; Cycles 2,4,& 6.
75607587|NCT02818465|Biological|Blood sample withdrawn|
75607588|NCT02818309|Drug|Lesogaberan|120 mg bid
75753435|NCT00299182|Drug|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
75607589|NCT02818309|Drug|Placebo|Placebo
75753436|NCT00467142|Biological|bevacizumab|
75753437|NCT00467142|Drug|fluorouracil|
75753438|NCT00467142|Drug|irinotecan hydrochloride|
75753439|NCT00467142|Drug|leucovorin calcium|
75753440|NCT00467142|Genetic|polymorphism analysis|
75753441|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
75753442|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
75753443|NCT05300789|Other|Follow-up|There is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded.
76072278|NCT02134392|Biological|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
75607590|NCT01238822|Drug|Methylphenidate|18 mg methylphenidate
75607591|NCT01238822|Drug|placebo|Placebo
75607592|NCT01238822|Drug|Methylphenidate|36 mg methylphenidate
75607593|NCT01238822|Drug|Methylphenidate|54 mg methylphenidate
75607594|NCT04303455|Diagnostic Test|blood sampling|sampling serum renin
75607595|NCT02818387|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
75753444|NCT00949091|Drug|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
75753445|NCT00944177|Drug|Metformin HCl|
76067313|NCT05450926|Procedure|Ultrasound-guided selective cervical nerve root block|The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
76067314|NCT05450185|Procedure|Critically ill patients with continuous renal replacement therapy|Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.
76067315|NCT05447026|Device|Control group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, the sites in the control group received only saline irrigation for 1 min.
75901677|NCT03611517|Behavioral|Sexual rehabilitation programme|The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
75901678|NCT05029492|Other|Low-calorie diet|Low-calorie diet of 1200 kcal for 3 months, modified every two weeks.
75456125|NCT01768104|Procedure|ESTD|"A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~Dissection was done along the margin of the tumor.~After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors… Endoscopy 2012; 44: 231-235)"
75607596|NCT02818387|Drug|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
75901679|NCT05029492|Other|Visceral manipulation with diet|Visceral manipulation to the pelvic organs and their related structures (8 sessions, once per week in the first month then once every other week for two months) added to the same low-calorie diet as the group (A).
75607597|NCT02818387|Drug|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
75901680|NCT02865915|Drug|MLE4901|For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
75753446|NCT00553475|Drug|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
75753447|NCT00553475|Drug|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
75753448|NCT00553475|Drug|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
75901681|NCT02865915|Drug|Placebo|Placebo to match active drug
75753449|NCT00329602|Drug|Placebo|Matching Placebo
75607598|NCT05296629|Drug|DFD-29|DFD-29 (40 mg) extended release capsules
75607599|NCT05296629|Drug|Doxycycline|Doxycycline 40 mg capsules
75607600|NCT05296629|Drug|Placebo|Placebo capsules
75753450|NCT00329602|Drug|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
75753451|NCT01060696|Drug|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
75901682|NCT05029648|Other|Cohort|Cohort
75901683|NCT05029258|Procedure|Biopsy of tumour|Cervical tumour biopsy during treatment. This will be used for gene expression (RNA) analysis against a hypoxia associated gene signature.
75901684|NCT05029258|Diagnostic Test|MRI scans|Multiple magnetic resonance imaging (MRI) scans before and during treatment using oxygen enhanced (OE) / tissues oxygen level dependent (TOLD) sequence
75753452|NCT01065610|Drug|Oxytocin|
75456126|NCT01768104|Procedure|VATS|"General anesthesia with double lumen intubation.~Three to four cameras or working ports are placed over the chest wall.~After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~The mass is exposed after the overlying muscle is split longitudinally.~The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
75753453|NCT01065610|Drug|Placebo|
75901685|NCT03097900|Drug|Caffeine Citrate|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
75901686|NCT03097900|Other|Water|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
75456127|NCT01768143|Behavioral|unexperienced endoscopy nurses|
75456128|NCT01768143|Behavioral|Experienced endoscopy nurses|
75456129|NCT01768156|Other|Experimental arm|"Serum samples are collected:~at time of diagnosis of recurrence (before 1st chemotherapy)~during each cycle of chemotherapy~after the end of chemotherapy~every 3 month until treatment failure (3-6 samples)~stop at the progression or after 18 months post chemotherapy"
75456130|NCT01768169|Dietary Supplement|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
75456131|NCT01768182|Dietary Supplement|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
75456132|NCT01768182|Other|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
75753454|NCT01062646|Behavioral|Multimodal music therapy|
75753455|NCT01062646|Behavioral|Community treatment as usual|
75607601|NCT00634153|Other|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
75753456|NCT00463866|Drug|Budesonide/formoterol|
75753457|NCT00313846|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
75901687|NCT03096652|Procedure|Approach for cancer resection|
75901688|NCT03096496|Other|QoL questionnaires|Quality of life questionnaires
75607602|NCT01238588|Drug|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
75753458|NCT00313846|Drug|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
75753459|NCT00949247|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
75753460|NCT00949247|Biological|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
75753461|NCT00949247|Drug|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
75753462|NCT00949247|Drug|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
75753463|NCT00949247|Other|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
75753464|NCT00551135|Drug|Pregabalin|150 mg BID
75753465|NCT00551135|Drug|placebo|Placebo
75753466|NCT00551135|Drug|Pregabalin|75 mg BID
75753467|NCT00551135|Drug|Pregabalin|25 mg BID
75753468|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
75753469|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
75901689|NCT00104676|Biological|bleomycin sulfate|At least one course administered
75607603|NCT04303143|Behavioral|Self-Hypnosis|Self-Hypnosis
75753470|NCT01529801|Device|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
75753471|NCT01529801|Device|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
75456133|NCT01768195|Drug|Entecavir prophylaxis|"Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis."
75753472|NCT01529801|Device|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
75753473|NCT00949481|Other|Pregnancy Test|Free pregnancy test strips will be supplied to family planning clinics
75901690|NCT00104676|Drug|cisplatin|At least one course administered
75901691|NCT00104676|Drug|etoposide|At least one course administered
75901692|NCT00104676|Drug|ifosfamide|Given in a dose-dense sequential fashion
75901693|NCT00104676|Drug|oxaliplatin|Given in a dose-dense sequential fashion
76072279|NCT02101385|Drug|Genomically Directed Monotherapy|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
75456134|NCT01768208|Drug|Saxagliptin|
75607604|NCT04303143|Behavioral|Direct Autonomic Experience Control|Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
75607605|NCT02818231|Other|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
75607606|NCT00627003|Drug|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
75607607|NCT00627003|Other|Placebo|Placebo oral tablets administered daily for 5 weeks
75607608|NCT04238611|Device|Microneedle|Lactate microneedle applied on the skin of participant
75607609|NCT04238611|Diagnostic Test|Blood lactate measurement|Serum lactate testing through conventional laboratory methods
75607610|NCT04238611|Other|Exercise regimen|Standardised aerobic exercise regimen
75753474|NCT00949481|Other|Job aid|"A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.~Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)"
75753475|NCT04012385|Behavioral|lifestyle counseling|Nutritional plan and Physical activity goals
75901694|NCT00104676|Drug|paclitaxel|Given in a dose-dense sequential fashion
75901695|NCT02149446|Device|Surgisis (C-SLRA-ECH60) made by COOK Medical|Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
75901696|NCT03543618|Device|Sloped|Placement of implant with sloped design
75901697|NCT03543618|Device|Control|Placement of implant with conventional design
75901698|NCT02149602|Radiation|Intensity modulated radiotherapy|Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
75901699|NCT05042284|Drug|Non-enteric coated pancreatic enzyme preparation|The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
75901700|NCT05047276|Biological|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
75901701|NCT05028556|Drug|Chort 1 of Y101D|Y101D, 1mg/kg, Q2W, intravenous infusion
75456135|NCT01768221|Behavioral|Caregiver Intervention|"Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.~The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.~In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist."
75456136|NCT01768234|Other|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
75607611|NCT02818153|Other|Self questionnaire for allergic rhinitis control|
75607612|NCT04238533|Other|eADAPT training|eADAPT training for myoelectric prosthesis users is the comparator training.
75607613|NCT04238533|Other|Conventional training|Conventional training with Myoboy has been the only training available to users.
75607614|NCT05657509|Other|Functional training|Functional training Length: 12 weeks; Training duration: 60 minutes; Intensity: 50 to 70% in the last weeks' intensity will be 60 to 70%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
75607615|NCT05657509|Other|No intervention|The Control group continues regular traditional training exercises for 12 weeks with a training duration of 60 minutes and three days per week.
75753476|NCT00956423|Behavioral|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
75456137|NCT01768247|Drug|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
75456138|NCT01768260|Device|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
75753477|NCT00956423|Behavioral|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
75753478|NCT00949559|Drug|EP-100|as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)
75901702|NCT05028556|Drug|Chort 2 of Y101D|Y101D, 3mg/kg, Q2W, intravenous infusion
75901703|NCT05028556|Drug|Chort 3 of Y101D|Y101D, 10mg/kg, Q2W, intravenous infusion
75901704|NCT05028556|Drug|Chort 4 of Y101D|Y101D, 20mg/kg, Q2W, intravenous infusion
76067316|NCT05447026|Device|Antimicrobial photodynamic therapy (aPDT) group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, aPDT group received additional application of a diode laser with a wavelength of 810 nm and a power rating of 200 mW (continuous mode). Indocyanine-green (ICG) as a photosensitizer at a concentration of 1 mg/ml was applied at the surgical site on both the buccal and the lingual sides of the flaps. Irradiation was performed in non-contact mode in a constant distance of 1 mm during 30 s per site
75456139|NCT01768260|Drug|Aspirin|Standard drug therapy
75456140|NCT01768273|Drug|Midazolam|
75456141|NCT01768273|Drug|PA-824|
75456142|NCT01766505|Drug|Candemore tablet|"Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure."
75901705|NCT05028556|Drug|Chort 5 of Y101D|Y101D, 30mg/kg, Q2W, intravenous infusion
75901706|NCT00354835|Drug|Cyclophosphamide|Given IV
76072280|NCT02101385|Other|Observation/Standard Therapy|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
75607616|NCT04238221|Drug|Doxofylline|Patients will receive a 4-week treatment with doxofylline 400 mg bid, in addition to their chronic usual inhalation therapy.
75607617|NCT02815423|Biological|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
75456143|NCT01766505|Drug|Cozzar tablet|Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
75901707|NCT00354835|Biological|Dactinomycin|Given IV
75901708|NCT00354835|Drug|Irinotecan Hydrochloride|Given IV
75901709|NCT00354835|Other|Laboratory Biomarker Analysis|Correlative studies
75901710|NCT00354835|Other|Questionnaire Administration|Ancillary studies
75901711|NCT00354835|Radiation|Radiation Therapy|Undergo radiotherapy
75901712|NCT00354835|Drug|Vincristine Sulfate|Given IV
75901713|NCT02768298|Drug|LCZ696|LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.
75901714|NCT02768298|Drug|Enalapril|"Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
75901715|NCT02768298|Drug|Placebo matching enalapril|Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.
75901716|NCT02768298|Drug|Placebo matching LCZ696|Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.
75456144|NCT01768299|Drug|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
75456145|NCT01768299|Drug|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
75456146|NCT01768312|Drug|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
75456147|NCT01768351|Drug|Paricalcitol|Zemplar cp 1 mcg/day per os
75456148|NCT01768351|Drug|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
75456149|NCT01768364|Drug|Trimetoprim-Sulfa (Bactrim)|
75456150|NCT01768364|Other|No antibiotics|
75456151|NCT01768377|Drug|Nerve block with Lidocain|Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg
75456152|NCT01768377|Drug|Fentanyl|Fentanyl 2 microgram/Kg BW IV
75456153|NCT01768377|Drug|Midazolam|Midazolam 0.05 mg/kg BW IV infusion
75456154|NCT01768390|Other|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
75456155|NCT01768390|Other|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
75607618|NCT02815423|Biological|Percutaneous|Percutaneous injection
75607619|NCT01047501|Drug|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
75607620|NCT01047501|Drug|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
75607621|NCT01047501|Drug|Placebo|Placebo 4 capsules/day for 12 weeks
75607622|NCT01238120|Drug|Ibuprofen|200 mg BID and 8 hours apart
75607623|NCT01238120|Behavioral|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
75607624|NCT01238120|Drug|Placebo|200mg BID and 8 hours apart
75607625|NCT05655481|Other|Aerobic and Resistance training with rehabilitation|Effects of home telerehabilitation program improve functional capacity variables
75607626|NCT05655481|Other|Health education|Telehealth and guidelines for the practice of physical activity and health education
75456156|NCT01768429|Behavioral|Fatty fish|
75607627|NCT01237340|Drug|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
75901717|NCT05028478|Drug|CN202|Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
75456157|NCT01768429|Behavioral|Lean Fish|
75456158|NCT01768429|Behavioral|Alpha-linolenic acid|
75456159|NCT01768429|Behavioral|Control|
75456160|NCT01768455|Drug|Gemigliptin and Glimepiride|Gemigliptin 50mg (qd) on Day1~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
75456161|NCT01768455|Drug|Glimepiride|Glimepiride 4mg (qd) on Day1
75456162|NCT01768468|Drug|LAYLA tablet|1 tablet twice a day
75607628|NCT02818075|Other|Mobile Phone Based Peer Support|Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
75607629|NCT02818075|Other|Usual Care|Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
75607630|NCT04303533|Device|Neuro-Feedback EFP|Neurofeedback (NF) - is a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Amygdala-EFP (EEG-finger-print, EFP) is an EEG-NF application that modulates amygdala response.
75607631|NCT02816593|Drug|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
75607632|NCT02816593|Drug|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
75607633|NCT02816593|Drug|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
75607634|NCT04237987|Drug|Interleukin-2|Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd
75607635|NCT04237987|Drug|ciclosporin and corticosteroid|ciclosporin and corticosteroid
75607636|NCT01045707|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
75901718|NCT05028322|Drug|IMIQUIMOD cream|Cream to apply before intra-dermal vaccine injection
75456163|NCT01768468|Drug|JOINS tablet|1 tablet at each time, 3 times a day
75456164|NCT01768481|Drug|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
75456165|NCT01768481|Drug|sugar pill|placebo controlled arm receives similarly looking placebo.
75456166|NCT01768507|Dietary Supplement|Resveratrol|5 g (10 capsules) as single oral dose on day 1
75456167|NCT01768546|Behavioral|Virtual Diabetes Prevention Program|Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
75456168|NCT01768546|Behavioral|Interactive tracking and problem solving web portal|
75456169|NCT01768585|Drug|Ivabradine|Please see description of Intervention Arm
75456170|NCT01768585|Drug|Placebo|
75607637|NCT01045707|Drug|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
75607638|NCT02816125|Dietary Supplement|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
75901719|NCT05028322|Biological|HEPATITIS B SURFACE ANTIGEN|HBV Vaccine
76072281|NCT02086175|Drug|Imprime PGG|
76072282|NCT02086175|Drug|Rituximab|
76072283|NCT02073838|Drug|Ribavirin|
75607639|NCT02816437|Biological|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
75607640|NCT04303221|Other|Exercise|The exercises will be performed three times a week (Mondays, Wednesdays and Fridays), lasting 60 min, 10 minutes of warm-up, 40 min of multisensory exercises, and 10 min of final relaxation, for 12 weeks.
75607641|NCT04238377|Procedure|Stellate Ganglion Block|"Using US with a linear array transduce, subfascial-C6- Stellate Ganglion Block. Patients will be supine with the neck slightly hyper- extended. After aseptic preparation of the skin, the transducer is placed on the neck to enable cross sectional visualization of anatomical structures at the level of C6. The carotid artery, internal jugular vein, thyroid gland, trachea, longus colli covered with the prevertebral fascia, root of C6, and transverse process of C6 are all visualized. The transducer will then gently be pressed between the carotid artery and trachea to retract the carotid artery laterally and to position the transducer close to the longus colli.~A 1.0-inch, 25-gauge long-bevel needle were paratracheal inserted toward the middle of the longus colli. The endpoint for injection were the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in the longus colli. After negative aspiration, 5 mL of 0.5% bupivacaine was injected"
75753479|NCT00949637|Behavioral|Scouting Nutrition and Activity Program|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
75753480|NCT00949637|Behavioral|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
75753481|NCT00299104|Drug|folate|Intravenous repeating dose
75456171|NCT01768598|Other|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
75456172|NCT01768598|Other|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
75753482|NCT00299104|Drug|methotrexate|Oral or parenteral repeating dose
75456173|NCT01768598|Other|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
75456174|NCT01768598|Other|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
75456175|NCT01768624|Procedure|dialysis, kidney transplant|
75607642|NCT04238377|Drug|Multimodal Analgesia|Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
75607643|NCT04302831|Behavioral|Strength training|weight lifting to increase muscle strength
75607644|NCT04302831|Behavioral|Endurance training|treadmill walking to increase endurance
75607645|NCT04302831|Behavioral|Flexibility training|stretches to improve flexibility
75607646|NCT04302831|Behavioral|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
75753483|NCT00299104|Drug|methylprednisolone|Intravenous repeating dose
75753484|NCT00299104|Drug|placebo|Intravenous repeating dose
75607647|NCT04302831|Behavioral|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
75753485|NCT00299104|Drug|rituximab|Intravenous repeating dose
75753486|NCT03979690|Device|NISInspire-C System|The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
75753487|NCT03979456|Drug|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
75901720|NCT03096340|Drug|IT-141|Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
75901721|NCT05041894|Other|tilt table|The tilt table provides passive standing for the stroke patients with tracheotomy
76072284|NCT02073838|Drug|Vismodegib|
76072285|NCT02073838|Drug|Decitabine|
75607648|NCT02817685|Other|3 months|
75607649|NCT02817685|Other|6 months|
76067317|NCT05447026|Device|LED photobiomodulation group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, irradiation was carried out with a LED device with a wavelength of 626 nm in the near-infrared region at a dose of 20 mw/cm2 for 20 min with a total energy of 222 J
75607650|NCT02817685|Other|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
75607651|NCT02874807|Drug|Empagliflozin|
75753488|NCT00313612|Drug|oxaliplatin|Given IV
75753489|NCT00313612|Drug|topotecan|Given IV
75753490|NCT00507416|Drug|Bortezomib|Bortezomib bolus intravenous (IV) injection
75753491|NCT00507416|Drug|Dexamethasone|Dexamethasone for oral administration
75753492|NCT00507416|Drug|Melphalan|Melphalan for oral administration
75753493|NCT00507416|Drug|Prednisone|Prednisone for oral administration
75753494|NCT00507416|Drug|Thalidomide|Thalidomide for oral administration
75901722|NCT05028244|Diagnostic Test|venous ultrasound of lower extremity|Patients inbed are explored for deep vein thrombosis in femoral-popliteal and distal veins of the legs with ultrasound compresión and doppler flow evaluation
75901723|NCT02152800|Drug|valacyclovir hydrocholoride|
75901724|NCT03543540|Biological|Nexvax2|Nexvax2 injections: 14 in total at twice weekly intervals
75901725|NCT03543540|Biological|Placebo|Placebo injections: 14 in total at twice weekly intervals
76067318|NCT05447026|Device|Topical ozone group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, topical ozone group received ozone application with an ozone generator at 80% concentration using probe #3 for 30 s per site
76067319|NCT05443256|Device|Transcranial Magnetic Stimulation|Figure 8 coil stimulation
75456176|NCT01768650|Behavioral|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
75607652|NCT02874807|Other|Placebo|
75607653|NCT02817529|Device|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
75607654|NCT02817529|Device|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
75607655|NCT02875431|Procedure|Patients undergo ACDF or cervical vertebral body replacement|
75607656|NCT02817607|Procedure|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
75607657|NCT00627159|Other|High risk assessment|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.
75753495|NCT00489476|Drug|Staccato Loxapine|
76072286|NCT02068443|Drug|Alogliptin|Alogliptin tablets
75753496|NCT00489476|Drug|Staccato Placebo|Placebo aerosol inhalation (0mg)
75753497|NCT00550745|Biological|Zoster Vaccine, Live|single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
75753498|NCT00550745|Biological|Comparator: placebo|single 0.65 mL Placebo injection. 6 month treatment period.
75753499|NCT00949793|Device|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
75753500|NCT00949871|Other|communication analysis|
75901726|NCT03096106|Device||the investigators just observe the pressure time curve on the ventilation
75901727|NCT02149758|Drug|Etoricoxib|
75607658|NCT00627159|Other|Low to moderate risk|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
75607659|NCT02814097|Drug|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
75753501|NCT00949871|Other|questionnaire administration|
75753502|NCT00949871|Procedure|psychosocial assessment and care|
75901728|NCT03094546|Dietary Supplement|Polyamine|12 months of polyamine supplementation (6 capsules/day)
75901729|NCT03094546|Dietary Supplement|Placebo|12 months of placebo intake (6 capsules/day)
75901730|NCT03542214|Combination Product|Calcium electroporation|Patients with inoperable colorectal cancer will be treated with calcium electroporation
75901731|NCT03094468|Drug|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
75901732|NCT03094468|Drug|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
75901733|NCT02156388|Biological|GW003|freeze-dried powder；single SC injection
75753503|NCT00949871|Procedure|support group therapy|
75753504|NCT00952601|Dietary Supplement|Modified Atkins diet|Low carbohydrate diet
75753505|NCT00956735|Other|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
75753506|NCT04216043|Dietary Supplement|RUSF skimmed milk powder|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
75753507|NCT04216043|Dietary Supplement|RUSF milk protein concentrate and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
75753508|NCT04216043|Dietary Supplement|RUSF soy protein and whey permeate|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
75753509|NCT04216043|Dietary Supplement|RUSF soy and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
75753510|NCT00952679|Device|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
75753511|NCT04416659|Device|Neuro-vascular access|Adjunctive device providing a conduit for retrieval device during thrombectomy
75753512|NCT00956969|Behavioral|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
75753513|NCT00956969|Behavioral|Relaxation Training|Teaches patients relaxation training
75753514|NCT00952835|Other|regular treatment|regular treatment
75753515|NCT00957125|Drug|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
75753516|NCT00957125|Drug|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
75607660|NCT02814097|Drug|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
75607661|NCT02814331|Device|multimodal high-resolution EEG-NIRS|
75607662|NCT02875275|Other|Glucose with grass jelly solution|50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
75607663|NCT02875275|Other|Glucose with grass jelly (solid)|50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
75753517|NCT00957125|Drug|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
75753518|NCT04327583|Behavioral|IPPACTTO|"The coordinated experimental pharmaceutical path consists of 7 pharmaceutical interviews or consultations. One initial pharmaceutical consultation with the hospital pharmacist. Five follow-up pharmaceutical interviews with the dispensary pharmacist. One follow-up pharmaceutical consultation with hospital pharmacist.~Each pharmaceutical interview or consultation will result in the drafting of a pharmaceutical report to be sent to the other participating health professionals. At each pharmaceutical consultation or interview, the pharmacists requested perform a clinical pharmaceutical analysis of drug prescriptions; Evaluate the patient's understanding; Detect adherence problems, Identify drug related problems; Alert the oncologist and / or the attending physician."
75753519|NCT04295837|Other|ABLE|Home-based occupational therapy compensatory programme addressing activities of daily living
75753520|NCT04295837|Other|Usual Care|Standard occupational therapy
75753521|NCT00957203|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
75753522|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
75753523|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
75753524|NCT00952913|Drug|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
75753525|NCT00952991|Drug|LAF237 = vildagliptin|
75753526|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 1
75753527|NCT00957437|Drug|AZD1305|ER formulation 1, bid for 5 days
75753528|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 2
75901734|NCT05029024|Other|30-minute mindful breathing|The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes.
75901735|NCT05029024|Other|control group|standard care alone
75901736|NCT02152878|Device|Sham stimulation|For sham tDCS, the device will be turned off after 30 seconds of stimulation.
75901737|NCT02152878|Device|Active stimulation|"For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials"
76067320|NCT05441306|Device|Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).
75607664|NCT02875275|Other|Porridge and juice with coconut oil|Add instant porridge with hot water with oil. Consume with commercially available orange juice
75753529|NCT00957749|Drug|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
75901738|NCT05026216|Drug|Qwo|Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids. Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids.
75901739|NCT03542136|Device|VibrosSense Meter®|A multi frequency tactilometry device to evaluate the vibrotactile sense to indicate the underlying (Oxaliplatin induced poly neuropathy) OIPN and then compare the results with the results of CTCAE (Common toxicity criteria of adverse events) assessment tool evaluation.
75901740|NCT05025982|Procedure|combination of lymphaticovenular anastomosis and liposuction|Surgeries were carried out under local anesthesia and light sedation.LVA was performed adopting supramicrosurgical technique.Liposuction was performed following completion of the LVA
75901741|NCT02156544|Drug|CKD-519|
75901742|NCT02156544|Drug|placebo|
75607665|NCT02875275|Other|Porridge and juice with coconut oil gel|Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
75456177|NCT01768650|Behavioral|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
75607666|NCT05636605|Diagnostic Test|Multiomics analysis|Genome, proteomics, single cell RNA sequencing, and space transcriptome sequencing，etc
75753530|NCT00953303|Drug|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
75753531|NCT00953303|Drug|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
75901743|NCT05025904|Behavioral|Real-time fMRI neurofeedback (rt-fMRI NFB)|Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
75901744|NCT05025904|Behavioral|Сognitive behavioral therapy (CBT)|A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.
75901745|NCT05025904|Behavioral|EEG neurofeedback (EEG NFB)|EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
75901746|NCT03543462|Device|thoracic Drain Tube 24 Fr.|Positioning of Thoracic Drain after diaphragmatic resection and consequently diaphragmatic repair
75901747|NCT03095950|Other|News items with spin|Interpretation of news items with spin
75901748|NCT03095950|Other|News items without spin|Interpretation of news items without spin
75901749|NCT03744546|Drug|ABBV-8E12|Solution for infusion
75901750|NCT05025592|Drug|Regorafenib|patients will received TACE-HAIC and regorafenib and anti-PD1 antibody or not
75456178|NCT01768663|Drug|Lumacaftor|tablet, 200mg taken every 12 hours
75456179|NCT01768663|Drug|Ivacaftor|tablet, 250mg taken every 12 hours
75901751|NCT05025592|Device|cTACE/DEB-TACE-HAIC|conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion
75901752|NCT04467034|Behavioral|Stanford Tobacco Prevention Toolkit curriculum|Stanford Toolkit curriculum delivered as a 5-session course in a school classroom setting.
75901753|NCT02775864|Drug|Antipsychotic|New initiation of any antipsychotic medication
75456180|NCT01768663|Drug|Ciprofloxacin|750 mg taken every 12 hours
75901754|NCT02775864|Drug|Antidepressant|New initiation of any antidepressant medications
75456181|NCT01768663|Drug|Itraconazole|200mg taken once daily
75456182|NCT01768663|Drug|Rifampin|600mg taken once daily
75456183|NCT01768689|Behavioral|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
75607667|NCT01054599|Drug|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
75607668|NCT01054599|Other|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
75753532|NCT05300555|Drug|Rivaroxaban 20 MG Oral Tablet|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
75753533|NCT05300555|Drug|Warfarin|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
75753534|NCT04010669|Drug|Somatostatin|2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days
75901755|NCT02775864|Drug|Benzodiazepine|New initiation of any benzodiazepine
75901756|NCT02775864|Drug|Mood stabilizer|New initiation of lithium or any mood stabilizing anti-epileptic drug
75901757|NCT03095872|Device|CO2-laser|Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
75901758|NCT03095872|Drug|Vaseline|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home."
75901759|NCT03095872|Drug|Bepanthen|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home."
75901760|NCT02156700|Procedure|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
75901761|NCT03096184|Drug|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
75901762|NCT03096184|Drug|Tegafur Gimeracil Oteracil Potassium Capsules|50mg bid p.o. every day for 14 days as a cycle
76067321|NCT05441306|Device|Epic®MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
75607669|NCT01054599|Drug|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
75753535|NCT04010669|Drug|Placebo|24 hours infusion of 1000ml Normal Saline solution 0.9%
75753536|NCT04010591|Device|impedance measurement during urodynamic study|Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
75753537|NCT04263311|Behavioral|CHW|Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
75753538|NCT00957983|Drug|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
76067322|NCT05432011|Procedure|PENG Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), PENG block with 20 mL of 0.5 % Ropivacaine will be executed as described by Giron-Arango et al. using a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
76072287|NCT02068443|Drug|Metformin hydrochloride|Metformin hydrochloride tablets
75607670|NCT02813863|Drug|SP2086|
76067323|NCT05432011|Procedure|Lateral Femoral Cutaneous Nerve Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), ultrasound guided Lateral Femoral Cutaneous Nerve Block will be performed with 10 mL of 0.5 % Ropivacaine using a high frequency linear probe. A 22G 50 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
75607671|NCT02813863|Drug|Metformin|
75607672|NCT02874729|Procedure|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
75607673|NCT02874729|Procedure|Urine collection|Urine will be collected in appropriate sterile holders provided.
75607674|NCT02874729|Procedure|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
75607675|NCT02874729|Procedure|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
75607676|NCT04275661|Procedure|Ultrasound (US) bi-level erector spinae block|nerve block
75607677|NCT04275661|Drug|levobupivacaine|20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
75607678|NCT04275661|Drug|Ketamine|2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle
75607679|NCT04275661|Drug|Magnesium Sulfate|2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
75607680|NCT02813941|Other|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
75607681|NCT02813941|Other|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
75607682|NCT02813941|Other|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
75607683|NCT02875041|Device|Transcranial Magnetic Stimulation (TMS)|
76067324|NCT05432011|Procedure|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.5 % Ropivacaine.
75607684|NCT02875041|Device|MAGSTIM Rapid2|
75607685|NCT02813707|Other|QoL questionnaire regarding the long term complication|Micronutrients evaluation
75607686|NCT04187521|Other|Meal A|A breakfast meal with a specific macronutrient proportions.
75607687|NCT04187521|Other|Meal B|A breakfast meal with a specific macronutrient proportions.
76067325|NCT05419908|Drug|Fezolinetant|Oral Capsule
75456184|NCT01768689|Behavioral|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
75456185|NCT01768689|Behavioral|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
75456186|NCT01768702|Biological|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
75607688|NCT00948766|Drug|Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine was supplied in a 5 cm^2 patch which released 4.6 mg/24 h. Patches were changed daily.
75607689|NCT00948766|Drug|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine was supplied in a 10 cm^2 patch which released 9.5 mg/24 h. Patches were changed daily.
75607690|NCT00948766|Drug|Rivastigmine 13.3 mg/24 h (15 cm^2)|Rivastigmine was supplied in a 15 cm^2 patch which released 13.3 mg/24 h. Patches were changed daily.
75607691|NCT00948766|Drug|Placebo|Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
75456187|NCT01768702|Biological|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
75456188|NCT01768728|Procedure|Laparoscopic left hemihepatectomy|participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
75456189|NCT01768728|Procedure|Open left hemihepatectomy|participants will be performed with traditional open left hepatectomy using laparotomic instruments
75753539|NCT05299463|Diagnostic Test|Exercise Testing|"Tele-Six-minute walk test (T6MWT)~1 Minute Sit-to-stand test (STS)~2-minute symptom-limited Step test (ST)~3-metre Timed up and go test (TUG)."
75753540|NCT00452790|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
75753541|NCT00452790|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
75753542|NCT00953381|Drug|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
75753543|NCT00953381|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
75753544|NCT00953381|Drug|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
75607692|NCT02813629|Device|tDCS plus PES|"transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability."
75753545|NCT00953381|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
75753546|NCT05300477|Drug|Acetazolamide|Carbonic Anhydrase Inhibitor
75753547|NCT05300477|Drug|Erythropoietin|Hormone for red blood cell
75456190|NCT01768741|Procedure|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
75901763|NCT02156778|Behavioral|Active Comparator: Extended Standard Care (Stroke Card)|"Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment."
75901764|NCT02156778|Behavioral|Active Comparator: Standard Care|"In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment."
75607693|NCT04206722|Device|Shock Wave Therapy|Shock Wave therapy - hip osteoarthritis program
75607694|NCT04206722|Device|Ultrasound|Ultrasound 0.7W/cm2
75607695|NCT01053663|Drug|Tamiflu|10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
75901765|NCT05028010|Behavioral|Capacity building|Four days of training on the promotion of maternal and child nutrition will be given. The training will be based on Pender's health promotion model. Supportive supervision will be conducted.
75607696|NCT00634387|Dietary Supplement|Anthocyans|Anthocyans
75456191|NCT01768741|Procedure|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
75456192|NCT01768754|Behavioral|Usual and Fast Walking Speeds|Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
75753548|NCT00953459|Drug|sunitinib malate|
75753549|NCT00953459|Other|laboratory biomarker analysis|
75753550|NCT00953459|Radiation|fludeoxyglucose F 18|
75753551|NCT00953537|Drug|capecitabine|
75753552|NCT00953537|Other|laboratory biomarker analysis|
75753553|NCT00953537|Other|pharmacological study|
75753554|NCT00463788|Drug|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m^2) followed by weekly doses of 250 mg/m^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
75753555|NCT00463788|Drug|cisplatin|"Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
75753556|NCT00548249|Device|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
75753557|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
75901766|NCT05027854|Other|TMS or tES|Transcranial magnetic or electric stimulation
75901767|NCT05027854|Other|sham TMS or tES|Sham transcranial magnetic or electric stimulation
75901768|NCT03542916|Drug|CJ-40001 60ug|CJ-40001 60ug SC, IV injection
75901769|NCT03542916|Drug|NESP 60ug|NESP 60ug SC, IV injection
75901770|NCT05025202|Other|Isometric exercise training|A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.
75901771|NCT05028088|Drug|sugammadex|This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.
75901772|NCT02156934|Biological|paraurethral injection|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
75901773|NCT02157012|Drug|The effectiveness of Xeljanz in rheumatoid arthritis patients|
75901774|NCT03096028|Other|maternal vitamin B12 folate level during pregnancy|Maternal Vitamin B12 and folate level at 18&28 weeks of pregnancy is the primary exposure of interest
75901775|NCT02149914|Device|Ryodoraku|Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication
75901776|NCT02149914|Device|ANSWatch|ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
75901777|NCT02149914|Device|UGI endoscopy|UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
75901778|NCT02149914|Other|GerdQ|GerdQ to assess the severity of GERD for each patient before and after taking the medication
75901779|NCT02149914|Drug|PPI|
75607697|NCT00634387|Other|placebo|
75607698|NCT00634387|Dietary Supplement|Anthocyans|
75607699|NCT01235546|Drug|Azithromycin and standard of care|500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
75901780|NCT03095794|Other|How people learn another's value preference during decision under risk|The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.
75607700|NCT01235546|Drug|Placebo and standard of care|250 cc normal saline, plus standard of care (cephazolin or clindamycin)
75607701|NCT02813395|Device|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
75901781|NCT03095794|Other|Neural mechanism of making a group decision under risk that influences on in-group members|how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.
75901782|NCT03095794|Other|Neural mechanism of making a group decision that influences on out-group members|Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.
75901783|NCT03095794|Other|fMRI|For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
75901784|NCT04976218|Biological|TGFβR-KO CAR-EGFR T Cells|Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10^5/kg, dose 2 will be 1×10^6/kg，and dose 3 will be 1×10^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
75901785|NCT02153190|Device|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
75901786|NCT02153190|Device|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
76067326|NCT05419908|Drug|Placebo|Oral Capsule
75607702|NCT02813395|Device|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
75607703|NCT01053429|Drug|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
75607704|NCT01233284|Drug|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
75753558|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
75607705|NCT01233284|Drug|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
75753559|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
75753560|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
75753561|NCT00463476|Biological|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right upper arm using 23 gauge needles.
75753562|NCT01025466|Drug|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
75753563|NCT01025466|Drug|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
75753564|NCT03910296|Behavioral|Acceptance & Commitment Therapy|ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
75753565|NCT04857918|Behavioral|Virtual running group program|The intervention will include an eight-week virtual running group program hosted on online platforms such as Zoom and the fitness application Strava. Participants will be placed in running groups of 6 people, and each running group will have the collective goal to run/walk the distance across the province of B.C., (940 km) and will meet weekly over Zoom to socialize and discuss running topics and their progress towards the group goal. Participants will receive a t-shirt with the STRIDE logo and a phone armband for carrying their smart phone during runs and walks.
75753566|NCT04857918|Behavioral|Attention Control: Fitness Application Strava|The attention control condition will be instructed to record their exercise using the Strava application, and will be encouraged to participate in 150 minutes of moderate-to-vigorous exercise each week of the intervention.
75753567|NCT01025544|Biological|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
75753568|NCT01025544|Biological|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
75753569|NCT03839940|Drug|Dexamethasone|Given as mouthwash
75753570|NCT03839940|Other|Placebo|Given as mouthwash
75607706|NCT01233284|Drug|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
75753571|NCT03839940|Other|Questionnaire|Ancillary studies
75607707|NCT01233284|Drug|tiotropium bromide 1.25µg once daily|IMP
75607708|NCT00627237|Behavioral|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
75753572|NCT03839940|Other|Quality-of-Life Assessment|Ancillary studies
75456193|NCT01768780|Device|the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine|"The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.~A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.~For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle."
75607709|NCT00627237|Behavioral|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
75607710|NCT00948688|Radiation|Radiation therapy|Once per day, 5 days a week for 6 weeks
75607711|NCT00948688|Drug|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
75607712|NCT00948688|Drug|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
75607713|NCT02857114|Other|massage|
75607714|NCT01233050|Drug|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
75753573|NCT03839940|Drug|Everolimus|Standard of care
75753574|NCT01025622|Biological|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
75753575|NCT01027494|Drug|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
75753576|NCT01027572|Device|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
75753577|NCT03839628|Other|Reduced Physical Activity|Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
75753578|NCT00462462|Drug|Ethanol 96% Gel|
75753579|NCT00462462|Drug|Ethanol 98% Solution|
75607715|NCT01233050|Drug|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
75607716|NCT01232894|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
75607717|NCT01232894|Drug|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
75607718|NCT01049217|Drug|pregabalin|Pregabalin 75 mg-300mg twice daily during the course of the study.
75607719|NCT01049217|Drug|placebo|Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
75607720|NCT01232738|Drug|rasagiline|rasagiline 2 mg daily for 12 months
75607721|NCT04206644|Other|biological analysis|biological analysis of the Concentration of CCL18
75607722|NCT00957268|Drug|Alogliptin|Alogliptin tablets
75456194|NCT01768793|Behavioral|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
75607723|NCT02888444|Drug|Varenicline|Two 0.5mg tablets taken twice daily
75901787|NCT05041738|Procedure|Intraoral Cryotherapy|small ice packs wrapped in sterile gauze placed in the mouth on the vestibular surface of the treated tooth
75901788|NCT05041738|Procedure|Intracanal Cryotherapy|Intracanal cryotherapy technique using 2.5°C cold saline irrigation as final irrigant
75607724|NCT02888444|Behavioral|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
75607725|NCT02888444|Drug|Placebo|Two 0.5mg tablets taken twice daily
75607726|NCT02888132|Procedure|Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum|
75607727|NCT02888132|Procedure|Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum|
75753580|NCT00462384|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
75607728|NCT02158858|Drug|Pelabresib (CPI-0610)|
75607729|NCT02158858|Drug|Ruxolitinib|
75753581|NCT00452400|Drug|BI 1744CL|
75753582|NCT00462306|Procedure|Survey: Berlin questionnaire|Completion of questionnaire
75456195|NCT01768793|Behavioral|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
75456196|NCT01768806|Behavioral|PLAY Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
75607730|NCT01230788|Drug|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
75607731|NCT04269694|Drug|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
75607732|NCT04269694|Device|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
75607733|NCT01230710|Drug|Erlotinib|Erlotinib was supplied as tablets.
75607734|NCT04269616|Behavioral|Order of pictographs provided to participants|The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).
75607735|NCT04269616|Behavioral|Level of description in survival pictograph|The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).
75607736|NCT00627081|Drug|remifentanil|dosage
75753583|NCT00461682|Drug|SB-705498|
75753584|NCT03776370|Procedure|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
75753585|NCT03776370|Procedure|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery.
75901789|NCT02149992|Dietary Supplement|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
76072288|NCT02068443|Drug|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
76072289|NCT02065869|Biological|BPX-501 T cells|1x10E6 cells/kg infused on Day 0
75456197|NCT01768806|Behavioral|Special education pre-school|Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
75753586|NCT01566474|Drug|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
75753587|NCT01566474|Drug|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
75456198|NCT01768819|Behavioral|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
75753588|NCT01025778|Drug|Clofarabine for remission induction|
75753589|NCT01025778|Drug|Etoposide for remission induction|
76067327|NCT05418972|Drug|Relatlimab and nivolumab fixed dose combination (FDC)|Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.
75753590|NCT01025778|Drug|Cyclophosphamide for remission induction|
75753591|NCT01025778|Drug|Clofarabine in conditioning before transplantation|
76067328|NCT05414383|Device|CADx|A novel CADx system for real-time histopathological prediction of colorectal neoplasia, by using non-magnified conventional white-light and image enhanced endoscopy.
75456199|NCT01768884|Drug|Nitric Oxide|
75456200|NCT01768884|Drug|Placebo|
75456201|NCT01768897|Drug|CPI-613|Given IV
75456202|NCT01768897|Drug|cytarabine|Given IV
75456203|NCT01768897|Drug|mitoxantrone hydrochloride|Given IV
75753592|NCT01025778|Drug|Thiotepa in conditioning before transplantation|
75753593|NCT01025778|Drug|Melfalan in conditioning before transplantation|
75753594|NCT01025778|Procedure|Haploidentical transplantation of T-cell depleted graft|
75753595|NCT01025778|Procedure|Donor lymphocyte infusion|
75753596|NCT00443430|Drug|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
75753597|NCT00443430|Drug|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
75753598|NCT01022658|Drug|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
75753599|NCT01025856|Other|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
75753600|NCT01025856|Other|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
75456204|NCT01768897|Other|laboratory biomarker analysis|Optional correlative studies
75901790|NCT02149992|Device|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
75901791|NCT02149992|Device|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
75901792|NCT05041660|Other|Virtual-reality-based training|Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
76072290|NCT02065869|Drug|Rimiducid|0.4mg/kg administered IV to treat GVHD
75456205|NCT01768897|Other|pharmacological study|Correlative studies
75753601|NCT01025856|Other|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
75753602|NCT01025856|Other|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
75753603|NCT01022736|Drug|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
75456206|NCT01768910|Other|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
75456207|NCT01768910|Other|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
75607737|NCT01230554|Device|Daily disposable cosmetic tint lens|Bausch & Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
75753604|NCT01022814|Device|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
75753605|NCT01025934|Drug|Bevacizumab|
75753606|NCT01025934|Other|sham|
75753607|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training.
75753608|NCT01026090|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
76067329|NCT05403697|Procedure|Individualized MAP|Hemodynamic optimization beginning after general anesthesia induction, and ending at the 24th hour postoperatively, which consists in obtaining a mean arterial pressure (MAP) which is at least 90% of the usual MAP of the patient.
76067330|NCT05402930|Diagnostic Test|Angiomammography|"Patients will receive their care in a standard manner. Breast MRI is one modality used by physicians to monitor response to neoadjuvant chemotherapy and will therefore be used as standard. A CESM exam will be added at the same time as the MRI.~Patients will have a physical exam, breast MRI and CESM before the start of chemotherapy (less than 2 weeks). These examinations will be repeated after cycle 2 (±1 week) and at the end of chemotherapy. After each cycle of chemotherapy, the tumor will be measured in two axes by the attending physician.~Histological examination of the surgical specimen will be used to determine the pCR. Responses observed on MRI and CESM will be compared to pCR."
75753609|NCT01026090|Drug|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
75753610|NCT01028040|Drug|AZD3043|Intravenous, single dose
75753611|NCT01028040|Drug|AZD3043|Infusion, single dose
75753612|NCT01028118|Other|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
75753613|NCT03891654|Diagnostic Test|Dynamic Contrast Enhanced Computed Tomography|Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
75753614|NCT00460746|Drug|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
75456208|NCT01768910|Other|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
75456209|NCT01768910|Other|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
75607738|NCT04302909|Other|focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
75607739|NCT04302909|Other|sham focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
75607740|NCT04302909|Other|night splint|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
75753615|NCT01026246|Drug|Placebo|The placebo used will be normal saline (0.9 percent NaCl).
75753616|NCT01026246|Biological|EBA-175 RII-NG Malaria Vaccine|EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
75753617|NCT01028274|Dietary Supplement|Placebo|Two capsules, twice daily with meals for 12 weeks.
75753618|NCT01028274|Dietary Supplement|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
75753619|NCT01028274|Dietary Supplement|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
75753620|NCT00443118|Device|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
75753621|NCT00443118|Device|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
75753622|NCT00443118|Device|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
75753623|NCT00460434|Device|TVT|Prophylactic TVT
75753624|NCT00460434|Other|Sham|Sham TVT
75753625|NCT01023048|Other|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
75753626|NCT01026558|Drug|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
75753627|NCT01023126|Behavioral|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
75753628|NCT01025700|Drug|Cesemat|1 mg capsule per day for 21 days
75607741|NCT02888054|Drug|lesinurad/allopurinol 200/300 FDC tablet|
75456210|NCT01768923|Procedure|SDAI remission|SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score [SDAI] <3.3)
75456211|NCT01768923|Procedure|Minimal disease activity remission|Minimal disease activity group aims at minimal disease activity (DAS28<2.6) (minimal disease activity group)
75456212|NCT01768949|Device|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
75456213|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
75456214|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
75456215|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
75456216|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
75456217|NCT01768988|Drug|Placebo|"Conventional treatment + placebo (during 90 days).~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~Paracetamol 1g/8h~Weak opioid (tramadol at maximal doses of 400 mg/24h)~Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS < 3)."
75456218|NCT01768988|Drug|Pregabalin|"Treatment during 90 days with conventional treatment + pregabalin.~Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:~Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~Paracetamol 1g/8h~Weak opioid (tramadol at maximal doses of 400 mg/24h)~Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS < 3)."
75607742|NCT02888054|Drug|lesinurad 200 mg|
75753629|NCT00373425|Drug|Erlotinib|150 mg tablet
75753630|NCT00373425|Drug|Placebo|Placebo tablet
75753631|NCT00459342|Drug|dasatinib|Given orally
75753632|NCT03510156|Behavioral|Behavior analytic treatment|Function-based treatment
75753633|NCT00443040|Drug|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
75753634|NCT00443040|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
75753635|NCT00442962|Drug|Efavirenz|600-mg tablet taken orally daily
75901793|NCT05041660|Other|Inhibitory Control Training|"Uses an active inhibitory control training which includes a stop signal."
75607743|NCT02888054|Drug|allopurinol 300 mg|
75607744|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
75753636|NCT00442962|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
75753637|NCT03995160|Procedure|Use of closed suction drainage following total knee arthroplasty|Use of closed suction drainage following total knee arthroplasty
75753638|NCT03995160|Procedure|Abstain of using a closed suction drainage|Abstain of using a closed suction drainage following total knee arthroplasty
75753639|NCT01028508|Drug|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
75753640|NCT01028508|Procedure|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
75753641|NCT01026636|Drug|Ceftobiprole|
75753642|NCT00313300|Drug|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
75753643|NCT00313300|Drug|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
75901794|NCT05041660|Other|Sham Inhibitory Control Training|"Uses an inhibitory control training which does not include a stop signal."
75901795|NCT05041660|Other|Computerized training|Uses a relatively simplistic computerized training.
75901796|NCT04833582|Drug|ZN-c3|ZN-c3 is an investigational drug.
75456219|NCT01769040|Drug|Rifaximin|550 mg two times daily for 28 days
75901797|NCT04833582|Drug|Gemcitabine|Gemcitabine is an approved drug
75607745|NCT05477810|Drug|Treatment A (investigational drug) followed by Treatment B (reference drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
75753644|NCT00313300|Drug|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
75753645|NCT00313300|Drug|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
75753646|NCT01023282|Drug|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
75753647|NCT01023282|Drug|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
75753648|NCT00459186|Drug|RAD001|Daily for two weeks
75901798|NCT02157090|Other|Herpes Patch SOS (Hansaplast®)|
75901799|NCT02157090|Other|Herpes vesicle patch of Compeed®|
75901800|NCT02153268|Procedure|Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study|"Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).~BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose."
75753649|NCT00459186|Drug|Docetaxel|Infusion once per cycle
75753650|NCT00459186|Drug|Prednisone|Prednisone 5 mg by mouth twice daily
75753651|NCT01026714|Drug|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
75753652|NCT01026714|Drug|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
75753653|NCT01026714|Drug|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
75753654|NCT03996252|Drug|Calcipotriene 0.005% Foam|Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
75901801|NCT05041582|Device|tDCS|dual tDCS with ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation, 2 weeks after SSRI treatment
75901802|NCT05041582|Drug|Citalopram|total 3 months, since 2-4 weeks after stroke
75901803|NCT05041582|Behavioral|Rehabilitation|hospitalized rehabilitation, 3 hours daily
75901804|NCT02157246|Other|Pimonidazole|
75901805|NCT02157246|Other|F-MISO PET|
75901806|NCT02157246|Other|pCT|
75901807|NCT02157246|Other|Functional MRI|
75901808|NCT02157246|Procedure|Biopsy|
75901809|NCT02157246|Procedure|Blood sample|
76025024|NCT01958476|Drug|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
75456220|NCT01769040|Drug|placebo|
75456221|NCT01769053|Other|Variable Ventilation|
75456222|NCT01769066|Drug|Sequential Gefitinib With Pemetrexed/Platinum|
75456223|NCT01769066|Drug|Pemetrexed/Platinum|
75456224|NCT01769079|Drug|Nitrate|Two arms: placebo and nitrate
75456225|NCT01769079|Drug|Placebo|
75456226|NCT01769118|Drug|Caffeine|Caffeine will be given according to departmental protocol
75456227|NCT01769144|Device|Acticoat Absorbent|wound dressing
75456228|NCT01769144|Device|BCT|wound dressing
75456229|NCT01769157|Drug|L-carnitine|
75456230|NCT01769157|Drug|Placebo|
75753655|NCT03996252|Drug|Efudex 5% Topical Cream|Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
75753656|NCT00328510|Device|GTC frame|
75753657|NCT00328510|Device|Thermoplastic facemask|
75753658|NCT00328510|Radiation|Stereotactic radiation therapy|
75753659|NCT00313144|Drug|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
75753660|NCT00459108|Drug|dasatinib|Given orally
75607746|NCT05477810|Drug|Treatment B (reference drug) followed by Treatment A (investigational drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
75901810|NCT04966156|Behavioral|CaRE-4-alloBMT plus usual care group|CaRE-4-alloBMT uses emerging eHealth technologies to reduce barriers to accessing and providing cancer rehabilitation which includes: 1) Individualized progressive exercise prescriptions that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials; 2) Individualized nutrition plans and stepped stratified care such as education, counselling, intervention based on nutritional status and delivered by registered dietitians; 3) On-line e-modules provide interactive education to promote self-management skills for stress management, nutrition, managing common symptoms, etc.; 4) Remote monitoring using FitbitTM devices to monitor patients physical activity, caloric intake, and sleep for duration of the program. CRS and alloBMT clinicians will have access to real-time Fitbit data through our clinical dashboard; 5) Remote clinical support: check-ins and health coaching sessions with a member of the CRS team (phone or MS Teams video).
75901811|NCT02150070|Drug|ASP2408|Intravenous (IV) infusion and subcutaneous (SC) injection
75901812|NCT02150070|Drug|Placebo|Intravenous (IV) infusion and Subcutaneous (SC) injection
75901813|NCT02150148|Behavioral|Experimental: Mentored Gardening Intervention|receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
75607747|NCT02815969|Other|vena punction|vena punction and urine collection
75607748|NCT02811367|Device|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
75607749|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
75753661|NCT00458484|Radiation|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions."
75753662|NCT00458484|Procedure|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
75901814|NCT03542838|Drug|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
75753663|NCT00458484|Procedure|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
75901815|NCT03542838|Drug|Saline|Saline is a normal physiological solution
75901816|NCT05027776|Biological|2-doses Group among 9-14 years|Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.
75753664|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
76067331|NCT05399173|Device|infrared (gallium aluminum arsenide laser)|Patient Position will be in supine & prone position, the area of these points is resolved utilizing anatomical landmarks and an arrangement of length measurements whose units are in respect to the physical extents of the individual patient. Acupuncture points used to treat nighttime enuresis are situated in regions that coincide with innervation by spinal sacral segments S2 through to S4 and expressed in the treatment conventions. The points of BL 23, BL 28, BL 32, RN 3, RN 4, RN 6, RN 12 impact the spinal micturition centers and parasympathetic innervation to the urinary tract, while excitement on scalp acupoints of DU 20 and DU 14 change cerebrum function through inner temporal, thalamencephalon and prefrontal cortical frameworks. Excitation of acupoints UB 20, UB 13, SP 6, ST 36, KI 3 and LU 9 are considered to strengthen spleen, vital energy and blood which encourage standardized bladder capacity
76067332|NCT05399173|Drug|medical treatment(desmopressin acetate)|participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) & advice
76067333|NCT05396534|Procedure|Atrial Fibrillation transcatheter ablation|We perform pulmonary veins isolation that remains remains the cornerstone of all catheter-based treatment strategies in atrial fibrillation
76067334|NCT05394246|Drug|FluoAB|Drug Injection: FluoAB (fluorescent-labeled IgG)
76067335|NCT05388877|Drug|Dabrafenib|Given PO
76067336|NCT05388877|Drug|MEK-1/MEKK-1 Inhibitor E6201|Given IV
75901817|NCT05027776|Biological|3-doses Group among 9-19 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
75456231|NCT01769183|Drug|Squalamine Lactate ophthalmic solution 0.2%|Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
75456232|NCT01769235|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
75607750|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
75607751|NCT01040793|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
75607752|NCT01040793|Drug|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
75901818|NCT05027776|Biological|3-doses Group among 20-26 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
75901819|NCT02150226|Device|Lava plus (3M) crowns and bridges|Zirconia monolithic dental crowns and bridges evaluation
75901820|NCT02153424|Drug|Apixaban|
76067337|NCT05371899|Drug|Chiauranib|Take Chiauranib 50mg orally once daily
76067338|NCT05370209|Device|Otinova® Ear Spray|Ear spray
76067339|NCT05362578|Device|transcutaneous electrical accustimulation at treatment point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
76067340|NCT05362578|Device|transcutaneous electrical accustimulation at sham point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
75456233|NCT01769235|Drug|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
75607753|NCT01040793|Drug|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
75607754|NCT04204447|Other|Hepatitis C Educational Brochure|Subjects will receive information about Hepatitis C through a brochure
75607755|NCT04204447|Other|Hepatitis C Educational Video|Subjects will receive information about Hepatitis C through a video
76067341|NCT05353959|Other|No intervention|No intervention
75901821|NCT05025436|Device|Acupoint stimulation with low energy laser (Erger laser pen)|Each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/-10%, The power is 200mW, and the Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module is selected according to the acupoints. The treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, after a 2-week pause, After the two groups crossed for 4 weeks, each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) with low-energy laser (Erjie laser pen) acupoint stimulation. Set wavelength 810nm +/-10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and treatment dose is 3 joules per acupoint three times a week for a period of time 4 weeks.
76067342|NCT05353881|Other|No intervention|No intervention
76067343|NCT05353868|Other|No intervention|No intervention
75456234|NCT01769235|Drug|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
75456235|NCT01769261|Other|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
75901822|NCT02157402|Behavioral|Social marketing activities and pop-up events to promote healthy lifestyles|
75456236|NCT01769261|Other|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
75456237|NCT01769261|Other|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
75456238|NCT01769300|Behavioral|Clinical decision support for medication titration|Electronic health record-based clinical decision support for ADHD medication titration.
76067344|NCT05353842|Behavioral|WOWii Program|Workout on Wheels Internet Internvention (WOWii) which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
76067345|NCT05353322|Behavioral|Sedentary Break (Walking) Condition|For the sedentary break (walking) condition, participants will be randomized to 1 of 25 combinations of frequency (5 doses: sedentary break every 30, 45, 60, 90, or 120 minutes) and duration (5 doses: sedentary break duration of 1, 3, 5, 7, or 10 minutes). Participants will complete a 9-hour study visit and will remain seated throughout the lab visit and will take regular sedentary breaks by walking on a treadmill at 2.0 mph and 0% incline at specific frequency and duration (as determined by the randomization method) for the entirety of the visit.
75456239|NCT01769313|Device|Laser-assisted cataract surgery|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
75456240|NCT01769313|Device|Manually performed cataract surgery|The anterior capsulotomy and lens fragmentation will be performed manually.
75456241|NCT01769417|Drug|Placebo|Placebo
75456242|NCT01769417|Drug|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
75456243|NCT01769482|Drug|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
75607756|NCT04155151|Other|6 minute walk test|A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
75607757|NCT02690233|Procedure|Elective Surgery|Elective laparoscopic inguinal hernia repair
75607758|NCT02811055|Biological|Blood sampling|Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
75607759|NCT02811055|Procedure|Blood Pressure Measurement|Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
75607760|NCT02811055|Device|electrocardiogram|Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
75607761|NCT02811055|Procedure|orthostatic test|Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
75607762|NCT02811055|Drug|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days
75607763|NCT02811055|Drug|Administration of placebo|Administration of placebo once per day during 14 days
75607764|NCT02810977|Device|Ultrasound|Ultrasound assessment of gastric content and volume
75456244|NCT01769482|Drug|placebo|
75456245|NCT01769495|Other|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
75456246|NCT01769521|Device|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
75456247|NCT01769547|Drug|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
75456248|NCT01769560|Behavioral|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
75456249|NCT01769625|Drug|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
75753665|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
75901823|NCT05027152|Other|Resistance training|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise. The repetitive task training group will carry out exercises involving upper and lower limbs.
75901824|NCT05027152|Other|Repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
75901825|NCT04434430|Drug|Gabapentin|Oral Gabapentin 600 mg
75901826|NCT04434430|Other|Placebo|Oral NaCl 500 mg
75901827|NCT03094156|Drug|Placebo|1 capsule of placebo [to be taken orally, with 240 mL of potable water]
75456250|NCT01769638|Drug|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
75456251|NCT01769638|Drug|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
75456252|NCT01769651|Other|methadone replacement therapy|Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
75456253|NCT01769664|Drug|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
75456254|NCT01769664|Drug|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
75607765|NCT04192903|Drug|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off
75607766|NCT02810899|Drug|dexmedetomidine|A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
75607767|NCT02810899|Drug|normal saline|Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
75607768|NCT02810665|Behavioral|Visual acuity measurement by ETDRS chart|All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
75753666|NCT01322880|Behavioral|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
75753667|NCT01322880|Behavioral|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
75753668|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
75901828|NCT03094156|Drug|BIA 6-512|1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg [to be taken orally, with 240 mL of potable water]
75901829|NCT03094156|Drug|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg [to be taken orally, with 240 mL of potable water]
75901830|NCT03094156|Drug|Comtan®|Entacapone 200 mg tablets [to be taken orally, with 240 mL of potable water]
75901831|NCT02964273|Drug|Tolvaptan|Tolvaptan spray-dried, immediate release tablets
75901832|NCT02964273|Drug|Tolvaptan Matching-placebo|Tolvaptan matching-placebo tablets
75456255|NCT01769664|Drug|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
75456256|NCT01769677|Drug|90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
75607769|NCT04237129|Drug|Gan & Lee Insulin Aspart|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
75607770|NCT02810587|Drug|Topical antibiotics following injection|Either receive or not receive topical antibiotics following intravitreous injection
75607771|NCT02810353|Device|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
75753669|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
75753670|NCT01028586|Drug|Placebo|matching placebo tablets
75753671|NCT03457350|Procedure|cervical negotiation|trial to bypass severe cervical stenosis
75753672|NCT01065688|Procedure|Roux-en Y reconstruction|surgical procedure
75753673|NCT01065688|Procedure|Billroth-I reconstruction|surgical procedure
75456257|NCT01769690|Other|DBS stimulator setting alteration|"2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy"
75901833|NCT05025046|Diagnostic Test|Thyroscan|To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.
75901834|NCT02773446|Biological|ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer|ETEC Bacteria
75753674|NCT00450450|Procedure|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
75753675|NCT00450450|Other|laboratory biomarker analysis|Correlative studies
75456258|NCT01769690|Other|virtual reality simulator|"This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test."
75753676|NCT00450450|Biological|filgrastim|Given IV
75753677|NCT03440892|Drug|methotrexate|folate antagonist
75753678|NCT03440892|Drug|sulfasalazine|Immunomodulatory
75753679|NCT03440892|Drug|abatacept|Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
75753680|NCT03440892|Drug|tocilizumab|IL-6 receptor antagonist
75753681|NCT03440892|Drug|tofacitinib/baricitinib|JAK inhibitor
75753682|NCT00442572|Drug|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
75753683|NCT04898322|Drug|SY-005|2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
75753684|NCT04898322|Drug|SY-005|5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
75753685|NCT04898322|Drug|SY-005|10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
75753686|NCT04898322|Drug|Placebo|Placebo
75753687|NCT01322958|Device|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
75753688|NCT01323036|Dietary Supplement|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
75901835|NCT05040724|Drug|Ivermectin|ivermectin placebo
75753689|NCT01323036|Dietary Supplement|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
75901836|NCT03542058|Drug|Carvedilol|Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.
75901837|NCT03611439|Dietary Supplement|ReBuilder|8-component botanical dietary supplement
75901838|NCT03611439|Dietary Supplement|Placebo|Inactive Placebo Capsule
75901839|NCT05040412|Device|difficult laryngoscopy|Patients will be intubated with the direct laryngoscope.
76067346|NCT05353322|Behavioral|Sitting (Control) Condition|While completing the sitting (control) condition, participants will complete the 9-hour study visit by remaining seated and only standing up/walking to use the restroom at specified times.
75901840|NCT03321513|Drug|intravitreous aflibercept|"Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique"
75901841|NCT03321513|Drug|Bevacizumab + Deferred Aflibercept Group|"Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.~Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.~Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using a sterile technique."
75901842|NCT05024110|Other|High intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
75901843|NCT05024110|Other|Moderate intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
75456259|NCT01769703|Drug|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
75456260|NCT01769716|Procedure|Umbilical cord blood transplantation|
75607772|NCT02810353|Device|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
75607773|NCT04187365|Other|Duration of Indwelling Catheter|Foley catheter
75607774|NCT02810275|Drug|Folinic Acid|Folinic acid 5 mg, taking in the morning, daily, during four weeks
75456261|NCT01769729|Behavioral|PEPP|
75456262|NCT01769729|Behavioral|Care management|
75456263|NCT01769742|Behavioral|Early mobility bundle|
75456264|NCT01769755|Biological|PDA001|"Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart."
75456265|NCT01769755|Drug|Vehicle Controlled Placebo|"Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart."
75607775|NCT02810275|Drug|Placebo|Placebo capsule received 1 tablet, taking in the morning, during four weeks
75607776|NCT05646745|Procedure|Autologous Transobturator Fascia Lata Sling|"Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, ~1 cm× ~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
75753690|NCT01023360|Drug|Clopidogrel and proton pump inhibitors|"baseline detection --> clopidogrel 75 mg PO QD for 1 week --> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week -->~1 week washout --> aspirin 100mg PO QD for 1 week"
75753691|NCT01023438|Other|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
75753692|NCT01023438|Other|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
75753693|NCT00442416|Drug|Epoetin alfa|As prescribed, SC
75753694|NCT00442416|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
75753695|NCT01023594|Procedure|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
75753696|NCT00441792|Drug|Etomidate|Etomidate at induction dose based on weight
75456266|NCT01769768|Drug|LDE225|LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
75753697|NCT00441792|Drug|midazolam|Midazolam at induction dose based on weight
75753698|NCT00312208|Drug|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
75456267|NCT01769768|Drug|Wafarin|15 mg single dose of warfarin (oral tablet) will be given to patients.
75456268|NCT01769768|Drug|Bupropion|75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
75456269|NCT01769781|Drug|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
75456270|NCT01769781|Drug|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
75456271|NCT01769794|Drug|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
75456272|NCT01769794|Drug|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
75753699|NCT00312208|Drug|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
75753700|NCT03979612|Genetic|inclusion of subjects in the GENEPY network|The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index): relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients (Claes 2003), the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.
75753701|NCT00297778|Drug|Pramipexole|Dopamine agonist
75607777|NCT02809807|Other|measurement of the work of breathing|We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
75901844|NCT03093376|Behavioral|Effortful Control Camp|"An interactive, child-friendly camp. Effortful control (EC) camp is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 12 different exercises that teach inhibitory and attentional control, as well as visuospatial and working memory skills, will be administered.~Tasks will allow for scaffolding (Halperin et al, 2013), or incremental increases in difficulty of the games over time. EC camp will occur over 4 mornings from 9AM to 12PM, on two consecutive weekends."
75607778|NCT02809807|Device|Gas Mask|Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
75901845|NCT02032797|Drug|Progesterone|
75901846|NCT05024266|Drug|Tislelizumab|Participants received 2 cycles Tislelizumab 200mg d1 + Albumin Paclitaxel 260mg/m2 d1 + Carboplatin AUC5 d1 every 3 weeks, and then were evaluated for surgery.
75901847|NCT03094078|Other|News item with spin|Interpretation of news item with spin
75607779|NCT00948064|Drug|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
75607780|NCT00948064|Drug|Azacitidine|75 mg/m^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
75607781|NCT02813239|Other|hCG|Oocyte maturation with hCG
75607782|NCT02813239|Other|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
75753702|NCT00297778|Other|Placebo|
75753703|NCT03848832|Drug|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol
75753704|NCT03848832|Drug|Placebo|Matching placebo oral solution
75901848|NCT03094078|Other|News item without spin|Interpretation of news item without spin
75901849|NCT03611361|Device|SpectralMD DeepView Wound Imaging System 2.0|The DeepView is an imaging device which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a machine learning (ML) algorithm to categorize microvascular blood flow and provide a quantitative assessment for selection of tissue healing.
75456273|NCT01769794|Drug|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
75456274|NCT01769807|Device|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
75456275|NCT01769820|Drug|Dexamethasone|studies 1&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
75456276|NCT01769820|Drug|placebo|
75607783|NCT02815501|Biological|blood samples|for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
75607784|NCT02854930|Other|questioning|
75607785|NCT02813161|Biological|cellular and tissue based therapy|
75456277|NCT01769833|Drug|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
75456278|NCT01769833|Drug|Nucleosides|
75753705|NCT00450372|Biological|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
75456279|NCT01769846|Other|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
75607786|NCT02813161|Device|negative pressure wound therapy|
75607787|NCT02813161|Procedure|debridement|
75607788|NCT02813161|Procedure|advanced wound therapy|
75607789|NCT02813161|Dietary Supplement|Nutritional screening|
75607790|NCT02813161|Device|off-loading|
75607791|NCT02813161|Device|Hyperbaric oxygen Therapy|
75753706|NCT00450372|Other|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
75753707|NCT00327340|Drug|custirsen (OGX-011)/mitoxantrone|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment."
75901850|NCT03094000|Behavioral|MIND|"Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .~The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP)."
75456280|NCT01769872|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
75456281|NCT01769898|Drug|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
75456282|NCT01769898|Drug|Theophylline|Theophylline 0.1 Q12H
75456283|NCT01769898|Drug|Placebo|Placebo for theophylline 0.1 Q12H
75456284|NCT01769911|Drug|carmustine|Given IV
75456285|NCT01769911|Drug|cytarabine|Given IV
75456286|NCT01769911|Drug|melphalan|Given IV
75456287|NCT01769911|Drug|etoposide|Given IV
75456288|NCT01769911|Drug|O6-benzylguanine|Given IV
75456289|NCT01769911|Procedure|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
75456290|NCT01769911|Procedure|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
75607792|NCT04271098|Procedure|Open-Heart Surgery for nine months duration|In a single group of patients including 340 patients undergoing open-heart surgery during a period of nine months, the collected parameters include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT) and albumin preoperatively and on postoperative days of 1, 3 and 7. All patients were divided into two groups as with or without hyperbilirubinemia, and this was defined by the occurrence of a plasma total bilirubin concentration of more than 34 µmol/L (2 mg/dL) in any measurement during the postoperative period. For each diagnostic test, a comparison within the group for different time points was statistically evaluated by analysis of variance tests.
75456291|NCT01769911|Other|laboratory biomarker analysis|Correlative studies
75456292|NCT01769937|Drug|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
75456293|NCT01769950|Other|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
75456294|NCT01769963|Other|Research diet|Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
75456295|NCT01769976|Other|Periodic fasting|
75456296|NCT01769976|Other|Energy restriction|
75456297|NCT01769976|Other|Energy balance diet|
75456298|NCT01769989|Procedure|Electrodermabrasion|
75456299|NCT01769989|Procedure|Dermabrasion|
75456300|NCT01770002|Procedure|Everted suture technique|
75456301|NCT01770002|Procedure|Non-everted suture technique|
75456302|NCT01770041|Other|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
75456303|NCT01770054|Other|obtention of a blood sample|a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
75456304|NCT01770080|Drug|Euminz®|3 to 5 time topical use of study drug.
75456305|NCT01770080|Drug|Placebo|3 to 5 time topical use of study drug.
75456306|NCT01770093|Other|Questionnaire|
75456307|NCT01770106|Drug|Denosumab|Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)
75456308|NCT01770106|Drug|Alendronate|Alendronate 70mg once weekly
75901851|NCT03094000|Behavioral|CBT-E|The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
75901852|NCT05026762|Other|Treatment|Following the collection of the baseline data, the study participant will be assigned to a volunteer(medical student) to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6-weeks. Each phone call is expected to last up to 1 hour.The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer.At the end of the 6-weeks phone calls, a group session will be held with the volunteers to engage in a debriefing and narrative medicine session.
75901853|NCT03611283|Other|Mouthwash treatment|60 seconds after meals (3 times/day) during 28 days
75456309|NCT01770119|Biological|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
75456310|NCT01770132|Drug|porfimer sodium|Given IV
75607793|NCT04271098|Other|Relation between possible risk factors and hyperbilirubinemia|Possible preoperative, intraoperative, and postoperative risk factors were investigated. The relations between hyperbilirubinemia and possible risk factors are sought by the use of the statistical analysis methods including logistic regression analysis.
75901854|NCT03611283|Other|Toothpaste treatment|3 minutes after the mouthwash (3 times/day) during 28 days
75901855|NCT03611283|Other|Mouthwash placebo|60 seconds after meals (3 times/day) during 28 days
75607794|NCT04271098|Other|Follow-up period|All patients were investigated for a period of ten days postoperatively. During this period, intensive care unit (ICU) stay, in-hospital stay, and all adverse events were recorded.
75607795|NCT02813005|Procedure|Jet ventilation group|MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
75901856|NCT03611283|Other|Toothpaste placebo|3 minutes after the mouthwash (3 times/day) during 28 days
75901857|NCT05040490|Drug|sugammadex as reversal drugs|use sugammadex to reverse neuromuscular blockade
75901858|NCT02773368|Drug|insulin degludec/liraglutide|IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
75901859|NCT02773368|Drug|insulin glargine|IGlar will be given subcutaneously ( s.c., under the skin) once daily.
75901860|NCT02032563|Drug|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
75901861|NCT03093532|Other|ED SBIRT-HTN|"Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
75456311|NCT01770132|Procedure|endoscopic ultrasonography|Undergo EUS-PDT
75456312|NCT01770132|Procedure|photodynamic therapy|Undergo EUS-PDT
75456313|NCT01770132|Drug|gemcitabine hydrochloride|Given IV
75456314|NCT01770171|Drug|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
75456315|NCT01770171|Drug|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
75456316|NCT01770184|Behavioral|Chronic Disease Self-Management Program (CDSMP)|
75456317|NCT01770197|Drug|IV rt-PA|IV rt-PA treatment
75607796|NCT02813005|Procedure|Standard ventilation group|apnea made by the anesthesiologist to the request of the radiologist
75607797|NCT02858206|Radiation|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
75607798|NCT02858206|Drug|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
75607799|NCT02858206|Drug|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
75901862|NCT03093532|Other|PACHT-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
75901863|NCT02032485|Drug|Indocyanine Green|An iv injection will be performed for the colorectal cancer patient before the operation.
75901864|NCT05026918|Other|MCPT|Postural Drainagewith percussion and vibration
75901865|NCT05026918|Other|ACBT|ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique
75901866|NCT05040022|Drug|Pneumoperitoneum pressure 10 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
75901867|NCT05040022|Drug|Pneumoperitoneum pressure 14 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
75901868|NCT03611205|Procedure|Computed Tomography|Undergo dPET/CT
75456318|NCT01770210|Drug|Patients on atorvastatin treatment|Statins Therapy
75456319|NCT01770223|Drug|boceprevir|
75456320|NCT01770223|Biological|PegIFN-2b|
75456321|NCT01770223|Drug|RBV|
75607800|NCT02858206|Drug|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
75607801|NCT02858206|Procedure|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
75607802|NCT05581615|Other|Inulin|Each intervention provided 10 g/d inulin split into two dosages of 5 g.
76072291|NCT02021006|Drug|nitrofurantoin|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
75901869|NCT03611205|Procedure|Positron Emission Tomography|Undergo dPET/CT
75901870|NCT03093298|Other|Enteroscopy with biopsy sampling and mixed meal test|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
75901871|NCT02254902|Behavioral|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
75456322|NCT01770236|Drug|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
75607803|NCT02810119|Drug|LO2A|
75901872|NCT05383443|Behavioral|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
75607804|NCT02810119|Drug|Placebo|
75607805|NCT02810041|Dietary Supplement|yoghurts enriched with XXS|
75901873|NCT05383443|Behavioral|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
75901874|NCT05383443|Behavioral|Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
75901875|NCT05383443|Behavioral|Capacitation to deal with cognitive decline|This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
75456323|NCT01770288|Other|Anaerobic wingate test|
75456324|NCT01770301|Drug|Paclitaxel|
75456325|NCT01770301|Drug|Bevacizumab|
75456326|NCT01770327|Behavioral|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
75456327|NCT01770340|Biological|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
75456328|NCT01770340|Procedure|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
75456329|NCT01770405|Device|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
75607806|NCT02810041|Dietary Supplement|yoghurts non enriched with XXS|
75901876|NCT05383443|Other|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
75607807|NCT02809885|Biological|Hepatitis E serology|
75901877|NCT05383443|Behavioral|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (once a week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
75901878|NCT05383443|Behavioral|Physical exercise|In-person group training (monthly): 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher.
75901879|NCT05383443|Behavioral|Nutrition education|In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants. The participants will have the opportunity to consume the prepared meals at home.
75901880|NCT05383443|Behavioral|Capacitation to deal with cognitive decline|In-person group 60-minute sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
75901881|NCT05383443|Behavioral|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
75901882|NCT03093142|Device|tDCS & neurofeedback|tDCs and neurofeedback
75901883|NCT03093142|Device|neurofeedback|Neurofeedback
75456330|NCT01770444|Other|Low-dose Cardiac CT protocol|"A cardiac CT protocol modified for reduction of radiation exposure~Prospective gating~Range: dedicated imaging (below carina to heart base)"
75456331|NCT01770444|Other|Conventional cardiac CT protocol|"Conventional CCTA protocol~Retrospective gating with tube current modulation~Range: dedicated imaging (below carina to heart base)"
75456332|NCT01770470|Dietary Supplement|Chitosan|The product chitosan is contained in a chewing gum formulation
75607808|NCT02815189|Procedure|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
75607809|NCT02815189|Drug|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
75607810|NCT02809963|Drug|Eplerenone|50 mg tablets, oral use.
75607811|NCT02809963|Drug|Placebo|50 mg tablets, oral use
75607812|NCT02815111|Drug|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
75607813|NCT02815111|Drug|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
75607814|NCT02815111|Drug|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
75607815|NCT02815111|Drug|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
75607816|NCT04236895|Drug|Gan & Lee Insulin Glargine Injection|All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.
75607817|NCT02809651|Device|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
75901884|NCT03093142|Device|sham neurofeedback|sham neurofeedback
75901885|NCT05026840|Procedure|GDM screening criteria|difference in risk factors and clinical outcomes between groups
75901886|NCT02033109|Drug|PC-1005|Intravaginal use
75456333|NCT01770496|Behavioral|Childhood vaccination reminder / recall notification|
75456334|NCT01770548|Genetic|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
75456335|NCT01770548|Genetic|DNA collection|DNA collection
75456336|NCT01770548|Other|Auditory evoked potentials|auditory evoked potentials
75456337|NCT01770561|Device|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
75456338|NCT01770574|Device|ReproBone|Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
75456339|NCT01770574|Procedure|calcaneal lengthening|Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
75456340|NCT01770587|Behavioral|Behavioral Insomnia Treatment|
75456341|NCT01770600|Other|placebo|placebo pill administered daily for 5 days
75456342|NCT01770600|Drug|Riperidone|1 mg risperidone administered orally for 5 days
75456343|NCT01770613|Biological|Stem cells|Allogeneic mesenchymal stem cells
75607818|NCT02809729|Drug|Cefazolin|2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction
75607819|NCT02809729|Drug|sterile saline|0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
75607820|NCT02809729|Procedure|oncologic breast surgery|The patient will be submitted to a conservative oncologic breast surgery
75901887|NCT02033109|Drug|HEC gel|
75901888|NCT02153658|Procedure|Subjects cleaned the foreskin with soapy water using a syringe once a day.|
75901889|NCT02153658|Procedure|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.|
75607821|NCT02809729|Other|Microbiology|Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
75607822|NCT04303377|Biological|Evolocumab|Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)
75607823|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
75607824|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
75901890|NCT05026294|Other|plyometric exercises|Exercises for strength and flexibility
75901891|NCT05026294|Other|Exercises for flat feet rehabilitation|Exercises for intrinsic muscles strength
75901892|NCT04962607|Other|Neo-Putty® as dressing agents in pulpotomized primary molars|"Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM"
75901893|NCT05040100|Other|3D Mediastinum Model|The 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
75901894|NCT01336647|Drug|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
75456344|NCT01770626|Other|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
75456345|NCT01770639|Procedure|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
75456346|NCT01770678|Other|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
75456347|NCT01770730|Device|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
75607825|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
75607826|NCT00953524|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
75607827|NCT02809573|Drug|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
75607828|NCT02809573|Drug|cyclophosphamide|On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m^2 in 5 minutes after chidamide administration
75607829|NCT02809573|Drug|adriacin|On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m^2 soon after cyclophosphamide administration.
75607830|NCT02809573|Drug|vincristine|On Day 1, vincristine is given in IV infusion at 1.4 mg/m^2 after adriacin administration.
75607831|NCT02809573|Drug|prednisone|On Day 1 to 5, prednisone is given orally at 100 mg once a day
75901895|NCT01336647|Drug|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
75901896|NCT01336647|Drug|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
75901897|NCT02157558|Drug|Fexofenadine|All subjects will receive 180 mg fexofenadine
75901898|NCT02157558|Drug|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
75901899|NCT05018182|Drug|Oxaliplatin|Oxaliplatin 85 mg/m² Q2w(2 h) before surgery rection and 130 mg/m² Q3w (2 h) after surgery
75901900|NCT05018182|Drug|Irinotecan|Irinotecan 150 mg/m² ivgtt(1.5 h) Q2w before surgery rection
75901901|NCT05018182|Drug|Folinic Acid|Folinic acid 400 mg/m² ivgtt(2 h) Q2w before surgery rection
75901902|NCT05018182|Drug|5FU|5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection
75456348|NCT01770769|Device|Hemi - arthroplasty|modular hemiarthroplasty
75456349|NCT01770769|Device|internal fixation|Two cancellous parallel screws - internal fixation of the femoral neck fracture
75901903|NCT05018182|Drug|Capecitabine|Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection
75901904|NCT01336569|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
75901905|NCT05018572|Behavioral|I AM|"I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks."
75901906|NCT04899505|Other|Evaluation on appearance of unpleasant body odors|Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.
75901907|NCT03092986|Drug|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
75901908|NCT03092986|Drug|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
75607832|NCT02812927|Device|Edelvaiss Multiline-8|Optimised infusion line
75607833|NCT02812927|Device|Standard infusion line|
75901909|NCT03092986|Drug|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
75901910|NCT03092986|Drug|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
75456350|NCT01770782|Procedure|Surgically Assisted Rapid Maxillary Expansion (SARME)|Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
75456351|NCT01770782|Other|Laser Scanner|Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
75456352|NCT01770795|Drug|Genexol-PM/Gemcitabine|
75456353|NCT01770808|Dietary Supplement|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.
75456354|NCT01770808|Dietary Supplement|AquaPT|AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.
75607834|NCT04388683|Drug|Nitric Oxide|"Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM."
75456355|NCT01770808|Dietary Supplement|Placebo|Subjects swallowed 4 capsules/day for six weeks.
75456356|NCT01770821|Other|Dietary supplement and/or physical training|
75456357|NCT01770873|Behavioral|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
75456358|NCT01770886|Drug|UE2343|Oral capsule
75607835|NCT02809261|Procedure|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
75901911|NCT03092986|Radiation|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
75901912|NCT03739086|Procedure|erector spinae plane block|unilateral or bilateral or bilevel erector spinae plane block performance for postoperative pain or acute pain
76072292|NCT02021006|Other|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
75456359|NCT01770886|Drug|Placebo|Oral capsule
75456360|NCT01770899|Drug|Montelukast|
75456361|NCT01770899|Drug|Placebo|Gelatin capsule given every 24 hours
75607836|NCT02809261|Procedure|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
75607837|NCT02809261|Drug|Normal Saline|Normal saline is safe for perineural injection.
75607838|NCT02809261|Drug|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
75456362|NCT01770925|Device|N-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
75901913|NCT04867759|Procedure|Endometrial Biopsy|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
75901914|NCT03092908|Dietary Supplement|mature vinegar|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
75901915|NCT03092908|Dietary Supplement|placebo (water)|Administer 5 ml placebo (water) three times a day.
75901916|NCT03543306|Drug|daborafenib plus trametinib|Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
75901917|NCT05039398|Behavioral|Treatment as usual|The workplace receives dialogue and guidance during the WEA workplace inspection as per WEA standard practice.
76067347|NCT05353322|Behavioral|Controlled Diet|Participants in both the experimental and control groups will eat a controlled diet (breakfast, lunch, dinner, snacks) for two full days before each lab visit. They will also eat a controlled diet (breakfast, lunch) during each of the two lab visits. Participants will choose 1 of 3 dietary menus to eat for the study duration. Each meal will be individualized to meet 33% of daily estimated energy requirements. Target macronutrient profile will be 12-15% energy from protein, 55-58% from carbohydrate and 29-31% from fat; as well as 55 mmol of sodium and 24 mmol of potassium.
75901918|NCT05039398|Behavioral|Dialogue and guidance over telephone|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance over telephone receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted over the telephone."
75901919|NCT05039398|Behavioral|Dialogue and guidance at physical meeting|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance at physical meeting receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted as a physical meeting."
75901920|NCT02157714|Drug|PRX002|
76067348|NCT05341960|Behavioral|Food Delivery|Food box with food to feed a family of four, delivered by the Greater Cleveland Food Bank every two weeks. Based on participant preferences, includes recipes.
75456363|NCT01770925|Device|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
75456364|NCT01770925|Device|NIPPV|The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water , a peak inspiratory pressure of 9 cm of water, RR of 35 and ti of 0.32
75456365|NCT01770938|Device|Effective light-emitting diode therapy|
75456366|NCT01770938|Device|Placebo light-emitting diode therapy|
75456367|NCT01770964|Drug|Pregabalin|
75607839|NCT05644639|Device|StimRouter Neuromodulation System|The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.
75456368|NCT01770964|Drug|placebo|
75456369|NCT01770964|Behavioral|Training Type A|
75607840|NCT01040403|Drug|olodaterol (BI 1744) low|olodaterol (BI 1744) low
75456370|NCT01770964|Behavioral|Training Type B|
75607841|NCT01040403|Drug|low tiotropium bromide|low tiotropium bromide
75607842|NCT01040403|Drug|olodaterol (BI 1744) high|olodaterol (BI 1744) high
75607843|NCT01040403|Drug|medium tiotropium bromide|medium tiotropium bromide
75901921|NCT02157714|Other|Placebo|
75901922|NCT02342665|Drug|Copanlisib (BAY80-6946)|Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
75901923|NCT03090724|Drug|BIA 5-453|100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
75901924|NCT02153892|Device|GDS Accucinch System|Percutaneous Coronary Intervention
75901925|NCT03090568|Drug|BIA 5-453|BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
75901926|NCT02157792|Drug|M6620|
75901927|NCT02157792|Drug|Gemcitabine|
75901928|NCT02157792|Drug|Cisplatin|
75901929|NCT02157792|Drug|Etoposide|
75901930|NCT02157792|Drug|Carboplatin|
75901931|NCT02157792|Drug|Irinotecan|
75901932|NCT03095716|Other|laparoscopic surgery|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
75901933|NCT05175391|Other|Meat based protein with added spice; Plant based protein with added spice|Either meat or plant based protein entrees will have herbs and spices added (in addition to salt and pepper in the base recipe) to intensify the flavor profile in order to see if protein consumption is affected.
76067349|NCT05341960|Other|Financial Support|Provides supplemental funds to purchase healthy foods; provides choice. Includes recipes for limited budgets and assistance locating healthy food options in their specific neighborhood.
75456371|NCT01770977|Device|Light-emitting diode therapy|
75456372|NCT01770977|Device|Placebo light-emitting diode therapy|
75456373|NCT01770990|Behavioral|Tel-PT including mail|Patients receive telephone-based psychotherapy and one letter after each telephone session.
75607844|NCT01040403|Drug|high tiotropium bromide|high tiotropium bromide
75607845|NCT01040403|Drug|Placebo|Placebo
75607846|NCT01040403|Device|Respimat|Respimat inhaler
75456374|NCT01770990|Behavioral|Tel-PT without mail|Patients receive telephone-based psychotherapy without additional letters.
75753708|NCT00327340|Drug|custirsen (OGX-011)/docetaxel|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment."
75753709|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
75901934|NCT05023954|Diagnostic Test|Blood test|Drop of blood for RNA and metabolic analysis
75901935|NCT02150538|Device|Cardiac resynchronization therapy pacemaker|biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
75607847|NCT02809339|Other|Questionnaires|
75901936|NCT02150538|Device|Dual chamber pacemaker|right ventricular stimulation with dual chamber pacemaker
75753710|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
75901937|NCT05023798|Device|ATD (device test)|Medical device test (no intervention)
75901938|NCT03742830|Device|C-MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
75901939|NCT05038774|Other|Face to face Educational Training|"Key points of current hypertension guidelines.~10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~checklists to assist in the diagnosis of secondary hypertension.~Patient information leaflet about hypertension."
75901940|NCT05038774|Other|Printed Education Material|"Key points of current hypertension guidelines.~10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~checklists to assist in the diagnosis of secondary hypertension.~Patient information leaflet about hypertension."
75901941|NCT02154126|Device|Continuous Glucose Monitoring Device (Senseonics)|
75456375|NCT01771003|Device|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
75456376|NCT01771042|Other|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
75456377|NCT01771068|Behavioral|"Triple P Positive Parenting Program Discussion Group Dealing with Disobedience"|
75456378|NCT01771081|Drug|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
75456379|NCT01771094|Behavioral|Effect of sweetness of the beverage in thirst sensation|"Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min."
75456380|NCT01771120|Other|Diagnostic tests, medical interview and questionnaires|All patients will perform these interventions.
75607848|NCT00957034|Drug|placebo|placebo patch
75607849|NCT00957034|Drug|testosterone|300 or 450 micrograms/day transdermal testosterone patch
75607850|NCT02812693|Drug|Imatinib Mesylate|Given PO
75607851|NCT02812693|Other|Laboratory Biomarker Analysis|Correlative studies
75607852|NCT02812693|Biological|Pembrolizumab|Given IV
75607853|NCT02812459|Other|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
75607854|NCT02812459|Other|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
75607855|NCT02857972|Device|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
75607856|NCT04270552|Drug|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
75901942|NCT05023408|Drug|Bleomycin Injection|Intralesional Bleomycin used for treatment of cutaneous warts.
75901943|NCT05023408|Procedure|Cryotherapy|Cryotherapy used for comparison of efficacy.
75901944|NCT02772978|Drug|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
75901945|NCT02772978|Drug|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
75901946|NCT03090490|Other|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients
75901947|NCT03090490|Other|Maintenance treatment discontinuation|Maintenance antipsychotic medication to stabilized patients
75456381|NCT01771133|Behavioral|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
75607857|NCT04270552|Drug|Placebo|Matched tablets without any active substance.
75753711|NCT01062724|Other|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
75607858|NCT04237597|Drug|K-877|K-877 tablets
75753712|NCT05300243|Diagnostic Test|HPV integration test|The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
75607859|NCT04237597|Drug|CSG452|CSG452 tablets
75607860|NCT02854462|Behavioral|Language comprehension intervention|
75607861|NCT02854462|Behavioral|Counting intervention|
75607862|NCT02812381|Procedure|KT|to aplicate neuromuscular bandage technique(KT)
75607863|NCT02812381|Procedure|SCS|To aplicate strain-counterstrain above trigger point
75607864|NCT02854774|Behavioral|Muscle activation exercises|Activation of either muscles activating the knee or hip.
75753713|NCT05299385|Behavioral|Conventional rehabilition treatment(e.g leaflet) educated by hospital|"Active Comparator: subjects who are trained in accordance with the conventional manual treatment of Respiratory rehabilitation in the clinical institution and taking care home-based management.~The manual contents~method of the conventional rehabilitation treatment~intensity for aerobic exercise and anaerobic exercise"
75753714|NCT05299385|Device|Digital treatment based on Respiratory Rehabilitation Software|"Experimental: subjects who use the software as a home-based Digital Respiratory Rehabilitation software~It is intended for subjects who are prescribed a respiratory rehabilitation exercise to improve their physical condition. The software also helps them to do self-rehabilitation exercise."
75753715|NCT00958139|Other|Permethrin|Permethrin 0.5% treatment of clothing one time
75753716|NCT00958139|Other|Placebo|water sprayed on clothing one time
75901948|NCT05038696|Biological|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.
75901949|NCT05300971|Other|Heat therapy|36 sessions (~3x per week for 12 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C, and 12 weeks of follow-up.
75901950|NCT05300971|Other|Thermoneutral water immersion|36 sessions (~3x per week for 12 weeks) of thermoneutral water immersion in 36°C water to prevent changes in body core temperature >0.2°C, and 12 weeks of follow-up.
75901951|NCT03543228|Diagnostic Test|MyoStrain|MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.
75901952|NCT03090334|Diagnostic Test|De-escalation|Antifungal therapy will be stopped according with BG results
75901953|NCT03090178|Other|electronic-Patient Report Outcome and wear of a wristband actigraph|Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
75607865|NCT02812849|Drug|Cu-64 DOTATATE|
75607866|NCT04117594|Diagnostic Test|WB-MRI|Whole body MRI with diffusion-weighted imaging (DWI)
75607867|NCT02812303|Other|Centralized support for population health management activities|
75607868|NCT02809495|Other|use of app in smartphone|
75607869|NCT04236973|Device|Molbio Truenat™ HCV assay (the investigational product)|The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
75901954|NCT05290363|Other|Blood sampling|A 51 mL blood sample will be collected during the study
75901955|NCT05290363|Other|synovial aspiration|If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study
75901956|NCT03092830|Genetic|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
75456382|NCT01771146|Drug|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
75456383|NCT01771159|Device|TBC|"The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor [bladder] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.~After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder."
75607870|NCT04236973|Other|Abbott RealTime HCV assay|Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
75607871|NCT02689999|Drug|Dexrabeprazole 10 mg Enteric-Coated Tablets|
75607872|NCT02808793|Drug|AK002|
75607873|NCT02809105|Drug|linaclotide|Oral administration once daily
75607874|NCT02809105|Drug|Placebo|Oral administration once daily
75901957|NCT00104052|Biological|peginterferon alfa-2b (PEG2b) (SCH 54031)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
75901958|NCT00104052|Drug|ribavirin (SCH 18908)|15 mg/kg/day for up to 48 weeks
75901959|NCT03092596|Behavioral|Patient-administered screening tool|screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
75901960|NCT03092596|Behavioral|Patient health navigator-administered screening tool|patient health navigator-administered screener
75901961|NCT03092596|Behavioral|Patient health navigator-assisted linkage to treatment|patient health navigator-assisted linkage to substance abuse treatment
75901962|NCT04434508|Procedure|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
75901963|NCT04434508|Procedure|Open right hemicolectomy with CME and central v|Open right hemicolectomy with CME and central v
75901964|NCT05038072|Drug|suprachoroidal injection of Triamcinolone Acetonide.|4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
75901965|NCT02777970|Drug|Tramadol Hydrochloride/Dexketoprofen Trometamol|
75607875|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
75607876|NCT00953056|Biological|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
75607877|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
75607878|NCT00953056|Biological|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
75607879|NCT02811289|Drug|Mirbetriq (Mirabegron)|50mg of Mirabegron will be administered orally at time 0 in protocol A.
75607880|NCT02811289|Other|cold exposure|Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
75607881|NCT02811289|Radiation|injection of 18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
75607882|NCT02811289|Radiation|injection of 11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
75607883|NCT02811289|Radiation|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of [3-3H]-glucose
75901966|NCT02777970|Drug|Tramadol Hydrochloride/Paracetamol|
75901967|NCT02777970|Drug|Placebo|
75901968|NCT03037489|Drug|MIV-711|MIV-711 administered orally once daily
75901969|NCT02150616|Behavioral|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
75901970|NCT02150616|Behavioral|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
75901971|NCT02150616|Drug|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
75753717|NCT00450216|Drug|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
75753718|NCT00450216|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
76067350|NCT05334797|Other|hot application|a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes.
76067351|NCT05322707|Drug|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation aerosol, 2 actuations orally inhaled twice daily
75607884|NCT02811289|Other|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
75901972|NCT02150616|Drug|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
75456384|NCT01771185|Procedure|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
75456385|NCT01771185|Drug|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
75456386|NCT01771198|Drug|SIMVASTATIN|SIMVASTATIN tablet of 40mg once a day during 30 days
75607885|NCT02811289|Other|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
76067352|NCT05322707|Drug|Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol|Inhalation aerosol, 2 actuations orally inhaled twice daily
76067353|NCT05322707|Drug|Placebo|Inhalation aerosol, 2 actuations orally inhaled twice daily
75607886|NCT02809027|Drug|Ginger|
75607887|NCT02809027|Drug|Placebo|
76067354|NCT05316233|Device|VOLITE XC|Intradermal Injection
76067355|NCT05316233|Device|VOLITE XC|Subdermal Injection
76067356|NCT05295160|Behavioral|weight loss by very low energy diet intake which may differ in protein or carbohydrate content|The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss
76072293|NCT02021006|Drug|Amoxicillin-Potassium Clavulanate Combination|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
75607888|NCT02857660|Other|Whole body Electromyostimulation (exercise)|1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
75607889|NCT02857660|Dietary Supplement|Protein|up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
75607890|NCT02874495|Behavioral|Psychological tests|Related to affective and cognitive dimensions of pain.
75753719|NCT00953693|Procedure|Biopsy|Skin biopsy
75753720|NCT01566006|Drug|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
75753721|NCT05300165|Dietary Supplement|Beer|A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
75753722|NCT00441480|Dietary Supplement|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
75753723|NCT00441480|Dietary Supplement|placebo|4 gr of corn oil
76067357|NCT05278598|Procedure|Erector Spinae Plane Block|"After skin sterilization, ESP block will be performed at the level of T9. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T9 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. Sonographic confirmation of the local anesthetic spread will be seen as an anechoic shadow in the paravertebral spaces from T7 to T12.~This procedure will be done on both sides."
75901973|NCT01336023|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
76067358|NCT05278598|Procedure|Thoracic Paravertebral Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be used to visualize the T10 paravertebral space in the paramedian sagittal plane. An injection into the paravertebral space will spread to multiple adjacent dermatomes, so exact identification of a specific level will be not necessary. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe and slowly be directed from lateral to medial until its tip was located at the apex of the paravertebral space and the endpoint for successful block will be anterior displacement of the pleura by injected local anesthetic where a single injection of 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
76067359|NCT05278598|Procedure|Quadratus Lumborum Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be positioned horizontally in the anterior axillary line halfway between the subcostal margin and iliac crest, to locate the triple abdominal muscle layers, then the probe will be relocated subsequently to the posterior axillary line until the quadratus lumborum muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process, this is a well-recognizable pattern of a shamrock with three leaves. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe passing in posterior to anterior direction through the quadratus lumborum to reach the border between it and psoas major, where 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
76067360|NCT05278247|Diagnostic Test|NIRS|Performance of a NIRS to monitor abdominal tissue oxygen saturation in preterm infants
76067361|NCT05273931|Other|Lifestyle intervention|Documents explaining the strategies to achieve and maintain recommended behaviours as part of a healthier lifestyle
76067362|NCT05270512|Device|Dermal Cooling System|Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
76067363|NCT05267080|Device|CLINIPORATOR|The CLINIPORATOR is used to perform percutaneous electrochemotherapy on liver tumours.
75753724|NCT00958451|Drug|Paricalcitol|"Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks."
75753725|NCT00958451|Drug|Ergocalciferol|"If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks."
75753726|NCT03372408|Other|Chart review|Retrospective chart review of program participation and socio-demographic & psychosocial characteristics
75753727|NCT05299307|Diagnostic Test|semen analysis and hormonal proflie|measure total prolactin and total testosterone and semen
75901974|NCT01336023|Drug|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
75901975|NCT01336023|Drug|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
75753728|NCT03372174|Device|Maintaining mechanical ventilation during surgery|dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
75753729|NCT03372174|Device|Absence of mechanical ventilation during surgery|absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
75753730|NCT05352191|Drug|Beclomethasone|inhaled 800ug
75753731|NCT01028664|Device|SENSIMED Triggerfish|2-hour continuous IOP monitoring
75456387|NCT01771211|Device|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
75456388|NCT01771224|Dietary Supplement|Palmitoleic acid|Palmitoleic acid and 5-ASA
75456389|NCT01771237|Behavioral|MyPeeps Manualized Group Intervention|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
75456390|NCT01771237|Behavioral|Standard Sexual Health Education|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
75753732|NCT00954005|Drug|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
75753733|NCT01023750|Drug|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
75456391|NCT01771263|Device|iControl-RP|
75456392|NCT01771276|Device|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
75456393|NCT01771289|Drug|docetaxel/cisplatin|weekly docetaxel/cisplatin combined with radiation
75456394|NCT01771289|Radiation|Radiation|chemoradiation
75456395|NCT01771302|Device|Bio-Oss|It is a bone substitute of bovine origin
75456396|NCT01771302|Device|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
75456397|NCT01771315|Behavioral|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
75456398|NCT01771328|Drug|Hydrocortisone|Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
75753734|NCT05300009|Combination Product|topical methotrexate hydrogel 1% coupled with microneedling.|Microneedling will be performed on each wart for a maximum 5 lesions per patient using dermapen (Ostar rechargeable dermapen, OB-DG 03N, Ostar Beauty Sci-Tech Co, Beijing, China) supplied with 12 needles arranged in rows. The penetration depth was adjusted at 2-mm, endpoint was pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the wart. Then topical methotrexate 1% gel will be applied on the lesions every session.
75753735|NCT05300009|Other|Liquid nitrogen|"The wart is frozen for 10 to 30 seconds until a 1- to 2-mm ice ball halo surrounds the targeted area.~The sessions were performed every 2 week until complete clearance for a maximum of six sessions."
75753736|NCT05352113|Drug|SSRIs|SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
75901976|NCT05037916|Other|laser speckle contrast imaging device|laser speckle contrast imaging device will be used for measurement of burn wound depth en to be compared to the golden standard the laser doppler imaging device
75901977|NCT05151445|Behavioral|mHealth dietary app + health coaching intervention|"The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart."
75753737|NCT05352113|Procedure|acupuncture|This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
75456399|NCT01771328|Drug|Cortisone acetate|Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
75753738|NCT05352113|Procedure|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
75456400|NCT01771341|Device|MAQUET SERVOi ventilator with Edi Catheter|NAVA respiratory modality
75607891|NCT02874495|Device|Magnetic Resonance Imaging|"With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability."
75607892|NCT02874495|Behavioral|Heart Rate Variability|During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
75753739|NCT05352113|Drug|placebo|Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
75753740|NCT00547703|Drug|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
75456401|NCT01771341|Device|MAQUET SERVOi ventilator|Pressure Support
75456402|NCT01771354|Biological|Engerix B Vaccine|
75456403|NCT01771354|Biological|Placebo|
75456404|NCT01771367|Biological|Fluad|
75456405|NCT01771367|Biological|Agrippal|
75607893|NCT02808949|Drug|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
75607894|NCT02854306|Procedure|Bariatric surgery|With mindfulness programm
75607895|NCT02854306|Procedure|Bariatric surgery|Without mindfulness programm
75607896|NCT02812147|Drug|L-DOPS|Added as described in the Arm/Group Descriptions.
75607897|NCT02812147|Drug|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
75753741|NCT00547703|Drug|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
76067364|NCT05259852|Behavioral|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|The intervention arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period. In addition, the intervention arm involves providing participants with economic assistance for food in the form of a reloadable debit card ($83 every 4 weeks for 12 weeks, for a maximum amount of $250).
75901978|NCT02255292|Drug|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study
76067365|NCT05259852|Behavioral|Food Assistance and Cessation Resources Navigation|The comparison arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period.
76067366|NCT05254340|Dietary Supplement|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent irritable bowel syndrome. Inulin is being used to study an individual's ability to ferment dietary fiber.
76067367|NCT05254054|Other|whole body vibration|The whole body vibration is used when vibrations (mechanical oscillations) of a certain frequency are transferred to the human body. Humans are exposed to vibration through a contact surface that is in a mechanical vibrating state. It has been considered as an alternative and safe method for neuromuscular training and may be incorporated into current neuromuscular rehabilitation programs so as to enhance muscle recovery
76067368|NCT05254054|Other|Conventional exercise training|A set of conventional exercises designed for ACL rehabilitation
76067369|NCT05251636|Radiation|Episcleral Brachytherapy|Minimally invasive, single fraction brachytherapy
76067370|NCT05251636|Drug|Aflibercept Injection|Standard of Care intravitreal aflibercept injection
75456406|NCT01771367|Biological|Placebo|
75607898|NCT02854150|Genetic|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
75753742|NCT00297232|Drug|Natalizumab|
75901979|NCT03092206|Drug|F/TAF|antiretroviral therapy
75901980|NCT03092206|Drug|E/C/F/TAF|antiretroviral therapy
76067371|NCT05221697|Device|PRESAGE CARE|Participants in this arm will be followed by HCA and might benefit from Nurse health interventions
76067372|NCT05216003|Behavioral|PATH4YOU|PATH4YOU offers patient-center, comprehensive, contraceptive counseling; pregnancy planning; and same to next day access to birth control. This clinical care program will reduce obstacles to contraception in Indiana and enables access to healthy pregnancy planning conversations.
76067373|NCT05214820|Biological|Radiopharmaceutical 68Ga-PSMA|Injection of 68Ga-PSMA followed by 3 PET/CT acquisitions
75456407|NCT01771393|Device|CBCT prior to MDCT|Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.
75456408|NCT01771393|Device|MDCT prior to CBCT|Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
75456409|NCT01771406|Drug|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
75456410|NCT01771406|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
75607899|NCT04303065|Drug|Dexamethasone Oral|It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
75607900|NCT04303065|Drug|Placebo oral tablet|The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
75607901|NCT02874417|Behavioral|CAST psychoeducation|
75607902|NCT02874417|Behavioral|PHET|
75753743|NCT00954083|Behavioral|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
75753744|NCT00954083|Behavioral|Routine care|Routine care
75901981|NCT03092206|Drug|R/F/TAF|antiretroviral therapy
75901982|NCT02154282|Behavioral|ipod games|Patients will be given ipod games for 4 weeks and tested in related and unrelated cognitive measures
75901983|NCT05289427|Procedure|ultrasound guided triple injection peri-sartorius block|Patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
75901984|NCT05289427|Procedure|Femoral Nerve Block|Patients will receive femoral nerve block (FNB) before surgical incision
75753745|NCT05351957|Procedure|Dry needling|Only dry needling of the lower limbs will performed in all patients with acupunture needling
75753746|NCT05351645|Behavioral|Treatment|"Once per day for a 14-day trial period, participants in the Treatment group were assigned to read a first-person narrative about a past issue with suicidal thoughts or behaviors. These narratives each contained positive elements, such as providing details about how the author had overcome issues with suicide, suggesting that people with suicidal thought are not alone, or encouraging people with suicidal thoughts/behaviors to have hope."
75753747|NCT01062802|Drug|Atorvastatin|Atorvastatin 80mg, once a day for four weeks.
75901985|NCT03092440|Other|serious game|"During three hours, each learner will play with the three different cases of the LabForGames Warning serious game."
75901986|NCT05017714|Drug|Recombinant cytokine gene derived protein injection|"Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care."
76067374|NCT05212649|Diagnostic Test|cardiopulmonary exercise test|CPET was performed in this HF cohort within one month after being discharged and interpreted as previously described. Patients underwent an upright graded cycle ergometer exercise using a personalized ramp protocol or a motorized treadmill using a modified Bruce or Cornell protocol. Peak VO2 data measured by cycle ergometer were increased by 10% to allow a comparison between the two different procedures. Peak VO2 was defined as the highest 30-second average value obtained during exercise. Submaximal CPET variables such as ventilatory efficiency were calculated by the slope of VE versus VCO2 below the ventilatory compensatory point (VCP). If the slope of VE/VCO2 can't be calculated, we used the nadir of VE/VCO2, or the ratio of VE/VCO2 at the anaerobic threshold (AT) as the variable of ventilatory efficiency. The AT was determined by the V-slope method.
75456411|NCT01771432|Drug|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
75607903|NCT02081248|Other|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
75901987|NCT02254980|Device|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
75753748|NCT01062802|Other|Placebo|Placebo given once daily for 4 weeks.
75753749|NCT00954161|Other|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
75901988|NCT02254980|Device|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
75456412|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
75456413|NCT01771445|Drug|IL-1Ra|100mg, s.c, once only
75456414|NCT01771445|Drug|Placebo|100mg, s.c., once only
75456415|NCT01771458|Drug|Targeted therapy based on molecular profiling : Imatinib|
75901989|NCT05017636|Device|shock wave therapy|The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.
75753750|NCT00954161|Other|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
75901990|NCT02150694|Procedure|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
75901991|NCT02150694|Procedure|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
75901992|NCT02150694|Other|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
75456416|NCT01771458|Procedure|Tumor biopsy|
75456417|NCT01771458|Drug|Standard Chemotherapy|
75456418|NCT01771458|Drug|Targeted therapy based on molecular profiling : Everolimus|
75456419|NCT01771458|Drug|Targeted therapy based on molecular profiling : Vemurafenib|
75456420|NCT01771458|Drug|Targeted therapy based on molecular profiling : Sorafenib|
75456421|NCT01771458|Drug|Targeted therapy based on molecular profiling : Erlotinib|
75607904|NCT02081248|Other|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
75901993|NCT02150694|Other|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
75901994|NCT05281003|Drug|Pembrolizumab|Biological: Pembrolizumab 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
76067375|NCT05211141|Device|HLS KneeTec Deep Dish|total knee arthroplasty with HLS KneeTec Deep Dish prosthesis
76067376|NCT05191797|Drug|Bomedemstat|Given PO
76067377|NCT05191797|Biological|Atezolizumab|Given IV
76067378|NCT05179889|Drug|mFOLFIRINOX|"Irinotecan 150 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion] 12 cycles per 2 weeks~mFOLFOX 6 [Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week"
76067379|NCT05179889|Drug|mFOLFOX 6|Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks
75456422|NCT01771458|Drug|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
75456423|NCT01771458|Drug|Targeted therapy based on molecular profiling : Dasatinib|
75456424|NCT01771458|Drug|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
75456425|NCT01771458|Drug|Targeted therapy based on molecular profiling : Abiraterone|
75456426|NCT01771471|Biological|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
75753751|NCT03982108|Procedure|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff."
75901995|NCT05281003|Drug|Paclitaxel|Drug: Paclitaxel 150 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
75901996|NCT05281003|Drug|Cisplatin|Drug: Cisplatin 80 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
75901997|NCT05017792|Biological|Astrazenica vaccine|COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.
76067380|NCT05173506|Other|Computer decision support for physician|The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
76067381|NCT05163522|Drug|VH4004280|VH4004280 will be administered.
75456427|NCT01771471|Other|Placebo|0.9% w/v Sodium Chloride for Injection, USP
75456428|NCT01771484|Device|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
75456429|NCT01771419|Device|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
75456430|NCT01771419|Device|Cannulotome CT-25mm Cook Medical|
75456431|NCT01771497|Device|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
75456432|NCT01771523|Procedure|Thyroidectomy|total thyroidectomy or lobectomy
75456433|NCT01771523|Device|use of drain|drain will be used
75456434|NCT01771575|Other|Placebo device|Placebo device
75456435|NCT01771575|Device|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance & gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
75901998|NCT03039283|Device|Nucleus CI532 cochlear implant|Retrospective study of the commercial CI532 cochlear implant
75901999|NCT02150772|Procedure|Shear Wave Elastography (SWE)|
76067382|NCT05163522|Drug|Placebo|Placebo will be administered.
76067383|NCT05163522|Drug|Midazolam|Midazolam will be administered
75456436|NCT01771588|Dietary Supplement|Human milk fortifier|
75456437|NCT01771614|Behavioral|Exercise|
76067384|NCT05163158|Other|Central vs brachial systolic blood pressure targeting|Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be <130 mmHg.
75902000|NCT03089476|Other|Evaluating atopy in infants|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
75902001|NCT03089476|Other|Evaluating TEWL and STS in adults|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
76067385|NCT05159960|Procedure|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
76067386|NCT05156723|Biological|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
75456438|NCT01771614|Procedure|Hyperglycemia|
75456439|NCT01771640|Biological|intrathecal injection|Intrathecal injection of mesenchymal stem cells in patients with ALS
75456440|NCT01771692|Other|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
75753752|NCT03982108|Procedure|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
75753753|NCT00954317|Procedure|epidural placed low|epidural placed low
75753754|NCT00954317|Procedure|high epidural|high epidural
75753755|NCT01062880|Behavioral|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
75753756|NCT03938909|Genetic|cif mtDNA biomarker|The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
76067387|NCT05156723|Biological|Placebo|solution for intramuscular injection, 0.5 ml
76067388|NCT05142735|Dietary Supplement|N-Acetylcysteine|2000 mg (4 x 500-mg tablets) every morning
75753757|NCT03867383|Drug|Calcium Chloride|"All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline"
75753758|NCT03867383|Drug|Placebo|60 milliliters normal saline
75753759|NCT05351567|Other|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY FOR INFERTILITY FEMALES
75902002|NCT02158104|Procedure|Deep dry needling|
76067389|NCT05142735|Dietary Supplement|Placebo|4 placebo tablets every morning
76067390|NCT05140915|Behavioral|Peer Messaging|Peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit.
76067391|NCT05140915|Behavioral|Peer Coaching via Text|Peer coaching, facilitated by texting
76067392|NCT05140915|Behavioral|Gamification|Gamification, designed to motivate participation
75456441|NCT01771692|Other|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
75456442|NCT01771705|Other|Dose adjust group (NFAT)|If the average residual expression of the 3 cytokines is <20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 60% the CNI daily dose will be increased by 15%.
75456443|NCT05318365|Drug|Polyethylene Glycol 3350|PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
75456444|NCT05318365|Behavioral|Urotherapy|Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
75456445|NCT01771783|Drug|ACEI-ARB-RI|
75456446|NCT01771783|Drug|ARB-RI-ACEI|
75456447|NCT01771783|Drug|RI-ACEI-ARB|
75456448|NCT01771796|Behavioral|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
75456449|NCT01771822|Drug|Ibuprofen 5% topical gel|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
75607905|NCT02808715|Other|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
75607906|NCT04302129|Procedure|Erector spinae plane block|20 ml local anaesthetic are injected bilaterally on each side of the surgical incision underneath the erector spinae muscle where the dorsal rami pass around the bases of the transverse processes.
75607907|NCT04302129|Drug|Multimodal analgesia|Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
75607908|NCT02814877|Other|promotion of appropriate use of antibiotics in hospital|promotion of appropriate use of antibiotics in hospital by visiting physicians
75607909|NCT02856958|Procedure|Nerve decompression|
75456450|NCT01771822|Drug|Topical gel vehicle|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
75902003|NCT05037604|Other|Questionnaire about associated factors|Questionnaire about age, prolonged sun exposure, intake of anticoagulants / antiplatelets, intake of oral steroids, chronic kidney disease. Maternal age> 40 years in their last child , time of lactation per pregnancy and cumulative time of lactation. Age of the first pregnancy and age of menopause onset.
75456451|NCT01771822|Drug|Sodium lauryl sulfate 0.2%|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
75456452|NCT01771822|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
75456453|NCT01771848|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
75607910|NCT02856958|Other|Non-operative|Physical therapy
75607911|NCT00952822|Biological|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
75607912|NCT02857738|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
75753760|NCT03855215|Diagnostic Test|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
75753761|NCT05351411|Other||Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
75753762|NCT00954395|Other|D-dimer|D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
75753763|NCT05351177|Other|Exercise Training|Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
75753764|NCT00954473|Other|laboratory biomarker analysis|Correlative studies
75902004|NCT05037604|Diagnostic Test|Self questionnaire diagnostic tool|Self questionnaire of physical characteristics
75902005|NCT05037604|Other|Physical Examination|Physical Examination made by a dermatologist
75902006|NCT02158182|Drug|Lactulose|30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
75902007|NCT02158182|Drug|L-ornithine L-aspartate|10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
75902008|NCT02158182|Drug|Rifaximin|2 tablets (400mg) three times daily. Duration of therapy: 7 days
75902009|NCT02158182|Drug|Placebo|"Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days."
75456454|NCT01771861|Other|Trauma team activation|When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
75456455|NCT01771874|Drug|MDMA|125 mg per os, single dose
75456456|NCT01771874|Drug|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
75456457|NCT01771874|Drug|Placebo|per os
75456458|NCT01771887|Behavioral|education program|education program in 6 hours and monitoring phone every 15 days
75456459|NCT01771926|Other|potatoes|Daily intake of assigned treatment for 8 weeks
75607913|NCT02857738|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
76067393|NCT05140915|Other|E-Cigarette Cessation Materials|Written e-cigarette cessation materials by the Research Coordinator at the time of study enrollment. The written materials will consist of two pamphlets from Journeyworks, selected based on: (1) their clear and attractive layout designed for a low-literacy audience, and (2) their providing both information re: e-cigarette use with a strong message about nicotine and nicotine addiction, E-Cigarettes: 8 Things Everyone Should Know, and support in quitting, How to Quit Vaping.
76067394|NCT05134363|Drug|Dexmedetomidine Hydrochloride 0.5 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a placebo group
76067395|NCT05134363|Drug|Dexmedetomidine Hydrochloride 0.75 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
76067396|NCT05134363|Drug|Placebo|equal volume of normal saline
76067397|NCT05116319|Diagnostic Test|point-of-care HbA1c|The Afinion2™ (Abbott, Oslo, Norway), will be used for the current study as it is recently validated. According to American Diabetes Association (ADA), pre-diabetes (pre-DM) is diagnosed if HbA1c is 5.7-6.4% and diabetes (DM) is diagnosed if HbA1c is ≥6.5%
75456460|NCT01771926|Other|other carbohydrate|Daily intake of assigned treatment for 8 weeks
76067398|NCT05113758|Diagnostic Test|muscle ultrasound|All participants will undergo a muscle ultrasound on admission and at discharge
76067399|NCT05110976|Drug|AZD8630|Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.
76067400|NCT05110976|Drug|Placebo|Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.
75456461|NCT01771939|Procedure|25-G vitrectomy and phacoemulsification|25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
76067401|NCT05104658|Other|Patient-targeted rehabilitation offers|In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
76067402|NCT05091060|Device|Erchonia HLS|56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
75456462|NCT01771939|Procedure|phacoemulsification (cataract surgery)|lens extraction after phacoemulsification and intra-ocular artificial lens implantation
75607914|NCT02854072|Drug|GV1001|At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
76067403|NCT05078047|Drug|Reduced dose intensity of IO|After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
76067404|NCT05072743|Device|Photobiomodulation Therapy|PBMT will be applied to the cervical spine using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
76067405|NCT05072340|Behavioral|Resilience Skills Enhancement (RISE)|The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton & Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.
75456463|NCT01771978|Drug|Placebo|Received 250 ml of a 5% dextrose solution as placebo
75456464|NCT01771978|Drug|Diltiazem|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
76067406|NCT05068648|Other|Manual Wheelchair (MWC) backrest configuration|Wheelchair backrest fitting, postural and functional assessment
75456465|NCT01771978|Drug|Acetylcystein|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
75607915|NCT02854072|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
75607916|NCT02854072|Drug|Capecitabine|Capecitabine 830 mg/m^2 will be orally given in the morning and evening (total dose of 1660 mg/m^2) for 21 days followed by 7 days' rest.
75607917|NCT01038297|Drug|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
75902010|NCT02033187|Other|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
75902011|NCT02033187|Other|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
76067407|NCT05063435|Diagnostic Test|Carotid ultrasonography|"Study takes 10 - 15 minutes to complete~Subject will be asked to lay still and quietly during procedure~The ultrasound probe will be placed on one side of the neck to capture images of the carotid artery. When images from one side have been captured, the probe will be moved to the other side of the neck to capture images from the other carotid artery.~Blood pressure and heart rate will be obtained during the study~Results will be anonymized, digitized and stored on CD with unique identifier"
75607918|NCT01038297|Drug|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
75607919|NCT02537314|Drug|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
75607920|NCT02537314|Other|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
75607921|NCT00631150|Drug|Levetiracetam (Keppra)|
75902012|NCT05037838|Procedure|Longitudinal strain obtained thanks to transesophageal ultrasound data recorded during liver transplantation|Longitudinal strain of Left Ventricule and longitudinal strain of Right Ventricule free wall obtained thanks to TransEosophagal Ultrasound performed during the Liver Transplant
75902013|NCT02154360|Drug|Aprepitant|Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
75902014|NCT02740257|Other|Photos|Photos will be taken of skin lesion markings using a smart phone or tablet
75902015|NCT05017870|Drug|KSR-001|(0 day) eye drops received one drop to both eyes once a day (1~5 day) eyedrops recieved one drop to both eyes four times a day
75753765|NCT03814889|Device|Vibration pattern|"PHASE 1 and PHASE 2 are pilot studies not included in the clinical trial.~Phase 2b: All participants try on several wearable prototypes in our laboratory that provide vibration to the arm. Sensors or electrodes taped onto the arm and hand will sense muscle activity and record any changes during periods of vibration and periods with vibration turned off.~PHASE 3: Patients will be given a wearable device to take home. The patient will wear the device daily. At the beginning and end of the phase, arm function will be tested.~PHASE 4: This study takes 3 or 6 months. 1) If the patient gets Botox injections in their hand and arm, their arm function will be measured for three months during this standard care. 2) Next, all patients will be given a wearable device to take home. The patient will wear the device while feeling vibrations for 3 hours during the day while awake for two months. During this time and 1 month after this intervention, arm function will be tested."
75753766|NCT03814889|Device|No vibration|These patients will wear a glove with a blinking light instead of feeling vibrations.
75902016|NCT05017870|Drug|KSR-004|(0 day) eye drops received one drop to both eyes once a day (1~5 day) eyedrops recieved one drop to both eyes four times a day
75902017|NCT05017870|Drug|KSR-001-02|KSR-001-02
76067408|NCT05063435|Diagnostic Test|Echocardiography, transthoracic|"Study takes 15 - 20 minutes to complete~Subject will be asked to lay still and quietly during procedure~The technician will apply an ultrasound probe to the chest. Images and movies will be acquired.~Results will be digitized and stored on CD"
76067409|NCT05063435|Procedure|Venipuncture|"10 mL of blood total will be drawn (5 mL in a blue top citrate tube, 5 mL in a purple top EDTA tube). Measurements of cytokines, clusterin, lipidomics, cathepsin S protease, and elastin (previously identified potential biomarker candidates) will be performed.~Blood will preferably be drawn via venipuncture, but if patient has a port-a-cath already implanted and is having blood drawn via port-a-cath for clinically required reasons, then study-related blood draw via port-a-cath can take place concurrently with clinically required blood draws."
76067410|NCT05063045|Behavioral|smart-cloth assisted home nursing care|Older persons with dementia or hip fracture were asked to wear a smart vest, which contained a coin-size monitor in a hidden inner pocket. Sensors were installed in bedrooms and living areas to receive signals from the smart clothing. The home care nurses then gave feedback from the sensor signals to family caregivers.
76067411|NCT05059834|Behavioral|online mindfulness resources|a free mindfulness resource online for patients with general anxiety disorder
76067412|NCT05059834|Behavioral|usual care|patient will continue to receive drug and advice from doctors and nurses for their anxiety disorder
75902018|NCT05017870|Drug|KSR-001-03|KSR-001-03
76067413|NCT05057026|Other|Training Program Adult Mental Health Practice Support Program|"The Adult Mental Health Practice Support Program (PSP) was designed in 2009 by the General Practice Services Committee (GPSC) to address needs expressed by the province's family physicians to improve patient care in British Colombia. Its content and delivery model has been designed using evidence-based key ingredients and implication factors understood to be important for effective stigma reduction. These include the following:~the use of contact-based education,~skills-building to increase confidence and provide another management option with or without drugs particularly if access to mental health support services is difficult or absent~tools - using the principles of cognitive behavioural theory~The training will be delivered virtually over a total of 4 sessions two weeks apart, covering an 8-week period. A two hour virtually delivered booster session will be provided to students approximately one year after the delivery of the initial training."
75902019|NCT02158260|Behavioral|Position changing|
75902020|NCT02033031|Drug|Lucentis intravitreal injection|Lucentis intravitreal injection
75456466|NCT01771978|Drug|diltiazem and acetylcystein|"Received a combination of drug :diltiazem and acetylcystein~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution~150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
75456467|NCT01772017|Device|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
75456468|NCT01772030|Other|Use of the Achieve catheter followed by ICE-guided mapping catheter|
75456469|NCT01772056|Drug|Fluticasone, cream|Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse
75456470|NCT01772056|Drug|Placebo,|Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
75456471|NCT01772082|Behavioral|Internet mediated walking program|
75753767|NCT03741101|Drug|Trametinib|treatment
75902021|NCT02033031|Drug|Avastin intravitreal injection|Avastin intravitreal injection
75902022|NCT05017402|Drug|Alglucosidase Alfa|Standard dose: 20-25 mg/kg every other week; Higher dose: >25 mg/kg every other week.
75902023|NCT02158338|Other|Asthma|mothers who have children that have been diagnosed with respiratory issues
75902024|NCT02158338|Other|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
75753768|NCT05350787|Biological|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
75607922|NCT02808559|Device|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
75456472|NCT01772108|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
75753769|NCT00449670|Biological|H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
75753770|NCT00449670|Biological|H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
75902025|NCT02033343|Radiation|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
75902026|NCT05034367|Diagnostic Test|Mannitol challenge|Inhalation challenge with dry powder of mannitol with a maximal cumulative dose of 635 mg
75456473|NCT01772173|Other|Vessel measurements|Measurement of retinal vessels
75456474|NCT01772186|Device|Real-time somatosensory cue|A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
75753771|NCT00449670|Biological|H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)|Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
75753772|NCT04011449|Device|Medtronic RC+S DBS system|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
75902027|NCT02033265|Procedure|Brachial plexus block|Ultrasound guided axillary brachial plexus block
75902028|NCT03608137|Other|Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships|To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
76067414|NCT05056662|Diagnostic Test|Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR|Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.
75456475|NCT01772199|Drug|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
75456476|NCT01772199|Drug|Placebo|White to almost white, round tablets. Once daily orally.
75456477|NCT01772212|Drug|Terbinafine 250 mg|Test product
75753773|NCT04010903|Diagnostic Test|assessment of biomarkers of insulin resistance|blood and urine sample collection for assays of BCAAs
75753774|NCT05350709|Other|mirror therapy|15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
75456478|NCT01772212|Drug|Terbinafine 250 mg|Reference product
75753775|NCT04010513|Behavioral|Hypnosis|Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
75753776|NCT04010513|Other|Standard of Care|Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
75753777|NCT00954629|Drug|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
75902029|NCT02150928|Drug|Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|"Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit"
75607923|NCT04278040|Drug|Melphalan|Inhalations with low doses of Melphalan for 5 consequent days
76067415|NCT05056311|Other|Decision Aid Website|The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
75607924|NCT02812069|Device|ThermaZone® Device|The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
75753778|NCT00954629|Drug|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
76067416|NCT05054309|Dietary Supplement|Bifidobacterium longum|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
75902030|NCT03611127|Other|pulmonary rehabilitation|pulmonary rehabilitation standardized program
75753779|NCT00296374|Drug|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
75753780|NCT00296374|Drug|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
75753781|NCT00296374|Drug|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
75902031|NCT04964518|Drug|APG 2575 ramp up arm|APG2575 ramp up + Azacitidine
75456479|NCT01772225|Other|Data collection|Medical record abstraction form and patient survey questionnaire.
75456480|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
75456481|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
75456482|NCT01772251|Drug|Oshadi Icp|
75456483|NCT01772264|Drug|PF-05089771|titration from 150mg BID to 450mg BID
75456484|NCT01772264|Drug|Placebo|matched placebo
75456485|NCT01772290|Drug|fluconazole|Multiple oral doses
75456486|NCT01772290|Drug|itraconazole|Multiple oral doses
75456487|NCT01772290|Drug|rabeprazole|Multiple oral doses
75456488|NCT01772290|Drug|vismodegib|Multiple oral doses
75456489|NCT01772303|Drug|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
75456490|NCT01772342|Other|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
75456491|NCT01772342|Other|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
75753782|NCT03839082|Other|Usual Care then FitBit|Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
75753783|NCT03839082|Other|FitBit then Usual Care|Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
75753784|NCT05350475|Radiation|Proton therapy|Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.
75753785|NCT05350475|Radiation|Photon therapy|Patients in the photon arm will receive standard treatment with photon therapy.
75753786|NCT05350241|Other|Split-belt treadmill training|Participants in the split-belt walking group (experimental group) performed repeated split-belt treadmill training with an error-augmentation strategy (exaggeration of the initial step-length asymmetry) for 60 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics.
75902032|NCT03543150|Drug|BOTOX|BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
75902033|NCT03611049|Dietary Supplement|High dose Vitamin D3|High dose arm- 5000IU given daily
75456492|NCT01772355|Device|semi automated core needle biopsy of orbital tumors|
75456493|NCT01772381|Drug|Dexamethasone|Long acting corticosteroid
75902034|NCT03611049|Dietary Supplement|Low dose Vitamin D3|Low dose arm-800 IU given daily
76067417|NCT05047510|Drug|Anti-GPC3-IRDye800CW|Drug Injection: Anti-GPC3-IRDye800CW
76067418|NCT05046704|Device|peripartum transperineal Ultrasound|The anovaginal distance (AVD) will be measured by transperineal ultrasound ,The distance between the anal edge of the internal sphincter and the probe will then be measured in millimeters The ultrasound assessment of the anal sphincters at rest and during contraction will be performed postnatally using a dynamic 2-dimensional transperineal ultrasound with the patient in a supine position, an empty bladder.
75902035|NCT05037448|Behavioral|Me & My Wishes|Me & My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me & My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
75902036|NCT02151006|Drug|DHEA|
75902037|NCT03610503|Other|Music|Participants in this arm will listen to music during the EMG testing
76067419|NCT05043961|Procedure|Palisade sacroiliac joint radiofrequency ablation using 3-tined needles|"Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion."
75456494|NCT01772394|Behavioral|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
75607925|NCT05641675|Diagnostic Test|right heart catheterization|Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
75607926|NCT00955708|Device|ACUITY Spiral Left Ventricular Lead|The implant of the ACUITY Spiral Lead
75456495|NCT01772394|Behavioral|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
75456496|NCT01772433|Dietary Supplement|Olive oil|Phonophoresis with Olive oil for 10 day, daily
75753787|NCT05350241|Other|Standard physical therapy|Participants in the control group received the standard physical therapy program. Each session lasted for 60 minutes, repeated three times a week, over 12 consecutive weeks. The program consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
75753788|NCT05304923|Procedure|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV are: driving pressure (DP) 15psi, respiratory rate (RR) 20 bpm, inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply 100% oxygen.
75753789|NCT05304923|Procedure|Nasal cannula oxygen supply|Oxygen supplementation at 2 liters min-1 is delivered via a nasal cannula
75902038|NCT05037058|Other|Quality improvement activities|Quality improvement activities
75902039|NCT03610893|Drug|Dexamethasone|Dexamethasone as perineural local anesthetic adjuvant
75902040|NCT03610893|Drug|Dexmedetomidine|Dexmedetomidine as perineural local anesthetic adjuvant
75456497|NCT01772433|Drug|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
75456498|NCT01772446|Behavioral|SMS MESSAGING|SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
75456499|NCT01772485|Behavioral|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
75456500|NCT01772485|Behavioral|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
75607927|NCT02811757|Procedure|tenotomy|
75607928|NCT02811757|Procedure|tenodesis|
75607929|NCT02814799|Other|bone removal|
75607930|NCT02856724|Drug|PGE2|10 mg PGE2 vaginal ovul(Propess)
75607931|NCT02808637|Other|Manual Pressure|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
75607932|NCT02808637|Other|Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
75753790|NCT01060774|Drug|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
75753791|NCT01060774|Drug|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
75902041|NCT05022940|Other|Usual gold-standard multidisciplinary rehabilitation for TBI|In individual and group interventions within a holistic interdisciplinary rehabilitation program focusing on resumption of daily activities and social roles. Interventions could include physiotherapy or physical training, occupational therapy, speech therapy, and neuropsychology/psychology, which aimed at reducing the impacts of cognitive difficulties in daily life by using self-guided and environmental strategies.
75902042|NCT02032719|Behavioral|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
75456501|NCT01772498|Behavioral|heart rate variability biofeedback|
75456502|NCT01772511|Behavioral|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
75607933|NCT02808637|Other|Manual Pressure + Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
76067420|NCT05034224|Device|Swan-Ganz catheter placed in the coronary sinus - deflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be kept deflated during sham intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
75456503|NCT01772524|Biological|ALD403|
75456504|NCT01772524|Drug|Placebo|
75456505|NCT01772589|Procedure|New saw blade|
75607934|NCT02808637|Other|Control|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
75607935|NCT02808325|Drug|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
75456506|NCT01772589|Procedure|Reprocessed saw blade|
75607936|NCT02808325|Drug|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
76067421|NCT05034224|Device|Swan-Ganz catheter placed in the coronary sinus - inflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be inflated to obtain coronary sinus occlusion during the active intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
75456507|NCT01772615|Drug|Ciprofloxacin|Antibiotic
75607937|NCT01037985|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
75607938|NCT01037985|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
75607939|NCT00955474|Drug|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
75607940|NCT00955474|Drug|escitalopram|"Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
75607941|NCT00955474|Drug|Sertraline|"Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
75456508|NCT01772615|Dietary Supplement|E. coli Nissle|Probiotic
75456509|NCT01772628|Behavioral|Classroom-based component|Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
75456510|NCT01772628|Behavioral|STI/HIV prevention education|"For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing youth friendly Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration."
75607942|NCT00955474|Drug|Citalopram|"Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
75902043|NCT02032719|Behavioral|Lifestyle counseling|Lifestyle counseling
76067422|NCT05031637|Behavioral|treatment of BP by using night-time BP|titration of BP medications to target according to night-time SBP
76067423|NCT05031637|Behavioral|treatment of BP by using daytime BP|titration of BP medications to target according to daytime SBP
76067424|NCT05028881|Other|blood sampling|blood sampling for determining antibody responses
75607943|NCT02808247|Drug|Nintedanib|Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH & Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
75607944|NCT02808247|Drug|Ifosfamide|Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
75607945|NCT02037334|Device|Pregnolia System|No intervention is done except for measuring the stiffness of the cervix in pregnant women
75607946|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
75902044|NCT03079492|Device|Magnetic resonance imaging|Magnetic resonance imaging will be used to estimate brain temperature and cerebral blood flow
75607947|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
75753792|NCT04011059|Biological|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
75753793|NCT00954785|Device|Ankle brace|Sports Stirrup ankle brace (Aircast)
75753794|NCT00954785|Drug|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
75753795|NCT00954785|Drug|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
75753796|NCT00326950|Drug|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
75902045|NCT05137093|Device|Actigraphy Device|Patients will wear actigraphy device which detects scratching events.
75902046|NCT02154438|Drug|Ketamine|ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
75902047|NCT02520921|Drug|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
76067425|NCT05020899|Behavioral|Sessions with a trained counselor|4 sessions will be provided with a trained counselor who will discuss the participant's' smoking habits with them and strategies to help them quit. The first session is in-person, lasts for 20 minutes, and typically happens when the participant comes to the HIV clinic to pick up their medication. Sessions 2 through 4 are over the telephone and last for 15 minutes each. These occur 1 week, 4 weeks, and 8 weeks after the first session.
75456511|NCT01772628|Behavioral|Homework assignment component|This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
75456512|NCT01772628|Behavioral|Parenting component|Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
75607948|NCT02808091|Radiation|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
75607949|NCT02807935|Device|Optical coherence tomography imaging|
75607950|NCT02874183|Behavioral|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
75607951|NCT02808013|Drug|NDS-446|
75607952|NCT02808013|Drug|Placebo|
75607953|NCT04302519|Biological|Dental pulp mesenchymal stem cells|On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
75607954|NCT02811991|Drug|Paracetamol injection|325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
75607955|NCT02811991|Drug|Normal Saline injection|32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
75607956|NCT02811991|Drug|Morhpine PCA|Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose<25mg/4h.
75753797|NCT03981874|Other|telephonic interview|Telephonic interview
75753798|NCT00548717|Drug|Sirolimus|
75607957|NCT02873793|Genetic|Extraction of total RNA from healthy and tumour tissues|
75607958|NCT02873637|Device|under sartorial catheter|
75607959|NCT02873637|Device|femoral catheter|
75607960|NCT04237675|Procedure|surgery and anesthesia|patients with MS who received general or regional anesthesia for a surgery or labor
75607961|NCT02807701|Procedure|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy~dissection~reconstruction"
75607962|NCT02807701|Procedure|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
75753799|NCT00548717|Drug|Mycophenolate mofetil|
75753800|NCT00548717|Drug|Bortezomib|
75753801|NCT00441168|Drug|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
75753802|NCT00441168|Drug|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
75753803|NCT00441168|Drug|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
75753804|NCT00441168|Drug|vincristine|vincristine: 0.4mg IV push on days 1 to 4
75753805|NCT00296140|Behavioral|self management of PSD symptoms|
75753806|NCT00296140|Procedure|screening and treatment of PSD|
75902048|NCT02520921|Drug|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
75902049|NCT05022628|Drug|Donafenib|"Donafenib treatment regimen.~Donafenib started on the day of the first radiation treatment.~starting dose 0.2 g bid twice daily orally on an empty stomach (1 hour before or 2 hours after a meal).~Surgery after at least 1 week off Donafinil; resume Donafinil dosing as soon as possible after postoperative wound healing until any of the following occurs, whichever occurs first: (i) the subject develops an intolerable toxic reaction that does not resolve after dose adjustment (see 5.3 for details); (ii) 12 months of postoperative dosing; (iii) the subject has the first imaging-confirmed recurrence of disease or withdraws from the study (whichever occurs first).~Dose adjustment/withdrawal: Subjects are allowed up to 2 dose adjustments if they experience an adverse event related to the trial drug during treatment."
75902050|NCT02154594|Drug|Acacia catechu|
76067426|NCT05020899|Other|Cell phone messages|Brief messages that give tips to help quit smoking will be sent to participants' cell phones using WeChat. 3 messages per day will be sent for the first week, 2 messages per day for the next 3 weeks, 1 message per day for the next 1 week, and 1-2 messages per week for the rest of the time
75607963|NCT05638165|Drug|NCP112|The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
75753807|NCT03669432|Radiation|Intensity Modulated Radiotherapy|"The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
76067427|NCT05020899|Other|Offered nicotine replacement therapy|Participants will be offered nicotine replacement therapy (gum or patch, depending on which one is available).
75753808|NCT03669432|Procedure|Surgery alone|This intervention is of no interest
75753809|NCT03958331|Behavioral|Automated Digital Reminders|Reminders from electronic monitors via texts or alarms/lights
75753810|NCT03958331|Behavioral|Individualized Adherence Feedback Report|Feedback report on individual adherence behaviors
75456513|NCT01772641|Other|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
75456514|NCT01772641|Other|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
75753811|NCT03958331|Behavioral|Individual Adherence Feedback Report with Social Norms|Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
75753812|NCT01062958|Other|Neevo® (a medical food)|
75753813|NCT01062958|Other|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
76067428|NCT05020899|Other|Self-help guide for quitting smoking|Participants will be offered a self-help guide with information about quitting smoking.
76067429|NCT05008120|Other|No intervention|No intervention
75456515|NCT01772641|Other|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
75607964|NCT05598853|Drug|intrathecal nivolumab and intrathecal ipilimumab|Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
75753814|NCT01566318|Behavioral|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
75753815|NCT03956615|Other|Blood sampling and bone marrow analysis|Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)
75753816|NCT01028976|Dietary Supplement|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
75753817|NCT01028976|Dietary Supplement|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
75753818|NCT01024140|Drug|Escitalopram|Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
75753819|NCT03956225|Device|Systane iLux® Dry Eye System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
75753820|NCT03956225|Device|LipiFlow® Thermal Pulsation System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
75753821|NCT01024218|Device|NovoFine® needle 8 mm|
75753822|NCT01024218|Device|autocover needle|
76067430|NCT05000385|Other|Assesment of masticatory efficiency with optical scanning method|Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.
76067431|NCT05000385|Diagnostic Test|body mass index|as an indication of nutritional status
76067432|NCT04997109|Other|APPLES-tele|The APPLES-tele intervention is 5 weekly telehealth sessions of therapist-demonstrated tasks, delivered over a 6 week period. Infant participants wear a soft-constraint harness (C-Mitt) on their less affected arm for 6 hours per day, while their parent encourages them to use their more affected arm to complete play-based activities as instructed by the study therapist. As the infant experiences success, heavier objects are provided. During times when the C-Mitt is not worn, parents engage therapist-demonstrated bimanual play of increasing difficulty.
75456516|NCT01772641|Other|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
75753823|NCT01027026|Other|Early discharge|The patients are discharged the same day as coronary angiography.
75753824|NCT01027026|Other|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
75753825|NCT05178329|Behavioral|Lifting exercise|Patients are instructed for a light lifting exercise after mastectomy.
75753826|NCT05178329|Behavioral|Standard exercise|Standard exercise program after mastectomy
75902051|NCT02154594|Drug|Chlorhexidine gluconate|
75753827|NCT02936609|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
75607965|NCT04237285|Other|Inhalation aromatherapy|Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
75753828|NCT00457626|Drug|Valsartan|Extemporaneous suspension of valsartan, orally.
75753829|NCT02748707|Drug|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
75753830|NCT02748707|Drug|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
75753831|NCT02748707|Drug|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
75753832|NCT02748707|Other|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
76067433|NCT04997109|Behavioral|Parent-centered Approach (PCA) Support Intervention|The PCA support intervention is 5 weekly telehealth sessions delivered over a 6 week period. The PCA curriculum includes 5 basic principles of positive parenting from Triple P: ensuring a safe engaging environment, creating a positive learning environment, using assertive discipline, having reasonable expectations, and looking after yourself as a parent. All of these elements, when taught to parents in an individualized manner, can help promote responsivity, structure and expectations that are tailored to their child's condition and developmental stage. In addition, a curriculum of CP-specific knowledge will address the challenges unique to parents of children with CP, such as understanding principles of infant learning of new movements, challenges and solutions for self-directed activity in infants with CP.
75753833|NCT05177861|Diagnostic Test|EMG|Electromyelography
75753834|NCT05175209|Diagnostic Test|EMG|Electromyelography
75753835|NCT05131061|Diagnostic Test|68Ga-Pentixafor PET/CT imaging|68Ga-Pentixafor PET/CT imaging
75753836|NCT04010279|Procedure|preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.
75902052|NCT02154594|Other|Distilled water|
75902053|NCT03610347|Device|Bare metal Stent plus Paclitaxel Balloon|
76067434|NCT04997109|Behavioral|Standard of Care|Participants will receive the usual care from being followed in high-risk infant follow-up (HRIF) programs in the Early Detection and Intervention (EDI) Network.
75607966|NCT04237363|Behavioral|Exercise|Underwater treadmill training and supplemental overground walk training
75607967|NCT01229150|Drug|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
75607968|NCT01229150|Drug|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
75607969|NCT01229150|Drug|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
75902054|NCT03610347|Device|Drug Eluting Stent|
76067435|NCT04993807|Other|Shared decision-making tool|Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.
76067436|NCT04982328|Diagnostic Test|Th17 cytokine profile|Screening for the components of metabolic syndrome
76067437|NCT04982328|Diagnostic Test|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
75902055|NCT05022706|Other|Community-based accompaniment and home visits|"Trained health promoters will accompany adolescents to their first appointments; facilitate enrollment in public health insurance and completion of other administrative requisites (e.g. obtaining a foreign identification card for migrants; transferring to a different health facility); help troubleshoot new logistical and/or social challenges; and will foster communication between the adult care providers and the patient.~Health promoters will visit the participant's home or another mutually-agreed upon location at least monthly, to review ART adherence, identify barriers to care and adherence, remind patients of upcoming medical encounters, screen and follow-up for clinical and social problems, and offer social support."
75607970|NCT00634465|Device|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
76067438|NCT04982328|Diagnostic Test|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
76067439|NCT04978610|Behavioral|Virtual Acceptance Commitment Therapy|"For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes."
75607971|NCT02807389|Drug|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
75607972|NCT02804737|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
75607973|NCT00952588|Drug|AZD1152|1200 mg, iv, 7 day infusion
75607974|NCT00952588|Drug|LDAC|20 mg, sc, bd, 10 days
75607975|NCT02814409|Drug|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|
75607976|NCT02814409|Drug|Intravenous Tenecteplase|
75753837|NCT05050487|Procedure|PENG block|"The PENG block is performed under US guid¬ance, . The pa¬tient is placed in the supine position a curvilinear low-fre¬quency ultrasound probe (2-5 MHz) is initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe approximately 30-45 degrees . .~The needle, usually a 22-G80-mm echogenic device, is inserted from lateral to medial with an in-plane approach to place the tip in the plane between the psoas tendon anteriorly and the pu¬bic ramus posteriorly .~After needle insertion and following negative aspiration, the local anesthetic is injected . The volume used of 20 ml of(L-bupivacaine; concentration 0,25% ) . This fascial plane appeared to continue in the hip pericapsular plane."
75456517|NCT01772667|Procedure|Inpatient Rehabilitation|"Rehabilitation program in Schoen Klinik Berchtesgadener Land"
75456518|NCT01772680|Dietary Supplement|Zinc Supplementation|25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
75456519|NCT01772706|Procedure|low level laser therapy|
75456520|NCT01772706|Procedure|placebo (laser low level energy nonfunctional)|
75456521|NCT01772732|Drug|Simotinib Hydrochloride|
75456522|NCT01772745|Procedure|SILS cholecystectomy|Single incision laparoscopic cholecystectomy will be performed
75456523|NCT01772745|Procedure|TPCL cholecystectomy|Three port laparoscopic cholecystectomy will br performed
75456524|NCT01772784|Other|Phenolic acids|Phenolic acids
75456525|NCT01772797|Drug|LDK378|LDK378 is a capsule to be taken daily by mouth.
75456526|NCT01772797|Drug|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
75456527|NCT01772810|Drug|Human spinal cord stem cells.|Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
75607977|NCT02804893|Procedure|VATS|Thorax thoracoscopic surgery (lobectomy)
75607978|NCT02804893|Procedure|RATS|Thorax robotic surgery (lobectomy)
75607979|NCT02853916|Dietary Supplement|500 mg InSea2®|
75607980|NCT02853916|Dietary Supplement|250 mg InSea2®|
75607981|NCT02853916|Dietary Supplement|Placebo|
75607982|NCT02853838|Other|Prolonged slow expiration+provoked coughing|"Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.~During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration."
75753838|NCT05050487|Procedure|lumbar erector spinae plane block|"The lumbar erector spinae block is performed under US guid¬ance, after adequate skin disinfection The patient is placed in the lateral decubitus position according to the selected site of surgical intervention.~The 4th lumbar vertebral level will determined The convex USG transducer was placed at the mid-vertebral line in the sagittal plane. The transducer was shifted from the midline, 3.5-4 cm laterally to the side of the surgery to visualize the erector spinae muscle and transverse process . 0.5-1 ml of the prepared LA solution (20 ml bupivacaine 0.25%). All LA was administered to this location between the transverse process and the erector spinae muscle."
75753839|NCT02249975|Device|C2 CryoBalloon Focal Ablation System|"The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.~Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.~Evaluations include, but are not limited to the following:~Device malfunctions~Adverse events~Patient Pain~Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus."
75456528|NCT01772836|Drug|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
75456529|NCT01772836|Drug|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
75753840|NCT01841957|Procedure|ISBCS|same-day cataract surgery
75753841|NCT01841957|Procedure|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
75753842|NCT05014061|Drug|Adenosine|Adenosine infusion 70 µg/kg/min for 6 hours
75753843|NCT05001503|Device|Stability UO|STABILITY UO is a standalone software, based on a Bayesian model, which quantifies the risk of an individual patient developing severe oliguria (0.3mg/kg/hr for 6 hours). The model identifies at risk patients by predicting future urine output, using only previously recorded urine output values for that individual, allowing clinicians to see the predicted risk of a patient developing severe oliguria in real time.
75902056|NCT05022706|Behavioral|Directly Observed Therapy|Among adolescents who have already initiated combination antiretroviral therapy (cART), directly observed therapy (DOT) will be provided to the subset of adolescents identified as being at high risk of non-adherence, defined by meeting at least one of the following criteria: 1) identified by the pediatric health provider as having unstable adherence; or 2) having a detectable viral load at one of their two previous measurements. In adolescents newly initiating cART, there will not be an adherence precedent. This group will choose whether they wish to receive DOT. As part of this research, trained community health workers (CHWs) will deliver DOT in participant's homes or in a mutually agreed upon location. CHWs will observe ingestion of cART daily, ensure it is taken as prescribed and record each dose as DOT, self-administered, not taken or not prescribed.
75607983|NCT02853838|Other|Manual chest wall vibration|"Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.~The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal."
75902057|NCT05022706|Behavioral|Monthly Peer Support Groups|The investigators will assign ALWH to a social support group with 9 to 11 other adolescents also participating in the research. The goal of the social support groups is to provide a venue for participants to share experiences and resources and provide encouragement and support to one another. Each group will last approximately 3 to 4 hours. Support groups will be led by adult peers or trained community health workers. The final group session will incorporate a discussion about the group experience, how it may change behavior, recommendations for improvement, and unmet needs that should be considered for a future intervention.
75607984|NCT02853838|Other|Standard Therapy|Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
75753844|NCT04977245|Other|Mindfulness-Based Stress Reduction|Eight MBSR sessions of 1.5 hours per week
75456530|NCT01772836|Drug|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
75456531|NCT01772849|Behavioral|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
75456532|NCT01772862|Behavioral|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
75607985|NCT05527717|Procedure|Culprit lesion only PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken culprit-lesion only PCI during primary PCI."
75607986|NCT05527717|Procedure|Immediate multi-vessel PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken immediate multi-vesesl PCI during primary PCI."
75607987|NCT04236505|Behavioral|Acceptance and Commitment Therapy (ACT) group based intervention|4 week ACT psychological intervention group based on Flaxman and McIntosh's ACT in the work place group format
75607988|NCT04236505|Behavioral|Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention|4 week Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention
75753845|NCT04977245|Other|Self-Guided Mindfulness eCourse|Six weeks of a mindfulness ecourse, and two weeks of coping skills training led by a licensed neuropsychologist
75753846|NCT00373113|Drug|Capecitabine|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
75753847|NCT00373113|Drug|Sunitinib malate|37.5 mg daily, continuous dosing
75607989|NCT04236505|Behavioral|Wait list Control group|this group are placed on a wait list for group treatment whilst the other experimental groups run. This group are offered the MBSR based mindfulness skills once the follow up data has been collected from the other two experimental groups
75753848|NCT01045941|Drug|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
75607990|NCT02804581|Dietary Supplement|Gum Arabic|Oral intake of GA in powder from30 grams per day
75753849|NCT01045941|Procedure|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
75753850|NCT00407511|Drug|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
75753851|NCT00384189|Drug|Ciclesonide|inhaled Ciclesonide
75456533|NCT01772875|Procedure|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
75456534|NCT01772901|Other|Influenza Vaccine Intervention|The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
75753852|NCT00384189|Drug|Placebo|Ciclesonide placebo-matching inhaler
75753853|NCT00384189|Drug|Salbutamol|Salbutamol inhalation powder
75456535|NCT01772927|Dietary Supplement|Parenteral Nutrition|Protein and energy intakes
75753854|NCT00326716|Drug|Atazanavir + Ritonavir + Combivir|Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
75753855|NCT01063192|Drug|Gemcitabine|Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
75456536|NCT01772940|Drug|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
75456537|NCT01772940|Drug|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
75456538|NCT01772940|Drug|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
75607991|NCT01227902|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
75607992|NCT02804659|Other|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
75607993|NCT00946192|Drug|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
75753856|NCT01063192|Drug|Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)|Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
75753857|NCT03983356|Other|Training program|An internet based training program will be offered to GPs. We will also offer face-to-face seminars with academic psychiatrists.
75753858|NCT03978910|Other|measurements of the accuracy of the reaching movements|Euclidian distance between final position and target
75753859|NCT01066078|Other|Echocardiography and SonR recording|
75753860|NCT01063426|Drug|High dose Atorvastatin+enoxaparin|High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
75753861|NCT01063426|Drug|Enoxaparin|Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
75753862|NCT00548405|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
75753863|NCT00548405|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
75753864|NCT00548405|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
75753865|NCT00958529|Dietary Supplement|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
75753866|NCT00958607|Behavioral|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care & by telephone during inpatient rehabilitation and community discharge. SSP provides support, information & guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
75902058|NCT03541824|Behavioral|Body Acceptance Program|The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
75607994|NCT00946192|Drug|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
75607995|NCT00946192|Dietary Supplement|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
75607996|NCT01037127|Drug|GSK1120212|Daily oral dosing
75753867|NCT00958607|Behavioral|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
75753868|NCT00958685|Dietary Supplement|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
75753869|NCT00958685|Dietary Supplement|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
75902059|NCT05016934|Biological|A vaccine composed of a recombinant S1 antigen|Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
75456539|NCT01772940|Drug|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
75456540|NCT01772953|Drug|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
75456541|NCT01772966|Procedure|Spinal manipulation|
75456542|NCT01772979|Drug|Trabectedin|
75456543|NCT01772992|Behavioral|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
75607997|NCT02806999|Drug|Berberine; Insulin|Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
75607998|NCT02806999|Drug|Insulin|Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
75607999|NCT02874261|Device|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
75608000|NCT02806921|Device|ZenLens|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
75608001|NCT04292613|Other|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
75608002|NCT02807077|Drug|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
75608003|NCT04302363|Other|Fecal microbiota detection and exfoliated cell gene detection|Fecal microbiota detection and exfoliated cell gene detection
75608004|NCT00946114|Drug|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
75608005|NCT00946114|Drug|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
75608006|NCT02804503|Behavioral|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
75608007|NCT02804503|Behavioral|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
75608008|NCT02804503|Behavioral|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
75608009|NCT04302285|Other|PKU type meal and Exercise|"Exercise was conducted prior to PKU type meal.~PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat."
75608010|NCT04302285|Other|PKU type meal|PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
75902060|NCT02151162|Behavioral|Mindfulness-based stress management program|Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
75902061|NCT02151162|Dietary Supplement|Omega-3 fatty acids pills|Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
75902062|NCT02151162|Behavioral|Psychoeducation leaflet|Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
75902063|NCT02151162|Dietary Supplement|Placebo pills|Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
75608011|NCT02804425|Other|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
75608012|NCT00627471|Drug|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
76067440|NCT04978129|Behavioral|Online and Text Messaging Intervention|The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
75608013|NCT00627471|Drug|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
75608014|NCT04269382|Device|Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements|Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
75608015|NCT02814721|Device|Sonic Window ultrasound device|
75608016|NCT04302441|Drug|Vinorelbine|vinorelbine 25mg/m2 on day 1 and 8,every 3 weeks
75608017|NCT04302441|Drug|Capecitabine|Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle
75608018|NCT04236427|Drug|Angong Niuhuang Wan|Angong Niuhuang Wan 3g
75753870|NCT00958763|Behavioral|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
75902064|NCT05016544|Drug|inetetamab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
75753871|NCT00958763|Behavioral|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
75753872|NCT00958763|Other|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
75753873|NCT00958997|Drug|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
75902065|NCT05016544|Drug|Pytotinib|"Starting pytotinib Dose of 240mg:~Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w."
75902066|NCT05016466|Other|Standard Care|Patients will followed during 5 years, and only 2 visits , baseline and 5 years
75902067|NCT05016466|Other|Standard Care plus oxidative stress study plus inflammation biomarkers study|Patients will followed during 5 years, Annual follo-up visits will be carried out during this period
75902068|NCT05016154|Behavioral|Online Group CBT intervention|Group of participants complete 10 weeks of Online Group CBT intervention
75456544|NCT01773005|Drug|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
75456545|NCT01773005|Drug|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
75608019|NCT04236427|Drug|Angong Niuhuang Wan Placebo|Angong Niuhuang Wan Placebo 3g
75608020|NCT02853682|Biological|plasma|assesment of glycocalyx protein
75608021|NCT02874027|Other|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
76067441|NCT04965649|Genetic|Phenotyping of total and innate CD8+T cells by flow cytometry|"Blood samples from patients in the active file of the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital will be analyzed (diagnosis already known). Samples will be representative of the different stages of the pathology.~For patients with a confirmed diagnosis of Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia), the remaining whole blood sample taken as part of the usual management will be sent for phenotyping of CD8+ TL (total and innate) by flow cytometry. Phenotyping will be performed on samples pooled at the end of the recruitment period."
76067442|NCT04954287|Biological|CVXGA1 low dose|see arm/group description
75456546|NCT01773018|Drug|Volitinib|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
75456547|NCT01773044|Drug|alkalinized lidocaine|recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
75456548|NCT01773044|Drug|Lidocaine|0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
75608022|NCT02800447|Drug|Natulan|Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1~14
75608023|NCT02800447|Drug|ABVD|Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
75608024|NCT01038921|Drug|Melatonin|8 mg dose of Melatonin
75608025|NCT01038921|Drug|Placebo|Placebo
75902069|NCT05016154|Behavioral|SilverCloud guided|Group of participants make use of the SilverCloud guided app
75902070|NCT05016154|Behavioral|SilverCloud Unguided|Group of participants make use of the SilverCloud Unguided app
75902071|NCT05016154|Behavioral|Mood Flow|Group of participants make use of the Mood Flow app
75753874|NCT00958997|Biological|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
75753875|NCT00959075|Dietary Supplement|Vitamin B1|100 mg Twice a day
75753876|NCT00959075|Dietary Supplement|Placebo|Sugar pill
75753877|NCT05299775|Diagnostic Test|World Health Organization Quality of Life -Brief -Taiwan version (WHOQOL-BREF-Taiwan version)|"WHOQOL-BREF-Taiwan version is used to measure the quality of life in HIV infected.~Wang Qi nine kinds of TCM constitution Questionnaire is used to measure the constitution of HIV infected."
75753878|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
75753879|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
75902072|NCT05016388|Other|Collaborative Multidimensional Model (CMD)|The teams enrolled in the CMD intervention will have a 22-hour training that integrates current knowledge of depression with skills for the management of functional variables, interpersonal, social, emotional regulation, and history of biographical adversity from childhood considering the trauma informed care paradigm. After the training, the PHC teams will implement the depression treatment according to a collaborative model.
76067443|NCT04954287|Biological|CVXGA1 high dose|see arm/group description
76067444|NCT04953767|Device|Blue light therapy|Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.
76067445|NCT04953767|Other|White light|White light is used as sham control.
75456549|NCT01773044|Drug|Placebo (for alcalinized lidocaine)|
75456550|NCT01773057|Other|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
75456551|NCT01773096|Drug|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
75753880|NCT00295750|Drug|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
75753881|NCT04910321|Other|diet, physical activities, sleep|lifestyle factors
75753882|NCT04850963|Device|Transcranial direct current stimulation (Anodal tDCS) + dual-task training|"anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
75902073|NCT05016388|Other|Standard Model (SM)|The teams enrolled in the SM intervention will have a 22-hour training that integrates the current national clinical guide for Depression in Chile. This guide offers a staggered treatment according to the severity of the depression. After the training, the PHC teams will implement the depression treatment according to the SM.
75902074|NCT05022160|Drug|pudendal nerve block|All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine
76067446|NCT04948671|Other|there will be no intervention, this is an observational study|this is an observational study
76067447|NCT04948632|Other|Complete LeoMed application|Access to the complete LeoMed application on the participant's smartphone. The day before surgery, participants will receive notifications encouraging them to use the platform to help prepare for their surgery. Safety instructions will also be sent. Postoperatively, notifications will be sent to the participants every day during the first 4 days and on the 7th day. These notifications will direct them to online forms that aim to assess their condition. On the 15th and 30th postoperative day, the platform will send a follow-up form. The platform will collect this information and classify it for appropriate management of their condition.
75608026|NCT01088542|Behavioral|Communities That Care|The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
75608027|NCT02804347|Device|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
75608028|NCT02804347|Device|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
75608029|NCT02804347|Other|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A & B, RAVLT
75456552|NCT01773096|Drug|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
75456553|NCT01773148|Device|Arstasis Access System (AXERA)|Placement of the AXERA device in the Femoral Artery.
75456554|NCT01773161|Procedure|Cerebral palsy, post hip surgery|All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
75608030|NCT02804191|Drug|LO2A|eye drop solution.
75608031|NCT02804191|Drug|Saline|Placebo
75902075|NCT05009446|Procedure|endoscopic surgery|endoscopic surgery or endoscope-assisted surgery open surgery
75456555|NCT01773174|Drug|dabigatran etexilate|age & weight adjusted equivalent of adult dose
75456556|NCT01773213|Procedure|Ice-water-test|
75456557|NCT01773239|Behavioral|TARA computer-based exercises|
75456558|NCT01773252|Device|Flow Detection System|
75456559|NCT01773304|Other|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
75902076|NCT05009446|Radiation|intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy|radiotherapy was administrated before surgery
75456560|NCT01773317|Other|Perturbation|All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
75608032|NCT02804113|Device|Supera Peripheral Stent System|
75608033|NCT02374372|Device|conventional hemodialysis|
75608034|NCT02374372|Device|hemodiafiltration On-line|
75608035|NCT04236349|Genetic|immunogenetics|blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
75608036|NCT01038687|Drug|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
75608037|NCT01038687|Drug|placebo|placebo
75608038|NCT02803957|Device|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
75608039|NCT02803957|Device|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
75608040|NCT02856568|Drug|Cisplatin|Given IV
75456561|NCT01773317|Other|Control|Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
75456562|NCT01773330|Procedure|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed.There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
75456563|NCT01773330|Dietary Supplement|Gatorade|The patient will be given Gatorade to drink at various times during the study.
75456564|NCT01773330|Other|Supine position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
75456565|NCT01773330|Other|Semi-recumbent position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
75608041|NCT02856568|Drug|Gemcitabine Hydrochloride|Given IV
75608042|NCT02856568|Other|Laboratory Biomarker Analysis|Correlative studies
75608043|NCT02856568|Other|Pharmacological Study|Correlative studies
75608044|NCT02856568|Drug|Ricolinostat|Given PO
75608045|NCT02804269|Other|Cardiovascular Magnetic Resonance|For the evaluation of heart function and structure of the cardiovascular system.
75608046|NCT02804269|Other|Fatmass measurement|It utilizes a scale machine to measure the body fat and skeletal muscle percentage
75608047|NCT04236583|Other|Telehealth|Post-discharge virtual visit
75608048|NCT02874105|Other|Group C: physiotherapy protocol with Conventional physiotherapy.|
75608049|NCT02874105|Other|Group S: physiotherapy protocol with Dynamic Humeral Centering.|
75608050|NCT04081831|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Follow clinical administration
75608051|NCT02807155|Behavioral|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
75608052|NCT02807155|Behavioral|Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
75608053|NCT02807155|Behavioral|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
75608054|NCT01081912|Drug|Placebo|Capsules, no active substance, shells identical to active comparator capsules
75608055|NCT01081912|Drug|Hydrocodone bitartrate|"dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg"
75608056|NCT02800525|Device|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
75902077|NCT05009446|Drug|Chemotherapy drug|Chemotherapy was administrated before surgery. Chemotherapy may also be administrated after surgery in selected cases.
75902078|NCT01518517|Drug|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
76067448|NCT04948632|Other|Basic LeoMed application|Access to a partial version of the LeoMed application on the patient's smartphone during a visit to the preoperative clinic. Before surgery, participants will receive a phone call to be summoned to the hospital and to remind them of the safety instructions. Postoperatively, their follow-up will not be standardized and will vary depending on their surgeon. On the 15th and 30th postoperative day, the platform will send a follow-up form. In the event of an emergency, they will receive the contact details of the CHUM Health Infoline to ensure the continuity of their care.
76067449|NCT04942665|Drug|Indocyanine green|Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).
75608057|NCT02800525|Device|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
76067450|NCT04942665|Device|PINPOINT Endoscopic Fluorescence|The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.
76067451|NCT04934748|Drug|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
76067452|NCT04934748|Drug|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
76067453|NCT04934748|Drug|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
76067454|NCT04934748|Drug|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
76067455|NCT04895982|Biological|BNT162b2|Intramuscular Injection
76067456|NCT04895605|Device|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
76067457|NCT04895605|Device|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
76067458|NCT04894500|Diagnostic Test|Flow fluorescence cytometry|Level of inflammatory markers in body fluid samples
76067459|NCT04889495|Drug|Zirabev|Bevacizumab biosimilar
76067460|NCT04868591|Other|Single session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.
76067461|NCT04868591|Other|Multiple session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
76067462|NCT04856319|Procedure|Dental implant placement|Insertion of not more than two dental implants at the same area
75456566|NCT01773330|Procedure|Sitting|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
75456567|NCT01773330|Procedure|Standing|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
75456568|NCT01773343|Procedure|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
75456569|NCT01773356|Dietary Supplement|Dihydrocapsiate|Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
75608058|NCT01038609|Drug|Hydrocodone/Acetaminophen Extended Release|
75608059|NCT01038609|Drug|Acetaminophen|
75608060|NCT01038609|Drug|Morphine Extended Release|
75608061|NCT01038609|Drug|Placebo|
75608062|NCT02803879|Device|Cardiogoniometry|
75902079|NCT01518517|Drug|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
76067463|NCT04856319|Drug|Antibiotic prophylaxis|Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
76067464|NCT04856319|Other|Placebo|Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
76067465|NCT04852796|Other|Patients with hemopathy|optimal humoral response at 1 month after COVID-19 vaccination
76067466|NCT04830813|Drug|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
76067467|NCT04830813|Drug|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
76067468|NCT04813120|Behavioral|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|For the UM-UT group, the participants will be seated in front of the new MT system, and will be instructed to watch the real-time image reflection of movements of the non-affected arm and hand on the screen carefully. At the same time, the patients will need to imagine that the movements were performed by their affected arm and hand. In this group, only the non-affected arm and hand will need to perform the movements, but the affected one will not need to move.
75608063|NCT02800759|Dietary Supplement|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
75902080|NCT02863575|Drug|Ibuprofen/Caffeine|Ibuprofen/Caffeine fixed-dose combination
76067469|NCT04813120|Behavioral|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|During the UM-BT, as similar as the first group (UM-UT), the participants will be also seated in front of the new MT system, and be instructed to watch the real-time image reflection of the non-affected arm and hand's movements on the screen carefully and imagine that the movements were performed by the affected arm. However, in this UM-BT group, the bilateral training mode is emphasized, and thus both arms and hands will need to move. That is, during therapy, the patient's affected arm and hand will be required to move at his/her best motor ability with the non-affected arm and hand at the same time.
76067470|NCT04813120|Behavioral|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|For the BM-BT group, the participants will be seated in front of this new MT system, and be instructed to observe the real-time image reflection of the non-affected arm and hand's movements transformed and superimposed on both arms and hands (i.e., bi-MVF), and to imagine that the movements were performed by both arms and hands. In this group, bi-MVF and bilateral training mode are emphasized, and thus both arms and hands will also need to move. The patient's affected arm and hand will be required to move as could as possible simultaneously.
75608064|NCT02800759|Dietary Supplement|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
75608065|NCT02800759|Dietary Supplement|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
76067471|NCT04813120|Behavioral|Traditional MT using a mirror box|During traditional MT, the participants will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm and hand of the participants will be placed inside the mirror box, and the non-affected arm and hand will be in front of the mirror. As similar to the UM-UT group, the participants will be instructed to watch the mirror reflection of the movements performed by the non-affected arm and hand carefully and to imagine that the movements were performed by the aﬀected arm and hand. In this group, the patient's affected arm and hand inside the mirror box will not need to move.
75753883|NCT04850963|Device|Transcranial direct current stimulation (tDCS dualsite) + dual-task traning|"tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
75902081|NCT02863575|Drug|Ibuprofen|Ibuprofen capsule
75902082|NCT02863575|Drug|Placebo|Placebo treatment
75902083|NCT05021770|Drug|Orelabrutinib|150mg or 200mg orally daily
75902084|NCT05021770|Drug|Orelabrutinib|RP2D
75902085|NCT05021770|Drug|Thiotepa|30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
75456570|NCT01773369|Behavioral|Early leg training|Children will engage in ~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therapist in the clinical setting.
75456571|NCT01773369|Behavioral|Delayed leg training|The training activity will be exactly the same as the Early leg training group, except that it will occur ~3 months after recruitment.
75456572|NCT01773369|Behavioral|Parent leg training|Children will engage in ~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
75456573|NCT01773382|Behavioral|weight reduction|"Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~Daily body weight measurement.~Record food diary"
75608066|NCT02800759|Dietary Supplement|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
75608067|NCT02857582|Biological|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
75608068|NCT02857582|Drug|Vancomycin|Active comparator to treatment with ACHIM
75608069|NCT02857582|Drug|Metronidazole|Primary treatment for C diff in all treatment arms
75753884|NCT04850963|Device|Transcranial direct current stimulation sham + dual-task training|"tDCS sham 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
75753885|NCT00959153|Device|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
75456574|NCT01773408|Drug|RO5503781 MBP|Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
75753886|NCT00959231|Drug|cyclophosphamide|
75753887|NCT00959231|Drug|cyclosporine|
75902086|NCT05008978|Other|Test 1|25g of available carbohydrates from White bread with 25g of available carbohydrates from Banana consumed simultaneously at time 0 min
75753888|NCT00959231|Drug|fludarabine phosphate|
75608070|NCT04301973|Other|Stool collection|There is no intervention with a product in this study. The healthy subject has just to come 2 times in the clinical trial unit for clinical exam including urinary pregnancy test, fill life habits and diet questionnaires, and provide one stool sample for the 2nd visit, after 2 weeks of alimentary restrictions.
75753889|NCT00959231|Drug|mycophenolate mofetil|
75456575|NCT01773408|Drug|RO5503781 SDP|Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
75902087|NCT05008978|Other|Test 2|25g of available carbohydrates from Banana consumed at time -15 min and 25g of available carbohydrates from white bread consumed at time 0 min
75456576|NCT01773408|Drug|Idarubicin|Idarubicin will be administered as per standard clinical practice.
75456577|NCT01773408|Drug|Daunorubicin|Daunorubicin will be administered as per standard clinical practice.
75608071|NCT02803801|Behavioral|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
75608072|NCT04301895|Behavioral|Continuous conversational interaction|Maintaining continuous conversation, requiring that the subject answer questions and engage in discussion without interruption.
75753890|NCT00959231|Other|laboratory biomarker analysis|
75753891|NCT00959231|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75753892|NCT00959231|Procedure|umbilical cord blood transplantation|
75902088|NCT05008978|Other|Test 3|25g of available carbohydrates from White bread consumed at time 0 min and 25g of available carbohydrates from Banana consumed at time 15 min
75902089|NCT05008978|Other|Test 4|25g of available carbohydrates from White bread with 25g of available carbohydrates from Papaya consumed simultaneously at time 0 min
75753893|NCT00959231|Radiation|total-body irradiation|
75753894|NCT03948581|Drug|Vedolizumab SC|Vedolizumab SC liquid.
75753895|NCT00548327|Drug|Atomoxetine|Comparison between Atomoxetine and Placebo
75456578|NCT01773408|Drug|Cytarabine|Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m^2 IV infusion daily.
75456579|NCT01773434|Drug|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
75456580|NCT01773447|Procedure|Set-back suture|
75753896|NCT00548327|Procedure|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
75753897|NCT00548327|Procedure|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
75902090|NCT05008978|Other|Test 5|25g of available carbohydrates from White bread with 25g of available carbohydrates from Apple consumed simultaneously at time 0 min
75456581|NCT01773447|Procedure|Vertical mattress suture|
75456582|NCT01773460|Drug|Everolimus|Everolimus is given beyond progress (comparison with placebo)
75608073|NCT04301895|Drug|Remifentanil infusion|10 minute remifentanil infusion
75753898|NCT00548327|Drug|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
75902091|NCT05021692|Behavioral|Web-based support program for pregnant women with preeclampsia based on the Health Promotion Model|support program
76067472|NCT04806503|Drug|UNR844|Ophthalmic solution for topical ocular administration
75902092|NCT05009056|Device|Postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
75902093|NCT03619525|Procedure|lung recruitment|During bypass, patients in this group will receive a lung protective design in the form of continuous positive airway pressure (CPAP) by closing APL valve at pressure of 5 Cm H2o combined with intermittent recruitment by sustained manual lung inflation at a pressure of 35 cmH2O for 30 seconds every (30-40) minute
75902094|NCT05230303|Dietary Supplement|Caffeine supplementation|Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
75902095|NCT05230303|Dietary Supplement|Placebo treatment|The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
75902096|NCT04287790|Behavioral|audit and feedback, educational meetings, and academic detailing to promote medication receipt|Our implementation intervention will incorporate the following strategies: 1) Formation of an alcohol-related care working group. This voluntary working group will consist of members of the research team and volunteer health professionals from YNHH. The group with supervise and support the other intervention components. 2) We will develop medication for alcohol use disorder marketing (posters and buttons) materials and educational (pamphlet) materials and distribute these materials to health professionals. 3) Building on the existing infrastructure and collaboration, the research team will assist in revising existing alcohol-related care daily monitoring systems to support auditing and feedback on the adoption of medications for alcohol use disorder at YNHH. 4) The research team will hold educational meetings and educational outreach visits (academic detailing) when invited during regular noon conferences and team meetings.
75902097|NCT04287790|Drug|Acamprosate, naltrexone, or disulfiram|Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
75902098|NCT01408615|Drug|corifollitropin alfa|100 or 150 microgram single subcutaneous injection
76067473|NCT04806503|Drug|Placebo|Placebo
76067474|NCT04788108|Drug|Dydrogesterone|Dydrogesterone tablet
75608074|NCT02357134|Procedure|Oxygen Therapy|Receive high-flow oxygen
76067475|NCT04788108|Drug|Placebo|Placebo tablet
76067476|NCT04747405|Other|therapy group|therapy group of maximum 8 people repeated twice
76067477|NCT04741724|Device|TEDS|An non-invasive intervention. During the intervention, the electrode was placed on the skin stimulated muscle.
76067478|NCT04741438|Drug|Nivolumab and IPILIMUMAB|"The combination of Nivolumab+Ipilimumab will be given to patients as follows:~Nivolumab: 3 mg/kg IV over 30 minutes every 2 weeks for 4 cycles.~Ipilimumab 1 mg/kg IV over 60 minutes every 6 weeks for 4 cycles. After completion of 4 courses with ipilimumab, patients continue receiving nivolumab IV at the dose of 480 mg Q4W in the absence of disease progression or unacceptable toxicity for a maximum of 18 months.~Nota Bene: A cycle is defined as a 6-weeks period.~The planned treatment period is 24 months~Nivolumab and Ipilimumab must be injected the same day every 6 weeks (Q6W). In case of toxicity, dose will be delayed, but will not be reduced."
75456583|NCT01773460|Drug|Everolimus-placebo|Everolimus-placebo
75456584|NCT01773512|Drug|Rosuvastatin|All patients will be using rosuvastatin 40 mg
75456585|NCT01773538|Drug|Lactulose and rifaximin|3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
75456586|NCT01773538|Dietary Supplement|Branched Chain amino acids|30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
75456587|NCT01773538|Other|Placebo|Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
75456588|NCT01773551|Other|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
75456589|NCT01773564|Device|Current hospital dressing|Patients were assigned to either arm following a randomization scheme 1:1.
75456590|NCT01773564|Device|3M™ IV Advanced Securement dressing|Patients were assigned to either arm following a randomization scheme 1:1.
75456591|NCT01773590|Other|Rhinovirus Infection|
75608075|NCT02357134|Procedure|Oxygen Therapy|Receive high-flow air
75608076|NCT02357134|Other|Quality-of-Life Assessment|Ancillary studies
75608077|NCT02357134|Other|Questionnaire Administration|Ancillary studies
75608078|NCT02357134|Procedure|Respiratory Therapy|Receive low-flow oxygen
75608079|NCT02357134|Procedure|Respiratory Therapy|Receive low-flow air
75608080|NCT04200781|Drug|Granules of Shengdi Dahuang Decoction|Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
75753899|NCT00959309|Behavioral|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
75753900|NCT00959309|Behavioral|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
75753901|NCT04720547|Drug|Zolpidem|A nonbenzodiazepine hypnotic
75753902|NCT04720547|Other|No Treatment|The Control condition in which participants do not receive medication.
76067479|NCT04741438|Drug|Pazopanib Oral Tablet [Votrient]|"Treatment by pazopanib 800 mg/day per os, continuously during a maximum 24 months.~In case of toxicity, dose will be delayed and reduced."
76067480|NCT04731961|Procedure|Standard of care (15 Botox injections)|The controls will be given the standard of care of 15 Botox injections.
75608081|NCT04200781|Drug|Placebo|Placebo granules has the same appearence, weight, shape and color as the experimental drug.
75608082|NCT04302675|Behavioral|Prevention, Maternal Immunization|"This intervention will be focused on behavior change, both through providers gaining context, knowledge, confidence, and skills in talking to pregnant mothers about vaccination during pregnancy, but also with patients having increased knowledge about immunization issues, and decreased anxiety about getting vaccinated.~There is only one intervention arm in this study, and this study is looking at prevention in a pre-post feasibility study."
75608083|NCT02806765|Dietary Supplement|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol every day for 6 months
75608084|NCT02806765|Other|Control|Placebo in Softgel form
75608085|NCT02853526|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
75608086|NCT02853526|Drug|Propranolol|Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
75753903|NCT00959387|Drug|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
75753904|NCT00959387|Radiation|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
75753905|NCT00959465|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
76067481|NCT04731961|Procedure|Experimental Arm (5 Botox injections)|5 Botox injections will be given, with each injection containing three times the amount of Botox than each of the 15 injections given in the standard of care arm.
75753906|NCT04718285|Drug|Montelukast Oral Tablet|3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
76067482|NCT04692337|Procedure|Intra-operative Ommaya Reservoir placement|An Ommaya reservoir is a small device implanted under the scalp that enables percutaneous access to cerebrospinal fluid.
75608087|NCT02853526|Procedure|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
75608088|NCT02853526|Drug|Warfarin|Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
75608089|NCT04200469|Diagnostic Test|Quantitative Flow Ratio (QFR) measurement|Quantitative flow ratio (QFR) is a novel approach enabling rapid computation of FFR pullbacks from three-dimensional quantitative coronary angiography (3D-QCA) without using a pressure wire.
75753907|NCT04718285|Drug|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
75753908|NCT04718285|Drug|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
75753909|NCT05299619|Device|Tixel|a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
75753910|NCT00959543|Other|MRI|MRI and clinical investigation
75753911|NCT00959621|Drug|Aspirin|ASA 100 mg once daily per os
75753912|NCT00959621|Drug|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
75753913|NCT00959621|Drug|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
75753914|NCT05299541|Dietary Supplement|Food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~All dishes will be photographed at the end of the meal by Android camera, iPhone~A NUTRITION DAY success photo form will be completed and collected ."
75753915|NCT05299541|Diagnostic Test|Indirect calorimetric|• The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
75753916|NCT05299541|Diagnostic Test|Bioimpedance|• The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
75753917|NCT05299541|Behavioral|Questioners|"At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM"
75902099|NCT04466332|Device|LifeCath-CT PICC easy™ (Vygon)|"ECG electrodes are placed on patient's chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify a suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The PICC is advanced into the central circulation and used as an intracavitary electrode (connection with Vygocard2™). Saline water instilled through the catheter ensures conductivity.~The ECG is then used until displayed intracavitary P-wave has a maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The PICC hub side is then trimmed and the catheter part connected. The PICC is caped with a neutral bidirectional valve.~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess the position."
75608090|NCT03898531|Procedure|hip prosthesis removed metal / polyethylene, simple mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation"
75753918|NCT05299541|Dietary Supplement|Plated food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~All dishes will be photographed at the end of the meal by Android camera, iPhone~A NUTRITION DAY success photo form will be completed and collected ."
75753919|NCT00959777|Drug|DA-3031|
75753920|NCT00959777|Drug|Filgrastim|
75753921|NCT04450745|Behavioral|Exercise in hypoxia|60 minutes training program of mixed exercise in normobaric hypoxic chamber
75753922|NCT04450745|Behavioral|Exercise in normoxia|60 minutes training program of mixed exercise in regular air conditions
75753923|NCT03953183|Other|P3P-1mg|P3P-1mg (P3P product containing 1mg of nicotine.)
75753924|NCT03953183|Other|P3P-2mg|P3P-2mg (P3P product containing 2mg of nicotine.)
75753925|NCT00959855|Other|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
76072294|NCT02021006|Drug|Trimethoprim/sulfamethoxazole|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
75456592|NCT01773603|Device|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
75456593|NCT01773616|Drug|Oral prednisolone|
75456594|NCT01773616|Drug|Rituximab|
76067483|NCT04682652|Device|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
76067484|NCT04675411|Device|Smart care|Home based nursing intervention with smart assisted technology
76067485|NCT04675411|Device|usual care|Routine hospital care with only in-hospital rehabilitation
75753926|NCT00961883|Biological|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 ^7 PFU
75608091|NCT03898531|Procedure|hip prosthesis removed metal / polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
75753927|NCT00961883|Biological|Placebo|Sodium Chloride for injection, delivered intramuscularly
75902100|NCT04466332|Device|PowerPICC-SOLO® (C.R. Bard)|"ECG electrodes are placed on patients chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The catheter's free end is cut to the anticipated length using anthropometric measurements (insertion/axillary crease+axillary crease/sternal notch+13cm) and the preloaded magnetic-tipped stylet (serving as intracavitary electrode) is put inside.~The PICC is advanced into central veins until intravascular ECG displays a P-wave with maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess position."
75456595|NCT01773616|Drug|Mycophenolate mofetil|
75456596|NCT01773616|Drug|Methyl prednisolone|
75456597|NCT01773629|Other|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
75456598|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
75608092|NCT03898531|Procedure|hip prosthesis removed ceramic/ polyethylene, simple mobility|"Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
75608093|NCT03898531|Procedure|hip prosthesis removed ceramic/ polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation."
75753928|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^10 PFU
75753929|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^9 PFU
75753930|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^8 PFU
75753931|NCT00959933|Drug|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
75753932|NCT00959933|Drug|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
75753933|NCT00960089|Device|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
75753934|NCT00960167|Radiation|3DCRT or IMRT|"All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)"
75753935|NCT00962195|Dietary Supplement|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
75753936|NCT00960245|Drug|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
75902101|NCT05015842|Other|Conventional Physical Therapy|This is a combine protocol of different therapeutic exercises and heat therapy.
75902102|NCT05015842|Other|Kinesio Tapping|Kinesio Tapping is an adhesive and elastic fiber used for different outcomes like pain and swelling reduction among physical therapists.
75902103|NCT03723967|Drug|Durvalumab with Carboplatin/Paclitaxel|Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
75902104|NCT05009212|Procedure|Endoscopic stricturotomy|Endoscopic stricturotomy for bowel stricture (<5 cm)
75902105|NCT05009212|Procedure|Endoscopic balloon dilatation|Endoscopic balloon dilatation for bowel stricture (<5 cm)
75456599|NCT01773642|Behavioral|Cognitive behavioral intervention to support pediatric HIV disclosure|
75753937|NCT00960245|Drug|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
76067486|NCT04675073|Procedure|Ventricular tachycardia substrate-based radiofrequency ablation|The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
76067487|NCT04672655|Behavioral|ONBOARD|Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM & social situations; Session 4: Building trust with your CGM
75902106|NCT05132569|Drug|Tolebrutininb|Pharmaceutical form: Film-coated tablet Route of administration: Oral
75902107|NCT05132569|Drug|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral
76067488|NCT04671693|Other|PASCA intervention|"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."
76067489|NCT04660331|Other|Communication Intervention|Undergo communication strategy intervention
76067490|NCT04660331|Other|Communication Skills Training|Undergo communication training sessions
76067491|NCT04660331|Behavioral|Healthcare Activity|Participate in interview
75608094|NCT03898531|Procedure|Primary implanted hip prosthesis|"Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis."
75608095|NCT03898531|Procedure|hip prosthesis removed metal/metal|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation"
75608096|NCT03898531|Procedure|hip prosthesis removed ceramic/ceramic|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation"
75608097|NCT02806531|Biological|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
75608098|NCT00630682|Drug|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
75608099|NCT00630682|Drug|Placebo|9 weeks of placebo 60mg capsules QD.
75608100|NCT04236193|Diagnostic Test|Ultrasound Shoulder and Immunological Phenotyping by FACS|Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements
75753938|NCT00962273|Behavioral|Interactive computerized learning resource|"In a series of interactive scenarios, participants can see themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties."
75753939|NCT00962273|Behavioral|Didactic computerized learning resource|In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
75753940|NCT00406653|Drug|abatacept|"Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months"
75753941|NCT00406653|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
75753942|NCT00406653|Drug|abatacept|"~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued"
76067492|NCT04660331|Behavioral|Healthcare Activity|Undergo environmental scan
76067493|NCT04660331|Other|Survey Administration|Complete survey
75608101|NCT00745420|Biological|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~Fludarabine: 30 mg/m^2/day IV on Days -8 through -4~Melphalan: 140 mg/m^2 IV on Day -3~Rest on Days -2 and -1~Transplant occurs on Day 0~GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
75753943|NCT03381651|Radiation|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
76067494|NCT04648540|Drug|Dexmedetomidine 0.5 mic/kg/h|"In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~Dexmedetomidine 0.5 mic/kg/h~Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours"
75608102|NCT02800681|Other|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
75753944|NCT03381651|Radiation|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
75753945|NCT00547157|Drug|Panitumumab|Arm 2 consists of panitmumab plus RT
75753946|NCT00547157|Drug|Cisplatin|Cisplatin
75753947|NCT00960479|Drug|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
75753948|NCT00960479|Drug|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
75753949|NCT00960557|Drug|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
75753950|NCT00960635|Drug|1,25-dihydroxy-vitamin D3 (calcitriol)|
75753951|NCT00960635|Drug|placebo|pill without agent
75753952|NCT00960713|Drug|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
75753953|NCT04009889|Dietary Supplement|capsule containing a probiotic blend of 5 different Lactobacilli|n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
75753954|NCT04009889|Other|capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.|n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
75753955|NCT00962351|Procedure|Total Hip Replacement|
75753956|NCT00962507|Drug|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
75753957|NCT00962507|Drug|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
75753958|NCT00962507|Other|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
75753959|NCT00962507|Other|pharmacological study|Pre-study, day 1 and day 26
75753960|NCT00960791|Device|AZD1656|Oral single dose
75753961|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
75753962|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
75753963|NCT00384033|Drug|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
75753964|NCT00384033|Drug|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
75753965|NCT00962663|Drug|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
76067495|NCT04648540|Drug|Fentanyl 1 mic/kg/hr|In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
76067496|NCT04645823|Drug|Fentanyl Citrate|Fentanyl citrate 20 µg in 2 ml of saline injected into csf
75608103|NCT02800681|Other|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
76067497|NCT04645823|Drug|Lidocaine 1% Injectable Solution|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
76067498|NCT04645823|Drug|Fentanyl Citrate|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
75753966|NCT00962663|Drug|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
75753967|NCT00962663|Drug|Placebo|"Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4."
75753968|NCT00962819|Biological|MMR vaccine|People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
75753969|NCT00961025|Drug|DA-1229|"single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg"
75608104|NCT02800681|Other|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
75608105|NCT02800681|Other|Other general interviewer ratings|1. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
75608106|NCT02806609|Other|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
75608107|NCT02806609|Other|immersion in water at room temperature|immersion in water at room temperature
75608108|NCT02806609|Other|active recovery - running|active recovery
75753970|NCT00961025|Drug|Placebo|placebo
75753971|NCT00962897|Procedure|Femoral-popliteal bypass|Surgical bypass of blockage in the thigh
75753972|NCT00962897|Procedure|Stent-graft placement|Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
75608109|NCT02806609|Other|rest in the chair|rest in the chair
75753973|NCT00962975|Drug|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
75753974|NCT01046097|Biological|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
75753975|NCT01046175|Procedure|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
76067499|NCT04645628|Other|MRI examination|All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
75753976|NCT01046175|Procedure|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
75753977|NCT04009655|Other|music|music selected by musician
75753978|NCT00075387|Drug|Carboplatin|Given IA
75753979|NCT00075387|Drug|Cyclophosphamide|Given IV
75753980|NCT00075387|Drug|Etoposide Phosphate|Given IV
75902108|NCT05008666|Drug|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~Exploring biomarkers that may have predictive effects."
75753981|NCT00075387|Other|Quality-of-Life Assessment|Ancillary studies
75753982|NCT00075387|Drug|Sodium Thiosulfate|Given IV
75753983|NCT00963131|Drug|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
75753984|NCT00963209|Drug|tamoxifen citrate|
75753985|NCT00963209|Other|laboratory biomarker analysis|
75753986|NCT00963209|Other|pharmacological study|
75753987|NCT00963287|Drug|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
76067500|NCT04638413|Behavioral|Walking (W)|Participants engage in 30 min of walking daily, for three weeks.
76067501|NCT04638413|Behavioral|Walking + PolyRules! (W+PolyRules!)|Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
76067502|NCT04629508|Drug|itacitinib|itacitinb Immediate Release (IR) will be dosed orally twice a day
76067503|NCT04619745|Other|Individualized Home and Play-Based Physical Activity Plans|Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
76067504|NCT04602468|Drug|Kaftrio|The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
75902109|NCT05008666|Drug|Chidamide|"To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~Exploring biomarkers that may have predictive effects."
75902110|NCT05008666|Drug|Azacitidine|"To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~Exploring biomarkers that may have predictive effects."
75902111|NCT05008666|Drug|L-DEP|L-DEP
76067505|NCT04594382|Diagnostic Test|Pupillometry-Opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~Opioid administration will be given by a single dose of piritramid (0.1 mg kg -1) in case of measured PDR values of ≥12 (high analgesic sensitivity as specified by the producer) after T30 and T60 stimulation. The pupillometry measurement will be repeated once on both eyes."
76067506|NCT04594382|Diagnostic Test|Pupillometry -standardized opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~A standardized single dose of piritramid (0,1 mg kg -1) will be given intravenously, regardless of the measured values. The pupillometry measurement will be repeated once on both eyes."
75608110|NCT02857348|Behavioral|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
75608111|NCT02857348|Behavioral|Educational Module|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
75608112|NCT05095870|Other|No intervention|Pure observational study
75753988|NCT00961337|Biological|Trivalent inactivated influenza vaccine|one dose
75753989|NCT00963365|Drug|AZD6765|Single oral dose and single IV infusion of AZD6765
75753990|NCT00963365|Drug|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
75753991|NCT00963443|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
75753992|NCT00963443|Drug|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
75753993|NCT00963443|Drug|Placebo|Matching Placebo
75753994|NCT00963521|Biological|therapeutic autologous dendritic cells|
75753995|NCT00961493|Behavioral|Acceptance based behavioral therapy|16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
75753996|NCT00961493|Behavioral|Applied relaxation|16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
75902112|NCT05021380|Other|GROUP|Non-invasive diagnosis of dental pain, dental root canal treatment, salivary specimen collection from the first visit to next and the last during 4 weeks of dental care
75902113|NCT03079648|Dietary Supplement|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
75902114|NCT03079648|Dietary Supplement|Placebo|Placebo for 12 weeks
75902115|NCT03659461|Drug|Sitagliptin|oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.
75902116|NCT03088618|Procedure|Nasal septoplasty|Type of surgery
75753997|NCT00961727|Other|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; [1] an expert derived, multi-centre validated severity of illness score, [2] an inter-professionally developed documentation record into which the severity of illness score is embedded, [3] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and [4] an educator-developed education-implementation program.
75753998|NCT00963833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
75753999|NCT00964067|Other|Exercise training|Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
75754000|NCT00967655|Biological|panitumumab|
75754001|NCT00967655|Drug|capecitabine|
75754002|NCT00967655|Drug|irinotecan hydrochloride|
75902117|NCT01227187|Drug|Drotrecogin alfa activated (Xigris)|We will test different dose regimens of Drotrecogin alfa activated (Xigris) to determine the optimal dose to achieve PTT between 65 and 100 secs. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via pre-filter arterial drip chamber via a standard IV pump. The PTT will be assessed at baseline,15,30,60,120 and 180 mins. Xigris dose will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains <65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
75608113|NCT04269460|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]|preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block using 1 ml/kg of Bupivacaine Hydrochloride 0.25%in pediatric patients undergoing pyeloplasty surgeries.
75902118|NCT03088072|Drug|Edoxaban|"Edoxaban 60mg once daily in patients with CrCl >50- ≤95 mL/min, or 30mg once daily in patients with CrCL 15-50 mL/min.~If at 6 week TEE LAA closure is deemed acceptable by the operator (i.e., peri-device flow <5mm), edoxaban will be discontinued. Aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up, then clopidogrel will be discontinued.~If LAA unacceptable on 6-week TEE due to peri-device flow ≥5mm, edoxaban will be continued for an additional 6 weeks, and LAA reassessed by TEE If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference."
75608114|NCT04236037|Procedure|ultrasound-guided pleural biopsy|Using ultrasound the optimal point of entry for thoracentesis is located. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site . Again, the area is wiped with disinfectant and a millimeter small skin incision is made with a pointed scalpel. Six US-guided biopsies of 1.2 millimetres using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core needle 18G, Temple, Arizona, USA). ) are taken from the parietal pleura. Thoracentesis is performed as described above using the same incision as the pleural biopsy.
75608115|NCT04236037|Procedure|Thoracentesis|The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.
75608116|NCT04236115|Drug|Articaine 4%|Articaine 4% is dental local anaesthetic agent
75608117|NCT04236115|Drug|Prilocain 3%|prilocaine is dental local anaesthetic agent
75608118|NCT04236115|Drug|Adrenalin|adrenaline is a vasoconstrictor
75608119|NCT04236115|Drug|Felypressin|Felypressin is a vasoconstrictor
75754003|NCT00967655|Procedure|neoadjuvant therapy|
75754004|NCT00967655|Procedure|therapeutic conventional surgery|
75754005|NCT00967655|Radiation|radiation therapy|
75608120|NCT02853370|Drug|Bendamustine and Rituximab|
75608121|NCT04044625|Device|High-intensity NPPV|In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
75754006|NCT01563419|Device|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens"
75608122|NCT04044625|Device|Low-intensity NPPV|In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
75754007|NCT00546377|Biological|filgrastim|
75754008|NCT00546377|Biological|pegfilgrastim|
75754009|NCT00546377|Biological|rituximab|
75754010|NCT00546377|Biological|sargramostim|
75754011|NCT00546377|Drug|cyclophosphamide|
75754012|NCT00546377|Drug|mitoxantrone hydrochloride|
75754013|NCT00546377|Drug|pentostatin|
75754014|NCT00546377|Genetic|fluorescence in situ hybridization|
75754015|NCT00546377|Genetic|gene rearrangement analysis|
75754016|NCT00546377|Genetic|polymerase chain reaction|
75754017|NCT00546377|Genetic|protein expression analysis|
75754018|NCT00546377|Other|flow cytometry|
75754019|NCT00546377|Procedure|biopsy|
75754020|NCT00967889|Genetic|gene expression analysis|
75754021|NCT00967889|Genetic|protein analysis|
75754022|NCT00967889|Other|biologic sample preservation procedure|
75608123|NCT02806219|Device|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
75608124|NCT02806219|Device|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
75754023|NCT00967889|Other|laboratory biomarker analysis|
75754024|NCT00964301|Other|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
75754025|NCT00964301|Other|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
75754026|NCT00967967|Drug|Medication Mometasone furoate and desloratadine|One month treatment with both drugs
75754027|NCT00968045|Drug|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
75754028|NCT00964379|Procedure|intraperitoneal or extraperitoneal colostomy|creation of colostomy
76067507|NCT04580680|Device|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|At each participating center, EBP treatments with commercial membranes will be delivered in accordance with local practice and local levels of expertise. Enrolled patients will not receive additional treatments other than those routinely administered in ICUs. Nonetheless, all parameters settings for EBP treatments will be recorded in the web-based registry and analyzed a posteriori to reveal potential correlations with patient outcomes.
76067508|NCT04579094|Other|Feces sampling at inclusion (J0)|Feces sampling at inclusion (J0)
75608125|NCT04068727|Other|Clinical Pharmacist Intervention|After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.
75608126|NCT05491837|Other|Device induce acute intermittent hypoxia 9 % of Oxygen|Interventional group will be provided a brief sequence of mild hypoxia consisting of 9% oxygen for one minute followed by normoxia 21% of oxygen for a total of 15 episodes
75608127|NCT05491837|Other|Normoxia 21% of oxygen|SHAM group will be provided normoxia 21% of Oxygen
75608128|NCT00954538|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
75608129|NCT02690155|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
75608130|NCT02690155|Drug|VKA (Vitamin K antagonist)|As prescribed by treating physicians
75608131|NCT00630760|Drug|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
75608132|NCT02806375|Procedure|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
75608133|NCT02806375|Drug|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
75608134|NCT02806375|Drug|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
75608135|NCT02806375|Drug|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
75608136|NCT02806375|Drug|Ruxolitinib|Days -8 through -2 15 mg tid
75608137|NCT02806375|Drug|Ruxolitinib|Days +5 through +100: 7.5 mg bid
75754029|NCT00964457|Drug|cetuximab|cetuximab 500mg per meter square every second week
75754030|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
75754031|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
75754032|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
75754033|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
75754034|NCT00964691|Drug|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
75754035|NCT00964691|Drug|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
75754036|NCT00964769|Biological|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
75754037|NCT00964847|Behavioral|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
75902119|NCT03088072|Device|WATCHMAN LAA Closure|Per Inclusion Criteria, enrolled subjects must have a successful Left Atrial Appendage (LAA) Closure using the WATCHMAN Device
76067509|NCT04573543|Diagnostic Test|Evaluation of the degree of fibrosis and steatosis|The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.
75754038|NCT00964847|Behavioral|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
75754039|NCT00968357|Drug|SCV-07|"SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy."
75754040|NCT00968435|Other|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
75754041|NCT00965003|Procedure|MRI scan|Standard of Care
75754042|NCT05253287|Drug|Growth Hormone|GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
75754043|NCT00968513|Behavioral|Brief Intervention|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
75754044|NCT00968513|Behavioral|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
75754045|NCT00968513|Behavioral|Usual Care|brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
75608138|NCT02856256|Dietary Supplement|RedBull® energy drink|Subjects consume 25 mL of RedBull® energy drink
75754046|NCT00968591|Drug|Everolimus|
75754047|NCT00968903|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
75754048|NCT00969059|Drug|GW856553|GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.
75754049|NCT00969059|Drug|PLACEBO|Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
75754050|NCT00969137|Drug|saline|intravenous saline
75754051|NCT00969137|Drug|Nicotine|Intravenous nicotine
75754052|NCT00965315|Drug|Rosuvastatin,SFC fenofibrate|"Rosuvastatin 10 mg once daily~Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
76072295|NCT02021006|Drug|Cefixime|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
76072296|NCT02018861|Drug|Parsaclisib|
75754053|NCT00969215|Device|Lumenis fractional carbon dioxide laser|Laser resurfacing of a burn scar
75754054|NCT00969293|Drug|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
75456600|NCT01773655|Other|tumor specimens|"All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome."
75608139|NCT02803489|Device|medical device intervention|
75754055|NCT00969371|Device|posterior chamber IOL implantation|
76072297|NCT02018861|Drug|Itacitinib|
75754056|NCT00969371|Device|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
75754057|NCT00969449|Drug|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
75608140|NCT02800603|Behavioral|Family Check Up|"The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings."
75754058|NCT00969449|Drug|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
75754059|NCT00965393|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
75754060|NCT00965393|Drug|Placebo|Systemic infusion of placebo (saline)
75754061|NCT00965393|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
75754062|NCT00965471|Drug|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
75456601|NCT01773668|Device|Integrated sensor and infusion set.|
75456602|NCT01773681|Drug|Cimzia|"For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.~After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen."
75754063|NCT00965471|Drug|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
75754064|NCT00965549|Drug|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
75754065|NCT00965549|Drug|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
75902120|NCT03088072|Drug|Aspirin and Clopidogrel|"If at 6 week TEE LAA closure is deemed acceptable by the operator edoxaban will be discontinued, and aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up. Then clopidogrel will be discontinued.~Aspirin 325mg daily rather than 81mg daily can be administered according to operator preference after the 6-week follow-up visit."
75902121|NCT03088072|Drug|Aspirin and Warfarin|If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference.
75456603|NCT01773681|Device|Magnetic Resonance Imaging (MRI)|MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
75754066|NCT00965549|Drug|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
75754067|NCT00969527|Dietary Supplement|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
75902122|NCT05008042|Drug|Mecobalamin 5 MG|The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly
75902123|NCT05008042|Other|Placebo Comparator : NaCl 9 mg/ml|Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.
75902124|NCT03619447|Drug|ESP block group|USG guided Erector spinae block (ESP) will perform bilaterally.
75902125|NCT03619447|Drug|serratus block group|USG guided serratus plane block will perform bilaterally
75902126|NCT05015140|Other|musıc therapy|calm music with nature sounds set by the music therapist
76072298|NCT02018861|Drug|Rituximab|
76072299|NCT02018861|Drug|Ifosfamide|
75902127|NCT05021302|Procedure|NOVAMAG NT-60|The Electromagnetic stimulation consists of 15 sessions with 20 minutes duration and three times a week. The total length of therapy is five weeks.
75754068|NCT00969527|Dietary Supplement|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
75608141|NCT04269148|Other|Measurement of Quality of Life|Quality of life will be measured using McMaster University Head and Neck Radiotherapy Questionnaire and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
75902128|NCT05021302|Behavioral|Kegel Exercises|Self-supporting pelvic floor muscle strengthening exercises performed at home by contracting and relaxing quickly (2 seconds of contraction and 4 seconds of rest), followed by a slow contraction (contraction for 5 seconds, and rest for 10 seconds with five times each) five sets per day. The average length of exercise for each session is 2 minutes, with total exercise per day is 50 times. Thus, the total length of exercise is 10 minutes. It was done every day for eight weeks.
76067510|NCT04573543|Diagnostic Test|Screening for the components of metabolic syndrome|"Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome."
76067511|NCT04573543|Diagnostic Test|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
76067512|NCT04573543|Diagnostic Test|Identification of semaphorin gene polymorphisms|Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
76067513|NCT04558112|Drug|L-DOPA|two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)
76067514|NCT04558112|Drug|Placebo|two gel capsules of placebo
76067515|NCT04548596|Diagnostic Test|Transcranial Doppler|"In this study, the investigators will primarily use the monitor mode of the Transcranial Doppler (TCD, non-invasive FDA approved device) to record cerebral blood flow velocity (CBFV) signals from the Middle Cerebral Artery and Internal Carotid Artery. TCD data and intracranial pressure (ICP) data will be collected in the following four scenarios. Each recording is up to 60 minutes in length:~External ventricular drain (EVD) closed to drainage for a 24 hour period as part of the EVD weaning protocol per standard of care (SOC): The Initial reading will be done within 4 hours of EVD closing. The second reading will be done within 4 hours of anticipated removal of EVD.~EVD closed most of the time and opened to drainage when the ICP becomes elevated per SOC~EVD with Intra-Parenchymal fiber optical ICP sensor per SOC~Intra-Parenchymal fiber optical ICP sensor per SOC"
75608142|NCT04269226|Procedure|Recruitment maneuver|Following intubation, patients will be ventilated according to the ideal weight within the scope of intraoperative protective ventilation strategy and in pressure-controlled ventilation (PCV) mode. Then, automatic recruitment maneuver will be applied to the recruitment group twice, after insufflation and desufflation. It will not be applied to the control group. During recruitment maneuver, PEEP (Positive end-expiratory pressure), where dynamic compliance is measured highest, will be the ideal peep for the patient, and PEEP will be adjusted at this value after recruitment.
75754069|NCT00969605|Procedure|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
75754070|NCT00969683|Device|Tracheal intubation|Tracheal intubation using a Double lumen tube without a hook
75754071|NCT00969683|Device|Tracheal intubation|Tracheal intubation with a Double lumen tube with a hook
75754072|NCT00965705|Behavioral|Therapy|Individual Therapy and Group Therapy
75754073|NCT00965783|Other|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
76067516|NCT04546230|Procedure|Low-Thoracic Epidural Anesthesia|"Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle & a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later & continued throughout the procedure."
75456604|NCT01773681|Device|High-resolution peripheral quantitative computed tomography (HR-pQCT)|HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
75456605|NCT01773694|Behavioral|Early Water Exposure|"The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.~On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing."
75456606|NCT01773746|Other|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
75754074|NCT00965783|Other|Extension|Bedtime is extended by 2 hours per night for 4 nights
75754075|NCT00969839|Device|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
75902129|NCT03079258|Other|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
75902130|NCT05021068|Other|Postural Assessment|Spinal mouse measurement
75902131|NCT05125081|Drug|Liuwei Dihuang Pill (marketed product in China)|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
76067517|NCT04546230|Procedure|General Anesthesia|General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen & infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
75754076|NCT00965861|Other|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
75754077|NCT04009187|Behavioral|In-person wheelchair propulsion training program|The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.
75754078|NCT04009187|Behavioral|30-minute education session|Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
75456607|NCT01773759|Behavioral|Intervention child care programs|Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
75754079|NCT00969917|Drug|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
75754080|NCT05246969|Other|Sepsis detection|The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.
76067518|NCT04532866|Behavioral|Isolation and Confinement|Eight months of isolation and confinement in the spaceflight analog NEK in Moscow
75754081|NCT05194163|Drug|MW150|oral-delivered capsule of study drug
75754082|NCT05194163|Drug|Placebo|oral delivered capsule matched to study drug capsule
75456608|NCT01773772|Drug|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those or = to 42 kg.
75456609|NCT01773772|Drug|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
75754083|NCT00966173|Device|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
75754084|NCT00966251|Drug|CT-011|CT-011
75754085|NCT00966329|Drug|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
75754086|NCT00966329|Drug|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :~1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~or ATV/unboosted (in a regimen without tenofovir)~or 1 NNRTI (nevirapine or efavirenz)."
75754087|NCT00970229|Drug|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not > 10% of 8 mCi limit)of [123I]MNI-420, followed by SPECT imaging.
75754088|NCT00970385|Drug|CHOP21|"CHOP regimen:~cyclophosphamide 750 mg/m2 intravenously (IV) day 1~doxorubicin 50 mg/m2 IV day 1~vincristine 1,4 mg/m2 (maximum 2 mg) day 1~prednisone 100 mg/m2/D from D1 to D5."
75754089|NCT00970385|Drug|VIP/ABVD|"VIP regimen:~etoposide 100 mg/m2/D IV from D1 to D3~ifosfamide 1000 mg/m2/D from D1 to D5~cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~doxorubicin50 mg/m2/D on D1 and D14~bleomycin 10 mg/m2/D~vinblastine 10 mg/m2/D~dacarbazine 375 mg/m2/D"
75754090|NCT00970385|Radiation|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
75754091|NCT00966485|Drug|80 mg ASA dosing|
75754092|NCT00966485|Drug|500 mg ASA dosing|
75754093|NCT00966563|Drug|Mangafodipir|Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
75456610|NCT01773798|Drug|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
75608143|NCT04269226|Procedure|No recruitment maneuver|Usual ventilation procedures will be applied.
75608144|NCT02803567|Behavioral|Brief psycho-educational intervention|Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
75608145|NCT04273984|Drug|Misoprostol|Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.
75608146|NCT02806297|Procedure|Early cholecystectomy with IOC|The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
75754094|NCT00966563|Drug|Placebo|
76067519|NCT04530071|Biological|CordSTEM-DD (0.7 x 10^7 cells)|CordSTEM-DD (0.7 x 10^7 cells)
76067520|NCT04530071|Biological|CordSTEM-DD (2.1 x 10^7 cells)|CordSTEM-DD (2.1 x 10^7 cells)
76067521|NCT04530071|Biological|Placebo|HA + saline + placebo comparator
76072300|NCT02018861|Drug|Carboplatin|
76072301|NCT02018861|Drug|Etoposide|
75456611|NCT01773798|Drug|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
75456612|NCT01773798|Drug|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
75754095|NCT00970541|Dietary Supplement|Cinnamon Supplementation|1, 3, or 6g of cinnamon per day for 40 days
76067522|NCT04519775|Behavioral|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
76067523|NCT04508751|Other|"3T Free-Breathing Fetal Magnetic Resonance Imaging"|Subject will have a one time MRI scan.
75608147|NCT02806297|Procedure|Late cholecystectomy with IOC|The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
75608148|NCT02857504|Device|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
76067524|NCT04506255|Device|Silicone tape|Medical grade tape with silicone adhesive
75754096|NCT00970541|Dietary Supplement|Placebo (wheat flour)|1, 3, or 6g of placebo per day for 40 days
75754097|NCT04083287|Other|Erector spinae plane block (Group E)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
76067525|NCT04489225|Other|Observational|Observational only without any intervention
75902132|NCT05125081|Drug|Liuwei Dihuang Pill（placebo ）|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
76067526|NCT04473482|Behavioral|Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool|The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
76067527|NCT04472936|Procedure|Single catheter approach|Single venous femoral access will be obtained and the ablation will be performed similar to Group A. After the ablation line is over, we will confirm CTI block using the PRI. During atrial pacing (10 V, 1.5 ms) at a stable cycle length (range 500-700ms) from the tip of the ablation catheter with a sweep speed of 300mm/s, the ablation catheter will be placed first at 5 o'clock (medial to CTI line), then at 7 o'clock (lateral to CTI line), and finally at 9 o'clock position, and the corresponding PRIs will be measured for each pacing site. CTI block is assumed when: (i) the PRI at 7 o'clock is >80ms longer than that at pacing sites of 5, and (ii) the PRI at 9 o'clock is shorter than the PRI at 7 o'clock.
75456613|NCT01773798|Drug|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
75456614|NCT01773798|Drug|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
75456615|NCT01773811|Behavioral|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
75456616|NCT01773811|Behavioral|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
75456617|NCT01773824|Behavioral|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
75456618|NCT01773824|Behavioral|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
75608149|NCT02857504|Device|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
75754098|NCT04083287|Other|Interscalen brachial plexus block (Group I)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
75754099|NCT00970619|Device|Ekos endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
75754100|NCT00970697|Drug|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
75754101|NCT00970697|Drug|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
75754102|NCT00970775|Drug|AZD2423|oral solution, single dose
75754103|NCT00970775|Drug|Placebo|oral solution,single dose
75754104|NCT00967031|Drug|capecitabine|
75754105|NCT00967031|Drug|lapatinib ditosylate|
75754106|NCT00967031|Other|circulating tumor cell analysis|
75754107|NCT00967031|Other|laboratory biomarker analysis|
75754108|NCT00967109|Other|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
75754109|NCT00967109|Other|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
75754110|NCT00545753|Drug|Spinosad|10 minute topical application product, following by a complete rinse off.
75754111|NCT00545753|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
75754112|NCT00545753|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
75754113|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
75754114|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
75754115|NCT00970931|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
75754116|NCT00970931|Drug|placebo|Oral placebo once a day, for 18 months
75456619|NCT01773837|Drug|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
75456620|NCT01773837|Drug|placebo|placebo (pill) p.o.
75608150|NCT02806453|Dietary Supplement|thickened formula|
75608151|NCT02806453|Dietary Supplement|Mg alginate|
75608152|NCT02806453|Behavioral|reassurance with lifestyle changes|
75608153|NCT04235803|Other|Telemedicine follow-up|A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
75608154|NCT00943852|Drug|losartan potassium|Single dose losartan 100 mg in one of five treatment periods
75608155|NCT00943852|Drug|Comparator: isosorbide mononitrate (ISMN)|Single dose ISMN 60 mg in one of five treatment periods
75754117|NCT00971009|Behavioral|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
75754118|NCT00971009|Behavioral|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
75608156|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
75902133|NCT03091972|Procedure|Pulmonary vein isolation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
76067528|NCT04472936|Procedure|Traditional approach|Double venous femoral access will be obtained. A duodecapolar catheter will be positioned in the right atrium around the tricuspid valve annulus (TVA) to record activation sequence around the tricuspid annulus. An ablation catheter will be positioned using fluoroscopic guidance in the central CTI, 6 o'clock in a left anterior oblique view. The distal ablation electrode position will then be adjusted toward or away from the TVA, based on the ratio of atrial and ventricular electrogram amplitudes with an optimal ratio of 1:2 or 1:4 at the TVA. After the ablation catheter is positioned, it will be very slowly withdrawn during ablation toward the inferior vena cava while radiofrequency energy is applied continuously. CTI block will be evaluated after ablation by determining the right atrial activation sequence during pacing from the low lateral right atrium and coronary sinus ostium.
75902134|NCT03091972|Procedure|Contact force assisted left atrial linear ablation|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
75902135|NCT03091972|Procedure|left atrial linear ablation without contact force monitoring|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
76067529|NCT04469686|Combination Product|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
76067530|NCT04469686|Combination Product|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator
76067531|NCT04469686|Combination Product|Twice daily placebo suppository administered with Sephure applicator|Twice daily placebo suppository administered with Sephure applicator
76067532|NCT04467619|Device|Functional Proprioceptive Stimulation|Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory & motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.
76067533|NCT04440735|Biological|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
76067534|NCT04440735|Biological|Atezolizumab|Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
75456621|NCT01773850|Device|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
75608157|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
75456622|NCT01773876|Drug|Micafungin|"MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%~infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis"
75456623|NCT01773876|Drug|PLACEBO|solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
75456624|NCT01773902|Dietary Supplement|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
75456625|NCT01773902|Dietary Supplement|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
75456626|NCT01773902|Dietary Supplement|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
75456627|NCT01773980|Other|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
75608158|NCT00943852|Drug|Comparator: Placebo|Single dose placebo only in one of five treatment periods
75608159|NCT02803645|Biological|blood sample|
75754119|NCT00971087|Device|Hologic Selenia Dimensions Digital Breast Tomosynthesis System|Subjects are enrolled from either a screening population or a biopsy population. Both groups are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects recruited in the biopsy population will be imaged on the investigational device prior to their biopsy procedure.
75754120|NCT00406419|Drug|Methotrexate|Methotrexate tablet was administered orally at a dose 7.5-25 mg
75754121|NCT00406419|Drug|ocrelizumab|Ocrelizumab was administered via IV infusion at a dose specified in arm description
75456628|NCT01773980|Other|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
75608160|NCT02853136|Drug|Fluvoxamine|single dose
75608161|NCT02853136|Drug|BI 409306|low single dose
75608162|NCT02853136|Drug|BI 409306|medium or high dose
75608163|NCT02800369|Biological|ZFN-603 and ZFN-758|Each suppository contain 500 µg of ZFN-603 or ZFN-758
75608164|NCT02803723|Procedure|Holding-cuddling|"The Holding-cuddling is started 5 minutes before veinipuncture."
75608165|NCT02803723|Procedure|Sucrose|The sucrose adminstration is started 2 minutes before veinipuncture.
75608166|NCT02803255|Device|MAHI Exo-II|
75754122|NCT00406419|Drug|Placebo|Matching placebo to ocrelizumab was administered via IV infusion
75754123|NCT00967265|Behavioral|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
75754124|NCT00967265|Other|Usual care|Usual care
75754125|NCT00967421|Drug|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
75754126|NCT00967421|Drug|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
75754127|NCT00967421|Other|Placebo drink|Placebo drink containing no alcohol + placebo pill
75456629|NCT01774006|Other|individual embryo culture or group culture|Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
75608167|NCT02803099|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number-SR15-63-Z13-084).
75754128|NCT00971165|Drug|losartan|Oral losartan up to 100 mg daily fo 18 months
75754129|NCT00971165|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
75754130|NCT00971399|Drug|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
75754131|NCT00971399|Drug|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
75754132|NCT01049295|Dietary Supplement|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
75456630|NCT01774032|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|
76067535|NCT04432311|Behavioral|Binge Focused Therapy (BFT)|The BFT group will be provided Binge Focused Therapy, a group-based, guided-self help intervention. Participants in this group will attend three online group sessions spread over six weeks (Week 1, Week 2, and Week 6) and complete homework between sessions. Following Session 3, there is a four week period where participants complete self-guided check-ins once per week to monitor continued progress and/or signs of relapse.
75754133|NCT01049295|Other|corn oil pearls|corn oil pearls 3 times a day
75754134|NCT00973505|Drug|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
75754135|NCT00971477|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
75754136|NCT00971477|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
75754137|NCT00973583|Dietary Supplement|vitamin D|vitamin D3 400 IU daily
75754138|NCT00973583|Dietary Supplement|placebo|placebo
75754139|NCT00971711|Biological|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
75754140|NCT04008953|Device|ultrasonography|Intravascular volume assessment using ultrasonography, CVP and echocardiography
75754141|NCT00973661|Behavioral|Electronic tool set for counseling overweight patients|"Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients."
76067536|NCT04432311|Behavioral|CBT Unguided Self Help (CBT USH)|The CBT USH group will be provided with the book, Overcoming Binge Eating by C. Fairburn, which is a well-established self-help book used to help individuals understand binge eating and control binge eating behaviours. After participants receive the book, they will have 10 weeks to read it and work through the exercises provided in the book.
76067537|NCT04422392|Drug|Carboplatin|(IV, Q3W)
76067538|NCT04422392|Drug|Pemetrexed or Nab-paclitaxel|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
76067539|NCT04422392|Drug|PD-1 antibody|(IV, Q3W)
75608168|NCT02803177|Biological|BMC2012|
75754142|NCT00973895|Biological|VRC-FLUDNA057-00-VP|DNA Vaccine Expressing H1 HA from Influenza A/California/04/2009 H1N1 Virus
75754143|NCT00972101|Radiation|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
75754144|NCT00972101|Drug|Melphalan|140 mg/m^2 by vein over 30 minutes as a single dose on Day -8
75456631|NCT01774058|Drug|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
75456632|NCT01774136|Behavioral|Enhanced HIV and MCH training for CHW|
75456633|NCT01774162|Device|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
75608169|NCT02803177|Device|beta-TCP Chronos® Synthes|
75608170|NCT04236661|Device|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
75754145|NCT00972101|Drug|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
75754146|NCT00972101|Drug|Fludarabine|40 mg/m^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
75754147|NCT00972101|Drug|Rituximab|"Regimen 1:~375 mg/m^2 may be given by vein over 4 - 6 hours on Day -9 if needed~Regimen 2:~375 mg/m^2 may be given by vein over 4 - 6 hours on Day -8 if needed"
75754148|NCT00972101|Drug|Etoposide|60 mg/m^2 by vein over 1-2 hours as a single dose on Day -3.
75754149|NCT00972101|Drug|Anti-thymocyte globulin (ATG)|"Regimen 1:~1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.~Regimen 2:~0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1."
75754150|NCT00972101|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
75754151|NCT00972101|Drug|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
75754152|NCT00972101|Procedure|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
76067540|NCT04414761|Drug|Progesterone|oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
75608171|NCT02806141|Drug|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
75608172|NCT02806141|Drug|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
75608173|NCT02805985|Device|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
75608174|NCT02806063|Procedure|intraoperative samples|
75608175|NCT02805751|Device|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
75608176|NCT02805751|Other|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
75608177|NCT02805751|Other|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
75608178|NCT02803021|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - SR15-47-Z13-076)
75754153|NCT00972101|Drug|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is > 2.5 x 10e^9/L.
75754154|NCT00972101|Procedure|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e^5 T cells/kg on Day 14+.
75754155|NCT00325468|Drug|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
75754156|NCT00972257|Drug|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
75754157|NCT00972257|Drug|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
76067541|NCT04414761|Drug|GnRH Antagonist|GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
75456634|NCT01774162|Device|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
75456635|NCT01774201|Other|Breathing exercises|Breathing exercises with positive expiratory pressure.
75754158|NCT00311584|Drug|irinotecan hydrochloride|Given IV
75754159|NCT00311584|Drug|temozolomide|Given IV
75754160|NCT03021681|Other|autologous bronchial basal cell transplantation|the investigators obtained extraction bronchial basal cells micro tissue from 3~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
75754161|NCT03992859|Procedure|Continuous serratus plane block|Peripheral nerve catheter placed by the surgeon at the end of surgery
75754162|NCT00383331|Drug|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
75608179|NCT02802787|Other|Camp Discovery|Activities will include physical, social, emotional, sensory and spiritual activities.
75754163|NCT00383331|Drug|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
75754164|NCT03934541|Biological|MPER-656 Liposome Vaccine|Administered by intramuscular injection
75902136|NCT05020834|Other|Functional Electrical Stimulation|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
76067542|NCT04400994|Drug|Rituximab|"Rituximab would be given intravenously.~IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~Maximum infusion rate is 400 mg/hr (400 ml/hr)~Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes"
76067543|NCT04400994|Other|IVIg|"IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min & beyond: 180ml/hour"
75463288|NCT05854758|Other|Conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform knee to chest, pelvic rotation, bridge and back extension exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes. Each exercise will be repeated 10 times, with 10 second holds, followed by a five-minute rest interval"
75608180|NCT04235881|Behavioral|Mindfulness-based stress reduction program|Mindfulness training through an adaptation of the standardized MBSR program. This program was conducted in person and in a group, with a maximum of 25 participants per group and a total duration of 8 weeks. The training was carried out in 8 sessions, one each week, with a duration of 2 h each session.
75608181|NCT04235881|Behavioral|App REM volver a casa|"The intervention was carried out through the computer application for mobile phone REM volver a casa. This application has been developed to carry out training in the emotional regulation program based on mindfulness, autonomously. The application is designed to carry out the program in 8 weeks."
75608182|NCT02805673|Procedure|Osteopathy|
75754165|NCT03934541|Biological|Placebo for MPER-656 Liposome Vaccine|Administered by intramuscular injection
75754166|NCT00325234|Drug|Pemetrexed|600 mg/m^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
75754167|NCT00325234|Drug|Carboplatin|AUC 5 mg*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
75754168|NCT00325234|Drug|Gemcitabine|1200 mg/m^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
75754169|NCT00325234|Drug|Vinorelbine|30 mg/m^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
75754170|NCT01063504|Drug|teriparatide|
75754171|NCT00366249|Drug|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
75754172|NCT00366249|Drug|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
76067544|NCT04383912|Drug|Botox Injectable Product|The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
76067545|NCT04383912|Other|No intervention (placebo)|This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
76067546|NCT04378062|Procedure|Digital nerve procedure|The type of procedure performed on the digital nerve at the time of amputation
75902137|NCT05020834|Other|TheraTogs Orthotic Undergarment|TheraTogs Arm The participating children worn TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
75608183|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
75456636|NCT01774214|Procedure|Push-Pull technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model."
75608184|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
75754173|NCT00325156|Biological|GSK Biologicals' combined DTPa-IPV/Hib vaccine|4 intramuscular injections
75608185|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
75754174|NCT01066234|Radiation|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
75902138|NCT05020756|Dietary Supplement|Isosource Junior Mix|Single arm study, collecting data on those who have been on Isosourcr Junior mix tube feed formula for 30 days
76067547|NCT04372485|Behavioral|mHealth Intervention|Adolescents will receive text messages to facilitate treatment adherence
75608186|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
75608187|NCT00952276|Biological|Normal saline solution|0.5 mL, Intramuscular on Day 0
75608188|NCT02802709|Device|SB-061|delivered via intra-articular injection
75608189|NCT02802709|Other|Placebo|Placebo
75608190|NCT02805829|Drug|Trastuzumab + NK cells|NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
75754175|NCT01066234|Drug|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
75754176|NCT03927911|Drug|EXPAREL and Bupivacaine|Drug: EXPAREL and Bupivacaine HCl 0.5%
75608191|NCT02856178|Drug|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
75754177|NCT03927911|Drug|Standard of Care|Standard of Care
75754178|NCT00383019|Drug|Xalatan|latanoprost 0.005%, one rop once daily in evening
75754179|NCT00383019|Drug|Xalacom|latanoprost 0.005% adn timolol 0.5%, one drop, once daily
75754180|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
75754181|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
75902139|NCT01077817|Drug|Alendronate|
76067548|NCT04367688|Drug|Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg|daily use for PrEP
76067549|NCT04354233|Device|Physical activity intervention with connected devices|"Participants randomized in the intervention arm will receive recommandations in physical activity. They will also receive an activity tracker Withings Steel to wear during 6 months. The tracker will be connected to the Withings Health Mate application and the ABLE02 application. Participants will be encouraged to practice at least three walking sessions weekly of more than 10 consecutive minutes. Concerning the number of steps per day, the first objective will be determined according to the 6-min walking distance and to participants' preferences and capacities. The objective will be recalculated monthly according to the number of steps performed the previous week and will be adapted by the physical activity (PA) instructor and participants. Phone calls with the participants are regularly planned. Weekly quizzes on PA and nutrition will be proposed through the ABLE02 application. A messaging system and a phone line will be available for participants to contact the study team."
75754182|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
75754183|NCT00310804|Biological|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
75754184|NCT01046409|Other|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
75902140|NCT01077817|Drug|Etidronate|
75902141|NCT01077817|Drug|Ibandronate|
75902142|NCT01077817|Drug|Risedronate|
75902143|NCT01077817|Drug|Raloxifene|
75902144|NCT03086902|Device|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
75902145|NCT03086902|Device|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
76067550|NCT04318678|Drug|CD123-CAR T|To treat relapsed/refractory CD123+ AML/MDS, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.
75902146|NCT04433962|Other|Exercise training|
75902147|NCT03085498|Other|No intervention|no intervention
75608192|NCT02856178|Drug|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
75902148|NCT02638012|Drug|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
75902149|NCT02638012|Other|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
76067551|NCT04318678|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
76067552|NCT04318678|Drug|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis
76067553|NCT04318678|Drug|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
76067554|NCT04318678|Drug|Rituximab|Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes
75608193|NCT02852980|Other|gestational diabetes women|No intervention.
75608194|NCT02800135|Drug|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
75608195|NCT02853058|Radiation|normal PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
76067555|NCT04315142|Device|Experimental TTNS|30-minute TTNS intervention is performed 2 days a week during a treatment period of 6 weeks
75608196|NCT02853058|Radiation|pathological PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
75608197|NCT00943384|Device|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
75754185|NCT01060852|Behavioral|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
75754186|NCT00590187|Drug|Sapacitabine, Arm A|200 mg b.i.d. x 7 days every 3-4 weeks
76067556|NCT04315142|Device|Sham TTNS|30-minute sham intervention is performed 2 days a week during a treatment period of 6 weeks
75754187|NCT00590187|Drug|Sapacitabine, Arm B|300 mg b.i.d. x 7 days every 3 - 4 weeks
75754188|NCT00590187|Drug|Sapacitabine, Arm C|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
75754189|NCT00590187|Drug|Sapacitabine, Arm D|200 mg b.i.d. x 7 consecutive days every 4 weeks
75754190|NCT00590187|Drug|sapacitabine, Arm E|300 mg q.d. x 7 consecutive days every 4 weeks
75754191|NCT00590187|Drug|sapacitabine, Arm F|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
75456637|NCT01774214|Procedure|Disconnect-Reconnect Technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles."
75456638|NCT01774227|Procedure|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
75456639|NCT01774227|Procedure|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
75456640|NCT01774279|Other|Tissue, blood and clinical data collection|
75456641|NCT01774292|Procedure|Endotracheal intubation with injection of liquid in the cuff|
75754192|NCT00590187|Drug|Sapacitabine, Arm G|200 mg b.i.d. x 7 consecutive days every 4 weeks
75754193|NCT00590187|Drug|Sapacitabine, Arm H|300 mg q.d. x 7 consecutive days every 4 weeks
75754194|NCT00590187|Drug|Sapacitabine, Arm I|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
75608198|NCT04235647|Other|Nurse led tutorial on lifestyle management and pedometer hand-out|Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out
75754195|NCT03978364|Drug|Azacitidine combined HHT|Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
75754196|NCT03978364|Drug|Azacitidine regimen|Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
75754197|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os"
75754198|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os"
75754199|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os"
75754200|NCT01046487|Procedure|Blood sampling|"ONLY FOR CYCLE 1, at day 15 and day 28 :~11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)"
75754201|NCT01069276|Other|No intervention in this study|No intervention in this study
76067557|NCT04310358|Other|4 short PLMs group 1|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
75754202|NCT01066390|Biological|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
75754203|NCT03978286|Drug|Vortioxetine|10 mg per day
75754204|NCT03978286|Drug|Sertraline|75 mg per day
75754205|NCT03826186|Device|Traditional (loss-of-resistance technique) thoracic epidural placement|Thoracic epidurals will be administered using the traditional loss-of resistance technique.
75754206|NCT03826186|Device|CompuFlo thoracic epidural placement|Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
76067558|NCT04310358|Other|4 short PLMs group 2|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
76067559|NCT04307238|Diagnostic Test|PLR|PLR measurements will be performed within the first 2 postoperative hours.
76067560|NCT04307238|Diagnostic Test|Alertness testing|Preoperative (baseline) and every 30 minutes postoperative computer based alertness testing will be performed.
76067561|NCT04307238|Procedure|Propofol anesthesia|Maintenance of anesthesia will be performed using propofol.
75456642|NCT01774318|Other|aEEG and conventional EEG measurement|aEEG and conventional EEG measurement including video-polysomnography
75456643|NCT01774370|Drug|Pradaxa (Dabigatran etexilate mesilate)|110 mg or 150 mg b.i.d.
75754207|NCT01069432|Other|No Intervention|No Intervention
75754208|NCT00382863|Device|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
75754209|NCT00382863|Drug|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
75754210|NCT03933449|Biological|pembrolizumab|IV infusion
76067562|NCT04307238|Procedure|Sevoflurane anesthesia|Maintenance of anesthesia will be performed using sevoflurane.
75456644|NCT01774396|Drug|Emervel® Touch|Emervel® Touch will be injected only in the intervention group.
75608199|NCT04235647|Other|Steps goal setting and supporting phone calls|A goal of minimum 7000 steps per day, phone calls to assess the goal meeting and to support goal achievement every 2 weeks
75754211|NCT03933449|Drug|paclitaxel|IV infusion
75754212|NCT03933449|Drug|docetaxel|IV infusion
75754213|NCT03933449|Drug|irinotecan|IV infusion
75456645|NCT01774396|Drug|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
75456646|NCT01774422|Device|Extracorporeal CO2 removal device|
75754214|NCT00974285|Drug|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
75754215|NCT00974285|Drug|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
75456647|NCT01774435|Drug|EN3342|
75608200|NCT02805205|Drug|PEG-rhG-CSF|
75608201|NCT02799979|Device|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
75902150|NCT05014906|Drug|Minocycline 45 MG|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
75608202|NCT02805439|Drug|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
76067563|NCT04289961|Diagnostic Test|Portal vein sampling|During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
75754216|NCT03932045|Device|SYB Filler (SF-01)|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
75754217|NCT03932045|Device|Ellansé M|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
75754218|NCT00972413|Radiation|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
75754219|NCT00972413|Radiation|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
76067564|NCT04282642|Behavioral|Cognitive Training|Participants (n=20) provided game console with cognitive training games and activities.
75608203|NCT02805439|Drug|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
75608204|NCT02805439|Drug|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
75456648|NCT01774448|Behavioral|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
75456649|NCT01774461|Other|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
75456650|NCT01774474|Drug|Bromfenac|
75608205|NCT02802163|Drug|Panobinostat|"Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase."
75608206|NCT02802163|Drug|Carfilzomib|Induction Phase: Carfilzomib will be administered at 20 mg/m^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m^2 or 36 mg/m^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
75754220|NCT00972413|Radiation|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
75754221|NCT00387075|Procedure|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
75902151|NCT05014906|Drug|Azelaic acid|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
75902152|NCT03085420|Diagnostic Test|Echocardiogram|A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
76067565|NCT04282642|Behavioral|WLC (Waitlist Control)|Participants (n=20) will receive the cognitive training intervention later, following week 8 assessments.
76067566|NCT04281940|Device|Transcatheter implantation of chordal repair system|Implantation of anchor via transcatheter delivery system to delivery chordal repair system tethering the mitral leaflets to the ventricle
76067567|NCT04278534|Other|Educational Intervention|Complete radiation therapist-led education module using virtual reality
76067568|NCT04278534|Other|Educational Intervention|Receive the usual verbal and written education materials
76067569|NCT04278534|Other|Educational Intervention|Complete radiation therapist-led face-to-face education module
76067570|NCT04278534|Other|Survey Administration|Ancillary studies
76067571|NCT04249557|Behavioral|exercise is medicine|a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
76067572|NCT04244656|Biological|CTX120|CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
76067573|NCT04237857|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
75456651|NCT01774474|Drug|Dexamethasone|
75754222|NCT00387075|Drug|[123I]β-CIT|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
75608207|NCT02802163|Drug|Lenalidomide|"Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21."
76067574|NCT04224571|Drug|Bortezomib Injection|Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;
75902153|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
75902154|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
75902155|NCT00103506|Drug|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
76067575|NCT04224571|Drug|rituximab injection|Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)
76067576|NCT04222062|Drug|Carmustine 7.7Mg Wafer|GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
76067577|NCT04218604|Procedure|Personalized atrial fibrillation ablation|Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
76067578|NCT04215029|Behavioral|Exercise Intervention|Receive exercise plan
76067579|NCT04215029|Other|Informational Intervention|Receive printed exercise materials
76067580|NCT04215029|Other|Informational Intervention|Receive physical activity and healthy eating information/materials
76067581|NCT04215029|Other|Interview|Participate in interview
76067582|NCT04215029|Other|Nutritional Assessment|Complete nutrition counseling sessions
75608208|NCT02802163|Drug|Dexamethasone|Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
75608209|NCT02799511|Biological|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
75608210|NCT02802007|Device|Elipse Intragastric Balloon|
75608211|NCT02801773|Dietary Supplement|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
75608212|NCT02801773|Other|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
75608213|NCT02802085|Device|VEGA Knee|TKA
75902156|NCT03541746|Biological|Platelet Rich Plasma|After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
75902157|NCT03541746|Device|Intrauterine Foley's Catheter|After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
75902158|NCT04992780|Radiation|Hypo-Fractionation|62.5 Gy in 25 fractions of 2.5 Gy/fraction
75902159|NCT04992780|Radiation|Standard-Fractionation|60 Gy in 30 fractions of 2 Gy/fraction
75902160|NCT02158650|Behavioral|Video-Based Informed Consent|
75902161|NCT02151240|Drug|Foscarnet Sodium|
75902162|NCT02151240|Drug|Acyclovir|
75902163|NCT02154750|Device|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
76067583|NCT04215029|Other|Questionnaire Administration|Ancillary studies
76067584|NCT04215029|Behavioral|Telephone-Based Intervention|Receive coaching calls
76067585|NCT04211506|Behavioral|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.
76067586|NCT04209569|Behavioral|Nutrition Impact and Positive Practice Circle (NIPP)|GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)
76067587|NCT04186598|Device|CPAP mask system|Intervention group will receive 15cm of H2O of positive end expiratory pressure
76067588|NCT04186598|Drug|Nifedipine 30 MG|All participants will receive this intervention
75754223|NCT00974441|Drug|Divalproex Sodium|500 mg Extended Release Tablet
75754224|NCT00974441|Drug|Depakote®|500 mg Extended Release Tablet
75754225|NCT01049451|Drug|ACTH|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
76067589|NCT04186598|Device|CPAP mask system without PEEP|Placebo group will receive high flow oxygen via altered CPAP mask system without providing any positive end expiratory pressure
76067590|NCT04166019|Behavioral|Peer-led self-management program|The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
75754226|NCT01049451|Drug|Methylprednisolone|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
75754227|NCT00974519|Drug|Fuzheng 3|"Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
75902164|NCT02154750|Device|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
75902165|NCT02154828|Behavioral|Integrative practices|
76067591|NCT04166019|Behavioral|Psycho-education group|The psycho-education group program is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
76067592|NCT04166019|Behavioral|Usual care|Routine care services consist of monthly psychiatric consultation and treatments prescribed by psychiatrist, nursing advice on community care, brief education (1-2 hourly sessions) about mental illness/treatments by psychiatric nurses, home visits by case managers, and/or referrals to community/welfare services.
76067593|NCT04123054|Device|Mobile App|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator.
76067594|NCT04123054|Device|Mobile App + Basal-Bolus Optimization Algorithm|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator. In addition, participants will receive weekly app notifications with personalized recommendations for insulin parameter adjustments made by the optimization algorithm.
76067595|NCT04103398|Combination Product|TACE+sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
75608214|NCT02801851|Behavioral|SCREEN-ED|SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
75608215|NCT02801929|Drug|Coppertone (BAY987518)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number - SR15-72_V27-010).
76067596|NCT04103398|Procedure|TACE|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
75608216|NCT02801461|Device|extracorporeal shock wave therapy|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
75902166|NCT04807530|Device|TMS|The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
75456652|NCT01774474|Drug|Bevacizumab|
75456653|NCT01774474|Drug|Triamcinolone Acetonide|
75456654|NCT01774513|Device|Procore-Needle|
75456655|NCT01774526|Other|Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes|
75456656|NCT01774539|Other|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
75456657|NCT01774565|Device|Fully Automated Closed-Loop Insulin Delivery|
75456658|NCT01774565|Device|Conventional insulin therapy|
75608217|NCT00943306|Drug|lomitapide|5-60 mg po every day
75608218|NCT02805049|Drug|Echinocandins|The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
75902167|NCT03736902|Other|Qualitative semi structured interview|One-to-one semi structured interviews, guided by the Physical Activity for people with a Disability Framework (van der Ploeg et al, 2004) which is a model for understanding the different factors that influence whether people with a disability engage in physical activity. Participants that agree to take part in the study, will be offered an interview either in a private clinic room at the hospital, at their home (if they live within a 40-mile radius of the hospital) or via a web-based video link. The interviews are expected to last one hour and will be conducted by the primary researcher.
75902168|NCT02159430|Other|Clinical and psychopathological assessment of HAE patients|
75902169|NCT02154984|Behavioral|behavioral dietary intervention|Follow tRD
75902170|NCT02154984|Behavioral|telephone-based intervention|Receive coaching calls
75902171|NCT02154984|Other|laboratory biomarker analysis|Correlative studies
76067597|NCT04098354|Diagnostic Test|home BP telemonitoring system .|Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
75456659|NCT01774656|Drug|Pharmacological Treatment|The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
75456660|NCT01774669|Device|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
75608219|NCT02799589|Drug|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
75608220|NCT02799589|Drug|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
75754228|NCT00974519|Drug|Fuzheng 1|"Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
75754229|NCT00974519|Drug|Placebo|"Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
75608221|NCT02799589|Drug|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
75608222|NCT02801695|Drug|Citrulline|Citrulline supplementation
75608223|NCT02801695|Drug|Placebo|Placebo
75608224|NCT02856100|Drug|18F DCFPyL- Radiopharmaceutical|
75608225|NCT02801539|Device|RMT therapy using modified RMT device|The exercises provided by the RMT device is intended to strengthen breathing muscles.
75608226|NCT02801539|Device|Sham-RMT therapy using modified RMT device|The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
75608227|NCT04272970|Diagnostic Test|Validation of a new gene / protein variant implicated in familial CT|Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
75608228|NCT02801383|Drug|Yallaferon®， the recombinant human interferon α-2b gel|
75608229|NCT02801383|Other|gel without active ingredient|
75608230|NCT02799355|Drug|Sofosbuvir, Ribavirin, With or Without Pegylated Interferon|Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
75754230|NCT01049529|Dietary Supplement|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
75902172|NCT02158962|Behavioral|Behavioral - Education|"Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections"
75902173|NCT03542604|Behavioral|Cognitive Behavioral Therapy for Insomnia|CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.
75902174|NCT03542604|Behavioral|Sleep Education|EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
75902175|NCT02159196|Drug|acetylcysteine and salbutamol|routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
75608231|NCT02856022|Device|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
76067598|NCT04067726|Drug|Denosumab|Denosumab is commercially available and will be provided at no cost to participants.
76067599|NCT04067726|Drug|Placebo|Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
75608232|NCT02856022|Procedure|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
76067600|NCT04067726|Drug|Calcium|-Participants will be instructed to take calcium (600 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
76067601|NCT04067726|Drug|Vitamin D3|Participants will be instructed to take vitamin D3 (800 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
75754231|NCT01049529|Dietary Supplement|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
75754232|NCT00972491|Procedure|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
75456661|NCT01774669|Other|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
75456662|NCT01774682|Procedure|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
75456663|NCT01774695|Behavioral|Increased physical activity|"The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.~The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week."
75608233|NCT02801305|Drug|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
75754233|NCT01045395|Dietary Supplement|Corn starch|90mg/d
75754234|NCT01045395|Dietary Supplement|Unique Marine Algae Concentrate (UMAC)|90mg/d
75754235|NCT01045395|Dietary Supplement|Golden brown algae|90mg/d
75754236|NCT00972569|Drug|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
75754237|NCT00972569|Drug|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
75754238|NCT01324557|Procedure|CSII and MDI|The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
75754239|NCT00972647|Procedure|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
75754240|NCT00974597|Device|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
76067602|NCT04067726|Procedure|Core needle biopsy|Baseline and 12 months
76067603|NCT04067726|Procedure|Blood draw|Baseline and 12 months
76067604|NCT04064840|Drug|IVF: Decapeptyl and hCG|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
76067605|NCT04064840|Drug|FET: Decapeptyl|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
76067606|NCT04064840|Drug|IVF: hCG and normal saline|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
76067607|NCT04064840|Drug|FET: Normal Saline|On the day of FET, normal saline will be injected subcutaneously.
76072302|NCT01995578|Drug|low dose 5'-azacitidine|5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
76072303|NCT01979393|Drug|Cabozantinib|
76072304|NCT01979393|Drug|Placebo|
76072305|NCT01949337|Drug|enzalutamide|Enzalutamide 160 mg daily, orally
76067608|NCT04052126|Other|Individualized physical activity program|"Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment."
75608234|NCT02801305|Drug|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
75754241|NCT00974753|Drug|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
75608235|NCT02801305|Drug|Vaseline|This is used as the topical placebo agent.
75608236|NCT02795845|Dietary Supplement|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
75608237|NCT02795845|Other|Placebo|capsule without active ingredient
75902176|NCT02159196|Drug|acetylcysteine|nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
76067609|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks|Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy
75902177|NCT02159196|Drug|salbutamol|nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
75608238|NCT00637975|Drug|oxycodone|"Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops."
75902178|NCT02765490|Drug|AL-335|AL-335 800 mg (2*400) tablet will be administered once daily.
75902179|NCT02765490|Drug|Odalasvir|Odalasvir 25 mg tablet will be administered once daily.
75754242|NCT00974753|Other|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
75902180|NCT02765490|Drug|Simeprevir|Simeprevir 75 mg capsule will be administered once daily.
76067610|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks|Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks
76067611|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks|Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy
76067612|NCT04042740|Drug|Glecaprevir/Pibrentasvir (G/P)|Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
75608239|NCT00637975|Drug|pregabalin|"Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops."
75608240|NCT02799433|Behavioral|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
75608241|NCT02799433|Behavioral|Usual services|Control condition
75902181|NCT02159508|Behavioral|Nutritional counselling|In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
75902182|NCT02155062|Other|Whole grain rye|
75608242|NCT02801149|Procedure|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
75754243|NCT04008719|Other|Thymic history|This interview concerns mainly the nature of the previous psychiatric and psychological care
75754244|NCT04008719|Other|Evaluation of the psychiatric disorders|Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.
75754245|NCT04008719|Other|Cognitive evaluation|They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.
75754246|NCT00974831|Other|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
75902183|NCT02155062|Other|Whole grain wheat|
76067613|NCT04042740|Drug|Ribavirin (RBV)|Tablets containing 200 mg of ribavirin. RBV dosed according to weight-based and renal dosing tables in study protocol.
76072306|NCT01949337|Drug|abiraterone|abiraterone 1000 mg daily, orally
76072307|NCT01949337|Drug|prednisone|prednisone 5 mg twice daily, orally
75754247|NCT00974831|Other|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
75754248|NCT00972803|Drug|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
75754249|NCT00972803|Drug|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
75902184|NCT02155062|Other|Refined cereal|
75902185|NCT03542526|Device|electrogradiogram|12 lead ecg ambulatory blood prussre
76072308|NCT01934881|Device|voltage adjustment only|Only voltage will be adjusted in all programming sections.
76072309|NCT01934881|Device|Multiple parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
76072310|NCT01893307|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75456664|NCT01774708|Device|Pressure sensitive pad|"The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.~This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient."
75456665|NCT01774734|Other|Physical therapy|"Physical therapy~Provided by 2 experienced physiotherapist~Applied to every patients 3 times weekly"
75456666|NCT01774734|Device|Neck Strength Exerciser (NSE)|"Neck strength exerciser use 10-20 minutes daily at home~Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
75608243|NCT02801227|Drug|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
75608244|NCT02801227|Drug|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
75754250|NCT00972803|Drug|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
75902186|NCT03542526|Device|ambulatory blood prussre|ambulatory blood pressure to measure blood pressure
75456667|NCT01774747|Drug|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
75608245|NCT02795611|Behavioral|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
75608246|NCT02795611|Behavioral|regular occupational therapy|regular occupational therapy
75608247|NCT02795611|Other|intervention done outside our hospital|intervention done outside our hospital
75754251|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
75754252|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
75754253|NCT02908269|Biological|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
75754254|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system
75754255|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
75902187|NCT02163018|Drug|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1
75902188|NCT02163018|Drug|Placebo|Subcutaneous administration of increasing doses of placebo
75754256|NCT00974987|Radiation|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
75754257|NCT00974987|Radiation|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
75754258|NCT00974987|Drug|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
75754259|NCT00975065|Drug|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
75754260|NCT00975065|Drug|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
75754261|NCT00972881|Biological|cetuximab|
75754262|NCT00972881|Drug|capecitabine|
75902189|NCT02639182|Drug|AGS-16C3F|Intravenous (IV) infusion
75902190|NCT02639182|Drug|Axitinib|Oral
75902191|NCT02863419|Drug|semaglutide|Oral semaglutide once-daily.
75456668|NCT01774747|Drug|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
75456669|NCT01774773|Drug|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
75608248|NCT02799121|Device|ReGenerCell™ Autologous Cell Harvesting Device|
75608249|NCT02795455|Behavioral|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
75902192|NCT02863419|Drug|liraglutide|Subcutaneous (s.c.) injection once-daily.
75902193|NCT02863419|Drug|placebo|Placebo once-daily.
75608250|NCT02795455|Behavioral|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
75608251|NCT02795455|Dietary Supplement|meal replacement shake|
75608252|NCT02795299|Drug|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
75608253|NCT02795299|Drug|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
75608254|NCT02795299|Drug|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
75608255|NCT02795299|Drug|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
75754263|NCT00972881|Drug|irinotecan hydrochloride|
75902194|NCT03541668|Drug|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
75608256|NCT03930277|Diagnostic Test|Electroencephalogram|Electroencephalogram for fetal brain activity monitoring.
75754264|NCT00972881|Procedure|neoadjuvant therapy|
75754265|NCT00972881|Procedure|therapeutic conventional surgery|
75902195|NCT03541668|Drug|Alteplase|Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
75608257|NCT02799043|Procedure|Standard PVI|Standard PVI procedure without FIRMap.
75608258|NCT02799043|Procedure|FIRM-Guided Procedure and PVI|
75608259|NCT02801071|Drug|15g L-citrulline daily p.o.|
75608260|NCT02801071|Drug|Placebo|
75608261|NCT02790619|Device|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
75608262|NCT02790619|Device|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
75754266|NCT00972881|Radiation|radiation therapy|
75754267|NCT00290758|Drug|placebo|Given orally
75754268|NCT00290758|Drug|genistein|Given orally
75754269|NCT00290758|Other|laboratory biomarker analysis|Correlative studies
75754270|NCT00975299|Drug|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
75902196|NCT02155140|Dietary Supplement|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
75902197|NCT05019898|Diagnostic Test|pupillometry|"Step 1: The triage will be carried out by the nurse. The nurse will then perform a self-assessment of the patient's pain using a simple verbal scale.~The nurse will then record the patient's self-assessment of his pain using the numeric scale for pain.~Step 2: Immediately after this first assessment, eligible patients will be approached by the study investigator to be included in the study.~Step 3: If the patient gives informed consent, the study investigator will perform~The quantification of their anxiety~An assessment of pain by a NeuroLight videopupillometer (iDmed, Marseille, France) using two dynamic tests, the Pupillary Unrest in Ambient Light (PUAL) and the pupillary light reflex.~Step 4: One hour after the triage, a second pain assessment will be performed. Step 5: The same pupillometry measurements will be taken immediately after the nurse has assessed the pain."
75608263|NCT04233931|Behavioral|PrEP medication adherence mobile app|Participants use a PrEP medication adherence mobile app for six weeks.
75608264|NCT03981757|Device|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
75902198|NCT02155218|Other|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
75902199|NCT02155218|Other|Patient Tailored Injection Rate|"Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves."
75902200|NCT02155218|Other|gadolinium contrast|
75754271|NCT00975299|Drug|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
76072311|NCT01893307|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMPT
75608265|NCT02799277|Drug|Testosterone|Effect of testosterone on moral decision making
75608266|NCT02799277|Drug|Placebo|Effect of testosterone on moral decision making
75608267|NCT04235179|Radiation|SABR|SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)
75608268|NCT01198002|Drug|LY2127399|Administered Subcutaneously (SC)
75608269|NCT01198002|Drug|Placebo Q2W|Administered SC
75608270|NCT01198002|Drug|Placebo Q4W|Administered SC
75608271|NCT01198002|Drug|Methotrexate|Methotrexate is a background therapy.
75608272|NCT02790307|Device|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
75608273|NCT02790151|Behavioral|Standard Therapy|Learning and practicing Memory strategies
75608274|NCT02790151|Behavioral|Experimental Intervention|Computerbased Working Memory Training in Combination with a Recollection Training
75608275|NCT02794909|Device|Cardiopulmonary ultrasound exam|The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
75608276|NCT02798887|Procedure|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
75608277|NCT02795065|Drug|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
75754272|NCT01060930|Drug|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
75754273|NCT00973037|Drug|Tamoxifen|Tamoxifen 20mg qd
75754274|NCT00973115|Drug|Simvastatin CR|
75902201|NCT04961632|Drug|Tamoxifen|Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of >30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.
75902202|NCT04961632|Drug|Tamoxifen|Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
75754275|NCT00975377|Procedure|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
75608278|NCT02795065|Drug|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
75754276|NCT00973193|Drug|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
75902203|NCT03079180|Other|Strength training at 80% 1RM|Detailed in Arms section's
75902204|NCT03079180|Other|Strength training at 55% 1RM|Detailed in Arms section's
75902205|NCT02155296|Behavioral|Restorative Practices Intervention|"RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension."
75608279|NCT02794987|Device|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
75754277|NCT00975533|Device|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
75754278|NCT00975533|Drug|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
75608280|NCT02789995|Procedure|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
75754279|NCT00372567|Drug|sunitinib malate|37.5 mg daily
75754280|NCT00372567|Drug|imatinib mesylate|800mg daily
75754281|NCT04008251|Genetic|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
75754282|NCT00973271|Drug|290 mg DCCR|290 mg diazoxide choline
75754283|NCT00973271|Drug|435 mg DCCR|435 mg diazoxide choline
75754284|NCT00973271|Drug|135 mg fenofibric acid|135 mg fenofibric acid
75754285|NCT00973271|Drug|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
75902206|NCT05020288|Drug|Orelabrutinib|Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.
75902207|NCT02155374|Drug|Sliding scale insulin|
75902208|NCT02155374|Drug|Intermediate acting insulin|
75902209|NCT02155374|Behavioral|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
75902210|NCT02155374|Drug|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
75902211|NCT02155374|Drug|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
75902212|NCT03078712|Other|Peripheral Perfusion guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.
75608281|NCT02790229|Other|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
75608282|NCT02790229|Other|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
75608283|NCT02798965|Biological|serodiagnosis|
75754286|NCT00973271|Drug|atorvastatin|20 mg atorvastatin
75754287|NCT00975767|Drug|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
75754288|NCT00975767|Drug|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
75754289|NCT00975845|Other|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
75754290|NCT00365547|Biological|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
75754291|NCT00365547|Drug|topotecan hydrochloride|Topotecan 4 mg/m^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
75754292|NCT00545441|Device|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
76067614|NCT04033224|Device|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
75754293|NCT00545441|Device|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
75754294|NCT03991767|Other|"POP-UP electronic alert"|"Implementation of the POP-UP electronic alert for all patients with eligibility criteria"
75608284|NCT02798809|Other|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
75754295|NCT03991767|Diagnostic Test|Serology HIV|Realization of HIV serology for included patients.
75754296|NCT00976001|Other|Information, further rehabilitation, additional drugs to prevent recurrent stroke|
75754297|NCT00976001|Other|As the general practitioner wants to do|
75754298|NCT00979589|Drug|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
75754299|NCT00979589|Drug|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
75754300|NCT00294658|Procedure|thymectomy plus prednisone|The thymectomy will be performed as soon as possible after randomization.
75754301|NCT00294658|Drug|prednisone alone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
75754302|NCT00979667|Drug|Oseltamivir|75 mg twice daily for 5 days
75754303|NCT00979667|Drug|Zanamivir|10 mg twice daily for 5 days
75754304|NCT00979667|Drug|Placebo of Oseltamivir|twice daily for 5 days
75754305|NCT00976079|Device|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
75754306|NCT00976079|Device|Placebo TENS|Placebo TENS use
75608285|NCT04233697|Drug|Copanlisib|Novel, pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with potent activity against both the δ and α isoforms9. Copanlisib has been evaluated for the treatment of a wide variety of malignancies, including lymphoma, either as a single agent or in combination with other investigational agents.
75608286|NCT04233697|Drug|Romidepsin|Indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
75754307|NCT03978052|Dietary Supplement|EGCG|"Participants that weight >50kg intake one oral dose in the morning for breakfast and a second dose in the afternoon in (266 + 266 mg/EGCG, 49 + 49 g of Font-up).~Participants that weight <50kg intake one oral dose in the morning for breakfast (266 mg/EGCG, 49 of Font-up"
75754308|NCT03978052|Dietary Supplement|Placebo EGCG|Participants that weight >50kg intake one oral dose in the morning for breakfast and a second dose in the afternoon in (266 + 266 mg/EGCG, 49 + 49 g of Font-up)
75754309|NCT03978052|Other|Personalized intervention|A personalized intervention include a physical activity plan,dietary intervention, mental health promotion interventions,
75754310|NCT03978052|Other|Lifestyle recommendations|The recommendations are to balance caloric intake and physical activity to achieve and maintain a healthy body weight; consume a diet rich in vegetables and fruits;
75754311|NCT03923933|Drug|Chlorthalidone|Chlorthalidone
75754312|NCT03923933|Drug|Bumetanide|Bumetanide
75754313|NCT00372489|Drug|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
76067615|NCT04009161|Procedure|Tooth extraction|Tooth extraction before the beginning of radiotherapy in patients irradiated for Head and Neck cancer
76067616|NCT04007744|Biological|Pembrolizumab|Given IV
76067617|NCT04007744|Drug|Sonidegib|Given PO
76067618|NCT04004247|Device|High Flow Nasal generator (AirVO2)|High Flow Nasal Oxygenation
75754314|NCT01066468|Drug|Gleevec/Glivec|
75902213|NCT03078712|Other|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
75902214|NCT02033577|Procedure|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
75754315|NCT00979823|Other|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
75902215|NCT02033577|Procedure|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
75902216|NCT03542448|Device|Swept source optical coherence tomography|Measurement of choroidal thickness in myopic patients
75902217|NCT03610191|Diagnostic Test|Serum biomarker tests|Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.
75608287|NCT04234009|Other|Healthy Lifestyle|"The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle."
75608288|NCT02857036|Other|rhythmic parameter recording|the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
75608289|NCT02857036|Behavioral|psychiatric assessment|different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
75608290|NCT04234087|Other|Additional balance and resistance training|Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
75608291|NCT02794753|Behavioral|Working memory training|
75754316|NCT00979823|Other|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
75754317|NCT01581190|Dietary Supplement|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
75754318|NCT00976157|Procedure|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
75902218|NCT03610191|Behavioral|Neuropsychological battery tests|both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.
75902219|NCT03610191|Procedure|Cardiac surgery|patients scheduled for cardiac surgery will accept the surgical procedure.
75902220|NCT04434118|Drug|Traditional antirheumatic drugs|Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine
75608292|NCT02794753|Behavioral|Game|
75608293|NCT02794519|Drug|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
75608294|NCT02794519|Drug|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
75608295|NCT02794519|Drug|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
75608296|NCT05463523|Device|A Real-time Augmented Reality Device with Artificial Intelligence Integration|Patients are diagnosed and treated with the assistance of artificial intelligence, augmented reality and new optical imaging technology, which is different from traditional model.
75608297|NCT03826303|Other|E-cigarette liquid with ethanol, 1 puff|E-cigarette liquid with ethanol, 1 puff
75608298|NCT03826303|Other|E-cigarette liquid without ethanol, 1 puff|E-cigarette liquid without ethanol, 1 puff
75608299|NCT03826303|Other|E-cigarette liquid with ethanol, 10 puffs|E-cigarette liquid with ethanol, 10 puffs
75608300|NCT03826303|Other|E-cigarette liquid without ethanol, 10 puffs|E-cigarette liquid without ethanol, 10 puffs
75608301|NCT02794675|Drug|Cesium 131|The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
75608302|NCT02798653|Drug|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
75754319|NCT00976235|Device|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
75902221|NCT02765100|Drug|Minocycline|Minocycline 100 mg twice a day
75902222|NCT05007574|Device|Microphone MI-305|Remote data collection
75902223|NCT02033655|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
75754320|NCT03977740|Other|chest PNF|Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
75754321|NCT03977740|Other|Conventional|conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
75902224|NCT02033655|Behavioral|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
75608303|NCT02798653|Drug|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
75608304|NCT02798653|Drug|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
75608305|NCT02794363|Biological|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
75754322|NCT00976313|Procedure|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
75754323|NCT00976313|Other|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
75754324|NCT03921047|Procedure|Biospecimen Collection|Undergo collection of blood samples
75902225|NCT02159664|Other|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
75902226|NCT03091894|Drug|Propofol|propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
75902227|NCT03091894|Drug|Dexmedetomidine|dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
75608306|NCT04234789|Diagnostic Test|cardiopulmonary exercise testing with dynamic hyperinflation maneuver|test performed as recommended by ATS guidelines
75608307|NCT04234789|Diagnostic Test|spirometry|test performed as recommended by ATS guidelines
75608308|NCT04234789|Diagnostic Test|pletysmography|test performed as recommended by ATS guidelines
75608309|NCT04234789|Diagnostic Test|forced oscillometry technique|test performed as recommended by ATS guidelines
75608310|NCT02794051|Behavioral|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
75754325|NCT03921047|Other|Laboratory Biomarker Analysis|Correlative studies
75754326|NCT00980135|Device|Sinecort cream|Application over 29 days
75754327|NCT00980135|Drug|Hydrocortison cream|Application over 29 days
75754328|NCT00980135|Other|Untreated skin|
75754329|NCT00980213|Drug|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
75754330|NCT04986527|Procedure|Chest tube suction|The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.
75902228|NCT05014594|Drug|Dapagliflozin (10Mg Tab) along with standard medical therapy|Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
75902229|NCT05014594|Drug|Placebo of dapaglifozin along with standard medical therapy|Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
76067619|NCT03983434|Dietary Supplement|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
75754331|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
75754332|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
75754333|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
75754334|NCT00976469|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
75754335|NCT00976469|Biological|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
75754336|NCT00372411|Device|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
75754337|NCT00372411|Other|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
75754338|NCT00372411|Other|Usual Care|The usual chronic stroke care as delivered at each participating medical center
75754339|NCT00976625|Procedure|Aortic Valve Replacement|Surgical valve replacement of the aorta
75754340|NCT00980603|Drug|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
75754341|NCT00980603|Drug|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
75754342|NCT00980603|Drug|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
75754343|NCT00955097|Drug|Definity®|Definity® injections given both pre-ablation and post-ablation
75754344|NCT00955175|Radiation|hypofractionated radiation therapy|Given 5 days a week for 20, 22, or 24 fractions
75754345|NCT00980759|Radiation|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
75754346|NCT00980759|Radiation|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
75754347|NCT00976859|Behavioral|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
75754348|NCT00976859|Behavioral|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
75754349|NCT04011293|Biological|CNCT19|0.5 to 4 x 10^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10^8 autologous CNCT19 transduced cells via intravenous infusion.
76067620|NCT03970057|Behavioral|Internet-based Cognitive Behavioural Therapy|"MoodUP is an iCBT intervention that is tailored to perinatal women. The core content is presented via different types of devices, such as smartphones, tablets, laptops, or desktops, connected to the internet. The program is designed as an integration of online sessions, self-monitoring, homework, peer support, and therapist support.~MoodUP consists of six online sessions focused on CBT skills for improving stress, anxiety, and depressive symptoms among at-risk antenatal women; each session takes between 30 and 40 minutes to complete. The content of the sessions will be as follows: Session 1: Managing mood, Session 2: Psychoeducation, Session 3: Cognitive restructuring, Session 4: Behavioural activation, Session5: Lifestyle modification, Session 6: Problem-solving."
76067621|NCT03970057|Other|Usual Care|Participants will receive a series of six, weekly online sessions comprising general antenatal education. The content of the sessions will be as follows: Session 1: Parenthood; Session 2: Diet; Session 3: Exercise; Session 4: Breastfeeding; Session 5: Rest and sleep and Session 6: Common pregnancy problems.
75754350|NCT03958019|Other|RESTORE II Program|Detailed in arm description
75754351|NCT00372255|Biological|Influsplit SSW® 2005/2006|Study influenza vaccine was administered intramuscularly in the non-dominant arm
75754352|NCT00977015|Drug|Treatment A|Inhaled, 750/150, single dose
75754353|NCT00977015|Drug|Treatment B|Inhaled, 750/150, single dose
75754354|NCT00274456|Drug|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
75754355|NCT00274456|Drug|Docetaxel|Docetaxel dosed q3w at 100 mg/m^2
75754356|NCT01045629|Other|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
75754357|NCT01049607|Procedure|Clamp-Crush technique|The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.
75754358|NCT01049607|Procedure|Stapler hepatectomy|The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
76067622|NCT03955627|Behavioral|Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)|Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks conducted by Zoom video, followed by an 8-week home-based version of the same program participants do on their own with bi-weekly coaching calls.
75754359|NCT00977093|Other|Perfusion CMR for detection of coronary artery disease|Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
75754360|NCT00977093|Other|Perfusion cardiac magnetic resonance imaging|Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
75754361|NCT00977249|Behavioral|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
75754362|NCT00977249|Drug|varenicline|
75754363|NCT00977249|Drug|placebo|
75754364|NCT01069822|Drug|AZD6765|IV solution
75754365|NCT01069822|Drug|midazolam|
75754366|NCT00977327|Device|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
75754367|NCT00977327|Device|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
75754368|NCT03977974|Drug|LY3526318|Administered orally
75754369|NCT03977974|Drug|Placebo|Administered orally
75754370|NCT00955565|Procedure|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
75902230|NCT03609645|Procedure|Fascia iliaca block|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
75902231|NCT03609645|Procedure|Femoral articular branches block(FAB)|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
75902232|NCT02761980|Drug|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg / Acetaminophen 500 mg
75902233|NCT02761980|Drug|Ibuprofen 250 mg|Ibuprofen 250 mg
75902234|NCT02761980|Drug|Acetaminophen 500 mg|1 APAP 500 mg caplet
75456670|NCT01774773|Drug|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
75456671|NCT01774773|Drug|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
75608311|NCT02789683|Other|Fine emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
75608312|NCT02789683|Other|Coarse emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
75754371|NCT00955565|Procedure|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
75754372|NCT03976180|Device|Stadard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
75754373|NCT03976180|Device|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
75902235|NCT02761980|Drug|Placebo|Placebo tablet
75902236|NCT04577157|Behavioral|"mHealth usingWhatsApp multifaceted educational and reminder module intervention to improve adherence"|"This multifaceted educational and reminder module is named Health@click. The content of the reminder module has been made based on The Health Belief Model and self-determination theory.~Daily notes for medication reminders,~Daily a voice message with the same content will be delivered.~Daily Graphics-based Reminder (GBR).~Twice-weekly Graphics-based Messages (GBM) according to Health believe model and Self-determination theory constituents.~Once-weekly lifestyle advice through video~Hypertension at a glance, complete information will be provided(Optional)~24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects, and interaction with different foods (Optional)."
75456672|NCT01774812|Dietary Supplement|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
75902237|NCT05007496|Biological|AV-COVID-19|DCL previously loaded with varying quantity of S-protein
75456673|NCT01774812|Dietary Supplement|Ergocalciferol|50,000IU 1x per week for 6 weeks
75456674|NCT01774825|Dietary Supplement|IQP-CL-101|2 softgels twice a day
75902238|NCT03609567|Other|Aromatherapy|Aromatherapy using essential oils
75902239|NCT03609567|Other|Placebo|Aromatherapy using odorless placebo oil
75754374|NCT03976180|Device|HFNO with intermediate FiO2 (50%)|In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
75754375|NCT03976180|Device|HFNO with high FiO2 (100%)|In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
75754376|NCT00364923|Drug|Pralatrexate Injection|Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
75754377|NCT01066702|Biological|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
75902240|NCT05007340|Other|Blood draws|Blood draws will be performed by personnel that are both qualified and authorized by their employer/institution to perform the procedures. The procedures will be performed with standards expected in the context of clinical care. 40 mL (2-3 tbsp) of blood will be drawn in order to collect DNA, RNA, serum and PBMCs. Blood tubes will be sent to the Bank as per the SOP for patient blood sampling and processing. The blood will be processed, centrifuged and stored by a trained laboratory technician.
75902241|NCT05007340|Other|Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid)|If the patient's medical care or their participation in a research project involves a biopsy or surgery to remove tissue, the tissue not required for diagnosis (excess tissue) or hospital archives will be included in the biobank. This may include healthy tissue as well as tissue affected by the patient's health condition. The Investigators will not conduct extra procedures in order to obtain samples for the sole purpose of this study and will only operate on what's available. These may include blood samples, skin, lung and muscle biopsies, and bronchoalveolar lavage, all of which will be obtained from the pathology department.
75902242|NCT05007340|Other|Clinical data collection|Participant's relevant medical information from medical records, general health questionnaires and clinical assessments. The data includes gender, date of birth, race/ethnicity, habits, height, weight, vital signs, medical history, family history, pregnancy history, imaging data pertinent to ILDs and SARDs, results of routine blood tests, environmental exposures, medication and treatment exposures and adherence, function and quality of life, patient's assessment of their own health, clinical symptoms.
75456675|NCT01774825|Other|Placebo|2 softgels twice a day
75456676|NCT01774838|Drug|Prasugrel|3 months treatment
75456677|NCT01774838|Drug|Clopidogrel|3 months treatment
75456678|NCT01774864|Drug|DA-8159 (Udenafil)|
75456679|NCT01774864|Drug|Placebo|
75456680|NCT01774877|Drug|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
75456681|NCT01774877|Drug|leflunomide|leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
75608313|NCT02789683|Other|Control|Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
75456682|NCT01774916|Genetic|blood samples|
75456683|NCT01774942|Procedure|Procedure/Surgery|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
75608314|NCT02789761|Dietary Supplement|High-flavanol milk choocolate|
75608315|NCT02789761|Dietary Supplement|Low-flavanol milk chocolate|
75608316|NCT02798497|Other|Serum and Blood samples|
75608317|NCT02789917|Other|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
75608318|NCT02789917|Other|Triple Therapy|"HAS-BLED-Score <3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
75608319|NCT03863587|Biological|HLX12|healthy volunters receive HLX12 (8mg/kg) once
75608320|NCT03863587|Biological|Cyramza (Ramucirumab)|healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
75754378|NCT01066702|Procedure|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
75754379|NCT00381849|Drug|Cystone|"Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
75754380|NCT00381849|Drug|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
75754381|NCT00273052|Drug|Carvedilol Phosphate modified release formulation|
75754382|NCT00273052|Drug|metoprolol succinate|
75754383|NCT01046721|Drug|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
75608321|NCT02789605|Drug|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
75608322|NCT02789605|Drug|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
75608323|NCT02789839|Procedure|Blood test|Blood test of 30mL
75608324|NCT02789839|Procedure|Medullar test|Medullar test for 2-5mL and a smear
75608325|NCT04233463|Dietary Supplement|Modulen|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
75754384|NCT01046721|Drug|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
75754385|NCT02808351|Drug|Berberine|
75754386|NCT02535195|Dietary Supplement|Ginger supplement|
75754387|NCT02535195|Dietary Supplement|Placebo (starch)|
75456684|NCT01774994|Other|stable isotope infusion for measurement of metabolism|
75456685|NCT01775020|Dietary Supplement|L-arginine|
75456686|NCT01775033|Other|Multicomponent intervention|Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
75456687|NCT01775059|Device|Integrated sensor and infusion set.|
75456688|NCT01775098|Drug|allopurinol|No arms will not be change as the study as been closed.
75608326|NCT04233463|Drug|Budesonide|Standard treatment for mild Crohn Disease patients
75608327|NCT02794129|Other|Functional Magnetic Resonance Imaging|
75608328|NCT02793973|Device|shoe lifts|
75608329|NCT02793895|Device|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
75754388|NCT01046799|Drug|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
75754389|NCT00290290|Drug|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
75456689|NCT01775111|Behavioral|Cognitive Training|
75456690|NCT01775111|Behavioral|Strength Training|
75456691|NCT01775111|Dietary Supplement|FortiFit|
75456692|NCT01775150|Other|health education|Health education via text messaging
75456693|NCT01775215|Radiation|Cardiac I123-MIBG Scintigraphy|
75456694|NCT01775215|Other|Cardiac MRI|
75456695|NCT01775215|Other|Stress and rest Echocardiogram|
75456696|NCT01775215|Other|High Sensitivity Troponin I|
75456697|NCT01775215|Other|Brain Natriuretic Peptide|
75456698|NCT01775228|Behavioral|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
75456699|NCT01775267|Procedure|Associating liver partition and portal vein ligation for staged hepatectomy|
75608330|NCT02793895|Other|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.
75754390|NCT00290290|Drug|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
75754391|NCT01049685|Drug|First-line Antiretroviral Therapy|"Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~Efavirenz: 01 capsules day, plus NRTI background"
75754392|NCT01580943|Drug|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
75902243|NCT05007340|Other|Genetic data/DNA/RNA|Results of the DNA or RNA sequencing, conducted for the Biobank and will be made available to future research; possible single nucleotide polymorphism (SNP) assays (including single SNP, low-plex or microarray-based assays).
75902244|NCT03609957|Other|Aerobic Exercise Training|Traditional, continuous aerobic exercise (cycling) at a moderate intensity
75754393|NCT01580943|Drug|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
75754394|NCT02534961|Drug|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
75754395|NCT01046955|Drug|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
75754396|NCT00272038|Drug|Tarceva|150mg QD
75754397|NCT01047033|Behavioral|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
75754398|NCT01047033|Other|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
75754399|NCT00271024|Drug|Naltrexone (drug)|50 mg q.d. for 13 weeks
75902245|NCT03609957|Other|Interval Training|High-intensity interval exercise consisting of short bursts of exercise interspersed with rest periods
75754400|NCT00271024|Drug|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
75754401|NCT00381693|Drug|azacitidine|
76067623|NCT03948724|Behavioral|Therapeutic education program|Patient will have 5 educational therapy workshops. The first educational therapy workshops will be realized at cycle 1 and the last one within 25 weeks after starting treatment
75902246|NCT03083938|Procedure|Omental Roll-up|Using omentum roll-up pancreato-jejunal anastomosis
76067624|NCT03948724|Behavioral|Usual Information|Patient receive usual informations
76067625|NCT03934814|Drug|TJ011133|TJ011133 will be administered weekly.
76067626|NCT03934814|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
76067627|NCT03934814|Drug|Rituximab|Rituximab will be administered weekly for 5 doses, then followed by monthly doses.
75456700|NCT01775267|Procedure|Portal vein embolization or ligation|
75456701|NCT01775280|Radiation|Injection of Ytttrium-90 microspheres into the hepatic artery|INjection of Y-90 particles into the hepatic artery using endovascular access
75456702|NCT01775293|Device|Non-absorbable polypropylene mesh|"2 step procedures~first step is insertion of Non-absorbable polypropylene mesh under the facial skin~second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
76067628|NCT03919799|Drug|Belumosudil (KD025)|ROCK-2 Inhibitor
76067629|NCT03919799|Drug|Placebo|Inactive substance
75456703|NCT01775319|Dietary Supplement|Biofortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
75456704|NCT01775319|Dietary Supplement|Fortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
75456705|NCT01775319|Dietary Supplement|Placebo|
75456706|NCT01775332|Other|Educational Intervention|A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
75754402|NCT00545363|Drug|Ibandronate|Participants will receive ibandronate 150 mg QM orally for 6 months.
75754403|NCT04011215|Other|wool clothing|superfine merino wool ensembles for baby/child wear
75754404|NCT04011215|Other|standard clothing|Standard clothing refers to the clothing normally worn by the infant/child. This will not be superfine merino wool as superfine merino is not generally available for baby wear. The exact nature of the standard clothing will be recorded by investigators. From previous data we expect it to be primarily cotton.
75754405|NCT00955643|Other|oxygen|
75754406|NCT00955643|Other|other|
75754407|NCT05059457|Device|Blood source: single and pooled capillary and venous blood|"A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
76067630|NCT03913351|Behavioral|Lifestyle modification|The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
76067631|NCT03911128|Other|Observational|Observational study - no intervention
76067632|NCT03885128|Device|High frequency extra thoracic oscillations vest|Oscillations applied extra thoracic through vest device aiming for airway clearance
76067633|NCT03885128|Device|Intrathoracic oscillatory quake|Oscillation introduced intrathoracic through quake device through placing quake in mouth and ordering patient to breathing to move secretions
76067634|NCT03884010|Other|No intervention|Cross-sectional
76072312|NCT01893307|Other|Laboratory Biomarker Analysis|Correlative studies
76072313|NCT01893307|Radiation|Photon Beam Radiation Therapy|Undergo IMRT
76067635|NCT03867578|Diagnostic Test|HR-MRI|The first 5 patients will undergo HR-MRI scans using different sequence parameters. Results in these patients will then be assessed along with standard CT Imaging to determine which sequences appear to best identify peritoneal disease. The optimal HR-MRI sequences will then be used for the next 19 patients in the Testing phase to formally define their performance compared to standard imaging.
75608331|NCT02793895|Device|CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device|The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
75456707|NCT01775345|Procedure|Isotonic exercises|"20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
75608332|NCT04234711|Procedure|Surgical strategy|To compare the efficacy between conventional repair and sutureless technique for total anomalous pulmonary venous connection
75608333|NCT02793427|Biological|blood sample collection|
76067636|NCT03867578|Diagnostic Test|Standard CT Imaging|Standard CT scans will be performed for preoperative imaging in all patients.
76067637|NCT03867578|Diagnostic Test|Ultrasound|Ultrasound Elastography will be performed using an FDA-Approved diagnostic GE ultrasound scanner
75608334|NCT02793739|Procedure|Hyaluronic acid filler injection|Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
75608335|NCT02793661|Device|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
75456708|NCT01775345|Procedure|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
75608336|NCT02793661|Other|Control|Hydration protocol following ESC Guidelines 2014
75608337|NCT03874039|Device|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
75754408|NCT05059457|Device|Blood source: single capillary and venous blood|"A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
75754409|NCT05059457|Device|Blood source: pooled capillary and venous blood|"Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
75754410|NCT00977405|Device|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
75754411|NCT00977639|Procedure|Pathwork TOO test|
75608338|NCT03874039|Device|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
75754412|NCT00981383|Dietary Supplement|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
75754413|NCT00981383|Other|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
75754414|NCT00977795|Drug|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
75754415|NCT00977873|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
75754416|NCT00977873|Dietary Supplement|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
75754417|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
76072314|NCT01893307|Radiation|Proton Beam Radiation Therapy|Undergo IMPT
75608339|NCT02798419|Drug|DFD05 Cream|
75608340|NCT02798419|Drug|Active01 Cream|
75754418|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
75754419|NCT00977951|Drug|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
75608341|NCT02793505|Drug|metformin|This is not an intervention but an observed exposure.
75608342|NCT02793505|Drug|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
76067638|NCT03866837|Dietary Supplement|Galacto-oligosaccharides|Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.
75608343|NCT02789371|Procedure|the first pass is made with 5ml suction technique|the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.
75608344|NCT02789371|Procedure|the first pass is made with modified wet suction technique|the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
75754420|NCT00977951|Drug|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
75754421|NCT00981539|Procedure|enema|"pre operative rectal enema~one adult bottle to be used rectally the night before surgery"
75902247|NCT02166684|Device|Do-it-yourself devices|"Medisana Vifit is worn every day all-day by each subject~Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.~Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks~Subjects use Medisana BS 440 BT scale daily~In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.~Subjects self-measure fasting blood glucose twice per week for 13 weeks.~Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120."
75608345|NCT02798575|Device|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
75608346|NCT02789293|Device|EyeOP1 device|Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
75608347|NCT02797873|Other|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
75608348|NCT02797873|Other|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
75608349|NCT02797873|Behavioral|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
75608350|NCT02797873|Other|SCID-II|See Detailed Study Description.
75608351|NCT02797873|Other|SDQ|See Detailed Study Description.
76067639|NCT03866837|Dietary Supplement|Bovine lactoferrin|Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.
76072315|NCT01893307|Other|Quality-of-Life Assessment|Ancillary studies
76072316|NCT01872598|Drug|Masitinib|
75608352|NCT02797873|Other|ASRS|See Detailed Study Description.
75608353|NCT02797873|Other|AQ|See Detailed Study Description.
75608354|NCT02797873|Other|TAS-20|See Detailed Study Description.
75608355|NCT02797873|Other|Raven's SPM|See Detailed Study Description.
75608356|NCT02797873|Other|Reading ability|See Detailed Study Description.
75608357|NCT02797873|Other|Ishihara's tests for colour deficiency|See Detailed Study Description.
76072317|NCT01872598|Drug|Placebo|
76072318|NCT01872598|Drug|Standard of care|stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
75608358|NCT02797873|Other|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
75608359|NCT02797873|Other|Brown-ADD|See Detailed Study Description.
75608360|NCT02797873|Other|MFQ|See Detailed Study Description.
75456709|NCT01775345|Procedure|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
75456710|NCT01775345|Procedure|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
75456711|NCT01775358|Drug|ALRN-5281 0.015 mg/kg|
75456712|NCT01775358|Drug|ALRN-5281 0.05 mg/kg|
75608361|NCT02797873|Other|STAI-T|See Detailed Study Description.
75754422|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
75754423|NCT00457392|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
75754424|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
75754425|NCT00457392|Drug|placebo|Placebo daily by oral capsules in a continuous regimen
75754426|NCT00545051|Drug|Placebo|po monthly for 12 months
75456713|NCT01775358|Drug|ALRN-5281 0.15 mg/kg|
75456714|NCT01775358|Drug|Placebo 0.015 mg/kg|
75456715|NCT01775358|Drug|Placebo 0.05mg/kg|
75754427|NCT00545051|Drug|ibandronate|150mg po monthly for 12 months
75754428|NCT00381615|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
75754429|NCT00381615|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
75754430|NCT00381615|Biological|DTaP-Hib-IPV|Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
75754431|NCT00381615|Biological|PC7|IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
75754432|NCT00381615|Biological|MenC-CRM|MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
75754433|NCT00381615|Biological|MenC-Hib|MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
75754434|NCT00381615|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
75754435|NCT00978107|Biological|MVA-FCU1, flucytosine|"TG4023: single IT injection; possibility to re-administer once,~Percutaneous IT injections, under radiological or ultrasound imaging guidance~Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~MTD injected to up to 3 different lesions (Cohort #4)~5-FC (5-fluorocytosine)/flucytosine~Dose and dosing schedule:~Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~Duration: 2 weeks.~Possible routes of administration:~PO: 500 mg tablets, qid~IV: 1% 250 mL vials, 45-minute infusions."
75754436|NCT00978185|Other|medical chart review|
75754437|NCT00978185|Other|questionnaire administration|
75754438|NCT00978185|Procedure|acupressure therapy|
75754439|NCT00978185|Procedure|quality-of-life assessment|
75754440|NCT00978185|Procedure|sham intervention|
75456716|NCT01775358|Drug|Placebo 0.15mg/kg|
75456717|NCT01775384|Dietary Supplement|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
75456718|NCT01775384|Dietary Supplement|Placebo|
75456719|NCT01775397|Drug|Fidaxomicin|capsule
75456720|NCT01775397|Drug|Vancomycin|capsule
75456721|NCT01775397|Drug|Placebo|Capsule
75608362|NCT02797873|Other|BIS|See Detailed Study Description.
75608363|NCT02797873|Other|DAWBA|See Detailed Study Description.
75608364|NCT02797873|Other|STAI-S|See Detailed Study Description.
75608365|NCT02797873|Other|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
75608366|NCT02797873|Other|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
75608367|NCT02797873|Behavioral|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
75608368|NCT02797873|Other|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
75608369|NCT02797873|Other|Structural T2 MRI scan|See Detailed Study Description.
75754441|NCT00978185|Procedure|standard follow-up care|
76072319|NCT01827384|Drug|Adavosertib|Given by mouth (PO)
76072320|NCT01827384|Drug|Carboplatin|Given intravenous (IV)
75456722|NCT01775436|Behavioral|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
75754442|NCT01029132|Drug|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
75754443|NCT00981695|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
75754444|NCT04008017|Diagnostic Test|Eosinophilic Cationic Protein biomarker|3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
75754445|NCT01049763|Drug|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
75754446|NCT00981773|Drug|Maraviroc|Maraviroc 150 mg bid
75754447|NCT00981773|Drug|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
75754448|NCT04007549|Behavioral|Brief motivational interview on tobacco/alcohol risk reduction|"The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention."
75754449|NCT00371865|Behavioral|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
75902248|NCT05007184|Behavioral|Chilean Warning Labels|These labels were implemented in Chile in 2016. They are shown on those less-healthy food and beverage products that do not fall within thresholds that are defined for the following nutrients: sugar, sodium, calories and saturated fats. The original labels are in Spanish but the ones that we displayed were in Arabic.
75456723|NCT01775436|Behavioral|Healthy Living Control|"Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
75754450|NCT00371865|Behavioral|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
75754451|NCT05057585|Behavioral|Turning in bed, arm and leg exercises|Exercises (arm and leg exercises, turning in bed) were applied only to the experimental group. It was applied for 15 minutes 12-24 hours before the operation.
75456724|NCT01775449|Behavioral|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
75902249|NCT05007184|Behavioral|Nutri-Score Labels|These labels were implemented by the French government in 2017. They are shown on all food and beverage products and range from A to E with the corresponding colours moving from Green to Red (symbolizing best to worst). The scores and grades are calculated based on 7 different nutrients grouped into 2 categories i.e. nutrients to consume (such as fibre) and nutrients to avoid (such as sugar). We modified the labels by adding % sugar per serving on the right side of the labels.
75902250|NCT04570605|Device|parasacral transcutaneous electrical nerve stimulation (PTENS)|electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.
75754452|NCT03935867|Behavioral|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
75754453|NCT01049841|Drug|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
75902251|NCT04570605|Other|Standard Urotherapy|standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
75754454|NCT00978263|Drug|metformin-based Oral Antidiabetic Drugs|
75754455|NCT00978263|Drug|Glargine|
75754456|NCT00981851|Drug|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
75754457|NCT00981851|Drug|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
76072321|NCT01827384|Drug|Everolimus|Given by mouth (PO)
76072322|NCT01827384|Drug|Temozolomide|Given by mouth (PO)
76072323|NCT01827384|Drug|Trametinib|Given by mouth (PO)
76072324|NCT01827384|Drug|Veliparib|Given by mouth (PO)
75902252|NCT02163174|Drug|Pentoxifylline (PTX)|Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics
75902253|NCT02163174|Drug|Placebo|Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
75902254|NCT01744912|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
76067640|NCT03866837|Dietary Supplement|Multiple micronutrient powders with 5 mg iron|The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg [(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg].
76067641|NCT03843957|Other|mPATH-CRC|mPATH-CRC is a self-administered iPad program that patients use in primary care clinics to help them receive CRC screening. The mPATH-CRC program also includes health questions to assist clinics with patient check-in, thereby incentivizing its use for all patients.
76067642|NCT03843957|Other|"high touch Implementation strategy"|"The high touch strategy consists of pre-implementation activities, training, and ongoing support.~Pre-Implementation Activities~Clinic champion identified.~Study team meeting with clinic champion~Implementation adaptations as needed for clinic flow~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~Phone/email technical support, as needed.~Access to web-based QA dashboard~Monthly program usage report sent to clinic champions~Scheduled phone-calls with clinic champion to review QA data and explore potential barriers.~Implementation adaptations as needed for clinic flow~Goal-triggered follow-up on-site trainings~Additional on-site trainings as requested.~Months 7 - 12~Phone/email technical support, as needed~Access to web-based QA dashboard"
76067643|NCT03843957|Other|"low touch Implementation Strategy"|"Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~Phone/email technical support, as needed.~Access to web-based QA dashboard~Months 7 - 12~Phone/email technical support, as needed~Access to web-based QA dashboard"
76067644|NCT03830476|Behavioral|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents of children with (any kind of) disabilities.
76067645|NCT03830476|Behavioral|Treatment as usual.|Treatment as usual within outpatient disability services.
76067646|NCT03820232|Device|temperature monitoring|In every patient observed in this prospective observational study, body core temperature will be contemporaneously monitored through the oesophageal probe and the heated controlled servo sensor. Both are routinely used for this purpose in clinical practice
76067647|NCT03809624|Drug|INBRX-105 - PDL1x41BB antibody|The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
75754458|NCT00978575|Drug|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
75754459|NCT00978575|Drug|Ferrosulfate|200mg daily for 12 weeks
75754460|NCT00978575|Drug|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
76067648|NCT03809624|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
75754461|NCT04007315|Device|SaeboGlove therapy|An individualised self-management training programme involving repetitive grasping and releasing movements over 6 weeks.
75754462|NCT04007315|Behavioral|Usual care|6-weeks of usual NHS care
75754463|NCT00981929|Drug|Tramadol|50 mg single oral dose
75754464|NCT00981929|Drug|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
75754465|NCT00981929|Drug|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
75754466|NCT00364845|Drug|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
75754467|NCT00364845|Drug|Placebo|Prefilled syringe placebo, to match active arm
75754468|NCT00978653|Drug|allopurinol|150 mg once a day
75754469|NCT00982241|Dietary Supplement|water|drinking water / normal dietary fluids for oral intake
75754470|NCT00978809|Other|Epley maneuver|
75754471|NCT00978809|Other|Semont maneuver|
75754472|NCT00978887|Other|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
75902255|NCT01744912|Drug|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
75902256|NCT03609879|Device|Ambu Perfect ACE|patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes
75902257|NCT03609879|Device|Philly One-Peace Collar|patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
75902258|NCT03609879|Device|Necloc Collar|patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
75754473|NCT00978887|Other|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
75754474|NCT04891445|Behavioral|Nursing monitoring program|A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.
75754475|NCT04891445|Behavioral|As usual|Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
75754476|NCT04007237|Drug|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
75754477|NCT00293722|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
75754478|NCT01070056|Behavioral|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
75754479|NCT01070056|Behavioral|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
75902259|NCT03609879|Device|NexSplit Plus|patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes
75902260|NCT03609879|Device|NECKLITE|patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
75902261|NCT03540810|Drug|Hydroxychloroquine|The patients will additionally receive this drug with their usual treatment to evaluate its efficiency to prevent new thrombotic events in primary antiphospholipid syndrome patients
75902262|NCT03540810|Drug|Placebo|The patients will receive placebo with their usual treatment
75902263|NCT03078400|Drug|SPL-108|Subcutaneous injection of 150 mg administered either one time or two times per day.
76067649|NCT03807414|Device|oXiris|Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
76067650|NCT03775343|Diagnostic Test|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
76067651|NCT03775343|Diagnostic Test|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
76067652|NCT03759678|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
75456725|NCT01775462|Drug|EDI200|3 or 10 mg/kg of EDI200
75456726|NCT01775488|Device|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
75902264|NCT03609723|Procedure|CABG|CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
75902265|NCT02159820|Drug|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
75902266|NCT02159820|Drug|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve [AUC] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
75902267|NCT05013658|Behavioral|pressure measurement|pressure measurement with pilot balloon palpation
75902268|NCT02862171|Drug|Dapivirine Vaginal Ring-004|To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
76067653|NCT03733886|Device|Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)|Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold
75456727|NCT01775527|Other|blood test|
75456728|NCT01775540|Drug|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
75456729|NCT01775540|Drug|Saline solution|Saline solution,1 drop used QID for 4 weeks
75456730|NCT01775540|Drug|Maxidex|Eyedrop-1 drop QID for 4 weeks
75456731|NCT01775579|Drug|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
75608370|NCT02797873|Other|DTI MRI scan|See Detailed Study Description and Outcome Measures.
75754480|NCT03976414|Other|eMOM|The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
75754481|NCT00381303|Drug|darunavir|600mg bid for 48 wks
75754482|NCT00381303|Drug|ritonavir|100mg bid for 48 wks
75754483|NCT00448812|Device|Bronchial Thermoplasty with the Alair System|Treatment of airways with the Alair System (Bronchial Thermoplasty) in the PREDECESSOR STUDY (NCT00214526).
75754484|NCT00364689|Drug|Rifaximin|
75754485|NCT00364689|Drug|Lactulose|
76067654|NCT03709199|Diagnostic Test|Ventilation Inhomogeneity|Ventilation inhomogeneity will be measured using the Lung Clearance Index (LCI), derived from multiple breath Nitrogen washout during tidal breathing, measured by a mouthpiece or mask covering nose and mouth.
76067655|NCT03709199|Diagnostic Test|Diaphragm Ultrasound|Diaphragm thickness and contractile activity measured during tidal breathing.
76067656|NCT03709199|Diagnostic Test|Respiratory Inductance Plethysmography|Measure of thoraco-abdominal asynchrony during tidal breathing
75754486|NCT00364689|Other|Placebo|
75754487|NCT00545129|Drug|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
75754488|NCT00545129|Drug|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
75754489|NCT05279339|Other|Exercise|Upper limb exercises using an elastic band.
75456732|NCT01775592|Drug|Arterakin (DHA-PPQ)|
75456733|NCT01775605|Drug|Synera|Synera Pain Patch
75456734|NCT01775618|Biological|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 EDs and a minimum of at least 6 months
75456735|NCT01775618|Biological|BAY94-9027|Twice per week prophylaxis: 25-60 IU/kg, intravenous infusion, for 12 weeks
75456736|NCT01775618|Biological|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 additional EDs to achieve at least 100 cumulative EDs, or until marketing authorization of the drug
75608371|NCT02797873|Other|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
75608372|NCT02793193|Dietary Supplement|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
75608373|NCT02793193|Dietary Supplement|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
75608374|NCT02793193|Drug|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
75608375|NCT02793193|Dietary Supplement|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
75754490|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
75754491|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
75754492|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
75754493|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
75754494|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose|100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
75754495|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose|100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
75754496|NCT00956111|Biological|placebo control|100 adults were assigned to receive 2 doses of placebo 21 days apart.
75608376|NCT02793271|Behavioral|RESHAPE|Mental health services users and primary care workers who have previously completed the training are trained using PhotoVoice and other techniques to participate as co-facilitators. They participate in introductions to the intervention, myth busting, recovery stories, psychosocial communication role plays, and collaborative activities addressing challenges and barriers to task sharing/ task shifting mental health services in primary care.
75754497|NCT00978965|Genetic|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
75754498|NCT00982475|Procedure|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
75754499|NCT00979355|Device|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
75754500|NCT00979433|Device|Bubble CPAP|Bubble CPAP will be delivered using Fischer & Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
75754501|NCT00979433|Device|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
75754502|NCT00982631|Drug|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
75754503|NCT00364611|Drug|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~On Day 1 of the 1st cycle over 120 minutes~On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
75902269|NCT05013814|Diagnostic Test|Semmes-Weinstein monofilament test|Tactile function was evaluated mainly as tactile registration by using 20-item Semmes-Weinstein monofilament (SWM) kit. The monofilament was applied three times with a pseudorandom order to distal pad of the thumb, index, 4th and 5th digits (C6, C7 and C8 dermatomes). The lowest value of monofilament was recorded which the child was able to correctly identify at least one touch out of three
75754504|NCT00364611|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
75754505|NCT00364611|Drug|Trastuzumab|"A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
75754506|NCT00979511|Other|milk and exercise|"milk fortified with 1000mg calcium or low-calcium milk~weight-bearing exercise or passive exercise"
75902270|NCT05013814|Diagnostic Test|Box and Block Test|Box and Block Test (BBT) was used for dexterity assessment. The BBT measures unilateral gross manual dexterity. The child was asked to move, one by one, the maximum number of blocks from one compartment of a box to another of equal size within 60 seconds
75902271|NCT05013814|Diagnostic Test|9-Hole Peg Test|9-Hole Peg Test (9-HPT) is used to measure finger dexterity. Firstly, the child takes the pegs from a container, one by one, and place them in the holes on the board; then participant removes the pegs from the holes and replaces them back into the container. The total time taken to complete the test is recorded in seconds.
75456737|NCT01775631|Biological|Urelumab|
75456738|NCT01775631|Biological|Rituximab|
75456739|NCT01775748|Other|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
75754507|NCT00956189|Drug|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
75902272|NCT05013814|Diagnostic Test|Duruöz Hand Index (DHI)|Duruöz Hand Index (DHI) is an 18-item self-report questionnaire regarding ability to carry out manual tasks. Individual items are scored on a 6-point Likert scale where 0=without difficulty and 5=impossible. The total score ranges from 0-90 with higher scores indicating poorer hand function.
75902273|NCT05013814|Diagnostic Test|Jamar hand dynamometer|Hand grip strength was measured by using Jamar hydraulic hand dynamometer. Measurement was done with the participant in sitting position and the elbow at 90 degrees of flexion. The force has most commonly been measured in kilograms according to the amount of static force that the hand can squeeze around the dynamometer.
75902274|NCT05013814|Diagnostic Test|Hydraulic pinch gauge|Hydraulic pinch gauge is used for evaluation of finger grip strength. The evaluation method was the same as Jamar hand dynamometer.
76067657|NCT03709199|Diagnostic Test|Spirometry|Measurement of Forced Expiratory Volume (FEV1), Forced Vital Capacity and other lung volumes using standard pulmonary function techniques
75456740|NCT01775748|Other|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
75456741|NCT01775761|Drug|Period 1|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
75456742|NCT01775761|Drug|Period 2|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
75754508|NCT00956189|Drug|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
75754509|NCT00984581|Drug|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
75608377|NCT02793271|Behavioral|PRIME/mhGAP|"Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions."
75608378|NCT02793349|Device|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
75608379|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily
75608380|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
75608381|NCT01197534|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
75754510|NCT00984581|Drug|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
75754511|NCT00984581|Drug|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
75754512|NCT00956267|Drug|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
75754513|NCT00956267|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
75754514|NCT04007003|Behavioral|training in optimal insulin injection technique|the training will be delivered in person as well as through online training modules via the BD and Me(TM) platform
75754515|NCT00982709|Behavioral|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
75754516|NCT04007081|Procedure|Bone Marrow Aspiration|collection of approximately 40 mL of bone marrow aspirate
76067658|NCT03709199|Diagnostic Test|Functional Residual Capacity|Measurement using body box plethysmography of functional residual capacity and other lung volumes using standard pulmonary function techniques
75754517|NCT04007081|Diagnostic Test|Ultrasound Imaging of Salivary Glands|Salivary gland size will be measured by ultrasound.
75754518|NCT04007081|Other|Salivary Assay|Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions
75754519|NCT04007081|Other|Quality of Life Instruments|Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
75754520|NCT00364533|Drug|Tapentadol IR (CG5503)|Fixed Dose 50, 75, & 100 mg BID for 3 days
76067659|NCT03709199|Diagnostic Test|MIP/MEP|Measurement of maximal inspiratory and expiratory pressures during airway occlusion
75754521|NCT00364533|Drug|Placebo|Fixed Dose Matching placebo for 3 days
76067660|NCT03709199|Diagnostic Test|6 minute walk test|Measurement of cardio-respiratory function and capabilities during treadmill walking for 6 minutes.
76067661|NCT03709199|Diagnostic Test|Neurocognitive Testing|Detailed in person neuro-cognitive testing using standardized inventories using either the Battelle Developmental Inventory, second edition (Battelle-2) (age birth to 5 years 11 months) and the Wechsler Intelligence Scale for Children, fifth edition (WISC-5, for age 6 years to 19 years).
75456743|NCT01775761|Drug|Period 3|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
75456744|NCT01775826|Other|Measurement|Measured usual (day-to-day) behavior with body-worn sensors.
75456745|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(oral)|oral administration of digoxin
75754522|NCT00364533|Drug|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
75456746|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(IV)|intravenous administration of digoxin
75456747|NCT01775878|Device|Telemonitoring Device|Telemonitoring device was installed in patients' homes
75456748|NCT01775891|Drug|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
75754523|NCT00364533|Drug|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
75754524|NCT00982787|Drug|Botanical extract from Passiflora incarnata|"Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period"
75754525|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
75754526|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
75754527|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
75754528|NCT01047423|Drug|Simvastatin|40mg encapsulated once daily for 12 weeks
75754529|NCT01047423|Drug|Placebo|Encapsulated oral once daily for 12 weeks
76067662|NCT03709199|Diagnostic Test|Emotional Health Assessment|In person and written assessments of children and parents using the Behavioral Assessment System for Children, third edition (BASC-3) for children ≥ 2 years and the UCLA PTSD Reaction Index (UCLA RI) for children ≥ 8 years.
76067663|NCT03709199|Diagnostic Test|Health Related Quality of Life|Standardized instruments to assess (in person, over the phone, or via mail) health related quality of life in children. Parent and child questionnaires.
75754530|NCT00984737|Drug|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
75754531|NCT01047579|Drug|Rivastigmine transdermal|
75754532|NCT04006847|Drug|Eicosapentaenoic Acid|Eicosapentaenoic Acid once per day orally
75754533|NCT04006847|Drug|Tyrosine kinase inhibitor|Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
75754534|NCT00984893|Drug|zoledronic acid|
75754535|NCT00984893|Drug|Any oral bisphosphonates marketed in Canada|
75754536|NCT02502747|Drug|rhu G-CSF|rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
75608382|NCT04234321|Drug|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
75754537|NCT02502747|Drug|optimal standard of care|Optimal standard of care
75754538|NCT02502747|Procedure|Myocardial Contrast Echocardiography|Myocardial Contrast Echocardiography with sulphur hexafluoride.
75754539|NCT00983021|Drug|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
75754540|NCT00983021|Drug|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
75902275|NCT03083626|Other|Cold pressor test|"The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached."
75902276|NCT05013346|Other|No intervention needed|No intervention required. Not a clinical trial
75902277|NCT04405791|Procedure|Active stimulation group Sham stimluation group|"Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week."
75902278|NCT03083314|Procedure|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
75902279|NCT03083314|Procedure|COMPLETE AXILLARY DISSECTION (ALND)|
75456749|NCT01775891|Drug|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
75456750|NCT01775969|Other|Text Message|A text message with instructions is sent to the patient
75456751|NCT01775969|Other|Voicemail|A voicemail with instructions is sent to the patient
75608383|NCT04234321|Drug|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
75608384|NCT04234321|Drug|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
75754541|NCT00983021|Drug|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
75754542|NCT00983021|Drug|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
75754543|NCT00984971|Drug|Tenofovir|Topical gel applied rectally
75754544|NCT00984971|Drug|HEC Placebo|Placebo gel applied rectally
75754545|NCT00984971|Drug|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
75754546|NCT00544817|Radiation|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
75754547|NCT00544817|Drug|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
75754548|NCT00544817|Drug|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
75754549|NCT00983099|Drug|Neramexane|single and multiple dose, tablets, oral
75754550|NCT04661423|Other|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.
75754551|NCT04812899|Behavioral|Parental guided self-help version of FBT-pre-recorded videos and readings from the book|"Each participant will receive a series of pre-recorded videos of parental guided self help version FBT. There will be10 videos of about 10 minutes each. The videos will include content on empowering parents to renourish their child and interrupt binge/purge behaviors. Readings will be assigned to each participant from the book Help Your Teenager Beat and Eating Disorder. There will be psychoeducational content on the dangers and medical complications of eating disorders. The readings will also contain content on coping skills for young people including relaxation, mindfulness strategies, and distress tolerance skills."
75902280|NCT05013112|Drug|SGLT2 inhibitor|Empagliflozin 20mg once daily from discharge
75608385|NCT02793115|Behavioral|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
75608386|NCT02793115|Behavioral|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
75456752|NCT01775982|Other|Psychiatric evaluation|"This evaluation is carried out in several stages:~Assessment of cognitive functioning;~Interview with a relative;~Interview with caregivers;~Evaluation of the presence of delirium according to DSM-IV criteria;~Evaluation of the presence of anxiety, depressive syndrome, dementia or other DSM IV;~Reports of adverse events.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
75902281|NCT05013112|Drug|Metformin|Metformin 500mg twice daily from discharge
75902282|NCT05013112|Other|Placebo|Placebo group
75902283|NCT03082144|Drug|MTX|MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
75456753|NCT01775982|Other|Geriatric evaluation|"This evaluation includes a brief interview with a caregiver, diverse scorings (CAM, Delirium Index, Mini Geriatric Depression Scale, Modified Early Warning Score, Clinical Global Impression sclae, Algo Plus), and adverse event reporting.~CAM scoring is carried out by a trained geriatrician and a trained nurse and/or a psychologist.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
76067664|NCT03709199|Diagnostic Test|Functional Status|Survey of overall functional status, administrated by asking a series of questions to patient and families.
75456754|NCT01776021|Other|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
75456755|NCT01776021|Other|placebo beverage|placebo beverage at a dose of one 8 oz. beverage per day for six months
75456756|NCT01776047|Drug|Exforge®|
75456757|NCT01776047|Drug|G-0081|
75456758|NCT01776060|Other|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
75456759|NCT01776073|Behavioral|Patient Navigation|
76067665|NCT03709199|Diagnostic Test|Respiratory Status Questionnaire|Survey of respiratory health, administrated by asking a series of questions to patient and families.
75456760|NCT01776086|Behavioral|Neurological testing|
75608387|NCT02793115|Behavioral|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
75608388|NCT02793115|Behavioral|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
76067666|NCT03703115|Behavioral|Fasting|No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
75456761|NCT01776099|Dietary Supplement|Dietary supplement (4 arms, 2 active, 2 placebo)|
75754552|NCT04005833|Diagnostic Test|spirometry|The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
75754553|NCT00289978|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
75754554|NCT00289978|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
75754555|NCT00289978|Drug|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
75754556|NCT00983177|Drug|Colchicine|0.5 mg twice daily for 4 months
76067667|NCT03697811|Drug|DE-117 Ophthalmic Solution|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
76067668|NCT03691649|Drug|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
76067669|NCT03691649|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
76067670|NCT03689946|Drug|Evolocumab|"Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector."
75754557|NCT00983177|Drug|lactose|lactose capsules twice daily
75902284|NCT03082144|Drug|Ara-C|Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
75902285|NCT03082144|Radiation|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
75754558|NCT00985283|Behavioral|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
75754559|NCT00985283|Behavioral|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
75754560|NCT03977428|Other|standard of care|No intervention, this a patient registry and is purely an observational study
75754561|NCT00983255|Drug|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 & 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
75902286|NCT05013034|Drug|Basiliximab Injection|Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
75902287|NCT05013034|Drug|Placebo|Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
75456762|NCT01776112|Other|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
76067671|NCT03689946|Diagnostic Test|18F-NaF PET|18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
75456763|NCT01776112|Other|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
75456764|NCT01776125|Other|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
75456765|NCT01776138|Other|Collect Blood and Survey Instruments|
75456766|NCT01776203|Drug|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
75608389|NCT02793115|Behavioral|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
75608390|NCT03832933|Behavioral|High Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
75608391|NCT03832933|Behavioral|Standard Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
75608392|NCT02797717|Radiation|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
75608393|NCT02797717|Drug|Vincristine|ARM A and ARM B
75902288|NCT02638948|Drug|BMS-986142|BMS986142 specific dose on specific days
75902289|NCT02638948|Drug|Placebo|Placebo of BMS-986142 specific dose on specific days
75902290|NCT02638948|Drug|Methotrexate|Methotrexate specific dose on specific days
75902291|NCT03091582|Behavioral|Cognitive factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress
75902292|NCT03091582|Behavioral|Behavioral factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.
75456767|NCT01776216|Other|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
75456768|NCT01776216|Other|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
75608394|NCT02797717|Drug|Etoposide|ARM B , 100mg/m2/day
75608395|NCT02797717|Drug|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
75754562|NCT00983255|Drug|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
75902293|NCT03091582|Behavioral|Increase engagement of pleasant events|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
75902294|NCT03091426|Drug|Omiganan|Omiganan 1%
75902295|NCT03091426|Drug|Omiganan|Omiganan 1.75%
75902296|NCT03091426|Drug|Omiganan|Omiganan 2.5%
75456769|NCT01776255|Behavioral|Healthy Children, Strong Families|"Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year."
75608396|NCT02797717|Drug|Doxorubicin|ARM B , 25mg/m2
75608397|NCT02797717|Drug|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
75754563|NCT05279261|Procedure|The axillary approach|The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
75754564|NCT00983333|Device|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
75754565|NCT00983411|Other|Non intentional leaks during non invasive ventilation|During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
75902297|NCT03091426|Drug|Placebo|Vehicle
75902298|NCT05020054|Device|Tecartherapy Intervention|therapeutic therapy with effective application, connected equipment
75902299|NCT05020054|Device|placebo tecartherapy|tecartherapy with equipment turned off
75608398|NCT02797717|Drug|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
75608399|NCT02793037|Device|Zirconia resin bonded bridge|
75608400|NCT02792725|Drug|Abemaciclib|Administered orally
75608401|NCT04235569|Drug|Warfarin Sodium 5 MG|warfarin sodium 5mg tablets
75902300|NCT05019820|Other|Knee strengthening exercises with isokinetic dynamometer|18 sessions of strengthening exercises around the knee with an isokinetic dynamometer 3 days a week
75902301|NCT05019820|Other|Strengthening around the knees with home exercise programe|18 sessions of strengthening exercises for the muscles around the knee at home, 3 days a week
75902302|NCT04465864|Drug|Intracanalicular Dexamethasone, 0.4 mg insert|Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery or inserted the day of surgery.
75608402|NCT04235569|Drug|Warfarin Sodium 3 MG|warfarin sodium 3mg tablets
75608403|NCT04235569|Drug|Enoxaparin Sodium 100 MG/ML Prefilled Syringe|"Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours."
75608404|NCT02789449|Other|assessment of DLNO and DLCO|
75902303|NCT03091504|Device|High flow nasal cannula|High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.
75902304|NCT03091504|Drug|Albuterol Sulfate|Albuterol is a short acting inhaled bronchodilator
75902305|NCT03091036|Other|Proactive healthcare intervention|There is an intervention in the coordination of health resources, and monitoring readmissions and know the benefit in total cost of care in 4 month.
75902306|NCT05019586|Drug|levofloxacin, amoxicillin, clarithromycin|Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
75902307|NCT03078634|Other|Multi-disciplinary clinic model|Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
75902308|NCT03078634|Other|Standard outpatient care|Standard care provided in outpatient clinics staffed by GI doctors only
75902309|NCT03081676|Drug|Glimepiride 1Mg Tablet|Glimepiride
75608405|NCT01197378|Drug|Cysteamine Bitartrate Delayed-release Capsules|"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
75608406|NCT02797639|Other|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
75754566|NCT00988403|Dietary Supplement|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
75754567|NCT00988403|Dietary Supplement|Fructan - 10|Subjects will consume 10 grams of fructan
75754568|NCT00988403|Dietary Supplement|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
75754569|NCT00988403|Dietary Supplement|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
75754570|NCT00988481|Drug|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
75902310|NCT03081676|Drug|Glucagon-like Peptide-1|GLP-1 infusion
75902311|NCT03081676|Drug|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
76067672|NCT03689946|Diagnostic Test|CCTA|CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
76067673|NCT03687190|Behavioral|Tai chi|participants were required to receive hospital-based Tai chi training at least once a month, and home-based Tai chi exercise at least three times a week over the next 9 months
75456770|NCT01776255|Behavioral|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
75456771|NCT01776281|Behavioral|Kangaroo Mother Care|
75456772|NCT01776281|Behavioral|Standard Care|
75456773|NCT01776320|Drug|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
75456774|NCT01776333|Behavioral|video decision aid|
75456775|NCT01776359|Dietary Supplement|High Protein|2.4g/kg of protein
75456776|NCT01776359|Dietary Supplement|Low Protein|1.2g/kg of protein
75456777|NCT01776372|Device|Medela Thopaz Thoracic Drainage System|
75754571|NCT03720821|Behavioral|Cognitive Training + fMRI|"Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training."
75754572|NCT00983567|Other|teen web|Min web
75754573|NCT00542321|Other|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
75754574|NCT00542321|Device|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
75754575|NCT00289900|Drug|MK-0524A|
75754576|NCT00289900|Drug|Atorvastatin|
75754577|NCT00289900|Drug|Simvastatin|
75754578|NCT01067014|Device|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
75754579|NCT00543725|Drug|TMC278|25 mg tablet once daily for 96 weeks
75902312|NCT03081676|Drug|Placebo Oral Tablet|Placebo
75902313|NCT03081676|Drug|Placebo infusion|Placebo (saline)
75902314|NCT05013268|Drug|Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin|"Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none"
76067674|NCT03687190|Drug|conventional medicine|participants without Tai chi training still received routine conventional medicine
75754580|NCT00543725|Drug|efavirenz|600 mg tablet once daily for 96 weeks
75754581|NCT00985361|Dietary Supplement|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
75754582|NCT00985361|Dietary Supplement|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
75754583|NCT00984035|Other|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
75754584|NCT00984035|Other|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
75754585|NCT00984035|Other|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
75754586|NCT00269152|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 4 cycles
75902315|NCT05005858|Procedure|Alveolar ridge splitting|Patients with Kennedy Class I. and II. mandibles with insufficient bone width were included in this study. Ridge splitting was carried out with the use of a piezoelectric surgery device by preparing osteotomies and after mobilization of the buccal cortical by placing an autologous bone block harvested from the retromolar region as a spacer between the buccal and lingual cortical plates. Block-grafts were stabilized by osteosynthesis screws. Implant placement was carried out after a 3-month healing period.
75902316|NCT05005858|Device|Creating osteotomies with piezoelectric device|Osteotomies were carried out with piezoelectric surgery device (NSK Variosurg3 Ultrasonic Bone Surgery System, NSK Europe GmbH, Eschborn, Germany)
75456778|NCT01776372|Device|Atrium Express Dry Seal Chest Drain|
75456779|NCT01776385|Other|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
75456780|NCT01776385|Other|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
75456781|NCT01776411|Drug|forodesine hydrochloride|
75608407|NCT02797639|Other|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
75608408|NCT02789527|Drug|Phenotyping|finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
75608409|NCT02789527|Genetic|Genotyping|DNA sampling from a saliva sample
75754587|NCT00269152|Drug|cisplatin|75 mg/m^2, intravenous (IV), every 21 days x 4 cycles
75754588|NCT00269152|Drug|carboplatin|area under the curve (AUC) 5 milligrams per milliliter*minute (mg/ml*min), intravenous (IV), every 21 days x 4 cycles
75754589|NCT00988715|Biological|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
75456782|NCT01776437|Drug|BMN 673|500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
75754590|NCT00988715|Drug|Cyclosporine|Given IV
75754591|NCT00988715|Drug|Mycophenolate Mofetil|Given PO
75754592|NCT00988715|Radiation|Total-Body Irradiation|Undergo total-body irradiation
75456783|NCT01776450|Device|Endovascular AAA repair|
75754593|NCT00988715|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
75456784|NCT01776463|Drug|Z-360|
75456785|NCT01776463|Drug|placebo|
75456786|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
75754594|NCT00988715|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
75754595|NCT00988715|Drug|Fludarabine Phosphate|Given IV
75754596|NCT00988715|Other|Pharmacological Study|Correlative studies
75902317|NCT03081208|Drug|Nolasiban 900mg|Nolasiban dispersible tablets for single oral administration
75456787|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
75456788|NCT01776528|Biological|NGM282|
75456789|NCT01776528|Biological|Placebo|
75456790|NCT01776567|Device|Everolimus eluting stents|
75456791|NCT01776619|Drug|PF-06305591|14 day repeated 20mg BID doses
75456792|NCT01776619|Drug|Placebo|14 day repeated BID doses
75456793|NCT01776619|Drug|PF-06305591|14 day repeated 80mg BID doses
75608410|NCT04233307|Diagnostic Test|Telethermographic images|Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
75608411|NCT02789215|Behavioral|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
75608412|NCT02792647|Drug|Placebo|Administered orally
75608413|NCT02792647|Drug|IX-01|Administered orally
75608414|NCT02792491|Drug|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
75754597|NCT00988715|Other|Laboratory Biomarker Analysis|Correlative studies
75754598|NCT01325740|Drug|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
75754599|NCT03975166|Drug|Test Product|2 inhalations in one study period
75754600|NCT03975166|Drug|Reference Product|2 inhalations in one study period
75754601|NCT01067092|Behavioral|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
75608415|NCT02792803|Drug|Xalatan|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
75754602|NCT01067092|Behavioral|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
75754603|NCT03976024|Other|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
75754604|NCT03976024|Other|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
75456794|NCT01776619|Drug|Placebo|14 day repeated BID doses
75456795|NCT01776619|Drug|PF-06305591|14 day repeated 40mg BID doses
75608416|NCT02792803|Drug|Apo-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
75608417|NCT02792803|Drug|Co-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
75754605|NCT01067170|Device|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
75754606|NCT01325818|Drug|pravastatin, rosuvastatin|"Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
75754607|NCT00379899|Drug|cinacalcet|Low dose vitamin D with cinacalcet
75456796|NCT01776619|Drug|Placebo|14 day repeated BID doses
75456797|NCT01776619|Drug|PF-06305591|14 day repeated BID doses
75456798|NCT01776619|Drug|PF-06305591|relative bioavailability tablet vs. solution and food effect at 50mg dose
75608418|NCT02792569|Procedure|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
75608419|NCT02797795|Drug|NEV801|Dose Escalation
75754608|NCT02535039|Drug|Methylprednisolone|Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg * d for application to the third day after surgery
75456799|NCT01776658|Drug|SYL1001|Ocular topical administration of SYL1001 for 10 consecutive days
75456800|NCT01776658|Drug|Placebo|Ocular topical administration of placebo for 10 consecutive days
75456801|NCT01776671|Drug|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
75456802|NCT01776684|Drug|EGFR TKIs (gefitinib, erlotinib, afatinib, et al)|
75456803|NCT01776697|Drug|pelubiprofen (30mg) tablet IR|
75456804|NCT01776697|Drug|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
75608420|NCT02789059|Other|muscle oxygenation|Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
75608421|NCT02797249|Drug|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
75754609|NCT02535039|Other|Physiological saline|The same volume of physiological saline will be given in Placebo group
75902318|NCT03081208|Drug|Placebo|Placebo dispersible tablets for single oral administration
75608422|NCT02797249|Other|Blank|Routine examination during pregnancy.
75608423|NCT02792335|Drug|apixaban|
75608424|NCT02792335|Drug|dabigatran|
75608425|NCT02792335|Drug|rivaroxaban|
75608426|NCT02792335|Drug|warfarin|
76067675|NCT03682523|Behavioral|Sedentary behavior reduction intervention|Participants will be provided with a device to measure physical activity and sedentary behaviours. A tablet will be in the research office and each afternoon, it will be synced to the device to assess the activity progress of the patient. The research team will deliver an upright time goal and will target a 20% increase in upright time from the previous hospital day. Physiotherapist research assistants will visit the participants every afternoon to monitor progress and safely mobilize participants to their maximum ability if they have not met their daily goal (including weekend). The maximum level of ability will be determined in consultation with the healthcare team. Participants who do not meet their goal will be mobilized in the late afternoon/ early evening.
76067676|NCT03655002|Drug|Cyclophosphamide|Given IV
76067677|NCT03655002|Biological|Cytokine-based Biologic Agent IRX-2|Given SC
75608427|NCT02792023|Other|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
75608428|NCT02792023|Device|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
75608429|NCT02792023|Device|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
75608430|NCT02792179|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of [18F]RO6958948 injected will be less than or equal to (</=) 10 micrograms (µg), injection volume </=20 mL. Target injected activity for [18F]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie [mCi]).
75608431|NCT01197300|Drug|Zoledronic acid|intravenous infusion
75754610|NCT02535117|Procedure|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
75902319|NCT00102960|Drug|Abacavir sulfate|Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
76067678|NCT03655002|Biological|Nivolumab|Given IV
75608432|NCT02797405|Radiation|Standard treatment|Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
75608433|NCT02791867|Drug|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
76072325|NCT01825694|Behavioral|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
76072326|NCT01758653|Other|No study intervention|There is no study-related intervention.
75608434|NCT04234243|Procedure|cytoreduction and HIPEC|cytoreduction CCR 0-1, and HIPEC close technique
75608435|NCT04200235|Drug|Dexmedetomidine hydrochloride nasal spray|"In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray."
75902320|NCT00102960|Drug|Didanosine|Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
75902321|NCT00102960|Drug|Efavirenz|Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
75902322|NCT00102960|Drug|Lamivudine|First Line Regimen: 4 mg/kg taken orally twice daily
75902323|NCT00102960|Drug|Lopinavir/Ritonavir|First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
75902324|NCT00102960|Drug|Nevirapine|Second Line Regimen: 150 - 200 mg/m^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
75902325|NCT00102960|Drug|Zidovudine|First Line Regimen: 240 mg/m^2 taken orally twice daily
75902326|NCT05019118|Other|Experimental milk|UNICLA milk naturally enriched in selenium and omega-3.
75754611|NCT02535117|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
75608436|NCT04200235|Drug|Dexmedetomidine hydrochloride nasal spray blank preparation.|"In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
75902327|NCT05019118|Other|Experimental yogur|UNICLA yogur naturally enriched in selenium and omega-3.
75608437|NCT02791789|Other|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
75902328|NCT05019118|Other|Experimental fresh cheese|UNICLA fresh cheese naturally enriched in selenium and omega-3.
75902329|NCT05019118|Other|Placebo milk|Conventional milk
75902330|NCT05019118|Other|Placebo yogur|Conventional yogur
75902331|NCT05019118|Other|Placebo fresh cheese|Conventional fresh cheese
75456805|NCT01776710|Behavioral|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
75456806|NCT01776749|Device|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
75608438|NCT02791711|Other|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
75608439|NCT02791243|Drug|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
75608440|NCT02791243|Drug|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
75608441|NCT02791243|Drug|Negative Control|0.9% aqueous NaCl
75608442|NCT02791477|Device|Attune FB PS knee arthroplasty|
75608443|NCT04234165|Device|TURBT|different power sources ( bipolar vs monopolar)
75754612|NCT00371787|Device|Soft contact lens|Soft contact lens
75902332|NCT05005702|Other|Inspiratory Muscle training|"Patients received IMT for 30-minute per day, 3 days per week for 3 weeks using the Threshold Inspiratory Muscle training device (product Phillips). During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training.~Inspiratory muscle training diaries were checked weekly. The inspiratory load was set at 40%of maximal inspiratory pressure."
75902333|NCT03078790|Device|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
75754613|NCT00363129|Dietary Supplement|vitamin E|Given orally
75754614|NCT00363129|Other|placebo|Given orally
75754615|NCT00268996|Drug|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
75754616|NCT00268996|Drug|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
75902334|NCT02166762|Procedure|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
75902335|NCT02163252|Behavioral|Standard|
75902336|NCT02163252|Behavioral|Early Intervention|
75754617|NCT00371397|Behavioral|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
75754618|NCT00371397|Behavioral|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
75902337|NCT05012800|Biological|COVID-19 Vaccine|Coronavirus vaccine was inoculated on day 0 and day 21, respectively.
75902338|NCT02166840|Procedure|Plastic stent (7-10Fr)|
75902339|NCT02166840|Procedure|Self Expanding Metal Stent|
75754619|NCT00379587|Drug|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
75754620|NCT00379587|Drug|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
75456807|NCT01776775|Device|Abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position."
75754621|NCT00289276|Device|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
75754622|NCT03975244|Behavioral|Exercise program|Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
75902340|NCT02858895|Drug|MDNA55|MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).
75902341|NCT04712136|Other|MRI|MRI cardiac
75902342|NCT04939714|Behavioral|Psychoeducational Intervention|The intervention is an online course providing education and training to caregivers over an 8 week period. The self-paced course provides information on caregiving for a PLWD during a pandemic, navigating the health care system for a PLWD, and managing daily life (including self-care).
75902343|NCT05018962|Device|Cutting balloon followed by paclitaxel coated balloon|Cutting balloon followed by paclitaxel coated balloon
75902344|NCT02160054|Drug|Graceptor®|oral
75902345|NCT03078322|Drug|AV-101|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
76067679|NCT03645226|Diagnostic Test|Colonoscopy|All subjects will undergo standard mechanical bowel preparation with 4 liters of polyethylene glycol (Klean-Prep, Norgine Ltd., Middlesex, UK). Total colonoscopy will be performed by experienced endoscopists under conscious sedation with intravenous benzodiazepines and narcotics. A conventional intermediate-length colonoscope (Olympus Corporation, Tokyo, Japan) will be used. One mucosal biopsy will be taken in the descending colon. Biopsies will be performed using standard biopsy forces without needle (Olympus Corporation, Tokyo, Japan). Half of the samples will be immersed in 4 oC normal saline solution. All samples will be immediately sent to pathology department and will be stored in a -80 oC freeze for processing of microbiota analyses.
76067680|NCT03621735|Device|Burst-SCS/sham SCS|"The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
76072327|NCT01704157|Device|Cryo-Touch III|Study treatment at Day 0.
75902346|NCT03078322|Drug|Placebo|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
75902347|NCT03609489|Drug|Capecitabine|Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
75902348|NCT03609489|Drug|Apatinib|Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
76072328|NCT01585194|Biological|Ipilimumab|Given IV
76072329|NCT01585194|Other|Laboratory Biomarker Analysis|Correlative studies
76072330|NCT01585194|Biological|Nivolumab|Given IV
75902349|NCT05019196|Device|GE 3.0T MRI|using GE 3.0T MRI to obtain anatomical and functional MR images and DTI images
75902350|NCT02033967|Procedure|vasodilator induced hypovolemia|
76072331|NCT01560663|Drug|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
75902351|NCT03541590|Procedure|Percutaneous transhepatic biliary drainage|When ERCPs failed or was not possible to be performed due to an altered anatomy in patients with malignant extrahepatic bile duct obstruction, PTBD was performed next in all patients. Percutaneous bile duct puncture was guided by Color Doppler ultrasound. The further procedure was guided by fluoroscopy. A self-expandable metal stent (SEMS) was inserted into the obstructed bile duct by endoscopic luminal guidance in the first session. After successful SEMS implantation, the percutaneous external catheter was removed at the end of the procedure.
75902352|NCT03090802|Behavioral|Mentoring Adolescent Mothers at School (MAMAS)|Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
75902353|NCT04765956|Device|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
76072332|NCT01463371|Drug|Azithromycin|250 mg three times a week during three months
75608444|NCT05393635|Biological|ITIL-168|"ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion."
75754623|NCT03977506|Diagnostic Test|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
75754624|NCT00289198|Drug|FF|fluticasone furoate 110 μg nasal spray
75608445|NCT02788825|Procedure|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
75608446|NCT02797483|Other|Test Fat Blue|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
75754625|NCT00289198|Drug|Placebo|placebo nasal spray
75754626|NCT01067404|Biological|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
75754627|NCT03741712|Drug|SHR3680|Tablet. Specifications of 80mg
75754628|NCT03741712|Drug|SHR2554|Tablet. Specifications of 50mg and 200mg
75902354|NCT03610113|Device|Reverse shoulder arthroplasty|The implantation of reverse shoulder prosthesis, and reattachment of greater and lesser tuberosities
75902355|NCT03081130|Procedure|Intravenous laser irradiation treatment|control group
75902356|NCT02163330|Drug|Acetazolamide|
75754629|NCT00363051|Drug|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
75754630|NCT00363051|Drug|Octreotide Depot|
75754631|NCT00379353|Drug|Thalidomide|100 mg capsules orally, once a day for 14 days.
75754632|NCT00379353|Drug|Placebo|Two placebo capsules orally, once a day for 14 days.
75754633|NCT03992391|Behavioral|Suicide Prevention Intensive Outpatient Program|participation in a suicide prevention intensive outpatient program
75754634|NCT01047657|Behavioral|Low caloric diet plus orlistat and sibutramine|All subjetcs
75754635|NCT00378573|Drug|docetaxel|
75754636|NCT00378573|Drug|gemcitabine|
75754637|NCT00378573|Drug|bevacizumab|
75754638|NCT01581099|Procedure|Digestive Adaptations III surgery|
75902357|NCT02163330|Drug|sugar pill|
75902358|NCT04186845|Drug|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
75902359|NCT02166996|Procedure|Suture removal time 7 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.
75902360|NCT02166996|Procedure|Suture removal time14 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
75754639|NCT01047891|Drug|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
75754640|NCT02534571|Device|Endoscopic Application of a Hemostatic Powder TC-325|Endoscopic Application of a Hemostatic Powder TC-325 <=150g once
75608447|NCT02797483|Other|Test Fat Green|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
75608448|NCT02797483|Other|Test Fat Red|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
75608449|NCT02791087|Other|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
75608450|NCT02791087|Other|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
75754641|NCT02534571|Device|Hemo-clipping|Hemo-clipping <=20 clips
75754642|NCT02534571|Drug|Epinephrine|epinephrine injection endoscopically <20 mls
75754643|NCT02534571|Device|thermo-coagulation|contact thermo-coagulation < = 4 pulses
75754644|NCT03831945|Biological|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
75754645|NCT03831945|Biological|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
75608451|NCT02797015|Drug|RPC1063|Oral capsule daily
75754646|NCT03831945|Biological|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
75754647|NCT00457002|Drug|Apixaban|"Apixaban: Twice daily, 30 days~Placebo: Once daily, 6-14 days"
75754648|NCT00457002|Drug|Enoxaparin|"Enoxaparin: Once daily, 6-14 days~Placebo: Twice daily, 30 days"
75754649|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
75754650|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
75754651|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
75754652|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
75754653|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
75754654|NCT00362115|Drug|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
75754655|NCT00362115|Drug|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
75754656|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily.
75754657|NCT00485264|Drug|Raltegravir chewable tablet|Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
75902361|NCT03080272|Other|no intervention will take place|Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
75608452|NCT02791009|Other|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
75608453|NCT02791009|Other|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
75902362|NCT03610035|Drug|NPT189|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
75608454|NCT02791009|Other|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
75754658|NCT00485264|Drug|Raltegravir oral granules for suspension (20 mg/mL)|Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
75754659|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet.
75754660|NCT00293254|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
75754661|NCT00293254|Drug|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
75902363|NCT03610035|Drug|Placebo|Placebo
75902364|NCT02163564|Behavioral|Cognitive Behavioral Therapy for Insomnia|A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
75902365|NCT03078244|Other|N/A, observational study|
75902366|NCT03609411|Procedure|Splenectomy|Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
75902367|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
76067681|NCT03621735|Device|Sham SCS/Burst-SCS|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
76067682|NCT03606980|Drug|Dexamethasone Sodium Phosphate|Dexamethasone sodium phosphate administered via iontophoresis
76067683|NCT03606980|Procedure|Iontophoresis|Iontophoresis on affected knee
76067684|NCT03606980|Procedure|Physical Therapy|Physical therapy of affected knee
76067685|NCT03596424|Drug|Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
76067686|NCT03596424|Drug|Dexmedetomidine Hydrochloride|Intraoperative bolus and infusion (see arm description)
76067687|NCT03596424|Combination Product|dexmedetomidine Hydrochloride and Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
75456808|NCT01776788|Drug|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
75608455|NCT02791009|Other|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
75608456|NCT02791009|Other|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
75902368|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
75902369|NCT05005468|Drug|Camrelizumab|Camrelizumab is given on the first day of each cycle, intravenous drip.
75902370|NCT05005468|Drug|Famitinib|Famitinib is administered orally, once a day.
75902371|NCT02034201|Drug|Lisdexamfetamine|
75902372|NCT02034201|Drug|Placebo|
75754662|NCT01018784|Drug|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
75456809|NCT01776788|Drug|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
75456810|NCT01776801|Other|Infusion|Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
75754663|NCT01047969|Drug|Adjuvant Chemotherapy|If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
75754664|NCT01047969|Procedure|Surgery|If after MRI + FDG-PET 8 weeks post CRF no further regression or growth of disease occurs the patient will be referred for surgery.
75754665|NCT01019018|Device|subtenon block|subtenon block with stevens cannula
75754666|NCT01019018|Device|subtenon block|subtenon block with Olive tip cannula cannula
75754667|NCT03977350|Device|EEG monitoring|EEG monitoring under general anesthesia
75902373|NCT03609333|Device|Multimodal Neuromonitoring|Application of multimodal neuromonitoring
75456811|NCT01776853|Dietary Supplement|Glucose|
76067688|NCT03592563|Behavioral|Neuro-QoL questionnaire|Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
76067689|NCT03586258|Behavioral|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests
75456812|NCT01776853|Dietary Supplement|Fructose|
76067690|NCT03586258|Other|Brain Imaging|Anatomical, diffusion, and/or functional MRI
76067691|NCT03586258|Other|Galvanic Vestibular Stimulation (GVS)|Stimulation versus Sham
75456813|NCT01776853|Dietary Supplement|Fructans|
76067692|NCT03579277|Procedure|Radial Forearm Free Flap|Subjects in this arm will undergo a radial forearm free flap.
76067693|NCT03579277|Procedure|Ulnar Forearm Free Flap|Subjects in this arm will undergo an ulnar forearm free flap.
75456814|NCT01776866|Procedure|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
75456815|NCT01776892|Drug|Collegenase injection|"Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent."
75456816|NCT01776892|Procedure|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
75456817|NCT01776931|Dietary Supplement|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
75754668|NCT04498611|Diagnostic Test|contrast-enhanced breast MRI|Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.
75754669|NCT03975010|Drug|Buprenorphine Transdermal Patch|"This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal."
75902374|NCT02034357|Other|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
75902375|NCT02034357|Other|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
76067694|NCT03569488|Diagnostic Test|FT-LARS questionnaire|FT-LARS questionnaire
76067695|NCT03531918|Drug|Cladribine|Given IV
76067696|NCT03531918|Drug|Cytarabine|Given IV
76067697|NCT03531918|Drug|Gemtuzumab Ozogamicin|Given IV
76067698|NCT03531918|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
76067699|NCT03531918|Other|Laboratory Biomarker Analysis|Correlative studies
76067700|NCT03531918|Drug|Mitoxantrone Hydrochloride|Given IV
75902376|NCT03608943|Other|There is no specific intervention other than an individual changing their treatment as part of their usual care|There is no specific intervention other than an individual changing their treatment as part of their usual care
75608457|NCT02791009|Other|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
75608458|NCT02790775|Drug|Anti-VEGF in quadrant 1|
75456818|NCT01776957|Device|Device: Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
75456819|NCT01776970|Drug|Cannabis Sativa extract Oromucosal spray|Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
75456820|NCT01776983|Device|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
75456821|NCT01776996|Drug|Continued Access Arm|All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
75608459|NCT02790775|Drug|Anti-VEGF in quadrant 2|
75608460|NCT02790775|Drug|Anti-VEGF in quadrant 3|
75608461|NCT02790775|Drug|Anti-VEGF in quadrant 4|
75608462|NCT04010695|Diagnostic Test|SD Biosensor G6PD Analyzer|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
75608463|NCT04010695|Diagnostic Test|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
75608464|NCT04010695|Diagnostic Test|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
75608465|NCT02790931|Other|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
75754670|NCT01050075|Other|acupuncture therapy|acupuncture therapy
75754671|NCT01050075|Other|questionnaire administration|Ancillary study
75754672|NCT01050075|Other|management of therapy complications|To be determined by the treating physician
75754673|NCT04534010|Device|NACgraft|Patients requiring reconstruction of their nipple and areola have a NACgraft surgically implanted on their breasts. A NACgraft is a novel decellularized cadaveric implant derived from human nipples.
75902377|NCT02637856|Drug|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
75754674|NCT01070134|Behavioral|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
75754675|NCT01070134|Behavioral|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
75754676|NCT01016990|Drug|valproic acid|
75754677|NCT01016990|Genetic|western blotting|
76067701|NCT03531645|Drug|Fulvestrant|"Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days."
75608466|NCT02790697|Other|Indirect calorimetry|Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
76067702|NCT03531645|Drug|Abemaciclib|"Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days."
76067703|NCT03499704|Drug|Pioglitazone + Alogliptin|Pioglitazone and Alogliptin FDC tablets
76067704|NCT03499704|Drug|Alogliptin|Alogliptin tablets.
75608467|NCT02790385|Device|Negative Pressure Wound Therapy|
75608468|NCT02790385|Other|Standard Gauze Treatment|
75608469|NCT02788435|Behavioral|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
75608470|NCT04233151|Drug|QL1203|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
76067705|NCT03499704|Drug|Metformin|Metformin tablets.
76067706|NCT03499704|Drug|Dapagliflozin|Dapagliflozin tablets.
76067707|NCT03498612|Other|Laboratory Biomarker Analysis|Correlative studies
75456822|NCT01777009|Procedure|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
75456823|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
75456824|NCT01777048|Dietary Supplement|Omega-3 Fatty Acids Supplementation|
75456825|NCT01777048|Dietary Supplement|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
75608471|NCT04233151|Drug|Placebo|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
75608472|NCT04233151|Drug|mFOLFOX6 regimen|The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m^2 on Days 1 and 5-fluorouracil 400 mg/m^2 IV bolus on day 1, then 1200 mg/m^2/dx2days(total 2400 mg/m^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
75608473|NCT04233541|Diagnostic Test|Fall assessment|Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
75754678|NCT01016990|Other|laboratory biomarker analysis|
76067708|NCT03498612|Biological|Pembrolizumab|Given IV
76067709|NCT03494660|Device|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the hip (Subchondroplasty (SCP) Procedure).
75754679|NCT01016990|Other|pharmacological study|
75754680|NCT01048047|Drug|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
75754681|NCT01011686|Biological|ANT-SM|autologous adipose-derived stem cell
75754682|NCT01324635|Drug|Panobinostat|Given PO
75754683|NCT01324635|Radiation|Stereotactic body radiation therapy|Undergo SBRT
75754684|NCT01324635|Procedure|Quality-of-life assessment|Ancillary studies
75754685|NCT01324635|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
75754686|NCT01017068|Drug|OME|4g/100ml) dose: п gutt tid x 1/52
75754687|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
75754688|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
75754689|NCT01017068|Drug|OME|(4g/100ml) dose: п gutt tid x 1/52
75754690|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
75754691|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
75754692|NCT04178564|Behavioral|Cognitive Stimulation|"The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom."
75902378|NCT02637856|Drug|Ocrelizumab|Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
75902379|NCT02858037|Combination Product|Dapivirine Vaginal Ring|Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
75608474|NCT02796703|Dietary Supplement|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
76067710|NCT03471338|Behavioral|Cognitive rehabilitation|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
75608475|NCT02796703|Dietary Supplement|Placebo|2 cc of milk will be given to control group
75608476|NCT02796547|Drug|Levobupivacaine|Infiltration of the banks of the episiotomy done with Levobupivacaine
75608477|NCT02796547|Other|Physiological serum|Infiltration of the banks of the episiotomy done with physiological serum
75608478|NCT01196988|Biological|Influenza vaccine GSK2321138A|intramuscular injections
75608479|NCT01196988|Biological|FluarixTM|intramuscular injections
75608480|NCT01196988|Biological|Influenza vaccine GSK2604409A|intramuscular injections
75608481|NCT02790541|Device|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
75608482|NCT02796469|Drug|Pentoxifylline|
75608483|NCT02796469|Drug|Corticosteroid|
75608484|NCT02796469|Drug|Placebo|
75754693|NCT04170608|Device|FARAPULSE Endocardial Multi Ablation System|Ablation using the FARAPULSE Endocardial Multi Ablation System
75754694|NCT00456846|Drug|ABI-007|100 mg/m^2 ABI-007 weekly for 3 weeks followed by 1 week rest
75754695|NCT01011764|Behavioral|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
75902380|NCT04433884|Device|Endotracheal intubation using a laryngoscope|Patients will undergo intubation using 2 different types of laryngoscopes and their hemodynamic response would be recorded
75456826|NCT01777061|Drug|[11C]Acetate|intravenous injection of an average of 40 mCi of [11C]Acetate
75456827|NCT01777074|Other|Data collection|Questionnaire, Vaccination book
75456828|NCT01777087|Other|gauze soaked with capsaicin|This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
75456829|NCT01777100|Drug|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
75608485|NCT02796157|Device|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold|Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
75608486|NCT02796157|Device|PCI with Xience everolimus-eluting metallic stent|Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
75754696|NCT03324282|Drug|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
75754697|NCT03324282|Drug|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
75902381|NCT03078088|Drug|Tham|alkalinizer
75902382|NCT03078088|Drug|Saline|Placebo
75902383|NCT05001334|Behavioral|Kangaroo care training|During perinatal period, mothers are given extra training (other than routine newborn care) about kangaroo care. Baby-mother diad is called for weight check-ups.
75456830|NCT01777113|Other|High intensity aerobic training|The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
75608487|NCT03328741|Behavioral|Online Osteoarthritis treatment|6 week online-program
76072333|NCT01419067|Procedure|Radical Surgery or Limited Surgery|Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.
75902384|NCT05011942|Device|Irrisept Irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects v. Normal saline irrigation will be used alone in control subjects at the same time points.
75608488|NCT03328741|Behavioral|Face-to-face osteoarthritis treatment|3 months face-to-face program
75608489|NCT02786797|Behavioral|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
75754698|NCT00448344|Behavioral|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
75754699|NCT00448344|Behavioral|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
75754700|NCT00484094|Drug|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
75754701|NCT01029288|Other|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
75754702|NCT01029288|Other|Statin Choice Decision Aid|Statin Choice Cards
75754703|NCT01029288|Other|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
75902385|NCT05011786|Procedure|hernia repair/ligation of the hernial sac|the inguinal hernia sac is ligated using sutures at the level of internal ring throught an inguinal incision in the open group and using laparoscopic instruments in the laparoscopic group
75754704|NCT01029288|Other|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
75754705|NCT01029444|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
75754706|NCT01024452|Device|DAWN AC|computerized dosing management system for anticoagulation clinics
75754707|NCT01024452|Device|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
75754708|NCT03995394|Other|Positive Reinforcement Text Message|"A text message comprising the words, Great job! We're so proud of you! Keep up the good work!"
75902386|NCT03077932|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
75902387|NCT05011630|Other|Pancreaticoduodenectomy|The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA
75754709|NCT01029522|Drug|Atorvastatin (Lipilou)|treatment of dyslipidemia administration : PO, qod
75754710|NCT01029522|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
75902388|NCT05011474|Biological|administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3|Adipose-derived mesenchymal stem cells isolated from subject's adipose tissue are pretreated with matrillin 3 and produced in spheroid form.
75902389|NCT03076528|Other|Sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
75902390|NCT03076528|Other|Non-technology foot and ankle exercise program|Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
75902391|NCT03077854|Radiation|Functional Lung Avoidance Thoracic Radiotherapy|"Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
75902392|NCT03077854|Radiation|Standard Thoracic Radiotherapy|"Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
75754711|NCT00447876|Biological|Botulinum toxin type A|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
75902393|NCT05005156|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)|All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
75902394|NCT05010928|Combination Product|mouthwash with tea|Using tea as a base, supplemented with licorice to make mouthwash to relieve stomatitis.
75902395|NCT05001100|Other|rehabilitation|rehabilitation
75456831|NCT01777113|Other|High Intensity Strength Training|Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
75456832|NCT01777113|Other|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
75456833|NCT01777178|Other|Low bicarbonate dialysis|
75456834|NCT01777230|Procedure|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
75754712|NCT00447876|Drug|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
75754713|NCT01029600|Procedure|Arthroscopic capsular release|Surgical division of thickened capsule in the shoulder
75902396|NCT04266340|Drug|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
75902397|NCT04266340|Drug|midazolam|0.5mg/kg oral midazolam
75902398|NCT04266340|Drug|midazolam|0.05mg/kg intravenous injection midazolam
75902399|NCT04266340|Drug|Saline|no premedication
75902400|NCT04338945|Behavioral|COVID-surgRES questionaire|The questionaire gives a multidimensional assessment of residents' impression with regard to impact of COVID emergency on Italian specialist training programs
75902401|NCT03079804|Other|Experimental MWM|Mobilization with Movement
75902402|NCT03079804|Other|Experimental Thrust|Mobilization grade 5 (Thrust)
75902403|NCT03079804|Other|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
75902404|NCT03609255|Behavioral|Reducing sedentary behavior|Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior
75902405|NCT03609255|Behavioral|Reducing stress|Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management
76067711|NCT03471338|Behavioral|Standard Psychological care|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
75608490|NCT02786797|Behavioral|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
76067712|NCT03362515|Drug|Furosemide|furosemide
75456835|NCT01777230|Procedure|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
75608491|NCT04200001|Other|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30~EORTC QLQ-BR23~EORTC SHQ-C22~CUPIDON 2 specific questionnaire"
75754714|NCT01029600|Procedure|Distention with steroid|Intraarticular distention with steroid, saline, contrast and local anaesthetic
75754715|NCT01565772|Radiation|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
75754716|NCT01565772|Drug|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
75456836|NCT01777230|Procedure|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
75456837|NCT01777243|Drug|GSK2398852|Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg [approximately equivalent to 0.1 mg/ kg]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
75754717|NCT01565772|Drug|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
75754718|NCT03995550|Drug|LEO 142397|A compound in development by LEO Pharma A/S
75754719|NCT03995550|Drug|Placebo|Placebo
76067713|NCT03362515|Drug|Placebo|placebo
76067714|NCT03339492|Device|RCStim Model 1114|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
76067715|NCT03328598|Behavioral|Positive psychology therapy group|This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.
75456838|NCT01777243|Drug|GSK2315698|Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
75608492|NCT01196052|Drug|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
75608493|NCT02689921|Drug|Exemestane|Aromatase inhibitor
75608494|NCT02689921|Drug|Letrozole|Aromatase inhibitor
75608495|NCT02689921|Drug|Anastrozole|Aromatase inhibitor
75754720|NCT00456612|Procedure|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
75754721|NCT00456300|Drug|Exenatide|In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
75754722|NCT00456300|Drug|Insulin|Each subject received a baseline study with insulin alone
75754723|NCT00267748|Drug|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
75754724|NCT00267748|Drug|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
75754725|NCT00267202|Drug|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
75754726|NCT00267202|Drug|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
75902406|NCT03609255|Behavioral|Control|An educational handout for sedentary behavior and weekly neutral topic videos
75902407|NCT03077464|Behavioral|Behavioral nutrition education|Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.
75754727|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
75754728|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
75754729|NCT01067638|Drug|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
75754730|NCT03977116|Drug|SLGT2|These patients will receive SLGT2 therapy after catheter ablation.
75754731|NCT03977116|Drug|Placebo|These patients will receive placebo therapy after catheter ablation.
75754732|NCT01067794|Drug|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
75754733|NCT00267046|Drug|Palifermin|180 mcg/kg 3 days prior to chemotherapy
75754734|NCT00267046|Drug|Placebo|Single dose 3 days prior to chemotherapy
75754735|NCT00267046|Drug|Adriamycin (Doxorubicin)|30 mg/m^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m^2).
75754736|NCT00267046|Drug|Ifosfamide|2.5 g/m^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m^2); for patients receiving the AI Regimen.
75754737|NCT00267046|Drug|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
76067716|NCT03328598|Behavioral|Resilience promotion therapy group|The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
75456839|NCT01777256|Drug|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
75456840|NCT01777256|Drug|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
75754738|NCT00267046|Drug|Cisplatin|120 mg/m^2 on day 0, for patients receiving the AP Regimen.
75754739|NCT00441090|Drug|Placebo|Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
75456841|NCT01777256|Drug|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
75456842|NCT01777256|Drug|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
75456843|NCT01777256|Drug|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
75608496|NCT02689921|Drug|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
75608497|NCT02689921|Drug|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
75608498|NCT02689921|Drug|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
75608499|NCT03116425|Device|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
75754740|NCT00441090|Drug|Avatrombopag tablets|Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
75754741|NCT03305406|Other|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
75754742|NCT03305406|Other|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
75754743|NCT00441012|Biological|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 & 12 months of age. Duration of treatment is 11 months.
75754744|NCT00441012|Biological|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
75754745|NCT01029678|Drug|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
75754746|NCT01029678|Drug|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
75754747|NCT01029678|Radiation|Radiotherapy|66Gy, 33 fractions, 6 week
75754748|NCT01323426|Procedure|Periurethral injection|Periurethral injection of autologous muscle fibers
75754749|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
76067717|NCT03328598|Other|Controlled routine activity|Conventional community activities is viewed as an active comparator for controlled group.
76067718|NCT03324477|Drug|hypertonic saline 3%|hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
75754750|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
75902408|NCT03079960|Device|Electrophysiological recording and measurement devices|Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.
75902409|NCT05000554|Procedure|Neoadjuvant Therapy|"Drug:~Camrelizumab 200mg,d1，Repeat every 21 days for 3 courses； Oxaliplatin 130mg/m² ,d1;S-1 40-60mg,Bid, d1-14; S-1: bsa<1.25m2,40mg/time，twice a day；bsa1.25~1.5m2，50mg/time，twice a day；bsa≥1.5m2,60mg/次，twice a day，d1-d14；~Procedure: Gastric cancer resection Distal gastrectomy combined with D2 lymph node dissection"
75456844|NCT01777295|Biological|Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
75456845|NCT01777295|Biological|EngerixTM-B|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
75754751|NCT00286468|Drug|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
75456846|NCT01777295|Biological|Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
75456847|NCT01777347|Drug|3% Saline|Two 4 mL nebulization of 3% saline with 20 minutes interval
75456848|NCT01777347|Drug|0.9% Normal Saline|Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
75754752|NCT00507026|Drug|IV Diclofenac|IV Diclofenac q6h
75456849|NCT01777360|Device|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
75902410|NCT02856555|Drug|Firsocostat|Capsules orally once daily.
75902411|NCT02856555|Drug|Placebo|Placebo matched to firsocostat orally once daily.
75456850|NCT01777386|Procedure|preexpanded perforator flap surgery|
75456851|NCT01777451|Other|Additional imaging or surgery|No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
75456852|NCT01777464|Biological|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
75608500|NCT03116425|Device|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
75608501|NCT03116425|Device|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
75608502|NCT03116425|Procedure|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
75754753|NCT00507026|Drug|IV ketorolac|IV ketorolac q6h
75754754|NCT00507026|Drug|Placebo|Placebo q6h
75754755|NCT00446550|Drug|afegostat tartrate|
75754756|NCT01029756|Device|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
75902412|NCT05000476|Other|eye mask and earplugs|Materials similar to those offered on long commercial flights
75902413|NCT05000476|Other|Nurse Education and Environmental Regulation|providing orientation to the patient (frequent orientation of the patient to the place, time and person), cognitive stimulation (objects such as clocks and calendars in the patient's field of view), reducing noise and light (minimizing monitors and fluid infusion pump alarms at night), providing early mobilization ( passive-active joint movements, sitting and walking in bed), reducing social deprivation (receiving visitors, telephone calls)
75902414|NCT03076450|Device|Lung Ultrasound|Adjust PEEP real-time in term of LUS-RAS chang.
75902415|NCT03076450|Diagnostic Test|Maximum Oxygenation|Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
76067719|NCT03292926|Drug|Bupivacaine|Bupivacaine will help treat pain and sensation after ACL repair
76067720|NCT03292926|Device|Ultrasound|Ultrasound will guide anesthesiologist in performing the different nerve blocks
76067721|NCT03292926|Drug|Dexamethasone|Dexamethasone will be used to prolong block duration
75456853|NCT01777464|Biological|sham|sham solution
75456854|NCT01777477|Drug|Chloroquine|Addition of Chloroquine to Gemcitabine
75456855|NCT01777477|Drug|Gemcitabine|
75456856|NCT01777503|Drug|prasugrel|prasugrel 5 mg o.d.
76067722|NCT03291392|Genetic|Gene expression or biomarkers exploration|
76067723|NCT03288324|Drug|Tofacitinib|Tofacitinib 5 mg twice daily
75902416|NCT03608787|Behavioral|S-STOP|Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.
75456857|NCT01777503|Drug|Clopidogrel|75 mg o.d.
76067724|NCT03282994|Device|Dermal Cooling System|Cryotherapy
76067725|NCT03266016|Other|Computerized Ventilator Protocol|Computerized Decision Support System which recommends changes to ventilator settings to promote physiologic levels of patient effort of breathing.
76067726|NCT03266016|Diagnostic Test|Esophageal Manometry|Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure
76067727|NCT03266016|Diagnostic Test|Respiratory Inductance Plethysmography (RIP)|RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials
76067728|NCT03266016|Diagnostic Test|Diaphragm Ultrasound|Daily measurement of diaphragm thickness and diaphragm contractile activity
75754757|NCT01029756|Device|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
75754758|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
76067729|NCT03266016|Diagnostic Test|Maximal Inspiratory Pressure|Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion
76067730|NCT03249220|Device|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
75456858|NCT01777529|Biological|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
75456859|NCT01777607|Device|IMPELLA® RP|
75456860|NCT01777633|Radiation|Palliative re-irradiation for progressive DIPG in children|
75456861|NCT01777646|Biological|MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF|
76067731|NCT03246932|Behavioral|Peer-led psycho-education group|A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
76067732|NCT03246932|Behavioral|Profession-led psycho-education group|A psychoeducation group program (12 sessions, bi-weekly).
76067733|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
76067734|NCT03245151|Drug|Lenvatinib|oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
75456862|NCT01777659|Device|Transcutaneous electrical nerve stimulation|Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
75456863|NCT01777672|Behavioral|Dietary and oral hygiene recommendations|
75456864|NCT01777672|Dietary Supplement|oral TRPV1 agonist|Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
75456865|NCT01777672|Device|pharyngeal electrical stimulation|Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.
75456866|NCT01777672|Device|transcutaneous electrical stimulation|Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
75456867|NCT01777685|Drug|Sulpiride|
75608503|NCT03116425|Procedure|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
75608504|NCT03116425|Procedure|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
76067735|NCT03245151|Drug|Everolimus|2 mg, 3 mg, or 5 mg tablets for oral suspension
76067736|NCT03216343|Drug|Chiauranib|CS2164
76067737|NCT03173534|Device|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
76067738|NCT03173534|Device|TAVR|Transcatheter Aortic Valve Replacement
76067739|NCT03127761|Other|Allogeneic Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
76067740|NCT03108443|Diagnostic Test|Optical Coherence tomography angiography|All subjects will have OCT angiography imaging performed
76067741|NCT03106376|Other|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
75754759|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
75902417|NCT03076138|Device|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
75754760|NCT01017224|Other|18F-FAZA|PET scan
75902418|NCT03077308|Procedure|Auditory and Visual Event-related Potentials and EEG|Specifically, through up to three standardized sessions (i.e., annual [every 10-14 months]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
75902419|NCT02237235|Drug|MMFS-202-302|"Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks"
75902420|NCT02237235|Drug|Placebo|Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
76067742|NCT03106376|Other|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
75902421|NCT03609099|Drug|Moxifloxacin|400 mg / day once a day oral treatment during 3 days.
75902422|NCT03609099|Drug|Placebo|once a day oral treatment during 3 days.
75902423|NCT03077230|Behavioral|Pre/Post Test of a Lung Cancer Screening Decision Aid|After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
75902424|NCT04463290|Other|No intervention, Patients selection based on clinical symptoms and radiological imaging|No intervention
75902425|NCT05004844|Diagnostic Test|Viscoelastic assays and aggregometry tests|Viscoelastic assays and aggregometry tests performed with ROTEM will allow us to characterize the clot forming abilities and platelet functions of our patients. ROTEM is used routinely for aiding clinicians in choosing the appropriate blood products for patients ROTEM requires samples of whole blood in an amount that does not entail additional burden or risk for patients. In our study, viscoelastic assays and aggregometry will be performed upon arrival, and 24-,48-,72-hours post-admission.
76067743|NCT03096275|Drug|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
75754761|NCT03847974|Drug|LIB003|300 mg SC Q4W
75754762|NCT01011842|Procedure|Radiotherapy|Standard of care
75754763|NCT01011842|Procedure|Align RT|Standard of care
75754764|NCT01011920|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
75754765|NCT01011920|Drug|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
75902426|NCT05000398|Other|Stretching the intrinsic muscles|Participants will be asked to dorsiflex the foot and stretch for 30 seconds. It will be done with 5 repetitions.
75902427|NCT05000398|Other|Thumb Abduction with MTF Joint Traction|participants will be held for 30 seconds by passively abducting the thumb within the limits of pain, and will be applied with 5 repetitions.
75902428|NCT05000398|Other|Thumb active extension exercise|An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. It will be desired to move the feet away from each other without moving the heels from the ground and the extension movement of the thumbs.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
76067744|NCT03096275|Drug|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
76067745|NCT03096275|Drug|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
76067746|NCT03096275|Drug|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
76067747|NCT03096275|Drug|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
76067748|NCT03070223|Drug|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
76067749|NCT03070223|Drug|Placebos|One tablet taken once daily, orally with or without food
76067750|NCT03012321|Drug|Olaparib|
76067751|NCT03012321|Drug|Abiraterone Acetate|
76067752|NCT03012321|Drug|Prednisone|
76067753|NCT03000101|Other|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
75754766|NCT01011920|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles
75754767|NCT01011920|Drug|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4
76067754|NCT03000101|Other|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
75902429|NCT05000398|Other|Toe spread out|In the first stage, active finger extension and abduction will be requested while the heel and metatarsal heads are in contact with the ground. In the second stage, while the other fingers are in extension, the smallest finger will be brought laterally and flexed to contact the ground. In the third stage, while in the second stage position, the thumb will be brought into abduction and flexion slowly and contact with the ground will be requested. These 3 phases will be repeated sequentially.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
75456868|NCT01777711|Behavioral|Mental Contrasting- Individual|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
75902430|NCT05000398|Other|Short foot|While standing , the medial arch will be raised by trying to bring the metatarsal heads closer to the heel . The patient will be asked to move the big toe closer to the heel without bending the toes and without lifting the heel off the ground.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
75902431|NCT05000398|Other|Heel rise|After taking a 5 cm high tape measure against the wall, the person will be asked to stand up on her heel by at least 5 cm.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
75902432|NCT05000398|Other|Towel toe curl|Patients will be asked to place their feet on the edge of the towel on the floor. An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. Next, they will be asked to grasp the towel with their fingers, flexing their toes, and forcefully dragging them under their feet.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
75902433|NCT05000398|Other|Gastrocnemius active static stretching exercise|The patient will be placed on the wall at eye level, 50 centimeters away from the wall. The leg that is desired to be stretched will be brought back, while the knee is straight, it will be requested to flex the front leg. During the test, it will be requested that the back heel does not rise from the ground and wait 30 seconds. 5 repetitions to be done
76067755|NCT02988895|Radiation|episcleral brachytherapy|The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
76067756|NCT02985593|Drug|KHK4083|
76067757|NCT02985593|Drug|Placebo|
76067758|NCT02981888|Radiation|X-Ray|X-ray of the abdomen will be performed to assess colonic transit
76067759|NCT02975895|Device|Hydrophobic IOL: Vivinex (HOYA)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
76067760|NCT02975895|Device|Hydrophilic IOL: INCISE (Bausch+Lomb)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
76067761|NCT02943525|Procedure|vaginal packing|Packing vagina with a Boric acid soaked gauze at the end of surgery
76067762|NCT02934477|Other|Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
76067763|NCT02858921|Drug|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
76067764|NCT02858921|Drug|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
75456869|NCT01777711|Behavioral|Mental Contrasting- Couple|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
75456870|NCT01777724|Behavioral|Combination of Triple P Discussion Groups and Stress Control|The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
75456871|NCT01777737|Drug|Cotrimoxazole|24 weeks of treatment
76067765|NCT02858921|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
76067766|NCT02836080|Behavioral|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
76067767|NCT02836080|Other|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
75608505|NCT02887638|Other|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:~Analysis of the sitting-posture profile:~o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~Analysis of the dural profile before and after the provoking task:~o Determination of the dural sensitivity by the use of the slump-test~Analysis of the pain profile before and after the provoking task:~Determination of pressure pain sensitivity by the use of pressure algometry~Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
75608506|NCT02786485|Biological|rivogenlecleucel|T cells transduced with iCasp safety switch
75608507|NCT02786485|Drug|Rimiducid|administered to treat GVHD
75754768|NCT01011920|Radiation|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
75754769|NCT01011920|Drug|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
75754770|NCT01011920|Other|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
75754771|NCT01017302|Drug|Placebo|Subcutenaous once weekly for 4 weeks
75754772|NCT01017302|Drug|Placebo|Single subcutaneous dose in week 5
75456872|NCT01777737|Drug|Placebo|Identical capsules to cotrimoxazole
75456873|NCT01777750|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
75456874|NCT01777815|Device|NeoChord DS1000 Artificial Chordae Delivery System|
75608508|NCT04198753|Diagnostic Test|Skin tape stripping|Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. Tape stripping will be collected from non-lesional skin up to 30 times. These discs will then be used to evaluate proteins and lipids. With every 5 tape strips collected, transepidermal water loss measurements will be performed.
75754773|NCT01017302|Drug|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
75754774|NCT01017302|Drug|RO5095932|Single subcutenaous dose in week 5
75754775|NCT01019330|Other|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
75754776|NCT01019330|Other|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
75754777|NCT03976102|Biological|DRL_RI (Proposed rituximab biosimilar)|Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion
75754778|NCT03976102|Other|MabThera®|Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion
75754779|NCT00506948|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
75754780|NCT00506948|Drug|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
75754781|NCT00506948|Drug|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
75902434|NCT05000398|Other|Plantar fascia and gastrocnemius stretching exercise on step|The patient will be asked to place both feet on the step and slowly stretch the heel downwards until a stretch is felt in the arch of the foot and wait 30 seconds. 5 repetitions will be done
75456875|NCT01777841|Other|Electronic Care plan delivery|
75456876|NCT01777841|Other|Standard care|
75608509|NCT04198753|Device|Skin barrier assessment|A small device will be used to measure transepidermal water loss (TEWL), which is the quantity of water that passes from inside the body through the skin to the surrounding atmosphere via diffusion and evaporation process. The device, a probe, is simply placed against the skin surface making superficial contact and kept there for a few seconds until the measurement terminates. This will be performed at baseline and after every 5 tape strips.
75608510|NCT04198753|Diagnostic Test|Blood draw|Subjects will undergo genetic testing of FLG mutation status (5mL of whole blood in lavender top tube) and vitamin D level (2mL of whole blood in red top tube) via blood draw.
75608511|NCT01195662|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
75754782|NCT00506948|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
75902435|NCT04925440|Dietary Supplement|Bifidobacterium longum 1714® strain|Probiotic capsules containing 5 x 10^9 CFUs, corn-starch and magnesium stearate.
75754783|NCT00286234|Drug|omega-3 acid ethyl esters|4 q qd
75754784|NCT00286234|Drug|extended release niacin|2 g qpm
75754785|NCT00286234|Drug|placebo|omacor placebo plus niaspan placebo
75754786|NCT00286234|Drug|omega-3 acid ethyl esters|4 g qd
75754787|NCT00286234|Drug|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
75754788|NCT01019408|Drug|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
75754789|NCT01067950|Procedure|Isolated Pancreas Transplant|
75754790|NCT01067950|Drug|Intensive Insulin Therapy|
75754791|NCT00445848|Biological|bevacizumab|
75754792|NCT00445848|Drug|erlotinib hydrochloride|
75754793|NCT01068028|Drug|ORM-12741|Ascending multiple doses to sequential panels
75754794|NCT01068028|Drug|Placebo for ORM-12741|
75754795|NCT00286156|Drug|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
75754796|NCT00455520|Drug|CG5503|100, 150, 200, 250 mg twice daily given for up to 15 weeks
75754797|NCT00455520|Drug|placebo|matching placebo twice daily for 12 weeks
75754798|NCT03244098|Behavioral|Transition Assistance Program|TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
75754799|NCT00440700|Behavioral|Anxiety Self-Management, Patient preferred relaxing music|Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
75754800|NCT00440700|Behavioral|Control 1: Noise-cancelling headphones|Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
75754801|NCT00440700|Behavioral|Control 2: Standard of Care|Usual ICU nursing care.
75754802|NCT01029834|Behavioral|family based lifestyle and behavioral counseling|16 group meetings
75754803|NCT01029834|Behavioral|counseling focused on the child|16 meetings
75754804|NCT00284050|Drug|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
75754805|NCT00284050|Drug|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
75456877|NCT01777867|Procedure|Cough Reflex Sensitivity|Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
75754806|NCT00284050|Drug|Sham injection|Non-treatment control for sham intravitreal injection.
75754807|NCT00293020|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
75754808|NCT00377637|Drug|Mycophenolate mofetil (MMF)|Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.
75754809|NCT00377637|Drug|Cyclophosphamide|"Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m^2. The target dose was 1.0 g/m^2, but doses were titrated by 0.25 g/m^2 increments to maintain nadir leukocyte count between 2500-4000/mm^3."
75754810|NCT00377637|Drug|Azathioprine|2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
75754811|NCT00377637|Drug|Placebo to Azathioprine|Placebo capsules matching Azathioprine taken orally once a day.
75754812|NCT00377637|Drug|Placebo to Mycophenolate mofetil|Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
75754813|NCT00377637|Drug|Corticosteroid|Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
75754814|NCT01050309|Drug|hexaminolevulinate (HAL)|Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
75754815|NCT00377403|Drug|Acetaminophen|"Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever"
75754816|NCT00377403|Drug|Amoxicillin|"Intervention drug:~Dose: 500mg tid for 10 days"
75754817|NCT00377403|Drug|Dextromethorphan hydrobromide with guaifenesin|"Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough"
75754818|NCT00377403|Drug|Guaifenesin|"Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions"
75754819|NCT00377403|Drug|Pseudoephedrine Sustained Action|"Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion"
75754820|NCT00377403|Drug|Saline spray (0.65%)|"Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion"
75902436|NCT04925440|Dietary Supplement|Placebo|Capsules containing corn-starch and magnesium stearate only.
75902437|NCT05000086|Drug|99Tc methylene diphosphonate|22mg qd，Once a day for 7 consecutive days
75754821|NCT00370149|Device|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
75754822|NCT00370149|Device|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
75754823|NCT00292942|Drug|Intravenous Artesunate|Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)
75754824|NCT00292942|Drug|Placebo|Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
75754825|NCT01068106|Device|Nobori® (Biodegradable polymer limus-eluting stents)|due randomization biodegradable polymer limus-eluting stents will be implanted
75754826|NCT01068106|Device|Xience-V® (Permanent polymer limus-eluting stent)|due randomization permanent polymer limus-eluting stent will be implanted
75754827|NCT00483938|Drug|Pegylated-interferon Alfa-2a|Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
75754828|NCT00483938|Drug|Ribavirin|Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
75456878|NCT01777867|Procedure|Methacholine Challenge|A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
75754829|NCT00370071|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
75754830|NCT00369915|Drug|Scopolamine|
75754831|NCT00369915|Drug|Scopolamine|
75754832|NCT01019564|Device|Complete Easy Rub Formula MPS|Multi-purpose solution
75754833|NCT01019564|Device|Aquify MPS|Multi-purpose solution
75754834|NCT03991845|Drug|Vit D|Vit D supplementation was done
75754835|NCT01017380|Drug|Celecoxib|celecoxib 400 mg 1 cap before surgery
75754836|NCT01017380|Drug|etoricoxib|120 mg 1 tab before surgery
75754837|NCT00369681|Drug|Bleomycin|
75754838|NCT00369681|Biological|Rituximab|
75754839|NCT00369681|Drug|Dacarbazine|
75902438|NCT03077074|Other|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
75902439|NCT05000008|Other|Exercises|Moderate aerobic and resistance exercise programe
75902440|NCT05004922|Other|Embryo transfer into upper cavity|Transfer of embryos in upper cavity
75902441|NCT05004922|Other|Embryo transfer into midcavity|Transfer of embryos in mid cavity
75456879|NCT01777893|Behavioral|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
75456880|NCT01777893|Behavioral|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
75608512|NCT01195662|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
75608513|NCT02786407|Drug|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
75608514|NCT02786407|Drug|Placebo|In these studies,patients received placebo administered to 20 injection sites
75608515|NCT03028519|Drug|Vitamin D3|Vitamin D3
75608516|NCT02786641|Drug|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
75608517|NCT02786641|Drug|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
75608518|NCT02786641|Drug|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
75608519|NCT02786641|Radiation|IMRT|IMRT for all patients
75754840|NCT00369681|Drug|Doxorubicin|
75754841|NCT00369681|Drug|Vinblastine|
75754842|NCT00266812|Drug|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
75754843|NCT00266812|Procedure|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
75754844|NCT00488774|Other|Placebo|Matching placebo for golimumab, intravenous infusion administered at Week 0
75754845|NCT00488774|Drug|Golimumab 1 mg per kg|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
75754846|NCT00488774|Drug|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
75754847|NCT00488774|Drug|Golimumab 4 mg per kg|Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
75754848|NCT00361569|Drug|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
75754849|NCT00361569|Drug|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
75754850|NCT00361569|Other|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
75754851|NCT00361569|Other|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
75754852|NCT01011998|Drug|Gleevec (imatinib), valproic acid|"Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.~Gleevec will be continued at the dose the patient was taking at the time of entry onto the study."
75754853|NCT02158377|Device|Trabecular metal dental implants (TM)|Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
75902442|NCT05010382|Procedure|Implant placement surgery|Under local anaesthesia, full-thickness mucoperiosteal flaps were elevated, the alveolar ridge measured, and a proper implant dimension (3.75 mm and 4.25 mm diameter; 8 mm, 10 mm and 11.5 mm length) and position selected. After site preparation, each patient was randomly allocated to the test or the control group. Patients in the test group received a modified implant design with the coronal third presenting a machined surface (hybrid surface (HS) group), while in the control group the same implant design with a titanium rough surface up to the implant shoulder was used (rough surface (RS) group). Implants were placed 1 mm sub-crestally. In the case of dehiscence or fenestrations around the implant, the patient was excluded from the study. Once inserted, healing abutments (ranging between 3 -5 mm) were placed, and flaps sutured around the abutments to allow for a transmucosal healing.
76067768|NCT02764476|Other|Embodied Virtual Reality Therapy|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
76067769|NCT02764476|Other|Virtual reality|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
76067770|NCT02667951|Other|A home-based caregiver-training program|A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
76067771|NCT02645149|Drug|Standard therapy or clinical trial|Patients with BRAF V600 mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
76067772|NCT02645149|Drug|Matched targeted therapy|Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.
76067773|NCT02645149|Drug|Trametinib and / or supportive care|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma for whom there is no actionable genetic aberration found on extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
76067774|NCT02645149|Drug|CDK4/6 and MEK inhibitor|"Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib."
76067775|NCT02645149|Drug|Compassionate Access Targeted Therapy|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
76067776|NCT02600429|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
75456881|NCT01777893|Behavioral|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
75608520|NCT02786641|Drug|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
75608521|NCT02787967|Drug|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
75754854|NCT02158377|Device|Tapered screw-vent implants (TSV)|Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
76067777|NCT02600429|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
76067778|NCT02588651|Drug|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
76067779|NCT02523859|Drug|Propofol|Hypnotic drug used for anesthesia
75608522|NCT02787967|Drug|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
75608523|NCT02788123|Drug|bismuth tripotassium dicitrate|oral
75608524|NCT02788123|Drug|pantoprazole|oral
75608525|NCT03631771|Drug|Iohexol|Iohexol administered intravascularly
75608526|NCT03631771|Drug|Iodixanol|Iodixanol administered intravascularly
75754855|NCT01017458|Drug|MK0773|Three 25mg oral tablets MK0773 bid, for 12 weeks
75754856|NCT01017458|Drug|Comparator: testosterone enanthate|intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
75754857|NCT01017458|Drug|Comparator: placebo oral tablet|placebo oral tablet bid, for 12 weeks
75754858|NCT01017458|Drug|Comparator: placebo injection|placebo intramuscular injection q14d, for 12 weeks
75754859|NCT02534415|Drug|Periodontal dressing material|Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
75754860|NCT02534415|Drug|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
75754861|NCT02534415|Drug|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
75754862|NCT00488618|Drug|Cariprazine (RGH-188)|Cariprazine 3 mg - 12 mg oral administration, once per day.
75902443|NCT01242267|Drug|Thalidomide+Melphalan +Bortezomib+stem cell transplant|Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
76067780|NCT02523859|Drug|Remimazolam|Benzodiazepine being developed for sedation and anesthesia.
75754863|NCT00488618|Drug|Placebo|Dose-matched placebo oral administration, once per day.
76067781|NCT02510625|Procedure|Anatomic Glenoid Reconstruction|Distal tibia bone graft
76067782|NCT02510625|Procedure|Arthroscopic bankart Repair|Arthroscopic bankart Repair
76067783|NCT02370329|Other|Laboratory Biomarker Analysis|Correlative studies
76067784|NCT02370329|Other|Quality-of-Life Assessment|Ancillary studies
75456882|NCT01777893|Behavioral|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
75456883|NCT01777919|Drug|Temozolomide|
75456884|NCT01777919|Drug|Disulfiram|
75456885|NCT01777919|Drug|Copper|
75456886|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
75456887|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
75754864|NCT01019642|Drug|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
75754865|NCT01019642|Drug|placebo|no active principles given.
76067785|NCT02370329|Biological|Ropeginterferon Alfa-2B|Given SC
76067786|NCT02229422|Drug|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
76067787|NCT02227199|Drug|Brentuximab Vedotin|Given IV
76067788|NCT02227199|Drug|Carboplatin|Given IV
76067789|NCT02227199|Drug|Etoposide|Given IV
76067790|NCT02227199|Drug|Ifosfamide|Given IV
75456888|NCT01778088|Drug|I-131-CLR1404 Injection|
75456889|NCT01778101|Drug|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
75456890|NCT01778114|Dietary Supplement|Vitamin D2 in orange juice|1000 IU dose
75456891|NCT01778114|Dietary Supplement|Vitamin D3 in orange juice|1000 IU
75456892|NCT01778114|Dietary Supplement|Vitamin D2|capsule, 1000 IU
75754866|NCT00266656|Drug|Humatrope|According to investigator's clinical practice and guided by the approved package insert
75754867|NCT00483704|Drug|Telcagepant 140 mg|Telcagepant 140 mg tablets
75754868|NCT00483704|Drug|Talcagepant 280 mg|Telcagepant 280 mg tablets
75754869|NCT00483704|Drug|Placebo|Placebo tablets
75754870|NCT00483548|Drug|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
75754871|NCT00483548|Drug|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
75754872|NCT00445770|Drug|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
75754873|NCT00445770|Drug|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
75754874|NCT00445770|Drug|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
75754875|NCT00266032|Drug|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
75754876|NCT00266032|Drug|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
75608527|NCT03631771|Drug|Iopromide|Iopromide administered intravascularly
75754877|NCT00266032|Drug|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
75754878|NCT01012076|Behavioral|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
75754879|NCT01019798|Drug|sunitinib, docetaxel, cisplatin|"Sunitinib given 10 days within 14 days of each cycle。~Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~Overall 12 cycles (24 weeks)"
75754880|NCT01012154|Device|Endomicroscope|Endomicroscopic images and biopsies are taken at several positions on the tumor.
75754881|NCT00483002|Drug|varenicline|As prescribed by physician in usual clinical practice.
75754882|NCT00482612|Drug|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
75754883|NCT00482612|Drug|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
75754884|NCT00282568|Drug|Tacrolimus Modified Release (MR)|Oral
75456893|NCT01778114|Dietary Supplement|Vitamin D3|capsule, 1000 IU
75456894|NCT01778114|Other|Placebo|Placebo
75456895|NCT01778140|Other|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
75456896|NCT01778140|Other|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
75456897|NCT01778153|Behavioral|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
75456898|NCT01778166|Drug|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
75456899|NCT01778166|Drug|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
75608528|NCT03631771|Drug|Ioversol|Ioversol administered intravascularly
75608529|NCT04317768|Behavioral|Basic oral health education and motivation|Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
75608530|NCT04317768|Behavioral|Intensive oral health education and motivation|Subjects will be educated and motivated by an intensive program consisting of verbal instructions, PowerPoint lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
75608531|NCT02787889|Other|Uneven Protein intake pattern|Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
75754885|NCT00282568|Drug|tacrolimus|Oral
75754886|NCT02532322|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
75754887|NCT02532322|Drug|normal saline|normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
75754888|NCT00265564|Behavioral|Modified Seeking Safety integrated into std outpatient SUD care|The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.
75754889|NCT00265564|Behavioral|Standard outpatient SUD care|"Patients assigned to standard care meet twice weekly in Recovery 1 groups, which focuses on building abstinence."
75754890|NCT01068184|Drug|AZD6553|Single or multiple oral dose
75902444|NCT03076294|Device|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
75902445|NCT03076294|Other|Manual therapy (MT)|This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
76067791|NCT02227199|Other|Laboratory Biomarker Analysis|Correlative studies
76067792|NCT02158793|Procedure|Craniomaxillofacial allotransplantation|Transplantation of donor face
75456900|NCT01778192|Drug|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
75608532|NCT02787889|Other|Even Protein Intake Pattern|Each participant will consume 33% of total protein consumed each meal
75456901|NCT01778192|Drug|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
75456902|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
75456903|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
75456904|NCT01778205|Other|Observational|
75608533|NCT04232995|Other|Balance Training|Balance enhancing exercises
75608534|NCT04232995|Other|General Exercises|General Exercises
75608535|NCT02796235|Other|Venous Doppler ultrasound of the lower limbs|Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
75608536|NCT02787733|Dietary Supplement|Citrus flavonoid|Daily dose of 500mg divided over two capsules
75608537|NCT02787733|Dietary Supplement|Placebo|Daily dose of 500mg divided over two capsules
75608538|NCT02787577|Behavioral|Sleep Lengthening|Behaviour change techniques targeting sleep hygiene
75608539|NCT01195272|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
75902446|NCT05004610|Drug|Sodium Lactate Solution|continuous intravenous infusion of half-molar sodium lactate
75608540|NCT02796079|Biological|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
75608541|NCT02796079|Biological|saline|saline injections
75608542|NCT01194804|Drug|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
75608543|NCT02785627|Other|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
75608544|NCT04232605|Other|GLP-1 peptide|Receive intravenous infusion of GLP-1. The dosage will be determined after a dose finding pilot study.
75754891|NCT01068184|Drug|Placebo|single or multiple oral dose
75754892|NCT00376623|Drug|BI 2536|Intravenous Infusion
75754893|NCT01027104|Other|Education|Firearm injury prevention anticipatory guidance curriculum
76067793|NCT02087865|Drug|donepezil HCL|
76067794|NCT02087865|Drug|Placebo|
76067795|NCT01980823|Drug|Metformin|"Metformin is an oral diabetes medicine that helps control blood sugar levels.~Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening~Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes."
76067796|NCT01980823|Drug|Atorvastatin|"Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).~Dosage/Frequency: 80 mg once a day at bedtime~Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors."
75754894|NCT01029990|Other|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
76067797|NCT01980823|Procedure|Breast surgery|(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
75608545|NCT04232605|Other|Placebo|Receive intravenous infusion saline
75608546|NCT00638053|Genetic|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
76067798|NCT01972347|Drug|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
76067799|NCT01972347|Drug|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
75608547|NCT02787421|Device|Breathe-Rite Nasal Dilator Strip|During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
75754895|NCT01029990|Other|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
75754896|NCT00445692|Drug|Clarithromycin|Given Orally (PO)
75754897|NCT00445692|Drug|Dexamethasone|Given PO
75754898|NCT00445692|Drug|Lenalidomide|Given Orally (PO)
75754899|NCT01024842|Biological|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu at week 0, 4 and 12.
75456905|NCT01778218|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
75456906|NCT01778231|Dietary Supplement|Nutrof Total|Antioxidant and trace element supplement
75456907|NCT01778231|Dietary Supplement|Placebo|
75456908|NCT01778244|Drug|metformin|1000mg/day for 24 weeks
75456909|NCT01778257|Dietary Supplement|Mate extract|Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.
75754900|NCT01024842|Other|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
75754901|NCT01024842|Biological|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu at week 0, 4 and 12.
75754902|NCT01024842|Other|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
75754903|NCT03824236|Biological|RTS,S/AS01E (SB257049)|Subjects from the P-Fx and NP-Fx groups will receive one Fx booster dose of RTS,S/AS01E at Day 1.
75754904|NCT00282412|Biological|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
75754905|NCT00282412|Drug|Fludarabine|inhibits DNA synthesis or repair
75754906|NCT00282412|Drug|Cyclophosphamide|Causes prevention of cell division by forming adducts with DNA
75754907|NCT00282412|Drug|Campath 1H|humanized monoclonal antibody against CD52 antigen
75754908|NCT00282412|Drug|GCSF|Hematopoietic growth factor
75754909|NCT00282412|Drug|Cyclosporins|immune suppressive drug
75754910|NCT00282412|Drug|Mycophenolate Mofetil|immune suppressive drug
76067800|NCT01942616|Other|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
76067801|NCT01942616|Other|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
75754911|NCT03976726|Device|Comparison of physcial parameters|Increasement of weight, volume expansion and decrease of density are measured.
75902447|NCT03608553|Device|MR Guided Focused Ultrasound|Blood Brain Barrier Disruption using FUS
75902448|NCT01741480|Other|Early warning system monitoring.|General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system monitoring developed at Washington University.
75902449|NCT01741480|Other|routine care|
75902450|NCT03608085|Behavioral|Pharmacist Heart failure MTM training|"The MTM training for pharmacists will consist of:~Online material for home self-study (10 contact hours);~Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~Monthly coaching conference calls/webinars with URI and Brown Faculty;"
76067802|NCT01942616|Other|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
75754912|NCT00282334|Device|Telemedical blood pressure monitoring|Measurement of home blood pressure, three times per week for three months and once a week for three months.
75902451|NCT03608085|Behavioral|Patient Heart failure MTM intervention|"The baseline visit will take place >= 7 but <= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers."
75902452|NCT04994158|Combination Product|Drugs, procedures|standard of care only. non interventional registry.
75902453|NCT05004766|Other|Robot assisted gait training with virtual reality|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
75902454|NCT04066413|Other|Standard infant formula|Standard infant formula
75902455|NCT04066413|Other|Infant formula supplemented with HMO|Infant formula supplemented with HMO
75902456|NCT02637232|Other|Mirvaso® / Onreltea TM|
75902457|NCT02715375|Device|CREON2000A|
75456910|NCT01778257|Dietary Supplement|Placebo|Amount and calorie of placebo are same with Mate extracts.
75456911|NCT01778270|Device|Body Bioimpedance Sensor|
75456912|NCT01778283|Biological|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
75456913|NCT01778309|Dietary Supplement|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise"
75456914|NCT01778335|Procedure|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
75608548|NCT03560635|Behavioral|Weight Loss Maintenance (Control vs. Reverse Diet)|Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
75608549|NCT02771353|Radiation|WT_vDIBH|
75754913|NCT00282256|Drug|tacrolimus modified release (MR)|Oral
75608550|NCT02771353|Radiation|VMAT_FB|
75608551|NCT02785861|Behavioral|supervision of physical activity|
75608552|NCT02785861|Behavioral|distance supervised physical activity|
75754914|NCT00282256|Drug|tacrolimus|Oral
75754915|NCT00265330|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
75754916|NCT00292318|Behavioral|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
75902458|NCT04993690|Drug|LP-168 tablet|Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily
75902459|NCT02855541|Device|DeskCycle|A small cycling ergometer that can fit under a desk at the workplace.
76067803|NCT01889992|Radiation|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short & long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 >/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
75902460|NCT02635984|Drug|Olanzapine|Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
75902461|NCT02635984|Drug|Placebo|Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
75902462|NCT03608319|Drug|A4250|9.6 mg
75754917|NCT00292318|Behavioral|control group|Medical counseling and ano-sphinctal exercises.
75754918|NCT00281632|Drug|GW786034|800 mg GW786034 administered orally on a daily basis.
75754919|NCT00543569|Drug|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
75754920|NCT00543569|Drug|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
75754921|NCT00543569|Drug|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
75754922|NCT00543569|Drug|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
75754923|NCT00543569|Drug|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
75754924|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
75754925|NCT01068574|Other|BASIC Score (Observational)|The BASIC Score will be assessed by a study staff, but there are no interventions.
75754926|NCT00984191|Radiation|99mTc-MIBI SPECT-CT|99mTc-MIBI SPECT-CT for abnormal cervical lymph node
75754927|NCT04773821|Other|Targeted biopsies|Prostate MpMRI at 12 month (after PCa focal treatment in standard care) and targeted biopsies in the presence of lesion(s) suggestive(s) of recurrence
75754928|NCT00984347|Drug|Oxytocin|"For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas [6th delivery and up] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol"
75754929|NCT00984347|Procedure|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
75754930|NCT00984425|Drug|Lapatinib and Sorafenib|Comparison of different dosages of two drug
75754931|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
75902463|NCT03076216|Device|OncoSil™|The implantation of OncoSil™ under EUS
75456915|NCT01778348|Device|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
75456916|NCT01778348|Device|Real-time CGM alone|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
75456917|NCT01778374|Other|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
75456918|NCT01778374|Other|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
75456919|NCT01778387|Procedure|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
75608553|NCT02786017|Biological|Conventional therapy|Patients will receive the conventional therapy.
75608554|NCT02786017|Biological|Injectable Collagen Scaffold + HUC-MSCs|Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5*10^8.
75608555|NCT02785549|Drug|Ibuprofen|600 mg/8hours
75608556|NCT02785549|Drug|Acetaminophen|1 g/8 hours
75754932|NCT00984503|Drug|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
75902464|NCT03076918|Device|FLEXITHERALIGHT PDT|Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
75902465|NCT03076918|Device|Aktilite® Galderma|Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
75902466|NCT03076372|Drug|MM-310|MM-310
75902467|NCT03076060|Behavioral|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD."
76067804|NCT01889992|Procedure|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
75608557|NCT02785549|Drug|Amoxicillin/clavulanic acid|875mg/125mg/8 hours
75608558|NCT02720653|Procedure|Endoscopic sinus surgery|
75608559|NCT03429829|Device|Flairesse varnish|"Flairesse is applied to enamel and dentine as protective varnish to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.~During the application, children sat upright; their teeth were first cleaned and dried with cotton wool rolls. After mixing the fluoride varnish, it was applied as a thin layer to all surfaces of the lower and upper dentition, including proximal surfaces (using floss in case of tight contact points) as well as pits and fissures (using a small brush that was provided together with the varnish by the manufacturer). Children were advised not to drink or eat directly after the application, while this could not be controlled."
75754933|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
75754934|NCT00984503|Drug|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
75608560|NCT02785705|Biological|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
75902468|NCT03076060|Behavioral|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD."
75902469|NCT03073408|Drug|Propofol|Closed loop control for propofol administration guided by the BIS.
76067805|NCT01889992|Other|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
76067806|NCT01889992|Drug|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels."
76067807|NCT01889992|Procedure|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
75608561|NCT02785783|Device|Standard colonoscopy|
75608562|NCT02785783|Device|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
75456920|NCT01778400|Procedure|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
75456921|NCT01778400|Procedure|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
75456922|NCT01778413|Drug|ATRIPLA|
75754935|NCT05596955|Drug|Buprenorphine injection|Extended release once-a-month buprenorphine injection . Study arm undergoes 2 fMRI examinations and weekly monitoring visits
75754936|NCT05596955|Drug|Naltrexone Injection|Extended release once-a-month naltrexone injection. Study arm undergoes 2 fMRI examinations and weekly monitoring visits
75754937|NCT00445458|Drug|HKI-272|
75754938|NCT00445458|Drug|Paclitaxel|
75754939|NCT00986063|Genetic|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
75754940|NCT00986063|Other|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
75754941|NCT01030068|Behavioral|Yoga|Yoga twice weekly
75456923|NCT01778439|Drug|OMP-52M51|
75456924|NCT01778452|Procedure|endometrial biopsy|endometrial biopsy
75754942|NCT01030068|Behavioral|Wellness|Health and wellness classes twice weekly
75754943|NCT01030068|Other|Smoking cessation therapy|Smoking cessation therapy
75456925|NCT01778517|Other|Group Psychotherapy|
75456926|NCT01778517|Other|Cognitive behavior therapy based on self help|
75754944|NCT03914417|Drug|Imiquimod 3.75% Cream|Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
75754945|NCT00988871|Device|PICC, CICC|PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
75754946|NCT00986141|Procedure|Surgery|Selective Laser Trabeculoplasty for glaucoma
75754947|NCT00986141|Procedure|Selective Laser Trabeculoplasty|Glaucoma Treatment
75456927|NCT01778621|Device|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
75456928|NCT01778660|Other|Type of Counselling (Mnemonic)|
75754948|NCT05586113|Drug|10-day Tegoprazan bismuth-containing quadruple therapy|10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
75754949|NCT00986297|Radiation|hypofractionated radiation therapy|hypofractionated radiation therapy
75902470|NCT03073408|Drug|Propofol|Manual control group: Propofol administration adjusted manually.
76067808|NCT01889992|Genetic|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
75608563|NCT02821507|Drug|sirolimus and cyclophosphamide|
75754950|NCT00541385|Drug|pyronaridine artesunate|The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
75754951|NCT00541385|Drug|arthemeter lumefantrine|The strength of the tablet is 20 mg artemether and 120 mg lumefantrine. Depending on their body weight, patients will receive either 1 or 2 crushed tablets twice a day (≥5 to <15 = 1 tablet, 15 to <25 kg = 2 tablets), for 3 consecutive days.
76067809|NCT01889992|Other|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
76067810|NCT01858740|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
76067811|NCT01858740|Drug|Fludarabine Phosphate|Given IV
75456929|NCT01778660|Other|Standard|
75754952|NCT00988949|Drug|PF-04455242|Single oral 18 mg dose of PF-04455242.
75754953|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
75754954|NCT00988949|Other|Placebo|Oral placebo.
75456930|NCT01778673|Procedure|Cast immobilization|
75456931|NCT01778686|Drug|Citalopram and Pindolol|"Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"
75754955|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
75754956|NCT00988949|Drug|PF-04455242|Single 30 mg oral dose of PF-04455242.
76067812|NCT01858740|Other|Laboratory Biomarker Analysis|Correlative studies
76067813|NCT01858740|Drug|Methotrexate|Given IV
76067814|NCT01858740|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
75456932|NCT01778686|Other|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
75456933|NCT01778686|Dietary Supplement|Acute tryptophan depletion|
75608564|NCT02787265|Device|spinal cord stimulation|
75608565|NCT02785393|Drug|Sugar Pill|The administration of a sugar pill
75608566|NCT02785393|Drug|Doxazosin|The administration of the Doxazosin medication
75608567|NCT02787109|Biological|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
75608568|NCT02787109|Biological|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
75608569|NCT02787109|Biological|Placebo|Saline
75608570|NCT03427255|Behavioral|CBT group treatment-plus|The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
75608571|NCT03427255|Other|Waiting-list control condition|Waiting-list control condition during length of active treatment (6 months).
75754957|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
75754958|NCT04760951|Dietary Supplement|TOTUM-070|5-g dose of TOTUM-070 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes
75902471|NCT04993222|Drug|Amphotericin B liposome for injection|IV infusion
75902472|NCT04993222|Drug|AmBisome®|IV infusion
75902473|NCT01147653|Biological|Autologous UCB Reinfusion|Autologous umbilical cord blood (UCB) reinfusion
75902474|NCT01147653|Other|Placebo|Placebo
76067815|NCT01858740|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
76067816|NCT01858740|Drug|Tacrolimus|Given IV or PO
76067817|NCT01858740|Drug|Thiotepa|Given IV
76067818|NCT01858740|Radiation|Total-Body Irradiation|Undergo TBI
76067819|NCT01839734|Drug|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
76067820|NCT01682083|Drug|Dabrafenib|Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
75456934|NCT01778699|Dietary Supplement|lozenges|"The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.~The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study)."
75754959|NCT04760951|Dietary Supplement|Placebo|Placebo. Eight capsules per day to consume orally in two intakes
75754960|NCT00989027|Drug|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
75754961|NCT00989027|Drug|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
75456935|NCT01778712|Behavioral|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
75754962|NCT00989027|Drug|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
75754963|NCT00989027|Drug|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
75754964|NCT00989027|Drug|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
75754965|NCT00265096|Biological|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
75754966|NCT00265096|Biological|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
75754967|NCT00265096|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
75754968|NCT00986375|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
75754969|NCT00986375|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
75754970|NCT00986531|Drug|AZD8529|2 capsules by mouth for 3 days
75754971|NCT00986531|Drug|Placebo to match AZD8529|2 capsules by mouth for 3 days
75754972|NCT05529329|Procedure|overlay|Lithium Disilicate partial coverage of hypo-mineralized defected enamel
75754973|NCT00989105|Other|immunohistochemistry staining method|
75754974|NCT00989105|Other|laboratory biomarker analysis|
75754975|NCT00989105|Other|pharmacological study|
75754976|NCT00989105|Procedure|computed tomography|
75754977|NCT00989105|Procedure|magnetic resonance imaging|
75754978|NCT00989105|Procedure|single photon emission computed tomography|
75754979|NCT00989105|Radiation|technetium Tc 99m demobesin-4|
75456936|NCT01778790|Device|Deep Brain Stimulation with Activa PC Multi-program Neurostimulator|"Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude"
75754980|NCT01068808|Procedure|skin prick test|skin prick test to aeroallergen
75754981|NCT00986609|Biological|MUC-1 peptide vaccine|Given subcutaneously
75754982|NCT00986609|Biological|poly ICLC|Given intramuscularly
75754983|NCT00986609|Biological|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
75754984|NCT00986609|Other|laboratory biomarker analysis|Correlative studies
75754985|NCT00986609|Other|enzyme-linked immunosorbent assay|Correlative studies
75754986|NCT00986609|Other|flow cytometry|Correlative studies
75754987|NCT00989183|Other|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
75754988|NCT00281320|Drug|Asenapine|Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
75754989|NCT00541307|Device|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
75754990|NCT01068886|Procedure|External pancreatic stent|stent through pancreatic anastomosis
75754991|NCT05502965|Other|dietary pattern|Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.
75754992|NCT05502965|Other|EEN|All energy and nutrients are obtained from exclusive enteral nutrition.
75754993|NCT03975556|Behavioral|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
75754994|NCT03975556|Behavioral|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate dietary recommendations
75754995|NCT05499689|Drug|Bupivacaine Hydrochloride|2.5 cc bupivacain injection will be administered by approaching the greater occipital nerve under ultrasound guidance.
75754996|NCT05499689|Other|Transcutaneous pulsed radiofrequency qurrent|Pulsed radiofrequency current will be applied through transcutaneous pads adhered over the greater occipital nerve trace on the nape.
75902475|NCT04993378|Device|EV-array|"Collect peripheral blood sample of 40 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect EV-score by EV-array. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
75754997|NCT01017614|Drug|Monofer|"administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained"
75754998|NCT01017614|Drug|Iron Sulphate|200 mg daily
75754999|NCT01012232|Drug|20 mL ropivacaine 5 mg/mL|
75456937|NCT01778803|Drug|defactinib|
75456938|NCT01778803|Drug|Paclitaxel|
75608572|NCT04232527|Diagnostic Test|Y Balance Test|The footballer will place one foot on the stationary platform of the test set during the test so that the top of the sneaker does not exceed the starting line. The second foot, or the tip of the foot, will push the movable part of the platform down the measuring tube, which is marked by half-inch intervals. Any lifting of the standing leg on the heel, on the toes or loss of balance will be considered a mistake and the attempt will be repeated. Mobility will be tested through 3 trial and 3 valid measurements of the lower limbs in the anterior, posteromedial, and posterolateral directions. The arms should rest on the hips.
75755000|NCT01012232|Drug|10 mL ropivacaine 10 mg/mL|
75755001|NCT03976570|Behavioral|Occupational Therapy|Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
75755002|NCT01017692|Procedure|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
75456939|NCT01778829|Procedure|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
75755003|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
75755004|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
75755005|NCT00541229|Drug|Comparator: Placebo|sitagliptin 100 mg & 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
75755006|NCT04006691|Drug|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
75755007|NCT00481988|Device|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
75456940|NCT01778829|Procedure|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
75456941|NCT01778842|Drug|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
75456942|NCT01778842|Drug|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
75456943|NCT01778881|Other|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
75456944|NCT01778881|Other|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
75456945|NCT01778881|Other|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
75755008|NCT00481988|Device|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
75902476|NCT04065087|Biological|GX-I7|Investigational drug
75902477|NCT04065087|Other|Placebo|Placebo drug
76067821|NCT01682083|Drug|Trametinib|Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
76067822|NCT01682083|Drug|Placebos|The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
75755009|NCT00481988|Device|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
75755010|NCT00481988|Device|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
75755011|NCT00986765|Drug|Lovenox® (enoxaparin)|Injectable solution 4000 UI
75755012|NCT00986765|Drug|Aspegic ® (Aspirin)|100 mg/day
75755013|NCT00986843|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
75902478|NCT03076762|Drug|intravesical onabotulinumtoxinA injection|Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
75902479|NCT03073252|Other|Normal Protein|Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl
75902480|NCT03073252|Other|HIgh Protein|Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl
75902481|NCT04993456|Procedure|Caridac surgery|Cardiac surgery
75755014|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
75755015|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
76067823|NCT01511068|Drug|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
76067824|NCT01437969|Genetic|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
76067825|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
75755016|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
75755017|NCT01012310|Drug|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
76067826|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
75755018|NCT04118270|Device|Afib 2gether TM Mobile Application|The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.
75755019|NCT01019876|Drug|Fludarabine|Fludarabine/Busulfan/Alemtuzumab
75755020|NCT01019876|Drug|Cyclophosphamide|Cyclophosphamide/Fludarabine/TMG
75456946|NCT01778881|Other|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
75456947|NCT01778907|Other|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
75755021|NCT01019876|Drug|Cyclophosphamide 40|Cyclophosphamide/Fludarabine/ATG/TBI
75755022|NCT01019876|Drug|Cyclophosphamide 30|Cyclophosphamide /Fludarabine/TMG
75755023|NCT01017770|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
75755024|NCT01017770|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
75755025|NCT00493142|Other|Exercise|
75755026|NCT00493142|Other|Usual care|
75755027|NCT04006535|Genetic|genetic analysis|Saliva sample collection for genetic analysis
75755028|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
75755029|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
75902482|NCT02747043|Biological|ABP 798|ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
75902483|NCT02747043|Biological|Rituximab|Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
75902484|NCT03075514|Other|MKD|Modified ketogenic diet
75902485|NCT03075514|Other|MCT|Medium chain triglyceride ketogenic diet
76067827|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
76067828|NCT01180790|Drug|Placebo|Powder in capsule once daily
75456948|NCT01778920|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
75456949|NCT01778933|Drug|EC17|
75456950|NCT01778959|Device|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
76067829|NCT01180790|Drug|Pegylated Interferon alpha-2a|180 micrograms (ug) once a week by subcutaneous injection
76067830|NCT01180790|Drug|Ribavirin|400 mg or 600 mg (morning [AM]) and 600 mg (evening [PM]) capsules taken orally twice daily
76067831|NCT00950001|Radiation|Stereotactic Radiosurgery|Undergo SRS
76067832|NCT00798122|Procedure|Intravascular ultrasound|intravascular ultrasound
75456951|NCT01778959|Device|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
75608573|NCT04232527|Diagnostic Test|Sit and Reach Test|This test involves sitting on the floor with your legs stretched straight forward. Shoes should be removed. The feet themselves are set straight against the box. Both knees must be stretched. With the palms facing down and the palms side-by-side or side-by-side, the subject approaches the measurement line as far as possible. It is important to keep your hands in the same position level, not that one reaches further than the other. Once the subject has reached the maximum distance, hold this position for one to two seconds and record the distance.
75608574|NCT04232527|Diagnostic Test|"Maximum Legs Abduction Test"|Seated legs abduction is a test to assess the flexibility of the groin region. Respondent without the shoe sits with its back and head resting against the wall. As a sign, the subject extends the legs (stretches) to the maximum extent. During the test, the legs should not be bent at the knee joint.
76067833|NCT00798122|Procedure|MRI|cardiac MRI
76067834|NCT00792675|Other|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
75608575|NCT04232527|Diagnostic Test|"S_RAG (reactive agility) Test"|The test consist of fast-moving forward, and a change of direction conditioned by visual stimuli.
75608576|NCT04232527|Diagnostic Test|S_CODS (change of direction speed) Test|S_CODS (change of direction speed) is a test that allows athletes to outperform their opponents in situations where they can pre-define a movement pattern.
75608577|NCT02787031|Procedure|Neuraxial anesthesia|
75608578|NCT02787031|Procedure|General anesthesia|
75608579|NCT03398395|Procedure|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
75608580|NCT03398395|Procedure|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
75608581|NCT02784301|Device|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
75755030|NCT04005911|Device|Themography|Using a FLIR camera, a thermographic recording will be taken of the patient while breathing. Simultaneously, the research investigator will record the thoracic impedance-based respiratory rate as well as manually count respirations in one minute.
75755031|NCT00481832|Drug|Cyclophosphamide|4 gm /m² IV over 2 hours on day 8
75902486|NCT05004142|Drug|FCN-437c+Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
76067835|NCT00721526|Drug|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
76067836|NCT00679042|Biological|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
76067837|NCT00505063|Biological|Immunization Schedule patients <7 years.|"Time 0 months: Prevnar 13 #1, Hib #1~Time 1 months: Pediarix #1~Time 2 months: Prevnar 13 #2, Hib #2~Time 3-4 months: Pediarix #2~Time 4-6 months: Draw post vaccine titers~Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
75456952|NCT01778959|Device|standard OVD|use of a standard cohesive OVD during cataract surgery
75456953|NCT01778959|Device|OVD|use of a highly cohesive OVD during cataract surgery
75456954|NCT01778972|Other|Otago home exercise programme|"Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
75456955|NCT01778972|Other|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
75608582|NCT02784301|Behavioral|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
75755032|NCT00481832|Drug|BCNU|"The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
75755033|NCT00481832|Drug|Etoposide|60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².
75755034|NCT00481832|Drug|Filgrastim|10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis
75755035|NCT00481832|Drug|Antithymocyte globulin|1.5 mg/kg/d, IV from day -11 to -7
75755036|NCT00481832|Drug|Cyclosporine|5mg/kgbid,variable, po or IV
75755037|NCT00481832|Drug|Mycophenolate mofetil|15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.
75755038|NCT00481832|Drug|Rituximab|375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..
75755039|NCT00481832|Procedure|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
76067838|NCT00505063|Biological|Immunization Schedule patients > or = to 7 years and <11 years of age|"Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1~Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2~Time 2-3 months: Prevnar 13 #2, Hib #2~Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
75456956|NCT01778998|Procedure|MICS-group|Micro incision cataract surgery is done
75456957|NCT01778998|Procedure|SICS-group|small incision cataract surgery is done
75608583|NCT02784301|Behavioral|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
75755040|NCT00481832|Procedure|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
75755041|NCT00481832|Procedure|Total lymphoid irradiation|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
75755042|NCT00481832|Drug|CD34+ Cells|2 x 10e6 CD34+ cells per kg actual body weight on Day 0
75456958|NCT01778998|Procedure|SICS pre-cut|Small incision cataract surgery with pre-cut is done
75456959|NCT01778998|Procedure|SICS stab-incision|Small incision cataract surgery with stab-incision is done
75456960|NCT01779063|Behavioral|web based multimedia intervention|cognitive therapy based web intervention
75456961|NCT01779063|Other|educational booklet|patient education booklet
75456962|NCT01779076|Procedure|30% oxygen|
75456963|NCT01779076|Procedure|100% oxygen|
75456964|NCT01779089|Drug|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
75456965|NCT01779089|Drug|placebo|
75456966|NCT01779102|Biological|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
75456967|NCT01779102|Biological|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
75456968|NCT01779102|Biological|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
75608584|NCT02784223|Device|Radiation : PET-CT with F18-choline examination|PET-CT with F18-choline examination will be performed before surgery
75608585|NCT05262751|Drug|Ofev®|Ofev®
75608586|NCT05262751|Drug|Nintedanib formulation 1|Nintedanib formulation 1
75608587|NCT05262751|Drug|Nintedanib formulation 2|Nintedanib formulation 2
75608588|NCT02785315|Behavioral|rehabilitation & remediation approach|The rehabilitation & remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
75755043|NCT00481832|Drug|Solu-Medrol|1 mg/kg, Day-11 to Day-7
75755044|NCT00987077|Device|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
75755045|NCT05407415|Other|Kardia Mobile 6L Device|"The KardiaAL is a software analysis library intended to assess ambulatory electrocardiogram (ECG) rhythms from adult subjects. The device supports analyzing data recorded in compatible fonnats from any ambulatory ECG devices such as event recorders, or other similar devices. The library is intended to be integrated into other device software. The library is not intended for use in life supporting, or sustaining systems, or ECG monitors, or cardiac alarm, or OTC use only devices.~The KardiaAI library provides the following capabilities:~ECG noise filtering,~heart rate measurement from ECGs,~detection of noisy ECGs, and~ECG rhythm analysis for detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia (when prescribed or used under the care of a physician)."
75755046|NCT04006067|Other|changing surgical gloves|All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
75755047|NCT00481676|Drug|Omalizumab 75-375 mg|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
75755048|NCT00481676|Drug|Placebo to omalizumab|Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
75755049|NCT00481676|Drug|Loratadine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
75755050|NCT00481676|Drug|Clemastine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
75755051|NCT00987155|Device|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
75755052|NCT04004975|Drug|Anlotinib|Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
76067839|NCT00505063|Biological|Immunization Schedule patients > or = to 11 years of age|"Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1~Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2~Time 2-3 months: Hib #2, Prevnar 13#2, Menactra~Time 3-6 months: IPV, Draw post vaccine titers~Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)"
75902487|NCT05004142|Drug|FCN-437c+Letrozole+Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
75902488|NCT03076684|Other|low-fructose diet|Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
75902489|NCT03076684|Drug|Allopurinol|Subjects in the drug arm will take the drug allopurinol daily.
75902490|NCT02034903|Other|Feedings warmed with commercial warmer|
75902491|NCT04999930|Device|Aerochamber|efficacy and patients satisfaction
75902492|NCT03607851|Drug|Lacosamide - conventional titration|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
76067840|NCT00350272|Drug|Elvucitabine|Elvucitabine 10 mg orally daily
75456969|NCT01779128|Procedure|PET-CT|
75902493|NCT03607851|Drug|Lacosamide - rapid titration 1|Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
75902494|NCT03607851|Drug|Lacosamide - rapid titration 2|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
75456970|NCT01779128|Procedure|MR-PET|
75608589|NCT02785315|Behavioral|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
75608590|NCT02785237|Device|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
75608591|NCT02785237|Device|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
75608592|NCT04231123|Procedure|PENG Block with local anesthetic|After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
75755053|NCT04086992|Other|Remote monitoring|Caregivers will be able to monitor blood pressure from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
75755054|NCT05318729|Device|Vibration tool|Therapeutic mini massager for scar management, desensitization, muscle stimulation, oral stimulation and sensory re-education. Seek pain relief for sore achy muscles, tendons or bones.
75755055|NCT01020032|Other|"Individual receptive music therapy by U sequence method"|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
75755056|NCT05712473|Diagnostic Test|PYLARIFY|PYLARIFY PET
75755057|NCT03976804|Other|low dose CT scan|Lung cancer screening will be based on the analysis of a low dose CT scan
75755058|NCT03976804|Other|blood sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
75755059|NCT03976804|Other|faecal sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
75755060|NCT01022372|Procedure|Endometrial biopsy|For all the groups
76067841|NCT00350272|Drug|Lamivudine|Lamivudine 300 mg orally daily
76067842|NCT00350272|Drug|Tenofovir|Tenofovir open-label 300 mg orally daily
75608593|NCT04231123|Procedure|PENG Block with 0,9% saline|After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
75608594|NCT04231279|Drug|synthetic human secretin|Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
75608595|NCT02782585|Other|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
75755061|NCT03727919|Behavioral|Exoskeleton-assisted gait training|In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.
75755062|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
75755063|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
75902495|NCT04999540|Drug|Tucidinostat|30 mg, administered orally twice per week (BIW)
76067843|NCT00350272|Drug|Efavirenz|Efavirenze open-label 600 mg orally daily
76067844|NCT00349011|Procedure|Personalized risk assessment|
76067845|NCT00349011|Procedure|genetic counseling intervention|
76067846|NCT02028884|Drug|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
75755064|NCT00987233|Drug|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
75755065|NCT04006301|Drug|JNJ-74699157|Participants will receive JNJ-74699157 orally.
75755066|NCT04715867|Drug|Rabix-VC|Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
75755067|NCT04004897|Diagnostic Test|Optic nerve sheath diameter measurement|Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.
75755068|NCT04377503|Drug|Tocilizumab 180 MG/ML|Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.
75755069|NCT04377503|Drug|Methylprednisolone Sodium Succinate|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
75755070|NCT00987311|Dietary Supplement|1- Dairy drink containing probiotics A|1- Dairy drink containing probiotics A
75755071|NCT00987311|Dietary Supplement|2- Dairy drink containing probiotics B|2- Dairy drink containing probiotics B
75755072|NCT00987311|Dietary Supplement|3- Dairy drink without probiotics (control)|3- Dairy drink without probiotics (control)
75755073|NCT00542789|Drug|Esomeprazole|20mg once daily oral
75902496|NCT04999540|Drug|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
75902497|NCT03607773|Behavioral|Mindfulness Behavioural Intervention (MBI) group|While every MBI session is different, in general they will help you develop skills in focused attention, and emotional and behavioural regulation in a group environment made up of other people with MS who may share common experiences with you. MBI sessions are group-based which means you will be attending the sessions with other people who are also in this study and facilitated by trained personnel .
75608596|NCT02782585|Other|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
75608597|NCT02782585|Other|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
75608598|NCT02605759|Device|CryoBalloon Focal Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
75755074|NCT00542789|Drug|Placebo|once daily oral
75755075|NCT00464672|Biological|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
75755076|NCT00464672|Biological|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
75902498|NCT03608007|Drug|X-396 Capsule|225 mg once daily
75902499|NCT02637076|Drug|Xyrem|single 3.0 gram dose
75902500|NCT02034669|Device|Laminectomy|surgical laminectomy with glial scar resection
75456971|NCT01779193|Dietary Supplement|lactic acid bacteria|oral lactobacillus capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
75456972|NCT01779193|Dietary Supplement|cranberry|oral cranberry capsule, one pill daily
75456973|NCT01779193|Dietary Supplement|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
75456974|NCT01779232|Drug|Danazol|100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
75755077|NCT03996434|Drug|Gonadotropin|withholding gonadotropin administration for at least 24 hours
75755078|NCT03996434|Drug|Antagonist|Cetrorelix acetate 0.25 mg
75755079|NCT00987701|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
75755080|NCT00987701|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
75755081|NCT01020266|Procedure|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
75902501|NCT02034669|Device|Intradural space|ADSCs injection into Intradural space at damage site
75902502|NCT02034669|Device|Intrathecal|ADSCs Intrathecal into lumbar puncture
75902503|NCT02034669|Device|Intravenous|ADSCs intravenous
76067847|NCT02028884|Drug|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
75755082|NCT01020266|Procedure|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
75608599|NCT02782273|Drug|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
75755083|NCT00987779|Drug|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
75902504|NCT02237391|Other|CIPAP Program|The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
75902505|NCT02237391|Other|Treatment as Usual (TAU)|Control group
75902506|NCT03075358|Drug|Lidocaine spray|Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
75902507|NCT03075358|Other|Normal saline spray|0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
75902508|NCT05003284|Device|acupressure wristband|acupressure after surgery
75902509|NCT05003284|Device|placebo wristband|acupressure after surgery
75902510|NCT04999150|Procedure|Micro-Osteoperforations|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced ~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)"
75902511|NCT04999150|Procedure|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed. The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex, until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)"
75902512|NCT04999072|Procedure|Colectomy for colon cancer|Segmental or total colectomy was performed for colorectal cancer.
75902513|NCT03073330|Diagnostic Test|GDM screening with 75 g 2 hour GTT|Patients will be diagnosed with gestational diabetes if they have one abnormal value: Fasting ≥ 92; 2 hour ≥ 180 mg/dl;1 hour ≥ 153 mg/dl.
75902514|NCT03073330|Diagnostic Test|GDM screening with two step approach|1 hour glucola with 50 g glucose load followed by 100 g glucose load if 1 hour glucola positive
75902515|NCT02854605|Drug|GS-9674|Tablet administered orally once daily
75608600|NCT02782273|Drug|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
75608601|NCT02782507|Behavioral|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon & Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.~Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
75902516|NCT02854605|Drug|Placebo to match GS-9674|Tablet(s) administered orally once daily
75608602|NCT02787811|Device|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
75902517|NCT04992910|Device|Functional electrical stimulation through medical device|"The patient will receive a therapy with functional electrical stimulation. For this, a device called Fesia Grasp will be used.~Duration: 80 min twice a week, for 6 weeks."
75902518|NCT04992910|Other|Standard therapy|Physical therapy applied to the subject. Duration: 80 min twice a week, for 6 weeks.
75902519|NCT04992988|Drug|Toripalimab|Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT
75902520|NCT03073096|Procedure|LVA at time of nodal dissection|Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
75755084|NCT00987779|Drug|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
75608603|NCT05179135|Other|Postprandial exercise of different modalities|Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
75755085|NCT01020344|Procedure|Lung volume reduction surgery|Lung volume reduction surgery
75902521|NCT05003596|Drug|Methylprednisolone Tablet|Subjects will take a quantity 21 4mg tablets over a 6 week taper.
75608604|NCT05342545|Other|Alert-based computerized decision support|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
75755086|NCT00987857|Procedure|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
75902522|NCT05003596|Other|Standard Mobilization Treatment|standard treatment of hand injuries with focus on mobilization. No anti-inflammatory medications. Pain management via Tylenol or narcotics if deemed necessary.
75902523|NCT04998994|Dietary Supplement|wheat sprouts supplement|Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy
75902524|NCT03607929|Procedure|optimal|Physiological Saline Solution
75456975|NCT01779232|Drug|placebo|administered daily like the active comparator
75902525|NCT03607929|Procedure|variability|Other solutions
75902526|NCT04433572|Drug|Temsirolimus|0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
75755087|NCT00987857|Procedure|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
75755088|NCT00987857|Procedure|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
76067848|NCT02028884|Drug|Baseline Treatment|As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
76067849|NCT02020694|Drug|Vitamin D|
76067850|NCT02020694|Drug|Placebo (for vitamin D)|
76067851|NCT02019875|Drug|Rifampin|P450 inducer
76067852|NCT02019875|Drug|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
75608605|NCT05342389|Drug|Camrelizumab|a PD-1 antibody
75608606|NCT05342389|Drug|Apatinib Mesylate|an oral tyrosine kinase inhibitor
76067853|NCT02019875|Other|Grapefruit Juice|CYP3A4 inhibitor in intestine
75608607|NCT04230655|Dietary Supplement|Low energy diet using meal replacements|The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.
75608608|NCT04230655|Behavioral|CBT-based group treatment|All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
75755089|NCT00987857|Procedure|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
75755090|NCT00987857|Procedure|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
75755091|NCT00987857|Procedure|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
75755092|NCT00987857|Procedure|screening method|All Barretts patients to be screened
75755093|NCT01020422|Procedure|Reduction mammaplasty|Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
75755094|NCT01018004|Other|follow-up care|
75755095|NCT01018004|Other|questionnaire administration|
75755096|NCT01018004|Procedure|quality-of-life assessment|
75755097|NCT04225286|Other|Human breast milk|Intranasal human breast milk
75755098|NCT01018160|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12 weeks
75755099|NCT01018238|Drug|NNC 0151-0000-0000|Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)
75755100|NCT01018238|Drug|placebo|Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
75755101|NCT03996512|Other|Early Active Controlled Motion (EACM)|Early active controlled wrist motion rehab protocol using that will allow midcarpal row motion.
75755102|NCT00473876|Drug|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
75755103|NCT00473876|Drug|Matched Placebo (Capsules)|Similar dosing regime as active comparator
75902527|NCT04433572|Drug|Saline placebo|Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
75902528|NCT03606135|Other|The Pneumonia Group|
75902529|NCT03606135|Other|The Control Group|
75902530|NCT03072940|Other|Clinical investigations|Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging
75902531|NCT03073018|Drug|Fosinopril|oral administration, capsules
75902532|NCT03073018|Drug|Pravastatin|oral administration, capsules
75902533|NCT03073018|Drug|Fosinopril Placebo|oral administration, capsules
75902534|NCT03073018|Drug|Pravastatin Placebo|oral administration, capsules
75902535|NCT03607617|Other|SDH Tool|The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.
75902536|NCT05003206|Other|Functional magnetic resonance imaging|Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.
75902537|NCT05003206|Device|Deep Brain Stimulation|For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan
75902538|NCT03607461|Device|Smartphone App|Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.
75902539|NCT03607461|Combination Product|Control Group|Home Health users will have received traditional home health physical therapy and skilled nursing services.
75456976|NCT01779245|Dietary Supplement|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
75456977|NCT01779245|Dietary Supplement|Placebo|
75456978|NCT01779258|Drug|glycerol, paraffin (liquid and white soft)|1 application in the morning and in the evening
75456979|NCT01779258|Device|Atopiclair®|1 application in the morning, in the afternoon and in the evening
75456980|NCT01779258|Drug|Locatop@|"During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days"
75456981|NCT01779258|Drug|Locapred@|"During the 3 months study treatment:~1 application in the evening in case of flare "
75456982|NCT01779271|Drug|Pelubiprofen|
75456983|NCT01779271|Drug|Loxoprofen|
75755104|NCT03996668|Other|Thigh High Compression Stockings|Thigh high compression stockings will be placed after induction of anesthesia and intubation.
75755105|NCT01020578|Other|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
75755106|NCT00463580|Drug|Infliximab|Participants will receive three infusions 5mg/kg of infliximab (at Baseline, Week 2 and Week 6)
75755107|NCT00463580|Drug|Placebo|Participants will receive three infusions of a placebo (at Baseline, Week 2 and Week 6)
75755108|NCT01020734|Biological|anti-thymocyte globulin|
75755109|NCT01020734|Drug|busulfan|
75755110|NCT01020734|Drug|cyclophosphamide|
75755111|NCT01020734|Drug|cyclosporine|
75755112|NCT01020734|Drug|fludarabine phosphate|
75755113|NCT01020734|Drug|methotrexate|
75755114|NCT01020734|Procedure|allogeneic hematopoietic stem cell transplantation|
75755115|NCT01021046|Procedure|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
75902540|NCT06205277|Procedure|Second TURBt|Second TURBt for pT1 NMIBC as per current EAU Guidelines.
75902541|NCT06205264|Other|Strength training at high and low speeds.|"The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises."
76067854|NCT02019875|Other|Placebo|
76067855|NCT01907009|Drug|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
75755116|NCT01021046|Procedure|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
76067856|NCT01907009|Drug|Lenograstim|"Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.~After the third cycle patient will receive 263mcg/day for 10 days."
76067857|NCT01882933|Drug|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
76067858|NCT01882933|Procedure|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
76067859|NCT01821976|Procedure|Ertl Procedure|
76067860|NCT01821976|Procedure|Burgess Procedure|
76067861|NCT01787929|Procedure|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
76067862|NCT01778738|Procedure|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
76067863|NCT01778738|Procedure|Sleeve gastrecomy|Vertical sleeve gastrectomy
76067864|NCT01778738|Procedure|Bastric bypass|Gastric bypass surgery
75456984|NCT01779284|Drug|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
75456985|NCT01779284|Drug|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
75456986|NCT01779336|Drug|PL225B|"Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~This 21 day administration will define a treatment cycle.~Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
75456987|NCT01779349|Device|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
75608609|NCT04230655|Device|Intragastric balloon|An IGB (Orbera IGB, Apollo Endosurgery Inc., Austin, Texas, (CE certified)) is set in place endoscopically by a gastroenterologist at Örebro University Hospital, Region Örebro county, and is left in the stomach for 6 months. A proton-pump inhibitor is prescribed to counteract an increased risk to develop a gastric ulcer. During the first 2 weeks, dietary adjustments are necessary to adapt to the IGB. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended identical to the control group. The IGB is removed endoscopically after 6 months IGB treatment.
75608610|NCT02784067|Drug|Sucraid|Study drug
75608611|NCT02784067|Drug|Placebo|Sucraid placebo
75608612|NCT05260099|Device|LPS Adsorber|LPS Adsorber, binding endotoxin caused by suspected or verified gram-negative bacteria.
76067865|NCT01744145|Other|Interventional 40-60|This group will receive the intervention aged 40-60
75456988|NCT01779362|Drug|Metformin|Titrated to 1000 mg BID
75456989|NCT01779362|Drug|Liraglutide|Titrated to 1.8 mg/day
75456990|NCT01779362|Drug|Glargine|Titrated to target fasting glucose <90 mg/dl
75755117|NCT00540449|Drug|TMC278|25 mg tablet once daily for 96 weeks
75755118|NCT00540449|Drug|Efavirenz|600mg once daily for 96 weeks
75755119|NCT04872023|Other|Blood and bone marrow sampling|Blood and bone marrow sampling
75755120|NCT05142527|Drug|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
75755121|NCT05142527|Other|Placebo|Placebo
75608613|NCT02268175|Drug|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
75608614|NCT02268175|Drug|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
75755122|NCT05137769|Behavioral|Body Scan|The body scan is a core element of mindfulness-based stress reduction. Participants will listen to a 20-minute audio guide instructing them to focus on sensations in the body, place attention on one area of the body at a time, and progressively move attention throughout areas of the body.
75755123|NCT04005131|Device|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 10 weeks
75755124|NCT04005131|Device|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 times a week for 5 weeks
75755125|NCT05135117|Other|NeuroRescue Cooling Collar|Between bouts of exercise subjects will be provided cooling on the neck with the NeuroRescue Collar. The custom sized cooling collar has ice water (which is kept around 2 degrees celsius) that is circulated through a neoprene sleeve that is attached to their neck for the cooling period.
75755126|NCT05135117|Other|Ice Towel|Between bouts of exercise subjects will be provided cooling on the neck with a towel. The towel will be kept in ice water (which is kept around 2 degrees celsius) and placed around the neck of the individual during the cooling intervention period.
76067866|NCT01744145|Other|Interventional 60 and above|This group will receive the intervention aged 60 and above.
76067867|NCT01713062|Device|Vitelene|THA
75456991|NCT01779362|Drug|Placebo|Matching to metformin 1000 mg BI
75456992|NCT01779401|Drug|Clopidogrel 75mg|
75456993|NCT01779401|Drug|Clopidogrel 150mg|
75608615|NCT02268175|Drug|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
75608616|NCT02268175|Drug|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
75608617|NCT02207647|Other|no intervention|
75608618|NCT02783989|Other|white wine|A dietary beverage: a market white wine, 13º alcohol
75608619|NCT02783989|Dietary Supplement|tyrosol|tyrosol in capsules
75456994|NCT01779401|Drug|Aspirin 100mg|
75456995|NCT01779401|Drug|Cilostazol 100mg|
75456996|NCT01779414|Other|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
75608620|NCT02783833|Drug|MMV390048 40mg|
75608621|NCT02783833|Drug|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
75608622|NCT02783755|Behavioral|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
75608623|NCT02783677|Procedure|Percutaneous balloon angioplasty|
75755127|NCT03911843|Drug|omega-3 supplementation|Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
75755128|NCT03911843|Drug|Vitamin D supplementation|Cholecalciferol 1000 IU/die
75755129|NCT04833335|Other|MRI perfusion sequence|Quantitative analysis
75755130|NCT00361335|Drug|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
75755131|NCT00361335|Drug|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
75755132|NCT00361335|Drug|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
75755133|NCT00264550|Drug|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
75755134|NCT00264550|Drug|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
75755135|NCT00264550|Drug|Methotrexate|Participants will receive methotrexate capsules weekly.
75755136|NCT00264550|Drug|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
76067868|NCT01713062|Device|XLPE|THA
76067869|NCT01686126|Drug|Levonorgestrel|Intrauterine device
75755137|NCT00264550|Drug|Placebo capsules|Participants will receive placebo capsules weekly
75902542|NCT06205251|Device|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
75902543|NCT06205238|Other|CGA|"CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up."
75902544|NCT06205225|Behavioral|Text4HF|Behavioral text messages about heart failure self-care
75902545|NCT06205225|Behavioral|MyApps|consumer mobile health apps and devices for heart failure self-care
75902546|NCT06205225|Behavioral|MyApps & Text4HF|Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care
75902547|NCT06205212|Other|high-flow nasal oxygen|preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min
75902548|NCT06205212|Other|facemask|preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min
75902549|NCT06205186|Behavioral|Army Health|A whole health mobile application for Soldiers
75902550|NCT06205173|Other|Hot compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
75902551|NCT06205173|Other|Cold compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
76067870|NCT01686126|Drug|Metformin|oral medication
75456997|NCT01779427|Behavioral|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
75456998|NCT01779466|Drug|Desmopressin|
75456999|NCT01779466|Drug|Placebo (not active)|
75457000|NCT01779479|Drug|Cabacitaxel|Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
75457001|NCT01779479|Drug|Paclitaxel|Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
75608624|NCT02782429|Drug|Ketamine|
76067871|NCT01531582|Drug|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
75608625|NCT02782429|Other|Saline|
75457002|NCT01779492|Drug|GL2907|once a day
75457003|NCT01779492|Drug|Oxycontine CR 10mg|twice a day
75457004|NCT01779505|Biological|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
75608626|NCT04229719|Drug|N-acetyl-5-methoxytryptamine|1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
75608627|NCT02782351|Biological|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
75608628|NCT04231903|Device|Aortic clamp|In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
75457005|NCT01779518|Drug|Sofosbuvir|
75608629|NCT02784847|Drug|Triheptanoin|Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
75608630|NCT04230889|Other|Usual Diet Group|three main meals and two snacks
75755138|NCT04271033|Device|Carotid Artery Stenting|"Carotid artery stenting according to local clinical experience and ESC/ESVS guidelines using exclusively CGuard™, MicroNet covered stent under proximal or distal intraprocedural cerebral protection according to tailored CAS algorithm."
75755139|NCT04004507|Drug|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
75755140|NCT04004507|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
75755141|NCT01070290|Drug|ARQ 197|120 mg capsule administered twice daily
75755142|NCT01070290|Drug|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
75755143|NCT05067257|Drug|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources
75902552|NCT06205160|Device|SOFT ECoG subdural grid electrode|"Test Device (SOFT ECoG subdural grid electrode): used for recording. During epilepsy surgery, in addition to standard clinical protocol (recording with comparator device), subjects will undergo ≥ 2 additional intracranial recordings with the SOFT ECoG flexible high density electrode grid (TD). Recording will be registered pre- and post-resection.~All procedures will be conducted according to standard clinical practice. Any medical decision making will be done using the standard of care CE-marked device (CD). The investigational, non-CE marked device is not used for clinical decision making."
75902553|NCT06205147|Device|Elastic Band|Using the newly patented product, the Muscle Exercise and Falling Prevention Elastic Strap (Patent Certificate No. M585601), the procedure involves securing the elastic strap to a high-back chair to administer elastic band intervention exercises for patients.Guided by continuous contextual action demonstration videos, participants will engage in the elastic band resistance intervention twice a day, each session lasting 20 minutes, over a span of five days. These videos are designed to provide a continuous contextual demonstration, incorporating them within the video itself.
76067872|NCT01512888|Genetic|CL20-i4-EF1α-hγc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
75608631|NCT04230889|Other|Group 1 Nutritional Shake|2 servings per day
75608632|NCT04230889|Other|Group 2 Nutritional Shake|2 servings per day
75902554|NCT06205134|Drug|A: Epinephrine injection|Autoinjector for intramuscular, single-use, 0.3mg
75902555|NCT06205134|Drug|B: FMXIN002 3.6mg|Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
76067873|NCT01512888|Drug|Busulfan|Given intravenously (IV).
76067874|NCT01512888|Device|CliniMacs|Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
76067875|NCT01500733|Drug|PCI 32765|420 mg daily
75608633|NCT01855867|Drug|Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
75608634|NCT02689843|Drug|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
75608635|NCT02689843|Drug|Metformin|Metformin 500mg three times daily
75608636|NCT02689843|Drug|Pioglitazone|Pioglitazone 30mg once daily
76067876|NCT01493453|Genetic|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
76067877|NCT01436864|Biological|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
76067878|NCT01422187|Drug|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
75457006|NCT01779518|Drug|Ribavirin|
75608637|NCT02783365|Behavioral|Photo-elicitation and online group support|See above information.
75608638|NCT02783521|Behavioral|Counseling sessions|During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
75755144|NCT05067257|Drug|Placebo|Vehicle solution
75755145|NCT01048203|Drug|ABR-215050|1 mg ABR-215050
75755146|NCT01070368|Other|Commercial extract and in-house wheat extract|Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.
75755147|NCT01070446|Dietary Supplement|Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1|This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
75755148|NCT01050387|Dietary Supplement|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
75457007|NCT01779518|Drug|Pegylated Interferon|
75457008|NCT01779544|Other|Brief intervention, an educational model|The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.
75457009|NCT01779544|Other|Exercise therapy|Patients are instructed to do prescribed exercises the first 3 months after surgery, and to log when they do these
75457010|NCT01779570|Drug|Macrolide treatment|
75457011|NCT01779596|Drug|Bosentan|
75457012|NCT01779596|Drug|Placebo|
75457013|NCT01779609|Drug|Bosentan|
75457014|NCT01779609|Drug|Placebo|
75755149|NCT01070524|Drug|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
75755150|NCT01070524|Drug|Budesonide extrafine pMDI|Budesonide extrafine pMDI
75902556|NCT06205134|Drug|C: FMXIN002 4.0mg|Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
75902557|NCT06205121|Drug|OATD-01|OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
75902558|NCT06205121|Drug|Placebo|Matching placebo tablets
75902559|NCT06205108|Device|taVNS stimulation|Non-invasive stimulation of the auricular branch of the vagus nerve (cymba conchae). Research device from tVNS technologies.
75902560|NCT06205108|Device|sham stimulation|Non-invasive stimulation of the ear lob (not innervated by the vagus nerve). Research device from tVNS technologies.
75755151|NCT01070524|Drug|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
76067879|NCT01191775|Drug|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
75457015|NCT01779609|Behavioral|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
75457016|NCT01779622|Other|Mixed meal|Ingestion of mixed meal
75608639|NCT02783521|Behavioral|Wait List Control|After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
75608640|NCT02781961|Other|cellvizio|pCLE during gastroscopy
75608641|NCT05171725|Diagnostic Test|EEG,PSG|concurrent overnight sleep study with full electroencephalography (in-lab or at home)
75608642|NCT05171725|Diagnostic Test|biosample collection (blood and CSF)|blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information
75902561|NCT06205095|Drug|Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII|Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
75902562|NCT06205095|Other|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.
76067880|NCT01116765|Other|no stimulation of the oral structure|
75457017|NCT01779635|Device|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
75457018|NCT01779635|Device|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
75608643|NCT05171725|Diagnostic Test|neuropsychological testing|paper and pencil, as well as tablet based cognitive testing
75457019|NCT01779661|Other|Infant Aquatics|Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
75457020|NCT01779661|Other|Infant Massage|Infant Massage
75457021|NCT01779687|Drug|raltegravir|Raltegravir 400 mg BID for 7 days
75608644|NCT05171725|Diagnostic Test|actigraphy|week long actigraphy assessment with concurrent sleep diary acquisition
75608645|NCT05171725|Diagnostic Test|clinician assessment|standard clinical assessment by an expert clinician in the respective field of brain disorders
75457022|NCT01779687|Drug|Atorvastatin|Atorvastatin 20 mg QD for 7 days
75457023|NCT01779713|Genetic|Case-control transcriptomic study|No intervention
75457024|NCT01779726|Radiation|CT scan before chest physician|Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician
75457025|NCT01779726|Radiation|Usual diagnostic workup|Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
75457026|NCT01779739|Procedure|Perineorrhaphy|Procedure to build up the vaginal opening
75457027|NCT01779765|Dietary Supplement|PHGG|
75457028|NCT01779765|Dietary Supplement|Maltodextrin|
75457029|NCT01779791|Drug|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
75608646|NCT05341999|Other|cold saline (cryotherapy)|using 20ml of 2.5°C cold saline for 5 min
75608647|NCT05341999|Drug|Ibuprofen 400 mg|patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
75608648|NCT05341999|Other|Final irrigation with normal saline|final irrigation will be done using normal saline at room temperature.
75755152|NCT01048359|Behavioral|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
75755153|NCT01048359|Behavioral|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
75902563|NCT06205082|Drug|LIT-00814|LIT-00814 is an oral tablet.
76067881|NCT01116765|Other|stimulation of the oral structure|
76067882|NCT01041989|Behavioral|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
76067883|NCT01041989|Behavioral|Exercise|Guided muscle strength training and aerobic exercise.
76067884|NCT01041989|Behavioral|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
75608649|NCT02781805|Drug|Alendronate|10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
75755154|NCT01048359|Behavioral|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
75755155|NCT01071304|Drug|Midazolam|A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
75755156|NCT01071304|Drug|Ridaforolimus|Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
75755157|NCT01050465|Other|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
76067885|NCT01041989|Other|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
76067886|NCT00823654|Other|Blood draw and questionnaires|"At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment~↓~Tests in the middle of chemotherapy (if applicable):~Blood draw and collection of monthly menstrual calendars ↓~Tests when chemotherapy is over (if applicable):~Blood draw and collection of monthly menstrual calendars~↓~Tests every 4 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire ↓~Tests every 6 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire~↓~Yearly follow-up for about 2 years:~Blood draw collection of monthly menstrual calendars, and questionnaire"
76067887|NCT00823654|Other|Blood draw and questionnaires|"Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent~↓ Register patients at Memorial Sloan-Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)~↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires~↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires"
76067888|NCT00667199|Drug|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
76067889|NCT00639301|Behavioral|Questionnaires|The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
76067890|NCT00605982|Procedure|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
76067891|NCT00537225|Behavioral|exercise|tailored multifactor CVD risk reduction
76067892|NCT00472212|Device|Spectacles|Hyperopic spectacle lenses
75608650|NCT02781493|Drug|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
76067893|NCT00472212|Device|Control|Plano (no power, control) spectacle lenses
76067894|NCT00460486|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
76067895|NCT00378105|Drug|Bortezomib|Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
76067896|NCT00378105|Drug|Lenalidomide|Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
75608651|NCT02781493|Drug|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
75608652|NCT02783287|Behavioral|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
75608653|NCT02783287|Behavioral|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
75608654|NCT02783053|Drug|Metformin|Metformin vs no metformin
75608655|NCT04230343|Behavioral|Self-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
75608656|NCT04230343|Behavioral|Other-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.
75755158|NCT01069042|Drug|Enalapril|All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
75755159|NCT00541931|Drug|Dietary Supplement: LifePak Nano|Daily use
75755160|NCT03976492|Diagnostic Test|diagnostic of specific biomarkers|Protein and metabolic product differences will be detected from blood or lesion samples of normal population, patients with traumatic brain injury and/or non-brain injury using mass spectrometry proteomics and metabolomics analysis platform. Diagnostic markers of potential traumatic brain injury will be found, and their differential diagnostic values were discussed.
75755161|NCT04004663|Drug|PF-06651600|PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
75755162|NCT01581346|Other|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
75902564|NCT06205069|Device|Tissue flossing|While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.
75608657|NCT02783209|Procedure|Cataract surgery|
75608658|NCT02689609|Radiation|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
75755163|NCT04759313|Behavioral|Image Narrative|Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
76067897|NCT00378105|Drug|dexamethasone|Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
75457030|NCT01779804|Procedure|OFAR|OFAR
75457031|NCT01779817|Behavioral|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
75755164|NCT00368979|Drug|Dutasteride|once daily
75755165|NCT00368979|Drug|Placebo|once daily
75755166|NCT00264238|Drug|Memantine|pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
75755167|NCT00540293|Drug|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
75755168|NCT01070602|Procedure|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
75755169|NCT01563653|Procedure|4 diagnostic tests for surgical success|Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
75755170|NCT04727645|Other|Philips interventional MRI suite (Philips Healthcare, Best, the Netherlands)|iSuite is an an electroanatomical mapping system (EAM) designed to support real-time MRI guided interventional procedures.
75755171|NCT04971941|Device|Dental Vibe|Use of Dental Vibe during dental anesthesia intervention
75755172|NCT01050621|Dietary Supplement|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
75755173|NCT04933643|Other||
75755174|NCT00359073|Drug|montelukast|10 mg everyday
75902565|NCT06205056|Biological|Ad26.Mos4.HIV [Arm 1]|Participants in Arm 1 will receive dose-consistent injections (5x10^10 vp/0.5 mL) at each product administration visit (Days 1, 57, and 169)
75902566|NCT06205056|Biological|Ad26.Mos4.HIV [Arm 2]|Participants in Arm 2 will initially receive a lower dose (2.5x10^10 vp/0.25 mL) on Day 1, which will increase to the Arm 1 dose (5x10^10 vp/0.5 mL) when subsequently administered on Days 57 and 169.
76067898|NCT00139477|Drug|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
76067899|NCT00139477|Behavioral|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
75457032|NCT01779830|Drug|LY2624803 - Capsules|Administered orally as capsules.
75457033|NCT01779830|Drug|Zolpidem - Tablets|Administered orally as tablets.
75457034|NCT01779830|Drug|Placebo - Capsules|Administered orally as capsules.
75457035|NCT01779830|Drug|Placebo - Tablets|Administered orally as tablets.
75457036|NCT01779843|Drug|Cytarabine|
75457037|NCT01779843|Drug|Idarubicin|
75755175|NCT00359073|Drug|placebo|like placebo
75755176|NCT03991143|Drug|ATH3G10|intravenous
75755177|NCT03991143|Drug|Placebo|intravenous
75755178|NCT03918239|Drug|SHP643|Participants will receive injection of SHP643.
75755179|NCT04699331|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
75755180|NCT00368745|Drug|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
75902567|NCT06205056|Biological|CH505 TF chTrimer+ALFQ [Arm 1]|Participants in Arm 1 will receive dose-consistent injections of CH505 TF chTrimer (300 µg) mixed with ALFQ (200 µg MPLA/ 100 µg QS 21) at each product administration visit on Days 1, 57, and 169
75755181|NCT00368745|Drug|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
75755182|NCT04645355|Drug|Guselkumab|All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44
75755183|NCT05711771|Behavioral|medication therapy management|Patients receive medication therapy management within the primary care office
75755184|NCT04573673|Device|PTNS de verum|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. The amplitude (Volt) will be adjusted by the patient according to the feeling.
75902568|NCT06205056|Biological|CH505 TF chTrimer+ALFQ [Arm 2]|"Participants in Arm 2 will receive 30 µg, 100 µg, 150 µg, and 300 µg doses of CH505 TF chTrimer mixed with ALFQ.~Day 1: CH505 (30 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 4: CH505 (100 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 8: CH505 (150 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 15: CH505 (300 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 57: CH505 (300 µg) +ALFQ (200 µg MPLA/ 100 µg QS 21)~Day 169: CH505 (300 µg) +ALFQ (200 µg MPLA/ 100 µg QS 21)"
76067900|NCT00139477|Behavioral|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
75755185|NCT04573673|Device|PTNS placebo|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. A resistor will be incorporated in the device to block the passage of electric current
75755186|NCT04188041|Other|TB Infection ECHO|A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
75755187|NCT01048437|Behavioral|Transplant education with video|1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
75755188|NCT01048437|Behavioral|Transplant education with speakers|1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
75755189|NCT01050699|Drug|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
75755190|NCT01050699|Drug|Midazolam and Fentanyl|"Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)"
75755191|NCT00454818|Genetic|MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
75902569|NCT06205056|Biological|ALFQ [Arm 1]|Participants in Arm 1 will receive dose-consistent injections of ALFQ (200 µg MPLA/100 µg QS-21) mixed with CH505 TF chTrimer on Days 1, 57, and 169
76067901|NCT00004935|Drug|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
76067902|NCT00004935|Drug|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
76067903|NCT00119158|Drug|Combination of pimecrolimus and fluticasone|Pimecrolimus cream twice a day and fluticasone cream once a day
75457038|NCT01779843|Drug|Alisertib|
76067904|NCT00119158|Drug|pimecrolimus|apply daily with fluticasone cream for flares
76067905|NCT00119392|Biological|rituximab|Given IV
76067906|NCT00119392|Drug|cyclosporine|Given orally
76067907|NCT00119392|Drug|fludarabine phosphate|Given IV
75457039|NCT01779882|Drug|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
75457040|NCT01779882|Drug|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
75755192|NCT00454818|Procedure|Placebo Infusion|Saline; epicardial coronary artery infusion
76067908|NCT00119392|Drug|mycophenolate mofetil|Given orally
76067909|NCT00119392|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
76067910|NCT00119392|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
75755193|NCT00454818|Genetic|MYDICAR Phase 2 (Placebo-controlled, Randomized Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
75755194|NCT03992625|Device|Deep Brain Stimulation|High frequency electrical stimulation of deep brain nuclei for the treatment of movement disorders
75755195|NCT03668873|Behavioral|Sleep Parent Training|SPT provides a comprehensive intervention that teaches parents the basic concepts and practical skills to address an array of sleep problems.
75457041|NCT01779895|Dietary Supplement|Lactobacillus paracasei probiotic strain|
75608659|NCT02783131|Device|MedNav|MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
75902570|NCT06205056|Biological|ALFQ [Arm 2]|"Participants in Arm 2 will receive a lower dose of ALFQ (50 µg MPLA/25 µg QS-21) mixed with CH505 TF chTrimer during the rapid, dose-escalating injections on Days 1, 4, 8, and 15~and a dose of ALFQ similar to that used in Arm 1 (200 µg MPLA/100 µg QS-21) mixed with CH505 TF chTrimer at subsequent injections on Days 57 and 169"
75902571|NCT06205043|Device|StimSearch programming algorithm software|This is an algorithm based method to program deep brain stimulation in patients of Parkinson's disease
75902572|NCT06205043|Device|Clinician based programming|This is Standard of Care programming performed for patients undergoing deep brain stimulation for Parkinson's disease
76067911|NCT00119392|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
76067912|NCT00119392|Radiation|total-body irradiation|Undergo TBI
76067913|NCT00218062|Drug|D-Amphetamine 30mg|
75608660|NCT02782975|Drug|aducanumab|
75457042|NCT01779895|Dietary Supplement|Placebo|maltodextrin
75755196|NCT03668873|Behavioral|Sleep Parent Education|SPE is a structured program intended to mimic competent treatment as usual. Thus, SPE is an accepted treatment and serves as an active comparator that controls for time and attention.
75755197|NCT04552457|Behavioral|No activity restrictions|"Patients in the No activity restrictions group will be allowed to return to their normal activity immediately."
75755198|NCT04552457|Behavioral|Activity restrictions|"Patients in the Activity restrictions group will not be allowed to perform strenuous exercise or lift anything greater than 10lbs. Strenuous exercise will be defined as is any activity that requires so much exertion that one cannot have a conversation comfortably while doing it."
75755199|NCT00445224|Other|Hip Progressive Resistive Exercise|Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
75902573|NCT06205017|Dietary Supplement|Foods for Special Medical Purposes|"In order to facilitate patient weaning and to improve the enjoyment of foods used in this semi-liquid phase, our Center intends to test Foods for Special Medical Purposes (AFMS) to ensure better nutritional intake, including vitamin D3 and calcium, good palatability, and thus better adherence to the recommended nutritional indications in the immediate postoperative period than the homogenized foods used in the standard diet."
75902574|NCT06205004|Other|Questionnaires|In the present study, the investigators aim to investigate the prevalence and effects of IA on the psychosocial well-being among adults in Hong Kong by measuring the level of Internet use, depression, anxiety, sleep quality, QOL together with basic demographic data in the current situation of COVID with popularity of Metaverse.
75902575|NCT06204991|Biological|ADP-TILIL7|Autologous tumor infiltrating lymphocytes genemodified (by a lentiviral vector) to produce IL-7 upon antigen engagement
75902576|NCT06204991|Drug|Cyclophosphamide|Lymphodepleting Chemotherapy
76067914|NCT00218062|Drug|D-Amphetamine 60mg|
76067915|NCT00218062|Drug|Modafinil 200mg|
76067916|NCT00218062|Drug|Modafinil 400mg|
76067917|NCT00218062|Behavioral|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
76067918|NCT00218062|Drug|Placebo|
76067919|NCT00121186|Drug|fludarabine phosphate|30 mg/m^2 on days -6 to -2 (2-6 days before transplant).
76067920|NCT00121186|Drug|melphalan|70 mg/m^2 on days -3 and -2 (2-3 days before transplant).
76067921|NCT00121186|Drug|methotrexate|5 mg/m^2 on days 1, 3, and 7 post-transplant.
76067922|NCT00121186|Drug|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
76067923|NCT00121186|Procedure|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
76067924|NCT00121186|Procedure|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
75457043|NCT01779908|Dietary Supplement|Vitamin D|
75457044|NCT01779908|Other|Placebo|
75457045|NCT01779921|Drug|activated recombinant human factor VII|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
75457046|NCT01779921|Drug|Fresh frozen plasma (Source unspecified)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
75457047|NCT01779921|Drug|Plasma-derived FVII (LFB)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
75457048|NCT01779921|Drug|Prothrombin Complex conc. (PCC)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
75457049|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII Baxter)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
75608661|NCT01324531|Procedure|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
76067925|NCT00121810|Drug|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
76067926|NCT00121810|Drug|Corticosteroids|As prescribed
75608662|NCT01324531|Procedure|Bankart repair|Bankart repair based on surgeon's preference
76067927|NCT00121810|Drug|Calcineurin inhibitors|As prescribed
76067928|NCT00121810|Drug|Sirolimus|As prescribed
75608663|NCT02782819|Drug|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
76067929|NCT00053014|Biological|therapeutic allogeneic lymphocytes|
76067930|NCT00053014|Drug|cyclosporine|
75608664|NCT02782819|Drug|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
75755200|NCT00445224|Other|Quad Progressive Resistive Exercises|Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
76067931|NCT00053014|Drug|fludarabine|
75755201|NCT02408315|Drug|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
76067932|NCT00053014|Drug|mycophenolate mofetil|
76067933|NCT00053014|Procedure|peripheral blood stem cell transplantation|
76067934|NCT00053014|Radiation|radiation therapy|
76067935|NCT00123604|Drug|Carvedilol|25 mg twice daily for five months.
76067936|NCT00123604|Drug|Metoprolol|200 mg twice daily for five months.
76067937|NCT00123682|Procedure|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
76067938|NCT00123682|Procedure|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
76067939|NCT00123682|Procedure|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
76067940|NCT00123682|Procedure|Self-help|Project staff send out self-help materials for smoking cessation
76067941|NCT00125788|Drug|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
76067942|NCT00125788|Drug|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
76067943|NCT00221338|Drug|Gabapentin|This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
76067944|NCT00223678|Drug|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
76067945|NCT04752436|Behavioral|Supra high intensity interval training|The exercise program will consist of eight 20-second all-out exercise bouts followed by 10 seconds of rest for a total of 4 minutes of total exercise duration. The intensity of exercise is all out. The exercise will be conducted 3 times a week for 8 weeks.
76067946|NCT00053482|Biological|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
76067947|NCT00053482|Biological|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
75755202|NCT01323114|Procedure|Laparoscopic duodenal exclusion|Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
76072334|NCT01419067|Device|Proton Therapy|Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.
75755203|NCT01323114|Other|Conventional Medical Treatment|Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
75755204|NCT01030146|Drug|NeilMed® Sinus Rinse™ System with Isotonic Saline|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
75755205|NCT05711693|Device|Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)|Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared
75755206|NCT05711693|Procedure|Blood pressure and heart rate measurement|"To all patients:~- blood pressure and heart rate will be measured"
75902577|NCT06204991|Drug|Fludarabine Phosphate|Lymphodepleting Chemotherapy
76072335|NCT01419067|Drug|^1^8F-fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
75755207|NCT05711693|Device|carotid to femoral PWW measurement|"To all patients:~- carotid to femoral PWW will be measured by LDV and tonometry for comparison"
75755208|NCT05711693|Procedure|Questionnaire completion|All patients will complete a questionnaire of acceptability
75457050|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII PFL)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
75755209|NCT04005365|Drug|Propranolol|add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
75608665|NCT04182217|Other|Epidemiological description|Description of the characteristics of Peritonitis in Haiti
75608666|NCT02781415|Procedure|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
75755210|NCT03994926|Device|Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye|Device measures smooth eye pursuit and response to light flash after pt smokes cannabis
76067948|NCT00130780|Drug|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
76067949|NCT00130780|Drug|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
75755211|NCT03994926|Drug|Cannabis cigarette - 4.0% THC|smoked cannabis 4.0% THC
75755212|NCT01027182|Drug|Raltegravir|One 400mg tablet on day 1.
75457051|NCT01779960|Other|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
75608667|NCT02781415|Drug|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
75608668|NCT02785003|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
75608669|NCT02785003|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.
75755213|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
75755214|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
75755215|NCT04512209|Procedure|MRI|"Patients will undergo an MR scan before undergoing cytoreductive surgery. If neoadjuvant chemotherapy is administered, an extra MR scan is planned before the start of the neoadjuvant chemotherapy.~During surgery, tissue samples will be taken for interstitial fluid pressure (IFP) measurement, immunohistochemistry (IHC) and characterization of biophysical properties (viscoelastic properties and hydraulic conductivity)."
75755216|NCT02534259|Other|Force monitoring of external fixator struts|
75755217|NCT04571801|Diagnostic Test|Standard diagnostics|Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
75902578|NCT06204991|Drug|Proleukin|IL-2
75755218|NCT04571801|Diagnostic Test|Next Generation Sequencing (NGS)|Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
75608670|NCT02785003|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
75755219|NCT03990987|Other|time of receiving operation|patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
75755220|NCT01048515|Drug|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
75755221|NCT04004195|Drug|BAY2327949|A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
75608671|NCT02785003|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
75902579|NCT06204952|Drug|Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract)|In patients with facet joint syndrome, Joins® (Clematidis Radix, Trichosanthes Root, Prunella Spike Extract) is administered at a dosage of 1 tablet three times a day for 12 weeks.
75755222|NCT01050777|Drug|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
75755223|NCT01050777|Drug|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
75755224|NCT01050777|Drug|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
75755225|NCT01050777|Drug|Placebo|Placebo
75755226|NCT04099589|Drug|Toripalimab|Gemcitabine/Cisplatin plus Toripalimab
75755227|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
75755228|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
75755229|NCT00264004|Drug|AZD2171|30 mg & 45 mg oral tablet
75902580|NCT06204952|Drug|Placebo|In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
76067950|NCT04752748|Drug|Drug protocol|"The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score> 3.2 and the Physician's Global Assessment (PGA)> 4.0 [0-10 cm]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~Failure 1: failure of the first DMARD (MTX) in week 12.~Failure 2: failure of the second DMARD (leflunomide) at week 24~Failure 3: failure of the first immunobiological (adalimumab) at week 48."
75608672|NCT02785003|Drug|Alvimopan|All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
75608673|NCT02781259|Procedure|Axillary lymph node dissection|Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
75608674|NCT02781259|Drug|Indocyanine green|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
75608675|NCT02781259|Device|Imaging devices|Near-infrared fluorescence is collected by imaging lenses and digital camera.
75608676|NCT05341531|Other|elderly patients undergoing non-cardiac surgery|Elderly patients 60 years and older undergoing major non-cardiac surgery > 2 hours
75755230|NCT01069198|Drug|Albendazole, Iron, Zinc and Vitamin A|single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged <5 and >=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.
75755231|NCT01069198|Other|Placebo|Placebo
75755232|NCT00368355|Drug|Ara-C|"day-8 through day-5~3 g/m2 q 12 hours"
75755233|NCT00368355|Drug|Cyclophosphamide|"day-7 and day-6~45 mg/kg"
75755234|NCT00368355|Biological|Campath-1H|"day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS"
75755235|NCT00368355|Radiation|Total Body Irradiation|"day-4 through day-1~175 cGy x 2 at 24 cGy/min"
75755236|NCT00368355|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
75755237|NCT01070680|Drug|Precedex|mkg/ml,continuous infusion at rate 0.7 µg/kg/h
75755238|NCT01070680|Drug|sodium chlorid 0,9%|continuous intravenous infusion
75755239|NCT00445146|Drug|EVG|Elvitegravir (EVG) tablet administered orally once daily with food
75755240|NCT00445146|Drug|RTV|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
75755241|NCT00445146|Drug|ARV regimen|The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
75755242|NCT01581736|Drug|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
75755243|NCT01581736|Other|Exercise|Single episode of exercise riding a stationary bike.
75902581|NCT06204939|Procedure|Randomizing for EPGB procedure|"Classic gastric bypass with 2 anastomoses but with an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
76067951|NCT00041392|Drug|Magnesium|100 mg/kg
76067952|NCT00041392|Drug|0.9% saline|Placebo
76067953|NCT02091778|Device|Fast gelling dressing|
75755244|NCT01030224|Drug|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
75755245|NCT01030224|Drug|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
75755246|NCT01030302|Drug|bortezomib|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
75755247|NCT00368277|Drug|Aliskiren|Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
75755248|NCT00368277|Drug|Ramipril|Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
75902582|NCT06204939|Procedure|Randomizing for OAGB procedure|"Gastric bypass with 1 anastomosis and an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
75755249|NCT00368277|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
75755250|NCT00368277|Drug|Amlodipine|Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
75755251|NCT03992547|Other|Robot-assisted Gait Training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
75608677|NCT05297617|Drug|Anti-aromatase inhibitor|"Treatment will be either:~Letrozole, given per os, 2.5 mg daily~Anastrozole, given per os, 1 mg daily~Exemestane, given per os, 25 mg daily"
75902583|NCT06204926|Diagnostic Test|AI diagnostic algorithm|The SMILE procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
75457052|NCT01779960|Other|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
75755252|NCT00280150|Biological|bevacizumab|Given IV
75902584|NCT06204913|Other|Menu label|Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
75457053|NCT01779973|Behavioral|Remote Observed Dosing|
75457054|NCT01779999|Other|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
75457055|NCT01780012|Behavioral|Osteoporosis prevention program|Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD
75457056|NCT01780038|Behavioral|Receipt of Genetic Results|Participants will receive the results of genotyping for RS1051730
75457057|NCT01780038|Behavioral|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
75608678|NCT02782897|Drug|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
75608679|NCT02782897|Other|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
75755253|NCT00280150|Drug|carboplatin|Given IV
75755254|NCT00280150|Drug|erlotinib hydrochloride|Given orally
75755255|NCT00280150|Drug|paclitaxel|Given IV
75755256|NCT00280150|Radiation|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
75755257|NCT03990753|Diagnostic Test|esophagogastroduodenoscopy|standard esophagogastroduodenoscopy
75755258|NCT01582126|Other|Group balance training|Balance training i group with focus on core stability exercises and dual attention activities.
75755259|NCT03990675|Procedure|FNA, FNB|Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy
75902585|NCT06204900|Device|Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
75902586|NCT06204874|Procedure|Pulsed radiofrequency ablation|See left.
75902587|NCT06204874|Procedure|Sham ablation|See left.
76067954|NCT04752046|Procedure|maxillary cancer resection|patient with maxillary cancer will resected and reconstructed
76072336|NCT01419067|Drug|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
76072337|NCT01377389|Drug|Ipilimumab|10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
76072338|NCT01377389|Drug|Leuprolide|7.5 mg intramuscular once a month for 8 months
76072339|NCT01377389|Drug|Goserelin|3.6 mg subcutaneous once a month for 8 months
76072340|NCT01377389|Drug|Degarelix|80 mg subcutaneous once a month for 8 months
75608680|NCT04229953|Device|US scan with 3D/4D VRU software|"Every patient will be evaluated by grayscale 2D-ultrasound and color Doppler. Then, a Samsung WS 80A Elite US scanner with 3D/4D VRU software will be used to assess the placental invasion by applying the two modes (crystal vue and realistic vue). The image analysis will be performed after obtaining the volume dataset. Data will be compared with the intraoperative findings and histopathological confirmation if hysterectomy will be done."
75608681|NCT05280847|Procedure|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
75755260|NCT01052571|Procedure|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
75608682|NCT00638131|Drug|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
75608683|NCT05142475|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
75608684|NCT02781181|Device|CAS with CPD|using a neuroprotection device
75608685|NCT02781181|Other|CAS without CPD|No Neuroprotection
75608686|NCT02781103|Other|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
75755261|NCT00279916|Drug|Triamcinolone acetonide nasal spray|"Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms)."
75457058|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."
75457059|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."
75457060|NCT01780064|Behavioral|interviews with a psychologist|interviews with a psychologist
75608687|NCT02781103|Other|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
75902588|NCT06204861|Other|Capacitive and Resistive Electric Transfer Therapy|In the initial phase, administer a 60% dosage using the capacitance mode with a 65mm treatment head, targeting the musculature surrounding the ankle joint through a 10-minute session of mobile therapy. Subsequently, transition to the resistance mode, maintaining a 65mm treatment head, and apply a 20% dosage for a further session of mobile therapy.
75902589|NCT06204861|Other|Functional Training|The training program consists of four exercises: one-legged stand, one-legged heel lift, one-legged squat, and one-legged standing catch. Each exercise is performed for two sets. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
75457061|NCT01780064|Behavioral|Questionnaires|Questionnaires
75457062|NCT01780077|Drug|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
75755262|NCT00279916|Drug|Placebo nasal spray|"Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily."
75457063|NCT01780077|Drug|Placebo|Multiple intradermal injections of placebo at incision sites
75755263|NCT02534337|Drug|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
75755264|NCT02534337|Drug|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
75755265|NCT01052649|Other|Blood sampling|
75457064|NCT01780090|Other|iPad software|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
75608688|NCT04229251|Behavioral|Online Mindfulness-based Intervention|The iMBI starts with psychoeducation about ADHD and defining mindfulness. Participants were then encouraged to discuss their experience of living with ADHD via a series of guided questions. Upon orientated to the program, the participants will be introduced to various topics of mindfulness and ADHD, as well as a wide range of in-session online mindfulness exercises. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session. Downloadable audio tracks for offline practices will be provided to the participants. Participants are expected to spend around 15 to 30 minutes each day to complete the weekly iMBI assignment.
75755266|NCT01325896|Drug|PEG-Intron sc injection|"This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse."
75755267|NCT01050933|Drug|250 ppm carbon monoxide|250 ppm of inhaled carbon monoxide over one hour
75608689|NCT04229251|Behavioral|Online Introductory Psychology Program|The online introductory psychology program is a mass online open course program, providing comprehensive overview about psychology as an academic discipline. Each week, participants will be presented with approximately 2-hours pre-recorded lecture. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session.Downloadable handouts for revision will be provided to the participants. Participants are encouraged to spend around 15 to 30 minutes each day to complete the weekly assignment.
75755268|NCT00358527|Drug|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
75755269|NCT00358527|Other|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
75608690|NCT02780245|Drug|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
75755270|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
75457065|NCT01780116|Behavioral|Adherence therapy|Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
75457066|NCT01780129|Drug|Polydatin Injectable|Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
75755271|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
75755272|NCT00251758|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
75755273|NCT03974776|Biological|PF-06946860|PF-06946860 administered subcutaneously
75755274|NCT03974776|Other|Placebo|Placebo administered subcutaneously
75755275|NCT00279214|Drug|drotrecogin alfa (activated)|
75755276|NCT00262834|Drug|vorinostat|Given orally, conventional surgery to follow.
75755277|NCT00262834|Other|conventional surgery|Undergo conventional surgery
75755278|NCT05711459|Drug|Bicyclol tablets|Take Bicyclol tablets for the treatment of liver injury.
75755279|NCT05709665|Other|Time to Decision for eCPR|We evaluate during high quality CPR the time for decision for eCPR
75755280|NCT05707715|Device|XSensor|"A pressure mapping system (X3 SENSOR PX 100:64.160.02, X-Sensor®, Calgary, Canada) was used to record the pressure distribution in mmHg of the head and shoulder section [18,19]. Pressure distribution was recorded for 1 minute for each lying position. The purpose of these measurements was to describe the pressure distribution created by the participants in the pillow and the supported areas, as well as to find out the differences that may occur between the pillows. Lower pressure values measured by the device were defined as high comfort, while more contact of the head area with the pillow was accepted as high support."
75755281|NCT04417361|Drug|Galcanezumab Prefilled Syringe|Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
75755282|NCT04417361|Drug|Placebo|Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
75457067|NCT01780181|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
75457068|NCT01780181|Drug|Chemotherapy|treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
75457069|NCT01780207|Device|PFO Closure|
75902590|NCT06204861|Other|Capacitive and Resistive Electric Transfer Therapy Combined with Functional Training|The training exercises mirror those of the functional training group, and the treatment protocol similarly commences with the application of a 60% dosage using the capacitance mode with a 65mm treatment head. This phase involves a 10-minute session of mobile therapy targeting the musculature surrounding the ankle joint. Subsequently, the intervention diverges as the treatment transitions to the resistance mode, maintaining a 65mm treatment head, and employs a 20% dosage for a focused, fixed-point therapy session.
75902591|NCT06204861|Other|Control Group|Control group received no intervention.
75902592|NCT06204835|Drug|RD-Cy7 fluorophore|Fluorophore targeting ITGA6 that is overexpressed in HCC cells
75902593|NCT06204796|Drug|vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case. In addition, a vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
75457070|NCT01780233|Drug|Fentanyl 400 µg sublingual spray|
75457071|NCT01780233|Drug|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
75457072|NCT01780233|Drug|Fentanyl citrate injection 100 µg intravenously|
75457073|NCT01780233|Drug|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
75457074|NCT01780246|Drug|nusinersen|Administered by intrathecal (IT) injection
75457075|NCT01780259|Drug|Esketamine|1 spray of 14 percent of esketamine solution (14 mg of esketamine per 100 microlitre) will be administered intranasally by nasal spray pump in each nostril once (Treatment A-total dose: 28 mg), twice with 5 minutes interval (Treatment B-total dose: 56 mg), thrice with 5 minutes interval between each repeated sprays (Treatment C-total dose: 84 mg), thrice with 10 minutes interval between each repeated sprays (Treatment D-total dose: 84 mg) and 4 times with 10 minutes interval between each repeated sprays (Treatment E-total dose: 112 mg). Treatment A, B, C, D will be administered in Cohort 1; Treatment D will be administered in Cohort 2; and Treatment E will be administered in Cohort 3.
75457076|NCT01780259|Drug|Placebo|Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
75608691|NCT02780245|Procedure|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
75608692|NCT00634699|Procedure|Active Comparator, ischemic compressions|Ischemic Compressions,3 times a week,5 weeks.
75608693|NCT05341063|Behavioral|Online Education|"Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again."
75608694|NCT05341063|Other|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
75608695|NCT05340985|Dietary Supplement|25(OH)D3|calcifediol
75608696|NCT05340985|Dietary Supplement|vitamin D3|Cholecalciferol
75608697|NCT05340829|Biological|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia
75608698|NCT02780791|Other|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
75608699|NCT02780791|Other|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
75608700|NCT02780947|Procedure|Ventricular tachycardia substrate ablation|"Study protocol~Baseline programmed ventricular stimulation performed from the LV~High density endocardial LV mapping using CARTO® 3 System~Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
75608701|NCT02784457|Drug|Cetrorelix|
75608702|NCT05338177|Other|Immunosuppression reduction|participants stop mycophenolate or azathioprine one week before additional vaccine dose. Overall medication is stopped for two weeks.
75457077|NCT01780259|Drug|Triazolam|Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution in the Treatment F of Cohort 3.
75755283|NCT01563887|Behavioral|DD.com|Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
75755284|NCT01563887|Behavioral|DD.com + MI|Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
76067955|NCT04752202|Behavioral|Individually balanced elimination/reducing diets|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced elimination/reducing diets, in accordance with the previously performed food sensitivity tests for 6 months. Laboratory tests for type III food sensitivity in the IgG1-3 class using the ELISA method were performed in an accredited medical laboratory. Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
76067956|NCT04752202|Behavioral|Individually balanced reducing diets (without elimination)|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced reducing diets (without elimination) for 6 months.Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
75755285|NCT04386239|Drug|Sarilumab Prefilled Syringe|Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
75755286|NCT04004585|Behavioral|Get Up For Your Health|"The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting."
75755287|NCT00541775|Drug|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
75755288|NCT00541775|Drug|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
75902594|NCT06204796|Drug|Systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case.
75902595|NCT06204783|Other|Pressure volume (PV) loop measurement|Pressure volume (PV) loop measurement using a conductance catheter
75902596|NCT06204770|Other|extensive hydrolyzed protein formula|NR Pepti is infant formula for special medical purposes based on extensive hydrolyzed whey protein for infants aged 0-12 months. This milk is intended for cow's milk protein allergy. This product is lactose free with medium chain triglycerides (MCT)
75457078|NCT01780272|Other|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
75902597|NCT06204757|Other|questionary|questionary relating to birth trauma are completed by midwives and patients
75902598|NCT06204744|Other|Home-based GRASP program|The home-based Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve the upper extremity function for people with stroke, including exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
75902599|NCT06204744|Other|Conventional occupational therapy home program|The conventional OT home program will be prescribed by the occupational therapists, customizing stroke rehabilitation exercises to individual patient goals, with a primary focus on improving upper extremity function.
75608703|NCT05338177|Other|No immunosuppression reduction|participants do not alter immunosuppresion
75608704|NCT02780323|Drug|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
75608705|NCT02780323|Drug|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
75608706|NCT02780323|Drug|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
75608707|NCT02780323|Drug|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
75755289|NCT00541775|Drug|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
75755290|NCT00541775|Drug|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of >= 1500 mg.
75755291|NCT05361473|Device|The NeoHilda Point of care method|This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
75755292|NCT05361473|Procedure|Traditional evaluation|Traditional way of evaluation
75755293|NCT04004117|Drug|Fentanyl citrate solution sublingual|Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
75755294|NCT04004117|Drug|Placebo oral liquid|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
75755295|NCT01563965|Dietary Supplement|Carbohydrate plus hydrolyzed protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
75755296|NCT01563965|Other|Preoperative fasting of 8h|Conventional protocol of 8h fasting before an operation
75755297|NCT00539513|Drug|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
75902600|NCT06204731|Other|Exercise and environmental conditions|Participants will engage in interval training and will reside and sleep at different altitudes for a period of 4 weeks. Aerobic and anaerobic capacity tests and an eccentric exercise test will be performed before and after the training intervention. Before and after the training program, somatic measurements will also be taken. Before and after the first and last workout, blood will be drawn for biochemical analysis.
76067957|NCT02091856|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
76067958|NCT00225784|Drug|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
76067959|NCT00225784|Procedure|Radiotherapy|Daily radiotherapy for 28 days
75608708|NCT05331859|Drug|Insulin|Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
75457079|NCT01780285|Device|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
75608709|NCT05331859|Drug|autologous serum (AS)|Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
75608710|NCT05331859|Drug|conventional|Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
75608711|NCT02784691|Device|Feeligreen patch|
75755298|NCT00539513|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
75755299|NCT04506047|Procedure|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
75755300|NCT04119791|Other|wild rice|30 grams of wild rice in the form salad, snack bar and soup
75755301|NCT04003727|Device|Mcgrath Mac Videolaryngoscope|Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
75755302|NCT04094441|Other|chest physiotherapy|chest physiotherapy
75755303|NCT04003883|Device|Holter ECG|A Holter ECG will be recorderd during shifts
75755304|NCT00454584|Drug|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
75755305|NCT00454584|Drug|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
75755306|NCT00454584|Drug|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
76067960|NCT02092168|Drug|BIA 9-1067|
76067961|NCT00132964|Device|Below knee walking cast|Not required
76067962|NCT00132964|Device|Removable ankle brace|not required
76067963|NCT01897246|Procedure|Corrective osteotomy with computer-assisted pre-operative planning|The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
76067964|NCT01897246|Procedure|Corrective osteotomy with conventional preoperative planning|The corrective osteotomy will be planned with conventional preoperative planning.
75755307|NCT03790644|Device|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
75755308|NCT02540915|Other|Standard of Care - Registry|Standard of Care - Registry
75755309|NCT04204343|Drug|Bupivacaine 0.7 ml/kg|Bupivacaine 0.25% 0.7 ml/kg
75755310|NCT04204343|Drug|Bupivacaine 0.5 ml/kg|Bupivacaine 0.25% 0.5 ml/kg
75457080|NCT01780285|Device|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
75457081|NCT01780311|Drug|antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)|
75457082|NCT01780311|Procedure|Catheter Ablation|
75755311|NCT02845271|Drug|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
75755312|NCT02845271|Drug|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
75755313|NCT02845271|Drug|acetaminophen or paracetamol|"Pharmaceutical form: tablet~Route of administration: oral"
75902601|NCT06204718|Other|Standard pelvic floor exercises|Pelvic floor muscle exercises will be given as 2 separate exercises including fast and slow contractions. For fast contractions, participants will be asked to contract their pelvic floor muscles strongly, hold them contracted for 5 seconds, and then relax them. For slow contractions, participants will be asked to gradually contract the pelvic floor muscles, hold them at maximum contraction for 5 seconds, and relax them gradually. Participants will be asked to perform 10 slow contractions after every 10 fast contractions. The aim is to train strength, coordination, endurance, and symmetry of pelvic floor muscles, motor learning and control, dynamic lumbopelvic stability, pelvic floor, and abdominal co-contraction. Every day, 10 fast, and 10 slow contractions with a total of 20 repetitions will be applied without changing the number by modifying the exercises every week. It will be applied for a total of 12 weeks.
75902602|NCT06204718|Other|Involuntary reflexive pelvic floor exercises|Reflexive exercises (jump, squat jump, etc.) with 20 repetitions per day will be applied to the participants for 12 weeks with modifications every week.
75902603|NCT06204692|Procedure|dental implant|consisted of 6 patients where computer guided dental implant placement
75608712|NCT04229407|Dietary Supplement|Dietary supplement|MRI eligibility evaluation Dietary supplement drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise) for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
75755314|NCT02845271|Drug|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule~Route of administration: oral"
75755315|NCT02845271|Drug|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet~Route of administration: oral"
75755316|NCT00445068|Drug|LBH589|
75755317|NCT02404337|Drug|Betaine|
75755318|NCT05361083|Drug|F18CETO|Injection of F18CETO or O15water followed by PET/CT
75755319|NCT02403089|Other|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
75902604|NCT06204679|Drug|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
75902605|NCT06204679|Drug|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
75457083|NCT01780376|Procedure|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
75755320|NCT02403089|Other|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
75755321|NCT00539279|Behavioral|Prolonged Exposure Therapy (PE)|PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
75755322|NCT00539279|Behavioral|Relaxation Training (RT)|RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
75755323|NCT05360147|Drug|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.
75755324|NCT05360147|Drug|Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides|oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
75755325|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
75902606|NCT06204679|Drug|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations
75902607|NCT06204666|Dietary Supplement|High Dose Hemp Fiber Bar|High dose hemp fiber bar with other ingredients
75902608|NCT06204666|Dietary Supplement|Low Dose Hemp Fiber Bar|Low dose hemp fiber bar with other ingredients
75902609|NCT06204666|Dietary Supplement|Placebo|Placebo bar with other ingredients
75608713|NCT04229407|Dietary Supplement|vitamin B|MRI eligibility evaluation vitamin B drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise)for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
75902610|NCT06204653|Device|HFNO group|100% oxygen supplied in proportion to body weight using the Optiflow THRIVETM system while maintaining jaw thrust. (0-12 kg; 2 L/kg/min, 13-15 kg; 30 L/min, 16-30 kg; 35 L/min, 31-50 kg; 40 L/min)
75902611|NCT06204653|Device|MV group|Mask ventilation using the one-hand E-C clamp technique and oropharyngeal airway (fresh gas flow 3 l/min, 100% O2, tidal volume 8-10 ml/kg, respiratory rate 20/min, I:E ratio 1:2, pop-off valve 13 cmH2O).
75902612|NCT06204640|Drug|Spironolactone|Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.
75457084|NCT01780402|Behavioral|Hand feeding techniques|"Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.~Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.~Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position."
75457085|NCT01780415|Other|blastocoele aspiration|
75457086|NCT01780467|Behavioral|Role of dopamine|
75457087|NCT01780480|Drug|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
75457088|NCT01780480|Drug|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
75608714|NCT05340595|Other|Orthodontic retainer bonding|Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.
75608715|NCT04231435|Drug|Fedratinib|Oral
75608716|NCT04231435|Drug|Digoxin|Oral
75608717|NCT04231435|Drug|Rosuvastatin|Oral
75608718|NCT04231435|Drug|Metformin|Oral
75755326|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5*10^6 CD34+ cells/kg were collected.
75755327|NCT00444912|Biological|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
75902613|NCT06204627|Device|TDCS|Technique of non-invasive brain stimulation by direct current (TDCS) which involves the modulation of excitability and brain activity, capable of promoting reorganization of the cortical representation of the body schema or motor planning, and consequently, pain relief.
75902614|NCT06204627|Device|Recognise (hand)- Laterality|This technique stimulates the ability to recognize hand images as right/left quicklPatients with chronic pain present delayed recognition of hand laterality, which is related to the duration of symptoms and the pain evoked by the execution of the movement. Thus, this technique can have beneficial effects in breaking the pain.
75902615|NCT06204627|Other|TDCS sham|TDCS sham: The device remains inactive for 20 minutes.
75902616|NCT06204627|Other|landscape recognition|Image recognition training that does not refer to right/left discrimination.
75902617|NCT06204614|Device|Implantable Micro-Device|The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.
75902618|NCT06204614|Drug|Methotrexate|Methotrexate will be placed in reservoir 1 of the implantable microdevice.
75755328|NCT00538733|Drug|thalomid|"Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)"
75755329|NCT00538733|Drug|lenalidomide|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle"
75755330|NCT00538733|Drug|clarithromycin|"During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)"
75755331|NCT00538733|Drug|dexamethasone|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)"
76067965|NCT00133978|Other|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
76067966|NCT00133978|Other|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
76067967|NCT00133978|Other|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
76067968|NCT00133978|Other|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
76067969|NCT01897324|Drug|Growth hormone (Norditropin, Novo nordisk)|
76067970|NCT01897948|Other|Milk-based beverage without DHA|
75608719|NCT05340517|Procedure|video-assisted rib planting|Give the patient intercostal nerve block and laryngeal mask anesthesia, after that, put the patient in lateral position. Make a 4-6cm posterolateral incision along the lower edge of the scapula，sever latissimus dorsi and serratus anterior and reach the rib surface. Lift the scapula with the abdominal retractor (or xiphoid retractor), Free adhesion tissue inside the scapula and put in the thoracoscopic lens. Free the tissue of the upper and lower edges of the ribs carefully, reset ribs and insert rib plate, which is fixed by 90° electric drill and locking screw.
75457089|NCT01780480|Procedure|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
75457090|NCT01780493|Procedure|The Direct Nipple Ureteroneocystostomy Technique|
75608720|NCT05340439|Drug|IncobotulinumtoxinA 100 UNT [Xeomin]|"In cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs.~In cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2.~In cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 600U) may be administered in the cycle 3 (if the patient has been treated with 16U/kg in cycle 2, a dose of 19U/kg may be injected in cycle 3)."
75755332|NCT00444678|Drug|Cetuximab|500 mg/m2, IV every two weeks
75755333|NCT00444678|Drug|Oxaliplatin|85 mg/m2, IV, q 2 weeks
75755334|NCT00444678|Drug|Capecitabine|2500 mg, po bid x 7 days every two weeks
75755335|NCT00358449|Drug|mepolizumab|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
75755336|NCT00539981|Biological|FluBlok®|Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
75755337|NCT00539981|Biological|Placebo|Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
76067971|NCT01897948|Other|Milk-based beverage with DHA at mid level|
76067972|NCT01897948|Other|Milk-based beverage with DHA at high level|
76067973|NCT00253708|Procedure|management of therapy complications|
76067974|NCT00253708|Procedure|massage therapy|
76067975|NCT00253708|Procedure|pain therapy|
76067976|NCT00253708|Procedure|psychosocial assessment and care|
75457091|NCT01780519|Drug|lorazepam|single dose of 1 mg lorazepam
75457092|NCT01780532|Procedure|Photoacoustic Imaging (PAI)|Standard of Care
75457093|NCT01780558|Other|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
75755338|NCT00990119|Device|Vapotherm High Flow Therapy|use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
75902619|NCT06204614|Drug|Carboplatin|Carboplatin will be placed in reservoir 2 of the implantable microdevice.
75902620|NCT06204614|Drug|Avelumab|Avelumab will be placed in reservoir 3 of the implantable microdevice.
76067977|NCT00253708|Procedure|quality-of-life assessment|
75755339|NCT00990119|Device|Non-invasive positive pressure ventilation|Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress.
75755340|NCT03992157|Device|ECG telemetry|ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
75608721|NCT05340361|Device|Optical coherence tomography-guided percutaneous coronary intervention|OCT examination is performed using a frequency-domain OCT system (C7 Dragonfly OPTIS Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
75755341|NCT00990197|Drug|Transdermal nicotine patch|Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
75755342|NCT03992079|Procedure|ReCOVER Enhanced Recovery Protocol|The experimental group will receive preemptive pain management before surgery, an opioid-free strategy during surgery, and an opioid-sparing multimodal pain management protocol after surgery.
75755343|NCT01051011|Drug|insulin glargine|initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks
75902621|NCT06204614|Drug|Paclitaxel|Paclitaxel will be placed in reservoir 4 of the implantable microdevice.
76067978|NCT00254410|Drug|Fludarabine|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
76067979|NCT00254410|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
76067980|NCT00254410|Drug|Mitoxantrone|Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
76067981|NCT00254410|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
76067982|NCT00254410|Drug|Filgrastim|Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
76067983|NCT00254488|Drug|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
76067984|NCT00254488|Drug|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
76067985|NCT00255970|Other|DFDBA|Demineralized Freeze Dried Allograft bone
76067986|NCT00255970|Device|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
75457094|NCT01780558|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
75457095|NCT01780571|Procedure|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
75755344|NCT01051011|Drug|metformin|as prescribed
75755345|NCT01051011|Drug|taspoglutide|10mg sc weekly, 24 (-52) weeks
75755346|NCT01051011|Drug|taspoglutide|10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
75755347|NCT05359913|Behavioral|Cervical cancer podcast for African American women|"The video podcast will deliver cervical cancer prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, & live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
75755348|NCT05361005|Drug|BDB-001 injection|Intravenous injection
75755349|NCT05361005|Drug|Placebo|Intravenous injection
75755350|NCT01324791|Procedure|anti-reflux surgery|
75755351|NCT05360927|Drug|BDB-001 injection|Intravenous injection
75755352|NCT05360927|Drug|Placebo|Intravenous injection
75755353|NCT01051089|Behavioral|Lifestyle modification|Exercise and diet education
75755354|NCT01048749|Other|aquatic vertical suspension.|Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
75755355|NCT01048749|Other|land-based supine flexion|The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
75755356|NCT01048827|Drug|Busulfan|"1250 uMol*min (AUC to time 6 hrs)^~1400 uMol*min (AUC to time 6 hrs~1550 uMol*min (AUC to time 6 hrs)^"
75755357|NCT01302327|Drug|Exenatide|Exenatide
75755358|NCT01659749|Behavioral|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
75902622|NCT06204614|Drug|Vinblastine|Vinblastine will be placed in reservoir 5 of the implantable microdevice.
75902623|NCT06204614|Drug|Gemcitabine/Cisplatin I|Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.
75902624|NCT06204614|Drug|Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
76067987|NCT01899118|Radiation|Preoperative irradiation|50.4Gy/28F/5.5w
76067988|NCT01899118|Drug|Nimotuzumab|400mg/w，0-5w
76067989|NCT01899118|Drug|Oxaliplatin|130mg/m2 d1
76067990|NCT01899118|Drug|Capecitabine|825mg/m2 bid d1-5/w,1-5w
76067991|NCT00256984|Procedure|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
75755359|NCT01048983|Drug|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
75755360|NCT01048983|Drug|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
75755361|NCT01048983|Drug|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
75755362|NCT01048983|Drug|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
75755363|NCT01048983|Behavioral|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
75608722|NCT05340361|Device|Optical coherence tomography-guided Onyx expansion|"Expansion of 2.25, 3.0, and 4.0 mm Resolute Onyx @ nominal pressure~OCT pullback~Expansion with over 0.5mm sized non-compliant balloon of each stent~OCT pullback~Expansion with over 1.0mm sized non-compliant balloon of each stent~OCT pullback~Expansion with over 1.25~1.5mm sized non-compliant balloon of each stent~OCT pullback~Evaluation of polymer status with overexpansion assessed by an electric microscope"
75608723|NCT01194414|Drug|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
75608724|NCT01194414|Drug|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
75608725|NCT01194414|Drug|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
75608726|NCT01194414|Drug|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
75608727|NCT01194414|Drug|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
75755364|NCT03929783|Procedure|Contrast Enhanced Digital Mammography|Undergo CEM
75902625|NCT06204614|Drug|Gemcitabine/Cisplatin II|Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.
75755365|NCT01052805|Procedure|harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
75902626|NCT06204614|Drug|Cisplatin|Cisplatin will be placed in reservoir 9 of the implantable microdevice.
76067992|NCT00231868|Drug|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
75902627|NCT06204614|Drug|Nivolumab|Nivolumab will be placed in reservoir 10 of the implantable microdevice.
75902628|NCT06204614|Drug|Pembrolizumab|Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.
75902629|NCT06204614|Drug|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.
76067993|NCT00231868|Procedure|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
75608728|NCT05340283|Procedure|physiotherapy|Patients received physiotherapy treatment at home for a certain period of time. Data were collected on the assessments made at the beginning and at the end of the physiotherapy treatment.
75608729|NCT02686411|Other|Survey Administration|Complete survey
75755366|NCT02534181|Drug|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
75755367|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
75608730|NCT05340127|Device|CEREBO®|Usability Study
75608731|NCT05327413|Other|CT and MRI|CT and MRI were conducted to measure the femoral external rotation
75608732|NCT02784769|Other|measurement of skin autofluorescence|
75608733|NCT02784769|Other|skin biopsy collection|
75755368|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
75755369|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
75902630|NCT06204614|Drug|Methotrexate/Vinblastine/Doxorubicin/Cisplatin|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
75902631|NCT06204614|Drug|Gemcitabine/Cisplatin/Nivolumab|(Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.
75902632|NCT06204614|Drug|Erdafitinib|Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
75902633|NCT06204614|Drug|Paclitaxel/Docetaxel/Ifosfamide|(Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
75902634|NCT06204614|Drug|Gemcitabine|Gemcitabine will be placed in reservoir 17 of the implantable microdevice.
75755370|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
75902635|NCT06204614|Drug|Gemcitabine/Carboplatin/Nivolumab|(Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.
75608734|NCT02173405|Drug|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
75608735|NCT02173405|Drug|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
75902636|NCT06204614|Drug|Enfortumab|Enfortumab will be placed in reservoir 19 of the implantable microdevice.
75902637|NCT06204614|Drug|Sacituzumab|Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
75902638|NCT06204601|Other|Education According to Meleis' Transitional Theory to Patients With Pacemaker|Patients in the experimental group will be trained according to Meleis's Transition Theory.
75902639|NCT06204588|Procedure|control group: SFA only|Single flap approach
75902640|NCT06204588|Procedure|Test group 1: VCMX + Low level LASER therapy + Single flap approach|using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
75902641|NCT06204588|Procedure|Test group 2: Low level LASER therapy + Single flap approach|Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).
75902642|NCT06204575|Other|Data collection|Data collection
75608736|NCT04228939|Behavioral|Recovery Record aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16."
75608737|NCT04228939|Behavioral|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.
75902643|NCT06204562|Behavioral|imitated laughter practice|"To imitate laughter, participants will practice Duchenne smile, which is reported to associate with positive emotion in people producing it If participants cannot imitate a Duchenne smile, they can hold a chopstick horizontally in their mouth tightly. To help timing the 3-minute and to enhance adherence, an audio recording with joyous music and vocal instruction will be played alongside the practice. Versions with or without laugh voice will be prepared for their preferences. A logbook will be given to each participant to record their practice. To remind participants to practise, a reminder will be made each day through the public announcement system of the respective nursing home, and the audio guide will be played."
75902644|NCT06204549|Other|Screening and management of cormobidities|"During the routine care assessment and as part of the research, patients will :~Fill in cardiovascular risk assessment score: Life's simple 7~Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection.~After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin/creatinine ratio, protein/ urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days."
75902645|NCT06204536|Other|Tech-enabled ABA treatment planning|The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.
76067994|NCT00231868|Drug|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
76067995|NCT00257686|Drug|Pitavastatin|
76067996|NCT00257686|Drug|Pravastatin|
75608738|NCT05017051|Behavioral|Chocolate cake|The participants will have to make a chocolate cake following an imposed recipe at 4 visits (initially (M0), after 12 months (M12), after 24 months (M24) and after 36 months (M36)).
75755371|NCT03990441|Device|TENS|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
75902647|NCT06204497|Procedure|Stent-based Diverting Technique|The stent-based diverting technique (SDT) contains two parts to achieve feces diversion One is a degradable solid intestinal stent to be implanted 20 cm from the terminal ileum and could be gradually degraded within 3-4 weeks. Another part is a drainage tube to be placed at the proximal 5-10 cm of the aforementioned stent. Given this SDT, intestinal contents could be diverted through the drainage tube, and the stent prevents the feces from entering the distal intestinal. After removing the drainage tube after 3-4 weeks, intestinal contents will freely access the distal intestinal space following the degradation of the stent. For patients, stoma reversal is avoided.
75902648|NCT06204484|Other|CAPEOX adjuvant therapy|In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
75902649|NCT06204484|Other|deferred CAPEOX adjuvant therapy|In MRD-negative deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
75902650|NCT06204484|Other|mFOLFOXIRI intensive adjuvant therapy|In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month mFOLFOXIRI intensive therapy, instead of the CAPEOX standard adjuvant therapy.
75902651|NCT06204471|Device|Helite hip protector|hip protector
75608739|NCT05017051|Behavioral|Lego model|The participants will have to build a Lego model at 4 visits (M0, M12, M24 and M36).
75902652|NCT06204471|Device|Wolk hip protector|Hip protectdor
75902653|NCT06204458|Other|mild hyperthermia group|The hyperthermia treatment is carried out in a cycle of two treatments per week, with at least one day in between, over a period of two weeks, according to the manufacturer's instructions. For better tolerability, the application takes place under administration of 10L/min oxygen. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
75457096|NCT01780610|Drug|Letrozole and human chorionic gonadotrophin|the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.
75608740|NCT05017051|Device|Measurement of sensorimotor abilities|The measurement of sensorimotor abilities is based on a multi-sensor device called Smart Flat specifically designed for this study at 4 visits (M0, M12, M24 and M36).
75608741|NCT05017051|Other|Measurement of facial expression of emotions|Participants will have to evoke an emotionally charged autobiographical story by modulating facial expressions through a mirror at 4 visits (M0, M12, M24 and M36).
75608742|NCT05339971|Other|block perforation|The bone block used for lateral bone augmentation will be perforated several times.
75608743|NCT02780557|Behavioral|Contingent Reading Intervention|Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
75755372|NCT03990441|Device|TENS Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
75902654|NCT06204458|Other|sham group|Within the application, patients in the Sham group will undergo a hyperthermia application with virtually no overheating. To achieve this, the patients are positioned on the hyperthermia device in the same way as the intervention group. An insulating foil applied beforehand prevents direct irradiation with water-filtered infrared-A radiation. This prevents an increase in temperature. Due to the insulating blanket and the natural heat from the device and body, patients in the Sham group experience a gentle warmth that cannot be compared with regular whole-body hyperthermia and an increase in core body temperature of around 1.5°C. The number of treatments, the lighting conditions and procedures including 10L/min oxygen supply, is equal to the treatments in the intervention group.
75902655|NCT06204445|Dietary Supplement|Green coffee|Each cup of coffee provides approximately 400 mg of hydroxycinnamic acids.
75902656|NCT06204445|Dietary Supplement|Roasted coffee|Each cup of coffee provides approximately 150 mg of hydroxycinnamic acids.
75457097|NCT01780610|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
75457098|NCT01780623|Device|Bright white light|
75457099|NCT01780623|Device|Dim red light|
75457100|NCT01780649|Procedure|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
75608744|NCT02780557|Behavioral|Book Provision Control|Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
76067997|NCT00234286|Behavioral|Comfort care education intervention|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
76067998|NCT01469013|Drug|Placebo|
76067999|NCT01469013|Drug|Baricitinib|
76068000|NCT01469013|Drug|Baricitinib|
76068001|NCT01469013|Drug|Baricitinib|
76068002|NCT01469013|Drug|Methotrexate|Administered orally as background therapy
76068003|NCT01493427|Drug|Travoprost 0.004%|Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
76068004|NCT01523457|Drug|Folfirinox|"Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~Leucovorin 400 mg/m2 IV over two hours~Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
76068005|NCT01523301|Drug|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
75608745|NCT04231045|Device|PiCCO device cardiac monitoring|"PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique.Haemodynamic monitoring~especially if complex mixed forms of shock (e.g. septic and cardiogenic) PAC unavailable or contra-indicated"
75608746|NCT04228471|Procedure|spontaneous breathing activity during APRV|Allowing spontaneous breathing activity with APRV throughout the first 48 hours.
75608747|NCT04228471|Procedure|No spontaneous breathing activity|No spontaneous breathing activity will be allowed with pressure controlled ventilation throughout the first 48 hours.
75457101|NCT01780649|Procedure|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
75457102|NCT01780688|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.
75608748|NCT02784145|Dietary Supplement|Resistant starch|
75457103|NCT01780688|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
75457104|NCT01780701|Procedure|Magnetic Resonance Spectroscopy Imaging with rectal probe|
75457105|NCT01780714|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
75457106|NCT01780714|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
75457107|NCT01780740|Drug|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
75608749|NCT02784145|Other|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
75608750|NCT05322031|Drug|Aripiprazole|Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.
75608751|NCT02779621|Procedure|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
76068006|NCT01523301|Drug|Placebo|"Transdermal Patch~Size:~10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo received matching placebo patches"
76068007|NCT02985567|Other|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
76068008|NCT01806506|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
75755373|NCT05359757|Other|Effect of Naturalistic Teaching Strategies in Children with autism spectrum disorder|"In this group, the patients will be provided with both the naturalistic therapeutic techniques the PECS Therapy.~A baseline of the kids in this group will be made using the portage guide and PECS~Incidental teaching trial, natural language paradigm, and time delay concepts will be incorporated in the therapy sessions and communication using picture cards will be made.~40 minutes session will be conducted in which 20 minutes session will be for naturalistic teaching techniques and 20 minutes will be for PECS.~This will be followed for 30 sessions"
75902657|NCT06204432|Drug|Sodium Citrate|Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
75902658|NCT06204432|Drug|Normal Saline|Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
75902659|NCT06204432|Other|"Olfactory Training Kit - The Olfactory Kit, by AdvancedRx"|All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray
75902660|NCT06204419|Drug|XH-S002 （A）|XH-S002 powder will be administered orally as per assigned treatment regimen.
75902661|NCT06204419|Other|Placebo（B）|XH-S002 Placebo (matched) will be administered orally as per assigned treatment regimen.
75902662|NCT06204406|Other|Observational|This is a prospective observational study with observation only and no intervention
75902663|NCT06204393|Other|Thyroid metabolic index|The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.
76068009|NCT01806506|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
75608752|NCT02779621|Procedure|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
75902664|NCT06204367|Diagnostic Test|Lung Ultrasonografisi|It is aimed to compare the agreement between lung ultrasonography and clinical score in the diagnosis and follow-up of newborn babies who are followed up in the neonatal intensive care unit due to bronchiolitis caused by frequently encountered RSV and other viral factors.
75902665|NCT06204341|Radiation|HYPOPRIME treatment|Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
75902666|NCT06204328|Other|Benson relaxation technique and mHealth psychoeducation|"Benson relaxation technique & mHealth psychoeducation (combined intervention) will receive: 6 months.~Benson relaxation technique: Definition, benefits, and instruction about the Benson relaxation technique will be provided through recorded video, and a nurse will guide individuals face-to-face after receiving training from a physiotherapist.~mHealth psychoeducation: There will be six sessions in a total of six months of intervention, and every session will be conducted at the beginning of each month. During each session, recorded videos based on the self-determination theory (symptom management, maintaining and enhancing relationships, problem-solving, stress and coping, self-care, and effective communication) will be provided face-to-face to the intervention group via smartphones, tablets, or handheld computers. As well as phone calls and SMS reminders will continue every week for follow-up and question and answer sessions."
75902667|NCT06204315|Radiation|Stereotactic Radiosurgery|Given by RTx
75902668|NCT06204289|Behavioral|Nurse-led Supportive Care Programme|Nurse-led supportive care programme was applied to family caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 40 minutes to interview with family caregivers at the clinic.
76068010|NCT01766336|Drug|Group 1 ELND005|
76068011|NCT01766336|Drug|Group 2 ELND005|
75457108|NCT01780740|Drug|Placebo|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
75608753|NCT02780011|Drug|Brentuximab Vedotin|Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
76068012|NCT01797536|Drug|Elbasvir|
76068013|NCT01797302|Dietary Supplement|Vitamin D3|Tablet form
76068014|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
75457109|NCT01780753|Drug|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
75457110|NCT01780779|Other|MRI|"MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment."
76068015|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
75457111|NCT01780792|Other|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
75457112|NCT01780818|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
75608754|NCT02780011|Drug|Alsertib|Aurora A kinase inhibitor
75608755|NCT02780479|Drug|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
75608756|NCT02780479|Drug|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
75755374|NCT05359757|Other|PECS Therapy only|"A baseline will be developed using the portage guide and PECS.~Communication strategies using the PECS picture cards will be made~30 minutes session will be conducted~This will be followed for 30 sessions"
75755375|NCT03990597|Other|Placebo Administration|Applied topically
75755376|NCT03990597|Other|Questionnaire Administration|Ancillary studies
75755377|NCT03990597|Drug|Wound Dressing Material|Applied StrataXRT topically
75755378|NCT01340417|Other|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
75608757|NCT05252923|Drug|Sulodexide|Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
75608758|NCT00634777|Other|pet scan|pet scan
75608759|NCT05097079|Drug|MYOBLOC Low Dose|Weight-based dose; 5.0 units/kg for submandibular gland and 25.0 units/kg for parotid gland
75608760|NCT05097079|Drug|MYOBLOC High Dose|Weight-based dose; 10.0 units/kg for submandibular gland and 40.0 units/kg for parotid gland
75755379|NCT01049061|Drug|MORAb-003|MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
75755380|NCT01049139|Behavioral|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
75755381|NCT01049139|Behavioral|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
75755382|NCT02533947|Behavioral|Exercise|The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.
75902669|NCT06204263|Other|finger feeding|The fathers of premature babies in intensive care will be interviewed and an educational booklet will be prepared about finger feeding, cleaning, hygiene, hand washing, the importance of sucking, and the rules to be followed to prevent infection in the newborn, and how to apply it will be explained by the researcher. Babies will be breastfed three times a day for seven days.
75902670|NCT06204211|Diagnostic Test|ophthalmologic examinations|All the included personnel underwent routine ophthalmologic examinations on binoculus, including slit lamp microscope observation, intraocular pressure, diopters of refractive error, best corrected visual acuity, AL measurement, fundus photography and optical coherence tomography, adhering to the established and normalized principles.
75902671|NCT06204198|Other|No intervention|No intervention
75457113|NCT01780818|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
75457114|NCT01780818|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
75608761|NCT05097079|Drug|Placebo|volume-matched placebo
75608762|NCT05339737|Device|Nociception Level (NOL) Index|The NOL integrates multiple physiologic parameters that are captured through a finger probe with disposable sensor. These parameters include heart rate, heart rate variability, photoplethysmography pulse wave amplitude, skin conductance and temperature, and their time derivatives. All these parameters are analyzed simultaneously to provide the NOL index which can range from 0 to 100. Values >25 were found to be indicative of nociception and related-pain in the field of anesthesia. The investigators will use the Pain Monitoring Device-200 (PMD-200)TM, which offers the multi-parametric NOL index (0-100) (Medasense Biometrics Ltd., Ramat Gan, Israel), and was approved by Health Canada for clinical use in September 2017.
75755383|NCT02533947|Behavioral|Control|A waitlist control group will get the intervention after 7 month of treatment as usual.
75755384|NCT00367341|Drug|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
75755385|NCT00367341|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
75755386|NCT01052961|Drug|Oseltamivir|oseltamivir 150 mg bd for 5 days
75755387|NCT02534025|Procedure|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
75755388|NCT00440466|Drug|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
75755389|NCT00440466|Drug|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
75755390|NCT00440466|Drug|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
75755391|NCT03992313|Other|Community-based HCV rapid test|HCV rapid tests will be done in the village
75755392|NCT03992313|Other|Facility-based HCV rapid test|HCV rapid tests will be done in the health center
75755393|NCT03992313|Other|Plasmatic HCV viral load|HCV viral load will be done in provincial hospital on plasma using GenXpert
75755394|NCT03992313|Other|DBS HCV viral load|HCV viral load will be done in Phnom Penh by DBS using Omunis kit
75608763|NCT02779309|Procedure|Home Care/RAI-HC Assessment|Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
75902672|NCT06204185|Drug|Metformin|Locally delivered Metformin gel in the treatment of periodontitis patients
75902673|NCT06204185|Drug|Placebo|Placebo gel consist of drug without the active component.
75902674|NCT06204172|Device|Intensive Neurowave Emotional Stimulation (INES)|Patients will undergo Neurowave-assisted multisensory stimulation five days a week for four weeks, featuring emotionally significant audio-visual content tied to personal history. Control group participants will experience primary auditory stimulation through familiar sounds, following a traditional rehabilitation approach mimicking the experimental group's frequency and intensity but without Neurowave use. This allows for a meaningful comparison of the two groups' experiences.
75902675|NCT06204172|Other|Intensive Sensorial Emotional Stimulation (ISES)|The Intensive Sensorial Emotional Stimulation (ISES) in the control group involves primary auditory stimulation with emotionally rich everyday sounds, including familiar voices, favorite songs, and sounds related to daily life and past activities. It mimics the experimental group's frequency and intensity, lasting 45 minutes per session, five days a week, for four weeks. Unlike the experimental group using Neurowave, the control group follows a traditional rehabilitation approach with paper materials, live photos, face-to-face interaction, and classic music tapes, facilitating a meaningful comparison between the two groups' experiences.
75902676|NCT06204146|Behavioral|massage|stressn level and preterm growth
75902677|NCT06204133|Other|Artificial intelligence model building|Using non-image medical data of cervical lesions and clinical pathology results in different medical institutions, machine learning is adopted to establish multiple multi-modal cervical cancer intelligent screening prediction models. This method was used to analyze the prediction performance of the multi-modal cervical cancer intelligent screening prediction and risk triage model, and to evaluate and optimize the self-learning ability of the established multi-modal cervical cancer intelligent screening prediction model.
75902678|NCT06204120|Drug|LPM3480392 Injection|PCA administration
75902679|NCT06204120|Drug|Placebo|PCA administration
75902680|NCT06204120|Drug|morphine hydrochloride injection|PCA administration
75902681|NCT06204107|Drug|CKD-379(Empagliflozin+sitagliptin+metformin) Test drug|oral, once
75902682|NCT06204107|Drug|CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug|oral, once
75902683|NCT06204094|Radiation|node-sparing short-course radiotherapy|5Gy*5d, radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes
75902684|NCT06204094|Drug|Sintilimab|200mg intravenous infusion d1 of each cycle*8cycles
75902685|NCT06204094|Drug|Capecitabine|1000mg/m2, PO, BID, d1-14 of each cycle*8cycles
75608764|NCT02780635|Behavioral|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
75902686|NCT06204094|Drug|Oxaliplatin|130mg/m2, intravenous infusion,d1 of each cycle*8cycles
75902687|NCT06204094|Procedure|TME surgery|laparoscopic or robotic TME surgery for non-cCR patients
75902688|NCT06204094|Procedure|watch and wait|WW for cCR patients
76068016|NCT04413968|Diagnostic Test|Rapid detection test|Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff
76068017|NCT04413968|Diagnostic Test|Nasopharyngeal swab|Posterior nasopharyngeal swabbing in children
76068018|NCT04413968|Diagnostic Test|Stool collection|Stool collection in children
76068019|NCT01804946|Drug|Ergoferon|Safety and Efficiency of Ergoferon in treatment of Influenza
76068020|NCT01804946|Drug|Oseltamivir|Safety and Efficiency in treatment of Influenza
76068021|NCT01737398|Drug|Inotersen|
75902689|NCT06204081|Device|CSO_without cueing|The sole is worn without using the cueing application
75902690|NCT06204081|Device|CSO_cueing|The sole is worn with using the cueing application
75902691|NCT06204068|Device|Spica cast|Spica cast is a cast that is placed while the child is sedated or under anesthesia, covering lower part of belly, waist, and both legs made up of fiberglass, also keeps legs in abduction and flexion. This device will be used as intended and is commonly used for the treatment of DDH.
75457115|NCT01780909|Drug|Paromomycin Sulfate Fasted State|
75457116|NCT01780909|Drug|Paromomycin Sulfate Fed State|
75457117|NCT01780909|Drug|Paromomycin Sulfate w/ domperidone|
75457118|NCT01780909|Drug|Paromomycin Sulfate w/ loperamide HCl|
75457119|NCT01780948|Drug|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
75457120|NCT01780948|Drug|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
75902692|NCT06204068|Device|Rhino brace|Hip abduction brace will be used, which keeps the legs abducted and flexed. A hip brace is a special type of brace that is designed to hold the hips in a flexed and abducted position. This position allows the hip joint to develop properly while it heals. This device will be used as intended and is commonly used for the treatment of DDH.
75902693|NCT06204055|Other|Intramuscular Dry-Needling|It is a minimally invasive procedure where a solid filament needle is inserted deeply into a myofascial trigger point (MTrP) within a muscle in an attempt to abate it and illicit a desired treatment effect.
76068022|NCT01737398|Drug|Placebo|
76068023|NCT01795898|Drug|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
76068024|NCT01736696|Drug|tofacitinib|5 mg BID For 13 days and once on Day 14
76068025|NCT01736696|Drug|tofacitinib|10 mg BID for 13 days and once on Day 14*
76068026|NCT01736696|Drug|tofacitinib|20 mg BID for 13 days and once on Day 14
75755395|NCT01051167|Drug|Cetuximab|500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
75755396|NCT00537485|Drug|SPM 962|transdermal application, 1 time per day
75755397|NCT00537485|Drug|placebo|transdermal application, 1 time per day
76068027|NCT01736696|Drug|tofacitinib|30 mg BID for 13 days and once on Day 14
76068028|NCT01736696|Drug|tofacitinib|60 mg tablet once a day (QD) for 14 days
76068029|NCT01736696|Drug|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
75457121|NCT01781000|Behavioral|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
75457122|NCT01781000|Behavioral|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
75457123|NCT01781000|Behavioral|Treatment as usual|standard treatment protocol of schizophrenia ward
76068030|NCT01736540|Device|MRI scan|MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2*, respectively).
75608765|NCT02780635|Behavioral|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
75608766|NCT02779387|Drug|Goserelin Acetate|
75755398|NCT00616967|Drug|carboplatin|Given IV
75755399|NCT00616967|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
75755400|NCT00616967|Drug|vorinostat|Given orally
75755401|NCT00616967|Other|placebo|Given orally
75755402|NCT04003571|Behavioral|Augmented Reality with Functional Electrical Stimulation group|Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.
75755403|NCT04003571|Behavioral|Traditional physiotherapy|Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
76068031|NCT01794338|Device|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
76068032|NCT01794338|Device|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
76068033|NCT01609478|Drug|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
76068034|NCT01609478|Drug|placebo|placebo delivered via Concept 1 inhaler
76068035|NCT01609478|Drug|mometasone furoate|via Twisthaler inhaler
76068036|NCT01764854|Drug|AZD1722 (in-patient)|doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting
76068037|NCT01764854|Drug|Placebo (in-patient)|Placebo, size and color matched to experimental drug administered in a CPU
75457124|NCT01781013|Other|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
75457125|NCT01781052|Drug|Ventavis (Iloprost, BAYQ6256)|Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
75457126|NCT01781065|Device|transcranial direct current stimulation|
75608767|NCT04228315|Drug|Primaquine|radical cure dosing
75608768|NCT04228393|Drug|6-mercaptopurine|6-mercaptopurine was administered orally to patients once daily.
75608769|NCT04228393|Procedure|Standard treatment|The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.
75608770|NCT04228393|Procedure|Individualized treatment|The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
75608771|NCT05246761|Device|Balloon catheter|In the two groups, if their bishop score <6, they will receive the cervical riening by the balloon catheter, and then the oxytocin if necessary.
75608772|NCT02779777|Drug|Tipifarnib|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
75608773|NCT05296915|Device|tVNS|An electric current with a frequency of 25 Hz (Figure 2) will be applied to the cymba conca of the left ear through a specific device (VITOS, Cerbomed, Germany; CE marking). The stimulation intensity will be customized between 0.1 and 5 mA according to the sensitivity threshold of each participant. Patients will be instructed to perform tVNS at home for 4 non-consecutive hours per day for 12 weeks, in accordance with the protocol reported in the literature for the treatment of major depression.
75457127|NCT01781091|Device|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
75902694|NCT06204029|Behavioral|Everyone can sing|"The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means."
75902695|NCT06204016|Drug|Estradiol Valerate|To elevate estradiol levels each woman will receive 12mg on two consecutive days (total 24mg) of estradiol valerate (Progynova21©)
75902696|NCT06204016|Drug|Placebo|Placebo tablets will be administered as placebo-controlled condition (P-Tabletten White 7mm, Lichtenstein)
75902697|NCT06204003|Drug|Cannabis/Hemp Isolate Extract|Formulation: CBD (99%; 0.1% THC isolate)
75902698|NCT06203990|Behavioral|Barre exercise|Group barre exercise class
75902699|NCT06203977|Drug|Colchicine|0.3mg and 0.6mg tablets
75902700|NCT06203964|Other|No intervention|No intervention
75457128|NCT01781091|Device|Conventionals Modes|
75457129|NCT01779323|Other|Pre and Post Sling Pelvic MRI|Pre and Post Sling Pelvic MRI
75608774|NCT05296915|Device|rTMS|"The stimulation will be carried out with a TMS STM9000 system (Ates, Medica Device s.r.l., Italy) equipped with a 70 mm butterfly cooled coil. The stimulation protocol followed will be the one approved by the FDA for major depression, that is, a stimulation at the level of the left dorsolateral prefrontal cortex at an intensity equal to 120% of the motor threshold, at the frequency of 10hz. Each stimulation session will last 37.5 minutes, and will consist of 75 trains lasting 4 seconds, with a 26-second break between each train. During each session, a total of 3000 stimuli will be administered. The sessions will take place 5 days a week, from Monday to Friday, for 4 weeks, and for a total of 20 sessions of stimulation."
75608775|NCT05296915|Behavioral|CBT-E|Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)
75608776|NCT02779933|Other|Epidemiology od HAP|no intervention
75457130|NCT01781117|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
75457131|NCT01781117|Device|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
75457132|NCT01781130|Procedure|Steroid injection|
75457133|NCT01781221|Device|Alpha-Bio's GRAFT Natural Bovine Bone|
75457134|NCT01781221|Device|Bio-Oss xenograft|
75457135|NCT01781247|Behavioral|Minimal behavioral intervention|The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
75457136|NCT01781247|Behavioral|Control intervention|"The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided."
75608777|NCT05286697|Diagnostic Test|measuring optic nerve diameter|During the measurement of the optic nerve diameter, a layer of sterile water-soluble gel will be applied on the closed eyelid with a linear 10-5 MHz ultrasound probe.
75608778|NCT05339425|Other|No additional intervention will be administered.|No additional intervention will be administered.
75608779|NCT05340049|Diagnostic Test|Online questionnaire of children's backgrounds|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children.
75608780|NCT05340049|Other|Academic behavioral intervention of teachers|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
75902701|NCT06203951|Diagnostic Test|Xpert® CT/NG and TV testing|Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment. Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment. Participants assigned to receive Xpert® testing will be counseled on CT/NG/TV testing, including the benefits of testing even in the absence of symptoms to detect asymptomatic infections (as informed by pilot evaluation). If a client accepts Xpert® testing, she will be instructed by the study nurse on how to self-collect a vaginal swab.
75902702|NCT06203938|Device|Transcranial infrared light stimulation|Trancranial infrared light stimulation administered via light-emitting diodes
75902703|NCT06203938|Device|Sham|Identical to TILS, but with lights off
76068038|NCT01764854|Drug|AZD1722 (out-patient)|doses between 5 and 45 mg BID
75755404|NCT00989339|Drug|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
75902704|NCT06203925|Diagnostic Test|Hepatitis C virus self-test (oral fluid HCVST)|"The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits."
75902705|NCT06203925|Diagnostic Test|Hepatitis C virus self-test (blood-based HCVST)|The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
75902706|NCT06203899|Behavioral|Op Volle Kracht|This is a preventive group training based on cognitive behavioural therapy for depression.
75902707|NCT06203899|Behavioral|Gatekeeperstraining|This is a training for teachers to detect and address depressive symptoms and suicidality in their students .
75902708|NCT06203886|Device|LumbaCure|LumbaCure® is a device developed to induce specific mobilization of the lower back in patients requiring physical rehabilitation for orthopaedic disorders, particularly chronic low back pain.
75902709|NCT06203873|Device|Biodegradable occluder|Patients assigned in this group will receive PFO occlusion with a biodegradable occluder.
75902710|NCT06203873|Device|Metal occluder|Patients assigned in this group will receive metal occluder for PFO occlusion
75902711|NCT06203860|Other|Cardio-Metabolic Clinic|"The Cardio-Metabolic Clinic will adhere to a standardized evaluation and treatment program based on the latest treatment guidelines from the European Cardiovascular Society. The assessment will include the following points:~Lipid management~Blood pressure management~Antithrombotic therapy~Glycemic targets~Prevention of diabetes-related complications~Treatment of vascular disease affecting the lower extremities~Evaluation of cardioprotective drugs~Counseling on lifestyle factors, including diet, smoking, alcohol, and exercise~Guidance on vaccinations"
75902712|NCT06203834|Dietary Supplement|I-Fiber Pearl|Eat 200g for once, and once a day.
75608781|NCT05340049|Procedure|Therapy sessions|"Seven sessions were given to each of the three groups according to their classification (placebo, TMR, TCS), being able to obtain a stable value in each of the treatments carried out. Before each session, the effect of the previous session was explored in order to evaluate its efficacy (from the second session onwards). Each of the therapies had the same number of sessions (1 per week for 7 weeks) in order to have equality in all the parameters evaluated.~The effectiveness values of the therapies were expressed as percentages of satisfaction with the classifications of 25% (apparent changes less than half of the sample in each therapy group), 50% (apparent changes in half of the sample plus one in each therapy group) and 75-100% (apparent changes in all or almost all of the sample in each therapy group)."
75608782|NCT05339347|Device|Photoneuromodulation|Treatments were administered daily for a period of 2 weeks (10 sessions) with a Light-Aid (Bright Photomedicine, SP, Brazil), continuous wave, 300 LED wavelength 850 nm) or with a placebo probe of the same appearance and display. The irradiation parameters created will be based on the disease, pain intensity and skin phototype. Each session has from 10 to 15 min, depending on skin phototype
75608783|NCT05044975|Behavioral|Sleep restriction|Participants will receive sleep restriction intervention
75608784|NCT05044975|Behavioral|Stimulus control|Participants will receive stimulus control intervention
75608785|NCT05044975|Behavioral|Systematic light exposure|Participants will receive systematic light exposure intervention
75608786|NCT05339191|Behavioral|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
75755405|NCT05401643|Other|Xemio mobile application|"The study consists in a mHealth intervention provided through the Xemio mobile application for breast cancer survivors. This application is installed in the personal smartphones of the participants after they are randomized in the mHealth intervention group. The Xemio app components are symptom tracking, up-to-date calendar of events organized by patient's organizations, virtual talks with experts, articles regarding new information of the disease, physical activity tracking, and evidence-based information regarding symptoms, non-pharmacological treatments for side effects, and information about common drugs to treat breast cancer. The participants can freely use the Xemio mobile application for a total of 12 months.~The control group does not have access to the Xemio application for the duration of the study but they are offered access to it at the completion of the intervention. The participants of both arms continued to receive the usual care from their oncology teams."
75902713|NCT06203834|Dietary Supplement|placebo|Eat 200g for once, and once a day.
75902714|NCT06203795|Other|Anticoagulation dosing|Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday
76068039|NCT01764854|Drug|Placebo|Placebo, size and color matched to experimental drug
76068040|NCT01764464|Drug|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
75755406|NCT00989417|Other|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
75755407|NCT00989495|Device|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
75755408|NCT00989651|Biological|Bevacizumab|Given IV
75755409|NCT00989651|Drug|Carboplatin|Given IV
75755410|NCT00989651|Drug|Cisplatin|Given IP
75755411|NCT00989651|Other|Laboratory Biomarker Analysis|Correlative studies
75608787|NCT05339035|Behavioral|Training based on IMB model, motivational interview technique, hippotherapy program|"In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen."
75608788|NCT01880359|Drug|Cisplatin|
75755412|NCT00989651|Drug|Paclitaxel|Given IV or IP
75755413|NCT00989651|Drug|Veliparib|Given PO
75755414|NCT05590559|Drug|Morphine|Opiates
75457137|NCT01781273|Other|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
75457138|NCT01781273|Other|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
75902715|NCT06203795|Other|Blood sampling|Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.
75902716|NCT06203795|Other|Duration of the dialysis session|Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday
75457139|NCT01781312|Dietary Supplement|ProTectis|
75457140|NCT01781312|Dietary Supplement|Gastrus|
75457141|NCT01781325|Device|IBEHR|physical therapy device to educate patients in physical therapy exercise performance
75457142|NCT01781351|Other|Taping the ankle|
75457143|NCT01781364|Behavioral|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
75457144|NCT01781377|Drug|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
75457145|NCT01781377|Drug|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
75457146|NCT01781377|Drug|PLACEBO|SALINE INFUSION
75608789|NCT01880359|Radiation|Radiotherapy|
75608790|NCT01880359|Drug|Placebo|
75608791|NCT01880359|Drug|Nimorazole|
75755415|NCT05590559|Other|Ultrasound-guided erector spinae plane block|PVB
75755416|NCT05359601|Procedure|Infusion set replacement intervals|24-hour or 96-hour infusion set replacement intervals
75608792|NCT05338489|Drug|Selpercatinib|Administered orally.
75608793|NCT05338489|Drug|Itraconazole|Administered orally.
75755417|NCT00989729|Drug|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
75755418|NCT00989729|Drug|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
75755419|NCT00989807|Drug|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
75755420|NCT00990431|Procedure|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
75755421|NCT00990431|Procedure|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
75902717|NCT06203795|Device|Choice of the hemodialyzer|Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
75902718|NCT06203782|Procedure|endoscopic stricturoplasty|Experimental Group: In the experimental group, 51 patients underwent endoscopic stricturoplasty. A transparent cap was mounted on the front end of the endoscope, and a needle knife was inserted through the working channel of the endoscope. Under direct visualization, a radial incision was made at the site of the stricture, with an effort to preserve normal mucosal tissue as much as possible. The stricture was gradually incised until the endoscope could smoothly pass through.
75755422|NCT01590095|Behavioral|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age."
75755423|NCT01590095|Behavioral|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
75755424|NCT01590095|Behavioral|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
75902719|NCT06203782|Procedure|endoscopic balloon dilation|Control Group: In the control group, 51 patients underwent endoscopic balloon dilation. The endoscope was advanced to the site of the stricture, and a dilation guidewire was inserted. After placing the balloon, it was progressively inflated with pressure, each inflation lasting 1-2 minutes, and this process was repeated 2-3 times until the endoscope and sheath could pass through the narrowed segment and enter the distal colon.
75902720|NCT06203769|Drug|14-day antibiotic therapy|The studied intervention will be 14-day antibiotic therapy after removal of infected material
75608794|NCT05338489|Drug|Rifampin|Administered orally.
75902721|NCT06203769|Drug|28-day antibiotic therapy|The comparator arm will be 28-day antibiotic therapy after removal of infected material
75902722|NCT06203756|Device|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC|Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type
75902723|NCT06203756|Device|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex PosteriorStabilized (PS) knee implant type
75902724|NCT06203756|Device|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex Revision knee implant type
75902725|NCT06203743|Procedure|caudal block group|PI, PVI measurements and hemodynamic data will be compared between groups
75902726|NCT06203743|Procedure|ilioinguinal-iliohypogastric nerve block group|PI, PVI measurements and hemodynamic data will be compared between groups
75902727|NCT06203691|Dietary Supplement|Supplementation with Nirvana Super Pro Liquid Supplements|Intervention will measure strength pre & post operatively. Intervention group will receive liquid supplements (3oz daily shots) pre (Prepare) and Post (Recover) operatively.
75902728|NCT06203691|Dietary Supplement|Non-Supplementation Group|Intervention will measure strength pre & post operatively. Intervention group will not receive liquid supplements.
75902729|NCT06203678|Other|Kinesio taping|therapeutic tape application
75902730|NCT06203678|Other|Exercise|Cervical stretching and strengthening exercises home program
75457147|NCT01781442|Drug|Temsirolimus|"The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.~Treatment will continue until disease progression or unacceptable toxicity.~The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity."
75902731|NCT06203678|Other|Sham taping|patch tape application
75608795|NCT02779699|Drug|AL2846|AL2846 p.o. qd
75608796|NCT05266417|Drug|INS-GSH|Intranasal INS-GSH Twice Daily
75457148|NCT01781494|Procedure|Immobilization followed by protected range of motion|
75457149|NCT01781494|Procedure|Immediate range of motion|
75457150|NCT01781507|Drug|Cetirizine|Cetirizine is an antihistamine currently indicated for allergic rhinitis
75457151|NCT01781507|Drug|Placebo|This placebo ( sugar pill) will provide the negative control for this study
75457152|NCT01781520|Biological|DC-CIK Treatment|The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
75608797|NCT05266417|Drug|Matched Placebos|Intranasal Matched Placebos Twice Daily
75608798|NCT02779465|Drug|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
75608799|NCT04985305|Behavioral|Teaching material|The GPs receive a power-point slide show to use at the nursing home. The slide show includes a description of BPSD symptoms, what the mechanism, effect and adverse events of antidepressants and a rationale for deprescribing.
75608800|NCT04985305|Behavioral|Pre-visit reflection tool|The GPs receive a checklist and an email template to ensure; 1) The home visit is planned on a day where the staff at the nursing home that knows the patient best is at work. 2) The staff at the nursing home contacts the relevant relatives and informs about the home visit. 3) The symptom assessment scale is complete by the nursing home staff and returned to the GP prior to the home visit
75608801|NCT04985305|Behavioral|Dialogue tool|The dialogue tool includes a list of questions to help the GP explore the nursing home staffs', patients' and relatives' concerns and views on deprescribing antidepressants, as well as information on when to contact the GP. The intervention has been developed during a tailoring process involving GPs, nursing home staff, interviews with patients and other experts in the field.
75755425|NCT01590095|Behavioral|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
75755426|NCT01590095|Behavioral|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
75755427|NCT01590095|Behavioral|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation & Hand washing (Combined WASH) Plus the intervention described above for nutrition.
75755428|NCT05359523|Device|Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia|B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees
75755429|NCT05590091|Other|Parenteral nutrition;Enteral nutrition|The intelligent nutrition management system was used to carry out standardized nutrition management of patients after hematopoietic stem cell transplantation
75755430|NCT00990587|Drug|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
75755431|NCT00988793|Procedure|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
75755432|NCT00988793|Procedure|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
75755433|NCT00989885|Other|Questionnaire and polysomnography|Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
75755434|NCT05589779|Other|Asthma and cardiovascular disease|To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease, as well as their relationship with eosinophil subtypes, biomarkers of chronic inflammation and bronchial remodeling.
75755435|NCT05358275|Device|surgical cutting guide with piezo|3D planned lid surgery
75755436|NCT05358275|Other|control|ordinary cyst enucleation
75902732|NCT06203665|Diagnostic Test|Recruitment Maneuver|The surgery would be performed under general anaesthesia according to the common practice using protective lung ventilation ( Vt= 6 ml /Kg ideal body weight , RR to maintain end-expiratory CO2 35-45 cmH2O and PEEP= 6- 8 cm H20). An incremental and decremental positive end-expiratory pressure alveolar recruitment maneuver would be performed after release of pneumoperitoneum.
75608802|NCT04985305|Behavioral|Educational session for GPs|Before randomization all participating GPs receive a ½-day course on the evaluation and treatment of neuropsychiatric symptoms that occur in patients with dementia. Elaborate information about antidepressants to this population and reasons to discontinue use. A sSpecialists in general practice, pharmacology and geriatrics/gerontopsychiatrics teaches the course. The course is mandatory for the participating GPs, but voluntary for the staff at the GPs office. The course is preferably held with actual attendance, but may be converted to an online meeting due to the COVID-19 pandemic.
75608803|NCT04985305|Behavioral|Symptom assessment scale|An email template containing 12 screening questions from the Neuropsychiatric Inventory Nursing Home Edition is given to the GPs to distribute to the nursing home prior to the home visit and 1 month after the home visit
75608804|NCT02779231|Other|Bi-directional texting|
75457153|NCT01781520|Drug|S1|The dose of S-1 is determined according to the body surface area as follows: <1.25 m2, 40 mg; 1.25-<1.5 m2, 50 mg; and >1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
75457154|NCT01781520|Other|Best supportive care|Best supportive care
75457155|NCT01781533|Procedure|algorithm|
75755437|NCT00537329|Drug|Anidulafungin|Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
75902733|NCT06203652|Other|Real-world regimen|The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
75902734|NCT06203613|Radiation|[18F]F-H3RESCA-3A12及[68Ga]Ga-NOTA-3A12|The dose of [18F]RCCB6 was calculated based on the patient's body weight to be 3.7 MBq [0.1 MCi]/kg, and the method of administration was intravenous push, with a single visualization administered once.
75457156|NCT01781546|Procedure|drug-eluting balloon (DEB)|The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is >20mm or stent malapposition is suspected).
75457157|NCT01781546|Procedure|bare-metal stent (BMS)|The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length >20mm or stent malapposition is suspected).
75457158|NCT01781559|Dietary Supplement|phenolic acid|phenolic acid
75608805|NCT02776189|Drug|Dexmedetomidine|intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
75902735|NCT06203600|Procedure|Biospecimen Collection|Undergo optional blood sample collection
75902736|NCT06203600|Procedure|Computed Tomography|Undergo CT scan
75608806|NCT02776189|Drug|propofol|intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
75608807|NCT02776189|Drug|Midazolam|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
75608808|NCT04841707|Device|uEXPLORER/mCT|Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.
75608809|NCT04226287|Device|Monterey Pneumatic Compression Device|The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
75755438|NCT00990743|Drug|SYL040012|Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
75755439|NCT05358197|Other|yoga|laughter yoga
75755440|NCT00990977|Behavioral|mindfulness based stress reduction (MBSR)|MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
75902737|NCT06203600|Procedure|Magnetic Resonance Imaging|Undergo MRI
75457159|NCT01781585|Procedure|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
75457160|NCT01781598|Device|Total knee arthroplasty (TKA) (Smith &Nephew®)|
75457161|NCT01781624|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
75457162|NCT01781650|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
75755441|NCT04002869|Diagnostic Test|Immunologic, molecular, metabolomic and radiolologic diagnostic|Evaluation and development of new technologies
75755442|NCT04730843|Drug|ES102|ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
75755443|NCT03897179|Device|INVSENSOR00032 and INVSENSOR00033|Investigational pulse oximeter device
75902738|NCT06203600|Biological|Nivolumab|Given IV
75902739|NCT06203600|Drug|Paclitaxel|Given IV
75902740|NCT06203600|Other|Questionnaire Administration|Ancillary studies
75902741|NCT06203600|Biological|Ramucirumab|Given IV
75902742|NCT06203587|Radiation|[68Ga]Ga/[18F]F-H3RESCA-WWH347|The dose of [68Ga]Ga/[18F]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8 MBq [0.05 MCi]/kg, and was administered as an intravenous push, with a single dose given once.
75902743|NCT06203574|Radiation|[18F]F/[68Ga]Ga-NOTA-T4|The dose of [18F]F/[68Ga]Ga-NOTA-T4 was calculated based on the patient's body weight to be 3.7 MBq [0.1 MCi]/kg, and the method of administration was intravenous push, with one single imaging administration.
76068041|NCT01764464|Drug|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
75608810|NCT04228003|Dietary Supplement|Pendulum Glucose Control formulation for T2D|"All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
75755444|NCT03905135|Drug|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
75457163|NCT01781650|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
75457164|NCT01781650|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
75755445|NCT03905135|Drug|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles
75608811|NCT02776267|Device|Angiolite stent|Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
75755446|NCT03905135|Biological|Avelumab|Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
75755447|NCT05589311|Other|Transformative Learning principles|Transformative Learning principles are incorporated into the pain education workshop to stimulate critical reflection and critical discourse during the learning process.
75755448|NCT05589311|Other|Conventional didactic approach|The conventional didactic approach focuses on lecture-based instruction as the teaching center, emphasizing the delivery of syllabus and concept.
75755449|NCT00991055|Drug|Pioglitazone|"A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)"
75755450|NCT04002557|Other|No intervention|Interviews contain no intervention, purely observational.
76068042|NCT01764386|Drug|NB|Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
75457165|NCT01781663|Device|KAM2904 Face Cream|
75457166|NCT01781663|Device|KAM3008 Body Lotion|
75457167|NCT01781663|Other|petrolatum-based moisturizer|
75457168|NCT01781702|Drug|Pelubiprofen 30 mg|
75457169|NCT01781702|Drug|Celebrex 200 mg|
75457170|NCT01781715|Device|Zotarolimus-eluting coronary stent|Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
75457171|NCT01781754|Procedure|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
75457172|NCT01781780|Behavioral|General Nutrition Recommendations|
75608812|NCT04225975|Diagnostic Test|electroencephalogram|Within the 5 min after birth the electroencephalogram of the neonates will be recorded with the aid of a patch on the scalp
75608813|NCT04225975|Diagnostic Test|oxymetry|Within the 5 min after birth the cerebral oxymetry of the neonates will be recorded with the aid of a patch on the scalp
75755451|NCT05589155|Other|Mobile health application|Intervention will be with mobile health application
75755452|NCT00991133|Drug|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
76068043|NCT01764386|Behavioral|CLI|The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
75457173|NCT01781780|Behavioral|Breakfast Recommendation|
75457174|NCT01781780|Behavioral|No Breakfast Recommendation|
75457175|NCT01781793|Other|Room air|Humidified room air (21% oxygen) will be inspired
75457176|NCT01781793|Other|Hyperoxia|60% oxygen will be inspired
75755453|NCT00991211|Drug|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
75755454|NCT00991211|Drug|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
75755455|NCT00357903|Biological|Etanercept|Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
75755456|NCT03990519|Drug|JNJ-26366821|Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
75755457|NCT03990519|Drug|Placebo|Participants will receive sodium chloride injection as placebo on Day 1.
75755458|NCT01053039|Drug|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
75608814|NCT02776345|Other|Ultrasound guided Needle Fragmentation|Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.
75608815|NCT02776345|Other|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
75608816|NCT02776345|Other|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
75608817|NCT02776111|Other|Blood Sample|A one time blood sample will be provided.
75755459|NCT01053039|Drug|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
75755460|NCT01051245|Behavioral|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
75755461|NCT01051245|Other|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
75755462|NCT01051401|Drug|rosuvastatin|Given PO
76068044|NCT01764386|Behavioral|Usual Care|Usual Care is a self-directed lifestyle intervention program
75755463|NCT01051401|Other|placebo|Given PO
75755464|NCT01051401|Other|survey administration|Correlative study
75755465|NCT01051401|Procedure|management of therapy complications|
76068045|NCT01763918|Biological|Evolocumab|Administered by subcutaneous injection
76068046|NCT01763918|Drug|Placebo|Administered by subcutaneous injection
75608818|NCT02775955|Drug|RX0041|Active
75755466|NCT03989973|Diagnostic Test|Gastroscopy|Gastroscopy
75755467|NCT01053117|Other|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
75755468|NCT00348933|Drug|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
75755469|NCT00348933|Drug|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
75755470|NCT00348933|Drug|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
75755471|NCT00348933|Drug|Vitamin B12|1 mg by mouth per day for all weights and ages
76068047|NCT01763684|Device|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
76068048|NCT01763684|Procedure|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
75755472|NCT01325103|Procedure|Stem Cell Transplantation|All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.
75755473|NCT01051479|Drug|C11-Choline|15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
75755474|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
75755475|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 2.5 mg Oral Single dose
76068049|NCT01606748|Biological|Necitumumab|"PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product"
75755476|NCT01055691|Drug|Metformin|metformin IR tablet 850 mg Oral Single dose
75608819|NCT04931407|Other|A 12-week interdisciplinary complex intervention|"The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian."
75755477|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
75755478|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 5 mg Oral Single dose
76068050|NCT01606748|Drug|Gemcitabine|"PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2"
76068051|NCT01606748|Drug|Cisplatin|"PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2"
76068052|NCT01597622|Drug|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
76068053|NCT01761266|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75755479|NCT01055691|Drug|Metformin|metformin IR tablet 1000 mg Oral Single dose
75755480|NCT02533869|Radiation|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis
75755481|NCT02533869|Procedure|Laparoscopic appendectomy|All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
76068054|NCT01761266|Drug|Sorafenib|400 mg twice daily (BID) oral dosing.
76068055|NCT01760954|Drug|Elagolix|Elagolix tablets administered orally
75755482|NCT03896477|Biological|Pneumosil|One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
75755483|NCT03896477|Biological|Prevenar 13|One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
75755484|NCT03896477|Biological|Synflorix|One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
75755485|NCT00444600|Drug|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
75755486|NCT00444600|Drug|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
76068056|NCT01760876|Device|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
76068057|NCT01759862|Drug|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
76068058|NCT01759862|Other|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
76068059|NCT01759862|Drug|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
76068060|NCT04579874|Diagnostic Test|LIVERFASt|blood draw
75755487|NCT00444600|Drug|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
75755488|NCT00444600|Drug|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
75755489|NCT00537095|Drug|Vandetanib|300 mg oral once daily oral dose
75755490|NCT00537095|Other|Placebo|
75755491|NCT01030380|Device|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
75755492|NCT00991367|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
75755493|NCT00991367|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
75755494|NCT00991445|Procedure|Minimal Invasive Surgery|After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
75755495|NCT00991445|Procedure|Conventional exposure|After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
75755496|NCT00991523|Dietary Supplement|protein|protein
75755497|NCT00991523|Dietary Supplement|placebo|placebo control
76068061|NCT01793792|Device|LVIS™ and LVIS™ Jr|The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
76068062|NCT01790984|Other|High sugar low starch diet|
75608820|NCT04947163|Device|Inspiratory Muscle Training|Participants will perform home-based IMT twice daily [once in the morning (between 7:00 and 12:00 am) and once in the evening (between 16:00 and 21:00 pm)], for 8 consecutive weeks, using a mechanical pressure threshold loading device. In addition, participants in this group will try to increase the inspiratory resistance when the participants feel that 30 breaths are achievable with ease or if the participants could reach 35 consecutive breaths.
75608821|NCT04947163|Device|Sham IMT|Participants will perform 60 slow breaths once daily at a load setting of 0 (corresponding to ~15% [baseline] MIP), using the same device as the IMT group. For the sham group, the ability to adjust the training load will be prevented using sticky tape applied to the device's load adjuster.
75755498|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
75755499|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 48 weeks
75755500|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
76068063|NCT01790984|Other|Low sugar high starch diet|
75755501|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 24 weeks
76068064|NCT01735994|Behavioral|Healthy Weight|Eating Disorder Prevention Program for Athletes
76068065|NCT01735994|Other|Brochure|Brochure on the Female athlete triad
76068066|NCT01790828|Drug|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
76068067|NCT01790594|Biological|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
75755502|NCT00537017|Drug|Preladenant|5 mg BID capsules
75755503|NCT00537017|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
75755504|NCT00537017|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
75755505|NCT05358041|Device|Robotic Bronchoscopy|Replace the Super-D EMN navigational platform with Ion Robotic bronchoscopy platform guided with shape sensing technology
75755506|NCT00348309|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
75755507|NCT00348309|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
75755508|NCT00348309|Other|Placebo|Placebo
75755509|NCT00348309|Other|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
76068068|NCT01790594|Drug|methylprednisolone|
76068069|NCT01790594|Biological|Anti-thymocyte Globulin (Rabbit)|
76068070|NCT01790594|Drug|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
75755510|NCT05581433|Other|Topical Cooling Spray|The process of cooling the area to be injected with a cooling spray before the application in order to reduce the pain.
75755511|NCT05581433|Other|Saline spray as Placebo|Application of saline spray without cooling effect to the area to be injected for placebo purposes
75755512|NCT04451837|Drug|Semaglutide|Ozempic s.c. once weekly for 6 months
75755513|NCT04451837|Drug|Dapagliflozin|Forxiga 10 mg p.o. once daily for 6 months
75755514|NCT05356871|Other|VO2max validity and reliability assesment|Reliability assessment of VO2max determination with three repeated measures for two methods.
75755515|NCT05580497|Device|Soft Wearable Robotic Knee System|Power assistance will be provided from the motor to the knee joint
75755516|NCT04003337|Other|Morpho-kinetics selection with time-lapse (Embryoscope) evaluation|Embryos in group B will be selected in blastocyst stage according to morpho-kinetics criteria before the embryo transfer
75755517|NCT05493683|Drug|Disitamab vedotin|2.0mg/kg，q2w
75755518|NCT05493683|Drug|Tislelizumab|400mg，q6w
75755519|NCT01053195|Behavioral|Lifestyle counseling|Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
75755520|NCT05440487|Other|Iron chelator|There is no treatment allocation. Patients administered approved Iron chelators by prescription that have started before inclusion of the patient into the study will be enrolled.
75755521|NCT01053273|Procedure|Caudal Epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
75755522|NCT01053273|Procedure|percutaneous adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
75755523|NCT00440310|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
75755524|NCT00440310|Procedure|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
75608822|NCT05045833|Drug|SYN-020 Delayed Release Capsule|Oral administration (by mouth)
75457177|NCT01781819|Procedure|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
75608823|NCT02778217|Procedure|Culture media renwal|
75608824|NCT02777983|Behavioral|Educational Video App|The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
75457178|NCT01781845|Procedure|AFRI-SVI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI)a new ultrasound technology in which unique sound waves create the images/pictures of the kidney beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
75755525|NCT00440310|Device|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
75755526|NCT00440310|Drug|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
75755527|NCT00440310|Drug|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
75755528|NCT01055847|Drug|Aztreonam for Inhalation (AI)|Aztreonam for Inhalation
75755529|NCT01055847|Drug|Placebo|Saline Placebo
75755530|NCT02533791|Biological|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10^10vp/1ml per dose
75755531|NCT02533791|Biological|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10^11vp/1ml per dose, with one dose to each arm at the same time
75755532|NCT02533791|Biological|placebo|
75755533|NCT05394935|Other|High-Intensity Exercise|Acute, low-volume HIIT 12x (1min:1min) Working intensity: >85% heart rate reserve Resting intensity: Active rest
75755534|NCT05394935|Other|Moderate-Intensity Exercise|Continuous, MISS 50mins Working intensity: 50-60% heart rate reserve
75755535|NCT01055925|Device|modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)|
75755536|NCT01055925|Device|Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing|
75755537|NCT00440232|Drug|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
75755538|NCT00440232|Drug|Placebo|Inert tab identical in appearance to Frovatriptan
75755539|NCT01564199|Drug|salmeterol / fluticasone propionate|100/1000 μg oral capsule
75755540|NCT02533323|Drug|gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
75755541|NCT02533323|Drug|oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
75755542|NCT02533323|Drug|pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
75755543|NCT02533479|Other|Caloric restriction|three alternate days weekly along 4 weeks.
75755544|NCT05357885|Diagnostic Test|SARS-CoV-2 Antibody test|SARS-CoV-2 antibody test at Jefferson is Roche Elecsys Anti-SARS-CoV-2 immunoassays performed under FDA's Emergency Use Authorization.
76068071|NCT01790594|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
76068072|NCT01790516|Drug|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
75457179|NCT01781871|Biological|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
75755545|NCT01031082|Procedure|Middle ear fluid, nasopharyngeal aspirate and urine sample.|Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
76068073|NCT01790516|Drug|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
76068074|NCT01790516|Radiation|Radiation|daily radiation for 7 weeks
76068075|NCT01790438|Drug|LY2605541|
76068076|NCT01790438|Drug|Human Insulin NPH|
75755546|NCT05311553|Procedure|Zona pellucida thinning|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through thinning. The laser thinning will be performed by making 2-3 holes without reaching the inner membrane at a depth of60-80% of the Zona pellucida thickness.
75755547|NCT05311553|Procedure|Zona pellucida drilling|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through drilling. The laser opening will be made from the outside to the inside of the Zona pellucida.
75755548|NCT01323348|Behavioral|Diabetes Education|"The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):~Measurement of HbA1c in office with immediate feedback~Measurement of blood pressure with immediate feedback~Assessment of retinopathy risk with immediate feedback~Personalized risk assessment reports based on current HbA1c~Brief assessment of patient understanding of key issues with immediate feedback~Supplemental diabetes management educational materials (provided at baseline only)~Feedback to primary care provider~Email reminder to study participants with email access of individualized risk assessment findings"
75755549|NCT05357807|Procedure|Standard RYGB|Roux-en-Y Gastric bypass
76068077|NCT01790438|Drug|Oral Antihyperglycemic Medications (OAM)|
76068078|NCT01735916|Device|CRT-P Implant|"The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care."
75755550|NCT05357807|Procedure|Extended Pouch RYGB|Roux-en-Y gastric bypass with an extended pouch
75755551|NCT05357807|Procedure|Banded extended pouch RYGB|Roux-en-Y gastric bypass with a banded extended pouch
75755552|NCT02968836|Dietary Supplement|Blend of amino acids|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
75457180|NCT01781871|Biological|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
75457181|NCT01781884|Drug|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
75457182|NCT01781884|Drug|Placebo|
75457183|NCT01781897|Device|acupuncture|sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
75457184|NCT01781897|Drug|mosapride|Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
75457185|NCT01781910|Dietary Supplement|Branched Chain Amino Acid drink supplement|
75457186|NCT01781910|Dietary Supplement|Placebo|
75457187|NCT01781923|Behavioral|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
75755553|NCT02968836|Dietary Supplement|Maltodextrin only|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
75755554|NCT04003181|Drug|Antibiotics|Ciprofloxacin or Rifaximin for 10 days.
75755555|NCT04003181|Drug|Bile Acid Binder|Cholestyramine or Colesevelam lifelong.
76068079|NCT01735916|Device|CRT-P OFF|Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
76068080|NCT01790126|Drug|ARN-509|
76068081|NCT01790126|Drug|LHRH Agonist|
76068082|NCT01734902|Drug|Hyoscine butylbromide|sugar coated tablets for oral administration
76068083|NCT01734902|Drug|Hyoscine butylbromide|drops for oral administration
76072341|NCT01326676|Drug|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
76025313|NCT03114007|Behavioral|Equipe program|"Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.~Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies."
75608825|NCT05214937|Behavioral|Intervention|During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action & coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.
76068084|NCT01790048|Dietary Supplement|Whey permeate RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier."
76072342|NCT01326676|Drug|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
76072343|NCT01287611|Procedure|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture
75608826|NCT05214937|Behavioral|FitBit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
75608827|NCT01194258|Drug|Insulin lispro|
75608828|NCT01194258|Drug|Insulin aspart|
75755556|NCT01031316|Other|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
75457188|NCT01781923|Behavioral|Small group social skills training|Meet once per week for duration of 40 weeks.
75457189|NCT01781936|Drug|Fluocinolone Acetonide|
75755557|NCT01031316|Other|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
75457190|NCT01781949|Other|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
75608829|NCT01194258|Drug|Recombinant human hyaluronidase PH20|
75755558|NCT00356889|Drug|erlotinib hydrochloride|Given orally, 150 mg, once daily.
75755559|NCT00356889|Biological|bevacizumab|Given IV, 5mg/kg on days 1 and 15 every cycle
75755560|NCT04741308|Behavioral|cognitive behavior therapy|The CBT intervention is a 8-times group-based intervention that meets 2-3 weeks.Each session will be performed during chemotherapy and will last for 60 min, including 45 min cognitive behavior therapy and 15 min relaxation training.Our CBT intervention is designed to be conducted in groups of 3 to 6 patients led by two group facilitators. Group leaders will: guide participants relaxation training, develop a supportive group environment, encourage emotional expression, assist participants develop a sense of self-confidence, identify maladaptive coping and encourage adaptive coping responses.
75755561|NCT03742323|Drug|Idelalisib|Idelalisib Dose: 100, 150, 200 or 300 mg (in four cohorts of six patients each).
75608830|NCT01194258|Drug|Insulin glulisine|
75902748|NCT06203548|Behavioral|Lifestyle modification programme|All patients will attend sessions weekly in the first 2 months and monthly in the remaining 4 months. The programme focuses on reducing caloric intake and increasing energy expenditure. At the first visit, the dietitian will perform a complete behavioural assessment including the patient's eating and lifestyle patterns, specific eating-related behaviours, knowledge, concerns and feelings. A target body weight will be set. During follow-up visits, the dietitian will review the patient's dietary pattern and provide recommendations. Each patient will be given an individualised meal plan. The dietary component and portion size are based on recommendations by the American Dietetic. The patients will be taught techniques to cope with at-risk situations such as parties and festival celebrations. In addition, the patients will be encouraged to have a combination of aerobic exercise and resistance training with intensity and frequency following the Physical Activity Guidelines.
76068085|NCT01790048|Dietary Supplement|Soy Protein RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources."
76072344|NCT01287611|Procedure|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked suturing
76072345|NCT01194271|Drug|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
75457191|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS <30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
75608831|NCT01194258|Drug|Insulin glargine|
75608832|NCT04883437|Drug|Acalabrutinib|Given PO
75608833|NCT04883437|Biological|Obinutuzumab|Given IV
75608834|NCT04883437|Other|Quality-of-Life Assessment|Ancillary studies
75608835|NCT04883437|Other|Questionnaire Administration|Ancillary studies
75608836|NCT02777905|Behavioral|Mindfulness Based Cognitive Therapy|
75608837|NCT01193556|Device|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
75755562|NCT04715022|Drug|Ascorbic acid solution (American Regent Laboratories Inc.)|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
75755563|NCT04715022|Drug|Saline|Placebo (saline) will be administered
75608838|NCT01193556|Device|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
75608841|NCT02775877|Drug|Letrozole|
75608842|NCT02775877|Drug|clomiphene|
75608843|NCT02775877|Drug|HMG|
75608844|NCT02775799|Other|Registration|Registration according to approved data sets
75608845|NCT02778763|Drug|CBLB612|4 μg CBLB612 SQ
76068086|NCT01789970|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
76068087|NCT01789970|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
76068088|NCT01788566|Drug|Necitumumab|Administered IV
76068089|NCT01788566|Drug|Gemcitabine|Administered IV
76068090|NCT01788566|Drug|Cisplatin|Administered IV
75608846|NCT02778763|Drug|Placebo|
75608847|NCT04228159|Device|Balance Tutor Biofeedback Rehabilitation System|Balance Tutor system is a unique technology which allows for several postural control ability assessments as well as reactive response training in both standing and walking using controlled perturbation in simple task or multitask performance. Together with proactive training the system allows for optimal rehabilitation outcome and recovery
75902749|NCT06203535|Other|Aerobic training|45 minutes of march walking on a treadmill three times a week for two months in addition to traditional physical therapy exercise program . The exercises started with a five to ten-minute treadmill warm-up and ended with an identically lengthened cool-down. a group cumulative exercise session lasts 35 minutes, with exercise intensities ranging from 60 to 75 percent of heart rate reserve, s. according to using the Karvonen formula.
75902750|NCT06203509|Behavioral|Thrive Intervention|• The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals being managed for both chronic diseases and serious mental illness following hospitalization.
76068091|NCT01733732|Other|SYSTANE® BALANCE Lubricant Eye Drops|
75457192|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
75755564|NCT05137691|Other|Adapted NHS weight management 1:1 programme|Adapted NHS 1:1 weight management programme with a low carbohydrate dietary focus, incorporating enhanced behaviour change via telehealth, step count and pedometer
76068092|NCT01733732|Other|SYSTANE® Gel|
76068093|NCT01732874|Drug|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
76068094|NCT01732874|Drug|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
76068095|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
76068096|NCT01732796|Drug|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
76068097|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
76068098|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
75608848|NCT04228159|Other|Balance and strengthening exercise|exercise training programs for fall prevention including walking and balance exercises, functional tasks, strength, flexibility and endurance
75608849|NCT04226989|Biological|CT-RD06|CT-RD06 cell injection by intravenous infusion
75608850|NCT04875013|Device|Vestibular rehabilitation with dynamic posturography|Rehabilitation exercises guided by an interactive display and measured by a footplate sensor
75608851|NCT05021107|Other|FDM with isometrics|FDM with isometrics will be done
75608852|NCT05021107|Other|FDM without isometrics|FDM without isometrics will be done
75755565|NCT05137691|Other|NHS 1:1 weight management programme|NHS 1:1 weight management programme
75755566|NCT01031394|Other|Frequency of Aerobic/Resistance Training - 3 to 3|comparing group results based upon frequency of exercise
76068099|NCT01732796|Drug|BI 201335 (Faldaprevir)|24 weeks of BI 201335
76068100|NCT01732796|Drug|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
76068101|NCT01732796|Drug|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
75755567|NCT05110079|Device|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage with guidewire is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the complete procedure is to achieved more than 70% opening."
75608853|NCT02777359|Procedure|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
75755568|NCT01031472|Drug|GSK2248761 formulation 1|100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
75755569|NCT01031472|Drug|GSK2248761 reference formulation|GSK2248761 100mg Gelucire reference capsule with food
75755570|NCT01031472|Drug|GSK2248761 formulation 3|100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
75755571|NCT01031472|Drug|GSK2248761 formulation 2 or 4|100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
75755572|NCT05091671|Other|Free From Pain Exercise Programme Variation 1|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets.
75755573|NCT05091671|Other|Free From Pain Exercise Programme Variation 2|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets, and the 12 Zoom online sessions.
75755574|NCT00356811|Drug|Lapatinib oral tablets|Lapatinib will be given as tablets contain 410 mg of lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib free base per tablet. Subjects will be given a 4 week supply of lapatinib tables and instructed to take 6 tablets daily (1500 mg daily dose) orally at the same time each day. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
75608854|NCT02777671|Drug|BIA 2-093|
75608855|NCT02777671|Drug|Gliclazide|tablets containing gliclazide 80 mg (Diamicron® 80 mg)
75608856|NCT02777515|Behavioral|using electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~measurement of blood pressure~An electrocardiogram~A Holter-ECG 10 minutes~A transthoracic echocardiogram"
75608857|NCT02777437|Drug|XELOX or FOLFOX chemotherapy|4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
75608858|NCT04226521|Procedure|Extracoropreal photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
75457193|NCT01781988|Drug|carboplatin, gemcitabine , pametrexed|"A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression."
75608859|NCT04817839|Behavioral|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
75755575|NCT00356811|Drug|Paclitaxel infusion|Subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle). Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
75457194|NCT01782001|Dietary Supplement|vitamin A|vitamin A with placebo
75457195|NCT01782001|Dietary Supplement|vitamin A and zinc|combination of vitamin A and zinc supplements
75457196|NCT01782014|Procedure|colonoscopy|colonoscopy using different methods of insufflation
75755576|NCT05357339|Other|20% Albumin|100ml boluses 20% Albumin
75755577|NCT05357339|Other|Crystalloid|250ml bolus of crystalloid
75902751|NCT06203496|Diagnostic Test|Blood sample|Blood sample
75755578|NCT00439218|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
75608860|NCT04817839|Behavioral|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
75755579|NCT01056003|Other|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
75755580|NCT02533635|Dietary Supplement|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
75755581|NCT01030614|Drug|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
75902752|NCT06203483|Drug|Adductor canal block|A linear ultrasound probe will be placed medial to the patella, the probe will be advanced to cephalad, and the superficial femoral artery will be visualized. The block site will be confirmed by injecting 5 ml of saline around the saphenous nerve in the subsartorial region under ultrasound guidance. Then, 30 ml of local anesthetic solution containing 0.25% bupivacaine (Marcain 0.5% AstraZeneca, England) will be administered.
75902753|NCT06203483|Drug|PENG block|The probe will be placed at the anterior superior level of spina iliaca, parallel to the inguinal ligament. The probe will be scanned gradually towards the caudal. After the anterior inferior of the spina iliaca is visible, the probe will be slightly turned medially until the hyperechoic shadow of the superior pubic ramus is visible. The psoas muscle tendon will be visualized above the superior pubic ramus, then 5 ml of saline will be injected under the psoas tendon and the block location will be confirmed. After that 30 ml of 0.25% bupivacaine will be administered.
76068102|NCT01732796|Drug|Faldaprevir (BI 201335)|24 weeks of 201335
75755582|NCT01030614|Drug|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
75755583|NCT03991689|Behavioral|solution-focused group therapy|Participants began a 90-minute solution-focused pain management group, which lasted for six weeks, and after the group ended, the questionnaire post-test was carried out, and a total of 26 participants thus completed their group journey. The group effect was evaluated by the difference between the scores of the questionnaires before and after the group.
75755584|NCT01030692|Drug|Placebo|The placebo groups will receive the same dosage throughout the study.
75755585|NCT01030692|Drug|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
76068103|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
75457197|NCT01782040|Other|Auriculotherapy group|It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
76068104|NCT01732640|Drug|Afatinib|Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
75457198|NCT01782053|Behavioral|Picture warning|Warning contains picture proposed for each text statement by FDA
75457199|NCT01782053|Behavioral|Control|
75457200|NCT01782066|Biological|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
75457201|NCT01782079|Dietary Supplement|L. brevis|
75457202|NCT01782092|Other|Chiropractic Adjustment|Chiropractic adjustments will be administered using Activator Methods Basic protocol
75457203|NCT01782105|Behavioral|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
75608861|NCT02775721|Other|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
75608862|NCT02775721|Other|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
75755586|NCT01030692|Drug|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
75755587|NCT01030692|Drug|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
75755588|NCT01030692|Drug|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
75755589|NCT01056081|Other|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
75902754|NCT06203470|Drug|Botulinum Toxin-A|Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.
75902755|NCT06203470|Drug|calcipotriol|topical vitamin D3 analogues
76068105|NCT01732640|Drug|Paclitaxel|Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
76072346|NCT01194271|Drug|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
75457204|NCT01782105|Behavioral|Control group|Evaluation of nutritional and physcial activity habits
75457205|NCT01782118|Dietary Supplement|Lactobacillus GG|
75457206|NCT01782144|Other|NutriSystem portion-controlled pre-packaged meals|
75457207|NCT01782170|Drug|Iocide Oral Rinse|
75755590|NCT04950959|Device|Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T|The system is used for trajectory planning and is intended to assist the physician in the positioning of an instrument, such as a needle, where CT imaging is used for target trajectory planning and intraoperative tracking. The XACT ACE Robotic System uses a computerized quantitative guidance system, which provides real-time, accurate needle guidance, including advancement and steering of the needle from the entry point on the subject's body to the target point within the body.
75608863|NCT02775721|Other|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
75755591|NCT01051713|Behavioral|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
75755592|NCT01051713|Behavioral|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
75755593|NCT03138252|Drug|Oxytocin|
75902756|NCT06203457|Biological|Efgartigimod|Patients receiving efgartigimod infusions
76068106|NCT01732640|Drug|Carboplatin|Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
76068107|NCT01732640|Drug|Cisplatin|Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
75608864|NCT02775721|Other|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
76068108|NCT01732640|Radiation|Intensity Modulated Radiation Therapy|Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
76068109|NCT01732484|Procedure|intraocular lens implantation|
75457208|NCT01782170|Drug|Placebo|
75457209|NCT01782183|Device|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
75457210|NCT01782196|Device|Enhanced one piece drainable pouch with Type A mouldable adhesive|
75457211|NCT01782196|Device|Enhanced one piece drainable pouch with Type B mouldable adhesive|
75457212|NCT01782235|Drug|Tocilizumab|
75457213|NCT01782235|Drug|Placebo|
75755594|NCT05021549|Device|nasal prong|apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong during preintubation apnia
75902757|NCT06203444|Drug|Tenapanor|The study drug will be administered in dose of 50 mg bid
75902758|NCT06203431|Drug|ET-26|freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
76068110|NCT01786148|Behavioral|mobile phone application|
76068111|NCT04560686|Drug|Bintrafusp Alfa|Given IV
76068112|NCT04560686|Procedure|Therapeutic Conventional Surgery|Undergo surgery
76068113|NCT01785602|Drug|QAW039|Capsules
76068114|NCT01785602|Drug|Placebo|Capsules
76068115|NCT01785524|Drug|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
76068116|NCT01785524|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
75457214|NCT01782248|Other|Questionnary and IRM|
75457215|NCT01782261|Drug|Liraglutide|once daily subcutaneous injection
76068117|NCT01757288|Drug|NAB-PACLITAXEL|nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
76068118|NCT01757288|Drug|PACLITAXEL|
76068119|NCT01757288|Drug|NAB-PACLITAXEL|nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
76068120|NCT01756898|Drug|5 mg ASB17061|Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
75457216|NCT01782261|Drug|Saxagliptin|once daily tablet
75457217|NCT01782274|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
75457218|NCT01782274|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
75457219|NCT01782287|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
75457220|NCT01782287|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
75457221|NCT01782300|Biological|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
75608865|NCT02775721|Other|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
75608866|NCT04903951|Device|Adaptive Servoventilation (ASV) therapy|Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated
75755595|NCT04994561|Drug|Study Drugs and Nutritional Supplements|"Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months."
75902759|NCT06203431|Drug|Etomidate Injectable Emulsion|lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
75902760|NCT06203418|Behavioral|Multi-Family Therapy|Multi family therapy for anorexia nervosa (MFT-AN) draws on the same principles as FBT but is delivered in a more intensive format to help families to overcome a sense of isolation and stigmatization and to maximize their own resources. In the case of eating disorders, this program utilizes FBT principles (both approaches are guided by the family-based treatment philosophy, which stresses the impact of ED on family functioning and attempts to mobilize families as the primary agents of change in achieving recovery), and also utilizes learning from structural, systemic, strategic, narrative, and psychodrama-based family therapy practices,(Knatz et al., 2015). Generally between 5-7 families take part in MFT, sharing their experiences, learning by example, and providing support for one another. Study will utilize virtual adaptation of manualized treatment published by Simic et al 2021
75902761|NCT06203405|Procedure|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|"Sedation will be adjusted initially to target light sedation (RASS 0 to -2).~Sedative drugs include IV fentanyl (25-75 mcg/h), midazolam (0.02- 0.1 mg/kg/h), propofol (5-50 mcg/kg/min), dexmedetomidine (0.2-0.7 mcg/kg/h).~Deep sedation and neuromuscular blocking agents are allowed to facilitate mechanical ventilation adjustment in patients with refractory hypoxemia.~Dose of cisatracurium is 0.15-0.2 mg/kg intravenous bolus, then continuous infusion at 5 -20 mg/h.~Then sedation adjustment will be guided by P0.1 measurement.~If P0.1 value of 1.5-3.5 cmH2O is achieved, no further adjustment is required.~If P0.1 value <1.5, sedation will be reduced.~If P0.1 value >3.5, sedation will be increased.~If P0.1 value is still >3.5 with deep sedation, cisatracurium will be allowed and titrated until P0.1 value <3.5 cmH2O.~The study protocol will be continued for 48 hours or until the patients are considered ready for weaning."
75902762|NCT06203405|Drug|Fentanyl|Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
75902763|NCT06203405|Drug|Midazolam|Continuous intravenous infusion of midazolam 0.02 - 0.1 milligrams/kilogram/hour
75608867|NCT04903951|Other|Best medical treatment|Best medical treatment for stroke, including rehabilitation
75902764|NCT06203405|Drug|Propofol|Continuous intravenous infusion of propofol 5 - 50 micrograms/kilogram/minute
76068121|NCT01756898|Drug|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
76068122|NCT01756898|Drug|10 mg ASB17061|Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
75457222|NCT01782300|Biological|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
76068123|NCT01756898|Drug|20 mg ASB17061|Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
75457223|NCT01782339|Drug|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
76068124|NCT01731938|Biological|Fibrin Sealant (FS) Grifols|Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
75457224|NCT01782365|Device|SHAM stimulation|no stimulation
75457225|NCT01782365|Device|0,75 Hz stimulation|
75457226|NCT01782391|Device|Stimulation|
75457227|NCT01782391|Device|SHAM|no stimulation
75457228|NCT01782404|Device|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
75608868|NCT02775565|Device|AngioVac|
75608869|NCT04811677|Other|radiology|image analysis
75608870|NCT04225741|Behavioral|Training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.
75608871|NCT02775253|Other|Chronic cold acclimation|
75608872|NCT04227691|Device|Long-pulsed Nd Yag laser treatment|One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients
75755596|NCT03096366|Device|Blood flow restriction|With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
75608873|NCT04227691|Device|IPL treatment|One treatment of the assigned axilla with IPL treatment in ten patients
75608874|NCT02775175|Behavioral|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
75755597|NCT03096366|Other|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
75755598|NCT01030770|Drug|Ranibizumab|Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
75755599|NCT01030770|Drug|0.9% Sodium Chloride|Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
75755600|NCT04941443|Drug|Methadone Pill|All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.
75755601|NCT04941443|Drug|Ibuprofen|All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
75902765|NCT06203405|Drug|Dexmedetomidine|Continuous intravenous infusion of dexmedetomidine 0.2 - 0.7 micrograms/kilogram/hour
75902766|NCT06203405|Drug|Cisatracurium|Continuous intravenous infusion of cisatracurium 5 - 20 milligrams/hour
75902767|NCT06203392|Other|Very low carbohydrate ketogenic diet|Very low carbohydrate ketogenic diet provided for six weeks
75902768|NCT06203392|Other|Mediterranean diet|Mediterranean diet provided for six weeks
75608875|NCT02777203|Device|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag.
75457229|NCT01782417|Behavioral|patient and provider intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
75755602|NCT01030848|Device|Total Knee Replacement (LCS rotating platform)|
75755603|NCT03994692|Device|PEEK eminoplasty|making obstacle at eminence using patient specefic PEEK device
75755604|NCT03994692|Procedure|autogenous onlay grafting eminoplasty|making obstacle at eminence using chin graft
75755605|NCT04868981|Drug|GST-HG141 tablets|Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
75902769|NCT06203379|Other|Neuromuscular Exercise Training|Neuromuscular Exercise Training
75902770|NCT06203379|Other|control exercise|Exercise Training
75608876|NCT02778841|Other|Exercise|This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
75755606|NCT04868981|Drug|Matching Placebos for GST-HG141 tablets|Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
75755607|NCT01030926|Drug|insulin degludec|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
75755608|NCT01030926|Drug|insulin glargine|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
75902771|NCT06203366|Procedure|Vojta therapy|Vojta therapy is an old treatment method which was discovered by Professor Vaclav Vojta, a neurologist and pediatrician. It has been used to treat children with impair motor function in Thailand since 2011. Vojta therapy encourage the movement of children via positioning and stimulate the specified zone.
75608877|NCT02775097|Device|OCT|OCT for all Arms
75608878|NCT01129687|Procedure|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
75608879|NCT01129687|Procedure|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
75608880|NCT02775019|Dietary Supplement|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
75608881|NCT02775019|Dietary Supplement|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
75608882|NCT04194853|Device|Electromyographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength .Electromyographic (EMG) biofeedback is a specific form of biofeedback. The biofeedback device records muscle activity through the application of electrodes superficially or subcutaneously when targeting specific muscles
75608883|NCT04194853|Other|Quadriceps Isometric exercises|In supine lying or sitting, Patient is asked to press down knee while contracting Quadriceps muscles.
75608884|NCT02774863|Other|Home passages|Three home passages between the 2nd and 3rd months of follow up.
75608885|NCT02778919|Drug|KLH-2109|
75608886|NCT02778919|Drug|Placebo|
75755609|NCT04822259|Device|JOURNEY II BCS Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
75902772|NCT06203353|Diagnostic Test|diaphragm ultrasound monitoring|Ultrasound measure the diaphragm excursion, thickening fraction and maximal contraction and relaxation velocities
75902773|NCT06203340|Other|Core stabilizasyon and lumbal back school|Lumbal back schooL
75902774|NCT06203314|Other|Diagnostic test: EBV antibody tests|Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
76068125|NCT01731938|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
76068126|NCT01731470|Biological|Liposomes|Intravesical instillation of liposomes.
76068127|NCT01756352|Drug|18F-FET|Radiotracer, surrogate marker for protein synthesis
75457230|NCT01782430|Procedure|- standard oxygenation|
75457231|NCT01782456|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
75457232|NCT01782508|Drug|imatinib|a selectively inhibits the KIT protein tyrosine
75457233|NCT01782508|Drug|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
75457234|NCT01782521|Procedure|No primer|Primer not used when bonding orthodontic brackets
75457235|NCT01782547|Behavioral|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
75608887|NCT02778919|Drug|Leuprorelin acetate|
75755610|NCT04822259|Device|JOURNEY II CR Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
75755611|NCT00535223|Behavioral|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
75755612|NCT00535223|Behavioral|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus."
75755613|NCT00536939|Drug|Enzastaurin|1125 milligrams (mg) loading dose on Day 1 of Cycle 1 only then 500 mg oral once daily, until disease progression
75755614|NCT00536939|Drug|Bevacizumab|10 milligrams per kilogram (mg/kg) intravenously, Days 1 and 15 every 28 days, until disease progression
76068128|NCT01756274|Device|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
76068129|NCT01756274|Device|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
76068130|NCT01756274|Device|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
76068131|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the evening (PM) for 28 days
76068132|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD in the PM for 28 days
75457236|NCT01782547|Other|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
75457237|NCT01782560|Drug|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
75608888|NCT02774629|Other|prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)
75608889|NCT00635011|Behavioral|psychotherapy|Cognitive Behavioral therapy
75608890|NCT02779153|Drug|Acthar low dose (40 U)|The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
75755615|NCT00536939|Drug|Paclitaxel|90 milligrams per square meter (mg/m^2), intravenously, Days 1 ,8, and 15 every 28 days until disease progression
75755616|NCT00536939|Drug|Placebo|Oral, daily, until disease progression
75755617|NCT03883217|Device|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
75755618|NCT00347919|Drug|pazopanib (GW786034) 400 mg|400 mg administered orally once daily
75902775|NCT06203301|Behavioral|resistance exercise and walking|"After receiving the cases, they were divided into 4 groups by random allocation:~Control group: No exercise intervention measures are performed, and the patients carry out their daily lives according to their past living habits.~Resistance exercise group: Resistance exercise training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. The patients are given resistance exercise training for 45 minutes each time, 3 times a week, for 12 consecutive weeks. Afterwards, the patient is asked to regularly perform resistance exercise on his own for at least 1 year.~Walking group: Walking training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. They should walk continuously for 15 minutes at least twice a day and continue walking at least 5 days a week. Or walk for at least 150 minutes a week and walk for at least 15 minutes continuously each time for 12 consecutive weeks of walk"
75902776|NCT06203275|Drug|Paroxetine|intervention group n=22 Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus paroxetine 12.5 mg daily
76068133|NCT01731002|Drug|Latanoprost ophthalmic solution 0.005%|Administered to study eye, QD in the PM for 28 days
76068134|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
76068135|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
75608891|NCT02779153|Drug|Acthar high dose (80 U)|The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
75755619|NCT00347919|Drug|lapatinib (GW572016) 1500 mg|1500 mg administered orally once daily.
76068136|NCT01783886|Procedure|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
75755620|NCT00347919|Drug|lapatinib (GW572016) 1000 mg|1000 mg administered orally once daily
75902777|NCT06203275|Drug|Placebo|Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
75902778|NCT06203262|Device|Catheter Ablation Ventricular Tachicardia|Catheter ablation is s minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
76068137|NCT01609556|Drug|Mirvetuximab soravtansine|Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
75457238|NCT01782560|Drug|Placebo|
75457239|NCT01782573|Drug|Chlorhexidine gluconate|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
75457240|NCT01782573|Drug|0.9% Sodium Chloride|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
75457241|NCT01782612|Procedure|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
75457242|NCT01782612|Procedure|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
75457243|NCT01782625|Other|NO exercise at depth|Subjects will NOT exercise while at depth
75755621|NCT00347919|Drug|pazopanib (GW786034) 800 mg|800 mg administered orally once daily
75755622|NCT03987321|Device|Infrarenal vena cava filter placement|Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
75755623|NCT01051869|Procedure|Simple decompression|"Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken."
75755624|NCT01051869|Procedure|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
75755625|NCT03987087|Radiation|Radiation|"Thoracic intensity modulated radiation therapy (IMRT)~+EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy"
75902779|NCT06203262|Device|Catheter Ablation Premature Ventricular Contractions|Catheter ablation is s minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
75902780|NCT06203236|Drug|Furosemide 20 MG|"The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation."
75902781|NCT06203236|Other|diuretic therapy|diuretic therapy
75755626|NCT03987087|Drug|Chemotherapy|EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
75902782|NCT06203223|Other|Ova-max|use Ova-max 3 months prior to treatment initiation
75457244|NCT01782625|Other|exercise at depth|Subjects will exercise while at depth
75902783|NCT06203223|Other|placebo|use placebo 3 months prior to treatment initiation
75902784|NCT06203210|Drug|Ifinatamab deruxtecan|12 mg/kg intravenous dose on Day 1 of each 21-day cycle
75902785|NCT06203210|Drug|Topotecan|Topotecan will be administered per local SoC.
75902786|NCT06203210|Drug|Amrubicin|Amrubicin will be administered per local SoC.
76068138|NCT00234832|Drug|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
76068139|NCT00234832|Drug|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
76068140|NCT00234832|Drug|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
76068141|NCT00259090|Drug|Fulvestrant|500 mg intramuscular injection
76068142|NCT00259090|Drug|Anastrazole|oral tablet
76068143|NCT00235456|Procedure|Perioperative supplemental oxygen|Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
75457245|NCT01782638|Behavioral|deep brain stimulation|
75457246|NCT01782651|Drug|Lapatinib plus capecitabine|Lapatinib plus capecitabine
75457247|NCT01782677|Procedure|Bilateral Surgical Resection of Carotid Bodies|
75457248|NCT01782755|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
75457249|NCT01782755|Other|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
75457250|NCT01782768|Device|noninvasive positive pressure ventilation|the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
75902787|NCT06203210|Drug|Lurbinectedin|Lurbinectedin will be administered per local SoC
75902788|NCT06203197|Other|Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)|intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS).
75902789|NCT06203184|Other|video based exercises|Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.
75902790|NCT06203145|Drug|Bortezomib|A reduction in serum FLCs level of more than 80% by day 14 of BCD is defined BCD-AutoHSCT group; A reduction in serum FLCs level of less than 80% by day 14 of BCD is defined BCD-KPD-AutoHSCT group.
76072347|NCT01194271|Procedure|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
75755627|NCT03987243|Behavioral|Structured Pressure Ulcer Prevention Education|Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.
75755628|NCT03987243|Other|Mobile Seat Interface Pressure Mapping System (IPM)|This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
75755629|NCT00439140|Biological|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
75755630|NCT00439140|Drug|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
75755631|NCT00356421|Drug|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
75755632|NCT00356421|Drug|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
76068144|NCT00235456|Procedure|Standard oxygen|Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
75755633|NCT01324869|Biological|KH902|Intravitreal injection of 0.5mg/eye/time KH902
75755634|NCT03990129|Drug|Metamizole|One week treatment with metamizole (500 mg tablets, 2-2-2)
75755635|NCT01051947|Drug|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
75755636|NCT01051947|Drug|Metoprolol|dosage prescribed prior to starting on study
75755637|NCT01052025|Drug|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
75755638|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
75755639|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 48 weeks
75755640|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
75755641|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 24 weeks
75755642|NCT00438672|Drug|Placebo Injection|Injection without steroid
75902791|NCT06203132|Drug|Doravirine + tenofovir DF + lamivudine|Oral administration
75902792|NCT06203132|Drug|Dolutegravir + tenofovir DF + lamivudine or emtricitabine|Oral administration
75902793|NCT06203106|Other|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
75902794|NCT06203093|Other|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
75902795|NCT06203080|Drug|ancetate gel|An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
75902796|NCT06203080|Drug|nonoxinol gel|The nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be utilized for the intervention. Each product weighs 5 g and contains 50 mg of N-9. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
75457251|NCT01782781|Drug|ropivacaine, ketorelac and epinephrine|Active group
75902797|NCT06203054|Device|Penditure™ LAA Exclusion System|Exclusion of the left atrial appendage using the Penditure™ LAA Exclusion System in subjects undergoing concomitant cardiac surgery.
75457252|NCT01782781|Drug|Placebo|Placebo group
75457253|NCT01782794|Other|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
75755643|NCT00438672|Drug|Steroid (dexamethasone) Injection|Injection with steroid (dexamethasone)
75755644|NCT01027260|Drug|Itopride HCI 50 mg|Variable dosing
75457254|NCT01782807|Procedure|Salpingectomy or Fimbriectomy|
75457255|NCT01782846|Drug|Ixprim®|
75457256|NCT01782846|Drug|Dafalgan-Codeine®|
75457257|NCT01782911|Dietary Supplement|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
75457258|NCT01782911|Dietary Supplement|Placebo pills|The patients will take placebo for 40 days.
75457259|NCT01782924|Drug|KHK4827|
75457260|NCT01782937|Drug|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
75755645|NCT01027260|Drug|Itopride HCI 100 mg|Variable dosing
75755646|NCT01027260|Drug|Placebo|Variable dosing
75755647|NCT01033968|Procedure|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
75755648|NCT01034046|Other|Low Carbohydrate Diet|Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.
75755649|NCT01034046|Other|Low Fat Diet|Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
75755650|NCT00438360|Drug|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
75755651|NCT00438360|Drug|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
75755652|NCT00536471|Drug|Duloxetine hydrochloride|
75755653|NCT00536471|Drug|Placebo|
75755654|NCT00359619|Biological|CervarixTM|Subjects were administered three doses of HPV vaccine
75755655|NCT00359619|Biological|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
75755656|NCT00437658|Drug|Elagolix|Provided as tablets for oral administration
75755657|NCT00437658|Drug|Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)|Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.
75755658|NCT00437658|Drug|Placebo to Elagolix|Matching placebo tablets for oral administration
75755659|NCT00437658|Drug|Placebo to DMPA-SC|Matching placebo for subcutaneous injection in a pre-filled syringe
75755660|NCT04689516|Device|Thoracic fluid content estimation|The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before the start and after the end of the infusion.
75902798|NCT06203041|Dietary Supplement|Vitamin D|Orally administered, daily dose of 5000 IU (125 mcg) Vitamin D3 for 28 days.
75902799|NCT06203015|Diagnostic Test|The Cambridge Neuropsychological Test Automated Battery.|to determine cognitive dysfunction
75902800|NCT06203015|Diagnostic Test|Venous blood samples|to measure levels of cytokines, endotoxin, and genetic markers.
75902801|NCT06203015|Diagnostic Test|brain MRI|to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations
76068145|NCT00236938|Drug|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
76068146|NCT00236938|Drug|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
75902802|NCT06203015|Diagnostic Test|the Montgomery-Åsberg Depression Rating Scale|to measure severity of depressive symptoms
75755661|NCT03808415|Device|EMG-driven|The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
75755662|NCT03757793|Device|FORE-SIGHT ELITE monitor|At end of surgery, one sensor of the FORE-SIGHT Elite monitor is placed on the DIEP flap or two sensors in case of bilateral DIEP flaps for monitoring perfusion and oxygen consumption in the free flap. A control sensor of the FORE-SIGHT Elite monitor placed on the abdomen where tissue is taken to perform the DIEP flap. This sensor reflects normal tissue oxygenation. Data obtained from the FORE-SIGHT Elite monitor will be compared to data obtained from physical examination, which is standard of care for flap monitoring.
75902803|NCT06203015|Other|questionnaire prepared by the researchers|collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.
75755663|NCT04002635|Drug|Letrozole|Letrozole ovulation induction
75755664|NCT04002635|Drug|estradiol valerate|hormonal replacement therapy
75755665|NCT01052181|Drug|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
75755666|NCT01052181|Drug|placebo|2 sachets monthly for an year
75755667|NCT01056237|Drug|Multi-target therapy|Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
75755668|NCT01056237|Drug|Azathioprine|1.0-2.0mg/kg/d
75755669|NCT02533557|Device|stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.~1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time."
75755670|NCT02533557|Drug|lidocaine mixed with epinephrine|2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
75755671|NCT03986775|Dietary Supplement|isomaltulose|replacement of sucrose with low-glycemic isomaltulose
75755672|NCT03986775|Dietary Supplement|sucrose|conventional beverage with sucrose
75755673|NCT00356265|Drug|Procedure: Regional phenylephrine arterial infusion|
75902804|NCT06203002|Drug|Placebo (blinded)|LX9211 matching placebo tablets
75902805|NCT06203002|Drug|LX9211 (blinded)|LX9211 (blinded) tablets
75902806|NCT06202989|Drug|Multiprofen-CC™ plus standard treatment|Multiprofen-CC™ [ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)] Dose: 1.0g, 3 times per day for 3 months after surgery
75902807|NCT06202989|Other|Placebo plus standard treatment|The placebo is the base cream with no medicinal ingredients
76068147|NCT01898728|Drug|topical povidone-iodine after premedication with topical liquid eye drops|
76068148|NCT01898728|Drug|topical povidone-iodine after premedication with topical gel|
76068149|NCT00260962|Drug|Olanzapine|After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
75755674|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg.
75608892|NCT04226443|Drug|Midazolam intravenous injection|The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.
75755675|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
75755676|NCT01052259|Drug|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
75755677|NCT01056549|Drug|exenatide|In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
75755678|NCT01052337|Drug|anaesthetics: sevofluorane|0.5%of sevofluorane with air
75755679|NCT00535145|Drug|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
75755680|NCT01052415|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
75755681|NCT01056627|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
75755682|NCT03990831|Diagnostic Test|Functional near-infrared spectroscopy (fNIRS)|Functional near-infrared spectroscopy (fNIRS) measurement
75755683|NCT03985995|Drug|CBD 800 mg p.o|cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
75755684|NCT03985995|Drug|Placebo p.o|single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
75755685|NCT01053585|Drug|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
75902808|NCT06202976|Other|Secondary data collection|clinical data
75902809|NCT06202963|Drug|Triamcinolone Acetonide|"group will receive ultrasound-guided hydrodilatation~group will receive ultarsound-guided coracohumeral hydrorelease in addition to the ultrasound-guided hydrodilaltation of shoulder"
75902810|NCT06202937|Behavioral|Mother Baby Yoga|Fragile Baby Perception Syndrome, Maternal Attachment, Depression-Anxiety-Stress Level
75755686|NCT01053585|Drug|Placebo|Placebo single 'dose' 90 minutes prior to study
75755687|NCT03986697|Drug|Biktarvy|Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
75755688|NCT01564355|Device|Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)|All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.
75755689|NCT01564355|Drug|Post-op Oral Steroids|Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
75902811|NCT06202937|Other|No intervention:control|the control group received the usual care
75902812|NCT06202911|Drug|oral n-acetyl cysteine|the active participants will receive oral N-acetyl cysteine with dose 20mg/dose every 6 hours for 10 days or until reaching full feeding or resolution of feeding intolerance
75457261|NCT01782950|Drug|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
75457262|NCT01782976|Drug|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
75457263|NCT01782976|Drug|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
75457264|NCT01782976|Behavioral|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
75457265|NCT01783002|Radiation|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
75902813|NCT06202911|Other|placebo|the control group will receive placebo
75902814|NCT06202898|Other|Baseline|At the baseline visits, all study participants will be complete an interviewer-assisted questionnaire using REDCap, and will also receive the SBIRT-T MI-based intervention. Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for strength sessions, and they will be provided with a schedule of strength session visits
75902815|NCT06202898|Other|ENTRSUT|Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for economic strength sessions, group-based economic training through photovoice activities and adapted screening brief intervention and treatment (SBIRT-T) adapted for transgender women delivered by a facilitator or digitally.
75902816|NCT06202898|Other|Control|participants assigned to the control arm will have the option of participating in the four additional strength sessions.
75608893|NCT04226443|Drug|Remifentanil intravenous bolus dose|A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
75608894|NCT02776891|Drug|Gallium citrate|Ga-68 citrate will be administered on an outpatient basis at the Center for Molecular and Functional Imaging at China Basin. It will be administered a single time point intravenously prior to PET imaging. The one-time nominal injected dose will be up to 15 mCi containing 10 - 25 μg Ga-68. A simultaneous MRI (PET/MRI) of the head will be used for attenuation correction and anatomic localization of gallium-68 citrate uptake and standardized uptake value (SUV) calculation.
76068150|NCT00260962|Behavioral|Day Hospital|Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
75755690|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
75755691|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
75755692|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
75608895|NCT02776813|Biological|ACTR087|
75608896|NCT02776813|Biological|rituximab|
75608897|NCT02776657|Other|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
75755693|NCT01056705|Biological|Oral Poliomyelitis Vaccine|Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
76068151|NCT00261040|Procedure|Minimally Invasive Surgery|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
75755694|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Salk strains).|3x0.5ml intramuscular injections, one month apart.
75755695|NCT00437268|Drug|enzastaurin|1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease
75755696|NCT00437268|Drug|irinotecan|300 milligrams per square meter (mg/m^2) intravenously on Day 1 of each 21-day cycle until progressive disease
76068152|NCT00261040|Procedure|Standard Surgery|The standard way that an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision.
76068153|NCT00237718|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
76068154|NCT00237718|Drug|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
75608898|NCT02776657|Device|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
75608899|NCT02776657|Procedure|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
75608900|NCT02774551|Behavioral|Physical activity intervention group|150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
75755697|NCT00437268|Drug|cetuximab|400 mg/m^2, intravenously on Day 1, 250 mg/m^2 on Day 8, Day 15 Cycle 1 then 250 mg/m^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
76068155|NCT00237718|Drug|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
76068156|NCT00237718|Drug|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
75608901|NCT02774317|Biological|Plasma|FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
75608902|NCT02774161|Other|Ultrasound Tomography|Undergo B-mode ultrasound imaging
75608903|NCT04936243|Behavioral|FOLLOW UP VISIT-TELEMEDICINE|Routine follow up care conducted remotely with video-conferencing tools
75755698|NCT04002089|Drug|Exparel Injectable Product|bupivacaine liposome injectable suspension
75755699|NCT04002089|Drug|Bupivacaine|1.3%, 13.3 mg/mL
75755700|NCT01056783|Drug|OC000459|OC000459 100mg, twice daily, tablet
75755701|NCT01056783|Drug|Placebo|Placebo tablets to match OC000459 tablets, twice daily
75755702|NCT04002245|Procedure|antiseptic application|The application of the antiseptic on the healthy and visibly clean skin of the bend of the elbow will be carried out for all participant
75755703|NCT01056861|Drug|Botulinum Toxin A|Not exceeding a total dose of 400 units, once every three months.
76068157|NCT00238108|Drug|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
76068158|NCT00238108|Drug|Placebo|Placebo
75755704|NCT05355467|Drug|Tenofovir disoproxil fumarate|Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.
75755705|NCT05355467|Other|Historical Data|Historical Data
75755706|NCT04139525|Biological|unfractionated heparin|A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.
75755707|NCT04139525|Biological|8% trisodium citrate|8% trisodium citrate in the dose of 150 ml/h.
75755708|NCT01058733|Other|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
76068159|NCT01899196|Biological|blood sampling,|
75608904|NCT04936243|Behavioral|FOLLOW UP VISIT-FACE TO FACE|Routine follow up care conducted in person
75608905|NCT02774083|Behavioral|Feuerstein Program|Mediated learning cognitive enhancement program
75608906|NCT02774083|Behavioral|Adler Program|Social and emotional group program
75457266|NCT01783002|Radiation|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
76068160|NCT01898962|Procedure|Complete Surgical Removal|
76068161|NCT01898962|Radiation|Stereotactic Radiosurgery|
76068162|NCT01898962|Radiation|Ablative external beam radiation dose|
76068163|NCT01898962|Procedure|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
75608907|NCT04175821|Radiation|Hypofractionated radiotherapy|35Gy/ 15#/3weeks to chest wall and 40Gy/15#/3 weeks to supraclavicular fossa
75608908|NCT05157997|Drug|Casirivimab and Imdevimab Antibody Cocktail|The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
75457267|NCT01783002|Radiation|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
75608909|NCT00635245|Biological|figitumumab|
75608910|NCT00635245|Other|imaging biomarker analysis|
75608911|NCT00635245|Other|laboratory biomarker analysis|
75608912|NCT00635245|Other|pharmacological study|
75608913|NCT00635245|Procedure|conventional surgery|
75755709|NCT00437034|Biological|aflibercept|Given IV
75755710|NCT01027338|Other|Tai chi exercise|
75755711|NCT00337467|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
75755712|NCT03285425|Other|Natural history|Parent interview
75755713|NCT01056939|Device|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with neurally adjusted ventilatory assist
75755714|NCT01056939|Device|Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with PC or PRVC ventilation.
75755715|NCT03989739|Device|Da Vinci|
75902817|NCT06202885|Drug|Immunotherapy|Immunotherapy
75902818|NCT06202872|Device|Gamma (40 Hz) tACS at the precuneus region|40 Hz tACS applied at a current of 3 milliampere peak-to-peak using a NuroStym transcranial electrical stimulation (tES) system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
76068164|NCT01898962|Radiation|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
76068165|NCT04752124|Other|Exercise Therapy|High intensity speed based interval treadmill training
76068166|NCT04752124|Other|conventional therapy|conventional physical therapy
76068167|NCT00266110|Biological|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
76068168|NCT00266110|Biological|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
75608914|NCT00635245|Procedure|magnetic resonance spectroscopic imaging|
75608915|NCT00635245|Procedure|neoadjuvant therapy|
75608916|NCT02776501|Drug|Coppertone (BAY987521)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: Y49-103)
75608917|NCT02776423|Procedure|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
75902819|NCT06202872|Device|Sham tACS at the precuneus region|Sham tACS applied with no effective stimulation between the ramp-up and ramp-down of the current using a NuroStym tES system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
75755716|NCT03985085|Other|Comprehensive package of sexual and reproductive health services|"Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction.~This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant."
75755717|NCT01057095|Genetic|RNA analysis|
75902820|NCT06202859|Device|MIE|Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.
75902821|NCT06202846|Genetic|cfDNA analysis|"In order to compare the performance of the ctDNA test with techniques used in routine diagnostics, we will compare the results obtained by the ctDNA test with those obtained by FISH.~compare the results obtained by the ctDNA test and FISH. This will enable us to identify a potential diagnostic gain. We will compare the percentage of patients for whom a positive test result result was obtained by the lncDNA test (Y chromosome detection) to the percentage of patients for whom a positive result was obtained by FISH."
75902822|NCT06202833|Device|Acupuncture with regulating immunity as the core of treatment|The patient was supine, the acupuncture points were disinfected with 75% ethanol, and the acupuncture points on the head and neck were first acupuncture, and then the acupuncture points on the abdomen and limbs. baihui: When the 1.5 inch millimeter needle is needled, the tip of the needle and the acupoint are at a 15-30 ° Angle, and the needle is about 1 inch flat along the subcutaneous area. The twisting speed is about 200 times per minute, and the stitches are once every 15 minutes, and each stitch is about 30 seconds. zhongwan, tianshu: 1.5 inch needle straight puncture 1 inch, small amplitude lifting and twisting. guanyuan, qihai: 1.5 inch millimeter needle downward oblique puncture 1 inch, small amplitude lifting and twisting. The above acupoints were measured by obtaining qi, and the needles were retained for 30min, once a day.5 days a week for 4 weeks.Twenty days in total.
76068169|NCT00266110|Biological|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
76068170|NCT00266110|Drug|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
76068171|NCT00240526|Biological|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
76068172|NCT00240526|Biological|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
76068173|NCT01899274|Device|bant iPhone application|
76068174|NCT00242632|Drug|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
75608918|NCT02776579|Other|Girls-only resistance training|
75608919|NCT02778373|Dietary Supplement|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
75608920|NCT02778373|Dietary Supplement|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
75755718|NCT01057095|Genetic|gene expression analysis|
75755719|NCT01057095|Genetic|reverse transcriptase-polymerase chain reaction|
75608921|NCT02778373|Other|Placebo: Water|
75608922|NCT02772835|Device|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
75608923|NCT02773147|Drug|Cyanocobalamin|
75608924|NCT02773147|Drug|Folate|
75608925|NCT02773147|Drug|Pyridoxine|
75608926|NCT02773927|Drug|Metformin|Metformin in tablet presentation of 500 mg
75608927|NCT02773927|Dietary Supplement|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
75608928|NCT02773927|Other|Placebo of agave inulin|Calcinated magnesia powder
75608929|NCT02773927|Other|Metformin placebo|Calcinated magnesia tablet
75755720|NCT01057095|Other|laboratory biomarker analysis|
75755721|NCT03778385|Other|Exercise|Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
75755722|NCT01058889|Device|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
75755723|NCT00337077|Drug|eribulin mesylate|Given IV
75755724|NCT00428220|Drug|sunitinib|sunitinib
75755725|NCT01057329|Drug|Atomoxetine|mg according to body weight
75755726|NCT01057329|Drug|Duloxetine|30 mg / die
75755727|NCT01057329|Drug|Olanzapine|5mg 1 wwek and 10 mg from second week
75755728|NCT01057329|Drug|Aripiprazole|5 mg from week 1, 10 mg from week 2
75755729|NCT01057407|Drug|ASP1585|oral
75755730|NCT01057407|Drug|Sevelamer hydrochloride|oral
75755731|NCT01037478|Drug|Resminostat (4SC-201)|oral administration
75755732|NCT01057485|Procedure|AF ablation and AV node ablation|AF ablation and AV node ablation
75755733|NCT01057485|Procedure|AV node ablation|AV node ablation
76068175|NCT01899352|Procedure|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
75457268|NCT01783028|Behavioral|Community Health Worker support|For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
75457269|NCT01783067|Other|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
75608930|NCT02773771|Dietary Supplement|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive >3g of HMB/ day.
75608931|NCT02773771|Dietary Supplement|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
75902823|NCT06202833|Device|Needles that are not on acupoints|In this group, acupuncture treatment was performed at 1cm side of the selected points of the Tongyuan acupoint acupuncture group.The piercing Angle is the same as the test group, only piercing, not twisting.Once a day, 5 days a week for 4 weeks.Twenty days in total.
75608932|NCT02773771|Dietary Supplement|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
75608933|NCT02773615|Procedure|Cardiac computed tomography|Non-invasive CT scan of the heart
75608934|NCT04175275|Other|Interview patient|Interview patient without scoring about the reasons for the implant, the complications, the reasons for abandonment, the evaluation of the satisfaction
75608935|NCT02773693|Behavioral|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
75608936|NCT02773693|Behavioral|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
75608937|NCT02773693|Behavioral|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
76068176|NCT01899040|Device|neuromodulation for episodic migraine headache|
76068177|NCT01899430|Drug|liraglutide|
76068178|NCT01899430|Drug|metformin|
76068179|NCT00245518|Drug|Isoflavone|
76068180|NCT00245518|Drug|Placebos|
76068181|NCT00267670|Drug|Pentoxifylline|400mg PO TID
75755734|NCT03986463|Other|Circulating tumour DNA (ctDNA)|Circulating tumour DNA (ctDNA) will be isolated from blood samples
75755735|NCT03986307|Dietary Supplement|Omega-3 polyunsaturated fatty acid supplementation|Daily supplementation with omega-3 capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
75755736|NCT03986307|Other|Resistance exercise|Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).
75902824|NCT06202820|Behavioral|CV Care Program|Comprised of two, in-clinic, counseling sessions with oncology nurse practitioner or physician assistant for education on cardiovascular disease (CVD) and cardiovascular risk factors as well as recommendations for management.
76068182|NCT00267670|Drug|Placebo|1 pill PO TID
76068183|NCT00247624|Drug|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
76068184|NCT00247624|Drug|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
76068185|NCT00247624|Drug|Placebo|Placebo every night for 8 weeks
75755737|NCT03986307|Dietary Supplement|Placebo - appearance-matched oil supplementation|Daily supplementation with placebo capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
75902828|NCT06202781|Drug|SOX plus PD-1 inhibitor|S-1, Oxaliplatin and nivolumab/sintilimab
75755738|NCT01059045|Procedure|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
75902829|NCT06202781|Procedure|Gastroscopic biopsy|Gastroscopy and biopsy
76068186|NCT00248560|Drug|docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
76068187|NCT00248560|Drug|Gemcitabine|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
76072348|NCT01192048|Other|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
75608938|NCT02773459|Drug|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
75457270|NCT01783067|Other|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
75457271|NCT01783093|Other|Data Collection|Collection of data from existing medical records
75608939|NCT02773303|Device|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
75608940|NCT02773303|Device|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
75608941|NCT02773225|Drug|Eltrombopag|"CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> partial or complete remission Eltrombopag and slow tapering of CSA~12 month after therapy start --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
75608942|NCT02773225|Drug|Placebo (for Eltrombopag)|"CSA + Placebo, evaluation after three month therapy start regarding dose escalation~6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --> dose escalation~12 month after start of eltrombopag --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
75608943|NCT02773381|Drug|semaglutide|Oral administration once-daily.
75608944|NCT02773381|Drug|placebo|Oral administration once-daily.
75755739|NCT01059045|Other|Control|No intervention
75457272|NCT01783106|Drug|Ciprofloxacin|experimental
75457273|NCT01783106|Drug|Doxycycline|experimental
75457274|NCT01783106|Drug|Hydroxychloroquine|oral
75457275|NCT01783106|Drug|Budesonide|active comparator
75457276|NCT01783119|Dietary Supplement|Aloe Barbadensis Miller|
75457277|NCT01783119|Dietary Supplement|placebo water|
75755740|NCT02873975|Drug|LY2606368|
75608945|NCT04818229|Drug|CBP-307|CBP-307 capsules oral administration.
75608946|NCT04818229|Drug|Placebo-matched CBP-307|Placebo-matched CBP-307 capsules oral administration.
75608947|NCT04818229|Drug|Moxifloxacin (Avelox)|Moxifloxacin tablets oral administration。
75755741|NCT01054131|Behavioral|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
75902830|NCT06202768|Other|data collection|data collection : age, gestational age, BMI, history of vaginal delivery after cesarean section, indication for cesarean section, preeclampsia for this pregnancy, the cervix dilatation, position in the pelvis, cervix consistency
75755742|NCT01057563|Device|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
75608948|NCT04818229|Drug|Placebo-matched Moxifloxacin|Placebo-matched Moxifloxacin tablets oral administration.
75755743|NCT01057563|Device|bare-metal stent (BMS)|BMS implantation
75457278|NCT01783132|Device|NIOX MINO|Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.
75755744|NCT01057563|Device|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
75457279|NCT01783158|Procedure|Esophagoscopy and chromoendoscopy|"Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.~Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy."
75457280|NCT01783171|Drug|Akt Inhibitor MK2206|Given PO
75457281|NCT01783171|Drug|Dinaciclib|Given IV
75457282|NCT01783171|Other|Laboratory Biomarker Analysis|Correlative studies
75608949|NCT02772991|Other|troponin measurement|Cardiac catheterization (for patients with >50% lesions) or discharge or in patients with intermediate risk.
75608950|NCT02773069|Behavioral|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
75608951|NCT02772523|Other|Lifestyle recommendations|Dietary, and physical, cognitive and social activity recommendations
75608952|NCT04771741|Drug|Acetominophen|1,000 mg every 6 hours
75608953|NCT04771741|Drug|Toradol|10 mg every 6 hours, days 0-3
75608954|NCT04771741|Drug|Meloxicam|15 mg once daily, beginning post-op day 4
75608955|NCT04771741|Drug|Cyclobenzaprine|10 mg every 8 hours
75608956|NCT04771741|Drug|Lyrica|75 mg every 12 hours
75755745|NCT00345579|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
75755746|NCT00345579|Biological|ActHIB|3-dose intramuscular injection
75755747|NCT00345579|Biological|Pediarix/Infanrix Penta|3-dose intramuscular injection
75755748|NCT05356559|Dietary Supplement|Intervention|12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
75755749|NCT05356559|Other|Control|Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
75755750|NCT04002323|Drug|Dolutegravir 50mg Tab|The subjects starts their ART with this drugs, once a day
75755751|NCT04002323|Drug|Lamivudine 300 mg|The subjects starts their ART with this drugs, once a day
75755752|NCT04002713|Other|ALT flap reconstruction|Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.
75755753|NCT04002713|Other|AMT flap reconstruction|Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
75755754|NCT05354921|Device|Indwelling Catheter|Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
76025314|NCT03114007|Behavioral|Inter-Action services|An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
76068188|NCT00248638|Drug|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
75608957|NCT02772445|Behavioral|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
76068189|NCT00248638|Drug|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
76068190|NCT00249496|Behavioral|Contingency management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
76068191|NCT00249496|Behavioral|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
76068192|NCT00268762|Drug|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
75755755|NCT05354921|Device|Intermittent Catheterization|"Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR>400 mL, an intermittent catheter will be used. If PVR> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.~It is expected that a small percentage of patients in either group will not have a PVR>400 mL preoperatively.~These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time."
76068193|NCT00252382|Drug|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
76068194|NCT00270634|Drug|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
75457283|NCT01783171|Other|Pharmacological Study|Correlative studies
75457284|NCT01783210|Behavioral|Specific Therapeutic Lifestyle Changes program in pregnancy|"TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the talk test (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks."
75755756|NCT04001855|Other|Dilute vinegar (acetic acid)|Dilute vinegar baths or gauze soaks
75755757|NCT04001855|Other|Dilute bleach|Dilute bleach baths or gauze soaks
76068195|NCT00270634|Drug|tacrolimus|tacrolimus 0.05 mg/kg po BID
75457285|NCT01783210|Behavioral|Dietary and behavioral counselling in pregnancy|"The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.~30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks."
75608958|NCT02772601|Drug|Caffeine|
75608959|NCT02772601|Drug|Warfarin|
75755758|NCT00335829|Biological|bevacizumab|
75755759|NCT00335829|Drug|chemotherapy|
76025315|NCT04557709|Other|Medical Chart Review|Review of medical charts
76025316|NCT05128721|Biological|Covi Vax|Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
76068196|NCT01899586|Other|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
76068197|NCT01899586|Other|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
75608960|NCT02772601|Drug|Omeprazole|
75608961|NCT02772601|Drug|Metoprolol|
75608962|NCT02772601|Drug|Midazolam|
75608963|NCT02772601|Drug|Risankizumab|
75608964|NCT02772055|Other|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
75755760|NCT00335829|Drug|embolization therapy|
75902831|NCT06202651|Device|Nd:YAG Laser|"Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen.~After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure."
75902832|NCT06202638|Device|HemoSphere monitor with Acumen Hypotension Prediction Index Software|Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
75902833|NCT06201923|Drug|Honey Mouthwash|0.2% thyme honey mouth rinse
75902834|NCT06201923|Drug|Normal saline|0.9% sodium chloride
75902835|NCT06201871|Drug|Lidocaine Hydrochloride|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
76068198|NCT04110340|Drug|Ciprofloxacin|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
75608965|NCT02772055|Other|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
75608966|NCT02772133|Procedure|Primary PCI|
76072349|NCT01172418|Drug|Alemtuzumab|Alemtuzumab used as part of combined Induction.
76072350|NCT01172418|Drug|Daclizumab|Daclizumab used as part of combined induction.
75608967|NCT02772211|Drug|Ketamine|"Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals."
75608968|NCT02772211|Drug|D-cycloserine|"Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:~Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~Week 7: Day 43-49 - 750mg/d, three pills per day~Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
75755761|NCT00335829|Procedure|hepatic artery infusion|
75608969|NCT02772211|Drug|Placebo|"Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:~Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~Week 7: Day 43-49 - 750mg/d, three pills per day~Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
75608970|NCT02767687|Other|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
75755762|NCT02533011|Other|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
75755763|NCT01057641|Procedure|Spacer|Implantation of a percutaneously implanted interspinous device (spacer)
75755764|NCT01057641|Other|physiotherapy|physiotherapy
75755765|NCT05262257|Drug|Metformin|Take it regularly for 12 weeks
75755766|NCT05262257|Drug|Dapagliflozin|Take it regularly for 12 weeks
75755767|NCT05262257|Behavioral|Lifestyle intervention|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
75755768|NCT03989817|Drug|Vasoactive Intestinal Peptide (VIP) and Saline|12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
75902836|NCT06201845|Other|Exercise awareness training|Group exercise training will consist of aerobic exercises including warm-up and cool-down exercises accompanied by music, and trunk strengthening training consisting of core exercises.
76072351|NCT01172418|Drug|Thymoglobulin|Thymoglobulin used as part of combined induction.
75457286|NCT01783249|Other|Stationary Exercise cycling|Stationary exercise cycling
75457287|NCT01783262|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
75457288|NCT01783262|Device|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
75457289|NCT01783275|Behavioral|Aerobic exercise|12 weeks of aerobic exercise with weight maintenance
75457290|NCT01783301|Drug|FSH|
75457291|NCT01783314|Procedure|MRI of liver|MRI of liver with intravenous gadoxetate disodium
75755769|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H ; Per Os ; 3 times/day 6 days
75755770|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
75755771|NCT03986385|Drug|Apatinib Capecitabine Oxaliplatin|apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
76068199|NCT04110340|Drug|Streptomycin|"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
75902837|NCT06201845|Other|physical activity awareness training|In the physical activity awareness training, the benefits of exercises on systemic, psychological effects and general body health will be explained and they will be informed about different exercise practice.
75902838|NCT06201546|Procedure|TAP block group|TAP block will be administrated after LSG. In TAP block local anesthetic(%0,25 bupivacaine-20ml)will be administrated the between the transversus abdominis muscle and the internal abdominal muscle fascia.
75902839|NCT06201546|Procedure|m-TAPA block group|m-TAPA block will be administrated after LSG. In m-TAPA block local anesthetic (0.25% bupivacaine-20ml) will be administrated between the transversus abdominis muscle and the internal abdominal muscle fascia under the costochondrial region
75608972|NCT02767297|Drug|FDL169|
76068200|NCT04110340|Drug|Gentamicin|"Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."
76068201|NCT00270790|Drug|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
76068202|NCT00270790|Drug|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
76068203|NCT00270790|Drug|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
76068204|NCT00270790|Device|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
76068205|NCT00271570|Drug|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
76068206|NCT00271570|Biological|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
75608973|NCT02772289|Biological|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
75608974|NCT02772289|Biological|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
75608975|NCT02772289|Biological|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
75755772|NCT03986385|Drug|Capecitabine Oxaliplatin|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
75755773|NCT01054287|Other|Multifactorial falls prevention program|
75755774|NCT01054287|Other|No falls prevention intervention|
75902840|NCT06201507|Drug|Brentuximab vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
76068207|NCT00273364|Procedure|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
76068208|NCT00273364|Drug|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
76068209|NCT05237596|Drug|Glucosamine Sulfate|Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
76068210|NCT02102932|Drug|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
76068211|NCT02102932|Drug|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
75755775|NCT03985137|Other|mucocutaneous sampling by swab at the balano-preputial furrow.|the sample is made by the patient
75755776|NCT01057719|Other|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
75755777|NCT00344019|Drug|Placebo Oral Tablet|placebo pre-PCI for ACS
75755778|NCT00344019|Drug|Atorvastatin 80mg|atorvastatin 80 mg pre-angio/PCI
75755779|NCT00344019|Other|Screening|Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
75755780|NCT03985059|Other|Transcranial Doppler|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet."
75755781|NCT01059591|Drug|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
75755782|NCT01059591|Drug|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
75755783|NCT01059591|Radiation|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
75755784|NCT00535847|Drug|Telaprevir|Tablet
75755785|NCT00535847|Drug|Ribavirin|Tablet
75755786|NCT00535847|Drug|Pegylated interferon alfa 2a|Solution for Injection
75755787|NCT03986151|Procedure|Coronary angiography +/- percutaneous coronary intervention|Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
75755788|NCT01059669|Other|diagnostic test|
75755789|NCT03606785|Drug|Tranexamic Acid Injection|The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision
75902841|NCT06201507|Drug|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
75902842|NCT06201507|Drug|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
75902843|NCT06201507|Drug|Vincristine|1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
75457292|NCT01783327|Behavioral|Teens-Connect|Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
75608976|NCT04225195|Drug|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period."
75755790|NCT03606785|Drug|placebo injection|patients will receive a placebo of 100 mL 0.9% normal saline
75755791|NCT03587753|Other|Dietary fatty acid partitioning|There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
75755792|NCT03441971|Device|GORE PV1|Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).
75755793|NCT00334893|Drug|eribulin mesylate|Given IV
75755794|NCT05356169|Drug|with or without venetoclax|Bcl-2 inhibitor
75902844|NCT06201507|Drug|Dacarbazine|375 mg/m2 will be administered on days 1 and 15
75902845|NCT06201377|Other|Periodontal Access Surgery+ Suture with chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture coated with chlorhexidine (Novosyn Chlorhexidine). Standardized post-surgical recommendations will be followed.
75902846|NCT06201377|Other|Periodontal Access Surgery+ Suture without chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture (Novosyn). Standardized post-surgical recommendations will be followed.
76068212|NCT02102932|Drug|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
76068213|NCT02102932|Drug|850 mg metformin|850mg metformin tablet
76068214|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
76068215|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
75755795|NCT01057797|Behavioral|Exercise-specific self-efficacy|Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
75755796|NCT01057797|Behavioral|Gentle chair exercise|Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
75755797|NCT01057797|Behavioral|upper body strength training|16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
75755798|NCT01059747|Other|no intervention applied|no intervention applied
75755799|NCT01057875|Other|caffeine|Starbuck's Grande Pike Roast coffee
75755800|NCT01057875|Other|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
75608977|NCT02771821|Other|Operative groups based on methodology of problematization|"The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.~Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months."
75755801|NCT05293691|Behavioral|Body, Breath & Mind|"The program Body, Breath & Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich & Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
75902847|NCT06201364|Procedure|The external oblique intercostal block|chest wall will be systematically scanned. Initially the probe will be placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle will be identified at the level ribs 6 and 7 in line with the xiphoid process to confirm correct identification of the external oblique muscle, the probe will be moved in the caudad direction following the external oblique muscle. At the subcostal level, the ultrasound probe will be rotated 90° to see the convergence with the internal oblique and transversus abdominus muscles. The probe will be then moved back to the initial identification point for the external oblique muscle. The EOI plane will be identified deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles. Local anesthetic agent will be 20 ml volume (10 ml bupivacaine, 10 ml saline) will be injected under ultrasound guidance and this will be done bilaterally.
75608978|NCT02771899|Device|spineEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
76068216|NCT02102932|Drug|850 mg metformin|850 mg metformin
76068217|NCT02102932|Drug|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
76068218|NCT02102932|Drug|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
76068219|NCT02102932|Drug|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
76068220|NCT02102932|Drug|500 mg metformin|500 mg metformin
76068221|NCT02102932|Drug|500 mg metformin|500 mg metformin
75608979|NCT02771899|Device|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
75608980|NCT04227223|Diagnostic Test|biochemical measurements|TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
76068222|NCT00273754|Drug|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
76068223|NCT00273754|Drug|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
76068224|NCT04751344|Drug|Liposomal bupivacaine|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
76068225|NCT04751344|Drug|Bupivacaine HCl|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
76068226|NCT05211232|Drug|Tislelizumab|GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
76068227|NCT05211232|Drug|Placebo|GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
76068228|NCT00273910|Drug|gp100:209-217 (210M)|
76068229|NCT00273910|Drug|Montanide ISA-51|
76068230|NCT00273910|Drug|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
75608981|NCT02771509|Drug|ANG-3777|6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
75608982|NCT02771509|Drug|Placebo|Normal saline
75608983|NCT02697019|Behavioral|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
75755802|NCT05293691|Behavioral|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored. The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
75755803|NCT04001387|Procedure|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the lateral position with the hip and knees flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance using dynamic needle tip positioning to administer the spinal anesthetic.
75755804|NCT00334737|Drug|Darbepoetin Alfa Injection|darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
75755805|NCT00334737|Drug|erythropoietin alfa injection|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
75755806|NCT00334737|Drug|sham injection|sham injection other names: not applicable
75902848|NCT06201364|Procedure|Paravertebral block|involve injection of local anaesthetic in a space immediately lateral to where the spinal nerves emerge from the intervertebral foramina. This technique is being used increasingly for not only intra-operative and post-operative analgesia but also as a sole anaesthetic technique for carrying out various procedures.
75457293|NCT01783327|Behavioral|Planet D|Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
75457294|NCT01783340|Drug|Azithromycin capsules|Azithromycin capsules will be administered at each immunization
75457295|NCT01783340|Drug|Placebo|Placebo capsules will be administered at each immunization
75457296|NCT01783340|Biological|Immunization with falciparum|three inoculations with 5 infected mosquito bites
75457297|NCT01783353|Dietary Supplement|Zinc gluconate|
75457298|NCT01783353|Dietary Supplement|Corn starch pill|
75608984|NCT02696941|Drug|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
75608985|NCT02696941|Drug|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
75608986|NCT02771665|Other|Mammographic breast density at diagnosis|Mammographic breast density at diagnosis
75755807|NCT05347823|Diagnostic Test|Hair analysis for drug concentration|Sample collection for the determination of treatment adherence
75755808|NCT01564433|Procedure|Device: Electromechanical gait trainer|The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
75755809|NCT01564433|Procedure|Convetional control treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
75755810|NCT03986073|Drug|TQ-F3083 capsule 10 mg|Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.
75457299|NCT01783366|Device|TUBE EXCHANGER|
75457300|NCT01783379|Drug|micafungin|100mg/day infusion in 1 hour
75457301|NCT01783392|Procedure|Transcutaneous Electrical Nerve Stimulation|
75457302|NCT01783431|Drug|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
75608987|NCT02767375|Drug|Oxaliplatin(OXA), 5-fluorouracil (5-FU)|for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 & 2 , IA，q4-6 Weeks
75608988|NCT02767375|Procedure|Hepatic arterial catheter implantation|for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
75902849|NCT06201260|Other|intermittent pneumatic compression protocol|A 30 min IPC protocol at about 200mmHg
75902850|NCT06201260|Other|Placebo treatment|The electrodes of an electrostimulation device (SP 4.0, Compex, Guildford, United Kingdom) will be positioned on participants' quadriceps. Participants will be informed that they are engaging an innovative microcurrent treatment. This procedure will last for 30 min.
75902851|NCT06201169|Procedure|implant placement|All patients received four implants in the lower arch
75755811|NCT03986073|Drug|TQ-F3083 capsule 20 mg|Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
75755812|NCT03986073|Drug|TQ-F3083 blank analog capsule|Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
75755813|NCT03986073|Drug|TQ-F3083 blank analog capsule|Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
75755814|NCT03986073|Drug|Linagliptin blank analog tablet|Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
75755815|NCT03986073|Drug|Linagliptin tablet|Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
75755816|NCT05279729|Other|Mobile health application|Intervention will be with two different mobile health (mHealth) applications, Weight Watchers and Healthi app (formerly iTrackBites)
75755817|NCT03989193|Device|Computer guided alveolar ridge splitting technique|"The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm."
75755818|NCT01060137|Drug|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
75902852|NCT06201117|Behavioral|Preparatory information for ICU stay|Preparatory information for ICU stay after cardiac surgery via 12-minute digital media
75457303|NCT01783431|Procedure|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
75457304|NCT01783457|Other|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
75457305|NCT01783457|Other|Individual psychoeducation|"Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request."
75457306|NCT01783587|Drug|Afatinib|Taken orally once per day
75457307|NCT01783587|Drug|Docetaxel|15 mg/m2, given intravenously once per week
75457308|NCT01783587|Radiation|Radiation Therapy|Daily, Monday-Friday, for six to seven weeks
75755819|NCT04001153|Other|Dental impressions|"Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state."
75755820|NCT01057953|Genetic|Blood drawn|Blood drawn for patient
75755821|NCT01058031|Behavioral|MBSR|Mindfulness Based Stress Reduction
75755822|NCT03090347|Other|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
75755823|NCT00991991|Genetic|gene expression analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
75755824|NCT00991991|Genetic|polymerase chain reaction|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
75755825|NCT00991991|Genetic|polymorphism analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
75902853|NCT06201117|Behavioral|Usual information|Preoperative information that is given to patients before having cardiac surgery
75457309|NCT01783600|Device|NanoCross .014 balloon catheter|
75457310|NCT01783613|Dietary Supplement|Docosahexaenoic acid administration: 50 mg/kg/day during 12 months|
75457311|NCT01783613|Dietary Supplement|Placebo: 50 mg/kg/day during 12 months|
75457312|NCT01783626|Device|Evodial|
75457313|NCT01783626|Device|Evodial+ Condition B1|
75457314|NCT01783626|Device|Evodial+ Condition B2|
75457315|NCT01783626|Device|Evodial+ Condition C|
75457316|NCT01783665|Other|aerobic exercise|
75902854|NCT06201026|Other|Traditional exercise|Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home
75755826|NCT00991991|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
75902855|NCT06201026|Other|Individualized exercise|Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.
75457317|NCT01783665|Other|home exercise program|
75902856|NCT06200948|Other|Aerobic Exercise|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
76068231|NCT04389034|Drug|Pollinex Quattro with tree- and grass pollen extracts and their mixtures|retrospective analysis of patient records of allergen-specific immunotherapy
76068232|NCT00274768|Drug|capecitabine|A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
75457318|NCT01783691|Drug|NKTT120|
75457319|NCT01783717|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
75457320|NCT01783756|Drug|lapatinib ditosylate|Given PO
75608989|NCT02767453|Procedure|Wound drainage|Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
75755827|NCT00991991|Other|medical chart review|Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.
75755828|NCT01058109|Other|calcium-rich diet|dietary calcium intake of 1500 mg/d
75755829|NCT01058109|Other|Calcium rich diet|dietary intake of 1500 mg/d from food
76068233|NCT00280384|Drug|E2014 (Botulinum toxin type B)|A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
76068234|NCT00280384|Drug|E2014 (Botulinum toxin type B) Placebo|A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
76068235|NCT01763996|Drug|Febuxostat|Febuxostat capsules
75608990|NCT02767453|Procedure|Total Shoulder Arthroplasty|"Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA."
75755830|NCT03989583|Other|Infrared thermography|Temperature observation in foot and footwear in healthy children
75755831|NCT00427908|Biological|GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)|One intramuscular dose.
75755832|NCT00427908|Biological|Mencevax™ ACWY|One subcutaneous dose.
76068236|NCT01763996|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
76068237|NCT01790464|Drug|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
76068238|NCT01790464|Drug|placebo|
75457321|NCT01783756|Drug|everolimus|Given PO
75457322|NCT01783756|Drug|capecitabine|Given PO
75457323|NCT01783756|Other|laboratory biomarker analysis|Correlative studies
75457324|NCT01783769|Behavioral|"Low O.R. Traffic"|"Low OR Traffic protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
75457325|NCT01783782|Behavioral|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
75457326|NCT01783782|Drug|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
75457327|NCT01783782|Drug|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
75457328|NCT01783795|Other|Genetic Analysis|
75457329|NCT01783834|Drug|Gefitinib|compare progression free survivla rate and safety to both drugs
75755833|NCT00427908|Biological|Meningitec™|One intramuscular dose.
75755834|NCT00992069|Drug|Efavirenz (EFV)|Oral dose of 600 mg daily, taken in the evening
75755835|NCT00992069|Drug|TMC207|Single oral dose of 400 mg in the morning
75755836|NCT01060215|Procedure|Normal saline|20 cc normal saline injection into the knee joint
75755837|NCT01060293|Drug|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
75755838|NCT01060293|Drug|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
75755839|NCT01060293|Drug|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
75902857|NCT06200948|Other|Complete Decongestive Treatment|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
75902858|NCT06200831|Procedure|Staged resection|Patients randomized to staged resection will be operated according to the decision made by the tumor board meeting (liver or colorectal cancer first, based on tumor burden and symptoms), but both resections have to be done within a time period of 4-12 weeks.
75902859|NCT06200831|Procedure|Simultaneous resection|In cases with simultaneous surgery, the liver resection is performed prior to colon resection in order to keep a low central venous pressure during the first part of the surgical procedure and to avoid congestion of the anastomosis line owing to possible Pringle manoeuvre.
75457330|NCT01783834|Drug|Pemetrexed|compare PFS rate, safety to both drugs
75608991|NCT02767141|Behavioral|Coping Strategies|Coping strategies for households in the US with food insecurity
75457331|NCT01783873|Other|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
75608992|NCT02767219|Drug|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
75608993|NCT02767219|Drug|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
75608994|NCT02767219|Drug|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
75608995|NCT02766829|Procedure|Cross leg sitting position|Subjects were set on cross leg sitting position before spinal anesthesia begun.
75755840|NCT03988959|Procedure|resection of mucoeidermoid carcinoma|Surgical resection parotid with preservation of facial nerve
75608996|NCT02766829|Procedure|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
75755841|NCT05343767|Dietary Supplement|Natural Wellness Low-Glu low dose|The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
75755842|NCT05343767|Dietary Supplement|Natural Wellness Low-Glu high dose|The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
75755843|NCT05343767|Other|Metformin|A total dose of 2000 mg was administered per day.
75902860|NCT06200727|Procedure|PRF membrane tamponade surgery in macular hole|A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.
75902861|NCT06200727|Procedure|ILM peeling in macular hole|The treatment of the macular hole was ILM peeling.
75902862|NCT06200727|Procedure|PRF membrane grafting in pterygium|Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.
75902863|NCT06200727|Procedure|Autologous conjunctival transplantation in pterygium|Used of autologous conjunctiva to cover exposed sclera after pterygium excision
75902864|NCT06200727|Procedure|autologous PRF membrane grafting in trabeculectomy for glaucoma|Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.
75902865|NCT06200727|Procedure|Amniotic membrane in trabeculectomy for glaucoma|Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.
75902866|NCT06200727|Procedure|PRF membrane grafting incorneal ulcer|After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing
75902867|NCT06200727|Procedure|Amniotic membrane in corneal ulcer|After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing
75902868|NCT06200233|Drug|Rivoceranib|700mg once daily
75902869|NCT06200064|Other|Self-stretching exercise group|Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
75902870|NCT06200064|Other|Post-isometric relaxation exercise group|"The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity."
75902871|NCT06199817|Behavioral|occupational therapies|music, garden-soil and sports practices for individuals diagnosed with schizophrenic disorder
75902872|NCT06199245|Other|emotional freedom technique experimental group|Participants in the experimental group, who had a cesarean delivery on the first postpartum day, filled out the sociodemographic and obstetric information form and the Breastfeeding Self-Efficacy Scale, and then were asked to breastfeed their babies and their breastfeeding was evaluated with the Bristol Breastfeeding Evaluation Scale. The participant was then asked to score her breastfeeding between 0 and 10 to evaluate her Subjective Units of Disturbance Scala (SUD) score. The next evaluation was made 2 hours after the participant received breastfeeding training, the Bristol Breastfeeding Rating Scale score was obtained, and the SUD was scored again after 2 rounds of Emotional Freedom Techniques (EFT) application. Finally, at the end of the day, 2 rounds of EFT application were performed by taking the SUD score before the EFT session, and after the application, the participant's Breastfeeding Self-Efficacy Scale, Bristol Breastfeeding Evaluation Scale and SUD scores were recorded.
76068239|NCT01790542|Other|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
76068240|NCT01790542|Other|Iron fortified cereal with fruit|
76068241|NCT01790542|Other|Meat|
76068242|NCT01899820|Drug|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
76068243|NCT01899820|Drug|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
76068244|NCT02099266|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
76068245|NCT04511338|Device|Dialyzer with Endexo|"Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)"
76068246|NCT04480528|Other|Blood Flow Restriction Training (BFRT)|A pressurized cuff is applied to the proximal thigh in order to partially occlude blood flow as the patient exercises.
76068247|NCT04480528|Other|Sham Blood Flow Restriction Training (Sham BFRT)|A minimally pressurized cuff is applied to the proximal thigh in order to mimic the active blood flow restriction unit as the patient exercises.
75608997|NCT04711993|Other|Aerobic exercise|"Patients will do aerobic exercise three days a week for 40 minutes during 8 weeks. Aerobic exercise protocol will consist of warm up, loading and cooling periods. . Exercise prescription will be prepared in line with the recommendations of The American College of Sports Medicine."
75608998|NCT04711993|Other|Stretchin exercise|Patients will do stretching exercise three days a week for 40 minutes during 8 weeks. Stretching exercises will start with active warm-up activities. Static stretching method will be used.
76068248|NCT02100748|Drug|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
76068249|NCT02100748|Drug|Morphine|Morphine 4 mg will be administered every 4 hours
76068250|NCT02100748|Drug|Placebo|Placebo will be administered every 4 hours
75608999|NCT02771587|Dietary Supplement|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
75609000|NCT02771587|Dietary Supplement|Alcohol|Multiple oral dose of alcohol
75609001|NCT02771587|Dietary Supplement|Energy drink|Multiple oral dose of energy drink
75609002|NCT02771587|Dietary Supplement|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
75755844|NCT01054521|Procedure|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
75755845|NCT01054521|Device|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
75609003|NCT04742725|Drug|Placebo|Placebo
75609004|NCT04742725|Drug|Prothione™ (6g)|Prothione is a pro-Glutathione compound includes free-form amino acids
75755846|NCT00334113|Behavioral|TLC-PED|Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
75755847|NCT00992147|Drug|Adipocell|autologous cultured adipocytes (ANTG-adip)
75902873|NCT06199089|Drug|CM313 Injection|"Intravenous CM313 administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to experimental group were treated with CD38 monoclonal antibody (CM313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
75902874|NCT06199089|Drug|Placebo Injection|"Intravenous Placebo administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to placebo comparator group were treated with placebo of CM313 once a week for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of placebo of CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after placebo administration."
75902875|NCT06198920|Procedure|Stenting of the superficial femoral artery|Submitted to stenting of the superficial femoral artery for stenosis or occlusion causing intermittent claudication or critical limb ischemia
75902876|NCT06198868|Procedure|Operable|Enrolled patients capable of surgical treatment
76068251|NCT00283504|Drug|ANTI-IGE THERAPY (XOLAIR)|Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
75902878|NCT06198660|Other|positional release technique|positional release techniques in addition to conventional therapy two sessions per week for 6 weeks
75902879|NCT06198660|Other|cognitive behavioral therapy|cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks
75902880|NCT06198660|Other|conventional therapy only|conventional therapy two sessions for 6 weeks
75609005|NCT02778451|Other|Measurement of competence|This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
75609006|NCT02771743|Drug|Cisplatin|
75609007|NCT02771743|Drug|Doxorubicin|
75609008|NCT02771743|Drug|Etoposide|
75609009|NCT02771743|Drug|Cyclophosphamide|
75609010|NCT02771743|Drug|Ifosfamide|
75609011|NCT02771743|Drug|Carboplatin|
75609012|NCT02771743|Procedure|Tandem HDCT/auto-SCT|
75609013|NCT02771743|Radiation|Radiotherapy|
75609014|NCT02771743|Drug|Interleukin-2|
75609015|NCT02771743|Drug|Isotretinoin|
75755848|NCT01060449|Other|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output"
76068252|NCT04407676|Other|Summary PIS and Online Video Modules|Complex trial information presented in alternative and more accessible formats
75609016|NCT02771743|Radiation|MIBG|
75609017|NCT02762851|Other|Sterile saline|0.5 ml dose injected intramuscularly
75609018|NCT02762851|Drug|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
75609019|NCT02771431|Other|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
75902881|NCT06197035|Procedure|Coping With and Caring for Infants With Special Needs|The early intervention programme for infants and young children focuses on the active inclusion of the whole family. The coaching of parents is a central component. Parents learn how they can independently and optimally support their child's development as part of the child's everyday life. The programme was developed at the beginning of the 2000s in the Netherlands by child physiotherapist Tineke Dirks and professor of developmental neurology Mijna Hadders-Algra.
75902882|NCT06197035|Procedure|Standard Physiotherapy|Pediatric physiotherapy techniques aimed at improving the development of the baby and young child from manual therapy tools, or baby management.
75902883|NCT06196723|Procedure|transjugular intrahepatic portal shunt|TIPS was performed by experienced clinicians in the Gastroenterology/Hepatology Department according to standard operating procedures, utilizing 8 mm or 10 mm expanded polytetrafluoroethylene-covered stents at the discretion of the local physician.
75902884|NCT06196385|Device|intensive Cervical Traction|A 30-minute cervical traction protocol, twice a day, for five consecutive days per week for 6 weeks. The main objective will be the evaluation of depression, insomnia, and quality of life. We evaluate at prior to the treatment and, at the end of the protocol, for depression, insomnia, and quality of life.
75902885|NCT06196359|Procedure|Combined Femoral and Popliteal nerve block|Patients who receive a combined femoral and popliteal nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
76068253|NCT04370236|Drug|INB03|Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
75902886|NCT06195995|Device|Transcranial alternating current stimulation-true stimulus|Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
75902887|NCT06195813|Dietary Supplement|Asparagus capsule|Asparagus capsule is categorized as dietary supplement.
75902888|NCT06195813|Other|Placebo capsule|Placebo capsule is categorized as other.
75902889|NCT06194981|Drug|Oxaliplatin and capecitabine/ S-1 and capecitabine|Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
75902890|NCT06194838|Device|Ossur Power Knee|Newest version of the commercially-available powered knee developed by Ossur.
75902891|NCT06194838|Device|Reboocon Intuy Knee|Commercially-available powered knee developed by Reboocon.
75902892|NCT06194045|Dietary Supplement|LC-MUFA oil|2 x 1 g capsules containing marine oil from North Atlantic fish
76068254|NCT04370236|Drug|Placebo|Patients will receive up to two once per week subcutaneous injections of Placebo
76068255|NCT00283816|Drug|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
75457332|NCT01783899|Device|Hemospray|"Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.~once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.~Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.~Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.~Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.~Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care"
75457333|NCT01783951|Biological|DC-CIK|Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
75902893|NCT06194045|Dietary Supplement|Placebo|2 x 1 g capsules containing corn oil
76068256|NCT00283816|Drug|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
76068257|NCT00283816|Behavioral|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise & behavior modification skills on a regular weekly basis over the 24 week study
76068258|NCT00283816|Behavioral|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
76068259|NCT00283816|Procedure|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
75902897|NCT06193317|Device|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
75902898|NCT06191965|Drug|MitoQ|"MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~CAS number: 444890-41-9 (phosphonium cation)~Molecular weight: 678.81~MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS986annex2.pdf?ua=1).~MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ."
76068260|NCT00283816|Procedure|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
76068261|NCT00283816|Procedure|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
75457334|NCT01783951|Drug|S-1|The dose of S-1 is determined according to the body surface area as follows: <1.25 m2, 40 mg; 1.25 to <1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
75457335|NCT01783951|Drug|Cisplatin|Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
75609020|NCT02770963|Procedure|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes."
76068262|NCT00283816|Procedure|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
76068263|NCT00283816|Drug|placebo|placebo capsules, two capsules BID
76068264|NCT00284518|Biological|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
75457336|NCT01783964|Drug|[14C]-Elacytarabine|Single intravenous administration
76068265|NCT00284518|Drug|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
76068266|NCT04339426|Drug|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
76068267|NCT01899898|Other|Simplified Modified Atkins Diet|"Modified Atkins diet with the following modifications:~Pictorial representation of various food items and exchange lists will be provided.~Instead of weights, we will provide standardized measures~We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures~We will formulate recipes and diets based on locally available and culturally acceptable foods.~We will develop a parent instruction manual.~We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.~We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes."
75457337|NCT01783977|Biological|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
75457338|NCT01783977|Biological|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10^8 PFU/ml; administered as 1 mL IM in participant's deltoid
75457339|NCT01783977|Biological|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10^6 PFU/ml for a planned maximum dose of 1.1x10^7 PFU/ml; administered as 1 mL IM in participant's deltoid
75457340|NCT01783977|Biological|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
75457341|NCT01783977|Biological|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
75902899|NCT06191965|Drug|Placebo|Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
75902900|NCT06191588|Procedure|INFANT CIMT/BIT|Constraint induced movement therapy (CIMT) and Bimanual Intensive therapy (BIT)
75902901|NCT06191263|Drug|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
75902902|NCT06191263|Drug|Venetoclax|Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis
75902903|NCT06190665|Device|DEB-TACE with visualable microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with visualable microspheres
75902904|NCT06190665|Device|DEB-TACE with PVA microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with polyvinyl alcohol microspheres
76068268|NCT01899898|Drug|Antiepileptic drugs alone|The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
76068269|NCT00286078|Device|Precision|Implantable neurostimulator
75755849|NCT04001699|Other|Preoperative geriatric assessment|In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
75457342|NCT01783977|Biological|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
75755850|NCT01054677|Behavioral|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
75902905|NCT06190275|Biological|GT201 in combination with PD-1 inhibitors|GT201 in combination with a PD-1 inhibitor for advanced (HNSCC)
75902906|NCT06188663|Dietary Supplement|Salt supplementation (encapsulated sodium chloride)|A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
76068270|NCT04217902|Other|Description of patients' experiences of diabetes care delivery and planning|Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).
75457343|NCT01784003|Device|Powered ankle-foot prosthesis|
75457344|NCT01784016|Radiation|[11C]-PHNO|[11C]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
75902907|NCT06185764|Drug|VX-670|Solution for intravenous administration.
75902908|NCT06185764|Drug|Placebo|Solution for intravenous administration.
75902909|NCT06183788|Behavioral|Remote cognitive rehabilitation program|Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent [PCT/ES2008/00677]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
75902910|NCT06183489|Drug|Elranatamab|Elranatamab will be administered via a subcutaneous injection (SC)
75755851|NCT00416598|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplantation
75755852|NCT00416598|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplantation
75755853|NCT00416598|Drug|Busulfan|Given IV
75902911|NCT06183398|Other|Skin prick test|Specific skin prick tests for 6 raw food: peach, apple, sesame, carrot, lemon and orange
75902912|NCT06182124|Biological|Multivalent Pneumococcal Vaccine - Formulation 1|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2).
76068271|NCT04217902|Other|Description of health care professionals needs and experiences in diabetes care delivery and planning|Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
76068272|NCT00287716|Drug|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
76068273|NCT00287716|Drug|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
75609021|NCT02770963|Procedure|Sham acupuncture|"Specially designed sham needles (0.3*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients."
75609022|NCT02771041|Procedure|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
75609023|NCT04224805|Device|Bone-borne CAD/CAM splint|3D printed splint that repositions the maxilla with the zygomatic buttress as a reference.
75902913|NCT06182124|Biological|Multivalent Pneumococcal Vaccine - Formulation 2|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2).
76068274|NCT00287872|Drug|bortezomib|
76068275|NCT00287872|Drug|thalidomide|
76068276|NCT00288574|Drug|Fluoxetine|
75457345|NCT01784042|Drug|Placebo|placebo
75457346|NCT01784042|Drug|Lovaza|
75457347|NCT01784042|Other|Dietary energy restriction|
75457348|NCT01784081|Other|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
76068277|NCT00288574|Drug|Placebo|
75457349|NCT01784094|Device|StromaGlide|
75457350|NCT01784107|Drug|Belotecan and Ifosfamide|
75457351|NCT01784120|Drug|Doxorubicin/Genexol-PM|
75609024|NCT04224805|Device|3D interocclusal conventional splint|Interocclusal splint that relies on the centric relation of the condyle as well as occlusion.
75609025|NCT04710433|Device|Non-invasive Neuromodulation|Sacral nerve stimulation via two adhesive electrodes (single current).
75609026|NCT04710433|Other|Medical and Behavioral Therapy|Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
75755854|NCT00416598|Drug|Cytarabine|Given IV
75755855|NCT00416598|Drug|Daunorubicin Hydrochloride|Given IV
75755856|NCT00416598|Drug|Decitabine|Given IV
75755857|NCT00416598|Drug|Etoposide|Given IV
75755858|NCT00416598|Biological|Filgrastim|Given SC
75755859|NCT00416598|Other|Laboratory Biomarker Analysis|Correlative studies
75902914|NCT06182124|Biological|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
75609027|NCT02767063|Drug|Pioglitazone|PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.
75755860|NCT00416598|Other|Pharmacological Study|Correlative studies
75755861|NCT00534599|Drug|Placebo|oral
75755862|NCT00534599|Drug|quetiapine fumarate XR|oral
75755863|NCT04001465|Procedure|Volumetric methacholine challenge unmodified|Bronchoprovocation challenge performed per volumetric method
75902915|NCT06181773|Behavioral|EPO Feeding Program|The EPO Feeding program focused on providing parents with information based on scientific evidence and the most current nutritional recommendations regarding positive feeding practices and healthy eating during the preschool years.
75902916|NCT06181656|Biological|Pneumonia vaccine|Given by SC
76068278|NCT01791010|Other|Inspiratory muscle training|
76068279|NCT01791010|Other|Training sham|Conducting fake training with the aim of blind the control group
76068280|NCT00288886|Behavioral|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
76068281|NCT00288886|Behavioral|Control arm|Routine residential treatment and orientation to continuing care.
76068282|NCT00289120|Drug|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
76068283|NCT00289120|Drug|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
75609028|NCT02767063|Drug|Avelumab|10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
75609029|NCT02766751|Behavioral|HIVPASS|The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
75609030|NCT02766751|Behavioral|Health Education|The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
75609031|NCT02766595|Other|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
75755864|NCT04001465|Procedure|Modified volumetric methacholine challenge|Bronchoprovocation challenge performed per volumetric method modified to include use of ultrasonic spirometer fitted with vibrating mesh nebulizer
75755865|NCT00992381|Drug|PN400|500mg Naproxen and 20mg esomeprazole
75755866|NCT00992381|Drug|Naprosyn|500mg Naproxen
75755867|NCT05320913|Procedure|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 120 mg of ropivacaine, epinephrine 0.2 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 40 mL. + PENG block with ropivacaine 40 mg and epinephrine 0.1 mg with normal saline to a total volume of 20 mL
75755868|NCT05320913|Procedure|isolated periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 150 mg of ropivacaine, epinephrine 0.3 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 50 mL
75755869|NCT00992537|Drug|insulin degludec|Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
75755870|NCT00992537|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
75755871|NCT00992537|Drug|insulin aspart|Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
75755872|NCT00992615|Procedure|prostate biopsy|prostate cores - 12 or 20
75755873|NCT05317715|Other|Group A, who will complete a questionnaire before receiving information about intrauterine devices|Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.
76068284|NCT04061590|Drug|Cisplatin|Given IV
76068285|NCT04061590|Biological|Pembrolizumab|Given IV
76068286|NCT04061590|Drug|Pemetrexed|Given IV
76068287|NCT04061590|Drug|Pemetrexed Disodium|Given IV
76068288|NCT04061590|Procedure|Therapeutic Conventional Surgery|Undergo surgery
76068289|NCT01791088|Drug|sirolimus|Given PO
76068290|NCT01791088|Other|pharmacological study|Correlative studies
75902917|NCT06179992|Device|GGED mobile app|The intervention will be done through an app named GGED, which is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
75755874|NCT05317715|Other|Group B who will answer a questionnaire after having the information about the intrauterine devices|Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
75902920|NCT06174220|Drug|Tideglusib|Tideglusib 1g po daily
75902921|NCT06174220|Drug|Placebo|Matching placebo 1g po daily
75902922|NCT06173687|Device|The impedance measurement task using the Mobile Research App (MRA)|Characterisation of impedance and real-world monitoring of hearing difficulty in range of listening environments.
76068291|NCT01791088|Other|laboratory biomarker analysis|Correlative studies
76068292|NCT00289744|Biological|TWINRIX™ ADULT|2 doses IM injection in primary study
76068293|NCT00289744|Biological|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
75457352|NCT01784146|Other|Oxygen|"For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen."
75457353|NCT01784146|Other|Heliox|"For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al."
75457354|NCT01784146|Other|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
75755875|NCT00992693|Drug|Ribavirin (Virazole) Injection|"The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60."
75755876|NCT00992771|Drug|varenicline|up to 1mg BID for 8 weeks
75755877|NCT00992771|Drug|placebo|placebo matching varenicline, up to 1mg BID for 8 weeks
75755878|NCT00992849|Drug|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
75755879|NCT00993005|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.
75755880|NCT00993005|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
75755881|NCT00993083|Biological|MVA-NP+M1|Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
75755882|NCT04001231|Drug|Exenatide Once-Weekly Suspension|A single dose will be administered as 2.0-mg dose of exenatide onceweekly suspension via subcutaneous (SC) injection followed by blood samples be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Subsequently Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14).
75755883|NCT00993161|Device|Motriplate|Number of contact couples
75755884|NCT00993161|Device|Motriplate|Number of contact couples
75755885|NCT01913795|Other|integrated pest management|integrated pest management and environmental strategy
76068294|NCT00291226|Drug|Glycine|Glycine 0.4 g/kg bid
76068295|NCT00291226|Drug|Placebo|Placebo
76068296|NCT01791166|Biological|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
76068297|NCT00291694|Drug|celecoxib|Celecoxib 400 mg BID
76068298|NCT00291694|Other|placebo|placebo
76068299|NCT00292162|Procedure|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
76068300|NCT00292162|Drug|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
75755886|NCT01913795|Other|air purifier|air purifiers
75755887|NCT01913795|Other|Sham air purifier|sham air purifiers
75755888|NCT00993239|Drug|Birinapant (TL32711)|30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
75755889|NCT00993395|Behavioral|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
75755890|NCT04001543|Dietary Supplement|Immunomodulating oral supplementation|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
75755891|NCT04001543|Dietary Supplement|Sip feed control|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
75755892|NCT03892889|Combination Product|Abilify MyCite®|Combination product of aripiprazole tablet embedded with sensor and wearable patch.
75755893|NCT00995189|Device|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
75755894|NCT00995189|Device|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
75755895|NCT00995189|Device|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
75755896|NCT00993551|Procedure|primary surgery for cleft palate|Surgery completed using the Sommerlad technique
75902923|NCT06172907|Behavioral|Young Adults Coping with Cancer Together Intervention|This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.
75755897|NCT00993629|Drug|pregnenolone|"Administered adjunctively to treatment as usual"
75755898|NCT00993629|Drug|placebo|adjunctive placebo
75755899|NCT00993707|Drug|CTX-100 (formerly ETX-100) (hyaluronic acid)|"3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort."
75755900|NCT01564511|Device|Gait trainer treatment|Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
75755901|NCT01564511|Other|Conventional treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
75755902|NCT00473330|Drug|Ranibizumab|Sterile solution for intravitreal injection.
75755903|NCT00473330|Drug|Sham injection|
75755904|NCT00416520|Drug|MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
75755905|NCT00416520|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
75755906|NCT00416520|Drug|Another phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
75755907|NCT00533429|Drug|enzastaurin|1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
75755908|NCT00533429|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
75902924|NCT06166342|Dietary Supplement|Placebo sachet|Consume 1 sachet daily
75902925|NCT06166342|Dietary Supplement|TCI153 probiotic sachet|Consume 1 sachet daily
75902926|NCT06165601|Procedure|Follow-up at D14|A blood test and urinary test will be performed at D14.
75902927|NCT06165601|Procedure|Follow-up at M1|A blood test and urinary test will be performed at M1.
75902928|NCT06165354|Drug|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 20 mL-bottle.
75755909|NCT00533429|Drug|carboplatin|Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
75755910|NCT00533429|Drug|bevacizumab|15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
75457355|NCT01784172|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
75755911|NCT00533429|Drug|Placebo|oral, daily
75755912|NCT01034124|Drug|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
75755913|NCT01034202|Drug|NNC126-0083|One of five dose levels administered subcutaneously (under the skin)
75755914|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
75755915|NCT01034202|Drug|placebo|Placebo comparator
75755916|NCT01034202|Drug|NNC126-0083|One of three dose levels administered subcutaneously (under the skin)
75755917|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
75755918|NCT00533273|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
75755919|NCT03891641|Behavioral|Treadwell Tredlr|Complete treadling exercise 3x per week (15 min sessions) for 6 weeks.
75755920|NCT00995267|Behavioral|parent-child interaction/activities based on Adler's methods|"Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories & pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations."
75755921|NCT00339183|Drug|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
75755922|NCT00339183|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m^2, leucovorin 400 mg/m^2 racemate (or 200 mg/m^2 I-leucovorin), 5-FU bolus 400 mg/m^2, 5-FU infusion 2400 mg/m^2.
75755923|NCT02533245|Other|Home-based indiviualized exercise training program|Based on these results of the cardiopulmonary exercise test (CPET) on a cycle ergometer, an individualized training program (cycling/hiking) is prescribed by a physical therapist for 6 months (3x/week, ≥30min/session).
75755924|NCT02533245|Other|Supervised group training sessions|7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist
75755925|NCT02533245|Other|Climb of the Mont Ventoux|Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)
75755926|NCT01058343|Biological|IFN-K|3 to 4 IM injections over 3 months
75755927|NCT01054833|Procedure|Needleless mid-urethral sling|The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
76068301|NCT00292162|Drug|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
76068302|NCT00292162|Drug|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
76068303|NCT00296296|Drug|Cyclosporin|Dose adjustment to pre-established targets
76068304|NCT00296296|Drug|Tacrolimus|Dose adjustment to pre-established targets
76068305|NCT00296296|Behavioral|'Diabetes Education / Management'|therapeutic adjustment to target ADA criteria
76072352|NCT01163968|Behavioral|MOMENTUM|The Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM) intervention is comprised of 6 modules, totaling 52 daily sessions promoting weight reduction, and 4 coaching sessions over the duration of the 12 week MOMENTUM intervention. The MOMENTUM intervention will be delivered using telehealth methods (Viterion telehealth device will be used to deliver the module content and coaching sessions). The intervention was purposively designed to overcome access barriers by using delivery modes accessible to patients in rural settings, in their home and at times convenient to their schedule.
75609032|NCT04224103|Drug|Inhaled nitric oxide|"Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation."
75609033|NCT02766439|Drug|etanercept|25-mg etanercept injection subcutaneously twice a week
75609034|NCT04651075|Other|music listening|The music selected by the participants was played to the music listening group.
75609035|NCT04651075|Other|individual training|Individual training group was trained on coronary angiography.
75755928|NCT01325025|Other|High-field MRI (3 Teslas)|"anatomical location~conventional anatomical sequence T1, T2, FLAIR~diffusion tensor sequence (21 directions)~high angular resolution diffusion (HARDI) sequence~field map~reflexology T1, T2~spectroscopic imaging sequence"
75755929|NCT01325025|Other|High-field MRI (3 Teslas)|"anatomical location~conventional anatomical sequence T1, T2, FLAIR~diffusion tensor sequence (21 directions)~high angular resolution diffusion (HARDI) sequence~field map~reflexology T1, T2~spectroscopic imaging sequence"
75755930|NCT01060605|Drug|rapamycin|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
75755931|NCT00333801|Behavioral|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
75755932|NCT00333801|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
75755933|NCT00532883|Drug|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
75755934|NCT00532883|Drug|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
75755935|NCT00532883|Other|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
75755936|NCT00993785|Device|Costar Coronary Stent Delivery System|
75609036|NCT04223869|Other|non-surgical periodontal treatment|scaling and root planing were performed
75609037|NCT02766361|Behavioral|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
75609038|NCT02766361|Other|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
75609039|NCT02766127|Other|Veritise Flow|Self-adhering composite
75609040|NCT02766127|Other|Universal Dentin Sealant|non-polymerizable, high molecular weight resin sealant
75609041|NCT02766127|Other|Clearfil Protect Bond|methacrylate-based resin, self-etching adhesive system
75755937|NCT00993863|Drug|Placebo|single dose
75755938|NCT00993863|Drug|ADL5859 30 mg|single dose
75755939|NCT00993863|Drug|ADL5859 100 mg|single dose
75755940|NCT00993863|Drug|ADL5859 200 mg|single dose
75755941|NCT00993863|Drug|ibuprofen 400 mg|single dose
75609042|NCT02766127|Other|Flor-Opal® Varnish|fluoride-based varnish
75609043|NCT02766049|Biological|DC|Autologous dendritic cells (3x10e7)
75609044|NCT02766049|Biological|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
75609045|NCT02766049|Biological|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
75755942|NCT00995423|Device|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
75755943|NCT00995423|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent
75755944|NCT00993941|Procedure|Autologous BMSCs transplantation|10 ml autologous BMSCs(7~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
75755945|NCT00993941|Drug|Conserved therapy|Oral or intravenous administration
75755946|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
75609046|NCT02765971|Other|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
75609047|NCT02765971|Drug|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
75609048|NCT02765971|Drug|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
75755947|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
75755948|NCT00994097|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
75755949|NCT00994097|Drug|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
75755950|NCT00994097|Drug|Gemcitabine|Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
75457356|NCT01784172|Device|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
75457357|NCT01784185|Procedure|virtual bronchoscopy guided transbronchial needle aspiration|
75902929|NCT06165354|Combination Product|LiveSpo X-secret|"In Vietnam, LiveSpo X-SECRET is manufactured as two product lines: (1) Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam and ISO 13485:2016 (Certificate No YT117-19) and (2) comestic (Product declaration No.14981/22/CBMP-HA) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam (Certificate No 118/CNĐĐKSXMP. Both product lines have the same probiotic composition.~The cosmetic type was used for the clinical trial conducted at Hanoi OGH. The Class-A medical device type was used for the clinical trial conducted at Bac Ninh CDC."
75609049|NCT02765815|Drug|Liposomal bupivacaine, 266mg|
75457358|NCT01784185|Procedure|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
75457359|NCT01784198|Dietary Supplement|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
75609050|NCT02765815|Drug|Bupivacaine 0.5 % with Epinephrine|
75609051|NCT02765815|Drug|Ketorolac 30mg|
75609052|NCT02765815|Drug|Morphine 10mg|
75609053|NCT02765815|Drug|Bupivacaine 0.25% with Epinephrine|
75609054|NCT02765893|Other|No Foley|Patients will have Foley catheter removed 6 hours post-op.
75609055|NCT02765581|Device|Verum acupuncture|"The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
75609056|NCT02765581|Device|Sham acupuncture|"We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun."
75609057|NCT02765581|Behavioral|Usual care|Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
75609058|NCT02765347|Drug|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
75609059|NCT02765347|Drug|Insulin|For arm 2, just accept insulin for 24 weeks
75755951|NCT00994097|Drug|Pemetrexed|Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
75755952|NCT00995735|Procedure|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
75755953|NCT00995735|Procedure|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
75755954|NCT04000919|Drug|5HTP|5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
75755955|NCT04000919|Drug|L-DOPA|L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)
75755956|NCT04000919|Drug|Placebo oral tablet|Placebo
75755957|NCT04000919|Drug|Carbidopa|Carbidopa (50mg)
75755958|NCT05223881|Device|13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)|After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
75609060|NCT02765425|Device|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
75609061|NCT04223713|Procedure|TriRec|Trileaflet Reconstruction of the Aortic Valve
75755959|NCT05222789|Procedure|TAP|The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
75755960|NCT00995813|Biological|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
75755961|NCT00994253|Drug|Aliskiren|Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.
75902930|NCT06162377|Drug|Methylnaltrexone|Given by SC (injection)
75902931|NCT06162091|Other|Data collection|"The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~Cognitive functioning (Levels of Cognitive Functioning, LCF);~disability (Disability Rating Scale, DRS);~level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months."
75457360|NCT01784224|Procedure|Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves|
75609062|NCT04223713|Procedure|Aortic valve replacement|Biological Prosthesis, Device: Edwards Perimount
75457361|NCT01784237|Procedure|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
75609063|NCT02764957|Dietary Supplement|green coffee extract|
75609064|NCT02764957|Dietary Supplement|placebo|
75609065|NCT02765113|Procedure|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
75609066|NCT02765113|Procedure|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
75609067|NCT04686175|Drug|INZ-701|INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
75609068|NCT02764879|Dietary Supplement|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
75609069|NCT02764879|Procedure|scaling and root planing|
75755962|NCT00994253|Drug|Hydrochlorothiazide|Hydrochlorothiazide will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
75755963|NCT00994331|Procedure|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
75755964|NCT00995969|Drug|placebo|1.0 g (w/w) placebo cream applied to both target lesions twice daily
75902932|NCT06159335|Radiation|F-Fluciclovine radiotracer|Participants will receive PET radiotracer and MRI
75609070|NCT02764879|Other|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
75755965|NCT00995969|Drug|CT 327|1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
75755966|NCT00994487|Other|High Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
75755967|NCT00994487|Other|Low Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
75755968|NCT00996047|Genetic|cytogenetic analysis|
75755969|NCT00996047|Genetic|fluorescence in situ hybridization|
75755970|NCT00996359|Biological|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
75755971|NCT00996359|Radiation|total-body irradiation|100 cGy TBI
75755972|NCT00994565|Behavioral|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
75755973|NCT00354159|Device|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
75457362|NCT01784237|Procedure|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
75457363|NCT01784250|Drug|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
75457364|NCT01784250|Drug|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
75457365|NCT01784250|Drug|Placebo|Sugar pill manufactured to mimic a drug
75755974|NCT00338949|Drug|Switch|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
75755975|NCT00338949|Drug|Control|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
75755976|NCT01325259|Other|neuropsychologic assessment|Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
75755977|NCT01325259|Radiation|[18F]AV-45 PET|intravenous injection of 4 MBq/kg of [18F]AV-45
75755978|NCT01325259|Radiation|18-FDG PET|intravenous injection of 100 to 120 MBq of FDG
76072353|NCT01119508|Drug|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
75755979|NCT01325259|Other|MRI|Magnetic Resonance Imaging
75755980|NCT01058499|Behavioral|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
75755981|NCT03988881|Procedure|Revascularization|PCI or CABG
75755982|NCT00332709|Drug|Letrozole|2.5 mg/day for 3 years
75755983|NCT00332709|Drug|Zoledronic acid|4 mg every 6 months
75755984|NCT03988725|Dietary Supplement|Vitamin E|Vitamin E 800 IU once daily
75755985|NCT03984279|Other|Patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control|Not applicable, all patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control on a period of 1 year will be taken into account
75755986|NCT03984123|Device|Brachial cuff, in order to achieve ischemic stimuli|Standard treatment with no brachial cuff inflation
75755987|NCT00332241|Drug|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
75755988|NCT00332241|Drug|Placebo|Tablets, Oral, once daily, 8 weeks
75755989|NCT01054989|Biological|Fat/Inflammation effects|Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
75609071|NCT02764645|Device|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
75755990|NCT01058577|Device|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
75755991|NCT01058577|Procedure|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
75755992|NCT03985683|Other|agility tests|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
75755993|NCT03985683|Dietary Supplement|Nutritional Interventional|Athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively.T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
75755994|NCT03983889|Drug|Midazolam|Midazolam is used as a common medication for sedation in all groups.
75755995|NCT03983889|Drug|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
75902933|NCT06156904|Device|Bone grafting for the treatment of surgically created bone defects or bone defects/voids resulting from traumatic injury to promote healing in the pelvis, upper and lower extremities.|"All patients enrolled in this clinical investigation will undergo a reconstruction of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone as per the standard of care at the investigational sites. Patients will be treated with b.Bone which will be used as a bone substitute in isolation or as a graft expander to promote healing in the pelvis, upper and lower extremities.~b.Bone is a bone substitute without initial mechanical properties, therefore it is to be used in conjunction with internal/external fixation devices suitable for primary stabilization."
75902934|NCT06154707|Drug|Denosumab Injection|Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
75902935|NCT06154707|Other|Normal saline injection (1.0ml/ branch)|Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements.
75902936|NCT06154252|Biological|CAB-201 following preconditioning with fludarabine and cyclophosphamide|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
75902937|NCT06146634|Behavioral|Hazard Perception Training|The hazard perception training is comprised of six modules-three covering hazard perception and the remaining three covering attention maintenance. Each module is comprised of four scenarios. Each hazard perception scenario has two activities, while each of the attention maintenance modules have one activity per scenario. Altogether, there are 36 activities across the six modules. The entire training is expected to take approximately an hour to complete. All participants assigned to the treatment group will complete this training.
75902938|NCT06146634|Behavioral|Vehicle Maintenance Training|For participants randomized into the placebo group, they will receive a brief training on vehicle maintenance using the REDCap platform. This will consist of two short videos (one that is approximately 7 minutes long and a second that is approximately 12 minutes long). These videos describe regular checks that drivers should do, such as checking windshield wiper fluid levels, and how to change engine oil. Following each video, several multiple-choice knowledge check questions will be given to participants.
75902939|NCT06143852|Behavioral|Mindfulness|12 minute daily guided meditation
75902940|NCT06143852|Behavioral|Social Media Reduction + Exercise|Reduce social media use at least 30 minutes daily and exercise instead
75902941|NCT06137118|Drug|AZD0486|Investigational Product administered via intervenous infusion.
75902942|NCT06136442|Drug|Atogepant|atogepant in real life in Italy
76072354|NCT01119508|Drug|Temozolomide|Induction Phase, 200 mg/m^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
76072355|NCT01092156|Behavioral|Education|Education on Infant-led latching
76072356|NCT01074814|Drug|Approved therapy will be assigned based on molecular profile and RPMA results|treatment will be assigned based on IHC< FISH, DNA microarray and RPMA results
75457366|NCT01784263|Behavioral|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
75457367|NCT01784263|Behavioral|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
75457368|NCT01784276|Behavioral|Video|"Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player."
75609072|NCT02764645|Device|22Fr curved Cannula|arterial cannula for use in cardiac surgery
75609073|NCT02770885|Drug|Dulaglutide|Treatment with dulaglutide for 3 weeks.
75609074|NCT02770885|Drug|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
75755996|NCT03983889|Drug|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
75755997|NCT03983889|Drug|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
75755998|NCT03983889|Drug|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
75755999|NCT00337935|Drug|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
75756000|NCT00337935|Other|Standard of care|
75756001|NCT00337779|Drug|Glatiramer Acetate (GA) 40 mg|Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
75756002|NCT00337779|Drug|glatiramer acetate 20 mg|Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
75756003|NCT03983811|Drug|Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
76068306|NCT03880786|Device|pudendal PNE test lead|All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
76068307|NCT01791400|Drug|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
76068308|NCT01791400|Drug|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
75457369|NCT01784302|Dietary Supplement|Multivitamins|
75457370|NCT01784302|Dietary Supplement|Sodium bicarbonate|
75457371|NCT01784302|Drug|Maalox Plus extra|
75457372|NCT01784302|Drug|Raltegravir 400 mg|
75457373|NCT01784315|Drug|Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax|4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
75457374|NCT01784315|Drug|Chloroquine and Primaquine|Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
75457375|NCT01784328|Device|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
75457376|NCT01784354|Other|Acupressure|
75457377|NCT01784354|Other|Acupressure dilatation|
75457378|NCT01784354|Behavioral|education|
75457379|NCT01784367|Device|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
75457380|NCT01784380|Drug|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
75457381|NCT01784393|Radiation|chemoradiation|
75756004|NCT03983811|Drug|Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
75756005|NCT03983811|Other|chemotherapy|Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy
75756006|NCT00352755|Procedure|Surgical debulking with peritonectomy|
75756007|NCT00352755|Drug|Intraperitoneal 5FU|
75756008|NCT00352755|Drug|FOLFOX|
75756009|NCT00533897|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
75756010|NCT00533897|Drug|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
75756011|NCT00426660|Drug|maraviroc|The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
75756012|NCT00426270|Drug|Octagam 10%|Octagam 10% was supplied as a ready-to-use solution in glass bottles.
76068309|NCT00298090|Device|StO2 monitoring|placement of the StO2 device/ external noninvasive
76068310|NCT00298558|Behavioral|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
76068311|NCT00299416|Drug|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
76068312|NCT00299416|Procedure|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
76068313|NCT00300430|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
75457382|NCT01784406|Behavioral|Autonomy supportive counselling|
75457383|NCT01784432|Device|Low-level laser therapy and training|
75457384|NCT01784432|Other|Training|
75609075|NCT02770651|Device|Everolimus-Eluting stent|Everolimus-Eluting stent with bioabsorbable polymer
75609076|NCT02770651|Device|Zotarolimus-Eluting stent|Zotarolimus-Eluting stent with permanent polymer
75609077|NCT02770573|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
75609078|NCT02770573|Other|Kuraray Teethmate™ Desensitizer|Calcium-Phosphate-based powder and a liquid mainly water-based.
75609079|NCT02770573|Other|Ghimas Dentin Desensitizer|a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
76068314|NCT00300430|Drug|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
75902943|NCT06132581|Device|Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
75902944|NCT06132581|Device|Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
76068315|NCT00300430|Drug|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
75457385|NCT01784445|Drug|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
75609080|NCT02770729|Drug|Moxifloxacin|Intracameral injection of moxifloxacin at conclusion of cataract surgery
75756013|NCT00330681|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
75756014|NCT00330681|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
75756015|NCT01061073|Drug|Omexel|
75756016|NCT01061073|Drug|spasfon|
75756017|NCT00329901|Biological|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
75756018|NCT00329901|Biological|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
76068316|NCT02104414|Drug|Exparel|266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
75756019|NCT00329901|Biological|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
75756020|NCT01061229|Drug|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
75756021|NCT01061229|Other|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
75756022|NCT00436956|Procedure|Magnetic Resonance Imaging (DCE-MRI)|Scans evaluate tumor tissue and blood flow.
75756023|NCT00436956|Drug|AZD2171|20 mg oral daily for 28 days
75756024|NCT00436956|Drug|Prednisone|10mg orally daily in combination with AZD2171 20mg daily.
75756025|NCT01323504|Other|Music|Patient are listen music during their local care
75756026|NCT01323504|Other|no music|There are no music during the local care
75756027|NCT00329745|Biological|Rotarix™|Oral administration, 2 doses
75756028|NCT00329745|Biological|Placebo|Oral administration, 2 doses
76068317|NCT02104414|Drug|Bupivacaine HCl with Epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
76068318|NCT02104414|Drug|Normal Saline|30mL Normal Saline
75457386|NCT01784471|Device|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
75457387|NCT01784484|Other|No intervention|
75457388|NCT01784510|Procedure|distance of dissection of gastrocolic ligament from pylorus|
75609081|NCT02770729|Drug|No injection of moxifloxacin|No intracameral injection of moxifloxacin at conclusion of cataract surgery
75609082|NCT02770807|Drug|EDS-EP dose range of ~5-10 mg DSP/infusion|infusion
75609083|NCT02770807|Drug|EDS-EP dose range of ~14-22 mg DSP/infusion|infusion
75609084|NCT02770807|Drug|Placebo|infusion
75609085|NCT02770495|Other|blood sample|
75609086|NCT02770417|Dietary Supplement|beta-alanine|Patients receive beta-alanine
75609087|NCT02770417|Dietary Supplement|placebo|Patients receive placebo
75609088|NCT02770417|Other|control|Healthy controls will be assessed to compare baseline muscle carnosine levels
75609089|NCT02770105|Other|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
75609090|NCT02770105|Other|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
75609091|NCT02770105|Other|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
75609092|NCT02770105|Other|Placebo|Oral administration of 200ml of distilled water
75609093|NCT02770027|Drug|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
75609094|NCT02770027|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
75457389|NCT01784549|Drug|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
75457390|NCT01784562|Drug|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
75756029|NCT01031784|Device|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
75756030|NCT01031784|Device|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
75756031|NCT01031862|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
75756032|NCT01324050|Behavioral|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
75756033|NCT01324050|Behavioral|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
75756034|NCT00436644|Drug|Lapatinib|1250 mg orally days 1 -28.
75756035|NCT00436644|Drug|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 & 15.
75756036|NCT01037556|Drug|PR104|Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
75756037|NCT00324987|Biological|Bevacizumab|Given IV
75756038|NCT00324987|Drug|Imatinib Mesylate|Given PO
75756039|NCT00324987|Other|Laboratory Biomarker Analysis|Correlative studies
75756040|NCT00324987|Other|Pharmacological Study|Correlative studies
75756041|NCT00324675|Drug|Rosiglitazone|4 mg tablets, bid, 12 months
75457391|NCT01784575|Other|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
75457392|NCT01784627|Behavioral|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
75457393|NCT01784640|Drug|Hsp90 inhibitor AUY922|Given IV
75457394|NCT01784640|Drug|pemetrexed disodium|Given IV
75457395|NCT01784640|Other|pharmacological study|Correlative studies
75756042|NCT00324675|Drug|Placebo|2 tablets per day
75756043|NCT03988413|Drug|25mg|SYHA1402 25mg or Placebo 25mg
75756044|NCT03988413|Drug|50mg|SYHA1402 50mg or Placebo 50mg
75756045|NCT03988413|Drug|100mg|SYHA1402 100mg or Placebo 100mg
75756046|NCT03988413|Drug|200mg|SYHA1402 200mg or Placebo 200mg
75756047|NCT03988413|Drug|400mg|SYHA1402 400mg or Placebo 400mg
75756048|NCT03988413|Drug|800mg|SYHA1402 800mg or Placebo 800mg
75756049|NCT01055145|Drug|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
75756050|NCT00436566|Biological|trastuzumab|
75756051|NCT00436566|Drug|cyclophosphamide|
75756052|NCT00436566|Drug|doxorubicin hydrochloride|
75756053|NCT00436566|Drug|lapatinib ditosylate|
75756054|NCT00436566|Drug|paclitaxel|
75756055|NCT00436566|Genetic|gene expression analysis|
75756056|NCT00436566|Genetic|reverse transcriptase-polymerase chain reaction|
75756057|NCT00436566|Other|fluorophotometry|
75457396|NCT01784640|Other|laboratory biomarker analysis|Correlative studies
75457397|NCT01784653|Behavioral|iMET|Self-completed, computerized motivational enhancement therapy
75457398|NCT01784653|Behavioral|MET|Clinician-delivered Motivational Enhancement Therapy
75457399|NCT01784692|Dietary Supplement|Immulina|
75756058|NCT00436566|Other|laboratory biomarker analysis|
75609095|NCT02769871|Behavioral|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
75609096|NCT02769871|Behavioral|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
75756059|NCT00436566|Other|mass spectrometry|
75756060|NCT00436566|Procedure|adjuvant therapy|
75756061|NCT00436566|Procedure|quality-of-life assessment|
75756062|NCT01060683|Biological|Hemoglobin determination + NaCl 0.9% bolus|
75756063|NCT01060683|Biological|hemoglobin determination + Venofundin bolus|
75756064|NCT01060761|Behavioral|Rehabilitation program|"Patient and their relative receive three supportive, structured conversation with a trained nurse.~Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities"
75756065|NCT01055301|Drug|bortezomib|
75756066|NCT01055301|Drug|cisplatin|
75756067|NCT01055301|Drug|cyclophosphamide|
75756068|NCT01055301|Drug|dexamethasone|
75756069|NCT01055301|Drug|doxorubicin hydrochloride|
75756070|NCT01055301|Drug|etoposide|
75756071|NCT01055301|Drug|lenalidomide|
75756072|NCT01055301|Drug|melphalan|
75756073|NCT01055301|Drug|thalidomide|
75756074|NCT01055301|Genetic|gene expression analysis|
75756075|NCT01055301|Genetic|microarray analysis|
75756076|NCT01055301|Other|laboratory biomarker analysis|
75609097|NCT02769637|Drug|PPI treatment|PPI treatment or no PPI treatment
75609098|NCT02769559|Procedure|Reduction mammaplasty|Surgical removal of excess breast tissue
75609099|NCT02696707|Procedure|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
75756077|NCT01055301|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|
75756078|NCT01055379|Drug|Rasagiline|1 mg/day for 12 weeks; orally
75756079|NCT01055379|Drug|Placebo|Once daily for 12 weeks; orally
75756080|NCT01031940|Device|macintosh laryngoscope|intubate with the macintosh laryngoscope
75756081|NCT01031940|Device|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
75756082|NCT01031940|Device|Airtraq device|intubate with the Airtraq device
75756083|NCT03988101|Drug|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
75756084|NCT03988101|Drug|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
75756085|NCT03987945|Device|left atrial appendage occlusion devices|All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
75756086|NCT00352365|Drug|lenalidomide|Given orally
75756087|NCT01055535|Drug|Microplasmin|125 µg intravitreal injection
75756088|NCT03987867|Biological|CIK cell|CIK cell injection
75756089|NCT03987867|Biological|Sintilimab Injection|IBI308 injection
75756090|NCT03987867|Drug|Pemetrexed|Pemetrexed injection
75756091|NCT03987867|Drug|Liposome paclitaxel|Liposome paclitaxel injection
75756092|NCT03987867|Drug|Carboplatin|Carboplatin injection
75756093|NCT00532493|Drug|prazosin|"Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually."
75756094|NCT00532493|Other|placebo|"sugar pill"
75756095|NCT00996515|Drug|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
75756096|NCT00996515|Drug|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
75756097|NCT00994799|Drug|ranibizumab|10mg/ml intravitreal injection
75756098|NCT00994799|Radiation|macular grid-pattern laser|macular grid-pattern laser therapy
75756099|NCT00533507|Biological|Synflorix|Intramuscular injection, 3 doses.
75902945|NCT06132581|Device|Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
75902946|NCT06129760|Device|Apple Watch|The wearable sensor device is the Apple Watch Series 6 or newer
75457400|NCT01784705|Device|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
75457401|NCT01784705|Device|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
75457402|NCT01784718|Drug|Buphenyl|
75457403|NCT01784731|Behavioral|Willingness to pay|
75457404|NCT01784744|Other|Hydroworx Pool at 98 degrees Fahrenheit|
75457405|NCT01784744|Other|Hydroworx Pool at 102 degrees Fahrenheit|
75457406|NCT01784757|Drug|ODM-201 Tablet A|Tablet A formulation of ODM-201
75756100|NCT00533507|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
75457407|NCT01784757|Drug|ODM-201 Tablet B|Tablet B formulation of ODM-201
75457408|NCT01784757|Drug|ODM-201 capsule formulation|Capsule formulation of ODM-201
75457409|NCT01784783|Behavioral|HOPE Intervention|"If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.~Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session."
75457410|NCT01784783|Behavioral|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
75756101|NCT00533507|Biological|Rotarix|Oral, 2 doses.
75756102|NCT04000607|Device|Atrial Shunt|Transcatheter treatment of symptomatic left heart failure patients
75756103|NCT00996671|Drug|GSK2256098|focal adhesion kinase inhibitor given as a single dose
75756104|NCT00996671|Drug|Placebo|Placebo to be used as comparator for GSK2256098
75756105|NCT00996749|Dietary Supplement|omega-3 fatty acid|Given PO
75756106|NCT00996749|Other|bone scan|Correlative studies
75756107|NCT00996749|Other|dual x-ray absorptometry|Correlative studies
75756108|NCT00996749|Other|laboratory biomarker analysis|Correlative studies
75756109|NCT00996749|Procedure|biopsy|Correlative studies
75756110|NCT00994955|Device|selective retina therapy (SRT)|laser treatment
75756111|NCT03886493|Drug|Dupilumab|dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
75902947|NCT06129721|Procedure|Emergent Stenting|Emergent Stenting In Acute Vertebrobasilar Occlusions
75609100|NCT02696707|Procedure|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
75609101|NCT02769715|Device|Laser-sintered removable partial denture|The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).
75609102|NCT02769715|Other|cast removable partial dentures|The denture was fabricated traditionally using lost-wax casting technique.
75609103|NCT02769793|Drug|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
75756112|NCT00352053|Drug|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
75756113|NCT00352053|Drug|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
75902948|NCT06126887|Device|Incrediwear Daytime Back Brace|Incrediwear Daytime Back Brace
75609104|NCT02769793|Drug|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
75609105|NCT02769325|Drug|Atropine|IV atropine 0.1%, 10 ml
75457411|NCT01784809|Behavioral|Multimedia WORTH|"The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. ***To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation"
75609106|NCT02769325|Drug|Placebo|IV saline, 10 ml
75756114|NCT00995033|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
75609107|NCT02769325|Drug|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
75609108|NCT02769325|Drug|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
75609109|NCT02769325|Drug|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
76068319|NCT02100826|Drug|Cephalexin|Administered orally.
75609110|NCT02769325|Drug|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
75609111|NCT02769325|Drug|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
75902949|NCT06126887|Device|Incrediwear Sham Daytime Back Brace|Incrediwear Sham Daytime Back Brace
76068320|NCT02101918|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
75609112|NCT02769325|Drug|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
75609113|NCT02770261|Drug|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
75609114|NCT02770261|Drug|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
75609115|NCT02770261|Drug|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
75609116|NCT02770261|Drug|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
75609117|NCT02770261|Drug|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
75609118|NCT02770261|Drug|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
75756115|NCT00995033|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
75756116|NCT00995033|Drug|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
75756117|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
75756118|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
75756119|NCT00998855|Behavioral|Exercise|12 wk aerobic or/ resistance exercise program
75756120|NCT00997061|Drug|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
75756121|NCT00351819|Drug|AndroGel|5g gel, applied once daily to the upper arms, upper back or shoulders.
75756122|NCT00351819|Other|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
76068321|NCT02101918|Other|Laboratory Biomarker Analysis|Correlative studies
76068322|NCT02101918|Biological|Ziv-Aflibercept|Given IV
76068323|NCT04271722|Other|Cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
76068324|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
76068325|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
75902950|NCT06126887|Device|Control Daytime Back Brace|Control Daytime Back Brace
76068326|NCT02102230|Behavioral|Desensitization Treatment for Insomnia|"This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing."
76068327|NCT00300742|Drug|Topiramate|Topiramate up to 300 mg per day.
76068328|NCT00301756|Drug|Belinostat|Given IV
75902951|NCT06126887|Device|Incrediwear 24 Hour Back Brace|Incrediwear 24 Hour Back Brace
75902952|NCT06123611|Behavioral|Adopting Comprehensive Training for FireArm Safety in Trauma centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
75756123|NCT00998933|Drug|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
75756124|NCT00997217|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min upper limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis or cardiopulmonary bypass)
75756125|NCT00999089|Procedure|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
75756126|NCT00999089|Procedure|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
75756127|NCT00999089|Procedure|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
75756128|NCT00351351|Device|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
75756129|NCT00351351|Device|single probe ultrasonic|FDA-approved - single probe ultrasonic
75756130|NCT00997451|Behavioral|Cognitive-behavioral self-management|Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
75902953|NCT06123039|Diagnostic Test|Tidal Volume Challenge|The tidal volume challenge is a fluid response test that consists of increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute and evaluating PPV. If PPV increases by more than 2%, it is considered positive, otherwise it will be negative.
75457412|NCT01784809|Behavioral|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
76068329|NCT00301756|Other|Laboratory Biomarker Analysis|Correlative studies
76068330|NCT00302068|Behavioral|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
76068331|NCT00302068|Drug|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
75457413|NCT01784809|Behavioral|Wellness Promotion|
75457414|NCT01784822|Device|Zenapro™ Hybrid Hernia Repair Device|Device will be placed during open or laparoscopic hernia repair.
75756131|NCT00997451|Behavioral|Symptom monitoring|Daily symptom via web diary
75756132|NCT03983187|Device|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min/ Bid for 1 month
75756133|NCT00999245|Other|High Demand / Low Infusion|HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
75756134|NCT00999245|Other|PCA Dosing Plan|LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
75756135|NCT03983109|Device|EpiFaith loss of resistance detect syringe|An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
75756136|NCT00323115|Biological|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
75756137|NCT00323115|Drug|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
75756138|NCT00323115|Procedure|Radiotherapy|RT is standard of care (SOC) post surgery
75756139|NCT00323115|Biological|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
75756140|NCT00322881|Drug|Paclitaxel|
75756141|NCT00322881|Drug|Carboplatin|
75756142|NCT01061307|Dietary Supplement|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
75756143|NCT00415194|Drug|pemetrexed|500 mg/m^2, IV, every 21 days, six 21 day cycles
75756144|NCT00415194|Drug|cisplatin|75 mg/m^2, administered IV, every 21 days, six 21 day cycles
75902954|NCT06123039|Procedure|Recruitment maneuver obtaining individualised PEEP|The alveolar recruitment maneuver is a well-studied procedure to open the lung during invasive mechanical ventilation, allowing us to achieve the best PEEP for that lung, which is individualised PEEP.
75902955|NCT06122779|Drug|BMS-986435|Specified dose on specified days
75902956|NCT06122779|Other|Placebo|Specified dose on specified days
76068332|NCT00302068|Drug|Placebo Pill.|Placebo pill, daily, for 16 weeks.
76068333|NCT00302848|Drug|Drospirenone|
76068334|NCT00302848|Drug|Levonorgestrel|
75756145|NCT00415194|Drug|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
75756146|NCT00436332|Biological|bevacizumab|
75756147|NCT00436332|Drug|erlotinib hydrochloride|
75756148|NCT01034436|Dietary Supplement|fatty acid quality and overweight|Duration 12 weeks
75756149|NCT00532259|Drug|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
75756150|NCT00322491|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
75756151|NCT01034514|Device|Real-time Position Management system|Standard of Care
75756152|NCT01034514|Device|Discovery ST multislice PET/CT scanner|Standard of Care
75756153|NCT01034514|Device|Infinia Hawkeye SPECT/CT gamma camera|Standard of Care
75756154|NCT01034514|Device|Pinnacle3 treatment planning system|Standard of Care
75756155|NCT01034514|Device|SKYLight nuclear camera|Standard of Care
75756156|NCT01034514|Drug|DTPA|1 mCi; inhalation
75756157|NCT01034514|Drug|TECHNETIUM TC 99M MAA|3 mCi; iv
75756158|NCT00999323|Device|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
75457415|NCT01784835|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
75756159|NCT00997529|Drug|nonmyeloablative stem cell transplant|Conditioning includes cytoxan 60mg/kg/d on Days 6 & 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 & 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction & immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression & do not have signs of GVHD, will receive a DLI
75756160|NCT00997607|Biological|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
75756161|NCT00997607|Biological|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
75756162|NCT00997607|Other|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
75756163|NCT00322023|Drug|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
75756164|NCT00322023|Drug|D-serine|
75756165|NCT00322023|Drug|D-serine|
75756166|NCT00322023|Drug|D-serine|
75756167|NCT00997685|Drug|Capecitabine plus oxaliplatin|"Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles"
75756168|NCT00414960|Drug|Enzastaurin|500 mg po QD for 6 months
75756169|NCT00414960|Drug|Placebo|po QD for 6 months
76068335|NCT00302848|Drug|Other progestin containing oral contraceptive|
76068336|NCT00138034|Procedure|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
76068337|NCT00303862|Drug|cediranib maleate|Given orally
76068338|NCT00303862|Other|laboratory biomarker analysis|Correlative studies
75457416|NCT01784835|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
75756170|NCT01061541|Biological|Tritanrix™-HepB low thio /|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
75756171|NCT01061541|Biological|Hib 2.5|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
75756172|NCT01061541|Biological|Tritanrix™-HepB|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
75756173|NCT01061541|Biological|Hiberix™|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
76068339|NCT00304096|Biological|synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine|
76068340|NCT05267392|Drug|Durvalumab|Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion
76068341|NCT05267392|Other|standard of care RT/RCT|standard of care RT/RCT
75756174|NCT01061541|Biological|Unconjugated Hib vaccine (plain PRP)|One dose as intramuscular injection at 10 months of age
75756175|NCT00997763|Device|XIENCE V|everolimus-eluting stent
75756176|NCT00997763|Device|CYPHER|sirolimus-eluting stent
75756177|NCT00997841|Procedure|Point-of-Care versus conventional coagulation management|Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
75457417|NCT01784887|Drug|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
75457418|NCT01784900|Drug|Catumaxomab 100µg|
75457419|NCT01784900|Drug|Catumaxomab 140µg|
75457420|NCT01784913|Biological|UV1 synthetic peptide vaccine and GM-CSF|
75609119|NCT02769403|Device|HeartMath EmWAVE Pro|"The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate"
75609120|NCT02769403|Other|Questionnaires|All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
75756178|NCT00321789|Behavioral|spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
75756179|NCT00997919|Drug|MABT5102A|single SC dose
75756180|NCT00997919|Drug|MABT5102A|single IV dose
75756181|NCT00414726|Drug|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
75756182|NCT00414726|Drug|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
75756183|NCT00997997|Drug|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
75756184|NCT00998075|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
75756185|NCT00998075|Drug|Esomeprazole - Nexium|Clinical Trial Capsule or MUPS Tablet, oral, single dose
75756186|NCT00998075|Drug|ASA|Tablet, oral, single dose
75756187|NCT00998153|Behavioral|Risk Reduction through Family Therapy|Component based intervention based on existing empirically supported treatments
75609121|NCT02769403|Other|Blood Pressure and Heart Rate|All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
75609122|NCT02769403|Other|Sick Days|Sick days during the 12 week study period will be collected
75609123|NCT02769403|Other|Patient Satisfaction|This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) & Physician Assistants [advance practice clinicians], and nurses) and will be linked to the consented research participant.
75756188|NCT00531947|Drug|Selegiline Transdermal System|EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
76068342|NCT00142168|Drug|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
75756189|NCT00531947|Drug|Placebo|Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
75609124|NCT04224649|Device|HARA Filler(Hyaluronic acid Filler)|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
75609125|NCT04224649|Device|Restylane® Lidocaine|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
75756190|NCT00998231|Biological|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
75457421|NCT01784952|Dietary Supplement|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
75756191|NCT00998465|Other|24-hour blood pressure|Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
75756192|NCT00998465|Other|Echocardiography|Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
75756193|NCT00998465|Other|Inert gas rebreathing|Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
75756194|NCT00998465|Radiation|Dexa-scan|Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
75756195|NCT00998465|Radiation|Plasma volume|The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
75756196|NCT00998465|Radiation|Glomerular filtration rate (GFR)|GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
75457422|NCT01784978|Drug|Sunitinib|50 mg pd
75457423|NCT01784978|Drug|Everolimus|10 mg pd
75457424|NCT01783652|Behavioral|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
75457425|NCT01785004|Dietary Supplement|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
75457426|NCT01785004|Drug|omega-3 fatty acids (fish oil)|
75457427|NCT01785030|Drug|50% Nitrous oxide|
75457428|NCT01785043|Drug|Liraglutide|Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
75457429|NCT01785043|Drug|Sitagliptin|Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
75609126|NCT02769169|Drug|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
75756197|NCT00998465|Other|Blood samples|p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
75756198|NCT00998465|Other|Urine analyses|24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
75756199|NCT00998465|Dietary Supplement|Diets with low and high sodium content|Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
75756200|NCT00998621|Other|Adherence questionnaire|Adherence questionnaire
75756201|NCT00998699|Drug|Xoma 052|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
75756202|NCT00998699|Drug|Placebo|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
75756203|NCT00998777|Procedure|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
75756204|NCT01003847|Drug|fenofibrate, fatty acid, placebo|fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
75756205|NCT01003925|Behavioral|Standard of care for osteoarthritis treatment|Standard of care educational materials to inform patients about choices for knee pain.
75756206|NCT01003925|Behavioral|Conjoint Analysis for Osteoarthritis|Conjoint Analysis computer software to inform patients about choices for knee pain.
75756207|NCT00530855|Drug|Lacosamide|50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
75756208|NCT01004237|Drug|pravastatin, valsartan, pravastatin+valsartan|pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
75756209|NCT01004315|Drug|KUC-7483|
75756210|NCT01004315|Drug|Placebo|
75756211|NCT01004315|Drug|Tolterodine|
75756212|NCT05165459|Device|Venous leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
75756213|NCT05239637|Other|Heparin stopped before ECMO decannulation|Heparin has been stopped for 1 hour before ECMO decannulation;The cannulas can be removed immediately with clots larger than 5 mm or enlarging clots in the circuit.
75756214|NCT05239637|Other|Heparin reduced after ECMO decannulation|Heparin gradually reduced within 24 hours after ECMO decannulation, If excess bleeding occured,decrease the heparin infusion rapidly or turn the heparin off immediately. Protamine can be given to reversing heparin if necessary.
75902957|NCT06121986|Behavioral|Modified Mediterranean Ketogenic Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).
75756215|NCT01004627|Procedure|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
75756216|NCT01004783|Genetic|DNA methylation analysis|
75756217|NCT01004783|Genetic|gene expression analysis|
75756218|NCT01004783|Genetic|loss of heterozygosity analysis|
75756219|NCT01004783|Genetic|microarray analysis|
75756220|NCT01004783|Genetic|mutation analysis|
75756221|NCT01004783|Genetic|polymerase chain reaction|
75756222|NCT01004783|Genetic|reverse transcriptase-polymerase chain reaction|
75756223|NCT01004783|Other|laboratory biomarker analysis|
75756224|NCT01005017|Procedure|Percutaneous Radiofrequent Lesioning|One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
75756225|NCT01005095|Dietary Supplement|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
75756226|NCT01005095|Dietary Supplement|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
75756227|NCT01005563|Other|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
75756228|NCT01005563|Other|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
75756229|NCT01005641|Drug|exemestane|25 mg daily
75756230|NCT01005641|Drug|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
75756231|NCT01005797|Drug|Panobinostat (LBH589), Sorafenib|Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
75902958|NCT06121986|Behavioral|Mediterranean Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet.
75902959|NCT06117891|Drug|Atezolizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
75902960|NCT06117891|Drug|Bevacizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
75756232|NCT01006031|Drug|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
75756233|NCT01006187|Drug|Liposomal lidocaine|4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection
75756234|NCT01006187|Drug|Vapocoolant spray|medium stream spray on arm for 4-10 seconds prior to injection
75756235|NCT01006187|Other|Rubbing adjacent to the injection site|rubbing adjacent to the injection site before and during injection
75756236|NCT01006187|Other|Distraction|By means of self-selected reading material or video
75756237|NCT01006343|Other|Higher Protein (HP)|
75756238|NCT01006343|Other|Lower Protein (LP)|
75756239|NCT00530777|Drug|valacyclovir|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
75902961|NCT06117891|Drug|Durvalumab|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
75457430|NCT01785056|Biological|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
75457431|NCT01785082|Drug|13-C-Methacetin|intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
75457432|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg|
75457433|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg X 2|
75756240|NCT00530777|Drug|placebo|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
75756241|NCT01006421|Dietary Supplement|GINGKO BILOBA|MEMOREX 60 MG BID
75756242|NCT01006499|Drug|Pentoxifylline, pentaglobin|Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
75756243|NCT01006577|Procedure|side-to-end anastomosis|Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
75902962|NCT06117891|Drug|Tremelimumab,|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
75902963|NCT06115811|Behavioral|Radiation Treatment Plan Evaluation Learning Tool|Web-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org.
75902964|NCT06114628|Drug|GSK3036656|Oral daily dosage of 20mg.
75902965|NCT06114628|Drug|BTZ-043|Oral daily dosage of 1000mg.
75902966|NCT06114628|Drug|Bedaquiline (B)|Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
75902967|NCT06114628|Drug|Delamanid (D)|Oral daily dosage of 300mg.
75902968|NCT06114628|Drug|Pretomanid (Pa)|Oral daily dosage of 200mg.
75902969|NCT06114628|Drug|Moxifloxacin (M)|Oral daily dosage of 400mg.
75902970|NCT06114628|Drug|Linezolid (L)|Oral daily dosage of 600mg for the first 8 weeks.
75902971|NCT06114628|Drug|Pyrazinamide (Z)|Oral daily dosage of 1200mg-2000mg depending on weight.
75902972|NCT06114628|Drug|Rifampicin (R)|Oral daily dosage of 450mg-750mg depending on weight.
75902973|NCT06114628|Drug|Isoniazid (H)|Oral daily dosage of 225mg-375mg depending on weight.
75902974|NCT06114628|Drug|Ethambutol (E)|Oral daily dosage of 825mg-1375mg depending on weight.
75902975|NCT06114108|Other|Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)|The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.
75902976|NCT06114108|Other|Surgery|Surgery
75902977|NCT06114108|Radiation|Radiotherapy|Radiotherapy
75902978|NCT06113952|Device|Sharps bin to collect used needles/injections|Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.
75457434|NCT01785108|Drug|Vitamin D|
75457435|NCT01785108|Drug|Ibuprofen|
75756244|NCT01006577|Procedure|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
75756245|NCT01006733|Genetic|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
75756246|NCT01006733|Drug|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
75756247|NCT01006811|Dietary Supplement|modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
75756248|NCT01006811|Other|modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
75756249|NCT01007201|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
75756250|NCT03882047|Drug|Mometasone furoate|Mometasone furoate nasal spray, 200 mg once daily
75756251|NCT03882047|Drug|Fluticasone propionate|Fluticasone propionate nasal spray, 200 mg once daily
75756252|NCT03882047|Drug|Mometasone furoate placebo|Mometasone furoate placebo matching nasal spray, once daily
75756253|NCT03882047|Drug|Fluticasone propionate placebo|Fluticasone propionate placebo matching nasal spray, once daily
75756254|NCT01007279|Drug|ROSUVASTATIN|40 mg before procedure
75756255|NCT00530621|Drug|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
75756256|NCT00530621|Drug|placebo|oral, daily
75756257|NCT00530621|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
75756258|NCT01007513|Procedure|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
75756259|NCT01007513|Procedure|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
75609127|NCT02769169|Drug|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
75756260|NCT00531479|Drug|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
75756261|NCT00531479|Drug|anidulafungin|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
75609128|NCT02768857|Behavioral|Sensorimotor reeducation programs|
75902979|NCT06112743|Drug|Mavacamten|Specified dose on specified days
75902980|NCT06112743|Other|Placebo|Specified dose on specified days
76068343|NCT00142168|Drug|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
76068344|NCT02501434|Drug|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
75609129|NCT02769013|Other|Pre-treatment follow up|No active intervention; medical support provided if needed
75609130|NCT02769013|Other|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
75609131|NCT02769013|Other|Post treatment follow up|No active intervention; medical support provided if needed.
75609132|NCT02769013|Other|Olfactometer experiment|No active intervention; medical support provided if needed.
75756262|NCT00531479|Drug|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
75756263|NCT04000451|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
75756264|NCT04000451|Device|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
75756265|NCT04000451|Drug|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
75902981|NCT06112431|Behavioral|Telehealth-Based Intervention|Participants randomized to the Telehealth-Based Intervention Arm who require referral to ophthalmology will be teamed up with a Patient Navigator who will provide telehealth-based support with scheduling an in-office glaucoma evaluation at either Columbia University Harkness Eye Institute, Harlem Hospital, or their own eye care provider. Participants will also receive telehealth-based support from a Peer Ambassador, who are individuals from the community with glaucoma or other eye diseases who have expressed interest in sharing their experiences. Each referred participant will receive several telehealth-based calls from a Peer Ambassador over 2 years to discuss their understanding of their new ocular diagnosis and encourage adherence to in-office glaucoma evaluation.
75902982|NCT06108050|Drug|JZP898|Investigational drug monotherapy
75609133|NCT02768779|Other|Hair analysis|Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
75609134|NCT02765503|Radiation|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
75902983|NCT06108050|Drug|Pembrolizumab|Approved anti-PD1 antibody
75902984|NCT06104319|Drug|GSK4532990|GSK4532990 will be administered
75902985|NCT06102824|Drug|Organoid-guided treatment|The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
75902986|NCT06102824|Drug|Taxane|Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
75609135|NCT02768545|Drug|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
75609136|NCT02768623|Other|Pharmacist led Asthma Management|
75902987|NCT06102824|Drug|Capecitabine|1000-1250mg/m2, PO, bid, days1-14, q3w
75756266|NCT03999905|Behavioral|Counseling training|Online training using Moodle.
75756267|NCT01007669|Behavioral|Physical activity and Health check|Strength training, aerobic capacity training.
75756268|NCT01007669|Behavioral|Health check only|Health check
75902988|NCT06102824|Drug|Gemcitabine|800-1200mg/m2, IV, days 1, 8, q3w
75902989|NCT06102824|Drug|Vinorelbine|20-35mg/m2, IV, days 1 and 8, q3w
75902990|NCT06102824|Drug|Eribulin|1.4mg/m2, IV, days 1 and 8, q3w
75902991|NCT06102824|Drug|Anthracycline|Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
75902992|NCT06102824|Drug|Carboplatin|Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
75902993|NCT06102824|Drug|Utidelone|30mg/m2, IV, once per day on days 1-5, q3w
75902994|NCT06102824|Drug|Trastuzumab deruxtecan|5.4mg/kg, IV, q3w
76068345|NCT02247232|Drug|Z-100|
75609137|NCT02768623|Other|Pharmacist Intervention (when requested by patient)|
75609138|NCT04224259|Procedure|Ultrasound pre-scan|Before cannulation, use ultrasound to mark the position of right internal jugular vein
75609139|NCT04224259|Procedure|Landmark guidance|The traditional landmark-guided technique for internal jugular vein cannulation, including recognizing the sternocleidomastoid muscle and palpating the carotid artery
75609140|NCT02764723|Drug|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
75609141|NCT02764723|Drug|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
75609142|NCT02764567|Other|Essential Oil|Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
75756269|NCT00999479|Drug|Norethindrone acetate and ethinyl estradiol tablets, USP|"Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc."
75902995|NCT06102824|Drug|Sacituzumab govitecan|10mg/kg, IV, days 1 and 8, q3w
75902996|NCT06097702|Drug|BX-001N Part 1|Dosage form- IV bolus Dosage- In the five cohorts, each participant receives a single IV bolus administration in one of the five doses based on body weight and followed up for 7 days.
75902997|NCT06097702|Drug|BX-001N Part 2|Dosage form- IV bolus Dosage- In the three cohorts, each participant receives a single IV bolus administration for 7 sequential days in one of the three doses based on body weight and followed up for 14 days.
75902998|NCT06097702|Drug|Placebo|Participants will receive matching placebo across Part 1 and 2 of the study.
75902999|NCT06091943|Drug|Tislelizumab IV|Planned doses will be administered intravenously.
75903000|NCT06091943|Drug|Tislelizumab SC|Planned doses will be administered via subcutaneous injection.
76068346|NCT02247232|Drug|Placebo|
76068347|NCT01791634|Procedure|proximal chevron osteotomy|
76068348|NCT01791634|Procedure|proximal open wedge osteotomy with LPS system|
75609143|NCT04664959|Drug|SB16 (Proposed Denosumab Biosimilar)|"Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously."
76068349|NCT02159560|Device|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
75609144|NCT04664959|Drug|Prolia® (Denosumab)|Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
76068350|NCT05267314|Device|pharyngeal exerciser + standard therapy|Use of Pharyngeal exerciser
75609145|NCT02762695|Other|Case Management|"A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.~The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes."
76068351|NCT01594372|Procedure|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
76068352|NCT01594372|Procedure|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
76068353|NCT00147316|Drug|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
75609146|NCT02762695|Other|Usual Care|Usual Care at Primary Health Care Center
75609147|NCT00951496|Biological|Bevacizumab|Given IV
75756270|NCT00999479|Drug|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
75756271|NCT05121311|Diagnostic Test|NeoprediX B1 algorithm|Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
75756272|NCT01007747|Other|Geranium oil|Daily topical application over neuropathic pain
75756273|NCT05114603|Drug|HLX208|level 1:600mg po Bid level 2:900mg po Bid
75756274|NCT00999557|Drug|bimatoprost ophthalmic solution|Applied topically
75756275|NCT00999557|Drug|placebo|Applied topically
75756276|NCT00999635|Device|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
75756277|NCT01007903|Behavioral|Tai Chi exercise|12-week tai chi exercise class
75756278|NCT05260385|Drug|KC1036|KC1036 are administered orally QD or BID in 21-day cycles.
75756279|NCT01008137|Biological|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
75756280|NCT01008137|Biological|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
75756281|NCT00999791|Drug|Bevacizumab|
75756282|NCT00999791|Drug|Diclofenac|
75756283|NCT00999869|Drug|Botulinum toxin type A|Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
75756284|NCT00999869|Drug|Triamcinolone acetonide|Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
75756285|NCT05103527|Device|Dorsal Root Ganglion Stimulation|Stimulation at L2, L3, L4 and S1 spinal levels
76068354|NCT00148798|Drug|cetuximab + cisplatin + vinorelbine|cetuximab given as an intravenous (i.v.) infusion every week (400mg/m^2 initial dose and 250mg/m^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
76068355|NCT00148798|Drug|cisplatin + vinorelbine|cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
76068356|NCT00148954|Device|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
76068357|NCT00148954|Device|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
75756286|NCT01000103|Device|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
75756287|NCT01000103|Device|Sham rTMS|"two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations"
75756288|NCT01008215|Other|Algorithm|Warfarin Dosing algorithm (paper and electronic version)
75756289|NCT01008293|Drug|VSL#3|VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
75756290|NCT01008293|Drug|Lactulose|30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
75756291|NCT01000181|Other|PET-CT with CuATSM|PET-CT with CuATSM
75756292|NCT03742661|Device|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
75756293|NCT01000259|Other|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
76072357|NCT00958737|Drug|FOLFOX regimen|6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))
76072358|NCT00958737|Drug|CAPOX|4 or 8 cycles
75903001|NCT06091943|Drug|Histology-Based Chemotherapy Doublet|"Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
76068358|NCT00149734|Drug|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
75609148|NCT00951496|Drug|Carboplatin|Given IV
75609149|NCT00951496|Drug|Carboplatin|Given IP
76068359|NCT00149734|Drug|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
75609150|NCT00951496|Drug|Cisplatin|Given IP
75609151|NCT00951496|Other|Laboratory Biomarker Analysis|Correlative studies
75609152|NCT00951496|Drug|Paclitaxel|Given IV
75609153|NCT00951496|Drug|Paclitaxel|Given IP
75756294|NCT01008527|Drug|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
75609154|NCT00951496|Other|Quality-of-Life Assessment|Ancillary studies
75609155|NCT02764177|Dietary Supplement|Protein drink|The protein drink was administered during this trial
75609156|NCT02764177|Dietary Supplement|Carbohydrate drink|The carbohydrate drink was administered in this trial
75609157|NCT02696629|Procedure|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
75609158|NCT02696629|Device|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
75756295|NCT01008527|Biological|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
75756296|NCT01008527|Biological|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
75756297|NCT01000415|Other|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
75756298|NCT05177783|Behavioral|Tuune health questionnaire|Participants complete the Tuune contraceptive decision aid health questionnaire.
75756299|NCT05177783|Behavioral|Control health questionnaire|Participants complete a standard physician intake health questionnaire.
75756300|NCT01008761|Drug|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
75609159|NCT02696629|Behavioral|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
75609160|NCT02696551|Other|Medical education|
75609161|NCT02764411|Drug|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
75756301|NCT01008761|Drug|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
75756302|NCT01008917|Drug|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
75756303|NCT01009073|Drug|ABT-263|"ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed."
75903002|NCT06084598|Drug|BMS-986446|Specified dose on specified days
75903003|NCT06084598|Other|Placebo|Specified dose on specified days
75903004|NCT06083454|Drug|Durvalumab|Given intravenous (IV) infusion as monotherapy or in combination with pharmacological ascorbate
75903005|NCT06083454|Drug|Pharmacological ascorbate|Given intravenously in combination with Durvalumab
75903006|NCT06083454|Procedure|Surgery (SOC)|Surgery SOC
75903007|NCT06082102|Drug|Orelabrutinib|Orelabrutinib Tablets
76068360|NCT00198328|Combination Product|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
76068361|NCT00198328|Procedure|Surgical Excision|Patients have their tumor surgically removed.
75609162|NCT02764099|Behavioral|Life Skills Training|The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
75609163|NCT02768077|Drug|Melatonin(Circadin®)|
75609164|NCT02768077|Drug|Placebo|
75756304|NCT01009073|Drug|erlotinib|150 mg of erlotinib is taken orally once daily.
75756305|NCT01009073|Drug|irinotecan (3-week schedule)|"180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
75609165|NCT01193244|Drug|Orteronel|Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
75609166|NCT01193244|Drug|Placebo|Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of <50 ng/dL.
75756306|NCT01009073|Drug|irinotecan (weekly schedule)|"75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
75756307|NCT00530075|Drug|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
75756308|NCT01001117|Device|LensAR laser surgery|Use of laser for cataract surgery
75756309|NCT01001117|Device|Phaco-emulsification cataract surgery|Phaco-emulsification cataract surgery
75756310|NCT01009151|Behavioral|Heart Self Care Tracker|Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.
75903008|NCT06082102|Drug|Lenalidomide|Lenalidomide Capsules
75903009|NCT06082102|Drug|Rituximab|Rituximab Injection
76068362|NCT00305578|Drug|Memantine|Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
75609167|NCT01193244|Drug|Prednisone|Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
75609168|NCT02768467|Procedure|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
75609169|NCT02768467|Procedure|No Stitches|Subject will not receive stitches post buccal mucosa removal.
76068363|NCT00305578|Drug|Placebo|No active medication, only placebo
76068364|NCT01790074|Other|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
75457436|NCT01785121|Behavioral|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
75457437|NCT01785121|Behavioral|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
75609170|NCT04224337|Drug|Durvalumab + doxorubicin + ifosfamide|Durvalumab: 1500mg via IV infusion on day 1 Q3W for 4 cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W for up to a maximum 12 months Doxorubicin 20mg/m2 via IV infusion on day 1 to day 3 Q3W (up to 4 cycles) Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)
75457438|NCT01785147|Drug|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
75457439|NCT01785147|Drug|Placebo|
75457440|NCT01785173|Procedure|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
75457441|NCT01785173|Procedure|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
75756311|NCT01009151|Behavioral|Heart Care Self Tracker|Web-based Home Tele-monitoring System
75903010|NCT06082102|Drug|Orelabrutinib Placebo|Orelabrutinib Placebo Tablets
75903011|NCT06082037|Drug|Belumosudil|Tablet, Oral
75903012|NCT06082037|Drug|Azithromycin|Tablet, Oral
75903013|NCT06082037|Drug|Placebo|Tablet, Oral
75903014|NCT06081049|Drug|Colchicine|0.5 mg once daily
75903015|NCT06081049|Drug|Placebo|Once daily
75903016|NCT06080698|Drug|Intravenous Antibiotics|Participants will continue to receive intravenous antibiotics until the completion of the treatment course
75903017|NCT06080698|Drug|Oral Antibiotics|Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course
75756312|NCT01009229|Dietary Supplement|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
75609171|NCT02768311|Procedure|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system
75756313|NCT01001273|Other|Hyperinsulinemic Normoglycemic Clamp|The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
75756314|NCT01009307|Genetic|polymorphism analysis|
75756315|NCT01009307|Other|laboratory biomarker analysis|
75756316|NCT01009307|Other|medical chart review|
75756317|NCT03999671|Other|Educational|Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
75756318|NCT03999671|Other|Maneuver control|Verify that the control and intervention group developed the assigned activities in each case.
75756319|NCT01001507|Procedure|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
75756320|NCT01001585|Drug|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
76068365|NCT01790074|Other|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
76068366|NCT01492101|Drug|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
76068367|NCT01492101|Drug|Treatment of Physician's Choice (TPC)|"One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel"
75609172|NCT02768311|Procedure|waveone rotary system (reciprocating system)|Procedure: waveone rotary system
75609173|NCT02768311|Procedure|hand files k-files|Procedure: hand files k-files
75609174|NCT02768233|Behavioral|Educational programme|The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
75609175|NCT02768155|Other|Amniotic Fluid 4.0ml dose|Injection of Amniotic Fluid
75609176|NCT02768155|Other|Amniotic Fluid 2.0ml dose|Injection of Amniotic Fluid
75609177|NCT02768155|Other|Placebo Control|Normal Saline
75609178|NCT04223167|Dietary Supplement|Red Bull Energy Drink|473 ml Reb Bull Energy Drink
75609179|NCT04223167|Dietary Supplement|Water|473 ml Water
75609180|NCT02763943|Behavioral|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
75609181|NCT02764021|Dietary Supplement|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
75609182|NCT02764021|Dietary Supplement|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
75756321|NCT01001663|Device|FemoSeal®|Closure device for femoral artery access closure
75756322|NCT01001663|Other|Manual compression|Conventional manual compression
75756323|NCT05734157|Device|Peripheral PTA with a drug coated balloon|Peripheral artery angioplasty
75756324|NCT01001741|Other|Cell phone text message|We will use cellular text messages to remind patients of impending drug prescription refills and scheduled visits to their healthcare provider.
75756325|NCT01001897|Drug|Misoprostol|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
75756326|NCT01001897|Drug|Placebo|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
75756327|NCT05734079|Other|Standard of care|A written hand out containing all information required for bowel preparation
75756328|NCT05734079|Other|Standard of care + Video call|Standard of care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application)
76068368|NCT01468311|Procedure|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
75756329|NCT05734079|Other|Standard of care + Video call + Educational video film|Standard of care and in addition to a video call, an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer
75756330|NCT01002053|Procedure|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
75756331|NCT05734001|Diagnostic Test|ROTEM Tests|"This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~EXTEM CT > 80 sec - FFP will be transfused at 15 ml/kg MCF < 35 mm- Platelet will be transfused at 10 ml/kg~FIBTEM MCF < 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
75756332|NCT05734001|Diagnostic Test|Conventional Haemostatic Tests|"To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~If INR: > 2.5 FFP will be transfused at 15 ml/kg~If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~If Fibrinogen < 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
75756333|NCT01002131|Device|CBCT|Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
75756334|NCT01002209|Procedure|Hyperbaric Oxygen treatment (HBO)|"HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).~HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital."
75756335|NCT01002209|Procedure|Sham HBO|"HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included."
75756336|NCT05064917|Diagnostic Test|Blood draw|The burden for child/parents in this study is low as it is limited to a single blood draw, which is already necessary for usual diagnostic care in about 70% of the children
75756337|NCT05061797|Dietary Supplement|Thermogenic Energy Drink - Active Study Product Formula|The Thermogenic Energy Drink is the Active Study Product (ASP). This energy drink formula combines, caffeine, guarana, Vitamins C, B3, B6, B12, Magnesium, Potassium, L-Citrulline, L-Arginine HCl, L-Glutamine, and Chlorogenic Acids from green coffee bean extract. Participants will consume an assigned amount of the beverage (355 ml), under observation. They will be monitored for the following 180 minutes with measurements of respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via Visual Analog Scale (VAS).
75756338|NCT05061797|Dietary Supplement|Placebo|A carbonated soft drink with the same appearance, flavor and aroma as the active study product. Study participants will consume an assigned amount of the beverage (355 ml) under observation. They will then be monitored for the subsequent 180 minutes with measurements for respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via a Visual Analog Scale (VAS).
75903020|NCT06071715|Device|ACTIVE cryoneurolysis|Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-second defrost period with helium. For active treatment, the argon will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.
75903021|NCT06071715|Device|SHAM cryoneurolysis|SHAM cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-second defrost period with helium. However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.
75903022|NCT06070441|Other|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
75756339|NCT01002365|Other|Oxygen delivery|
75756340|NCT01002365|Other|Oxygen administration|
75903023|NCT06070441|Device|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
75903024|NCT06070441|Other|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
75903025|NCT06070428|Other|PAC provision at hospital discharge|Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.
75903026|NCT06070428|Other|Control non-intervention; PAC without filter|Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
75903027|NCT06067737|Drug|Psilocybin|High-dose psilocybin (30 mg) session will be administered following standard-of-care outpatient buprenorphine induction to evaluate its effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
76068369|NCT01468311|Drug|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
75756341|NCT01002443|Drug|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
75756342|NCT01002443|Drug|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
75756343|NCT01002599|Device|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
75756344|NCT01002599|Device|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
75756345|NCT01002677|Behavioral|Advocacy training curriculum|Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.
75756346|NCT01002677|Behavioral|Self-directed|Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
75756347|NCT05733299|Device|aflo™ digital respiratory management platform|medical device, user app, clinician portal, data analytics hub
75756348|NCT05733299|Other|Standard care|Health service standard care will be continued
75756349|NCT01002833|Biological|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
75756350|NCT01002911|Drug|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
75756351|NCT01002911|Drug|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
75756352|NCT05733221|Device|3D Printed Model|3D Printed Model generated pre-operatively of the patients mandible.
75756353|NCT01003145|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
76068370|NCT01468311|Radiation|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
76068371|NCT01468311|Radiation|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
75756354|NCT01003223|Other|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
75457442|NCT01785199|Procedure|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
75756355|NCT05733065|Other|saliva sample|Adult twins will be asked to send saliva samples in a reply envelope to Maastricht University, department of Genetics and Cell Biology, where they will be frozen and stored before analysis. DNA will be extracted from the saliva using a commercially available kit according to the manufacturer's instructions.
75457443|NCT01785212|Device|Stapler|stapler hepatectomy
75457444|NCT01785212|Device|CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)|CUSA is a well established device used for hepatic resection using ultrasound
75609183|NCT02762617|Drug|Tenofovir disoproxil fumarate intravaginal ring|The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
75903028|NCT06067737|Drug|Psilocybin|A very low dose (1 mg) psilocybin session following standard-of-care outpatient buprenorphine induction will be used as a comparator arm to the high-dose psilocybin arm in evaluating psilocybin's effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
75903029|NCT06063317|Biological|CF33-CD19 IT|"Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28-day cycle."
76072359|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
76072360|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
76072361|NCT00907868|Radiation|partial breast irradiation|Patients undergo radiation tumor bed boost
76072362|NCT00907868|Radiation|whole breast irradiation|Patients undergo whole breast irradiation
75756356|NCT05733065|Other|questionnaire|Along with saliva samples, adult twins, will be asked to complete a questionnaire about their health. Study subjects will be asked to self-report height and weight. Additionally, questions will focus on cardiometabolic risk, including questions about smoking, physical activities, medical diagnoses, current medications, family history of cardiometabolic disease, and for female twins an obstetric and gynaecological history, including number of pregnancies and pregnancy complications (such as gestational diabetes and pre-eclampsia). The questionnaire will take the form of a self-completed, web-based questionnaire which will be hosted by the Qualtrics platform (Qualtrics.com). This platform is supported by the University of Maastricht due to its security and privacy measures.
75756357|NCT00531011|Device|XIENCE V® Everolimus Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
75756358|NCT00531011|Device|TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
75756359|NCT05051267|Other|Non-Pharmacological Methods|All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.
75756360|NCT04000295|Drug|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d
75756361|NCT04000295|Drug|Etoposide|Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
75756362|NCT04000295|Drug|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
75756363|NCT01003457|Other|ultrasonography|transvaginal ultrasonography of bladder wall thickness
75756364|NCT01003613|Drug|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
75756365|NCT01003613|Other|Beriplast P|0.1 ml to attach graft
75903030|NCT06063317|Biological|CF33-CD19 IV|"Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28-day cycle."
75903031|NCT06063317|Biological|Blinatumomab|Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.
75903032|NCT06061939|Other|Blood Flow Restriction training with Oclussion Cuff.|A strength training program with blood flow restriction will be performed for 12 weeks, with 30-45 minute sessions on Mondays, Wednesdays and Fridays. Each session includes a warm-up, the main part with specific exercises and a cool-down with stretching.
75609184|NCT02762617|Drug|Placebo intravaginal ring (IVR)|The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
75609185|NCT02696473|Dietary Supplement|Carrot|
75609186|NCT02696395|Device|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
75609187|NCT02696395|Device|DePuy Corail® femoral stem + Deltamotion® acetabular component|
75609188|NCT01192152|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
75609189|NCT01192152|Drug|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
75756366|NCT05732597|Procedure|Coronary angiography|A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.
75756367|NCT00529217|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
75756368|NCT05732441|Drug|Huange capsule|Huange Capsule was orally administered (Zhejiang Kangenbe Pharmaceutical Co., Ltd., specification: 0.4g×60 tablets/bottle, GuoYaoZhunZi Z20110006). Administration method: 1.6g each time, three times a day, 40min after breakfast, lunch and dinner. The treatment course was four weeks.
75756369|NCT05592977|Device|Intra-Oral Distalizing Device|The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars. The anterior component of the inner bow is 3 mm free from the labial surface of anterior teeth
75756370|NCT00471146|Drug|AG-013736|oral administration, starting dose 5 mg twice daily [BID] every day until unacceptable toxicity or tumor progression.
75756371|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
75903033|NCT06058923|Procedure|M-MIST|This is characterized by a vestibular mucoperiosteal envelope flap without relaxing incisions. Sulcular incisions will be made on the vestibular surface of the teeth included in the surgical area, adjacent to the infraosseous defect. The mesiodistal extension of the flap will be kept to a minimum necessary to access the defect. In the papillary area over the infraosseous defect, an oblique or horizontal incision will be made at the level of the interdental papilla, following the contour of the bone crest. The vestibular flap will be elevated, leaving the lingual/palatal portion adhered, only to allow access to the bone defect. The defect will be instrumented with mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after this procedure. Primary closure will be achieved with internal vertical and/or horizontal mattress sutures, which may be complemented with simple sutures, all using specific suture threads.
75609190|NCT01192152|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
76025317|NCT03161119|Device|Ultrasound guided embryotransfer with Cook K-Jets-551910-S|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
75756372|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
75457445|NCT01785225|Device|A product type of the modified commercial drape Tegaderm (R)|We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
75457446|NCT01785238|Other|renal echography|renal echography to analyse the kidney
75457447|NCT01785238|Other|Blood sampling|Blood sampling to analyse different parameters of renal function
75457448|NCT01785238|Other|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
75457449|NCT01785238|Other|Blood pressure measurement|
75457450|NCT01785251|Device|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
75457451|NCT01785264|Procedure|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
75609191|NCT02763553|Dietary Supplement|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
75609192|NCT02763553|Dietary Supplement|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
75609193|NCT04317924|Device|Polyglycolic acid felt|Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.
75609194|NCT04317924|Other|Standard of care|Standard of care after air leak post lung resection
75756373|NCT00471146|Drug|placebo|placebo
75457452|NCT01785264|Procedure|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
75609195|NCT04222933|Device|Motorized cryotherapy|application of motorized cryotherapy after ACL reconstruction
75756374|NCT04027556|Other|low dose CT contrast media - lean body weight|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.
75756375|NCT04027556|Other|Standard dose CT contrast media|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.
75756376|NCT01021358|Drug|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
75756377|NCT01021358|Drug|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
75756378|NCT00469898|Drug|Carboplatin|"Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~*up to 6 cycles at physician's discretion"
75756379|NCT00469898|Drug|irinotecan hydrochloride|"50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes."
75756380|NCT01021436|Drug|Amikacin inhalation solution (BAY41-6551)|Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
75903034|NCT06058923|Procedure|MIST|A vestibular envelope flap, without vertical relaxing incisions, will be raised on the vestibular and lingual/palatal sides. Primary intrasulcular incisions will be made to the alveolar crest, encompassing the teeth included in the surgical area. In the interproximal area, incisions will follow the principle of preserving the papilla (Modified Papilla Preservation Technique = MPPT or Simplified Papilla Preservation Flap = SPPF), depending on the available interproximal space (Cortellini et al., 1995, 1999). The mesiodistal extension of the flap will be minimized to provide adequate access to the defect. The defect will be instrumented using mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after these procedures. Flap closure will be achieved with internal horizontal and/or vertical mattress sutures, which may be modified or complemented with simple sutures, all using specific suture threads.
75903035|NCT06058663|Procedure|Angiography|Undergo mapping angiography
75903036|NCT06058663|Procedure|Biopsy|Undergo biopsy
75903037|NCT06058663|Procedure|Biospecimen Collection|Undergo blood sample collection
75903038|NCT06058663|Procedure|Computed Tomography|Undergo CT
75903039|NCT06058663|Biological|Durvalumab|Given IV
75903040|NCT06058663|Procedure|Magnetic Resonance Imaging|Undergo MRI
75457453|NCT01785264|Procedure|Mini-invasive surgery|"We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.~All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none."
75457454|NCT01785290|Drug|Haloperidol 1 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~aged ≥ 80 years~weight ≤ 50 kg~liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
75609196|NCT04222933|Device|Classical cryotherapy|application of an ice bag
75609197|NCT02758249|Drug|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
75609198|NCT02758249|Drug|propofol|patients are anesthetized by using propofol infusion
75609199|NCT02758405|Drug|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
75609200|NCT02758405|Drug|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
75609201|NCT02758405|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
75609202|NCT02763787|Drug|BIA 3-202|single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
75609203|NCT02763787|Drug|Placebo|Identical placebo
75609204|NCT02763631|Other|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
75756381|NCT00529763|Drug|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
75756382|NCT00486902|Drug|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
75756383|NCT00486902|Drug|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
75756384|NCT05559125|Drug|STSA-1002 Injection|Intravenous injection
75756385|NCT05559125|Drug|STSA-1005 Injection|Intravenous injection
75903041|NCT06058663|Procedure|Positron Emission Tomography|Undergo PET/CT
75903042|NCT06058663|Biological|Tremelimumab|Given IV
75903043|NCT06058663|Procedure|Yttrium-90 Microsphere Radioembolization|Receive transarterial Y90 radioembolization
75903044|NCT06056024|Drug|BI 3706674|BI 3706674
75903045|NCT06053827|Other|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
75609205|NCT02763631|Other|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
75903046|NCT06053268|Device|Headspace|The intervention will be delivered via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control
75903047|NCT06039397|Behavioral|Semifowler 30' Right Lateral Body Position|Semifowler 30' Right Lateral Body Position Is a regulation of body position by placing the patient's body in a semi-fowler and lateral resting position of 30 degrees
75903048|NCT06038812|Diagnostic Test|GCF sample collection|collecting GCF from deepest sites by paper points
75609206|NCT02763631|Other|Sham Comparator: Stand Care Arm|No change will be made to participants care
75609207|NCT02762305|Other|RSVP Bone Builders Group Exercise|
75609208|NCT04223011|Behavioral|In-Hospital Recovery Coach Intervention|The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
75609209|NCT02758327|Drug|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
75609210|NCT02758093|Behavioral|Speed of Processing Training|These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
75756386|NCT05728541|Drug|SYH2043|Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
75756387|NCT04000139|Drug|Standardized anthocyanin-rich extract|3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
75756388|NCT04000139|Drug|Placebo|3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
75756389|NCT05708729|Device|MCS surgery for CPSP|The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.
75756390|NCT05708729|Device|Vc-DBS surgery for CPSP|For the deep brain stimulation procedure, we will use Vercise stimulators from Boston Scientific together with the Cartesia Directional Leads or the Percept PC stimulator from Medtronic.
75756391|NCT03687827|Drug|Insulin degludec|Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
75903049|NCT06038812|Procedure|non-surgical periodontal treatment|performing scaling and root planning using ultrasonic device and manual curettes
75903050|NCT06037668|Device|BVR-100|Experimental self-guided VR intervention for the treatment of SAD
75903051|NCT06037668|Device|BES-100|Active at-home VR intervention comparator
75903052|NCT06037031|Drug|Drug: PF-07923568|A single dose of PF-07923568 administered orally as 4 capsules
75903053|NCT06034275|Drug|VIP943|VIP943 will be administered by IV Infusion weekly
75903054|NCT06031259|Drug|Idursulfase-IT|Idursulfase-IT intrathecally via IDDD.
75903055|NCT06031259|Drug|Elaprase|Elaprase IV infusion.
75903056|NCT06030700|Other|Controlled Conditions|Use of FoodImage app to take pictures of food and/or receipts.
75903057|NCT06030687|Other|Ad libitum data collection|Food purchase, prep, eat and toss data
75903058|NCT06030635|Device|Measurement of compartment compressibility using the CPMX1 device|Patients will be monitored about every hour (+/- 30 min) for a total of 8 hours. Measurement time might be extended in case the patient undergoes trauma-related surgery during the measurement period and/or in case measurements are spaced further apart. Remaining measurements will be completed after the surgery. At each time point, three measurements of compartment compressibility will be conducted using the CMPX1 on both the affected (potential ACS) and healthy limb.
75903059|NCT06029127|Drug|BGB-A445|Administered intravenously at protocol defined dose
75903060|NCT06029127|Drug|Docetaxel|75 milligrams per square meter (mg/m^2) administered intravenously
75903061|NCT06029127|Drug|Tislelizumab|Administered intravenously at protocol defined dose
75903062|NCT06029127|Drug|Sitravatinib|Administered orally at protocol defined dose
75903063|NCT06029127|Drug|Ramucirumab|10 mg/kg administered intravenously
75903064|NCT06029127|Drug|Selected Interventions|Administered at protocol defined dose
75457455|NCT01785290|Drug|Haloperidol 2 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~aged ≥ 80 years~weight ≤ 50 kg~liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
75457456|NCT01785290|Drug|Placebo|Sodium Chloride 0.9%
75457457|NCT01785303|Behavioral|CBT-I|Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
75609211|NCT02758093|Other|Internet Navigational|This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
75609212|NCT02763475|Drug|cyclophosphamide|60mg/kg by vein on day -6
75609213|NCT02763475|Drug|Fludarabine|25mg/m2 iv daily on day -5 to -1
75609214|NCT02763475|Procedure|NK cell infusion|"First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
75609215|NCT02763475|Drug|IL-2|1x10^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
75609216|NCT02762383|Drug|Peginterferon Alfa-2|Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
75609217|NCT02763163|Behavioral|Sun exposure routine|
75609218|NCT02763241|Drug|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
75903065|NCT06029127|Drug|BGB-15025|Administered orally at protocol defined dose
75903066|NCT06028022|Dietary Supplement|Mushroom|Given Reishi mushroom extract PO
75903067|NCT06028022|Drug|Placebo Administration|Given PO
75903068|NCT06028022|Other|Quality-of-Life Assessment|Ancillary studies
75903069|NCT06028022|Other|Questionnaire Administration|Ancillary studies
75903070|NCT06027255|Diagnostic Test|IL-6|"Compare IL-6 level , as a marker of inflammation in all the 3 groups:~POTS patients~post-COVID-19 POTS~gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae."
75903071|NCT06027255|Diagnostic Test|cytokines (IL-17, and IFN-ɣ)|"Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:~POTS patients~post-COVID-19 POTS~gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae"
75903072|NCT06027255|Behavioral|Compass 31|Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients
75609219|NCT02763241|Drug|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
75756392|NCT03687827|Drug|Insulin glargine|Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
75609220|NCT02763397|Device|NBM-DBS|DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
75609221|NCT02763397|Device|DBS|DBS will be switched off
75756393|NCT00529529|Drug|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
75609222|NCT04223245|Behavioral|exercise+multi-modal sensory feedback (MMSF)|home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
75903078|NCT06013176|Other|Encounter-based PRO monitoring|This arm consists of usual practice plus the addition of patient reminders to complete PRO questionnaires and triage nurse alerts for severe symptoms. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
75903079|NCT06013176|Other|Remote PRO monitoring|This arm will consist of weekly PRO questionnaires administered via the patient portal, de-linked from clinical encounters. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
75609223|NCT04223245|Behavioral|Exercise only|3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
75609224|NCT02758015|Other|Standardized Meal|
75609225|NCT02758015|Dietary Supplement|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
75609226|NCT02758015|Dietary Supplement|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
75609227|NCT02758015|Dietary Supplement|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
75609228|NCT02757937|Behavioral|Health & Wellness Website|Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
75457458|NCT01785303|Procedure|CPAP|CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
75457459|NCT01785329|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
75609229|NCT02757937|Other|Control Arm|Continue with standard diabetes care without getting access to the intervention website.
75756394|NCT00529529|Drug|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
75756395|NCT00529529|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
75609230|NCT04221685|Other|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg
75756396|NCT00529529|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
75756397|NCT05685953|Biological|DNA vaccine OC-007|Plasmid DNA vaccine
75756398|NCT05685953|Other|Placebo|0.9% NaCl solution
75609231|NCT04221685|Other|Artinibsa|"Powerful local anaesthetic with a short latency time.~Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains:~Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg"
75756399|NCT05655377|Device|FitMi PD|Exercise using the motion sensing devices and a tablet computer
75756400|NCT04973111|Drug|CT-868 as SC Injection|CT-868
75756401|NCT04973111|Drug|Placebo as SC Injection|Placebo
75756402|NCT04973111|Drug|Active Comparator as SC Injection|Active Comparator
75903080|NCT06011733|Other|Placebo|Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.
75903081|NCT06011733|Drug|Bimekizumab|Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
75903082|NCT06010914|Other|No Intervention|"Following the manner of observational study, no intervention will be provided in the study.~The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information."
75756403|NCT00486434|Drug|SMC021 Oral Calcitonin|0.8mg SMC021 (Oral Calcitoinin) twice daily
75609232|NCT02762461|Procedure|IVF or ICSI|
75756404|NCT00486434|Drug|SMC021 Placebo|Placebo orally, twice daily
75756405|NCT04972019|Device|Telerehabilitation Experimental Group|"Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals and subjective pain level being measured and logged.~They will wear a computer system modified with biosensors, then do motor and cognitive baselines. Subsequently, participants will play an increasing number of games, targeted at cognitive domains of executive function (primary), memory and attention. At the end of every session vitals and subjective pain will be measured and logged.~Clinical Coordinator will call homes weekly to ascertain general health and issues with participation.~At the end of week 4 and 8 participants and their caregivers in the experimental group will fill a subjective evaluation questionnaire to gauge perceived benefits and technical difficulties when using the experimental system. Questions will be scored on a 5-point Likert scale."
75609233|NCT02762539|Drug|omega-3 enriched SMOF lipid emusion|
75609234|NCT02757703|Drug|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
75756406|NCT04972019|Other|Telerehabilitation Sham Control Group|"Sham control group will train playing web games while wearing a biosensor connected to a laptop provided, showing the web games. However biosensor data will not be used to control game difficulty.~Sham group controls will start every session with vitals and subjective pain levels being measured and logged. Then participants will play the same frequency and duration of sessions, however those will consist of web games training the same domains (memory, focusing, executive function). Interaction will be through a mouse, and data will be downloaded to a server maintained by the company doing the web games. Data will then be transferred to the research team.~At the end of every session vitals and subjective pain levels will again be measured and logged.~Once a week the Clinical Coordinator will call the home to ascertain general health and determine is there were issues with that week participation."
75756407|NCT00424632|Drug|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
75756408|NCT00529451|Drug|Aliskiren|Aliskiren
75756409|NCT00529451|Drug|Ramipril|comparator
75756410|NCT03876743|Other|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
75756411|NCT03876743|Other|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
75756412|NCT03876743|Other|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
75756413|NCT03876743|Other|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
75609235|NCT02757703|Drug|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
75609236|NCT02757703|Drug|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
75756414|NCT05641259|Drug|LP-108|Oral administration for 21 or 28 days on a 28-day cycle
75756415|NCT05641259|Drug|Azacitidine|Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.
75903083|NCT06010758|Drug|Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
75903084|NCT06010758|Drug|Colgate Cavity Protection Toothpaste|Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
75457460|NCT01785355|Other|Dental treatment|"The preliminary stage deals with:~assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~education of the patient regarding correct oral hygiene habits;~Phase I Therapy:~plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~evaluation of response to the treatment~Phase II Therapy - surgical phase:~extraction of hopeless teeth~evaluation of the surgical results.~Maintenance phase:~periodic reevaluation of plaque and calculus and of periodontal conditions."
75756416|NCT05408975|Device|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
75903085|NCT06010758|Drug|Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
75903086|NCT06010758|Other|Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
75457461|NCT01785368|Other|Implementation of guidelines|The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.
75609237|NCT02757703|Device|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
75609238|NCT02757781|Behavioral|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
75609239|NCT02763007|Drug|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
75903087|NCT06010641|Other|head-down position|-20° Trendelenburg as an adjunct to guideline-based treatment,
75903088|NCT06010303|Drug|LBL-007|LBL-007 will be administered at a standard dose intravenously.
75903089|NCT06010303|Drug|Tislelizumab|Tislelizumab will be administered at a standard dose intravenously.
75903090|NCT06010303|Drug|Chemotherapy Doublet|"Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
75903091|NCT06006546|Biological|426c.Mod.Core-C4b|100 mcg and 300 mcg
75903092|NCT06006546|Other|Adjuvant 3M-052-AF+Alum|5 mcg
75903093|NCT06004856|Drug|Orelabrutinib|Orelabrutinib once daily (QD)
75903094|NCT06004856|Drug|Placebo|Placebo once daily (QD)
75903095|NCT06001840|Behavioral|Promotion factors|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
75903096|NCT06001840|Behavioral|Mitigation strategies|"Health Communications. The first narrative describes a person unknown to the participant who purchases from the illegal market and experiences negative life outcomes (e.g., ill health from contaminants). The second narrative incorporates cognitive biases of social proof (i.e., portraying a choice as the opinion of the majority).~Availability of Nicotine Replacement Therapies (NRT): Transdermal NRT will be available in the LETM at two different prices. In one condition, transdermal NRT will be available at a 50% subsidy in the form of coupons. In the other condition, a five-day supply of NRT will be available for free.~Penalties: Penalties will be presented in different fine magnitudes along with a description of the consequences of illegal purchases (i.e., a criminal record)."
75457462|NCT01785368|Other|Baseline observation|During this period of the study, baseline data will be collected.
75457463|NCT01785381|Other|Added value of coordinator|Added value of coordinator
75457464|NCT01785394|Drug|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
75457465|NCT01785407|Dietary Supplement|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
75609240|NCT02763007|Drug|alogliptin|nesina add on metformin
75609241|NCT02763007|Drug|pioglitazone|actos add on metformin
76072363|NCT00754338|Drug|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
76072364|NCT00754338|Drug|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
75903097|NCT06000228|Procedure|Recession coverage with CTG using minimally invasive access technique in shallow vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
76068372|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
76068373|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
75903098|NCT06000228|Procedure|Recession coverage with CTG using minimally invasive access technique in deep vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
75903099|NCT05999136|Other|Pulses diet|Subjects in the PulD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PulD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with servings of pulses.
76072365|NCT00754338|Drug|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
75609242|NCT02753101|Drug|[18F]-FTC-146|10 mCi± 1 mCi of [18F]FTC-146 intravenously
75903100|NCT05999136|Other|Plant proteins diet|Subjects in the PPD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PPD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with a mixture of pulses and plant-based meat substitutes.
75903101|NCT05999136|Other|Habitual diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
75457466|NCT01785446|Drug|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
75457467|NCT01785446|Drug|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
75457468|NCT01785485|Other|Integrative medicine primary care model|An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
75457469|NCT01785498|Behavioral|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
75457470|NCT01785511|Radiation|UVA Radiation|UVA radiation exposure for 20 minutes
75756417|NCT05408975|Device|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
75756418|NCT05405387|Drug|Budesonide EC|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
75756419|NCT05405387|Drug|Placebo|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
75756420|NCT05401799|Device|BURT|Use of Barrett Upper extremity Robot (BURT) to improve strength and mobility of hemiplegic upper extremity.
75756421|NCT05401799|Procedure|Other Occupational Therapy|Standard occupational therapy sessions will be 60-90 minutes a day and are UE neuroeducation sessions are typically focused on improving strength and mobility of the hemipelagic arm.
75756422|NCT03999437|Drug|TERBINAFINE HYDROCHLORIDE (1%)|Topical liquid solution
75756423|NCT03999437|Drug|BUTENAFINE HYDROCHLORIDE (1%)|Topical liquid solution
75756424|NCT03999437|Drug|Vehicle Control|Topical liquid solution
75903102|NCT05998902|Procedure|Trophic enteral feeding combined with supplemental parenteral nutrition|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
75903103|NCT05998902|Procedure|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
75903104|NCT05997615|Drug|AMX-500 (SAR446329)|Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
75903105|NCT05997381|Device|Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.|An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.
76068374|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose level 2 of 80 mg/m^2, Escalated/Dose level 3 of 100 mg/m^2, and Escalated/Dose level 4 of 120 mg/m^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
76068375|NCT05267002|Procedure|Suture removal timing|Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
76068376|NCT00308230|Procedure|Six minute walk test|
76068377|NCT00308230|Behavioral|Minnesota Living with Heart Failure Questionnaire|
76068378|NCT00325078|Drug|Infliximab|
75756425|NCT05311631|Behavioral|Breastfeeding support|"The core of the intervention is a trustful relation between the health visitor and the families based on principles of needs based communication. Health visitors will enhance parents' action competence based on breastfeeding self-efficacy, focusing on parents' wishes and needs.~The breastfeeding support includes four main messages: joint parenting task, skin-to-skin contact, frequent breastfeeding, and good positioning.~Training of health visitors includes e-learning and a two-day course with physical attendance. Supportive materials are developed including communicative support tools and a web-page providing support and knowledge when the health visitor is off hours.~All families in intervention sites accepting the health visitor program will receive the improved breastfeeding support. Families in the high-risk group are offered an intensified intervention with close follow-up by telephone in planned time-intervals, thus a higher dose of the intervention."
75756426|NCT05637281|Drug|Indometacin|Besides the conventional treatment, indomethacin will be given to the patients in the convention + indomethacin group.
76068379|NCT00325780|Drug|Pitavastatin|Pitavastatin 4 mg once daily
76068380|NCT00326170|Drug|5-Azacytidine (5-aza)|Start at 75 mg/m^2 subcutaneously daily for 7 days.
76068381|NCT00326170|Drug|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
75756427|NCT05637281|Other|conventional treatment|All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
75756428|NCT00486278|Drug|eptacog alfa (activated)|90 mcg/kg, injected i.v.
75756429|NCT00486278|Drug|vatreptacog alfa (activated)|5 mcg/kg, injected i.v.
75756430|NCT00486278|Drug|vatreptacog alfa (activated)|10 mcg/kg, injected i.v.
75609243|NCT02762227|Device|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
75756431|NCT00486278|Drug|vatreptacog alfa (activated)|20 mcg/kg, injected i.v.
75756432|NCT00486278|Drug|vatreptacog alfa (activated)|40 mcg/kg, injected i.v.
75756433|NCT00486278|Drug|vatreptacog alfa (activated)|80 mcg/kg, injected i.v.
75756434|NCT00321711|Drug|Placebo|Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
75756435|NCT00321711|Biological|AMG 531 (Romiplostim)|AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
75756436|NCT00321711|Drug|Azacitidine|hypomethylating agent
75756437|NCT00321711|Drug|Decitabine|hypomethylating agent
75756438|NCT00486044|Drug|Simvastatin|40 mg tablet each night for one month, then 80 mg for 8 months
75756439|NCT00486044|Drug|Placebo|Matching tablet each night for 9 months
75756440|NCT01018472|Dietary Supplement|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
75756441|NCT01018472|Other|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
75903106|NCT05997381|Procedure|Arthroscopic rotator cuff repair|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
75457471|NCT01785550|Other|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
75756442|NCT04193462|Other|Post-partum depression- Dyadic psychotherapy-|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity. Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant. During the whole therapy-trial, the therapist will also use cognitive-behavioral approach to address the mother's perception of her infant and of herself as a mother.
75756443|NCT04193462|Other|Post-partum depression- Psycho-educational therapy|Mothers will receive a therapy in their homes for 8 weeks, 1.5 hours for each session by a therapist arriving at their home. Each session will address a different developmental aspects of the baby (feeding, movement, social-emotional development etc.). Therapist will ask the mother about her baby, will give information about developmental needs and expectations and will help mother to enrich child's development and deal will potential problems
75903107|NCT05996913|Other|Imagery rescripting|The current project aims to explore the feasibility of intervention featuring imagery rescripting (ImRs) and grounding in the management of somatic flashbacks amongst this population. ImRs was developed as a method to help activate a traumatic memory, bring corrective information into the memory, create a more favourable outcome to the memory and to support the participant to discover and express inhibited trauma-related emotional responses (Arntz & Weertman, 1999).
75457472|NCT01785576|Behavioral|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
75609244|NCT02762227|Device|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
75609245|NCT02762227|Procedure|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
75457473|NCT01785589|Procedure|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
75457474|NCT01785641|Drug|ceftazidime+ciprofloxacin|2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
75457475|NCT01785641|Drug|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
75756444|NCT00351273|Drug|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
75756445|NCT00351273|Drug|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
75756446|NCT00351273|Drug|Placebo|Methylcellulose
75756447|NCT01018628|Drug|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
75756448|NCT01018628|Drug|Placebo|For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
75756449|NCT03996356|Other|No study intervention - observational study|This is an observational study where the comparative groups will be determined by the genetic variants (SNPs) of subjects and not an intervention, per se.
75903108|NCT05995717|Dietary Supplement|PKU UP|"PKU UP is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in children aged from one (1) to ten (10) years.~PKU UP is a neutral-flavoured, ready-to-drink, low-phenylalanine protein substitute containing a blend of glycomacropeptide (GMP) isolate, essential and non-essential amino acids, fat, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA)."
75903109|NCT05993559|Radiation|Arm I (No PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
75457476|NCT01785641|Drug|cefazolin+gentamicin|cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
75457477|NCT01785641|Drug|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
75457478|NCT01785693|Drug|levobupivacaine, clonidine|
75457479|NCT01785732|Procedure|Renal Denervation|Sympathetic renal denervation via renal arteries
75457480|NCT01785745|Other|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
75457481|NCT01785745|Other|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
75457482|NCT01785758|Drug|Sugammadex (4 mg/Kg)|Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
75457483|NCT01785784|Drug|rhGM-CSF Gel|
75457484|NCT01785797|Device|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
75609246|NCT00635323|Drug|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
75609247|NCT01191840|Drug|Vancomycin|Duration
75609248|NCT01191840|Drug|Vancomycin|Duration
75609249|NCT02752711|Procedure|the PECARN clinical decision rule|the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma
75609250|NCT04534543|Radiation|MRI/Spectroscopy|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
75756450|NCT00327717|Drug|Zonisamide|Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
75756451|NCT00327717|Drug|Placebo|Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
75756452|NCT03917810|Other|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
75903110|NCT05993559|Radiation|Arm II (PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
75903111|NCT05989074|Device|ALLEGRA TAVI System TF|Patients receive ALLEGRA TAVI System TF. Patient will receive medication according to routine practice of the hospital
75903112|NCT05989074|Device|Ballon-expandable valve system|Patients receive any kind of CE-marked balloon expandable valve system, used at the hospital. Patient will receive medication according to routine practice of the hospital.
75609251|NCT05656950|Procedure|Assessment|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
75756453|NCT03995810|Dietary Supplement|Carnosine, capsulle, 2 g/day, 8 weeks|We will administer supplemental carnosine (2 grams per day) for 8 weeks
75756454|NCT00463346|Drug|Acamprosate|Acamprosate 1998 mg tid
75756455|NCT00463346|Drug|Placebo|Placebo
75756456|NCT01025024|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
75756457|NCT01022528|Drug|Dexamethasone (0.1 mg/kg)|
75756458|NCT01022528|Drug|Dexamethasone (0.2 mg/kg)|
75756459|NCT01022528|Other|Saline|
75756460|NCT01025102|Drug|Naropin 0.1% cum sufentanil|20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
75903113|NCT05988580|Other|Pasta dish with resistant starch|Pasta dish with 20-22% of resistant starch
75609252|NCT02752555|Other|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
75903114|NCT05988580|Other|Original version of pasta dish|Original pasta dish, not reinforced with resistant starch
75903115|NCT05988216|Biological|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
75457485|NCT01785823|Other|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
75756461|NCT00462488|Drug|Vicinium|Intravesical administration of Vicinium
75756462|NCT01025180|Other|Procalcitonin level|"The duration of antibiotic treatment is based on PCT level:~< 0.25 ng/ml: antibiotic should be stopped~0.25 < PCT <0.5: antibiotic prescription is not recommended~> 0.5 ng/ml: antibiotic should be used"
75756463|NCT00454142|Drug|pazopanib hydrochloride|Given PO
75756464|NCT00454142|Other|pharmacological study|Correlative studies
75903116|NCT05986864|Genetic|SKG0106|SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
75457486|NCT01785823|Other|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
75609253|NCT04472377|Device|Self sampling kit for collecting discharge from vaginal fornix|A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.
75903117|NCT05984680|Other|Surveys and Interviews - Arm A|For Arm A, this outpatient study will administer surveys, interviews, concept mapping exercises, guided tours of oncology clinics, design team workshops, and phone calls for follow-up questions
75903118|NCT05984680|Other|COPD Care Pathway|The COPD care pathway will consist of an initial assessment followed by monthly follow-up assessments, which occur during regularly scheduled immunotherapy infusions. At each of these three visits, the study team will administer symptom measures, counsel participants on the management of COPD, and give algorithm-generated general recommendations to the patient and provider regarding possible options for COPD-directed care.
75903119|NCT05978817|Device|Damon Ultima bracket|It is metal twin bracket with their recommended arch wire
75609254|NCT00624546|Drug|Prevacid Solutabs|BID Prevacid Solutabs
75609255|NCT00624546|Procedure|Antireflux surgery|Lap Nissen
75756465|NCT00454142|Procedure|computed tomography|Correlative studies
75756466|NCT00424476|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
75756467|NCT00424476|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
75756468|NCT00424476|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
75756469|NCT03994536|Behavioral|A Person-Centred Transition Program to Empower Adolescents With Type 1 Diabetes in the Transition to Adulthood: the STEPSTONES-DIAB Project|Behavioral: Transition program Participants will be part of a transition program that aim to prepare them for adult life and adult care wich includes eight key components: 1. A transition coordinator; 2. Education on diabetes, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the adult diabetes service: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Preparation and transfer to adult diabetes service.
75903120|NCT05970978|Drug|regular treatment|IBI112 200mg s.c. at week 0, 12, 24 and 36.
75903121|NCT05970978|Drug|Intensive treatment|IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
75903122|NCT05970016|Drug|TCC1727 tablet|TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
75903123|NCT05962827|Diagnostic Test|lipoprotein (a)|dosage of lipoprotein (a)
75903124|NCT05962398|Genetic|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891).
75903125|NCT05962151|Drug|Nalbuphine ER|Oral tablets
75903126|NCT05962151|Drug|Placebo|Oral tablets
75903127|NCT05961085|Procedure|Adductor Canal Catheter|Ultrasound guided Adductor Canal Catheter for total knee arthroplasty analgesia
76068382|NCT00326170|Drug|All-Trans Retinoic Acid (ATRA)|45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
76068383|NCT00326872|Drug|Cediranib Maleate|
76068384|NCT05266690|Dietary Supplement|Roquette Glucidex 2|Roquette Glucidex 2: Maltodextrins with high degree of polymerization
75756470|NCT03994536|Other|Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
75756471|NCT01037634|Drug|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
75903128|NCT05959733|Procedure|Bridging Reconstruction using BioBrace|Patients in the reconstruction group will undergo maximal repair with interposition bridging using BioBrace. This technique will follow a previously described technique by the principal investigator with differences allocated to the graft, it's preparation and insertion. The bursa will be debrided, and rotator cuff edged will be shaved down to stable tissue. BioBrace is bioinductive scaffold composed of highly porous type I collagen and bio-resorbable poly (L-lactide) (PLLA) microfilaments, and will be used as the graft in this trial.
75903129|NCT05959733|Procedure|Repair|Patients in the maximal repair group will undergo a SCOI-row rotator cuff repair with adequate tension as described previously, with recreation of the rotator cable. Briefly, the SCOI-row rotator cuff repair uses one triple loaded suture anchor for each 1.2cm of torn tendon. This technique has been completed in a previous randomized controlled trial.
75903130|NCT05956964|Behavioral|Sleep Restriction|5 hours of sleep for 3 days
75903131|NCT05956964|Behavioral|Sleep Adequate|9 hours of sleep for 3 days
75903132|NCT05956041|Drug|Pembrolizumab|400mg Intravenously
75903133|NCT05956041|Drug|Mogamulizumab|1mg/kg Intravenously
75903134|NCT05955365|Drug|P2Y12 inhibitor|The choice of P2Y12 inhibitor is left at investigator's discretion.
75457487|NCT01785823|Other|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
75756472|NCT00453986|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
75756473|NCT00453986|Biological|Mencevax™ACWY|One subcutaneous dose
75457488|NCT01785836|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
75756474|NCT00453986|Biological|Fluarix™|One intramuscular dose
75756475|NCT01032252|Other|Exercise intervention|"16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.~Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training."
75756476|NCT00435942|Device|Relay Thoracic Stent-Graft|implant
75756477|NCT00435942|Procedure|Open Repair|Open surgery
75756478|NCT01034748|Drug|[14C]PF00299804|Single 45 mg oral dose of radiolabelled PF-00299804
75903135|NCT05955365|Drug|Aspirin|Aspirin is administered for up to 1 month after PCI at investigator's discretion
75903136|NCT05955365|Drug|DOAC|The choice of DOAC is left at investigator's discretion.
75903137|NCT05955339|Other|NOTES|The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
75903138|NCT05955339|Other|AUDIO|The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
75457489|NCT01785836|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
75756479|NCT01037712|Drug|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
75903139|NCT05954559|Drug|Elucirem (Gadopiclenol)|Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.
75903140|NCT05948436|Procedure|Clamping the uterine artery bilaterally during Cesarean section|We clamped the uterine artery by Darmklemmen clamp, which grasps the tissue delicately without damage, after the delivery of the baby before the delivery of placenta. The clamp is released after the suturing of Munro-Kerr incision is finished, before bleeding control. The duration of clamping time is recorded.
75756480|NCT01037712|Drug|Placebo|placebo
75756481|NCT00453362|Other|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).
75756482|NCT00453362|Other|3'-deoxy-3'-[18F]fluorothymidine (FLT)|FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.
75756483|NCT00453362|Drug|erlotinib HCl|Tablets taken orally 150 mg/day.
76068385|NCT05266690|Dietary Supplement|Pharmacosmos Dextran 10|Pharmacosmos Dextran 10: Dextran with high degree of polymerization
76068386|NCT05266690|Dietary Supplement|Roquette Glucidex 40|Roquette Glucidex 40: Glucose syrup
76068387|NCT05266690|Dietary Supplement|Promitor 70|Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
75457490|NCT01785836|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
75457491|NCT01785836|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
75457492|NCT01785862|Drug|Ibuprofen 25 mg|Lozenge, Oromucosal administration
75457493|NCT01785862|Drug|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
75756484|NCT00424398|Drug|Bepreve|sterile ophthalmic solution
75756485|NCT00424398|Drug|Placebo|sterile ophthalmic solution
75457494|NCT01785901|Other|without interventions|without interventions
75457495|NCT01785927|Other|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
75756486|NCT00424398|Drug|Bepotastine Besilate|sterile ophthalmic solution
75756487|NCT00461786|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
75756488|NCT01021592|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
75756489|NCT01021670|Drug|Dapoxetine hydrochloride|One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
75756490|NCT01021670|Other|Alternate care/non-dapoxetine hydrochloride treatment(s)|As prescribed or directed
75756491|NCT01025258|Behavioral|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
75756492|NCT01025258|Behavioral|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
76068388|NCT00328042|Behavioral|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
76068389|NCT00328042|Behavioral|Information Only|This is an individual self-paced at home study program.
75756493|NCT01025414|Drug|enteral nutrition|Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines
75756494|NCT01025414|Drug|Parenteral nutrition|Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
76068390|NCT00329524|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
76068391|NCT01730534|Drug|Dapagliflozin 10 mg|Oral dose (od)
76068392|NCT01730534|Drug|Placebo tablet|Oral dose (od)
75756495|NCT00435162|Drug|Valsartan 0.25 mg/kg|once daily
75756496|NCT00435162|Drug|Valsartan 1.0 mg/kg|once daily
75756497|NCT00435162|Drug|Valsartan 4.0 mg/kg|once daily
75756498|NCT03836664|Drug|Timolol|Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
75756499|NCT03836664|Drug|Placebo|Placebo is normal saline solution that will be supplied in container matched to Timolol container.
75756500|NCT01037868|Other|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
75756501|NCT01032408|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
75756502|NCT01032408|Biological|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
75756503|NCT00350727|Drug|pazopanib|Pazopanib is a novel compound being developed for the treatment of various cancers.
75903141|NCT05943431|Device|paired taVNS|The stimulator will be placed on the left ear of the patient. While the patient performs the action training, the EMG signal feature evoked by the action will trigger an electrical stimulation of the transcutaneous auricular vagus nerve. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
75903142|NCT05943431|Device|Unpaired taVNS|The stimulator will be placed on the patient's left ear. Patients will receive taVNS with pulses every 5-7 seconds. Following the stimulation, motor training will be performed. The motor training will be identical to that of the paired group. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
75903143|NCT05943431|Device|Sham taVNS|The stimulator will be placed on the patient's left ear. The amplitude of the electrical stimulation will be adjusted at 0 mA. The intervention will be performed daily for 14 days.
75903144|NCT05928390|Drug|Pasireotide Diaspartate|Injectable ampoules
75903145|NCT05926661|Other|NCC Support Toolkit|"Pre-discharge intervention-~Set expectations for parents/caregivers to spend time bedside and attend rounds~iPad for the families to use the Nemours App, download education materials and Facetime communication with medical personnel.~Download Nemours App and teach them how to use it~Education materials- to ease the use of medications, Oxygen and feeding~Assistance with transportation, child care, parental work schedule for discharge teaching~Post Discharge intervention (Day 1-2):~• Video/Facetime call with the family to check equipment, home environment and answer questions about medications and formula~Post discharge intervention (Day 3-7):~• Phone call to the family to ensure transportation for their first follow-up appointment, answer questions about medications, Oxygen and feeding."
75609256|NCT05656872|Procedure|Transverse Abdominis Plane Block|Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.
75756504|NCT00350727|Drug|lapatinib|Lapatinib is a novel compound being developed for the treatment of various cancers.
75756505|NCT01032486|Drug|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
75756506|NCT01032564|Other|The elastography (elasticity imagery)|This diagnosis mean use the ultrasonography to measure the tissues answer under pressure
75756507|NCT01032642|Device|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
75756508|NCT01061697|Drug|Pregabalin|At week 0, pregabalin 75mgbd will be given for 1 month. If visual analogue scale is not reduced by 50% after 1 month, pregabalin will be increased to 150mgbd for the second month
75756509|NCT00434304|Drug|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
75903146|NCT05920083|Other|CPAP withdrawal|2 weeks of CPAP withdrawal
75756510|NCT00424008|Drug|Mometasone furoate/formoterol (MF/F) MDI|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.
75756511|NCT00424008|Drug|Fluticasone propionate/salmeterol (F/SC) DPI|Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
75756512|NCT03994068|Diagnostic Test|VIVO non invasive mapping|non invasive pre-procedural localization of PVC / VT origin
75756513|NCT00423930|Biological|bevacizumab|
75756514|NCT00423930|Drug|cisplatin|
75457496|NCT01785940|Procedure|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
75609257|NCT05656872|Procedure|Ilioinguinal-iliohypogastric block|Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
75609258|NCT02757469|Drug|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
75609259|NCT05656716|Behavioral|Nutritional intervention|The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants
75903147|NCT05915767|Dietary Supplement|Olive leaf tea|Fresh olive leaves will be procured from Chakwal, Pakistan. The leaves will be rinsed to remove dust and debris and dried at 40℃ in the oven. The leaves will be ground into powder form and then incorporated in tea bags containing 1.8 g leave powder/tea bag. Participants in treatment group will be instructed to dip the tea bag in 200-250 ml boiling water for 3-5 minutes.
75903148|NCT05912231|Radiation|Accelerated Proton Beam Radiation Therapy (PBT)|per protocol
75609260|NCT05656716|Behavioral|Physical exercise intervention|Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
75609261|NCT02762149|Device|Nerve stimulator|The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
75609262|NCT02757391|Biological|Adoptive Immunotherapy|Undergo CD8 +T cell therapy
75609263|NCT02757391|Biological|Aldesleukin|Given SC
75609264|NCT02757391|Drug|Cyclophosphamide|Given IV
75609265|NCT02757391|Other|Laboratory Biomarker Analysis|Correlative studies
75609266|NCT02757391|Biological|Pembrolizumab|Given IV
75609267|NCT04564417|Biological|W0180|Participants will receive W0180 in a 21-day cycle.
75756515|NCT00423930|Procedure|conventional surgery|
75756516|NCT00423930|Radiation|intensity-modulated radiation therapy|
75756517|NCT00423852|Biological|filgrastim|
75756518|NCT00423852|Drug|carboplatin|
75756519|NCT00423852|Drug|ifosfamide|
75756520|NCT00423852|Drug|paclitaxel|
75756521|NCT00423852|Procedure|autologous hematopoietic stem cell transplantation|
75756522|NCT00423852|Procedure|peripheral blood stem cell transplantation|
75756523|NCT01037946|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
75756524|NCT00461708|Drug|Erlotinib|100 mg, PO, once per day
75903149|NCT05912231|Radiation|Accelerated Photon Radiation Therapy (XRT)|per protocol
75609268|NCT04564417|Drug|Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.
75609269|NCT02757157|Behavioral|Water-based walking|"Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
75609270|NCT02757157|Behavioral|Land-based walking|"Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
75756525|NCT00461708|Drug|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
75756526|NCT01032720|Procedure|Ultrasound|Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
75609271|NCT02757079|Drug|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
75609272|NCT04221217|Drug|Icosapent|Icosapent (MND-2119) capsules.
75609273|NCT02696161|Other|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
75756527|NCT01032720|Procedure|Sham ultrasound|Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
75756528|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
75756529|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
75756530|NCT01038024|Dietary Supplement|1 tablet composed of antioxidants and minerals|1 tablet daily
75756531|NCT03982875|Device|Alfred SmartBag|The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
75457497|NCT01785966|Behavioral|Daily checklist and clinician prompting|"Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items."
75457498|NCT01785979|Drug|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
75609274|NCT02696161|Other|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
75609275|NCT02887560|Procedure|transoesophageal echocardiography|
75756532|NCT03982719|Other|Brief protocol|This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
75756533|NCT03982719|Other|Intense protocol|This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
75756534|NCT00461630|Drug|ER niacin/laropiprant|
75756535|NCT00461630|Drug|simvastatin|40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
75756536|NCT00461630|Drug|ezetimibe/simvastatin|10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
75756537|NCT01061853|Drug|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE*)1mg/ml bid during 3 months
75756538|NCT01061853|Drug|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE*)0.05% bid during 3 months
75756539|NCT03982641|Procedure|all colorectal cancer surgical procedures|colorectal cancer surgical procedures
75756540|NCT00461552|Drug|Leptin|weight based, sub-cutaneous injection, twice daily
75756541|NCT00461552|Other|Placebo|weight based, sub-cutaneous injection, twice daily
75756542|NCT01325415|Drug|NKTR-118|25 mg tablet
75756543|NCT01325415|Drug|moxifloxacin|400 mg tablet
75756544|NCT01325415|Drug|Placebo|tablet
75756545|NCT00453206|Procedure|allogeneic bone marrow transplantation|
75457499|NCT01785979|Drug|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
75457500|NCT01785992|Drug|Irosustat|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
75457501|NCT01786005|Device|Transcranial magnetic stimulation|
75457502|NCT01786018|Drug|Thiotepa|
75457503|NCT01786018|Drug|Busulfan|
75756546|NCT00453206|Procedure|allogeneic hematopoietic stem cell transplantation|
75756547|NCT00453206|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75756548|NCT00453206|Procedure|peripheral blood stem cell transplantation|
75756549|NCT03900806|Behavioral|online cognitive rehabilitation|The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
75756550|NCT03894254|Other|no intervention|This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).
75756551|NCT03850496|Device|Revitive IX Neuromuscular Stimulation Device|Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.
75756552|NCT03995888|Drug|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
75756553|NCT01022606|Other|Arterial sampling|Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
75756554|NCT01022684|Other|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
75457504|NCT01786018|Drug|Fludarabin|
75457505|NCT01786018|Procedure|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10^7 CD3 cells/kg recipient weight and cryopreserved.
75457506|NCT01786018|Radiation|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
75609276|NCT04220749|Radiation|Radiation|Standard of Care: Radiation +/- Chemotherapy
75609277|NCT04220749|Procedure|Trans-Oral Surgery (TOS) + Neck Dissection|Trans-Oral Surgery (TOS) + Neck Dissection (plus radiation, if required)
75609278|NCT05655858|Other|Management of allergic rhinitis|Collection of patient data in real-life
75756555|NCT01022840|Drug|S-Ketamine|drug
75756556|NCT01022840|Other|Placebo Comparison|saline control
75756557|NCT01025570|Drug|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
75756558|NCT03983876|Drug|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease"
75756559|NCT00327015|Drug|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
75756560|NCT00327015|Drug|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
75756561|NCT00327015|Drug|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
75903150|NCT05911334|Behavioral|ROADE Program|Outpatient Behavioral Intervention for Eating Disorder
75903151|NCT05910411|Device|Inelastic compression|Inelastic compression used in the treatment of lymphedema
75457507|NCT01786018|Drug|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
75457508|NCT01786018|Drug|Cyclosporine|"CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below."
75457509|NCT01786018|Drug|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
75756562|NCT00327015|Drug|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
75756563|NCT00327015|Drug|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
75756564|NCT00434148|Drug|Pasireotide|
75756565|NCT03983655|Device|High Frequency Low Intensity TMS|125 hz, 10 gauss, 2 times daily for 6 monts
75756566|NCT03983499|Behavioral|Special Intervention|The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)
75756567|NCT01063569|Drug|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
75756568|NCT01063569|Drug|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
75756569|NCT00468728|Drug|PAR-101/OPT-80|capsules
75903152|NCT05909683|Diagnostic Test|Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.|After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.
75457510|NCT01786018|Drug|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
75457511|NCT01786018|Procedure|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
75457512|NCT01786031|Other|metastasis biopsy|
75457513|NCT01786044|Behavioral|MasterMed|An online interactive educational program
75457514|NCT01786044|Behavioral|Usual Care|
75903153|NCT05909683|Other|Standard of Care|Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
75756570|NCT00468728|Drug|Vancomycin|Capsules
75756571|NCT01061931|Procedure|Arctic Front® catheter vs. HD Mesh Ablator® catheter|Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
75756572|NCT00433914|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
75756573|NCT00433914|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
75756574|NCT03983265|Other|Bilateral Sagittal Split Osteotomy|after BSSO condyle will be re positioned by using computer guided device
75756575|NCT00468650|Drug|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
75756576|NCT00423150|Drug|Temozolomide|Temozolomide capsules 150 mg/m^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
75903154|NCT05909176|Behavioral|GYN Residency Training|The combined care model will be implemented and during months 5-14.
75903155|NCT05909176|Behavioral|Social Media Campaign|The social media campaign will be implemented along with the combined care model in months 15-18.
75903156|NCT05905458|Drug|HRS9950 tablets|HRS9950 tablets, oral, once a week, low dose
75903157|NCT05905458|Drug|HRS9950 tablets|HRS9950 tablets, oral, once a week, high dose
75903158|NCT05905458|Drug|HRS9950 placebo tablets|HRS9950 placebo tablets, oral, once a week.
76068393|NCT00329836|Other|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
76068394|NCT00330382|Drug|Bowman-Birk inhibitor concentrate|Given orally
76068395|NCT00330382|Other|placebo|Given orally
76068396|NCT00330382|Other|laboratory biomarker analysis|Correlative studies
76068397|NCT01791712|Procedure|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
76068398|NCT01791712|Procedure|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
75609279|NCT02752321|Device|eDischarge|Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
75609280|NCT02768389|Drug|Bevacizumab|Subjects receive Bevacizumab as standard of care
75609281|NCT02768389|Behavioral|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (< 20gm/day).
75609282|NCT04529005|Drug|Angiotensin II|If intraoperative or postoperative hypotension occurs (e.g. SBP < 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.
75756577|NCT01038102|Other|PUFA Diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
75756578|NCT01038102|Other|SFA diet|Diet high in saturated fat (15E%)
75756579|NCT00433836|Drug|Valsartan|Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
75756580|NCT00433836|Drug|Enalapril|Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
75756581|NCT01038258|Procedure|PET scan after course 1 and surgery after 8 courses|PET scan and surgery
75756582|NCT01022918|Drug|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
75756583|NCT01022918|Drug|Temodal/radiotherapy|
75756584|NCT00433446|Biological|CNTO 328|
75756585|NCT00468104|Drug|Alteplase|25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
75756586|NCT00468104|Drug|Placebo|Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
75756587|NCT00326625|Drug|40 mg glatiramer acetate|parenteral drug
75756588|NCT00326625|Drug|Placebo|
75756589|NCT00433290|Drug|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
75756590|NCT00433290|Drug|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
75903159|NCT05901610|Behavioral|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
75903160|NCT05901610|Behavioral|Control Episodic Thinking|Participants will generate descriptions of vivid positive past events.
75903161|NCT05901610|Device|Low-intensity Focused Ultrasound|A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.
75903162|NCT05901610|Device|Sham Low-intensity Focused Ultrasound|All of the same actions done during LIFU will be performed, but the device will be inactive.
75903163|NCT05900895|Drug|Olaparib|Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
75903164|NCT05900895|Drug|17b-estradiol|17b-estradiol will be taken orally three times per day.
75903165|NCT05895786|Drug|PF-06823859|anti-interferon beta therapy
75903166|NCT05895786|Drug|Placebo|Placebo for PF-06823859
75903167|NCT05895292|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.|The patients will receive complete removable dentures designed based on the bone-support concept and digitally manufactured using a milling machine.
76068399|NCT05266534|Drug|Terlipressin|the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
75756591|NCT00467870|Drug|Testosterone Undecanoate 750 mg|
75756592|NCT00467870|Drug|Testosterone Undecanoate 1000 mg|
75756593|NCT01021904|Biological|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
75756594|NCT01022060|Dietary Supplement|Renalof|One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
75756595|NCT01022060|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
75756596|NCT00467558|Drug|Naltrexone|daily
75756597|NCT00467558|Drug|Sugar pill|daily
75756598|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, intramuscular (IM)
75756599|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, IM
75756600|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 Ml dose, IM
75756601|NCT00422292|Biological|Measles, Mumps, Rubella and Varicella|0.5 mL dose, SC
75903168|NCT05895292|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machine
75609283|NCT05357040|Drug|Nitrous oxide gas for inhalation|"60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
75903169|NCT05891600|Device|Smartclic|The SmartClic® autoinjector is a reusable, electromechanical, and single-patient device for the administration of subcutaneously administered biologics.
75756602|NCT01038414|Behavioral|Extended Duration Behavioral Smoking Cessation Counseling|Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
75756603|NCT00452348|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
75756604|NCT00452348|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
75756605|NCT00452114|Device|In-Exsufflator Cough Assist Device|
75457515|NCT01786057|Procedure|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
75457516|NCT01786057|Procedure|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
75609284|NCT05357040|Drug|Placebo|"60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
75756606|NCT00452114|Device|Active Comparator: Flutter Valve Device|Active Comparator
75756607|NCT01323062|Drug|Bavituximab|Administered 3 mg/kg weekly
75756608|NCT00320541|Drug|gemcitabine|1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
75756609|NCT00320541|Drug|paclitaxel|90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
75903170|NCT05888870|Drug|SCT800 and Daratumumab|SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
75903171|NCT05888870|Drug|SCT800|SCT800 50IU/kg TIW alone
76068400|NCT05266534|Drug|Carbetocin|the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
76068401|NCT05266534|Drug|Saline|the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
75457517|NCT01786070|Drug|Budesonide|
75457518|NCT01786070|Drug|placebo|
75457519|NCT01786083|Behavioral|Application of Problem Solving Technique|
75756610|NCT00320541|Drug|bevacizumab|10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
75756611|NCT03982563|Behavioral|Growth Mindset|Reading and writing activities designed to instill the belief that people can change.
75756612|NCT03982563|Behavioral|Gratitude|Reading and writing activities designed to practice noticing and appreciating good things in life.
75756613|NCT03982563|Behavioral|Behavioral Activation|Reading and writing activities designed to identify and schedule positive activities.
75756614|NCT03982563|Behavioral|Study Skills|Reading and writing activities designed to learn evidence-based study strategies.
75756615|NCT00320385|Drug|Lapatinib|oral lapatinib once daily
75756616|NCT00320385|Biological|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
75609285|NCT05655390|Behavioral|Safety Intervention Planning|The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
75756617|NCT01063725|Dietary Supplement|Femarelle|A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily
75609286|NCT00943072|Biological|VEGF Trap-Eye 2.0mg|Monthly intravitreal injection out to the Week 24 Primary endpoint
75609287|NCT00943072|Drug|Sham|Monthly sham intravitreal injection out to Week 24 Primary Endpoint
75756618|NCT01063725|Other|Placebo|Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
75756619|NCT00326001|Device|Gold tip catheter|Radiofrquency ablation using gold tip catheter
75756620|NCT00326001|Device|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
75756621|NCT00309777|Drug|Pitavastatin|Pitavastatin once daily
75756622|NCT00309777|Drug|Simvastatin|Simvastatin once daily
75756623|NCT00309387|Dietary Supplement|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
75609288|NCT02757001|Other|Inferior vena cava filter placement and retrieval|"There are really no interventions in this study. This is an prospective observational study of patients that have been implanted a inferior vena cava filter with intention to be retrieved.~Patients are recruited when the filter is implanted, and the investigators observe when is it finally retrieved, and if there is any complication at the retrieval of the filter."
75609289|NCT04222855|Drug|Diltiazem|Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
75609290|NCT00942994|Drug|Aliskiren/Amlodipine|"Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)"
75609291|NCT00942994|Drug|Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)|"Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)"
75609292|NCT02756767|Other|Survey|
75756624|NCT00309387|Other|Placebo|placebo tablets manufactured to mimic Centrum tablets.
75756625|NCT03982797|Biological|Instillation of IMUNO BCG Moreau RJ|Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .
75756626|NCT00325143|Biological|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
75756627|NCT00325143|Biological|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
75756628|NCT00319839|Drug|Abraxane|260 mg/m2 IV over 30 minutes every 3 weeks
75756629|NCT00319839|Drug|Cetuximab|Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
75756630|NCT01062087|Drug|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
75609293|NCT05658432|Other|Exercise via telehealth|Same as arm/group description
75756631|NCT00319449|Drug|Ezetimibe|10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
75756632|NCT00319449|Drug|Placebo|10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
75756633|NCT00319449|Drug|Atorvastatin 10 mg|10 mg/day atorvastatin, orally, (ongoing treatment in participants)
75756634|NCT00308997|Device|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
75756635|NCT00308997|Device|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
75756636|NCT00308685|Drug|Albuterol|Albuterol 90mcg
75756637|NCT00308685|Drug|Placebo|Placebo
75756638|NCT01060839|Behavioral|Single session counseling|For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
75756639|NCT01060917|Device|Non-invasive CGMS (continuous glucose monitoring system)|A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
75756640|NCT01060917|Procedure|Hyperglycemic and hypoglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
75903172|NCT05886400|Other|SCAT6|The SCAT6 is a standardized assessment tool to diagnose a concussion. This tool will be used for the experiment utilizing the 6th edition to recreate the methods used in an athletic situation. The SCAT6 is broken down into multiple subtests to focus on specific aspects of a person's wellbeing that could be affected by a possible concussion. The assessments are created to measure an athlete's subjectively experienced symptoms, cognitive functioning and balance and postural stability (mBESS).
75903173|NCT05886400|Other|Visual/ Auditory Distraction|The purpose of this study is to examine the effect of environmental distractions on one's ability to complete the SCAT6. The environmental distractions will be visual and auditory by playing a sports event or sports clips during the completion of the assessment. The goal of this is to simulate the distraction of a sideline like a SCAT6 is typically used within athletic training.
75903174|NCT05885464|Biological|BEAM-201|A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
75903175|NCT05876351|Drug|Eculizumab|Weight-based doses of Eculizumab will be administered intravenously as an induction dose followed by maintenance dose at Day 8, 15, or 29 depending on weight; then every 2 or 3 weeks, depending upon weight.
75903176|NCT05874635|Device|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
75903177|NCT05873348|Procedure|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the use of functional microorganisms in the feces of healthy people to form capsules and orally administer them to the intestinal tract of patients to reconstruct the intestinal flora of patients, so as to achieve the purpose of treating intestinal and exenteric diseases.
75903178|NCT05865496|Drug|611|611 subcutaneous (SC) injection.
75903179|NCT05865496|Drug|Placebo|Placebo subcutaneous (SC) injection.
75903180|NCT05860972|Device|Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.|After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
76025318|NCT03161119|Device|Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
75457520|NCT01786096|Drug|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
75609294|NCT05658432|Other|Exercise unsupervised|Same as arm/group description
75609295|NCT02761525|Other|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
75609296|NCT02761525|Other|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
75609297|NCT04317222|Device|eCRRT|"eCRRT was define as:~Initiated within the first 24 post-transplant hours;~High volume (35-50ml/kg) hemofiltration;~Continuous at least 12 hours per day for 3 days;~Standard treatment"
75609298|NCT04268602|Other|local anesthetic injection|1% lidocaine
75457521|NCT01786122|Other|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
75756641|NCT01060917|Device|Non-invasive CGMS (GlucoDay)|The minimally-invasive glucose sensor GlucoDay, was used as a control measure
75756642|NCT03981159|Other|Physical training|Physical training for three months, twice per week (60 minutes per session).
75756643|NCT03981237|Device|Laser-activated irrigation with a pulsed Er:YAG laser|The root canals and the pulp chamber are filled with NaOCl 3%. Per canal, the laser tip is placed above the root canal entrance and activated (frequency 20 Hz, pulse energy 20 mJ and pulse length 50 μs) for 30s. TThe canal is then rinsed with NaOCl using a 27G needle, followed by a second application of laser, identical to the first.
75756644|NCT03981237|Device|Ultrasonically activated irrigation|The root canals and the pulp chamber are filled with NaOCl 3%. An Irrisafe file, driven by an ultrasonic unit according to the manufacturers' instructions, is held at 1-3 mm from WL (precurved if canal is curved) and activated for 30 s. The canal is then rinsed with NaOCl using a 27G needle. This cycle is repeated three times (i.e. 3*20s).
76068402|NCT01730378|Biological|Prepandrix™|2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
76068403|NCT01730378|Biological|Fluarix™|1 dose administered intramuscularly in the deltoid region of non-dominant arm.
75457522|NCT01786122|Behavioral|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
75457523|NCT01786135|Drug|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
75457524|NCT01786200|Drug|Aspirin|
75756645|NCT03981237|Procedure|Orthograde root canal treatment|After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
75756646|NCT03982251|Procedure|High frequency whole body vibration|1 single session ( 8 minutes) of whole body vibration therapy at 30 Hz
75756647|NCT03982251|Procedure|Low frequency whole body vibration|1 single session ( 12 minutes) of whole body vibration therapy at 20 Hz
75457525|NCT01786200|Drug|Ibuprofen|
75457526|NCT01786226|Drug|Oral administration of mifepristone 2.5 mg daily for three months|Experimental: 1
75457527|NCT01786226|Drug|Oral administration of mifepristone 5 mg daily for three months|Experimental: 2
75457528|NCT01786278|Radiation|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
75457529|NCT01786278|Procedure|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
75756648|NCT00317109|Biological|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
75756649|NCT00317109|Biological|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
75756650|NCT00317109|Biological|Mencevax™ ACW|One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
75756651|NCT03982329|Device|navigated repetitive transcranial magnetic stimulation|
75756652|NCT03982329|Procedure|physical therapy|
75756653|NCT03981081|Drug|Prednisone|Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
76068404|NCT01783496|Device|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
76068405|NCT04559750|Behavioral|Internet delivered behavior therapy (I-BT)|10 weeks of I-BT
76068406|NCT00314236|Device|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
76068407|NCT00314236|Procedure|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
76068408|NCT01729208|Device|Dual Focus Soft Contact Lens|
76068409|NCT01729208|Device|Single Vision Soft Contact Lens|
75756654|NCT03979287|Other|Interferential Current and Therapeutic Exercise Program|"The Interferential Current Program will be based on a bipolar application using the Sonopuls 692 device (Enraf Nonius, Rotterdam, The Netherlands). The current parameters will be: a) 4000Hz carrier frequency; and b) 60 Hz AMF with a modulation frequency of 90 Hz. The intensity of the current will be adapted to the sensitivity of each patient.~The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~Ergonomic advices on reducing repetitive movements and/or maintained positions~A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
75756655|NCT03979287|Other|Therapeutic Exercise Program|"The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~Ergonomic advices on reducing repetitive movements and/or maintained positions~A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
75756656|NCT01062243|Behavioral|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
76068410|NCT00331162|Drug|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
75609299|NCT05658354|Other|Computerized cognitive program|BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
75609300|NCT02756455|Other|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
75609301|NCT00942604|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
76072366|NCT00752154|Drug|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
75609302|NCT00942604|Drug|Vehicle gel|two day treatment
75609303|NCT04314336|Drug|Public procurement|Cost minimisation study through public procurement
75609304|NCT04314336|Drug|Drug and Therapeutics Committee|Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
75756657|NCT03979209|Drug|Nasal Mometasone Rinse|Nasal irrigation twice a day (BID) of assigned dose.
75756658|NCT00316719|Drug|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
75756659|NCT00316719|Drug|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
76072367|NCT00745134|Drug|Capecitabine|Given PO
75609305|NCT02756221|Dietary Supplement|Probiotics|One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1
75609306|NCT02756221|Other|Placebo|Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
75609307|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
75609308|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
75609309|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
75756660|NCT03979053|Device|Multiparametric MRI Scan|Patients attending the clinic will have a MRI scan added to their standard of care.
75609310|NCT00624702|Drug|Placebo|
75609311|NCT02857192|Biological|Blood samples|
75609312|NCT02756377|Drug|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
75609313|NCT02756377|Drug|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
75609314|NCT02852824|Drug|BI 655130|
75609315|NCT02852824|Drug|Placebo|
75609316|NCT02752009|Procedure|Axillary Lymph Node Sampling Clip|
75609317|NCT04220437|Other|no interventin|Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
75756661|NCT01065987|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
75756662|NCT01063959|Procedure|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
75756663|NCT01063959|Procedure|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
75756664|NCT03978975|Behavioral|Food intake|"For all those session, subjects will take a standardized breakfast (570kcal) three hours before experimental session.~Control session (CON): subject will stand sited without any activity during 40 min.~Subjects will be submitted to three aquatic cycling exercise session:~session 27°C :aquatic cycling at 27°C without water jet during 40 min~session 27°C+ water jets : aquatic cycling at 27 °C with water jets during 40 min~session 18°C : aquatic cycling at 187°C without water jet during 40 min Every exercise session will be set at 70% of theorical maximal heart rate During each session, oxygen consumption and carbon dioxide production will be analysed with gas analysis system. Appetite and hunger sensation will be measured with a specific scale at different time point of each day of experimental session. Thirty minutes after the end of each experimental session subjects will have a buffet meal for lunch time."
75609318|NCT02752477|Drug|Opioid-free general anesthetic|An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
75609319|NCT02752477|Drug|Traditional general anesthetic|Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
75609320|NCT02761681|Behavioral|ACT-CL Web-based guided self-help|
75609321|NCT02761681|Behavioral|Control Web-based guided self-help|
75609322|NCT04220593|Other|tDCS associated with Tcog|2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
75756665|NCT01064115|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
75756666|NCT00422058|Drug|liraglutide|Injected s.c. (under the skin) once daily
75756667|NCT00422058|Drug|orlistat|120 mg capsule. Administered thrice daily
75756668|NCT00422058|Drug|placebo|Injected s.c. (under the skin) once daily
75756669|NCT01032798|Drug|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
75756670|NCT02720952|Drug|Infacort®|dry granule formulation of hydrocortisone
75756671|NCT00413244|Drug|AndroGel 5 Grams|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
75756672|NCT00413244|Drug|Placebo|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
75756673|NCT01033032|Drug|Amrubicin|"Phase I: dose-escalating portion with the starting dose of amrubicin at 90mg/m^2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m^2; DL3 - 110mg/m^2; and DL4 - 120mg/m^2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days"
75756674|NCT01032876|Procedure|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
75756675|NCT01032876|Procedure|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
75756676|NCT01038492|Behavioral|p16 Methylation and Lung Cancer Education|"patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~patients are called again at three months and asked about any changes in their attitudes or smoking habits."
75756677|NCT00420420|Drug|MK0249|MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
75756678|NCT00420420|Drug|Comparator: Placebo (unspecified)|MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
75457530|NCT01786304|Procedure|Sacral nerve stimulation|implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
75457531|NCT01786317|Device|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
75457532|NCT01786356|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
75457533|NCT01786356|Other|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B&L MI60 in one eye
75756679|NCT01038570|Drug|Syntocinon®/- Spray|3 sprays corresponding to 24 IU in each nostril
75756680|NCT01038570|Drug|Physiological serum (Sodium chloride)|Sodium chloride 0.9 % (0.3 ml) in each nostril
76025319|NCT04496609|Device|Stimulation and automated rehabilitation / automated rehabilitation|Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
75457534|NCT01786382|Drug|PPI-668|
75457535|NCT01786382|Drug|Midazolam|
75457536|NCT01786382|Drug|Omeprazole|
75457537|NCT01786382|Drug|Telaprevir|
75457538|NCT01786395|Drug|UF-021|
75457539|NCT01786395|Drug|Placebo|
75457540|NCT01786408|Device|TAP20-C|
75457541|NCT01786408|Device|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
75457542|NCT01786460|Other|Blood draw at Days 0, 7, 14, and 21|
75457543|NCT01786473|Drug|Testogel 1%|
75457544|NCT01786473|Drug|Placebo|
75457545|NCT01786499|Behavioral|Relaxation Response Training|
75457546|NCT01786525|Behavioral|House Calls|60-minute home based educational intervention which will be administered by a health educator
75756681|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
75756682|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
75756683|NCT00420342|Drug|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
75756684|NCT00432744|Drug|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
75756685|NCT00432744|Drug|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
75756686|NCT01038648|Drug|Sitagliptin|100mg/day
75756687|NCT01038648|Other|life style modification at base line|Advice on physical activity, diet and drug adherence.
76072368|NCT00745134|Dietary Supplement|Curcumin|Given PO
76072369|NCT00745134|Other|Laboratory Biomarker Analysis|Correlative studies
75609323|NCT04204096|Biological|Vi-DT (Multi-dose formulation)|"Manufacturer: SK bioscience Co., Ltd.~Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~Storage Conditions: +2 to +8°C"
75609324|NCT04204096|Biological|Vi-DT (Single dose formulation)|"Manufacturer: SK bioscience Co., Ltd.~Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~Storage Conditions: +2 to +8°C"
75609325|NCT04204096|Biological|Control Vaccine|"For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject."
75609326|NCT05376852|Combination Product|based decitabine and olverembatinib（HQP1351)chemotherapy|"AP-CML treated with decitabine 10mg/m2 d1-5 intravenously (IV) over 60 minutes on days 1-5 and HQP1351 40mg qod every 28 days.After completion of HQP1351 lead-in, patients will receive HQP1351 PO qod on days 1-28 of subsequent cycles.~BC-CML:treated with decitabine 20mg/m2 d1-5 IV on days 1-5 and HQP1351 40mg qod every 28 days,with or without other chemotherapy Drugs"
75756688|NCT00432666|Drug|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
75756689|NCT00432666|Drug|Placebo|Placebo
75756690|NCT00451958|Drug|Degarelix 80 mg / Degarelix 80 mg|
75457547|NCT01786525|Behavioral|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
75457548|NCT01786538|Drug|Regorafenib/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
75457549|NCT01786538|Drug|Placebo/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
75457550|NCT01786577|Other|Magnetic Resonance Imaging|Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
75457551|NCT01786577|Behavioral|Cognitive assessment testing|Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
75756691|NCT00451958|Drug|Degarelix 160 mg / Degarelix 160 mg|
75756692|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 80 mg|
75756693|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 160 mg|
76025320|NCT04496609|Device|Automated rehabilitation / Stimulation and automated rehabilitation|Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
76072370|NCT00745134|Other|Pharmacological Study|Optional correlative studies
76072371|NCT00745134|Other|Placebo|Given PO
76072372|NCT00745134|Other|Quality-of-Life Assessment|Ancillary studies
76072373|NCT00745134|Radiation|Radiation Therapy|Undergo radiation therapy
75457552|NCT01786616|Drug|Formoterol|
75756694|NCT03775694|Device|dMRI Scan|Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.
75756695|NCT01023152|Procedure|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
75756696|NCT01025882|Drug|gemcitabine hydrochloride|Given IV
75756697|NCT01025882|Radiation|stereotactic body radiation therapy|Given as a single fraction
75756698|NCT01025960|Procedure|Standard Inspection Colonoscopy|The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
75756699|NCT01025960|Procedure|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
75756700|NCT01026116|Drug|Epirubicin|75 mg/m2 every-3-week for four cycles
75756701|NCT01026116|Drug|Cyclophosphamide|600 mg/m2 every-3-week for four cycles
75756702|NCT01026116|Drug|Paclitaxel|175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
75903181|NCT05853289|Other|Maternal Opioid use Disorder Management and Care Resources (MOM CARE) in Custody|MOM CARE is a web-based implementation resource designed for jail staff to help the staff provide evidence-based, trauma-informed and patient-centered care and support to pregnant people with opioid use disorder in and leaving custody. MOM CARE's content will include medical guidance and best-practices from intake to discharge, reentry steps and recommendations, and implementation 'how to' content. There will be specific content for jail administrators, medical and custody staff. Content will be curated from existing resources regarding this topic with new original tools specific to pregnant people with OUD in jail.
75903182|NCT05852860|Other|Clinician Nudge|"The clinician nudge will use the BPA functionality within the electronic medical record to deliver a message with a defaulted option to refer to the health system's tobacco treatment program. Changing the default to no referral will require an explanation using the options provided or by entering free text."
75903183|NCT05852860|Other|Patient Nudge|The patient nudge will deliver a message within 72 hours of a patient's next scheduled clinic visit. The message will be delivered through the Penn patient portal (MyPennMedicine) or by text with security measures for privacy.
75903184|NCT05849922|Drug|SAR442970|1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
75903185|NCT05849922|Drug|Placebo|1 mL extractable volume of placebo filled in 2 mL glass vial
75903186|NCT05846581|Device|GORE® ACUSEAL Vascular Graft|"The device placement will be performed according to each participating site's standard practice. No specific procedures are required by the protocol.~At the time of the GORE® ACUSEAL Vascular Grafts implantation, procedural and adverse event information will be collected."
75457553|NCT01786655|Drug|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
75457554|NCT01786655|Drug|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
75756703|NCT00432276|Drug|Alogliptin|Alogliptin tablets.
75756704|NCT00432276|Drug|Pioglitazone|Pioglitazone tablets.
75756705|NCT00432276|Drug|Metformin|Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
75756706|NCT00432276|Drug|Placebo|Matching placebo tablets.
75756707|NCT01022216|Device|Procellera™ Wound Dressing with V.A.C.® Therapy|Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
75756708|NCT01022216|Device|V.A.C.® Therapy|Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
75756709|NCT01022294|Drug|Nitrousoxide-oxygen and atmospheric air|Nitrousoxide-oxygen and atmospheric air
75756710|NCT01022294|Drug|Atmospheric air; nitrousoxide-oxygen|Atmospheric air; nitrousoxide-oxygen
75756711|NCT01027442|Device|Mucosa-supported single-type guides|Compute generated Mucosa-supported single-type guides
75756712|NCT01027442|Device|Bone-supported guides|Computer generated, Multiple type Bone-supported guides
75756713|NCT01027442|Device|Dental Implants|Dental implants placed via conventional free-hand method
75903187|NCT05840159|Drug|Doxycycline|Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.
75903188|NCT05840159|Other|Placebo|Placebo
75903189|NCT05838768|Drug|HRO761|Tablet
75903190|NCT05838768|Biological|tislelizumab|Concentrate for solution for infusion
75903191|NCT05838768|Drug|irinotecan|Concentrate for solution for infusion
75903192|NCT05836220|Drug|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
75903193|NCT05836220|Drug|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
75903194|NCT05836220|Drug|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
75903195|NCT05832931|Drug|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
75756714|NCT01027520|Other|application of coban dressing|application of a intraoperative coban dressing with reapplications following dressing removal.
75756715|NCT01023230|Drug|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
75756716|NCT01023230|Drug|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
75903196|NCT05832931|Drug|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
75903197|NCT05832931|Drug|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
75903198|NCT05827016|Drug|Iberdomide|Specified dose on specified days
75903199|NCT05827016|Drug|Lenalidomide|Specified dose on specified days
75903200|NCT05826990|Drug|cefepime and enmetazobactam combination|Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
75903201|NCT05822583|Drug|abatacept infusion|The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of >175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)
75903202|NCT05822583|Drug|Placebo group|Placebo group (IV infusion of normal saline) + baseline IM
75756717|NCT03993990|Behavioral|individual empowerment-based intervention|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
75756718|NCT01027676|Drug|Study treatment|Gefitinib 250mg/QD plus vorinostat D1~7 & D15-21 / QD q 4weeks
75756719|NCT01027832|Drug|Piperacillin/Tazobactam for 7 days|Piperacillin/Tazobactam for 7 days
75457555|NCT01786655|Drug|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
75457556|NCT01786655|Other|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
75457557|NCT01786681|Procedure|Positive pressure|
75457558|NCT01786694|Device|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
75457559|NCT01786733|Behavioral|Behavioral Activation|
75457560|NCT01786733|Behavioral|Supportive Therapy|
75457561|NCT01786746|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy. 12 sessions.
75756720|NCT00413010|Drug|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
75756721|NCT00413010|Drug|placebo|placebo + concurrent GAD treatment from the open-label study period
75756722|NCT00459290|Drug|mifepristone|
75756723|NCT00443534|Drug|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
75756724|NCT00419952|Drug|Budesonide/formoterol (SYMBICORT) pMDI|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
75756725|NCT00419952|Drug|Budesonide HFA pMDI|Budesonide HFA pMDI 160 ug x 2 actuations BID
75903203|NCT05821478|Drug|ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy|a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
75903204|NCT05821478|Drug|Lymecyclin and corresponding placebos of the experimental arm|12-week course of oral lymecycline.
75903205|NCT05820087|Device|HistoSonics Edison System|Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
75903206|NCT05817786|Device|electrical stimulation of the brachial plexus nerve roots|treated by chronic electrical stimulation of the brachial plexus nerve roots
75903207|NCT05817786|Other|sham stimulation|treated by sham stimulation
75903208|NCT05816395|Drug|RHH646|RHH646 capsule for oral use
75903209|NCT05816395|Drug|Placebo|RHH646 placebo capsule for oral use
75903210|NCT05809934|Drug|AZD2693|AZD2693 solution SC once per month
75903211|NCT05809934|Other|Placebo|Sodium chloride 0.9% solution SC once per month
75903212|NCT05800782|Behavioral|Face Memory Training|Computer-based training using faces targeting face memory
75903213|NCT05800782|Behavioral|Face Perception Training|Computer-based training using faces targeting improving face perception
75903214|NCT05800782|Behavioral|Placebo control training|Computer-based training using faces not targeting improving face perception or memory
75756726|NCT00443456|Drug|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
75756727|NCT00419562|Drug|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
75756728|NCT00419562|Drug|Placebo|Placebo capsule designed to match active drug
75609327|NCT02756143|Behavioral|Exercise|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
75756729|NCT03557294|Drug|1.0mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
75609328|NCT05657730|Dietary Supplement|Water Kefir beverage|Participants will consume the water kefir beverage for two weeks.
75609329|NCT02756299|Other|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
75903215|NCT05796492|Device|Pulsed splenic ultrasound|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to the spleen.
75609330|NCT02756299|Other|Standard Support|General information about OSA and PAP treatment at baseline
75609331|NCT05657574|Drug|D377|oral, once daily, 8 weeks
75903216|NCT05796492|Device|Ultrasound probe (no energy applied)|A General Electric LOGIQ E10 ultrasound probe will be placed over the spleen with no energy applied
75903217|NCT05787678|Biological|Dupilumab|600 mg (two 300 mg injections), followed by 300 mg monthly
75903218|NCT05781399|Drug|JNT-517 Suspension|JNT-517 in on-site compounded suspension
75903219|NCT05781399|Drug|Placebo Suspension|On-site compounded placebo suspension
75903220|NCT05781399|Drug|JNT-517 Tablet|JNT-517 tablets, 25 mg and 75 mg
75903221|NCT05781399|Drug|Placebo Tablet|Matching film-coated placebo tablet
75903222|NCT05781009|Drug|Pregnenolone|300mg
75903223|NCT05781009|Drug|Placebo|placebo
75903224|NCT05775380|Drug|Pioglitazone 45 mg|We investigated the role of pioglitazone hydrochloride 45mg/day for five days in patients admitted for coronary artery bypass grafting (CABG) in order to investigate vascular SPhk1 expression, vascular transcriptome and proteome remodeling, as well as S1P content in HDL
75609332|NCT05657574|Drug|CKD-331|oral, once daily, 8 weeks
75609333|NCT05657574|Drug|D086|oral, once daily, 8 weeks
75609334|NCT05657574|Drug|Placebo (for D377)|oral, once daily, 8 weeks
75609335|NCT05657574|Drug|Placebo (for CKD-331)|oral, once daily, 8 weeks
75609336|NCT05657574|Drug|Placebo (for D086)|oral, once daily, 8 weeks
75756730|NCT03557294|Drug|0.5mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
75756731|NCT03557294|Drug|0.0mg placebo Varenicline b.i.d.|Product that looks like active varenicline, but contains no active ingredient
75756732|NCT01026350|Dietary Supplement|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
75756733|NCT01026428|Drug|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
75756734|NCT01026428|Other|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
75903225|NCT05768854|Drug|Bisphosphonate|Administered per investigator discretion via intravenous (IV) infusion
75903226|NCT05768854|Biological|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
75903227|NCT05760313|Drug|Linaclotide|Capsule; oral
75903228|NCT05760313|Drug|Placebo|Capsule; oral
75903229|NCT05759377|Device|V-A ECMO AUTO Mode algorithm|"The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings (events) has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software."
75903230|NCT05755568|Other|No Intervention|As this is an observational study, no intervention will be administered.
75903231|NCT05752448|Behavioral|POSTCare Survivorship transition process|Survivorship coaching intervention
75756735|NCT00432042|Biological|ProQuad®|Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose [CCID]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units [PFU]).
75903232|NCT05751720|Drug|GIP/GLP-1a|The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
75609337|NCT02761447|Other|Treatment Traditional and Imaginary Motor Program|Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.
75903233|NCT05748405|Drug|Placebo|Matching Tablets
75609338|NCT02761447|Other|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
75903234|NCT05748405|Drug|AEF0217|Tablets of 100 mcg AEF0217
75903235|NCT05736705|Procedure|Endoscopic Submucosal Dissection|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the monopolar electrocautery knife.
75903236|NCT05736705|Device|Bipolar electrocautery knife|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the bipolar electrocautery knife.
75903237|NCT05735015|Drug|encaleret|Oral administration, twice a day
75903238|NCT05731713|Behavioral|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
75903239|NCT05727657|Drug|Satralizumab|120mg subcutaneous Day 0 and Day 14
75903240|NCT05725668|Behavioral|dual-task tai ji quan|dual-task tai ji quan training
75903241|NCT05725668|Behavioral|standard tai ji quan|standard tai ji quan training
75903242|NCT05725668|Behavioral|stretching|stretching exercise
75609339|NCT00061282|Drug|Clotrimazole|One retention enema, administered nightly
75903243|NCT05723653|Behavioral|Project nGage|"Project nGage (nGage) is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black sexual minority men. The nGage intervention consists of (1) selection and invitation of a Support Confidant (SC), (2) a face-to-face intervention between the Intervention Case Manager and the Index and SC, and (3) quarterly interactive mini-booster sessions delivered to the Index and SC via text or telephone, based on participant preference."
75903244|NCT05717140|Biological|Aerosol Sargramostim|Given via inhalation with nebulizer
75609340|NCT02756065|Other|no intervention|no intervention is used
75756736|NCT00432042|Biological|Infanrix® hexa|Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
75903245|NCT05717140|Procedure|Biospecimen Collection|Undergo collection of blood samples
75903246|NCT05717140|Procedure|Computed Tomography|Undergo CT
75903247|NCT05717140|Procedure|Magnetic Resonance Imaging|Undergo MRI
75903248|NCT05717140|Other|Medical Device Usage and Evaluation|Use Aerogen Solo nebulization device
75903249|NCT05717140|Biological|Nivolumab|Given IV
75903250|NCT05714202|Drug|TAR-200|TAR-200 will be administered intravesically.
75903251|NCT05714202|Biological|Cetrelimab|Cetrelimab will be administered.
75609341|NCT04268524|Combination Product|drug: miltefosine with thermotherapy|see previous
75609342|NCT05657418|Drug|JS107|JS107, i.v., q3w
75609343|NCT05657418|Combination Product|JS107 combination with Toripalimab|JS107 i.v., q3w combine with Toripalimab
75903252|NCT05714202|Biological|BCG Vesiculture|BCG will be administered intravesically.
75903253|NCT05714059|Device|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
75903254|NCT05713955|Device|Obsidian|To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
75903255|NCT05712889|Drug|VIP236|VIP236 will be administered by IV infusion once every 3 weeks.
75903256|NCT05707377|Drug|Zanubrutinib|Participants will receive zanubrutinib once daily
75903257|NCT05707377|Drug|Tacrolimus|Participants will receive tacrolimus twice daily
75903258|NCT05707377|Drug|Zanubrutinib|Participants will receive zanubrutinib twice daily
75756737|NCT00308139|Drug|exenatide, long acting release|
75609344|NCT02695693|Behavioral|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
75756738|NCT00308139|Drug|exenatide|
75756739|NCT00459134|Dietary Supplement|ArginMax|Given orally
75756740|NCT00459134|Dietary Supplement|Placebo|Given orally
75756741|NCT00459056|Drug|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
75756742|NCT00459056|Drug|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
75756743|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
75903259|NCT05703477|Procedure|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
75903260|NCT05702437|Other|assessment of cognitive performance|evaluation of the cognitive and physical performance of the participants by two separate researchers at the same time
75609345|NCT02695693|Behavioral|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
75609346|NCT02695693|Behavioral|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
75609347|NCT02695693|Behavioral|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
75609348|NCT02855632|Drug|G-CSF|7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
75756744|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
75756745|NCT01062477|Biological|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
75756746|NCT01026506|Dietary Supplement|conjugated linoleic acid|3 g/d of an esterified CLA preparation free of t10,c12-CLA (75% c9,t11-CLA, 87% purity) or placebo oil mixed in yoghurt for 12 weeks
75756747|NCT01323374|Drug|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
75756748|NCT01323374|Drug|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
75903261|NCT05695898|Drug|XmAb22841|Given intravenously (IV)
75903262|NCT05695898|Drug|XmAb23104|Given intravenously (IV)
75903263|NCT05694650|Behavioral|Focus Group|Participants can meet with an interviewer alone. The focus group should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
75903264|NCT05694650|Behavioral|Interview|Participants can meet with an interviewer alone. The interview should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
75903265|NCT05689840|Procedure|Receiving inpatient surgical intervention|Receiving inpatient surgical intervention in Peking Union Medical College Hospital
75756749|NCT01323374|Drug|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
75756750|NCT01323374|Drug|Placebo|Oral, placebo TID
75756751|NCT00431964|Drug|azithromycin 250 mg tablets|"One (1) tablet three times weekly for patients who weigh 40-79 lbs~Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
75756752|NCT00431964|Drug|placebo tablets|"One (1) tablet three times weekly for patients who weigh 40-79 lbs~Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
75756753|NCT03531476|Behavioral|Online Chronic Pain Management Program|With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program. The study therapist is a registered health professional. The program will consist of 5 weeks of mindfulness training. The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
75903266|NCT05689736|Behavioral|Motivational Enhancement|"Motivational Enhancements (ME) will include three features:~Personalized change plan. Parents will describe their intervention goals, motivation for participation, steps they are willing to take to meet those goals, as well as potential barriers to engagement and strategies to try to overcome such barriers. We will display the change plan to remind parents of their personalized responses. ME will also integrate participants' change plan responses into intervention content.~Assessment feedback. We will provide norm-referenced feedback for each selected parenting measure after the week 1 assessment. For simplicity, feedback will graphically categorize the parent or child in 3 categories per outcome: red (≥90th %ile), yellow (70-89th %ile), and green (<70th %ile).~Modified, personalized SMS text nudges. Parents will receive 2 weekly personalized SMS messages based on their change plan responses."
75903267|NCT05689736|Behavioral|Simplification|We will follow recommendations of research on improving the readability of patient-directed text (e.g., fewer, shorter, less complex words, minimizing colons, semicolons, and decimal points). We will employ the Dale-Chall Readability (DCRI) score, which was developed for health education materials and, compared to other readability metrics, has higher correlations with comprehension. The target DCR score is 7 (8th grade reading level). We will avoid lower DCR scores because moderate levels of complexity enhance, attention, absorption, satisfaction, and ultimately engagement.
75609349|NCT02855632|Drug|Normal saline|7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
75609350|NCT02855632|Drug|hormone therapy|In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
75609351|NCT02855632|Other|Cook balloon|At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
75609352|NCT05657340|Diagnostic Test|Video-head impulse testing|Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.
75609353|NCT02761213|Drug|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
75609354|NCT02761213|Drug|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
75609355|NCT02852746|Behavioral|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
75609356|NCT05657262|Other|Pre-post test|Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
75609357|NCT00635635|Behavioral|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
75609358|NCT00635635|Behavioral|Music Audio|Music only audio to be listened to 5x per week
75609359|NCT02852668|Other|Power Training|This experimental groups underwent an intervention period of power training
75609360|NCT02852668|Other|Strength Training|This experimental groups underwent an intervention period of strength training
75609361|NCT04220281|Drug|Propofol|propofol infusion during surgery
75609362|NCT04220281|Drug|Nitroglycerin|nitroglycerin infusion during surgery
75756754|NCT01322906|Other|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
75756755|NCT01322906|Other|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
75756756|NCT01322906|Other|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
75756757|NCT01028066|Other|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
75609363|NCT02852512|Procedure|sacrocolpopexy|Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
75609364|NCT02751619|Drug|Lidocaine patch 5%|Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
75609365|NCT02751619|Drug|Placebo patch|A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
75609366|NCT04316988|Diagnostic Test|Ultrasonography|A real time 2D ultrasound evaluation was done over the trachea of the patient.
75609367|NCT02751541|Drug|Sunscreen Sport Spray (BAY987519)|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
75756758|NCT01028066|Behavioral|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
75756759|NCT00412854|Biological|Infanrix™/Hib|
75756760|NCT00412854|Biological|Infanrix|
75756761|NCT00412854|Biological|Hiberix|
75457562|NCT01786746|Behavioral|culturally adapted cognitive behavioral therapy|culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
75457563|NCT01786759|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
75609368|NCT02751541|Other|Untreated Skin|This site is patched without treatment as irradiated control.
75609369|NCT02755753|Drug|Lansoprazole|Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
75457564|NCT01786759|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
75457565|NCT01786772|Other|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
75609370|NCT02755753|Drug|Rebamipide|Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
75609371|NCT02755753|Drug|Rebamipide-placebo|Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
75609372|NCT02755987|Drug|ANG1005|
75609373|NCT01188564|Drug|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
75609374|NCT01188564|Drug|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
75756762|NCT00431496|Drug|Cinacalcet|Cinacalcet tablets
75609375|NCT02755909|Behavioral|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
75609376|NCT04222777|Diagnostic Test|Cinematographic Recording|A cinematographic recording during the second half of extension of the cervical spine will be made during 16 seconds at two timepoints with an interval of two weeks.
75756763|NCT00316173|Drug|topotecan|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
75756764|NCT00316173|Drug|CARBOPLATIN|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
75756765|NCT00412542|Drug|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
75756766|NCT00412542|Drug|CPT-11|125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
75756767|NCT00412542|Procedure|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
75756768|NCT00412542|Procedure|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
75756769|NCT00316017|Drug|7.5% hypertonic saline/6% Dextran-70 (HSD)|250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
75756770|NCT00316017|Drug|7.5% hypertonic saline (HS)|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
75609377|NCT04316598|Drug|Cannabis Sativa|"Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol <1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC."
75756771|NCT00316017|Drug|0.9% normal saline|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
75756772|NCT00451178|Drug|enzastaurin|1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years
75756773|NCT00451178|Drug|rituximab|375 milligrams per square meter (mg/m^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
75756774|NCT00451178|Drug|cyclophosphamide|750 mg/m^2, IV, Day 1 every 21 days, six 21-day cycles
75756775|NCT00451178|Drug|doxorubicin|50 mg/m^2, IV, Day 1 every 21 days, six 21-day cycles
75609378|NCT04316598|Drug|Cannabis placebo|"Subjects will receive a total of 4 inhaled doses of cannabis placebo (THC <0,2%) in 3 days.~Placebo cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing cannabinoids <0.2%. To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of cannabis placebo."
75756776|NCT00451178|Drug|vincristine|1.4 mg/m^2, IV, Day 1 every 21 days, six 21-day cycles
75756777|NCT00451178|Drug|prednisone|100 mg, oral, Days 1-5, six 21-day cycles
75756778|NCT00450866|Biological|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
75903268|NCT05689736|Behavioral|Gamification|"Gamification will include four features:~Game-like graphical environment (e.g., avatars to represent the participant).~Digital rewards. Parents will receive points and badges for completing intervention activities.~Leaderboard. A leaderboard will be used to activate competitive motives and social referencing. The leaderboard will display the points/badges of the participant relative to 4 other actual or simulated anonymized parents who are at a similar point in the intervention; their number of points and badges will be determined by those of the participant.~Modified, personalized SMS text nudges. SMS text nudges will alternate between Core content (e.g., reminder to complete a module) and reminders about game features such as badges and standings."
76068411|NCT00331162|Drug|Anti-Thymocyte Globulin|"1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr < 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature > 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours"
75756779|NCT01322984|Behavioral|Pictures|The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.
75756780|NCT01322984|Behavioral|Startle eliciting noise|Startle will be elicited by 95 dB noise, presented at different times after picture onset.
75756781|NCT01026584|Drug|Aripiprazole|6 week prospective study
75756782|NCT01023386|Drug|YM155|I.V.
75756783|NCT01026662|Procedure|Ablation and skin resurfacing|Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
75756784|NCT01026662|Device|eMatrixCO2|
75756785|NCT01028456|Other|Light Therapy|10,000 lux / 30 minutes a day
75756786|NCT01028456|Other|100 lux|Placebo light
75457566|NCT01786772|Other|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
75756787|NCT01023464|Other|FID114657|artificial tears
75756788|NCT01023464|Other|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
75903269|NCT05689736|Behavioral|Low Engagement Nudges|SMS text nudges will be sent to participants who have fallen behind in completing specific intervention tasks within a given time window; e.g., failing to log-in to the next module by a predetermined date, timed to program enrollment or in a prespecified number of days since completing the previous module.
75756789|NCT01023542|Drug|delayed, low-dose CNI|immunosuppression
75756790|NCT01023542|Drug|BU-CNI|Immunosuppression
75756791|NCT01023542|Drug|BU-Everolimus|Immunosuppression
75756792|NCT01026740|Drug|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
75756793|NCT03848312|Behavioral|Cognitive Training|Participants will be completing a total of 45 computerized sessions.
76068412|NCT01790230|Device|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
76068413|NCT01790308|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
75756794|NCT03848312|Behavioral|Computerized Cognitive Stimulation|Participants will be completing a total of 45 computerized cognitive stimulation sessions.
75756795|NCT01028534|Drug|Olmesartan and Azelnidipine|"Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
75903270|NCT05689736|Behavioral|Essentials for Parenting Toddlers and Pre-schoolers (EFP)|"All parents will receive the Core intervention content, including text, demonstrations (videos and vignettes), and interactive activities (e.g., skill-building), and comprising five modules: Communicating with Your Child; (2) Giving Directions; (3) Creating Structure; (4) Using Discipline and Consequences; and (5) Using Time-out. The Core intervention will be augmented with more prescriptive behavioral skills practice exercises and SMS text nudges to remind participants to complete intervention modules.~All conditions will be housed on Westat servers accessible through any device that can use the Internet, including computers, tablets, and smartphones. Westat has extensive technical capacities for web programming/hosting."
75903271|NCT05685004|Biological|TVI-Brain-1|Attenuated autologous cancer cells and activated autologous blood-derived t cells
75903272|NCT05685004|Procedure|Standard of Care|Surgery for tumor removal or debulking to minimize tumor burden
75903273|NCT05685004|Radiation|Radiotherapy|Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.
75903274|NCT05685004|Drug|Temozolomide|All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .
76068414|NCT01790308|Drug|Liraglutide|CSII for 2~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
76068415|NCT01609010|Drug|rituximab|375 mg/m2 rituximab i.v. weekly for 4 weeks
76068416|NCT01609010|Drug|interferon-a-2a|3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
76068417|NCT01608308|Drug|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
76068418|NCT01608308|Drug|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
75609379|NCT02761369|Device|A multi-channel deep TMS device with an H-coil (Brainsway Ltd)|A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
76068419|NCT00332644|Drug|nicotine patch|used according to FDA package label
75457567|NCT01786798|Device|Transvaginal sonography|"Transvaginal sonography will be performed to:~measure the endometrial thickness~detect the endometrial pattern"
75609380|NCT02761291|Drug|Gemcitabine|Gemcitabine will be administrated 600~1250 mg/m^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m^2. If no subject suffered the dose limit toxicity, 1000 mg/m^2 and even 1250 mg/m^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m^2, the 600 mg/m^2 will be started.
75609381|NCT02761291|Drug|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
76068420|NCT00332644|Drug|nicotine lozenge|used according to FDA-approved package directions
76068421|NCT00332644|Drug|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
75756796|NCT03995342|Dietary Supplement|Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
75756797|NCT03995342|Dietary Supplement|Maltodextrin|Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution
75756798|NCT01023698|Procedure|laser photocoagulation|Laser photocoagulation
75756799|NCT00442598|Drug|Glufosfamide|
75756800|NCT01028612|Radiation|thermal ablation with external beam radiation|thermal ablation with external beam radiation
76068422|NCT00332644|Drug|bupropion|dosage according to FDA-approved instructions
76068423|NCT00332644|Drug|bupropion + lozenge|dosage according to FDA approved standard instructions
76068424|NCT00332644|Drug|placebo|dosage same as active drug conditions
76068425|NCT01755416|Drug|Closed loop with sensor and Insulin|Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
76068426|NCT01755416|Drug|Closed loop with sensor, Insulin and Liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
76068427|NCT01755026|Drug|cefazolin|2 gram dose for pre-operative prophylaxis
76068428|NCT01755026|Drug|cefazolin|4 gram dose for pre-operative prophylaxis
76068429|NCT00332722|Procedure|Cervical facet joint nerve blocks|
76068430|NCT01491945|Device|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
76068431|NCT00333814|Drug|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
76068432|NCT00333814|Drug|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
75457568|NCT01786811|Behavioral|Training|"Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.~Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person."
75457569|NCT01786824|Drug|Hydration strategy using saline|For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
75609382|NCT02761291|Drug|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and < 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
75609383|NCT01187550|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit [IU]/kg body weight) per day by subcutaneous injection.
75609384|NCT02755363|Other|osteopathic manual therapy|"suboccipital decompression - atlanto-occipital joint relaxation technique.~deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
76068433|NCT00333814|Drug|Sham injection|Sham injection at Day 0
76068434|NCT01728584|Drug|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
75756801|NCT00442286|Device|Rheos® Baroreflex Hypertension System|Electrical activation of the Carotid Baroreflex
75756802|NCT00441974|Drug|adefovir dipivoxil|adefovir dipivoxil once daily one tablet 10mg orally
75756803|NCT01023854|Procedure|Continuous Paravertebral block|"The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.~Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space."
76068435|NCT01728584|Other|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~Low insufflation pressure - a starting pressure of 8 mmHg will be used."
76068436|NCT01728584|Drug|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
76068437|NCT00315328|Drug|Atropine|Atropine 1% each weekend day in the sound eye
76068438|NCT00315328|Device|Patching|Patching 2 hours per day
76068439|NCT00315328|Procedure|Near activities|near visual activities for at least one hour per day
76068440|NCT05265988|Drug|Cabozantinib|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
76068441|NCT04345822|Procedure|Decompression surgery|The surgeries aim to relieve the myelopathy from cord compression
76068442|NCT01522443|Drug|cabozantinib|Tablets taken orally once daily.
76068443|NCT01522443|Drug|mitoxantrone|Given by IV once every 3 weeks.
75756804|NCT00441584|Biological|PegIntron (peginterferon alfa-2b)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
75609385|NCT02755363|Other|control group|"manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
75609386|NCT00602368|Other|histological technique|
75756805|NCT00441584|Drug|Rebetol (ribavirin)|200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
75756806|NCT03368534|Device|Autologous Regenerative Technology (ART)|ART device with single-needle, fluid-assisted skin tissue harvesting technology.
75756807|NCT01028690|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
75756808|NCT01028690|Dietary Supplement|Placebo|placebo
75756809|NCT00430716|Drug|Sildenafil citrate|oral, 20 mg, tid
76068444|NCT01522443|Drug|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
75457570|NCT01786824|Drug|Hydration strategy using sodium bicarbonate|For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.
75609387|NCT00602368|Other|laboratory biomarker analysis|
75457571|NCT01786824|Drug|L-carnitine|"Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed."
75756810|NCT00430716|Drug|Sildenafil citrate|oral 1 mg, tid
75457572|NCT01786824|Procedure|Coronarography|All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
75457573|NCT01786837|Device|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
75609388|NCT00602368|Procedure|colposcopic biopsy|
75609389|NCT00602368|Procedure|colposcopy|
75756811|NCT00430716|Drug|Sildenafil citrate|oral 5 mg, tid
76068445|NCT00334204|Device|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
76068446|NCT00336700|Drug|Gemcitabine|1500mg/m2 IV over 150 min IV q 2 weeks 4 months
76068447|NCT00336700|Drug|Erlotinib|150 mg/d Daily, oral 12 months
76068448|NCT01468233|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
76068449|NCT01468233|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
76068450|NCT01468077|Drug|Tocilizumab|8 mg/kg infusion
75609390|NCT00602368|Procedure|light-scattering spectroscopy|
75609391|NCT00602368|Procedure|loop electrosurgical excision procedure|
75609392|NCT00602212|Behavioral|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
76068451|NCT01522365|Device|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
75609393|NCT00602212|Behavioral|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
75609394|NCT02755675|Other|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
75756812|NCT00430716|Drug|Sildenafil citrate|oral 20 mg, tid
75756813|NCT01023932|Device|Cochlear Implants|
75756814|NCT01028768|Drug|Teduglutide|10 mg, one-time subcutaneous
76068452|NCT01522365|Device|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
75609395|NCT02855866|Procedure|thyroidectomy|
75609396|NCT02855866|Other|cryotherapy|
75756815|NCT02648256|Other|Polymerase Chain Reaction on Oropharyngeal rinse|
75756816|NCT00441272|Drug|Pioglitazone|
75756817|NCT01038726|Other|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
75756818|NCT01038726|Other|Cognitive Training|Based on cognitive training program Brain Fitness®
75756819|NCT01038726|Other|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
75756820|NCT01038726|Other|Educational Sessions|DVD-based educational programs on history, art, and literature
75756821|NCT01566552|Drug|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
76068453|NCT03026673|Other|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
75756822|NCT01028924|Drug|Teduglutide|subcutaneous (SC), single dose
75756823|NCT00430638|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
75756824|NCT00430638|Drug|Placebo|Oral tablets administered for once daily for 12 weeks
75756825|NCT01029080|Other|no interventions|No interventions
75756826|NCT01566110|Dietary Supplement|Gluten Free Diet|Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
75756827|NCT03671330|Drug|Ribociclib Placebo|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
75756828|NCT03671330|Drug|Ribociclib|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
75756829|NCT03671330|Drug|NSAI: Letrozole or Anastrazole|"Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole."
75756830|NCT03671330|Drug|Letrozole|Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
75756831|NCT03671330|Drug|Goserelin|Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
75903275|NCT05684094|Behavioral|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
76068454|NCT01754402|Drug|Bendamustine|Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
76068455|NCT01754402|Drug|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
75609397|NCT02855866|Drug|cortisone aerosol|
75609398|NCT02855866|Drug|Dexamethasone acetate|
75609399|NCT02855866|Drug|paracetamol|
75609400|NCT02751463|Drug|Sunscreening Sport Spray Rest (BAY987519)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
76068456|NCT01754402|Drug|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
75457574|NCT01786850|Procedure|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
75756832|NCT01038882|Drug|Midazolam|Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of >2 min to maintain conscious sedation
75903276|NCT05684094|Behavioral|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
75903277|NCT05681481|Biological|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
75903278|NCT05681481|Drug|Prednisone|Oral Prednisone
76068457|NCT01783418|Behavioral|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
75609401|NCT02751463|Other|Untreated skin|One site is patched without treatment as control
75609402|NCT04316520|Dietary Supplement|Ketogenic diet|Ketogenic diet 2:1
76068458|NCT01521897|Biological|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
75609403|NCT02751307|Drug|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
75609404|NCT02751307|Drug|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
75609405|NCT05356494|Other|Postural drainage|(Group A will be treated with postural drainage)
75609406|NCT05356494|Other|Positive expiratory pressure|(Group B will be treated with positive expiratory pressure technique).
75756833|NCT01038882|Other|Physiological serum|We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
75756834|NCT00430482|Behavioral|Cognitive Behavioral Therapy|12 weekly sessions and 3 booster sessions of cognitive behavioral therapy
75756835|NCT00430482|Behavioral|Individual Counseling|12 weekly sessions and 3 booster sessions of individual counseling
75457575|NCT01786863|Procedure|Neuromuscular blockade|
75457576|NCT01786889|Biological|blood and urine|Blood collection and urine collection after consent of the patient
75457577|NCT01786889|Behavioral|Questionnaire|The patient complete the questionnaire alone at home
75457578|NCT01786889|Behavioral|Telephone interview|The patient will be contacted by the CRA for a telephone interview of around one hour
75457579|NCT01786915|Drug|Bendavia 10mg|
75457580|NCT01786915|Drug|Bendavia 50mg|
75609407|NCT04220359|Device|non-invasive monitoring|Prospective monitoring with retrospective big-data analysis
75609408|NCT00638209|Drug|Human insulin|
75609409|NCT00638209|Drug|Saline|
75609410|NCT02760745|Other|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
75609411|NCT04220047|Procedure|Left Atrial Appendage Resection and Marshall Ligament Amputation|Left Atrial Appendage Resection and Marshall Ligament Amputation during the cardiac surgery
75609412|NCT05429749|Drug|Ferinject|Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
75756836|NCT00449930|Drug|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
75756837|NCT00449930|Drug|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
75756838|NCT01033110|Behavioral|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
75756839|NCT01034982|Drug|AZD9668|20 mg
75756840|NCT01034982|Drug|AZD9668|60 mg
75756841|NCT01038960|Behavioral|Exercise training|3 months supervised interval training
76068459|NCT01782872|Procedure|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous (IV): saline
75457581|NCT01786915|Drug|Placebo|
75457582|NCT01786928|Other|Resistance training|Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
75756842|NCT01039038|Radiation|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
75903280|NCT05679011|Other|4 and 6 meters walking test|A 10-meter and other 6-meter flats pathways were identified. Two-meter are provided for the acceleration zone and two-meter for deceleration for 6-meter walk test. One meter to acceleration and another to deceleration for 4-meter walk test. The participants are randomly to perform 3-time to comfortable speed and 3-time faster speed for 4-meter and 6-meter.
75903281|NCT05678673|Drug|XL092|Specified doses on specified days
75903282|NCT05678673|Drug|Nivolumab|Specified doses on specified days
75903283|NCT05678673|Drug|Sunitinib Malate|Specified doses on specified days
75903284|NCT05677711|Device|ultimaster|Subjects who received Ultimaster stent will be included.
75756843|NCT00449696|Device|Gel-200|Single intra-articular injection
75756844|NCT00449696|Device|Placebo|Single intra-articular injection
75756845|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.
75756846|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 4 questionnaires about symptoms their overall health of patients, 30 minutes to complete. Review session about use of computer system and suggested changes.
75903285|NCT05675631|Other|Suspension training|This group will perform training using suspension devices.
75903286|NCT05675631|Other|Strength training|This group will perform training using weights and elastic bands.
75903287|NCT05673187|Drug|Adagrasib|Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
75903288|NCT05668403|Drug|B007|Drug: B007 injection Drug: Placebo injection
75903289|NCT05668403|Drug|B007|Drug: B007 injection Drug: Placebo injection
76068460|NCT01782872|Procedure|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
75457583|NCT01786941|Other|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
75609413|NCT05429749|Drug|Normal saline|Normal saline 250ml is administered between the admission day and the surgery day.
75609414|NCT05429671|Procedure|total knee arthroplasty|Participants will have total knee arthroplasty
75609415|NCT05429671|Drug|Tobramycin|Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
75609416|NCT05429671|Drug|Gentamicin|Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
75609417|NCT05429671|Device|Antibiotic cement spacer|participants getting an antibiotic-loaded cement spacer during surgery comprised of vancomycin and tobramycin.
75609418|NCT02754973|Behavioral|an integrated experiential training program with coaching|The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability.
75609419|NCT02754973|Behavioral|Placebo Control|When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The placebo activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet which will be conducted for 30 minutes.The participants will also receive a 30-minute English tutorial session with the research assistants in each home visit.
75756847|NCT01566188|Dietary Supplement|omega-3 from vegetal origin|6 months of supplementation with omega-3 from vegetal origin
75457584|NCT01786941|Other|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
75457585|NCT01787019|Other|Oral feeding|
75457586|NCT01787045|Other|Early and Active Physical Therapy|"Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc."
75756848|NCT01566188|Dietary Supplement|Placebo|6 months of supplementation with placebo
75756849|NCT01029158|Drug|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
75756850|NCT01029158|Drug|RN1006 (Avotermin)|250 ng, intradermal injection, twice
75756851|NCT01029158|Drug|RN1006 (Avotermin)|205 ng, Intradermal injection, once
75756852|NCT01029158|Drug|RN1006 (Avotermin)|500ng, intradermal injection, once
75756853|NCT01029158|Drug|Juvista (Avotermin)|250 ng, intradermal injection, twice
75903290|NCT05668403|Drug|B007|Drug: B007 injection Drug: Placebo injection
75756854|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
75756855|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
75756856|NCT01029158|Drug|RN1006 (Avotermin)|500 ng, intradermal injection, twice
75756857|NCT01029158|Drug|Placebo|Placebo
75756858|NCT00441116|Drug|Dutasteride 0.5mg oral tablets|Dutasteride
75756859|NCT01029236|Other|Medifast Metabolism-boosting Beverages|Medifast metabolism-boosting beverages containing 90 mg EGCG and 100 mg caffeine.
75756860|NCT01024322|Drug|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
75903291|NCT05668312|Other|Tele-prehabilitation|Preoperative tele-rehabilitation using a virtual reality system.
75903292|NCT05668312|Other|Standard prehabilitation|Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
76068461|NCT01782872|Procedure|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
76068462|NCT01782872|Procedure|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
76068463|NCT01490697|Drug|Mifepristone|1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.
75903293|NCT05666622|Other|Only routine non-surgical periodontal treatment was applied to the patients.|The study included 70 systemically healthy individuals, as a test group of 35 patients with Stage 3, Grade A periodontitis and a control group of 35 individuals with no periodontal disease. Blood samples were taken for the examination of DNI, white blood cells (WBC), immature granulocytes (IG), procalcitonin, C-reactive protein (CRP), lymphocyte count and neutrophil count. For the patients with periodontitis, blood sample assays were repeated 3 months after non-surgical periodontal treatment
75903294|NCT05664113|Drug|Fecal microbiota transplant (FMT)|FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
75609420|NCT04222621|Other|Pregnant women without intervention|Pregnant women with those exposures of interest determined in specific research based on the registry
75903295|NCT05663710|Drug|177Lu girentuximab|Given by IV (vein)
75903296|NCT05663710|Drug|Nivolumab|Given by IV (vein)
75903297|NCT05663710|Drug|Cabozantinib|Given by PO
75903298|NCT05663710|Drug|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV (vein)
75903299|NCT05657106|Behavioral|Harm reduction kiosk|The intervention involves enhancing an existing staffed harm reduction program (syringe service program) located in a local health department with a Kentucky Outreach Service Kiosk (KyOSK).
75903300|NCT05653778|Device|Scrambler therapy|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
75903301|NCT05653778|Device|TENS treatment|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
76068464|NCT01490697|Drug|d-Cycloserine|100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.
76068465|NCT01490697|Drug|Placebo-matching Mifepristone|Placebo-matching mifepristone tablets
76068466|NCT01490697|Drug|Placebo-matching d-Cycloserine (DCS)|Placebo-matching DCS capsules
76068467|NCT01728194|Drug|Escitalopram|20 mg target dose for 12 weeks
76068468|NCT01728194|Other|Magnetic Resonance Imaging|Structural and functional MRI of the brain for research purposes.
76068469|NCT04408911|Drug|Midazolam vs. Lormetazepam|In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
76068470|NCT01782482|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
76068471|NCT01782482|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
75609421|NCT01186770|Drug|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
75609422|NCT01186770|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
75609423|NCT02754817|Drug|insulin degludec/liraglutide|This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
76068472|NCT01466673|Drug|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
75609424|NCT02755051|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:~Sleep education~Sleep scheduling, limit setting, and stimulus control~Teaching relaxation strategies and other adaptive coping skills~Parenting strategies (differential attention, rewards, consequences)~Identification of maladaptive & adaptive cognitions~Problem solving & communication skills~Sleep restriction; bright light to change circadian rhythms~Review gains and plan for long-term maintenance"
75609425|NCT05429515|Procedure|HFR-SUPRA|HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.
75903302|NCT05650554|Biological|Quadrivalent Influenza mRNA Vaccine MRT5413|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
75903303|NCT05650554|Biological|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
75903304|NCT05650554|Biological|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
75903305|NCT05650554|Biological|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
75903306|NCT05650437|Device|Ultraviolet Radiation|The therapist cut three holes, each measuring 2 by 2 cm, into a piece of cardboard that was about 4 by 20 cm in size.The first hole was exposed for 90 seconds, the second for 60 seconds, and the third for 30 seconds
76068473|NCT01466673|Drug|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
76068474|NCT01753856|Drug|Teriparatide|Administered SC
76068475|NCT01753856|Drug|Denosumab|Administered SC
76068476|NCT01753856|Drug|Demeclocycline|Administered orally
76068477|NCT01753856|Drug|Tetracycline|Administered orally
76068478|NCT01753856|Drug|Calcium Supplement|Administered orally
76068479|NCT01753856|Drug|Vitamin D|Administered orally
76068480|NCT01464255|Device|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
76068481|NCT01464255|Device|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
76068482|NCT04559204|Biological|IIV4 and PPV23|imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
76068483|NCT04559204|Biological|IIV4|administrated with IIV4 only
76068484|NCT04559204|Biological|PPV23|administrated with PPV23 only
75756861|NCT01024322|Drug|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
75756862|NCT01024322|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
75903307|NCT05650437|Behavioral|Aerobic exercise|The postmenopausal women in groups (A and B) exercised on the treadmill; women should always warm up before beginning exercise and stop if they experience pain or shortness of breath. Each session lasted 30 minutes and included 5 minutes of warming up and 20 minutes of walking at 60% of their maximum heart rate (MHR). The maximum heart rate that the circulatory system can support during physical exercise is MHR=220. Three sessions a week for three months, followed by a five-minute cool-down
75903308|NCT05650437|Dietary Supplement|Vitamin D supplementation|Throughout three months, vitamin D supplements (800 IU) will be given to all postmenopausal women in both groups (A&B)
75609426|NCT05429515|Procedure|hemodialysis|hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.
75609427|NCT05429515|Drug|Chemotherapy|chemotherapy protocol will be made by hematologists.
75609428|NCT01186692|Device|Melody® Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
75903309|NCT05644418|Device|Flow Controlled Ventilation (FCV)|FCV is started with the same settings as PCV (PEEP, Ppeak, FiO2) and after 30 minutes FCV is optimized concerning the driving pressure and PEEP using the dynamic compliance. After a total of 60 minutes the flow is adjusted based on the arterial blood gas.
75457587|NCT01787045|Other|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
75457588|NCT01787058|Other|Dubai Cares beneficiary|Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
75756863|NCT03320642|Drug|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
75756864|NCT03320642|Drug|Calcineurin inhibitor|The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
75756865|NCT01566266|Drug|Amoxicillin|2 capsules of 250mg, 3 times per day during 1 week
75756866|NCT01566266|Drug|Placebo capsule|2 capsules of 250mg, 3 times per day during 1 week
75756867|NCT01024400|Biological|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
75903310|NCT05643560|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice.
75903311|NCT05643118|Genetic|OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)|Clear colorless solution dissolved in 1X PBS and injected intravitreally
75903312|NCT05635708|Drug|Tislelizumab|Administered by intravenous infusion
75903313|NCT05635708|Drug|BGB-A445|Administered by intravenous infusion
76068485|NCT01753310|Biological|Botulinum toxin type A|Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
75457589|NCT01787071|Other|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
75457590|NCT01787084|Device|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
75457591|NCT01787110|Drug|Oxygen|see arm description
75457592|NCT01787123|Drug|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
75457593|NCT01787123|Drug|Normal Saline|14-day course of intravenous normal saline started within 4 days of ictus
75457594|NCT01787136|Drug|Dextromethorphan|added on therapy
75609429|NCT04230031|Drug|Daratumumab|Experimental
75609430|NCT01186458|Drug|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
75609431|NCT01186458|Drug|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
75609432|NCT01186458|Drug|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
75756868|NCT00430248|Drug|Febuxostat|Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
75756869|NCT00430248|Drug|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
75609433|NCT01185834|Device|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
75457595|NCT01787149|Drug|DMARDs|
75457596|NCT01787162|Other|Echocardiography, spiroergometry, cardiac catheterization|patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
75457597|NCT01787214|Dietary Supplement|Full dose|20% of daily energy needs supplied by walnuts
75457598|NCT01787214|Dietary Supplement|Half dose|10% of daily energy needs supplied by walnuts
75756870|NCT00430248|Drug|Allopurinol|"Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.~Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily."
75756871|NCT00449540|Device|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
75756872|NCT00449540|Device|Sham TMS Device|Simulated Sham treatment without TMS delivery
75756873|NCT01029470|Drug|Luveris|Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
75903314|NCT05635708|Drug|LBL-007|Administered by intravenous infusion
75903315|NCT05635708|Drug|Carboplatin|Investigator's choice; administered by intravenous infusion
75903316|NCT05635708|Drug|Cisplatin|Investigator's choice; administered by intravenous infusion
75903317|NCT05635708|Drug|pemetrexed|Investigator's choice; administered by intravenous infusion
75903318|NCT05635708|Drug|Paclitaxel|Investigator's choice; administered by intravenous infusion
75756874|NCT00411762|Drug|Capecitabine|
75903319|NCT05635708|Drug|Nab paclitaxel|Investigator's choice; administered by intravenous infusion
75609434|NCT01185600|Biological|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
75756875|NCT00411762|Drug|PHY906|
75756876|NCT00429858|Drug|S-1|S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
75756877|NCT00429858|Drug|gemcitabine hydrochloride|Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
75903320|NCT05635708|Drug|BGB-15025|Administered Orally
75903321|NCT05635227|Drug|Dexamethasone phosphate|See description of arms
75903322|NCT05635227|Drug|Isotonic sodium chloride (0.9%)|See description of arms
75903323|NCT05635227|Drug|Olanzapine 10 MG|Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
75903324|NCT05635227|Drug|Placebo capsule|capsule identical to capsule containing olanzapine
75903325|NCT05635227|Procedure|Flow-targeted hemodynamic management|See description of arms
75903326|NCT05635227|Procedure|Pressure-targeted hemodynamic management|See description of arms
75609435|NCT01185600|Biological|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
75609436|NCT02754895|Other|Positive Psychology (PP)|Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
75756878|NCT01323738|Behavioral|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
75756879|NCT01035216|Drug|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
75756880|NCT01039116|Behavioral|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
75457599|NCT01787214|Dietary Supplement|Control|Walnut free meals
75457600|NCT01787227|Device|xTAG RPP|
75457601|NCT01787318|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
75457602|NCT01787318|Device|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
75756881|NCT01039116|Behavioral|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
75756882|NCT01035294|Behavioral|mindfulness based intervention (MBI)|Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.
75903327|NCT05635227|Procedure|Low tidal-volume ventilation|See description of arms
75903328|NCT05635227|Procedure|No ventilation|See description of arms
75903329|NCT05634746|Drug|APT-1011|"APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate"
75903330|NCT05634746|Drug|Placebo oral tablet|"Placebo orally disintegrating tablet.~Other Names:~PBO"
75903331|NCT05634746|Procedure|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
75903332|NCT05625867|Other|Psychological and quality of life questionnaires|At 4/5 months and at 9 months
75903333|NCT05625867|Other|Interdisciplinary consultation at 4/5 months|About ten days after the questionnaires were administered
75903334|NCT05625191|Diagnostic Test|Acoustic voice analysis|Acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in different voice conditions. Control participants will produce voice in breathy, typical, and pressed conditions. Patient participants will produce voice in typical production and in a resonant voice production. High-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition. Data will be collected using a head-mounted microphone.
75457603|NCT01787344|Drug|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
75609437|NCT02754895|Other|Motivational Interviewing (MI)|"MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.~Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session."
75756883|NCT01035294|Behavioral|usual care|The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
75756884|NCT01035372|Dietary Supplement|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
75756885|NCT00449150|Drug|Cetrorelix 78 mg + 78 mg|
75756886|NCT00449150|Drug|Cetrorelix 78 mg + 52 mg|
75756887|NCT00449150|Drug|Placebo|
75756888|NCT00428844|Drug|daptomycin|6 mg/kg
75903335|NCT05625191|Diagnostic Test|High-speed videoendoscopy|High-speed videoendoscopy will occur on one repetition of a sustained /i/ in each requested condition. Exams will be recorded using the Phantom V311 high-speed camera (Vision Research, Wayne, NJ) connected to a Storz 70° rigid laryngoscope using a 400 Watt Xenon light source (Titan 400E).
75903336|NCT05624879|Behavioral|Accelerated Resolution Therapy|A brief psychotherapeutic intervention delivered by trained therapists in a maximum of 4 sessions. Sessions will focus on providing relief from the distress related to an anticipated loss and to shift focus from distress and loss back to the relationship.
75903337|NCT05624879|Other|Information and Support|4 sessions of a standardized social work intervention. Standard of care including education and active listening.
75903338|NCT05624281|Drug|nintedanib|nintedanib, for patients with fibrosing interstitial lung disease (ILD); in this EAP limited to children and adolescents
75903339|NCT05620407|Drug|Deucravacitinib|Specified dose on specified days
75903340|NCT05620407|Other|Placebo|Specified dose on specified days
75903341|NCT05617677|Drug|Deucravacitinib|Specified dose on specified days
75903342|NCT05617677|Other|Placebo|Specified dose on specified days
75903343|NCT05609370|Drug|LBL-007|Low dose intravenously (IV) once every 3 weeks.
75609438|NCT01185366|Drug|Everolimus|10 mg by mouth once a day.
75609439|NCT01185366|Drug|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
75609440|NCT01185288|Biological|Adalimumab|Adalimumab in pre-filled syringes
75756889|NCT00428844|Drug|daptomycin|8 mg/kg
75756890|NCT00428844|Drug|vancomycin|1 gram
75756891|NCT00428844|Drug|teicoplanin|6 mg/kg; used only at UK sites
75756892|NCT00428844|Drug|nafcillin|1-2 gram
75756893|NCT00428844|Drug|oxacillin|1-2 gram
75756894|NCT00428844|Drug|flucloxacillin|1-2 mg
75756895|NCT00457418|Drug|PEG-Intron|
75756896|NCT01039194|Drug|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
75756897|NCT01039194|Drug|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
75756898|NCT01039194|Drug|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
75756899|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
75756900|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
75756901|NCT00449072|Drug|TAA-AQ, Nasacort® AQ|110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
75756902|NCT00449072|Drug|Claritin®|Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
75756903|NCT00428610|Drug|LY573636-sodium|LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
75903344|NCT05609370|Drug|LBL-007|Medium dose IV once every 3 weeks
75903345|NCT05609370|Drug|LBL-007|High dose IV once every 2 or 3 weeks
75903346|NCT05609370|Drug|Tislelizumab|Low dose IV once every 3 weeks
75903347|NCT05609370|Drug|Tislelizumab|High dose IV once every 4 weeks
75903348|NCT05609370|Drug|Bevacizumab biosimilar|7.5 mg/kg IV every 3 weeks
75903349|NCT05609370|Drug|Bevacizumab biosimilar|5 mg/kg IV once every 2 weeks
75903350|NCT05609370|Drug|Capecitabine|850 milligrams per square meter (mg/m^2) twice daily orally for 2 weeks, followed by a one-week treatment break every 3 weeks
75903351|NCT05609370|Drug|5-Fluorouracil|1600 to 2400 mg/m^2 IV every 2 weeks
75903352|NCT05607017|Drug|Losartan|Taken Orally
75903353|NCT05607017|Radiation|Radiation Therapy|Photon Radiation Therapy
76068486|NCT01753310|Drug|Placebo|Up to 2mL
76068487|NCT01463631|Drug|LY3007113|Administered orally
75756904|NCT02593656|Behavioral|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
75756905|NCT02593656|Behavioral|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
75756906|NCT01033266|Diagnostic Test|CPET|CPET will be done on patients with overlap syndrome before and after clinical CPAP treatment.
75756907|NCT00419094|Drug|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
75903354|NCT05595369|Drug|Experimental: Paxlovid 25 day dosing|Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
75609441|NCT01185288|Drug|Methotrexate|Methotrexate capsule
75609442|NCT01184508|Drug|Placebo|Administered orally, once daily, for 12 weeks
75756908|NCT00419094|Drug|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
75756909|NCT00448916|Drug|Pregabalin|Orally-administered pregabalin
75756910|NCT00418938|Drug|Panitumumab|6mg/kg IV
75756911|NCT00418938|Drug|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
75903355|NCT05595369|Drug|Experimental: Paxlovid 15 day dosing|Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
75903356|NCT05595369|Drug|Placebo Comparator: Control|Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
75457604|NCT01787344|Drug|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
75457605|NCT01787357|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose of canagliflozin (JNJ-28431754) (comprising one 100 mg over-encapsulated tablet and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Day 1 of Treatment A. One 1,200 mg dose of canagliflozin (comprising six 200 mg over-encapsulated tablets) taken orally on Day 1 of Treatment B.
75457606|NCT01787357|Drug|Placebo|Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
75756912|NCT00418938|Drug|Leucovorin|400mg/m^2 IV (in the vein)
75756913|NCT00418938|Drug|Irinotecan|180mg/m^2 IV (in the vein)
75756914|NCT00418938|Drug|5-Fluorouracil|400mg/m^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m^2 thereafter if no significant side effects
75756915|NCT03279224|Biological|Allogenic FMT|"Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
75903357|NCT05585840|Device|Biofeedback-based virtual reality game|The application will be a biofeedback-based virtual reality game developed by the researchers in collaboration with engineering in line with the literature review.
75457607|NCT01787357|Drug|Moxifloxacin|One 400 mg over-encapsulated tablet of moxifloxacin taken orally (by mouth) on Day 1 of Treatment D.
75457608|NCT01787396|Drug|Gemigliptin 50mg|
75457609|NCT01787396|Drug|Placebo(Metformin)|
75457610|NCT01787396|Drug|Metformin|
75457611|NCT01787396|Drug|Placebo(Gemigliptin)|
75903358|NCT05585619|Other|Pain treatment|Any pain treatment to include medications, procedures, or referrals
75903359|NCT05582889|Behavioral|Fitbit Intervention|Participants receive a Fitbit activity tracker and the free Fitbit smartphone app. A trained health coach provides technical support to set up and use the Fitbit and app. The health coach also provides motivational counseling to help participants to gradually increase the number of steps per day during the 12-weeks.
75457612|NCT01787422|Other|Traditional versus Telemedicine office visit|
75457613|NCT01787435|Drug|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy"
75457614|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
75609443|NCT01184508|Drug|LY2300559|300 milligrams (mg) administered orally, once daily, for 12 weeks
75609444|NCT02887014|Procedure|SPECIFIC VERBAL INSTRUCTIONS|Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
75903360|NCT05582616|Device|Transcranial Direct Current Stimulation|See treatment arm description
75903361|NCT05582616|Device|Sham Transcranial Direct Current Stimulation|See sham comparator arm description
75756916|NCT03279224|Biological|Autologous FMT|"1. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
75756917|NCT01029626|Procedure|Endoscopy|Realization of an upper GI endoscopy
75756918|NCT03996122|Other|fMRI|3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)
75756919|NCT00448760|Drug|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
75756920|NCT00448760|Drug|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
75756921|NCT00448760|Drug|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
75756922|NCT00448760|Drug|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
75756923|NCT00448760|Genetic|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
75756924|NCT00448760|Genetic|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
75756925|NCT00448760|Procedure|Conventional surgery|Surgical removal of tumor for correlative studies
75756926|NCT00418314|Device|Control|Empiric programming or one-time optimization using a non-IEGM method.
75756927|NCT00418314|Device|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
75756928|NCT01033344|Biological|Placebo|Intradermal injection 1x8 administrations 2 weeks apart
75903362|NCT05581498|Behavioral|Exercise, Bike exercise and muscle strength exercise.|"Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks."
75903363|NCT05578612|Procedure|Dorsal Spanning Bridge Plate Fixation|Dorsal spanning bridge fixation will be performed by board-certified orthopedic surgeons per standard technique.
75903364|NCT05578612|Procedure|Dorsal Spanning Bridge Plate Removal|Dorsal spanning bridge removal will be performed by board-certified orthopedic surgeons per standard technique.
75457615|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
75457616|NCT01787448|Drug|Sodium lauryl sulfate 0.1%|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
75457617|NCT01787448|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
75457618|NCT01787474|Drug|Cytarabine|Given IV
75457619|NCT01787474|Biological|Filgrastim|Given SC
75457620|NCT01787474|Biological|Filgrastim-sndz|Given SC
75756929|NCT01033344|Biological|Cat-PAD|Intradermal injection 1x8 administrations 2 weeks apart
75756930|NCT01033344|Biological|Cat-PAD|Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
75756931|NCT01039350|Drug|Darbepoetin alfa|Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
75756932|NCT00448448|Device|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
76068488|NCT04100577|Other|Today Not Tomorrrow Pregnancy and Infant Support Program|The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
75457621|NCT01787474|Drug|Fludarabine Phosphate|Given IV
75457622|NCT01787474|Other|Laboratory Biomarker Analysis|Correlative studies
75609445|NCT01184118|Drug|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
75609446|NCT01183884|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in > or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
75609447|NCT05344248|Biological|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Subcutaneous injection
75756933|NCT00448448|Other|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
75756934|NCT01039506|Drug|CPT-11 based regimens|
75756935|NCT01033500|Drug|Belatacept|Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
75756936|NCT01033578|Other|PVIC, TACE|"PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles."
75756937|NCT01035450|Device|Everolimus-eluting stent|Everolimus-eluting stent
75756938|NCT01035450|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
75756939|NCT01035528|Drug|insulin glargine|antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
75609448|NCT05344248|Biological|JS005 placebo|Subcutaneous injection
75756940|NCT01035528|Drug|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
76068489|NCT01521507|Device|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
76068490|NCT01521507|Device|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
75756941|NCT03994458|Behavioral|Smartphone Full version application|Android smartphone experimental application include: rehabilitative self-administered evidence-based exercises (Strengthening and stretching), ergonomics, and education related to low back pain. The application includes videos, photos, text, and reminders.
75457623|NCT01787474|Biological|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given IV
75609449|NCT01183260|Device|Trabecular Metal Revision Cup|Revision of the acetabular cup
75609450|NCT01183260|Device|Trabecular Metal Modular Cup|Revision of the acetabular cup
75609451|NCT01191762|Drug|sevelamer carbonate|2400 mg with each meal for 4 weeks
76068491|NCT01521117|Drug|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
76068492|NCT01521117|Drug|Placebo|Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
75457624|NCT01787513|Other|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
75609452|NCT01191762|Drug|placebo|3 tablets with each meal
75609453|NCT04315974|Drug|Rivaroxaban|Rivaroxaban therapy for at least 4 weeks.
75609454|NCT04315974|Procedure|Catheter ablation|Radiofrequency catheter ablation or cryoballoon ablation.
75457625|NCT01787513|Other|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
75609455|NCT04316208|Procedure|PEEP variations|Patients will be ventilated with a PEEP of 5 cmH2O during induction of anesthesia. After craniotomy, the PEEP will be reduced to 0 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Next, PEEP will be increased to 5 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Finally, PEEP will be increased to 10 cmH2O for 5 minutes and data will be collected at the end of 5 minutes.
75609456|NCT02855788|Drug|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
75457626|NCT01787526|Drug|ferric carboxymaltose|1 g intravenously per infusion
75457627|NCT01787526|Drug|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
75609457|NCT02852278|Other|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
75609458|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
75609459|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
75609460|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
75609461|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
75756942|NCT03994458|Behavioral|Samartphone limited version application|Android smartphone placebo application include: ineffective content that does not help in treating low back pain. The application includes only five posts in the general instruction and advises section about proper nutrition and few irrelevant reminders.
76068493|NCT01466595|Drug|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
76068494|NCT02073747|Drug|Normal Saline|One hour inhaled normal saline
76068495|NCT02073747|Drug|Albuterol|One hour inhaled ten milligrams of albuterol
76068496|NCT01728116|Device|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
76068497|NCT01728116|Procedure|Sham Procedure|Endoscopic evaluation but no device placement
76068498|NCT01465659|Drug|temozolomide|Given PO
75756943|NCT01039662|Dietary Supplement|L-arabinose and indigestible dextrin|
75756944|NCT01039662|Dietary Supplement|Placebo|
75756945|NCT01033656|Drug|anakinra|100 mg subcutaneous injection daily
75756946|NCT01033656|Drug|comparators|po drugs, comparators
75903365|NCT05562674|Behavioral|Support group|"This is a group-based, peer specialist and clinician co-facilitated psychosocial intervention for Veterans with SMI, called Veteran Voices and Visions (VVV). VVV is an adaptation of a community-based support group model called the Hearing Voices (HV) approach. The approach facilitates group cohesion around and normalization of the common psychotic symptoms of SMI: hallucinations, delusions, and social isolation."
75903366|NCT05562674|Behavioral|Healthy Lifestyles|This will be a group matched with the experimental condition for location, format, degree of interaction, and duration, but with a distinct content, that focuses on nutrition and lifestyle.
75903367|NCT05560646|Drug|OG-6219|OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
75903368|NCT05560646|Drug|Placebo|Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
75903369|NCT05560009|Drug|Fluorodopa F 18|Given IV
75903370|NCT05560009|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
75903371|NCT05560009|Procedure|Positron Emission Tomography|Undergo PET/MRI
75903372|NCT05560009|Radiation|Radiation Therapy|Receive standard of care radiation therapy
75609462|NCT02852356|Device|MIRI-TL Incubator|MIRI-TL Timelapse incubator
75609463|NCT02886858|Device|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
75609464|NCT02886858|Device|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
75609465|NCT04268290|Combination Product|Single incision plus one port laparoscopic surgery|SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.
75756947|NCT03991806|Other|Obsservational|The frailty and the health adverse events of older adults will be assessed by using a questionnaire called: Association of Centre of Excellence Self-Administered questionnaire (CESAM).
75756948|NCT01039740|Drug|Mirtazapine|Mirtazapine administration for 6 weeks under therapeutic dose
75756949|NCT01036308|Dietary Supplement|pure fibre-product|The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
75756950|NCT01036308|Dietary Supplement|reference fibre|The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
75756951|NCT00405912|Drug|Placebo|Placebo (inactive drug) given 3 times per day
75756952|NCT00405912|Drug|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tables -3 times per day
75756953|NCT00405912|Drug|St. John's Wort-1800mg/day|St. John's Wort - 600 mg tables - 3 times per day
75756954|NCT00448136|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
75756955|NCT00448136|Drug|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
75756956|NCT00448136|Drug|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
75756957|NCT00448136|Drug|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
75756958|NCT00447902|Drug|tipranavir|
75756959|NCT00447902|Drug|ritonavir|
75756960|NCT00307437|Drug|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
75756961|NCT00307437|Drug|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
75903373|NCT05560009|Procedure|Surgical Procedure|Undergo standard of care surgery
75903374|NCT05556343|Drug|MYK-224|Specified dose on specified days
75903375|NCT05556265|Drug|Deucravacitinib|Specified dose on specified days
75903376|NCT05556265|Other|Placebo|Specified dose on specified days
75903377|NCT05545306|Dietary Supplement|+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
75903378|NCT05545306|Dietary Supplement|fasting|Fasting for at least 24 hours
75903379|NCT05545306|Dietary Supplement|-50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-50% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
76068499|NCT01465659|Drug|pazopanib hydrochloride|Given PO
75903380|NCT05545306|Dietary Supplement|+150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
75903381|NCT05545306|Dietary Supplement|+200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+200% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
75903382|NCT05545306|Dietary Supplement|-25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
75903383|NCT05545306|Dietary Supplement|+150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
75609466|NCT00604318|Drug|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
76068500|NCT03027531|Behavioral|eKISS: electronic KIOSK for Safer-Sex|An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
76068501|NCT01753076|Drug|Ozanezumab|Ozanezumab injection solution
75457628|NCT01787539|Drug|Postoperative Chemotherapy|"Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery."
76068502|NCT01753076|Drug|Placebo|Normal saline (0.9% sodium chloride) infusion
75457629|NCT01787552|Drug|LDE225|
75457630|NCT01787552|Drug|INC424|
75457631|NCT01787565|Other|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
76068503|NCT01463007|Radiation|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
75457632|NCT01787565|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
76068504|NCT01463007|Other|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
76068505|NCT01462929|Drug|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
76068506|NCT01462929|Drug|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
76068507|NCT01462929|Drug|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
76068508|NCT01462695|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
76068509|NCT01462695|Other|Pharmacological Study|Correlative studies
76068510|NCT01462695|Drug|Sunitinib Malate|Given PO
76068511|NCT01465347|Drug|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
75457633|NCT01787578|Drug|Sobetirome|50 mcg or 100 mcg once-daily oral
75609467|NCT01190436|Drug|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
75609468|NCT02852122|Drug|C-11 choline|This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA > 20 ng/mL, or Gleason score 8-10, or clinical stage >T2c) would be included.
75609469|NCT01035255|Drug|LCZ696 200 mg BID|LCZ696 200 mg BID
75609470|NCT01035255|Drug|Enalapril 10 mg BID|Enalapril 10 mg BID
75756962|NCT00307437|Drug|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
75756963|NCT03978819|Device|ANI|"ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI>80 + Remifentanil >6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis."
75756964|NCT00440726|Drug|Bortezomib|Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.
75903384|NCT05544019|Drug|SGR-1505|SGR-1505 will be administered orally.
75903385|NCT05529316|Drug|Botensilimab|An anti-CTLA-4 monoclonal antibody
75609471|NCT04268056|Diagnostic Test|Collection of skin culture samples|Collection of skin culture samples using a sterile swab. the swab will gently rubbed on the skin on the 3 different skin areas. The target areas are i) regions surrounding the RT treatment area (if possible, not from the scar area or from skin folds areas), ii) a control site of the normal (healthy) breast , iii) a control area on the forehead.
75756965|NCT00440726|Drug|Dexamethasone|10 mg/m2/day divided BID, oral administration for 14 days.
75756966|NCT00440726|Drug|PEG-asparaginase|2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22
75756967|NCT00440726|Drug|Doxorubicin|60 mg/m2/day IV over 15 minutes on Day 1
75756968|NCT00440726|Drug|Cytarabine|"Given intrathecally on Day 1 of course 1 at the dose defined by age below.~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients >3 years of age"
75756969|NCT00440726|Drug|Methotrexate|"Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
75756970|NCT00440726|Drug|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.
75756971|NCT00440726|Drug|Triple IT Therapy|"Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:~Methotrexate-~<2 years: 8 mg~2 - <3 y: 10 mg~3 - <9 y: 12 mg~>=9 y: 15 mg~Cytarabine:~<2 years: 16 mg~2 - <3 y: 20 mg~3 - <9 y: 24 mg~>=9 y: 30 mg~Hydrocortisone:~<2 years: 8 mg~2 - <3 y: 10 mg~3 - <9 y: 12 mg~>=9 y: 15 mg"
75609472|NCT00631072|Biological|INKT|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
75609473|NCT00631072|Drug|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
75609474|NCT00602524|Drug|Pilocarpine|
75609475|NCT01189890|Drug|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
75609476|NCT01189890|Drug|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
75609477|NCT01189890|Drug|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
75609478|NCT01189890|Drug|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
76068512|NCT03027687|Device|tDCS|tDCS is an electrical brain stimulation method
75457634|NCT01787617|Behavioral|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
75457635|NCT01787617|Behavioral|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
75457636|NCT01787630|Device|Hyaluronic acid|Injection in connection with ultrasound
76068513|NCT01465191|Drug|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
76068514|NCT01519947|Drug|Methoxy polyethylene glycol-epoetin beta|Participants received 50-250 mcg SC according to local label
75609479|NCT01189812|Drug|Lithium Carbonate|300 mg one time per day for 4 weeks
75609480|NCT01189812|Drug|Placebo|Take one time daily for 4 weeks
76068515|NCT01462227|Drug|Naltrexone High Dose|Naltrexone 100mg for two administrations.
76068516|NCT01462227|Drug|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
76068517|NCT01464879|Drug|Testosterone Gel (FE 999303)|
76068518|NCT01519869|Drug|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
75457637|NCT01787669|Drug|Avastin (Bevacizumab)|Avastin (Bevacizumab) administered intravitreally
75457638|NCT01787669|Drug|Ozurdex (dexamethasone)|Ozurdex (dexamethasone) given intravitreally
75609481|NCT01189812|Drug|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
76068519|NCT03026205|Drug|ARMS-I|
75609482|NCT00950950|Drug|Romosozumab|Administered by subcutaneous injection
75609483|NCT00950950|Drug|Placebo|Administered by subcutaneous injection
75903386|NCT05529316|Drug|Balstilimab|An anti-PD-1 monoclonal antibody
75903387|NCT05527600|Diagnostic Test|intensity of acute pain evaluation|the facial expression of each patient will be collected from a short video of 10 seconds, follow by with the evaluation of the pain intensity.
75903388|NCT05526755|Drug|Osimertinib 80 mg/40 mg|Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
75903389|NCT05523726|Behavioral|pCBT-I|Telehealth coaching
75903390|NCT05521685|Procedure|Endoscopic Ultrasound (EUS) administration of cyanoacrylate tissue adhesive to control bleeding gastric varices|Subjects will have undergone treatment and been enrolled into the existing registry.
75903391|NCT05514496|Drug|NX-019|NX-019 will be administered orally.
76068520|NCT01519791|Biological|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
76068521|NCT01519791|Other|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
75756972|NCT01029938|Procedure|Covered stent|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
75457639|NCT01787695|Procedure|UVA1|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
75457640|NCT01787708|Procedure|Red light|
75609484|NCT00950872|Device|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
75609485|NCT04302597|Procedure|Staples|Skin closure using surgical stapler.
75609486|NCT04302597|Procedure|Tissue adhesive|Skin closure using 2-octylcyanoacrylate tissue adhesive.
75609487|NCT01189500|Drug|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
75609488|NCT01189500|Drug|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
75609489|NCT02874339|Device|High flow nasal oxygen therapy|In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
75609490|NCT02874339|Device|Non invasive ventilation|In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
75609491|NCT00627315|Procedure|Gastric bypass|NOTE: Surgery will not be paid by the study
75609492|NCT00627315|Procedure|Gastric banding|NOTE: Surgery will not be paid by the study
75609493|NCT00938860|Drug|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
75609494|NCT00938860|Drug|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
75609495|NCT05381584|Procedure|laparoscopy|laparoscopy will be done under anesthesia for management for cases with blind vagina
75609496|NCT00604396|Drug|insulin detemir|
75609497|NCT00604396|Drug|insulin NPH|
75903392|NCT05509166|Behavioral|LGBTQ-affirmative Cognitive Behavioral Therapy|10-session LGBTQ-affirmative psychotherapy using CBT techniques
75903393|NCT05509166|Behavioral|LGBTQ-affirmative Treatment-As-Usual|10-session LGBTQ-affirmative psychotherapy
75457641|NCT01787721|Procedure|Ankle manipulation|
75457642|NCT01787721|Other|Sham manipulation|
75457643|NCT01787747|Drug|AVP-786 Dose 1|
75457644|NCT01787747|Drug|AVP-786 Dose 2|
75457645|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 1|
75457646|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 2|
75457647|NCT01787747|Drug|AVP-786 Dose 2/Q Dose 2|
75457648|NCT01787747|Drug|AVP-923|
75756973|NCT01029938|Procedure|Coil|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
75903394|NCT05506943|Drug|CTX-009|IV infusion on day 1 and 14 of every 28 day cycle
75903395|NCT05506943|Drug|Paclitaxel|IV infusion on day 1, 8, and 15 of every 28 day cycle
75457649|NCT01787773|Device|Veniti Inferior Vena Cava Filter|
75457650|NCT01787851|Drug|Triheptanoin oil|
75457651|NCT01787903|Device|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
75457652|NCT01787942|Device|Tear Science LipiView|The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
75457653|NCT01787955|Procedure|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
75609498|NCT00938470|Drug|capecitabine|Given PO
75609499|NCT00938470|Drug|docetaxel|Given IV
75609500|NCT00938470|Drug|fluorouracil|Given IV
75609501|NCT00938470|Drug|oxaliplatin|Given IV
75756974|NCT03192722|Device|Colored near reading glasses|Participants are provided with colored near vision glasses.
75756975|NCT03192722|Device|Lighting as determined by LuxIQ/2 or OttLite Cobra|Participants are provided preferred lighting (either OttLite or lamp with findings from LuxIQ/2)
75756976|NCT01030016|Drug|atenolol|25 mg/day, twice a day for 6 weeks
75756977|NCT03995420|Behavioral|Virtual Reality Therapy (V-NeST)|V-NeST is a 12-session therapy using psychological intervention principles based on Cognitive Remediation and CBT partly based in Virtual Reality.
75457654|NCT01787955|Procedure|conventional PPPD|
75609502|NCT00938470|Radiation|radiation therapy|Undergo radiation therapy
75609503|NCT00938470|Procedure|therapeutic conventional surgery|Undergo surgery
75609504|NCT00602680|Drug|SSR180711C|duration of treatment: 4 weeks
75609505|NCT00602680|Drug|donepezil|duration of treatment: 4 weeks
75609506|NCT00602680|Drug|placebo|duration of treatment: 4 weeks
75609507|NCT02852200|Other|SEGAm|
75609508|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
75609509|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
75756978|NCT03995420|Other|Treatment as Usual|multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.
75756979|NCT03996278|Other|Grafalon|None interventional study but there are two groups
75756980|NCT00447590|Device|LAP-BAND System|Restriction of food intake
75756981|NCT01024634|Behavioral|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
75756982|NCT00447278|Drug|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
75756983|NCT00447278|Drug|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
75756984|NCT01030094|Drug|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
75903396|NCT05503875|Biological|adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate|Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
75903397|NCT05493215|Drug|Imatinib|Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
75903398|NCT05492682|Drug|PeptiCRAd-1|All patients will receive 6 doses of PeptiCRAd-1.
75903399|NCT05492682|Drug|Cyclophosphamide|All patients will be pre-treated with one single dose of Cyclophosphamide.
75457655|NCT01787994|Genetic|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.|
75457656|NCT01788007|Drug|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
75457657|NCT01788007|Drug|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
75457658|NCT01788007|Drug|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
75457659|NCT01788033|Drug|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
75609510|NCT00602758|Behavioral|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
75609511|NCT00602758|Behavioral|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
75756985|NCT01030094|Drug|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
75756986|NCT01030094|Drug|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
75756987|NCT01030094|Drug|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
75457660|NCT01788033|Drug|Placebo|0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
75457661|NCT01788059|Other|injection the mesenchymal stem cell in non union site|
75756988|NCT01565798|Other|Copper-alloy surfaced patient care objects|Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
75756989|NCT01030328|Drug|Placebo|2 sugar pills by mouth once a day.
75756990|NCT01030328|Drug|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
75756991|NCT00446966|Drug|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
75903400|NCT05492682|Drug|Pembrolizumab|All patients will receive 6 doses of Pembrolizumab within the study.
75903401|NCT05490329|Behavioral|Tough Talks COVID|Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
75903402|NCT05488847|Drug|Celecoxib|preoperative pain medication given to all patients
75903403|NCT05488847|Drug|Pregabalin|preoperative and discharge pain medication given to all patients
75903404|NCT05488847|Drug|Tramadol|preoperative pain medication given to all patients
75903405|NCT05488847|Drug|Dexamethasone|Intraoperative and discharge pain medication given to all patients
75903406|NCT05488847|Drug|Acetaminophen|Intraoperative and discharge pain medication given to all patients
75903407|NCT05488847|Drug|Ropivicaine|Intraoperative pain medication given to all patients
75903408|NCT05488847|Drug|Epinephrine|Intraoperative pain medication given to all patients
75903409|NCT05488847|Drug|Ketorolac|Intraoperative pain medication given to all patients
75903410|NCT05488847|Drug|Tizanidine|Discharge pain medication given to all patients
75903411|NCT05488847|Drug|Magnesium|Discharge pain medication given to all patients
75903412|NCT05488847|Drug|Ibuprofen|Discharge pain medication given to all patients
75609512|NCT02851888|Drug|Ropivacaine|Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.
76068522|NCT01519791|Biological|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
76068523|NCT01461993|Biological|rLP2086 and Gardasil|Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.
75609513|NCT02851888|Other|Normal Saline Sham Injection|Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.
75609514|NCT02851888|Procedure|General Anesthesia|Patients were induced and maintained in a fashion consistent with standard practices.
75609515|NCT05381428|Drug|Indomethacin suppository|Control Group: Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
75609516|NCT05381428|Combination Product|Indomethacin suppository and high-flow lactated ringer infusion combination|Interventional group: Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
75609517|NCT00604474|Device|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
75609518|NCT02852044|Behavioral|Rest|Allowed to watch television or read for one hour prior to oral glucose tolerance test
75756992|NCT01565876|Device|"Minkal- Auxiliary device to alleviate backload"|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
75756993|NCT00446654|Drug|CGC-11047|16.5 mg (3.3%) subconjunctival injection
75756994|NCT03162302|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
76068524|NCT01461993|Biological|rLP2086|Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.
76068525|NCT01461993|Biological|Gardasil|Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
76068526|NCT01782326|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
75609519|NCT02852044|Behavioral|Exercise|One hour of cycling at 50% of maximal power output
75609520|NCT02852044|Other|Dorsal Hand Vein Cannulation (heated hand technique)|
75609521|NCT02852044|Other|Venous Cannulation|
75609522|NCT02851654|Device|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
75609523|NCT02851966|Procedure|mTESE|mTESE time may be postponed or advanced.
75609524|NCT02851732|Behavioral|Quality Improvement Intervention|The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
75756995|NCT00405756|Drug|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
76068527|NCT01782326|Drug|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
75756996|NCT00405756|Drug|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
76068528|NCT01439373|Drug|GSK2336805|Active Investigational Drug
76068529|NCT01439373|Drug|Pegylated interferon alfa-2a|Standard of Care drug
76068530|NCT01439373|Drug|Ribavirin|Standard of Care drug
76068531|NCT01439373|Drug|GSK2336805 Matching Placebo|Placebo of Investigational Drug
76068532|NCT04077801|Diagnostic Test|diagnostic test|diagnostic test
75609525|NCT02855320|Other|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
75609526|NCT04204174|Dietary Supplement|Tyrosine, brand name: myprotein|tyrosine at a dose of 100 mg/kg is then administered orally to the participants once
75609527|NCT01022853|Drug|BI 6727|intravenous each 21 days
75756997|NCT00405756|Drug|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
75756998|NCT00405756|Drug|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion"
75903413|NCT05488847|Drug|Oxycodone Hydrochloride 5 Mg|Only given to active comparator group
75903414|NCT05485662|Other|Hydroxyapatite toothpaste|10% Hydroxyapatite toothpaste
75903415|NCT05485662|Other|Sodium Fluoride Toothpaste|1450 parts per million sodium fluoride toothpaste
75903416|NCT05483400|Drug|Tiragolumab and atezolizumab|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
75903417|NCT05460780|Device|MATTISSE TEC|Tissue engineering chamber MATTISSE
75903418|NCT05457283|Drug|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 540 ±7 days.
76068533|NCT01461369|Drug|Diclofenac|35 mg bid Capsules
75457662|NCT01788072|Drug|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
75609528|NCT01022853|Drug|BIBF 1120|oral continuously
75756999|NCT00405756|Drug|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
75757000|NCT00405756|Drug|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
75609529|NCT00937768|Drug|Goserelin Acetate|Given SC
75757001|NCT00405756|Drug|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
75757002|NCT00456092|Drug|Apremilast|Capsules for oral administration
75757003|NCT00456092|Drug|Placebo|Capsules for oral administration
76068534|NCT01461369|Drug|Diclofenac|35 mg tid Capsules
76068535|NCT01461369|Drug|Placebo|Capsules
76068536|NCT04414124|Other|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
76068537|NCT04414124|Other|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
76068538|NCT04575662|Radiation|STAR Treatment|Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.
75457663|NCT01788072|Drug|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
75457664|NCT01788085|Device|Bravo pH monitoring procedure|Bravo pH monitoring procedure
75457665|NCT01788111|Other|Low back exercises 1|Excentric / concentric extension type exercises
75903419|NCT05456880|Biological|BEAM-101|Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
75903420|NCT05451017|Drug|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition|a single dose of 1 mg AEF0117 in fed condition
75903421|NCT05451017|Drug|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition|a single dose of 1 mg AEF0117 in fasting condition
75903422|NCT05446376|Drug|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
75903423|NCT05437510|Biological|Nirsevimab|Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular
75903424|NCT05435664|Behavioral|Progressive relaxation exercise|It consists of sessions involving deep breathing and stretching and relaxing the body.
75457666|NCT01788111|Other|Low back exercise 2|Traditional low back training
75457667|NCT01788137|Drug|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
75457668|NCT01788137|Drug|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
75457669|NCT01788176|Drug|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
75457670|NCT01788176|Drug|Placebo|one single intravenous infusion of 100ml of saline.
75609530|NCT00937768|Other|Laboratory Biomarker Analysis|Correlative studies
75609531|NCT00937768|Drug|Leuprolide Acetate|Given IM
75609532|NCT00937768|Other|Quality-of-Life Assessment|Ancillary studies
75903425|NCT05432284|Drug|Placebo|Placebo (ambient air)
75903426|NCT05432284|Drug|THC|Pure THC vapor
75903427|NCT05432284|Drug|Beta-Myrcene|Pure beta-myrcene vapor
75903428|NCT05430035|Drug|HIPEC|Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
75903429|NCT05427695|Drug|Lactobacillus sakei proBio65|Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
76068539|NCT01727258|Device|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
76068540|NCT01727258|Drug|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
75757004|NCT01040442|Other|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
75757005|NCT01030640|Other|placebo|single dose of the drug formulation
75757006|NCT01030640|Biological|tanezumab|single dose of the active drug tanezumab at a dose level of 20 mg
75757007|NCT00411450|Biological|Panitumumab|Administered by intravenous infusion
75757008|NCT00411450|Drug|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
75903430|NCT05427695|Other|Isotonic Saline Solution|Saline sinus irrigations (SAL group): NeilMed® Isotonic Sinus Rinse™ is marketed as a saline sinus irrigation formula. Subjects will be given instructions to mix one unlabeled packet (containing NeilMed® premixed buffered salt powder) with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
75903431|NCT05421169|Diagnostic Test|diastolic hyperemia-free ratio (DFR)|diastolic hyperemia-free ratio uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure
75903432|NCT05408832|Behavioral|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A=mindfulness meditation, B=yoga, and C=brisk walking.
75903433|NCT05408832|Behavioral|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.
75903434|NCT05408832|Behavioral|Stress Management Techniques with No Randomization Sequence (or order)|Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.
75903435|NCT05406739|Other|Test Meals|"For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute [60 kcal]; 2 slices of bread [120 kcal] with 30 g strawberry jam [75 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute [120 kcal]; 4 slices of bread [240 kcal] with 60 g strawberry jam [150 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water."
76068541|NCT01727258|Drug|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
76068542|NCT04583306|Other|Raman analysis of saliva, characterization of the Raman database and building of the classification model|Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
76068543|NCT01781390|Other|Placebo|Matching placebo solution for infusion.
75457671|NCT01788189|Drug|Lenalidomide|
75457672|NCT01788254|Drug|Codeine|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
75457673|NCT01788254|Drug|Midazolam|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
75457674|NCT01788254|Drug|pravastatin|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
75903436|NCT05406713|Drug|Pembrolizumab|400 mg intravenously
76068544|NCT01781390|Biological|Mesenchymal Precursor Cells (MPC) 12.5 M|MPC 12.5 M solution for infusion.
76068545|NCT01781390|Biological|Mesenchymal Precursor Cells (MPC) 25 M|MPC 25 M solution for infusion.
75457675|NCT01788254|Drug|Talinolol|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
75457676|NCT01788254|Drug|torsemide|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
75457677|NCT01788267|Other|scan examination HR-pQCT|
75757009|NCT00404820|Drug|Zoledronic acid 5 mg solution|Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
75757010|NCT00404820|Drug|Alendronate 70 mg tablets|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
75757011|NCT00404820|Drug|Calcium/Vitamin D|Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
75757012|NCT00417612|Drug|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
75757013|NCT00417612|Other|Placebo|Placebo sugar pill
76068546|NCT01781234|Drug|Intranasal Insulin|
75609533|NCT04204018|Other|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case."
75609534|NCT02851810|Behavioral|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
75757014|NCT00446030|Drug|Docetaxel|"75 mg/m^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg)."
75757015|NCT00446030|Drug|Doxorubicin|50 mg/m^2 administered IV on Day 1 for Cycles 1-6
75757016|NCT00446030|Drug|Carboplatin|6 mg/mL/min (target area under the curve [AUC] dose) administered IV on Day 1 for Cycles 1-6
76068547|NCT01781234|Drug|Placebo|
75457678|NCT01788280|Drug|Fluciclitite , PET imaging, and Bevacizumab|[18F] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
75757017|NCT00446030|Drug|Cyclophosphamide|500 mg/m^2 administered IV on Day 1 for Cycles 1-6
75457679|NCT01788293|Other|Intervention group|"Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.~This PVI cut-off value was chosen according to previous reports [Cannesson et al., 2008; Zimmermann et al., 2010].~During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation."
75757018|NCT00446030|Drug|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
75757019|NCT00446030|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
75457680|NCT01788319|Procedure|lasertrabeculoplasty|
75609535|NCT02851810|Behavioral|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
75757020|NCT00411216|Other|Control exercises|saccadic eye movements against a plain background; no head movements
75609536|NCT02851810|Behavioral|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
75757021|NCT00411216|Other|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
75757022|NCT03995732|Drug|PC-SOD|PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
75757023|NCT03995732|Drug|placebo|Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
75757024|NCT01323816|Other|Medically directed care|There is no research directed care. Patients are treated as medically indicated.
75757025|NCT01027052|Other|Hamburger meat patty with salt|hamburger meat cooked with salt
75757026|NCT01027052|Other|Hamburger meat patty with spice blend|hamburger meat cooked with spice mixture
75757027|NCT00410514|Drug|Mirabegron|oral
75757028|NCT00410514|Drug|Placebo|oral
75757029|NCT03847610|Drug|Phenoxymethyl Penicillin|Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study
75757030|NCT03847610|Device|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
75757031|NCT03995498|Other|Physical activity|Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.
75757032|NCT03995498|Other|FreeStyle Libre|Glucose levels will be measured by the FreeStyle Libre
75757033|NCT03995498|Other|SenseWear Armband|Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
75757034|NCT01036854|Drug|EUR-1025|orally, 24 mg, daily for 6 days
76068548|NCT01752842|Drug|Fenofibrate|
76068549|NCT01752842|Drug|Placebo for fenofibrate|
76068550|NCT01461057|Drug|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
76068551|NCT01461057|Drug|Cisplatin|80 mg/m2 on Day 1 of each cycle
76068552|NCT01461057|Drug|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
76068553|NCT01461057|Drug|Pertuzumab|840 mg once every three weeks
76068554|NCT01461057|Drug|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
75757035|NCT01036854|Drug|EUR-1025|orally, 8 mg, twice daily over 6 consecutive days
75903437|NCT05403853|Diagnostic Test|Venepuncture|Venous blood draw
75903438|NCT05403853|Diagnostic Test|Fingerstick|Capillary Blood Draw
75903439|NCT05400200|Diagnostic Test|questionnary administration|questionary
75903440|NCT05395299|Procedure|SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )
75903441|NCT05383170|Drug|CyPep-1|Intratumoral injection
75457681|NCT01788332|Drug|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
75457682|NCT01788332|Other|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water
75457683|NCT01788345|Other|non- invasive ventilation|non-invasive bi-level ventilation with IPAP and EPAP.
75457684|NCT01788371|Drug|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
75457685|NCT01788371|Drug|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
75457686|NCT01788384|Drug|Clindamycin Phosphate / Benzoyl Peroxide Gel|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
75903442|NCT05383170|Drug|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
75903443|NCT05382520|Diagnostic Test|Questionares and practice|Questionares and practice
75609537|NCT02851810|Behavioral|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
75609538|NCT02851810|Behavioral|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
75609539|NCT00602914|Device|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
75609540|NCT00602914|Device|MicronJet|MicronJet, Intradermal Injection
75609541|NCT00940888|Device|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
75609542|NCT05381116|Device|Avation System|Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.
75757036|NCT01036854|Drug|EUR-1025|orally, 8 mg, three times a day over 6 consecutive days
75757037|NCT01036854|Drug|EUR-1025|orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
75757038|NCT03843632|Biological|VARIVAX™|VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).
75757039|NCT01030796|Behavioral|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
75757040|NCT03994718|Other|Music intervention|The music therapist will work with subjects for up to 60 minutes each session.
75903444|NCT05378100|Drug|Ketamine|Infusion of ketamine 0.5 mg/kg over 40 minutes
75903445|NCT05378100|Drug|Midazolam|Infusion of midazolam 0.05 mg/kg over 40 minutes
75903446|NCT05364931|Drug|Cotadutide|Cotadutide administered subcutaneously once daily
75903447|NCT05364931|Drug|Placebo|Placebo administered subcutaneously once daily
75903448|NCT05361967|Device|The Tack Endovascular System|The Tack Endovascular System is designed to treat vascular dissections with Tack implant(s) following angioplasty.
75903449|NCT05351593|Drug|Tafasitamab|Given IV
75903450|NCT05351593|Drug|Lenalidomide|Given Orally
75903451|NCT05350150|Device|Auricular Vagal Nerve Stimulation|The Parasym device will be placed on the patient's left tragus to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
75903452|NCT05348876|Drug|Darolutamide (Nubeqa, BAY1841788)|600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
75757041|NCT03994718|Other|Visual arts intervention|The visual artist will work with subjects for up to 60 minutes each session.
75757042|NCT03994718|Other|Creative writing intervention|The creative writer will work with subjects for up to 60 minutes each session.
75757043|NCT00455858|Drug|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
75457687|NCT01788384|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
75609543|NCT05381116|Device|Sham Avation System|Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.
75609544|NCT00631228|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
75609545|NCT02851576|Other|Infusion of ADV specific T cells|Cell engineering
75757044|NCT00439556|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
75757045|NCT00439556|Biological|Anti-Thymocyte Globulin|Given IV
75757046|NCT00439556|Drug|Bortezomib|Given IV
75757047|NCT00439556|Drug|Carmustine|Given IV
75757048|NCT00439556|Drug|Cytarabine|Given IV
75757049|NCT00439556|Drug|Etoposide|Given IV
75757050|NCT00439556|Biological|Filgrastim|Given SC
75757051|NCT00439556|Drug|Melphalan|Given IV
75903453|NCT05348733|Drug|Kerendia (Finerenone, BAY94-8862)|Decision will taken by the treating physician to initiate treatment with finerenone.
75457688|NCT01788384|Drug|Placebo (Vehicle Gel)|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
75757052|NCT00439556|Drug|Methotrexate|Given IV
75757053|NCT00439556|Biological|Rituximab|Given IV
75757054|NCT00439556|Drug|Tacrolimus|Given IV and PO
75757055|NCT00410202|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
75757056|NCT00410202|Drug|Tenofovir|Tablets, Oral, 300 mg, once daily
75457689|NCT01788397|Behavioral|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
75757057|NCT00410202|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
75757058|NCT00410202|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
75757059|NCT03802058|Drug|Nab-paclitaxel|Nab-paclitaxel 40mg/m2 for Injection weekly
75757060|NCT03802058|Drug|Carboplatin|Carboplatin AUC=2 for Injection weekly
75757061|NCT03802058|Radiation|Thoracic radiation therapy|Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
75757062|NCT00445328|Drug|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
75757063|NCT00445328|Drug|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
75757064|NCT00455312|Drug|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
75757065|NCT00455312|Drug|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
75757066|NCT00455312|Drug|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
75757067|NCT00455312|Procedure|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
75757068|NCT00455312|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
75757069|NCT00455312|Drug|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
75903454|NCT05337137|Drug|Relatlimab|Specified dose on specified days
75903455|NCT05337137|Drug|Nivolumab|Specified dose on specified days
75903456|NCT05337137|Drug|Bevacizumab|Specified dose on specified days
75903457|NCT05337137|Other|Placebo|Specified dose on specified days
75757070|NCT00455312|Drug|Methylprednisolone|2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
75903458|NCT05334004|Drug|Lopinavir / Ritonavir|Human Immunodeficiency Virus (HIV) antiviral, given via suppository
75903459|NCT05328752|Drug|XXB750|XXB750
75903460|NCT05328752|Drug|Placebo|Placebo
75903461|NCT05307094|Behavioral|Improving Parents as Communication Teachers|A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.
75903462|NCT05304442|Drug|Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]|Single Dose of IV Iron
75903463|NCT05304442|Drug|Ferrous Sulfate 65 mg elemental iron (325 mg tablets)|Once daily by mouth for 42 days
75903464|NCT05302375|Other|iPath*D|Online pathway from screening to treatment for depression in cancer patients.
75903465|NCT05297825|Behavioral|Vegan diet|Healthy vegan diet.
75457690|NCT01788436|Behavioral|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
75757071|NCT01031030|Drug|cyclophosphamide|
75457691|NCT01788436|Behavioral|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
75757072|NCT01031030|Drug|epirubicin hydrochloride|
75757073|NCT01031030|Drug|fluorouracil|
75757074|NCT01031030|Drug|methotrexate|
75903466|NCT05297825|Behavioral|Omnivore diet|Healthy omnivore diet.
75903467|NCT05291091|Drug|EDG-5506 10 mg|EDG-5506 is administered orally once per day
75903468|NCT05291091|Drug|EDG-5506 5 mg|EDG-5506 is administered orally once per day
75903469|NCT05291091|Drug|EDG-5506 12.5 mg|EDG-5506 is administered orally once per day
75903470|NCT05291091|Drug|Placebo|Placebo is administered orally once per day
75903471|NCT05288062|Procedure|Bone Marrow Biopsy|Undergo bone marrow aspirate/biopsy
75457692|NCT01788462|Drug|Tesamorelin (Egrifta)|We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
75457693|NCT01788488|Other|Use of procalcitonin as biomarker to guide therapy|
75757075|NCT01031030|Other|laboratory biomarker analysis|
75757076|NCT01031030|Procedure|adjuvant therapy|
75903472|NCT05288062|Drug|Dexamethasone|Given orally
75903473|NCT05288062|Drug|Lenalidomide|Given orally
75903474|NCT05288062|Drug|Pomalidomide|Given orally
75457694|NCT01788501|Drug|Tacrolimus|D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
75757077|NCT01031108|Drug|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
75757078|NCT01031108|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
75757079|NCT01024712|Drug|carboplatin|
75757080|NCT01024712|Drug|gefitinib|
75757081|NCT01024712|Drug|paclitaxel|
75757082|NCT01024712|Procedure|quality-of-life assessment|
75757083|NCT01031186|Drug|GSK356278|GSK356278
75757084|NCT01031186|Drug|PLACEBO|PLACEBO
75757085|NCT01323452|Drug|Entecavir|once daily
75903475|NCT05286112|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
75903476|NCT05286112|Behavioral|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
75903477|NCT05284747|Drug|Evolocumab|Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.
75903478|NCT05284747|Drug|Routine Lipid Management|Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
75757086|NCT03994640|Combination Product|Cannabis Cream|Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
75457695|NCT01788501|Drug|Cyclosporine|D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
75457696|NCT01788501|Drug|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
75457697|NCT01788514|Other|Videogame|Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
75757087|NCT03994640|Combination Product|Placebo Cream|Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
75757088|NCT00444626|Device|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
75757089|NCT00444626|Device|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
75757090|NCT00444626|Drug|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
75609546|NCT05381038|Device|QPOP|QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.
75757091|NCT01024790|Behavioral|Exercise group|24 week group exercise class supplemented with behavioral activation strategies
75757092|NCT01024868|Drug|Ropivacaine 0,5%|Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
75757093|NCT04748120|Procedure|Operative management|Patients will undergo surgical removal of the affected organ. The initial approach will be in a minimally invasive, laparoscopic fashion. If necessary, conversion to an open operation may be performed. These patients will be treated preoperatively and postoperatively with similar antibiotic regimens, however the duration of antibiotic therapies will be dependent on factors such as intraoperative findings, resolution of laboratory abnormalities, and tolerance of oral medications.
75903479|NCT05282550|Drug|Trazodone|50mg of trazodone administered for 4 weeks.
75903480|NCT05282550|Drug|Placebo|Placebo administered for 4 weeks.
75903481|NCT05272878|Drug|IRBESARTAN, tablet, 150 mg|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
75457698|NCT01788527|Device|CGM|Real Time Continuous Glucose Monitoring
75457699|NCT01788540|Drug|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
75457700|NCT01788579|Behavioral|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
75903482|NCT05272878|Drug|Placebo, tablet, 150 mg|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
75903483|NCT05268562|Drug|Ketamine|1-2 mg/kg induction with additional medication administered as needed to achieve intubating conditions
75903484|NCT05268562|Drug|Propofol|0.5-1 mg/kg induction with additional medication administered as needed to achieve intubating conditions
75903485|NCT05256199|Behavioral|Multidomain lifestyle intervention|A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.
75903486|NCT05252832|Procedure|Superficial Cervical Plexus Block|Location of injection for block.
75903487|NCT05252832|Procedure|Local Infiltrate|Local infiltration location.
75903488|NCT05251259|Drug|Atuliflapon|Randomised participants will receive Atuliflapon
75903489|NCT05251259|Drug|Placebo|Randomised participants will receive placebo
75757094|NCT04748120|Procedure|Non-operative management|"Patients will be treated with 3 days of intravenous antibiotics followed by 7 days of oral antibiotics, as described below:~Non-penicillin allergic patients~piperacillin/tazobactam 3.375g IV every 6 hours for 3 days~amoxicillin/clavulanate 875/125mg by mouth every 12 hours for 7 days~Penicillin allergic patients~ertapenem 1g IV every 24 hours for 3 days~ciprofloxacin 500mg every 12 hours AND metronidazole 500mg every 8 hours for 7 days~Patients may be considered to have failed non-operative management (e.g. treatment failure) if they experience absence of clinical improvement, worsening abdominal pain and/or localized/diffuse peritonitis in the judgment of the treating surgeon at any point within the study window. If this occurs, then surgeons may proceed with rescue appendectomy or percutaneous drainage in the setting of appendicitis, or with placement of a percutaneous cholecystostomy tube in the setting of acute cholecystitis."
75609547|NCT05381038|Device|CURATE.AI|"CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment.~The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant.~The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months."
75757095|NCT03795194|Drug|ampicillin/clavulanate|FDA-approved antibiotic
75757096|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
75757097|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
75757098|NCT00404352|Drug|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
75757099|NCT03994380|Drug|RhDNAse Inhalation Solution|rhDNAse 2.5 mg nebulizer daily for 4 weeks
75757100|NCT00439244|Drug|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
75903490|NCT05242250|Device|Catheter Ablation|Ablation RF technologies manufactured by Abbott.
75903491|NCT05239039|Drug|spesolimab|spesolimab
75903492|NCT05227703|Drug|CVL-231 15 mg|CVL-231 15 mg, oral (tablet), once per day for 6 weeks
75457701|NCT01788579|Behavioral|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
75903493|NCT05227703|Drug|Required CVL-231 30 mg|CVL-231 30 mg, oral (tablet), once per day for 6 weeks
75457702|NCT01788605|Drug|ramosetron|
75609548|NCT05381038|Drug|Azacitidine + docetaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
75609549|NCT05381038|Drug|Azacitidine + paclitaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
75609550|NCT05381038|Drug|Azacitidine + irinotecan|"Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8.~Each chemotherapy cycle will be 21 days."
75757101|NCT00439244|Drug|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
75757102|NCT00439244|Drug|Teriparatide|"Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days."
75757103|NCT01031342|Procedure|Early colonoscopy|Colonoscopy within 12 hours of presentation
75757104|NCT01031342|Procedure|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
75757105|NCT04844762|Behavioral|Menthol cigarettes substitutes|In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.
75903494|NCT05227703|Drug|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
75903495|NCT05227690|Drug|CVL-231 10 mg|CVL-231 10 mg, oral (tablet), once per day for 6 weeks
75903496|NCT05227690|Drug|Required CVL-231 30 mg|CVL-231 30 mg, oral (tablet), once per day for 6 weeks
75903497|NCT05227690|Drug|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
75903498|NCT05208125|Biological|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).|Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)
75903499|NCT05208125|Other|Normal saline solution|Intramuscular administration of normal saline solution
75903500|NCT05201079|Biological|MBK-01|A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
75903501|NCT05201079|Drug|Dificlir|Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
75903502|NCT05200247|Drug|spesolimab|solution for infusion
75609551|NCT00603070|Other|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
75757106|NCT04844762|Behavioral|Usual brand menthol cigarettes and substitutes|In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.
75757107|NCT04844762|Behavioral|Menthol cigarettes substitutes and menthol cigarettes|In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.
75757108|NCT03794024|Device|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
75757109|NCT03794024|Device|The Axium Neurostimulator System|The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
75757110|NCT01323218|Drug|25 OH vitamin D|After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
75757111|NCT01323296|Other|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
75757112|NCT00438464|Drug|Finasteride|Given PO
75757113|NCT00438464|Other|Placebo|Given PO
75757114|NCT00438464|Procedure|Prostatectomy|Undergo prostatectomy
75903503|NCT05197621|Biological|mRNA COVID-19 vaccine (Pfizer or Moderna)|mRNA vaccine received at any time during pregnancy course
75903504|NCT05191446|Behavioral|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|"Step 1 includes three sessions of motivational interviewing (MI). MI will consist of three video (Zoom) or telephone sessions: an initial 45-minute session, followed by two 20-minute sessions. Treatment is based on Motivational Interviewing by Miller and Rollnick, and includes exploring ambivalence about change, reflective listening, expressing empathy, and discussion about change. To support increased motivation to reduce drinking, discussion will center on effects of hazardous drinking on liver disease.~Step 2 includes referral to addiction medicine for participants who do not reduce unhealthy alcohol use. Specialty addiction services include both direct treatment and coordination of addiction care. After an evaluation, the addiction medicine physician may recommend pharmacotherapy (in consultation with hepatology provider if indicated), and/or referral to intensive outpatient, or residential level of care depending on clinical judgement."
75457703|NCT01788618|Other|Cognitive exams|"Psychopathological assessment (T0 and T3):~Scale of Spielberger~The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)"
75457704|NCT01788618|Other|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
75609552|NCT00603070|Other|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
75609553|NCT05380960|Device|cbc coaglation profile|The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
75757115|NCT00438464|Other|Laboratory biomarker analysis|Correlative studies
75903505|NCT05191446|Other|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
75903506|NCT05176483|Drug|XL092|XL092 orally once daily (qd)
75609554|NCT02851498|Other|Food product: high-protein pasta and cereal|
75609555|NCT02690272|Behavioral|Psychic processes|Quantitative and qualitative aprroche of the psychic process
75609556|NCT02851420|Other|spectroscopy|
75609557|NCT00604630|Drug|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
75757116|NCT00437294|Drug|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease
75757117|NCT00437294|Drug|placebo|oral, daily, 21-day cycles until progressive disease
75757118|NCT00437294|Drug|capecitabine|1250 mg/m^2, BID, days 1-14 of each 21-day cycle until progressive disease
75903507|NCT05176483|Drug|Nivolumab|360 mg IV infusion once every 3 weeks (q3w)
75903508|NCT05176483|Drug|Ipilimumab|1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses
75903509|NCT05176483|Drug|Nivolumab|3 mg/kg IV infusion once every 3 weeks (q3w) for first four doses, and then 480 mg IV infusion once every 4 weeks (q4w)
75903510|NCT05176483|Drug|Nivolumab|480 mg IV infusion once every 4 weeks (q4w)
76068555|NCT01460901|Biological|GD2 CAR modified Tri-virus specific cytotoxic t-cells|This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
75457705|NCT01788618|Other|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
75457706|NCT01788618|Other|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
75457707|NCT01788670|Dietary Supplement|Ethanol|
75609558|NCT00604630|Drug|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
75757119|NCT01033760|Drug|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
75757120|NCT01033760|Drug|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
75757121|NCT00436982|Device|Cemented Triathlon total knee system|Orthopaedic implant
75457708|NCT01788670|Other|Water|
75757122|NCT00436982|Device|Duracon total knee system|Orthopaedic implant
75457709|NCT01788696|Radiation|Group A - Early Imaging|Total of 3 scans
75757123|NCT00443846|Biological|RotaTeq®|Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.
75457710|NCT01788696|Radiation|Group B - Delayed Imaging|Total of 2 scans
75457711|NCT01788709|Other|preparation cleaning solution|
75457712|NCT01788722|Drug|Dienogest (Visanne, BAY86-5258)|Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
75609559|NCT05380882|Drug|TQB2930 injection|TQB2930 is an anti-HER2 bispecific antibody.
75609560|NCT01189266|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
75609561|NCT01189266|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
75609562|NCT01189266|Other|Laboratory Biomarker Analysis|Correlative studies
75609563|NCT01189266|Drug|Vorinostat|Given PO
75609564|NCT01189032|Drug|DE-089 ophthalmic solution|
75609565|NCT01189032|Drug|DE-089 ophthalmic solution|
75903511|NCT05176483|Drug|Nivolumab + Relatlimab|IV administration of nivolumab + relatlimab
75903512|NCT05174767|Device|AMDS|AMDS Implantation
75903513|NCT05161767|Diagnostic Test|Brain MRI (neuroimaging)|Structural and functional brain scans will be taken.
75903514|NCT05156827|Drug|TB006|TB006 diluted in normal saline, administered through IV infusion over an hour
75903515|NCT05156827|Drug|Placebo|Normal saline administered through IV infusion over an hour
75903516|NCT05145413|Drug|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
75903517|NCT05145413|Drug|Placebo|Placebo Capsules
75903518|NCT05136651|Behavioral|OurRelationship|The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
75903519|NCT05135000|Drug|LTP001|LTP001 will be administered orally once daily in the morning
75903520|NCT05135000|Drug|Placebo|Placebo to LTP001 will be administered once daily in the morning
75609566|NCT01189032|Drug|Placebo ophthalmic solution|
75609567|NCT01188798|Drug|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
75903521|NCT05130151|Behavioral|Youth Health SMS|The intervention is comprised of an automated two-way text messaging and interactive voice recognition service that provides sexual reproductive health (SRH) and HIV prevention information. The proposed intervention will add PrEP information and mental health and alcohol use screeners to the platform with the goal of promoting linkage to HIV clinics and to phone-based mental health counseling for symptomatic participants.
76068556|NCT01519635|Drug|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
75609568|NCT01188798|Drug|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
75609569|NCT04316052|Other|Aerobic training|After the baseline assessment, Following randomization into the exercise group, participants will undergo an exercise program orientation, which will be conducted individually.At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine. Participants will be instructed to walk for 45 minutes, including a 5-minute warm-up and 5 min cool-down, at 50% to 80% of their age-predicted maximum heart rate.Over the course of 4 months, each patient will complete 48 sessions. The morning after the 24th and 48nd sessions of aerobic physical exercise, each participant will be assessed completely
75457713|NCT01788748|Device|bipolar radiofrequency and infrared|
75609570|NCT04316052|Other|strength training|After the baseline assessment, participants will undergo exercise program orientation, which will be conducted individually. Participants will be instructed to perform 45 min session, two sets of 8 to 12 repetitions of each exercise (2 second hold each up and down hold) for the first 2 weeks to provide an introductory period. In the first session, muscular strength will be assessed using a standardized 10-repetition maximum approach, from which one repetition maximum (1-RM) will be estimated. The exercise prescription for strength training will be made at approximately 50% of the estimated 1-RM.The strength training activities included horizontal leg press, leg extension, leg curl, hip adduction, hip abduction, and seated rotary calf press.
75457714|NCT01788748|Device|fractional bipolar radiofrequency|
75609571|NCT01183104|Drug|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=< <50).
75609572|NCT01183104|Drug|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
75457715|NCT01788761|Dietary Supplement|Probiotic Supplemented Group|
75457716|NCT01788761|Dietary Supplement|Control Group|
75457717|NCT01788787|Behavioral|Quitline-Delivered Proactive Telephone Counseling|Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.
75457718|NCT01788787|Behavioral|Follow-Up Phone Call|Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.
75609573|NCT02886468|Other|skin ultrasound|
75609574|NCT04188132|Other|EEG -BCI based Feedback for rehabilitation|Subjects will undergo EEG based BCI as feedback for rehabilitation
75609575|NCT04187664|Behavioral|Postoperative Monitoring|Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.
75757124|NCT00443846|Biological|NeisVac-C®|Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.
75757125|NCT01027208|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
75757126|NCT03619772|Other|Bilateral|Participants will control game using EMG from both upper limbs.
75757127|NCT03619772|Other|Unilateral|Participants will control game using EMG from the more impaired upper limb.
76068557|NCT01519635|Drug|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
75757128|NCT01031732|Procedure|MIS-2 THA|MIS two-incision THA
75757129|NCT01031732|Procedure|MIS-WJ|MIS-Watson Jones THA
75757130|NCT01031732|Procedure|MIS-AL THA|Transgluteal approach
75757131|NCT01031732|Procedure|MIS-PL THA|Posterolateral approach
75757132|NCT02923544|Procedure|YUMI manipulator|
75757133|NCT01033838|Procedure|rectosigmoid resection|
75757134|NCT01033994|Biological|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
75757135|NCT02911610|Device|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
75757136|NCT02911610|Device|Volar plate|surgery of wrist fractures with volar plate
75757137|NCT01031888|Drug|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
75757138|NCT01031888|Drug|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
75757139|NCT00436826|Drug|Cladribine|Participants were administered with cladribine tablets orally as cumulative dose.
75757140|NCT00436826|Drug|Placebo|Participants were administered with placebo orally.
75903522|NCT05129371|Other|Breathing exercise|Following the protocol prepared, the breathing exercise group is given breathing exercises for about 20 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application. Reminders (by text message or voice call) are used for the remaining 4 days of the week, allowing the patient to do it on their own.
76068558|NCT01519323|Drug|vemurafenib|Cohort 1 (participants >=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants <45 kg): starting dose 480 mg
75457719|NCT01788787|Behavioral|Smoking Cessation Training|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.
75457720|NCT01788787|Behavioral|Qualitative Interviews Concerning the Implementation of AAC|MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
75457721|NCT01788800|Behavioral|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
75609576|NCT04187664|Diagnostic Test|High-sensitivity cardiac troponin testing|High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
75757141|NCT00436826|Drug|Interferon-beta (IFN-beta)|Participants received IFN-beta therapy (Rebif® new formulation [RNF] 44 microgram [mcg] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
75903523|NCT05129371|Other|Placebo Breathing Group|The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group for 10-15 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application.
76068559|NCT01519245|Drug|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
76068560|NCT01519245|Drug|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
75457722|NCT01788813|Drug|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
75457723|NCT01788813|Drug|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
75457724|NCT01788826|Procedure|Prophylactic mesh|Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.
75609577|NCT02885532|Other|University of California, San Diego Brief Assessment of Capacity to Consent Tool|Non-pregnant, English speaking patients older than 18 with evidence of acute alcohol intoxication were considered eligible for participation. Patients were asked to complete the 10 question tool on arrival to the emergency department. Patie
75609578|NCT02885688|Dietary Supplement|Liquid Nutrition|Participants receive liquid nutrition by vein non-stop for up to 7 days.
75757142|NCT00410124|Drug|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
75757143|NCT00410124|Drug|Placebo|
75757144|NCT01036932|Drug|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
75757145|NCT01036932|Drug|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
75757146|NCT00410046|Drug|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
75757147|NCT00416624|Drug|darbepoetin alfa|
75757148|NCT00416624|Drug|epoetin alfa|
75757149|NCT00416624|Procedure|fatigue assessment and management|
75757150|NCT00416624|Procedure|quality-of-life assessment|
75757151|NCT01037504|Drug|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
75757152|NCT01037504|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
75757153|NCT00262600|Drug|warfarin|once a day
75903524|NCT05124912|Procedure|Radiation Therapy|Post-op hypofractionated therapy or no radiation therapy
76068561|NCT01519167|Drug|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
76068562|NCT01519167|Drug|Midazolam|0.025 - 2 mg/kg IV
76068563|NCT01519167|Drug|Fentanyl|0.5 - 3 mcg/kg IV
76068564|NCT00343564|Drug|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
76068565|NCT00343564|Drug|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
76068566|NCT00318136|Drug|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
76068567|NCT00318136|Drug|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
75457725|NCT01788826|Procedure|No prophylactic mesh closure|Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
75457726|NCT01788865|Device|cSEMS(Covered self-expandable dual-layered metal stent) implant|
75609579|NCT02885688|Procedure|Insulin Drip|"Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU."
75609580|NCT00950248|Drug|Idebenone|idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
75457727|NCT01788878|Behavioral|Questionnaires|"A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.~Medical data will be collected via the CRF."
75457728|NCT01788930|Device|CPAP|
75457729|NCT01788956|Device|Mespere Venous Oximeter|Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
75457730|NCT01788956|Device|Co-Oximeter|
75457731|NCT01788969|Drug|Lexapro|Agent + training vs Placebo + training
75609581|NCT00950248|Other|placebo|lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
75609582|NCT04269928|Procedure|Endovascular chemical ablation of adrenal gland|Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
75609583|NCT00950170|Procedure|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
75757154|NCT00262600|Drug|Dabigatran dose 1|twice daily
75757155|NCT00262600|Drug|Dabigatran dose 2|twice a day
75757156|NCT00409578|Drug|Placebo|Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
75903525|NCT05124912|Drug|Steroid Therapy|Best medical management with steroid therapy
75903526|NCT05124912|Procedure|Laser Interstitial Thermal Therapy|Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
75903527|NCT05123001|Device|Biostrap arm band|The Biostrap mobile app will connect with the Biostrap arm band and temperature sensor.
75457732|NCT01788969|Drug|Placebo|Agent + training vs Placebo + training
75903528|NCT05114876|Other|Multicomponent delirium-risk prevention bundle|"This multidisciplinary intervention will introduce new practices including:~Direct-to-Patient Education Program~Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation~Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols).~Reinforce CHASM best practices with regular educational sessions for nurses."
75903529|NCT05107674|Drug|NX-1607|Oral NX-1607
76068568|NCT00318136|Drug|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
76068569|NCT00318292|Drug|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
76068570|NCT00318292|Drug|Placebo|20 ml normal saline injection.
75757157|NCT00409578|Drug|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
75457733|NCT01788982|Drug|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
75457734|NCT01788982|Drug|Placebo|
75757158|NCT00409578|Drug|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
75757159|NCT00409578|Drug|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
75609584|NCT05380804|Diagnostic Test|cutaneous silent period (CSP) measurement|CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
75757160|NCT03884088|Other|Limits of Stability|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
75757161|NCT03881436|Diagnostic Test|MRI with DTI sequence|"At the end of the planned sequence, but before any contrast agent injection:~Acquisition of a an additional anatomical T2 SPACE sequence~Acquisition of a tractography DTI sequence"
75757162|NCT01037322|Drug|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
75457735|NCT01789021|Device|4 blood glucose monitoring systems|
75457736|NCT01789060|Other|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
75457737|NCT01789073|Dietary Supplement|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
75457738|NCT01789086|Drug|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
75457739|NCT01789086|Drug|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
75757163|NCT01037322|Drug|placebo in drops|olive oil containing no drug given in drops twice daily
75757164|NCT01039818|Radiation|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
75757165|NCT01039818|Radiation|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
75757166|NCT01070758|Drug|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
75457740|NCT01789099|Biological|UV1 synthetic peptide vaccine and GM-CSF|
75757167|NCT01039896|Drug|Period I : SLM0807, Period II : HKB0701 and SLM0807|
75757168|NCT01039896|Drug|Period I : HKB0710 and SLM0807, Period II : SLM0807|
75757169|NCT00428090|Drug|Rosiglitazone|XR (extended release) oral tablets
75903530|NCT05107674|Drug|Paclitaxel|Paclitaxel IV
75457741|NCT01789112|Other|Blood sample|Taking of blood sample
75457742|NCT01789125|Drug|Nicotine Patch|
75457743|NCT01789125|Behavioral|Smoking Termination and Anxiety Reduction Treatment|Integrated smoking cessation and anxiety reduction treatment
75457744|NCT01789125|Behavioral|Education-Supportive Psychotherapy|
75457745|NCT01789151|Device|Technetium labelled glucosamine|Nuclear medicine imaging of arthritic joints using radioactive glucosamine
75457746|NCT01789177|Device|Incentive Spirometry|Patients will be provided with plastic, disposable incentive spirometers postoperatively
75457747|NCT01789177|Other|Postoperative chest physiotherapy|Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
75457748|NCT01789216|Drug|NSAID|
75457749|NCT01789216|Drug|Gabapentinoids|
75457750|NCT01789216|Drug|placebo|
75457751|NCT01789242|Drug|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
75609585|NCT02851030|Behavioral|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
75903531|NCT05104736|Drug|PT-112|PT-112 will be administered intravenously on Days 1, 8 and 15 of a 28-day cycle at a dose of 360 mg/m2
75903532|NCT05098132|Drug|STK-012|pegylated alpha/beta-biased engineered interleukin-2
75903533|NCT05098132|Drug|Pembrolizumab|anti-PD-1 humanized monoclonal antibody
75903534|NCT05095779|Behavioral|Standard Care + Financial Incentives|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
75903535|NCT05095779|Other|Standard Care|Financial Incentives participants will receive standard care for completing counseling calls.
76068571|NCT01791868|Drug|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
76068572|NCT01791868|Drug|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
75457752|NCT01789242|Drug|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with <VGPR after 4 cycles.
75757170|NCT00416312|Device|Patient-specific dosimetry|"Tumor absorbed dose calculation using patient-specific 3D-RD dosimetry software.~Patients receive dosimetric tositumomab IV over 60 minutes followed by iodine I 131 (^131I) tositumomab IV over 20 minutes on day 0. Patients undergo PET/CT scans and SPECT/CT scans on days 0; 2, 3 or 4; and 6 or 7. Patients who have acceptable biodistribution receive therapeutic tositumomab IV over 60 minutes followed by ^131I tositumomab IV over 20 minutes on approximately day 7."
75757171|NCT00416312|Device|conventional dosimetry|"Doses calculated using conventional dosimetry software.~Patients receive dosimetric rituximab IV followed by indium In 111 (^111In) ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo positron emission tomography (PET)/CT scans and single-photon emission computed tomography (SPECT)/CT scans between 2-24, 48-72, and 90-120 hours after ^111In ibritumomab tiuxetan administration. Patients who have acceptable biodistribution receive therapeutic rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes between days 7-9."
75757172|NCT01031966|Biological|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
75903536|NCT05095116|Drug|APT-1011 3 mg HS|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
75903537|NCT05092412|Radiation|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
76068573|NCT01791946|Procedure|Binocular Treatment|The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
76068574|NCT01791946|Procedure|Sham Binocular Treatment|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
76068575|NCT02105740|Behavioral|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
76068576|NCT02105740|Behavioral|Control|The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
76068577|NCT01792180|Behavioral|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
75903538|NCT05092412|Drug|Durvalumab|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.
76068578|NCT00320242|Device|1 mo baseline before visual cue|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
76068579|NCT00347308|Behavioral|Eyebrow Position|Photography of brow positions
75457753|NCT01789294|Drug|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
75457754|NCT01789294|Behavioral|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists. To ensure the correct adherence to diet with no nutritional impairment, a scheme of admitted foods and an appropriate calcium supplement dose were given to patients.
75457755|NCT01789307|Dietary Supplement|corn syrup solids|oral ingestion 50 grams, 2 doses
75757173|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
75757174|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
75757175|NCT00436436|Drug|O6-benzylguanine|
75757176|NCT00436436|Drug|temozolomide|
75757177|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
75757178|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
76068580|NCT00348946|Drug|androgen oxandrolone|Oxandrolone ,06 >mg/kg/day, orally, for 2 years
76068581|NCT00348946|Other|placebo|an inactive substance
75757179|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
75903539|NCT05092412|Drug|Etoposide, and cisplatin/carboplatin|Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide [80 to 100mg/m2] via intravenous infusion and carboplatin [ The area under the curve (AUC) is 5-6] by intravenous infusion or cisplatin [75-80 mg/m2] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.
75903540|NCT05091567|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
75903541|NCT05091567|Drug|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
75757180|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
75757181|NCT00436280|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
75757182|NCT00436280|Drug|gemcitabine|1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles
76068582|NCT00349336|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
76068583|NCT00349336|Drug|XELOX|As prescribed
75457756|NCT01789307|Dietary Supplement|sucrose|oral ingestion 50 grams, 2 doses
75757183|NCT00436280|Drug|rituximab|375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles
75757184|NCT00436280|Drug|oxaliplatin|100 mg/m², IV, once every two weeks, four to eight 2 week cycles
75757185|NCT00394836|Drug|Ofatumumab|Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
75757186|NCT00394836|Drug|Ofatumumab|followed by 7 weekly infusions of 1000mg ofatumumab
75757187|NCT00250588|Behavioral|Problem solving skills training|See description in Results
75903542|NCT05091567|Drug|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
75903543|NCT05091567|Drug|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
75903544|NCT05072158|Other|None, this is an observational study|This is a qualitative study, we will be asking for patient experiences with PFDs and the impact on their sexual function.
75903545|NCT05059977|Biological|TAK-881|Participants will receive subcutaneous infusion of TAK-881 on Day 1.
76068584|NCT00349336|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
76068585|NCT00349336|Drug|FOLFOX-4|As prescribed
76068586|NCT04888468|Biological|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
76068587|NCT04751188|Drug|Bezafibrate 200 MG Oral Tablet|Bezafibrate one tablet every 12 hours for six months.
76068588|NCT04751188|Drug|Placebo|Placebo one tablet every 12 hours for six months.
76068589|NCT04751188|Drug|Ursodeoxycholic Acid|At a dose of 13 to 15 mg per Kg per day.
75457757|NCT01789359|Other|Blueberry Juice|Dietary intervention
75457758|NCT01789385|Drug|Dexmedetomidine|Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
75457759|NCT01789398|Drug|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
75457760|NCT01789411|Other|Drawing blood samples|Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
75457761|NCT01789411|Device|Coronary intravascular ultrasound imaging|Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
75757188|NCT00250588|Behavioral|Asthma care coordination|See description in Results
75757189|NCT00250588|Other|Usual Care|Usual clinical care
75757190|NCT00416078|Behavioral|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
75757191|NCT00416078|Behavioral|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
75757192|NCT01040598|Biological|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
75903546|NCT05051384|Diagnostic Test|Doppler technology|The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors
75903548|NCT05037851|Drug|Opelconazole|Nebulizer suspension
75903549|NCT05037851|Drug|Standard of Care|Standard of Care
76068590|NCT00352612|Drug|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
76068591|NCT00352612|Drug|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
75457762|NCT01789411|Device|Coronary near-infrared spectroscopy|Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
75609586|NCT04267666|Device|incentive spirometer|Patient had to produce a high inspiratory pressure. The ball serves as visible feedback of the inspiratory flow and indicates the obtained flow on a calibrated scale on the transparent cylinder of the spirometer. If the patient flows greater than 300 milliliters per second, the float ball in first chamber will rise. As patient flow increases to 600 milliliters per second the second ball float will rise. If the patient flow exceeds 900 milliliters per second all three will be suspended. Patient should encourage holding the balls up for a few seconds
75757193|NCT01039974|Drug|GSK962040|"GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"
75757194|NCT01039974|Drug|Ketoconazole|400 mg
75757195|NCT01032122|Drug|rituximab|induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
75757196|NCT01040676|Behavioral|Automated Telephone Nutrition Support|See Intervention Group description.
75757197|NCT02481674|Drug|VX15/2503|VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
75757198|NCT02481674|Drug|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
75903550|NCT05036278|Biological|Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).|"Dosage Levels:~40 IU/kg/dose two times per week~50 IU/kg/dose every 5 days~60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU."
75457763|NCT01789437|Device|Dexamethasone Intravitreal Implant (Ozuredex)|
75903551|NCT05035771|Device|Pressure wire measurement in peripheral vascular disease|The aim of IMPACT PAD is to examine the safety and feasibility of intraprocedural flow, pressure and resistance rate changes to help predict the success of a peripheral endovascular intervention.
75903552|NCT05032157|Drug|LOU064 (blinded)|LOU064 (blinded) active treatment
76068592|NCT01793584|Procedure|Laparoscopic hysterectomy|LAVH, TLH
76068593|NCT01793584|Procedure|Abdominal hysterectomy|TAH
75457764|NCT01789450|Procedure|Section of Periareolar Dermis in Breast Reduction.|
75457765|NCT01789463|Other|Self rehabilitation|
75757199|NCT00394524|Device|Glucommander|Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG- 60).
75903553|NCT05032157|Drug|Placebo|Placebo
75903554|NCT05032157|Drug|LOU064 (open-label)|LOU064 (open -label) active treatment
75903555|NCT05024851|Other|Questionnaires|Evaluation of the Psychogenic and Neurogenic Components using questionnaires
76068594|NCT01793740|Behavioral|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
76068595|NCT00323284|Device|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
75457766|NCT01789463|Other|Self rehabilitation plus physiotherapy|
75457767|NCT01789489|Device|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
75457768|NCT01789502|Device|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
76068596|NCT00323284|Procedure|Cataract surgery only|Cataract surgery only
75457769|NCT01789502|Device|Plastic stents|Plastic stents were inserted by ERCP
76068597|NCT00323362|Drug|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
76068598|NCT00323362|Drug|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
76068599|NCT01793896|Behavioral|Control period|Analysis at recruitment and after a month without any intervention
76068600|NCT01793896|Behavioral|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
75903556|NCT05022472|Behavioral|COVID-19 Individual Awareness and Education.|The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities. These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration [2-dose series and importance of vaccine completion]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs. This information will be updated monthly to ensure the most up to date information.
75609587|NCT04267666|Other|Inspiratory muscle trainer device|The threshold trainer is a small plastic handheld device supplied by respironics. It includes a mouthpiece and a calibrated spring loaded valve. The valve controls a constant inspiratory pressure training load and the patient must generate the inspiratory pressure in order for the inspiratory valve to be opened and allow inhalation of air.
75609588|NCT00604864|Drug|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
75609589|NCT00604864|Drug|placebo|Placebo
75457770|NCT01789528|Drug|CAZ-AVI|IV infusion
75457771|NCT01789528|Drug|CXL|IV infusion
75457772|NCT01789554|Other|MLS dispatch for bystander CPR|
75457773|NCT01789580|Other|Gambling moderator|
75457774|NCT01789593|Other|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
75609590|NCT01227824|Drug|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
75609591|NCT01227824|Drug|raltegravir|raltegravir 400mg taken twice daily
75609592|NCT01227824|Other|GSK1349572 Placebo|GSK1349572 placebo taken once daily
75609593|NCT01227824|Other|ABC/3TC|Abacavir/Lamivudine background therapy once daily
75757200|NCT00394524|Other|Standard insulin infusion algorithm|Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving >80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
75757201|NCT01032278|Other|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
75757202|NCT01032278|Behavioral|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
75457775|NCT01789619|Drug|Extended release tacrolimus (Advagraf®)|
75457776|NCT01789645|Other|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
75609594|NCT01227824|Other|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
75609595|NCT01227824|Other|raltegravir Placebo|raltegravir placebo taken twice daily
75609596|NCT00949702|Drug|vemurafenib|960 mg b.i.d. continuous oral dosing
75609597|NCT01034631|Drug|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
75609598|NCT01034631|Drug|BNC105P|BNC105P, up to 16 mg/m^2
75757203|NCT00409344|Drug|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
75609599|NCT01227668|Drug|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
75757204|NCT00409344|Other|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
75757205|NCT01040754|Other|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
75757206|NCT00415610|Drug|nicardipine|"Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~Started at 5mg/h~Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour *Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued."
76068601|NCT01793896|Behavioral|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
76068602|NCT01793896|Behavioral|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
76068603|NCT00390364|Drug|everolimus|
76068604|NCT00390364|Procedure|antiangiogenesis therapy|
76068605|NCT00390364|Procedure|biopsy|
75609600|NCT01227668|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
75609601|NCT00603460|Biological|DCVax-L and T Cells|"Arm A~Optional DCVax-L prior to chemotherapy~Apheresis~Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~Infusion of activated T cells~DCVax-L vaccine~End of study visit~Arm B~Optional DCVax-L prior to chemotherapy~Apheresis~Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~Infusion of activated T cells~DCVax-L vaccine~Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~End of study visit"
76068606|NCT00390364|Procedure|diagnostic procedure|
76068607|NCT00390364|Procedure|gene expression analysis|
76068608|NCT00390364|Procedure|immunohistochemistry staining method|
76068609|NCT00390364|Procedure|laboratory biomarker analysis|
76068610|NCT00390364|Procedure|mutation analysis|
76068611|NCT00390364|Procedure|protein tyrosine kinase inhibitor therapy|
76068612|NCT00390364|Procedure|reverse transcriptase-polymerase chain reaction|
76068613|NCT00354484|Drug|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
76068614|NCT00354484|Drug|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
75609602|NCT02851186|Device|Acupuncture|
76068615|NCT00354640|Drug|anastrozole|1 milligram tablet PO QD for 14 days
76068616|NCT00354640|Drug|simvastatin|40 milligram tablet PO QD for 14 days
76068617|NCT00354640|Other|pharmacological study|laboratory analysis
76068618|NCT00354640|Procedure|adjuvant therapy|laboratory analysis
76068619|NCT02107300|Drug|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
76068620|NCT02107300|Drug|Placebo Comparator|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
76068621|NCT00392236|Device|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
76068622|NCT00392236|Behavioral|Treatment as usual|Participants will receive treatment as usual.
76068623|NCT00392392|Drug|nab-paclitaxel|ABI-007
76068624|NCT00392392|Drug|Bevacizumab|Bevacizumab
75609603|NCT02851186|Device|Sham acupuncture|
75757207|NCT00394212|Device|Transoral Suturing|suturing of anastomosis
75757208|NCT00394212|Other|Sham Endoscopy|suturing not performed
75757209|NCT01722812|Drug|Cromoglicate|Twice daily topical treatment for 14 days
75757210|NCT01722812|Drug|Placebo|Twice daily topical treatment for 14 days
75757211|NCT01323842|Procedure|EDTU|bedside ultrasound imaging by the treating emergency physician
76068625|NCT00392392|Drug|Trastuzumab|Trastuzumab
76068626|NCT01519089|Drug|CP-690,550|10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
75609604|NCT04319432|Behavioral|Voice rest|The first days will take place in hospitalization to assess patient complience to voice rest. Patients will be instructed to continue voice rest at home up to 7 days accourding to group allocation in the study. The confirmation of voice rest will relay on patient report (telephonic approval), after the voice rest period will end.
75757212|NCT01032356|Device|Wrist Extension Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
76068627|NCT01519089|Drug|CP-690, 550|5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
75757213|NCT00250432|Drug|caspofungin acetate|Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. Duration of Treatment - 14-90 days.
75757214|NCT00250276|Biological|Cervarix™|GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
75757215|NCT02532088|Dietary Supplement|Oil Palm Phenolics|Palm fruit derived phenolics compound
75757216|NCT02532088|Dietary Supplement|Placebo|Placebo
75757217|NCT00249808|Drug|Efalizumab - anti-CD11a recombinant human monoclonal antibody|Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment [FT]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
76068628|NCT00392704|Drug|Bevacizumab|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
76068629|NCT00392704|Drug|Erlotinib|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
76068630|NCT00392704|Drug|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
76068631|NCT00392704|Drug|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
75457777|NCT01789645|Procedure|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
75457778|NCT01789658|Other|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
75457779|NCT01789671|Behavioral|Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
75457780|NCT01789684|Other|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
75457781|NCT01789697|Other|cellular device/computers|A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
75457782|NCT01789710|Drug|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
75609605|NCT01227512|Drug|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
75609606|NCT01227512|Other|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
75609607|NCT01227278|Other|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
75609608|NCT01227278|Biological|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
76068632|NCT00392704|Radiation|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
75757218|NCT00278512|Biological|Autologous Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
75903557|NCT05022472|Behavioral|COVID-19 Community Outreach & Health Promotion.|Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine. The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
75457783|NCT01789710|Drug|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
75609609|NCT01034397|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
75609610|NCT01034397|Drug|placebo|iv every 4 weeks for 24 weeks
75609611|NCT01034397|Drug|non-biological DMARDs|stable dose at investigator's prescription
75609612|NCT01227044|Drug|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
75609613|NCT01227044|Other|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
75609614|NCT02872779|Procedure|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
75757219|NCT00278512|Biological|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed after conditioning
75757220|NCT00278512|Drug|Cyclophosphamide|Causes prevention of the cell division
75903558|NCT05022472|Behavioral|COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
75457784|NCT01789710|Behavioral|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
75457785|NCT01789723|Drug|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
75457786|NCT01789723|Drug|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
75457787|NCT01789749|Other|Snare Tip Soft Coagulation|
75457788|NCT01789749|Other|No Snare Tip Soft Coagulation|
75457789|NCT01789762|Biological|Autologous plasma|Transfusions of platelet concentrates re-suspended in autologous plasma
75457790|NCT01789762|Biological|Additive solution|Transfusions of platelets prepared in additive solution (Intersol)
75457791|NCT01789762|Biological|Pathogen reduction process|Patients transfused with platelets treated by pathogen reduction process
75609615|NCT01225952|Device|Crystalens AO|Bausch & Lomb model silicone multi-piece accommodating IOL.
75609616|NCT01225952|Device|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
75609617|NCT01225952|Device|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
75609618|NCT01034163|Drug|Panobinostat|
75609619|NCT01034163|Drug|Placebo|Placebo
75609620|NCT01033851|Behavioral|Mindfulness Based Stress Reduction|8 week course
75757221|NCT00278512|Drug|ATG (rabbit)|A rabbit polyclonal antibody to lymphocyte
75757222|NCT00278512|Drug|G-CSF|Hematopoietic growth factor
75757223|NCT00278512|Drug|Campath-1h|Humanized monoclonal antibody against CD52 antigen
75757224|NCT00278512|Drug|Fludarabine|inhibits DNA synthesis or repair
75757225|NCT00278512|Drug|Tacrolimus|immune suppressive drug
76068633|NCT00392782|Biological|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
75457792|NCT01789788|Drug|Placebo|Matching placebo, multiple doses
75757226|NCT00278512|Drug|Mesna|Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
75903559|NCT05022472|Biological|Pop-up community vaccination sites|We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine. We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations. Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish. Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
75903560|NCT05018416|Biological|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
75903561|NCT05016310|Dietary Supplement|High Dose Vitamin D|High dose vitamin D: Subjects will receive 50,000 IU vitamin D2 weekly x 16 weeks followed by 4,000 IU of vitamin D3 daily with a goal 25(OH)D level of ≥45 but ≤80 ng/mL.
76068634|NCT00392782|Drug|fludarabine phosphate|Fludarabine 40 mg/m^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m^2).
75609621|NCT01033851|Behavioral|Stress Management Education|8 week course
75609622|NCT01162122|Biological|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
75757227|NCT03974698|Procedure|Hemiarthroplasty|Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.
75457793|NCT01789788|Drug|RO6811135|multiple ascending doses
75609623|NCT01162122|Biological|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
75609624|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
75757228|NCT01072240|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
75757229|NCT00427934|Drug|Maraviroc|300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
75457794|NCT01789801|Procedure|RAP palpation only|Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.
75457795|NCT01789801|Procedure|RAP with ultrasound guidance|Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
75457796|NCT01789827|Other|Laboratory Biomarker Analysis|Correlative studies
75457797|NCT01789827|Procedure|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
75757230|NCT00427934|Drug|Maraviroc Placebo|Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
75757231|NCT03974542|Behavioral|telephone outreach|The navigator should make at least five (5) attempts to reach the participants on different days (at least one (1) attempt in weekend) and different time slots (at least one (1) attempt each in am, pm and evening). If the navigator only reached voice mail after the 1-month intervention period, a standard script will be read and a contact number will be provided.
75903562|NCT05016310|Dietary Supplement|Standard of Care Vitamin D|Standard of Care Vitamin D: Vitamin D will be supplemented to 25(OH)D levels, with a goal 25(OH)D level of >30 ng/mL according to Endocrine Society Practice Guidelines.
75609625|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
75903563|NCT05014828|Drug|lenvatinib|Capsules administered orally
75903564|NCT05014828|Drug|Tislelizumab|intravenous (iv) infusion
75903565|NCT05013736|Device|Magnetic Resonance Imaging|3 Tesla Discovery MR750 MRI scanner (GE Healthcare, Waukesha, WI) will be used to perform structural imaging, diffusion MRI, relaxometry and microstructural imaging. The exact scan length and parameters of each scan type (T1, T2, DWI) will be set for this study to optimize the quality of data and decrease the length of scanning session for each type of scan. All of the imaging methods have been previously implemented at UW-Madison. Each sequence will take approximately 5-10 minutes.
75903566|NCT05013736|Behavioral|Behavioral Assessments|The behavioral assessments (GMA: General Movements Assessment; HINE: Hammersmith Infant Neurological Examination; Baby Observation of Selective Control AppRaisal (BabyOSCAR); Bayley-4 / Bayley Scales of Infant and Toddler Development 4th ed; Pediatric Evaluation of Disability Inventory -Computer Adaptive Test (PEDI-CAT)) are infant and age-specific and will be administered by trained pediatric occupational and physical therapists.
75903567|NCT05013736|Device|Non invasive Transcranial Magnetic Stimulation|TMS will be used to assess cortical excitability and circuitry (not as a neuromodulation intervention). Single-pulse TMS (Magstim 200², Magstim, UK) with a scalp surface coil will be used to assess how the brain is developing and how connected the tract is, between the brain and a target muscle on the arm. 10-20 TMS stimulation pulses will be delivered at a range of stimulation intensities (50-100%) increasing by 5% maximal stimulator output (MSO) at each stage. In sum, around 150 stimulation pulses per hemisphere are expected for TMS assessment for each infant.
75903568|NCT05011123|Biological|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection - Subcutaneous
75903569|NCT05011123|Biological|Yellow fever vaccine|Powder and diluent for suspension for injection - Subcutaneous
76068635|NCT00392782|Drug|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
75609626|NCT01033071|Drug|Olmesartan medoxomil and hydrochlorothiazide|"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
75609627|NCT04313946|Diagnostic Test|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
76068636|NCT00392782|Procedure|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
75757232|NCT00435188|Behavioral|Multi-component physical activity counseling program|A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
75457798|NCT01789827|Biological|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
75457799|NCT01789853|Behavioral|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
75457800|NCT01789853|Behavioral|Conventional Physical Therapy|Regular physical therapy for 8 weeks
75457801|NCT01789892|Drug|methylprednisolone|Given IV
75457802|NCT01789892|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT scan
75757233|NCT00427778|Device|incontinence ring|"Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra."
75457803|NCT01789892|Procedure|positron emission tomography|Undergo FDG PET/CT scan
75457804|NCT01789892|Procedure|computed tomography|Undergo FDG PET/CT scan
75457805|NCT01789918|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
75457806|NCT01789931|Device|"Lifebeam"|"The lifebeam sensor will be attached to the participant's skin during the HTT."
75457807|NCT01789944|Behavioral|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
75457808|NCT01789957|Drug|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
75457809|NCT01789996|Procedure|alternative six minute walk test|"Alternate instructions will be given Subjects will~walk as fast as they can in 6 minutes~walk as normally as they can in 6 minutes~walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
75457810|NCT01789996|Procedure|Standard six minute walk test|Subjects will walk as far as they can in 6 minutes
75609628|NCT04125030|Other|Validation of questionnaires|Participants will complete i) the RAS (24 items, 5-point Likert scale), ii) the CM (23 items, 5-point Likert scale), and the iii) the RSA for consumers (32 items, 5-point Likert scale). These participants have already completed these other measures (clinical recovery): iv-Anxiety: Anxiety State-Trait Anxiety Inventory Form Y6 (STAI-Y6) (6 items); v- Depression: Depression Patient Health Questionnaire (PHQ-9) (9 items) ; vi- Alcohol Dependence: Alcohol Use Disorders Identification Test (AUDIT-10) (10 items) ; vii- Drug Dependence: Drug Abuse Screening Test (DAST-10) (10 items) ; viii- Psychosis : Psychosis Screening Questionnaire (PSQ 12 items) ; ix- Social functioning : World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12 items).
75609629|NCT01032915|Biological|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
75609630|NCT01032915|Biological|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
75757234|NCT02848196|Radiation|Stereotactic Body Radiation Therapy|The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.
75757235|NCT00427700|Drug|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
75903570|NCT04985773|Device|Lacrosse NSE ALPHA coronary dilatation catheter|The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
76068637|NCT00392782|Radiation|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
76068638|NCT01795300|Radiation|Carbon Ion Radiotherapy|"Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
75757236|NCT00427700|Drug|raloxifene|100mg PO on days 5-9 of the menstrual cycle
75757237|NCT01324076|Drug|doxorubicin-eluting beads|
75757238|NCT01324076|Drug|sorafenib tosylate|
75757239|NCT01324076|Other|laboratory biomarker analysis|
75757240|NCT01324076|Other|pharmacogenomic studies|
75457811|NCT01790620|Other|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
75609631|NCT01032915|Biological|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
75609632|NCT01032915|Drug|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
75757241|NCT01324076|Other|pharmacological study|
75757242|NCT01324076|Procedure|quality-of-life assessment|
75757243|NCT00409188|Biological|Tecemotide (L-BLP25)|After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
75757244|NCT00409188|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
75757245|NCT00409188|Drug|Placebo|A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
75609633|NCT00627783|Other|a bicycle exercise test|
75757246|NCT00434954|Drug|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
75757247|NCT00434954|Drug|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
75757248|NCT00276484|Drug|atorvastatin|Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
75757249|NCT00276484|Drug|atorvastatin|Atorvastatin 40 mg by mouth, once a day for 6 weeks
75757250|NCT00276484|Drug|ezetimibe|Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
75757251|NCT00426842|Drug|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
75903571|NCT04968808|Procedure|Staged in-hospital complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
76068639|NCT01795300|Radiation|Proton Therapy|"As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
75609634|NCT01161498|Biological|Talimogene Laherparepvec|Administered by intratumoral injection
75609635|NCT01161498|Radiation|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
75609636|NCT01161498|Drug|Cisplatin|Administered by intravenous infusion
75757252|NCT00434876|Drug|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
75609637|NCT02873559|Drug|testosterone|Testosterone supplemented in 5 months
75609638|NCT02873559|Other|Progressive muscle training|Progressive muscle training during 4 months
75609639|NCT01180998|Device|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
75757253|NCT00434876|Drug|Placebo.|Inactive or inert pill which will be used as a comparator.
75757254|NCT01072318|Drug|Letrozole|Letrozole 2.5mg
75757255|NCT01072474|Procedure|Capnography|Capnographic monitoring
75757256|NCT01072474|Procedure|Standard monitoring|Standard monitoring
75757257|NCT00276094|Drug|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
75757258|NCT00276094|Drug|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
75757259|NCT00276094|Drug|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
75757260|NCT00276094|Drug|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
75757261|NCT03975088|Procedure|Sub-macular injection of Ranibizumab|In this study, authors describe a new surgical technique for the treatment of refractory non tractional DME. The technique consists of vitrectomy with ILM peeling with subretinal injection of Ranibizumab.
75757262|NCT00276016|Drug|phenylephrine|immediate-release 12 mg capsules for oral administration
75757263|NCT00276016|Drug|pseudoephedrine|60 mg immediate-release tablets for oral administration
75757264|NCT00276016|Drug|placebo|placebo capsules
75609640|NCT01180998|Device|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
75757265|NCT00434642|Drug|Carboplatin|Carboplatin was provided as commercially available drug.
75757266|NCT00434642|Drug|Gemcitabine|Gemcitabine was provided as commercially available drug.
75757267|NCT00434642|Drug|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL [25 mg/mL]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
75757268|NCT00434642|Drug|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
75757269|NCT01032434|Drug|sertraline|sertraline: 50-200mg/day
75757270|NCT01032512|Dietary Supplement|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
75609641|NCT01029795|Drug|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
75757271|NCT01032512|Dietary Supplement|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
75757272|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
75757273|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
75903572|NCT04968808|Procedure|Immediate complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
75903573|NCT04963413|Biological|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
75903574|NCT04956640|Drug|LY3537982|Oral
75903575|NCT04956640|Drug|Pembrolizumab|Intravenous
75609642|NCT01029795|Drug|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
75757274|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
75903576|NCT04956640|Drug|Cetuximab|Intravenous
75903577|NCT04956640|Drug|Pemetrexed|Intravenous
75903578|NCT04956640|Drug|Cisplatin|Intravenous
75903579|NCT04956640|Drug|Carboplatin|Intravenous
75903580|NCT04943536|Drug|bicalutamide|localized anti-androgen therapy
75903581|NCT04943536|Radiation|Stereotactic body radiation therapy|localized radiation therapy
75903582|NCT04942483|Diagnostic Test|Blood eosinophil count|Peripheral blood eosinophil count will be measured from a finger prick blood sample, using the Haemocue machine, allowing a result in approximately 2 minutes. The test will allow to assess the presence or not of eosinophilia and if it can predict future wheezing exacerbations and response to inhaled corticosteroids (ICS).
75609643|NCT01029795|Drug|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
75609644|NCT04124874|Other|There will be no intervention|There will be no intervention
75609645|NCT02885766|Drug|PF-114|
75609646|NCT02885454|Drug|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
75609647|NCT02885454|Drug|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
75757275|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
75757276|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
75757277|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
75903583|NCT04942483|Diagnostic Test|Atopic sensitization|Skin prick tests will be performed to: (a) house dust mite, (b) grass pollen, (c) tree pollen, (d) cat hair, (e) dog hair, as well as normal saline and histamine which will act as negative and positive controls respectively. In addition, skin prick tests will allow the assessment of which aeroallergen is the most useful predictor of outcomes in preschool children.
75903584|NCT04942483|Diagnostic Test|FeNO (offline method)|The child will breathe normally into a sample bag that will be collected for later analysis of FeNO levels. The test will be performed twice.
75903585|NCT04941898|Biological|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
76068640|NCT01795300|Radiation|Hypofractionated Photon Radiotherapy|"Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.~To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions."
75609648|NCT02885454|Drug|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
75609649|NCT02885454|Drug|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
75757278|NCT01588964|Procedure|HIPEC|surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
75609650|NCT02885610|Biological|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
75609651|NCT02885610|Biological|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
75757279|NCT00426764|Drug|Romidepsin|Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
75757280|NCT01032590|Behavioral|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
75757281|NCT01034150|Device|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
75757282|NCT01034150|Device|Placebo stimulation|Placebo stimulation
75903586|NCT04935372|Other|Observational|"Cross sectional analyses The two main variables for the analysis will be: Values of biomarker concentrations in blood and their correlations with CSF biomarkers and the development of prodromal AD for the cognitively unimpaired SCD population. Other variables of interest for the study are, among others, risk factors, cognitive status, measurements of brain structure and function, mental health, chronic diseases, environmental exposures, age and sex.~Longitudinal analyses Longitudinal analyses will estimate the association between the intensity of the subjective complaint and the rate of progression between the diagnostic categories; The association of biomarkers, risk factors and other clinical variables with the rate of progression between the diagnostic categories; The association of cognitive and neuroimaging variables with the rate of progression between the diagnostic categories; The evolution of the complaint itself and its relation to the other variables described."
75609652|NCT02885610|Biological|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
75609653|NCT02885610|Biological|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
75903587|NCT04925219|Behavioral|Remotely supervised exercise programme|Electronic walking log Fortnightly video/telephone calls with physiotherapist
75903588|NCT04925219|Behavioral|Self-directed exercise|Electronic walking log and instructions to exercise 4 times per week.
75903589|NCT04920812|Genetic|diagnosis of mitochondrial myopathy|• Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
75609654|NCT04314180|Device|Taking slit-lamp images|The participant only needs to take several slit-lamp images as usual.
75903590|NCT04911816|Drug|Hydroxychloroquine sulfate|Hydroxychloroquine, oral, dose escalated (400mg, 800mg, 1200mg) beginning concurrent with mFOLFIRINOX and extending 2 weeks post-operatively. Dose will be assigned to patients using 3+3 Algorithm to identify the Maximum Dose Tolerated.
75903591|NCT04908189|Drug|Deucravacitinib|Specified dose on specified days
75903592|NCT04908189|Other|Placebo|Specified dose on specified days
75903593|NCT04908189|Drug|Apremilast|Specified dose on specified days
75757283|NCT01032668|Drug|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
75757284|NCT01034228|Other|ORS + Isoleucine|ORS with Isolelucine for treatment of diarrhoeal in children
75757285|NCT01034228|Other|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
75609655|NCT01032837|Drug|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
75609656|NCT01032837|Drug|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
75609657|NCT01032837|Drug|Placebo|Matching placebo provided as capsules and as a suspension.
75609658|NCT04314102|Other|No intervention will be made.|No intervention will be made. Only checks will be made
75609659|NCT01180296|Drug|oral micronized progesterone|oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
75609660|NCT01180296|Drug|Identical Placebo tablet|Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
75609661|NCT01160640|Drug|Ceftriaxone|ceftrixone 250mg IM single dose
75757286|NCT00434252|Drug|bevacizumab|15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
75757287|NCT00434252|Drug|carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
75757288|NCT00434252|Drug|paclitaxel|175 mg/m^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
75609662|NCT01160640|Drug|Doxycycline|Doxycycline 100 mg PO bid x 14 days
75609663|NCT01160640|Drug|Metronidazole|metronidazole 500 mg PO bid x 14 days
75609664|NCT01160640|Drug|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
75757289|NCT00434252|Drug|placebo|Administered by IV infusion on the first day of each 3-week cycle
75757290|NCT01032746|Other|educational intervention|
75903594|NCT04865133|Procedure|Biospecimen Collection|Undergo blood sample collection
75903595|NCT04865133|Other|Electronic Health Record Review|Medical record reviewed
75609665|NCT01160484|Drug|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
75757291|NCT01032746|Other|internet-based intervention|
75609666|NCT01032291|Drug|cetuximab|Intravenous infusions of cetuximab (400 mg/m^2 Cycle 1 Day 1, thereafter 250 mg/m^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
75903596|NCT04864782|Drug|QL1604|Intravenous Infusion
76068641|NCT01795300|Radiation|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.
75609667|NCT01032291|Drug|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
76068642|NCT01518699|Drug|Ha44|Abametapir Lotion 0.74%
76068643|NCT01518699|Drug|Ha44 Placebo|Ha44 Vehicle Gel without Abametapir
75609668|NCT01159938|Drug|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
75757292|NCT01032746|Procedure|evaluation of cancer risk factors|
75757293|NCT01032746|Procedure|fecal occult blood test|
75757294|NCT01032746|Procedure|screening colonoscopy|
75757295|NCT00425750|Drug|bortezomib|1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
75757296|NCT00425750|Drug|docetaxel|40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
75757297|NCT00425750|Other|laboratory biomarker analysis|Tissue and blood collection.
75757298|NCT00425750|Other|pharmacological study|Blood collection.
75757299|NCT03994250|Other|Kinematic Alignment for total knee replacement surgery|Using Kinematic Alignment for total knee replacement surgery
75757300|NCT03994250|Other|Mechanical Alignment for total knee replacement surgery|Using mechanical alignment for total knee replacement surgery
75757301|NCT00414908|Drug|Pancrelipase delayed release capsule|24,000 unit capsule
75903597|NCT04864782|Drug|Paclitaxel injection|Intravenous Infusion
75903598|NCT04864782|Drug|Cisplatin/Carboplatin|Intravenous Infusion
75903599|NCT04862780|Drug|BLU-945|Oral administration
75903600|NCT04862780|Drug|osimertinib|Osimertinib tablets for oral administration
76068644|NCT01518699|Drug|Moxifloxacin Placebo|Moxifloxacin Placebo
76068645|NCT01518699|Drug|Moxifloxacin|Moxifloxacin 400mg
76068646|NCT04556266|Biological|CAR T-Cell Infusion|Dose Level -1: 1 x 10^4 cells/kg Dose Level 1: 1 x 10^5 cells/kg Dose Level 2: 2 x 10^5 cells/kg Dose Level 3: 4 x 10^5 cells/kg
76068647|NCT01792648|Other|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
76068648|NCT01792648|Other|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
75757302|NCT00414908|Drug|Placebo Comparator|Placebo
75757303|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
75757304|NCT01037582|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
75757305|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
75903601|NCT04842331|Drug|RESP301 (a nitric oxide generating solution)|Administration is simple and convenient; each dose of RESP301 is administered 3 times daily (at least 4 hours apart) via inhalation using a portable handheld vibrating mesh nebuliser for approximately 8-10 minutes.
75903602|NCT04842331|Drug|Standard of Care (SOC)|Participants will receive institutional SOC for the treatment.
75903603|NCT04835831|Other|adapted physical activity + Dietetic advice|adapted physical activity during 24 weeks
75757306|NCT01037582|Drug|placebo|Subjects will be randomized to receive a single dose of placebo.
75903604|NCT04829578|Other|Hypnosis|Chronic idiopathic pruritus is treated by hypnosis
75903605|NCT04827862|Drug|Pembrolizumab|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
75903606|NCT04817007|Drug|BMS-986158|Specified dose on specified days
75903607|NCT04817007|Drug|Ruxolitinib|Specified dose on specified days
75903608|NCT04817007|Drug|Fedratinib|Specified dose on specified days
75903609|NCT04814368|Biological|canakinumab|intra-articular injection (into the knee)
75903610|NCT04814368|Biological|LNA043|intra-articular injection (into the knee)
75757307|NCT01037582|Drug|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
75903611|NCT04814368|Other|Placebo to canakinumab|intra-articular injection (into the knee)
75903612|NCT04804735|Device|REV : local anesthesia and virtual reality|REV : local anesthesia and virtual reality in Implanted Venous Access Device (IVAD) procedure under local anesthesia
75903613|NCT04804735|Device|MUS : local anesthesia and music therapy|MUS : local anesthesia and music therapy in Implanted Venous Access Device (IVAD) procedure under local anesthesia
75609669|NCT02873871|Device|Standardized compressive dressing|Standardized compressive dressing
75609670|NCT02873871|Device|Hemostasis with TerumoBand®|Hemostasis with TerumoBand®
75609671|NCT04301739|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
75903614|NCT04803305|Drug|PF-06946860|subcutaneous injection
75903615|NCT04803305|Drug|Placebo for PF-06946860|subcutaneous injection
75903616|NCT04801329|Drug|Vyndamax (tafamidis 61mg)|As prescribed in real world practice
76068649|NCT01792648|Other|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
76068650|NCT01792726|Radiation|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
76068651|NCT01518309|Drug|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
76068652|NCT04067895|Procedure|epiphysiodesis|All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
76068653|NCT01419717|Drug|Denosumab|Administered by subcutaneous injection every 4 weeks (Q4W)
76068654|NCT04748133|Device|acupuncture needles|"Site of acupuncture points:~Du 26: At junction of the upper and middle third of philtrum.~Ren 17: On the midline level with the 4th intercostal space midway between the nipples.~LI4 (Large Intestine 4): On the dorsum of the hand, between the 1st and 2nd metacarpal bones~HT7 (Heart 7): On the ulnar end of the transverse crease of the wrist, in the small depression between the pisiform and ulna bones~LV3 (Liver 3): On dorsum of the foot in a depression distal to the junction of the 1st and 2nd metatarsal bones.~ST36 (Stomach 36): Antero-lateral leg, 1 middle-finger breadth next to the anterior crest of tibia, 3 cun under the depression lateral to the patellar ligament.~PC6 (Pericardium 6): Palmar aspect of the forearm, between the tendons, 2 cun away from the transverse crease of the wrist"
75609672|NCT04301739|Drug|nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|chemotherapeutics
75609673|NCT04301739|Drug|Placebo|Placebo
75609674|NCT04301583|Dietary Supplement|procyanidin B2 enriched cocoa|Volunteers will intake 5 grams per day of dietary supplement for 10 weeks
76068655|NCT04748133|Other|placebo|no treatment
76068656|NCT01458951|Drug|tofacitinib|10 mg oral BID
76068657|NCT01458951|Drug|Placebo|Placebo oral BID
75757308|NCT01037582|Drug|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
76068658|NCT01458639|Drug|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
75609675|NCT01029405|Drug|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
75609676|NCT01029405|Drug|Placebo|Ointment B Vehicle applied once or twice daily
75609677|NCT02872623|Radiation|Enterography-MRI without enteroclysis|
75609678|NCT02872623|Radiation|enteroCT with enteroclysis|
75609679|NCT01021683|Drug|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
75757309|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
75757310|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
75757311|NCT00242710|Drug|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
75757312|NCT00242710|Other|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
75757313|NCT00408876|Drug|Duloxetine|
75757314|NCT00408876|Drug|Placebo|
75609680|NCT01021293|Biological|Poliorix™|3 doses, intramuscular administration
75609681|NCT01021293|Biological|Oral Poliovirus vaccine|3 doses, oral administration
75903617|NCT04795908|Device|Transcranial Magnetic Stimulation|rTMS will be delivered using a MagStim Super Rapid2 TMS therapy system.
75903618|NCT04795908|Behavioral|Comprehensive behavioral intervention|Patients will receive CBIT with a therapist trained in CBIT. Each session will last about an hour and will be delivered remotely via telemedicine. Sessions will be tailed to the patient's individual needs.
75903619|NCT04782687|Drug|Selinexor|oral drug that comes in 20 mg tablets
75903620|NCT04782687|Drug|Dexamethasone Oral|Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those >75 years old may be administered a weekly dose of 20 mg dexamethasone.
75903621|NCT04782687|Drug|Daratumumab|"Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter."
75609682|NCT04625725|Drug|AZD7442|"Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366"
75757315|NCT00240994|Drug|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
75757316|NCT00240994|Drug|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
75757317|NCT00240994|Drug|Mycophenolate mofetil|Per recommendation
75757318|NCT00240994|Drug|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
75757319|NCT01070836|Drug|natalizumab|Administered as specified in the treatment arm
75903622|NCT04782687|Drug|Lenalidomide|Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
75757320|NCT00239590|Drug|Testosterone undecanoate|Licensed for androgen deficiency
75757321|NCT00433160|Drug|Teriparatide|daily, subcutaneous
76068659|NCT01458639|Drug|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
75903623|NCT04781907|Procedure|Tissue Expansion|Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
75609683|NCT04625725|Drug|Placebo|Single dose (× 2IM injections) of saline placebo on parent study Day 1.
75609684|NCT01021215|Drug|Zileuton|1200 mg twice daily given orally (PO) for 6 days
75757322|NCT00433160|Drug|Placebo|daily, subcutaneous
75903624|NCT04775472|Procedure|Early left atrial septostomy within 12 hours after VA-ECMO implantation|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation. Left atrial septostomy will be done using percutaneous technique.
75903625|NCT04775472|Procedure|Selective left atrial septostomy|Left atrial septostomy will be done in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
75903626|NCT04770402|Other|Acupuncture|12 acupuncture sessions over 10 weeks
75903627|NCT04770402|Other|Standard of Care CIPN management|Investigator directed standard of care management of CIPN
75903628|NCT04765137|Drug|Atorvastatin Oral Tablet|Atorvastatin pill 40 mg to be taken every night
75757323|NCT00239356|Drug|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
75609685|NCT01021215|Drug|Celecoxib|200 mg twice daily given orally for 6 days
75757324|NCT03974386|Device|oXiris blood purification set|Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.
75609686|NCT01021215|Other|laboratory biomarker analysis|Correlative studies
75609687|NCT02760979|Drug|Denosumab|Denosumab treatment one year after surgery
75609688|NCT02760979|Drug|Placebo|Serum one year after surgery
75609689|NCT04301115|Other|attachment|unilateral attachment from rehine 83
75609690|NCT04301115|Other|bridge|tooth implant supported bridge
75757325|NCT00393510|Drug|TCM|"The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The formula consisted of 12 herbs, viz:~Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae"
75757326|NCT00393510|Drug|Placebo|"Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The placebo was made with starch and colouring materials."
75903629|NCT04760691|Drug|Truvada alone|TDF/FTC 300 mg (milligrams) / 200 mg by mouth once daily
75903630|NCT04760691|Drug|Truvada plus Leuprolide|TDF/FTC 300mg/ 200 mg by mouth once daily Leuprolide 11.25 mg im once
75903631|NCT04760691|Drug|Truvada plus Estradiol 1 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily
75903632|NCT04760691|Drug|Truvada plus Estradiol 6 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily
75903633|NCT04760691|Drug|Estradiol 6 mg alone|Estradiol 3 mg by mouth twice daily
76068660|NCT01437423|Biological|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
76068661|NCT00393796|Drug|SUTENT|"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
76068662|NCT00393796|Other|Placebo|
75609691|NCT04301115|Other|CONVENTIONAL|conventional metalic partial denture
75609692|NCT05429281|Other|Pilates-based Core Strengthening Exercises|The PsCS group performed eight Pilates exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the supervision of a physical therapist who had more than 5 years of experience in Pilates.
75609693|NCT05429281|Other|Plyometric-based Muscle Loading Exercises|The PlyoML group performed 10 plyometric exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
75757327|NCT01040910|Drug|smoking of cannabis|smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
75757328|NCT01040910|Drug|smoking cigarettes with placebo|smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
75903634|NCT04741230|Device|Gebauer Lenticule|The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
75903635|NCT04711915|Drug|0.1 mg/kg Dimethyltryptamine (DMT)|0.1 mg/kg DMT
75903636|NCT04711915|Drug|0.3 mg/kg Dimethyltryptamine (DMT)|0.3 mg/kg DMT
76072374|NCT00673010|Radiation|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
75609694|NCT05429281|Other|Combined Pilates and Plyometrics|The combined training group performed the same exercises as the PsCS and PlyoML groups, although with half the number of sets/repetitions over 45 minutes, three times per week for 12 successive weeks. The PsCS and PlyoML were executed within the same session, with a 10-to-15-minute rest interval. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
75609695|NCT02873325|Other|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
75757329|NCT00425438|Drug|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
75757330|NCT00425438|Drug|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
75757331|NCT00425438|Drug|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
75757332|NCT00425438|Drug|Cyclophosphamide|0.75 g/m^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m^2 to maintain a minimum WBC count of ≥ 2500 per mm^3 from Weeks 5 through 24
75903637|NCT04700098|Behavioral|Internet-based behavioral treatment for insomnia|Internet version of cognitive-behavioral treatment for insomnia
75757333|NCT01041066|Drug|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
75903638|NCT04700098|Behavioral|Online insomnia patient education|Online insomnia patient education
75757334|NCT01041066|Drug|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
75903639|NCT04668157|Drug|TAK-536|TAK-536 granule formulation
75609696|NCT02873403|Device|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
75609697|NCT02873403|Device|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
75757335|NCT01323608|Drug|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
75757336|NCT01323608|Drug|Placebo|Placebo
75757337|NCT00275002|Drug|O6-benzylguanine|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
75757338|NCT00275002|Drug|temozolomide|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
75903640|NCT04663308|Drug|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
75903641|NCT04663308|Drug|Placebo|Capsules matched to study drug minus active substance
75757339|NCT00433004|Drug|Plan B (Levonorgestrel)|PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
75757340|NCT00238264|Radiation|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
75757341|NCT00414596|Device|DRX9000™|Device is designed to apply spinal decompressive forces.
75757342|NCT00393042|Drug|Dexmethylphenidate|10, 20, 25-30 mg.
75757343|NCT00393042|Drug|Mixed Amphetamine Salts, ER|10, 20, 25-30
75757344|NCT00393042|Drug|placebo|randomized placebo week during each 4 week period
75903642|NCT04660721|Combination Product|sFilm-FS|sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.
75903643|NCT04660721|Combination Product|TACHOSIL®|TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.
75903644|NCT04660201|Biological|AV7909|AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant
75903645|NCT04660201|Biological|AV7909|AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
75457812|NCT01790620|Other|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
75903646|NCT04637763|Genetic|CB-010|CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
75903647|NCT04637763|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
75903648|NCT04637763|Drug|Fludarabine|Chemotherapy for lymphodepletion
75903649|NCT04619420|Drug|JNJ-63733657|JNJ-63733657 low or high dose will be administered by IV infusion.
75903650|NCT04619420|Drug|Placebo|Placebo matching to JNJ-63733657 will be administered by IV infusion.
75903651|NCT04617457|Drug|nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)|preoperative chemotherapy
75903652|NCT04607135|Device|Acoustic radiation force impulse (ARFI)|"Sound waves are sent in a series and are expected to push on the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system"
75757345|NCT03742362|Device|MRI scans of distal radius|MRI scans to monitor the fat fraction in the bone marrow of the distal radius
75903653|NCT04607135|Device|Ultrasound|Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen
76072375|NCT00610883|Drug|LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU|LSA4 intervention includes three phases: induction, consolidation and maintenance
76072376|NCT00574496|Drug|cyclophosphamide|
75757346|NCT00392808|Biological|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
75757347|NCT03766464|Diagnostic Test|Evaluation of TMD and pain sensitivity|Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
75757348|NCT03766464|Diagnostic Test|Evaluation of SB|The presence or absence of SB will be diagnosed by Polysomnography
76072377|NCT00574496|Drug|cyclosporine|
76072378|NCT00574496|Drug|fludarabine phosphate|
75757349|NCT03766464|Diagnostic Test|Evaluation of AB|A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
75757350|NCT01041144|Behavioral|lifestyle counseling|supporting diabetes patients using Internet communication
75757351|NCT01040286|Drug|Flurbiprofen|2.0 mg
75757352|NCT01040286|Drug|Chlorhexidine|2.5mg
75757353|NCT01041222|Drug|ISIS 333611|5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
75757354|NCT01041300|Device|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).~Total Duration of device: 15 minutes"
75903654|NCT04599140|Drug|CXCR1/2 Inhibitor SX-682|Given PO
75903655|NCT04599140|Biological|Nivolumab|Given IV
75903656|NCT04597411|Radiation|225^Ac-PSMA-617|administered intravenously under the dose escalation schedule
75903657|NCT04597411|Radiation|68^Ga-PSMA-11|administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)
75903658|NCT04591093|Device|FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
75903659|NCT04590885|Behavioral|Couple Communication Skills Training|Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.
75903660|NCT04590885|Behavioral|Healthy Lifestyle Information|Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.
75903661|NCT04586127|Other|AYA NA-SB Questionnaire|Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
75903662|NCT04574778|Drug|Acetaminophen|1000 mg of oral acetaminophen preoperatively administered
76072379|NCT00574496|Drug|gemcitabine hydrochloride|
76072380|NCT00574496|Drug|ifosfamide|
76072381|NCT00574496|Drug|mechlorethamine hydrochloride|
76072382|NCT00574496|Drug|melphalan|
76072383|NCT00574496|Drug|methotrexate|
76072384|NCT00574496|Drug|mycophenolate mofetil|
75609698|NCT02754505|Other|Early rehabilitation|The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
75757355|NCT01041300|Device|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).~Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).~Total Duration with Device: 2 hours and 30 minutes"
75609699|NCT02754505|Other|Usual care|exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
76068663|NCT00393874|Behavioral|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
75757356|NCT03761550|Combination Product|pMDT(Process Implementation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
75757357|NCT01041378|Drug|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
75757358|NCT03546192|Biological|Fluzone Quadrivalent Influenza Vaccine|0.5-mL, Intramuscular, SH 2015 formulation
75609700|NCT04301193|Device|Quantra Analyzer|Subjects blood will be manipulated in the lab and will be tested with the Quantra Analyzer
75609701|NCT02760901|Drug|Acetazolamide|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
75609702|NCT02760901|Drug|Acetylcysteine|patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
75609703|NCT02760901|Drug|Mannitol|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
75609704|NCT02760901|Drug|saline|saline hydration 2500 ml before cisplatin therapy
75609705|NCT02760901|Drug|Cisplatin|patients with tumours already prescribed cisplatin
75609706|NCT04301427|Other|Bone mineral density|Bone mineral density will be measured twice in all included patients.
75609707|NCT00635713|Drug|Fulvestrant|125mg
75609708|NCT00635713|Drug|Anastrozole|ARIMIDEX
75757359|NCT01043796|Other|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
75757360|NCT01043796|Other|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
75757361|NCT01043952|Drug|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
76068664|NCT00393874|Drug|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
76072385|NCT00574496|Drug|prednisone|
76072386|NCT00574496|Drug|procarbazine hydrochloride|
76072387|NCT00574496|Drug|vincristine sulfate|
75457813|NCT01790711|Procedure|FMT through mid-gut|
75457814|NCT01790854|Drug|Prasugrel dose 5 mg/day|
75457815|NCT01790854|Drug|Prasugrel dose 10 mg/day|
75463289|NCT05854732|Other|Inclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a experimental group with fixed speed of 5.0 mph and increased inclination of 1% after every one minute. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and increased inclination of 1% after every one minute for 30 minutes ending with Cool down for 5 minutes.
75757362|NCT01043952|Drug|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
75757363|NCT01043952|Device|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
75757364|NCT03973450|Other|Registration of familial forms and associated neoplasia|Retrospective registration of associated endocrine and non-endocrine neoplasia and potential familial setting
75757365|NCT00274846|Biological|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
75757366|NCT00274846|Biological|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10^9
75757367|NCT00274846|Drug|cyclophosphamide|Days -5 and -4: 60 mg/kg
75757368|NCT00274846|Drug|fludarabine phosphate|Days -5 through -2: 25 mg/m^2
75757369|NCT00274846|Procedure|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
75757370|NCT01073722|Device|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
75757371|NCT01073722|Device|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
75757372|NCT01072708|Other|Prospective cohort with an annual follow-up|"Annualfollow-up including :~oral glucose tolerance test~dietary survey~biological evaluation~bacteriological and respiratory measures~dual-energy x-ray absorptiometry~physical activity survey"
75757373|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30)
75757374|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30-200,201)
75757375|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30)
75757376|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30-200,201)
75757377|NCT01072786|Biological|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
75757378|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
75757379|NCT01071460|Device|FlexStent Femoropopliteal Self-Expanding Stent System|"Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy~Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:~Contralateral retrograde common femoral cross-over access or antegrade access~Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion~Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis~Deployment of an appropriately sized FlexStent® to cover target lesion~Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter~Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications"
75757380|NCT03974308|Other|Comprehensive physiotherapy including balneotherapy and filling questionaire|Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.
76068665|NCT00393874|Drug|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
76068666|NCT01458249|Drug|eribulin mesylate|Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
76068667|NCT00394888|Device|MRI|MRI of the spine.
76068668|NCT00394888|Device|MRI of head and neck|MRI of head and C-spine
76068669|NCT00394888|Other|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
75463290|NCT05854732|Other|Uninclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a active comparator with fixed speed of 5.0 mph and fixed inclination. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and fixed inclination for 30 minutes ending with Cool down for 5 minutes.
75463291|NCT05854706|Device|Theta Burst Stimulation|Theta Burst Stimulation
75757381|NCT03974308|Other|Comprehensive physiotherapy without balneotherapy and filling questionaire|Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire
75757382|NCT03974308|Other|No intervention, only filling questionaire|No physiotherapy nor balneotherapy applied but three time filling questionaire
75757383|NCT03970798|Drug|Midazolam|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
75757384|NCT03970798|Drug|Caffeine|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
75757385|NCT03970798|Drug|Rosuvastatin|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
75757386|NCT03970798|Drug|KW-6356|In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.
75757387|NCT00237796|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
75757388|NCT00237796|Behavioral|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
75757389|NCT03970876|Biological|ATGC-100|Clostridium Botulinum Type A
75757390|NCT03970876|Biological|Botox®|Clostridium Botulinum Type A
75457816|NCT01791270|Device|Continuous positive airway pressure (CPAP) therapy|"Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~- Respiratory Polygraphy~- Ambulatory Blood Pressure Monitoring~- Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~- ß1en subunit expression in peripheral blood leukocytes."
75609709|NCT00635713|Drug|Fulvestrant|250mg
75757391|NCT00414440|Drug|Placebo|placebo comparator
75609710|NCT02760823|Drug|Alpha Lipoic Acid (Thioctacid)|600 mg/12 hours, IV (in the vein)
75609711|NCT02760823|Drug|Placebo (for Alpha Lipoic Acid)|Normal saline in syringe simulating Alpha Lipoic Acid 600mg
75609712|NCT04222543|Combination Product|RGD PET/CT|Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
75757392|NCT00414440|Drug|Everolimus|experimental
75757393|NCT00209560|Drug|fospropofol disodium|
75757394|NCT01073800|Drug|atorvastatin 80 mg per os daily|atorvastatin 80 mg per os daily
75757395|NCT01073800|Drug|placebo|placebo
75757396|NCT03971032|Procedure|Hysteroscopy|Diagnostic procedure
75903663|NCT04568564|Other|Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|The exercise program includes breathing exercises (chest-abdominal-lateral basal breathing; 10 repetitions), use of intensive spirometry (20 repetitions) and assisted coughing. Apart from this, a progressive mobilization program will be applied considering patient tolerance and hemodynamic parameters, starting after the patient is taken to the service room. The teleconference exercise call will be continued from the postop 1st day until discharge, twice a day.
75609713|NCT01020747|Drug|Avastin® (bevacizumab)|Bevacizumab injections (~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
75757397|NCT03971032|Device|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of malignancy
75757398|NCT01037660|Drug|Metformin|Metformin 1 gram per day
75757399|NCT01072864|Other|Walnuts|Consumption of 5 g of walnuts.
75757400|NCT01072864|Other|Walnuts|Consumption of 20 g of walnuts.
75757401|NCT01072864|Other|Walnuts|Consumption of 30 g of walnuts.
75757402|NCT01072864|Other|Walnuts|Consumption of 40 g of walnuts.
75757403|NCT01032824|Behavioral|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
75757404|NCT01032824|Other|Group Arm|10-session didactic telephone group
75757405|NCT01032824|Other|Book Arm|Book only.
75757406|NCT01032902|Device|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
75757407|NCT00236080|Drug|PROVIGIL 200 mg|PROVIGIL 200 mg/day
75757408|NCT00236080|Drug|Armodafinil 250 mg|Armodafinil 250 mg/day
75757409|NCT00236080|Drug|Armodafinil 200 mg|Armodafinil 200 mg/day
75757410|NCT00236080|Drug|Armodafinil 150 mg|Armodafinil 150 mg/day
75757411|NCT00236080|Drug|Placebo|Matching placebo tablets
75757412|NCT01033058|Drug|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
75757413|NCT01033058|Drug|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
75757414|NCT03973138|Drug|Ranibizumab|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA) under the pro re nata (PRN) treatment regimen. The retreatment were conducted if BCVA was reduced by 0.1 logarithm of the minimal angle of resolution (logMAR) value or more from maximum acuity or if OCT central subfield thickness was more than 300μm.
75757415|NCT01326130|Behavioral|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
75757416|NCT01071616|Drug|Cannabis Cigarette|
75757417|NCT03970564|Diagnostic Test|Neck ultrasound guide lymph node sampling|Neck ultrasound done first and lymph nodes larger than 5 mm that are technically feasible are sampled using fine needle aspiration and/or core needle biopsy
75757418|NCT00432380|Biological|Rotarix™|oral doses
75757419|NCT00432380|Biological|Placebo|oral dose
75757420|NCT03970486|Procedure|Dry needling|For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.
75757421|NCT03974074|Drug|Albumin infusion|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
75757422|NCT01072942|Drug|Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
75757423|NCT01072942|Drug|Placebo|Placebo TID for 10 days
75757424|NCT01582516|Biological|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
75757425|NCT00234052|Biological|bevacizumab|5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
75757426|NCT00234052|Drug|carboplatin|Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
75757427|NCT00234052|Drug|pemetrexed|Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
75903664|NCT04568564|Other|Exercise booklet|Patients will be interviewed by videoconferencing method at least 1 day before the operation, their first evaluation will be taken and an exercise booklet will be given.
75903665|NCT04567537|Device|Laser Treatment|Patients will receive three laser treatments at one-month intervals.
75903666|NCT04566315|Procedure|Arteriography knee arteriography|arteriography and an injection of inert microparticles of 75 μm in neovessels
75903667|NCT04554485|Drug|Blinatumomab|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
75903668|NCT04543331|Drug|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
75609714|NCT01020747|Drug|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
75609715|NCT02760511|Dietary Supplement|Anthocyanin|Capsules with different anthocyanin content
75609716|NCT02760511|Dietary Supplement|Placebo|Placebo capsules
75609717|NCT05428579|Procedure|Retroperitoneal Liposarcoma resection|Retroperitoneal Liposarcoma resection
75609718|NCT02754739|Drug|Pravastatin|Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
75609719|NCT02754739|Drug|Placebo (for Pravastatin)|Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
75609720|NCT02754739|Behavioral|Nutritional education only|Only nutritional education by a nutritionist
75609721|NCT04300101|Other|molecular characterization|"immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off>50%), MUM1/IRF4, c-myc (cut off>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis"
75757428|NCT00408408|Biological|bevacizumab|15 mg/kg IV
75757429|NCT00408408|Drug|capecitabine|825 mg/m2 orally
75757430|NCT00408408|Drug|cyclophosphamide|600 mg/m2 IV
75757431|NCT00408408|Drug|docetaxel|100 mg/m2 IV
75757432|NCT00408408|Drug|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
75757433|NCT00408408|Drug|gemcitabine hydrochloride|1000 mg/m2 IV
75757434|NCT00414050|Biological|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
75757435|NCT00414050|Biological|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
75903669|NCT04539392|Other|Questionnaires on sexuality|Panel of questionnaires assessing sexuality, relationship satisfaction, and body image
75903670|NCT04529772|Drug|acalabrutinib|Investigational Product
75903671|NCT04529772|Drug|placebo|Placebo comparator
75903672|NCT04529772|Drug|Prednisone|Investigational Product
75903673|NCT04529772|Drug|Rituximab|Investigational Product
75903674|NCT04529772|Drug|Cyclophosphamide|Investigational Product
75757436|NCT00414050|Biological|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
75757437|NCT03970408|Procedure|MNT1|"Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping."
75903675|NCT04529772|Drug|Vincristine|Investigational Product
75903676|NCT04529772|Drug|Doxorubicin|Investigational Product
75903677|NCT04525885|Drug|Gefapixant 45 mg twice daily (BID)|Gefapixant 45 mg tablet to be administered orally BID
75903678|NCT04525885|Drug|Gefapixant 15 mg BID|Gefapixant 15 mg tablet to be administered orally BID
75903679|NCT04525885|Drug|Placebo|Placebo tablet administered orally BID
75903680|NCT04525885|Drug|Gefapixant 45 mg BID|Gefapixant 45 mg tablet to be administered orally BID
75903681|NCT04517149|Biological|4D-125 IVT Injection|4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
75903682|NCT04517149|Other|Observational|Natural History
75757438|NCT01034618|Dietary Supplement|Protein hydrolyzation|
75903683|NCT04496726|Other|Pacran and Sapnov P quillaja|Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.
75457817|NCT01791387|Drug|Dovitinib|"Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.~If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions."
75457818|NCT01791790|Device|Stimulation|
75457819|NCT01791790|Device|SHAM|no stimulation
75457820|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
75457821|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
75609722|NCT01020435|Other|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
75609723|NCT01020435|Other|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
75903684|NCT04489823|Device|Amplatzer Valvular Plug III|Transcatheter closure of a paravalvular leak using Amplatzer Valvular Plug III
75903685|NCT04482660|Procedure|Positron emission tomography with 18F-RO6958948|tau PET ()
75903686|NCT04473378|Device|FreeStyle Libre Pro|The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
75903687|NCT04466891|Drug|ZW25 (Zanidatamab)|Administered intravenously
75903688|NCT04466527|Device|Laser Intervention|Subjects with undergo laser exposure of their active acne vulgaris.
75903689|NCT04459559|Device|Tactile Cueing Device|Each participant receives an individual training on how to use the Tactile Cueing Device and the set-up of the TCD will be done according to the results of a 10MWT and the participant's preferences. Gait assessments with an activated or deactivated TCD are executed using the Timed Up and Go test, the 2-Minute Waling test and a treadmill (C-Mill). Also a long-term test run of the TCD during one day is planned.
75903690|NCT04454723|Procedure|Blood and/or platelet transfusion|The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.
75903691|NCT04454723|Procedure|Complete blood count (CBC) collection|CBC will be collected from patients weekly while on this protocol.
76068670|NCT00394888|Other|Cardiac examination|Complete cardiac examination
75757439|NCT01419860|Procedure|Elective colon resection|In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
75757440|NCT03973840|Drug|Testosterone Undecanoate|dose was given orally and allowed to reach steady state
75757441|NCT00413972|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
75757442|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
75609724|NCT02754349|Device|SphygmoCor version 7, AtCor Medical, Sydney, Australia|Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
75757443|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
75757444|NCT00413972|Drug|Placebo|Placebo once daily for a total of eight weeks
75757445|NCT01037738|Procedure|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
75757446|NCT00259012|Drug|pantoprazole sodium enteric-coated spheroid suspension|pediatric suspension taken daily x 7 days
75903692|NCT04446962|Drug|Lenalidomide|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
75903693|NCT04446962|Drug|Ibrutinib|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
75903694|NCT04438824|Drug|INCMGA00012|INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
75903695|NCT04438824|Drug|Palbociclib|Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days
75457822|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
75457823|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)
75457824|NCT01792063|Drug|Sevoflurane|
75609725|NCT02873949|Biological|Crevicular samples (1-10µl)|"In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site"
75609726|NCT02873949|Biological|Saliva samples (1ml)|
75757447|NCT01044108|Drug|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
75457825|NCT01792063|Drug|Sevoflurane|
75457826|NCT01792232|Other|Allergen|Subject specific allergen is placed in the lungs on day 1 of each triad
75457827|NCT01792232|Other|Saline|Saline will be placed in the lung on day 1 of each triad
75457828|NCT01792258|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
75609727|NCT02873949|Other|Etiologic treatment|education on oral hygiene, scaling and root planing
75757448|NCT01044108|Drug|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
75757449|NCT01044108|Drug|placebo|Placebo will be administered as a comparator at each dose level.
75757450|NCT01044186|Drug|ICL670|
75757451|NCT03970174|Other|Care Connector care transition module|Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
75757452|NCT01073878|Device|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
75903696|NCT04433975|Behavioral|Psychosocial Pain Management (PPMI)|The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
75903697|NCT04433975|Behavioral|Enhanced Usual Care (EUC)|The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
75903698|NCT04431401|Device|Magstim rTMS|The device is made in London,UK
76072388|NCT00574496|Drug|vinorelbine tartrate|
75457829|NCT01792297|Dietary Supplement|Bovine colostrum|
75457830|NCT01792297|Dietary Supplement|Whey protein|
75609728|NCT02873949|Other|Psychometric tests|Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
75903699|NCT04426006|Other|PRO-SERO-COV|"At inclusion, 3 months and 12 months :~blood sample (2 x 5ml)~self-administered questionnaire"
76068671|NCT00394888|Device|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
75757453|NCT03993600|Diagnostic Test|Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)|"three groups:~Healthy volunteers~Patients with Cystic fibrosis~Heterozygous subjects"
75757454|NCT00209170|Behavioral|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
75457831|NCT01792349|Behavioral|STARFISH intervention|STARFISH is a behavioural intervention to encourage the user to become more physically active
75457832|NCT01792414|Device|Sham TES|Neuroconn Eldith device
75757455|NCT00209170|Drug|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
75757456|NCT00209170|Drug|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
75757457|NCT01071694|Drug|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
75757458|NCT00413894|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
75757459|NCT03973216|Behavioral|A primary care group-based therapeutic yoga program|The intervention includes therapeutic yoga training and education sessions on benefits of yoga and effects of stress on the body.
75757460|NCT03970018|Other|Intra-peritoneal pressure|Measurement of intra-peritoneal pressure
75757461|NCT03972748|Drug|Itraconazole 200 mg|Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.
75757462|NCT01581814|Drug|Metformin|500 mg of Metformin per 3/die
75757463|NCT01581814|Drug|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
75757464|NCT01581814|Drug|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
75757465|NCT00407550|Drug|gemcitabine HCL|1250 mg/m^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 & 8 of each cycle (21 days) x6 cycles.
75757466|NCT00407550|Drug|pemetrexed disodium|500 mg/m^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
75757467|NCT00407550|Drug|gemcitabine HCL|1500 mg/m^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
75757468|NCT00209092|Drug|Docetaxel|"Sequential Therapy: Docetaxel will be given at 100 mg/m^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m^2 IV Day 1."
75757469|NCT00209092|Drug|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
75757470|NCT01073098|Other|Vascular occlusion test|Reperfusion slope after vascular occlusion test
75903700|NCT04418713|Other|active video-games|An intervention with active video-games to increase physical activity and improve body composition
75903701|NCT04413123|Drug|Cabozantinib|Cabozantinib predetermined protocol dosage po daily
75903702|NCT04413123|Drug|Nivolumab|Nivolumab predetermined protocol dosage via IV every 3 weeks
75903703|NCT04413123|Drug|Ipilimumab|Ipilimumab predetermined protocol dosage via IV every 3 weeks
75903704|NCT04408066|Diagnostic Test|Sample Collection/Performance Evaluation (A)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab~Whole Venous Blood"
75457833|NCT01792414|Device|Active TES|Neuroconn Eldith device
75757471|NCT03969862|Device|NOVEOS® system|"The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark."
75757472|NCT03972982|Drug|Simplified intensive insulin therapy regimen|Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
75457834|NCT01792570|Drug|RPV + DRV/r|Switch to dual HAART
75457835|NCT01792570|Drug|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
75457836|NCT01792622|Other|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
75757473|NCT03972982|Drug|Traditional Short-term Intensive insulin therapy|Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up
75757474|NCT00403494|Other|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
75757475|NCT00403494|Drug|Sapropterin Dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
75757476|NCT00403260|Drug|Pyronaridine - artesunate|once a day for 3 days
75757477|NCT00403260|Drug|Mefloquine plus artesunate|once a day for 3 days
75757478|NCT01324362|Drug|Placebo|Twice daily dosing
75757479|NCT01324362|Drug|Placebo|Twice daily dosing
75757480|NCT01324362|Drug|FP 100mcg|Twice daily dosing
75757481|NCT01324362|Drug|FP 250mcg|Twice daily dosing
75757482|NCT01324362|Drug|FP 500mcg|Twice daily dosing
75903705|NCT04408066|Diagnostic Test|Sample Collection/Performance Evaluation (B)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~Whole Venous Blood~Fingerstick Capillary Sample"
76068672|NCT01458171|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
76068673|NCT00395044|Drug|Placebo|Placebo
76068674|NCT00395044|Drug|Gabapentin|
76068675|NCT01457703|Drug|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
76072389|NCT00574496|Procedure|allogeneic bone marrow transplantation|
76068676|NCT01457703|Drug|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
75757483|NCT01324362|Drug|FSC 100/50mcg|Twice daily dosing
75757484|NCT01324362|Drug|FSC 250/50mcg|Twice daily dosing
75903706|NCT04343924|Other|Scuba diving activities|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
75903707|NCT04343924|Other|Virtual reality activities|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates
75903708|NCT04343313|Device|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
75903709|NCT04341350|Drug|Propofol + analgesic drug|sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
76068677|NCT01457703|Drug|Recombinant LH|Used to stimulate ovarian function in women.
76068678|NCT01457703|Drug|Letrozole|An aromatase inhibitor.
76068679|NCT04445428|Biological|oral polio vaccine + information|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
76068680|NCT04445428|Behavioral|Information|Advice regarding how to protect oneself from COVID-19
76068681|NCT00356434|Device|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
75757485|NCT01324362|Drug|FSC500/50mcg|Twice daily dosing
75757486|NCT00406848|Drug|duloxetine hydrochloride|Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
75757487|NCT00406848|Drug|placebo|Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
76068682|NCT00356434|Device|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
75457837|NCT01792622|Other|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
75457838|NCT01792661|Other|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
75457839|NCT01792661|Other|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
75457840|NCT01792661|Other|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
75457841|NCT01792674|Other|In situ simulation|
75457842|NCT01792674|Other|Off site simulation|
75457843|NCT01792804|Drug|Trimethoprim-Sulfamethoxazole|study drug 1
75457844|NCT01792804|Drug|Clindamycin|study drug 2
75457845|NCT01792804|Drug|Linezolid|study drug 3
75457846|NCT01792804|Drug|Flucloxacillin|study drug 4
76068683|NCT01419015|Device|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
76068684|NCT00357214|Dietary Supplement|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
76068685|NCT00357214|Dietary Supplement|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
76068686|NCT00357214|Dietary Supplement|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
76068687|NCT00357214|Dietary Supplement|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
76068688|NCT01418937|Biological|CervarixTM (GSK580299)|Three intramuscular injections
76068689|NCT02076321|Drug|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
75757488|NCT00406692|Drug|Zonisamide|Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
75757489|NCT00004494|Drug|vasoactive intestinal peptide|
75903710|NCT04341350|Drug|Isoflurane + analgesic drug|sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
75903711|NCT04322084|Other|Wearable Sensors|To develop predictive algorithms that identify early onset of sepsis in children being treated for ALL. This study will use a two-stage design. The initial stage (the feasibility phase) will evaluate the feasibility of data collection, and the second stage (the completion phase) will provide data for the design of predictive models.
75903712|NCT04318366|Other|Observational Study|Not required
75757490|NCT00315705|Drug|clofarabine|Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
75757491|NCT00315705|Drug|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
75757492|NCT00315705|Drug|Cyclophosphamide|Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
75757493|NCT03982017|Other|Mobile Health Technology Platform|When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
75757494|NCT03982017|Other|Usual care|Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
75757495|NCT03982173|Drug|Tremelimumab|tremelimumab 75mg
75757496|NCT03982173|Drug|Durvalumab|Durvalumab 1500mg
75757497|NCT01062633|Dietary Supplement|A, erythritol|2,5 g 3 times a day
75757498|NCT01062633|Dietary Supplement|xylitol|2,5 g 3 times a day
75757499|NCT01062633|Dietary Supplement|C, sorbitol|2,5 g 3 times aday
75757500|NCT00307125|Drug|Rituximab plus immunosuppression|"Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific."
75757501|NCT00307125|Drug|Placebo plus immunosuppression|"Placebo dosing: Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
75903713|NCT04305795|Biological|200 mg Pembrolizumab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
75903714|NCT04305795|Biological|350 mg Cemiplimab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
75903715|NCT04305795|Combination Product|ASP-1929|"ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months."
75457847|NCT01792804|Drug|Cloxacillin|study drug 5
75457848|NCT01792804|Drug|Vancomycin|study drug 6
75457849|NCT01792804|Drug|Daptomycin|study drug 7
75457850|NCT01792804|Drug|Cefazolin|study drug 8
75457851|NCT01792856|Other|Recovery-oriented intervention|Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
75903716|NCT04296006|Drug|Sustained Release d-amphetamine|Twice daily administration of active or placebo d-amphetamine
75903717|NCT04296006|Behavioral|Money|Three money values offered as alternatives to cocaine
75903718|NCT04292054|Drug|active intervention|The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
75903719|NCT04292054|Other|placebo intervention|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
75609729|NCT02754271|Other|Fit for Dialysis|A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
75757502|NCT01066299|Drug|Syntocinon®|single dose of OXT (24 IU)
75903720|NCT04285372|Procedure|Side branch protection/ballooning|Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
75609730|NCT01031979|Drug|Yohimbine|alpha-2 adrenergic receptor antagonist
75609731|NCT01031979|Drug|Placebo|Placebo
75609732|NCT04502173|Device|Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).
75609733|NCT02754193|Other|moderate hypothermia|moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
75609734|NCT02753803|Drug|Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
75609735|NCT02753803|Drug|Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
75609736|NCT02753803|Drug|Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
75609737|NCT02753803|Drug|Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
75609738|NCT02753803|Drug|Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD
75609739|NCT02753803|Drug|Evogliptin+Pioglitazone, Pioglitazone, Evogliptin|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
75757503|NCT01066299|Drug|inactive nasal spray|single dose (24 IU)
75903721|NCT04285372|Procedure|No side branch protection/ballooning|No intervention on the side branch
75903722|NCT04279847|Drug|INCB057643|INCB057643 dose escalation and dose expansion.
75457852|NCT01792856|Other|psychoeducation|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
75457853|NCT01793038|Drug|Aromatase inhibitor (litrezole) plus uFSH arm|literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
75457854|NCT01793038|Drug|clomiphene citrate-uFSH arm|clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
75463292|NCT05854693|Device|transCranial direct current stimulation|The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS
75609740|NCT04219579|Drug|Antithrombin III, continuous infusion|Antithrombin-III is administered continuously
75609741|NCT04219579|Drug|Antithrombin III, Intermittent infusion|Antithrombin-III is administered intermittently
75609742|NCT04613947|Behavioral|Informed consent|The style of informing patients about the procedure they will undergo
75609743|NCT04613947|Procedure|Third molar surgery|Surgical extraction of the third molar tooth
75609744|NCT00635401|Drug|Varenicline|0.5 mg BID for 7 weeks
75757504|NCT00307047|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
75757505|NCT00307047|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
75757506|NCT01066377|Dietary Supplement|Prebiotic and probiotic mix|The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10^8 - 10^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested).
75757507|NCT00306891|Drug|Cediranib|45 mg oral dose
75757508|NCT00306891|Drug|Cediranib 30 - 90 mg|oral tablet dose escalation
75757509|NCT00314145|Biological|ChimeriVax™-JE|0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
75903723|NCT04279847|Drug|Ruxolitinib|Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
75903724|NCT04276584|Device|Positive expiratory pressure|Three blocks of 10 deep inspiration followed by expiration against a positive airway pressure device of 10-15 cm of water pressure. Repeated three times. Estimated time of 3 minutes time.
75903725|NCT04276584|Other|Speaking loudly during about 3 minutes|A specified swedish text
75609745|NCT04199065|Other|Good Practice Guidelines implementation|Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
75609746|NCT05424055|Behavioral|Multicomponent exercise|The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance-training and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening). The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L., Madrid, Spain) combined with balance and gait retraining exercises that will progress in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
75457855|NCT01793090|Drug|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
75609747|NCT02753959|Other|Acute Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~Electrical impedance tomography (EIT)~EMGpara~SpO2~tcCO2~Respiratory inductance plethysmography~EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~Manual techniques only~MIE at low pressure (+30 to -30)~MIE at high pressure (+60 to -60)"
75609748|NCT02753959|Other|Stable Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~Electrical impedance tomography (EIT)~EMGpara~SpO2~tcCO2~Respiratory inductance plethysmography~EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~Manual techniques only~MIE at low pressure (+30 to -30)~MIE at high pressure (+60 to -60)"
75609749|NCT02753725|Drug|Fentanyl|The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
75609750|NCT02753725|Drug|Normal saline|the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
75609751|NCT01020123|Drug|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
75609752|NCT01020123|Drug|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
75609753|NCT01020123|Drug|Glipizide|Glipizide administered to 1 group of patients
75757510|NCT00314145|Biological|JE-VAX®|0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
75757511|NCT00313911|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
75757512|NCT00313911|Biological|Tritanrix-HepB/Hib|0.5 mL, Intramuscular
75757513|NCT03980847|Drug|Alendronate 20 mg|The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
75757514|NCT03980847|Procedure|Nanocrystal hydroxyapatite|Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
75757515|NCT03978195|Device|Non-invasive device for middle ear ventilation|Daily use of the device
75757516|NCT00391872|Drug|Ticagrelor|Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
75757517|NCT00391872|Drug|Clopidogrel|Clopidogrel 75 mg once daily dose (ODD)
75757518|NCT00391170|Drug|Topical Dexamethasone|dexamethasone 0.01%
75757519|NCT00391170|Drug|Placebo|Placebo
75757520|NCT00402324|Drug|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
75757521|NCT00402324|Drug|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
75757522|NCT00402324|Drug|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
75757523|NCT00294723|Drug|liraglutide|1.8 mg for s.c. (under the skin) injection
75903726|NCT04276493|Biological|ZW25|Administered as specified in the treatment arm
75457856|NCT01793090|Other|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
75457857|NCT01793337|Other|Exposure to cold environmental temperature (-20°C)|
75457858|NCT01793779|Procedure|cold water immersion|
75457859|NCT01793779|Dietary Supplement|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
75457860|NCT01793779|Dietary Supplement|Placebo|
75457861|NCT01793818|Biological|Tat Oyi|Three injections in the arm
75457862|NCT01794104|Drug|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
75757524|NCT00294723|Drug|glimepiride|8 mg capsule
75757525|NCT00294723|Drug|liraglutide|1.2 mg for s.c. (under the skin) injection
75757526|NCT00294723|Drug|placebo|Glimepiride placebo, 8mg capsule
75757527|NCT00294723|Drug|placebo|Liraglutide placebo, 200 mcl
75903727|NCT04276493|Drug|Docetaxel|Administered as specified in the treatment arm
75903728|NCT04276493|Biological|Tislelizumab|Administered as specified in the treatment arm
75903729|NCT04276493|Drug|Capecitabine|Administered as specified in the treatment arm
75903730|NCT04276493|Drug|Oxaliplatin|Administered as specified in the treatment arm
75903731|NCT04273022|Other|Exercise|A single bout of standardized, moderate exercise
75903732|NCT04269239|Behavioral|Healthy Habits|Participants in this group will be coached during four hour-long sessions on topics such as physical activity, nutrition, pain coping skills, bladder health, diabetes, heart health, eyes/vision, hearing, and doctor-patient communication.
75903733|NCT04269239|Behavioral|Sleep Habits|Participants in this group will be coached during four hour-long sessions on topics such as sleep education, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education, and relapse prevention.
75609754|NCT04603027|Drug|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
75609755|NCT04603027|Drug|Placebo|Placebo oral capsule
75903734|NCT04258293|Diagnostic Test|Blood sampling|fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
75903735|NCT04257058|Behavioral|Electronic educational material|Electronic media via email
75903736|NCT04253262|Drug|Rucaparib|Rucaparib (PO twice daily continuous)
75903737|NCT04253262|Drug|Copanlisib|Copanlisib (IV day 1, 8, 15; 28 day cycle)
75903738|NCT04251936|Behavioral|Exercise training|The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.
75609756|NCT04300959|Drug|Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks."
75609757|NCT04300959|Drug|Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks."
75609758|NCT04299711|Other|Exposed to the novel coronavirus disease 2019|Exposed to the novel coronavirus disease 2019
75757528|NCT00294723|Drug|placebo|Liraglutide placebo, 300 mcl
75757529|NCT00402246|Other|Remote Management|"The Remote Management method of treating patients consists of 3 components:~CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)~Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line~CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.~The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action."
75757530|NCT00402246|Other|In-Office Care|Routine in-office care
75903739|NCT04251936|Behavioral|Smoking cessation group program|Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
75903740|NCT04245150|Other|Stool sample|Stool sample
75457863|NCT01794182|Drug|Glyburide for Injection|Administered as specified in the treatment arm.
75457864|NCT01794182|Drug|Placebo|Administered as specified in the treatment arm.
75457865|NCT01794208|Drug|Follitropin Epsilon|
75457866|NCT01794208|Drug|Follitropin Alfa|
75457867|NCT01794247|Drug|Magnesium sulfate|
75457868|NCT01794247|Drug|Fentanyl|
75457869|NCT01794247|Drug|Lidocaine|
75457870|NCT01794364|Drug|PF-06291874|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
75457871|NCT01794364|Other|placebo|Correspondingly, placebo doses will be administered as suspension.
75457872|NCT01794429|Drug|Exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
75457873|NCT01794429|Drug|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
75609759|NCT02753569|Other|Imaging - DW-MRI|
75903741|NCT04245150|Other|Skin Swab Sample|Skin Swab Sample
75903742|NCT04243837|Drug|LYT-100 MAD|"LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.~HV subjects will receive multiple ascending doses, starting at 100 mg BID up to 1000 mg, with food for 5-days."
75903743|NCT04243837|Other|Matching Placebo for MAD|Inactive capsule(s)
75903744|NCT04243837|Drug|LYT-100 Food Effect|"LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.~HV subjects will receive one dose of LYT-100 or Placebo"
75903745|NCT04243837|Drug|LYT-100 BCRL|BCRL patients will receive LYT-100 BID for 6 months
75903746|NCT04243837|Drug|Placebo BCRL|BCRL patients will receive Placebo BID for 6 months
75903747|NCT04243837|Drug|Placebo Food Effect|inactive capsules
75903748|NCT04242147|Drug|KD033 (SAR445710)|Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
75903749|NCT04215978|Drug|BGB-A445|Administered as specified in the treatment arm
75903750|NCT04215978|Drug|tislelizumab|Administered as specified in the treatment arm
75903751|NCT04185337|Procedure|Fine-Needle Aspiration|Undergo ultrasound-guided FNA
75903752|NCT04185337|Procedure|Lymph Node Biopsy|Undergo ultrasound-guided lymph node biopsy
75903753|NCT04185337|Procedure|Photoacoustic Imaging|Undergo ultrasound-guided PAI
75903754|NCT04185337|Procedure|Ultrasound|Undergo ultrasound
75903755|NCT04185337|Device|Multispectral optoacoustic tomography (MSOT) acuity instrument|Use multispectral optoacoustic tomography (MSOT) acuity instrument
76068690|NCT02076321|Drug|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
75903756|NCT04178005|Drug|Cladribine|All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI
75903757|NCT04174742|Drug|pegfilgrastim|It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
75457874|NCT01794494|Procedure|Bypass surgery|Patients are treated with femoro-popliteal bypass
75609760|NCT02753569|Radiation|FDG PET-CT|
75609761|NCT02760355|Drug|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
75609762|NCT02760355|Drug|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks.
75609763|NCT01028391|Drug|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
75757531|NCT00375492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
75757532|NCT00375492|Drug|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
75757533|NCT00306189|Drug|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
75757534|NCT00306189|Drug|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
75757535|NCT00306189|Drug|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
75757536|NCT00306189|Drug|Placebo|Placebo SC every 6 months
75457875|NCT01794494|Procedure|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
75457876|NCT01794754|Other|Care as usual|
75609764|NCT01028391|Drug|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
75609765|NCT01028391|Drug|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
75609766|NCT02753491|Behavioral|Motivational short interview|New designed motivational short interview model
75609767|NCT01179672|Drug|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
75609768|NCT01179672|Drug|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
75757537|NCT00312897|Drug|Omega-3 Fatty Acids|10 wk treatment period
75457877|NCT01794754|Other|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
75457878|NCT01794819|Device|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
75457879|NCT01795248|Drug|Liraglutide|1.8 mg liraglutide
75457880|NCT01795248|Drug|Placebo|Liraglutide without the GLP-1 analogue
75463293|NCT05854693|Device|sham stimulation|The sham group consisted of 10 daily 20-min sessions of sham stimulation
75757538|NCT00312897|Drug|corn oil|placebo comparator
75757539|NCT00312663|Biological|Falciparum Malaria Protein 11 with AS01B adjuvant.|malaria experimental vaccine
75757540|NCT02532699|Dietary Supplement|AC mycelia|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
75903758|NCT04167514|Biological|Alpha-1 antitrypsin (AAT)|AAT is a lyophilized product for intravenous administration
75903759|NCT04167514|Drug|Placebo|Albumin solution administered intravenously
75903760|NCT04164199|Drug|Tislelizumab|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
75903761|NCT04164199|Drug|Pamiparib|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
75757541|NCT02532699|Dietary Supplement|Placebo|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
75757542|NCT00294645|Other|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
75757543|NCT00294645|Other|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
75757544|NCT00305877|Biological|cetuximab|Given IV
75757545|NCT00305877|Drug|gemcitabine hydrochloride|Given IV
75757546|NCT00305877|Drug|capecitabine|Given orally
75757547|NCT00305877|Radiation|radiation therapy|Undergo radiation therapy
75757548|NCT00305877|Biological|bevacizumab|Given IV
75903762|NCT04164199|Drug|Pemetrexed 500 mg/m² IV|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
76068691|NCT01417377|Drug|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
76068692|NCT00358462|Drug|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
75609769|NCT02872545|Procedure|Rest tomoscintigraphy in forward tilted|Rest tomoscintigraphy in forward tilted position
75609770|NCT02872545|Procedure|Rest tomoscintigraphy in semi sitting position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
75609771|NCT02872545|Procedure|Rest tomoscintigraphy in dorsal decubitus position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
75609772|NCT04321915|Other|Analysis of intestinal microbiota in autism spectrum desorder|This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
75609773|NCT04321915|Other|Analysis of neuroinflammation markers in autism spectrum desorder|This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
75757549|NCT00305877|Other|laboratory biomarker analysis|Correlative studies
75903763|NCT04164199|Drug|Capecitabine 1000 mg/m² PO BID|Day 1 to Day 15 of each 21 day cycle, to be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
75903764|NCT04164199|Drug|Temozolomide 120, 80, 40 or 20 mg PO Once Daily (QD)|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
75903765|NCT04164199|Drug|Sitravatinib|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
75609774|NCT04301349|Drug|vaginal dinoprostone|two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
75609775|NCT04301349|Drug|vaginal misoprostol|two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
75609776|NCT04301349|Drug|placebo|two tablets of placebo given 3 hours prior to IUD insertion
75609777|NCT02753647|Drug|Rituximab|
75609778|NCT02753647|Drug|Cyclophosphamide|
75609779|NCT02753647|Drug|Doxorubicin|
75609780|NCT02753647|Drug|Vincristine|
75609781|NCT02753647|Drug|Prednisone|
75903766|NCT04164199|Drug|Ociperlimab|Participants will receive tislelizumab followed by the administration of ociperlimab on Day 1 of each 21-day cycle (ie, once every 3 weeks)
75609782|NCT02753647|Drug|Chidamide|
76068693|NCT00358462|Drug|Doxycycline|one 100mg capsule administered twice daily for seven days
76068694|NCT00396292|Drug|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
75757550|NCT01064193|Procedure|biopsy|"The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~Insert carefully the pipelle de Cornier® in the uterus through the cervix.~Withdraw the piston to create a negative pression~Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~Withdraw the pipelle de Cornier® when filled with tissue~Reinsert internal piston to deposit sample in cup filled with a fixative."
75903767|NCT04164199|Drug|BAT1706|Participants will receive tislelizumab followed by the administration of BAT1706 on Day 1 of each 21-day cycle (ie, once every 3 weeks). If applicable, ociperlimab will be administered after completion of the BAT1706 infusion
75903768|NCT04164199|Drug|Fruquintinib|Fruquintinib will be self-administered orally once daily for 21 days, followed by 7 days off in 28-day cycles with or without food.
75903769|NCT04163315|Other|dMRI, fMRI and electrocorticography|Patients included in the study will perform the pre-operative MRI (fMRI and fMRI) with a specific High Resolution Angular Diffusion (HARDI) sequence and a functional rest sequence. The additional scan time for this specific sequence is approximately 25 minutes, with no foreseeable negative impact on the patient
75903770|NCT04153422|Drug|Panzyga IVIG|Immune Globulin Infusion 10% (Human)
75903771|NCT04153422|Drug|Placebo|0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
75609783|NCT02872389|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
75609784|NCT02872389|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
75609785|NCT02760199|Drug|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
75609786|NCT02760199|Device|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
75757551|NCT01064193|Procedure|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
75903774|NCT04137289|Drug|BI 905711|BI 905711
75903775|NCT04130542|Biological|LVGN6051|IV infusion once every 3 weeks (Q3W).
75903776|NCT04130542|Biological|KEYTRUDA® (pembrolizumab)|IV infusion once every 3 weeks (Q3W).
75903777|NCT04115033|Device|Alpha-stim|The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
76068695|NCT00396292|Drug|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
76068696|NCT00397150|Behavioral|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
76068697|NCT01437267|Biological|Vi-CRM197 vaccine|
76068698|NCT01437267|Biological|Pneumococcal conjugate vaccine|
75609787|NCT02695927|Device|Computer rehabilitation glasses|
75609788|NCT04307251|Device|Navio™ Robotics-assisted Surgical System, LEGION Total Knee System|Robotic TKA uses computer software to convert anatomical information into a virtual patient-specific 3D reconstruction of the knee joint.The surgeon uses this virtual model to plan optimal bone resection, implant positioning, bone coverage, and limb alignment based on the patient's unique anatomy.
75903778|NCT04105530|Device|Anodal tDCS treatment|The Anodal intervention excites neuronal activity. For condition one, the anode will be attached to the left frontal region (Fp1) and the cathode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
75903779|NCT04105530|Device|Cathodal tDCS treatment|The Cathodal intervention inhibits or reduces neuronal activity. We propose that the use of the cathodal tDCS to the superior temporal gyrus in survivors of childhood ALL may facilitate the inhibition of over connected motor-sensory and auditory neural networks. For condition two, the cathode will be attached to the left temporal region (T3) and the anode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
76068699|NCT01437267|Biological|Vi Polysaccharide (PS) vaccine|
76072390|NCT00574496|Procedure|allogeneic hematopoietic stem cell transplantation|
75609789|NCT04307251|Device|Conventional, LEGION Total Knee System|Total Knee Arthroplasty (TKA) is a widespread orthopaedic procedure for restoring functionality and minimizing pain due to end stage osteoarthritis. Conventional TKA, well-accepted as the standard of care, is performed with manual instrumentation guided by intramedullary or extramedullary alignment rods, as well as rotational guides that are not patient-specific.
75609790|NCT01030965|Drug|GSK573719 125mcg|125mcg once-daily
75757552|NCT03978273|Device|Night-time brace + virtual-brace|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
75757553|NCT03978273|Other|Night-time brace only|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
75757554|NCT03981315|Diagnostic Test|Bile test|Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
75757555|NCT03981315|Diagnostic Test|Blood test|Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
75457881|NCT01795274|Radiation|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
75609791|NCT01030965|Drug|GSK573719 250mcg|250mcg once-daily
75457882|NCT01795482|Device|Forced-air warming|In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
75457883|NCT01795872|Procedure|Several diagnostic procedures|No drug will be assigned, diagnostic assessment within the study.
75457884|NCT01796132|Drug|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
75609792|NCT01030965|Drug|GSK573719 500mcg|500mcg once-daily
75609793|NCT01030965|Drug|Placebo|once-daily
75609794|NCT02753179|Other|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
75609795|NCT02753179|Other|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
75609796|NCT02753179|Other|VEMPs & VEMPo|VEMPs & VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
75457885|NCT01796223|Behavioral|Feedback|The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
76068700|NCT00397462|Device|calf muscle pump stimulation|Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
76068701|NCT01456221|Dietary Supplement|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
76068702|NCT01456221|Dietary Supplement|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
76072391|NCT00574496|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75457886|NCT01796223|Behavioral|Control|
75463294|NCT05854641|Biological|Stempeucel®|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
75609797|NCT02753179|Other|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
75757556|NCT03981315|Diagnostic Test|Gall stone study|Study of the extracted gall stones, analyzing their composition, type, etc.
75757557|NCT03981315|Diagnostic Test|Microbiological bile test|Determination of the microbiological composition of the bile
75903780|NCT04105530|Device|Sham treatment|The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes. Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial.
75903781|NCT04105530|Other|NIH Toolbox List Sorting Working Memory Test|List Sorting is using information processing and storage. Performance tends to peak in early adulthood and then decline across the life span. This task assesses working memory and requires the participant to sequence different visually- and orally-presented stimuli. The list scoring task takes approximately 7 minutes to administer. List Sorting is scored by summing the total number of items correctly recalled and sequenced on Lists-1 and -2, which can range from 0-26.
75903782|NCT04105530|Other|NIH Toolbox Flanker Inhibitory Control and Attention Test|The Flanker tests inhibitory control and attention and the capacity for new learning and information processing novel situations. This performance also reaches a peak in early adulthood and tends to decline across the life span. A total of 40 trials require 4 minutes. Scoring is based on both accuracy and reaction time, which will we evaluate individually as well as in combination. The raw scores are converted to a scale score with a mean of 100 and SD of 15. Higher scores indicate higher executive function.
76068703|NCT01794052|Other|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~Treating patients as per a standard clinical guidelines~Giving health education to patients on lifestyle changes for better self-care~Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
76068704|NCT01437111|Drug|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
76068705|NCT04767477|Other|Face-to-face rehabilitation|Aerobic training will be performed with 60% to 80% of the maximum VO2 obtained through the CPET. The exercise will be performed on the treadmill, with a total time of 40 minutes, with 5 minutes of warm-up, 30 minutes of conditioning, 5 minutes of cooling down. Resistance training will be performed for upper and lower limbs and the load used in the exercises will be 60% of the maximum repetition test (1RM), with load progression every six sessions. The exercises are performed in three series of 12 repetitions.
75609798|NCT02753179|Other|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
75457887|NCT01796314|Behavioral|Therapeutic Educational Program|"The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.~These collective sessions focus on :~Knowledge of the disease~Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia~Crisis situations. Prevention of caregiver's exhaustion~Assistive devices and care pathways.~Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures."
75457888|NCT01796327|Drug|dacomitinib oral|Dacomitinib 45 mg oral tablet
75457889|NCT01796327|Drug|dacomitinib intravenous|Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
75457890|NCT01796353|Other|sexual rehabilitation|exercise plus psycho-education
75457891|NCT01796353|Other|Usual care|usual care
75609799|NCT02753257|Other|Non-Interventional|Non-Interventional
75609800|NCT02752867|Drug|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
75757558|NCT01062711|Dietary Supplement|Whey or soy protein|Whey and casein are isolated milk proteins
75757559|NCT00312195|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
75757560|NCT00312195|Drug|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch applied for 7-day wear.
75757561|NCT01062789|Device|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
76068706|NCT04767477|Other|Telerehabilitation|The telerehabilitation protocol will consist of stretching the muscles of the upper and lower limbs and accessory muscles of breathing. The conditioning phase will consist of stationary walking, side running, jumping jump and stationary running, 3 times of 40 seconds with a 30-second passive rest interval between them. Resistance training will be applied to the muscles of the upper limbs and lower limbs, with specific exercises for each musculature, using elastic bands as resistance.
76068707|NCT04065555|Drug|TAK-981|Intratumoral microdose injection by the CIVO device.
76068708|NCT04065555|Biological|Cetuximab|Intratumoral microdose injection by the CIVO device.
75757562|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
75757563|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
75757564|NCT01062867|Drug|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
75609801|NCT02752867|Other|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
75609802|NCT01179516|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
75757565|NCT02532777|Drug|Prednisone|
75757566|NCT02532777|Drug|Cyclophosphamide(CTX)|
75757567|NCT02532777|Drug|Mycophenolate mofetil(MMF)|
75757568|NCT02532777|Drug|Leflunomide(LEF)|
75757569|NCT02532777|Drug|Angiotensin-converting enzyme inhibitor(ACEI)|
76068709|NCT04065555|Biological|Avelumab|Intratumoral microdose injection by the CIVO device.
76068710|NCT04065555|Combination Product|TAK-981 + Cetuximab|Intratumoral microdose injection by the CIVO device.
76068711|NCT04065555|Combination Product|TAK-981 + Avelumab|Intratumoral microdose injection by the CIVO device.
75757570|NCT02532777|Drug|Methylprednisolone|
75757571|NCT03977805|Drug|Hetrombopag Olamine|a single oral taking
76068712|NCT00359944|Drug|AC-3933|5mg twice daily
76068713|NCT00359944|Drug|AC-3933|AC-3933, 20 mg twice daily
76068714|NCT00359944|Other|Sugar Pill|Sugar Pill twice daily
75609803|NCT01179516|Drug|Placebo|Vortioxetine placebo-matching capsules
75609804|NCT02752945|Other|One-day CBT workshop|One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
75609805|NCT02752945|Other|Usual care|Usual care afforded by local CAMHS services
76068715|NCT00360724|Drug|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
76068716|NCT00398398|Drug|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
76068717|NCT00398476|Drug|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
76068718|NCT00398476|Drug|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
76068719|NCT01436643|Drug|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
76068720|NCT01436643|Drug|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
76068721|NCT01436643|Drug|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
75757572|NCT01062945|Drug|Placebo|Matching administration of a placebo pill.
75757573|NCT01062945|Drug|Doxazosin|The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
75903783|NCT04105530|Other|Grooved Peg Board Test|The Grooved Peg Board test measures visual-motor coordination and motor speed. Additionally, it is cognitively challenging and has been associated with attention, perceptual speed and non-verbal reasoning. Performance is better in the dominant/preferred hand and tends to improve in childhood and decline with advancing age. The test consists of placing metal pegs with ridges along onside in matching slots as quickly as possible. The score is the time in seconds required to compete the array with each hand. Longer times reflect worse performance. Times are compared to normative data that is organized by ethnicity, age, gender and education. The test takes approximately 5 minutes to complete.
75757574|NCT01063023|Drug|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
75903784|NCT04105530|Other|Buschke Selective Reminding Test|This selective reminding task purports to distinguish verbal memory into short-term and long-term components. Scores are organized by short- and long-term storage and retrieval with normative scores organized by age and gender. The task requires participants to remember a list of orally-presented words and recall them with selective reminders of the words that they didn't recall. The test will last 5-10 minutes and is available in four different versions, thus reducing rehearsal effects.
75457892|NCT01796379|Behavioral|High Intensity Interval Training|9 months of high intensity interval based aerobic exercise (3 times/week)
75457893|NCT01796379|Behavioral|Moderate Training|
75609806|NCT01018953|Drug|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
75609807|NCT04219657|Biological|mesenchymal stem cell application|
75609808|NCT04315740|Other|Particles from candles|Generating fine and ultrafine particles from lit candles
75757575|NCT01063023|Drug|BMS-650032|Tablets, Oral, 600 mg, BID
75757576|NCT01063101|Other|Fucoidan (extract of Laminaria japonica)|Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
75903785|NCT04104776|Drug|CPI-0209|CPI-0209 alone
75903786|NCT04103593|Behavioral|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
75903787|NCT04078997|Other|nasopharyngeal swab|A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
75903788|NCT04064242|Drug|CMK389|single i.v. dose every 4 weeks
76068722|NCT01436643|Drug|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
76068723|NCT00399880|Behavioral|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
75457894|NCT01796418|Drug|Beraprost sodium|
75757577|NCT01063101|Other|Placebo|Cellulose filled capsule - oral administration - 5 different dose levels - BID
75757578|NCT00305253|Device|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
75457895|NCT01796496|Other|Manipulative Therapy Techniques|"Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction."
75757579|NCT01066611|Drug|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
75757580|NCT01066611|Drug|Placebo|CAL-263 10 mg or placebo once daily for 7 days
75757581|NCT01066689|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
75757582|NCT01066689|Drug|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
75757583|NCT03980691|Biological|Chidamide with CAR-T or TCR-T cell therapy|HIV-1 specific therapy
75757584|NCT00293709|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
75757585|NCT01063257|Drug|Clofarabine|"The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:~DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).~The DLa will be the following:~DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation."
75757586|NCT03977649|Drug|erenumab|erenumab 140 mg sc every 4 weeks
75757587|NCT03977649|Drug|placebo|placebo sc every 4 weeks
75757588|NCT01066767|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
75757589|NCT03980613|Other|Triage|Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
75903789|NCT04064242|Drug|Placebo|single i.v. dose every 4 weeks
75457896|NCT01796496|Other|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
75457897|NCT01796522|Drug|progesterone 200 mg / day vaginally|
75609809|NCT04315740|Other|Particles from cooking|Generating fine and ultrafine particles from frying pork in an oven
75609810|NCT04315740|Other|Clean Air|Nothing but clean air
75609811|NCT04314024|Drug|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
75609812|NCT00635791|Drug|Sorafenib|Given by mouth
75757590|NCT03980379|Drug|304 injection|Monoclonal antibodies, 100mg/10ml per injection
75757591|NCT03980379|Drug|rituximab injection|100mg/10ml per injection ，manufactured by Roche
75903790|NCT04064060|Drug|Luspatercept|Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
75903791|NCT04062812|Other|the same citrate dosification in both types|match concentrated and dilute citrate protocol
75903792|NCT04051619|Drug|intranasal oxytocin, 40 IU, twice a day for 7 days|Adjunct therapy
75903793|NCT04044690|Drug|human immunoglobulin G|human immunoglobulin G administered subcutaneously
75609813|NCT00635791|Drug|Vorinostat|Given by mouth
75903794|NCT04044690|Drug|Placebo|contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
75903795|NCT04042402|Drug|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
75457898|NCT01796522|Drug|nifedipine (60 mg / day orally)|
75457899|NCT01796717|Drug|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
75457900|NCT01796717|Drug|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
75457901|NCT01796730|Drug|bambuterol|Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
75457902|NCT01796730|Drug|Placebo|
75609814|NCT04219501|Other|VIVO|Non-invasive mapping system software product that combines patient-specific images (MRI or CT) of the torso and cardiac structures and a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart.
75609815|NCT02753023|Other|no intervention|No intervention related
75757592|NCT01064271|Drug|Risperidone|Risperidone Tablets 1 mg
75757593|NCT01066845|Drug|tadalafil|prescribed in accordance with usual clinical practice
75757594|NCT01064349|Drug|Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer|Trastuzumab or Lapatinib
75757595|NCT00311181|Device|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
75757596|NCT01063491|Procedure|bypass graft angiography|
75903796|NCT04038203|Device|Resonance Raman Spectroscopy (RPS)|RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
75757597|NCT00293397|Device|Drug-eluting beads loaded with doxorubicin hydrochloride|Doxorubicin eluting beads
75757598|NCT03981627|Drug|ADO09 formulation|Subcutaneous injection of ADO09 formulation
75757599|NCT03981627|Drug|NovoRapid®|Subcutaneous injection of insulin aspart
75757600|NCT01064505|Drug|QPI-1007 at various doses|Single Intravitreal Injection
75757601|NCT01069263|Other|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
75757602|NCT01069263|Drug|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
75457903|NCT01796808|Procedure|Pedal Fat Grafting|"Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
75757603|NCT01067079|Other|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
75757604|NCT01069497|Other|Prevention of infections program|"The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:~a slide-show of recommendations (commented by an expert),~recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec."
75903797|NCT04029337|Device|HighLife Transcatheter Mitral Valve Replacment|Transcatheter mitral valve replacement
75903798|NCT04028765|Drug|Misoprostol|Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated
75903799|NCT04028765|Drug|Oxytocin|IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
75903800|NCT03993054|Behavioral|Cognitive behavioral stress management|The SmartManage CBSM intervention includes content that is of clinical relevance to sexual minority men dually diagnosed with HIV and cancer. Intervention content includes: co-management of HIV and cancer, strategies for self-advocacy, partnering with the health system and health providers, intimacy and disclosure concerns regarding both conditions, and contextual stressors (e.g., racial/ethnic minority status), stigmatization, assertiveness and communication skills, and self-efficacy in care coordination. Participants receive weekly 1.5 hour interactive group sessions online that focus on stress and self-management skill-building, and also receive access to didactic information regarding intervention content via the intervention website. Intervention length is 4 weeks.
75903801|NCT03993054|Behavioral|Culturally-tailored cognitive behavioral stress management|This intervention will be a version of SmartManage that is culturally-tailored for Latino populations.
75903802|NCT03974750|Device|Bimanual motor skill learning with the REAplan(R) rehabilitation robot|REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
75609816|NCT01158924|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
75609817|NCT02760121|Drug|Acetazolamide|
75609818|NCT02760121|Drug|Methazolamide|
75609819|NCT02760121|Drug|Placebo|
75757605|NCT01064583|Other|cocoa|dissolved in water twice-daily intervention
75757606|NCT01067235|Drug|BF2.649|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
75757607|NCT01067235|Drug|BF2.649 add on Modafinil|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
75757608|NCT01069575|Biological|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
75757609|NCT01067313|Device|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
75757610|NCT01067313|Device|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
75757611|NCT00290745|Drug|letrozole|
75757612|NCT00290745|Drug|tamoxifen citrate|
75757613|NCT00290745|Procedure|conventional surgery|
75757614|NCT00290745|Procedure|neoadjuvant therapy|
75757615|NCT01069653|Biological|HLA-A*2402-restricted CDCA1 and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
75903803|NCT03960463|Device|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
75903804|NCT03959241|Procedure|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
76072392|NCT00574496|Procedure|peripheral blood stem cell transplantation|
75609820|NCT05218447|Device|Robotic Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
75609821|NCT05218447|Other|Usual Care (UC) Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will complete gait training with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
75757616|NCT03980223|Drug|Doxycycline Hyclate Delayed-Release 200 mg|200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
75757617|NCT01067391|Drug|tadalafil|20 mg tablet, administered once per study protocol
75609822|NCT00635869|Behavioral|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
75757618|NCT01067391|Drug|placebo|placebo tablet administered once per study protocol
75757619|NCT00402168|Drug|Belatacept|IV, IV Infusion, 5 mg/kg once every 28 days for one year
75757620|NCT00402168|Drug|Cyclosporine A|Tablets, Oral, Trough of 100-250 ng/mL, 2* daily for one year
75457904|NCT01796808|Other|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.~Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. <200ml). Only a few cc's of fat are needed for injection into the foot."
75457905|NCT01796925|Device|aura6000 THN System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
75457906|NCT01796990|Behavioral|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
75457907|NCT01796990|Behavioral|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
75609823|NCT00635869|Behavioral|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
75609824|NCT00635869|Behavioral|Placebo|didactic education sessions on physical assessment
75609825|NCT05215873|Drug|Misoprostol|a synthetic prostaglandin E1 analogue
75609826|NCT05215873|Drug|Syntocinon|synthetic oxytocin
75609827|NCT02759887|Procedure|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
75757621|NCT00402168|Drug|Tacrolimus|Tablets, Oral, Trough of 5-10 ng/mL, 2* daily for one year
75757622|NCT01064661|Dietary Supplement|Single probiotic arm of L-NCFM alone|Single probiotic of L-NCFM alone pills BID (2x10^10 cfu total bacteria per day)
75757623|NCT01064661|Dietary Supplement|Blend probiotic arm of L-NCFM and B-LBi07|Blend probiotic arm of L-NCFM and B-LBi07 pills BID (2x10^10 cfu total bacteria per day)
75757624|NCT00290589|Drug|Intramuscular methylprednisolone acetate|Intramuscular methylprednisolone acetate 160mg
75757625|NCT00290589|Drug|Placebo|Normal saline intramuscular injection
75757626|NCT01067547|Drug|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
75757627|NCT01067547|Drug|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
75757628|NCT00290511|Drug|Fludarabine|25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4.
75757629|NCT00290511|Drug|Mitoxantrone|10 mg/m^2 IV over 5-30 minutes on Day 2.
75757630|NCT00290511|Drug|Rituximab|375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
75757631|NCT00290511|Drug|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
76072393|NCT00574496|Procedure|umbilical cord blood transplantation|
76072394|NCT00574496|Radiation|total-body irradiation|
76072395|NCT00533624|Drug|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
75757632|NCT00290511|Drug|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
76072396|NCT00533624|Drug|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
75609828|NCT02759887|Other|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
75757633|NCT00290433|Drug|Cyclophosphamide|Cycle 1: 300 mg/m^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
75757634|NCT00290433|Drug|Mesna|Cycle 1: 600 mg/m^2 by vein Continuous Infusion Over Days 1, 2, and 3.
75757635|NCT00290433|Drug|Vincristine|Cycle 1: 1.4 mg/m^2 by vein On Day 4 and 11.
75757636|NCT00290433|Drug|Methotrexate|Cycle 1 and 2: 200 mg/m^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m^2 IV Over 22 Hours on Day 1.
75903805|NCT03959241|Drug|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
75609829|NCT02759887|Other|caregiver questionnaire|
75903806|NCT03959241|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
75903807|NCT03959241|Procedure|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
76068724|NCT04239196|Drug|tocilizumab and IV steroids combination|"Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.~Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week)."
75457908|NCT01797211|Dietary Supplement|Mediterranean diet|Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
75609830|NCT02759887|Procedure|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
75457909|NCT01797289|Other|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
75457910|NCT01797653|Other|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
75457911|NCT01797653|Procedure|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
75609831|NCT02759887|Procedure|MRI|Magnetic resonance imaging of the head and brain.
75609832|NCT02759887|Procedure|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
75757637|NCT00290433|Drug|Ara-C|Cycle 1 and 2: 3 Gm/m^2 Over 2 Hours Twice Daily On Days 2 and 3.
75757638|NCT00290433|Drug|Dexamethasone|Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
75757639|NCT00290433|Drug|G-CSF|Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
75757640|NCT00290433|Drug|Doxil|Cycle 1: 25 mg/m^2 by vein Over 1 Hour on Day 2.
75757641|NCT04323033|Device|PERS stent|"PERS® is a cobalt-chromium stent, made of cobalt-chromium alloy with drug (Sirolimus) and biodegradable polymer controlling drug elution.~The length of the stent is selected to cover the treated lesion with a margin of 5 mm proximal and distal, while the diameter of the stent will be selected based on the QVA measurement (balloon to vessel ratio 1:1)."
75457912|NCT01797718|Drug|Testosterone|1mg/kg every 4 weeks for 6 months
75457913|NCT01797718|Drug|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
75457914|NCT01797796|Drug|PF-06305591|150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
75609833|NCT02759887|Procedure|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
75457915|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
75457916|NCT01797796|Drug|Placebo|Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
75609834|NCT02759887|Procedure|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
75757642|NCT04323033|Device|NEPTUN C stent|Neptun C is balloon-expanding cobalt-chromium stent.
75757643|NCT00304083|Biological|filgrastim|Given subcutaneously
75757644|NCT00304083|Drug|doxorubicin hydrochloride|Given IV
75757645|NCT00304083|Drug|etoposide|Given IV
75757646|NCT00304083|Drug|ifosfamide|Given IV
75757647|NCT00304083|Procedure|conventional surgery|Patients undergo surgery
75757648|NCT00304083|Radiation|radiation therapy|Patients undergo radiotherapy
75757649|NCT00293241|Device|Managed Ventricular Pacing programmed ON/OFF|Device programming
75757650|NCT01069809|Biological|AGS-004|HIV-1 Immune Therapy
75757651|NCT01069809|Biological|Placebo|Inactive Placebo Injection
76068725|NCT04239196|Other|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
76068726|NCT01795378|Biological|donor natural killer cell infusion|"Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.~The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).~For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.~The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
76068727|NCT00361972|Drug|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
75609835|NCT02750917|Drug|Lornoxicam|At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
76068728|NCT00361972|Drug|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
75609836|NCT02750917|Drug|Etoricoxib|At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
75757652|NCT01067625|Device|TOGA® System|Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
75757653|NCT03977337|Procedure|Major emergency abdominal surgery|Major emergency gastrointestinal surgery performed within 72 hours of an acute admission or an acute reoperation.
76068729|NCT00362440|Drug|Leptin|
76068730|NCT00362440|Drug|Pioglitazone or metformin|
76068731|NCT00362440|Drug|Placebo|
75457917|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
75757654|NCT03977103|Biological|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
75463295|NCT05854615|Biological|Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
75757655|NCT01069965|Drug|BGP-15 100 mg QD|Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
75757656|NCT01069965|Drug|BGP-15 100 mg BID|One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
75757657|NCT01069965|Drug|Placebo BID|Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
75757658|NCT01069965|Drug|BGP-15 200 mg QD|Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
75757659|NCT01069965|Drug|BGP-15 200 mg BID|Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
76068732|NCT00401518|Device|Non-randomized ACADIA® Facet Replacement System|Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
76068733|NCT00401518|Device|Randomized ACADIA® Facet Replacement System|Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
76072397|NCT00515060|Other|Sensory Tests|Tests to find the threshold at which perceive stimuli.
75463296|NCT05854589|Drug|Sodium Chloride Granules|Sodium Chloride crystals
75463297|NCT05854589|Other|Water|Plain distilled water
75463298|NCT05854576|Procedure|vascular acess|AVF
75609837|NCT02750839|Procedure|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
75609838|NCT02759809|Other|Pasteurized donor human breastmilk|
75609839|NCT02759809|Other|Preterm formula|
75757660|NCT01069965|Drug|BGP-15 400 mg QD|Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
75757661|NCT03979833|Genetic|Whole exome sequencing|DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
75757662|NCT01067703|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
75757663|NCT01067703|Procedure|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
75757664|NCT01064895|Device|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
75757665|NCT00391092|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
75757666|NCT00391092|Drug|Docetaxel|100mg/m2 iv every 3 weeks
75757667|NCT00391092|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
75757668|NCT00374868|Drug|pemetrexed|"Phase 1: 300 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m^2, 400 mg/m^2, and 500 mg/m^2)~Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
75757669|NCT00374868|Drug|cisplatin|"Phase 1: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles~Phase 2: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
75757670|NCT01044342|Drug|AZD1446|capsule; single oral dose
75757671|NCT01044342|Drug|AZD1446|capsule, single oral dose
75609840|NCT02750995|Biological|NPMW-peptide vaccine|Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
75757672|NCT01044342|Drug|donepezil|capsule, single oral dose
75903808|NCT03959241|Drug|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
75757673|NCT01044342|Drug|Placebo|capsule, single oral dose
75757674|NCT00374556|Drug|Placebo|3mg placebo capsule, once daily at bedtime
75903809|NCT03959241|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
75903810|NCT03959241|Drug|Cyclophosphamide|Cyclophosphamide [50 mg/kg ideal body weight (IBW); if actual body weight (ABW) < IBW, use ABW] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
75903811|NCT03958474|Drug|Oxycodone|Participants receive oxycodone or placebo.
75903812|NCT03958474|Drug|Remifentanil|Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.
75757675|NCT00374556|Drug|Eszopiclone|3mg capsule, once daily at bedtime
75903813|NCT03907488|Procedure|Biospecimen Collection|Undergo peripheral blood collection
75903814|NCT03907488|Drug|Brentuximab Vedotin|Given IV
76068734|NCT00401518|Device|Randomized Instrumented posterolateral fusion (PLF)|Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
75609841|NCT02750995|Drug|Azacitidine|Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
75757676|NCT00290355|Biological|GSK 249553 vaccine|Intramuscular injection, 13 doses
75757677|NCT00290355|Biological|Placebo|Intramuscular administration, 13 doses
75757678|NCT03977025|Diagnostic Test|Lumbar punction|Patients will be evaluated prior to surgery with the Montreal Cognitive Assessment (MoCA) to determine the presence of cognitive impairment, and CSF samples, obtained by lumbar punction, will be analyzed by immunodetection of Aβ40, Aβ42, tau and ptau with multiplex technology
75757679|NCT01064973|Drug|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
75757680|NCT03741855|Device|Cloud Dx Kit with self-monitoring|Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.
75757681|NCT03741855|Device|Cloud Dx Kit with remote-monitoring|"Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~The RT will also check on patients once a week irrespective of the value of the vitals."
75609842|NCT01027845|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
75609843|NCT01027845|Biological|DTPa|Subcutaneous injection, 4 doses
75609844|NCT04219345|Device|Transcranial direct current stimulation|Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
75757682|NCT00374322|Drug|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
75757683|NCT00374322|Other|placebo|6 tablets daily for 12 months
75757684|NCT00303459|Drug|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
75757685|NCT00303459|Drug|placebo|Matching bosentan placebo/b.i.d.
75757686|NCT00289887|Drug|Comparator: losartan +/- HCTZ|Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
75757687|NCT00289887|Drug|Comparator: Placebo|Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
75757688|NCT01325649|Procedure|total mesorectal excision / long course radiochemotherapy|long course 5-FU based radiochemotherapy before total mesorectal excision
75757689|NCT01325649|Radiation|long course 5-FU bases radiochemotherapy|
76068735|NCT02109640|Drug|Targinact|Post-operative analgesia
76068736|NCT02109640|Drug|Oxycodone|Postoperative analgesia
75609845|NCT05113225|Procedure|Micro-swim up technique|processing and selection of the sperm for ICSI in the same dish
75609846|NCT04221919|Drug|β -Blockers|Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
75609847|NCT04299633|Drug|Vadadustat|2 x 150 mg oral tablets
75609848|NCT04299633|Drug|Sevelamer carbonate|2 x 800 mg oral tablets
75757690|NCT01067937|Procedure|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
75757691|NCT00303069|Biological|V710|Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
75757692|NCT00303069|Biological|Comparator: Placebo|Single dose of saline placebo intramuscularly
75757693|NCT01325727|Other|Brief computerized feedback|Brief computerized feedback
75757694|NCT01325727|Other|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
75903815|NCT03907488|Procedure|Computed Tomography|Undergo PET/CT or CT scan
75903816|NCT03907488|Drug|Dacarbazine|Given IV
75903817|NCT03907488|Drug|Doxorubicin Hydrochloride|Given IV
75903818|NCT03907488|Biological|Filgrastim|Given SC or IV
75903819|NCT03907488|Procedure|Magnetic Resonance Imaging|Undergo MRI
75457918|NCT01798108|Radiation|Radium-223 dichloride (BAY88-8223)|- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
75903820|NCT03907488|Biological|Nivolumab|Given IV
75903821|NCT03907488|Biological|Pegfilgrastim|Given SC
75903822|NCT03907488|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75609849|NCT04299633|Drug|Calcium acetate|2 x 667 mg oral gelcaps
75609850|NCT04299633|Drug|Auryxia®|2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
75757695|NCT01068015|Other|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
75903823|NCT03907488|Other|Quality-of-Life Assessment|Ancillary studies
75903824|NCT03907488|Other|Questionnaire Administration|Ancillary studies
75903825|NCT03907488|Radiation|Radiation Therapy|Receive radiation therapy
75609851|NCT02695459|Drug|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
75609852|NCT04288713|Drug|Eculizumab|A distal complement inhibitor.
75609853|NCT02759497|Other|serum amyloid A level|serum amyloid A level (SAA)
75609854|NCT00627549|Procedure|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
75609855|NCT00627549|Procedure|Conventional surgery (anterior repair)|Anterior repair surgery
75609856|NCT04299789|Other|Validating the Military Service Identification Tool|This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.
75609857|NCT04217863|Behavioral|GDP|Guided Disclosure Protocol
75609858|NCT02872233|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
75757696|NCT01068093|Drug|Ezetimibe|10mg daily
75757697|NCT00401544|Drug|darbepoetin alfa|Darbepoetin alfa administered by subcutaneous injection.
75757698|NCT00401544|Drug|IV iron dextran|Administered by intravenous (IV) injection.
75757699|NCT01044420|Drug|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
75903826|NCT03907488|Drug|Vinblastine Sulfate|Given IV
75903827|NCT03888950|Diagnostic Test|FDG PET-CT|FDG PET/CT for oncological imaging of adult patients
75903828|NCT03878485|Device|MRIdian Linac System from ViewRay|"0.35T MRI combined with a linear accelerator~This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy"
76068737|NCT02109640|Procedure|Laparoscopic segmental colectomy|
75757700|NCT00289731|Biological|TWINRIX™|Intramuscular injection, 3 doses
75757701|NCT00289731|Biological|Engerix™-B|Intramuscular injection, 3 doses
75757702|NCT00289731|Biological|HAVRIX™|Intramuscular injection, 2 doses
75757703|NCT00289731|Biological|HB VAX PRO™|Intramuscular injection, 3 doses
75903829|NCT03878485|Radiation|Stereotactic MRI-guided Adaptive Radiotherapy|-The MR-linac will be delivering the radiation
75903830|NCT03856515|Drug|Nicotine Replacement|Received NRT (Electronic Cigarette - With Nicotine)
75903831|NCT03856515|Other|Questionnaire Administration|Ancillary studies
75903832|NCT03856515|Device|Electronic Cigarette|Electronic Cigarette - with Nicotine
75903833|NCT03856515|Device|Electronic Cigarette|Electronic Cigarette -without Nicotine
75903834|NCT03851523|Other|No intervention|No intervention
75903835|NCT03847272|Drug|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)
75903836|NCT03847272|Other|Ophthalmologic examination|Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography
75903837|NCT03847272|Other|Questionnaires|VFQ-25 and SF-36
75903838|NCT03847272|Biological|Blood samples|Additional blood samples for immunomonitoring
75903839|NCT03833180|Drug|Zilovertamab vedotin|Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
75757704|NCT00289731|Biological|Vaqta™|Intramuscular injection, 2 doses
75757705|NCT00289185|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
75609859|NCT02872233|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
75757706|NCT00289185|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
75757707|NCT00289185|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
75609860|NCT04219423|Behavioral|Multimodal physical therapy|see description in arm/group description
75757708|NCT03980067|Other|Virtual Reality Game|The virtual reality headset, device, and software, created by Stanford's Childhood Anxiety Reduction through Innovation and Technology (CHARIOT)program/Weightless Studio, LLC will be utilized in this study. Children in the VR intervention group will be allowed to select a distraction-based game to play with active VR content featuring interactive avatars and interactive experiences tailored to the pediatric population that allow players to do things such as control penguins sliding down a mountain while collecting pebbles for points, control puppies running in space to collect treats to the rhythm of music, and control an asteroid miner exploring an asteroid belt and collecting points based on color of asteroids collected. The game will last a minimum of 5 minutes in duration, provided participant tolerance. The participant may play longer if desired prior to receiving procedural sedation and the total length of activity played will be documented.
75903840|NCT03813615|Behavioral|treadmill walking (Proof-of-Concept)|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology. setting.
76068738|NCT00401986|Device|Bronchial thermoplasty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
75757709|NCT00292461|Drug|Zonisamide|Tablet once or twice daily orally for 16 weeks
75757710|NCT00292461|Drug|Lamotrigine|Tablet once daily orally for 16 weeks
75757711|NCT03976869|Drug|AZD7594|During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
75757712|NCT00288639|Drug|Pregabalin|"Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).~Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID)."
75757713|NCT01068171|Other|type of footwear|comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
75457919|NCT01798329|Dietary Supplement|probiotic VSL#3|"VSL#3 is a probiotic that reduces:~urease faecal activity~faecal pH~inflammatory cytokine"
75457920|NCT01798355|Behavioral|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
75457921|NCT01798355|Behavioral|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
75457922|NCT01798446|Drug|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
75609861|NCT04599231|Diagnostic Test|Quality of Recovery -15|The investigators plan to evaluate patients' quality of recovery at postoperative day (POD) 1, 2, and 3.
75609862|NCT04219267|Behavioral|character strengths-based intervention|"Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths."
75609863|NCT04219267|Behavioral|early memories|In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
75609864|NCT01017549|Radiation|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
75757714|NCT01068171|Other|collagen dressing with and without silver|silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
75609865|NCT00635947|Other|isotonic solution|1.5 L- during 2-4hours
75757715|NCT00390858|Drug|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
75757716|NCT00390780|Drug|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
75903841|NCT03813615|Behavioral|treadmill walking Dose-Finding / Escalation|Six doses of aerobic training ( 90mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/wk & 450mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity & duration) or non-linear (i.e., exercise dose is continually altered & progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 3 to 6 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented & may be monitored using TeleEx. Patients may also perform up to three aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided a plan for their unsupervised session(s) verbally or via Portal Secure Messaging (PSM), as appropriate.
75903842|NCT03805789|Biological|Alpha-1 antitrypsin (AAT)|Alpha-1 antitrypsin is a lyophilized product for intravenous administration.
75457923|NCT01798680|Dietary Supplement|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
75757717|NCT00390780|Drug|Clotrimazole|10mg troches administered Five Times a Day for 14 days
75757718|NCT00390546|Drug|Digoxin|
75757719|NCT00390546|Drug|Propranolol|
75757720|NCT00390468|Drug|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
75903843|NCT03805789|Biological|Placebo|Albumin solution administered intravenously
75903844|NCT03805464|Other|Knee Joint Effusion|60mL saline injection into the supra-patellar region of the knee
75903845|NCT03788837|Drug|Ilomedin|The patient will receive treatment with intravenous Ilomedin therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.
75903846|NCT03788837|Drug|NaCl|The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
75903847|NCT03785262|Device|Uroshield|The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
75457924|NCT01798680|Other|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
75457925|NCT01798823|Procedure|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
75457926|NCT01798836|Procedure|Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol|
75457927|NCT01798836|Procedure|GnRH agonist or antagonist protocol without oestradiol pre-treatment|
75457928|NCT01798862|Procedure|Endometrial injury by hysteroscopy or pipelle sampling|
75609866|NCT00635947|Other|water|1.5 L- during 2-4hours
75609867|NCT00635947|Other|water|200mL- during 2-4hours
75609868|NCT04299243|Device|Contact Lenses|Contact lenses for vision correction
75609869|NCT05112991|Drug|Envafolimab+Lenvatinib|"Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle."
75757721|NCT00400764|Drug|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
75757722|NCT00400764|Drug|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
75757723|NCT00302211|Drug|Inhaled Iloprost (5 μg)|iloprost inhalation solution (Ventavis) (5 μg)
75757724|NCT00302211|Drug|Inhaled Placebo|inhaled placebo
75757725|NCT00302211|Drug|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
75757726|NCT00302211|Drug|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
75757727|NCT01045902|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
75757728|NCT01045902|Drug|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
75757729|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
75903848|NCT03785262|Device|Sham Uroshield|The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
76072398|NCT00499083|Biological|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
75609870|NCT05112991|Drug|Envafolimab|Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
75609871|NCT01030341|Device|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
75757730|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
75757731|NCT01041690|Drug|Bevacizumab|
75757732|NCT01041768|Procedure|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
75757733|NCT01041846|Drug|No intervention|This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
75609872|NCT02750449|Drug|Sun screening Sport Lotion, (BAY987516)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
75757734|NCT00288015|Biological|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
75757735|NCT00389064|Drug|Quetiapine XR|Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
75757736|NCT00389064|Drug|Placebo|Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
75609873|NCT02750449|Other|Untreated skin|This site is patched without treatment as control
75757737|NCT01045980|Drug|Bioimpedance and Vitamin D|Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.
75757738|NCT01045980|Drug|Usual care and placebo|Usual care (not bioimpedance guided volume management) and Placebo
75757739|NCT01045980|Drug|Usual care and Vitamin D|Usual care (not bioimpedance guided volume management) and Vitamin D
75757740|NCT01045980|Device|Bioimpedance and Placebo|Bioimpedance guided volume management and Placebo
75757741|NCT00388674|Drug|entecavir|Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
75757742|NCT00388674|Drug|Other anti-HBV medication|Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
75903849|NCT03775096|Drug|Carvedilol|At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
75457929|NCT01798862|Procedure|Proceed to COH directly|
75457930|NCT01798901|Drug|HDAC inhibitor AR-42|Given PO
75457931|NCT01798901|Drug|decitabine|Given IV
75457932|NCT01798901|Other|laboratory biomarker analysis|Correlative studies
75457933|NCT01798901|Other|pharmacological study|Correlative studies
75457934|NCT01799148|Other|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
75457935|NCT01799304|Procedure|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
75457936|NCT01799304|Procedure|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
75757743|NCT00388362|Drug|Sirolimus|Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
75757744|NCT00388362|Drug|Prednisone|Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
75757745|NCT03463980|Behavioral|Compassion meditation (CM)|CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.
75757746|NCT03463980|Behavioral|Support group (SG)|SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
75757747|NCT01041924|Other|Carbon dioxide|2% inhaled CO2 for up to 8 hours.
75757748|NCT01041924|Other|Carbon dioxide|Up to a maximum of 2% CO2, only delivered for a maximum of up to 20 seconds per 60 seconds for 8 hours
75757749|NCT01042002|Behavioral|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
75757750|NCT01046058|Drug|TMC435|150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
75757751|NCT01046214|Drug|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
75757752|NCT01046214|Drug|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
75757753|NCT01324284|Drug|Lubiprostone|Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
75757754|NCT00387894|Drug|erlotinib hydrochloride|Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
75757755|NCT03992976|Other|Online Chronic Pain Management Intervention for Teenagers|The intervention itself is currently under development. This development study is used to gather patient (teenager) insights, as well as insights from parents of these patients, which will inform the content and structure of the proposed intervention. This is done using qualitative-only techniques. Initial ideas for the intervention design mirror current clinical practices in paediatric chronic pain management. There are likely to be several different online modules, which include psychological techniques, medicine (advice), nursing (advice and guidance on non-pharmacological physical pain management), and physiotherapy (guidance for pacing and physiotherapy exercises). The intervention is intended to help teenagers employ a vast range of self-management techniques from these disciplines. Exact content is not yet refined as this is a development study.
75757756|NCT00387426|Drug|sunitinib malate|Given PO
75757757|NCT00387348|Drug|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
75757758|NCT00387348|Drug|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
76068739|NCT00365872|Biological|Dendritic Cell (DC) Injections|"DCs (10^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~One additional DC injection was given before surgery to assess DC migration~Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
75457937|NCT01799304|Procedure|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
75457938|NCT01799304|Procedure|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
75457939|NCT01799343|Other|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
75457940|NCT01799512|Device|experimental: real-time continuous glucose monitoring|
75457941|NCT01799512|Device|Active comparator: blinded continuous glucose monitoring|
75457942|NCT01799694|Drug|Inject of Autologous Adipose-derived stem cells|Inject in muscle of autologous adipose derived stem cells
75609874|NCT04301037|Procedure|Tension band wires|medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression
75457943|NCT01799863|Drug|Ketorolac trometamol 0.45% with carboxymethylcellulose|
75457944|NCT01799863|Drug|Preservative free artificial tear|
75457945|NCT01800006|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
75457946|NCT01800019|Drug|Nicotine Replacement Therapy (NRT)|
75457947|NCT01800019|Drug|Varenicline|
75457948|NCT01800019|Behavioral|HIV Tailored Quit Smoking Counseling|"A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24."
75457949|NCT01800045|Drug|Pitolisant|1 capsule in the morning before breakfast
75457950|NCT01800045|Drug|Placebo|1 capsule in the morning before breakfast
76068740|NCT00365872|Procedure|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
76068741|NCT00365872|Procedure|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
76068742|NCT00366028|Behavioral|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
75757759|NCT03993522|Other|Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test|Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
75757760|NCT03992820|Device|TENS machine|"The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
75757761|NCT03992820|Combination Product|EMLA cream|"The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
75757762|NCT01042080|Device|NAVA|Assisted mechanical ventilation according to the electrical activity of the diaphragm recorded with a 16-FR naso-gastric tube mounted with EMG electrodes
75757763|NCT01042080|Other|Expiratory trigger (ET)|Varying the cycling criterion according to the percentage of peak inspiratory flow
75757764|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
75903850|NCT03769454|Drug|PP-001|PP-001 eye drops
75903851|NCT03769454|Other|Placebo|Placebo eye drops
75457951|NCT01800071|Drug|MVA-EBNA1/LMP2 vaccine|
75457952|NCT01800084|Device|Asir Image Acquisition|In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
75457953|NCT01800097|Drug|modafinil|Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months
75457954|NCT01800097|Drug|placebo|Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
75457955|NCT01800110|Dietary Supplement|pomegranate juice|
75609875|NCT04301037|Procedure|Cannulated screws|In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
75757765|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
75457956|NCT01800136|Device|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
76068743|NCT00366028|Behavioral|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
75457957|NCT01800149|Procedure|Ridge Augmentation|After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
75457958|NCT01800175|Device|Punctum Plug|
75457959|NCT01800188|Procedure|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
75609876|NCT02750293|Drug|Cholecalciferol|Vitamin D preparation
75609877|NCT02750293|Drug|Placebo|placebo
75609878|NCT04217785|Drug|Optive, Ophthalmic Solution|6 drops per day, for 8 weeks
75757766|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
75757767|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
75757768|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
75757769|NCT00413660|Drug|CP-690,550|Oral tablets
75757770|NCT00413660|Other|placebo|Placebo
75757771|NCT01234532|Drug|entinostat|orally
75757772|NCT01234532|Drug|anastrozole|Given PO
75757773|NCT01234532|Other|diagnostic laboratory biomarker analysis|"Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
75757774|NCT01234532|Procedure|therapeutic conventional surgery|Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
75903852|NCT03752697|Behavioral|metacognitive performance|Paper and pencil/computerized tests of metacognition
75903853|NCT03744910|Biological|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
75903854|NCT03744910|Drug|Physiologic saline solution|Normal saline
75903855|NCT03734731|Device|Monochromatic Infrared Photo Energy (MIRE)|Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve
75903856|NCT03734731|Device|Transcutaneous Electrical Nerve Stimulation|Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve
75903857|NCT03734731|Drug|Opioids|Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
76068744|NCT01454739|Drug|rFVIIIFc|Administered as specified in the treatment arm.
75757775|NCT00431834|Device|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
75757776|NCT00431834|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
75757777|NCT00431444|Drug|Raloxifene|
75757778|NCT00431444|Drug|Zoledronic acid|
75457960|NCT01800188|Procedure|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
75609879|NCT04217785|Biological|Umbilical Cord Serum eye drops|UCS eye drops (6 drops per day, for 8 weeks)
75757779|NCT00431444|Drug|Placebo oral pills|
75757780|NCT00431444|Drug|Placebo intravenous (i.v.) infusion|
75757781|NCT01323686|Other|Imaging guided optimal LV lead placement|"LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate <30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used."
75903858|NCT03734731|Drug|Cannabis|Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
75903859|NCT03720990|Drug|Cholic Acid|Participants will be treated with cholic acid for 8 weeks
75903860|NCT03709264|Drug|Amino Acids|Patients randomized to experimental arm receive a continuous infusion of a balanced mixture of amino acids in a dose of 2 g/kg ideal body weight/day (to a maximum 100 g/day) from the operating room admission up to either death, start of RRT, ICU discharge or 72 hours after treatment initiation, trough a central venous line
75457961|NCT01800188|Procedure|Meal test|A 3 hour standardized liquid meal test without dialysis
75609880|NCT04217785|Drug|Genteal lubricant gel|Genteal lubricant gel (2 drops per day, for 8 weeks)
75903861|NCT03709264|Drug|Placebos|Placebo: standard treatment
75903862|NCT03705169|Biological|SAR441236|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
76068745|NCT00366106|Drug|bortezomib|Patients will be treated with bortezomib at 1.3mg/m^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
76068746|NCT00366106|Drug|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
76068747|NCT00366106|Drug|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m^2 on Day 4 every 28 days (cycle).
76068748|NCT01794286|Other|Provider bulletins|
75457962|NCT01800227|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
75457963|NCT01800240|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
75457964|NCT01800253|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
75609881|NCT01026831|Drug|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
75609882|NCT01026831|Drug|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
75609883|NCT04299165|Device|Kaia COPD Application|The study intervention consists of training sessions conducted daily by the patient via the COPD-App.
75609884|NCT04299165|Other|Usual Care|The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
75609885|NCT05103943|Other|SPECT MPI|SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR
75609886|NCT02759341|Other|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
75609887|NCT02759341|Other|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
75609888|NCT02759341|Other|State-Trait Anxiety Inventory form Y (STAI-Y)|
75757782|NCT00430352|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 8 weeks
75757783|NCT00287469|Biological|Hepatitis E vaccine, recombinant (Sar 56 kDa)|20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)
75903863|NCT03705169|Biological|Placebo|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
75903864|NCT03695939|Biological|realSKIN (skin xenotransplant)|3+3 Dose-escalation Study Design; 2 dosage strengths will be utilized during this Phase 1/2 Trial; an expansion cohort (9 patients) receive the highest dose.
75903865|NCT03695939|Biological|Human Cadaver Allograft|HCA is used as a temporary wound dressing between debridement and definitive closure in many well-resourced contexts.
75903866|NCT03687957|Drug|rhIL-7-hyFc|-Given by intramuscular injection
75903867|NCT03687957|Drug|Placebo|-Given by intramuscular injection
75903868|NCT03687957|Drug|Temozolomide|-Standard of care
75903869|NCT03687957|Radiation|Radiation therapy|-Standard of care
76068749|NCT01794286|Other|Trigger alerts|
75609889|NCT02759341|Other|SF-36 Health-Related Quality of Life|
75609890|NCT02759341|Other|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
75757784|NCT00287469|Other|Placebo|PBS buffer placebo containing alum
75903870|NCT03687957|Procedure|Blood sample|"Week 1 (prior to the 1st dose of rhIL-7-hyFc)~Week 2 (one week after rhIL-7-hyFc)~Week 3 (two weeks after rhIL-7-hyFc)~Week 4 (three weeks after rhIL-7-hyFc)~Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~Week 14 (one week after rhIL-7-hyFc)~Week 16 (three weeks after rhIL-7-hyFc) - optional~Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~At the time of tumor progression"
75457965|NCT01800253|Procedure|Blood samples|Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
75457966|NCT01800253|Procedure|Tissue samples|Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
75457967|NCT01800253|Procedure|Oral glucose tolerance test|75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
75457968|NCT01800253|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
75757785|NCT01068405|Drug|Methotrexate|Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
75757786|NCT01068405|Drug|Placebo|Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
75609891|NCT05052385|Drug|Ruxolitinib|As per treating physician's decision - non interventional study
75609892|NCT05052385|Device|Extracorporeal photopheresis|As per treating physician's decision - non interventional study
75609893|NCT05052385|Drug|Ibrutinib|As per treating physician's decision - non interventional study
75757787|NCT00429572|Drug|Fludarabine|30 mg/m^2 intravenously Daily for 5 Days
75757788|NCT00429572|Drug|Melphalan|70 mg/m^2 intravenously Daily for 2 Days
75903871|NCT03684109|Device|3T MRI Scanner|3T MRI Scanner providing Mega-laser sequence for single-voxel Magnetic Resonance Spectroscopy (MRS) data for 2 hydroxyglutarate (2HG) quantitation.
76068750|NCT03858868|Behavioral|Church and park-based intervention|Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.
75457969|NCT01800266|Behavioral|Supervision Practices of TF-CBT|Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
75463299|NCT05854563|Other|Observational only, all subjects; measure DNA mutation and proteomic survey.|Observational only, all subjects; measure DNA mutation and proteomic survey.
75609894|NCT04956757|Other|Exercise Intervention|Scapula retraction exercises at varying shoulder abduction angles will be applied
75609895|NCT01016067|Device|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
75609896|NCT01016067|Procedure|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
75609897|NCT04905511|Biological|natural human collagen arteriovenous graft for hemodialysis access|The True Vascular Graft will be implanted in the forearm or upper arm in a straight or curved configuration.
75609898|NCT04843891|Drug|[64]Cu Macrin|Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.
75757789|NCT00429572|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
75757790|NCT00287079|Drug|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
75757791|NCT00287079|Other|No Treatment|No treatment for 96 weeks
75757792|NCT03976167|Device|Oxygen administration with Common nasal cannula|Oxygen administration during elective flexible bronchoscopy in children with high flow nasal cannula with inspired oxygen fraction 1.
75757793|NCT03976167|Device|Oxygen administration with high flow nasal cannula, device Airvo2 Fisher and Pykel|
75903872|NCT03677037|Other|Short-term MBT|Short-term mentalization-based therapy
75903873|NCT03677037|Other|Long-term MBT|Long-term mentalization-based therapy
75903874|NCT03672487|Drug|Benznidazole|Benznidazole tablet
75903875|NCT03672487|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic Benznidazole
75903876|NCT03656835|Procedure|Molecular Nanotechnology|Undergo ILN biochip testing
75903877|NCT03655769|Device|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
75903878|NCT03655769|Device|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
76068751|NCT03858868|Behavioral|Standard health education on physical activity|Participants will receive publicly available brochures, tip sheets, etc. about physical activity
75757794|NCT03975933|Diagnostic Test|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
75757795|NCT03975933|Diagnostic Test|Free pregnancy test for the future use|We will provide a free pregnancy test in for the future use.
75757796|NCT03975933|Diagnostic Test|Pregnancy test for the future use with randomzied price|We will provide an opportunity to buy a pregnancy test for the future use with randomized price.
75757797|NCT00429494|Drug|Leuprolide Acetate|22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
75757798|NCT00429494|Behavioral|Questionnaire|Questionnaires taking about 15 minutes to complete.
75609899|NCT04830475|Device|Non invasive ventilation (NIV)|Patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
75609900|NCT04830475|Device|Conventional Venturi Mask|Patients were offered VenturiMask with Fio2 60% at 15 l / m.
75757799|NCT00429494|Procedure|Hematopoietic Stem Cell Transplantation|Stem cell infusion on Day 0.
75757800|NCT00429416|Drug|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
75757801|NCT00429416|Drug|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
75757802|NCT00429416|Drug|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
75757803|NCT00429416|Drug|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
75609901|NCT00636103|Drug|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
76068752|NCT00368290|Drug|Modafinil|300mg a day for 8 weeks
75609902|NCT00636103|Other|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
75609903|NCT04423393|Biological|VIR-3434|VIR-3434 given by subcutaneous injection or intravenous infusion.
75757804|NCT00429416|Drug|Tacrolimus|Tacrolimus given before and after HSCT infusion
75757805|NCT00429416|Drug|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
75757806|NCT00429416|Biological|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
75757807|NCT00429416|Procedure|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
75757808|NCT00429182|Drug|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
75757809|NCT00429182|Drug|Cyclophosphamide|1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
75757810|NCT00429182|Drug|Thiotepa|120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
75757811|NCT00429182|Procedure|Stem Cell Transplant|Stem Cell Transplant on Day 0.
75757812|NCT00429104|Drug|Herceptin|4 mg/kg IV Over 90 Minutes
75757813|NCT00429104|Drug|GM-CSF|250 mcg/m^2 Subcutaneously
75757814|NCT00429026|Drug|Fludarabine|25 mg/m^2 intravenous (IV) daily for 5 Days
75757815|NCT00429026|Drug|Melphalan|70 mg/m^2 IV Daily for 2 Days
75757816|NCT00429026|Drug|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
75757817|NCT00429026|Procedure|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
75757818|NCT00301821|Biological|epratuzumab|
75757819|NCT00301821|Biological|rituximab|
75757820|NCT00301821|Drug|cyclophosphamide|
75757821|NCT00301821|Drug|doxorubicin hydrochloride|
75757822|NCT00301821|Drug|prednisone|
75757823|NCT00301821|Drug|vincristine sulfate|
75757824|NCT03976713|Drug|Bufei Yishen granule|Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
75757825|NCT03976713|Drug|Placebo Bufei Yishen granule|Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
75757826|NCT03976713|Drug|Tiotropium Bromide Powder for Inhalation|Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
75757827|NCT01068483|Drug|BKM120|
75757828|NCT00372996|Drug|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
76068753|NCT00368290|Drug|placebo|placebo pills for 8 weeks
76068754|NCT00368290|Behavioral|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
76068755|NCT00369226|Drug|Bortezomib (Velcade)|Infusion for a total of 3 doses
75757829|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day.
75903879|NCT03590288|Procedure|Transjugular intrahepatic portosystemic shunt|"Covered stents will be used, that will be dilated to 8 mm. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected."
75903880|NCT03588299|Drug|BAY2599023 (DTX201)|Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
76068756|NCT00369226|Drug|Tacrolimus|Taken until Doctor determines it is not necessary any more
75457970|NCT01800279|Other|Physiotherapy Protocol|"Kinesitherapy~Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.~Tongue in the palate for all applied exercises.~Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).~Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.~Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid."
75609904|NCT04423393|Other|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
75609905|NCT02750137|Drug|Tetracaine|Application of Ametop prior to intravenous cannulation
75609906|NCT04687735|Other|Intervention after nerve block|Brachial plexus block + Physical therapy
75609907|NCT02760043|Drug|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
75609908|NCT02760043|Other|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
75609909|NCT02760043|Drug|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
75609910|NCT02696005|Other|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
75609911|NCT02750059|Drug|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
75609912|NCT02750059|Drug|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
75609913|NCT02759029|Drug|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
75609914|NCT02759263|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
75609915|NCT02749825|Drug|Trelstar|As labeled
75609916|NCT02749825|Drug|Lupron|As labeled
75609917|NCT02749825|Drug|Zoladex|As labeled
75609918|NCT02758873|Genetic|Personalised medicine (Salmeterol)|If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
75609919|NCT02758873|Genetic|Personalised medicine (Montelukast)|If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
75757830|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
75757831|NCT00372996|Drug|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
75757832|NCT00399516|Device|Precision|
75757833|NCT01046292|Drug|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
75903881|NCT03588260|Other|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
75903882|NCT03556228|Drug|VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)|Taken orally once daily
75757834|NCT00399360|Drug|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
75757835|NCT00399360|Drug|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
75903883|NCT03555851|Drug|Cyclophosphamide|Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
75903884|NCT03555851|Other|Specimen collection|Buccal swabs will be obtained from donors for pharmacogenomics.
75903885|NCT03519971|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
76068757|NCT00369226|Drug|Methotrexate|Infusion for a total of 4 doses
75609920|NCT02758873|Other|Standard care|If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
75609921|NCT02749747|Drug|Sulpiride use|50mg sulpiride once a day use for 60 days
75609922|NCT02749747|Drug|Placebo|50mg placebo once a day use for 60 days
75609923|NCT02749591|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
75609924|NCT02749591|Other|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
75757836|NCT00399360|Behavioral|Lifestyle Modification|Lifestyle Modification
75757837|NCT00428948|Drug|Tolvaptan|Tolvaptan was supplied as tablets.
75757838|NCT00428948|Drug|Placebo|Placebo was supplied as tablets.
75757839|NCT00428792|Drug|Methylphenidate 20 mg long-acting capsules|
75757840|NCT01037894|Procedure|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
75757841|NCT01037894|Procedure|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
75757842|NCT00300885|Drug|Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
75903886|NCT03519971|Other|Placebo|Placebo IV (intravenous infusion)
75903887|NCT03519971|Drug|Cisplatin/ Etoposide|Cisplatin/ Etoposide, as per standard of care
75903888|NCT03519971|Drug|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
75903889|NCT03519971|Drug|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
75903890|NCT03519971|Drug|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
75903891|NCT03519971|Radiation|Radiation|5 fractions/ week for ~6 weeks (±3 days) (Total 60 Gy)
75903892|NCT03496883|Biological|Recombinant Activated Factor VII (rFVIIa)|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
76068758|NCT00369226|Procedure|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
76068759|NCT01416441|Drug|Aripiprazole|Aripiprazole tablets orally once daily.
75757843|NCT00300885|Drug|Carboplatin plus Paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
75757844|NCT00386334|Drug|Eszopiclone|2 mg tablet once per day in the evening
75757845|NCT00386334|Drug|Placebo|Tablet one per day in the evening.
75757846|NCT01143116|Device|"Silver-nitrate coated catheter (Catheter A)"|Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.
75757847|NCT01143116|Device|"Degradable silver particle-coated catheter (Catheter B)"|Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
75757848|NCT01037972|Behavioral|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
75757849|NCT01037972|Behavioral|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
75757850|NCT01034774|Drug|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
75757851|NCT01034774|Drug|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
75903893|NCT03496883|Biological|Placebo|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
75903894|NCT03493945|Biological|M7824|1,200 mg IV once every 2 weeks
75903895|NCT03493945|Drug|N-803|8-15 mcg/kg subcutaneous every 2 weeks
75609925|NCT02749591|Other|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
75609926|NCT02749591|Other|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
76068760|NCT01793194|Other|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
75609927|NCT04460833|Device|Feedback modalities given through an augmented reality headset|All children wear the augmented reality headset. After a habituation period to the holograms, they start the protocol. It consists of a warm-up session, training session (which three feedback modalities are presented), calibration session (to get the maximal speed and spontaneous speed of the child), and test session. During test session, all the children walk on the 30m corridor. They have 6 feedback modalities + the control, given randomly. On the way out, they have to walk fast as possible ; on the return they have to walk at intermediate speed.
75609928|NCT04359979|Drug|Tamsulosin|selective alpha1 receptor antagonist
75757852|NCT00428714|Drug|enzastaurin|Administered orally
75757853|NCT01033214|Device|Endovascular repair of TAA in the descending Thoracic Aorta|Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
75757854|NCT00292227|Drug|Rotigotine|"Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
75757855|NCT00292227|Other|Placebo|"Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
75757856|NCT00292227|Drug|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
75757857|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
75757858|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
75757859|NCT00386100|Drug|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
75757860|NCT00386100|Drug|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
75757861|NCT00386100|Drug|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
75903896|NCT03493945|Biological|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
75903897|NCT03493945|Biological|FPV-Brachyury|FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
75903898|NCT03493945|Drug|Epacadostat|600 mg orally twice daily (1200 MG total)
75903899|NCT03484702|Drug|JCAR017|Specified dose on specified days
76068761|NCT00406276|Drug|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
76068762|NCT00406276|Drug|Docetaxel|In combination with RAD001
75757862|NCT00386100|Drug|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
75757863|NCT00386100|Drug|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
75757864|NCT00386100|Drug|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
75757865|NCT00386100|Drug|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
75757866|NCT00386100|Drug|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
75757867|NCT01068561|Biological|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
75609929|NCT04218955|Combination Product|Silver Diamine Flouride|Material used to arrest caries in children
75463300|NCT05854537|Procedure|Sphenopalatine ganglion block using bupivacaine: xylocaine|Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
75903900|NCT03480061|Drug|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).
75903901|NCT03467958|Drug|Ozanimod|Specified dose on specified days
75903902|NCT03464097|Drug|Ozanimod|Specified dose on specified days
75609930|NCT04180813|Drug|Linagliptin|drug
75609931|NCT04180813|Drug|Acarbose|drug
75903903|NCT03464097|Other|Placebo|Specified dose on specified days
75903904|NCT03440450|Drug|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
75903905|NCT03440372|Drug|Ozanimod|Specified dose on specified days
75903906|NCT03440372|Other|Placebo|Specified dose on specified days
75903907|NCT03435510|Behavioral|Live Donor Champion Program|Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
75903908|NCT03433456|Behavioral|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
75903909|NCT03433456|Behavioral|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
75609932|NCT04221607|Other|Sensate Focus exercise|Structured exercise to enhance intimacy
75609933|NCT04148443|Other|Preoxygenation|participants will receive 3 minutes of preoxygenation before intubation
75757868|NCT00300495|Drug|Amiodarone|Perioperative orally administered
75757869|NCT00300495|Other|Control arm, standard care|Control
75903910|NCT03414684|Drug|Carboplatin|Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
75903911|NCT03414684|Drug|Nivolumab|Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
75609934|NCT04148443|Other|Preoxygenation (longer)|participants will receive 5 minutes of preoxygenation before intubation
75609935|NCT04116775|Biological|Fecal microbiota transplant|A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.
75757870|NCT01068639|Behavioral|No treatment given|No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
75903912|NCT03400085|Other|mHealth application|The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
75757871|NCT03979989|Drug|Tapentadol IR capsule|Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.
75609936|NCT04116775|Drug|Pembrolizumab|Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.
75757872|NCT03979989|Drug|Omeprazole capsule|Omeprazole capsule containing 40 mg omeprazole.
75757873|NCT02532387|Other|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
75757874|NCT01070199|Behavioral|liquid to liquid|"• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid."
75757875|NCT01070199|Behavioral|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
75757876|NCT01070199|Behavioral|solid to liquid|"• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form."
75757877|NCT01070199|Behavioral|solid to solid|"Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage."
75757878|NCT01325571|Drug|Tacrolimus capsule|oral
75757879|NCT01325571|Drug|Placebo|oral
75757880|NCT00386022|Drug|GnRH|GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
75757881|NCT00386022|Drug|NAL-GLU GnRH antagonist|A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
75457971|NCT01800279|Other|Deontology Therapy|"For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):~Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).~Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).~Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid."
75757882|NCT00386022|Drug|Estrogen patch|transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
75457972|NCT01800292|Drug|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
75757883|NCT01068795|Drug|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
75757884|NCT03979755|Other|Application of questionnaires|Application of questionnaires described by telephone.
75757885|NCT01068951|Biological|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
75757886|NCT00286455|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
75457973|NCT01800305|Drug|Pegylated rhEPO|
75609937|NCT04116775|Drug|Enzalutamide|Daily oral dose.
75457974|NCT01800305|Drug|EPIAO®|
75457975|NCT01800331|Behavioral|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
75457976|NCT01800344|Device|LMA|
75457977|NCT01800344|Device|Ultra|Ultra
75757887|NCT00286455|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
75757888|NCT00286455|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
75757889|NCT00385944|Drug|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
75457978|NCT01800357|Drug|infusion of mildronate|infusion of mildronate(500mg) once a day and for 14 days
75457979|NCT01800357|Drug|placebo|infusion of plabcebo once a day and for 14 days
75457980|NCT01800357|Drug|aspirin|infusion of aspirin (100mg) once a day for days
75609938|NCT04172857|Procedure|anterior vitrectomy combined with hyaloidotomy, zonulectomy and iridectomy|First, a 23-G incision was made at the peripheral inferior temporal sector of the cornea and connected with an anterior chamber infusion cannula. Another corneal incision was made at the superior temporal sector or superior nasal sector, and Viscoat® (Bausch & Lomb, Shandong, China) was infused though the incision to fill the anterior chamber. Iridotomy was performed through the incision using Wescott scissors and toothed forceps. Hyaloidectomy and zonulectomy were performed through a peripheral iris defect using an anterior chamber approach to set up a pathway between the anterior chamber and the vitreous cavity. We repeatedly carried out vitrectomy around the pathway to reduce the risk of postoperative re-obstruction of the tunnel created.
75757890|NCT00385944|Drug|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
75757891|NCT01046370|Behavioral|Amygdala Retraining Program|Mind-body intervention.
75903913|NCT03374449|Procedure|continuation of the RAS-inhibitors|drug intake
75757892|NCT00286221|Drug|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
75757893|NCT00286221|Drug|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
75757894|NCT03976635|Device|Removable Mandibular Retractor|The appliance will be used 18 hours per day. It can only be removed for eating meals.
75757895|NCT03976635|Device|Bone-anchored intermaxillary traction|The patients will be instructed to wear the upper removable appliance for 18 hours per day. The elastics should be extended from the upper appliance towards the lower mini-screws.
75757896|NCT00285207|Drug|placebo|5 days of 28 day cycle for 2 cycles
75757897|NCT00285207|Drug|A007|5 days of 28 day cycle
75757898|NCT00398112|Drug|sunitinib malate|Given orally
75757899|NCT00398112|Other|pharmacological study|Correlative studies
75757900|NCT00398112|Other|laboratory biomarker analysis|Correlative studies
75757901|NCT01065129|Drug|G-CSF|
75757902|NCT01065129|Drug|Plerixafor|
75757903|NCT01065129|Drug|Azacitidine|
75757904|NCT03976791|Procedure|enlarged internal incision|enlarging the internal incision about 0.4mm
75757905|NCT03976791|Procedure|regular 2.2mm incision|2.2mm microincision coaxial phacoemulsification
75757906|NCT01042314|Drug|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
75903914|NCT03374449|Procedure|discontinuation of the RAS-inhibitors|no drug intake
75903915|NCT03357536|Procedure|Human biological samples|"Blood sample~Skin biopsy~Saliva"
75903916|NCT03346083|Drug|Betrixaban|Factor Xa inhibitor.
75903917|NCT03298451|Drug|Durvalumab|Durvalumab IV (intravenous infusion).
75903918|NCT03298451|Drug|Tremelimumab (Regimen 1)|Tremelimumab IV (intravenous infusion).
75903919|NCT03298451|Drug|Tremelimumab (Regimen 2)|Tremelimumab IV (intravenous infusion).
75903920|NCT03298451|Drug|Sorafenib|Sorafenib, as per standard of care
75903921|NCT03298451|Drug|Durvalumab (Regimen 1)|Durvalumab IV (intravenous infusion).
75903922|NCT03298451|Drug|Durvalumab (Regimen 2)|Durvalumab IV (intravenous infusion).
75903923|NCT03279081|Drug|Cx601|Cx601 eASCs intralesional injection.
75757907|NCT01042314|Drug|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
75757908|NCT01044654|Genetic|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
75757909|NCT01065207|Biological|blood test at day one|"Epidemiological, clinical, virological, and immunological data will be collected.~Clinical events as neoplasia will be collected"
75757910|NCT01046604|Drug|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
75757911|NCT00424346|Drug|Canakinumab|
75757912|NCT00424346|Drug|Placebo|
75757913|NCT00283959|Drug|migalastat HCl|
75757914|NCT01069107|Other|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
75757915|NCT00372528|Drug|pregabalin (LYRICA)|150 mg up to a maximum of 600 mg per day bid or tid as required
75757916|NCT00283803|Drug|Exisulind|Oral antineoplastic agent that induces apoptosis in cancerous cells.
75757917|NCT00283803|Drug|luteinizing hormone-releasing hormone (LHRH) agonist|Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
75757918|NCT00283803|Drug|Antiandrogen|Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
75757919|NCT01044810|Drug|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
75757920|NCT01033370|Drug|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes & titrated to the desired BP lowering effect to SBP goal of < 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
75903924|NCT03279081|Other|Placebo|Cx601 placebo-matching eASCs intralesional injection.
75903925|NCT03243513|Other|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
75903926|NCT03173976|Drug|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
75903927|NCT03156946|Behavioral|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
75903928|NCT03156946|Behavioral|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
75903929|NCT03073967|Drug|Pritelivir|100 mg oral tablets
75757921|NCT03976089|Behavioral|Recipe 4 Success|"The Recipe 4 Success intervention consisted of 10 weekly lessons in which parents and toddlers prepared simple snacks or meals.~All Recipe 4 Success lessons started and ended with some evidence-based information for the parents about children's self-regulation skills or healthy eating habits. Most of each lesson in Recipe 4 Success was devoted to the snack or meal preparation activities. Each week, home visitors coached the parents as they worked with their toddlers to make increasingly challenging snacks and meals. During these activities, home visitors pointed out opportunities for parents to practice sensitive scaffolding strategies. At the same time, these meal and snack preparation activities allowed children to practice multiple age-appropriate self-regulation skills."
75757922|NCT03976089|Behavioral|Treatment as Usual Early Head Start|Treatment as Usual Early Head Start consisted of an evidence-based curriculum (usually Parents as Teachers) in which home visitors and parents worked with children on activities to support their physical, cognitive, and social-emotional development.
75757923|NCT01044888|Drug|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
75757924|NCT03975777|Other|LO|Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at ~73% of peak aerobic work rate interspersed with 1 min recovery periods)
75757925|NCT03975777|Other|HI|Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at ~100% of peak aerobic work rate interspersed with 1 min recovery periods)
75757926|NCT03742466|Drug|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
75757927|NCT03742466|Drug|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
75757928|NCT01065285|Biological|Evaluation of vaccines against flu|evaluate efficacy and tolerance
75903930|NCT03073967|Drug|Investigator's choice|Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
75903931|NCT02988375|Behavioral|dCBTI|
75903932|NCT02988375|Behavioral|Sleep Education|
75903933|NCT02965950|Drug|Cyclophosphamide|I.v. infusion
75457981|NCT01800370|Drug|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
75757929|NCT01033526|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
75903934|NCT02876757|Drug|5ARI|Exposure to finasteride/dutasteride
75903935|NCT02844465|Device|Visualase MRI-Guided Laser Ablation|All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
75903936|NCT02843035|Drug|venglustat (GZ402671)|"Pharmaceutical form: capsule~Route of administration: oral"
75903937|NCT02843035|Drug|imiglucerase|"Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous"
75903938|NCT02841930|Other|ActionHealth NYC|care coordination, covered preventive services, and standardized costs for ambulatory care
75903939|NCT02728817|Procedure|End-cephalic vein to side-radial artery fistula creation|"Circumferential dissection of the cephalic vein (4-5cm long)~Longitudinal arteriotomy (~10mm)~End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture"
76068763|NCT01436253|Behavioral|Lifestyle Changes|Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
75903940|NCT02728817|Procedure|RADAR fistula creation|"Dissection of the anterior-medial aspect of the cephalic vein (~15mm) without grasping or clamping the venous wall~Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~Ligation and section of the radial artery (distal)~Longitudinal venotomy (~10mm)~End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture"
76068764|NCT01436253|Drug|Hypolipemics|Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
76068765|NCT03854656|Other|Time-restricted eating|"Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority."
75457982|NCT01800370|Drug|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
75609939|NCT02749435|Other|Use of digital disease management tool in participants with T2DM|The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
75757930|NCT01033526|Drug|Placebo|1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
75757931|NCT01038050|Drug|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
75757932|NCT00397488|Drug|sunitinib malate|
75757933|NCT01038206|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
75757934|NCT01581411|Drug|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
75609940|NCT04217083|Diagnostic Test|Breath sampling|The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
75903941|NCT02723994|Drug|Ruxolitinib|In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
76068766|NCT00408070|Drug|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
76068767|NCT00408070|Drug|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
76068768|NCT00408070|Drug|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
76068769|NCT00408460|Drug|imatinib mesylate|Given PO
76068770|NCT00408460|Drug|paclitaxel|Given IV
75457983|NCT01800370|Other|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds."
75609941|NCT04216849|Biological|human umbilical cord mesenchymal stem cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
75609942|NCT04216849|Other|saline|Saline solution containing human serum albumin will be infused to the control group
75757935|NCT02900664|Biological|PDR001|Powder for solution for infusion
75757936|NCT02900664|Biological|ACZ885|Solution for injection
75757937|NCT02900664|Biological|CJM112|Solution for infusion
75757938|NCT02900664|Drug|TMT212|Tablets
75757939|NCT02900664|Drug|EGF816|Tablets
75757940|NCT03975699|Other|Assessment of psychological repercussions of SCD|Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.
75757941|NCT01033604|Procedure|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
75757942|NCT01033604|Procedure|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
75903942|NCT02723994|Drug|Asparaginase Erwinia Chrysanthemi|
75903943|NCT02723994|Drug|Cyclophosphamide|
75757943|NCT03976557|Device|BIP CVC|Central venous access with noble metal coated CVC
75757944|NCT03976557|Device|Standard CVC|Central venous access with standard uncoated CVC
75757945|NCT01065363|Behavioral|standardized exercise program and dietary counseling|Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
75757946|NCT01324596|Drug|Intravenous|Chemoimmunotheraphy
75757947|NCT01324596|Drug|Bortezomib|Chemoimmunotheraphy
75757948|NCT00424190|Drug|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
75757949|NCT00424190|Drug|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
75757950|NCT02859012|Drug|Axitinib|Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
75757951|NCT02859012|Other|Observation|this group is observational ones.
75757952|NCT00428246|Drug|paricalcitol|1 mcg or 2 mcg for 4 weeks.
75757953|NCT00428246|Drug|Placebo|Placebo
75757954|NCT00274287|Drug|GM CSF|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
75757955|NCT01042626|Other|Oral peptones load|Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
75457984|NCT01800370|Procedure|Blood Draws|Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
75457985|NCT01800370|Other|Fasting procedure|Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
75757956|NCT02581670|Radiation|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
75457986|NCT01800396|Dietary Supplement|Milk protein|
75457987|NCT01800396|Dietary Supplement|Milk protein rich in phospholipids|
75757957|NCT01045200|Other|Comparison of follow-up|Comparison of follow-up by nurse or surgeon after rectal cancer surgery
75757958|NCT01065441|Biological|AlloStim|Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10^7 cells
75757959|NCT01065441|Procedure|Cryoablation|Percutaneous cryoablation of selected tumor lesion under CT or US guidance
75903944|NCT02723994|Drug|Cytarabine|
75903945|NCT02723994|Drug|Dexamethasone|
75903946|NCT02723994|Drug|Doxorubicin|
75457988|NCT01800409|Device|AFES|During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
75457989|NCT01800422|Drug|telapristone acetate|Given orally
75457990|NCT01800422|Other|placebo|Given orally
75457991|NCT01800422|Procedure|therapeutic conventional surgery|Undergo surgical resection
75757960|NCT01065441|Biological|AlloStim|intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10^7 cells
75757961|NCT01065441|Biological|AlloStim|intravenous AlloStim-TM at doses between 1 x 10^7 to 1 x 10^9 cells
75757962|NCT01065441|Biological|AlloStim|Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
75757963|NCT01065441|Biological|AlloStim|Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10^7 cells.
75757964|NCT01065441|Biological|AlloStim|Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM
75757965|NCT01045278|Drug|Pegylated interferon-alfa-2b and ribavirin|Pegylated interferon-alfa-2b 1.5 microg/kg subcutaneously once weekly plus weight based ribavirin 800-1200 mg PO for a variable period depending on their HCV genotype and response to treatment.
75757966|NCT01046760|Behavioral|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
75757967|NCT00423800|Drug|Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)|"Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks"
75757968|NCT03932708|Behavioral|CDC Core Elements of Outpatient Stewardship|The intervention is described above and includes components of leadership, action of policy and practice, tracking and reporting, and education and expertise.
75757969|NCT00405548|Drug|BNP (nesiritide)|
75757970|NCT00405548|Drug|Placebo|
75757971|NCT00405392|Drug|Ibandronate (SB743830HD)|
75757972|NCT00282243|Drug|tacrolimus modified release (MR)|Oral
75757973|NCT00282243|Drug|tacrolimus|Oral
75757974|NCT00272961|Drug|Placebo|placebo tablet once daily for 12 weeks
75757975|NCT00272961|Drug|TBC3711|10 mg tablets once daily for 10 weeks
75757976|NCT00272961|Drug|TBC3711|50 mg tablet once daily for 10 weeks
75757977|NCT00272961|Drug|TBC3711|100 mg tablet once daily for 10 weeks
75903947|NCT02723994|Drug|Leucovorin Calcium|
75903948|NCT02723994|Drug|Mercaptopurine|
75903949|NCT02723994|Drug|Methotrexate|
75903950|NCT02723994|Drug|Pegaspargase|
75903951|NCT02723994|Drug|Prednisone|
75457992|NCT01800422|Other|laboratory biomarker analysis|Correlative studies
75457993|NCT01800422|Other|questionnaire administration|Ancillary studies
75757978|NCT00272961|Drug|TBC3711|200 mg tablet once daily for 10 weeks
75757979|NCT00282087|Drug|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
75757980|NCT00404924|Drug|ZD6474 (vandetanib)|once daily oral tablet
75757981|NCT00404924|Other|Best Supportive Care|standard of care
75903952|NCT02723994|Drug|Thioguanine|
75903953|NCT02723994|Drug|Vincristine Sulfate|
75903954|NCT02685969|Procedure|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
75903955|NCT02586857|Drug|ACP-196|Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
75903956|NCT02512926|Drug|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
75609943|NCT02749357|Device|30 minutes Lokomat|"30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
75903957|NCT02512926|Drug|Cyclophosphamide|
75903958|NCT02512926|Drug|Etoposide|
75903959|NCT02502318|Procedure|Video-thoracoscopy|
75903960|NCT02502318|Procedure|thoracotomy|
75903961|NCT02427451|Drug|Bcl-2 Inhibitor GDC-0199|Given PO
75903962|NCT02427451|Biological|Obinutuzumab|Given IV
75903963|NCT02427451|Drug|Ibrutinib|Given PO
75457994|NCT01800435|Drug|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
75457995|NCT01800435|Drug|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
75457996|NCT01800461|Other|OPC-Stroke|Occupational therapy coaching intervention
75457997|NCT01800461|Other|Usual care|Usual community care
75457998|NCT01800487|Drug|silymarin|140 mg three times a day for 4 weeks
75609944|NCT02749357|Device|60 minutes Lokomat|30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
75609945|NCT03933553|Other|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
75757982|NCT00281697|Drug|Bevacizumab|The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
75903964|NCT02427451|Other|Pharmacological Study|Correlative studies
75903965|NCT02427451|Other|Laboratory Biomarker Analysis|Correlative studies
75903966|NCT02427451|Other|Quality-of-Life Assessment|Ancillary studies
75903967|NCT02397083|Drug|Everolimus|Given PO
75457999|NCT01800487|Drug|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
75458000|NCT01800513|Procedure|Endometrial Biopsy|
75458001|NCT01800513|Procedure|Sham Procedure|
75458002|NCT01800526|Drug|N-Acetylcysteine|Oral and Intravenous administration of NAC
75757983|NCT00281697|Drug|Placebo|
75757984|NCT00281697|Drug|Standard chemotherapy|"Patients received one of the following four standard chemotherapies for metastatic breast cancer.~Taxane - Paclitaxel (Taxol) 90 mg/m^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m^2 IV every 3 weeks.~Gemcitabine (Gemzar) 1250 mg/m^2 IV on Days 1 and 8 of each 3-week cycle.~Vinorelbine (Navelbine) 30 mg/m^2 IV every week of each 3-week cycle.~Capecitabine (Xeloda) 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week cycle."
75757985|NCT00271947|Biological|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
75757986|NCT00232180|Drug|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
75757987|NCT00280683|Drug|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
75903968|NCT02397083|Other|Laboratory Biomarker Analysis|Correlative studies
75903969|NCT02397083|Device|Levonorgestrel-Releasing Intrauterine System|Placed in the uterus
75903970|NCT02386800|Drug|ruxolitinib|ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study
75903971|NCT02386800|Drug|panobinostat|panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
75903972|NCT02310321|Drug|gilteritinib|Once-daily oral administration on 14 consecutive days in every cycle in each period.
75903973|NCT02310321|Drug|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m^2 idarubicin on 3 consecutive days.
75903974|NCT02310321|Drug|Cytarabine|"Induction period: Once-daily intravenous injection of 100 mg/m^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m^2 cytarabine on Days 1, 3, and 5."
75903975|NCT02293980|Drug|MK-3795|Oral administration
75609946|NCT02758561|Behavioral|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
75903976|NCT02293980|Drug|Nivolumab|IV infusion
75903977|NCT02293980|Drug|Cabozantinib|Oral administration
75903978|NCT02291848|Biological|TAA-specific CTLs|"Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10^6 cells/m2 and Day 14: 5 x 10^6 cells/m2~Dose Level Two:~Day 0: 1 x 10^7 cells/m2 and Day 14: 1 x 10^7 cells/m2~Dose Level Three:~Day 0 2 x 10^7 cells/m2 and Day 14 2 x 10^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
75757988|NCT00280683|Drug|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
75903979|NCT02291848|Biological|TAA-specific CTLs- fixed dose|"Fixed dose of 2 x 10^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
75458003|NCT01800552|Procedure|Intentional infiltration of a peripheral IV site|An intentional infiltration of isotonic saline solution is performed by pushing the needle through the vein wall into the subcutaneous tissue. A total volume less than or equal to 5 cc of saline is infiltrated into the tissue.
75757989|NCT00270855|Procedure|Arm Crank Ergometry|Use of an upper body cycle to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
75458004|NCT01800565|Other|Measurement of LH in first-voided urine|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
75757990|NCT00270855|Procedure|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
75458005|NCT01800565|Other|collection of first-voided urine sample for LH level|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
75757991|NCT01070277|Drug|Tinidazole and Albendazole|Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days
75757992|NCT01070277|Drug|Placebo control|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
75757993|NCT01070355|Drug|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
75903980|NCT02288247|Drug|Enzalutamide|Oral
75903981|NCT02288247|Drug|Docetaxel|intravenous infusion
75458006|NCT01800578|Device|monitor for depth of hypnosis|"evaluation of depth of hypnosis~--------------------------------------------------------------------------------"
75609947|NCT03913741|Drug|tisotumab vedotin|Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
75757994|NCT01070355|Drug|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
75757995|NCT00404768|Drug|GSK221149A|6mg/h and 12 mg/h
75757996|NCT00404768|Drug|Placebo|Matched Placebo to Drug
75903982|NCT02288247|Drug|Prednisolone|Oral
75903983|NCT02288247|Drug|Placebo|Oral
75458007|NCT01800591|Behavioral|Financial incentive|
75903984|NCT02255799|Drug|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
75757997|NCT00270231|Drug|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
75757998|NCT00270231|Drug|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
75757999|NCT02532309|Drug|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C>1.1mmol/L and <1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
75758000|NCT02532309|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg/day
75758001|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
75758002|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
75758003|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
75458008|NCT01800604|Behavioral|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
75758004|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
75758005|NCT03909620|Diagnostic Test|Low-dose computed tomography of chest|Eligible subjects will undergo a single round of LDCT screening. The LDCT will be considered as positive if a solid nodule or part-solid nodule of size ≥6 mm or non-solid nodule of size ≥20 mm is identified. Evaluation of positive nodules will be performed as per existing standard recommendations
75903985|NCT02255799|Drug|Placebo|Placebo capsule once daily for 70 days.
75903986|NCT02244463|Drug|MLN0128|
75609948|NCT02758639|Behavioral|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
75609949|NCT02749669|Other|Qualitative research|Semi-structured Interviews
75609950|NCT02758795|Dietary Supplement|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
75609951|NCT02758795|Dietary Supplement|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
75609952|NCT02749123|Drug|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
75609953|NCT02749123|Drug|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
75609954|NCT02749123|Drug|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
75758006|NCT00269919|Drug|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
75758007|NCT01038284|Behavioral|Patient education|Pharmaceutical care of patients with PAH
75758008|NCT01038284|Other|Data collection|Clinical and biological data, treatment, medication errors and ADEs
75903987|NCT02234388|Other|Observation|There are no interventions associated with this registry as it is purely observational.
75903988|NCT02181257|Combination Product|Extracorporeal Photopheresis (ECP)|"Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen"
75903989|NCT02176902|Behavioral|behavioral dietary intervention|Receive dietary counseling
75903990|NCT02176902|Behavioral|behavioral dietary intervention|Receive guidelines for low-fat diet
75903991|NCT02176902|Dietary Supplement|omega-3 fatty acid|Given PO
76068771|NCT02111200|Drug|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
75609955|NCT02758483|Other|Control diet|Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
75458009|NCT01800604|Behavioral|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
75609956|NCT02758483|Other|Test Diet|Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
75609957|NCT04172545|Procedure|stapling|staples are fired through the gastric wall after waiting several seconds for compression without attention to blood pressure, fluids given or intra abdominal pressure, but these might have an impact on quality of stapling. therefore the conditions during stapling will be recorded during stapling.
75609958|NCT04218253|Dietary Supplement|300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber|300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).
75609959|NCT04218253|Behavioral|Dietary mission|Dietary education was conducted according to preoperative nutritional requirements
75609960|NCT02748811|Other|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
75463301|NCT05854537|Procedure|Sphenopalatine ganglion block using normal saline|Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
75609961|NCT02748733|Other|Adapted double mini PET|The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
75609962|NCT02748733|Other|Standard double mini PET|The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
75758009|NCT01038362|Other|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
75758010|NCT01038362|Other|No Almonds|NCEP Step 1 diet without almonds
75758011|NCT01065675|Other|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
75903992|NCT02176902|Other|laboratory biomarker analysis|Correlative studies
75758012|NCT00258154|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
75758013|NCT00258154|Biological|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
75758014|NCT00258154|Biological|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
76068772|NCT02111200|Drug|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
75758015|NCT00257920|Drug|Zemplar® injection|6 mcg QOD
75758016|NCT00257920|Drug|Hectorol® injection|3.6 mcg QOD
75758017|NCT00268983|Biological|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
75758018|NCT00268983|Biological|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
75903993|NCT02139397|Drug|DFMO|
75903994|NCT02139397|Drug|Bortezomib|
75903995|NCT02079740|Procedure|Biopsy|Undergo biopsy
75903996|NCT02079740|Procedure|Biospecimen Collection|Undergo collection of blood samples
75903997|NCT02079740|Procedure|Computed Tomography|Undergo conventional CT or PET/CT
75903998|NCT02079740|Procedure|Magnetic Resonance Imaging|Undergo MRI
75903999|NCT02079740|Biological|Navitoclax|Given PO
75758019|NCT01065753|Behavioral|Lifestyle Counseling|Diet control with exercise
75904000|NCT02079740|Procedure|Positron Emission Tomography|Undergo PET/CT
75904001|NCT02079740|Drug|Trametinib|Given PO
75904002|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
75904003|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
75904004|NCT02038777|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
75904005|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
75904006|NCT02038777|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
75758020|NCT01070511|Drug|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
75758021|NCT01070511|Drug|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
75904007|NCT02038777|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
75904008|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
76068773|NCT02111746|Drug|Exparel|Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
75458010|NCT01800604|Behavioral|Pain Self-Management Intervention #3|"Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable."
75609963|NCT02748967|Drug|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
75609964|NCT02748967|Drug|Placebo|Participant will receive single dose of Placebo on Day 1.
75609965|NCT02748655|Other|Alkaline ionized water|
75904009|NCT02038777|Drug|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
75904010|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
75458011|NCT01800604|Behavioral|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
75458012|NCT01800617|Drug|Liothyronine, Sodium|
75458013|NCT01800630|Drug|Gemcitabine HCl Oral Formulation|
75458014|NCT01800643|Other|Analyze the pharmacokinetics of busulfan for transplantation|"Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target."
75904011|NCT02038777|Drug|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
75609966|NCT02748655|Other|Tap water|
75609967|NCT00635557|Drug|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
75609968|NCT02748499|Other|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
75609969|NCT02748499|Other|Control|Participants maintain their daily acitvities.
75609970|NCT02748577|Other|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
75904012|NCT01991457|Drug|Fludarabine|
75904013|NCT01991457|Procedure|Total Body Irradiation|
75609971|NCT02748577|Other|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
75609972|NCT02748187|Other|CBASP|Interpersonal psychotherapy for chronic depression
75609973|NCT02748421|Procedure|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
75609974|NCT02748421|Procedure|Conventional Microscope|macular membrane dissection without OCT RESCAN
75609975|NCT02748265|Drug|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
75609976|NCT02748265|Drug|Sevoflurane|Volatile maintenance anesthesia
75609977|NCT02748265|Drug|Propofol|Intravenous maintenance anesthesia
75609978|NCT01015833|Drug|Doxorubicin Hydrochloride|Given IV
75758022|NCT01070667|Drug|Dronedarone|400mg orally once per day for 3 months
75758023|NCT01070667|Drug|Placebo|1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
75758024|NCT00257608|Drug|bevacizumab|Intravenous repeating dose
75758025|NCT00257608|Drug|placebo|Oral repeating dose
75758026|NCT00257608|Drug|erlotinib HCl|Oral repeating dose
75904014|NCT01943994|Drug|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
75904015|NCT01943994|Drug|Nicotine Replacement Therapy (NRT)|
75458015|NCT01800656|Procedure|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
75458016|NCT01800656|Procedure|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
75609979|NCT01015833|Other|Laboratory Biomarker Analysis|Correlative studies
75609980|NCT01015833|Other|Pharmacogenomic Study|Correlative studies
75609981|NCT01015833|Drug|Sorafenib Tosylate|Given PO
75758027|NCT01073176|Other|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
75758028|NCT00231478|Drug|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
75758029|NCT00231478|Drug|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
75758030|NCT00413192|Drug|E7389|1.4 mg/m^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
75758031|NCT01038440|Dietary Supplement|Safflower Oil|One softgel consumed daily with food
75758032|NCT01038440|Dietary Supplement|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
75758033|NCT01038440|Dietary Supplement|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
75758034|NCT00207142|Drug|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
75758035|NCT00207142|Drug|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
75758036|NCT00268905|Drug|E7389 + carboplatin AUC 5|Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
75758037|NCT00268905|Drug|E7389 + carboplatin AUC 6|"After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).~If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5."
75758038|NCT00268905|Drug|E7389+carboplatin AUC 6|In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
75758039|NCT03974997|Diagnostic Test|Determination of the circulating serum concentration of cytoquine TWEAK|Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
75758040|NCT00206518|Drug|Taxotere/Docetaxel|Taxotere
75758041|NCT00206518|Drug|Adriamycin/Cytoxan|Adriamycin/Cytoxan
75758042|NCT00206518|Drug|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
75904016|NCT01899989|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
76068774|NCT02111746|Drug|Bupivacaine hydrochloride|Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
76072399|NCT00499083|Drug|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
75609982|NCT04218175|Other|neuromobilization exercises|Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
75609983|NCT03523273|Drug|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
75609984|NCT03523273|Drug|Placebo|Placebo administration will match the study drug.
75609985|NCT02746939|Behavioral|InSciEd Out Fitness and Nutrition Curriculum|Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
75758043|NCT01065831|Behavioral|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
75609986|NCT04217941|Procedure|Health education with practical demonstration of nasal ointment|Health education with practical demonstration of medicine was compared to health education without practical demonstration
75609987|NCT04217941|Drug|Health Education and practical demonstration of Nasal spray and intranasal ointment|We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
75758044|NCT03972904|Dietary Supplement|Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance|Subjects will be given the Light-Fat Rice® combined with Active Peptide® with a lifestyle guidance to assist diabetes management. The method of taking the product has two parts: 1.Light-Fat Rice®: 80g (1 pack) per day as a staple meal replacement, used as a separate staple food or mixed with other staple foods, taking 4 weeks; 2.Active Peptide®: 20g (2 packs) per day (1 pack each morning and evening), served with 300ml of 40°C warm water each time before meals and take it for 4 weeks.
75904017|NCT01899989|Drug|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
75904018|NCT01817166|Drug|Vitamin D|Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
75458017|NCT01800682|Drug|Tramodol Extended-Release (ER)|Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
75758045|NCT03972904|Dietary Supplement|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin (both produced by the same manufacturer) with a lifestyle guidance will be given by the professional to assist in diabetes management. The product is taken as follows: 1.equal-energy staple food containing a small amount of dietary fiber: 80g (1 pack) per day, used as an independent staple food or mixed with other staple foods, taking for 4 weeks; 2.equal-energy maltodextrin: 20g(2 packs) per day(1 pack each morning and evening),take it with 300ml of 40°C warm water for 4 weeks.
75758046|NCT00423722|Drug|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
76072400|NCT00499083|Drug|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
76072401|NCT00499083|Drug|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
75458018|NCT01800695|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
75458019|NCT01800695|Drug|Temozolomide|Temozolomide will be administered per label and local prescribing regulations.
75458020|NCT01800695|Radiation|Whole Brain Radiation|Whole Brain radiation will be administered in 30 fractions.
75458021|NCT01800708|Drug|Triamcinolone acetonide|
75458022|NCT01800708|Drug|Prednisolone syrup|
75458023|NCT01800721|Behavioral|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
75458024|NCT01800721|Behavioral|SNAP Control|Behavioral: SNAP control 7 group sessions
75609988|NCT04217629|Drug|SY-005|This single-dose group will be initiated in healthy subjects at a 0.75mg dose that is the maximum recommended starting dose(MRSD). Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are2.5mg, 5mg, 10mg, 15mg, 20mg successively. The dose of multiple-doses groups are depending on the results of single-dose groups.
75758047|NCT00423722|Drug|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
75758048|NCT03899012|Procedure|Incisional Hernia Surgery|Verification of the accuracy in the collection of 21 selected variables in the Spanish EVEREG Incisional Hernia Surgery Registry
75904019|NCT01817166|Drug|Placebo|Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
75904020|NCT01817166|Other|Imaging|All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
75904021|NCT01817166|Biological|Lumbar puncture|A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
75904022|NCT01817166|Biological|Blood sampling|Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
75609989|NCT02748343|Device|allograft bone|Use of the allograft bone to treat the bone defect in patients
75904023|NCT01817166|Biological|Urine samples|Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
75904024|NCT01590862|Device|Deep Brain Stimulator|Medtronic Deep Brain Stimulation device turned on and off
75758049|NCT00206440|Drug|esomeprazole|nexium
75758050|NCT00206440|Other|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
75904025|NCT01571986|Procedure|Non-invasive ventilation|Non-invasive ventilation
75904026|NCT00902044|Genetic|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
75904027|NCT00902044|Drug|Fludarabine|"Fludarabine will be administered for 5 days prior to the T cells~The dose:~>10 kg: 25 mg/m2/day;~<10 kg: 1 mg/kg/day IV over 30 minutes"
75904028|NCT00902044|Drug|Cyclophosphamide|"Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~>10 kg: 25 mg/m2/day; <10 kg: 1 mg/kg/day IV over 30 minutes"
75904029|NCT00902044|Genetic|Autologous CAR Positive T cells|Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.
75758051|NCT00268437|Drug|carboplatin|carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
75758052|NCT00268437|Drug|Pemetrexed|Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
75463302|NCT05854511|Drug|Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets|Daclatasvir 30 mg orally once daily plus Sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks.
75463303|NCT05854459|Other|HIIT and Nordic Curl exercise program|The training program in the HIIT+NC group was divided into the following parts: i) warm-up (10 minutes); ii) HIIT (25 minutes) consisting of a circuit of eight exercises; iii) Nordic curl exercise (10 mintues); and iv) stretching.
75609990|NCT02748343|Device|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
75609991|NCT02695381|Drug|Etodolac-lidocaine topical patch|Once daily
75609992|NCT02695381|Drug|Placebo|Once daily
75609993|NCT02748109|Behavioral|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
75758053|NCT00268437|Procedure|conventional surgery|
75609994|NCT02748109|Behavioral|Vestibular Rehabilitation|Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
75758054|NCT00268437|Procedure|neoadjuvant therapy|
75758055|NCT00268437|Radiation|radiation therapy|Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
75758056|NCT00423488|Drug|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
75758057|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
75758058|NCT00423488|Drug|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
75758059|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
75904030|NCT00250809|Procedure|Placement of a central venous catheter|Placement of a central venous catheter
75904031|NCT00187473|Procedure|liver biopsy|Liver biopsy every 5 years
75458025|NCT01800734|Other|Clamp-Mixed Meal Arm|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
75458026|NCT01800747|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
75458027|NCT01800773|Behavioral|Written Exposure Therapy|Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
75458028|NCT01800773|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
75458029|NCT01800799|Drug|Baktar 800mg h.s.|Antimicrobial agent (Baktar 800mg h.s.)
75758060|NCT00423488|Drug|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
75758061|NCT03969472|Drug|probiotics|apply probiotic after operation
75458030|NCT01800799|Drug|Celecoxib 200mg QD|Anti-inflammatory agent (Celecoxib 200mg QD)
75758062|NCT03969472|Device|Electrophysiologic Therapy|Pelvic floor electrophysiological therapy is used after surgery
75904034|NCT04992364|Other|Burnout and Clinical performances questionnaires|Subjects were given questionnaires to assess burnout score and clinical performances
75904035|NCT03608241|Drug|PF-06651600|200 mg by mouth (PO) Once daily (QD) for 11 days
75458031|NCT01800812|Biological|Injections of OM-174|
75458032|NCT01800825|Drug|Clindamycin|Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
75904036|NCT03608241|Drug|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
75904037|NCT03072784|Procedure|aortic cross clamping|duration of cross clamping, less than 90 minutes, or more than 90 minutes
75904038|NCT03606057|Drug|JNJ-64565111|Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.
75458033|NCT01800825|Drug|Placebo|This will be an identical placebo comparator made of starch.
75758063|NCT00404066|Drug|Lapatinib|1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)
75758064|NCT00404066|Drug|Doxorubicin|60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
75758065|NCT00404066|Drug|Cyclophosphamide|600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
75758066|NCT00404066|Drug|Docetaxel|100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
75758067|NCT00404066|Drug|Pegfilgrastim|6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
75758068|NCT00404066|Drug|Filgrastim|300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
75758069|NCT00404066|Drug|Dexamethasone|8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
75758070|NCT00404066|Drug|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
75758071|NCT01581645|Device|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
75904039|NCT03606057|Drug|Moxifloxacin|Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.
75904040|NCT03606057|Drug|JNJ-64565111-matching Placebo|Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.
75758072|NCT01581723|Device|Monopolar diathermy|monopolar diathermy
75758073|NCT01581723|Device|Bipolar diathermy|bipolar diathermy
75758074|NCT03993860|Dietary Supplement|Fish Powder|Dry small fish (Chisense) is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
75758075|NCT03993860|Dietary Supplement|Sorghum powder|Dry sorghum is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
75758076|NCT03993548|Behavioral|Wellness Element 1 - Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
76068775|NCT02111746|Drug|Patient Controlled Analgesia (PCA)|Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
76068776|NCT02111980|Device|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
76068777|NCT01793272|Other|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
76068778|NCT00369928|Drug|PG-760564|100 mg BID, of oral PG-760564
76068779|NCT00369928|Drug|Placebo dose|placebo, BID, oral for 12 weeks
75458034|NCT01800851|Other|Energy expenditure evaluation in calorimetric chamber|
75458035|NCT01800864|Other|obesity|
75758077|NCT03993548|Behavioral|Wellness Element 2 - Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
75758078|NCT03993548|Behavioral|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
75458036|NCT01800929|Device|N6|Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
75458037|NCT01800942|Drug|Azithromycin and Placebo|A single oral dose of 2g of Azithromycin will be given to the women in labour
75458038|NCT01800955|Device|resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)|The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.
75758079|NCT03993548|Behavioral|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on Social Connectedness; adherence documented online daily
75758080|NCT03993548|Behavioral|Wellness Element 5 - Nutrition|Daily wellness element focusing on Nutrition; adherence documented online daily
75758081|NCT03993548|Behavioral|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
75758082|NCT03993548|Behavioral|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
75758083|NCT01038674|Drug|anti-IL-20|Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
75758084|NCT01038674|Drug|placebo|Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
75904041|NCT03606057|Drug|Moxifloxacin-matching Placebo|Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
76068780|NCT00369928|Drug|PG-760564|25 mg BID, of oral PG-760564
76068781|NCT03650920|Procedure|Liver Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive liver graft
76068782|NCT00409240|Other|MEDIC|Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
76068783|NCT02110108|Device|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
76068784|NCT05287750|Diagnostic Test|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
75458039|NCT01800955|Other|sham placebo resistive capacitive diathermy treatment|"The sham treatment is administered with the diathermy device set on on but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group"
75458040|NCT01801020|Other|temperature measuremts|temporal artery temperature measurements will be taken from the forehead
75458041|NCT01801020|Other|temperature measuremts|different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
75458042|NCT01801046|Drug|mitoxantrone hydrochloride|Given IV
75458043|NCT01801046|Drug|cytarabine|Given IV
75458044|NCT01801046|Procedure|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
75458045|NCT01801046|Other|laboratory biomarker analysis|Correlative studies
75758085|NCT00423332|Drug|Cediranib|45 mg oral tablet
75758086|NCT00423332|Drug|Cediranib Placebo|oral tablet
75758087|NCT01040468|Procedure|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
75904042|NCT04998760|Drug|ATG-008|ATG-008 will be orally administered at 30 mg QD combined with chemotherapies. And about 8-12 subjects plan in each cohort.
75904043|NCT04998760|Drug|ATG-010|ATG-010 will be orally administered at 30 mg QD and 80 mg QW combined with chemotherapies. And about 8-12 subjects plan in each cohort.
76068785|NCT05287438|Diagnostic Test|Next-Generation DNA Sequencing|NGS is a technique of microbiological sequencing, using 16s ribosomal RNA molecular identification has been implemented to detect bacteria and fungi present in the sample
75758088|NCT01040468|Procedure|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
75758089|NCT01040468|Behavioral|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
75758090|NCT00413036|Drug|lenalidomide|once daily oral capsule
75758091|NCT01034852|Procedure|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
75458046|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video and brochure
75758092|NCT00412958|Drug|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
75904044|NCT03607383|Drug|Red Rice Yeast Extract|adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
75458047|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video
75609995|NCT02746861|Behavioral|Peer-Supported DSMS|Phone, SMS/text, and smartphone-based intervention.
75609996|NCT02746783|Drug|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
75609997|NCT02746783|Drug|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
75758093|NCT00412958|Drug|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
75758094|NCT00412958|Drug|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
75904045|NCT03607383|Drug|Statin|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
75904046|NCT04998526|Other|Experimental group|The cold gel pack will be applied to the nape.
75904047|NCT04998526|Other|Placebo group|The gel pack kept at room temperature will be applied to the nape.
75904048|NCT03607305|Procedure|BP limb 70cm|Performance of RYGB with a BP limb of 70cm
75458048|NCT01801059|Other|questionnaire administration|Ancillary studies
75904049|NCT03607305|Procedure|BP limb 120cm|Performance of RYGB with a BP limb of 120cm
75458049|NCT01801137|Drug|Everolimus (Afinitor®)|
75458050|NCT01801150|Device|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
75458051|NCT01801163|Drug|Sorafenib|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
75458052|NCT01801163|Radiation|Stereotactic radiotherapy|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
75609998|NCT02748031|Procedure|slit-lamp-adapted anterior segmental photography|The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
75609999|NCT02747953|Drug|Gilotrif|50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
75610000|NCT02747797|Drug|Lucitanib|10 mg orally daily
75610001|NCT02747719|Behavioral|Light and exercise|Exposure to light and exercise
75610002|NCT02747641|Procedure|Pixel CO2 Laser System|
75610003|NCT02747563|Other|Blood test (PSA)|Measurement of blood PSA levels
75758095|NCT00412958|Drug|Placebo|Intravitreal injection of placebo
75758096|NCT01040546|Behavioral|Individualized education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months."
75904050|NCT05002894|Other|Pilates exercises|Pilates exercises for flexibility and stability
75904051|NCT05002894|Dietary Supplement|medical standard care for fatigue|supplements and medical care
75458053|NCT01801176|Other|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
75458054|NCT01801202|Device|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
75458055|NCT01801228|Drug|Eplerenone|
75463304|NCT05854459|Other|HIIT-only program|The HIIT group performed the same exercises in the warm-up, HIIT and stretching sections as the HIIT+NC group, however, they did not perform the NC eccentric exercises.
75610004|NCT02735239|Drug|Durvalumab|
75610005|NCT02735239|Drug|Tremelimumab|
75904052|NCT02696499|Drug|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
75904053|NCT02696499|Drug|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
75904054|NCT05003128|Device|LED screen (InnoLux, Taiwan)|Participants watch a short movie on an LED screen (InnoLux, Taiwan) for 15 minutes in a bright room. The viewing distance was approximately 1.5 meters.
75758097|NCT01040546|Behavioral|Grouped education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months."
75758098|NCT00423176|Drug|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
75758099|NCT00423176|Drug|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
75758100|NCT01040702|Drug|methylphenidate|a single doses of 10-20 mg in each one of two visits
75758101|NCT01040702|Dietary Supplement|sweetener pill|a capsule containing a sweetener pill
75758102|NCT00412880|Drug|BI 2536|Intravenous Infusion
75758103|NCT00268203|Biological|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
75758104|NCT00384930|Drug|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
75758105|NCT00384930|Drug|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
76068786|NCT05287438|Diagnostic Test|Standard Culture|Standard of care culture and sensitivity
75610006|NCT02735239|Drug|Oxaliplatin|IV administered Chemotherapy
75904055|NCT03607227|Drug|Levobupivacaine|Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
75904056|NCT03607227|Drug|Saline Solution|Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
75904057|NCT03607149|Drug|Pemetrexed|"standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)"
75904058|NCT04998292|Device|Piezo-surgery with low level laser therapy|Low level laser therapy
75904059|NCT04998292|Device|Piezo-surgery only|Piezo-surgery only
75458056|NCT01801254|Other|STRIDES|Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
75610007|NCT02735239|Drug|Capecitabine|orally-administered chemotherapy
75610008|NCT02735239|Radiation|Radiotherapy|
75610009|NCT02735239|Drug|Paclitaxel|IV administered Chemotherapy
75458057|NCT01801254|Other|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
75610010|NCT02735239|Drug|Carboplatin|IV administered Chemotherapy
75610011|NCT02735239|Drug|5-fluorouracil (5-FU)|IV administered Chemotherapy
75610012|NCT02735239|Drug|Leucovorin|orally-administered chemo-protective agent
75904060|NCT02035293|Other|PEP|
75610013|NCT02735239|Drug|docetaxel|IV administered Chemotherapy
75610014|NCT02655523|Drug|Triamcinolone|1 mL of 40 mg of Triamcinolone
75610015|NCT02655523|Drug|Dexamethasone|1 mL of 4mg of Dexamethasone
75610016|NCT02655523|Drug|Normal Saline|1 mL of preservative free normal saline
75610017|NCT02655523|Drug|Bupivacaine|2 mL of 0.5% bupivacaine
75610018|NCT02644291|Drug|Mebendazole|chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
75610019|NCT01015677|Drug|MK-6913|
75610020|NCT01015677|Drug|17-β estradiol|
75610021|NCT01015677|Drug|Placebo to MK-6913|
75758106|NCT00384930|Drug|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
75758107|NCT00384930|Drug|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
75758108|NCT00384930|Drug|placebo|Placebo tablet taken by mouth one a day for twelve weeks
75758109|NCT00423098|Drug|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
75904061|NCT04998838|Drug|Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG)|Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV
75904062|NCT04998838|Drug|Regular Myanmar treatment|Treated according to normal Myanmar processes for HBV positive patients
75758110|NCT00423098|Drug|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
75758111|NCT00423098|Drug|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
75758112|NCT01042704|Drug|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
75758113|NCT01042704|Drug|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
75758114|NCT01042704|Drug|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
75904063|NCT03605823|Device|Express Mini shunt|Implantation of Express Mini shunt through pars plana in vitrectomized eyes
75904064|NCT03607071|Drug|Prednisolone and taper|Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
75904065|NCT02035215|Drug|Atorvastatin 20mg|
75904066|NCT02035215|Drug|Omega-3-acids ethylesters 90 4g|
75610022|NCT01015677|Drug|Placebo to 17-β estradiol|
75904067|NCT02035215|Other|Placebo(Omega-3-acids ethylesters 90)|
75904068|NCT04992442|Drug|TAK-935 Oral Tablet|TAK-935 tablet
75904069|NCT04992442|Drug|[14C]TAK-935 IV Infusion|[14C]TAK-935 IV infusion
75904070|NCT04992442|Drug|[14C]TAK-935 Oral Solution|[14C]TAK-935 oral solution
75904071|NCT03606993|Other|Lucky Iron Fish (TM) - An iron ingot that is a Cooking supplement|For Mother-infant dyads enrolled into the LIF arm, mother receives one ~ 200g iron ingot, instructions on use: add 2-3 drops of lemon juice to one-liter of water, place iron ingot in water, bring to boil for 10 minutes, remove iron fish from water and then use that water for cooking or drinking.
76068787|NCT00410488|Drug|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
76068788|NCT00410488|Drug|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
75610023|NCT01015677|Drug|MK-6913 25 mg|
75610024|NCT02281981|Dietary Supplement|Curcumin|333mg CurcuWin OAHTCUR002-2014
75610025|NCT02281981|Dietary Supplement|Placebo|OAHTCUR005-2014
75610026|NCT00628017|Dietary Supplement|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
75758115|NCT01042704|Drug|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
75758116|NCT01042704|Drug|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
75758117|NCT01042704|Drug|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
75758118|NCT01042704|Other|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
75904072|NCT03605589|Drug|Blinatumomab|Continuous IV infusion
75904073|NCT03605589|Drug|Pembrolizumab|IV infusion
75904074|NCT04992130|Behavioral|Pre-season supplementary neurologic training program|A two-month standardized, pre-season, supplementary multi-modal training program will be prescribed to 200 athletes (intervention cohort) by a team of experienced sport science and medicine professionals targeting the specific intrinsic risk factors of interest identified in the current concussion and ACL prevention literature.
75904075|NCT03072472|Device|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
75904076|NCT03075436|Behavioral|Enhanced demand-side sanitation, hygiene|The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
76068789|NCT00410488|Drug|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
76068790|NCT00410488|Drug|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
76068791|NCT00410488|Drug|Zinecard|750 mg/m2 as an IV bolus.
76072402|NCT00499083|Drug|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
75904077|NCT03075436|Behavioral|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
75610027|NCT04298619|Diagnostic Test|Standard cohort: Clinical lab follow-up|
75904078|NCT03075124|Device|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
75904079|NCT05002036|Device|Trium eyedrops|given three times daily from day 1 after surgery to end of Week 4
76068792|NCT00410488|Drug|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
75610028|NCT04298619|Diagnostic Test|Imaging cohort: integrated imaging follow-up|
75610029|NCT04297839|Drug|Citrate Anticoagulation Solution|Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
75610030|NCT04297839|Drug|Control Group (heparin or continuous saline)|Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
75610031|NCT02746549|Other|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
75610032|NCT02751229|Behavioral|Honest Open Proud (HOP)|"five lessons in three modules, two for each two-hour session~Considering pros and cons of disclosing:~hurtful and helpful attitudes about mental illness~identify beliefs participants hold about themselves~explore five-step process to challenge their personally hurtful beliefs~weigh pros and cons of coming out in order to facilitate a decision on whether to disclose~Different ways to disclose:~different levels of (non-) disclosure and how to weigh the cons and pros~disclosure via social media versus disclosing face to face~how to find people that are better to disclose to than others and how to 'test them out'~participants will discuss how others might respond to their disclosure and how that will affect them~Telling your story:~how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt"
75904080|NCT03074968|Drug|Benzydamine Hydrochloride|Benzydamine Hydrochloride application
75904081|NCT03074968|Drug|Normal saline|normal saline application
75610033|NCT02751151|Other|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
75610034|NCT02747251|Other|Strengthen your Shoulder|A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
75610035|NCT02747251|Other|Usual Care|"Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder."
75904082|NCT05002348|Device|Laser acupoint stimulation(Laser pen)|Select 5-7 acupuncture points according to physical fitness. Each acupoint is performed once a day. The acupuncture point stimulation process takes about 3-5 minutes. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat and blood oxygen) with a physiological monitor. , If the patient has any discomfort, the procedure will be stopped for a maximum of 10 days.
75904083|NCT03075202|Device|e-cigarette, brand name JUUL|This is not an experimental study/trial, rather a prospective observational study. Device will be offered to cohort, but they are not mandated to take or use the device.
75904084|NCT04991584|Drug|Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
75904085|NCT03072706|Device|Corin OPS™|The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
75904086|NCT03072706|Other|2D X-ray templating technology|Standard care where hip replacement is planned using 2D X-ray templating software
75904087|NCT04997746|Behavioral|Multiprofessional educational interventions|Preventive educational interventions
75904088|NCT04997746|Other|Measurement of anthropometric measurements|Measurement of height (in meters), weight (in kilograms), knee height, arm circumference and calf circumference (in centimeters)
76068793|NCT00410488|Drug|Vincristine|"2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only."
76068794|NCT00410488|Drug|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
75610036|NCT04216537|Diagnostic Test|Glioma groups based on molecular pathology or genetic variation|Patients with newly diagnosed glioma that receive tumor resection
75610037|NCT02695303|Drug|Coppertone (BAY 987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75758119|NCT01042704|Other|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
75758120|NCT01042704|Other|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
75758121|NCT01042704|Other|Post-Treatment Follow Up|"After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:~Physical exam~Performance status (check of ability to perform daily functions)~Recording of any new symptoms and any new medications being taken~Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)~Urine test (24hr urine)~Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).~A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse."
75758122|NCT00750698|Drug|Entinostat|Entinostat (10 milligrams [mg] fixed dose orally [PO] every 2 weeks [Q2W]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles
75758123|NCT00750698|Drug|Erlotinib|Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
75758124|NCT01046838|Drug|Sildenafil|40 mg three times daily for 9 weeks
75458058|NCT01801267|Procedure|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
75758125|NCT01046838|Drug|Placebo|tablet 3 times daily for 9 weeks
75458059|NCT01801267|Procedure|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
75458060|NCT01801293|Drug|GS-5806|
75458061|NCT01801306|Device|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
75458062|NCT01801319|Device|Libra Deep Brain Stimulation System|
75458063|NCT01801332|Dietary Supplement|intensive nutrition|"Patients randomized in  intensive enteral nutrition  arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde."
75610038|NCT04216459|Drug|oral lactobacillus probiotics plus intramuscular cholecalciferol|According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR < 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement
75610039|NCT04216459|Drug|intravenous vitamin C plus thiamine|starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
75610040|NCT02747485|Device|Cardiac MRI|
75758126|NCT03633240|Other|ER assessment|"To measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps:~The first step will be limited to its assessment component in order to learn how to use the tool.~The second step will be to follow the recommendations provided after the assessment.~Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days."
75758127|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|"Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~Pre-incision: SLN is identified~Inject blue dye into patient's arm~Complete procedure (SLNB and/or ALND)"
75758128|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|"Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~Pre-incision: SLN is not identified (No localization)~Inject blue dye into breast (nothing in arm)~i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)"
75758129|NCT01042782|Drug|RAD001 and MitomycinC|"RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks"
75758130|NCT01038986|Biological|CureXcell|The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.
75758131|NCT00411788|Drug|Rapamycin|oral rapamycin 6 mg daily
75758132|NCT00411788|Drug|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
75904089|NCT05001412|Drug|Camrelizumab; apatinib; carboplatin; etoposide|2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
75758133|NCT01046994|Procedure|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
75758134|NCT01046994|Drug|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
75904090|NCT04997590|Biological|Umbilical cord blood mononuclear cells|injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.
75610041|NCT02747485|Biological|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
75758135|NCT01040936|Drug|Atorvastatin|patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
75758136|NCT01040936|Drug|Atorvastatin|patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
75758137|NCT01041014|Behavioral|Professional medical interpreter|All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
75758138|NCT01041092|Drug|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
75758139|NCT01041170|Drug|THC|
75758140|NCT01041170|Drug|Rimonobant|
75758141|NCT01041170|Drug|Rimonabant|
75758142|NCT01041326|Radiation|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
75758143|NCT01041326|Procedure|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
75758144|NCT01041482|Drug|sorafenib|sorafenib 400mg twice daily
75758145|NCT00422942|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
75610042|NCT02747485|Procedure|myocardial biopsy|
75610043|NCT02747485|Genetic|blood samples|extract DNA to look for genomic mutations associated with the disease.
75610044|NCT04216771|Drug|Idarubicin|Idarubicin 10mg/m²/day, D1 (IV)
75610045|NCT04216771|Drug|ID cytarabine|Cytarabine 1.5g/m² /12h, D1-D3 (IV)
75610046|NCT02747095|Device|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
75610047|NCT00636259|Drug|Bicalutamide (Casodex)|150mg
75610048|NCT02737033|Drug|Rhodiola|Rhodiola rosea 800mg
75610049|NCT02737033|Drug|Placebo|innocuous pill manufactured to mimic Rhodiola
75758146|NCT00422942|Drug|Methotrexate|10-25mg po weekly
75904091|NCT04997590|Drug|Staphylococcal Enterotoxin C|injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
75904092|NCT04997512|Device|Freestyle libre|A glucose sensor (flash) which measures interstitial blood glucose every 15 minutes or on demand.
75904093|NCT04997512|Other|Nurse led structured intervention - hypoglycaemia education and diabetes treatment modification modification|An education programme surrounding avoidance of hypoglycaemia at baseline. Regular review (weeks 2, 4, 12 and 24) and adjustment of diabetes medications based on freestyle libre data.
75904094|NCT04997122|Other|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
75904095|NCT04997122|Other|High oleic acid sunflower oil|Volunteers consumed during 4 weeks 45 g/d of oleic acid-rich sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
75610050|NCT02736799|Device|Sham vibrating capsule|Sham device without vibration
75758147|NCT01039142|Drug|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
75758148|NCT00422162|Drug|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
75904096|NCT04996810|Biological|PROTOXIN|Botulinum toxin Type A
75610051|NCT02736799|Device|Vibrant Capsule (1 vibration)|1 vibration/min
75904097|NCT04996810|Biological|Botox®|Botulinum toxin Type A
75904098|NCT04991896|Drug|Flecainide Injectable Product|Flecainide is given as an IV infusion of 1.5 mg/kg (max 150 mg) in DW 5% over 10 min under continuous monitoring. Concomitant administration of a b-blocker is also applied in all patients. The dose and type of b-blocker are selected according to heart rate during the AF and patient's medical history.
75610052|NCT02736799|Device|Vibrant Capsule (3 vibration)|3 vibration/min
75610053|NCT02736799|Device|Vibrant Capsule (5 vibration)|5 vibration/min
75610054|NCT02736487|Device|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
75610055|NCT02736487|Device|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
75610056|NCT03565939|Biological|Trichuris suis ova|Eggs from the pig whipworm
75610057|NCT03565939|Biological|Placebo|Solution without TSO
75610058|NCT02736331|Dietary Supplement|Treatment 1|Treatment 1 Beverage
75758149|NCT00422162|Drug|Placebo|placebo capsule by mouth
75758150|NCT00411632|Drug|Bexarotene|400 mg/m^2 by mouth daily x 28 Days
75758151|NCT00411632|Drug|Erlotinib|150 mg by mouth daily x 28 Days
75904099|NCT03072394|Drug|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
75904100|NCT03072394|Drug|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
75904101|NCT04991428|Other|Transcranial direct current stimulation|tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.
75904102|NCT03072004|Device|LLLT|The LLLT will be applied using a diode laser device (Recover Laser MMOptics, São Carlos/SP- Brazil) with parameters: 808nm, continuous output, 100mW, 8J. Laser probe will be applied directly and perpendicularly in skin contact (5 points), the time of irradiation will be 80 seconds per point, and treatments will be applied for three times a week for 12 sessions.
75904103|NCT03072004|Device|Sham LLLT|"That group receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the LLLT group"
75904104|NCT03072082|Drug|Danlou Tablet|Conventional western medicine & Danlou Tablet
75610059|NCT02736331|Dietary Supplement|Treatment 2|Treatment 2 Beverage
75610060|NCT02736019|Drug|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
75610061|NCT02736019|Drug|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
75610062|NCT02736019|Drug|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
75758152|NCT01039220|Biological|naso-pharyngeal swab|Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection.
75758153|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
75758154|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
75758155|NCT00422084|Drug|Pyronaridine artesunate|Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)
75904105|NCT03072082|Drug|DanLou Tablet placebo|Conventional western medicine & placebo (for Danlou Tablet)
75904106|NCT03072082|Drug|Aspirin Enteric-coated Tablets|100 mg tablet, one tablet daily.
75610063|NCT02736019|Drug|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
75904107|NCT03072082|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|One tablet daily. (for patients who can't use aspirin)
75758156|NCT00422084|Drug|Coartem® (artemether lumefantrine)|AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
76068795|NCT01794598|Behavioral|Receiving educational material of depression care|The educational material provides patients about depression management
75610064|NCT02735863|Drug|ABX464|50 mg or 150mg once daily for 28 days
75610065|NCT02735863|Drug|Placebo|ABX464 matching placebo
75904108|NCT03072082|Drug|Atorvastatin calcium|10 mg tablet, two tablets each night.
75458064|NCT01801332|Dietary Supplement|usual meals|"Patients randomized in  classical oral nutrition  arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily."
75610066|NCT02735785|Behavioral|Harnessing Online Peer Education (HOPE) Social Media Intervention|
75610067|NCT04286581|Device|I-Gel Laryngeal Mask Airway|The I-Gel Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
75610068|NCT04286581|Device|Ambu Auragain Laryngeal Mask Airway|The Ambu Auragain Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
75610069|NCT04284397|Drug|Low dose ASA|A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.
75758157|NCT00421928|Drug|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
75458065|NCT01801345|Other|Fatigued|
75458066|NCT01801345|Other|Rested|
75458067|NCT01801371|Drug|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
75610070|NCT04284397|Other|Control|All participants will be tested with no treatment.
75610071|NCT05595889|Drug|Surufatinib|250 mg/day p.o. QD
75610072|NCT05595889|Drug|Irinotecan|Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
75610073|NCT02735629|Drug|CX1739 - 300 mg|Ampakine CX1739 - 300 mg
75610074|NCT02735629|Drug|CX1739 - 600 mg|CX1739 - 600 mg
75610075|NCT02735629|Drug|CX1739 - 900 mg|CX1739 - 900 mg
75610076|NCT02735629|Drug|Placebo|Placebo to 300 mg CX1739
75610077|NCT02735395|Procedure|Scaling and root planing (SRP)|SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
75610078|NCT02735395|Drug|Metronidazole 250 (7 days)|Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
75758158|NCT00421928|Drug|placebo|matching placebo twice a day (BID) during 15 weeks
75758159|NCT00421928|Drug|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
75904109|NCT03072082|Drug|Isosorbide Mononitrate Tab 20 MG|One tablet two times daily.
75904110|NCT03072082|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
75458068|NCT01801397|Drug|osteoanabolic therapy|
75458069|NCT01801410|Device|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
75458070|NCT01801410|Drug|Misoprostol|25mcg every 2 hours for maximum of 12 doses
75904111|NCT03072082|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
75904112|NCT03072316|Other|3D surface imaging|3D photography
75904113|NCT03072316|Other|semi-structured interview|qualitative analysis using semi structured interview
75904114|NCT03072316|Other|applanation tonometry|measurement of breast compressibility
75904115|NCT03076840|Other|Kinesio tape|Kinesio Taping is another option for the treatment of poor hamstring extensibility, It was developed by Kenzo Kase in 1970 and gained a wide popularity by the elite athletes during the various championships and Olympic Games
76068796|NCT00412516|Biological|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
76068797|NCT01793350|Drug|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
76068798|NCT03303898|Procedure|Blood sampling|sampling of 7 blood tubes
76068799|NCT01794676|Genetic|Blood draw|Blood draw
75758160|NCT00383292|Drug|tasisulam|Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
75758161|NCT01042860|Dietary Supplement|Lutein|Lutein supplement, 10 mg daily
75758162|NCT01042860|Dietary Supplement|Placebo|Placebo
75758163|NCT01047072|Drug|fludarabine phosphate|Given IV
75610079|NCT02735395|Drug|Metronidazole 400 (7 days)|Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
75758164|NCT01047072|Radiation|total-body irradiation|Undergo total-body irradiation
75758165|NCT01047072|Drug|tacrolimus|Given orally
75758166|NCT01047072|Drug|mycophenolate mofetil|Given orally
75758167|NCT01047072|Biological|rituximab|Given IV
75758168|NCT01047072|Drug|cyclophosphamide|Given orally
75758169|NCT01047072|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
75758170|NCT01047072|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
75758171|NCT01043016|Procedure|Photodynamic therapy|patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
75758172|NCT00372060|Drug|sitagliptin phosphate|Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
75758173|NCT00372060|Drug|Comparator: sitagliptin phosphate (MK0431)|Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
75758174|NCT00372060|Drug|Comparator: pioglitazone|pioglitazone once daily for 52 weeks
75610080|NCT02735395|Drug|Metronidazole 250 (14 days)|Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
75610081|NCT02735395|Drug|Metronidazole 400 (14 days)|Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
75458071|NCT01801423|Drug|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at ~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
75458072|NCT01801462|Other|Simulation-based training|
75458073|NCT01801514|Device|Computed Tomography scan|Routine Computed Tomography scan
75610082|NCT02735395|Drug|Amoxicillin|Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
75610083|NCT02735395|Other|Placebo 250 (7 days)|Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
75610084|NCT02735395|Other|Placebo 400 (7 days)|Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
75758175|NCT00372060|Drug|Comparator: placebo (unspecified)|Placebo once daily for 12 weeks
75758176|NCT00421304|Biological|Motavizumab|A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
75458074|NCT01801527|Behavioral|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
75458075|NCT01801540|Dietary Supplement|L-arabinose - effect on glucose metabolism|L-arabinose is mixed into the dough of the buns and cup cakes
75758177|NCT00421304|Other|Placebo|A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
75758178|NCT01043172|Drug|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
75758179|NCT01045434|Drug|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
75758180|NCT01039454|Drug|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
75758181|NCT01039454|Drug|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
75758182|NCT01045512|Drug|fluvastatin|40-80mg once daily
75758183|NCT01045590|Drug|titration|Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
75904116|NCT04990960|Other|Physiotherapy|During each session (45 minutes)the patient was assessed and trained in self-treatment exercises assigned to treat their cords. This later method was chosen to ensure regular participation in their exercises and early correction of any inaccuracies in the implementation of the exercises regarding AWS treatment . Or the Physiotherapist worked actively on cords with soft or vigorous stretching.
76068800|NCT05286970|Drug|AK115|Abdominal subcutaneous injection
75758184|NCT01045590|Drug|titration|Patients in the glibenclamide + rosiglitazone treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
75758185|NCT01047384|Procedure|acupuncture-moxibustion therapy|
75758186|NCT01047384|Procedure|Regular therapy|
75610085|NCT02735395|Other|Placebo 400 (14 days)|Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
75904117|NCT04996732|Procedure|hospitalization|Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization
75904118|NCT04934020|Other|Pre-pandemic stroke related metrics|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
75904119|NCT04934020|Other|Stroke related metrics during the pandemic|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
75904120|NCT03074890|Device|Application Protocol|Application lMassive Transfusion Protocol
75904121|NCT04931914|Other|Clinical pharmacy sharing in the patient care regimen|antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
75458076|NCT01801553|Other|Spinal manipulation|"-In the intervention group :~True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:~If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.~-In the control group:~Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body."
75458077|NCT01801553|Other|sham spinal manipulation|
75458078|NCT01801553|Other|Usual medical care|
75458079|NCT01801566|Procedure|Single implant-retained mandibular overdenture|60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
75458080|NCT01801605|Procedure|rTMS|Active session with stimulation and placebo session with fictive stimulation
75458081|NCT01801631|Other|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
75458082|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
75610086|NCT02735395|Other|Placebo 500|Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
75610087|NCT02741947|Drug|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
75610088|NCT02741947|Drug|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
75610089|NCT05629195|Device|tunneled PICC|PICC catheter is inserted into the superior vena cava through the upper brachial vein by establishing a subcutaneous tunnel
75610090|NCT02741869|Device|photodynamic therapy (Ondine: MRSAid™)|Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
75610091|NCT02741557|Drug|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
75904122|NCT04987450|Drug|Methylprednisolone, prednisone|The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
75904123|NCT03074656|Other|Therapeutic drug monitoring|Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
75904124|NCT03074656|Other|Standard care|Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
75904125|NCT03074578|Behavioral|Watching Video-clip 1|Video -clip 1 contains violent images and text
75904126|NCT03074578|Behavioral|Watching Video-clip 2|Video -clip 2 contains neutral images and text
75904127|NCT04996888|Device|AI based preoperative automatic reminder system|the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time. The system is an non-invasive AI system.
75904128|NCT03071848|Other|No Intervention|This was an observational study.
76068801|NCT05286970|Drug|Placebo|Abdominal subcutaneous injection
75904129|NCT03070210|Procedure|EUS-celiac ganglia block (EUS-CGB)|The intervention technique of EUS-CGB is the realization of EUS-guided celiac block with injection of bupivacaine directly into the ganglia for patients with chronic pancreatitis.
75904130|NCT03070210|Procedure|EUS-celiac plexus block (EUS-CPB)|In the arm of EUS-CPB, the procedure is going to be performed with the standard EUS-guided celiac plexus block with injection of bupivacaine into the retroperitoneal space.
75610092|NCT02741557|Drug|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
75610093|NCT02741557|Drug|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
75904131|NCT03074422|Procedure|Hypnosis|Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
76068802|NCT00414700|Drug|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
75904132|NCT03071614|Other|News items with spin|Interpretation of news items with spin
75458083|NCT01801644|Drug|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
75458084|NCT01801670|Procedure|Biopsy|Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
75458085|NCT01801670|Procedure|Blood|Peripheral blood (10 mls) to be drawn and used for cytokine analysis.
75463305|NCT05854446|Other|Survey|In this survey, The experts will be asked open-ended questions based on the literature research and patient surveys carried out by the researchers in the first round to identify key themes related to myofascial pain syndrome, including the disease burden, patient journey, and unmet diagnosis and treatment needs. In subsequent rounds, the experts will rate the importance of each theme and provide additional feedback.
75610094|NCT02741479|Other|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
75610095|NCT02741401|Other|Usual post-operative care|Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
76068803|NCT00414700|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
75610096|NCT02741401|Other|Hand-foot massage|Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
75904133|NCT03071614|Other|News items without spin|Interpretation of news items without spin
75904134|NCT04991194|Drug|BIA 5-1058|Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours [Day (D)2 to D9] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.
76068804|NCT00415870|Behavioral|Printed Material|Printed Material
75758187|NCT01043406|Device|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
75463306|NCT05854433|Other|Non-interventional study|No intervention will be administered as part of this study.
75758188|NCT01047462|Procedure|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
75758189|NCT00396630|Biological|Rotarix|Two-dose oral vaccination.
75758190|NCT00396630|Biological|Placebo|Two-dose oral administration.
75758191|NCT01043484|Drug|Bevacizumab + Capecitabine + Radiotherapy|Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
75758192|NCT01043484|Drug|Capecitabine + Radiotherapy|Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
76068805|NCT00415870|Behavioral|Weekly Weighing|Weekly Weighing
76068806|NCT00415870|Behavioral|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
76068807|NCT00415870|Device|Text Message|Text Message
76068808|NCT00415870|Behavioral|Diet Goals via Cell Phone|Diet Goals via Cell Phone
76068809|NCT00415870|Behavioral|Food Monitoring|Food Monitoring
75610097|NCT02695225|Behavioral|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
75463307|NCT05854420|Procedure|Modified anterior Lamellar Recession|ALR is one of the procedures used to treat cicatricial entropion and trichiasis. Few studies present the effect of modifications to this procedure in trachomatous entropion and trichiasis. Because trachoma is common in our country, there is a probability that the number of surgeries for TT will rise.
75610098|NCT02695225|Behavioral|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
75610099|NCT02741167|Procedure|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
75610100|NCT02740933|Drug|Demeclocycline|
75758193|NCT00396318|Drug|tenecteplase|"2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.~Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg)."
75758194|NCT00396162|Drug|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
75758195|NCT00396162|Other|Placebo|Placebo pill
75758196|NCT00381888|Drug|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
75758197|NCT03992898|Other|No special intervention was suitable for this observational study|Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.
75758198|NCT00267969|Drug|ustekinumab|Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
75610101|NCT02741089|Procedure|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
75610102|NCT02740855|Device|Alcomed 3011®|Endtidal ethanol measurement
75758199|NCT00267969|Drug|placebo|Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
75758200|NCT00280293|Drug|Lamotrigine|Lamotrigine
75904135|NCT04990648|Device|Buzzy|Buzzy ® device (Buzzy ® Mini Healthcare) has been used to reduce pain by using local cold application and vibration effect. Buzzy ® was developed by Dr. Amy Baxter in 2009. The size of the Buzzy ® device measures 2⅞ꞌꞌ x 1⅞ꞌꞌ x ⅞ꞌꞌ (7,2 cm x 4,8 cm x 2,2 cm). It is a bee-shaped device made of hard plastic with a vibrating motor (2 settings - fixed and pulsed), powered by a 2AAA battery. There are 4 ice packages and elastic fastening strap. On the part where the device touches the skin, there is an ice package in the shape of a wing. When the button on the device is pressed, it vibrates.
75904136|NCT04920058|Device|Continuous Glucose Monitor|Continuous glucose monitor - a device that monitors blood glucose levels in a continuous closed-loop manner. This can also refer to the process of continuous glucose monitoring
75758201|NCT00280293|Drug|Placebo|Placebo
75758202|NCT00421148|Drug|Sugammadex 0.5 mg/kg|IV infusion
75758203|NCT00421148|Drug|Sugammadex 1 mg/kg|IV infusion
75758204|NCT00421148|Drug|Sugammadex 2 mg/kg|IV infusion
75758205|NCT00421148|Drug|Sugammadex 4 mg/kg|IV infusion
75758206|NCT00421148|Drug|Placebo|IV infusion
75758207|NCT00421148|Drug|Rocuronium bromide|IV infusion
75758208|NCT00403754|Drug|Indacaterol|In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
75904137|NCT04920058|Other|<Active Comparator?>|<describe, Comprehensive Wellness Program incorporating a low carbohydrate diet (<50g/day) and associated education >
76068810|NCT01795612|Other|physical activity|
76068811|NCT00416182|Drug|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
76068812|NCT00416182|Drug|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
75758209|NCT00403754|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
75758210|NCT00403754|Drug|Salmeterol|Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
75463308|NCT05854394|Behavioral|Multimodal prehabilitation management Multimodal prehabilitation management|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including drug treatment recommendations for chronic disease, quit smoking and abstinence).
75610103|NCT02694991|Other|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
75904138|NCT04987060|Device|Intrastromal Fresh Human Lenticule Implantation|The stromal pocket diameter was set 8.0 mm and cap thickness was set to 140 μm from corneal surface and a 2mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 2 mm superior incision. Incision position changed according to the position of the highest K values.
75904139|NCT02853435|Drug|Gepotidacin RC Tablet|The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
75904140|NCT02853435|Drug|Gepotidacin HSWG Tablet|The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
75904141|NCT02853435|Drug|Gepotidacin Capsule|It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
75904142|NCT04996186|Other|Clinical interviews|Semi-qualitative interviews and questionnaire STAR-Q
75904143|NCT03071770|Drug|ivosidenib (AG-120)|A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
76068813|NCT00416494|Biological|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
75758211|NCT00280059|Drug|Pregabalin|dose 150-600 mg/day given BID
75758212|NCT00280059|Drug|Lamotrigine|dose 100-500 mg/day given BID
75758213|NCT00403130|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
75758214|NCT00403130|Drug|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
75904144|NCT04986982|Drug|Opicapone 50 mg|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI) (L-dopa/DDCI).
75904145|NCT04986982|Other|Matching placebo|Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
75904146|NCT04990570|Other|Telemedicine in the form Virtual clinic via video consultation|"Pediatric patients, with age ranging from 1 month-14 years, with surgical problems, encountered during the era of Covid-19 pandemic.~Some of them seen at the OPD clinic, while the majority failed to attend because of Covid-19 associated lock-down and Curfew, thus, rendering their approach to the service.~Telemedicine, in the form of Virtual clinic, was utilized to address the distressing problem of difficult approach of patients to the pedia surgery OPD because of Covid-19 pandemic restrictive regulatory precautions, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship & encounter."
75758215|NCT00403130|Drug|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
75758216|NCT00402740|Device|Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)|All subjects will receive the Xact™ Rapid Exchange Carotid Stent System. The first 220 consecutively enrolled subjects will be treated with the investigational filter system, the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5). The remaining subjects will be treated with the FDA approved Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3).
75904147|NCT03606915|Behavioral|pain evaluation|collect CSF during spinal anesthesia
75904148|NCT03074344|Device|XLHA+CoQ10|XLHA+CoQ10 for four times a day for 12 weeks.
75904149|NCT03074344|Device|Hyaluronic acid (HA)|Hyaluronic acid (HA) for four times a day for 12 weeks.
75904150|NCT03605511|Diagnostic Test|ADAMTS 13, complement and angiogenic biomarkers|ADAMTS 13, complement and angiogenic biomarkers
76068814|NCT00416494|Drug|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
76068815|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
75758217|NCT03993704|Drug|LHF-535|Oral suspension administered once daily for 14 days
75904151|NCT03069898|Behavioral|TRUE Dads|The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
76068816|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
75610104|NCT02741011|Other|Radiological examination|During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
75758218|NCT01039610|Drug|GSK945237|Dose detailed in Arm description
75758219|NCT01039610|Drug|Placebo|matching placebo tablet
75758220|NCT01039610|Drug|Linezolid|600 mg BID, 14 Days
75758221|NCT01039610|Drug|Moxifloxacin|40 mg single dose
75904152|NCT02035371|Drug|Faster-acting insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
75904153|NCT02035371|Drug|insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
75904154|NCT03274947|Device|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
75904155|NCT03274947|Device|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
76068817|NCT02616172|Genetic|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
76068818|NCT02463760|Other|Medical imaging|
76068819|NCT02460484|Biological|Autologous Cord Blood Infusion|Intravenous infusion
76068820|NCT00416572|Behavioral|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
76068821|NCT00416572|Behavioral|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
75463309|NCT05854355|Other|C-SLAMM Study|The intervention arm includes using innovative behavioural, pedagogical, and environmental strategies within the classroom, school, and home settings to get children moving more and sitting less. The strategies were based on strategies used in Transform-Us! involved incorporating movement into everyday class lessons - the delivery of the lesson changes, not the content. Resources included health lessons, active lessons, active breaks, active homework to do with parents, active environments, and newsletters for parents.
75463310|NCT05854342|Other|bicarbonate-calcium water|water with high content of bicarbonate and calcium, low sodium
75463311|NCT05854290|Behavioral|CRT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
75463312|NCT05854290|Behavioral|CBT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
75758222|NCT00581672|Behavioral|questionnaires of quality of life|Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
75758223|NCT00420290|Drug|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
75758224|NCT00420290|Drug|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
76068822|NCT00417274|Drug|Quinacrine|100 mg daily
75904156|NCT04990414|Other|Cognitive Behavioural Therapy|Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.
75904157|NCT03069820|Drug|docetaxel and cisplatin|Patients receive TP (docetaxel and cisplatin) chemotherapy
75904158|NCT03605433|Drug|Rivaroxaban|Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
75904159|NCT03071302|Other|EVALUATION OF VSX1, SOD1, and TIMP3 genes|Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
75904160|NCT03606681|Drug|Calcium Hydroxide|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
75904161|NCT03606681|Drug|Mineral Trioxide Aggregate|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
75904162|NCT03606681|Drug|TheraCal LC|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
75904163|NCT03071380|Drug|Repatoxaban|1 tablet contains 10 mg rivaroxaban
75904164|NCT03071380|Drug|Xarelto|1 tablet contains 10 mg rivaroxaban
75904165|NCT03070990|Drug|Enfortumab vedotin|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
75904166|NCT04995718|Other|Intelligent Physical Exercise Training (IPET)|Wind technicians performed 1-hour weekly individualized physical exercise training during working hours. The specific content of the exercise program was based on the specific job exposure profile, the physical capacity profile and the physical health profile of the employee.
75904167|NCT03605199|Drug|Denosumab|Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
75904168|NCT04986436|Drug|HS-10360|Single or multiple dose(s) of HS-10360
75904169|NCT04986436|Drug|Placebo|Single or multiple dose(s) of Placebo
75904170|NCT03605121|Procedure|cardiac surgery|The relationship between body mass index or waist circumference and clinical outcome in patients undergoing cardiac surgery will be assessed
75904171|NCT04995250|Other|corrective exercise training for knee|All patients received 12 weeks (3 days per week) physiotherapy sessions with hot pack, TENS and Ultrasound session for 10 mints and knee isometric, quad strengthening, adductor and abductor strengthening, calf stretch, hamstring stretch, Maitland mobilization, Unconventional Corrective knee exercise protocol treatment: standing on one extremity, up and down on bosu exercise, walking to lateral direction, walking to anterio-posterior direction, walking to anterio-posterior and lateral for 20 mints. Data were collected at baseline, at week 4 and at post treatment (week 12).
75458086|NCT01801683|Other|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
75610105|NCT02740465|Behavioral|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
75610106|NCT02740465|Behavioral|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
75610107|NCT00636337|Behavioral|Attention Training|Computer program training for attention difficulties.
75610108|NCT00636337|Behavioral|Placebo|Comparison computer program
75610109|NCT02740387|Drug|OTO-104|
75758225|NCT00267189|Drug|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
75758226|NCT00267189|Drug|Calcineurin inhibitors (CNI)|
75758227|NCT00267189|Drug|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
75758228|NCT00267189|Drug|Steroids|
75758229|NCT03834350|Other|BREATHES Program|Participants will complete inhaler education using the virtual education module at the baseline visit of the study. Additionally, they will be asked to complete the lesson at least once before their 30 day follow-up visit on their personal device once they have been discharged from the hospital. At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
75758230|NCT03834350|Device|BREATHES SpiroPD or Propeller Health|At the time of their initial study visit, study participants may be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
75758231|NCT01589120|Behavioral|Video decision aid|Video decision aid of the goals of care
75610110|NCT03699163|Diagnostic Test|Breath sample|Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
75758232|NCT00402116|Drug|enzastaurin|"Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles"
75758233|NCT00402116|Drug|temozolomide|75 milligrams per meter squared (mg/m^2), oral, daily, 6 weeks then 200 mg/m^2, oral, daily, twelve 28 day cycles
75758234|NCT00402116|Radiation|radiation therapy|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
75758235|NCT00401960|Drug|Daptomycin|daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
75904172|NCT03606525|Procedure|subarachnoid block|Vertebral column length and abdominal girth will be measured before routine subarachnoid block is given to recruited patients
76068823|NCT01793428|Other|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
76068824|NCT04749940|Other|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
76068825|NCT01976962|Radiation|Stereotactic body RT with MR-guided boost|Patients will receive radiotherapy over 5 fractions delivered once per week over 29 days, with 7.25 Gy per fraction to the whole prostate and 8 Gy per fraction to the dominant intraprostatic lesion. There will be a minimum of 120 hours and maximum of 192 hours between fractions. The entire course of treatment should be completed within no less than 27 days and no longer than 30 days.
76068826|NCT05286346|Drug|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
76068827|NCT05286346|Drug|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
75610111|NCT02746393|Other|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
75610112|NCT02746393|Other|211 Information Sheet|Receive a printed list of community resources to address social needs.
75610113|NCT02740309|Behavioral|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
75610114|NCT02740309|Behavioral|Treatment as usual|Facilitated community referral for mental health treatment
75610115|NCT02746237|Drug|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
75610116|NCT02746237|Drug|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
75610117|NCT02739841|Other|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
75610118|NCT02739841|Other|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
75758236|NCT00401726|Drug|Venlafaxine ER|
75758237|NCT00401726|Behavioral|Dialogues Time to Talk Program|
75758238|NCT00371826|Drug|Everolimus (RAD001)|
75758239|NCT00371826|Drug|Cyclosporine (Calcineurin Inhibitor (CNI))|
75758240|NCT00371826|Drug|Methylprednisone/prednisone|
75758241|NCT00371826|Drug|Mycophenolate sodium (MPA)|
75758242|NCT03993366|Combination Product|Fiasp+Pramlintide Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin and pramlintide
75758243|NCT03993366|Device|Fiasp Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin alone
75758244|NCT02457702|Other|Orally administered labeled glycerol|Oral administration of labeled glycerol
75758245|NCT00396084|Drug|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
75758246|NCT00396084|Drug|Isoniazid|Isoniazid 300 mg/day x 7 days.
75904173|NCT03606447|Drug|Uproleselan|[14C]-Uproleselan
75904174|NCT03074266|Diagnostic Test|GEM Hemochron 100 ACT|Activated Clotting Time
75904175|NCT03605043|Other|Blood pressure management in the HIV program|Integrated care for hypertension and HIV in the HIV program
75610119|NCT02739763|Biological|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
75758247|NCT00396084|Drug|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
75758248|NCT00396084|Drug|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
75758249|NCT00396084|Drug|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
75904176|NCT03606369|Drug|Palonosetron|Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.
75904177|NCT03606369|Drug|Ondansetron|Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
75904178|NCT03604965|Drug|GP+CCRT|Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
75758250|NCT01043718|Behavioral|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
75758251|NCT01043718|Behavioral|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
75758252|NCT00395850|Drug|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
75610120|NCT02739685|Device|Everolimus-eluting bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
75758253|NCT00420212|Drug|BG00012|
75758254|NCT00420212|Drug|Placebo|
75758255|NCT00401258|Drug|duloxetine|30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
75758256|NCT00380874|Drug|Pregabalin|150- 600 mg/day (double blind in divided doses)
75758257|NCT00380874|Drug|Placebo|Placebo
75758258|NCT00420056|Drug|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
75758259|NCT00411554|Drug|sitagliptin phosphate|sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
75758260|NCT00411554|Drug|Comparator: voglibose|voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
75758261|NCT00400712|Behavioral|physical rehabilitation|two weeks intensive physical rehabilitation
75904179|NCT03604965|Drug|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
75904180|NCT02237313|Behavioral|psychological support and therapeutic education program|
75904181|NCT02635204|Drug|DFD06 Cream|Twice daily topical application for 14 days.
75904182|NCT02635204|Drug|Vehicle Cream|Twice daily topical application for 14 days.
75904183|NCT03604887|Diagnostic Test|ultrasonography|"Ultrasound evaluation will be done with transducer abdominal probe. The amount of amniotic fluid and umbilical cord sections will be determined by evaluating the images obtained from the sagittal plane in the ultrasound evaluations in the 4 abdominal quadrants.~When the anatomical structure of the umbilical cord is considered, it is folded in amniotic fluid. The folds appear as umbilical cord rings, side-by-side at the sagittal sections.~Scoring of umbilical cord length index~1 point will be given for each quadrant where the umbilical cord was observed.~0.5 point will be given for each umbilical cord ring in one quadrant. Every quadrant will be evaluated in this manner, and the total score will be calculated."
76072403|NCT00499083|Drug|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
75463313|NCT05854290|Behavioral|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
75463314|NCT05854290|Behavioral|Usual care Psychoeducation|"Participants will receive 15-minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).~Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking."
75610121|NCT02739685|Device|Everolimus-eluting stent|Implantation of everolimus-eluting stent in chronic total occlusion
75610122|NCT02735317|Drug|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
75610123|NCT02735317|Drug|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
75610124|NCT02735161|Other|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
75904184|NCT03069430|Behavioral|SELFY (Self Management for Youth with SCD)|The intervention will be delivered via a mobile device (tablet) and consists of three components. 1. Education, will consist of continuous access to electronic educational resources on the SCD process, treatment, home management strategies, symptom prevention and management strategies. To address potential literacy barriers, an application that reads PDF files aloud will be downloaded onto devices. 2. symptom monitoring and tracking, will consist of an application for tracking and monitoring pain in SCD that also permits upload of symptom logs and text alerts to a health care provider. 3. caregiver-provider communication, consists of SMS messaging with a nurse who will: respond to alerts, monitor pain symptoms delivered via the mHealth application, and respond to text messages.
75610125|NCT02735161|Other|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
75610126|NCT02746315|Drug|HS-20004|
75610127|NCT02746315|Drug|Placebo|
75758262|NCT00380718|Drug|pemetrexed|"500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.~*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets <50 x 10^9/L; absolute neutrophil count <1.0 x 10^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade >2; Skin Grade >2; Serum bilirubin >3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase >10 x ULN; Other non-hematologic toxicities Grade >2 (except nausea, vomiting)."
75758263|NCT01047696|Device|Plancha|locally developed chimney stove
75758264|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
75758265|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
75758266|NCT00380250|Drug|Lubiprostone|
75758267|NCT00380250|Drug|Placebo|
75758268|NCT00400400|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
75904185|NCT03074032|Drug|ONC1-0013B|ONC1-0013B per os daily
75904186|NCT00102804|Drug|Pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV) administration, every (q) 21 days, until disease progression
75904187|NCT00102804|Drug|Placebo|IV administration, q 21 days
75904188|NCT00102804|Other|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
75904189|NCT04989634|Behavioral|Intensive dietary and weight management|health education , nutritional analysis and individualized dietary guidance
75758269|NCT00400400|Drug|Mycophenolate mofetil|Mycophenolate mofetil supplied as 250 mg capsules.
75904190|NCT04989634|Behavioral|Standard care|Standard prenatal education on diet, nutrition and physical activity
75904191|NCT01814072|Behavioral|12 Telephone Coaching Sessions|Participants will receive 12 telephone coaching sessions
75904192|NCT01814072|Behavioral|24 Telephone Coaching Sessions|Participants will receive 24 telephone coaching sessions
75904193|NCT01814072|Behavioral|Report to Primary Care Physician|Participants will have a report detailing their weight loss progress sent to their primary care physician
75463315|NCT05854277|Other|educational video|To explain the novel score, a six-minute instructional video was compiled and available to watch, as well as an online tool on the GIEQs website that could be used to grade the image-sets using the score.
75463316|NCT05854264|Dietary Supplement|standard enteral nutrition|standard enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
75463317|NCT05854264|Dietary Supplement|specialized nutrition|specialized enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
75463318|NCT05854238|Device|TIRA-VoM|"treat persistent atrial fibrillation~The ablation temperature range is 50-60℃~About 2 minutes per ablation"
75463319|NCT05854225|Drug|Thiotepa|Thiotepa is an alkylating agent that is routinely used in solid tumors, but it is able to cross the blood-brain barrier into the center.
75463320|NCT05854212|Behavioral|Behavioral economics-enhanced user interface|The intervention changes the ordering platform visible to food agencies using behavioral economics strategies to promote healthier food choices.
75463321|NCT05854199|Behavioral|Telehealth solution|Telehealth nutrition education platform
75463322|NCT05854186|Behavioral|Telehealth solution: video conferencing|Telehealth solution: video conferencing
75463323|NCT05854173|Diagnostic Test|Pendulum Exercises|Compare The Effect of Pendulum Exercises Among the Patients of Adhesive Capsulitis
75463324|NCT05854173|Diagnostic Test|Kaltenborn Mobilization|Compare The Effect of Kaltenborn Mobilization Among the Patients of Adhesive Capsulitis
75758270|NCT00400400|Drug|Placebo to mycophenolate sodium|Placebo to mycophenolate sodium matching tablets.
75758271|NCT00400400|Drug|Placebo to mycophenolate mofetil|Placebo to mycophenolate mofetil matching capsules.
75610128|NCT05548621|Other|Decision aid|Online interactive decision aid for RCC
75610129|NCT02739529|Drug|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
75758272|NCT01041716|Other|None - Observational study|None - Observational study
75610130|NCT02739607|Behavioral|Transdiagnostic program|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
75904194|NCT01814072|Behavioral|Text Messages|Participants will receive regular text messages
76068828|NCT05286268|Diagnostic Test|Ischemia Modified Albumin|"Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system."
75610131|NCT05629975|Dietary Supplement|Oral Nutritional Supplements|"Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum& bifidobacterium (500 mg) every day for 7 days."
76068829|NCT00422032|Drug|Clofarabine|"Group A: 15 mg/m^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m^2 IV over 1 hour daily for 5 days"
75610132|NCT02739451|Procedure|standard oxygen|"Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~low-flow oxygen [including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask]~or medium-flow oxygen [Venturi masks and medium-flow facemasks]"
75463325|NCT05854147|Diagnostic Test|Treadmill Training With Visual and Auditory Cues|Comparison of Effects of Treadmill Training With Visual and Auditory Cues
75610133|NCT02739451|Procedure|HFNO|The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher&Paykel, Courtaboeuf, France).
75610134|NCT02734927|Other|realization of computerized exercises|
75758273|NCT00395694|Drug|lamictal|anti-epileptic drug
75758274|NCT00419744|Drug|Budesonide/formoterol (SYMBICORT) pMDI|
75758275|NCT00419744|Drug|Formoterol Turbuhaler|
75463326|NCT05854147|Diagnostic Test|Treadmill Training Without Visual and Auditory Cues|Comparison of Effects of Treadmill Training Without Visual and Auditory Cues
75463327|NCT05854134|Diagnostic Test|Closed Chain|Effectiveness of Closed Chain for Strengthening and Improving Quality of Life in Post Stroke Patients
75463328|NCT05854134|Diagnostic Test|Aerobic Exercise|Effectiveness of Aerobic Exercise for Strengthening and Improving Quality of Life in Post Stroke Patients
75463329|NCT05854121|Diagnostic Test|Functional Electrical Stimulation|Functional Electrical Stimulation for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
75758276|NCT00395538|Drug|PTH 1-34|Given twice daily by subcutaneous
75758277|NCT01047774|Dietary Supplement|Isolated soy protein|30-50g of protein powder daily for 2 weeks.
75758278|NCT01047774|Dietary Supplement|Isolated milk protein|30-50g of protein powder daily for 2 weeks.
75758279|NCT00395460|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
75758280|NCT00395460|Drug|Magnevist|0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
75758281|NCT01047852|Procedure|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
75758282|NCT00395304|Drug|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
75758283|NCT00395304|Drug|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
75904195|NCT01814072|Behavioral|Recommendations to use meal replacements|Participants will receive recommendations from their coach to use meal replacements
75904196|NCT01814072|Behavioral|Buddy Training|Participants will have a buddy that will be trained via webinars to be a supportive buddy
75904197|NCT04986124|Other|treatment as usual|No inervention. Treatment regime remains unchanged.
75904198|NCT02167152|Other|Ischemic preconditionin|Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
76068830|NCT01856140|Biological|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
76068831|NCT01388920|Drug|Tesamorelin|
75610135|NCT05629819|Device|Non-invasive phrenic nerve stimulation|Some studies have shown that PNS can relieve diaphragmatic atrophy and reverse diaphragmatic dysfunction.
75758284|NCT00395304|Drug|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
75458087|NCT01801696|Other|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
75458088|NCT01801696|Other|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
75758285|NCT00395226|Drug|zinc sulfate|zinc sulfate 220 mg bis for 90 days
75758286|NCT00395226|Drug|placebo|placebo bid for 90 days
75758287|NCT01047930|Behavioral|Exercise|"Each 3-day experimental period will include one of the following conditions:~Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~No exercise - subject will watch television or read and they will be required to remain sedentary."
75758288|NCT00394914|Drug|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
75758289|NCT00394914|Drug|Placebo to Pleconaril|Placebo nasal suspension
76068832|NCT01388920|Drug|Placebo|
75904199|NCT03038113|Drug|RO7062931|Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.
76068833|NCT00422656|Drug|Perifosine|
76068834|NCT00422812|Drug|Inhaled Placebo|Inhaled Staccato Placebo
76068835|NCT00422812|Drug|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
75458089|NCT01801748|Dietary Supplement|oral wheat challenge|
75458090|NCT01801774|Drug|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
75458091|NCT01801774|Drug|Placebo|
75758290|NCT00366444|Drug|diclofenac potassium (XP21L)|25 mg every 6 hours
75458092|NCT01801787|Device|tDCS|active vs. sham tDCS left hemisphere
75610136|NCT02735005|Other|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
75610137|NCT04257097|Device|RPM - Osteogenics Lubbock Texas USA|25 patients will undergo bone regeneration with a reinforced PTFE mesh, manually shaped and modelled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption
75610138|NCT04257097|Device|Yxoss CBR - Reoss Filderstadt Germany|25 patients undergo bone regeneration with a custom-made titanium mesh, digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption
75610139|NCT04245943|Behavioral|Exercise training|18 weeks supervised strength and aerobic exercise training.
75610140|NCT05628805|Device|iTBS|intermittent theta burst stimulation with TMS
75758291|NCT00366444|Drug|Placebo|Placebo every 6 hours
75758292|NCT00365976|Drug|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
75758293|NCT00365976|Drug|Placebo|Placebo nightly over duration of double blind study phase
75904200|NCT03038113|Drug|Placebo|Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
75904201|NCT03038113|Drug|Immune Modulator|Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
75904202|NCT02160210|Device|Ultrafine Endoscope|Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
75904203|NCT02163642|Device|Cyranose® 320|Detection of patterns of specific Volatile Organic Compounds in exhaled air
76068836|NCT00422812|Drug|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
75458093|NCT01801800|Procedure|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
76068837|NCT00422812|Drug|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
76068838|NCT00423358|Dietary Supplement|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
75458094|NCT01801813|Other|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
76068839|NCT00423358|Dietary Supplement|placebo|matching placebo
76068840|NCT00423436|Behavioral|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
76068841|NCT00423436|Behavioral|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
76068842|NCT00423436|Behavioral|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
76072404|NCT00499083|Genetic|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
75758294|NCT01049490|Biological|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
75758295|NCT00379236|Device|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
75758296|NCT00379236|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
75610141|NCT02739217|Drug|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily.
75610142|NCT02739373|Drug|BMS-986189|
75758297|NCT00379080|Procedure|conventional surgery|Undergo surgery
75758298|NCT00379080|Drug|tandutinib|Given orally
75610143|NCT02739373|Other|Placebo|
75758299|NCT00379080|Other|pharmacological study|Correlative studies
75758300|NCT00379080|Other|Tissue samples|Correlative studies
75758301|NCT00378534|Device|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selection and delayed T cell depletion add back
75758302|NCT00378534|Drug|Fludarabine|Therapeutic
75458095|NCT01801826|Device|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
75904204|NCT02163720|Drug|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
75904205|NCT04995640|Procedure|open cardiovascular repair or endovascular treatment (TEVAR)|Surgery type: open cardiovascular repair and endovascular treatment (TEVAR)
75904206|NCT03487952|Other|Questionnaire Administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.
76068843|NCT00424840|Drug|Bortezomib 1.3 mg/m2|"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"
76068844|NCT00424840|Drug|Bortezomib 1.6 mg/m2|Level II (every 21 day cycle, D8), 1.6 mg/m2
75458096|NCT01801852|Biological|NKT cells|
75458097|NCT01801878|Biological|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
75758303|NCT00378534|Drug|Cyclosporine|Therapeutic
75758304|NCT00378534|Drug|Cyclophosphamide|Therapeutic
75758305|NCT00378534|Other|FILGRASTIM (G-CSF)|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. Stem cell Donors will receive G-CSF for stem cell mobilization. The stem cell collection aspect of this protocol is not investigational.
75758306|NCT00377676|Drug|Cycloset|Usual diabetes therapy plus Cycloset
75758307|NCT00377676|Drug|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
75758308|NCT00377520|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
75758309|NCT00377364|Drug|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
76068845|NCT00424840|Drug|Bortezomib 1.8 mg/m2|Level III (every 21 day cycle, D8) 1.8 mg/m2
76068846|NCT00424840|Drug|Carboplatin AUC 6|Carboplatin AUC6
76068847|NCT00424840|Drug|Bevacizumab|Bevacizumab 15 mg/kg
76068848|NCT00424840|Drug|Taxotere|Taxotere 70 + G-CSF
75458098|NCT01801878|Biological|Normal saline|Normal saline inject to the half of irradiated breast
75458099|NCT01801891|Device|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
75458100|NCT01801891|Other|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
75458101|NCT01801956|Behavioral|physical activity|free membership of a sport club
75610144|NCT02738983|Drug|Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
75610145|NCT02738983|Radiation|Radiotherapy|Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
75610146|NCT02739139|Dietary Supplement|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
75610147|NCT02739061|Behavioral|cognitive behavioral group therapy|"Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time."
75610148|NCT02739061|Drug|sertraline, fluvoxamine|Select specified drugs (sertraline, fluvoxamine)
75758310|NCT03831282|Device|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
75758311|NCT00365508|Drug|nicotine lozenge|nicotine lozenge
75758312|NCT00365508|Drug|nicotine patch|transdermal nicotine patch
75758313|NCT01048008|Drug|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
75758314|NCT01049568|Behavioral|Cell Phone Intervention|"Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
75758315|NCT00365352|Drug|XP13512 600MG|XP13512 600MG ONCE DAILY
75758316|NCT00365352|Drug|XP13512 1200MG|XP13512 1200MG ONCE DAILY
75758317|NCT00365352|Drug|PLACEBO|PLACEBO ONCE DAILY
75758318|NCT03992118|Behavioral|Parent coaching|Parents will be coached to implement behavioural strategies to address factors which are contributing to difficult mealtime behaviours and feeding challenges.
75758319|NCT01045746|Device|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
75758320|NCT01045746|Device|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
76068849|NCT00425386|Drug|erlotinib hydrochloride|"Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~150 mg/day, continuous daily"
75610149|NCT02739061|Other|cognitive behavioral group therapy and drug therapy|Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
75758321|NCT00376506|Device|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
75758322|NCT00376506|Device|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
75758323|NCT00410384|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
76068850|NCT00425386|Drug|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
75458102|NCT01801956|Other|Motivational interview|Four motivational interviews by instructors of the local sport club
75610150|NCT02746003|Other|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
75610151|NCT02745925|Drug|Ibuprofen|
75758324|NCT00410384|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
75758325|NCT00410384|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
75758326|NCT00370032|Drug|alosetron|
75758327|NCT00410072|Drug|Entecavir|Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
75758328|NCT00410072|Drug|Entecavir + Tenofovir|Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
75758329|NCT00409838|Drug|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg <60 kg); (750 mg 60-100 kg); (1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
75758330|NCT00409838|Drug|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
75758331|NCT00409838|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
75758332|NCT00409838|Drug|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
75758333|NCT00409838|Drug|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
75758334|NCT01041872|Drug|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
76068851|NCT00425386|Procedure|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
76068852|NCT04345978|Behavioral|Fasting hours|Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
76068853|NCT01164202|Drug|sunitinib malate|placebo 3cps/days 4 weeks over 6 during 1 year
75610152|NCT04374253|Drug|Gantenerumab|Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
75610153|NCT04374253|Drug|Gantenerumab|Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
75758335|NCT01041872|Drug|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
75758336|NCT01041872|Drug|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
75758337|NCT01041872|Drug|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
75758338|NCT01041872|Drug|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
75758339|NCT01041872|Drug|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
75758340|NCT01041950|Procedure|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
75758341|NCT00399542|Drug|Lubiprostone|
75758342|NCT00399542|Drug|Placebo|
75758343|NCT01039766|Drug|Oxytocin|A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
75758344|NCT01039766|Drug|placebo - saline nasal spray|A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
76068854|NCT01164202|Drug|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
76068855|NCT01164202|Procedure|transarterial chemoembolization|Chimioembolisation
75610154|NCT02738905|Drug|Rifaximin|One 550 mg tablet taken orally two times a day.
75610155|NCT02738827|Procedure|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
75758345|NCT00409682|Biological|Adalimumab|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
75758346|NCT00409682|Biological|Adalimumab|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
76068856|NCT01794910|Other|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
76068857|NCT05281588|Procedure|Micro-osteoperforations|All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
76068858|NCT02112370|Drug|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
75610156|NCT02738749|Device|Implantable cardioverter-defibrillator (ICD)|Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
75610157|NCT02738671|Behavioral|Cognitive assessment|
75610158|NCT02738671|Other|functional magnetic resonance imaging|
75610159|NCT02738671|Other|olfactory function measurement|
75610160|NCT02738671|Procedure|bariatric surgery|Only a subgroup of the subjects will have the bariatric surgery.
75610161|NCT02738437|Device|Kryptonite-bone cement|
75610162|NCT02734459|Drug|cataract surgery|"the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery."
75610163|NCT02745613|Other|8 weeks of combined exercise intervention|The subjects will undergo an 8 week combined exercise intervention
75758347|NCT00409682|Biological|Adalimumab|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
75758348|NCT01034930|Procedure|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
75758349|NCT03993782|Other|A19010-R|A snus product
75758350|NCT03993782|Other|B19010-O|A snus product
76068859|NCT02112370|Other|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
76068860|NCT02112838|Drug|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
76068861|NCT02112838|Drug|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
76068862|NCT02112838|Drug|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
75458103|NCT01801956|Other|Virtual arena|Uploading of training data from a GPS-watch to a virtual arena
75458104|NCT01801969|Other|Rehabilitation service|"Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~Size of the municipality responsible for providing rehabilitation services after discharge from hospital"
75458105|NCT01802008|Procedure|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
75458106|NCT01802008|Procedure|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
75458107|NCT01802021|Drug|Astagalus-based Formula: Qingshu-Yiqi-Tang|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months"
75610164|NCT02745691|Other|Surgery|Thoracic surgery for lung cancer
75610165|NCT02745691|Other|Radiochemotherapy|Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
75758351|NCT01039844|Drug|LOC-paclitaxel|"Phase I Starting Dose: 100 mg/m^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
75758352|NCT01042028|Drug|Everolimus, Cetuximab, Irinotecan|Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
75758353|NCT01042028|Drug|Capecitabine, Oxaliplatine|Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
75758354|NCT03993626|Drug|CXD101 in Combination With Nivolumab|HDAC inhibitor in combination with anti-PD-1 monoclonal antibody
75758355|NCT01042106|Drug|DSP-8658|Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
75758356|NCT01042106|Drug|Placebo|Placebo 2.5, 10, 20, 40 mg orally once daily
75758357|NCT01042184|Drug|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
75758358|NCT01042184|Drug|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
75758359|NCT01042184|Drug|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
75758360|NCT01035008|Procedure|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
75758361|NCT00398216|Drug|DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor|
75758362|NCT00398138|Biological|WT-1 analog peptide vaccine|
75758363|NCT00398138|Biological|incomplete Freund's adjuvant|
75758364|NCT00398138|Biological|sargramostim|
76068863|NCT00427336|Drug|Fludarabine|30 mg/m^2 by vein daily over 30 minutes
76068864|NCT00427336|Drug|Cyclophosphamide|300 mg/m^2 by vein daily over 2 hours
76068865|NCT00427336|Drug|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
75758365|NCT00398138|Genetic|polymerase chain reaction|
75758366|NCT00398138|Other|flow cytometry|
75758367|NCT00398138|Other|immunoenzyme technique|
75610166|NCT02745691|Other|Targeted therapy|New targeted therapies for lung cancer
75758368|NCT01042262|Other|Oxygen|100% Oxygen at a flow of 2 L/min
76068866|NCT00371176|Behavioral|Exposure therapy|A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
75458108|NCT01802047|Procedure|milk expression with electric pump|
75758369|NCT01042262|Other|Placebo|No oxygen flow
75758370|NCT00397982|Biological|Bevacizumab|Given IV
75758371|NCT00397982|Other|Laboratory Biomarker Analysis|Correlative studies
75758372|NCT00397982|Drug|Temsirolimus|Given IV
75758373|NCT00397982|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection
75758374|NCT03993470|Behavioral|Short foot excercise for intrinsec muscles of the foot|to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
75758375|NCT01040000|Drug|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
75758376|NCT01035086|Dietary Supplement|fabricated food|The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
75758377|NCT00408902|Drug|tandutinib|Given orally, 500 mg bid daily
75758378|NCT00408902|Other|laboratory biomarker analysis|Correlative studies
76068867|NCT00371176|Drug|D-Cycloserine|A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
75458109|NCT01802099|Other|Enteral nutrition|
75610167|NCT02745691|Other|Immunotherapy|New immunotherapies for lung cancer
76068868|NCT00371176|Other|Placebo pill|
75458110|NCT01802099|Other|Parenteral nutrition|
76068869|NCT00371644|Behavioral|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
75458111|NCT01802112|Dietary Supplement|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
75458112|NCT01802112|Other|placebo|15gr placebo
75458113|NCT01802125|Other|laboratory biomarker analysis|Correlative studies
75458114|NCT01802138|Biological|Activated T lymphocyte|intravenous dripping of 200 ml (10^9~2*10^10 lymphocytes) for 1 hour.
75610168|NCT02734381|Other|Elderly patients|Elderly patients who visited the Emergency Department
75610169|NCT05628415|Procedure|Non-powered AeonTM Endostapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the non-powered Aeon™ Endostapler (Lexington medical) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
75758379|NCT00397514|Procedure|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
75758380|NCT03715166|Drug|Bumetanide Oral Solution|Oral Solution dosed at 0.5mg/mL Taken twice daily
75758381|NCT03715166|Drug|Placebo|Oral Solution Taken twice daily
75758382|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
75758383|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
75758384|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
75758385|NCT00397046|Drug|neratinib|HKI-272
75758386|NCT01042340|Other|Calogen® - an energy dense oleic acid based formula|A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
76068870|NCT00371644|Behavioral|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
75610170|NCT05628415|Procedure|Echelon FLEX™ Powered plus Stapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the Echelon FLEX™ Powered plus Stapler (Ethicon) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
75758387|NCT01035242|Behavioral|"association splitting"|"Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened."
75758388|NCT01035242|Behavioral|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
75758389|NCT01042418|Other|Effect of breakfasts with whole vs milled rye kernels on appetite|Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
75758390|NCT01042574|Drug|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
75758391|NCT01042652|Drug|Raltegravir|Raltegarvir 400mg bid
75758392|NCT01040078|Biological|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
75904207|NCT02163798|Behavioral|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
76068871|NCT00428584|Drug|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
75610171|NCT02745769|Drug|Ramucirumab|Administered IV
75610172|NCT02745769|Drug|Merestinib|Administered orally
75610173|NCT02745769|Drug|Abemaciclib|Administered orally
75758393|NCT01040078|Biological|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
75758394|NCT01040078|Biological|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
75610174|NCT04370041|Device|Dokimos Plus aortic valve|Dokimos Plus aortic valve
75610175|NCT05629663|Device|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
75758395|NCT01035320|Drug|Ezetimibe|After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
76068872|NCT00428584|Drug|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
75610176|NCT03636607|Diagnostic Test|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
76068873|NCT00428974|Drug|CF101 1mg|CF101 1 mg q12 hours for 12 weeks
76068874|NCT00428974|Drug|CF101 2mg|CF101 2 mg q12 hours for 12 weeks
76068875|NCT00428974|Drug|CF101 4mg|CF101 4 mg q12 hours for 12 weeks
76068876|NCT00428974|Drug|Placebo|Placebo tablets q12 hours for 12 weeks
76068877|NCT05187286|Drug|Apixaban|Administered as directed by treating physician
76068878|NCT00372970|Drug|Botulinum toxin A|200 U given by injection into the pylorus.
76068879|NCT00372970|Drug|Placebo|saline injection into pylorus.
76068880|NCT00373360|Drug|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
76068881|NCT00430768|Biological|rAAV1-CB-hAAT|
75758396|NCT01042730|Drug|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
75904208|NCT02163798|Behavioral|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
75758397|NCT00396812|Drug|Rituximab|"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
75758398|NCT01566578|Drug|Human recombinant epidermal growth factor|topical
75758399|NCT01566578|Other|Placebo cream|Dermal cream without EGF
75758400|NCT01040234|Procedure|Bilateral dual TAP block|Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
75758401|NCT01042886|Behavioral|PILI 'Ohana Lifestyle Program|9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
75758402|NCT01042886|Behavioral|Standard Behavioral Weight Loss Maintenance Program|9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
75758403|NCT00396656|Drug|Atenolol|100 mg tablets orally once a day (od) in the morning.
75758404|NCT00396656|Drug|Hydrochlorothiazide (HCTZ))|12.5 or 25 mg tablets orally once a day (od) in the morning.
75758405|NCT00396656|Drug|Valsartan|80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
75758406|NCT01042964|Drug|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
75458115|NCT01802164|Device|A non-absorbable composite mesh (Ethicon Physiomesh)|To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
75610177|NCT02737969|Device|Transesophageal Echocardiography/angiography (TEE/Angio)|"The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.~The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor."
75758407|NCT01043042|Other|No interventions will be used in this study|No interventions will be used in this study
75610178|NCT02734225|Other|Functional Recovery|Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
75610179|NCT02734225|Other|Balance Training|Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
75610180|NCT02734225|Other|Dynamometric Platform Training|Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
75758408|NCT00408434|Drug|CS-7017|CS-7017 0.05mg and 1.0mg tablets
75758409|NCT01043120|Drug|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
75758410|NCT01043120|Drug|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
75758411|NCT01043198|Genetic|Clinical examination and blood sampling for biological and genetic analysis|"Clinical examination and precise description of the phenotype (questionnaire)~Standardized screening with :~radiological (hands, feet, spine ; and renal ultrasonography)~biological (hormonal, metabolic, and basic genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))"
75758412|NCT01323764|Device|ShuntCheck test|Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
75758413|NCT01040312|Drug|CPT-11|CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
75758414|NCT01040312|Drug|Platinum analogues|Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
75758415|NCT01043276|Drug|Treatment A|PF-00258210 220 µg using inhaler A
75758416|NCT01043276|Drug|Treatment B|PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
75758417|NCT01043276|Drug|Treatment C|PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
75904209|NCT04461002|Other|Retrospective analysis|Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
75458116|NCT01802177|Procedure|UVB excimer light|
75458117|NCT01802190|Genetic|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
75458118|NCT01802229|Procedure|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
75458119|NCT01802229|Procedure|Fascial suture|The port-site hole is closed with simple suture of the fascia
75458120|NCT01802255|Drug|Sevoflurane|Sedation with inhaled anesthetic via AnaConDa.
75458121|NCT01802255|Drug|Midazolam|Intravenous sedation.
75610181|NCT02745223|Drug|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
75904210|NCT04985578|Other|Dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
75904211|NCT04985578|Other|Sham dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds with a sham needle without tip.
75458122|NCT01802268|Drug|Conversion from Tacrolimus to Sirolimus|
75458123|NCT01802268|Drug|Maintenance on tacrolimus|
75758418|NCT01043276|Drug|Treatment D|PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
75458124|NCT01802294|Behavioral|Parenting Program|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
75458125|NCT01802307|Radiation|Brachytherapy|
75610182|NCT02745223|Drug|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
75758419|NCT01043276|Drug|Treatment E|PF-00258210 220 µg using inhaler B
75758420|NCT01043354|Behavioral|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
75758421|NCT01043354|Behavioral|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
75758422|NCT01043354|Behavioral|attention placebo intervention|6 monthly counseling sessions about general health topics
75758423|NCT00418184|Dietary Supplement|Phosphatidylserine-Omega3|Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
75758424|NCT00418184|Other|Colored cellulose tainted with fishy odor|as arm 1
75758425|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)"
75758426|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)"
75758427|NCT00407030|Drug|Placebo|Placebo
75758428|NCT00406718|Behavioral|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
75758429|NCT00406718|Behavioral|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
75758430|NCT00406718|Behavioral|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
75758431|NCT01035476|Behavioral|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
75758432|NCT01043510|Drug|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
75758433|NCT01043510|Drug|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
75758434|NCT01043588|Procedure|TURP|TransUrethral Resection of the Prostate
75758435|NCT01043588|Procedure|PVP|Photo selective Vaporization of the Prostate
75758436|NCT01043666|Drug|YM178|oral
75758437|NCT01043666|Drug|Placebo|oral
75758438|NCT01043666|Drug|tolterodine ER|oral
75904212|NCT03487874|Procedure|Conventional interscalene block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are blocked.
75904213|NCT03487874|Procedure|Interscalene block with C8 root block|Under ultrasound guidance, the 5th to 8th cervical nerve roots are blocked.
75904214|NCT03487874|Drug|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
75904215|NCT03074110|Device|Isocapnic hyperventilation|Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
75458126|NCT01802359|Drug|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
75610183|NCT02737813|Drug|Isobaric marcaine|Isobaric marcaine 2.2 mL for spinal block
75610184|NCT02737813|Drug|Hyperbaric marcaine|Hyperbaric marcaine 2.2 mL for spinal block
75610185|NCT03630913|Procedure|Tagged axillary metastatic node|"First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy."
75610186|NCT02745379|Procedure|BFPSCs+ DFDBA+ PRF|
75610187|NCT02745379|Procedure|DFDBA + PRF|
75904216|NCT02160366|Other|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
75610188|NCT02745301|Other|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
75758439|NCT01035554|Other|Self-Paced Programmed Instruction (SPPI)|If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.
75758440|NCT01035554|Other|Home Blood Pressure Monitor|The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.
75758441|NCT01035554|Other|Usual Care|Standard care
75458127|NCT01802372|Behavioral|WHO CVD risk assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
75758442|NCT01035554|Other|Printed Materials|National Institutes of Health Printed Materials on hypertension
75758443|NCT01040390|Drug|Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
75758444|NCT00394706|Device|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
75758445|NCT00394706|Device|Sham ITD|Sham ITD
75758446|NCT00394706|Other|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
75758447|NCT00394706|Other|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
75758448|NCT00394472|Drug|AZD3355|
75758449|NCT00419120|Biological|Autologous neo bladder construct|augmentation cystoplasty with autologous neo-bladder construct
75758450|NCT00395642|Device|Kronos LV-T, Lumax HF-T|Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
75458128|NCT01802372|Behavioral|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
75458129|NCT01802424|Behavioral|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
75610189|NCT02737735|Drug|standard chemotherapy medicine combined with Chinese herbs|
75610190|NCT02737735|Drug|standard chemotherapy medicine|
75610191|NCT02738515|Drug|0.75 % Boric Acid|After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
75610192|NCT02738515|Drug|placebo|After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
75758451|NCT00395486|Drug|Rosuvastatin|10mg
75758452|NCT00395486|Drug|Atorvastatin|10mg
75758453|NCT01043744|Drug|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~1 tablet (for patients weighing 5-14 kg)~2 tablets (for patients weighing 15-24 kg)"
75758454|NCT00395018|Drug|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
75758455|NCT01036412|Drug|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
76072405|NCT00499083|Genetic|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
75758456|NCT01036412|Behavioral|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
75610193|NCT02744599|Device|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
75758457|NCT00375518|Drug|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
75758458|NCT00375518|Drug|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
75758459|NCT01045772|Drug|rilonacept|160mg of rilonacept 1x/week
75758460|NCT01045928|Drug|lenalidomide|Given orally
75758461|NCT01045928|Biological|rituximab|Given IV
75904217|NCT04989400|Drug|Ulipristal Acetate|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
75610194|NCT00636415|Drug|morphine|1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
75610195|NCT02733835|Drug|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
75610196|NCT02737423|Drug|cholecalciferol|Effect of Vitamin D on the symptoms of diabetic neuropathy
75904218|NCT04989400|Drug|Misoprostol|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
75458130|NCT01802450|Drug|Dasatinib|
75610197|NCT02694913|Other|Non Interventional|This is a non therapeutic, pilot study.
75610198|NCT02737345|Other|Rotem|
75610199|NCT05629507|Device|Virtual Reality|"The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios)."
75758462|NCT01045928|Genetic|polymerase chain reaction|Correlative study
75758463|NCT01045928|Genetic|nucleic acid sequencing|Correlative study
75458131|NCT01802476|Drug|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
75458132|NCT01802476|Drug|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
75458133|NCT01802489|Drug|Amiloride|
75458134|NCT01802489|Drug|Placebo|Placebo capsule identical in appearance to Amiloride 10mg capsule
75458135|NCT01802502|Drug|Rifampicin intravenous|
75458136|NCT01802502|Drug|Oral rifampicin|
75458137|NCT01802541|Dietary Supplement|diacylglycerol oil|
75758464|NCT01045928|Genetic|polymorphism analysis|Correlative study
75758465|NCT01045928|Other|flow cytometry|Correlative study
75758466|NCT01045928|Other|laboratory biomarker analysis|Correlative study
75758467|NCT00256750|Drug|Cyclosporine (CsA)|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
75758468|NCT00256750|Drug|Belatacept LI (less intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
75758469|NCT00256750|Drug|Belatacept MI (more intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
75758470|NCT00279201|Drug|Insulin glargine|Subcutaneous injection daily
75904219|NCT02167230|Procedure|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
75758471|NCT00279201|Drug|Lispro Low Mix|Subcutaneous injection twice daily.
75758472|NCT00279201|Drug|Lispro Mid Mix|Lispro Mid Mix subcutaneous injection 3 times daily.
75758473|NCT00279201|Drug|Lispro|Lispro subcutaneous injection 3 times daily.
75758474|NCT03741634|Other|Multi-sectoral agricultural intervention|Adult participants in the intervention arm receive a loan (~$175) from a well-established Kenyan bank used to get a human-powered water pump, seeds, fertilizers and, pesticides, and education in financial management and sustainable farming practices.
75758475|NCT03969394|Diagnostic Test|Medical imaging|Medical Imaging consisting of 1 MRI and 1 echocardiography at baseline
75758476|NCT03973060|Device|Concentric-eccentric muscular work|For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.
75758477|NCT03973060|Genetic|Genetic polymorphism|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.
75758478|NCT03969784|Other|blood draw, tumoral biopsy tissus|Patient will have specific blood draw and part of their tumoral tissu biopsied
75758479|NCT01073956|Procedure|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
75758480|NCT01073956|Procedure|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
75758481|NCT01073956|Procedure|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
75458138|NCT01802541|Dietary Supplement|triacylglycerol oil|
75458139|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
75758482|NCT00203476|Drug|Niacin|
75758483|NCT00203476|Drug|Colestipol|
75758484|NCT00203476|Drug|Ezetimibe|
75758485|NCT00203242|Drug|Depacon IV and Depakote ER|
76072406|NCT00499083|Genetic|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
75458140|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks"
75458141|NCT01802619|Other|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
75458142|NCT01802619|Other|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
75458143|NCT01802645|Drug|Cetuximab|
75458144|NCT01802645|Drug|Bevacizumab|
75458145|NCT01802645|Drug|Irinotecan|
75458146|NCT01802645|Drug|Oxaliplatin|
75458147|NCT01802645|Drug|5-FU|
75458148|NCT01802645|Drug|Folinic Acid|
75458149|NCT01802658|Drug|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
75458150|NCT01802658|Drug|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
75758486|NCT00200356|Drug|Edaravone|Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
75758487|NCT00200356|Drug|Sodium Ozagrel|Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
75758488|NCT01326052|Procedure|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
75758489|NCT01326052|Procedure|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
75758490|NCT00227344|Device|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
75758491|NCT00227344|Drug|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
75758492|NCT00227266|Drug|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
75758493|NCT00227266|Drug|Placebo|
75758494|NCT00256282|Drug|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
75758495|NCT00256282|Drug|Docetaxel|40mg/m2 IV over 1 hour every 14 days
75758496|NCT00256282|Drug|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
75758497|NCT01074112|Device|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
75758498|NCT01074112|Device|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
75904220|NCT02167230|Procedure|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
75458151|NCT01802671|Other|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
75904221|NCT04989088|Device|ProComp5 Infiniti System w/BioGraph Infiniti Software|Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)
75904222|NCT04989088|Device|ProComp5 Infiniti System w/recorded videos|Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)
75904223|NCT03485768|Procedure|percutaneous disc decompression with coblation nucleoplasty|PDCN was performed using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA) under local anesthesia. The introducer cannula was then pierced into the target intervertebral disc through an anterior lateral approach. The tip of the cannula stylet was aimed for the center of the nucleus in both the coronal and sagittal planes. The stylet was withdrawn from the introducer cannula and replaced with the Perc-DC SpineWand. The wand was advanced until its tip extended approximately 5 mm beyond the tip of the cannula. A short initial coagulation was performed upon wand insertion to ensure correct placement, if stimulation or movement was detected, the wand was repositioned. As the wand was drawn back out through the disc, ablation energy was set to level three and three ablation cycles of 5-12soconds each were performed, rotating the wand tip 180 degree each time to form three consecutive pockets within the disc.
75904224|NCT03485768|Procedure|Manual Therapy (SNAGs plus PJMs)|"(1) sustained natural apophyseal glides (SNAGs): Use the methods described in Mulligan BR. Manual therapy NAGS, SNAGS, MWMS etc. 5th ed. Wellington, New Zealand: Plane View Services; 2004. Three sessions per week and for a total of four to six weeks according to the patients' condition, they were asked to continue the self-SNAG once daily until the last follow-up, and recorded in a diary. (2) passive joint mobilisations (PJMs): Use the methods described in Maitland G. Vertebral manipulation. 6th ed. Oxford: Butterworth Heinemann; 2001. For three repetitions weekly and for a total of four to six weeks according to the patients' condition, then once a day were commenced as a home exercise to be continued until the last follow-up, and recorded in a diary."
75610200|NCT02737267|Behavioral|Moderately high protein diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction."
75610201|NCT02737267|Behavioral|Low fat diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat"
75610202|NCT02744911|Device|SpeechVive device|The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
75758499|NCT01074112|Procedure|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
75758500|NCT01074112|Device|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
75758501|NCT01074112|Device|Cardiac Ultrasound|Ultrasound views of the heart
75758502|NCT00266877|Drug|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
75904225|NCT02163954|Drug|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
75758503|NCT02532075|Other|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
75758504|NCT02532075|Other|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
75758505|NCT02532075|Other|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
75758506|NCT02532075|Other|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
75758507|NCT00256204|Drug|Rasagiline Mesylate|tablet, 1mg once daily
75758508|NCT00256204|Drug|Rasagiline Mesylate|tablet, 2mg once daily
75904226|NCT02163954|Drug|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
75458152|NCT01802671|Behavioral|cognitive behavioural therapy (CBT)|"Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~Cognitive restructuring techniques~Behavioural therapy and activity pacing~Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions."
75463330|NCT05854121|Diagnostic Test|Constrained Induced Movement Therapy|Constrained Induced Movement Therapy for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
75758509|NCT00256204|Other|Placebo|Placebo
75463331|NCT05854108|Diagnostic Test|Cervical Traction|Cervical Traction to Improve Pain and Quality of Life in Cervical Radiculopathy
75610203|NCT02744911|Behavioral|Telemedicine interaction|Participants will interact with the speech-language pathologist using the telemedicine platform from their home.
75610204|NCT02744911|Behavioral|In person interaction|Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
75758510|NCT00256126|Drug|Saizen|Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
75463332|NCT05854108|Diagnostic Test|Snag|Snag to Improve Pain and Quality of Life in Cervical Radiculopathy
75463333|NCT05854095|Device|Pivot Bridge|transcatheter for short-term treat Functional Tricuspid regurgitation
75758511|NCT00256126|Drug|Saizen|Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
75758512|NCT03972358|Drug|Mifepristone|All participants will receive 200 mg mifepristone, to be taken orally on day 1.
75758513|NCT03972358|Drug|Misoprostol|All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
75758514|NCT01073332|Dietary Supplement|Arginine antioxidant supplements|The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
75758515|NCT01073332|Dietary Supplement|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
75758516|NCT03969316|Procedure|Transversus abdominis plane block, Quadratus lumborum block|The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
75758517|NCT03972046|Drug|Talimogene laherparepvec (T-Vec)|Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
75758518|NCT03972046|Drug|Dabrafenib (BRAF Inhibitor)|Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
75904227|NCT04985656|Drug|Pevonedistat|Pevonedistat IV infusion
75904228|NCT04985656|Drug|Decitabine|Decitabine tablets
75758519|NCT03972046|Drug|Trametinib (MEK Inhibitor)|Trametinib (MEK Inhibitor) 2 mg by mouth once a day
75610205|NCT02737111|Behavioral|Initial Screening Process|The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.
75758520|NCT01073488|Behavioral|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
75758521|NCT01071772|Drug|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
76068882|NCT00455650|Drug|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
75458153|NCT01802671|Behavioral|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
76068883|NCT00455650|Drug|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
75458154|NCT01802684|Biological|aflibercept|Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
75458155|NCT01802697|Drug|IdeS|
75758522|NCT01074346|Drug|Interferon-β-1a|Interferon-β-1a according to the standard practice
75758523|NCT03971890|Other|Dance therapy|The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.
75758524|NCT03971890|Other|Educational group|The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
75758525|NCT00278889|Drug|AZD2171|oral tablet
75458156|NCT01802697|Drug|Placebo|
75458157|NCT01802736|Behavioral|Motivational intervention counselling plus SPP|
76068884|NCT00455650|Drug|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
76068885|NCT01794988|Behavioral|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
76068886|NCT01794988|Behavioral|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
76068887|NCT01794988|Behavioral|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
76068888|NCT01794988|Behavioral|NO TIVR|Control - no intervention
75458158|NCT01802762|Device|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
75758526|NCT00278889|Drug|5-fluorouracil|intravenous infusion
75758527|NCT00278889|Drug|Leucovorin|intravenous infusion
75758528|NCT00278889|Drug|Oxaliplatin|intravenous infusion
75758529|NCT00278889|Drug|Bevacizumab|intravenous infusion
76068889|NCT02114164|Device|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
75758530|NCT01070745|Drug|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
75758531|NCT01070745|Drug|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
75758532|NCT01071057|Drug|Naloxone|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
75758533|NCT01071057|Drug|Saline/Morphine|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
75758534|NCT00278109|Drug|cyclophosphamide|chemotherapy
75904229|NCT04985656|Drug|Cedazuridine|Cedazuridine tablets
75904230|NCT02167308|Device|Laser acupuncture|a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
76068890|NCT02114164|Device|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
75458159|NCT01802801|Other|embryo development|intra- and inter-observator analysis
75458160|NCT01802814|Drug|SR-A + Epratuzumab|
75458161|NCT01802814|Drug|SR-B + Epratuzumab|
75458162|NCT01802853|Drug|RO6811135|Single subcutaneous dose
75610206|NCT02737111|Behavioral|Information and Informed Consent|The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation
75610207|NCT02737111|Behavioral|Interview|Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.
75458163|NCT01802853|Drug|RO6811135|Single intravenous dose
75458164|NCT01802892|Drug|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
75458165|NCT01802892|Drug|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
75458166|NCT01802892|Drug|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
75458167|NCT01802905|Genetic|in depth genomic sequencing|Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
75458168|NCT01802918|Drug|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
75610208|NCT02737111|Behavioral|Validated Questionnaires|Each member of the family will complete the mood and quality of life questionnaires.
75458169|NCT01802918|Drug|Placebo|Visually matching GSK2838232
75458170|NCT01802918|Drug|Ritonavir|100mg tablets once daily for 12 days
75458171|NCT01802931|Drug|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
75758535|NCT00278109|Drug|Doxorubicin|doxorubicin
75758536|NCT00278109|Radiation|radiation|radiation
75758537|NCT00296517|Drug|323U66 (Bupropion Hydrochloride Sustained Release)|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
75758538|NCT00296517|Drug|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
75904231|NCT03071224|Drug|[18F] MNI-946|Subjects will undergo PET imaging using [18F]MNI-946, a PET radioligand for imaging tau.
75904232|NCT03071224|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-946.
76068891|NCT00374842|Biological|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
76068892|NCT00374842|Biological|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
76068893|NCT00431626|Drug|Dutasteride (Avodart)|
76068894|NCT00431626|Drug|Placebo|Placebo before and after treatment of TURP
76068895|NCT01796626|Device|M22 ResurFX module|The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
75758539|NCT00224770|Drug|MIS+Cathflo Activase (drug)|MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
75758540|NCT00224770|Procedure|Intraoperative stereotactic CT-Guided Endoscopic Surgery|Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
75904233|NCT04682990|Device|Tor Vergata Electronic Nose (TV eNose)|Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
75904234|NCT04682990|Other|Survey & Physical Exam|Perform a oriented survey for risk factors, symptoms and a complete physical exam.
75904235|NCT04682990|Diagnostic Test|TB LAMP test|Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
75458172|NCT01802931|Drug|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
76068896|NCT00376558|Behavioral|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
76068897|NCT00455962|Drug|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
76068898|NCT00455962|Drug|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
76068899|NCT00434278|Drug|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
76068900|NCT00434278|Drug|placebo|2.5 mg inhalation dose twice daily for 14±2 days
76068901|NCT00434356|Drug|bevacizumab|Intravenous repeating dose
75610209|NCT02737111|Behavioral|Debrief|At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.
75610210|NCT02733679|Drug|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
75904236|NCT04682990|Other|Sputum Samples|Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
76068902|NCT00434356|Drug|sunitinib|Oral repeating dose
75458173|NCT01802944|Drug|Intranasal Insulin|
75458174|NCT01802944|Drug|Placebos|
75610211|NCT02733679|Drug|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
75610212|NCT02736877|Procedure|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
75610213|NCT02736877|Procedure|Conventional Microscope|corneal transplantation guided by Conventional Microscope
75904237|NCT04682990|Other|Chest X-Ray|Perform anteroposterior chest X-ray (if required by the medical staff)
75904238|NCT04682990|Other|Follow Up 5 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
75904239|NCT04682990|Other|Follow Up & 15 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
76068903|NCT00434356|Drug|paclitaxel|Intravenous repeating dose
76068904|NCT00376948|Dietary Supplement|genistein|
76068905|NCT00376948|Drug|erlotinib hydrochloride|
76068906|NCT00376948|Drug|gemcitabine hydrochloride|
76068907|NCT01795768|Drug|AZD 4547|
76068908|NCT01795924|Drug|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
76068909|NCT01796080|Other|Mueller manoeuvre|
76068910|NCT01796080|Other|Inspiratory threshold|
76068911|NCT01796080|Other|Expiratory apnoea|
76068912|NCT01796080|Other|Steady state normal breathing|
76068913|NCT00438100|Drug|Capecitabine|1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
75458175|NCT01802957|Other|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
75463334|NCT05854082|Drug|Lidocaine 2% Polyampoule|Three intervention conditions in a repeated measures design - lidocaine; no perturbation, candy (lollipop)
76068914|NCT00438100|Drug|S-1|80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
75463335|NCT05854056|Procedure|Accelerated rehabilitation protocol|See Arms section
75463336|NCT05854056|Procedure|Conservative rehabilitation protocol|See Arms section
75610214|NCT02695147|Procedure|TAVI|
75610215|NCT02744443|Dietary Supplement|Leucine|
75610216|NCT02744443|Dietary Supplement|Placebo|
75610217|NCT02732353|Dietary Supplement|Minced beef|Cow meat protein supplement
75610218|NCT02732353|Dietary Supplement|Hydrolyzed beef|Cow meat protein supplement
75610219|NCT02731963|Drug|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
75758541|NCT02531776|Device|Subcutaneous insertions of needles|"Various types of needles with different designs and mechanical properties.~Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson & Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).~Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.~Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.~No drugs are injected. Only the needle insertion is evaluated."
75758542|NCT00266409|Drug|Niravam|
75458176|NCT01802957|Other|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
75758543|NCT00266409|Drug|SSRI/SNRI|Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
75758544|NCT00277095|Device|ProACT (Adjustable Continence Therapy)|Implantable device to reduce urinary stress incontinence
75904240|NCT04682990|Other|Follow Up & 30 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
75904241|NCT02164032|Drug|Intranasal insulin administration|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
76068915|NCT00438490|Drug|Recombinant Human Prolactin|
76068916|NCT00456508|Drug|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
75458177|NCT01802957|Other|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
75458178|NCT01802957|Other|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
75610220|NCT02731807|Dietary Supplement|Dose A: TA-65 24mg, powder|
75610221|NCT02731807|Dietary Supplement|Dose B: TA-65, 8mg, powder|
75610222|NCT02731807|Dietary Supplement|Dose C: TA-65 3.2mg, capsule|
75610223|NCT02731807|Dietary Supplement|Dose D: TA-65 8mg, capsule|
75758545|NCT00265785|Drug|pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
75610224|NCT02731807|Dietary Supplement|Dose E: TA-65 32mg, capsule|
75610225|NCT02744521|Other|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
75610226|NCT04189705|Drug|MCT-SR|Rebamipide 150mg
75610227|NCT04189705|Drug|Mucosta Tab.|Rebamipide 100mg
75610228|NCT02731651|Procedure|open hysterectomy|Hysterectomy with laparotomy incision.
75610229|NCT02731651|Procedure|laparoscopic assisted vaginal hysterectomy|Hysterectomy with laparoscopic assisstance.
75758546|NCT00276159|Drug|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
75758547|NCT02532153|Drug|Ketamine Hydrochloride|Single open-label infusions
75758548|NCT01072227|Procedure|Sample Collection|Tissue
76068917|NCT02115646|Device|fractionated carbon dioxide laser|patients will have serial laser treatments
76068918|NCT00457366|Drug|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
76068919|NCT00457366|Drug|Haloperidol|given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
76068920|NCT00457366|Drug|Lorazepam|given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
76068921|NCT00457366|Drug|Cogentin|given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
76068922|NCT00458848|Drug|asparaginase|
76068923|NCT00458848|Drug|daunorubicin hydrochloride|
76068924|NCT00458848|Drug|etoposide|
76068925|NCT00458848|Drug|idarubicin|
76068926|NCT00458848|Drug|imatinib mesylate|
76068927|NCT00458848|Drug|mercaptopurine|
76068928|NCT00458848|Drug|methotrexate|
76068929|NCT00458848|Drug|methylprednisolone|
76068930|NCT00458848|Drug|mitoxantrone hydrochloride|
76068931|NCT00458848|Drug|prednisone|
76068932|NCT00458848|Drug|vincristine sulfate|
75758549|NCT00265395|Drug|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|"Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
75758550|NCT00265395|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"
75758551|NCT01582113|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
75610230|NCT02744131|Drug|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
75758552|NCT01582113|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
75904242|NCT02164032|Drug|Insulin Dilution Buffer (Novo Nordisk)|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
75904243|NCT02164032|Other|1H magnetic resonance spectroscopy|1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
75904244|NCT04985734|Diagnostic Test|Specific diagnostic work-up for ATTR-CM patients|Technetium-scintigraphy
75904245|NCT04682288|Drug|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
75904246|NCT00968149|Drug|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
75904247|NCT00968149|Drug|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
75904248|NCT02160444|Behavioral|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
76068933|NCT00458848|Procedure|allogeneic hematopoietic stem cell transplantation|
76068934|NCT00458848|Procedure|autologous hematopoietic stem cell transplantation|
76068935|NCT00458848|Procedure|peripheral blood stem cell transplantation|
75610231|NCT02744131|Drug|Metformin 1500mgs per day|
75610232|NCT02731885|Drug|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
75610233|NCT02731885|Drug|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
75610234|NCT05468749|Drug|CTP-543|Single 12 mg oral dose administered on Day 1
75610235|NCT02731495|Dietary Supplement|EGCG|EGCG (Epigallocatechin -3-gallate)
75610236|NCT02731495|Dietary Supplement|Placebo (deionized water)|
75758553|NCT00195442|Drug|Moroctocog alfa|Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
75758554|NCT01070823|Drug|Tysabri® (natalizumab)|Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
75610237|NCT02731573|Drug|D-PLEX|D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
75904249|NCT02160522|Device|Cuffed ETT|Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
75610238|NCT02731573|Procedure|Open heart surgery|Subject will undergo open heart surgery according to standard of care
75904250|NCT02167386|Behavioral|Enhanced PrEP Adherence|
75904251|NCT02167386|Behavioral|Standard PrEP Adherence|
75904252|NCT03989882|Other|Wheat germ energy ball|wheat germ mixed other ingredients to make an energy ball
75904253|NCT03989882|Other|Control|corresponding control without wheat germ
75904254|NCT02164110|Biological|Euvichol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
75904255|NCT02164110|Biological|Shanchol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
75904256|NCT03489512|Drug|A (Chloraprep)|Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
75904257|NCT03489512|Drug|B (Clorhexidine 2%)|Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
75904258|NCT02167464|Drug|Renin treatment-guided Therapeutics|Patients are treated based upon their renin levels according to an approved algorithm.
75904259|NCT02167464|Other|Referral Hypertension specialist|Patients are referred to a hypertension specialist.
75904260|NCT02167464|Drug|Aldosterone Antagonist|Spironolactone 12.5 - 25mg daily
76068936|NCT00458848|Radiation|radiation therapy|
76068937|NCT00459862|Other|laboratory biomarker analysis|Correlative study
76068938|NCT00459862|Drug|pazopanib hydrochloride|Given orally
76068939|NCT00461734|Other|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
75758555|NCT01071135|Drug|Quetiapine XR|Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
75758556|NCT03971968|Procedure|Skin replacement with artificial skin|Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
75758557|NCT00275301|Drug|olanzapine|Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
75758558|NCT02531997|Behavioral|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
75758559|NCT02531997|Behavioral|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
75758560|NCT03969238|Behavioral|Helpline|This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
75758561|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
75758562|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
75758563|NCT00251745|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
75758564|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
75904261|NCT03485612|Diagnostic Test|Change of Optic Nerve Sheath Diameter|In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
75758565|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
75904262|NCT05200351|Behavioral|Equine assisted Therapy (EAT)|15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.
75610239|NCT02733523|Behavioral|"Program Sentirnos bien (Feeling well)"|"Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food."
75610240|NCT02743975|Drug|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
75610241|NCT02743663|Procedure|Bronchodilator response|Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
75610242|NCT02743663|Procedure|Allergy Skin Test|Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
75758566|NCT03973762|Device|DR Grading with CAD|A CAD system is used to make DR grading.
75758567|NCT03973762|Other|DR Grading by expert panel|DR Grading by expert panel
76068940|NCT00438802|Drug|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
76068941|NCT00377572|Biological|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
75610243|NCT02743663|Procedure|Multiple-Breath Washout|Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach ~2%. Each test in duplicate and average is calculated.
75758568|NCT00359424|Drug|IV rt-PA alone|Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
75758569|NCT00359424|Other|endovascular therapy|Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
75610244|NCT02743663|Procedure|Forced Oscillation Technique|Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
75610245|NCT02743663|Procedure|Spirometry|Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
75758570|NCT03991026|Behavioral|Healthy food and Education/Cooking Classes|The intervention includes providing weekly seasonal produce and healthy foods to participants in addition to an education/cooking class that will be tailored to Diabetes Mellitus, Type II.
75758571|NCT02535234|Device|Novel System|A Novel full Continuous Positive Airway Pressure (CPAP) system - Prototype Device, Mask + Accessories
75758572|NCT02535234|Device|Traditional System|A Traditional full Continuous Positive Airway Pressure (CPAP) system- Released Device + Accessories, Prototype Mask
75904263|NCT02164188|Behavioral|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
75610246|NCT02743663|Drug|salbutamol|Given during bronchodilator response.
75610247|NCT02743663|Procedure|Nasal Brush|Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
75610248|NCT02743663|Procedure|Blood sample|8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
75610249|NCT02743663|Procedure|Basophil activation test|Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
75904264|NCT03485456|Drug|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
76068942|NCT00377572|Biological|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
76068943|NCT00438880|Drug|Agatolimod Sodium|Given IV
75904265|NCT03487562|Drug|DWP14012 Amg|DWP14012 Amg
75904266|NCT03487562|Drug|DWP14012 Bmg|DWP14012 Bmg
75904267|NCT03487562|Drug|Clarithromycin|Clarithromycin 500 mg
76068944|NCT00438880|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
75458179|NCT01802957|Other|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
75458180|NCT01802957|Other|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
75458181|NCT01802957|Other|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
75610250|NCT02743663|Procedure|Nasal swab|Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
75758573|NCT01049646|Drug|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
75758574|NCT01049646|Drug|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
75758575|NCT02286414|Drug|Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban|Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban
75758576|NCT02286414|Drug|Vitamin K antagonist: warfarin, fluindione, acenocoumarol|Exposure to vitamin K antagonist
75904268|NCT03487562|Drug|Amoxicillin|Amoxicillin 1 g
75904269|NCT03487562|Drug|Lansoprazole|Lansoprazole 30 mg
75904270|NCT02160600|Other|Standard multiphase CT|
75904271|NCT02160600|Other|split bolus Dual energy CT|
75904272|NCT03541434|Diagnostic Test|Complete Blood Count|White blood cell subgroups count
75758577|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
76068945|NCT00438880|Other|Laboratory Biomarker Analysis|Correlative study
75458182|NCT01802957|Other|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
75458183|NCT01802970|Drug|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
75458184|NCT01802996|Drug|Magnesium Isoglycyrrhizinate Injection|200mg IV on day 1-5
75610251|NCT02731417|Other|acupuncture|Acupuncture for women with post partum urinary retention
75610252|NCT02731417|Device|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
75610253|NCT02731339|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
75758578|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
75758579|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
75758580|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
75610254|NCT02731339|Behavioral|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
75758581|NCT01049724|Other|Tear collection|Tear collection
75758582|NCT00254566|Other|Moxifloxacin Placebo|1 capsule once daily for 5 days
75758583|NCT00254566|Drug|Moxifloxacin|1 X 400mg capsule once daily for 5 days
75758584|NCT00254566|Other|Azithromycin SR Placebo|single dose, oral.
75758585|NCT00254566|Drug|Azithromycin SR|single dose 2.0 g oral
76068946|NCT00438880|Procedure|Radionuclide Imaging|Undergo imaging scans
76068947|NCT00438880|Biological|Rituximab|Given IV
75758586|NCT02531542|Device|Echocardiography according to the READ method.|"Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.~A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels."
75758587|NCT00358956|Drug|ZD6474 (vandetanib)|100 mg once daily oral tablet
76068948|NCT00438880|Procedure|Single Photon Emission Computed Tomography|Undergo imaging scans
76068949|NCT00438880|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
76068950|NCT00462124|Device|Absorbable perirectal spacer|biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
76068951|NCT00378352|Drug|Epoetin alfa|Randomized
75610255|NCT02731339|Behavioral|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
75610256|NCT02731339|Behavioral|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
75610257|NCT02733211|Device|MD- Logic Closed Loop System|Closed Loop System
75610258|NCT02733211|Device|sensor augmented pump therapy|Sensor augmented pump therapy
75610259|NCT02743585|Device|Filmarray Blood Culture ID (BCID) panel|The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in < 1 - 1.5 hours
75758588|NCT01048086|Drug|Retinoic Acid|160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children <12 kg.
75758589|NCT01048086|Drug|Placebo|Placebo will be given in the same manner as retinoic acid in capsules that look identical.
75758590|NCT01052610|Drug|sublingual house dust mites allergen extract|Staloral 300 IR, Stallergenes, France
75758591|NCT01052610|Drug|placebo in sublingual applicator|placebo for Staloral 300 IR, Stallergenes, France
75758592|NCT03830892|Other|E-cigarette Lab Session 15 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
75758593|NCT03830892|Other|E-cigarette Lab Session 15 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
76068952|NCT00462280|Drug|lovastatin|Given PO
76068953|NCT00462280|Other|placebo|Given PO
76068954|NCT00462280|Procedure|biopsy|Correlative studies
76068955|NCT00462280|Procedure|laboratory biomarker analysis|Correlative studies
75610260|NCT02743585|Device|Rosco Diagnostica ESBL/carbapenemase screen kit|These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
75758594|NCT03830892|Other|E-cigarette Lab Session 30 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
75458185|NCT01803009|Behavioral|Patient views NCI CRC RAT|
75458186|NCT01803009|Behavioral|View presentation regarding current chance of having an advanced adenoma|
75904273|NCT03541434|Diagnostic Test|Tympanometry|Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance
75904274|NCT03541434|Procedure|Tonsillectomy and/or adenoidectomy|Excision of palatine and/or pharyngeal tonsils.
75904275|NCT05150522|Biological|BCMA CAR-T cells|BCMA CAR-T cells infusion
75904276|NCT02167542|Device|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
75458187|NCT01803035|Drug|LTX-109 1 %|
75904277|NCT02167542|Device|CPAP valve (Boussignac)|"Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2>92%."
75904278|NCT02167620|Drug|Metformin|Metformin will be dispensed on a biweekly basis, and pill counts conducted at each visit.
75904279|NCT02167620|Drug|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
76068956|NCT00381004|Drug|Cyclophosphamide|Course 1: 250 mg/m^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
76068957|NCT00381004|Drug|Fludarabine|Course 1: 25 mg/m^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
76068958|NCT00381004|Drug|Sargramostim|Course 1: 250 mcg/m^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m^2 SQ on Days -1 and Days 4 - 10
75458188|NCT01803035|Drug|LTX-109 2 %|
75458189|NCT01803035|Drug|Placebo gel|
75458190|NCT01803061|Behavioral|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
75458191|NCT01803087|Drug|Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1|
75458192|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).|
75458193|NCT01803087|Drug|BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)|
75458194|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) (CTR)|
75458195|NCT01803100|Other|No intervention|There is no intervention in this trial
75458196|NCT01803113|Device|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
75758595|NCT03830892|Other|E-cigarette Lab Session 30 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
75758596|NCT03830892|Other|Own Brand Session - E-cigarette|E-cigarette paired with own brand liquid and preferred power
75758597|NCT03830892|Other|Own Brand Session - E-cigarette/Cigarette|Own brand cigarette OR E-cigarette paired with own brand liquid and preferred power
75758598|NCT01048164|Procedure|Massage|Chair Massage
75904280|NCT03485300|Diagnostic Test|Liver and kidney function tests for patients with chronic liver or kidney diseases|Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected
75904281|NCT03485300|Behavioral|Non compliance of the patient|I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up
75458197|NCT01803139|Device|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
75458198|NCT01803178|Dietary Supplement|Plant Sterols|
75904282|NCT03485300|Drug|Drug or food interactions|The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
75904283|NCT02160756|Drug|JNJ-56021927 Softgel Capsule|Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
75904284|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 1|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
75904285|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 2|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
75904286|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 3|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
75458199|NCT01803178|Dietary Supplement|Placebo Product|
75458200|NCT01803191|Drug|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
75458201|NCT01803191|Drug|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
75458202|NCT01803217|Other|pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function|
75458203|NCT01803230|Dietary Supplement|creatine supplementation|creatine supplementation
75458204|NCT01803230|Dietary Supplement|Placebo|
75610261|NCT02733445|Drug|dasatinib|
75610262|NCT02733445|Drug|nilotinib|
75610263|NCT02731261|Other|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
75610264|NCT02731105|Drug|Acnatac® Gel left face|topical application
75758599|NCT01049880|Drug|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
75758600|NCT00253630|Other|Laboratory Biomarker Analysis|Correlative studies
75904287|NCT00963469|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
75610265|NCT02731105|Drug|Epiduo® Gel right face|topical application
76068959|NCT00381004|Drug|Rituximab|Course 1: 375 mg/m^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m^2 by vein over 2-6 Hours on Day 1
75610266|NCT02731105|Drug|Acnatac® Gel right face|topical application
75610267|NCT02731105|Drug|Epiduo® Gel left face|topical application
75610268|NCT02743429|Drug|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days."
75610269|NCT05454553|Other|myocardial perfusion SPECT|"For all participants, myocardial perfusion SPECT will be performed :~at 3, 6 and 12 months (post irradiation)"
75610270|NCT02730949|Dietary Supplement|D-chiro-inositol|Treated group
75758601|NCT00253630|Drug|Vorinostat|Given PO
75610271|NCT02730949|Dietary Supplement|Folic Acid|Control group
75458205|NCT01803243|Other|Ankle foot orthosis|Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.
75610272|NCT04205929|Drug|Placebo|Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
75758602|NCT00358644|Drug|Decitabine|20 mg/m^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
75758603|NCT01324908|Procedure|extracorporeal photopheresis|Undergo ECP
75758604|NCT01324908|Other|laboratory biomarker analysis|Correlative studies
75758605|NCT01048320|Drug|Gemcitabine|"The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.~Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:~Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute."
75758606|NCT01048320|Drug|Oxaliplatin|Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
75758607|NCT01048320|Drug|Imatinib|"Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.~Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total."
75904288|NCT00963469|Drug|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
75904289|NCT00963469|Drug|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
76068960|NCT00440050|Drug|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
76068961|NCT00440050|Drug|Placebo|2 placebo capsules twice a day for 18 months
76068962|NCT00440596|Behavioral|Mindfulness based stress reduction|8 weeks group MBSR
75458206|NCT01803243|Other|Shoe insole|The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.
75458207|NCT01803243|Other|Modified shoe with sole lift|The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
75610273|NCT04205929|Drug|Curcumin|Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
75610274|NCT03856645|Drug|OKG-0301|OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
75610275|NCT02695069|Procedure|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
75610276|NCT04190797|Device|Photobiomodulation + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
75758608|NCT03990480|Drug|valsartan (160 mg/d)|Group I treated with valsartan (160 mg/d, n = 100)
75758609|NCT03990480|Drug|amlodipine (10 mg/d).|Group II amlodipine (10 mg/d, n = 100).
75610277|NCT04190797|Device|Placebo + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
76068963|NCT00440596|Behavioral|Progressive Muscle Relaxation|8 weeks PMR in group format
76068964|NCT00381550|Drug|fludarabine phosphate|Given IV
75458208|NCT01803295|Device|40 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
75610278|NCT02743195|Dietary Supplement|Polyphenol/prebiotic blend|
75758610|NCT01052688|Other|Maternal blood draw of 30 to 50ml|Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
75758611|NCT01052766|Procedure|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
75758612|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
75758613|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
75758614|NCT00369486|Procedure|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
76068965|NCT00381550|Drug|triapine|Given IV
75904290|NCT05150366|Procedure|Trans thoracic echocardiography|trans thoracic echocardiography at the beggining and at the end of the placement of the Saint Jude Medical AMULET type prosthesis
75904291|NCT03733392|Device|Advisor HD Grid Mapping Catheter, Sensor Enabled|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
76068966|NCT00381550|Procedure|laboratory biomarker analysis|Correlative study
76068967|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
76068968|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
75904292|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
75458209|NCT01803295|Other|Standard of care MMC mixed with water|Standard of care 40mg MMC mixed with water
75458210|NCT01803295|Device|80 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
76068969|NCT00440830|Drug|placebo|placebo patch applied to smokers
75458211|NCT01803308|Drug|SB9200|Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.
75458212|NCT01803308|Drug|SB9200|Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
75610279|NCT02743039|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
75758615|NCT00369486|Drug|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
75758616|NCT00369486|Drug|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
76068970|NCT00440830|Drug|placebo|placebo patch applied to nonsmokers
76068971|NCT00464464|Behavioral|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
76068972|NCT00381628|Procedure|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
76068973|NCT00427804|Drug|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
75458213|NCT01803308|Drug|Placebo|Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
75458214|NCT01803321|Drug|rilonacept (IL-1 Trap)|
75458215|NCT01803321|Other|Placebo|
75610280|NCT03308773|Other|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
75610281|NCT02731183|Procedure|fecal microbiota transplantation|Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
76068974|NCT00381862|Drug|aprepitant|Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
76068975|NCT00381862|Drug|dexamethasone|Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
76068976|NCT00381862|Drug|fluorouracil|as per institutional standard of care
76068977|NCT00381862|Drug|irinotecan hydrochloride|as per institutional standard of care
75458216|NCT01803334|Other|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
75458217|NCT01803347|Drug|◦Drug: ASCs. + fibrin glue|Experimental group
75758617|NCT00369486|Drug|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
75758618|NCT00369486|Drug|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
75758619|NCT03992664|Other|EDUCATION|"The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects.~The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks."
75758620|NCT00363480|Drug|Salmeterol/Fluticasone 50/250 mcg|Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
75758621|NCT00363480|Drug|Salbutamol 100 mcg|This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
75758622|NCT00363480|Device|DISKUS™ powder inhalers|Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
75758623|NCT03990714|Procedure|Right hemicolectomy|It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal
75758624|NCT00223990|Biological|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine
75610282|NCT00636493|Device|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
75758625|NCT00223990|Biological|RabAvert|RabAvert rabies vaccine
75758626|NCT01052922|Other|3 sample g-SENSA|Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
75758627|NCT01052922|Other|2 sample InSure|Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
75904293|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
75904294|NCT03487484|Behavioral|Quality of Life Questionnaire for gastrointestinal tract|To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
75904295|NCT03487484|Behavioral|Quality of Life Questionnaire|To assess quality of life, the SF-36 questionnaire will be applied
75458218|NCT01803347|Drug|fibrin glue|•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
75458219|NCT01803360|Drug|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
75458220|NCT01803373|Drug|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
75458221|NCT01803373|Drug|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
75458222|NCT01803373|Drug|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
75610283|NCT02742961|Other|Peripheral nerve block|A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
75610284|NCT02730637|Other|Early nephrologist consultation|
75610285|NCT02730559|Other|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
75610286|NCT02730481|Drug|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
75610287|NCT05423353|Device|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
75610288|NCT05423353|Device|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
75610289|NCT02733055|Other|posturographic evaluation|subjects will undergo CDP testing using one of the ext_mCTSIB tests without (baseline) and with oculomotor task
75758628|NCT01052922|Other|1 sample OC-Micron|Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
75758629|NCT03990636|Drug|Metil 5-aminolevulinate|Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
75758630|NCT01048398|Drug|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
75758631|NCT01048398|Drug|paracetamol|Control group: intravenous paracetamol 1g
75758632|NCT03971812|Biological|Blood sample|A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
75758633|NCT03990324|Procedure|Manual stretching|Manual stretching for the upper trapezius and levator scapulae muscle
75758634|NCT01073644|Drug|Sunitinib malate|sunitinib 50 mg, 4 weeks on, 2 weeks off
75610290|NCT02732977|Other|expert system development|data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
75758635|NCT02534922|Biological|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
75758636|NCT03992586|Other|Wearing pink glasses|Wearing pink-colored lenses
75758637|NCT03992586|Other|Wearing clear glasses|Wearing clear glasses
75610291|NCT02732821|Procedure|Gastric Per Oral Endoscopic Myotomy|Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.
75758638|NCT01048476|Dietary Supplement|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
75758639|NCT01048476|Dietary Supplement|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
75758640|NCT01048476|Dietary Supplement|placebo|Dietary Supplement: placebo; daily supplementation one year
75758641|NCT01048476|Drug|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
76068978|NCT00381862|Drug|leucovorin calcium|as per institutional standard of care
76068979|NCT00381862|Drug|oxaliplatin|as per institutional standard of care
75610292|NCT02742727|Biological|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
75610293|NCT02730091|Drug|Letrozole|Letrozole 2.5 mg daily
75610294|NCT02730091|Drug|Anastrozole|anastrozole 1 mg daily
75758642|NCT01581060|Drug|WX-554|Capsules of WX-554
75758643|NCT03990246|Other|Acid stable emulsion with solid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are crystalline. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.2% of the emulsifier sorbitan monooleate (Tween80)
75758644|NCT03990246|Other|Acid stable emulsion with liquid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.2% of the emulsifier sorbitan monooleate (Tween80)
75758645|NCT03990246|Other|Acid unstable emulsion with solid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are solid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.5% of the emulsifier sorbitan monostearate (Span60)
75904296|NCT03487484|Behavioral|Faecal Incontinence Score|To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
75904297|NCT02164266|Drug|Placebo|Matching placebo daily oral administration
75610295|NCT02730091|Drug|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
75904298|NCT02164266|Drug|RO6799477|Daily oral administration of RO6799477
75904299|NCT05150288|Other|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
75904300|NCT02163876|Drug|HuCNS-SC cells|surgery arm
75904301|NCT00897949|Drug|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
75904302|NCT00897949|Drug|Comparator: placebo|Placebo to rizatriptan
75610296|NCT02730013|Behavioral|Square Stepping Exercise|"Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged."
75610297|NCT02742805|Dietary Supplement|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
75610298|NCT02742805|Dietary Supplement|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
75610299|NCT02742805|Drug|Omalizumab|Standard of care dose.
75610300|NCT02742571|Other|non applicable|
75904303|NCT04260776|Behavioral|Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with a corresponding 1-way text messages
76068980|NCT00381862|Drug|palonosetron hydrochloride|Palonosetron 0.25 mg IV push on day 1 only.
76068981|NCT00381862|Procedure|quality-of-life assessment|baseline
76068982|NCT00464698|Drug|Duloxetine|Participants received increasing amounts of Duloxetine for 7 weeks.
76068983|NCT00465088|Drug|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
76068984|NCT00465088|Drug|atorvastatin|40 mg at bedtime
76068985|NCT01796782|Drug|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
75758646|NCT03990246|Other|Acid unstable emulsion with liquid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.5% of the emulsifier sorbitan monostearate (Span60)
75758647|NCT03992742|Behavioral|Initial phase: personalized instant messaging (PIM)|"intervention Group participants will receive three months of personalized interaction through IM Apps (e.g. WhatsApp, WeChat). Our counsellors will trigger the conversation and encourage the participants to set a quit day. A total of pre-set 26 messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. These messages covered generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and encouragement to quit and use SC services.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PIM (subgroup C). Incomplete responders (smokers) will be randomized to continue PIM (subgroup B) or receive OCI (subgroup A)."
75458223|NCT01803386|Device|EIM Measurements|EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
75758648|NCT03992742|Behavioral|Second phase: optional cocktail interventions (OCI)|For incomplete respondents (subgroup A) randomized to OCI, the available intervention options include multi-media messages, active referral plus financial incentive, phone counseling, family/peer support and medications (NRT). Participants will be guided by cessation counsellors at 1-month follow-up telephone survey to choose any combination of OCI based on their preference. If OCI participants cannot be followed up at 1-month, they will receive multi-media messages by default.
75758649|NCT03992742|Behavioral|Initial phase: regular instant messaging (RIM)|"Participants enrolled in the Control Group will receive regular messages via IM services (e.g. WhatsApp, WeChat) since initial contact and until 3-month after baseline with a tapering schedule: 1) Baseline to 4-week (1-month): 2 times/ week (8 in total); 2) 4-week to 12-week (2- & 3-month): 1 time/week (8 in total).~SC messages will generally include benefits of SC, encouragement on abstinence and use of SC services, tips on avoiding/ handling craving and reminder of participating in telephone follow-up. A reminder to participate in the telephone follow-up will also be sent at 1-, 2-, 3- and 6-month, making up a total of 20 messages.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive RIM (subgroup F). Incomplete responders (smokers) will be second randomized to continue RIM (subgroup E) or receive PIM (subgroup D). Those who are unable to follow up at 1-month will be considered as nonresponsive to the intervention."
75758650|NCT03992742|Behavioral|Second phase: personalized instant messaging (PIM)|"For incomplete responders allocated to PIM (subgroup D), participants will receive the same intervention as the Group A delivered at the initial stage. Participants will receive two months of personalized interaction through IM application. Please refer to Intervention Group Initial phase: personalized instant messaging (PIM) for details."
75904304|NCT04260776|Behavioral|Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with corresponding interactive, 2-way text messages
75904305|NCT04260776|Behavioral|Phase 2: re-engagement text messages|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive interactive text messages designed to promote re-engagement
76068986|NCT01796782|Drug|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
75458224|NCT01803399|Drug|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
75458225|NCT01803399|Drug|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
75458226|NCT01803399|Drug|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
75458227|NCT01803399|Drug|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
75458228|NCT01803425|Other|Synflorix™ data collection|Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
75458229|NCT01803438|Device|cryoballoon ablation system|
75758651|NCT03992742|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
75758652|NCT03992742|Behavioral|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
75758653|NCT03992742|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
75758654|NCT03992742|Behavioral|COSH booklet|A general smoking cessation self-help booklet
75758655|NCT00221104|Drug|Pravastatin|
75758656|NCT00189202|Drug|Sirolimus|Thymoglobulin induction, sirolimus and no maintenance corticosteroid
75758657|NCT01071928|Drug|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
75758658|NCT01071928|Drug|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
75758659|NCT03969160|Behavioral|Imaginal exposure|Imaginal exposure to mental imagery of phobic and neutral stimuli
75758660|NCT00187486|Drug|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
75758661|NCT00187486|Drug|Temodar|Temodar 200 mg/m^2/day x 5 days every 28 days
75758662|NCT00187486|Procedure|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
75758663|NCT00220636|Drug|Aripiprazole|Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
75758664|NCT00362232|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
75758665|NCT00362232|Drug|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
75758666|NCT00362232|Drug|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
75758667|NCT00362232|Drug|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
75904306|NCT04260776|Behavioral|Phase 2: re-engagement emails|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive a personalized email designed to promote re-engagement
75458230|NCT01803438|Drug|Antiarrhythmic Drugs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
75458231|NCT01803477|Drug|once daily for two consecutive days (Picato)|
75458232|NCT01803503|Drug|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks
75458233|NCT01803503|Drug|Sunitinib|7 days of sunitinib 12.5mg orally daily during each cycle
75458234|NCT01803516|Behavioral|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
75458235|NCT01803529|Other|heat-pack with massage|
75458236|NCT01803529|Other|heat-pack only|
75458237|NCT01803568|Other|Exercise|12 weeks of exercise; 4 times pr week
75610301|NCT03204643|Behavioral|BH-VPN|A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
75758668|NCT03968926|Other|Arterial pressure management during circulatory support by VA-ECMO|Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
75758669|NCT01048554|Drug|Temozolomide|Temozolomide 75mg/m2 for six continuous weeks
75904307|NCT03541278|Procedure|MIT|periareolar intraparenchymal, high volume and ultrasonographic guidance
75904308|NCT03541278|Procedure|IM-SLNB|IM-SLNB was performed for IMLN visualized patients
75458238|NCT01803581|Other|X92001327|
75458239|NCT01803581|Other|RID shampoo|
75458240|NCT01803659|Dietary Supplement|b-carotene|
75904309|NCT03489200|Other|EH301|1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene
75610302|NCT02729779|Other|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
75758670|NCT01048554|Drug|Bevacizumab|Bevacizumab 10mg/kg every 2 weeks without interruption
75758671|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
75758672|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
75758673|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
75758674|NCT00219544|Drug|Placebo|Placebo
75904310|NCT03489200|Other|Placebo|No intervention- placebo
75904311|NCT03540342|Procedure|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
75758675|NCT00357552|Drug|Emtricitabine/Tenofovir disoproxil fumarate|Once daily
75758676|NCT00357552|Drug|Lopinavir/Ritonavir|Twice daily
75758677|NCT00187096|Drug|Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|See Detailed Description section for additional details of treatment interventions.
75758678|NCT00187096|Procedure|Natural Killer Cell Infusion|See Detailed Description section for additional details of treatment interventions.
75758679|NCT00187096|Device|CliniMACS System|See Detailed Description section for additional details of treatment interventions.
75758680|NCT00357396|Biological|graft versus host disease prophylaxis/therapy|
75758681|NCT00357396|Drug|busulfan|
75758682|NCT00357396|Drug|melphalan|
75458241|NCT01803659|Dietary Supplement|retinyl palmitate|
75758683|NCT00357396|Drug|thiotepa|
75758684|NCT00357396|Procedure|allogeneic bone marrow transplantation|
75758685|NCT00357396|Procedure|allogeneic hematopoietic stem cell transplantation|
75610303|NCT02729779|Other|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
75610304|NCT02729857|Dietary Supplement|SFA muffin|Muffin rich in saturated fat.
75758686|NCT00357396|Procedure|peripheral blood stem cell transplantation|
75758687|NCT00186628|Procedure|Total lymphoid irradiation|Total lymphoid irradiation (TLI) administered at 80cGy for 10 days
75758688|NCT00186628|Drug|Rituximab|Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
75610305|NCT02729857|Dietary Supplement|PUFA muffin|Muffin rich in polyunsaturated fat.
75610306|NCT02732743|Dietary Supplement|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
75758689|NCT00186628|Drug|Anti-thymoglobulin, rabbit (ATG, rabbit ATG)|Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
75458242|NCT01803659|Dietary Supplement|placebo|
75610307|NCT02732431|Other|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
75610308|NCT02742259|Device|Blood Draw|Blood draws only - non-diagnostic, non-treatment
75610309|NCT02729623|Drug|Kite Systems cannaHALER cannabis Inhaler.|
75610310|NCT04189549|Diagnostic Test|CNA Rapid Sepsis Dx|Novel biomarker based on circulating cell-free DNA (cfDNA) in the human blood stream
75610311|NCT04190719|Other|multimodal prehabilitation|"Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics"
75610312|NCT02690389|Drug|Flumazenil|used alone or with acupuncture
75758690|NCT00186628|Drug|Cyclosporine|Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates > 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
75458243|NCT01803672|Behavioral|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.
75458244|NCT01803672|Behavioral|Placebo control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
75758691|NCT00186628|Drug|Mycophenylate mofetil|Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
75758692|NCT00186628|Drug|Filgrastim|Filgrastim provided as needed for neutrophil support
75904312|NCT04952636|Procedure|arthroscopic Cuistow|peforming the Cuistow Procedure under arthroscopy
75904313|NCT04952636|Procedure|open Cuistow|peforming the Cuistow Procedure with the traditional open process
75458245|NCT01803698|Behavioral|Training in the use of IOM charts|
75758693|NCT00186628|Drug|Granisetron|Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
76068987|NCT00441766|Drug|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
75458246|NCT01803750|Behavioral|in-depth, semi-structured interviews|In-depth interviews will be conducted by the Principle Investigator and will use a combination of open-ended and closed, fixed response questions. Interviews will be audio recorded if the participant agrees, and answers to fixed response questions will be marked for complete analysis. The data collection portion of the study is estimated to take approximately 8 months. Areas to be addressed in the open-ended portion of the interview include: 1) Knowledge, attitudes and beliefs toward evidence-based cancer screening and prevention approaches 2) Barriers to implementing evidence-based cancer screening practices in the individual provider's clinical setting 3) Preferences for mechanisms of information dissemination and implementation and 4) Ideas and methods to facilitate evidence-based practices to improve cancer screening in the Latino population. A community-based participatory committee (CBPC) will be formed with 5-7 key informants identified during the interview process.
75610313|NCT02690389|Procedure|Acupuncture|used alone or with flumazenil
75758694|NCT00186628|Drug|Solumedrol|Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
75458247|NCT01803763|Drug|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
75458248|NCT01803763|Drug|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
75610314|NCT03838861|Behavioral|NEMO: NEw MOdel of follow-up|The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
75610315|NCT02732197|Drug|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
75610316|NCT02732197|Drug|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
75610317|NCT02729935|Drug|Parecoxib|40 mg of intravenous parecoxib 30 min before surgery
75610318|NCT02729935|Drug|Placebo|An equal volume of saline
75758695|NCT00186628|Drug|Acetaminophen|Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
75758696|NCT00186628|Drug|Diphenhydramine|Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
75758697|NCT00186628|Drug|Hydrocortisone|Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
75458249|NCT01803776|Behavioral|lifestyle counseling|The physical activity and dietary intervention is based on the Finnish physical activity and dietary recommendations. The children and their parents in the intervention group undergo individualized and family-based physical activity and dietary intervention between the baseline and 2-year follow-up examinations. The children and their parents meet a physical activity specialist and a nutritionist who give detailed and individualized instructions on health promoting physical activity and diet at months 0, 1.5, 3, 6, 12, and 18 with a specific topic at each visit. Between the 2-year follow-up and 8-year follow-up examinations, the intervention continues with yearly physical activity and dietary counseling sessions. The children in the intervention group, particularly those who do not attend organized sports or exercise, will also be encouraged to participate in after-school exercise clubs organized by trained exercise instructors of the study.
75758698|NCT00368550|Drug|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
75758699|NCT00368550|Drug|Placebo|Placebo for 14-week treatment period
75458250|NCT01803789|Device|Single Kirschner Wire|
75758700|NCT01072162|Drug|Eltrombopag|25 mg tablet
75458251|NCT01803789|Device|Double Kirschner Wire|
75458252|NCT01803802|Behavioral|Expressive writing|Five sessions of 30 minutes of expressive writing
75458253|NCT01803828|Drug|Tadalafil|20 mg/die (1 capsule)
75458254|NCT01803828|Drug|Placebo|Placebo 20 mg/die (1 capsule)
75610319|NCT02742415|Behavioral|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
75758701|NCT01072162|Drug|Eltrombopag|25 mg powder for oral suspension
75758702|NCT01050036|Procedure|autologous hematopoietic cell transplantation|"Autologous peripheral blood stem cell (PBSCs) harvesting~After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy~Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy~Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.~Conditioning regimen for autologous HCT~Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)~Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)~Autologous cell infusion and waiting for engraftment"
75758703|NCT03968692|Diagnostic Test|Prostate-Specific Antigen test|Prostate-Specific Antigen (PSA) test as opportunistic screening or in the presence of symptoms
75758704|NCT00368472|Drug|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
75758705|NCT00357006|Drug|Estradiol|100 mcg adjunctive transdermal estradiol
75758706|NCT00357006|Drug|Estradiol|200 mcg adjunctive transdermal estradiol
75758707|NCT00357006|Other|placebo|adjunctive transdermal placebo
75904314|NCT03732456|Procedure|Shoulder surgery and post-op pharmacological treatment|Usual care surgery (shoulder arthroscopy) and post-operative pain management protocol
75904315|NCT03487406|Drug|Ticagrelor|One 90 mg tablet, oral, twice daily for 6 months.
75904316|NCT03487406|Drug|Aspirin|One 75 mg tablet, oral, once a day, for 6 months.
75904317|NCT03487406|Drug|Placebo Aspirin|Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
75458255|NCT01803841|Procedure|Transradial coronary angiography and intervention|
75610320|NCT02721667|Device|Telemonitoring|Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
75610321|NCT02721667|Other|Case Management|Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
75610322|NCT02729389|Behavioral|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
75610323|NCT02729389|Behavioral|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
75610324|NCT02729233|Other|patients receiving biopsies|Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
75610325|NCT02729467|Drug|JNJ-53718678|JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
75610326|NCT02729467|Drug|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
75904318|NCT03487406|Drug|Placebo Ticagrelor|Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
75904319|NCT02164344|Dietary Supplement|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
75610327|NCT02729467|Drug|Rifampicin|Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
75758708|NCT01050114|Drug|onaBoNT-A|"onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder."
75758709|NCT01050114|Drug|Oxybutynin ER|Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
75758710|NCT01324674|Other|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
75904320|NCT04653571|Other|CASPR2 encephalitis|Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.
75904321|NCT02097758|Device|Transcatheter device closure|"Closure of atrial septal defect with device~choosing device size with 3D image and the formula~we do not use sizing balloon for choosing of the device size"
75904322|NCT02760810|Device|Marketed Contact Lens|Narafilcon A
75904323|NCT04574869|Drug|RLS-0071 10 mg/kg|Single dose IV infusion of 10 mg/kg RLS-0071
75904324|NCT04574869|Drug|RLS-0071 40 mg/kg|Single dose IV infusion of 40 mg/kg RLS-0071
75458256|NCT01803841|Procedure|Transfemoral coronary angiography and intervention|
75458257|NCT01803867|Drug|rHIgM22|Administered via IV infusion
75458258|NCT01803919|Device|Silver Alloy-Coated Urinary Catheters|
75458259|NCT01803919|Device|Conventional Urinary Catheter|
75458260|NCT01803932|Behavioral|Male-focused group violence prevention intervention|
75458261|NCT01803945|Drug|AVE8112|
75458262|NCT01803945|Drug|Placebo|
75458263|NCT01803958|Radiation|partial breast irradiation|
76068988|NCT00441766|Drug|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
75458264|NCT01803958|Radiation|whole breast irradiation|
75458265|NCT01803971|Other|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
75458266|NCT01803984|Device|MRI|
75758711|NCT01324674|Other|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
75758712|NCT01048632|Drug|Oxandrolone|2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
75758713|NCT00165646|Drug|E3810|E3810 5mg: once daily orally for 4 weeks
75758714|NCT00165646|Drug|E3810|E3810 10mg: once daily orally for 4 weeks
75758715|NCT00165646|Drug|Placebo|Placebo: once daily orally for 4 weeks
75904325|NCT04574869|Drug|Placebo|The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia [USP]).
75904326|NCT04574869|Drug|RLS-0071 10 mg/kg|Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
76068989|NCT00441766|Drug|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
76068990|NCT00441766|Drug|placebo|Part A: placebo capsule every 12 hours for 4 weeks
76068991|NCT00466960|Biological|sargramostim|Given SC
75610328|NCT02727205|Drug|Rotigotine Transdermal System|
75610329|NCT02721433|Drug|Pamidronate|Bone-targeted agent as standard of care
75610330|NCT02721433|Drug|Denosumab|Bone-targeted agent as standard of care
75610331|NCT02721433|Drug|Zoledronate|Bone-targeted agent as standard of care
75758716|NCT01050270|Drug|Ondansetron|4mgs iv bolus
75758717|NCT01050270|Drug|acetylcysteine|100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
75610332|NCT02726893|Other|no intervention|
75610333|NCT02729155|Procedure|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
75610334|NCT02729155|Procedure|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
75610335|NCT02729155|Procedure|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
75610336|NCT02729155|Procedure|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
75758718|NCT01050270|Drug|acetylcysteine|150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
75758719|NCT03968458|Behavioral|CON|. Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75758720|NCT03968458|Behavioral|EX-30|Condition with an acute exercise set 30 minutes before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75758721|NCT03968458|Behavioral|EX-90|condition with an acute exercise set 90 minutes before lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75758722|NCT03992508|Device|intermittent pneumatic compression|
75758723|NCT03992508|Procedure|complex decongestive therapy|
75758724|NCT03968770|Dietary Supplement|Experimental group|Probiotic (Lactobacillus casei) once daily taken by 6 weeks.
75758725|NCT03968770|Dietary Supplement|Control group|Placebo of Probiotic once daily taken by 6 weeks.
76068992|NCT00466960|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
76068993|NCT00466960|Other|laboratory biomarker analysis|Correlative studies
76068994|NCT00466960|Other|immunologic technique|Correlative studies
76068995|NCT00383266|Drug|Pemetrexed|
76068996|NCT00383266|Drug|Carboplatin|
76068997|NCT00384670|Biological|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
76068998|NCT00384670|Biological|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
76068999|NCT00467038|Behavioral|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
76069000|NCT00467350|Drug|PEG 3350|PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance
75758726|NCT03968770|Other|Usual medical care|NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
75758727|NCT00367770|Drug|Tracleer®|Patients will receive up to 125 mg b.i.d. of Tracleer.
75758728|NCT00185614|Procedure|Autologous hematopoietic cell transplant (Auto-HCT)|The target cell dose is 2.6 x 10e6 CD34+ cells/kg
75758729|NCT00185614|Procedure|Allogeneic hematopoietic cell transplant (Allo-HCT)|The target cell dose is 5 x 10e6 CD34 cells/kg
75458267|NCT01803984|Device|EndoPAT|The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
75758730|NCT00185614|Drug|Cyclophosphamide|Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
75758731|NCT00185614|Drug|Filgrastim|"Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)"
75904327|NCT04574869|Drug|RLS-0071 40 mg/kg|Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
75458268|NCT01803984|Other|Neuropsychological battery|The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
75458269|NCT01803997|Behavioral|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
75758732|NCT00185614|Drug|Melphalan|Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
75758733|NCT00185614|Radiation|Total body irradiation (TBI)|200 centigray (cGy) total body irradiation delivered on Day 0
75758734|NCT00185614|Procedure|Cyclosporine (CSP)|Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
75758735|NCT00185614|Drug|Mycophenolate Mofetil (MMF)|Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
75758736|NCT01075438|Biological|Prevenar® (7-valent pneumococcal conjugate vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
75904328|NCT04047056|Other|Labor Kinesiotherapy|"The intervention group will perform 5 minutes of warm-up with free active exercises, 10 minutes of specific resistance exercises for the cervical and upper limbs and 5 minutes of stretching and muscle relaxation.The initial free active exercises will be performed in 3 sets of 15 repetitions; Resistance exercises will be performed in 3 sets of 10 repetitions and stretching will be performed in 3 sets of 30 seconds.~Regarding the intervals between exercises, active recovery will be adopted to counteract the effects of muscle fatigue."
76069001|NCT00467350|Drug|milk and molasses enema|enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
75458270|NCT01804010|Drug|Ivabradine and placebo|Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
75458271|NCT01804023|Other|HEC placebo gel applicators|"Participants will handle, but not insert, 4 applicators containing HEC placebo gel.~Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators."
75458272|NCT01804127|Drug|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
75458273|NCT01804153|Drug|Adipose-derived expanded stem cells|Intralesional application ASC
75610337|NCT02721199|Other|Neural Respiratory Drive Automated EMGpara assessment|Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
75610338|NCT02721043|Biological|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
75758737|NCT01075438|Biological|Pneumovax® (pneumococcal polysaccharide vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
75758738|NCT00162370|Drug|Perflutren Lipid Microsphere Injectable Suspension|Activated DEFINITY 10ug/kg by bolus injection
75758739|NCT00361842|Drug|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
75758740|NCT01324752|Drug|PA21 and Losartan with Food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
75758741|NCT01324752|Drug|No PA21; Losartan with food|The maximum dose of Losartan will be 100 mg/day.
75758742|NCT01324752|Drug|PA21 with food and Losartan 2 hours later|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
75904329|NCT02760654|Device|Proactive Self Management Program for Effects of Cancer Treatment|
75904330|NCT00725491|Drug|ganirelix|On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
76069002|NCT00444028|Drug|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
76069003|NCT00444028|Drug|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
76069004|NCT00444028|Drug|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
76069005|NCT00444028|Drug|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
76069006|NCT00444028|Drug|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
76069007|NCT00444028|Drug|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
75758743|NCT01050348|Drug|Atorvastatin calcium|Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
75758744|NCT01050348|Drug|Inactive Placebo|Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
75758745|NCT00361296|Biological|K562/GM-CSF cell vaccine|
75758746|NCT03990090|Drug|TG103|Administered SC
75610339|NCT02721043|Drug|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
75758747|NCT03990090|Drug|Placebo|Administered SC
75758748|NCT01053390|Drug|Somatostatin|Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
75904331|NCT00725491|Drug|triptorelin|a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 <= 50 pg/ml (<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
75904332|NCT03487328|Procedure|Sacrospinous-Sacrotuberous fixation|Sacrospinous-Sacrotuberous fixation
76069008|NCT00444964|Drug|Nutropin AQ|0.0125 mg/kg/day
75458274|NCT01804192|Other|Acu-TENS|Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
75458275|NCT01804205|Drug|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
75458276|NCT01804205|Drug|Placebo|100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
75610340|NCT02721043|Drug|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
75610341|NCT02721121|Procedure|circumferential pulmonary vein isolation|
75610342|NCT02721121|Procedure|Linear ablation in addiction to circumferential pulmonary vein isolation|
75610343|NCT02729311|Behavioral|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
75610344|NCT02729077|Device|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
75758749|NCT01053390|Drug|epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）|
75610345|NCT02728999|Procedure|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
75758750|NCT01048710|Other|No intervention|
75758751|NCT00356148|Drug|Ampicillin/Sulbactam|Ampicillin/Sulbactam 1 gr, once within onr hour before surgery
75758752|NCT00361218|Drug|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
75758753|NCT02534532|Other|AF screening|Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
75758754|NCT02534688|Drug|LNG-IUS|
75758755|NCT02534688|Drug|DMPA|
75758756|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (<=) 14 years.
75758757|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
75904333|NCT00724789|Drug|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
75904334|NCT00724789|Drug|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
75904335|NCT03485144|Biological|TV003|Live attenuated virus vaccine-TetraVax-DV
75904336|NCT03485144|Biological|Placebo for TV003|Placebo
75904337|NCT02164500|Drug|Ruxolitinib|
76069009|NCT00445588|Drug|erlotinib hydrochloride|150mg Given orally once daily
76069010|NCT00445588|Drug|sorafenib tosylate|400mg Given orally twice daily
76069011|NCT00445588|Other|pharmacological study|Correlative studies
76069012|NCT00445744|Drug|cyclophosphamide|Given IV
76069013|NCT00445744|Drug|busulfan|Given IV
76069014|NCT00445744|Drug|tacrolimus|Given IV or PO
76069015|NCT00445744|Drug|methotrexate|Given IV
76069016|NCT00445744|Genetic|cytogenetic analysis|Correlative studies
76069017|NCT00445744|Other|flow cytometry|Correlative studies
76069018|NCT00445744|Other|pharmacological study|Correlative studies
76069019|NCT00445744|Other|pharmacogenomic studies|Correlative studies
75758758|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to < 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
75610346|NCT02728999|Procedure|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
75758759|NCT02534610|Drug|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
75758760|NCT02534610|Drug|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
76069020|NCT00445744|Procedure|peripheral blood stem cell transplantation|Undergo PBPC transplantation
75458277|NCT01804218|Drug|Nadolol|
75458278|NCT01804218|Drug|Placebo|
75458279|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
75758761|NCT02534298|Other|functional magnetic resonance imaging|functional magnetic resonance imaging
75904338|NCT03489356|Behavioral|Addressing Behavior Change (ABC)|The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
76069021|NCT00445744|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
75610347|NCT02727049|Other|Osteopathic manipulative medicine (OMM)|Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
75610348|NCT02842723|Radiation|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
75610349|NCT02720887|Procedure|Nanoparticles load|Pregnant women will have a sampling of amniotic fluid to measure load and composition of nanoparticles.
76069022|NCT00468208|Drug|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:~500 mg of abatacept for body weight less than 60 kg~750 mg of abatacept for body weight between 60 and 100 kg~1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion."
76069023|NCT00384748|Behavioral|TR intervention|The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.
75458280|NCT01804244|Drug|TMC278|1 25-mg tablet [27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
75458281|NCT01804283|Procedure|ischemic postconditioning|"multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest."
75458282|NCT01804283|Procedure|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
75458283|NCT01804283|Device|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
75458284|NCT01804283|Device|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
75458285|NCT01804309|Procedure|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
75458286|NCT01804322|Other|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~The cause and nature of the adverse event and/or drug interaction~The tolerability profile of each drug present in the schedule~The clinical manifestations associated with the current drug interactions~Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~The reasons for and the potential benefits of the suggested treatment change~An encouragement to withdraw any potentially interfering or contraindicated drug"
75458287|NCT01804322|Other|usual care|usual care according to the participating Epilepsy Centers
75458288|NCT01804335|Drug|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
75610350|NCT02728921|Drug|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
75758762|NCT01050426|Other|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
75758763|NCT01050426|Other|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
75904339|NCT03925142|Other|Controlled healthy vegetarian diet|The controlled healthy vegetarian diet will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern.
75758764|NCT01053468|Behavioral|Physical Activity Resource Kit|"The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.~Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration)."
75758765|NCT01053468|Behavioral|Standard Materials|Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency
75758766|NCT03990168|Device|Anodal tDCS|1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
75758767|NCT03990168|Behavioral|fluency intervention/ Delayed Auditory Feedback|Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
75758768|NCT03990168|Device|Sham tDCS|The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
75758769|NCT01053546|Behavioral|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
75758770|NCT01053546|Other|questionnaire administration|Ancillary study
75758771|NCT01053546|Procedure|quality-of-life assessment|Ancillary study
75758772|NCT01049100|Procedure|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
75758773|NCT01049100|Other|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--> CT controlled biopsy
75758774|NCT01053624|Procedure|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
75904340|NCT03925142|Other|Controlled beef diet|The controlled beef diet will incorporate various cuts of lean unprocessed red meat into the healthy vegetarian eating pattern, as approved by the American Heart Association's Food Certification Program. The beef diet will isocalorically replace starchy vegetables and/or refined grains with 6 oz. of beef/day for five weeks.
75458289|NCT01804348|Device|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
75904341|NCT00711607|Drug|nomegestrol acetate and estradiol|Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
76069024|NCT00384748|Behavioral|In-home messaging device.|The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
75458290|NCT01804361|Drug|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
76069025|NCT00384748|Behavioral|Usual care|Routine VA care.
76069026|NCT00385138|Drug|Cangrelor|cangrelor bolus (30 mcg/kg) & cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
76069027|NCT00385138|Drug|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
76069028|NCT00385138|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
76069029|NCT00385138|Drug|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
75610351|NCT02728921|Drug|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
75610352|NCT02728843|Drug|Deferiprone|600 mg tablets
76069030|NCT00385138|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
76069031|NCT00446290|Drug|Docetaxel, Capecitabine and Oxaliplatin|
76069032|NCT00385216|Drug|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
76069033|NCT00385216|Other|Placebo|Placebo nasal spray 0mg x 1 before surgery
75610353|NCT02728843|Drug|Placebo|Tablets that match the deferiprone tablets in appearance
75610354|NCT02726503|Drug|Lenvatinib|"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
75758775|NCT00367458|Drug|Atorvastatin|80 mg atorvastatin oral daily
75458291|NCT01804361|Drug|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
75458292|NCT01804374|Drug|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
75458293|NCT01804374|Drug|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
75458294|NCT01804387|Drug|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
75758776|NCT00367458|Drug|Placebo|patients will be administered placebo
75758777|NCT01053702|Drug|R475|IV
75758778|NCT01053702|Drug|Placebo|Placebo
75758779|NCT01050738|Procedure|Position of catheter|Position of catheter for administration of local anestesia.
75904342|NCT03893318|Drug|IV lidocaine|an amide-type, short-acting local anesthetic and delivered as an aqueous solution for intravenous administration. It has a half-life of 1.5-2 hours. A traditional method of administration is via epidural delivery. Epidural lidocaine is effective and this effect is due, in part, to systemic absorption. Systemic (intravenous) administration of lidocaine is a Food and Drug Administration approved method of delivery. Low plasma levels are needed for effective use, 0.5µg/mL to 5.0µg/mL. Given this low concentration required and the short half-life, continuous infusion of lidocaine is thought to be generally safe with low risk of complication.
75904343|NCT03893318|Drug|Placebos|Saline
75458295|NCT01804387|Drug|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
75458296|NCT01804400|Drug|QAW039|
75458297|NCT01804400|Drug|Montelukast|
75458298|NCT01804400|Drug|Placebo|
75458299|NCT01804413|Drug|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
75758780|NCT00162136|Drug|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 & 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
75758781|NCT00252694|Drug|candesartan|32 mg oral tablet
75758782|NCT00185458|Drug|LNG IUS|LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
75458300|NCT01804413|Drug|Regular insulin|0.1-0.15 units/kg
75458301|NCT01804478|Behavioral|Mild pneumatic compression|
75610355|NCT02720965|Other|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
75758783|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
75904344|NCT03625531|Other|Acupuncture|Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.
75904345|NCT03625531|Drug|Letrozole|Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
75904346|NCT03625531|Drug|Placebo letrozole|Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
75904347|NCT02161224|Drug|FG-4592|Oral
75904348|NCT02167698|Device|Airway Pressure Release Ventilation (APRV)|This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
75904349|NCT02167698|Other|Low-tidal volume ventilation|This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
75458302|NCT01804491|Other|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
75458303|NCT01804504|Behavioral|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
75458304|NCT01804530|Drug|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
75458305|NCT01804543|Drug|Ranolazine|ranolazine 500 mg, then 1000 mg twice a day
75610356|NCT02726815|Other|Questionnaire|Questionnaire based study using a symptom assessment tool
75610357|NCT02728765|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
75758784|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
75758785|NCT00185380|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
75758786|NCT01326208|Procedure|PEEP titration|PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
75758787|NCT01074424|Genetic|proteomic profiling|
75758788|NCT01074424|Other|laboratory biomarker analysis|
75758789|NCT03968302|Drug|ARM A Triple therapy for helicobacter pylori|The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
75758790|NCT03968302|Drug|ARM B Quadruple therapy for helicobacter pylori|Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
75758791|NCT01077388|Behavioral|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
75758792|NCT01077466|Drug|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
75758793|NCT00160654|Drug|Levetiracetam|"Pharmaceutical form: oral tablets~Concentration: 500 mg~Route of administration: Oral use"
75758794|NCT01582672|Drug|Standard Treatment|Standard treatment for Renal Cell Carcinoma
75758795|NCT01582672|Biological|AGS-003|Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
75758796|NCT00366678|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
75458306|NCT01804556|Procedure|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 ~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
75458307|NCT01804569|Other|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
75458308|NCT01804595|Other|Sunscreen|
75610358|NCT02720497|Behavioral|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
75458309|NCT01804595|Behavioral|Text-Message Reminders|
75458310|NCT01804595|Other|Sunscreen and Text Message Reminders|
75458311|NCT01804595|Behavioral|Education|
75610359|NCT02720497|Behavioral|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
75458312|NCT01804608|Other|Strength|
75458313|NCT01804608|Other|Sensorimotor|
75610360|NCT05372107|Drug|AG-80308|AG-80308 Eye Drop Solution
75610361|NCT02726737|Drug|sodium bicarbonate|
75610362|NCT02726737|Drug|Lidocaine|
75610363|NCT02726737|Drug|sterile distilled water|
75610364|NCT02720575|Other|Consumption of capsule/bread with vitamin D|
75610365|NCT02720341|Device|ARMin|single sessions of about one hour each
75758797|NCT00366678|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
75758798|NCT00366678|Drug|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
75758799|NCT01053780|Other|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
75758800|NCT01053780|Behavioral|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
75758801|NCT01049178|Drug|Oral Silymarin|Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
75904350|NCT02167698|Drug|Methylprednisolone|Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
75758802|NCT01049178|Drug|Oral Silymarin, maintenance dose|The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
75758803|NCT01049178|Drug|Placebo|
75758804|NCT01053858|Procedure|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
75758805|NCT01049256|Other|carbon dioxide|sinusoidal carbon dioxide administration
75758806|NCT02534454|Behavioral|Active Retraining|
75758807|NCT02534454|Behavioral|Sham Retraining|
75904351|NCT02167698|Other|Restrictive fluid therapy|Fluid & hemodynamics would be titrated as per pre-designed decision-making protocols
75904352|NCT02167698|Drug|sedo-analgesia titration|
75458314|NCT01804621|Behavioral|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
75458315|NCT01804647|Other|No study treatments administered - blood draws only|
75458316|NCT01804660|Other|No study treatments administered|
75758808|NCT02534454|Device|Active transcranial direct current stimulation (TDCS)|
75904353|NCT02167698|Other|Protocolized early enteral nutrition|Early enteral nutrition and attempt to meet calorie-protein goals
75904354|NCT02167698|Other|Protocolized supportive care|Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care & bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
75904355|NCT02167698|Other|Biomarker Assay|Biomarker Assay for patients in both arms
75904356|NCT04050943|Other|observational cohort|Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
75904357|NCT02164656|Behavioral|mindfulness for smokers|
75458317|NCT01804712|Drug|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
75458318|NCT01804738|Other|Jasmine rice|Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
75458319|NCT01804738|Other|Parboiled basmati rice|Standardised rice:cooking liquid for 50g available carbohydrate portion
75458320|NCT01804777|Drug|Amiloride|"Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet."
75458321|NCT01804777|Drug|HCTZ|"HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet"
75758809|NCT02534454|Device|Sham transcranial direct current stimulation (TDCS)|
75758810|NCT02534454|Drug|Nicotine Replacement Therapy (Habitrol)|Administration of Nicotine Replacement Therapy Patches
75904358|NCT02634580|Biological|Evolocumab|Administered by subcutaneous injection
75904359|NCT02634580|Drug|Ezetimibe|Tablet for oral administration
75904360|NCT02634580|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
75904361|NCT02634580|Drug|Placebo Ezetimibe|Tablet for oral administration
75904362|NCT02225366|Biological|LL37|Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
75758811|NCT01050972|Behavioral|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
75758812|NCT01051050|Behavioral|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
75758813|NCT01051050|Behavioral|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
75758814|NCT00355368|Drug|Succinylcholine|1mg/kg iv
75758815|NCT00355368|Drug|Rocuronium|0.6mg/kg iv
75758816|NCT01054014|Drug|JNJ-40346527/Placebo|Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
75758817|NCT01054014|Drug|JNJ-40346527/Placebo|JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
75758818|NCT01054014|Drug|JNJ-40346527|JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
75458322|NCT01804803|Procedure|Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.|"Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made hot for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS)."
75458323|NCT01804803|Procedure|Use of regular glucometer|
75458324|NCT01804855|Behavioral|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
75458325|NCT01804855|Device|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
75758819|NCT01054092|Drug|ipragliflozin|oral
75758820|NCT03989622|Other|evaluation of the visual field on the ground|evaluation of the visual field on the ground
75758821|NCT02534220|Device|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter & Gamble, Cincinnati, OH
75458326|NCT01804868|Other|case vignette tutorial|The web tutorial will be composed of 4 case vignettes. A case vignette is a clinical scenario based on clinical practice. It will ask a clinical problem the student will have to answer by reading a research article on a randomized clinical trial. Then he will have to answer questions about this article which are related to the major methodological points of a randomized trial. All these steps are available on a secured website.
75458327|NCT01804868|Other|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation. It will allow to preserve a minimal blinding of participants, since the participants will not be informed of the intervention evaluated and will have the opportunity to follow the other intervention after the evaluation.
75458328|NCT01804907|Behavioral|Cognitive Behavioral Therapy|
75458329|NCT01804907|Behavioral|Behavioral Modification|
75458330|NCT01804920|Dietary Supplement|D-serine|
75458331|NCT01804920|Dietary Supplement|Placebo|
75758822|NCT02534220|Device|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter & Gamble, Cincinnati, OH
75758823|NCT00360282|Drug|Rizatriptan|10 mg Rizatriptan in an unlabeled pill given once on one of two visits
75758824|NCT00360282|Other|Placebo|In an unlabeled pill given once on one of two visits.
75458332|NCT01804933|Drug|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
75458333|NCT01804959|Dietary Supplement|Vivomixx probiotics|
75458334|NCT01804972|Other|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
75610366|NCT02726425|Behavioral|Diabetes Self Management Medical Group Visits|The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians & peer leaders lasting ~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
75610367|NCT02726191|Behavioral|Spatial Match Exercise|
75610368|NCT02726191|Behavioral|Temporal Sequence Reconstruction Exercise|
75610369|NCT02726191|Behavioral|Token Task Exercise|
75610370|NCT02726191|Behavioral|Story Recall Exercise|
75610371|NCT02726191|Behavioral|Sample-Match (Within Modality) Exercise|
75610372|NCT02726191|Behavioral|Pair-Match (Across-Modality) Exercise|
75610373|NCT02726191|Behavioral|Triad-FiguresExercise|
75610374|NCT02726191|Behavioral|Monster Garden Exercise|
75610375|NCT02726191|Behavioral|Memory Match Exercise|
75610376|NCT02726191|Behavioral|Memory Matrix Exercise|
75610377|NCT02726191|Behavioral|Familiar Faces Exercises|
75610378|NCT02726191|Behavioral|Lost in Migration Exercise|
75758825|NCT00373958|Biological|13 valent pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
75758826|NCT00373958|Biological|7vPnc pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
75758827|NCT00373880|Drug|Aripiprazole + Cocaine|Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
75758828|NCT00373880|Drug|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
75458335|NCT01804972|Other|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
75458336|NCT01804985|Drug|Imatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
75758829|NCT00184600|Drug|biphasic insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
75904363|NCT02225366|Other|Photographs|Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
75904364|NCT03540264|Device|Clearfil Majesty TM|Tooth wear - composite resin
75904365|NCT03540264|Device|Vita-Enamic®|Tooth wear - polymer-infiltrated-ceramic-network
75904366|NCT00697255|Drug|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
75904367|NCT00697255|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
75904368|NCT00697255|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
75904369|NCT00697255|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
75904370|NCT01957748|Behavioral|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
75904371|NCT00548912|Drug|Spironolactone|
75904372|NCT02161302|Device|transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
75904373|NCT02161302|Device|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
75458337|NCT01804985|Drug|nilotinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
75610379|NCT02726191|Behavioral|Playing Koi Exercise|
75458338|NCT01804985|Drug|dasatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
75610380|NCT02728609|Device|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
75610381|NCT02728609|Device|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
75458339|NCT01805011|Other|minimum 4 months of breastfeeding|
75458340|NCT01805050|Procedure|Arthroscopically repair of the anterior shoulder instability|Arthroscopically repair of the anterior shoulder instability
75610382|NCT02728453|Drug|Empagliflozin|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
75610383|NCT02728453|Drug|Glimepiride|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
75610384|NCT02728687|Drug|Mannitol|Apply cream as needed up to 4 times daily to the painful foot and leg
75610385|NCT02728687|Drug|Menthol|Apply cream as needed up to 4 times daily to the painful foot and leg
75758830|NCT00184600|Drug|insulin detemir|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
75904374|NCT04460300|Other|Aromatherapy-inhalation method|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil will be dropped directly on a sterile gauze and individuals will be allowed to breathe from a distance of 10 cm for 5 minutes."
75758831|NCT00184600|Drug|insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
75758832|NCT03967756|Device|Automatic polyp detection system|When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
75758833|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
75610386|NCT00636571|Behavioral|Exercise|Upright bike intervention for post-surgical lung cancer survivors.
75904375|NCT04460300|Other|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
75758834|NCT00265317|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
75904376|NCT05002933|Drug|Insulin glargine 300 U/ml|Solution for injection Subcutaneous injection
75904377|NCT03487250|Device|TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
75904378|NCT03071068|Drug|Anti-PlGF recombinant monoclonal antibody, 4mg dose|3 intravitreal injections of THR-317 4mg approximately 1 month apart
75904379|NCT03071068|Drug|Anti-PlGF recombinant monoclonal antibody, 8mg dose|3 intravitreal injections of THR-317 8mg approximately 1 month apart
75758835|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
75758836|NCT00265317|Drug|placebo|Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
75758837|NCT00373490|Drug|Vorinostat|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
75758838|NCT00373490|Drug|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
75758839|NCT00251589|Drug|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
75904380|NCT06161441|Drug|Fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
75904381|NCT06161441|Drug|Cemiplimab|Administered IV Q3W
75904382|NCT06161441|Drug|Pemetrexed|Administered IV Q3W
75904383|NCT06161441|Drug|Paclitaxel|Administered IV Q3W
75904384|NCT06161441|Drug|Carboplatin|Administered IV Q3W
75904385|NCT06161441|Drug|Cisplatin|Administered IV Q3W
75904386|NCT06161441|Drug|Placebo|Administered IV Q3W
75458341|NCT01805063|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
75458342|NCT01805063|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
75458343|NCT01805115|Drug|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
75458344|NCT01805115|Drug|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
75610387|NCT02720263|Drug|ASP4345|Oral
75610388|NCT02720263|Drug|Matching Placebo|Oral
75610389|NCT02726269|Drug|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
75610390|NCT02726269|Drug|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
75610391|NCT02720029|Device|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
75758840|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
75758841|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
75758842|NCT00251589|Drug|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
75758843|NCT00251589|Drug|erlotinib|erlotinib 150 mg once a day.
75758844|NCT00265239|Drug|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
75758845|NCT00350298|Biological|GS-CDA1/MDX-1388|One Intravenous dose
75758846|NCT00350298|Biological|normal saline|One Intravenous dose
75758847|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight >20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight >45 kg: 80 mg 3 times a day (tid)
75758848|NCT00159874|Drug|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight >20 kg
75758849|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight >20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight >45 kg: 40 mg 3 times a day (tid)
75904387|NCT06161415|Drug|Laquinimod eye drops|n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned
75904388|NCT06161389|Device|Partially inflated mask|Manikin ventilation with a partially inflated mask
75904389|NCT06161389|Device|Fully inflated mask|Manikin ventilation with a fully inflated mask
75904390|NCT06161376|Other|S1P level|Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.
75904391|NCT06161363|Other|The Morisky Medication Adherence Scale|The Morisky Medication Adherence Scale will be completed bu the patients
76069034|NCT00385996|Drug|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
75904392|NCT06161350|Combination Product|Structured multi-disciplinary approach|Since 2010, a structured multidisciplinary team was formed to evaluate the child medically, support its nutrition, teach, treat and educate the children and parents and guide them through the process to obtain a normal and independent feeding behavior. The multidisciplinary team must have special expertise regarding digestive and nutritional as well as sensory and oral motor problems in children requiring artificial nutrition. The team must at least consist of a pediatrician, a dietician with experience in artificial nutrition in children, a speech therapist and/or physical therapist and a psychologist or orthopedagogue. The team should also be able to rely on a nurse with experience in artificial nutrition, a social assistant and a secretary.
75758850|NCT03966430|Procedure|damage control surgery|"Emergency surgery stage, (a) the hybrid operating room restores mesenteric vascular patency. (b) excision of the necrotic intestine (c) retention of suspicious intestinal ducts, double stoma (d) establishment of catheter thrombolysis pathway (e) apply TAC to maintain open abdominal.~ICU phase, including (a) fluid resuscitation; (b) anti-infective and organ function support therapy; (c) continued local anticoagulation, thrombolysis (d) arrange planned re-laparotomy (e) early EN.~Definitive surgical procedures, including (a) Deterministic fascia closure or further removal of the necrotic intestine. (b) Intestinal stoma care and enteral nutrition support treatment. (c) An enterostomy was performed about 6 months after the first operation."
75758851|NCT03966430|Procedure|non-damage control surgery|"The patients are diagnosed with AMI and treated for mesenteric thrombosis and ischemic bowel.~The patient retains the endoluminal catheter after the DSA was diagnosed as AMI.~After diagnosis, the operation is performed in the general operating room, and the intestinal fistula double or the anastomosis is performed according to the judgment of the surgeon.~After the operation, re-laparotomy is performed on demand."
75758852|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
75758853|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
75758854|NCT00184054|Drug|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
75758855|NCT00184054|Drug|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
75758856|NCT03989856|Device|2-0 polyglican absorbable sutures|The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
75904393|NCT06161337|Dietary Supplement|Meals|"Each subject will participate in 4 visits with a 1-week washout period in between visits.~Each visit will be either a morning (8 a.m.) or evening (6 p.m.) consumption of a standardized mixed meal of containing 800 calories (standard control) or 2400 calories (overeating meal) - meals will have the same nutrient composition. The meal components will be weighed before and after consumption to quantify the caloric intake by participant.~Participants will also be provided meals preceding each visit to best standardize daily caloric intake and mitigate any secondary effect this may have on results."
75758857|NCT03989856|Device|Diathermy|bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
75758858|NCT02533908|Drug|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
75758859|NCT02533908|Drug|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
75758860|NCT01051128|Device|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
75758861|NCT02533986|Dietary Supplement|Berry peel drink|
75458345|NCT01805115|Drug|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
75758862|NCT02533986|Dietary Supplement|Control drink|
75758863|NCT00183430|Drug|Prazosin|Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
75758864|NCT00183430|Drug|Placebo|Placebo capsules are taken orally twice per day at 10 am and bedtime.
75758865|NCT00183430|Behavioral|Psychotherapy|All participants will undergo psychotherapy during medication treatment period.
75758866|NCT00183274|Drug|Venlafaxine XR|Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d
75758867|NCT00183274|Drug|Placebo|six month intervention with placebo drug
75758868|NCT00183196|Drug|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
75758869|NCT00183196|Drug|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
75758870|NCT00183196|Other|Inactive Placebo|Placebo
75758871|NCT00349752|Biological|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
75758872|NCT00349752|Other|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
75758873|NCT01055652|Drug|Dapagliflozin|10mg, oral, once daily
75758874|NCT01054326|Other|Exercises|
75904394|NCT06161324|Other|Pelvic floor muscle exercises|3 intervention arms (telerehabilitation, traditional physiotherapy and control) based on a progressive pelviic floor muscle exercise protocol will be used, including the same execise parameters (endurance, sntrength, positioning etc.) for all patients. However, exercise protocols will be individually presribed based on clinical assessment of PFMs by an experienced physiotherapist.
75904395|NCT06161311|Device|DIMS lenses|Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children
75758875|NCT00174460|Drug|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
75610392|NCT02728375|Other|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
75758876|NCT00174460|Other|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
75758877|NCT00348816|Drug|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
75758878|NCT00348816|Drug|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
75904396|NCT06161272|Drug|Fluzoparib|single
75610393|NCT02728375|Other|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
75610394|NCT02719951|Drug|[18F]FPEB PET imaging|PET exam
75904397|NCT06161272|Drug|Fluzoparib+Apatinib|combination
75904398|NCT06161259|Drug|Leritrelvir(Ray1216)|Participants receive Leritrelvir orally.
75904399|NCT06161246|Device|Vibrating Beauty Bar|A vibrating beauty bar will be used at the injection site for patient comfort.
75904400|NCT06161233|Device|CAPABLE cohort|The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing
75904401|NCT06161220|Drug|Carbidopa capsule|Dose: 4x 100 mg
75610395|NCT02719951|Other|Biological samples|blood sample and urine sample
75610396|NCT02719951|Other|MRI|MRI exam
75610397|NCT02719717|Device|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
75758879|NCT00348816|Procedure|Radical prostatectomy|Radical prostatectomy as part of standard care
75758880|NCT00348816|Radiation|Radiation therapy|Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
75758881|NCT03989310|Drug|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle
75758882|NCT03989310|Drug|nab-paclitaxel|Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
75758883|NCT03989310|Drug|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
75758884|NCT03989310|Drug|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
75904402|NCT06161220|Drug|Moxifloxacin Tablets, USP|Dose: 400 mg
75904403|NCT06161220|Drug|Placebo|Placebo capsules matching the carbidopa capsules
75904404|NCT06161168|Device|Bootle Blast Play Phase (B)|"Bootle Blast will be trialed for 14 weeks in the homes of 60 young people (6 to 17 years) with any motor condition that could be addressed by the Bootle Blast system, regardless of their diagnosis. The investigators will assess feasibility (e.g. independent home setup, ability to set/meet self-directed play time goals), enablers/barriers to use, and perceived value.~During the 8-week intervention phase (B), children will have Bootle Blast at home and play it according to their family-directed playtime goals. Weekly logs of therapy activities and problems encountered while playing will be collected through survey links. Additionally, families will record a video of their child performing the tasks associated with their COPM goals on a weekly basis. After the 8-week intervention (B) phase, participants will enter a second 3-week baseline (A) phase, during which they'll be asked to stop playing Bootle Blast, and the game will be programmatically locked to prevent further play."
75610398|NCT02728219|Procedure|TACE|In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)
75610399|NCT02728219|Procedure|Hepatectomy|Repeat Hepatectomy after postoperation recurrence
75610400|NCT02728297|Procedure|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
75610401|NCT02694289|Drug|Metformin|Treatment/continuation of metformin therapy during admission
75610402|NCT02694289|Drug|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
75610403|NCT02728063|Dietary Supplement|Lactibiane Tolerance|probiotics
75610404|NCT02719873|Other|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
75610405|NCT02727985|Procedure|Pharmacist weaning schedule|individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
75610406|NCT02728141|Other|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
75610407|NCT02728141|Other|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
75610408|NCT02719795|Drug|Ropivacaine|Local injection of local anesthetic into the fascial spaces
75610409|NCT02719795|Drug|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
75610410|NCT02719561|Behavioral|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
75758885|NCT01051206|Drug|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
75758886|NCT03966898|Drug|SHR6390 Tablets|SHR6390 Tablets
75758887|NCT03966898|Drug|Placebo Tablets|Placebo Tablets
75758888|NCT03966898|Drug|Letrozole or Anastrozole Tablets|Letrozole or Anastrozole Tablets
75758889|NCT03989544|Biological|Tezepelumab|Tezepelumab subcutaneous injection
75758890|NCT03966196|Other|Measurements of oxygen saturation and finger pressure during deep inspiration|Measurements during deep inspiration of oxygen saturation with pulse oximeter and finger pressure with pressure cuff
75610411|NCT02727829|Device|pefusion index measurement|perfusion index measurement using massimo radical 7 device
75610412|NCT02726347|Biological|PPV-23|one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
75610413|NCT02726035|Drug|Naltrexone|oral naltrexone 50 mg daily
75610414|NCT02726035|Other|Placebo|oral placebo (appearing identical to naltrexone) once daily
75610415|NCT02719405|Dietary Supplement|Lactobacillus GG|Lactobacillus GG
75610416|NCT02719405|Dietary Supplement|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
75610417|NCT02719405|Dietary Supplement|Amino Acid Formula|Amino Acid Formula
75610418|NCT02725957|Drug|Trehalose for IV Infusion|
75610419|NCT02725957|Drug|Saline 0.9% IV|
75758891|NCT03987594|Procedure|Transurethral fulguration of the Hunner lesion|Hunner lesion of the bladder is fulgurated with electronic surgical device under cystoscopic inspection. For the intervention, general or spinal anesthesia is required.
75758892|NCT03987594|Procedure|Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion|Prior to Hunner lesion fulguration, bladder hydrodistension is performed for 8 minutes at pressure of 80cmH2O. And then transurethral fulguration is performed on the Hunner lesion.
75758893|NCT03989700|Drug|Thiamine Mononitrate|Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
75758894|NCT03987750|Drug|Safinamide Methanesulfonate 150mg|150 mg (free base)
75610420|NCT02725879|Other||
75610421|NCT02719483|Device|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
75610422|NCT02719483|Procedure|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
75458346|NCT01805115|Drug|Control|The control group was not given any cervical priming agents or placebo.
75458347|NCT01805128|Other|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
75458348|NCT01805128|Other|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
75458349|NCT01805128|Other|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
75610423|NCT02719249|Other|Dried blood spot test|
75904405|NCT06161155|Combination Product|Protein digestibility|"Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation."
75904406|NCT06161142|Diagnostic Test|Second alkaline phosphatase measurement|(2-4 weeks after the 1st measurement)
75904407|NCT06161142|Diagnostic Test|Extended laboratory diagnostics|Laboratory testing investigating features that support the diagnosis of hypophosphatasia or exclude it by indicating secondary hypophosphatasemia for other reasons (including parameters such as serum calcium, inorganic serum phosphate, vitamin B6, vitamin B12, folic acid, bone-specific alkaline phosphatase, vitamin D3, and more).
75904408|NCT06161142|Diagnostic Test|Symptom and clinical findings checklist for hypophosphatasia|Checklist including numerous symptoms and clinical findings regarding the musculoskeletal system and non-musculoskeletal body parts
75904409|NCT06161142|Diagnostic Test|SF-36|Quality of life questionnaire
75458350|NCT01805167|Other|Electrophysiological study of the interindividual variability of vocal performance|
75458351|NCT01805193|Other|Computed tomography myocardial perfusion imaging|
75458352|NCT01805193|Other|Oxygen 15 labelled water positron emission tomography|
75458353|NCT01805206|Other|Assessment of urinary iFABP|
75458354|NCT01805206|Other|Administration of enteral feedings|
75458355|NCT01805219|Other|GPS and accelerometer recording (s) during exercises|
75458356|NCT01805232|Drug|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
75458357|NCT01805232|Drug|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
75610424|NCT05130385|Device|High-resolution optical coherence tomography (High-Res-OCT)|Imaging with high-resolution optical coherence tomography
75610425|NCT05130385|Device|Standard spectral domain OCT (SD-OCT)|Imaging with standard spectral domain OCT
75758895|NCT03987750|Drug|Safinamide Methanesulfonate 100mg|100 mg (free base)
75758896|NCT03987750|Drug|Safinamide Methanesulfonate matching placebo|placebo
75904410|NCT06161142|Diagnostic Test|Short physical performance battery (SPPB) score|The short physical performance battery is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older or disease-affected people. The scores range from 0 (worst performance) to 12 (best performance). The SPPB has been shown to have predictive validity showing a gradient of risk for mortality, nursing home admission, and disability.
75904411|NCT06161142|Diagnostic Test|Physical examination|A full rheumatological examination will be performed.
75904412|NCT06161142|Diagnostic Test|Recording of vital signs|(including body temperature, blood pressure, heart rate)
75458358|NCT01805245|Behavioral|Mindfulness Based Stress Reduction|Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
75458359|NCT01805258|Drug|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
75458360|NCT01805258|Drug|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
75458361|NCT01805310|Other|Bowel preparation|Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
75458362|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
75610426|NCT02725723|Device|Therm-AppTM TH, thermographic camera|
75610427|NCT02725723|Drug|epidural injection|
75610428|NCT02727595|Device|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
75610429|NCT02727517|Procedure|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
75610430|NCT02727517|Procedure|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
75610431|NCT02719093|Drug|recombinant FSH|Subcutaneous injection
75610432|NCT02727439|Other|Acute Exhausting Exercise (AE)|A single progressive rowing training to maximal exhaustion (AE).
75458363|NCT01805336|Other|Assessment of attentional functions by traditional tests|For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
75458364|NCT01805336|Other|Assessment of attentional functions by virtual reality tests|For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
75758897|NCT01055730|Other|Pulmonary rehabilitation|Structured education and supervised exercise program, lasting between 6 and 9 weeks.
75758898|NCT01051284|Radiation|Cyberknife radiation and gemcitabine|25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
75758899|NCT01051362|Drug|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
75758900|NCT01055808|Drug|Insulins|Individual dose and frequency and duration as determined by the treating physician
75758901|NCT00265083|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
75610433|NCT02725255|Dietary Supplement|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
75758902|NCT00265083|Biological|Golimumab (CNTO 148); placebo|SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
75758903|NCT00265083|Biological|golimumab|50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
75758904|NCT03971097|Behavioral|Six Step Model of Self-Forgiveness|"The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process."
75758905|NCT03971097|Behavioral|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
75758906|NCT00264849|Drug|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
75758907|NCT00264849|Other|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
75758908|NCT01073709|Drug|Acetaminophen|
75904413|NCT06161142|Diagnostic Test|Bioelectrical Impedance Analysis|A body composition measurement by BIA (Bioelectrical Impedance Analysis [proportional mass of muscle, water and fat in kg]) will be performed.
75458365|NCT01805336|Other|Assessment of executive functions by traditional tests|For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
75610434|NCT02725255|Drug|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
75904414|NCT06161142|Diagnostic Test|Genetic testing of the alkaline phosphatase gene|Investigation of mutations regarding the alkaline phosphatase gene
75904415|NCT06161129|Device|Lenses|The filter lenses will be worn by participants for one month all day.
75904416|NCT06161103|Procedure|3D Printed Prefabricated Composite Resin Crown Group|3D Crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
75610435|NCT02725255|Dietary Supplement|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
75610436|NCT02718859|Biological|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
75458366|NCT01805336|Other|Assessment of executive functions by virtual reality test|For assessment of executive functions, virtual reality test include : VAP-S.
75458367|NCT01805336|Other|Evaluation of cognitive complaint, fatigue, anxiety and depression|The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
75458368|NCT01805362|Other|Randomization that determine the time of treatment|
75458369|NCT01805375|Drug|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
75610437|NCT02718859|Procedure|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
75610438|NCT00636727|Procedure|arthrocentesis|Irrigate the TMJ with lactated ringers
75758909|NCT03974607|Behavioral|Physical Activity Program (PAP)|A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
75758910|NCT00211809|Behavioral|Cognitive Behavioral Therapy|standard psychiatric evaluation
75758911|NCT00211809|Drug|Venlafaxine|start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
75758912|NCT01071291|Drug|Niaspan|Niaspan™
75758913|NCT01071291|Drug|Comparator: Placebo|Placebo
75758914|NCT03970941|Other|Cost evaluation|The cost for the hospital of the strategy of management will be evaluated.
75758915|NCT03970941|Other|Questionnaire|The quality of life of patients will be measured.
75758916|NCT01073787|Drug|Normal saline|10 ml/kg of normal saline will be administered over 30 minutes
75758917|NCT00129766|Biological|motavizumab (MEDI-524)|Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
75758918|NCT00129766|Biological|palivizumab|Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
75758919|NCT00150592|Drug|SPD503 (Guanfacine HCl)|
75758920|NCT00150592|Drug|Placebo|
75758921|NCT00149890|Drug|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight <35 kg) or 20 mg (body weight ≥35 kg) strength.
75758922|NCT00149890|Drug|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
75758923|NCT00149890|Drug|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
75758924|NCT00174382|Drug|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
75904417|NCT06161103|Procedure|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
75904418|NCT06161090|Biological|CM310|CM310 injection
75758925|NCT00355134|Drug|Fingolimod|Fingolimod capsules for oral administration
75758926|NCT00355134|Drug|Placebo|Matching placebo capsules for oral administration.
75904419|NCT06161090|Drug|Placebo|subcutaneous injection
75610439|NCT00636727|Procedure|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
75610440|NCT00636727|Procedure|arthroplasty|The disc will be surgically repositioned with open surgery
75610441|NCT02727361|Radiation|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
75610442|NCT02727361|Other|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
75904420|NCT06161064|Drug|Hyaluronic acid|hyaluronic acid is temporary material using for augmentation of vocal folds in patients with glottal insufficiency
75904421|NCT06161038|Device|LASER|LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
75904422|NCT06161038|Device|Ultrasound|1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.
75904423|NCT06161038|Drug|Prolotherapy|Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
75458370|NCT01805388|Drug|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
75458371|NCT01805388|Procedure|Control Non-Study Drug Group|Endodontic RTC with no study drug
75458372|NCT01805401|Device|Transcranial Direct Current Stimulation|Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
75458373|NCT01807507|Device|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
75758927|NCT03987516|Other|Active exercising|Patients allocated to the experimental group were included in an active exercising program adapted to each patient
75758928|NCT00171730|Drug|Pasireotide|
75758929|NCT00355056|Other|Sham Procedure|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.
75758930|NCT00355056|Device|AMPLATZER PFO Occluder|Patients in this arm will receive the AMPLATZER PFO Occluder device
75904424|NCT06160986|Behavioral|Horizons Group Intervention|The Horizons Group intervention in English or Spanish language (per participant preference) contains 8 weekly group sessions delivered via video conference by a bone marrow transplant clinician and behavioral health specialist, over approximately 8 weeks, approximately 1.5 hours per session every week. The intervention pairs state-of-the-science information about survivorship and chronic graft versus host disease with self-management strategies. Intervention sessions will be delivered via video conference (Zoom), which participants may access by computer, laptop, tablet, or smart phone. As part of the intervention, participants will have access to an intervention manual and audio-recorded relaxation exercises to support learning and skills practice.
75904425|NCT06160960|Other|OCT Scan, Video of pupil movement, video of toric lens|A picture of the central macular area is taken, video of pupil movment, video of toric lens rotation.
75904426|NCT06160947|Other|Usual Medical Care|In both the intervention and control arms of the study, usual medical care will be defined as any and all medical care provided to patients with chronic non-cancer back or neck pain at an Ontario CHC, including: primary care provider consultation visits, prescription medication (e.g., muscle relaxants, anti-inflammatories, anti-depressants, opioid and non-opioid analgesics), referral for diagnostic testing (e.g., lab work, imaging) or specialist consultation, as well as other co-interventions (e.g., visits with nurses, dieticians, social workers, or physiotherapists) as required. All participants will also receive opioid-reduction encouragement as per each CHC's current practices. Due to socioeconomic disadvantages, most CHC patients will be unlikely to access private health care services, including chiropractic care, elsewhere. Nevertheless, the investigators will collect data on other health care utilization and conduct all analyses using an intention-to-treat principle.
76069035|NCT01796158|Behavioral|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
76069036|NCT01796158|Behavioral|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
75610443|NCT02719015|Drug|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10^11 vp. Subsequently enrolled patients injected at the same dose of 1x10^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have >/=2 injectable lesions, at the same injection dose of 1x10^10 up to three separate sites/lesions if patients have > 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
75610444|NCT02719015|Drug|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
75610445|NCT02727283|Drug|GSK3179106|GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
75610446|NCT02727283|Drug|Placebo|Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
75758931|NCT00348348|Drug|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
75758932|NCT00348348|Drug|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
75758933|NCT01324986|Procedure|Laparoscopic anti-reflux surgery|
75758934|NCT03989388|Behavioral|Occupational self-analysis|"The Occupational Self-Analysis program provides participants with a space where they can learn to analyse the barriers and supports for occupational participation."
75758935|NCT03989388|Behavioral|Vocational guidance|To explore participant´s job interests and learned how to find a job and define a professional profile.
75758936|NCT03989388|Behavioral|Usual Rehabilitation|Usual rehabilitation: occupational therapy and/or physiotherapy.
75758937|NCT01054482|Drug|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
75758938|NCT01054482|Other|Pre-operative concurrent chemoradiation therapy|"Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op & Post-Op: 2 cycles (total 4 cycles).~Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx"
75758939|NCT02534064|Dietary Supplement|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
75758940|NCT02534064|Dietary Supplement|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
75758941|NCT02533830|Biological|sugarless gum|"One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
75758942|NCT02533830|Other|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
75758943|NCT03987438|Behavioral|Lifestyle intervention with APP|The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management. Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management. Psychological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP. The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
75758944|NCT02533362|Drug|ANF-Rho|Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
75758945|NCT00347958|Biological|Tetanus-diphtheria-acellular pertussis (Tdap) vaccine|0.5mL, Intramuscular (IM)
75758946|NCT00354744|Biological|dactinomycin|"Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), < 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV"
75758947|NCT00354744|Drug|cyclophosphamide|"Age based dosage: ≥ 3 years 1200 mg/m2, <3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV"
75904427|NCT06160947|Other|Usual Medical Care + Chiropractic Care|Treatment sessions may include high-velocity, low-amplitude spinal manipulative therapy, as well as any or all of the following: spinal mobilization, soft-tissue massage/trigger point therapy, education and reassurance (e.g., pain management, ergonomic and activities of daily living recommendations), and home advice (e.g., icing, spinal stretching, and core muscle strengthening exercises). Primary care providers will also engage participants in a formal collaborative effort with the chiropractic clinicians to reduce opioid use. Consistent with current clinical practice guidelines, participants will be provided up to a maximum of 12 chiropractic visits during the active care period, although participants may continue with treatment after the 8-week period (e.g., one visit, every 2-4 weeks) to manage further episodes of exacerbation/flare-up. Aside from the experimental intervention, participants in both study groups will follow the same protocol to minimize non-specific effects.
75904428|NCT06160934|Behavioral|T1D Parent Check-in|The Type 1 Diabetes (T1D) Parent Check-in is an innovative, 3-session, T1D-specific intervention for parents of newly diagnosed children and adolescents that can be delivered via telehealth. The T1D Parent Check-in is an adaptation of The Parent Check-In, a brief, prevention-based parenting intervention developed by Grolnick, Levitt, Caruso, & Lerner (2021). The T1D Parent Check-in is designed to promote parenting skills on dimensions of autonomy support, structure and involvement that facilitate children's adjustment and motivation, and integrates skills from cognitive-behavioral therapy, customized to be highly relevant to families with a child 6-12 months from new diagnosis of T1D. The intervention is intended to promote diabetes-related resilience and positive psychological and medical outcomes among families of children with T1D.
75904429|NCT06160921|Other|Standard therapy|Individualized blood pressure reduction program
75904430|NCT06160882|Other|Powered Prosthesis Training and EMG data collection|"Participants are fit for a custom instrumented socket for collection of surface EMG signals and use with the powered lower limb prosthesis.~EMG control sites will be located using clinical best practices. Once socket fit is completed, the prosthetist will attach and align the powered prosthesis. The participant will be instructed to walk with the powered prosthesis for level ground walking, incline walking, stair climbing and non-weight bearing independence control activities. A non-weight bearing independent control system will be configured. These data are used to train a pattern recognition control system which can control the leg knee and ankle joints respectively, either in a virtual environment or with the physical prosthesis The participants will complete functional, biomechanical, metabolic, and patient reported outcome measures."
75904431|NCT06160882|Procedure|Perform Osseointegration (OI) surgery and Targeted Muscle Reinnervation (TMR)|"Participants will undergo OI Surgery 1 +TMR and recovery. Following recovery, participants will receive OI surgery 2 where the abutment is connected to the fixture with in the femur. Participants will receive standard post-surgical care and participate in the OPRA rehab program through the Shirley Ryan AbilityLab. The participant uses their clinically prescribed prosthetic knee unit for training in the OPRA rehab program.~Post-Surgery Fitting and Powered Leg Prosthesis Training: EMG signals are measured using a custom fit electrode band on the residual limb that is tethered to the prosthesis. Participants are fit with the powered prosthesis using their OI interface and trained on its use. The participant will complete non-weight-bearing neural control tasks as done prior to surgery. The participants will complete functional, biomechanical, metabolic, and patient-reported outcome measures using the OI interface and the powered leg prosthesis."
75904432|NCT06160869|Behavioral|Acceptance and commitment therapy|"The psychoeducational intervention will consist of seven structured sessions aimed at introducing patients with primary psychosis to the principles and practices of Acceptance and Commitment Therapy (ACT). The primary focus of the intervention is to empower participants to effectively manage distressing thoughts and feelings while pursuing meaningful and valued life goals. Each session covers specific aspects of ACT.~Acceptance and commitment therapy will be adminitered in addition to treament as usual provided to patients."
75758948|NCT00354744|Drug|doxorubicin hydrochloride|"Age based dosage: ≥ 1 year: 37.5mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV"
75610447|NCT02725333|Procedure|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
75758949|NCT00354744|Drug|etoposide|"Age based dosage: ≥ 1 year: 100 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
75758950|NCT00354744|Drug|ifosfamide|"Age based dosage: ≥ 1 year: 1800 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
75758951|NCT00354744|Drug|irinotecan hydrochloride|"Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV"
75758952|NCT00354744|Drug|vincristine sulfate|"Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and < 3 years 0.05 mg/kg (max dose 2 mg), < 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV"
75758953|NCT00354744|Procedure|conventional surgery|"Resection of the primary tumor with a surrounding envelope of normal tissue"
75758954|NCT00354744|Radiation|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
75610448|NCT02718937|Drug|BTA-C585 oral capsule|
75904433|NCT06160869|Combination Product|Treatment as usual|The treatment as usual (TAU) for all patients regardless of condition will consist of hospital treatment, including daily medication management sessions with a psychiatrist (e.g., antipsychotic and other medications as appropriate), community meetings, other group therapy, case management, occupational therapy, open air walks, discharge planning, physical examination, and other services (e.g., medical testing).
75610449|NCT02718937|Drug|Matching placebo capsules|
75610450|NCT04189237|Other|Electroacupuncture|needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints.
75758955|NCT00354744|Biological|filgrastim|"5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously."
75758956|NCT01051674|Other|High fiber vs. low-carbohydrate diets|High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
75758957|NCT01055964|Drug|Tacrolimus|
75758958|NCT03989076|Procedure|Interscalene Brachial Plexus Block|Analgesic nerve block as part of routine care with pre- and post-block ultrasonographic imaging of the diaphragm and inferior vena cava
75758959|NCT03987204|Drug|Ivabradine|Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.
75758960|NCT01056042|Drug|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
75758961|NCT01056042|Drug|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
75758962|NCT01051830|Other|Diabetes interdisciplinary program|Diabetes consulting, rehabilitation program
75758963|NCT01056120|Device|Pro Kinetic Energy bare metal stent|PCI
75758964|NCT00373256|Drug|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
75904434|NCT06160856|Diagnostic Test|Abdominal ultrasound|Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score
75904435|NCT06160843|Drug|Pembrolizumab IV infusion Q3W, with daily oral Olaparib.|Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
75758965|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
75758966|NCT00373256|Drug|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
75758967|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
75904436|NCT06160830|Dietary Supplement|synbiotic|Two capsules of synbiotic per day, each containing 500 mg of synbiotic
75904437|NCT06160830|Other|placebo|Two capsules of placebo containing maltodextrin per day
75758968|NCT01324544|Drug|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
75758969|NCT00394082|Drug|ABI-007|125 mg/m^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
75904438|NCT06160804|Procedure|Skeletal traction|A pin through the bone with weights attached
75904439|NCT06160804|Procedure|Femoral shaft splinting|A splint of the broken thigh bone
75904440|NCT06160791|Drug|Ruxolitinib|Administered Orally (PO)
75458374|NCT01807533|Behavioral|Family-centered intervention program|This program was in-hospital intervention, after-discharge intervention, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
75758970|NCT00394082|Drug|Bevacizumab|Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
75904441|NCT06160791|Drug|Etoposide|Administered IV
75904442|NCT06160791|Drug|Dexamethasone|Administered PO or IV
75904443|NCT06160791|Procedure|Non-interventional Imaging|Participants undergo abdominal ultrasound and/or magnetic resonance imaging (MRI)
75904444|NCT06160791|Procedure|Research Biopsy|Bone marrow biopsy and lymph node biopsy will be obtained during screening and as clinically indicated throughout the trial.
75610451|NCT02725489|Biological|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
75610452|NCT02725489|Drug|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
75610453|NCT02693899|Other|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
75758971|NCT00393848|Drug|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
75758972|NCT00393848|Drug|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
75758973|NCT00393848|Drug|Placebo|Placebo for Ketoconazole
75758974|NCT00393458|Drug|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
75758975|NCT00393458|Drug|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
75610454|NCT02718781|Behavioral|Health talk|Health talk on zero-time exercise.
75610455|NCT02718781|Behavioral|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
75610456|NCT02718781|Device|Handgrip|This is a home-based equipment
75758976|NCT00393458|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
75758977|NCT00393458|Drug|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
75758978|NCT01046006|Drug|Bortezomib, Rituximab, Dexamethasone|"Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.~On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.~Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv"
75758979|NCT01046162|Drug|Alprazolam|Single tablet
75758980|NCT01046162|Drug|Alprazolam|Single tablet
75758981|NCT00417482|Drug|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
75758982|NCT01043900|Procedure|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
75904445|NCT06160791|Procedure|Biospecimen Collection|Undergo blood sample collection
75904446|NCT06160778|Drug|Ketorolac Tromethamine|Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
75904447|NCT06160778|Drug|Morphine Sulfate|Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
75904448|NCT06160778|Drug|normal saline|Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
75904449|NCT06160778|Drug|Normal saline|Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
75904450|NCT06160752|Drug|Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
75758983|NCT00417248|Drug|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
75758984|NCT00417248|Drug|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
75758985|NCT00417248|Procedure|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
75758986|NCT00417248|Drug|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
75904451|NCT06160752|Drug|Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
75904452|NCT06160739|Drug|Sirolimus 1Mg Oral Tablet|patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam & ultrasound & MRI to compare lesion size before & after use of the drug with observation of potential side effects & after exclusion of it before use of the drug
75758987|NCT01046240|Drug|Palonosetron|Palonosetron 3 mg administered SC or IV
75758988|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
75758989|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
75758990|NCT00392288|Drug|Placebo|Placebo MDI over twelve weeks
75758991|NCT00417170|Drug|Aliskiren|Aliskiren 300 mg tablets taken orally once daily
75758992|NCT00417170|Drug|Amlodipine|Amlodipine 5 mg capsule taken orally once daily
75904453|NCT06160674|Other|COPD|A vowel segmentation data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques on different segments of a vowel recording.
75904454|NCT06160661|Device|mandibular saggital split osteotomy|orthognathic surgery
75904455|NCT06160648|Other|Management according to Mechanical Diagnosis and Therapy|MDT management is based on the patient response to repeated end range movements.
76069037|NCT00470392|Drug|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
75458375|NCT01807533|Behavioral|Usual care intervention program|This program was in-hospital intervention, after-discharge consultation, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The after-discharge service was provided 7-phone calls for the general health consultation.
76069038|NCT00470392|Drug|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
75758993|NCT00417170|Drug|Placebo Aliskiren|Placebo Aliskiren taken orally once daily.
75758994|NCT00417170|Drug|Placebo Amlodipine|Placebo Amlodipine taken orally once daily
75758995|NCT01046318|Drug|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
75904456|NCT06160648|Other|Management according to the Cervical Spine Clinical Practice Guidelines|CPG management is based on clinical research regarding management of people with neck pain.
75610457|NCT02716519|Biological|Santyl|Collagenase ointment applied topically once per day for up to six weeks
75610458|NCT02716519|Other|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
75610459|NCT02716831|Behavioral|Nutritional Counseling & Acceptance-based Therapy|
75610460|NCT02716831|Behavioral|Cognitive Behavioral Therapy for Eating Disorders|
75610461|NCT02339233|Device|Standing and Stepping with spinal cord Epidural Stimulation|Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
75758996|NCT00392990|Drug|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
75904457|NCT06160622|Drug|Leritrelvir|Oral
75904458|NCT06160609|Drug|Belantamab Mafodotin|Belantamab Mafodotin will be administered.
76069039|NCT00470548|Drug|Abraxane|ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
75904459|NCT06160609|Drug|GSK3174998|GSK3174998 will be administered.
75758997|NCT00392990|Drug|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
75758998|NCT01046474|Behavioral|lifestyle|"Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.~Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.~Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted."
75758999|NCT01046552|Procedure|preoperative ERCP and LC|preoperative ERCP followed by LC
75904460|NCT06160596|Genetic|Long term survival multimodal analysis|"To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~To describe global signatures in the overall population (pan-cohort).~To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"
75759000|NCT01046552|Procedure|Intraoperative ERCP and LC|LC and intraoperative ERCP
75904461|NCT06160570|Radiation|Intensive Modulated Radiation Therapy|Radiotherapy technique: IMRT
76069040|NCT00470548|Drug|Alimta|Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
75458376|NCT01807559|Device|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
75759001|NCT01043978|Behavioral|Use of baby bottle nipple|Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
75759002|NCT01044134|Behavioral|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
75759003|NCT00249873|Drug|clopidogrel (SR25990C)|oral administration (tablets)
75759004|NCT00249873|Drug|placebo|oral administration (tablets)
75759005|NCT00392210|Genetic|Voiding Trial|Post-void residual and uroflow study will be done twice
75759006|NCT01037348|Drug|ranibizumab 0.5mg|
75759007|NCT03490292|Combination Product|Avelumab combined with Chemoradiation|Co-administration of avelumab with chemoradiation in pre-operative period.
75759008|NCT03490292|Drug|Carboplatin|Weekly Carboplatin (AUC2) [intravenous infusion on days 1, 8, 15, 22, & 29]
75759009|NCT03490292|Drug|Paclitaxel|Weekly paclitaxel [intravenous infusion on days 1, 8, 15, 22, & 29]
75904462|NCT06160570|Radiation|3-Dimension Conformal Radiation Therapy|Radiotherapy technique: 3DCRT
75904463|NCT06160531|Drug|CC-42344|Anti-influenza A agent
75759010|NCT03490292|Radiation|Radiation|Radiation therapy [23 fractions, M-F, estimated completion day 35]
75904464|NCT06160531|Drug|Placebo|Matching placebo
75904465|NCT06160518|Behavioral|Virtual reality|artificial construction of 3D environment via mobile technology. It included a head-mounted device (HMD) with 3D-enabled goggles, sensory input devices and headphones, which together allow a multisensory experience to divert a child's attention.
75904466|NCT06160505|Device|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
75904467|NCT06160479|Drug|Calcium supplement|Different amount of calcium supplement in pregnancy
76069041|NCT04388488|Device|CONNECT TF adaptable socket system|Prefabricated, adaptable socket system
75458377|NCT01807663|Device|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
75458378|NCT01807663|Device|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
75458379|NCT01807676|Device|ET View Double Lumen Tube|
75458380|NCT01807676|Device|conventional Double Lumen Tube|
75610462|NCT04124263|Other|Educational short message texts|Educational messages for patient engagement
75759011|NCT01046630|Drug|AZD6765|single infusion
75759012|NCT01046630|Drug|Ketamine|single infusion
75759013|NCT01046630|Drug|Placebo|single infusion
76069042|NCT04388488|Device|Any conventional handmade socket|Subjects current socket
76069043|NCT00472576|Drug|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
75610463|NCT04124263|Other|Adherence short message texts|Reminder messages of medication use time
75610464|NCT02718547|Drug|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
75610465|NCT02725099|Drug|Chewing Ticagrelor|180 mg Chewing Ticagrelor
75610466|NCT02725099|Drug|Oral Ticagrelor|180 mg oral Ticagrelor
75610467|NCT02718703|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
75610468|NCT02325427|Device|tDCS|tDCS could deliver either real or sham stimulation.
75759014|NCT01037426|Other|Fill out Questionnaire|"Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect~History of falls and fractures during the 12 months before pacemaker implantation~Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)~History of falls and fractures during the 12 months after pacemaker implantation~Medical and Arrhythmia History~Cardiovascular Events~Cardiovascular Medication~Device programming information"
75759015|NCT01046708|Drug|micronized progesterone|600mg in 3 separate doses per day
75759016|NCT01046786|Biological|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
75759017|NCT01046786|Drug|Methylprednisolone|30 mg/kg methylprednisolone
75759018|NCT01046786|Drug|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
75759019|NCT00391976|Drug|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
75759020|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section.
75759021|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
75904468|NCT06160466|Device|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a follow-up pateints in the screening population.
75904469|NCT06160466|Device|White light|White light endoscopy
75458381|NCT01807702|Drug|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
75904470|NCT06160440|Drug|SC1011|Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
76069044|NCT00472576|Drug|Placebo|Daily double-blind administration of placebo
75759022|NCT00762554|Drug|Fentanyl|Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
75904471|NCT06160427|Biological|CTM Boost|Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.
75904472|NCT06160427|Biological|PRP|"PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing.~At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon."
75759023|NCT00391898|Drug|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
75904473|NCT06160401|Drug|Singletine|Singletine orally administered
75904474|NCT06160401|Drug|Placebo|Placebo orally administered
75904475|NCT06160388|Device|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
76069045|NCT00388414|Drug|duloxetine|30-60mg of duloxetine daily
76069046|NCT00388414|Drug|Placebo|Placebo pill once daily
76069047|NCT00475150|Drug|cediranib maleate|Given orally
76069048|NCT00475150|Other|laboratory biomarker analysis|Correlative studies
75458382|NCT01807741|Drug|Asenapine|Available in 5 and 10 mg.
75458383|NCT01807741|Drug|Placebo|
76069049|NCT04388410|Biological|convalescent plasma|Plasma obtained from volunteers who have recovered from SARS-Cov-2 infection. Two 200 ml infusions will be administered with 24-72 hours in between.
75458384|NCT01807754|Procedure|X-ray and ultrasound imaging scanning|Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. The participant will be seated and her breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.
75610469|NCT02724865|Device|Somnodent® (Oral appliance therapy)|
75610470|NCT02724865|Device|Herbst® (Oral appliance therapy)|
75610471|NCT01225211|Drug|Lumacaftor|Tablet
75610472|NCT01225211|Drug|Ivacaftor|Tablet.
75610473|NCT01225211|Drug|Lumacaftor Placebo|Matching placebo tablet.
75610474|NCT01225211|Drug|Ivacaftor Placebo|Matching placebo tablet.
75610475|NCT02685709|Drug|Octreotide capsules|
75610476|NCT02265367|Drug|Levomilnacipran|
75610477|NCT02265367|Drug|Placebo|
75610478|NCT02718469|Biological|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
75610479|NCT02718469|Biological|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
75904476|NCT06160375|Diagnostic Test|pain assessment after video assisted thoracoscopic lung surgeries|a scalp needle with an extended tube will be inserted into the paravertebral space at the T4 level under thoracoscopic direct vision before closing the chest. One centimeter adjacent to the vertebrae will be inserted vertically 0.5 cm under the parietal pleura with the needle, and 20 ml 0.25% bupivacaine will be injected then the field will be observed for 5 min to make sure that there is no hemorrhage or hematoma.
75759024|NCT00391898|Drug|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
75759025|NCT03993080|Device|Virtual reality relaxation|1-3.5 minute 360° videos
75759026|NCT01046864|Drug|5-FU|IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
75759027|NCT01046864|Drug|Leucovorin|IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
75759028|NCT01046864|Drug|5-FU|IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
75759029|NCT01046864|Drug|Irinotecan|IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
75904477|NCT06160362|Biological|CART-19 and 20 cells|Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
75904478|NCT06160362|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
76069050|NCT00450424|Other|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
75759030|NCT01046864|Drug|Brivanib|Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
75759031|NCT01046864|Drug|Brivanib|Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
75759032|NCT01046864|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
75759033|NCT01046942|Drug|Clopidogrel+acetylsalicylic acid|loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
75759034|NCT01046942|Drug|acetylsalicylic acid|aspirin 75 mg daily, started 6-24 hours after surgery
75759035|NCT01049282|Biological|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
75759036|NCT01049282|Biological|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
75759037|NCT01049438|Drug|nasal mupirocin|twice daily for 10 days
75759038|NCT01049438|Drug|topical 3% hexachlorophene body wash|daily for 10 days
75759039|NCT01049438|Drug|oral anti-MRSA antibiotic|The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
75904479|NCT06160362|Drug|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
75904480|NCT06160323|Procedure|EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis|"The EUS scope was first inserted into the stomach, and the coeliac trunk was visualized by scanning from the lesser curve of the gastric body. After visualization, the scope was rotated clockwise, enabling visualization and identification of the left adrenal gland. The coeliac ganglia are often seen to the left of the coeliac artery, between the aorta and the left adrenal gland, at the level between the coeliac artery and the left adrenal artery. They are also visualized cephalad to the coeliac artery in some cases. Hypoechoic nodular structures linked by hypoechoic threads residing in the periphery of this region were defined as the coeliac ganglia . A 19G or 22G needle was used for puncture of the CGN. After confirming the lack of backflow of blood with aspiration, a mixture of 5ml of 0.25-0.5% bupivacaine and 5ml absolute alcohol was injected.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed."
75759040|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
75759041|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
75759042|NCT01047098|Dietary Supplement|Placebo|Placebo capsule
75759043|NCT01047254|Drug|Elontril|flexible dose of Bupropion 150-300 mg
75759044|NCT01047254|Drug|placebo|
75904481|NCT06160297|Procedure|Modified Otago Exercise|"The exercises are as follows;~Warm-up exercises (5 min)~Strengthening exercises (weight attached to ankle)~Knee extension while sitting on a chair~Knee flexion while standing with support from a chair~Hip abduction while standing with support from the chair~Strengthening exercises (weight removed from ankle)~Standing on tiptoe with support from a chair~Rising on the heels with support from a standing chair~Balance Exercises (progressively, with support - without support)~Mini squats~Toe walking~Walking on heels~Tandem stance~Tandem walking~Walking backwards (10 steps)~Standing on one leg~Assisted side walking~Side walking without support~Sit and stand on the chair~Figure eight walking"
75458385|NCT01807754|Procedure|Photoacoustic imaging scans for breast cancer screening|The participant will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the participant's chest to allow the computer to record ultrasound blood flow in the breast. The low intensity laser light will be focused on the targeted area of the breast.
75610480|NCT02718469|Biological|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
75610481|NCT02718469|Biological|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
75904482|NCT06160297|Procedure|Neuromuscular Exercise|"Proprioceptive stabilization of the knee with ball~Bridging with ball~Stepping forward, sideways and backwards by holding on to a fixed support while standing~Doing the same movements with the support leg on a different surface~Hip abduction-adduction with resistance band~Knee flexion-extension with resistance band~Climbing and descending steps by taking steps~Balancing on the step~Standing up from the chair"
75610482|NCT02716363|Device|Rotational Atherectomy by Rotablator|
75610483|NCT02716285|Drug|Ileocolonic release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
75610484|NCT02716285|Drug|Placebo|Placebo capsule, containing microcrystalline cellulose
75904483|NCT06160284|Drug|Psilocybin|Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants < 70 kg) or 25 mg (among participants >70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline [11C]-UCB-J PET.
75458386|NCT01807767|Drug|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
75458387|NCT01807767|Drug|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
75458388|NCT01807780|Biological|biological monitoring|
75458389|NCT01807793|Behavioral|Psychoeducation|
75458390|NCT01807806|Behavioral|Role-playing game|Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
75458391|NCT01807832|Other|capsaicin challenge|
75458392|NCT01807845|Dietary Supplement|enriched skimmilk with VD|enriched skimmilk with VD
75458393|NCT01807845|Dietary Supplement|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
75458394|NCT01807845|Dietary Supplement|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
75610485|NCT02716285|Drug|Small intestinal release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
75610486|NCT02725021|Behavioral|Education Against Tobacco school-based intervention by medical students|
75610487|NCT01224821|Biological|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
75610488|NCT02684851|Drug|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
75610489|NCT02684851|Drug|Placebo|Placebo
75610490|NCT01224431|Drug|Buffered Lidocaine J-tip|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
75759045|NCT01047410|Other|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
75759046|NCT01047410|Other|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
75904484|NCT06160271|Drug|PET scan of 68Ga-FAPI|Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
75904485|NCT06160245|Other|exercise therapy|core stabilization exercises
75904486|NCT06160232|Drug|Psilocybin (high dose)|Psilocybin-assisted therapy
75904487|NCT06160232|Drug|Active placebo (low dose of psilocybin)|Placebo-assisted therapy
75458395|NCT01807858|Dietary Supplement|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
75458396|NCT01807858|Dietary Supplement|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
75458397|NCT01807858|Other|Maltodextrin|Maltodextrin
75458398|NCT01807858|Dietary Supplement|İnulin|900 mg inulin per day will be given
75610491|NCT02724943|Behavioral|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
75610492|NCT02724943|Behavioral|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
75610493|NCT02724943|Behavioral|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
75458399|NCT01807884|Procedure|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
75610494|NCT02724943|Behavioral|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
75610495|NCT02724943|Behavioral|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
75904488|NCT06160219|Drug|Hydroxycobalamin|prophylactic to prevent vasoplegia in high risk patients undergoing CABG or valvular surgeries
75904489|NCT06160206|Biological|Bevacizumab|Given IV
75904490|NCT06160206|Procedure|Biospecimen Collection|Undergo blood sample collection
75904491|NCT06160206|Procedure|Computed Tomography|Undergo CT
75904492|NCT06160206|Other|Electronic Health Record Review|Ancillary studies
75904493|NCT06160206|Radiation|Hypofractionated Radiation Therapy|Undergo radiation therapy
75904494|NCT06160206|Procedure|Magnetic Resonance Imaging|Undergo MRI
75904495|NCT06160206|Biological|Retifanlimab|Given IV
75904496|NCT06160180|Drug|Dexamethasone|Submucosal application
75904497|NCT06160167|Drug|IMiD treatment|Participants with MM treated with IMiDs
75904498|NCT06160167|Drug|No IMiD treatment|Participants with MM not treated with IMiDs
75904499|NCT06160167|Drug|Systemic therapy|Participants with MM treated with systemic therapy
75904500|NCT06160154|Other|no intervention|all patients undergoing minimally invasive distal pancreatectomy, no intervention, no randomization
75610496|NCT02716129|Drug|Morphine|38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
75610497|NCT02716129|Drug|Morphine plus Nalbuphine|39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
75458400|NCT01807884|Other|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
75610498|NCT01223183|Drug|hypertonic saline (7%)|single treatment by inhalation
76069051|NCT00450424|Other|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
76069052|NCT00451048|Drug|sunitinib malate|Given orally
75610499|NCT01223183|Drug|isotonic saline|single treatment by inhalation
75610500|NCT02718391|Biological|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
75610501|NCT02718235|Other|Overall survival|Observation of overall and disease free survival
75610502|NCT02724709|Procedure|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
75610503|NCT02724709|Procedure|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
75610504|NCT02920333|Procedure|conventional rehab training|Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
75759047|NCT00391586|Drug|Erlotinib|"Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient"
75759048|NCT00391586|Drug|Platinum-based chemotherapy|Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
75458401|NCT01807910|Drug|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
75610505|NCT02920333|Device|tDCS|tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
75610506|NCT02920333|Device|rTMS|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
75759049|NCT00391430|Drug|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
75759050|NCT00391430|Behavioral|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
75759051|NCT00391274|Drug|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
75759052|NCT00391274|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
75759053|NCT00391118|Drug|enzastaurin|
75759054|NCT00391118|Drug|carboplatin|
75759055|NCT00391118|Drug|paclitaxel|
75759056|NCT00391118|Drug|placebo|
76069053|NCT00388804|Procedure|Radiation Therapy|Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
76069054|NCT00388804|Drug|Bicalutamide|50 mg By Mouth (PO) Daily
75458402|NCT01807962|Drug|rapidocain and bethametsaone|"lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine~bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)"
75458403|NCT01807962|Drug|sterile saline|Placebo = 5ml of sterile saline solution
75458404|NCT01807975|Other|Forced oscillation|
75610507|NCT02920333|Device|sham tDCS|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
75610508|NCT02724553|Device|Acrylic lens implantation|
75610509|NCT02718079|Biological|Plasma Exchange|
75610510|NCT02718079|Other|Management of cerebral edema/intracranial hypertension:|
75610511|NCT02718079|Other|Transfer to Intensive Care Unit|
75610512|NCT02718079|Drug|Prophylactic Antibiotics|
76069055|NCT00388804|Drug|Leuprolide|22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
75610513|NCT02718079|Other|Intubation of trachea|
75610514|NCT02718079|Other|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
75759057|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
75610515|NCT02718079|Other|Volume Replacement|
75610516|NCT02718079|Other|Pressor Support|
75610517|NCT02718079|Drug|N-acetyl-L-cysteine|
75759058|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
76025321|NCT05128175|Drug|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
75759059|NCT01047488|Drug|Imipramine|Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
75759060|NCT01047488|Drug|Pregabalin|Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
75759061|NCT01047488|Drug|Imipramine, pregabalin|Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
75759062|NCT01047488|Drug|Placebo|Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
75759063|NCT01047566|Drug|Dronedarone|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)
75759064|NCT01047566|Drug|Beta blocker or calcium antagonist or digoxin|Dose increase of beta blocker or calcium antagonist or digoxin
76069056|NCT00388804|Drug|Goserelin|10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
76069057|NCT00388804|Drug|Flutamide|250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
75759065|NCT00365846|Drug|Campath-1H|
75759066|NCT00264537|Drug|Placebo injections|SC injections
75610518|NCT02718079|Other|Correction of metabolic parameters|
75458405|NCT01807988|Behavioral|iCBT|Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
75610519|NCT02718079|Dietary Supplement|Correction of nutrition|
75759067|NCT00264537|Drug|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
75759068|NCT00264537|Drug|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
75759069|NCT00264537|Biological|Golimumab 50 mg injections|SC injections
75759070|NCT00264537|Biological|Golimumab 100 mg injections|SC injections
75759071|NCT00371462|Behavioral|Use of PDA + support to reduce weight and pain|participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
75759072|NCT00371462|Behavioral|MOVE! level 2 group weight loss counseling|Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
76069058|NCT00388804|Behavioral|Questionnaire|Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
76069059|NCT01795066|Device|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
76069060|NCT00389818|Biological|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
76069061|NCT00389818|Biological|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
75458406|NCT01808014|Drug|nefopam|The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
75458407|NCT01808040|Drug|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
75610520|NCT02717923|Other|maintenance treatment with capecitabine plus cetuximab|Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
75610521|NCT02724475|Procedure|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
75610522|NCT02724475|Procedure|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
75610523|NCT02716207|Device|CyberKnife|Radiation Therapy
75610524|NCT02716051|Device|MRI|Whole body MRI with cardiac and pulmonary synchronization
75610525|NCT02716051|Device|PET|
75610526|NCT02717845|Device|Ellipse|diagnostic CT scan imaging
75610527|NCT02717845|Device|Tomofix|diagnostic CT scan imaging
75759073|NCT00371150|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
75759074|NCT00264303|Drug|Levocetirizine|5mg oral capsules, once daily, 4 week duration
75759075|NCT00264303|Drug|Desloratadine|5mg oral capsules, once daily, 4 week duration
75759076|NCT01071369|Drug|Xylocaine|0.5% Xylocaine
75759077|NCT01071369|Drug|Xylocaine and Celestone|non-particulate Celestone
75458408|NCT01808053|Device|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
75759078|NCT01072305|Device|Intermittent pneumatic compression (IPC)|Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
75759079|NCT01072305|Device|IPC - placebo|ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
75759080|NCT00370682|Biological|T-DEN F17|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
75759081|NCT00370682|Biological|T-DEN F-19|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
75759082|NCT00370682|Other|Placebo Comparator|A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
75759083|NCT00264147|Drug|etoricoxib|Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
75759084|NCT00264147|Drug|etoricoxib|Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
75759085|NCT00264147|Drug|etoricoxib|Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
75759086|NCT00264147|Drug|etoricoxib|Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
75759087|NCT00264147|Drug|Comparator: placebo|Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
75759088|NCT00264147|Drug|etoricoxib|Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
75759089|NCT00264147|Drug|Comparator: diclofenac|Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
75458409|NCT01808079|Other|Laboratory Biomarker Analysis|Correlative studies
75458410|NCT01808105|Other|Control Formula|Feeding ad libitum
75458411|NCT01808105|Other|Experimental Formula 1|Feeding ad libitum
75458412|NCT01808105|Other|Experimental Formula 2|Feeding ad libitum
75610528|NCT02715973|Dietary Supplement|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
75759090|NCT01044368|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
75759091|NCT01044446|Drug|Icodextrin|one exchange daily
75458413|NCT01808105|Other|Human Milk|Feeding ad libitum
75759092|NCT01044446|Drug|glucose-based peritoneal dialysate|original exchange frequency
75759093|NCT00263757|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
75759094|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
75759095|NCT01072383|Drug|BT061|administration of BT061 either intravenous or subcutaneous
75759096|NCT01072383|Drug|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
75759097|NCT01072461|Behavioral|HAS Training|Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
75759098|NCT01072461|Behavioral|HAT training|Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
76069062|NCT00389818|Biological|rituximab|375 mg/m2 IV Day 1 of each cycle
75458414|NCT01808131|Drug|Lesinurad|Tablets, 200 mg QD
75458415|NCT01808131|Drug|Lesinurad|Tablets, 400 mg QD
75610529|NCT02715973|Dietary Supplement|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
75610530|NCT02724397|Device|LCI/BLI then white endoscopy|First use of Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy to detect colonic adenomas.
75610531|NCT02724397|Device|White endoscopy and then LCI/BLI|First use of White Light Endoscopy and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) to detect colonic adenomas.
75610532|NCT02717533|Other|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
75759099|NCT01072461|Behavioral|Bimanual Training|Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
75759100|NCT03970863|Diagnostic Test|Prostate Health Index|Use Prostate Health Index for the follow-up after focal therapy.
75759101|NCT03971019|Drug|statins|On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).
75759102|NCT03971019|Behavioral|Dietary intervention group (control group)|Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol < 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2~3 g/d Water soluble dietary fiber 10~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
75759103|NCT03970707|Other|Small Number of Players training protocol A|8 participants each side game (4vs4), size of pitch area 25*20 m. In total, 6 consecutive 4-minutes bouts interspersed by a 3-minutes rest between each bout will be executed.
75759104|NCT03970707|Other|Large Number of Players training protocol B|16 participants each side game (8vs8), size of pitch area 25*20 m. In total, 3 consecutive 8-minutes bouts interspersed by a 1-minutes rest between each bout will be executed.
75759105|NCT03974685|Drug|99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)|Single dose
75759106|NCT03970551|Other|Physical Counter-maneuver|Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.
75759107|NCT03970551|Other|Stress Test|Stress test involving submerging your hand in ice water or performing mental arithmetic to increase sympathetic activity.
75759108|NCT03970551|Other|Functional Electrical Stimulation|A mild electrical stimulus to passively induce a leg muscle contraction with minimal sympathetic activation.
75759109|NCT03970473|Other|Pulmonary recruitment maneuver (PRM)- 30 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
75759110|NCT03970473|Other|Pulmonary recruitment maneuver (PRM)- 15 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
75759111|NCT00263211|Drug|Plavix|
75759112|NCT00263211|Drug|Aspirin|
75759113|NCT03970317|Device|Broad Band Light|Broad Band Light Device
75759114|NCT00248625|Drug|N-acetylcysteine|The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
76069063|NCT00389818|Biological|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
76069064|NCT00389818|Drug|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
76069065|NCT00389818|Drug|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
76069066|NCT00389818|Drug|prednisone|100 mg PO Days 1-5 of each cycle
76069067|NCT00389818|Drug|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
75458416|NCT01808157|Drug|CT327 ointment|
75458417|NCT01808157|Drug|placebo|
75610533|NCT02715817|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.
75610534|NCT02715817|Other|Conventional therapeutic exercises|It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.
75610535|NCT02715817|Other|Virtual Rehabilitation and Conventional Therapeutic Exercise|It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
75759115|NCT00248625|Drug|Placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
75759116|NCT00262821|Drug|cisplatin|Given IV
75759117|NCT00262821|Drug|tirapazamine|Given IV
76069068|NCT00389818|Other|immunohistochemistry staining method|tissue specimen collected at baseline
75610536|NCT02717689|Other|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
75610537|NCT02717065|Other|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
75610538|NCT02717065|Other|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
75610539|NCT02694367|Other|Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins|
75610540|NCT04864171|Device|near-infrared spectroscopy|Near-infrared spectroscopy is an intravascular imaging device to visualize lipid-rich plaque of coronary artery.
75610541|NCT02715739|Other|No intervention|
75759118|NCT00262743|Biological|Polyphenon E|"Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day~Phase II: 2000 mg orally twice a day"
75759119|NCT03974529|Behavioral|Intensive running|The patients who are assigned to this group will be required to finish a 90 minutes of training protocol, containing 30 minutes' warm-up stretching, and 60 minutes of supervised progressive aerobic endurance track running. The training takes place two time per week, for 24 weeks.
75759120|NCT03974529|Behavioral|Physiotherapy|The patients who are assigned to this group will be required to finish a 60 minutes of physiotherapy session. The training takes place once per week, for 24 weeks.
75759121|NCT01326117|Drug|tadalafil|7 days of Cialis for Daily Use (5mg)
75759122|NCT03970239|Drug|Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)|"Imaging of the serotoninergic system with Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg) of [11C]-DASB immediately prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 2.1 milliSievert (mSv).~On a separate day, subjects will receive a single intravenous administration of approximately 3.7 MBq/kg of [18F]-altanserin for 120 minutes prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 8.4 mSv."
75759123|NCT03970239|Drug|Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)|Imaging of the serotoninergic system with Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 3.7 Megabecquerel/kilogram (MBq/kg) of [18F]-altanserin 120 minutes prior to imaging using Positron Emission Tomography. The effective dose in human body is about 8.4 mSv.
75759124|NCT03970161|Device|routine ophthalmic examination|Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
75759125|NCT03974295|Behavioral|Vaginal unprotected intercourse|Patients will allowed to engage in vaginal unprotected intercourse as many times as desired after 24 hours of pelvic rest after a frozen embryo transfer.
75759126|NCT00262119|Device|Pacemaker Medtronic EnRhythm|Pacemaker specific programming
75759127|NCT00170950|Drug|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
75759128|NCT00170950|Drug|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
75759129|NCT00170950|Drug|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
75759130|NCT00170950|Drug|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
75759131|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
75458418|NCT01808170|Procedure|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
75610542|NCT02715661|Other|exercise|six-month interval of exercise
75610543|NCT04860817|Biological|Target CD7 CAR-T cells|"Enrolled participants are allocated to one of three different dose levels of target CD7 CAR-T cells. The infusion dose of CAR-T cells will start at low dose and then rise to higher dose after completion of low dose group.~Dose level one: 0.6×10^7 cells/kg;~Dose level two: 1×10^7 cells/kg;~Dose level three: 1.5×10^7 cells/kg. Before CAR-T infusion, all participants will receive a preconditioning therapy suggested as: Fludarabine 30 mg/m^2×6d, Cyclophosphamide 300 mg/m^2×6d or Cyclophosphamide 600 mg/m^2×6d. After completion of preconditioning therapy, infusion of CAR-T cells needs to start within 1 week. Participants will receive one infusion of CAR-T cells which will take between 15 and 30 mins."
75610544|NCT02717221|Other|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
75610545|NCT02715895|Dietary Supplement|Friso|Friso formula feeding on demand for 3 months
75759132|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
75610546|NCT02715895|Dietary Supplement|Wyeth|Wyeth formula feeding on demand for 3 months
75610547|NCT02715895|Dietary Supplement|Breast milk|Breast milk feeding on demand
75610548|NCT02717299|Device|Verasense|Verasense will collect balancing data on all patients in this trial.
75610549|NCT04189315|Drug|asfotase alfa|Asfotase alfa is administered subcutaneously.
75610550|NCT02724163|Drug|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
75610551|NCT02724163|Drug|Liposomal daunorubicin|"Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug."
75610552|NCT02724163|Drug|Mitoxantrone|DNA-reactive agent
75610553|NCT02724163|Drug|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
75759133|NCT00239577|Biological|Live attenuated tetravalent dengue vaccine|Live attenuated tetravalent dengue vaccine
75610554|NCT02724163|Drug|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
75759134|NCT00239577|Biological|Placebo|Placebo
75759135|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, adjuvanted|
75759136|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, unadjuvanted|
75759137|NCT00262041|Biological|MenACWY polysaccharide vaccine|
75759138|NCT03969849|Drug|REGN5713-5714-5715|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
75759139|NCT03969849|Drug|Matching placebo|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
75759140|NCT01071447|Other|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
75759141|NCT00208767|Drug|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
75759142|NCT00208767|Drug|Placebo|A matched placebo pill will be given orally daily.
75759143|NCT03969771|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program was developed by the University of Massachusetts Medical School.
76025322|NCT05341427|Device|electromagnetic device|electromagnetic waves for burn wound
75759144|NCT02531529|Drug|dexmedetomedine|intraoperative infusion
75759145|NCT02531529|Drug|Fentanyl|
75759146|NCT01071525|Drug|Niacin\Laropiprant|Hypercholesterolemic patients with low HDL will receive Niacin\Laropiprant
75759147|NCT03969537|Other|Telemedicine follow-up visit|Study participants will experience two telemedicine (live audio/video) visits.
75610555|NCT02724163|Drug|Busulfan|Alkylsulfonate
75610556|NCT02724163|Drug|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
75759148|NCT03969615|Device|SuperNO2VA nasal positive airway pressure devic|SuperNO2VA nasal positive airway pressure device utilizes supplemental oxygen and an adjustable pressure limiting valve to maintain upper airway latency
75759149|NCT03969615|Device|Supplemental oxygen|5lpm of supplemental oxygen
75610557|NCT02723851|Device|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
75610558|NCT02717377|Behavioral|physical activity|
75610559|NCT02486965|Device|thermode (TSA-II model)|thermal stimulation with test thermode
75610560|NCT02486965|Other|Adapted Physical Activity|
75610561|NCT02486965|Other|Physical activity|
75610562|NCT02723539|Drug|MBN-101|Topical application
75610563|NCT02723539|Drug|Placebo|Topical application
75759150|NCT01072695|Drug|GS-9256|75 mg BID x 28 days
75759151|NCT01072695|Drug|GS-9190|40 mg BID x 28 days
75759152|NCT01072695|Drug|Ribavirin|1000-1200 mg/day given BID
75610564|NCT02723617|Other|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
75610565|NCT02723617|Other|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
75610566|NCT02723617|Other|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
75610567|NCT02723617|Other|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
75759153|NCT01072695|Drug|Peginterferon alfa-2a|180 ug q week
75759154|NCT00390806|Drug|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
75759155|NCT00390806|Radiation|Radiation|Whole brain radiation
75759156|NCT01049516|Behavioral|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
75759157|NCT01049516|Behavioral|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
75759158|NCT01049516|Behavioral|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
75759159|NCT01049516|Behavioral|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
76025323|NCT05119205|Diagnostic Test|Bone marrow biopsy and compete blood count|Bone marrow biopsy and compete blood count will be done for follow up in patients with multiple myeloma
76025324|NCT04184453|Drug|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patients.
76025325|NCT05127707|Behavioral|Words Matter - Visual Campaign|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
76069069|NCT00389818|Other|laboratory biomarker analysis|tissue specimen collected at baseline
76069070|NCT00452374|Drug|Cytarabine|1 g/m^2 given IV for two days (Days 2 and 3).
75759160|NCT00390572|Behavioral|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
75759161|NCT01047644|Other|Reduced port-flush schedule|3-month port-flushing
75904501|NCT06160141|Other|Resistance training|"Resistance training program. The RT program was performed over 48 weeks, three times per week (Mondays, Wednesdays, and Fridays), during the morning, in the University fitness facility. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise) with substantial RT experience to ensure consistent and safe exercise performance.~Participants performed four exercises for the trunk and upper limbs and four exercises for the lower limbs in three sets of 8-12 repetitions. T Rest intervals were 1-2 and 2-3 min between sets and exercises. The training load was individually adjusted for each exercise weekly, according to the number of repetitions performed during the last training session, to ensure that the subjects kept performing at the ideal intensity for the repetition zone. In these situations, training loads were increased by 2-5% for upper-limb exercises and 5-10% for lower-limb exercises."
75904502|NCT06160115|Device|Flow cytometry|"Profiling of NK cells using flow cytometry on peripheral blood and bone marrow aspirate samples.~Isolation and identification of pathogens causing BSI and bacterial drug susceptibility testing using VITEK compact fully automatic microbial identification instrument."
75759162|NCT00135200|Drug|Iodine I 131 Tositumomab|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose."
75759163|NCT01047722|Drug|Aspirin ingestion followed by doing a Bleeding Volume Test|Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
75458419|NCT01808170|Procedure|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
75759164|NCT01047722|Procedure|Gatorade Placebo followed by Bleeding Volume Test.|Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
75759165|NCT01047800|Behavioral|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
75759166|NCT00390416|Drug|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
75759167|NCT00261495|Drug|OROS hydromorphone HCl|8 to 32 mg once daily for 52 weeks (flexible dosing)
76025326|NCT05127707|Behavioral|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
76069071|NCT00452374|Drug|Fludarabine|30 mg/m^2 given IV for two days (Days 2 and 3).
75458420|NCT01808235|Behavioral|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
75759168|NCT00261495|Drug|Oxycodone|10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
75759169|NCT00168844|Drug|Tiotropium Inhalation Solution|
75759170|NCT00168844|Other|Placebo|
75759171|NCT00365456|Drug|Parathyroid Hormone (PTH)|Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
76069072|NCT00452374|Drug|Oxaliplatin|Starting dose of 17.5 mg/m^2 IV for 4 days (Days 1 through 4).
75759172|NCT00365456|Drug|Risedronate|Orally once weekly as one 35 mg tablet.
75759173|NCT01047956|Drug|Methadone; NAC|Methadone NAC
75759174|NCT01047956|Drug|Methadone|Methadone
75759175|NCT00147238|Drug|Ferumoxtran-10 (USPIO)|Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
75759176|NCT00147238|Procedure|MR lymphangiography|First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
75759177|NCT02531464|Other|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
75759178|NCT00206427|Drug|GW572016|Lapatinib, 500 mg
75759179|NCT00206427|Drug|lapatinib|Lapatinib 500 mg PO
75759180|NCT00146848|Device|Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices|"All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm."
75759181|NCT00205881|Device|HiRes 90K Bionic Ear System|Cochlear implant system
75759182|NCT00365378|Biological|Comparator: HPV 16 L1 Vaccine|A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
75759183|NCT00365378|Biological|Comparator: Placebo|A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
75759184|NCT00389324|Biological|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
75759185|NCT00365300|Drug|pantoprazole|
75759186|NCT00365300|Drug|Placebo|
75759187|NCT01048034|Drug|Azacitidine|100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
75759188|NCT01048034|Drug|Erythropoetin|For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
75759189|NCT02535182|Other|Blood Draw|"Lab will draw one tube of blood to be stored in 8 mL Becton Dickinson (BD) Vacutainer Cell Preparation Tube (CPT) tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.~Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells."
75759190|NCT00370292|Drug|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
75759191|NCT00370292|Drug|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
75759192|NCT03992690|Device|Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol|Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
75759193|NCT03992690|Device|Training with traditional physiotherapy protocol|Stretching
75458421|NCT01808261|Drug|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
75458422|NCT01808261|Drug|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
75458423|NCT01808274|Device|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
75458424|NCT01808287|Device|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
75458425|NCT01808300|Drug|Pregabalin 300mg, Thioctic acid 600mg|"A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B"
75458426|NCT01808352|Drug|FTC/TDF|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
75759194|NCT01049672|Drug|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
75759195|NCT01049672|Drug|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
75759196|NCT00369824|Biological|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
75759197|NCT00369824|Biological|Menactra TM|One dose of vaccine administered intramuscularly
75759198|NCT00369824|Biological|Boostrix TM|One dose of vaccine administered intramuscularly
75759199|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
76069073|NCT00452374|Drug|Rituximab|375 mg/m^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
75904503|NCT06160102|Other|Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities|"Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project.~Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework.~Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation."
75904504|NCT06160089|Other|Isoinertial training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (inertial). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
75904505|NCT06160089|Other|Gravitational training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (gravitational). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
76069074|NCT01454583|Drug|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
76069075|NCT01454583|Drug|ACE-I/ARB|
76069076|NCT01454583|Drug|No RAS-inhibition|
75759200|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
75759201|NCT00369668|Behavioral|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
75759202|NCT01048112|Biological|Campylobacter jejuni strain CG8421|Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
75759203|NCT02161874|Device|T3 with DCD tapered Prevail implant|T3 with DCD implant with Certain (internal) connection and platform-switch design
75759204|NCT02161874|Device|Nanotite Certain tapered implant|Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
75759205|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
75759206|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
75759207|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
75759208|NCT02076698|Procedure|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
75759209|NCT02076698|Drug|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
75759210|NCT01048268|Drug|glucose-dependent insulinotropic polypeptide|"For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight"
75759211|NCT01048268|Drug|Placebo|copy GIP infusion rates
75759212|NCT03993236|Drug|Experimental: Rosuvastatin/Ezetimibe 10|"Rosuvastatin/Ezetimibe 10/10mg~orally administered once daily for 90 days"
75759213|NCT03993236|Drug|Active Comparator: Rosuvastatin 20mg|"Rosuvastatin 20mg~orally administered once daily for 90 days"
75759214|NCT00388154|Drug|Gemcitabine|900 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
76069077|NCT03286114|Drug|Pembrolizumab|200mg IV every 21 days
76069078|NCT00476242|Drug|Vivitrol|intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
76069079|NCT00476242|Drug|memantine|Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
76069080|NCT00476788|Device|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
76069081|NCT01795144|Drug|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
76069082|NCT01795144|Drug|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
75458427|NCT01808365|Procedure|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
75458428|NCT01808365|Other|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
75458429|NCT01808378|Drug|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
75759215|NCT00388154|Drug|Cisplatin|30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
75759216|NCT00387764|Drug|pazopanib|800 mg daily dosing continously until progression
75904506|NCT06160076|Device|Radiofrequency|Patient with atrial fibrillation ablated per catheter using radiofrequency energy
75610568|NCT02902003|Behavioral|Empowering Families|A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
75759217|NCT02535104|Drug|Ranpirnase|Topical application by subject
75759218|NCT02535104|Drug|Vehicle|Vehicle control
75759219|NCT01580930|Behavioral|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
75759220|NCT01580930|Behavioral|sedentary time reduction|participants provided with strategies to decrease sitting
75759221|NCT01580930|Behavioral|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
75759222|NCT01049750|Other|type 2 diabetic patients|males; type 2 diabetic patients
75759223|NCT00386360|Drug|Placebo comparator|oral weekly for one year
75610569|NCT02715427|Other|Conventional care|
75904507|NCT06160076|Device|Pulsed electric field|Patient with atrial fibrillation ablated per catheter using pulsed electric field
75904508|NCT06160063|Behavioral|Education intervention|Board game was created in line with current literature. In each interview, it is expected that the child's negative behaviors will be transformed into positive behaviors.
75904509|NCT06160037|Behavioral|Transportation and Developmental Screening|Arm 1. Transportation and Screening The 514 families in this condition received: 1) free transportation for scheduled prenatal care; and 2) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
75904510|NCT06160037|Behavioral|Transportation, Screening, and Nurse-Visitation during Pregnancy and Infancy|"Arm 2. Transportation, Screening, and Nurse-Visitiation During Pregnancy and Infancy~The 228 families in this condition received: 1) free transportation for scheduled prenatal care; 2) intensive nurse home-visitation services during pregnancy and through the child's second birthday; and 3) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life."
75610570|NCT02715427|Other|Enhanced recovery|
75759224|NCT00386360|Drug|risedronate|35 mg risedronate, once a week for one year
75759225|NCT03436940|Other|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
75759226|NCT03436940|Other|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
75759227|NCT00369278|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
75759228|NCT00529373|Drug|Odanacatib|50 mg tablet orally once weekly (OW)
75759229|NCT00529373|Drug|Placebo for Odanacatib|50 mg tablet orally OW
75759230|NCT00529373|Dietary Supplement|Vitamin D3|5600 IU orally OW
75759231|NCT00529373|Dietary Supplement|Calcium carbonate|If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
75759232|NCT00369122|Biological|Bevacizumab|Given IV
75759233|NCT00369122|Drug|Cisplatin|Given IV
75759234|NCT00369122|Radiation|External Beam Radiation Therapy|Undergo EBRT
75759235|NCT00369122|Radiation|Internal Radiation Therapy|Undergo brachytherapy
75759236|NCT03687125|Drug|Tinostamustine|Participants received tinostamustine IV injection.
75759237|NCT03687125|Procedure|Autologous Stem Cell Transplant (ASCT)|Undergo autologous stem cell transplant
75759238|NCT03999281|Other|Human Allograft (Theraskin)|Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.
75759239|NCT05000489|Other|No intervention being administered|No intervention will be administered. Each patient will participate in a qualitative focus group discussing their beliefs/attitudes about their reproductive health and birth control
76025327|NCT05127707|Behavioral|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
75759240|NCT05173493|Drug|Amoxicillin,Furazolidone|Amoxicillin-Furazolidone-containing quadruple group
75759241|NCT05173493|Drug|Amoxicillin,Levofloxacin|Amoxicillin-Levofloxacin-containing quadruple group
75759242|NCT05173493|Drug|Tetracycline,Furazolidone|Tetracycline-Furazolidone-containing quadruple group
75759243|NCT04907513|Other|Assessment of the Motivational State|A motivational interviewing algorithm developed in Rothschild Hospital for this study will be used. The results range between 0% (worst motivational state) to 100% (best motivational state).
75610571|NCT02715349|Behavioral|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
75759244|NCT03872843|Drug|Norco 5milligram-325milligram Tablet|Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
75759245|NCT03872843|Drug|Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED|Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
75759246|NCT00146770|Biological|Aldurazyme|Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
75759247|NCT00146770|Biological|Aldurazyme|0.58 mg/kg Aldurazyme every week for 208 weeks
75904511|NCT06160024|Behavioral|Program to improve data quality of national quality indicators|"Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program."
75904512|NCT06160011|Other|Electrical dry needling + Conventional physiotherapy|Electrical dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
75904513|NCT06160011|Other|Dry needling + Conventional physiotherapy|Dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
75904514|NCT06160011|Other|Conventional physiotherapy|Conventional physiotherapy treatment (massage, pressure release): 2 sessions
75904515|NCT06159985|Procedure|left posterior pericardiostomy|In patients assigned to the study group, a 4-5 cm vertical incision posterior to the phrenic nerve and extending from the left inferior pulmonary vein to the diaphragm is performed.
76069083|NCT01436175|Drug|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
76069084|NCT00453388|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
76069085|NCT00453388|Drug|Cyclophosphamide|Given IV
76069086|NCT00453388|Drug|Cyclosporine|Given IV or PO
76069087|NCT00453388|Drug|Fludarabine Phosphate|Given IV
76069088|NCT00453388|Other|Laboratory Biomarker Analysis|Correlative studies
76069089|NCT00453388|Drug|Mycophenolate Mofetil|Given PO
75610572|NCT02715505|Drug|Umbilical cord blood transplantation with HSC835|Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
75610573|NCT02716909|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
75610574|NCT02723695|Other|Evaluation of postural performances|Postural tests
75610575|NCT02723461|Drug|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
75610576|NCT02723461|Drug|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
76069090|NCT00453388|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
76069091|NCT00453388|Radiation|Total-Body Irradiation|Undergo TBI
76069092|NCT00389974|Drug|sunitinib malate|Given PO
76069093|NCT01453725|Biological|Golimumab|Golimumab 50 mg SC injection every 4 weeks
76069094|NCT01453725|Biological|Placebo|Placebo SC injection every 4 weeks
75610577|NCT02715037|Other|Throat swabbing|
75610578|NCT02723227|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
75610579|NCT02723227|Behavioral|Referral to Social Services|
75610580|NCT02716597|Drug|25% Albumin|
75610581|NCT02716597|Drug|Placebo|
75759248|NCT00146770|Biological|placebo|Placebo for 26 weeks
75759249|NCT03874013|Drug|MOD-4023|"MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN.~MOD-4023 will be administered as a SC injection once weekly, using a delivery device."
75759250|NCT03874013|Drug|Genotropin|"Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections.~A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated.~Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week)."
75759251|NCT03967678|Dietary Supplement|Three portions per week (690g beef (raw weight)) for 5 weeks|Lunches served in Human Intervention Studies Unit
75759252|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
75610582|NCT04857619|Other|None (Observational study)|The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients' medical records (both alive and deceased).
75610583|NCT02715193|Biological|REMD-477|
76069095|NCT04076241|Other|Osteopathic manipulative treatment|The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures. Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration. Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
75904516|NCT06159972|Device|EndoFLIP|EndoFLIP is a small balloon catheter that is inserted through the endoscope at the time of endoscopy.
75904517|NCT06159959|Drug|Carbetocin|To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
75610584|NCT02715193|Biological|Placebo Comparator|
75610585|NCT01223027|Drug|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
75759253|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
75759254|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
75759255|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
75759256|NCT03999125|Drug|Aflibercept,|Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.
75458430|NCT01808404|Behavioral|Web-Based Guided Self-Help|"The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness."
75458431|NCT01808417|Drug|Near Infrared Imaging|The intervention to be administered is the drug indocyanine green.
75458432|NCT01808430|Procedure|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
75458433|NCT01808443|Other|Cryotherapy|up to a maximum of four treatments every 21-28 days
75458434|NCT01808443|Other|laser|up to a maximum of four treatments every 21-28 days
75458435|NCT01808469|Biological|Monoclonal antibody|
75759257|NCT03999125|Drug|Ranibizumab Injection|Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.
75759258|NCT03999125|Drug|Ozurdex Drug Implant Product|Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
75759259|NCT01077778|Procedure|Gadolinium-enhanced Magnetic Resonance Imaging|Gadolinium-enhanced Magnetic Resonance Imaging
75904518|NCT06159946|Device|Access-H2O faucet|The assigned invention was developed to test the feasibility of the prototype of the Access-H2O faucet by assessing whether subjects can activate the faucet to control water outputs via the motion sensor, eye gaze, and a speech speaker. To activate the faucet via the motion sensor, each subject was asked to place his or her hand near the motion sensor. To activate the faucet via the eye gaze, each subject was asked to look directly at the eye gaze sensor. To activate the faucet via the speech speaker, each subject was asked to speak to the speaker. Each subject performed the same function three times. The water from the faucet was used for drinking, rinsing, and grooming.
75904519|NCT06159920|Diagnostic Test|diagnostic accuracy|The aim of this retrospective study is to evaluate the diagnostic and prognostic value of PET/MRI and PET/CT with the use of different radiopharmaceuticals (68Ga-DOTATOC -edotreotide, and 18F-FDG - fluorodeoxyglucose) for the study of patients suffering from neuroendocrine tumors. To this end, both traditional imaging parameters and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies.
75759260|NCT05092139|Device|endovascular treatment|all enrolled patients must receive endovascular treatment
75759261|NCT05085119|Procedure|Stepwise modifications of FiO2|FiO2 will be increased stepwise from 30 to 100% (40, 60 and 80%), and then decreased with the same FiO2 reverse steps.
75458436|NCT01808482|Drug|Part A: 100 mg/mL GSK2618960|100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
75610586|NCT01223027|Drug|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
75610587|NCT02714959|Drug|Proleukin|
75610588|NCT04805671|Drug|ADG20|Single dose of ADG20
75610589|NCT04805671|Drug|Normal saline|Single dose of normal saline
75610590|NCT02714647|Behavioral|Attentional prime|
75759262|NCT00168064|Drug|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
75759263|NCT00166114|Drug|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
75759264|NCT00166114|Drug|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
75759265|NCT03686969|Drug|Octanorm|Octanorm 0.5g/kg/week
75759266|NCT03686969|Other|Placebo|Placebo
75759267|NCT05035901|Other|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
75759268|NCT00145600|Drug|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
75759269|NCT00145600|Drug|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
75759270|NCT00145600|Drug|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
75759271|NCT00145600|Drug|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
75759272|NCT05032781|Drug|Intra-arterial cold saline, minocycline, and magnesium|See study design
75759273|NCT00991601|Procedure|FNAC (fine needle aspiration cytology)|UL guided biopsy
75759274|NCT04003415|Device|Investigational Device: Contactless heart rate and respiratory rate monitor|Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.
75759275|NCT04003415|Diagnostic Test|Heart Rate (EKG) Monitor|Participant will undergo 3-lead EKG testing to measure heart rate during testing.
75904520|NCT06159907|Diagnostic Test|the diagnostic and prognostic value of PET/MRI and PET/CT with 18F-FDG in patients presenting with gynecological tumors|"For the evaluation of patients affected by endometrial cancer, the correlations between semi-quantitative PET parameters (SUVmax, SUVmean, MTV and TLG calculated at different SUVmax thresholds) and histological data, such as for example myometrial invasion, will be investigated. lymph node invasion, tumor grade and type, risk level, probability of mutation of the p53 gene, etc.~In addition to traditional imaging parameters we will also investigate the usefulness of radiomic features, i.e. quantitative data extracted from PET images (PET/CT or PET/MRI), in predicting and explaining histological data"
75904521|NCT06159881|Procedure|Corneal Cross Linking|Total fluence adapted to thinnest point pachymetry
75904522|NCT06159855|Other|Intervention group: nurse-led education for bowel preparation of colonoscopy|"PRE-TEST~a) Patients will be evaluated using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~INTERVENTION~Patients will be given face-to-face training in the clinic training room of the unit.~After face-to-face training is given, an educational brochure will be given to the patient.~If the patient is constipated, the bowel preparation diet is requested to be started 5 days in advance. If the patient is not constipated, the bowel preparation diet is started 3 days in advance.~After the intervention group is given bowel preparation training, reminders about colonoscopy will be made via instant messaging 3 to 5 days before the day of the colonoscopy.~LAST TEST~Data will be collected again using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~The cleanliness of the intestines will be evaluated by the physician using the Ottawa Bowel Preparation Scale."
75458437|NCT01808482|Drug|Part A: matching placebo|Matching placebo
75458438|NCT01808482|Drug|Part B: Dose of GSK2618960 decided from Part A|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
75458439|NCT01808482|Drug|Part B: matching placebo|Matching placebo
75458440|NCT01808482|Drug|Part C: Dose of GSK2618960 decided from Part A and B|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
75458441|NCT01808495|Drug|Mitomycin C|
75458442|NCT01808521|Drug|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
75458443|NCT01808586|Procedure|Betamethasone|6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
75458444|NCT01808586|Procedure|Dexamethasone|4mg/mL
75458445|NCT01808586|Procedure|Intramuscular Lidocaine|2%
75458446|NCT01808586|Behavioral|Home Exercise|Standardized home exercise program
75610591|NCT02714647|Behavioral|Sham prime|
75610592|NCT02714725|Drug|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
75610593|NCT02714725|Drug|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
75610594|NCT02714725|Drug|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
75759276|NCT04003415|Diagnostic Test|Respiratory rate Monitor|Participant will have an elastic band around their chest for monitoring respiratory rate during testing.
75759277|NCT04003415|Diagnostic Test|Pulse Oximetry|Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
75759278|NCT03968380|Other|Population survey with biological and physical measurements.|Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants.
75759279|NCT00129376|Drug|Doxorubicin|
75759280|NCT00129376|Drug|Cyclophosphamide|
75759281|NCT00129376|Drug|Docetaxel|
75759282|NCT05359289|Behavioral|Forest therapy training|Participants will experience nature-based interventions including forest hiking, horticultural therapy and green wellness activities for their mental health and physical conditions.
75904523|NCT06159842|Combination Product|Aminolevulinic Acid 20% Topical Solution with Blue Light|Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
75904524|NCT06159829|Behavioral|experimental|intervention group used VR with a natural landscape and relaxing musical accompaniment during the upper endoscopy procedure.
75904525|NCT06159803|Behavioral|Qualitative Interview|One-to-one semi-structured interviews and Think Aloud interviews
75904526|NCT06159790|Drug|GME751|Drug: GME751 Concentrate for solution for infusion, Biologic, Liquid in vial, 100 mg, 200 mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
75904527|NCT06159790|Drug|Keytruda-EU|Drug: Keytruda-EU Concentrate for solution for infusion, biologic, liquid in vial, 100 mg, 200mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
75904528|NCT06159764|Procedure|Cardioneuroablation|radiofrequency ablation to destroy cardiac ganglionated plexi located in epicardial fat pads around the atrias
75458447|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
75458448|NCT01808638|Drug|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
75458449|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
75610595|NCT01015287|Drug|Placebo|Administered once orally
75610596|NCT01015287|Drug|Prasugrel|Administered orally
75610597|NCT02714803|Behavioral|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
75610598|NCT02714803|Behavioral|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
75759283|NCT05359289|Behavioral|Senior fitness training|The fitness program includes physics fitness of stamina, coordination and aerobic exercise in 12 weeks. Participants will join the senior fitness program including physical fitness, aerobic exercise and exercise prescription during the 12 weeks program.
75759284|NCT05359289|Behavioral|Board Games|Participants will play board games with each other.
75759285|NCT04878107|Drug|Camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd
75759286|NCT04878107|Drug|Apatinib|Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor
75759287|NCT04878107|Drug|Docetaxel injection|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
75759288|NCT04878107|Radiation|SBRT|Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.
75759289|NCT04878107|Radiation|LDRT|low dose radation therapy
75759290|NCT03998969|Drug|Pantoprazole|Pantoprazole 40mg tablet
75759291|NCT03998969|Drug|DA-5204|DA-5204 tablet
75759292|NCT03998969|Drug|Placebo|Film-coated tablet manufactured to mimic DA-5204
75904529|NCT06159751|Other|serum albumin level|serum albumin level in gonarthrosis
75610599|NCT02714803|Behavioral|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
75904530|NCT06159712|Other|Blood samples|Extra blood samples
75904531|NCT06159686|Drug|Hemp|The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
75610600|NCT04028713|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.
75610601|NCT04028713|Procedure|Dried blood spot|A subset of patients will sample additionally by using the dried blood sampling technique.
75610602|NCT04028713|Drug|Dose reduction|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
75610603|NCT04772365|Drug|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels;
75610604|NCT04772365|Drug|Placebo|Placebo will be subcutaneously administered with different dose levels;
75610605|NCT02714491|Other|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
75610606|NCT02714491|Other|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
75610607|NCT02714491|Other|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
75610608|NCT02714179|Drug|Paracetamol was given intravenously in both group at different times|
75610609|NCT02714413|Dietary Supplement|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
75904532|NCT06159686|Drug|Placebo|The application of the placebog cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
75904533|NCT06159621|Drug|PD-1inhibitor - LVGN 3616|Administration of one dose of LVGN 3616 - 300mg
75904534|NCT06159621|Drug|CD 40 Agonist - LVGN 7409|Administration of one dose of LVGN 7409 - 1mg/kg
75904535|NCT06159608|Drug|Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)|Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
75610610|NCT02714413|Dietary Supplement|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
75610611|NCT02714413|Other|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
75458450|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
75610612|NCT01015131|Radiation|18F-FLT-PET/CT Imaging|Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
75759293|NCT01564043|Behavioral|website and pedometer|use of pedometer and website
75759294|NCT04708847|Drug|GYM329|GYM329 subcutaneous injection
75759295|NCT04708847|Drug|Placebo|Placebo subcutaneous injection
75759296|NCT01564667|Behavioral|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
75759297|NCT01564745|Other|Functional respiratory evaluation|Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
75458451|NCT01808664|Behavioral|Standardized Patient Instructor Intervention|"In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.~During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques."
75458452|NCT01808664|Behavioral|Control|"In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
75610613|NCT02714101|Other|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
75610614|NCT02714023|Procedure|Normal Saline|Intra-operative irrigation with normal saline
75610615|NCT02714023|Procedure|Sterile Water|Intra-operative irrigation with sterile water
75610616|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
75610617|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
75610618|NCT02723383|Drug|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
75610619|NCT02723383|Drug|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
75610620|NCT02723149|Behavioral|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
75759298|NCT04658381|Genetic|Genetic analysis|Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
75458453|NCT01808677|Other|Thoracic Reirradiation Registry|Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
75458454|NCT01808703|Device|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
75759299|NCT04658381|Procedure|Ophthalmologic exam|Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
75759300|NCT00129220|Drug|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
75759301|NCT00129220|Drug|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
75904536|NCT06159608|Other|Chronic estrogen exposure|differences in urine estrogen levels across the menstrual cycle between women groups only
75904537|NCT06159595|Device|Intracranial electrodes|Surgically-implanted intracranial electrodes.
75759302|NCT00129220|Drug|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
75759303|NCT04640051|Procedure|LAAO|LAAO by use of 3D in silico simulation by FEops HEARTguide as part of the pre-procedural assessment and device size selection
75759304|NCT03686813|Drug|Sildenafil Citrate|Oral sildenafil, 50 mg
75759305|NCT03686813|Drug|Placebo Oral Tablet|Placebo
75759306|NCT04003259|Behavioral|Lifestyle management programme|The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
75759307|NCT00128830|Drug|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
75759308|NCT00128830|Drug|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
75904538|NCT06157424|Other|Thread Embedding Acupuncture|Thread Embedding Acupuncture is applied at acupoints including CV-12, CV-13, ST-36, PC-6, BL-17, BL-18, BL-21 on both sides of the body every 2 weeks, totaling 2 sessions over 4 weeks of intervention.
75904539|NCT06157424|Other|Auricular acupuncture|Auricular acupuncture is administered using adhesive patches with small needles (0.25 x 1.3 mm) placed at acupoints TF4, AH6, CO12, CO4, CO2 once a week, totaling 4 sessions over the 4-week intervention period.
75904540|NCT06157424|Other|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
75904541|NCT06154525|Other|RO water|Aquafina's reverse osmosis (RO) water, produced by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively. The RO water ampoules are produced using a similar process as the LIVESPO Preg-Mom/ KIDS but contain 5ml of high-quality RO water from Aquafina (proper noun)
75458455|NCT01808703|Procedure|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
75458456|NCT01808716|Device|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
75759309|NCT00128830|Drug|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
75759310|NCT00128830|Drug|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
75904542|NCT06154525|Dietary Supplement|LiveSpo Preg-Mom|LiveSpo® Preg-Mom has a registration number 7695/2020/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
75904543|NCT06154525|Dietary Supplement|LiveSpo KIDS|LiveSpo® KIDS has a registration number 1537/2023/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
75458457|NCT01808742|Device|Treatment with CryoTouch III Device|Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
75458458|NCT01808768|Drug|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
75610621|NCT02722915|Procedure|fMRI|collection of functional brain data for 1 hour per day
75610622|NCT02722915|Behavioral|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 & 4; controls without AVH: Days 2 & 3)
75610623|NCT02722915|Other|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
75610624|NCT02722915|Other|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
75610625|NCT02722915|Other|SF36|questionnaire about life quality after 1 week during a telephone interview
75458459|NCT01808781|Other|Exercises plus walking program|"Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become somewhat active or active by the end of the 8-week intervention."
75458460|NCT01808781|Other|Walking only program|Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
75610626|NCT05269537|Radiation|Transthoracic Echocardiography|Measurement of cardiac output in supine position with left lateral tilt at baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection
75458461|NCT01808859|Device|Tourniquet|hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
75610627|NCT05269537|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 25-gauge spinal needle
75610628|NCT05269537|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
75610629|NCT05269537|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
75759311|NCT01074892|Drug|Provera (medroxyprogesterone/progestin)|10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
75610630|NCT05269537|Drug|Crystalloid Coload 1000 mL|Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
75759312|NCT01074892|Drug|Provera (medroxyprogesterone)|10 mg per oral tablet. One tablet per day for 6 months
75759313|NCT01074892|Device|Mirena (levonorgestrel)|Inserted in the uterine cavity and kept in situ for 6 months
75759314|NCT03686033|Drug|Placebo|Participants will receive E2082-matched placebo tablets orally.
75759315|NCT03686033|Drug|E2082|Participants will receive E2082 tablets orally.
75759316|NCT00128206|Drug|Isoniazid|Isoniazid 900 mg twice weekly
75759317|NCT00128206|Drug|Rifampin|Rifampin 600mg once per day
75759318|NCT01075828|Drug|Cetuximab|Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
75759319|NCT01565057|Other|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
75759320|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
75759321|NCT01074970|Drug|Rucaparib|Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
75759322|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
75904544|NCT06153368|Drug|Cadonilimab+mFOLFIRINOX|"Cadonilimab 6 mg/kg，IVD，D1，Q2W~+mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle."
75904545|NCT06152913|Behavioral|HANDS-ON treatment|"The HANDS-ON treatment consists of three phases:~Phase I (preparatory phase, 3 weeks) entails motivation for and commitment to treatment (including meaning in life), collaboration with parents and school professionals, setting individual treatment goals, preparing related exposure exercises. Phase II (intensive phase, 4 weeks) contains intensive, therapist-assisted exposure in a child's natural environment. Phase III (consolidation, 2 weeks) consists of continuation of exposure and consolidation. In this phase, there are weekly sessions with the therapist."
75904546|NCT06152874|Other|consumption of glucose solution 1|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
75904547|NCT06152874|Other|consumption of glucose solution 2|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
75904548|NCT06152874|Other|consumption of Bread A and oral processing|bread made with 95% durum wheat fine semolina (< 400 micrometer) + 5% of gluten + 1.2% of yeast + 1% of salt + 59%of water) (portion corresponding to 50 g available carbohydrates) + 250 mL water
75904549|NCT06152874|Other|consumption of Bread B and oral processing|bread made with 80% durum wheat fine semolina (< 400micrometer) + 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
75904550|NCT06152874|Other|consumption of Bread C and oral processing|bread made with 80% durum wheat coarse semolina (> 500micrometer)+ 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
76025328|NCT05127707|Behavioral|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
75458462|NCT01808885|Drug|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
75458463|NCT01808885|Drug|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
75458464|NCT01808898|Procedure|Local Anaesthetic|On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
75458465|NCT01808911|Drug|Steroid + cyclophosphamide|
75610631|NCT05269537|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision and uterine exteriorization
75610632|NCT05269537|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
75610633|NCT05269537|Drug|Oxytocin|Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
75610634|NCT02722993|Dietary Supplement|Probiotics|
75610635|NCT02722993|Dietary Supplement|Placebo|
75610636|NCT01222715|Biological|Bevacizumab|Given IV
75610637|NCT01222715|Drug|Cyclophosphamide|Given IV
75610638|NCT01222715|Other|Laboratory Biomarker Analysis|Correlative studies
75610639|NCT01222715|Drug|Temsirolimus|Given IV
76025329|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
75458466|NCT01808911|Drug|Steroid + rituximab|
75458467|NCT01808976|Other|Problem Solving Therapy|this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
75458468|NCT01808976|Behavioral|Evolution|This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.
75458469|NCT01808976|Behavioral|Basic health push app|This is an app that send daily tips for improving your mood.
75610640|NCT01222715|Drug|Vinorelbine Tartrate|Given IV
75610641|NCT02723071|Drug|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
75610642|NCT02722759|Other|hemoglobin measurement|
75458470|NCT01809028|Procedure|EUS FNA with 2 passes|biopsy with 2 passes
75458471|NCT01809028|Procedure|EUS FNA with 4 passes|biopsy with 4 passes
75458472|NCT01809067|Other|Lavender aromatherapy inhalers|Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
75458473|NCT01809093|Biological|Blood draw|3-4 tablespoons of blood will be drawn, one time.
75458474|NCT01809119|Procedure|Partial nephrectomy|
75458475|NCT01809145|Other|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
75458476|NCT01809158|Drug|minocycline|
75458477|NCT01809158|Drug|placebo|
75610643|NCT02722681|Procedure|Blood and urine sampling|Collection of blood and urine samples taken during usual clinical management
75610644|NCT02722681|Procedure|Cerebrospinal fluid sampling|Collection of cerebrospinal fluid samples taken during usual clinical management
75610645|NCT02722447|Drug|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
75610646|NCT02722447|Drug|Placebo|Placebo for 6 weeks
75610647|NCT01222403|Biological|Fluad_MF59-adjuvanted trivalent influenza subunit vaccine|
75610648|NCT01222403|Biological|Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine|
75610649|NCT02722369|Drug|Gemcitabine|Chemotherapy
75610650|NCT02722369|Drug|Carboplatin|Chemotherapy
75610651|NCT02722369|Drug|Etoposide|Chemotherapy
75610652|NCT02722369|Drug|Hydroxychloroquine|Maintenance Agent
75610653|NCT04657393|Procedure|mechanical ventilation|change of ventilation frequency
75610654|NCT02722291|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
75610655|NCT02694211|Behavioral|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
75759323|NCT03685643|Behavioral|Intervention - Dating application topic|The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.
75759324|NCT03685643|Behavioral|Control - Health and exercise topic|The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
75610656|NCT02694133|Procedure|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
75610657|NCT02694133|Procedure|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
75610658|NCT01222247|Drug|Betamethasone|The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
75610659|NCT01222247|Drug|Placebo|Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
75610660|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
75610661|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
75610662|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
75610663|NCT02713555|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
75610664|NCT02713555|Procedure|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
75610665|NCT00628173|Procedure|AGV implantation|
75759325|NCT03968146|Procedure|Erector Spinae Plane Block|The linear multi-frequency 6-13 megahertz transducer will be used. In the prone position,under aseptic conditions, the probe will be placed in a longitudinal position 2-3 cm lateral to the vertebral column. The transverse processes of the vertebrae at (mid) level of surgery, the Erector Spinae muscle and the psoas muscle are identified. A 22 gauge echogenic needle will be inserted in an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, A test dose of 5% dextrose in water can expand the fascial plane and confirm needle-tip location prior to injection of local anaesthetic. Then, 0.5 ml/kg of bupivacaine 0.25% with 0.1 mg/kg dexamethasone and adrenaline 1 : 200000 will be injected between erector spinea muscle and transverse process, taking in consideration not exceeding the toxic dose of bupivacaine; 4 mg/kg . the same procedure will be repeated on the contralateral side.
75904551|NCT06152627|Behavioral|Standard of care voice therapy with novice clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will be trained to use the RTSS-Voice in their clinical documentation.
76025330|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
75458478|NCT01809171|Drug|Vitamin D3|ampoule
75458479|NCT01809171|Drug|Placebo|ampoule
75458480|NCT01809184|Drug|insulin 287|Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
75458481|NCT01809184|Drug|insulin glargine|Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
75458482|NCT01809184|Drug|placebo|Oral placebo adminstered corresponding to insulin 287 treatment
75458483|NCT01809223|Drug|conbercept, Fixed|intravitreal injection of 0.5 mg conbercept per month, fixed injection
75610666|NCT00611065|Device|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
75610667|NCT04299477|Procedure|non-surgical periodontal treatment|supra- and subgingival scaling, and root planning
75610668|NCT03982537|Drug|N-Acetyl-L-Cysteine dietary supplement|Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
75610669|NCT03982537|Radiation|Chemotherapy and Radiation|Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
75610670|NCT05260593|Device|Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
75610671|NCT05260593|Device|Placebo Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
75610672|NCT05260593|Device|Wrist splint|Patients were instructed to wear a neutral volar splint at night and while performing strenuous activities during the day for 5 weeks. Patients were given forms in order to check if they won't be compliant to the splint application and will be asked to bring the forms at the post treatment evaluation. Patients who won't check the form more than once a week will be regarded as non-compliant to splinting.
75458484|NCT01809223|Drug|conbercept, PRN|intravitreal injection of 0.5 mg conbercept as need, PRN
75458485|NCT01809223|Other|sham injection|sham intravitreal injection per month, fixed injection
75610673|NCT05260593|Other|tendon and nerve gliding exercises|During tendon-gliding exercises, the fingers will be placed in five discrete positions (straight, hook, fist, tabletop, and straight fist). During the median nerve-gliding exercise, six different hand and wrist positions will be used to mobilize the median nerve. During these exercises, the patient must maintain the neck and the shoulder in neutral position with a supinated forearm and elbow flexed 90 degrees. Each position must be maintained for 5 seconds. Each exercise will be repeated 10 times at each session and patients will be encouraged to apply exercise 3-5 times per day for 5 weeks.
75610674|NCT02713477|Drug|Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75610675|NCT02713477|Drug|Insulin glargine HOE901|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75458486|NCT01809236|Biological|Conbercept|intravitreal injection of 0.5 mg Conbercept
75610676|NCT02713477|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75610677|NCT00611299|Dietary Supplement|BB-12 and CRL 431|
75610678|NCT01221623|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
75759326|NCT03968146|Drug|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
75759327|NCT03968146|Drug|additional Fentanyl|patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
75759328|NCT03968146|Drug|Morphine|After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
75759329|NCT03968146|Drug|rescue Morphine|Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
75759330|NCT03968146|Drug|pethidine|After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
75759331|NCT03968146|Drug|Ketorolac|patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
75759332|NCT03968146|Drug|Acetaminophen|patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
76069096|NCT04076241|Other|Yoga respiratory training|Nadishodhana pranayama (Alternate nostril breathing), Ujjayi pranayama (Psychic breath) and Bhramari pranayama (Humming bee breath) were used for the study. Nadishodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one. The patients performed 2 sets of 8 breathing cycles with a resting time of 2 minutes between the sets. Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis. The patients performed 2 sets of 10 breathing cycles per session with an inspiration:expiration phase as 1:2. Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils. The patients applied 2 sets of 10 breathing cycles per session with a respiration rate of 3-4/min.
76069097|NCT00454324|Drug|Carboplatin|Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
76069098|NCT00454324|Drug|Abraxane|"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"
75458487|NCT01809275|Drug|QBECO|
75458488|NCT01809275|Drug|Placebo|
75458489|NCT01809301|Drug|Niaspan|
75458490|NCT01809301|Drug|TRIA-662|
75458491|NCT01809340|Drug|Minocycline|In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
75610679|NCT01221623|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
75759333|NCT03966118|Drug|Avelumab|Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle
75759334|NCT03966118|Drug|Ramucirumab|Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
76069099|NCT02076399|Drug|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
76069100|NCT02076399|Drug|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
75759335|NCT03966118|Drug|Paclitaxel|Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
75610680|NCT02722213|Behavioral|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
75759336|NCT03968224|Drug|Dapagliflozin/Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
76069101|NCT02110264|Drug|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
76069102|NCT02110264|Behavioral|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
76069103|NCT02110264|Behavioral|ETAU|Participants assigned to the ETAU group will receive drug education.
75759337|NCT03968224|Drug|Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
76069104|NCT01795222|Drug|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
75458492|NCT01809340|Drug|Placebo|Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
75610681|NCT02693587|Drug|Misodel and Angusta|
75610682|NCT01014585|Drug|Placebo|Placebo tablets administered orally twice daily
75610683|NCT01014585|Drug|Milnacipran|Milnacipran tablets administered orally twice daily
75759338|NCT01075126|Drug|Depakote|
75759339|NCT01075126|Drug|Lithium|
75759340|NCT03823378|Drug|Elsubrutinib|Elsubrutinib capsule will be administered orally.
76069105|NCT01795222|Drug|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
76069106|NCT01415349|Drug|SSP-002358|1 mg, oral, once
76069107|NCT01415349|Drug|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
75458493|NCT01809340|Drug|Ketamine|In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
75458494|NCT01809353|Drug|JNJ-54452840|Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg
75458495|NCT01809353|Other|Placebo|Single matching intravenous dose
75458496|NCT01809366|Procedure|seminal plasma insemination|
75458497|NCT01809392|Drug|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
75458498|NCT01809418|Device|keePAP|
75458499|NCT01809431|Behavioral|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
75610684|NCT02722135|Drug|Volasertib|
75610685|NCT00611143|Drug|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
75610686|NCT01221233|Other|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
75759341|NCT03823378|Drug|Upadacitinib|Upadacitinib tablet will be administered orally.
75759342|NCT03823378|Drug|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
75759343|NCT03823378|Drug|Placebo for upadacitinib|Upadacitinib placebo tablet will be administered orally.
75759344|NCT00142792|Device|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
76069108|NCT00528190|Drug|Itraconazole|Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
75458500|NCT01809444|Drug|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
76069109|NCT02334813|Drug|Prednisone|Continuous daily therapy
76069110|NCT02334813|Drug|Dexamethasone|4-day pulses every 3 weeks
76069111|NCT00478036|Drug|Acular LS|Details covered in arm description
76069112|NCT00478036|Drug|Pred Forte|Details covered in arm description
76069113|NCT00478036|Other|Refresh Tears|Placebo
76069114|NCT04048863|Device|B. Braun Peripheral Advantage (PA) Program|B. Braun PA includes: Christie VeinViewer® Vision2 , Introcan Safety® IV Catheters, STEADYCare™ Smallbore Extension Set, and the PA Education
76069115|NCT04048863|Device|Hospital Standard of Care|Standard of Care for PIVC access per hospital protocol
76069116|NCT04522557|Drug|IFNα-2a|After mastectomy, it is used in the cavity of breast before conducting implantation.
76069117|NCT01453023|Drug|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
76069118|NCT01453023|Drug|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
75904552|NCT06152627|Behavioral|Standard of care voice therapy with expert clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will have completed their RTSS-Voice training and using the RTSS-Voice in their clinical documentation.
75759345|NCT02531620|Other|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
76069119|NCT04767321|Drug|LTX-109 gel, 3% w/w|LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
76069120|NCT04767321|Drug|Placebo|Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
76069121|NCT01452789|Drug|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
76069122|NCT01452789|Drug|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
75759346|NCT02531620|Other|Routine Care|Usual care for your disease process
75759347|NCT00141778|Drug|Placebo|Matching placebo taken once a day
75759348|NCT00141778|Drug|Ramipril|Taken orally, once a day
75759349|NCT00141778|Drug|Spironolactone|Taken orally, once a day
75759350|NCT03967132|Other|Control Infant Formula|Ready to feed infant formula, feed ad libitum
76069123|NCT01451931|Other|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
76069124|NCT01451931|Radiation|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
76069125|NCT01451931|Other|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
76069126|NCT00478192|Drug|Conivaptan|premix bag
76069127|NCT00478192|Drug|Placebo|premix bag
76069128|NCT04048551|Behavioral|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
76069129|NCT04048551|Behavioral|Young Women's Health CoOp (YWHC)|In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
75458501|NCT01809444|Drug|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
75458502|NCT01809457|Other|educational poster|educational poster for dental trauma
75458503|NCT01809470|Behavioral|FIFA2013|Playing FIFA2013 for 1 hour
75759351|NCT03967132|Other|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
75759352|NCT03967132|Other|Reference Group|Human milk, breast feeding ad libitum
75458504|NCT01809470|Behavioral|Call of Duty|Playing Call of Duty for 1 hour
75458505|NCT01809470|Behavioral|Watching TV|Watching TV for 1 hour
75458506|NCT01809483|Device|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
75458507|NCT01809483|Device|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
75458508|NCT01809496|Behavioral|Informational Counseling|
75458509|NCT01809496|Behavioral|Patient Centered Counseling|
75759353|NCT00127660|Behavioral|Menu: calories=yes, value pricing=no|
75759354|NCT00127660|Behavioral|Menu: calories=yes, value pricing = yes|
75759355|NCT00127660|Behavioral|Menu: calories=no, value pricing = no|
75610687|NCT01221233|Other|Moist Heat|"For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
76069130|NCT01414257|Drug|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
75610688|NCT04300569|Other|Non-interventional|No intervention will be administered.
75610689|NCT04488393|Device|MaterniT21 PLUS and GENOME Laboratory-Developed Tests|Both the MaterniT21 PLUS and GENOME are intended for use as laboratory developed test that analyze ccfDNA extracted from a maternal blood sample utilizing Massively Parallel Sequencing (MPS) technology.
75610690|NCT02713165|Other|Raisins|Participants will consume 84g of raisins per day for 14 days.
75610691|NCT02712619|Drug|Metformin|
75610692|NCT00611221|Procedure|Massage|Massage therapy by an RMT during labour
75610693|NCT00611221|Procedure|Massage|Massage by anyone else, eg. husband, nurse, doula
75610694|NCT01220609|Drug|Ixabepilone|Given IV
75610695|NCT01220609|Other|Laboratory Biomarker Analysis|Correlative studies
75610696|NCT02713087|Drug|Ephedrine|Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20%
75610697|NCT02713087|Drug|Phenylephrine|Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20%
75610698|NCT02722603|Drug|gabapentin|75 mg/ml gabapentin syrup
75610699|NCT02722603|Drug|tramadol|100 mg/ml tramadol oral drops
75610700|NCT02722603|Other|placebo tramadol|placebo tramadol oral drops
75610701|NCT02722603|Other|placebo gabapentin|placebo gabapentin syrup
75610702|NCT03975517|Behavioral|PrEP|Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.
75610703|NCT02712853|Other|Saliva collection|Collection of saliva via swab for miRNA processing
75610704|NCT02712853|Other|Vineland Adaptive Behavior Scale-II Assessment|
75610705|NCT02712697|Drug|WM (Shentong Granules)|Shentong Granules with Prednisone
75610706|NCT02712697|Drug|Hormone (prednisone)|Oral prednisone
75610707|NCT02708563|Procedure|Immediate intubation|Infants that are not vigorous at delivery will receive immediate tracheal suctioning
75610708|NCT02708563|Procedure|Immediate resuscitation|Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
75610709|NCT02708797|Other|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
75759356|NCT01077934|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
75759357|NCT03817528|Drug|ITI-007|ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events
75759358|NCT01078012|Behavioral|Trained counselling|
75610710|NCT02708797|Other|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
75610711|NCT02708719|Procedure|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
75759359|NCT01326520|Dietary Supplement|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
75759360|NCT01326520|Dietary Supplement|diary product|The patients will consume daily 250 mL of a common dairy product.
75759361|NCT01079884|Drug|esomeprazole 40 mg|40 mg daily for 4 weeks
75610712|NCT01220297|Drug|Sirolimus|"Immunosuppressant administered orally to:~Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~Children < 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
75610713|NCT01220297|Drug|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
75610714|NCT01220297|Drug|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
75610715|NCT01220297|Drug|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
75610716|NCT01220297|Drug|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
75610717|NCT01220297|Drug|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
75610718|NCT02721901|Behavioral|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
75759362|NCT03965884|Other|Physical therapy and rehabilitation|Physical therapy and rehabilitation
75759363|NCT03965806|Behavioral|SURVEY|SURVEY
75759364|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
75759365|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
75610719|NCT02721901|Behavioral|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
75610720|NCT02888015|Other|upper extremity exercise program|five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
75610721|NCT02712775|Drug|Minocycline (yes/no)|
75610722|NCT02712775|Drug|Placebo|Saline
75610723|NCT01219985|Other|standard and respiratory-gated PET acquisitions|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
75610724|NCT04318847|Drug|Ondansetron 4 MG|Administration of ondansetron 4 mg or 8 mg according to weight
75759366|NCT01076062|Procedure|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
75759367|NCT00115336|Drug|Intravenous Ketorolac|Intravenous ketorolac
75610725|NCT02721823|Behavioral|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
75759368|NCT00115336|Drug|Ibuprofen|Ibuprofen, taken orally
75759369|NCT01076140|Drug|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
75759370|NCT01076140|Drug|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
75759371|NCT00205803|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
75759372|NCT00205803|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
75759373|NCT01076218|Device|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
75759374|NCT03974373|Procedure|BFP removal|The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
75759375|NCT00127192|Drug|sitagliptin phosphate|sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
75759376|NCT00127192|Drug|Comparator: placebo (unspecified)|placebo QD 12-weeks
75759377|NCT00205179|Drug|Novasoy|100mg/day soy isoflavones
76069131|NCT00528268|Drug|Sodium phenylbutyrate (NaPB)|The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
75458510|NCT01809509|Procedure|Endometrial biopsy|
75458511|NCT01809522|Procedure|Posterior reconstruction of the rhabdosphincter|
75759378|NCT00205179|Drug|Placebo|100mg/day matching placebo
75458512|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
75759379|NCT03973125|Drug|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
75759380|NCT00127036|Drug|XELOX|XELOX: Oxaliplatin 130 mg/m^2 intravenously (IV); Capecitabine 825 mg/m^2 by mouth (po)
75759381|NCT00127036|Drug|XELIRI|XELIRI: Irinotecan 240 mg/m^2 IV; Capecitabine 825 mg/m^2 by mouth (po)
75759382|NCT00127036|Drug|Bevacizumab|7.5 mg/kg intravenously (IV)
75759383|NCT00259857|Drug|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
75759384|NCT02531919|Drug|Sodium Bicarbonate|Given PO
75759385|NCT01071681|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
75759386|NCT01072851|Behavioral|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
75759387|NCT01072851|Behavioral|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
75759388|NCT01072851|Behavioral|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
75759389|NCT00203307|Drug|Olanzapine during first intervention period and placebo during second intervention period|Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
75759390|NCT00203307|Drug|Placebo during first intervention period, then olanzapine during second intervention period|Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
75904553|NCT06152185|Behavioral|Mindfulness Training|The mindfulness intervention includes 28 daily 20-minute audio lessons plus brief daily practice prompts. The first 14 lessons train techniques for developing foundational mindfulness skills through didactics and guided practice; the second 14 lessons review these techniques through guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts delivered 3 times daily encourage participants to practice brief moments of mindful awareness.
75759391|NCT01581801|Procedure|Gastric Bypass|"Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.~An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection."
75458513|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
75610726|NCT02721823|Behavioral|Control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
75759392|NCT01581801|Procedure|Sleeve Gastrectomy|Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
75759393|NCT00126568|Drug|sorafenib tosylate|Given orally
75904554|NCT06152185|Behavioral|Enhanced Usual Care|Participants in the EUC condition will have no study requirements during the 4-week intervention period, but they will receive a list of stress management resources upon randomization (websites, books, health tracking apps, and mental health services) with no additional intervention support.
75759394|NCT00114634|Dietary Supplement|Egg yolk preparation with cholesterol|Egg yolk preparation with cholesterol
75759395|NCT00114634|Dietary Supplement|Egg substitute, without cholesterol|Placebo control. Egg substitute, without cholesterol
75458514|NCT01809561|Procedure|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
75458515|NCT01809587|Device|IQP-PO-101|
75610727|NCT02691221|Behavioral|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
75759396|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
75759397|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
75759398|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
75904555|NCT06152133|Other|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
75904556|NCT06152094|Other|BP Activate Letter|"Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss."
75904557|NCT06152094|Other|Control Letter|Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
75904558|NCT06151873|Diagnostic Test|Adapted sport|control group sample, healthy subjects without musculoskeletal, neurological or vestibular alterations can participate.
75904559|NCT06151873|Diagnostic Test|Adapted sport|Subjects with cerebral palsy/acquired brain damage belonging to the Spanish National Soccer Team with cerebral palsy and acquired brain damage may participate as an experimental group.
75904560|NCT06151613|Device|continuous eCTG monitoring using the NFMS|Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
75458516|NCT01809600|Other|No intervention (observational study)|
75458517|NCT01809613|Procedure|Functional Magnetic Resonance Imaging (fMRI)|During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
75904561|NCT06150768|Device|Cobalt Chromium Removable Partial Denture|The patient will receive Removable Partial Denture to restore missing teeth in Kennedy Class II cases.
75610728|NCT02721745|Behavioral|Natural Fatigue|Experimental: EEG Indirect Calorimetry Pupillometry
75610729|NCT02721745|Device|tDCS|Experimental: EEG Indirect Calorimetry Pupillometry
75610730|NCT02721745|Device|TMS|Experimental: EEG Indirect Calorimetry Pupillometry
75610731|NCT02721511|Drug|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
75759399|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
75458518|NCT01809626|Drug|Zolpidem|
75458519|NCT01809626|Other|Placebo|
75458520|NCT01809652|Other|Remote Implant Support Capability|Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
75458521|NCT01809665|Device|ICD/CRT-P therapy|
75458522|NCT01809665|Other|MRI|
75458523|NCT01809678|Behavioral|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
75759400|NCT00201201|Other|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
75759401|NCT00201201|Other|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
75759402|NCT00126490|Biological|Aldesleukin|Given subcutaneously
75759403|NCT00126490|Biological|Bevacizumab|Given IV
75759404|NCT00126490|Other|Laboratory Biomarker Analysis|Correlative studies
75759405|NCT00346632|Drug|KW-2449|Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).
75610732|NCT02708329|Procedure|T-provisional stenting|Standard endovascular T-provisional stenting technique
75759406|NCT00200967|Drug|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
75759407|NCT00200967|Drug|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
75759408|NCT02533440|Procedure|EXPAREL and Local Anesthetics|Patients will receive EXPAREL and local anesthetics, as well as opioid and non-opioid analgesics prescription, (only use if needed, for post surgical pain)
75759409|NCT02533440|Procedure|Oral Opioid and Local Anesthetics|Patients will receive local anesthetics, as well as oral opioid or non-opioid analgesics, (only use if needed, for post surgical pain)
75904562|NCT06150768|Device|Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture|The patient will receive Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
75904563|NCT06150768|Device|Implant-Supported Zirconia Fixed Partial Denture.|The patient will receive Implant-Supported Zirconia Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
75458524|NCT01809678|Behavioral|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
75610733|NCT02708329|Procedure|Mini-crush stenting|Standard endovascular Mini-crush stenting technique
75458525|NCT01809678|Other|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
75458526|NCT01809717|Other|Weight Lifting Exercises|
75458527|NCT01809743|Drug|Regadenoson central -central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
75458528|NCT01809743|Drug|Regadenoson peripheral - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
75610734|NCT02708329|Procedure|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
75610735|NCT02708407|Procedure|Peritoneal Dialysis|One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
75610736|NCT02712307|Drug|Phenoxymethylpenicillin|
75610737|NCT02708251|Drug|glyceryl trinitrate cream|
75610738|NCT02708251|Drug|lidocaine cream|
75610739|NCT02708251|Drug|placebo cream|
75610740|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
75610741|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
75610742|NCT00611611|Biological|fluzone|once
75610743|NCT00611611|Biological|pneumovax|once
75759410|NCT02533518|Procedure|Rigid bronchoscopy with ultraviolet transmission|
75759411|NCT02533518|Other|Biopsy|
75759412|NCT01052064|Device|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
75904564|NCT06149247|Drug|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
75904565|NCT06149247|Drug|Mechlorethamine Topical Gel|Valchlor is an FDA-approved drug for the treatment of CTCL.
75458529|NCT01809743|Drug|Regadenoson central - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
75610744|NCT04188925|Device|Laser Acupuncture|"The LA is using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The LA treatment will be applied to EX-LE5, ST35, and BL40 for 80 seconds, under power 150mW, to deliver a total treatment dose of 6 Joule/ cm2.~The EA is the combination of acupuncture and transcutaneous electrical nerve stimulator. The transcutaneous electrical nerve stimulator is produced by Ching Ming Medical Device Company. This machine is verified by Department of Health in Taiwan, with the ID number 001147. We perform acupuncture on GB33, GB34, SP9, SP10, and ST36."
75458530|NCT01809743|Drug|Regadenoson peripheral - central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
75759413|NCT01052142|Biological|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
75759414|NCT03991572|Device|repeated transcranial magnetic stimulation with real coil|repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons
75759415|NCT03991572|Device|repeated transcranial magnetic stimulation with sham coil|repeated transcranial magnetic stimulation with sham coil is a placebo
75759416|NCT01052220|Behavioral|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
75759417|NCT01052220|Behavioral|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
75759418|NCT01054638|Drug|HAART Treatment|"Using pharmacy records, identify all patients with HAART dispensing during baseline & follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past & non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), & Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline & follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs."
75759419|NCT01054794|Device|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
75759420|NCT03742284|Device|SoftOx Wound Irrigation Solution|"The SoftOx Wound Irrigation Solution is a Medical device that contains a combination of hypochlorous acid and acetic acid in purified water. SWIS is primary intended for mechanical irrigation of acute wounds whereas hypochlorous acid acts as a ancillary medicinal (drug) substance with potential antimicrobial effects.~Acute wounds will be rinsed according to protocol and safety (AEs/ADEs/SAEs/SADEs) is the primary objective."
75904566|NCT06148506|Other|Ribociclib|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with ribociclib+ET by prescription within the study enrollment timeline will be recruited.
75458531|NCT01809743|Drug|Adenosine|Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
75458532|NCT01809756|Other|Caphosol|Caphosol 4 times a day
75458533|NCT01809769|Biological|Mesenchymal stem cells low-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
75458534|NCT01809769|Biological|Mesenchymal stem cells mid-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
75458535|NCT01809769|Biological|Mesenchymal stem cells high-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
75458536|NCT01809795|Other|Blueberry Smoothie|
75759421|NCT00354432|Dietary Supplement|oral soy protein/isoflavones powder|Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
75759422|NCT00354432|Drug|Venlafaxine|Patients receive oral venlafaxine 75mg.
75904567|NCT06148506|Other|Combination chemotherapy|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with CT by prescription within the study enrollment timeline will be recruited.
75610745|NCT04188925|Device|Sham Laser Acupuncture|Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description. Both of the LaserPen in two groups are labeled with A and B, one of them is revised by the company to become the sham LA. The outward of both LaserPen are the same and our physician does not know which one is the real.
75904568|NCT06146582|Behavioral|Laguna Coach and App Intervention Group|Behavioral, mental and contextual support was delivered through personal interactions with Laguna Coaches via mobile app, phone, video, or web chat. Care interventions were individualized to best match each participant's needs and strengths. Support will be provided to participants through interactions over approximately 90 days.
75904569|NCT06145256|Device|MRI brain, MSCT brain, Transcranial Ultrasound|MRI, MSCT and transcranial Ultrasound are an important diagnostic modalities in the assessment of severity and outcome of HIE
75904570|NCT06140147|Other|Protocolised reduction of non-resuscitation fluids|Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)
75904571|NCT06140147|Other|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.~Medications: concentrated per local protocol"
75904572|NCT06140030|Behavioral|Mindfulness training|Mindfulness-training mobile health application
76069132|NCT04490044|Other|Under & Over rehabilitation tool|Under & Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.
75759423|NCT00354432|Dietary Supplement|Placebo Powder|Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
76069133|NCT00528580|Drug|Simvastatin|80 mg once daily PO/NG x 4 days
75759424|NCT00354432|Drug|Placebo Pill|Patients receive oral placebo pill.
75759425|NCT00140140|Drug|ABI-007|Weekly intravenous infusions over 30 minutes.
75458537|NCT01809795|Other|Sham Smoothie|
75610746|NCT03906643|Drug|HS-201|HS-201 will be administered intravenously as a single dose
75610747|NCT01218659|Drug|migalastat hydrochloride|150-mg capsule administered orally QOD
75610748|NCT01218659|Biological|agalsidase|Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
75759426|NCT00140140|Drug|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
75759427|NCT00140140|Drug|Trastuzumab|"Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor."
75904573|NCT06136793|Behavioral|HomeStyles-China|2-arm ~10 week educational intervention
75904574|NCT06132282|Behavioral|Substance Use and Health Risk Intervention (SUHRI)|Technology-based intervention designed as 4 sessions administered on a tablet as a self-directed approach (requiring an onsite proctor) for addressing factors that increase risk for significant health problems. Topics such as SU and risky sex are important but often sensitive or difficult for juvenile justice staff to address in their role as probation officers.
75904575|NCT06121271|Drug|Lu-177 DOTATATE (Lutathera®)|Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
75904576|NCT06119607|Device|TRIFLO Heart Valve|Surgical Aortic Valve Replacement - Mechanical Valve
76069134|NCT00528580|Drug|Identical-appearing placebo|once daily x 4 days
76069135|NCT00529126|Drug|SKY0402|SKY0402
76069136|NCT00529126|Drug|Bupivacaine HCl|Bupivacaine HCl
76069137|NCT01434693|Biological|Trichuris suis ova|single dose
76069138|NCT01434693|Other|Placebo|
76069139|NCT00529204|Drug|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
76069140|NCT01451541|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
75610749|NCT02712229|Behavioral|CONNECT|"Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver."
75610750|NCT05172037|Biological|Novaferon|a novel recombinant antiviral protein drug
75458538|NCT01809821|Behavioral|Online Sleep Education|
75610751|NCT05172037|Biological|Placebo|Saline
75610752|NCT02708017|Procedure|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
75759428|NCT00140140|Biological|G-CSF|"During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was >20,000/mm^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor."
75759429|NCT03966976|Device|ECG monitoring & record|This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
75759430|NCT03966976|Other|Conventional follow-up|Conventional follow-up
75759431|NCT00346398|Biological|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
75759432|NCT00346398|Biological|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
75759433|NCT00346164|Drug|doxorubicin hydrochloride|Given IV
75759434|NCT00346164|Other|clinical observation|Patients undergo observation
75759435|NCT00346164|Procedure|therapeutic conventional surgery|Patients undergo surgery
75759436|NCT00346164|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
75904577|NCT06119178|Device|EX-PRESS P-50 filtration device|FDA-approved, stainless steel device with a 50-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
75904578|NCT06119178|Device|EX-PRESS P-200 filtration device|FDA-approved, stainless steel device with a 200-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
75904579|NCT06117345|Behavioral|PICU Journal|A hard-copy, customizable educational/therapeutic/expressive journal for parents/caregivers to seek information and document their child's PICU experiences and outcomes.
75904580|NCT06109181|Genetic|LX2020|LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)
75904581|NCT06105411|Diagnostic Test|68Ga-labelled TAFC PET/CT scan|68Ga-labelled TAFC PET/CT scan (whole body)
75904582|NCT06101641|Other|Shellac nail polish application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the shellac nail polish is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
75458539|NCT01809847|Drug|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
75458540|NCT01809860|Drug|isavuconazole|Oral
75759437|NCT00346164|Drug|ifosfamide|Given IV
75759438|NCT03991260|Diagnostic Test|SPECT|One single injection of 99mTc- ADAPT6, followed by gamma camera imaging directly post-injection and after 2, 4 and 6 hours.
75759439|NCT03986892|Behavioral|Physical Activity|Physical Activity
75904583|NCT06097520|Other|VR Intervention|For the VR Intervention a VR head-mounted display, the Pico G2 4K, will be used. This intervention involves wearing VR glasses and experiencing non-interactive videos with sound through a headset. The footage consists of different immersive 360-degree scenarios from natural environments (e.g., forest), while corresponding sounds, meditation or classical music harmoniously tuned to these scenarios and are played through noise-cancelling headphones.
75904584|NCT06096090|Drug|Interleukin-2|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
75904585|NCT06096090|Drug|Placebo|Placebo administration
76069141|NCT01451541|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
76069142|NCT01451541|Drug|Placebo|Placebo - one dose per nostril
75458541|NCT01809860|Drug|sirolimus|Oral
75759440|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
75759441|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
75904586|NCT06095141|Drug|Cisplatin|Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.
75904587|NCT06089135|Device|Intravascular Lithotripsy|Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
75904588|NCT06089135|Device|Cutting Balloon|Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
75904589|NCT06084845|Procedure|Biospecimen Collection|Undergo blood sample collection
76069143|NCT00530764|Drug|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
75904590|NCT06084845|Drug|Carboplatin|Given IV
75904591|NCT06084845|Procedure|Chest Radiography|Undergo chest x-ray
75904592|NCT06084845|Drug|Cisplatin|Given IV
75904593|NCT06084845|Procedure|Computed Tomography|Undergo CT and/or PET-CT
75904594|NCT06084845|Radiation|Image Guided Radiation Therapy|Undergo IGRT
75904595|NCT06084845|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
76069144|NCT00530764|Drug|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
75904596|NCT06084845|Procedure|Magnetic Resonance Imaging|Undergo MRI
75904597|NCT06084845|Procedure|Positron Emission Tomography|Undergo PET-CT
75904598|NCT06084845|Drug|Xevinapant|Given PO
75904601|NCT06081829|Drug|Ivosidenib|Subjects will take 2 tablets (500 mg total) orally once daily.
75904602|NCT06081179|Drug|Psilocybin|Single dose of psilocybin (15mg), orally in form of capsules
75904603|NCT06081179|Drug|3,4 Methylenedioxymethamphetamine|Single dose of MDMA (100mg), orally in form of capsules
75904604|NCT06081179|Drug|Methylphenidate|Single dose of methylphenidate (60mg), orally in form of capsules
75904605|NCT06075264|Drug|Artesunate ointment|topical ointment, as a non-surgical treatment
76069145|NCT00530764|Drug|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
76069146|NCT00532480|Drug|Duloxetine|60 mg capsules
76069147|NCT00483262|Drug|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
76069148|NCT00483262|Drug|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
76069149|NCT00483496|Drug|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
75904606|NCT06075264|Drug|Placebo ointment|topical placebo ointment
75610753|NCT02708017|Procedure|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
76069150|NCT00483496|Drug|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
76069151|NCT00483496|Drug|bisoctrizole 10% alone (formula RV3131A-MV1237)|
75610754|NCT00612625|Drug|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
75610755|NCT00612625|Drug|Saline|continuous infusion of saline
75610756|NCT02712073|Other|Questionnaire|Self administered questionnaire to evaluate the preparation quality of colonoscopy
75610757|NCT00612001|Biological|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
75904607|NCT06061185|Device|Multimodal CT|Non-contrast computed tomography, computed tomography angiography and computed tomography perfusion
75904608|NCT06061172|Other|gp-multitool.de|"The intervention is based on a digital tool, which implements recommendations of the S3 guideline multimorbidity of the German College of General Practitioners and Family Physicians. The tool includes nine questionnaires addressing four dimensions of care:~preferences (including a. treatment goals, and b. involvement of other persons in decision making);~activities (including a. activities and participation, and b. social support);~treatment (including a. problems with medication, and b. treatment burden);~complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~The GPs can send the questionnaires by email to the patients and the patients can fill out the questionnaires at their home or in the waiting room of the GP's practice using their own smartphones, tablets or computers. The digital tool also includes instructions for conducting a medication review. Results from talks between GPs and patients can be documented in the tool."
75759442|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
75759443|NCT01052298|Drug|Placebo|Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
75904609|NCT06060821|Other|No intervention|No intervention
75759444|NCT03987048|Other|Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.|"Data were collected regarding medical background, medical condition and management, both at admission and during the ICU stay. These included demographics, clinical, biological and therapeutic data.~Outcome at ICU discharge and at one year were also recorded."
75759445|NCT03986658|Device|Linear Asymmetric rTMS System|Linear Asymmetric rTMS System
75904610|NCT06057454|Drug|R-5280|Modified Superior Starch
75904611|NCT06057454|Other|Placebo|Food Grade Starch
75904612|NCT06053411|Drug|Diclofenac|25 mg capsule
75904613|NCT06053411|Dietary Supplement|curcumin|2,000 mg tablet
75904614|NCT06047301|Behavioral|Pathways|Delivered by a nurse or other healthcare provider, includes 2 in-person sessions, and phone check-ins, and occurs primarily during infusion visits. Includes a Pathways Toolkit with handouts on values and goal setting, as well as resources on symptom management, lung cancer stigma, communication strategies, and other cancer center resources.
76069152|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
76069153|NCT00483496|Drug|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
75759446|NCT01052376|Device|Confocal endomicroscopy|
75759447|NCT01052454|Behavioral|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
76069154|NCT00483496|Drug|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
76069155|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
76069156|NCT00483496|Drug|V0096 CR vehicle (formula RV3131A-MV1197)|
75458542|NCT01809873|Behavioral|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
76069157|NCT00484354|Drug|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
76069158|NCT00484354|Other|Normal saline|IV Normal saline with volume given determined by patient weight
76069159|NCT00484354|Other|Bicarbonate|IV bicarbonate, dosed by weight
76069160|NCT00484354|Other|Placebo|Normal saline, with volume given based on patient weight
75458543|NCT01809886|Drug|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
75458544|NCT01809886|Drug|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
76069161|NCT00485836|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
76069162|NCT00485836|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
76069163|NCT00485836|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
76069164|NCT00534118|Biological|donor lymphocytes|Given IV
76069165|NCT00487396|Device|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
76069166|NCT04249024|Device|Laser treatment|The participants in the laser group are treated with a 970 nm diode laser and if calculus is present scaling and root planning (SRP). The peri-implant pocket will be radiated with the 970 nm laser, removing bacteria, diseased epithelium and granulation tissue. The laser will be used at a maximum of 20s intervals before water irrigation. Laser settings continuous wave mode and power between 1.0-1.3W. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
75458545|NCT01809912|Drug|Recombinant human apolipoprotein(a) Kringle V|
75458546|NCT01809925|Dietary Supplement|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
75759448|NCT00114244|Drug|sorafenib tosylate|Given PO
75610758|NCT02711761|Device|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
75759449|NCT00114244|Drug|gemcitabine hydrochloride|Given IV
75610759|NCT02711917|Drug|MAC 0.5|0.5 MAC Sevoflurane
75759450|NCT00114244|Other|laboratory biomarker analysis|Correlative studies
75904615|NCT06047301|Behavioral|Enhanced Usual Care|Pathways Toolkit handouts on symptom management, lung cancer stigma, communication strategies, and other cancer center resources provided to participants. The Toolkit will be reviewed with patients in person to orient them to its purpose and contents.
75904616|NCT06044740|Drug|Sevoflurane|After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration is reached. During the two drug conditions, subjects will first receive low-dose sevoflurane (0.4% corresponding to 0.2 Minimum Alveolar Concentration) and then a higher dose sevoflurane condition (0.8% corresponding to 0.4 Minimum Alveolar Concentration).
75904617|NCT06044740|Device|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
75904618|NCT06040463|Behavioral|Diabetes Self-Management Training (DSMT)|The American Diabetes Association endorses the use of small-group diabetes self-management training (DSMT), for people living with diabetes to improve lifestyle, HbA1c levels, and overall quality of life. A certified diabetes care and education specialist will teach a four-part series of one-hour sessions providing culturally competent group education and discussion for groups of 5-8 patients: Session 1 - Living with diabetes - physiology of diabetes, integrating diabetes into your daily life, long term outcomes of diabetes; Session 2 - Culturally competent food education & portion control; Session 3 - Tips & Tricks for dining out and special occasions; Session 4 - Advanced tools and psychosocial implications of living with diabetes. While patients will be encouraged to move through the series together as a cohort, there will be make-up sessions and flexibility to ensure high-quality participation.
75610760|NCT02711917|Drug|MAC 0.75|0.75 MAC Sevoflurane
75610761|NCT02711917|Drug|MAC 1.0|1.0 MAC Sevoflurane
75610762|NCT02711917|Drug|Propofol|Propofol consumption
76069167|NCT04249024|Procedure|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
75610763|NCT02711917|Drug|Etomidate|Etomidate consumption
75610764|NCT02711917|Drug|Rocuronium|Consumption of Rocuronium
75610765|NCT02707783|Device|Bioresorbable vascular scaffold (BVS) implantation|
75610766|NCT02711449|Drug|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
75759451|NCT01056588|Behavioral|CO-Contingent|In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).
75759452|NCT01056588|Behavioral|Control condition|In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
75759453|NCT01058694|Behavioral|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
75759454|NCT02533128|Drug|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 60 mmHg
75759455|NCT02533128|Drug|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 75 mmHg
75759456|NCT01054872|Biological|HIV-1 DNA plasmid vaccine|4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
75759457|NCT01054872|Biological|HIV-1 recombinant Ad5 vaccine|1 x 10^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
75759458|NCT01054950|Behavioral|Counseling|Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
75759459|NCT01054950|Behavioral|Placebo phone call|Phone call w/ no behavioral counseling
75458547|NCT01809925|Dietary Supplement|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
75458548|NCT01809977|Procedure|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
75458549|NCT01809977|Procedure|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
75458550|NCT01809990|Behavioral|Internet-delivered Cognitive Behavior Therapy|
75458551|NCT01810003|Dietary Supplement|High DHA|10 week supplementation period
75458552|NCT01810003|Dietary Supplement|High EPA|10 week supplementation period
75458553|NCT01810003|Dietary Supplement|Placebo|10 week supplementation period
75759460|NCT01058772|Other|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score < 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
75759461|NCT01056666|Device|Conveen Optima is a urisheath to be used together with a collecting bag for urine|Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis
75759462|NCT01056666|Device|absorbent protection|The patient use his usual absorbent protection (same brand), and change it when needed
75759463|NCT00138658|Drug|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
75759464|NCT00337662|Drug|olanzapine|10-20 milligrams (mg), oral, daily, 10 weeks.
75759465|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, for 10 weeks.
75904619|NCT06040463|Behavioral|Remote Glucose Monitoring (RGM)|Remote Glucose Monitoring (RGM) is an automated process of transmitting glucose levels directly from a personal smartphone device to a healthcare provider using a remote data transmitter. Since 2020, Sinai has worked with Glooko Inc. to provide the RGM platform and technical assistance to patients and for Sinai providers to access data remotely. Via the app, patients can: document their glucose levels; sync data from a meter, insulin pump, pen or continuous glucose monitoring device; track their weight; log food and meals; access educational resources; track steps; and track blood pressure. Remotely uploading data provides patients with a direct line to their provider for regular feedback on progress and answers to questions between clinic visits. Patients also receive one one-hour education session on RGM and the Glooko application.
75904620|NCT06040463|Behavioral|Community Health Worker tailored support|CHWs are frontline public health workers who are trusted members of and/or have an unusually close understanding of the community served. The Center has two bilingual (Spanish/English) CHWs; additional bilingual CHWs will be added to the team to support the proposed study. While approaches will differ slightly depending on the patient and study condition, all patients paired with a CHW will be screened for social needs utilizing a standard social determinants of health (SDoH) screening tool, receive referrals to resources to address unmet social/health needs, and aided in navigating health and social systems.
75904621|NCT06035575|Behavioral|Educational video|Development of the original video used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script will typically be shown to the patient within 48-72 hours of the acute care visit, with a maximum window of 5 days post visit.
75904622|NCT06034509|Other|No intervention. This is an observational study.|There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.
75904623|NCT06032156|Dietary Supplement|Low Dose β-OHB|Ingestion of a low dose [R]-3-hydroxybutyl [R]-3-hydroxybutyrate (0.3 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
75610767|NCT02711449|Drug|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
75610768|NCT04419103|Other|no intervention|Natural exposure of iodine.
76069168|NCT04249024|Behavioral|Oral hygiene instructions|Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.
76069169|NCT04200508|Other|Targeted gown and gloves use|Gown and glove use for high risk care activities in high risk residents
76069170|NCT00488488|Drug|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
75759466|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, 10 weeks
75759467|NCT00138424|Drug|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
75759468|NCT00138424|Drug|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
75759469|NCT00368966|Biological|13-valent Pneumococcal Conjugate Vaccine|
75759470|NCT00368966|Biological|7-valent Pneumococcal Conjugate Vaccine|
75759471|NCT00114166|Drug|topotecan hydrochloride|
75610769|NCT02707705|Device|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :~The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.~Data collected :~T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
75759472|NCT00125242|Behavioral|Semantic Feature Analysis (SFA)Training|SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
75759473|NCT03992534|Combination Product|LACTIN-V|Vaginal supplementation with L. crispatus CTV-05.
75759474|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
75759475|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
75759476|NCT00337428|Biological|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
75759477|NCT00337428|Biological|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
75759478|NCT01049828|Other|No intervention|No treatment for tinnitus will occur in this study.
75759479|NCT01044524|Radiation|SLV 334|2000 mg via i.v. solution
75759480|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
75759481|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
75759482|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
75759483|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
75759484|NCT03741465|Procedure|The SFP technique|The USG, and the 5-point NRS evaluation in the SFP
75759485|NCT03741465|Procedure|The ASP technique|The USG, and the 5-point NRS evaluation in the ASP
75759486|NCT00113386|Biological|filgrastim|Consolidation chemotherapy
75759487|NCT00113386|Biological|pegfilgrastim|Consolidation chemotherapy
75759488|NCT00113386|Drug|cisplatin|
75759489|NCT00113386|Drug|docetaxel|
75759490|NCT00113386|Procedure|adjuvant therapy|
75904624|NCT06032156|Dietary Supplement|High Dose β-OHB|Ingestion of a high dose [R]-3-hydroxybutyl [R]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
75904625|NCT06032156|Other|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
75759491|NCT00113386|Procedure|conventional surgery|
75759492|NCT00113386|Procedure|neoadjuvant therapy|
75759493|NCT00113386|Radiation|radiation therapy|
75904626|NCT06032000|Biological|LEM-mR203|mRNA vaccine using Lemonex's Drug Delivery System (DDS), DegradaBALL
75610770|NCT02707705|Device|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.~Data collected :~T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
76069171|NCT00489268|Device|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~******Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
75610771|NCT02707705|Procedure|Disinfection|The ear is disinfected by applying Chlorhexidine®.
75610772|NCT00612079|Drug|Sertindole|oral 3 x 4mg
75759494|NCT00353262|Drug|Avastin|7.5mg/kg iv (cycle 3 only)
75759495|NCT00353262|Drug|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
75759496|NCT00353262|Drug|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
75759497|NCT01056744|Device|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:~- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
75759498|NCT00337272|Drug|Placebo|Placebo taken 30 minutes before bedtime days 1-28 of treatment period
75904627|NCT06032000|Biological|Placebo|0.9% Sodium Chloride Solution
75610773|NCT00612079|Drug|Placebo|3 x 4mg Placebo
75610774|NCT00940498|Drug|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
75759499|NCT00337272|Drug|Ramelteon|8 mgs daily for days 1-28 of treatment period
75759500|NCT00125164|Drug|rhIGF-1 (mecasermin, Tercica, Inc.)|Twice Daily Injection
75759501|NCT03985410|Drug|ETX2514|intravenous infusion
75759502|NCT03985410|Drug|Placebo|intravenous infusion
75759503|NCT03985410|Drug|moxifloxacin|oral tablet
75759504|NCT05126290|Other|Collection of personal and family history from CAFÉ Study participants|Personal medical and genetic history, as well as relevant information about family history, will be collected from participants in the CAFÉ Study through an online data entry system
75759505|NCT01056900|Procedure|Autologous Chondrocyte Implantation|"Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected."
75904628|NCT06027814|Behavioral|Patient Navigation and mHealth (PN+mHealth)|Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
75904629|NCT06025799|Behavioral|Mindfulness-based stress reduction intervention|The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
75904630|NCT06022003|Drug|AzaCITIDine Oral Tablet|AML study treatment
75904631|NCT06022003|Drug|Xospata|R/R FLT3-mutated AML standard treatment
75904632|NCT06021808|Procedure|Thoracoscopic LAA clipping|The surgeons measured the length of the base of the LAA, an appropriately sized LAA clip is then inserted with the aid of a thoracoscope and placed parallel to the base of the LAA.
76069172|NCT01450761|Biological|Ipilimumab|
76069173|NCT01450761|Biological|Placebo matching Ipilimumab|
76069174|NCT01450761|Drug|Etoposide|
76069175|NCT01450761|Drug|Cisplatin|
76069176|NCT01450761|Drug|Carboplatin|
75759506|NCT03988686|Procedure|Radical prostatectomy plus standard care|To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer
75759507|NCT03988686|Drug|Standard of care for metastatic prostate cancer|androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
75759508|NCT00136318|Drug|Escitalopram|
75759509|NCT00136318|Drug|Placebo|
75759510|NCT00136318|Drug|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
75759511|NCT00136318|Drug|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
75759512|NCT03988218|Behavioral|perceptive tests|many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
75759513|NCT01058850|Biological|Rindopepimut|250 or 500 mcg; intradermal injection
75759514|NCT00136084|Drug|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
75759515|NCT00136084|Drug|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
75759516|NCT00364832|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
75759517|NCT01326598|Device|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
75610775|NCT03820531|Diagnostic Test|Next Generation Sequencing|DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes
75759518|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
76069177|NCT04075539|Other|Home-based cycling program|"Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements"
76069178|NCT04075539|Other|usual care|A prescription of 6 sessions of outpatient physiotherapy
75610776|NCT03820531|Diagnostic Test|CEA and lipase|"Measuring CEA and lipase level in pancreas cyst fluid:~CEA > 192 ng/ml and lipase > 200 U/l = mucinous cyst"
75610777|NCT03820531|Diagnostic Test|Cytology|"Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma"
75610778|NCT03820531|Diagnostic Test|Histology of resected pancreas cyst|Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
75759519|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
75759520|NCT00235755|Drug|Placebo|Oral tablet.
75759521|NCT01581879|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
75759522|NCT00337194|Biological|monoclonal antibody SGN-30|Given IV
75759523|NCT00337194|Other|placebo|Given IV
75759524|NCT00337194|Drug|vinorelbine tartrate|Given IV
75759525|NCT00337194|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
75759526|NCT00337194|Drug|gemcitabine hydrochloride|Given IV
75759527|NCT00337194|Other|laboratory biomarker analysis|Correlative studies
75759528|NCT00337194|Other|pharmacological study|Correlative studies
75759529|NCT03973749|Other|Low salycilate diet|Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.
75904633|NCT06021808|Drug|Novel oral anticoagulant|For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
75904634|NCT06017973|Diagnostic Test|MRI scan including arterial spin labelling of the brain|Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded
75610779|NCT02711527|Other|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
75610780|NCT02711527|Other|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
75610781|NCT05115721|Other|no intervention|It's only observational study. No interventions.
75610782|NCT02850718|Drug|Sublingual Sildenafil|50 mg sildenafil sublingual wafer.
75610783|NCT02850718|Drug|Oral Sildenafil|50 mg oral sildenafil (Viagra)
75610784|NCT02707393|Drug|Fludarabine|infusion
75610785|NCT02707393|Drug|Thiotepa|infusion
75610786|NCT02707393|Drug|Melphalan|infusion
75610787|NCT02707393|Drug|ATG|infusion
75610788|NCT02707393|Drug|Cyclosporine A|infusion, orally if possible
75610789|NCT02707393|Drug|Mycophenolate mofetil|infusion
75610790|NCT02707393|Biological|bone marrow or peripheral blood stem cells|infusion
75610791|NCT02711605|Device|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
75610792|NCT00940342|Drug|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
75610793|NCT00940342|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly for four weeks
75610794|NCT02707549|Drug|balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)|
75610795|NCT02707549|Drug|0.9% sodium chloride|
75610796|NCT00936910|Drug|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome [2 mg/ml]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
75610797|NCT02707627|Device|Laser Therapy|Laser therapy is a technology that can be used to treat hypertrophic burn scars.
75610798|NCT02707315|Drug|Gemcitabine|
75610799|NCT02707315|Radiation|Stereotactic Radiosurgery|
75610800|NCT00604942|Procedure|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
75610801|NCT00604942|Procedure|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
75904635|NCT06017973|Diagnostic Test|CT perfusion scan of the brain|Siemens Naeotom Alpha with quantum technology (photon-counting)
75904636|NCT06017973|Diagnostic Test|FDG-PET scan of the brain|An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)
75458554|NCT01810029|Behavioral|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
75458555|NCT01810068|Procedure|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
75458556|NCT01810068|Procedure|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
75458557|NCT01810068|Procedure|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
75458558|NCT01810068|Procedure|Diagnostic cystoscopy|Cysto-urethroscopy
75458559|NCT01810094|Device|Fracture Fixation|Thoracolumbar Fracture Fixation
75610802|NCT00604942|Drug|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
75759530|NCT01074021|Drug|Nimotuzumab|"Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy:~Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
75759531|NCT01074021|Drug|placebo plus chemoradiotherapy|"Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
75904637|NCT06015685|Other|Embedded Clinic|Once a week, a Primary Care clinic half-day will be dedicated to multi-disciplinary, team-based DM care. The inter-professional team will include an Internal Medicine attending physician, an Internal Medicine resident, a DM educator, a nurse trained in professional CGM, a behavioral health provider, and a social worker to assist in finding resources for housing, food, and patient assistance programs.
75904638|NCT06015685|Other|Routine Care|Researchers will use a 2:1 ratio of control to intervention patients. Using the CDW, researchers will identify a control population [patients who receive routine care (i.e., referral to subspecialty care)], who will be a propensity-matched cohort of individuals with similar age, gender, race/ethnicity, zip codes, insurance type, visit dates, and co-morbidities (Charlson Comorbidity Index) as the intervention group.
75904639|NCT06010420|Device|insoles|Insoles are support devices that take the shape of the foot structure and enable the foot to press in a correct form.
75610803|NCT00604942|Drug|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
75610804|NCT02711683|Drug|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
75610805|NCT02711683|Drug|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
75610806|NCT02854618|Other|additional blood sample|
75610807|NCT04266808|Device|An interactive telehealth monitoring and biofeedback system|A pressure sensitive mat located under the user's wheelchair seat cushion and a wheelchair propulsion monitoring device attached to the chair which are interfaced with a phone App based user interface to provide feed back to promote physical activity and pressure relief maneuver performance among wheelchair users.
75610808|NCT04266808|Behavioral|Education Control|Participants will receive education on importance of pressure relief maneuvers and physical activity and the recommended amounts of each for prevention of pressure ulcer/injury and for physical health.
75610809|NCT05079061|Drug|Misoprostol|sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
75610810|NCT00605800|Other|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
75610811|NCT00605800|Other|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
75610812|NCT02693431|Other|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.~The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.~At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
75610813|NCT00605020|Drug|insulin detemir|
75610814|NCT00605020|Drug|insulin aspart|
75759532|NCT03969381|Radiation|diffusion weighted magnetic resonance image in lymphoma|compare between result of positron emission tomography /computed tomography and diffusion weighted imaging in followup of lymphoma
75759533|NCT01326195|Behavioral|Cognitive-Behavioral Dating Violence and HIV Prevention Group|Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females
75458560|NCT01810107|Procedure|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
75759534|NCT01326195|Behavioral|Psycho-educational Dating Violence and HIV prevention group|Knowledge based intervention matched for time and attention to skills arm
75904640|NCT06010407|Other|Survey|"Working Alliance Inventory~Attitude Towards Psychiatry-30 Scale"
76069179|NCT02120716|Behavioral|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
76069180|NCT00491374|Drug|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
76069181|NCT00491374|Drug|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
75610815|NCT00605020|Device|biphasic insulin aspart|
75610816|NCT02707081|Drug|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
75610817|NCT02707081|Drug|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
75904641|NCT06010394|Other|conventional physiotherapy|ultrasound electrotherapy cold applications
75904642|NCT06010394|Other|exercises for the knee area|range of motion exercises strengthening exercises exercises to reduce edema
76069182|NCT00538642|Drug|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
76069183|NCT00539110|Drug|zolipidem|zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
76069184|NCT00539110|Drug|ramelteon|ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
76069185|NCT03846232|Other|No intervention|No intervention
76069186|NCT00539656|Biological|Ex vivo expansion of cord blood|Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
76069187|NCT01433991|Drug|Golvatinib|Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
76069188|NCT01433991|Drug|Lenvatinib|Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
76069189|NCT01433991|Drug|Lenvatinib|Participants will receive lenvatinib 24 mg (1*4 mg capsule + 2*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
75458561|NCT01810120|Biological|TCR alfa beta T cell depletion|total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
75610818|NCT02707081|Drug|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
75610819|NCT02707081|Drug|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
75610820|NCT02711371|Other|fMRI|
75610821|NCT02707237|Other|Verbal counseling|Verbal counseling done by physician
75610822|NCT02707237|Other|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
75904643|NCT06010394|Other|payment oriented massage|10 / 15-minute massage treatments to reduce payment
75904644|NCT06006533|Other|taping|Kinesio taping will be applied in accordance with the fascia correction technique, including the plantar flexor muscles, and it will be requested to stay on the skin for 3 days.
75904645|NCT06006533|Other|massage|Percussive Massage will be applied to the posterior part of the sural fascia, including the plantar flexor muscles, 3 times a week for 5 minutes.
76069190|NCT01450683|Drug|Itraconazole|"600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
75458562|NCT01810146|Other|Digestive functions investigations|
75458563|NCT01810159|Other|Integrated collaborative care|
75458564|NCT01810159|Other|Education and Resources|
75458565|NCT01810172|Device|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
75458566|NCT01810172|Device|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
75458567|NCT01810185|Drug|Low dose naltrexone|4.5 mg daily for 12 weeeks
75458568|NCT01810185|Drug|Placebo|
75458569|NCT01810198|Procedure|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
75904646|NCT06006520|Other|control|No exercises will be given.
76069191|NCT01433055|Drug|Minocycline|"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
75458570|NCT01810198|Procedure|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
75458571|NCT01810211|Other|Horizontal Adduction Stretch and Pendulums|
75458572|NCT01810211|Other|Modified Sleeper Stretch and Pendulum|
75458573|NCT01810224|Procedure|Surgical revascularization|The final intervention (surgical revascularization) will be the same for both arms.
75759535|NCT03985254|Other|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]), and in subsequent weeks the goal will be the development of muscle strength (load> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
75458574|NCT01810237|Drug|Dabigatran.|Dabigatran will be used instead of LMWH for anticoagulation bridging.
75458575|NCT01810276|Other|Saline|400 mL of Saline will be given intravenously over 2 hours once
75458576|NCT01810276|Other|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
75458577|NCT01810315|Drug|TFV 1% gel|
75610823|NCT00605098|Drug|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
75610824|NCT00605098|Drug|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
75610825|NCT02711215|Diagnostic Test|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
75904647|NCT06006520|Other|oro-granary exercises.|soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises
75904648|NCT06006520|Other|aerobic exercises|We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; It includes activities such as walking, cycling, jogging, aerobic dancing, swimming.
75904649|NCT06006481|Other|Survey|Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale
75904650|NCT06006377|Other|conventional physiotherapy|hotpack electrotherapy ultrasound exercises
75904651|NCT06006377|Other|Backup therapy|The backup spine health device is in the form of a mat and provides segmental electrical stimulation to the spines. At the same time, the mat can heat up to 40 degrees during the treatment process. Backup spine health device is very effective in both reducing pain and strengthening the muscles with electrical stimulations by reaching even the deep muscles around the spine. Sessions consist of 30 minutes
75458578|NCT01810315|Drug|Estradiol vaginal cream|
75458579|NCT01810328|Other|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
75458580|NCT01810328|Other|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
75458581|NCT01810354|Drug|Cefazolin|
75458582|NCT01810367|Drug|ABX Combined With Cisplatin|
75458583|NCT01810367|Drug|Gemcitabine Combined With Cisplatin|
75458584|NCT01810393|Drug|Trastuzumab|Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
75458585|NCT01810406|Procedure|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
75458586|NCT01810406|Procedure|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
75458587|NCT01810419|Device|Vscan Ultrasound (GE Healthcare, USA)|Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
75759536|NCT03985254|Other|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]). However, in subsequent weeks the goal will be to develop strength (load> 70% 1RM) and muscle power (load between 40-60% 1RM).
75904652|NCT06006364|Other|Survey|"The scales and forms used are respectively:~Demographic Information Form~Nomophobia Scale~Cornell Musculoskeletal Disorder Questionnaire~Smart phone Addiction Scale~Pittsburgh Sleep Quality Index~International Physical Activity Survey~McGill Melzack Pain Questionnaire"
75904653|NCT06005948|Other|exercise|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 8 weeks
75904654|NCT06005948|Other|control|No intervention will be made.
75904655|NCT06005922|Other|physiotherapy|ultrasound hotpack electrotherapy joint range of motion exercises isometric neck exercises stretching exercises
75904656|NCT06005922|Other|TMJ exercises|tongue relaxation position TMJ isometric strengthening exercises Posture exercises Isometric neck extension in neutral position back extension Strengthening the abdominal muscles Supine dorsal stretch pectoral stretch
75904657|NCT06003907|Other|conventional|hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises
75904658|NCT06003907|Other|traditional and complementary medicine methods|"The Graston Technique is a form of manual therapy known as instrument assisted soft tissue mobilization. Graston massage is performed using titanium-coated metal rods specially designed for different parts of the body.~Cupping therapy is a treatment method that creates a regional vacuum to increase the blood circulation of the person and provide healing."
75904659|NCT06003387|Genetic|CSL222 (AAV5-hFIXco-Padua)|Administered as a single IV infusion.
75904660|NCT06002984|Device|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
75904661|NCT05998330|Behavioral|LiverPAL|The intervention include integrating early palliative care with usual hepatology care to evaluate and treat patients' symptoms, enhance their illness and prognostic understanding, support their coping, and coordinate their serious illness, transitional, and end-of-life care.
75458588|NCT01810419|Device|Conventional Ultrasound|Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
75610826|NCT02711215|Drug|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
75610827|NCT02711215|Drug|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
75759537|NCT01074333|Drug|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
75759538|NCT01058928|Other|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
75458589|NCT01810458|Device|Abdominal ultrasound|Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
75458590|NCT01810458|Procedure|History and physical|Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
75610828|NCT02711215|Drug|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
75610829|NCT04254406|Other|Descriptive study|Evaluation of routine treatment
75610830|NCT04310215|Biological|CARTISTEM®|"*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~Procedure: Microfracture~Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)"
75904665|NCT05992506|Diagnostic Test|POD risk estimation using PEUMA|A software will analyze intraoperative EEG recording for the estimation of a POD Risk Index
75904666|NCT05992103|Procedure|Fundic Ablation in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
75904667|NCT05992103|Device|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
75904668|NCT05992103|Device|Apollo ESG|Using only Apollo ESG as approved per label
75904669|NCT05989997|Drug|68Ga-NOTA-SNA002|68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
75610831|NCT04310215|Procedure|Microfracture|"*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture"
75610832|NCT00603772|Drug|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
75610833|NCT02706613|Behavioral|Face to Face Pulmonary Rehabilitaton|6 week face to face, incremental exercise and education programme for people with COPD
75759539|NCT01582581|Behavioral|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
75759540|NCT01582581|Behavioral|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
75759541|NCT01057056|Other|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
75759542|NCT03826914|Dietary Supplement|CardioFlex Q10|CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
75759543|NCT03826914|Dietary Supplement|Placebo|Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
75610834|NCT02706613|Behavioral|Online Pulmonary Rehab|6 week online, incremental exercise and education programme for people with COPD
75458591|NCT01810458|Procedure|Intravenous catheter|Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
75458592|NCT01810458|Procedure|Blood draw|At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
75458593|NCT01810458|Other|Liver questionnaire|At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
75610835|NCT00605332|Device|inferior vena cava filter|Crux Biomedical IVC Filter
75610836|NCT02706769|Drug|Placebo|Study medication contains blinded placebo
75610837|NCT02706769|Drug|Paracetamol|Study medication contains blinded paracetamol
75610838|NCT05044117|Drug|Capecitabine|Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year
75610839|NCT05031715|Dietary Supplement|Berberine Phytosome|2 tablets of 550 mg per day (1 before lunch and 1 before dinner)
75759544|NCT01059006|Procedure|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
75904670|NCT05989932|Other|Upadacitinib|Real-world on the use of Upadacitinib
75458594|NCT01810458|Procedure|Liver Biopsy|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
75759545|NCT01055340|Drug|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
75759546|NCT01055340|Drug|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
75759547|NCT01055340|Drug|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
75759548|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
75458595|NCT01810458|Drug|Midazolam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
75610840|NCT05029609|Drug|Intranasal Foralumab Solution|The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
75610841|NCT05029609|Drug|Placebo|The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
75610842|NCT02693197|Drug|T-817MA|A single oral dose of 448 mg
75904671|NCT05989308|Behavioral|Email|Email message sent to guardian with proxy information.
75904672|NCT05989308|Behavioral|Text|Text message sent to guardian with proxy information.
75904673|NCT05989308|Behavioral|Patient Portal Message|Patient portal message (MyChart) to guardian with proxy information.
75904674|NCT05984836|Behavioral|Implement health education|"Implement health education class for the rural mothers in the for of one session will take about 30 minutes and it will include the following:~First aid (fracture, burn, bleeding, injuries and food poising). Critique malpractice for injuries management behavior at home.~About 10 mothers will be included in the session. Each session will take 30 minutes (in the family health center), to cover all theoretical contents.~The researcher will use different teaching methods as demonstration and discussion, learning aids as handout, video and pictures."
75904675|NCT05983692|Device|Magnesium Zinc Gadolinium alloy wire|MZG wire will be used as a braiding suture to braid tendon graft, which is a standard preparation of graft and is not related to fixation of the tendon graft
75904676|NCT05981430|Biological|Fecal microbiota transplant|Active comparator will receive infusion of 125mL fecal suspension via enema
75904677|NCT05981430|Biological|Sham fecal microbiota transplant|Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
75904678|NCT05980091|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
75610843|NCT02711293|Other|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count >350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been >350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.
75610844|NCT02711293|Other|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
75759549|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
75759550|NCT00385736|Biological|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
75610845|NCT03961165|Drug|Butylscopolamine Bromide 20 MG/ML|1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
75759551|NCT03742206|Device|Parasacral Transcutaneous Electrical Stimulation|Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
75759552|NCT03742206|Device|Transcutaneous Posterior Tibial Nerve Stimulation|Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
75759553|NCT01057212|Drug|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
75759554|NCT01057212|Drug|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
75759555|NCT01057290|Genetic|gene expression analysis|
75904679|NCT05980091|Diagnostic Test|Serum LH, E2, P4|In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels
75904680|NCT05980091|Drug|Estradiol Valerate 2 MG|"Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)"
75904681|NCT05980091|Drug|Progesterone 100 Mg Vaginal Insert|The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
75904682|NCT05980091|Diagnostic Test|Serum P4 day of ET|On the day of embryo transfer (ET), a blood test is taken to measure serum P4
75904683|NCT05980091|Procedure|Embryo transfer|Procedure in which embryo is transferred into the uterus
75458596|NCT01810458|Drug|Fentanyl|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
75610846|NCT03961165|Drug|Sodium Chloride 9mg/mL|1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
75610847|NCT03807973|Drug|[Zr-89]Oxine-labeled leukocytes PET/MRI|All study participants will undergo an investigational imaging study using autologous [Zr-89]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using [Zr-89]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
75759556|NCT01057290|Genetic|protein expression analysis|
75759557|NCT01057290|Other|fluorescence activated cell sorting|
75759558|NCT01057290|Other|immunologic technique|
75759559|NCT01057290|Other|laboratory biomarker analysis|
75759560|NCT03988452|Drug|Darunavir|Antiretroviral therapy
75759561|NCT03988452|Drug|Ritonavir|Antiretroviral therapy
75759562|NCT03988452|Drug|Dolutegravir|Antiretroviral therapy
75904684|NCT05974475|Radiation|SBRT|State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).
75904685|NCT05974475|Procedure|Surgery|State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.
75904686|NCT05973773|Drug|TAS6417|oral tablets/capsules
75904687|NCT05966233|Drug|R-DHAP|"Rituximab 375 mg/m2 IV on D0 or D1~Dexamethasone 40 mg/day IV or PO on D1-4~Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~Cisplatin 100 mg/ m2 IV on D1"
75610848|NCT02706457|Other|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
75610849|NCT02706535|Drug|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
75610850|NCT02706535|Drug|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
75610851|NCT02706535|Drug|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
75759563|NCT03988452|Drug|Zidovudine|Antiretroviral therapy
75759564|NCT03988452|Drug|Tenofovir|Antiretroviral therapy
75759565|NCT03988452|Drug|Lamivudine|Antiretroviral therapy
75759566|NCT01048580|Drug|Perifosine|Perifosine 50 mg orally once a day (Days 1-21)
75759567|NCT01048580|Drug|Capecitabine|Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
75759568|NCT03988140|Device|Dental Implant Placement and subsequent prosthetic reabilithation|Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
75904688|NCT05966233|Drug|Pola-R-DHAP|"Polatuzumab Vedotin 1.8 mg/kg IV on D1~Rituximab 375 mg/m2 IV on D0 or D1~Dexamethasone 40 mg/day IV or PO on D1-4~Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~Cisplatin 100 mg/ m2 IV on D1"
75904689|NCT05965726|Drug|Paxlovid 25 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 30 days
75904690|NCT05965726|Drug|Paxlovid 15 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 15 days then ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 15 days
75904691|NCT05965726|Drug|Control|ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 30 days
75904692|NCT05963074|Drug|Ibrutinib|Ibrutinib capsules will be administered orally.
75759569|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
75610852|NCT02711059|Procedure|parathyroidectomy|surgical treatment of hyperparathyroidism
75610853|NCT02706223|Other|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
75759570|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
75759571|NCT02533050|Device|CPAP treatment|Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
75759572|NCT00195819|Biological|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
75904693|NCT05963074|Drug|Venetoclax|Venetoclax tablets will be administered orally.
75458597|NCT01810458|Drug|Lidocaine|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
75610854|NCT02706223|Other|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
75610855|NCT02706379|Other|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
75610856|NCT03960073|Dietary Supplement|MitoQ|4 week 20mg oral daily dose of Mito Q
75610857|NCT03960073|Dietary Supplement|Placebo|4 week oral daily dose of TTP placebo
75610858|NCT02706301|Behavioral|Telephone-Based Coping Skills Training (CST)|
75610859|NCT02710825|Other|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
75759573|NCT00195819|Biological|placebo|Placebo every other week (eow)
75759574|NCT00527735|Drug|Ipilimumab|Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
75759575|NCT00527735|Drug|Placebo|Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
75759576|NCT00527735|Drug|Paclitaxel|175 mg/m^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
75759577|NCT00527735|Drug|Carboplatin|Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
75759578|NCT03969147|Device|ManMaxAirway oropharyngeal airway adjunct|Healthy volunteers will self-place the ManMaxAirway.
75759579|NCT03969147|Device|Guedel Oropharyngeal airway adjunct|Healthy volunteers will self-place the standard Guedel OPA.
75759580|NCT03969147|Device|No airway adjunct|Healthy volunteers will have no airway adjunct in place.
75759581|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
75759582|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
75759583|NCT00336492|Biological|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
75759584|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
75904694|NCT05953090|Device|7-0940|A non-hormonal and non-steroidal gel that supports vulvovaginal mucosal conditions and speeds up recovery post vaginal rejuvenation. It is a suitable alternative to vaginally administered estrogen and topical corticosteroids, that promotes a moist healing environment leading to faster re-epithelialization. The gel relieves symptoms such as itchiness, tenderness, dryness, burning sensation, painful intercourse (dyspareunia), painful urination (dysuria), rectal and defecating pain. It improves erythema, mucosal tissue thinning, erosions, fissures, ulcerations, scarring/adhesions and swelling. It is indicated for long-term use to maintain the health of the vaginal mucosa without the side effects of vaginally administered hormonal therapy and topical corticosteroids.
76069192|NCT01433055|Drug|Placebo|"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
75904695|NCT05936385|Behavioral|Healthy Lifestyle|Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.
75904696|NCT05936385|Behavioral|Standard of Care|Weight checks and lifestyle counseling with primary care provider every other month.
75904697|NCT05934175|Behavioral|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
75904698|NCT05934175|Behavioral|Weekly delivered prolonged exposure|Weekly delivered prolonged exposure sessions for 15 weeks
75904699|NCT05934162|Behavioral|Therapist-supported internet-delivered prolonged exposure|10 weeks of therapist-supported internet-delivered prolonged exposure
75904700|NCT05934162|Behavioral|Therapist-supported internet-delivered CBT|10 weeks of therapist-supported internet-delivered CBT
75904701|NCT05929430|Behavioral|Mindfulness program|Six weeks mindfulness program. The program is explained in arm descriptions.
75904702|NCT05929430|Behavioral|Mindfulness program with Virtual Reality|Six weeks mindfulness program. The program is explained in arm descriptions.
76069193|NCT01450137|Drug|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
75610860|NCT02710825|Other|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
75759585|NCT00194025|Drug|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
75759586|NCT01057368|Behavioral|Day of intensive meditation practice|Long-term meditators practice for ~6 hours of meditation at each time point
75904703|NCT05929287|Procedure|Tablet-based CT|This group will perform digital CT tasks.
75904704|NCT05929287|Procedure|Paper-and-pencil CT group|This group will perform paper-and-pencil CT tasks.
76069194|NCT01450137|Drug|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
76069195|NCT01412229|Drug|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
76069196|NCT01412229|Drug|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
76069197|NCT01412229|Drug|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
76069198|NCT01412151|Drug|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
76069199|NCT01432275|Device|ADC blood glucose meter|Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
75610861|NCT00612703|Drug|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
75610862|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
75610863|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
75610864|NCT00612157|Drug|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
75610865|NCT00612157|Drug|Placebo control|Matching placebo
75610866|NCT05265559|Procedure|Partial Indirect Restoration|Dental restorative treatment
75610867|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
75610868|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
75610869|NCT02710903|Procedure|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
75610870|NCT05265403|Drug|Commercially-available energy storage and return prosthetic foot|Each patient will walk in the Freedom Highlander, a commercially-available energy storage and return prosthetic foot. The foot will be sized based on the patient's foot size and weight.
75759587|NCT01057368|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
75759588|NCT01057368|Behavioral|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
75759589|NCT02531685|Other|Placebo|Placebo: 0.9% Sodium Chloride injection.
75458598|NCT01810458|Drug|Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
75610871|NCT05265403|Device|MIT-Lower Leg Trajectory Error (LLTE) customized prosthetic feet|Each patient will walk in prosthetic feet designed by the researchers at MIT. These feet will be customized for the user based on their body size (ie, height, foot length) and weight.
75759590|NCT02531685|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.
75759591|NCT03969303|Device|Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)|OCT SCAN
75759592|NCT03969069|Device|MAPLe|Additional assessment with MAPLe
75759593|NCT00368108|Drug|2 mg perampanel|2 mg perampanel
75759594|NCT00368108|Drug|4 mg perampanel|4 mg perampanel
75759595|NCT00368108|Drug|placebo comparator|placebo comparator
75759596|NCT00364130|Device|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
75759597|NCT00364130|Device|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
75759598|NCT00521339|Drug|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
75759599|NCT01044602|Other|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
75759600|NCT01044602|Other|Best Medical Management|Standard of care.
75759601|NCT01044602|Procedure|Roux-en-Y gastric bypass surgery|Surgical treatment.
75759602|NCT00363896|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
75759603|NCT00363896|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
75759604|NCT00527423|Drug|VEGF Trap Eye|Intravitreal injection
75759605|NCT01044680|Dietary Supplement|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
76025331|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
75759606|NCT01044680|Dietary Supplement|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
75759607|NCT00527111|Drug|Cetuximab|
75759608|NCT00527111|Drug|5-fluorouracil|
75759609|NCT00527111|Radiation|Pelvic irradiation|
75759610|NCT00384956|Drug|Azacitidine|
75759611|NCT04090697|Drug|Oxandrolone|Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
75759612|NCT00367640|Drug|100 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
75759613|NCT00367640|Drug|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
75759614|NCT00367640|Drug|500 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
75759615|NCT00367640|Drug|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
75759616|NCT01325220|Drug|arbaclofen|5 mg bid
75759617|NCT01325220|Drug|arbaclofen|10 mg bid
75759618|NCT01325220|Drug|arbaclofen|10 mg tid
75759619|NCT01325220|Drug|Placebo|tid
75759620|NCT01055418|Dietary Supplement|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
75759621|NCT00367484|Biological|Rebif® (clone 484-39)|s.c. administered Rebif®
75759622|NCT01324778|Device|OsseoSpeed TX|OsseoSpeedTM TX implants of lengths 6-17 mm
75759623|NCT01324778|Device|OsseoSpeed|OsseoSpeedTM implants of lengths 6-17 mm
75759624|NCT01057524|Device|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
75610872|NCT04971655|Other|Music therapy|Music therapy will be applied throughout diabetes education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered to individuals as an option and will be listened to throughout the process. Instrumental works will be uploaded to the computer by the researchers and will be played on the loudspeaker during the training.
75610873|NCT04612699|Drug|Jaktinib|Administered orally
75759625|NCT01057524|Other|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
75759626|NCT00526799|Drug|Sorafenib|"Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"
75610874|NCT04612699|Drug|Placebo|Administered orally
75610875|NCT04267432|Dietary Supplement|Placebo|Blank
75610876|NCT04267432|Dietary Supplement|TCI633|Probiotics
75610877|NCT04267432|Drug|Type 2 collagen|Positive control group
75610878|NCT04970173|Other|use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy|Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
75610879|NCT04267354|Other|Arm cycling|The arm cycle will be placed on table with height adjusted to be the same as the acromion (highest point on shoulder). Participants will start arm cycling at a low intensity and increase as per tolerance. They will exercise for a maximum of two minutes at a time, followed by a rest period for 30 seconds. In this manner 5 cycles of exercise and rest will be performed. The exercise sessions are anticipated to last a maximum of 20 minutes, depending on the patient's abilities.
75610880|NCT05382988|Drug|Sodium zirconium cyclosilicate|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
75610881|NCT05379868|Procedure|Posterior column osteotomy|Apical full facet joint resection. Study intervention does not involve a device.
75610882|NCT05379868|Procedure|No osteotomies|Standard treatment
75610883|NCT02710747|Genetic|CYP2C9;VKORC1|
75610884|NCT05382832|Combination Product|SCS|SCS-experimental treatment
75759627|NCT00526799|Drug|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
75759628|NCT01059084|Drug|Valacyclovir|1000 mg tid
75759629|NCT03992144|Drug|Amoxicillin 500 Mg|Amoxicillin 500mg an hour before tooth extraction
75759630|NCT03992144|Drug|metronidazole 400mg|400mg of metronidazole an hour before extraction
75610885|NCT05382832|Combination Product|SCS|SCS-placebo
75610886|NCT00936598|Drug|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women = or > 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
75759631|NCT03992144|Drug|metronidazol 400mg and amoxicillin 500mg|400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
75759632|NCT01059162|Device|Laser Assisted Non-penetrating glaucoma surgery|A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.
75759633|NCT02534870|Drug|ABT-450/r/ABT-267|Tablet
75759634|NCT02534870|Drug|ABT-333|Tablet
75759635|NCT00526331|Device|Vigileo Monitor|Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
75759636|NCT00526331|Device|FloTrac Sensor|Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
76069200|NCT01432275|Device|Comparator blood glucose meter|Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
75759637|NCT03992066|Drug|Vadadustat|oral 150 mg tablet
75759638|NCT03992066|Drug|Darbepoetin alfa|solution intravenous injection
75759639|NCT03992066|Drug|Epoetin alfa|solution for intravenous injection
75759640|NCT03992222|Device|Physical exercise programs PEP targeted on appropriate muscle strengthening devices allows|administration of a Physical exercise program for 24 weeks.The participants will be followed at the 24 and 52nd weeks.
75759641|NCT03986268|Drug|Vit D|The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
75759642|NCT01048736|Behavioral|Exercise Only|4 d/wk of aerobic exercise
75759643|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss).
75610887|NCT00936598|Drug|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
75759644|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
75759645|NCT01048814|Other|ChemoFx|Chemoresponse Marker Assay
75610888|NCT04159441|Other|None intervetion|None intervetion
75759646|NCT01048892|Biological|Seneca Valley virus-001|
75759647|NCT01048892|Drug|cyclophosphamide|
75759648|NCT01048892|Other|laboratory biomarker analysis|
75610889|NCT01025817|Drug|Everolimus and tacrolimus|"Everolimus:~Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~Dose: 1.5 mg per day~Frequency: 0.75 mg twice daily~Tacrolimus:~Dose adjusted to maintain specific blood levels"
75610890|NCT01025817|Drug|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
75610891|NCT02710513|Dietary Supplement|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
75610892|NCT00939640|Behavioral|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
75610893|NCT05264545|Device|PrimeTaper EV|The PrimeTaper EV Implant is a screw shaped dental implant with a defined surface achieved through grit blasting, followed by a process involving a treatment in diluted hydrofluoric acid. There is a conical connection between the implants and the abutments for a tight and stable connection.
75610894|NCT00636883|Drug|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
75759649|NCT01048892|Other|pharmacological study|
75759650|NCT01259648|Drug|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
75759651|NCT01259648|Drug|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
75759652|NCT01259648|Drug|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
75759653|NCT01048970|Other|Nutritional Assessment|Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
75759654|NCT01048970|Dietary Supplement|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
75759655|NCT01049048|Dietary Supplement|Vitamin D3|2500 IU Vitamin D3
75759656|NCT01049048|Dietary Supplement|Placebo|No (0 IU) vitamin D3 added to cookie.
75759657|NCT01049126|Other|ChemoFx|Chemoresponse Marker Assay
75904705|NCT05925309|Drug|Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem|Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
75759658|NCT01044836|Biological|HD203|Injectable form
75759659|NCT00520481|Drug|IMC-A12 (Cixutumumab)|10 mg/kg i.v. infusion over 1 hour every 2 weeks or 20 mg/kg i.v. infusion over 1 hour every 3 weeks.
75759660|NCT01044992|Radiation|H215O PET|H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
75759661|NCT01044992|Drug|Levodopa|Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
75759662|NCT00520403|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
75759663|NCT00520403|Drug|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
75759664|NCT00520403|Drug|Vinblastine|0.1mg/kg iv every 3 weeks
75904706|NCT05925309|Drug|Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor|Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
75759665|NCT04810403|Behavioral|SOMEBODY Eating Disorder Prevention Program|Participants will receive daily activities to complete on their most frequently used social media platform for 14 consecutive days. Daily activities have been adapted from the Body Project - an intervention that has been demonstrated to reduce internalization of the thin ideal and reduce risk for eating disorders. Examples of activities to be piloted include unfollowing social media accounts the participant perceives as reinforcing the thin-ideal and posting a selfie without makeup or editing. Based on feedback from participants, the intervention may be altered to improve acceptability, feasibility, and preliminary evidence of potential efficacy.
75904707|NCT05921812|Diagnostic Test|real time pcr|evaluate the expression of certain circulating microRNAs by real time pcr
76069201|NCT01432275|Device|ADC blood glucose meter with insulin calculator active|Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
75759666|NCT00520013|Drug|bevacizumab|
75759667|NCT00520013|Drug|erlotinib|
75759668|NCT00520013|Drug|paclitaxel|
75759669|NCT00520013|Drug|carboplatin|
75759670|NCT03998891|Other|restricted dietary salt intake|These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
76069202|NCT03025815|Other|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
75759671|NCT00519779|Dietary Supplement|omega-3 supplementation|2.5 g/day omega-3
75759672|NCT00519779|Dietary Supplement|Oral omega-3 fish oil placebo|to match experimental dosage
75759673|NCT00526097|Drug|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
76069203|NCT03025815|Other|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
76069204|NCT01411995|Drug|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
75759674|NCT00526097|Drug|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
75610895|NCT02872155|Other|Oral hydratation|500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
75610896|NCT02872155|Drug|Bicarbonate endovenous hydratation|Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
75759675|NCT00525785|Drug|5-Fluorouracil|"2.2 Gm/m^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump."
75759676|NCT00525785|Drug|Folinic Acid|200 mg/m^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
75904708|NCT05919693|Drug|EYE103|EYE103 is a humanized antibody formulated for IVT administration
76069205|NCT01411995|Drug|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
76069206|NCT01411917|Procedure|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
75610897|NCT02872155|Drug|Saline endovenous hydratation|If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
75759677|NCT00525785|Drug|Oxaliplatin|"100 mg/m^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week)."
75904709|NCT05918185|Procedure|Biospecimen Collection|Undergo blood sample collection
75904710|NCT05918185|Other|Comprehensive Geriatric Assessment|Undergo cGA
75904711|NCT05918185|Other|Electronic Health Record Review|Medical records are reviewed
75904712|NCT05918185|Other|Survey Administration|Complete surveys
76069207|NCT01411839|Behavioral|Cognitive-Behavioral Therapy (CBT-AD)|CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
76069208|NCT01411215|Drug|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
76069209|NCT01449279|Drug|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
75759678|NCT00525785|Radiation|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
75759679|NCT00525785|Procedure|Surgery|4-6 weeks after completion of chemoradiotherapy, restaged & surgical resection of the primary tumor and lymph nodes attempted.
75904713|NCT05908773|Drug|TTX-MC138-NODAGA-Cu64|TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging.
75904714|NCT05908669|Diagnostic Test|Deuterium metabolic imaging|MRI after oral administration of 75g of [6,6'-2H2]glucose.
75904715|NCT05905536|Device|Vitalstream|The device will be placed on the subject and monitoring started in the holding room on the morning of surgery. Monitoring will continue postoperatively until the pulmonary artery catheter (PAC) is removed (Standard of Care) or discharged, or at study team discretion. At Intensive Care Unit (ICU) admittance and again 3 hours later a straight leg raise will be done to monitor for changes in hemodynamics.
75759680|NCT04746287|Drug|CKD-510 single dose|Investigational drug
75759681|NCT04746287|Drug|CKD-510 food effect|Investigational drug
75610898|NCT00605956|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
75610899|NCT00605956|Drug|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
75610900|NCT00605956|Drug|Blank Patch|Blank Patch
75610901|NCT02710357|Procedure|Mandibular Overdenture|Placement of an implant in the mandibular midline.
75759682|NCT04746287|Drug|CKD-510 multiple dose|Investigational drug
76069210|NCT01449279|Radiation|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
75759683|NCT04746287|Drug|Placebo|Matching placebo
75759684|NCT04487561|Device|hemopatch|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
75759685|NCT04487561|Procedure|Aspirative drainage|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
76069211|NCT04408053|Device|Preventive fixation of the contralateral femoral neck (Stryker Trauma and Depuy Synthes screws)|6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
75759686|NCT00525161|Drug|sorafenib|400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
75904716|NCT05904652|Device|"Fisher and Paykel HealthCare Airvo™ 3 high flow system"|High Flow Nasal Oxygen Delivery Device
75904717|NCT05904652|Device|Conventional Oxygen Therapy|Low flow oxygen delivery device (Flow rate between 2 litres per minute and 15 litres per minute)
75904718|NCT05903170|Device|360J LifePak Monitor/Defibrillator|The LifePak Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 360J.
75904719|NCT05903170|Device|200J Philips HeartStart MRx Monitor/Defibrillator|The Philips HeartStart MRx Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 200J.
75904720|NCT05897385|Drug|Lignocaine|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
75904721|NCT05897385|Drug|Normal Saline|Intraperitoneal 20ml of 0.9% normal saline
75610902|NCT02710357|Procedure|Mandibular complete denture|No intervention. Maintenance of the dentures will be done when needed.
75904722|NCT05881811|Drug|HSK16149，probenecid, cimetidine|40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1~D4 200mg cimetidine QID from D1~D4
75610903|NCT02871999|Device|Acupuncture therapy|
75610904|NCT02871999|Procedure|Laparoscopic Surgery|
75610905|NCT05382676|Device|Eyeswift Pro|assessment of visual function parameters
75610906|NCT01218113|Biological|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
75610907|NCT01218113|Drug|Placebo|1 or 3 doses according to protocol schedule
75610908|NCT05264467|Biological|Platelet rich fibrin on colorectal anastomosis|Platelet rich fibrin on colorectal anastomosis
75759687|NCT00135694|Drug|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
75759688|NCT00135694|Procedure|liver transplant|Occurs at study entry
75759689|NCT00135694|Drug|corticosteroids|3-month course of corticosteroids
75759690|NCT00135694|Other|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
75759691|NCT00524459|Drug|docetaxel|
75759692|NCT00524459|Drug|pegylated liposomal doxorubicin hydrochloride|
75759693|NCT00524459|Procedure|conventional surgery|
75759694|NCT00524459|Procedure|neoadjuvant therapy|
75610909|NCT02871453|Device|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
75458599|NCT01810458|Drug|Lorazepam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
75610910|NCT02871453|Other|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
75759695|NCT00519623|Other|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
75610911|NCT00605410|Drug|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
75458600|NCT01810458|Drug|Oxycodone/Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
75610912|NCT00605410|Drug|placebo|Matched placebo
75759696|NCT01076530|Drug|vorinostat|
75759697|NCT01076530|Drug|temozolomide|
75610913|NCT02710201|Behavioral|Descriptive Social Norm|
75759698|NCT01076530|Other|diagnostic laboratory biomarker analysis|
75610914|NCT02710201|Behavioral|Descriptive-plus-Injunctive Social Norm|
75759699|NCT01076530|Other|pharmacological study|
75759700|NCT03966664|Diagnostic Test|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.|Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
76069212|NCT01447719|Drug|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
76069213|NCT01431963|Drug|Lamictal|No comparison.
76069214|NCT01447407|Biological|NDV-3 vaccine with alum IM|One dose administered IM
76069215|NCT01447407|Biological|NDV-3 vaccine without alum IM|One dose administered IM
76069216|NCT01447407|Biological|Placebo with alum IM|One dose administered ID
76069217|NCT01447407|Biological|NDV-3 vaccine without alum ID|One dose administered ID
76069218|NCT04056819|Biological|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
76069219|NCT04055025|Other|Placebo|Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.
76069220|NCT04055025|Other|Ghrelin|Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
75610915|NCT04300881|Drug|Eplerenone|Following intravitreal ocriplasmin therapy
75610916|NCT04203940|Procedure|Cyanoacryale|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue
75610917|NCT04203940|Procedure|Suture|mesh fixation was done with polypropylene 2/0 sutures
75610918|NCT00603850|Device|ForeseeHome|human factor
75610919|NCT03873493|Drug|Venetoclax|Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.
75904723|NCT05878223|Device|Extracorporeal shock waves|Both group received extracorporeal shock waves therapy
76069221|NCT01446237|Other|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
76069222|NCT00540982|Drug|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
76069223|NCT00540982|Drug|lidocaine|1 mg/kg will be administered to determine metabolic capacity
75759701|NCT03966664|Diagnostic Test|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood|Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
75904724|NCT05876754|Drug|Ivosidenib Oral Tablet|Ivosidenib 500 mg
75904725|NCT05875181|Device|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
75759702|NCT03966664|Diagnostic Test|Biomolecular analysis of plasma proteins.|Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
75904726|NCT05875181|Device|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
75759703|NCT00519077|Drug|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
75904727|NCT05871177|Device|Pre-filled syringe of HiLow Hyaluronic Acid Sodium Salt|The medical device consists of a pre-filled syringe containing 3.2% Hyaluronic Acid Sodium Salt with high and low molecular weight [32 mg (HHA) + 32 mg (LHA) / 2 ml]
75904728|NCT05863884|Behavioral|Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake|CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
76069224|NCT00540982|Drug|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
76069225|NCT00540982|Other|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
76069226|NCT00540982|Other|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
75904729|NCT05863039|Other|Blood flow restriction|Strength training of the lower leg muscles using blood flow restriction
75904730|NCT05863039|Other|Regular training type 1|Strength training of the lower leg muscles using high loads
75458601|NCT01810458|Drug|Ondansetron|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
75458602|NCT01810471|Device|Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)|
75458603|NCT01810497|Procedure|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
75610920|NCT03873493|Drug|Ibrutinib|Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.
75610921|NCT05264311|Other|Pilates exercise program|"The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study [31]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP."
75904731|NCT05863039|Other|Regular training type 2|Strength training of the lower leg muscles using low loads
75904732|NCT05859295|Device|Red Low-Level Light Therapy|Visible red light (633nm) projected onto the face using an light emitting diode (LED) mask
75904733|NCT05856370|Device|Follow-up schedule: pre-operative baseline to index surgery|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to index surgery for those receiving eligible Medtronic Powered Systems, Instruments, and Imaging device(s)
76069227|NCT00540982|Other|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
76069228|NCT00540982|Other|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
75904734|NCT05856370|Device|Follow-up schedule: pre-operative baseline to discharge|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to index surgery for those receiving eligible Advanced Energy device(s)
75610922|NCT05264233|Dietary Supplement|Coconut oil|50 g of coconut oil will be added to the test meal for breakfast and 30 g of coconut oil will be added to the test meal for lunch
75610923|NCT05264233|Dietary Supplement|Butter|50 g of butter will be added to the test meal for breakfast and 30 g of butter will be added to the test meal for lunch
75904735|NCT05856370|Device|Follow-up schedule: pre-operative baseline up to 24-months post-procedure|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to index surgery for those receiving eligible Medtronic Robotics and Navigation, Rods and Screws, Interbodies and Biologics, Spinal Tethers, and Other Spinal Hardware device(s)
75904736|NCT05849714|Other|Peri-intervention Diabetes Management Algorithm (DIAPI)|Patients and healthcare workers will apply DIAPI's orders.
75610924|NCT05264233|Dietary Supplement|Vegetable oil|50 g of vegetable oil will be added to the test meal for breakfast and 30 g of vegetable oil will be added to the test meal for lunch
75610925|NCT00611689|Drug|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in < 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
75610926|NCT05264077|Drug|Dexmedetomidine Hydrochloride|Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
75904737|NCT05849714|Other|Usual Care|Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.
75610927|NCT04892641|Drug|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
75610928|NCT04892641|Drug|Placebo|Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
75610929|NCT03757819|Device|tDCS|Brain Stimulation
75610930|NCT03757819|Device|SHAM|Placebo device
75610931|NCT04160845|Procedure|cardiac surgery|cardiac surgery with hypothermic cardiopulmonary bypass
75610932|NCT00612859|Drug|levetiracetam|
75610933|NCT04866901|Behavioral|Slow-Paced Breathing (SPB)|see arm description
75904738|NCT05849090|Drug|Cephalosporin or clindamycin/vancomycin antibiotics..|Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
75904739|NCT05849090|Drug|Vancomycin and Tobramycin antibiotics.|Vancomycin (1 gram) and tobramycin (1.2 grams).
75610934|NCT04866901|Behavioral|Mindfulness (M)|see arm description
75610935|NCT04866901|Behavioral|Yogic Breathing (SPB+M)|see arm description
75759704|NCT03966508|Procedure|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
75759705|NCT00124618|Biological|cetuximab|
75759706|NCT00124618|Radiation|radiation therapy|
75759707|NCT00124462|Device|Realigning knee brace and custom orthodic|A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
75904740|NCT05847361|Diagnostic Test|BH4 blood level|from admission to END OF PREGNANCY, a blood sample is taken.
75610936|NCT00612391|Procedure|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
75610937|NCT00612391|Procedure|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
75759708|NCT00124462|Device|Non realigning knee brace and flat orthodic|A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
75904741|NCT05846646|Drug|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
75458604|NCT01810510|Procedure|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
75458605|NCT01810510|Procedure|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
76069229|NCT00540982|Other|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
75458606|NCT01810523|Behavioral|Narrative|Narrative form as described above.
75458607|NCT01810523|Behavioral|Control|Blank piece of paper
75458608|NCT01810536|Device|Hi-flow nasal cannula|Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
75458609|NCT01810536|Device|Venturi mask|
75458610|NCT01810549|Drug|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
75759709|NCT00124072|Drug|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
75759710|NCT00124072|Dietary Supplement|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
75759711|NCT00124072|Drug|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
75759712|NCT00124072|Drug|Placebo|Placebo vitamin B12/folic acid tablet once daily
75759713|NCT02531386|Device|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
75759714|NCT01080352|Drug|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
75759715|NCT00362648|Biological|RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent|2.0 mL oral dose of RotaTeq™. 14 week treatment period
75759716|NCT00362648|Biological|Comparator: Placebo|Arm 2: Placebo. 14 week treatment period
75904742|NCT05846646|Drug|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label
75904743|NCT05846646|Radiation|PULSAR|1st day of Cycles 1, 2 and 3.
76069230|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
75458611|NCT01810549|Drug|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
75610938|NCT02709811|Drug|Electrochemotherapy|
75610939|NCT04216147|Other|PNE|Percutaneous Needle Electrolysis: the application of galvanic current through an acupuncture needle.
75759717|NCT01045148|Radiation|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
75759718|NCT01045148|Radiation|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
75759719|NCT00524303|Drug|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
75759720|NCT00524303|Drug|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
75759721|NCT00524303|Drug|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
75759722|NCT00524303|Drug|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
75610940|NCT04216147|Procedure|Surgery for CTS|Median nerve release
75610941|NCT05261035|Behavioral|stretching exercises|For the stretching exercises group; the researchers explained to the women how to perform the stretching exercises through different visual materials like videos & pictures, provided a demonstration of each step, and emphasized that they could perform this exercise at any comfortable position, standing, sitting, or dorsal.
75759723|NCT04461041|Drug|Empagliflozin|Single oral tablet
75759724|NCT04461041|Drug|Placebo|Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
75759725|NCT00335556|Drug|Doxorubicin Hydrochloride|Given IV
75759726|NCT00335556|Drug|Irinotecan Hydrochloride|Given IV
75904744|NCT05846451|Dietary Supplement|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.
75904745|NCT05846451|Drug|Oxycodone|Immediate-release oral tablet, 10 mg
75904746|NCT05844033|Other|Screening|Blood tests
75904747|NCT05842876|Device|Continuous Renal NIRS Monitoring|Renal oxygenation data collected every 6 seconds
75458612|NCT01810562|Other|Specific treatment in addition to standard stroke care|"Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.~Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.~Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.~Scrolling with spiked ball over the same area as brushing for two minutes evenly.~Firm pressure for two minutes evenly in the same area."
75610942|NCT05261035|Other|thermotherapy|women were instructed to warm the water to 43-47 C° using a water thermometer or test it with the inner aspect of their wrists. They are also advised to avoid using too hot or too cold water. Then immerse their legs for 20 minutes in the warm water at a h
75759727|NCT00335556|Procedure|Conventional Surgery|Patients undergo resection
75759728|NCT00335556|Drug|Cyclophosphamide|Given IV
75759729|NCT00335556|Drug|Etoposide|Given IV
75904748|NCT05842876|Diagnostic Test|Standard Clinical Care|q6 h BP, q6 h Pulse ox, Echo at 24-72h
75904749|NCT05842876|Diagnostic Test|Standard Clinical Care|Renal oxygenation data collected every 6 seconds, q6 h BP, continuous Pulse ox, Echo at 12-72h
76069231|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
75759730|NCT00335556|Drug|Carboplatin|Given IV
75759731|NCT00335556|Biological|Dactinomycin|Given IV
75759732|NCT00335556|Drug|Vincristine Sulfate|Given IV
75904750|NCT05842876|Other|Satisfaction Survey|Survey to assess which method of monitoring is preferred
75458613|NCT01810601|Drug|GnRh, HMG, HCG, Progesterone|GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
75610943|NCT04848805|Procedure|liver transplantation|total hepatectomy material was examined by pathology laboratory
75904751|NCT05839925|Diagnostic Test|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II|The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).
75904752|NCT05837884|Diagnostic Test|blood sampling|Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
75904753|NCT05836870|Other|Enhanced Usual Care|Participants will receive general recommendations to maintain physical activity.
75904754|NCT05836870|Behavioral|Tele-supervised resistance exercises|Participants will take part in a monitored exercise program.
75904755|NCT05824026|Device|Gelling fiber wound dressing with silver|intervention involving a wound dressing with silver
75759733|NCT00335556|Radiation|Radiation Therapy|Undergo radiotherapy
75759734|NCT00335556|Other|Laboratory Biomarker Analysis|Correlative studies
75759735|NCT00518687|Biological|V710|0.5-mL single injection of V710 (60 µg)
75759736|NCT00518687|Biological|Placebo|0.5-mL single injection of matching placebo
75759737|NCT00134056|Drug|atrasentan hydrochloride|Given orally
75759738|NCT00134056|Drug|docetaxel|Docetaxel given IV and prednisone given orally
75759739|NCT00134056|Drug|prednisone|Docetaxel given IV and prednisone given orally
75759740|NCT00134056|Other|placebo|Given orally
75759741|NCT00518531|Drug|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
75458614|NCT01810614|Other|ADPKD Diet|Diet specifically designed for people with ADPKD
75610944|NCT04841005|Other|The Square-Step Exercise Training|The Square-Step Exercise is instructed to walk according to the step pattern shown on a 100 * 250 cm mat, divided into 40 squares of 25 cm each. It includes forward, backward, lateral and diagonal steps, and step patterns are progressively made more complex. Each pattern consists of two to 16 steps; Individuals are asked to repeat the step pattern until they reach the end of the mat. Each step pattern is repeated 4-10 times to ensure that individuals can complete the pattern. The individuals included in the study will exercise in easy-difficulty patterns for the first 2 weeks, medium-difficulty patterns in the 3rd and 4th weeks, medium and advanced patterns in the 5th and 6th weeks, and advanced patterns in the 7th and 8th weeks. The square-step exercise group will perform 15 minutes of warm-up exercise, 30 minutes of progressive square-step exercise, and 10 minutes of cool-down exercise accompanied by a physiotherapist, 3 days a week.
75759742|NCT00518531|Drug|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
75759743|NCT00351468|Drug|eltrombopag olamine (SB-497115-GR)|Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
75759744|NCT01326364|Procedure|Stereotactic body radiotherapy|Standard of Care
75759745|NCT01326364|Drug|Iodixanol|IV, calculated per patient
75759746|NCT01326364|Drug|Iohexol|IV, Calculated per patient
75759747|NCT01080430|Other|rehabilitation maneuver|rotation in the direction of the weak vestibular response, every 3-7 days over a period of a month. Each rotation lasts about 2 minutes and a total of 3-7 rotations are used per session.
75759748|NCT01326442|Other|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
75759749|NCT01326442|Dietary Supplement|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
75759750|NCT00523991|Drug|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
75759751|NCT00523991|Drug|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
75759752|NCT00350844|Drug|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
75759753|NCT00345540|Drug|NOV-002|60 mg / mL / day / 20-23 Days
75759754|NCT00345540|Drug|Carboplatin|AUC 5 following IV bolus administration of NOV-002
75458615|NCT01810627|Radiation|MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
75458616|NCT01810640|Procedure|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
75759755|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
75759756|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
75458617|NCT01810653|Drug|Macrogol (Transipeg, BAY81-8430)|Up to 4 sachets per day based on individual titration
75458618|NCT01810653|Drug|Macrogol (Forlax)|Up to 4 sachets per day based on individual titration
75458619|NCT01810679|Device|Perceval S Aortic Heart Valve|Perceval S Sutureless Aortic Heart Valve
75759757|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
75759758|NCT03986346|Device|pulsed dye laser|The scar will receive PDL 585 nm using a 7 mm spot size. First treatment will be within 1 year post injury.
75759759|NCT03986346|Other|standardized care|the scar will receive standardized care such as scar massage.
75759760|NCT01059396|Drug|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
75458620|NCT01810731|Biological|Quadrivalent Inactivated Influenza Vaccine (QIV)|
75458621|NCT01810731|Biological|Inactivated Polio Vaccine|
75458622|NCT01810731|Biological|Double Dose QIV|
75759761|NCT01059396|Drug|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
75759762|NCT01059396|Drug|placebo|placebo propranolol / carvedilol
75759763|NCT01057680|Dietary Supplement|creatine monohydrate|Powder, 0.1 g per day, 12 months
75759764|NCT01057680|Dietary Supplement|sugar placebo|powder, 0.1 g/day, 12 months
75759765|NCT00523367|Procedure|24 hour pH testing|24 hour pH testing will be used to screen patients
75904756|NCT05815017|Device|Yoomi Physical Therapy Software|Physical Therapy software via a computer/monitor will be set up for the patient. It will begin with a tutorial video for different exercises in the form of games and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
75904757|NCT05811065|Device|OPTIVF dosage|Opt-IVF dosage
75904758|NCT05811065|Device|traditional drug treament|Traditional drug treatment
75904759|NCT05805085|Device|Lens A (Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
75904760|NCT05805085|Device|Lens B (Silicone Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
75904761|NCT05805059|Device|Control Contact Lens (stenfilcon A)|one week wear
75904762|NCT05805059|Device|Test Contact Lens (senofilcon A)|one week of wear
75458623|NCT01810744|Other|capillaroscopy|
75458624|NCT01810744|Other|blood pressure measurement|
75458625|NCT01810757|Radiation|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
75610945|NCT04841005|Other|Strengthening Exercise Training|Thera-Band brand elastic bands will be used to apply resistance in strengthening training. To determine the intensity of the exercise, the perceived difficulty level after 15 repetitions with the elastic band will be evaluated with the Borg scale. If the perceived difficulty level is at the level of 12-14 (slightly difficult), it will be considered as the starting difficulty level.In the strengthening exercise group will perform, shoulder abduction, shoulder press after elbow flexion, horizontal abduction, punching with an elastic band, triceps strengthening, external rotation of the shoulder, hip abduction with external rotation and sit-to-stand exercises for 8 weeks, 3 days / week , 3 sets / sessions, 8-12 repetitions. For each exercise, it will be applied as 8 repetitions in the initial workload. In the next exercise sessions, the number of repetitions will be increased until the patient can comfortably perform 12 repetitions with the same load.
75759766|NCT01059474|Drug|transdermal DMPS|"12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS."
75759767|NCT01059552|Drug|vorinostat|vorinostat once daily for 12 weeks of therapy
75759768|NCT03741894|Drug|Iodoform|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
75759769|NCT03741894|Other|Wound closure using sutures|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
75759770|NCT03741894|Drug|Chlorhexidine|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
75759771|NCT03755765|Drug|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
75759772|NCT03755765|Biological|BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
75759773|NCT03755765|Other|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
75759774|NCT01061112|Drug|Flurbiprofen Control - Flurbiprofen Only|A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
75904763|NCT05803824|Other|exercise therapy program|"patients will receive Baduanjin Qigong exercise plus selected exercise. the subjects will recive Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks.~The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .~Selected Exercise Program: Patients will receive~balance exercises is composed of three phases, including warm-up, balance training and cool down.~Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises"
75904764|NCT05801939|Drug|Cevostamab|Cevostamab will be given as an IV infusion once every 3 weeks, starting roughly 10 weeks (day 70 +/- 4 days) post-CAR T cell infusion, with subjects planned to receive 8 cycles initially. Subjects receive a single step-up dose of 3.6 mg of cevostamab on cycle 1, day 1 (C1D1), followed by the recommended target dose (160 mg, 132mg, or 90 mg based on results of safety run-in data and safety review) on C1D8. Myeloma responses are assessed every cycle, and a repeat bone marrow aspirate and biopsy (BMbx) is performed at the start of cycle 8. If participants are not in an MRD-negative CR at this timepoint (or if the BM bx is inevaluable/indeterminate for CR or MRD testing), they continue with another 8 cycles (C9-16) of cevostamab. If they are in MRD-negative CR at start of C8, they stop therapy after receiving this cycle and are observed.
76069232|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
76069233|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
75759775|NCT01061112|Drug|Flurbiprofen Inhibition - Flurbiprofen & Fluconazole|A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
75759776|NCT01061112|Drug|Ketoprofen Control - Ketoprofen Only|A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
75759777|NCT01061112|Drug|Ketoprofen Inhibition - Ketoprofen & Fluconazole|A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
75759778|NCT01061112|Drug|Tolbutamide Control - Tolbutamide Only|A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
75458626|NCT01810757|Radiation|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
75458627|NCT01810770|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
75458628|NCT01810796|Drug|Ranolazine|Ranolazine versus placebo
75759779|NCT01061112|Drug|Tolbutamide Inhibition - Tolbutamide & Fluconazole|A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
75759780|NCT04780841|Drug|RDX013|RDX013 is an experimental drug that is a potassium secretagogue
75759781|NCT04780841|Drug|Placebo|Placebo treatment that looks identical to experimental treatment
75610946|NCT02709733|Behavioral|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
76069234|NCT00543400|Drug|M118|intravenous (IV) infusion
75759782|NCT01061190|Drug|Propranolol|oral application of 160 mg Propranolol for 30 days
75759783|NCT00344448|Drug|Raptiva|During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
75759784|NCT00324168|Drug|Antibiotics|moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
75610947|NCT00939484|Other|Pharmacological Study|Correlative studies
75610948|NCT00939484|Drug|Vismodegib|Given PO
75610949|NCT01010217|Drug|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
75759785|NCT00324168|Drug|Topical corticosteroid|prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
75759786|NCT00324168|Drug|Placebo|0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
75759787|NCT00517829|Drug|Docetaxel|Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
75759788|NCT00517829|Drug|cetuximab|ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
75904765|NCT05794126|Device|Soft Multifocal Hydrogel Contact Lens 1|soft multifocal hydrogel contact lens 1 - first period of 15 minutes
75904766|NCT05794126|Device|Soft Multifocal Silicone Hydrogel Contact Lens 2|soft multifocal silicone hydrogel contact lens 2 - second period of 15 minutes.
76069235|NCT00543400|Drug|Unfractionated Heparin|IV infusion
76069236|NCT01796938|Drug|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
76025332|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
76025333|NCT05018975|Drug|Tazemetostat|Tazemetostat 800mg BID PO dosing for 15 days
76025334|NCT03741881|Other|No treatment given|Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
76025335|NCT02673697|Device|Perceval valve|Sutureless Aortic Biological Valve
76069237|NCT00492544|Biological|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
76069238|NCT00492622|Drug|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
76069239|NCT00492622|Drug|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
75610950|NCT01010217|Drug|Fludarabine|40 mg/m^2 IV over 1 hour on Days -6, -5, -4, and -3.
75610951|NCT01010217|Drug|Melphalan|140 mg/m^2 IV (or 100 mg/m^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
75610952|NCT01010217|Drug|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
75610953|NCT01010217|Drug|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
75610954|NCT01010217|Procedure|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
75610955|NCT01010217|Drug|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
75610956|NCT01010217|Drug|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
75610957|NCT01010217|Drug|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
75610958|NCT01010217|Drug|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery > 1000/mcl.
75759789|NCT00517829|Drug|oxaliplatin|Eloxatin 130 mg/m2 IV over 2 hours
75759790|NCT00343512|Drug|docetaxel|Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
75759791|NCT00343512|Genetic|protein expression analysis|protein expression analysis
75759792|NCT00343512|Other|laboratory biomarker analysis|laboratory biomarker analysis
75759793|NCT00343512|Procedure|biopsy|biopsy
75759794|NCT00343512|Procedure|conventional surgery|conventional surgery
75759795|NCT00343512|Procedure|neoadjuvant therapy|neoadjuvant therapy
75759796|NCT00334542|Drug|simvastatin|24-28 weeks of simvastatin
75759797|NCT01059942|Other|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
75759798|NCT01059942|Other|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
75759799|NCT00112294|Drug|Paclitaxel (Taxane)|IV, 225 mg/m^2
75759800|NCT00112294|Drug|Docetaxel (Taxane)|IV, 75 mg/m^2
75759801|NCT00112294|Drug|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
75610959|NCT00605488|Procedure|novel PET tracer FACBC|Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
75610960|NCT04268212|Dietary Supplement|Bitter melon juice (100 ml)|Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.
75610961|NCT04268212|Behavioral|Exercise|The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
75759802|NCT00112294|Drug|Cetuximab|Intravenous, 400 mg/m^2, initial dose followed by 250 mg/m^2, weekly starting on Week 2
75759803|NCT00235443|Drug|lacosamide|Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
75759804|NCT03973437|Device|Artificial inteligence associated ulcerative colitis severity scoring system|Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
75904767|NCT05772910|Behavioral|EDUcation|The education intervention will consist of an individualized educative program based on intrinsic capacity optimization through lifestyle changes. To develop the program, the program creation team will be multidisciplinary (psychologists, medical doctor, dietitian…) and will discuss goal setting, the education strategy, and retention of motivation. The experts are required to create the education program such that the participants can manage their health by themselves. The goal will be self-management of dietary habits and increases in physical activity levels for each individual case. The education program will be in Spanish or in English; as it will consist in personal counselling, even with a low level of the language the communication will be possible. The nutritional education program will be conducted every 2 weeks for 10 consecutive weeks, with 20-min counselling sessions by an expert.
75904768|NCT05772910|Other|EXERcise|The intervention period will have 10 weeks, in which the EXER group will carry out 2-3 sessions a week (total of 20-30 sessions). In this concurrent program, exercises of the lower extremities (leg press, abduction and plantar flexion) will be performed mainly on weight training machines. Intensity in each exercise will be individualized for each participant through a test to determine muscle power. In addition, in the last part of each session the participants will perform an endurance training type high insensitive interval training on a cycle ergometer (60-80 rpm). The intensity will be individualized to each patient through an incremental stress test until volitional exhaustion, and the subjects will alternate intervals of 30 seconds at 90% of the maximum workload, with intervals of 90 seconds at 40% of the maximum. Each session is estimated to have a total duration of 30-50 minutes.
75904769|NCT05772910|Other|EDU-EXER|This group will carry out the same two previous interventions together.
75904770|NCT05772910|Other|CONtrol|CONtrol group will continue the usual clinical treatment and their normal life
75904771|NCT05769608|Drug|Placebo|Placebo once daily for 12 weeks
75610962|NCT00604006|Drug|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
75610963|NCT00604006|Drug|Placebo|Placebo (lactose in capsules for blinding) once daily
75610964|NCT00604084|Drug|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
75759805|NCT03973437|Device|Conventional human scoring|Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
75759806|NCT00234039|Drug|gemcitabine hydrochloride|
75904772|NCT05769608|Drug|lorundrostat Dose 1|lorundrostat Dose 1 once daily for 12 weeks
75458629|NCT01810809|Procedure|articular lavage with saline injection|Patients will receive articular lavage with saline injection
76069240|NCT00494494|Drug|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
76069241|NCT00494494|Drug|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
76069242|NCT00494806|Other|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
75904773|NCT05769608|Drug|lorundrostat Dose 2|lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria
76069243|NCT03145558|Drug|Tirapazamine|Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
76069244|NCT03145558|Drug|Doxorubicin|Standard of care for TACE
76069245|NCT03837496|Other|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
76069246|NCT03837496|Other|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
75458630|NCT01810809|Drug|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
76069247|NCT04750018|Other|surgery|Patients were divided into surgery and no disease.
76069248|NCT01797874|Drug|Pazopanib|Experimental
75458631|NCT01810809|Drug|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
75458632|NCT01810809|Drug|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
75610965|NCT00604084|Drug|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
75610966|NCT02691052|Other|Quality of Life questionnaire|EORTC QLQ-C30 questionnaire
75610967|NCT05379478|Diagnostic Test|Laboratory assessment of antibody profiles|Antibody profiles will be determined on submitted plasma samples
76069249|NCT01797874|Drug|Placebo|placebo arm
76069250|NCT04750174|Other|Kinesiotaping|Kinesiotape (KT) has been used by Dr. Kenzo Kase for the first time as based on the opinion that more successful results can be obtained in a banding method similar to the structural characteristics and flexibility of human skin without limiting the joint movements for edema control, joint protection, and proprioception training. In recent years, KT have been applied with a wide variety of techniques including muscle techniques for the inhibition and stimulation of muscles, fascia correction technique which aims to reduce tension and adhesions by making vibration movement between the fascia layers and field correction technique aiming to reduce regional pressure in the presence of pain, inflammation or edema as well as lymphatic correction technique for regulating lymphatic circulation .
75759807|NCT03973359|Behavioral|Hygienic recommendations|Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.
75759808|NCT02531451|Drug|Ibuprofen|
75759809|NCT02531451|Drug|Acetylsalicylic acid|
75904774|NCT05766852|Behavioral|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
75904775|NCT05766124|Drug|Tissue Plasminogen Activator|Intrapleural administration of tissue plasminogen activator
75904776|NCT05763628|Device|Control Contact Lens (stenfilcon A Daily Disposable Multifocal Contact Lens)|two weeks of wear
75904777|NCT05763628|Device|Test Contact Lens (senofilcon A Daily Disposable Multifocal Contact Lens)|two weeks of wear
75904778|NCT05754411|Drug|[14C]STI-1558|Fasting oral administration of 600 mg [ 14C ] STI-1558 ( about 100 μCi ) solution.
75458633|NCT01810848|Device|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
75458634|NCT01810848|Other|Control|Control is puncture of the skin at the site of the knee.
75458635|NCT01810874|Procedure|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
75458636|NCT01810874|Procedure|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
75458637|NCT01810887|Drug|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
75458638|NCT01810887|Drug|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
75458639|NCT01810900|Device|Protescal|
75458640|NCT01810926|Biological|polyclonal antibody|iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)
75610968|NCT04267042|Drug|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
75610969|NCT04267042|Device|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
75759810|NCT01073007|Drug|Simvastatin|Simvastatin 40 mgrs daily for three months.
75759811|NCT03741621|Dietary Supplement|Viscous Fibre Blend|High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
75759812|NCT03741621|Dietary Supplement|Psyllium|Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
75759813|NCT03741621|Dietary Supplement|Wheat Bran|All Bran cereal (All Bran®; Kellogg Company)
75759814|NCT00323622|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
75759815|NCT00323622|Biological|Engerix™-B|IM injection in the deltoid muscle
75759816|NCT00323622|Biological|Hiberix®|IM injection in the deltoid muscle
75759817|NCT00323622|Biological|Prevnar™|IM injection in the deltoid muscle
75759818|NCT00323622|Drug|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
75458641|NCT01810926|Drug|Rituximab|single infusion of200 mg/m2 on day -1
75458642|NCT01810926|Drug|Treosulfan|iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)
75759819|NCT00323622|Drug|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
75759820|NCT00189423|Device|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|"The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR."
75458643|NCT01810926|Drug|Fludarabine|iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan
75458644|NCT01810926|Drug|Thiotepa|iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
75458645|NCT01810926|Drug|Cyclosporine A|iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL
75458646|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
75458647|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
75458648|NCT01810965|Procedure|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
75458649|NCT01810978|Dietary Supplement|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
75759821|NCT00189423|Procedure|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
75759822|NCT01325961|Radiation|Intensity-Modulated Radiation Therapy|
75759823|NCT00323310|Drug|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
75759824|NCT01326039|Drug|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
75759825|NCT01326039|Drug|saline|perineural isotonic saline 20 ml
75759826|NCT01057758|Drug|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
75759827|NCT01057758|Drug|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
75458650|NCT01810978|Dietary Supplement|Maltodextrin|same amount of maltodextrin per day will be given as placebo
75458651|NCT01811017|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
75759828|NCT00186537|Drug|Rosiglitazone|
75759829|NCT00186537|Drug|Fenofibrate|
75759830|NCT00186537|Behavioral|Weight Loss|
75759831|NCT03968835|Other|Bacitracin|For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.
75759832|NCT03968835|Other|Skin Graft|For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.
75759833|NCT01073085|Behavioral|"Web-based automated coaching by e-mails"|
75759834|NCT01073085|Behavioral|Self-help guide|
75759835|NCT00517751|Device|X-STOP PEEK|Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
75904779|NCT05753384|Drug|treatment of TKI in CML|continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
75458652|NCT01811056|Drug|Mifepristone|Mifepristone use outside of the center
75458653|NCT01811069|Procedure|Head up|30˚ reverse trendelenburg body position
75458654|NCT01811082|Drug|Coenzyme A|Coenzyme A 400mg per day.
75458655|NCT01811082|Drug|Pantethine|Pantethine 600mg per day.
75458656|NCT01811095|Other|Training|"Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score."
75458657|NCT01811121|Drug|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
75458658|NCT01811121|Drug|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
76025336|NCT02673697|Device|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
76069251|NCT00497770|Drug|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
76069252|NCT00498550|Drug|Clozapine|Clozapine up to 550mg per day
75759836|NCT00322842|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
75759837|NCT00255723|Drug|carboplatin|Given IV
75904780|NCT05753046|Drug|Early TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
75904781|NCT05753046|Drug|Late TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the conclusion of the procedure (immediately proceeding removal of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
75759838|NCT00255723|Drug|etoposide|Given IV
75458659|NCT01811134|Device|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
75458660|NCT01811134|Device|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
75458661|NCT01811160|Drug|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
75610970|NCT04267042|Device|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
75904782|NCT05738603|Device|Hypotension Prediction Index|Hemodynamic perioperative monitoring with the Hypotension Prediction Index
75904783|NCT05712694|Drug|ADI PEG20|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
75458662|NCT01811160|Drug|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
75610971|NCT04266652|Procedure|tooth block|tooth root blocks were used to increase the bone width
75610972|NCT04266652|Procedure|autogenous bone block|autogenous bone block were used to increase the bone width
75610973|NCT01217957|Drug|Ixazomib|Ixazomib capsules
75610974|NCT01217957|Drug|Lenalidomide|Lenalidomide capsules
75610975|NCT01217957|Drug|Dexamethasone|Dexamethasone tablets
75610976|NCT00939094|Drug|AZD2066|Capsule, once daily
75610977|NCT00939094|Drug|Placebo|Capsule, once daily
75759839|NCT00255723|Drug|ifosfamide|Given IV
75759840|NCT01060176|Drug|Tranexamic Acid|
75759841|NCT01060176|Drug|Saline Solution|
75904784|NCT05712694|Other|Placebo|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
75904785|NCT05708612|Procedure|Medical Device (SimplyFI)|Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
75904786|NCT05706012|Other|Survey|Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients
75904787|NCT05705024|Biological|Mesenchymal Stromal Cells|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.
75904788|NCT05705024|Other|Control Solution|For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.
75610978|NCT04297371|Diagnostic Test|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
75458663|NCT01811173|Other|Nurse-physician comprehensive care|"Components of the intervention include:~Complete assessment of the patient's and family's needs conducted by the nurse.~Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~Multimorbid care plan integrating all care aspects.~Action Plan for patients, supporting self management~Proactive monitoring according to the plan."
75458664|NCT01811251|Drug|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|
75610979|NCT01217801|Drug|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
75610980|NCT01217801|Drug|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
75610981|NCT00935818|Drug|Varenicline|varenicline - 1 mg bid for 12 weeks
75610982|NCT00935818|Drug|placebo|placebo for 12 weeks
75610983|NCT00935818|Drug|bupropion SR|bupropion sr - 150 mg bid for 12 weeks
75610984|NCT01216319|Device|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
75610985|NCT00607516|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
75610986|NCT00607516|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
75610987|NCT04804345|Other|standard of care|retrospective study: standard of care
75610988|NCT02709265|Drug|amikacin/fosfomycin|single aerosolized dose
75610989|NCT00611845|Drug|Aprotinin (Trasylol, BAYA0128)|Trasylol at either 1,000,000 KIU or 2,000,000 KIU
75610990|NCT02709499|Device|0J LLLT|perform with the machine off
75610991|NCT02709499|Device|6J LLLT|irradiation will be perform with 4J
75759842|NCT04719845|Procedure|Endoscopic laser resection|Laser resection
75759843|NCT04719845|Procedure|Dilatation|Dilatation
75759844|NCT01071837|Drug|APG101|400mg weekly as intravenous infusion
75759845|NCT01071837|Procedure|Blood drawing|Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
75759846|NCT01057836|Behavioral|Neck endurance training|
75759847|NCT01057836|Behavioral|Stretching|
75759848|NCT04305977|Behavioral|WAVE-TW|The WAVE-TW open pilot trial of the intervention consists of 5 sessions conducted individually with each part participant. Each session lasts approximately 30-50 minutes. The first session will be the LifeSteps Adherence session that focuses on cognitive-behavioral and problem-solving techniques to promote adherence. The next four sessions will be dedicated to trauma writing.
75759849|NCT00132808|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous
75904789|NCT05702385|Other|Educational Materials for a new diagnostic test|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
75904790|NCT05699018|Diagnostic Test|eLIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elstometry ≥ 8 kPa and < 15 kPa)
75904791|NCT05693493|Device|Proprioceptive knee brace|For the intervention group that randomly consisted of 15 subjects will be using a design of knee brace (Reaction Web®; DonJoy, Vista, CA). The elastomeric web design helps to reduce pain by dispersing load across the knee. The web acts like a spring to absorb shock and shifts the peak loads away from the painful area of the knee. Elastomeric web acts to dynamically stabilise the patella on all sides, bringing the patella into proper tracking position to reduce pain for patients with general patellofemoral instabilities. Reaction Web® has dual-axis hinges that are flexible, creating synergy with the elastomeric web for optimal fit and support, and providing energy dispersion to the knee.
75904792|NCT05685719|Drug|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
75904793|NCT05685719|Drug|Itraconazole|A strong CYP3A4 inhibitor
75904794|NCT05685719|Drug|Rifampin|A strong CYP3A4 inducer
75904795|NCT05671055|Other|Custom study version of icompanion app|Patients complete patient-reported outcomes on cognition and covariates, as well as objective cognitive tests through a version of icompanion app customized specifically for this study. Patients complete all assessments remotely in an at-home situation.
75904796|NCT05665751|Drug|TLC-3595 Dose 1|Tablets administered orally
75904797|NCT05665751|Drug|TLC-3595 Dose 2|Tablets administered orally
75904798|NCT05665751|Drug|Placebo|Tablets administered orally
75904799|NCT05653427|Drug|Amivantamab|Amivantamab will be administered intravenously.
75904800|NCT05650190|Device|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
75904801|NCT05650190|Device|Spectacle lenses|Single vision, impact resistant spectacle lenses
75759850|NCT00132808|Drug|Placebo|Physiologic 0.9% normal saline
75759851|NCT03983148|Behavioral|Motivational interviewing|There are 3 sessions. Each session is an about 60-minute individual motivational interviewing held by a trained registered nurse. The first session aims to develop an action plan that enables the parents to promote physical activity (PA) for their children. The second session targets to review the adherence to the action plan. The nurse will discuss the progress. In the last session, the aim is to motivate the parents promoting PA for their children in the long run. As such, the benefits of PA throughout the survivorship will be emphasized. And the nurse will work with the parents to identify the resources that can help maintain the designed action plan.
75759852|NCT03983148|Behavioral|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
75759853|NCT03741387|Other|Gain-frame questionnaire|Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.
75759854|NCT03741387|Other|Loss-frame questionnaire|Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
75759855|NCT04714463|Procedure|Implant-based breast reconstruction|All types of implant based breast reconstructions
75759856|NCT04714463|Procedure|Autologous breast reconstruction|All types of autologous breast reconstructions
75904802|NCT05649995|Other|Pain science education driven physiotherapy program|Pain science training will be carried out as described by Moseley and Butler. Topics covered within the scope of pain science education are planned to include: neurophysiology of pain, synapses, peripheral sensitization, central sensitization, plasticity of the nervous system. The aim of the training will be to teach participants that pain is a multifactorial experience rather than just tissue injury. Participants in this group will be told about the importance of physical activity integrated with pain science education (i.e., explaining that physical activity is the key to bioplasticity and causing changes in our system) and why sedentary behaviors should be reduced (reducing sedentary behaviors reduces the overprotectiveness of the pain system).
75458665|NCT01811264|Behavioral|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
75904803|NCT05649995|Other|Biomedical education driven physiotherapy program|Participants in this group will be planned to increase their knowledge of knee anatomy, knowledge of knee OA and knee OA risk factors, and the importance of increasing physical activity and reducing sedentary behavior in reducing osteoarthritic pain and improving overall health. The importance of physical activity by integrating it with biomedical education (as physical activity can help strengthen muscles, protect joint function, and improve sleep and general health) and the necessity of reducing sedentary behaviors will be discussed within the framework of biomedical education.The main difference of standard education from pain science education will be that it does not contain information about pain mechanisms mentioned in pain science education.
75458666|NCT01811277|Drug|SOX sequential S-1|"4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1"
75458667|NCT01811381|Drug|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
75610992|NCT01216163|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
75904804|NCT05645380|Drug|Carboplatin|AUC=6, IV
75610993|NCT01216163|Drug|Acetaminophen|Single-dose of acetaminophen (1000mg)
75904805|NCT05645380|Drug|Docetaxel|75 mg/m2, IV
75458668|NCT01811381|Behavioral|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
75610994|NCT01216163|Drug|Placebo|Single-dose of placebo
75610995|NCT05260411|Biological|AK102|Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
75610996|NCT05260411|Biological|AK102|Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
75610997|NCT05260411|Drug|Placebo|Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
75610998|NCT05260255|Drug|vitamin D2 ( calciferol )|add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks
75610999|NCT05260255|Drug|Placebo|add on placebo ( 2 cap ) for 12 weeks
75611000|NCT00612469|Drug|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
75611001|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
75759857|NCT04714463|Procedure|Combined methods|All types of breast reconstructions combining autologous and implant based techniques
75759858|NCT03982992|Drug|Blinatumomab in combination with donor lymphocyte infusion|Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion
75759859|NCT01061268|Drug|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
75759860|NCT01061268|Drug|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
75759861|NCT01061346|Other|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
75759862|NCT01061346|Other|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
75611002|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
75458669|NCT01811381|Behavioral|non aerobic yoga|"Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home."
75458670|NCT01811381|Dietary Supplement|Placebo|Subjects will take 4 capsules x BID of placebo
75611003|NCT00612469|Drug|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
75611004|NCT00933244|Dietary Supplement|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
75759863|NCT01061346|Other|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
75759864|NCT01057914|Dietary Supplement|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
75759865|NCT01057914|Other|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
75759866|NCT01057914|Other|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
75759867|NCT00517361|Drug|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
75759868|NCT00517361|Drug|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
75759869|NCT03984552|Behavioral|This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years|"These rapid tests are based on lateral flow immunochromatography technology, in which a nitrocellulose membrane is impregnated with the antigen of interest. The patient sample (blood, serum, plasma, oral fluid, etc.) is applied in this membrane which facilitates the interaction of antibodies in the sample with the antigens on the membrane. This reaction becomes visible to the naked eye thanks to a color developing revelator.~The entire testing process, from sample collection to result reading takes no more than 40 minutes and does not depend on laboratory facilities."
75759870|NCT03984864|Other|Exercise therapy|3-4 items from a list of 10 general exercises - intended for treatment of low back pain
75759871|NCT00516893|Biological|BG00002-E (natalizumab high titer)|
75759872|NCT01565135|Behavioral|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~Practice-based reminder/recall~Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
75759873|NCT01565213|Behavioral|CBT|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
75759874|NCT01565213|Behavioral|MMI|group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
75759875|NCT01565213|Behavioral|CAU|Care as usual by the GPs
75759876|NCT04270955|Procedure|Embolization of the Middle Meningeal Artery|Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
75904806|NCT05645380|Drug|Doxorubicin|60 mg/m2, IV
75611005|NCT00933244|Dietary Supplement|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
75904807|NCT05645380|Drug|Cyclophosphamide|600 mg/m2, IV
75611006|NCT00933244|Dietary Supplement|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
75611007|NCT02709187|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
75611008|NCT02709187|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
75611009|NCT02709187|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
75611010|NCT02708953|Procedure|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
75904808|NCT05645380|Drug|Pembrolizumab|200 mg, IV
75904809|NCT05641142|Other|monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease|"Monitoring:~hemoglobin and ferritin levels~transfusion or intravenous iron~hospitalization for bleeding or thrombose~digestive bleeding and/or another haemorrhagic accident~severity of epistaxis~quality of life"
75458671|NCT01811407|Behavioral|Precommitment announcement|
75458672|NCT01811407|Behavioral|Results announcement|
75458673|NCT01811407|Behavioral|Walking program|
75458674|NCT01811420|Procedure|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
76069253|NCT00498550|Drug|Treatment as usual|Remain on pre-study antipsychotic treatment
75759877|NCT04270955|Procedure|Standard of care including possible surgical evacuation of subdural hematoma|Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
75611011|NCT02708953|Procedure|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
75759878|NCT04171661|Biological|SASS|SASS applied on chronic skin wounds as skin graft
75759879|NCT04171115|Drug|G03-52-01|G03-52-01 administered intramuscularly
75759880|NCT04171115|Drug|Placebo|Placebo administered intramuscularly
75759881|NCT00522431|Drug|Testosterone|2% gel
75759882|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
75611012|NCT04262830|Diagnostic Test|Cardiac magnetic resonance imaging (MRI)|Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics
75759883|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
75759884|NCT00516737|Drug|Comparator: rizatriptan benzoate|Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
75759885|NCT00516737|Drug|Comparator: Placebo|Matching placebo; one dose, treatment of a single migraine attack
75904810|NCT05633537|Procedure|pulpectomy procedure and the clinical evaluation|in this study, pulpectomy procedure was performed in a single visit and the root canals were filled with different obturating materials. The clinical follow up evaluation was carried out after three, six and twelve months after pulpectomy procedures. The teeth were clinically evaluated each follow up visit for the following clinical features: absence of spontaneous pain, no tenderness with percussion, no abnormal mobility and absence of swelling & sinus or fistula. If the tooth exhibited any one of above clinical features, the pulpectomy was considered to be a failure (F); otherwise, it was regarded as clinical success (S).
75611013|NCT04262830|Diagnostic Test|Echocardiography|Echocardiography, heart ultrasound, will be performed in conjunction with cardiac MRI.
75611014|NCT04262830|Diagnostic Test|Electrocardiogram|Measuring conduction abnormalities
75611015|NCT05258929|Other|Data collection (Prior and planned treatments, allograft)|MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
75611016|NCT00930046|Device|Ropivacaine wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
75611017|NCT00930046|Device|Saline wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
75759886|NCT03540485|Drug|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
75759887|NCT03540485|Other|Placebo|Daily administration of placebo orally, for 24 months between 10pm to 11pm
75759888|NCT01582035|Drug|TMC647055|type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
76025337|NCT02891993|Other|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
75759889|NCT01582035|Drug|TMC647055|type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
76069254|NCT00498628|Drug|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
76069255|NCT00498628|Other|Placebo|Placebo
75759890|NCT01582035|Drug|TVR|type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
75759891|NCT01582035|Drug|TVR|type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
75759892|NCT01582035|Drug|TVR|type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
75759893|NCT01582035|Drug|PegFN|type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
75759894|NCT01582035|Drug|RBV|type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
75759895|NCT00132730|Drug|MK-0873 2.5 mg|
75904811|NCT05633537|Radiation|radiographic evaluation|Radiographic evaluation was performed immediately after teeth restoration (base line radiograph), then after three, six and twelve months. The parallel periapical technique was performed using the rinn (XCP) periapical film holder and a long cone which was mounted to the x-ray tube. The criteria for radiographic success were no evidence of extensive pathologic root resorption, reduction or no change in pre-operative pathologic inter-radicular radiolucency and no evidence of new postoperative pathologic radiolucency.
75759896|NCT00132730|Drug|MK-0873 1.25 mg|
75904812|NCT05633121|Procedure|Rheopheresis|Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
75904813|NCT05627739|Drug|Mycophenolate Mofetil|Glucocorticoid is started at a dose of 0.5-0.8 mg/kg/day, and 60 mg daily was the highest dose. Mycophenolate mofetilwas is started at a dose of 0.5-1.0g bid.
75458675|NCT01811420|Procedure|Conventional method|Dental caries removal using rotatory instrument
75759897|NCT00132730|Drug|MK-0873 0.75 mg|
75759898|NCT00132730|Drug|Placebo to MK-0873|
76025338|NCT02891993|Other|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
76025339|NCT02433509|Other|HUCB monocyte cells|"The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million ~ 500 million will used.~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
76025340|NCT04533919|Procedure|Biospecimen Collection|Undergo collection of dorsal root ganglia
76069256|NCT04749706|Behavioral|Physical training alone|The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
75458676|NCT01811446|Device|Muscle Activation with Niveus and Intelect Devices|Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
75458677|NCT01811459|Drug|Quetiapine|PO
75458678|NCT01811459|Drug|Haloperidol|IV
75458679|NCT01811459|Drug|Placebo|PO or IV
75458680|NCT01811511|Dietary Supplement|Chungkookjang|
75458681|NCT01811511|Dietary Supplement|Placebo|
75458682|NCT01811537|Device|Artificial Chordae|
75458683|NCT01811550|Other|Glycemic Control|
75759899|NCT00132730|Drug|Usual Care|
75759900|NCT02531841|Drug|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|"Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~Rituximab 375 mg/m²/d i.v. (d0)~Dexamethasone 40 mg/d i.v. (d1-3)~Etoposide 100 mg/m²/d i.v. (d1-3)~Ifosfamide 1500 mg/m²/d i.v. (d1-3)~Carboplatin 300 mg/m² i.v. (d1)"
75759901|NCT02531841|Drug|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|"4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~Carmustine* 400 mg/m² i.v. (d-6)~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)~* if carmustine is not available at the investigation site, busulfan can be administered instead:~Busulfan 3,2 mg/kg/d (d-8-(-7))~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)"
75458684|NCT01811589|Device|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
75759902|NCT01074411|Drug|Bortezomib|Given IP
75759903|NCT01074411|Drug|Carboplatin|Given IP
75759904|NCT01074411|Other|Laboratory Biomarker Analysis|Correlative studies
75759905|NCT01074411|Other|Pharmacological Study|Correlative studies
75759906|NCT00232557|Device|TLC-Asthma|Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
75759907|NCT00232557|Device|TLC-health education|A telephone-linked communication system (TLC) to provide general health education.
75904814|NCT05621980|Behavioral|Actuated Virtual Keyboard (AVK) system|"The participant controls an avatar hand by the movement of their own digits. Each avatar digit corresponds to a given virtual key. Sufficient digit flexion results in playing of that key, with visual and auditory feedback of key strike. Participants will wear a soft exoskeleton, the PneuGlove, with embedded bend sensors to provide real-time measurement of digit flexion. Pneumatic resistance to flexion can be applied to each digit independently, along with extension assistance, through air chambers running through the glove. The FES is intended to assist finger flexion by activating extrinsic finger flexor muscles. A high-density 2×8 stimulation electrode grid will be placed over the median and ulnar nerves at the medial side of the upper arm. The stimulator can deliver electrical stimulation to any pair of electrodes. At the beginning of each session, the investigators will identify the electrode pairs which best produce flexion of each digit with minimal discomfort."
75904815|NCT05621980|Behavioral|Occupational Therapy (OT)|Traditional occupational therapy training sessions.
75904816|NCT05621668|Drug|Cyclophosphamide|Given by IV (vein)
75611018|NCT05244031|Procedure|superficial erector spina plane block|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
75611019|NCT05244031|Procedure|Standard (opioid-based) analgesia|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
75611020|NCT05155306|Drug|BI 1358894, intended Commercial Formulation (iCF) (T)|Test Treatment (T)
75611021|NCT05155306|Drug|BI 1358894, Trial Formulation 2 (TFII) (R)|Reference Treatment (R)
75759908|NCT03973983|Procedure|Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)|Ultrasound-guided transgluteal pudendal nerve local anesthetic injections
75759909|NCT03973983|Procedure|Finger-guided transvaginal pudendal nerve injection (TV-PNI)|Finger-guided transvaginal pudendal nerve local anesthetic injections
75759910|NCT03973047|Drug|Bremelanotide|Sterile aqueous solution for injection, provided as an autoinjector pen
75759911|NCT03973047|Drug|Zofran|8 mg tablet (over-encapsulation in a capsule)
75759912|NCT03973047|Drug|Placebo|capsule
75759913|NCT00522275|Drug|lacosamide|50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
75759914|NCT01074567|Drug|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
75904817|NCT05621668|Drug|attIL2-T cells|Given by IV (vein)
75759915|NCT01582659|Other|Telephone counseling|2 planned telephone counseling sessions are conducted.
75759916|NCT01582659|Other|Web access|Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
75759917|NCT00522041|Drug|Cellegesic|Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
75759918|NCT00522041|Drug|Placebo|Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
75759919|NCT00122980|Procedure|Red Cell Transfusions|Red Blood Cell Transfusions
75759920|NCT00122980|Procedure|Iron Chelation|Iron Chelation Therapy
75759921|NCT00122980|Drug|Hydroxyurea|Hydroxyurea
75759922|NCT00122980|Procedure|Phlebotomy|Phlebotomy
75759923|NCT04671251|Drug|AEVI-007|50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
75759924|NCT01080508|Other|tracheal ventilation with regular tube|Description of the pressure waveforms during tracheal ventilation
75759925|NCT01080508|Other|ventilation after intubation with special tube|Description of the pressure waveforms during esophageal ventilation
75458685|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
75904818|NCT05620342|Biological|iC9.GD2.CAR.IL-15 T Infusion|iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
76025341|NCT05168579|Behavioral|Deliberate practice|As above
75611022|NCT04262752|Device|intermittent colonic exo-peristaltic massage treatment with the MOWOOT medical device|"The MOWOOT massager belt is connected to the desktop device and is the component which is in contact with the subject giving the abdominal massage action.~The massager belt, which is placed on the user's abdominal area, administers a specific abdominal massage on the ascendant and descendent segments of the colon. This massage emulates the techniques used by professional therapists through a series of pneumatic actuators operating like the movement of a wave transmitting movement through the colon. The type and speed of the massage can usually be regulated by an algorithm that controls the operation from the desktop device.~For the present clinical trial, time and force will stay fixed on 20 minutes and force 3 (0'6-0'7 bar). Subjects will not be able to choose other massage options. Subjects should use the MOWOOT device once a day for 20 min (1 complete treatment) ideally at the same hour every day for the 4 weeks of the interventional treatment period."
75611023|NCT03823651|Behavioral|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
75458686|NCT01811602|Other|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
75611024|NCT03823651|Behavioral|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
75611025|NCT03823651|Behavioral|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
75611026|NCT03823651|Behavioral|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
75611027|NCT04712071|Drug|Ketamine Hydrochloride|Patients with a diagnosis of Gulf War Illness using Kansas Criteria will be enrolled to receive a single 40 minute infusion of 0.5 mg/kg ketamine.
75611028|NCT02708875|Other|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
75759926|NCT03868631|Dietary Supplement|Whey protein supplement|19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
75759927|NCT03868631|Dietary Supplement|Soy protein supplement|26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
75759928|NCT06169774|Other|Educational video|Watch the 17-minute educational video as many times as needed within a 12-month period.
75759929|NCT06169722|Drug|TDI01 suspension|200mg or 400mg oral once a day
76025342|NCT00719225|Drug|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
76025343|NCT05404607|Other|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
76025344|NCT05404607|Other|Fascial distortion method|27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
75458687|NCT01811602|Other|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
75611029|NCT02708875|Other|Glucose Challenge|Glucose drink (50g glucose)
75759930|NCT06169683|Device|Lyric4|Lyric4 Hearing instrument use
75759931|NCT06169670|Device|Viality|"Viality is a lipoaspirate wash system designed to be used in the operating room in conjunction with, and attached to, a user-provided liposuction cannula, a vacuum source, and a waste canister.~Viality is to be used to filter and wash aspirated, harvested autologous adipose tissue for aesthetic body contouring. The system should be used with a legally marketed vacuum or aspirator apparatus as a source of suction. If harvested fat is to be re-implanted, the harvested fat is to be used without any additional manipulation. Viality is not intended to process autologous adipose tissue other than for aesthetic body contouring uses."
75759932|NCT06169657|Device|Body-weight-supported treadmill training (BWSTT)|Walking on a treadmill in a harness with body weight support as needed
75759933|NCT06169657|Device|EksoNR exoskeleton gait training|Walking in the EksoNR exoskeleton
75759934|NCT06169657|Device|Overground gait training|Walking overground in a harness with body weight support as needed
75759935|NCT06169631|Device|Gen0b|The ultrasound will be administered to the brain region of interest.
75759936|NCT06169618|Other|cervical radiculopathy|this group will have patients with cervical radiculopathy
75759937|NCT06169618|Other|normal group|this group will have normal subjects
75759938|NCT06169605|Procedure|removal of primary tumor, neck dissection|removal of the primary tumor with safety margins and removal of the neck lymph node levels I, II, III and IV. histological assessment of tumor thickness and whether it is associated with positive nodes in level IV or not.
75759939|NCT06169592|Procedure|Liver transplantation|Related transplantation of the right lobe of the liver
75759940|NCT06169579|Drug|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
75904819|NCT05619796|Procedure|pulpectomy procedure|single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin & isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained & the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points & root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
76025345|NCT05404451|Diagnostic Test|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
75458688|NCT01811615|Other|alcohol-free experimental mouth rinse|
75458689|NCT01811615|Other|alcohol-containing mouth rinsing|
75458690|NCT01811628|Behavioral|Questionnaire|Questionnaire completion taking about 10-15 minutes.
75458691|NCT01811628|Behavioral|Interview|Audio-recorded interview that will last about 1 hour.
75458692|NCT01811641|Other|season, dietary intake|
75458693|NCT01811667|Drug|Sirolimus|
75611030|NCT00609388|Drug|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
75611031|NCT00609388|Other|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
75759941|NCT06169579|Drug|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
75759942|NCT06169579|Drug|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
75759943|NCT06169579|Drug|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
75759944|NCT06169579|Drug|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
75759945|NCT06169579|Drug|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
75759946|NCT06169579|Drug|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
75759947|NCT06169579|Drug|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
75759948|NCT06169566|Dietary Supplement|synbiotics|synbiotics
75759949|NCT06169566|Combination Product|placebo|placebo
75759950|NCT06169553|Other|Holistic injection-related injection treatment|Participants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs.
75759951|NCT06169514|Other|No intervention|No intervention
75759952|NCT06169501|Behavioral|App-based Mindfulness Intervention|Participants in the trial will engage in a 30-day app-based mindfulness program called Unwinding Anxiety that they can complete over a maximum of 60 days. During this time, they will practice short daily mindfulness lessons and respond to a set of brief questions regarding their anxiety levels. Ultimately, we want to assess whether this intervention helps these caregivers feel less stressed and anxious.
75759953|NCT06169488|Procedure|Lumbar Interbody Fusion|Fusion of one or two lumbar levels with either a transforaminal lumbar interbody fusion (TLIF) or an anterior lumbar interbody fusion (ALIF) procedure.
75759954|NCT06169488|Behavioral|Multidisciplinary rehabilitation|Outpatient multidisciplinary rehabilitation based on the treatment model described by Brox et al and Hellum et al consisting of a cognitive approach and supervised physical and functional training.
75904820|NCT05619796|Radiation|Post-operative Cone Beam Computed Tomography|"post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique ."
75904821|NCT05619796|Other|Post-operative pain assessment|The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
75458694|NCT01811719|Behavioral|Enhanced NFP (NFP+)|Women in the experimental group received three possible interventions. First they received regular and periodic structured intimate partner violence (IPV) assessments from their nurse. Those who indicted any IPV - whether physical violence or emotional abuse or controlling behavior - were then given the Parker-McFarlane Brochure Intervention. Finally, all women were provided the Markman and Stanley Within My Reach curriculum according to their needs and interests.
75611032|NCT02709031|Drug|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
75904822|NCT05617794|Device|Diffusion Optics Technology (DOT) Pattern Spectacle Lens|DOT Pattern Spectacle Lens
75904823|NCT05617794|Device|Control Spectacle Lens|Control Spectacles
76025346|NCT05404451|Diagnostic Test|Mckenzie Exercises|Using Mckenzie Exercises
75458695|NCT01811719|Behavioral|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
75458696|NCT01811745|Behavioral|Jaques-Dalcroze eurhythmics training|12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
75904824|NCT05611112|Behavioral|Problem Solving Therapy|Problem Solving Therapy is a well-established evidence-based therapy form that is highly effective in patients with mental health issues. Initially, the patient makes a problem list and for each problem, possible solutions will be outlined. Considering pros and cons for each solution, the patient is asked to choose the one considered most appropriate. The patient is encouraged to put this solution into action and a follow-up consultation is planned.
75759955|NCT06169475|Drug|Dexmedetomidine Hydrochloride|The continuous intravenous infusion of dexmedetomidine (0.1mg/ml) will start at 0.1ug/kg/h, increasing every 20 minutes by a step change of 0.05-0.2ug/kg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stopped if the heart rate fall below 80b.p.m..
75904825|NCT05601882|Drug|Upadacitinib|Oral Tablets
75904826|NCT05601882|Drug|Dupilumab|Subcutaneous Injection
75611033|NCT02709031|Drug|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,
75904827|NCT05597137|Dietary Supplement|Zinc Gluconate|Each participant should receive a regular zinc diet for weeks 1-2 and take zinc supplements for weeks 3-4.
75904828|NCT05590416|Drug|Adalimumab|Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
75904829|NCT05579886|Device|Control Contact Lens|Control Contact Lens - first period of 2 weeks (14-21 days)
75458697|NCT01811745|Behavioral|Multicomponent exercise training|12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
75458698|NCT01811758|Behavioral|Culturally Specific CBT|
75458699|NCT01811758|Behavioral|Standard CBT|
75611034|NCT05233111|Behavioral|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.
75611035|NCT05233111|Behavioral|Treatment as Usual|This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
75611036|NCT04262674|Other|Cognitive-motor training|Simultaneous cognitive-motor training and strength training
75611037|NCT02887937|Drug|Definity|The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
75611038|NCT00606112|Drug|Trodusquemine (MSI-1436)|A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
75611039|NCT05232955|Device|PET/MR scanner|Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
75611040|NCT00606190|Procedure|Retrograde brain perfusion|observational
75611041|NCT00606190|Procedure|Antegrade brain perfusion|observational
75611042|NCT05225545|Drug|Sucrosomial Iron|Experimental Arm
75611043|NCT05225545|Drug|Oral Iron|Active Comparator
75759956|NCT06169475|Drug|Esmolol Hydrochloride|The continuous intravenous infusion of esmolol (10mg/ml) will start at 20mg/h, increasing every 20 minutes by a step change of 20mg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stop if the heart rate fall below 80b.p.m..
75904830|NCT05579886|Device|Test Contact Lens|Test Contact Lens - second period of 2 weeks (14-21 days)
75904831|NCT05578287|Drug|Anti-HER2 ADC|Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
75611044|NCT04168957|Drug|Oraxol|"Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets"
75759957|NCT06169449|Behavioral|Weight management--diet|The diet structure adopts an energy-limited balanced diet. In this structure, the total daily energy intake is reduced by 500~1000 kcal based on the target energy intake; however, the balance is maintained for the energy supply ratio of the three major nutrients (with carbohydrate, protein, and fat accounting for 55~60%, 10~20%, and 15~30% of the total daily energy, respectively). Combined with the patient's eating habits, the food exchange portion method is used as a guide; each portion providing 90 kcal is considered as one portion. Specific recipes are formulated after calculating the ideal weight and the total daily calorie intake based on activity intensity, determining the number of six food exchange portions and the distribution of three meals according to the total calorie and diet structure, and combining the equivalent food exchange table based on individual tastes and preferences; this ensures patient acceptability and implementation.
75759958|NCT06169449|Behavioral|Weight management--exercise|Exercise goals are divided into four levels based on individual health conditions and personal preferences; these include: cultivating exercise habits, improving cardiopulmonary function, enhancing muscle strength, and improving flexibility. Individualized exercise prescriptions that specify the exercise type, intensity, time, and frequency are formulated.
75904832|NCT05574478|Behavioral|Patients and Caregivers Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications & Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
75611045|NCT00935584|Behavioral|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
75904833|NCT05567731|Drug|ultrashort GnRHa|"the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm"
75611046|NCT05201443|Device|Diode laser|Diode Laser is applied to one group as an adjunctive therapy.
75611047|NCT05201443|Device|Titanium curettes|Non-surgical treatment with titanium curettes were administrated to both groups.
75611048|NCT00612547|Drug|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
75611049|NCT04266262|Behavioral|High-intensity interval training (HIIT)|"Supervised HIIT sessions (2x/week) will comprise cycling 10 x 60 secs at 85-95% maximum heart rate (HRmax) interspersed by 60 secs of low-intensity recovery.~Unsupervised HIIT sessions (1x/week) will involve 10 x 60 secs of walking or alternative (intensity of 7-9 on the 0-10 RPE) interspersed by 60 secs of walking or cycling at low intensity recovery (RPE 3-5)."
75611050|NCT04266262|Behavioral|High-Intensity resistance training (HIRT)|"Supervised HIRT sessions (2x/week) will comprise 2-3 sets of 6-8 repetitions progressively achieving 85% of 1RM.~Unsupervised HIRT sessions (1x/week) will involve 2-3 sets of 15-20 repetitions using a resistance exercise band when necessary."
76069257|NCT04749706|Behavioral|physical training + protein intake|"The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine"
75759959|NCT06169449|Behavioral|Weight management--accompany|This component involves the inclusion of patients in online management. Online groups are established, daily feedback is obtained regarding weight management implementation, self-sharing is encouraged, and peer support is established; a total of 6 sessions of online health education are provided once every 4 weeks for 20-60 minutes at each session. This includes information regarding the risks associated with overweightness and obesity; weight management benefits; knowledge regarding diet and nutrition, exercise and sports, and behavioral styles; and problem exchange and sharing, among others. Professional support is provided by weekly communication with patients one-on one via WeChat or telephonic conversations. The patient's diet and exercise record sheet are checked, patients are asked questions regarding implementation of the current program and any discomfort or difficulties; corresponding guidance is provided as appropriate.
75759960|NCT06169449|Behavioral|Weight management--refresh|According to the dietary nutrition guidelines for Chinese residents, patients are advised to drink 2500 ml or more of water daily; they are also advised to work and rest regularly to ensure sufficient sleep time, ensure smooth bowel movements, take deep breaths when waking up in the morning, pay attention to the work-rest balance, avoid being sedentary, and stand up and move around at least once every 50 minutes, maintain physical vitality by adjusting daily living habits.
75759961|NCT06169449|Behavioral|Control group|The relationship between overweightness and obesity and endometrial cancer risk was explained to patients in the control group and their willingness for self-weight management was respected. Communication was maintained with patients from treatment initiation to 3 and 6 months after treatment; patients' questions regarding weight reduction were answered and suggestions were provided regarding nutrition, exercise, and lifestyle management.
75759962|NCT06169436|Procedure|Nephroureterectomy|Removal of cancer mass by urether and kidney complete resection.
75759963|NCT06169423|Other|Educative intervention|"an activity for simulation-based learning First, a theoretical session was carried out in order to acquire theoretical knowledge, skills to provide support for perinatal grief, and improve self-awareness. Prior to this, a pre-questionnaire was carried out in order to previously evaluate these aspects.~Subsequently, a first session was held to make contact with the simulation, teach the scenarios, material, etc. After this, two questionnaires were passed: one related to the acquisition of knowledge, skills to provide support, self-awareness and another on the students' satisfaction with the simulation."
75759964|NCT06169384|Device|Endoscopic adenoidectomy|Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .
75759965|NCT06169345|Other|Echocardiographic evaluation|Echocardiographic follow-up
75759966|NCT06169319|Biological|EN3835|Biologic: Intrafascial injection
75759967|NCT06169319|Other|Placebo|Intrafascial injection
75904834|NCT05567731|Drug|short GnRHa|"Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of >18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture."
75904835|NCT05567731|Drug|long GnRHa|In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low estradiol (E2) < 50 and Luteinizing Hormone < 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
75904836|NCT05560867|Device|robot-assisted training|These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
76069258|NCT04749472|Other|Sling|Participants wore six different shoulder slings in a randomized order.
75611051|NCT00606268|Drug|Micafungin|IV
75611052|NCT05194189|Drug|Vitamin C|12 g vitamin C (48 ml) will be intravenously injected by a infusion pump every 12 h for 4 days or at ICU discharge
75611053|NCT05194189|Drug|5% glucose injection|5% glucose solution 48 ml every 12 h for 4 days or at ICU discharge.
75611054|NCT05342935|Device|Inteligent Dialysis Assistant (IDA)|The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
75611055|NCT04262518|Device|Outcomes4Me Mobile App|A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
75611056|NCT05342857|Drug|Aflibercept Injection [Eylea]|Aflibercept 2.0 mg with the T&E criteria in Taiwan local consensus
75611057|NCT04264624|Device|Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
75611058|NCT04264624|Device|Airflow and Erythritol powder and ultrasonic debridement|Airflow combined with Erythritol powder will be used as an adjunct therapy
75759968|NCT06169293|Behavioral|I-AM-WELL|"The I-AM-WELL program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher.~Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics.~Overall, the program will be delivered over in one week lasting six hours."
75759969|NCT06169228|Device|mandibular advancement|The multidisciplinary sleep unit assessment and follow-up protocol will be followed for this group of patients based on the Spanish Clinical Practice Guideline of the Spanish Sleep Society (SES) on the use of mandibular advancement devices in the treatment of patients with obstructive sleep apnea
75759970|NCT06169215|Procedure|Biospecimen Collection|Undergo collection of blood samples
75759971|NCT06169215|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75759972|NCT06169215|Drug|Bortezomib|Given SC
75759973|NCT06169215|Procedure|Computed Tomography|Undergo CT
75759974|NCT06169215|Biological|Daratumumab|Given IV
75759975|NCT06169215|Drug|Daratumumab and Hyaluronidase-fihj|Given SC
75759976|NCT06169215|Drug|Dexamethasone|Given PO
75759977|NCT06169215|Drug|Lenalidomide|Given PO
75904837|NCT05560230|Drug|Clonidine|A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
75904838|NCT05560230|Drug|Isotonic saline|A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
75611059|NCT05342779|Procedure|stripping of great saphenous vein|"I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure."
75611060|NCT00606424|Drug|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
75904839|NCT05557552|Radiation|standar thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
75904840|NCT05557552|Radiation|decreased thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
75904841|NCT05543213|Behavioral|Action Observation Therapy|A video clip of a series of exercises is shown to the patients, then they practice them according to mirror neurons and observational learning.
75904842|NCT05532410|Device|Fundus Camera|The fundus camera is suitable for photographing, displaying and storing data relating to the retina and surrounding parts of the eye. These photographs assist with the diagnosis and follow-up of eye diseases, which can be visually monitored and photographically documented.
75904843|NCT05519449|Biological|JANX007|JANX007 is dosed via IV weekly in a 21-day cycle
75759978|NCT06169215|Procedure|Magnetic Resonance Imaging|Undergo MRI
75759979|NCT06169215|Procedure|Positron Emission Tomography|Undergo PET
75759980|NCT06169215|Drug|Selinexor|Given PO
75759981|NCT06169202|Device|fruquintinib|4 mg orally once daily, D1-14, repeated every 3 weeks.
75759982|NCT06169202|Drug|Irinotecan|180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1*28 and *6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).
75759983|NCT06169202|Drug|Capecitabine|1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
75759984|NCT06169189|Behavioral|global warming-climate change based education|The experimental group will be given 8 weeks of global warming-climate change based training. No intervention will be applied to the control group.
75759985|NCT06169176|Biological|RAPA-501 Autologous T cells|Experimental: Intermediate size expanded access cohort. Single-agent RAPA-501 T cells, 80 x 10EE6 cells per infusion.
75759986|NCT06169163|Other|Exhaled breath sampling|Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.
75759987|NCT06169137|Behavioral|Early Time-Restricted Eating|Participants will be provided all meals to consume within a 6-hour timeframe (9:30-3:30p)
75759988|NCT06169137|Behavioral|Conventional dietary regimen (12-hr, 9:30a-9:30p)|Participants will be provided all meals to consume within a 12-hour timeframe (9:30a-9:30p)
75759989|NCT06169111|Biological|REGulatory T cells in Autism induced by maternal Immune activation|REGulatory T cells in Autism induced by maternal Immune activation
75759990|NCT06169085|Drug|Leritrelvir|Oral
75904844|NCT05518617|Other|Positron Emission Tomography (PET) scan using DASB tracer|"DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with [123I]FP-CIT SPECT,"
75759991|NCT06169059|Drug|JLP-2004|administration of JLP-2004(COX-2 inhibitor)
75611061|NCT04266184|Other|Kinesio tape (KT)|"For abdominal taping, four I-shaped tapes will be used. Two of them will start from the superior symphisis pubis, follow the rectus abdominis muscle, and finish at the xiphoid process. Other two I-shaped tapes will start from the mid-symphisis pubis, follow the external oblique abdominals, and finish at the spina iliaca anterior superiors.~Symphisis pubis taping will be applied with two I-shaped tapes, by forming a X shape.~For lumbopelvic taping, three I-shaped KTs will be used. Two tapes will be applied bilaterally and longitudinally on the lumbar erector spinal muscles. The third tape will start from one sacroiliac joint and end at the other, vertically to the previous two tapes, forming a H-shape.~All tapings will be applied with 15-25% tension (tape-off tension). KTs will stay three days. They will be removed from the site, and the skin will be checked and cleaned. Then, they will be reapplied for the next three days."
75611062|NCT04266184|Other|Pelvic belt (PB)|The women in this group will use the belts, after adjusting them at a comfortable tension, after getting up the bed in the mornings, during daily activities and walking. Evaluation will be made three days after the first application and they will be asked to continue using it for the second three-day period.
75759992|NCT06169059|Drug|JC-013|administration of JC-013(COX-2 inhibitor))
75759993|NCT06168994|Drug|Eplerenone|Amiodarone vs eplerenone in AF
75759994|NCT06168968|Behavioral|Life and Medication Recommendations|Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
75904845|NCT05516732|Other|Positron Emission Tomography (PET) scan using CIMBI-36 tracer|This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
75611063|NCT04266184|Other|Educational program|This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
75759995|NCT06168955|Other|skin biopsy|skin biopsy for cell culture and N-homocysteinylation study
75759996|NCT06168942|Device|Experimental: Laminar Left Atrial Appendage Closure System|Participants will be treated with the Laminar Left Atrial Appendage Closure System.
75759997|NCT06168942|Device|Active Comparator: WATCHMAN / Amulet|Participants will be treated with a WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder.
75759998|NCT06168916|Diagnostic Test|PET/CT with contrast medium in a single session.|Patients will undergo low dose PET/CT with FDG. Following the PET exam, a Standard CT with contrast medium will be acquired, using the CT tomography inserted inside the PET.
75759999|NCT06168903|Procedure|Ultrasound guided EOI block|"Before receiving general anesthesia, patients will be randomly assigned to one of the two study groups: the EOI block group or the ESPB group.~Using Ultrasound (Siemens ACUSON X300 Ultrasound System), guided blocks will be administered immediately after the induction of anesthesia and prior to surgical incision by consultant anesthesiologists who have experience in regional anesthesia and are familiar with the EOI and ESPB blocks"
75760000|NCT06168890|Diagnostic Test|PET/CT with choline in the restaging phase of prostate cancer.|PET/CT with choline in the restaging phase of prostate cancer in patients suffering from prostate cancer with biochemical recovery of the disease during hormonal therapy.
75904846|NCT05516732|Other|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
75760001|NCT06168877|Diagnostic Test|Execution of 18F-FDG PET/CT and contrast-enhanced CT scan.|PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer).
75760002|NCT06168864|Diagnostic Test|Artificial intelligence models for segmentation and characterization of prostate cancer|rtificial intelligence algorithms for the automatic segmentation of prostate cancer lesions on medical images.
75904847|NCT05516732|Other|Positron Emission Tomography (PET) scan using DASB tracer|To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
75904848|NCT05516732|Other|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
75904849|NCT05516732|Other|Lumbar puncture|A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
75760003|NCT06168851|Drug|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
75904850|NCT05516719|Other|Positron Emission Tomography (PET) scan using BU99008 tracer|A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
76069259|NCT00498706|Behavioral|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
75611064|NCT04188691|Biological|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
75611065|NCT04188691|Biological|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
76069260|NCT00498706|Behavioral|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
75904851|NCT05516719|Other|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
75904852|NCT05516719|Other|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
75904853|NCT05516719|Other|Lumbar puncture|A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
75904854|NCT05516485|Other|Assessment|Undergo grading and recording of tumor consistency/stiffness
75904855|NCT05516485|Device|Magnetic Resonance Elastography|Undergo MRE
75904856|NCT05513352|Device|tACS - transcranial alternating current stimulation|"TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The stimulation will be applied over the left temporo-parietal cortex at participants' individual alpha frequency. The stimulation intensity will be 2 milliampere (mA, peak-to-peak value, corresponding to a sine wave of ±1 mA amplitude). Stimulation will be delivered through conductive rubber electrodes."
75611066|NCT04188691|Biological|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
75611067|NCT04188691|Biological|Normal saline|Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
75611068|NCT04188691|Biological|Aluminum adjuvant|Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
75611069|NCT04264546|Biological|sIPV|The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
75611070|NCT02691208|Other|Kinesiotherapy|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
75611071|NCT02691208|Other|Acupuncture|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
75611072|NCT01215851|Drug|PA-824|200 mg tablet, once daily for 14 days
75611073|NCT01215851|Drug|Pyrazinamide|Dosed by Weight
75611074|NCT01215851|Drug|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
75611075|NCT01215851|Drug|Rifafour|Rifafour e-275
75611076|NCT01215851|Drug|Moxifloxacin|moxifloxacin 400 mg
75611077|NCT05378698|Drug|Application of Tralokinumab|2 Arms 20 patients 5 healthy controls
76069261|NCT01446159|Drug|MEDI-573|Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
76069262|NCT01446159|Drug|Aromatase Inhibitor|Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
75611078|NCT00613093|Drug|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
76069263|NCT00498940|Device|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
75760004|NCT06168838|Drug|Anticoagulant|Know the casuistry of spontaneous intracranial hemorrhages and secondary to the use of both oral and parenteral anticoagulants
75760005|NCT06168799|Drug|Ilofotase alfa|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
76069264|NCT00498940|Device|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
76069265|NCT00499096|Behavioral|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
76069266|NCT00499408|Dietary Supplement|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
75611079|NCT00933166|Device|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
76069267|NCT00499408|Dietary Supplement|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
75611080|NCT03696277|Radiation|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
76069268|NCT01446003|Drug|MK-8457|10 x 10-mg capsule BID for 10 days
76069269|NCT01446003|Drug|Placebo for MK-8457|10 x 10-mg capsule BID for 10 days
76069270|NCT03025659|Other|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
76069271|NCT03019666|Biological|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"Cyclophosphamide 40 mg/kg x 1 day on Day -5~Fludarabine 25 mg/m^2 x 3 days (Day -5, Day -4, day-3)"
76069272|NCT00500578|Drug|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
76069273|NCT00500578|Drug|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
76069274|NCT01430559|Drug|Meloxicam|7.5mg x2 once a day for 12 weeks
76069275|NCT01430559|Drug|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
75611081|NCT04262362|Procedure|Root canal treatment|Incidence of pain that may occur due to sodium hypochlorite extrusion
75611082|NCT00607750|Drug|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
75611083|NCT00607750|Drug|Placebo|Placebo eyedrops, BID, 48 weeks
76069276|NCT01410357|Behavioral|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
75611084|NCT04262050|Device|transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)|
75760006|NCT06168799|Drug|Placebo|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
75760007|NCT06168773|Drug|Haloperidol Injection|to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.
75760008|NCT06168760|Diagnostic Test|Anthropometric Measurements|Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
75760009|NCT06168747|Other|Passive Joint Mobilization|Wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals. Applications were made 6 times with 3 repetitions
75760010|NCT06168734|Drug|Cefepime-taniborbactam|Cefepime-taniborbactam administered 2.5g q8h intravenously (IV) over a 4-hour period for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
75760011|NCT06168734|Drug|Meropenem|Meropenem will be administered 2g q8h IV over 4 hours for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
75760012|NCT06168708|Procedure|Transurethral resection of the prostate (TURP)|TURP with addition of gentamicin on irrigation fluid to reduce infectious complications
75760013|NCT06168708|Drug|Gentamicin|gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)
75760014|NCT06168708|Drug|normal saline|normal saline (2 ml) on the irrigation solution (placebo)
75760015|NCT06168695|Device|removable anterior expansion screw|"For the upper and lower arches, precise and profound alginate impressions were obtained and plaster study models were created. The removable appliance was constructed using acrylic resin with bilateral occlusal coverage for posterior teeth. The removable appliance was inserted in the patient's mouth and the patient was recalled after 24 hours to check the appliance fit.~Patient was recalled every four weeks until the dental cross-bite was corrected."
75760016|NCT06168695|Diagnostic Test|Speech and language evaluation|"speech evaluation was done by a Phoniatrician and all children were subjected to the Protocol of speech evaluation before expansion screw appliance insertion and after complete correction of anterior crossbite using an articulation test, intelligibility test, and spectrographic analysis.~Articulation test: Five speech sounds were chosen to be studied /s/, /s /, /z/, /z/, /∫ /. The consonants were tested in the initial, medial, and final word positions.~Speech intelligibility test : The general intelligibility score was calculated using Speech intelligibility in context: 5 -point scale:~Spectrographic analysis: Using the computerized speech lab, the child was seated in an upright position & allowed to talk freely & repeated syllables were said to him/her."
75760017|NCT06168695|Other|Oral Health Related Quality of Life (OHRQoL) Assessment|The Child Perceptions Questionnaire (CPQ 8-10) in Brazilian version was used to gauge how the anterior cross bite affected the children's OHRQoL. It has twenty-five items total, broken down into four health domains (subscales): five questions each about oral symptoms (OS), five questions about functional limitations (FL), five questions about emotional wellbeing (EW), and ten questions about social well-being (SW). The responses never (0), once/twice (1), occasionally (2), often (3), and every day/almost every day (4) are provided for each question on an ordinal scale. The sum of the scores for all questions is used to calculate the scores for each subscale. The CPQ 8-10 was used to assess the OHRQoL before appliance insertion and after complete correction of anterior crossbite.
75904857|NCT05513352|Device|sham - transcranial alternating current stimulation|"During sham stimulation (placebo), tACS will be ramped up and down for 12 seconds , that is, no electric stimulation wil be applied during the actual experiment. The up and down ramping will be repeated at the end of the experiment.~The sham condition serves to evoke sensations associated with tACS stimulation, but without stimulating during the actual experiment."
75904858|NCT05513352|Device|NF - Neurofeedback|"Neurofeedback (NF) is a non-invasive approach that combines neurophysiological recordings with real-time sensory feedback (most studies use visual feedback). Through real-time NF, individuals thus can learn to regulate their brain activity.~In this study, NF will be based on concurrent EEG recordings. During NF, participants will observe a space ship automatically navigating through a narrow tunnel. The modulation of their neural alpha power lateralization into the trained direction will be rewarded by the acceleration of the space ship, a modulation in the opposite direction will reduce speed and autopilot accuracy."
75611085|NCT05271955|Device|"e-GOLIAH"|"Usual care plus electronic tablet with games application e-GOLIAH (Gaming Open Library for Intervention in Autism at Home)"
75611086|NCT05271955|Behavioral|Usual care|Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.
75611087|NCT00609544|Drug|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
75611088|NCT04908475|Drug|Risankizumab|Subcutaneous injection
75611089|NCT04908475|Drug|Apremilast|Oral Tablets
75611090|NCT04261816|Procedure|extubation in the operating room|Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
75611091|NCT04261816|Procedure|extubation in the ICU|Patients who underwent liver transplantation extubation in the ICU following liver transplantation
75611092|NCT05127070|Device|Neotree|The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
75611093|NCT04611139|Drug|SP-2577|Daily oral doses
75611094|NCT04611139|Drug|Pembrolizumab|200mg Q3W by IV infusion
75611095|NCT00935272|Device|Restylane®|Restylane® injections in the lips
75611096|NCT00935272|Device|Non-Treatment|Non- Treatment
75611097|NCT04570501|Drug|Angiotensin-(1-7)|Ang (1-7) administered by continuous intravenous (IV) infusion
75611098|NCT04570501|Drug|Placebo|Placebo (normal saline) administered by continuous intravenous (IV) infusion
75611099|NCT04114747|Other|Starting at high or low blood pressure|Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
75760018|NCT06168682|Device|SuperNO2VA™ Et by Vyaire Medical, Inc.|SuperNO2VA™ Et provides a nCPAP between 3 to 10 cmH20 using a oxygenflowrate of 6l/O2
75760019|NCT06168682|Device|nasal oxygen cannula|Standard Operating Procedure (SOP) for endoscopy: Using a nasal oxygen cannula with oxygenflowrate of 6l/O2
75760020|NCT06168669|Diagnostic Test|xBar system|xBar system is surgical drain with embedded sensors. Collected data will be evaluated for an ability to identify anastomotic leaks. The xBar system does not have therapeutic indication.
75760021|NCT06168656|Behavioral|Mobile Application|"The mobile application will include the following features:~Direct Message Section: This section will allow expectant fathers to ask specialized questions directly to experts or specialists.~Forum Section: Expectant fathers can use this section to engage in discussions and connect with each other.~Education Section: This section is specifically designed to cater to the educational needs of expectant fathers."
75904859|NCT05507723|Other|Treat-to-target|Treatment to achieve urate target using supported self-management approach
75760022|NCT06168643|Other|Core stability|Physical therapy interventions will include core stability exercises which will be demonstrated and will be checked if they are being performed correctly. The exercises guided shall be performed 3 times daily and logbook will be provided to keep the record of exercise program.
75760023|NCT06168643|Other|Core stability with pregnancy support belt|Participants will receive same information and exercises as those in Group A. they will also receive pregnancy support belt. The logbook will be provided to keep the record of hours the belt has been worn along with exercise record.
75760024|NCT06168630|Other|Manual lymph drainage|It consists of patients who will receive manual lymph drainage everyday for 5 days. The subject's position will be supine with their knees bent. Every session will be of 45 minutes. Manual lymph drainage will with abdominal lymph drainage, after which central lymph stimulation will be performed. Then, by stimulating the bilateral axillary lymph nodes, the flow of fluid over the right and left breasts will be directed toward the axillary lymph nodes. While the patients in the prone position, bilateral axillary lymph nodes will be stimulated, and each manual lymph drainage will be performed from the dorsum to the axillary lymph node .
75760025|NCT06168630|Other|Control group|The other group will receive massage for 20 minutes every day for 5 days from first day of treatment. Massage will be done using the index and middle fingers in a spiral motion towards the nipples.
75760026|NCT06168578|Device|ultrasound|Optic nerve diameter will be measured by ultrasound at certain stages of the operation in Group I (ARM-) and Group II (ARM+)
75760027|NCT06168552|Diagnostic Test|Injection of fluorescent developer (anti-EGFR-IR800CW)|The patient underwent Da Vinci robot or fluorescent laparoscopy-assisted radical resection of pancreatic cancer, and anti-EGFR antibody-IR800CW imaging agent was injected in the day before surgery, and fluorescence detection was performed
75760028|NCT06168526|Behavioral|Acute physical activity|Regarding the first aim, participants will go through five different conditions using a within-participants cross-over design in a randomized order: control group (quietly sitting), light intensity (40% VO2max), moderate intensity (63% VO2max), or vigorous intensity (100% VO2max) exercise. All conditions will last 16 minutes and 15 seconds. The exercise conditions will be organized following an interval protocol, which includes 22 bouts of 30 seconds running at the established intensity with 15 seconds of passive rest between bouts. In addition, to achieve the second aim, the active break will be designed taking into account the intensity of physical activity that proves to have the greatest benefits on cognition and well-being.
75760029|NCT06168500|Procedure|Test group|3.0mm diameter implant
75904860|NCT05507723|Other|Treat-to-flare|Treatment escalation based on reported flares of gout
75904861|NCT05490264|Biological|[68Ga]Ga-NOTA-SNA002|[68Ga]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
75904862|NCT05487040|Drug|PF-07321332 (nirmatrelvir)/ritonavir|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
75904863|NCT05485701|Diagnostic Test|Screening tools for common mental disorders|A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.
75611100|NCT00607906|Drug|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
75611101|NCT00607906|Drug|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
75611102|NCT00607906|Drug|Placebo|Subjects will also receive placebo capsules.
75611103|NCT02692963|Biological|BCG vaccination|BCG vaccine InterVax
75611104|NCT04266106|Drug|SuperBio probiotic|One capsule po BID for 28 days
75611105|NCT04266106|Drug|Placebo|One capsule po BID for 28 days
75611106|NCT04264468|Combination Product|neoadjuvant chemotherapy|This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
75904864|NCT05483218|Device|Nocturnal wrist orthosis wearing|Nocturnal wearing of one of the 2 wrist orthosis kind
75904865|NCT05473910|Drug|SOC + TSC-100|HA-1 positive
75904866|NCT05473910|Drug|SOC + TSC-101|HA-2 positive or HA-1 negative
75760030|NCT06168500|Procedure|Control group|4.0 diameter implant + guided bone regeneration
75760031|NCT06168487|Drug|Telmisartan|Patients will be given telmisartan alone or with standard of care chemotherapy.
75760032|NCT06168487|Other|Standard of Care Regimen|Standard of Care Regimen
75760033|NCT06168474|Other|Simplified layered consent form|The simplified consent form includes all essential elements of trial consent including an explanation of the trial procedures, data and sample collection, and follow-up information. The form also outlines important ethical considerations for patients, such as confidentiality, regulatory and safety requirements, the ability to drop out, and the necessary process and contact numbers for grievances or feedback. In addition to the text, the form includes links to additional written information and videos that can be accessed on top of the simplified informed consent form (i.e., the additional layers in the layered consent process). These materials are hosted on the main SNAP trial website (https://www.snaptrial.com.au/patients) and are available in English and French. Participants will be able to access these directly through embedded hyperlinks using provided electronic tablets.
75611107|NCT05198791|Drug|Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets|Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
75760034|NCT06168474|Other|Full-length consent form|The full-length informed consent form contains all information upfront. Links to additional information will not be provided on the form but are freely available on the Internet should the participant wish to access them.
75760035|NCT06168461|Drug|Aspirin|162mg aspirin capsule
76069277|NCT00500656|Drug|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
76069278|NCT00500656|Drug|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
75611108|NCT05198791|Other|Stratification and standard care|Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
75611109|NCT04261660|Other|NO intervention|NO INTERVENTION
75611110|NCT01010061|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
75611111|NCT01010061|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
75611112|NCT01010061|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
75611113|NCT00607984|Drug|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
75760036|NCT06168461|Drug|Placebo|placebo capsule
75760037|NCT06168448|Other|Oral and written information|Legal oral and written information given by physicians concerning additional examinations
75904867|NCT05473910|Other|Control|SOC alone
75904868|NCT05469919|Drug|Ceralasertib|Ceralasertib taken orally
75904869|NCT05461508|Biological|Amoxicillin combined with vonoprazan and fucoidan|Fucoidan was used in combination with amoxicillin and vonoprazan. The purpose of this study was to explore the effect of fucoidan on the eradication rate of Helicobacter pylori and the intestinal flora of subjects.
76069279|NCT00500656|Drug|Oral Placebo|hard capsule matched to tranexamic acid
76069280|NCT00500656|Drug|S.C. Placebo|solution for injection, matched to icatibant for injection
76069281|NCT01409811|Drug|zoledronic acid|Given IV
75760038|NCT06168448|Other|Video information|Explanatory video applied after physician's formal information
75904870|NCT05461508|Other|Amoxicillin combined with vonoprazan|Amoxicillin and vonoprazan were used as the study control group
75904871|NCT05452902|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
75904872|NCT05452902|Behavioral|Nutrition Education|12 weeks of implementing eating tips and tracking food.
76069282|NCT01409811|Other|laboratory biomarker analysis|Correlative studies
76069283|NCT01409811|Procedure|therapeutic conventional surgery|Undergo definitive lumpectomy or mastectomy
76069284|NCT01445847|Drug|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
76069285|NCT01445847|Other|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
76069286|NCT00501592|Drug|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
76069287|NCT00501592|Drug|Placebo|Placebo
75760039|NCT06168435|Other|eIMPAQc|e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard.
75760040|NCT06168422|Device|DES|drug eluting stent
75760041|NCT06168422|Device|DCB|drug-coated balloon
75760042|NCT06168409|Drug|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~• 2 mg per tablet."
75904873|NCT05449769|Behavioral|eNutriCardio personalised nutrition advice|eNutriCardio is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutriCardio Team, including a registered dietitian and registered nutritionist, are in line with UK dietary guidelines (primarily the EatWell Guide), and promote a Mediterranean-style diet (in line with NICE guidance). Therefore, the advice builds on the generalised advice given during the usual NHS CR programme.
75611114|NCT04019353|Genetic|cf-DNA Collection|"For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations."
75611115|NCT00609778|Device|LUCAS|Mechanical chest compression
75611116|NCT00609778|Other|Conventional manual resuscitation method|Manual compression
75611117|NCT05143801|Device|High-intensity interval exercise with surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask
75904874|NCT05440929|Behavioral|Clinician Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications & Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
75904875|NCT05433415|Behavioral|Black Girls Move|Goal setting and monitoring. All BGM daughters will self-monitor their progress towards PA goals using a PA device, Fitbit®. Additionally, BGM daughters will self-monitor their progress towards diet goals using a mobile application, Start Simple with My Plate®. Further, all BGM mothers will use Fitbit® and Start Simple with My Plate® for self monitoring, however, mothers' data will not be analyzed for this study. Since the daughter/ mother relationship is critical to achieving behavioral change, BGM mothers will utilize Fitbit® and Start Simple with My Plate® as a mechanism to communicate, problem solve and support daughters' behavioral goals.BGM is situated within the contexts of environmental, cultural, interpersonal, and developmental factors impacted by structural racism. Intentionally engaging mothers and daughters in an asset based program provides a framework for mothers to model responses to structural racism i.e. racial socialization.
76069288|NCT01445769|Drug|Ruxolitinib|Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 & 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10^9/L at wk 12 or ≥ 150 x 10^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets <100 x 10^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level < 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
76069289|NCT00502216|Drug|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
76069290|NCT00502216|Drug|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
76069291|NCT00545662|Drug|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
75611118|NCT05143801|Device|High-intensity interval exercise with surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
75611119|NCT05143801|Other|High-intensity interval exercise without using a surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask
75760043|NCT06168409|Drug|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
75458700|NCT01811771|Biological|Shanchol vaccine|Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
75458701|NCT01811784|Behavioral|Ask people not to drink raw sap|
75760044|NCT06168370|Radiation|CT guided strategy|"With signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI are switched from SAPT to apixaban. Patients fulfilling the dose reduction criteria according to the drug label, or with a Clinical Frailty Scale ≥4 will receive 2.5mg bid, patients not meeting these criteria will receive a standard dose of 5mg bid.~Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI, without another indication for antiplatelet therapy stop their SAPT.~Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI with another indication for antiplatelet therapy continue life-long SAPT."
75760045|NCT06168344|Other|Web-Based Education Program|This study was assessed the impact of a web-based education program provided to mothers of infants with congenital heart diseases on their quality of life and self-efficacy levels
76069292|NCT00545662|Drug|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
75760046|NCT06168305|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
75611120|NCT05143801|Other|High-intensity interval exercise without using a surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
75760047|NCT06168292|Procedure|ID-RFA and Radiotherapy|The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.
75760048|NCT06168279|Procedure|hand occlusal articulation|The upper and lower cast will be scanning separately then will be articulated manually in the final occlusion then scanned after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
75760049|NCT06168279|Procedure|digital occlusal articulation|Both upper and lower casts will be scanning separately, then the 3D casts will be articulating by using 3d virtual program to obtained the final occlusion after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
75458702|NCT01811784|Behavioral|Ask people not to drink sap or drink sap from skirt protected trees|Behavioural
75458703|NCT01811784|Other|No Intervention|
75760050|NCT06168227|Drug|Disitamb Vedotin|RC48-ADC based therapy
75458704|NCT01811784|Other|No Intervention|
75458705|NCT01811797|Device|Low Intensity Shockwave by Renova|
75458706|NCT01811797|Device|Sham treatment|Sham treatment that looks, sounds and feels like the real LISW treatment.
75458707|NCT01811810|Radiation|Radiation therapy (XRT)|
75458708|NCT01811810|Other|Androgen Deprivation Therapy (ADT)|
75458709|NCT01811810|Other|Chemotherapy|
75611121|NCT00929734|Drug|Rosuvastatin|10mg tablets, once daily in three months
75611122|NCT00929734|Drug|Placebo|1 tablet, once daily in three months
75760051|NCT06168188|Drug|Neulasta® (pegfilgrastim)|Intravitreal injection of Neulasta® (pegfilgrastim) after TON
75760052|NCT06168175|Drug|Sodium lactate|2 mmol/kg, intravenous, daily for 5 consecutive days
75760053|NCT06168175|Drug|Placebo|intravenous, daily for 5 consecutive days
75458710|NCT01811823|Biological|Trivalent Inactivated Influenza Vaccine|"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~A/California/7/2009 (H1N1)pdm-like virus~A/Victoria/361/2011 (H3N2)-like virus~B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
75611123|NCT05378542|Behavioral|Mobile application usage|The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
75611124|NCT04251676|Other|Observational study|Observational study
75611125|NCT04248634|Procedure|Delayed colo-anal anastomosis|"Colo-anal anastomosis performed in two surgical steps:~- Step one: the colon is exteriorized transanally and 5 cm of the colon is left outside without anastomosis creation.~Step two: after 7 days, the excess colon is resected and the colo-anal anastomosis is created."
76069293|NCT00545974|Drug|memantine|memantine 10mg BID
76069294|NCT00545974|Drug|Placebo pill|Placebo pill BID
75760054|NCT06168162|Other|titated PEEP to best static compliance|the Intraoperative PEEP will be titrated to best static compliance for each patient
75611126|NCT00609856|Drug|pioglitazone|tablet, 30 mg, once daily, 26 weeks
75760055|NCT06168149|Diagnostic Test|fetal lung elastography measurement|"Elastography measurements are planned to be performed as in the studies Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study and Feasibility of 2-D ultrasound shear wave elastography of fetal lungs in case of threatened preterm labour: a study protocol in the literature examples section of the file."
75904876|NCT05433129|Procedure|Transient hyperemic response|The transient hyperemic response will be tested via carotid compression method. This test will consist of 5 carotid compressions lasting 5 seconds each with a 60 seconds interval between each compression to allow normalization of the CBF to precompression levels, and the total time for this block would be 6 minutes. The ipsilateral common carotid artery will be compressed for this method, and the response of the middle cerebral artery (MCA) blood flow velocity will be assessed using transcranial doppler (TCD) probe (EMS-9D, Delica). The carotid compressions will only be accepted when there is no further decrease in blood flow velocity can be achieved and stable conditions remained during the whole period of the compression. Otherwise, the compression will be terminated and repeated again after 60 seconds. Satisfactory compression is typically considered to result in a reduction in MCA velocity of 50%, at a minimum.
75904877|NCT05433129|Procedure|Orthostatic challenge|The orthostatic challenge response will be evaluated by lying-to-sit and sit-to-stand methods 5 times where sitting and standing positions will be held for 3 minutes each for a total block time of 35 minutes. A baseline in lying position will be collected at the start of the block, then the position will be changed from lying to sit for 3 minutes and then position will be changed to standing for another 3 minutes.
75904878|NCT05433129|Procedure|Vascular chemo-reactivity|vascular chemo-reactivity will be assessed by varying CO2 concentrations through slow and fast breathing exercises with Capnostream 35 Portable Respiratory Monitor (Medtronic Canada) to monitor EtCO2 through nose clip. The breathing trials will occur two times and each of them will have fast and slow trials along with an interval of normal breathing. First time, the normal, fast and slow breathing trials will be 2.5 minutes long while the second time, these breathing trials will be 1.5 minutes long. The normal respiratory rate for adults is 12 breaths/minute, the target slow respiratory rate will be 5 breaths/minute and fast respiratory rate will be 25 breaths/minute as set by metronome. It has been shown that the EtCO2 has a 10% increase during hypoventilation and almost 50% decrease during hyperventilation compared to normal breathing.
75904879|NCT05433129|Procedure|Neurovascular coupling|The fourth block will evaluate the neurovascular coupling using Automated Neuropsychological Assessment Metrics (ANAM) General Neuropsychological Screening (GNS) Clinical Toolkit which contains 5 tests explained as follows 1) Standard Continuous Performance test will assess sustained attention, concentration and working memory. 2) Manikin test will assess 3D spatial rotation ability, left-right orientation, problem solving and attention. 3) Pursuit Tracking test will measure the visuo-motor control. 4) Switching test will assess divided attention, mental flexibility, and executive function. 5) Stroop test will assess the processing speed, selective attention, interference, and executive functioning with three trial blocks.
75458711|NCT01811836|Dietary Supplement|Zinc|Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
75458712|NCT01811849|Drug|Insulin LISPRO|
75611127|NCT00609856|Drug|insulin glargine|subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
75611128|NCT02873169|Other|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
75458713|NCT01811849|Drug|Insulin LISPRO|
75458714|NCT01811849|Drug|Insulin LISPRO|
75458715|NCT01811888|Behavioral|Quantitative sensory testing (QST)|
75458716|NCT01811901|Other|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
75458717|NCT01811914|Other|intraoperative TTE|
75611129|NCT05116813|Drug|Dipraglurant|Oral 50 mg and 100 mg tablet
75611130|NCT04527757|Procedure|Inhalation induction|For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
75611131|NCT04527757|Procedure|Intravenous induction|For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
75611132|NCT00613249|Drug|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
75611133|NCT00613249|Drug|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
75611134|NCT00613249|Drug|HEC-based Placebo Gel|intravaginal gel, dosed daily
75760056|NCT06168136|Other|protein diet|this group of patients will receive high protein intake (target: 1.8 g protein/kg BW/d)
75760057|NCT06168136|Other|Normal protein diet|this group of patients will receive normal protein intake (target: 1.2 g protein/kg BW/d)
75760058|NCT06168123|Behavioral|Quality of life questionnaires will be assessed in addition to standard care|Quality of life questionnaires will be assessed in addition to standard care
75904880|NCT05432934|Drug|Dexamethasone|Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
76069295|NCT02928718|Procedure|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
76069296|NCT00507208|Device|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
76069297|NCT00507208|Other|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
75458718|NCT01811927|Device|PRO-Kinetic Energy Stent|Bare-metal stent
75458719|NCT01811966|Other|Volume|
76069298|NCT00548470|Drug|Varenicline|Varenicline 1-2 mg/day
76069299|NCT02732704|Device|JenaValve Pericardial TAVR System|TAVR with JenaValve Pericardial Valve and Delivery System
75611135|NCT00613561|Drug|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
75611136|NCT01009983|Biological|panitumumab|Given IV
75611137|NCT01009983|Drug|paclitaxel|Given IV
76069300|NCT00548860|Drug|Ferric Carboxymaltose|
76069301|NCT00548860|Drug|Standard Medical Care (SMC)|
76069302|NCT00508300|Procedure|Epidural analgesia|Thoracic epidural analgesia until day 2
76069303|NCT00508300|Procedure|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
76069304|NCT00509002|Drug|Gefitinib|250 mg by mouth once a day, every day, at about same time in morning.
75611138|NCT01009983|Drug|carboplatin|Given IV
75611139|NCT01009983|Procedure|laboratory biomarker analysis|Correlative study
75611140|NCT01009983|Procedure|immunohistochemistry staining method|Correlative study
75611141|NCT04474795|Behavioral|Staff -Educational training|Nurses and community health workers will complete 4 hours of online modules on gestational diabetes - Module 1: GDM Disease, Diagnosis and Complications; Module 2: Nutrition and Physical Activity Management; Module 3: Monitoring, Medications, and Avoiding Hypoglycemia; Module 4: Future Diabetes Risk and Prevention. Effectiveness of the training will be evaluated with pre/post evaluation of diabetes knowledge, attitudes, and self efficacy.
75760059|NCT06168110|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control
76069305|NCT02231008|Drug|tasimelteon|
76069306|NCT02231008|Drug|placebo|
76069307|NCT00509392|Device|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
76069308|NCT00509392|Device|Endovenous Laser|laser catheter
76069309|NCT01797172|Procedure|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
76069310|NCT01797172|Procedure|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
76069311|NCT00550654|Other|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
76069312|NCT00550654|Radiation|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
75458720|NCT01811966|Other|Control|
75458721|NCT01811979|Dietary Supplement|Oral sucrose solution|Oral sucrose solution plus topical anesthetics
75458722|NCT01811979|Dietary Supplement|Steril water|steril water plus topical anesthetics
75458723|NCT01811992|Biological|Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care."
75458724|NCT01812018|Drug|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
75458725|NCT01812018|Drug|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
75458726|NCT01812018|Drug|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
75760060|NCT06168097|Procedure|100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis|"We Will take Both blood and tissue samples used to study them.~We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
75611142|NCT00628485|Device|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
75611143|NCT00628485|Device|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
75904881|NCT05431361|Other|Prehabilitation|A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns [NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
75904882|NCT05429853|Dietary Supplement|Sondalis® HP 2 kcal (with or without fibre)|The participants will take the study product during the two months of the study.
75904883|NCT05424159|Radiation|Carbon ion radiotherapy|Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
76069313|NCT00550654|Radiation|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
75458727|NCT01812031|Other|medical imaging|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
75611144|NCT00628485|Device|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
75611145|NCT04471363|Behavioral|Cancer-Specific Exercise education|An audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
75760061|NCT06168097|Procedure|women with intraoperative and / or histopathology findings suggestive of endometriosis|"We Will take Both blood and tissue samples used to study them.~We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
75760062|NCT06168084|Drug|Vonoprazan|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
76069314|NCT00550654|Radiation|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
75458728|NCT01812070|Behavioral|ACT|
75458729|NCT01812070|Behavioral|CBT|
75458730|NCT01812096|Other|Subcutaneous bortezomib|
75458731|NCT01812096|Other|Intravenous bortezomib|
75458732|NCT01812122|Drug|Glimepiride|
75458733|NCT01812122|Drug|Vildagliptin|
75458734|NCT01812135|Biological|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
75458735|NCT01812148|Procedure|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
75458736|NCT01812161|Other|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
76069315|NCT00550654|Radiation|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
75458737|NCT01812161|Other|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of <5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
75458738|NCT01812187|Behavioral|SHIFT Cognitive Behavioral Therapy|Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
75458739|NCT01812200|Drug|Dabigatran, Ticagrelor, ASA|
75611146|NCT04297215|Device|DermaCura® Chitosan based antimicrobial therapeutic clothing|"DermaCura® antimicrobial therapeutic clothing (D&M) consists of 98% TENCEL® and 2% elastane. 1% chitosan has been added to TENCEL®~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
75611147|NCT04297215|Device|Binamed® silver based antimicrobial therapeutic clothing|"The Binamed® antimicrobial therapeutic clothing (BAP Medical) consists of micro-modal, lycra and woven silver filaments as antibacterial agent.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
75760063|NCT06168084|Drug|amoxicillin|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
75760064|NCT06168084|Drug|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
75760065|NCT06168084|Drug|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
75760066|NCT06168084|Drug|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
75760067|NCT06168084|Drug|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
75760068|NCT06168071|Device|taVNS|Recently, implantable VNS received FDA approval for augmenting motor recovery from ischemic stroke-induced hemiplegia when used during standard physical and occupational therapy sessions. VNS is FDA-approved for epilepsy therapy in children and is used for generalized refractory epilepsy. VNS may be achieved through an implantable stimulator on the left vagus nerve in the carotid sheath, or transcutaneously through the auricular branch of the vagus nerve (taVNS). All participants will be fitted with the device by attaching adhesive contacts to the left ear. Stimulation sessions will occur once for 30 minutes. The investigators will obtain baseline measure, tolerability questionnaires, vital signs, and EEG data.
75760069|NCT06168032|Biological|Any Chinese government-recommended COVID-19 booster vaccine|Any Chinese government-recommended COVID-19 booster vaccine(such as Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine(Sf9 Cell) and so on) will be once administered in the sixth month after COVID19 infection.
75760070|NCT06167993|Behavioral|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy; It consists of manual therapy, skin care, compression therapy and therapeutic exercise.
75760071|NCT06167967|Diagnostic Test|ctDNA methylation|A blood-based circulating tumor DNA methylation assay that uses 6 different methylation markers, SEPT9 region1, SEPT9 region2, BCAT1, IKZF1, BCAN and VAV3.
76069316|NCT00887380|Drug|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
75458740|NCT01812200|Drug|Rivaroxaban, Ticagrelor, ASA|
75458741|NCT01812200|Drug|Phenprocoumon, Ticagrelor, ASA|
75458742|NCT01812213|Drug|[18F]NAV4694|
75458743|NCT01812239|Drug|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
75458744|NCT01812239|Procedure|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
75458745|NCT01812239|Drug|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
75458746|NCT01812265|Drug|PF-06305591|single Dose
75760072|NCT06167967|Diagnostic Test|standard treatment|This group was treated according to standard procedure
75760073|NCT06167941|Biological|Lung cancer types|Cancer tissue matched to normal tissue, all from the same patient
75760074|NCT06167902|Other|Ginseng oligopeptide (Ginseng extract）|The experimental group was given ginseng oligopeptide preparation 1.2g per day orally.
75760075|NCT06167902|Other|Maltodextrin|The control group was treated with placebo maltodextrin 1.2g/d
75760076|NCT06167863|Diagnostic Test|radiomics|extracted image features from CT or MRI
75760077|NCT06167850|Procedure|Copenhagen plank|Performing Copenhagen adduction as prevention for adductor injury.
75760078|NCT06167837|Drug|Metoclopramide Sulfone|Metoclopramide 10mg+NSS 10 ml IV 30-60 minutes before EGD
75760079|NCT06167837|Drug|Normal Saline 10 mL Injection|Normal saline 10 ml IV 30-60 minutes before EGD
75760080|NCT06167798|Other|biopsy|two 2 mm gingival biopsies were obtained.
75760081|NCT06162494|Biological|Recombinant Zoster Vaccine|After giving consent, participants will be given first dose of vaccine. Participants will be brought back 30-60 days post-vaccine for follow up testing and second dose of vaccine
75760082|NCT06162000|Other|The group that will use the developed software in case studies|"In the study, a case study will be conducted with students in the control and intervention groups once a week for four weeks.~Students in the control group will be given printed cases and asked to prepare care plans on ready-made paper templates.~Case preparation activities of the students in the intervention group will be carried out in line with the software planned to be developed. Before the case preparation activities begin, an information/promotional meeting will be held regarding the use of the application planned to be developed. Students will log in to the application with their e-mail addresses and the password they will choose when they first log in. Students will be asked to review the software and questions regarding usage will be answered. Students will record patient data in the cases into KSDE-HBPYS and prepare care plans with the software. At the end of the case studies, a posttest case and Clinical Decision Making Scale will be applied to both groups."
75760083|NCT06161935|Other|no intervention|no intervention, it is a retrospective study .
75760084|NCT06161194|Other|Supervised group exercise therapy|Participants will participate in a 90 minutes supervised group exercise therapy program 2 times a week for 8 consecutive weeks.
75458747|NCT01812265|Drug|PF-06305591|single Dose
75458748|NCT01812265|Drug|Placebo|Single Dose
75458749|NCT01812278|Behavioral|ACT|
75458750|NCT01812278|Behavioral|CBT|
75458751|NCT01812317|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
75458752|NCT01812317|Procedure|Badimon Chamber Study|Ex-vivo assessment of thrombus formation using the Badimon Chamber
75458753|NCT01812330|Drug|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
75760085|NCT06160336|Other|Transcutaneous Electrical Nerve Stimulation|"Phase 1: Participants undergo a comprehensive assessment in a single experimental session (mapping session) aimed at mapping the regions and sensations that can be electrically stimulated. This mapping protocol is conducted on both the intact and amputated limbs.~Phase 2: This phase comprises a 4-week experimental protocol, including:~four mapping sessions conducted at the onset of each week, where the protocol is randomly applied to the participant's intact and amputated limb.~three stimulation sessions held over three consecutive days in the initial week to assess the participant's ability to discern stimuli of varying intensities.~ten sessions utilizing an end-effector gait rehabilitation robot, aiming to train the participant in walking using the proposed sensory feedback restoration system based on TENS under controlled and repeatable experimental conditions."
75760086|NCT06160258|Behavioral|Ready to Eat (RTE)|Participants will be provided precooked and individually packaged whole grains in the ready-to-eat (RTE) condition for reheating and consumption at home.
75611148|NCT04297215|Device|Binamed® therapeutic clothing without antimicrobial agents|"The Binamed® therapeutic clothing without antimicriobial agents (BAP Medical) is therapeutic clothing made of micro-modal and lycra. Micro-madal is a semi-synthetic wood cellulose fiber. This fiber has a high strength hand elasticity, a high moisture-permeability and feels soft. Lycra ensures an optimal fit on the skin.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
75904884|NCT05423808|Other|Health Professional Consortium|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
75904885|NCT05423808|Device|Holis Dashboard - Holis Patient App|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
76069317|NCT00887380|Radiation|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
75760087|NCT06160258|Behavioral|Dried|Participants will be provided with dried whole grains for home preparation and consumption
75904886|NCT05420064|Behavioral|Intervention Arm At-risk Relative/ARR Contacts|Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
75760088|NCT06159933|Procedure|Supine positioning|According to our local protocol, until November 2021, all patients developing PGD >1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
75904887|NCT05400616|Procedure|Microbiome Transplant|A raw microbiome, is collected from a donor without any sinonasal health problems, as a nasal lavage.
75760089|NCT06159933|Procedure|Early pronation|According to our local protocol, until November 2021, all patients developing PGD >1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
75904888|NCT05400616|Procedure|Placebo|Normal saline.
76069318|NCT00887380|Drug|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
76069319|NCT01445613|Device|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
76069320|NCT00551200|Drug|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
76069321|NCT00551200|Drug|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
76069322|NCT00557284|Drug|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
75458754|NCT01812330|Drug|Ticagrelor|90mg Bid
75458755|NCT01812356|Device|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
75760090|NCT06159933|Procedure|Late pronation|According to our local protocol, until November 2021, all patients developing PGD >1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
75760091|NCT06159478|Drug|Binimetinib 15 MG|Binimetinib 45mg is orally administered twice daily.
75760092|NCT06159387|Drug|Cannabis Extract Oil SR Capsule|"After randomization, in a double blind model, subjects receive cannabis extract or placebo conditioned in identical vials with the same volume of substance.~Everyone will undergo psychotherapy in the CBT (cognitive behavioral therapy) model"
75760093|NCT06159374|Other|exercise and environmental conditions|Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.
75760094|NCT06159309|Other|Hyperbaric oxygen therapy|HBOT per local protocol, i.e. 40 sessions 2.4 ATA, at the discretion of the hyperbaric physician
75760095|NCT06158503|Device|AID|Initiation of an automated insulin delivery system
75760096|NCT06158490|Drug|JYP0061 tablet Dose1|JYP0061 tablet oral, once daily（QD）
76069323|NCT00557284|Drug|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
76069324|NCT00551746|Dietary Supplement|Purple Grape Juice|Grape Juice
76069325|NCT00552448|Device|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
76069326|NCT00557362|Drug|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
76069327|NCT00557362|Drug|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
76069328|NCT00557362|Procedure|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
75904889|NCT05383417|Device|EndoClip|Clip attached to mid portion of the endotracheal tube.
75458756|NCT01812356|Device|Cryomaze procedure using Argon|Cryomaze procedure using Argon
75458757|NCT01812369|Drug|GEMCITABINE CISPLATINE|
75458758|NCT01812369|Drug|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
75458759|NCT01812382|Drug|Retapamulin Microdialysis|After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
76069329|NCT00558844|Drug|Arikayce™ 560 mg|"Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
75760097|NCT06158490|Drug|JYP0061 tablet Dose2|JYP0061 tablet oral, once daily（QD）
75760098|NCT06158490|Drug|JYP0061 Placebo|JYP0061 Placebo oral, once daily（QD）
75760099|NCT06158477|Drug|JYP0035 Experimental Drug Treatment|Single dose intervention
75760100|NCT06156215|Behavioral|Vaccine Messaging|"Video clips - short (approximately 3-minute) Public Service Announcement type videos to be viewed by participant using a QR code on their smartphone. If no smartphone is available, the video will be shown to the participant on an iPad.~Printed materials - one page information sheets handed to subjects by CRCs.~Face to face messaging - short (< 1 minute), scripted message from the patient's providers in the ED (nurse or provider)~Each site will maintain a library of A. 5 versions of the videos - the version used in any participant will be tailored to that participant's stated race/ethnicity.~B. 5 versions of printed flyers - likewise, the version will be tailored to the participant's stated race/ethnicity.~C. 1 version of scripted message to be delivered in English or Spanish."
75760101|NCT06156215|Behavioral|Vaccine Acceptance Question|"The last question in the Vaccine Acceptance Survey in both the Intervention M and Intervention Q arms of the study is Would you accept the COVID-19 booster vaccine in the emergency department today if your doctor asked you?"
75760102|NCT06154083|Drug|Follitropin-delta (Rekovelle) 20 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
75904890|NCT05377398|Behavioral|Digital individual-level intervention (Bit Habit)|"All participants in the intervention group receive access to the BitHabit app for the 1-year intervention period. The BitHabit app was designed in the StopDia project, and it aims to help its users to adopt healthier lifestyles and habits.The content and approach of the app is based on habit formation theories and the Self-Determination Theory. The app provides an extensive library of suggested lifestyle habits that was created according to lifestyle guidelines and recommendations. The habits are related to diet, physical activity, sleep, positive mood, stress management, smoking, and alcohol consumption. Users of the app select these habits from the library to their shopping basket to complete in their everyday life. The app also allows the users to report and monitor their performance and progress."
75904891|NCT05377398|Behavioral|Group-based healthy lifestyle and green power intervention|The group-based healthy lifestyle intervention is based on the Supportive Environment Theory (SET). The intervention is implemented in accordance with DiClemente and Prochaska's Stages-of-Change Model which is often used as framework for lifestyle change as well as Shazer and Berg's Solution Focused Brief Therapy. We expect participants to increase knowledge about healthy lifestyle choices and notice the beneficial effect of exercise, healthy diet and staying in nature. The intervention includes 12 to 16 hours of group activities during a period of 8 weeks. Interventions comprehend guided activities in nature, related to healthy relationship to food and exercise, as well as reflecting on shared experiences. In addition to group meetings, participants have access to material for mental well-being on an electronic learning environment.
75458760|NCT01812395|Device|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
75611149|NCT04850989|Device|Pico Goblin VR headset|We worked with Limbix to tailor content on a Pico Goblin VR headset by creating two exposure therapy themes (general social skills training/dinner party or job interview) based on CBT principles and literature. The Pico Goblin VR headset projected a 5.5-inch diagonal screen size (depth: 139.7 mm; height: 122mm; width: 68mm) with 2560 x 1440-pixel resolution, 3 degrees of freedom, 92° field of view, a refresh rate of 70Hz, and 54-71mm interpupillary distance (Kyoto, 2017). It was chosen because displays of the pre-recorded VRE videos could be smoothly operated wirelessly with a tablet that showed the selected scenes in real-time. Further, the headset could be conveniently switched on and off, and dovetailed the participant's head motion. These scenes were filmed with a 360° stereoscopic camera, each lasting between 1.5 to 10 min.
75611150|NCT02873091|Procedure|Epidural analgesia|
75611151|NCT02873091|Procedure|Continuous epidural infusion|
75611152|NCT02873091|Procedure|Intermittent epidural bolus|
75458761|NCT01812395|Procedure|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
75611153|NCT02873091|Drug|ropivacaine|
75611154|NCT02873091|Drug|sufentanil|
75760103|NCT06154083|Drug|Follitropin-delta (Rekovelle) 15 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
75458762|NCT01812421|Other|Hypertension Health Education Protocol (HHEP)|
75458763|NCT01812434|Drug|Sildenafil|20mg three time daily for 28 days
75458764|NCT01812434|Drug|Placebo|20 mg three times daily for 28 days
75458765|NCT01812460|Other|Intervention-training-group|As descriped in Arm Description
75458766|NCT01812486|Radiation|dose de escalation|
75458767|NCT01812486|Radiation|standard dose|
75760104|NCT06153550|Other|preparation in Respiratory Physiotherapy|"preparation in Respiratory Physiotherapy consist to:~3 sessions per week with the physiotherapist~spirometry and pulse oximetry test 3 weeks before surgery, the day before surgery and the day after surgery."
75760105|NCT06153498|Drug|Remimazolam besylate|After a loading dose of 0.05mg/kg, a maintaining dose of 0.2mg/kg/h is given; It is recommended to adjust the infusion rate of Remazolam besylate for injection at a amplitude of 0.05mg/kg/h, mainly based on the RASS score of the subjects (the adjustment range is 0-1.0 mg/kg/h, and the maximum infusion rate is not more than 1.0mg/kg/h) until the subjects reach the optimal sedation level (-3≤RASS≤0).
75611155|NCT03905083|Other|Exercise Rehab|Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
75760106|NCT06152497|Drug|Placebo|Oral placebo
75760107|NCT06152497|Drug|H1 blockade: Telfast: 180mg Fexofenadine|H1 blockade: oral blockade with 180mg Fexofenadine
75760108|NCT06152497|Behavioral|Resistance training|Resistance training: lower body exercise
75760109|NCT06152120|Other|Nurse-facilitated advance care planning intervention|"The intervention consists of two components:~Component 1. Palliative care needs assessment - The research nurse will conduct a palliative care needs assessment and also review related information from the medical chart, which will enable the nurse to provide tailored information on the patient's illness, prognosis, and palliative care needs during subsequent ACP consultations.~Component 2: Structured nurse-facilitated ACP consultations - The research nurse will conduct post-discharge ACP consultations with the family surrogate, with content that includes: assess readiness for discussions, introduce video decision aides to provide related ACP information and share examples of family surrogates with similar experiences."
75611156|NCT04298775|Procedure|spinal anesthesia with morphine|
75760110|NCT06151145|Behavioral|Usual care|Participants in usual care will be emailed monthly educational modules with information on maintaining weight loss.
75760111|NCT06151145|Behavioral|SELF|"The SELF group will receive a wireless smart body weight scale and wearable physical activity tracker, and text messages."
75760112|NCT06151145|Behavioral|STEP|The STEP intervention consists of 4 steps that are progressive and based on response to treatment. Step 1: Digital health intervention. The first step will be the digital health intervention as described under SELF. Step 2: Monthly, in-person counseling. Participants who move to Step 2 will be provided with monthly, in-person counseling. Step 3: Twice per month counseling. Step 3 will be twice-monthly counseling, spaced at every other week. Step 4: Meal replacements. Participants will be prescribed a partial meal replacement program.
75760113|NCT06149377|Procedure|Test cohort|
75760114|NCT06148896|Behavioral|GrExPACT|Combining physiotherapy group exercise with acceptance and commitment therapy delivered by physiotherapy
75760115|NCT06148896|Behavioral|GrEx|Group physiotherapy exercise
75760116|NCT06146621|Behavioral|Low-touch text messaging|To address families' lack of awareness of the Earned Income Tax Credit (EITC) and the ways they may benefit from filing taxes, one study arm will receive low-touch text messages. These act in part by increasing awareness of programs and eligibility rules and in part as reminders to overcome limited attention to filing. Study participants receiving this intervention will receive behavioral science-informed text messages in English or Spanish from WIC that inform them about the EITC throughout tax season (i.e., January-April) 2024. We will personalize message contents (e.g., EITC benefit size mentioned in message based on participant income, marital status, and number of dependents) due to suggestive evidence that a tailored, individualized text message has the potential to be effective
75904892|NCT05377398|Behavioral|Individual-level healthy lifestyle intervention|The individual-level healthy lifestyle intervention follows the principles and theoretical background of the group-based intervention, but the intervention is carried out entirely on the electronic learning environment. The participants complete activities and exercises independently or with a friend in their own time.
75458768|NCT01812512|Behavioral|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
75458769|NCT01812525|Drug|NaCl 3%|NaCl 3%: 4ml QID
75611157|NCT04298775|Procedure|spinal anesthesia without morphine + peripheral nerve block|
75611158|NCT04285359|Procedure|Intracranial Interventions|Neurosurgical elective intracranial interventions: supra- and infratentorial craniotomies, transnasal endoscopic interventions.
75611159|NCT01215227|Drug|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
75611160|NCT01215227|Drug|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
75760117|NCT06146621|Behavioral|Personal tax filing support|Participants randomized to this intervention will be connected with a human assistor who will work with them to ensure they access resources to help them file taxes and apply for the EITC. The English- and Spanish-speaking assistors will be study team staff trained to provide personalized support to help families access resources for which they are eligible. The assistor will be available by text or phone to talk with people if they encounter barriers and will call to follow-up on a mutually agreed upon schedule.
75760118|NCT06146621|Behavioral|Information about free tax-filing support|Basic information about where to find free tax filing support in their community will be provided to all participants by email once upon enrollment.
75760119|NCT06146621|Behavioral|Financial assistance|Participants randomized to this intervention will receive a $100 cash incentive for tax filing, designed to offset the time, hassle, and resources spent on tax preparation and filing, as well as psychological frictions like inattention that prevent some people from filing. This will be provided to recipients as soon as they show proof of tax filing, to provide a more immediate reward relative to the delays in receiving a federal tax refund. We will test the feasibility of delivering this via gift card, check, or other modalities, in addition to evaluating the framing and incentive amount.
75760120|NCT06145763|Procedure|Biospecimen Collection|Ancillary studies
75760121|NCT06145763|Behavioral|Smoking Cessation Intervention|Use iCanQuit smartphone app
75760122|NCT06145763|Behavioral|Smoking Cessation Intervention|Use NCI QuitGuide smartphone app
75760123|NCT06145763|Other|Survey Administration|Ancillary studies
76069330|NCT00558844|Drug|Placebo for 560 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
75760124|NCT06142890|Other|No cooling (control)|Participants are exposed to 31°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants remain in supine position with slight (~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure.
76069331|NCT00558844|Drug|Arikayce™ 70 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
75760125|NCT06142890|Other|Cooling with ceiling fan|Participants are exposed to 31°C, 45% relative humidity for 8 hours. Drinking water is available ad libitum. Participants remain in supine position with slight (~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure. Participants will remain under a commercially available ceiling fan generating a standard air flow throughout the duration of exposure.
76069332|NCT00558844|Drug|Arikayce™ 140 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
76069333|NCT00558844|Drug|Placebo for 70 mg / 140 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
75611161|NCT01215227|Drug|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
75611162|NCT01215227|Drug|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
75760126|NCT06142539|Radiation|CT Radiation Doses|Obtaining Low CT Radiation Doses by Adjusting Dose Levels
76069334|NCT00512278|Drug|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
76069335|NCT00512278|Drug|Placebo|Placebo
76069336|NCT01445535|Biological|Rituximab|Rituximab will be given with siplizumab and etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin every 21 days
76069337|NCT01445535|Drug|Etoposide|Etoposide will be given with siplizumab and prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
76069338|NCT01445535|Biological|Siplizumab|Siplizumab will be given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
75611163|NCT05429957|Other|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) three times per week for 8 weeks.~MET of the Iliopsoas~MET of Piriformis muscle~MET of Quadratus Lumborum muscle~MET of Erector Spinae muscle"
76069339|NCT01445535|Drug|Prednisone|Prednisone will be given with siplizumab and etoposide, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
75760127|NCT06142396|Combination Product|Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone|"This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure."
75760128|NCT06140290|Drug|Etrasimod Immediate Release (IR)|An immediate release tablet
75760129|NCT06139588|Device|acellular dermal matrix implant for breast reconstruction|acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy
75760130|NCT06138795|Drug|AZD2389|Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.
75760131|NCT06138795|Drug|Placebo|Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
75760132|NCT06131775|Biological|Blood sampling|One blood sample of 10mL is realized before initiation of immunotherapy
76069340|NCT01445535|Drug|Vincristine|Vincristine will be given with siplizumab and etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab every 21 days
76069341|NCT01445535|Drug|Cyclophosphamide|Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
75760133|NCT06131775|Biological|Blood sampling|Three blood samples of 10mL are realized at distinct steps of patients disease management : one before the curative surgery, one after three months and one after six months.
75760134|NCT06131645|Diagnostic Test|IASLC grading system|A cohort of 2160 patients with invasive nonmucinous EGFR-mutant LADCs were retrospectively collected and classified according to the IASLC grading system. The role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy was investigated.
75760135|NCT06128551|Drug|Assigned interventions|Drug: RMC-6291 and RMC-6236 Oral tablets
75760136|NCT06123741|Behavioral|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma) .
75760137|NCT06123741|Behavioral|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
75760138|NCT06119555|Dietary Supplement|Cinnamon Capsules|The intervention consists of four cinnamon capsules (each 1.5 grams, totaling 3 grams) a day, with two with breakfast and two with dinner for 60 days
76069342|NCT01445535|Drug|Doxorubicin|Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
75760139|NCT06118983|Other|I-TRANSFER-HF|"I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies (hospital-HHC agency dyads) across the US."
75760140|NCT06112379|Drug|Dato-DXd|Experimental drug IV infusion
75760141|NCT06112379|Drug|Durvalumab|Experimental drug IV Infusion
76069343|NCT01445301|Drug|GSK2585823(CLDM 1%-BPO 3% gel)|Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg
76069344|NCT01445301|Drug|CLDM 1% gel twice daily|Topical gel containing clindamycin 10 mg/1 g gel
76069345|NCT01409031|Drug|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
76069346|NCT01409031|Other|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
76069347|NCT01430403|Biological|Omalizumab|Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.
75760142|NCT06112379|Drug|Pembrolizumab|IV Infusion Active comparator
76069348|NCT01430403|Drug|Inhaled Corticosteroid Boost Therapy (ICS)|Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
75458770|NCT01812525|Other|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
75760143|NCT06112379|Drug|Doxorubicin|IV infusion Experimental/Active Comparator
75760144|NCT06112379|Drug|Epirubicin|IV Infusion Experimental/Active Comparator
75760145|NCT06112379|Drug|Cyclophosphamide|IV infusion Experimental/Active Comparator
75458771|NCT01812538|Drug|DIC075V|"Four single dose treatments:~Placebo (normal saline)~Moxifloxacin (positive control)~DIC075V 37.5 mg~DIC075V 75 mg~All subjects receive each of the 4 treatments."
76069349|NCT01430403|Biological|Placebo omalizumab|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
75760146|NCT06112379|Drug|Paclitaxel|IV infusion Experimental/Active Comparator
75760147|NCT06112379|Drug|Carboplatin|IV infusion Experimental/Active Comparator
75760148|NCT06112379|Drug|Capecitabine|Tablet Oral route of administration Experimental/Active Comparator
75760149|NCT06112379|Drug|Olaparib|Tablet Oral route of administration Experimental/Active Comparator
75904893|NCT05377398|Behavioral|Mini-intervention for substance use|The mini-intervention for substance use follows the principle of the ASSIST-linked brief intervention created by WHO. This brief intervention is a phone-call lasting 3 to 15 minutes and given to the participant according to their risk score calculated with the ASSIST questionnaire which is included in the baseline survey. The intervention includes presenting the participant with their test score and associated health problems related to their level of risk. Especially in primary health care context, brief intervention according to the ASSIST score has been found to be successful in moderating risk for substance use. The intervention is not intended as a stand-alone treatment and in cases where high risk substance use is detected, the professional should encourage the participant to seek specialized drug and alcohol assessment and treatment.
76069350|NCT01430403|Biological|Placebo fluticasone|Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
76069351|NCT01429623|Drug|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
75760151|NCT06111339|Drug|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
76069352|NCT01429623|Drug|Placebo|Placebo comparator
75458772|NCT01812551|Drug|Alendronate|As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
75458773|NCT01812551|Drug|Placebo|Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
75760152|NCT06111339|Other|Saline Solution|The placebo will be a 0.9% saline solution administered over 40 minutes.
75760153|NCT06108544|Drug|TAK-279|Specified drug on specified days.
76069353|NCT01408641|Drug|Topiramate|Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
75458774|NCT01812564|Biological|Platelet Poor Plasma (PPP)|
75458775|NCT01812564|Biological|Platelet Rich Plasma (PRP)|
75458776|NCT01812590|Behavioral|Exercise|
75458777|NCT01812629|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
76069354|NCT01408641|Drug|Placebo|Placebo capsules without topiramate
76069355|NCT01429077|Drug|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
76069356|NCT01429077|Drug|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
75458778|NCT01812642|Drug|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
75458779|NCT01812642|Other|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
75458780|NCT01812720|Drug|carfilzomib|Given IV
75458781|NCT01812720|Drug|dexamethasone|Given PO
75458782|NCT01812720|Other|laboratory biomarker analysis|Correlative studies
75458783|NCT01812746|Drug|BIND-014|
75458784|NCT01812772|Device|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
75760154|NCT06108544|Drug|Placebo|Specified drug on specified days.
75760155|NCT06108544|Drug|Apremilast|Specified drug on specified days.
75760156|NCT06105632|Drug|PF-07220060|Experimental
75760157|NCT06105632|Drug|Fulvestrant|Experimental and Active comparator
75760158|NCT06105632|Drug|Everolimus|Active Comparator
75760159|NCT06105632|Drug|Exemestane|Active Comparator
75760160|NCT06103513|Drug|Somatropin|The treatment of children with subcutaneous recombinant human growth hormone (rhGH) is the current gold standard of care for children with diagnosed GHD. This study will serve only to investigate the optimal dose of treatment in the first year of treatment with rhGH.
75760161|NCT06100068|Behavioral|Mental Exercises and Temporal Alteration|Mental exercises during L-DIBH to distort the awareness of passage of time
75760162|NCT06099171|Drug|Cannabidiol and β-Caryophyllene Patch|Cannabidiol with its decongestant activity has a soothing action in the area of application, thanks to the association with B-caryophyllene which assists its activity
76069357|NCT01428453|Drug|250mg rilapladib|Experimental Drug
76069358|NCT01428453|Drug|placebo|Placebo comparator
76069359|NCT01408563|Drug|Fludarabine|30 mg/m2/day IV x 6 days
76069360|NCT01408563|Drug|Melphalan|100 mg/m2/day IV x 1 day
76069361|NCT01408563|Radiation|Total Body Radiation|200 cGy on Day 0
76069362|NCT01408563|Biological|Cord Blood|2 cord blood units IV
76069363|NCT01442493|Other|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
76069364|NCT01442493|Other|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
76069365|NCT04069923|Other|Magnesium-based Bone Void Filler|Given intraoperatively
75760163|NCT06099171|Device|Oxygen-Ozone Therapy|Ozone (O3) is a molecule consisting of 3 atoms of oxygen in a dynamically unstable structure. O3 has the capacity to modulate inflammation. O3 when in contact with human fluids and tissues rapidly reacts, generating many reactive oxygen species, as hydrogen peroxide (H2O2), superoxide ion, and hydroxyl radical (OH-). It is suggested that through moderate oxidative stress generated by these reactive byproducts, O2O3 might produce positive effects in several pathologies, including musculoskeletal affections. Moreover, O2/O3 may directly regulate prostaglandins (PGS) and bradykinin, and suppress several proinflammatory mediators, such as IL-6, IL-8 and TNF-α
75611164|NCT05429957|Other|Aerobic Exercises|"Aerobic exercise (treadmill walking) three times per week for 8 weeks~Warm-up phase: in which each patient alternately steps their legs forward, backward, and sideways in each direction for 5 min~Active phase: Treadmill speed was 3km/hour for 5 weeks and progress to 4km/hour after 5 weeks for 20 min.~Cool down phase: During a cool down period take a deep breath with both arms overhead and exhale while bringing the arms down, shaking out the legs and arms for 5 min."
75760164|NCT06093906|Behavioral|Positive Processes and Transition to Health|See arm/group description for details regarding this intervention
75760165|NCT06093906|Behavioral|Progressive Muscle Relaxation|See arm/group description for details regarding this intervention
75904894|NCT05368103|Biological|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
76069366|NCT01442181|Procedure|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
76069367|NCT01442181|Other|Medical therapy|Patients are treated with rhythm and rate control medications.
76069368|NCT04407975|Other|Betamethasone|A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
75458785|NCT01812772|Device|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
75611165|NCT01009515|Drug|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
75611166|NCT04550481|Procedure|Biospecimen Collection|Undergo blood sample collection
75611167|NCT04550481|Drug|Lisinopril|Given PO
75611168|NCT04550481|Procedure|Liver Ultrasonographic Elastography|Undergo transient elastography (Fibroscan)
75611169|NCT04550481|Procedure|Magnetic Resonance Elastography|Undergo PDFF MRE
75611170|NCT04550481|Procedure|Magnetic Resonance Imaging|Undergo PDFF MRI
75611171|NCT04550481|Procedure|Proton Density Fat Fraction|Undergo PDFF MRI/MRE
75611172|NCT04550481|Other|Questionnaire Administration|Ancillary studies
75611173|NCT01214915|Drug|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
75611174|NCT04297527|Procedure|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
75458786|NCT01812798|Other|Double Blind Placebo Controlled Food Challenge|"All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour."
75611175|NCT04297527|Procedure|Mulligan Mobilization|Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
75611176|NCT01009281|Drug|AIN457|
75611177|NCT01009203|Drug|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
75760166|NCT06093295|Device|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)|"The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~Total stimulation time ~190 seconds~Intensity: 80% of active motor threshold~2 seconds train, repeated every 10 seconds~In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses"
75904895|NCT05367440|Drug|AZD5305|Patients will receive an oral dose of AZD5305 once daily
75904896|NCT05367440|Drug|Enzalutamide|Patients will receive an oral dose of Enzalutamide once daily
76069369|NCT04407975|Other|Placebo|A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
75760167|NCT06093100|Device|wearable technology|Three wearable devices
75760168|NCT06089187|Procedure|Endotracheal intubation using an endotracheal tube with cuff inflated with air|After endotracheal intubation, the endotracheal tube cuff is inflated with air
76069370|NCT01442103|Device|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
75760169|NCT06089187|Procedure|Endotracheal intubation using an endotracheal tube with cuff inflated with saline|After endotracheal intubation, the endotracheal tube cuff is inflated with saline
76069371|NCT04069767|Procedure|ICoreDIST|"The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking."
75760170|NCT06088043|Drug|TAK-279|Specified drug on specified days.
75760171|NCT06088043|Drug|Placebo|Specified drug on specified days.
75760172|NCT06088043|Drug|Apremilast|Specified drug on specified days.
75760173|NCT06086899|Procedure|Cervical motion style acupuncture treatment(Trapezius, Rhomboid, Scalene)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
75760174|NCT06086899|Procedure|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
76069372|NCT04069767|Procedure|Standard Care|According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
75611178|NCT01009203|Drug|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
75760175|NCT06086756|Behavioral|Exposure intervention plus positive mood induction|Positive mood induction followed by a brief VR exposure session for public speaking anxiety.
75611179|NCT01009047|Drug|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
75760176|NCT06086756|Behavioral|Exposure intervention plus negative mood induction|Negative mood induction followed by a brief VR exposure session for public speaking anxiety.
75760177|NCT06084663|Drug|Apremilast 30 mg Tablets|Each film-coated tablet contains 30 mg of apremilast
75760178|NCT06084663|Drug|Otezla 30 mg film-coated tablets|Each film-coated tablet contains 30 mg of apremilast
76069373|NCT01428219|Drug|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
76069374|NCT01428063|Drug|Daclatasvir|
76069375|NCT01428063|Drug|Asunaprevir|
76069376|NCT01428063|Drug|Pegylated interferon alfa-2a|
76069377|NCT01428063|Drug|Ribavirin|
76069378|NCT00513292|Drug|Cyclophosphamide|Given IV
76069379|NCT00513292|Drug|Epirubicin Hydrochloride|Given IV
75760179|NCT06083844|Drug|Pembrolizumab|Given by IV (vein)
75760180|NCT06083844|Drug|Bevacizumab|Given by IV (vein)
75760181|NCT06083844|Drug|Cyclophosphamide|Given by mouth
75760182|NCT06071442|Drug|Vemircopan|Participants will receive oral tablets of Vemircopan.
75760183|NCT06071442|Drug|Rosuvastatin|Participants will receive oral coated tablets of Rosuvastatin.
75760184|NCT06071442|Drug|Metformin|Participants will receive oral film-coated tablets of Metformin.
75760185|NCT06071442|Drug|Levonorgestrel / Ethinyl Estradiol|Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.
75760186|NCT06071442|Drug|Carbamazepine|Participants will receive oral chewable tablets of Carbamazepine.
75904897|NCT05367440|Drug|Abiraterone Acetate|Patients will receive an oral dose of Abiraterone Acetate once daily
75904898|NCT05367440|Drug|Darolutamide|Patients will receive an oral dose of Darolutamide twice daily
75904899|NCT05359848|Other|Diet|Using dietary interventions as an adjuvant tool may represent an effective step toward advancing the treatment options of cancer. Dietary modifications can impact the growth and proliferation of tumors via multiple mechanisms
75760187|NCT06063330|Combination Product|RQ-001|"Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator. Drug Product RQ-001 has been developed with an Aptar Bidose liquid nasal spray unit device (BDSI V3) capable of intranasally delivering a 200 uL total volume of drug product (specifically, 100 uL per nare, which delivers a 200 uL of total volume). The combination product comprises the drug constituent (RQ-01) and the assembly of commercially available, off-the-shelf device components.~Study staff will be responsible for assembling the drug product RQ-001 and subjects will self-administer under the supervision of study staff in the clinic."
75760188|NCT06063330|Other|Placebo|Matching placebo will be manufactured just as RQ-01 drug substance, with the active ingredient addition step omitted. Placebo will appear similar to RQ-01 drug substance as a clear to hazy, colorless to yellowish liquid. Matching placebo will be administered the same way as RQ-01
75760189|NCT06060418|Other|aromtherapy|aromatherapy with essential oil is being used as a non-pharmacological nursing intervention within the health care setting. This approach aims to manage the patient's discomfort and alleviate the symptoms of postoperative nausea and vomiting. One of the most beneficial oils is Lavender Essential Oil (LEO), which is used to treat a variety of digestive issues.
75904900|NCT05357950|Drug|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
75760190|NCT06057129|Device|Supervised and minimally-supervised therapy with ReHandyBot|During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a supervisor (i.e., therapist or researcher). Minimally-supervised therapy means that participants try to perform therapy with the device by themselves, while the supervisor is still present but helps only in case participants encounter problems or if they have any questions. During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes.
75904901|NCT05357950|Drug|Placebo|Placebo matches active drug in size, color and taste
75904902|NCT05356182|Other|Diet|Control diet consisting of 20% protein, intervention diet consisting of 10% protein
75904903|NCT05354570|Radiation|Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
75458787|NCT01812824|Behavioral|Intervention (Virtual Patient Advocate)|"Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week."
75904904|NCT05350423|Device|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
75904905|NCT05350423|Device|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
75904906|NCT05344235|Other|SBRT|stereotactic radiotherapy of the primary prostate
75904907|NCT05334485|Drug|Pyridostigmine Bromide|Oral 60mg pyridostigmine bromide
76069380|NCT00513292|Other|Laboratory Biomarker Analysis|Correlative studies
76069381|NCT00513292|Drug|Paclitaxel|Given IV
76069382|NCT00513292|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75611180|NCT01009047|Drug|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
75611181|NCT04205097|Drug|Neostigmine + glycopyrate|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
75611182|NCT04205097|Drug|Sugammadex|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
75611183|NCT04285047|Other|Advancing Patient Experience (APEX) in COPD|Involves both EMR and PRIO data
75611184|NCT04283955|Drug|High-dose MTX based chemotherapy|Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
75611185|NCT04205565|Drug|High dose group: L-oxiracetam Injection|L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
75611186|NCT04205565|Drug|Low dose group: L-oxiracetam Injection|L-oxiracetam injection, 3 vials, once a day, IV. Placebo injection of l-oxiracetam, 1 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
75611187|NCT04205565|Drug|Control group: Oxiracetam Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.
75611188|NCT04205565|Drug|Placebo group: Placebo Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
75611189|NCT04205253|Diagnostic Test|Ultrasonography imaging|This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
75904908|NCT05334485|Other|Placebo|Oral starch placebo
75904909|NCT05324943|Genetic|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
75904910|NCT05315999|Drug|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II & III)
75904911|NCT05315999|Drug|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II & III)
76069383|NCT00513292|Biological|Trastuzumab|Given IV
76069384|NCT00513370|Biological|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
76069385|NCT00559468|Drug|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
76069386|NCT00559468|Drug|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
75904912|NCT05308290|Other|Blood pressure management according to cerebral autoregulation|Intraoperative blood pressure will be targeted based on limits of cerebral autoregulation.
75611190|NCT04297059|Other|Ajyal Salima|It comprises in class-activities, meetings with parents and improvement of school foodservice
76069387|NCT00559468|Drug|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
75458788|NCT01812863|Procedure|Supraclavicular nerve block|"Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.~If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels."
75458789|NCT01812889|Drug|TOL-463 Vaginal ovule|TOL-463 Vaginal Ovule
75458790|NCT01812889|Drug|TOL-463 Vaginal gel|TOL-463 Vaginal Gel
75611191|NCT04300725|Other|Video Counseling|Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
75611192|NCT04300491|Other|Suspension walking training|Physiotherapy session, objective wlaking with body weight support using a specific device
76069388|NCT00559468|Drug|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
76069389|NCT00560560|Biological|CP-751, 871|Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
76069390|NCT00561418|Drug|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
75611193|NCT04296669|Device|Ergotron LearnFit Sit-Stand desk|An adjustable sit-stand desk design for children
75611194|NCT01025193|Drug|Belimumab|Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
75904913|NCT05308290|Other|Blood pressure management according to usual care|Intraoperative blood pressure will be targeted based on usual care.
75904914|NCT05304117|Behavioral|Advance Care Planning|Community Information Session and Private Sharing Session with trained social worker
76069391|NCT00561418|Other|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
76069392|NCT00514852|Drug|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
75458791|NCT01812902|Procedure|Radical Prostatectomy|
75458792|NCT01812915|Device|Cylindrical-shape cuff ETT (Group C)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt Hi-Lo(TM) endotracheal tube.
75458793|NCT01812915|Device|Tapered-shape cuff ETT (Group T)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt TaperGuard(TM) endotracheal tube.
75458794|NCT01812928|Drug|Diclofenac|
75458795|NCT01812941|Other|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
75611195|NCT01025037|Device|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
75904915|NCT05301842|Drug|Tremelimumab|Tremelimumab IV (intravenous)
75904916|NCT05301842|Drug|Durvalumab|Durvalumab IV (intravenous)
75904917|NCT05301842|Procedure|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
75904918|NCT05301842|Drug|Lenvatinib|Lenvatinib (oral)
75904919|NCT05294978|Diagnostic Test|OCT|Macular optical coherence tomography (OCT)
75904920|NCT05294809|Behavioral|PsyPills|Prescribing personalized rational thinking strategies to change levels of dysfunctional emotionality.
76069393|NCT00514852|Drug|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
76069394|NCT00555880|Drug|Midodrine hydrochloride|one dose, 10-30mg, given orally
75760191|NCT06057129|Device|Unsupervised therapy|"After the familiarization phase, participants train without supervision at the clinic until discharge and then at home for two weeks.~If the therapist thinks that the participant have properly learnt how to use the device and can train with it safely, the participant can keep training with the device unsupervised (both at the clinic and at home).~If participants are not ready for unsupervised therapy with the device, they receive a booklet of exercises to perform without supervision (both at the clinic and at home). These exercises do not imply the use of the robot but are exercises discussed with the therapists and meaningful for the specific patient."
75760192|NCT06057012|Drug|BRII-296|2 intramuscular injections 300 mg each of BRII-296 admixed with Depo Medrol 40 mg/mL per injection, will be administered in participants with PPD.
75760193|NCT06055803|Behavioral|Intake Session|Each of the program components will have an individualized assessment with plan and goals set at the program intake visit.
75611196|NCT01214837|Biological|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
75611197|NCT01214837|Biological|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
75904921|NCT05294809|Behavioral|Online-Contingent Attention Training, OCAT|Facilitating the disengagement from negative content and engagement of positive one of personally relevant information by providing instruction and feedback on performance.
75904922|NCT05294809|Behavioral|shamOCAT|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
75611198|NCT01214837|Biological|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
75611199|NCT01024959|Other|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
75760194|NCT06055803|Behavioral|Individual Sessions|Individual sessions will occur in person or virtual every other week during the 12-week intervention with a health promotion specialist (nurse or exercise physiologist). These sessions will include review of progress towards goals, update exercise prescription, make plan for the next two weeks.
75760195|NCT06055803|Behavioral|Group Sessions|Group sessions for wellness and education will be delivered by medical multi-disciplinary staff in person or virtual every other week during the 12-week intervention.
75760196|NCT06055803|Behavioral|Graduation|At the conclusion of the 12-week intervention, there will be a graduation session to honor the participant's achievement and establish a plan for maintenance after the intervention
75760197|NCT06055803|Behavioral|Exercise|Participants will exercise as part of individual and group sessions. Participants will also be asked to exercise on their own, with a goal of working up to meeting US Physical Activity guidelines (150 minutes per week of moderate to vigorous exercise + 2 episodes of strength training).
75904923|NCT05294367|Drug|Magnesium Chloride-based Lotion|Given topically
75904924|NCT05294367|Other|Quality-of-Life Assessment|Ancillary studies
75904925|NCT05294367|Behavioral|Special Diet Therapy|Consume magnesium rich foods
75904926|NCT05292521|Other|Best Practice|Receive usual care
75904927|NCT05292521|Other|Informational Intervention|Receive QOL fact sheet
75904928|NCT05292521|Other|Questionnaire Administration|Ancillary studies
76069395|NCT00555880|Drug|Placebo|Placebo
75458796|NCT01812941|Other|healthy volunteers: blood collection|blood collected at designated time intervals
75904929|NCT05288452|Behavioral|Digital Health Coaching|The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.
75458797|NCT01812941|Other|Burn: blood collection|blood collected at designated time intervals
75904930|NCT05288452|Dietary Supplement|Food Box Delivery|The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.
76069396|NCT00563290|Drug|dasatinib|Given PO
76069397|NCT00563290|Other|laboratory biomarker analysis|Correlative studies
76069398|NCT00556504|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
76069399|NCT00556504|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
75458798|NCT01812954|Drug|Methotrexate|
75458799|NCT01812954|Drug|Cyclosporins|
75458800|NCT01812954|Drug|fumaric acid|
75458801|NCT01812954|Drug|Acitretin|
75458802|NCT01812954|Drug|Infliximab|
75458803|NCT01812954|Drug|etanercept|
75458804|NCT01812954|Drug|Adalimumab|
75458805|NCT01812954|Drug|Ustekinumab|
75458806|NCT01812967|Dietary Supplement|Milk Fat|
75458807|NCT01812967|Dietary Supplement|Milk Protein|
75458808|NCT01812967|Dietary Supplement|Lactose|
75458809|NCT01812967|Other|Whole milk (3.25% M.F.(|Commercially available milk from the grocery store
75458810|NCT01812967|Dietary Supplement|Simulated Milk Beverage|Added lactose + fat + protein together to form a mixture
75760198|NCT06050070|Other|FMRI with sham controlled feedback|"During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.~In order to see if the neurofeedback is really helping change the size of the circular pattern, the study team will have a control condition. In this controlled condition, subjects will see the circular pattern change, and the study team will ask participants to try and increase the size, except that the changing size will not actually be determined by your brain activity. This a called a sham condition because the feedback signal is not real."
76069400|NCT00556504|Drug|Ribavirin|conventional treatment of Hepatitis C
76069401|NCT00556504|Drug|Placebo|Placebo, without acting ingredient.
76069402|NCT05560828|Other|Zio XT service|There will be no intervention. Standard of care at participating NHS organizations will not be affected.
76069403|NCT02127892|Biological|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
75458811|NCT01812980|Biological|Trivalent Inactivated Influenza Vaccine|"WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
76069404|NCT02127892|Biological|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
76069405|NCT02127892|Biological|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
76069406|NCT02127892|Device|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
76069407|NCT02128828|Drug|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
75458812|NCT01812993|Device|Non-invasive ventilatory treatment with auto-BPAP|
76069408|NCT00520234|Drug|Caspofungin|50 mg IV daily
76069409|NCT00520234|Drug|Normal Saline|100 cc IV daily
76069410|NCT05560672|Other|Human Umbilical Cord blood mononuclear cells|Intravenous infusion of cord blood mononuclear cells
76069411|NCT00520468|Drug|Erythropoietin|40,000 units injected under the skin (SQ) weekly
76069412|NCT00520468|Drug|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
76069413|NCT00520468|Drug|G-CSF|300 mcg injected under the skin (SQ) two times per week
76069414|NCT00520468|Drug|Prednisone|60 mg per day for 7 days, taper over 1 month
76069415|NCT01908712|Drug|Lamazym|ERT, i.v. infusions weekly
76069416|NCT05622526|Drug|Group 1 or Experimental group|Capsules of fecal microbiota transplantation
76069417|NCT05622526|Other|Group 2 or Control group|capsules of placebo
76069418|NCT05560438|Device|Tyromotion Amadeo and Armeo Senso|Robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso
76069419|NCT05622448|Other|RPD with PEEK framework|removable partial denture with CAD designed PEEK framework
76069420|NCT05622448|Other|RPD with metallic framework|removable partial denture with cobalt chromium framework
76069421|NCT05559268|Drug|Denosumab 60 MG/ML Injectable Solution [Prolia]|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
75760199|NCT06050070|Other|FMRI with real time feedback|During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.
75760200|NCT06048731|Device|Defibrillation using EV-ICD|Device: Defibrillation using the Extravascular ICD (EV-ICD)
75760201|NCT06047717|Other|Virtual Reality Driving Task|"Participants will steer a virtual car with the goal of staying in the center of a single-lane roadway while traveling at a constant speed of 26.6 m/s (approximately 60 miles/hr). The roadway alternates between a series of straights and turns of different radii to both the left and the right. This allows for careful control of task difficulty, and for the repeated presentation of specific conditions across multiple trials (i.e. turns in the road) in a randomized order. In addition, the density of the visual texture elements in the virtual environment that provide optic flow (OF) signal is also varied. The low-density OF condition has no road texture or foliage, and only the solid road edges on a flat-black ground plane. The medium-density OF condition has sparse textural elements distributed on the ground plane, and the high-density OF condition has high density road texture and a canopy of road-side trees that provide texture extending far above the horizon."
75760202|NCT06046820|Drug|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
75760203|NCT06046820|Drug|Control Arm (Conventional Therapy)|Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.
75760204|NCT06045650|Other|baseline serum oxytocin levels|Both cases and controls will be assessed for their baseline serum oxytocin levels
75760205|NCT06045650|Other|Emotional Sensitivity test|To assess the level of emotional sensitivity in the participant
75760206|NCT06045650|Other|Neuro-economical game|A game played to assess the trust-index of participants
75904931|NCT05288452|Behavioral|Remote Patient Monitoring (RPM)|The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
75904932|NCT05288452|Behavioral|Diabetes Education Class|The diabetes education class will be administered by a certified diabetes educator.
75904933|NCT05282654|Behavioral|ePRO Application|The intervention consists of a patient portal, EHR-integrated web-app to communicate risk of post-discharge adverse events using patient-reported outcome questionnaires, discharge preparation checklist during hospitalization. After discharge, the intervention will provide real-time symptom monitoring using ePROs and facilitate communication with clinicians based on prediction model-informed ePRO score trends exceeding escalation thresholds.
75904934|NCT05252988|Drug|Neratinib|Neratinib orally once daily for 13 cycles, unless patient discontinues earlier.
75904935|NCT05252988|Drug|Loperamide|Loperamide orally.
76069422|NCT05559268|Drug|Placebo|1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
76069423|NCT02338960|Drug|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
76069424|NCT02338960|Drug|Placebo|Placebo
75458813|NCT01813006|Drug|Omega-3|
75458814|NCT01813006|Drug|placebo|
76069425|NCT05622214|Dietary Supplement|Else nutrition formula|Plant based nutrition from almond and buckwheat
75458815|NCT01813032|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
75458816|NCT01813032|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
75458817|NCT01813045|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
75904936|NCT05252988|Drug|Colesevelam|Colesevelam capsules orally, 2 times a day for the first month (28 days).
75904937|NCT05251363|Device|Solia S lead|The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
75904938|NCT05247333|Other|Minor ailment service|The service had several components: agreed standard operational procedures between community pharmacists and primary care physicians for 31 minor ailments, IT based consultation protocol and training before and during the study for the pharmacists. Practice change facilitators were used to confirm the fidelity of the intervention.
76069426|NCT05621902|Other|Weekly symptom monitoring|Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
76069427|NCT02121418|Drug|Cytarabine|Given IV
76069428|NCT02121418|Drug|Decitabine|Given IV
75904939|NCT05243563|Device|MonaLisa Touch|3 laser treatments at 6 week intervals for 6 months by a single trained operator
75611200|NCT01008423|Drug|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
75611201|NCT01008423|Drug|Placebo|Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
75611202|NCT02872077|Other|Auricular acupuncture|
75904940|NCT05243563|Drug|Topical steroid|self-applied topical steroid therapy using clobetasol propionate 0.05%
75611203|NCT04296825|Dietary Supplement|Camel milk containing Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
75611204|NCT04296825|Dietary Supplement|Camel milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
75611205|NCT04296825|Dietary Supplement|Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
75611206|NCT04296825|Dietary Supplement|Cow milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
75611207|NCT01012947|Behavioral|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
75611208|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
75904941|NCT05208164|Behavioral|Mindfunlness Meditation|Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms
75904942|NCT05207462|Behavioral|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
75611209|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
75611210|NCT01012947|Behavioral|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
75611211|NCT01012947|Behavioral|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
75611212|NCT00627627|Drug|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
75611213|NCT04296513|Diagnostic Test|High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by
75611214|NCT04296513|Diagnostic Test|High-definition magnification with digital chromoendoscopy.|Subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
75760207|NCT06045650|Other|Childhood Trauma Questionnaire|to assess childhood trauma score
75760208|NCT06045650|Other|Relationships Questionnaire|to assess attachment type
75760209|NCT06045650|Other|demographic questionnaire|To obtain basic data on demographics
75760210|NCT06044233|Drug|STI-1558|STI-1558 test preparation and reference preparation
75760211|NCT06043297|Drug|Apixaban 5MG|Each film-coated tablet contains 5 mg apixaban
75760212|NCT06043297|Drug|Eliquis 5 mg|Each film-coated tablet contains 5 mg apixaban
75760213|NCT06038916|Drug|STSA-1002 Injection Placebo|Intravenous infusion
75760214|NCT06038916|Drug|STSA-1002 Injection|Intravenous infusion
75904943|NCT05206279|Drug|Ureteral injection of Indocyanine Green Powder (diluted)|The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
75904944|NCT05205291|Drug|Lipopolysaccharide|All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with [11C]PBR28 and four hours before the second PET/MR scan with [11C]PBR28.
75904945|NCT05205291|Radiation|PET/MR with [11C]PBR28|A PET/MR scan using the tracer [11C]PBR28 will be performed to all participants before and four hours after the administration of LPS
76069429|NCT02121418|Other|Laboratory Biomarker Analysis|Correlative studies
75611215|NCT03832153|Procedure|thrombus aspiration|Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
75760215|NCT06035939|Behavioral|Voice Crisis Alert V2|The mHealth self-management intervention consists of the following components: 1) condition-specific electronic educational materials; 2) pain/symptom monitoring and tracking; 3) health history information documentation; 4) medication tracking; 5) secure messaging with a provider; 6) functioning monitoring and tracking; and 7) transmission of health information (graphs with recorded pain and functioning histories) to a provider.
75760216|NCT06035939|Behavioral|Electronic educational materials|The control arm will receive enhanced usual care, which will consist of usual educational materials distributed at the clinic plus a version of the intervention (Voice Crisis Alert V2) that only includes the electronic educational materials.
75611216|NCT04735861|Drug|Sintilimab|Sintilimab 200mg iv. q3w, up to 2 years.
75904946|NCT05200468|Other|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
75904947|NCT05200468|Other|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
75904948|NCT05200468|Other|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
75904949|NCT05197790|Device|FDA approved pulse oximeter and DOVE device prototype|The objective is to assess reasonable detection of hypoxic episodes
75458818|NCT01813045|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
75458819|NCT01813045|Radiation|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
75458820|NCT01813084|Drug|RV1729 single dose|Safety and tolerability of single escalating doses
76069430|NCT01441635|Drug|Elagolix|Elagolix tablets
75611217|NCT04735861|Drug|Bevacizumab Biosimilar IBI305|Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
75611218|NCT04395859|Procedure|Questionnaire|At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
75611219|NCT04395859|Other|Data collection up to 1 year|Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
75458821|NCT01813084|Drug|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
75458822|NCT01813084|Drug|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
75458823|NCT01813084|Drug|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
75458824|NCT01813123|Behavioral|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
75458825|NCT01813136|Drug|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
75611220|NCT02693275|Device|Quotient® System iPad Test|See arm/group description
75611221|NCT04152031|Other|Prompting|Participants receive medication reminders on a smartphone. The reminders are generated through machine learning algorithms that automate the process of medication prompting according to successful medication contexts that occurred in the past.
76069431|NCT01441635|Drug|Placebo|Matching placebo tablets
76069432|NCT01441635|Drug|Estradiol/Norethindrone acetate (E2/NETA)|A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.
76069433|NCT01441635|Drug|Estradiol|1.0 mg micronized estradiol tablets administered once a day
76069434|NCT01441635|Drug|Progesterone|Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle
75611222|NCT03717571|Diagnostic Test|Glenohumeral translation assessment|amount of glenohumeral translation under load
75611223|NCT03685747|Drug|Vancomycin|Vancomycin one-time 20 mg/kg intraperitoneal dose.
75611224|NCT00614341|Device|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
75611225|NCT02692573|Other|positioning|prone positioning for the initial 5 minutes of life
75760217|NCT06034184|Other|Virtual Reality|The nursing students use glasses and handcontrollers (High Fidelity Simulation) in the VR scenario for training and learning mass casualty incidents.
75611226|NCT02692573|Other|positioning|supine positioning for the initial 5 minutes of life
75760218|NCT06031181|Procedure|Sublobar Resection|Sublobar Resection includes segmentectomy and wedge resection
75760219|NCT06029712|Drug|Heart failure polypill|Copackaging of once-daily heart failure medications (beta blocker, SGLT2i, and MRA) in an overencapsulated polypill. Individual tablets will be hand-packed into a single capsule at the level of the pharmacy. Specific medications and doses will be individualized to the participant.
75760220|NCT06029712|Drug|Control Rx|GDMT delivered as individual tablets
76069435|NCT01408485|Device|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~IBI 1500T9 V1.43 RF Generator"
76069436|NCT01427907|Drug|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
76069437|NCT01427907|Drug|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
76069438|NCT03026595|Other|no intervention|no intervention
76069439|NCT02985333|Drug|Paclitaxel|Paclitaxel 170 mg/m(2) IV over 3 h d1
76069440|NCT02985333|Drug|Cyclophosphamide|Cyclophosphamide 200mgmg/m(2) IV d1,3,5
76069441|NCT02985333|Drug|Dexamethasone|Dexamethasone 20mg iv d1-4
76069442|NCT01427751|Drug|dexamethasone intravitreal implant|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
76069443|NCT01427751|Biological|ranibizumab|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
75458826|NCT01813136|Drug|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
75458827|NCT01813162|Drug|Tenofovir 1% gel|
75458828|NCT01813162|Drug|Vaginal product|
75611227|NCT04327921|Behavioral|Peer navigation social support for smoking cessation|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's. Also, motivational interviewing/guidance will also be used to determine whether enhanced treatment (using a Peer Navigator to navigate smoking cessation, obtain medication and treatment, improve adherence to treatment, and provide social support for quitting) will increase participant's quit attempts and smoking cessation rates.
75611228|NCT04327921|Behavioral|Standard Condition|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's.
75611229|NCT04154761|Procedure|Resection of inferior vena cava and reconstruction|Resection of inferior vena cava and reconstruction with primary repair, resection with autologous or prosthetic patch repair, and circumferential resection with graft replacement
75611230|NCT03586687|Drug|Triamcinolone|Ultrasound guided glenohumeral shoulder joint injection
76069444|NCT01920061|Drug|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
75611231|NCT04324099|Other|neuroimaging session (with simultaneously acquired eye-tracking)|neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
75760221|NCT06028750|Procedure|Dynamic Computer Assisted Surgery|Surgical navigation system (X-Guide guided surgery system) Navigation system X-Guide
75760222|NCT06028750|Procedure|Freehand|Freehand implant placement
75760223|NCT06027489|Behavioral|Music|In the second and third months, participants listened to a song that lasted 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song to be played was determined by examining the literature, the song was composed by researcher Juan Sebastian Martin-Saavedra and was named Occasio Adolore (Music Piece No. 5-559-355 and Phonogram No. 12-105-295) by the author copyright institution of Colombia. registered under. While the researcher is composing the song, it is to create a piece of music that will reduce the pain felt, activate positive emotions and relax the person. The composed song is available online within the scope of the published article (https://soundcloud.com/jss-martin/occasio-adolore).
76069445|NCT01920061|Drug|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m^2
76069446|NCT01920061|Drug|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m^2
76069447|NCT01920061|Drug|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
76069448|NCT01426425|Device|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
76069449|NCT02074995|Biological|BVS857|Group 1A&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
75760224|NCT06027489|Behavioral|Drawing Group|: In the second and third months, the participants will be asked to paint for 29 minutes and 32 seconds (the duration of the intervention was determined in parallel with the music group in order not to create variability between the groups) for four days (three days before menstruation and the first day of menstruation). The type of paint to be used in the drawn picture (dry pen, crayon or watercolor) is left to the availability of the participants, and it will be stated that they prefer colors and drawings that will raise their emotions, focus their drawings and feed positive emotions in the picture to be drawn.
76069450|NCT02074995|Other|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
76069451|NCT01426347|Drug|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
75760225|NCT06021054|Drug|VRDN-001 10 mg/kg Drug:|Drug: 5 Infusions of VRDN-001 10mg/ Placebo: 5 Infusions of placebo
76069452|NCT01426347|Drug|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
76069453|NCT01882465|Device|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
76069454|NCT01882465|Device|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
76069455|NCT01882465|Device|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
76069456|NCT04612309|Drug|Immunotherapy|patient treated with at least 1 immunotherapy administration
76069457|NCT04415983|Drug|Nitazoxanide|Nitazoxanide twice daily
75458829|NCT01813175|Other|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
76069458|NCT04415983|Drug|Clarithromycin|Klacid twice daily
76069459|NCT04415983|Drug|Metronidazole|Metronidazole twice daily
76069460|NCT04415983|Drug|Proton pump inhibitor|Omeprazoe twice daily
76069461|NCT01426269|Drug|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads), oral, one capsule daily in the morning
76069462|NCT01426269|Drug|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
75458830|NCT01813175|Other|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
75611232|NCT04324099|Other|Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))|The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
75611233|NCT04324099|Other|Social and Health Assessment (SAHA) questionnaire (for children)|Self reported survey assessing social and mental health with four aspects of parenting determined (parental involvement, parental warmth, parental control, and inconsistency of parenting).
75611234|NCT04324099|Other|Massachusetts Youth Screening Instrument (MAYSI-2) (for children)|"The Massachusetts Youth Screening Instrument (MAYSI-2) is a screening instrument developed for detecting mental health needs in youth aged 12-17. Designed as a low-cost, easily administered tool, it screens for multiple issues and can be administered in 10-15 minutes. It is divided into seven scales composed of 52 questions that are designed to detect alcohol/drug use, angryirritable behavior, depression-anxiety, somatic complaints, suicide ideation, thought disturbance, and traumatic experience. Youths answer YES or NO concerning whether each item has been true for them within the past few months."
76069463|NCT01426269|Drug|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
76069464|NCT01426113|Drug|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
76069465|NCT01426113|Drug|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
76069466|NCT01426113|Drug|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
75611235|NCT04324099|Other|Interpersonal Reactivity Index (IRI) (for children)|The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales
75611236|NCT04324099|Other|Youth Psychopathic Traits Inventory (YPI) (for children)|self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.
75611237|NCT04324099|Other|Reactive Proactive Questionnaire (RPQ) (for children)|The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
76069467|NCT01864603|Other|Universal ART in a streamlined care model|immediate ART start for all HIV+ in community with streamlined care
75458831|NCT01813175|Other|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
75458832|NCT01813188|Procedure|ABM seeded onto a porous TCP and DBM|"cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)"
76069468|NCT01864603|Other|Annual Community Health Campaigns|HIV and multi-disease testing for all community members
76069469|NCT01864603|Other|Targeted PrEP and Targeted testing interventions|
76069470|NCT01864603|Other|Baseline community-based HIV and multi-disease testing|HIV and multi-disease testing for all community members at baseline only
76069471|NCT01892293|Drug|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
75904950|NCT05180695|Drug|Pazopanib|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
75458833|NCT01813188|Procedure|autologous bone graft|autologous bone graft
76069472|NCT04415593|Dietary Supplement|High dose of peanuts|Patients will receive a high dose of ground peanuts (300 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
75760226|NCT06018792|Diagnostic Test|Molecular Culture|PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.
75458834|NCT01813201|Drug|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
75458835|NCT01813201|Drug|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
76069473|NCT04415593|Dietary Supplement|Low dose of peanuts|Patients will receive a low dose of ground peanuts (150 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
76069474|NCT01393899|Drug|Placebo|oral tablets twice daily
75611238|NCT04324099|Other|Emotion Regulation Questionnaire (for children)|10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
75611239|NCT04324099|Other|Basic Empathy Scale (BES) (for children)|The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.
75611240|NCT04324099|Other|Pubertal Development Scale (PDS) (for children)|self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
75458836|NCT01813240|Drug|Minocycline|
75458837|NCT01813240|Drug|placebo|
75458838|NCT01813253|Drug|Irinotecan|150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops
75458839|NCT01813253|Drug|Nimotuzumab|400mg IV once weekly until progression or unacceptable toxicity develops
75611241|NCT04324099|Other|Alabama Parenting Questionnaire (APQ) (for parents)|The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
75760227|NCT06017011|Other|Total contact cast|Total contact cast will be put on the patient at the diagnosis of Acute charcot neuroarthropathy and the patient will be followed till clinical remission and after that till 6months post clinical remission. F18 Fluoride PET scan and MRI of the foot with DWI and ADC sequence to be done at baseline, Clinical remission, 3months post clinical remission and 6months post clinical remission to quantitate the process of remission.
75760228|NCT06010966|Device|rTMS|intermittent theta-burst stimulation (iTBS)
75760229|NCT06003712|Behavioral|Mindfulness|Participants will engage in a 10-15 minute mindfulness exercise three times weekly for one month. This mindfulness exercise utilizes guided attention on the breath through an instructional video, aiming to cultivate calmness and alleviate stress.
76069475|NCT01393899|Drug|CP-690,550|oral tablets twice daily
75458840|NCT01813279|Other|the cell therapy|the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
75458841|NCT01813318|Drug|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
75458842|NCT01813318|Drug|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
75458843|NCT01813383|Other|There is not any intervention|
75458844|NCT01813396|Other|joint mobilization plus massage|
75458845|NCT01813396|Other|joint mobilization/shoulder physical activity guide|
75458846|NCT01813448|Drug|Fidaxomicin|oral
75458847|NCT01813448|Drug|Placebo|oral
75458848|NCT01813461|Drug|14C-labeled prodrug isavuconazonium sulfate|oral
75458849|NCT01813487|Drug|HBsAg vaccine with Entecavir|
75458850|NCT01813500|Other|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
75458851|NCT01813513|Drug|IDX719|50 mg tablet for oral administration
75458852|NCT01813513|Drug|Simeprevir|150 mg capsule for oral administration
75458853|NCT01813526|Other|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
75458854|NCT01813552|Drug|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
75611242|NCT04324099|Other|Inventory of Callous Unemotional Traits (ICU) (for parents)|24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits.The ICU has three subscales: Callousness, Uncaring, and Unemotional. The ICU is made up of statements with a 4-point Likert scale, ranging from 0 (Not at all true) to 3 (Definitely True), with higher scores indicating greater CU traits.
76069476|NCT01393899|Drug|CP-690,550|oral tablets twice daily
75611243|NCT04324099|Other|Child Behavior Checklist (CBCL) (for parents)|"The eight empirically-based syndrome scales are:~Aggressive Behavior~Anxious/Depressed~Attention Problems~Rule-Breaking Behavior~Somatic Complaints~Social Problems~Thought Problems~Withdrawn/Depressed. Higher scores indicate greater Problems."
75760230|NCT06003686|Behavioral|PVA Consumer Guide|"Subject's will receive education on the PVA consumer guide 3 times over the course of the study.~Each session will be approximately 10-15 minutes and will consist of a general review of the nutrition, exercise, and general healthy living guidelines content included."
75760231|NCT06003686|Behavioral|WebMD|Subject's will receive education on how to navigate the WebMD site and find information on health, exercise and nutrition 3 times over the course of the study. Each session will be approximately 10-15 minutes and will consist of a general review of the health and wellness content available on the website. At study completion, subjects in this group will be provided with the PVA guide and a brief orientation of the nutrition, exercise, and general healthy living guidelines content included in the guide.
75760232|NCT05997082|Other|Mindfulness Self-Compassion Course|This course is designed to reduce burnout and compassion fatigue among specialist rehabilitation providers. Course materials are adapted from the Center for Mindful Self-Compassion (CMSC).
75904951|NCT05180695|Drug|HDM201|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
75458855|NCT01813552|Drug|Omeprazole|40 mg delayed-release oral capsules, once daily
75904952|NCT05176951|Drug|Treprostinil Palmitil|Oral inhalation using a capsule-based dry powder inhaler device.
75904953|NCT05176951|Drug|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
75904954|NCT05157672|Dietary Supplement|Cinnamon (2 g)|oral capsules, 2 g
75904955|NCT05157672|Drug|Nicotine gum (2.5 mg)|gum, 2.5 mg
76069477|NCT01393743|Drug|Perampanel|
76069478|NCT01393743|Drug|Placebo comparator|
76069479|NCT02078193|Drug|Belatacept|Patients will be converted from their MMF to Belatacept
76069480|NCT01405911|Drug|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
76069481|NCT01405911|Drug|Placebo for Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
75458856|NCT01813552|Drug|Ritonavir|100 mg oral tablets, once daily
75458857|NCT01813565|Drug|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
75458858|NCT01813578|Other|Exercise|Intensive aerobic and muscle endurance exercise
75458859|NCT01813591|Drug|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
75611244|NCT04324099|Other|Griffith Empathy Measure (GEM) (for parents)|self-report 23-item measure of empathy in which the respondent answers each item on a nine-point Likert scale from strongly disagree to strongly agree
75760233|NCT05993026|Behavioral|Mental health course|The student course involves classroom-based teaching of eight lessons over eight weeks. The aim is to strengthen students' faith in their own abilities (self-efficacy) and ability to understand themselves and others (mentalization). In this way, students become better at entering into positive relationships and communities as well as better at handling everyday challenges both academically and socially. The student course includes teaching, exercises and training in simple tools for mastery and mentalization. The student courses in the classes are handled by staff close to the students and are based on both physical and digital material as well as an app for the students. The employees initially participate in a competency development course.
75760234|NCT05992311|Drug|Montelukast|This group will receive the montelukast treatment.
75760235|NCT05992311|Other|Placebo|This group will receive a placebo pill instead of montelukast
75760236|NCT05989802|Diagnostic Test|Oral swab molecular testing|Swab-based testing provides a non-invasive approach to collect respiratory specimens for TB testing. Data in adults suggests that swab-based testing could be valuable when sputum collection is not feasible or available.
75760237|NCT05989802|Diagnostic Test|Automated Cough Sound Analysis|Cough sounds can be collected through a mobile phone and tablet, and then analyzed with machine learning algorithms to predict TB.
75760238|NCT05989802|Diagnostic Test|Automated Lung Sound Analysis|Lung sounds can be collected with a non-invasive digital stethoscope, and then saved on a tablet or phone and analyzed by machine learning algorithms to predict TB.
75904956|NCT05157672|Drug|Letrozole (2.5 mg)|tablet, 2.5 mg
75904957|NCT05152758|Device|PARx|Prescription Physical Activity Programming Application
75904958|NCT05147454|Other|Quantitative Sensory Testing|Non-invasive assessment of Sensory Profile
75904959|NCT05147090|Drug|Empagliflozin 10 MG|Empagliflozin 10mg daily
76069482|NCT01405911|Drug|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
76069483|NCT01405911|Drug|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
76069484|NCT01425801|Drug|LAS100977 0.313 μg|Dry powder inhalation, once-daily, single-dose
76069485|NCT01425801|Drug|LAS100977 0.625 μg|Dry powder inhalation, once-daily, single-dose
76069486|NCT01425801|Drug|LAS100977 1.25 μg|Dry powder inhalation, once-daily, single-dose
76069487|NCT01425801|Drug|LAS100977 2.5 μg|Dry powder inhalation, once-daily, single-dose
76069488|NCT01425801|Drug|Salbutamol 400 μg|Pressurized inhalation suspension, once-daily, single-dose
75611245|NCT04324099|Other|Social Responsiveness Scale (SRS) (for parents)|Social Responsiveness Scale (SRS) measures social ability of children from 4 years to 18 years old. It is used primarily with individuals with Autism Spectrum Disorder (ASD), family members of individuals with ASD, and others who have social impairments. Parent or teacher questionnaire (65 items on a 4-point Likert scale). High scores are associated with more severe social impairments.
75760239|NCT05989802|Other|Chest X Ray Computer Aided Detection|Several artificial intelligence algorithms have been developed to predict TB, though this has not yet been validated in children.
75760240|NCT05989737|Behavioral|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods & Twohig, 2008).
75760241|NCT05987007|Device|Acoustic slow-wave activity enhancement|The acoustic enhancement of slow-wave activity will be conducted using the Dreem2 headband. This device utilizes five dry-EEG electrodes (O1, O2, FpZ, F7, and F8), a 3D accelerometer, and a pulse oximeter to detect slow-wave activity and generates acoustic stimulation of slow-waves to augment slow-wave sleep.
76069489|NCT01425801|Drug|Salbutamol placebo|Pressurized inhalation, once-daily
75458860|NCT01813604|Biological|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
75904960|NCT05147090|Drug|Placebo pills|Identical in appearance to empagliflozin 10mg daily
75904961|NCT05137639|Procedure|Platelet-rich fibrin (PRF)|PRF was only applied in the experimental arm to improve wound bed conditions
75760242|NCT05987007|Behavioral|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia (CBTI) is a well-established first-line or complimentary treatment for insomnia which consists of cognitive and behavioral modifications, including addressing maladaptive sleep-related behaviors, controlling sleep environment, and limiting time spent in bed.
75760243|NCT05984381|Drug|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) orally
75760244|NCT05984381|Drug|Dapsone|Dapsone 100 mg/day
75760245|NCT05984381|Drug|Methotrexate|Methotrexate 15 mg weekly
75760246|NCT05978141|Other|Optional Blood Sample and Nail Sample|Participants may provide optional research blood and nail samples for biobanking and future use
76069490|NCT01425801|Drug|LAS100977 placebo|Dry powder inhalation, once-daily
75904962|NCT05121012|Other|Study procedures|"All participants will undergo a collection of demographic data, a neurological examination and administration of clinical scales relevant for MSA-P. All participants will undergo a collection of venous blood sample for routine analyses.~Participants will undergo one PET scan with the tracer [11C]UCB-J, and one PET scan with the tracer [18F]FDG. All participants will also undergo one MRI scan.~Participants will also undergo one lumbar puncture (optional).~All procedures will be performed at baseline and after one-year follow-up."
75904963|NCT05115747|Other|weight off-loading aerobic exercise training.|"Mild to moderate intensity weight off-loading aerobic exercise training on the anti-gravity Alter-G treadmill. (speed 8-12 mph, 50%-70% heart rate reserve HRR, 12-16 score on the Borg's scale)"
75458861|NCT01813604|Biological|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
75458862|NCT01813604|Biological|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
75611246|NCT03584737|Diagnostic Test|rapid in vitro diagnostic test|IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
75611247|NCT03584737|Diagnostic Test|bacterial culture|Quantitative bacterial culture assay with isolate identification by MALDI-TOF.
75611248|NCT03584737|Diagnostic Test|PCR assay|Semiquantitative real-time PCR assay
75611249|NCT01214603|Drug|LY2090314|Administered intravenously
75611250|NCT02692729|Procedure|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
75760248|NCT05965609|Behavioral|CBTI|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
75760249|NCT05965609|Behavioral|MRTI|Intervention includes education about sleep and behavioral and relaxation strategies to improve sleep
75904964|NCT05112575|Radiation|Postoperative imaging with magnetic resonance imaging or computed tomography|Postoperative imaging control with magnetic resonance or computed tomography after craniotomy for vascular or neurooncological operations.
76069491|NCT03025503|Other|nipple stimulation|
76069492|NCT02335125|Behavioral|Motivational Interviewing|
76069493|NCT02335125|Behavioral|Cognitive Behavioral Therapy Elements|
76069494|NCT02335125|Drug|Psychotropic Drugs|
76069495|NCT02335125|Other|Care Management|
76069496|NCT01425723|Biological|rFIXFc|Administered as specified in the treatment arm.
76069497|NCT02076243|Drug|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
76069498|NCT01424397|Drug|SB-705498|12mg intranasal
76069499|NCT01424397|Drug|FP|200ug intranasal
75611251|NCT02692729|Procedure|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
75760250|NCT05965011|Other|Exercise training|The intervention will be a combination of both supervised and unsupervised sessions. Participants in the Nordic Walking (NW) treatment group will attend 5 one-hour group sessions, which will incorporate coaching principles.
75760251|NCT05962242|Radiation|Radiation Therapy|External Beam Radiation to Head and Neck
75760252|NCT05961956|Drug|NVDX3|NVDX3 is implanted during a single surgical intervention.
75760253|NCT05958121|Biological|IMA402 (Phase Ia)|Intravenous infusions in escalating dose levels
75760254|NCT05958121|Biological|IMA402 (Phase Ib)|Treatment at MTD and/or RDE (Phase Ib)
75760255|NCT05958121|Biological|IMA402 (Phase II)|Treatment at MTD/RDE based on a manageable/favorable safety profile and initial signs of anti-tumor activity of selected ISEC (Phase II)
75760256|NCT05957536|Biological|D3L-001|Intravenous administration
75760257|NCT05957211|Drug|0.09% cyclosporine A ophthalmic solution|Cequa is an ophthalmic solution used to treat moderate to severe dry eye disease. The typical dosage is one drop in each eye, twice a day. The drug is packaged in sterile, single use bottles.
75904965|NCT05104229|Drug|Aspirin 81Mg Ec Tab|Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
75904966|NCT05104229|Drug|Standard of Care|Standard of Care VTE prophylaxis
75760258|NCT05951166|Device|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure
75904967|NCT05103436|Other|TENS|Electrical nerve stimulation
75458863|NCT01813604|Biological|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
75458864|NCT01813604|Biological|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
75458865|NCT01813617|Drug|Immunosuppressive Agents|Patients in the cohort received medical treatment according to standard care.
75458866|NCT01813630|Drug|DA-3002|
75458867|NCT01813630|Drug|Genotropin®|
75904968|NCT05089734|Biological|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
75904969|NCT05089734|Drug|Docetaxel|Administered intravenously
75458868|NCT01813643|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
75904970|NCT05076500|Procedure|Biopsy and blood sample collection|"A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy [irradiated site]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected."
75458869|NCT01813643|Drug|Aripiprazole|Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
75458870|NCT01813656|Drug|Aripiprazole|Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
75458871|NCT01813656|Drug|placebo|placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
75611252|NCT02692807|Procedure|Arthroscopic surgical procedures|See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
75611253|NCT04308889|Drug|Lovaza|Lovaza contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources.
75760259|NCT05948462|Drug|Lorlatinib|Participants will receive assigned dose of daily oral lorlatinib continuously for each cycle. Each cycle is 3 weeks.
75760260|NCT05948462|Drug|Cisplatin or Carboplatin|Participants will receive standard of care intravenous Cisplatin or Carboplatin, both chemotherapy medications, on day 1 of each cycle every 3 weeks, for Cycles 1-4. Each cycle is 3 weeks.
75760261|NCT05948462|Drug|Pemetrexed|Participants will receive intravenous Pemetrexed, a chemotherapy medication, on day 1 of each cycle. Each cycle is 3 weeks.
75904971|NCT05067777|Procedure|Massage Therapy|Receive SMT
75904972|NCT05067777|Other|Questionnaire Administration|Ancillary studies
75904973|NCT05067777|Procedure|Sham Intervention|Receive light touch control procedure
75904974|NCT05057247|Drug|Duvelisib|"Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months."
75904975|NCT05057247|Drug|Docetaxel|Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months
75904976|NCT05055063|Drug|Belantamab mafodotin|by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
76069500|NCT01424397|Drug|placebo|placebo intranasal
75458872|NCT01813682|Other|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
75904977|NCT05051033|Procedure|Mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.
75904978|NCT05051033|Device|Transcatheter edge-to-edge repair|Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
76069501|NCT01392963|Drug|botulinum toxin type A neurotoxin complex|29-40 U injection
75611254|NCT04308889|Other|Cantharone|Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.
75611255|NCT04308889|Other|Phlebotomy|Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.
75611256|NCT01212185|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
76069502|NCT01392963|Drug|Placebo|29-40 U 0.9% NaCl injection
75611257|NCT01212185|Other|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
75611258|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
75611259|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
75904979|NCT05049096|Device|focused power ultrasound mediate inferior perirenal adipose tussue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
76069503|NCT01392573|Drug|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
76069504|NCT01392573|Drug|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
76069505|NCT01392495|Drug|Imatinib|200 mg or 400 mg qd
76069506|NCT01405053|Drug|Rufinamide|Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
76069507|NCT01405053|Drug|Any other approved Antiepileptic Drug|Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
76069508|NCT01403805|Biological|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
76069509|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
76069510|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
75458873|NCT01813682|Other|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
75458874|NCT01813708|Behavioral|Intensive Life-Style|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
75458875|NCT01813708|Behavioral|Collaborative Education|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
75611260|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
75760262|NCT05945277|Behavioral|Critical Time Intervention - Peer Support|CTI-PS is a time-limited, 9-month long intervention, provided at the critical time when a person is discharged from an inpatient psychiatric treatment facility.
75904980|NCT05049096|Device|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
75611261|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
75904981|NCT05042479|Other|Usual distraction and pain prevention techniques.|"For the first painful procedure, the child will benefit usual distraction and pain prevention techniques.Pain prevention and management techniques commonly used in the conduct of care:~Application of a patch or anaesthetic cream 1 hour before the treatment~Vigilant sedation using a premedication for lumbar punctures: Midazolam /Nalbuphine/Hydroxyzine/Morphine.~Apart from care using VR, MEOPA can be given to the child for all assessed care on prescription.~Apart from care using VR, the usual distraction techniques are left to the patient's choice (electronic tablet, smartphone, games, songs...)~The presence of the parents"
75611262|NCT03626233|Other|collect of placenta, blood and urinary samples at delivery|collect of placenta, blood and urinary samples at delivery
75458876|NCT01813747|Device|1440 nm wavelength laser with handpiece (Cynosure)|To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
75611263|NCT04460131|Diagnostic Test|soluble ST2|Serum sST2 was measured on a monoclonal electrochemiluminescence immunoassay. Samples were exposed to two freeze cycles before analysed. Samples were exposed to two thawfreeze cycles before analysed.
75611264|NCT04424797|Other|Prone Positioning|Intervention is patient in prone positioning
75611265|NCT04424797|Other|Supine Positioning|Intervention is patient in supine positioning
75458877|NCT01813760|Device|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
75458878|NCT01813773|Drug|Intravitreal Aflibercept Injection (IAI)|EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
75458879|NCT01813786|Device|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
75458880|NCT01813786|Device|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
75611266|NCT03369301|Drug|Gammanorm|Gammanorm given per standard of care
75611267|NCT03369301|Drug|Other Subcutaneous Immunoglobulins|Other Subcutaneous Immunoglobulins given per standard of care
75611268|NCT00614419|Device|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
75611269|NCT00614419|Device|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
75611270|NCT03229915|Behavioral|cognitive processing therapy|Group therapy for PTSD patients
75611271|NCT05345431|Device|endovascular denervation|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
75611272|NCT05345431|Device|PTA|Treating with balloon dilation or stent implantation
75760263|NCT05939999|Other|Experimental: Elastic tape (ET)|The elastic tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
75458881|NCT01813786|Device|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
75458882|NCT01813799|Drug|DA-9801 300mg|300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
75458883|NCT01813799|Drug|DA-9801 600mg|600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
75458884|NCT01813799|Drug|DA-9801 900mg|900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
75458885|NCT01813799|Drug|Placebo|Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
75458886|NCT01813812|Drug|DA-6034|
75760264|NCT05939999|Other|Sham Comparator: Sham (SH)|The micropore tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
75760265|NCT05934604|Other|Functional magnetic resonance imaging (fMRI)|Healthy subjects will complete two fMRI sessions after initial assessment and training in the Rest Focus Task (RFT). The first session will be the localizer session to identify the networks involved in switching in the RFT. The second fMRI session, real time functional magnetic resonance imaging neurofeedback (rtfMRI-NF) session, will use localizer information from the first fMRI session to develop a mask for the rtfMRI-NF, and deliver a neurofeedback (NF) stimulus while simultaneously measuring Blood Oxygenation Level Dependent (BOLD) activity for the STOP>RECALL contrast.
75760266|NCT05930886|Other|Focus Group|Black or Hispanic/Latino parents, caregivers or family members of children with ADHD symptoms and/or emotional dysregulation, will discuss: (1) impact of child's mental health, treatments, care received; (2) perceived and actual barriers to future study participation, including discussion about acceptability of bio-specimen collection methods for urine and blood. Each group will comprise individuals who self-identify as Hispanic/Latino, Black, or mixed race. Groups are anticipated to comprise individuals who identify with one or the the other race/ethnicity in order to create space to hear perspectives that may differ between these broadly defined groups.
75760267|NCT05925088|Other|Focus group|Participants will take part in a 1 hour focus group.
75760268|NCT05923424|Drug|REGN17092|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
75760269|NCT05923424|Drug|Matching Placebo|Single ascending IV or SC administration per the protocol
75760270|NCT05911399|Drug|Tiratricol|Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.
75760271|NCT05910619|Device|Neurolith Transcranial Pulse Stimulation Active|5hz (200-300 milliseconds) stimulation pulses transcranial pulse stimulation (TPS) will be applied to each of the following five regions twice per session in sequential order with the specified stimulation parameters: left dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses), right dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses; ROI volume ~136/164 cms), the left lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume ~122/147 cms), the right lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume ~122/147 cms), and the extended precuneus cortex (2x600 pulses; ROI volume 66/92 cms). With a repetition time of 5hz (0.00333 seconds) per pulse at a total of 6,000 pulses per participant, the duration of stimulation is about 20 minutes, not including transition time between ROI localization.
75904982|NCT05042479|Other|Virtual reality|For the 2nd painful procedure, the child will use a VR (virtual reality) headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age.
75458887|NCT01813812|Drug|Rebamipide 300mg|
75458888|NCT01813825|Other|Registry|
75458889|NCT01813838|Drug|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
75458890|NCT01813838|Drug|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
75458891|NCT01813838|Drug|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
75611273|NCT05345275|Other|The facial expressions analyzed|The facial expressions associated with pain were analyzed by the researchers in the OpenFace program. The patient's pain scores were estimated in the Python program by combining the numerical outputs of facial expression analyses with machine learning algorithms.
75611274|NCT01995175|Procedure|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
75611275|NCT01995175|Procedure|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
75458892|NCT01813851|Device|Exercise training in addition to nutritional support|
75611276|NCT01995175|Other|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
75760272|NCT05910619|Device|Neurolith Transcranial Pulse Stimulation Sham|The intervention procedure described in the Active condition above will also be repeated in participants randomized to the Sham procedure, with the exception of the insertion of a lens over the device by the interventionist to prevent stimulation from reaching the brain.
75760273|NCT05909085|Device|Traditional ultrasound|Labor epidural will be performed after marking patient skin using traditional ultrasound guidance
75760274|NCT05909085|Device|Automated ultrasound|Labor epidural will be performed after marking patient skin using an automated ultrasound device
75760275|NCT05908292|Procedure|Pelvic Floor Scar Tissue Self-Scar Massage|Self scar-massage intervention of healed pelvic floor scar tissue for 5 minutes, 3x/week for 6 weeks.
75760276|NCT05906797|Procedure|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
75760277|NCT05903196|Device|Mygen V-1000 RF system|The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation & ablation of vessel, tissue & bone
75611277|NCT03611101|Combination Product|¹³C-Methacetin Breath Test|A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
75760278|NCT05897541|Drug|S-217622|Administered as a tablet.
75760279|NCT05897541|Drug|Placebo|Administered as a tablet.
75760280|NCT05894109|Dietary Supplement|zinc citrate 50 mg|will take zinc citrate 4 days before and 1 week after botulinum toxin injection
75760281|NCT05894109|Other|Placebo Microcrystalline Cellulose|will take placebo 4 days before and 1 week after botulinum toxin injection
75611278|NCT03611101|Drug|BMS-986036|Investigational drug for NASH treatment in Main BMS protocol
75760282|NCT05892757|Drug|Atogepant|Oral Tablet
75458893|NCT01813877|Radiation|FDOPA PET/CT|Positron emission tomography (PET) is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of substances (tracers) that are injected via a hand or arm vein. These substances can track certain features of cancers that can be visualized by using the PET/CT scanner, in this instance the amino acid 18F-DOPA.
75760283|NCT05892757|Drug|Ubrogepant|Oral Tablet
75760284|NCT05888337|Device|Contoura LASIK with Phorcides planning strategy|Bilateral treatment with topography guided LASIK
75760285|NCT05888337|Device|Contoura LASIK with manifest refraction planning strategy|Bilateral treatment with topography guided LASIK
75760286|NCT05887544|Other|Exposure: Plant-based diet pattern|From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.
75760287|NCT05887544|Other|Intervention: Fermented dairy products|1000g of the product to be consumed 1-2 days prior to spot urine sample.
75760288|NCT05887544|Other|Exposure: individual foods and food groups|From the dietary records, average intake of specific foods or food groups will be calcualted.
75458894|NCT01813903|Behavioral|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
75458895|NCT01813903|Behavioral|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
75611279|NCT03611101|Device|BreathID MCS device|The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate.
75611280|NCT05345119|Drug|Sirolimus|2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
75611281|NCT05345119|Drug|Methylprednisolone|500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
75611282|NCT03529123|Drug|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
75458896|NCT01813916|Other|proteomic analysis|
75458897|NCT01813955|Drug|Papaverine or placebo|Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
75458898|NCT01813981|Dietary Supplement|Low roast coffee|Instant coffee
75611283|NCT03529123|Drug|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
75611284|NCT03529123|Drug|Metformin|"Pharmaceutical form: Tablet~Route of administration: Oral"
75760289|NCT05886244|Drug|Eculizumab|Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
75760290|NCT05882058|Drug|BI 764532|BI 764532
75760291|NCT05879744|Drug|CLN-978|CD19xCD3 T cell engager
75760292|NCT05876923|Procedure|Biospecimen Collection|Undergo collection of blood
75760293|NCT05876923|Other|Cardiopulmonary Exercise Testing|Undergo CPET
75760294|NCT05876923|Procedure|Dual X-ray Absorptiometry|Undergo DEXA scan
75760295|NCT05876923|Other|Electronic Health Record Review|Ancillary studies
75760296|NCT05876923|Other|Exercise Intervention|Undergo aerobic based training program
75760297|NCT05876923|Procedure|Physical Examination|Undergo measurement of height/weight and vital signs
75760298|NCT05876923|Other|Quality-of-Life Assessment|Ancillary studies
75760299|NCT05876923|Other|Questionnaire Administration|Ancillary studies
75760300|NCT05876923|Procedure|Spirometry|Undergo spirometry
75760301|NCT05876923|Other|Physical Performance Testing|Undergo muscular strength and functional endurance measurements
75760302|NCT05876923|Other|Best Practice|Receive usual care
75760303|NCT05872204|Drug|Abemaciclib|150 mg tablet twice daily
75760304|NCT05872204|Drug|Letrozole|2.5 mg tablet once daily
75760305|NCT05870566|Device|Corneal Crosslinking|"Riboflavin solution (0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2.~To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device with maximal diameter of 11 mm will be used. Additionally, the limbal area will be protected by a custom-cut limbal stell cell protection shield."
75760306|NCT05865561|Other|VOC sampling|"Systematic sampling during the day: Samples every 3 hours (9am, 12pm, 3pm, 6pm, 9pm) until the end of the follow-up period.~Sampling in case of epileptic seizure : Sampling during the seizure (from t0 to t+5 min), whatever the time.~The samples will be taken using a compress on the forehead, the palms of the hands and the back of the neck. The compress will then be placed in a freezer bag and the person with epilepsy will be asked to exhale into the bag, if he/she is able to do so, before closing it."
75760307|NCT05862467|Behavioral|Written Exposure Therapy (WET) via telehealth|Written Exposure Therapy (WET) via telehealth
75760308|NCT05854927|Diagnostic Test|3D T1 MRI sequences injected with fat saturation and black blood|3D T1 MRI sequences injected with fat saturation and black blood
75760309|NCT05854667|Drug|Treatment as Usual plus Placebo|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
75760310|NCT05854667|Drug|Treatment as Usual plus Placebo plus Contingency Management|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
75760311|NCT05854667|Drug|Treatment as Usual plus lisdexamfetamine (LDX-01)|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15)."
75760312|NCT05854667|Drug|Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13."
75760313|NCT05852691|Drug|Tobemstomig|Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
75760314|NCT05852691|Drug|Pembrolizumab|Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
75611285|NCT03529123|Drug|Insulin Glulisine (HMR1964)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
75760315|NCT05852691|Drug|Nab-Paclitaxel|Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
75760316|NCT05848583|Other|Compleat 1.5|EN Formula
75760317|NCT05847699|Other|MRI sequences and biopsies|Addition of a contrast injection and optimized SWI sequences during the pre-DH MRI examination performed as part of the care Addition of two 1x1 cm biopsy samples of cortex in two different non-functional ischemic areas, one of which is within the SWI hyposignal remodeling, during the DH. This will be a cold pial dissection without the use of coagulation.
75760318|NCT05844137|Behavioral|NAFLD Education|NAFLD Education
75760319|NCT05844137|Behavioral|diet/lifestyle support|diet/lifestyle support
75760320|NCT05844137|Drug|T2D medication management|T2D medication management
75611286|NCT04074187|Drug|Caplacizumab (ALX-0081)|Pharmaceutical form:Lyophilized powder for solution for injection Route of administration: IV (first dose), SC (all subsequent doses)
75611287|NCT04074187|Drug|Plasma exchange (PE)|Pharmaceutical form:Plasma (e.g. fresh frozen plasma) Route of administration: Plasma exchange
75611288|NCT04074187|Drug|Corticosteroid treatment (Methylprednisolone or prednisolone)|Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
75611289|NCT04074187|Drug|Immunosuppressive treatment (eg, rituximab)|Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
75760321|NCT05844137|Diagnostic Test|clinically-indicated liver testing and care|clinically-indicated liver testing and care
75760322|NCT05841797|Behavioral|In-Person Program Management Plus (PM+)|PM+ sessions conducted via home visits from community mentor mothers
75760323|NCT05841797|Behavioral|Mobile Program Management Plus (mHealth PM+)|PM+ sessions conducted via phone
75760324|NCT05829356|Biological|H3 mRNA / LNP Vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular"
75760325|NCT05829356|Biological|Quadrivalent recombinant influenza Vaccine (RIV4)|"Pharmaceutical Form: Solution for injection in a pre-filled syringe~Route of Administration: Intra-Muscular"
75760326|NCT05826054|Dietary Supplement|Montbretin A|The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA).
75458899|NCT01813981|Dietary Supplement|High roast coffee|Instant coffee
75458900|NCT01813981|Dietary Supplement|Control (Caffeine dissolved in water)|Caffeine dissolved in water
75458901|NCT01813994|Drug|Arm1: Statin|"Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
75611290|NCT02670031|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
75611291|NCT02670031|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
75760327|NCT05825105|Biological|Platelet-Rich Plasma|The PRP will be prepared using a single centrifugation process. Approximately 30 ml of peripheral blood will be drawn and collected into a vacutainer tubes with sodium citrate anticoagulant 0.129 mol/l (3.8%). The tubes will then be centrifuged at 900 RPM for 12 minutes at room temperature in a benchtop centrifuge. We will separate the lower third of the plasma fraction from all tubes with a syringe and needle, taking care to avoid the leukocyte layer. The PRP will be refrigerated at 4°C for no less than 1 hour. We will not use any exogenous factors to stimulate the platelet activation process. The periauricular skin surface will be disinfected with a povidone iodine solution, and an intra-articular local anesthetic with 1% lidocaine will be applied. A 21-gauge needle will be placed at the point of application. Finally, PRP will be injected into the joint, and the needle will be removed.
75760328|NCT05820685|Drug|Standard of care|Participants in this arm will get acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, gabapentin 300 mg every eight hours, and Tramadol 50 mg every six hours as needed for breakthrough pain
75611292|NCT02670031|Other|Electrocardiogram|To examine specific function of the heart.
75760329|NCT05820685|Drug|Dronabinol|Participants in this arm will get Dronabinol 10 mg in addition to standard of care pain medication as needed for breakthrough pain
75611293|NCT02670031|Device|Ambulatory Blood Pressure Monitoring|A 24-hour test.
75904983|NCT05042479|Other|Choice between usual distraction or virtual reality|"For the 3rd painful procedure, the child will choose his/her favorite technique between :~Usual distraction and pain prevention techniques or virtual reality"
75904984|NCT05033184|Behavioral|Brief Action Planning Exercise|The Brief Action Planning exercise is a previously developed goal-setting exercise which has been designed to incorporate aspects of motivational interviewing such as compassion, acceptance, evocation, and partnership. It is a tool that allows participants to identify an aspect of their life they would like to improve upon and guides them through the process of making a specific, measurable, achievable, realistic, and timely (SMART) goal. It also assesses their confidence in achieving this goal so as to assist with making alternative plans if confidence is low.
75904985|NCT05033184|Behavioral|Goal Setting Exercise|The Goal Setting exercise allows participants to identify an aspect of their life they would like to improve upon without incorporating aspects of motivational interviewing components or providing any guidance on how to set this goal.
75904986|NCT05028075|Behavioral|Cobalt +|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
75904987|NCT05018273|Biological|VB10.NEO|The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.
75904988|NCT05010629|Drug|9-ING-41|Intravenous infusion
75904989|NCT05010629|Drug|Carboplatin|Intravenous infusion
75904990|NCT05010304|Drug|Amoxicillin|Two-dose amoxicillin challenge
75611294|NCT02670031|Other|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
75611295|NCT03128905|Drug|Colchicine opocalcium 1mg|"International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone."
75611296|NCT03128905|Drug|Prednisone : Cortancyl 20mg|"International non-proprietary name: Prednisone~Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.~Composition :~Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate."
75611297|NCT00613795|Dietary Supplement|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
75611298|NCT00613795|Dietary Supplement|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
75760330|NCT05813912|Drug|Insulin Icodec|Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.
75611299|NCT02430181|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
75611300|NCT02430181|Drug|peginterferon alfa-2a|immunomodulator
75611301|NCT02430181|Drug|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
75611302|NCT03100591|Drug|14C-radiolabeled ACT-132577|Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie [μCi]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
75611303|NCT00613873|Procedure|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
75611304|NCT00614653|Drug|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
75611305|NCT00614653|Drug|Erlotinib|100 mg by mouth Once Daily on days with radiation.
75611306|NCT00614653|Drug|Capecitabine|400 mg/m^2 PO Twice Daily on days with radiation.
75760331|NCT05813912|Drug|Semaglutide|Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
75760332|NCT05812664|Other|enteral feeding|The amount of enteral nutrition that should be given daily was calculated by the nutritionist using the Harris-Benedict formula. Formula at room temperature was given with a nasogastric foley catheter and a feeding pump. The position of the nasogastric Foley catheter in the stomach was confirmed by the PAAC graph when it was first inserted, and by listening before each feeding. Feeding was done in a position with the head at 30 degrees.
75760333|NCT05812664|Procedure|blood glucose measurements|Blood glucose values were measured in all groups at 06:00, 12:00, 18:00 and 24:00, 4 times a day for 7 days. The sample was taken from the patient's cannula and examined in the biochemistry lab. The targeted range in the measurements was accepted as 70-180 mg/dl.
75760334|NCT05812664|Procedure|Evaluation of feeding intolerance with gastric residue|gastric residue assessment; 30 minutes after the feeding was stopped, the N/G tube was drained and the amount coming 30 minutes later was evaluated. Residue positive was defined as the return of more than half of the amount of formula in the last cycle. The same was continued without increasing the amount given. If the incoming amount was less than half, the residue was evaluated as negative and the formula was continued by increasing the predetermined amount.
75760335|NCT05812352|Behavioral|Audio kit|MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application
75760336|NCT05812352|Behavioral|Instructional flashcard|Single page (instructional flashcard) with pictures corresponding to each of the 6 steps of tourniquet application
75611307|NCT00614653|Radiation|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
75760337|NCT05812352|Behavioral|In-person training|Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt
75760338|NCT05798611|Drug|ART0380|Randomized patients will orally receive ART0380.
75611308|NCT05344807|Diagnostic Test|Renal DMSA Scintigraphy|patient injected with Tc99mDMSA then imaged after 2-4 hours by gamma camera
75611309|NCT05344729|Drug|TQB3616 Capsule|It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
75611310|NCT03909451|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
75611311|NCT03909451|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
75611312|NCT03463135|Drug|Glucopyranosyl Lipid A (GLA)|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
75611313|NCT03463135|Drug|Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Pharmaceutical form:Solution Route of administration: Sublingual
75760339|NCT05789082|Drug|Divarasib|Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.
75760340|NCT05789082|Drug|Pembrolizumab|Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
75760341|NCT05789082|Drug|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles.
75760342|NCT05789082|Drug|Cisplatin|Participants will receive IV cisplatin Q3W for four 21-day cycles.
75611314|NCT03463135|Drug|Placebo for GLA|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
75611315|NCT03463135|Drug|Placebo for SLIT PE|Pharmaceutical form:Solution Route of administration: Sublingual
75611316|NCT03859765|Behavioral|HCT Symptoms and Steps|HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
75760343|NCT05789082|Drug|Pemetrexed|Participants will receive IV pemetrexed Q3W.
75760344|NCT05783167|Diagnostic Test|Self-sampling for HPV infection|After informed consent has been provided, the woman will be asked to collect firstly a first-void urine sample using the Collipee device and secondly to collect a vaginal self-sample using the dry Evalyn® Brush device. Socioeconomic, demographic and clinical data will be collected in the Bissau HIV Cohort database and through study questionnaires to collect background information on risk factors for HPV persistence and development of cervical cancer (HIV genotype, immune status, parity). Questionnaires will collect additional information on the acceptance of cervical screening measures to better evaluate the feasibility of implementing self-collected screening among HIV infected women in Guinea-Bissau.
75760345|NCT05780983|Behavioral|education and coaching on developing healthy nighttime sleep and daytime activity behaviors|The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
75760346|NCT05780879|Drug|Venetoclax|Venetoclax administered orally once daily on days 3-16.
75760347|NCT05780879|Drug|FLAG or CLAG Protocol|FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count >50,000 - 5mcg/kg; WBC count <50,000 - hold Tbo-filgrastim. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
75760348|NCT05779163|Drug|LBL-033 for Injection|Initial dose - MTD; Q2W; intravenous infusion
75760349|NCT05776862|Drug|Ursolic Acid|Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
75760350|NCT05776862|Other|Strength Training|Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session. Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets. The arm selected for exercise will be randomized.
75611317|NCT03596125|Drug|N-acetylcysteine|N-acetylcysteine supplementation
75611318|NCT03596125|Drug|Placebo|per os: jelly tablets Intravenous Route: Glucidion G5
75611319|NCT02118727|Drug|Memantine|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
75611320|NCT02118727|Drug|Placebo (for Memantine)|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
75611321|NCT05343637|Combination Product|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
75611322|NCT03776227|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
75611323|NCT03369613|Device|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
75611324|NCT00614809|Drug|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
75760351|NCT05776108|Drug|Cabotegravir IR Formulation (reference)|Cabotegravir IR Formulation (reference) will be administered.
75760352|NCT05776108|Drug|Cabotegravir DT Formulation (test 1)|Cabotegravir DT Formulation (test 1) will be administered.
75760353|NCT05776108|Drug|Cabotegravir DT Formulation (test 2)|Cabotegravir DT Formulation (test 2) will be administered.
75760354|NCT05768334|Drug|Lubiprostone 24Mcg Oral twice daily|"The patients will be randomized (closed envelopes) into one of two groups:~Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks."
75611325|NCT02964013|Biological|vibostolimab|Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
75611326|NCT02964013|Biological|pembrolizumab|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
75611327|NCT02964013|Drug|pemetrexed|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
75611328|NCT02964013|Drug|carboplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
75611329|NCT02964013|Biological|pembrolizumab/vibostolimab coformulation|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
75611330|NCT02964013|Drug|cisplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
75760355|NCT05761301|Drug|ALN-KHK|ALN-KHK will be administered by subcutaneous (SC) injection.
75760356|NCT05761301|Drug|Placebo|Placebo will be administered by subcutaneous (SC) injection.
75904991|NCT05008523|Behavioral|Opioids and Police Safety Occupational Risk Reduction Training (OPS)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
75611331|NCT02964013|Drug|etoposide|Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4
75611332|NCT03562741|Procedure|Fecal Microbiota Transplantation|Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
75611333|NCT01752907|Other|General Education DVD|A general chemotherapy side effects education DVD
75760357|NCT05758272|Behavioral|mobile phone-based simple physical exercise reminder to help quit smoking|Regular messages supporting participants in practicing simple physical exercises and assist in managing cravings will be sent to participants via IM apps and scheduled in a tapering manner for 3 months (twice per week in the first month to once per week in the third month). Images and videos explaining and demonstrating the simple physical exercises will be sent to the participants via IM apps, which serves as a reminder and supporting materials for participants. The benefits of exercise in SC will be explained. The investigator will also encourage the practice of moderate/ vigorous exercises to further improve the physical activity and well-being of the participants. Various delivery formats of messages will be considered to attract participants' interest such as text, emojis, voice, image, animation, and video. The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises and c) resistance exercises.
75760358|NCT05758272|Behavioral|regular text-based intervention|The control group will receive 6 regular messages via IM at twice per month within 3 months. These messages cover simple cessation advice and reminders for telephone follow-ups.
76069511|NCT01403805|Other|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
76069512|NCT01423617|Dietary Supplement|Zenoctil|3 tablets 2 times daily
76069513|NCT01423617|Other|Placebo|3 tablets 2 times daily
76069514|NCT01392183|Drug|Pazopanib|800 mg by mouth daily in 4 week study cycle.
75611334|NCT01752907|Other|Bone Pain Education DVD|
76069515|NCT01392183|Drug|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
75611335|NCT00614731|Biological|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
75611336|NCT02692261|Procedure|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
75611337|NCT02692261|Procedure|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
75611338|NCT03181087|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
75611339|NCT02704663|Procedure|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
75611340|NCT02704663|Procedure|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
75760359|NCT05751642|Biological|ALXN1920|Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.
75760360|NCT05751642|Biological|Placebo|Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.
75611341|NCT02526355|Behavioral|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
75760361|NCT05751642|Biological|ALXN1920|Participants will receive a single dose of ALXN1920 by SC infusion.
75611342|NCT03439189|Combination Product|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
75611343|NCT03439189|Drug|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
75611344|NCT03439189|Drug|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
75611345|NCT01211483|Drug|U3-1287|Liquid 70 mg/mL for IV infusion at high dose or low dose
75611346|NCT01211483|Drug|Erlotinib|Tablet 150 mg for oral administration
75611347|NCT01211483|Drug|Placebo|Placebo liquid matching U3-1287 for IV infusion
75760362|NCT05751642|Biological|ALXN1920|Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.
76069516|NCT01392183|Behavioral|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
76069517|NCT01392183|Drug|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
76069518|NCT02985489|Dietary Supplement|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
76069519|NCT01402947|Drug|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
76069520|NCT01402947|Drug|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
76069521|NCT03025893|Drug|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
76069522|NCT03025893|Drug|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
76069523|NCT01402869|Drug|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
75760363|NCT05742321|Genetic|Genotyping|Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).
75611348|NCT00615823|Drug|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
75760364|NCT05742321|Diagnostic Test|Histology|Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis
75760365|NCT05742321|Other|Collection of data|Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
75760366|NCT05732701|Other|Algorithm-guided DAPT duration|"PRECISE-DAPT score ≥25~Chronic Coronary Syndromes (CCS): Aspirin + clopidogrel for 1 month, followed by clopidogrel monotherapy~Acute Coronary Syndromes (ACS): Aspirin + ticagrelor for 1 month, followed by ticagrelor monotherapy~PRECISE-DAPT score <25:~Non-complex CCS: Aspirin + clopidogrel for 6 months, followed by clopidogrel monotherapy~Non-complex ACS: Aspirin + potent P2Y12 inhibitor for 6 months, followed by potent P2Y12 inhibitor monotherapy~Complex CCS or ACS: Aspirin + P2Y12 inhibitor for 12 months, followed by P2Y12 inhibitor monotherapy (potent P2Y12 inhibitor mandatory for ACS)"
75760367|NCT05732701|Other|Standard-of-care DAPT duration|DAPT strategy at the operators´ discretion in accordance with applicable guidelines
75760368|NCT05727488|Other|Exercise|Participants will be asked to practice home exercises every day of the week for 12 weeks. The SARAH exercise program consists of 7 mobility and 4 strengthening exercises. Progress will be made by increasing the repetitions and duration of the exercises every week.
75611349|NCT00615823|Drug|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
75611350|NCT02704195|Procedure|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
75611351|NCT02704195|Procedure|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
75611352|NCT02699281|Drug|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
75611353|NCT02699281|Drug|Placebo|um-PEA like placebo twice a day
75611354|NCT04320485|Diagnostic Test|Active Anthrax Detect™ Plus (AAD Plus)|A lateral flow immunoassay rapid test (AAD Plus) for early and presumptive diagnosis of inhalational anthrax.
75611355|NCT02699359|Device|HS-1000 recording|
75611356|NCT00615979|Device|Miniature echo machine|Images captured and real-time and store-and-forward file transfers performed
75611357|NCT02704507|Drug|Triamcinolone|topical application nightly to half the face for 4 weeks
75611358|NCT02704507|Drug|Tretinoin|topical application nightly for 8 weeks
75760369|NCT05723640|Drug|177Lu-LNC1004 Injection group 1 radionuclide therapy|The treatment regimen will consist of a single dose 30mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
75611359|NCT02704507|Drug|Emollient|topical application nightly to half the face for 4 weeks
75760370|NCT05723640|Drug|177Lu-LNC1004 Injection group 2 radionuclide therapy|The treatment regimen will consist of a single dose 60mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
75611360|NCT02699203|Behavioral|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
75611361|NCT02699203|Behavioral|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
75611362|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 low dose
75611363|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
75611364|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
75611365|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
75611366|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
75760371|NCT05723640|Drug|177Lu-LNC1004 Injection group 3 radionuclide therapy|The treatment regimen will consist of a single dose 80mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
75760372|NCT05723640|Drug|177Lu-LNC1004 Injection group 4 radionuclide therapy|The treatment regimen will consist of a single dose 100mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
75760373|NCT05717686|Drug|AHB-137 injection|AHB-137 will be administered
75904992|NCT05008523|Behavioral|Opioids and Police Safety Occupational Risk Reduction Training (COVID)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
76069524|NCT01402869|Drug|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
75458902|NCT01813994|Drug|Arm2: Placebo|"Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
75611367|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
75611368|NCT02699047|Dietary Supplement|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
75611369|NCT02699047|Dietary Supplement|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
75611370|NCT00624455|Drug|Gabapentin|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
76069525|NCT01391793|Drug|Placebo|Twice daily for 3 days
75458903|NCT01814020|Drug|MOB015B|
75458904|NCT01814033|Other|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
75458905|NCT01814033|Other|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
75458906|NCT01814059|Drug|sirolimus|
75458907|NCT01814085|Drug|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
75458908|NCT01814098|Drug|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
75458909|NCT01814111|Procedure|renal sympathetic denervation|The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
75458910|NCT01814124|Other|Manual therapy plus exercise|
75458911|NCT01814124|Other|Advice and home exercise|
75611371|NCT00624455|Drug|Placebo|Placebo
75611372|NCT01127659|Drug|testosterone|intramuscular every 2 weeks
75611373|NCT01127659|Drug|placebo|saline intramuscular every 2 weeks
75611374|NCT01209689|Drug|Tocilizumab|
75611375|NCT01209689|Drug|Placebo|
75611376|NCT02698969|Drug|Sugammadex|
75611377|NCT02698969|Device|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
75611378|NCT02698969|Drug|Neostigmine|
75611379|NCT02698969|Drug|Atropine|
75611380|NCT02698969|Device|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
75760374|NCT05717686|Drug|Placebo|Placebo will be administered
75760375|NCT05716724|Drug|Semaglutide|Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
75760376|NCT05712759|Other|Influenza-like illness group|"Each patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing.~ILI is defined by fever > 37,8°C or/and cough or sore throat."
76069526|NCT01391793|Drug|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
75458912|NCT01814163|Drug|paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
75458913|NCT01814176|Device|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
75458914|NCT01814189|Drug|Sumatriptan+Promethazine (SPr)|
75458915|NCT01814202|Other|PTM202|
76069527|NCT01422915|Drug|Colestipol|2 grams morning and bedtime for 90 days.
76069528|NCT04037943|Dietary Supplement|Walnuts 30 grams|Roasted walnuts without salt or sugar.
76069529|NCT04037943|Dietary Supplement|Walnuts 60 grams|Roasted walnuts without salt or sugar.
76069530|NCT01727024|Drug|Tiotropium|Tiotropium via Respimat® device once a day
76069531|NCT01727024|Drug|Indacaterol|Indacaterol via Breezhaler® device once a day
76069532|NCT01422213|Drug|Placebo|capsules; daily; orally
75611381|NCT02698969|Drug|Rocuronium|Rocuronium will be administered 0.6 mg*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
75760377|NCT05706181|Other|Home-based leg heat therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
75760378|NCT05706181|Other|Home-based sham therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
75760379|NCT05704985|Biological|DK210 (EGFR)|Solution for SC administration
75611382|NCT02698969|Drug|Fentanyl|Fentanest will be administered 2 mcg*kg-1 at the induction of general anesthesia and titrated 0.5 mcg*kg-1 every 30 minutes
75760380|NCT05704985|Radiation|Radiation therapy|Short regimen radiation therapy (10 fractions or less)
75760381|NCT05704985|Biological|Immune checkpoint blockers|IV administration of approved PD1 blocker
75760382|NCT05704985|Drug|Chemotherapy|Single agent or combination of not more than two
75760383|NCT05701852|Other|reward learning task|during usual follow-up patients will complete a remard learning task questionnaire. This questionnaire cannot be assimilated to a clinical intervention.
75904993|NCT05002608|Behavioral|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Session 1- Insurance Plan Basics; Session 2- Your Plan in Relation to Legal Policy; Session 3- Navigating Your Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs; Session 5- Understanding Your Medical Bills.
75904994|NCT04992832|Biological|human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group.
75458916|NCT01814202|Other|Placebo|
75458917|NCT01814215|Behavioral|Keys to Healthy Family Child Care Homes|The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
75611383|NCT02698969|Drug|Propofol|Propofol will be administered 2 mg*kg-1 at the induction of general anesthesia
75611384|NCT02698969|Drug|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
75611385|NCT00848731|Drug|nitric oxide|nitric oxide gas is delivered by facemask
75611386|NCT00537589|Procedure|Ultrasound guided arthrocentesis|Guidance of joint aspiration by ultrasound guidance
75611387|NCT01209143|Drug|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
75611388|NCT01209143|Drug|Rosiglitazone|Rosiglitazone was supplied in tablets.
75611389|NCT01209143|Drug|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
75611390|NCT00454285|Drug|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
75611391|NCT00614965|Drug|Irinotecan|Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
75760384|NCT05694624|Drug|Para Aminohippurate|Measurements of renal plasma flow and glomerular filtration rate
75760385|NCT05690581|Drug|CM369|Specified dose on specified days.
75760386|NCT05674162|Behavioral|Unobserved|Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher.
75760387|NCT05674162|Behavioral|Observed|Participants walk a distance of 40 meters wearing the sensors, observed by the researcher.
75760388|NCT05674162|Radiation|Unobserved & Measured|Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher and aware of the gait measurement by the sensors.
75760389|NCT05664789|Drug|N acetyl cysteine|N-acetylcysteine (NAC) is an over-the-counter dietary supplement that is relatively well tolerated and exhibits minimal side effects, even at high dosages. N
75760390|NCT05664789|Drug|Placebo|matched placebo
75760391|NCT05662423|Behavioral|Expressive Writing about Childbirth|Participants will write repeatedly about their deepest emotions and thoughts related to their recent childbirth, focusing on the most stressful experiences.
75904995|NCT04992832|Other|human serum albumin|Saline solution containing 1 percent human serum albumin will be infused to the control group.
76069533|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
76069534|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
75458918|NCT01814228|Procedure|transcatheter ablation of ganglionated plexi in right atrium|
75760392|NCT05662423|Behavioral|Neutral Writing|Participants will write repeatedly about neutral daily events/tasks not related to childbirth.
75760393|NCT05661916|Drug|ALN-TTRSC04|ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
76069535|NCT01390857|Drug|Valaciclovir|
75760394|NCT05661916|Drug|Placebo|Placebo will be administered by SC injection.
75760395|NCT05659576|Drug|Sucralfate|"Sucralfate, 1 gram/10 mL oral suspension By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.May increase frequency up to 4 times per day, per physician discretion. Or~Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.~The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion. May increase frequency up to 4 times per day, per physician discretion."
75760396|NCT05659576|Other|Usual Care|Standard supportive care by using opioids.
75760397|NCT05659576|Other|One consent|Patient will sign one consent form.
75760398|NCT05659576|Other|Two consent|Patient will sign two consent forms.
75760399|NCT05656794|Radiation|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
75760400|NCT05654779|Biological|LCAR-AMDR Cells Product|Subjects will receive a conditioning regimen before treatment with LCAR-AMDR cells
75760401|NCT05629962|Drug|Bemnifosbuvir (BEM)|BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
75760402|NCT05629962|Drug|Placebo|Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
75760403|NCT05629013|Behavioral|After-Action Review|After-action reviews, or debriefs, are a relatively simple, inexpensive, and quick, tool to improve learning, performance, and the effectiveness of teams and individuals. After-action reviews are active self-learning processes wherein participants reflect on specific performance episode to actively engage in self-discovery and improve learning in a non-punitive/non-judgmental manner to result in enhanced performance. This proposal aims to apply the team effectiveness intervention of the after-action review (AAR) to the services intervention of the Child and Family Team (CFT) meetings currently used in the CWS.
75760404|NCT05621525|Drug|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
75760405|NCT05620875|Diagnostic Test|Cerebral injury markers|Blood tests at given time points perioperatively.
76069536|NCT01725386|Drug|Capecitabine|Oral tablet(s) administered according to prescribing information
76069537|NCT01402011|Procedure|25% dextrose in shoulder entheses|injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
75611392|NCT00614965|Drug|Cisplatin|Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
75611393|NCT00614965|Drug|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
75611394|NCT00405613|Drug|Aspirin|
75611395|NCT02703883|Device|BWST|BWST (six weeks, 3 times/week)
75611396|NCT02703805|Other|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
75611397|NCT02703805|Other|Standard YMCA membership|A 12 week standard YMCA membership.
75611398|NCT02703961|Drug|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
75611399|NCT02703961|Drug|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
75760406|NCT05620875|Diagnostic Test|Cerebral oximetry index|Cerebral oximetry index measurements with the aid of Near Infrared Spectroscopy
76069538|NCT01402011|Procedure|.1% lidocaine in shoulder entheses|injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
76069539|NCT01402011|Procedure|.1% lidocaine subcu. above shouldr enth.|injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
76069540|NCT01421667|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
75611400|NCT02703961|Radiation|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
76069541|NCT01421667|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion
76069542|NCT01390779|Device|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
76069543|NCT01891669|Drug|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
76069544|NCT01891669|Drug|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
76069545|NCT01421511|Drug|TR-701 FA|"TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~TR-701 FA Tablets, 200 mg, orally once daily"
75904996|NCT04992169|Behavioral|Smartphone-App Parent Training in Pivotal Response Treatment|Parents are trained in Pivotal Response Treatment, Pivotal Response Treatment is a well-known, scientifically supported treatment that focuses on using child motivation, play-based lessons, and parent involvement to target the language skills and social engagement of children with autism. The core smartphone app will offer eight interactive lessons in PRT, consisting of video examples, slides, and brief quizzes.
75611401|NCT02703961|Radiation|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
75904997|NCT04987775|Drug|N-Acetyl Cysteine|900mg 2x daily
75904998|NCT04987775|Drug|Placebo|Matching placebo bid
75904999|NCT04982315|Procedure|Standard Acupuncture|The standard acupuncture intervention is based on classical Chinese acupuncture therapy. Participants randomized to standard acupuncture will receive up to 15 acupuncture treatments over 3 months with the total number being determined by the patient and acupuncturist together. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
75905000|NCT04982315|Procedure|Enhanced Acupuncture|The enhanced acupuncture intervention includes the 3 months of standard acupuncture plus an additional 3 months of maintenance acupuncture. Participants randomized to enhanced acupuncture will receive up to 21 acupuncture treatments over 6 months. The maintenance acupuncture treatment sessions are expected to consist of the same intervention used in the first 3 months of care described in the standard acupuncture arm, plus up to 6 treatments during the maintenance phase. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
75905001|NCT04981470|Device|baroloop System|vagal nerve stimulation
75905002|NCT04977804|Other|Exercise|The interventions are a form or exercise, specifically resistance exercise.
75905003|NCT04977804|Other|Eccentric plus blood-flow restriction|Eccentric plus blood-flow restriction
75905004|NCT04969939|Drug|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
75905005|NCT04969939|Drug|Semaglutide 2.4 mg and placebo 2.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
75905006|NCT04969939|Drug|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
75905007|NCT04969939|Drug|Semaglutide 2.4 mg and placebo 1.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
75905008|NCT04967664|Drug|Qutenza (capsaicin) 8% topical system|High concentration capsaicin
75905009|NCT04967664|Drug|capsaicin 0.04% topical system|Low-dose capsaicin control
75611402|NCT02703961|Drug|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
75760407|NCT05615831|Behavioral|Resistance Training with Blood flow restriction|Participants will perform six weeks of blood flow restriction (60% occlusion) combined with resistance training at 30% of 1RM. The intervention comprises five exercises: incline chest press, seated row, leg press, knee extension, and knee flexion. The protocol is as follows: 30 repetitions followed by three sets of 15 repetitions for a total of four sets and 75 repetitions per exercise. There will be a one-minute recovery between sets where the cuffs remain inflated and a four-minute recovery between exercises where the cuffs will be deflated.
75760409|NCT05611307|Diagnostic Test|Lipid profile|Advanced lipid profile
75760410|NCT05611307|Diagnostic Test|Coronary artery assessment|Coronary artery assessment via CT scans
75760411|NCT05611307|Diagnostic Test|Hormone levels for hypogonadism|Hormone levels for hypogonadism
75905010|NCT04949841|Drug|Delgocitinib|Delgocitinib cream 20 mg/g
75905011|NCT04947735|Device|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
75905012|NCT04947735|Device|Spectacle lenses|Single vision, impact resistant spectacle lenses
75905013|NCT04937907|Drug|Hydroxychloroquine Sulfate 100 milligram (mg) Tab|Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
75905014|NCT04937907|Drug|Benazepril hydrochloride 10 milligram (mg) Tab|Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
75905015|NCT04934475|Drug|Isatuximab|treatment with Isa-KRD during induction and consolidation , with revlimid or Iberdomide +isatuximab during maintenance phase
75905016|NCT04934475|Procedure|ASCT|ASCT for ams B, C and D during consolidation
75905017|NCT04930003|Biological|QazCoVac-P -COVID-19 Subunit Vaccine|QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
75905018|NCT04930003|Other|Placebo|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
75611403|NCT02703649|Drug|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
75611404|NCT02703571|Drug|ribociclib|Combination treatment with LEE and TMT
75611405|NCT02703571|Drug|Trametinib|Combination treatment with LEE and TMT
75611406|NCT00615355|Radiation|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
75611407|NCT00615355|Device|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
75458919|NCT01814267|Other|telemedicine|"Intervention group: care and follow-up through telemedicine (e-consultations)~1 hospital consultation at inclusion time, week 0~then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.~1 hospital consultation to validate that the wound is well-healed"
75611408|NCT02703727|Behavioral|Extended polymedication check|"Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
75611409|NCT02703415|Drug|Bupivacaine|caudal block with bupivacaine (0.25%) 1mg/kg
75760412|NCT05589259|Procedure|Axillary Brachial Plexus Block plus Physiotherapy|"Participants will receive a single-shot axillary-approach brachial plexus block. For the procedure, a 22g or larger peripheral intravenous cannula will be placed, and skin will be sterilized with chlorhexidine. Using aseptic technique, the anesthesiologist will anesthetize the skin and tract with 5cc of 1% lidocaine using a 25g 1.5 needle. After this, a 50mm 21g Pajunk needle will be guided under ultrasound with an in-plane technique to anesthetize the median, ulnar, radial, and musculocutaneous nerves. Identification of the axillary artery, vein and surrounding vessels will be done to ensure an intravascular injection is avoided. Once proper location is confirmed, the anesthesiologist will aspirate to ensure the needle is not intravascular. Once aspiration is confirmed negative, bupivacaine 0.25% 1.5mg/kg (lean body weight) will be injected in divided doses.~30 minutes after placement of the block, the standardized physiotherapy protocol will begin."
75611410|NCT02703415|Drug|Tramadol|caudal block with tramadol 1 mg/kg
75458920|NCT01814267|Other|conventional|"conventional group: iterative diabetes physicians consultations at hospital~1 consultation at inclusion time, week 0~1 consultation 2 weeks after inclusion, week 2~1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period~1 consultation to validate that the wound is well-healed"
75458921|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
75760413|NCT05589259|Procedure|Physiotherapy alone|"Participants in the EXP arm and the CON arm will complete the same physiotherapy program.~PHYSIOTHERAPY PROTOCOL The physiotherapy program will include manipulation with or without a block. The goal of manipulation is to break up adhesions, possibly overcoming microvascular dysfunction. After the manipulation, participants will take part in a 6-week program which will include a weekly one-hour session with a physiotherapist at the KHSC-CPC and a home exercise program (HEP). During each session, the physiotherapist will work with the participants to increase ROM and limb function using manual therapy, stretching, and strengthening exercises specific to the affected joint(s) and most importantly using GMI. At the end of each session, the physiotherapist will prescribe exercises to complete at home."
75760414|NCT05579626|Drug|high-intensity statin arm|•high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily
75611411|NCT02703181|Drug|Epelsiban (GSK557296)|White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
75611412|NCT02703181|Drug|Placebo to match GSK557296|White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
75760415|NCT05579626|Drug|low-intensity statin plus ezetimibe|•low-intensity statin plus ezetimibe strategy (experimental arm): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
75760416|NCT05564546|Procedure|FeNO (fractional exhaled nitric oxide)|"FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.~The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.~FeNO is considered normal for values of 16-25 ppb. A FeNO value > 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment."
75611413|NCT03297697|Procedure|Tumor biopsy|Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
75611414|NCT03297697|Procedure|Peripheral blood draw|-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
75611415|NCT03297697|Procedure|Lymphotrack TCR clonality assay|-Assay with high sensitivity that can be performed with peripheral blood
75611416|NCT04215835|Drug|letrozole then misoprostol|"Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
75611417|NCT04215835|Drug|placebo then misoprostol|"Drug: Placebo placebo for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
75611418|NCT01023789|Device|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
75611419|NCT02702947|Dietary Supplement|Prunus domestica extract|Prosman 1 capsule twice a day
75611420|NCT00637039|Drug|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
75611421|NCT02703103|Other|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
75611422|NCT02703103|Device|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
75611423|NCT01208207|Drug|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
75760417|NCT05564546|Procedure|Spirometry|"Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.~Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.~The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.~Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV <80% or FEV <80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment."
75760418|NCT05564546|Other|Physical examination|"A pulmonary clinical examination will be carried out by the investigator, including:~Cough,~Sputum,~Vesicular murmur (MV),~Added noises (BSA),~Vocal vibrations (VV),~Tympanism,~Dullness,~Signs of acute respiratory distress (ARD),~…"
75905019|NCT04928235|Diagnostic Test|Thermal Imaging as Diagnostic Adjunct|Thermal images of the participants lower extremities will be taken and skin surface temperature values will be provided to the healthcare provider for review during the emergency department encounter.
75905020|NCT04904302|Biological|Nivolumab|Given IV
75458922|NCT01814293|Device|Handheld humidifier|Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
75905021|NCT04904302|Other|Quality-of-Life Assessment|Ancillary studies
75905022|NCT04904302|Other|Questionnaire Administration|Ancillary studies
76069546|NCT01421511|Drug|Linezolid|"Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~Linezolid Tablets, 600 mg, orally every 12 hours"
75458923|NCT01814306|Device|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
75458924|NCT01814306|Device|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
75611424|NCT01208207|Drug|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
75611425|NCT01208207|Drug|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
75611426|NCT01208207|Drug|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
75611427|NCT01208207|Drug|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
75611428|NCT01208207|Drug|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
75905023|NCT04904302|Drug|Sitravatinib|Given PO
75458925|NCT01814319|Drug|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
75458926|NCT01814319|Drug|Placebo|Matching placebo oral twice daily
75458927|NCT01814384|Device|prosthesis GMK ® without the ancillary MyKnee ® LBS|
75458928|NCT01814384|Device|Matched patient cutting blocks MyKnee ® LBS|
75905024|NCT04901884|Drug|PET/MR with 18F-FDG|(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
75905025|NCT04896385|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
75905026|NCT04896385|Drug|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
75905027|NCT04895735|Biological|Pembrolizumab|Given IV
75458929|NCT01814410|Drug|Intravenous ethanol placebo plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
75458930|NCT01814410|Drug|intravenous ethanol 40mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
75458931|NCT01814410|Drug|intravenous ethanol 100mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
75905028|NCT04895735|Drug|Pemetrexed Disodium|Given IV
75905029|NCT04884724|Other|Adaptive Dance Exercise Program|It is planned to include balance, stabilization, mobility, speed and rhythm activities for the exercises applied in Cerebral Palsy rehabilitation and based on the principles of motor learning, and to apply the dance steps and figures to be applied with visual and auditory stimuli.
75905030|NCT04879225|Behavioral|Tobacco e-liquids|Marketplace includes tobacco flavored e-liquids
75458932|NCT01814423|Drug|Chloroquine-base 50 mg|
75458933|NCT01814423|Drug|Chloroquine-base 70 mg|
75458934|NCT01814436|Device|scaffold-free SHED-derived pellet|The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
75611429|NCT01208207|Drug|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
75611430|NCT01208207|Drug|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
75611431|NCT01208207|Drug|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
75611432|NCT01208207|Drug|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
75905031|NCT04879225|Behavioral|Menthol and Tobacco e-liquids|Marketplace includes menthol and tobacco flavored e-liquids
75611433|NCT01208207|Drug|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
75611434|NCT01208207|Drug|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
75611435|NCT02703025|Dietary Supplement|GCB-70|green coffee bean extract
75905032|NCT04879225|Behavioral|Mint, Menthol and Tobacco e-liquids|Marketplace includes mint, menthol and tobacco flavored e-liquids
76069547|NCT01864525|Drug|Octanoic acid|
76069548|NCT01864525|Drug|Inactive capsule|
76069549|NCT01421277|Drug|Statin Therapy|Investigator's choice of any statin.
76069550|NCT01891357|Procedure|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
76069551|NCT01891357|Drug|paclitaxel|
75760419|NCT05564546|Other|Interrogation|"Participants will undergo an interview with the medical team to collect the following information in particular:~Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc."
75760420|NCT05561140|Drug|Voxelotor Oral Tablet|Synthetic small molecule supplied as 500 mg tablets, administered Orally
75760421|NCT05561140|Other|Placebo|Placebo
75611436|NCT03292471|Device|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
75611437|NCT05420285|Drug|Dapagliflozin|Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
75611438|NCT04147663|Other|describe the management of the adult population suffering from suspected seizure by the emergency structures|For 3 consecutive days, all patients with suspected epileptic seizures (assessed by the Emergency medical assistance service ( SAMU), paramedical team and the emergency unit) will be included in the study. With the use of questionnaries, information will be collected from patients or witnesses by the SAMU, the paramedical team or physicians of the emergency unit. A 7-day follow-up will be carried out by the principal investigator (PI) of each center.
75611439|NCT01012713|Drug|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
75905033|NCT04879225|Behavioral|All e-liquid flavors|Marketplace includes fruit, dessert, mint, menthol and tobacco flavored e-liquids
75611440|NCT01012713|Drug|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
75905034|NCT04866303|Diagnostic Test|Home-based SARS-CoV-2 test kit|A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
75905035|NCT04865939|Procedure|sterile water irrigation|Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
75905036|NCT04865939|Drug|Gemcitabine|Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
75905037|NCT04864899|Diagnostic Test|Cardiac Magnetic Resonance Imaging (CMR)|Imaging
75458935|NCT01814449|Other|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
75458936|NCT01814449|Drug|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
75760422|NCT05554133|Device|High Resolution Microendoscope (HRME)|The High Resolution Microendoscope (HRME) take pictures of a very small area of the lining of the mouth, about the size of a pencil tip, but at high magnification.
75905038|NCT04864899|Diagnostic Test|Blood test|Blood investigation
75905039|NCT04864899|Diagnostic Test|6-minute walk test|Correlating the cardiac MRI parameters with functional capacity
76069552|NCT01891357|Drug|lapatinib|
76069553|NCT01891357|Drug|trastuzumab|
75760423|NCT05554133|Device|Optical Mapping Scope|The optical mapping scope displays a wide area of the lining of the mouth (about the size of the top of a soda can) by shining different colors of light into the mouth and taking pictures.
75760424|NCT05554133|Drug|Proflavine hemisulfate|A coloring substance (a fluorescent dye which glows green in the dark), called proflavine hemisulfate, will be painted on areas of the mouth with a cotton tip applicator to help improve the pictures
75760425|NCT05546476|Drug|ponsegromab|Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment
75760426|NCT05546476|Drug|Placebo for ponsegromab|Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
75760427|NCT05538130|Drug|PF-07799544|Tablet
75760428|NCT05538130|Drug|PF-07284890|Tablet
75760429|NCT05538130|Drug|PF-07799933|Tablet
75760430|NCT05538130|Drug|encorafenib|Capsule
75760433|NCT05520710|Behavioral|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
75760434|NCT05520710|Other|Education|Educational materials, designed to help people with traumatic brain injury manage their everyday cognitive challenges will be provided through Zoom video conferencing software.
75760438|NCT05505565|Device|Abbott Freestyle Libre 2|Subjects will be educated on use of Abbott Freestyle Libre 2 and educated on how daily activities impact glucose.
75905040|NCT04860570|Device|Double-ring wound-edge protector|Double-ring wound-edge protector: Alexis Applied Medical ®, Rancho Santa Margarita, California.
76069554|NCT01420965|Drug|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
76069555|NCT01420965|Other|Sipuleucel-T (Provenge)|Vaccine
76069556|NCT01420965|Drug|Cyclophosphamide|Low dose- Immune Enhancer
76069557|NCT04033575|Drug|Colgate Total SF|1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
75458937|NCT01814462|Device|6 months CPAP|
75458938|NCT01814475|Drug|A: Fludarabine + Busulphan|Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
75458939|NCT01814475|Drug|B: Fludarabine + Thiotepa|Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
75760439|NCT05505565|Other|Standard physical activity and nutritional counseling for prediabetes management|Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.
75760440|NCT05494398|Drug|N-acetylcysteine|12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
75760441|NCT05491382|Procedure|Uphill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 10 degree (17.6%) incline.
75760442|NCT05491382|Procedure|Flatland running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 0 degree (0%) incline.
75760443|NCT05491382|Procedure|Downhill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a -10 degree (-17.6%) decline.
75760444|NCT05486728|Drug|SHJ002/Vehicle|Topical ophthalmic
75760445|NCT05484895|Behavioral|WeTest-WeLink|"WeTest-WeLink application on the WeChat platform provides videos on HIV self-testing and linkage to care; informational articles on HIV, sexually transmitted infections (STI), testing, antiviral treatment (ART), and care; online behavioral self-assessments; linkage to providers; local data reports; stories about coping, wellness, and social support; two-way communication with NGO; and free, additional HST."
75760446|NCT05484895|Behavioral|Control condition|Contact information of local NGO for emergency referrals; free additional HST.
75760447|NCT05468385|Device|Vagus nerve stimulation via tragus|The device will send stimulus intensity of around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
75760448|NCT05468385|Device|Sham stimulation via earlobe|The device will send stimulus intensity of around 0.5mA via the earlobe in the left ear (based on participants' subjective reports), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
75760449|NCT05432830|Other|E-liquid Flavor 1|E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.
75905041|NCT04819737|Procedure|SC MRI|SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.
75760450|NCT05432830|Other|E-liquid Flavor 2|E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.
75760451|NCT05432830|Other|E-liquid Flavor 3|E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.
75760452|NCT05424016|Drug|Propranolol|120 mg/d propranolol started in a progressive way (with control of Blood Pressure and heart rate during the consultations) neurosurgical consultation and an MRI every six months
75458940|NCT01814501|Biological|panitumumab|Given IV
75760453|NCT05424016|Other|follow-up|routine follow-up (neurosurgical consultation and an MRI every six months)
75760454|NCT05419648|Biological|1 additional tube of blood|For all the patients included, a specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
75760455|NCT05417828|Device|Emulation of Active Daily Living tasks with a robotic device (SPINDLE)|SPINDLE will provide an assistive and resistive force to aid in rehabilitating the subject's upper limb
75760456|NCT05395117|Drug|AZD5462|"Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~Midazolam~Rosuvastatin~Digoxin~Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~Midazolam~Rosuvastatin~Digoxin"
75760457|NCT05395117|Drug|Midazolam|Participants will receive a single dose of midazolam in the morning of Day 1 and in the morning of Day 15 in both the arms.
75760458|NCT05395117|Drug|Rosuvastatin|Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
75458941|NCT01814501|Drug|irinotecan hydrochloride|Given IV
75458942|NCT01814501|Drug|fluorouracil|Given IV
75458943|NCT01814501|Drug|leucovorin calcium|Given IV
75458944|NCT01814514|Drug|Timolol-trusopt|
75458945|NCT01814514|Drug|placebo|
75458946|NCT01814527|Dietary Supplement|Docosahexaenoic acid|5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
75458947|NCT01814527|Drug|Placebo|5 capsules that are identical to the treatment.
75458948|NCT01814579|Device|Unidirectional Barbed Suture (V-Loc)|Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
75458949|NCT01814579|Device|polyglactin 910 (Vicryl)|Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
75611441|NCT01012713|Procedure|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
75611442|NCT02702713|Dietary Supplement|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
75611443|NCT02702713|Dietary Supplement|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
75611444|NCT02702713|Dietary Supplement|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
75611445|NCT02702713|Dietary Supplement|Bakery placebo|Bakery placebo: Biscuits without enrichment
75611446|NCT02702713|Dietary Supplement|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
75611447|NCT02702713|Dietary Supplement|Egg placebo|Egg placebo: Frozen pancakes without enrichment
75611448|NCT02698813|Biological|umbilical cord mesenchymal stem cells and hyaluronic acid|
75611449|NCT02698813|Drug|hyaluronic acid|
75611450|NCT04205331|Device|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
75905042|NCT04819737|Other|patient questionnaire|12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability
75905043|NCT04817969|Device|Zimmer Biomet Persona Ti-Nidium Total Knee System|Primary Knee Total Arthroplasty
75458950|NCT01814592|Procedure|coronally partial thickness flap plus connective tissue|The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
75458951|NCT01814592|Procedure|coronally mucosal thickness flap|The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
75458952|NCT01814605|Procedure|Infragluteal space group|"Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
75458953|NCT01814605|Procedure|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
75458954|NCT01814618|Drug|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
75611451|NCT02702635|Procedure|DCE MRI of the brain|An MRI of the brain including a DCE sequence
75611452|NCT02871531|Procedure|Pneumatic retinopexy|
75611453|NCT02871531|Procedure|Vitrectomy|
75611454|NCT02702791|Behavioral|Telecoaching|Pedeometer based goals and telecoaching support
75611455|NCT02702791|Other|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
75760459|NCT05395117|Drug|Digoxin|Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
75760460|NCT05372185|Behavioral|VA Coordinated Anxiety Learning and Management- Substance Use Version|VA Coordinated Anxiety Learning and Management- Substance Use Version (VA CALM-S) is a cognitive behavior therapy (CBT) program that employs computer assistance to empower providers to deliver CBT with high fidelity. The computer program guides both providers and patients in a course of CBT, and in this study the content will focus on using transdiagnostic treatment elements to address co-occurring anxiety and substance use disorders.
75611456|NCT02702557|Other|Elastic Band Exercises|
75611457|NCT02702479|Other|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
75905044|NCT04805190|Behavioral|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
75905045|NCT04805190|Behavioral|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
75905046|NCT04777994|Drug|ABBV-CLS-484|Oral Capsule
75905047|NCT04777994|Drug|Programmed Cell Death-1 (PD-1) Inhibitor|Intravenous (IV) infusion
75905048|NCT04777994|Drug|Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)|Oral Tablet
75905049|NCT04766749|Other|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
75611458|NCT02702479|Other|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
75760461|NCT05372185|Behavioral|Usual care|Veterans will engage in VA care using the standard procedures of their facility.
75760462|NCT05371600|Drug|Midazolam|midazolam IV at 0.04 mg/kg
75760463|NCT05371600|Other|Saline|an equal volume of saline IV
76069558|NCT04033575|Drug|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
76069559|NCT04767087|Drug|Honey|0.5 gm/Kg/day honey
75611459|NCT04422093|Device|OrthoKontrol|Fixing OrthoKontrol Sensor on multibracket appliance to measure cooperation
75611460|NCT02702323|Drug|Apatinib|apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
75611461|NCT02702323|Procedure|TACE|one times every 4-6 weeks.
75611462|NCT01007253|Drug|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
75611463|NCT01007253|Drug|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
75611464|NCT01007253|Drug|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
75760464|NCT05368259|Device|AGBS|The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
75611465|NCT01007253|Drug|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
75611466|NCT02702167|Device|High-frequency rTMS|10 Hz active stimulation, once daily
75458955|NCT01814631|Other|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
75611467|NCT02702167|Device|Low-frequency rTMS|1 Hz active stimulation, once daily
75611468|NCT02702167|Device|Sham rTMS|Sham stimulation, once daily
75611469|NCT02691949|Drug|Mycophenolate mofetil|mycophenolate mofetil 1# BID-2# BID
75611470|NCT04146961|Device|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
75611471|NCT02698501|Drug|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
75611472|NCT02698501|Drug|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
75611473|NCT02702245|Dietary Supplement|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
75760465|NCT05368194|Dietary Supplement|Isocaloric Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
75760466|NCT05368194|Dietary Supplement|Isocaloric Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
75905050|NCT04761458|Diagnostic Test|Olfactory function testing|Olfactory function will be evaluated through the Burghart Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The extended version of this test will be used and consist of three tests of olfactory function, namely tests for odor threshold, odor discrimination and odor identification.
76069560|NCT04767087|Drug|Nigella sativa seed|40 mg/Kg/day
75611474|NCT02702245|Dietary Supplement|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
75458956|NCT01814631|Other|image quality and resolution|image quality and resolution will be viewed on the EU-me2
75458957|NCT01814644|Behavioral|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
75458958|NCT01814644|Behavioral|Standard Care|Individual assessment, lifestyle counseling
75458959|NCT01814683|Drug|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
75458960|NCT01814683|Drug|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
75611475|NCT02702245|Other|Placebo Comparator: Control|75 g pure glucose.
75611476|NCT04296747|Drug|induction chemotherapy|Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles
75611477|NCT04296747|Procedure|surgery|After induction chemotherapy, patients with resectable hypopharyngeal cancer would accept surgery within 2-4 weeks and investigator-selected postoperative treatment
75611478|NCT04296747|Radiation|chemoradiotherapy|After induction chemotherapy, patients with unresectable hypopharyngeal cancer who achieved CR/PR/SD in the tumor evaluation according to RECIST1.1 would accept another cycle of chemotherapy, and then radical chemoradiotherapy with cisplatin 100mg/m2, q21d
75611479|NCT04298931|Other|Series of ventilator settings|"Before a planned fluid administration, the investigators will apply a series of 10 ventilator settings for 30 seconds each.~The settings are the following combinations of respiratory rate (RR) and tidal volume (TV):~RR (min^-1), TV (ml/kg predicted body weight)~31, 6~31, 8~24, 6~24, 8~17, 6~17, 8~10, 4~10, 6~10, 8~10, 10~(the order of the respiratory rates: 17 to 31, will be randomized. 10/min will always be last. Tidal volume is always applied from lowest to highest for each respiratory rate)."
75611480|NCT02686879|Device|Multifocal contact lenses|
75611481|NCT02686879|Device|Single vision contact lenses|
75611482|NCT04296591|Diagnostic Test|fetal heart doppler findings|Doppler data of main pulmonary artery and right pulmonary artery, mitral valve e/a wave ratio and lamellar body count were determined as the main research parameters. In both groups, fetal thorax and heart circumference ratio, mitral e/a wave ratio, right pulmonary artery and main pulmonary doppler indexes (PI, RI, S / D, AT / ET) were evaluated before cesarean section.
75458961|NCT01814683|Drug|Placebo|14 days placebo.
75458962|NCT01814709|Drug|GDC-0032|Oral doses of GDC-0032
75458963|NCT01814709|Drug|Itraconazole|Oral doses of Itraconazole
75458964|NCT01814709|Drug|Rifampin|Oral doses of Rifampin
75458965|NCT01814826|Drug|MLN4924|"MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles"
75760467|NCT05368194|Dietary Supplement|Excess Calorie Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
75760468|NCT05368194|Dietary Supplement|Excess Calorie Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
75760469|NCT05366842|Drug|Stravix lyopreserved placental tissue (LPT)|Participants will undergo surgical implantation of Stravix lyopreserved placental tissue (LPT) during a standard of care radical prostatectomy.
75760470|NCT05366842|Procedure|Radical prostatectomy|Standard care (no placement of tissue)
75760471|NCT05361577|Device|Exoplulse Mollii suit|Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
75760472|NCT05361577|Device|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
75760473|NCT05359679|Behavioral|Value Champion Training Program|Clinicians from primary care clinic sites randomized to the intervention arm of the study will complete a 6-month clinician value champion training program by participating in a series of 12 web-based training sessions. No intervention will be conducted at clinics in the control arm.
75760474|NCT05359679|Other|No Intervention|Usual clinical care - no value champion present at this clinical setting
75760475|NCT05358691|Drug|AN0025|To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants
75760476|NCT05357989|Drug|Buntanetap|HPMC (vegetarian source) capsule shells
75760477|NCT05357989|Drug|Placebo|HPMC (vegetarian source) capsule shells
75760478|NCT05346120|Biological|allogeneic marrow stromal cells (MSCs)|stem cell infusion
75905051|NCT04761458|Diagnostic Test|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
75905052|NCT04761458|Diagnostic Test|Clinical Frailty Scale|The Clinical Frailty Scale (CFS) uses clinicians' judgement to evaluate frailty. It comprises assessment of specific domains including comorbidity, function, and cognition. Score ranges from 1 (very fit) to 9 (terminally ill).
76069561|NCT04767087|Other|Placebo|empty capsule with sugar water
75458966|NCT01814826|Drug|Azacitidine|"Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles"
75611483|NCT01006707|Drug|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
75611484|NCT02698657|Drug|ASP5094|Intravenous (IV)
75458967|NCT01814839|Drug|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
75458968|NCT01814839|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
75611485|NCT02698657|Drug|Placebo|Intravenous (IV)
75611486|NCT04298385|Other|Traction orthosis|Traction applied to a finger using elastic thread and sports tape and attached to an orthosis
75611487|NCT04216615|Behavioral|preoperative anxiety|patients who are anxious
75611488|NCT04296279|Drug|FMP014|Falciparum Malaria Protein-14
75611489|NCT04296279|Drug|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
75611490|NCT00616057|Dietary Supplement|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
75611491|NCT00616057|Dietary Supplement|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
75611492|NCT04296201|Device|DMA treatment|Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
75458969|NCT01814852|Device|Shockwave system|
75760479|NCT05333978|Device|MSOT Device|The MSOT Device will be used to take images of the areas of inflammation in patients with inflammatory diseases such as GVHD, Colitis, and IBD, prior to, and after 4 weeks of treatment.
76069562|NCT01390389|Drug|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~Visit 1 (baseline) start at 400mg once a day for two weeks~Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
76069563|NCT03835533|Drug|NKTR-214 (Cohort A)|NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
75611493|NCT00615511|Dietary Supplement|placebo pregnenolone|Sugar pill, taken twice a day
75611494|NCT00615511|Dietary Supplement|pregnenolone|500mg in tablet form taken orally twice a day
75611495|NCT04215133|Other|exercise therapy|inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
75611496|NCT02702089|Procedure|Rectal cancer surgery|Rectal cancer resection
75905053|NCT04761458|Diagnostic Test|Neuropsychological test battery|Patients will undergo a neuropsychological test battery preoperatively and postoperatively. This test consists of a battery of psychometric assessments with the ability to objectively assess specific cognitive domains such as attention, executive function, learning and memory, language, perceptual-motor, or social cognition.
75905054|NCT04757155|Behavioral|Internet Adaptation of Managing Cancer and Living Meaningfully (iCALM)|A online psychotherapy designed for patients with advanced and metastatic cancer.
75760480|NCT05333978|Procedure|Temperature Measurement|The temperature of the skin will be measured prior to and after each instance of MSOT imaging.
75760481|NCT05329376|Device|Smart Speaker Echo Dot|"Participants will receive the Smart Speaker EchoDot 3rd Gen (Amazon Echo®) device (i.e., Alexa) for home use, installed during a home visit following the study enrollment. In addition to the usual functionality of the system, the device will be programmed using a standard model developed by the research team, applied to each patient. The proposed model involves automatic interactions between the device and the patient, comprising:~Medication reminders~Glucose test reminders:~Educational health tips~Weekly educational podcasts~Good morning and good night routine"
75760482|NCT05329376|Other|Usual Care|Participants will maintain usual care during the study period and will receive a booklet with general advice following enrollment
75905055|NCT04746833|Behavioral|SUMMIT|multicomponent web-based application focused on pain self-management skills
75905056|NCT04746833|Behavioral|control|My Pain Diary app
75611497|NCT01006629|Biological|palivizumab|palivizumab 15 mg/kg intramuscularly
75611498|NCT04215055|Device|vibraject|VibraJect; is a small battery-operated attachment that snaps on to the standard dental syringe. It delivers a high-frequency vibration to the needle which is strong enough for the patient to feel.
75760483|NCT05318105|Device|Aquadex Smartflow® System|ultrafiltration
75905057|NCT04745949|Drug|Brentuximab Vedotin|Given IV
75905058|NCT04745949|Drug|Cyclophosphamide|Given IV
75905059|NCT04745949|Drug|Doxorubicin|Given IV
76069564|NCT03835533|Drug|Nivolumab (Cohort A, B and C)|Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
76069565|NCT03835533|Radiation|Stereotactic body radiation therapy (SBRT) (Cohort B)|Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
76069566|NCT03835533|Drug|CDX-301 (Cohort B and C)|CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
76069567|NCT03835533|Drug|Poly-ICLC (Cohort B)|Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
75760484|NCT05318105|Drug|IV Loop Diuretics|diuretics
75760485|NCT05306444|Drug|CLN-418|Intravenous (IV) administration
75760486|NCT05305547|Drug|S-217622|Administered as a round tablet.
76069568|NCT03835533|Drug|INO-5151 (Cohort C)|INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
76069569|NCT03835533|Device|Cellectra 2000|Electroporation device
76069570|NCT03025347|Other|Control|Participants complete a resting control condition instead of a run.
75760487|NCT05305547|Drug|Placebo|Administered as a round tablet.
75905060|NCT04745949|Biological|Nivolumab|Given IV
75905061|NCT04745949|Drug|Prednisone|Given PO
75905062|NCT04745949|Other|Quality-of-Life Assessment|Ancillary studies
75905063|NCT04745949|Biological|Rituximab|Given IV
75905064|NCT04735666|Device|TauroPace™|TauroPace™ is intended to be used as a disinfecting solution during any CIED related surgery procedure or handling of any uncoated or silicon-, epoxy- or polyurethane-coated CIED (including its components, e.g., leads) made of titan or stainless steel in any adult patient requiring or carrying a CIED.
75611499|NCT04214977|Procedure|Spinal Anesthesia for Anorectal Surgeries in Prone Position|Spinal anesthesia in sitting position was done under complete aseptic technique through a standard midline approach. One and a half millilitres of 0.5% bupivacaine (7.5 mg) was injected through a 25 Gauge pencil-point needle into the subarachnoid space at L3-L4 or L4-L5 interspace. All patients were kept in a head-up position for 3 minutes. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
75760488|NCT05303467|Device|TheraSphere GBM|Single treatment of TheraSphere GBM device
75760489|NCT05297864|Drug|Niraparib|The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.
75760490|NCT05295472|Behavioral|Grapholearn|GL is a computer game based on the phonics-method (i.e., graphem-phoneme correspondence). It was developed at Jyväskylä University in Finland, in several languages, among others also for Swedish.
75760491|NCT05295472|Behavioral|Vector|A computer game focusing on children's development of mathematic skills
75760492|NCT05295472|Behavioral|Usual schooling|No GL or Math computer games, only the usual schooling
76069571|NCT03025347|Other|Exercise|Participants complete a 60 minute run at 70% of their maximal oxygen uptake
76069572|NCT01401465|Drug|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
76069573|NCT01401465|Drug|mometasone|200 mcg mometasone aqueous nasal spray once daily
75760496|NCT05289375|Drug|Vacucis autovaccine|A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)
75905065|NCT04721613|Other|Assessment of Melatonin level|Measuring the plasma or serum melatonin in pg/ml during the first 24 hours after delirium diagnosis in two-hour intervals.
75905066|NCT04717375|Drug|SAR444881|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
75905067|NCT04717375|Drug|Pembrolizumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
75905068|NCT04717375|Drug|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
75905069|NCT04717375|Drug|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
75905070|NCT04717375|Drug|Pemetrexed|Pharmaceutical form: Powder for concentrate for solution for infusion or concentrate for solution for infusion; Route of administration: Intravenous
75760497|NCT05289375|Drug|Placebo|A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
75760498|NCT05289284|Other|No intervention|No intervention
75760499|NCT05288153|Drug|Metformin|Subjects will be instructed to take one tablet(500mg) of metformin after breakfast every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
75905071|NCT04700111|Device|DOT Pattern|DOT Pattern Spectacle Lens
75905072|NCT04700111|Device|Control Spectacles|Control lens
75905073|NCT04693793|Other|Education Materials and Janssen Test|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations."
76069574|NCT01401153|Other|Skipping lunch|Just water.
75905074|NCT04681625|Behavioral|Pelvic floor muscle training (PFMT) with suppressive urgency technique|"Pelvic floor muscle training with suppressive urgency technique:~Education about proper urination training in the period without pathological urgency.~Education about conscious urgency suppression through PFMT - suppressive urgency technique.~Education on the principle and effect of PFMT.~Exercises of varying intensity of pelvic floor muscles in different positions.~Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day."
75905075|NCT04675320|Biological|blood samples|Blood sampling during PARP inhibitor therapy
75905076|NCT04667494|Combination Product|Sonotherapy|Use of high mechanical index ultrasound therapy with intravenous Definity contrast infusion
75905077|NCT04654013|Device|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (May 2022). The duration of the treatment for the Intervention participants will depend on when they leave employment at the factor. If they stayed for the full duration of the trial, they will have undergone a maximum of 18 months (December 2023).
76069575|NCT01890967|Drug|LY3015014|Administered SC
76069576|NCT01890967|Drug|Placebo|Administered SC
76069577|NCT01890967|Drug|Statin|Administered orally
76069578|NCT01890967|Drug|Ezetimibe|Administered orally
75760500|NCT05288153|Drug|Folate|Subjects will be instructed to take one tablet(5mg) of folate three times every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
75760501|NCT05278871|Device|Constructive Shearwave Interference (CSI)|handheld ultrasound
76069579|NCT01400919|Device|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
76069580|NCT01864291|Device|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
75760504|NCT05267522|Other|Egg diet|30% fat [6% saturated fat], 20% protein, 40% carbohydrate, 600 mg cholesterol
76069581|NCT01400841|Device|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
75760505|NCT05267522|Other|Egg-free Diet|30% fat [12% saturated fat], 25% protein, 40% carbohydrate, 300 mg cholesterol
75760506|NCT05267522|Other|Control Diet|30% fat [12% saturated fat], 25% protein, 40% carbohydrate, 600 mg cholesterol
75611500|NCT04214977|Procedure|General Anesthesia Using Laryngeal Mask Airway for Anorectal Surgeries in Prone Position|General anesthesia was induced using fentanyl 2 mcg/kg and Propofol 2-3 mg/kg. Any stomach contents were then suctioned through an oro-gastric tube to reduce the risk of regurgitation. Proper (weight-based) classic laryngeal mask airway was then blindly inserted. laryngeal mask airway was then properly fixed to the face and anesthesia was maintained with isoflurane 1-2% in 50% Oxygen/air mixture.
75760507|NCT05261269|Drug|DAN-222|Administered IV every week to subjects
75760508|NCT05261269|Drug|Niraparib|Administered orally once daily
75760509|NCT05260320|Other|Standardized Anesthetic Course from Premedication to Induction|See information in intervention group description
75611501|NCT02701933|Drug|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
75760510|NCT05259930|Other|Amino MP9|Name used by Nualtra for their product of BCAA
75760511|NCT05250765|Device|Twistflex retainer|twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)
75760512|NCT05250765|Device|Orthoflex retainer|Ortho-flextech (Reliance orthodontic products, Itasca III, USA)
75760513|NCT05240898|Drug|KSQ-4279 Monotherapy (Dose Escalation and Expansion)|Administered orally in capsule
76069582|NCT01863667|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
76069583|NCT01863667|Drug|Glimepiride|Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
75611502|NCT02701933|Drug|Saline|Saline, intravenous infusion
75611503|NCT04295967|Other|formalin fixed paraffin embedded blocks|The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
75760514|NCT05240898|Drug|KSQ-4279 Combination Therapy (Dose Escalation and Expansion)|KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor) and combination with a platinum-based chemotherapy.
75760515|NCT05239091|Drug|Dextrose solution|A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.
75760516|NCT05239091|Drug|Lidocain|A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.
75760517|NCT05238961|Drug|[18F]DPA-714|Investigational PET Tracer [18F]DPA-714
75760518|NCT05234190|Drug|QEL-001|QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
75760519|NCT05229653|Drug|Ketamine|Participants in this arm will receive intravenously (IV) ketamine (0.6 mg/kg) while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver 0.6 mg/kg ketamine over at least 30 minutes.
75760520|NCT05229653|Drug|Placebo|Participants in this arm will receive intravenously (IV) matching equal dose of placebo while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver equal volume saline over at least 30 minutes.
75760521|NCT05226598|Biological|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
75760522|NCT05226598|Drug|Carboplatin|Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
75760523|NCT05226598|Drug|Cisplatin|Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
75760524|NCT05226598|Drug|Paclitaxel|Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
75760525|NCT05226598|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
75760526|NCT05226598|Drug|Pemetrexed|Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
75760527|NCT05226598|Biological|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
75760528|NCT05217043|Other|intracranial brain recording|Any patient benefiting from a long-term intracranial brain recording.
76069584|NCT01863667|Drug|Omarigliptin Placebo|Matching placebo to omarigliptin capsule administered orally once weekly
75458970|NCT01814852|Device|Sham treatment|Sham treatment that looks, sounds and feels like real LI-ESWT treatment by Renova.
75611504|NCT01012323|Biological|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
75760530|NCT05208242|Drug|hyperoncotic human albumin solution|20% human albumin solution (presented in 100ml glass bottles)
75760531|NCT05208242|Drug|Buffered crystalloid solutions|Buffered crystalloids solutions for all intravenous fluid therapy
75760532|NCT05186025|Drug|MATA trees or MATA grass|Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
75760533|NCT05175196|Diagnostic Test|CandyCollect|The CandyCollect device is a novel, micro-engineered, lollipop-inspired platform. It has functionalized open microchannels for pathogen capture and concentration. It also has time-controlled flavoring release to make the platform more patient-centric.
75760534|NCT05175196|Diagnostic Test|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Child participants are instructed to suck on the swab for 10 seconds, as they would suck on a lollipop. Participant will be asked to take this test twice."
75760535|NCT05171205|Device|Spinal cord stimulation|Spinal cord stimulation (SCS) is a very thin electrode implanted in the dorsal epidural space of the spinal cord to improve the patient's symptoms by stimulating the spinal nerves with pulsed electrical currents, which attenuate or enhance the flow of nerve impulses from the periphery to the central system, i.e., stimulating thick fibers to achieve therapeutic results. SCS system consists of three components: an electrode implanted in the epidural space of the patient's spinal cord, a stimulator implanted subcutaneously in the abdomen or buttocks that delivers electrical impulses, and an extension cord that connects the two.
75760536|NCT05169684|Biological|BMS-986218|Specified dose on specified days
76069585|NCT01863667|Drug|Glimepiride Placebo|Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
75760537|NCT05169684|Drug|Docetaxel|Specified dose on specified days
76069586|NCT01614769|Drug|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
75458971|NCT01814865|Drug|Abiraterone Acetate|1000 mg PO OD x 2 weeks
75458972|NCT01814865|Drug|Prednisone|5 mg PO OD x 2 weeks
75458973|NCT01814865|Drug|Aromatase Inhibitor|1 mg PO OD x 2 weeks
75458974|NCT01814891|Other|Orange maize feeding|This group was fed orange maize.
75760538|NCT05169684|Biological|Nivolumab|Specified dose on specified days
75760539|NCT05168267|Behavioral|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
75760540|NCT05165654|Device|Transcranial Electrical Stimulation|Transcranial electrical stimulation
75760541|NCT05162794|Other|Laparoscopy with excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. Then, the relevant tissue will be excised and a histology will be performed.
75760542|NCT05162794|Other|Laparoscopy without excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. However, no tissue will be excised and histology will not be performed.
76069587|NCT01614769|Drug|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
76069588|NCT01614769|Drug|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
76069589|NCT01614769|Procedure|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
76069590|NCT01614457|Drug|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
75458975|NCT01814891|Other|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
75458976|NCT01814891|Other|Oil only|This group received a small amount of plain oil without vitamin A.
75458977|NCT01814904|Drug|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
75458978|NCT01814904|Drug|colestilan-M|BSAeq 6 g/day
75458979|NCT01814904|Drug|colestilan-H|BSAeq 9 g/day
75458980|NCT01814904|Drug|CBPB|
75458981|NCT01814917|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
75458982|NCT01814917|Drug|CBPB|
75760543|NCT05162794|Other|Medical treatment-as-usual|Patients continue their hormonal and analgesic treatment-as-usual.
75760544|NCT05160415|Drug|EDG-5506|Daily oral dose
75760545|NCT05160233|Behavioral|Standard implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
75760546|NCT05160233|Behavioral|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
75905078|NCT04650438|Device|Transcranial Magnetic Stimulation (TMS) over the left inferior frontal gyrus (IFG)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
75611505|NCT02871765|Other|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
75905079|NCT04650438|Device|Transcranial Magnetic Stimulation (TMS) over the left inferior parietal lobule (IPL)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
75611506|NCT02870751|Biological|TW11681 or TW10722|
75611507|NCT01011933|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
75611508|NCT01011933|Drug|Selumetinib|Given PO
76069591|NCT01614457|Drug|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
75458983|NCT01814930|Behavioral|Brief standardized contraceptive counseling intervention|The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
75458984|NCT01814956|Drug|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
75458985|NCT01814956|Drug|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
75458986|NCT01814969|Radiation|Hyperfractionated Radiochemotherapy|28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
75458987|NCT01814969|Radiation|Hyperfractionated Radiotherapy|28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
75458988|NCT01814982|Drug|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
75458989|NCT01814995|Behavioral|Nutrition/Physical Activity Intervention|Please see Arm description.
75458990|NCT01815021|Dietary Supplement|amorphous calcium carbonate|
75458991|NCT01815021|Dietary Supplement|crystalline calcium supplements|
75458992|NCT01815047|Dietary Supplement|Vitamin D3 Supplementation|
75458993|NCT01815073|Biological|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|
75458994|NCT01815073|Biological|Live Attenuated Varicella Vaccine|
75611509|NCT02549209|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
75611510|NCT02549209|Drug|Paclitaxel|"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
75611511|NCT02549209|Drug|Carboplatin|"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
75611512|NCT03405883|Other|Vaginal swab + endometrial biopsy|In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
75905080|NCT04643002|Drug|Isatuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
75905081|NCT04643002|Drug|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
75905082|NCT04643002|Drug|Pomalidomide|Pharmaceutical form: Capsule; Route of administration: Oral
75905083|NCT04643002|Drug|Belantamab mafodotin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
75905084|NCT04643002|Drug|Pegenzileukin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
75905085|NCT04643002|Drug|SAR439459|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
75905086|NCT04643002|Drug|Belumosudil|Pharmaceutical form: tablet; route of administration: oral
75905087|NCT04643002|Drug|Evorpacept|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
75905088|NCT04642261|Drug|Empagliflozin 10 MG|Empagliflozin 10mg daily
76069592|NCT01863433|Biological|Trivalent Influenza Vaccine|
76069593|NCT01862029|Drug|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
76069594|NCT01835431|Drug|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
76069595|NCT01835431|Drug|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
75458995|NCT01815073|Biological|live attenuated JE vaccine|
75905089|NCT04642261|Drug|Placebo pills|Identical in appearance to empagliflozin 10mg daily
76069596|NCT01835431|Drug|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
75905090|NCT04612621|Diagnostic Test|combination of diagnostic tests|capsule endoscopy, MRE , intestinal ultrasound, fecal microbiota, blood and serum biomarkers as described
75905091|NCT04582500|Drug|Iohexol|Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
75905092|NCT04555785|Drug|Wilate|Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.
75905093|NCT04555785|Other|Placebo|Empty placebo will be given with platelets in cases of severe bleeding.
75905094|NCT04551482|Drug|Oxytocin nasal spray|24 IU nasal spray, 4 times per day for 12 weeks
75905095|NCT04551482|Drug|Placebo|24 IU nasal spray, 4 times per day for 12 weeks
76069597|NCT01835431|Drug|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
75611513|NCT03278587|Other|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
75611514|NCT03278587|Other|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
75611515|NCT03278587|Other|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
75905096|NCT04517851|Biological|Elotuzumab|Given IV
75905097|NCT04517851|Other|Questionnaire Administration|Ancillary studies
75905098|NCT04514705|Other|Exercise|Exercise with treadmil and weight training station
75905099|NCT04499690|Behavioral|Managing Cancer and Living Meaningfully|A brief, individual, manualized psychosocial intervention for patients with advanced and metastatic cancer
75905100|NCT04498026|Device|Adherus Dural Sealant System|Adherus Dural Sealant, In situ polymerizing sealant
75905101|NCT04498026|Device|DuraSeal Exact Dural Sealant System|DuraSeal Exact (P080013b)
76069598|NCT01880593|Drug|Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
76069599|NCT01880593|Drug|Ketamine|
76069600|NCT01880593|Drug|Placebo|Subjects in this arm take placebo pills at night for duration of the study.
76069601|NCT01400451|Drug|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
75905102|NCT04495153|Biological|Aglatimagene besadenovec|Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
75760547|NCT05160233|Behavioral|Practice Facilitation|A trained facilitator provides support for implementation by delivering the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
75760548|NCT05155319|Biological|UFluA 20 µg each antigen/dose|Low dose
75458996|NCT01815086|Biological|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
75760549|NCT05155319|Biological|UFluA 60 µg each antigen/dose|High Dose
75458997|NCT01815112|Other|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
75458998|NCT01815112|Other|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
75458999|NCT01815125|Drug|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
75905103|NCT04493164|Drug|Ivosidenib|Given PO
75905104|NCT04493164|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
75905105|NCT04484181|Other|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
75459000|NCT01815125|Drug|PLacebo|placebo
75459001|NCT01815164|Behavioral|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
75459002|NCT01815164|Behavioral|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
75459003|NCT01815203|Drug|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
75459004|NCT01815203|Drug|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
75459005|NCT01815216|Procedure|Bariatric surgery|Gastric bypass surgery
75459006|NCT01815216|Behavioral|Brain activity in resting state|Measure of activity in brain networks during resting state
75459007|NCT01815216|Behavioral|Memory performance|"Assess concentration in 2D-location task (i.e. memory game)"
75459008|NCT01815255|Drug|tenofovir (TDF)|
75459009|NCT01815268|Biological|HD Vaccine|Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
75459010|NCT01815268|Biological|SD Vaccine|Nursing home residents are allocated to receive standard-dose vaccine.
75459011|NCT01815268|Biological|Free Vaccine|Nursing home facilities are provided free standard-dose vaccine for their staff.
75459012|NCT01815268|Biological|Usual Care|Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
75459013|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
75459014|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
75459015|NCT01813669|Behavioral|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
75459016|NCT01815307|Drug|Gemcitabine|1000mg/m2, day 1 every 2 weeks
75459017|NCT01815307|Drug|S-1|80mg/m2/day, day 1-28, every 6 weeks
75459018|NCT01815320|Procedure|Contrast-enhanced ultrasound (CE-US)|
75459019|NCT01815320|Device|SonoVue|
75611516|NCT02698267|Drug|BIIB074|Administered as specified in the treatment arm
75611517|NCT02698267|Drug|Itraconazole|200 mg twice daily [BID] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
75611518|NCT01011465|Drug|intranasal oxytocin|The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
75760550|NCT05155319|Biological|Placebo|Placebo
75760551|NCT05149768|Drug|Brentuximab vedotin|Dose 0.6mg/kg will be given every 3 weeks for 16 cycles (48 weeks), in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil (MMF, cellcept) and mycophenolic acid (myfortic)
75760552|NCT05142332|Other|Covid-19 vaccine education materials|videos and flyers containing Covid-19 vaccine educational information
75760553|NCT05130450|Drug|Olezarsen|Olezarsen will be administered by SC injection.
75905106|NCT04484181|Other|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer will be based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
76069602|NCT01400451|Drug|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
76069603|NCT01400139|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
76069604|NCT01399905|Drug|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
76069605|NCT01725308|Drug|FK949E|Taken by mouth (orally).
75760554|NCT05117476|Drug|CLN-619|Anti-MICA/MICB monoclonal antibody
75905107|NCT04473469|Device|Medtronic Interstim II Model 3058 Neurostimulator|Patients will undergo stimulation of the pudendal nerve. All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
75905108|NCT04455620|Biological|BNT151|intravenous
75905109|NCT04455230|Genetic|FLT190|FLT190 is a recombinant adeno-associated viral (AAV) vector (AAVS3) containing the human αGLA gene as a single stranded (ss) deoxyribonucleic acid (DNA).
75905110|NCT04431752|Radiation|Magnetic Resonance Imaging Scan|The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
75905111|NCT04417465|Drug|ABBV-CLS-579|Oral Capsule
75905112|NCT04417465|Drug|PD-1 inhibitor|Intravenous (IV) infusion
75905113|NCT04417465|Drug|VEGFR TKI|Oral Tablet
75611519|NCT01011465|Drug|Placebo|Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
75611520|NCT01011465|Behavioral|Social support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
75611521|NCT01011465|Behavioral|No Social Support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
75760555|NCT05117476|Drug|Pembrolizumab|Keytruda
75760556|NCT05115188|Dietary Supplement|Dex4/ dextrose|Participants will be asked to ingest 21 Dex4® tablets and no more than 300ml of water within 5 minutes. Blood draws will be performed at fasting (before ingesting the dextrose monohydrate tablets), as well as 1 hour after (+/- 15 minutes) and 2 hours (+/- 15 minutes) after ingesting the dextrose monohydrate tablets.
75459020|NCT01815346|Procedure|Acupuncture|"One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes."
75459021|NCT01815346|Behavioral|Questionnaires|Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
75760557|NCT05115188|Dietary Supplement|Glucose beverage|For the 2 hour oral glucose tolerance test (OGTT), women fast for 8 hours and then consume 75g of glucose beverage, and serum glucose levels are taken at fasting, 1 and 2 hours after drinking the glucose beverage. The 75g OGTT is the gold standard and is performed for GDM diagnosis.
75760558|NCT05113095|Biological|Darvadstrocel|Darvadstrocel injection
75611522|NCT02701855|Behavioral|Cognitive tests|"Cognitive tests include:~The MMSE (Mini Mental State Examination)~Free and Cued Selective Recall Reminding Test (FCSRT).~Executive functions (fluencies, TMT A and B, span).~Tests of verbal fluency (literal and category)~Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~The Clinical Dementia Rating Scale~The IADL scale evaluates autonomy.~Geriatric Depression screening Scale (GDS)"
75760559|NCT05112549|Drug|Nivolumab [Opdivo]|Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
75760560|NCT05110599|Drug|Bryophyllum 50% chewable tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g
75905115|NCT04405635|Other|No intervention or exposure|No intervention or exposure
75905116|NCT04405180|Drug|Placebos|Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
75905117|NCT04405180|Drug|20mg sodium nitrite tid|Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
75760561|NCT05110599|Other|Placebo|Lactose with adaption in appearance and tast
75760562|NCT05100082|Drug|Cabozantinib|Cabozantinib tablets
75905118|NCT04376138|Other|BCI intervention|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
75905119|NCT04376138|Other|Conventional Therapy|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
75905120|NCT04359823|Drug|Lovastatin 2%, 2% Cholesterol Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
75459022|NCT01815346|Other|Hand Function and Balance Tests|Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
75459023|NCT01815372|Procedure|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
75905121|NCT04359823|Drug|Lovastatin 2% Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
75459024|NCT01815372|Procedure|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
75459025|NCT01815398|Behavioral|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
75611523|NCT02701855|Biological|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
75611524|NCT02701855|Radiation|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
75760563|NCT05097976|Drug|Methylprednisolone|21 x 4mg tablets beginning on POD 1
75760564|NCT05097976|Drug|Placebo|21 sugar tablets beginning on POD 1 with standard management
75905122|NCT04359680|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
75905123|NCT04359680|Drug|Placebo|Placebo administered orally twice daily for six weeks
75905124|NCT04359680|Dietary Supplement|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
76069606|NCT01725308|Drug|Placebo|Taken by mouth (orally).
76069607|NCT01724528|Drug|Febuxostat|Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)
76069608|NCT01724528|Drug|Allopurinol|Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
76069609|NCT01779440|Behavioral|Electronic Decision Support System|
76069610|NCT01750346|Drug|Topical acetyl hexapeptide-8|
76069611|NCT01750346|Drug|Placebo|
76069612|NCT01750268|Behavioral|Medical Management Counseling|Brief alcohol and medication counseling
76069613|NCT01750268|Drug|Topiramate|Experimental medication
76069614|NCT01750268|Drug|Placebo|Placebo comparator
76069615|NCT01880437|Drug|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
75459026|NCT01815398|Behavioral|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
75760565|NCT05083208|Drug|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II: Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks (including the treatment received in Phase Ib).~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
75905125|NCT04359641|Device|CoMET Display|Display and presentation of predictive monitoring score CoMET
76069616|NCT01880437|Drug|vismodegib|Cohorts 1 and 2: 150 mg orally daily
76069617|NCT01861717|Drug|lanreotide|Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
76069618|NCT01834729|Drug|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
76069619|NCT01834729|Other|Placebo|placebo capsule identical to the study drug
76069620|NCT01860703|Drug|Deferiprone|Ferriprox 500 mg tablets
76069621|NCT01860703|Drug|deferiprone matching placebo tablets|deferiprone matching placebo tablets
76069622|NCT01860703|Drug|moxifloxacin|Active control
76069623|NCT01860703|Drug|placebo|moxifloxacin-matching placebo
76069624|NCT01399593|Drug|Eculizumab|
75459027|NCT01815411|Dietary Supplement|Mushroom extract|The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
75611525|NCT02701855|Other|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
76069625|NCT01833169|Drug|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
76069626|NCT03814083|Device|Active-tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
76069627|NCT03814083|Device|Sham-tDCS|Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
76069628|NCT03814083|Other|Wait-list|No intervention
75760566|NCT05083208|Drug|Chidamide|"Phase Ib: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast until disease progression, death or unacceptable toxicity developments."
75905126|NCT04345003|Device|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
75905127|NCT04333966|Behavioral|Interactive Social Networking Site Parent Based Intervention|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
75611526|NCT04294485|Behavioral|Physical therapy|Electrostimulation combined with exercise
75905128|NCT04333966|Behavioral|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call to Action: A Guide for Families.
75905129|NCT04317846|Other|Intravenous administration of vasodilatory drugs|Administration of the vasodilatory drugs in a different pattern than intra-arterially
75905130|NCT04304625|Drug|Tranexamic Acid / Sodium chloride|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
75611527|NCT02494141|Drug|Curcumin|Dietary Supplement
75905131|NCT04286022|Other|Speed Loss 20% Strength Training|Strength training based on the control of speed loss in execution.
75905132|NCT04286022|Other|Reduced Rest Time Strength Training|Strength training based on a protocol that includes reduced rest times between sets.
76069629|NCT01860079|Procedure|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
76069630|NCT04407819|Radiation|WHOLE BODY DXA|Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
75611528|NCT02494141|Other|Placebo|
75611529|NCT01011387|Procedure|NPWT System|Dressing change 3 times per week
75611530|NCT01011387|Device|NPWT system|3 dressing changes/week for maximum 4 weeks.
75760567|NCT05082662|Drug|Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)|One Diclofenac tablet was administered orally.
75760568|NCT05082662|Drug|Cataflam® 50 coated tablet|One Diclofenac tablet was administered orally.
75760569|NCT05079334|Behavioral|MeTree Questionnaire|"MeTree is a patient driven risk assessment program with Clinical Decision Support (CDS) that enables collection of a three plus generation family health history (FHH) on 128 conditions. CDS is provided in a report with a pedigree and tailored evidence-based guidelines. While patient drive, MeTree also includes a provider-facing report with additional references. These reports promote engagement by both patients and providers and enhance shared decision-making.~MeTree first generates information imported from the participant's EHR record. These data include basic demographic information, any recent lab results, and any listed diseases or conditions from the EHR. Next, MeTree gives the participant an opportunity to fill out a family history tree. The more information the participant provides on their own health and their family member's health, the better MeTree can provide recommendations from current literature."
75760570|NCT05071859|Other|Whole Genome Sequencing|Saliva collection and request for banked blood and tumor samples for sequencing
76069631|NCT01388985|Biological|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
76069632|NCT01388907|Other|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
75459028|NCT01815437|Dietary Supplement|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
75459029|NCT01815437|Dietary Supplement|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
75459030|NCT01815437|Dietary Supplement|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
75459031|NCT01815437|Dietary Supplement|Mushroom Extract|Same quantity of mushroom extract in a capsule
75463337|NCT05854043|Other|Modified ERAS protocol|"Modified ERAS protocol for OLIF mainly include perioperative analgesic drug management, operation optimization in the anesthetic management, management of gastrointestinal function, and early mobilization management.~Perioperative analgesic usage:~Nonsteroidal anti-inflammatory drugs (NSAIDs) given when Visual Analogue Scale (VAS)>3. Prehabilitation: Respiratory function exercise; walk at least 200 meters daily. Gastrointestinal function management: Oral lactulose use routinely. Sedation and analgesia: patient status index (PSI) 25-50; analgesia nociception index (ANI) 50-70. Local anesthetic: local infiltration around the psoas muscle. Postop off-bed activity: start mobilization within 24h."
75611531|NCT02701621|Other|MIRT-AT|Aquatic therapy
75611532|NCT02701621|Other|MIRT|Land-based Therapy
75611533|NCT02698345|Device|drug-eluting balloon (In.PACT Admiral, Medtronic)|
75611534|NCT04215211|Diagnostic Test|Survival prediction for glioma patients|Survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
75611535|NCT02701465|Other|Exercise: local high intensity interval exercise|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
75905133|NCT04274023|Drug|TSR-042|TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
76069633|NCT01388907|Device|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
76069634|NCT01388361|Drug|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
75760571|NCT05071859|Other|Questionnaire Administration|Study questionnaire will include modules that collect information on maternal reproductive history, exposure to known teratogens, medical history, and previous genetic testing.
75760572|NCT05071859|Other|Biospecimen collection|Saliva collection and request for banked blood and tumor samples for sequencing and biomarker analysis
75760573|NCT05071859|Other|Laboratory Biomarker Analysis|Saliva collection and request for banked blood and tumor samples for biomarker analysis
75760574|NCT05059132|Behavioral|Tele-rehabilitation|The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.
75760575|NCT05059132|Other|Education only|The education only arm will receive information on the importance of general exercise following lung cancer treatment.
75905134|NCT04271969|Device|SmartVest Airway Clearance System|Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)
75905135|NCT04268550|Drug|Selpercatinib|Given PO
75905136|NCT04259632|Behavioral|Time Restricted Eating (TRE)|daily eating window restricted to 8 hours
75905137|NCT04259632|Behavioral|Caloric Restriction (CR)|15% daily caloric deficient
76069635|NCT01388361|Drug|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
76069636|NCT01388361|Drug|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
75459032|NCT01815476|Radiation|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
75459033|NCT01815528|Drug|Catumaxomab|"Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~10 µg on day 0~20 µg on day 3~50 µg on day 7~150 µg on day 10"
75459034|NCT01815541|Drug|teicoplanin|
75459035|NCT01815593|Device|Enhanced external counterpulsation|Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
75459036|NCT01815606|Procedure|biopsy with 19 gauge needle|biopsy with 19 gauge needle
75459037|NCT01815606|Procedure|biopsy with 25 gauge needle|biopsy with 25 gauge needle
75611536|NCT02701465|Other|Exercise: best clinical practice|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
75611537|NCT00616135|Procedure|ADRC-Enhanced Autologous Fat Transplant|Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.
75611538|NCT01011309|Biological|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
75611539|NCT01011309|Drug|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
76069637|NCT04028895|Diagnostic Test|Dosage of IRAP during OGTT|Visit 1: oral glucose tolerance test. visit 2: hyperinsulinemic euglycemic clamp
76069638|NCT05368935|Drug|Nitazoxanide|500 mg Twice Daily for 7 days
75459038|NCT01815632|Other|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
75459039|NCT01815632|Other|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
75611540|NCT04214821|Drug|Levofloxacin Ophthalmic Solution|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
75611541|NCT04214821|Drug|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
75611542|NCT00616213|Biological|filgrastim|filgrastim will be administered at a standard dose and schedule
75611543|NCT00616213|Drug|PR104|PR104 is administered intravenously once every 21 days
75611544|NCT00616213|Other|F-18-fluoromisonidazole|F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan
75760576|NCT05053191|Behavioral|Partnership, Assessment, Care and Transition training intervention|Partnership, Assessment, Care and Transition to psychosocial resources. Nurses who participate in PACT will receive 8 hours of training in a single, full-day workshop. We will train nurses in clusters of 10-12 nurses at one time, which will allow for cross-coverage with minimal disruption to workflow, and provide a more intimate, small-group learning environment.
75905138|NCT04255602|Drug|Ticagrelor 60mg|Ticagrelor 60mg plus Aspirin 100mg for experimental group
75905139|NCT04255602|Drug|Ticagrelor 90mg|Ticagrelor 90mg plus Aspirin 100mg for active comparator group
75905140|NCT04240756|Behavioral|Behavioral Parent Training|Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
75905141|NCT04240756|Drug|Extended release mixed amphetamine salts (MAS)|The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
75905142|NCT04236596|Device|Medtronic Interstim II Model 3058 Neurostimulator|All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
75905143|NCT04229446|Behavioral|Music based caregiving|The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement.
75905144|NCT04228263|Drug|Hydroxychloroquine|400mg
75905145|NCT04228263|Drug|Folic Acid|5 mg
75905146|NCT04228263|Drug|Low-dose aspirin|75 mg
75905147|NCT04222634|Other|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
75905148|NCT04205812|Drug|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
75905149|NCT04205812|Drug|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
75905150|NCT04205812|Drug|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.
75459040|NCT01815658|Device|Carbon fiber intramedullary nail (PEEK-CF)|Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
75459041|NCT01815684|Drug|ASP3652|Oral
75459042|NCT01815684|Drug|Placebo|Oral
75611545|NCT00615667|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
75611546|NCT00615043|Procedure|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
75611547|NCT04295655|Other|Global Exercise intervention|The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
75611548|NCT04295655|Other|Functional Electrostimulation Group|"The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
75611549|NCT04295655|Other|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
75611550|NCT02697955|Drug|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
75611551|NCT02697955|Other|Placebo|9 mg sodium chloride pr. ml (0,9 %)
75611552|NCT04294329|Procedure|US-guided Quadratus lumborum block.|Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
75611553|NCT04294329|Drug|Bupivacaine|Bupivacaine
75760577|NCT05051072|Procedure|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"
75760578|NCT05036499|Behavioral|Personalized Feedback Intervention|Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety
75760579|NCT05032976|Biological|Tozinameran 12 Years of age and older|BNT162b2 (purple cap) is administered with dilution, while BNT162b2 (grey cap) is administered without dilution. Both formulations are administered by intramuscular injection (IM) of 0.3 mL. According to the approved and authorized label, the recommended dose of BNT162b2 is a series of two doses (1 day 1 dose, 0.3mL each) 21 days apart and administered IM.
75760580|NCT05032976|Biological|Tozinameran 5 to 11 Years of age|"BNT162b2 (orange cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, the recommended dose of BNT126b2 is a series of two dose (1day 1dose, 0.2mL) 21days apart and administered IM.~But, a third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised aged 5 to 11 years of age."
75905151|NCT04205812|Drug|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
75905152|NCT04205812|Drug|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
75905153|NCT04205812|Drug|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
75459043|NCT01815697|Device|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
75459044|NCT01815710|Other|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
75611554|NCT04294329|Drug|Saline|normal saline
75611555|NCT02871609|Other|Stent examination, urinary analysis, USSQ questionnaire|
75611556|NCT02701309|Device|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
75611557|NCT03250507|Drug|Bupivacaine|0.25% bupivacaine for TAP block
75905154|NCT04205812|Drug|nab-Paclitaxel|nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
75760581|NCT05032976|Biological|Tozinameran 6 months to 4 years of age|"BNT162b2 (maroon cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, it is recommended that the recommended dose of BNT162b2 is administered by intramuscular injection (IM) twice (once a day, each 0.2mL) at least of 21 days apart, and Dose 3 at least 8 weeks later.~Children who will turn from 4 years to 5 years of age between their doses in the vaccination course should receive their age-appropriate dose at the time of the vaccination and the interval between doses is determined by the child's age at the start of the vaccination course.~The interchangeability of BNT162b2 with COVID-19 vaccines from other manufacturers to complete the vaccination course has not been established.~BNT162b2 (6 months to 4 years of age) should be used only for infants and children 6 months to 4 years of age."
75760582|NCT05032976|Biological|Riltozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 1) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 1) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 1) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
75760583|NCT05032976|Biological|Famtozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
75760584|NCT05032976|Biological|Famtozinameran 5 to 11 Years of age|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age (orange cap) is administered after dilution by intramuscular injection (IM) of 0.2mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
75760585|NCT05032976|Biological|Raxtozinameran 12 years of age and older|"BNT162b2 OMI XBB.1.5 (grey cap) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.~For individuals who have previously been vaccinated with a COVID-19 vaccine, BNT162b2 OMI XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine."
75760586|NCT05032976|Biological|Raxtozinameran 6 months to 4 years of age|BNT162b2 OMI XBB.1.5 (maroon cap) is administered intramuscularly after dilution. For infants and children 6 months to 4 years of age without history of completion of a COVID-19, each 0.2 mL of dose is administered for a total of three vaccinations. The second dose is administered 3 weeks after the first dose followed by a third dose administered at least 8 weeks after the second dose. For infants and children 6 months to 4 years of age with history of completion of a COVID-19 primary course or prior SARS CoV-2 infection, a single dose of 0.2 mL is administered.
75760587|NCT05027971|Device|Flexiva Pulse High Power Single-Use Laser Fibers|Flexiva Pulse High Power Single-Use Laser Fibers are intended to be used as a device that transmits Ho:YAG laser energy from cleared laser consoles to urological anatomy.
75760588|NCT05018091|Drug|Dexamethasone 4mg|4mg intravenous dexamethasone, administered shortly after induction of anesthesia
76069639|NCT01399125|Drug|Rivastigmine Patch|Once-daily target patch size 10 cm²
76069640|NCT01399125|Drug|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
76069641|NCT01399125|Drug|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
76069642|NCT01399125|Drug|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
75459045|NCT01815710|Other|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
75459046|NCT01815723|Drug|FP187|500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks
75611558|NCT03250507|Drug|Liposomal bupivacaine|Exparel for TAP block
75611559|NCT03250507|Drug|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
75459047|NCT01815723|Drug|Dimethyl fumarate|720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks
75459048|NCT01815723|Drug|FP187 placebo|FP187 matching placebo tablets in the same regimen as for FP187 arm
75459049|NCT01815723|Drug|Fumaderm® placebo|Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
75611560|NCT00997893|Dietary Supplement|Soy Phytoestrogen|Novasoy® pill (55 mg)
75611561|NCT00997893|Drug|Estradiol|Estradiol pill (1 mg)
75611562|NCT00997893|Drug|Medroxyprogesterone Acetate (MPA)|medroxyprogesterone acetate (MPA) (10mg)
75459050|NCT01815762|Other|Active arm|"In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.~If the patient does not tolerate the intervention (as described above), he will continue the study in the medication arm, where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication."
75611563|NCT00997893|Drug|Soy Placebo|oral placebo pill (0mg Soy Phytoestrogen)
75611564|NCT00997893|Drug|MPA Placebo|oral placebo pill (0mg MPA)
75611565|NCT02697877|Drug|Regadenoson|
75611566|NCT04214665|Drug|Alpha Lipoic acid 600 mg HR film coated tablets|
75611567|NCT02870673|Drug|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
75611568|NCT02870673|Drug|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
75611569|NCT02870673|Device|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
75611570|NCT02870673|Device|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
75459051|NCT01815775|Other|clinical and imaging examinations|"Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation"
75905155|NCT04201132|Device|Carotid artery stenting with Neuroguard IEP System|Carotid artery stenting (treatment) with the Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection
75905156|NCT04198870|Device|MitraClip™ device implantation|Transcatheter repair of the mitral valve using MitraClip™ device
75905157|NCT04198870|Procedure|Mitral Valve Repair Surgery|Surgical repair of the mitral valve
75905158|NCT04175886|Drug|Tofacitinib|Patients will be treated with tofacitinib
75459052|NCT01815801|Other|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
75459053|NCT01815801|Other|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
76069643|NCT04015791|Other|NOCISCAN-LS Disc MR Spectroscopy|The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain
75459054|NCT01815814|Other|Rolfing / Myofascial Structural Integration|"Rolfing is similar to deep massage. It is also known as myofascial structural integration."
76069644|NCT04026633|Behavioral|CAA|Participants will write about the use of PBS and alcohol use.
76069645|NCT04026633|Behavioral|Control|Participants will write about eating and exercise.
76069646|NCT01399047|Drug|Mycophenolate mofetil|The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
76069647|NCT01399047|Drug|Liquid Placebo|The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
76069648|NCT05369169|Behavioral|Resonance breathing|Participants will synchronize their breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
75459055|NCT01815827|Drug|inclacumab|single intravenous doses
75459056|NCT01815853|Radiation|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
75459057|NCT01815853|Drug|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
75459058|NCT01815853|Procedure|R0 D2 Gastrectomy|
75459059|NCT01815853|Drug|Adjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
75459060|NCT01815866|Procedure|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
75459061|NCT01815892|Drug|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
75459062|NCT01815892|Drug|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
75760589|NCT05018091|Drug|Dexamethasone 8 Mg/mL Injectable Suspension|8mg intravenous dexamethasone, administered shortly after induction of anesthesia
75760590|NCT05018091|Drug|Dexamethasone 16mg|16mg intravenous dexamethasone, administered shortly after induction of anesthesia
75760591|NCT05015621|Drug|Surufatinib plus Toripalimab|Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
75760592|NCT05015621|Drug|5-fluorouracil, Calcium folinate and Irinotecan|Irinotecan 180 mg/m^2, Calcium folinate 400 mg/m^2, 5-FU total 2800 mg/m^2 will be administrated once two weeks.
75760593|NCT05007548|Drug|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
75760594|NCT04993131|Procedure|Liver transplant|Liver transplant.
75611571|NCT02701231|Device|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
75905159|NCT04151901|Other|Resistance Exercise Rehabilitation|Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.
75760595|NCT04984291|Device|Alliance Glenoid|Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
76069649|NCT05369169|Behavioral|Low demand cognitive task|Different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles
75611572|NCT02701231|Drug|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
75611573|NCT02701231|Device|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
75611574|NCT02701075|Device|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
75760596|NCT04984291|Device|Identity Stem|Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
75760597|NCT04977830|Device|Xenon-129|Patients will undergo a hyperpolarized MRI with administered Xenon gas
75760598|NCT04974528|Biological|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
75760599|NCT04974528|Biological|Rapid-acting Insulin Analog|"Pharmaceutical form: clear and colorless solution for injection~Route of administration: subcutaneous"
75905160|NCT04151901|Other|Walking-based rehabilitation|Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
75905161|NCT04151082|Drug|Methylprednisolone|Given IV
76069650|NCT01387737|Drug|TA-7284-Low|TA-7284-Low
76069651|NCT01387737|Drug|TA-7284-High|TA-7284-High
75905162|NCT04151082|Drug|Prednisone|Given PO
76069652|NCT01387347|Drug|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
76069653|NCT01387347|Drug|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
76069654|NCT04040439|Drug|Dexmedetomidine Hydrochloride|"[Sedation during and after mechanical ventilation in the intensive care setting] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate."
75459063|NCT01815905|Other|Mobile program for occupational and speech therapy|
75459064|NCT01815905|Other|Traditional rehabilitation therapy|
75459065|NCT01815944|Drug|0.75% Ropivacaine|
75459066|NCT01815944|Drug|Normal saline|
75459067|NCT01815944|Drug|Dextrose 5%|
75459068|NCT01815970|Behavioral|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
75459069|NCT01815996|Other|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
75459070|NCT01814735|Other|Brown rice|
75459071|NCT01814735|Other|White rice|
75760600|NCT04974528|Biological|Basal Insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75905163|NCT04151082|Other|Quality-of-Life Assessment|Ancillary studies
75905164|NCT04151082|Other|Questionnaire Administration|Ancillary studies
76069655|NCT04012827|Drug|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
75611575|NCT02701075|Device|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
75611576|NCT00615745|Drug|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
75611577|NCT04216069|Other|Total 12 regimen|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Subjects from the Group 1 will use a regimen with Colgate Total 12 toothpaste + Plax mouthwash + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
75905165|NCT04139499|Procedure|Drug-induced sleep endoscopy (DISE)|DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.
75905166|NCT04139499|Procedure|High-resolution manometry (HRM):|After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.
75905167|NCT04135066|Other|Refine grain breakfast|After wearing continuous glucose monitoring device (CGM) on baseline, participants will be provided with breakfast A on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast A is pseudorandom. Breakfast A contains white bread (100g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
75905168|NCT04135066|Other|Whole grain breakfast|After wearing CGM on baseline, participants will be provided with breakfast B on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast B is pseudorandom. Breakfast B contains plain oats (70g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
75905169|NCT04134884|Drug|Talazoparib|Talazoparib will be taken on days 4-21, 6-21 or 1-21 at a dose level of 0.25, 0.5, 0.75 or 1.0 mg depending on cohort assignment
75905170|NCT04134884|Drug|ASTX727|ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
76069656|NCT01859923|Drug|Delamanid|Participants received adult formulation delamanid as per regimen specified in the arm description. Morning dose of the delamanid BID regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard dinner meal.
76069657|NCT01859923|Drug|Delamanid Pediatric Formulation (DPF)|Participants received delamanid as an extemporaneous suspension using the delamanid pediatric dispersible tablet formulation. Morning dose of the delamanid BID/once daily (QD) regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard meal.
75459072|NCT01816009|Other|duration of antibiotic treatment|Used antibiotics already have the AMM in this indication
75459073|NCT01816035|Other|Laboratory Biomarker Analysis|Correlative studies
75459074|NCT01816035|Other|Pharmacological Study|Correlative studies
75459075|NCT01816035|Biological|Trastuzumab Emtansine|Given IV
75459076|NCT01816087|Other|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
75459077|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
75459078|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
75459079|NCT01816113|Biological|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
75459080|NCT01816113|Biological|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
75459081|NCT01815177|Device|Arthroscopic transosseous fixation|
75760601|NCT04973696|Behavioral|Toolkit for Optimal Recovery after Orthopedic Injury|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
75760602|NCT04973696|Other|Minimally Enhanced Usual Care (MEUC)|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
75760603|NCT04966507|Drug|Listerine Antiseptic Mouthwash Product|COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
75760604|NCT04966507|Drug|Biotene Mouthwash|Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
75760605|NCT04962490|Procedure|Repair: suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich)|Repair tendon flexor sections in the hand: Suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich). The surgery depends on the anatomical area of the tendon section and the time between the injury and the operation.
75760606|NCT04961658|Biological|GEM00220|Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion
75760607|NCT04947800|Device|Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points
75760608|NCT04947800|Device|Pulmonary rehabilitation program + Lv7/Gb26|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points
75760609|NCT04933617|Biological|Rituximab|Rituximab 375 mg/m2 IV per protocol on Day 1 of each cycle up to 6 cycles
75760610|NCT04933617|Drug|Etoposide|Etoposide 50 mg/m2/day CIVI on Days 1-4 of each cycle up to 6 cycles
75760611|NCT04933617|Biological|Copanlisib|Copanlisib IV is administered at a fixed dose (30 mg, 45 mg, or 60 mg) on days 1 and 5 of each 21-day cycle for up to 6 cycles
75760612|NCT04933617|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on Day 5 of each cycle up to 6 cycles
75760613|NCT04933617|Drug|Doxorubicin|Doxorubicin 10 mg/m2/day CIVI on Days 1-4 of each cycle up to 6 cycles
75905171|NCT04133168|Device|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~POLARx™ or POLARx™ FIT Cryoablation Catheter~POLARMAP™ Catheter~POLARSHEATH™~SMARTFREEZE™ Console~Diaphragm Movement Sensor (DMS)~Related Accessories"
75905172|NCT04132960|Drug|DS-8201a|Anti-HER2-antibody drug conjugate (ADC)
76069658|NCT01859923|Drug|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e. OBRs) was based on Search Results Web result with site links~World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study Investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results."
75905173|NCT04116671|Device|Neuromechanical Gait Assist|A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
76069659|NCT01832155|Behavioral|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
75459082|NCT01815177|Device|Suture anchors|
75459083|NCT01816178|Behavioral|communication training|Participants were instructed in the use of a voices output communication aid.
75760614|NCT04933617|Drug|Vincristine|Vincristine 0.4 mg/m2/day (no cap) CIVI on Days 1-4 of each cycle up to 6 cycles
75760615|NCT04933617|Drug|Prednisone|Prednisone 60 mg/m2 PO BID Days 1-5 (total 120mg/m2/day)
75760616|NCT04931485|Other|Fluid management according to the REDUCE Fluid Protocol|Fluid management according to the protocol will be guided by pre-defined clinical signs for impaired perfusion and fluid overload.
75760617|NCT04931485|Other|Standard of care|Fluid resuscitation and de-resuscitation will be managed according to the standard of care
75760618|NCT04913415|Other|Low Suction Strategy of Chest Tube Management|A digital chest tube will be set to a low pressure mode (-8mmHg) during recovery after minimally invasive lung resection.
75760619|NCT04913415|Other|Standard Suction Strategy of Chest Tube Management|A digital chest tube will be to the standard suction mode (-20mmHg) during recovery after minimally invasive lung resection.
75760620|NCT04906928|Device|MRI|"standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence.~3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)"
75905174|NCT04111094|Diagnostic Test|No intervention|No intervention
76069660|NCT01832155|Behavioral|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
75760621|NCT04904614|Drug|Letermovir|Open label trial of the licensed drug, letermovir, in a population of heart transplant recipients for which it is not yet licensed
75760622|NCT04901078|Drug|KNX100|KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
75611578|NCT04216069|Other|Toothbrushing alone|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Group 2 will use Colgate Cavity Protection Toothpaste + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
75760623|NCT04899921|Drug|Ipilimumab|Intravenous injection
75905175|NCT04101357|Drug|BNT411|intravenous
75905176|NCT04101357|Drug|Atezolizumab|intravenous
75905177|NCT04101357|Drug|Carboplatin|intravenous
75905178|NCT04101357|Drug|Etoposide|intravenous
75611579|NCT02697721|Behavioral|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
75905179|NCT04069793|Device|Commercially available device|A commercially available and registered with the FDA prosthesis equipped with a powered single-degree of freedom wrist and powered hand.
75905180|NCT04069793|Device|Non FDA registered device|An experimental, non FDA registered prosthesis equipped with a multi function wrist and a powered hand.
75905181|NCT04063592|Procedure|Residual limb revision|Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
75905182|NCT04057924|Other|abstention from CIN2 treatment and surveillance for at least 2 years|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
75905183|NCT04049825|Drug|OPB-111077|OPB-111077+bendamustine
75905184|NCT04049825|Drug|OPB-111077|OPB-111077+rituximab+bendamustine
75905185|NCT04046224|Biological|ST-920|Single dose of investigational product ST-920
75905186|NCT04040166|Diagnostic Test|PET/MRI of carotid arteries with 68Ga DOTATATE|PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
75611580|NCT02697721|Other|Control with delayed intervention|Control with delayed intervention
75611581|NCT04215367|Dietary Supplement|High phenolic EVOO intake|During the pilot dietary intervention patients with CLL consumed before their meals, 40 ml/day high phenolic EVOO for 6 months
75611582|NCT04215367|Dietary Supplement|No High phenolic EVOO intake|Medical record of each patient's was followed during 6 month before dietary the intervention
75760624|NCT04899921|Drug|Nivolumab|Intravenously (IV) into the vein
75760625|NCT04899921|Drug|Troriluzole|Taken orally
75760626|NCT04899921|Drug|Placebo|Taken orally
75760627|NCT04890834|Other|Best Practice|Receive standard care
75760628|NCT04890834|Other|Exercise Intervention|Participate in yoga sessions
75760629|NCT04890834|Other|Questionnaire Administration|Ancillary studies
75905187|NCT04040088|Procedure|Computed Tomography|Undergo PET/CT
75905188|NCT04040088|Drug|Gallium Ga 68-DOTATATE|Given IV
75905189|NCT04040088|Procedure|Positron Emission Tomography|Undergo PET/CT
75905190|NCT04037228|Device|KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)|The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
75611583|NCT02697799|Behavioral|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
75760630|NCT04880317|Diagnostic Test|Cardiac Magnetic Resonance|All enrolled patients will undergo a contrast-enhanced CMR examination for the assessment of extracellular volume
75760631|NCT04880317|Diagnostic Test|Additional CT acquisition|All enrolled patients will undergo an additional CT scan at 5 minutes post-contrast injection to evaluate myocardial relative enhancement
75760632|NCT04880317|Diagnostic Test|Blood tests|Patients will undergo blood tests to review hematocrit, Sars-CoV-2 antibody status and cardiac fibrosis biomarkers
75760633|NCT04858256|Drug|Pacritinib|Pacritinib will be dosed at 200mg twice daily.
75760634|NCT04850430|Procedure|Gastric venous reconstruction|Patients will be assigned to study after intraoperative evaluation of gastric venous drainage after coronary vein resection during TP, and the gastric venous outflow will be reconstructed after TP.
75760635|NCT04848038|Behavioral|Exercise|Standard public health exercise recommendations
75760636|NCT04812717|Device|CytoSorb device|The CytoSorb device will be placed in the CPB circuit in half of the study population during their cardiac operation.
75760637|NCT04802954|Other|Video acquisition|One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).
75760638|NCT04798859|Other|Family centered in-home rehabilitation|Goal-oriented individualized intervention targeting brain injury related areas noted as challenging by the child and family
75905191|NCT04019119|Behavioral|Digital intervention|The information group will receive through a mobile application tips to reduce sedentary lifestyle and promote healthy living habits.
75905192|NCT04000672|Procedure|3D printed patient specific metal jigs (PSI jig)|PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.
75905193|NCT04000672|Procedure|HTO with navigation|In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
75905194|NCT03979170|Procedure|Lung tumor resection|lung tumor resection
76069661|NCT05364333|Procedure|Remote ischemic preconditioning|For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
76069662|NCT01879579|Other|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
75611584|NCT02697799|Behavioral|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
75611585|NCT02700607|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
75611586|NCT02700607|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
75760639|NCT04798859|Other|Control|Usual follow-up in the municipality
75760640|NCT04790344|Device|Investigational LUX-Dx ICM Implant|All subject will receive an investigational version of the LUX-Dx ICM device.
75760641|NCT04784832|Device|Transcranial magnetic stimulation|Magnetic stimulation of the cortex
75459084|NCT01816191|Drug|Diltiazem Hydrochloride Cream and Oral Diltiazem|
75459085|NCT01816204|Behavioral|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
75459086|NCT01816204|Behavioral|face-to-face individual therapy|weekly individual counseling as usual.
75760642|NCT04784832|Device|Peripheral Nerve Stimulation|Electric stimulation of the nerves
75459087|NCT01816217|Device|Intubation with The McGrath Mac videolaryngoscope|
75459088|NCT01816282|Drug|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
75459089|NCT01816321|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
75459090|NCT01816321|Drug|recombinant FSH|recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
75760643|NCT04784832|Device|Transcranial direct current stimulation|Electric stimulation of the cortex
75611587|NCT04782739|Other|None - Descriptive study|Descriptive study
75760644|NCT04784832|Device|Paired Associative Stimulation|Combined magnetic and electric stimulation of cortex and nerve, respectively
75760645|NCT04784832|Device|Wrist|Short-term immobilization of the arm
75611588|NCT04215913|Other|The investigators will extract total protein, DNA and RNA from PSC patients.|The investigators will extract total protein, DNA and RNA from PSC patients.
75760646|NCT04784832|Device|Robotic arm|External perturbation of force field induced by robotic arm
75760647|NCT04784832|Device|Cervicomedullar stimulation|Electric stimulation of the muscle
75760648|NCT04784832|Other|Physical training|Training to perform the task by actually doing the task
75760649|NCT04784832|Other|Mental training|Training to perform the task by imaging doing the task
75760650|NCT04783727|Diagnostic Test|Individualised treatment duration based on RNA transcriptomic model|Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.
75760651|NCT04781309|Drug|NT-I7|NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc). NT-I6 has a molecular weight of 104 kD. The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
75760652|NCT04777331|Drug|Prasinezumab|Prasinezumab will be administered as an IV infusion to participants Q4W.
75760653|NCT04777331|Drug|Placebo|Prasinezumab placebo will be administered to participants.
75760654|NCT04765488|Procedure|WashIn /WashOut|"According Wash In / WashOut procedure in study group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
75459091|NCT01816321|Drug|Ganirelix|Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
75459092|NCT01816321|Drug|hp HMG|hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
75611589|NCT02697643|Behavioral|BHCDS-based recommendations|
75611590|NCT02697643|Behavioral|Non-tailored recommendations|
75760655|NCT04761471|Device|TI transcranial electrical stimulation|"Participants will undergo transcranial electrical stimulation, which will be delivered with low current amplitudes (<= 2 mA) established with international safety guidelines for electrical stimulation. Threshold for the current amplitude will be established by participants themselves, such that they cannot distinguish when stimulation is applied and not applied.~Duration of stimulation will not last longer than 30 minutes."
75760656|NCT04751747|Procedure|Computed Tomography|Undergo CT simulation
75760657|NCT04751747|Other|Contrast Agent|Given IV
75459093|NCT01816334|Drug|methylprednisolone|
75459094|NCT01816334|Drug|Ketoprofen|
75459095|NCT01816334|Drug|Sodium Chloride|
75459096|NCT01816347|Procedure|Routine PCI|
75459097|NCT01816360|Other|Olfactory aromatherapy|Inhalation of essential oils.
75459098|NCT01816360|Other|Yogatherapy|Yogatherapy respiratory exercises.
75459099|NCT01816373|Device|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
75611591|NCT05324839|Drug|Botulinum toxin type A|injecting different dosage to different group
75459100|NCT01816399|Procedure|Routine coronary angiography|
75459101|NCT01816412|Device|MD02-LDCB Paclitaxel coated balloon catheter|
75459102|NCT01816412|Procedure|Standard Uncoated Balloon Angioplasty Catheter|
75611592|NCT02700685|Dietary Supplement|Pycnogenol|Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
75611593|NCT02700685|Drug|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release.
75611594|NCT02700685|Other|Placebo|Placebo treatment (identical capsules containing excipients only)
75611595|NCT02700763|Other|[18F]dabrafenib molecular imaging|A [18F]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
75611596|NCT04188613|Device|Percutaneous tracheostomy|Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
75611597|NCT00616291|Biological|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
76069663|NCT01386645|Other|low glycemic index (LGI) diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index <35) for 4 weeks with all food provided by the Human Nutrition Lab
75760658|NCT04745832|Drug|Zandelisib|Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
75760659|NCT04745832|Drug|Rituximab|Rituximab IV 375 mg/m2 for 6 cycles
75905195|NCT03970304|Drug|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
75905196|NCT03965494|Drug|BGB 324 (before surgery)|Given by mouth either BEFORE therapeutic conventional surgery
76069664|NCT01386645|Other|high glycemic index (HGI) diet plus placebo (PLAC)|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
76069665|NCT01386645|Drug|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
76069666|NCT01387269|Drug|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
76069667|NCT01387269|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
75459103|NCT01816425|Device|Thermoplastic partial denture|
75760660|NCT04745832|Drug|Bendamustine|Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
75760661|NCT04745832|Drug|CHOP|Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
75905197|NCT03965494|Drug|BGB 324 (after surgery)|Given by mouth either AFTER therapeutic conventional surgery
75905198|NCT03921008|Drug|Paclitaxel|-Commercial supply
75905199|NCT03921008|Radiation|Radiation therapy|-Patients may be treated with electrons, 3D conformal photon radiotherapy, intensity modulated photon radiotherapy (IMRT), proton radiation therapy, or a combination of these.
76069668|NCT01859143|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
76069669|NCT01859143|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
76069670|NCT01878253|Device|Sidus Stem-Free Total Shoulder Arthroplasty System|
76069671|NCT01878175|Behavioral|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
75459104|NCT01816425|Device|CoCr partial denture|
75463338|NCT05854043|Other|routine protocol|Perioperative analgesic usage: NSAIDs given follow the patients requirement. Prehabilitation: None. Gastrointestinal function management: None. Sedation and analgesia: bispectral index (BIS) 40-60. Local anesthetic: None. Postop off-bed activity: mobilization follow the patients wish.
75611598|NCT03151681|Drug|Propranolol Pill|1mg/kg of propranolol 60 minutes prior to memory reactivation
75611599|NCT05324605|Procedure|Questionnaire and use of 3 D tools|Resulting computer tomography(CT) results are transferred to a 3 D projection. Patients will be asked to wear 3 D glasses to be able visualizing the diagnosed vascular pathology. The physician will explain the disaese and treatment. The patient is ask to fill out a questionnaire post 3D consulting
75611600|NCT02700373|Drug|PDC-APB|
75611601|NCT02700373|Drug|Placebo|
75905200|NCT03921008|Procedure|Research blood draw|-Within 1 week (prior to cycle 1 of paclitaxel preferred but not required), pre-radiation therapy (any time weeks 5-7 as long as radiation therapy has not started), post-radiation therapy (day of last fraction), 14 days post-radiation therapy, and within 2 weeks post-surgery
75905201|NCT03915106|Device|Brace|Wear a rigid brace
75611602|NCT04215445|Drug|Empagliflozin 25 MG|Tab.empagliflozin 25mg once daily for 28 days
75611603|NCT04215445|Device|OCT-A|Optical coherence tomography angiography (OCT-A) is a non-invasive method to study the microvasculature of the retina and choroid.
75905202|NCT03915106|Procedure|Surgical correction using implants|Surgical correction of spine using implants (metallic rods and metallic screws)
75905203|NCT03914742|Drug|PARP Inhibitor BGB-290|Given PO
75905204|NCT03914742|Drug|Temozolomide|Given PO
75905205|NCT03914742|Procedure|Therapeutic Conventional Surgery|resection surgery
75905206|NCT03901053|Device|Reaktiv AFO|This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.
75760662|NCT04745572|Behavioral|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
75760663|NCT04745572|Behavioral|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
75760664|NCT04744584|Other|Medication reconciliation|MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
75760665|NCT04744584|Other|Medication reconciliation|After inclusion of the patient, the MR will be carried out retrospectively, that is to say that the information concerning the treatments taken by the patient at the time of the first assessment will be retrieved during the period of the first reassessment (therefore with a delay of 12 months depending on the deadline for the first assessment). All these discrepancies will be considered medication errors if the reason for the discrepancy was not entered in the patient's computerized medical record (IMR).
75760666|NCT04742400|Drug|tolebrutinib 60mg|60 mg orally
75760667|NCT04742400|Drug|tolebrutinib 120mg|120 mg orally
75760668|NCT04740567|Behavioral|Cognitive Training|The cognitive training program regimen and its degree of difficulty will be tailored to the patient's current level of cognitive functioning and interests. Patients will be asked to work through progressively more challenging exercises pertaining to orientation, attention, problem-solving, and memory. These cognitive training exercises will be significantly difficult but when they can be completed easily (>85% mastery), their difficulty will be increased, and this process will be repeated as appropriate. They will also perform puzzles, games, or cognitive tasks related to their hobbies.
75760669|NCT04740567|Behavioral|Goal Management Training|"Goal management training will (1) teach patients compensatory strategies such as stop techniques [e.g., to stop and think about consequences of a decision before making it]; (2) help them to take complex tasks and divide them into manageable subtasks to increase the likelihood of completing the task; and (3) enable them to learn to regain cognitive control when their behavior becomes incompatible with their intended goals. GMT is anchored in sustained and vigilant attention theory and it enables patients to actively attend to higher order goals critical to functioning. GMT is tailored to the individual needs of the patient. During the initial session, the Cognitive Intervention Specialist will meet with the subject and their family member or caregiver to identify these functional and cognitive deficiencies."
75760670|NCT04726592|Drug|Clorazepate Dipotassium|Clorazepate Dipotassium : 20 mg intravenous injection
75760671|NCT04726592|Drug|Placebo|Placebo IV
75760672|NCT04726592|Drug|Ketoprofen|Ketoprofen 100 mg IV
75905207|NCT03901053|Device|PhatBrace AFO|Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
75905208|NCT03889613|Other|prospective follow-up with videocapsule|prospective follow-up with videocapsule
75459105|NCT01816464|Biological|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe."
75459106|NCT01816490|Drug|Intravenous Silibinin (iSIL)|
75459107|NCT01816503|Drug|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
75760673|NCT04726592|Drug|Metoclopramide|Metoclopramide 10 mg IV
75905209|NCT03880344|Device|Vibration Therapy|Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
75905210|NCT03880344|Combination Product|Physiotherapy|Physiotherapy as post-operative rehabilitation programme for 6 months.
75905211|NCT03870919|Drug|Palbociclib|"The included patients will first receive the following systemic treatment according standard of care:~Non-steroidal aromatase inhibitor (letrozole)~Palbociclib~Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option."
76069672|NCT01878097|Behavioral|Green Dot Bystander Intevention|Intervention allocated at the school level
76069673|NCT01878097|Behavioral|Control|Awareness Education
75905212|NCT03870919|Other|locoregional treatment|After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
75905213|NCT03867357|Drug|GnRH agonist|Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.
75611604|NCT01032265|Behavioral|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
75905214|NCT03855800|Diagnostic Test|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
75905215|NCT03855800|Procedure|Pancreatic Surgery|Surgical resection of pancreatic cyst
75459108|NCT01816516|Behavioral|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
75611605|NCT01032265|Behavioral|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
75611606|NCT00951457|Drug|Bendamustine|
75611607|NCT00951457|Drug|Alemtuzumab|
75760674|NCT04713982|Drug|Deutetrabenazine|Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor
75611608|NCT05324527|Other|Hand Massage|Hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
75611609|NCT02691871|Drug|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
75611610|NCT02691871|Drug|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
75611611|NCT02691871|Drug|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
75611612|NCT02700217|Procedure|Bupivacaine and Diamorphine|
75611613|NCT02700217|Procedure|Remifentanil, Propofol and Cistracurium|
75611614|NCT02700217|Procedure|Bupivacaine and Rectus Sheath injection|
75611615|NCT02690467|Device|Insupen G34x3,5mm|
75611616|NCT02690467|Device|Insupen G32x4mm|
75760675|NCT04712721|Drug|68Ga-FF58|Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
75760676|NCT04711356|Drug|Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection|Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
75760677|NCT04711135|Drug|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
75905216|NCT03855800|Procedure|Endoscopy Exam|Clinically indicated endoscopic ultrasound
75905217|NCT03851198|Procedure|Standard Care or Usual Clinical Practice|The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.
75905218|NCT03850574|Drug|Tuspetinib|Daily (QD), continuous dosing
75905219|NCT03850574|Drug|Venetoclax Oral Tablet|Venetoclax will be given to patients in combo treatment group (Part C) either in 50 mg or 100 mg tablets
75905220|NCT03830320|Drug|[64Cu]FBP8|Injection of Copper-64 radiopeptide to detect thrombosis
75905221|NCT03830320|Device|PET/MR|Whole body imaging using Siemens mMR PET/MR scanner
75905222|NCT03830320|Procedure|Blood Collection|A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
75905223|NCT03830320|Procedure|Electrocardiogram|A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
76069674|NCT01750190|Drug|Roxadustat|Oral tablets
76069675|NCT01750190|Drug|Placebo|Oral tablets
75760678|NCT04708600|Behavioral|Pitch Elevation Therapy|"Goal: mean fundamental frequency of 180Hz (range 140 and 300Hz); Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~auditory discrimination of lower and higher tones~pitch glides~pitch glides using straw phonation and resonance tube phonation~practice of higher pitch voice (target: 180Hz) in isolated vowels - syllables - mono and bisyllabic words -phrases - sentences and texts - conversation (generalization to spontaneous speech)"
75760679|NCT04708600|Behavioral|Articulation Resonance Therapy|"Goal: increase in lipspreading, forward tongue carriage, larynx elevation, forward resonance, precise articulation; 5 sessions Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~auditory and visual discrimination of forward vs backed tongue carriage and lip spreading vs lip rounding)~practice of technique on isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~practising larynx elevation through the twang technique, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~forward resonance, focusing on oral forward resonance rather than chest resonance, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~clear, precise articulation and cork exercise"
75760680|NCT04708600|Behavioral|Sham therapy|"Goal: active sham treatment, 4 sessions Doses and duration: 4 one hour and 15 minutes sessions (5h), 4 weeks~Content:~providing information about vocal function, vocal surgery, vocal hygiene, transgender health care~discussing communication aspects and patterns, possible exercise contexts, communication partners, expectations of voice modification, conversational subjects~active intervention on nonverbal communication (Kinesics, gestures and sign language, facial expression, haptics, proxemics, occulsics, and physical appearance)~practising costo abdominal breathing patterns"
75760681|NCT04707170|Device|MRI with gadolinium injection|"Patients presenting for imaging for whom an MRI examination with gadolinium injection has been prescribed and who meet the inclusion and non-inclusion criteria will be offered to participate in the study.~The patients included, hospitalized at the A. de Rothschild Foundation Hospital for at least 24 hours, may be included in the ancillary study to meet secondary objective number 5."
75905224|NCT03828357|Other|Study MRI scan|At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.
75905225|NCT03820479|Other|Protocol|Best practice of protocol
75905226|NCT03819764|Behavioral|Aerobic Exercise|Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
75905227|NCT03819764|Behavioral|Upper Extremity Repetitive Task Practice|Repetitive arm exercises
75905228|NCT03818880|Device|Novel spectacle lens design|Spectacle lens to control progression of myopia
75611617|NCT02700139|Device|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
75905229|NCT03800394|Other|Observational PK study|Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
75611618|NCT02699827|Drug|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
75611619|NCT02699827|Drug|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
75905230|NCT03800381|Other|Observational PK study|The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
75905231|NCT03798301|Biological|CMV-specific T-cells|Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMVspecific CD4+ and CD8+ T-cells
75463339|NCT05854030|Diagnostic Test|collect plasma samples and clinical features|8ml of peripheral blood need to be collected from pre- and post-treatment advanced pulmonary squamous carcinoma separately
75463340|NCT05854004|Diagnostic Test|Therapeutic Ultrasound|Therapeutic Ultrasound to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
75463341|NCT05854004|Diagnostic Test|Myofascial Release Technique|Myofascial Release Technique to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
75463342|NCT05853965|Drug|Belantamab mafodotin, Venetoclax|Belantamab mafodotin (IV) Venetoclax (PO)
75611620|NCT02699827|Drug|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
75611621|NCT02700061|Procedure|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
75611622|NCT02700061|Procedure|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
75611623|NCT02705989|Drug|BMS-986195|Specified dose on specified day
75905232|NCT03785249|Drug|MRTX849|MRTX849 will be administered orally once or twice daily in a continuous regimen
75905233|NCT03785249|Drug|Pembrolizumab|Pembrolizumab is administered as an intravenous infusion once every 3 weeks
75905234|NCT03785249|Drug|Cetuximab|Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
75905235|NCT03785249|Drug|Afatinib|Afatinib will be administered orally once a day in a continuous regimen
76069676|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
76069677|NCT01831765|Drug|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
75611624|NCT02705989|Other|Placebo|Specified dose on specified day
76069678|NCT01831765|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
75611625|NCT00616447|Device|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
75760682|NCT04707144|Device|MRI 1.5 tesla|"standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), o 3D STIR sequence.~3D PSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes)"
75760683|NCT04698915|Drug|Drug GC4711|15 Minute IV Infusion
75760684|NCT04698915|Drug|Placebo|15 Minute IV Infusion
75760685|NCT04696861|Behavioral|IDEAS for Hope|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
75760686|NCT04696861|Behavioral|Enhanced Standard of Care (Safety Planning)|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
75905236|NCT03773198|Other|Energy Resonance through Cutaneous Stimulation|"The ERCS method involves listening to the body by applying fingers to the acupuncture skin points, developed according to the energy imbalance caused by illness, pain and emotional disorders."
76069679|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
75611626|NCT00616447|Device|placebo sham|Sham treatment will mimic active treatment mentioned above.
75611627|NCT05323747|Other|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
75611628|NCT02706067|Drug|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent [%] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
75611629|NCT05323669|Diagnostic Test|Molecular testing|Molecular testing of thyroid nodules
75760687|NCT04693403|Procedure|HFNC|40-60l/min humidified oxygen by nasal cannula
75760688|NCT04693403|Procedure|CPAP|Oxygen therapy by boussignac Continuous positive airway pressure face mask
75760689|NCT04693403|Procedure|Standard Oxygen|Oxygen therapy by low flow (upto 15l/min) by Non-rebreather face mask
75760690|NCT04691908|Biological|QazCovid-in®-vaccine against COVID-19|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
75760691|NCT04691908|Other|Placebo|Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)
75905237|NCT03773198|Other|questionnaires|Measurement of anxiety-trait and state-anxiety (Spielberger), pain ( numerical scale) and satisfaction (numerical satisfaction scale)
75905238|NCT03715946|Drug|Nivolumab Injection|A fully human anti-programmed death 1 (PD-1) monoclonal antibody
75905239|NCT03715946|Radiation|Radiotherapy (RT)|45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
75905240|NCT03701763|Drug|Apremilast (CC-10004)|Apremilast (CC-10004)
75905241|NCT03701763|Other|Placebo|Placebo
75905242|NCT03700541|Drug|Morphine|Morphine intravenous
75905243|NCT03700541|Drug|Piritramid|Piritramid intravenous
75905244|NCT03700411|Drug|Morphine|Morphine intravenous
75905245|NCT03700411|Drug|Piritramid|Piritramid intravenous
75905246|NCT03700411|Drug|Epidural|Perioperative epidural analgesia
75905247|NCT03651505|Other|No intervention|Access to any treatment is through authorized commercial use and not as a part of this DMP
76069680|NCT01749800|Device|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
76069681|NCT01749800|Device|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
76069682|NCT01749800|Device|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
76069683|NCT04556396|Diagnostic Test|Cone beam CT|On-table CT scan in the operating room to determine residual kidney stone burden at end of procedure
76069684|NCT04414891|Device|Non invasive ventilation|"Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland)."
76069685|NCT01830595|Drug|Recombinant Lactoferrin|
76069686|NCT01830595|Drug|Placebo|
76069687|NCT01748552|Drug|Placebo|Administered orally as capsules
76069688|NCT01748552|Drug|LY2922083|Administered orally as capsules
76069689|NCT01748162|Drug|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
76069690|NCT01748162|Drug|Prednisolone IF needed|
75905248|NCT03641378|Other|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
75760692|NCT04686851|Other|Comprehensive Geriatric Assessment and follow-up|"All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.~Follow-up on initial treatment plan is scheduled to one month after baseline CGA."
75760693|NCT04686799|Drug|Doxycycline Hyclate 20 MG|Subjects will receive doxycycline 20 mg BID
75459109|NCT01816516|Behavioral|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
75611630|NCT04215757|Procedure|peripheral nerve block|peripheral nerve blocks with low dose lignocaine in acute radiculopathy
75611631|NCT02699905|Other|phlebotomy|phlebotomy
75760694|NCT04675840|Procedure|Robotic-assisted hysterectomy|Robotic-assisted surgery
75760695|NCT04675294|Drug|Evorpacept|IV Q3W
75760696|NCT04675294|Drug|Pembrolizumab|IV Q3W
75611632|NCT02699671|Device|Bioresorbable Vascular Scaffold|
75760697|NCT04663802|Behavioral|RT-targeted accountable justification|This strategy will require that the RT enter an explicit rationale in the EHR if he/she enters a tidal volume value greater than 6 cc/kg into the flowsheet, similar to the physician-targeted accountable justification strategy.
75760698|NCT04663802|Behavioral|Default order set|With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 cc/kg of the patient's ideal body weight (as determined by each patient's height and gender, which are entered into the EHR on admission). The physician will have the option to opt out of any of the specified LPV settings and select other values.
75760699|NCT04663802|Behavioral|physician-targeted accountable justification|When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg ideal body weight, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.
75905249|NCT03641378|Other|Standard Transplant Care|Standard care per hospital guidelines
75905250|NCT03633032|Diagnostic Test|Acquiring of ultrashort echo time (UTE) MRI sequences|Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
75905251|NCT03624101|Drug|Trikafta|CFTR modulator
75905252|NCT03624101|Drug|symdeko/Trikafta|CFTR modulator
76069691|NCT01724216|Device|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
75760700|NCT04663802|Other|Standard of Care|ICUs and clinicians will deliver standard of care to patients with no intervention
75459110|NCT01816529|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
75760701|NCT04663126|Drug|Tc-99m tilmanocept|IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m
75905253|NCT03624101|Drug|Ivacaftor/Trikafta|CFTR modulator
75905254|NCT03623074|Device|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
75905255|NCT03623074|Device|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
75905256|NCT03586661|Drug|Copanlisib|Given IV
75905257|NCT03586661|Drug|Niraparib|Given PO
75905258|NCT03575897|Diagnostic Test|Assessment of infant body composition|Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
75905259|NCT03557957|Other|Targeted correction of plasma sodium levels|Targeted correction of hyponatremia
75905260|NCT03557957|Other|Standard care|Standard care of hyponatremia
75905261|NCT03502733|Procedure|Biopsy|Undergo tumor biopsy
76069692|NCT01723904|Drug|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
75905262|NCT03502733|Procedure|Biospecimen Collection|Undergo blood sample collection
75905263|NCT03502733|Procedure|Computed Tomography|Undergo CT scan
75905264|NCT03502733|Drug|Copanlisib|Given IV
75905265|NCT03502733|Procedure|Echocardiography|Undergo ECHO
75905266|NCT03502733|Biological|Ipilimumab|Given IV
75905267|NCT03502733|Procedure|Magnetic Resonance Imaging|Undergo MRI
75905268|NCT03502733|Biological|Nivolumab|Given IV
75905269|NCT03493048|Drug|Irinotecan|Irinotecan 130 mg/m²
75905270|NCT03493048|Drug|Cetuximab|Cetuximab, iv, 500mg/m2
76069693|NCT01747772|Device|Shear Wave Sonoelastography|Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
76069694|NCT01830127|Drug|Ribavirin|24 Weeks
76069695|NCT01830127|Drug|BI 207127 high dose|24 Weeks
76069696|NCT01830127|Drug|Faldaprevir|24 Weeks
76069697|NCT01830127|Drug|Ribavirin|24 Weeks
76069698|NCT01830127|Drug|BI 207127 low dose|24 Weeks
76069699|NCT01830127|Drug|Faldaprevir|24 Weeks
75760702|NCT04626024|Other|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal|Stop taking TKI medication
75905271|NCT03493048|Drug|5-fluorouracil|5-FU 2400 mg/m² cont. inf.
75905272|NCT03493048|Drug|Oxaliplatin|oxaliplatin 85 mg/m²
75905273|NCT03493048|Drug|Leucovorin|leucovorin 200 mg/m²
75905274|NCT03449706|Drug|Early combination anti-retroviral treatment|Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
75905275|NCT03439748|Behavioral|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
75905276|NCT03439748|Behavioral|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
75905277|NCT03434730|Radiation|Total Body Irradiation|Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.
75459111|NCT01816529|Drug|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
76069700|NCT04611295|Procedure|Teleneurological evaluation and support|The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
75459112|NCT01816529|Drug|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
75459113|NCT01816529|Drug|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
75459114|NCT01816542|Other|patch tests on healthy skin|Patches will be placed on healthy skin.
75459115|NCT01816555|Dietary Supplement|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
75611635|NCT00615277|Dietary Supplement|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
75611636|NCT05323201|Biological|fhB7H3.CAR-Ts|fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion. Three dose levels will be evaluated: Dose Level 1 (1×10^6/kg), dose Level 2 (3×10^6/kg) and dose Level 3 (5×10^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10^6/kg /infusion) will be evaluated.
75611637|NCT05323201|Drug|Fludarabine|30 mg/m2 i.v. for 3 consecutive days (Day -5~Day -3)
75760703|NCT04626024|Drug|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation|Re-start TKI medication
75760704|NCT04623502|Other|13C-Glucose|Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
76069701|NCT01614067|Drug|Ganirelix acetate|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
76069702|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number. The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
75905278|NCT03434730|Drug|Cyclosporine|Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.
75611638|NCT05323201|Drug|Cyclophosphamide|750 mg/m2 i.v. for once (Day -5)
76069703|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences - HI FIVES|In addition to the usual care activities outline in the Control arm, Caregivers in the HI-FIVES group will receive three individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. The calls will be tailored to the individual needs of Veteran-caregiver dyad. After the phone calls, caregivers will participate in four evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator and the PI and VA Caregiver Support Staff. The sessions will be targeted to address common needs of Veterans and their caregivers. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
76069704|NCT01397409|Drug|AGN-150998|AGN-150998 Intravitreal injection.
75459116|NCT01816568|Procedure|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
75611639|NCT02905825|Device|BreathID® Hp System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
75760705|NCT04623502|Other|13C-Acetate|Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
75760706|NCT04623502|Other|13C-Lactate|Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
75760707|NCT04623502|Other|13C-Glutamine|Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
75760708|NCT04623502|Other|13C-Fructose|Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
75760709|NCT04621279|Procedure|Normothermia|Usual care for first 72 hours for neonates with mild encephalopathy maintaining core temperature (36.5°C ± 1 C).
75760710|NCT04621279|Procedure|Whole body therapeutic hypothermia|Whole-body therapeutic hypothermia (33.5°C ± 0.5°C) for 72 hours began by 6 hours of age for neonates with mild encephalopathy per site standard of care practice.
75905279|NCT03434730|Drug|Mycophenolate Mofetil|A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.
75905280|NCT03434730|Drug|Tocilizumab|For participants < 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.
75905281|NCT03434730|Drug|Filgrastim|The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; > 60 kg = 480 mcg subcutaneously daily.
75905282|NCT03433001|Drug|Ixazomib|Ixazomib capsules
75905283|NCT03433001|Drug|Lenalidomide|Lenalidomide capsules
75905284|NCT03433001|Drug|Dexamethasone|Dexamethasone tablets
75905285|NCT03432078|Other|Hypnotherapy|Non-pharmacological treatment
75905286|NCT03422822|Drug|Abrocitinib 100 mg|In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
75905287|NCT03422822|Drug|Abrocitinib 200 mg|In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
75905288|NCT03422822|Drug|Placebo|For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
75459117|NCT01816568|Procedure|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
75459118|NCT01816581|Drug|Targin|
75459119|NCT01816581|Drug|Oxynorm|
75459120|NCT01816581|Drug|Morphine|
75459121|NCT01816607|Procedure|new functional magnetic resonance imaging (MRI) protocols|diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
75459122|NCT01816620|Drug|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
75459123|NCT01816633|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
75611640|NCT02905825|Drug|BreathID® Hp Lab System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
75611641|NCT02905825|Diagnostic Test|Stool Test|Each subject was asked to perform a stool test in parallel to the breath test.
75611642|NCT01208051|Drug|Cediranib|Given PO
75611643|NCT01208051|Drug|Cediranib Maleate|Given PO
75611644|NCT01208051|Other|Laboratory Biomarker Analysis|Correlative studies
75760711|NCT04596540|Drug|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR"
75760712|NCT04596540|Drug|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR"
75760713|NCT04596540|Other|Placebo|Normal saline
75760714|NCT04576065|Other|WFIT|access to nurse practitioner for telehealth visits and activity monitor for 6 months after hospital discharge
75760715|NCT04566120|Drug|cinnamon extract mouthwash|cinnamon extract mouthwash
75760716|NCT04566120|Drug|chlorohexidine based mouthwash|chlorohexidine based mouthwash
75905289|NCT03422822|Drug|Abrocitinib 100 mg|For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
75611645|NCT01208051|Drug|Lenalidomide|Given PO
75611646|NCT00616837|Other|Telemedicine consultation|Outpatient consultation by help of telemedicine (video conference)
75611647|NCT00616837|Other|Standard care in orthopaedic outpatient clinic|Standard care in orthopedic outpatient clinic (usual care)
75905290|NCT03422822|Drug|Abrocitinib 100 mg|In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
75905291|NCT03422822|Drug|Abrocitinib 200 mg|In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
75905292|NCT03422328|Drug|macitentan|macitentan 10 mg, film-coated tablet, oral use
75905293|NCT03412565|Drug|Daratumumab|Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
75611648|NCT04214197|Drug|Crisaborole 2% Top Oint|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
75760717|NCT04565717|Drug|ALN-HSD|ALN-HSD will be administered by subcutaneous (SC) injection.
75760718|NCT04565717|Drug|Placebo|Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
75760719|NCT04561375|Drug|Sufentanil|30 µg tablet of sublingual sufentanil
75760720|NCT04561375|Drug|Fentanyl|50 µg fentanyl
75905294|NCT03412565|Drug|Bortezomib|Bortezomib will be administered as 1.3 mg/m^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
75905295|NCT03412565|Drug|Lenalidomide|Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
75905296|NCT03412565|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
75459124|NCT01816646|Drug|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
75905297|NCT03412565|Drug|Melphalan|Melphalan will be administered as 9 mg/m^2 orally in Cycles 1 to 9.
75905298|NCT03412565|Drug|Prednisone|Prednisone will be administered as 60 mg/m^2 orally in cycles 1 to 9.
75905299|NCT03412565|Drug|Carfilzomib|Carfilzomib will be administered as 20 mg/m^2 IV on Day 1 of Cycle 1 only then 70 mg/m^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
75905300|NCT03383575|Drug|Azacitidine|Given IV or SC
75905301|NCT03383575|Drug|Enasidenib|Given PO
75905302|NCT03383575|Other|Quality-of-Life Assessment|Ancillary studies
75905303|NCT03330847|Drug|Olaparib Continuous (28-Day cycle) 300 mg BD.|Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
75905304|NCT03330847|Drug|Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).|Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
75905305|NCT03330847|Drug|Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).|Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
75905306|NCT03324893|Diagnostic Test|[F-18]-FCH PET/MRI|Subjects will undergo the [F-18]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
75905307|NCT03314935|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
75760721|NCT04556838|Drug|VVN001 Ophthalmic Solution 1%|VVN001 Ophthalmic Solution 1%
75760722|NCT04556838|Drug|VVN001 Ophthalmic Solution 5%|VVN001 Ophthalmic Solution 5%
75459125|NCT01816646|Drug|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
75459126|NCT01816659|Drug|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
75459127|NCT01816672|Device|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
75459128|NCT01816672|Other|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
75760723|NCT04556838|Drug|Vehicle|VVN001 Ophthalmic Solution Vehicle
75760724|NCT04549363|Drug|Belantamab mafodotin|Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.
75760725|NCT04539509|Behavioral|Exercise Prescription|A specific exercise prescription, based on the results of a treadmill test.
75760726|NCT04539509|Behavioral|Treadmill Test|A symptom-limited treadmill test, using the Buffalo Concussion Treadmill Test (BCTT) protocol.
75760727|NCT04539509|Device|Monitoring|Activity monitoring using a Fitbit.
76069705|NCT01397409|Drug|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
75760728|NCT04535362|Drug|Nicotine|session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.
75760729|NCT04534205|Biological|BNT113|IV injection
75760730|NCT04534205|Biological|Pembrolizumab|IV infusion
75905308|NCT03314935|Drug|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
76069706|NCT01397409|Other|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
76069707|NCT04407429|Diagnostic Test|Laboratory Analyses|Storage of serum for SARS-CoV-2-antibodies and biomarkers
75905309|NCT03314935|Drug|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
75905310|NCT03314935|Drug|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
75905311|NCT03314935|Drug|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
76069708|NCT01397253|Other|Automated communication tools|"Automated communication tools will include:~PCP notification of patient admission and location~Data on medications begun on admission~Automated alerts on changes in patient status and location while the patient is hospitalized~Links to the EMR and to hospital physician contact information on all email alerts~Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~Automatic reporting to PCPs of test results pending at discharge~Electronic delivery of final discharge summaries"
76069709|NCT04766775|Device|Silver Diamine Fluoride|Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
75905312|NCT03314935|Drug|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
75905313|NCT03314935|Drug|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
75905314|NCT03299530|Other|patients with corneal astigmatism|The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
76069710|NCT01777334|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
76069711|NCT01777334|Drug|Tiotropium 18 mcg|Inhalation Powder
76069712|NCT03024879|Drug|Erythromycin|
75611649|NCT04214275|Other|pulmonary rehabilitation|Simple breathing techniques, secretion-removal techniques, airway-cleaning techniques, mobilization techniques and use of an incentive spirometer
75611650|NCT05322889|Drug|Telmisartan tablets|12 weeks treatment
75611651|NCT04214431|Behavioral|Mindfulness-Based Childbirth Education|8-week mindfulness-based childbirth education
75611652|NCT02705521|Device|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
75611653|NCT00616915|Drug|Wellbutrin XL|Wellbutrin XL 300mg daily
75611654|NCT01207583|Other|Non-interventional observational study|Non-interventional observational study
75611655|NCT01207427|Drug|Placebo|
75611656|NCT01207427|Drug|ADL5945 0.1 mg|
75611657|NCT01207427|Drug|ADL5945 0.25 mg|
75611658|NCT05410223|Drug|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Yolk antibody: 7g*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
75760731|NCT04526795|Drug|Cytarabine|Given IV
75760732|NCT04526795|Drug|Fludarabine|Given IV
75760733|NCT04526795|Drug|Pegcrisantaspase|Given IV
75760734|NCT04523779|Behavioral|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
75905315|NCT03263351|Behavioral|Cognitive-behavioral therapy group|Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
75905316|NCT03263351|Behavioral|Health education group|Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
76069713|NCT03024879|Drug|Saline|
75760735|NCT04523181|Drug|Antroquinonol|double-blind for antroquinonol and Placebo with same out-look and same frequency.
75760736|NCT04523181|Other|Placebo|Capsule without active compound
75760737|NCT04518293|Drug|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Single pill
75760738|NCT04518293|Drug|telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg|Signle pill
75760739|NCT04518293|Drug|Telmisartan 20 mg/amlodipine 2.5 mg .|oral tablet
75760740|NCT04518293|Drug|telmisartan 40 mg/amlodipine 5 mg|oral tablet
76069714|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
75760741|NCT04518293|Drug|Telmisartan 20 mg/indapamide 1.25 mg|oral tablet
76069715|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
75905317|NCT03255174|Biological|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
76069716|NCT05369637|Behavioral|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
76069717|NCT05369637|Behavioral|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
75905318|NCT03249350|Behavioral|Standard Contingency Management (CM)|"CM utilizes behavior modification & cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
75611659|NCT05410223|Drug|IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
75905319|NCT03249350|Behavioral|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
75905320|NCT03211793|Drug|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
76069718|NCT05369637|Behavioral|Behavioral: Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
76069719|NCT05369637|Behavioral|Psychoeducation|This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.
75611660|NCT05410223|Drug|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline|"Yolk antibody: 7g*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd."
75905321|NCT03211793|Other|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
75760742|NCT04518293|Drug|telmisartan 40 mg/indapamide 2.5 mg|oral tablet
75760743|NCT04518293|Drug|Amlodipine 2.5 mg/indapamide 1.25 mg|oral tablet
75760744|NCT04518293|Drug|amlodipine 5 mg/indapamide 2.5 mg|oral tablet
75760745|NCT04488809|Other|Exercise|Exercise sessions will include 10 minutes of warming up, 30 minutes of loading, and 10 minutes of cooling down. The exercises will be performed two times in a week for eight weeks.
75760746|NCT04476797|Drug|GC4711|15 minute IV Infusion prior to SBRT
75760747|NCT04476797|Drug|Placebo|15 minute IV infusion prior to SBRT
75760748|NCT04475276|Drug|Placebo|Lifestyle modification with placebo for 12 weeks
75760749|NCT04475276|Drug|Alphalipoic acid|Lifestyle modification with Alphalipoic acid for 12 weeks
75905322|NCT03181100|Drug|Atezolizumab|Given IV
75905323|NCT03181100|Biological|Bevacizumab|Given IV
75905324|NCT03181100|Drug|Cobimetinib|Given PO
75760750|NCT04472429|Drug|carboplatin|carboplatin will be administered intravenous on Day 1 of each 28 day cycle
75760751|NCT04472429|Drug|paclitaxel|paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle
75905325|NCT03181100|Drug|Nab-paclitaxel|Given IV
75905326|NCT03181100|Drug|Paclitaxel|Given IV
76069720|NCT05369637|Other|Diagnosis and correction of hearing impairment|This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.
76069721|NCT05368545|Drug|High intensity lipid lowering|Two different regimens of drugs with different effects on LDL lowering
75905327|NCT03181100|Drug|Vemurafenib|Given PO
75459129|NCT01816698|Drug|Taurine granule|1 package(1.6g taurine granule) once a day after meals, 12 weeks
75905328|NCT03171818|Drug|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
75905329|NCT03171818|Drug|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
75905330|NCT03169361|Drug|Ixazomib|Ixazomib capsules
75905331|NCT03149861|Procedure|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS >=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
75760752|NCT04472429|Drug|retifanlimab|retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
75760753|NCT04456387|Drug|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.
75760754|NCT04456387|Drug|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/kg every three days.
75760755|NCT04451265|Other|MRI|Diffusion sequence (8 minutes long) added to the initial MRI
75611661|NCT05410223|Drug|IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
75611662|NCT04713553|Biological|BNT162b2|Intramuscular injection
75611663|NCT04713553|Biological|BNT162b2.B.1.351|Intramuscular injection
75760756|NCT04446442|Device|tDCS|A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
75760757|NCT04439799|Drug|Testosterone Cypionate 200 Mg/ML|Participants in this group will receive intramuscular testosterone cypionate injections of 1 cc (200mg) once every 14 days for four months.
75760758|NCT04439799|Drug|Intranasal Testosterone|Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
75760759|NCT04435782|Drug|JNJ-67896049|Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
75760760|NCT04431674|Drug|Definity Suspension for Injection|MRI-guided ultrasound-stimulated microbubble-treatment
75760761|NCT04431648|Drug|DEFINITY|MRI-guided ultrasound-stimulated microbubble-treatment
75905332|NCT03149861|Procedure|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
75905333|NCT03108703|Radiation|SBRT|35-40 Gy delivered in 5 fractions
75905334|NCT03101748|Drug|Cyclophosphamide|Given IV
75905335|NCT03101748|Drug|Doxorubicin|Given IV
75459130|NCT01816698|Drug|Placebo|Placebo: 1 package once a day after meals, 12 weeks
75459131|NCT01816750|Device|Cardiac GSI|A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
75459132|NCT01816789|Drug|rFSH|
75459133|NCT01816789|Drug|buserelin|
75459134|NCT01816802|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
75459135|NCT01816815|Drug|BAY1002670|
75459136|NCT01816815|Drug|Placebo|
75459137|NCT01816828|Behavioral|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
75459138|NCT01816828|Other|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
75459139|NCT01816841|Procedure|fluorescence imaging|Undergo DVFE
75905336|NCT03101748|Other|Laboratory Biomarker Analysis|Correlative studies
75905337|NCT03101748|Drug|Neratinib|Given PO
75905338|NCT03101748|Drug|Paclitaxel|Given IV
75905339|NCT03101748|Biological|Pertuzumab|Given IV
75905340|NCT03101748|Biological|Trastuzumab|Given IV
75905341|NCT03054129|Other|Rehabilitation and balance training|"Stretching will be applied as hold-relax technique in Proprioceptive Neuromuscular Facilitation for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
75905342|NCT03054129|Other|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
75905343|NCT03052114|Device|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
75905344|NCT03031847|Device|Cardiac Resynchronization Therapy Pacemaker|Patients randomized to the pacemaker arm will receive a CRT-P device.
75760762|NCT04431648|Device|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
75459140|NCT01816841|Procedure|biopsy|Undergo scalpel biopsy
75760763|NCT04428528|Device|Photoacoustics Imaging System|Characterizing breast masses for photoacoustic markers measurements
75611664|NCT01206101|Drug|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
75611665|NCT01206101|Drug|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
75611666|NCT01205165|Drug|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
75459141|NCT01816841|Procedure|examination|Undergo COE
75611667|NCT00997503|Device|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
75760764|NCT04428515|Device|Photoacoustic Imaging System|Photoacoustic Imaging investigate changes of measured PA markers and compare these to radiological assessment of response of lymph node involvement to chemoradiation therapy for head and neck cancer
75760765|NCT04415944|Procedure|Second look laparoscopy reassessment surgery (SLLRS)|Performed less than 12 weeks after intravenous chemotherapy cycles are completed.
75905345|NCT03031847|Device|Cardiac Resynchronization Therapy Defibrillator|Patients randomized to the defibrillator arm will receive a CRT-D device.
75760766|NCT04415944|Drug|HIPEC with Carboplatin|"Patient receives HIPEC with CBDCA 800 mg/m2 for 90 minutes.~Patients who exhibit the following will not receive the HIPEC procedure:~Extraperitoneal disease noted at the time of the second look procedure~Macroscopic intraperitoneal disease which is not resectable to R1~Technical problems which prevent continuous, adequate flow to maintain intraperitoneal temperature to 41°C during perfusion~Intraoperative complications such as cardiac or pulmonary instability precluding HIPEC~Participation will consist of completing surveys regarding their cancer and allowing researchers to use information from their medical records for research."
75760767|NCT04415944|Other|FACT-O Quality of Life Questionnaire|Participants will be asked to do this three times (pre-study, 3 months and 6 months). Surveys will be given at follow up visits for surgery. They should take about 10-15 minutes to complete.
75905346|NCT02926404|Device|UNiD Rods|Spinal osteosynthesis
75611668|NCT00997503|Drug|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
75611669|NCT00997503|Drug|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
75905347|NCT02831764|Drug|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
75905348|NCT02831764|Drug|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
75459142|NCT01816841|Procedure|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
76069722|NCT01396395|Drug|Nicorandil|The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
75459143|NCT01816854|Device|Stenting|
75459144|NCT01816867|Device|Intramesh T1 implantation|
75611670|NCT00997503|Drug|aspirin|"Oral, as prescribed by physician through end of study.~."
75459145|NCT01816919|Other|collecting breath samples|
75459146|NCT01816958|Other|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
75459147|NCT01816997|Drug|Pravastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
75459148|NCT01816997|Drug|Rosuvastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
75459149|NCT01816997|Drug|Control|placebo
75459150|NCT01817010|Behavioral|Multi-Component Rehabilitation (CMC)|
75459151|NCT01817010|Behavioral|Control (CON)|
75611671|NCT02705443|Other|No Intervention|Standard of Care Only
75611672|NCT02705053|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
76069723|NCT01396395|Drug|Standard Treatment|The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
76069724|NCT01396317|Drug|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
76069725|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
75760768|NCT04405596|Drug|Ambroxol Hydrochloride|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
75760769|NCT04405596|Other|Placebo|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
75760770|NCT04396821|Drug|TST001|TST001 is a humanized IgG1 monoclonal antibody.
75760771|NCT04396821|Drug|Nivolumab Injection [Opdivo]|Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
75760772|NCT04396821|Drug|mFOLFOX6|mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
75760773|NCT04396821|Drug|Gemcitabine|Chemotherapy medication
75760774|NCT04396821|Drug|Albumin-Bound Paclitaxel|Chemotherapy medication
75905349|NCT02831764|Drug|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
75905350|NCT02772731|Procedure|Partial mastectomy plus additional Shave Margin|"For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin."
75905351|NCT02772731|Procedure|Partial mastectomy|Surgeons will be instructed to close after partial mastectomy with no further excision.
75905352|NCT02754011|Drug|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
75905353|NCT02732860|Other|Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures|Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
75905354|NCT02719847|Procedure|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
75760775|NCT04395391|Diagnostic Test|SARS-CoV-2|Determine usability of study materials and kit
75459152|NCT01817023|Radiation|SIB-IMRT|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
75760776|NCT04382898|Biological|BNT112|Intravenous bolus injection
75760777|NCT04382898|Drug|Cemiplimab|Intravenous infusion
75905355|NCT02702310|Other|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
75905356|NCT02702310|Other|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
75905357|NCT02678962|Device|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
75459153|NCT01817023|Drug|Cisplatin|Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
75459154|NCT01817036|Dietary Supplement|Placebo|placebo
75459155|NCT01817036|Dietary Supplement|Vitamin D|400 IU vitamin D per pill
75459156|NCT01817049|Behavioral|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
75459157|NCT01817049|Behavioral|placebo attention control|
75611673|NCT02705053|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
75760778|NCT04354259|Drug|Peginterferon Lambda-1A|Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
75760779|NCT04354259|Other|placebo|injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
75905358|NCT02678962|Device|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
75905359|NCT02678962|Device|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
75905360|NCT02678962|Device|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
75905361|NCT02678962|Device|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
75905362|NCT02678962|Device|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
75905363|NCT02653118|Biological|V503|
75905364|NCT02653118|Biological|GARDASIL|
75905365|NCT02567422|Drug|Berzosertib|Given IV
76069726|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
75905366|NCT02567422|Drug|Cisplatin|Given IV
75905367|NCT02567422|Other|Laboratory Biomarker Analysis|Correlative studies
75905368|NCT02567422|Radiation|Radiation Therapy|Undergo radiation therapy
75459158|NCT01817088|Procedure|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
75459159|NCT01817088|Procedure|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
75611674|NCT01204775|Drug|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
75905369|NCT02530034|Drug|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Given IV
76069727|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
75459160|NCT01817101|Dietary Supplement|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
76069728|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
75459161|NCT01817114|Device|Auto Remote Ischemic Conditioning (AutoRIC) device|
75459162|NCT01817153|Drug|hydrocortison hemisuccinate|
75459163|NCT01817153|Drug|placebo followed by hydrocortisone hemisuccinate|
75611675|NCT01204775|Drug|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
75611676|NCT01204775|Drug|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
75611677|NCT01204775|Drug|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
75905370|NCT02530034|Other|Laboratory Biomarker Analysis|Correlative studies
75905371|NCT02530034|Other|Pharmacological Study|Correlative studies
75905372|NCT02528175|Device|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
75905373|NCT02528175|Radiation|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
75905374|NCT02528175|Drug|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
75905375|NCT02396199|Device|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
75905376|NCT02339532|Drug|FEC100|"3 cycles of FEC 100 administered IV q3w~5-Fluorouracil (5-FU) 500 mg/m²~Epirubicin 100 mg/m²~Cyclophosphamide 500 mg/m²"
75611678|NCT01204775|Drug|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
75611679|NCT02705131|Device|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
75905377|NCT02339532|Drug|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV
75905378|NCT02339532|Drug|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
75905379|NCT02339532|Drug|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
75905380|NCT02339532|Drug|Carboplatin|CARBOPLATIN AUC 6 IV q3w
75905381|NCT02284919|Drug|[18F]ISO-1|[18F]ISO-1 PET/CT scan
75905382|NCT02278848|Other|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
75905383|NCT02112188|Behavioral|In-depth Patient Interviews|
75459164|NCT01817179|Other|FES neuroprosthesis to dorsiflexors on affected leg|
75905384|NCT02112188|Behavioral|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
75905385|NCT02112188|Behavioral|Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)|The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.
75611680|NCT02705131|Device|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
75611681|NCT02844907|Drug|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
75611682|NCT02844907|Drug|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
75611683|NCT02844907|Other|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
75611684|NCT00628719|Drug|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
75611685|NCT00628719|Drug|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
75611686|NCT00616993|Drug|Difluprednate|Difluprednate
75459165|NCT01817205|Procedure|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
75459166|NCT01817218|Drug|Platelet Rich Plasma|
75611687|NCT00616993|Other|Placebo|Vehicle
75611688|NCT02870361|Drug|intranasal insulin|
75611689|NCT02870361|Drug|Placebo|
75611690|NCT00617071|Other|medical chart review|
75611691|NCT00617071|Other|survey administration|
75611692|NCT00617071|Procedure|fecal occult blood test|
75611693|NCT00617071|Procedure|screening colonoscopy|
75611694|NCT00616681|Drug|Oxcarbazepine|
75905386|NCT02101944|Drug|Carfilzomib|Given IV
75905387|NCT02101944|Drug|Dexamethasone|Given IV
75905388|NCT02101944|Other|Laboratory Biomarker Analysis|Correlative studies
75905389|NCT02101944|Biological|Pelareorep|Given IV
75905390|NCT02034981|Drug|Crizotinib|"Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.~-250 mg twice daily for adults ≥ 18 years of age~280 mg/m² twice daily for children and adolescents aged from 1 to 17 (except ALCL).~165 mg/m² twice daily for ALCL patients aged from 1 to 17."
75905391|NCT02003222|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic SCT
75905392|NCT02003222|Procedure|Biospecimen Collection|Undergo blood sample collection
75905393|NCT02003222|Biological|Blinatumomab|Given IV
75905394|NCT02003222|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
75905395|NCT02003222|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75611695|NCT00997035|Drug|Voriconazole|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing <40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment."
75611696|NCT00997035|Drug|Placebo|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment."
75905396|NCT02003222|Drug|Cyclophosphamide|Given IV
75905397|NCT02003222|Drug|Cytarabine|Given IT, IV, or SC
75905398|NCT02003222|Drug|Daunorubicin|Given IV
75905399|NCT02003222|Drug|Daunorubicin Hydrochloride|Given IV
75611697|NCT00617149|Behavioral|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
75611698|NCT01204697|Drug|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
75611699|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
75611700|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally as monotherapy
75611701|NCT02705209|Other|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
75611702|NCT02705209|Other|Placebo Cataplasm|Poultice of Kaolin and Water
75611703|NCT01001325|Biological|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
75611704|NCT01001325|Biological|Normal saline|0.5 mL intramuscular
75611705|NCT02968459|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
75760780|NCT04341896|Other|Caregivers|Individuals who cared for themselves and their transplant recipient before and after kidney donation
75760781|NCT04341896|Other|Non-caregivers|Individuals who donated a kidney as a living donor but did not serve as the primary caregiver for their recipient
75760782|NCT04341740|Procedure|Bone Marrow Aspirate|bone marrow aspiration
75760783|NCT04341064|Behavioral|SHINE Intervention|[see arm/group descriptions]
75760784|NCT04332861|Other|Initial clinical and laboratory evaluation|"Initial evaluation, prior to administration of any antibiotics if possible, includes history, physical exam, and labs including:~Urinalysis~Urine culture~Blood cultures~Complete blood count with differential~Comprehensive metabolic panel~Lactate~Procalcitonin~Other inflammatory markers"
75905400|NCT02003222|Drug|Dexamethasone|Given PO
75905401|NCT02003222|Drug|Etoposide|Given IV
75905402|NCT02003222|Procedure|Lumbar Puncture|Undergo lumbar puncture
75905403|NCT02003222|Drug|Mercaptopurine|Given PO
75905404|NCT02003222|Drug|Methotrexate|Given PO, IT or IV
75905405|NCT02003222|Drug|Pegaspargase|Given IM or IV
75905406|NCT02003222|Drug|Prednisone|Given PO
75905407|NCT02003222|Biological|Rituximab|Given IV
75905408|NCT02003222|Drug|Vincristine|Given IV
75905409|NCT02003222|Drug|Vincristine Sulfate|Given IV
75905410|NCT02003222|Procedure|X-Ray Imaging|Undergo x-ray imaging
75905411|NCT01897480|Biological|LY2875358|Administered IV
75905412|NCT01897480|Drug|Erlotinib|Administered Orally
75905413|NCT01736748|Behavioral|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
75905414|NCT01736748|Behavioral|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
75905415|NCT01721343|Behavioral|telephone-based intervention|Undergo telephonic monitoring
75905416|NCT01721343|Other|case management|Participate in an individualized conditioning program with an RCM
75905417|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
75905418|NCT01721343|Procedure|physical therapy|Participate in an individualized conditioning program with an RCM
75760785|NCT04332588|Drug|[18F]FMISO PET/MRI imaging|[18F]FMISO PET/MRI imaging
75760786|NCT04317482|Behavioral|Standard social stress task|Participants will be asked to respond in detail to three scenarios. This is a standard social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
75611706|NCT02968459|Other|0.9% Saline|Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
75760787|NCT04317482|Behavioral|Stressful experience in the ED|Participants will be asked to imagine and then describe both feelings and bodily sensations experienced at their most stressful ED visit, in order to help them more fully re-experience the situation. In this regard, the second condition is more similar to stress imagery employed by Sinha et al, which elevated cortisol to a greater degree than a social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
75905419|NCT01721343|Other|questionnaire administration|Ancillary studies
75611707|NCT02870595|Device|Microvibratory Stimulator|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
75760788|NCT04317417|Behavioral|EMPOWER|"Participants will receive weekly material for a total of 5 weeks consisting of 1-2 days of didactic content and several days of brief, real-life skills practice and reporting taking approximately 10-15 minutes to complete. Adolescents and young adults cannot skip ahead, but they can return to old lessons or exercises if they choose. Most exercises are done in a diary format in which past responses are displayed next to their new ones, so that every time they visit that exercise they see their growing list of past positive experiences. Participants will be permitted up to 8 weeks to complete this self-guided intervention."
76069729|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
75459167|NCT01817218|Device|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
75611708|NCT02870595|Device|Microvibratory Stimulator'|As above, Microvibratory Stimulator will be used as a sham device in parallel group.
75760789|NCT04278898|Drug|N-Acetylcysteine|N-acetylcysteine Single Dose 2700 mg taken orally
75760790|NCT04272658|Diagnostic Test|value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of ICI"
75760791|NCT04254666|Behavioral|Physical Literacy & Food Literacy Intervention.|A 12-week intervention designed to expose adolescents with ID to a variety of sports skills and healthy eating concepts to equip them with skills and confidence to participate in sports and make healthy food choices. The program will follow a protocol adapted to meet the needs of a diverse group of children with ID. Sessions will be held 1 time/week for 75 minutes virtually; 35 minutes will focus on sport skills activities with 35 minutes devoted to healthy eating.
75760792|NCT04246047|Drug|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
75760793|NCT04246047|Drug|Daratumumab|Anti-cluster of differentiation 38 [CD-38] monoclonal antibody
75760794|NCT04246047|Drug|Bortezomib|Proteasome Inhibitor
75760795|NCT04246047|Drug|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
75905420|NCT01721343|Procedure|quality-of-life assessment|Ancillary studies
75905421|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care
75905422|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care
75905423|NCT01721343|Other|educational intervention|Participate in an individualized conditioning program with an RCM
75459168|NCT01817244|Other|care management|6-month care management
75459169|NCT01817257|Drug|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
76069730|NCT01396083|Drug|Ranibizumab|
76069731|NCT01396083|Drug|Dexamethasone implant and sham injections|
76069732|NCT04345263|Procedure|MTA pulpotomy|Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
76069733|NCT01723826|Drug|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
76069734|NCT01721954|Drug|FOLFOX6m|
75905424|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM
75905425|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM
75611709|NCT02704975|Device|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
75905426|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
75905427|NCT01665144|Drug|BAF312|0.25, 0.5, 1, and 2 mg film-coated tablets
75905428|NCT01665144|Drug|Placebo|Film-coated tablets
75905429|NCT01661881|Drug|Rituximab|
76069735|NCT01721954|Device|SIR-Spheres microspheres|
76069736|NCT01776554|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
76069737|NCT01776008|Drug|Akt Inhibitor MK2206|Given PO
76069738|NCT01776008|Drug|Anastrozole|Given PO
76069739|NCT01776008|Drug|Goserelin Acetate|Given SC
76069740|NCT01776008|Other|Laboratory Biomarker Analysis|Correlative studies
76069741|NCT01776008|Procedure|Neoadjuvant Therapy|Given before standard-care surgery
75611710|NCT02704975|Device|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
75611711|NCT01203917|Drug|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
76069742|NCT01776008|Other|Pharmacological Study|Correlative studies
75611712|NCT02704741|Device|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
76069743|NCT01776008|Procedure|Therapeutic Conventional Surgery|Undergo standard-care surgery
76069744|NCT01746368|Other|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
75760796|NCT04242017|Drug|Triptoreline|Comparison of the duration of ADT (Triptoreline)
75760797|NCT04240002|Drug|gilteritinib|Administered orally.
75760798|NCT04240002|Drug|fludarabine|Administered by intravenous (IV) infusion
75760799|NCT04240002|Drug|cytarabine|Administered by intravenous (IV) infusion
76069745|NCT01746368|Other|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
75760800|NCT04240002|Drug|granulocyte colony-stimulating factor (G-CSF)|Administered by subcutaneous injection
75905430|NCT01661881|Drug|Bendamustine|
75905431|NCT01661881|Drug|Cytarabine|
75905432|NCT01640652|Biological|MenPF-1.|A new vaccine against meningococcal disease.
75905433|NCT01638949|Behavioral|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
75905434|NCT01638949|Biological|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
75905435|NCT01638949|Genetic|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
75905436|NCT01638949|Other|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
75905437|NCT01582269|Drug|LY2157299 monohydrate|Orally administered as tablets
75905438|NCT01582269|Drug|Lomustine|Orally administered as capsules
75905439|NCT01582269|Drug|Placebo|Orally administered as tablets
75905440|NCT01550003|Drug|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
76069746|NCT01381575|Biological|GSK Biologicals' HPV vaccine 580299|Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.
76069747|NCT01858363|Device|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
76069748|NCT01858363|Device|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
76069749|NCT01877551|Drug|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
75760801|NCT04228068|Other|Rehabilitation Program|"PT visits (two visits): The first visit will happen within a week of discharge. During this visit, the PT will assess participants, tailor the program to their needs, and coach them in carrying out the exercises at home. The last visit will be 12 weeks after the first. During this visit, the PT will reassess the participants and make adjustments to the program. The participants will be encouraged to continue exercising beyond the 12 weeks.~The PTA will visit the participants' homes with the PT and will conduct additional solo visits every other week (i.e. 7 PTA visits in total, in 1st week and at 2, 4, 6, 8, 10, and 12 weeks). The PTA will facilitate and progress the exercise program as prescribed and directed by the PT and help in delivering the education component of the program."
75760802|NCT04228068|Other|Pain self management|In addition to the exercise program, the intervention group will receive a pain self-management support tailored by the PT to the participants' needs.
75905441|NCT01550003|Drug|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~10 to < 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~20 to < 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);"
75905442|NCT01474148|Device|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
76069750|NCT01877551|Other|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
76069751|NCT01396005|Drug|boceprevir|boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
76069752|NCT01396005|Drug|methadone|methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
76069753|NCT01396005|Drug|buprenorphine/naloxone|buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
76069754|NCT01877239|Other|non-intervention|observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
76069755|NCT03024957|Drug|Morphine Sulfate|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
75459170|NCT01817270|Biological|Live Attenuated Varicella Vaccine|
75459171|NCT01817283|Drug|Triptolide|Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
75459172|NCT01817283|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
75459173|NCT01817283|Drug|placebo|Placebo pills produced the same as Triptolide wilfordii.
75459174|NCT01817296|Procedure|Testicular Biopsy|Micro-dissection testicular sperm extraction for sperm retrieval
75459175|NCT01817309|Other|endotoxin assay in peritoneal dialysis effluent|endotoxin level by Limulus Amebocyte Lysate (LAL) assay
75760803|NCT04228068|Other|Conventional care|The control group will receive the usual care provided by the healthcare system.
75760804|NCT04217317|Drug|CPI 613|CPI-613 is to be given as 2-hr IV infusion via a central venous catheter. The starting dose of CPI-613 will be 2500 mg/m2 which was determined to be the MTD in the previous phase I clinical trial.
75760805|NCT04217317|Drug|Bendamustine|Bendamustine at 90 mg/m2 is infused by IV over 10 minutes on Days 1 and 2 of each treatment cycle. Bendamustine is given immediately after CPI-613 administration.
76069756|NCT03024957|Drug|Dexmedetomidine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
76069757|NCT03024957|Drug|Bupivacaine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
76069758|NCT03025113|Drug|ketoprofen and cyclobenzaprine association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
76069759|NCT03025113|Drug|Cyclobenzaprine|The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
76069760|NCT01877083|Drug|Lenvatinib|Starting dose of 24 mg orally, once per day
76069761|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
76069762|NCT01380327|Other|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume [w/v]) was achieved.
75905443|NCT01353313|Drug|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
75905444|NCT01353313|Drug|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
75611713|NCT02704819|Other|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
75905445|NCT01245712|Radiation|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
75611714|NCT02704819|Other|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
75459176|NCT01817322|Drug|Standard Dose of Myfortic and Reduced Dose of Myfortic|Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
75459177|NCT01817322|Drug|Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group|500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
75760806|NCT04210596|Procedure|Soft tissue augmentation at the buccal aspect of single implants|Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
75760807|NCT04198701|Device|Medtronic PulseSelect Pulsed Field Ablation (PFA) System|Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.
75760808|NCT04195984|Device|Mi-thos® valve and transapical delivery system|Transcatheter mitral valve replacement system
75760809|NCT04194216|Drug|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."|Treatment Arm A
75760810|NCT04194216|Drug|"Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days"|Treatment Arm B
75905446|NCT01245712|Radiation|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
75905447|NCT01245712|Other|Quality-of-Life Assessment|Ancillary studies
75905448|NCT01209871|Biological|Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Given ID
75905449|NCT01209871|Other|Laboratory Biomarker Analysis|Correlative studies
75905450|NCT01083862|Behavioral|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
75905451|NCT01083862|Behavioral|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
75905452|NCT00959452|Behavioral|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
75459178|NCT01817322|Drug|Basiliximab injected both control group and experimental group|The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
75459179|NCT01817335|Procedure|psychosocial assessment and care|Participate in psycho-educational program
75459180|NCT01817335|Other|educational intervention|Participate in psycho-educational program
75459181|NCT01817335|Other|communication skills training|Participate in psycho-educational program
75760811|NCT04164641|Device|Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic|Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
75760812|NCT04150939|Procedure|Core Biopsy|Undergo core biospy
75760813|NCT04150939|Procedure|Cryosurgery|Undergo cryoablation
75760814|NCT04150939|Drug|Immunotherapeutic Agent|Receive standard of care immunotherapy
75760815|NCT04144790|Dietary Supplement|ferrous sulfate|Although established guidelines do not currently exist for iron supplementation for children, studies have demonstrated effectiveness of a 3-month treatment regimen of 5mg/kg per day of orally-administered ferrous sulfate in reducing PLMS and subjective RLS symptoms and in increasing serum ferritin levels. Ferrous sulfate 80 mg/day resulted in improvement of ADHD symptoms in iron-deficient children.
75760816|NCT04143516|Diagnostic Test|[18-F]- FDG - PET|Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion
75760817|NCT04143516|Procedure|Tumor ablation (TA)|Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.
75760818|NCT04143516|Diagnostic Test|PET/CT Scan|Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
75760819|NCT04130763|Biological|FMT capsule|FMT capsules administration starts in the first week of enrollment. Capsules are taken for three consecutive days in the first week. From week 2, anti-PD-1 therapy will be administrated in combination with the maintenance dose of FMT treatment once every two weeks for up to 6 times.
75760820|NCT04130503|Device|PAP|Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).
75459182|NCT01817335|Other|questionnaire administration|Ancillary studies
75459183|NCT01817348|Procedure|Lidocaine group|"Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle~Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine."
75760821|NCT04130503|Behavioral|HLE|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
75905453|NCT00580515|Behavioral|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
75760822|NCT04113408|Other|FABIR sequence|The FABIR sequence with a duration of 8 minutes is added to the imaging protocol.
75760823|NCT04093739|Device|G7 Freedom Constrained Liners|Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
75760824|NCT04090983|Behavioral|Cognitive-behavioral therapy (Hesslinger protocol)|Cognitive-behavioral therapy in a group format focusing on improving symptoms of ADHD, specifically by using skills in counteracting hyperactivity and impulsiveness, and promoting mindful awareness.
75760825|NCT04090983|Behavioral|Cognitive-behavioral therapy (CADDI protocol)|Cognitive-behavioral therapy in a group format focusing on improving inattentive symptoms of ADHD, specifically by using skills in organizing, executing, and completing activity, and promoting mindful awareness.
75459184|NCT01817348|Other|Physiotherapy (PT)|- Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
75459185|NCT01817387|Behavioral|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
75459186|NCT01817387|Behavioral|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
75611715|NCT02704819|Other|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
75760826|NCT04080804|Drug|Nivolumab|A fully human anti-programmed death 1 (PD-1) monoclonal antibody checkpoint inhibitor, that blocks a signal that prevents activated T cells from attacking the cancer cells.
75760827|NCT04080804|Drug|Relatlimab|A monoclonal antibody with anti-Lymphocyte-activation gene 3 (LAG-3) (immune checkpoint receptor protein found on the cell surface) activity.
75760828|NCT04080804|Drug|Ipilimumab|A monoclonal anitibody that targets CTLA-4, a protein receptor, that down regulates the immune system.
75760829|NCT04077047|Behavioral|iEngage|The intervention is a network-based, social support intervention to improve Adolescents living with HIV (ALWH) retention in HIV care and antiretroviral therapy (ART) adherence
75611716|NCT02704819|Other|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
75611717|NCT02704819|Other|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
75611718|NCT04318379|Biological|HCVax|HCVax is a lentiviral vector encoding several HCV antigens
75760830|NCT04071626|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg once a day for 12 weeks
75760831|NCT04071626|Drug|Placebo oral tablet|Placebo oral tablet once a day for 12 weeks
75611719|NCT04213651|Other|No intervention|There is no intervention for this study
75760832|NCT04070768|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 3mg/m^2, Days 1,4,7
75760833|NCT04070768|Drug|Venetoclax|Venetoclax, 100,200,400, or 600mg Daily Dose
75760834|NCT04069338|Procedure|Lithotripter|Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
75611720|NCT04213495|Other|Anesthesia|Patients undergoing anesthesia from the cooperating Anesthesia center
75611721|NCT02688517|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
75611722|NCT02688517|Other|Laboratory Biomarker Analysis|Correlative studies
75611723|NCT04318223|Drug|Palbociclib|Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
75611724|NCT02704897|Other|Wound Assessment Tool|A set of questions relating to the symptoms of wound infection
75760835|NCT04058743|Device|TKA with nickel free components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
76069763|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
75611725|NCT01202903|Drug|Omalizumab|The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
75611726|NCT01202903|Drug|Placebo|The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
75611727|NCT01001169|Biological|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
75611728|NCT00618631|Drug|Nicotine|
75760836|NCT04058743|Device|TKA with standard cobalt chromium components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
75760837|NCT04057742|Diagnostic Test|AlloSure ddcfDNA assay|2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
75760838|NCT04057742|Diagnostic Test|AlloMap assay|10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
75611729|NCT00618631|Drug|Carfentanil|
75760839|NCT04057742|Diagnostic Test|Inflammatory Cytokines|10 mL collection at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A
75760840|NCT04057742|Diagnostic Test|Immune Cell Phenotypes|Collection of up to 1 cup of urine for per participant each study visit
75760841|NCT04051008|Behavioral|Online - use of online grocery shopping platform|The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
75760842|NCT04051008|Behavioral|Default - use of online grocery shopping platform with default shopping carts|The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
75760843|NCT04047810|Biological|Mesenchymal Stem Cells|0.5- 2 million cells/kg, intravenously once
75760844|NCT04036682|Drug|CLN-081|CLN-081 tablets
75760845|NCT04024670|Other|Arts Intervention|If selected for the arts activity, an artist in residence will visit you 3 times a week for a total of 3 weeks during your hospital stay. Two visits will focus on the arts activity and one visit will be the administration of the questionnaire. Each visit will be approximately 25 minutes at a time.
75760846|NCT04002167|Behavioral|Neurofeedback|The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.
75905454|NCT00580515|Behavioral|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
75611730|NCT01202747|Device|LipiFlow System|In-office treatment for meibomian gland dysfunction
75760847|NCT04002167|Behavioral|Cognitive training|The Cognitive training group will receive computerized working memory training with performance feedback.
75905455|NCT00580515|Behavioral|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
75905456|NCT00319813|Behavioral|Education|
75905457|NCT00151853|Drug|PPSB-SD|
75611731|NCT04213339|Behavioral|Kegel Exercises|"Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~Squeeze the muscles in anus like holding a bowel movement focus penile area~Relax the pelvic floor muscles after each attempt.~Repeat this exercise 10 to 20 times.~While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises"
75760848|NCT03987126|Dietary Supplement|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
75760849|NCT03987126|Other|Placebo|Sachet manufactured to mimic 10g of HMO
75760850|NCT03971409|Biological|Anti-OX40 Antibody PF-04518600|Given IV
75760851|NCT03971409|Drug|Avelumab|Given IV
75760852|NCT03971409|Drug|Binimetinib|Given PO
75760853|NCT03971409|Biological|Utomilumab|Given IV
75760854|NCT03971409|Drug|Liposomal Doxorubicin|Given IV
75760855|NCT03971409|Drug|Sacituzumab Govitecan|Given IV
75905458|NCT03487172|Device|poly-L-lactic acid to right knee|Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.
75905459|NCT03487172|Device|poly-L-lactic acid to left knee|Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
75760856|NCT03963583|Behavioral|HEROIC|"The HEROIC intervention will include individualized, nurse-led sessions focused on;~a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals."
75905460|NCT02167776|Behavioral|Church-based teaching|In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
75760857|NCT03962647|Dietary Supplement|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
75760858|NCT03962647|Drug|Letrozole|2.5 mg taken once daily by mouth
75760859|NCT03962543|Drug|Mirdametinib (PD-0325901) oral capsule or dispersible tablet|Mirdametinib (PD-0325901) capsule or dispersible tablet
75905461|NCT04460378|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy with Focus on guided exposure
75905462|NCT03069508|Drug|Clemizole Hydrochloride|Clemizole Hydrochloride will be administered orally for up to 24 weeks
75905463|NCT03481478|Diagnostic Test|CT and MRI|For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.
75905464|NCT04995016|Drug|Pembrolizumab|PD-1 inhibitor，Pembrolizumab 200mg IV, every 3 weeks.
75905465|NCT04995016|Drug|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
75905466|NCT03485066|Behavioral|Tetris|The video game Tetris is a cognitively challenging task, which requires mental rotation, problem solving and fast visuo-spatial and motor coordination.
75905467|NCT02764320|Other|Migraine Prophylactic Therapy Only|Start of new migraine preventive therapy or adjustment of current preventive therapy without immediate discontinuation of the overused medication(s)
75611732|NCT04213573|Drug|silver diamine fluoride|38% silver diamine fluoride liquid will be applied with a brush
75611733|NCT04213573|Drug|MI Varnish|topical fluoride varnish with calcium and phosphate
75611734|NCT05154175|Device|Ottobock helmet|Patients treated in current practice
75611735|NCT04395027|Device|atrial septal defect closure|The iatrogenic septal defect will be closed in the usual manner
75611736|NCT04294173|Behavioral|video education|tracheostomy care will be given to student nurses with video training
75611737|NCT02869659|Behavioral|Weight Loss Group|All participants will follow the Medifast Achieve TM 4 & 2 & 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack
75611738|NCT02869659|Behavioral|Delayed Weight Loss|18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
75905468|NCT02764320|Other|Discontinuation of Overused Medication|Immediate discontinuation of the overused medication(s) and the start of new migraine preventive therapy or adjustment of current preventive therapy
75905469|NCT04994860|Drug|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
75905470|NCT04994860|Drug|Sildenafil|Oral Sildenafil ( Revatio) 20 mg film coated tablets
75905471|NCT03481400|Drug|Calcitonin Gene-Related Peptide|Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)
75905472|NCT03481400|Other|Placebo|Isotonic saline
75905473|NCT02851407|Drug|Defibrotide|
75905474|NCT02851407|Other|Best Supportive Care|
75905475|NCT03481322|Dietary Supplement|Cooked diet with controlled amount of salt|Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
75905476|NCT02167854|Drug|BYL719|
75760860|NCT03947684|Device|Transcranial Magnetic Stimulation Device|The TMS device electrically stimulates the intended parts of the brain. In this study, the investigator plan to target the part of the brain cortex that is responsible for the voluntary motion of the leg muscles, whose functions are under investigation.
75760861|NCT03933215|Drug|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
75760862|NCT03928210|Drug|Digoxin|Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
75760863|NCT03925194|Drug|Anakinra|Application of Anakinra once daily for 28 days
75760864|NCT03914807|Other|Whole (3.25%) cow's milk recommendation|Children randomized to the whole milk recommendation will receive a recommendation a primary care recommendation to consume 500 mL of whole fat (3.25%) milk instead of transitioning to reduced fat (1%) milk at 2 years of age. The primary care physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children in the whole milk recommendation group will be provided with the same age-appropriate nutritional recommendations as children in the reduced fat recommendation group as part of routine healthcare according to the Rourke Baby Record.
75760865|NCT03914807|Other|Reduced (1%) fat milk|Children randomized to the reduced fat group will receive a primary care recommendation to transition from whole milk to 500 mL reduced fat (1%) milk daily once the child is two years of age (consistent with current guidelines). The physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children who receive the reduced fat recommendation will be provided with the same age-appropriate nutritional recommendations as children who receive the whole fat recommendation as part of routine healthcare according to the Rourke Baby Record.
75760866|NCT03908684|Device|Ultrasound Imaging|Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
75760867|NCT03897881|Drug|mRNA-4157|Individualized Neoantigen Therapy
75760868|NCT03897881|Biological|Pembrolizumab|Intravenous infusion
75760869|NCT03857321|Drug|Insulin|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
75760870|NCT03857321|Other|Placebo|Matching placebo (sterile saline) to 20 IU Humulin® R U-100
75760871|NCT03857321|Device|intranasal nebulizer-like device|Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.
75905477|NCT02167854|Drug|LJM716|
75905478|NCT02167854|Drug|TRASTUZUMAB|
75905479|NCT03541122|Diagnostic Test|pelvic X-ray examinations|Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads.
75905480|NCT03071146|Device|Bard® LifeStent® 5F Vascular Stent System|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
75905481|NCT02759562|Drug|Andecaliximab|Administered via subcutaneous injection
75905482|NCT02759562|Drug|Placebo|Administered via subcutaneous injection
76069764|NCT01829425|Drug|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
75459187|NCT01817400|Other|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
75459188|NCT01817400|Dietary Supplement|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
75459189|NCT01817400|Drug|Aspirin|
75760872|NCT03831711|Drug|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
75760873|NCT03831711|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
75760874|NCT03831711|Procedure|Positron Emission Tomography|Undergo PET/MRI
75760875|NCT03831711|Device|Investigational software and coils in PET/MR scan|General Electric (GE) Healthcare non-approved PET scanner coils and software
75760876|NCT03831386|Procedure|Vacuum-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via suction.
75905483|NCT03604809|Other|OT Guided Cognitive Interventions|"RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission."
75905484|NCT02167932|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
75905485|NCT04984954|Drug|MUSK pill|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
75905486|NCT02938377|Behavioral|Computerized Brief Intervention (CBI)|A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
75905487|NCT02938377|Behavioral|CBT4CBT|9 computerized modules delivered at the participant's pace
75905488|NCT02938377|Drug|Recommendation and Counseling for Alcohol Pharmacotherapy|The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
75905489|NCT02161614|Drug|Estradiol valerate|
75905490|NCT02161614|Drug|Placebo|
75905491|NCT04994626|Drug|Ibrutinib Combined With Rituximab|"Drug: ibrutinib ibrutinib 560mg administered orally once daily. Other Name: Imbruvica~Drug: rituximab rituximab 375mg/m² administered intravenously (IV)"
75905492|NCT03604731|Device|cytokine adsorbtion during extracorporeal circulation|preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
75905493|NCT02168010|Drug|Analgecine|Analgesic drug under test
75905494|NCT02168010|Drug|Neurotropin|Analgesic drug as positive control
75760877|NCT03831386|Procedure|Gravity-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via gravity.
75463343|NCT05853952|Device|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA
75760878|NCT03818152|Other|Functional strength assessment|Functional strength exercises to assess strength in lower limbs.
75760879|NCT03815656|Device|STN alone|DBS stimulation of STN alone
75760880|NCT03815656|Device|GPi alone|DBS stimulation of GPi alone
75760881|NCT03815656|Device|STN + GPi|cooperative DBS stimulation of STN and GPi sites
75760882|NCT03815656|Device|Closed-loop stimulation|adaptive DBS stimulation of STN and/or GPi sites
75760883|NCT03812185|Device|Suctioning orogastric tube which is attached to TEE probe cover|Suctioning orogastric tube which is atttached to TEE probe cover.
75760884|NCT03811561|Drug|Semaglutide|Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
75760885|NCT03811561|Drug|Placebo (semaglutide)|Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
75760886|NCT03789110|Drug|Nivolumab|Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
75760887|NCT03789110|Drug|Ipilimumab|Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
75760888|NCT03777800|Behavioral|Body therapy|"Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session."
75760889|NCT03777800|Behavioral|Treatment as usual|Standard treatment
75760890|NCT03777176|Drug|Dasiglucagon|Glucagon analog
75611739|NCT04210063|Other|Inspiratory Muscle Training (IMT)|IMT is a breathing training technique customized to participant's breathing capacity. Using a handheld electronic manometer (Pro2Fit from Smithfield), a study personnel will initiate training at 40-60% maximal inspiratory pressure. Adjustments will be customized to where the participant reports a difficulty of training between 4-6 out of 10. Training sessions will be performed about 30 minutes a day for 28 consecutive days.
75760891|NCT03777176|Other|Standard of Care|Standard of care according to site and/or country
75760892|NCT03759522|Drug|DPA-714 PET/MRI|DPA-714 PET/MRI
75459190|NCT01817400|Drug|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
75760893|NCT03749122|Procedure|Waiting time for hip fracture surgery|Time from hospital admission to start of hip fracture surgery
75760894|NCT03738098|Behavioral|Standard of Care|Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
75760895|NCT03738098|Behavioral|GUÍA|GUÍA for the ROR1 visit.
75459191|NCT01817413|Procedure|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
75905495|NCT02168010|Drug|Placebo|Blank tablet as placebo.
75459192|NCT01817413|Procedure|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
75459193|NCT01817439|Drug|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
75459194|NCT01817465|Drug|Motilitone ®|
75459195|NCT01817465|Drug|Pantoline®|
75760896|NCT03721341|Radiation|Palliative Radiation|Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
75459196|NCT01817465|Drug|Motilitone® and Pantoline®|
75611740|NCT02870439|Other|Blood drawn|
75611741|NCT04209751|Diagnostic Test|Stool removal|Stool removal; freezing an aliquot at -20 ° C and performing a direct examination. DNA extraction and serial PCR (Polymerase chain reaction).
75611742|NCT00618709|Drug|ATX-101|ATX-101 single dose
75611743|NCT00620269|Drug|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
75760897|NCT03721341|Drug|Chemotherapy|Chemotherapy may be given as indicated.
75760898|NCT03721341|Drug|Immunotherapy|Immunotherapy may be given as indicated.
75760899|NCT03721341|Drug|Hormones|Hormones may be given as indicated.
75760900|NCT03721341|Other|Observation|Observation only is acceptable if this is the standard practice.
75611744|NCT00620269|Drug|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
75905496|NCT04994314|Drug|nCaF2 primer|Calcium fluoride nanoparticles was added to conventional orthodontic primers to develop bioactive primer. This primer was examined previously for its biological and physical properties
75459197|NCT01817478|Other|microbiologic sample|
75611745|NCT00620269|Drug|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 & 8 every 3 weeks X 2 cycles
75905497|NCT04994314|Drug|Control primer|Conventional orthodontic primer
75905498|NCT02161692|Drug|Cyclophosphamide|
75905499|NCT02161692|Drug|Etoposide|
75905500|NCT02161692|Drug|Cisplatin|
75905501|NCT02161692|Drug|Bleomycin|
75905502|NCT02161692|Drug|Carboplatin|High dose carboplatin
75905503|NCT03070756|Device|Minimal-Intervention - Specification of device settings|- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration <=15 min, softPAP Level is selected based on patient comfort
75905504|NCT02746575|Drug|metoprolol|
75905505|NCT02161770|Drug|AZD9291 tablet dosing|Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
75905506|NCT02161770|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291 pharmacokinetic parameters.
75611746|NCT00620269|Radiation|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
75760901|NCT03721341|Radiation|Stereotactic Ablative Radiotherapy|Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).
75760902|NCT03704350|Dietary Supplement|controlled diet|Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
75760903|NCT03701581|Drug|4-Aminopyridine|FDA-approved tablets.
75760904|NCT03701581|Other|Placebo|Placebo will be tooled to look similar to the study drug.
75760905|NCT03692910|Drug|SAGE-217|SAGE-217 capsule
75760906|NCT03692910|Drug|Placebo|SAGE-217 matching placebo capsule
75760907|NCT03689543|Drug|ER beta agonist|We propose to evaluate the efficacy of a selective estrogen receptor (ER) beta agonist (Lilly Compound LY500307) to prevent estradiol withdrawal-induced mood symptoms. The effects of estradiol primarily occur through activation of two receptor subtypes, often with opposing outcomes: estrogen receptor (ER) alpha, and ER beta. We focus on ER beta because the beta estrogen receptor is reported to mediate the effects of estradiol on the serotonergic system and mediate the antidepressant-like effects of estradiol in the forced-swim test.
75760908|NCT03689543|Other|Placebo|Placebo
75760909|NCT03682289|Drug|Ceralasertib|Given orally
75760910|NCT03682289|Drug|Olaparib|Given orally
75760911|NCT03682289|Drug|Durvalumab|Given intravenously (IV)
75760912|NCT03675256|Biological|immediate Gardasil 9, delayed MenVeo vaccine|Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine
75760913|NCT03675256|Biological|immediate MenVeo vaccine, delayed Gardasil 9|Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9
75760914|NCT03675256|Biological|immediate Cervarix, delayed MenVeo vaccine|Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
75760915|NCT03645863|Drug|MT-6548|Oral tablet
75905507|NCT02161770|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
75905508|NCT04989244|Behavioral|Weight loss program|Women with obesity were included to the weight loss program which included physical exercise and dietary guidelines
75905509|NCT03604575|Drug|Insulin Lispro|
75905510|NCT03604575|Drug|Humalog®|
76069765|NCT01829425|Behavioral|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
75611747|NCT04213417|Other|Bobath therapy and Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.
75760916|NCT03645863|Drug|Iron supplement A|Oral tablet
75760917|NCT03645863|Drug|Iron supplement B|Oral tablet
75760918|NCT03645863|Drug|Iron supplement C|Oral tablet
75760919|NCT03645863|Drug|Iron supplement D|Oral tablet
75760920|NCT03643367|Drug|Sevoflurane|Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.
75760921|NCT03643367|Drug|Control Group|Included patients randomized in control group, intravenouse sedation is continued with propofol
75760922|NCT03626038|Device|A.L.P.S. Proximal Humerus Plating System|Anatomically contoured, locking plates that can be customized intra-operatively, multidirectional screws allow for stable fixation for a wide variety of patients.
75760923|NCT03587844|Drug|brentuximab vedotin|MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.
75760924|NCT03587844|Drug|brentuximab vedotin|LyP Brentuximab vedotin 0.9 mg/kg2
75760925|NCT03587844|Drug|brentuximab vedotin|MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
75760926|NCT03584152|Drug|Norco 5Mg-325Mg Tablet|Opioid Analgesics
75760927|NCT03584152|Drug|Tylenol 325Mg Caplet|Non opioid analgesics
75760928|NCT03584152|Drug|Ibuprofen 200 mg|Non opioid analgesics
75760929|NCT03584100|Device|Tourniquet 8000|Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure
75760930|NCT03563677|Other|dual expert guidance structure|Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
75760931|NCT03545464|Drug|Placebo Oral Tablet|Placebo of cortancyl Oral Tablet 20mg
75760932|NCT03545464|Drug|Cortancyl Oral Tablet|Cortancyl oral Tablet 20 mg
75760933|NCT03545464|Drug|Levocetirizine Oral Tablet|Levocetirizine Oral Tablet 5 mg
75760934|NCT03523338|Drug|Apalutamide|Participants will receive apalutamide 240 mg orally once daily.
75760935|NCT03523338|Drug|ADT (Standard of Care)|Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
75760936|NCT03517228|Device|BAUM device|The robotic manipulator will be placed at the start of each case. The manipulator will be cleaned and sanitized using the same process as other reusable OR devices. Feasibility will be determined by the rate of successful robotic manipulator docking and if the manipulation of the uterus was successful for the duration of the procedure. The V-Care is an FDA approved uterine manipulator which will attach to the investigational BAUM. Placement of a BAUM will be noted on the operative note.
75905511|NCT04988932|Drug|Inhaled nitric oxide|Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
75905512|NCT03602313|Device|Body Weight Support Gait Training|
75905513|NCT03602313|Other|Traditional Gait Training|
75760937|NCT03505905|Drug|Pregnenolone|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
75459198|NCT01816386|Other|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
75760938|NCT03505905|Drug|Placebo|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
75459199|NCT01816386|Other|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
75459200|NCT01817543|Device|AutoloGel|Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
75459201|NCT01817556|Drug|Stillen Tab.|
75459202|NCT01817556|Drug|Mucosta Tab.|
75760939|NCT03456076|Drug|Alectnib|Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
75760940|NCT03456076|Drug|Cisplatin|"Participants will receive Cisplatin 75 milligrams per square meter (mg/m^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
75760941|NCT03456076|Drug|Vinorelbine|Participants will receive Vinorelbine 25 mg/m^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
75459203|NCT01817595|Other|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
75459204|NCT01817595|Other|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
75760942|NCT03456076|Drug|Gemcitabine|Participants will receive Gemcitabine 1250 mg/m^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
75905514|NCT03625466|Drug|LUM/IVA|FDC tablets or granules for oral administration.
75459205|NCT01817621|Behavioral|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
75459206|NCT01817621|Behavioral|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
75905515|NCT03625466|Drug|LUM/IVA|FDC granules for oral administration.
75905516|NCT03625466|Drug|Placebo|Placebo matched to LUM/IVA for oral administration.
75905517|NCT04989010|Drug|89Zr-NY005|89Zr-NY005 injection followed by 89Zr-NY005 PET scan
75905518|NCT03604419|Drug|PB-119 100 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
75905519|NCT03604419|Drug|PB-119 150 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
75905520|NCT03604419|Drug|PB-119 200 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
75905521|NCT03604419|Drug|PB-119 placebo + Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
75905522|NCT03540654|Other|Budget impact|Budget impact, using a probabilistic markov model, of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with current practice (treatment during entire life), from the healthcare system point of view
75905523|NCT04994548|Procedure|Endosocpic resection of early esophageal tumor|under general anesthesia, by mucosectomy or endoscopic submucosal dissection
75760943|NCT03456076|Drug|Pemetrexed|"Participants will receive 500 mg/m^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
75760944|NCT03456076|Drug|Carboplatin|For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
75905524|NCT03484988|Dietary Supplement|Placebo oil|The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
76069766|NCT03796689|Device|Smartphone-linked HBPM and associated app|Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publicly available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.
76069767|NCT03796689|Device|Standard HBPM|Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publicly available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
75459207|NCT01817634|Dietary Supplement|Fish powder corn-soy blend'+ Fish oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
76069768|NCT05630079|Device|Treatment with Metaneb®|"Every patient of this group receive 3 daily treatments of 20 minutes each, performed at approximately 4-hour intervals.~Each treatment with MetaNeb system consists of four cycles: : 5 minutes of Continuous Positive Expiratory Pressure (CPEP) for lung re-expansion (Cycle I), 5 minutes of Chest High Frequency Oscillation (CHFO) for secretion clearance (Cycle II), 5 min of CPEP (Cycle III), 5 minutes of CHFO (Cycle IV). Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It's associated with the administration of aerosols with 10 ml of saline solution 0.9% and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount."
75459208|NCT01817634|Dietary Supplement|Fish powder corn-soy blend + corn oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
75459209|NCT01817634|Dietary Supplement|Corn-soy blend + fish oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
75459210|NCT01817634|Dietary Supplement|Corn-soy blend + corn oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
75459211|NCT01817647|Procedure|Colorectal surgery|
75459212|NCT01817660|Procedure|Open repair of popliteal artery|
75459213|NCT01817660|Procedure|Endovascular repair of popliteal artery|
75611748|NCT04213417|Other|Bobath therapy|Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
75611749|NCT00618865|Dietary Supplement|Omega-3 fatty acids|
75611750|NCT04213183|Diagnostic Test|Hepatobiliary Disorders|The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
75760945|NCT03449381|Drug|BI 907828|Film-coated tablet
75760946|NCT03422302|Device|Biphasic Positive Airway Pressure|Receive BiPAP
76069769|NCT05630079|Device|Treatment with IPV®|Each treatment with IPV provides 3 daily treatments of 20 minutes with the high percussion frequency tolerated by the patient. and I/E ratio: 1/1.2. Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It is associated with the administration of aerosols with 10 ml of saline solution 0.9% [-] and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount.
76069770|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week|450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
75459214|NCT01817673|Dietary Supplement|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
75459215|NCT01817673|Dietary Supplement|placebo|
75760947|NCT03422302|Procedure|Computed Tomography|Undergo CT simulation scans
75760948|NCT03422302|Procedure|Continuous Positive Airway Pressure|Receive CPAP
75760949|NCT03422302|Procedure|Deep Inspiration Breath Hold|Complete DIBH
75760950|NCT03422302|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo CT simulation scans
75760951|NCT03422302|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75760952|NCT03403699|Biological|Generation of inducible pluripotent stem cells|Generation of inducible pluripotent stem cells from peripheral blood cells.
75760953|NCT03403283|Other|15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy|
75760954|NCT03403283|Other|Healthy Controls 15 age matched control subjects|
75760955|NCT03351348|Drug|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
75760956|NCT03351348|Behavioral|patient-reported pain scores|Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain. Patients may be discharged when table either on the day of surgery or post-operative day 1 (on pill diary for same-day discharge patients).
76069771|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week|150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
75760957|NCT03351348|Other|saline|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 ± 30 minutes hours postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
75760958|NCT03326791|Drug|Acetylsalicylic acid|Trombyl 160 mg once daily
75760959|NCT03326791|Drug|Placebo Oral Tablet|Placebo one tablet daily
76069772|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week (QW)|450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
76069773|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week (TIW)|150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
75459216|NCT01817686|Other|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
75459217|NCT01817686|Other|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
75459218|NCT01817686|Other|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
75459219|NCT01817699|Other|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
75459220|NCT01817699|Dietary Supplement|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
75611751|NCT00617617|Dietary Supplement|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
75611752|NCT00617617|Other|Placebo|Control Group - Control Group participants will receive an identical placebo.
75760960|NCT03281902|Procedure|Biopsy|Undergo tumor biopsy
75760961|NCT03281902|Procedure|Biospecimen Collection|Undergo collection of blood, urine, stool, and saliva
75760962|NCT03281902|Other|Laboratory Biomarker Analysis|Correlative studies
75760963|NCT03280563|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
75760964|NCT03280563|Drug|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
75760965|NCT03280563|Drug|Entinostat|Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
75760966|NCT03280563|Drug|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
75760967|NCT03280563|Drug|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
75905525|NCT03484988|Dietary Supplement|Echium oil|The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
75905526|NCT03484988|Dietary Supplement|Mixed oil|The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
75905527|NCT02168166|Behavioral|Executive Function Training|
75905528|NCT02168166|Behavioral|Placebo|Placebo version of executive function training
75611753|NCT05104957|Other|Dynamic tape|The experimental group will use a special dynamic patch made of cotton, coated with a hypoallergenic acrylic heat-activated adhesive arranged in sinusoidal-shaped layers. The tape will be applied using the muscle technique with a Y-shaped cut patch directly to the dried and non-greased skin. The application will be performed in a standing position, with the participant's lower extremities straight. The therapist will place the beginning of the tape (the base) on the participant's sacrum and then, asking them to bend 45 degrees forward, tape the tails of the tape along the spine on the extensor muscles of the lumbar region, without changing the tension of the tape, keeping the base in the initial position.
75905529|NCT02237547|Biological|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
75905530|NCT04984720|Behavioral|Smartphone based digital application|Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
75760968|NCT03280563|Drug|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
75760969|NCT03280563|Drug|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
75760970|NCT03280563|Drug|Abemaciclib|Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
75760971|NCT03220776|Drug|N-Acetylcysteine|5 day trial of N-acetylcysteine with titration to 2,400mg
75905531|NCT02168244|Other|Heating Pack|Application of heat to skin for 2-3 minutes prior to injection of biologic drug
75905532|NCT02168244|Other|Ice pack|Application of cold to skin for 2-3 minutes prior to injection of biologic drug
76069774|NCT04407663|Other|Telemedicine to remote outpatient visit in bariatric patient|Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
75760972|NCT03220776|Drug|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
75760973|NCT03220776|Drug|Placebo Oral Tablet|5 day trial of matched placebo
75760974|NCT03201874|Behavioral|Pain self-management|The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
75760975|NCT03201874|Behavioral|Education|Education about sickle cell disease to increase disease knowledge
75760976|NCT03171025|Drug|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
75760977|NCT03130036|Other|[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan|A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study
75905533|NCT03484832|Device|Walter Ritter Ethyl Chloride Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
75459221|NCT01817738|Biological|CV9104|Intradermal injection of CV9104
75459222|NCT01817738|Biological|Placebo|Intradermal injection of placebo
75459223|NCT01817803|Drug|furosemide/no spironolactone|furosemide (doubling previous furosemide dose)
75459224|NCT01817803|Drug|metolazone/no spironolactone|metolazone (add 2.5mg qod)
75459225|NCT01817803|Drug|furosemid/spironolactone|furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
75459226|NCT01817803|Drug|metolazone/spironolactone|metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
75459227|NCT01817816|Procedure|Botox_A|
75459228|NCT01817816|Procedure|Botox_B|
75459229|NCT01817829|Drug|paracetamol|500 mg oral tablet
75459230|NCT01817829|Drug|placebo|
75611754|NCT05104957|Other|Sham tape|In the control group, a plain paper patch will be used to conduct the study, which, like the dynamic patch, will be applied using the same form of tape cutting and the same application technique. The entire method of applying the patch will also take place in the participant's standing position with forward bending. The paper patch will be placed at the levels from the L3 segment to the sacrum, along the spine on the lumbar extensor muscles.
75760978|NCT03122197|Drug|Letrozole Oral Tablet|Administration: Letrozole will be given orally once daily.
75760979|NCT03122197|Drug|Temozolomide|50 mg/m2 TMZ administered orally once daily
75760980|NCT03099434|Behavioral|Facebook App|This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.
75760981|NCT03099434|Behavioral|Live Donor Champion + Facebook App|"A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs."
75760982|NCT03059823|Drug|retifanlimab|Anti-PD-1 monoclonal antibody
75760983|NCT03029702|Drug|Insulin|Insulin will be used for GDM treatment
75760984|NCT03029702|Drug|Glyburide|Glyburide will be used for GDM treatment
75905534|NCT03484832|Other|Placebo Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
75905535|NCT03484832|Other|Placebo Cream|Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
75905536|NCT03484832|Drug|EMLA Cream|Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
76069775|NCT05632653|Procedure|CTO-PCI|Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF <50%).
75611755|NCT04212637|Other|MRI|Examine BOLD activity in relation to eye movements measures
75611756|NCT04212403|Drug|Levofloxacin|The control group receives AMP.
75760985|NCT03029702|Drug|Metformin|Metformin will be used for GDM treatment
75760986|NCT03014648|Drug|Atezolizumab|Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
76069776|NCT01829347|Biological|ELAD|ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
76069777|NCT01829347|Other|Standard of Care treatment|Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
76069778|NCT01394523|Drug|Bupivacaine|0.25% or 0.5%
76069779|NCT01857973|Device|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
76069780|NCT04304469|Other|surveys|delivery of the survey at a domestic violence consultation
76069781|NCT04304469|Other|follow-up|follow-up of women 6 months after their consultation
76069782|NCT04407273|Drug|observational|observational study
75760994|NCT03009045|Drug|Tedizolid|200mg oral tedizolid one pill per day
75760995|NCT03006926|Drug|lenvatinib|4 mg capsules
76069783|NCT01857583|Drug|15mg DU-176b|
76069784|NCT01857583|Drug|30mg DU-176b|
76069785|NCT01857583|Drug|Fondaparinux|
75760996|NCT03006926|Drug|pembrolizumab (200 mg)|30-minute intravenous infusion
75760997|NCT02982629|Behavioral|Reminder letter Intervention|Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
75905537|NCT04985110|Drug|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
75905538|NCT04985110|Drug|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
75459231|NCT01817842|Behavioral|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
75459232|NCT01817842|Behavioral|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
75611757|NCT00618943|Behavioral|Tobacco Use Cessation|The proposed intervention will proceed in three steps. Step 1, provided to all intervention participants, includes multimedia, stage-based, expert-system contacts at intake, 3- and 6-months follow-up supported with brief (15-min) motivational counseling sessions. Step 2, reserved for intervention participants interested in quitting, consists of 12-weeks of individual CBT sessions for smoking cessation. Step 3, a 12-week course of nicotine patch, will be offered to adolescents who enter the CBT Cessation Treatment, who do not have any medical contraindications, and who smoke an average of 5 cigarettes or more per day in the past month.
75459233|NCT01817842|Behavioral|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
75459234|NCT01817868|Other|Recombinant Factor VIII (Kogenate, BAY14-2222)|All dosage, frequency and duration for drugs will be under the decision of the treating physician.
75459235|NCT01817894|Drug|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
75611758|NCT00637117|Biological|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
75611759|NCT02052193|Drug|Dabrafenib|Measurement of toxicity related to UV exposure
75611760|NCT02052193|Drug|Vemurafenib|Measurement of toxicity related to UV exposure
75905539|NCT02164812|Drug|Moxifloxacin|
75459236|NCT01817920|Behavioral|integrated multidisciplinary fall prevention program|
75459237|NCT01817933|Behavioral|physical therapy|
75459238|NCT01817946|Other|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
75459239|NCT01817972|Biological|Certolizumab pegol|Subcutaneous injection
75459240|NCT01817972|Drug|Azathioprine|50mg tablets
75459241|NCT01817985|Drug|GS-5816|
75459242|NCT01817998|Other|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
75459243|NCT01818011|Drug|GSK1322322 Initial fit for purpose tablets|Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
75611761|NCT00617695|Drug|Zolmitriptan|5mg nasal spray
75611762|NCT00617695|Drug|Placebo|
75611763|NCT02704585|Device|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
75611764|NCT02704585|Device|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
75611765|NCT00619021|Drug|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m^2, 800 mg/m^2, 1000 mg/m^2, 1200 mg/m^2
75760998|NCT02972840|Drug|Acalabrutinib|Administered orally (PO)
75760999|NCT02972840|Drug|Bendamustine|Administered intravenously (IV)
75761000|NCT02972840|Drug|Rituximab|Administered intravenously (IV)
75761001|NCT02972840|Drug|Placebo|Placebo comparator
75761002|NCT02966899|Dietary Supplement|Omega-3 fatty acids|
75761003|NCT02890641|Genetic|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
75761004|NCT02886650|Procedure|Thermocoagulation|Thermocoagulation During pre-surgical Invasive EEG Monitoring
75761005|NCT02861417|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
75761006|NCT02861417|Drug|Busulfan|Given IV
75761007|NCT02861417|Drug|Cyclophosphamide|Given IV
75761008|NCT02861417|Drug|Fludarabine|Given IV
75761009|NCT02861417|Drug|Fludarabine Phosphate|Given IV
75905540|NCT02164812|Drug|Placebo|
75905541|NCT02164812|Drug|Efavirenz|
76069786|NCT04000347|Drug|2.5% benzoyl peroxide gel|2.5% benzoyl peroxide gel was given to patients for 2 weeks
76069787|NCT04000347|Drug|5% benzoyl peroxide gel|5% benzoyl peroxide gel was given to patients for 2 weeks
75761010|NCT02861417|Other|Laboratory Biomarker Analysis|Correlative studies
75761011|NCT02861417|Drug|Mycophenolate Mofetil|Given PO
75761012|NCT02861417|Other|Pharmacological Study|Correlative studies
75905542|NCT04988776|Other|ultrasUltrasound-guided Intercostobrachial nerve block supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 m|patients recieved ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
75905543|NCT04988776|Other|ultrasound-guided pectoral nerves block type II supplemental to supraclavicular block|Patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
75459244|NCT01818011|Drug|GSK1322322 over granulated tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
75459245|NCT01818011|Drug|GSK1322322 intended commercial tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
75905544|NCT02853123|Drug|Tiotropium|fixed dose combination once daily
75905545|NCT02853123|Drug|Olodaterol|fixed dose combination once daily
75905546|NCT02853123|Drug|Tiotropium|
76069788|NCT01829191|Device|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
75459246|NCT01818011|Drug|Placebo tablets|Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
75611766|NCT00620347|Drug|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
75611767|NCT01918735|Drug|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
75611768|NCT01918735|Drug|GWP42006|"Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects."
75611769|NCT04213105|Drug|QL1206|subcutaneous injection of 60 mg (1ml) only once,on the first day.
75611770|NCT04213105|Drug|Prolia®|subcutaneous injection of 60 mg (1ml)only once,on the first day
75611771|NCT01887301|Drug|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
75905547|NCT02255370|Drug|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
75761013|NCT02861417|Drug|Tacrolimus|Given IV or PO
75761014|NCT02861417|Drug|Thiotepa|Given IV
75761015|NCT02850900|Behavioral|Internet Survey|Weekly survey will be emailed, subjects should complete them
75761016|NCT02845505|Other|Intravascular Ultrasound, coronary computed tomography angiography|
75905548|NCT04985188|Diagnostic Test|Quantitative ultrasound (QUS) technique|Measurement of quantitative ultrasound parameter using clinical US machine (RS85)
76069789|NCT01829191|Device|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
76069790|NCT05360745|Dietary Supplement|ARACOMPLEX®|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
75761017|NCT02807636|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
75761018|NCT02807636|Drug|Carboplatin|Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
75459247|NCT01818011|Drug|13C-GSK1322322 stable isotope powder|White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
75761019|NCT02807636|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
75761020|NCT02807636|Other|Placebo|Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
75761021|NCT02807636|Drug|Cisplatin|Cisplatin will be administered at a dose of 70 mg/m^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
75761022|NCT02769338|Other|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
75459248|NCT01818011|Drug|GSK1322322 for injection|White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
75905549|NCT04459832|Procedure|stretch hamstring|Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
75459249|NCT01818011|Drug|Placebo injection|A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
75761023|NCT02760498|Drug|cemiplimab|
75905550|NCT02161848|Other|Magnetic Resonance Imaging|MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
75905551|NCT04984252|Behavioral|Self-compassion comprising compassionate body scan-1, compassion body scan-2 and short noticing practice|This intervention includes 3 short meditations that are identified as the active component in the previous study (ID: NCT04665167)
75611772|NCT00618085|Behavioral|Motor imagery practice|During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.
75611773|NCT00618085|Other|Standard physiotherapy and occupational therapy|Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
75905552|NCT04984252|Behavioral|Self-compassion comprising self-compassion break, loving kindness meditation, and breathing exercise.|This intervention includes 3 short meditations that are identified as the inactive component in the previous study (ID: NCT04665167)
75905553|NCT04984252|Behavioral|Distraction group|Participants will be asked to listen recording on irrelevant topic.
75905554|NCT03481166|Other|Education on breastfeeding pain|A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
75905555|NCT02161926|Other|dietary restrictions|Dietary restrictions during 8 weeks
75905556|NCT03073642|Other|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
75905557|NCT03073642|Other|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
75905558|NCT03487094|Other|Infant formula|Multi-centered, prospective, randomized clinical trial
75905559|NCT03604029|Device|Near Infrared Spectroscopy|Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.
75905560|NCT02168322|Device|collagen membrane|bovine collagen membrane used for selective tissue regeneration
75905561|NCT02168322|Device|collagen membrane|collagen bovine occlusive membrane for selective tissue regneration
75905562|NCT04984408|Biological|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration: Intramuscular~Storage Conditions: 2 to 8 degree Celsius"
76069791|NCT05360745|Dietary Supplement|placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
75761024|NCT02684058|Drug|Dabrafenib|Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients < 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients < 12 years old and < 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and <19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
75761025|NCT02684058|Drug|trametinib|"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients <6 years old and <26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients <6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg < 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"
75761026|NCT02684058|Drug|Carboplatin|"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."
75761027|NCT02684058|Drug|Vincristine|"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m^2 as weekly IV bolus infusion (0.05 mg/kg if child is <12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m^2 as weekly IV bolus infusion (0.05 mg/kg if child is <12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."
75905563|NCT04984408|Biological|influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)|"The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~Mode of Administration: Intramuscular~Storage Conditions: 2 to 8 degree Celsius"
75905564|NCT03602001|Behavioral|Attentive eating smartphone application.|A smartphone application that encourages a more attentive eating style.
75905565|NCT03602001|Behavioral|Standard dietary advice and text tips.|Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.
75905566|NCT02168556|Behavioral|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
75905567|NCT02168556|Behavioral|Video|Subject watches an informational video prior to undergoing urodynamic testing.
75905568|NCT02168556|Other|Standard of care|Standard of care
75905569|NCT03073564|Diagnostic Test|Endurance test for upper limbs|Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.
76069792|NCT00211185|Drug|Denileukin diftitox|Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.
76069793|NCT00211185|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
76069794|NCT00211185|Drug|Doxorubicin|Doxorubicin will be administered IV at a dosage of 50 mg/m^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
76069795|NCT00211185|Drug|Vincristine|Vincristine will be administered IV at a dosage of 1.4 mg/m^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
75459250|NCT01818024|Drug|Single IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
76069796|NCT00211185|Drug|Prednisone|Prednisone will be administered orally at a dosage of 100 mg on Days 3 to 7 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
75459251|NCT01818024|Drug|Matching placebo single dose IV infusion|Matching placebo solution available for IV administration.
75611774|NCT00996801|Drug|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
75611775|NCT00996801|Drug|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
75611776|NCT00996801|Drug|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
75611777|NCT00996801|Drug|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
75459252|NCT01818024|Drug|Single IH dose of GSK2862277|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
75459253|NCT01818024|Drug|Matching placebo single dose IH|Matching placebo nebulised solution available for IH administration.
75459254|NCT01818024|Drug|Repeat IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
75459255|NCT01818024|Drug|Matching placebo repeat dose IV infusion|Matching placebo solution available for IV administration.
75611778|NCT00996801|Drug|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
76069797|NCT00211185|Other|Pegfilgrastim|Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting on Day 4 and continued until absolute neutrophil count (ANC) was less than 5000/millimeter squared (mm^2) for 2 days post-nadir.
75761028|NCT02644369|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
75761029|NCT02571036|Drug|DCC-2618|50 mg formulated tablets
75905570|NCT03073564|Diagnostic Test|Functional test|The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
75905571|NCT03484754|Biological|botulinum toxin|injection of botulinum toxina in two different facial sites
75905572|NCT03601845|Other|Stimuli|Visual stimulation while using additional sequencing
75905573|NCT03601845|Other|No stimuli|Additional sequencing only
75905574|NCT02162004|Procedure|Continuous Correction|
75905575|NCT04890652|Behavioral|4-week intervention|All participants will receive a digital intervention to reduce drinking for 4 weeks. There will be two therapy sessions each week using alcohol treatment combined with breathing-based stress management.
75905576|NCT04459676|Drug|Standard of Care (SOC) + ANG-3777|Standard of Care (SOC) + ANG-3777
76069798|NCT00210639|Drug|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
75459256|NCT01818024|Drug|Repeat IH dose selected of GSK2862277 from Part 2|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
75611779|NCT00996801|Drug|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
75611780|NCT00619333|Drug|follitropin and lutropin|follitropin and lutropin
75905577|NCT04459676|Drug|Standard Of Care (SOC) + Placebo|Standard Of Care + Placebo
75459257|NCT01818024|Drug|Matching placebo repeat dose IH|Matching placebo nebulised solution available for IH administration.
75459258|NCT01818037|Procedure|Cataract surgery|
75459259|NCT01818050|Other|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
75459260|NCT01818089|Device|Lung sound analyzer|Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
75459261|NCT01818102|Device|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
75611781|NCT02692027|Other|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
75905578|NCT03540966|Combination Product|CapulinTM|a kind of camouflage agent
75761030|NCT02571036|Drug|DCC-2618|10 mg and 50 mg formulated tablets
75761031|NCT02561273|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
75761032|NCT02561273|Drug|Cyclophosphamide|Given IV
75761033|NCT02561273|Drug|Doxorubicin Hydrochloride|Given IV
75761034|NCT02561273|Drug|Etoposide|Given IV
75905579|NCT03540966|Other|Chinese version of the vitiligo life quality index, VLQI-C|a questionaire designed for patients with vitiligo
75905580|NCT04984564|Other|None. As this was an observational study.|Observational study.
75905581|NCT02162082|Device|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
75761035|NCT02561273|Other|Laboratory Biomarker Analysis|Correlative studies
75761036|NCT02561273|Drug|Lenalidomide|Given PO
75761037|NCT02561273|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
75761038|NCT02561273|Drug|Prednisone|Given PO
75761039|NCT02561273|Drug|Vincristine Sulfate|Given IV
75761040|NCT02506959|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
75459262|NCT01818102|Device|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
75761041|NCT02506959|Drug|Busulfan|Given IV
75761042|NCT02506959|Drug|Gemcitabine Hydrochloride|Given IV
75761043|NCT02506959|Other|Laboratory Biomarker Analysis|Correlative studies
75905582|NCT04984642|Other|diet|have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
75905583|NCT02164890|Other|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
75905584|NCT03484676|Device|Titinium|custom made plate at one point after 3D virtual simulation and reduction of the complex using Mimics software.
76069799|NCT05632029|Device|active laser|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
75459263|NCT01818115|Device|Hydrus Implant|
75459264|NCT01818115|Procedure|IOL placement|
75459265|NCT01818128|Device|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
75459266|NCT01818128|Device|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
75459267|NCT01818180|Dietary Supplement|URELL|
75611782|NCT02692027|Other|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
75611783|NCT04212871|Other|watch food video 1|A 2 minutes video, with food content. The first study used a ramen mukbang here, the second study used a hotpot mukbang.
75459268|NCT01818180|Other|Placebo|
75611784|NCT04212871|Other|watch food video 2|A 2 minutes video, with food content (different content from video 1). The first study used a donut mukbang here, the second study used a hotpot cooking show here.
75611785|NCT04212871|Other|watch a non-food content video|a 2 minutes video without food content. The first study used a documentary introducing the forbidden city, the second study used a documentary introducing Cornell University.
75611786|NCT04924621|Device|Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.|"The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists.~After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg."
75761044|NCT02506959|Drug|Melphalan|Given IV
75761045|NCT02506959|Drug|Panobinostat|Given PO
75459269|NCT01818206|Other|Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.|Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
75761046|NCT02506959|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
75761047|NCT02506959|Other|Pharmacological Study|Correlative studies
75761048|NCT02502006|Drug|Celecoxib|
75761049|NCT02502006|Drug|Naproxen|
75761050|NCT02502006|Drug|Placebo|
75761051|NCT02457598|Drug|Tirabrutinib|Capsules or tablets administered orally
75761052|NCT02457598|Drug|Idelalisib|Tablets administered orally twice daily
75761053|NCT02457598|Drug|Entospletinib|Tablets administered orally
75761054|NCT02457598|Drug|Obinutuzumab|Administered intravenously
75761055|NCT02447692|Other|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
75905585|NCT03603561|Device|cTBS|In the cTBS arm, the patients will receive 5 daily session cTBS (5 times uninterrupted train of 900 pulses) separated by a 15 min interval. Patients will be treated with in total 20 cTBS sessions over the right dorsolateral prefrontal cortex, spread over 4 days. A stimulation intensity of 100 % of the resting motor threshold (rMT) of the right abductor pollicis brevis muscle will be used.
75905586|NCT03603561|Device|Sham cTBS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
75905587|NCT01045226|Procedure|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
75905588|NCT01045226|Other|Quality-of-Life assessment|Quality of Life Assessment
75459270|NCT01818219|Procedure|Records of EADI derived parameters|
75459271|NCT01818271|Behavioral|conventional physical therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
75905589|NCT01045226|Other|Questionnaire Administration|Questionnaire Administration
75905590|NCT02634346|Drug|ALK3831|Daily dosing
75463344|NCT05853952|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
75905591|NCT02634346|Drug|Olanzapine|Daily dosing
75761056|NCT02447692|Other|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
75761057|NCT02359825|Drug|Polyethylene glycol (PEG)|For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.
75761058|NCT02355301|Procedure|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
75761059|NCT02347670|Behavioral|Efficacy-patient navigator to improve follow-up adherence|Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.
75761060|NCT02347670|Behavioral|Office-Based Usual Care|"Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.~This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital."
75761061|NCT02327455|Procedure|Stress Dobutamine Echocardiographic using 4DE System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
75905592|NCT02634346|Drug|Placebo|Daily dosing
75905593|NCT03601689|Procedure|rectal resection|total mesorectal excision
75905594|NCT00936728|Other|therapeutic nutritional supplementation|Given orally
75905595|NCT00936728|Dietary Supplement|white wine|Given orally
75459272|NCT01818271|Behavioral|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~Treadmill walking exercise program."
75905596|NCT00936728|Other|questionnaire administration|Ancillary studies
75905597|NCT02168634|Drug|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
75905598|NCT02168634|Drug|Placebo|1cc normal saline, local injection
75905599|NCT02237781|Drug|Gonadotropins|The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
75905600|NCT04459208|Device|Manta|plug-based vascular closure
75905601|NCT04459208|Device|ProGlide|suture-based vascular closure
75905602|NCT02168712|Other|Moderate continuous exercise training|
75905603|NCT02168712|Other|Interval exercise training|
75905604|NCT00849147|Biological|Haploidentical Bone Marrow Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor."
75905605|NCT00849147|Biological|GVHD prophylaxis|"The GVHD prophylaxis regimen will consist of the following:~Cy: 50 mg/kg IV on Days 3 and 4~Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm^3 for 3 consecutive days"
75905606|NCT00812240|Drug|Masitinib|
75905607|NCT00812240|Drug|Imatinib|imatinib 400 mg or 600 mg per day, per os
75905608|NCT02165046|Drug|Budesonide|
75905609|NCT02165046|Drug|Procaterol|
75611787|NCT04924621|Device|Mask ventilation|The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.
75611788|NCT04924621|Drug|Midazolam(T group)|Midazolam 0.05mg/kg, intravenous injection
75611789|NCT04924621|Drug|Sufentani(T group)|Sufentanil 0.02-0.05ug/kg, intravenous injection
75611790|NCT04924621|Drug|Propofol(T group)|Propofol 2-3ug/ml, intravenous injection
75611791|NCT04924621|Drug|Rocuronium(T group)|Rocuronium 0.06mg/kg, intravenous injection
75611792|NCT04924621|Drug|Drug use target(T group)|Make BIS < 60 .
75611793|NCT04924621|Drug|Sufentanil(C group)|Sufentanil 5ug, intravenous injection
75611794|NCT04924621|Drug|Midazolam(C group)|Midazolam 0.05mg/kg, intravenous injection
75611795|NCT04924621|Drug|Propofol|Propofol 1-2ug/ml, intravenous injection
75761062|NCT02323698|Drug|Caffeine|Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.
75761063|NCT02323698|Other|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
75761064|NCT02323698|Other|Placebo|This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 30min after consumption to mimic the caffeine drug protocol. Throughout experimentation, blood oxygenation, blood pressure and heart rate will be monitored.
75761065|NCT02323698|Other|SHAM|This is a placebo counterpart to breathing intermittent low oxygen. Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
75611796|NCT04924621|Drug|Tetracaine(C group)|2ml tetracaine was injected with cyclothyroid membrane puncture.
75905610|NCT03070678|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
75905611|NCT03070678|Drug|Mefenamic acid|"Pharmaceutical form: capsule~Route of administration: oral"
75905612|NCT00101166|Biological|Bystander-Based Autologous Tumor Cell Vaccine|The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
75611797|NCT04924621|Drug|Drug use target|Make the BIS between 70 and 80.
75459273|NCT01818310|Biological|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
75459274|NCT01818310|Biological|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
75459275|NCT01818310|Biological|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
75459276|NCT01818310|Procedure|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
75761066|NCT02308072|Drug|Olaparib|50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.
75761067|NCT02308072|Drug|Cisplatin|35 mg/m^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m^2)
75459277|NCT01818349|Other|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
75459278|NCT01818349|Other|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
75459279|NCT01818362|Biological|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
75459280|NCT01818362|Biological|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
75459281|NCT01818375|Procedure|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
75459282|NCT01818375|Other|Standard fluid therapy|
75611798|NCT02869737|Device|Coagucheck, Roche, France|Capillary puncture for POC INR measurement
75611799|NCT00619411|Behavioral|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
75611800|NCT04293705|Device|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
75611801|NCT04211467|Other|No Intervention|There is no intervention for this study
75761068|NCT02308072|Radiation|IMRT|2 Gy delivered in 35 fractions, on days 1-3, 1-4 or 1-5 each week for up to 7 weeks (total overall dose delivered 70 Gy)
75761069|NCT02304809|Drug|Vemurafenib|Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
75761070|NCT02246270|Drug|Intravesical Heparin|Heparin bladder instillation
75761071|NCT02246270|Other|Placebo|Intravesical saline
75761072|NCT02115880|Behavioral|Prevention programme|Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
75761073|NCT02101008|Drug|disulfiram and chelated zinc|
75761074|NCT02025010|Drug|abiraterone acetate|Abiraterone acetate is a selective and irreversible inhibitor of CYP17 which has demonstrated clinical efficacy in patients with CRPC. Currently, AA is administered with concomitant prednisone.
75761075|NCT02006576|Drug|600 mg ibuprofen three times daily for 48 weeks|
75761076|NCT02006576|Other|Placebo three times daily|
75761077|NCT01913730|Drug|Bortezomib|
75761078|NCT01913730|Drug|Dexamethasone|
75611802|NCT00996489|Device|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
76069800|NCT05632029|Device|sham laser|32 lupus prediabetic women will receive laser acupuncture (sham laser, i.e power of device will be zero watt) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
75611803|NCT00618163|Drug|Meloxicam|
75611804|NCT04295343|Diagnostic Test|Three-dimensional (3D) rectal water contrast transvaginal ultrasonography|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
75611805|NCT04295343|Diagnostic Test|Computed colonography|Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.
75611806|NCT04212949|Device|Repetitive transcranial magnetic stimulation (rTMS)|Stimulation will be performed from the contralateral M1 cortex of the painful side. Each stimulation session will consist of 1500 pulses (30 trains of 5 seconds each, with an inter-train interval of 25 seconds) delivered at a frequency of 10 Hz. The stimulation intensity will be set at 80% of the resting motor threshold.
75611807|NCT04212949|Drug|Transforaminal epidural steroid injection|"An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)"
75611808|NCT04295421|Procedure|adductor canal block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
75761079|NCT01851122|Dietary Supplement|L-theanine capsule|L-theanine 250mg capsule
75761080|NCT01851122|Dietary Supplement|Placebo capsule|
75761081|NCT01667952|Genetic|Family History Questionnaire (FHQ)|"Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the You in the questionnaire refers to their child."
75761082|NCT01667952|Genetic|Salvia sample|The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.
75761083|NCT01667952|Other|Blood sample|Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
75761084|NCT01651403|Drug|Tenofovir DF|"Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~Participants weighing < 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg."
75761085|NCT01651403|Drug|TDF Placebo|"Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~Participants weighing < 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily."
75459283|NCT01818388|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
75459284|NCT01818401|Device|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
75761086|NCT01515748|Drug|Docetaxel (XRP6976)|Pharmaceutical form:solution for infusion Route of administration: intravenous
75761087|NCT01515748|Drug|Oxaliplatin (SR96669)|Pharmaceutical form:solution for infusion Route of administration: intravenous
75459285|NCT01818401|Device|Matched patient cutting blocks MyKnee ® LBS|
75459286|NCT01818440|Other|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
75459287|NCT01818440|Other|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
75761088|NCT01515748|Drug|S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)|Pharmaceutical form:Tablet Route of administration: Oral
75611809|NCT04295421|Procedure|IPACK block|IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
75761089|NCT01480440|Device|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
75611810|NCT02187601|Device|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
75611811|NCT02187601|Device|BreathID|BreathID is the name of the original Exalenz breath analyzer system
75761090|NCT01398085|Radiation|I131 1.1 GBq|Radio-iodine
75761091|NCT01352520|Drug|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
75761092|NCT01309672|Drug|abiraterone acetate|1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily
75761093|NCT01309672|Drug|Prednisone|5 mg, oral, 5 mg twice daily
75611812|NCT00628797|Radiation|UVA1|intraindividual half body irradiation
75611813|NCT00628797|Other|UVA1|60 J/cm2 at least 36 tx
75905613|NCT04994236|Drug|Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)|The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
75611814|NCT00618241|Drug|lamotrigine|100 mg
75905614|NCT03601611|Drug|Tocilizumab (RoACTEMRA®)|Prednisolon will be given in case of worsening of symptoms
75611815|NCT00618241|Drug|Raltegravir|400 mg BD
75611816|NCT04213027|Procedure|native tissue repair procedures with conventional surgical instruments|Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).
75761094|NCT01088750|Drug|cyclophosphamide|
75761095|NCT01088750|Drug|prednisolone|
75761096|NCT01088750|Drug|vinblastine sulfate|
75761097|NCT01088750|Other|watchful waiting|
75905615|NCT03597945|Procedure|lidocaine with epinephrine|lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
75905616|NCT03597945|Procedure|normal saline|normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
76069801|NCT05631873|Other|Assistance with implementing Epic Smartlist|A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
75761098|NCT01088750|Procedure|therapeutic conventional surgery|
75611817|NCT00619567|Behavioral|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
75611818|NCT04212715|Radiation|Pelvic SABR with intra-prostatic SABR|SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
75761099|NCT01085435|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
75761100|NCT00508443|Radiation|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
75761101|NCT00393471|Drug|Etanercept|
75761102|NCT01078480|Procedure|Operation using a precontoured titanium plate and screws|Operation using a precontoured titanium plate and screws
75761103|NCT01078480|Procedure|Displaced midshaft fracture of the collar bone|Displaced midshaft fracture of the collar bone treated with an arm sling
75761104|NCT02536079|Drug|NeuroAiD|
75761105|NCT00340704|Drug|tamsulosin hydrochloride|oral
75761106|NCT00132496|Drug|rabeprazole sodium|administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
75761107|NCT01080586|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
75761108|NCT03965416|Other|White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
75761109|NCT03965416|Other|Without White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
75761110|NCT02531230|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
75611819|NCT04211623|Other|Constraint induced movement therapy|"Constrained on more affected side for three hours. To minimize the learned non use in hemiplegic CIMT is applied and criteria of applying CIMT is;~10 degrees active wrist extension on the affected hand,~10 degrees active thumb abduction,~10 º active extension of any two digits on the side or hand which is limited due to damage.~In order to gain the maximum good results from CIMT technique following points should also be considered attentively. Affected arm should move to 45 degrees shoulder flexion and abduction, and 90 degrees of elbow flexion and extension.~Constrained with cotton sling. 3 to 5 upper limb functional activities like~using fork or a spoon,~combing hair~brushing teeth~writing~dressing all activities are performed for 10 t0 15 minutes in period of three hours on alternate days in a week"
75761111|NCT03984630|Behavioral|Dietary Fiber Intervention|Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
75761112|NCT00231777|Drug|Comparator: MK0517|a single administration of 40 mg MK0517 by IV immediately prior to surgery
76069802|NCT01829113|Drug|OGX-427|Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
76069803|NCT01829113|Drug|Placebo|Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
75761113|NCT00231777|Drug|Comparator: ondansetron|a single administration of 4 mg ondansetron by IV immediately prior to surgery
75761114|NCT01076842|Drug|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
75761115|NCT01076842|Drug|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
75905617|NCT03597945|Procedure|Magnesium sulfate|Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
75905618|NCT02162160|Device|probiotic creme|Probiotic creme applied
76069804|NCT00219297|Drug|Patupilone|
76069805|NCT01857271|Drug|Erlotinib Hydrochloride|Given PO
76069806|NCT01857271|Procedure|Therapeutic Conventional Surgery|Undergo thoracotomy
76069807|NCT01857271|Other|Laboratory Biomarker Analysis|Correlative studies
75761116|NCT01076842|Drug|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
75761117|NCT01076842|Device|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
75761118|NCT01076842|Device|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
75761119|NCT01060332|Other|Body Constitution Questionnaire|Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
75761120|NCT01060410|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
75905619|NCT02162160|Drug|Placebo|Creme without probiotics applied in same manner
75905620|NCT03486782|Device|IFG stimulation|stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
76069808|NCT00216255|Drug|Pagoclone|
75761121|NCT01060410|Drug|Cyclophosphamide|intravenous injection, 0.2g, once every two days
75905621|NCT03486782|Device|DLPFC stimulation|stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
75761122|NCT01060410|Other|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
75761123|NCT01061424|Behavioral|community health worker|community health worker provides home visits for education
75761124|NCT01061424|Behavioral|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
75905622|NCT03486782|Behavioral|aphasia therapy|aphasia therapy for 30 minutes during transcranial direct current stimulation
75905623|NCT04993846|Diagnostic Test|Dental plaque sampling|Dental plaque sampling
75905624|NCT04993846|Diagnostic Test|qPCR|qPCR
75905625|NCT03603483|Procedure|procedure|"Patients of sever aortic stenosis 1: increase the diameter of aortic anulus by prosthetic patch or pericardial patch.~Patients of sever aortic stenosis 1:only conventional aortic valve prosthesis will be used"
76069809|NCT00216255|Drug|Placebo|
76069810|NCT01745120|Genetic|LentiGlobin BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.
76069811|NCT03024723|Device|nasal mask CPAP|CPAP and ventilation administered via nasal mask
75611820|NCT04211623|Other|Bimanual activities|"Bimanual activities of both hands are performed like~Set of bimanual activities is used to assess the bimanual hand function. Five bimanual activities are performed such as~carrying a tray,~cutting a fruit with a knife,~holding and cutting the paper with scissor,~buttoning and~Carrying heavy objects with both hands.~Every activity was performed for 10 t0 15 minutes on alternate days for a period of 6 weeks session."
75761125|NCT00231465|Drug|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
75761126|NCT00231465|Drug|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
75761127|NCT03986112|Biological|carotid sonography and inferior vena cava sonography|Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
75761128|NCT01061502|Device|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
75761129|NCT01061502|Device|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
75761130|NCT00254397|Drug|Leuprolide|A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
75761131|NCT00254397|Biological|GP100: 209-217(210M) Peptide|1.0 ml subcutaneous injection in extremities.
75761132|NCT00254397|Biological|MAGE-3 Peptide|1.0 ml subcutaneous injection in extremities.
75761133|NCT03972735|Other|Psychiatric interview|PANSS, MADRS, PSP, YMRS
75761134|NCT03972735|Other|Clinical, diagnostic and functional evaluation|ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS
75611821|NCT00618397|Drug|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
76069812|NCT01828567|Behavioral|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
76069813|NCT04019535|Device|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
75611822|NCT04857151|Behavioral|App based mindfulness program (ABMP)|App based mindfulness program (ABMP)
75761135|NCT03972735|Other|neuropsychological assessment|WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS
75905626|NCT04459910|Procedure|Arthroscopic Brostrom combined with Arthroscopic Deltoid Repair|After anesthesia and surgical site preparation, traditional arthroscopic portals were performed. A 4.5mm set was used to clean the joint and assess possible associated injuries. Anterolateral and anteromedial impacts were resected when needed. Lateral and medial instability were confirmed arthroscopically, and ligament repairs prepared, starting by the lateral compartment. A traditional Arthroscopic Brostrom was performed, using one anchor and suture passers. Sutures are passed but not tightened. Medial anchor insertion is executed at the medial malleolus, in the quadrant described by Vega et al. Sutures were passed respecting the safe zone illustrated by Acevedo at al. The ankle was positioned in neutral (no posterior drawer) and the lateral sutures tightened with arthroscopic knots. Finally, the medial repair is finalized by tightening the deltoid sutures with the ankle at the same position. Portals were closed and a dressing applied.
75905627|NCT04984018|Drug|chidamide + camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
76069814|NCT01721486|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
76069815|NCT01721486|Drug|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
76069816|NCT04610905|Behavioral|Reducing sedentary behaviour|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours. The participants will receive a diary to write down whether they stand up.
75463345|NCT05853939|Device|repetitive transcranial magnetic stimulation|Repetitive TMS targeted by neuronavigation to left lower visual field of primary visual cortex. Randomized to 10 Hz or 1 Hz on different treatment days. Stimulation at 110% of phosphene threshold, or 110% resting motor threshold if phosphenes not detectable. 1 Hz: 1000 pulses total over 1000 seconds. 10 Hz: 1000 pulses over 10 10 second pulse trains, with 50 second intertrain intervals
75463346|NCT05853926|Diagnostic Test|Spinal Manipulation With Laser Therapy|Spinal Manipulation With Laser Therapy in Chronic Lower Backache
75761136|NCT03972735|Other|NECT PROGRAM|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.
75761137|NCT00254163|Drug|Fludarabine|
75761138|NCT00254163|Drug|Cyclophosphamide|
75761139|NCT00254163|Drug|Rituximab|
75761140|NCT00254163|Drug|Pentostatin|
75463347|NCT05853926|Diagnostic Test|Dry Needling|Dry Needling in Chronic Lower Backache
75761141|NCT03869333|Biological|Invaplex[AR-DETOX]|Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex[AR-Detox]) Vaccine
75761142|NCT03869333|Other|Placebo|Saline
75761143|NCT00110890|Drug|cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
75459288|NCT01818453|Behavioral|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
75905628|NCT02162238|Device|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
75459289|NCT01818479|Biological|stem cell transplant|Open label, dose finding trial with two treatment regimens, Busulfan and Total Body Irradiation (TBI) with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.
75459290|NCT01818479|Procedure|Stem cell transplant|
75459291|NCT01818544|Drug|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
75459292|NCT01818544|Drug|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
75611823|NCT04211779|Device|Real tDCS|Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.
75611824|NCT04211779|Device|Sham tDCS|Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
75611825|NCT04211779|Other|Exercise|The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
75761144|NCT00110890|Other|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
75761145|NCT00182637|Drug|bortezomib|
75761146|NCT01076920|Genetic|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
75761147|NCT00182325|Behavioral|personalized web prenatal information|
75761148|NCT00182325|Behavioral|general web prenatal information|
75761149|NCT01076998|Other|Lubricant eye drop FID 115958D|1 drop in each eye, one time
75761150|NCT01076998|Other|Refresh PM Ointment|1 drop in each eye, one time
75761151|NCT00122278|Drug|Dexamethasone|Dexamethasone 10mg IV
75761152|NCT00122278|Other|Placebo|Placebo Dexamethasone 10mg IV
75905629|NCT03601533|Drug|Phenol|1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
75459293|NCT01818557|Behavioral|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
75611826|NCT00618475|Behavioral|Cognitive behavioral therapy|"10 sessions~1 hour per week"
75611827|NCT04211545|Drug|Rabeprazole|Rabeprazole
75611828|NCT04211545|Drug|CC-92480|CC-92480
75761153|NCT00182091|Drug|Recombinant human growth hormone|Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
75761154|NCT00182091|Drug|Saline|To maintain study-subject blinding, doses were sham adjusted.
75761155|NCT01072071|Drug|furosemide|"Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.~Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h."
75761156|NCT00181155|Drug|Allopurinol|intravenous infusion of allopurinol (300mg)
75761157|NCT00181155|Drug|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
75761158|NCT00322452|Drug|Gefitinib|oral tablet
75761159|NCT00322452|Drug|Carboplatin|IV
75761160|NCT00322452|Drug|Paclitaxel|IV
75761161|NCT03968523|Procedure|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
75761162|NCT03968523|Procedure|TAP block|TAP block technique
75459294|NCT01818570|Drug|PPC-5650|A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
75459295|NCT01818570|Drug|Placebo|A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
75459296|NCT01818583|Drug|Potassium chloride|
75459297|NCT01818583|Drug|Glucose 50 MG/ML|
75459298|NCT01818609|Behavioral|Step reduction|taking less than 1500 steps/d
75459299|NCT01818622|Device|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
75905630|NCT03484598|Device|SPEAC System|A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
75905631|NCT04983784|Behavioral|walking|walking for 12 weeks at home
75905632|NCT04983784|Other|Routine care|Routine care
75459300|NCT01818622|Device|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
75459301|NCT01818648|Drug|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
75459302|NCT01818648|Drug|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
75459303|NCT01818674|Behavioral|Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)|A 6-month intervention program (sessions and educational materials) aims to increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement.
75459304|NCT01818674|Behavioral|Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)|This basic program (6 month) aims to increase participants knowledge about diabetes self-management, but without structured social interaction programming. While group classroom setting is still used for delivery of the educational curriculum, the education program in group B have no group-based or team-building activities, group goal setting, and classroom program is lecture style with more limited class participation and interaction.
75459305|NCT01818687|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
75459306|NCT01818713|Drug|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
75611829|NCT00620581|Drug|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
75611830|NCT01739569|Other|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
75611831|NCT04211311|Other|hybrid high-intensity training|FES-legcycling combined with either arm skiergometer or arm-cycling in 4 x 4 min. intervals at 90% peak power output, 3 times a week for 8 weeks
75611832|NCT01000311|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
75611833|NCT01000311|Biological|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
75611834|NCT01000311|Biological|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
75611835|NCT01000311|Biological|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
75761163|NCT01073241|Procedure|transurethral ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
75905633|NCT02165280|Behavioral|Guided IMagery (GIM)|It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
75459307|NCT01818778|Other|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
75459308|NCT01818778|Other|Standard Friendly Visit|"Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident."
75761164|NCT01073241|Procedure|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP
75761165|NCT00110812|Drug|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
75761166|NCT00516269|Drug|Methylphenidate|18 mg by mouth daily for 2 weeks
75761167|NCT00516269|Drug|Placebo|Capsule by mouth daily for 2 weeks
75761168|NCT04642859|Behavioral|Computerized Cognitive abilities training battery for reading (CATB-R)|Specially designed Arabic computerized training program for dyslexia
75905634|NCT03486626|Drug|Metformin|Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
75905635|NCT04983550|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w
75761169|NCT04639037|Device|Automated adjustment of vasopressor|The objective of this randomized controlled superiority study is to demonstrate that, in patients admitted to intensive care after a major surgery, tight control of MAP using a closed-loop system for vasopressor administration will result in MAP being more often within a MAP range of 80-90 mmHg compared to the same management without this automated closed-loop system (nurse adjustment of vasopressor administration)
76069817|NCT04610905|Behavioral|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. It can include walking, to ride a bike, jogging, tennis, football,... Additionnaly they need to be active in periods of at least 10 minutes. The participants will receive a diary to write down which activity they did and also for how long.
76069818|NCT05631639|Device|PillSense System|The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
76069819|NCT05366517|Device|Dornier Aries 2 device|For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
75761170|NCT04639037|Device|Manual adjustment of vasopressor|Fluid and vasopressor will be delivered as standard of care (manual adjustment of both fluid and vasopressor infusion rate by the nurse)
75761171|NCT00229203|Drug|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
75761172|NCT03973515|Drug|glucokinase activator|PB-201 is a kind of dual and partial GKA
76069820|NCT05631483|Device|DAISe|Use of the DAISe Thrombectomy Device
76069821|NCT01775930|Drug|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
75459309|NCT01818791|Behavioral|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
75459310|NCT01818791|Behavioral|Making Proud Choices AND Getting To Outcomes|"In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality-i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors."
75459311|NCT01818843|Other|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
75459312|NCT01818856|Drug|Ritonavir withdrawal, atazanavir 200 mg/12h|
76069822|NCT01856569|Other|no intervention|in real life of drug,dosage,frequency and duration
76069823|NCT03024645|Behavioral|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
76069824|NCT03024645|Other|Treatment as usually (TAU)|performed in primary care settings
76069825|NCT01721408|Drug|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
75459313|NCT01818856|Drug|Telaprevir interactions|
75905636|NCT04983550|Drug|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection 40mg/m ^2 q4w
75905637|NCT02255682|Drug|Simvastatin|
75761173|NCT03973515|Drug|Placebo|Placebo oral tablet
75761174|NCT00228813|Drug|Granulocyte Colony Stimulating Factor|"FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection"
75761175|NCT00322374|Drug|Ixabepilone|Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.
75761176|NCT00322374|Drug|Epirubicin|Infusion, intravenous (IV): 75 mg/m^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
75761177|NCT00174447|Drug|Ziprasidone|Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
75761178|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
75761179|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
75761180|NCT00321984|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
75761181|NCT03982758|Other|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
75761182|NCT03982758|Other|isometric of the lower limbs|Isometric session for lower limbs: 4 sets with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute rest.
75761183|NCT01060488|Other|GHRH+Arg, GHRH+Arg, ITT|GHRH+Arg repeatability test (2 tests) + comparison with one IT test
75905638|NCT02255682|Dietary Supplement|Q10|
75905639|NCT05153486|Procedure|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
75905640|NCT05153486|Procedure|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
75459314|NCT01818869|Drug|AZD8848|Multiple doses inhaled IMP via a nebulizer
75459315|NCT01818869|Drug|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
75459316|NCT01818882|Other|Standard care|Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.
75459317|NCT01818882|Device|Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI)|Standard care (as described for the other intervention) + pleuropulmonary ultrasound using the Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI).
75459318|NCT01818908|Drug|DA-EPOCH|DA-EPOCH regimen
75459319|NCT01818934|Procedure|hip ultrasound|Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
75459320|NCT01818960|Procedure|IRA-PCI|IRA only PCI at the time of Primary PCI
75761184|NCT01060488|Other|ITT, ITT, GHRH+Arg.|IT repeatability test (2 tests) + comparison with one GHRH+Arg test
75905641|NCT05153486|Procedure|Surgical ablation|Patients receive surgical ablation.
75905642|NCT03597711|Device|IVcannulation|Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants
75905643|NCT04607096|Behavioral|Intermittent fasting|The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.
75761185|NCT01060566|Drug|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
75761186|NCT01060566|Drug|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
75761187|NCT02533284|Drug|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
75905644|NCT04607096|Behavioral|Control diet|Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
75905645|NCT02261142|Device|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
75905646|NCT03136263|Drug|Oxytocin nasal spray|Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
75905647|NCT03136263|Drug|Placebo nasal spray|Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
75905648|NCT04988542|Dietary Supplement|Circadian Wellness sleep SL strip|Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.
75905649|NCT03540186|Dietary Supplement|Epigenorm Antivir|1 capsule of Epigenorm Antivir twice daily for 3 months
76069826|NCT01721408|Drug|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
76069827|NCT03998709|Drug|Somatostatin|Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study
75761188|NCT02533284|Drug|bupevecaine|US guided TAP using Bupevecaine 0.25 %
75761189|NCT02533284|Drug|saline|US guided TAP using placebo (saline)
75761190|NCT00515099|Drug|Antithymocyte globulin|Daily 4-day escalating dose
75761191|NCT00515099|Drug|Placebo|Daily 4-day saline solution
75761192|NCT03998423|Biological|Fecal Microbiota Transplant|Double-encapsulated Fecal Microbiota Transplant Capsules
75761193|NCT00110266|Drug|Deferasirox|20 mg/kg/day over one year in patients with MDS
75761194|NCT00174291|Drug|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
75761195|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
75761196|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
75761197|NCT01074645|Drug|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
75905650|NCT03540186|Procedure|Acupuncture|Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
75905651|NCT02035449|Device|McGrath MAC|McGrath MAC is a videolaryngoscope
75905652|NCT04988854|Behavioral|Facial expression video|Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.
76069828|NCT03998709|Other|Dextrose|intravenous glucose will be used to raise fasting glucose in people with NFG / NGT
76069829|NCT03998709|Drug|Insulin|insulin will be used to lower fasting FFA and glucose in people with IFG / IGT
76069830|NCT03998709|Other|Intralipid|intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
76069831|NCT03025191|Behavioral|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
75459321|NCT01818960|Procedure|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
75459322|NCT01818973|Drug|Xeloda|po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
75459323|NCT01818973|Drug|Oxaliplatin|iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
75459324|NCT01818973|Drug|Bevacizumab|iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
75459325|NCT01818973|Radiation|Radiation|Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
75459326|NCT01818973|Procedure|surgery|Total Mesorectal Excision (TME)
75459327|NCT01818999|Drug|IXABEPILONE|injection
75459328|NCT01818999|Radiation|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
75459329|NCT01819012|Drug|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
75459330|NCT01819012|Drug|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
75459331|NCT01819012|Drug|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
75459332|NCT01819025|Behavioral|4 face-to-face therapy session and a smartphone-app|An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
75611836|NCT01000311|Biological|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
75761198|NCT00252057|Behavioral|Re-Engineered Hospital Discharge|"The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist."
75905653|NCT03601377|Behavioral|Training away from threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
75611837|NCT04211701|Procedure|Connective Tissue Massage|Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
75761199|NCT00132028|Drug|vorinostat|Given orally
75905654|NCT03601377|Behavioral|Training towards threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
75905655|NCT03601377|Behavioral|Placebo|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
75905656|NCT03481088|Procedure|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~Stage- I (pre-treatment),~Stage- II (after pre-functional therapy)~Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
75905657|NCT04983706|Procedure|MRI/Ultrasound Fusion Saturation Biopsy|MRI/Ultrasound fusion saturation biopsy: the core number and location are designed according to the lession condition.
75905658|NCT02165436|Other|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
75761200|NCT00132028|Other|laboratory biomarker analysis|Correlative studies
75761201|NCT01080664|Drug|AS703569|"Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops"
75905659|NCT02165436|Other|Control|No intervention will be assessed for this group.
75905660|NCT03486548|Drug|bupivacaine and dexamethasone|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
75459333|NCT01819025|Behavioral|CBT, treatment as usual|10 sessions of face-to-face therapy, full behavioral activation
75459334|NCT01819038|Procedure|continuous renal replacement therapy|
75459335|NCT01819051|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to great toenail 1X/week for three weeks
75459336|NCT01819077|Procedure|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
75459337|NCT01819090|Device|Elysee 150 ventilator|
75459338|NCT01819090|Device|Elysee 150 ventilator with a ventilation switch control|
75459339|NCT01819142|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
75459340|NCT01819155|Biological|Adjuvanted seasonal trivalent inactivated influenza vaccine|
75459341|NCT01819155|Biological|Seasonal trivalent inactivated influenza vaccine|
75761202|NCT01080664|Drug|AS703569|"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
75761203|NCT03992378|Device|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.
75761204|NCT03992378|Device|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the ear lobe delivered by Parasym device.
75761205|NCT01045304|Drug|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75761206|NCT01045304|Drug|Gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75761207|NCT01045304|Drug|Carboplatin|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75905661|NCT03486548|Drug|bupivacaine and lidocaine|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml
75905662|NCT03486548|Device|Ultrasound|ultrasound
75905663|NCT03068338|Device|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
75905664|NCT03068338|Device|Intermittent pneumatic compression|Conventional device used by hospitals
75611838|NCT04211701|Procedure|Classical Massage|Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
75611839|NCT04209439|Drug|30 ml %0.25 bupivacaine|Ultrasound-guided erector spinae plane block
75611840|NCT04209439|Drug|Dexketoprofen-trometamol|50 mg Dexketoprofen-trometamol intravenous
75611841|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
75611842|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:~For children >/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~For children < 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
75611843|NCT00619879|Other|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
75761208|NCT01080742|Drug|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
75761209|NCT01582828|Procedure|Epicardial (surgical) ablation|"Pulmonary vein isolation with bipolar clamps and bipolar box lesion~Epicardial atrial appendage closure"
75761210|NCT01582828|Procedure|Hybrid|"Epicardial (surgical) ablation~Pulmonary vein isolation with bipolar clamps and bipolar box lesion~Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation"
75905665|NCT02255448|Device|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
75611844|NCT00619879|Radiation|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.~Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) < 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:~Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count~Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
75611845|NCT04212559|Other|Received negative pressure ventilation|Patients who received a negative pressure during inspiratory phase.
75611846|NCT05228041|Drug|Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks)
75761211|NCT03992300|Device|Clinical adjustment|Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
75761212|NCT00131248|Drug|Metaclopramide|
75761213|NCT00131248|Drug|Ranitidine|
75761214|NCT00131248|Drug|placebo|
75761215|NCT00362414|Drug|Dual Growth Factor|"10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation"
75761216|NCT01080820|Drug|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
75761217|NCT01080820|Drug|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
75611847|NCT01003899|Drug|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
75611848|NCT04160377|Drug|Fluvoxamine|Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .
75611849|NCT04150393|Drug|MaaT033 capsule|Oral capsule
75611850|NCT04142203|Other|23 h surgery|Patients were treated in 23 surgical unit
75611851|NCT01000155|Drug|vorinostat|
75611852|NCT00621595|Dietary Supplement|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
75761218|NCT01080820|Drug|Viread|One single oral dose of 300mg Viread.
75761219|NCT01080898|Other|tests|color photographs, FLUORESCEIN angiography and OCT
75761220|NCT01048346|Behavioral|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
75761221|NCT03964558|Drug|[14C]-acebilustat solution|Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
75761222|NCT02534792|Other|Revalvulation|
75459342|NCT01819155|Biological|Saline (bacteriostatic 0.9% sodium chloride for injection)|
75459343|NCT01819207|Other|blood test by thromboelastography|
75459344|NCT01819220|Drug|amlodipine/valsartan|"This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
75459345|NCT01819220|Drug|hydrochlorothiazide/telmisartan|"When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
75459346|NCT01819246|Procedure|Aphersis Treatment Arm|
75459347|NCT01819246|Other|Control Arm|
75611853|NCT00318487|Procedure|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
75611854|NCT00999921|Drug|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
75611855|NCT00999921|Drug|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
75611856|NCT02869581|Other|Data collection|
75761223|NCT01082770|Device|TEGO|A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
75761224|NCT01082770|Device|Standard|Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
75761225|NCT01049204|Drug|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
75761226|NCT01049204|Drug|placebo|Placebo twice daily for 24 weeks
75761227|NCT00096382|Biological|aldesleukin|high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
75459348|NCT01819259|Drug|Nicotine nasal spray|This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
75459349|NCT01819259|Drug|Placebo|
75459350|NCT01819285|Procedure|Immediate Orchiectomy or depot LHRH|
75459351|NCT01819285|Procedure|Delayed Orchiectomy or depot LHRH|
75611857|NCT00620737|Biological|Autologous Human Fibroblasts (Isolagen TherapyTM)|"Collection of skin biopsy.~Administration of 2 study injections~Performance of various study assessments during clinic visits"
75611858|NCT00620737|Biological|Placebo|"Collection of skin biopsy.~Administration of 2 study injections~Performance of various study assessments during clinic visits"
75611859|NCT02869347|Drug|Conestat alfa|Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.
75611860|NCT02869347|Drug|Sodium chloride 0.9%|Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
75761228|NCT00096382|Biological|filgrastim|10 mcg/kg/day daily subcutaneously until neutrophil count >1x10^9/1.
75761229|NCT00096382|Biological|therapeutic tumor infiltrating lymphocytes|Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
75761230|NCT00096382|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously over 1 hour
75761231|NCT00096382|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggyback daily over 15-20 minutes for 5 days
75761232|NCT00096382|Radiation|radiation therapy|Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
75761233|NCT00359294|Drug|PM00104|Intravenously over 1 hour daily for 5 days, every 3 weeks.
75761234|NCT00384332|Drug|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
75761235|NCT00384332|Drug|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
75761236|NCT00096226|Drug|Induction Carboplatin|
75761237|NCT00096226|Drug|Induction Paclitaxel|
75761238|NCT00096226|Procedure|Resection|
75761239|NCT00096226|Drug|Consolidation Carboplatin|
75761240|NCT00096226|Radiation|Radiation Therapy|
75761241|NCT00096226|Drug|Consolidation Paclitaxel|
75459352|NCT01819324|Behavioral|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
75611861|NCT00621673|Drug|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
75611862|NCT05008393|Drug|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 daily for 10 days.
75905666|NCT02870816|Procedure|Tissue Engineered Skin Substitute|Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
75905667|NCT02870816|Device|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
75905668|NCT02870816|Procedure|Amnionic Membrane Graft|Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
75611863|NCT05008393|Drug|PJS-539 Dose 2|Patients will receive PJS-539 Dose 2 daily for 10 days.
75761242|NCT01078714|Drug|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
75761243|NCT01081054|Other|Ambulatory versus hospitalisation|Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
75761244|NCT03964324|Diagnostic Test|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
75761245|NCT01078792|Other|CT pulmonary angio, blood tests|
75761246|NCT03963076|Other|nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)|One spray of nasal hypertonic spray morning and evening every day during 30 days
75761247|NCT00105508|Drug|Sarizotan|Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
75761248|NCT00105508|Drug|Placebo|Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
75761249|NCT01082848|Drug|aripiprazole|10 mg QD during 26 weeks
75761250|NCT01082848|Drug|placebo|QD during 26 weeks
75761251|NCT01082926|Biological|therapeutic allogeneic lymphocytes|Given intratumorally
75761252|NCT01082926|Biological|aldesleukin|Given intratumorally
75761253|NCT01082926|Other|laboratory biomarker analysis|Optional correlative studies
75761254|NCT01082926|Procedure|positron emission tomography|Optional correlative studies
75611864|NCT05008393|Drug|Placebo|Patients will receive placebo daily for 10 days.
75611865|NCT02869503|Other|Data collection|
75761255|NCT01083004|Procedure|Indocyanine green|Using indocyanine green as intraoperative dye
75761256|NCT01083004|Procedure|Brilliant blue arm|Using brilliant blue as intraoperative dye
75761259|NCT01078870|Drug|Lexapro|10mg/cap 1~2# QD
75761260|NCT01078870|Drug|Cymbalta|30mg/cap 30~60mg/QD
75905669|NCT03540108|Dietary Supplement|Lactobacillus plantarum ECGC 13110402|The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).
75611866|NCT04210921|Device|Acupuncture|"The acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi ."
75611867|NCT04210921|Device|The park sham needle|When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin.
75611868|NCT05662657|Diagnostic Test|Diagnostic Test: PCL-S Questionnaire|PCL-S and HADS questionnaires
75611869|NCT01002573|Drug|ibuprofen|Ibuprofen, 10 mg/kg
75611870|NCT01002573|Drug|acetaminophen|Acetaminophen, 10mg/kg
75761261|NCT01078870|Drug|Placebo|1~2#/cap QD
75761262|NCT01078948|Device|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
75761263|NCT03965338|Diagnostic Test|fMRI|Screening
75761264|NCT00105196|Drug|Aripiprazole+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
75761265|NCT00105196|Drug|Placebo+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
75761266|NCT03820024|Behavioral|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
75761267|NCT03819634|Device|Inset II with Lantern Technology|Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure. The infusion set will be used with their usual insulin pump.
75905670|NCT03540108|Dietary Supplement|Placebo Comparator: Maltodextrin|Please see intervention description above.
75905671|NCT04988230|Behavioral|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
75905672|NCT04988230|Behavioral|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
75905673|NCT02168790|Device|Amniotic membrane ring|The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
75761268|NCT00104572|Drug|Androgel (Testosterone Gel)|1 mg tablet for 12 months
75761269|NCT00104572|Drug|Anastrozole (Aromatase Inhibitor)|
75761270|NCT00104572|Drug|Placebo tablet|Daily for 12 months
75761271|NCT00104572|Drug|Placebo gel|Daily for 12 months
75761272|NCT00104572|Dietary Supplement|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
75761273|NCT01083238|Drug|AZD5069|120mg single oral dose
75761274|NCT02531074|Behavioral|Mobile Application|
75761275|NCT02531074|Behavioral|Food Journal|
75761276|NCT02531074|Behavioral|Usual Care|
75761277|NCT03964168|Drug|Biologic Agent|Patients who discontinued a bioloic agent
75761278|NCT01083394|Device|PTA|PTA using a conventional balloon
75761279|NCT01083394|Device|PTA with PEB|PTA using a paclitaxel eluting balloon
75761280|NCT01083394|Procedure|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
75611871|NCT00620893|Drug|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
75611872|NCT00620893|Drug|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
75611873|NCT04211233|Device|invasive subdural grid electrode|A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.
75611874|NCT04211233|Other|Control arm|Standard Treatment based on Brain Trauma Foundation
75611875|NCT00999687|Drug|Indigo Naturalis Extract in Oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
75611876|NCT00999687|Other|Olive Oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
75611877|NCT04211077|Other|Date collection|Data collection from national SNIIRAM and PMSI database
75611878|NCT04293315|Behavioral|Improvement Cycles|"This is a multi-component intervention following the Institute for Healthcare Improvement (IHI)'s Collaborative Model for Achieving Breakthrough Improvement by implementing plan-do-study-act (PDSA) improvement cycles. The investigators will conduct 8 participative learning sessions for the primary care team. These sessions will be aimed at identifying opportunities for improvement oriented to the design and application of innovative approaches based on best practices."
75611879|NCT04293549|Drug|Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops|"rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment"
75611880|NCT02691715|Procedure|Endometrial saline plus curettage|
75611881|NCT02691715|Procedure|Endometrial curettage|
75611882|NCT00996333|Drug|Gemcitabine, Docetaxel, Capecitabine|"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."
75761281|NCT01079104|Device|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
75761282|NCT01079104|Procedure|Standard Medical Therapy|Standard of care treatment
75761283|NCT01081444|Device|rTMS|effective and active cortical magnetic stimulations
75761284|NCT01081444|Device|Placebo rTMS|non active cortical magnetic stimulation
75761285|NCT03963934|Other|Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention|Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
75761286|NCT00514943|Drug|BIBW 2992|experimental drug taken once daily orally
75761287|NCT00514943|Drug|Cetuximab|active comparator administered weekly intravenously
75761288|NCT01083550|Other|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
75761289|NCT01079260|Dietary Supplement|Standard ONS|Standard ONS
75761290|NCT01079260|Dietary Supplement|High Energy, low volume ONS|High energy, low volume ONS
75761291|NCT03864653|Behavioral|MoodGym|"MoodGym is a preexisting Internet-based CBT program that uses interactive content and character-driven narratives to help alleviate symptoms of depression and comorbid anxiety. The program also aims to improve the individual's functioning by promoting the development of skills and strategies to manage depression.~MoodGym consists of an introduction module, five structured intervention modules, and a workbook of assessments. Each MoodGym session takes place entirely on an Internet-connected tablet while in the physical co-presence of a Study Counselor, who can answer questions should they arise. Each session takes approximately one hour to complete."
75761292|NCT00103402|Drug|Alfuzosin|
75761293|NCT00103402|Drug|Placebo|
75761294|NCT03864341|Behavioral|Referral to homelessness prevention services|Referral to Homebase homelessness prevention services offered by community-based organizations in NYC
75761295|NCT03864341|Behavioral|Substance use services|Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital
75905674|NCT04983160|Drug|Allopurinol|Allopurinol
75905675|NCT04983160|Drug|Placebo|Placebo
75611883|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
75761296|NCT03864341|Behavioral|Follow-up|Follow-up to assist participants in receiving homelessness prevention services
75761297|NCT00095836|Drug|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
75459353|NCT01819324|Behavioral|Standardized Lifestyle Management|SLM material (every other week for 4 months)
75611884|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
75761298|NCT00168831|Drug|Tiotropium Inhalation Solution|
75761299|NCT00168831|Other|Placebo|
75611885|NCT00621907|Drug|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
75761300|NCT00103012|Drug|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
75761301|NCT00103012|Drug|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
75761302|NCT00103012|Drug|Panax ginseng|Panax ginseng 500 mg twice daily
75761303|NCT00512135|Drug|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
75761304|NCT03235505|Drug|Nicotine|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
75761305|NCT03235505|Drug|Varenicline Tartrate|Varenicline + Innokin Endura T20S electronic inhaler but without any nicotine content + MI
75761306|NCT03235505|Behavioral|Motivational Interview|Placebo-varenicline + Innokin ENdura T20S electronic inhaler but without any nicotine content +MI
75761307|NCT00251979|Drug|Esomeprazole|
75459354|NCT01819350|Other|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
75459355|NCT01819350|Other|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
75459356|NCT01819363|Procedure|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
75459357|NCT01819376|Other|Facebook Status Update|
75459358|NCT01819389|Drug|Imatinib and Nilotinib|
75611886|NCT00621907|Drug|sodium chloride|sodium chloride : 0,9% 30 ml
75761308|NCT00511901|Drug|placebo|
75459359|NCT01819402|Drug|Pioglitazone vs Glimepiride|
75761309|NCT00511901|Drug|epoetin alpha|
75761310|NCT00511901|Drug|Niferex|
75761311|NCT04580147|Drug|Intravitreal aflibercept injection|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
75761312|NCT04580147|Other|Sham control|Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
75761313|NCT03862625|Device|a modular adaptive seating system|
75761314|NCT03862625|Other|home exercise program for scoliosis|
75761315|NCT00163215|Drug|Somatropin|Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
75761316|NCT00228423|Drug|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel
75761317|NCT00228423|Drug|water pill daily|Daily dose of water pill (placebo)
75761318|NCT00511667|Drug|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
75761319|NCT00511667|Drug|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
75761320|NCT00227877|Behavioral|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
75905676|NCT02255526|Device|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
75611887|NCT04140799|Device|vocal cord ultrasonography|assess vocal cord motion and recurrent nerve function by Transcutaneous laryngeal Ultrasonography in patients scheduled for anterior cervical spine surgeries
75611888|NCT04717219|Other|Blood drawing|Blood will be drawn after inclusion of the participants.
75611889|NCT02870985|Device|Coronary Stent|
75611890|NCT01349101|Radiation|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
75611891|NCT01349101|Drug|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
75761321|NCT00227877|Behavioral|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
75761322|NCT04610099|Device|Banded Sleeve Gastrectomy|banded sleeve gastrectomy
75761323|NCT04610099|Device|Standard SG|Standard SG
75761324|NCT00513695|Drug|sunitinib malate|Given PO
75761325|NCT00513695|Drug|paclitaxel|Given IV
75761326|NCT00513695|Drug|doxorubicin hydrochloride|Given IV
75761327|NCT00513695|Drug|cyclophosphamide|Given PO
75761328|NCT00513695|Biological|filgrastim|Given SC
75761329|NCT00513695|Procedure|therapeutic conventional surgery|Undergo surgery
75761330|NCT00513695|Other|laboratory biomarker analysis|Correlative studies
75761331|NCT00513695|Other|flow cytometry|Correlative studies
75761332|NCT00162981|Drug|Clobazam Low Dose|5 to 10 mg/day with doses in the morning and at bedtime; orally
75761333|NCT00162981|Drug|Clobazam High Dose|5 to 40 mg/day with doses in the morning and at bedtime; orally
75761334|NCT00511433|Drug|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles."
75761335|NCT00511433|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
75761336|NCT00099268|Drug|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
75761337|NCT00099268|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
75761338|NCT00511355|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
75761339|NCT00511355|Drug|Levonorgestrel and Ethinyl Estradiol|Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
75761340|NCT01083784|Drug|Use of prophylactic anticonvulsants (valproate, clonazepam)|start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
75459360|NCT01819428|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
75459361|NCT01819441|Drug|Azelnidipine|8mg or 16mg
75459362|NCT01819441|Drug|Perindopril|4mg or 8mg
75459363|NCT01819441|Drug|hydrochlorothiazide|12.5mg or 25mg
75459364|NCT01819454|Device|pH monitoring (Restech)|"see in detail description of the study part of the protocol"
75459365|NCT01819467|Device|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
75459366|NCT01819493|Behavioral|Lifestyle Intervention|Family-based group lifestyle intervention
75459367|NCT01819493|Behavioral|Standard Family-Based intervention|Comparison intervention
75611892|NCT01349101|Drug|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
75611893|NCT01349101|Drug|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
75611894|NCT01349101|Drug|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
75611895|NCT01349101|Drug|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
75611896|NCT01349101|Genetic|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
75611897|NCT02870049|Behavioral|Inreach strategy|Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
75611898|NCT02870049|Behavioral|Outreach strategy|Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
75611899|NCT02870049|Behavioral|Both Inreach and Outreach strategies|Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
75611900|NCT02870049|Behavioral|Usual care|Usual care: FIT kit delivery as part of usual care
75611901|NCT04295109|Drug|the drug of intravenous patient-controlled analgesia|At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
75611902|NCT00620971|Drug|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
75611903|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
75761341|NCT01083784|Drug|Control group|Control group
75905677|NCT05450380|Device|LIFT001|"The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
75905678|NCT04455412|Procedure|Laser Assisted ICSI|using OCTICS laser device to do small opening or zona thinning to improve ICSI outcome
76069832|NCT03025191|Behavioral|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
76069833|NCT03025191|Behavioral|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
76069834|NCT03025191|Behavioral|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
75459368|NCT01819519|Behavioral|Educational Intervention|The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q&A.
75611904|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
75459369|NCT01819532|Procedure|Milking group|"The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord."
75459370|NCT01819532|Procedure|Immediate cord clamping|The umbilical cord will be clamped and cut immediately after delivery of the neonate.
75459371|NCT01819558|Biological|recwt1-A10+AS01B|
75905679|NCT03070288|Other|Red-green-blue measurements of nasal mucosa image|Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
75611905|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
75459372|NCT01819571|Drug|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
76069835|NCT01744496|Drug|Rotigotine|Patches will contain 4 mg / 24 h (20 cm^2), 6 mg/ 24 h (30 cm^2), or 8 mg /24 h (40 cm^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
75459373|NCT01819610|Drug|SPRIX|
75611906|NCT00620971|Drug|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
75611907|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
75611908|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
75761342|NCT03998345|Drug|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
75905680|NCT05635942|Drug|optimized quadruple therapy|Association of amoxicillin 3 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
75905681|NCT05635942|Drug|standard quadruple therapy|Association of amoxicillin 2 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
75905682|NCT04987684|Diagnostic Test|SCINSEV and PECAP|To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
75905683|NCT02759016|Drug|BI 836826|
75905684|NCT02759016|Drug|Ibrutinib|Standard of Care
75459374|NCT01819623|Other|Non-pharmacological therapy|It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid
75611909|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
75761343|NCT04576637|Procedure|Neurophysiological monitoring during intubation|In the operating room patients will be connected to the anesthesia monitor and an IV line as standard clinical practice. Participants will receive oxygen and an IV infusion of 1-3 ng/ml remifentanil via TCI infusion pump to achieve mild sedation. Patients will then be connected to the neurophysiological electrodes to monitor for EEG, EMG, SSEP and MEP signals. After preparing the videolaryngoscope, anesthesia induction will be achieved with the use of IV ketamine 2mg/kg. Then the anesthesiologist will perform a clinical and ECG reading assessment to ensure that the patient is anesthetized and will be able to titrate more ketamine as needed to achieve hypnosis. A biteblock will be located to prevent teeth damage. A neurophysiological baseline recordings will then be performed by a neurophysiologist. The videolaryngoscope will then be inserted, during which a second neurophysiological testing will be performed to ensure the patients safety. Then mechanical ventilation will be initiated.
75761344|NCT00095212|Drug|1 Transdermal Testosterone (Patch)|300 micrograms twice a week
75611910|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
75611911|NCT04673773|Behavioral|A Massive Open Online Course|Same as intervention
75611912|NCT00995865|Biological|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10^8 VE/0.5mL and Mid dose = 2.2 x 10^7 VE/0.5mL
75611913|NCT00995865|Biological|Placebo|NaCl Injectable 0.9%
75761345|NCT00095212|Drug|2 Placebo Patch|Placebo patch (0 micrograms of testosterone) applied twice a week
75761346|NCT04606979|Device|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
75761347|NCT02999399|Other|Brussel Sprouts|Subjects are given ~150 g of Brussels sprouts once daily for 7 consecutive days.
75611914|NCT04210531|Dietary Supplement|Beetroot juice (BJ) acute supplementation|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
75611915|NCT04210531|Dietary Supplement|Placebo acute supplementation|One serving placebo drink (0.08 mmol of NO3-; Salud Viva, Nano Salud 32 S.L) after an overnight fast and 3 h before initiating the testing session.
75611916|NCT04223661|Drug|Lenalidomide Pill|Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
75611917|NCT04223661|Drug|Dexamethasone|Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
75611918|NCT04223661|Drug|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
75761348|NCT02999399|Drug|Deuterated Phenanthrene|Subjects are given 1 microgram of deuterated phenanthrene [D10]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
75761349|NCT02801279|Other|Conventional bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
75761350|NCT02801279|Other|Kinect-based bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
75459375|NCT01819636|Other|sparkling highly mineral bicarbonated sodium water|1,25 liter a day at the mealtimes
75761351|NCT00120874|Behavioral|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
75761352|NCT00120874|Drug|Memantine|Patients receive 10 milligrams of memantine twice daily.
75761353|NCT00120406|Device|Zilver® PTX™ Drug Eluting Vascular Stent|Stenting of the Superfemoropopliteal Artery
75761354|NCT00120406|Procedure|Angioplasty|Angioplasty of the Superfemoropopliteal Artery
75761355|NCT00120250|Drug|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
75761356|NCT01081600|Other|Imaging with 89Zr-trastuzumab PET|Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
75761357|NCT01079338|Other|caffeine|
75761358|NCT00511199|Drug|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year)."
75761359|NCT00511199|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
75611919|NCT04208503|Diagnostic Test|thyroid ultrasound|After meeting enrolment criteria the thyroid ultrasound will be performed at 32 and 36 weeks of gestation, blood test for TSH and FT4 will be obtained at 14-21 day of life, at 32 and 36 weeks of gestation
75611920|NCT04220853|Diagnostic Test|Rhinomanometry in patients after septoplasty and/or turbinoplasty|Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.
75611921|NCT04220853|Diagnostic Test|Acoustic rhinometry in patients after septoplasty and/or turbinoplasty|Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.
75761360|NCT03964012|Biological|NmCV-5|Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A&X conjugated to tetanus toxoid and C,Y&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
75761361|NCT03964012|Biological|Menactra|Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
75761362|NCT01083940|Other|Computerized reminders on hypertension intensification|Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
75761363|NCT01009385|Procedure|cervical epidural steroid injection|"After aseptic preparation and skin infiltration with 1% lidocaine~20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~identification of the epidural space confirmed by injection of contrast medium under fluoroscope~injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~Post-procedure, patients were observed for any adverse effects and followed with a neurological examination"
75611922|NCT05662501|Device|Pleioflow-RF|Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
75761364|NCT01009385|Procedure|epidural pressure measurement|"The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~Identification of the epidural space and measurement of EP was performed with a closed measurement system."
75459376|NCT01819649|Dietary Supplement|SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S|
75459377|NCT01819662|Other|Enhanced standard management|Echocardiogram followed by letter to GP about results.
75459378|NCT01819662|Other|Optimised heart failure management|Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction
75459379|NCT01819662|Other|Standard management|Usual care
75459380|NCT01819675|Device|Low frequency rTMS|
75459381|NCT01819675|Device|High frequency rTMS|
75459382|NCT01819675|Device|Sham rTMS|
75459383|NCT01819688|Procedure|laparoscopic liver resection|
75459384|NCT01819701|Dietary Supplement|LC-1000|L-carnitine 1000 mg /d
75761365|NCT01084018|Behavioral|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
75761366|NCT01084096|Behavioral|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:~Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
75761367|NCT00384176|Drug|Cediranib|oral tablet once daily
75761368|NCT00384176|Drug|Bevacizumab|intravenous infusion
75761369|NCT00384176|Drug|5-fluorouracil ( in FOLFOX)|intravenous infusion
75761370|NCT00384176|Drug|Leucovorin (in FOLFOX)|intravenous infusion
75761371|NCT00384176|Drug|Oxaliplatin (in FOLFOX)|intravenous infusion
75761372|NCT00513305|Drug|Arsenic trioxide|Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
75761373|NCT00513305|Drug|Low-dose cytarabine alone|Cytarabine will be administered at a dose of 10 mg/m^2 subcutaneously (sc) twice a day (bid).
75761374|NCT00513071|Drug|saracatinib|Given orally
75761375|NCT00513071|Other|laboratory biomarker analysis|Correlative studies
75761376|NCT00510887|Drug|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
75761377|NCT00510887|Drug|Rituximab|Rituximab 375 mg/m2 IV on day 1
75761378|NCT00510887|Drug|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
75761379|NCT00510887|Drug|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
75761380|NCT00510887|Drug|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
75761381|NCT01012349|Drug|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
75761382|NCT01012349|Drug|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
75905685|NCT02169024|Behavioral|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
75905686|NCT02169024|Other|Standard individual prenatal care|Standard of care- individual prenatal care
75905687|NCT02169102|Other|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
75459385|NCT01819701|Dietary Supplement|LC-2000|L-carnitine: 2000 mg/d
75459386|NCT01819701|Dietary Supplement|Q10-150|Coenzyme Q10: 150 mg/d
75459387|NCT01819701|Dietary Supplement|Q10-300|Coenzyme Q10: 300 mg/d
75459388|NCT01819701|Other|Placebo|
75459389|NCT01819714|Other|Multi-sensory supportive care|"The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.~The impact of this multisensory strategy will be evaluated using a before-after design."
75459390|NCT01819740|Other|"determine the levels of the HEM substance in seminal plasma"|
75761383|NCT01012427|Procedure|percutaneous cryoablation|All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase > 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
75761384|NCT01012505|Other|adding pad with maternal milk in hte incubator|"2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol"
75761385|NCT03997877|Other|Physical activity|Increase physical activity Balanced diet
75611923|NCT04210453|Drug|Vitamin C|"Participants in Vitamin C group are administered IV vitamin C diluted in 100 cc normal saline 1 day before surgery, at rewarming during surgery, 3 hours after surgery, and every 6 hours thereafter until postoperative 24 hours."
75761386|NCT00358826|Drug|VIA-2291|oral dosing, 1 time daily for 12 or 24 weeks
75905688|NCT02169102|Radiation|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
75905689|NCT02169102|Radiation|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
75905690|NCT02169102|Radiation|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
75905691|NCT02852967|Drug|Belumosudil|
75611924|NCT04210453|Drug|Control (Normal saline)|"Participants in Control group are administered IV 100cc normal saline at the same timepoint as above."
75611925|NCT00622141|Drug|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
75611926|NCT04210765|Drug|Clomiphene Citrate|Clomiphene citrate used in incremental doses in nonresponsive cases.
75611927|NCT00622219|Other|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
75761387|NCT00358826|Drug|Placebo|oral dosing, 1 time daily for 12 or 24 weeks
75761388|NCT04564313|Drug|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
75905692|NCT02852967|Drug|Placebo|Placebo tablets matching belumosudil
75459391|NCT01819753|Procedure|Percutaneous nephrolithotomy|The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
75459392|NCT01818232|Drug|[14C]-LX4211|
75905693|NCT02162316|Drug|Motilitone®|
75905694|NCT02162316|Drug|A-Cilin®, Clari® and Pantoline®|
75905695|NCT05635864|Procedure|Catheter ablation|Catheter ablation of atrial tachyarrhythmia (atrial fibrillation, atrial flutter)
75905696|NCT02162394|Device|Observational ambulatory ECG monitoring|
75905697|NCT02169180|Drug|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
75905698|NCT03593044|Drug|0.01% concentration atropine drops|One drop of 0.01% concentration atropine in each eye at night for seven days.
75459393|NCT01819779|Drug|Exforge tab. 10/160mg|
75459394|NCT01819779|Drug|Lodivixx tab. 5/160mg|
75459395|NCT01819792|Other|Multiplex respiratory viral PCR|
75761389|NCT01009541|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for three days.
75761390|NCT01009541|Drug|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for three days.
75761391|NCT01009541|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for three days.
75761392|NCT01009541|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for three days
75761393|NCT01052558|Device|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
75761394|NCT01052558|Procedure|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
75905699|NCT03597087|Procedure|Anesthesia before transurethral resection of the bladder tumor|"General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle"
75905700|NCT03597087|Drug|Anesthesia|"General anaesthesia : propopol~Spinal anaesthesia : bupibacaine"
75905701|NCT02169258|Procedure|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis > 70% of the major epicardial vessels and bypass graft vessel or their major branches (> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
75905702|NCT03603327|Drug|Direct acting anti-viral agents|Standard of care for Hepatitis C treatment
75905703|NCT05635630|Other|ctDNA and adjuvant therapy|Patients of ctDNA positive group receive individual adjuvant chemotherapy. The ctDNA status are evaluated every 2 months.
75905704|NCT05635630|Other|ctDNA|Patients of ctDNA negative group are monitored by ctDNA every 3 months.
75905705|NCT03596775|Drug|Dexmedetomidine|Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
75611928|NCT05662267|Other|Pancreatic islet transplantation after kidney transplantation|Pancreatic islet transplantation consists in the intrahepatic transplantation of pancreatic islets, as a result of enzymatic digestion of a deceased-donor pancreas.
75611929|NCT00621205|Behavioral|Weight reduction, Resistance training, Aerobic exercise training, Control|Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
75611930|NCT04210609|Device|Vaporous Hyperoxia Therapy|55 minutes of treatment, 2 times per week
75761395|NCT00510653|Drug|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
75905706|NCT03596775|Drug|saline|Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
75761396|NCT04554095|Other|Clinical data collection|Respiratory parameters, analytic values, lung ultrasound and echocardiography
75761397|NCT01565525|Behavioral|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
75761398|NCT01565525|Behavioral|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
75459396|NCT01819805|Drug|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
75459397|NCT01819818|Drug|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
75459398|NCT01819857|Drug|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
75459399|NCT01819857|Drug|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
75459400|NCT01819857|Drug|Zofran 8 mg|intravenous administration of 8 mg ondansetron
75459401|NCT01819870|Drug|Dilatrend SR capsule 32mg|"1 capsule, oral, once daily, 7days~over the period I&II(crossover)"
75459402|NCT01819870|Drug|Dilatrend IR tablet 25mg|"1 tablet, oral, once daily, 7days~over the period I&II(crossover)"
75459403|NCT01819896|Drug|Pacemaker and defibrillator|
75459404|NCT01819948|Dietary Supplement|PhytoMed™|
75459405|NCT01819961|Drug|MCT/LCT and fish oil|
75459406|NCT01819961|Drug|MCT/LCT|
75761399|NCT01565681|Drug|ASP1240|infusion
75761400|NCT01565681|Drug|Placebo|infusion
75761401|NCT01009697|Drug|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
75761402|NCT00362336|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
75761403|NCT00362336|Biological|CombAct-HIB®|0.5 mL, IM
75761404|NCT00362336|Biological|Engerix B® Pediatric|0.5 mL, IM
75761405|NCT01009853|Drug|Codeine Sulfate|15 mg tablet
75905707|NCT03601299|Other|Traditional food|Increasing traditional food consumption through Head start programs in Alaska
76069836|NCT01744496|Drug|Placebo|Placebo patches match the size of active patches 20 cm^2, 30 cm^2, or 40 cm^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
75611931|NCT00621283|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
76069837|NCT05366205|Dietary Supplement|Oral nutritional supplement|Enteral nutritional emulsion(TPF-T) will be given by oral intake,400ml per day, lasting for 7-10 days.
75611932|NCT00138853|Device|Tibial component|Tibial component inserted at the time of surgery
75611933|NCT00995709|Drug|AIN457|
75611934|NCT00995709|Drug|AIN457|
75761406|NCT05408273|Diagnostic Test|Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device|We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
75761407|NCT01052636|Other|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
75905708|NCT03066466|Drug|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
75905709|NCT03066466|Drug|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
75611935|NCT00995709|Drug|Placebo|
75905710|NCT03066466|Drug|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
75905711|NCT03601221|Other|Sample collection|Collection of one sampling pouch from each blood donor
76069838|NCT05366205|Behavioral|Nutrition consultation|Nutritional treatment advice will be given
75905712|NCT03603249|Drug|Trimetazidine|Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in >80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several-not yet fully understood-mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).
75905713|NCT03603171|Diagnostic Test|DM1-ActivC|A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)
75905714|NCT03603171|Diagnostic Test|R-PAct|A Rasch-built Pompe-specific activity scale.
75905715|NCT03603171|Diagnostic Test|Beck depression inventory|A self-reported depression inventory administered verbally or self administered.
75905716|NCT03603171|Diagnostic Test|McGill pain questionnaire|The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.
75905717|NCT03603171|Diagnostic Test|Brief Pain Inventory Short-Form|A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning
75905718|NCT03603171|Diagnostic Test|Fatigue and Daytime Sleepiness Scale|A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.
75761408|NCT00506285|Drug|Methylphenidate Transdermal System (MTS)|MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
75761409|NCT00506285|Other|placebo patch|This patch is designed to appear identical to the actual intervention patch
75761410|NCT00506129|Drug|Fludarabine|25 mg/m^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
75761411|NCT00506129|Drug|Melphalan|70 mg/m^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
75761412|NCT00506129|Procedure|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
76069839|NCT01721330|Drug|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
76069840|NCT01721330|Drug|Placebo|Placebo twice a day for 6 weeks
76069841|NCT05366127|Other|IGA score|IGA score will be assessed by 2 blinded investigators
75761413|NCT00506129|Drug|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
75761414|NCT00358670|Biological|infliximab|"Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2)."
75611938|NCT04208113|Behavioral|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
75611939|NCT00629031|Drug|Paromomycin|11 mg/kg for 14 days
75611940|NCT00629031|Drug|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
75761415|NCT00358670|Biological|infliximab|"Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 [NCT00251641] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a >=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse."
75761416|NCT01010087|Drug|Oseltamivir|standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
75761417|NCT00505661|Drug|Letrozole|2.5 mg PO Once Daily
75761418|NCT00383786|Drug|NK1 Antagoist (GR205171)|
75761419|NCT00383786|Procedure|Psychophysiology (Trauma Script)|
75761420|NCT00383786|Procedure|Psychophysiology (Verbal Threat)|
75761421|NCT00383786|Procedure|Psychophysiology (Fear Conditioning)|
75761422|NCT00383786|Procedure|Psychophysiology (Affective Modulation)|
75905719|NCT03603171|Diagnostic Test|Myotonia Behaviour scale|It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
75905720|NCT03603171|Diagnostic Test|Hand opening time|A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.
75905721|NCT03603171|Diagnostic Test|Pressure pain threshold|Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.
75905722|NCT03603171|Diagnostic Test|Manual muscle testing|The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.
75611941|NCT04295265|Device|smartphone message|Receive daily whatsapp/ SMS message to remind the drug intake
75611942|NCT00621361|Drug|AZD2171|Oral
75611943|NCT00621361|Drug|Etoposide|Intravenous
75611944|NCT00621361|Drug|Cisplatin|Intravenous
75611945|NCT05661565|Other|No intervention|We try to find an association between insulin resistance with ovarian hormonal and morphological characteristics in patients with polycystic ovarian syndrome
75611946|NCT04208581|Drug|Yiqi Huoxue Huatan granule|Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
75761423|NCT00383786|Procedure|Psychophysiology (Heart rate variability)|
75761424|NCT00383786|Procedure|Lumbar Puncture|
75761425|NCT00383786|Procedure|24-hour plasma sampling|
75761426|NCT00383786|Procedure|MRI|
75905723|NCT03603171|Diagnostic Test|Quantitative muscle testing|Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference > 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.
75611947|NCT04208581|Drug|Placebo Yiqi Huoxue Huatan granule|Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
75611948|NCT03551899|Other|Different ventilation parameters|mode of ventilation, tidal volume per body weight and PEEP settings
75611949|NCT02696863|Behavioral|questionnaire|
75611950|NCT05368831|Drug|1024|Drug Drug interactions between 1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
75611951|NCT05368675|Drug|medication for opioid use disorder|This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
75611952|NCT04208425|Behavioral|Project Personality|"The intervention includes five components: 1. An introduction to the brain, including a lesson on the concept of neuroplasticity, describing how and why our behaviors are controlled by thoughts and feelings in their brains, which have potential for change; 2. Written testimonials from older youths who describe their beliefs that people's personal traits (e.g., sadness, anxiety) are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits (i.e., a self-persuasion exercise)."
75611953|NCT04208425|Behavioral|Sharing Feelings Intervention|The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the web-based growth mindset intervention; it also mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
75611954|NCT04208269|Other|postcard campaign|Post card sent to parent only
75611955|NCT04208269|Other|Health Information Technology system|Accessed by adolescent and provider only
75611956|NCT05368051|Combination Product|long course radiotherapy + capecitabine + PD-1 monoclonal antibody|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
75611957|NCT02648113|Procedure|Restrictive transfusion|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
75611958|NCT02648113|Procedure|Liberal transfusion|transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL
75611959|NCT02648113|Biological|red blood transfusion|
75611960|NCT02641873|Drug|BBI608|240 mg twice daily (480 mg total daily dose)
75611961|NCT02641873|Drug|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
75611962|NCT02641873|Drug|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
75611963|NCT02641873|Drug|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
75611964|NCT02641873|Drug|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
75611965|NCT00998985|Drug|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
75611966|NCT00998985|Drug|Placebo|Placebo tablet, orally, once a day for 7 days
75611967|NCT05240391|Drug|Midodrine Hydrochloride|Midodrine hydrochloride for PICD prevention
75611968|NCT05240391|Drug|Human Albumin 20%|Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
75611969|NCT00628953|Drug|Esomeprazole|40mg twice a day
75611970|NCT00628953|Drug|Placebo|40mg twice a day
75611971|NCT04294875|Drug|MPT0B640|PO, every 3 days. dose escalation per MTD
75611972|NCT02870127|Other|blood sample|
75611973|NCT04294953|Drug|Duloxetine|Each Patient will receive oral Duloxetine capsule 60mg at the night before operation(12hrs before surgery), the 2nd dose 60 mg Duloxetine capsule 1hr before operation and 3rd dose 60mg capsule after 24hrs postoperative
75611974|NCT04294953|Drug|Placebo oral tablet|Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
75611975|NCT04293861|Device|HYMOVIS|HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
75905724|NCT03603171|Diagnostic Test|Scale for Assessment and Rating of Ataxia|SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.
75905725|NCT03603171|Diagnostic Test|Berg balance scale|It is a 14 item objective measure designed to assess static balance and fall risk in adult populations
75905726|NCT03603171|Diagnostic Test|Quick motor function test|Assessment of proximal motor function.
76069842|NCT05366127|Other|BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)|BPDAI will be assessed by 2 by 2 blinded investigators
76069843|NCT05631015|Other|AI recongnize disease and generate recommendations|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
76069844|NCT03595605|Behavioral|Ambulation|This group will be encouraged twice daily to ambulate
75611976|NCT02869815|Procedure|ICG+Methylene Blue|"ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
75611977|NCT04293081|Drug|Preemptive chlorepheniramine maleate intravenous injection|Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
75611978|NCT04293081|Drug|normal saline|participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
75611979|NCT00995553|Behavioral|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
75611980|NCT00995553|Behavioral|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
75611981|NCT04293003|Other|fasting|6-hour fasting
75761427|NCT05358977|Biological|Tisseel|Intraoperatively, the intervention side will receive topical administration of Tisseel to the blepharoplasty incision. A 2mL syringe of Tisseel product will be used as per the product monograph for an area of < 8cm2. There will be no variation in surgical counselling or technique, with the exception of the use of Tisseel in one eyelid closure. Both eyelids will otherwise receive standard blepharoplasty surgical techniques. There will be no monitoring of compliance necessary, given the Tisseel will be utilized intraoperatively.
75761428|NCT01010243|Drug|Lenalidomide, Pioglitazone, dexamethasone, treosulfan|"Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.~Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy"
75761429|NCT05358665|Other|mask use|long term mask use
75761430|NCT00383708|Drug|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
75761431|NCT00383708|Drug|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
75761432|NCT00504881|Drug|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
75761433|NCT00504881|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
75761434|NCT00504725|Drug|Ketamine|Interventional
75761435|NCT00504725|Drug|0.9% saline|placebo
75761436|NCT01010321|Device|confocal microscopy|non-invasive imaging
75459407|NCT01819974|Other|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
75761437|NCT05407883|Behavioral|School traffic warden programme|Trained school traffic wardens placed at school crossing points to help children cross
76069845|NCT03595605|Other|Standard of Care|Care as usual at inpatient NYU Langone
76069846|NCT04407195|Other|Exposure to the SARS-CoV-2|This is an observational design. Participants are exposed to the Covid-19 pandemic.
75459408|NCT01819987|Behavioral|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
75459409|NCT01819987|Behavioral|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
76069847|NCT03592407|Drug|Epacadostat|Given PO
76069848|NCT03592407|Other|Laboratory Biomarker Analysis|Correlative studies
76069849|NCT03592407|Biological|Pembrolizumab|Given IV
76069850|NCT03592407|Other|Pharmacodynamic Study|Correlative studies
76069851|NCT03593187|Drug|Cal-1 (LVsh5/C46) drug product|Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
75761438|NCT00383240|Drug|mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
75761439|NCT00383240|Drug|Mometasone furoate MDI (MF MDI) 200 mcg|MF 200 mcg via metered dose inhaler twice daily for 26 weeks
75761440|NCT00383240|Drug|formoterol fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
75761441|NCT00383240|Drug|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
75761442|NCT00362180|Drug|mipomersen|200 mg subcutaneous injections
75761443|NCT00362180|Drug|Placebo|subcutaneous injections
75761444|NCT00383162|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
75761445|NCT00383162|Drug|Placebo|Matching placebo tablet.
75761446|NCT01050140|Dietary Supplement|high sugar diet|25% of dietary energy from fructose or glucose
75761447|NCT03990584|Procedure|three irrigation activation methods|passive ultrasonic irrigation, sonic irrigation, manual dynamic irrigation
75761448|NCT03990584|Procedure|conventional needle irrigation|conventional needle irrigation
75761449|NCT01052792|Drug|Naproxen Sodium|Naproxen Sodium Tablets 550 mg
75761450|NCT03990350|Other|Fecal Sample Collection|With permission from the parent/guardian, stool collected in a sterile container will be brought within 12 hours of defecation from home or the outpatient clinic to a separate clinical laboratory where feces will be collected through use of FLOQswab brush x 3 (Copan Diagnostics, Murrieta, CA) The swabs will be pre-labeled with a de-identified code reflecting patient number, sample number, and date and the sample will be placed into dry ice then transferred to a -80 degrees Celsius freezer until retrieval by the research staff for transfer to CHOP Microbiome Center.
75761451|NCT03990350|Other|Physical Activity Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Physical Activity Questionnaire (Physical Activity Questionnaire for Older Children) with the subject and parent.
75761452|NCT03990350|Other|Food Frequency Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.
75611982|NCT04293003|Other|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
75611983|NCT04293003|Other|Mediterranean|Consumption of a Mediterranean-type breakfast
75761453|NCT03990350|Other|24-hour dietary recall diary|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.
75761454|NCT01052870|Drug|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
75761455|NCT00358436|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
75761456|NCT00358436|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
75761457|NCT01053026|Drug|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
75761458|NCT00383084|Behavioral|Lifestyle physical activity (LPA)|Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
75761459|NCT00383084|Behavioral|Fibromyalgia education|Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
75761460|NCT01045382|Biological|Mesenchymal stem cells|Mesenchymal stem cell injection
75611984|NCT04295187|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
75611985|NCT04295187|Other|Physical development and General Health|Physical development and General health examination
75611986|NCT04295187|Other|Developmental Red flags|Developmental Red flags Questionnaires
75611987|NCT02868723|Other|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
75611988|NCT02869269|Device|Early stage|patients who classed as clinical stage 1 and 2
75611989|NCT02869269|Device|Late stage|patients who classed as clinical stage 3 and 4
75611990|NCT04291833|Behavioral|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
75611991|NCT04291833|Behavioral|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
75761461|NCT01045382|Other|Isotonic solution|Isotonic solution injection
75761462|NCT01045538|Drug|Vorinostat, capecitabine, and cisplatin|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
75761463|NCT00361634|Drug|Etanercept|
75761464|NCT03992924|Procedure|function or imaging guided PCI|FFR may be good tools to differentiate patients with STEMI who may not need stent implantation from those who need Optical coherence tomography (OCT) can visualize the microstructure of culprit and the OCT characteristics were validated by histology
75761465|NCT00357968|Drug|Prasugrel|Administered orally
75761466|NCT00357968|Drug|Clopidogrel|Administered orally
75761467|NCT00357968|Drug|Placebo for Prasugrel|Administered orally
75761468|NCT00357968|Drug|Placebo for Clopidogrel|Administered orally
75761469|NCT03990272|Drug|AIT drops|once a day
75761470|NCT03990272|Drug|placebo drops|once a day
75905727|NCT03603171|Diagnostic Test|GSGC|GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
75459410|NCT01820000|Procedure|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
75761471|NCT01324934|Drug|ATG-Fresenius S|"Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids)."
75611992|NCT04291833|Behavioral|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
75761472|NCT01053182|Procedure|Ivor-Lewis Esophagectomy|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
75761473|NCT01053182|Procedure|Sweet Esophagectomy|Esophagectomy through Left Side Thoracotomy
75761474|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period <= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always >= 0.4 mL/h."
75761475|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period <= 5 minutes (maximum infusion rate, 10 mL/min).
75761476|NCT00357500|Drug|celecoxib|
75761477|NCT00357500|Drug|cyclophosphamide|
75611993|NCT02868801|Drug|Placebo|same intervention as the experimental group
75611994|NCT02868801|Drug|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
75761478|NCT00357500|Drug|etoposide|
75611995|NCT02868801|Drug|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
75611996|NCT02868801|Drug|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
75761479|NCT00357500|Drug|fenofibrate|
75761480|NCT00357500|Drug|thalidomide|
75761481|NCT00357110|Drug|Fulvestrant|intramuscular injection
75761482|NCT00357110|Drug|Anastrozole|1 mg oral tablet
75761483|NCT01053260|Behavioral|LEARN Program|Participants will receive weekly counseling based on the LEARN Program for Weight Management
75761484|NCT01053260|Behavioral|Contingency Management|Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
75761485|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
75761486|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
75761487|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
75761488|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
75459411|NCT01820013|Device|Customised Dynamic Elastomeric fabric Orthoses|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
75459412|NCT01820013|Device|Serola Sacroiliac Belt|Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
75459413|NCT01820026|Drug|Imipenem|second line therapy
75761489|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
75611997|NCT00991887|Radiation|Radiation Therapy (XRT)|The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
75761490|NCT01079416|Device|Capsule endoscopy, Esophagogastroduodenoscopy|
75611998|NCT01002339|Drug|Tacrolimus with rapid steroid withdrawal|"Basiliximab induction (4 mg i.v., days 0 and 4).~Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
75459414|NCT01820026|Drug|Vancomycin|Second line therapy
75611999|NCT01002339|Drug|Tacrolimus with steroids minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)~Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
75612000|NCT01002339|Drug|CsA with steroid minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)~Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~Mycophenolate mofetil 1 gr b.i.d"
75612001|NCT01002105|Drug|Baclofen|Baclofen 50mg per day for 12 weeks and psychosocial intervention
75612002|NCT01002105|Other|Control group|psychosocial intervention and placebo for 12 weeks
75612003|NCT02605993|Biological|Ravulizumab|All treatments were given as IV infusions.
75612004|NCT00995085|Drug|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
75761491|NCT02531152|Drug|Latanoprost|
75761492|NCT02531152|Drug|SAR366234|
75761493|NCT01084408|Device|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
75459415|NCT01820026|Drug|azithromycin|Second line therapy
75761494|NCT01084408|Device|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
75761495|NCT01079494|Other|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
75761496|NCT00098254|Drug|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
75761497|NCT00095056|Drug|sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.
75761498|NCT00095056|Drug|Placebo to Sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.
75459416|NCT01820026|Drug|Cefotaxime|Standard antibiotic therapy
75459417|NCT01820026|Drug|Amoxicillin|Standard therapy
75459418|NCT01820039|Other|FertiScreen|FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
75459419|NCT01820052|Drug|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
75459420|NCT01820052|Drug|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
75459421|NCT01820065|Procedure|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
75459422|NCT01820078|Drug|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
75459423|NCT01820078|Other|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
75459424|NCT01820091|Drug|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
75612005|NCT02867787|Drug|Botox arm|
75761499|NCT00095056|Drug|glipizide|One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
75459425|NCT01820091|Drug|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
75761500|NCT00095056|Drug|Placebo to glipizide|One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
75761501|NCT00098020|Drug|Isotretinoin|
75459426|NCT01820104|Drug|lansoprazole, 30 mg per day for 6 days|
75761502|NCT00381680|Drug|vincristine sulfate|Given IV
75761503|NCT00381680|Drug|prednisone|Given PO
75761504|NCT00381680|Drug|doxorubicin hydrochloride|Given IV
75459427|NCT01820117|Other|Neurocognitive Evaluation|The neurocognitive evaluation will include measures of academic achievement, intelligence, sustained attention, memory, processing speed, executive functions, functional behavior, and emotional functioning.
75459428|NCT01820117|Other|Quantitative Brain Imaging|Imaging will include raw images to both quantify white matter hyperintensities and hemosiderin deposits, as well as cortical thickness and tissue segmentation. Brain imaging will be repeated on participants who are concurrently enrolled on BRIGHT and MIND protocols at St. Jude and who completed prior brain imaging during the BRIGHT clinic visit. The repeat MRI will be done at their 6 month MIND clinic visit.
75612006|NCT02868489|Dietary Supplement|LactoWise®|blend of bacillus coagulans and galactomannans
75761505|NCT00381680|Drug|pegaspargase|Given IM
75761506|NCT00381680|Drug|cytarabine|Given IT or IV
75459429|NCT01820117|Other|Neurologic Evaluation|Evaluation includes a complete review of neurologic symptoms, and interview and examination by the neurologist, assessment of neurologic symptoms and determination of their impact on day-to-day living, and quantified neurologic examination by the neurologist.
75459430|NCT01820117|Other|Health Questionnaire|Participants will be asked to complete an approximately 450-item survey to assess health history and status, social and demographic factors, health behaviors, and psychosocial constructs.
75459431|NCT01820117|Other|Vascular Testing|Digital assessment of endothelial function will be studied, and central blood and pulse pressure and carotid-femoral pulse wave velocity will be non-invasively measured.
75459432|NCT01820117|Other|Cardiopulmonary Exercise Testing|Study participants will undergo cardiopulmonary exercise testing by treadmill. Those participants whose physical performance does not permit walking safely on the treadmill (extreme deconditioning, lower extremity paralysis, balance disorder, acute lower extremity injury) will perform cardiopulmonary exercise testing on a bicycle or upper extremity ergometer using a comparable testing protocol.
75459433|NCT01820117|Other|Echocardiography|A complete 3D as well as 2D echocardiogram with Doppler and M-mode will be performed.
75905728|NCT03603171|Diagnostic Test|30 seconds sit to stand test|It is a measurement that assesses functional lower extremity strenght in older adults.
75905729|NCT03603171|Diagnostic Test|Functional Index-2|Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.
75459434|NCT01820117|Other|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volume measurements by body plethysmography, and single-breath carbon monoxide-diffusion capacity (DLCO).
75459435|NCT01820117|Procedure|Serum Biomarkers|Blood for serum biomarkers associated with cardiovascular morbidity will be drawn, including high-sensitivity C-reactive protein, serum homocysteine.
75905730|NCT03603171|Diagnostic Test|Six minute walking test|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
75612007|NCT02868489|Other|Placebo|Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium citrate)
75612008|NCT04209049|Drug|NNC0174-0833|A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
75612009|NCT02868645|Biological|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
75612010|NCT00136123|Procedure|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
75612011|NCT04208893|Behavioral|Exercise training|See description of Arms
75612012|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
75612013|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet
75761507|NCT00381680|Drug|methotrexate|Given IT or IV
75761508|NCT00381680|Drug|dexamethasone|Given PO
75761509|NCT00381680|Drug|etoposide|Given IV
75761510|NCT00381680|Drug|cyclophosphamide|Given IV
75761511|NCT00381680|Drug|leucovorin calcium|Given IV or PO
75761512|NCT00381680|Biological|filgrastim|Given IV or SC
75761513|NCT00381680|Drug|asparaginase|Given IM
75459436|NCT01820117|Other|Ophthalmology Examination|Ophthalmology examination will include a review of symptoms, examination, and fundus imaging. The examination will consist of visual acuity testing, refraction testing, retinoscopy, ocular pressure, and examination under mydriasis. Fundus photography will be used to capture an image of the retina for examination of potential hypertensive retinopathy.
75459437|NCT01820130|Device|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
75459438|NCT01820143|Drug|Ilaprazole|
75459439|NCT01820143|Drug|Esomeprazole|
75612014|NCT02478151|Device|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
75612015|NCT02471911|Drug|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
75612016|NCT02471911|Drug|Rituximab|IV Rituximab 375 mg/m2 on D1
75612017|NCT02471911|Drug|Etoposide|IV Etoposide 100 mg/m2 on D1-3
75612018|NCT02471911|Drug|Carboplatin|IV Carboplatin AUC 5 on D2
75612019|NCT02471911|Drug|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
75612020|NCT02471911|Drug|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
75612021|NCT02323321|Device|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
75612022|NCT00622375|Drug|mesalamine|encapsulated mesalamine granules
75612023|NCT02239861|Biological|TAA-Specific CTLs|"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
75612024|NCT02691559|Device|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
75612025|NCT02691325|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
75905731|NCT03603171|Diagnostic Test|Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)|A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
75459440|NCT01820156|Device|Home Respiratory Polygraphy|
75612026|NCT02691325|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose.
75612027|NCT02691325|Drug|Activated charcoal|The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
75612028|NCT02689687|Behavioral|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
75612029|NCT02689687|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
75612030|NCT02689687|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
75905732|NCT03068260|Drug|Ropivacaine|30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
75612031|NCT02689687|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
75612032|NCT00621439|Drug|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
75612033|NCT00621439|Drug|Placebo|Patients will receive placebo.
75459441|NCT01820156|Device|Standard Polysomnography|
75459442|NCT01820169|Device|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
75459443|NCT01820195|Drug|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
75459444|NCT01820195|Drug|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
75459445|NCT01820195|Drug|Placebo group|The patients in this group will be received both oral placebo and IV placebo
75459446|NCT01820208|Drug|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
75905733|NCT03068260|Drug|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
75905734|NCT03068260|Drug|Acetaminophen|1 g orally administered postoperatively
75905735|NCT03068260|Drug|Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet|orally administered postoperatively
75761514|NCT00381680|Drug|mercaptopurine|Given PO
75761515|NCT03292250|Drug|BYL719|Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
75761516|NCT03292250|Drug|Poziotinib|Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
75761517|NCT03292250|Drug|Nintedanib|Initial dose 200 mg twice per day orally according to study protocol.
75612034|NCT00622453|Other|Screening|Electrocardiography Blood Test
75612035|NCT02689765|Dietary Supplement|Anthocyanins|Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
75612036|NCT02689765|Dietary Supplement|Placebo|Placebo capsules is identically packaged.
75612037|NCT00622531|Device|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
75612038|NCT00622531|Other|hidden BNP value|no intervention
75612039|NCT05661877|Other|DengueAid mobile application|•Education materials regarding dengue fever and self-care. The education section (My Dengue Knowledge) consists of seven modules (dengue essentials, risk, symptoms, aedes mosquito, self-care, prevention and interesting facts) with gamification properties. Each module contains a series of multiple-choice questions. After answering each question, the user would be instantly notified if they had answered the question correctly and be provided with some facts related to the question. A progress meter would allow users to keep track of each module answered. A medal would be awarded to users who have completed 100% of each module. The self-care section consists of basic information about dengue fever and points to look out for self-care. It contains information on dengue fever phases, signs of dengue, importance of keeping hydrated, complementary therapy, medicine to avoid and prevention practices.
75612040|NCT05661877|Other|MyHealth website|MyHealth is developed by Ministry of Health, Malaysia (http://www.myhealth.gov.my/en/dengue-fever/) to provide information on dengue.
75612041|NCT04631107|Drug|AD109 dose1- A|Oral administration at bedtime
75612042|NCT04631107|Drug|AD109 dose2- B|Oral administration at bedtime
75612043|NCT04631107|Drug|Placebo- C|Oral administration at bedtime
75612044|NCT02691481|Dietary Supplement|Oatmeal breakfast|
75612045|NCT02691481|Dietary Supplement|Glucerna formula|
75612046|NCT02691481|Dietary Supplement|Ultra Glucose Control formula|
75612047|NCT01449409|Other|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
75612048|NCT00622609|Drug|GSK249320A|GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
75761518|NCT03292250|Drug|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
75761519|NCT03292250|Drug|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
75905736|NCT03068260|Device|ultrasound-guided nerve block|Transmuscular quadratus lumborum block, ultrasound-guided
75612049|NCT00622609|Drug|Placebo|Sodium chloride intravenous infusion will be given as matching placebo.
75612050|NCT04187287|Other|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session
75612051|NCT04187287|Other|Deep Friction Massage|Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
75612052|NCT04208737|Procedure|recruitment maneuver|30 cmH2O pressure 15 seconds
75761520|NCT01053338|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
75761521|NCT01050374|Drug|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
75761522|NCT01050374|Drug|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
75905737|NCT03068260|Drug|Morphine|intravenously administered morphine via PCA-pump
75905738|NCT03068260|Device|Patient-controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
75459447|NCT01820208|Drug|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
75459448|NCT01820221|Procedure|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
75459449|NCT01820234|Other|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
75459450|NCT01820234|Other|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
75459451|NCT01820247|Drug|enteral nutrition|
75459452|NCT01820247|Drug|Tripterygium glycosides|
75761523|NCT00360698|Drug|Insulin Glargine|One daily injection at bedtime
75761524|NCT00360698|Drug|Glimepiride|At same dosage as during the run-in period
75761525|NCT00360698|Drug|Insulin Glulisine|One bolus given before the main meal
75761526|NCT00360698|Drug|Metformin|At same dosage as during the run-in period
75905739|NCT02762994|Drug|BCD-085|
75905740|NCT02762994|Other|Placebo|
75905741|NCT05635552|Diagnostic Test|Dynamic retinal vessel analysis (DVA)|DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.
75612053|NCT05661799|Behavioral|Intervention Group|The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.
75612054|NCT05661799|Behavioral|Control Group|The programme is a PA programme consisting of one weekly session for 12 weeks.
75612055|NCT04548037|Other|PET-CT examination|The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
75612056|NCT04325737|Drug|SEP-363856|Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
75612057|NCT04325737|Drug|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
75612058|NCT00457873|Drug|0.9% saline in 5% dextrose (intravenous)|
75612059|NCT00457873|Drug|0.45% saline in 5% dextrose (intravenous)|
75612060|NCT02689375|Device|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
75612061|NCT04504357|Behavioral|Tablet based U=U app|"Tablet based app focusing on TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing."
75612062|NCT04504357|Behavioral|U=U videos played in clinic waiting rooms and integrated into HIV counseling session|TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing.
75612063|NCT04504357|Other|Text messages|Monthly text messages reinforcing intervention content
75612064|NCT02697565|Behavioral|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
75761527|NCT03990194|Drug|Leuprolide Acetate|Administration of Leptoprol implant every 3 months
75761528|NCT03990116|Procedure|Lateral|Posture lateral kangaroo care
75761529|NCT03990116|Procedure|Prone|Posture prone kangaroo care
75761530|NCT01053416|Procedure|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
75761531|NCT02534558|Biological|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
75905742|NCT05635552|Diagnostic Test|Optical coherence tomography (OCT)|OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.
75905743|NCT05635552|Diagnostic Test|Biochemistry and immune phenotyping|Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.
75905744|NCT05635552|Diagnostic Test|Handgrip strength test|Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.
75905745|NCT05635552|Diagnostic Test|Questionnaires (Patient reported outcomes)|The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms
75905746|NCT03603015|Diagnostic Test|Penile cuff test|Comparison of invasive vs non-invasive urodynamics
75612065|NCT02697565|Behavioral|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
75612066|NCT04208191|Behavioral|Quality Improvement Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH and FP services
75612067|NCT02697409|Behavioral|Education Against Tobacco intervention|
75612068|NCT02697331|Drug|Progesterone|"women will receive progesterone vaginal pesarries containing 200mg of progesterone twice daily . it will be used by the patient as one vaginal pessary per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 -24 weeks and stopped at 36+6 weeks"
75612069|NCT02697331|Other|Placebo|women will receive placebo pessary twice a day. women will be showed how to use tablets . medication will be started at 20-24 weeks and stopped at 36+6 weeks
75612070|NCT02697175|Device|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
75612071|NCT02697175|Other|No Live Video-Colposcopy|The TV will be shut off during colposcopy
75612072|NCT04187911|Behavioral|Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. The role of the therapist during sessions is to maintain an attuned relationship with both child and parent - modelling and encouraging development of a similarly attuned relationship between the child and parent. Therapists are trained to use Playfulness, Acceptance, Curiosity and Empathy (PACE). Our research suggests that key mechanisms of action in DDP might include the active participation of the parents and increased carer empathy and emotional warmth for the child. DDP experts believe this helps build parental capacity for attuned dialogue with the child, co-creation of the meanings underlying child behaviour, and co-regulation of experienced emotions aiming to address four main problem areas: 1. child emotional regulation 2. parental stress 3. the parent-child relationship 4. child mental health.
75612073|NCT04187911|Behavioral|Services as Usual (SAU)|"SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise. At the time of our UK mapping and modelling work, these services were usually CAMHS based. This may have changed, at least for adoptive families, with the advent of the Adoption Support Fund, which, since May 2015, has allowed local authorities / adoption agencies to apply for funding for essential therapeutic services. A wide range of interventions, many with a scant evidence base, have been purchased - sometimes from private practitioners - since 2015. In addition, relevant NICE guidelines, particularly those on Looked After and Accommodated Children, Attachment and Child Abuse and Neglect, have been published or updated.Our detailed qualitative and quantitative process evaluation throughout all study Phases will be crucial to carefully characterise SAU in all study sites."
75612074|NCT04278625|Drug|Acetaminophen|IV acetaminophen given as part of standard of care.
75612075|NCT02689141|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
75612076|NCT02689141|Drug|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
75905747|NCT03070834|Device|Cook 'Celect' retrievable inferior vena cava filter|Cook 'Celect' device will be deployed If randomized to rIVCF insertion
75459453|NCT01820286|Behavioral|Positive psychology intervention|
75459454|NCT01820286|Behavioral|Recollection intervention|
75459455|NCT01820299|Drug|Grape Seed Extract|All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
75459456|NCT01820299|Drug|Vitamin D|From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
75459457|NCT01820312|Radiation|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
75459458|NCT01820325|Drug|Buparlisib|
75459459|NCT01820325|Drug|Buparlisib placebo|Placebo + Carboplatin + Paclitaxel
75761532|NCT00380978|Procedure|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
75761533|NCT00380978|Procedure|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
75761534|NCT02534480|Drug|NGP 555|Gamma-secretase modulator for the treatment of Alzheimer's disease
75905748|NCT02165514|Procedure|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
75905749|NCT03601065|Other|Videos of polyps, resection of polyps|Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
76069852|NCT04254159|Other|Superimposed Neuromuscular Electrical Stimulation|NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
75905750|NCT02166060|Drug|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
75905751|NCT03305614|Procedure|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA
75459460|NCT01820325|Drug|Carboplatin|
75459461|NCT01820325|Drug|Paclitaxel|
75459462|NCT01820338|Behavioral|Behavioral Child Tx Contacts|Each parent and child dyad will participate in group meetings. Children and parents will meet in simultaneous, but separate, groups at each meeting. The intervention will include 12 sessions over 16 weeks. Families will also participate in a maintenance intervention for the next eight months. The primary treatment objectives will be to decrease caloric intake in a nutritionally sound manner and to increase moderate intensity exercise. Changes in dietary habits will be addressed via a modified version of the Stoplight System. Children and adults will be encouraged to eat a well-balanced diet based on the food guide pyramid. Parents and children will also be given pedometers and they will be asked to keep track of the number of steps they take each day. Each week parents and children will set goals to gradually increase physical activity. Parent and their children will be asked to record what they eat and drink, as well as their physical activity on daily food logs.
75459463|NCT01820338|Behavioral|Behavioral Parent-Tx Contacts|Only the participating parent(s) will attend group meetings. The intervention will include weekly sessions for the first 8 weeks and biweekly sessions for the next 8 weeks. They will also participate in a maintenance intervention for eight months. Each session will last 90 minutes. The sessions for parents in the parent-only program will be structured the same as the parents sessions for the family-based intervention and will also cover the same topics. As with the family-based intervention, the parent and their children assigned to the parent-only intervention will be asked to record what they eat and drink, as well as their physical activity, on a daily basis. Each week group interventionists will model the goal setting process with parents and suggest a general range of age-appropriate dietary and physical activity targets that might be appropriate for each child and parent.
75612077|NCT02689141|Drug|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
75905752|NCT03305614|Procedure|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
75905753|NCT03600987|Behavioral|Simultaneous music and reading lyrics|listening to music with singing of the lyrics simultaneously with reading the written lyrics.
75905754|NCT03600987|Behavioral|Priming with music|priming by listening to music and singing of the lyrics followed by reading the written lyrics.
75905755|NCT03600987|Behavioral|Control|control condition using reading materials without music.
75905756|NCT05635474|Dietary Supplement|Bacillus Coagulans|Bacillus coagulans is a Gram-positive bacterium belonging to the genus Bacillus and does not exist in the intestinal microbiota, because it has the characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains.
75905757|NCT05635474|Dietary Supplement|Placebo|The placebo was also administered in the form of capsules consisting of maltodextrin, silicon dioxide, and magnesium stearate.
75612078|NCT00622687|Drug|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
75612079|NCT00622687|Drug|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
76069853|NCT04254159|Other|Quadriceps Strengthening|Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
76069854|NCT04254159|Behavioral|Patient Education Program|The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
75612080|NCT00622687|Drug|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
75612081|NCT04432051|Behavioral|mechanical ventilator settings and position|Mechanical ventilation settings and patient position will be re-evaluated
75459464|NCT01820338|Other|Dietary and Physical Activity Information|Both the child and parent will attend the treatment sessions in this program. The condition will include a series of meetings addressing key aspects of nutrition, physical activity, and health promotion such as national guidelines regarding proper nutrition, guidelines for physical activity, strategies to cope with stress, healthy sources and guidelines for intake of fiber, calcium, protein, grains & carbohydrates. Topics will also include use of vitamin & mineral supplements, dental and sleep hygiene, self-esteem, family communication, and assertiveness training in dealing with peer victimization. The families in the Health Education group will not receive training in behavioral self-regulation strategies, such as goal setting and self-monitoring. Children will participate in a group physical activity during each session such as frisbee, jump rope, stoplight tag. They will also sample healthy snacks such as pretzels or fruits and vegetables.
75612082|NCT02687659|Device|TEMIS system|Wearing TEMIS system over the day during one week
75612083|NCT04220983|Radiation|MR-Guided Prostate SBRT|Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
75612084|NCT05662735|Device|Mesh repair|Augmentation of hiatal hernia repair with TiMESH® reinforcement
75761535|NCT00162123|Drug|Ipilimumab|Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
75761536|NCT00227721|Drug|Docetaxel|40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
75761537|NCT00227721|Drug|Gemcitabine hydrochloride|800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
75612085|NCT05662735|Procedure|Suture repair|Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures
75761538|NCT01074723|Dietary Supplement|b-cryptoxanthin and phytosterols|Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
75905758|NCT02237859|Drug|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
75761539|NCT01074801|Other|Closed-loop insulin delivery|Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.
75612086|NCT02691403|Drug|levo-bupivacaine|
75612087|NCT02691403|Drug|normal saline|
75612088|NCT02685319|Procedure|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
75612089|NCT04184713|Dietary Supplement|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.
75612090|NCT04184713|Dietary Supplement|Control Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
75761540|NCT01074801|Other|Standard insulin pump treatment|Subcutaneous insulin delivery to be performed based on subjects' standard treatment
75761541|NCT01074879|Dietary Supplement|Whey protein|Dietary supplement after training
75761542|NCT01074879|Dietary Supplement|Milk protein|Dietary supplement after training
75761543|NCT01074879|Dietary Supplement|Carbohydrates|Dietary supplement after training
75905759|NCT02237859|Dietary Supplement|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
75905760|NCT02166138|Procedure|Non-Abilative Laser treatment|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
75612091|NCT00995007|Drug|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
75612092|NCT00995007|Drug|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
75612093|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
75612094|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
75612095|NCT02685475|Drug|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
75612096|NCT00909883|Drug|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
75612097|NCT00909883|Drug|Placebo|Placebo injection
75612098|NCT00639925|Biological|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
75612099|NCT00994461|Drug|Celecoxib|Celecoxib 100mg tablet twice a day with meal for 2 weeks
75612100|NCT00994461|Drug|Loxoprofen|Loxoprofen 60mg tablet three times a day with meal for 2 weeks
75612101|NCT00994461|Drug|Placebo|Placebo tablet three times a day with meal for 2 weeks
75459465|NCT01820351|Other|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
75459466|NCT01820377|Behavioral|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
75612102|NCT02685553|Device|NIR|Laparoscopic use of NIR
75612103|NCT04185961|Device|EVERA-RAPHA with 60mmHG|Apply EVERA-RAPHA with 60mmHG for 4weeks
75612104|NCT04185961|Device|EVERA-RAPHA with 100mmHG|Apply EVERA-RAPHA with 100mmHG for 4weeks
75612105|NCT00993915|Drug|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
75761544|NCT03972423|Other|With or wiyhout a checklist|The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice
75905761|NCT03594825|Drug|Valsartan|Different time of taking medicine
75905762|NCT05635396|Device|Wearable, non invasive sensor for seizure detection|The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
75459467|NCT01820403|Other|portion size kcal of box lunch|
75459468|NCT01820442|Drug|Lofexidine HCl|Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
75459469|NCT01820442|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
75612106|NCT04174911|Drug|BOL-DP-o-08|BOL-DP-o-08 sublingual drops
75612107|NCT04174911|Drug|Placebo|sublingual drops
75612108|NCT01202591|Drug|AZD4547|Tablet oral twice daily
75612109|NCT01202591|Drug|Exemestane|Tablet oral once daily
75612110|NCT01202591|Drug|Placebo|Tablet oral twice daily
75612111|NCT01202591|Drug|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
75612112|NCT00639067|Device|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
75612113|NCT02687503|Dietary Supplement|Probiotic|All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
75761545|NCT00226941|Drug|Cetuximab|Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
75761546|NCT00226941|Drug|Oxaliplatin|Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
75761547|NCT00226941|Drug|Capecitabine|Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
75761548|NCT00226941|Radiation|Radiotherapy|"Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)"
75905763|NCT02162550|Drug|Bydureon|once weekly injection
75459470|NCT01820455|Drug|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
75459471|NCT01820455|Drug|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
75612114|NCT01202279|Drug|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
75761549|NCT00226941|Drug|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
75761550|NCT01074957|Device|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
75761551|NCT01074957|Device|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
75761552|NCT01074957|Other|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
75761553|NCT01075503|Procedure|brachial plexus block|0.5% Ropivacaine 40ml
75761554|NCT02531763|Behavioral|Social incentive intervention|Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
75905764|NCT02162550|Drug|placebo|once weekly injection
76069855|NCT04254159|Other|Aerobic Exercise Training|Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
76069856|NCT03595371|Drug|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
75459472|NCT01820468|Behavioral|Adapted critical time intervention team|
75459473|NCT01820481|Drug|WIN-901X dose level 1|100mg Bid, PO, 12weeks
75459474|NCT01820481|Drug|WIN-901X dose level 2|200mg Bid, PO, 12weeks
75459475|NCT01820481|Drug|WIN-901X dose level 3|300mg Bid, PO, 12weeks
75459476|NCT01820481|Drug|Placebo|Bid, PO, 12weeks
75459477|NCT01820494|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
75459478|NCT01820507|Device|Optiflow (Fisher&Paykel)|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
75459479|NCT01820507|Device|Nasal cannulae or controlled oxygen concentration mask|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
75459480|NCT01820520|Drug|brilliant blue G|Double staining with brilliant blue G 0.025% for macular surgery
75612115|NCT01202279|Device|Placebo|Placebo bid for 7 days
75612116|NCT03877315|Device|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
75612117|NCT03877315|Device|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
75612118|NCT02687347|Drug|oral methadone|Oral methadone is the study drug
75612119|NCT02687347|Drug|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
75761555|NCT01075581|Drug|Epinephrin (Intranasal injection)|A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
76069857|NCT03978585|Device|high tone external muscle stimulation|Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
75612120|NCT01201967|Other|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
75612121|NCT01201967|Other|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
75612122|NCT02687425|Drug|Pioglitazone|15mg/day,po
75612123|NCT02687425|Drug|imatinib mesylate|400mg/day,po
75612124|NCT02537665|Other|heating precondition|
75612125|NCT02687269|Drug|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
75612126|NCT02687269|Drug|Placebo|Patients receive Placebo twice daily in the three days before surgery
75612127|NCT02689297|Other|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
75612128|NCT02689297|Other|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
75612129|NCT04186741|Drug|Hyperbaric oxygen|Patients already on treatment by hyperbaric oxygen therapy for medical conditions requiring treatment by it
75761556|NCT01075581|Drug|Epinephrin (Topical administration)|An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
75761557|NCT00356408|Biological|Certolizumab pegol|"Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).~Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2."
76069858|NCT03978585|Device|transcutaneous electrical nerve stimulation (TENS) therapy|Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
75459481|NCT01820533|Other|Cell Phone Survey|Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
75459482|NCT01820598|Device|Multisite NMES training during 6 weeks|
75459483|NCT01820611|Device|Arcos Revision Stem System|Revision Hip System
75459484|NCT01820624|Drug|tretinoin|Given PO
75459485|NCT01820624|Drug|lithium carbonate|Given PO
75459486|NCT01820624|Other|laboratory biomarker analysis|Correlative studies
75459487|NCT01820663|Other|Modified Atkins Diet|A high fat, high protein, low- carbohydrate diet
75612130|NCT04185805|Drug|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
75612131|NCT04185805|Drug|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
75612132|NCT03758755|Device|Blood Flow Restriction Therapy|A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
75612133|NCT03758755|Other|ACL Reconstruction rehabilitation|post-operative rehabilitation according to current standards of care
75612134|NCT01201811|Drug|Azacitidine|Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
75761558|NCT00509795|Biological|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
75459488|NCT01820663|Other|Control diet|The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
75459489|NCT01820689|Other|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
75761559|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
75761560|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
75761561|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
75761562|NCT05407649|Radiation|Radiotherapy Combined with GM-CSF|Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
75612135|NCT04186897|Procedure|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
75761563|NCT00165789|Drug|E2007|
75459490|NCT01820702|Other|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at ~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against ~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
76069859|NCT02079987|Behavioral|ED-to-home care transition intervention|The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.
75459491|NCT01820715|Drug|600㎍ of DA-3030 Injection|
75612136|NCT04186897|Procedure|Sham occlusal reduction|The occlusal surface left intact. No actual occlusal reduction.
75761564|NCT01564121|Drug|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
75761565|NCT03968367|Procedure|Magnetic activated sperm sorting|MACS is a technique which allows the spermatozoa with the best characteristics to be selected for use in assisted reproduction treatments. This technique removes apoptotic spermatozoa - those which will die without achieving fertilisation - and selects the healthy ones, thus increasing the possibility of pregnancy.
75761566|NCT00504257|Drug|Avastin|Day 1, every 21 day cycle
75612137|NCT05400785|Other|Circadian Rhythms for Mood (CRM) application - Active|The study subjects participating in this clinical trial wear wearable activity tracker 24 hours a day for a continuous period of time and run the CRM app once a day to check their conditions (feelings, vitality, sleep, etc.) in the Daily Symptom Assessment (eMoodChart). The active intervention group are provided with mood prediction results and instructions as feedback through the 'life report' and push notification in the application.
75761567|NCT00504257|Drug|Docetaxel|Day 1, 8, every 21 day cycle
75459492|NCT01820715|Drug|Placebo|
75761568|NCT03997955|Other|Myofascial induction|Myofascial induction in plantar fascia
75761569|NCT03997955|Other|Sham myofascial induction|Sham myofascial induction in plantar fascia
75761570|NCT05407181|Other|Blood and Liver Function test|Data was collected through routine blood and liver function tests using a hematology analyzer and ELISA, respectively.
75761571|NCT00509093|Drug|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
76069860|NCT02079987|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
76069861|NCT03996135|Device|Cannulation with AccuVein AV400|Cannulation using AccuVein AV400 device
75459493|NCT01820728|Drug|DA-3801 Injection|
75761572|NCT00509093|Genetic|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
75761573|NCT00509093|Genetic|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
75761574|NCT00509093|Genetic|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
75761575|NCT00509093|Other|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
76069862|NCT03995511|Procedure|Bilateral Sagittal Split Osteotomy|Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
75459494|NCT01820728|Drug|Gonal-F®|
75761576|NCT00509093|Procedure|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
75761577|NCT05407103|Other|Cold Acupressure|For the cold acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the cold acupressure pouches were kept in a freezer for 40 minutes.
75905765|NCT05635318|Device|FDA approved medications for ADHD plus Quantitative EEG Neurofeedback|A mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG.NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training.
75905766|NCT05635318|Drug|FDA approved medications for ADHD|Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)
75905767|NCT03602937|Dietary Supplement|Renastep|Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.
75905768|NCT02162628|Device|Exair Prolapse Repair System|
75905769|NCT02162628|Procedure|Total Native Tissue Repair|
76069863|NCT03595137|Device|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
76069864|NCT03595137|Device|Sono only|In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
75459495|NCT01820767|Drug|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
75459496|NCT01820767|Drug|Paricalcitol, atorvastatin|"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."
75459497|NCT01820767|Drug|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
75459498|NCT01820780|Other|Natriuretic peptides levels to J7 and J14|
75459499|NCT01820780|Other|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
75459500|NCT01820780|Other|Phone calls in 6 months and 12 months|
75459501|NCT01820780|Other|Natriuretic peptides levels at 6 months|
76072480|NCT04145739|Other|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
75761578|NCT05407103|Other|Warm Acupressure|For the warm acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the warm acupressure pouches were heated in a microwave at 600 W for one minute.
75459502|NCT01820780|Other|Consultation with the general doctor or the cardiologist to J30 with blood results|
75761579|NCT05406869|Device|Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic Generater|Deliver Pulsed Sonic Balloon Dilatation Catheter to the target vessel prior to placing a coronary stent or others
75761580|NCT00160641|Biological|Certolizumab Pegol|"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
75761581|NCT04544501|Behavioral|Culturally-Targeted Video|"Culturally targeted narrative video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. With R03 funding (R03CA191543) we developed a culturally targeted narrative video for at-risk Latinas. A multidisciplinary team of researchers collaborated with filmmakers to develop the script and video. The script was informed by health behavior conceptual models, evidence-based risk communication strategies, and formative research (40 interviews with providers and at-risk Latinas). The script addressed identified knowledge gaps (e.g., incorrect belief that pap smears screen for ovarian cancer), facilitators (e.g., inform family cancer risk), barriers (e.g., emotional concerns), and cultural factors (e.g., respect). The 18-minute video illustrates the GCRA process with the story of Rosa, a Latina cancer survivor at increased risk of HBOC. Rosa learns about HBOC risk factors, overcomes barriers, and attends genetic counseling."
75761582|NCT04544501|Other|FORCE Fact Sheet|A publically available Spanish-language fact sheet about HBOC and GCRA developed by FORCE.
75761583|NCT03997331|Other|CRx Health|CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).
75905770|NCT05306860|Other|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
75905771|NCT02162706|Other|Non intervention study|
75905772|NCT02852265|Drug|Etonogestrel contraceptive implant|Place nexplanon
75905773|NCT02162784|Drug|Budesonide/Procaterol, 180/10mcg X1|one puff
75905774|NCT02162784|Drug|Budesonide/procaterol 180/10 mcg X 2|2 puffs
75905775|NCT02162784|Drug|Albuterol HFA MDI 100mcg X2|HFA MDI, 100mcg, 2 puffs
75459503|NCT01820793|Drug|Cefoxitin|proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
75459504|NCT01820806|Drug|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
75459505|NCT01820832|Drug|Calcitriol|Calcitriol 0.5 ug/BIW for 24 weeks.
75459506|NCT01820871|Other|Self-Management Using Smartphone Application for Type2 DM|
75459507|NCT01820871|Other|self-management using booklet for management type 2 DM|
75459508|NCT01820897|Drug|Fosfomycin-Trometamol|
75459509|NCT01820897|Drug|Sulfamethoxazole trimethoprim|
75612138|NCT05400785|Other|Circadian Rhythms for Mood (CRM) application - Sham|The study subjects assigned to the sham intervention group are provided with feedbacks operated by dummy algorithm. The application is visually indistinguishable from active CRM, and it is designed to minimize behavioral change.
75612139|NCT05392127|Drug|SHR0302 Tablets|SHR0302 Tablets once daily
75459510|NCT01820923|Device|Transcranial direct current stimulation (tDCS)|2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
75612140|NCT05392127|Drug|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
75612141|NCT05392127|Drug|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
75612142|NCT05392127|Drug|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
75612143|NCT05392127|Drug|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
75612144|NCT05392127|Drug|Repaglinide Tablets|Repaglinide Tablets single dose
75612145|NCT05378399|Drug|Descovy or Truvada|Descovy or Truvada prescribed with digital pills for PrEP
75612146|NCT05378399|Device|ID-Cap System|Digital pills overencapsulating Descovy or Truvada for PrEP
75612147|NCT05378399|Device|Beiwe|Digital phenotyping app
75761584|NCT03997331|Other|Chronicare|Chronicare is a disease management program comprising self-management data from the CRx Health solution syncing to an automated support system (Intervention Engine) and a remote care application (CRx Care) used by a team of clinicians to remotely monitor and support patients.
75459511|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
75761585|NCT00493025|Drug|cisplatin|Cisplatin IV
75761586|NCT00493025|Drug|gefitinib|Gefitinib IV
75761587|NCT00493025|Drug|paclitaxel|Paclitaxel IV
75761588|NCT00493025|Procedure|adjuvant therapy|Postoperative ZD1839
75761589|NCT00493025|Radiation|radiation therapy|Radiotherapy
76072481|NCT04145661|Device|Hearing aids programmed conventionally.|All participants will wear their hearing aids programmed in this way for around six weeks.
75761590|NCT01075113|Drug|sorafenib tosylate|Given orally
75761591|NCT01075113|Drug|vorinostat|Given orally
75612148|NCT02687113|Device|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
75761592|NCT03972267|Procedure|Free gingival graft|Free Gingival Graft removal from the palate donor area for socket preservation
75761593|NCT03972267|Device|Enamel Matrix Derivate|EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
75761594|NCT01073319|Other|Placebo|Administration of placebo pill
75761595|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
75761596|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
75761597|NCT01073397|Behavioral|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
75761598|NCT00160563|Drug|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
75459512|NCT01820923|Device|Transcranial Direct Current Stimulation (SHAM)|The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
75612149|NCT02685163|Other|Antioxidant ice-cream|Narutal Antioxidant ice-cream
75612150|NCT02685163|Other|Control Ice-cream|Natural Control Ice-cream
75761599|NCT00160563|Other|Placebo|Oral drops, bid for 18 months
75761600|NCT00380744|Drug|LY2189102|
75761601|NCT00380744|Drug|placebo|
75761602|NCT01050452|Drug|albendazole|albendazole (400 mg on dose)
75761603|NCT01050452|Drug|mebendazole|mebendazole (500 mg one dose)
75761604|NCT01050452|Drug|ivermectin|ivermectin (200 microgram/kg body weight)
75612151|NCT00638599|Device|LMA®|LMA® is placed after anesthesia induction and removed after the operation
75612152|NCT00638599|Device|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
75761605|NCT01050452|Drug|albendazole + ivermectin|albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
75761606|NCT01050452|Drug|mebendazole + ivermectin|mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
76072482|NCT04145661|Device|Hearing aids programmed with compression activated.|All participants will wear their hearing aids programmed in this way for around six weeks.
76072483|NCT03923673|Procedure|Pericardiotomy|The minimally invasive procedure that creates a small opening in the sac that surrounds the heart.
75459513|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (SHAM)|The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
75459514|NCT01820936|Drug|Sequence 1: PCI-32765|Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
75459515|NCT01820936|Drug|Sequence 2: PCI-32765|Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
75459516|NCT01820936|Drug|Sequence 3: PCI-32765|Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
75761607|NCT00380588|Drug|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
75761608|NCT00380588|Drug|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
75761609|NCT00379808|Drug|montelukast|10 mg tablet (masked by capsule) daily for 1 month
75761610|NCT00379808|Drug|Placebo|1 lactose-containing capsule daily for 1 month
75761611|NCT03990038|Drug|Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h|Group C receive the intervention Group U receives the placebo See arm description
75761612|NCT03990038|Drug|Extended Release Capsule|"Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description"
75761613|NCT01053494|Procedure|massage therapy|Undergo massage therapy
75761614|NCT01053494|Other|questionnaire administration|Ancillary studies
75761615|NCT01053494|Procedure|quality-of-life assessment|Ancillary studies
75761616|NCT01053494|Other|intervention by caregiver|Undergo massage by caregiver
75761617|NCT01053494|Procedure|standard follow-up care|Undergo standard follow-up care
75761618|NCT00355784|Other|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
75761619|NCT00355784|Drug|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
75459517|NCT01820936|Drug|Sequence 4: PCI-32765|Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
75612153|NCT00640003|Drug|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
75761620|NCT01053572|Procedure|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
75761621|NCT02534636|Drug|BMS-986165|
76069865|NCT03594903|Behavioral|video intervention (therapy expectation violation)|The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).
76069866|NCT03594903|Behavioral|video intervention (symptoms+ expectation)|Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
76069867|NCT05633589|Biological|Sc610 cell injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell product preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and amplification factor, and cell quantity are amplified. The obtained Sc610 is used for one-time intravenous infusion."
76069868|NCT01828021|Biological|Margetuximab|Anti-HER2 monoclonal antibody
76069869|NCT03594669|Other|Intervention|Multi-modal sensorimotor training interventions, including vestibular, oculomotor, neuromotor, and postural control/ balance exercises.
76069870|NCT03994653|Other|Risk Factor Questionnaire|For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.
75612154|NCT00640003|Drug|Placebo|placebo drug
75612155|NCT01201343|Drug|Interferon beta-1a|
75612156|NCT04185727|Other|Supervised strength training|12 weeks supervised strength training exposure. The study will allocate patients to groups consisting of 4 members who receive strength training for 12 weeks. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session.
75612157|NCT04185649|Biological|BAT8001 for injection|3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
75612158|NCT04185649|Drug|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
76069871|NCT03994653|Other|Clinical Questionnaire|For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.
75459518|NCT01820936|Drug|Sequence 5: PCI-32765|After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
75459519|NCT01820962|Procedure|heparin|when not in use CVCs are locked with heparin
75612159|NCT04185649|Drug|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
75612160|NCT01201265|Drug|Bevacizumab|15 mg/kg iv every 3 weeks
75612161|NCT01201265|Drug|Carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
75761622|NCT02534636|Drug|Interferon alpha-2a recombinant|
75761623|NCT02534636|Drug|Famotidine|
75761624|NCT02534636|Other|Placebo|
75459520|NCT01820962|Procedure|concentrated citrate|when not in use the CVC is locked with concentrated citrate
75459521|NCT01820975|Dietary Supplement|High protein intake|
75459522|NCT01820975|Other|Placebo comparator|No protein intake
75459523|NCT01821001|Drug|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
75459524|NCT01821014|Other|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
75459525|NCT01821014|Other|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
75761625|NCT01053650|Drug|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
75761626|NCT03990740|Procedure|Corneal sampling|Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.
75761627|NCT01053728|Drug|SAR161271|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
75905776|NCT03602703|Diagnostic Test|Flow cytometry and Western Blot analysis|Diagnostic tests
75761628|NCT01053728|Drug|Insulin glargine HOE901|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
76069872|NCT05633199|Other|cytoreductive surgery|Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
75761629|NCT01050608|Device|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
75761630|NCT01050608|Drug|62% ethanol based hand cleanser|"CDC based guidelines with regard to utilization in the health care environment the nest"
75761631|NCT01050608|Behavioral|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
75761632|NCT01050608|Behavioral|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
75761633|NCT01053806|Drug|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
75761634|NCT00355472|Drug|KW-0761|IV administration at 4 escalating dose levels.
75761635|NCT01053884|Drug|Anidulafungin|"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC > 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."
75905777|NCT02166294|Other|NEOX® CORD 1K|Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
75905778|NCT02166294|Procedure|Standard of Care (Pressure Bandage)|Standard of Care wound, pressure dressing applied as needed at each visit.
76069873|NCT03594279|Behavioral|Community Mobilization|Community Mobilization
76069874|NCT03594279|Behavioral|Community Mobilization and Community Incentive|Community Mobilization and Community Incentive
76069875|NCT03784599|Drug|Trastuzumab emtansine|Infusion
76069876|NCT03784599|Drug|Osimertinib|Tablet
76069877|NCT01827943|Drug|Temsirolimus|Temsirolimus
75612162|NCT01201265|Drug|Gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
75612163|NCT02688673|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
75612164|NCT00624533|Behavioral|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
75612165|NCT00624533|Behavioral|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
75612166|NCT04246801|Drug|Clobetasol propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
75612167|NCT04246801|Drug|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
75761636|NCT03282266|Procedure|PADN|PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
75905779|NCT03600753|Other|culturomic|Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
75905780|NCT03600753|Other|Metagenomic|Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
75905781|NCT02166372|Other|Observation of natural course of Diabetes Mellitus Type 2|
75905782|NCT03600675|Other|No intervention element, observational study.|No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.
75905783|NCT03539718|Drug|Taurolidine heparin|Taurolock-hep 500 at end of session
75905784|NCT03539718|Drug|Heparin Sodium|Heparin sodium 5000 at end of session
75905785|NCT02166450|Drug|Nystatin|100 000 IU every 6 h as a suspension
75905786|NCT03600519|Device|NOTAL OCT V2.5|AMD Patients
76069878|NCT03594201|Other|semen pretreatment|semen pretreatment
76069879|NCT02985255|Drug|Docetaxel|Neoadjuvant Arm
75612168|NCT02686567|Procedure|with TDT|After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
75612169|NCT02686567|Procedure|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
75612170|NCT01200797|Drug|SJG-136|Given IV
76069880|NCT02985255|Drug|Cisplatin|Neoadjuvant Arm
75905787|NCT03540498|Dietary Supplement|AB-DENTALAC [Probiotics (study)]|Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
76069881|NCT02985255|Drug|5FU|Neoadjuvant Arm
75459526|NCT01821027|Drug|Simvastatin|One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
75612171|NCT01200797|Other|laboratory biomarker analysis|Correlative studies
75612172|NCT00638677|Dietary Supplement|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
75761637|NCT03282266|Procedure|Sham operation|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
75612173|NCT00638677|Dietary Supplement|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
75761638|NCT01050686|Procedure|insertion of subcutaneous wound drain|after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
75761639|NCT01050686|Procedure|no insertion of subcutaneous wound drain|closure of abdominal wall and skin without insertion of subcutaneous wound drain
75905788|NCT03540498|Dietary Supplement|Placebo (control)|Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
75612174|NCT00638677|Dietary Supplement|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
75612175|NCT02686723|Other|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
75612176|NCT01200485|Drug|Rasburicase|"Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2."
75612177|NCT01200485|Drug|Allopurinol|Arm B: 300 mg/day by vein, as standard of care, over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
75612178|NCT02688907|Drug|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first & second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
75761640|NCT03991754|Procedure|transcatheter aortic valve implantation|transcatheter aortic valve implantation
75459527|NCT01821027|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
75761641|NCT00492557|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
75761642|NCT00492557|Biological|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
75761643|NCT00508391|Device|Optimized interventricular delay biventricular pacing|Lumax HF-T with optimized interventricular delay biventricular pacing
75905789|NCT03600363|Drug|Metformin|metformin (1.0g, bid) as a maintenance therapy in patients with complete remission
75905790|NCT03600363|Drug|Placebos|oral placebos as a maintenance therapy
76069882|NCT02985255|Radiation|Radiotherapy|Neoadjuvant Arm
76069883|NCT02985255|Procedure|Glossectomy|Neoadjuvant Arm
76069884|NCT04609813|Diagnostic Test|Sponge cytological test|Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device. A prediction model will be built based on digital cytopathological features of participants.
75459528|NCT01821040|Drug|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
75459529|NCT01821040|Drug|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
75459530|NCT01821066|Drug|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
75459531|NCT01821066|Drug|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
75459532|NCT01821066|Drug|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
75761644|NCT01010711|Dietary Supplement|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
75761645|NCT01015157|Procedure|Roux-en-Y laparoscopic gastric bypass for morbid obesity|Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
75761646|NCT01010789|Drug|Armodafinil|flexible dose 150-250mg/day
75761647|NCT01010789|Drug|Armodafinil|150-250mg/day; flexible dose
75761648|NCT01010789|Drug|Matching placebo|Placebo comparator
75761649|NCT01015235|Drug|Placebo|Subcutaneous infusion-once over 4 hours
76069885|NCT03593967|Behavioral|ARTISAN|"In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~Week 1: Food and Play as our National Heritage~Week 2: Our Voices, Our Singapore: Strengthening Bonds~Week 3: Overcoming Adversities: Stories of Resilience~Week 4: Beholding the Future: Dreams and Aspirations~Week 5: Passing It On: The Stories We Share"
75612179|NCT02686645|Biological|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
75612180|NCT02686645|Drug|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
75761650|NCT01015235|Drug|KAI-1678|Subcutaneous infusion-once over 4 hours
75761651|NCT01015235|Drug|Ketorolac Tromethamine|Active comparator, IV infusion, once
75761652|NCT00508157|Drug|Aripiprazole|Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
75761653|NCT00508157|Drug|Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)|Tablets, Oral, According to summary of product characteristics (SmPC)
75761654|NCT04331717|Device|Bead Block 300-500 um|These patients will undergo embolization with 300-500µm Bead Block particles.
75761655|NCT04331717|Behavioral|Weight Management|All participants will be enrolled in weight management through the Johns Hopkins Weight Management Center. During weeks -4 through 0, participants will be required to go to weekly visits. Weight management will include counseling on diet, exercise and behavior change. Food programs, pharmacotherapy and other procedures will not be utilized.
75761656|NCT04331717|Drug|Lupron|22.5 mg will be given as a single intramuscular or subcutaneous injection once every 12 weeks according to the standard of care for prostate cancer. If leuprolide acetate, 22.5 mg for 3-month administration is not available, a suitable substitute may be allowed upon approval by the principle investigator
75761657|NCT01015313|Other|intensive sodium management|"dietary sodium restriction~avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms"
75761658|NCT00378560|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
75761659|NCT00378560|Biological|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
75761660|NCT00508001|Drug|Vandetanib|ZD6474 300mg
75761661|NCT00508001|Drug|Vandetanib|ZD6474 100 mg
75761662|NCT00508001|Drug|Best Supportive Care|Placebo + Best Supportive Care
75761663|NCT01015391|Drug|T2|1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
75761664|NCT01015391|Drug|Azathioprine|2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
76069886|NCT05632887|Other|no intervention|no intervention
75459533|NCT01821066|Drug|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
75459534|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
75612181|NCT02686645|Drug|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
75612182|NCT02686645|Drug|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
75459535|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
75459536|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
75612183|NCT04318067|Drug|Melatonin 3 mg|Melatonin 3 mg is given ones a day - at bedtimes for 6 month
75459537|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
75459538|NCT01821092|Procedure|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
75459539|NCT01821092|Device|osseointegrated implant|Osseointegrated Implant Insertion
75612184|NCT04185181|Other|virtual reality|wii video game based exercise
75612185|NCT04185181|Other|proprioceptive neuromuscular facilitation|PNF with breathing
75612186|NCT04185181|Other|complete decogestive therapy|pneumatic compression, manual lymph drainage, skin care and home exercise program
75761665|NCT04544033|Diagnostic Test|interleuken 6 level measurment|Detection of IL6 level using ELISA technique.
75761666|NCT04544033|Diagnostic Test|Interleukin-6 Gene-174C detection|The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
75761667|NCT01015469|Procedure|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
75761668|NCT01015469|Procedure|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
75761669|NCT01010945|Drug|erlotinib|administered orally
75761670|NCT01010945|Drug|gemcitabine|administered intravenously
75761671|NCT01010945|Drug|nab-paclitaxel|administered intravenously
75761672|NCT01011023|Other|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
75761673|NCT00507689|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
75761674|NCT00507689|Drug|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
75761675|NCT00491387|Drug|Metoprolol Succinate|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
75761676|NCT04539899|Other|VR+|Use of a virtual reality helmet during IUD insertion
75761677|NCT01011257|Drug|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
75905791|NCT02162940|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
75612187|NCT01200407|Drug|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
75612188|NCT04186975|Device|Non-Invasive fetal ECG|Non-Invasive fetal ECG
75612189|NCT04186975|Device|Fetal heart rate monitor|Fetal heart rate monitor
75905792|NCT02162940|Other|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
75905793|NCT03600285|Device|TB1-K|Use of TB1-K for preservation and transport of donated kidneys
75905794|NCT03540888|Other|Deep transverse Friction Massage|The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur
76069887|NCT05632731|Procedure|double cleavage-stage or single blastocyst stage embryos transfer|Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
76069888|NCT03596541|Device|Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)|We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
75612190|NCT02685085|Drug|Misoprostol ( Prostaglandin E2)|
76069889|NCT00214851|Drug|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
75612191|NCT02685085|Device|Foley's catheter|
75612192|NCT02688595|Device|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
75612193|NCT02688595|Other|General anesthesia|Scheduled operation under general anesthesia
75612194|NCT01200329|Drug|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
75612195|NCT01200329|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5."
75612196|NCT01200329|Drug|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
75612197|NCT01200329|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
75612198|NCT01200329|Drug|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
75612199|NCT04185493|Diagnostic Test|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis with the use of CT imaging post-processing techniques.
75612200|NCT04186273|Drug|Fibrosis-Inhibiting-Compound-FS2|There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
75612201|NCT04186273|Other|Vehicle moisture balancing base|Vehicle base without FS2.
75612202|NCT01199939|Drug|Etravirine|400mg once daily orally for 48 weeks
75612203|NCT01199939|Drug|Ritonavir|100mg once daily orally for 48 weeks
75612204|NCT01199939|Drug|Darunavir|800mg once daily orally for 48 weeks
75761678|NCT01011257|Drug|Clopidogrel|clopidogrel 75 mg bid
75761679|NCT01011491|Other|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 & 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
75761680|NCT01011491|Other|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 & 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
75905795|NCT03540888|Other|Dynamic stretching intervention|Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
75905796|NCT03540888|Other|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
75905797|NCT03600207|Other|Complex training|The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.
75905798|NCT03600207|Other|Diaphragm training|The training program contains strengthening exercises on the diaphragm muscle.
76069890|NCT00212121|Radiation|high dose boost|high dose boost
76069891|NCT00212121|Procedure|boost|low dose versus high dose
76069892|NCT00217971|Drug|Dronabinol|Dronabinol
76069893|NCT00217971|Drug|Placebo|placebo
76069894|NCT03593421|Drug|synthetic PreImplantation Factor|peptide
75761681|NCT01015547|Drug|Infliximab plus methotrexate|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
75761682|NCT01015547|Drug|Combination of DMARDs|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
75761683|NCT01015547|Drug|Methotrexate alone|Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
75761684|NCT00491075|Drug|Pemetrexed|500 mg/m^2 IV Over 10 Minutes on Day 1.
75761685|NCT00491075|Drug|Gemcitabine|1500 mg/m^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
75761686|NCT04302623|Behavioral|Yoga|Upa Yoga program consisting of physical postures, breathing techniques, chanting, and meditation.
75905799|NCT04731246|Other|Video-oculography / Neuropsychological evaluations|Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.
75905800|NCT03600129|Procedure|Qadratus Lumborum Block|Bilateral, ultrasound - guided Quadratus Lumborum Block
75905801|NCT03600129|Drug|30 milliliters of 0.375% Ropivacaine|30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block
75905802|NCT03600129|Drug|30 milliliters of 0.9% NaCl|30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
75905803|NCT02169570|Dietary Supplement|Vitamin D|
75905804|NCT02169570|Dietary Supplement|Calcium|
75612205|NCT02688439|Other|Sciatic Nerve block|
75905805|NCT02169570|Dietary Supplement|Placebo Vit D|
75905806|NCT02169570|Dietary Supplement|Placebo Calcium|
75612206|NCT02688439|Other|Leg raised 30°|
75612207|NCT02688439|Other|Distal tourniquet placed on the lower part of the leg|
75612208|NCT02688439|Other|Leg in a neutral position|
75459540|NCT01821157|Procedure|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
75459541|NCT01821157|Procedure|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
75459542|NCT01821170|Drug|Methylphenidate|Patient will take treatment during two months
75459543|NCT01821170|Device|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
75905807|NCT03600051|Device|Automated Heart Murmur Detection AI|"Automated AI algorithm-based analysis of digital heart sound recordings to detect pathological heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. Algorithm results for each recording included: AHA classification (I pathologic versus III innocent/no murmur), murmur timing, murmur grade, heart rate and S1/S2 identification."
75459544|NCT01821170|Behavioral|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
75459545|NCT01821170|Other|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
75612209|NCT02688361|Drug|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
75612210|NCT02688361|Drug|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
75612211|NCT02686489|Other|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher & Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
75612212|NCT02686489|Other|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
75612213|NCT01199861|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
75612214|NCT01199861|Drug|Placebo|Matching placebo capsules for oral administration.
75612215|NCT01199861|Biological|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
75612216|NCT01199861|Biological|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
75612217|NCT03196219|Drug|C16G2|C16G2
75612218|NCT03196219|Drug|Placebo|Varnish Placebo
75612219|NCT02684929|Dietary Supplement|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
75612220|NCT05398211|Behavioral|Preferred Recorded Music (PRM)|Preferred Recorded Music (PRM) involves a credentialed music therapist in planning and administering, which qualifies it as music therapy, which is defined as a professional use of music and its elements to improve physical, social, communicative, emotional, intellectual, and spiritual health, optimize quality of life and wellbeing(Aigen, 2013; Bruscia, 2014). PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. During the PRM intervention the MT will start/stop the music and otherwise not engage with the participants during the listening session.
75612221|NCT05398211|Behavioral|Preferred Live Music (PLM)|Preferred Live Music (PLM) involves a credentialed music therapist in planning and administering which qualifies it as music therapy, which is defined as professional use of music and its elements to improve physical, social, communicative, emotional, intellectual and spiritual health, optimize quality of life and wellbeing (Aigen, 2013; Bruscia, 2014).PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. The MT will be more actively engaged in a musical interaction with the participants in the PLM interventions.
75612222|NCT02684773|Procedure|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
75612223|NCT02684773|Procedure|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
75612224|NCT00640081|Biological|cetuximab|
75612225|NCT00640081|Drug|capecitabine|
75612226|NCT00640081|Drug|fluorouracil|
75612227|NCT00640081|Drug|leucovorin calcium|
75612228|NCT00640081|Drug|oxaliplatin|
75612229|NCT00640081|Other|immunohistochemistry staining method|
75612230|NCT00640081|Other|laboratory biomarker analysis|
75612231|NCT01199705|Biological|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
75612232|NCT02688127|Drug|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
75612233|NCT02686333|Other|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
75612234|NCT02688283|Other|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
75459546|NCT01821196|Procedure|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
75459547|NCT01821209|Procedure|Placement of sling|Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
75612235|NCT04185571|Device|PEPA|
75612236|NCT02686255|Other|complete blood count|complete blood count during follow up in the heart institute
75612237|NCT04185025|Drug|Ceramides|"On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected."
75612238|NCT04295239|Procedure|MRI|Pre and Post operative MRI
75612239|NCT02688205|Other|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
75612240|NCT02688205|Device|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
75612241|NCT04136665|Other|Physical Activity Adapted program|6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
75761687|NCT03998267|Device|Droobi|A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.
75761688|NCT03998267|Other|Standard of care|Standard of care including physicians, dietetics and diabetes educators support
75612242|NCT02684695|Other|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
75612243|NCT02684695|Other|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
75612244|NCT04184947|Drug|SGLT2 inhibitor|New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice
75612245|NCT04184947|Drug|GLP-1 receptor agonist|New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
75761689|NCT00507455|Drug|solifenacin succinate|Solifenacin succinate tablets
75761690|NCT00507455|Drug|tamsulosin hydrochloride|Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
75761691|NCT00507455|Drug|Placebo to solifenacin|
75761692|NCT00507455|Drug|Placebo to tamsulosin|
75905808|NCT03539640|Other|PEEP: 5 cmH2O|During second part of the study (MRI)
75905809|NCT03539640|Other|PEEP: 10 cmH2O|During second part of the study (MRI)
75905810|NCT03539640|Other|PEEP: 15 cmH2O|During second part of the study (MRI)
75905811|NCT03913143|Drug|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
75905812|NCT03913143|Other|Sham|Sham-Procedure (no experimental drug administered)
75905813|NCT02169648|Drug|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
75905814|NCT03594591|Drug|Antidiabetic treatment by usual care|Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
75905815|NCT02170896|Drug|BIBR 1048 MS Capsule A|
76069895|NCT00217581|Biological|Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
76069896|NCT00217581|Drug|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
75612246|NCT04186507|Combination Product|Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)|"To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat."
75612247|NCT02684383|Biological|rDEN3∆30|10^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
75612248|NCT02684383|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
75761693|NCT03997565|Procedure|TKR|No intervention provided, but investigation of the ability to modulate motor performance during specific and functional tasks in subjects undergoing TKR compared with healthy subjects.
75761694|NCT01013363|Other|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
75761695|NCT04275713|Drug|Metformin|Metformin is an oral antidiabetic drug
75761696|NCT04275713|Drug|Cisplatin|Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles
75761697|NCT01011725|Drug|MK 0773|25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
75761698|NCT01011725|Drug|Placebo|Placebo oral tablet b.i.d for 12 weeks
75761699|NCT01011803|Other|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
75905816|NCT02170896|Drug|BIBR 1048 MS Capsule B|
75905817|NCT02170896|Drug|BIBR 1048 MS Capsule C|
75905818|NCT02170896|Drug|BIBR 1048 MS Capsule D|
75905819|NCT02170896|Drug|BIBR 1048 MS tartaric acid solution|
75905820|NCT02170896|Drug|Pantoprazole|
75905821|NCT03594513|Procedure|MCAF|Periodontal surgical technique to treat gingival recessions.
75905822|NCT03594513|Procedure|PR|Restorative procedure to treat tooth structure loss.
75905823|NCT03594513|Procedure|CTG|Autogenous graft harvested from palate placed in the surgical site.
75905824|NCT03594513|Procedure|XMD(Mucoderm®)|Xenogenous graft placed in the surgical site.
75905825|NCT03594513|Drug|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
75905826|NCT03594513|Drug|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
75905827|NCT02633800|Drug|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
75905828|NCT02633800|Drug|Cetuximab|Cetuximab 400 mg/mg/m^2 IV loading dose, followed by 250 mg/m^2 weekly
76069897|NCT00217581|Drug|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
76069898|NCT03991455|Device|Apyx device|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
75612249|NCT04186351|Behavioral|Encounter notification service|The caring support and services provided by SCHSA will consist of multiple components, including standard call & care center support, medical appointment reminder, assistance to reschedule appointment, follow-up calls with either nurse or health workers to monitor health situation of service recipients, assessing needs of service recipient for elderly home care and/or rehabilitation services, providing elderly home care and/or rehabilitation services based on assessment, assessing needs of service recipient for emotional and community support, providing additional emotional support via either social calls by volunteers or counseling by social workers, and making referrals for community support services.
75761700|NCT01013441|Biological|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
75761701|NCT01011881|Other|pleural level of procalcitonin|no intervention
75761702|NCT00506831|Drug|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
75761703|NCT04269551|Drug|BIVV020|Pharmaceutical form:solution for injection Route of administration: intravenous
75761704|NCT03996941|Behavioral|Harm reduction of informal PrEP use|"Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.~Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit."
75761705|NCT03996941|Other|PrEP follow up based on point of care testing|The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.
75761706|NCT01015859|Device|Pacing mode|To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
75761707|NCT00506753|Behavioral|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
75761708|NCT00506753|Behavioral|RT/SU|Relaxation Training followed by Treatment as Usual
75905829|NCT02633800|Drug|Cisplatin|Cisplatin at 100 mg/m^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
75905830|NCT02633800|Drug|Carboplatin|Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
75612250|NCT00638833|Drug|Memantine|Memantine 30 mg/day (20-10-0)
75905831|NCT02633800|Drug|Placebo|Placebo to match patritumab
75612251|NCT00638833|Drug|Placebo|Placebo pills
75612252|NCT01198145|Drug|sulfasalazine|Given orally
75612253|NCT01198145|Other|placebo|Given orally
75761709|NCT00490919|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
75761710|NCT00490919|Drug|Placebo|transdermal system (placebo) worn for 7 days
75761711|NCT01011959|Biological|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
75761712|NCT00503867|Device|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
75905832|NCT02169804|Drug|Androxal 25 mg|
75761713|NCT01015937|Drug|Turmeric extract|turmeric 500 mg TID for 45 days
75761714|NCT01015937|Drug|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
75761715|NCT01012193|Drug|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
75761716|NCT00503399|Drug|Teriparatide|20 µg/day sc for 18 months
75761717|NCT00503399|Drug|Risedronate|35 mg/week po for 18 months
75761718|NCT00506519|Drug|Antithrombin alfa (INN name)|
75761719|NCT00506519|Drug|Control (Standard treatment)|
75761720|NCT00503009|Drug|fluticasone propionate/salmeterol|comparator
75761721|NCT00503009|Drug|fluticasone propionate|Comparator
75761722|NCT00503009|Drug|placebo|Placebo
75761723|NCT01016093|Drug|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
75761724|NCT01016093|Drug|Placebo|Placebo
75761725|NCT01012271|Other|MRI|MR arthrography is used to evaluate wrist abnormalities
75905833|NCT03829657|Drug|ampreloxetine|Oral tablet, QD (Daily)
75905834|NCT03829657|Drug|Placebo|Oral tablet, QD
76069899|NCT03593343|Behavioral|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
75905835|NCT02170974|Drug|BIBR 1048 MS polymorph II|
75905836|NCT02170974|Drug|BIBR 1048 MS polymorph I|
75905837|NCT03539250|Radiation|IMRT|IMRT with and without chemotherapy
75905838|NCT03593733|Other|Photobiomodulation Therapy|Photobiomodulation Therapy
75905839|NCT03593733|Other|Cold Water Immersion|Cold Water Immersion
75761726|NCT00160251|Drug|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
75761727|NCT00160251|Biological|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
75905840|NCT02174718|Dietary Supplement|Transdermal D Patch|
75905841|NCT02174718|Dietary Supplement|Oral vitamin D3|
75905842|NCT02174718|Dietary Supplement|Placebo patch|
75905843|NCT02174718|Dietary Supplement|Oral placebo|
75905844|NCT02238171|Drug|Atrovent® inhalets|
75905845|NCT02174796|Procedure|surgical treatment|patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
75905846|NCT02174796|Procedure|orthopedic treatment|orthopedic treatment by vacuum bell.
75905847|NCT03069586|Procedure|Pulmonary recruitment|At the end of surgery a manual pulmonary recruitment (5 sec, max 40 cmH2O) is given to the patiënt
75905848|NCT03069586|Procedure|No pulmonary recruitment|At the end of surgery no intervention was completed
75905849|NCT02237703|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
75612254|NCT02684539|Device|tilt table Erigo®|tilting table with onset of syncope
75761728|NCT00160251|Drug|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight [weight-based dosing {WBD}])
75761729|NCT01075425|Drug|bortezomib|Given IV
75761730|NCT01075425|Drug|belinostat|Given IV
75761731|NCT01075425|Other|laboratory biomarker analysis|Correlative studies
75612255|NCT02687737|Procedure|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
75612256|NCT02687737|Procedure|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
75612257|NCT02687737|Procedure|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
75761732|NCT01075425|Genetic|western blotting|Correlative studies
75761733|NCT01075425|Other|pharmacological study|Correlative studies
75761734|NCT01075425|Other|flow cytometry|Correlative studies
75761735|NCT00506441|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
75761736|NCT00506441|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
75761737|NCT04190693|Drug|IMCY-0098 or placebo|Long-term follow-up
75761738|NCT00378014|Drug|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
75761739|NCT00378014|Drug|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
75761740|NCT00378014|Drug|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
75761741|NCT00485303|Drug|Abiraterone acetate|Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
75761742|NCT00485303|Drug|Prednisone|Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
75761743|NCT00490841|Device|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
75761744|NCT01018823|Drug|Ertugliflozin|Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
75761745|NCT01018823|Drug|Placebo to Ertugliflozin|Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
75761746|NCT01016249|Drug|Treatment 1. (5% Hypertonic saline + Epinephrine)|Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
75761747|NCT01016249|Drug|Treatment 3. (3% Hypertonic saline + Epinephrine)|Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
75905850|NCT02169882|Drug|Placebo|"Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs."
75612258|NCT02687737|Behavioral|Swallowing Tasks|"These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP."
75612259|NCT02686099|Device|SternaLock 360|Sternal closure with SternaLock 360
75612260|NCT02686099|Device|Wire Cerclage|Sternal closure with standard wire cerclage
75761748|NCT01016249|Drug|Treatment 2. (Normal saline + Epinephrine)|Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
75761749|NCT00377858|Drug|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
75761750|NCT00377858|Drug|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
75761751|NCT00502775|Drug|fluticasone furoate, fexofenadine|
75761752|NCT00502697|Behavioral|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
75761753|NCT00502697|Other|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
75761754|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
75761755|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
75761756|NCT01018901|Other|Survey Administration|Patients complete survey
76069900|NCT03593265|Other|MUNIX|Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
75761757|NCT01054040|Other|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
75761758|NCT01019057|Procedure|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
76069901|NCT01856257|Biological|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
76069902|NCT01856257|Biological|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
76069903|NCT01856257|Drug|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
75761759|NCT01054118|Drug|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
76069904|NCT01856257|Biological|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
76069905|NCT01856257|Drug|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
75761760|NCT01054118|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
75761761|NCT01054118|Drug|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
75761762|NCT01054118|Drug|Placebo|Placebo suspension and placebo capsule administered as single doses
76069906|NCT01856257|Drug|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
75459548|NCT01821222|Device|Wired mothers|"The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider."
75761763|NCT03997253|Other|blood and urine samples|various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12.
75761764|NCT03989726|Procedure|AF ablation|AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
75761765|NCT03989804|Behavioral|Targeted follow-up|2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
75761766|NCT01054274|Device|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
75761767|NCT01054274|Device|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
75905851|NCT02169882|Drug|Rifampicin|"Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section."
76069907|NCT00215943|Drug|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
76069908|NCT00215943|Drug|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
76069909|NCT00215943|Drug|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
76069910|NCT00215943|Drug|vincristine|As outlined in VAD Treatment Arm
75761768|NCT03989648|Other|Esmarch bandages|Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.
75761769|NCT03989648|Other|simple leg elevation|simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
75761770|NCT01050842|Drug|bicalutamide|Given orally
75761771|NCT01050842|Drug|raloxifene|Given orally
75761772|NCT01050842|Procedure|quality-of-life assessment|Ancillary study
75761773|NCT02534246|Device|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) from single lesion.
75761774|NCT02534246|Device|Ultrasound biopsy needle SharkCore|
75761775|NCT00485069|Drug|ROP|Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
75761776|NCT00485069|Drug|ROP+L-Dopa|Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
75905852|NCT02169882|Drug|Other TB drugs|"Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
75905853|NCT02169882|Drug|Adjuvant dexamethasone|Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
75905854|NCT03592173|Diagnostic Test|Paired TMS & Peripheral Nerve Stimulation|Method of assessing neurophysiology and activity of the spinal cord
75905855|NCT03602547|Drug|CM082 plus JS001|CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
75905856|NCT02169960|Behavioral|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
75905857|NCT02169960|Behavioral|Breaking Free|Online based intervention for Drug and Alcohol Use
75612261|NCT02688049|Biological|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
75905858|NCT02169960|Behavioral|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
75905859|NCT02169960|Behavioral|Resiliency Training|Op Volle Kracht (OVK)
75612262|NCT02688049|Biological|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
75612263|NCT02687893|Behavioral|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
75761777|NCT01054352|Drug|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
76069911|NCT00215943|Drug|adriamycin|As outlined in VAD Treatment arm
76069912|NCT03593031|Behavioral|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
75761778|NCT01054352|Drug|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
75761779|NCT01054352|Drug|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
75761780|NCT01054352|Drug|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
76069913|NCT03990207|Device|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
76069914|NCT01827163|Drug|Paclitaxel|
76069915|NCT01827163|Drug|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
75761781|NCT03989336|Drug|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
75612264|NCT02687893|Behavioral|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
75612265|NCT04317677|Other|Study of the effect of bladder voiding on sleep fragmentation during day and night sleep|Vigilance state of babies will be continuously recorded during the first 24 hours of hospitalization by polysomnography and actigraphy. In parallel, bladder voiding episodes will be detected with an innovative device placed on babies diapers.
75612266|NCT01197911|Drug|aleglitazar|single oral dose
75612267|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily
75761782|NCT03989336|Drug|nab-paclitaxel|Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
75761783|NCT03989336|Drug|Platinum chemotherapy|Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve [AUC] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
75761784|NCT03989336|Drug|Sintilimab|Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
75761785|NCT01054430|Drug|avanafil|200 mg avanafil tablets QD
76069916|NCT01827163|Drug|Lapatinib|
76069917|NCT01827163|Drug|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
76069918|NCT00215553|Drug|A.1 Lucinactant|3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
76069919|NCT00215553|Other|B.3 SoC|Standard ARDS management and ICU care
76069920|NCT00215553|Drug|A.2 Lucinactant|3 30 mL aliquots at a concentration of 10 mg/mL each
76069921|NCT00215553|Drug|A.3 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
76069922|NCT00215553|Drug|A.4 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
75612268|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
75612269|NCT01197755|Drug|placebo|Placebo twice daily
75612270|NCT01179048|Drug|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
75612271|NCT01179048|Drug|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
75612272|NCT00603265|Drug|ADL5859|
75612273|NCT00603265|Drug|Duloxetine|
75612274|NCT00603265|Drug|Placebo|
75612275|NCT02686177|Drug|Liraglutide|
75612276|NCT02686177|Drug|Metformin or sulfonylurea|
75612277|NCT04010227|Behavioral|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
75612278|NCT04010227|Behavioral|Education/Support|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
75612279|NCT02885298|Procedure|Upright intubation|Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
75761786|NCT00355082|Drug|lamotrigine, 300 mg/day|300 mg/day
75761787|NCT00355082|Drug|lamotrigine, 250 mg/day|250 mg/day
75761788|NCT00502307|Drug|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
75761789|NCT00502307|Drug|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
75761790|NCT01325012|Procedure|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.
75761791|NCT01325012|Procedure|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
75761792|NCT00484679|Drug|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
75761793|NCT00377312|Drug|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
75761794|NCT00377234|Drug|Risedronate|35mg po weekly for 12 weeks
75761795|NCT00377234|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 months
75761796|NCT00377156|Radiation|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
75761797|NCT00377156|Radiation|stereotactic radiosurgery|
75761798|NCT00376688|Other|Laboratory Biomarker Analysis|Correlative studies
75761799|NCT00376688|Drug|Temsirolimus|Given IV
76069923|NCT00215553|Drug|B.1 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
76069924|NCT00215553|Drug|B.2 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
75612280|NCT00639613|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
75761800|NCT00376220|Drug|Riluzole|Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.
75761801|NCT00376220|Other|Placebo|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
75761802|NCT00375752|Drug|Letrozole|2.5 mg.tablet.
75761803|NCT00375752|Drug|Zolendronic Acid|4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
75905860|NCT04277299|Device|IcorySolution|The ICory-solution programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery. The healthcare professional have received face-to-face training on how to use the BuddyCare dashboard and BuddyCare has been in the hospital in earlier studies.The Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support, games and distraction to children and a virtual tour to the hospital before children´s operation.
75905861|NCT03602469|Drug|Bupivacaine|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline
75905862|NCT03602469|Drug|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)
75905863|NCT03602469|Drug|Propofol|Using propofol 1.5-2.5 mg/kg
75612281|NCT00639613|Other|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
75905864|NCT03602469|Device|Ultrasound|Ultrasound-guided suprascapular nerve block
75612282|NCT02686021|Drug|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
76069925|NCT03592953|Other|Serious game simulation training sessions|"Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios."
75761804|NCT00484289|Drug|Abatacept|Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants > 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
75761805|NCT01013831|Drug|Erlotinib Hydrochloride|Given PO
75905865|NCT03602469|Drug|Sevoflurane|Sevoflurane 0.7-1.5 MAC in 40% oxygen
75905866|NCT03602469|Drug|Rocuronium|Rocuronium 0.6 mg/kg
75905867|NCT02174952|Behavioral|Self-help version of the New Forest Parenting Programme|
76069926|NCT00214461|Biological|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
76069927|NCT00214461|Biological|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
76069928|NCT00214461|Biological|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
76069929|NCT00214461|Biological|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
75905868|NCT02170038|Drug|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
75905869|NCT02170038|Drug|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
75905870|NCT05001373|Biological|Core-g28v2 60mer mRNA Vaccine|100µg, Intramuscularly
75905871|NCT05001373|Biological|eOD-GT8 60mer mRNA Vaccine|100µg, Intramuscularly
76069930|NCT03592875|Behavioral|Professional nurses|The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
75905872|NCT03591939|Diagnostic Test|laboratory test|role of T- regulatory cells in the patients of diabetic nephropathy
75905873|NCT02171052|Drug|Dabigatran etexilate|
76069931|NCT03599583|Behavioral|STOP-HPV prompts intervention|This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
75612283|NCT02686021|Drug|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
75612284|NCT02686021|Drug|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
75612285|NCT02886390|Device|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
75761806|NCT01013831|Other|Laboratory Biomarker Analysis|Correlative studies
75905874|NCT02171052|Drug|Digoxin|
75905875|NCT03675919|Device|Scale|self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
75905876|NCT03675919|Device|Step counter|self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
75905877|NCT03675919|Device|Blood glucose meter with test stripes|self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal
75905878|NCT03675919|Other|Access to the online portal|self-monitoring of health parameters
75905879|NCT03675919|Other|Telemedical coaching|regular telephone calls providing information about T2DM, healthy lifestyle, low-carbohydrate diet and physical activity
75905880|NCT03591549|Drug|Faslodex|intramuscular injection monthly
75905881|NCT03591549|Drug|Zoladex|intramuscular injection monthly
75905882|NCT02261220|Biological|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
75905883|NCT02261220|Biological|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
75612286|NCT02685787|Behavioral|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
75761807|NCT01013831|Other|Pharmacological Study|Correlative studies
75905884|NCT02237937|Drug|Paroxetine|
76069932|NCT04407351|Device|Green LED light|Investigators arrange 12 weeks green LED light phototherapy.
76069933|NCT04407351|Device|Red LED light (placebo)|Investigators arrange 12 weeks red LED light phototherapy (placebo).
75761808|NCT01016327|Drug|NMS-1116354|Oral daily administration for 7 consecutive days every 14 days
75761809|NCT03996629|Other|Patient education and compliance|When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
75761810|NCT01013909|Drug|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
75761811|NCT01013909|Drug|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
75761812|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
75761813|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
75761814|NCT01013909|Drug|Lamisil Once|One application of Lamisil Once
75905885|NCT02237937|Drug|Sertraline|
75905886|NCT02237937|Drug|Citalopram|
75905887|NCT02237937|Drug|Venlafaxine|
75905888|NCT02237937|Drug|Amitriptyline|
75905889|NCT02237937|Drug|Escitalopram|
75905890|NCT02237937|Drug|Amitriptylinoxide|
75905891|NCT02237937|Drug|Nortriptyline|
75905892|NCT02237937|Drug|Trimipramine|
75905893|NCT02238015|Procedure|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
75905894|NCT02170116|Drug|BIBR 1048 MS dose 1|
75905895|NCT02170116|Drug|BIBR 1048 MS dose 2|
75905896|NCT02170116|Drug|BIBR 1048 MS dose 3|
75905897|NCT02170116|Drug|BIBR 1048 MS dose 4|
75905898|NCT02170116|Drug|BIBR 1048 MS dose 5|
75905899|NCT02170116|Drug|Placebo to BIBR 1048 MS|
75905900|NCT03035227|Procedure|Catheter Ablation|Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.
75905901|NCT03035227|Drug|Anti-Arrhythmics|Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
76069934|NCT00214383|Behavioral|CHESS Internet telehealth|CHESS Internet telehealth
76069935|NCT03599973|Other|Plasmalyte A Viaflo|Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
76069936|NCT00212355|Drug|NPC-02|zinc acetate
76069937|NCT03599895|Procedure|3D printing model|Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy
75905902|NCT03591393|Diagnostic Test|questionnaire|"Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire."
75459549|NCT01821235|Drug|Neurontin® (gabapentin) batch A|Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times
75459550|NCT01821235|Drug|Neurontin® (gabapentin) batch B|Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
75612287|NCT02685787|Behavioral|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
75612288|NCT04186039|Diagnostic Test|Functional magnetic resonance imaging - Blood Oxygenation Level Dependent|"First Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence under ambient air.~Oxygenation of 5 minutes at a rate of 12 l / min. Second Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence."
75612289|NCT01158534|Drug|celecoxib|Given orally
75612290|NCT01158534|Biological|recombinant interferon alfa-2b|Given subcutaneously
75612291|NCT01158534|Other|polymerase chain reaction|Correlative studies
75612292|NCT01158534|Other|laboratory biomarker analysis|Correlative studies
75612293|NCT01158534|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
75612294|NCT01158534|Other|immunologic technique|Correlative studies
75612295|NCT01158534|Other|immunohistochemistry staining method|Correlative studies
75612296|NCT01158534|Other|flow cytometry|Correlative studies
75612297|NCT02687971|Drug|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
75761815|NCT03996551|Behavioral|ExeRTiOn online resource|This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
75612298|NCT02685631|Other|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
75612299|NCT02683213|Drug|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
75761816|NCT01013987|Drug|maraviroc|maraviroc: one 150 mg pill twice daily
75761817|NCT01013987|Drug|Raltegravir|raltegravir : one 400 mg pill twice daily
75905903|NCT02170194|Behavioral|Resilience Enhancement Training via Smart Phone|
75459551|NCT01821235|Drug|Gabasandoz® (gabapentin) batch A|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times
75905904|NCT02170194|Behavioral|Daily Text Messages|
75905905|NCT02170272|Behavioral|Home-based Lymphedema Care Program|Undergo HBLCP
75459552|NCT01821235|Drug|Gabasandoz® (gabapentin) batch B|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
75459553|NCT01821248|Drug|Gemcitabine, Cisplatin, S-1|"Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7"
75612300|NCT02683213|Drug|Placebo|Matching placebo.
75612301|NCT04185103|Drug|Sacubitril-Valsartan|After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
75612302|NCT04033939|Drug|HSK3486|
75612303|NCT04033939|Drug|Propofol|
75612304|NCT04033939|Drug|Placebo|
75612305|NCT02685943|Behavioral|Psychotherapy|
75612306|NCT00639691|Biological|omalizumab|sc
75612307|NCT02684149|Procedure|relational touch|
75612308|NCT02684071|Drug|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
75612309|NCT02684071|Drug|topotecan|To be administered in conjunction with methotrexate
75612310|NCT02684071|Drug|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
75612311|NCT01158378|Device|Adherus Dural Sealant|In situ polymerizing sealant
75612312|NCT00640861|Biological|CpG oligodeoxynucleotide|
75612313|NCT00640861|Biological|HER-2/neu peptide vaccine|
75612314|NCT00640861|Biological|MUC-1 peptide vaccine|
75612315|NCT00640861|Biological|incomplete Freund's adjuvant|
75612316|NCT00640861|Biological|sargramostim|
75761818|NCT01013987|Drug|Darunavir/ritonavir|"darunavir : two 300 mg pills twice daily with meal~ritonavir: one 100 mg pill twice daily with meal"
76069938|NCT03599895|Procedure|non 3D printing model|da Vinci robot assisted radical gastrectomy
75612317|NCT00640861|Other|immunoenzyme technique|
75459554|NCT01821261|Device|Mouth Rinse 19668-012|20 ml of experimental mouth rinse 19668-012 for 30 seconds, twice daily
75612318|NCT00640861|Other|immunologic technique|
75612319|NCT04184011|Device|SRT-100™|SRT delivers a precise, calibrated dose of radiotherapy following surgical excision for large and more difficult-to-treat keloids that cannot otherwise be treated by or have failed more conservative measures.
75612320|NCT04183855|Dietary Supplement|Generation UCAN supplementation|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
75612321|NCT04183855|Dietary Supplement|Mirexus PhytoSpherix supplementation|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
75612322|NCT04183855|Behavioral|satiety ratings|questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
75612323|NCT04184089|Device|High flow nasal cannula (15 L/m)|nasal cannula at a flow rate of 15 l/min and FiO2 of 40%
75612324|NCT04184089|Device|High flow nasal cannula (30 L/m)|nasal cannula at a flow rate of 30l/min and FiO2 of 40%
75612325|NCT04184089|Device|High flow nasal cannula (60 L/m)|nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.
75612326|NCT01158222|Drug|sunitinib malate|Given orally
75612327|NCT02682979|Other|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
75612328|NCT02886780|Behavioral|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
75612329|NCT02886780|Behavioral|Self-help|
75612330|NCT02684305|Drug|Administration of Propess|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
75761819|NCT04150445|Behavioral|Internet treatment for overweight and obese patients|The behavioral treatment is provided via the Internet and comprises 12 modules that the patient follows for 6 months. The treatment modules include self-monitoring, goal setting, relapse prevention, psycho-education about nutrition, eating behavior, physical activity, sleep and stress management. Each module ends with one or more exercises to be completed before the next module is activated.
75761820|NCT01019213|Other|Septal pacing|Septal lead activated
75761821|NCT01019213|Other|His lead activated|His lead will be activated 80 ms before septal lead
75761822|NCT01019291|Other|Formaldehyde and NO2 (Exposure to indoor pollutants)|Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
75761823|NCT01019291|Other|Placebo (Exposure to indoor pollutants)|Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
75612331|NCT02684305|Device|balloon|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
75761824|NCT01019447|Other|Vicryl Plus|Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
75761825|NCT01019447|Other|Vicryl|Polyglactin 910 antimicrobial sutures (Vicryl)
76069939|NCT03592797|Other|Laser acupuncture therapy|Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
75459555|NCT01821261|Drug|Mouth Rinse 500347078842|10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
75459556|NCT01821261|Drug|Toothpaste 035000513007|Approximately one inch of toothpaste 035000513007, twice daily
75459557|NCT01821274|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
75459558|NCT01821274|Drug|Vehicle Cream|0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
75459559|NCT01821274|Drug|0.1% solution o sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
75459560|NCT01821274|Drug|Saline 0.9%|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
75761826|NCT00490529|Biological|CpG-MCL vaccine|CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection.
75761827|NCT00490529|Biological|PF-3512676|PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions.
75459561|NCT01821287|Other|CHD|The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
75459562|NCT01821313|Other|Moderate exercise|
75905906|NCT02238405|Other|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
75905907|NCT03539562|Drug|Morphine Sulfate and Promethazine|Morphine sulfate and promethazine
75905908|NCT02238249|Drug|Alesion®|Dry Syrup
75905909|NCT03590769|Drug|18F-FDG|All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
75905910|NCT03675763|Other|Manual treatment|Craniosacral therapy protocol.
75905911|NCT00394069|Drug|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
75905912|NCT03598959|Drug|tofacitinib|orally 10 mg daily
75905913|NCT03598959|Drug|chidamide|orally 20 mg twice weekly
75905914|NCT05634928|Other|collection data|collection data
75905915|NCT03598179|Biological|chimeric antigen receptor T cells|Dose CAR+ cells/kg B-cell lymphoma 4×10^6 Acute lymphocytic leukemia 2×10^6 Chronic lymphocytic leukemia 10×10^6
75905916|NCT05730478|Device|ASOCT&UBM|glaucoma assesment by ASOCT &UBM
75612332|NCT02684305|Drug|Intravenous oxytocin infusion|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
75612333|NCT02885376|Device|Dentoxol|Mouthrinse
75761828|NCT00490529|Procedure|Vaccine-primed T-cells|Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells.
75761829|NCT00490529|Procedure|Autologous hematopoietic stem cell transplant (HSCT)|Regular medical procedure
75905917|NCT02238717|Drug|PF-06372865 (65mg)|single oral dose (65 mg)
75905918|NCT02238717|Drug|PF-06372865 (15mg)|single oral dose (15mg)
75905919|NCT02238717|Drug|Pregabalin|single oral dose (300mg)
75905920|NCT02238717|Drug|Placebo|matching oral placebo
75905921|NCT03625453|Drug|ABX-1431|Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration
75905922|NCT03625453|Drug|Placebo|Part 1: 8 weeks with daily administration
75761830|NCT00490529|Drug|Rituximab|375 mg/m² by infusion
75459563|NCT01821313|Other|High Intensity Interval Exercise|
75459564|NCT01821404|Drug|Atorvastatin|Capsules including 80 mg of atorvastatin
75459565|NCT01821404|Drug|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
75612334|NCT02885376|Device|Placebo|Mouthrinse
75612335|NCT02940769|Device|light glasses|light glasses
75612336|NCT02940769|Device|sham glasses (placebo)|sham light glasses
75612337|NCT04315584|Procedure|Positron Emission Tomography|Undergo PET/CT Scans
75905923|NCT03066388|Other|Pulse pressure variations|Stroke volume and, pulse pressure variations obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin.
76069940|NCT03592797|Other|Sham laser acupuncture therapy|Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
76069941|NCT03592719|Behavioral|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
76069942|NCT03592719|Behavioral|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
76069943|NCT00211887|Drug|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
75761831|NCT00490529|Drug|Standard induction chemotherapy|Patient-specific, regular medical care treatment as determined by treating oncologist
75905924|NCT03581955|Other|Banana Cavendish|240g of fruit plus 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)
75905925|NCT03581955|Other|Tomato|"300g of raw tomato (coeur de boeuf) with refined sunflower oil (12g) and 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)."
75905926|NCT03581955|Other|Fresubin ® 2kcal fiber neutral flavor|250 ml Fresubin ® 2kcal fiber neutral flavor
76069944|NCT00211887|Drug|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
76069945|NCT00211887|Other|placebo|an inactive substance
76069946|NCT04002453|Procedure|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
75612338|NCT04315584|Procedure|Computed Tomography|Undergo PET/CT Scans
75612339|NCT04315584|Procedure|Multiparametric Magnetic Resonance Imaging Scan|Undergo a multiparametric MRI scan
75612340|NCT04315584|Radiation|Fludeoxyglucose F-18|IV (intravenous) administration of radiotracer
75612341|NCT04315584|Radiation|fluorine F 18 fluorodopa|IV (intravenous) administration of radiotracer
75612342|NCT02683993|Device|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
75612343|NCT02683291|Drug|sirolimus|
75612344|NCT02683291|Drug|tacrolimus|
75612345|NCT02683291|Drug|mycophenolate|
75612346|NCT02683291|Drug|Prednisone|Prednisone 30mg/day
75612347|NCT02683291|Drug|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
75612348|NCT02683291|Drug|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
75612349|NCT02685865|Device|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
75612350|NCT02685865|Device|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
75612351|NCT02685397|Drug|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
75612352|NCT02685397|Drug|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
75612353|NCT02685397|Drug|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
75612354|NCT02685397|Drug|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
75612355|NCT02685397|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
75612356|NCT02682745|Drug|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
75761832|NCT00490529|Drug|Cyclophosphamide|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
75761833|NCT00490529|Drug|Filgrastim|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
75761834|NCT00333840|Drug|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
75761835|NCT00333840|Drug|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day.
75905927|NCT03568123|Device|MC polyethylene bearing|"Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients >65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
75761836|NCT00333840|Drug|cytarabine (ARA-C)|cytarabine 20 mg/m^2/day (max 40 mg) SC for 10 days every month.
75761837|NCT00490451|Drug|LY573636-sodium|LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
75761838|NCT01019603|Drug|Tazarotene|Topical Tazarotene foam applied daily for 22 days.
75761839|NCT01019603|Drug|Tazaroc Gel|Topical tazarotene gel applied daily for 22 days.
75761840|NCT00321906|Drug|azathioprine|azathioprine 2mg/kg
75761841|NCT00321906|Drug|sirolimus|sirolimus 2-4mg daily
75761842|NCT00339144|Drug|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
75761843|NCT00339144|Drug|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
75761844|NCT00339144|Drug|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
76069947|NCT03599817|Behavioral|Healthy lifestyle promotion program|Before implementing the healthy lifestyle program, it will be adapted according to the characteristics of the Yaqui community, their type of food and the activities they carry out, so that the intervention program is culturally accepted by the community. The intervention will consist of two stages, an intensive phase and a maintenance phase. In the intensive phase, 16 weekly group sessions will be given with the aim of achieving a 5% body weight loss and ensuring that the participants do at least 150 minutes of physical activity per week. In the maintenance phase, 6 monthly group sessions will be given in order to maintain the results achieved in the first stage. In the same maintenance phase, but from 12 to 18 months, the lifestyle trainers will make home visits to the participants. Lifestile trainers will record body weight, physical activity and food consumption. In this period there will be no sessions, only monthly visits.
75612357|NCT02682745|Drug|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
75612358|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily
75612359|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
75612360|NCT01197521|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
75612361|NCT02683915|Procedure|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
75612362|NCT02683837|Drug|Remifentanil|
75612363|NCT02683837|Device|Pupillometry|Pupillary diameter measured every 5 minutes
75612364|NCT02683837|Drug|Sevoflurane|Administered to maintain a Bispectral Index between 40 and 60
75612365|NCT02002507|Other|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
75612366|NCT01157676|Procedure|Open radical cystectomy|Standard of care removal of urinary bladder.
75612367|NCT01157676|Procedure|Robotic assisted radical cystectomy|Standard of care removal of urinary bladder using DaVinci robot.
75612368|NCT01157676|Device|DaVinci robot|DaVinci robotic surgical system.
75612369|NCT02680873|Other|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
75612370|NCT04183543|Device|Pulsed Electromagnetic Fields|The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
75612371|NCT04183543|Device|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy
75761845|NCT00321828|Biological|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
75761846|NCT00321828|Drug|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
75761847|NCT00321828|Drug|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
75612372|NCT02680951|Drug|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
75612373|NCT02680951|Drug|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
75612374|NCT02680951|Drug|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
75761848|NCT00321828|Drug|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
75761849|NCT01061580|Device|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
75761850|NCT00333138|Drug|FTY720|FTY720 capsule was taken orally once a day
75761851|NCT00333138|Drug|Placebo|Placebo 1.25 mg capsule was given once daily
75761852|NCT01058226|Biological|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
75761853|NCT00332202|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
75761854|NCT00332202|Drug|placebo|oral, daily
75761855|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
75905928|NCT03568123|Device|CR polyethylene bearing|"Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients >65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
75905929|NCT05730400|Drug|BMAC loaded on bovine graft|Bone marrow aspirate concentrate loaded on bovine graft for sinus floor augmentation
75612375|NCT02680951|Drug|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
76069948|NCT03592485|Procedure|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
76069949|NCT03592485|Procedure|Pectoral Fascia block|Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
76069950|NCT03592485|Drug|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
76069951|NCT03592485|Procedure|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
75612376|NCT02680951|Drug|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~30 mg for patients age 1 - 1.99~50 mg for patients age 2 - 2.99~70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
75612377|NCT02680717|Drug|Clobetasol|ointment, twice daily (alternating weeks)
75612378|NCT02680717|Drug|Calcipotriene|ointment, twice daily
75612379|NCT02680717|Drug|Tacrolimus|ointment, 0.1%, twice daily
76069952|NCT03592485|Drug|paracetamol|Paracetamol will be given i.v. every 6 hours.
75612380|NCT05663983|Behavioral|Description of therapeutical results|Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
75612381|NCT04182529|Device|Photoneuromodulation therapy|low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800
75612382|NCT04182529|Other|Sham|Sham, no active stimulation will be given to subjects
75612383|NCT02680795|Drug|Belinostat IV|"Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
75761856|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
75761857|NCT01061658|Other|Placebo|Placebo
75761858|NCT03982836|Dietary Supplement|Soluble Dietary Fibers|All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
75761859|NCT01058382|Drug|Progesterone Vaginal Suppositories|Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
75905930|NCT05730400|Drug|Bovine graft only|Bovine graft only for sinus floor augmentation
75761860|NCT01058382|Drug|Intramuscular Progesterone-in-Oil|Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
75761861|NCT01061814|Drug|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
75761862|NCT01061814|Drug|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
75761863|NCT01058460|Procedure|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
75905931|NCT03558217|Device|Collared Femoral Implant|Corail collared femoral implant for total hip arthroplasty
75905932|NCT03558217|Device|Collarless Femoral Implant|Corail collarless femoral implant for total hip arthroplasty
75761864|NCT00331422|Drug|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
75612384|NCT00640237|Dietary Supplement|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
76069953|NCT04199013|Drug|Ropivacaine 0.75% Injectable Solution|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
76069954|NCT04199013|Drug|Fentanyl Citrate|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
76069955|NCT03592251|Dietary Supplement|Olive Oil Placebo|6 months placebo supplementation
75612385|NCT02683759|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
75761865|NCT00331422|Drug|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
75761866|NCT00331422|Procedure|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
75612386|NCT02683759|Drug|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
75612387|NCT02682589|Procedure|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
75612388|NCT02682589|Procedure|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
75612389|NCT03072433|Behavioral|Counseling Intervention Package|Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
75761867|NCT00331344|Drug|mitoxantrone hydrochloride|Given IV
75612390|NCT03072433|Behavioral|Standard of Care|Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
75761868|NCT00331344|Drug|ixabepilone|Given IV
75761869|NCT00331344|Drug|prednisone|Given orally
75761870|NCT03983928|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
76069956|NCT03592251|Dietary Supplement|EPA-rich|6 months placebo supplementation
76069957|NCT03592251|Dietary Supplement|DHA-rich|6 months placebo supplementation
75761871|NCT03983928|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
75761872|NCT01058538|Drug|L19IL2|Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
75761873|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
75761874|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
75905935|NCT03587259|Diagnostic Test|Tomosynthesis|DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
75761875|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
75905936|NCT03587259|Diagnostic Test|2D mammography|2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
75905937|NCT03470311|Biological|Benralizumab|30mg in 1mL pre-filled syringe
75905938|NCT03470311|Biological|Placebo|Matched placebo (1mL) in pre-filled syringe
76069958|NCT04747665|Other|Patient and endoscopist reported experience|Exploration of patient and endoscopists experiences of colonoscopy.
76069959|NCT03592095|Device|Dry needling|Real dry needling will be conducted according to Hong description, fast-in and fast-out interventions. The intervention will be applied until a total of four local twitch responses will be elicited
76069960|NCT03592095|Device|Placebo needle|Sham dry needling with be conducted with a sham needle (Steitberger's Park sham device (PSD). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient.
76069961|NCT04198935|Device|Span Health Mobile Application|A 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
76069962|NCT01855945|Biological|Swine Influenza|Comparison of different dosages of vaccines
75612391|NCT00991341|Biological|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored <=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
75612392|NCT00991341|Biological|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored >=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
75761876|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
75761877|NCT03985566|Dietary Supplement|Fibre Grain|Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
75612393|NCT04291989|Device|Optimal Blood Sampling Site for Point of Care Lactate Assessment using the handled Lactate-Pro 2 device|This study aims to compare lactate levels using the Lactate Pro 2 device from the same patient at the same time with blood samples taken from three locations - fingertip, earlobe and forearm venepuncture
75761878|NCT03985566|Dietary Supplement|Jasmine white rice|Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
75761879|NCT00321048|Device|Active Breathing Coordinator|A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
75761880|NCT01061970|Drug|Fispemifene|once daily for 4 weeks
75761881|NCT00330174|Drug|Acamprosate|2 333mg tablets three times daily
75761882|NCT03985488|Radiation|Radiation exposure|Radiation exposure via Eview Fluoroscopy machine.
75905939|NCT04051021|Behavioral|Comfort Coach|A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
76069963|NCT03592017|Device|Long-wavelength autofluorescence imaging|Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
76069964|NCT04198389|Procedure|PARTIAL KNEE REPLACEMENT|PARTIAL KNEE REPLACEMENT
76069965|NCT04766541|Other|no intervention|There is no intervention.
76069966|NCT04198467|Biological|Platelet rich plasma|Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular
76069967|NCT04198467|Drug|Hyaluronic Acid|Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
76069968|NCT04198155|Radiation|stereotactic body radiotherapy (SBRT)|Image-guided stereotactic body radiation therapy
76069969|NCT03591705|Drug|TACE-HAIC|transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
76069970|NCT03591705|Drug|HAIC|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
76069971|NCT03599505|Procedure|localization group|Intraoperative ultrasonographic localization will be performed using an ultrasound system (HI VISON Ascendus), which is equipped with a 5-10MHz mechanical probe (EUP-OL531). The accuracy rate of localization will be evaluated using gray scale mode and elastography mode.
76069972|NCT03599427|Drug|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
76069973|NCT03599427|Drug|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
75459566|NCT01821430|Drug|Pregabalin|Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
75612394|NCT04291677|Other|intervention musical|Intervention group in which musical intervention will be applied the first or third day of mechanical ventilation.
75612395|NCT04291677|Other|Without intervention musical|Control group with standard treatment without musical intervention.
75612396|NCT04292691|Drug|40ml of Ropivacaine 0.5% Injectable Solution|already outlined in the arm/group description
75612397|NCT04292691|Drug|40ml of Ringer's Lactate|already outlined in the arm/group description
75612398|NCT00990249|Drug|Busulfan|Test Dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
75761883|NCT01058616|Drug|LTX-315 (Oncopore™)|5 mg/ml-70 mg/ml. Dosing will be done as transdermal injection of a calculated volume at day 1 and 8. Additionally weekly injections up to a maximum of 4 injections.
75761884|NCT00320424|Drug|Fondaparinux|
75905940|NCT04051021|Other|Usual Care|Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
75459567|NCT01821430|Drug|Placebo|Placebo group will follow the same titration as the pregabalin group
75459568|NCT01821443|Other|Stereotactic radiosurgery (SRS)|"Dose & prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% [maximum=100%]), as defined by target delineation on the imaging studies.~The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL)."
75459569|NCT01821456|Drug|Antiinfectives|To analyze to efficacy of (novel) drug therapies
75459570|NCT01821469|Behavioral|psychoeducation|Bipolar disorders are educated to learn about their pathology
75459571|NCT01821482|Biological|Dendritic and Cytokine-induced Killer Cells|
75459572|NCT01821495|Biological|DC-CIK|
75459573|NCT01821495|Biological|Dendritic and Cytokine-induced Killer Cells|Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment
75761885|NCT02533206|Procedure|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
75905941|NCT03580707|Drug|BRV vs LEV in randomized double blinded, crossover fashion|Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
75905942|NCT03068026|Device|VitaBreath|The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
75612399|NCT00990249|Drug|Clofarabine|40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3
76069974|NCT01855789|Drug|Tocilizumab (TCZ)|TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to [>/=] 100 kilograms [kg]) or every 2 weeks (if body weight was less than [<] 100 kg).
76069975|NCT01855789|Drug|Methotrexate (MTX)|MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
76069976|NCT01855789|Drug|Placebo (PBO)|PBO matching to MTX will be administered orally.
75612400|NCT00990249|Drug|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
75459574|NCT01821508|Other|Clinical Treatment|metabolic surgery for diabetes and weight control
75612401|NCT00990249|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
75612402|NCT02846545|Biological|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
75612403|NCT02846545|Biological|Placebo|Matching Placebo to golimumab.
75761886|NCT02533206|Procedure|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
75459575|NCT01821508|Procedure|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
75761887|NCT00338286|Other|Standard supportive care (packed RBC transfusion)|Per doctor prescription
75761888|NCT00338286|Drug|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
75459576|NCT01821521|Drug|AGSPT_L20|
75459577|NCT01821521|Drug|Pantoloc 40mg|
75459578|NCT01821547|Drug|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
75459579|NCT01821573|Drug|botulinum toxin type A|"Experimental arm group:~150 Units in rectus femoris ( 3 ml and 3 points)~70 units in medial gastrocnemius (1.4 ml and 1 point)~70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~60 units in soleus ( 1.2 ml and 3 points)"
75612404|NCT04291755|Drug|Pembrolizumab Injection|Any checkpoint inhibitor is acceptable
75612405|NCT05663827|Drug|Ruxolitinib|A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
75612406|NCT04292769|Drug|Decitabine|Decitabine 10mg / d, intravenous administration d-5 ～ d-1
75761889|NCT00329784|Biological|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
75761890|NCT00337818|Biological|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
75905943|NCT03068026|Other|Pursed Lip Breathing technique|Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
75905944|NCT03580005|Drug|methylphenidate HCl ERCT|methylphenidate HCl ERCT
75905945|NCT03580005|Drug|Placebo|Placebo to Match Quillichew ERCT
75612407|NCT04292769|Biological|DC-CIK|Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
75612408|NCT00640939|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
75612409|NCT00640939|Drug|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
75612410|NCT04291443|Procedure|Heavy Force (225g)|Orthodontic Force
75612411|NCT04291443|Procedure|Light Force (25g)|Orthodontic Force
75612412|NCT05663749|Drug|Metformin|1000mg for 8 weeks
75612413|NCT05663749|Drug|Topiramate|50mg for 8 weeks
75905946|NCT00293995|Procedure|Repair of unilateral inguinal hernia|
75905947|NCT04412512|Procedure|VATS approach|video-assisted thoracic surgery approach
75905948|NCT04412512|Procedure|Thoracotomy approach|
75905949|NCT03579927|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
75905950|NCT03579927|Drug|Carmustine|Given IV
75905951|NCT03579927|Drug|Cytarabine|Given IV
75905952|NCT03579927|Drug|Etoposide|Given IV
75905953|NCT03579927|Biological|Filgrastim|Given SC
75905954|NCT03579927|Drug|Melphalan|Given IV
75905955|NCT03579927|Biological|Rituximab|Given IV
75905956|NCT03579927|Biological|Umbilical Cord Blood-derived Natural Killer Cells|Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
75905957|NCT05634850|Device|Kinder|Participants will test at their urine with at home with in the device. Results are sent via an app back to the clinic for reporting.
75905958|NCT05180890|Drug|Danavorexton|Danavorexton intravenous infusion.
76069977|NCT03591627|Diagnostic Test|Transesophageal echocardiography|Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
76069978|NCT04198233|Drug|Diazepam|Diazepam 10 mg compounded suppository
76069979|NCT04198233|Drug|Placebos|Placebo suppository
76069980|NCT04197375|Behavioral|Thermal stress and performance using a pre-cooling protocol|One hour before a tennis match, participants were wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes. During the tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
75905959|NCT05180890|Drug|Placebo|Placebo intravenous infusion.
76069981|NCT04197375|Biological|Thermal stress and performance without a pre-cooling protocol|During a tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
76069982|NCT03986853|Procedure|Blood sampling|Blood sampling under general anesthesia
76069983|NCT03591471|Drug|Glycosides Of Tripterygium Wilfordii Hook(GTW)|"For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time"
76069984|NCT03591471|Drug|Sulfotanshinone Sodium Injection|Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
75612414|NCT02682433|Device|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
76069985|NCT03591471|Drug|Chinese herbs based on syndrome differentiation|"For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome."
75459580|NCT01821573|Drug|injection of NaCl 0.9%|"Placebo comparator group: injection of NaCl 0.9%:~3 ml of NaCl 0.9% in rectus femoris in 3 points~1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~1.2 ml of NaCl 0.9% in soleus in 3 points"
75459581|NCT01821586|Other|Modified ORS-1|
75612415|NCT02682433|Device|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
75612416|NCT00990093|Device|test intermittent catheter|CH 12 hydrophilic coated catheter
75612417|NCT00990093|Device|Intermittent catheterization|CH 12 hydrophilic catheter
75612418|NCT04184167|Other|intermittent fasting 4 months before ICSI|women will start intermittent fasting before starting ICSI by 4 months
75612419|NCT02867553|Drug|rituximab|
75612420|NCT02867553|Radiation|Multi-fields radiotherapy|
75612421|NCT05663671|Diagnostic Test|Diagnostic Test|30% of IBD patients are misdiagnosed. This affects surgical care of patients. Investigators have unveiled a signature discriminator between UC&CC that also predicts the outcome of IC patients into authentic UC/CC. This is a bioassay that is specific, sensitive, linear, affordable, minimal risk, non-invasive and constitutes an inexpensive, simple to use, point-of-care test format. Investigators published data which have shown robust presence of DEFA5 in the colon crypt mucosa with aberrant expression of apparent crypt-cell-like cells (CCLCs) in areas identified with ectopic colon ileal metaplasia consistent with CC. Investigators propose to validate that UC/CC, the two unsolved medical sub-types of pathology can accurately be distinguished among IC patients by examining CCLCs secreted DEFA5 levels in endoscopy biopsies instantly. Diagnostics relies on the expression/localization/activation of DEFA5 and the ectopic CCLCs in the mucosal crypt of CC patients.
75905960|NCT00100932|Drug|E7389 28 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
75905961|NCT00100932|Drug|E7389 21 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1 and 8 of a 21 day cycle.
75459582|NCT01821586|Other|Modified ORS-2 (ReSoMal)|
75459583|NCT01821586|Other|Modified ORS-3 (Benefibre)|
75459584|NCT01821599|Other|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
75761891|NCT03981666|Other|Questionnaires|"To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~Ad hoc questionnaire for demographics and medical data;~Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion."
75612422|NCT02682277|Device|polygucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
75612423|NCT02682277|Other|placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
75905962|NCT03579849|Diagnostic Test|Pulmonary tomoscintigraphy|The included patients will benefit from pulmonary tomoscintigraphy within 24 hours after the diagnosis of pulmonary embolism. Each tomoscintigraphy will be interpreted blindly by 3 nuclear physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
76069986|NCT03591471|Drug|Prednisone Acetate Tablets|Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
76069987|NCT03591471|Drug|Benazepril Hydrochloride Tablets|In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
76069988|NCT03591471|Drug|Low Molecular Weight Heparin Calcium Injection|In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
76069989|NCT03591471|Drug|Dipyridamole Tab 25 MG|In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
75612424|NCT00909961|Drug|Zoledronic acid|
75612425|NCT05663593|Drug|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
75612426|NCT05663593|Drug|Placebo, tablet|Matching placebo
75905963|NCT05634772|Device|dormia basket|Use of dormia basket in management of proximal stent migration
75905964|NCT05634772|Device|Extraction biliary ballon|Use of extraction biliary balloon in management of proximal stent migration
76069990|NCT03591471|Drug|Chinese medicine placebo|In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
75616408|NCT04554784|Procedure|Bowen|"Patients will be referred to Occupational therapist for Bowen Therapy. There will be a week washout period before the start of Bowen Therapy. During a week washout period and study period, patients can continue taking analgesia, but advised to stop the concurrent treatments which can affect the deep tissue such as massage, physiotherapy, and chiropractic to minimize the counteracting effect on the Bowen's action.~During a Bowen Therapy session, patients will lie relaxed on the examination couch wearing loosely fitting clothing or only the affected area being exposed. The therapist applies a series of gentle movements across the body. The gentle movements focus on a body of muscle, tendon or nerve and release tension through the nerve within the area. Each session will last for 30 minutes to an hour. After each session, the next appointment will be given to patients. The first four sessions will be scheduled on weekly basis, and the remaining four on biweekly session."
75616409|NCT04549480|Drug|Bosutinib capsule|100 mg dose of bosutinib pediatric capsule
75616410|NCT04549480|Drug|Bosutinib tablet|100 mg dose of bosutinib tablet
75616411|NCT05336578|Other|Platelet rich fibrin application|PRFs were prepared by obtaining10 ml blood samples from each patinet and inserting them in a centrifuge device (Intra-Lock International Inc., Boca Raton, USA), under 2700 rpm for 12 min using high speed. The platelet-rich fibrin layer remaining between the acellular plasma and red blood cells in the tube was separated with the help of scissors or a scalpel. After the tooth extraction in the experimental group PRF located to the extraction socket.
76069991|NCT04407039|Device|PET/CT, H-MRS and MRI|Use imaging methods to get metabolic parameters.
75612427|NCT02680249|Drug|CTP-656|
75612428|NCT04184557|Behavioral|Staying Calm in the OR|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) ir Mindfulness Self Compassion (MSC)."
75612429|NCT00641017|Biological|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
75761892|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
75761893|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
75761894|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
75761895|NCT00375674|Drug|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
75459585|NCT01821599|Other|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
75612430|NCT00641017|Biological|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
75761896|NCT00375674|Other|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
75761897|NCT00350402|Behavioral|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
75761898|NCT03991910|Drug|Placebos|the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.
76069992|NCT04406805|Diagnostic Test|Measurement of plasma and urine trimethylamine-N-oxide concentration|Information already included in arm/group descriptions.
75612431|NCT00642577|Drug|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
75612432|NCT00642577|Drug|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
75612433|NCT00642577|Drug|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
75459586|NCT01821612|Drug|oxaliplatin|IV
75459587|NCT01821612|Drug|irinotecan|IV
75459588|NCT01821612|Drug|leucovorin|IV
75459589|NCT01821612|Drug|5-fluorouracil|IV
75459590|NCT01821612|Drug|capecitabine|PO
75459591|NCT01821612|Radiation|radiation|
75612434|NCT00642577|Drug|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
75761899|NCT03991910|Drug|Ramipril 5Mg Oral Capsule|the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
75761900|NCT01055600|Drug|eltrombopag|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
75905965|NCT03587025|Drug|Amitriptyline|Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.
75905966|NCT03587025|Drug|Placebo|Placebo
75905967|NCT02170350|Procedure|Meditation therapy|Use brief mindful meditation practice
76069993|NCT01610791|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
75459592|NCT01821612|Procedure|surgery|
75459593|NCT01821612|Drug|gemcitabine|IV
75459594|NCT01821651|Device|HeartNavigator|Procedure with software
75459595|NCT01821651|Device|EchoNav|Procedure with software
75459596|NCT01821651|Other|Control-Group EN|Procedure without software
75459597|NCT01821651|Other|Control-group HN|Procedure without software
76069994|NCT03832491|Other|Home based therapy|Airway clearence techniques
76069995|NCT03832491|Other|Game and home based therapy|Game based approach programme and airway clearence techniques
75612435|NCT02679937|Behavioral|Fit4Duty|Small (<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
75612436|NCT02679937|Other|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
75612437|NCT02682121|Drug|Metformin|Metformin 850 mg twice daily
75612438|NCT02682121|Drug|Placebo|Placebo twice daily
75612439|NCT02680405|Procedure|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
75612440|NCT02680405|Procedure|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
75612441|NCT02680405|Procedure|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
75612442|NCT02537587|Other|Control 1|67g of control bar
75612443|NCT02537587|Other|Control 2|86g of control bar
75612444|NCT02537587|Other|15/0|66g of experimental bar 15/0
75612445|NCT02537587|Other|15/0LS|84g of experimental bar 15/0LS
75612446|NCT02537587|Other|15/5|75g of experimental bar 15/5
75612447|NCT02537587|Other|10/5|72g of experimental bar 10/5
75612448|NCT02537587|Other|10/10|80g of experimental bar 10/10
75612449|NCT02683603|Drug|"AS colistin and imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
75612450|NCT02683603|Drug|"IV colistin  and imipenem ."|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
75612451|NCT02683603|Drug|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
75612452|NCT02683603|Drug|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
75612453|NCT02683603|Drug|AS colistin and imipenem|IV imipenem 1 g three times per day.
75612454|NCT02683603|Drug|IV colistin and imipenem|IV imipenem 1 g three times per day
75612455|NCT00641095|Biological|rituximab|concentrate for solution for infusion
75612456|NCT00641095|Drug|Cyclophosphamide|Tablets
75612457|NCT00641095|Drug|Fludarabine|Film coated tablet
75612458|NCT00984165|Procedure|Single fraction radiation|8-Gy fraction of radiation
76069996|NCT03591315|Diagnostic Test|resting state fMRI|Define the visual resting state network.
75612459|NCT00984165|Biological|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
75612460|NCT00984165|Procedure|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
75905968|NCT02170350|Other|Quality-of-life assessment|Ancillary studies
76069997|NCT03591315|Diagnostic Test|visual tasking state fMRI|Using visual task stimulation to identify the activation characteristic of primary visual cortex.
76069998|NCT03591315|Diagnostic Test|diffusion tensor imaging|Define the integrity of white matter fibers in the visual pathway.
76069999|NCT03591315|Diagnostic Test|automated visual field|Identify the existence and type of visual field defect.
75612461|NCT02869113|Drug|BAY98751 (Y65-110)|10 µL in one eye
75612462|NCT02869113|Drug|BAY 98751 (Y65-102)|10 µL in one eye
75612463|NCT02869113|Drug|BAY 98751 (Y65-106)|10 µL in one eye
75612464|NCT02869113|Drug|Standard shampoo mixture (Control)|10 µL in other eye
75612465|NCT00993291|Procedure|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
75612466|NCT00993291|Procedure|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
75612467|NCT02867631|Behavioral|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
75612468|NCT01196975|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
75612469|NCT01196975|Biological|FluLavalTM-VB|Single intramuscular dose
75612470|NCT01196975|Biological|FluLavalTM-YB|Single intramuscular dose
75612471|NCT00992589|Drug|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
75612472|NCT00992589|Drug|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
75612473|NCT00992589|Drug|Placebo|Matching placebo capsules once daily in the morning.
76070000|NCT03591315|Diagnostic Test|visual acuity|Assess the visual acuity by using ETDRS scales.
76070001|NCT03591081|Other|Intellin smart phone application|This feasibility study will explore if creating an electronic platform Intellin smart phone application can promote and support timely self-referral for individuals with a recently healed DFU. It will explore the software applications acceptance and ease of use for patients.
75761901|NCT00320190|Drug|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
75612474|NCT01196741|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
75905969|NCT02170350|Other|Questionnaire administration|Ancillary studies
75761902|NCT00320190|Drug|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
75761903|NCT01050920|Biological|Blood collection|
75459598|NCT01821664|Device|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
75459599|NCT01821703|Drug|LY3045697|Administered as oral solution
75459600|NCT01821703|Drug|Placebo|Administered as oral solution
75459601|NCT01821703|Drug|Spironolactone|Administered as capsule
75612475|NCT01196741|Drug|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
75612476|NCT01196741|Drug|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
75612477|NCT02868255|Procedure|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
75612478|NCT00629187|Drug|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
75459602|NCT01821703|Drug|Placebo|Administered as capsule
75612479|NCT04291287|Drug|Antithrombotic Agent|"Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~Clopidogrel (Plavix®)~Prasugrel (Efient®)~Ticagrelor (Brilique®)~DOACs therapy include:~Apixaban (Eliquis®)~Dabigatran (Pradaxa®)~Edoxaban (Lixiana®)~Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~Warfarin (Counmadin®)~Acenocumarol (Sintrom®)"
75905970|NCT05730088|Other|health education|Health Education: While they are still in the hospital, a 30-minute individually planned education about their disease will be given to patients using the COPD patient education booklet. step 1. Smoking cessation, step 2. Vaccination, step 3. Correct drug use, step 4. Regular exercise, step 5. Healthy eating, step 6. Coping with stress, step 7 Coping with attacks, step 8. Includes regular oxygen therapy. Let's learn nhaverug treatments in coping with COPD, under the title of pulmonary rehabilitation (Respiratory Rehabilitation), methods of coping with shortness of breath, indoor air pollution and outdoor air pollution subheadings.
75905971|NCT05730088|Other|Mobile application (Creating a WhatsApp group):|A group will be created through the WhatsApp application for participants in health education and visual and audio materials will be shared through this group every week. In the coming weeks, the researcher will provide consultancy services to those who have problems with the application.
75459603|NCT01821716|Biological|Prick test Dermatophagoides pteronyssinus allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
75459604|NCT01821742|Other|Ultrasound cardiac output measurement|
75459605|NCT01821755|Behavioral|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
75459606|NCT01821768|Procedure|Sentinel Lymph Node Biopsy|
75761904|NCT02534402|Drug|Prednisone|Administration of prednisone to determine the effect on whole blood gene expression.
75761905|NCT00320112|Behavioral|Reciprocal Diabetes Peer Support Program|participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
75761906|NCT00320112|Behavioral|Nurse Case management|patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
75761907|NCT00320112|Behavioral|group outpatient counseling visits|Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
75761908|NCT03982524|Behavioral|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
75761909|NCT03982524|Behavioral|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
75761910|NCT01063608|Biological|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
75612480|NCT04291365|Diagnostic Test|Blood pressure measurement|Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)
75761911|NCT00319956|Drug|Azithromycin|Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
75761912|NCT00319956|Drug|Placebo|vehicle dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
75761913|NCT01062048|Drug|Sitagliptin|Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
75761914|NCT01062048|Drug|Sulfonylurea|Sulfonylurea administered in general use according to the local label
75761915|NCT01062048|Biological|Insulin|Insulin administered in general use according to the local label
75761916|NCT01060722|Drug|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
75459607|NCT01821820|Other|Pistachios|
75761917|NCT01060722|Drug|Placebo|Single subcutaneous dose of placebo material
75761918|NCT00349622|Drug|ceftriaxone|"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
75905972|NCT05730088|Other|Home visit:|Participants will be visited at home three times. During the home visit, any questions about their illness and the oxygen concentrator they use will be answered. During the home visits, the researcher will provide consultancy services.
76070002|NCT01876381|Drug|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
75612481|NCT00983385|Drug|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
75761919|NCT00349622|Other|placebo|an inactive substance
75761920|NCT03987698|Biological|SHR-1210|SHR-1210 injection
75761921|NCT03987698|Biological|CIK cells|CIK cells injection
75761922|NCT01051076|Drug|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
75761923|NCT01325090|Drug|BOTOX|A syringe of 1 ml contain 25 Allergan units.
75761924|NCT01325090|Other|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
75761925|NCT03989258|Diagnostic Test|Mammography outside official screening|Radiologic study
75761926|NCT00354614|Device|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
75761927|NCT03989960|Procedure|LISA+SNIPPV|The LISA+SNIPPV group receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation.
75761928|NCT03989960|Procedure|traditional InSurE|The traditional InSurE group receives intubation-surfactant- extubation technique and selects CPAP ventilation.
75761929|NCT00360308|Drug|Placebo|
75761930|NCT00360308|Drug|E2007|
75612482|NCT00983385|Other|Observation period|Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
75612483|NCT00983385|Drug|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
75761931|NCT00360308|Drug|E2007|
75761932|NCT01054508|Drug|nicotinic acid/laropiprant|Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
75761933|NCT00348686|Drug|Candesartan|16 mg once daily in oral tablet form
75761934|NCT00348686|Drug|Candesartan|32 mg once daily in oral tablet form
75761935|NCT00348686|Drug|Felodipine|5 mg once daily in oral tablet form
75761936|NCT00348686|Drug|Felodipine|10 mg once daily in oral tablet form
76070003|NCT03591003|Diagnostic Test|Yellow fever neutralizing antibodies measure|Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
75459608|NCT01821846|Drug|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
75459609|NCT01821872|Drug|Administration of paracetamol|Administration of 1g intravenous paracetamol
75459610|NCT01821885|Behavioral|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
75612484|NCT02867475|Other|Physical activity motivation|Physical activity motivation
75612485|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
75612486|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
75612487|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
75612488|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
75612489|NCT02868177|Dietary Supplement|Totum-63|Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
75761937|NCT01055678|Drug|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
75761938|NCT01055678|Procedure|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
75761939|NCT00360230|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|2 different formulations are tested. For each formulation, 3 different dosing schedules are tested
75761940|NCT00360230|Biological|Rabipur|3-dose intramuscular injection.
75761941|NCT03988946|Device|Transcatheter Mitral Valve Replacement via Transseptal Access|The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
75761942|NCT03988712|Diagnostic Test|Colonoscopy, gastroscopy, virtual colonoscopy, CT scan|Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
75761943|NCT03989024|Drug|Gonadorelin|Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
75905973|NCT05730088|Other|Telephone interview:|Participants will be called every month by the researcher and asked if there are any hospital visits in that month, especially if they are chest disease visits.
75905974|NCT02171208|Drug|dimethyl fumarate - Reference form|single dose 240 mg
75905975|NCT02171208|Drug|dimethyl fumarate - Test form|single dose 240 mg
75612490|NCT02868177|Dietary Supplement|Placebo|Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
75612491|NCT02868099|Drug|Romiplostim|
75905976|NCT03180307|Drug|OTL38|0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
75905977|NCT03180307|Device|near infrared camera imaging system|Infrared imaging used to excite OTL38 for fluorescence
75612492|NCT02868099|Drug|Placebo|
75761944|NCT03989024|Drug|Clomiphene|Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
75761945|NCT03988790|Device|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
75905978|NCT03180307|Procedure|laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
75905979|NCT05634694|Other|No interventions.|No interventions.
75905980|NCT05139784|Other|Biosampling|Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.
75905981|NCT00140881|Drug|MK0476; montelukast sodium|
75905982|NCT00140881|Drug|Comparator: placebo|
75905983|NCT02917213|Other|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
75761946|NCT03987308|Drug|Beinaglutide|Five-week Beinaglutide pump treatment group
75761947|NCT03987308|Drug|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
75459611|NCT01821885|Behavioral|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
75459612|NCT01821911|Biological|Zagreb2-1-1|Injection on day 0、7、21
75761948|NCT01051154|Dietary Supplement|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
75905984|NCT02917213|Other|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
75905985|NCT02917213|Other|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
75612493|NCT02868021|Device|Strength testing|Test the strength of subject's lower extremity muscles on the dynamometer system
75905986|NCT02917213|Other|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
75459613|NCT01821911|Biological|Essen|Injection on day 0、3、7、14、28
75459614|NCT01821950|Behavioral|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
75612494|NCT02868021|Behavioral|Short Physical Performance Battery (SPPB)|The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
75612495|NCT02868021|Behavioral|Six-minute walk (SMW)|Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
75612496|NCT02868021|Behavioral|Numerical pain scale|Measure pain using an 11-point numerical pain scale.
75612497|NCT02868021|Behavioral|Self-assessed function|Using the Late Life Function and Disability Instrument.
75612498|NCT02868021|Procedure|Muscle biopsies|During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
75612499|NCT02868021|Device|Determination of 1 Repetition Maximum (1-RM)|Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
75612500|NCT02868021|Device|Blood flow restriction exercise|Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
75761949|NCT01051154|Dietary Supplement|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
75761950|NCT00348374|Drug|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
75459615|NCT01821989|Dietary Supplement|Lactoferrin|dose of 100 mg/day
75459616|NCT01821989|Dietary Supplement|Lactoferrin|dose of 150 mg/kg/ twice daily
75459617|NCT01821989|Dietary Supplement|Placebo|in form of distilled water
75459618|NCT01822002|Procedure|Canalith repositioning maneuver|
75459619|NCT01822028|Drug|Treatment A|Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
75459620|NCT01822028|Drug|Treatment B|"Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day)."
75761951|NCT00348374|Drug|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
75761952|NCT02533388|Device|Hwato Electronic Acupuncture Treatment Instrument|Thirty minutes prior to the induction of anaesthesia, the patients in the TEAS group started to receive TEAS by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model No.: SDZ-II, Suzhou Medical Appliances Co., Ltd., Suzhou, China) to the right hand, forearm and neck by an experienced acupuncturist at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints. TEAS was peformed with an alternate dense-disperse frequency of 2 and10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, The stimulus continued until 5 min before the end of surgery.
75761953|NCT02533388|Device|Placebo|The patients in the Sham group were also connected to the apparatus, but electronic stimulation was not applied.
75761954|NCT01054898|Behavioral|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
75761955|NCT01054898|Behavioral|usual community services|standard care for abused women in the community
75905987|NCT02917213|Procedure|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
75761956|NCT03742232|Drug|PEG3350|"PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
75761957|NCT03742232|Drug|Macrogol 4000|"SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
75612501|NCT02868021|Behavioral|Borg CR10 scale|Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
75761958|NCT00353366|Biological|Rotarix|Two doses of the oral vaccine
75761959|NCT00353366|Other|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
75459621|NCT01822041|Drug|ARN-509|Single oral dose of 240 mg ARN-509
75459622|NCT01822080|Drug|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
75459623|NCT01822080|Drug|Placebo|Matching placebo once daily by mouth
75459624|NCT01822093|Biological|Cytovir-ADV|"A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results > 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at ≥ 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.~This is a feasibility/pilot study and has no control group"
75459625|NCT01822106|Other|Placebo|
75459626|NCT01822145|Device|ICD|
75612502|NCT02868879|Other|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
75612503|NCT02867319|Biological|A dose of ACYW135 meningococcal polysaccharide vaccine|A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
75612504|NCT02869035|Drug|Escitalopram|Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
75612505|NCT02869035|Drug|Duloxetine|Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
75612506|NCT04121871|Other|No intervention|Not required
75761960|NCT03988478|Behavioral|Detoxification & psychotherapeutic support|
75761961|NCT00352664|Drug|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
75905988|NCT02917213|Other|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
75905989|NCT02917213|Other|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
75459627|NCT01822158|Other|Vaginal Delivery Debrief Checklist|Participating team members will utilize Vaginal Delivery Debrief checklist
75459628|NCT01822171|Other|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
75459629|NCT01822171|Other|Home medication if needed|Patient will be provided with medication to take home, when needed.
75459630|NCT01822171|Other|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
75459631|NCT01822210|Drug|Botox|injection by gastroscopy (100 Allergen units)
75761962|NCT00352664|Drug|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
75761963|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
75761964|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
75905990|NCT02848833|Drug|JARDIANCE 10mg|T2DM with JARDIANCE 10mg
75459632|NCT01822236|Other|Craniosacral Therapy Program|The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
75459633|NCT01822236|Other|One technique of craniosacral therapy|Decompression L5-S1: lumbosacral decompression
75905991|NCT02848833|Drug|JARDIANCE 25mg|MT2DM with JARDIANCE 25mgax
75905992|NCT05634616|Device|Motor imagery and motor execution based BCI|We designed a motor imagery and motor execution-based BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed
75459634|NCT01822249|Drug|EPI-743|
75905993|NCT05634616|Device|Sham BCI|The training equipment was the same, but the program was changed to record only the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set training performance data of the previous pretest patients, i.e., sham neurofeedback.
75905994|NCT02170506|Device|Urostim 2 stimulation|Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
75459635|NCT01822249|Drug|Placebo|
75612507|NCT02868957|Other|impression data from reference scanner|To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
75612508|NCT02868957|Device|iTero|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
75612509|NCT02868957|Device|Trios|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
75612510|NCT04290819|Dietary Supplement|Creatine Monohydrate|0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
75612511|NCT04290819|Dietary Supplement|Creatine Monohydrate and Caffeine|0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.
75612512|NCT04290819|Dietary Supplement|Caffeine|3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.
75612513|NCT04290819|Dietary Supplement|Placebo|0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
75761965|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
75761966|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
75761967|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
75761968|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
75459636|NCT01822262|Procedure|minimally invasive cholecystolithotomy with gallbladder reservation|
75459637|NCT01822262|Procedure|laparoscopic cholecystectomy|
75459638|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
75459639|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
75761969|NCT03991442|Drug|Fimasartan/Amlodipine|Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
75761970|NCT03742310|Drug|Vitamin D|Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
75905995|NCT03539328|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy.
75905996|NCT03539328|Drug|Gemcitabine|Chemotherapy medication
75612514|NCT02867943|Other|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
75612515|NCT01196429|Drug|Carboplatin|Given IV
75612516|NCT01196429|Drug|Docetaxel|Given IV
75612517|NCT01196429|Other|Laboratory Biomarker Analysis|Correlative studies
75612518|NCT01196429|Drug|Paclitaxel|Given IV
75612519|NCT01196429|Drug|Temsirolimus|Given IV
75612520|NCT02887703|Behavioral|Sensory Augmentation|Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
75612521|NCT01157364|Drug|bimatoprost 20 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.
75612522|NCT01157364|Drug|bimatoprost 15 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
75459640|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers earned independent of cocaine use
75459641|NCT01822340|Drug|HM10560A|Once weekly HM10560A
75612523|NCT01157364|Drug|bimatoprost 10 µg generation 2|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
75612524|NCT01157364|Drug|bimatoprost 6 µg generation 2|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
75612525|NCT01157364|Drug|bimatoprost 15 µg generation 1|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
75612526|NCT01157364|Drug|bimatoprost 10 µg generation 1|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
75612527|NCT01157364|Drug|bimatoprost 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
75905997|NCT03539328|Drug|Paclitaxel|Chemotherapy medication
75612528|NCT01195415|Drug|Gemcitabine Hydrochloride|Given IV
75612529|NCT01195415|Other|Laboratory Biomarker Analysis|Correlative studies
75612530|NCT01195415|Drug|Vismodegib|Given PO
75612531|NCT01195103|Drug|Fospropofol disodium|10 mg/kg bolus
75612532|NCT01195103|Drug|Fospropofol disodium|6.5 mg/kg bolus
75612533|NCT01195103|Drug|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients <60 kg; 1.5 mg for patients ≥60 kg to <90 kg; or 2 mg for patients ≥90 kg
75905998|NCT03539328|Drug|Liposomal Doxorubicin|Chemotherapy medication
75459642|NCT01822340|Drug|Genotropin|Once daily Genotropin
75459643|NCT01822379|Procedure|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
75459644|NCT01822392|Behavioral|Online Parent Management Training (Interactive)|
75459645|NCT01822392|Behavioral|Online Parent Management Training (Recorded)|
75459646|NCT01822405|Drug|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
75459647|NCT01822405|Other|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|"pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment."
75459648|NCT01822418|Drug|agomelatine|Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day
75459649|NCT01822431|Radiation|metaiodobenzylguanidine scintigraphy|
75612534|NCT01195103|Drug|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients <60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
75612535|NCT01194869|Drug|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
75612536|NCT01194869|Drug|Cisplatin|75 mg/m² given IV
75612537|NCT01194869|Drug|Paclitaxel|175 mg/m² given IV
75612538|NCT04317833|Drug|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
75905999|NCT03361189|Device|Closed loop stimulation|Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.
75761971|NCT03988556|Device|Photobiomodulation using CareMin650 at 6 Joules (curative intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2."
75761972|NCT03988556|Device|Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2."
75761973|NCT03988244|Device|HeartLight X3|Pulmonary vein isolation
75906000|NCT03361189|Device|Standard rate response|Standard rate response is an algorithm to increase heartrate based on movement
75459650|NCT01822483|Drug|Mycophenolate sodium|The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.
75459651|NCT01822483|Drug|Mycophenolate mofetil|Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg*h ml-1.
75761974|NCT01055210|Device|Optimisation of VV delay|Programmed VV delay altered on device
75761975|NCT00490139|Drug|Lapatinib|Small molecule inhibitor
75906001|NCT03579537|Other|Intradyalisis without exercise programe|patients on hemodialysis are evaluated with all the variables at first (T1) and without intervening in the treatment for 3 months they are evaluated again (T2).
76070004|NCT03984513|Behavioral|Surviving and Thriving in the Real World|The Surviving and Thriving in the Real World intervention consists of 14 weekly concurrent adolescent and parent group sessions. The daily living skills to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning daily living skills and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
75459652|NCT01822600|Drug|Human albumin|Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels < 25 g/L.
75612539|NCT04317833|Drug|Placebo|matched placebo
75612540|NCT01177800|Drug|Placebo|Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
75612541|NCT01177800|Drug|Infliximab|5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
75612542|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
75612543|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
75612544|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
75761976|NCT00490139|Biological|Trastuzumab|Antibody
75761977|NCT00348140|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
75761978|NCT00348140|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
75459653|NCT01822600|Drug|Omeprazole|"After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up."
75612545|NCT01177722|Biological|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
75612546|NCT02884986|Drug|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
75459654|NCT01822613|Drug|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
75761979|NCT00348140|Other|Placebo|Placebo
75459655|NCT01822613|Drug|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
75459656|NCT01822613|Drug|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
75612547|NCT02884986|Drug|Placebo|120mg of placebo
75612548|NCT04124562|Other|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
75761980|NCT01055990|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
75612549|NCT01177410|Drug|Placebo|placebo capsules once daily for 12 weeks
75761981|NCT01055990|Other|blood fix|The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
75761982|NCT01051388|Drug|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
75761983|NCT01051388|Drug|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
75761984|NCT01051388|Drug|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
75761985|NCT00490061|Drug|Lapatinib|1500 mg po daily orally
75761986|NCT00490061|Procedure|Radiotherapy (radiation)|Standard of Care
75906002|NCT03579537|Other|Intradyalisis with exercise programe|After 3 first month without intervention and also during the time of hemodialysis, the patients star the exercise programe, the first part of the session, an exercise was carried out for cardiovascular work (pedaling on ergometer) and muscle toning, with special attention to the muscular development of the lower limbs (exercises with elastic bands and / or weighted ankles). The session increased in duration and intensity as the physical action program progressed throughout the duration of the permitted period (3 months) and always attending to the individual needs of each subject. In addition, each of the participants will be given a series of recommendations of exercise practice to be carried out during non-hemodialysis days, in order to complement the work done during the sessions.3 month later the investigator evaluated all the variable again (T3)
75612550|NCT01177410|Drug|Mesalamine Granules 750 mg|750 mg mesalamine granules once daily for 12 weeks
75612551|NCT01177410|Drug|Mesalamine Granules 1500 mg|1500 mg mesalamine granules once daily for 12 weeks
75612552|NCT02884596|Drug|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
75612553|NCT05264220|Behavioral|ACT Matrix|Participants will receive a 4 session psychological intervention based on the ACT Matrix
75612554|NCT01156116|Device|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~________________________________________"
75761987|NCT00490061|Device|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|Standard of Care, used to deliver IMRT
75761988|NCT00490061|Device|DCE-MRI|A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
75761989|NCT01055366|Drug|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
75761990|NCT03988322|Other|Low-dose CT screening with quantitative assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 256-slice CT system). The CT images will be obtain according to the pre-defined CT scan protocol. This CT protocol is developed for quantitative assessment of lung nodules, COPD and coronary artery calcium. Detected lung nodules will be managed according to the European volume-based protocol, based on the volume and volume doubling time of lung nodule. COPD will be management according to the result of lung function test. The imaging biomarkers (eg., emphysema index, airway wall thickness, and coronary artery calcium ) will be quantitatively registered. In addition, a number of participants' characteristics will be collected: physical examination (weight, height, blood pressure), laboratory measurements (eg., fasting plasma glucose, total cholesterol, HDL-cholesterol). The social-demographic characteristics, risk factors of the 3 diseases, and health status of the participants will be collected through questionnaires.
75906003|NCT02171364|Procedure|Virtual ablation in based 3D CT of patient who diagnosed AF|
75906004|NCT02171364|Procedure|conventional ablation based on physician's personal experience|
75906005|NCT05634460|Drug|potassium hydroxide|Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
75459657|NCT01822613|Drug|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
75459658|NCT01822613|Drug|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
75612555|NCT01156116|Drug|Placebo|oral placebo tablet
75612556|NCT01155726|Device|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
75761991|NCT03988322|Other|Low-dose CT screening with visual assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 64 MDCT system). The CT images will be obtain according to the routine CT scan protocol for lung cancer screening in the hospital. Detected lung nodules will be managed according to the diameter of the nodule based on the NCCN Clinical Practice Guideline in Oncology for Lung Cancer Screening. Detected emphysema and/or bronchial wall thickness, coronary artery calcium will be qualitatively recorded (yes/no).
75906006|NCT00111709|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
75612557|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
75612558|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
75612559|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
75612560|NCT01155726|Device|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
75612561|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
75612562|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
75612563|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
75612564|NCT04205916|Drug|Dexamethasone|Drugs to be administer during cataract surgery to experimental group
75612565|NCT04205916|Other|Standard of care surgery|Standard method used for surgery and the use of post operative drops
75612566|NCT02886546|Procedure|pneumoperitoneum|
75761992|NCT04140695|Drug|Tradipitant|BID
75906007|NCT00111709|Drug|Comparator: placebo / Duration of Treatment - 1 day|
75906008|NCT02171442|Drug|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
75906009|NCT02171442|Drug|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
75906010|NCT02035527|Drug|sorafenib tosylate|Given daily PO in the a.m.
75906011|NCT02035527|Drug|cisplatin|Given IV over 1 hour following Docetaxel administration
75906012|NCT02035527|Drug|docetaxel|Given IV 1 hour prior to cisplatin administration
75906013|NCT02035527|Other|Correlative Studies|Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
75906014|NCT00092131|Drug|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
75906015|NCT00092131|Drug|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
75612567|NCT02886546|Device|oesophageal Doppler monitor|
75612568|NCT04315428|Behavioral|swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
75612569|NCT04315428|Behavioral|no swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
75906016|NCT05729854|Other|acupressure ( traditional and complementary medicine)|Acupressure will be applied to the shoulders, hands and legs of the women in the experimental group by the researcher.
75906017|NCT02170584|Drug|BIBR 953 ZW IV|
75906018|NCT02170584|Drug|BIBR 1048 MS tablet|
75906019|NCT02170584|Drug|BIBR 1048 MS oral solution|
75761993|NCT04140695|Drug|Placebo|BID
75906020|NCT02170584|Drug|BIBR 953 ZW IV Placebo|
75906021|NCT03577977|Drug|Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)|Betaferon was injected subcutaneously as prescribed by the treating physician.
75906022|NCT02175264|Genetic|Blood sample|
75459659|NCT01822626|Behavioral|motivational counseling|A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
75906023|NCT02668783|Drug|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
75906024|NCT02668783|Drug|Placebo vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
75761994|NCT01019681|Biological|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
75761995|NCT01019759|Procedure|pulmonary vein isolation|The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
75761996|NCT00483119|Drug|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
75761997|NCT00483119|Drug|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
75906025|NCT02668783|Drug|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
75906026|NCT03577899|Biological|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
75612570|NCT04315662|Other|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
75761998|NCT03996707|Other|Weight Bearing|Immediate protected weight bearing in a CAM walking boot following foot & ankle surgery
75761999|NCT03996707|Other|Strict non-weight bearing|Strict non weight bearing for 6 weeks following foot & ankle surgery
75906027|NCT03577899|Biological|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
75906028|NCT03577899|Biological|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
75906029|NCT02175342|Drug|Tiotropium 0.625 mcg/puff|
75906030|NCT02175342|Drug|Tiotropium 1.25 mcg/puff|
75612571|NCT04315662|Other|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
75762000|NCT00483041|Other|PLACEBO|Placebo administered as a single intravenous infusion
75762001|NCT00483041|Biological|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
75762002|NCT01016639|Other|oxaliplatin, capecitabine, radiotherapy|
75762003|NCT00501293|Drug|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
75459660|NCT01822639|Drug|GSK2944404 FDC|Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
75762004|NCT01014221|Other|Acupuncture|acupuncture administered in 8 sessions over 4 weeks
75762005|NCT01014221|Drug|Prednisolone|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
75762006|NCT00482729|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
75762007|NCT00482729|Drug|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
75762008|NCT01019837|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
75762009|NCT01014299|Other|Recruitment maneuver|"Assigned interventions:~No intervention after tracheal intubation (control group)~Alveolar recruitment maneuver (RM group) immediately after intubation"
75762010|NCT01014377|Device|VascuActive|
75762011|NCT00359762|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
75762012|NCT00359762|Drug|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
75762013|NCT03988010|Drug|Amantadine Sulfate|200mg/500ml i.v. solution for infusion
75762014|NCT03988010|Drug|Placebo (for amantadine sulphate)|500 cc 0.9% sodium chloride
75762015|NCT01055522|Drug|Arm 1: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
75762016|NCT01055522|Drug|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
76070005|NCT03984513|Behavioral|Program for the Education and Enrichment of Relational Skills|Program for the Education and Enrichment of Relational Skills is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning a get-together with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
75906031|NCT02175342|Drug|Tiotropium 2.5 mcg/puff|
75762017|NCT01055522|Drug|ARM 2: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
75762018|NCT03987152|Drug|Sirolimus|Daily intake of Sirolimus during Challenge and Rechallenge phase
75906032|NCT02175342|Drug|Tiotropium 5 mcg/puff|
75459661|NCT01822639|Drug|Amlodipine 5 mg|Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.
75459662|NCT01822639|Drug|Enalapril Maleate 20 mg|Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
75459663|NCT01822704|Device|Low intensity whole body vibration|
75612572|NCT01155024|Device|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
75762019|NCT01056146|Behavioral|Internet-based Interacting Together Everyday: Recovery After Childhood TBI|Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
75906033|NCT02175342|Drug|Placebo solution|
75906034|NCT02175342|Drug|Tiotropium-18 lactose powder|
75906035|NCT02175342|Drug|Placebo lactose powder|
76070006|NCT01855399|Behavioral|Peer Coaching|All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
75459664|NCT01822704|Device|High intensity whole body vibration|
75459665|NCT01822704|Behavioral|Leg exercises|
75612573|NCT01155024|Device|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
75612574|NCT01176240|Drug|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
75612575|NCT01176240|Other|Placebo|Placebo
75459666|NCT01822717|Behavioral|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
75459667|NCT01822717|Behavioral|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
75459668|NCT01822730|Drug|paliperidone|Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
75459669|NCT01822730|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
75459670|NCT01822769|Other|Cardiopulmonary rehabilitation|See Arm Description
75459671|NCT01822769|Other|Standard of care|See Arm Description
75612576|NCT00988221|Drug|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
75762020|NCT01056146|Behavioral|Internet Resources Comparison|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
75762021|NCT02533856|Other|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
75906036|NCT02175342|Drug|Tiotropium 10 mcg/puff|
75906037|NCT02175342|Device|Respimat|
75906038|NCT02175342|Device|Handihaler|
75906039|NCT02504203|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
76070007|NCT01855399|Behavioral|Decision Aid|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
75459672|NCT01822782|Biological|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
75612577|NCT00988221|Drug|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
75612578|NCT02884830|Device|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
75612579|NCT02886312|Device|Supplemental Oxygen Delivery System|
75459673|NCT01822795|Procedure|Lung volume reduction coïl treatment|
75459674|NCT01822795|Other|Regular medical treatment|
75906040|NCT04236934|Other|Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis|Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
75906041|NCT02171520|Drug|Dabigatran etexilate generation I|
75459675|NCT01822808|Drug|Hydralazine|Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
75459676|NCT01822808|Drug|Isosorbide Dinitrate|Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
75459677|NCT01822860|Drug|Chlorthalidone 12.5 mg|
75459678|NCT01822860|Drug|Hydrochlorothiazide 25 mg|
75459679|NCT01822860|Drug|Placebo|
75459680|NCT01822912|Other|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
75612580|NCT01149096|Procedure|Bone Marrow Donation|Undergo bone marrow harvest
75612581|NCT01149096|Biological|Filgrastim|Given subcutaneously
75612582|NCT01149096|Other|Laboratory Biomarker Analysis|Optional correlative studies
75612583|NCT02867397|Drug|Teysuno (S1) in combination with epirubicin and oxaliplatin|
75612584|NCT04291053|Drug|Huaier Granule|standard treatment + Huaier Granule 20g po tid for 2weeks
75762022|NCT00347438|Drug|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
75762023|NCT03987230|Drug|Sensitive Eyes® Plus Saline Solution|Sensitive Eyes® Plus Saline Solution
75459681|NCT01822912|Other|Heart Failure Usual Care|Subjects will receive standard of care.
75459682|NCT01822938|Other|incentive program for physical activity|
75459683|NCT01822951|Drug|Cerebrolysin|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
75612585|NCT02884518|Device|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
75762024|NCT03987230|Other|Oust™ Demodex® Wipes™|Oust™ Demodex® Wipes™
75906042|NCT02171520|Drug|Dabigatran etexilate generation II|
75906043|NCT03069118|Behavioral|Treatment - Workit Health Online Program|"The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI."
75906044|NCT03069118|Behavioral|Control - Resource List|Tailored list of resources.
75906045|NCT00092053|Drug|Placebo|tablets
75762025|NCT03987230|Other|I-LID N LASH PLUS® Eyelid Cleanser|I-LID N LASH PLUS® Eyelid Cleanser
75762026|NCT03987230|Other|Blephadex Lid Wipes|Blephadex Lid Wipes
75762027|NCT03987230|Other|Eye Cleanse Lid Wipes|Eye Cleanse Lid Wipes
75762028|NCT03987230|Other|Blephademodex|Blephademodex
75762029|NCT00329238|Drug|Dabigatran|Dabigatran 150 mg BID (twice daily)
75762030|NCT00329238|Drug|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
75762031|NCT00329160|Drug|Rosuvastatin|2.5-20 mg
75762032|NCT00329160|Drug|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
75762033|NCT00328926|Drug|Luveris® 75 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol [E2] levels). Total duration will be of 3 treatment cycles.
75762034|NCT00328926|Drug|Luveris® 25 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
75906046|NCT00092053|Drug|ibandronate|50 mg tablets
75906047|NCT03068182|Device|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
75459684|NCT01822951|Drug|Donepezil|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20."
75459685|NCT01822964|Device|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
76070008|NCT01875991|Drug|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
76070009|NCT01875991|Drug|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
75612586|NCT02884518|Behavioral|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
75612587|NCT02866851|Other|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
76070010|NCT04203927|Drug|Empagliflozin 25 MG|SGLT-2 inhibitor
76070011|NCT04196985|Diagnostic Test|PET/MRI|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
76070012|NCT04196985|Diagnostic Test|PET/CT|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
75612588|NCT01175382|Behavioral|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
75762035|NCT00328926|Drug|Placebo|Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
75762036|NCT00328926|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
75906048|NCT03068182|Device|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
75906049|NCT03068182|Other|Exercise|
75906050|NCT00101010|Biological|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
75906051|NCT00101010|Biological|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
75906052|NCT00101010|Biological|Rituximab|375 mg/m^2 intravenous piggy back (IVPB) on day 1, administered 1st
75459686|NCT01822964|Device|Placebo - current clinical practice, no cooling|
75459687|NCT01822977|Drug|omeprazole|
75459688|NCT01823003|Radiation|34 Gy in a single fraction|34 Gy in a single fraction in case of Distance to chest wall > 1 cm, tumour size < 2 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
76070013|NCT04201431|Biological|PvDBPII/Matrix-M1|50ug PvDBPII in 50ug Matrix M1
76070014|NCT01855243|Drug|regular insulin|
76070015|NCT01855243|Drug|70/30 insulin|
76070016|NCT01855243|Drug|Glargine|
76070017|NCT01855243|Drug|glulisine|
75762037|NCT00328926|Drug|Recombinant human chorionic gonadotropin (r-hCG)|When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
75906053|NCT00101010|Drug|Cyclophosphamide|750 mg/m^2 IVPB on day 1
75906054|NCT00101010|Drug|Pegylated liposomal doxorubicin hydrochloride|40 mg/m^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
75459689|NCT01823003|Radiation|54Gy 18Gy/fr. x 3 fractions|54Gy administered in 3 fractions of 18Gy in case of distance to chest wall > 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
75459690|NCT01823003|Radiation|60Gy (12 x 5 fr.s)|50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall < 1 cm, tumour size < 5 cm and distance to main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
75612589|NCT01175382|Drug|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
75612590|NCT01175382|Other|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
75612591|NCT01194245|Drug|Insulin lispro|
75612592|NCT01194245|Drug|recombinant human hyaluronidase PH20|
75612593|NCT01194245|Drug|Insulin aspart|
75612594|NCT01194245|Drug|Insulin glulisine|
75612595|NCT01194245|Drug|Insulin glargine|
75612596|NCT02887547|Procedure|micro-osteoperforation|
75612597|NCT04311528|Biological|9-valent HPV vaccine|9-valent HPV vaccine
75612598|NCT00979407|Biological|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
75612599|NCT00979407|Biological|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
75762038|NCT03982446|Genetic|Mutations|
75762039|NCT01063686|Device|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
75762040|NCT00319254|Drug|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
75762041|NCT00319098|Biological|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
75762042|NCT00319098|Biological|Fluarix|One intramuscular injection
75762043|NCT00319098|Biological|Placebo|One intramuscular injection
75762044|NCT00347360|Drug|lisinopril|
75906055|NCT00101010|Drug|Prednisone|40 mg/m^2 oral days 1 - 5.
75906056|NCT00101010|Drug|Vincristine Sulfate|2 mg IV, day 1
75906057|NCT03069040|Procedure|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
75762045|NCT00347360|Drug|carvedilol controlled release formulation|
75762046|NCT00319020|Drug|Bosentan|32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
75762047|NCT02532738|Drug|Routine Treatment of CD|The Drug including 6MP, AZA, infliximab and thalidomide
75906058|NCT03069040|Procedure|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
75906059|NCT03539172|Drug|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course
75906060|NCT03209401|Drug|Niraparib|an oral PARP inhibitor
75906061|NCT03209401|Drug|Carboplatin|a platinum-based injection
75906062|NCT05729698|Device|Baby warmer swaddle|Baby Swaddle with Heating System
75906063|NCT05729698|Other|polyethylene bag|polyethylene food bag
75906064|NCT02175420|Biological|BCG|
76070018|NCT03590847|Behavioral|Intermittent Fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
76070019|NCT04196829|Drug|silver diamine fluoride ⁄ potassium Iodide|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application
76070020|NCT04196829|Drug|Silver Diamine Fluoride|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
75906065|NCT02175420|Biological|TFV|
76070021|NCT03023787|Drug|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
76070022|NCT03023787|Drug|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
75612600|NCT01148862|Device|The MiniMed Paradigm® X54 System|"The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends."
75612601|NCT02884674|Device|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
75612602|NCT02884674|Device|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
75762048|NCT02532738|Biological|MSC treatment 01|Injection of 3×10E6/kg of MSC
75762049|NCT02532738|Biological|MSC treatment 02|Injection of 6×10E6/kg of MSC
75762050|NCT02532738|Other|NS|Injection of NS
75762051|NCT01056224|Drug|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
75762052|NCT03982680|Drug|Toripalimab|3mg/kg on d1 and d15 q4W*4cycles，then 3mg/kg q3w for 1 year in total
75762053|NCT03982680|Drug|Gemcitabine|1250mg/m2 on d1 and d15 q4W*4cycles
75762054|NCT03982680|Drug|5- fluorine pyrimidine|400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W*4cycles
75762055|NCT00352118|Biological|filgrastim|subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
75762056|NCT00352118|Biological|pegfilgrastim|If applicable on day 5, repeating every 3 weeks for 2 courses.
75762057|NCT00352118|Drug|cisplatin|Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
75906066|NCT03586011|Behavioral|Predicting factors for increased physical activity|
75906067|NCT02170740|Drug|BIBR 1048 MS - low dose|
75906068|NCT02170740|Drug|BIBR 1048 MS - high dose|
75906069|NCT02170740|Drug|BIBR 1048 MS + Pantoprazole|
75762058|NCT00352118|Drug|docetaxel|Intravenous over 1 hour on day 1.
75762059|NCT00352118|Drug|fluorouracil|Intravenous continuously on days 1-4.
75762060|NCT00352118|Procedure|conventional surgery|As appropriate, neck dissection.
75906070|NCT02848599|Drug|morphine|
75906071|NCT02848599|Drug|levobupivacaine|
75906072|NCT02175498|Drug|Homoeopathic medicines|4 pills once a week of the indicated Similimum
75906073|NCT03069274|Behavioral|Intervention|General nutritional recommendations, change drinking habits
75906074|NCT03069274|Behavioral|General nutritional recommendations|Only general nutritional recommendations were given
75906075|NCT02171598|Drug|Clopidogrel|
75906076|NCT02171598|Drug|Dabigatran high dose|
75906077|NCT02171598|Drug|Dabigatran low dose|
75906078|NCT03579303|Other|Homoeopathic Remedies|comparison between homoeopathic treatment and integrated approach of homoeopathy and yoga in menstrual disorders of females with PCOS
76070023|NCT03832725|Other|High Protein (HP) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HP diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
75906079|NCT03068962|Other|beetroot Juice|Beetroot Juice
75612603|NCT02866773|Behavioral|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
75762061|NCT00352118|Radiation|radiation therapy|60 Gy 5 days/week x 6 weeks with cisplatin
76070024|NCT03832725|Other|High carbohydrate (HC) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HC diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
76070025|NCT01825837|Drug|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
76070026|NCT01825837|Drug|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
76070027|NCT01825837|Drug|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
76070028|NCT01825837|Drug|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
75612604|NCT02866773|Behavioral|PA2: Education sessions, Reminders|"The intervention includes two components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
75762062|NCT01325376|Behavioral|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
75762063|NCT01325376|Behavioral|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
75762064|NCT00318474|Drug|Mycophenolate Mofetil (MMF)|Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.
75762065|NCT00318474|Drug|MMF Placebo|Placebo only, oral administration
75762066|NCT00318474|Drug|ACEi|Administer same as pre-treatment regimen.
75762067|NCT00318474|Drug|FOS|Administer same as pre-treatment regimen
75762068|NCT00350870|Drug|disulfiram|250mg per day of Disulfiram plus CBT
75762069|NCT00350870|Drug|Placebo|Placebo plus CBT
76070029|NCT04197063|Behavioral|Sweetened beverage portion size limit|
76070030|NCT03599115|Behavioral|Inhibitory Control Training|Computerized go/no-go task where individuals make responses to certain items (go trials) and withhold responses from certain items (no-go trials, in this case, trials surrounded by a black box). Intervention is designed to target and improve inhibitory control cognitive mechanisms in general (generic arm) or towards high-calorie foods specifically (food arm).
75762070|NCT00350870|Behavioral|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
75762071|NCT00350870|Drug|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
75762072|NCT03982290|Other|Probiotic, Lactobacillus plantarum PS128|PS128 capsules, 2 capsules per day
75762073|NCT03982290|Other|Placebo, microcrystalline cellulose|Placebo capsules, 2 capsules per day
75906080|NCT03068962|Other|Buxton water|natural mineral water
75906081|NCT03068962|Other|antiseptic mouthwash then beetroot juice|Chlorhexidine glocunate
75906082|NCT02171676|Drug|Docetaxel|
76070031|NCT04196673|Device|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
75762074|NCT00350792|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles
75762075|NCT00350792|Drug|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
75762076|NCT00317772|Drug|Topotecan|"Phase I Starting Dose: 2 mg/m^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."
75762077|NCT00317772|Drug|Gefitinib|"Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days."
75762078|NCT02533778|Device|mechanical thrombectomy|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
75762079|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
75762080|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
75762081|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
75762082|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
75906083|NCT02171676|Drug|BIBW 2992|
76070032|NCT04196673|Device|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
76070033|NCT03590379|Drug|CHF 5993 DPI|BDP/FF/GB DPI
76070034|NCT03590379|Drug|CHF5993 pMDI|BDP/FF/GB pMDI
76070035|NCT03590379|Drug|CHF 1535 pMDI|BDP/FF pMDI
75612605|NCT02866773|Behavioral|PA3: Education sessions, Whataps group|"The intervention includes two components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
75612606|NCT02866773|Behavioral|PA4: Education sessions|"The intervention includes one component only:~- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
75762083|NCT01325454|Device|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
75762084|NCT00350636|Drug|Oxybutynin topical gel|1 application daily to skin for 12 weeks
75762085|NCT00350636|Other|Placebo topical gel|1 application daily to skin for 12 weeks
75762086|NCT01051544|Drug|FVIII Concentrates|Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
75762087|NCT01051544|Drug|FVIII/VWF concentrates|Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
75762088|NCT03985670|Drug|teripalimab plus chemotherapy|teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
75762089|NCT03985670|Drug|chemotherapy plus teripalimab|paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
75762090|NCT01058720|Dietary Supplement|Vitamin D3|2000 IU orally once daily for 12 weeks
75762091|NCT00346268|Drug|Morphine, Parecoxib|Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
75906084|NCT03579225|Device|MATRx plus test|The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
75906085|NCT02170818|Other|Educational Workshop on Speaking-Up|Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
75906086|NCT02170818|Other|Unrelated Education (CPR)|Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
75906087|NCT03577743|Drug|Bevacizumab|-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
75906088|NCT04794790|Drug|Buprenorphine/naloxone|Buprenorphine/Naloxone induction via a standard dose protocol
75906089|NCT02171754|Drug|BIBW 2992|
75906090|NCT02171754|Drug|Ritonavir|
76070036|NCT03590379|Drug|Placebo DPI|CHF 5993 DPI matched placebo
76070037|NCT03590379|Drug|Placebo pMDI|CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
76070038|NCT03590301|Behavioral|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.
75459691|NCT01823003|Radiation|60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size < 5 cm and distance to the main bronchus < 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
75459692|NCT01823029|Drug|erythropoietin|
75459693|NCT01823029|Drug|enteral nutrition.|
75459694|NCT01823029|Drug|injection of iron|
75459695|NCT01822509|Biological|Ipilimumab|Given IV
75459696|NCT01822509|Other|Laboratory Biomarker Analysis|Correlative studies
75459697|NCT01822509|Biological|Nivolumab|Given IV
75762092|NCT00346268|Drug|Morphine, Placebo|Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
75612607|NCT02866773|Behavioral|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
75612608|NCT02866773|Behavioral|HD2: Education sessions, Reminders|"The intervention includes two components:~Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
75612609|NCT02866773|Behavioral|HD3:Education sessions, Whataps group|"The intervention includes two components:~Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
75612610|NCT02866773|Behavioral|HD4: Education sessions|"The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
75612611|NCT00975975|Drug|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
75762093|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
75762094|NCT00327444|Drug|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
75762095|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
75762096|NCT01051622|Other|Labeling Ceretec|Technetium-99m is used to radiolabel cells of interest i.e PBMC's
75762097|NCT03982134|Drug|PDR001|PDR001 is a humanized IgG4 antibody
75762098|NCT03982134|Drug|Panobinostat|Panobinostat is a Histone deacetylase inhibitor (HDACi).
75762099|NCT00337610|Drug|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
76070039|NCT03590301|Behavioral|Healthy Toddler Parent Group|The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
75762100|NCT00337610|Drug|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
75762101|NCT01062204|Device|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
75906091|NCT02238327|Procedure|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
75906092|NCT02238327|Procedure|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
75762102|NCT01062204|Device|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
75762103|NCT01062282|Drug|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
75459698|NCT01823042|Drug|azathioprine+enteral nutrition|
75459699|NCT01823042|Drug|Azathioprine|
75459700|NCT01823055|Procedure|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
75459701|NCT01823068|Drug|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
75459702|NCT01823081|Drug|Intravitreal injection of bevacizumab (Avastin)|
75459703|NCT01823081|Drug|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
75459704|NCT01823120|Other|Supportive and interactive text messages|
75459705|NCT01823133|Drug|gemigliptin only|gemigliptin 50mg qd on day 1~7
75459706|NCT01823133|Drug|rosuvastatin only|rosuvastatin 20mg qd on day 1~7
75762104|NCT01324856|Procedure|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
75762105|NCT01324856|Procedure|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
75762106|NCT03981042|Device|Monitoring|"After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed"
75762107|NCT03985280|Device|Cooled radiofrequency|Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.
75612612|NCT04021485|Other|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~Standardized neurological exam~Morphometric measurements including height, weight, head circumference~Blood pressure measurement~Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~Social Relativeness, using Social Relativeness Scale parental questionnaire,~Parental stress using PSI questionnaire"
75762108|NCT03985280|Drug|Intraaticular steroids and local anesthetic injections|Intraaticular steroids and local anesthetic injections
75762109|NCT01058876|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
75762110|NCT03986918|Device|Routine Total Hip Arthroplasty|Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.
75762111|NCT03986840|Other|Exercise training|A multicomponent exercise program
75762112|NCT03986762|Drug|Clavulanic Acid|~10 days of Clavulanic Acid
75762113|NCT01051700|Drug|GW786034|Investigational product
75762114|NCT01051700|Other|Placebo|Placebo
75762115|NCT01051934|Drug|SS1 (dsFv) PE38|
75612613|NCT01193153|Drug|Placebo|monthly by i.m. injection for 15 months
75612614|NCT01193153|Drug|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
75762116|NCT01051934|Drug|Paclitaxel|
75762117|NCT01051934|Drug|Carboplatin|
75762118|NCT01051934|Drug|Bevacizumab|
75762119|NCT01056458|Other|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
75762120|NCT01056458|Other|sham acupressure|use only tape without ear adhesive beads under the same ways
75762121|NCT01325168|Drug|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
75762122|NCT01325168|Drug|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
75762123|NCT00316914|Drug|calcium gluconate|Given IV
75459707|NCT01823133|Drug|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1~7
75459708|NCT01823159|Drug|retigabine|Single oral administration of a 400 mg tablet.
75459709|NCT01823159|Drug|placebo|Single oral administration of a tablet
75612615|NCT02867007|Drug|KHK2455|oral dosing
75762124|NCT00316914|Drug|magnesium sulfate|Given IV
75762125|NCT00316914|Other|placebo|Given IV
75612616|NCT02867007|Drug|Mogamulizumab|i.v. administration
75612617|NCT04289883|Combination Product|Nano-particulated whey protein vs non-particulated whey protein (control)|Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.
75612618|NCT04289883|Combination Product|High molecular weight whey protein-alginate coacervates vs calcium alginate (control)|Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
75612619|NCT05387057|Behavioral|Exergame training according to the 'Brain-IT' exergame-based training concept|For an overview, our 'Brain-IT' exergame-based training concept consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) visuospatial skills. According to the training concept, each participant is instructed to train 5x/week for 24 min per session resulting in a weekly exercise volume of 120 min. All training sessions are planned to take place at participant's homes using the exergame training system 'Senso Flex' (Dividat AG, Schindellegi, Switzerland). For a detailed description of the complete 'Brain-IT' exergame-based training concept with sufficient details to allow full replication, consider our methodological paper (doi: 10.3389/fnagi.2021.734012).
75612620|NCT05387057|Behavioral|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
75762126|NCT01059032|Other|Using a 3 dimentional post processing filter|Using a 3 dimentional post processing filter
75762127|NCT03991676|Behavioral|Values-Based Behavioral Treatment|The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
75762128|NCT02532816|Dietary Supplement|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
75762129|NCT00336284|Other|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
75762130|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
75762131|NCT00316602|Biological|IMVAMUNE|Subjects receiving two subcutaneous vaccinations
75762132|NCT00335972|Drug|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
75762133|NCT00335972|Drug|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
75762134|NCT03983304|Device|The ZELTIQ System|The EMS device will be used to perform the treatments.
75762135|NCT03983460|Drug|Dupilumab|Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
75762136|NCT03983460|Drug|Optimized TCS treatment|Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
75459710|NCT01823172|Procedure|Methylene blue dye injection of sentinel lymph node|Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
75459711|NCT01823185|Drug|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
75762137|NCT03983460|Procedure|Biopsies|"Four skin biopsies (5 mm diameter) and ten microbiopsies (2 & 3 mm diameter) will be performed according the following schedule:~Day 0~a 5 mm section biopsy from a non-lesional skin~a 5 mm section biopsy from an active lesion~a 3 mm section microbiopsies from a non-lesional skin~a 3 mm section microbiopsies from an active lesion~a 2 mm section microbiopsies from a non-lesional skin~a 2 mm section microbiopsies from an active lesion~Day 28~a 5 mm section biopsy on improved/healed lesion~a 3 mm section microbiopsies on improved/healed lesion~a 2 mm section microbiopsies from non lesional skin identified at V1~a 2 mm section microbiopsies on improved/healed lesion~Day 168~a 5 mm section biopsy on improved/healed lesion~a 3 mm section microbiopsies on improved/healed lesion~a 2 mm section microbiopsies from non-lesional skin identified at V1~a 2 mm section microbiopsies on improved/healed lesion"
75906093|NCT02238327|Procedure|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
75906094|NCT02238327|Procedure|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to <88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
75906095|NCT02238327|Radiation|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
75459712|NCT01823185|Drug|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
75612621|NCT04289337|Dietary Supplement|Combined probiotics (1)|Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
75612622|NCT04289337|Dietary Supplement|Combined probiotics (2)|Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
75906096|NCT02238327|Procedure|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
75612623|NCT04289337|Dietary Supplement|Combined heat-killed probiotics (1)|Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
75612624|NCT04289337|Dietary Supplement|Combined heat-killed probiotics (2)|Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
75612625|NCT04289337|Dietary Supplement|Probiotic metabolites|Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
75612626|NCT04289337|Dietary Supplement|Placebo|Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
75459713|NCT01823250|Behavioral|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
75459714|NCT01823250|Behavioral|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
75762138|NCT03983460|Procedure|Skin prick-test|"Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~Negative control : saline solution~Positive control : histamine solution~Positive criteria of prick tests results are:~Positive control's diameter ≥ 3mm~And negative control's diameter < 3 mm~And tested allergen with wheal ≥ positive control, i.e. 3mm"
75612627|NCT02865369|Drug|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
75612628|NCT04290585|Other|Questionnaire Administration|Ancillary studies
75906097|NCT02238327|Procedure|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
75906098|NCT05729620|Device|Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
75762139|NCT03983460|Procedure|Blood sample collection|"A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA."
75762140|NCT01056614|Drug|fludarabine phosphate|Given IV
75762141|NCT01056614|Drug|busulfan|Given IV
75762142|NCT01056614|Biological|anti-thymocyte globulin|Given IV
75459715|NCT01823250|Behavioral|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
75459716|NCT01823250|Behavioral|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
75459717|NCT01823263|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
75612629|NCT04290585|Behavioral|Telephone-Based Intervention|Receive text message reminders
75612630|NCT01192295|Drug|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
75762143|NCT01056614|Drug|tacrolimus|Given IV and orally
75906099|NCT02995369|Device|DryShield|DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
75906100|NCT02995369|Other|Cotton rolls|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
75906101|NCT02171832|Drug|BI 1744 CL, low dose|
75762144|NCT01056614|Drug|methotrexate|Given IV
75459718|NCT01823263|Procedure|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
75762145|NCT01056614|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
75762146|NCT01056614|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
75762147|NCT01056614|Other|laboratory biomarker analysis|Correlative studies
75906102|NCT02171832|Drug|BI 1744 CL, high dose|
75459719|NCT01823263|Procedure|Interference task|30-minute interference task
75612631|NCT02866929|Procedure|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
75612632|NCT02866929|Device|Orthodontics|Self-ligation brackets in upper and lower teeth
75612633|NCT02866929|Drug|Mucograft|Porcine naturally cross-linked collagen matrix
75612634|NCT04289181|Other|Medically Tailored Meals|4 weeks of medically tailored meals
75612635|NCT02865291|Device|ForConti device|
75612636|NCT04317365|Other|Women receiving extra remembering by healthcare|Women receiving extra remembering by healthcare in covid infection
76070040|NCT03599037|Other|ICOUGH Recovery App v2.0|"The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol."
75906103|NCT05633524|Other|blood sample analysis|All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
76070041|NCT03598881|Other|Treatment|
75459720|NCT01823263|Behavioral|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
75459721|NCT01823263|Behavioral|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
75459722|NCT01823263|Behavioral|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
75459723|NCT01823276|Other|Tyrosine-Containing Bar|
75459724|NCT01823276|Other|Placebo Bar|
75459725|NCT01823302|Dietary Supplement|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
75612637|NCT04289103|Biological|Inolimomab (Leukotac)|"Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~Treatment phase - Leukotac will be given up to D28~Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion."
75612638|NCT04316897|Device|Echocardiography|It is a an observational cross-sectional echocardiographic screening study in Assiut Governate conducted after seeking approval from the local institutional review board and human subjects' protection.
75459726|NCT01823302|Other|nutritional counseling|nutritional counseling
75612639|NCT04272879|Other|Observational Group|Those requiring NIV following an acute exacerbation of COPD
75612640|NCT01154166|Drug|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
75612641|NCT01154166|Drug|Placebo|Placebo
75612642|NCT04290195|Drug|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Intravitreal injection of 1.25 mg of ziv aflibercept in patients
76070042|NCT04196517|Other|Educational Tool, PALS|The Patient Activated Learning System is a free, health education platform.
76070043|NCT04196517|Other|WebMD|WebMD is a widely used educational platform for health information.
75612643|NCT05656937|Procedure|internal jugular venous cannulation|internal jugular venous cannulation
75762148|NCT03983538|Other|Mathematical modeling to predict response to chemotherapy|Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.
75762149|NCT00346034|Drug|Pregabalin|150 to 600mg/day
75762150|NCT00345878|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
75762151|NCT00345878|Biological|HPV-16/18 L1 VLP AS04 (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
75762152|NCT01052090|Drug|PHN121|a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
75762153|NCT01056692|Drug|OC000459|Capsules twice daily for 15 days
75762154|NCT01056692|Drug|Placebo|Capsules twice daily for 15 days
75762155|NCT01059110|Drug|Salicylate ointment|cream, one application every night, for 90 days
76070044|NCT03590223|Procedure|Coronary Bypass Revascularization|analysis of perioperative major cardiovascular events in diabetic patients
75612644|NCT04317131|Diagnostic Test|Research Diagnostic Criteria of Functional Disorders of the Masticatory System BKD / ZCURNŻ - Polish version|Interview and clinical examination of stomatognathic system based on standardized tool BDK/ZCURNŻ.
75612645|NCT04317131|Device|Clinical examination of the stomatognathic system (structural and functional)|Examination with the use of JMA+Analyser (Jaw Motion Analyser) to analyse movement and function of the temporomandibular joints, mandibular position, condyle position (EPA), and access the muscle action potentials through bipolar skin surface electrodes EMG, assessment of occlusion by visual method according to Angle Classification.
75612646|NCT04317131|Device|3D examination of the body posture|Comprehensive, three- dimensional examination of the body posture (static and dynamic) in the area of the spine, lower limbs and feet, performed by photogrammetric method (4th Generation MORA) and non- invasive image acquisition technology with the aid of infrared (Kineod) and The CQElektronik system.
75612647|NCT04317131|Device|Functional assessment of the spine and lower limbs|Functional assessment of the spine and lower limbs mobility trough a wireless motion sensor Moover.
75612648|NCT04317131|Device|Complementary tests|Anthropometric measurements (height, weight, waist and hip circumference, skin folds), foot pressure on the ground and body balance accessed by pedobarograph FreeMed, body mass components measured by the Tanita MC 980 MA (BIA method), evaluation of 7-days of physical activity by accelerometer ActiGraph GT3X-BT, blood pressure measurement by Medel Connect Cardio MB 10 monitor.
75612649|NCT02865603|Behavioral|PAX Good Behavior Game|PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
75612650|NCT05656859|Behavioral|Single group|Survey
75612651|NCT04289259|Other|TMB assessment|Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).
75612652|NCT04313556|Procedure|Lateral patellar release|Arthroscopic lateral patellar reticular release
75762156|NCT01059110|Drug|Imiquimod|cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
75762157|NCT01059110|Drug|5-Fluoro-Uracil|cream, one application every night, during 12 hours, for 90 days
75762158|NCT01059110|Drug|Cryotherapy|2 cycles of 5 seconds after obtention of halo of white
75762159|NCT01059266|Drug|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
75762160|NCT03991364|Other|Constant gait speed group|The speed of the robot-assisted gait treatment is constantly applied for 5 times a week for 2 weeks.
75459727|NCT01823315|Drug|MTX 1|MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
75459728|NCT01823315|Drug|MTX 2|MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, >4h)
75459729|NCT01823315|Biological|Act-d|Act-d 0.6mg/m(2), IV, on day1,2
75459730|NCT01823354|Other|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
75762161|NCT03991364|Other|Increasing gait speed group|The speed of the robot-assisted gait treatment is gradually increase for 5 times a week for 2 weeks.
75762162|NCT03985436|Behavioral|Trek for Surgical Success|Cognitive behavioral therapy for pain
75762163|NCT03985124|Behavioral|Tuning in to Kids for Teachers|This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
75612653|NCT05656781|Other|Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)|Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
75612654|NCT05656703|Device|BIS guidance of anesthesia|Anesthesia is to be directed to a specific (light) level by the dosage of administered hypnotics and analgesics
75612655|NCT05656703|Other|Standard of Care|Anesthesia is administered as usual
75612656|NCT02866617|Device|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
75612657|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
75762164|NCT00335738|Drug|liposomal vincristine sulfate|Given IV
75762165|NCT00335738|Drug|carboplatin|Given IV
75762166|NCT00335738|Drug|etoposide|Given IV
76070045|NCT04196361|Diagnostic Test|Ultrasound|Point of care ultrasound as part of routine physical examination
76070046|NCT03590067|Other|Questionnaire|The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
75612658|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
75612659|NCT02865213|Device|OBA|"The intrusion of posterior teeth using removable appliance OBA."
75612660|NCT02865213|Device|Miniplates|"The intrusion of posterior teeth using temporary anchorage Miniplates."
75906104|NCT05225701|Behavioral|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.
76070047|NCT01854697|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
75612661|NCT02865213|Device|Miniscrews|"The intrusion of posterior teeth using temporary anchorage Miniscrews."
76070048|NCT01854697|Drug|Ribavirin|Tablet
76070049|NCT01854697|Drug|Telaprevir|Film-coated tablet
75612662|NCT05656079|Drug|Pegylated liposomal doxorubicin|Drug: Pegylated liposomal doxorubicin (35 mg/m2) will be administered by an intravenous infusion on day 1 of each21-day cycle.
75612663|NCT05656079|Drug|Epirubicin|Drug: Epirubicin (90 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
75762167|NCT02533076|Other|Challenge agent: capsaicin|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging."
75762168|NCT02533076|Other|Challenge agent: placebo|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging."
75762169|NCT02533076|Device|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
76070050|NCT01854697|Drug|Pegylated Interferon alpha 2-a (PegIFN)|Pre-filled syringe
76070051|NCT03591159|Other|Membran Sweeping|Cervical Membrane Sweeping by digital examination
76070052|NCT03590535|Diagnostic Test|4th Gen cTnT|"Current Fourth Generation Cardiac Troponin T Enzyme Assay"
76070053|NCT03590535|Diagnostic Test|5th Gen cTnT|"New Fifth Generation (High-sensitivity) Troponin T Enzyme Assay"
76070054|NCT01824979|Device|CPAP mask ( Pilairo)|
76070055|NCT01824979|Procedure|Other CPAP mask|
76070056|NCT03598803|Other|Survey|Urinary Incontinence Survey
76070057|NCT04195971|Diagnostic Test|Liver CT|Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.
76070058|NCT01824823|Drug|afatinib|Given PO
75459731|NCT01823354|Other|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
76070059|NCT01824823|Other|placebo|Given PO
76070060|NCT04196205|Biological|Anti-CD19 CAR-T|1 - 2×10^6 Anti-CD19 CAR-T cells/kg body weigh
76070061|NCT03598725|Drug|Coagulation Factor VIII|Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
75459732|NCT01823354|Other|Assessment of executive functions|"Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing)."
75459733|NCT01823354|Other|Medical consultation|open questions
76070062|NCT03598725|Drug|Prednisone|2mg/kg every day for 4 weeks then typering in 3 months
76070063|NCT03598725|Drug|Rituximab|375mg/Square meter for consecutive 4 months
75906105|NCT05225701|Behavioral|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
75459734|NCT01823367|Behavioral|Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
75612664|NCT05656079|Drug|Cyclophosphamid|Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
75459735|NCT01823380|Procedure|Blood test|Blood test
75459736|NCT01823393|Drug|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
75762170|NCT02533076|Device|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
75762171|NCT01056770|Drug|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
75762172|NCT03991598|Other|Exercise program|Exercise program in communities / Exercise program at home
75762173|NCT03991520|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
75762174|NCT03991520|Drug|Placebo|The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
75762175|NCT01056926|Behavioral|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
75762176|NCT01056926|Drug|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
75762177|NCT01056926|Drug|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
75762178|NCT01059422|Drug|Raltegravir; Abacavir/Lamivudine|Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
75762179|NCT02533700|Drug|CEOP/IVE/GDP chemotherapy regimen|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4"
75762180|NCT02533700|Drug|CEOP chemotherapy regimen for 6 cycles|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses"
75906106|NCT02175654|Drug|Regorafenib|
75906107|NCT02171910|Drug|Doxapram|
75612665|NCT05656079|Drug|Trastuzumab|Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
75459737|NCT01823393|Drug|NaCl|valvuloplasty is performed without heparin (placebo injection)
75459738|NCT01823406|Procedure|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
75459739|NCT01823406|Procedure|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
75459740|NCT01823445|Other|Xylitol disk|
75459741|NCT01823458|Behavioral|Lottery Insurance|
75459742|NCT01823458|Behavioral|Standard Lottery|
75459743|NCT01823471|Other|The use of I-scan in the detection of polyps in HNPCC|Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
75459744|NCT01823484|Device|AN 69 ST hemofilter|
75459745|NCT01823484|Device|AN 69 hemofilter|
75459746|NCT01823523|Drug|Cefazolin, Cephalexin, Clindamycin|
75459747|NCT01823562|Drug|lyophilized black raspberry confection|Given PO
75612666|NCT05656079|Drug|Pertuzumab|Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
75612667|NCT05656079|Drug|Docetaxel|Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
75612668|NCT00975585|Device|senofilcon A|soft contact lens, 2-week replacement indicated
75612669|NCT00975585|Device|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
75906108|NCT02171910|Drug|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
75906109|NCT05061355|Procedure|Heart valve surgery|Heart valve surgery will be performed as soon as possible and preferably within 48 hours
76070064|NCT04196127|Other|Bite force testing|Maximum bite force examination with a force intra-oral measuring device
76070065|NCT03598569|Other|dyspnea|dyspnea assessment
75762181|NCT01059500|Device|Webtool|Webtool provides the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP <2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP >5.5%: proceed to provocative testing. For PE, PTP<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP>20% consider empiric anticoagulation with heparin if no contraindications.
75906110|NCT02975167|Other|Outpatient Cervical Ripening|The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
75762182|NCT01052246|Drug|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
75762183|NCT01052246|Device|Pulsed dye laser|"Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~Wavelength 585 nm~Energy fluence 3 J/cm2~Pulse duration 0.35 msec~Spot size 7 mm"
75762184|NCT01059578|Drug|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
75762185|NCT01059578|Drug|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
75762186|NCT01059578|Radiation|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
75906111|NCT02975167|Other|Inpatient Cervical Ripening|Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
75906112|NCT02975167|Procedure|Foley catheter placement|Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
75906113|NCT02975167|Behavioral|Pre-Foley Questionnaire|Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
75906114|NCT02975167|Behavioral|Post-Foley Questionnaire|Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
75906115|NCT02975167|Procedure|Fetal Non-Stress Test|Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
75459748|NCT01823562|Other|laboratory biomarker analysis|Correlative studies
75459749|NCT01823562|Dietary Supplement|dietary intervention|Follow a low polyphenol diet
75459750|NCT01823562|Dietary Supplement|dietary intervention|Follow a low ellagitannin diet
75459751|NCT01823562|Procedure|quality-of-life assessment|Ancillary studies
75459752|NCT01823562|Other|questionnaire administration|Ancillary studies
75459753|NCT01823575|Device|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
75459754|NCT01823575|Device|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
75459755|NCT01823588|Behavioral|Nurse-led reminder through email.|"Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form."
75459756|NCT01823601|Behavioral|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
75459757|NCT01823601|Behavioral|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
75459758|NCT01823627|Procedure|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
75459759|NCT01823640|Other|placebo|
75612670|NCT01181921|Drug|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
75612671|NCT02883894|Other|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
75762187|NCT01059656|Drug|Pazopanib|Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
75762188|NCT00334958|Drug|Placebo|For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
75762189|NCT00334958|Drug|Rufinamide|For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
75762190|NCT01059734|Genetic|DNA analysis|
75906116|NCT04518930|Other|Peanuts or plain Greek yogurt|Two different types of dietary snacks
75906117|NCT03068884|Device|Cathodal Transcranial direct current stimulation|Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
75906118|NCT03068884|Dietary Supplement|L-Tyrosine|Administration of 2 grams tyrosine
75906119|NCT03068884|Device|Transcranial direct current stimulation (sham)|Sham tDCS
75906120|NCT03068884|Dietary Supplement|Cellulose (placebo)|Administration of 2 grams cellulose
75459760|NCT01823640|Other|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
75459761|NCT01823692|Other|ultrasonography|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
75459762|NCT01823705|Device|Exilis Implantable Gastric Electrical Stimulation (GES)|
75459763|NCT01823718|Biological|Injection of allogenic CTL EBV specific|
75459764|NCT01823744|Dietary Supplement|micronutrient supplementation|
75459765|NCT01823757|Other|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
75762191|NCT01059734|Genetic|RNA analysis|
75762192|NCT01059734|Genetic|mutation analysis|
75762193|NCT01059734|Genetic|polymerase chain reaction|
75762194|NCT01059734|Genetic|polymorphism analysis|
75762195|NCT01059734|Other|laboratory biomarker analysis|
75906121|NCT02175732|Behavioral|'KnowIt'|"Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
75906122|NCT02175732|Behavioral|'OnTrack'|"Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
75612672|NCT05655923|Biological|ozonized olive oil|ozonized oil will be mixed with xenograft in group II and Group III
75612673|NCT05655923|Biological|xenograft bone substitute|Xenograft bone substitutes in all Groups
75612674|NCT02867241|Behavioral|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
75762196|NCT03986528|Drug|Kanglaite Injection+Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.
75906123|NCT04957225|Behavioral|MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)|Multimodal intensive treatment of aphasia and AOS
75762197|NCT03986528|Drug|Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
75762198|NCT01057082|Dietary Supplement|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
75762199|NCT01057082|Dietary Supplement|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
75762200|NCT00326898|Other|Laboratory Biomarker Analysis|Correlative studies
75762201|NCT00326898|Other|Placebo|Given PO
75762202|NCT00326898|Other|Quality-of-Life Assessment|Ancillary studies
75459766|NCT01823770|Drug|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
75762203|NCT00326898|Drug|Sorafenib Tosylate|Given PO
75762204|NCT00326898|Drug|Sunitinib Malate|Given PO
75762205|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
75762206|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
75762207|NCT01062360|Drug|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
75762208|NCT01062360|Drug|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
75906124|NCT02178306|Drug|Telmisartan low dose|
75906125|NCT02178306|Drug|Telmisartan high dose|patients switch to high dose if mean SBP >= 85 mmHg after 4 weeks of treatment
75762209|NCT01062438|Genetic|DNA analysis|
75762210|NCT01062438|Genetic|RNA analysis|
75762211|NCT01062438|Genetic|gene expression analysis|
75762212|NCT01062438|Genetic|gene rearrangement analysis|
75762213|NCT01062438|Genetic|mutation analysis|
75762214|NCT01062438|Other|laboratory biomarker analysis|
75906126|NCT02178306|Drug|Placebo|Run-in phase
75906127|NCT05729386|Drug|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
75906128|NCT05729386|Drug|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
75906129|NCT05729386|Drug|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
75906130|NCT05729386|Drug|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
75906131|NCT02178384|Procedure|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
76070066|NCT04766307|Drug|Interleukin-2|Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
75459767|NCT01823770|Drug|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
75612675|NCT02867241|Behavioral|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
75612676|NCT02867085|Other|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
75762215|NCT03982056|Other|this is an observational study there are no interventions|development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics
75762216|NCT01063842|Drug|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
75612677|NCT05655767|Other|4D-flow MR & CT-scan|4D-flow MR and CT-scan after cardiac surgery (until 12 months afterwards), for the purpose of obtaining more precise data on (hemo)dynamic processes within the cardiovascular system, in combination with data extraction from the established biobank and databank (FIBAA-bank).
75612678|NCT04317443|Procedure|Super-mini percutaneous nephrolithotomy (SMP)|SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
75612679|NCT04317443|Procedure|Extracorporeal Shock Wave Lithotripsy (ESWL)|ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
75762217|NCT01063842|Drug|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
75459768|NCT01823783|Other|Muscle biopsy|Muscle biopsy
75459769|NCT01823796|Other|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
75459770|NCT01823796|Other|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
75459771|NCT01823809|Device|adenosine stress Cardiac Magnetic Resonance Imaging|
75459772|NCT01823822|Dietary Supplement|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
75762218|NCT01063920|Drug|LT-NS001|1200 mg b.i.d. p.o. for 12 weeks
75762219|NCT01063920|Drug|Naprosyn®|500 mg b.i.d. p.o. for 12 weeks
75762220|NCT01062516|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
75762221|NCT01062516|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
75762222|NCT01063998|Other|Urine Marker|Urinary KIM-1 measurements
75762223|NCT03981120|Procedure|Laser and Traditional Acupuncture|Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
75762224|NCT01062594|Other|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
75762225|NCT01062594|Other|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
75762226|NCT01062594|Other|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
75906132|NCT02178384|Device|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
75459773|NCT01823822|Dietary Supplement|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
76070067|NCT03024801|Drug|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
76070068|NCT03024801|Drug|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
76070069|NCT03591237|Behavioral|Mindfulness-Based Cognitive Therapy|The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
76070070|NCT04195191|Other|ANM|communication intervention
76070071|NCT04195191|Other|Placebo|regular assistance in community pharmacies
75459774|NCT01823874|Procedure|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
75459775|NCT01823887|Device|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
75459776|NCT01823900|Drug|Test formulation|Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
75459777|NCT01823900|Drug|Reference formulation|Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
75459778|NCT01823913|Drug|Test formulation|A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
75459779|NCT01823913|Drug|Reference formulation|A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
75612680|NCT01174446|Biological|BAX 326|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX~Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only~Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1"
75612681|NCT01174446|Biological|BeneFIX|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.~BeneFIX only used in Part 1 of this study.~Study Part 2 and 3 only utilized BAX326"
75612682|NCT04316273|Other|colonic surgery|resection of duplicated colon
75612683|NCT00932698|Drug|Ixazomib|Ixazomib capsules
75612684|NCT00978627|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
75612685|NCT00978627|Drug|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
75612686|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
75762227|NCT00326118|Biological|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
75762228|NCT00326118|Biological|Priorix™|One subcutaneous dose at 12-18 months of age
75762229|NCT00326118|Biological|Hiberix™|One intramuscular dose at 12-18 months of age.
75762230|NCT00326118|Biological|Meningitec™|One intramuscular dose at 12-18 months of age
75762231|NCT00334802|Drug|gemcitabine|"Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)~Phase 2: dose determined by phase 1"
75762232|NCT00334802|Drug|paclitaxel|"Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles~Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"
75762233|NCT03985358|Other|Opioid counseling plus standard of care instructions|Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
75906133|NCT02178384|Procedure|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
75906134|NCT03068806|Diagnostic Test|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
76070072|NCT01875367|Drug|Trastuzumab Injectable Solution|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
76070073|NCT01875367|Drug|Trastuzumab Injectable Product|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
76070074|NCT01875367|Drug|Trastuzumab Injection|Powder for concentrate for solution for infusion. 1 cycle
75762234|NCT01052324|Drug|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
75762235|NCT00307164|Drug|NucleomaxX|36 g sachet taken orally three times daily
75762236|NCT00307164|Drug|NucleomaxX placebo|36 g placebo sachet taken orally three times daily
75762237|NCT01059890|Drug|cefotaxime|
75762238|NCT01059890|Drug|Metronidazole|
75762239|NCT01059890|Drug|Ciprofloxacin|
75762240|NCT01059890|Drug|Fosfocine|
75762241|NCT01057160|Drug|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
75762242|NCT01057238|Other|Intensive Communication System|Regular family meetings once a week, using a standard protocol
75762243|NCT03990974|Drug|postoperative antimicrobial prophylaxis|The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
75762244|NCT03990974|Other|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy unless necessary.
75762245|NCT03827564|Device|Intranasal Tear Neurostimulator (ITN) [TrueTear®]|The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
75762246|NCT00307086|Drug|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
75762247|NCT00307086|Drug|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
75762248|NCT00307086|Procedure|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
75762249|NCT03741998|Device|Nasopharyngeal airway|THRIVE with a regular nasopharyngeal airway.
75762250|NCT01060202|Drug|No intervention|This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
75762251|NCT01057316|Device|Formula PTX Stent - Dose 1|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
75762252|NCT01057316|Device|Formula PTX Stent - Dose 2|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
75762253|NCT01057316|Device|Formula PTX Stent - Dose 3|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
75762254|NCT02533544|Drug|tenofovir disoproxil fumarate|
75762255|NCT01052402|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
75762256|NCT03991208|Drug|Malarone|Malarone
75906135|NCT05729308|Procedure|caudal epidural block|"The patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound guidance using SonoSite M Turbo(USA).The scanning probe is the linear multi-frequency 6-13 MHz transducer (L25 x 6-13 megahertz linear array)that is covered in sterile plastic bag.Short axis (transverse view) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal view) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.25% bupivacaine will expand the epidural space"
75612687|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
75612688|NCT01181609|Drug|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
75762257|NCT00325416|Drug|melphalan|(Days -4,-3,-2) 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2)
75762258|NCT00325416|Drug|topotecan (TPT)|"Phase I Dose Escalation: Level 1 - 20 mg/m^2; Level 2 - 30 mg/m^2; Level 4 - 54 mg/m^2; Level 5 - 72 mg/m^2; Level 6 - 96 mg/m^2; Level 7 - 127.8 mg/m^2; Level 8 - 170.1 mg/m^2~Phase II: Treatment at maximum tolerated dose (MTD)"
75762259|NCT00325416|Procedure|Autologous Stem Cell Rescue|Day 0
75762260|NCT01060280|Behavioral|Education on active management|Routine clinical practice plus education on active management.
75612689|NCT01154010|Device|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
75612690|NCT01154010|Device|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
75612691|NCT02866305|Procedure|VATS bullectomy and mechanical pleuradesis.|Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.
75612692|NCT02866305|Procedure|Chest tube insertion|Conventional chest tube insertion.
75762261|NCT01060280|Other|Group GDS physiotherapy|Routine clinical practice (which will be substituted by Group GDS) plus education on active management.
75612693|NCT02866305|Drug|Epidural|All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
75612694|NCT02866305|Radiation|High-resolution Computer Tomography|All participants included in this study had a HRCT performed.
75612695|NCT04261426|Drug|Intravenous Immunoglobulin|IVIG 0.5g/kg/d for 5 days
75612696|NCT04261426|Other|Standard care|Standard care
76070075|NCT04194879|Diagnostic Test|multi-target FIT-DNA analysis|ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
75459780|NCT01823926|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
75612697|NCT04264078|Biological|CD7 UCAR-T cells|Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg
75612698|NCT04264078|Drug|Fludarabine|30mg/m^2 per day for 6 days
75612699|NCT04264078|Drug|Cytoxan|600mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline
75612700|NCT04264078|Drug|Melphalan|50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
75612701|NCT04290273|Diagnostic Test|MED Test|Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
76070076|NCT04197999|Drug|GMI-1359|Injection 10 mg/mL
75459781|NCT01823926|Device|Jet nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min."
75459782|NCT01823926|Device|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
75612702|NCT04290273|Device|Wearing device|Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.
75612703|NCT00608218|Drug|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
75612704|NCT01174368|Biological|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
75612705|NCT02884050|Drug|Topiramate|antiepilepsy drug
75612706|NCT02884050|Drug|Placebo|non-active placebo
75612707|NCT00609934|Drug|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
75612708|NCT00609934|Radiation|external beam radiotherapy|3000cGy in 10 fractions
76070077|NCT04195659|Procedure|Mastectomy and chest masculinization|A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
76070078|NCT03598335|Device|Ultrasound|Ultrasound imaging of women arriving at clinic for routine care
76070079|NCT04194957|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.
75612709|NCT01147926|Drug|Placebo|Placebo matched to Prucalopride tablet orally once daily.
75612710|NCT01147926|Drug|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
75612711|NCT05115136|Drug|Doxepin|25mg dose of Doxepin will be administered one time, by mouth
75612712|NCT05115136|Drug|Diphenhydramine|50 mg dose of Diphenhydramine will be administered one time, by mouth
75612713|NCT00608374|Drug|chlorambucil|
75612714|NCT00608374|Drug|fludarabine phosphate|
75612715|NCT00608374|Procedure|quality-of-life assessment|
75612716|NCT00975507|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
75612717|NCT00975507|Biological|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
75762262|NCT01060280|Other|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
75762263|NCT01060358|Procedure|method (non-surgical) to measure neuromuscular neutral zones|
75762264|NCT00314808|Drug|Dronabinol|Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
75762265|NCT03984734|Procedure|Pancreatoduodenectomy with antrectomy|
75762266|NCT03984734|Procedure|Pylorus-preserving pancreatoduodenectomy|
75906136|NCT05729308|Procedure|bilateral erector spinae plane block|The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of T12. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T12 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 15 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side
75906137|NCT05729308|Procedure|general anesthesia with intravenous analgesia.|"Multimodal therapy with acetaminophen, and nonsteroidal anti-inflammatory drugs (NSAIDs) will be used.~Vital data will be monitored as mentioned Intraoperatively, if the pulse rate and/or mean blood pressure increased above 20% of the baseline, IV fentanyl will be administered as an incremental dose of 50 µg.~The patients will be monitored for heart rate and blood pressure at regular 10-minute intervals. If blood pressure decreased more than 20% from baseline, then the patient will receive 500 mL saline infusion; if no response is seen, then 5 mg ephedrine will be administered. If heart rate decreased to 45 beats per minute, an IV injection of 0.1 mg /kg atropine will be administered."
75906138|NCT00778999|Drug|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
75612718|NCT00975507|Biological|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
75612719|NCT00975507|Biological|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
75612720|NCT00625014|Drug|Haloperidol|Haloperidol 3 mg/day for 8 days
75762267|NCT01060436|Device|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
75762268|NCT03981276|Other|Clinical rating scale to measure disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
75762269|NCT03981276|Diagnostic Test|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
75762270|NCT01060514|Drug|Pazopanib|dose escalation, administered orally, daily
75762271|NCT01060514|Drug|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
75762272|NCT03986606|Biological|PSB205|PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
75762273|NCT01057550|Procedure|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
75762274|NCT01057550|Procedure|TVT|Standard TVT as described by Ulmsten 1996
75762275|NCT01057550|Procedure|Pelvicol|retropubic mid urethral sling made from Pelvicol
75762276|NCT01061216|Device|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
75762277|NCT01061216|Device|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
75906139|NCT02171988|Drug|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
75612721|NCT04261348|Other|No intervention|There is no intervention
75612722|NCT04271163|Device|MemorEM|The MemorEM device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range to the entire forebrain, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. Everyday for the 12M treatment period, the subject's caregiver will administer one or two 1-hour treatments (two daily treatments during the first 2M period).
75459783|NCT01823939|Drug|iOWH032|"Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032."
75459784|NCT01823965|Drug|ranibizumab|
75762278|NCT00314574|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
75762279|NCT00314574|Drug|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
75762280|NCT00314574|Drug|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
75762281|NCT00314574|Drug|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
75762282|NCT01064154|Drug|Carvedilol|Carvedilol Tablets 25 mg
75612723|NCT04083339|Drug|AT-001|"AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date"
75762283|NCT00314340|Behavioral|Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity|The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
75762284|NCT00314340|Drug|ER Morphine|
75762285|NCT00314340|Drug|hydrocodone plus acetaminophen|
75762286|NCT00314340|Drug|placebo|
75762287|NCT00306852|Procedure|Baerveldt implant|Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
75762288|NCT00306852|Procedure|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant
75906140|NCT02171988|Drug|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
75906141|NCT02171988|Drug|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
75762289|NCT00314262|Drug|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."
75906142|NCT02171988|Drug|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
75906143|NCT05729230|Behavioral|Questionnaire|"Physician/data nurse and the patients will complete a questionnaire. The physician or data nurse must complete a descriptive form including the patient's age and gender as well as some information about the tumour and the underlying liver disease.~Based on the 4 open questions, patient will be classified into 2 groups after assessment of his answers by a group of digestive oncologists and psychologists. Group A includes patients with an accurate perception of the disease whereas group B will gather patients with unrealistic expectations. Psychosocial aspect, quality of the physician's communication, comprehension of the disease and treatment expectations are assessed by multiple-choice questions (Liker scale evaluation). Depression and anxiety were evaluated by the Hospital Anxiety and Depression Scale (HADS) that has been validated as a good scale with a high sensitivity and specificity for depression and anxiety for cancer patients."
75762290|NCT00333866|Drug|pregabalin|600mg/day
75762291|NCT00333866|Drug|pregabalin|450mg/day
75762292|NCT00333866|Drug|pregabalin|300mg/day
75762293|NCT00333866|Drug|placebo|placebo
75762294|NCT00324740|Drug|vorinostat|Given orally
75762295|NCT00324740|Drug|isotretinoin|Given orally
75762296|NCT00333788|Biological|Certolizumab pegol (CDP870)|400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
75906144|NCT00725413|Drug|etonogestrel implant (Implanon)|subdermal etonogestrel implant
75906145|NCT02172066|Behavioral|Narrative Exposure Therapy (NET)|
75906146|NCT02631850|Behavioral|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
76070080|NCT04194957|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are heterozygous carriers of c.1236G>A or c.2846A>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.
75612724|NCT04083339|Drug|Placebo|Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
75459785|NCT01823978|Biological|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
75459786|NCT01824004|Drug|S-1|
75459787|NCT01824017|Other|Blood Draw|
75612725|NCT01147848|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
75612726|NCT01147848|Drug|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
75612727|NCT01147848|Drug|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
75612728|NCT01147848|Drug|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
75762297|NCT00324116|Drug|pegaptanib sodium (Macugen)|0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
75762298|NCT00332696|Drug|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
75762299|NCT00332696|Drug|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
75762300|NCT00332696|Drug|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
75906147|NCT02631850|Behavioral|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
75906148|NCT02631850|Behavioral|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
75906149|NCT02631850|Behavioral|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
75762301|NCT00332696|Drug|Placebo|Physiologic saline solution
75612729|NCT00610090|Device|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
75762302|NCT00313716|Drug|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
75762303|NCT00313716|Other|placebo|an inactive substance
75762304|NCT00313170|Drug|Fulvestrant|intramuscular injection 250 mg & 500 mg
75762305|NCT00332462|Drug|Cyclosporine (Sandimmun® i.v.)|Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
75762306|NCT00332462|Drug|Cyclosporine (Sandimmun® Optoral)|Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
75762307|NCT03986450|Other|Enhanced recovery after surge(ERAS) protocol|"The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~Preoperative care:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization"
75762308|NCT00324038|Drug|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
75906150|NCT00103038|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
75762309|NCT00324038|Drug|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
76070081|NCT04194957|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
76070082|NCT04194645|Drug|BI 474121|Single dose
75459788|NCT01824030|Device|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
75459789|NCT01824030|Device|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
75459790|NCT01824056|Drug|18F-FDG|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
75459791|NCT01824069|Other|Intramuscular injection of a suspension of adult mesenchymal stem cells derived|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
75459792|NCT01824095|Dietary Supplement|Dietary supplement|
75612730|NCT00606658|Procedure|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
75612731|NCT02864823|Procedure|Perichondrium Autografts|Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
75612732|NCT00929656|Procedure|Real rTMS|rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
75612733|NCT00929656|Procedure|Sham rTMS|sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
75762310|NCT03984110|Drug|Ozurdex|Intravitreal injection
75762311|NCT03984110|Drug|Eylea|Intravitreal injection
75762312|NCT00159861|Drug|Sildenafil citrate|
75762313|NCT01057628|Drug|ipragliflozin|oral
75762314|NCT01057628|Drug|placebo|oral
75762315|NCT03967821|Other|Questionnaire|Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
75762316|NCT00331760|Drug|cisplatin|
75762317|NCT00331760|Radiation|intensity-modulated radiation therapy|
75762318|NCT00225147|Drug|Recombinant Human C1 Inhibitor|IV
75762319|NCT00225147|Drug|placebo|saline solution
75762320|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
75762321|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
75762322|NCT00313014|Drug|Oxycodone Immediate-Release|Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
75906151|NCT00103038|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DCE-MRI
75906152|NCT00103038|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DSC-MRI
75906153|NCT00103038|Drug|Ferumoxytol|Given IV
75906154|NCT00103038|Drug|Gadolinium|Given IV
75906155|NCT00103038|Procedure|MRI-Based Angiogram|Undergo MRA
75906156|NCT00620035|Drug|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
75762323|NCT01075659|Drug|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
75762324|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
75762325|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
75612734|NCT00929656|Procedure|Unimanual paretic UE Training|UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
75762326|NCT01077453|Drug|letrozole|Given orally
75762327|NCT01077453|Other|quality-of-life assessment|Ancillary studies
75762328|NCT01077453|Other|laboratory biomarker analysis|Correlative studies
75612735|NCT00629577|Genetic|microarray analysis|
75762329|NCT00157209|Biological|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
75762330|NCT00157209|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
76070083|NCT04194645|Drug|Placebo|Single dose
75459793|NCT01824108|Procedure|Lumbar discectomy|All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.
75612736|NCT00629577|Other|flow cytometry|
75612737|NCT00629577|Procedure|biopsy|
75612738|NCT00629577|Procedure|colposcopy|
75612739|NCT02866539|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
75459794|NCT01824108|Procedure|Lumbar discectomy combined with Wallis interspinous dynamic stability system|The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
75459795|NCT01824121|Biological|stem cell therapy|Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
75762331|NCT00157209|Other|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
75762332|NCT00312858|Biological|Comparator: VAQTA™ (Hepatitis A vaccine)|VAQTA™ 0.5 mL injection
75762333|NCT00312858|Biological|Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)|ProQuad™ 0.5 mL injection
76070084|NCT03023943|Other|Instrument Assisted Soft Tissue Mobilization|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
75612740|NCT02866539|Drug|Placebo|Similar looking inactive powder
75612741|NCT04261270|Drug|ASC09F+Oseltamivir|ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
75612742|NCT04261270|Drug|Ritonavir+Oseltamivir|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
75612743|NCT04261270|Drug|Oseltamivir|75mg ,once a day
75612744|NCT00977613|Behavioral|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
75612745|NCT01152996|Drug|Vortioxetine|Vortioxetine tablets
75612746|NCT04265716|Other|Topical L. reeuteri|Tubes with ointment containing L. reuteri DSM17938
75612747|NCT00608452|Other|Symptom Assessment Scale|"Memorial Symptom Assessment Scale~History and neurologic examination"
75612748|NCT00624936|Drug|Vidaza|Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
75612749|NCT00624936|Drug|Velcade|Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
75612750|NCT00979953|Drug|ADL5859|
75612751|NCT00979953|Drug|ADL5747|
75612752|NCT00979953|Drug|Oxycodone CR|
75612753|NCT00979953|Drug|Placebo|
75762334|NCT00312858|Biological|Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)|Prevnar™ 0.5 mL injection
75906157|NCT03068104|Other|No intervention|
75459796|NCT01824134|Other|Klean & Klear The Dandy Day Corp|
76070085|NCT03024021|Device|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia [36.5 C]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
76070086|NCT03598101|Device|TONEFITreha|The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
75459797|NCT01824134|Other|The Skin Gel Herbal Answers, Inc|
75459798|NCT01824173|Other|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
75459799|NCT01824173|Other|Aerobic exercise|Moderate intensity for 45 minutes
76070087|NCT04194567|Other|Black Ragi|Pancakes made out of the dark ragi
76070088|NCT04194567|Other|White Ragi|Pancakes made out of the white ragi
76070089|NCT04177797|Drug|Toripalimab|Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
76070090|NCT04194255|Dietary Supplement|ferrous fumarate|iron (100 mg) supplement in form of ferrous fumarate
76070091|NCT04194255|Dietary Supplement|ferrous fumarate + 15 g GOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
76070092|NCT04194255|Dietary Supplement|ferrous fumarate + 15 g FOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g FOS)
76070093|NCT04194255|Dietary Supplement|labelled iron as ferrous fumarate + 15 g acacia gum|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g acacia gum)
75459800|NCT01824186|Procedure|SILC|Underwent single-incision laparoscopic cholecystectomy
75459801|NCT01824186|Procedure|LC|Underwent conventional 4-port laparoscopic cholecystectomy
75459802|NCT01824199|Drug|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
75459803|NCT01824225|Drug|Aflibercept|
75762335|NCT03972189|Drug|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
75762336|NCT00312702|Biological|Falciparum Malaria Protein 11 with AS02A adjuvant|vaccine
76070094|NCT03598023|Device|Cytal® Burn Matrix|Cytal® Burn Matrix
76070095|NCT03598023|Device|EZ-Derm® Porcine Xenograft|EZ-Derm® Porcine Xenograft
76070096|NCT04406883|Drug|Extraction + filled with Simvastatin solution impregnated gelatin sponge|All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
76070097|NCT04199949|Behavioral|Inactivity|On days 1 and 6 of each main trial, the participants will be asked to attend the laboratory after an overnight fast of at least 8 to 12h to undergo brachial and popliteal arteries FMD measurements (30 min apart) using duplex-Doppler ultrasound, followed by assessment of the hand grip strength of their non-dominant hand using a hand dynamometer.
75459804|NCT01824238|Drug|Anacetrapib|
75459805|NCT01824238|Drug|Placebo for anacetrapib|
75459806|NCT01824251|Drug|NPB-01|
75459807|NCT01824264|Drug|LIK066|Experimental treatment doses
75459808|NCT01824264|Drug|Sitagliptin|Active comparator treatment dose
75459809|NCT01824264|Drug|Placebo|Placebo comparator dose
75459810|NCT01824277|Other|Structured Pre-operative Diabetes Optimization|Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
75762337|NCT01060878|Drug|PYM50028|IMP
75762338|NCT01060878|Drug|Placebo|Matching placebo comprising identical vehicle to active doses
75762339|NCT00156819|Drug|fluticasone|fluticasone (100 microgram twice daily) treatment
75762340|NCT00156819|Drug|montelukast|Montelukast (5 or 10 mg each night).
75906158|NCT03068728|Device|Arista|
75906159|NCT03068728|Device|Nexfoam|
75762341|NCT00156819|Drug|Fluticasone plus salmeterol|fluticasone (100 microgram) plus salmeterol (50 microgram) each night
75459811|NCT01824329|Procedure|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
75762342|NCT02532894|Device|Electronic cigarette|Inhaling e-cigarette vapor
75762343|NCT01077531|Drug|Otelixizumab|Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
75906160|NCT03068728|Device|Nasopore|
75906161|NCT02175888|Dietary Supplement|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
75906162|NCT02175888|Dietary Supplement|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
75906163|NCT05577637|Drug|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
75906164|NCT02176044|Drug|Sodium Nitroprusside infusion|
76070098|NCT04194177|Other|mechanical ventilation during robotic surgery|protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg
76070099|NCT04199559|Drug|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal
75459812|NCT01824329|Procedure|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
75612754|NCT05086198|Behavioral|Mindfulness-based intervention|An instructor trained in Mindfulness-based Stress Reduction (MBSR; Kabat-Zinn, 1990) will conduct meditations lasting 15 to 30 minutes. The participants will have a mobile application designed ad hoc with the practice of the week so they can do it individually at home.
75612755|NCT05086198|Behavioral|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The participants will watch it in a video platform. They will not be able to do anaerobic exercise like weight lifting. The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
75762344|NCT01077531|Drug|Matching placebo|Matching placebo for intravenous infusion
75762345|NCT03825042|Dietary Supplement|A mix of bioactive natural compounds|A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets
75762346|NCT03825042|Dietary Supplement|Placebo|Inactive compound in oral tablets
75762347|NCT01060956|Other|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
75762348|NCT01060956|Other|"reporting mixed growth on urine culture"|"reporting mixed growth on urine culture"
75762349|NCT00129987|Behavioral|Self management education|
75762350|NCT00224133|Drug|Silodosin|8 mg daily
75906165|NCT02176044|Other|Placebo|
75906166|NCT03067870|Biological|Stem Cell Transplantation|"Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~Transplantation of autologous bone marrow derived stem cells in joints."
75762351|NCT00224055|Drug|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
75906167|NCT05054491|Behavioral|Group Antenatal Care|Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
75906168|NCT02176122|Drug|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
75762352|NCT00224055|Drug|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
75906169|NCT02176122|Drug|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
75906170|NCT04887064|Drug|Sotorasib|Sotorasib will be administered as an oral tablet.
75906171|NCT02967757|Drug|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
75906172|NCT05632276|Device|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
75906173|NCT02261298|Drug|ONO-4538|
75906174|NCT02178618|Device|Deployment of Partially covered biliary self expandable metal stent|
75906175|NCT02178618|Device|Deployment of uncovered biliary self expandable metal stent|
76070100|NCT03597867|Other|Placebo|Artificial tears for 3 days preoperatively
76070101|NCT03597867|Drug|Dicloftil|Dosing of drug 3 days prior to surgery
76070102|NCT03597867|Drug|Nevanac|Dosing of drug 3 days prior to surgery
76070103|NCT03597867|Drug|Indom|Dosing of drug 3 days prior to surgery
76070104|NCT03597867|Drug|Yellox|Dosing of drug 3 days prior to surgery
76070105|NCT03597477|Drug|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
75762353|NCT03966573|Radiation|Radiographic imaging|Evaluating arthritis in knee and hip bilaterally. Evaluating axis deficiancy and leg length discrepancy.
75762354|NCT03966573|Other|Evaluating function|Test function and physical capasity
75762355|NCT03966573|Other|Forms|Forms for evaluating quality of life, pain, function
75762356|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, early treatment
75612756|NCT01181531|Drug|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
75762357|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, deferred treatment
76070106|NCT04199715|Biological|Heplisav-B|This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.
75762358|NCT01077609|Drug|Intermittent, sub-chronic and chronic Flixonase use|Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
76070107|NCT04193319|Drug|Fluzoparib|PARP inhibitor
75459813|NCT01824368|Procedure|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
75459814|NCT01824381|Procedure|Place amniotic membrane in large wounds|"After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.~The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.~We will place a new membrane weekly to a maximum of 6 times."
75906176|NCT02176200|Drug|Berodual® Respimat®, low inspiratory flow rate|
75906177|NCT02176200|Drug|Berodual® Respimat®, medium inspiratory flow rate|
75459815|NCT01824381|Procedure|Obtaining and Cryopreservation of amniotic membrane|
75459816|NCT01824381|Drug|amniotic membrane|
76070108|NCT04193319|Drug|Fluconazole|inhibitor
75612757|NCT01181531|Drug|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
75906178|NCT02176200|Drug|Berodual® Respimat®, high inspiratory flow rate|
75906179|NCT02176200|Drug|Berodual® HFA-MDI, low inspiratory flow rate|
75906180|NCT02176200|Drug|Berodual® HFA-MDI, medium inspiratory flow rate|
75906181|NCT02176200|Drug|Berodual® HFA-MDI, high inspiratory flow rate|
75906182|NCT03577665|Radiation|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
75906183|NCT03537612|Drug|Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
76070109|NCT03962985|Other|Guided tour at the Montreal Museum of Fine Arts|"The duration of the participation -3 months~The duration of the guided tour-45 minutes, each week~All participants will be asked to fill out some specific online questionnaires during their participations in the study"
75459817|NCT01824407|Device|Electrohydraulic-generated shock wave|
75459818|NCT01824407|Device|Sham device plus standard of care|
75459819|NCT01824420|Drug|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
75459820|NCT01824420|Drug|Detrusitol 4mg QD|Control group
75459821|NCT01824433|Drug|venlafaxine|venlafaxine 75-225mg qd
75459822|NCT01824433|Drug|fluoxetine|fluoxetine 20-60mg qd
75459823|NCT01824459|Drug|S-1|S-1：40~60mg bid，d1~14 q3W
75459824|NCT01824459|Drug|Oxaliplatin|oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W
75459825|NCT01824459|Drug|Cisplatin|cisplatin：60mg/m2，iv drip ，d1,q3W
75459826|NCT01824485|Drug|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
75459827|NCT01824485|Drug|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
75459828|NCT01824511|Behavioral|Smokers cease smoking|Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
75612758|NCT01152450|Drug|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
75906184|NCT03537612|Other|Morphine|Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
75612759|NCT01152450|Drug|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
75906185|NCT03579147|Device|Treatment with BTL EMSCULPT device|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
75612760|NCT01152450|Drug|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
75612761|NCT05085262|Diagnostic Test|Bloodwork, Echocardiogram, PET/MRI|The study will use blood samples from COVID biobank at University Health Network. Samples will be collected at time of admission to ER in patients discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers. Echocardiography studies will be assessed for structural and functional abnormalities. All included patients will have prospective short-term follow-up (3-6 months) for assessment of clinical events and subclinical cardiovascular disease. 50 patients who had clinical cardiac MRI at our center within 5 years prior to COVID-19 (January 2015-January 2020) and have since tested positive for COVID-19 will be recruited for research cardiac MRI to compare changes between baseline (pre-COVID) and follow-up (post-COVID imaging). A subgroup of 50 patients will undergo cardiac PET/MRI at 1-3 months post COVID-19 diagnosis to evaluate for myocardial inflammation and other imaging markers of cardiac injury.
75612762|NCT05085262|Diagnostic Test|Bloodwork, Echocardiogram, MRI|The study will involve use of blood samples from the COVID biobank at UHN (University Health Network) for measurement of blood biomarkers. Echocardiography Studies will be systematically assessed for structural and functional abnormalities. All included patients assessment of clinical events and subclinical cardiovascular disease.
75612763|NCT00610246|Drug|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
75612764|NCT04265560|Other|Progressive Resistance Training|Progressive resistance training programme for individuals following spinal cord injury.
75612765|NCT01181141|Drug|DU-176b (edoxaban)|
75612766|NCT01181141|Drug|Enoxaparin sodium 20mg|
75612767|NCT00606814|Drug|IPI-504, docetaxel|"IPI-504 administered IV at a dose of 300mg/m2~Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
75906186|NCT02172144|Drug|BI 1744 CL solution for inhalation|
75459829|NCT01824524|Drug|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
75459830|NCT01824550|Other|home-based exercise training condition|Home based endurance exercise training
75459831|NCT01824563|Other|Observational study|
75459832|NCT01824615|Drug|Sunitinib|37.5mg everyday from D1-D28
75459833|NCT01824641|Device|Eliminate aspiration catheter|Eliminate aspiration catheter
75459834|NCT01824641|Procedure|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
75459835|NCT01824654|Other|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
75612768|NCT01173120|Device|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
75612769|NCT05332691|Procedure|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
75612770|NCT00977379|Radiation|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
75906187|NCT02172144|Drug|Placebo matching BI 1744 CL|
75906188|NCT02172144|Drug|Moxifloxacin (Avalox®)|
75906189|NCT03579069|Other|Ductus venosus Doppler|Ductus venosus Doppler
75762359|NCT01077609|Drug|Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase|Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
75762360|NCT00223977|Drug|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
75762361|NCT00223977|Drug|Sodium Ferric Gluconate Complex|250 mg weekly x 4
75762362|NCT00223977|Drug|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
75762363|NCT01326273|Procedure|Lymphopheresis|Lymphopheresis
75762364|NCT01326273|Procedure|CMV specific lymphocyte infusion|CMV specific lymphocyte infusion
75762365|NCT01326273|Procedure|Peripheral blood for CMV DNA PCR|Peripheral blood for CMV DNA PCR
75762366|NCT01326273|Procedure|Haematology/Blood chemistry|Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.
75762367|NCT00148941|Biological|SB213503 lot 1|SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
75762368|NCT00148941|Biological|SB213503 lot 2|SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
75762369|NCT00148941|Biological|SB213503 lot 3|SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
75762370|NCT00148941|Biological|Infanrix|Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
75762371|NCT00148941|Biological|IPOL|IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
75459836|NCT01824654|Other|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
75459837|NCT01824667|Dietary Supplement|B-GOS|
75612771|NCT00977379|Drug|Capecitabine|825 mg/m^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
75612772|NCT00977379|Drug|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
75459838|NCT01824667|Dietary Supplement|Maltodextrin|
75459839|NCT01824680|Behavioral|Physical activity|"There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session"
75612773|NCT04263844|Drug|Intranasal dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
75612774|NCT04263844|Drug|Intranasal Midazolam|subject will receive premedication with intranasal midazolam thirty minutes before induction
75612775|NCT01180985|Device|galyfilcon A prototype lens|silicone hydrogel contact lens
75612776|NCT01180985|Device|comfilcon A|silicone hydrogel contact lens
75762372|NCT00148941|Biological|M-M-R II|M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
75762373|NCT01073553|Drug|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
75762374|NCT01073553|Drug|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
75762375|NCT00148317|Drug|Bortezomib|During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
75762376|NCT00148317|Drug|dexamethasone|During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
75762377|NCT00148317|Drug|liposomal doxorubicin|If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
75762378|NCT00148317|Drug|cyclophoshamide|During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
75762379|NCT00148317|Drug|filgrastim|During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
75762380|NCT01077765|Device|Eutrophill|Polyacrylamide Hydrogel
75459840|NCT01824706|Procedure|craniectomy|craniectomy
75612777|NCT00610324|Drug|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
75612778|NCT00610324|Drug|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
75612779|NCT01147536|Biological|HSPPC-96|
75762381|NCT00323882|Drug|MDX-010|selected dose administered IV every 3 weeks
75906190|NCT05729074|Drug|IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
75906191|NCT05729074|Drug|IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
75906192|NCT05729074|Drug|IN-A002 Ointment 1% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
75906193|NCT05729074|Drug|IN-A002 Ointment 3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
75906194|NCT05729074|Drug|IN-A002 Ointment 5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
75906195|NCT05729074|Drug|IN-A002 Ointment 1%|Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
75906196|NCT05729074|Drug|IN-A002 Ointment 3%|Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
75906197|NCT05729074|Drug|Elidel Cream 1% (pimecrolimus)|Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
75906198|NCT02176512|Drug|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
75906199|NCT02176512|Drug|BIBR 277 SE|Treatment B - Monocomponent
75459841|NCT01824758|Drug|Lidocaine|Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
75612780|NCT01154088|Biological|Mencevax ACWY|One dose, Subcutaneous injection
75906200|NCT02176512|Drug|HCTZ|Treatment B -Monocomponent
75906201|NCT03537534|Drug|Lidocaine Jet Injector|Applying Lidocaine following endourologic procedure
75906202|NCT03537534|Drug|Placebos|Applying surgilube following endourologic procedure
75459842|NCT01824758|Drug|Esmolol|Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
75459843|NCT01824758|Drug|rocuronium|0.05 mg/kg rocuronium
75459844|NCT01824758|Drug|Placebo|Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
75459845|NCT01824810|Procedure|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
75612781|NCT01154088|Biological|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
75612782|NCT02864901|Drug|KSL-W|Plaque reducing gum
75612783|NCT02864901|Drug|Chewing Gum Placebo|
75612784|NCT04288791|Other|Equia Forte Fil|Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.
75612785|NCT04288791|Other|Zirconomer Improved|Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
75762382|NCT00331682|Drug|alvocidib|Given IV
75762383|NCT00331682|Drug|docetaxel|Given IV
75762384|NCT00323492|Drug|Truvada|Truvada + NNRTI or PI.
75762385|NCT00323492|Drug|Current HAART regimen|Maintain baseline regimen
75762386|NCT00331136|Drug|Pyronaridine-Artesunate|Once a day for 3 days
75906203|NCT03578991|Device|Smart pillbox|The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
75906204|NCT03578991|Other|Interactive digital platform|The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
76070110|NCT04192851|Procedure|Tent Pole Technique|"All patients were operated under local or general anaesthesia according to the case and patient tolerability.~The oral cavity was prepared by 0.12% chlorhexidine mouthrinses solution* for thirty seconds.~Full thickness incision down to the bone with blade no.15.~A periosteal elevator was used to perform mucoperiosteal flap.~Gentle elevation of the flap~Fixation of the screws over the alveolar ridge with about 5 mm of the screw threads will be exposed~Bone graft was mixed with the patient blood and placed to cover the screws completely.~PRF membrane was be placed over the grafted sites.~Repositioning of the flap and suturing with 3/0 black silk suture material"
75612786|NCT04260724|Device|TMS|"stimulation intensity : motor threshold 100%~stimulation frequency : 1600 pulses for 20 minutes~stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )"
76070111|NCT03957135|Procedure|Laparoscopic distal pancreatectomy|Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer
76070112|NCT03957135|Procedure|open distal pancreatectomy|Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
75612787|NCT04260724|Device|sham coil stimulation|no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
75612788|NCT04313322|Biological|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
75612789|NCT02884284|Other|clinical biological database collection|
75612790|NCT02884128|Drug|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
75612791|NCT02884128|Drug|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
75762387|NCT03983798|Other|Simulation training in psychiatry|"Each participant will complete 6 hours of psychiatric simulation training, dealing with mood disorders, anxious disorders, eating disorders, borderline disorders, substance abuse and schizophrenia. Simulation training will be supplemented by brief lecture on concept map and portfolio at the beginning of the first hour.~Curriculum integration of simulation training in psychiatric course assure that each pathology studied is supplemented by a one-hour lecture and 1 to 3 hours clinical cases and MCQ training. A part of the medical students are supplemented by clinical practice ; whereas the other won't benefit from clinical practice."
75762388|NCT01057706|Other|chiropractic|spinal manipulation and mobilization
75762389|NCT01057706|Behavioral|exercise|strengthening, stretching, balance
75762390|NCT00323414|Drug|Polyunsaturated fatty acid (Opti-EPA)|Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)[360 mg EPA and 240 DHA in each capsule] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
75762391|NCT00323414|Drug|Placebo|Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
75762392|NCT03984032|Device|LMA Protector Cuff Pilot|Assessing the clinical performance of LMA Protector Cuff Pilot
75762393|NCT03984032|Device|LMA Supreme|Assessing the clinical performance of LMA Supreme
75906205|NCT05632198|Other|Survey|Valid and reliable questionnaires covering perceived uncertainty, self-care behaviors and quality of life will be administered.
75612792|NCT02884128|Drug|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
75612793|NCT00629343|Drug|Azacitidine In Combination With Temozolomide|mg, oral
75612794|NCT02864745|Device|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
75612795|NCT02864745|Other|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
75762394|NCT01325324|Device|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
75762395|NCT03983642|Device|Wii balance board|"Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level."
75906206|NCT02604277|Behavioral|Interpersonal and Social Rhythm Therapy (ISRT)|Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.
76070113|NCT03956979|Drug|JM-010 group A|JM-010 fixed combination drug (Group A) + Placebo 2
76070114|NCT03956979|Drug|JM-010 group B|JM-010 fixed combination drug (Group B) + Placebo 1
76070115|NCT03956979|Drug|Placebos|Placebo 1 + Placebo 2
76070116|NCT04190901|Behavioral|Simulated Black Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
76070117|NCT04190901|Behavioral|Simulated Black Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
75762396|NCT00330668|Drug|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
75762397|NCT00306384|Drug|Alogliptin|Alogliptin tablets.
75762398|NCT01062750|Biological|adipose tissue derived stromal cells dosage|single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
75762399|NCT03980964|Device|Active NMES|Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
75762400|NCT01062828|Diagnostic Test|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
75762401|NCT01062906|Drug|Lidocaine|1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
75762402|NCT01062906|Drug|Fentanyl|Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
75459846|NCT01824810|Procedure|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
75612796|NCT01180049|Drug|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
75762403|NCT00305604|Drug|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
75762404|NCT00305604|Drug|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
75762405|NCT03979014|Biological|Gardasill 9™ vaccine|3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
75762406|NCT01064232|Drug|Risperidone|Risperidone Tablets 1 mg
75906207|NCT02604277|Behavioral|Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.
75906208|NCT02604277|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MBSR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.
75612797|NCT01180049|Drug|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
75612798|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
75612799|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
75612800|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
75612801|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
75612802|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
75906209|NCT02604277|Behavioral|Psycho-education & Understanding Bipolar Medications Therapy|Psycho-education & Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education & Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
75459847|NCT01824810|Procedure|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
75762407|NCT03979092|Behavioral|IP-ACLS|"Three senior consultants and 12 trainers conduct 2-day IP-ACLS training.~Pre-class activities: preparation First exposure reading on provider manual and lecturer notes about a new knowledge of ACLS to enhance self-directed learning.~Interactive lecture sessions: 10 topics Interactive lectures (15-20 minutes per topic) introduce a new knowledge, which anchor to their existing knowledge according to ACLS algorithms.~Simulation sessions: 10 sessions Skill sessions (50 minutes per session) used high-fidelity simulation mannequin in a team approach. Students learn through role-playing with different practical scenarios. Experiential learning is focused on hands-on and collaborative strategies for enhancing a deeper learning.~Debriefing: feedback and reflection Trainers provide immediate feedback and discussion throughout the scenarios. Debriefing is focused on the positive aspect and areas for improvement."
75762408|NCT03979092|Behavioral|Waitlist|Waitlist group will participate in subsequent IP-ACLS training.
75762409|NCT00501059|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|100mg enteric coated Aspirin, taken daily
75612803|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
75612804|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
75612805|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
75612806|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
75612807|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
75612808|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
75612809|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
75612810|NCT01172808|Drug|Placebo|Placebo that represents comparator
75612811|NCT01172808|Drug|tiotropium Respimat® low dose|IMP
75612812|NCT01172808|Drug|Placebo|Placebo that represents comparator
75612813|NCT01172808|Drug|Placebo|Placebo that represents comparator
75612814|NCT01172808|Drug|tiotropium Respimat® high dose|IMP
75612815|NCT01172808|Drug|50 mcg salmeterol HFA MDI|Active comparator
75612816|NCT01172808|Drug|Placebo|Placebo that represents BI drug
75612817|NCT01172808|Drug|Placebo|Placebo that represents BI drug
75612818|NCT04315194|Drug|clarithromycin-naproxen-oseltamivir|to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
75612819|NCT01151280|Device|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
75612820|NCT02884362|Other|clinical biological data collection on melanoma|collection and centralization of clinical and biological data of patients with melanoma
75612821|NCT01149486|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
75612822|NCT01149486|Drug|Hyzaar®|100/25 mg Tablets
75612823|NCT00601705|Drug|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
75612824|NCT00601705|Drug|epirubicin hydrochloride|50 mg/m2 IV bolus
75612825|NCT00601705|Drug|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
75762410|NCT00501059|Drug|Placebo|Placebo, taken daily
75762411|NCT00344318|Biological|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
75762412|NCT00344318|Biological|Prevenar|3 Intramuscular injections
75762413|NCT00344318|Biological|Tritanrix-HepB|3 Intramuscular injections
75762414|NCT00344318|Biological|Hiberix|Reconstituted with Tritanrix before injection
75762415|NCT00344318|Biological|Polio Sabin.|3 oral doses.
75762416|NCT00344318|Biological|Poliorix.|3 intramuscular injections
75612826|NCT00601705|Drug|oxaliplatin|130 mg/m2 IV infusion over 2 hours
75612827|NCT00601705|Procedure|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
75612828|NCT00601705|Procedure|neoadjuvant therapy|"Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).~Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible."
75612829|NCT02680093|Other|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
75612830|NCT01179737|Drug|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
75612831|NCT01179737|Drug|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
75612832|NCT04033705|Device|Freestyle Libre Pro glucose sensor|Participants will wear a Freestyle Libre Pro glucose sensor for approximately 2 weeks prior to elective surgery and then for 2 weeks following surgery.
75612833|NCT02679859|Other|BNP guided medical therapy optimisation|
75906210|NCT03538236|Device|Intragastric balloon|Intragastric balloon insertion will be performed by an endoscopist under monitored anesthesia care. The Intragastric BalIoon (GB) comes as a deflated balloon pre-loaded on a catheter, which is inserted transorally into the proximal gastric body. An endoscope is then inserted alongside the device allowing for direct visualization of the balloon. Once in place, the intragastric balloon will be filled with saline through an external port. The balloon is inserted for 6 months then retrieved endoscopically
75612834|NCT05664529|Diagnostic Test|Chatoor Feeding Scale|Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
75612835|NCT03125083|Biological|Biological dosage from plasma|The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
75612836|NCT00641173|Drug|paroxetine|treatment with SSRI paroxetine
75612837|NCT00641173|Drug|placebo|treatment with placebo
75612838|NCT05664373|Procedure|Coronally advanced flap and deepithelized free gingival graft|Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.
75612839|NCT02679625|Device|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
75459848|NCT01824810|Procedure|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
75612840|NCT02679703|Device|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
75612841|NCT02679703|Device|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
75612842|NCT02679703|Other|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
75762417|NCT00323258|Behavioral|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
76070118|NCT04190901|Behavioral|Simulated White Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
76070119|NCT04190901|Behavioral|Simulated White Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
76070120|NCT03597321|Biological|prophylactic donor lymphocyte infusion (DLI)|DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
75762418|NCT00323258|Device|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
75762419|NCT00323258|Device|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
75762420|NCT00323258|Behavioral|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
75906211|NCT03538236|Behavioral|Lifestyle intervention|All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
76070121|NCT03597243|Other|Cash Transfer|Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
75459849|NCT01824849|Procedure|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
75459850|NCT01824849|Procedure|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
75459851|NCT01824888|Drug|JUC solution|1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
75459852|NCT01824888|Drug|propan-2-ol|1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
75459853|NCT01824914|Device|McGrath Videolaryngoscope|A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
75762421|NCT00323258|Behavioral|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
76070122|NCT04193007|Drug|molecular targeted therapies|if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）
75612843|NCT02681965|Behavioral|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
75762422|NCT00323258|Behavioral|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
75762423|NCT00323258|Behavioral|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
75762424|NCT00323258|Other|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
75762425|NCT00322868|Drug|pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.
75762426|NCT01016717|Drug|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
75762427|NCT01016717|Drug|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
75762428|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
75762429|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
75762430|NCT01016795|Drug|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
75762431|NCT04260737|Other|Decision Aid for Men with Localized Prostate Cancer|The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.
75762432|NCT00343382|Drug|pilocarpine hydrochloride|Given orally
75459854|NCT01824927|Procedure|First eye (FE)|Phacoemulsification cataract extraction surgery
75459855|NCT01824927|Procedure|Second eye (SE)|Phacoemulsification cataract extraction surgery
75612844|NCT00641875|Procedure|Nocturnal Hemodialysis|
75762433|NCT00343382|Other|placebo|Given orally
75906212|NCT03068650|Biological|rindopepimut|Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
75906213|NCT02238873|Drug|Pegfilgrastim|
75459856|NCT01824927|Drug|Steroids eye drops|Use steroids eye drops to decrease the pain.
75459857|NCT01824940|Behavioral|Standard care|"Standard Care:~Exclusive breastfeeding promotion for all infants, birth to 6 months~Strengthened PMTCT (prevention of mother to child transmission of HIV) services~Strengthened Village Health Worker system"
75459858|NCT01824940|Other|WASH|"WASH:~Standard care interventions~Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths."
75612845|NCT00929110|Drug|Glycopyrronium bromide|Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
75612846|NCT00929110|Drug|Placebo to glycopyrronium bromide|Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
75612847|NCT00929110|Drug|Tiotropium|Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
75612848|NCT00922519|Other|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 4 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
75762434|NCT00481871|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
75762435|NCT00481871|Drug|Gemcitabine Hydrochloride|"Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.~Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
75459859|NCT01824940|Dietary Supplement|Infant and young child feeding|"IYCF:~Standard care interventions~Provide 20 g/d Nutributter from 6-18 months~Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness."
75612849|NCT00640549|Drug|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
75459860|NCT01824940|Other|WASH and Nutrition|"WASH AND IYCF interventions~Standard care interventions~All WASH interventions~All IYCF interventions"
75459861|NCT01824992|Drug|Yallaferon®|
75459862|NCT01825018|Behavioral|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
75612850|NCT00640549|Drug|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
75762436|NCT00481871|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
75762437|NCT00481871|Dietary Supplement|Folic Acid|"1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
75762438|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
75762439|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
75459863|NCT01825018|Behavioral|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
75459864|NCT01825031|Drug|Raltegravir|400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
75459865|NCT01825031|Drug|Fluconazole|100mg once daily for 12 weeks
75459866|NCT01825031|Drug|Azithromycin|500mg once daily for 5 days
75459867|NCT01825031|Drug|Albendazole|a single dose 400mg
75459868|NCT01825031|Drug|Isoniazid|300mg taken immediately in combination with cotrimoxazole
75459869|NCT01825031|Dietary Supplement|Ready to Use Supplementary Food|2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
75762440|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
75762441|NCT03983174|Procedure|Drainage seton with flap|Seton is placed around the external sphincter then mucosal advancement flap will be constructed
75762442|NCT03983174|Procedure|EAS sparing seton|Rerouting of the seton around the internal sphincter only sparing the external sphincter
75762443|NCT00329108|Drug|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
75762444|NCT00329108|Drug|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
75762445|NCT01061294|Procedure|Advanced CustomVue™ iLASIK procedure|
75762446|NCT01061294|Device|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
75762447|NCT00329030|Drug|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
75762448|NCT00329030|Drug|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
75762449|NCT00328562|Drug|ZD1839 (Iressa)|
75762450|NCT00328562|Radiation|Thoracic Radiotherapy|
75762451|NCT00328172|Drug|Placebo|Placebo matching BI 1356
75762452|NCT00328172|Drug|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
75906214|NCT05141994|Drug|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
75906215|NCT05141994|Drug|4mg of BAT5906|Specification: 4mg of BAT5906
75459870|NCT01825044|Drug|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
75762453|NCT00328172|Drug|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
75762454|NCT00328172|Drug|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
75906216|NCT02238951|Other|Mobile Health (mHealth)|Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
75906217|NCT02238951|Other|No mHealth|Participants receive the same evidence-based care coordination without mHealth technology
75906218|NCT03034057|Drug|Sayana Press|Sayana Press in the Uniject injection system
75906219|NCT04630366|Drug|NST-1024|NST-1024
75906220|NCT04630366|Drug|Placebo|Matching placebo to NST-1024
75906221|NCT03578913|Other|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.
75906222|NCT03578913|Other|PFM Crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
75906223|NCT05628844|Procedure|Continuous enteral feeding|Enteral nutrition by continuous infusion for 10 hrs at a dose corresponding to 25 kcal/kg body weight/day
75906224|NCT05728684|Biological|CM310|CM310 Injection
76070123|NCT04193007|Radiation|Brain Radiotherapy|SRS was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain)was used for more than 3 intracranial lesions
75459871|NCT01825044|Drug|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
75762455|NCT00328172|Drug|Metformin|Metformin
75762456|NCT01060748|Biological|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
75762457|NCT01060748|Biological|Placebo|Placebo
75762458|NCT01057784|Procedure|Bariatric surgery.|Bariatric Surgery
75762459|NCT01061372|Drug|Placebo|Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
75762460|NCT01061372|Drug|pregabalin|pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
75762461|NCT01061372|Drug|pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
75762462|NCT00328094|Drug|continuous intravenous insulin infusion|Tight glucose control versus standard of care
75906225|NCT05616286|Behavioral|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile health adaptation of MBTR-R, mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The Mindfulness-SOS for Refugees intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs.
75906226|NCT02757768|Drug|Mirabegron|Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
75906227|NCT02757768|Drug|Placebo|Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
75459872|NCT01825070|Dietary Supplement|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
75459873|NCT01825083|Drug|Ketamine|Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
75459874|NCT01825083|Drug|Placebo|0.9 % normal saline group receives same volume as the ketamine dose
75459875|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
75459876|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
75459877|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
75612851|NCT02683369|Dietary Supplement|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~15 mg of Vitamin C~400 mcg of Folate~30 mcg Vitamin of B-12~26 mg of Iron~125 mg of Beet Root"
75612852|NCT01147068|Biological|0.5mL Intramuscular Injection|0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
75612853|NCT02683135|Behavioral|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
75906228|NCT02757768|Drug|Tamsulosin Hydrochloride|Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
75906229|NCT05615662|Behavioral|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
75459878|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
75459879|NCT01825135|Device|Neuromuscular electrical stimulation|
75459880|NCT01825135|Device|sham stimulation|sham stimulation will be applied to the quadriceps
75459881|NCT01825148|Other|radiolabeled Exendin|
75459882|NCT01825174|Behavioral|Ball games program|twice a week different ball games 90min
75459883|NCT01825174|Behavioral|Nutrition counseling|9 units of 90min each of nutrition counseling
75762463|NCT00500903|Drug|Alisertib|Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
75762464|NCT00295932|Biological|rituximab|Given IV
75762465|NCT00295932|Drug|bortezomib|Given IV
75906230|NCT05615662|Behavioral|Treatment as Usual|Treatment as Usual in this study will include all of the regular standards of care for mental health needs. These standards of care may include, but are not limited to psychotherapy, pharmacotherapy, or complementary therapy.
75906231|NCT05728606|Procedure|Robot-assisted D2 distal gastrectomy|Robot-assisted D2 distal gastrectomy after 3-Cycle SOX neoadjuvant chemotherapy
75612854|NCT02683135|Behavioral|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
75906232|NCT05225389|Drug|300 mg [C14] CT1812|Single dose of 300 mg CT1812 with microtracer dose of [C14]
75612855|NCT02683135|Behavioral|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning ~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
75612856|NCT00640627|Drug|Celecoxib|200 mg oral capsule once daily for 6 weeks
75459884|NCT01825213|Device|Multispectral CT of the liver|Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
75459885|NCT01825226|Other|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
75459886|NCT01825239|Other|Collection of measurements during LV pacing during electrophysiology study|During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
75612857|NCT00640627|Drug|Placebo|Matched oral placebo for 6 weeks
75612858|NCT01146912|Other|Text Message|Text message vaccine reminders
75612859|NCT01146912|Other|automated call|Automated call
75612860|NCT00641251|Other|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
75612861|NCT00641251|Other|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
75762466|NCT00295932|Drug|cyclophosphamide|Given IV
75762467|NCT00295932|Drug|prednisone|Given orally
75762468|NCT01063140|Biological|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
75762469|NCT01063140|Biological|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
75762470|NCT00305448|Drug|Fulvestrant|250 intramuscular injection
75762471|NCT00305448|Drug|Fulvestrant|500 mg intramuscular injection
75762472|NCT01063218|Other|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
75762473|NCT01066182|Dietary Supplement|DHA (docosahexaenoic acid)|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
75762474|NCT01066182|Dietary Supplement|Sunflower oil capsules|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
75906234|NCT05552833|Other|High intensity interval training|Participants will undergo 12 weeks of supervised HIIT training (3 times per week). The HIIT protocol will consist of 4x4 min.
75906235|NCT03066076|Drug|Antithyroid Drug|Antithyroid drug
75906236|NCT03066076|Procedure|Total thyroidectomy|Operation
75906237|NCT05225077|Drug|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
75906238|NCT05577286|Other|regular care|the regular medical treatment without change of their daily activity routine
75762475|NCT03981198|Device|Soliton Rapid Acoustic Pulse (RAP)|Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
75612862|NCT02682043|Device|Toy car|"The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long."
75612863|NCT02679547|Other|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
75612864|NCT00641953|Drug|IMX-150|(0.3%) 0.5g topically BID to each foot for 4 weeks
75762476|NCT03980652|Procedure|Change of gloves and sterile instruments|Change of gloves and use of separate , sterile instruments before closing the abdominal wall
75762477|NCT00305058|Drug|Morphine|0.05 mg/kg Intravenous
75762478|NCT00305058|Drug|Hydromorphone|0.0075 mg/kg intravenous
75762479|NCT01064388|Drug|AZD9742|IV infusion, 15 days
75762480|NCT01064388|Drug|Placebo|IV infusion, 15 days
75762481|NCT00295854|Drug|MN-001 BID|Eligible patients received 500 mg MN-001 bid
75906239|NCT05577286|Other|plyometric training|designed plyometric training program for 30 minutes, three times a week for two successive months
75906240|NCT04942093|Dietary Supplement|With low-calorie, high-protein diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
75906241|NCT04942093|Dietary Supplement|Without low-calorie, high-protein diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
75906242|NCT03067558|Diagnostic Test|Children's automated respiratory rate monitor|"The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities."
75459887|NCT01825252|Behavioral|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
75459888|NCT01825252|Behavioral|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
75612865|NCT00641953|Drug|IMX-150|(0.6%) 0.5g topically BID to each foot for 4 weeks
75612866|NCT00641953|Drug|Placebo|0.5 g topically BID to each foot for 4 weeks
75612867|NCT02681887|Drug|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
75612868|NCT02681887|Drug|Placebo|placebo tablet identical to circadian
75612869|NCT01134042|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
75762482|NCT00295854|Drug|MN-001|Eligible patients received 500 mg MN-001 once daily (qd)
75762483|NCT00295854|Drug|Placebo|Eligible patients received placebo
75762484|NCT00327470|Drug|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
75762485|NCT03983408|Dietary Supplement|Korean Red Ginseng|Participants are provided with 2 Korean Red Ginseng extract tablets twice a day for total 24 weeks.
75762486|NCT03983408|Dietary Supplement|Placebo|Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets. Participants are parovided with 2 placebo tablets twice a day for first 12 weeks, following Korean Red Ginseng extract tablets twice a day for another 12 weeks.
75762487|NCT01061450|Drug|Simvastatin|80 mg once a day
75762488|NCT01061450|Drug|Placebo|1 pill once a day
75762489|NCT03983330|Behavioral|Brief Motivational Interviewing (i-BMI)|"The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
75459889|NCT01825304|Device|titrated setting peep|titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
75459890|NCT01825317|Device|NeuroAD|synchronized TMS+COGNITIVE TRAINING
75459891|NCT01825317|Device|Sham device|Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
75459892|NCT01825330|Device|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
75906243|NCT03067558|Diagnostic Test|MK2 Acute Respiratory Infection (ARI) Timer|The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
76070124|NCT04190355|Other|Irrigant type|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on postoperative pain using different uniforms will be evaluated.
76070125|NCT04190355|Drug|5.25% NaOCl|5.25% NaOCl solution
75612870|NCT01134042|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
75612871|NCT01134042|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
75612872|NCT01134042|Other|Placebo Inhalation Powder 1|Placebo in novel dry powder inhaler once daily
75612873|NCT01134042|Other|Placebo Inhalation Powder 2|Placebo in Diskus inhaler twice daily
75612874|NCT02681419|Procedure|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
75762490|NCT03983330|Behavioral|Control|Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
75762491|NCT03986294|Drug|S1 + Nal-IRI|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
75762492|NCT03986294|Drug|Nal-IRI+Leucovorin+5-FU|Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
75762493|NCT00322556|Drug|Immunoglobulins Intravenous (Human)|Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
75762494|NCT00321932|Dietary Supplement|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
75762495|NCT00321932|Dietary Supplement|cholecalciferol|Given orally
75762496|NCT00321932|Drug|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
75762497|NCT01057940|Procedure|DBE PEJ placement|One time procedure with follow-up telephone call.
75906244|NCT04909567|Behavioral|Optimisation|Defined optimisation
75906245|NCT03067792|Drug|5-fluorouracil, irinotecan and leucovorin|In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
75906246|NCT03067792|Drug|docetaxel and cisplatin|In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
75906247|NCT05224999|Drug|nivolumab|nivolumab 3mg/kg (every 2 weeks)
75906248|NCT03066154|Drug|oral docetaxel (ModraDoc/r)|Weekly once- or twice daily ModraDoc/r
75906249|NCT03066154|Drug|androgen deprivation therapy|ADT according to the standard of care
76070126|NCT04190355|Drug|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water
76070127|NCT04193163|Device|Hip prosthesis - ESOP 2 cementless femoral stem|ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.
75459893|NCT01825330|Device|sham|
76070128|NCT03023475|Device|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
75459894|NCT01825369|Drug|IV L-carnitine|See arm description
75459895|NCT01825382|Device|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
75459896|NCT01825395|Drug|3, 4-Diaminopyridine|
75459897|NCT01825421|Other|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
75459898|NCT01825434|Dietary Supplement|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
75459899|NCT01825447|Drug|Placebo|0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
75459900|NCT01825447|Drug|Oxycodone + Naltrexone|Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
75459901|NCT01825447|Drug|Oxycodone|Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
75906250|NCT03066154|Radiation|high-dose intensity-modulated radiation therapy|77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
76070129|NCT03023475|Device|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
75906251|NCT05224687|Other|Retroactive review of patient data of those receiving a dose of daptomycin|A retrospective analysis will be conducted using patient data of those receiving a dose of daptomycin at MCMC, Methodist Dallas Medical Center, Methodist Richardson Medical Center, or Methodist Mansfield Medical Center.
75906252|NCT02753946|Drug|ZTI-01|6g ZTI-01 intravenous infusion TID q8 hours
75906253|NCT02753946|Drug|Piperacillin-tazobactam|4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
76070130|NCT03596931|Drug|Statins (Cardiovascular Agents)|Prescribed with statins
75459902|NCT01825460|Other|Manual Therapy Protocol|The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
76070131|NCT03596853|Other|Progressive mobilization|"Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6)."
75612875|NCT02681419|Procedure|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
75612876|NCT00642031|Drug|Triciribine|15 mg/m^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
75612877|NCT01179347|Drug|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
75612878|NCT01179347|Drug|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
75612879|NCT04182295|Device|acupuncture|A sterilised stainless steel needle (diameter 0.25mm X length 40mm, Dongbang Acupuncture Inc., Boryeong, Chungchenongnam-do, Korea) will be given at PC3, LI4, LI11, and LU5 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
75612880|NCT04182295|Device|Park Sham Needle|A Park Sham Needle (Meridius Medical Ltd. & DongBang Acuprime Ltd., Exeter, UK), non-penetrating sham acupuncture, will be given at two points on the belly of biceps brachii, 1 cun proximedially from LI11, and 1 cun laterally from PC3 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
75762498|NCT02533310|Other|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
75762499|NCT02533310|Other|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
75459903|NCT01825460|Other|Two manual techniques|The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
75459904|NCT01825473|Drug|Erythromycin|
75459905|NCT01825473|Device|Multi-channel intra-luminal impedance (MII) pH monitoring|
75459906|NCT01825473|Drug|Placebo (D5W)|
75459907|NCT01825486|Behavioral|accidental falls|
75612881|NCT04182139|Other|Static Stretching Exercise|Each intervention group received a different duration and intensity of static stretching exercise protocol.
75612882|NCT04104373|Other|Observational Cohort|
75762500|NCT00326612|Drug|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
75762501|NCT00326612|Drug|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
75762502|NCT01060826|Other|fisiologic serum|250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure
75762503|NCT01060826|Drug|somatostatin, intravenous bolus|250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic
75762504|NCT01060826|Drug|somatostatin|Intravenous bolus 250 micrograms
75762505|NCT00325130|Biological|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
75762506|NCT00325130|Biological|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
75612883|NCT01146288|Drug|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
75906254|NCT04959487|Other|Food support|1. Diabetes-tailored food support. Project Open Hand will provide intervention participants six months of supplemental food support meeting on average 75% of their daily energy requirements. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian.
75906255|NCT04959487|Other|Nutritional Counseling and education|2. Nutritional counseling and education: The registered dietitian will provide individual nutritional counseling two times (at baseline and month 5-6) during the intervention. In addition, group-based DM nutrition education will be conducted over four 1-hour-long sessions. The nutrition education will be conducted by a POH dietitian, and the curriculum will be consistent with published diabetes self- management education principles, utilizing effective strategies in lower wealth, lower literacy populations.
75906256|NCT00431431|Drug|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
75612884|NCT01146288|Drug|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
75762507|NCT00325130|Biological|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
75906257|NCT00431431|Drug|raloxifen|2 years treatment with raloxifene (60 mg)
75906258|NCT05566210|Device|acupuncture|acupuncture
75762508|NCT00325130|Biological|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
75762509|NCT00325130|Biological|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
75906259|NCT05566210|Device|Sham acupuncture|Sham acupuncture
75762510|NCT00321854|Drug|pramipexole|
75762511|NCT03983252|Drug|[F-18]PBR06|PET radiopharmaceutical
75762512|NCT03982862|Drug|Triamcinolone|Triamcinolone 4mg diluted to 0.1 ml
75762513|NCT03982862|Drug|Lidocaine|0.1ml 2% Xylocaine
75762514|NCT03982862|Drug|Botulinum toxin A|4U Botox® diluted to 0.1 ml
75762515|NCT01060904|Drug|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
75762516|NCT01060904|Drug|doxorubicin|25 mg/m2 IV every 2 weeks
75762517|NCT01060904|Drug|vinblastine|6 mg/m2 IV every 2 weeks
75762518|NCT01060904|Drug|dacarbazine|375 mg/m2 IV every 2 weeks
76070132|NCT03596853|Other|Usual Care|This group will receive standard usual, which will be monitored, but not protocolised.
76070133|NCT04192617|Drug|SM03|SM03: 600 mg intravenous (IV)
76070134|NCT04192617|Drug|Placebo|Placebo: 600 mg intravenous (IV)
76070135|NCT04192617|Drug|Methotrexate|methotrexate: 7.5-20 mg/week oral
75762519|NCT01060904|Drug|bleomycin|10 units/m2 IV every 2 weeks
75762520|NCT01060904|Drug|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
75762521|NCT01058174|Drug|micafungin|intravenous infusion
75762522|NCT01058174|Drug|fluconazole|intravenous infusion
75762523|NCT01058174|Drug|liposomal amphotericin B|intravenous infusion
75762524|NCT01058174|Drug|caspofungin|intravenous infusion
75762525|NCT01061762|Behavioral|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
75762526|NCT01061762|Behavioral|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
75762527|NCT01061762|Behavioral|Health Counseling|3-session of health improvement counseling to serve as an attention control.
75906260|NCT04945057|Device|Mindpax monitoring system|All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns, during the active 12 months of followup.
75906261|NCT03067480|Device|iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
75906262|NCT02172222|Drug|BI 10773|
75906263|NCT02172222|Drug|Linagliptin|
75906264|NCT03625219|Drug|Prednisone|40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
75906265|NCT03625219|Drug|Placebo|8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
75906266|NCT02176590|Behavioral|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
75906267|NCT02176590|Other|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
75762528|NCT01058252|Combination Product|INVOCell, Letrozole 2.5 mg, recFSH 75 IU|"OVARIAN STIMULATION:~In previous cycles, cycle length and ovulatory status must be assessed and documented.~STEP 1: ANOVULATION by ORAL CONTRACEPTION~Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.~Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst > 10 mm).~Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.~STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).~On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.~Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder."
75459908|NCT01824043|Drug|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
75612885|NCT02683057|Other|International Physical Activity Questionnaire (IPAQ)|all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
75906268|NCT02255916|Other|Music|live sound-bed music intervention
75906269|NCT02178852|Device|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
75906270|NCT05536999|Other|Blood sample taking , like to measure hormonal level like LH, FSH, Perlakan ,in a follicular fluid after the oocyte retrival|Blood test measure basal FSH, follicular fluid testing
75906271|NCT05553964|Diagnostic Test|In Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
75906272|NCT02255994|Device|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
76070136|NCT04192539|Diagnostic Test|Taurine|Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT
76070137|NCT04192383|Radiation|Cyberknife stereotactic radiosurgery|Hypofractionated stereotactic radiosurgery
76070138|NCT01874665|Drug|Ponatinib|Ponatinib 45 mg, tablets, orally, once-daily.
76070139|NCT04192305|Procedure|LPV|LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.
75459909|NCT01825525|Device|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
75612886|NCT01146054|Device|CyberKnife based stereotactic radiotherapy|"Initial orthogonal images will be obtained to confirm location of fiducial seeds.~Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.~Quality assurance will be performed as per standard practice at each participating institution."
75612887|NCT01146054|Drug|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
75906273|NCT02255994|Procedure|No mesh.|Patients in this arm had subvesical plication without reinforcement.
76070140|NCT04192305|Procedure|routine LV|Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
75459910|NCT01825551|Drug|Granulocyte Colony Stimulating Factor|
75459911|NCT01825551|Drug|Placebo|
75612888|NCT01146054|Drug|Fludeoxyglucose (18F) (FDG)|FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
75612889|NCT00640705|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
75612890|NCT00640705|Drug|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
75612891|NCT01145898|Drug|(Cosopt®, prostaglandin)|We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
75906274|NCT03065842|Behavioral|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
75459912|NCT01825590|Other|Dialysate and serum sodium concentration aligned|
75459913|NCT01825616|Dietary Supplement|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
75906275|NCT03065842|Behavioral|Usual Standards|Usual standards according to the school curriculum in Kenya.
76070141|NCT04192149|Other|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
75459914|NCT01825616|Other|Placebo|Mushroom powder without vitamin D2
76070142|NCT03596619|Device|PBN|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
75612892|NCT04181905|Other|Questionnaire|Firstly, demographic information (name-surname, date of birth, gender, age, height, body weight, dominant hand, family structure, social security, educational status, occupation, smoking, alcohol use, assistive device drug use, resume, surname, complaints). Data collection tools will then be applied to patients by face to face interview technique. Evaluation of kinesiophobia Assessment of quality of life in asthma patients with TAMPA questionnaire Assessment of physical activity level with Asthma Quality of Life Questionnaire (AQLQ) Assessment of physical activity level with International Physical Activity Questionnaire-Short Form (IPAQ) is planned.
75762529|NCT01058252|Procedure|STEP-3: LH Suppression & Monitoring|"Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.~• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.~The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)~No need of LH testing, or E2 testsing during the stimulated cycle."
75612893|NCT02681653|Drug|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
76070143|NCT04191525|Dietary Supplement|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
75459915|NCT01825629|Other|Multidisciplinary therapy|"Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.~Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.~Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks."
75459916|NCT01825629|Other|Placebo|
75762530|NCT01058252|Procedure|STEP-4: HCG Timing|"IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:~E2 level is over 150 pg/ml/per mature follicle (> 15 mm)~Domminent follicle is greater than 18 mm in mean diameter~LH Remains as Baseline, OR~The day when Urinary LH Surge is positive"
75762531|NCT01058252|Procedure|STEP-5: OPU, ET, Cancellation|"Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.~Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.~Maximum of 2 embryos are transferred, using ultrasound guided transfer.~Cancellation Criteria:~Poor patient compliance~Premature Ovulation~Premature LH Surge~Endometrium < 7 mm~Poor Follicular Development~E2 Level > 2,500 pg/ml"
76070144|NCT04191525|Dietary Supplement|Placebo|Placebo masked with the same presentation as the experimental product 1 capsule/day
76070145|NCT04029987|Procedure|Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
76070146|NCT04029987|Procedure|Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
76070147|NCT04029987|Procedure|Control|Conventional analgesia
76070148|NCT04191837|Other|Self-administered acupressure treatment group|Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.
75612894|NCT02681653|Drug|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
75612895|NCT04181983|Other|Personalized exercise program|Home-based personalized exercise program using a smart phone app
75762532|NCT01058252|Procedure|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 100000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
75762533|NCT01058330|Other|Plyometric training program|The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of five lower extremity exercises and five upper extremity exercises
75762534|NCT01058408|Radiation|Intensity modulated radiotherapy|Administered daily 5 days per week
75762535|NCT01058408|Drug|RAD001|Taken orally once a day
75762536|NCT01058408|Drug|cisplatin|Administered intravenously once a week
75762537|NCT01060982|Device|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
75762538|NCT01061060|Drug|Prostaglandin I2|oral
75762539|NCT01061060|Drug|Placebo|oral
75762540|NCT00310388|Drug|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
75906276|NCT04939519|Behavioral|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine."
76070149|NCT04191837|Other|Knee health education control group|Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
75612896|NCT04181983|Other|WHO exercise guidelines|Standard exercise counselling according to WHO guidelines
75612897|NCT04315116|Drug|pyrotinib maleate|a single oral dose of pyrotinib maleate on day 1 & day10 .
75612898|NCT04315116|Drug|Loperamide|Loperamide 4 mg bid from day 7 to day 13
75762541|NCT03981770|Drug|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
75612899|NCT02886078|Procedure|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
75612900|NCT02886078|Procedure|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
75612901|NCT04183933|Other|Pilates Exercise|Pilates exercises will be given for 6 weeks, 3 days in a week.
75612902|NCT04183933|Other|Combined Exercise|Combined exercise will be given for 6 weeks, 3 days in a week.
75762542|NCT00500357|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
75762543|NCT03981692|Other|Consecutive dual task|8 weeks and 2 days per week, one session 45 min. Consecutive dual task creates the idea that it may provide more workable work without creating stress while doing secondary task during dual task.
75762544|NCT03981692|Other|Integrated dual task|8 weeks and 2 days per week, one session 45 min. Integrated dual task is a proven mode of work that has positive effects on geriatrics
75762545|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
75762546|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
75612903|NCT02883114|Drug|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
75762547|NCT03981458|Device|Hyalofemme|Gel made with hyaluronic acid to be applied vaginally to treat atrophic vaginitis.
75612904|NCT02883114|Drug|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
75762548|NCT03981458|Device|Ialuril|Bladder instillation of hyaluronic acid to treat recurrent UTI.
75762549|NCT01019915|Device|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
75612905|NCT00640783|Behavioral|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
75612906|NCT00640783|Behavioral|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, <30%).
75612907|NCT04183387|Drug|Simvastatin 40mg|
75762550|NCT04110041|Behavioral|Aerobic Exercise|Thrice-weekly aerobic exercise sessions lasting ~45 minutes, for 12 consecutive weeks.
75762551|NCT00309842|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days.
75762552|NCT00309842|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW > 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
75762553|NCT00309842|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of > 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
75762554|NCT00309842|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
75762555|NCT00309842|Drug|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day."
75906277|NCT04939519|Behavioral|Patient Navigation (PN)|Participants in the PN condition will receive a message alerting them that a Community Health Worker will contact them to assist with the process of scheduling a vaccine. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to vaccination such as logistics and transportation, as well as fear, skepticism, and hesitancy.
75906278|NCT02176746|Biological|cancer stem cell vaccine|
75762556|NCT00309842|Procedure|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
75906279|NCT05551546|Behavioral|Functional Medicine Health Coaching for Elimination Diet for Elimination Diet|"All participants will receive 5 coaching sessions to support them through the elimination diet.~First session: The foundation session is where the coach and participant begin to develop rapport and outline the participant's goals. This occurs before the start of the Elimination Diet for motivation, expectations, education, and preparation.~Second session: This can occur during week 1 of the elimination diet to support working through the implementation.~Third session: This session is recommended to occur during week 3 of the diet to prepare for the reintroduction of foods.~Fourth session: A session is recommended while the participant is reintroducing foods as this is typically the most difficult part of the diet as participants may be experiencing symptoms to reactive foods.~Fifth session: A wrap up session is recommended after all of the food re-introductions to support the participant with maintenance, goals to move forward, and reflection."
75762557|NCT00309842|Radiation|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
75762558|NCT00325754|Device|E-Cylinder|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
75762559|NCT00325754|Device|Lightweight Cylinder|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
75762560|NCT01019993|Procedure|conventional OLV followed with IL-HFPPV|The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory [I: E] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio <0.3 and R.R 60 breaths/min.
75612908|NCT01133418|Other|Computerized Progressive Attention Training|Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
75612909|NCT01133418|Other|Sham Comparator Cognitive Training|Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
75612910|NCT02677909|Device|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
75612911|NCT02679313|Device|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
75612912|NCT04314804|Combination Product|PPP001|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
75612913|NCT04314804|Combination Product|Placebo|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
75612914|NCT02678065|Device|InPact Admiral DEB|
75612915|NCT04183153|Device|Repetitive Transcranial Magnetic Stimulation|Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.
75612916|NCT00625092|Drug|fluorouracil|Post-operative day 1 and day 2, 600mg/m^2 intraperitoneal (IP) held for 23 hours
75612917|NCT00625092|Drug|leucovorin calcium|Day 0 200 mg/m^2 intraperitoneal held for 2 hours
75612918|NCT00625092|Drug|oxaliplatin|Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m^2
75612919|NCT00625092|Procedure|cytoreductive surgery|Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
75612920|NCT00931918|Drug|Bortezomib|Bortezomib IV
75612921|NCT00931918|Drug|Rituximab|Rituximab IV
75612922|NCT00931918|Drug|Cyclophosphamide|Cyclophosphamide IV
75612923|NCT00931918|Drug|Doxorubicin|Doxorubicin IV solution
75612924|NCT00931918|Drug|Vincristine|Vincristine IV
75762561|NCT01063790|Behavioral|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
75762562|NCT03985982|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
75612925|NCT00931918|Drug|Prednisone|Prednisone tablet
75612926|NCT04183075|Dietary Supplement|FontActiv Superprotein/Hypercaloric Fiber|The product under study has a liquid presentation, in 200 ml bottles, ready to take
75612927|NCT04183075|Dietary Supplement|Carbohydrates and C Vitamin|The control product will be prepared with equal presentation and taste as similar as possible tan study product
75459917|NCT01825642|Procedure|nerve-sparing radical prostatectomy|
75612928|NCT00642109|Procedure|midurethral sling procedure|quality of life, voiding dysfunction
75612929|NCT02681575|Behavioral|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
75612930|NCT02679001|Drug|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
75612931|NCT02678221|Drug|Sildenafil citrate|
75612932|NCT02678221|Drug|Aspirin|
75612933|NCT04033783|Other|6MWT - accompanied|Assessor walks behind the patient
75612934|NCT04033783|Other|6MWT - not accompanied|Assessor does not walk behind the patient
75612935|NCT00641329|Drug|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
75612936|NCT00641329|Drug|Placebo|Matching placebo tablets
75762563|NCT03985982|Drug|Placebo|injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
75762564|NCT00499889|Drug|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
75762565|NCT00499889|Drug|Fludarabine (Fludara)|40 mg/m^2 by vein daily for 4 Days
75762566|NCT00499889|Drug|Busulfan|130 mg/m^2 by vein daily for 2 Days
75762567|NCT00499889|Drug|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
75906280|NCT05551546|Behavioral|Self-guided Elimination Diet|"The Elimination Diet course materials include self-guided materials designed to guide participants through all phases of a comprehensive elimination diet, including preparation, elimination, and reintroduction phases.~All participants in this wait-list control group will be presented via email with the opportunity to receive the five sessions of coaching (described above) at the conclusion of the study."
75459918|NCT01825642|Procedure|seminal vesicle-sparing radical prostatectomy|
75459919|NCT01825668|Other|Plant Sterols|
75459920|NCT01825668|Other|High cholesterol|
75459921|NCT01825668|Other|Placebo|
75459922|NCT01825681|Behavioral|Positive Affect|Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
75459923|NCT01825707|Drug|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg (oral) on day1
75762568|NCT00499889|Drug|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
75762569|NCT00499889|Drug|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
75762570|NCT00499889|Procedure|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after >4 weeks of imatinib.
75762571|NCT00499889|Procedure|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
75459924|NCT01825720|Drug|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
75459925|NCT01825720|Drug|normal saline group|same rate of normal saline
75459926|NCT01825733|Drug|ramosetron|Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
75459927|NCT01825733|Drug|palonosetron|palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
75459928|NCT01825746|Other|Implementation of the MOHR assessment in primary care workflow|The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
75459929|NCT01825759|Drug|danshen dripping pill|
75459930|NCT01825811|Biological|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10^6 cells mixed with fibrin-glue
75459931|NCT01825811|Biological|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10^6 cells mixed with fibrin-glue
75459932|NCT01825824|Radiation|Stereotactic ablative radiotherapy|The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
75459933|NCT01825850|Drug|Gemigliptin|
75459934|NCT01825850|Drug|Irbesartan|
75459935|NCT01825863|Drug|Ropivacaine|
75459936|NCT01825863|Drug|Saline 9%|
75459937|NCT01825902|Drug|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
75459938|NCT01825902|Radiation|fludeoxyglucose F 18|Undergo 18F-FDG PET
75459939|NCT01825902|Procedure|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
75459940|NCT01825902|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
75459941|NCT01825902|Other|laboratory biomarker analysis|Correlative studies
75459942|NCT01825915|Procedure|Laparoscopic Hysterectomy|
75459943|NCT01825915|Procedure|Laparoscopic Supracervical Hysterectomy|
75459944|NCT01825928|Drug|Paliperidone|Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
75459945|NCT01825928|Drug|placebo|placebo group,3mg/pill,3mg/day forced titration method,last 84 days
75459946|NCT01825967|Other|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
75762572|NCT03982472|Other|transcutaneous electric stimulation|transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
75459947|NCT01825993|Drug|L-BUPIVACAINE ; MORPHINE|
75459948|NCT01825993|Drug|MORPHINE|
75459949|NCT01826006|Device|Excimer laser|
75459950|NCT01826006|Device|Manual Thrombus Aspiration|
75906281|NCT02178930|Other|Integrated self management support|The intervention comprises a consultation engagement, at home exploration, phone and web-based health coaching.
75906282|NCT02179008|Drug|DE-117 Low Dose ophthalmic solution|Low Dose DE-117 ophthalmic solution
75906283|NCT02179008|Drug|DE-117 Low/Middle Dose ophthalmic solution|Low/Middle Dose DE-117
75906284|NCT02179008|Drug|DE-117 Middle Dose ophthalmic solution|Middle Dose DE-117
75906285|NCT02179008|Drug|DE-117 Middle/High Dose ophthalmic solution|Middle/High Dose DE-117
75762573|NCT01058486|Behavioral|Self-Management and Motivational Interviewing|"Post hospital discharge, patients will be referred (<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.~A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.~Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts."
75762574|NCT04252703|Procedure|Percutaneous coronary intervention (PCI)|Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.
75762575|NCT00309608|Drug|Linagliptin|Linagliptin medium dose tablet once daily
75906286|NCT02179008|Drug|DE-117 High Dose ophthalmic solution|High Dose DE-117
75906287|NCT02179008|Drug|latanoprost ophthalmic solution 0.005%|0.005% latanoprost
75906288|NCT05545150|Procedure|Intraoperative Imaging|Clarix Imaging Volumetric Specimen Imager
75906289|NCT05545150|Device|Lumpectomy|Per standard of care (SOC)
75906290|NCT02172300|Drug|Tiotropium inhalation capsules|
75906291|NCT02172300|Drug|Placebo inhalation capsules|
75906292|NCT05223907|Drug|Etomidate|Etomidate will be used for general anesthesia
75463348|NCT05853874|Other|Nutrition intervention (dietary protocol)|The nutrition intervention sought to improve participants' overall diet quality, taking into account a sufficient intake of carbohydrates, lipids, fibres and micronutrients (vitamins and minerals), promoting proper fruits and vegetables consumption and variety. About water intake, considering the high dehydration risk in older persons highlighted by the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines, its adequate consumption is recommended and encouraged.
75463349|NCT05853874|Other|Hospital standard of care|The standard clinical procedures following the malnutrition diagnoses will be implemented according to the routine of the two hospitals
75906293|NCT05223907|Drug|Propofol|Propofol will be used for general anesthesia
75906294|NCT03537456|Device|mRDX-02-17|"mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5."
75906295|NCT04799353|Drug|Budigalimab|Subcutaneous (SC)
75906296|NCT04799353|Drug|Placebo|Subcutaneous (SC)
75906297|NCT04799353|Drug|Budigalimab|Intravenous (IV)
75612937|NCT02681107|Radiation|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
75612938|NCT01179191|Drug|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
75612939|NCT01169844|Biological|AIN457A|
75612940|NCT01169844|Other|Other|
75612941|NCT00642421|Drug|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
75612942|NCT00642421|Drug|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
75612943|NCT00642187|Drug|budesonide|
75612944|NCT00642187|Drug|Placebo|
75612945|NCT05663125|Procedure|Laser interstitial thermal therapy|Ablation of the tumor will be done by MRI-guided laser interstitial thermal therapy with the assistance of neuro-navigation.
75612946|NCT05663125|Drug|Temozolomide|Temozolomide will be administered continuously from the 1st to the 21st day after LITT surgery. The oral dose of temozolomide is 75 mg/m2. And then, it will be given at a routine dose from the second month after surgery.
75906298|NCT04799353|Drug|Placebo|Intravenous (IV)
75906299|NCT03065998|Drug|Opipramol|PO
75906300|NCT03065998|Drug|Baclofen|PO
75906301|NCT02172378|Drug|Tiotropium inhalation capsules|
75906302|NCT02172378|Drug|Placebo inhalation capsules|
75906303|NCT05728528|Drug|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
75762576|NCT00309608|Drug|Linagliptin|Linagliptin high dose tablet once daily
75612947|NCT05655533|Diagnostic Test|Magnetic resonance Imaging scanners of sacroiliac joints.|"Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not"
75762577|NCT00309608|Drug|Linagliptin|Linagliptin low dose tablet once daily
75906304|NCT05728528|Drug|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
75906305|NCT03625375|Other|Exercise|Intervention consist of aerobic, stretchig, pelvic motions, kegels and relaxation exercises
75612948|NCT01132482|Drug|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
75612949|NCT01132482|Drug|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
75612950|NCT02678767|Drug|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
75612951|NCT02678455|Biological|TV005 vaccine|Delivered by subcutaneous injection; contains 10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31, and 10^3 PFU of rDEN4Δ30.
75906306|NCT02176824|Behavioral|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
75459951|NCT01826019|Other|Intervention|In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
75459952|NCT01826019|Other|Usual Care|At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
75612952|NCT02678455|Biological|Placebo|Delivered by subcutaneous injection
75762578|NCT00309608|Drug|Placebo|Placebo tablets once daily
75762579|NCT00309608|Drug|Glimepiride|Glimepiride tablets once daily
75762580|NCT00309452|Behavioral|Cognitive Behavioral Group Therapy|once per week
75762581|NCT00309452|Behavioral|Cognitive remediation|as needed
75762582|NCT00309452|Drug|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
75762583|NCT00309452|Behavioral|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
75762584|NCT00309452|Behavioral|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
75906307|NCT02176824|Behavioral|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
75906308|NCT02176824|Other|Treatment as usual|
75906309|NCT05728450|Device|Light amplification by stimulated emission of radiation (LASER)|"The points for application of laser acupuncture will be cleaned before application. All patients in the study group will be submitted to infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~The plug of the laser unit will inserted into the main current supply and on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~Acupuncture detector (Pointer Excel II) will be used for definite location of acupuncture points"
75906310|NCT03625297|Other|shelter cat|families will adopt a shelter cat
75906311|NCT02256228|Drug|Ropivacaine|Active Group
75906312|NCT02256228|Drug|Saline|Placebo Comparator
75906313|NCT03067168|Drug|Bupivacaine|5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
75906314|NCT03067168|Drug|normal saline 0.9%|5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
75762585|NCT00309452|Other|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
75762586|NCT00308750|Drug|enzastaurin|1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
75762587|NCT00308750|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease
75762588|NCT00308750|Drug|docetaxel|75 mg/m^2, IV, q 21 days, six 21 day cycles or progressive disease
75762589|NCT00308750|Drug|carboplatin|Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease
75906315|NCT04051177|Behavioral|"Interactive Communication with Openness, Passion, and Empowerment ICOPE"|"The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions."
75906316|NCT04051177|Behavioral|Nutrition Curriculum|"The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)"
75906317|NCT02176980|Behavioral|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
75906318|NCT02176980|Behavioral|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
75906319|NCT04774237|Drug|BRIMOCHOL™|A single drop in each eye at a visit.
75459953|NCT01826032|Device|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
75459954|NCT01826032|Other|Standard care for OSA|sleep higiene and dietary counseling
75459955|NCT01826045|Drug|Poly-gamma Glutamic Acid|
75459956|NCT01826045|Drug|Placebo|
75459957|NCT01826058|Radiation|Stereotactic body radiation therapy|
75459958|NCT01826071|Other|Static Stretch|
75459959|NCT01826071|Other|Active Elongation|
75459960|NCT01826097|Device|La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration|
75459961|NCT01826110|Drug|[11C]PIB|Approximately 15 mCI [11C]PIB IV x1
75459962|NCT01826123|Device|Conventional laboratory testing (Central laboratory)|aPTT, INR, fibrinogen concentration, platelet count
75463350|NCT05853822|Other|FirmTech Tech Ring|Participants will utilize the FirmTech Tech Ring at least twice during a two-week time period and complete a survey
75762590|NCT01061918|Device|Tecnis MF|20 patients in the Tecnis MF group.
75762591|NCT01061918|Device|ReSTOR|20 patients in the ReSTOR group.
75762592|NCT03985826|Other|Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood|The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood
75762593|NCT03985748|Device|BAN|Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)
75762594|NCT03985748|Device|SN|Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
75762595|NCT00489359|Drug|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
75762596|NCT00489359|Drug|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
75762597|NCT00489359|Drug|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m^2, administered IV, every 21 days x 6 cycles
75906320|NCT04774237|Drug|BRIMOCHOL™ F|A single drop in each eye at a visit.
75906321|NCT04774237|Drug|Carbachol|A single drop in each eye at a visit.
75906322|NCT04488250|Other|Robot Therapy|Robot Therapy
75906323|NCT02172456|Drug|99mTc-radiolabelled tiotropium|
75906324|NCT02172456|Drug|non-radiolabelled tiotropium|
75906325|NCT05223595|Drug|Gentuximab|Gentuximab: 8mg/kg or 12mg/kg intravenous (IV) infusion administered on Day 1 and 15 of each cycle; Almonertinib: 110 mg orally once daily.
75906326|NCT03067246|Device|VBM Intubating Laryngeal Tube|The position of the VBM Intubating Laryngeal Tube will be assessed using a fibreoptic scope following balloon inflation of the cuff. Seal pressure will be assessed with the presence of the inflated cuff. Endotracheal intubation through the intubating laryngeal tube with a size 7 VBM reinforced tube will be assessed using a fiberoptic scope.
75762598|NCT00489359|Drug|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL*min, administered IV, every 21 days x 6 cycles
75762599|NCT00481247|Drug|Dasatinib|Tablets, oral, dasatinib 50-140 mg once daily (QD)
75762600|NCT00481247|Drug|Imatinib|Tablets, oral, imatinib 200-800 mg, QD
75762601|NCT04101461|Drug|Iron|PharaFerro27; Devart Lab Company, Egypt
75762602|NCT04101461|Diagnostic Test|Complete blood count|to assess the anemia
75762603|NCT04101461|Diagnostic Test|Serum ferritin|to assess the anemia
75762604|NCT04101461|Diagnostic Test|Serum hepcidin|to assess the iron abosrption
75459963|NCT01826123|Device|POC testing|ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
75459964|NCT01826136|Device|Acapella device|
75459965|NCT01826149|Drug|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
75459966|NCT01826149|Drug|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
75459967|NCT01826149|Drug|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
75459968|NCT01826162|Other|acetate or placebo infusion|
75612953|NCT02678845|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
75612954|NCT00931762|Drug|Panobinostat|Panobinostat oral capsules
75612955|NCT02886455|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
75762605|NCT04101461|Diagnostic Test|Serum Iron|to assess the anemia
75762606|NCT04101461|Diagnostic Test|Serum total iron binding capacity|to assess the anemia
75762607|NCT01020071|Procedure|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
75762608|NCT01016951|Drug|AZD9164 Turbuhaler®|"Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg."
75762609|NCT01016951|Drug|Placebo Turbuhaler®|Dry powder for inhalation via Turbuhaler, MAD
75762610|NCT01020149|Other|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
75762611|NCT01017107|Drug|Activated protein C|24 micrograms/kg/hour intravenously for 96 hours
75762612|NCT01020227|Behavioral|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
75459969|NCT01826175|Drug|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
75459970|NCT01826175|Drug|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
75459971|NCT01826175|Device|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
75459972|NCT01826188|Drug|THC 5mg/ml and CBS 50mg/ml|olive oil containing THC and CBD
75459973|NCT01826188|Drug|Placebo|olive oil without cannabis
75463351|NCT05853822|Other|Giddy Penile Constriction Ring|Participants will utilize the Giddy Penile Constriction at least twice during a two-week time period and complete a survey
75612956|NCT02886455|Other|New adhesive strip|This a newly developed adhesive strip.
75612957|NCT00641407|Drug|NPL insulin|Starting dose 10 IU bedtime and then titration
75612958|NCT00641407|Drug|Insulin glargine|10 IU bedtime and then titration
75612959|NCT00624689|Dietary Supplement|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
75612960|NCT02677597|Drug|Cisplatin Combined With S-1|
75612961|NCT02677597|Drug|Cisplatin Combined With Paclitaxel|
75612962|NCT00606970|Dietary Supplement|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
75612963|NCT00606970|Dietary Supplement|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
75762613|NCT01017185|Drug|HF10|
75762614|NCT03996863|Device|Otoband|Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
75762615|NCT03996863|Device|Placebo device|Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
75762616|NCT03997019|Procedure|opioid analgesia|opioid analgesia will be used with general anaesthesia
75762617|NCT03997019|Procedure|ESP block|ultrasound guided ESP Block before anaesthesia induction
75762618|NCT00480857|Drug|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
75762619|NCT00480779|Behavioral|GLB Group|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
75762620|NCT00480779|Behavioral|GLB DVD|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
75762621|NCT04061993|Procedure|Strength and Sensory-Motor Training|Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).
75762622|NCT04061993|Procedure|Current Standard Physiotherapy|Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
75762623|NCT00499031|Biological|Cetuximab|Given IV
75762624|NCT00498797|Drug|Zactima (vandetanib)|
75762625|NCT00498797|Drug|Docetaxel|
75906327|NCT03067246|Device|I-Gel|The position of the I-Gel will be assessed using a fibreoptic scope. The seal pressure will be assessed with the specified design of the I-Gel in the absence of a cuff. Endotracheal intubation through the I-Gel with a size 7 reinforced endotracheal tube will be assessed using a fiberoptic scope.
75459974|NCT01826240|Behavioral|MBCT+SPI|Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
75459975|NCT01826253|Drug|hydroxyethylstarch 130/0.4|Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
75459976|NCT01826266|Drug|PER977, Placebo|
75459977|NCT01826279|Dietary Supplement|Resveratrol|500mg 3 times daily for 1 month
75612964|NCT02681029|Procedure|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
75612965|NCT02681029|Procedure|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
75612966|NCT01132326|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
75612967|NCT05662969|Device|MACHINE PERFUSION|Different outcomes of MP use in low/mid-volume and high-volume LT centres
75612968|NCT05372146|Procedure|GSV radiofrequency ablation with concomitant phlebectomy|Radiofrequency ablation with concomitant phlebectomy
75612969|NCT02882880|Device|The Luco Hybrid OSA Appliance|Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
75612970|NCT02677675|Behavioral|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
75459978|NCT01826279|Other|Placebo|1 placebo tablet 3 times daily for 1 month
75463352|NCT05853809|Diagnostic Test|FeNO measurement|FeNO measurement to guide anti-inflammatory asthma treatment
75612971|NCT04260568|Other|Semi-structured interviews|Patients with a diagnosis of 3PD will be sought from a multidisciplinary balance clinic. Consenting participants will take part in a face-to-face interview about their diagnosis. Data collection will consist of recorded semi-structured interviews, which will be transcribed.
75612972|NCT00642343|Behavioral|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
75612973|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
75612974|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
75612975|NCT00642343|Behavioral|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
75762626|NCT00498797|Drug|Prednisolone|
75762627|NCT00498485|Drug|Placebo|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
75906328|NCT02030184|Drug|Rhenium Re 188-P2045|Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
75463353|NCT05853783|Other|STRATICYTE™ Test|Assessment for risk of progression to oral cancer
75612976|NCT01178411|Drug|Tivantinib|Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.
75906329|NCT04235998|Diagnostic Test|Systematic lung ultrasound|"Patients will undergo a systematic lung ultrasound including review of:~Sonographic characteristic of effusion~Parietal, diaphragmatic and visceral pleura~Pleural nodules~Lung parenchyma~Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment."
76070150|NCT04191759|Diagnostic Test|Test-Retest reproducibility|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
75612977|NCT01178411|Drug|Anti-Cancer Combination Therapy|Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
76070151|NCT03596463|Other|Breast cancer treatment|Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
75459979|NCT01826305|Procedure|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
75459980|NCT01826305|Procedure|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
75612978|NCT04263688|Other|Non-Intervention|Non-Intervention
75612979|NCT02681263|Drug|Temocillin|Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
75612980|NCT00608686|Dietary Supplement|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
75612981|NCT02675803|Biological|VAY736|VAY736 treatment
76070152|NCT04191603|Device|MONOPOLAR HOOC|COLPOTOMY WITH MONOPOLAR HOOC
76070153|NCT04191603|Device|PLASMAKINETIC BIPOLAR SPATULA|COLPOTOMY WITH BIPOLAR SPATULA
75762628|NCT00498485|Drug|Sodium Oxybate|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
75762629|NCT01017341|Device|PSU hip protector|hip protetor
75762630|NCT00480077|Device|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
76070154|NCT04029909|Drug|Gimatecan 0.6mg/m2/d|0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
76070155|NCT04029909|Drug|0.8mg/m2/d|0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
75459981|NCT01826318|Behavioral|Stress coping|"Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud (what is the patient's condition?, what immediate action is needed?) to overcome the negative consequences of feeling overwhelmed by stress."
75459982|NCT01826331|Behavioral|Incentives for Participation|Participants will receive three smoking cessation programs
75459983|NCT01826331|Behavioral|Incentives for Cessation|Participants will have access to a smoking cessation program
75612982|NCT02675803|Biological|VAY736 placebo|VAY736 placebo
75612983|NCT02678611|Dietary Supplement|Basis 250|
75612984|NCT02678611|Dietary Supplement|Basis 500|
75612985|NCT02678611|Dietary Supplement|Placebo|
75612986|NCT02677519|Drug|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
75612987|NCT01145508|Drug|Docetaxel|Given IV
75612988|NCT01145508|Other|Laboratory Biomarker Analysis|Correlative studies
75762631|NCT01017419|Behavioral|Counseling|Informational Counseling provided after hearing aid fitting
75906330|NCT02172534|Drug|Tiotropium bromide low|
75906331|NCT02172534|Drug|Tiotropium bromide medium|
75906332|NCT02172534|Drug|Tiotropium bromide high|
75906333|NCT02172534|Drug|Placebo|
75906334|NCT02256306|Other|Plasma|1 unit of Plasma From Young Donors (Male, aged 30 or younger)
75459984|NCT01826383|Behavioral|Active-Video|This group will watch an active-video with pain management strategies for parents
75459985|NCT01826383|Behavioral|Placebo Video|This group will watch a placebo-video describing immunization generally.
75612989|NCT01145508|Drug|Prednisone|Given PO
75612990|NCT01145508|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
75612991|NCT01145508|Biological|Rilimogene Galvacirepvec|Given SC
75762632|NCT05045261|Drug|administration of SLGN in arm C|administration of 3mg SLGN weekly for 24 weeks in arm C
75762633|NCT05045261|Drug|Discontinuation of NUC treatment in arms B and C|NUC treatment will be stopped after 28 weeks in arms B and C
75762634|NCT00498173|Drug|Atomoxetine|Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
75762635|NCT00498173|Drug|Placebo|Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
75612992|NCT02675881|Device|DSM|Monopolar RFA using dual switching mode (DSM)
75612993|NCT02675881|Device|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
75612994|NCT00931528|Drug|Tadalafil|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
75612995|NCT00931528|Other|Placebo|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
75612996|NCT04312152|Dietary Supplement|Q10 Ubiquinol|Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
75612997|NCT04312152|Dietary Supplement|Vitamin E|Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
75612998|NCT04312152|Dietary Supplement|Multi-Vitamin B complex|Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
75612999|NCT00975195|Drug|tiotropium inhalation|
75613000|NCT00975195|Drug|salmeterol xinafoate|
75613001|NCT00975195|Drug|fluticasone propionate|
75613002|NCT00975195|Drug|placebo matched for fluticasone propionate|
75613003|NCT00642499|Drug|Dronabinol|2.5 mg to 40 mg
75613004|NCT00642499|Drug|Placebo|placebo
75613005|NCT00644215|Drug|5-FU and Mitomycin|"5-FU injection 5mg~Mitomycin drop 0.02%"
75613006|NCT01145352|Drug|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
75762636|NCT04442009|Other|Group SCPB|In group SCBP, SCBP block will be performed. Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
75762637|NCT00295620|Drug|Anastrozole|1mg tablet daily
75459986|NCT01826396|Drug|Irinotecan|Comparison of standard and high dose irinotecan
75459987|NCT01826409|Dietary Supplement|Fermented Red Ginseng|Fermented red ginseng 2.7g/day for 4 weeks
75459988|NCT01826409|Dietary Supplement|Placebo|Placebo 2.7g/day for 4 weeks
75613007|NCT01178099|Drug|Prasugrel|Oral, daily for 12 days
75613008|NCT04016545|Device|Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)|Aortic aneurysm exclusion through endovascular procedure
75613009|NCT05323188|Other|Tryptase dosage|Collection of biological waste from a blood test for complete blood count (CBC) of care. Centrifugation to recover the plasma, then dosage of the tryptase.
75613010|NCT02673463|Drug|Spironolactone|25 mg once daily
75613011|NCT02673463|Drug|Placebo|Visually identical to spironolactone, once daily
75613012|NCT00610636|Procedure|Hepatic resection|Hepatic resection
75613013|NCT01169532|Drug|ridaforolimus|Given PO
75613014|NCT01169532|Drug|vorinostat|Given PO
75613015|NCT01169532|Procedure|biopsy|Optional correlative studies
75613016|NCT01169532|Other|pharmacological study|Correlative studies
75613017|NCT01169532|Other|laboratory biomarker analysis|Correlative studies
75762638|NCT01063374|Dietary Supplement|low glycemic diet instruction|
75762639|NCT01063374|Dietary Supplement|high cereal fibre diet instruction|
75762640|NCT01063452|Device|Truvalve|Atkinson Product Design urinary slide valve
75762641|NCT01063452|Other|Control (catheter drainage bag)|urinary catheter drainage bag
75762642|NCT03980496|Drug|Omeprazole|
76070156|NCT04029909|Drug|0.4mg/m2/d|0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
75613018|NCT02537353|Device|Metal clips|The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
75613019|NCT02537353|Drug|Hemospray|The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
75613020|NCT02537353|Procedure|Endoscopy Exam|All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
75613021|NCT02537353|Drug|Adrenaline|The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
75613022|NCT04181671|Other|Low Resistance training with venous blood flow restriction|"Total 20 males will participate in this group after warmup , Blood flow restriction will be provided through sphygmomanometer optimum pressure will be measured through following formula occlusion pressure (mmHg) = 0.514 (SBP) + 0.339 (DBP) + 1.461 (Arm circumference) + 17.236 then 30% of 1RM will be used for training . The standard protocol will be used which is four sets (1st set-30 repetitions, 2nd set-15 repetitions, 3rd set-15 repetitions, and 4th set-15 repetitions) with 30-60 s of interval between sets. ( the cuff must be deflated between sets of exercise) for 8 weeks (24) sessions on non-consecutive days. participants will be re-assessed for all baseline variables after 8 weeks of training biceps curls will be used for training.~Heart Rate and oxygen saturation will be measured during the session through Pulse oximeter"
75762643|NCT02532504|Other|CBT|"8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;~Five Areas vicious circle~Bad thought spotter~Amazing Bad thought Busting Programme (ABTPB)~Easy 4 Step plan~Things you do that mess you up/Confidence sheet~Happy List/ Things you do that boost how you feel sheet~Planner and Review sheets"
75762644|NCT01066260|Dietary Supplement|Probiotic formulation|Twice a day for 24 days
75762645|NCT01066260|Other|Placebo|Twice a day for 24 days
75762646|NCT01064544|Procedure|light therapy with the device: EnergyLight|2 hr of light therapy during each hemodialysis session
75762647|NCT03981510|Diagnostic Test|3D-Transit|3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
75613023|NCT04181671|Other|High Resistance training|Total 20 males will participate in this group after warm up. 80% of 1RM will be used for training, 3 sets of 8 repetitions will be used with 30-60 s of interval between sets. for 8 weeks (24) sessions on non-consecutive days.No blood flow restriction will be applied to this group Participants will be re-assessed for all baseline variables after 8 weeks of training. Bicep curls will be used for training.
75613024|NCT00928564|Drug|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
76070157|NCT04190979|Device|Medyria TrackCath System|The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.
76070158|NCT03596307|Dietary Supplement|Ashwagandha extract|Shoden 180 mg capsule.
75459989|NCT01826435|Behavioral|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
75613025|NCT00928564|Drug|Placebo|5ml of saline at each block site.
75613026|NCT02883036|Other|blood sampling|sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro
75613027|NCT02883036|Other|blood sampling|sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
75762648|NCT02532426|Procedure|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
75762649|NCT01063530|Device|DIammine SIlver fluoride|Application of Diammine SIlver Fluoride in cervical lesions
76070159|NCT03596307|Dietary Supplement|Placebo|Placebo 180 mg (Sucrose) capsule.
75459990|NCT01826461|Drug|PDI-192|
75762650|NCT01063530|Device|DIstilled water|Application of distilled water in cervical lesions
75459991|NCT01826461|Drug|Vehicle|
75762651|NCT00310440|Device|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
75762652|NCT00310440|Other|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
75762653|NCT03978390|Behavioral|behavioral priming|Priming the children with images of superheroes in order to behave desirably during the dental injection
75906335|NCT04713631|Drug|Artesunate|Artesunate is approved for the treatment of malaria and is on the World Health Organization list of Essential Medicines. Artesunate has a hemisuccinate group which confers substantial water-solubility and high oral bioavailability and therefore a convenient oral route of administration. Artesunate has a good safety and tolerability profile, having been used to treat millions of adults and children globally.
76070160|NCT04406337|Device|Low intensity pulsed ultrasound|Low intensity pulsed ultrasound therapy will use ultrasound with frequency of 1.5 MHz, power intensity of 30 mW/cm^2 (0.03 W/cm^2 ) and 20% duty cycle.
75613028|NCT00643357|Drug|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
75762654|NCT03978390|Behavioral|endowment effect|Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure
75762655|NCT03978390|Behavioral|Positive reinforcement|Giving rewards to the children at the end if they cooperate desirably during the treatment
75906336|NCT04713631|Drug|Curcumin|Curcumin has been used in Indian cuisine and traditional medicine for centuries. It has low solubility in aqueous solution and yields low serum levels following oral administration. In the setting of inflammatory bowel disease where the required site of action is the bowel, systemic absorption may be less relevant. Curcumin and its reduced metabolites undergo conjugation in the liver. Curcumin has a half life of 6-7 hours. It has been found to be safe at oral doses of 2 gm and 3 gm a day in patients with ulcerative colitis, for up to 1 year. In a dose titration study conducted in children with inflammatory bowel disease 2 gm twice daily of curcumin was well tolerated
75906337|NCT04713631|Drug|Placebo A|Artesunate looking placebo
75906338|NCT04713631|Drug|Placebo C|Curcumin looking placebo
75906339|NCT04459078|Drug|Camrelizumab|Intravenous administration of (200mg/3weeks)
75906340|NCT04459078|Drug|Albumin Paclitacxel|intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
75906341|NCT04459078|Drug|Apatinib|Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
75906342|NCT02179242|Other|Cardiac rehab|
75906343|NCT04693195|Drug|BLU-5937|Oral administration of BLU-5937 tablets
75459992|NCT01826474|Drug|PRO045, 0.15 mg/kg/week|Subcutaneous injection
75906344|NCT04693195|Drug|Placebo|Oral administration of matching placebo for BLU-5937 tablets
75906345|NCT03067090|Device|Aquamid Reconstruction|"AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.~The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle."
75906346|NCT02756832|Drug|Alogliptin Benzoate|Alogliptin benzoate tablets
75906347|NCT05728216|Other|Dynamic full-field optical coherence tomography analysis of kidney biopsy|Dynamic full-field optical coherence tomography analysis of kidney biopsy in the nephrology department before conventional histopathological analysis
75906348|NCT00108810|Drug|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
75906349|NCT00108810|Drug|Placebo transdermal patch|12 hours application for 28 days
75459993|NCT01826474|Drug|PRO045, 1.0 mg/kg/week|Subcutaneous injection
75459994|NCT01826474|Drug|PRO045, 3.0 mg/kg/week|Subcutaneous injection
75613029|NCT00643357|Drug|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
75613030|NCT01177943|Drug|Atomoxetine|Administered orally, once.
75613031|NCT00608920|Other|Single Photon Emission Computed Tomography (SPECT)|
75613032|NCT01131312|Device|Thinprep|Pap test
75613033|NCT01131312|Device|Hybrid capture 2|Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
75613034|NCT01131312|Procedure|Colposcopy|Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
75762656|NCT00304356|Drug|Nitazoxanide|500 mg bid
75762657|NCT01066416|Procedure|Endoscopic Sinus Surgery|
75762658|NCT01066416|Other|medical therapy|Subjects will undergo surgery 6 months after randomization
75762659|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
75762660|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
75459995|NCT01826474|Drug|PRO045, 6.0 mg/kg/week|Subcutaneous injection
75459996|NCT01826474|Drug|PRO045, 9.0 mg/kg/week|Subcutaneous injection
75459997|NCT01826474|Drug|PRO045, selected dose|Subcutaneous injection
75459998|NCT01826500|Other|blood test|blood test
75459999|NCT01826526|Device|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
75460000|NCT01826539|Procedure|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
75762661|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
75906350|NCT02172612|Other|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
75906351|NCT03067402|Other|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
75906352|NCT03067402|Diagnostic Test|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
75762662|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
75906353|NCT00106080|Behavioral|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
76070161|NCT04406337|Device|High intensity continuous ultrasound|High intensity continuous ultrasound therapy will use ultrasound with frequency of 1 MHz, power intensity of 3 W/cm^2 and 100% duty cycle.
76070162|NCT04029441|Other|the eradication Hp|the eradication of Hp based on antimicrobial susceptibility test
75762663|NCT00321620|Drug|zoledronic acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
75906354|NCT02177214|Procedure|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
76070163|NCT04766151|Drug|Transdermal glyceryl trinitrate 10mg patches|Transdermal patches applied to skin 30 minutes before cardiac catheterization
76070164|NCT04766151|Drug|Placebo patches|Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
76070165|NCT04029207|Procedure|Cesarean section|Abdominal, operative delivery of the fetus
76070166|NCT04191213|Dietary Supplement|Acacia Senegal extract|Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks
76070167|NCT04191213|Dietary Supplement|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
75613035|NCT04181281|Diagnostic Test|Contrast enhanced ultrasound|This is a regular ultrasound scanner used with an ultrasound contrast agent injected through veins to allow for kidney perfusion acquisition.
75613036|NCT04181281|Diagnostic Test|Arterial Spin Labelling -Magnetic Resonance Imaging|Arterial spin labelling is an MRI technique allow for measuring tissue perfusion. It uses magnetically labelled arterial blood water protons as a tracer.
75613037|NCT02865057|Procedure|Vaginal assessment|Vaginal assessment of position prior to delivery
75613038|NCT04314960|Device|Functional electrical stimulation device (NESS L300Plus, Bioness, Valencia, CA)|Functional electrical stimulation (FES) is the application of high-intensity intermittent electrical stimuli to generate muscle contractions that may bypass spinal and supraspinal inhibition, and which is coupled with a functional task such as gait. Gait training will be conducted on a treadmill.
75613039|NCT04178785|Drug|Remifentanil|Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
75613040|NCT01177787|Device|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
75613041|NCT01177787|Device|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
75613042|NCT02864589|Behavioral|Internet-delivered habit reversal training|The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
75762664|NCT00321620|Biological|denosumab|Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
75762665|NCT00304278|Drug|Erlotinib (Tarceva)|150 mg daily X 7 weeks
75762666|NCT00304278|Drug|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
75762667|NCT00304278|Radiation|Radiation Therapy (RAD)|5 days per week X 7 weeks
75762668|NCT03981068|Radiation|Re-irradiation|Cisplatin for all eligible patients, nimorazole for all SCC
75762669|NCT02532686|Drug|DAAOI-2|500-2000mg/d, oral, for 6 weeks
75762670|NCT02532686|Drug|placebo|oral, for 6 weeks
75762671|NCT01063946|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion"
75762672|NCT00291018|Device|Total Disc Replacement|Total Disc Replacement using ProDisc-C
75762673|NCT00291018|Device|ACDF|Anterior Cervical Discectomy and Fusion
75762674|NCT00320606|Drug|Immunosuppression Withdrawal|Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
75906355|NCT05588284|Device|AngioJet device|A device can be used for thrombus aspiration and thrombolysis.
75906356|NCT05588284|Other|anticoagulation alone|a medicine for anticoagulation therapy
75906357|NCT02256150|Drug|Mizoribine (MZR)|
75906358|NCT02256150|Drug|Cyclophosphamide (CTX)|
75906359|NCT02179320|Procedure|Dry needling|Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm
75906360|NCT02179320|Device|acupuncture needle 0,25 x 40mm|
75906361|NCT02177370|Drug|Fenoterol MDI|
76070168|NCT03024177|Drug|Vapendavir|Vapendavir Tablets, 264 mg
76070169|NCT03024177|Drug|Placebo Oral Tablet|Vapendavir 264 mg matching tablets
76070170|NCT01874431|Drug|Finerenone (BAY94-8862)|
76070171|NCT01874431|Drug|Placebo|
75762675|NCT01064102|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
75762676|NCT01064700|Device|Litebook Bright Light Box|Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.
75613043|NCT02864589|Behavioral|Internet-delivered exposure and response prevention|The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual & workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
75762677|NCT01064700|Device|Litebook inactivated negation ion generator (the placebo)|Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
75762678|NCT02532114|Drug|Enzalutamide|Given PO
75762679|NCT02532114|Other|Laboratory Biomarker Analysis|Correlative studies
75762680|NCT02532114|Drug|Niclosamide|Given PO
75762681|NCT02532114|Other|Pharmacological Study|Correlative studies
75762682|NCT00307736|Drug|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
75762683|NCT00307736|Drug|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
75460001|NCT01826552|Device|Osiro Hybrid Drug-Eluting Stent|Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
75460002|NCT01826552|Device|Resolute Integrity|Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
75613044|NCT02676037|Device|foot pressure plate form|
75762684|NCT00307736|Drug|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
75762685|NCT00307736|Procedure|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
75762686|NCT00320528|Drug|atomoxetine|0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
75762687|NCT03979586|Other|Laser-assisted hyaluronic acid delivery|The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
75762688|NCT00294762|Drug|Tarceva|oral tablet
75762689|NCT00294762|Drug|carboplatin|IV
75762690|NCT00294762|Drug|paclitaxel|IV
75762691|NCT00294684|Drug|Corticosteroids|"Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop"
75460003|NCT01826565|Procedure|Rotational technique|90 degree rotation
75460004|NCT01826578|Procedure|using only one port for laparoscopic surgery|using only one port for laparoscopic surgery
75460005|NCT01826630|Other|CLn BodyWash|Comparing two washes to determine change in bacterial load.
75762692|NCT00294684|Drug|Placebo|"Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop"
75762693|NCT00307034|Biological|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
75762694|NCT00307034|Biological|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
75762695|NCT00307034|Biological|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
75906362|NCT02177370|Drug|DSCG MDI|
75460006|NCT01826630|Other|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
75460007|NCT01826656|Procedure|tooth extraction|Patients from both groups will follow the extraction of an hopeless tooth
75460008|NCT01826656|Radiation|CBCT scan|A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
75613045|NCT00928486|Drug|Lenalidomide|Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
75460009|NCT01826656|Radiation|DXA scan|DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
75460010|NCT01826656|Radiation|Panoramic radiograph|As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
75460011|NCT01826669|Procedure|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
75613046|NCT00928486|Drug|Dexamethasone|Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
75613047|NCT05528029|Device|Leadless Pacemaker (Micra)|Micra leadless pacemaker is implanted in the right ventricle via femoral vein. The Micra introducer/dilator assembled system is inserted over a stiff guidewire in the right atrium. After the removal of the guidewire and the dilator, the delivery system is advanced into the introducer and the Micra is placed under fluoroscopy guidance, preferably in the septal region of the right ventricle.
75613048|NCT02887391|Other|No intervention - observational study|No intervention - observational study
75613049|NCT04056117|Biological|Shigella 4V|Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
75762696|NCT01061996|Drug|Basiliximab|Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
75762697|NCT01069458|Other|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
75762698|NCT01064180|Drug|Carvedilol|Carvedilol Tablets 25 mg
75762699|NCT01069536|Drug|metoclopramide 10 mg|
75762700|NCT01069614|Device|TopClosure 3S System|
75762701|NCT03980106|Other|Reciprocal Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract antagonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
75762702|NCT03980106|Other|Post-Isometric Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract agonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
76070172|NCT04028817|Device|photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied sublingual laser in a single point, with wavelength of 808 nm, diameter of 0.4 cm, with irradiance of 0.8 w / cm2, for 360 s, the laser applied will be of continuous wave with energy of 36J.
75613050|NCT04056117|Biological|MenACWY|Control vaccine administrated to adults and infants
75613051|NCT04056117|Biological|Rabies|Control vaccine administrated to children
75613052|NCT04056117|Biological|Diphtheria, Tetanus and Pertussis (DTaP)|Control vaccine administrated to infants
75613053|NCT04056117|Biological|Placebo|Control administrated to adults
75613054|NCT05655221|Drug|B1344|multi-site abdominal s.c. injections (maximum 2 mL at each site)
75613055|NCT05655221|Other|Placebo|multi-site abdominal s.c. injections (maximum 2 mL at each site)
75613056|NCT00610792|Drug|bortezomib|1.3 mg/m2 on Days 1, 4, 8 & 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
75613057|NCT00610792|Drug|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
75613058|NCT02677441|Procedure|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
75613059|NCT02677441|Procedure|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
75762703|NCT03976674|Behavioral|Cognitive Behavioural Therapy (CBT)|5 group sessions (2h30/session) before the surgery
75762704|NCT01064778|Other|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
75613060|NCT00610870|Drug|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
75613061|NCT05655143|Behavioral|Balance training|Participants will undergo a 4-week balance training protocol modified from that described by McKeon et al.15 Participants will undergo supervised exercise three times per week for approximately 30 minutes per session, The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task.
75762705|NCT01064778|Other|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
75762706|NCT00320216|Drug|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
75762707|NCT00320216|Drug|Placebo|Patients in the placebo group will receive placebo medication.
75762708|NCT00290706|Drug|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
75762709|NCT00290706|Drug|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
75762710|NCT03978156|Drug|Dronabinol 2.5 MG|Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.
75762711|NCT03978156|Drug|Microcrystalline cellulose|Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
76070173|NCT04028817|Device|placebo photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
76070174|NCT04190511|Dietary Supplement|Prebiotic-containing dairy|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition. On this basis, intervention was carried out using prebiotic-containing dairy products (200g/day).
75613062|NCT04181593|Drug|Omega 3 fatty acid|Omega 3 fatty acid Softgels
75613063|NCT04181593|Drug|Placebos|Mineral oil Softgels
75613064|NCT04265326|Other|Measurement of Quality of Life|Quality of life will be measured using Head and Neck Cancer Inventory and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
75613065|NCT01168596|Drug|Rasagiline|"Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
75613066|NCT01168596|Drug|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
75613067|NCT02537275|Device|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
75613068|NCT02537275|Device|EyeLIKe Shine, Koryo Eyetech Co|clear lens
76070175|NCT04190511|Dietary Supplement|Dietary intervention|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.
76070176|NCT04028739|Dietary Supplement|curmin|curcumin 90mg/day cross-over
76070177|NCT04028661|Device|3D printed Modified Twin Block Appliance|It is a functional appliance for mandibular advancement designed digitally on virtual models.
75613069|NCT05658419|Procedure|socket sheild|the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.
75613070|NCT02675647|Drug|Heparin, IV route, based on patients body weights (UI/kg)|
75613071|NCT02675647|Procedure|Cardiopulmonary bypass|
75613072|NCT02675647|Drug|Protamin administration|
75613073|NCT05370898|Drug|Caltrate D|Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
75613074|NCT05370898|Drug|Chinese medicine prescription|The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
75613075|NCT05370898|Drug|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
75613076|NCT04315805|Other|Integrative Yoga Therapy|Yoga therapy will be based on personalised care consisting of Yoga relaxing posture, strengthening exercise, Yoga breathing, meditative psychotherapy, sound and imagery yoga practices, relaxation, yoga diet and life style management.
75613077|NCT02677363|Other|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
75613078|NCT00610948|Biological|panitumumab|Given IV
75613079|NCT00610948|Drug|everolimus|Given orally
75613080|NCT00610948|Drug|fluorouracil|Given IV
75762712|NCT03978234|Drug|AbobotulinumtoxinA 300 UNT|AbobotulinumtoxinA 300 UNT
75762713|NCT01064934|Procedure|Lipid apheresis|Weekly lipid apheresis procedure for lipoprotein(a) lowering
75762714|NCT01064934|Other|Standard care|Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
75613081|NCT00610948|Drug|leucovorin calcium|Given IV
75613082|NCT00610948|Drug|oxaliplatin|Given IV
75613083|NCT04206137|Other|Group A (PNF rhythmic initiation group )|Lifting of arms and push the head back through the pattern of flexion -abduction-external rotation and neck in extension to the left in opposition of therapist hand resistance will be asked to do. At the end range of motion extensor muscles of back will start to contract.Then, reversing of that movement pattern to extension-adduction-internal rotation and neck flexion to right against the therapist resisting hands will be asked. this will be repeated on both sides
75613084|NCT04206137|Other|Group B (Swiss ball exercises)|"Supine position: A ball will be placed under patient neck, and will be asked to bend hip and knee up to 90°. 5 times, 10 seconds hold Supine position: With a ball below the pelvis, knees bent, the ball press will be done with pelvis. 5 times, for 10 seconds hold.~Crawling position: With a ball below one knee while keeping toes away from contact with the floor, the patient will balance first to stabilize the posture and slowly raise the other lower limb. This exercise will be performed in turn for the two lower limbs 10 times, with 10 seconds hold.~Prone position: the patient will place a ball in front of pelvis and will repeatedly raise and lowered the two lower limbs alternately. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set."
75613085|NCT04314726|Drug|Amelogenin|amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
75613086|NCT04314726|Drug|Placebos|placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
75613087|NCT04178395|Device|bihemispheric transcranial direct stimulation|"tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA)."
76070178|NCT04028583|Other|PIM-Check|In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
75762715|NCT01066494|Drug|Amonafide + cytarabine|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
75762716|NCT03977766|Procedure|Chemotherapy prevalidation|"Outpatient Chemotherapy prevalidation will done~with the help of a nurse, using the digital application, for cycle 2 and 3.~by the patient alone, using the digital application, for cycle 4 and 5."
75762717|NCT03977688|Device|Cytokin Adsorption|Haemadsorption with Cytokin Adsorber (Cytosorb)
75762718|NCT01069770|Drug|Sunitinib|50mg daily(4 weeks on & 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops
75762719|NCT00303108|Drug|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
76070179|NCT04028583|Other|STOPP/START|In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
76070180|NCT04028505|Drug|Terlipressin Injectable Product|"Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH."
76070181|NCT01824355|Device|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
76070182|NCT04042623|Drug|AVB-S6-500|AVB-S6-500 is experimental drug
75762720|NCT00303108|Drug|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
75613088|NCT01177553|Procedure|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
75762721|NCT00303108|Drug|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
75613089|NCT01177553|Device|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
75762722|NCT00302952|Drug|Lovastatin|Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
75906363|NCT03538080|Device|ACCUVEIN plus ultrasound|"Intervention is marking of the saphenous veins with ACCUVEIN system. The AccuVein® AV400 vein illumination system is a laser imaging system that detects superficial veins up to 10 mm deep and digitally displays, through a projected red light, a map of the vascularization on the surface of the skin. in real time, allowing clinicians to check vein permeability and position.~This system is portable and lightweight. It can be easily cleaned, and requires no calibration or adjustment. It does not require any contact with the patient. Second time is completion of marking by ultrasound if necessary"
75906364|NCT03538080|Device|Ultrasound only|Intervention is marking with ultrasound imaging as in usual practice.
75762723|NCT00302952|Drug|Placebo|Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
75906365|NCT03538782|Procedure|Percutaneous biliary drainage|The initial puncture of the bile duct with an access needle is performed by ultrasound guidance or by fluoroscopic guidance. After injection of the radiopaque contrast media into the bile duct system the rest of the examination is performed by fluoroscopic guidance. All different PTBD procedures are analyzed: insertion, exchange or removal of a plastic catheter, metal stent implantation, PTBD with cholangioscopy, PTBD with ballon dilatation, PTBD with lithotrypsy or diagnostic percutaneous transhepatic cholangiography.
75906366|NCT02172690|Procedure|Laparoscopic Staging|Laparoscopic Staging
76070183|NCT04190745|Drug|Toripalimab+Apatinib mesylate|Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
76070184|NCT04190745|Drug|paclitaxel|paclitaxel 80mg/m2, q3w
76070185|NCT01823341|Device|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
76070186|NCT04028427|Behavioral|Values-plus-goals intervention|The VGI is a four-week intervention, adapted from an existing online value-affirmation and goals intervention (Kingston & Ellett, 2014) and an existing 'Living Well with Physical Health Conditions' programme handbook. Participants are first introduced to the concept of values as understood in Acceptance and Commitment Therapy. They are then asked to complete a card-sort task, which involves organising ten life domains according to their perceived level of importance. Participants will be asked to choose one values that is the most important and meaningful to them and to write for up to 10 minutes about it, thinking about why it is meaningful to them. Following this, participants will be given information on how to set value-based 'SMART' goals and asked to choose one to focus on over the next month. Participants will be sent a reminder e-mail every week over the 4 weeks, asking them to review their progress towards the SMART goal they set themselves.
76070187|NCT04028427|Behavioral|Mindfulness-based intervention|The MBI is a four-week intervention, where participants are introduced to the concept of mindfulness and acceptance as understood in ACT (Hayes et al., 1999). They will be asked to complete a 10-minute health-focused mindfulness meditation exercise by listening to a recording of a script focusing on cultivating mindful awareness of internal experiences, particularly in relation to diabetes, and practising making room for any difficult internal experiences. This will be followed by some prompts to promote reflections related to their diabetes following the exercise. They will be asked to practise this exercise 3-4 times a week over a four-week period. As a manipulation check, participants will be sent a reminder e-mail every week over the four weeks to record how many times they practised the exercise over the past week.
76070188|NCT04190121|Dietary Supplement|prosure|The study group will receive the dietary supplement preoperatively and for three months after the operation
75762724|NCT00302718|Behavioral|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
75762725|NCT00302718|Behavioral|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
75762726|NCT00302718|Behavioral|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
75762727|NCT03976206|Biological|Very small embryonic-like stem cell|We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
75906367|NCT03538704|Drug|Metformin|Metformin is given to patients 1-1.5g/d.
76070189|NCT04028349|Drug|Ad26.ZEBOV/MVA-BN-Filo|Candidate Ebola Vaccine
76070190|NCT01853137|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
75613090|NCT04178239|Diagnostic Test|fMRI, questionnaires, pneumologic diagnostics|fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
75762728|NCT01069848|Device|Vedera KXS|One treatment session with Vedera KXS
75762729|NCT01066572|Drug|Lisinopril|5-10 mg Lisinopril per day for seven days, depending on blood pressure.
75762730|NCT01066572|Drug|Placebo|Matched placebo; identical tablets to Lisinopril.
75762731|NCT01066650|Device|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
76070191|NCT04028271|Device|Comfort-in injection system|local anesthesia during dental treatment
75762732|NCT01066650|Device|Xience V (Everolimus-eluting stent)|Drug eluting stent
75762733|NCT00302328|Procedure|macular hole operation|macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
75762734|NCT01066728|Other|CO2 inhalation|Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
75762735|NCT01066728|Drug|Theophylline|
75762736|NCT01069926|Drug|AZD1656|Single dose oral tablet
75762737|NCT01070004|Other|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
75762738|NCT01070004|Other|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
75762739|NCT01325610|Dietary Supplement|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
75762740|NCT03977844|Other|Technical Assistance|"TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery."
75762741|NCT03977844|Other|Community Engagement and Planning|CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles [48, 64]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.
75762742|NCT03977844|Other|Community Resources (CR)|The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
75906368|NCT03538548|Behavioral|CBT-RP|CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
75906369|NCT02633020|Biological|AMG 714|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
75906370|NCT02633020|Biological|Placebo|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
75906371|NCT02172768|Other|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
76070192|NCT04028271|Other|conventional injection with dental needle|for local anesthesia during dental treatment
75460012|NCT01826682|Other|Physiotherapy program+medical treatment|Patients included in this group are going to receive physiotherapy during their hospital stay 45 minutes every day. The physical training is based on respiratory exercises, the use of a flutter (positive expiratory pressure), pedaling and theraband exercises.
75460013|NCT01826682|Other|Medical treatment|Standard medical treatment without physiotherapy.
75613091|NCT04260178|Other|An Education-Based Intervention Program and handbook (EBIP, hospital and home)|A handbook was developed in line with the literature and input from two specialist physicians. The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior.
75613092|NCT04260178|Other|PFT, BMI, BDI, SCMP-G|pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale
75460014|NCT01826695|Other|Neurodynamic technique group|"Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.~The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks."
75762743|NCT03977844|Other|Community Resources + eBT|"The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities [65]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app."
75762744|NCT00301080|Drug|D-cycloserine|
75762745|NCT00301080|Other|Placebo|
75762746|NCT01066806|Behavioral|counseling on increasing calcium intake|The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
75762747|NCT01066806|Other|observation|observe normal dairy intake
75762748|NCT03977610|Drug|Ga-68 PSMA ligand|For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of [68Ga]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi [68Ga]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
75906372|NCT02172768|Other|daily dosing|micafungin daily for 8 days
75906373|NCT02172768|Drug|micafungin|
75906374|NCT02172846|Radiation|Proton beam radiation therapy (PBT)|
75906375|NCT02172846|Drug|Paclitaxel|
75906376|NCT02172846|Drug|Carboplatin|
75906377|NCT02172924|Biological|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
75762749|NCT01066884|Drug|erlotinib [Tarceva]|150mg po daily
75762750|NCT01581216|Other|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
75762751|NCT01581216|Other|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
75762752|NCT01581216|Other|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
75762753|NCT00290238|Device|Vertis Percutaneous Neuromodulation Therapy (PNT)|"Ten PNT sessions in eleven weeks~On average, one PNT session per week~Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~Forty-five minutes of electrical stimulation for each session~Electrical stimulation parameters:~Continuous 50 Hz current~Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level"
75906378|NCT02172924|Biological|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
75906379|NCT05726578|Other|Lung recruitment|establishment of lung recruitment using high frequency ventilation and assessment with chest ultrasound and echocardiography
75906380|NCT02173002|Other|myIBDcoach|
75906381|NCT02173002|Other|Standard care|
75906382|NCT00106626|Drug|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
75460015|NCT01826695|Other|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
75906383|NCT02179476|Device|Glyder|The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation in one or two lumbar facet levels
75906384|NCT03538470|Other|Spa Treatment|"Bath with immersion shower~Overall penetrating shower~Multiple local application cataplasm~Individual physiotherapy~Mobilisation pool"
75906385|NCT03537378|Procedure|Hybrid APC|• HybridAPC is integrated with traditional APC and water-jet technique, which has been successfully applied for endoscopic treatment of mucosal lesions in GI, such as Barrett esophageal and lesions in colon. Submucosal injection of water jet can elevate superficial lesion, and then APC can be more effective in ablation of superficial tumor with a protection for muscular layer. The application of HybridAPC in respiratory intervention could theoretically protect cartilage, adventitia, reduce damage and formation of scare, and increase ablation energy to reach radical treatment. • High-frequency EBUS, could display the boundary between cartilage endomembrane and cartilage, in order to determine the depth of tumor.
75906386|NCT03538392|Device|Serranator® Alto|Serranator® Alto PTA Serration Balloon Catheter
75906387|NCT02177448|Drug|BIBR277 low dose|
76070193|NCT03595839|Procedure|Fistulotomy|The fistula track is laid open after complete probing till the internal opening
76070194|NCT03595839|Procedure|Marsupialization|The laid open track will be marsupialized using interrupted absorbable sutures
76070195|NCT01823107|Device|Meso BioMatrix Device|
76070196|NCT04190277|Device|Open-loop condition|Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
76070197|NCT04190277|Device|Closed-loop condition|Closed-loop algorithm system paired with continuous glucose monitoring sensor
75906388|NCT02177448|Drug|BIBR277 medium dose|
75762754|NCT00290238|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|"Ten TENS sessions in eleven weeks~On average, one TENS session per week~Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~Forty-five minutes of electrical stimulation for each session~Electrical stimulation parameters:~Current at 2 Hz-low frequency~Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~Intensity titrated according to subject's sensory threshold~To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device."
75762755|NCT02532270|Drug|phenylephrine|When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug in Group C and Group N.If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
75613093|NCT02675413|Drug|Dimethyl Fumarate|Open-label
75613094|NCT02675725|Device|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
75762756|NCT01581450|Drug|Nitrous Oxide|35%
75613095|NCT00928408|Drug|Cinacalcet|
75762757|NCT01581450|Drug|Nitrous Oxide|50%
76070198|NCT01874275|Device|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
75762758|NCT01325766|Other|Yoga|Yoga 2 sessions per week for 8 weeks
75762759|NCT03976284|Behavioral|Garden-fresh produce and exercise|The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
76070199|NCT01873729|Drug|Naltrexone|Adults with ADHD
76070200|NCT01873495|Drug|Omacetaxine|"Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.~Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles"
76070201|NCT04027959|Dietary Supplement|Vitamin B12|Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current
76070202|NCT04027569|Other|Patient Specific Functional Scale|A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
76070203|NCT04027569|Other|PROMIS PF|A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
75613096|NCT04179877|Behavioral|IPS|Occupational rehabilitation and support Integrated with clinical treatment
75613097|NCT02675257|Behavioral|Diabetes-related affective problems analysis|Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
75762760|NCT00289848|Drug|sitagliptin phosphate|Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
75762761|NCT00289848|Drug|Comparator: placebo|placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
75762762|NCT00289770|Biological|Twinrix™|Intramuscular injection, 3 doses
75762763|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
75762764|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
75762765|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
75762766|NCT00289458|Behavioral|exercise|A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
75762767|NCT00289458|Behavioral|2|Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
75906389|NCT02177448|Drug|BIBR277 high dose|
75906390|NCT02177448|Drug|Enalapril low dose|
75906391|NCT02177448|Drug|Enalapril medium dose|
75906392|NCT02177448|Drug|Enalapril high dose|
75906393|NCT02177448|Drug|Placebo matching BIBR277|
75906394|NCT02177448|Drug|Placebo matching enalapril|
76070204|NCT01852825|Biological|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
76070205|NCT01852825|Other|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
75460016|NCT01826708|Biological|Identification of breakpoints|Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
75460017|NCT01826721|Other|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
75460018|NCT01826747|Drug|crinone (progesterone 8%, vaginal application)|
75460019|NCT01826760|Other|Using training and testing groups to construct ANN based on laboratory tests|
75460020|NCT01826773|Drug|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
75613098|NCT02675257|Behavioral|Goal setting towards improvement of glycaemic control|Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
75613099|NCT02675257|Behavioral|Diabetes-specific problem-solving therapy|Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
75613100|NCT02675257|Behavioral|Interventions to increase diabetes treatment motivation|Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
75613101|NCT02675257|Behavioral|Activation of personal and social resources|Activation of personal and social resources with a view to diabetes control and affective problems
75613102|NCT02675257|Behavioral|Reduction of barriers to self-care/glycaemic control|Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
75613103|NCT02675257|Behavioral|Cognitive restructuring of diabetes-related problems|Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
75613104|NCT02675257|Behavioral|Goal definition regarding self-care/glycaemia/well-being|Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
75613105|NCT02675257|Behavioral|Health care and specific topics (e. g. blood pressure)|Education on health care and specific topics (e. g. blood pressure)
75613106|NCT02675257|Behavioral|Healthy foods, cooking recommendations, recipes|Education on healthy and unhealthy foods, cooking and recipes
75613107|NCT02675257|Behavioral|Sports, activities and exercise|Education on sports, activities and exercise
75613108|NCT02675257|Behavioral|Foot care: exercises, care & control, injuries, neuropathy|Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
75613109|NCT02675257|Behavioral|Diabetes complications|Education on diabetes complications
75613110|NCT02675257|Behavioral|Social aspects of living with diabetes|Education on social aspects of living with diabetes
75613111|NCT00928252|Drug|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
76070206|NCT01852825|Biological|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
76070207|NCT04027413|Dietary Supplement|fortisip compact protein|(24% protein; 41% carbohydrate; 35% fat)
75613112|NCT02673073|Other|Patient's diary|"Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.~Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade."
75613113|NCT02673073|Other|Patient's education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
75613114|NCT02673229|Drug|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
75613115|NCT02673229|Drug|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
75613116|NCT00644293|Drug|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
75613117|NCT00644293|Drug|placebo|placebo
75613118|NCT00644293|Drug|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
75613119|NCT00644293|Drug|placebo|placebo
75613120|NCT01177007|Device|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
75613121|NCT00930982|Drug|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
76070208|NCT04027413|Dietary Supplement|preOp|(100% carbohydrate).
76070209|NCT04344951|Drug|UNIKINON (Chloroquine phosphate) 200mg tablets|Two and a half tablets (500mg) twice daily for seven days.
76070210|NCT01822561|Drug|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
76070211|NCT02080455|Drug|lomitapide|20 mg dose
76070212|NCT02080455|Drug|Atorvastatin|80 mg
76070213|NCT01852591|Biological|PCV 13|
75613122|NCT00930982|Drug|Placebo|Inhalation of matching placebo twice a day
75613123|NCT02673307|Behavioral|1 chewing gum over 45 minutes|
75762768|NCT00289458|Behavioral|Control|no exercise
75762769|NCT00288912|Behavioral|Health Education|12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
75762770|NCT00288912|Behavioral|Osteoarthritis Self-Management|12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
75762771|NCT01066962|Drug|darunavir/ritonavir QD + raltegravir BID|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)"
75762772|NCT01066962|Drug|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)"
75906395|NCT02177526|Device|Imaging|15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
75613124|NCT02677285|Other|Different type of wound|
75906396|NCT02179632|Behavioral|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
75613125|NCT05662891|Other|Blood Flow Restriction|After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.
75613126|NCT01176773|Device|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
75613127|NCT04102033|Drug|Eltrombopag|Thrombopietic agent approved for its efficacy in chronic immune thrombocytopenia in pediatric patients
75613128|NCT05029180|Other|Termination of resuscitation|Do estimate the approaches used worldwide when terminating resuscitative efforts
75613129|NCT04180111|Device|CATS Tonometer|CATS Tonometer Prism
75613130|NCT02887625|Drug|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
75613131|NCT02887625|Drug|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c <7.0%
75613132|NCT04180033|Diagnostic Test|Colonoscopy surveillance|Participants will be asked to undergo a first colonoscopy surveillance.
75613133|NCT02886377|Biological|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
75613134|NCT05662813|Drug|Almonertinib|Almonertinib 110mg p.o qd. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
75613135|NCT02675335|Drug|Sitagliptin|
75906397|NCT02177604|Other|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)"
75906398|NCT02177604|Other|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
75613136|NCT02675335|Drug|Placebo|
75613137|NCT02675101|Other|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
75762773|NCT01067118|Drug|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
75762774|NCT01067118|Drug|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
75762775|NCT01067274|Drug|Vesanoid (ATRA)|45 mg/m2/day in two divided doses from D8 to D28
75762776|NCT01067274|Drug|AZACITIDINE (VIDAZA)|75 mg/m2/12h SC from D1 to D5
75762777|NCT01067274|Drug|CYTARABINE|Cytarabine : 60 mg/m2/12h SC from D1 to D5
75762778|NCT01065246|Drug|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
75762779|NCT01325844|Procedure|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
75762780|NCT01067430|Drug|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
75762781|NCT01067430|Drug|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
75762782|NCT00305864|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
75762783|NCT00305864|Drug|Motexafin Gadolinium|Given IV
75762784|NCT00305864|Drug|Temozolomide|Given orally
75762785|NCT00295880|Procedure|umbilical cord blood transplantation|The graft will be given by slow injection into each posterior iliac crest.
75906399|NCT02177604|Other|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
75906400|NCT02173236|Other|platform-switched implants|
75906401|NCT02173236|Other|platform-matched implant|
75906402|NCT03537300|Behavioral|DCF muscles training using pressure biofeedback in addition to conventional exercises|DCF muscles training using pressure biofeedback in addition to conventional exercises
75906403|NCT03537300|Behavioral|conventional exercises|conventional exercises
75613138|NCT02675101|Other|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
75613139|NCT02675101|Other|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
75613140|NCT00928018|Drug|Sirolimus|Taken orally for at least 12 months
75762786|NCT01066130|Behavioral|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
75762787|NCT01066130|Behavioral|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
75906404|NCT03537144|Drug|Indomethacin|IV indomethacin will be given every 12 hours for 3 doses. If <48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If >7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
76070214|NCT04027491|Behavioral|Virtual Reality|"The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period."
75613141|NCT00928018|Drug|Methotrexate|Given intravenously on the first, third and sixth day after transplant
75762788|NCT03979196|Other|Inpatient Management|"Admission for a minimum of three days, administration of betamethasone, and clinical reassessment by obstetrician after three days. After the initial three day admission, further management will be at the discretion of their obstetrician who will continue their care and decide if further admissions are needed.~Weekly cervical length assessment will be performed until 28 weeks and patient readmission will be decided by their Obstetrician.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
75613142|NCT00928018|Drug|Tacrolimus|Taken orally or given intravenously for at least 6 months
75762789|NCT03979196|Other|Outpatient Management|"Avoid heavy lifting and core exercise, avoid intercourse, weekly assessment of cervical length by ultrasound and administration of betamethasone. Patients will continue with outpatient management for the remainder of their pregnancy with no admission unless the patient develops contractions, PPROM, bleeding, or the cervix is dilated to ≥1cm.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
75613143|NCT00928018|Drug|Cyclosporine|Taken orally or given intravenously for at least 6 months
75613144|NCT00928018|Drug|MMF|Taken orally for about 2 months
75762790|NCT03978962|Device|Guided Tissue Regeneration|"Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction."
75762791|NCT01325480|Device|Cardiac Pacing|
75762792|NCT03982784|Procedure|single-injection TQLB(transmuscular quadratus lumborum block)|Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
75762793|NCT03982784|Drug|Morphine given as IPCA(intravenous patient controlled analgesia)|PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
75762794|NCT03978884|Drug|Losartan 50Mg Tab|Take 1 tab daily
75762795|NCT03978884|Drug|Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET|Take 1 tab daily
75906405|NCT03537144|Drug|Acetaminophen|15mg/kg/dose every 6 hours for 12 doses
76070215|NCT04596241|Device|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
75906406|NCT02632786|Drug|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
75460021|NCT01826786|Drug|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
75460022|NCT01826786|Drug|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
75460023|NCT01826864|Biological|sargramostim|Given SC
75460024|NCT01826864|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
75460025|NCT01826864|Other|laboratory biomarker analysis|Correlative studies
75460026|NCT01826864|Other|hypertonic saline|Given SC
75460027|NCT01826877|Biological|AdGMCAIX-transduced autologous dendritic cells|Given ID
75460028|NCT01826877|Biological|therapeutic autologous dendritic cells|Given ID
75460029|NCT01826877|Other|laboratory biomarker analysis|Correlative studies
75460030|NCT01826890|Other|NAVA Technology|Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
75613145|NCT04099225|Diagnostic Test|Multiple breath washout (MBW) testing|Lung clearance index (LCI), acinar (Sacin) and conductive (Scond) ventilation heterogeneity were derived from triplicate SF6-MBW measurements. Global ventilation heterogeneity was calculated for the 2.5% (LCI2.5) and 5% (LCI5) stopping points.
75613146|NCT02672839|Drug|LGD-6972 Solution|15 mg of LGD-6972
75613147|NCT02672839|Drug|LGD-6972 Capsules|15 mg LGD-6972
75613148|NCT00643435|Behavioral|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
75613149|NCT00643435|Behavioral|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
75762796|NCT03978884|Drug|Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET|Take 1 tab daily
75762797|NCT03978884|Drug|Amlodipine 5mg|Take 1 tablet daily
75762798|NCT00319982|Drug|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
75762799|NCT00319982|Drug|Placebo|Placebo comparator (double-blind allocation of study medication)
75762800|NCT00319592|Biological|ChimeriVax™-JE vaccine|0.5 mL, subcutaneously
75762801|NCT00319592|Biological|JE-VAX® vaccine|1.0 mL, subcutaneously
75762802|NCT00295490|Drug|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
75762803|NCT00295490|Drug|Placebo|Placebo has same dosing freq as for active intervention and for same time period
75762804|NCT03980990|Drug|Metformin|Continuation of Metformin
75762805|NCT03980756|Drug|AD-206 20mg|1 tablet administered before the breakfast during 7 days
75762806|NCT03980756|Drug|Esomeprazole 20mg|1 tablet administered before the breakfast during 7 days
75906407|NCT02632786|Drug|Placebo|Saline Bag
75906408|NCT02173314|Other|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
75906409|NCT02173470|Other|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
75460031|NCT01826916|Drug|DX-88 (ecallantide)|solution for injection 10 mg/mL
75613150|NCT00927940|Device|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
75762807|NCT03980756|Drug|AD-206 40mg|1 tablet administered before the breakfast during 7 days
75762808|NCT03980756|Drug|Esomeprazole 40mg|1 tablet administered before the breakfast during 7 days
75762809|NCT00305006|Procedure|Constraint-Induced Movement Therapy (CIMT)|90 hours
75762810|NCT00305006|Procedure|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
75762811|NCT01064258|Device|CPAP|CPAP at 4 cm H2O
75762812|NCT01064258|Device|autoCPAP|autoCPAP working between 4 and 15 cm H2O
75762813|NCT01064336|Drug|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
75762814|NCT03980444|Device|Basket of wire|(using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
75906410|NCT02173626|Behavioral|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
75906411|NCT03067012|Other|Oncometabolic reconstruction|The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
75906412|NCT02177682|Drug|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
75906413|NCT03066934|Other|noninvasive ventilation respiratory support|
75460032|NCT01826929|Other|Therapeutic education|
75460033|NCT01826942|Device|Lumenis UltraPulse single fractional CO2 laser treatment thin skin|
75906414|NCT03065764|Drug|89Zr-Pembrolizumab|"eligible subjects will undergo two whole body immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with and one without a preceding cold therapeutic dose of pembrolizumab."
75460034|NCT01826942|Device|Single fractional CO2 treatment at surgical area closure procedure on thick skin|
75463354|NCT05853770|Other|TGfU volleyball intervention|"Duration of intervention: 16 week; Duration of each session: 45 minutes; Frequency: One session per week during the third PE class;~The structure of each TGfU session had three parts:~The introduction part comprised 10 minutes of moderate-intensity warm-up activities; The main part comprised mini-volleyball and small-sided games (25-30 minutes); The last part of the session was the cool-down period (5 min)."
75762815|NCT03980444|Procedure|control group, no basket|"In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
75906415|NCT02755818|Drug|Heparin|This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
75762816|NCT03980600|Device|FibDex wound dressing|Treatment of donor sites of 24 patients with the dressing Type 4 (final product i.e. FibDex) until the self-detachment of the wound dressing i.e. epithelialization
75906416|NCT05723926|Device|Vine Filter|The Vine filters are designed to be implanted in the common carotid arteries in order to capture emboli coming from the heart or great vessels, before they can enter the anterior intracranial circulation. The filter is deployed percutaneously using a 22G needle under ultrasound guidance.
75762817|NCT03980600|Device|NFC wound dressing Types 1-3|Treatment of donor sites of 9 patients with the NFC dressing's (proto)Types 1-3 until the self-detachment of the wound dressing i.e. epithelialization
75613151|NCT02677129|Other|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
75762818|NCT03980600|Device|Suprathel (comparator)|Treatment of donor sites of 22 patients with Suprathel dressing, which was used as a reference (comparator) product, until the self-detachment of the wound dressing i.e. epithelialization
75762819|NCT03978572|Behavioral|Resistance Training|Exercise intervention designed to improve muscular strength and power
75762820|NCT03978572|Behavioral|Moderate-Intensity Continuous Cycling|Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
75762821|NCT03978572|Behavioral|High-Intensity Interval Cycling|Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
75762822|NCT00319436|Behavioral|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
75762823|NCT00319436|Behavioral|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
75762824|NCT03978494|Drug|Advagraf®|Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
75906417|NCT02177760|Drug|Sirolimus|
75906418|NCT05723380|Procedure|Erector spinae plane block|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
75463355|NCT05853770|Other|Regular physical education classes|Regular physical education classes following national physical education curriculum for second semester of seventh grade in primary school in Serbia.
75463356|NCT05853718|Drug|Tenofovir Alafenamide Tablets|Take 25mg TAF daily from week 28-32 of gestation until delivery
75463357|NCT05853692|Device|Zinc Gluconate|Three times a day (spray)
75463358|NCT05853692|Device|Sodium Bicarbonate|Five times a day (rinse)
75613152|NCT00609154|Drug|glucagon like peptide-1|GLP-1 1 pmole/kg/min
75613153|NCT00609154|Dietary Supplement|glucose control|glucose without GLP-1
75613154|NCT00910117|Drug|nimotuzumab|nimotuzumab 400 mg d1
75613155|NCT00910117|Drug|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
75613156|NCT04264936|Drug|RC48-ADC and JS001|Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection
75613157|NCT04181437|Drug|NVP-1203-R1|1 tablet, Single oral dosing
75613158|NCT04181437|Drug|NVP-1203-R2|1 tablet, Single oral dosing
75613159|NCT04181437|Drug|NVP-1203-R1 and NVP-1203-R2|NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
75613160|NCT04181125|Other|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
75613161|NCT04181125|Other|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
75906419|NCT02179710|Behavioral|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
75906420|NCT02173782|Drug|Berodual® Respimat ® high dose|
75906421|NCT02173782|Drug|Berodual® Respimat ® low dose|
75762825|NCT03978494|Drug|Generic tacrolimus|Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
75762826|NCT03978416|Behavioral|Healthy Weight for Living for Hispanics|"The Healthy Weight for Living (HWL) intervention, previously developed at the Energy Metabolism Laboratory (HNRCA), is broadly informed by the same behavior change theories as other interventions. For example, it also recognizes individual and environmental factors as potential areas to support behavior change for weight regulation, and provides practical tools for facilitating new habits. However, the HWL places greater emphasis on the role of biology in influencing eating behavior, giving a central role to hunger and food cravings as modulators of eating behavior. Therefore, HWL does not emphasize self-monitoring food intake and does not require increasing physical activity for effectiveness. The new intervention also targets autonomous motivation and prioritizes ease of implementation.~Information from focus groups and sequential pilots will be used to develop a culturally tailored prototype version of Healthy Weight for Living that is acceptable for Hispanic older adults."
75762827|NCT03980288|Drug|CAR-GPC3 T Cells|Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion
75762828|NCT03980678|Dietary Supplement|Mineral Rich Algae|Lithothamnion species is rich in calcium, magnesium (Mg) and 72 other trace elements absorbed from sea-water during the organisms life. Mineral-rich 'fronds' break off from the living organism, fall to the ocean floor and are harvested (AquaminF). The mineral extract in soluble form contains ~13.1% Calcium, ~1.04% Magnesium and measurable levels of 72 other trace minerals. Following or prior to a washout period (crossover intervention), participants will consume the Aquamin Soluble equivalent of 1000mg Calcium in 250 ml of orange flavored water for a 7 day loading period.
75906422|NCT02173782|Drug|Berodual® MDI|
75762829|NCT03980678|Dietary Supplement|Orange flavoured water with maltodextrin as the placebo|Following or prior to a washout period (crossover intervention), participants will consume 250 ml of orange flavoured water (containing 20mg of Calcium with maltodextrin) for a 7 day period.
75906423|NCT02173782|Drug|Placebo|
75906424|NCT02179866|Drug|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) [14C]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
75460035|NCT01826968|Procedure|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
75906425|NCT05719948|Procedure|Flouroscopic guidance cervical medial branch radiofrequency ablation|Electromagnetic wave deposition near nerve tissue for pain management
75906426|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-air exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
75613162|NCT00927862|Genetic|IWPC adapted genotype-guided dosing algorithm for warfarin|"Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
75906427|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-SF6 exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
75906428|NCT02177916|Other|Education|
75906430|NCT02173860|Procedure|FFR-guided surgical revascularization|
75460036|NCT01826994|Device|heart type fatty acid binding protein testing|
75460037|NCT01827007|Other|Volume expansion with gelofusine|
75906431|NCT02173860|Procedure|Angio-guided surgical revascularization|
75906432|NCT04210336|Device|PAPILOCARE|"Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera."
75906433|NCT04210336|Device|PLACEBO|The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.
75906434|NCT02173938|Other|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
75613163|NCT00927862|Genetic|Modified IWPC genetic-guided warfarin dosing algorithm|"Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
75762830|NCT01064492|Drug|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
75762831|NCT01064570|Drug|all-trans retinoic acid (ATRA)|
75762832|NCT01581164|Biological|Influenza vaccine|Influenza vaccine: Injection, post transplant
75762833|NCT01581164|Biological|Varicella vaccine|Varicella vaccine: Injection, post transplant
75762834|NCT00319046|Drug|Miglustat|Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)
75762835|NCT03980366|Device|Electroconvulsive Therapy (ECT)|Bilateral Electroconvulsive Therapy (ECT) to treat self-injurious behavior in adults with Autism Spectrum Disorder (ASD).
75762836|NCT03980210|Procedure|Hyperbaric oxygen therapy|"FiO2 0.21 - 1 ATA~FiO2 1 - 1 ATA~FiO2 1 - 2.5 ATA~FiO2 0.21 - 2.5 ATA~FiO2 0.21 - 1 ATA"
75762837|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 40 and 50 ug.
75762838|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 20 ug.
75762839|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
75762840|NCT03978338|Dietary Supplement|brain polypeptide solution|The experimental group will take the brain polypeptide solution 60ml per day which contains nitrogen 90mg, soybean oil ,glycerin and soybean phospholipids in 84days.
75762841|NCT03978338|Other|same package of placebo|The control group was treated with the same package of placebo 60ml per day which contains soybean oil ,glycerin and soybean phospholipids in 84 days.
75762842|NCT00303602|Drug|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
75762843|NCT00303602|Drug|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
75762844|NCT03979976|Drug|Ramipril|Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
75762845|NCT00299130|Drug|Folate|A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
75762846|NCT00299130|Drug|Methotrexate|A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
75762847|NCT00299130|Drug|Methylprednisolone|Intravenous infusion
75762848|NCT00299130|Drug|Placebo|Placebo to rituximab intravenous infusion
75762849|NCT00299130|Drug|Rituximab|Intravenous infusion
75762850|NCT00288054|Biological|cetuximab|"Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles."
75762851|NCT00288054|Drug|docetaxel|"Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2."
75762852|NCT00288054|Radiation|radiation therapy|"Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications."
75762853|NCT00287586|Drug|Testosterone Gel (Androgel)|7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
75762854|NCT00287586|Drug|Placebo|Placebo-matching testosterone gel daily for 3 years
75906435|NCT02180022|Drug|Placebo|After randomization, placebo was treated for 12 weeks
75762855|NCT03979716|Device|fMRI|fMRI examination
75762856|NCT01070160|Drug|Endometrin (progesterone 100mg vaginal inserts)|once a day, 6-8 days as specified (prior to each EMBx)
75762857|NCT01070160|Drug|Metformin|per clinical care guidelines
75762858|NCT00287118|Drug|Efalizumab|Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
75762859|NCT03977298|Procedure|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
75762860|NCT03977298|Procedure|CTG|CTG will be positioned in the buccal aspect of the peri-implant tissue
75762861|NCT03977220|Drug|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
75762862|NCT01065402|Dietary Supplement|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
75762863|NCT01065402|Dietary Supplement|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
75762864|NCT00293202|Drug|Etanercept|Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week
75762865|NCT00293202|Drug|Placebo|Hemodialysis patients will receive Saline by subcutaneous injection twice a week
75762866|NCT00298896|Drug|SNS-595|
75906436|NCT02180022|Drug|Onion peel extract|After randomization, onion peel extract was treated for 12 weeks
75613164|NCT00927862|Other|Standard of care treatment|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients >=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
75762867|NCT03977376|Other|Guide of hosting|Guide of hosting with information about hospitalization to decrease anxiety
75762868|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
75762869|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
75906437|NCT05717374|Drug|caudal block using dexamethasone|patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus
75906438|NCT05717374|Drug|caudal block using methylprednisolone|patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
75762870|NCT00286494|Drug|Pioglitazone|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
75460038|NCT01827020|Drug|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
75613165|NCT02672527|Drug|Trabectedin|
75762871|NCT03976050|Drug|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
75762872|NCT00298740|Device|Aventis U-400 Insulin|
75762873|NCT03979326|Procedure|Static stretching|Static stretching lasting 3 x 45 seconds will be performed in each of the examined women three times in different phases of the menstrual cycle: follicular, ovulatory and luteal. Before and after the intervention, a series of tests assessing the influence of stretching on biomechanical parameters will be carried out
75762874|NCT03975972|Other|Occupational Therapy Based Literacy Intervention|Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
75762875|NCT01067820|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
75762876|NCT01067820|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
75906439|NCT03537768|Drug|Ulipristal Acetate|UPA Tablet
75906440|NCT03537768|Drug|Levonorgestrel|LNG Tablet
75906441|NCT03537768|Drug|Levonorgestrel|LNG Tablet (x2)
75906442|NCT02180256|Procedure|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
75460039|NCT01827020|Drug|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
75460040|NCT01827020|Drug|Saline|12 mL saline (0.9% isotonic solution)
75460041|NCT01827033|Behavioral|meditation training|
75460042|NCT01827059|Drug|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
75460043|NCT01827059|Drug|Placebo|
75460044|NCT01827072|Drug|NPB-01|
75460045|NCT01827085|Device|Conventional Macintosh laryngoscope|
75460046|NCT01827085|Device|Stortz videolaryngoscope|
75460047|NCT01827124|Drug|Carbetocin|
75460048|NCT01827124|Drug|oxytocin|
75613166|NCT02672527|Drug|Dexamethasone|
75906443|NCT02174094|Drug|Clobazam|
75613167|NCT04263220|Device|Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back|Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions
75762877|NCT01067898|Dietary Supplement|vitamin D3 (cholecalciferol)|vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
75762878|NCT01067898|Other|olive oil|10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
75762879|NCT01067898|Dietary Supplement|calcium carbonate|1000 mg calcium per os every day for one year
75762880|NCT01065636|Behavioral|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
75762881|NCT01065636|Behavioral|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
75762882|NCT01065636|Behavioral|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
75762883|NCT03979248|Drug|BMS-986165|Specified dose on specified days.
75762884|NCT03979248|Drug|Rabeprazole|Specified dose on specified days.
75762885|NCT00285012|Drug|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
75906444|NCT02174094|Drug|Placebo|
75906445|NCT02174172|Drug|Atezolizumab|Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.
75762886|NCT00285012|Drug|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
75613168|NCT04263220|Other|protocol will be performed without exoskeleton|protocol will be performed without exoskeleton
75613169|NCT00976989|Drug|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
75613170|NCT00976989|Drug|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
75613171|NCT00976989|Drug|FEC|5-fluorouracil 500 mg/m^2, epirubicin 100 mg/m^2 and cyclophosphamide 600 mg/m^2.
75613172|NCT00976989|Drug|Docetaxel|75 mg/m^2 for the first dose; 100 mg/m^2 if no dose limiting toxicity occurs.
75762887|NCT00284934|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
75762888|NCT00284934|Drug|Tacrolimus|
75762889|NCT00284934|Drug|Corticosteroids|At a dose of at least 5 mg/day.
75762890|NCT00284856|Drug|montelukast sodium|montelukast 10 mg tablet once daily, 6 month treatment period
75762891|NCT00284856|Drug|Comparator: Placebo|fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
75762892|NCT00284856|Drug|Comparator: fluticasone|fluticasone propionate 250 mcg twice daily, 6 month treatment period
75762893|NCT00284856|Drug|Comparator: Placebo|montelukast 10 mg Pbo tablet once daily, 6 month treatment period
75762894|NCT00298272|Biological|IDEC-C2B8 (rituximab)|Participants will receive 500 mg rituximab on Day 1 and Day 15
75762895|NCT00298272|Drug|Placebo|Participants will receive placebo on Day 1 and Day 15
75762896|NCT00298272|Drug|Methotrexate|Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
75762897|NCT00298272|Drug|Etanercept|Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
75762898|NCT00298272|Drug|Adalimumab|Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
75906446|NCT02174172|Drug|Bevacizumab|Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.
75906447|NCT02174172|Drug|Interferon alfa-2b|Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.
75906448|NCT02174172|Drug|Ipilimumab|Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).
75762899|NCT00298272|Drug|Methylprednisolone|Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
75762900|NCT00298272|Dietary Supplement|Folate|All subjects also received a stable dose of folate (≥5 mg per week).
75613173|NCT00976989|Drug|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m^2. All treatments were given every three weeks by the IV route.
75613174|NCT05449171|Other|high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D|Patients will take an association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, from the first visit at the experimental center (within the 12th week of gestation) for 3 months.
75762901|NCT00283842|Drug|DVS SR|
75613175|NCT00927784|Biological|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
75613176|NCT00927784|Drug|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
75613177|NCT02675023|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
75762902|NCT00283842|Drug|Placebo|
75762903|NCT01068054|Drug|tacrolimus|0.1% ointment,apply bid, 8 weeks
75762904|NCT01068054|Drug|cyclosporins|2% eyclosporine eye drops apply 1 drop to each eye QID
75762905|NCT03975816|Device|Analgesia nociception index|Monitor the maternity with Analgesia nociception index
75762906|NCT00298038|Drug|Rifaximin|Oral
75906449|NCT02174172|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).
75613178|NCT04290117|Behavioral|Acceptance and Commitment Training|During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
75613179|NCT04290117|Behavioral|Sleep Hygiene and bright light in the morning|During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
75613180|NCT02672605|Other|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
75762907|NCT00298038|Drug|Placebo|Oral
75762908|NCT00283686|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
75762909|NCT00283686|Drug|Telmisartan|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
75762910|NCT00283686|Drug|Placebo|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
75762911|NCT00283686|Other|Standard Blood Pressure Control|Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
75762912|NCT00283686|Other|Low Blood Pressure Control|Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
75762913|NCT00297882|Drug|1. Artemether-Lumefantrine (AL)|Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
75762914|NCT00297882|Drug|2. Amodiaquine-Artesunate (AQ-AS)|Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg
75762915|NCT01065870|Drug|Neoadjuvant gemcitabine, capecitabine, and docetaxel|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment."
75762916|NCT01065870|Drug|Gemcitabine, capecitabine, docetaxel followed by radiotherapy|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.~Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.~Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm."
75762917|NCT03975894|Biological|Serial prophylactic exchange blood transfusion (SPEBT).|"Serial prophylactic exchange blood transfusion (SPEBT) will be given via automated apheresis technology. SPEBT will be carried out on the haematology day unit or on the antenatal day unit/ward in accordance with local policies in participating units. The procedure will be carried out using standard operating procedures, by the clinical or research nurse/midwife, haematology day unit staff or specialist sickle nursing staff. Venous access will be via peripheral access if possible or by femoral line access if not.~SPEBT will be commenced between 6 and 18+0 weeks gestation. It will be repeated at 6-10 weekly intervals aiming to maintain HbS% <30%. It will continue throughout pregnancy and be stopped at the end of pregnancy.~Number of red cell units used per transfusion will depend on patient weight and pre-transfusion HbS%, but will usually be between 6 and 8 units of red cells on each occasion of exchange transfusion."
75906450|NCT02174172|Drug|PEG-interferon alfa-2a|Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).
75906451|NCT02180334|Drug|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
75762918|NCT00297648|Biological|Certolizumab pegol|Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
75762919|NCT03741816|Drug|Indirect pulp capping|Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
75762920|NCT01068132|Drug|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
75613181|NCT04260100|Behavioral|Diabetes Care Self-Management Mobile Health Application|In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
75906452|NCT02180334|Drug|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
75906453|NCT02180334|Drug|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
75906454|NCT03033745|Drug|IgPro20|A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
75762921|NCT01068132|Drug|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
75762922|NCT00283296|Device|Endeavor|Collapsible, forward folding manual wheelchair
75762923|NCT00297492|Behavioral|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
75460049|NCT01827137|Biological|WT1 Analog Peptide Vaccine|Preparation of a suspension of liquid vaccine drug product preparation (100 mcg of each peptide x 4 WT1 peptides within the GPS mixture; total weight: 400 mcg) 1:1 v/v with Montanide (oil depot emulsifier) to a total volume of ~1 ml, which is then injected s.c. to the patient. GPS is administered subcutaneously with Montanide adjuvant, with the first dose within 22 days of ASCT with melphalan conditioning (200 mg/sq.m.) and biweekly administration thereafter, for a total of 6 initial doses. Subsequently, patients continued to receive booster GPS administrations every 4 weeks, for an additional set of 6 doses, assuming they remain non-progressors per International Myeloma Working Group (IMW) criteria and are also clinically stable.
75460050|NCT01827137|Biological|Sargramostim (GM-CSF)|Granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine®) is administered s.c. at a dose of 70 μg on day -2 and day 0 of each GPS administration.
75460051|NCT01827137|Drug|lenalidomide|IMiD (lenalidomide; 10 mg p.o. daily) OR -in select patients- proteasome inhibitor (bortezomib; 1.3 mg/sq.m. s.c. every 2 weeks) maintenance starting 3-months post auto SCT.
75762924|NCT00297492|Behavioral|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
75762925|NCT00297492|Behavioral|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
75906455|NCT02174250|Drug|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
75906456|NCT02174250|Drug|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
75906457|NCT01672294|Other|Preparation and life completion|Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
75906458|NCT01672294|Other|Attention Control|Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
75460052|NCT01827150|Drug|Redbull, energy drink|A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
75460053|NCT01827176|Other|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
75906459|NCT02174328|Drug|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
75906460|NCT02174328|Drug|Placebo|Placebo once a day until 36 week
75906461|NCT02177994|Drug|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
75613182|NCT04179487|Diagnostic Test|OPTICA CTPA Protocol|Low dose CT pulmonary angiogram protocol
75613183|NCT04270227|Other|Survey study|The questionnaire including Exercise Benefits / Barriers Scale, IPAQ (International Physical Activity Survey), The Bady Awareness questionnaire and demographic information will be filled in one time by face-to-face interview method.
75613184|NCT05331352|Behavioral|Semi-structured interviews|Interview
75762926|NCT00297492|Drug|Pre-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke."
75762927|NCT00297492|Drug|Post-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke."
75762928|NCT00297258|Drug|pazopanib|oral tablet
75762929|NCT00496769|Drug|Apixaban|Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
75762930|NCT00496769|Drug|Acetylsalicylic acid|Tablets, oral, 81-324 mg, once daily, up to 156 weeks
75460054|NCT01827189|Other|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
75460055|NCT01827202|Other|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
75460056|NCT01827202|Drug|Aliskiren|
75460057|NCT01827202|Drug|Candesartan|
75762931|NCT01014845|Biological|hepatitis E vaccine|Intramuscularly given at 0, 1, 6m for three doses.
75762932|NCT01014845|Biological|Hepatitis B vaccine|Intramuscularly given at 0, 1, 6m for three doses.
75906463|NCT02755116|Drug|Olanzapine|10mg of olanzapine by mouth prior to anesthetic induction
75906464|NCT02755116|Drug|Placebo|placebo by mouth prior to anesthetic induction
75906465|NCT02178150|Dietary Supplement|Magnesium Oxide|This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.
75906466|NCT02178150|Dietary Supplement|Placebo|
75906467|NCT04411030|Drug|ASTX660|Form: capsule; Route of administration: oral
75906468|NCT04411030|Drug|Midazolam|Form: syrup; Route of administration: oral
75460058|NCT01827215|Behavioral|Virtual Patient Advocate (VPA)|Intervention participants will have access to the Virtual Patient Advocate (VPA) system for a period of 12 months. They will be encouraged to log on every two weeks or twice a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
75460059|NCT01827228|Other|Assays|May vary across sites
75460060|NCT01827228|Other|HIV medical care|This will be expedited and assisted via community outreach for Recents and Acutes
75460061|NCT01827228|Other|Social network and venue tracing|This is described in Arms 1 and 2
75460062|NCT01827228|Other|Community alerts|When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
75460063|NCT01827228|Other|Community education|Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
75460064|NCT01827228|Behavioral|HIV counseling|As part of HIV testing, we will provide participants with standard counseling
75460065|NCT01827241|Other|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
75460066|NCT01827280|Drug|Vildagliptin|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
75460067|NCT01827293|Drug|Promethazine|
75460068|NCT01827293|Drug|Lorazepam|
75906469|NCT04411030|Drug|Itraconazole|Form: capsule; Route of administration: oral
75460069|NCT01827345|Dietary Supplement|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
75460070|NCT01827397|Biological|EN41-UGR7C HIV vaccine|
75460071|NCT01827397|Biological|NaCl|
75613185|NCT05331352|Behavioral|Projective methode|Rorschach + thematic aperception test
75613186|NCT05331352|Behavioral|Selfreported|RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R
75613187|NCT00644371|Drug|Ibritumomab Tiuxetan (Zevalin)|"Conditioning Regimen~Rituximab, 250 mg/m2 on days -21 and -14.~Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~Melphalan 70 mg/m2/day on day -2 as a 15-min infusion."
75613188|NCT04963972|Behavioral|Behavioral Intervention|Participate in Lucid Lane therapy program
75613189|NCT04963972|Other|Best Practice|Receive standard of care opioid education
75762933|NCT00478673|Device|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
75762934|NCT00478673|Device|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
75762935|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate venous blood sampling
75613190|NCT04963972|Other|Questionnaire Administration|Ancillary studies
75613191|NCT02677207|Drug|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
75613192|NCT02677207|Drug|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
75613193|NCT02864199|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
75762936|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
75762937|NCT04400591|Biological|Nonconforming Lisocabtagene Maraleucel|Nonconforming lisocabtagene maraleucel is lisocabtagene maraleucel that does not meet the commercial release specifications, however is deemed acceptable to administer as an investigational product in the Expanded Access Protocol setting.
75613194|NCT02864199|Drug|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
75762938|NCT04400357|Procedure|Robotic pancreaticoduodenectomy|Patients in this arm will undergo a pancreaticoduodenectomy with robotic-assisted techonology.
75762939|NCT04400357|Procedure|Open pancreaticoduodenectomy|Patients in this arm will undergo an open pancreaticoduodenectomy which is the standard surgical approach.
75762940|NCT00488345|Drug|Tygacil|
75762941|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
75762942|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
75762943|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
75762944|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
75460072|NCT01827423|Device|Surgical removal of sinonasal papiloma|An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
75460073|NCT01827436|Behavioral|Conventional physical therapy|
75460074|NCT01827436|Behavioral|Asymmetrical gait training|
75460075|NCT01827449|Device|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
75613195|NCT05911191|Other|Exercise based prehabilitation|A peripheral muscle strengthening program
75613196|NCT05911178|Radiation|[11C]-UCB-J|"PET tracer binding to SV2A protein, used to study synaptic vesiscle density."
75460076|NCT01827501|Device|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
75460077|NCT01827540|Drug|Cenicriviroc|
75460078|NCT01827540|Drug|Dolutegravir|
75460079|NCT01827540|Drug|Midazolam|
75460080|NCT01827566|Other|gluten|
75460081|NCT01827566|Other|gluten free flour|
75613197|NCT05911178|Radiation|[18F]-DPA-714|"PET tracer binding to TSPO protein, used to study microglial activation."
75613198|NCT05911178|Radiation|[18F]-RO-948|"PET tracer binding to tau protein, used to study the topograhpy of tau deposition."
75613199|NCT05911178|Radiation|[11C]-PiB|PET tracer binding to Aβ40 and Aβ42 fibrils and insoluble plaques containing the aforementioned Aß peptides, used to study the topography of amyloid deposition.
75613200|NCT05911126|Drug|Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet|Tablet form received prior to the procedure
75613201|NCT05911113|Other|sensory re-education training|the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition
75460082|NCT01827618|Drug|Rapamycin|
75460083|NCT01827631|Drug|GSK1605786 capsule|Swedish Orange, size 0, hard gelatine capsules
75762945|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
75613202|NCT05911113|Other|traditional treatment|the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
75613203|NCT05911087|Biological|Phase II:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
75762946|NCT00282984|Drug|placebo|1 mg placebo twice daily by mouth for 12 weeks
75906470|NCT03066856|Other|Dietary intervention|"The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:~reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.~reducing high glycemic index food and high insulinemic foods.~reducing sources of saturated fat (red and processed meat, milk and dairy products).~eating mostly food of plant origin, with a wide variety of seasonal products."
76070216|NCT04406493|Diagnostic Test|Lung impedance technique|"COVID 19 patients are admitted to the Infectious Diseases Unit; they will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization, each patient will undergo this examination twice a day until discharge.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation.~The time between lung impedance started to decrease (expression of the lung fluids accumulation), and the need for mechanical ventilation will be measured."
75762947|NCT00282984|Drug|Varenicline|1 mg twice daily by mouth for 12 weeks
75762948|NCT02532348|Other|Blood samples|Blood samples
75762949|NCT00282438|Biological|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
75762950|NCT00282438|Biological|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
75762951|NCT01065948|Device|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
75762952|NCT00296400|Drug|Rosuvastatin|
75762953|NCT00296400|Drug|Atorvastatin|
75762954|NCT04282356|Drug|Intraperitoneal chemotherapy during surgery|During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
76070217|NCT04021251|Device|P0.2|Investigational Medical Device collecting spectral raman data from tissue.
75762955|NCT01068288|Procedure|Laparoscopic or open appendectomy|
75906471|NCT02754492|Device|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
75460084|NCT01827644|Drug|Afuresertib GC - Fasted State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state
75460085|NCT01827644|Drug|Afuresertib HPMC capsule - Fasted State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
75460086|NCT01827644|Drug|Afuresertib ECT - Fasted State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state
75460087|NCT01827644|Drug|Afuresertib GC - Fed State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state
75460088|NCT01827644|Drug|Afuresertib HPMC capsule - Fed State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
76070218|NCT03961581|Behavioral|Using electric car|Child will use little electric cars to go to the reception of operating theatre to operating room.
76070219|NCT04021407|Device|LMA group|patients were ventilated with LMA
76070220|NCT04021407|Device|AirQ group|patients were ventilated with AirQ airway
76070221|NCT04021173|Drug|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
76070222|NCT04021173|Drug|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
76070223|NCT04027881|Behavioral|Sit Together and REad|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
75762956|NCT01068288|Procedure|Expectant Management|"A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.~For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy."
75906472|NCT04068688|Behavioral|Early Start Denver Model (ESDM)|"Twelve one hour sessions, skill is introduced by Help is in your hands Community ESDM videos. Session skills include specific strategies caregivers can use to increase their child's attention to people and their child's communication; strategies to identify, create and use joint activity routines to engage with and teach their child; in addition to ways to use the ABCs of learning to teach their child new behaviors. Help is in your hands Community ESDM materials also provide video examples of other caregivers using the session skill with their child. The early childhood development practitioner then coaches the caregiver in the session skill, in at least two activities. The goal of coaching was to provide enough support for the caregiver to experience success in implementing the new skill with their child. Coaching is followed by caregiver reflection and a discussion of generalization of the new skill across various daily activities, using a daily activities visual aid."
75762957|NCT00296244|Drug|Steroids|Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
75460089|NCT01827644|Drug|Afuresertib ECT - Fed State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state
75460090|NCT01827657|Drug|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
75906473|NCT04068688|Behavioral|Telehealth coaching|The telehealth coaching intervention was informed by the Community-Early Start Denver Model (C-ESDM) materials. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) were developed by the research team. Over 12, 1-hour asynchronous caregiver coaching sessions that are delivered by non-specialists, caregivers were coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors. The session itself being delivered via phone. Prior to the coaching session staff shared session materials with the family via WhatsApp. Prior to the session the caregiver shared a 6-min video of an interaction with their child. During the session, the caregiver and coach reviewed the video, and the caregiver completed a self-reflection checklist.
75613204|NCT05911087|Biological|Phase II:SW-BIC-213;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
75613205|NCT05911087|Biological|PhaseIII:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
75906474|NCT02174640|Dietary Supplement|Coffee|Coffee Beverage
76070224|NCT04027335|Device|leva|Vaginal device used for pelvic floor muscle exercises
75460091|NCT01827683|Other|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
75460092|NCT01827696|Dietary Supplement|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
75460093|NCT01827722|Drug|Ozurdex|Intravitreal injection of Ozurdex
75762958|NCT00296244|Drug|Basiliximab|Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
75762959|NCT00296244|Drug|Tacrolimus|Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
75460094|NCT01827722|Drug|Ranibizumab|Intravitreal Injection of Ranibizumab
75460095|NCT01827722|Drug|Combination Ozurdex with Ranibizumab PRN|Intravitreal Injection of combination medication Ozurdex and Ranibizumab
75613206|NCT05911087|Biological|PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
75613207|NCT05908565|Behavioral|Demographic Matching|At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.
75762960|NCT00296244|Drug|Enteric-coated Mycophenolic acid (EC-MPA)|This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
75762961|NCT00274716|Drug|MK0736|
75762962|NCT00274716|Drug|MK0916|
75762963|NCT00274716|Drug|Placebo|
75762964|NCT01068444|Drug|Pioglitazone|"Name: GLITOS（Pioglitazone）~Dosage form: Tablets~Dose(s): 30mg~Dosing schedule: QD~Duration: 6 months"
75762965|NCT01068444|Drug|placebo|placebo 30 mg/d for 6 months
75762966|NCT00282048|Drug|AG-013736 (axitinib)|AG-013736 5 mg twice daily [bid] continuous dosing in 28 day cycles.
75460096|NCT01827735|Drug|Aldesleukin (Proleukin)|A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
75762967|NCT03975348|Device|High flow nasal cannula|High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
75762968|NCT03975348|Device|Continuous positive airway pressure|Positive airway pressure applied through a sealed face mask
75762969|NCT03975348|Device|Facemask|Oxygen therapy through a conventional facemask
75460097|NCT01827748|Device|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
75460098|NCT01827748|Device|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
75460099|NCT01827774|Device|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
75460100|NCT01827800|Behavioral|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
75463359|NCT05853666|Behavioral|CNH+|CNH+ is a bundled intervention targeting all four of Bandura's factors associated with improved self-efficacy (i.e., Mastery [evidence-based parent targeted education platform]; Vicarious Experience [observing other families similar to them succeeding in a task i.e., videos and photos]; Verbal Persuasion [in-person/virtual medical rounds and provision of social support]; and Physiological States [notifications and encouragement through mHealth text messaging, parent feedback, and tailored clinical care pathway]).
75463360|NCT05853653|Behavioral|Using dolls in breastfeeding education|Using dolls in breastfeeding education
75762970|NCT03975192|Device|Percutaneous Electrical Nerve Field Stimulation|Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
75762971|NCT00474539|Biological|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
75762972|NCT00474539|Biological|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
75762973|NCT01017809|Drug|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
75762974|NCT01014923|Behavioral|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
75906475|NCT02174640|Dietary Supplement|Water|Water
75762975|NCT01020539|Drug|Fludarabine|Conditioning Regimen
75762976|NCT01020539|Drug|Busulfan|Conditioning Regimen
75906476|NCT04437654|Drug|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
75906477|NCT05526508|Device|Rebound exercise|Exercise training on the rebounder/ mini-trampoline with stability handles attached
75906478|NCT03973918|Drug|Encorafenib|450mg QD 28 day cycle
75906479|NCT03973918|Drug|Binimetinib|45mg BID 28 day cycle
75906480|NCT03973918|Biological|Research Bloods|Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
76070225|NCT04027725|Behavioral|Neurofeedback|Neurofeedback experiment will consist of 20 sessions of neurofeedback training, twice or three times a week during seven weeks. Each session will last for 40 minutes. The experimental group will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-trianing (T1) and 1 month follow-up (T2). Electroencephalography will be recorded by a technician in EEG for each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T1 and T2.
75762977|NCT01020539|Drug|GVHD Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
76070226|NCT01852045|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
76070227|NCT04027257|Behavioral|Sit Together and Read (STAR)|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
75762978|NCT01020539|Drug|Gemtuzumab Ozogamicin|Dose Escalation
75762979|NCT01020539|Drug|Anti-Thymocyte Globulin|Unrelated Donors only
75762980|NCT01020539|Drug|Isotretinoin|JMML patients only
75762981|NCT01015001|Procedure|Active rTMS x sham (placebo) rTMS|"Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations."
75762982|NCT01015001|Procedure|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
75906481|NCT03973918|Biological|Tumor Tissue|at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides
75906482|NCT02185638|Other|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
75906483|NCT02185716|Drug|Levobupivacaine 0.25 %|
76070228|NCT03960957|Biological|AbobotulinumtoxinA|Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
76070229|NCT03960957|Other|Placebo|Treatment of glabellar facial lines with placebo
75460101|NCT01827813|Procedure|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
75906484|NCT02185716|Drug|Levobupivacaine 0.5%|
75906485|NCT01671748|Device|MIST ultrasound therapy|Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
76070230|NCT03960645|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
75460102|NCT01827813|Procedure|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
75762983|NCT01015001|Procedure|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
75762984|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
75762985|NCT00281580|Drug|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
75762986|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
75906486|NCT01671748|Other|Standard Care|Compression bandaging, non-adherent dressing, and debridement if required.
76070231|NCT04020939|Device|SPY imaging|Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.
76070232|NCT04020939|Drug|Indocyanine Green|Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
76070233|NCT04027179|Drug|0.12% chlorhexidine digluconate mouthwash|0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
76070234|NCT04027179|Procedure|Periodontal instrumentation|Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
76070235|NCT04027179|Drug|Placebo mouthwash|placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
75762987|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
75906487|NCT02182050|Drug|BIBF 1120 ES low dose|
75906488|NCT02182050|Drug|BIBF 1120 ES high dose|
75906489|NCT02182050|Drug|Placebo to BIBF 1120 ES|
75906490|NCT02182128|Drug|BIBF 1120|
75906491|NCT02182206|Drug|BIBF 1120|
75906492|NCT02180490|Drug|UHAC 62 XX tablet|
75906493|NCT02180490|Drug|UHAC 62 XX capsule|
75762988|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
75762989|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
75906494|NCT03963544|Drug|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR
75906495|NCT02180568|Procedure|Lipiodol|Lipiodol-guided lung localization technique
75613208|NCT05908565|Behavioral|Supervision Intensity|Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.
75613209|NCT05908539|Behavioral|Equipment box|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction only.
75613210|NCT05908539|Behavioral|Equipment box with briefing|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction, and they are given verbal briefing on how to use the equipment.
75613211|NCT05908539|Behavioral|Exercise training|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises.
75762990|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
75762991|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
75762992|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
75460103|NCT01827813|Procedure|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
75762993|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
75762994|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
75762995|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
75762996|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
75762997|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
75906496|NCT02180568|Procedure|Hookwire|Hookwire-guided lung localization technique
75906497|NCT02180568|Drug|Lipiodol|
75906498|NCT02657889|Drug|niraparib|
75463361|NCT05853627|Behavioral|Memory reactivation procedures|In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.
75463362|NCT05853627|Drug|Propranolol|Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
75762998|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
75762999|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
75763000|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
75906499|NCT02657889|Biological|pembrolizumab|
75906500|NCT02182284|Drug|low dose BI 201335 NA soft gelatine capsule (SGC)|
75906501|NCT02182284|Drug|high dose BI 201335 NA soft gelatine capsule (SGC)|
75906502|NCT02182284|Drug|low dose BI 201335 NA powder in bottle (PIB)|
75906503|NCT02182284|Drug|high dose BI 201335 NA powder in bottle (PIB)|
75613212|NCT05908539|Behavioral|Exercise training with behavioral modification|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises. After finishing the exercise training program, a 6-week behavioral modification is provided. Two home visits and four telephone visits are conducted to empower the participants for exercise at home.
75763001|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
75763002|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
75763003|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
75613213|NCT05908513|Drug|N-acetylcysteine|Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
75613214|NCT05908513|Drug|Placebo|Similar chemical structure of NAC but without function
75763004|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
75763005|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
76070236|NCT04199169|Biological|HeV-sG-V|A Hendra virus soluble glycoprotein vaccine formulated in phosphate buffer and adjuvanted with aluminum hydroxide. Placebo is normal saline.
75463363|NCT05853614|Behavioral|Quality of Life Intervention|Comprised of three components: (1) establishment of clinical research nurse (CRN) and patient relationship, (2) assessment and monitoring of physical, psychological, social, and spiritual well-being and patient-reported outcomes, and (3) weekly, interdisciplinary team meetings led by CRN.
75463364|NCT05853588|Other|training|On-the-job (toolbox) training given to the experimental group and containing brief information, lasting at most 10 minutes
75463365|NCT05852730|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel
75613215|NCT05908500|Other|CPR Training|Various methods of CPR training are implemented and compared
75763006|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
75763007|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
75763008|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
75763009|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
75763010|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
75763011|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
75763012|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
75906504|NCT03536286|Behavioral|Encouragement|Households will be visited and encouraged to enroll in Asili
75463366|NCT05852730|Drug|Other (e.g., promethazine, meclizine)|Subjects will self-administer other medications as available.
75763013|NCT03997175|Other|Biodiversity powder|Biodiversity sand contained biodiversity powder that contains a highly diverse and rich microbial community but no known pathogens.
75906505|NCT03536208|Drug|Warfarin|5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
75906506|NCT03034915|Drug|UMEC/VI 62.5/25 mcg via ELLIPTA|ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
75906507|NCT03034915|Drug|UMEC 62.5 mcg via ELLIPTA|The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
75906508|NCT03034915|Drug|Salmeterol 50 mcg via DISKUS|The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
75763014|NCT03997175|Other|Placebo|Sand that looks like intervention sand but does not have high biodiversity
75763015|NCT04393181|Procedure|Heart transplantation 1|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with left ventricular dysfunction, defined as an ejection fraction less than 50% or regional hypokinesia.
75763016|NCT04393181|Procedure|Heart transplantation 2|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with normal function, according to the recommendations from The International Society for Heart and Lung Transplantation (ISHLT).
75763017|NCT01017887|Device|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
75763018|NCT01017887|Device|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
75763019|NCT01020617|Dietary Supplement|Ls-33|10~10 CFU/day
75763020|NCT01017965|Device|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
75763021|NCT00495755|Drug|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
75763022|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
76070237|NCT04199169|Biological|Normal Saline Placebo|0.9% Saline
75906509|NCT03034915|Drug|Placebo via ELLIPTA|Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
76070238|NCT04021095|Device|Head protection prototype device|The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
76070239|NCT04026789|Other|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
76070240|NCT04026789|Other|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
75460104|NCT01827826|Behavioral|Telephonic intervention to prevent Diabetes Mellitus, Type 2|Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
75613216|NCT05908448|Device|13 CGM (continuous glucose monitor)|The I3 CGM consists of three main components: a Sensor Pack (Applicator-Sensor assembly), a Transmitter Pack (with Bluetooth Low Energy (BLE)) and a mobile application (I3 CGM App). The user can view their glucose data on the I3 CGM App running on a compatible mobile device.
75613217|NCT05908422|Device|Alvision™ Interventional Cardiology Diagnostic Catheter|The Alvision™ Interventional Cardiology Diagnostic Catheter is a single use only, thin, flexible single lumen tube, with a proximal hub, sterilized with ethylene oxide (EO) gas, non-pyrogenic. The product is defined as a catheter to inject a contrast medium into selected blood vessels.
75613218|NCT05908370|Procedure|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
75906510|NCT03034915|Drug|Placebo via DISKUS|Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
75906511|NCT02182362|Drug|BI 201335 NA|
75460105|NCT01827865|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
76070241|NCT04191291|Behavioral|Lunch period length|We are randomly allocating a 10 minute or 20 period of seated lunch time.
76070242|NCT04026555|Other|MEWS++ Monitoring|Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
76070243|NCT04026555|Other|Predictor Score|A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
75460106|NCT01827865|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
75613219|NCT05908318|Behavioral|olfactory training|In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
75613220|NCT05908305|Drug|articaine@ (4% 1:100000 epinephrine) dental anesthesia|Administration, calculation and adjustment of dental local anesthesia doses.
75613221|NCT02672995|Radiation|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
75613222|NCT02672995|Drug|bevacizumab|"Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
75906512|NCT02182362|Drug|Placebo|
75906513|NCT05373459|Biological|Third COVID-19 booster|Third COVID-19 booster
75906514|NCT02180802|Behavioral|motivational interviewing|
75906515|NCT02180802|Behavioral|motivational interviewing with parental involvement|
75906516|NCT02180802|Behavioral|Control group|
76070244|NCT04026321|Drug|SQ001 125mL/day|SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
75613223|NCT05908279|Other|Walking test|Walk with and without a metronome
75763023|NCT01070862|Drug|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
75763024|NCT01070862|Drug|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
75763025|NCT01070862|Drug|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
75763026|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
76070245|NCT04026321|Drug|SQ001 250mL/day|SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
76070246|NCT04026321|Drug|SQ001 500mL/day|SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
75460107|NCT01827878|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
75460108|NCT01827878|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
75460109|NCT01827891|Procedure|remote ischemic preconditioning (RIPC)|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
75460110|NCT01827917|Biological|rabies vaccine|Injection on day 0、7、21
75460111|NCT01827956|Other|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
75613224|NCT05908279|Other|Disease assessement|Disease stage assessed by a doctor
76070247|NCT04026321|Drug|SQ001 625mL/day|SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
75460112|NCT01827969|Procedure|ablathermy focused ultrasound|ablathermy focused ultrasound
75460113|NCT01827982|Drug|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
75460114|NCT01827982|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
75460115|NCT01827982|Drug|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
75613225|NCT05908266|Other|Reaching movements|Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.
75613226|NCT05908266|Other|Disease Assessment|Disease stage assessed by trained professionals
75613227|NCT05908201|Behavioral|early time restricted eating|The intervention group will eat in a prescribed daily feeding window (9am-5pm) and follow their normal exercise and resistance training routines. We will allow up till +/-1 hour for the eating window start and end times while aiming for an 8 hour eating window.
75613228|NCT05908175|Other|FES-assisted gait training|The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
75613229|NCT05908162|Diagnostic Test|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils
75613230|NCT05908019|Other|Web-based health care program|"According to the participants' feedback and recommends, we will modify this program to make it more suitable.~In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH."
75613231|NCT05908006|Device|Velacur|Imaging Procedures Comparison
75763027|NCT00495677|Drug|PF-00232798|Solution, 20 mg. once daily, 10 days
75763028|NCT00495677|Drug|PF-00232798|Solution, 150 mg. once daily, 10 days
75763029|NCT00495677|Drug|PF-00232798|Solution, 5 mg. once daily, 10 days
75763030|NCT00495677|Drug|PF-00232798|Solution, 40 mg. once daily, 10 days
75763031|NCT00495677|Drug|PF-00232798|Solution, 300 mg. once daily, 10 days
75763032|NCT00495677|Drug|PF-00232798|Solution, 400 mg. once daily, 10 days
76070248|NCT04026321|Drug|Saline 0.9%|Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
76070249|NCT04026243|Procedure|QL block|U/S guided Transmuscular Quadratus Lumborum Block
76070250|NCT04026243|Procedure|TF block|U/S guided Transversalis Fascia Plane Block
76070251|NCT01821937|Drug|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
76070252|NCT01821937|Drug|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
75460116|NCT01827982|Drug|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
75460117|NCT01827982|Drug|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
75460118|NCT01827982|Drug|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
75460119|NCT01827982|Drug|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
75460120|NCT01827982|Drug|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
75763033|NCT01020851|Behavioral|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
75763034|NCT01020851|Behavioral|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
75763035|NCT01018043|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
75763036|NCT01020929|Device|Blunt Coude|Type of needle tip
76070253|NCT03832335|Diagnostic Test|Measurement of aniseikonia tolerance|Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
76070254|NCT03820089|Diagnostic Test|Ultrasonography TP|TP us will be made to the included women
75763037|NCT01020929|Device|Quincke|Type of needle tip
75763038|NCT01020929|Device|Trucath|Type of needle tip
75763039|NCT00495521|Drug|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
75763040|NCT00273858|Other|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
75763041|NCT01070238|Dietary Supplement|Isomaltulose|
75763042|NCT03975426|Procedure|open reduction and internal fixation with fixation by absorbable screws|Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws.
75763043|NCT01068522|Device|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
75763044|NCT01068522|Other|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
75460121|NCT01827982|Drug|Placebo|Matching placebo will be given as a single oral dose.
75613232|NCT05907941|Device|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system [V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
75613233|NCT05907941|Other|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
75613234|NCT05907941|Procedure|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
75613235|NCT05907928|Other|Scotchbond universal adhesive plus|New generation BPA free universal adhesive
75613236|NCT05907928|Other|Single bond Universal|Radiolucent universal adhesive
76070255|NCT01821625|Drug|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
75763045|NCT00494507|Drug|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
75763046|NCT00494507|Drug|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
75763047|NCT00494507|Drug|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
76070256|NCT03022929|Behavioral|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
75460122|NCT01827995|Other|Self assessment|Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.
75460123|NCT01827995|Other|Routine assessment|Follow up in the clinic
75763048|NCT01018121|Behavioral|LAUNCH|A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
75763049|NCT01018121|Other|Pediatrician Counseling|A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
75763050|NCT00292188|Drug|pregabalin|pregabalin
75763051|NCT00292188|Drug|Placebo|placebo
75763052|NCT00272844|Drug|crystalline cholesterol oil-based suspension|200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
75763053|NCT00271596|Drug|20mg daily citalopram|a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
75763054|NCT00271596|Drug|Placebo|a daily matching placebo administered over 16 weeks
75763055|NCT01068756|Drug|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
75763056|NCT01068756|Drug|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
76070257|NCT03022695|Device|High Intensity Focused Ultrasound|
75763057|NCT01068834|Genetic|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
75763058|NCT00291642|Drug|Placebo drops|"Pharmaceutical form: Drops for oral administration~Route of administration: Oral use"
75763059|NCT00291642|Drug|Placebo tablets matching to levocetirizine|"Pharmaceutical form: Tablets for oral administration~Route of administration: Oral use"
75763060|NCT00291642|Drug|Placebo tablets matching to cetirizine|"Pharmaceutical form: Tablets for oral administration~Route of administration: Oral use"
75763061|NCT00291642|Drug|Levocetirizine drops|"Pharmaceutical form: Drops for oral administration~Concentration: 5 mg/ml~Route of administration: Oral use"
75613237|NCT05907915|Device|low level laser therapy|They recieved LLLT 1 session daily, 3 session per week for 3 weeks,with the following parameters( 650 nm wavelength, 150 mw power output, 0.25 cm2 radiation area, 0.6 W/cm2 power density, continuous mode, 2 j/ cm2, 90 seconds / cm2) in addition to the conventional medical treatment and traditional wound care (dressing)
75763062|NCT00291642|Drug|Levocetirizine tablets|"Pharmaceutical form: Tablets for oral administration~Concentration: 5 mg~Route of administration: Oral use"
75460124|NCT01828047|Device|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
75460125|NCT01828060|Dietary Supplement|Jobelyn™|Sorghum bicolor leaf sheath extract
75613238|NCT05907915|Behavioral|placebo|They received placebo laser 1 session daily, 3 session per week for 3 weeks in addition to the conventional medical treatment and traditional wound care (dressing)
75613239|NCT05907902|Drug|Aspirin Enteric-coated Tablets|low-dose aspirin 100 mg once daily (one 100mg tablet).
75613240|NCT05907863|Other|Use of intracardiac echocardiography|intracardiac echocardiography guided slow pathway ablation in patients with AVNRT
75763063|NCT00291642|Drug|Cetirizine drops|"Pharmaceutical form: Drops for oral administration~Concentration: 10 mg/ml~Route of administration: Oral use"
75763064|NCT00291642|Drug|Cetirizine tablets|"Pharmaceutical form: Tablets for oral administration~Concentration: 10 mg~Route of administration: Oral use"
75763065|NCT01070472|Drug|Misoprostol|titrated oral misoprostol solution
75460126|NCT01828060|Dietary Supplement|Placebo|Placebo capsules
75460127|NCT01828086|Biological|CJM112|Monoclonal antibody
75613241|NCT05907798|Procedure|LIMA Blood flow|30 minutes after induction
75613242|NCT05907772|Other|No intervention|No intervention
75613243|NCT05907733|Diagnostic Test|Genotyping.|5 ml biood withdrawen by venipuncture in EDTA tube DNA extraction will be done after centrifucation and used for quantatitive Real-time polymerase chain reaction.
75763066|NCT00280566|Drug|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
75763067|NCT00280566|Drug|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
75763068|NCT00270894|Drug|epirubicin|epirubicin (100 mg/m^2) every 2 weeks for 4 cycles
75613244|NCT05907642|Other|Prune (dried plum)|Subjects who are assigned to the treatment group consume a total of 100 g of prune per day for 18 days and the subjects who are assigned to the control group are allowed to have a normal meal without prune for 18 days.
75763069|NCT00270894|Drug|cyclophosphamide|cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles
75763070|NCT00270894|Drug|docetaxel|docetaxel (75 mg/m^2) every 2 weeks for 4 cycles
75460128|NCT01828086|Biological|Secukinumab|Monoclonal antibody
75460129|NCT01828086|Other|Placebo|Liquid for subcutaneous injection without active drug.
75460130|NCT01828125|Procedure|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-[6,6-2H2] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-[6,6-2H2] glucose. A third catheter will be inserted for sampling. D-[6,6-2H2] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
75460131|NCT01828125|Drug|Glucagon|
75613245|NCT05907603|Drug|RD13-02 cell infusion|CAR-T cells
75763071|NCT00270894|Drug|trastuzumab|trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments
75613246|NCT05907590|Other|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
75763072|NCT01070628|Drug|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
75906517|NCT05141136|Procedure|Ultrasound probe sagittal group|Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.
75906518|NCT05141136|Procedure|Ultrasound probe transverse group|Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.
75613247|NCT05907590|Other|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
75613248|NCT05907590|Other|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
75613249|NCT05907590|Other|Proprioceptive accuracy measurement during postural control|"The effect of muscle vibration on center of gravity displacement (center of pressure or COP) will be examined. Muscle vibration of the m. triceps surae (ankle muscles) and the lumbar multifidus (back muscles) (Johanson et al., 2011; Brumagne et al., 2008; Claeys et al., 2011; Cleays et al., 2015) will be used to examine the role of proprioception during postural control."
75613250|NCT05907590|Other|Proprioceptive accuracy measurement of the neck|The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).
75613251|NCT05907577|Other|Observational|No interventions.
75613252|NCT05907538|Other|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
75763073|NCT01070628|Drug|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
75763074|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
75763075|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
76070258|NCT04406571|Other|Data record|Data record
75763076|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
75763077|NCT01070940|Drug|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
75763078|NCT00317642|Drug|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m^2 / day up to 3 cycles
76070259|NCT04020783|Other|NO Intervention|NO Intervention
75460132|NCT01828138|Dietary Supplement|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
75460133|NCT01828138|Dietary Supplement|Placebo|Placebo are given in 5 days
75460134|NCT01828151|Device|Noninvasive ventilation mask|
75460135|NCT01828177|Drug|PDI-320|
75460136|NCT01828177|Drug|PDI-320 Monad #1|
75460137|NCT01828177|Drug|PDI-320 Monad #2|
75460138|NCT01828177|Drug|Vehicle|
75460139|NCT01828203|Drug|Minocycline|
75460140|NCT01828203|Drug|Placebo|
75763079|NCT00317642|Drug|placebo|placebo (sodium Chloride) 1-hour IV infusion
75763080|NCT00317642|Drug|cytarabine|cytarabine IV infusion 1g/m^2/day for up to 3 cycles
75763081|NCT01064726|Drug|Ibuprofen|800 mg oral
75763082|NCT01064726|Drug|Fluticasone propionate|200 mcg intra-nasal
75763083|NCT01064726|Drug|Placebo|Placebo
75763084|NCT01064804|Drug|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
76070260|NCT01821391|Drug|NDL-PDT|Metvix natural daylight photodynamic therapy
76070261|NCT01821391|Drug|c-PDT|Metvix conventional photodynamic therapy
76070262|NCT01821391|Drug|placebo c-PDT|Metvix placebo conventional photodynamic therapy
75906519|NCT03578757|Behavioral|21-day residential program|"Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes…). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up."
75763085|NCT01064960|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
75460141|NCT01828203|Procedure|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
75763086|NCT00295022|Drug|Placebo|"Pharmaceutical form: Over-encapsulated tablet~Route of administration: Oral use"
75763087|NCT00295022|Drug|Montelukast|"Pharmaceutical form: Over-encapsulated tablet~Concentration: 10 mg~Route of administration: Oral use"
75763088|NCT00295022|Drug|Levocetirizine|"Pharmaceutical form: Over-encapsulated tablet~Concentration: 5 mg~Route of administration: Oral use"
75460142|NCT01828203|Procedure|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
75763089|NCT01062152|Drug|Ezatiostat Hydrochloride|Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM & 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
75763090|NCT01062152|Drug|Lenalidomide (Revlimid®)|10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
75763091|NCT00303446|Drug|Dutasteride|Dutasteride 0.5 mg/day
75763092|NCT00303446|Drug|Placebo|Matched placebo
75906520|NCT03577509|Drug|ABCD|Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
75460143|NCT01828229|Behavioral|female inactivity and hypercaloric diet|female inactivity and hypercaloric diet for 2 weeks
75460144|NCT01828229|Behavioral|inactivity|inactivity for 2 weeks
75460145|NCT01828229|Behavioral|inactivity and hypercaloric diet|inactivity and hypercaloric diet for 2 weeks
75460146|NCT01828229|Behavioral|normal activity and hypercaloric diet|normal activity and hypercaloric diet for 2 weeks
75460147|NCT01828229|Behavioral|inactivity and iso-caloric diet|inactivity and iso-caloric diet for 2 weeks
75460148|NCT01828242|Behavioral|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
75460149|NCT01828242|Other|Control group following conventional approach|Control group following conventional approach
75460150|NCT01828294|Drug|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
75460151|NCT01828307|Behavioral|Motivational enhancement therapy (MET)|MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
75460152|NCT01828307|Behavioral|Contingency management|Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
75460153|NCT01828307|Behavioral|Standard Aftercare Treatment|Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
75460154|NCT01828320|Behavioral|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
75763093|NCT00316706|Biological|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
75763094|NCT00316706|Biological|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
75763095|NCT03980132|Drug|Lugols Strong Iodine|5 L.I. drops / 8 hours for 10 days before surgery
75763096|NCT01065038|Drug|Anagrelide|
75763097|NCT01065038|Drug|Hydroxyurea|
75460155|NCT01828320|Behavioral|Psychoeducation|
75460156|NCT01828333|Other|No intervention|No intervention
75763098|NCT03980054|Drug|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
75763099|NCT03980054|Drug|Placebo|placebo 400mg, orally once daily for one year
75460157|NCT01828346|Drug|Birinapant|"Dose escalation part: (Drug escalation dose levels)~Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
75460158|NCT01828346|Drug|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
75460159|NCT01828359|Drug|Amosartan® tab|comparison of different combination of anti-hypertension drug
75460160|NCT01828359|Drug|Cozaar® plus pro tab|comparison of different combination of anti-hypertension drug
75763100|NCT02532608|Other|Acute sleep deprivation|Participants will stay awake for 36 hours
75763101|NCT00291486|Drug|Capecitabine|Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
75763102|NCT00291486|Drug|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients received a dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 comprised a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I-huA33 therapy dose was determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
75763103|NCT00301964|Biological|bevacizumab|Given IV
75906521|NCT02631538|Drug|Belimumab|Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
75906522|NCT02631538|Drug|Rituximab|Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
75906523|NCT02631538|Drug|Placebo belimumab|The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
76070263|NCT04020393|Procedure|SPGB|SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
75460161|NCT01828372|Other|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
76070264|NCT04020705|Device|Citicoline eye drops (OMK1)|(OMK1) will be prescribed in the dosage of 1 drop 3 times a day
75460162|NCT01828385|Drug|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
75460163|NCT01828385|Drug|Saline|Saline + rocuronium + sugammadex
75460164|NCT01828398|Device|real-tDCS + UE robot-assisted therapy|
75460165|NCT01828398|Device|sham-tDCS + UE robot-assisted therapy|
75460166|NCT01828411|Device|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
75460167|NCT01828411|Device|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
75613253|NCT05907538|Other|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the The Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
75613254|NCT05907538|Other|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
75613255|NCT05907499|Drug|Decitabine|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
75613256|NCT05907499|Drug|Granulocyte Colony-Stimulating Factor|5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
75613257|NCT05907499|Drug|Thrombopoietin Receptor Agonist|Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
75906524|NCT02631538|Drug|Placebo rituximab|Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
76070265|NCT04020705|Other|Placebo Comparator: hypromellose based ocular lubricant|will be prescribed in the dosage of 1 drop 3 times a day
76070266|NCT04020627|Other|BiPAP Group|"BIPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device"
76070267|NCT04020627|Other|CPAP Group|"CPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device"
76070268|NCT01873417|Drug|BG00012 (DMF)|
76070269|NCT04025697|Other|Complete Denture|A conventional CD will be constructed
76070270|NCT04025697|Other|Rapid prototyped denture|A 3d printed complete denture will be constructed
76070271|NCT03934827|Drug|MRx0518 Capsules|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
76070272|NCT03934827|Drug|MRx0518/placebo Capsules|MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
76070273|NCT01872715|Drug|Oracea|
76070274|NCT04025385|Other|High Intensity Interval Training|Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
75460168|NCT01828437|Drug|Pyridoxine plus prednisolone|
75460169|NCT01828437|Drug|Prednisolone|
75460170|NCT01828463|Drug|Nitisinone|doses 1, 2, 4 & 8 mg plus no treatment arm
75460171|NCT01828489|Drug|Randomisation course 1 mitoxantrone versus DaunoXome|In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
75460172|NCT01828489|Drug|Randomisation course 2 ADxE versus FLADx|The second course is randomised to either ADxE (standard arm) or FLADx
75460173|NCT01828502|Behavioral|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
75460174|NCT01828502|Behavioral|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
75460175|NCT01828528|Procedure|Sleeve gastrectomy|An intra-operative liver biopsy was performed in 20 patients
75460176|NCT01828541|Behavioral|Hypnosis|Patients in this group will receive standard care plus 4 sessions of hypnosis.
75460177|NCT01828541|Other|Standard of Care|
75460178|NCT01828580|Device|active laparoscope positioner (AutoLap)|
75763104|NCT00301964|Other|laboratory biomarker analysis|Correlative studies
75906525|NCT03577353|Behavioral|Dual Task Walking (DTW)|Each training session began with 8 min of general warm-up and 2 min walk around the gym. Then, for safety reasons, the participants were attached to a harness. The participants began walking slowly on the treadmill for 3 min. In the following phases the participants walked at the same speed, while training with 3 VR games. Each session lasted 3 min, and 3 min of single walking was performed between VR sessions. After the final VR session, 2 min of single-task walking was performed in order to allow for recovery. The time walked in each trial from the starting point to the destination was kept constant at 20 min.
75460179|NCT01828606|Device|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
75613258|NCT05907499|Drug|Recombinant human erythropoietin|10000 U/day when hemoglobin ≤ 85 g/L
76070275|NCT01871545|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
76070276|NCT04020315|Procedure|Non-surgically performed scaling and root planing|Non-surgically performed scaling and root planing
75460180|NCT01828606|Device|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
75460181|NCT01828619|Procedure|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
75460182|NCT01828632|Procedure|Respiratory Physical Therapy|Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
75460183|NCT01828645|Dietary Supplement|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
75460184|NCT01828658|Other|Strict bioimpedance guided dry weight prescription|Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
75613259|NCT05907486|Drug|N-acetyl-cysteine|8g/d (>=45kg); 200mg/kg.d (<45kg), intravenously for at least 4 hours, day -9 to day +45
75763105|NCT03976986|Device|continuous-flow portable oxygen concentrator (cPOC)|SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
75763106|NCT03976986|Device|pulsed-flow portable oxygen concentrator (pPOC)|InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
75763107|NCT01070706|Drug|Paclitaxel,Gemcitabine,Sunitinib|"To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15."
75763108|NCT01581528|Genetic|gene expression analysis|
75763109|NCT01581528|Other|cell culture procedure|
75763110|NCT01581528|Other|flow cytometry|
75460185|NCT01828671|Other|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
75613260|NCT05907486|Drug|Busulfan|3.2mg/kg, day-7 to day -5, intravenously
75613261|NCT05907486|Drug|Cytarabine|2g/m2, day -8, intravenously
75613262|NCT05907486|Drug|Cyclophosphamide|1.8g/m2, day -4 to day -3, intravenously
75613263|NCT05907473|Other|Virtual Reality Therapy|Patients in this group will play balance-based games with the Virtual Reality System.
75613264|NCT05907473|Other|Conventional Rehabilitation|In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
75613265|NCT05907447|Other|No interventions need to be specified for this study|No interventions need to be specified for this study
75763111|NCT01581528|Other|laboratory biomarker analysis|
75763112|NCT01581528|Other|metabolic assessment|
75763113|NCT03978026|Behavioral|Nap|Each participant is compared to himself in 4 conditions,
75763114|NCT00268242|Drug|Gemcitabine Hydrochloride|10 mg/m2/ min IV for 12 hours
75763115|NCT00268242|Drug|Mitoxantrone Hydrochloride|12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
75763116|NCT00294554|Drug|Memantine|Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
75763117|NCT00294554|Drug|Placebo Oral Tablet|Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
75763118|NCT00294398|Other|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
75763119|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
75763120|NCT00279708|Drug|Atorvastatin|Placebo vs. Atorvastatin
75763121|NCT00279708|Other|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
75460186|NCT01828671|Other|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
75763122|NCT03978182|Device|accelerated deep rTMS|A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
75763123|NCT01066442|Drug|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
75763124|NCT01581372|Other|Pharmacist care|Pharmacist prescribing, education, drug management
75763125|NCT01069146|Procedure|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
75763126|NCT00299702|Drug|Abilify|10-30 mg once daily for 104 weeks
75763127|NCT00299702|Drug|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
75763128|NCT03979898|Biological|ASTROSTEM|Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10^7cells/5mL 15kg ~ 25kg : 1x10^8cells/10mL 25kg over : 1.5x10^8cells/15mL
75763129|NCT00291330|Drug|dabigatran etexilate 150 mg|twice daily
75906526|NCT03577353|Behavioral|Single-task Treadmill Walking (TMW)|this intervention, participants performed 8 min of general warm-up and 2 min walk around the gym, and then continued to walk for another 20 min on the treadmill at a speed that was equivalent to the intensity of 60%-70% of their heart rate reserve.
75613266|NCT05907382|Drug|JMKX003002 will be administered orally|oral once
75906527|NCT03584061|Procedure|Fat grafting|The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
75460187|NCT01828671|Other|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
75906528|NCT03578679|Drug|Ivermectin Oral Product|treatment of pediculosis (head lice)
75906529|NCT04930783|Drug|CDX-301|Administered as an injection given underneath the skin
75460188|NCT01828671|Other|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
75460189|NCT01828671|Other|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
75613267|NCT05907382|Drug|JMKX003002 will be administered orally|oral once
75613268|NCT05907382|Drug|JMKX003002 will be administered orally|oral once
75613269|NCT05907382|Drug|Placebo in Cohorts 1 to 5|oral once
75613270|NCT05907382|Drug|Placebo in 2 Cohorts|oral once
75613271|NCT05907330|Drug|CU104|CU104 will administer the study drug once a day after a meal
75763130|NCT00291330|Drug|warfarin (INR 2-3)|prn to maintain INR (2-3)
75460190|NCT01828684|Other|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
75460191|NCT01828684|Other|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
75613272|NCT05907330|Drug|Placebo|Placebo will administer the study drug once a day after a meal
75613273|NCT05907265|Behavioral|Behavioral: ONCOBrain_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
75613274|NCT05907265|Behavioral|Behavioral: Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
75613275|NCT05907187|Behavioral|Cervical Cancer Prevention Education|Participants will receive in-person, one-time health education on the importance of cervical cancer screening using a short intervention/educational script; and motivation to encourage women to have human papillomavirus (HPV) screening. Participants will also be informed of the nature and risks of HPV infection, and the importance of seeing a doctor including having a gynecologic exam.
75763131|NCT03975036|Drug|Anlotinib|Anlotinib Hydrochloride Capsules
75763132|NCT03975036|Drug|pd-1 antibody|Pembrolizumabinjection
75763133|NCT00267150|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
75763134|NCT03741504|Procedure|micro-osteoperforations (MOPs)|three (3) micro-osteoperforations (MOPs) in the cortical and medullar bone, distal to the upper canine. These MOPs will be at the apical, medial and gingival zone of the bone located at the distal surface of the canine in the buccal and in the palatal side. The deep of the MOPs will be at 6 mm. It is going to be done with a PROPEL
75906530|NCT04930783|Biological|NEOVAX|Personalized neoantigen vaccine administered as an injection given underneath the skin
75906531|NCT04930783|Drug|Nivolumab|Administered intravenously (IV)
75906532|NCT03583281|Dietary Supplement|Capsules containing flax oil|Capsules containing flax oil to provide 4 grams ALA per day for 4 weeks
75906533|NCT03583281|Dietary Supplement|Capsules containing DHA-enriched fish oil|Capsules containing fish oil to provide 4 grams DHA per day and 0.8 grams EPA per day for 4 weeks
75906534|NCT05479981|Drug|Placebo|Placebo will be administered by intravenous (IV) infusion.
75906535|NCT05479981|Drug|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
75906536|NCT05666206|Procedure|fibrin sealant in hypospadias|fibrin sealant will be used over the suture line
75613276|NCT05907109|Behavioral|Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.|"Parents receive manualized protocols, instructional videos, and toy and material kits to administer EIs at home.~New modules are provided according to infant age or stage of intervention during the length of brief interventions or 12-months.~The families will be monitored by clinical researchers weekly. -High risk infants will receive supplemental EI services at the clinic according to developmental needs.~Infants will receive outcome evaluations within a 42-month follow-up clinic."
75763135|NCT01582230|Drug|Vildagliptin|Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
75763136|NCT01582230|Drug|Placebo|Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
75763137|NCT00278148|Drug|carboplatin|AUC2 weekly x 3 weeks
76070277|NCT04020549|Behavioral|Growth, Gratitude, & Positive Activities|Reading and writing activities based on growth (designed to instill the belief that people can change), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities).
76070278|NCT04020549|Behavioral|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
75460192|NCT01828723|Biological|SVF|
75460193|NCT01828736|Biological|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
75613277|NCT05907096|Biological|ARGX-117|Intravenous administration of ARGX-117
75613278|NCT05907096|Other|Placebo|Intravenous administration of placebo
75613279|NCT05907083|Radiation|cone beam computer tomography|Cone Beam CT Radiation
75613280|NCT05906992|Biological|CT-P53|Intravenous(IV) infusion
75613281|NCT05906992|Biological|US-Ocrevus|Intravenous(IV) infusion
75763138|NCT00278148|Drug|Erlotinib|Daily
75763139|NCT00278148|Drug|paclitaxel|50mg/m2/weekly x 3 weeks
75460194|NCT01828736|Drug|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
75460195|NCT01828736|Drug|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
75460196|NCT01828736|Drug|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
75460197|NCT01828762|Biological|DC-TC+GM-CSF|
75460198|NCT01828775|Other|palliative care|Receive early PCI
75763140|NCT00278148|Procedure|conventional surgery|conventional surgery
75613282|NCT05906992|Biological|EU-Ocrevus|Intravenous(IV) infusion
75613283|NCT05906966|Other|Phone contact|. All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
75763141|NCT00278148|Radiation|radiation therapy|150 cGy bid
75763142|NCT00299546|Drug|Placebo|SC injections
75763143|NCT00299546|Biological|Golimumab 50 mg|SC injections
75763144|NCT00299546|Biological|Golimumab 100 mg|SC injections
75906537|NCT03583203|Device|personalized information about lung damage|Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
75906538|NCT05474287|Procedure|SJOV|SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
75460199|NCT01828775|Other|palliative care|Receive delayed PCI
75460200|NCT01828775|Procedure|quality-of-life assessment|Ancillary studies
75460201|NCT01828775|Other|survey administration|Ancillary studies
75460202|NCT01828788|Drug|Ropivacaine|
75460203|NCT01828788|Drug|placebo|
75613284|NCT05906901|Other|Cranial listening technique|5 minutes
75763145|NCT01071018|Drug|MK2206 every other day|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
75763146|NCT01071018|Drug|MK2206 once weekly|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
75763147|NCT03975270|Drug|Sintilimab and Nab-paclitaxel|Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
75763148|NCT01065116|Drug|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
75763149|NCT01065116|Drug|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
75763150|NCT03977792|Drug|BOR15001L7|BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
75763151|NCT03977792|Drug|Docosanol Cream 10%|Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
75763152|NCT01062542|Procedure|Blood Draw and Ultrasound|Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
75763153|NCT01066598|Drug|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
75763154|NCT01066676|Drug|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
75763155|NCT01066676|Drug|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
75613285|NCT05906901|Other|Suboccipital muscles inhibition technique|6 minutes
75763156|NCT01065194|Drug|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
75763157|NCT01065194|Drug|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
75763158|NCT01065272|Drug|Dexamethasone|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days"
75763159|NCT01065272|Drug|Placebo|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days"
75763160|NCT00299156|Drug|Clofarabine|Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
75763161|NCT00277212|Drug|Lamotrigine + Aripiprazole|"Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~Aripiprazole 10-30 mg/day"
75763162|NCT00277212|Drug|Lamotrigine + Placebo|"Tablets, Oral, once daily, Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~placebo 0 mg/day"
75763163|NCT02532296|Behavioral|Transition Coach (TC)|"TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care."
75763164|NCT02532296|Behavioral|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
75763165|NCT03982628|Diagnostic Test|Abdominal CT imaging|Routine abdominal CT imaging
75906539|NCT05474287|Procedure|HFNO|HFNO is conducted. Oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%.
75906540|NCT05661214|Other|Teaching|The intervention in this study is teaching. Researchers, will create a pressure injury teaching content and assess this effectiveness and also, intervention groups will use Clinical Decision Support System (CDSS) as a tool to plan nursing interventions.
75613286|NCT05906823|Other|Detection of pleural effusion|Detection of pleural effusion
75906541|NCT02035605|Drug|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
75613287|NCT05906810|Procedure|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
75906542|NCT02035605|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
75906543|NCT03619369|Procedure|Circumcision|Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
75906544|NCT03578601|Other|Thyroid surgery|Patient undergoing thyroid surgery
75906545|NCT04421508|Combination Product|INOpulse|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
75906546|NCT04421508|Combination Product|Placebo|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
75906547|NCT03578523|Other|3 Tesla multiparametric MR|Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.
75460204|NCT01828801|Device|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
75460205|NCT01828827|Drug|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
75460206|NCT01828866|Behavioral|EMDR|EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
75460207|NCT01828866|Behavioral|Community Reinforcement Approach|"CRA is based on behavioural therapy principles:~Functional analysis~Communication skills~Problem-solving skills~Sobriety sampling~Social networking~Refusal of substances~Reinforcing activities~Relapse management~Medication monitoring"
75613288|NCT05906758|Procedure|Angiography|Coronary angiography with less than 20cc of contrast materials
75613289|NCT05906719|Other|video recording|Patients' performance of MDS-UPDRS III will be recorded.
75763166|NCT01066754|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
75906548|NCT03578523|Other|renal histopathology scoring|Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)
75906549|NCT03578523|Biological|Blood and urine sampling|"Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis"
75906550|NCT03578523|Biological|Iohexol clearance test|Iohexol clearance to measure GFR within 1 week of the scan session
75763167|NCT02531958|Other|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
75763168|NCT00276744|Biological|cetuximab|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
75763169|NCT00276744|Drug|capecitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
75763170|NCT00276744|Drug|docetaxel|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
75763171|NCT00276744|Drug|Erlotinib|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
75763172|NCT00276744|Drug|Gemcitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
75763173|NCT00276744|Drug|Irinotecan|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
75763174|NCT00276744|Drug|mitomycin C|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
75906551|NCT03578445|Device|EUS-guided microbiopsy|Use of EUS-guided through-the-needle microbiopsy forceps for obtainment of tissue from the wall of the cystic lesion
76070279|NCT03933657|Device|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
76070280|NCT04020237|Behavioral|Education about particulate matter practice score|"For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~1) Start air purifier~2) Do not go out and make it to the minimum when absolutely necessary~3) It is recommended to wear a mask when going out.~4) The investigators recommend a lot of water, fresh fruit and vegetables.~5) Prepare an inhaler and use it when symptoms get worse."
75460208|NCT01828879|Drug|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
75460209|NCT01828892|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
75460210|NCT01828892|Procedure|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
75613290|NCT05906680|Procedure|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
75460211|NCT01828892|Drug|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
75460212|NCT01828892|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
75460213|NCT01828905|Device|"CERAMENT™|BONE VOID FILLER"|ceramic bone void filler
75613291|NCT05906667|Behavioral|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
75613292|NCT05906654|Behavioral|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Behavioral intervention to increase physical and social activity. In triads, participants walk 1-mile neighborhood routes three times per week and engage in image-based conversational reminiscence.
75906552|NCT03578445|Diagnostic Test|Next Generation Sequencing|Prevalence of genetic mutations in known cancer-associated genes in the microbiopsy tissue examined using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, USA). The multigene panel explores selected regions of 50 cancer-associated genes, among others KRAS, GNAS, CDKN2A and SMAD4 genes.
75460214|NCT01828905|Procedure|Autologous cancellous bone graft|autologous cancellous bone graft
75460215|NCT01828918|Genetic|microRNAs|
75460216|NCT01828931|Behavioral|Lifestyle Intervention|A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity
75460217|NCT01828931|Other|Usual Care|Care as usual
75460218|NCT01828944|Dietary Supplement|olive oil|
75460219|NCT01828957|Biological|Pneumostem®|
75460220|NCT01828957|Other|Normal Saline|
75613293|NCT05906576|Drug|Infliximab|Infliximab in the treatment of Crohn's disease in children
75613294|NCT05906563|Drug|Melatonin gel|local application of Melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
75763175|NCT00276744|Drug|rapamycin|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
75763176|NCT00276744|Procedure|conventional surgery|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
75763177|NCT00251316|Drug|Lithium Carbonate|30 mCi of 131I
75763178|NCT00251316|Drug|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
75763179|NCT02532192|Drug|Belinostat|"Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
75763180|NCT02532192|Drug|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
75460221|NCT01828970|Drug|Basal-bolus detemir-aspart insulin regimen|After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
75460222|NCT01828996|Device|Shock wave therapy|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
75460223|NCT01828996|Device|Placebo|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
75460224|NCT01829009|Other|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
75763181|NCT02532192|Drug|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
75763182|NCT02532192|Drug|Cytarabine|"Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours."
75763183|NCT02532192|Drug|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
75460225|NCT01829022|Procedure|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
75763184|NCT02532192|Drug|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
75763185|NCT02532192|Drug|Fluconazole|100 mg by mouth daily for 10 days.
75613295|NCT05906563|Drug|Metformin and melatonin gel|local application of Metformin and melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
75613296|NCT05906563|Drug|placebo gel|Local application of empty nanoparticles gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack.
75613297|NCT05906563|Procedure|scaling and root planning|full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.
75613298|NCT05906550|Diagnostic Test|Vascular access monitoring|Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.
75763186|NCT00293462|Biological|sargramostim|
75763187|NCT00293462|Other|oral salt and soda mouthwash|Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
75763188|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
75763189|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
75763190|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
75763191|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
75763192|NCT00316082|Drug|Placebo|Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
75763193|NCT00316082|Drug|metformin|Tablets, Oral, 500-2000 mg, as needed (12 months LT)
75763194|NCT00316004|Drug|7.5% Hypertonic Saline in 6% Dextran-70 (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
75763195|NCT00316004|Drug|7.5% Hypertonic Saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
75763196|NCT00316004|Drug|0.9% Normal Saline (NS)|250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
75763197|NCT01066832|Drug|Paclitaxel|Paclitaxel-coated balloon (3 µg/mm2)
75763198|NCT00298766|Drug|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
75763199|NCT03979664|Device|Activapatch intellidose 2.5 using active Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
75906553|NCT02185872|Other|High-Intensity Functional Training|Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.
75906554|NCT02185872|Other|Aerobic and Resistance Training|The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
76070281|NCT04025307|Drug|bacTRL-IL-12|bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
76070282|NCT01613599|Drug|Rituximab|Participants received rituximab at the discretion of their treating physicians.
75613299|NCT05906550|Diagnostic Test|Vascular access blood flow measurement|Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume <500mL/min.
76070283|NCT04025619|Device|tape|Sports tape
76070284|NCT01850641|Drug|PA21|
76070285|NCT04020081|Other|Yoga breathing exercises and Meditation|"8 Breathing exercises.The first set of 6 exercises is of the Upper Lobe breathing (Upper and Middle Lobe of the Lungs) while 7th exercise is abdominal breathing,8th exercise is yogic breathing.~6-steps Nirmal Dhyan (meditation).Step 1: Breath awareness,Step 2: Body awareness,Step 3: Thought awareness,Step 4: Refreshing awareness,Step 5: Gap awareness,Step 6: Expanding awareness."
76070286|NCT01850563|Device|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
76070287|NCT03931473|Other|Bed nets|Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
75613300|NCT05906537|Drug|SKB410 for injection|SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
75613301|NCT05906524|Drug|KD6001|KD6001 will be administered intravenously.
75613302|NCT05906524|Drug|Tislelizumab|Tislelizumab will be administered intravenously.
75906555|NCT05649982|Behavioral|ALVA|Behavioural digital self-help intervention
76070288|NCT03930771|Drug|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
76070289|NCT03930771|Drug|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
76070290|NCT04024683|Procedure|Serratus block with ropivacaine 2mg/ml|The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
75613303|NCT05906524|Drug|Bevacizumab|Bevacizumab will be administered intravenously.
75613304|NCT05906498|Drug|Acetyl cysteine|N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.
75613305|NCT05906498|Drug|Vitamin E|vitamin E possessing an anti-inflammatory action
75613306|NCT05906485|Behavioral|fNIRS Neurofeedback-VR Training|In the fNIRS Neurofeedback-VR Training, we have designed a classroom scenario modeled and children are expected to learn how to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
76070291|NCT04024527|Drug|Esomeprazole|Proton pump inhibitor
76070292|NCT04024527|Drug|Amoxicillin|Antibiotic for H. pylori eradication
76070293|NCT04024527|Drug|Metronidazole|Antibiotic for H. pylori eradication
76070294|NCT04024215|Device|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
76070295|NCT06061965|Behavioral|Web-based resilience-building intervention|There are 6 modules on the website. Participants will be encouraged to verbalize their impressions of the website prototype.
76070296|NCT06061913|Behavioral|Breast Pump suction pattern|Mothers who have reached secretory activation and are pumping <350 mLs/day will be randomized to one of three breast pump suction patterns.
76070297|NCT06061887|Other|Fall evaluation|Evaluation of the frequency of falls in patients with acute stroke and determining the risk factors associated with recurrent falls within the first six months after stroke
75763200|NCT03979664|Device|Activapatch intellidose 2.5 using inactive Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
75763201|NCT03979664|Drug|Dexamethasone|Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
75763202|NCT01325558|Biological|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
75763203|NCT00315458|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
75763204|NCT00315458|Drug|Placebo transdermal patch|Placebo to match buprenorphine transdermal patch 10 or 20.
75763205|NCT01065662|Drug|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
75763206|NCT01065662|Drug|cediranib|Taken orally daily
75906556|NCT02256462|Drug|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (> 40kg 160/80/40 mg every 2 weeks or < 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
75763207|NCT01062620|Drug|AXL1717|Phase I study with increasing dosage and treatment duration
75763208|NCT01065740|Other|Patient education|
75763209|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
75763210|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
75763211|NCT01581242|Drug|Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil|Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15
75763212|NCT01581242|Drug|Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;
75763213|NCT01581242|Drug|Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15
75763214|NCT03982238|Drug|Insulin|Continuous subcutaneous insulin infusion therapy for 1 month
75763215|NCT03982238|Drug|Metformin|Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
76070298|NCT06061874|Diagnostic Test|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is applied intravenously for molecular imaging of FAP expression with FAPI PET/CT.
75763216|NCT03982238|Drug|Dapagliflozin|Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
75763217|NCT00293384|Drug|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
75763218|NCT00293384|Drug|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
75763219|NCT00293384|Drug|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
75763220|NCT00293384|Drug|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
75763221|NCT00297830|Drug|Zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
75763222|NCT00297830|Drug|Alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
75763223|NCT00297830|Other|Placebo Zoledronic Acid|Infusion of placebo zoledronic acid during the first 5 weeks after transplantation
75763224|NCT00297830|Other|Placebo Alendronate|Placebo alendronate 70 mg once weekly
75763225|NCT00296816|Drug|Bevacizumab (Avastin®)|15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
75763226|NCT00296816|Drug|Docetaxel (Taxotere®)|75 mg/m^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
75763227|NCT00296816|Drug|Oxaliplatin (Eloxatin®)|85 mg/m^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
75763228|NCT01066988|Other|ORB Ocular Emulsion|lubricant eye drop
75763229|NCT01066988|Other|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
75763230|NCT00314132|Biological|ChimeriVax-JE, Japanese Encephalitis vaccine|0.5 mL, Subcutaneous
76070299|NCT06061835|Other|Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: MRA scan Philips Ingenia 1.5 T (Royal Philips, Netherlands)~Preprocedural patient's preparation: the study was performed on an empty stomach (at least 8 hours of fasting).~Type of patient positioning. MRA scanning was performed in the prone position.~Additional devices. The investigators placed the patient on her abdomen on a special coordinate system mesh, for the most precise and convenient way of marking.~Scanning protocol. The investigators added T2 pulse sequence to increase the accuracy of muscle localization assessment and the point of vessel immersion into the muscle at TR and TE using a fat suppression program, wich allows receiving information from moving objects (including blood within the vascular lumen).~Scan viewer program. OsiriX 10.0 Release"
75763231|NCT00314132|Biological|0.9% Saline|0.5 mL, Subcutaneous
75763232|NCT03977558|Behavioral|Intervention group|Isocaloric diet including ~50g canola oil
75763233|NCT03977558|Behavioral|Control group|ESC/EAS Guidelines for the management of dyslipidemias
75906557|NCT04587271|Dietary Supplement|Moringa oleifera (high dose)|Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.
75460226|NCT01829035|Other|Conventional Transarterial Chemoembolization (cTACE)|"Concurrent use of the following material/drug is defined as cTACE in this trial.~Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~Anti-tumor drug:~Unapproved drug/embolization material from each regulatory agency should not be used.~To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"
75906558|NCT04587271|Dietary Supplement|Moringa oleifera (low dose)|Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.
75906559|NCT04587271|Dietary Supplement|Placebo|Mothers and children will receive porridge with placebo.
75906560|NCT02631148|Drug|Melatonin|2mg controlled release melatonin tablet
75460227|NCT01829087|Drug|Botox|
75460228|NCT01829087|Drug|placebo|
75763234|NCT01081756|Drug|r-hCG|r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
75906561|NCT02631148|Drug|Placebo|placebo tablet identical to circadin
75763235|NCT01081756|Drug|Urinary-hCG|Urinary hCG (10,000 IU) injection s.c. or i.m.
75763236|NCT03965182|Drug|PEG|2 sachets of PEG will be used as the bowel prep regimen.
75763237|NCT03965182|Drug|PEG plus SPMC|one sachet of PEG and one sachet will be administered as the bowel prep regimen
75763238|NCT03965182|Drug|SPMC|2 sachets will be administered as the bowel prep regimen.
75763239|NCT01081990|Drug|cyclobenzaprine|Cyclobenzaprine 5 mg TID for 7 days
75763240|NCT01079572|Other|in-person|Follow-up appointments will be completed in-person as per usual
75763241|NCT01079572|Other|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
75763242|NCT01084486|Drug|Metformin|
75763243|NCT01082146|Drug|Lurasidone|40 mg suspension, PO, for 7 days
75763244|NCT01084720|Drug|V0034 CR|
75763245|NCT00117988|Drug|tanespimycin|
75763246|NCT03963466|Drug|tranexamic acid|Oral tranexamic acid group(menstrual period>2days) 250mg bid（exclude menstrual period ）
75763247|NCT03963466|Radiation|1064-nm Q-Switched fractional laser|Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
75763248|NCT03963466|Radiation|1064-nm Q-Switched laser|Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
75763249|NCT01084876|Drug|CT-P6|Administered every 3 weeks
75613307|NCT05906485|Behavioral|Computerized Cognitive Training|In the Computerized Cognitive Training, children will complete a range of tasks covering attention control and working memory using a conventional training programme, namely Cogmed.
75613308|NCT05906472|Other|Feeds continued|Enteral feeds are continued up until time of surgery
75613309|NCT05906472|Other|Feeds held|Enteral feeds are stopped 6 or more hours before surgery
75613310|NCT05905796|Other|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
75613311|NCT05904639|Genetic|Decoding Your Diet|We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.
75613312|NCT05903911|Other|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
75613313|NCT05902156|Behavioral|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires)
75763250|NCT01084876|Drug|Herceptin|Administered every 3 weeks
76070300|NCT06061835|Other|CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: Device: Toshiba Aquilion 64 CTA scan machine (Toshiba Medical Systems, Tokyo, Japan).~Preprocedural patient's preparation: A catheter was placed in the antecubital vein of one arm, and a bolus injection of 80 ml contrast medium (Omnipaque 300 mg/ml, GE Healthcare, Oslo, Norway, registration number P N015799/01 from July 31, 2003, international nonproprietary name is a Iohexol) was administered through a power injector (M. Schilling GmbH Medical Products, Germany) at 4 ml/s.~Type of patient positioning. CTA scanning was performed in the supine position.~Scan viewer program. OsiriX 10.0 Release"
75613314|NCT05902156|Behavioral|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (only self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format.)
75763251|NCT01084876|Drug|Paclitaxel|Administered every 3weeks
75763252|NCT00117676|Drug|TDF|300 mg tablet administered orally once daily
75763253|NCT00117676|Drug|ADV|10 mg tablet administered orally once daily
75763254|NCT00117676|Drug|TDF placebo|Tablet administered orally once daily
75906562|NCT02030496|Procedure|open reduction and internal fixation|The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
75613315|NCT05901961|Drug|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
75613316|NCT05901961|Drug|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
76070301|NCT06061822|Diagnostic Test|AI-assisted cardiac magnetic resonance imaging|An AI algorithm will be used to automatically position (plan) the scan planes used in a cardiac MRI scan. The resultant images will be compared with standard radiographer-positioned images.
75613317|NCT05901961|Drug|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
75613318|NCT05901584|Drug|Cadonilimab|Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle.
75613319|NCT05900765|Drug|Zimberelimab 240mg|"AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV"
75613320|NCT05898243|Procedure|Reduction|An Rx will be performed before and after the reduction of the dislocation. After that, the neurovascular state will be checked and also if there is some associated injury.
75613321|NCT05896358|Behavioral|ketogenic diet|a low calorie ketogenic diet
75763255|NCT00117676|Drug|ADV placebo|Tablet administered orally once daily
75763256|NCT00117676|Drug|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
75763257|NCT00251004|Drug|Everolimus|oral, bis in diem/twice a day (bid)
75763258|NCT00251004|Drug|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
75763259|NCT00251004|Drug|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
75763260|NCT00251004|Drug|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
75763261|NCT00251004|Drug|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
75763262|NCT03973632|Drug|SH-1028 Tablets|200mg of SH-1028 Tablets, orally once every cycle.
75763263|NCT01325922|Procedure|DFT Testing with a 50/50% tilt|
75763264|NCT00275340|Other|Peer Support|
75763265|NCT00275262|Drug|Leuprolide acetate depot (LAD) 11.25 mg 3 Month|LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
75763266|NCT00275262|Drug|Matched placebo|Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
75763267|NCT00275028|Drug|cediranib maleate|Given orally
75763268|NCT01072266|Drug|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
75763269|NCT01072422|Behavioral|smoking cessation|Use of trying to quit smoking instrument and quit smoking advice
75763270|NCT00471497|Drug|nilotinib|Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
75763271|NCT00471497|Drug|imatinib|Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
75763272|NCT01018199|Other|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
75763273|NCT01018199|Other|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
75763274|NCT04357457|Drug|Almitrine|Intravenous almitrine at a dose of 2 µg.kg-1.min-1 during 5 days
75763275|NCT04357457|Drug|Placebo|Intravenous glucose 5% during 5 days
75613322|NCT05892510|Drug|Intra-arterial tenecteplase injection at the completion of thrombectomy|Intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion, or in direct contact with the residual thrombus
75613323|NCT05892510|Drug|Placebo|intra-arterial bolus of 0.9% Sodium Chloride solution
75613324|NCT05887414|Other|Baseline|Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.
75613325|NCT05887414|Other|30 Day Follow Up|Measure Ottawa Decisional Regret after 30 days.
75613326|NCT05886270|Other|Housing Assessment/Safety Modifications|A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
75763276|NCT00493649|Drug|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
75763277|NCT00493649|Drug|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
75763278|NCT00493649|Drug|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
75763279|NCT00471107|Device|DC brain polarization|0.08 mA/cm2
75763280|NCT01018277|Other|Mobilization (walking)|25 meters twice
76070302|NCT06061783|Drug|Hypotonic Solution|"Intravenous administration of 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day.~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily."
75763281|NCT00488033|Procedure|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
75763282|NCT01021163|Drug|N-acetylcysteine, saline|Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
75763283|NCT01021241|Biological|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
75763284|NCT01018355|Device|Percutaneous device closure of patent foramen ovale|Percutaneous device closure of patent foramen ovale
75763285|NCT01021397|Drug|rHPIV3cp45|10^5 TCID50 nasal drops
75763286|NCT01021397|Drug|rHPIV3cp45 placebo|1X-L15 nasal drops
75763287|NCT01022333|Dietary Supplement|Diindolylmethane (DIM)|300 mg per day of DIM for six weeks.
75763288|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
75763289|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
75763290|NCT00117598|Drug|Investigator's choice|"Any of the following single agent treatments:~Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~Prednisone 40 (20-60) mg/m2 PO daily or every other day~Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day"
75763291|NCT01082302|Drug|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
75763292|NCT01082302|Other|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
75763293|NCT01082458|Drug|remifentanil / lidocaine|"Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.~Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery."
75763294|NCT00469859|Drug|cytarabine|given IV
75763295|NCT00469859|Drug|idarubicin|Given IV
75763296|NCT00469859|Drug|lestaurtinib|Given orally
75763297|NCT03964948|Diagnostic Test|Kidney MRI|An MRI examination will be completed per research MRI protocol.
75763298|NCT01021475|Procedure|Visceral Manipulation|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
75613327|NCT05881551|Device|eEgg|In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
75906563|NCT02030496|Other|Closed reduction and plaster|Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
75613328|NCT05881551|Other|NRS|Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
75763299|NCT01021475|Drug|PPIs and/or Domperidone|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
75763300|NCT04265170|Device|BlastX with negative pressure therapy|Blast-X in combination with NPWT on,bacterial bio-burden in pressure ulcers assessed by Fluorescence imaging and quantitative biopsy.
75763301|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
75763302|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
75906564|NCT02239107|Drug|N-Acetyl cysteine|
75906565|NCT02239107|Procedure|laparoscopic ovarian drilling|
75906566|NCT02182518|Drug|Epinastine|
75906567|NCT02182518|Drug|Pseudoephedrine|
75906568|NCT02182518|Drug|Placebo|Placebo during run-in period
75906569|NCT04339621|Device|LiverMultiscan|The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores
75613329|NCT05879835|Device|KiteLock 4% Sterile Catheter Lock Solution|KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
75613330|NCT05879835|Device|Heparin Lock Solution|Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
75906570|NCT02239185|Procedure|Hernial sac ligation in continuity|Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
76070303|NCT06061783|Drug|Water Purified|administration of bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
76070304|NCT06061770|Other|Adapted physical activity program|Rehabilitation
76070305|NCT06061770|Other|Adapted physical activity self-program|Rehabilitation
75763303|NCT01085032|Drug|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
75763304|NCT01085032|Drug|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used."
75763305|NCT01018433|Behavioral|T-SIB|Treatment for self-injurious behaviors; study psychotherapy
75763306|NCT01018433|Other|Treatment as usual|Can include other psychotherapy and pharmacotherapy
75763307|NCT01021709|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 & 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
75763308|NCT01021787|Drug|Titanium dioxide|Topical cream
75763309|NCT03998111|Diagnostic Test|Oral glucose tolerance test|Participants will ingest 75 g anhydrous glucose dissolved in water and the blood responses will be measured over the following 2-hours using a venous cannula.
75763310|NCT00093808|Biological|trastuzumab|
75763311|NCT00093808|Drug|capecitabine|
76070306|NCT06061757|Device|Imaging guidance with TEE and ICE for Left atrial appendage closure|The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
75763312|NCT00093808|Drug|vinorelbine tartrate|
75613331|NCT05871853|Behavioral|Improved breastfeeding support|Cross-sectoral intervention to improve breastfeeding support among women giving birth at Slagelse Hospital, Region Zealand, Denmark
76070307|NCT06061744|Other|Minimally invasive surgery|laparoscopic or robotic surgical approach for the treatment of gallbladder cancer
76070308|NCT06061731|Drug|low-frequency acupoint electrical stimulation|In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
76070309|NCT06061718|Drug|iDose TR|anchored intracameral implant containing travoprost
76070310|NCT06061692|Drug|Tongxinluo Capsule|4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
76070311|NCT06061679|Device|Omron C28P nebuliser|switch from portable inhalers to the Omron C28P nebuliser
76070312|NCT06061666|Other|Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days)|Self-administration of the food supplement or placebo (1 gtt/10 kg/day before bedtime for 15 days)
76070313|NCT06061614|Genetic|NGGT002|NGGT002
76070314|NCT06061601|Device|Exoskeleton stroke group|The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
76070315|NCT06061549|Biological|AAV1/SERCA2a|3E13 viral genomes fixed dose
76070316|NCT06061497|Other|Abdomino-diaphragmatic breathing|Breathing should be done twice a day for 10 minutes.
75613332|NCT05871164|Procedure|Pancreatic radiofrequency|Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
75763313|NCT00469079|Drug|Nicotine gum and lozenge|Nicotine replacement
75763314|NCT00469079|Other|Taboka|smokeless tobacco product
75763315|NCT00469079|Other|Camel Snus|smokeless tobacco product
75763316|NCT01326754|Drug|Artemether-lumefantrine combination|Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
75763317|NCT01326754|Drug|Artesunate-amodiaquine combination|Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
75763318|NCT01326754|Drug|Dihydroartemisinin-piperaquine|Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
75763319|NCT00093496|Drug|gemcitabine hydrochloride|Given IV
75763320|NCT00093496|Drug|tanespimycin|Given IV
75763321|NCT00117286|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
75763322|NCT01589380|Drug|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
75763323|NCT01589380|Drug|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
75763324|NCT00265122|Drug|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
75763325|NCT00265122|Drug|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
75763326|NCT00265122|Drug|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
75763327|NCT00265122|Drug|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
75763328|NCT00116584|Drug|heliox|continuous heliox therapy
75763329|NCT00116584|Drug|oxygen|continuous oxygen therapy
75763330|NCT00096538|Drug|valganciclovir|
75763331|NCT00239928|Drug|pegaptanib sodium|1 drop per dosed eye per protocol.
75763332|NCT00116428|Device|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
75763333|NCT00116428|Drug|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
75763334|NCT03971214|Drug|PD-1 inhibitor JS-001|The extensive-stage SCLC patients will receive PD-1 inhibitor treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
76070317|NCT06061497|Behavioral|Usual Care|Health education Review of inhaler technique Check adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity
76070318|NCT06061484|Dietary Supplement|ready-to-use therapeutic food (RUTF)|Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
75613333|NCT05868850|Behavioral|auricular point sticking|"Acupoint selection: Select Shenmen, spleen, stomach, liver, sympathetic, tongue, digestive system under the cortex, three focal, ear-back spleen.~Operation: Use 75% ethanol to disinfect auricular broad skin; To be dry, use tweezers to pick up the middle of the small square tape stuck with Wang do not line seeds, align the indentation and stick well, press gently with the finger abdomen, the strength to the patient feel acid swelling, pain and heat sense and can tolerate it.~Press frequency and course of treatment: it is asked to press 4 times a day, once in the morning, middle and evening before going to bed, 3-5 minutes each time, the duration of hospitalization for patients with chemotherapy is generally 3-5 days, intervention begins on the first day of chemotherapy medication, the day of discharge for patients to replace the other side of the ear acupoint, removed after 4 days of discharge. A total of 2 chemotherapy courses were treated."
75613334|NCT05866718|Behavioral|Self-Compassionate Touch Intervention|Participants will be taught the micropractice (<20-second/day personal practice) via video recording.
75763335|NCT01073748|Drug|paracetamol|single dose of paracetamol 15mg/kg.
76070319|NCT06061484|Drug|Amoxicillin|Standard weight-based dosing per Ehtiopian national guidelines
76070320|NCT06061445|Combination Product|Radiotherapy combined with TKI and Anti-PD-1 Antibody|After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.
75613335|NCT05866718|Behavioral|Habit Formation Tools|Participants will receive evidence-based tools for promoting habit-formation.
75763336|NCT00468845|Drug|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
75763337|NCT00468845|Drug|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
75763338|NCT00468845|Drug|matched placebo|matched placebo
75763339|NCT03996317|Other|Room air|Avoidance of hyperoxygenation
75763340|NCT00468299|Drug|Misoprostol and placebo|Women in this group receive 800 mcg misoprostol plus a placebo
75763341|NCT00468299|Drug|Mifepristone and misoprostol|This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
75763342|NCT01021865|Drug|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|"GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"
75763343|NCT00468143|Drug|Adderall ® Immediate Release|Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
75763344|NCT00468143|Drug|Adderall XR ®|Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.
75763345|NCT00467831|Drug|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
75763346|NCT00467831|Drug|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
75763347|NCT00467831|Drug|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
75763348|NCT00467831|Drug|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
75763349|NCT00467831|Drug|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
75763350|NCT00467753|Drug|Oxcarbazepine|Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
75613336|NCT05833490|Other|Repetitive Peripheral Magnetic Stimulation (rPMS)|Repetitive Peripheral Magnetic Stimulation (rPMS) is an external device that delivers repetitive pulsed magnetic fields of sufficient magnitude, will be applied on the tibialis anterior muscle belly at ~ 10% of motor threshold, in order to induce neural action potentials in the lower extremities.
75613337|NCT05833490|Other|Sham Priming|Sham Priming using the Repetitive Peripheral Magnetic Stimulation (rPMS), it will be applied on the dorsal part of the foot with a minimal intensity at 5% of maximum stimulator output, that is of insufficient magnitude to induce changes in the muscle or nerves of lower extremities.
75613338|NCT05831800|Device|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid balance. It is designed as an adhesive patch with four integrated electrodes. The outer electrodes are used to supply a low current, while the inner electrodes are used for voltage measurements.
75613339|NCT05827341|Other|No intervention|No intervention needed
75763351|NCT00467753|Other|Placebo/sugar pill|Dosage similar to active drug
75763352|NCT01021943|Drug|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
75763353|NCT01021943|Drug|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
75763354|NCT01022021|Drug|Rituximab|Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
75613340|NCT05816447|Behavioral|interview|Interview patient's perception
75613341|NCT05806593|Behavioral|Get Back pilot|A health-promoting program, targeting physical activity behavior, with a person-centred approach led by a physiotherapist digitally during 12 weeks.
75763355|NCT01022021|Drug|Bendamustine|Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
75763356|NCT00467597|Drug|Levodopa (delivered intravenously)|"IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit."
75763357|NCT00115804|Drug|Fluoxetine|Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
75763358|NCT01085188|Behavioral|ACC|Weekly community based behavioral counseling and case management
75763359|NCT01085188|Behavioral|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
75763360|NCT01085188|Behavioral|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
75763361|NCT00467519|Biological|Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|0.5 mL, IM
75763362|NCT00467519|Biological|DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)|0.5 mL, IM
75763363|NCT00264810|Procedure|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
75460229|NCT01829100|Behavioral|Group Behavioral Activation Therapy (GBAT)|GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
75763364|NCT00264810|Device|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
75763365|NCT00467363|Drug|acetylsalicylic-acid (aspirin)|81mg of low-dose aspirin plus 400micrograms of folic acid.
75763366|NCT00467363|Dietary Supplement|Folic acid|400micrograms of folic acid.
76072407|NCT00499083|Other|immunoenzyme technique|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
75460230|NCT01829152|Device|CHM|
75460231|NCT01829178|Drug|Silymarin|Silymarin 420 mg in 3 divided dose plus standard chemotherapy
75906571|NCT02239185|Procedure|Hernial sac disconnection|Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
75460232|NCT01829178|Drug|Placebo|placebo tablets: 420 mg in 3 divided dose
75906572|NCT05412433|Behavioral|Patient Level|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations
75906573|NCT05412433|Behavioral|Multilevel|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations, provider electronic health records (EHR) alerts
75906574|NCT05412433|Behavioral|Control|Standard of care
75906575|NCT05486182|Drug|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
75613342|NCT05802589|Procedure|Lumbar Erector Spinae Plane Block|Erector spinae plane block was applied with a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) using in-plane technique using a convex USG transducer from the 4th lumbar vertebral level.
75613343|NCT05802589|Procedure|Pericapsular Nerve Group Block|Pericapsular nerve group block was performed using a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) and a convex USG transducer using an in-plane technique under the iliopsoas muscle in the plane between the iliopsoas tendon and the periosteum and between the anterior inferior iliac spine and the iliopubic eminence.
75763367|NCT03970980|Other|fraction of inspired oxygen (FIO2)|Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
75763368|NCT00091390|Radiation|High Dose brachytherapy boost|19 Gy in two fractions (on day of placement and 6-24 hours later) before or after external beam radiotherapy, such that all study treatment occurs within 8 weeks.
75763369|NCT00091390|Radiation|External beam radiotherapy|45 Gy as 1.8 Gy five days a week for five weeks.
75763370|NCT00239226|Procedure|IAS pacing - study group|site of implant and permanent pacing
75906576|NCT03574935|Drug|External Chinese medicine|"External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome."
75906577|NCT03574935|Drug|External Western medicine|"For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear)."
75460233|NCT01829178|Drug|chemotherapy|All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
75613344|NCT05802589|Procedure|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
75763371|NCT00239226|Procedure|IAS pacing control group|site of implant and permanent pacing
75906578|NCT02239029|Drug|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
75763372|NCT00239226|Procedure|Pacing RAA study group|site of implant and permanent pacing
75763373|NCT00239226|Procedure|Pacing RAA control group|site of implant and permanent pacing
75763374|NCT01022099|Procedure|Implantation of a Total Knee Arthroplasty|"In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides."
75763375|NCT01022177|Procedure|acupuncture|acupuncture of the eye in traditional chinese schematics
75460234|NCT01829256|Behavioral|Pharmacist telehealth intervention|A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
75763376|NCT01022255|Biological|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
75763377|NCT00264576|Biological|Influenza Virus Vaccine|
75763378|NCT01071174|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
75763379|NCT01071174|Other|Placebo|Vaginal Ring containing no drug substance
75763380|NCT00466505|Biological|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
75763381|NCT00466505|Drug|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
75763382|NCT00466505|Genetic|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
75763383|NCT00466505|Other|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
75906579|NCT02239029|Drug|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
75763384|NCT00466505|Other|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
75763385|NCT00466505|Other|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
76072408|NCT00499083|Other|immunohistochemistry staining method|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
75460235|NCT01829282|Behavioral|Risk Reduction|
75763386|NCT02531568|Drug|Warfarin|
75763387|NCT02531568|Drug|MT-3995|
75763388|NCT00467051|Drug|Carboplatin|Given IV
75763389|NCT00467051|Biological|Filgrastim|Given IV or subcutaneously
75763390|NCT00467051|Drug|Ifosfamide|Given IV
75763391|NCT00467051|Other|Laboratory Biomarker Analysis|Optional correlative studies
75763392|NCT00467051|Drug|Paclitaxel|Given IV
75763393|NCT00264498|Drug|Gefitinib|oral tablet
75763394|NCT00264498|Drug|Gemcitabine|intravenous injection
75906580|NCT03578289|Behavioral|Telemental Health - CBT|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
75906581|NCT03574857|Drug|Metolazone Oral Tablet|Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO
75906582|NCT03574857|Drug|Chlorothiazide Injection|Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
75906583|NCT03578133|Diagnostic Test|InBios® Active Melioidosis DetectTM-Lateral Flow Assay|Evaluation of a lateral flow assay for the detection of B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen from sputum
75906584|NCT02753400|Drug|emixustat hydrochloride|Tablet for oral administration
75460236|NCT01829308|Behavioral|The brief interventions are delivered by behavioral health counselors (Specialist)|Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
75763395|NCT00264498|Drug|Carboplatin|intravenous injection
75763396|NCT00466193|Drug|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
75906585|NCT02753400|Other|Placebo|Placebo tablets for oral administration contain only inactive ingredients
75906586|NCT03578055|Drug|BDD with UDCA|Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
75906587|NCT03578055|Drug|Placebo|Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
75906588|NCT02185950|Device|ultrasound|
75906589|NCT02185950|Device|paraffin|
75906590|NCT02185950|Device|endermotherapy|
75613345|NCT05767619|Diagnostic Test|Troponin hs-cTnI|One sample of Troponin (hs-cTnI) is obtained and analyzed at the scene. Capillary blood sample or venous (lithium heparin) if peripheral venous catheter is inserted for standard care reasons. The sample is disposed after the result has been recorded in the clinical report form. The clinicians participating in the study are instructed and have been educated about the study to only collect the data (report form with measurements) and provide care as constituted by the guidelines. Patients will be monitored by board members that standard clinical care is provided.
75763397|NCT00466193|Drug|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
75763398|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
75763399|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
75763400|NCT01072734|Drug|Vaccine|Influenza vaccine
75763401|NCT03971058|Biological|IXIARO®- Japanese Encephalitis vaccine|Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
75763402|NCT01025141|Device|Skeletal anchorage (MINISCREW)|Skeletal anchorage
75763403|NCT01025141|Device|dental anchorage|dental anchorage (reference)
75763404|NCT03970668|Drug|Linagliptin 5 mg Oral Tablet|Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
75906591|NCT02238639|Procedure|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|"If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation."
75460237|NCT01829308|Behavioral|The brief interventions are delivered by the primary care provider (Generalist)|Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
75460238|NCT01829321|Drug|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
75460239|NCT01829321|Drug|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
75460240|NCT01829334|Other|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
75613346|NCT05767619|Diagnostic Test|Plasma glucose|One sample of plasma glucose is obtained and analyzed at the scene. The sample is then disposed and the measured value is recorded in the clinical report form. P-glucose measurement is clinical practice in standard care and is measured on all patients with diabetes and patients with altered mental status or at the ambulance nurse discretion.
75763405|NCT03970668|Drug|Insulin|Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
75906592|NCT02186028|Drug|Vitamin D|Vit D 400 IU vs. Vit D 200 IU
75906593|NCT02182596|Drug|Mylotarg|Dose level study
75906594|NCT03574701|Dietary Supplement|Vitamin A|The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
75906595|NCT02180880|Drug|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
75906596|NCT05471440|Drug|Direct boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
75906597|NCT05471440|Drug|Direct boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
75906598|NCT05471440|Drug|Post-poned boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
75460241|NCT01829334|Other|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
75460242|NCT01829334|Other|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
75460243|NCT01829334|Other|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
75613347|NCT05760807|Drug|Oxytocin nasal spray|Intranasal oxytocin, administered dose 24 international units (IU) twice daily, delivered over 7 days of a residential inpatient withdrawal admission.
75763406|NCT01022411|Dietary Supplement|Brown rice/White rice|ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
75763407|NCT00263562|Drug|Steroid arm|Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
75763408|NCT00263562|Other|Placebo|Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
75763409|NCT00454181|Drug|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
75763410|NCT00454181|Other|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
75763411|NCT03970434|Other|Venous blood collection|Venous blood collection
75763412|NCT03970434|Other|Peripheral blood collection|Peripheral blood collection
75906599|NCT05471440|Drug|Post-poned boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
75906600|NCT02186106|Drug|Cholecalciferol|
75763413|NCT01073826|Behavioral|Sport|
75763414|NCT01073826|Drug|Tocilizumab|
75763415|NCT01073826|Drug|Sitagliptin|
75763416|NCT00237744|Device|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
76070321|NCT06061432|Procedure|Endoscopic restoration of gastrointestinal continuity after Hartmann procedure|EndoHARP is a new technique proposed to restore gastrointestinal continuity after the Hartmann's procedure. For EndoHARP, a fixed loop of the large intestine will be identified on endosonography after an echoendoscope is inserted into the rectal stump under endoscopic guidance. Then, using the set for inserting self-expandable metal transmural endoprosthesis (20 mm in diameter and 10 mm in length) with electrocautery (as in endoscopic gastroenterostomy), EUS-guided anastomosis of the rectal stump to the large intestine loop will be performed, allowing the natural passage of intestinal contents through the endoscopic anastomosis, restoring gastrointestinal continuity. The aim of leaving the self-expandable transmural endoprosthesis in the anastomosis is not only to maintain the patency of the intestinal anastomosis of at least 20 mm in diameter, but also to diminish the risk of endoscopic intestinal anastomotic leak by completely covering the prosthesis with a polymer layer.
75460244|NCT01829373|Biological|vaccine 1650-G|
75460245|NCT01829412|Other|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
75460246|NCT01829438|Behavioral|Listening to fast music|
75613348|NCT05746442|Behavioral|Smartphone-delivered Automated Messaging|An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.
75613349|NCT05746442|Drug|Nicotine patch|Participants will be provided with a 8 week supply of nicotine patches
75613350|NCT05746442|Behavioral|Brief Advice to Quit and Smoking Cessation Self Help Materials|Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
75613351|NCT05746442|Behavioral|Diet Assessment|Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
75613352|NCT05736874|Drug|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
75763417|NCT00237744|Device|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
75763418|NCT00237744|Other|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
75906601|NCT02181036|Other|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
75906602|NCT02239419|Procedure|CO2-Enriched Tap Water (Carbothera)|Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
76070322|NCT06061419|Other|Huel Powder|Huel Powder v3.0 white, vanilla flavour
75763419|NCT01072812|Drug|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
75763420|NCT00237042|Behavioral|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
75763421|NCT00237042|Behavioral|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
75460247|NCT01829438|Behavioral|Listening to preferred music|
75460248|NCT01829438|Behavioral|Listening to slow music|
75460249|NCT01829451|Other|Hyaluronic acid gel|"Hyaluronic acid gel is placed into the uterus after endometrial ablation~--------------------------------------------------------------------------------"
75460250|NCT01829490|Biological|ChAdOx1 85A|Intramuscular injection
75460251|NCT01829490|Biological|MVA85A|Intramuscular injection
75763422|NCT00237042|Drug|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
75763423|NCT00465647|Drug|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
75763424|NCT00465569|Drug|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
75763425|NCT00465569|Other|Placebo|
75763426|NCT00090766|Drug|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
75763427|NCT01086904|Biological|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
75906603|NCT02239419|Procedure|Non-CO2-Enriched Tap Water|Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
75906604|NCT03943147|Drug|BMS-986165|Specified dose on specified days
76070323|NCT06061406|Device|smart visit app|"Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician."
76070324|NCT06061380|Other|no intervation taken|
76070325|NCT06061341|Diagnostic Test|TruGraf®|TruGraf® is a non-invasive blood-based test to assist the clinician in lowering immunosuppression in liver transplant patients. It is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients.
76070326|NCT06061315|Dietary Supplement|Effect of collagen peptides, in combination with resistance training, on body composition and muscle strength compared to placebo in untrained men|The effects of collagen peptide consumption in combination with resistance training will be tested
75460252|NCT01829529|Drug|Amoxicillin|Amoxicillin
75460253|NCT01829542|Dietary Supplement|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
75460254|NCT01829542|Dietary Supplement|Control|Macro- and micro-nutrient matched control in water
75460255|NCT01829555|Behavioral|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
75613353|NCT05736874|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
75613354|NCT05712460|Drug|sisunatovir|Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV
75613355|NCT05712460|Drug|Placebo|Placebo for sisunatovir
75763428|NCT01082692|Biological|PENNVAX-B|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
75763429|NCT03961828|Drug|Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]|The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
75763430|NCT01087060|Procedure|partial or radical nephrectomy|
75460256|NCT01829581|Other|no intervention, only descriptive data analysis|
75763431|NCT01582984|Other|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
75906605|NCT03943147|Drug|Placebo|Specified dose on specified days
75906606|NCT03943147|Drug|Mycophenolate Mofetil|Specified dose on specified days
75906607|NCT03536130|Device|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter. Management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms and surgeon preference following standard clinical practice of general thoracic patients
76070327|NCT06061315|Dietary Supplement|Placebo Control intervention: Effect of resistance training in combination with placebo (silicon dioxide), on body composition and muscle strength in untrained men|The effects of placebo consumption in combination with resistance training will be tested
76070328|NCT06061289|Dietary Supplement|SP Detox Program|The production use and disposal of toxic chemicals and synthetic materials have increased the risk of exposure to health-threatening toxins. Causal relationships between toxic chemicals and diseases have been well established. However, many patients endure chronic symptoms that are associated with exposure to toxins before advanced stages of specific diseases are realized. Thus, there is a great demand for noninvasive laboratory tests that can provide timely assessment of chemical exposure and the capability of hepatic detoxification
75460257|NCT01829594|Other|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
76070329|NCT06061276|Procedure|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
75763432|NCT00465179|Drug|Sunitinib Malate|50 mg by mouth daily for 4 weeks, then 2 weeks off.
75763433|NCT00465101|Device|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
75763434|NCT00084136|Drug|Atazanavir|400 mg taken orally daily
75763435|NCT00084136|Drug|Didanosine (enteric-coated)|400 mg taken orally daily
75763436|NCT00084136|Drug|Efavirenz|600 mg taken orally daily
75763437|NCT00084136|Drug|Emtricitabine|200 mg taken orally daily
75763438|NCT00084136|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg/300 mg taken orally once daily
75763439|NCT00084136|Drug|Lamivudine/Zidovudine|150 mg/300 mg taken orally twice daily
75763440|NCT03812380|Drug|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
75763441|NCT03812380|Other|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
76070330|NCT06061276|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75460258|NCT01829607|Other|Functional electrical stimulation of peripheral muscles|
75460259|NCT01829620|Behavioral|TAU|This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.
75613356|NCT05710380|Other|Risk Map Decision Support System (DSS).|The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
75613357|NCT05710380|Radiation|Magnetic Resonance Imaging (MRI)|A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
75613358|NCT05710380|Procedure|Magnetic Resonance Imaging (MRI) Guided Biopsy|A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
75613359|NCT05699655|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
75613360|NCT05699655|Drug|apatinib|Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
75613361|NCT05699655|Drug|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
75613362|NCT05699655|Drug|S-1|Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
75613363|NCT05697042|Behavioral|MY-Skills for Long COVID|8 week online intervention with therapeutic yoga and self-management education
75763442|NCT01583140|Behavioral|Wellness control|Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.
75763443|NCT01583140|Behavioral|Physical Activity Intervention|Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
75763444|NCT01085422|Drug|ABT-888|Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
75763445|NCT01085422|Drug|temozolomide|Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
75763446|NCT01090570|Drug|PLX3397|Once-daily oral capsules
75763447|NCT01085656|Drug|OXi4503|"Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent."
76070331|NCT06061276|Drug|Camrelizumab|200mg intravenously every 2 weeks
76070332|NCT06061263|Other|follow up|collecttion of clinicopathological data from a prespectively collected databse, including survival data.
76070333|NCT06061224|Behavioral|early mobilization (physical therapy)|"The investigators will consult rehabilitation department for Physical Therapy and patients will be grouped as clinically allocation.~Protocols for consideration of initiation The timing is 72 hours after admission to ICU, early mobilization doses and duration is as the protocol of rehabilitation department"
76070334|NCT06061198|Device|a virtual reality device|the patient will wear a masque tht will provide a virtual reality experience using a VR Gear connected to a mobile phone through an application installed on the mobile phone
75763448|NCT03961984|Procedure|Biodesign® anal fistula plug|Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
75763449|NCT03961906|Behavioral|physiotherapy|Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
76025347|NCT05127239|Behavioral|Smartphone Application with lifestyle modification Intervention|The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
76070335|NCT06061120|Device|Recording of an extended high-resolution ECG|Recording of an extended high-resolution ECG
76070336|NCT06061094|Drug|Imatinib|Imatinib 600mg QD plus Chemotherapy
76070337|NCT06061094|Drug|Ponatinib|Ponatinib 45 mg QD plus chemotherapy
76070338|NCT06061094|Drug|Blinatumomab|Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy
76070339|NCT06061094|Other|Indication for stem cell transplantation|Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.
75460260|NCT01829620|Behavioral|CCVT+TAU|"Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, & 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.~Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures."
75460261|NCT01829633|Procedure|Physiotherapy|Shoulder physiotherapy with exercises
75460262|NCT01829659|Drug|Ticagrelor|
75460263|NCT01829672|Radiation|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
75460264|NCT01829685|Drug|Entecavir, Adefovir|
75460265|NCT01829698|Drug|tauroursodeoxycholic|Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
75460266|NCT01829698|Drug|ursodeoxycholic acid|ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
75460267|NCT01829711|Drug|Moxetumomab pasudotox|
75460268|NCT01829711|Drug|IV Bag Protectant for Moxetumomab pasudotox|
75460269|NCT01829763|Drug|injection botox|
75460270|NCT01829776|Behavioral|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
75460271|NCT01829789|Behavioral|Group Community Reinforcement Training for Parents|
75460272|NCT01829789|Behavioral|Individual Community Reinforcement Training for Parents|
75613364|NCT05695079|Other|No cooling (control)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7.
75613365|NCT05695079|Other|Electric fan (low airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 2 m/s to the front of the body.
75763450|NCT01087138|Behavioral|exercise|exercise class 3x's/week
75763451|NCT01087138|Behavioral|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
75763452|NCT00464945|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2,3,4 and 12 months of age
76070340|NCT06061081|Drug|VH3739937|VH3739937 will be administered.
76070341|NCT06061081|Drug|Placebo|Placebo will be administered.
76070342|NCT06061055|Device|Intubation with VentiBronc Anchor endobronchial double-lumen tube|Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).
76070343|NCT06061055|Device|conventional double-lumen intubation|Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
76070344|NCT06061042|Behavioral|Early time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
76070345|NCT06061042|Behavioral|Late time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM
75460273|NCT01829802|Drug|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
75460274|NCT01829802|Drug|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
75460275|NCT01829802|Drug|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
76025348|NCT05127083|Radiation|Patients will be treated with localized PBM with a diode laser|Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
75613366|NCT05695079|Other|Electric fan (high airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 4 m/s to the front of the body.
75460276|NCT01829815|Behavioral|Parents Make the Difference|"The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children."
75460277|NCT01829828|Behavioral|No intervention|This is an observational study with no investigational drug administered.
75460278|NCT01829841|Drug|Famitinib|Famitinib 25 mg p.o. qd
75460279|NCT01829841|Drug|Sunitinib|Sunitinib 50 mg p.o. qd
75613367|NCT05687500|Drug|Glibenclamide|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
75763453|NCT01025219|Genetic|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
75613368|NCT05687500|Biological|Pharmacokinetics study|"0.2 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant ,apparent clearance and volume of distribution"
75763454|NCT01025297|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
75763455|NCT01025375|Dietary Supplement|inulin|10gram/day inulin for 13-day treatment
75763456|NCT01025375|Dietary Supplement|inulin|16gram/day inulin for 13-day treatment
76070346|NCT06061029|Behavioral|Brief Yoga- and Mindfulness-Based Psychoeducation Program|A unique mindfulness psychoeducation program incorporating features of Hatha yoga and mindfulness-based cognitive therapy, plus the main concepts of self-compassion
75613369|NCT05687500|Biological|C-peptide proinsulin ratio|blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio
75613370|NCT05687500|Biological|Blood glucose on fluorinated tube|0.3 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.
75763457|NCT01025375|Dietary Supplement|placebo|16gram/day maltodextrin (placebo) for 13-day treatment
75763458|NCT00464087|Drug|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
75763459|NCT00452699|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
75763460|NCT00452699|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
76025349|NCT04566497|Other|No stress testing|No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic
76025350|NCT04566497|Procedure|stress testing|Systematic annual stress testing during the patient follow up (up to 48 months)
75613371|NCT05687500|Biological|Routine biological monitoring|If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.
75613372|NCT05687500|Biological|glycose holter monitor|glucose levels will be collected with a smarter continuous glucose monitoring system, placed on inclusion and until the end of treatment
75613373|NCT05683184|Drug|[11C]OMAR|For each [11C]OMAR PET scan, up to 20 mCi of [11C]OMAR will be administered.
76025351|NCT05134337|Drug|LOXO-305|Oral LOXO-305
76025352|NCT05134337|Drug|Itraconazole|Oral itraconazole
75613374|NCT05680064|Behavioral|Tongue, lip, chin exercise group|In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.
75763461|NCT00069784|Drug|insulin glargine (HOE901)|Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
76070347|NCT06060990|Other|trace elements|trace elements as biomarkers for response to systemic therapy in metastatic BTCs
75460280|NCT01829867|Drug|sNN0031|
75460281|NCT01829893|Drug|In combination of 0.2mg finasteride and 5mg tamsulosin|oral medication with 240 mL water
75460282|NCT01829893|Drug|GL2701 capsule|oral medication with 240 mL water
75460283|NCT01829906|Behavioral|Multidisciplinary outpatient programme|
75460284|NCT01829906|Behavioral|Inpatient lifestyle programme|
75460285|NCT01829932|Dietary Supplement|Factor Altered Diet|
75460286|NCT01829971|Drug|MRX34|micro RNA therapy
75763462|NCT00069784|Drug|omega-3 polyunsaturated fatty acids (PUFA)|Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
76025353|NCT05134337|Drug|Rifampin|Oral rifampin
75763463|NCT00069784|Drug|placebo|Matching placebo gelatin capsules (containing olive oil) for oral administration
75613375|NCT05676073|Drug|SHEN26 dose 1|Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
75763464|NCT00069784|Device|reusable pen device for insulin injection|
75763465|NCT01087216|Device|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
75763466|NCT01087216|Drug|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
75906608|NCT03617133|Radiation|Increased use of IC/IS technique in BT|In EMBRACE II, the improved therapeutic window (through increased application of IC/IS) will be exploited for tumour dose-(de-)escalation and/or OAR dose de-escalation. In tumours with large residual CTVHR volumes at time of brachytherapy, dose-escalation has the potential to improve local control significantly. In limited size CTVHR volumes dose-de-escalation will be performed since dose de-escalation has minor impact on local control while it has potential to reduce morbidity. The strategy of EMBRACEII is to aim for an application of the IC/IS technique in at least 20% of the patients in each institution. The threshold of 20% is relevant for a classical stage distribution of ~20% IB, ~50% IIB, ~20% IIIB and ~10% others. If a given patient population includes significantly higher proportions of limited or extensive disease, the threshold of 20% IC/IS applications must be adapted.
75906609|NCT03617133|Radiation|Reduction of vaginal source loading|A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
75906610|NCT03617133|Radiation|Systematic utilisation of IMRT|Many institutions deliver 3D conformal radiotherapy (3D CRT) based on a four-field box technique although IMRT has been available for a number of years. The practice in EMBRACEI has been utilisation of IMRT and 3D CRT in 27% and 73% of the patients, respectively. However, EMBRACE morbidity data as well as data published by Mundt et al (Mundt AJ. et al. 2003) indicate that IMRT significantly reduces the incidence of bowel morbidity, and therefore IMRT is considered as instrumental for reducing the incidence of bowel morbidity and with a potential also to be beneficial for urinary morbidity.
75460287|NCT01829984|Other|Verbal and Written Instruction|"Pre-teaching Evaluation: Patient~Pre-teaching Evaluation: Caregiver~o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.~Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection."
75460288|NCT01829984|Other|Verbal and Written Plus Simulation|"Post-injection Evaluation: Patient~Post-injection Evaluation: Caregiver~o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).~Nurse Evaluation: Control~Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study."
76070348|NCT06060964|Other|Breathe Easier Progressive Web Application|The Breathe Easier Progressive Web Application is an 8-week, mindfulness based cancer recovery training program consisting of breathing retraining exercises, mindfulness meditation, gentle yoga, and cancer-specific educational activities, guided by a combination of written instructions, video, and audio. The progressive web application can be downloaded onto any mobile device.
76070349|NCT06060951|Diagnostic Test|Estimated intraperitoneal pressure|"The following anthropometric measurements are required:~Height: measured standing with shoes off~Weight: dry weight should be used~The distance from the decubitus plane to the mid-axillary line was measured~Waist circumference: measured with a tape measure wrapped above the iliac crests around the level of the umbilicus.~The estimated IPP will be assessed using different equations."
75460289|NCT01830010|Drug|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
75613376|NCT05676073|Drug|SHEN26 dose 2|Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
75613377|NCT05676073|Drug|SHEN26 placebo|Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
75613378|NCT05675163|Dietary Supplement|Vitamin K2|(K2VITAL® 1% MCT Oil)
75613379|NCT05675163|Dietary Supplement|Placebo|Sunflower oil
75613380|NCT05672589|Diagnostic Test|Relaxed Rotational Thromboelastometry|Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
75763467|NCT03811834|Drug|Mobocertinib|Mobocertinib capsule, [14C]-Mobocertinib intravenous infusion, [14C]-Mobocertinib oral solution.
75763468|NCT01085890|Behavioral|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
75460290|NCT01830010|Drug|Study Part 2: KRP203 lower dose|
75613381|NCT05672589|Diagnostic Test|Standard Coagulation Tests|Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
75613382|NCT05664334|Biological|IVX-121|75 mcg of IVX-121 without MF59®
75763469|NCT03958084|Diagnostic Test|Straight Leg Raise|The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.
75460291|NCT01830010|Drug|Study Part 2: KRP203 higher dose|
75763470|NCT00090610|Drug|Docetaxel|"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
75763471|NCT00090610|Drug|Carboplatin|"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
75763472|NCT03957772|Procedure|Extrafascial injection|Extrafascial injection of local anaesthetic under ultrasound guidance
75763473|NCT03957772|Procedure|Intrafascial injection|Intrafascial injection of local anaesthetic under ultrasound guidance
75763474|NCT01326988|Procedure|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
75763475|NCT03962296|Drug|Vitis vinifera extract|Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group
75906611|NCT03617133|Radiation|Utilisation of daily IGRT (set-up according to bony structures)|PTV margins of 10 mm to the elective lymph node target are currently applied in many institutions. This margin is related to set-up uncertainties with patient positioning performed based on skin marks. However, currently, most institutions have in-room imaging available which makes it possible to perform daily imaging and couch correction according to fusion on bony anatomy. With daily imaging, bony image fusion, and couch correction, a margin reduction from 10mm to 5mm can be performed without compromising target coverage (Laursen LV. et al. 2012). The 5mm margin reduction has potential to decrease the volume irradiated to 43Gy by approximately 500cm, which is expected to decrease bowel morbidity by ~50%.
76025354|NCT04499495|Other|PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)|"The 5-ASAs of interest in the study are mesalazine (5-ASA); sulfasalazine (5-ASA+sulfapyridine); and balsalazide (5-ASA) and will be grouped together as 5-ASA. For sulfasalazine and balsalazide, the equivalent dose to 5-ASA will be calculated as: balsalazide 6.75g is equivalent to 2.4g of mesalamine; and Sulfasalazine 4g is equivalent to 1.6g of mesalamine.~The dose will be stratified by oral monotherapy, rectal monotherapy, oral and rectal combination therapy."
75613383|NCT05664334|Biological|IVX-241|75 mcg of IVX-241 without MF59®
76070350|NCT06060925|Diagnostic Test|Ultrasound imaging|B-mode, color Doppler, shear wave elastography
75613384|NCT05664334|Biological|Placebo|Diluent
75613385|NCT05664334|Biological|IVX-121|75 mcg of IVX-121, without MF59®
75613386|NCT05664334|Biological|IVX-241|150 mcg IVX-241, without MF59®
75613387|NCT05664334|Biological|IVX-241|225 mcg of IVX-241, without MF59®
75613388|NCT05664334|Biological|IVX-121|75 mcg of IVX-121, with MF59®
75613389|NCT05664334|Biological|IVX-241|75 mcg of IVX-241, with MF59®
75613390|NCT05664334|Biological|IVX-241|150 mcg IVX-241, with MF59®
75613391|NCT05664334|Other|MF59®|MF59® as an adjuvant
75613392|NCT05655156|Device|OrthoPure XT|"Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~Size 5~- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~Size 6~- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~Size 8~Primary ACL reconstruction where autograft tissue is not suitable~Revision ACL reconstruction~Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~Size 10~Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)"
76070351|NCT06060925|Diagnostic Test|Bioimpedance spectroscopy|Multifrequency bioimpedance spectroscopy
75613394|NCT05636449|Other|Group Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
75613395|NCT05636449|Other|Group Periarticular Infiltration|A total volume of 80 ml local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
76070352|NCT06060925|Diagnostic Test|Electromyography|High density electromyography
76070353|NCT06060925|Diagnostic Test|Physical examination|Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing
76070354|NCT06060899|Procedure|Pneumoperitoneum 14mmHg|Performing surgery in 14mmHg pneumoperitoneum pressure
76070355|NCT06060899|Procedure|Pneumoperitoneum 10mmHg|Performing surgery in 10mmHg pneumoperitoneum pressure
76070356|NCT06060886|Drug|Aripiprazole|Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
75763476|NCT03962296|Drug|Calcium Dobesilate|Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group
75763477|NCT03962296|Drug|Placebo|Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
75763478|NCT01086046|Drug|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days."
76070357|NCT06060886|Drug|Paliperidone|Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
76070358|NCT06060834|Dietary Supplement|Topical Botanical Agent|Cayenne Pepper, Coconut Water, Kelp, Lemon Juice, Oxynex LM, Potassium Sorbate, Red Palm Oil, Rose Water, Saw Palmetto, vitamin C
75460292|NCT01830075|Behavioral|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
75460293|NCT01830153|Drug|RAD001|
76070359|NCT06060808|Genetic|gene polymorphism|gene polymorphism of NFKBIA and PTPN22 genes
76070360|NCT06060795|Diagnostic Test|Electro-conductance measurement|Interventions are done to diagnose Autonomic Nervous system Troubles
76070361|NCT06060782|Drug|Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen|"All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days"
75460294|NCT01830231|Drug|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
75460295|NCT01830231|Drug|Vinflunine|"Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~280 mg/m2 in patients aged >75 - ≤80 years or with PS 1 or prior pelvic radiation,~250 mg/m2 in patients aged >80 years."
75613396|NCT05618509|Device|STENDO session|"It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. The capacity for physical exercise is potentially improved.~STENDO : 45 minutes, 2 legs and the pelvis, pression of 65mm Hg"
75613397|NCT05618509|Other|A six-minute walking distance test|Before and after STENDO session, the patient has to walk 6 minutes in a flat corridor (30m long)
75613398|NCT05618509|Other|Near Infrared Spectroscopy|The goal is to measure the evolution of the oxygen consumption of the right leg during an effort on a bicycle at constant power for 5 minutes.
75763479|NCT01090648|Drug|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
75763480|NCT04224064|Diagnostic Test|Blood sampling|Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
75763481|NCT03741244|Drug|apatinib|Apatinib is an oral small molecule antiangiogenic targeted drug developed in China. More and more studies found that antiangiogenic drugs have outstanding performance in treating glioma. From the perspective of clinical and molecular mechanism, the combination of Temozolomide and apatinib may have synergistic effect especially to TMZ insensitivity patients(MGMT gene promoter unmethylated) and poor prognosis (IDH1 wild type) population
75763482|NCT03741244|Drug|Temozolomide|Temozolomide，alkylating agent， is the standard first-line chemotherapy of glioma.
75763483|NCT03962218|Procedure|aquatic physiotherapy|specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
76070362|NCT06060743|Other|INS-MOBILE: Mobile Application Developed for Insulin Use|After determining the application and control groups in the research, the purpose of the research was explained to both groups. Participants were informed that the application would last 1 month. It was explained that data collection forms would be filled out before the application (Z0), on the 14th day of the application (Z1), and on the 28th day of the application (Z2). On the 0th and 28th days of the follow-up, the participants' insulin administration skills were evaluated face-to-face by the researcher using the Insulin Therapy Skill Observation Form. In addition to the standard training given by diabetes training nurses, a mobile application on insulin use was sent to the application group, while the control group was given standard training only by diabetes training nurses.
76070363|NCT06060717|Device|F&P Caramel|Nasal mask
76070364|NCT06060574|Device|Platelet rich fibrin device|"Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes."
76070365|NCT06060561|Other|Non-Interventional Study|Non-interventional study
75613399|NCT05618509|Device|STENDO placebo|STENDO placebo : 45 minutes, on 2 legs and the pelvis, pression of 10 mmHg
75613400|NCT05616793|Biological|AAV8.hLCA5|Adeno-associated virus vector expressing human LCA5 gene
75763484|NCT01090726|Device|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
75763485|NCT01090726|Device|Airtraq|Airtraq being used for the actual intubation
75460296|NCT01830244|Drug|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
75906612|NCT03617133|Radiation|EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring|New target concepts are introduced for EBRT related to primary tumor: initial CTV-T, initial CTV-HR, initial CTV-LR and ITV-LR. Use of this novel contouring approach in conjunction with available MRI allows to target safely the visible tumor (CTV-T) and the high risk region (CTV-HRintitial) while consenting for dose to a low risk region (CTV-LRinitial). Anatomical changes due to organ filling variation and cervix/uterus position are considered. ITV-LR is outlined using planning scan and MR images in patients with MRI in treating position while a fixed margin is added to the CTV-LR initial in patients with only diagnostic MRI. New concepts are introduced for OAR contouring. Bowel loops are outlined in one volume restricted to the outer contour, including the mesenterium, for better approximation of the bowel volume and dose constraints. Rectum/sigmoid structures are contoured distinctly. Vaginal lower border is 2,5cm from the caudal extend of the tumor (2cm ITV-LR initial + 0,5cm PTV).
75906613|NCT03617133|Radiation|EBRT dose prescription and reporting|There is currently a significant variation with regard to EBRT dose and fractionation in the EMBRACE study with doses ranging from 45Gy to 50Gy and being delivered in 25-30 fractions. Furthermore, there is a wide variety of lymph node boosting strategies. In EMBRACEII, the EBRT dose and fractionation to the elective lymph node CTV and initial CTV-T is fixed at 45Gy in 25 fractions, and lymph node boosting must be performed as a simultaneous integrated boost. The dose de-escalation from 50Gy to 45Gy has potential to reduce morbidity. A system of reporting dose to targets and OARs is introduced in terms of dose volume parameters and a system of point dose reporting for the vagina.
75906614|NCT03617133|Radiation|Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence|"EMBRACEII applies a risk adapted target concept for nodal CTV. This target concept is based on pattern of nodal recurrence analysis which shows 50% of recurrences beyond the classical L5/S1 cranial pelvic field border. A target volume Large Pelvis is defined for intermediate risk patients and includes internal, external, common iliac, obturator and presacral nodes. For high risk patients, defined as common iliac or >2 nodes involved, the para-aortic region is included. For low risk patients, defined as stage IA/IB1/IIA1, N0, small cell carcinoma (SCC), no uterine invasion, Small Pelvis is defined which is Large Pelvis without common iliac nodes. Intermediate risk is defined as not high and not low risk."
75906615|NCT03617133|Drug|Systemic application of simultaneous chemotherapy|According to international standard and evidence, simultaneous chemotherapy (CHT) (min. 5x40 mg/m2 cis Platinum) was prescribed in the EMBRACE protocol for all patients, who qualify for its administration. Certain rules were given for adaption according to international guidelines. 90-95% of EMBRACE patients received simultaneous CHT. Most of the EMBRACE cohort is consecutive patients representing the cervix cancer patient population in the respective centers. About 70% of patients received ≥5 cycles, while 30% received 0-4 cycles. CHT has impact on systemic control, which is pronounced in high risk patients (node positive and/or stage III/IV) with a 20% difference in systemic recurrence. A center effect has been found in the ability to administer chemotherapy with 15-85% of the patients receiving ≥5 cycles of CHT. To reach optimal outcome, particularly in the high risk group, the EMBRACEII protocol also focusses on appropriate administration of CHT following international guidelines.
76070366|NCT06060548|Other|Monitoring of patients presenting with PVCs|Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs to assess for the incidence of all cardiac arrhythmias. They will also be evaluated for clinical, biomarker and radiological evidence of myocarditis to understand association with incident arrhythmias.
76070367|NCT06060535|Behavioral|Suicide Attempt Risk Model Care Pathway|The suicide attempt risk model uses documented histories of medical and psychiatric diagnoses, medications, and health service utilization to predict risk of a suicide attempt in the 90 days following an outpatient visit in behavioral health clinics.
76070368|NCT06060483|Device|CGM|Wear CGM continuously and manage patients based on CGM. The treatment goals are TIR>70%, TBR<4%, TAR<25%, and HbA1c<7.0%. After the treatment reaches the standard, CGM is worn every six months.
76070369|NCT06060444|Other|Telemedicine Consult|Neurological consultation completed remotely
76070370|NCT06060444|Other|In-person Consult|Neurological consultation completed in-person
75460297|NCT01830270|Drug|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
75763486|NCT00463385|Drug|Pomalidomide|
75763487|NCT00463385|Drug|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
75763488|NCT00463385|Drug|Placebo to pomalidomide|Matching pomalidomide placebo tablets
75763489|NCT00463385|Drug|Placebo to prednisone|Matching prednisone placebo tablets
75763490|NCT01022489|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
75763491|NCT01022489|Device|Placebo (sham coil) treatment|Sham coil treatment
75460298|NCT01830270|Drug|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
75460299|NCT01830270|Drug|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
75460300|NCT01830270|Procedure|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
75460301|NCT01830504|Drug|BKM120|"BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment."
75460302|NCT01830530|Drug|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
75763492|NCT00463229|Other|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
75763493|NCT03839693|Biological|botulinum toxin, Type A|topical liniment
75763494|NCT03839693|Biological|Vehicle|Vehicle Formulation
75763495|NCT00068692|Radiation|Radiotherapy|Undergo external beam radiation therapy
75763496|NCT00068692|Drug|Fluorouracil|Given IV
75763497|NCT00068692|Drug|Leucovorin Calcium|Given IV
75906616|NCT03617133|Other|Reduction of overall treatment time|Several studies indicate that maintaining an overall treatment time (OTT) of <=50 days is important for local control. RetroEMBRACE data confirms that OTT remains of importance in the realm of IGABT. As there is significant variation of OTT across patients and institutions in retroEMBRACE, the EMBRACEII study aims to reduce the OTT so that the majority of patients (>80%) will adhere to the <=50 day threshold. The measures to reduce OTT in EMBRACE is to systematically apply 25 fractions of EBRT including lymph node boost, and furthermore to carefully plan the BT schedule, so that brachytherapy is delivered towards the end of EBRT and/or directly after EBRT.
75906617|NCT02182674|Drug|Placebo Combivent HFA|
75906618|NCT02182674|Drug|Combivent HFA|
75906619|NCT02182674|Drug|Combivent (CFC)|
75906620|NCT02182674|Drug|Placebo Combivent (CFC)|
76070371|NCT06060431|Other|Pain Science Education|The Pain Science Education program consists of two workshops, 90 and 60 minutes in length, one week apart. The content of the workshops aims to provide students with information about the contemporary pain paradigm and to re-conceptualize pain.
76070372|NCT06060379|Other|GiochiAMO a 626|The subjects of the intervention group will play three different games: a role-playing game, a card game and a board game.
76070373|NCT06060340|Drug|class II furcation defects management using propolis|"A full thickness flap will be elevated using muco-periosteal elevator to gain full access to the furcation defect. Then granulomatous tissue will be debrided from the osseous defect and the root surfaces will be carefully scaled and root planed by ultrasonic and hand instruments.~The diagnosis of the class II furcation defect was then confirmed using a Naber's probe.~Propolis preparation:~Pure propolis will then be mixed with saline to give a proper mix/consistency and applied to completely fill the furcation defect."
76070374|NCT06060327|Drug|Tranexamic acid|Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.
76070375|NCT06060314|Procedure|Conservative Approach|Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred
75906621|NCT02182752|Drug|Ropivacaine - Tramadol|Interscalene block using ropivacaine plus tramadol
75906622|NCT02182752|Drug|Ropivacaine|Interscalene block using ropivacaine
75906623|NCT03703258|Behavioral|App-based intervention|A app-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults
75906624|NCT02186184|Device|Orthokeratology|
75906625|NCT02186184|Device|Spectacle|
75906626|NCT03572439|Diagnostic Test|Sensory block level check using ice|Patients are asked to report when the ice feels as cold as it does on the forehead.
76070376|NCT06060314|Procedure|Surgical Approach|Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)
76070377|NCT06060301|Drug|sulfasalazine 500 MG|The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
76070378|NCT06060301|Drug|corticosteroids|The patients will use topical corticosteroids 4 times per day.
75460303|NCT01830530|Drug|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
75460304|NCT01830530|Drug|placebo|two tablets daily in the morning
75763498|NCT00068692|Drug|Oxaliplatin|Given IV
75763499|NCT00068692|Drug|Irinotecan|Given IV
75763500|NCT00463151|Drug|rebamipide|0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
75763501|NCT01025687|Dietary Supplement|water with noncalorie sweetener|
75763502|NCT01025687|Dietary Supplement|water with glucose|
75763503|NCT01025687|Behavioral|TV program showed while feeding|
75763504|NCT01025687|Behavioral|TV program showed while feeding|
75763505|NCT00068380|Drug|imatinib mesylate|Given orally
75763506|NCT00068380|Other|laboratory biomarker analysis|Correlative studies
75460305|NCT01830907|Dietary Supplement|carbohydrates|
75460306|NCT01830907|Dietary Supplement|vitamins|
75460307|NCT01831037|Other|Regression of fibrosis|Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (>50% of cases).
75763507|NCT01087684|Procedure|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
75763508|NCT01087684|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
75763509|NCT00067990|Drug|Losartan 100mg|To be started within three months of transplant and continued for five years.
75763510|NCT00067990|Drug|Placebo|No treatment with continued follow-up for five years.
75763511|NCT01086436|Biological|Rotarix ™|Oral, single dose
75906627|NCT03572361|Biological|V3-MOMMO|Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months
75906628|NCT03730987|Behavioral|HoMBReS intervention|Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
75763512|NCT01086436|Biological|Placebo|Oral, single dose
75763513|NCT01090804|Device|BreatheMAX breathing device|secretion clearance, breathing exercise
75763514|NCT00090220|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1
75763515|NCT00090220|Biological|Comparator: Placebo|Placebo intramuscular injection in three 0.5 mL doses over 6 months.
75763516|NCT00263328|Drug|Tacrolimus|Standard of care
75763517|NCT00263328|Drug|CP-690,550|CP-690,550 5 mg BID
75763518|NCT00263328|Drug|CP-690,550|CP-690,550 10 mg BID
75763519|NCT03741660|Dietary Supplement|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ [100kcal] of glucommanan)
75763520|NCT03741660|Dietary Supplement|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
75763521|NCT00262860|Drug|bortezomib|
75460308|NCT01831037|Other|Specific risk factors related to hepatocellular carcinoma|Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
75613401|NCT05601843|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS pads will be applied in a frame pattern around the area of maximal pain, as pointed out by the patient. The pads will be no more than 6 cm and no less than 3 cm away from the subjective area of maximal pain. The frequency of the TENS machine will be set to 100 Hz and the patient will be instructed on how to increase and decrease the amplitude based on their comfort. The patient will also be instructed on how to turn off the machine if they wish for any reason. Research assistants will be standing by during the intervention period to intervene if the patient requires assistance with the device.
75763522|NCT00262860|Drug|gemcitabine hydrochloride|
76070379|NCT06060223|Other|Teach Back Method|"Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary."
76070380|NCT06060184|Genetic|Next-Generation Sequencing (NGS)|Sequencing of genomes (Long read NGS)
76070381|NCT06060158|Behavioral|Cognitive Behavioral Therapy for Insomnia|6 sessions
76070382|NCT06060145|Other|Plants placed in an office environment|The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
76070383|NCT06060145|Other|Devoid of any plant presence in an office environment|Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
75613402|NCT05601323|Device|Suizenji|HIFU treatment
75613403|NCT05601323|Drug|Nal-IRI/FL|Nanoliposomal irinotecan, Fluorouracil, Levofolinate
75613404|NCT05601323|Drug|mFOLFIRINOX|Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
76070384|NCT06060132|Drug|Sodium arsenite chloride injection|Patient use of arsenite sodium chloride injection
75613405|NCT05601323|Drug|Gem/nab-PTX|Gemcitabine, nab-Paclitaxel
75613406|NCT05596786|Drug|Rituximab|One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
75763523|NCT00236184|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
75763524|NCT00236184|Other|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
75763525|NCT00296504|Drug|fosamprenavir (GW433908)|
75763526|NCT00296504|Drug|ritonavir|
75460309|NCT01831050|Biological|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
75763527|NCT00313820|Drug|Pregabalin|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
76070385|NCT06060119|Device|microneedling|The operative sites will be anaesthetized with 2% lignocaine hydrochloride with adrenaline(1:80,000).Electric microneedling pen device model THAPPINKTM is used. Microneedling is carried out on the isolated site involving one tooth mesially and distally and 1.5mm apical to marginal gingiva each for 30-40 second intermittently. When pin point bleeding observed on the area of gingiva it is irrigated with sterile saline solution. Patient will be instructed to refrain from consuming hot beverage and brushing in that area for one day to avoid mechanical trauma. A total of 4 session of micro needling procedure will be carried out in one subject at 10 days intervals upto 40days
76070386|NCT06060106|Procedure|Endoscopic submucosal dissection|The patient was positioned in the left lateral decubitus position.Marking dots were made with a dual knife/hybrid knife around the lesion, and a solution of glycerin fructose with indigo carmine was injected into the submucosal layer to lift the lesion. Finally, after pre-cutting of the mucosal and submucosal layers around the lesion and dissection of the submucosa, the lesion was removed en bloc.
76070387|NCT06060106|Procedure|Esophagectomy|The main surgical methods of esophagectomy include the McKeown operation, Lvor-lewis, Sweet and minimally invasive radical resection of esophageal cancer (MIE)
75763528|NCT00313820|Drug|Placebo|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
75763529|NCT00462761|Drug|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
75763530|NCT01065974|Behavioral|Behavior Therapy|Weight loss using CBT and continued CBT during weight loss maintenance.
75763531|NCT01065974|Dietary Supplement|Meal Replacements|Weight loss using CBT and meal replacements.
75763532|NCT01065974|Behavioral|Nutritrol|To make widespread nutritional changes to participants personal food environments.
75906629|NCT03730987|Behavioral|Families Talking Together (FTT)|The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
75906630|NCT03730987|Behavioral|Diabetes Prevention Intervention|Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
76070388|NCT06060093|Dietary Supplement|Placebo|Water, 5% collagen(w/w), octoacetate (1 mM)
75460310|NCT01831050|Biological|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
75460311|NCT01831050|Biological|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
75460312|NCT01831050|Biological|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
75906631|NCT02186340|Procedure|Inspiratory muscle training|
75906632|NCT03572205|Dietary Supplement|LA|The source of linoleic acid (LA) will be sunflower oil (62-63 % LA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
75763533|NCT00235872|Biological|adalimumab|40 mg eow, sc
75613407|NCT05596786|Other|Placebo|One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
75763534|NCT00461981|Biological|TIV, Trivalent Inactivated Influenza Virus Vaccine|0.25 mL will be administered intramuscularly for each of two doses
75763535|NCT00461981|Biological|FluMist, Influenza Virus Vaccine Live|0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
75763536|NCT03970122|Drug|GFB-887|IMP
75763537|NCT03970122|Drug|Placebo|Matching
75763538|NCT00296036|Dietary Supplement|pyridoxine hydrochloride|Given orally
75763539|NCT00296036|Drug|urea/lactic acid-based topical cream|Applied topically
75763540|NCT00296036|Other|placebo|Given orally or applied topically
75763541|NCT01072890|Drug|Temsirolimus, Pazopanib|Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
75460313|NCT01831050|Biological|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
75460314|NCT01831050|Biological|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India [SII]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
75613408|NCT05582707|Drug|Pioglitazone 15mg|Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
76070389|NCT06060093|Dietary Supplement|Ketone ester|A total of 75g ketone ester supplementation will be administered in 3 bouts of 25g in order to establish intermittent exogenous ketosis: twice immediately after training, and one 30 minutes before sleep. The ketone ester used is (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
75613409|NCT05571306|Other|four core components care|"The intervention progresses throughout the first three months for the recently diagnosed T2DM patients and is divided into four core components: 1) Improve of cross-sectoral communication and information sharing, 2) ensure systematism in care, 3) guarantee participation at a one-stop-shop and a start-up conversation at the municipality, and 4) improve patients coping skills."
75613410|NCT05566392|Diagnostic Test|Brain MRI|Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation
75763542|NCT00089674|Drug|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
75763543|NCT00089674|Drug|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
76070390|NCT06060080|Drug|pegylated recombinant human granulocyte-colony stimulating factor|Lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
75763544|NCT01090882|Drug|Bupivocaine|20ml 0.25% at beginning of operation
75763545|NCT01090882|Drug|0.9% normal saline solution|20ml 0.9% NaCl
75763546|NCT04187482|Other|Exercise training|All participants with DM1 will undergo a 12-week aerobic exercise training intervention on a cycle ergometer
75763547|NCT01090960|Drug|GDC-0068|Oral repeating dose
75763548|NCT03976388|Device|Clinical Virtual Simulator|Interactive medical case delivered using touch-sensitive screens in small group sessions.
75763549|NCT03976388|Other|Small-Group Discussion|Small group discussion led by a physician.
75763550|NCT01067066|Drug|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
76070391|NCT06060067|Biological|TDV|TDV SC injection on Day 1 and Day 90 of the study
76070392|NCT06060067|Biological|Placebo|Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
76070393|NCT06060015|Drug|5mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg
76070394|NCT06060015|Drug|10mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10 mg
76070395|NCT06060002|Procedure|Group A - Stent exchange if cholecystectomy dated beyond 3 months|Stent removal and cholangiogram and stone clearance (if recurrent stone/s is/are found). Stent exchange if cholecystectomy dated beyond 3 months
75763551|NCT01067066|Drug|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m^2 by mouth (PO) daily, Day 1 to 5.
75763552|NCT01069250|Other|There are no interventions in this study|
75763553|NCT00313586|Drug|Azacitidine|Given SC
75763554|NCT00313586|Drug|Entinostat|Given PO
75763555|NCT00313586|Other|Laboratory Biomarker Analysis|Correlative studies
75763556|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 200 mg orally BID interrupted dosing
75460315|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
75613411|NCT05564611|Drug|Omalizumab 150mg|A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
75613412|NCT05559164|Drug|Lipitor 40mg Tablet|LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
75613413|NCT05553405|Drug|Intralipid Infusion|Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids. It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
75613414|NCT05544760|Other|CatchU Intervention|The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
75613415|NCT05543083|Behavioral|Cognitive-Behavioral Therapy followed by Exercise Training|6-week group CBT (cognitive-behavioral therapy; 1 hour/week for 6 weeks) followed by 6-week group exercise training (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
75763557|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg orally BID interrupted dosing
75763558|NCT01069328|Drug|Bevacizumab|Bevacizumab 2.5 mg/kg intravenously
75763559|NCT01069328|Drug|Bevacizumab|Bevacizumab 5 mg/kg intravenously
75763560|NCT01069328|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenously
75763561|NCT01069328|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenously
75763562|NCT01069328|Drug|Paclitaxel|Paclitaxel 200 mg/m² intravenously
75763563|NCT01069328|Drug|Carboplatin|Carboplatin AUC 6 intravenously
75763564|NCT01067222|Drug|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
75763565|NCT01067222|Drug|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
75763566|NCT01067222|Drug|Placebo|Placebo oral capsules, 4 capsules per day
75763567|NCT00312572|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
75763568|NCT01067300|Procedure|Transplantation of unrelated cord blood unit(s)|Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
75763569|NCT01067378|Other|Peer-led debriefing|
75763570|NCT01067378|Other|Expert instructor debriefing|
75906633|NCT03572205|Dietary Supplement|ALA|The source of alpha-linolenic acid (ALA) will be camelina sativa oil (30-35 % ALA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
75763571|NCT00290888|Procedure|Acromioplasty|
75763572|NCT01069640|Biological|HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
75763573|NCT00290732|Drug|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
75906634|NCT02181192|Device|PET/CT|PET/CT
75906635|NCT02181192|Radiation|Instant Radiotherapy according to guidelines|Instant Radiotherapy according to guidelines
75906636|NCT02181192|Radiation|Radiotherapy after achievement of PSA marginal value|Radiotherapy after achievement of PSA marginal value
75763574|NCT00290732|Drug|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
75763575|NCT00312494|Drug|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
75613416|NCT05543083|Behavioral|Exercise Training followed by Cognitive-Behavioral Therapy|6-week group exercise training (1 hour/week for 6 weeks) followed by 6-week group CBT (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
75763576|NCT00312494|Drug|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
75763577|NCT00312494|Drug|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
75763578|NCT00312338|Drug|VIGAMOX|1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
75763579|NCT00290498|Drug|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
75763580|NCT00290498|Drug|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
75763581|NCT00290498|Drug|Doxorubicin|Arm A: Doxorubicin 50 mg/m^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
75763582|NCT00290498|Drug|Vincristine|"Arm A: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
75763583|NCT00290498|Drug|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
75763584|NCT00290498|Drug|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
75906637|NCT03536598|Drug|Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg|
75906638|NCT03536598|Drug|Amlodipine 10 mg + Valsartan 160 mg|
75906639|NCT03536598|Drug|Valsartan 160 mg + Rosuvastatin 20 mg|
75906640|NCT03574467|Behavioral|Bobath Neurodevelopmental Treatment Approach|The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.
75613417|NCT05543083|Behavioral|Cognitive-Behavioral Therapy Only|6-week group CBT (1 hour/week for 6 weeks), with continuation of group CBT for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
75613418|NCT05543083|Behavioral|Exercise Training Only|6-week group exercise training (1 hour/week for 6 weeks), with continuation of group exercise for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
75763585|NCT00290498|Drug|Cytarabine|Arm B: Cytarabine 3 g/m^2 by vein over 2 hours every 12 hours X 4 doses on days 3 & 4, cycle 2 and alternating cycles.
75763586|NCT00290498|Drug|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
75763587|NCT01069796|Drug|Paclitaxel|80 mg/m² weekly
75763588|NCT01069796|Drug|Bevacizumab|10 mg/kg d1 d15
75763589|NCT01069796|Drug|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 & 3
75763590|NCT01067534|Drug|Salbutamol|Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
75763591|NCT02532530|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
75763592|NCT00451451|Drug|BG00012|
75763593|NCT00451451|Drug|Placebo|
75763594|NCT00451451|Drug|Glatiramer Acetate|
75763595|NCT01062698|Drug|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
75763596|NCT01062698|Procedure|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
75763597|NCT03976232|Device|Trans cranial Direct Current Stimulation (tDCS)|Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.
75763598|NCT03976232|Other|Craniosacral therapy (CST)|Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.
75763599|NCT03976232|Other|tDCS+ CST|This group will receive tDCS along with CST
75763600|NCT03977324|Procedure|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
75906641|NCT03536988|Procedure|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of IPAA will be performed.
75906642|NCT03536988|Procedure|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of IPAA will be performed.
75763601|NCT03977324|Procedure|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
75763602|NCT01069874|Dietary Supplement|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
75613419|NCT05541848|Other|Cervical supervised exercises with laser-guided feedback (ELGF)|"Cervical supervised exercises with laser-guided feedback (ELGF) is defined as a procedure of proprioceptive training based on a type of therapeutic exercise that provides external feedback to exercise, achieving an improvement in range of motion and postural control in subjects with spinal pain. For the performance of the exercise program, Motion Guidance Clinician Kit (Motion Guidance LLC, Denver, CO, USA.) was used. The program consisted of 4 exercises, which progressed in difficulty according to the tolerance achieved over the course of the sessions: a) Maintaining the head position (cervical stabilisation); b) Cervical flexion-extension; c) Right-left rotations; d) Right-left lateral-flexions. Each exercise consisted of 4 series of 8 repetitions, except the first one, in which the head position is maintained by pointing the laser at the centre of the panel for 30 seconds (4 series). The average time to complete the entire program did not exceed 14 minutes."
75763603|NCT01069874|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
75763604|NCT01022645|Device|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
75763605|NCT01022645|Device|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
75763606|NCT01025765|Drug|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
75763607|NCT01025765|Drug|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
75906643|NCT03576963|Drug|Guadecitabine|Given SC
75763608|NCT01025765|Drug|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
75763609|NCT03773159|Biological|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
75763610|NCT03824912|Drug|Ketoconazole Cream 2%|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
75763611|NCT03824912|Drug|Ketoconazole Cream 2% (G&W Laboratories Inc.)|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
75763612|NCT03824912|Drug|Placebo|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
75763613|NCT01022879|Procedure|vitrectomy|
75906644|NCT03576963|Biological|Nivolumab|Given IV
75906645|NCT02186496|Drug|CKD-330 8/5mg|
75906646|NCT02186496|Drug|Candesartan 8mg and Amlodipine 5mg|
75906647|NCT05615194|Drug|Dexmedetomidine|0.6 mcg/kg in infusion over 10 minutes
75906648|NCT05615194|Drug|Placebo|Volume equivalent in infusion over 10 minutes
75906649|NCT03572127|Other|Diet|High protein diet derived from either animal or non-animal sources.
75906650|NCT02186574|Drug|Tenofovir disoproxil|
75906651|NCT02186574|Drug|Placebo Oral Tablet|
75906652|NCT04974268|Other|Specific supervised exercise and weight loss program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal, manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
75906653|NCT02181270|Other|high intensity exercise|Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be ~45 minutes
75763614|NCT01069952|Device|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
75763615|NCT03765281|Other|Navigation|Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
75763616|NCT03765281|Other|Resource List|Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
75763617|NCT01062776|Biological|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
75763618|NCT01062776|Biological|Placebo|No dehydration is induced
76070396|NCT06060002|Diagnostic Test|Group B - Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months|Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months to see recurrence of CDL. ERC and stone clearance (if recurrent stone/s found on EUS/MRCP/USG abdomen)
75763619|NCT01070030|Drug|Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)|The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
75763620|NCT01025999|Other|No intervention|
75460316|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
75460317|NCT01831440|Behavioral|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
75460318|NCT01831440|Drug|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
75763621|NCT02532218|Drug|ARI-3037MO|Lipid lowering treatment Statins
75763622|NCT01022957|Genetic|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
75460319|NCT01831648|Other|Blood sample|
75460320|NCT01831908|Other|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
75460321|NCT01831986|Dietary Supplement|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
75460322|NCT01831986|Other|Placebo|Caps
75460323|NCT01832311|Drug|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
75763623|NCT00461123|Drug|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
75763624|NCT00461123|Drug|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
75763625|NCT00290342|Biological|DTPa-IPV|3 intramuscular injections
75763626|NCT00290342|Biological|DTPa|3 intramuscular injections
75763627|NCT00290342|Biological|IMOVAX Polio®|3 intramuscular injections
75763628|NCT00460811|Drug|Linaclotide Acetate|Oral, once daily
75763629|NCT00460811|Drug|Matching placebo|Oral, once daily
75763630|NCT00290186|Device|Hyperbaric Oxygen Treatment|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
75763631|NCT00290186|Device|Hyperbaric Air Treatment|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
76070397|NCT06059989|Drug|Infliximab subcutaneous|Mono and combination therapy group
76070398|NCT06059989|Drug|Immunosuppressive Agents|Combination group only
76070399|NCT06059950|Behavioral|Mindfulness Flow Program|The mindfulness flow program (MFP) consisted of eleven 60-minute sessions via Zoom, with one session per week. Additionally, a 120-minute in-person sport-specific session were conducted.
76070400|NCT06059937|Other|Patient with pre-eclampsia|Cardiovascular risk assessment by the general practitioner in the year following pre-eclampsia
75613420|NCT05541848|Other|Interferential current electro massage (ICE)|Interferential current electro-massage (ICE) is defined as a technique which combines simultaneously manual therapy (massage) and ICT. We used a current bipolar mode, using a carrier frequency of 4000 Hz at constant voltage and an amplitude-modulated frequency of 100 Hz (Sonopuls 692®; Enraf-Nonius BV, Rotterdam, The Netherlands), was administered. The intensity was set to provide a strong and comfortable tingling, without evoking muscle twitches even though a slight vibration (fasciculation) was allowed. The sequence combined (A) superficial stroke over the neck-shoulder for 30-45 seconds; (B) deep sliding movements, alone or (C) combined with shoulder drop, for 4-5 minutes; (D) bilateral kneading of the upper trapezius (4-5 minutes); (E) slight stretching of cervical muscles (upper trapezius, sternocleidomastoid, and levator scapulae); and repetition of step (A). The electro-massage protocol lasted 15 minutes.
75613421|NCT05539937|Other|Quality of life questionnaire|Before TAVI, 30 days, 6 months and twelve months after TAVI, patients will answer TASQ questionnaire,
75763632|NCT01325636|Other|Cell therapy|"Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.~A second injection could be made at day 21"
75763633|NCT01070108|Drug|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
75763634|NCT01070108|Drug|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
75763635|NCT01070108|Drug|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
75763636|NCT01067690|Drug|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
75763637|NCT03977246|Behavioral|Open-placebo|Application of the open-placebo intervention
75906654|NCT02181270|Other|continuous moderate exercise|Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
75906655|NCT03066700|Device|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
75906656|NCT02240901|Device|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
75613422|NCT05526768|Device|VITLS Device|VITLS remote vital sign monitoring device will be applied to consented patients so data obtained by the device can be compared to data obtained by traditional inpatient hospital monitoring devices.
75613423|NCT05511701|Behavioral|CHW Care Model|The CHW will measure the participant's blood pressure (BP) and along with other demographic variables, calculate the participant's absolute CVD risk score, using the mHealth (mobile health) app. If the participant's risk is > 10%, they are asked to sign the informed consent. The CHW will electronically schedule an appointment at the PCC. The participant will receive a SMS appointment confirmation. S/he will have their cholesterol tested by nurses using a home POCT. Nurses will repeat POCT lipids and BP measurements at all PCC visits and other clinical information will be entered into the electronic decision support tool that will generate a guideline based treatment recommendation for the physician. CHWs will make up to four home visits or telephone calls to intervention participants over the 12 month study period to check on medication adherence, as well as to determine if the patient is in possession of the medication
75763638|NCT03977246|Behavioral|Control|Application of the control session
75763639|NCT03977480|Drug|Hemay007|Hemay007 will be orally administered.
75906657|NCT02240901|Device|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
76070401|NCT06059924|Other|Anastomotic leakage|Anastomotic leakage was defined as a defect of the intestinal wall at the anastomotic site leading to a communication between the intra- and extraluminal compartments. It was diagnosed by clinical, laboratory, radiological (ultrasound, endosonography, computed tomography), endoscopic, and/or surgical findings.
76070402|NCT06059898|Device|GBR surgery including membrane placement|After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured
75763640|NCT03977480|Drug|Placebo|Placebo
75763641|NCT03977090|Drug|Geptanolimab Injection|GB226 3mg/kg, q2w, iv.
75763642|NCT03977090|Drug|Fruquintinib|Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off
75906658|NCT03066544|Drug|Bupivacaine|Nerve blocks with bupivacaine will be performed at initial visit
75906659|NCT03066544|Drug|Naratriptan Pill|one pill will be administered twice each day for 5 days
75906660|NCT03066544|Drug|Dexamethasone|one tablet will be administered twice each day for 3 days
75906661|NCT03066544|Drug|Ketorolac|ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
75906662|NCT03574311|Drug|Ferric carboxymaltose|A single dose of drug or placebo is administered preoperatively to participants
75906663|NCT03574311|Other|Physiological saline|Single infusion 100 ml physiological saline infusion preoperatively
76070403|NCT06059898|Procedure|Biopsy|After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration
76070404|NCT06059885|Drug|Tislelizumab plus tyrosine kinase inhibitor|Lenvatinib, tyrosine kinase inhibitor (TKIs)
75763643|NCT01067924|Behavioral|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
75613424|NCT05511701|Behavioral|Usual Care Model|All study participants will be visited in their home by a CHW and a nurse for eligibility assessment, screening, and enrollment. The CHW will then measure the participant's blood pressure and the readings along with other demographic variables already collected, to calculate the participant's absolute CVD risk score. In the usual care arm the CHW will use the WHO paper-based non-lab CVD risk calculator and, if the participant's risk is > 10%, they are asked to sign the informed consent and s/he will have their cholesterol tested by nurses using POCT during a home enrollment visit. The CHW will further verbally encourage her/him to schedule an appointment with a primary care physician at the PCC for evaluation. This is the usual care practice.
75613425|NCT05510726|Device|shearwave elastography|shearwave elastography on upper or lower limb
75763644|NCT00460655|Drug|GSK1358820|botulinum toxin type A
75763645|NCT00460655|Drug|Placebo|Placebo
75906664|NCT02844543|Device|EYE-SYNC eye-tracking device|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
75906665|NCT02844543|Other|SCAT-3|The Symptom subtest of SCAT-3 assessment tool will be administered to participants.
75613426|NCT05494177|Diagnostic Test|bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS|"All participants will be assessed on the following clinical indexes:~Binocular uncorrected distant visual acuity (bUDVA) at four meters distance~Binocular uncorrected intermediate reading acuity (bUIRA) at 60 cm~Binocular uncorrected near reading acuity (bUNVA) at 40 cm~Binocular uncorrected intermediate Critical Print Size (bUICPS) at 60 cm~Binocular uncorrected near Critical Print Size (bUNCPS) at 40 cm~All the above parameters are obtained using the Democritus Digital Acuity & Reading Test (DDART)."
75763646|NCT03982004|Device|Epicutaneous cryoimmunotherapy|Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.
75763647|NCT03982004|Drug|Topical imiquimod|Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).
75763648|NCT03982004|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion
75763649|NCT03982004|Other|Dermatologic Quality of Life Index|"10 questions about how much skin problems has affected the participant's life over the past week~The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3~The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired."
75763650|NCT03982004|Other|Functional Assessment of Cancer Therapy|"5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)~Answers ranging from 0=Not at all to 4 = very much~Each item is rated on a 5-point Likert scale.~The higher the score on the social/family well-being and functional well-being indicate higher quality of life~The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life"
75763651|NCT03982004|Drug|Intra-lesional GM-CSF|250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
75763652|NCT03982004|Device|Cry-AC|-Device used to give the cryoimmunotherapy
75906666|NCT02844543|Device|Desktop Eye-Tracker|Eye movements are recorded with an eye tracking system (Desktop Eye-Tracker, Eyelink CR, SR Research) with up to 1000 Hz temporal resolution. The target stimulus is presented on a computer screen approximately 50 cm from the participant. Participants are asked to follow a dot with their eyes, as the dot moves on the monitor screen of the desk-top eye-tracking device.
75906667|NCT04137562|Biological|ADSTEM Inj.|Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10^8 cells/5mL
75906668|NCT04137562|Other|Placebo|330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
75906669|NCT03063424|Diagnostic Test|Eucapnic voluntary hyperventilation|
75906670|NCT03063424|Diagnostic Test|Exercise challenge on a cycle ergometer|
75460324|NCT01832350|Drug|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
75460325|NCT01832389|Device|PiCCO|
75460326|NCT01832545|Other|Aquatic Exercise|
75460327|NCT01832545|Behavioral|Educational Program|Control Group
75460328|NCT01832584|Dietary Supplement|RGC|
75460329|NCT01832584|Dietary Supplement|Placebo|
75460330|NCT01832688|Other|Programmatic prenatal care optimization|To further integrate and improve nutrition-related services and messages in the prenatal care package.
75460331|NCT01832740|Device|brain stimulation|oscillating direct current brain stimulation
75460332|NCT01832740|Device|SHAM|no stimulation
75763653|NCT03982004|Procedure|Cutaneous tumor biopsy|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
75763654|NCT03982004|Procedure|Peripheral blood draw for research|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
75763655|NCT01062854|Other|Soft earplugs are worn during sleep study|"Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups."
75906671|NCT03576807|Drug|CD20 CAR-T cells|A total of 1 - 20×10^6 CD20 CAR-T cells/kg will be administered by IV infusions.
75906672|NCT03182179|Drug|Ondansetron 4 MG|Ondansetron is taken orally BD
75906673|NCT03182179|Drug|Placebo|Placebo is taken orally BD
75763656|NCT03981848|Other|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
75763657|NCT01026155|Other|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
75763658|NCT01025921|Drug|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
75763659|NCT01025921|Other|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
75763660|NCT01026233|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
76070405|NCT06059859|Procedure|Augmented reality robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.
75460333|NCT01833104|Behavioral|Presence - Perspective - Affect|"PRESENCE: Cultivate attentional skills & interoceptive body awareness. 2 exercises: Breathing Meditation & Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, & other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation & Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation & Affect Dyad."
76070406|NCT06059859|Device|Mixed reality intraoperative frozen section analysis|Microsoft Hololens head-mounted display system will be used for inking prostate margins during intraoperative frozen section analysis
76070407|NCT06059859|Procedure|Robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction.
76070408|NCT06059833|Diagnostic Test|Magnesium|The aim of the study is to evaluate serum Mg level in type 2 DM patients.
76070409|NCT06059807|Device|maxillary expansion|Maxillary Expansion Using Hyrax and Hybrid Hyrax Appliances
75460334|NCT01833104|Behavioral|Presence - Affect - Perspective.|As specified above however the order is interchanged between the cohorts TC1 and TC2.
75460335|NCT01833104|Behavioral|Affect|"AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation & Affect Dyad."
75460336|NCT01833221|Drug|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
75460337|NCT01833325|Radiation|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
75460338|NCT01833598|Procedure|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
75613427|NCT05494177|Diagnostic Test|Contrast sensitivity|Contrast sensitivity is assessed with the Pelli-Robson test.
75613428|NCT05487261|Drug|Sacubitril-valsartan|level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday
75613429|NCT05487261|Drug|Enalapril|level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day
75613430|NCT05487261|Drug|placebo|placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan
75613431|NCT05487261|Drug|Placebo|placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
75613432|NCT05479240|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 cycles.
75613433|NCT05479240|Drug|Capecitabine|Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
75613434|NCT05479240|Drug|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.
75613435|NCT05479240|Radiation|short-range radiotherapy|5*5Gy，d1-d5
75613436|NCT05454462|Drug|IMP Application KM-001|KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
75763661|NCT01062932|Drug|Cycloserine|Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
75763662|NCT01062932|Drug|Placebo|Oral administration of matching placebo pill on Days 1, 4, 7, and 10
75763663|NCT01026311|Drug|Coenzyme q 10|200 mg of Coenzyme q 10
75763664|NCT01026311|Drug|placebo|1 placebo q d during treatment period
75763665|NCT01063010|Drug|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
75763666|NCT01063010|Drug|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
75763667|NCT00460577|Drug|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
75763668|NCT00460577|Drug|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
75613437|NCT05454462|Diagnostic Test|Chemistry|patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
75613438|NCT05454462|Diagnostic Test|Hematology|patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
75460339|NCT01833598|Procedure|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
75460340|NCT01834131|Behavioral|Comprehensive Intervention|The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
75460341|NCT01834300|Behavioral|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
75613439|NCT05454462|Diagnostic Test|Urinalysis|Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
75613440|NCT05454462|Diagnostic Test|Serelogy|Patients will provide a blood sample for serelogy test at day -14 (screening visit)
75613441|NCT05454462|Diagnostic Test|12-Lead ECG|patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
75613442|NCT05454462|Diagnostic Test|Pregnancy test|Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
75613443|NCT05454462|Diagnostic Test|Blood PK sampling|PK test will be performed on day 1, 7, 28, 35 and on ET visit
75763669|NCT01063088|Biological|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
75763670|NCT01581320|Drug|Test group|Once a month, administration of DP-R206 & placebo for 16 weeks
75763671|NCT01581320|Drug|Reference group|Once a month, administration of Bonviva & placebo for 16 weeks
75763672|NCT04909463|Device|Chest Splint|Those receiving intervention will be given the Duracore chest splint for use throughout the trial.
75763673|NCT01068236|Behavioral|Healthy lifestyle managment|Exercise, yoga, food diaries, provider consultation
75613444|NCT05454462|Procedure|Physical Examination|patients will undergo a physical examination on all the clinical visits
75613445|NCT05454462|Procedure|Vital signa|patient's vital signs will be measured on all the clinical visits
75613446|NCT05454462|Diagnostic Test|Investigator's Global Assessment|patient's disease evaluations will be evaluated on all the clinical visits
75763674|NCT00289016|Drug|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
75763675|NCT00288860|Behavioral|Telephone monitoring|Three months of biweekly telephone monitoring and support
75763676|NCT00288860|Other|Treatment-As-Usual|Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
75763677|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
75763678|NCT00288704|Drug|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
75763679|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
75763680|NCT00288626|Drug|Granulocyte-colony stimulating factor (G-CSF) and prednisone|Growth factor regimen; occurs at study entry
75613447|NCT05454462|Diagnostic Test|Itch Assessment via PP-NRSj|patient's disease evaluations will be evaluated on all the clinical visits
75613448|NCT05454462|Other|E-diary data|The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
75613449|NCT05449457|Other|2-Octyl cyanoacrylate|Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
75613450|NCT05447247|Other|Acupuncturing Ba Liao point under ultrasound guidance|Acupuncturing Ba Liao point under ultrasound guidance
75613451|NCT05442684|Biological|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O
75613452|NCT05442684|Biological|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O-IH
75613453|NCT05442684|Biological|mRNA-based COVID-19 vaccine|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of mRNA-based COVID-19 vaccine
75613454|NCT05435859|Behavioral|Speech Tasks|Listen to 25-minutes of speech sounds in English.
75763681|NCT00288626|Drug|Carmustine, etoposide, cytarabine, and melphalan (BEAM)|High-dose chemotherapy; occurs seven or more days following collection of autologous graft
75763682|NCT00288626|Procedure|Autologous hematopoietic stem cell transplant|Occurs after growth factor regimen and collection of autologous graft
75763683|NCT01063244|Device|foley balloon only|place foley balloon only in cervix
75763684|NCT01063244|Device|foley balloon with weight attached|foley balloon with 1000cc IV bag attached
75763685|NCT00087490|Drug|linezolid|
75763686|NCT00087490|Drug|vancomycin|
75763687|NCT00087178|Drug|cyclophosphamide|Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
75763688|NCT00087178|Drug|adriamycin|adriamycin 60 mg/m2 IV every 21 days for 4 cycles
75763689|NCT00087178|Drug|epirubicin|epirubicin 100 mg/m2 IV every 21 days for 6 cycles
75763690|NCT00087178|Drug|fluorouracil|fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
75763691|NCT00288080|Drug|Dexamethasone|Premedication of dexamethasone prior to docetaxel, per institutional standards.
75763692|NCT00288080|Drug|Prednisone|10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.
75763693|NCT00288080|Drug|docetaxel|75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.
75763694|NCT00288080|Drug|Oral antiandrogen|Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
75763695|NCT00288080|Radiation|Radiation therapy|46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.
75763696|NCT00288080|Drug|LHRH agonist|LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
75763697|NCT01086514|Procedure|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
75460342|NCT01834300|Behavioral|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
75460343|NCT01834820|Drug|Epinephrine and Dexamethasone|
75460344|NCT01834820|Drug|Hypertonic Saline|
75460345|NCT01834820|Drug|Normal Saline|
75460346|NCT01834846|Procedure|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
75460347|NCT01834846|Procedure|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
75613455|NCT05434936|Procedure|Oophorectomy|Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
75613456|NCT05431114|Diagnostic Test|MRI|Images of the injured shoulder will then be taken with magnetic resonance (MR) scanner. MRIs of each participant's shoulder will be acquired before and after completion of an exercise protocol.
75613457|NCT05566496|Diagnostic Test|Brain MRI|All participants receive brain MRI evaluation and clinical evaluation of tic severity.
75613458|NCT05415735|Behavioral|Stress Management and Resiliency Training Program|This is a multimodal mind-body program designed to teach participants a variety of different strategies to reduce their physiologic stress response.
75763698|NCT03957460|Other|SpHb monitoring|Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).
75763699|NCT01091194|Other|Interval-based aerobic exercise|High intensity interval-based aerobic exercise training. Duration: 1 year. Three 8-weeks supervised periods of physical training 3 times per week. Individual training 2 times per week between these periods.
75763700|NCT01086592|Other|No intervention|Daily life activities
75763701|NCT01086592|Other|Strong progressive strengthening exercises of lower limbs|Lower limb weight
75763702|NCT01086592|Other|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
75763703|NCT01086592|Other|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
75763704|NCT01068314|Other|Repetitive arm exercise|After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
75763705|NCT03957538|Behavioral|Virtual reality angiogram experience video|The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
75763706|NCT01068392|Drug|Oxaliplatin, Prednisolone|"OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks"
75763707|NCT01086826|Drug|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
75763708|NCT01086826|Drug|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
75763709|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)"
75763710|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times."
75763711|NCT01091272|Drug|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
75763712|NCT01091272|Drug|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
75763713|NCT01091272|Drug|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
75763714|NCT01091272|Drug|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
75763715|NCT00287690|Drug|Genistein|Drink taken once daily
75763716|NCT00287690|Drug|Placebo|Drink taken once daily
76070410|NCT06059781|Other|Rhtyhmical auditory stimulation and Visual cues (Experimental group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~For visual stimulation, white chalk will use to draw visual signals on the ground. For gait recovery, a 10-meter walkway will draw on the floor with parallel lines 2.5cm broad and 90cm long. Interline distance will maintain at 110% of the length of the initial step.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Experimental group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
75460348|NCT01834859|Behavioral|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
75460349|NCT01834859|Behavioral|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
75460350|NCT01835002|Device|Transcorneal electrostimulation|Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
75460351|NCT01835028|Other|Echocardiography|Observational Study using Imaging and Biomarkers
75460352|NCT01835028|Other|Computed tomography|Observational Study using Imaging and Biomarkers
75460353|NCT01835028|Other|Magnetic resonance imaging|Observational Study using Imaging and Biomarkers
75460354|NCT01835028|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
75460355|NCT01835028|Other|Stress echocardiography|Observational Study using Imaging and Biomarkers
75460356|NCT01835054|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
75460357|NCT01835054|Genetic|DNA collection|Observational Study using Imaging and Biomarkers
75613459|NCT05396469|Diagnostic Test|National guideline treatment|All discovered diseases will recieve national guideline treatment and follow up
75613460|NCT05380388|Biological|Malaria Vaccine|blood stage Plasmodium vivax malaria vaccine
75613461|NCT05380388|Biological|HBV vaccine|HBV Vaccine
75613462|NCT05374616|Genetic|Observation|Retrospective and prospective Natural History Study
75763717|NCT01063400|Other|Observation|monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
75763718|NCT00286754|Behavioral|SMI|Stage-matched intervention
75763719|NCT00286754|Behavioral|HEI|Health Education Intervention
75763720|NCT00286754|Behavioral|UC|Usual Care
75763721|NCT00286754|Behavioral|SMI|Stage-matched intervention
75763722|NCT00286754|Behavioral|HEI|Health Education Intervention
75763723|NCT00286754|Behavioral|UC|Usual Care
75763724|NCT01070186|Drug|Sunitinib|50mg/day for 4 weeks
75763725|NCT01070186|Other|Tumor biopsy|Conducted prior to administration of sunitinib therapy
75906674|NCT04118452|Behavioral|Telephone-based early childhood developmental care coordination|The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
75460358|NCT01835054|Other|Echocardiography|Observational Study using Imaging and Biomarkers
75460359|NCT01835054|Other|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
75763726|NCT01070186|Procedure|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
75763727|NCT01070186|Other|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
75460360|NCT01835054|Other|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
75460361|NCT01835054|Other|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
75763728|NCT00066742|Drug|tirapazamine|Given IV
75906675|NCT03576651|Biological|JHL1149|Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
75906676|NCT03576651|Biological|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
75906677|NCT03576651|Biological|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
75906678|NCT03064906|Device|Insulet AP (artificial pancreas) System|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
75906679|NCT03034135|Drug|Disulfiram/Copper|Disulfiram/copper gluconate is taken three times a day.
75460362|NCT01835054|Other|Holter ECG|Observational Study using Imaging and Biomarkers
75460363|NCT01835197|Drug|PF-04965842|Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
75460364|NCT01835197|Drug|Placebo|Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
75460365|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
75460366|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
75763729|NCT00066742|Drug|cisplatin|Given IV
75763730|NCT00066742|Drug|etoposide|Given IV
75763731|NCT00066742|Radiation|radiation therapy|Undergo radiation therapy
75763732|NCT00066742|Other|laboratory biomarker analysis|Correlative studies
75763733|NCT01093924|Behavioral|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
75763734|NCT01091350|Device|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
75763735|NCT01091350|Device|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
75763736|NCT03956914|Other|Placebo|Placeob water 440 ml/day for 8 weeks
75763737|NCT03956914|Other|Deep sea water|Deep sea water 440 ml/day for 8 weeks
75763738|NCT00460265|Drug|ARM 2|Subjects will receive Cisplatin plus 5FU
75763739|NCT00460265|Drug|ARM 1|Subjects will receive Panitumumab plus cisplatin and 5FU
75906680|NCT03034135|Drug|Temozolomide (TMZ)|TMZ is given per standard of care
75763740|NCT03956290|Behavioral|TREAT pilot intervention|Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
75763741|NCT01094002|Other|Occupational therapy intervention|"Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities."
75763742|NCT03742583|Other|Square Knot|Standard square knot
75906681|NCT05411458|Other|Aerobic and Relaxation Exercises|"12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~Aerobic exercise (AE) program:The aerobic training program was applied as walking for 40 minutes in the open air. The Rating of Perceived Exertion (RPE) Borg Scale (6-20) was used to determine the walking pace, and they were asked to walk according to the light (11-12) level according to the Borg scale.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
75906682|NCT03574155|Behavioral|Pre-operative Counseling and Education|"Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS) Post-operative Immediate (1 OP) Application of the Questionnaire to assess HADS and ESAS Anxiety (Patient)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)~Late postoperative (2 - 4 weeks) Questioning the patient and companion evaluating the degree of satisfaction regarding the preoperative guidelines."
75763743|NCT03742583|Other|RHAP Knot|Reversing half-hitch alternating post knot
75460367|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
75906683|NCT02239731|Drug|FDX104 (4% Doxycycline)|FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
75460368|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
75460369|NCT01835197|Drug|PF-04965842|Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
75460370|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
75460371|NCT01835197|Drug|PF-04965842|Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
75460372|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
75460373|NCT01835418|Drug|Amlodipine|crossover comparison of amlodipine vs lisinopril
75460374|NCT01835444|Other|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
75460375|NCT01835678|Drug|Linagliptin|orally 5 mg/d for 4 weeks
75460376|NCT01835678|Drug|Placebo|orally once a day for 4 weeks
75460377|NCT01835808|Device|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
75763744|NCT01091506|Other|Placebo|Placebo once a day for 12 weeks
75763745|NCT01091506|Other|L-methylfolate|L-methylfolate 15mg once a day for 12 weeks
75763746|NCT01026467|Drug|cisplatin|Given IV
75763747|NCT01026467|Drug|carboplatin|Given IV
75763748|NCT01026467|Other|questionnaire administration|
75763749|NCT01094080|Other|standard infant formula|infants are fed a commercial formula
75763750|NCT01094080|Other|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
75763751|NCT01094080|Other|breast milk|infants are breast fed
75763752|NCT01094158|Drug|Aramchol|100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
75763753|NCT01094158|Drug|Aramchol|300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
75763754|NCT01094158|Drug|Placebo|tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
75763755|NCT01094236|Behavioral|On the Playground behavior management program|Treatment school playground supervisors were show the CD intervention. Control school playground supervisors were given a video on playground equipment safety. All school staff subjects were assessed before the intervention and 75 days following the supervisor intervention. Students were assessed before the intervention, and then 45 days and 75 days following the supervisor intervention. School Administrators were assessed before the intervention, and then 30 and 60 days after the supervisor intervention - school administrators at treatment schools had access to a treatment binder with CDs and worksheets, while the control school administrators did not.
75763756|NCT01094314|Other|embryo culture medium|comparison between two types of embryo culture medium
75763757|NCT01091584|Device|distress thermometer|to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
75763758|NCT00460109|Biological|denileukin diftitox|
75613463|NCT05370157|Behavioral|TeamTRACS|TeamTRACS is a team training intervention adapted from TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), a widely used evidence-based team training developed by the Agency for Healthcare Research and Quality. TeamTRACS targets knowledge, skills, and attitudes related to team member roles, shared awareness, communication, mutual support, and goal-setting. TeamTRACS is structured, easy to use, flexible in length and intensity, and requires few resources. It incorporates didactic instruction, discussion, and interactive activities and can be delivered virtually or in-person.
75763759|NCT00460109|Biological|rituximab|
75763760|NCT03956212|Drug|Doxycycline 7 days|Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
75763761|NCT03956212|Drug|Doxycycline 14 days|Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
75763762|NCT01091740|Device|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
75763763|NCT01091740|Device|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
75763764|NCT01094470|Device|Body weight support system on ground level|Gait training with body weight support on ground level with sessions of 45 minutes, three times a week, on alternating day during six weeks, completing a total of 18 sessions.
75613464|NCT05365334|Behavioral|Low intensity exercise session|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
75763765|NCT01091818|Drug|dexmedetomidine|Dexemedethomidine is given as major sedative drug
75763766|NCT01091818|Drug|Midazolam|Midazolam is given as major sedative drug
75906684|NCT05409118|Device|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
75906685|NCT05409118|Device|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
75906686|NCT03571893|Behavioral|Weight Watchers Freestyle (Flex)|Participants will be referred to their local Weight Watchers meeting and provided with a promotional code to allow them to participate in the Weight Watchers program free of charge for 12 months. At the randomization visit, study staff will help participants identify a convenient Weight Watchers meeting location and download the program app onto their smartphone.
75613465|NCT05365334|Behavioral|Moderate intensity exercise session|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
75613466|NCT05365334|Behavioral|High intensity exercise session|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
75460378|NCT01836237|Device|Alexis - a wound protector|Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
75460379|NCT01836354|Behavioral|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
75460380|NCT01836614|Drug|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
75763767|NCT01091896|Drug|Bevacizumab|1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
75763768|NCT01091896|Drug|bevacizumab|1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
75763769|NCT00065260|Drug|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
75763770|NCT00065260|Drug|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
75763771|NCT00065260|Drug|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
75763772|NCT01327066|Drug|Droxidopa|600 mg, single oral dose
75763773|NCT01327066|Drug|Droxidopa|2000 mg, single oral dose
75763774|NCT01327066|Drug|Moxifloxacin|400 mg, single oral dose
75763775|NCT01327066|Drug|Placebo|Placebo matching Droxidopa or Moxifloxacin
75763776|NCT01094626|Drug|Secretin|Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
75763777|NCT03956134|Drug|Tapentadol Test Product 1|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
75613467|NCT05365113|Procedure|alveolar recruitment maneuver|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
75763778|NCT03956134|Drug|Tapentadol Test Product 2|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
75763779|NCT03956134|Drug|Tapentadol Prolonged-release Reference Product|Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
75763780|NCT00460031|Drug|ketoconazole|400 tid
75763781|NCT00460031|Drug|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
75763782|NCT00460031|Drug|therapeutic hydrocortisone|20mg qam 10mg qhs
75763783|NCT00451217|Drug|Sugammadex|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered
75763784|NCT00451217|Drug|Neostigmine|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
75763785|NCT01023113|Procedure|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
75906687|NCT03571893|Behavioral|DIY Personal Plan|Participants will be provided with a written resource with descriptions of a variety of approaches that have been shown to promote healthy weight loss through behavioral modification. Participants will be encouraged to assess their preferences for dietary change and physical activity and adopt an approach that will lead to negative energy balance and moderate (1-2 lbs. per week) weight loss.
76070411|NCT06059781|Other|Rhtyhmical auditory stimulation (Control group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Control group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
75460381|NCT01836939|Drug|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
75460382|NCT01836939|Drug|TSO 7500|12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
75460383|NCT01837134|Device|telemedical (TM) group|telemedical devices (weighing machine and step counter)
75460384|NCT01837134|Behavioral|telemedical coaching (TMC) group|care calls once per week for 12 weeks
75763786|NCT01023113|Procedure|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
75460385|NCT01837251|Drug|Carboplatin|
75460386|NCT01837251|Drug|PLD|
75460387|NCT01837251|Biological|Bevacizumab|
75460388|NCT01837264|Device|Magellan®|
75460389|NCT01837290|Drug|dexmedetomidine infusion for premedication|Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
75460390|NCT01837290|Drug|Midazolam|intravenous Midazolam 0.02 mg/kg for premedication
75613468|NCT05364957|Device|Intragastric balloon device|Patients in the experimental arm will benefit from the placement of an Intra Gastric Balloon endoscopically
75763787|NCT00459953|Drug|Extended treatment|All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
75763788|NCT00459875|Drug|sunitinib malate|
75763789|NCT00311402|Drug|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
75763790|NCT00311402|Other|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
75763791|NCT01026545|Drug|PF-04287881|500 mg once daily for 10 days
75763792|NCT01026545|Drug|Placebo|To match 500 mg dose once daily for 10 days
75763793|NCT01026545|Drug|PF-04287881|750 mg once daily for 10 days
75763794|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
75763795|NCT01026545|Drug|PF-04287881|1100 mg once daily for 10 days
75906688|NCT03064828|Radiation|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
76070412|NCT06059755|Other|Cross education|For strength training resistance exercises with a load of 60% of one repetition maximum will be performed targeting the muscle involved in upper limb function. Strength will be measured using the grip strength test/hand held dynamometer. Patients will undergo 45 minute session per day, 3 days per week for 6 weeks.
75906689|NCT03064828|Radiation|CT colonoscopy (low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
75460391|NCT01837290|Drug|saline infusion|Saline infusion to facilitate blinding
75460392|NCT01837290|Drug|Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg|Hyperbaric bupivacaine injection for spinal block
75763796|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
75460393|NCT01837433|Drug|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
75460394|NCT01837433|Drug|Prednisone 6 weeks|Guidelines recommend
75613469|NCT05364957|Procedure|Dietary|The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).
75613470|NCT05364957|Procedure|Exercise intervention|Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.
75763797|NCT01026545|Drug|PF-04287881|Optional cohort with dose not greater than 1100 mg
75613471|NCT05358106|Biological|AntiBKV|AntiBKV neutralising antibody
75906690|NCT02035683|Procedure|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
76070413|NCT06059755|Other|Mirror Therapy|Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks
75460395|NCT01837446|Drug|2% morphine solution|
75460396|NCT01837446|Drug|Magnesium aluminum hydroxide|
75460397|NCT01837446|Drug|2% viscous lidocaine|
75460398|NCT01837446|Drug|Diphenhydramine|
75460399|NCT01837472|Drug|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
75460400|NCT01837472|Drug|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
75460401|NCT01838057|Device|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
75460402|NCT01838057|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
75613472|NCT05358106|Biological|Placebo|Solution with no active ingredients
75613473|NCT05356949|Behavioral|Intervention|The participants receive a psychological intervention including six weekly sessions. The intervention is based on methods of cognitive-behavioral therapy and delivered by a psychiatric nurse working in the participant's school.
75763798|NCT01026545|Drug|Placebo|Optional cohort to match dose not greater than 1100 mg
75763799|NCT01026545|Drug|PF-04287881|750 mg dose once daily for 10 days
76070414|NCT06059742|Other|Action Observation Therapy with Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
76070415|NCT06059742|Other|Action Observation Therapy without Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
76070416|NCT06059716|Behavioral|Continuous telemedicine monitoring plus gluten detection technology|Portable technologies to sense gluten before or after ingestion
76070417|NCT06059716|Behavioral|Continuous telemedicine monitoring|Regular follow-up with an expert dietitian
76070418|NCT06059703|Procedure|Blood punction|Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
76070419|NCT06059703|Procedure|Central blood sampling|Central blood sampling (2 ml) at inclusion and 3 months after treatment
76070420|NCT06059703|Procedure|Intracranial pressure measurement|Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
75763800|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
75763801|NCT01026545|Drug|PF-04287881|1100 mg dose once daily for 10 days
75763802|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
75763803|NCT03996083|Other|Multicomponent exercise intervention|"Strength exercises were focused on lower limb strengthening. Individual bilateral intensities were calculated to estimate one repetition maximum (1-RM) for the leg and arm. This test was performed on the 2nd and 7th weeks of the intervention. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. No external loads were applied to the rest of the exercises due to their complex execution technique and subsequent risk of adverse events. In these cases, training progression was achieved through volume (number of repetitions) and execution velocity increments.~Balance exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention."
75906691|NCT03064594|Procedure|Cornual pregnancy|we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
75613474|NCT05332444|Drug|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
75763804|NCT03996083|Other|Walking intervention|"To comply with the walking goals, walking distance was calculated based on each participant´s performance on the 6-minute walking test and using a rule of thumb. Therefore, every participant had an itinerary to follow to comply with the minimum walking time each week. Distance rather than time was used with participants for practical reasons and the inability of most of them to measure time. Moreover, time and distance were individually adapted according to each participant´s performance on the previous week.~To ensure that participants complied with the walking goals, each of them (if they were cognitively able) was given a record sheet in which they had to write down their everyday walking routines. In addition, the caregivers were also informed about the walking routines and ensured that those participants who needed close supervision had someone to walk with and filled the sheet of those that were unable to do so."
75763805|NCT01023191|Procedure|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
75906692|NCT02239809|Procedure|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
76072484|NCT04021953|Behavioral|People Like Us Online Video Series Intervention|"People Like Us miniseries incorporates key sexual health messages to:~Increase viewers' knowledge and perceptions of HIV and other STI risk;~Address homophobia and sexual orientation disclosure;~Increase safer-sex negotiation self-efficacy;~Promote positive attitudes towards condom use and other safe sex behaviors;~Build skills and self-efficacy for practicing safer sex;~Provide information on HIV and other STI testing and its benefits;~Provide information on resources for HIV/STI testing and other mental health services;~Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men."
75613475|NCT05332444|Drug|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
75613476|NCT05328570|Diagnostic Test|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
75763806|NCT01023191|Procedure|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
75613477|NCT05323825|Dietary Supplement|Probiotic|Fermented milk product containing a probiotic
75613478|NCT05323825|Dietary Supplement|Placebo|Product with identical characteristics to the experimental product.
75763807|NCT00450749|Other|placebo|Given PO
75763808|NCT00450749|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
75906693|NCT02239809|Procedure|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
75906694|NCT03571815|Drug|5% sodium fluoride varnish|application of sodium fluoride varnish on teeth
75906695|NCT03571815|Other|WATER ON TEETH|control group
75906696|NCT04050358|Dietary Supplement|NRPT|Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
75906697|NCT04050358|Dietary Supplement|Placebo oral capsule|Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks
75906698|NCT02985073|Device|Veritas®|Biologic mesh
75906699|NCT02985073|Device|TIGR®|Non biologic mesh
75906700|NCT02239887|Device|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
76070421|NCT06059690|Diagnostic Test|pH Measurement of in vivo tissue|The investigator will identify multiple (2-5) 5-8mm diameter spherical targets on GI maps for use in stereotactic pH measurement and biopsy acquisition. All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target. After the pH probe is removed, the biopsy needle will be placed into the cannula and standard-of-care biopsy tissue will be obtained from the same area where pH measurements were recorded.
76070422|NCT06059677|Drug|Active smoked cannabis|Assessment of active cannabis smoking and driving impairment
75763809|NCT00450749|Other|laboratory biomarker analysis|Correlative studies
76070423|NCT06059677|Drug|Placebo smoked cannabis|Assessment of placebo cannabis smoking and driving impairment
76070424|NCT06058910|Diagnostic Test|Bilistick System 2.0 point-of-care testing device|The routine standard-of-care blood sample collection involves a 0.5 milliliter whole blood draw by the heel stick method for bilirubin assessments under current reference clinical methodology for total bilirubin. An additional 0.035 milliliter of whole blood will be collected for measurement in the point-of-care Bilistick System 2.0 (Bilistick point-of-care testing device). The resulting Bilistick System 2.0 data (i.e., total bilirubin) will be recorded, but will not be entered into the patients' electronic medical records or used for any diagnostic or medical decision purposes.
76070425|NCT06058546|Drug|Jiuweihuaban Pill placebo|Jiuweihuaban pill placebo 1 bag(12 g placebo per bag),p.o.,tid,for 12weeks.
76070426|NCT06058546|Drug|low dose Jiuweihuaban Pill|Low dose Jiuweihuaban pill 1 bag(3 g placebo per bag and 9 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
76070427|NCT06058546|Drug|high dose Jiuweihuaban Pill|High dose Jiuweihuaban pill 1 bag(12 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
76070428|NCT06058468|Procedure|Cardioneuroablation of right anterior ganglionated plexus|Right anterior ganglionated plexus will be localized using anatomical approach. Radiofrequency energy will be delivered until heart rate acceleration >30% is achieved or if radiofrequency time exceeds 120 seconds.
76070429|NCT06058468|Procedure|Pulmonary vein isolation|Application sites near the ostia of pulmonary veins will be determined. Radiofrequency energy will be delivered using point-by-point technique. After applications, the acute PVI endpoint will be confirmed by the elimination of PV potentials and lack of capture during pacing from the ablation lines.
76070430|NCT06058026|Other|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
75763810|NCT00450749|Drug|lycopene|Given PO
76070431|NCT06057896|Dietary Supplement|inositol, phytoestrogens, cocoa polyphenols|myo-inositol, soy isoflavones and cocoa polyphenols
76070432|NCT06057714|Combination Product|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing
76070433|NCT06057662|Other|personalized comprehensive diabetes support|personalized comprehensive diabetes support
75763811|NCT00292370|Drug|Open Label (OL) Paroxetine|Open-label Paroxetine
75460403|NCT01838135|Device|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
75613479|NCT05314491|Device|Multigen Plus CCK|Total Knee Arthroplasty
75613480|NCT05314491|Device|AMF TT cones|To fill a proximal tibia or distal femur defect
75613481|NCT05291481|Behavioral|CAPAS-yOUTH|11-week parent training intervention exclusively delivered to parents
75613482|NCT05290740|Drug|Norepinephrine 5 mcg|norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
75763812|NCT00292370|Drug|Placebo|Double-blind placebo taken with OL paroxetine
75763813|NCT00292370|Drug|Quetiapine|Double-blind quetiapine taken with OL paroxetine
75763814|NCT00065182|Drug|Topotecan/Docetaxel combination|
75763815|NCT00065182|Drug|Docetaxel|
75763816|NCT01026701|Drug|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
75613483|NCT05290740|Drug|Norepinephrine 10 mcg|norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
75613484|NCT05269186|Device|Virtual reality software|The patient will undergo a 20-minute virtual reality session before the planning CT scan
75763817|NCT01092052|Drug|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
75763818|NCT01094860|Drug|Nelarabine|Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
75460404|NCT01838278|Behavioral|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
75613485|NCT05255393|Other|Questionnaires|"A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module."
75763819|NCT01092130|Drug|Vitamin D|2000 IU vitamin D daily, for 6 weeks
75763820|NCT00064792|Drug|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
75763821|NCT00064792|Drug|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
75763822|NCT01095016|Drug|Meptin swinghaler|"Dose: 10ug/puff, 2 puffs daily~Frequency: QD (total 20ug/day)~Treatment duration: 2 days"
75763823|NCT01095016|Drug|Berotec|"Dose: 100ug/puff, 2 puffs daily~Frequency: QD (total 200ug/day)~Treatment duration: 2 days"
75763824|NCT01092286|Other|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
75613486|NCT05241665|Device|SpectraWAVE Imaging System|Coronary imaging
75613487|NCT05234554|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
75763825|NCT03956992|Other|Mouth gel|Stop using the mouth gel
75906701|NCT04096378|Behavioral|EMBRace Intervention Group|The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.
75906702|NCT04096378|Behavioral|EMBRace Waitlist Group|The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
75906703|NCT03701815|Behavioral|Wellness in Rehabilitation program|The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
75906704|NCT03571737|Drug|Ibuprofen|Ibuprofen tablet
75763826|NCT00450437|Biological|MenACWY CRM|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
75763827|NCT00450437|Biological|Meningococcal ACWY Conjugate vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
75763828|NCT01095172|Drug|Rituximab|375mg/m^2, single dose given 2-4 weeks prior to transplantation
75906705|NCT03571737|Drug|Lidocaine Patch 4%|Lidocaine patch
75906706|NCT03064672|Device|transcervical Balloon Catheters|induction of labor by transcervical Balloon Catheters insertion
75906707|NCT03571659|Procedure|Laser|
75906708|NCT03705013|Other|Cologuard|Observational
75613488|NCT05234554|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
75613489|NCT05233800|Behavioral|Faster Asleep Smart Speaker Program|Participants will receive a smart speaker device with a pre-loaded Faster Asleep program. Participants will be asked to engage with the program daily, either using the voice-activated speakers or an accompanying smart-phone app. The study duration is six-weeks and is completed individually using fully automated interaction to deliver components of cognitive behavioral therapy for insomnia.
75613490|NCT05233800|Behavioral|Faster Asleep Website|Controls will have access to a website with information about CBT-I and breast cancer survivorship and will be told to engage with the website as desired. The content will be drawn from the education script that is programmed into the phone app accompanying the smart speaker program.
75613491|NCT05231655|Diagnostic Test|Functional drug screen|High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles
75763829|NCT01095172|Drug|Tacrolimus|dose calculated to give levels of 3-7ng/ml
75906709|NCT03576339|Procedure|Free Gingival Graft|Free gingival graft removal from palate for socket preservation
75906710|NCT03576339|Device|SHAM Electric stimulation|Simulation of electric stimulation protocol for 120 seconds once a day in five consecutive days. In Sham stimulation non current will be applied.
75906711|NCT03576339|Device|Electric Stimulation|Local Electric Stimulation for 120 seconds once a day in five consecutive days.
76070434|NCT06057636|Behavioral|Self-Administered Hypnosis|Participants will choose from one of three 20-minute prerecorded hypnosis audio files. Practices using the recordings will be documented on the hypnosis practice log.
76070435|NCT06057636|Behavioral|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recording for 6 weeks and will be encouraged to practice daily. Practices using the recordings will be documented on the hypnosis practice log.
76070436|NCT06057623|Other|Evaluation of central and peripheral neuromuscular fatigue|To define peripheral and central component of fatigue, the investigators will test, before, during and after the fatigue task, the force produced during a Maximal Voluntary Contraction (MVC) and the force produced by the electrically evoked Resting Twitch (RT) produced, at rest, 5 seconds after the MVC.
75460405|NCT01838564|Other|Routine Data collection|"Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.~Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST."
75460406|NCT01838564|Other|Feedback of patient-reported outcomes|Patients, parents and primary providers received printed reports summarizing patient/parent reported outcomes for last five visits. When child reported moderate-severe distress an email was automatically sent to primary providers (oncologist, nurses and psychosocial clinicians), as well as to the pain and palliative care services.
75460407|NCT01838733|Other|Observational study|
75763830|NCT01095172|Drug|Mycophenylate mofetil|Mycophenylate mofetil 2g/day in divided doses
75763831|NCT01095172|Drug|Hydrocortisone|100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
75906712|NCT03571503|Procedure|Doin (conduction exercise)|An acupuncture physician will administer acupuncture at 4-8 acupoints in the low back and gluteal area (mandatory points: BL54, and GB30 ipsilateral to the dysfunctional site; and selective points: BL23, BL24, BL25, BL26, BL31, BL32, Ah-shi points, local acupuncture points and/or trigger points. Doin (conduction exercise) will be performed as active and passive movement with the needles in situ to the aim of effective treatment of pain and functional disability by increasing the hip joint range of motion (flexion and extension) with physician guidance and isometric resistance exercise (flexion and extension) as needed. Doin (conduction exercise) sessions will be performed 1 session/day for the duration of hospitalized treatment while the patient presents radiating leg pain (NRS≥1).
76070437|NCT06057610|Drug|SHR-A1811 Injection|SHR-A1811 Injection
76070438|NCT06057610|Drug|SHR-A1811 Injection ； Pertuzumab Injection|SHR-A1811 Injection ； Pertuzumab Injection
76070439|NCT06057610|Drug|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
75763832|NCT01095172|Drug|Prednisolone|Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
75763833|NCT01095172|Drug|Prednisolone|Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
75763834|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
75763835|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
75763836|NCT00286442|Drug|Metformin|Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
75763837|NCT00063934|Biological|oblimersen sodium|Given IV
75763838|NCT00063934|Drug|doxorubicin hydrochloride|Given IV
75906713|NCT03571503|Drug|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
75763839|NCT00063934|Drug|docetaxel|Given IV
75763840|NCT00063934|Biological|filgrastim|Given SC
75763841|NCT00063934|Biological|pegfilgrastim|Given SC
75763842|NCT00063934|Procedure|therapeutic conventional surgery|Undergo surgical resection
75763843|NCT00063934|Other|pharmacological study|Optional correlative studies
75763844|NCT00063934|Other|laboratory biomarker analysis|Optional correlative studies
76070440|NCT06057584|Behavioral|somatosensory-motor integration training|Participants will use both hands to perform functional tasks requiring somatosensory discrimination to provide different somatosensory stimuli to facilitate motor control. The experimental group will receive somatosensory-motor integration training, 3-5 sessions a week, for a total of 15 sessions.
75906714|NCT03571503|Procedure|Chuna manual therapy|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered at the physician's discretion.
75906715|NCT03571503|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
76070441|NCT06057584|Behavioral|pure somatosensory training|Participants will use the affected hand to perform somatosensory discrimination tasks, including limb position discrimination and object discrimination.The experimental group will receive pure somatosensory integration training, 3-5 sessions a week, for a total of 15 sessions.
75460408|NCT01838850|Drug|CS8635 20/5/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day."
75763845|NCT03955744|Other|3D translabial ultrasound|All patients will undergo 3D translabial ultrasound with vaginal manometry
75763846|NCT00458783|Biological|Prolonged RBC storage|Transfusion with oldest available matching RBCs
75763847|NCT00458783|Biological|Short RBC storage|Transfusion with youngest available matching RBCs
75763848|NCT00063154|Drug|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
75763849|NCT01092520|Drug|Gabapentin|Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
75763850|NCT03955588|Diagnostic Test|aCGH|
75763851|NCT03996161|Other|patient position|After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.
75763852|NCT00311168|Device|Intervention/treatment|"Device: VIP On~Device: VIP Off"
75763853|NCT00458705|Drug|bortezomib|
75763854|NCT00458705|Drug|dexamethasone|
75763855|NCT00458705|Drug|pegylated liposomal doxorubicin hydrochloride|
75763856|NCT00458705|Drug|thalidomide|
75763857|NCT00062374|Drug|Cisplatin|Given IV
75763858|NCT00062374|Procedure|Computed Tomography|Undergo FDG and FLT PET/CT
75763859|NCT00062374|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
75763860|NCT00062374|Other|Fluorothymidine F-18|Undergo FLT-PET/CT
75763861|NCT00062374|Drug|Irinotecan Hydrochloride|Given IV
75763862|NCT00062374|Procedure|Positron Emission Tomography|Undergo FDG and FLT PET/CT
75763863|NCT00062374|Procedure|Therapeutic Conventional Surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
75763864|NCT00285818|Drug|Mifepristone|Mifepristone is a glucocorticoid receptor antagonist.
75763865|NCT00285818|Drug|Placebo Oral Capsule|Placebo is a capsule without a pharmacological active ingredient
75763866|NCT01323023|Behavioral|varies by project|
75763867|NCT01023347|Drug|Paclitaxel (Genexol®)|
75763868|NCT01023347|Drug|Paclitaxel loaded polymeric micelle (Genexol-PM®)|
75763869|NCT06202755|Drug|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
75613493|NCT05214378|Device|Finetech-Brindley Sacral Anterior Roots Stimulation System|Electrodes implanted on sacral roots connected to implanted induction coil. External controller box administers stimulation via induction through skin to electrodes. Stimulation activates nerves to modulate bladder, bowel, and sexual functions.
75906716|NCT03571503|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
75763870|NCT06202755|Drug|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
75763871|NCT06202742|Behavioral|cognitive behavioral therapy for insomnia|Online meeting, weekly for 8 weeks, to deliver CBTI by psychologist/ psychiatrist
75906717|NCT03571503|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75906718|NCT03571503|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75906719|NCT03571503|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
75460409|NCT01838850|Drug|Olmetec® Plus 20/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day."
75763872|NCT06202742|Behavioral|Health education|Online meeting, weekly for 8 weeks, to deliver general health knowledge
76070442|NCT06057584|Behavioral|pure motor training|Participants will conduct bilateral task-oriented training, but the training task does not require somatosensory discrimination. Each round only uses the same target and target position to repeatedly practice the functional task movements, but the target or target position is different in different rounds. The experimental group will receive pure motor integration training, 3-5 sessions a week, for a total of 15 sessions.
75763873|NCT06202729|Other|Questionnaire|GAD-7, VAS-A, NRS
75763874|NCT06202716|Drug|Cadonilimab plus CapeOX chemotherapy|Cadonilimab plus oxaliplatin/capecitabine (CapeOX) chemotherapy as first-line treatment in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma: Cadonilimab 10mg/kg, iv, q3w + oxaliplatin 130mg/m2, vd, d1 + capecitabine 1000mg/m2, po, bid, d1-d4, q3w (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
75763875|NCT06202703|Drug|Pneumococcal Vaccine|vaccination with pneumococcal vaccine (PCV13)
75906720|NCT03571503|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
75906721|NCT04445584|Diagnostic Test|7 Tesla MRI|7 Tesla MRI
75906722|NCT03574077|Behavioral|Instant Messaging (IM)|Tailored automatic, fix- scheduled regular messages will be sent and counselors will interact with smokers in the intervention group through WhatsApp since initial contact and until 2-month after baseline. The interaction will follow the principle of Motivational Interviewing, which will focus on enabling change through the enhancement of intrinsic motivation and the exploration and resolution of ambivalence. Counsellors will identify discrepancies between participants' thought and their action, support their autonomy, be empathetic towards the participant, avoid confrontation, and adjust to resistance. Any smokers who do not use IM or refuse to receive IM messages will be contacted via SMS messages or telephone calls. For smokers who do not respond to regular messages, 3 additional prompt messages will be sent in the 1st month to initiate a conversation.
75906723|NCT03574077|Behavioral|AWARD advice|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
75906724|NCT03574077|Behavioral|NRT sampling|One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.
76070443|NCT06057558|Biological|Probiotic throat spray|Throat spray containing Lacticaseibacillus casei AMBR2
76070444|NCT06057545|Drug|Envarsus®|Treatment sequence: 4 weeks prolonged-release tacrolimus (Envarsus®) once daily
76070445|NCT06057545|Drug|Prograf|Treatment sequence: 4 weeks intermediate-release tacrolimus (Prograf®) twice daily
75460410|NCT01839201|Other|control|No psychological intervention
75460411|NCT01839201|Other|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
75460412|NCT01839201|Other|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
75613494|NCT05212311|Device|Chitosan Phonophoresis|Therapeutic pulsed ultrasound using EMS physio Ltd ultrasound device in presence of chitosan gel will be applied over the elbow. The following parameters will be used: US treatment was applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2.
75613495|NCT05212311|Device|Therapeutic Ultrasound|US treatment will be applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2 using aquasonic gel.
75763876|NCT06202690|Procedure|Single-port robotic-assisted thoracic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the SP robotic system.~A 4-cm single incision will be made below the subcostal margin. A chest tube will be inserted in same incision."
75763877|NCT06202690|Procedure|Single-port video-assisted thoracoscopic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the VATS.~A 4-cm single incision will be made at 5th intercostal space. A chest tube will be inserted in same incision."
75613496|NCT05212311|Device|Splinting|"Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures."
75906725|NCT03574077|Behavioral|Active referral|SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
75906726|NCT03574077|Behavioral|SMS messaging|All smokers will receive fix-schedule general messages on SC through short message service (SMS) since their initial participation until 2-month after baseline. These messages include: (a) brief health warning, (b) benefit of quitting, (c) methods to quit and to cope with craving, and (d) SC services and their effectiveness. General SC messages will be sent twice per week in the 1st month and once per week in the 2nd month after joining this study.
76070446|NCT06057532|Dietary Supplement|UCAN SuperStarch|Intervention patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the intervention study drink and record information about how they feel before and after consumption.
75613497|NCT05212311|Other|Neural mobilization exercises of the ulnar nerve|Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
75613498|NCT05201404|Drug|Namodenoson|Adenosine A3 Receptor (A3AR) agonist
75763878|NCT06202677|Device|Self-guided program on obsessive compulsive disorder|This is an 8-day program that provides psychoeducational on what obsessions and compulsions are, and how to identify them. Subsequently, through a series of content learning and daily exercises that increase in difficulty, participants are guided to conduct exposure exercises while tolerating distress and refraining from compulsions. Participants are also guided to set goals and type down the specific content of their intrusive thoughts and compulsive behaviours to keep track of their progress. Each session of the program is estimated to be approximately 5 minutes.
75763879|NCT06202677|Device|Self-guided program on cooperation|This 8-day program on cooperation aims to improve participants' collaborative skills and interpersonal wellness through a series of content learning and practice exercises. The time and duration of this program is matched to the obsessive compulsive disorder program to ensure that participants spend a similar amount of time and effort across both the intervention and active control conditions.
75613499|NCT05201404|Drug|Placebo|Control arm
75460413|NCT01839227|Other|Neurologic and neuropsychologic tests|"Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery."
75613500|NCT05179837|Device|Optical coherence tomography probe|The OCT probe is attached to an approximately 3-meter wire that is attached to the OCT fiber probe system setup. This setup consists of a power supply unit, and a control platform that controls fiber probe rotation and retraction. The OCT probe will be advanced through the colonoscope instrument channel
75460414|NCT01839305|Other|Hydrotherapy|Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
75460415|NCT01839344|Dietary Supplement|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
75613501|NCT05176353|Other|VAP diagnostic stewardship bundle|Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
75613502|NCT05174416|Drug|Mavacamten|Mavacamten Capsules
75613503|NCT05174416|Drug|Placebo|Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
75460416|NCT01839344|Drug|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
75613504|NCT05159752|Drug|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
75763880|NCT06202664|Procedure|Erector Spinae Block|Erector Spinae block under ultrasound guidance will be administered bilaterally at T6 level. The block will be administered after induction of general anesthesia with 1mg of IV Midazolam, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. After induction patient will be placed in lateral position and then under ultrasound guidance Erector Spinae Block will be administered at T6 level. Drugs administered in the block will include 30ml of 0.25% Bupivacaine and 10ml of 1% Lignocaine (bilaterally). Skin incision for trocar insertion will be given 15 mins after administration of Erector Spinae Block.
75763881|NCT06202664|Drug|Opioid Analgesic|This group of patient will receive general anesthesia induction with 1mg of IV Midazolam, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. Along with these drugs 1 Mcg/kg of IV Fentanyl, 1g of IV Paracetamol and 30 mg of IV Ketorolac will be given at induction of anesthesia before skin incision for trocar insertion.
75763882|NCT06202625|Drug|avatrombopag|The avatrombopag 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT<50×10^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase avatrombopag dosage to 40 mg/d; When PLT≥80×10^9/L and without PLT transfusion within avatrombopag dosage at 40 mg/d, decrease avatrombopag dosage to 20 mg/d; When PLT≥80×10^9/L for 7 consecutive days or PLT≥300×10^9/L and without PLT transfusion, stop avatrombopag; When PLT<50×10^9/L or PLT transfusion-dependent after stopping avatrombopag , reuse avatrombopag at 40 mg/d.
75763883|NCT06202625|Drug|Placebo|The placebo 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT<50×10^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase placebo dosage to 40 mg/d; When PLT≥80×10^9/L and without PLT transfusion within placebo dosage at 40 mg/d, decrease placebo dosage to 20 mg/d; When PLT≥80×10^9/L for 7 consecutive days or PLT≥300×10^9/L and without PLT transfusion, stop placebo; When PLT<50×10^9/L or PLT transfusion-dependent after stopping placebo, reuse placebo at 40 mg/d.
75613505|NCT05157724|Procedure|PLASMA|"The aim is to remove the prostatic adenoma by enucleation, i.e. to pass through the plane between the adenoma and the prostatic capsule, as opposed to resection, which also consists of removing the adenoma, but by making small cuts in the prostatic tissue, without necessarily reaching this anatomical plane between the adenoma and the capsule. This means removing less adenoma and therefore increasing the risk of adenomatous regrowth in the long term or obtaining worse results than enucleation in the short to medium term.~The other advantage of using this approach is that it reduces intra- and post-operative bleeding and does not require the systematic discontinuation of anti-aggregating or anticoagulant treatments prior to the operation. The field of indications is thus potentially enlarged."
75763884|NCT06202612|Drug|SHR0302 quick release tablets|SHR0302 quick release tablets 8 mg
75763885|NCT06202612|Drug|SHR0302 sustained-release tablets|SHR0302 sustained-release tablets 10 mg
75763886|NCT06202586|Procedure|low FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 30% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 30% (2L oxygen +14L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 30% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
75763887|NCT06202586|Procedure|high FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 80% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 80% (14L oxygen +2L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 80% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
75763888|NCT06202573|Procedure|rhinoplasty|patients who have a step counter and we do not motivate them to walk
75906727|NCT03064516|Procedure|Endocrown|In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.
75460417|NCT01839344|Drug|placebo|An oral single dose of a solid, colored empty capsule.
75613506|NCT05155267|Other|Biomonitoring study to detect MNPLs in biological samples and study of their health effects|Determination of MNPLs levels, genotoxic damage and immunological effects
75613507|NCT05139173|Device|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) and the exercise is started on the tablet, while patients are performing physiotherapy exercises.
75763889|NCT06202560|Drug|Tofacitinib 5 MG|Participants in the research will receive oral Tofacitinib medication with a dosage of 5 mg, twice a day, for 12 weeks. They will be scheduled to come for follow-up every 4 weeks throughout the 12-week period, and will continue to be followed up for 4 weeks after stopping the medication. The total duration of the research will be 16 weeks. The purpose is to evaluate the effectiveness and safety of the medication.
75763890|NCT06202547|Biological|Intra-ovarian injection of bone marrow mesenchymal stromal cells-derived extracellular vesicles|he patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
75763891|NCT06202534|Other||radiotherapy
75763892|NCT06202521|Drug|CX-4945 (SARS-CoV-2 domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
75763893|NCT06202521|Drug|Placebo (SARS-CoV-2 domain)|The dosage and frequency is the same as active drug.
75906728|NCT03064516|Procedure|Onlay and fiber pin|In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
75906729|NCT03573999|Drug|Mannitol|4.6 ml/kg will be administered before dura opening
76070447|NCT06057532|Dietary Supplement|Gatorade|Active control patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the active control study drink and record information about how they feel before and after consumption.
76070448|NCT06057519|Drug|Optimised dose rifampicin|Optimized dose of rifampicin
75613508|NCT05130762|Device|BD PureHub™ Disinfecting Cap Placements: Attachments/removals|Attachment/Removals of BD PureHub™ Disinfecting Cap
75613509|NCT05126381|Behavioral|Smoking|The Study contains patients who are allowed to smoke
75613510|NCT05126381|Behavioral|non-somking|The Study contains patients who are not allowed to smoke
75613511|NCT05124561|Biological|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
75906730|NCT03573999|Drug|NaCl 7.5%|2 ml/kg will be administered before dura opening
76070449|NCT06057519|Drug|Standard dose rifampicin|Standard dose rifampicin
76070450|NCT06057506|Device|Paranix® Shampoo|well established medical device for the treatment of head lice infestation (osmolone based)
76070451|NCT06057506|Device|Paranix® Lotion|well established medical device for the treatment of head lice infestation (dimethicone based)
75613512|NCT05124561|Biological|Placebo|Nebulized inhalation through the mouth
75613513|NCT05115890|Other|Exercise training|Patients with HFpEF will undergo 8 weeks of exercise training.
75613514|NCT05093322|Drug|Surufatinib in combination with Gemcitabine|Surufatinib in combination with Gemcitabine
76070452|NCT06057493|Other|Retinal Imaging with Optina4C Camera|"The study consists of 2 visits and 8 Imaging sessions:~The participant will go through four (8) imaging sessions in two visits with the Optina-4CTM cameras to get pictures of your retina. These imaging sessions will be done by three qualified operators who have been trained on the study device by Optina Diagnostics."
76070453|NCT06057441|Device|Auditory noise stimulation|Auditory white noise stimulation delivered at 78dB through earphones
76070454|NCT06057441|Device|Visual noise stimulation|Visual white pixel noise stimulation, backgound pixel noise visible at computer screen
75613515|NCT05085561|Drug|REC-994|REC-994 200 mg tablets
75613516|NCT05085561|Drug|Placebo|Placebo Tablets
75613517|NCT05074355|Drug|Azacitidine|Azacitidine is a hypomethylating agent that works by activating certain genes in the body to help cells mature and to kill abnormal bone marrow cells.
75613518|NCT05074355|Drug|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells.
75906731|NCT04863703|Drug|Bulevirtide|Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.
75906732|NCT03571425|Other|Oral Placebo|A placebo beverage will be consumed orally
75906733|NCT03571425|Other|Oral Protein|A protein beverage will be consumed orally
75906734|NCT03571425|Other|Enteral Protein|A protein beverage will be consumed via a naso-gastric feeding tube
75906735|NCT03063190|Drug|Vitamin D|patients will receive vitamin D supplementation according to guidelines
76070455|NCT06057415|Procedure|HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation|Tactile-kinaesthetic and Oral sensorimotor Stimulation
76070456|NCT06057389|Dietary Supplement|aronia melanocarpa extract|aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst；twice a day，one at a time) combined with an energy-restricted diet
76070457|NCT06057376|Other|Low-FODMAP diet group (LFD)|Each participant will be following a low-FODMAP diet group for 3 weeks, followed by 3 week break prior to second diet intervention.
75763894|NCT06202521|Drug|CX-4945 (Influenza virus domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
75613519|NCT05071586|Device|Soterix 1x1 tDCS LTE Stimulator Device Model 1401|Participants will receive 20 minutes of 1.5 mA (Milliampere) transcranial direct current stimulation (tDCS) via Soterix 1x1 tDCS LTE Stimulator Device Model 1401 with a bilateral M1 montage.
75613520|NCT05056987|Device|Lehfilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
75613521|NCT05056987|Device|Senofilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
75763895|NCT06202521|Drug|Placebo (Influenza virus domain)|The dosage and frequency is the same as active drug.
75763896|NCT06202495|Device|Laser and Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) in association 980nm diode laser (doctor smile wiser by Lambda s.p.a. Via dell'Impresa, 1, 36040 Brendola VI, Italy) 1.5 W, pulsed mode 2 mm from tooth surface
75763897|NCT06202495|Other|Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States)
75613522|NCT05056987|Device|AOSEPT PLUS with HydraGlyde|Hydrogen peroxide-based cleaning and disinfecting solution
75763898|NCT06202482|Other|Connect Active Program|Younger adults will help older adults increase their digital literacy, skills, and desire to exercise and become more physically active via the proposed intervention. The Connect Active Program will consist of two components: walking exercises and mobile apps.
75763899|NCT06202469|Dietary Supplement|Supplement 1|Creatine monohydrate (5 g/day)
75763900|NCT06202469|Dietary Supplement|Supplement 2|Creatine monohydrate (5 g/day) plus ubiquinol (200 mg/day)
75613523|NCT05055206|Diagnostic Test|SPECT-CT|99m-Technetium Sulfur Colloid will be injected prior to the scan.
75460418|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~4% trisodium citrate solution~Calcium chloride solution (100 mmol/L)~Dialysate flow rate: 35 ml/kg/h~Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~Blood flow adapted to the acid-base status"
75613524|NCT05053035|Drug|AL001|Administered via intravenous (IV) infusion
75613525|NCT05053035|Drug|Placebo|Administered via intravenous (IV) infusion
75613526|NCT05051046|Procedure|Colonoscopy under hypnosis|The hypnosis used will be of the Ericksonian type. Before the colonoscopy begins, the IDE puts the patient in a hypnotic situation.
75613527|NCT05043441|Behavioral|Acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with psychoeducation materials provided.
75763901|NCT06202469|Dietary Supplement|Placebo|Placebo (inulin)
75763902|NCT06202456|Drug|Huazhi Rougan granule|Huazhi Rougan granule
75763903|NCT06202430|Procedure|High Thoracic Erector Spinae Plane Block|High Thoracic-ESPB The patient was placed in the lateral decubitus. The transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.
75763904|NCT06202430|Procedure|Shoulder Block|"Shoulder Block Suprascapular nerve block (SSNB) approach: The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle.~Axillary nerve block technique:~The nerve approach had been described in plane from cranial to caudal. After local infiltration of the skin with 1% lidocaine, the needle tip must be visualized within the fascia below the teres minor muscle and just above the PCHA. After cautious aspiration, 10 ml of 0.5% bupivacaine was injected on the posterior aspect of the humerus."
75763905|NCT06202417|Drug|Fruquintinib|an oral tyrosine kinase inhibitor (TKI)
75906736|NCT03063190|Drug|Placebo Oral Tablet|patients will receive placebo oral tablets
76070458|NCT06057376|Other|Low Sugar diet group (LAS)|Each participant will be following a low added sugar diet group for 3 weeks, after 3 week break.
76070459|NCT06057363|Other|volumetric evaluation of gingival augmentation around dental implants|objective volumetric and clinical assesment of vestibular gingival soft tissues changes upon treatment with laser-aided pouch roll augmentation technique and implant placement over a 12-month follow-up
75763906|NCT06202391|Procedure|Autogenic Inhibition-MET|Autogenic Inhibition-MET protocol: 3-5 repetitions of post isometric relaxation (PIR) (30- 50% isometric contraction of the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold. A total of 12 sessions, four times a week, for three consecutive weeks.
75763907|NCT06202391|Procedure|Reciprocal Inhibition-MET protocol|Reciprocal Inhibition-MET protocol: 3-5 repetitions of Reciprocal Inhibition (RI) MET (30- 50% isometric contraction of the muscle opposite to the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold A total of 12 sessions, four times a week, for three consecutive weeks
75763908|NCT06202365|Device|Whole body Vibration|A vibrating platform (WBV) will be used in this study with 6 training exercises for 4 minutes, 2 times /week for 6 weeks. Feet should be parallel at shoulder width apart and knees hold constant. WBV sessions were conducted from low to medium-vibration mode
75763909|NCT06202365|Other|Sham Whole body vibration|They will receive the same intervention while the device turned off for 4 minutes, 2 times /week for 6 weeks.
75763910|NCT06202352|Behavioral|Meditation and Yoga|The yoga and meditation intervention will use a 60-minute vinyasa yoga class once a week, followed by a guided yoga instruction booklet that takes an average of 30 minutes to read. The intervention will be carried out in the last eight weeks of the spring semester, when hospital practices are most intense and before the final exams. Posttest forms will be filled out the week of final exams. The time devoted to meditation will be increased every week for the last two weeks, starting with 5 minutes and gradually increasing to 20 minutes in the eighth week.
75763911|NCT06202339|Device|DaRT seeds|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
75763912|NCT06202326|Device|renal artery doppler|doppler ultrasound follow up
75763913|NCT06202313|Biological|Cadonilimab|Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m^2 IV on Days 1 and 8 of each 21-day cycle.
75763914|NCT06202313|Drug|Eribulin|Participants receive Eribulin 1.4mg/m^2 IV on Days 1 and 8 of each 21-day cycle.
75763915|NCT06202300|Other|Inflammation burden|Coronary artery disease patients undergone multimodality imaging with different level inflammation burden
75763916|NCT06202287|Other|Balance measurements using the HUR Smart balance device, balance tests, and other surveys.|50 stroke patients will undergo balance measurements using the HUR Smart balance device and other tests.
75763917|NCT06202261|Drug|TQB2930 for injection|TQB2930 for injection is a HER2 bispecific antibody.
75906737|NCT03992638|Procedure|leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF|Completing root coverage by coronally advanced flap technique in combination with L-PRF.
75906738|NCT03992638|Procedure|CAF|Completing root coverage by coronally advanced flap technique alone
75906739|NCT03573843|Other|Prevention software|All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
75613528|NCT05043441|Behavioral|Psychoeducation|The psychoeducation control group will receive care as usual with psychoeducation materials provided.
75906740|NCT03573843|Other|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
75613529|NCT05023096|Other|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
75613530|NCT05014555|Biological|COVID-19 Vaccine|Three-dose mRNA COVID-19 vaccine per standard of care
75763918|NCT06202261|Drug|Docetaxel injection|Docetaxel injection is a phase M specific drug.
75763919|NCT06202248|Device|Experimental: DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
75763920|NCT06202209|Procedure|Circumferential Pulmonary Vein Isolation|Circumferential pulmonary vein isolation (CPVI) is a type of cardiac ablation procedure. Cardiac ablation procedures involve creating small scars in the heart using thermal or cold energy to block irregular electrical signals and restore normal heart rhythm. CPVI specifically creates small scars in the area where the four pulmonary veins connect to the left atrium of the heart. The pulmonary veins carry oxygen-rich blood from the lungs to the heart.
75763921|NCT06202183|Behavioral|Exercise Program|A 12 week, home-based, virtually supervised, aerobic and resistance exercise training program comprised of 36 sessions. Participants will be provided with a home stationary bike, resistance bands, and Fitbit. Virtually supervised sessions will be accessible via Zoom platform. For participants who do not have a device, a Wi-Fi-enabled tablet will also be provided.
75906741|NCT03573765|Procedure|Shoulder arthroplasty|Any form of joint replacement of the glenohumeral joint including prosthetic and excision.
75906742|NCT03573765|Procedure|Elbow arthroplasty|Any form of joint replacement of the elbow joint including prosthetic and excision.
75906743|NCT03573765|Procedure|Hand and wrist arthroplasty|Any form of joint replacement of joints of the hand and wrist including prosthetic and excision.
75906744|NCT03573765|Procedure|Nerve decompression|Open or endoscopic release of peripheral nerve entrapment - subdivided by anatomical site of compression. Specific subgroups will include carpal tunnel and cubital tunnel release.
75906745|NCT03573765|Procedure|Tendon repair|Open or arthroscopic repair or reconstruction of tendons of the shoulder, hand and upper limb in general.
75906746|NCT03573765|Procedure|Joint stabilisation|Any procedure designed to increase stability of a joint, including soft tissue and bony blocking procedures.
75906747|NCT03573765|Procedure|Excision/division/release of palmar fascia|Any procedure performed for treatment of Dupuytren's contracture.
76070460|NCT06057324|Device|AI-based Apps|Families which will use the digital interactive tools to empower parents in their daily dietary choices.
76070461|NCT06057324|Behavioral|Mediterranean-based diet toolkit and activities|Families which will receive educational materials and adolescents will perform educational activities.
75763922|NCT06202157|Other|LMB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (LMB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
75763923|NCT06202157|Other|DHB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (DHB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
75763924|NCT06202118|Device|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
75763925|NCT06202105|Procedure|Laparoscopic gastrectomy|Gastrectomy with laparoscopic approach
75763926|NCT06202079|Drug|GZR4 Injection|GZR4 injection s.c., once-weekly, treat-to-target dose
75763927|NCT06202079|Drug|Insulin Degludec|Insulin Degludec s.c., once-daily, treat-to-target dose
75763928|NCT06202066|Procedure|Biospecimen Collection|Undergo blood sample collection
75763929|NCT06202066|Procedure|Computed Tomography|Undergo CT scan
75763930|NCT06202066|Biological|Incomplete Freund''s Adjuvant|Given SC
75763931|NCT06202066|Procedure|Magnetic Resonance Imaging|Undergo MRI
75763932|NCT06202066|Biological|Sargramostim|Given SC
75763933|NCT06202066|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
75763934|NCT06202066|Drug|Temozolomide|Given PO
75763935|NCT06202053|Procedure|Type of surgical incision|"The experimental group (patients received periareolar incision):~An arc-shaped incision was made on the lateral side of the patient's affected areola. The subcutaneous tissue was then dissociated between the lateral mammary gland and the skin to the level of the fourth intercostal space in front of the midaxillary line. The fatty tissue behind the breast was separated horizontally to expose the serratus anterior muscle, and an intercostal incision was made. The skin was pulled back throughout the procedure to expose a better surgical field and avoid damage to the mammary gland.~The control group (patients underwent an axillary incision):~For patients in the control group, an incision was made into the fourth intercostal space in the midline of the axilla, where subcutaneous tissue was separated and entered the chest."
75763936|NCT06202001|Drug|Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab|These patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.
75763937|NCT06201975|Other|Thyme honey|Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters
75763938|NCT06201962|Other|Massage|Massage applications will be performed for 15 minutes every morning and evening for two days.
75613531|NCT05014009|Behavioral|FIFA11+ and multidirectional training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time."
75763939|NCT06201962|Other|Foot Reflexology|In the reflexology group, the researcher will hold the baby's foot with his left hand and gently massage each foot with the thumb of his right hand for 15 minutes.
75763940|NCT06201962|Other|Control|Newborns will receive routine medical treatment and nursing care and will not undergo any procedures.
75763941|NCT06201949|Other|Articaine infiltration technique|infiltration will be performed with articaine and epinephrine 1/100 000 (Artinibsa, Inibsa, Barcelona, Spain) for all patients on their second pri-mary molar. The needle tip was placed in the buccal vestibule and then directed to the apex of the tooth and about one-third to one-fourth of the cartridge will be slowly discharged
75763942|NCT06201949|Other|Articaine nerve block technique|this technique will be performed with articaine and epinephrine 1/100 000 for all patients on their second primary molar with conventional technique inferior alveolar nerve block. The thumb will be placed on the occlusal surface of intended side and protruded toward the inner oblique ridge of ramus and then placed in touch with retromolar pad. The syringe will be directed between the two mandibular primary molars of opposite side and the needle will be pushed forward until hitting the bone, then the injection will be slowly done. After three to five minutes, treatment will be started, after numbness in the lower lip is achieved
76070462|NCT06057324|Other|Healthy plant-based snacks|Families in which children will include the snacks in their diet.
75763943|NCT06201936|Behavioral|Preliminary information on neuroaxial procedures|Pre-existing information of pregnant women on neuroaxial pain-relieving procedures for childbirth and their informative sources
75763944|NCT06201910|Other|Observation of Blood loss|Retrospetive observation of bloodloss and RBC transfusions.
75763946|NCT06201884|Device|Early rehabilitation through Adapted Physical Activity|From the day after surgery, 1 to 2 walking sessions with walking platform, lasting 6 to 30 minutes (min-max), will be proposed daily until the day of discharge.
76070463|NCT06057324|Other|AI-based Apps + Mediterranean-based diet toolkit and activities|Families which will use the digital interactive tools and receive educational material, and adolescents will perform educational activities.
76070464|NCT06057324|Other|AI-based Apps + Healthy plant-based snacks|Families which will use the digital interactive tools and children will include the snacks in their diet.
75613532|NCT05014009|Behavioral|FIFA11+ and linear sprint training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time."
75763949|NCT06201780|Diagnostic Test|serum levels of Janus Kinase 1and 2|assessment of serum levels of Janus Kinase 1and 2 by ELISA
75763950|NCT06201754|Other|Measure air quality|Measure air quality, including PM2.5、PM10
75763951|NCT06201728|Other|Follow-up in a flare-up clinic|Follow-up in the clinic based on the time frame specified above. Additional interventions during the clinic visit, other than specified above, includes: An overview by a pulmonologist of new exacerbations, systemic steroid use, or other hospitalizations, active medications and compliance to treatment, inhaler using technique, possible medication side-effects, and the asthma control test (ACT) score. The physician will provide information on smoking cessation when relevant and pulmonary rehabilitation. In addition, decision on change of treatment and further evaluations outside of the clinic, including initiation of biologic treatment.
75763952|NCT06201702|Dietary Supplement|pomegranate extract|Drink 2 mL of pomegranate extract three times a day for 10 days during the 3 menstrual cycles (from 7 days before to 3 days after the estimated onset of menstruation).
75763953|NCT06201676|Drug|Ketorolac Injection|Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin Reference ID: 3281582 3 synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
75763954|NCT06201676|Other|Normal Saline|0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+) 154 mEq; chloride (Cl-) 154 mEq. The osmolarity is 308 mOsmol/L (calc.).
75763955|NCT06201663|Drug|Romiplostim|Weekly subcutaneous injections
75763956|NCT06201650|Diagnostic Test|Neurofilament light chain|Neurofilament light chain as biomarker for amyotrophic lateral sclerosis
75613533|NCT05006417|Drug|Botox|reconstituted at 100 units/mL, dosage will be based upon the affected muscles
75613534|NCT05001152|Drug|Ozanimod|Taste assessment
75763957|NCT06201637|Other|Performance Test|Performance Test
75763958|NCT06201624|Drug|Isotretinoin|Patients will receive 1mg/kg/day for 3 months
75763959|NCT06201624|Drug|Triple combination formula|Patients are instructed to apply the triple combination formula at night daily for 3 months
75763960|NCT06201611|Drug|Nebivolol+ Standard care arm|This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
75763961|NCT06201611|Drug|Epalrestat + Alpha Lipoic Acid +Standard care|This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
75763962|NCT06201611|Drug|Standard care alone|Patients in this arm will receive standard care as judged by their treating physicians which is generally pain modifying treatment.
75763963|NCT06201585|Device|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
75906748|NCT03573765|Procedure|Surgical fixation of fractures|Any internal or external fixation of upper limb fractures - analysed by anatomical site.
75906749|NCT03573765|Procedure|Soft tissue release/debridement/excision|Any removal or release of soft tissue for treatment of stiffness, functional impairment or pain. Specific subgroups will include trigger finger release, subacromial surgery and surgery for frozen shoulder.
75460419|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~Standard dialysate for CRRT : Prismasol® K2 solution~Dialysate flow rate: 35 ml/kg/h~Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of"
75460420|NCT01839669|Device|Foot Orthoses Only|patients wear foot orthoses as a treatment condition - no further therapy
75460421|NCT01839669|Procedure|Foot Orthoses and Eccentric Exercise|patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
75763964|NCT06201572|Other|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared. The data management platform provides intelligent management of patients' out-of-hospital follow-up, and the dynamic physiological indicators and psychological assessment data of patients are mastered through the hospital port, so as to provide telemedicine guidance for patients, so as to improve the prognosis of hypertensive emergency patients.
75763965|NCT06201559|Drug|Albendazole IP 400 mg|Albendazole IP 400 mg tablets will be administered under fed conditions
75763966|NCT06201559|Drug|Albendazole 400 mg|Albendazole 400 mg tablets will be administered under fed conditions
75763967|NCT06201533|Behavioral|combined physical-cognitive exercise|A combined physical-cognitive exercise will be delivered in the form of exergame, where the participants move their body to interact with the game.
75763968|NCT06201520|Procedure|manual acupuncture|manual acupuncture
75763969|NCT06201520|Device|laser acupuncture|laser acupuncture therapy
75906750|NCT03573765|Procedure|Intra-articular injection|Any intra-articular injection
76070465|NCT06057324|Other|Mediterranean-based diet toolkit and activities + Healthy plant-based snacks|Families which will receive educational material, adolescents will perform educational activities, and children will include the snacks in their diet.
75763970|NCT06201520|Device|sham laser acupuncture|sham laser acupuncture
75763971|NCT06201520|Device|wrist splint|wear wrist splint at night
75763972|NCT06201481|Procedure|anterior and posterior full coverage crowns|Teeth preparation,crown fitting and cementation
75763973|NCT06201468|Other|Group A SCAPULAR MOBILIZATION|"Two treatment groups will receive interventions as follows:~Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks."
75763974|NCT06201455|Procedure|PEI+GT|After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
75906751|NCT03573687|Dietary Supplement|Micellar Casein Protein|The micellar casein protein supplement (PRO, total protein content: 30 g, 120 kcals; 30 g micellar protein) and non-caloric sensory-matched placebo (PLA, 0kcals) will be specifically formulated by Dymatize® Nutrition FrieslandCampina® and consumed in a randomized order. Participants will consume the daytime supplement 30 minutes after RT and the nighttime supplement about 30 minutes before bedtime. The supplements will be premixed, taste-matched (chocolate), and provided in opaque shaker bottles.
76070466|NCT06057324|Other|AI-based Apps + Mediterranean-based diet toolkit and activities + Healthy plant-based snacks|Families which will use the digital interactive tools and will receive educational material, children will include the snacks in their diet, and adolescents will perform educational activities.
76070467|NCT06057285|Device|An ACLs cart training course was developed using augmented reality (AR) technologies|The developed first aid cart learning system was applied to ACLs drills in a regular ACLs training program, and an AR group used this learning system to assist in their learning. The AR group scanned the dedicated AR marker using a mobile device
76070468|NCT06057259|Device|Joint position sense measurement|The participants' wrist joint position sense was evaluated.
75460422|NCT01839669|Device|Sham Foot Orthoses|patient wear sham foot orthoses (control condition)
75613535|NCT05000632|Behavioral|Smoke Free SafeCare|SFSC is the systematically braided curriculum which combines both SafeCare and STBO programs, but in a new delivery format. To take full advantage of the home delivery mechanism of SafeCare, the content delivery of STBO has been adapted so that original mailings will be delivered in the SafeCare sessions. STBO has been fully braided into the Health and Safety modules. One of these interventions will be delivered first throughout the course of the study. The Smoke Free SafeCare intervention will involve 25 providers receiving training for the SFSC program. They will each recruit 10 mothers and conduct the SFSC program for each family. Overall, 250 families will receive the SFSC intervention.
75763975|NCT06201455|Procedure|PEI+MED|Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.
75763976|NCT06201442|Other|Imaging - magnetic resonance imaging (MRI)|MRI knee - not standard of care
75763977|NCT06201442|Other|Blood sampling|blood sample taken and analysis - not standard of care
75763978|NCT06201442|Other|Assessment of functionality and strength|Movements and posture Analysis Laboratory Leuven measurement (3D motion analysis) and Biodex measurement - not standard of care
75763979|NCT06201442|Other|Activity monitoring|Actigraph measurement- not standard of care
75906752|NCT03573687|Other|Resistance Exercise Training|Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)
75763980|NCT06201442|Other|Imaging - x-ray scan (RX)|RX Knee and EOS radiography full leg - not standard of care
75763981|NCT06201442|Behavioral|Questionnaires|Patient reported outcomes (PROMS)
76070469|NCT06057220|Other|No intervention sample collection only|No intervention
75763983|NCT06201351|Device|adaptive radiotherapy|MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
75763984|NCT06201338|Procedure|Screening of preoperative frailty|"The day before the surgery, a multimodal evaluation is performed regarding :~Cognitive assessment: Mini mental State evaluation (MMSE) test Physical functional assessment: Chair raising Addiction assessment: Fagerstrom Assessment of the social environment: environmental assessment Nutritional assessment: Grip test Quality of life: completion of SF 36 scale and QOR15 scale"
75763985|NCT06201325|Other|virtual reality based exercises|play VR games
75763986|NCT06201325|Other|conventional physical therapy|streching and strengthening exercises
75763987|NCT06201325|Other|home exercises program|home exercises
75763988|NCT06201312|Other|COP exercise|crossover point intensity exercise
75763989|NCT06201286|Other|Mulligan Concept|"Mulligan Concept was applied by the physiotherapist who received A-B module trainings. Mulligan techniques were performed with 3 sets of 10 repetitions and 15-20 seconds rest between sets. Mobilisations were applied to the spinous process of each vertebra of the lumbar region with 3 sets of 10 repetitions of SNAG and 3 sets of 10 repetitions of NAGS techniques. In the standing position, the physiotherapist took a position next to the patient and stabilised the patient by grasping the abdomen with one arm.~Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds."
75906753|NCT03576027|Other|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
76070470|NCT06057207|Diagnostic Test|serum levels of adiponectin|adiponectin level will be measured on a day of surgery, 24 hours and 72 hours after surgery
75763990|NCT06201286|Other|Stretching and strengthening exercises|Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds.
75613536|NCT05000632|Behavioral|Standard SafeCare|SafeCare is a brief parenting intervention that is highly effective in reducing child maltreatment perpetration and improving behavioral outcomes for CPS-involved parents of young children (0 to 5 years) as the result of child physical abuse or neglect (the two most common forms of substantiated maltreatment). The Standard SafeCare intervention will involve 25 SafeCare providers delivering the SafeCare program as usual. They will each recruit 10 mothers and conduct SafeCare for each family. Overall, 250 families will receive the standard SafeCare.
75613537|NCT04999956|Procedure|dynamic navigation surgery|immediate implant placement using dynamic navigation
76070471|NCT06057207|Diagnostic Test|IL-6|IL-6 level will be measured on a day of surgery, 24 hours and 72 hours after surgery
75613538|NCT04999956|Procedure|freehand surgery|immediate implant placement using freehand surgery
75763991|NCT06201273|Behavioral|High-Intensity Interval Training|This High-Intensity Interval Training (HIIT) program, structured to span 12 weeks, incorporates three sessions per week. Each session comprises 8 to 10 exercise intervals on a cycle ergometer. During these intervals, participants are required to reach an intensity level between 8 and 10 points, based on the modified Borg scale, which ranges from 1 to 10 points. A typical interval involves 1 minute of intensive pedaling, followed by a 2-minute rest period without any activity. To facilitate progressive development, the resistance of the cycle ergometer will be adjusted biweekly to increase the pedaling challenge. Despite these adjustments, participants should consistently maintain their effort intensity within the 8 to 10 point range on the modified Borg scale for each interval.
75763992|NCT06201273|Behavioral|Resistance Training|"This training protocol, spanning a duration of 12 weeks, consists of three weekly sessions. In each session, participants will engage in Elastic Resistance Exercises (ERE) using Theraband CLX elastic bands. The focus will be on both concentric and eccentric contractions, maintaining an intensity level of 8 to 10 as per the OMNI-RES scale. Each exercise will be conducted for 1 minute, followed by a 2-minute rest period. Each exercise will be repeated three times within the session.~The specific exercises include bicep curls, seated horizontal rows, and wide squats. To ensure proper progression and adaptation, the exercise load will be adjusted biweekly. This adjustment will be based on the physiological adaptations of the subjects to the training, aiming to recalibrate the loads to new resistance thresholds and maintain a consistent intensity of 8 to 10 on the OMNI-RES scale for each exercise."
75763993|NCT06201247|Drug|JD123 injection|JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.
75763994|NCT06201234|Drug|Niraparib + Elacestrant|Niraparib 200mg orally daily and elacestrant 400mg orally daily
75613539|NCT04999306|Behavioral|Hypnosis|one weekly session during 6 weeks (6 sessions of 30min/1 hour).
75613540|NCT04999306|Behavioral|CBT|one weekly session during 6 weeks (6 sessions of 1 hour).
75763995|NCT06201234|Drug|Niraparib|Niraparib 200mg orally daily
75763996|NCT06201221|Procedure|single-port laparoscopy surgery|The two groups underwent different surgical procedures.
75763997|NCT06201221|Procedure|multiport laparoscopy surgery|The two groups underwent different surgical procedures.
75763998|NCT06201208|Behavioral|The ST-Facilitation Psychoeducation Program|"One of the important roles of the psychiatric nurse, who helps healthy/sick individuals and their families to improve their mental health, prevent and cope with diseases, is their educational role. The psychiatric nurse determines the psychosocial care needs of the patient and his family and plans, implements and evaluates psychoeducational interventions, which are an evidence-based practice, to meet these needs.~Psychiatric nurses can benefit from existing programs when developing a psychoeducation program, or they can be advised to create programs that include educational and psychosocial goals based on theory specific to the problems of the relevant population. The theoretical basis is of great importance when planning a psychoeducation program. In this study, the psychoeducation program was based on the Self-Transcendence Theory of Pamela G. Reed, a psychiatric nurse."
75763999|NCT06201195|Procedure|Adductor canal blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
75764000|NCT06201195|Procedure|Distal adductor canala blockade and anterior cutaneus nerve blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
75764001|NCT06201156|Device|Metered Dose Inhaler With Spacer Device|Bronchodilator Therapy
75906754|NCT03571269|Procedure|Optical coherence tomography-guided reperfusion strategy|Optical coherence tomography will be used to detect the detailed characteristics of culprit lesion and to decide and optimize the reperfusion strategy according to the established algorithm in the protocol.
75613541|NCT04979078|Device|Photobiomodulation therapy (PBMT)|Patients will receive PBM on the sole of their feet and palms of their hands
75613542|NCT04978636|Other|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
76070472|NCT06057207|Other|Postoperative systemic infflamation|systemic infflamatory response syndrome (SIRS) will be estimated in firs 72 hours after surgery by clinical criteria: apperance of at least 2 from 4 major clinical signs of SIRS: heart rate>90/min, body temperature >38 C or <36 C, WBC >12 000 or <4000, hyperventilation, CRP >50mg/L, PCT > 0.5 ug/L.
76072485|NCT04021953|Behavioral|Sexual Health Pamphlet (Standard of Care)|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
75764002|NCT06201104|Other|Patient empowerment education|"After the pre-test is administered to the patients in the experimental group, patient empowerment training (intervention) will be given. Patients will be divided into groups of 15 people and the training will be given in a total of 6 sessions, all in one session. The Patient Empowerment Handbook prepared by the researchers will be used during the training. The training was planned to last 1 hour (45 minutes of theoretical training, 15 minutes of question and answer). The training was planned to be carried out in an interactive manner (question and answer method, sharing of patient experiences, group discussion). The Patient Empowerment Handbook will be delivered to patients after the training for them to read whenever they want. How to use the manual will be explained to patients."
75764003|NCT06201065|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
75764004|NCT06201065|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
75764005|NCT06201065|Drug|Toripalimab|240 mg iv.drip Q3W
75764006|NCT06201065|Drug|oxaliplatin , fluorouracil, and leucovorin|FOLFOX-HAIC
75764007|NCT06201052|Other|Exercise test|Beep Test for measuring aerobic power
75764008|NCT06201039|Drug|0.5% Lidocaine Hydrochloride|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI block will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.
75764009|NCT06201039|Drug|0.9% Normal Saline|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 72 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI placebo will start immediately at a speed of 4ml/h containing 0.9% normal saline + 1:400000 adrenaline.
75764010|NCT06201013|Behavioral|urotherapy|Participants were asked to undergo a 30-min session every 6 weeks at follow-up, including (1) education about the disease to dispel doubts about it and to understand the benefits of curing the dysfunction in order for the child to have a better therapeutic outcome, (2) urination at regular intervals and the establishment of good urination habits, (3) dietary instructions to avoid constipation, (4) accurate recording of symptoms of OAB, and (5) communication with the research team every 2 weeks.
75764011|NCT06201013|Drug|Solifenacin Succinate|In addition to urotherapy, take Solifenacin succinate 5mg once daily, maximum dose 10 mg/day
75906755|NCT01671280|Drug|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
75906756|NCT03573531|Other|Laboratory analysis|Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity
76070473|NCT06057207|Other|Postoperative complications|Complications in early postoperative period during hospitalisation will be including: surgical operation site related: anastomotic dehiscence, wound/local infection, postoperative bleeding, reoperation and systemic complications: sepsis, pneumonia, uroinfection, noncardiac respiratory failure, (need for noninvasive oxygen therapy), prolonged mechanical ventilation >24 hours postoperative, reintubation, repeated mechanical ventilation atrial fibrillation, congestive heart failure, myocardial infarction, acute kidney injury/failure. Length of ICU and overall hospital stay with final outcome after discharge from hospital will be documented.
76070474|NCT06057194|Drug|Letermovir 240 mg Oral Tablet|Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.
76070475|NCT06057181|Genetic|Exome sequencing|Exome sequencing will be completed on each sample submitted.
76070476|NCT06057168|Drug|Elucirem|Intravenous administration
75613543|NCT04978636|Other|Continuous low tidal volume ventilation with using FiO2 of 1.0|The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
75613544|NCT04978636|Other|Apnea During CPB|There will be no ventilation used. But, during the sub-study part of the Apnea CPB extra blood samples will be drawn before and after CPB.
75613545|NCT04967391|Procedure|Tumescence During STSG Harvest|Tumescence injections performed prior to STSG harvest
75906757|NCT01405963|Drug|Placebo|Administered in a 1-hour intravenous infusion
75906758|NCT01405963|Biological|Tezepelumab|Administered in a 1-hour intravenous infusion
75906759|NCT03571113|Other|Survival / not survival|Outcome with good neurological status vs. bad neurological status at hospital discharge
75906760|NCT03575715|Device|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
75906761|NCT03065374|Biological|IMM-529|IMM-529
75906762|NCT03065374|Other|Placebo|Matching placebo
76070477|NCT06057168|Drug|Dotarem|Intravenous administration
75613546|NCT04930653|Procedure|Extracorporeal Photopheresis|Undergo ECP
75613547|NCT04930653|Biological|Mogamulizumab|Given IV
75613548|NCT04930653|Other|Quality-of-Life Assessment|Ancillary studies
75613549|NCT04930653|Other|Questionnaire Administration|Ancillary studies
76070478|NCT06057116|Other|massage|Massage and acupressure were applied when cervical dilatation was 3-4, 5-7 and 8-10 cm in latent active and transitional phases.
76070479|NCT06057103|Drug|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
75613550|NCT04922268|Other|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
75764012|NCT06201013|Drug|Vitamin D3|In addition to urologic therapy, vitamin D drops containing 400 IU of vitamin D3 per capsule, 1,200 iu per oral dose, twice daily, for a total of 2,400 iu/d; serum vitamin D levels need to be rechecked at every 6-week follow-up visit
75764013|NCT06200974|Radiation|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate.
75764014|NCT06200961|Device|Transnasal Endoscopy|Unsedated endoscopic evaluation through the nose.
75764015|NCT06200961|Procedure|Esophagogastroduodenoscopy|Sedated endoscopic evaluation through the mouth.
75764016|NCT06200935|Dietary Supplement|Probiotic blend|Administration of one stick of combined probiotics per day for 5 months
75764017|NCT06200922|Other|Pelvic physiotherapy|All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.
75764018|NCT06200896|Device|Self Forming Magnets used to Create A Compression Anastomosis|Self Forming Magnets used to Create A Compression Anastomosis connecting the Duodenum to the ileal in Post Sleeve Gastrectomy Patients and Jejunum to jejunum in Roux-en-Y patients.
75764019|NCT06200883|Drug|Placebo oral vial|In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
75764020|NCT06200883|Drug|Choline Bitartrate|In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
75764021|NCT06200844|Biological|ROTAVAC 5D|Rotavirus Vaccine (ROTAVAC 5D), is a monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells, containing NLT 105.0 FFU and administered as a three-dose regimen, 4 weeks apart.
75906763|NCT03575637|Drug|Olanzapine|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
75906764|NCT03573219|Radiation|Short-wave diathermy|The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.
76070480|NCT06057103|Drug|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
76070481|NCT06057103|Drug|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
76070482|NCT06057103|Drug|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
76070483|NCT06057103|Drug|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
75613551|NCT04922268|Other|External focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
75613552|NCT04902170|Procedure|25 gauge pars plana vitrectomy|25 gauge pars plana vitrectomy
75613553|NCT04889079|Behavioral|Contraceptive use (continuation/switching/discontinuation)|Assessing contraceptive continuation/switching/discontinuation over 12-months
75764022|NCT06200844|Other|Placebo|Placebo is administered as three doses 4 weeks apart
75460423|NCT01839994|Radiation|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
75460424|NCT01839994|Radiation|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
75764023|NCT06200818|Procedure|Diode laser|
75764024|NCT06200818|Procedure|Er:CrYSGG|
75764025|NCT06200818|Procedure|Formocresol|
75764026|NCT06200805|Behavioral|tai ji quan|24-Style Taijiquan as an Intervention for College Students with Insomnia
75764027|NCT06200779|Diagnostic Test|Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test|"Described in Arms section"
75764028|NCT06200779|Drug|Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)|"Described in Arms section"
76070484|NCT06057103|Drug|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
75764029|NCT06200779|Drug|PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-sensitive strain
75906765|NCT04852198|Procedure|OAGB|Simplified gastric bypass procedure
75906766|NCT04852198|Procedure|RYGB|Roux-en-Y gastric bypass. Standard procedure in the Netherlands
76070485|NCT06057103|Drug|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
76072486|NCT02979717|Dietary Supplement|High protein, high fiber dietary supplement|
76072487|NCT02979717|Other|Low protein, low fiber comparator|
75764030|NCT06200779|Drug|PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-sensitive strain
75764031|NCT06200779|Drug|Bismuth quadruple therapy (Pylera®) for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-resistant strain
75460425|NCT01839994|Drug|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
75764032|NCT06200766|Drug|Mometasone furoate as a nasal spray|Subjects received 2 presses in each side nostrils at the same time point (± 1h).
75764033|NCT06200753|Procedure|Mechanical Thrombectomy|"Mechanical Thrombectomy: A stroke treatment method involving the use of a device to extract a blood clot from the blood vessels, restoring blood flow and reducing brain damage.~Ischemic Post-conditioning: After thrombectomy, a procedure involving inflating and deflating a balloon in situ for four cycles of 2 minutes each, reducing reperfusion injury and minimizing neural damage.~Selective Hypothermia: Administering cold saline either intra-arterially or within the cerebral sinus to lower brain temperature, mitigating ischemia-induced injury."
75906767|NCT04792255|Procedure|Carotid artery stenting with standard contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
75906768|NCT04792255|Procedure|Carotid artery stenting with reduced contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
75906769|NCT04792255|Diagnostic Test|Carotid Duplex Ultrasound|Pre- and postinterventional assessment of the treated internal carotid artery.
76070486|NCT06057090|Behavioral|Therapy Dog|Certified, volunteer therapy dogs and their handlers will be present in the room during procedures in the experimental arm to see if their presence reduces anxiety and improves behavior in pediatric dental patients.
76070487|NCT06057077|Drug|Semaglutide weekly injection|semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity
76070488|NCT06057025|Biological|"Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition"|"Single intramuscular injection of Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition."
76070489|NCT06056986|Diagnostic Test|multimodal ultrasound|Dynamic contrast-enhanced ultrasound and shear wave elastography are perfomed on target intestinal loop
76070490|NCT06056973|Drug|jinghua weikang capsule|Oral Jinghua Weikang Capsule, two capsules each time, three times a day
76070491|NCT06056960|Other|Tailored Physical Activity|"The intervention will comprise 16 sessions (2 sessions/week). 30 minutes of walking training wearing a heart rate (HR) monitor to keep exercise intensity below 70% of maximal HR.~Right after, 30 minutes of balance exercises will be performed. An experienced physical therapist will tailor exercises. Subjects will be taught how to perform the exercises by themselves. A booklet will be provided to provide guidelines. A physical therapist will call subjects, every training day to check for any problem."
76070492|NCT06056947|Drug|EVEGYN A|EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
75764034|NCT06200740|Device|Sonara|web application facilitating asynchronous observation of methadone dosing
75613554|NCT04881487|Radiation|Additional stereotactic body radiation therapy|5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
75613555|NCT04880733|Procedure|Acupuncture for pain management|A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.
75613556|NCT04880733|Other|Usual care for pain management|Patient will receive usual care for pain management.
75613557|NCT04874402|Procedure|Prepectoral approach|Two sheets of contour, fenestrated ADM sutured together are trimmed in accordance with the measurement of the expander/implant and fixed to the pectoralis major muscle (superiorly, medially, and inferiorly) and serratus fascia (laterally), covering the entire anterior surface of the device
75764035|NCT06200688|Other|PEANUT BALL|"Experimental Group: Pregnant women who were applied with a peanut ball were informed about the necessary information related to the ball by the midwife with a visual representation of the positions. A total of 5 positions were shown to the pregnant women. Peanut ball was started to be used when the cervical dilation reached 6 cm. Pregnant women in the active phase, the transition phase, and the second stage of labor where the peanut ball was applied were directed to change positions every 30-45 minutes. Importance was given to selecting positions where the pregnant woman felt comfortable.~Control Group: No intervention was made other than routine practices within the clinic for pregnant women. It was generally observed that pregnant women spent the time until delivery lying down and connected to electronic fetal monitoring."
75764036|NCT06200675|Other|Compassion-based intervention|Participants assigned to this intervention will be asked to engage in one brief compassion-focused exercise, where they will be asked to be asked to connect to their inner compassionate self. They will be asked to stay connected to that feeling while rereading what they wrote about their feelings of shame and imagining it was someone else who wrote it. Participants will then be asked to write a compassionate response to themselves. Participants will then be asked to reread this response while remaining connected to their compassionate self.
75460426|NCT01840020|Procedure|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
75764037|NCT06200675|Other|Logic-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online logic-based exercise that was adapted from a CBT thought record. Participants will be asked to reread what they wrote about their feelings of shame and chose a thought central to their shame to use for this exercise. Participants will be asked to generate evidence for and against their chosen thought, and then generate a more balanced thought. After the exercise, participants will be asked to reread their newly generated more balanced thought.
75764038|NCT06200675|Other|Placebo control condition|"Participants assigned to this intervention will be asked to listen to an audio recording of The Hobbit and then re-read what they wrote about their feelings of shame. They will then be asked to write a reflection about the thoughts and feelings arising from doing so. They will then be asked to re-read what they wrote in this reflection."
75906770|NCT03575559|Behavioral|Individual planning|Each participant forms up to three action and up to three coping plans individually, without consulting the participating friend, but discussing the plans with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
76070493|NCT06056947|Drug|EVEGYN B|EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
75460427|NCT01840020|Procedure|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
75460428|NCT01840033|Device|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
76070494|NCT06056947|Drug|Gynomax® XL Vaginal Ovule|200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)
75613558|NCT04874402|Procedure|Partial Subpectoral approach|The leading edge of the pectoral muscle is elevated and a subpectoral pocket is fashioned. The lower medial origin muscle fibers are released for anatomical expander seating. An ADM sling is sutured from the leading edge of the pectoralis muscle to the inframammary fold (over the expander) and laterally to close the expander pocket. In both groups, the size of the expander and the intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities.
75613559|NCT04869202|Diagnostic Test|COVID-19 test|Naso-pharyngeal swab test
76070495|NCT06056921|Biological|CD19 targeted CAR-T cells|A single infusion of CD19 CAR-T cells will be administered intravenously
76070496|NCT06056882|Other|CLE-guided cryobiopsy|During bronchoscopy, that is performed for suspicious pulmonary lesions, it is planned to use the CLE probe and cryoprobe simultaneously wafter detection of the round focus.
76070497|NCT06056856|Procedure|Penile skin graft substituttion urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
76070498|NCT06056856|Procedure|Buccal Mucosal Graft substitution urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
75613560|NCT04841057|Procedure|50 cm BP limb length|50 cm biliopancreatic limb length
75613561|NCT04841057|Procedure|100 cm BP limb length|100 cm biliopancreatic limb length
75613562|NCT04841057|Procedure|150 cm BP limb length|150 cm BP limb length
75613563|NCT04840394|Drug|BDB018|BDB018 is an immunotherapy agent.
75613564|NCT04840394|Drug|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
75764039|NCT06200662|Other|Analgesic strategies during the S visit:|Analgesic strategies during the S visit: standard and recommended non-pharmacological analgesic strategies used by the CRI: administration of sugar solution, support for non-nutritive sucking with a dummy and wrapping in a nappy.
75613565|NCT04839679|Behavioral|Culturally Oriented Educational Brochure|Culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner
75764040|NCT06200662|Other|Analgesic strategies at visit M|Analgesic strategies at visit M: overall non-pharmacological analgesic strategies carried out by the mother: sucking on a sugar solution, supporting non-nutritive sucking with a dummy, contact, etc.
75764041|NCT06200636|Device|Use of the PELSA System for dISF extraction|Dermal interstitial fluid will be extracted using the investigational device, for further analysis.
75764042|NCT06200597|Drug|LAD603|LAD603 SC injection.
75764043|NCT06200597|Other|Placebo|Matching placebo SC injection.
75613566|NCT04839679|Behavioral|Mayo Clinic Educational Booklet|"An Introduction to Radiation Simulation and Treatment- Barbara Woodward Lips, Patient Education Center"
75613567|NCT04839549|Drug|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
75613568|NCT04839549|Drug|Fluoromethalone .01%|Fluoromethalone .01%
75613569|NCT04837404|Procedure|Ultrasound guided femoral access for complex PCI|Ultrasound guided femoral access for complex PCI
75764044|NCT06200584|Drug|Risperidone|Antipsychotic Agent
75460429|NCT01840033|Device|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
75460430|NCT01840059|Device|Renal sympathetic denervation|A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia
75460431|NCT01840085|Drug|0.03% DSC127 topical gel|
75764045|NCT06200584|Drug|Olanzapine|Antipsychotic Agent
75764046|NCT06200584|Drug|Quetiapine|Antipsychotic Agent
75764047|NCT06200584|Drug|Risperidone and Vitamin D and Vitamin E|vitamin
75764048|NCT06200584|Drug|Olanzapine and Vitamin D and Vitamin E|vitamin and Antipsychotic agent
75764049|NCT06200584|Drug|Quetiapine and Vitamin D and Vitamin E|Vitamin and Antipsychotic agents
75764050|NCT06200532|Other|FOOTSAK (FOOTwear self-assessment kit)|FOOTSAK is a Footwear Self-Assessment Kit intended to empower people with diabetes by providing the necessary tools and instructional materials to enable self-assessment to determine whether footwear has adequate length and width. It includes measuring tools (an internal footwear length gauge, scale dividers for measuring internal footwear width, a slide rule for measuring foot length and width, a ruler and magnifying glass for reading off measurements) and instructional materials (booklet instructions and video materials)
76070499|NCT06056817|Device|Calyan Pacemaker|The Calyan pacemaker is a device designed for implantation in the chest below the xiphoid process, and includes a FlexArm containing stimulation and sensing electrodes. The Calyan pacemaker is implanted using a set of delivery tools and clipped onto the xiphoid process; the FlexArm electrodes are oriented to make contact with the pericardial surface of the heart. Pacing parameters are adjusted wirelessly with a tablet-based programmer that communicates with the Calyan pacemaker via secure Bluetooth.
76070500|NCT06056726|Procedure|BIB positioning|BIB positioning in obese patients with rectal cancer elegible for neoadjuvant therapy
75764051|NCT06200506|Device|Transabdominal radiofrecuency application|"A transabdominal radiofrequency application will be performed, with a suprapubic active plate and a passive plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks.~Frequency: 3 times a week sessions will be held three times a week for three weeks"
76070501|NCT06056713|Behavioral|Hand Massage|The hand massage application lasted 10 minutes, 5 minutes on each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
76070502|NCT06056700|Behavioral|Education|All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
76072488|NCT04145193|Drug|Standard of Care - mFOLFOX6|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
75613570|NCT04837404|Procedure|Fluoroscopy guided femoral access for complex PCI|Fluoroscopy guided femoral access for complex PCI
75613571|NCT04836221|Behavioral|Support|"Community Health Workers will conduct weekly phone calls to monitor blood pressure or blood glucose, to check in on patient need for social, practical or emotional supports, and to encourage healthy lifestyle modification.~Participants will also have access to a mobile app to support chronic disease management (Either diabetes or hypertension)."
75613572|NCT04829292|Behavioral|Supportive therapy and CBT|In this open trial participants are first offered supportive therapy followed by CBT
75613573|NCT04826185|Drug|IMB-1018972|Modified release (MR) oral tablet
75613574|NCT04826185|Drug|Placebo|Matching oral tablet
75613575|NCT04812314|Behavioral|Exercise|Participants will complete a moderate intensity continuous exercise 4 days/week.
75613576|NCT04812314|Behavioral|No exercise|Participants will remain sedentary throughout the duration of the study.
75613577|NCT04807179|Device|Experimental: RF Device Arm|Non-invasive radiofrequency Alexandrite laser
75613578|NCT04794569|Drug|tinzaparin|low molecular weight heparin
75613579|NCT04794569|Drug|Rivaroxaban|direct oral anticoagulant
76070503|NCT06056635|Device|Karl Storz Curved (11508AAK) and Straight (11506AAK) Fetoscopes|These fetoscopes will be used to view target areas during in-utero procedures. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
75764052|NCT06200506|Device|Intracavitary radiofrequency application|"An intracavitary vaginal radiofrequency application will be performed, with an active intracavitary head and with a fixed plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks. Frequency: 3 times a week sessions will be held three times a week for three weeks."
75764053|NCT06200480|Other|Telephone by nurse|Patient-initiated follow-up at week 2 and 6
75764054|NCT06200454|Device|neuromuscular ultrasound of cranial nerves|neuromuscular ultrasound of cranial nerves.
75764055|NCT06200428|Other|sleep support pillow|A sleep support pillow will be used in this study.
75764056|NCT06200402|Drug|Antibiotic loaded|This is the intervention for the study group. It involves the use of bone cement mixed with antibiotics (typically gentamicin or similar) in the hip prosthesis surgery. The purpose of this intervention is to assess whether the antibiotic-loaded cement reduces the incidence of postoperative infections compared to standard cement
75764057|NCT06200402|Other|Placebo|Placebo
75764058|NCT06200389|Diagnostic Test|microbiology testing|Vulvovaginal Candidiases patients diagnosed by microbiology testing can be included
75764059|NCT06200376|Drug|T3011|T3011 will be administered intraperitoneally twice a week.
75764060|NCT06200363|Drug|T3011|T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle.
75764061|NCT06200363|Drug|Regorafenib|Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance.
75764062|NCT06200337|Procedure|Fine needle acupuncture|All participants underwent three 24-hour apart sessions. In each session, the acupuncturist inserted two sterile needles into the left and right acupoints with a 90-degree angle and 0.5 to 1 cun in depth for TB3, 0.3 to 0.5 cun for BL65, and 0.3 to 0.5 cun for SP3. The acupuncturist rotated the needle at an angle of 180-270 degrees within 1 minute, with a frequency of 60 - 120 times/minute for stimulation.
75764063|NCT06200324|Other|Ready-to-Use Parenteral Nutrition|"In newborns weighing less than 1000 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum volume of 128 ml/kg/day, with a provision of 4 grams/kg/day of protein and a metabolic rate of 12 mg/kg/minute.~For newborns weighing between 1001-1500 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum of 110 ml/kg/day.~When enteral intake exceeds 70 ml/kg/day, a gradual decrease in the volume of parenteral nutrition is initiated. We discontinue parenteral nutrition in newborns weighing less than 1000 grams with enteral volume of 120 ml/kg/day, and for those between 1000 grams and 1500 grams, enteral nutrition volume of 100 ml/kg/day."
75764064|NCT06200298|Procedure|Erector spinae plane block with naropeine [3,75 mg/mL]|"Erector spinae plane block Procedure:~Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~Once the thorny process is identified, horizontal shift to the transverse process.~When the transverse process is spotted, sagittal rotation of the ultrasound probe~Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the ESPB group, a long-acting local anaesthetic: ropivacaine 3.75 mg/mL, 30 mL.~Repetition of the gesture for the transverse controlateral process"
75764065|NCT06200298|Procedure|ESPB with saline 0,9%|"Procedure for the Erector spinae plane block Procedure by NaCl 0.9%:~Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~Once the thorny process is identified, horizontal shift to the transverse process.~When the transverse process is spotted, sagittal rotation of the ultrasound probe~Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the control group: saline isotonic serum 30 mL.~Repetition of the gesture for the transverse controlateral process"
76070504|NCT06056622|Other|Combined Exercises|"The treatment involving multisensory stimulation through active movement was structured into two distinct segments. The initial segment encompassed exercises executed on a wobble board, comprising tasks such as squats, passing a ball between hands and to another individual, maintaining a single-leg stance, and gently destabilizing each other's balance. The subsequent segment involved exercises performed on a soft mat, including activities such as jumping from a small box and landing with both knees flexed, passing the ball to a team member during a two-leg jump, executing a two-leg jump while rotating the trunk by 90 degrees, and leaping from a small box onto a soft mat while balancing on one leg. Each of these exercises was repeated ten times within each session.~Balance-related exercises were conducted with participants assuming a shoulder-width stance on both firm and soft surfaces."
75613580|NCT04787042|Biological|ST-067|ST-067 is an engineered variant of human interleukin-18.
75764066|NCT06200285|Other|Registry of patients with accidental hypothermia|
75764067|NCT06199856|Diagnostic Test|ultrasound scan|ultrasound scan
75764068|NCT06199492|Device|tVisio-1|Standard of Care Biopsy
75764069|NCT06198426|Drug|IBI3004|IBI3004 will be administered. The Dose Limiting Toxicity (DLT) will be observed in the first treatment cycle. After completion of the DLT observation period, subjects will continue to receive IBI3004 until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
75764070|NCT06198322|Other|Platelet-rich Fibrin|Platelet-rich Fibrin will be injected distal to the canine on the experimental side
75613581|NCT04787042|Biological|Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
75613582|NCT04787042|Biological|pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
75764071|NCT06198322|Other|Vitamin D3|Vitamin D3 will be injected distal to the canine on the experimental side
75764072|NCT06197893|Procedure|gingival unit graft+modified sling suture technique|The GUG was obtained from the maxillary premolar area. A sulcular incision including the marginal gingival tissue, and two vertical incisions, including the distal and mesial papillae, was made in the palatial parts of the premolars. Then, the incision lines were combined and a 1-1.5 mm thick graft of the desired dimensions was dissected. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique. First, the needle was passed through the graft slightly apical to the mesial papilla on the buccal side and removed from the lingual aspect including lingual papilla. Subsequently, on the distal side, the needle was passed from the lingual side to the buccal side, and it was passed through the graft slightly apical to the distal papilla and removed from the lingual gingiva again. Then it was knotted on the buccal graft by returning to the buccal starting point on the mesial side.
75764073|NCT06197893|Procedure|Gingival unit graft and conventional suture technique|The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique. Conventional suture technique includes a horizontal matrix suture and 2 simple sutures. First the coronal part of the dissected graft was fixed to the recipient bed with a horizontal matrix suture, then with 2 simple sutures along the vertical incision line from mesial and distal sides with 5/0 polypropylene suture.
75906771|NCT03575559|Behavioral|Collaborative planning|Both friends together create up to three if-then plans on when, where, and how both will implement PA together. In addition, up to three coping plans will be formed together. This jointly developed plan is discussed with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans refers to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in PA). All materials are formulated using the plural.
75906772|NCT03575559|Behavioral|Education and motivation treatment|Adolescents will watch a movie from the Federal Office of Public Health Switzerland including the guidelines of physical activity (PA) for adolescents. All adolescents respond to a quiz afterwards. After the quiz, the experimenter repeats the guidelines for PA based on a brochure that all adolescents can take home with them. In addition, the experimenter asks for barriers and benefits of PA the adolescents perceive. Next to it, the experimenter explains that a weight gain might be possible due to PA in the beginning. Furthermore, the experimenter presents how the data of the accelerometer should look like if one is sufficiently physical active. As a last part self-efficacy as an important aspect of goal success is mentioned. The materials exclude any planning statements.
75906773|NCT03062956|Drug|MYK-491 or placebo|Oral suspension
75906774|NCT03704779|Behavioral|Multimodal mindfulness activity program|"This program will provide the opportunity for participants to engage in in-person and online activities. The in-person activities will be held from 12:00 pm to 12:45 pm in the Georgian Physical Therapy Lab (and offered twice per week). The online activities will be available at all times during the study at convenience. There are one 40-minute in-person and four 10-minute online mindfulness activities per week (combined time of 1 hour and 20 minutes per week).~In-person activities will consist of mindfulness activities including guided imagery meditation, yoga, Tai Chi, progressive muscle relaxation, creating a Zen garden, aromatherapy, journaling, self-massage, and pet therapy. Online materials will additionally include guided and unguided meditations."
75906775|NCT03062800|Drug|Thalidomide|100-200mg/d,oral ,qn
75906776|NCT03062800|Drug|pemetrexed|(500mg/m^2) on day 1 of 21-days cycle,ivgtt
75906777|NCT03062800|Drug|cisplatin|(75mg/m^2) on day 1 of 21-days cycle, ivgtt
75906778|NCT03062800|Drug|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
75460432|NCT01840098|Dietary Supplement|low leucine content drink|
75460433|NCT01840098|Dietary Supplement|high leucine content drink|
75613583|NCT04780971|Diagnostic Test|post-PCI Pd/Pa|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
75613584|NCT04779931|Behavioral|Convoy-Pal|12 week mobile self-management intervention with palliative care resources.
75613585|NCT04737577|Procedure|Supramarginal resection|Tissue removal beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
75613586|NCT04737577|Procedure|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
75460434|NCT01840098|Dietary Supplement|low leucine + HMB drink|
75460435|NCT01840098|Dietary Supplement|Control/carbohydrate|
75460436|NCT01840098|Behavioral|36 hour fasting|
75460437|NCT01840111|Behavioral|Quit Smoking 6 hours|participants will quit smoking 6 hours prior to the cue-exposure sessions
75460438|NCT01840111|Behavioral|Quit Smoking 24 hours|participants will quit smoking 24 hours prior to the fMRI scan
75613587|NCT04725903|Radiation|High-Dose Rate Brachytherapy|Receive high-dose rate brachytherapy boost
75613588|NCT04725903|Radiation|Proton Beam Radiation Therapy|Undergo proton beam therapy
75613589|NCT04725903|Other|Quality-of-Life Assessment|Ancillary studies
75613590|NCT04725903|Other|Survey Administration|Ancillary studies
75613591|NCT04697810|Drug|Namodenoson|25 mg q12hours x 36 weeks
75613592|NCT04697810|Drug|Placebo|Matching capsules q12hours x 36 weeks
75613593|NCT04682301|Behavioral|Behavioral Intervention|Receive SDM intervention
75613594|NCT04682301|Other|Discussion (focus group)|Attend focus group
75613595|NCT04682301|Other|Discussion (feedback on SDM)|Provide feedback on SDM
75613596|NCT04682301|Other|Interview|Attend a telephone interview
75613597|NCT04682301|Other|Survey Administration|Ancillary studies
75764074|NCT06197893|Procedure|Conventional graft and modified sling suture technique|Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The exterier edges of the foil were drawn with a scalpel and the 1-1.5 mm thick graft was dissected from the donor site. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique.
75764075|NCT06197893|Procedure|Conventional graft and conventional suture technique|Conventional graft obtained from the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique.
75906779|NCT05709015|Other|Neutral electrolyzed water|Use of mouthwash containing neutral electrolyzed water twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
75906780|NCT05709015|Drug|Placebo|Use of mouthwash containing placebo twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
75460439|NCT01840124|Procedure|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
75460440|NCT01840137|Other|Baseline Strength Test|A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
75613598|NCT04679194|Biological|Mana 312|"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."
75613599|NCT04672720|Drug|L-carnitine 1000 Mg|Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
75906781|NCT05709015|Drug|Chlorhexidine digluconate|Use of mouthwash containing chlorhexidine digluconate twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
75906782|NCT02524041|Device|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
75460441|NCT01840137|Other|Exercise|Treadmill and muscle exercises.
75460442|NCT01840176|Procedure|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
75460443|NCT01840189|Other|Cortef|Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
75613600|NCT04647448|Diagnostic Test|Application of sensor patch|Application of sensor patch to chest to record acoustic signals due to disturbed blood flow.
75613601|NCT04644224|Other|Educational Activity|Attend health coaching session
75613602|NCT04644224|Other|Educational Intervention|Attend resource navigation session
75613603|NCT04644224|Other|Informational Intervention|Receive handbook
75764078|NCT06196866|Other|Conventional Therapy|The control group will develop only conventional treatment for the whole trial (weeks 1-28), consisting of carrying out daily routine activities and/or 1 session/week of physiotherapy (which includes manual therapy, active exercises of repetition of functional movements, walking, stairs and stretching) with a time of 45 minutes/session.
75764079|NCT06196866|Device|Nintendo Ring Fit Adventure + Conventional Therapy|"In the exergaming group 1, the intervention will be 12 weeks (weeks 5-16) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle toning) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Jogging: Begginia or Transient Temple.~Minigames: Squat Goals, Squattery Wheel, Gluting Gallery, Thigh Rider, Bank Balance or Dreadmill.~Lower Limbs Training: Knee Lift or Hip Lift.~Yoga: Tree Pose or Chair Pose."
75764080|NCT06196866|Device|Nintendo Wii Fit + Conventional Therapy|"In the exergaming group 2, the intervention will be 12 weeks (weeks 5-16) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle toning) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Aerobics: Basic Run or Hula Hoop.~Strength Training: Rowing Squat, Single-Leg Extension, Sideways Leg Lift or Single-Leg Twist.~Balance Games: Ski Jump, Balance Bubble, Table Tilt or Penguin Slide.~Yoga: Chair or Standing Knee."
75764081|NCT06195930|Drug|Vericiguat (BAY1021189) 5 mg|Vericiguat (BAY1021189) will be taken as 5 mg tablet 1x daily over at least 14 days up to 18 days (+ 4 days time window allowed)
75764082|NCT06195540|Drug|Rivaroxaban 10 MG|"Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb.~Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment).~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
75906783|NCT02524041|Other|blood specimen|blood specimen
75906784|NCT03573141|Other|Physical Therapy|Subjects received a comprehensive physical therapy evaluation after baseline data collection and received a normal course pf physical therapy treatment based on impairments identified.
76070505|NCT06056622|Other|Placebo Exercise|Participants allocated to the control group will receive placebo treatment sessions, which entailed a 10-minute exposure to a visual evoked potential (VEP) measurement screen while holding a mouse. During this time, participants were given instructions to click the mouse whenever the screen exhibited a change in color. These activities were carried out while seated in a chair equipped with arm support
76070506|NCT06056609|Other|Yoga|An 8 week online mother and baby yoga programme to include daily diary completion and questionnaires at designated study timepoints
75613604|NCT04644224|Other|Questionnaire Administration|Ancillary studies
75613605|NCT04644224|Procedure|Support Group Therapy|Attend support group
75613606|NCT04629417|Device|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.
75613607|NCT04624178|Drug|Rucaparib|Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
75613608|NCT04624178|Drug|Nivolumab|Nivolumab 480mg intravenously on day 1 of every four-week cycle.
76070507|NCT06056570|Drug|dontinurad|dotinurad alone
76070508|NCT06056570|Drug|dotinurad + allopurinol|dotinurad + allopurinol 300mg
76070509|NCT06056570|Drug|allopurinol|allopurinol 300 mg alone
76070510|NCT06056531|Other|Near infrared light imaging|The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers.
76070511|NCT06056531|Other|Isometric exercise with stress ball|Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball.
75315578|NCT05030597|Drug|68Ga-DOTA-FAPI|Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
75315579|NCT05030597|Device|PET/CT|Each subject undergoes PET/CT imaging within 20-30 minutes after injection.
75613609|NCT04563338|Drug|Atezolizumab|Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.
75764083|NCT06195540|Drug|Low Heparin Molecular Weight|"Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
75764084|NCT06193824|Device|Experimental: downhill treadmill walking at -10% and -20% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% or -20% incline)
75906785|NCT03573063|Other|Androgen metabolism after starvation|"The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant."
76070512|NCT06056492|Behavioral|Experience of nitrous oxide sedation at assessment|Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.
76070513|NCT06056453|Behavioral|Interpersonal Psychotherapy|IPT group-virtual
75315580|NCT05025384|Other|Acupressure|"Acupressure stickers will be applied to one ear in accordance with the NADA protocol acupuncture technique. Application will occur at designated points including Shen Men, Liver, and Lung: in the room with the mother; and potentially during breast feeding, holding, skin to skin contact or bottle feeds. Stickers will remain in place for 24 hours.~At 24 hours, skin will be assessed, and stickers will then be rotated to the opposite ear every 48 - 72 hours if there are no adverse effects such as skin irritation."
75315581|NCT05022680|Behavioral|mhealth|the peer-led intervention with mHealth technology (an application (APP) and Sports bracelet)
75315582|NCT05016947|Drug|Venetoclax|Tablet, taken by mouth
75460444|NCT01840189|Other|Solu-cortef|"Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.~This part of the study will take 2 months."
75315583|NCT05016947|Drug|Dexamethasone|Taken orally
75315584|NCT05016947|Drug|Inotuzumab Ozogamicin|Intravenous infusion
75460445|NCT01840241|Drug|sodium bicarbonate|BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
75613610|NCT04563338|Drug|Bevacizumab|Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
75613611|NCT04562610|Drug|Intravenous Infusion group|The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
75460446|NCT01840241|Drug|normal saline|
75613612|NCT04562610|Drug|All oral administration group|Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
75764085|NCT06193434|Drug|IBI356 for MAD|Receive IBI356 in a multiple dose.
75764086|NCT06193434|Drug|Dupilumab for MAD|Active comparator
75460447|NCT01840254|Drug|dexmedetomidine|
75460448|NCT01840254|Drug|normal saline|
75460449|NCT01840267|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
75460450|NCT01840332|Drug|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is < 30 after 4 weeks the study continues up to 6 weeks.
75460451|NCT01840358|Other|Observation of hypoglycemias frequency 3 days before and after pump initiation|
75460452|NCT01840371|Drug|Conventional sedation|"Propofol Meperidine : 25 mg IV just before procedure~IV bolus of 1 mg/kg for sedation induction,~Infusion of 60 mcg/min/kg for maintenance of sedation~Additional bolus dose of 10mg as needed for adequate sedation"
75460453|NCT01840371|Drug|Experimental sedation|"Fentanyl~IV bolus of 1 µg/kg for sedation induction~Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~IV bolus of 0.4 mg/kg for sedation induction~Infusion of 30 µg/min/kg for maintenance of sedation~Additional bolus dose of 10mg as needed for adequate depth of sedation"
75460454|NCT01840384|Dietary Supplement|Multi-micronutrients|
75460455|NCT01840384|Dietary Supplement|Maltodextrin and Lactose|
75613613|NCT04558957|Device|FLEBOGRIF|The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.
75764087|NCT06193434|Drug|IBI356 for SAD|Receive IBI356 in a single dose.
75764088|NCT06193434|Drug|Placebo for SAD|Receive placebo in a single dose.
75764089|NCT06193434|Drug|Placebo for MAD|Receive placebo in a multiple dose.
75906786|NCT03571035|Diagnostic Test|Mandibular movements recordings by a mono vision system|To examine the mandible's movements, vision analysis was employed and performed with the digital camera which featured 1920 x 1080 resolution and was fixed on an aluminium extension arm attached to a headset worn by the subject.The camera was aligned parallel to the subject's face at a distance of 0.3 meters. The study used two 10 mm x 5 mm reference markers, which were accurately reproduced on the camera recorded images. In line, one marker was put on the medial cleft above the upper lip, and the other one was positioned below the first one in a straight line, in the middle of the chin. Then, the patient was asked to open maximally and close the mouth twice.To establish the mandible's trajectory, the line was drawn between the positions of the two markers to connect the two points. The line's parameters were calculated only during initial measurements and were constant throughout the study.
75906787|NCT03572907|Other|Rhinoplasty questionnaire|Each patient will complete a validated rhinoplasty questionnaire (Rhinoplasty Outcome Evaluation) before and after the intervention
75906788|NCT03570957|Drug|MT-2990|MT-2990 solution for injection in vial
75906789|NCT03570957|Drug|Placebo|Placebo solution for injection in vial
76070514|NCT06056440|Procedure|Virtual reality|"The VR intervention program for the experimental group will be carried out with a frequency of 3 sessions/week, duration of approximately 45 minutes, and for a total of 12 weeks, being performed in addition to the patient's usual treatment program.~The Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. Specifically, the specific functional rehabilitation program will be used, which comprises exercises that are easy to perform, with a playful component, and which encourage the patient's continuous attention to the task performed, acting as a distractor phenomenon in the face of restrictive movement factors such as fear of pain or movement. This software offers the possibility of adjusting the number of repetitions and characteristics of the exercises, thus allowing an individualized physical rehabilitation"
75906790|NCT04050631|Behavioral|maternal arrest simulation on L&D floor|AFE on L&D
76070515|NCT06056440|Other|Control group|The control group will only receive their usual treatment program for the 12-week duration of the study.
75906791|NCT03575481|Diagnostic Test|The RAT and The TST|The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
76070516|NCT06056427|Biological|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive autologous HB-adMSCs through intravenous infusion only, with a treatment duration of 18 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1 and infusion 2, and 4 weeks between the remaining infusions.
76070517|NCT06056414|Other|Energy Resonance by Cutaneous Stimulation|Energy Resonance by Cutaneous Stimulation session
75315585|NCT04992416|Procedure|immediate implant placement with ATBG and SMV|immediate implant placement using ATBG as a graft material, with SMV
75315586|NCT04992416|Procedure|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without SMV
75315587|NCT04987944|Drug|Zavegepant|150 mg BID
75315588|NCT04987944|Drug|Placebo|Placebo matching active drug
75315589|NCT04980066|Procedure|Sticky bone and EDTA|treatment using Sticky bone after EDTA root surface biomodification
75460456|NCT01840423|Drug|ODM-104|ODM-104
75460457|NCT01840423|Drug|Placebo|Placebo
75613614|NCT04524910|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
75613615|NCT04518917|Behavioral|Mentally Singing|Participants sing their song in their head and match their footfalls to the beat.
75613616|NCT04518917|Behavioral|Listening to music|Participants listen to their song and match their footfalls to the beat.
75460458|NCT01840423|Drug|Entacapone|entacapone + levodopa/carbidopa
75460459|NCT01840423|Drug|levodopa/carbidopa|entacapone + levodopa/carbidopa
75613617|NCT04518917|Behavioral|Singing|Participants will sing their song out loud and match their footfalls to the beat.
75613618|NCT04506424|Other|CT Guided Cochlear Implant Programming|Flat Panel (high resolution) CT scans of the temporal bones, including the inner ears, will be obtained. The research team will use the scans to generate custom cochlear implant (CI) programs for use by the participants.
75613619|NCT04505501|Drug|N-803|N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.
75764090|NCT06192446|Drug|Survey using a questionnaire.|An observational study conducted in a cross-sectional manner using a questionnaire.
75764091|NCT06191952|Diagnostic Test|Cognigram|Cognigram (previously known as the Cogstate Brief Battery) is a brief, computer-administered cognitive test battery requiring about 20-25 minutes for administration, consisting of four cognitive tasks to measure psychomotor function, attention, working memory, and learning and memory. Eisai owns the commercial rights for Cognigram and has kindly agreed to offer the required licenses for the present project free of charge. Digital cognitive testing will take place in the respective social and care centers on a tablet which is not connected to the internet. Testing will be performed pseudonymized and data from the cognitive tests will be downloaded regularly by the study team and added to the database at LMU hospital.
75315590|NCT04980066|Procedure|Sticky bone|treatment using Sticky bone
75315591|NCT04963712|Drug|Zadaxin|1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.
75460460|NCT01840436|Device|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
75460461|NCT01840436|Device|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
75460462|NCT01840449|Drug|Somatuline Autogel® 60, 90 or 120 mg|
75613620|NCT04486586|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm^2; estimated total charge 0.048 C/cm^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).
75613621|NCT04486586|Device|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
75613622|NCT04465955|Biological|NGM621|NGM621 Dose 1
75764092|NCT06191952|Diagnostic Test|Subjective cognitive decline questionnaire (SCD-Q)|The SCD-Q is a validated questionnaire assessing the presence of subjective cognitive deterioration in abilities such as memory, attention, language, and executive function. The scale includes 24 dichotomous questions (yes/no), evaluating decline in daily life during the last two years. The SCD-Q score ranges from 0 to 24, with higher scores indicating greater perceived cognitive change (cut-off classified as SCD equal or greater as 7).
75764093|NCT06191952|Diagnostic Test|blood-based biomarkers|Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer. All test results (including the respective cut-off measurements for normal vs abnormal) will be forwarded directly to the participants' GPs. No further explanations and instructions will be provided to avoid any unwanted bias, and participants will only be informed about their results by their doctors. Roche has kindly offered to provide blood biomarker assays free of charge for the present project.
75764094|NCT06191952|Diagnostic Test|ki:elements digital speech biomarker for cognition (ki:e SB-C)|The ki:elements digital speech biomarker for cognition (ki:e SB-C) can be collected remotely in fully automated telephone visits, taking 15 minutes to complete based on three specific assessments measuring learning and memory, processing speed, executive function, and language capabilities. The ki:e SB-C uses artificial intelligence and automatic speech analysis to process and transcribe speech, followed by an extraction of relevant features, combined into four subdomain and one global cognition score.
75764095|NCT06191510|Procedure|Bio-Oss Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Geistlich Bio-Oss) and left exposed to the oral environment.
75764096|NCT06191510|Procedure|Mucograft Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Bio-Oss; Geistlich) and covered by a collagen matrix (Mucograft; Geistlich).
75764097|NCT06189716|Device|High flow oxygen through nasal cannula|High flow oxygen through nasal cannula and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions.
75764098|NCT06189313|Device|Cleaner Pro Thrombectomy System|"The Cleaner™ Pro Thrombectomy System (Cleaner Pro) is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister."
75764099|NCT06186427|Diagnostic Test|68Ga-DOTA-GPFAPI-04 PET/CT|The same group of patients underwent 68Ga-DOTA-GPFAPI-04 PET/CT and FDG PET/CT examinations respectively
75764100|NCT06186284|Diagnostic Test|nerve conduction study|sensory and motor nerve conduction study of both median nerves and ulnar nerves
75764101|NCT06186284|Diagnostic Test|ultrasonography wrists|assess the cross-sectional area of the median nerves and the ulnar nerves
75764102|NCT06186284|Diagnostic Test|Boston carpal tunnel questionnaire|assess the severity of symptoms and the functional impact related to carpal tunnel syndrome
76072489|NCT04145193|Drug|E1 - mFOLFOX and durvalumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)"
75460463|NCT01840488|Drug|Irosustat (BN83495)|"Three parts (A, B & C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression."
75460464|NCT01840501|Drug|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
75460465|NCT01840501|Drug|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
75613623|NCT04465955|Biological|NGM621|NGM621 Dose 2
75613624|NCT04465955|Other|Sham Comparator|Sham Comparator
75613625|NCT04457193|Device|TIF|Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
75764103|NCT06186284|Diagnostic Test|clinical provocative tests for carpal tunnel syndrome|Tinel and Phalen's test to evaluate the presence of carpal tunnel syndrome
75764104|NCT06184919|Other|Process Mapping: Observations|Direct observations of the POSH clinic visit.
75764105|NCT06184919|Other|Process Mapping: Interviews|Semi-structured interviews of patients and providers involved in the POSH clinic.
75764106|NCT06184919|Other|Process Mapping: Focus Group|Focus group of providers and staff who conduct the POSH clinic.
75764107|NCT06184919|Other|Participatory Design|"Participatory design, also called co-design is a systems engineering approach where the researchers and participants work together in designing the workflow of an intervention. There will be two groups (design teams) of patients/caregivers and healthcare professionals per location, for a total of four groups."
75613626|NCT04450368|Device|Sylvee|The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
75460466|NCT01840501|Drug|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
75460467|NCT01840501|Drug|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
75460468|NCT01840540|Drug|Arterial infusion of autologous mesenchymal stem cells|
75613627|NCT04444895|Drug|Lanadelumab|Rollover participants will receive 300 mg of lanadelumab solution in a PFS SC injection once Q2W or Q4W for 26 consecutive weeks.
75764108|NCT06184659|Drug|Meropenem|For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion
75764109|NCT06184659|Drug|Piperacillin/Tazobactam|Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion
75764110|NCT06181435|Drug|Amlitelimab|Pharmaceutical form:Injection solution-Route of administration:SC injection
76072490|NCT04145193|Drug|E2 - mFOLFOX6, durvalumab and oleclumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)"
75764111|NCT06181435|Drug|Placebo|Pharmaceutical form:Injection solution-Route of administration:SC injection
75764112|NCT06181136|Drug|DNL126|intravenous repeating dose
75764113|NCT06175611|Device|COVID-19/Flu A/Flu B/RSV Test Kit|"The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.~Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.~This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants."
75906792|NCT03572829|Drug|Aprepitant|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1. AND then patients received aprepitant 80mg, dexamethasone 8mg on day 2-5 at every chemotherapy cycle.
75315592|NCT04911920|Other|Questionnaire Patient Rated Tennis Elbow Evaluation|Participants are asked to complete questionnaires at three measurement time points.
75315593|NCT04888845|Behavioral|Safety Plan|The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
75315594|NCT04888845|Behavioral|Crisis Response Plan|Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
75315595|NCT04888845|Behavioral|Structured interview|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach.
75315596|NCT04888845|Behavioral|Narrative Assessment|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis."
75315597|NCT04855734|Behavioral|FAmily CEntered (FACE) pACP Intervention|The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach [Sessions 1 & 2] and Respecting Choices [Session 3].
75460469|NCT01840553|Drug|oral sodium phosphate tablets|
75460470|NCT01840553|Drug|polyethylene glycol|
75613628|NCT04411823|Device|EndoFLIP measurement|EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
75764114|NCT06175065|Drug|RLS-0071|RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.
75764115|NCT06175065|Drug|Placebo|Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.
75764116|NCT06175052|Other|Dietary Intervention|Four nutrition counselling sessions conducted over eight weeks, in conjunction with food items to assist in meal preparation and with weekly educational information messages sent via email.
75764117|NCT06171659|Drug|FDG radiotracer|Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
75764118|NCT06171659|Device|PET/MRI|positron emission tomography and magnetic resonance imaging
75764119|NCT06171659|Device|PET/CT imaging|positron emission tomography and computed tomography imaging
75764120|NCT06166927|Device|Cuffed endotracheal tube|Patients will be intubated using a cuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
75613629|NCT04410653|Drug|Afatinib 40 MG|single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
75613630|NCT04377087|Drug|Olaparib|Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.
75613631|NCT04341779|Combination Product|Point-of-care viral load testing and tenofovir adherence testing|Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
75613632|NCT04322994|Device|Transnasal Humidified Rapid-Insufflation Ventilatory Echange|The use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
75906793|NCT04050787|Procedure|D2 Lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
75764121|NCT06166927|Device|UnCuffed ETT|Patients will be intubated using an uncuffed ETT (Flexicare-UK) with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
75906794|NCT04050787|Procedure|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
75764122|NCT06165887|Other|No intervention|This is an observational study, no intervention will be implemented.
75764123|NCT06165887|Other|No intervention|This is an observational study, no intervention will be implemented.
75764124|NCT06163118|Diagnostic Test|Deglut'G test|"Two tests to assess swallowing disorders using the Deglut'G tool will be carried out by a nurse or a caregiver from the Geriatric Short-Stay Unit, at visit 1.~The tests can be taken successively, or spaced apart by a time defined by the medical team, and will be taken blind to each other.~The average test administration time will be measured during the study, but the test should not exceed 10 minutes depending on the patients.~The Deglut'G tool consists of an initial administration of gelled water (1 to 3 teaspoons), to identify if a cough occurs. In the event of a cough, the oral treatment is stopped; if the cough is absent, a new step this time consists of the administration of water (1 to 3 sips). In case of cough, the food will be mixed, the liquids thickened, and the medicinal treatments crushed. If there is no cough, foods and liquids can be taken as normal."
75906795|NCT03570879|Device|Power morcellation|Power morcellation of surgical specimens after laparoscopic myomectomy.
75906796|NCT03570879|Procedure|Transvaginal extraction|Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
75906797|NCT04050475|Dietary Supplement|Fasting Mimicking Diet|The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
75906798|NCT05367921|Device|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - 4 measurements on both legs of each healthy volunteer will be performed
75315598|NCT04783012|Procedure|Catheter removal|Catheter management strategy after surgery
75315599|NCT04754243|Drug|Gonadotropin|Giving patients gonadotropins and antagonist cetrotide
75315600|NCT04754243|Drug|Standard protocol in IUI|Giving patients gonadotropins without antagonist cetrotide
75460471|NCT01840618|Device|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
75460472|NCT01840631|Behavioral|Nutritional Counseling|Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.
75315601|NCT04750616|Drug|Niacinamide|Niacinamide 3 grams on the day of surgery and post-surgical days one and two
75315602|NCT04750616|Drug|Placebo|Matched placebo on the day of surgery and post-surgical days one and two
75460473|NCT01840644|Other|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
75460474|NCT01840670|Drug|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
75764125|NCT06163118|Diagnostic Test|SLP swallowing test|"At visit 1, 1 to 2 hours after the last Deglut'G test, a second swallowing test will be carried out by a SLP according to his skills and according to his usual practice, independently of the Deglut'G tool.~This test should not exceed 20-30 minutes depending on the patient."
75764126|NCT06163118|Diagnostic Test|ENT doctor swallowing test|"At Visit 2 (day 7 +/- 3 days after the inclusion), still as part of the short-stay hospitalization, the patient will meet an ENT doctor who will carry out an examination aimed at detecting swallowing disorders, according to his usual practice, of independent of the Deglut'G tool.~The examination should not exceed 20-30 minutes depending on the patient."
75764127|NCT06162559|Drug|Tucatinib|Tucatinib 300mg is taken orally twice daily
75764128|NCT06162559|Drug|Trastuzumab|Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
75764129|NCT06162559|Drug|Pertuzumab|Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
75460475|NCT01840683|Device|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|
75906799|NCT02239497|Procedure|Femoral block by ultrasound and neurostimulation|
75906800|NCT02239497|Drug|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
75906801|NCT03572751|Diagnostic Test|Bed-, wrist- and ECG-sensor monitoring|Bed-, wrist- and ECG-sensor monitoring
75906802|NCT03705403|Drug|Darleukin|The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
75764130|NCT06155513|Other|Omega-3 monoglyceride based topical treatment|Successive application of omega-3 monoglyceride based serum and cream on a daily basis.
75764131|NCT06154239|Device|DAYE Diagnostic Tampon|The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746). The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion.
75906803|NCT03705403|Radiation|Radiation|Radiotherapy
75906804|NCT02239653|Behavioral|Physician communication|
75906805|NCT03705325|Device|Spirobank Smart spirometer|The spirometer is a compact, portable, home-based spirometer that pairs with a smartphone app. Exhaled air flow causes the turbine to rotate, generating a voltage analogous to the rate of air flow across the turbine. The spirometer measures Forced expiratory volume in 1 second (FEV1), or the volume of air that is exhaled in the first second. The device prompts the user to perform a minimum of three expiratory maneuvers in and records the best of the three maneuvers. The information generated is then transmitted to the VitalFlo App (password protected) on the user's iPhone. The user is alerted, by the App, if their expiratory effort is inadequate (such as early termination of exhalation) and is provided coaching for proper technique.
75906806|NCT03575247|Drug|Glucocorticoids|Long-term use of glucocorticoids
75906807|NCT03572673|Device|Flexima 3S|Flexima 3S (2-piece appliance) with drainable pouch
75906808|NCT03572673|Device|New 2-piece ostomy appliance|New 2-piece ostomy appliance with drainable pouch
76070518|NCT06056401|Behavioral|record Hemodynamic variables, respiratory variables and arterial blood gas at specific times|Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .
75460476|NCT01840696|Drug|Regadenoson|Vasodilator stress testing
76070519|NCT06056388|Device|Straumann BLX implant|Implant system with a deep fixture thread depth.
75764132|NCT06154239|Diagnostic Test|Vaginal self-swab|A vaginal self-swab typically consists of a long, slender, and flexible stick or handle, often made of plastic or a similar material. At one end, there's a soft, absorbent tip made of cotton or synthetic material. This tip is designed to collect a sample from the vaginal walls or cervix.
75764133|NCT06154239|Diagnostic Test|Clinician vaginal swab|A clinician vaginal swab is a medical tool used by healthcare professionals to collect samples from the vaginal canal for diagnostic purposes. It's typically a long, thin, and flexible instrument. At one end, there's a cotton, rayon, or synthetic tip designed to collect cells, discharge, or other materials from the vaginal walls, cervix, or other areas within the vaginal canal.
75764134|NCT06151730|Other|Non-Interventional Study|Non-interventional study
75906809|NCT04784065|Device|Hand orthosis|An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
75906810|NCT03575091|Other|Non-individualized|Comparing two experimental interventions with standard care
75906811|NCT03575091|Other|Individualized|Comparing two experimental interventions with standard care
75906812|NCT03704623|Drug|Paracetamol|Paracetamol 1g IV
75906813|NCT03704623|Drug|Parecoxib|Parecoxib 40 mg IV
75906814|NCT03570723|Procedure|A glove-loaded Foley's catheter tamponade|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
75906815|NCT03570723|Procedure|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
75460477|NCT01840709|Behavioral|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
75460478|NCT01840735|Drug|GS-5737|
75460479|NCT01840735|Drug|Placebo|
75460480|NCT01840761|Drug|herbal drug|
75906816|NCT03701659|Procedure|Surgery combinate with Endocrine therapy|TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.
75906817|NCT03701659|Drug|Endocrine therapy|MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
75906818|NCT03065296|Behavioral|Musculoskeletal (MSK) Prescription Didactic Lectures|In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
75460481|NCT01840761|Drug|placebo|
75460482|NCT01840774|Drug|Low-dose pain medication (Ketalar) and saline placebo|
75906819|NCT03065296|Other|Musculoskeletal (MSK) home exercise hand-outs|In between phase 1 and phase 2, residents will use home exercise hand-outs readily available and educate their patients in regards to those.
75906820|NCT03572595|Diagnostic Test|F-18 FDG-PET/CT|imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence
75460483|NCT01840787|Device|balafilcon A (8.6)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
75906821|NCT03572517|Procedure|Subarachnoid block|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) associated with subarachnoid block (bupivacaine and morphine)
75906822|NCT03572517|Procedure|Spinal morphine|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) and spinal analgesia with morphine
75906823|NCT03952546|Device|Saline-coupled Bipolar Sealer|The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.
76070520|NCT06056388|Device|Straumann BLT implant|Implant system with a regular fixture thread depth.
75460484|NCT01840787|Device|balafilcon A (8.3)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
75460485|NCT01840787|Device|senofilcon A|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
75460486|NCT01840800|Drug|Ropivacaine|
75460487|NCT01840800|Drug|placebo|
75460488|NCT01840813|Drug|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
75613633|NCT04319367|Drug|Investigational Medicinal Product|Recombinant human monoclonal antibody (mAb) or placebo
75906824|NCT03952546|Device|Unipolar electrocautery|The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
75906825|NCT03570645|Drug|Dexmedetomidine Group|combination of ropivacaine and dexmedetomidine 100 ug every time
75906826|NCT03570645|Drug|dexamethasone group|combination of ropivacaine and dexamethasone 10mg every time
75906827|NCT03570645|Drug|control group|block with only ropivacaine
75906828|NCT05354037|Procedure|Enamel matrix derivative application for treatment of intrabony defects|EMD application will be associated to M-MIST approach in control group and flapless approach in test group.
75906829|NCT03705091|Diagnostic Test|Magnetic resonance imaging|ASL and DWI MRI
75906830|NCT03940690|Drug|Anti-VEGF injections of bevacizumab|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9)
75906831|NCT03940690|Device|Laser|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
76070521|NCT06056375|Behavioral|Reclaiming Nature Intervention|The purpose of the community intervention is to prevent health disparities in Black, Latinx, Pilipinx, and Pacific Islander communities of San Francisco, California.
76070522|NCT06056362|Diagnostic Test|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3. The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
76070523|NCT06056362|Diagnostic Test|68Ga-DOTATATE|All patients in arm A will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
76070524|NCT06056362|Diagnostic Test|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
76070525|NCT06056362|Diagnostic Test|68Ga-NODAGA-LM3|All patients in arm B will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-NODAGA-LM3. 68Ga-NODAGA-LM3 PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
75460489|NCT01840813|Drug|Normal saline|It is a placebo group
75460490|NCT01840826|Other|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
75460491|NCT01840839|Device|brain stimulation|
75460492|NCT01840839|Device|Sham Stimulation|
75460493|NCT01840865|Device|brain stimulation|oscillating direct current brain stimulation
75460494|NCT01840865|Device|no stimulation|sham Stimulation
75460495|NCT01840891|Behavioral|Lactose H2 breath test (LH2BT)|Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
75460496|NCT01840982|Dietary Supplement|Mixed grain 1|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
75460497|NCT01840982|Dietary Supplement|Mixed grain 2|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
75613634|NCT04286776|Other|Direct electrical stimulation|Stimulation lasting from 500 to 2000 milliseconds on bipolar target electrode pairs at one of two target frequencies (e.g. 10 Hz and 200 Hz), up to 1.5 milliamperes in amplitude on depth contacts and 3.5 milliamperes in amplitude on surface contacts. (Pulse shape - Charge-balanced biphasic rectangular pulses with pulse width of 300 microseconds in duration per phase).
75613635|NCT04272996|Procedure|Craniotomy only|evacuation of SDH
75613636|NCT04272996|Procedure|Craniotomy + Endovascular embolization of the middle meningeal vessels|evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
75764135|NCT06150872|Device|DurVena Photochemical Tissue Passivation|Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.
75613637|NCT04258436|Procedure|Serratus anterior block|Serratus anterior block will be performed using an ultrasound guided transducer to inject 2mg/kg of 0.2% ropivacaine
75613638|NCT04257214|Behavioral|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
75613639|NCT04814732|Drug|Surufatinib|HMP-012
75764136|NCT06144255|Drug|Intranasal insulin|"Enrolled Participants for this trial will come for 3 study visits. The doses will be administered in varying order: participants will be randomized to one six possible permutations of the intranasal study doses (0, 500, 1000 U) of intranasal insulin at each visit.~Participants will undergo a fMRI scan before and after receiving intranasal doses. Additionally, participants will have blood samples taken."
75764137|NCT06139991|Drug|Treatment A (BDA MDI HFO)|Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.
75764138|NCT06139991|Drug|Treatment B (BDA MDI HFA)|Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.
75906832|NCT03567135|Drug|Apatinib|These drugs are planned to inhibit the proliferation and metastasis of tumors.
75906833|NCT03567135|Drug|Temozolomide（TMZ）|Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
75906834|NCT03570567|Device|Piranha Treatment|The piranha device is used with an endoscope to breakup/dislodge the food bolus.
75906835|NCT03624439|Device|Standard double-lumen tube|intubation using standard double-lumen tube with Macintosh laryngoscope
75906836|NCT03624439|Device|Double-Lumen Tube Vivasight-DL|intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
75315603|NCT04734652|Combination Product|Biktarvy®|"Biktarvy® is a fixed dose combination, single tablet containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) for oral administration.~BIC is an integrase strand transfer inhibitor (INSTI). FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Each tablet contains 50 mg of BIC (equivalent to 52.5 mg of bictegravir sodium), 200 mg of FTC, and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose."
75315604|NCT04734652|Combination Product|TLD- fixed-drug combination single tablet|Standard of care Dolutegravir-based regimen
75315605|NCT04697576|Biological|Ipilimumab|immune checkpoint inhibitor
75315606|NCT04697576|Biological|Nivolumab|immune checkpoint inhibitor
75315607|NCT04697576|Biological|Pembrolizumab|immune checkpoint inhibitor
75315608|NCT04697576|Biological|Quadrivalent Inactivated Influenza Vaccine|Given IM and intratumorally. For this protocol the U.S. F.D.A recently approved the use of recently expired influenza vaccine (only until new seasonal vaccine is available anticipated Sept 1). Use of expired vaccine will not exceed 4 months past June 30th expiry date (October 30th).
75613640|NCT04252859|Drug|[18F]Fluoroestradiol (FES) PET/CT|[18F]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
75764139|NCT06139341|Drug|BI 765845|BI 765845
75764140|NCT06139341|Drug|Placebo|Placebo
75906837|NCT05708937|Behavioral|Mindfulness based phone app|"Creating mindfulness-based suggestions for infertile women:~Mindfulness-based content was created by taking the opinions of experts in the fields of women's health nursing, psychology and linguistics. It consists of 6 different parts. The content of meditation that the patient will apply according to the treatment stage is different. Infertility mindfulness departments; Breath Awareness, Body & Uterus Awareness, Needle Therapy and Ovarian Awareness, Pre-Egg Collection (OPU) Diaphragm Breathing, Pre-embryo Transfer Uterine Awareness, Embryo and Uterine Awareness (Post transfer).~Audio recordings of mindfulness-themed meditation content:~After the meditation contents are planned; the sound recording was taken with a professional recorder (Sony ICD-PX470). The audio recordings taken were professionally edited by the expert. Mp3 recordings were created by adding background music to sound recordings in computer environment. Audio recordings of mindfulness-themed meditation content"
75906838|NCT03698383|Drug|Trastuzumab biosimilars(Herzuma), Gedatolisib|"Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg"
75315609|NCT04697576|Procedure|Resection|Undergo surgical resection
75315610|NCT04697576|Biological|Nivolumab + Relatlimab|immune checkpoint inhibitor
75613641|NCT04247711|Behavioral|OTCH|OTCH is structured in three phrases (i. engagement and initial needs assessment, ii. ongoing intervention and monitoring, and iii. transition to long-term services) and lasts an average of two years. OTCH will maintain the central characteristics of the OnTrack model, as well as its core principles, which include (1) Person-centered care, (2) Shared decision-making, (3) Recovery orientation, and (4) Culturally-competent care.
75613642|NCT04247711|Behavioral|Usual FEP Services|These include services such as psychiatric medication, psychotherapy, and psychoeducation for people with FEP and are usually provided at outpatient mental health clinics.
75613643|NCT04246476|Behavioral|Mentally singing|All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
75613644|NCT04246476|Behavioral|Listening to music|All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
75613645|NCT04205838|Biological|Anakinra|Given SC
75613646|NCT04205838|Biological|Axicabtagene Ciloleucel|Given via infusion
75764141|NCT06138197|Procedure|Robotic-assisted hysterectomy|Robotic-assisted hysterectomy following usual surgical technique
75764144|NCT06132243|Drug|Jaktinib Hydrochloride Tablets|Orally, one tablet at a time
75764145|NCT06129214|Procedure|Prepectoral|Remove all visible synovium in suprapatellar area under distal quadriceps tendon. All other procedures (Total Knee arthroplasty) are same with no intervention arm.
75613647|NCT04205838|Drug|Cyclophosphamide|Given via infusion
75613648|NCT04205838|Drug|Fludarabine|Given via infusion
75764146|NCT06129214|Procedure|Subpectoral|No remove any synovium in suparapatellar area under distal quadriceps tendon. All other preocedures are same with experimental arm.
75906839|NCT04760782|Drug|Abaloparatide|Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)
75906840|NCT04760782|Device|Hard collar immobilization|Hard collar immobilization of the cervical spine for 12 weeks
75906841|NCT03569163|Device|Spry Loop oximeter|Oximetry was performed on the subjects and accuracy was determined based on comparison with blood gas analysis.
75906842|NCT03698305|Drug|ASP5354|Intravenous
75906843|NCT03698305|Drug|Placebo|Intravenous
75906844|NCT03566901|Device|G-EO System|The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.
75906845|NCT03566901|Other|Conventional Physiotherapy|Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
75906846|NCT04743232|Other|Decision tool for clinicians|Clinical decision aid, using a structured approach to advanced care directives and a comprehensive view of available risk scores.
75906847|NCT04740580|Dietary Supplement|Glycine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
75906848|NCT04740580|Dietary Supplement|N-acetylcysteine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
75906849|NCT04740580|Dietary Supplement|Alanine|The placebo arm will supplement Alanine
75906850|NCT03704389|Behavioral|Clinical decision support|Clinical decision support nudges within the electronic health record
75906851|NCT03064282|Other|Placebo|observation of skin changes if any
75906852|NCT03064282|Drug|papaverine|observation of symptoms
75906853|NCT04770025|Device|High-density transcranial alternating current stimulation|High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range
75613649|NCT04205838|Drug|Fludarabine Phosphate|Given via infusion
75315611|NCT04673422|Drug|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
75613650|NCT04196530|Drug|BDB001|BDB001 is an immunotherapy agent.
75613651|NCT04196530|Drug|Atezolizumab|Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
75613652|NCT04170543|Drug|MEDI3506|Dose 1, Dose 2, Dose 3, Dose 4
75315612|NCT04673422|Drug|Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
75613653|NCT04170543|Drug|Placebo|Placebo
75613654|NCT04170543|Drug|Dapagliflozin|Dapagliflozin 10 mg
75613655|NCT04163016|Drug|Pharmacokinetics of certolizumab pegol|"The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician."
75613656|NCT04161391|Drug|TPX-0046|Oral TPX-0046 capsules
75613657|NCT04147013|Drug|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
75613658|NCT04147013|Drug|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
75613659|NCT04121182|Other|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
75764147|NCT06128564|Genetic|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
75764148|NCT06128369|Drug|Dexamethasone Ophthalmic Suspension|Ophthalmic Suspension,1.5% [15 mg/mL] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
75764149|NCT06128369|Other|Vehicle of OCS-01|inert vehicle of OCS-01 ophthalmic suspension Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
75906854|NCT04770025|Device|Sham stimulation|High-density electrode configuration with sham stimulation
75906855|NCT04770025|Behavioral|Motivational interviewing|Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
75906856|NCT04679818|Drug|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
76070526|NCT06056336|Drug|Tislelizumab|Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
75764151|NCT06125704|Behavioral|Moderate intensity walking or stepping|30 minutes of moderate intensity walking or stepping (i.e., at a pace of approximately 100 steps per minute), varied by time of day it is performed: morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) versus late afternoon/evening (i.e., between 4pm-8pm, within 30-40 minutes of dinner).
75764152|NCT06122714|Drug|AZD4144 Part A|Part A: Participants will be administered a single oral dose on Day 1.
75764153|NCT06122714|Drug|AZD4144 Part B|Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 12 (inclusive).
75764154|NCT06122714|Drug|Placebo Part A|Part A: Participants will be administered a single oral dose of matching placebo on Day 1.
75906857|NCT04679818|Device|PMD-200 Nol-guided opioid administration|PMD-200 NOL values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
76070527|NCT06056284|Behavioral|Progressive relaxation exercises and sleep hygiene training|Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients. After seven weeks, an appointment will be given for the post-test. In the second week, those in the experimental group will be taught progressive relaxation exercise using a compact disc (CD) prepared by the Turkish Psychological Association in the hospital and after the sleep hygiene training, progressive relaxation exercise brochure and sleep hygiene training brochure will be distributed. Starting from the second week, the individuals in the experimental group will be expected to apply the trainings given in the hospital accompanied by the researcher two days a week for six weeks and to apply the trainings given to the individuals at home on the other days of the week.
76070528|NCT06056206|Radiation|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list.
76070529|NCT06056193|Procedure|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list
75315613|NCT04646356|Drug|Tacrolimus capsule (low-dose)|low-dose Tacrolimus will be given for 6 months followed by a washout period for 6 months
75315614|NCT04645810|Radiation|High-Dose-Rate Brachytherapy|High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
75315615|NCT04628936|Drug|KZR-616|KZR-616 subcutaneous injection
75315616|NCT04623801|Procedure|Percutaneous Laser Ablation (PLA)|Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.
75460498|NCT01840982|Dietary Supplement|White rice|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
75460499|NCT01840982|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.
75460500|NCT01840995|Procedure|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
75460501|NCT01841008|Drug|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
75613660|NCT04121182|Other|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
75613661|NCT04111900|Behavioral|Sleep/Circadian Friendly|This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
75613662|NCT04084717|Drug|Crizotinib|"Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle."
75613663|NCT04081038|Diagnostic Test|Brush biopsy|Brush biopsy will be performed by dentists and dental hygienists
75613664|NCT04079868|Behavioral|Bone Health Service Model|Patients in PACTs randomized to the BHS model will have osteoporosis screening, education, and follow-up handled centrally by the bone health team.
75613665|NCT04061070|Other|Supplementation with mix of threalose plus polyphenols|The patients will be treated with a mix of trehalose plus polyphenols for 60 days
75613666|NCT04061070|Other|No Supplementation with mix of threalose plus polyphenols|The patients will not be treated with a mix trehalose plus polyphenols for 60 days
75764155|NCT06122714|Drug|Placebo Part B|Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 12 (inclusive).
75764156|NCT06117774|Drug|Tarlatamab|Intravenous (IV) infusion
75764157|NCT06117774|Drug|Placebo|IV infusion
75460502|NCT01841008|Drug|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
75764162|NCT06113211|Drug|Narcotic pain medication|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
75613667|NCT04039841|Diagnostic Test|Motor Imagery Test|"Imagined Timed Up and Go (iTUG) is the imagined version of the actual Timed Up and Go (rTUG) described above). It is possible to calculate the absolute value of the difference between the time of execution of the TUG imagined and actually executed. This difference is called isochrony index. The alteration of this isochrony index is correlated with the decrease in walking speed during the double task. This test is performed during the osteoporosis screening consultation.~For patients who agree to participate in the FallMI study, the name and contact information of the attending physician will be collected during the same consultation.~Standardised email will be sent to the attending physicians to collect the presence of falls and its consequences. They will be classified as fatal, severe, moderate and inconsequential."
75764163|NCT06113211|Drug|Nonnarcotic pain medications|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
75764164|NCT06110715|Other|theta tACS stimulation|The low intensity transcranial electrical stimulation will be administered with a battery-powered, current-controlled, multi-channel stimulator from Neuroelectrics® Starstim 8. This device comes with a neoprene headcap to hold the electrodes in place. TACS will be delivered concurrently with the task. The multichannel, current-driven stimulator (Neuroelectrics StarStim 8) will be used to control independent stimulation electrodes on the scalp of the volunteer. The stimulation intensity will be up to 2 mA.
75764165|NCT06110715|Other|sham tACS stimulation|A placebo control stimulation will use an identical montage to the stimulation montage. However, polarities of the electrodes will be such that only a minimal amount of current reaches the brain, which is achieved through controlled current shunting between neighboring electrodes. This so-called ActiSham protocol is a verified method to imitate the sensations of actual tACS, with minimal stimulation of the brain .
75906858|NCT04440982|Combination Product|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
75906859|NCT02628418|Other|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
75906860|NCT02628418|Device|Specific hand rehabilitation by Gloreha device|"Each training session consisted of six parts:~A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);~7 min of a number sequence (counting from one to five);~A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)~A sequence of wave-like finger movements (7 min)~A sequence of fist opening/closing (7 min)~A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min)."
75906861|NCT02628418|Other|Specific hand rehabilitation performed by physiotherapist|"The activities were:~Flexion-extension of the fingers (10 min);~Thumb opposition with the other fingers keeping the forearm in supine position (10 min);~Adduction and abduction of the fingers (10 min);~Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min)."
75906862|NCT03027609|Drug|AR-105|monoclonal antibody
75906863|NCT03027609|Drug|Placebo|matching placebo (+ SOC antibiotics)
75906864|NCT03704311|Procedure|Muscle biopsy|Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
75906865|NCT03063112|Device|Radiofrequency generator device|sympathetic blockade or ablation of thoracic splanchnic nerves
75906866|NCT03063112|Drug|Lidocaine|sympathetic blockade or ablation of thoracic splanchnic nerves
75906867|NCT03063112|Device|C arm fluoroscopic device|sympathetic blockade or ablation of thoracic splanchnic nerves
76070530|NCT06056167|Drug|Degludec insulin|"Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital & Research Center (KFSH&RC) protocol.~Patients with two capillary point of care glucose levels of > 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol."
75315617|NCT04620239|Drug|padeliporfin VTP|During treatment, placement at the target area of an optical light fiber, through the working channel of the ureteroscope. Intravenous administration of padeliporfin at the dose of 3.66 mg/kg infused over 10 minutes. Each target area will be illuminated for 10 minutes.
75315618|NCT04618016|Device|UHMWPE with Vitamin E|e.motion Pro (PS and UC) with MXE gliding surface
75315619|NCT04618016|Device|UHMWPE without Vitamin E|e.motion Pro (PS and UC) with β-PE gliding surface
75613668|NCT04029922|Drug|MT-5111 (experimental study drug)|Experimental treatment with MT-5111
75315620|NCT04586452|Diagnostic Test|AAA Group (Aim 3A)|"The primary goal is to relate preoperative 64Cu-DOTA-ECL1i AAA uptake with CCR2+ cell activity in AAA tissue collected at the time of open repair. We will image AAA patients pre-operatively and collect tissue at the time of open repair in an attempt to demonstrate ex-vivo tissue corroboration of our imaging findings (n=20, 10 women and 10 men).~Participants with AAA will undergo routine clinical evaluation including ultrasound, CT scan and scheduling of open surgical repair. We will record age and tobacco use. If a renal function blood test has not been performed within the past 90 days, we will draw ~2 teaspoons of blood for a creatinine test. A contrast dye will be used for the CT portion of the PET-CT scan. Those having open surgery, their PET/CT imaging will be within 7-14 of the surgery and if available, collection of discarded aortic tissue at the time of surgery."
75460503|NCT01841034|Drug|Conceptio EA|The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
75460504|NCT01841086|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
75764166|NCT06110520|Device|Violet Light Lamp|Medical grade lamps with Violet LEDs enabled
75764167|NCT06110520|Device|White Light Lamp|Standard bedside lamp with standard 4000K LED light bulb.
75460505|NCT01841086|Drug|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
75460506|NCT01841099|Drug|Mesalamine|Mesalamine granules
75460507|NCT01841099|Drug|Placebo granules|Provided by Ferring Pharma
75764168|NCT06109779|Drug|Rilvegostomig|Rilvegostomig IV (intravenous) Q3W
75764169|NCT06109779|Drug|Placebo|Placebo IV (intravenous) Q3W
75764170|NCT06109779|Drug|Capecitabine|Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
75764171|NCT06109779|Drug|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
75764172|NCT06109779|Drug|S-1 [Tegafur/Oteracil/gimeracil]|S-1 [Tegafur/Oteracil/gimeracil] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
75764173|NCT06105723|Behavioral|Pathway to Healthy Aging care|In the care mapping phase, participants receive a care mapping guided by the critical pathway using the WHO ICOPE assessment, and receive a personalized Healthy Aging Pass (HA Pass) which documents a series of goal-directed actions required to reduce the health risks of accelerating aging. In the empowerment cycle phase, participants are empowered to attain goals, which includes a series of activities, including 1) communicating assessment results with participants to increase their healthy self-awareness; 2) motivating participants' goal setting to integrate health behaviors into daily life; 3) personalizing goal setting to participants' preferences and contexts; 4) supporting participants to implement their action plans in a partnership relationship; 5) monitoring the level of goal attainment of participants and to support them to resolve the barriers.
75460508|NCT01841112|Drug|BI 409306|tablet
75460509|NCT01841112|Drug|BI 409306|tablet
75460510|NCT01841112|Drug|BI 409306|tablet
75460511|NCT01841112|Drug|BI 409306|tablet
75460512|NCT01841112|Drug|placebo|placebo tablet
75460513|NCT01841112|Drug|placebo|placebo tablet
75764174|NCT06103760|Drug|Esketamine Nasal Spray [Spravato]|This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
75764175|NCT06102798|Device|Acunpuncture|"For the bilateral BL25, sterile disposable steel needles (Hwato, China; 0.3 mm×75 mm) will be inserted through adhesive pads to a depth of 50-70mm until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Hwato, China; 0.3 mm×40 mm) will be inserted through adhesive pads to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi."
75764176|NCT06102798|Device|Sham acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
75764177|NCT06092931|Drug|DC-806|Oral tablets
75764178|NCT06092931|Drug|Midazolam|Oral syrup
75906868|NCT03063112|Drug|Ethyl alcohol|sympathetic blockade or ablation of thoracic splanchnic nerves
75906869|NCT04767217|Drug|artemether-lumefantrine (ALN)|Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
75906870|NCT04767217|Drug|dihydroartemisinin-piperaquine (DHA-PPQ)|dihydroartemisinin-piperaquine (DHA-PPQ)
75906871|NCT03828994|Behavioral|Tech-PN|"text messaging(daily medication reminders and tri-weekly messages following the 14-day treatment period)~enhanced community health nurse visits on day 3-5, 14 and 30~field based treatment visits~clinical assistance with notification, testing and treatment"
76070531|NCT06056115|Drug|Tislelizumab,Platinum|"Induction therapy stage:~Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy ."
76070532|NCT06056089|Dietary Supplement|ready-to-use supplementary food (RUSF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/media/16636/file/S0000248-RUSF-Specification.pdf
75460514|NCT01841112|Drug|BI 409306|tablet
75460515|NCT01841125|Drug|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
75460516|NCT01841125|Drug|Placebo|placebo 15mg, QD(once a day), Oral medication
75460517|NCT01841151|Behavioral|SCP training|
75460518|NCT01841151|Behavioral|Live Z-score training|
75460519|NCT01841151|Behavioral|WM training|
75906872|NCT03701503|Behavioral|Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women|
75460520|NCT01841164|Drug|Montelukast|
75460521|NCT01841164|Drug|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
75460522|NCT01841164|Other|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
75460523|NCT01841242|Drug|alcoholic povidone iodine|
75460524|NCT01841242|Drug|alcoholic chlorhexidine|
75460525|NCT01841255|Device|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
75764179|NCT06092931|Drug|Repaglinide|Oral tablets
76070533|NCT06056089|Dietary Supplement|ready-to-use therapeutic food (RUTF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
75613669|NCT04020575|Biological|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
75315621|NCT04586452|Diagnostic Test|Non-AAA Group|We will determine the retention of 64Cu-DOTA-ECL1i in abdominal aorta of non-AAA volunteers (n=10, 5 women and 5 men). This group of participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard care. Both men and women, above the age of 40, with or without active tobacco use will be considered for participation.
75315622|NCT04586452|Other|Ex Vivo Human AAA Specimens (Aim 2A)|The primary objective of this sub-aim is to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens from the Washington University Vascular Surgery Biobank (VS-BB). We will first perform a histopathological evaluation of human AAA specimens (n=75, including samples from this study) and categorize them based on clinical status (e.g, diameter) and degree of inflammation. We will consider healthy, nonatherosclerotic aorta (n=25) as negative controls, and non-aneurysmal aortas (n=25) from patients that have undergone surgery for aortoiliac occlusive disease as positive controls.
75315623|NCT04586452|Other|Relationship between radiotracer and CCR2 (Aim 2B)|The objective of this sub-aim is to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair. We will correlate the level of MMP expression and activity, as well as cytokine profiles, of each specimen, with the associated histopathological features. The relationship between 64Cu-DOTA-ECL1i binding and CCR2 expression in tissues with different degrees of disease severity will be evaluated using Pearson or Spearman correlation coefficients. This will allow us to speculate as to how tracer uptake will perform in vivo and what that uptake represents in regard to disease severity.
75460526|NCT01841255|Device|facemask|
75460527|NCT01841294|Drug|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
75460528|NCT01841294|Drug|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
75460529|NCT01841307|Drug|Cromolyn Sodium|
75460530|NCT01841320|Other|Integrated methadone and antiretroviral therapy (iMART) clinic|
75613670|NCT04020575|Biological|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
75764180|NCT06092931|Drug|Digoxin|Oral tablets
75764181|NCT06092931|Drug|Rosuvastatin|Oral tablets
75906873|NCT03704233|Procedure|Transbronchial cryobiopsy|Transbronchial cryobiopsy procedure
75906874|NCT02752776|Drug|Secukinumab|Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
76070534|NCT06056089|Drug|Amoxicillin|Standard weight-based dosing per Ehtiopian national guidelines
76070535|NCT06056076|Other|Mini Squats Training|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
75460531|NCT01841346|Procedure|Procedure: PCI|
75460532|NCT01841372|Other|Second Life|Second Life is an online virtual reality environment.
76070536|NCT06056076|Other|Endurance Training|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
75613671|NCT04007510|Combination Product|EPI-CAL data network|This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.
75764182|NCT06083051|Device|6Fr Percuflex ureteral stents|The Percuflex stent is a 6Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
75764183|NCT06083051|Device|6Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 6 Fr is the diameter.
75764184|NCT06083051|Device|4.8Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 4.8 Fr is the diameter.
75906875|NCT03704155|Drug|Botulinum toxin type A|Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.
76072491|NCT04145193|Drug|E3 - mFOLFOX6, durvalumab and monalizumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)"
76072492|NCT04021563|Drug|SR419|Ascending single and multiple doses of SR419 orally
75460533|NCT01841372|Behavioral|Group Phone Conference Call|
75460534|NCT01841385|Other|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
75460535|NCT01841398|Behavioral|Multimedia Lifestyle Improvement|"Goal setting to improve diet, physical activity or smoking behaviours~Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference."
75460536|NCT01841398|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
75613672|NCT04007510|Diagnostic Test|Community DUP Assessment Tool|A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
75315624|NCT04586452|Diagnostic Test|AAA Group (Aim 3B-Reproducibility)|We will demonstrate consistent 64Cu-DOTAECL1i uptake by performing repeated imaging studies in a separate group of non-surgical AAA patients (n=20, 10 women and 10 men). Completion of this sub-aim will provide support for the use of 64Cu-DOTA-ECL1i PET for evaluating AAA disease in a reliable fashion. These participants will have another PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results of Cu-64-DOTA-ECL1i. The physician will assess the participant's willingness and eligibility to have a second PET/CT scan.
75315625|NCT04567849|Behavioral|message|patient portal message
75315626|NCT04567849|Behavioral|provider|nudging calling the patient's provider
75613673|NCT03991819|Drug|Binimetinib|Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.
75613674|NCT03991819|Drug|Pembrolizumab|Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
75906876|NCT03704155|Other|Physical Therapy|"Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~Passive stretching of lower limbs,~Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~Strengthening of the antagonist muscles with the application of BoNT-A;~Static and dynamic balance training;~Up and down stairs;~Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion."
75613675|NCT03919552|Drug|Docetaxel,Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.
75906877|NCT03698227|Drug|Olaratumab|iv infusion
75613676|NCT03919552|Drug|Docetaxel,Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.
75613677|NCT03919552|Radiation|Carboplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.
75613678|NCT03919552|Radiation|Cisplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
75613679|NCT03900845|Device|Dynamic Air Exchange - Rising Edge Design (DAE-RED)|The DAE-RED suspension system expels perspiration to the prosthesis exterior using a hybrid battery-powered pump and a body-weight activated pump. To use the DAE-RED, subjects will be fit with a modified patellar tendon-bearing socket that fits over a custom liner and sock. Up to four air intake ports are located proximally on the liner, approximately 25 mm superior to the socket brim. These ports incorporate a microvalve that allows air to flow into the liner-skin interstitial space while still maintaining a vacuum suspension. Distally, the pin lock has a 3-mm hole along its longitudinal axis that allows perspiration to be expelled into a distal reservoir. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot with Unity pump and foot cover.
75764185|NCT06081153|Drug|Evolocumab|See arm description.
75315627|NCT04567849|Behavioral|tele-nurse|nudging calling the tele-nurse
75315628|NCT04558554|Other|pharmacy-based PrEP delivery|The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.
75764186|NCT06081153|Drug|Placebo|See arm description.
75764187|NCT06080646|Other|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
75764188|NCT06079671|Biological|Volrustomig|IV Infusion
75764189|NCT06079671|Other|Placebo|IV Infusion
75315629|NCT04553731|Behavioral|empowerment program with mHealth|empowerment program with mHealth
75315630|NCT04528706|Drug|MIN-102|Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
75315631|NCT04515472|Drug|Botnia Clamp|This clamp technique is designed to obtain independent measures of insulin secretion and insulin sensitivity during the same test. In brief, 0.3g/kg body wt of a 20% glucose solution is given at time 0. Blood samples for the measurement of plasma glucose and serum insulin are obtained at -10, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, 120, and 180 min.
75315632|NCT04515472|Other|Withdrawal of Gender Affirming Hormone Therapy (GAHT)|GAHT, either estrogen or testosterone therapy will be withdrawn after the Botnia Clamp.
75315633|NCT04508023|Drug|Rivaroxaban|Participants will receive rivaroxaban 10 mg tablet orally once daily.
75315634|NCT04508023|Other|Placebo|Participants will receive matching placebo tablet orally once daily.
75764190|NCT06078501|Drug|Misoprostol 400mcg buccal|Misoprostol 400mcg buccal administration 2-3 hours prior to procedure
75764191|NCT06078501|Drug|Placebo|Placebo buccal administration 2-3 hours prior to procedure
75764192|NCT06077994|Behavioral|digital Remote Patient Monitoring+BEPR+ (dRPM+)|In addition to the BEPR+ program as described, patients will use the Cloud Dx Connect Health System to take daily physiological readings (Blood pressure, heart rate, oximetry, body temperature and body weight). These data will be transmitted to a secured server supported by the provincial health care system. Participants and therapists will interact with these data in their respective dashboards and in conjunction with participants' determined medical action plan, engage in or make changes to participants current self-management regimens.
75764193|NCT06077994|Behavioral|Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)|Patients will attend the BEPR+ program 3 days per week for 6 weeks or 2 days per week for 8 weeks (total of 16 sessions). Patients will receive 90 minutes of personalized and supervised exercise training (aerobic and resistance) and 60 minutes of education designed to promote self-management. Patients will also received one-on-one sessions with a therapist to review their medical action plan for exacerbation management, program and lifestyle goals (including physical activity), determine referral needs for other health services (i.e. smoking cessation, weight management, and psychological support). Patients will use an activity monitor for feedback and motivation for physical activity.
75906878|NCT03698227|Drug|Dexrazoxane|iv infusion
75460537|NCT01841411|Drug|N-Acetyl cysteine|N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
75460538|NCT01841411|Drug|Metronidazole + N-Acetyl cysteine|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
75460539|NCT01841411|Drug|metronidazole|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
75613680|NCT03900845|Device|Perforated elastomeric liner|The unique element of this perforated elastomeric liner are small perforations (~0.3 mm diameter), uniformly distributed on a 4 x 5 mm grid, but with no perforations on the distal umbrella, that allow perspiration to be exuded into the liner-socket interstitial space. To use the perforated elastomeric liner, subjects will be fit with a modified patellar tendon-bearing socket that fits over a sock and the perforated elastomeric liner with a pin lock. The sock, worn between the socket and the liner, is used to absorb perspiration that is transported through the perforations in the liner. When needed for residual limb volume control, additional socks will be donned and included in tare weighing. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot and cosmesis.
75315635|NCT04508023|Other|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
75613681|NCT03900845|Device|As-prescribed prosthesis|The individual's as-prescribed suspension system is the prosthesis prescription that the patient and their clinical care team believes is the best prosthesis for their needs.
75315636|NCT04505098|Drug|Icosapent ethyl|2 g by mouth twice daily for at least 6 months
75315637|NCT04504981|Behavioral|Y2Prevent|Y2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals
75315638|NCT04489732|Biological|Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells|"Single dose, starting at~Dose Level 0: 10 x 10^6 injected into one submandibular gland on Day 1"
75613682|NCT03897595|Device|MPact Cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
75613683|NCT03897530|Behavioral|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
75613684|NCT03897530|Other|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
75315639|NCT04484636|Diagnostic Test|FoundationOne®CDx and FoundationOne®Liquid|FoundationOne CDx is a FDA-approved broad companion diagnostic (CDx) that is clinically and analytically validated for solid tumors. The test is designed to provide physicians with clinically actionable information - both to consider appropriate therapies for patients and understand results with evidence of resistance - based on the individual genomic profile of each patient's cancer. Every test result includes microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions. FoundationOne®Liquid is a liquid biopsy test for solid tumors that analyzes circulating tumor DNA (ctDNA) in blood.
75315640|NCT04451746|Drug|Combined Oral Contraceptive|The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
75315641|NCT04425018|Drug|Paclitaxel|Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.
75315642|NCT04425018|Drug|Pertuzumab|Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
75764194|NCT06073743|Other|Conventional Physiotherapy|The conventional physiotherapy program will be applied 2 days a week, 60 minutes a day for 10 weeks and consist of weight bearing on the upper and lower extremities, strengthening, functional stretching exercises, walking training and balance exercises.
75764195|NCT06073743|Other|Video Game Based Exercise Training|In the Video Game Based Exercise Training program, in addition to the same conventional physiotherapy application for 30 minutes a day, 2 days a week for 10 weeks, 30 minutes of Microsoft Xbox Kinect video games such as reflex ridge and rallyball are used.
75906879|NCT03698227|Drug|Doxorubicin|iv infusion
75315643|NCT04425018|Drug|Margetuximab|Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
75315644|NCT04425018|Drug|Trastuzumab|Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
75315645|NCT04384172|Device|Tibial e-stim|For tibial nerve stimulation, the two electrodes will be placed just above the medial malleolus and the ipsilateral calcaneus on one leg near the ankle.
75315646|NCT04384172|Device|Genital e-stim|For dorsal genital nerve stimulation, two electrodes will be placed on either side of the clitoris.
75315647|NCT04334109|Behavioral|Family Diabetes Self-Management Education and Support|Family Diabetes Self-Management Education and Support demonstrates the effectiveness of family-centered models of DSME that explicitly address diabetes self-management within a family context by educating both patients and family members and focusing on family motivational interviewing, family goal setting, understanding supportive and nonsupportive behaviors, and family behavioral changes.
75764196|NCT06072833|Behavioral|Patient Financial Education / Navigation|The investigator anticipates that this will include a baseline financial assessment and educational content, likely using a virtual platform. Participants will be connected with a PAF case manager. There will be monthly follow-ups to the participant for 6-months to address any financial concerns through additional counseling/navigation.
75315648|NCT04334109|Behavioral|Standard Diabetes Self-Management Education and Support|Diabetes Self-Management Education and Support demonstrates the effectiveness of individual model DSMES that explicitly address diabetes self-management within an individual context by educating individual patients on individual motivational interviewing, individual goal setting, and individual behavioral changes.
75460540|NCT01841424|Behavioral|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
75613685|NCT03897530|Other|Questionnaire Administration|Ancillary studies
75764197|NCT06071494|Other|Tropical fruits|papaya, mango, banana, orange
75764198|NCT06067828|Drug|Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
75764199|NCT06067828|Drug|Treatment B: Budesonide and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
75764200|NCT06067828|Drug|Treatment C : Placebo|Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
75764201|NCT06066515|Drug|survodutide|once weekly subcutaneous injection
75764202|NCT06066515|Drug|Placebo|once weekly subcutaneous injection
75764203|NCT06061328|Behavioral|OASIS DA training|The OASIS decision aid is a novel implementation strategy selection tool developed by a multidisciplinary team of experts using machine learning algorithms and user-centered design approaches.
75764204|NCT06061328|Behavioral|Current DA Tool training|The CFIR-ERIC Matching Tool is a currently available decision aid tool for selecting implementation strategies that is based on expert opinion.
75906880|NCT03697915|Device|Experimental|Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.
75460541|NCT01841437|Device|iStent|
75460542|NCT01841450|Device|iStent|Implantation of one iStent in conjunction with cataract surgery
75460543|NCT01841450|Procedure|Cataract surgery|Cataract surgery alone
75613686|NCT03853707|Drug|Atezolizumab|Given IV
75613687|NCT03853707|Drug|Capecitabine|Given PO
75613688|NCT03853707|Drug|Carboplatin|Given IV
75613689|NCT03853707|Drug|Ipatasertib|Given PO
75613690|NCT03853707|Drug|Paclitaxel|Given IV
75764205|NCT06060665|Drug|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for up to 52 weeks
75764206|NCT06060665|Drug|Placebo|One capsule daily for up to 52 weeks
76072493|NCT04021563|Drug|Placebo|Ascending single and multiple doses of placebo orally
75764208|NCT06055686|Diagnostic Test|Electrical Epidural Stimulation Test|Electrical stimulation test measures sensory/motor responses
75764209|NCT06054230|Device|Genomic Sequencer|Genomic Sequencing Device
75764210|NCT06053164|Drug|Exertional Oxygen|Use of a portable oxygen concentrator for exertional activities lasting >2 minutes
75764211|NCT06053164|Behavioral|Education and Support|Participants will receive disease-specific educational material (Living Well with Pulmonary Fibrosis: Oxygen), and will have scheduled phone appointments with a certified respiratory educator after 1, 3, and 5 weeks of oxygen therapy in order to address individual barriers to oxygen use and facilitate the optimal use of portable oxygen.
75764212|NCT06048263|Behavioral|interpersonal psychotherapy (IPT)|The ROSE intervention is a five-session intervention developed to build communication skills, improve social support, and improve stress management. It is easy to learn and does not require a healthcare professional or mental health specialist to deliver. For this study, the investigators plan to deliver to individuals during inpatient visits, in-person appointments or via telemedicine (phone or videoconference), as appropriate or per participant preference. The first four sessions are approximately 60 minutes in length.
75764213|NCT06048263|Drug|Ketamine|During the first four post-cesarean days, the investigators will administer subcutaneous ketamine (0.5 mg/kg) and a repeated dose of 0.5 or 0.7 mg/kg ~24 hours later (the second dose will be increased to 0.7 mg/kg if no severe adverse effects are reported after the first dose and the patient is in agreement with the dose escalation).
75764214|NCT06046898|Device|non-invasive ventilation with or without resistance|non-invasive ventilation with or without resistance.
75764215|NCT06046833|Device|FreeStyle Libre 3 continuous glucose monitoring sensor|The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute
75613691|NCT03853707|Other|Quality-of-Life Assessment|Ancillary studies
75613692|NCT03853707|Other|Questionnaire Administration|Ancillary studies
75613693|NCT03758950|Drug|Placebo|Once daily inhaled placebo for 48 weeks
75613694|NCT03758950|Drug|Mometasone|Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
75764216|NCT06046833|Other|Nutritional drink|Balanced nutritional drink (Boost plus 8 ounces/237 mL)
76072494|NCT03021837|Other|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
76072495|NCT04765839|Other|Educational, culturally appropriate COVID-19 messages|Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.
75460544|NCT01841463|Drug|P1446A-05|- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) & vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 & vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, & 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples & undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
75613695|NCT03751371|Device|Training with HWA device|Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
75613696|NCT03751371|Other|Usual Care|The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
75613697|NCT03738410|Behavioral|Mobile Health Messaging application|Mobile messaging sent to participants over a 12-month period.
75613698|NCT03738410|Other|Standard of Care Treatment|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat HIV/AIDS. SOC associated procedures and policies may vary across clinical settings.
75613699|NCT03711279|Drug|SHR-1210 plus Apatinib|SHR-1210 (200mg lyophilized powder in a single-dose vial for reconstitution) q3w+ Apatinib (250mg/375mg tablets) qd
75906881|NCT03697837|Behavioral|Parent Management Training|The online digital parent training (DPT) program consists of 8 self-guided courses that take approximately 10 minutes to complete and include text and animated parent-child simulations. The courses are designed to closely parallel the content of existing evidence-based parent management training approaches that exist in numerous parenting books.
75315649|NCT04327635|Drug|PEP|A biological drug made of certain parts of blood from living blood donors obtained from a certified blood bank. At the time of cardiac catheterization patients will undergo one-time intracoronary infusion of 10 milliliters of PEP dosage consisting of approximately 5%, 10%, or 20% PEP. PEP dose will be infused immediately distal to the newly placed stent over approximately 5 minutes.
75613700|NCT03711279|Drug|ADM plus IFO or IFO alone|ADM 60mg/m2 D1 + IFO 2mg/m2 D1-D4 q3w；if the cumulative doses of ADM is beyond 450mg/m2, the monotherapy of IFO (2mg/m2 D1-D5 q3w) will be used.
75764217|NCT06045754|Drug|Vedolizumab|Vedolizumab intravenous infusion.
75613701|NCT03658538|Device|Active HEPA Air Cleaner|The active treatment arm will receive two active air cleaners with HEPA and carbon filters to support a home smoking ban and SHS reduction.
75764218|NCT06045754|Drug|Adalimumab|Adalimumab subcutaneous injection.
75764219|NCT06045754|Drug|Ustekinumab|Ustekinumab intravenous infusion.
75764220|NCT06045754|Drug|Ustekinumab|Ustekinumab subcutaneous injection.
75764221|NCT06042205|Device|TISSIUM™ Adhesive Hernia Repair System (TAHRS)|The TAHRS is intended for fixation of prosthetic material to soft tissue
75906882|NCT02186730|Behavioral|Stressbusters|cCBT
75613702|NCT03658538|Behavioral|Motivational interviewing|"The active treatment arm will receive 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).~The Control arm will receive only continued counseling for smoking cessation."
75613703|NCT03658538|Device|Sham Air Cleaner|The Control arm will receive sham air cleaners
75613704|NCT03657368|Procedure|Low tidal Volume|Tidal volume = 6 ml/kg predicted body weight
75764222|NCT06042179|Behavioral|Frequent PT|Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
75613705|NCT03657368|Procedure|High tidal Volume|Tidal volume = 10 ml/kg predicted body weight
75613706|NCT03657368|Procedure|Low PEEP|PEEP = 5 cm H2O
75613707|NCT03657368|Procedure|High PEEP|PEEP = 8 cm H2O
75613708|NCT03645590|Behavioral|Stroke Ready|Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
75764223|NCT06042179|Behavioral|Intense PT|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
75764224|NCT06036004|Drug|Intranasal OXT|"Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment."
75906883|NCT02186730|Behavioral|Websites|Self help websites
75906884|NCT01342965|Drug|Erlotinib|Erlotinib was supplied as tablets.
75906885|NCT01342965|Drug|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
75906886|NCT02181348|Drug|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
75906887|NCT02181348|Drug|placebo (edible oil)|
75906888|NCT02186886|Drug|Golimumab|Physiological Intermolecular Modification Spectroscopy
75906889|NCT02186964|Procedure|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
75764225|NCT06036004|Other|Placebo nasal spray|"The placebo will contain no OXT but, otherwise, be identical to the intranasal OXT product with respect to the other ingredients.~Placebo is given twice daily for 28 (± 2) days of treatment."
75613709|NCT03641456|Drug|bortezomib|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.
75613710|NCT03641456|Drug|Lenalidomide|The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.
75613711|NCT03641456|Drug|Dexamethasone|The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
75764226|NCT06034470|Procedure|Biospecimen Collection|Undergo blood sample collection
75764227|NCT06034470|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspirate
75764228|NCT06034470|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75764229|NCT06034470|Drug|Cytarabine|Given IV
75315650|NCT04300595|Procedure|Combination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery|"all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).~In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes."
75315651|NCT04279652|Other|Combined exercise|Combined exercise program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
75315652|NCT04272060|Diagnostic Test|CT angiography|Diagnostic CT angiography
75315653|NCT04272060|Diagnostic Test|Invasive coronary angiography|Diagnostic invasive coronary angiography
75315654|NCT04256954|Behavioral|Peer navigation intervention|A peer navigator will assist those assigned to the intervention group access community mental health, medical care and substance use services. Peer navigators will help create linkages to services
75315655|NCT04212026|Drug|Nivolumab|The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
75315656|NCT04210492|Radiation|45 Gray (Gy) regimen|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
75315657|NCT04201444|Diagnostic Test|Patient group|Patients with Cushing Disease (CD) receiving a medical treatment: n = 30 Plasmatic cortisol UFC Urine biocollection Salive biocollection
75315658|NCT04201444|Diagnostic Test|Remission control group|Patients in remission of CD and having recovered a normal pituitary function for at least 12 months following pituitary surgery (normal UFC associated to: cortisol suppression following dexamethasone suppression test, or normal LNSC, or midnight serum cortisol < 200 nmol/L) n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
75613712|NCT03639688|Procedure|Threading on the left lip commissure|Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
75613713|NCT03639688|Procedure|Threading on the right lip commmissure|Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
75613714|NCT03572660|Biological|Bone marrow derived mononuclear cells and G-CSF|Intra-coronary infusion
75613715|NCT03564626|Other|Health-IT +/- Scheduled Follow Up|"Training patient and caregiver on Patient Buddy and EncephalApp~Counseling regarding readmission~Daily contact through app~Standard of care counseling regarding readmission and discharge instructions~Follow up phone calls at Week 1 and Week 3~In-person follow up visits at Week 2 and Week 4"
75613716|NCT03503097|Procedure|Biospecimen Collection|Provide saliva samples
75613717|NCT03503097|Other|Genetic Counseling|Undergo counseling
75613718|NCT03503097|Other|Genetic Testing|Undergo genetic testing
75613719|NCT03503097|Other|Laboratory Biomarker Analysis|Correlative studies
75613720|NCT03503097|Behavioral|Questionnaire|Complete questionnaire
75764230|NCT06034470|Procedure|Echocardiography|Undergo ECHO
75764231|NCT06034470|Drug|Fludarabine|Given IV
75764232|NCT06034470|Drug|Granulocyte Colony-Stimulating Factor|Given SC
75764233|NCT06034470|Drug|Idarubicin|Given IV
75764234|NCT06034470|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
75764235|NCT06034470|Drug|Pivekimab Sunirine|Given IV
75764236|NCT06030583|Other|Scales and Forms|This study does not involve any interventions. Information will be collected from the study group and the control group through scales and forms.
75764237|NCT06030336|Behavioral|Home Health Report|The Home Health Report has been described in the intervention arm description.
75764238|NCT06028932|Drug|Sacituzumab govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
75764239|NCT06027879|Biological|Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
75764240|NCT06027606|Drug|Salbutamol 400mcg|Salbutamol is a short-acting beta-agonist used primarily as a rescue inhaler for respiratory disease such as asthma
75764241|NCT06027606|Drug|Budesonide/formoterol|Budesonide/formoterol is a inhaled corticosteroid with long-acting beta-agonist component primarily used as a maintenance inhaler for respiratory conditions such as asthma
75315659|NCT04201444|Diagnostic Test|Bilateral surrenalectomy control group|Patients with previous CD, treated with bilateral adrenalectomy and receiving weight adjusted doses of hydrocortisone for at least 6 months. Last daily dose of Hydrocortisone should be administered no later than 5 pm. n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
75764242|NCT06027606|Drug|Placebo|Practice inhaler primarily used in training scenarios so looks identical to medical inhalers
75315660|NCT04187144|Drug|Gepotidacin|Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
75315661|NCT04187144|Drug|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
75315662|NCT04187144|Drug|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
75315663|NCT04187144|Drug|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
75315664|NCT04172038|Behavioral|Physical Therapy|Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).
75315665|NCT04172038|Behavioral|Move 2 Health (M2H)|"Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~Sleep~Physical Activity~Nutrition~Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.)."
75315666|NCT04172038|Behavioral|MORE Mindfulness|"Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~Mindfulness~Cognitive reappraisal~Savoring of positive experiences"
75315667|NCT04159545|Other|Qualitative and quantitative interviews|Qualitative semi-structured interviews and quantitative questionnaires
75315668|NCT04096638|Drug|SB 11285|SB 11285 2mg lyophilized powder for IV infusion
75315669|NCT04096638|Drug|Atezolizumab|1680 mg every 4 weeks
75315670|NCT04027946|Drug|LMB-100|Participants will receive LMB-100 on days 1, 3 and 5 of a 21-day cycle for up to 2 cycles.
75315671|NCT04027946|Drug|pembrolizumab|Participants will receive pembrolizumab on day 1 of each subsequent 21-day cycle.
75315672|NCT04027946|Diagnostic Test|Mesothelin Expression|Testing for mesothelin expression performed at screening
75460545|NCT01841463|Drug|Vemurafenib (Zelboraf®)|"In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.~In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle~Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration."
75460546|NCT01841476|Drug|POL6326|
75460547|NCT01841489|Drug|Treatment A|1600 mg GS-9973 (Formulation 1)
75460548|NCT01841489|Drug|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
75460549|NCT01841489|Drug|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
75613721|NCT03493152|Drug|Everolimus|mTOR inhibitor
75613722|NCT03492671|Drug|Gemcitabine 1000 mg|Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
75764243|NCT06023927|Other|Clinical observation, diagnostic testing|Glaucoma evaluation including structural and functional diagnostic testing at baseline and 3 subsequent follow-up visits over a period of 9 months
75460550|NCT01841489|Drug|Treatment D|1600 mg GS-9973 (Formulation 2)
75460551|NCT01841489|Drug|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
75460552|NCT01841489|Drug|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
75460553|NCT01841489|Drug|Treatment G|1600 mg GS-9973 (Reference formulation)
75460554|NCT01841489|Drug|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
75764244|NCT06023589|Biological|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab
75613723|NCT03492671|Drug|nab-paclitaxel|Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
75613724|NCT03492671|Radiation|Stereotactic Body Radiation Therapy|Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
75613725|NCT03486301|Drug|BDB001|BDB001 is an immunotherapy agent.
75764245|NCT06023589|Other|Placebo|Participants will be receiving subcutaneous injection of matching placebo
75764246|NCT06013475|Drug|Apalutamide|Decision by the treating physician
75764247|NCT06013475|Drug|Darolutamide (BAY 1841788)|Decision by the treating physician
75764248|NCT06013475|Drug|Enzalutamide|Decision by treating physician
75764249|NCT06012409|Device|Hall Technique Prefabricated Metal Crown|The Hall Technique is a type of minimally invasive dental treatment. Hall Technique involves sealing the carious lesion under a Prefabricated Metal Crown to stop its progression preventing pain and/or infection.This makes the technique less invasive and it can be more acceptable to children than a traditional filling involving injections and drilling.
75764250|NCT06008717|Device|active subthalamic nucleus deep brain stimulation plus optimal drug therapy|active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy
75764251|NCT06008717|Device|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy|optimal drug therapy alone with DBS device turned off
75315673|NCT04027946|Diagnostic Test|TrueSight Oncology 500|Testing for ROS oncogene 1 (ROS1) gene, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) variations performed at screening.
75460555|NCT01841489|Drug|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
75906890|NCT02186964|Procedure|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
75460556|NCT01841489|Drug|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
75906891|NCT02186964|Procedure|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
75906892|NCT02182908|Other|PET-Scan|PET-Scan
75906893|NCT02245893|Procedure|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
75906894|NCT02182986|Procedure|transplant|All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).
75906895|NCT02182986|Drug|Immunosuppressive Drugs|Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
75315674|NCT04017468|Drug|Vancomycin|Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
75315675|NCT03996824|Other|Peroperative collect of inner ear cells|"After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach.~The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture."
75315676|NCT03987282|Other|Enhanced usual care (EUC)|Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
75460557|NCT01841502|Drug|Paroxetine|paroxetine 20 mg once daily
75460558|NCT01841502|Drug|telaprevir|telaprevir 1125 mg twice daily
75613726|NCT03486301|Drug|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
75764252|NCT06006013|Biological|Atezolizumab|Given IV
75764253|NCT06006013|Procedure|Biospecimen Collection|Undergo collection of blood samples
75764254|NCT06006013|Drug|Cabozantinib S-malate|Given PO
75764255|NCT06006013|Procedure|Computed Tomography|Undergo CT
75460559|NCT01841515|Drug|Desmopressin administration|
75460560|NCT01841528|Other|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
75613729|NCT03442322|Other|transdisciplinary approach|This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
75613730|NCT03442322|Other|multidisciplinary approach|This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
75764256|NCT06006013|Procedure|Magnetic Resonance Imaging|Undergo MRI
75764257|NCT06005610|Drug|Estradiol|Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.
75906896|NCT03570411|Diagnostic Test|T-SPOT®.CMV Test|The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
75906897|NCT03536910|Other|Copeptin|Level of copeptin in maternal blood and umbilical cord blood
75764258|NCT06000631|Behavioral|Ride-On Car Training in a standing posture with a 2-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
75764259|NCT06000631|Behavioral|Ride-On Car Training in a standing posture with a 1-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 24-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of the participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
75764260|NCT06000631|Behavioral|Conventional Therapy with a 1-hour session|The other independent OT will be responsible for providing conventional therapy in the same location as the ROC-Stand training for a total of 24-week intervention based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general purpose of the training is to facilitate the developmental scales and improve mobility, socialization, and upper limb use in functional tasks.
75906898|NCT05354817|Drug|mFOLFIRINOX|mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU
75906899|NCT02181582|Drug|Emapunil|Single peroral administration
75906900|NCT02181582|Device|PET|Positron emission tomography, which creates images by detecting radioactivity.
75906901|NCT05354739|Device|The vibration cold device (BUZZY)|If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized
75906902|NCT02181660|Drug|Gilteritinib|oral
75906903|NCT03566745|Diagnostic Test|Blood for protein activity|Blood for protein activity
75906904|NCT03697759|Other|Usual care + selfBACK|"The selfBACK intervention is a digital Decision Support System (DSS) for self-management of LBP provided to the participant via a smartphone app (selfBACK app). In addition, the participant is provided with a step-detecting wristband (Xiaomi Mi Band 2) that interacts with the selfBACK app.~The DSS provides individually tailored self-management plans including content from three categories; 1) information/education, 2) physical activity monitoring through wearing the step-detecting wristband, and 3) strength and flexibility exercises. The weekly plans are individually tailored to the specific patient, using the data available from the patient, and each week the patients report back their progress on physical activity (step count) and exercise (volume completed). These data are matched with the patients follow-up data to create a self-management plan that is up to date and adaptable to variation in health-status of the individual patient."
75906905|NCT03566589|Dietary Supplement|Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
75460561|NCT01841528|Other|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
75460562|NCT01841541|Behavioral|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
75613731|NCT03439852|Behavioral|Light-to-Moderate Physical Activity / Sedentary Time|12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
75613732|NCT03401385|Drug|Datopotamab Deruxtecan (Dato-DXd)|A total anti-TROP2 antibody and MAAA-1181a
75613733|NCT03401385|Drug|Steroid Containing Mouthwash|A mouthwash containing a steroid ingredient administered in sub-study
75613734|NCT03401385|Other|Non-Steroid Containing Mouthwash|A mouthwash containing a non-steroid ingredient administered in sub-study
75613735|NCT03391479|Drug|Avelumab|Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).
75613736|NCT03391479|Other|Best Supportive Care|As required.
75613737|NCT03355300|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
75764261|NCT05999734|Drug|Bupivacaine|Before skin incision, under complete aseptic precautions and sterilization, the patient will be placed in a lateral position. The spinous process of the fourth thoracic vertebra will be identified and marked. The ultrasound guided MTP block will be done by high frequency linear transducer will be placed in position just lateral to the spinous processes of thoracic vertebra target of the paravertebral space. A 50 mm 22-gauge echogenic needle will be inserted in an in plane technique from a caudal to a cephalad direction and will be advanced. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline will be injected. Once the needle tip has been confirmed and after careful aspiration to demonstrate the absence of air or blood, 0.5mL/kg 0.25% bupivacaine will be injected.
75906906|NCT03536832|Procedure|Cesarean Section with Vicryl|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.
75906907|NCT03536832|Procedure|Cesarean Section with Prolen|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
75906908|NCT03697681|Drug|Tranexamic acid|Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.
75906909|NCT03697681|Drug|0.9% NaCl (normal saline)|The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
75315677|NCT03987282|Behavioral|Peer-based counseling|Peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT
75906910|NCT03566355|Radiation|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
75906911|NCT02187276|Drug|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
75906912|NCT03697525|Device|Vibration|Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).
75906913|NCT02183064|Drug|Meloxicam|
75906914|NCT02183064|Drug|NSAID|
75315678|NCT03976310|Drug|48 weeks of Benralizumab|Benralizumab is administered for 48 weeks (week 0 to week 48) every 4 weeks for the first 3 injections (30 mg sc per injection), and then every 8 weeks for the following 5 injections.
75315679|NCT03976310|Other|Computed tomography|Computed tomography of the thorax is performed at the beginning (week 0), middle (week 24) and towards the end (week 48) of Benralizumab therapy. A sinus scan is also added on weeks 0 and 48.
75460563|NCT01841658|Dietary Supplement|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
75460564|NCT01841671|Biological|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
75460565|NCT01841671|Biological|bOPV|As indicated
75460566|NCT01841671|Biological|mOPV type 2|Administered at 28 weeks of age to all study participants
75613738|NCT03350529|Device|MRI guided transurethral HIFU ablation of prostatic tissue|The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
75613739|NCT03345420|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75613740|NCT03333031|Drug|HS-196|HS-196 will be administered intravenously as a single dose
75613741|NCT03332056|Drug|Belladonna and Opium|
75613742|NCT03332056|Other|Placebo suppository|
75764262|NCT05999045|Other|Singing activity|The singing activity will involve a 1-hour performance, rehearsal, or lesson.
75764263|NCT05997433|Procedure|7days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid*7days
75764264|NCT05997433|Procedure|14 days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid*14days
75906915|NCT03624907|Radiation|Daily Stereotactic Body Radiotherapy|After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.
75906916|NCT03624907|Radiation|Non-Daily Stereotactic Body Radiotherapy|After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.
75906917|NCT03704077|Biological|Relatlimab + Nivolumab|Specified dose on specified days
75906918|NCT03704077|Biological|Nivolumab|Specified dose on specified days
75906919|NCT03704077|Drug|Paclitaxel|Specified dose on specified days
75906920|NCT03704077|Drug|Ramucirumab|Specified dose on specified days
75906921|NCT02256618|Other|Autologous umbilical cord blood cells|Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused
75906922|NCT04433416|Diagnostic Test|hypertension|If the patient has two or more blood pressure values ≥140/90mmHg in a calm state, he is included in this group
75906923|NCT02183142|Drug|Mobic, China, 7.5 mg|
75906924|NCT02183142|Drug|Mobic, Germany, 7.5 mg|
75906925|NCT03568773|Other|High-intensity interval training|HIIT training is being conducted on a three-day weekly frequency on a stationary bike. The protocol consisted of two weeks of adaptation with 12 weeks of training that alternated between sprints ranging from 30 s to 60 s (> 95% VO2max), and active recovery ranging from 180 s to 120 s (30 W on the bicycle).
75613743|NCT03255434|Drug|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
75764265|NCT05997407|Behavioral|Organic Conceptions mindset management program|"Organic Conceptions is a theoretical model and corresponding 9-step cognitive-based therapy program that enables people to understand where they are in their fertility journey, and provides them with coping strategies to reframe the painful emotional side effects of infertility. In addition to the 9-step program, there are mini-classes on the key triggers that people face when dealing with infertility.~The intervention consists of a series of assignments that participants in the intervention group will complete for a ten-week period. These assignments will take approximately three hours per week to complete. In addition, participants will complete biweekly live support group sessions led by certified coaches and will have the option to join a Facebook support group."
75764266|NCT05996744|Drug|Obeldesivir|Tablet administered orally with or without food
75460567|NCT01841671|Biological|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
75764267|NCT05995964|Drug|PF-07275315|subcutaneous injection
75613744|NCT03255434|Drug|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
75764268|NCT05995964|Drug|PF-07264660|subcutaneous injection
75764269|NCT05995964|Other|Placebo|subcutaneous injection
75764270|NCT05988632|Drug|Regular Human Insulin then Placebo|Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
75764271|NCT05988632|Drug|Placebo then Regular Human Insulin|Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
75764272|NCT05987930|Device|bone lid technique|group I ten patients with mandibular lesion will be undergo excision of lesion using bone lid technique with piezo-electric device then reposition of buccal bone cortex
75764273|NCT05987930|Device|standard technique|group II ten patients with mandibular lesion will be undergo excision of lesion using surgical bur to remove buccal cortex to get access to lesion
75764274|NCT05977725|Diagnostic Test|Hand Doppler Ultrasound|Hand Doppler Ultrasound to assess the Hand Acceleration Time (HAT)
75764275|NCT05975073|Drug|AMG 193|Administered PO
75764276|NCT05975073|Drug|IDE397|Administered PO
75764277|NCT05974046|Drug|[14C]IDV184001AN|[14C]-IDV184001AN 200 mg/~100 µCi/ 15 g oral suspension
75764278|NCT05973890|Behavioral|WhatsApp|Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.
75906926|NCT03568773|Other|Aerobic exercise moderate intensity|The aerobic training is performed in a walking or running mode, with three weeks of adaptation (2x / wk - 20 to 30 minutes / session, <threshold 1) and 12 weeks of training (3 to 5x / wk - 40 to 60 minutes / session, with prescribed intensities between the anaerobic threshold - L1 and the respiratory compensation point - L2).
75906927|NCT03568773|Other|Control Group|The control group is participating in lengthening classes to increase the adherence and control of the influencing variables. Classes are being held once a week for 60 minutes.
75315680|NCT03949764|Drug|Sofosbuvir/velpatasvir (Epclusa®)|The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
75315681|NCT03943615|Drug|Voxelotor|
75315682|NCT03943160|Device|Diamondback 360 Extended Length Orbital Atherectomy System|All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.
75315683|NCT03930212|Drug|Progesterone|received rectal progesterone suppositories 400 mg once daily
75315684|NCT03930212|Drug|Placebos|received placebo suppositories rectally once daily.
75460568|NCT01841684|Drug|Anacetrapib|100 mg tablet orally, once daily for 12 weeks
75460569|NCT01841684|Drug|Placebo|Placebo for anacetrapib orally, once daily for 12 weeks
75460570|NCT01841749|Procedure|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
75460571|NCT01841775|Drug|interferon α 2b + ribavirin|"interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks~ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks"
75764279|NCT05973890|Behavioral|docudrama|Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.
75764280|NCT05973422|Device|SIGI Insulin Management System|Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor using the Dexcom App.
75764281|NCT05972135|Drug|Teclistamab|- Participants will receive the recommended dosage of Teclistamab according to the TECVAYLI™ USPI (step-up dosing followed by weekly treatment dosing).
75764282|NCT05972135|Drug|Tocilizumab|Tocilizumab will be administered as a pretreatment medication in advance of administration of the first step-up dose of teclistamab on Cycle 1 Day 1.
75906928|NCT03703999|Device|Type 1 diabetic patients freestyle libre|patients selected to use freestyle libre
75460572|NCT01841788|Device|Thermal Adhesion Patch|
75460573|NCT01841788|Device|Marketed Thermal Adhesion Patch|
75613745|NCT03243422|Other|Successful aging health education intervention|"The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over approximately 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization."
75764283|NCT05968898|Device|Optellum Virtual Nodule Clinic|The Optellum Virtual Nodule Clinic is an FDA-approved (Class II) device for risk stratification of pulmonary nodules. It uses a convolutional neural network to evaluate CT imaging data to provide an estimate of malignancy risk for indeterminate pulmonary nodules.
75764284|NCT05966480|Drug|ESK-001|Oral tablet
75764285|NCT05966480|Drug|Placebo|Oral tablet
75764286|NCT05966051|Behavioral|Educational interventions|The educational interventions will consist in:
76070537|NCT06056037|Behavioral|Experimental: Making ART Work|A culturally tailored, theoretically grounded provider-facilitated group-based social support intervention (4 sessions) that emphasizes a collective approach to ART adherence and includes establishing a common understanding of ART, identifying potential barriers to ART adherence with a focus on social and structural barriers (e.g., stigma, relationship influences, family support, economic stressors), developing practical strategies to increase self-esteem and self-efficacy to enhance ART adherence, and generating and maintaining peer norms and support for ART adherence within one's social group. These sessions will include SGM youth-specific video vignettes that address the social/contextual realities faced by SGM YLWH in Brazil. Lastly, the intervention includes daily SMS text messaging that serve as both reminders and cognitive cues to take medication as prescribed.
75764287|NCT05960578|Drug|Apalutamide|Given PO
75764288|NCT05960578|Procedure|Biopsy|Undergo tumor biopsy
75906929|NCT03701425|Dietary Supplement|Mediterranean diet and exercise plan|"Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%"
75906930|NCT03566277|Behavioral|Self-monitoring|Participants will have access to a wrist-worn activity monitor and have a daily step goal
75906931|NCT03566277|Behavioral|Incentives|Participants will have a deposit contract, wherein they will lose money if a goal is not reached, or double their money if a goal is reached
75906932|NCT03566277|Behavioral|Feedback|Participants will receive text message feedback each day about progress towards their goal
75906933|NCT02181972|Drug|Gingko biloba|
75906934|NCT02181972|Drug|Placebo|
75906935|NCT05708781|Other|Core strengthening exercise|"Isolated lumbar stabilization muscle training:~Bridge track:~Dead bug track:~Quadruped Track:~Supine Track:~Side-support Track:~Prone Track:~Standing Track:"
76070538|NCT06056037|Behavioral|Standard of Care|Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.
75315685|NCT03913208|Procedure|Priority to freeze|Priority for cryopreservation and later on embryo transfer in artificial cycle with endometrium preparation by the exogenous administration of estrogen-progesterone.
75764289|NCT05960578|Procedure|Biospecimen Collection|Undergo collection of blood samples
75315686|NCT03913208|Procedure|Fresh embryo transfer|usual strategy of giving the priority for fresh embryo transfer
75315687|NCT03903536|Procedure|Thrombectomy|A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.
75315688|NCT03903536|Procedure|Hemorrhoidectomy|A surgery to remove the hemorrhoid, including the blood vessels and clot.
75764290|NCT05960578|Procedure|Computed Tomography|Undergo CT scan
75764291|NCT05960578|Drug|Golimumab|Given SC
75764292|NCT05960578|Procedure|Magnetic Resonance Imaging|Undergo MRI
75764293|NCT05960578|Procedure|PSMA PET Scan|Undergo PSMA PET
75764294|NCT05950984|Other|Drug Infusion Pump Monitoring|Intravenous vancomycin administration accuracy will be determined by comparing data obtained from drug infusion pumps with manually input administration times from the electronic Prescribing and Medicines Administration (ePMA) system.
75764295|NCT05946044|Behavioral|Diet and Exercise|Group and individual weight loss and weight maintenance sessions combined with exercise throughout the 48 months.
75764296|NCT05946031|Behavioral|Reat ETM|Exclusive cigarette smokers will be recruited and will be exposed to the real ETM condition in which tobacco purchases are real and they receive products from one randomly selected trial.
75764297|NCT05946031|Behavioral|Hypothetical ETM|Exclusive cigarette smokers will be recruited and will be exposed to the hypothetical ETM condition in which tobacco purchases are hypothetical and they don't receive any products.
75764298|NCT05943665|Drug|MDMA|medication and therapy combined
75764299|NCT05941767|Drug|Dexmedetomidine nebulization|The patient will receive nebulized dexmedetomidine via face mask nebulizer 10 minutes before induction of general anesthesia.
75764300|NCT05941767|Drug|Lidocaine nebulization|The patient will receive nebulized lidocaine 4% (3 mg /kg) 10 minutes before induction of general anesthesia.
75764301|NCT05941767|Drug|Dexmedetomidine IV|The patient will receive intravenous infusion via a syringe pump of dexmedetomidine (1 ml= 4mcg) started at a dose of 1 mcg/kg 20 minutes before induction of general anesthesia.
75764302|NCT05941767|Drug|Lidocaine IV|The patient will receive 1.5 mg/kg lidocaine 2% (1 ml = 20mg) completed to 10 ml with normal saline 0.9% intravenous 90 seconds before induction of general anesthesia.
75764303|NCT05940857|Device|OCS Liver|The TransMedics® Organ Care System (OCSTM) Liver is an FDA approved portable extracorporeal liver perfusion and monitoring system.
75764304|NCT05939167|Drug|mesenchymal stem cell|Mesenchymal stem cell dose is 0.75-1.0×10*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).
75764305|NCT05939167|Other|saline|saline is used as placebo in the placebo comparator group
75764306|NCT05938452|Drug|Glyceryl Tribenzoate|Oral Solution
75764307|NCT05927402|Other|Laughter Therapy Based on Kolcaba Comfort Theory|The laughter yoga will be applied to experimanetal group. Every laughter yoga practice is 45 minutes long and is planned 3 times a week for a total of 6 sessions. Control group patients will take only routine nursing care.
75764308|NCT05926024|Behavioral|Exercise Recall Patient Reported Outcomes|Questionnaire items inquire about (1) the number of days of the week participants engage in walking for pleasure or exercise and (2) the number of minutes per day that participants engage in walking for pleasure or exercise. The same two questions are repeated pertaining to exercise in general. Completion of these items takes 1 minute to complete.
75315689|NCT03898908|Drug|encorafenib|"Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death."
75315690|NCT03898908|Drug|binimetinib|Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
75460574|NCT01841788|Device|Placebo Patch|
75613746|NCT03243422|Other|Hearing intervention|The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
75613747|NCT03136393|Behavioral|Community based dietary counselling|The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
75613748|NCT03136393|Behavioral|Community based antenatal counselling|The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
75315691|NCT03898908|Radiation|Whole brain radiation therapy|"The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.~Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks."
75460575|NCT01841801|Device|Thermal Adhesive Patch|
75764309|NCT05926024|Behavioral|Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes|Health Behavior Questionnaire (HBQ)30 -- Questionnaire items pertain to the history of smoking, engagement in vigorous physical activity, alcohol consumption, and mortality status of parents, and take less than 1 minute to complete.
75764310|NCT05926024|Behavioral|Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes|"Functional Assessment of Cancer Therapy-General (FACT-G) is a quality of life and function measure developed and validated over 20 years ago that has been used in hundreds of cancer studies worldwide. It consists of four well-being domains -- physical, social/family, emotional, and functional. The FACT-G (Version 4) is a 27-item instrument that is formatted for self-administration and uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. It takes 6-8 minutes for an average patient to complete."
75906936|NCT05708781|Other|intensive dynamic back exercise|"Trunk lifting Prone on a couch, hips at the edge, upper part of the body free but supported by the hands against the floor. Strap fixation over the calves. With hands on the forehead, the trunk is lifted to the greatest possible extension in hips and spine. If necessary, starting with support from physical therapist. During pauses a chair in front of the couch supports the patient.~Leg lifting Standing by the end of the couch, leaning over to a prone position with the hips against the edge in 90 degree flexion, knees 45 degree and feet on the floor. Strap fixation over the chest. Straps around knees to keep legs together. Both legs are straightened and lifted to the greatest possible extension in hips and spine. Again support from physical therapist is necessary.~Pull to neck Sitting on a tool with the arms straight and abducted over the head and hands grasping a weight lever. Against sub-maximal resistance the lever is pulled behind neck and shoulders."
75906937|NCT05708781|Other|Control group|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.
76070539|NCT06056011|Device|Connex CSVM with Timmy3 module|Connex Vital Signs Monitor with the Timmy3 Investigational module
76070540|NCT06055907|Diagnostic Test|Serum anti-Xa activity|4 hours after third dose of dalteparin, serum anti-Xa activity is measured
76070541|NCT06055868|Other|Group Meeting (Focus Group)|Focus Group Discussions (FDGs) will be recorded, transcribed, and coded.
76070542|NCT06055868|Other|Questionnaires|Given electronically or via phone by study team staff
75460576|NCT01841801|Device|Marketed Thermal Adhesive Patch|
75460577|NCT01841801|Device|Placebo Patch|
75460578|NCT01841814|Radiation|Bone densitometry.|
75460579|NCT01841827|Drug|Cilostazol|
75460580|NCT01841827|Drug|Placebo|
75460581|NCT01841840|Other|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
75460582|NCT01841840|Other|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
75764311|NCT05926024|Behavioral|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes|"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is a 13-item scale that uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. This measure takes about 1 minute to complete."
75764312|NCT05926024|Behavioral|Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a)|PROMIS Cognitive Function (Short Form 8a) includes 8 items on a 5-point Likert-type scale ranging from very often/several times a day = 1 to never = 5, with higher scores indicating greater perceived loss of cognitive function. This measure takes less than 1 minute to complete.
75906938|NCT02187510|Procedure|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
75906939|NCT02187510|Procedure|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
75906940|NCT03568695|Diagnostic Test|Two samples on each of the three sites (pharynx, rectum, urine)|two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
75906941|NCT02183220|Drug|Metamizol|
75906942|NCT02183220|Drug|Acetylsalicylic acid (ASA)|
75906943|NCT02183220|Drug|Metamizol placebo|
75906944|NCT02183220|Drug|ASA placebo|
75906945|NCT03701347|Device|Reeve's model|Reeves, K. O., Young, A. E., & Kaufman, R. H. (1999). A simple, inexpensive device for teaching the loop electrosurgical excision procedure. Obstetrics and Gynecology, 94(3), 474-5.
75315692|NCT03898908|Radiation|Radiosurgery/stereotactic radiosurgery|"Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.~Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.~For GTV > 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week."
75906946|NCT03701347|Device|Hefler's model|Hefler, L., Grimm, C., Kueronya, V., Tempfer, C., Reinthaller, A., & Polterauer, S. (2012). A novel training model for the loop electrosurgical excision procedure: An innovative replica helped workshop participants improve their LEEP. American Journal of Obstetrics and Gynecology, 206(6)
75315693|NCT03893617|Drug|Propranolol|A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
75315694|NCT03893617|Drug|Placebo oral capsule|A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
75460583|NCT01841853|Behavioral|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
75906947|NCT03701347|Device|Ida's model|Reusable, portable and modular 3D printed simulator
75906948|NCT03566121|Other|Pelvic ultrasound / Urodynamic ultrasound|Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
76070543|NCT06055855|Procedure|Traditional Two-Needle Arthrocentesis|Participants in this group will undergo arthrocentesis using the traditional two-needle technique. The procedure involves the placement of one or two needles into the temporomandibular joint (TMJ) to irrigate the joint space. Needle placement is guided by anatomical landmarks.
76070544|NCT06055855|Procedure|Surgery-Guided Arthrocentesis|Participants in this group will receive arthrocentesis facilitated by a surgical guide. The guide is generated through pre-operative planning and is designed to aid in the accurate placement of the needle into the TMJ.
76070545|NCT06055829|Drug|Insulin injection and blood glucose|The FreeStyle Libre sensor continuously measures glucose every minute and saves the glucose data. Scan the sensor at least every 8 hours for a full glycemic profile. The below data is displayed after a typical 1-second scan of the FreeStyle LibreLink app or FreeStyle Libre reader via the sensor:
75460584|NCT01841866|Other|LMA removal|
75613749|NCT03115359|Behavioral|Mindfulness Meditation|"The Mindfulness Meditation intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
75906949|NCT02190084|Device|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
75906950|NCT03697291|Device|PS wire|The wiring connection used to convey ECG signal from inside the body
75906951|NCT03565965|Behavioral|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
75613750|NCT03115359|Behavioral|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
75764313|NCT05926024|Behavioral|Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12)|Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) is a questionnaire that includes 12 items inquiring about symptoms in the past 7 days (0=not at all to 4=very much) pertaining to numbness or tingling in hands/feet, discomfort in hands/feet, joint pain or muscle cramps, weakness all over, trouble hearing, ringing/buzzing in ears, buttoning buttons, trouble feeling the shape of small objects in hands, trouble walking, and pain in hands/feet in cold temperatures. This measure takes about t 1 minute to complete.
75764314|NCT05926024|Behavioral|Patient Reported Outcomes PROMIS|PROMIS Measures Global Health (10 items), Anxiety (6 items), Depression (8 items), and Stress (10 items). All items are on a 5-point Likert-type scale form never to very often. Completion of all 34 items should take no more than 3 minutes to complete.
75764315|NCT05926024|Behavioral|Patient Reported Outcomes FACT-Endocrine Symptoms|FACT-Endocrine Symptom is a 19-item questionnaire inquiring about hot flashes, cold sweats, night sweats; vaginal discharge, itching/irritation, bleeding or spotting, dryness; pain or discomfort with intercourse, loss of interest in sex; weight gain; lightheadedness; vomiting; diarrhea; headaches; bloating; breast sensitivity/tenderness; mood swings; irritability; pain in joints. Responses are on a 5- point Likert-type scale from not at all to very much. This measure takes about two minutes to complete.
75764316|NCT05926024|Behavioral|Patient Reported Outcomes Penn Arthralgia Aging Survey|Penn Arthralgia Aging Survey is an 8-item scale inquiring about joint pain, with a 4-point response scale from not at all to complete. Items pertaining to slowing down, stopping, being hesitant, unable to do this, and feeling unusually aged. This measure takes less than a minute to complete.
75764317|NCT05926024|Behavioral|Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE)|"PRO-CTCAE (patient-reported CTCAE) is Patients will be asked about the side effects of chemotherapy treatment at baseline, every 3 weeks during chemotherapy, at the end of chemotherapy, and at 6 months post-chemotherapy. Patients are asked to rate in the past 7 days the average severity, frequency, and intensity and a scale from 1=none/never/not at all to 5=very severe/very much/almost all of the time. Symptom list: Abdominal pain, Constipation, Diarrhea. Mucositis oral, Nausea, Vomiting, Edema limbs, Fatigue, Pain, Arthralgia, Myalgia, Peripheral sensory neuropathy, Anxiety, Depression, Insomnia, Dyspnea, Rash maculopapular, Hot flashes. Completion of these measures takes 5 minutes for an average patient"
75764318|NCT05926024|Diagnostic Test|p16 tumor suppressor gene|Blood samples will be obtained to test the p16 tumor suppressor gene from the subjects It is voluntary..
75764319|NCT05923242|Behavioral|Computerized Intervention Authoring Software (CIAS)|CIAS is a web based intervention. The CIAS tool walks the participant through a Motivational Interviewing process whereby they think through the reasons for and against completing screening. CIAS makes use of an automated avatar (Emmi) who is programed to ask them questions and lead them through several topic areas related to screening. The CIAS pathways include options for participants to request a link of resources after they complete each session and for patients to request a list of the cancer treatments listed in their study records in order to confirm their understanding of their cancer history.
76070546|NCT06055816|Drug|Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
75315695|NCT03893617|Behavioral|Acute stress task|Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
75315696|NCT03893617|Behavioral|No stress task|Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
75460585|NCT01841879|Behavioral|Intervention Program|"Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.~Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.~Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced."
76070547|NCT06055777|Drug|SZEY-2108 for injetion|Part1（Single-dose intravenous infusion dose-escalation trial）:100mg，200mg，500mg, 1000mg, 2000mg，4000mg and the dose of last cohort to be determined. Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：1000mg at Q8h，2000mg at Q8h, and one dose level of 1000mg, 1500mg or 2000mg at Q6h. Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1~D7 and on the morning of D8.
75315697|NCT03856047|Drug|NNC0174-0833|Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
75460586|NCT01841879|Behavioral|Delayed Intervention|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
75460587|NCT01841892|Behavioral|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
75460588|NCT01841905|Other|Observational Study|Observational Study
75613751|NCT03093350|Biological|TAA-specific CTLs|"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10^7 cells/m2~Day 28: 2 x 10^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
75460589|NCT01841918|Biological|Avian Flu Vaccine|
75613752|NCT03087903|Dietary Supplement|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
75613753|NCT03074045|Drug|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
75613754|NCT03074045|Drug|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
75613755|NCT03003052|Procedure|Dental implants|Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.
76070548|NCT06055777|Drug|Placebo|Part1（Single-dose intravenous infusion dose-escalation trial）:250mL/500mL，Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：250mL,Multiple intravenous doses of placebo at Q8h or Q6h on D1~D7 and on the morning of D8.
75764322|NCT05918484|Device|Intermittenly scanned continuous glucose monitoring|"Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria:~Time in range 70-180 mg/L >70%~Glycemic management index <7%~Coefficient of variation <36%"
75315698|NCT03856047|Drug|Placebo (NNC0174-0833)|Participants will get one dose of Placebo (NNC0174-0833) once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
75764323|NCT05918484|Other|MODY genetic diagnostic test|"Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion:~diagnosis before 35 years of age~first-degree family history of diabetes.~negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8)~preserved pancreatic beta cell function defined as C-peptide > 0.2 ng/mL in the presence of plasma glycemia >140 mg/dL).~Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test."
75764324|NCT05913908|Device|DUO Transcatheter Tricuspid Coaptation Valve System|Reduction of tricuspid regurgitation through a transcatheter approach
75315699|NCT03856047|Drug|Liraglutide 3.0 mg|Participants will get one dose of liraglutide 3.0 mg once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily. The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.
75315700|NCT03856047|Drug|Placebo (Liraglutide 3.0 mg)|Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg. The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.
75315701|NCT03855566|Behavioral|Intensive behavioral therapy for obesity|Approximately 24, 20 minute sessions over 12 months focused on diet and physical activity behavior change goals to promote weight loss. Framework includes health belief model, transtheoretical model and motivational interviewing.
75315702|NCT03737136|Drug|Bortezomib|one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)
75315703|NCT03734523|Combination Product|Flourish Vaginal Care System|This is not technically an intervention. All women who enroll in the study will be those who have opted to use the Flourish Vaginal Care System. This system is comprised of a vaginal wash (Balance), an intravaginal moisturizing gel (Restore), and a vaginal probiotic supplement (BiopHresh). Balance will be used daily. Restore will be used every other day. BiopHresh will be used twice a week with Restore. All products will be started after the first visit and continue throughout the 6-month study.
75315704|NCT03647163|Biological|VSV-IFNβ-NIS|Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
75315705|NCT03647163|Biological|Pembrolizumab|Pembrolizumab
75460590|NCT01841944|Drug|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
75460591|NCT01841944|Other|Corn oil|Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
75460592|NCT01841983|Other|Be Well Work Well|"The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.~Overall intervention objectives:~Motivate individual staff members to engage in targeted health and safety behavior changes;~build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;~facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and~promote co-worker and supervisor support for targeted health and safety behaviors."
75460593|NCT01841996|Drug|ME1111 solution|Once a day for 28 days
75460594|NCT01841996|Drug|Vehicle Solution|Once a day for 28 days
75460595|NCT01842009|Device|High Definition transcranial Direct Current Stimulation|
75460596|NCT01842022|Dietary Supplement|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
75315706|NCT03647163|Biological|ipilimumab + nivolumab|Intravenous ipilimumab 1mg/kg in combination with nivolumab 360mg
75764325|NCT05911009|Drug|BC 007 or matching placebo|Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
75764326|NCT05910606|Behavioral|Digital Exercise|Fall Prevention Program: Our fall- risk reduction program overs digitally delivered exercise with real time feedback from expert instructors.
75764327|NCT05909917|Other|Half-Day First Responder Training|Participants in both study arms will undergo a half-day first responder training course designed for laypeople. The course will consist of five curricular categories: scene management, airway and breathing, hemorrhage control, fracture management, and victim transport. Course material will not differ between in-person and virtual arms, however the method of information dissemination will vary.
76072496|NCT04145271|Device|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive damage control procedure for life-threatening abdominal and/or pelvic haemorrhage. It involves temporary occlusion of the aorta with an endovascular balloon, providing proximal control to the site of vascular injury whilst supporting cerebral and myocardial perfusion
75315707|NCT03635749|Drug|Intensive antiplatelet|"Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day~Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day~Day22 - 90: clopidogrel 75mg/day+aspirin placebo"
75906952|NCT03565965|Behavioral|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
75906953|NCT03703843|Device|ARTUS MONO|Temporarily implant and activation of the medical device
75315708|NCT03635749|Drug|Standard antiplatelet|"Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo"
75315709|NCT03635749|Drug|Immediate high-intensity statin|"Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day"
75315710|NCT03635749|Drug|Delayed high-intensity statin|"Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day"
75315711|NCT03599453|Procedure|Biopsy|Undergo Biopsy
75460597|NCT01842022|Dietary Supplement|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
75460598|NCT01842022|Dietary Supplement|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
75613756|NCT02982564|Behavioral|Exercise Program Low Intensity|This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
75613757|NCT02982564|Behavioral|Exercise Program Moderate Intensity|This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
75613758|NCT02948543|Biological|Bacillus of Calmette-Guerin (BCG)|A strain of tubercle bacillus which modifies biologic response.
75460599|NCT01842048|Other|Hyperthermia|
75460600|NCT01842048|Radiation|External-beam radiotherapy|
75613759|NCT02948543|Drug|Mitomycin (MM)|An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
75906954|NCT02187588|Drug|Eschscholtzia Californica - low dose|
75906955|NCT02187588|Drug|Eschscholtzia Californica - high dose|
75906956|NCT02187588|Drug|Ibuprofen|
75315712|NCT03599453|Procedure|Chemokine Modulation Therapy|Undergo chemokine modulation therapy
75315713|NCT03599453|Drug|Celecoxib|Given by mouth
75315714|NCT03599453|Biological|Recombinant Interferon Alfa-2b|Given intravenously
75315715|NCT03599453|Drug|Rintatolimod|Given intravenously
75315716|NCT03599453|Biological|Pembrolizumab|Given intravenously
75315717|NCT03573960|Drug|Lenvatinib|Lenvatinib capsules.
75315718|NCT03554291|Drug|Famotidine 20 MG|Famotidine 20 mg capsule taken daily for 24 weeks.
75460601|NCT01842074|Drug|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
75460602|NCT01842087|Other|Control Food|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
75613760|NCT02925780|Device|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
75764334|NCT05903313|Drug|Chang Gung ECG Abnormality Detection Software|This device is expected to be used for the static 12-lead ECG to detect whether there are abnormal ECG signals related to diseases and outputs the results.
75764335|NCT05903287|Device|Chang Gung Pleural Effusion Detection Software|"The Chang Gung Pleural Effusion Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pleural effusion. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pleural effusion.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
75906957|NCT02187588|Drug|Eschscholtzia Californica - low dose Placebo|
75906958|NCT02187588|Drug|Eschscholtzia Californica - high dose Placebo|
75906959|NCT02187588|Drug|Ibuprofen Placebo|
75764336|NCT05896774|Drug|Maplirpacept|Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
75460603|NCT01842087|Other|Fiber Fortified Food|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
75613761|NCT02925780|Device|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
75764337|NCT05896202|Other|taVNS Video|One third of the participants will see the taVNS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
75613762|NCT02901184|Drug|Spironolactone|Treatment with Spironolactone tablets on top of standard care
75460604|NCT01842100|Drug|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
75613763|NCT02901184|Other|Standard care|Standard care does not involve Spironolactone
75613764|NCT02901041|Drug|Zonisamide|ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
75613765|NCT02901041|Behavioral|Take Control|"Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.~Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic"
75764338|NCT05896202|Other|Educational materials|Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.
75764339|NCT05896202|Other|TMS Video|One third of the participants will see the TMS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
75764340|NCT05890118|Drug|Stelara|A commercial formulation of ustekinumab for SC control (0.5mg)
75613766|NCT02901041|Drug|Placebo (for Zonisamide)|Sugar pills manufactured to mimic Zonisamide capsules.
75613767|NCT02840227|Procedure|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
75764341|NCT05890118|Combination Product|RT-111 (0.5mg)|RaniPill capsule containing ustekinumab with a dose of 0.5mg
75613768|NCT02840227|Procedure|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
75613769|NCT02797964|Drug|SRA737|SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
75764342|NCT05890118|Combination Product|RT-111 (0.75mg)|RaniPill capsule containing ustekinumab with a dose of 0.75mg
76072497|NCT04141215|Biological|BIOBank bone paste|BIOBank bone paste (PPT322)
75764344|NCT05888779|Other|Beverage One (Milk)|Participant will consume beverage one (milk) and complete novel cognitive assessment questionnaire on paper.
75764345|NCT05888779|Other|Beverage Two (Juice)|Participant will consume beverage two (fruit drink) and complete novel cognitive assessment questionnaire on paper.
75315719|NCT03554291|Other|Placebo|Placebo capsule taken daily for 24 weeks.
75764346|NCT05888493|Biological|Tisagenlecleucel|Tisagenlecleucel is a solution for infusion of 0.6 to 6 x 10^8 CAR-positive viable T-cells taken intravenously (i.v.).
75764347|NCT05888493|Drug|Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.|Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
75315720|NCT03553576|Drug|Low volume bolus|Administration of a low-volume bolus (6.25 mL) of greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
75315721|NCT03553576|Drug|High volume bolus|Administration of a high-volume bolus (10 mL) of lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
75315722|NCT03525431|Diagnostic Test|Whole Exome Sequencing|Whole Exome Sequencing is a form of Next Generation Sequencing allowing investigators to assess the coding regions of many thousands of genes to find variants implicated in disease.
75613770|NCT02717403|Behavioral|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
75764348|NCT05888493|Drug|Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles|Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5
75315723|NCT03464461|Drug|Ketorolac|IV drug
75460605|NCT01842100|Other|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
75460606|NCT01842113|Drug|Rifaximin|Rifaximin 550mg by mouth twice a day
75460607|NCT01842113|Drug|Lactulose|Lactulose 30ml by mouth three times a day
75460608|NCT01842113|Drug|Lactulose Placebo|Lactulose Placebo 30ml three times a day
75460609|NCT01842113|Drug|Rifaximin Placebo|Rifaximin Placebo twice a day
75613771|NCT02717403|Behavioral|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
75613772|NCT02717403|Behavioral|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
75315724|NCT03456115|Device|Mechanical nasal dilator|Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
75764349|NCT05888493|Drug|Lymphodepleting chemotherapy|"Fludarabine (25 mg/m^2 intravenously [i.v.] daily for 3 doses) OR Cyclophosphamide (250 mg/m^2 i.v. daily for 3 doses starting with the first dose of fludarabine).~OR Bendamustine 90 mg/m^2 i.v. daily for 2 days (If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the participant demonstrated resistance to a previous cyclophosphamide-containing regimen)"
75764350|NCT05888493|Other|Corticosteroids and/or Radiation (Bridging therapy)|Corticosteroids and/or Radiation
75764351|NCT05885646|Drug|Sulthiame|Sulthiame add-on according to good clinical practice in these childhood epilepsy syndromes
75764352|NCT05882214|Dietary Supplement|β-nicotinamide Mononucleotide|After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.
75315725|NCT03440437|Drug|FS118|Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.
75764353|NCT05882214|Dietary Supplement|Maltodextrin|After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.
75764354|NCT05876871|Diagnostic Test|Pelvic Binder Radiography|One series of radiographic exposures
75764355|NCT05875584|Diagnostic Test|rbcDNA test|fecal immunochemical test
75764356|NCT05870254|Other|ExeRVIEM Program|Virtual exercise based program
75764357|NCT05870254|Other|Usual center program|Usual center cares
75764358|NCT05869825|Procedure|High Flow Nasal Canula following extubation|Participants in this group will be randomized to receive High Flow Nasal Cannula support after extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
75764359|NCT05869825|Procedure|Non-Invasive Positive Pressure Ventilation following extubation|Participants in this group will be randomized to receive NIPPV respiratory support following extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
75315726|NCT03440437|Drug|Paclitaxel|Dosing on Days 1, 8 and 15 of each 28 day cycle in combination with FS118 given on days 1, 8, 15 and 22 of each 28 day cycle.
75315727|NCT03374956|Drug|Phentermine-Topiramate|Extended Release at dose of 7.5/46 mg oral daily
75315728|NCT03374956|Drug|Liraglutide|dose of 3 mg subcutaneous daily
75315729|NCT03374956|Drug|Naltrexone/bupropion|Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
75315730|NCT03374956|Drug|Phentermine|15-37.5 mg oral daily
75315731|NCT03334682|Drug|spironolactone|Dispensation of spironolactone at each visit according to the arm description described above.
75315732|NCT03334682|Drug|Doxycycline|Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
75460610|NCT01842126|Biological|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
75460611|NCT01842126|Biological|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
75460612|NCT01842126|Drug|Placebo IV|Ascending Doses intravenous (IV) of Placebo
75613773|NCT02717403|Behavioral|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
75613774|NCT02705508|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
75613775|NCT02705508|Drug|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
75613776|NCT02705508|Drug|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
75613777|NCT02705508|Radiation|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
75906960|NCT03568617|Device|rTMS|The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.
75906961|NCT03697213|Other|Online study|20 hypothetical patient summaries
76072498|NCT04141215|Biological|BIOBank cortico-cancellous bone powder|BIOBank cortico-cancellous bone powder (PPT6)
75460613|NCT01842126|Drug|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
75460614|NCT01842139|Biological|basiliximab|Given IV
75460615|NCT01842139|Biological|WT1 126-134 peptide vaccine|Given SC
76072499|NCT04141059|Dietary Supplement|Oligopin|Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.
76072500|NCT04141059|Dietary Supplement|Placebo|Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate
76072501|NCT03022227|Other|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
75315733|NCT03221374|Behavioral|Mindfulness Based Stress Reduction|8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
75460616|NCT01842139|Drug|Montanide ISA 51 VG|Given SC
75460617|NCT01842139|Drug|poly ICLC|Given SC
75460618|NCT01842139|Other|laboratory biomarker analysis|Correlative studies
75460619|NCT01842178|Procedure|scratching|"Endometrial Injury~Done between 18-24 days prior to embryo transfer cycle.~Using transfer catheter.~Introduction of the same to the uterine fundus.~Systematic scrapping of the four uterine walls, lengthwise.~Performed by a skilled doctor.~Subsequent ultrasound control."
75460620|NCT01842191|Dietary Supplement|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
75460621|NCT01842191|Dietary Supplement|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
75764360|NCT05865301|Other|Questionnaire for patients receiving therapy|Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.
75315734|NCT03219879|Behavioral|Telephone-administered continuation therapy|The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
75315735|NCT03219879|Other|Usual care|Usual care without any study-related intervention
75315736|NCT03112603|Drug|Ruxolitinib|Ruxolitinib twice daily at the protocol-defined starting dose.
75764361|NCT05862935|Other|Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2|20-30 min/session, 3 times/week for 4 weeks. After a 5-min warm-up, participants perform a moderate-intensity functional training program. This program is designed in circuit mode consisting of 6 global functional exercises: i) sit and stand, ii) forward lunges, iii) chest press, iv) high row, v) lateral shoulder raises and vi) heel raises. Participants must complete the highest number of repetitions and/or rounds as possible (AMRAP) in 15-min without a designated rest.
75315737|NCT03112603|Drug|Extracorporeal photopheresis (ECP)|Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
75315738|NCT03112603|Drug|Low-dose methotrexate (MTX)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
75315739|NCT03112603|Drug|Mycophenolate mofetil (MMF)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
75460622|NCT01842217|Procedure|FES-PET|
75460623|NCT01842230|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~over the period I & II(cross-over)"
75460624|NCT01842230|Drug|Telmisartan 80mg and S-amlodipine 5mg|"Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~over the period I & II(cross-over)"
75460625|NCT01842243|Procedure|Apical pacing|Pacemaker set to pace at right ventricular apex initially.
75460626|NCT01842243|Procedure|Septal pacing|Pacemaker set to pace at right ventricular septum initially.
75460627|NCT01842243|Device|Pacemaker|MR conditional Pacemaker implanted in all study patients
75460628|NCT01842256|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~oral intake, once in a period~over the period Ⅰ&Ⅱ(crossover)"
75460629|NCT01842256|Drug|atorvastatin 40mg|"1 Tablet (atorvastatin 40mg),~oral intake, once in a period~over the period Ⅰ&Ⅱ(crossover)"
75460630|NCT01842269|Drug|Mycophenolate Mofetil 500mg|
75460631|NCT01842269|Drug|Mycophenolate Mofetil 250mg|
75460632|NCT01842295|Other|Blood and sperm samples|Blood and sperm samples will be done in each visit
75460633|NCT01842321|Drug|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
75460634|NCT01842347|Other|Fecal microbiota|
75460635|NCT01842373|Drug|LMX4|
76072502|NCT04747743|Other|a self structured questionnaire|A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
75315740|NCT03112603|Drug|mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
75460636|NCT01842373|Drug|BLT|
75460637|NCT01841645|Dietary Supplement|CLA depletion-repletion|
75460638|NCT01842412|Behavioral|exercise|one bout of exercise training
75460639|NCT01842477|Procedure|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
75460640|NCT01842503|Drug|GET 73|300 mg tid on 3 days cycle
75460641|NCT01842503|Drug|inactive ingredients capsule|3 capsules tid on 3 days cycle
75460642|NCT01842516|Drug|LCB01-0371 800mg|LCB0-0371 800mg
75460643|NCT01842516|Drug|LCB01-0371 1200mg|LCB01-0371 1200mg
75460644|NCT01842516|Drug|Placebo|Placebo
75460645|NCT01842529|Biological|botulinum toxin injection|
75460646|NCT01842529|Biological|0.9% normal saline injection|
75460647|NCT01842529|Device|Implantable loop recorder|
75613778|NCT02673398|Other|Comprehensive Geriatric Assessment|Ancillary studies
75613779|NCT02673398|Other|Laboratory Biomarker Analysis|Correlative studies
75613780|NCT02673398|Drug|Neratinib|Given PO
75613781|NCT02673398|Other|Pharmacological Study|Correlative studies
75613782|NCT02636322|Drug|Cyclophosphamide|Given IV
75613783|NCT02636322|Drug|Doxorubicin Hydrochloride|Given IV
75613784|NCT02636322|Drug|Etoposide|Given IV
75613785|NCT02636322|Drug|Ibrutinib|Given PO
75613786|NCT02636322|Drug|Lenalidomide|Given PO
75613787|NCT02636322|Drug|Prednisone|Given PO
75613788|NCT02636322|Biological|Rituximab|Given IV
75613789|NCT02636322|Drug|Vincristine Sulfate|Given IV
75613790|NCT02547987|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
75613791|NCT02547987|Drug|Carboplatin|Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
75764362|NCT05862935|Other|Supervised Physical Activity: Phase 1|40-60 min/session, 3 times/week for 12 weeks. After a 5-min warm-up, participants performed 6 global functional exercises: i) sit-to-stand; ii) chest press, iii) forward lunges; iv) unilateral shoulder raises; v) unilateral row; and vi) heel raises. The initial volume is 2 sets and 8 repetitions and it will progressively increase until 3 sets and 12 repetitions.
75764363|NCT05861128|Drug|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
75764364|NCT05860634|Procedure|Catheter self-discontinuation|Self-discontinuation of a transurethral catheter
75764365|NCT05848128|Drug|5% Tavilermide ophthalmic solution|Twice a day topicial dosing
75764366|NCT05848128|Other|Vehicle ophthalmic solution|Twice a day topical dosing
75764367|NCT05838521|Drug|Sacituzumab govitecan|This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
75764368|NCT05836571|Procedure|Biopsy|Undergo biopsy
75315741|NCT03112603|Drug|Infliximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
75315742|NCT03112603|Drug|Rituximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
75315743|NCT03112603|Drug|Pentostatin|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
75315744|NCT03112603|Drug|Imatinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
75315745|NCT03112603|Drug|Ibrutinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
75460648|NCT01842542|Device|NeuroStar Transcranial Magnetic Stimulation (TMS)|"Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.~3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician."
75460649|NCT01842555|Other|Registry|Registry
75460650|NCT01842659|Genetic|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
75460651|NCT01842685|Procedure|Bladder Thermal Distention|Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
75460652|NCT01842698|Device|ultrasoundguided paravertebral catheter|
75460653|NCT01842724|Procedure|Motec total wrist arthroplasty|
75460654|NCT01842724|Procedure|Remotion total wrist arthroplasty|
75460655|NCT01842737|Procedure|Spinal treatment|This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
75460656|NCT01842737|Procedure|Massage|The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
75613792|NCT02523040|Drug|Lenalidomide|
75613793|NCT02513199|Radiation|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
75764369|NCT05836571|Procedure|Biospecimen Collection|Undergo collection of blood
75764370|NCT05836571|Drug|Cabozantinib|Given PO
75315746|NCT03075917|Other|Self Questionnaire|self questionnaire for allergic rhinitis control
75460657|NCT01842750|Device|Endorectal Balloon insertion|
75460658|NCT01842802|Device|Diode Laser|Diode Laser for treatment of subcutaneous fat
75460659|NCT01842802|Device|YAG laser|YAG laser for treatment of subcutaneous fat
75460660|NCT01842828|Other|Standard care plus electronic cigarettes|
75460661|NCT01842828|Behavioral|Standard care|
75613794|NCT02513199|Drug|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
75613795|NCT02440672|Device|JOURNEY™ II CR Total Knee System (J II CR TKS)|TKA with Journey II CR Total Knee System
75613796|NCT02396043|Drug|induction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22"
75613797|NCT02396043|Drug|induction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59
75613798|NCT02396043|Drug|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
75764371|NCT05836571|Procedure|Computed Tomography|Undergo CT
75764372|NCT05836571|Biological|Ipilimumab|Given IV
75764373|NCT05836571|Procedure|Magnetic Resonance Imaging|Undergo MRI
75764374|NCT05836571|Biological|Nivolumab|Given IV
75764375|NCT05834673|Drug|Inclisiran Prefilled Syringe|Inclisiran, 284 mg, 1.5 ml Liquid in a single-use prefilled syringe (PFS) for s.c. administration and any standard medications to be used within registered indication and at the treating physician's discretion.
75764376|NCT05834673|Other|SMS messages|Participants will receive monthly SMS messages regarding cardiovascular health (low touch engagement nudges)
75764377|NCT05834673|Other|Telephone-based support calls|Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.
75764378|NCT05829226|Drug|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
75764379|NCT05829226|Drug|Venetoclax|Bcl-2 inhibitor
75764380|NCT05829226|Drug|Azacitidine|Hypomethylating agent
75764381|NCT05829226|Drug|Decitabine|Hypomethylating agent
75315747|NCT03073317|Diagnostic Test|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
75764384|NCT05821374|Drug|Deucravacitinib|6 mg tablet
75764385|NCT05812027|Diagnostic Test|Tumor and HLA Profiling|HLA genotyping and tumor tissue profiling for certain TAA and LOH.
75764386|NCT05807126|Procedure|Biopsy|Undergo biopsies
75764387|NCT05807126|Procedure|Biospecimen Collection|Undergo collection of blood samples
75613799|NCT02396043|Drug|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
75315748|NCT03050216|Biological|ALT-803|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total"
75764388|NCT05807126|Procedure|Computed Tomography|Undergo CT
75460662|NCT01842893|Drug|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
75764389|NCT05807126|Procedure|Magnetic Resonance Imaging|Undergo MRI
75764390|NCT05807126|Biological|Magrolimab|Given IV
75460663|NCT01842919|Other|Kinesthetics tests|
75460664|NCT01842919|Other|Psychological questionnaires|
75460665|NCT01842919|Other|structural Magnetic ResonanceImaging (MRI)|
75460666|NCT01842932|Drug|Phloroglucin|Premedication of colonoscopy
75460667|NCT01842932|Drug|Cimetropium bromide|Premedication of colonoscopy
75460668|NCT01842932|Procedure|Colonoscopy|Diagnostic examination of colon
75613800|NCT02396043|Drug|reinduction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8"
75613801|NCT02396043|Drug|reinduction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
75613802|NCT02396043|Drug|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
75764391|NCT05807126|Drug|Olaparib|Given PO
75764392|NCT05806021|Drug|Triamcinolone Acetonide|Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
75764393|NCT05795595|Biological|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
75764394|NCT05795062|Drug|apixaban|patients treated with apixaban
75764395|NCT05795062|Drug|warfarin|patients treated with warfarin
75764396|NCT05791240|Behavioral|Family Initiated Interpretation|Interpreter tablet will be given to families so they can contact an interpreter themselves.
75460669|NCT01842932|Drug|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
75764397|NCT05774197|Behavioral|Cognitive Behavioral Therapy for pain|Patient participating in this study will have survey assessments at baseline, 4 weeks (end of 4-week intervention period), and 6 weeks (end of 2-week post intervention period) assessing patient reported concerns, quality of life outcomes and usability of STAMP+CBT app. During this time, Patient will receive algorithm-based advice in response to their daily pain and mood surveys. These patients will be introduced to the extensive multi-media library of educational content covering medication support (e.g. using short and long-acting opioids, managing side effects, opioid safety); pain psychology (e.g. pain perception, pain and the stress response); health behaviors and pain (e.g. sleep hygiene); and skills training (e.g. activity pacing/ relaxation recordings).
75764398|NCT05765487|Drug|Sildenafil|Sildenafil Cream, 3.6%
75764399|NCT05765487|Drug|Vehicle|No Active or experimental ingredients
75764400|NCT05765487|Drug|Placebo|Cream with only L-arginine
75764401|NCT05764161|Drug|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
75764402|NCT05764161|Drug|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
75764403|NCT05762757|Other|Colposcopy educational material|-Will consist of a handout featuring education and information regarding colposcopies.
75764404|NCT05762328|Behavioral|Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia|Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
75613803|NCT02258919|Procedure|Decompressive craniectomy (DC) and best medical treatment|"Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively."
75764405|NCT05752526|Drug|Diclofenac 1%|vaginal hydrogel containing 1% Diclofenac
75764406|NCT05752526|Drug|Diclofenac 3%|vaginal hydrogel containing 3% Diclofenac
75764407|NCT05752526|Drug|Placebo|vaginal hydrogel, no active ingredient
75764408|NCT05742776|Other|Assessment of Sleep Quality|Assessment of Sleep Quality
75764409|NCT05742776|Other|Assessment of Sleep Quality|Assessment of Sleep Quality
75764410|NCT05740722|Dietary Supplement|Nicotinamid riboside|500 mg x 2 po
75764411|NCT05740722|Dietary Supplement|Placebo|Placebo tablets
75764412|NCT05740566|Drug|Tarlatamab|Tarlatamab will be administered as an IV infusion.
75764413|NCT05740566|Drug|Lurbinectedin|Lurbinectedin will be administered per local SOC.
75764414|NCT05740566|Drug|Topotecan|Topotecan will be administered per local SOC.
75764415|NCT05740566|Drug|Amrubicin|Amrubicin will be administered per local SOC.
75764416|NCT05725083|Procedure|Lower thoracic epidural|before induction of anesthesia,first the investigators identify the correct targeted thoracic level. All epidural block will be performed under all aseptic precautions with a 17-gauge Tuohy needle and 19 G flex-tip catheters. Using the loss of resistance to saline technique, catheter will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection. Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the epidural catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15ml/h .for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1 mg bolus , 10 min lockout period . The catheter will be removed under complete aseptic precautions after 48 hrs.
75460670|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
75764417|NCT05725083|Procedure|Erector spinae plane block|before induction of anasthesia ,highfrequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle.confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.Then the catheter placement 5cm into the space under the erector spinae muscle and suitable test dose will be administered . Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h , for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1mg bolus,10 min lockout period.The catheter will be removed under complete aseptic precautions after 48 hrs.
75764420|NCT05721989|Drug|Ziltivekimab B|Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
75764421|NCT05721989|Drug|Ziltivekimab D|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
75315749|NCT02984241|Behavioral|eHealth Coping Skills Training|Access to a specialized coping skills training website
75315750|NCT02984241|Behavioral|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
75460671|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
75460672|NCT01842971|Procedure|two stage hepatectomy|
75460673|NCT01842984|Behavioral|I-SOCIAL intervention|The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
75460674|NCT01842997|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
75460675|NCT01843010|Drug|Parecoxib|Parecoxib 40mg will be intravenously infused.
75613804|NCT02258919|Procedure|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
75613805|NCT02232191|Biological|Pneumovax-23|
75764422|NCT05721989|Drug|Ziltivekimab C|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
75315751|NCT02984241|Behavioral|Coach Support|Access to a professional coach by phone
75315752|NCT02829593|Other|hypoglycemia (low blood sugar) and MRI|hypoglycemia (low blood sugar) and MRI
75315753|NCT02736266|Drug|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
75315754|NCT02725528|Drug|collagenase injection|injection
75764423|NCT05720338|Device|19 French Blake Drain|19 French Blake Intraperitoneal Drain will be placed near the pancreatic resection margin
75764424|NCT05719441|Biological|VRC07-523LS|10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry
75764425|NCT05719441|Biological|PGT121.414.LS|5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry
75764426|NCT05719441|Other|Placebo|Sodium Chloride for Injection USP, 0.9%
75764427|NCT05719441|Drug|ART|Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
76070549|NCT06055764|Device|PET/CT|"Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room.~Procedure:~All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital.~PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images."
76070550|NCT06055738|Drug|Zimberelimab|240mg,d1,iv,Q21D
76070551|NCT06055738|Drug|Albumin-bound Paclitaxel|260mg/m2,d1,iv,Q21D
75764428|NCT05716373|Behavioral|pain|reiki
75764429|NCT05713006|Drug|Alectinib Oral Product|Alectinib is administered with a sequential dose escalation every 21 days from 300 to 600mg twice daily in the phase 1 portion. In phase 2, patients received an investigator-chosen dose based on the PK analysis.
75764430|NCT05710133|Other|food|alectinib-d6 will be administered with breakfast on day 1 to determine the food-effect
75764431|NCT05710133|Other|fast|alectinib-d6 will be administered after an overnight fast of minimal 10 hours on day 9 to determine the food-effect
75764432|NCT05709028|Drug|Fosfomycin|"Fosfomycin trometamol is a white crystalline powder which is very soluble in water. The granules are mixed with 90ml of cool water for the constitution to dissolve and will be administered soon after reconstitution. Each 30ml will contain 1g fosfomycin base.~Children ≥ 1 to 11 years will be administered 60ml (=2g fosfomycin base) of dissolved solution and the remainder discarded for each dose. Children ≥12 and <18 years will be administered the entire 90ml solution (= 3g fosfomycin base) for each dose.~Children with an uncomplicated UTI will receive a single dose of fosfomycin trometamol. A second dose will be administered 48 hours later for children with persistent fever and/or ongoing clinical symptoms attributable to their UTI.~Children with a complicated UTI will receive repeat doses fosfomycin trometamol every 48 hours until a total 10-day course of antibiotics with presumed or proven efficacy against the urinary pathogen has been administered."
75764433|NCT05709028|Drug|Standard of care antibiotics|"Standard of care antibiotics will be chosen by the treating clinician according to institutional prescribing practices, local antibiograms and medication availability.~Children with an uncomplicated UTI will receive a 3-day course of standard of care antibiotics with proven efficacy against the urinary pathogen. An additional 48 hours of antibiotic therapy will be administered to children who have persistent fever and/or ongoing clinical symptoms attributable to their UTI at 72 hours after enrolment.~Children with a complicated UTI will receive a total 10-day course of standard of care antibiotics with proven efficacy against the urinary pathogen."
75764434|NCT05697952|Drug|E1K 1,200 ㎍/joint|Injection of E1K 1,200 ㎍/joint/ml on target lesion
75906962|NCT05364489|Drug|Bevacizumab combined with Oxaliplatin and TAS-102|"Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
75906963|NCT02183298|Drug|BI 1356 BS - intravenous|
75906964|NCT02183298|Drug|BI 1356 BS - Tablet|
76070552|NCT06055738|Drug|Cisplatin|75mg/m2,d1,iv,Q21D
76070553|NCT06055699|Other|Fecal sampling|"Stool samples are a collection of products derived from the human body that is not invasive in any way and samples not taken as part of usual care.~Stool samples will be collected at home within 7 days of the visit M0, M3 and M6 and within 14 days of the visit M12 in an ethanol tube and in DNA/RNA shield, and transported at room temperature to Saint-Antoine Hospital (CRB SAT, AP-HP, Pr. SIMON ), samples will be aliquoted (3 aliquots per tubes) and stored at -80°C for a period of 5 years (renewable) At the end of the research, stool samples will be analysed using metagenomics sequencing.~DNA extraction will be performed following the standards of the The International Human Microbiome Standards . DNA will be stored at -80°C."
75764435|NCT05697952|Drug|E1K 2,400 ㎍/joint|Injection of E1K 2,400 ㎍/joint/ml on target lesion
75764436|NCT05697952|Drug|placebo|Injection of 3ml saline on target lesion
75764437|NCT05693363|Device|AURA10 Specimen Imager|High-resolution specimen imaging using the AURA10 PET-CT specimen imager during thoracic surgery.
75764438|NCT05692024|Drug|Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.|Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.
75764439|NCT05692024|Drug|Placebo|Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
75764440|NCT05691829|Drug|Pembrolizumab|Pembrolizumab 200mg solution administered intravenously every 3 weeks for 6 cycles followed by maintenance therapy until progression of disease or unacceptable toxicity (standard of care). Administered alongside chemotherapy.
75764441|NCT05691829|Radiation|Radiation|One-time, up-front radiation delivered at up to five metastatic subsites at a 4 Gy x 5 radiation dose fractionation schedule. Radiation will be delivered within five days before or after initiation of first cycle of pembrolizumab treatment. Radiation modality and technique will be determined at the discretion of the treating radiation oncologist.
75764442|NCT05691829|Drug|Chemotherapy|Administered alongside pembrolizumab every 3 weeks for 6 cycles per institutional standard of care. For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and paclitaxel or nab-paclitaxel
75906965|NCT02183298|Drug|Placebo|
75906966|NCT03569943|Device|Robot Based Transtympanic drain placement|Placement of a transtympanic drain with a robot based device assistance called RobOtol
75764443|NCT05691218|Device|Standard Nebulization|Beta-2 adrenergic agonist administred by standrad nebulization
75764444|NCT05691218|Device|A - Vibrating mesh nebulization|Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
75764445|NCT05691218|Device|B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen|"High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device"
75764446|NCT05691010|Radiation|Intensity-modulated radiation therapy|After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
76070554|NCT06055699|Other|Blood sampling|"Blood samples (serum, 15 ml) are an additional and minimal collection performed following a sample taken as part of usual care.~Blood samples (serum) will be collected during the visit at M0, M3 (± 7 days), M6 (± 7 days) and M12 (± 7 days).~In the hours following collection, the samples must be aliquoted and stored at -80°C in a secure place in the participating centre."
75764447|NCT05691010|Drug|Carboplatin|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
75764448|NCT05691010|Drug|Paclitaxel|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
75764449|NCT05690308|Other|Visual perturbation treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill in a virtual reality environment (Gait Real-time Analysis Interactive Lab system, MOTEK) with projected visual perturbations.
75764450|NCT05690308|Other|Regular treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill
75764451|NCT05689788|Device|High-intensity laser therapy|punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used.
75764452|NCT05689788|Procedure|Stretching exercise|Three sets of bilateral passive static stretching will be performed for the upper trapezius, levator scapulae, and scalene muscles. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
75764453|NCT05689788|Device|Sham High-intensity laser therapy|Intervention in which the therapist performs a HILT simulation application, performing all of the steps and movements for an administration without actually receiving the treatment.
75764454|NCT05687097|Device|Home-based sleep screening test or hospital-unattended sleep screening test|ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.
75906967|NCT03697135|Behavioral|Respondent Driven Sampling|Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
75906968|NCT02190162|Drug|Tantum Verde® mouthwash|
75906969|NCT02190162|Other|Placebo mouthwash|Mouthwash with placebo solution
75906970|NCT03565809|Other|Incidence analysis|Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.
76070555|NCT06055673|Genetic|DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD|Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.
75460676|NCT01843010|Drug|Placebo|Normal saline 5ml will be intravenously infused.
75460677|NCT01843049|Radiation|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
75460678|NCT01843049|Drug|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
75906971|NCT03697057|Procedure|General anaesthesia|Standard general anaesthesia for gynecologic surgery in patient group
75315755|NCT02725528|Procedure|limited palmar fasciectomy|surgery
75315756|NCT02661451|Device|SAPIEN 3 THV|
75315757|NCT02661451|Biological|Optimal Heart Failure Therapy|
75315758|NCT02629614|Device|Cala ONE Device|The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.
75315759|NCT02627963|Drug|Tivozanib hydrochloride|Tivozanib hydrochloride
75315760|NCT02627963|Drug|Sorafenib|Sorafenib
75315761|NCT02589691|Drug|Rocuronium|
75315762|NCT02589691|Other|Sodium chloride 0.9%|
75315763|NCT02585258|Drug|Prednisolone|1 capsule containing a tablet of 5 mg prednisolone/ day
75315764|NCT02585258|Drug|Placebo|1 capsule containing a placebo tablet / day
75315765|NCT02525432|Biological|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
75315766|NCT02525432|Biological|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
75315767|NCT02408952|Behavioral|Primary Care Physician|The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
75460679|NCT01843075|Drug|Liraglutide|Daily subcutaneous injection
75764455|NCT05687097|Device|Cardiovascular beat-to-beat monitoring|CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.
75764456|NCT05687097|Device|ECG monitoring|Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.
75315768|NCT02408952|Behavioral|Behavioral Medicine Specialist|The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
75764457|NCT05684523|Drug|Valerian-Hop Extract|herbal drug
75764458|NCT05684523|Drug|Placebo|Placebo
75764459|NCT05672095|Procedure|Biopsy|Undergo needle or core biopsy
75764460|NCT05672095|Procedure|Biospecimen Collection|Undergo blood sample collection
76070556|NCT06055660|Genetic|Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma|Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
76070557|NCT06055647|Genetic|immunohistochemical approach|Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.
75460680|NCT01843075|Drug|Placebo|Daily subcutaneous injection
75460681|NCT01843088|Drug|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
75764461|NCT05672095|Drug|Niraparib|Given PO
75764462|NCT05672095|Other|Questionnaire Administration|Ancillary studies
75764463|NCT05672095|Dietary Supplement|Selenium|Given IV
76070558|NCT06055634|Genetic|genotyping of SIRT1 in chronic obstructive patients|genotyping of SIRT1 in chronic obstructive patients
75460682|NCT01843088|Drug|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
75460683|NCT01843101|Device|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
75460684|NCT01843114|Device|FDOCT|Measurement of retinal blood velocities
75460685|NCT01843114|Other|Dynamic Vessel Analyzer|Measurement of retinal vessel diameters
76070559|NCT06055595|Diagnostic Test|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
75460686|NCT01843127|Drug|Ranolazine|
76072447|NCT04765917|Other|Selected physical Therapy program|"-Facilitation of balance reactions from standing position including: Standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing, standing on balance board and pushing the child in different directions.~Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~Strengthening exercises for weakened muscles in upper and lower limbs muscle.~Strengthening exercises for back and abdominal muscles.~Stretching exercises for tight muscles in upper and lower limbs.~Gait training activities for correction of gait pattern including: walking on balance beam, walking on balance board, walking on uneven surface, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~Jumping in place and jumping a board."
75460687|NCT01843127|Drug|Placebo|
75460688|NCT01843127|Drug|Exenatide|
75460689|NCT01843153|Drug|Ropivacaine|
75460690|NCT01843166|Drug|Premarin vaginal cream|2g at bedtime twice weekly
75460691|NCT01843166|Drug|Placebo cream|2g at bedtime twice weekly
75764464|NCT05669664|Procedure|Biopsy|Undergo biopsy
75764465|NCT05669664|Procedure|Biospecimen Collection|Undergo collection of blood
75764466|NCT05669664|Procedure|Computed Tomography|Undergo CT
75764467|NCT05669664|Drug|Darolutamide|Given PO
75764468|NCT05669664|Drug|Leuprolide Acetate|Given IM
75460692|NCT01843179|Drug|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
75460693|NCT01843179|Drug|Sulindac|Taken orally twice per day at home for 12 months
75460694|NCT01843218|Other|Evaluation of erectile dysfunction|Register R / P and self-administered questionnaire IIEF-5
75764469|NCT05669664|Procedure|Magnetic Resonance Imaging|Undergo MRI
75764470|NCT05669001|Biological|TCD601|Investigational Product
75764471|NCT05669001|Biological|belatacept|Study Product
75764472|NCT05669001|Drug|ATG|Comparator
75764473|NCT05669001|Drug|TAC|Comparator
75764474|NCT05669001|Drug|MPA|Immunosuppression Therapy
75764475|NCT05669001|Drug|Corticosteroids|Immunosuppression Therapy
75764476|NCT05666713|Device|TELLTALE BASILICA procedure|The TELLTALE BASILICA procedure has five steps: (1) engagement of the target leaflet with a guiding catheter; (2) electrosurgical leaflet traversal with the TELLTALE guidewire, (3) preparation and positioning of the TELLTALE guidewire electrosurgical leaflet laceration surface; (4) electrosurgical leaflet laceration with the TELLTALE guidewire, immediately followed by (5) TAVR. These are all guided by fluoroscopy, with adjunctive echocardiography as needed.
75764477|NCT05657912|Device|ECG monitoring|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
75764478|NCT05657054|Other|Exercise Intervention Targeting Hip Strengthening|An initial 16-week exercise intervention of 45 minutes of training 3 times a week in the patient's own home or at a rehabilitation center. Patients will be instructed by a physiotherapist during the first 3 sessions, in order to be able to perform the exercises at home. Subsequently, there are physiotherapist-supervised sessions once every second week. The delivery of the supervised sessions is based on the patient's preferences, either by physical attendance or remotely in the patient's home. The intervention will consist of 4 exercises adapted from the NEMEX program targeting lower extremity muscle strength, stability, postural function, and postural orientation. Progression is made when an exercise is performed with good sensorimotor control and good performance quality and with minimal exertion and adequate movement control. Progression is primarily provided by 3 levels of difficulty and secondly by varying the number of repetitions or where possible, by increasing the weight load.
75906972|NCT03701191|Procedure|Inverted periosteal pedicle flap|The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
75906973|NCT02183376|Drug|BI 1356|
75764479|NCT05657054|Other|Usual Care|The intervention will consist of a rehabilitation intervention corresponding to standard care in the participating municipalities (i.e. content and duration of intervention). The intervention will be delivered individually or as group training, based on a clinical assessment of the individual patients' needs. The intervention can be supported by home-based exercises following instruction from a physiotherapist, supplemented by the provision of written information or access to a virtual training program. The intervention occurs in either the rehabilitation center's gym or the patient's home. The training sessions may consist of some of the following parameters: Strength training, stretching, functional training e.g. walking and stair climbing, stability training, balance training, endurance training, and gait correction.
75764480|NCT05656534|Drug|Suvorexant|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). Suvorexant (SUV) will be placed in opaque capsules with dextrose filler. After the pre-treatment visits participants will take one pill of SUV at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete an EMG. Laboratory assessments will occur during peak concentration, 2 hours post-ingestion. At the end of the visit, participants will be given a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side effects and potential drug-drug interactions. At the end of the 28 days, participants will complete post-treatment lab visits.
75764481|NCT05656534|Other|Placebo|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). The placebo pill will be identical in appearance to suvorexant but will contain only dextrose. Following the pre-treatment visits, participants will take one pill at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete the EMG paradigm. At the end of the visit participants will be provided a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side. At the end of the 28 days, participants will complete post-treatment lab visits.
75764482|NCT05650164|Drug|avelumab|as provided in real world practice
75764483|NCT05650164|Drug|axitinib|as provided in real world practice
75764484|NCT05642845|Drug|Atorvastatin film-coated tablet 40 mg|Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.
75764485|NCT05642845|Drug|Liprimar® film-coated tablet 40 mg|"Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin."
75764488|NCT05637489|Behavioral|PING|Brief survey of goals and preferences
75764489|NCT05637294|Device|splinting|neutral-positioned wrist orthosis
75906974|NCT03696979|Other|Myofascial induction therapy|Myofascial induction therapy is a therapy concept focused on optimizing function and balance within the fascial system. The approach aims at global recovery, local correction and painless body use.
76072503|NCT04144335|Biological|N-803 and bNAbs|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
75460695|NCT01843231|Device|g-CathTM EZ Suture Anchor Delivery Catheter|Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
76072504|NCT04144335|Biological|haNK™ Cells|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
75906975|NCT03696979|Other|Therapeutic pain education|Therapeutic pain education is a training intervention that aims to reduce pain and disability by helping patients better understand the biological processes that support pain states. The neurobiology of pain and pain processed by the nervous system is explained to the patient in detail. Changes the patient's olab viewpoint to pain. For example, the patient believes that the cause of pain is caused by tissue damage. The patient who receives pain training understands that the cause of pain is the hypersensitive central nervous system. As a result, the patient's fear avoidance behavior decreases and he starts to move more easily. Because the sensitivity of the central nervous system will be alleviated, the perceived pain will decrease.
75906976|NCT03565731|Behavioral|ACT-PA|The overall goal of the intervention is to increase bout-related moderate-to-vigorous physical (MVPA) activity to greater than 200 minutes per week. The basic structure is an initial on-site, group-based intervention workshop, written materials, weekly emails, and monthly phone calls for a total of 3 months.
75460696|NCT01843231|Other|Diet and Exercise Control Group|Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
75460697|NCT01843257|Other|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
75460698|NCT01843257|Other|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
75460699|NCT01843270|Device|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
75460700|NCT01843270|Device|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
75460701|NCT01843283|Behavioral|Daily Enhancement Meaningful Activity (DEMA)|
75460702|NCT01843283|Behavioral|Information Support (IS)|
75764490|NCT05630963|Device|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
75906977|NCT02187822|Drug|TPI 287|TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).
75315769|NCT02394626|Procedure|Surgery followed by adjuvant second-line therapy|"Surgery:~Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.~Adjuvant second-line therapy:~Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol."
75315770|NCT02394626|Procedure|Second-line therapy alone|Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
75460703|NCT01843296|Drug|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
75460704|NCT01843296|Procedure|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
75906978|NCT02187822|Procedure|Fractionated Stereotactic Radiotherapy (FSRT)|The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
75906979|NCT03696901|Drug|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration [e.g. hospital, ICU]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
75906980|NCT03063034|Other|PD21864AA|A king size menthol cigarette.
76070560|NCT06055296|Other|COMPRENDO Peer Navigation Intervention|"Parents randomized to the intervention, COMPRENDO, will receive culture, language, and health literacy-concordant pre-accrual, accrual, and post-accrual activities in person led by a peer navigator for up to 4 weeks. Visit 1 (V1) will provide anticipatory guidance and education on a) general concepts of pediatric cancer research (standard of care, clinical trials, randomization); b) informed consent/assent, research affiliations (e.g., Children's Oncology Group); c) clinical trial types (therapeutic, non-therapeutic); d) voluntariness; and e) frequently asked questions, resources. Navigators will follow a script supported by culture, language and health-literacy concordant handouts and graphic materials, decision aids, and short video-clips. Navigators also provide support with decision-making and answer parents' questions. Three follow-up peer navigator visits (V2, V3, V4) over 4 weeks are tailored to the parents' needs."
75613806|NCT02143752|Behavioral|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
75906981|NCT03063034|Other|PD21864AB|A king size menthol cigarette.
75906982|NCT03565653|Other|High dietary salt|~4,000 mg Na+/day
75906983|NCT03565653|Other|Placebo|dextrose
76070561|NCT06054945|Procedure|SIFIB (suprainguinal fascia iliaca block)|Ultrasound guided Suprainguinal Fascia Iliaca Block for Knee Arthroplasty Patients
75315771|NCT02339545|Device|Coronary Orbital Atherectomy plus Stenting|
75315772|NCT02203604|Biological|aldesleukin|Given IV
75315773|NCT02203604|Biological|ipilimumab|Given IV
75460705|NCT01843296|Drug|Bupivacaine|
75613807|NCT02143752|Behavioral|Quit Line|see arm
75764491|NCT05630963|Drug|PET radiotracer|"A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer ([11C] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels."
75460706|NCT01843296|Drug|Fentanyl|
75906984|NCT02187900|Drug|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
75460707|NCT01843309|Drug|Spironolactone 100mg|
75460708|NCT01843309|Drug|Spironolactone 200mg|
75906985|NCT02187900|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
75460709|NCT01843309|Drug|Placebo|
75460710|NCT01843322|Procedure|endoleak repair procedure (navigation technology )|
75460711|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
75613808|NCT02141828|Drug|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
75613809|NCT02015871|Drug|Degarelix|
75613810|NCT02000050|Drug|FOLFOX4|FOLFOX4
75906986|NCT03062644|Drug|MR308|two times daily; Mode of Administration:oral
75613811|NCT02000050|Radiation|Tomotherapy|Tomotherapy
75613812|NCT02000050|Procedure|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
75613813|NCT01765491|Other|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
75906987|NCT03062644|Drug|MR308|four times daily; Mode of Administration:oral
75906988|NCT03062644|Drug|MR308|two times daily; Mode of Administration:oral
75906989|NCT03062644|Drug|MR308|given four times daily to maintain the blind; Mode of Administration:oral
75906990|NCT04749355|Drug|BST-236|BST-236 is a conjugate of cytarabine and asparagine, provided as a sterile lyophilized powder for IV administration
75906991|NCT02190318|Drug|Losartan|
75764492|NCT05608369|Drug|Cisplatin|Cisplatin (100 mg/m2 every 3 weeks)
75906992|NCT02190318|Drug|spirolactone|
75906993|NCT02190318|Other|blank control|
75906994|NCT02246361|Procedure|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
75906995|NCT03701113|Dietary Supplement|Milk-based protein matrix (MBPM)|Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention
75906996|NCT03701113|Dietary Supplement|Habitual dietary behaviour|Subjects to maintain habitual dietary behaviour for the 24 week intervention
75906997|NCT03062722|Procedure|keyhole approach|The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
75906998|NCT02183454|Device|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
75906999|NCT03703687|Behavioral|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
75907000|NCT03503968|Drug|MDG1011|PRAME-T-Cell Receptor Gene Modified Autologous T Cells
75907001|NCT03503968|Other|Investigator Choice therapy|Any intervention/therapy chosen by the investigator
75907002|NCT02246829|Procedure|Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
75315774|NCT02203604|Other|laboratory biomarker analysis|Correlative studies
75315775|NCT02132611|Device|Diamondback 360® Coronary OAS Micro Crown|The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
75315776|NCT01989013|Other|biweekly intervention|10 step craniosacral therapy protocol through manual therapy at feet , thoracic diaphragm, neck and cranium
75315777|NCT01941030|Device|Orbital Atherectomy System|Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
75460712|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
75460713|NCT01843400|Drug|Regorafenib (Stivarga, BAY73-4506)|Patients treated with Regorafenib under practical manner for colorectal cancer.
75460714|NCT01843426|Drug|Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
75460715|NCT01843439|Dietary Supplement|Magnesium|
75460716|NCT01843439|Behavioral|Education for asthma action plan|
75460717|NCT01843439|Behavioral|hot-lines for acute exacerbation of asthma|
75315778|NCT01941030|Device|Balloon Angioplasty|Type of balloon selected is driven by preference of the operator.
75315779|NCT01899339|Other|submassive PA treatment with Ekosonic endo device|Ultra Sound energy along with tPA to treat submassive pulmonary embolism
75764493|NCT05608369|Radiation|Radiation therapy|Radiation therapy (70 Gy) for total of 7 weeks
75764494|NCT05608369|Drug|Vorinostat|Pre-treatment; 300 mg every other day
75764495|NCT05606679|Genetic|Analysis combinations of maternal KIR and HLA-C genotypes|Analysis of combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients
75764496|NCT05603754|Drug|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle
75764497|NCT05603754|Drug|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
75907003|NCT02183532|Drug|BI 1356 BS|single dose
75907004|NCT02183532|Drug|BI 1356 BS|multiple doses
75907005|NCT03569787|Diagnostic Test|MRI Pituitary|Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
75907006|NCT04741477|Drug|CBD|CBD will be topically applied
75907007|NCT04741477|Drug|THC|THC will be topically applied
75907008|NCT04741477|Drug|Placebo|a placebo product (without cannabinoids) will be topically applied
75907009|NCT03569709|Behavioral|Aerobic Exercise|Progressive sub-threshold aerobic exercise
75907010|NCT03569709|Behavioral|Rest|No structured exercise.
75907011|NCT03569709|Behavioral|Stretching|Gentle progressive upper and lower extremity stretching program
75907012|NCT03696823|Procedure|laparoscopic cholecystectomy|treatment of chronic calcular cholecystitis laparoscopically
75907013|NCT03569631|Drug|BPN14770|25 mg BPN14770 capsules
75907014|NCT03569631|Drug|Placebo|Placebo capsules to mimic 25 mg BPN14770 capsules
75613814|NCT01765491|Other|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
75907015|NCT03696745|Other|autologous umbilical cord blood stem cells|autologous umbilical cord blood stem cells treatment for brain injury for safety and effect evaluation
75907016|NCT03696745|Drug|0.9% Sodium-chloride|0.9% Sodium-chloride in control group
75907017|NCT03568227|Procedure|Hypnosis|The hypnosis intervention consists of two elements: A hypnotic induction and a hypnotic deepening. The induction aims at guiding the participant into the first hypnotic state (state 1). The participants will remain in this state for 10 minutes, the duration of the fMRI-scan. The hypnotic deepening guides the participants into a very deep hypnotic state (state 2). Participants also remain in this state for 10 minutes, during which their brain activity is measured using fMRI
75907018|NCT03568227|Procedure|Control|The control intervention consists of texts corresponding to the induction and deepening of the hypnosis intervention. They are matched in duration and consist of textually matched excerpts from www.wikipedia.org. Control induction will be presented, resulting in the control state 1 (10 min). Then the control deepening will be performed, leading to the control state 2 (10 minutes). During both control states the brain activity will be recorded using fMRI.
75907019|NCT03700957|Dietary Supplement|Docosahexaenoic Acid|100 milligrams of Docosahexaenoic Acid
75907020|NCT03700957|Other|placebo|placebo
75907021|NCT03565419|Device|Smart glasses|Participants confirm the real-time ultrasound image displayed on the viewer of smart glasses.
75907022|NCT03568149|Procedure|assessment of pain symptoms at first medical examination|First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
76070562|NCT06054945|Other|IPACK (Interspace between the popliteal artery and capsule of the posterior knee )|Ultrasound guided IPACK (Interspace between the popliteal artery and capsule of the posterior knee ) Block for Knee Arthroplasty Patients
76070563|NCT06054945|Device|Patient controlled anagesia device|Those who were administered opioids with PCA as rescue analgesic in the postoperative analgesia plan on the selected dates will be included in the study.
76070564|NCT06054724|Other|Yoga-Based Respiration Training|The selected asanas, believed to be beneficial for urinary incontinence, will be practiced with a focus on breath. After the assessment session, participants will engage in three days of face-to-face yoga sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
76070565|NCT06054724|Other|Pilates-Based Respiration Training|Before starting the 6-week practice protocol, participants will be taught the transversus abdominis muscle activation and centering, pilates-specific lateral costal breathing and other key elements of pilates. Pilates exercises chosen as beneficial for urinary incontinence will be performed with a focus on breath. After the assessment session, participants will engage in three days of face-to-face pilates sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
76070566|NCT06054399|Other|educational program|Education resources in Spanish through social media directed to the targeted audience mentioned above. There will be at least three interventions along the study, one for each pregnancy trimester, including topics such as: Migraine criteria, management strategies, risks of medication overuse, alarm symptoms, etc. These educational interventions will be conducted by trained health care professionals, mainly using audio-visual media.
76070567|NCT06054165|Other|Clinical pathway|Evidence-based and expert-opinion-based clinical pathway regarding the diagnostic and treatment strategy
76070568|NCT06053723|Other|Fonseca's Anamnestic Questionnaire|The questionnaire includes 10 questions about joint, head and neck pain, pain during masticatory activity, parafunctional habits, decreased joint motion, impaired occlusion and emotional stress.
75315780|NCT01543698|Drug|LGX818|
75315781|NCT01543698|Drug|MEK162|
75315782|NCT01543698|Drug|LEE011|
75315783|NCT01366417|Drug|ChloraPrep One-Step|1.5 ml applicator patient preoperative skin preparation
75315784|NCT01366417|Drug|70% isopropyl alcohol|Curity Alcohol Prep Pads
75315785|NCT01315106|Device|Magnetic Resonance Image Scanner|Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
75315786|NCT01228240|Drug|Metformin|
75315787|NCT01092416|Device|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
75460718|NCT01843439|Behavioral|Inhaler technique training|
75613815|NCT01684150|Drug|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
75613816|NCT01525966|Drug|carboplatin|Given IV
75613817|NCT01525966|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
75613818|NCT01525966|Other|laboratory biomarker analysis|Correlative studies
75613819|NCT01273610|Drug|Lapatinib|250 mg tablets
75613820|NCT01273610|Drug|Trastuzumab|Intravenous injection
75613821|NCT01273610|Other|laboratory biomarker analysis|
75613822|NCT01273610|Other|pharmacological study|
75613823|NCT01165762|Drug|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting."
75460719|NCT01843452|Radiation|RADIOTHERAPY|"External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.~Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).~Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV."
75613824|NCT00999804|Drug|Lapatinib|1000 mg of Lapatinib by mouth daily
75764498|NCT05602571|Other|ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught a home exercise program including stretching and eccentric strengthening exercises by an experienced physiotherapist. The eccentric exercises consisted of the following: three sets of 10 repetitions for wrist and elbow ﬂexion; two sets of 10 repetitions for wrist extension strengthening, starting with 50% of maximum strength and density and increasing the resistance each week; and ﬁnally, two sets of 10 repetitions for the wrist ﬂexor and extensor muscle groups comprising 20s of stretching and 10s of relaxing using the unaﬀected hand. Exercise program will be done twice a day for 3 months."
75764499|NCT05602571|Procedure|PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged. Approximately 3 cc of the PRP obtained will be applied to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
75764500|NCT05602571|Procedure|Sham PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~In Sham-PRP group,10 ml of venous blood will be taken and after the same waiting time 3 cc of 0.9% saline will be injected to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
75764501|NCT05589792|Drug|Placebo oral capsule|Placebo before sleep for 3 nights before the study (inclusive)
75764502|NCT05589792|Drug|Acetazolamide|Acetazolamide 250 mg 3 nights before the study at bedtime, Acetazolamide 500 mg for 2 nights before the study (inclusive) at bedtime.
75764503|NCT05587712|Drug|Sotatercept|SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
76070569|NCT06053723|Other|Numeric Pain Scale|It is a simple, reliable and short-term method that is frequently used to measure pain intensity in the clinic.
76070570|NCT06053723|Other|Jaw Functionality Limitation Scale-20|"It includes a total of 20 items, with 0 indicating no limitation and 10 indicating severe limitation in each item, about the function of the TMJ during different activities, difficulty in chewing and jaw limitation."
76070571|NCT06053502|Other|filtering facepiece respirator|Graded exercise test with filtering facepiece respirator
76070572|NCT06053385|Other|Melatonin sleep lotion|7 g of lotion applied to hands and arms one hour before bedtime
76070573|NCT06053385|Other|Placebo control lotion|7 g of lotion applied to hands and arms one hour before bedtime
75315788|NCT00701220|Drug|Atorvastatin Calcium|Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
76072505|NCT02707497|Drug|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
75315789|NCT00677924|Drug|Zalutumumab|Solution for infusion
75315790|NCT00251303|Drug|Riluzole|Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
75315791|NCT00251303|Drug|Placebo|Capsules matched active drug in appearance.
75460720|NCT01843452|Biological|PANITUMUMAB|6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
75460721|NCT01843452|Drug|MITOMYCIN|10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
75315792|NCT00303823|Drug|placebo|Given orally
75315793|NCT00303823|Dietary Supplement|defined green tea catechin extract|Given orally
75315794|NCT00303823|Other|laboratory biomarker analysis|Correlative studies
75315795|NCT00300677|Drug|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
75460722|NCT01843452|Drug|CAPECITABINE|825mg/m2 orally twice daily on study days 1 through 45.
75613825|NCT00999804|Drug|Letrozole|Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
75613826|NCT00999804|Drug|Trastuzumab|6 mg/kg intravenously, every 3 weeks
75613827|NCT00797888|Behavioral|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
75613828|NCT00544830|Drug|Bicalutamide|Given PO
75613829|NCT00544830|Drug|Goserelin Acetate|Given SC
75613830|NCT00544830|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75613831|NCT00544830|Other|Laboratory Biomarker Analysis|Correlative studies
75613832|NCT00544830|Drug|Leuprolide Acetate|Given via injection
75613833|NCT00349869|Behavioral|yoga|8-week yoga program.
75613834|NCT00309933|Procedure|cognitive assessment|
75613835|NCT00309933|Procedure|psychosocial assessment and care|
75764504|NCT05587647|Other|Transition to Adulthood Education Program|"YEGEP was developed by the authors based on the information in the literature, based on the needs of mothers of children who have reached adulthood or are going through. Three training modules are planned in line with current requirements. Education will also be supported by audio-visual and written materials. It is planned that the trainings, which will last for 3 weeks in total, for 1 hour a week for each group, in the form of 3 sessions of 1 hour with these contents, will be held at a disabled center. Titles of training modules:~Developmental Period Characteristics of Young Adults with Intellectual Disabilities (Transition to Adulthood, Future Planning / Social Life (employment, peers, etc.)~Protecting and Sustaining the Health of Young Adult with Intellectual Disabilities~Coping with Stress"
75764505|NCT05586594|Diagnostic Test|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B)|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B) to look for common non-syndromic MODY in Emirati population
75764506|NCT05584358|Dietary Supplement|Dry protein blend ingestion|Ingestion of protein blend powders mixed in water
75764507|NCT05584358|Dietary Supplement|Extruded protein blend ingestion|Ingestion of protein blend powders mixed in water
75315796|NCT05747547|Diagnostic Test|Central visual acuity|Measurement of central visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) optotypes or Snellen optotype chart.
75764508|NCT05581199|Drug|Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
75764509|NCT05581199|Drug|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
75764510|NCT05581199|Drug|Placebo|Matching placebo SC
75315797|NCT05747547|Diagnostic Test|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
75315798|NCT05747547|Diagnostic Test|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
75764511|NCT05578677|Other|Biopsy technique|"Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively."
76072506|NCT02707497|Drug|Placebo|The control group will not use any platelet-increased drugs.
76072507|NCT02702895|Behavioral|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
75315799|NCT05747547|Diagnostic Test|Retinal oximetry|Performing of retinal oximetry with an Oxymap T1 instrument (Oxymap ehf.) paired with a Topcon TRC-50DX retinal camera.
75315800|NCT05747547|Diagnostic Test|Optical coherence tomography and angiography|Performing of optical coherence tomography and angiography with the Spectralis Optical Coherence Tomography Plus (Heidelberg Engineering).
75315801|NCT00303901|Procedure|cryosurgery|
75315802|NCT00303901|Procedure|positron emission tomography|
75315803|NCT00252629|Other|Nasal CPAP treatment during sleep|After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
75315804|NCT00559845|Drug|5-fluorouracil|600 milligrams per meter squared (mg/m^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
75315805|NCT00559845|Drug|Epidoxorubicin|90 mg/m^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
75315806|NCT00559845|Drug|Cyclophosphamide|600 mg/m^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
75315807|NCT00559845|Drug|Paclitaxel|Paclitaxel was administered at 80 mg/m^2 i.v. over 1 hour weekly for 12 weeks.
75315808|NCT00559845|Biological|Bevacizumab|Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
75315809|NCT00304187|Drug|Erythromycin|Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
75315810|NCT00304187|Drug|Placebo|Placebo, 250 mg or 500 mg, three times a day for 6 weeks
75460723|NCT01843478|Other|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
75460724|NCT01843478|Other|Usual Care|
75460725|NCT01843491|Biological|Ad-PfCA|Vaccine
76072508|NCT04144257|Drug|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo [F-18]PBR06-PET (microglial activation).
75315811|NCT01867515|Other|Acoustic distortion of speech|
75315812|NCT00324701|Behavioral|Telepsychology|therapy done at patients house
75315813|NCT00324701|Behavioral|Face-to-face therapy|therapy delivered at the VAMC
75460726|NCT01843543|Other|Mindfulness Based Stress Reduction Course|The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
75460727|NCT01843569|Biological|In Vitro maturation|
75613836|NCT00309933|Procedure|quality-of-life assessment|
75613837|NCT00303914|Procedure|assessment of therapy complications|
75613838|NCT00303914|Procedure|cognitive assessment|
75613839|NCT00303914|Procedure|psychosocial assessment and care|
75613840|NCT00130221|Drug|2% chlorhexidine gluconate impregnated cloth|
75613841|NCT00130221|Other|Daily bathing with Bar soap|bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
75613842|NCT00077129|Drug|carboplatin|
75613843|NCT00077129|Drug|paclitaxel|
75613844|NCT00052884|Biological|filgrastim|
75613845|NCT00052884|Drug|amifostine trihydrate|
75613846|NCT00052884|Drug|melphalan|
75613847|NCT00052884|Procedure|bone marrow ablation with stem cell support|
75613848|NCT00052884|Procedure|peripheral blood stem cell transplantation|
75764512|NCT05577676|Drug|Ultrasound-guided Hydrodissection of the Median Nerve|Hydrodissection for CTS includes injecting fluid around the median nerve (MN) with 5 ml volume, 3 ml of which is given in between the transverse carpal ligament & MN, and 2 ml below the MN under Ultrasound guidance in-plane ulnar approach.
75764513|NCT05572398|Behavioral|STAC-T|Middle school participants will complete online modules to learn about anti-bullying techniques and bystander intervention.
75764514|NCT05564104|Drug|Cagrilintide|Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection.
75907023|NCT03568149|Procedure|assessment of pelvic vascular insufficiency signs|"Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~Ovarian vein diameter <4mm~Slow ovarian blood flow (<3cm/sec)~Retrograde blood flow~Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~Standard 2D study, to measure vessels diameter~Vascular doppler study, to evaluate flow direction and blood speed~3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree."
75315814|NCT02482389|Radiation|Single fraction of 7 Gy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
75613849|NCT00040807|Drug|docetaxel|
75764515|NCT05555589|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
75315815|NCT00324857|Behavioral|Decision Aid Video|"The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
75460728|NCT01843595|Behavioral|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
75315816|NCT00324857|Behavioral|Motivational Interviewing|The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
75315817|NCT00324857|Behavioral|MI plus Decision aid|Patient viewed the video and then underwent MI.
75764516|NCT05555589|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
76072509|NCT04144257|Drug|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo [C-11]MRB-PET (norepinephrine transporter binding).
75315818|NCT00324857|Other|Attention control|patients received a booklet.
75315819|NCT00334633|Drug|tinidazole, metronidazole|Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
75315820|NCT01790477|Procedure|Auricular Acupuncture|Application of auricular acupuncture to 5 points on the ear
75315821|NCT01393964|Drug|Lenalidomide|Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug
75315822|NCT01393964|Drug|Dexamethasone|Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
75315823|NCT01393964|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on days 8, 15 & 22 (cycle 1); days 8 &22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
75613850|NCT00040807|Drug|irinotecan hydrochloride|
75764517|NCT05549063|Other|Mobility and Stability Exercise|Mobility and stability exercises
75315824|NCT01393964|Drug|Dexamethasone|Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
75315825|NCT01393964|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
75613851|NCT00028678|Drug|dalteparin|
75613852|NCT00028678|Radiation|radiation therapy|
75613853|NCT00005095|Other|Ca-125|Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
75613854|NCT00005095|Other|screening questionnaire administration|Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
75764518|NCT05549063|Other|Stretching Exercise|Balance and reaching exercise
75764519|NCT05544110|Device|Active transcranial magnetic stimulation|The coil parallel to the scalp is placed on the target for real and effective stimulation.
75613855|NCT00005095|Procedure|Surgery|Subjects will be assessed for high risk factors.
75613856|NCT00004223|Drug|docetaxel|
75613857|NCT00004223|Drug|gemcitabine hydrochloride|
75613858|NCT00003764|Drug|cyclophosphamide|
75613859|NCT00003764|Drug|fludarabine phosphate|
75613860|NCT00003601|Drug|fenretinide|
75613861|NCT00003601|Drug|tretinoin|
75613862|NCT00003266|Drug|methylphenidate hydrochloride|
75613863|NCT00003266|Procedure|quality-of-life assessment|
75764520|NCT05544110|Device|Sham transcranial magnetic stimulation|The coil is placed perpendicular to the scalp above the target for ineffective stimulation.
75764521|NCT05538208|Drug|Mycophenolate Mofetil|MMF dosed 600mg/m2 body surface area per dose about every 12 hours
75907024|NCT03700879|Radiation|MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler|Patients presented with clinical picture and radiography suggestive of acute ischemic stroke will be subjected to a comprehensive evaluation with MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler
75764522|NCT05538208|Drug|Mycophenolate Mofetil|MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA >=60-70 mg*h/L
75907025|NCT03568071|Drug|MOR 106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
75315826|NCT04721171|Device|The Bridge device|he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
75613864|NCT00003236|Biological|ISIS 3521|
75907026|NCT03568071|Drug|Placebo|A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
75315827|NCT01869075|Other|Knowledge Translation (KT) toolkit|KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
75315828|NCT01790555|Drug|Namisol|
75315829|NCT01790555|Drug|Diazepam/placebo|
75315830|NCT05747313|Drug|Chidamide|"Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal."
75315831|NCT00304265|Biological|COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)|0.5 mL, Intramuscular
75315832|NCT00335725|Drug|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
75315833|NCT00335725|Drug|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
75613865|NCT00003236|Drug|ISIS 5132|
75907027|NCT02629822|Drug|Doravirine/lamivudine/tenofovir disoproxil fumarate|FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
75613866|NCT00003057|Drug|loperamide hydrochloride|
75613867|NCT00003057|Drug|octreotide acetate|
75613868|NCT00002922|Drug|paclitaxel|
75613869|NCT00002514|Biological|sargramostim|
75613870|NCT00002514|Drug|asparaginase|
75613871|NCT00002514|Drug|cyclophosphamide|
75764523|NCT05537766|Biological|Brexucabtagene Autoleucel|Administered intravenously
75764524|NCT05537766|Drug|Cyclophosphamide|Administered intravenously
75764525|NCT05537766|Drug|Fludarabine|Administered intravenously
75764526|NCT05531578|Device|INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)|Transfemoral implantation of the INOVARE® transcatheter valve
75764527|NCT05528796|Diagnostic Test|Whole genome sequencing|"The investigators will study the genes in a fetus' or child's DNA using a test called genome sequencing. Genes are the instructions passed from individuals to a child, and genes determine how bodies are built and grow. Some medical conditions are caused by differences in genes, and the genome sequencing test looks for changes in genes and other parts of a person's genetic sequence (the genome).~Genetic material will be extracted from bio-specimens. Genome sequencing for this study will be performed at the UCSF Genomic Medicine Laboratory at UCSF. When the genome sequencing results are available, the investigators will arrange an in person or telehealth meeting to explain the test results and what the results mean for the fetus, pregnancy, and family."
75315834|NCT01697371|Radiation|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
75315835|NCT01697371|Radiation|Proton Radiation|
75315836|NCT01791673|Device|Ultrasound glaucoma treatment|Ultrasound glaucoma treatment with EYEOP1 device
75315837|NCT01393730|Drug|Abiraterone acetate|
75315838|NCT01393730|Drug|Dutasteride|
75315839|NCT01393730|Drug|Prednisone|
75315840|NCT00336817|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days
75315841|NCT00336817|Drug|CellCept|CellCept 500mg or 1000mg BID for 90 days
75613872|NCT00002514|Drug|cytarabine|
75613873|NCT00002514|Drug|daunorubicin hydrochloride|
75613874|NCT00002514|Drug|dexamethasone|
75613875|NCT00002514|Drug|etoposide|
75613876|NCT00002514|Drug|imatinib mesylate|
75613877|NCT00002514|Drug|leucovorin calcium|
75613878|NCT00002514|Drug|mercaptopurine|
75613879|NCT00002514|Drug|methotrexate|
75613880|NCT00002514|Drug|prednisone|
75613881|NCT00002514|Drug|thioguanine|
75613882|NCT00002514|Drug|vincristine sulfate|
75613883|NCT00002514|Procedure|allogeneic bone marrow transplantation|
75613884|NCT00002514|Procedure|autologous bone marrow transplantation|
75764528|NCT05518214|Dietary Supplement|Beetroot|Participants receive a 12-week supply of beetroot juice.
75907028|NCT02247297|Procedure|Blood collection|Diagnostic blood collection
75907029|NCT04433104|Biological|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval
75907030|NCT04433104|Drug|drug therapy according to Vietnamese MOHS procedure|Salbutamol, Terbutaline
75907031|NCT03565341|Device|PiQo4|PiQo4 Laser System for treatment of Melasma
75907032|NCT03700801|Drug|Triple combination therapy group|Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
75907033|NCT03700801|Drug|Premixed insulin therapy group|Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
76070574|NCT06053294|Other|CS- Beverage|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose. Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include preand post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
75315842|NCT00337987|Drug|Ontak|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
75764529|NCT05518214|Dietary Supplement|Placebo|Participants receive a 12-week supply of placebo beetroot juice.
75764530|NCT05512741|Other|Feces collection|"Feces will be collected, at home, by the patient., by using a collection kit. The stools are collected in the 2 last days before surgery.~After surgery, the first stool is collected, during the hospitalization, by using the same kit. Stools are conserved in the same condition, before being frozen in our local biologic ressources center."
75764531|NCT05509062|Procedure|Pressure|Subjects are randomized to one of three treatment groups
75764532|NCT05508906|Drug|OP-1250|OP-1250 is a small molecule and a CERAN being developed for the treatment of patients with advanced or metastatic HR+ and HER2- breast cancer.
75907034|NCT03696667|Device|BCI|As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
75907035|NCT03700723|Biological|Resusix|spray-dried solvent/detergent treated plasma (blood product)
75764533|NCT05508906|Drug|Ribociclib|All subjects in Treatment Group 1 will receive OP-1250 in combination with ribociclib.
75907036|NCT03700723|Biological|FP24 (Frozen Plasma)|plasma frozen within 24 hours of phlebotomy
75315843|NCT00337987|Drug|CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
76070575|NCT06053294|Other|CS+Fast|(CS+): Flavored beverage solution with 75 calories of sucrose. Participants will consume flavored beverage solutions containing 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement preand post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
75907037|NCT03696511|Device|Orthodontic miniscrew insertion|orthodontic treatment using miniscrews as anchorage reinforcement
76072510|NCT04147845|Other|Fractional Carbon Dioxide Laser|"The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly"
75764534|NCT05508906|Drug|Alpelisib|All subjects in Treatment Group 2 will receive OP-1250 in combination with alpelisib.
75764535|NCT05508867|Biological|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
75907038|NCT03700645|Drug|Allopurinol|Allopurinol
75907039|NCT03569319|Behavioral|"THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
75907040|NCT03569319|Behavioral|"THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
75315844|NCT01393106|Drug|Idelalisib|Idelalisib tablets administered orally
75613885|NCT00002514|Procedure|peripheral blood stem cell transplantation|
75613886|NCT00002514|Radiation|radiation therapy|
75613887|NCT05448469|Procedure|ultrasound guided erector spinae plane block|patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
75613888|NCT05448469|Procedure|ultrasound guided paravertebral block|patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
75613889|NCT05448469|Drug|conventional analgesia|patients will receive combined general anesthesia and conventional analgesia
75613890|NCT00607282|Drug|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
75613891|NCT02674789|Behavioral|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
75613892|NCT00609310|Dietary Supplement|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
75613893|NCT02674867|Other|Blood draw|
75907041|NCT03569319|Behavioral|Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention)."
75907042|NCT05181982|Other|FIT contract with global treatment budget|Several SHI funds have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT hospital, Pfalzklinikum). This contract encourages the model hospital an alternative treatment of their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment. The contract is based on a global treatment budget (pre-defined fix budget for a specified number of patients independent from the setting of treatment in the hospital).
75907043|NCT03567915|Other|Evaluation of gastric volume and content|The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.
75315845|NCT05267353|Behavioral|Exercise intervention program|"It was developed, along with usual care, to prevent restricted ROM in both upper body and limited general physical functioning. Patients in exercise intervention group received verbal instructions about stretching major muscles and phsical activity recommendations from a trained nurse (intervenor), and then received the booklet plus DVD.~The physical therapist who developed and adjusted this program also trained the intervenor. After verifying the intervenor has performed exercise interventions were consistent with the physical therapist, he/she was responsible for all interventions. Therefore, if pain or discomfort persists for more than an hour, the patient should inform the intervenor. The intervention group patients also received telephone follow-up from the intervenor every two weeks until the end of the intervention."
75764536|NCT05508867|Drug|bendamustine|IV infusion
75764537|NCT05508867|Drug|gemcitabine|IV infusion
76070576|NCT06053294|Other|CS+Slow|(CS+): Flavored beverage solution with 75 calories of maltodextrin and fiber. Participants will consume flavored beverage solutions containing 75 calories of maltodexrin in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry easurement preand post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
75764538|NCT05505734|Drug|BDA MDI|Participants will receive Budesonide and Albuterol Sulfate MDI 80/90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
75764539|NCT05505734|Drug|AS MDI|Participants will receive Albuterol Sulfate MDI 90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
75764540|NCT05498727|Diagnostic Test|Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics|This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.
75764541|NCT05487625|Behavioral|High-ventilated cigarette alone|High-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
75764542|NCT05487625|Behavioral|Low-ventilated cigarette alone|Low-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
75764543|NCT05487625|Behavioral|High- and low-ventilated cigarette with high-ventilated cigarettes increasing in price|High- and low ventilated cigarettes are available in the Experimental Tobacco Marketplace with high-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
75764544|NCT05487625|Behavioral|Low- and high-ventilated cigarette with high-ventilated cigarettes increasing in price|Low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with low-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
75764545|NCT05487625|Behavioral|Usual, high- and low-ventilated cigarette with usual cigarettes increasing in price.|Usual cigarette, low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with usual cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
75764546|NCT05481021|Other|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
75764547|NCT05477160|Drug|STAR-0215 (SC)|STAR-0215 will be administered as an SC bolus injection.
75764548|NCT05477160|Drug|Placebo (SC)|Placebo will be administered as an SC bolus injection.
75764549|NCT05477160|Drug|STAR-0215 (IV)|STAR-0215 will be administered as an IV bolus injection.
75764550|NCT05477160|Drug|Placebo (IV)|Placebo will be administered as an IV bolus injection.
75764551|NCT05473689|Device|Continuous positive airway pressure (CPAP) therapy|Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
75764552|NCT05468489|Drug|Serplulimab + chemotherapy (carboplatin-etoposide)|"Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~Drug: carboplatin and etoposide chemotherapeutics"
75315846|NCT00553059|Drug|dexamethasone|10 mg IV 30 minutes prior to administration of chemotherapy
75315847|NCT00553059|Drug|dronabinol|5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
75315848|NCT00553059|Drug|palonosetron hydrochloride|0.25 mg IV 30 minutes prior to administration of chemotherapy
75315849|NCT00553059|Other|placebo|1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
75613894|NCT04265248|Device|Virtual Reality Headset|The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
75613895|NCT04265248|Behavioral|Exercise|The subjects will perform evidence-based exercises for the neck.
75613896|NCT00643591|Other|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
75613897|NCT05437705|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
75613898|NCT00927472|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
75613899|NCT00927472|Drug|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
75613900|NCT00642655|Drug|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
75613901|NCT00643747|Biological|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
75315850|NCT04389385|Biological|COVID-19 Specific T Cell derived exosomes (CSTC-Exo)|The virus-specific T-cells (VSTs) are body's natural immune defense against various disease-causing viruses. Donor originated COVID-19 specific T-cells (CSTC) are in vitro activated and expanded by exposing to viral peptide fragments in the presence of natural immune stimulant proteins called cytokines. These Covid-19 specific fragment peptides activate specific T-cells and stimulate the secretion of potent mediators including IFN gamma in forms of exosomes. We propose treatment of Covid-19 patients -who are at early stages of pulmonary disease- with CSTC-exomes to control disease progression.
75764553|NCT05468489|Drug|Atezolizumab + chemotherapy (carboplatin-etoposide)|"Drug: Atezolizumab is a monoclonal antibody targeting PD-L1，developed by Roche Pharma AG.~Drug: carboplatin and etoposide chemotherapeutics"
75764554|NCT05445128|Biological|MGTA-145|MGTA-145 will be administered as an IV infusion
75764555|NCT05445128|Drug|Plerixafor|240 µg/kg administered subcutaneously
75764556|NCT05438212|Procedure|Brain Surgery|Undergo surgery per standard of care
75613902|NCT00642733|Drug|erlotinib [Tarceva]|100mg po daily
75764557|NCT05438212|Other|Quality-of-Life Assessment|Ancillary studies
75764558|NCT05438212|Other|Questionnaire Administration|Ancillary studies
75764559|NCT05438212|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
75764560|NCT05437757|Device|Surgical implantation of the PCL Breast scaffold with autologous fat grafting|Single shot of prophylactic perioperative antibiotics is given to the patient. A suitable incision is made to provide access followed by mobilisation of the breast gland.If present, the silicone implant is removed and capsulectomy performed. The implant pocket shall be rinsed with saline or antiseptic and a surgical drain shall be placed in the pocket at the discretion of the PI. The PCL Breast scaffold shall be inserted into the pocket and fixed using 2 to 4 sutures. The incision is closed. Liposuction is performed from another area of the body and lipofilling is performed within the breast scaffold. Sterile bandaging is applied and a daily wound revision is performed whilst an inpatient. A prophylactic antibiotic shall be administered to the patient.The patients shall be hospitalized overnight for clinical observation.
75764561|NCT05437211|Device|Virtual-reality (VR) Based Solution|VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII or Factor IX infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).
75315851|NCT02989311|Dietary Supplement|Fortified maize porridge (MNP and Iron)|Maize porridge fortified with MNP and labelled iron compound
75764562|NCT05427019|Procedure|Distal adductor canal block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.
75764563|NCT05427019|Procedure|Distal adductor canal block and Periarticular block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
75907044|NCT03624673|Procedure|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
75613903|NCT00642733|Drug|gemcitabine|1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
75613904|NCT02672371|Device|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
75613905|NCT02672371|Device|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
75613906|NCT00927394|Drug|Aliskiren|Aliskiren 150 mg tablet
75613907|NCT00927394|Drug|Valsartan|Valsartan 160 mg capsules
75613908|NCT00927394|Drug|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
75613909|NCT00927394|Drug|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
75613910|NCT04179253|Diagnostic Test|office micro hysteroscopy|One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
75764564|NCT05424042|Behavioral|In-Person Caloric Restriction|20% CR delivered in-person by dietitian/coach
75764565|NCT05424042|Behavioral|Remote Caloric Restriction|20% reduction in caloric intake, meeting schedule, and physical activity goal delivered remotely.
75764566|NCT05424042|Behavioral|Time-restricted|8-hour TRE with ad libitum caloric intake. This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake.
75907045|NCT03624673|Procedure|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
75613911|NCT05014126|Behavioral|Pain, Stress and Emotions|2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.
75613912|NCT00643825|Drug|Temozolomide|Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
75613913|NCT00643825|Drug|Temozolomide|Observation till Progression then rechallenging with TMZ
75764567|NCT05416554|Behavioral|Neuropsychological testing|Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing
75764568|NCT05415371|Behavioral|Standard Care + Financial Incentives|Financial incentive participants will receive standard care and receive incentives for completing counseling calls and for abstinence.
75764569|NCT05415371|Other|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
75764570|NCT05415293|Dietary Supplement|Expecta 200mg DHA|
75613914|NCT04178863|Device|CATS Tonometer|latanoprost vs. timolol
75907046|NCT03064360|Other|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
75764571|NCT05415293|Dietary Supplement|Promise 275mg DHA|
75764572|NCT05411484|Drug|NanoDOX® Hydrogel|NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
75764573|NCT05411484|Device|CO2 Ablative Fractionla Laser|CO2 Ablative Fractional Laser will be applied to healthy skin areas
76070577|NCT06053242|Drug|CELZ-201-DDT|Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
76070578|NCT06053242|Other|Placebo|Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
75764579|NCT05405413|Other|Treatment recommendations made by Molecular Tumor Board.|"Molecular Tumor Board recommendations may include any of the following:~(A) a tumor-targeted drug (alone or in combination)~(B) an antibody-based immunotherapy (alone or in combination)~(C) neither (A) nor (B).~(D) referral to the Familial Cancer Program~(E) referral for germline genetic testing"
75315852|NCT02989311|Dietary Supplement|Fortified Maize porridge (MNP + Iron + GOS)|Maize porridge fortified with MNP + GOS and labelled iron compound
75764580|NCT05382130|Diagnostic Test|Test all|"In the test all arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results."
75764581|NCT05378113|Drug|Ondansetron|Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.
75764582|NCT05378113|Drug|Lidocaine|Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.
75907047|NCT03064360|Device|Patient Activity|Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
75613915|NCT04178863|Drug|Latanoprost|latanoprost IOP reduction
75613916|NCT05329636|Other|FMT|FMT through capsules- patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen capsules on two consecutive days.
75613917|NCT05329636|Other|Placebo capsules|Patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen placebo-capsules on two consecutive days.
75613918|NCT05329636|Other|FMT- enema|3.FMT through enema- patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema. Enemas will be administered with the assistance of the study nurse. Patients will be asked to hold the enema content for at least 15 minutes.
75613919|NCT04264858|Drug|Immunoglobulin of cured patients|0.2g/kg, ivdrip, once a day, for 3 days
75613920|NCT04264858|Drug|γ-Globulin|0.2g/kg, ivdrip, once a day, for 3 days
75764583|NCT05376358|Device|MoodRing App|"Adolescents and parents in the MR arm will receive instructions to download the MR app and AWARE app, customize the app, utilize an app-based self-guided onboarding, and review questions with the research team. The MR app provides the adolescent and their parent a notification to view a weekly report predicting their mood score (i.e. depression severity level similar to the Patient health questionnaire-9). The MR app will provide a library of coping strategies for adolescents and opportunities to self-track their mood.~Clinicians in the MR Arm will get access to a MR portal online. They will be able to view patients they are a provider for. The clinician will receive in-person and/or video-based training to use the portal."
75764584|NCT05376358|Other|Usual Care|Adolescents and parents in the usual care arm will receive instructions to download the AWARE app. This app will only track data and will not be interactive. Otherwise they will receive care as per routine by their healthcare provider team.
75764585|NCT05370144|Radiation|Hypofractionated radiotherapy|Hypofractionated radiation 23 Gy in 5 fractions with a simultaneous integrated boost of 26 Gy in 5 fractions to the gross tumor volume (GTV) given concurrently over 1 week during week 3 of chemotherapy.
75764586|NCT05356988|Behavioral|Physical activity experiment|The Physical Activity (PA) group will have access for one year to the PA website to help increase aerobic and strength training activities.
75764587|NCT05356988|Behavioral|Balance and flexibility control|The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure around stretching and balance exercises.
75764588|NCT05353439|Procedure|Biopsy|Undergo biopsy
75764589|NCT05353439|Procedure|Biospecimen Collection|Undergo collection of blood
75764590|NCT05353439|Procedure|Computed Tomography|Undergo CT scan
75764591|NCT05353439|Biological|Pembrolizumab|Given IV
75764592|NCT05353439|Drug|Tazemetostat Hydrobromide|Given PO
75764593|NCT05353439|Drug|Topotecan Hydrochloride|Given IV
75764594|NCT05353335|Other|Re-timing of anti-hypertensive drug|The intervention will consist of shifting the anti-hypertensive medication from morning/early dose to an evening/later dose
75764595|NCT05353335|Other|Current regimen|The participants will begin on their current regimen.
75764596|NCT05352815|Drug|IcoSema|Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
75764597|NCT05352815|Drug|Insulin icodec|Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
75764598|NCT05350202|Drug|Empagliflozin|Empagliflozin
75907048|NCT03064360|Behavioral|Questionnaires|Symptom and quality of life questionnaire at baseline, and every week following to study completion
76070579|NCT06052956|Drug|Methylene Blue|Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
76070580|NCT06052956|Drug|Lipid Emulsion|The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
75613921|NCT04178473|Procedure|total abdominal hysterectomy|total abdominal hysterectomy at time of sacrocolpopexy
76070581|NCT06052956|Device|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
76070582|NCT06052956|Device|Laser Illumination (pre-defined dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.
76070583|NCT06052956|Device|Optical Spectroscopy Measurement|The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
75315853|NCT00869713|Biological|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 & 14, & once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer <1:40. Initial non-responders: Individual who has a PRNT80 titer <1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 <1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of <1:40.
75613922|NCT04178473|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy at time of sacrocolpopexy
75613923|NCT00976911|Drug|Bevacizumab|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
75613924|NCT00976911|Drug|liposomal doxorubicin|40mg/m2 iv every 4 weeks
75613925|NCT00976911|Drug|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
75907049|NCT03565185|Other|robot-assisted gait training|Investigators will use robot-assisted gait training for rehabilitation of stroke
75460729|NCT01843608|Other|Physical Intervention|The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
75907050|NCT03565185|Other|placebo|Investigators will use only conventional treatment without robot-assisted gait training
75764602|NCT05346393|Procedure|TIPS|A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver
75613926|NCT00976911|Drug|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
75613927|NCT04177927|Device|Capnostream 20p / Coviden|The special nasal canule is used for detection carbondioxide from breathe of patients
75613928|NCT04177927|Device|Rutine monitoring|peripheric Oxygen saturation is monitored.
75613929|NCT05336968|Drug|Triamcinolone acetonide-Ketorolac-Ropivacaine|Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
75613930|NCT04178161|Device|Laser treatment|Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
75613931|NCT02674555|Drug|radio-labeled naquotinib|Oral administration
75613932|NCT02674555|Drug|naquotinib|Oral administration
75613933|NCT00934648|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
75764603|NCT05346393|Drug|Standard of Care|Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
75764604|NCT05342701|Behavioral|Motor Skills Intervention|"The behavioral motor skill intervention (CHAMP) is an intervention strategy that uniquely address differences in children's development. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to development improvement in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP consists of 35 minutes/day X 3-4 days/week for 19 weeks (dose of 1995 - 2240 minutes). Each session will consist of three parts: (a) 3-5 min of motor skill introductory activity, (b) 25 min of motor skill instruction and practice, and (c) 3-5 min motor skill closure activity."
75613934|NCT00934648|Drug|methotrexate|10-25mg weekly
75764605|NCT05338970|Drug|Patritumab Deruxtecan|Intravenous administration, 5.6 mg/kg every 3 weeks (q3W)
75315854|NCT04047134|Other|Action Observation Treatrment|Participants will be asked to carefully observe the videos showing different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes, totally lasting 12 min/video. At the end of each motor act presentation, participants will be asked to execute with the affected hand the observed motor sequence for 2 minutes (20 minutes/session). 10 daily actions will be recorded. Each video will be presented to participants twice a day, in order to complexity as judged by the experimenter. Only 1 typology of motor task per day for each condition, starting from the easiest and ending with the most complex action throughout 15 sessions spread on 5 weeks (3 sessions/week). Tasks will be based on some relevant activities of daily living belonging to at least one between feeding, self-care or external actions category on the affected side. Each session will last about 15 minutes and will be repeated twice a day, at least 60 minutes apart.
75764606|NCT05338970|Drug|Platinum-based chemotherapy|Intravenous, pemetrexed 500 mg/m^2 plus either cisplatin (75 mg/m^2) or carboplatin (target area under the plasma concentration time curve of 5 [AUC5] by using the Calvert formula) q3W
75907051|NCT03703531|Procedure|Cardiopulmonary resuscitation|CPR performed because of out-of-hospital cardiac arrest
75907052|NCT03564951|Procedure|Atrial fibrillation ablation|ablation of Atrial fibrillation using spatio-temporal dispersion
75907053|NCT03564951|Procedure|Atrial fibrillation ablation|ablation of concordance zones using isochrone and voltage maps
75907054|NCT04499053|Drug|Durvalumab|durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
75907055|NCT04499053|Drug|Tremelimumab|tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.
76070584|NCT06052956|Device|Laser Illumination (patient-specific dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.
75764607|NCT05333458|Biological|Atezolizumab|Given IV
75764608|NCT05333458|Procedure|Biopsy|Undergo biopsy
75764609|NCT05333458|Procedure|Biospecimen Collection|Undergo collection of blood samples
75907056|NCT03472300|Other|Survey about knee pain and treatment|All citizens are surveyed to describe the prevalence of knee pain in a danish community.
75907057|NCT05353413|Device|Neuroimaging|Magnetic resonance diffusion tensor imaging of the brain
75907058|NCT05353413|Diagnostic Test|VEP - visual evoked potential|Electrophysiology of the visual pathway.
75907059|NCT05353413|Diagnostic Test|Ophthalmology examination.|Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
75907060|NCT03567681|Drug|Extended release oxcarbazepine vs Immediate release oxcarbazepine|Extended release oxcarbazepine vs Immediate release oxcarbazepine
76070585|NCT06052956|Procedure|Standard of care abscess drainage|Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
76070586|NCT06052943|Behavioral|Mindfulness-Based Intervention|Learning 2 BREATHE (L2B) is an evidence based curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
75315855|NCT04047134|Other|Observation of videos with Non Motor contents|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
75613935|NCT00643903|Behavioral|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
75613936|NCT00643903|Behavioral|Standard care|Participants will receive standard of care for HIV infections.
75613937|NCT00643903|Behavioral|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
75613938|NCT04178083|Diagnostic Test|medical examination|medical examination
75764610|NCT05333458|Procedure|Computed Tomography|Undergo CT
75764611|NCT05333458|Procedure|Magnetic Resonance Imaging|Undergo MRI
76070587|NCT06052943|Behavioral|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition and 3) physical activity. The parents set weekly goals to implement the parent education lessons into everyday living.
75764612|NCT05333458|Drug|Selinexor|Given PO
76070588|NCT06052943|Behavioral|Physical Activity|Combines aerobic and resistance training though game play.
76070589|NCT06052943|Behavioral|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education based on the Learning to BREATHE curriculum.
76070590|NCT06052943|Behavioral|Preschool Curriculum|Preschool age children learn about and try new foods.
75764613|NCT05330429|Drug|Magrolimab|Administered intravenously
75907061|NCT03462706|Procedure|Cold Snare|Subjects randomized to Cold Snare Intervention will have any polyps sized 6mm to 15mm removed using cold snare techniques (no electrocautery, no submucosal injection.)
75907062|NCT03462706|Procedure|Hot Snare|Subjects randomized to Hot Snare Intervention will have any polyps sized 6mm to 15mm removed using hot snare techniques (with electrocautery, no submucosal injection.)
75907063|NCT03462706|Procedure|Cold EMR|Subjects randomized to Cold EMR will have any polyps sized 6mm to 15mm removed using cold EMR techniques (no electrocautery, with submucosal injection.)
76070591|NCT06052943|Behavioral|Cooking Matters|Nutrition education and hands-on cooking lessons for the whole family
75764614|NCT05330429|Drug|Bevacizumab|Administered intravenously
75764615|NCT05330429|Drug|Irinotecan|Administered intravenously
75764616|NCT05330429|Drug|Fluorouracil|Administered intravenously
75764617|NCT05330429|Drug|Leucovorin|Administered intravenously
75764618|NCT05330234|Device|OnTrack Tools|"The intervention is the OnTrack Tools system consisting of a graphical user interface (GUI) used to manage patients who are users of the OnTrack rehabilitation system. Participants will be asked to complete clinical and non-clinical tasks in simulation using OnTrack Tools. The themes for the scenarios of use presented in each of the three phases are summarised below:~Phase 1 - Account creation, system onboarding and general system navigation. Phase 2 - Individual patient management. Phase 3 - Content and data management."
75764619|NCT05325294|Device|MiniMed 780G System|MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc
75764620|NCT05322850|Biological|Orca-Q|All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
75764621|NCT05321810|Drug|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
75764622|NCT05321810|Drug|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
75315856|NCT02015611|Dietary Supplement|Vitamin D|2,000 IU/ day of Vitamin D3
75764623|NCT05317364|Drug|Estradiol 0.01% Vag Cream|1g estradiol vaginal cream 0.01% or placebo will be administered nightly for 2 weeks then twice weekly to complete 6 months therapy
75764624|NCT05317364|Drug|Placebo vaginal cream|Placebo cream
75764625|NCT05317078|Drug|AMG 794|Short-term intravenous (IV) infusion.
75764626|NCT05315531|Dietary Supplement|Water Intake|Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.
75907064|NCT03462706|Procedure|Hot EMR|Subjects randomized to Hot EMR will have any polyps sized 6mm to 15mm removed using hot EMR techniques (with electrocautery, with submucosal injection.)
75764627|NCT05308407|Other|Focus Groups|No intervention involved in this phase of the study
75764628|NCT05308407|Other|Pilot randomized controlled trial|The intervention is a virtually delivered, 12 weekly group-based active video game-centered lifestyle physical activity intervention (POWER UP) targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors.
75907065|NCT02840253|Device|NIRS|
76070592|NCT06052787|Drug|Cerebrolysin|Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.
76070593|NCT06052787|Drug|amantadine sulfate|The dopaminergic agonist amantadine enhances presynaptic dopamine release and inhibits dopamine reuptake, resulting in an increased amount of dopamine in the synaptic cleft. Amantadine may also increase the density of postsynaptic dopamine receptors and alter the conformation of these receptors. Amantadine acts as an NMDA receptor antagonist, blocking glutamate, an NMDA channel activator. This effect may be responsible for amantadine's possible beneficial effect soon after TBI
76070594|NCT06052774|Procedure|Non-Surgical periodontal therapy|Supra and Subgingival debridement for all patients except periodontally healthy individuals
75764629|NCT05307328|Drug|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
75764630|NCT05307328|Drug|Placebo|Inactive tablets identical to SPI-62 tablets
75764631|NCT05304611|Biological|L9LS (VRC-MALMAB0114-00-AB)|Administered one time via subcutaneous route.
75764632|NCT05304611|Other|Normal saline|Administered one time via subcutaneous or intravenous administration.
75315857|NCT02015611|Dietary Supplement|Placebo|Placebo
75764633|NCT05283148|Other|Dual-energy X-ray absorptiometry|Measure bone mineral density at the lumbar spine, left total hip, left forearm, and whole body
75764634|NCT05283148|Other|Vertebral fracture analysis|Obtain thoracolumbar morphometry in DXA scan, then determine presence and severity of vertebral compression fractures by VFA
75764635|NCT05283148|Other|Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire|Calculate patient-reported total pain scores to determine the pain phenotype of each study participant
75764636|NCT05277051|Drug|GSK4381562|GSK4381562 will be administered.
75315858|NCT01872819|Other|antitumor drug screening assay|Undergo high throughput drug sensitivity assay
75315859|NCT01872819|Drug|chemotherapy|Patients receive 1 of 160 possible interventions
75764637|NCT05277051|Drug|Dostarlimab|Dostarlimab will be administered.
75764638|NCT05277051|Drug|GSK4428859A|GSK4428859A will be administered.
75764639|NCT05275101|Behavioral|Crisis Response Planning|Individuals complete an experimental collaborative suicide intervention.
75764640|NCT05275101|Behavioral|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
75764641|NCT05250687|Procedure|MR- High intensity focused ultrasound|The intervention treatment is MR-HIFU, which will be given as a standalone treatment. MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastasesThe ExAblate focused ultrasound device operates in conjunction with an MRI machine. Gadavist is being administered intraveneously as contrast medium for MRI.
75907066|NCT03567447|Drug|Droxidopa|starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
75907067|NCT03567447|Other|Placebo|appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
75907068|NCT03567369|Drug|Dexamethasone|Dexamethasone 4,0 mg/mL
75907069|NCT03567369|Drug|Traumeel S|Traummel S 2,2 mg/mL
75907070|NCT03397654|Drug|Pembrolizumab|Pembrolizumab solution
75764642|NCT05250687|Radiation|External beam radiotherapy|Standard of care for pain palliation of bone metastases consists of single fraction external beam radiotherapy of 8-16 Gray (Gy) or a multi-fraction regime of 20 Gy in 5 fractions, 24 Gy in 6 fractions or 30 Gy in 10 fractions. The radiation schedule is at the discretion of the treating radiation oncologist.
75764643|NCT05247450|Device|Functional electrical stimulation therapy (FES-t)|Functional electrical stimulation therapy (FES-t) that will use a multichannel device (MyndSearch device).
75907071|NCT03397654|Combination Product|Trans-arterial chemoembolization|Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour
75315860|NCT01872819|Biological|biological therapy|Patients receive 1 of 160 possible interventions
75613939|NCT01175213|Biological|SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37."
75460730|NCT01843647|Drug|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
75613940|NCT01175213|Biological|SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose."
75907072|NCT05354271|Other|High-intensity interval training|Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
75315861|NCT01413542|Drug|Sitagliptin (DPP4 inhibitor)|Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
75907073|NCT05354271|Other|Moderate-intensity continuous training|Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the Moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
75907074|NCT03390322|Device|DiaGone™|Duodenal Glycemic Control™ using the DiaGone™ system
75315862|NCT01413542|Drug|Substance P,|Substance P intra-brachial artery (2,4,8 pmol/min)
75907075|NCT05354427|Other|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with implantabale spacers.
75315863|NCT01413542|Drug|bradykinin|bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
75460731|NCT01843647|Drug|Chemotherapy|"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression."
75460732|NCT01843686|Device|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
76070595|NCT06052644|Other|Exercise Dose-Response|"The intervention will last for 12 weeks. Depending on the group, participants will engage in the intervention either four times a week or only two times, with the duration ranging from 30 to 60 minutes per session. Each session will consist of three phases: an initial warm-up phase, a central phase, and a cool-down phase.~The warm-up phase will focus on joint mobility, beginning with flexion-extension, rotation, and lateral neck flexion while maintaining eye contact with a fixed point. This will be followed by trunk mobility exercises, including rotations.~The central phase will consist of aerobic and strength training performed at an intensity of 80-85% of the maximum heart rate. Each exercise will be performed intensely for 20 to 30 seconds, followed by a rest period of 10 to 15 seconds before repeating the exercise."
76070596|NCT06052579|Procedure|new hand-held retractor systems-assisted WiltseTLIF surgery|patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery
76070597|NCT06052540|Dietary Supplement|Probiotic supplement|"Stick: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Maltodestrins~Drops: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Medium chain triglycerides, vegetable fats, emulsifier, and maltodextrin."
75460733|NCT01843686|Other|Placebo Saline Gel and Usual and Customary Standard of Care|
75613941|NCT01175213|Biological|IV treatment with IGSC, 10%|During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
75764644|NCT05247450|Other|Conventional physiotherapy|Conventional physiotherapy is the current standard of care for rehabilitation of C5 palsy
76070598|NCT06052540|Dietary Supplement|Placebo|"Drops: Medium Chain Triglycerides, vegetal oil, E471, and maltodextrin~Stick: Maltodextrin."
76070599|NCT06052488|Behavioral|Strength After Breast Cancer|Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist
75315864|NCT01413542|Drug|enalaprilat (ACE inhibitor)|intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
75315865|NCT01413542|Drug|Glucagon-like peptide 1|intra-brachial artery (0.45-3.60 pmol/min)
75764645|NCT05233397|Drug|Tocilizumab|For < 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
75315866|NCT01413542|Drug|brain natriuretic peptide|Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
75315867|NCT05267795|Behavioral|Experimentally-induced pain|Specific pain levels were applied on the participants' fingernails in each of 40 experimental trials using pressure algometry.
75460734|NCT01843699|Drug|Topiramate flexible dosage|
75460735|NCT01843699|Drug|Placebo matching tablets|
75613942|NCT02865837|Other|brachytherapy|"The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.~Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.~Right after, a scanner is performed with urinary catheter declamping and emptied bladder.~Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.~Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared."
76070600|NCT06052475|Device|Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)|The approach for physiological pacing upgrade will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
75764646|NCT05222126|Procedure|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc of 5% dextrose.
75764647|NCT05222126|Procedure|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc normal saline.
75907076|NCT03266146|Drug|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.
76070601|NCT06052475|Device|Continued RV Pacing (Right Ventricular Pacing)|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
75613943|NCT00643981|Biological|MESENDO|"2 ml of the final cell mixture will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel."
75460736|NCT01843699|Behavioral|4-session gambling cognitive restructuring|
75613944|NCT04287699|Other|labor dance|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
75764648|NCT05222126|Procedure|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc 5% dextrose.
75764649|NCT05222126|Procedure|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc normal saline.
76070602|NCT06052020|Drug|Alirocumab|alirocumab (75 mg every 2 weeks)
76070603|NCT06052020|Drug|Atorvastatin|Atorvastatin 20-40mg
75613945|NCT00644449|Other|placebo|placebo
75613946|NCT00644449|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
75613947|NCT00644449|Other|placebo|placebo
76070604|NCT06051565|Drug|Polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
75907077|NCT03266146|Drug|48 weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
76070605|NCT06051487|Other|titanium dioxide nanoparticles in test group|Titanium dioxide nanoparticles added to acrylic baseplate in test group
76070606|NCT06051253|Drug|TDM-based infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously given as an induction therapy at a dose of 5 mg/kg at week 0, 2, and 6. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
76070607|NCT06051253|Drug|Standard infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
75460737|NCT01843725|Drug|capecitabine|escalation dose of capecitabine continuously
75460738|NCT01843725|Drug|aflibercept|Intravenous 6mg/kg every 3 weeks
75460739|NCT01843725|Drug|Capecitabine|dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
75460740|NCT01843738|Radiation|Radiation therapy|Per standard of care
75460741|NCT01843738|Drug|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
75460742|NCT01843764|Device|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
75613948|NCT00644449|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
75764650|NCT05219344|Procedure|Tissue flossing|After the standardized warm-up, participants will be instructed to stand still with their legs shoulder-width apart. The floss band (1.3 mm thick, 50 mm wide, 2 meters long, and strength level 3), consisting of a thick elastic latex band (COMPRE Floss, Sanctband), will be applied bilaterally around the distal third of the thigh. The applied pressure will be individualized by thigh circumferences, whereas low target pressure was chosen for this study, showing potential to elicit the most beneficial outcomes following flossing. The pressure will be monitored by the PicoPress device, which was placed at the middle distance of the application of the floss band to ensure that the entire surface of the pressure sensors was always completely covered. The flossing will be applied for 2 minutes with 2 minutes rest between sets. During flossing application subjects will be instructed to conduct 10 deep squats followed by 15 repetitions of knee extensions without added weight.
75460743|NCT01843790|Drug|GCS-100|The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
75764651|NCT05218798|Diagnostic Test|Cardio Respiratory Fitness testing|"In a randomized cross over designed study, we will measure Vo2max by using different tests:~Continous Treadmill Running Test~Continous 2-mile run test~30-15 Intermittent Fitness Test - first trial and second trial"
75460744|NCT01843790|Drug|Placebo, Saline|The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
75764652|NCT05217641|Biological|BG505 MD39.3 mRNA|Administered by IM injection
75764653|NCT05217641|Biological|BG505 MD39.3 gp151 mRNA|Administered by IM injection
75907078|NCT03703453|Device|ER-REBOA catheter|The ER-REBOA™ catheter is a device that has been gaining increased use in the setting of severe trauma for the purposes of stopping intra-abdominal hemorrhage. The catheter is advanced through a femoral artery sheath into the aorta, where a balloon at its tip is inflated, occluding all distal blood flow (and stopping any hemorrhage while the patient can be prepared for definitive operative intervention).
75907079|NCT03700489|Other|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
75907080|NCT03695965|Procedure|magnetic resonance imaging.|1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
75907081|NCT04529824|Device|Dexcom G6 Continuous Glucose Monitor (CGM) System|Participants wear a blinded Dexcom G6 CGM and a Fitbit Charge 3 activity tracker for 10 days.
75315868|NCT05267275|Procedure|extended resection with splenic flexure mobilization|During the operation, the splenic flexure of the colon was first freed, and then the physiological adhesion site of the sigmoid colon was located. Routine laparoscopic or open rectal cancer radical resection (D3 dissection + high ligation) was performed. The proximal end of the colon is disconnected 10-15cm away from the physiological adhesion site of the sigmoid colon. The anastomosis method was manual anastomosis or stapler anastomosis, and a prophylactic ileal loop ostomy was routinely performed.
75460745|NCT01843829|Drug|Oxaliplatin|
75460746|NCT01843829|Drug|Capecitabine|
75460747|NCT01843829|Drug|Carboplatin|
75460748|NCT01843829|Drug|Paclitaxel|
75907082|NCT02800941|Drug|Oral anticoagulant treatment|The treatment is delivered according to the usual practice.
75907083|NCT03695887|Drug|Nitrous Oxide Inhalant Product|Nitrous Oxide Inhalant Product
75907084|NCT03695887|Drug|Placebo|Inactive comparator
75907085|NCT04432714|Drug|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1~d10# 21days a cycle
75907086|NCT04432714|Drug|Rituximab|Rituximab 375 mg/m2，IV, d0
75907087|NCT04432714|Drug|Etoposide|Etoposide 50 mg/m2/day CI24h d1-d4
76070608|NCT06051058|Behavioral|Care Transitions App|Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.
76070609|NCT06051045|Drug|Bulevirtide|Hepcludex, 2 mg daily subcutaneous injection
75315869|NCT05267717|Other|Non-interventional study, all patients being tested with AG Pregnolia System to assess the values of the Cervical Stiffness|Non-interventional study,
75764654|NCT05217641|Biological|BG505 MD39.3 gp151 CD4KO mRNA|Administered by IM injection
75764655|NCT05214768|Drug|CC-93538|Specified dose on specified days
75764656|NCT05214768|Drug|Placebo|Specified dose on specified days
76070610|NCT06048991|Diagnostic Test|Thermographic assessment|Patients will undergo a termographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
75315870|NCT04389125|Dietary Supplement|Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures|One packet once a day, after breakfast, for 12 week
75315871|NCT04389125|Dietary Supplement|Placebo|Placebo for 12 week
75460749|NCT01843829|Radiation|Radiotherapy|
75460750|NCT01843829|Procedure|Surgery|Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
75460751|NCT01843855|Drug|Exendin 9,39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
75460752|NCT01843855|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
75460753|NCT01843868|Drug|Standard anti-emetics in conjunction with R-CHOP|
75460754|NCT01843881|Drug|Exendin 9, 39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
75460755|NCT01843881|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
75460756|NCT01843894|Biological|RU-101|Recombinant human serum albumin
75460757|NCT01843907|Behavioral|Empowerment|To give patients the necessary resources to take care of their own health
75460758|NCT01843907|Other|Conversation with nurse|To find out, if the nurse, using her ....
75315872|NCT05267119|Procedure|Swab|The scalp was swabbed with five strokes which were performed each in a vertical, horizontal, left diagonal, and right diagonal direction. The swab was moved back and forth for 10 times
75315873|NCT05267405|Other|no interventions, only observation|no interventions, only observation
75315874|NCT01873989|Drug|Testosterone replacement|
75315875|NCT01873989|Other|Waitlist control|
75315876|NCT01432730|Drug|Gefapixant|Oral tablets, BID
75315877|NCT01432730|Drug|Placebo|Oral tablets, BID
75315878|NCT05267327|Other|Verzenios|Study drug is Verzenios, it is an observational study.
75315879|NCT01897207|Biological|Dendritic cell application|S.C. injection of peptide pulsed autologous dendritic cells
75315880|NCT04441229|Behavioral|ABMT mobile application|"After consent/assent, participants will complete 1 hour-long, in-person or remote, baseline study visit at the Multiple Sclerosis Comprehensive Care Center. During this visit, participants will complete baseline study surveys and a brief computerized attention bias assessment and be trained on the use of the ABMT mobile application. Participants will then complete at-home game play 4 days a week, for 30 days, using an iOS mobile device, approximately 10-15 minutes each day. Subjects will complete weekly online study surveys via REDCap or MyCap (Mobile REDCap Application). At the conclusion of participation, participants will complete online end of study surveys via REDCap or MyCap.~Parents of participants will complete surveys at the baseline visit, followed by online surveys at Week 2 and at the end of study. For participants who are 18 years old or older, parental participation will not be required."
75460759|NCT01843998|Drug|Sirolimus 0.1% Ointment|Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
75613949|NCT04287777|Drug|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
76070611|NCT06048497|Device|Corrected carotid flow time measurement guided fluid preload|Preoperative FTcs of pregnant women who underwent C/S operation were measured, and those below the cut-off value (327 ms) determined in previous studies were preloaded with Ringer Lactate until FTc was > 327 ms.
75315881|NCT05564091|Device|Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device|360 degree microcatheterization and viscodilation of Schlemm's canal
75764657|NCT05200923|Device|Sacral Neuromodulation|Sacral neuromodulation delivers electrical stimulation to a sacral nerve
76070612|NCT06048276|Drug|Herbal medicines (e.g., Yunkang granules, Duzhong granules)|Herbal medicines (e.g., Yunkang granules, Duzhong granules) exposure at the early gestation.
75315882|NCT05564091|Procedure|Cataract surgery|Cataract surgery alone
75460760|NCT01844011|Other|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
75460761|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
75460762|NCT01844037|Device|OneShot Ablation System|Renal denervation
75315883|NCT04067245|Device|Tetrasodium EDTA catheter lock solution|Home parenteral nutrition patients who meets inclusion criteria is to receive tetrasodium edta catheter lock solution. Patient will receive standard catheter lock solution of heparin/saline for 1 month, followed by tetrasodium EDTA catheter lock solution using withdrawal method for 1 month and followed by tetrasodium EDTA catheter lock solution using flush method for 1 month. In total, patient will stay in the study for 3 months. A phone call will be conducted before the start of the study to give instruction to patient regarding the use of catheter lock solution. Time taken to connect and disconnect TPN will be recorded by patients, twice a month on first and last mondays of the month for 3 months. A survey regarding the ease of use of catheter lock solution will be conducted at the end of each month via phone by nurse coodinator.
75315884|NCT05267249|Procedure|Autotransplantation and Apicoectomy|Autotransplantation of a mature teeth with simultaneous extra-oral root-end resectoin
75460763|NCT01844050|Drug|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
75460764|NCT01844050|Drug|Placebo|
75460765|NCT01844063|Genetic|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
75460766|NCT01844063|Genetic|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
75613950|NCT04287777|Drug|Mupirocin ointment|Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days
75613951|NCT04287777|Drug|Placebo|Topical administration of Placebo (ointment) TID during 7 days
75764658|NCT05194566|Device|tACS|Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.
75613952|NCT04180657|Genetic|Protein C deficiency|The effect of protein C deficiency on ghrelin levels are investigated.
75764659|NCT05194098|Device|TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil|Active Session: Single session of standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes
75315885|NCT01875159|Drug|Caffeine citrate 6 mg/kg/day|Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
75613953|NCT02676583|Procedure|Tonsillectomy|Closure or not closure of tonsil fossa
75613954|NCT00642889|Drug|Safinamide|
75613955|NCT00642889|Drug|Safinamide|
75613956|NCT00642889|Drug|Placebo|
75613957|NCT00629655|Other|motor task, sensory stimulation|"motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation"
75613958|NCT03920163|Other|Enhanced Recovery Measures|Perioperative measures
75907088|NCT04432714|Drug|Doxorubicin|Doxorubicin 10 mg/m2/day CI24h d1-d4
75764660|NCT05194098|Device|SHAM (inactive) TMS stimulation|Sham neurostimulation (SHAM) entails use of the sham side of the D-B80 A/P placed over the same anatomical target, without any active stimulation.
75764661|NCT05188170|Drug|Niclosamide|Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
75907089|NCT04432714|Drug|Vincristine|Vincristine 0.4mg/m2/day CI24h d1-d4
75315886|NCT04065685|Other|serious game named Go Wish|"The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences."
75315887|NCT04065685|Other|usual care|Standardized information on anticipated directives (ADs): the imad nurse are trained to promote AD to clients to help nurses to describe and explain ADs, to identify and to mobilize the required interview condition to promote ADs to clients to facilitate and initiate discussion on ADs
75315888|NCT01432574|Biological|Gardasil|The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
75315889|NCT01875783|Device|OCT imaging|Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
75315890|NCT00339079|Drug|Fluoxetine|Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
75315891|NCT00339079|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
75460767|NCT01844063|Drug|Conventional treatment|"Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma."
75460768|NCT01844102|Device|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
75460769|NCT01844128|Dietary Supplement|weight loss|
75907090|NCT04432714|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2/day IV d5
75907091|NCT04432714|Drug|Prednisone|Prednisone 60 mg/m2/bid oral or IV d1-d5
76070613|NCT06046456|Other|Prenatal Affective CogntiiveTraining|A psychological intervention using computer- and virtual reality based exercises to modify negative cognitive bias and improve emotion regulation
76070614|NCT06046040|Drug|TmPSMA-02 CAR T Cells|TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
75764662|NCT05179759|Behavioral|Tealeaf|Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
75764663|NCT05179759|Behavioral|Enhanced Usual Care|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment
76070615|NCT06045676|Device|ECG|ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.
76070616|NCT06045468|Other|Amputation-specialized rehabilitation|Study center; amputation-specialized unit within rehabilitation facility; fully practicing national guidelines
76070617|NCT06045468|Other|Non-amputation-specialized rehabilitation|Control clinics; treating some amputated patients each year but do not practice national guidelines or partially practicing national guidelines
75764664|NCT05178472|Other|Immunotherapy|Receive SOC immunotherapy
75764665|NCT05178472|Radiation|Stereotactic Radiosurgery|Undergo SRS
75907092|NCT02752074|Drug|pembrolizumab + epacadostat|"Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~Epacadostat will be administered orally daily starting at Day 1 (Week 1)"
75907093|NCT02752074|Drug|pembrolizumab + placebo|"Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~Placebo will be administered orally daily starting at Day 1 (Week 1)"
75907094|NCT03564795|Device|KeraStat Gel|Wound dressing for partial thickness burns
75907095|NCT03564795|Device|Silver Sulfadiazine|Wound dressing for partial thickness burns
75764666|NCT05178472|Procedure|Vertebroplasty|Undergo vertebroplasty
75907096|NCT03624595|Drug|Dexmedetomidine|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
76070618|NCT06045351|Drug|Vitamin D|"Intervention Group Initial 12 weeks;~VD supplementation (600,000 IU I/M) once during the study period~Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~Glucophage XR 750 mg once at dinner for 15 days then twice daily~Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~Calcium 1000 mg/day"
75315892|NCT00339079|Other|Supportive Therapy|The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
75613959|NCT00974259|Device|Management protocol based on pBrO2 and ICP values.|For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (> 20 mm Hg) or pBrO2 (< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
75764667|NCT05172258|Procedure|Biopsy|Undergo biopsy
75315893|NCT00339079|Drug|Placebo|Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
75315894|NCT01392560|Drug|BI 10773|Oral once daily
75315895|NCT01875861|Other|Evidence-Based Quality Improvement Plus Facilitation|The intervention involves researchers partnering with clinical stakeholders, offering tailoring in local implementation strategies to address barriers to metabolic side-effect monitoring and management. External facilitation to support, problem-solve and refine implementation will be provided for a six-month implementation phase.
75315896|NCT00329771|Other|No intervention: We are testing for the presence of allodynia|We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
75460770|NCT01844141|Drug|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
75764668|NCT05172258|Procedure|Biospecimen Collection|Undergo collection of blood samples
75315897|NCT00342355|Drug|Zidovudine|600 mg once daily
75613960|NCT00974259|Device|Management protocol based on ICP values only.|For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
75764669|NCT05172258|Procedure|Computed Tomography|Undergo CT
75460771|NCT01844141|Drug|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
75613961|NCT04177615|Procedure|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
75907097|NCT03624595|Drug|Placebo|Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
75907098|NCT03063970|Device|Dynamic Lycra Orthosis|Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.
75907099|NCT03063970|Other|Usual Rehabilitation|Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
75315898|NCT00342355|Drug|Stavudine|40 mg once daily
75315899|NCT00342355|Drug|Didanosine|<60 kg/125 mg twice daily or >60kg/200 mg twice daily
75613962|NCT00927082|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
75613963|NCT02672137|Behavioral|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
75315900|NCT00342355|Drug|Lamivudine|300 mg once daily
75315901|NCT00342355|Drug|Efavirenz|600 mg once daily
75764670|NCT05172258|Drug|Ipatasertib|Given PO
75764671|NCT05172258|Biological|Pembrolizumab|Given IV
75764672|NCT05171387|Drug|Darolutamide 600 mg twice daily|The participants will take 2 tablets (300 mg each tablet) of study treatment (darolutamide) orally bid at about 12 hour intervals.
75764673|NCT05171387|Drug|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body.
75764674|NCT05155059|Device|MagStim|Bursts of three at 50Hz with an inter burst interval of 200 ms will be given for 190 seconds and this session will be repeated 3 times with 20 minutes between each session in one day. The set of 3 sessions will be repeated 5 times in 5 consecutive days.
75764675|NCT05155059|Other|Sham Comparator|Sham TMS stimulation using a sham coil
75764676|NCT05139602|Biological|Lutikizumab|Subcutaneous Injection
75907100|NCT03564717|Other|Segmented three dimensionally printed transfer tray|Segmented indirect bonding transfer tray
75907101|NCT03063892|Drug|Tranexamic Acid (TXA)|Tranexamic acid is an antifibrinolytic used to control bleeding
75907102|NCT03063892|Drug|Saline solution|Saline solution is used as the placebo comparator
75315902|NCT00342355|Drug|Lopinavir/Ritonavir|r/LPV 400mg/100mg twice daily
75315903|NCT00306163|Drug|Ciclesonide|inhaled Ciclesonide 160 µg, once daily in the morning
75460772|NCT01844167|Procedure|Noxipoint Therapy (NT)|"• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation."
75613964|NCT02864511|Procedure|Nefertiti lift|
75613965|NCT04287933|Device|Drain insertion|insertion of a drain
75613966|NCT02674243|Drug|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
75613967|NCT02674243|Drug|Talc|In this group, Talc will be used as pleurodesis substance
75613968|NCT04256200|Drug|Dienogest 2 MG Oral Tablet|Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg
75613969|NCT04256200|Drug|Yasmin|0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
75764677|NCT05139602|Drug|Placebo|Subcutaneous Injection
75764678|NCT05126680|Other|Supervised exercise therapy: intermittent treadmill walking exercise and moderate intensity functional training|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (15-30 min.) and moderate intensity functional training (MIFT) (15 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min. In MIFT, subjects must complete in 15 min. the highest number of repetitions / rounds possible (AMRAP) to a circuit composed of 6 global functional exercises from which they performed 10 repetitions with a rating of perceived exertion (RPE) of 5-7 on a 1 to 10 scale in each exercise.
75764679|NCT05126680|Other|Supervised exercise therapy: intermittent treadmill walking exercise|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (30-45 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min.
76070619|NCT06045351|Other|Active Comparator|"Active Comparator (Group B; n=71):~Initial-- 12 weeks;~Standard PCOS;~Glucophage XR 750 mg once at dinner for 15 days then twice daily~Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks~VD supplementation (600,000 IUI/M) once during the study period~Calcium 1000 mg/day~Standard PCOS Continued"
76070620|NCT06044558|Drug|Combined with voriconazole|Renal transplant patients taking tacrolimus-based triple immunotherapy and voriconazole drug combination.
76070621|NCT06044558|Drug|Combined with caspofungin|Renal transplant patients taking a combination of tacrolimus-based triple immunotherapy and caspofungin drugs.
76070622|NCT06044558|Drug|Tacrolimus-alone treatment|Renal transplant patients treated with tacrolimus-based triple immunotherapy alone
76070623|NCT06043063|Procedure|Topical lidocaine|Topical anesthetic
75613970|NCT05294029|Other|standard of care for patients with neuromotor disability|clinical examination, radiological, biological and physiological examinations.
75613971|NCT04265014|Other|Goal-directed fluid treatment|Goal-directed fluid treatment for major abdominal surgery
75613972|NCT04265014|Other|Liberal Fluid Therapy|Liberal Fluid Therapy for major abdominal surgery
75613973|NCT02674009|Drug|Vismodegib|Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
75613974|NCT00976677|Drug|erlotinib hydrochloride|Given PO
75613975|NCT00976677|Drug|paclitaxel|Given IV
75613976|NCT00976677|Drug|carboplatin|Given IV
75613977|NCT00976677|Biological|bevacizumab|Given IV
75764680|NCT05120271|Biological|CAR-GPC3 T Cells|Five dose levels each with LD chemotherapy
76070624|NCT06043063|Procedure|EMLA cream|Topical anesthetic
76070625|NCT06043063|Procedure|Periurethral block|5 cc 1% lidocaine or 0.25% bupivacaine at 3 and 9 o'clock (periurethral tissues) to depth of 1.5 cm using 25G needle
76070626|NCT06041308|Other|valve|bioprothetic valve versus mechanical valve
76070627|NCT06036810|Other|Shared Medical Decision Tool|standard of care
75315904|NCT00306163|Drug|Fluticasone|inhaled Fluticasone 100 µg, twice daily
75315905|NCT01861665|Drug|Marcaine- 0.25%|Marcaine 0.25% administered pre-incision.
75315906|NCT01861665|Drug|Marcaine 0.25%.|Marcaine 0.25% administered post-incision.
75315907|NCT00330161|Drug|vorinostat|Given orally
75315908|NCT00330161|Other|laboratory biomarker analysis|Correlative studies
75613978|NCT05329480|Dietary Supplement|Creatine Monohydrate|Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.
75613979|NCT05329480|Dietary Supplement|Maltodextrin|Maltodextrin powder, 4 separate 5g doses per day for 7 days.
75613980|NCT04179331|Other|Neurotensin|Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.
75613981|NCT04179331|Other|Saline|Isotonic saline will serve as a placebo.
76070628|NCT06036810|Behavioral|Engaging Patients in Decision Making|standard of care
76070629|NCT06036810|Behavioral|Literacy Spanish Language|standard of care
76070630|NCT06036238|Behavioral|Healthy Living Intervention (HLI)|The Healthy Living Intervention (HLI) is a brief alcohol counseling intervention developed using the Information, Motivation, and Behavioral skills (IMB) model, a framework in which information, motivation, and behavioral skills are key determinants of health behavior. Participants initiating PrEP will be randomized to either HLI or standard of care alcohol counseling.
76070631|NCT06036238|Behavioral|Standard of Care|Participants who are randomized to the control arm will receive basic alcohol counseling through the Ministry of Health if it is provided as standard of care.
76070632|NCT06035250|Drug|Neoadjuvant Chemotherapy|Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.
75613982|NCT02676271|Procedure|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
75764685|NCT05111574|Drug|Cabozantinib S-malate|Given PO
75764686|NCT05111574|Procedure|Computed Tomography|Undergo CT
75764687|NCT05111574|Procedure|Magnetic Resonance Imaging|Undergo MRI
75764688|NCT05111574|Biological|Nivolumab|Given IV
75764689|NCT05111574|Drug|Placebo Administration|Given PO
75764690|NCT05111574|Procedure|Positron Emission Tomography|Undergo PET
75315909|NCT00552279|Biological|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
75764691|NCT05104853|Drug|CNP-104|CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of ~1 μg of PDC-E2 peptide per mg of PLGA particles.
75460773|NCT01844167|Procedure|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
75764692|NCT05104853|Drug|Placebo|CNP-104 Placebo
75764693|NCT05097326|Drug|Mifepristone|Mifepristone 200mg taken orally
75764694|NCT05097326|Drug|Misoprostol|Misoprostol 50 mcg taken orally, and may receive additional doses of misoprostol 50 - 100 mcg as needed
75764695|NCT05096884|Drug|Metoprolol Succinate|The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
75764696|NCT05094336|Drug|AMG 193|AMG 193: Orally via tablet
75315910|NCT00552279|Biological|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
75764697|NCT05094336|Drug|Docetaxel|Docetaxel: Intravenous infusion
75764698|NCT05094336|Drug|Comparator AMG 193 Test Tablet|Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
75764699|NCT05093530|Drug|Neumifil|Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
75315911|NCT01898273|Drug|I-124-CLR1404|single-dose, intravenous
75460774|NCT01844219|Procedure|elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)|
75764700|NCT05093530|Drug|Placebo|Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
75764701|NCT05074160|Device|OCS Liver|Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.
75764702|NCT05072145|Other|Telemedicine|Receiving care in a tele-ED hospital
76072511|NCT04147845|Other|Microneedling using dermapen|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling."
75315912|NCT00309751|Drug|Pitavastatin|Pitavastatin 4 mg QD
75315913|NCT00309751|Drug|Atorvastatin|Atorvastatin 20 mg
75315914|NCT04380233|Drug|Investigational drug for Functional Dyspepsia-Postprandial Distress Syndrome|The investigational drug is a new pure type of gastrointestinal function modulator traditional Chinese medicine, composed of 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. The preliminary clinical trial showed that it has a good therapeutic effect on FD patients, its Fructus Aurantii Immaturus promotes gastric emptying by stimulating the cells to release motilin, thereby significantly improving patients' symptoms of fullness, epigastric pain, eructation, and nausea and vomiting.
75613983|NCT02674165|Behavioral|HART|Skills based sexual education intervention plus PTSD awareness
75613984|NCT04288167|Diagnostic Test|Sample collection|Samples of urine and saliva will be collected from participants using customary sample collection means.
75764703|NCT05069831|Drug|Abrocitinib|Abrocitinib daily for 4 months
75764704|NCT05061368|Drug|Sildenafil Citrate|Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.
75764705|NCT05061368|Other|Placebo|Placebo
75764706|NCT05050253|Device|Super-oxidized solution (SOS)|Peritoneal lavage with super-oxidized solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
75764707|NCT05050253|Device|Ringer's solution|Peritoneal lavage with Ringer's solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
75764708|NCT05049772|Behavioral|Telerehabilitation-based motor imagery training|10 weeks of motor imagery training and stabilization exercises.
75764709|NCT05049772|Behavioral|Stabilization exercises group|10 weeks of stabilization exercises.
75315915|NCT04380233|Drug|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
75764710|NCT05038852|Device|smartphone applications|app is designed to help you learn relaxation skills.
75764711|NCT05038852|Device|smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
75764712|NCT05031416|Combination Product|LTQ|The investigators will test the LTQ-Connect application and a standard 10-week course of nicotine replacement therapy (NRT) nicotine patches, and Facebook groups, which will run for a total of 3 months with research study participants
75764713|NCT05024968|Drug|Sintilimab|Given by IV
75764714|NCT05024552|Drug|Gilteritinib|Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation
75764715|NCT05024552|Drug|Vyxeos|Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.
75764716|NCT05023460|Device|Paresthesia-free (burst) ONS|Stimulation intensity target of 60% of paresthesia threshold.
75764717|NCT05023460|Device|Placebo|ONS system deactivated
75315916|NCT04346095|Drug|Oral Sedatives with or Without Analgesia|The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
75907103|NCT05708313|Behavioral|lifestyle modification|Participants will undergo an exercise program designed by AHH
75315917|NCT04346095|Drug|Intravenous Sedatives with or Without Analgesia|The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
75460775|NCT01844245|Procedure|Radiofrequency ablation (RFA)|The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
75460776|NCT01844258|Procedure|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
75764718|NCT05019716|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
75764719|NCT05019716|Procedure|Biopsy|Undergo biopsy
75764720|NCT05019716|Procedure|Chest Radiography|Undergo chest x-ray
75907104|NCT03063736|Drug|Entolimod|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
75460777|NCT01844258|Procedure|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
75460778|NCT01844271|Device|Low Level Laser (LLL)|"Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.~We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.~In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups."
75460779|NCT01844297|Drug|TDF+3TC+EFV|
75460780|NCT01844310|Drug|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
75764721|NCT05019716|Drug|Cisplatin|Given IV
75764722|NCT05019716|Procedure|Computed Tomography|Undergo CT or PET-CT
75764723|NCT05019716|Drug|Etoposide|Given IV
75764724|NCT05019716|Procedure|FDG-Positron Emission Tomography|Undergo FDG-PET
75764725|NCT05019716|Procedure|Magnetic Resonance Imaging|Undergo MRI
75764726|NCT05019716|Procedure|Positron Emission Tomography|Undergo PET-CT
75764727|NCT05018598|Drug|Administration via pressurized metered dose inhaler (pMDI)|CHF5993 pMDI
75907105|NCT03063736|Biological|Td Vaccine|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
75907106|NCT03695731|Procedure|cold induced activation of brown adipose tissue|cold exposure wearing a cold life jacket
75907107|NCT03063814|Behavioral|APP|See arm description
75907108|NCT03063814|Behavioral|PHY|see arm description
75907109|NCT02190474|Behavioral|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
75907110|NCT03703219|Other|Mothers Touch Program|Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
75907111|NCT05353179|Drug|Meperizumab injection|Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
75460781|NCT01844310|Drug|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
75460782|NCT01844323|Other|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
75460783|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
75460784|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
75764728|NCT05018598|Drug|Administration via pressurized metered dose inhaler (pMDI)|CHF1535 pMDI or CHF5993 pMDI
75764729|NCT05016557|Dietary Supplement|Protein ingestion|Bolus ingestion of 25g protein
75764730|NCT05011981|Device|Left Atrial Appendage Occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
75460785|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
75460786|NCT01844336|Device|PBASE system 1.1 + CT100 (active treatment)|
75764731|NCT05007821|Drug|Linezolid 600 mg|One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26
75764732|NCT05007821|Drug|Linezolid 1200 mg (QD)|Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4
75764733|NCT05007821|Drug|Linezolid 1200 mg (TIW)|Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26
75764734|NCT05007821|Drug|Bedaquiline 200 mg|Two 100mg tablets taken orally once daily in the morning during weeks 1-8
75907112|NCT05353179|Drug|NUCALA®|NUCALA® is a humanized monoclonal antibody of IgG1 injection
75613985|NCT00642967|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
75907113|NCT03063580|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
75613986|NCT00926536|Device|C-arm CT + DSA as needed|C-arm CT images obtained and supplemented with DSA if needed
75613987|NCT00926536|Device|DSA only|DSA imaging only
75315918|NCT02988999|Dietary Supplement|D-allulose|D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.
75764735|NCT05007821|Drug|Bedaquiline 100 mg|One 100mg tablet taken orally once daily in the morning during weeks 9-26
75764736|NCT05007821|Drug|Delamanid 300 mg|Six 50mg tablets taken orally once daily in the morning during weeks 1-26
75764737|NCT05007821|Drug|Clofazimine 300 mg|Three 100mg capsules taken orally once daily in the morning during weeks 1-2
76072512|NCT04147845|Other|Triamcinolone Acetonide|triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly
75460787|NCT01844336|Device|PBASE system 1.1 + CT100 (placebo treatment)|
75460788|NCT01844401|Drug|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
76072513|NCT04147845|Other|Platelet-rich plasma|The applied PRP will be spread over the whole affected area
75460789|NCT01844401|Drug|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
75315919|NCT02988999|Dietary Supplement|erythritol|non-calorie sweetener
75460790|NCT01844414|Behavioral|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
75613988|NCT02864043|Device|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
75613989|NCT02864043|Procedure|esophagogastroduodenoscopy (EGD)|Standard of care EGD
75613990|NCT04287231|Device|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
75613991|NCT00607360|Behavioral|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
75613992|NCT02865993|Other|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
75764738|NCT05007821|Drug|Clofazimine 100 mg|One 100mg capsule taken orally once daily in the morning during weeks 3-26
75460791|NCT01844414|Behavioral|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
75460792|NCT01844414|Behavioral|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
75764739|NCT05007782|Drug|GS-1811|Administered intravenously
75764740|NCT05007782|Drug|Zimberelimab|Administered intravenously
75764741|NCT05002140|Drug|XRD-0394|Single ascending dose
75764742|NCT05002140|Radiation|Palliative radiotherapy|4 Gy × 5 daily fractions
75764743|NCT04996160|Drug|Palbociclib|Oral
75764744|NCT04996160|Drug|Dexamethasone|8 mg/m2/day divided BID, PO, NG, or IV
75460793|NCT01844427|Drug|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
75460794|NCT01844427|Drug|Placebo|
75460795|NCT01844440|Procedure|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
75460796|NCT01844453|Procedure|Endometrial Biopsy|The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
75460797|NCT01844466|Procedure|Physiotherapy and speech therapy|
75764745|NCT04996160|Drug|Bortezomib|1.3 mg/m2/dose, IV (preferred) or SC
75764746|NCT04996160|Drug|Doxorubicin|25 mg/m2/dose IV
75764747|NCT04995484|Drug|Belzutifan|Two 40 mg tablets given as a single oral 80 mg dose.
75764748|NCT04993404|Drug|Jaktinib Hydrochloride Tablets|A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.
75764749|NCT04985929|Drug|Sildenafil 50 mg|Sildenafil is a phosphodiesterase type-5 inhibitor, which augments/prolongs the naturally occurring nitric oxide mediated vasodilatory pathway. Sildenafil pill is over-encapsulated to be identical in appearance to the placebo intervention.
75907114|NCT03063580|Drug|Rifampicin|"Pharmaceutical form: capsules~Route of administration: oral"
75907115|NCT03700255|Procedure|PickUpSimTM simulation training program|"The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians."
75613993|NCT02865993|Other|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
75907116|NCT02187978|Other|Early total enteral feeding (ETEF)|In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
75907117|NCT02187978|Other|Conventional enteral feeding (CEF)|CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
76070633|NCT06035003|Behavioral|Internet-based Mindfulness Intervention for Emotional Distress (iMIED)|Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
76070634|NCT06034821|Drug|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.
76070635|NCT06034821|Device|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks. The Initial ECT treatment will be Right Unilateral (RUL) ultra-brief pulse at 6x seizure threshold determined during titration at first visit. If there is not satisfactory improvement with RUL the investigator may change to Bilateral (BL) utilizing brief pulse using 0.5 modified half-age method to determine stimulus intensity. The seizure threshold may increase during the course of treatment and the dose of the electric stimulus may need to be increased incrementally. It is suggested to change to bilateral after three to five RUL treatments if response to treatment is not satisfactory. Treatments will be given three times a week for up to 4 weeks.
76070636|NCT06034756|Other|TMJ dysfunction|Fonseca's Anamnestic Questionnaire (FAQ) was used for TMJ dysfunction. The diagnostic accuracy of the FAQ was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
75460798|NCT01844492|Behavioral|The PARTNER Intervention|The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.
76070637|NCT06034756|Other|Maximum pain-free mouth opening (MMO)|The maximum pain-free mouth opening was recorded using a 15 cm ruler
76070638|NCT06034756|Other|Forward head posture|Forward head posture was evaluated by CVA using a goniometer. CVA was measured in degrees as the angle between the horizontal plane, the seventh cervical vertebra and the ear hole
75460799|NCT01844492|Other|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
75460800|NCT01844544|Other|inspection of medical records|
75460801|NCT01844557|Other|Swallowing Exercises|Participants perform 3 swallowing exercises.
75460802|NCT01844557|Behavioral|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
75460803|NCT01844557|Behavioral|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
75460804|NCT01844596|Behavioral|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
75613994|NCT02865759|Behavioral|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
75764750|NCT04985929|Drug|Placebo|Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.
75764751|NCT04982562|Other|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
75764752|NCT04977583|Behavioral|Unmet Need Screening|"Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization."
75764753|NCT04977583|Behavioral|Unmet Need Referral - Resource Sheet|Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.
75764754|NCT04977583|Behavioral|Unmet Need Referral Assistance|Participants receive assistance from a Social Worker (SW) to facilitate connection to resources that can help to address unmet need(s) identified in the index screen. Assistance includes 1) conducting a standardized bio-psychosocial assessment; 2) motivational interviewing methods to uncover details of the Veteran's unmet needs and identify barriers to resolving the unmet needs, and; 3) developing an action plan for the Veteran to connect with resources and address needs. The SW will conduct initial follow-up by phone one week after the interview/action plan development, with planned subsequent phone outreach every two weeks for up to seven weeks.
75764755|NCT04976335|Device|Versawrap membrane|Versawrap membrane will be placed between distal radius plate and flexor tendons
75764756|NCT04972981|Drug|ADCT-901|Intravenous infusion
75764757|NCT04969328|Other|ParTNer-STEPs|"The intervention is a transfer program (ParTNer-STEPs), offered to the parents 1½ - ½ year before their child´s transfer to adult care.~ParTNer-STEPs consist of~an informative website available for parents from recruitment until follow-up.~online educational events for parents. The teaching events are offered twice a year as a web based seminar with short presentations on different topics. The seminars will not be available for parents after their child has transferred to adult care.~transfer consultations across the paediatric and adult department. The transition consultations consist of:~a preparatory consultation (3-6 months before transfer) with the paediatric nurse.~a farewell consultation with the paediatric nurse (0-3 months before transfer).~a joint consultation (at transfer) where both the pediatrician and the adult physician will be present.~a welcoming consultation with the nurse from the adult care (0-3 months after transfer)."
75764758|NCT04968756|Device|Selective retina therapy SPECTRALIS CENTAURUS device|Microsecond laser microsurgery by using the SPECTRALIS CENTAURUS device
75907118|NCT05353101|Drug|Cyclosporine 0.05% eye drops|Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC
75907119|NCT05353101|Drug|Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%|Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.
75907120|NCT03700333|Drug|S-1 therapy|accept S-1(50mg, twice a day, morning and night, if<1.5m2; 75mg, twice a day, morning and night,if >1.5m2 )chemotherapy after finishing first-line therapy(>21 days).
75764759|NCT04966637|Other|COPD cohort|as this a retrospective descriptive study no intervention will be administered to study participants
75764760|NCT04960280|Device|©VoqX stethoscope|Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.
76070639|NCT06034756|Other|Tongue strength and endurance|Tongue strength and endurance were evaluated with IOPI (Medical LLC, Redmond, WA), which has been clinically validated and reliable
76070640|NCT06034756|Other|Static endurance evaluation of the trunk muscles|The Trunk Flexors Endurance Test and the Biering Sorenson Test were used. These static tests are measurements targeting the local core muscles.
75315920|NCT04751305|Behavioral|Health Coaching|The weekly health coaching (HC) calls were structured to be participant-centered, built on a coach participant relationship, and include participant-determined goals, a self-discovery process to find solutions, patient accountability, and education. Before each HC call, the participants received a short questionnaire on fatigue, QOL, stress, loneliness, and social support which enabled tailoring the HC call to the individual. Educational topics are discussed in the following order: Goal Setting, Monitoring Behaviour, Barrier Management, Social Support, Stress Management, Adapting the Program, Self-Compassion, Sleep & Nutrition, Reflection, Health Media, Remote Resources, and Maintaining Motivation. However, the order of the educational topics can be adjusted based on the specific participants' needs each week. At the half-way point of the intervention, the participant provided feedback on the HC calls, ensuring optimization of HC impact.
75460805|NCT01844596|Behavioral|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
75907121|NCT03700333|Drug|Pemetrexed therapy|accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(>21 days).
75907122|NCT03703141|Dietary Supplement|sucralose 48 mg (splenda)/day for ten weeks|volunteers will take sucralose or placebo daily for 70 days
75907123|NCT02190630|Device|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
76070641|NCT06034756|Other|Dynamic endurance evaluation of the core muscles|The Sit-ups and the Modified Push-ups Tests were used. These dynamic tests are measurements targeting the global core muscles.
76070642|NCT06032533|Device|Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of Remote Ischemic Conditioning performed on the leg. One cycle consists of 5 minutes of arterial occlusion followed by 5 minutes of reperfusion. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
76070643|NCT06032533|Device|Sham Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of sham-treatment performed on the leg. One cycle consists of 5 minutes of sham-treatment followed by 5 minutes of pause. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
75460806|NCT01844609|Behavioral|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
75764761|NCT04958785|Drug|Magrolimab|Administered intravenously
75764762|NCT04958785|Drug|Nab-Paclitaxel|Administered intravenously
75764763|NCT04958785|Drug|Paclitaxel|Administered intravenously
75764764|NCT04958785|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
75764765|NCT04945460|Drug|Sotatercept 0.3 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
75764766|NCT04945460|Drug|Placebo|Administered by subcutaneous injection
75764767|NCT04945460|Drug|Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
75764768|NCT04925960|Drug|Epalrestat|Epalrestat is a noncompetitive and reversible aldose reductase inhibitor (ARI) used for the treatment of diabetic neuropathy in Japan. The drug's ability to safely improve symptoms of neuropathy alone by reducing oxidative stress, increasing glutathione levels, and reducing intracellular sorbitol accumulation make it a desirable medication for PMM2-CDG patients who commonly suffer with various neuropathies. However, work recently conducted by Perlara, a public benefit company with the mandate to screen existing commercially available drugs for possible application in rare diseases, has demonstrated that Epalrestat can also elevate the level PMM2 produced endogenously. This may reduce the severity of the morbidities associated with PMM2-CDG.
75764769|NCT04925960|Drug|Placebo|The placebo capsule with be identical in appearance to the Epalrestat capsule. It will contain microcrystalline cellulose filler in a gelatin capsule.
75907124|NCT05352555|Device|Automated vertigo repositioning chair|"Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn.~Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below).~Dix-Hallpike (for posterior canal involvement)~Supine roll (for horizontal canal involvement)~(Optional) Deep Head Hanging (for anterior canal involvement)~If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below).~Epley's and/or Semont's maneuver (for posterior canal involvement)~Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Yacovino's maneuver (for anterior canal involvement)~10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention.~A follow-up was done one week later at the earliest."
76070644|NCT06029413|Procedure|myo + fascial injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as well as for fascial layers as described.
76070645|NCT06029413|Procedure|traditional trigger point injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as described.
76070646|NCT06028360|Other|Progressive Muscle Relaxation|Intervention will be applied for 15-20 minutes 3 consecutive days a week for 1 week
76070647|NCT06028360|Device|Virtual Reality Therapy|Therapy through VR will be given for 8 minutes 3 times a week on consecutively for 1 week
76072448|NCT04765917|Other|Motor imagery training program|"As a preparation each child will be shown a video of 5 minutes of normal movements.~They will be positioned in a comfortable position. The screen is in the child's visual field. Children will be asked to close their eyes and imagine they will perform the physically practiced task for 10 minutes, similar to one shown in the video. Sequence of the task will be verbally explained to the child for better recalling of sensations in muscles during the movements. During the entire exercise schedule child's attention will be focused on the position, and movement of their body, on proprioceptive inputs coming from the leg muscles and on the tactile sensations of foot floor contact.~Thereafter, the child will be asked to perform the sequence of tasks, rehearsed mentally for 20 minutes."
75460807|NCT01844609|Behavioral|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
75315921|NCT04751305|Behavioral|Online delivered Exercise Classes|The group based remote exercise program was delivered over the Zoom application (2x/wk for first 2 weeks; 1x/wk for the remaining weeks). Classes were one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretch. Each class was followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
75460808|NCT01844622|Other|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
75460809|NCT01844635|Drug|Thymoglobulin|
75460810|NCT01844648|Drug|NH004 tropicamide|Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
75460811|NCT01844648|Drug|NH004 Placebo|Intra-oral slow dissolving muco-adhesive thin film
75764770|NCT04922723|Drug|Daratumumab|Daratumumab will be administered by IV infusion to subjects in combination with current therapeutic strategies of surgical resection followed by a course of Temozolomide and radiation therapy.
75460812|NCT01844661|Biological|CELYVIR|
75460813|NCT01844674|Drug|Tizanidine|Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast >/= 10 hours.
75460814|NCT01844674|Drug|Vemurafenib|Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
75460815|NCT01844713|Behavioral|Workbook|Subjects will read a workbook about sun protection
75460816|NCT01844739|Drug|NVN1000 4% Gel|Applied topically twice daily
75613995|NCT00923260|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
75764771|NCT04907851|Drug|RXC004|RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
75907125|NCT05352555|Other|Canalith Reposition Maneuver|"Patients were seated on a examination table and given videonystagmography goggles (VNG).~Manual diagnostic procedures are performed to determine vertigo subtype and orientation.~The manual diagnostic procedures for Left and Right sided semicircular canals are:~Dix-Hallpike (for posterior canal involvement)~Supine roll and Bow and Lean (for horizontal canal involvement)~If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually.~The automated treatment maneuvers are:~Epley's maneuver (for posterior canal involvement)~Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention.~A second follow-up was done one week later at the earliest."
75907126|NCT03252340|Drug|ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."
75907127|NCT03695653|Behavioral|Drink Tracking (MA)|Weekly drink tracking for self-monitoring and assessment
76070648|NCT06028048|Behavioral|PLACES|"The PLACES intervention is based on eight IPS principles, ensuring competitive employment, client choice, service integration, personalized benefits counseling, rapid job search, systematic development, and individualized support.~Coaches: Certified IPS coaches receive training from Phrenos IPS knowledge center and Re-turn. Ongoing support includes video lectures, clarifications with researchers, and biannual collective sessions. Coaches, regionally specialized, implement interventions autonomously.~Intervention Phases:~Intake and Assessment: Participants meet IPS coaches within three days to discuss goals, procedures, and responsibilities, continuing until objectives are met.~Acquisition and Application: Coaches assist job search and placement, aiming for employment within 30 days.~Placement and Support: Coaches offer personalized support, adapting to needs, scheduling meetings based on preferences.~The intervention ends at 12 months or when goals are achieved."
75907128|NCT03695653|Behavioral|Adaptive Tailored (TA)|Messages are sent more frequently and tailored to some baseline characteristics and adapt to progress
75907129|NCT03695653|Behavioral|Tailored (TO)|Messages are sent more frequently and tailored to some baseline characteristics
76070649|NCT06017739|Device|Bronchial Clearance A|EFA technology: the patient has to breathe at tidal volume by a mouthpiece at level 5 for half an hour twice a day.
76070650|NCT06017739|Device|Bronchial Clearance B|High Flow Technology: patient has to wear nasal cannula and breathe his nose for one hour twice a day. After he has to use EFA technology level 5 for half an hour twice a day.
76070651|NCT06017687|Device|OptiBP Study app|Each participant will use OptiBP Study app to measure their blood pressure optically by applying their fingertip to their smartphone camera, and subsequently enter the blood pressure values obtained by measuring it with their own blood pressure cuff.
75460817|NCT01844739|Drug|Vehicle Gel|Applied topically twice daily
76070652|NCT06016673|Procedure|Transcranial Magnetic Stimulation (TMS)|Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
76070653|NCT06016465|Drug|Dexamethasone Oral|Two 4mg pills
76070654|NCT06016465|Drug|Placebo|2 placebo pills
75907130|NCT05708391|Drug|Realgar-Indigo Naturalis Formulation|"Radiotherapy: after 4 courses of chemotherapy, radiotherapy was started 13 weeks later. The radiotherapy was performed by three-dimensional conformal intensity modulated radiation (IMRT) technique with a dose of 45-50.4 grey, and radiotherapy was performed 5 times per week for 5-6 weeks.~Oral administration of Realgar-Indigo naturalis formula from 1 week before radiotherapy to the whole radiotherapy period.~Dosage: oral, according to body weight, 3 times a day.Because the patient constitution is different, may first start from the half dose, within 3 days gradually increases the dose.In this study, the dosage of Realgar-Indigo naturalis formula (250mg per tablet) was determined according to the patient's weight stage.In each body weight segment, 60 mg/kg realgar-indigo naturalis formula were given according to the upper limit of body weight"
76070655|NCT06011577|Drug|REL-1017|REL-1017 tablet
76070656|NCT06011577|Drug|Placebo|Placebo tablet
76070657|NCT06008314|Other|ePNa|"Real-time, automated clinical decision support tool for pneumonia (called ePNa)"
75907131|NCT05708391|Radiation|Radiotherapy|Radiotherapy
75907132|NCT03700177|Drug|Dexamethasone|modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.
75907133|NCT03700177|Drug|Placebo|modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
75907134|NCT03700177|Drug|Ropivacaine Injection [Naropin]|30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
75907135|NCT02183610|Drug|[14C] BI 1356 as oral (p.o.) solution|
75460818|NCT01844752|Drug|NVN1000 1% Gel|Twice daily NVN1000 1% Gel for 12 weeks
75764772|NCT04907851|Drug|RXC004|RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
75764773|NCT04907851|Drug|RXC004|RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
75764774|NCT04907851|Biological|Denosumab|Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
75764775|NCT04907851|Biological|Pembrolizumab|Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
75907136|NCT02183610|Drug|[14C] BI 1356 solution for i.v. infusion|
76070658|NCT06007547|Drug|Poractant Alfa|Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
75460819|NCT01844752|Drug|NVN1000 4% Gel|Twice daily NVN1000 4% Gel for 12 weeks
75460820|NCT01844752|Drug|Vehicle Gel|Twice daily Vehicle Gel for 12 weeks
75460821|NCT01844791|Drug|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
75460822|NCT01844791|Drug|Platinum|Platinum is given as standard chemotherapy each cycle
75460823|NCT01844791|Drug|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
75460824|NCT01844804|Biological|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
75460825|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
75907137|NCT04434352|Device|Storz Duolith Low-Intensity Shockwave Therapy|"A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete.~B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete."
75764776|NCT04905407|Drug|Tamibarotene|Tamibarotene tablets will be administered per dose and schedule specified in the arm.
75764777|NCT04905407|Drug|Venetoclax|Venetoclax tablets will be administered per dose and schedule specified in the arm.
75764778|NCT04905407|Drug|Azacitidine|Azacitidine injection will be administered per dose and schedule specified in the arm.
75907138|NCT03699943|Procedure|CaverStem|
75907139|NCT02183688|Drug|Low dose ASA|
75907140|NCT02183688|Drug|High dose ASA|
75907141|NCT02183688|Drug|Low dose paracetamol|
75460826|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
75764779|NCT04855357|Behavioral|Resident counselling|One hour, one-on-one counseling for residents
75907142|NCT02183688|Drug|High dose paracetamol|
75907143|NCT02183688|Drug|Caffeine|
75907144|NCT02183688|Drug|Placebo|
75907145|NCT03695575|Device|Bone-conduction headset|A bone-conduction headset paired with a microphone will be used.
75907146|NCT02190708|Drug|PQ912|from day2 up to day6 twice daily oral dose of PQ912
76070659|NCT06006117|Drug|Mosunetuzumab + Lenalidomide|"Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~C2 to C12: 45 mg D1 28-days cycles~Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)"
76070660|NCT06006117|Drug|- Rituximab + Lenalidomide (28-days cycles|"Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~Rituximab* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12"
75764780|NCT04855357|Behavioral|Staff Training|A two-hour training for PSH staff on how to provide referrals to smoking cessation programs using materials previously developed from UCSF's 'Rx for change' curriculum for service providers, directed toward empowering PSH staff to provide referrals to local cessation services using the ask, advise, and refer approach. The training will address nicotine addiction, tobacco use among PSH residents, pilot data, brief cessation counseling (ask, advise, and refer), and local resources for cessation. Because PSH resident-PSH staff encounters will take place as part of routine care, the study team will request permission from a random sample of staff and resident dyads (n=40) to record these interactions to assess fidelity.
75907147|NCT02190708|Drug|Midazolam|single oral dose on day1 and day 6
75907148|NCT02190708|Drug|Omeprazole|single oral dose on day1 and day6
76072449|NCT04023903|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
75460827|NCT01844843|Device|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
75460828|NCT01844869|Drug|omacetaxine mepesuccinate|
75764781|NCT04841967|Behavioral|TELL Tool Intervention|A 60-minute session with decision support information delivered digitally to parents at their homes or other private, quiet location.
75460829|NCT01844908|Procedure|Electroacupuncture|
75460830|NCT01844934|Other|Prehabilitation|The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
75764782|NCT04841967|Behavioral|eBook Attention Control|A 60-minute session with good parenting principles delivered digitally to parents at their homes or other private, quiet location.
75764783|NCT04841252|Device|FDA approved GE LOGIQ E9 (LE9) ultrasound|Ultrasound
75764784|NCT04841252|Device|Alpinion clinical ultrasound machine|Ultrasound
75764785|NCT04840199|Drug|Letermovir 240 MG Oral Tablet|240 mg tablets. Administered orally as two tablets once daily with or without food.
75764786|NCT04840199|Drug|Letermovir 480 MG Oral Tablet|480 mg tablet. Administered orally as one tablet once daily with or without food.
75764787|NCT04840199|Drug|Combination ART|ART (antiretroviral therapy) medications will be prescribed by participants' health care providers. ARV medications will not be provided by the study.
75907149|NCT02835495|Behavioral|HELP Vets Intervention|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
75907150|NCT02835495|Behavioral|Individual Education Program|Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
75907151|NCT02190786|Drug|KUX-1151|
75907152|NCT04864132|Diagnostic Test|6-minute walk test|This test assesses submaximal exercise capacity.
75907153|NCT04864132|Diagnostic Test|Incremental shuttle walk test|This test assesses maximal exercise capacity.
76072450|NCT04023903|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
76072451|NCT04023981|Device|Parafricta bootees|Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
75764788|NCT04829383|Drug|Atezolizumab|1,200 mg
75764789|NCT04829383|Drug|Bevacizumab|15 mg/kg
75907154|NCT05338983|Drug|Topical anesthetic|20% Benzocaine gel will be applied on the area of infiltration
75907155|NCT05338983|Device|Avent baby bottle warmer|Warming device
75315922|NCT01876485|Behavioral|Empowering Patients in Chronic Care (EPIC)|EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
75315923|NCT01876485|Behavioral|Enhanced Usual Care (EUC)|Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
75764790|NCT04821063|Drug|ITF2357 10 mg/mL|Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral
75907156|NCT05338983|Drug|Sodium bicarbonate|0.1ml of 8.4% of sodium bicarbonate will be removed from the 50ml vial by one ml insulin syringe , directly injected into the local anesthetic cartridge and will be shacked 5 times to mix the solution.
75907157|NCT05338983|Device|Buzzy device|"Bee-shaped apparatus consisting of two parts: the main vibrating body of a bee and detachable ice wings.~External application of Buzzy device during administration of dental anesthetic."
75764791|NCT04821063|Drug|ITF2357 10 mg/mL|Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
75907158|NCT05338983|Drug|Mepivacaine Hydrochloride|Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration
76070661|NCT06006117|Drug|- Rituximab + Bendamustine (28-days cycles)|"Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~Rituximab* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6** (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). **For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6."
76070662|NCT06006117|Drug|- Rituximab + CHOP (21-days cycles)|"CHOP, IV standard dose from cycle 1 to 6~Rituximab* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)"
76070663|NCT05991323|Drug|Dupilumab|Injection solution; subcutaneous
76070664|NCT05988892|Behavioral|Physical Activity|Use Exercise to increase physical activity (PA), as measured by cardiovascular endurance, muscular strength, and balance in underserved cancer survivors >60 years of age and/or those of any age residing at a rural address and to increase quality of life (QOL), as measured by physical functioning and fatigue, in underserved cancer survivors >60 years of age and/or those of any age residing at a rural address.
76070665|NCT05987566|Other|Morning meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten after 1 hour of waking up in the morning
76070666|NCT05987566|Other|Evening meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten within 1 hour of going to bed
75315924|NCT00313729|Drug|temozolomide|Chemotherapy
75613996|NCT00923260|Procedure|Omentectomy|After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
75613997|NCT04180735|Procedure|Liver transplantation|Liver transplantation
75613998|NCT04256278|Other|Spermotrend|oral administration of antioxidants for three months
75613999|NCT04287543|Drug|Melatonin|25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
75614000|NCT04287543|Drug|Placebos|25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
76070667|NCT05985590|Drug|BMS-986278|Specified dose on specified days
75614001|NCT04100395|Device|sonoclot|Sonoclot Analyzer is best described as a microviscometer. The electronics are sensitive to any resistance to motion that the oscillating probe encounters as it moves within the test sample.
75764792|NCT04821063|Drug|Placebo|Dose: 20 mL; Dosage form: suspension; Route of administration: oral
76070668|NCT05985590|Drug|Drospirenone/Ethinyl Estradiol|Specified dose on specified days
76070669|NCT05979493|Drug|Bupivacain|30cc IM injection in each quadratus lumborum muscle (60cc total).
75764793|NCT04821063|Drug|Moxifloxacin Hydrochloride|Dose: 400 mg; Dosage form: tablet; Route of administration: oral
75764794|NCT04821063|Drug|Placebo|Dose: 30 mL; Dosage form: suspension; Route of administration: oral
76070670|NCT05979493|Drug|Saline|30cc IM injection in each quadratus lumborum muscle (60cc total).
76070671|NCT05978388|Diagnostic Test|Analysis of coronary CT Angiography and CAC scoring prior to catheter ablation|Analysis of coronary CT angiography and CAC scoring and derived treatment prior to catheter ablation.
75315925|NCT00559377|Other|18F-fluoromisonidazole|Undergo ^18F FMISO PET scan
75315926|NCT00559377|Radiation|fluorodeoxyglucose F 18|Undergo ^18F FDG PET scan
75315927|NCT00559377|Procedure|positron emission tomography|Undergo ^18F-FMISO and ^18F FDG PET scan
75315928|NCT00559377|Other|tissue oxygen measurement|Undergo ^18 F FMISO PET and ^18F FDG PET
75764795|NCT04804644|Drug|Memantine Hydrochloride|Given PO
75764796|NCT04804644|Other|Neurocognitive Assessment|Ancillary studies
75764797|NCT04804644|Radiation|Stereotactic Radiosurgery|Undergo SRS
75764798|NCT04804644|Radiation|Whole-Brain Radiotherapy|Undergo HA-WBRT
75764799|NCT04799470|Device|Novel DBS stimulation patterns|Stimulation patterns
75764800|NCT04798768|Device|mCRM Therapy System|Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
75764801|NCT04779229|Behavioral|Parent Activation|Parent Activation (PA) is comprised of concrete social learning theory steps (i.e., direct instruction, modeling, practice opportunities, and reinforcement) that aim to enhance a parent's confidence, knowledge, and ability to manage his/her child's health. PA is applicable across a range of conditions, including behavioral and psychiatric problems, and it can be delivered by varied providers, including paraprofessionals.
75764802|NCT04779229|Behavioral|Usual Services|This intervention refers to the typical techniques that JPOs employ to monitor the juveniles on their caseloads (e.g., regular meetings with youth and parents to ensure the youth is following conditions of probation and issuing swift sanctions [community service; detention] if conditions are not being followed).
75764803|NCT04762875|Biological|MGTA-145|MGTA-145 will be be administered as an IV infusion
75764804|NCT04762875|Biological|Plerixafor|240 µg/kg subcutaneously
75764805|NCT04762121|Procedure|Peripheral IV|Insertion of peripheral intravenous catheter
75907159|NCT02183766|Dietary Supplement|Galactooligosaccharide prebiotic|6 mL once a day
75907160|NCT02183766|Drug|Maltodextrin|6 mL once a day
75907161|NCT03063658|Drug|Paracetamol|The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
75907162|NCT03063658|Drug|Ibuprofen 800 mg|The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
76070672|NCT05976828|Drug|IBRX-042|"Dose cohort 1: 1e11 virus particles (VP)/dose~Dose cohort 2: 5e11 VP/dose~If needed, dose cohort -1 (de-escalation): 5e10 VP/dose"
75315929|NCT01790191|Behavioral|Repeated consumption of basic artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
75315930|NCT01790191|Behavioral|Repeated consumption of sweet artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
75460831|NCT01844947|Drug|Vinflunine|"Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance >60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.~For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days."
75460832|NCT01844947|Drug|Sorafenib|"Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):~Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed."
75460833|NCT01844960|Procedure|Single Incision Gastric Band Insertion|Insertion of gastric band though single abdominal incision
75460834|NCT01844960|Procedure|Multiple Incision Gastric Band Insertion|Insertion of gastric band though multiple abdominal incisions
75460835|NCT01844973|Drug|M518101|Proper quantity twice a day
75614002|NCT02676505|Behavioral|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
75614003|NCT02676505|Behavioral|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
75614004|NCT04287387|Drug|Glucophage 500Mg Tablet|0.5g three times daily
75614005|NCT04287387|Drug|Acarbose Tablets|50mg three times daily
75460836|NCT01844973|Drug|Vehicle|Proper quantity twice a day
75614006|NCT04287387|Drug|Sitagliptin tablet|100mg once daily
75614007|NCT04287387|Drug|Dapagliflozin Tablet|10mg once daily
75614008|NCT04287387|Drug|Pioglitazone Tablets|30mg once daily
75614009|NCT04287387|Drug|Glimepiride Tablets|2mg once daily
75764806|NCT04761627|Drug|Ustekinumab|Participants will receive subcutaneous (SC) injection of ustekinumab.
75764807|NCT04761627|Drug|ABP 654|Participants will receive SC injection of ABP 654.
75764808|NCT04754321|Radiation|External Beam Radiation Therapy|Undergo EBRT
75764809|NCT04754321|Radiation|Intraoperative Radiation Therapy|Undergo IORT
75764810|NCT04754321|Biological|Pembrolizumab|Given IV
75764811|NCT04754321|Other|Quality-of-Life Assessment|Ancillary studies
75907163|NCT03695263|Behavioral|Choice of one of five behavioral interventions|All participants will choose one of the five intervention options.
75907164|NCT03535896|Other|HSR|"Participants will complete a heel raise standing with the forefoot on a step. The toes are maximally dorsiflexed by placing a towel underneath them. The heel raise is performed with a raise to maximal plantar flexion and to maximal dorsi flexion.~The exercise is performed with a load as heavy as possible but no heavier than 8RM and for as many sets as possible every other day."
75614010|NCT00644527|Other|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
75315931|NCT01790191|Behavioral|Repeated exposure to fat artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
75764812|NCT04754321|Procedure|Salvage Surgery|Undergo salvage surgery
75764813|NCT04749823|Other|Blended treatment program|A combined treatment program with specific active neck exercises and general aerobic training in counteractive amount will be executed during 12 weeks. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
75764814|NCT04749823|Other|Specific strength exercise program|This program includes an individual, patient-tailored exercise program with the aim of retraining the neck musculature. A detailed exercise programme will be constructed in which all exercises are listed with the amount of repetitions and series of each exercise. Strength exercises will be performed by means of dumbbells with different weights and elastic bands with different degrees of resistance. The amount of weight or resistance, and the amount of series and repetitions will be evaluated during the first session. This exercise programme will be re-evaluated repeatedly during the course of the program. Specific strength neck exercises will be performed for 30 minutes. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
75460837|NCT01844999|Behavioral|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
75315932|NCT05531019|Dietary Supplement|Echinochrome A|Dietary Supplement with Echinochroma A Simple randomized design, in this arm patients will take 6ml of a 0.025% Echinochroma A solution twice a day for 90 days. 3 mg of Echinochroma A will be consumed per day.
75315933|NCT05531019|Other|Control|Simple randomized design, in this arm patients will take 6ml of an fructose aqueous solution twice a day for 90 days with the same flavor as the treatment
75315934|NCT05266651|Drug|Tadalafil 5mg|oral tablets for one month duration
75315935|NCT05266651|Drug|Placebo|oral tablets for one month duration
75460838|NCT01844999|Behavioral|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
75460839|NCT01845012|Other|Daily hemodialysis at low dialysate flow|Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
75460840|NCT01845038|Drug|OTX-TPa ~4µg/day over 2 mos. with natural tears drops|OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of ~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
75614011|NCT00644527|Other|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
75614012|NCT04287153|Device|Cryotherapy on abdomen and saddlebags|Application of variable temperature (-10°c to -7°c) on the treated areas using the cryotherapy device FG660L-006 (Beijing ADSS Development CO., Ltd)
75315936|NCT05266573|Other|Exercise Group|The exercise program is led by an individual who has a background in exercise physiology and is trained by the Physical Therapist. The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components: warm-up period (dual task activity and walking progressively), stretching/strengthening/balance (gradual progression of activities and repetitions for 30 minutes), and obstacle course (6 to 15 minutes of obstacle course and challenged walking).
75614013|NCT00644605|Drug|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
75764815|NCT04749823|Other|General aerobic exercise program|This control group will receive a general aerobic exercise program. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
75460841|NCT01845038|Drug|OTX-TPb ~3µg/day over 3 months with natural tears drops|OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of ~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
75460842|NCT01845038|Drug|Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
75614014|NCT00644605|Drug|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
75614015|NCT00644605|Drug|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
75614016|NCT00644605|Drug|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
75614017|NCT02865681|Drug|Menopur|Nasal versus injectable
75614018|NCT02865681|Drug|Synarel|nasal
75764816|NCT04742452|Procedure|Superior Capusular Reconstruction|Superior capsular reconstruction is one treatment option for massive and irreparable rotator cuff tears. The superior shoulder capsule, a thin membranous structure located on the inferior surface of the supraspinatus and infraspinatus muscles, is often torn in this type of rotator cuff tear. In superior capsular reconstruction, this structure is reconstructed with acellular dermal allograft.
75764817|NCT04742452|Procedure|Partial Rotator Cuff Repair|Partial rotator cuff repair can be performed, in conjunction with other procedures such as subacromial decompression and biceps tenodesis, when a rotator cuff tear is not amenable to a complete repair.
75764818|NCT04739800|Procedure|Biospecimen Collection|Undergo collection of blood
75764819|NCT04739800|Drug|Cediranib Maleate|Given PO
75764820|NCT04739800|Procedure|Computed Tomography|Undergo CT
75764821|NCT04739800|Procedure|Computed Tomography with Contrast|Undergo CT with contrast
75764822|NCT04739800|Biological|Durvalumab|Given IV
75764823|NCT04739800|Procedure|Echocardiography|Undergo ECHO
76070673|NCT05973240|Other|Participation in an web-based survey|Patients who agree to participate will access a web-based survey (SurveyMonkey) via social media, mobile messages, or emails. The invitation will provide study details, eligibility criteria, and tasks. Patients will confirm inclusion/exclusion criteria upon access, and those ineligible will opt out. Data collection will take approximately 10 minutes per patient. Collected data will be sent to an electronic data collector and saved as an eCRF file in REDCap. The study will conduct two cross-sectional data collection rounds using web surveys to ensure anonymity. Convenience sampling will target anticoagulated patient associations' webpages and social media (e.g., Feder-AIPA, AICCA). In the second round, participants will be informed not to resubmit if they have already completed the survey to avoid overlapping responses.
76070674|NCT05971147|Dietary Supplement|Fish oil|Participants in this group will receive 5g fish oil with high EPA and DHA content per day
76070675|NCT05967247|Other|The experimental group used App for MBSR intervention|"The experimental group used App for MBSR intervention The main app of this experiment is Mindfulness in Life (Taiwan) (this system is only applicable to Android devices). The content is divided into two parts. The course is compressed and simplified, mainly focusing on mindfulness learning and practicing audio-visuals. There are eight-week themed audio-visuals and mindful caring words guided by mindfulness-based stress reduction, mindfulness-stretching guidance, and the function of recording the reading time of the research subjects. App platform for researchers to communicate."
76070676|NCT05967247|Other|"the Heart Care Life app"|"Control group serves as a waiting list with priority given to placebo Placebo for the Heart Care Life app."
75614019|NCT02865681|Drug|HCG trigger|injectable
75764824|NCT04739800|Procedure|Magnetic Resonance Imaging|Undergo MRI
75764825|NCT04739800|Procedure|Multigated Acquisition Scan|Undergo MUGA
75764826|NCT04739800|Drug|Olaparib|Given PO
76070677|NCT05967247|Other|Phone interview once a week|Phone interview once a week
75460843|NCT01845064|Drug|DM199|
75460844|NCT01845064|Drug|Placebo|
75764827|NCT04739800|Drug|Paclitaxel|Given IV
75460845|NCT01845090|Drug|Lanthanum carbonate|the effect on serum FGF23
75460846|NCT01845090|Drug|Calcium Carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
75764828|NCT04739800|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75614020|NCT02865681|Drug|Clomiphene citrate|oral
75764829|NCT04739800|Drug|Topotecan Hydrochloride|Given IV
75764830|NCT04735770|Procedure|Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine|Postoperative pain management
75764831|NCT04732663|Other|No Intervention|Cross-sectional study, no intervention.
75764832|NCT04721912|Drug|Probiotic dietary supplement|GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
75764833|NCT04709549|Behavioral|Diabetes Prevention Program + Job and Legal Services|"Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.~Job readiness services will be provided by YMCA SF service connectors, trained staff with expertise in employment services who are bi-lingual in English/Spanish and/or Cantonese/English to serve the needs of the community. Service Connectors will assist with providing employment services (e.g job search, potential placement and retention services, relationship development with partners and employers) and job readiness instruction/training."
75764834|NCT04709549|Behavioral|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
75315937|NCT05746689|Drug|Sirolimus|Sirolimus The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
75315938|NCT01412060|Drug|Placebo|Placebo was supplied in capsules.
75315939|NCT01412060|Drug|Cariprazine|Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
75460847|NCT01845129|Device|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
75460848|NCT01845129|Device|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
75460849|NCT01845142|Drug|single administration of 100.000 I.U. vitamin D|
75614021|NCT02865681|Drug|Letrozole|Oral
75315940|NCT00345865|Drug|carmustine|Day -6, 300 mg/m^2 over 2 hour
75460850|NCT01845142|Drug|Placebo|
75460851|NCT01845168|Other|Computer-alert|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids
75614022|NCT04287309|Other|CAR-T cells|CD19 targeted CAR-T treatment
75614023|NCT00644137|Drug|pregabalin|Help stop smoking
75614024|NCT00644137|Other|cigarettes|help stop smoking with study medication
75614025|NCT04286997|Device|GRAIL population|each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
75614026|NCT02672059|Other|Observation|No intervention
75764835|NCT04709380|Other|Radiotherapy plus Toripalimab|Intensity modulated radiotherapy has shown important role in the treatment of hepatocellular carcinoma (HCC), especially for advanced disease with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis. Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
75764836|NCT04709380|Drug|Sorafenib|Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.
75764837|NCT04700527|Drug|Short Chain Fatty Acid|Participants will take the supplement as prescribed to determine if it can help with GI toxicity
75764838|NCT04700527|Drug|Tapioca Flour|Participants taking this will be used as a control group compared to those receiving the SCFA supplement
75764839|NCT04666155|Device|Intermittent Colonic Exoperistalsis with MOWOOT device|"Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks. They should continue with their individualized standard of care againts constipation for the first 4 weeks. During the following 8 weeks of the interventional period of 12weeks, their use of SocTAI will be considered rescue intervention. The 8weeks following the 12weeks of intervention, they can keep on using ICE device.or SocTAI or both."
75764840|NCT04666155|Device|Standard of care with Trans-Anal Irrigation|Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.
75614027|NCT04256356|Dietary Supplement|Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
75315941|NCT00345865|Drug|cyclophosphamide|"NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing."
75315942|NCT00345865|Drug|etoposide|"NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.~HL without radiation: 150 mg/m^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4."
75315943|NCT00345865|Procedure|peripheral blood stem cell transplantation|Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
75315944|NCT00345865|Radiation|irradiation therapy|"Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~> 1000 cGy to whole lung, kidney, or abdominal bath.~> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~> 3600 cGy to whole brain."
75315945|NCT00345865|Biological|G-CSF|"Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) > 1500/μl x 3 consecutive days.~If ANC falls <1000/μL, restart G-CSF."
75764841|NCT04658472|Drug|SAR445088 (IV)|Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
75764842|NCT04658472|Drug|SAR445088 (SC)|Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
75614028|NCT04256356|Dietary Supplement|Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
75764843|NCT04644068|Drug|AZD5305|Oral PARP inhibitor
75764844|NCT04644068|Drug|Paclitaxel|IV Anti-microtubule agent
76070678|NCT05966961|Device|Novosyn® in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
75614029|NCT04256356|Other|Feeding infants with standard formula milk|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
75614030|NCT04256356|Other|Breastfeeding infants|reference group
75764845|NCT04644068|Drug|Carboplatin|IV Platinum chemotherapeutic
75764846|NCT04644068|Drug|T- Dxd|IV Antibody-drug conjugate
76070679|NCT05966961|Device|Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
76070680|NCT05965427|Other|No intervention|Study is retrospective data collection only
76070681|NCT05965089|Biological|Placebo|Placebo
76070682|NCT05965089|Biological|AX-202|Humanized monoclonal antibody
76070683|NCT05963243|Other|Ultrasound Scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
75315946|NCT00345865|Drug|Cytarabine|100 mg/m^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
75315947|NCT00551421|Biological|pertuzumab|Given IV
75315948|NCT00551421|Biological|cetuximab|Given IV
75315949|NCT00551421|Drug|irinotecan hydrochloride|Given IV
75315950|NCT00551421|Other|immunohistochemistry staining method|Correlative study
75315951|NCT00551421|Other|fluorescence in situ hybridization|Correlative study
75614031|NCT02864121|Other|all patients included in IDAHO study|
75614032|NCT04177537|Device|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
75614033|NCT00934102|Device|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
75614034|NCT00934102|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
75614035|NCT00934102|Device|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
75764847|NCT04644068|Drug|Dato-DXd|IV Antibody-drug conjugate
75764848|NCT04644068|Drug|Camizestrant|Oral SERD Molecule
75764850|NCT04632069|Combination Product|N acetyl cysteine + vagus nerve stimulation|NAC x 14 days, taVNS x 10 days
75764851|NCT04627064|Drug|Abemaciclib|Tablet taken orally
75764852|NCT04627064|Drug|MK-6482|Tablet taken orally
75764853|NCT04625946|Drug|Metformin|"Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control.~Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout."
75764854|NCT04625946|Behavioral|Recommendations for lifestyle modification.|All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.
75764855|NCT04625946|Device|AliveCor|Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.
75764856|NCT04624217|Drug|SHR-1701|PDL1/TGFβ
75764857|NCT04621786|Device|Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface|The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.
75764858|NCT04617769|Behavioral|Psychoeducation|psychoeducational materials on trauma and safety behaviors
75764859|NCT04617769|Behavioral|Exposure|six 3-minute video exposure trials with an inter-trial interval of 2 minutes
75764860|NCT04612751|Drug|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
75764861|NCT04612751|Drug|Durvalumab|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
75764862|NCT04612751|Drug|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
75764863|NCT04612751|Drug|AZD2936|Intravenous infusion prior to Dato-DXd
75764864|NCT04612751|Drug|MEDI5752|Intravenous infusion prior to Dato-DXd
75764865|NCT04612751|Drug|AZD7789|Intravenous infusion prior to Dato-DXd
75764866|NCT04601740|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75460852|NCT01845168|Device|A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids
75460853|NCT01845168|Device|Computer-alert|
75614036|NCT05587153|Other|perfusion index in all parturient recruited for the study|Using perfusion index and positional hemodynamic changes for the prediction of postspinal hypotension in all parturient recruited for the study
75764870|NCT04596631|Drug|Oral semaglutide|Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
75460854|NCT01845181|Drug|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
75614037|NCT03760419|Behavioral|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
75614038|NCT00910195|Device|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
75614039|NCT00910195|Device|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
75614040|NCT04285905|Other|Access to Fast Track TB clinic|Male partner can attend clinic with dedicated services for men
75764871|NCT04596631|Drug|Placebo (semaglutide)|Placebo treatment for 52 weeks.
75764872|NCT04595773|Other|Aerobic Exercise Training|Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.
75764873|NCT04595773|Other|Education|Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.
75460855|NCT01845181|Drug|Placebo|1 or 2 or 3 capsules of placebo.
75614041|NCT04285905|Other|Information leaflet for male partner|Female participants will be provided with a letter asking their male partner to attend the clinic for tuberculosis screening
75460856|NCT01845194|Drug|Codeine|"Treatment period 2:~5 mg Codeine once"
75614042|NCT04285905|Other|Home sputum collection|Female participants will be provided with sputum cups to take home and collect a sample of sputum from their male partner
76070684|NCT05954494|Biological|BPAN Patients|Patients, children or adults with a neurological impairment (epilepsy, dystonia, cognitive impairment...) related to a pathogenic variant of the WDR45 gene
75315952|NCT00551421|Other|gene expression analysis|Correlative study
75764874|NCT04594642|Drug|AZD0486 IV|AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
76070685|NCT05953337|Device|EYE90 Microspheres Treatment|Y90 glass microspheres
75315953|NCT00551421|Other|mutation analysis|Correlative study
75614043|NCT04285905|Other|Home HIV testing|Female participants will be provided with an oral HIV self-test kit to be given to their male partner with instructions for use
75315954|NCT00551421|Other|polymerase chain reaction|Correlative study
75315955|NCT00551421|Other|laboratory biomarker analysis|Correlative study
75315956|NCT00348205|Device|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
75315957|NCT01791751|Drug|Clomifene Citrate|Clomiphene citrate 100 mg daily for 5 days
75315958|NCT05266261|Drug|Ibandronate Oral Tablet|150 mg of ibandronate + 24,000 IU of cholecalciferol
75315959|NCT03022383|Device|DRI OCT Triton plus|OCT Machine used for diagnostic purposes
75315960|NCT05745363|Drug|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor
75315961|NCT00317239|Drug|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
75315962|NCT00317239|Drug|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
75460857|NCT01845194|Drug|Midazolam|"Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once"
75460858|NCT01845194|Drug|Pravastatin|"Treatment period 2:~5 mg Pravastatin once"
75614044|NCT04285905|Other|Financial incentive|Female participants will be provided with a voucher for MKW5000 which can be redeemed when the male partner attends the clinic for TB testing
75764875|NCT04579224|Drug|Docetaxel|Given IV
75764876|NCT04579224|Drug|Eribulin Mesylate|Given IV
75764877|NCT04579224|Drug|Gemcitabine Hydrochloride|Given IV
76072452|NCT04146675|Device|TRICOT JERSEY VANISE DOUBLE FACE|"Short sleeve t-shirt : TRICOT JERSEY VANISE DOUBLE FACE  THERMOLACTYL EVOLUTION  with ceramic fibers.~A Tinetti test will be performed while wearing the T-shirt, as well as an evaluation of the equilibration on posturography platform under static conditions and an assessment of dynamic equilibrium and locomotion in motion analysis."
75315963|NCT05266105|Drug|OP-1250|Complete Estrogen Receptor Antagonist
75315964|NCT05266105|Drug|Palbociclib|Palbociclib is an approved CDK 4/6 Inhibitor drug
75315965|NCT01891643|Drug|Lenalidomide|
75315966|NCT01891643|Drug|Dexamethasone|
75315967|NCT01891643|Biological|Elotuzumab|
75315968|NCT05265793|Drug|Camrelizumab Combined With Apatinib|After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur
75315969|NCT04005599|Drug|Remifentanil group|Venous general anesthesia with propofol and remifentanil.
75315970|NCT04005599|Drug|Magnesium sulfate group|Venous general anesthesia with propofol and magnesium sulfate
75315971|NCT00330863|Drug|Risperidone microspheres|Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
75315972|NCT00330863|Drug|Risperidone|Target dose is 4 mg/day.
75315973|NCT00330863|Drug|Olanzapine|Target dose is 15 mg/day.
75315974|NCT00330863|Drug|Quetiapine|Target dose is 600 mg/day.
75315975|NCT00330863|Drug|Ziprasidone|Target dose is 120 mg/day.
75315976|NCT00330863|Drug|Aripiprazole|Target dose is 20 mg/day.
75315977|NCT00330863|Drug|Paliperidone|Target dose is 6 mg/day.
75315978|NCT01899521|Procedure|Bronchoscopy|Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
75315979|NCT01899521|Dietary Supplement|Zinc sulfate 220 mg once daily|
75315980|NCT01899521|Dietary Supplement|S-adenosylmethionine 400 mg twice daily|
75315981|NCT01790009|Dietary Supplement|Flavanol rich drink|
75315982|NCT01790009|Drug|Acetaminophen|2x500 mg Acetaminophen
75460859|NCT01845194|Drug|Torsemide|"Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once"
75460860|NCT01845194|Drug|Talinolol|"Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once"
75460861|NCT01845194|Drug|Caffeine|"Treatment period 1:~50 mg Caffeine 3x"
75460862|NCT01845194|Drug|Metoprolol|"Treatment period 1:~5 mg Metoprolol 3x"
75460863|NCT01845246|Device|Prospective TDM Arm of colistin|
75460864|NCT01845259|Drug|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
75460865|NCT01845259|Drug|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
75460866|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
75460867|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
75614045|NCT04203784|Other|Plasma concentration measurements|Plasma concentration measurements
75614046|NCT02671825|Drug|PUR0200|PUR0200 dry powder inhalation
75614047|NCT02671825|Drug|Reference Product|Dry Powder Inhalation Reference Product
75764878|NCT04579224|Drug|Paclitaxel|Given IV
75907165|NCT03535896|Drug|Corticosteroid injection|Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
75907166|NCT03695107|Drug|Nifedipine controlled released tablets|lower blood pressure
75907167|NCT02835339|Drug|Magnesium sulfate 4g loading dose, 1g/hr infusion|
75614048|NCT04256122|Other|No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT.|evaluate an immunophenotypical profile related to mitochondrial functions in tumors responders vs non-responder to intravescical chemotherapy or immunotherapy. Verify the possible prognostic differences in clinical behavior between the two populations.
75614049|NCT04176367|Drug|Nicergoline from China|This is the test arm of China local manufactured Nicergoline
75315983|NCT05461989|Other|Anthropometric measurement|It will be measured with the Xiaomi Body Composition Scale II, and a total of 9 measurements will be made as a result of the measurements.
75315984|NCT05461989|Other|Level of Physical Activity|The scale to be used for this purpose is the Child Physical Activity Questionnaire (CPAQ) developed by Kowalski et al. It is a seven-day self-reported recall scale designed to assess moderate-intensity physical activity in children aged 8-14 years. CFAQ is designed to be implemented throughout the school year.
75614050|NCT04176367|Drug|Nicergoline from Italy|This is the reference arm of Italy originator Nicergoline.
75315985|NCT05461989|Other|Physical Activity Barriers Scale|"It consists of three surveys in total, which are:~A) Scale of Expectations Regarding Physical Activity for Children~B) Children's perception of family support regarding physical activity scale~C) Physical Activity Barriers Scale for Parents"
75764879|NCT04561167|Other|Cuspal reduction in MOD cavity in endodontically treated teeth|Not only the quality of endodontic treatment that affects the prognosis of the endodontically treated tooth, but the subsequent restorative treatment as well. Coverage, Endocrowns, Onlays, Inlays Restorations on Fracture Resistance of Endodontically Treated Molars, it was found that the worst results came to the inlay restorations and this was attributed to geometric form of preparation that exert a wedging force acting to split the tooth when under occlual stress however, onlay and full coverage direct the force along the long axis by overlaying the cusp tips and a portion of buccal and lingual surface thus opposing the wedging action created by internal design of restoration (Magne P and Belser C. et al 2003) That's why, choosing such a design as a comparator to the design of the cuspal reduction and further coverage (onlay) is crucial to show the importance of cuspal coverage for the indirect resin composite restoration in the endodontically treated teeth.
75614051|NCT04259476|Drug|Ketamine Hydrochloride|low dose perioperative ketamine infusion. and its effects on post-operative pain.
75315986|NCT05461989|Other|Hand Grip Strength|Hand grip strength will be measured using a hand dynamometer (Jamar, Sammons Preston, Rolyon, Bolingbrook, IL).
75315987|NCT05461989|Other|Arterial stiffness|Arterial stiffness will be evaluated using the pulse wave velocity (PWV) technique with the blood pressure holter-ABPM (Mobil-O-Graph, I.E.M., Stolberg, Germany) device. The measurement is made from the non-dominant arm based on the principle of blood pressure measurement with the appropriate cuff determined according to the arm diameter. After two consecutive measurements taken 30 seconds apart, the average of the measurement values will be recorded.
75315988|NCT04751357|Diagnostic Test|ECA-Test (Clot-Pro)|Thrombelastometric ECA-Test performed on Clot-Pro
75614052|NCT04177147|Other|Clinical decision support via alert tool|The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
75614053|NCT04255732|Device|extent of retinal area viewing Optos, Daytona, Optos PLC, Dunfermline, UK|Comparison of the extent of retinal periphery view between two wide field imaging devices.
75907168|NCT02835339|Drug|Magnesium sulfate 6g loading dose, 2g/hr infusion|
76072514|NCT03920709|Other|Blood sample and Nasal swabs (right an left) samples|"Nasal swabs (right and left) will be performed (FLOQSwabTM)~Blood samples of 20 mL EDTA will be taken in addition to the current care report"
75315989|NCT02106065|Behavioral|Education and Skill-Building Rehabilitation (ESBR)|ESBR intervention consists of four, 90-minute sessions over a 4-6 week period. These four sessions are supplemented with booster sessions at 3 and 9 months post-intervention. Each group session (10 or fewer participants) is attended either in-clinic or via video telehealth technology within the VAPAHCS.
75315990|NCT02106065|Other|Supplemental Education Materials|Participants randomized to the Usual Care (UC) group will receive supplemental educational materials related to aging and dementia.
75460868|NCT01845285|Device|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
75460869|NCT01845298|Drug|Rifampicin 600 mg|The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
75460870|NCT01845350|Other|M2 macrophage introduction|"Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~Intrathecal introduction of autologous M2 macrophages"
75460871|NCT01845363|Drug|Cefazolin used in antimicrobial prophylaxis|"Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by HPLC."
75460872|NCT01845376|Procedure|local anesthesia group|Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
75460873|NCT01845376|Procedure|spinal anesthesia group|Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
75460874|NCT01845376|Procedure|general anesthesia group|Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
75460875|NCT01845389|Device|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
75460876|NCT01845389|Device|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
76070686|NCT05952726|Other|Expiratory cycling change at different levels of pressure support ventilation|"Four different levels of expiratory cycling will be randomly applied at 3 different degrees of pressure support.~Three end-inspiratory and three end-expiratory occlusion manoeuvres will be carried out at the end of 10 minute steps of ventilation during each set value expiratory cycling and pressure support level.~Total study time will be about 120 minutes. Levels of pressure support wil be clinical pressure support ± 4 cmH2O; expiratory cycling percentages applied for each pressure support step will be 15%, 30%, 45% and 60% of peak inspiratory flow."
75460877|NCT01845402|Biological|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
76070687|NCT05950477|Diagnostic Test|Depression Questionnaires|Center of Epidemiological Studies-Depression Scale (CES-D) Patient Health Questionnaire (PHQ-9) Diabetes Treatment Satisfaction Questionnaire (DTSQ) Well-Being Index (WHO-5)
75460878|NCT01845415|Behavioral|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
75764880|NCT04561167|Other|No cuspal reduction in MOD cavity in endodontically treated teeth|In an invitro study done by (Ahmed Hamdy 2015) investigating the effect of Full The amount of lost internal tooth structure as well as the coronal hard tissue in an endodontically treated tooth is considered the main factors that make the tooth susceptible to biomechanical failure when compared to a vital tooth. (Guo J et al 2016) .
75460879|NCT01845415|Behavioral|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
75460880|NCT01845428|Drug|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
75460881|NCT01845454|Device|trūFreeze™ Spray Cryotherapy|The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
75460882|NCT01845480|Behavioral|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
75764881|NCT04557501|Diagnostic Test|PSMA PET/CT guided intensification of therapy|PSMA PET/CT prior to treatment.
75907169|NCT04473040|Drug|alpelisib|Alpelisib is provided as 50 mg and 200 mg film coated tablets as individual patient supply, packaged in bottles. Alpelisib will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. Alpelisib will be administered at a starting dose of 300 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.
75764882|NCT04557501|Other|Control Arm|Control - Treatment without PSMA PET/CT
76070688|NCT05945953|Other|Incentive spirometer as visual feedback|"Incentive spirometer as deep breathing then UE movement in sitting: Frequency: 2 sets of 10x Intensity: Up to tolerance (hold breath for 2-4 secs). Time: Twice a week Type: Deep breathing exercise UE movement: Gentle ROMs (5 reps)~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
75764883|NCT04555837|Drug|Alisertib|Given PO
76072515|NCT01849783|Drug|dexamethasone|Given PO
76072516|NCT01849783|Drug|cisplatin|Given IV
75460883|NCT01845493|Dietary Supplement|Alpha Sprout Homogenate|Alpha Sprout Homogenate
75460884|NCT01845493|Dietary Supplement|Sulforaphane Homogenate|Active
75460885|NCT01845506|Device|Cardiorespiratory monitor|Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.
75764884|NCT04555837|Biological|Pembrolizumab|Given IV
75764885|NCT04544124|Behavioral|Contingency management|Incentives will be provided for treatment attendance over a 12-week period.
75764886|NCT04541017|Procedure|Biospecimen Collection|Undergo blood sample collection
75764887|NCT04541017|Procedure|Computed Tomography|Undergo PET/CT or diagnostic CT
75764888|NCT04541017|Biological|Magrolimab|Given IV
75764889|NCT04541017|Biological|Mogamulizumab|Given IV
75764890|NCT04541017|Procedure|Positron Emission Tomography|Undergo PET/CT
75764891|NCT04541017|Procedure|Punch Biopsy|Undergo skin punch biopsy
75907170|NCT03695029|Drug|Tenofovir Alafenamide|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
75907171|NCT02259855|Drug|Tipranavir|
75907172|NCT02259855|Drug|Ritonavir|
75907173|NCT02259855|Drug|Pegylated interferon|
75907174|NCT02259855|Drug|Ribavirin|
75907175|NCT04465084|Other|Case|Battery of standardised and normalised tests evaluating different cognitive functions Experimental language tasks MRI
75315991|NCT05737329|Drug|Transdermal estradiol gel 0.1% 1.5mg/ day|Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg
75315992|NCT05737329|Drug|Transdermal estradiol gel 0.1% 2.0mg/ day|Estradiol gel 0.1% 2.0mg/ daily + Micronized Progesterone 200mg
75315993|NCT05267015|Procedure|Gingival coverage using coronally advanced flap and a connective tissue graft|A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using a subepithelial connective tissue graft
75764892|NCT04533438|Device|RhinAer Stylus|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session.
75764893|NCT04533438|Device|Sham|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
75907176|NCT04465084|Other|Withness|Experimental language tasks MRI
75907177|NCT02188212|Device|NobelProcera Crown Shaded Zirconia|
75315994|NCT05267015|Procedure|Gingival coverage using coronally advanced flap and platelet rich fibrin membranes|A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using platelet rich fibrin membranes
75315995|NCT00317941|Drug|Betaferon/Betaseron|250ug administrated with Betaject
75460886|NCT01845506|Device|Wireless pressure sensor|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
75315996|NCT00317941|Drug|Rebif|44ug administered with Rebiject II
75315997|NCT00317941|Drug|Betaferon/Betaseron|250ug administrated with Betaject light
76070689|NCT05945953|Other|Diaphragmatic breathing exercise (Mirror mediated therapy)|"Diaphragmatic breathing exercise (Mirror mediated therapy): In front of mirror deep breathing with UE movement in sitting: Frequency: 1 cycle of 10x Intensity: Up to tolerance. Time: 3 times per week. Type: Deep breathing exercise. UE movement: Gentle ROMs (5 reps).~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
75315998|NCT04346069|Other|PCIT (parent child interaction therapy)|Parent child interaction therapy is a treatment strategy that nurture parent child relationship and teach effective parenting strategies to decrease child non compliance behavior (BodifordMcNeil; Hembree-Kigin, 2010).Parent-Child Interaction Therapy (PCIT; Eyberg; Robinson, 1982 ; Zisser; Eyberg, 2008 ) is a manualized parent training intervention that has received substantial empirical support in the treatment of disruptive behavior across multiple reviews (e.g., Brestan; Eyberg, 1998 ; Gallagher, 2003 ; Thomas &amp; Zimmer-Gembeck, 2007 ). PCIT established strong relation among parenting, social learning, and attachment theories and proceeds.
75460887|NCT01845519|Behavioral|Tailored Email|Participants will receive tailored emails.
75460888|NCT01845519|Behavioral|Targeted Email|Participants will receive targeted emails.
76072517|NCT01849783|Drug|doxorubicin|Given IV
76072518|NCT01849783|Drug|cyclophosphamide|Given IV or PO
75907178|NCT03703063|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
75907179|NCT03703063|Drug|nab paclitaxel|Administered by intravenous infusion over 30-40 minutes.
75315999|NCT04751565|Other|Bleeding on Probing change reduction following peri-implant mucositis non surgical therapy|Statistically significant different in terms of Bleeding on Probing will be recorded between groups.
75460889|NCT01845532|Drug|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25~0.5% lidocaine, 0.125% bupivacaine)
75460890|NCT01845532|Drug|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
75460891|NCT01845545|Other|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
75460892|NCT01845558|Drug|Wobenzym® plus|
75907180|NCT03703063|Drug|Onivyde|Administered by intravenous infusion over 90 minutes.
75907181|NCT03703063|Drug|Leucovorin|Administered by intravenous infusion over 30 minutes.
75907182|NCT03703063|Drug|5-fu|Administered by intravenous infusion over 46 hours.
75907183|NCT04094337|Behavioral|Internet-assisted treatment|Internet-assisted treatment
75907184|NCT04450966|Behavioral|Computer-facilitated Screening and Brief Intervention|cSBI includes: 1) computer self-administered screening that adolescents complete prior to seeing their clinician, immediately followed by 2) computer-delivered brief psychoeducation on the health risks of substance use to prime patients for the clinician encounter, and 3) a Clinician Report Form with screen results and prompts that clinicians use to provide motivational interviewing-based individualized counseling during the visit.
75316000|NCT02277639|Device|CliniMACs device|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
75316001|NCT01790087|Drug|ANX-188 Therapeutic Dose|
75316002|NCT01790087|Drug|ANX-188 Supratherapeutic dose|
75316003|NCT01790087|Drug|Saline|
75316004|NCT01790087|Drug|Moxifloxacin|
75316005|NCT01791907|Behavioral|Structured education in carbohydrate counting|
75316006|NCT01791907|Behavioral|Structured education in healthy food choices and low glycemic index|
75316007|NCT05134207|Dietary Supplement|oral carbohydrate solution|Patients in the intervention group; Preop oral carbohydrate solution was ingested orally twice within 10 minutes, as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the surgery.
75460893|NCT01845558|Other|Placebo|
75460894|NCT01845584|Drug|NPB-01|
75460895|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
75460896|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
75460897|NCT01845623|Drug|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
76070690|NCT05939765|Drug|Antipsychotic|Participants will undergo a systematic neuropsychiatric assessement at regular intervals. Any change in medication, together with aggressive or dysfunctional behaviour will be continually recorded. The time period prior to the change in medication will be classified as control, the time after as case; therefore each patient becomes his own control.
76072453|NCT04146675|Device|TRICOT JERSEY SIMPLE|Short sleeve t-shirt : TRICOT JERSEY SIMPLE The comparator T-shirt has the same weight, the same appearance, and will be used by patients in the same way and under the same conditions as the T-shirt with ceramic fibers.
75764899|NCT04508088|Diagnostic Test|Coronal T1 weighted spin echo images|Coronal T1 weighted spin echo images will be obtained through the knee with a field of view of 16cm to include distal femoral and proximal tibial metaphyses.
75764900|NCT04508088|Diagnostic Test|Spin-lattice relaxation (T1)|Spin-lattice relaxation (T1) relaxometry acquisition consisting of seven fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
76072519|NCT01849783|Drug|etoposide|Given IV
75316008|NCT04239131|Other|Skin prick test|a Skin prick test is planned in all patients
75316009|NCT04750837|Procedure|debridement of the wound|The edges and the floor of the wound were firstly debrided, and any callosities around the wound were removed. This was repeated if needed when callosities around the wound reappeared. By this technique, the chronic wound was transformed into an acute one
75316010|NCT04750837|Biological|platelet rich plasma|Part of activated PRP was injected around the wound and under the base of the wound, while another portion of PRP was left over the floor of the wound and let to coagulate and form a gel.
75316011|NCT04750837|Procedure|conventional dressing|The wound was irrigated by normal saline, covered by vaseline gauze then sterile dressing. Repeated dressing every two days till 20 weeks, if the wound failed to heal at that time
75316012|NCT00332579|Drug|Naltrexone|daily
75316013|NCT00332579|Drug|Placebo|daily
75614054|NCT04255732|Device|extent of retinal area viewing Clarus, 500 Carl Zeiss, Meditec AG, Jena, Germany|Comparison of the extent of retinal periphery view between two wide field imaging devices.
75460898|NCT01845623|Drug|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
75460899|NCT01845623|Other|Placebo Concept 1|Placebo administered via the Concept 1 device.
75460900|NCT01845623|Other|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
75460901|NCT01845662|Other|Surgical or non-surgical management|Retrospective surgical (splenectomy) or non-surgical management (embolization or conservative management)
75460902|NCT01845675|Drug|temozolomide or dacarbazine-based chemotherapy, endostatin|
75460903|NCT01845701|Drug|Artesunate-Amodiaquine|"Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.~Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.~The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®)."
75460904|NCT01845701|Drug|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis[1-(7-chloro-4 quinolyl)-4- piperazinyl]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
75460905|NCT01845701|Drug|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
75460906|NCT01845714|Procedure|Corneal Cross Linking|
75460907|NCT01845714|Procedure|Corneal Cross Linking combined with topoguided PRK|
75460908|NCT01845727|Drug|Topical Amphotericin B at 3%|
75460909|NCT01845740|Drug|milatuzumab|Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
75460910|NCT01845740|Drug|Placebo|Placebo will be administered subcutaneously once weekly for 4 weeks.
75460911|NCT01845753|Other|Observation|Observation
75460912|NCT01845766|Other|exercise rehabilitation|
75460913|NCT01845779|Drug|DCF regimen|
75460914|NCT01845844|Drug|Ranibizumab 0.3mg/0.05cc|"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."
75614055|NCT04177459|Behavioral|Health promoting dialogue|Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
75614056|NCT04177459|Other|standard treatment / treatment as usual|Follow-up from primary and secondary health care, and from schools.
75764901|NCT04508088|Diagnostic Test|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at echo times of 20, 30, 40, and 50 ms using 32 signal averages per echo time with a TR of 2.5 s (total scan time = 5.4 minutes). Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
75764902|NCT04508088|Diagnostic Test|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and to perform immune studies. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). We will also evaluate molecular gene signatures from the blood samples that correlate with the previously described bone imaging phenotypes. At that point, the information will be used to develop a CyTOF panel to evaluate differences in immune cellular populations between CD patients with normal versus low BMD, and matched controls.
75460915|NCT01845857|Behavioral|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
75316015|NCT00318409|Drug|Bupropion|
76070691|NCT05937971|Other|plantar sensitivity training|"Plantar sensory training protocol:~Applying a moisturizing cream by washing the feet with warm water and drying them (before coming to the session)~Dynamic gastro-soleus stretching (20 sec, 5 reps, 2 min)~Plantar fascia stretch (20 sec, 5 reps, 2 min)~Picking up sheets with feet (10 reps, 2 min)~Pushing the small roller under the foot back and forth (10 reps, 2 min)~Holding the spiny proprioception ball on the plantar surface of the foot while sitting, moving it in anterior-posterior and circular directions (2x2.5 min=5 min)~Keeping the carpet pieces of different softness and texture on the plantar surface of the foot and moving them in anterior-posterior and circular directions (2x2.5 min=5 min) Soft tissue mobilizations applied to the soles of the feet by the physiotherapist (2 minutes)"
75316016|NCT00318409|Drug|Placebo|
75316017|NCT00333437|Drug|Mycophenolate mofetil|
76072454|NCT03022149|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
75764903|NCT04500392|Device|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min
76072455|NCT03022149|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
75316018|NCT04389307|Other|Electrical stimulation (IVES)|IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24 session treatment program of IVES.
75764904|NCT04500392|Device|Regular nasal cannula|Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
75764905|NCT04493203|Drug|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of Immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
75316019|NCT04389307|Other|Bladder Training|Bladder Training
75316020|NCT00334061|Device|Penumbra System|
75316021|NCT04129619|Drug|ORP-101|Oral tablet
75316022|NCT04129619|Drug|Placebo|Oral tablet
75316023|NCT00353119|Drug|Placebo comparator|Patients received placebo subcutaneously twice weekly
75316024|NCT00353119|Drug|Etanercept|Patients received etanercept 50 mg subcutaneously twice weekly
75316025|NCT00353431|Drug|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
75316026|NCT05266547|Device|OCT guided coronary intervention|patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group
75316027|NCT05073445|Behavioral|SDNN measurement|SDNN measurement during pediatric simulation
75316028|NCT01790789|Behavioral|Daily stress reduction program|Subjects will participate in activities of a daily stress reduction program.
75316029|NCT01790789|Other|Attention control|Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
75316030|NCT02983253|Other|blood sample|none, only laboratory tests on blood serum
75316031|NCT05266391|Other|subacromial corticosteroid injections|Patients with SAIS whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate).
75316032|NCT00353977|Biological|ALVAC-CMV (vCP260)|"ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.~Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.~Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)"
75316033|NCT00320281|Drug|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
75460916|NCT01845883|Procedure|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
75460917|NCT01845896|Behavioral|Training|
75460918|NCT01845909|Other|ECG and survey screening|
75460919|NCT01845922|Dietary Supplement|Low sodium diet|Low sodium diet
75460920|NCT01845935|Device|Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)|Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
75764906|NCT04493203|Drug|Axitinib|Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1-3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours)
76072520|NCT01849783|Drug|bortezomib|Given IV
76072521|NCT01849783|Drug|thalidomide|Given PO
76072522|NCT01849783|Drug|melphalan|Given IV
76072523|NCT01849783|Procedure|autologous stem cell transplant|
76070692|NCT05937971|Other|aerobic exercise training|Warm-up exercises; will consist of stretching exercises (20-30 s, 5 repetitions), breathing exercises (6-10 s, 5 repetitions) and range of motion exercises (8-10 s, 5 repetitions) for the whole body. Conventional exercises will include balance (10 s, 5 reps), coordination (5-10 s, 5 reps), stabilization (5-10 s, 5 reps) and strengthening exercises (8-10 s, 5 reps), specific to each patient. Aerobic exercise training was started at 40% of the maximum heart rate on the treadmill and gradually increased at three-week intervals (40% in weeks 1-3, 50% in weeks 4-6, 60% in weeks 7-9, and 70% in weeks 10-12). ) will be progressed. Cool-down exercises will include a gradual lowering of the treadmill speed (3 min) and ankle range of motion exercises. Plantar sensory training begins with a duration of 5 minutes and progresses from a sitting position to a standing position at three-week intervals (1-3 weeks 5 minutes, 4-6 weeks 10 minutes, 7-9 weeks 15 minutes, 10-12 weeks 20 minutes). will be.
75764907|NCT04491396|Behavioral|Gentle Yoga and Yogic Breathing|"Gentle Yoga (GY) postures can be done while seated on a chair (sometimes called Chair Yoga) and have been shown to benefit people with symptoms associated with cancer.12 However, Yoga is under-studied in the area of scleroderma. While most traditional Yoga postures can be practiced by anyone, people with scleroderma often have limited physical movement and can be prone to injury. Gentle Yoga postures are physically much easier to do than traditional Yoga and, thus, may be more accessible for SSc patients with musculoskeletal and other impairments. Gentle Yoga postures that are done while seated on a chair also combine easily with YB, but little is known about the specific benefits of the GY+YB combination (GYYB). Further study is needed to determine whether GYYB may be an effective strategy for improving QoL in SSc patients. The Yoga intervention to be used in this study specifically involves GY done while seated in combination with YB."
75764908|NCT04482933|Drug|Biological G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
75764909|NCT04452344|Drug|opioid-containing analgesic|hydrocodone/ acetaminophen combination product
75907185|NCT02183844|Behavioral|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
75907186|NCT03564249|Device|MiniCap|The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
76072456|NCT04194333|Procedure|Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm|Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
75907187|NCT03702985|Radiation|Radiation|Pelvic Radiation: 50Gy/25Fx
76072457|NCT04023279|Other|TENS|100 Hz and 100 usec for 20 minutes
75764910|NCT04452344|Drug|two over-the-counter analgesics|combination of over-the-counter analgesics (ibuprofen/acetaminophen)
76072458|NCT04023279|Other|Myofascial therapy|Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding of myofascial release therapy
76072459|NCT04023123|Other|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
75764911|NCT04425031|Drug|Oxygen|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
75907188|NCT03702985|Drug|Capecitabine|625mg/m2 bid Monday-Friday per week
75614057|NCT00970281|Drug|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
75614058|NCT00970281|Drug|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
75614059|NCT00607438|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
75764912|NCT04425031|Drug|Oxygen|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
75764913|NCT04408963|Biological|VRC-HIVMAB0102-00-AB|The VRC-HIVMAB0102-00-AB (CAP256V2LS) broadly neutralizing monoclonal antibody (bNAb) targets the V1V2 region of the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
75907189|NCT03702985|Drug|Irinotecan|80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
75907190|NCT03702985|Drug|Amifostine|400mg/m2 per week
75907191|NCT02256930|Drug|M518101|
75907192|NCT02256930|Drug|M518101 Vehicle|
75907193|NCT02256930|Other|Sodium lauryl sulfate|
75907194|NCT02256930|Other|Saline|
75907195|NCT04056351|Diagnostic Test|Post-Operative (OP) Computer Tomography (CT)|Post-OP CT of the treated shoulder
75907196|NCT04056351|Other|Questionnaires on patient activity and comorbidities|"Shoulder activity scale (Marx)~Parker Mobility Scale~Barthel index~Charlson Comorbidity Score"
75907197|NCT04056351|Other|Grip strength measurement|Grip strength will be measured using a CE marked hydraulic hand dynamometer device.
75907198|NCT04056351|Other|Non-invasive shoulder activity tracking usinig wearable sensors|Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
75907199|NCT02183922|Dietary Supplement|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
75907200|NCT02183922|Dietary Supplement|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
75316034|NCT00320281|Other|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
75614060|NCT00607438|Drug|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
75614061|NCT00643045|Drug|Safinamide|
75614062|NCT00643045|Drug|Safinamide|
75614063|NCT00643045|Drug|Placebo|
75460921|NCT01845948|Behavioral|parental training programme|In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.
75907201|NCT02183922|Dietary Supplement|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
75316035|NCT01792375|Procedure|Concurrent membrane sweeping with Dinoprostone|"Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix."
75316036|NCT01792375|Drug|10mg Dinoprostone vaginal insert|"For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening"
75316037|NCT02108821|Biological|Fecal Microbiota Transplantation (FMT)|The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
75614064|NCT04203706|Other|Neurofunctional imaging|Subjects will be submitted to a functional neuroimaging scanning procedure
75316038|NCT02108977|Other|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
75316039|NCT02108977|Other|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
75460922|NCT01845948|Behavioral|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
75460923|NCT01846000|Procedure|low-level laser treatment|A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
75460924|NCT01846013|Behavioral|Stand|Stand at least half of the workday at work.
75460925|NCT01846013|Behavioral|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
75460926|NCT01846013|Behavioral|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
75614065|NCT02670733|Procedure|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
75614066|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
75614067|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
75907202|NCT03699787|Other|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
75907203|NCT03564405|Device|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
75907204|NCT03702829|Drug|Inotersen|Open Label Study
75316040|NCT01392326|Drug|Secukinumab (75 mg)|Secukinumab (75 mg)
75316041|NCT01392326|Drug|Secukinumab (150 mg)|Secukinumab (150 mg)
75316042|NCT01392326|Drug|Placebo Comparator|Placebo Comparator
75316043|NCT04944901|Drug|SB-121|SB-121 is a formulation of L. reuteri
75316044|NCT04944901|Drug|Placebo|Placebo oral formulation
75316045|NCT04890769|Device|Moisture sensor wound dressing|Clinical procedure for change of wound dressing
75460927|NCT01846026|Drug|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
75460928|NCT01846026|Drug|placebo|
75460929|NCT01846078|Device|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
75460930|NCT01846117|Dietary Supplement|secoisolariciresinol diglucoside, vitamin D|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
75460931|NCT01846130|Dietary Supplement|Leucine|
75460932|NCT01846130|Behavioral|Exercise|
75460933|NCT01846130|Dietary Supplement|Whey protein|
75460934|NCT01846143|Biological|pBCAR3-phosphopeptide|
75614068|NCT02676427|Procedure|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
75614069|NCT03747627|Diagnostic Test|Genetic profiling|All participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen)
75614070|NCT05275465|Drug|HH-006|Different dose levels of HH-006
75614071|NCT05275465|Drug|Placebo|Different dose levels of placebo
75614072|NCT02862639|Device|Experimental group|patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
75614073|NCT02862639|Device|control group|patient receive intra articular injection (hip joint) of corticosteroid alone
75614074|NCT04177069|Dietary Supplement|Visucomplex Plus|capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.
75614075|NCT03746301|Drug|Rivaroxaban(Xarelto,BAY 59-7939)|10mg, 15mg and 20 mg film-coated tablets
75614076|NCT00925990|Drug|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
75614077|NCT00925990|Drug|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
75316046|NCT00320671|Drug|Aripiprazole|The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
75316047|NCT00320671|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
75460935|NCT01846143|Biological|pIRS2-phosphopeptide|
75614078|NCT00925990|Drug|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
75614079|NCT02670655|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
75614080|NCT02670655|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
75614081|NCT02670655|Drug|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
75764914|NCT04375904|Radiation|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) delivered in 8 fractions of 7.5 Gy. OAR constraints must be respected but a minimum dose coverage to 95% of the PTV will be allowed down to 75% and a minimum dose to 99% of the GTV allowed at 75%. Respiratory monitoring/active respiratory management will be used. Plans will be created and delivered using photon beams with energies between 6-10 MV.
75764915|NCT04375631|Drug|Cladribine|Given IV
76070693|NCT05937295|Drug|Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination."
76070694|NCT05936346|Dietary Supplement|Salvia haenkei 175mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
76070695|NCT05936346|Dietary Supplement|Salvia haenkei 350mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
76070696|NCT05931770|Procedure|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by the child. will be determined by children preference
75764916|NCT04375631|Drug|Cyclophosphamide|Given IV
75764917|NCT04375631|Drug|Cyclosporine|Given IV then PO
75316048|NCT00320749|Drug|Capecitabine|Will be give on days 8-21
75316049|NCT00320749|Drug|Docetaxel|Will be given on days 1 and 8,
75316050|NCT00320749|Drug|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
75316051|NCT00322231|Biological|zoster vaccine live (ZOSTAVAX™)|1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
75764918|NCT04375631|Drug|Cytarabine|Given IV
75764919|NCT04375631|Biological|Filgrastim|Given SC
75764920|NCT04375631|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
76070697|NCT05931770|Procedure|Parent (mother or father) selection according to parents' preference|Accompanying parentwho will accompany during the perioperative period will be determined by the parents. to be determined by
76070698|NCT05929651|Biological|MenACYW conjugate vaccine|Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection
76070699|NCT05928806|Drug|Botensilimab|Botensilimab 75mg IV
76070700|NCT05928806|Drug|Balstilimab|Balstilimab 450mg IV
75316052|NCT00322231|Biological|Comparator: Placebo|1 dose 0.65 mL/dose subcutaneous injection of placebo.
75460936|NCT01846143|Biological|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
75460937|NCT01846156|Drug|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics & Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
75460938|NCT01846169|Behavioral|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
75460939|NCT01846247|Other|Standard Care + VEM|Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
75460940|NCT01846247|Other|Standard care|
75460941|NCT01846273|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab
75614082|NCT02670655|Device|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
75764921|NCT04375631|Drug|Mitoxantrone|Given IV
75764922|NCT04375631|Drug|Mycophenolate Mofetil|Given IV or PO
75764923|NCT04375631|Drug|Mycophenolate Sodium|Given PO
75764924|NCT04375631|Radiation|Total-Body Irradiation|Undergo TBI
75764925|NCT04375631|Drug|Idarubicin|Given IV
75764926|NCT04375631|Drug|Fludarabine|Given IV
75764927|NCT04375631|Drug|Cytarabine|Given IV
75764928|NCT04375631|Procedure|Multigated Acquisition Scan|Undergo MUGA
75764929|NCT04375631|Procedure|Echocardiography|Undergo ECHO
76070701|NCT05928806|Drug|Ipilimumab|Ipilimumab 1mg/kg IV
75764930|NCT04375631|Procedure|X-Ray Imaging|Undergo x-ray
76070702|NCT05928806|Drug|Nivolumab|Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
75614083|NCT02670655|Device|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
75614084|NCT04176991|Biological|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
76070703|NCT05928585|Drug|HIB210|Experimental monoclonal antibody
76070704|NCT05928585|Drug|Placebo|Placebo
76070705|NCT05926479|Other|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
76070706|NCT05926479|Other|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
76070707|NCT05926479|Other|Reliability|The reliability of the materials will be tested with Cronbach alpha.
76070708|NCT05926336|Drug|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
76070709|NCT05926336|Drug|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
76070710|NCT05925621|Drug|Lecanemab|Observational study
75316053|NCT00354913|Drug|hydroxyurea|Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
75460942|NCT01846273|Drug|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
75460943|NCT01846273|Drug|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
75460944|NCT01846312|Other|No treatment given|The participants will not receive any treatment.
75614085|NCT04176991|Biological|Placebo|Placebo Comparator
75614086|NCT03744351|Other|Biological Samples|Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).
75614087|NCT03744351|Other|Biological Samples|"Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal."
76070711|NCT05921591|Drug|IRL201104|Lyophilised powder for reconstitution for IV dosing
76070712|NCT05921591|Drug|Placebo|Matching placebo for IRL201104
76070713|NCT05920577|Other|exergames and resistance training|"In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software Nintendo Switch Sports will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training."
76070714|NCT05920577|Other|Resistance training|The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
75460945|NCT01846325|Dietary Supplement|vitamin E|
75460946|NCT01846325|Dietary Supplement|DHA|
75614088|NCT03744351|Other|Biological Samples|The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.
75764931|NCT04375631|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
75764932|NCT04375631|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
75764933|NCT04340193|Drug|nivolumab|Specified dose on specified days
75460947|NCT01846325|Other|placebo|
75460948|NCT01846338|Dietary Supplement|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
75764934|NCT04340193|Drug|ipilimumab|Specified dose on specified days
75764935|NCT04340193|Procedure|TACE|TACE (Trans-arterial ChemoEmbolization)
75764936|NCT04336982|Drug|CC-90009|Injection
75764937|NCT04336982|Drug|Venetoclax|Tablet
75764938|NCT04336982|Drug|Azacitidine|Injection
75764939|NCT04336982|Drug|Gilteritinib|Tablet
75764940|NCT04333576|Drug|Elagolix|Tablet:Oral
75316054|NCT00354913|Drug|imatinib mesylate|"Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.~Dose for Imatinib:~Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.~If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately."
75316055|NCT01432262|Biological|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
75316056|NCT01432262|Biological|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
75316057|NCT00322309|Other|Placebo|Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84
75316058|NCT00322309|Drug|Mirtazapine|Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
75316059|NCT04751149|Procedure|Removal of Urinary Catheter|Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
75764941|NCT04333576|Drug|Placebo|Tablet:Oral
75764942|NCT04333576|Drug|Combined Oral Contraceptive|Tablet:Oral
75764943|NCT04327154|Device|TISSIUM™ Nerve Coaptation Device|Placement of the TISSIUM™ Nerve Coaptation Device on repair site to achieve an end-to-end nerve coaptation.
75614089|NCT03744351|Other|Biological Samples|"Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal"
75764944|NCT04326010|Device|Surgery|THA surgery
75460949|NCT01846364|Dietary Supplement|Diindolylmethane (DIM)|300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
75460950|NCT01846377|Behavioral|G4H-Diab-Nano|The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
75460951|NCT01846403|Device|Semi-quantitative urine pregnancy test|
75614090|NCT01131078|Drug|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
75614091|NCT01131078|Drug|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m^2 twice daily (Day 2 to 15) or as 650 mg/m^2 twice daily on Days 1 to 21.
75764945|NCT04324463|Drug|Colchicine|oral medication
75764946|NCT04324463|Drug|Interferon-Beta|subcutaneous injection
76072524|NCT01611883|Drug|Ezetimibe|10 mg oral dose once daily for 24 weeks
75460952|NCT01846429|Drug|Sodium Bicarbonate|Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
75460953|NCT01846468|Drug|LHW090|1 mg, 12.5 mg, 100 mg capsules
75460954|NCT01846468|Drug|Placebo|Matching placebo capsules
75460955|NCT01846520|Other|educational intervention|Receive FCPCI home education sessions
75460956|NCT01846520|Behavioral|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
75614092|NCT01131078|Drug|Irinotecan|Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
75460957|NCT01846520|Procedure|quality-of-life assessment|Ancillary studies
75460958|NCT01846520|Other|questionnaire administration|Ancillary studies
75614093|NCT03738501|Other|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
75614094|NCT03738501|Other|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
75614095|NCT04180501|Combination Product|SRS sequential sintilimab|The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
75764947|NCT04324463|Drug|Aspirin|oral medication
75764948|NCT04324463|Drug|Rivaroxaban|oral medication
75764949|NCT04297137|Dietary Supplement|Protein ingestion|Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
75764950|NCT04291079|Biological|SRK-181|anti-latent TGFβ1 monoclonal antibody
75764951|NCT04291079|Biological|anti-PD-(L)1 antibody therapy|approved anti-PD-(L)1 antibody therapy for each tumor type
75764952|NCT04278989|Drug|Anti-tumor B|1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).
75764953|NCT04278989|Drug|Placebos|Placebos taken seven to 28 days (dependent on scheduled surgery).
75764954|NCT04267393|Drug|BMS-986263|Specified dose on specified days
75764955|NCT04267393|Other|Placebo|Specified dose on specified days
75907205|NCT03064984|Other|CBS eyedrops|CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
75907206|NCT03064984|Other|PBS eyedrops|PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
75907207|NCT02184078|Drug|Nevirapine|
75764956|NCT04259762|Behavioral|Breast, Colorectal, and Cervical Cancer Screening Interventions|Adult men and women will receive age- and gender-specific interventions. Women age 50-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 50-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The 4-week interventions, delivered once a week, will consist of educational sessions that discuss cancer-specific information (i.e., breast, colorectal, and cervical cancer): breast (colorectal, cervical) cancer myths and facts, risk factors and symptoms, screening, and review/action plan. The educational sessions will be complemented by cancer-specific small media (brochure).
76070715|NCT05916677|Other|Virtual Reality-training in Theory of Mind|"Two social scenarios will be used in a virtual environement. Experimenter and subject participate in the scenario as friends of the main character, Nicolas. During the training session, experimenter asks structured questions about participant's awareness of a mental state. In the case of a wrong answer, a feedback-correction is provided via the avatar's thought bubbles. The participant has access to all avatars thought bubbles. In this way, he is able to compare the desires, beliefs or false beliefs of each story character.~Participants included in this condition will also have an eye-tracking assessment before and after the training procedure."
75907208|NCT02184078|Drug|Rifabutin|
75907209|NCT03702673|Drug|K-877 CR Tablet A|K-877 Controlled Release Tablet A
75907210|NCT03702673|Drug|K-877 CR Tablet B|K-877 Controlled Release Tablet B
75907211|NCT03702673|Drug|K-877 CR Tablet E|K-877 Controlled Release Tablet E
75907212|NCT03702673|Drug|K-877 IR Tablet|K-877 Immediate Release Tablet
76070716|NCT05916677|Other|Traditional training in Theory of Mind|The same two social scenarios are presented to the participant in a story-telling form. Participant has access to thought bubbles via an illustrated book. These trainings will take place in the same number of sessions and took place for a duration equivalent to those used in low immersion Virtual Reality mode. Each training session (EFB, BE, SOFB, ERA, FP, EFP) will be illustrated via visual aids taken from screenshots of the two virtual environments and the target protagonists.
76070717|NCT05916625|Other|neuropsychological assessment|a consultation to assess cognitive and psycho-behavioral functions with questionnaires
76070718|NCT05916625|Other|biological sample|10 mL intravenous whole blood collection in EDTA tube
76070719|NCT05916625|Procedure|medical imagery|Pet scan with the specific radioligand [11C]SB207145 and MRI
75907213|NCT03694951|Behavioral|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (i.e., action planning and coping planning) to reduce sedentary behaviour.
75907214|NCT04323436|Drug|Spartalizumab|Concentrate for solution for infusion
75316060|NCT04407728|Other|early ultrasound screening|"Women whose fetus is at high risk of congenital heart disease at the end of the 1st trimester screening ultrasound (EchoT1), will benefit from an early heart-centered morphological ultrasound (EchoMorpho-T1) by a referring sonographer between 11 and 14 SA +/- an early fetal cardiac ultrasound (EchoCoeur-T1) between 11 and 15 SA by a cardio-paediatrician in case of EchoMorpho-T1 abnormality.~The results of the early morphological and cardiac ultrasounds will be compared with those of the 2nd trimester ultrasound at 18-22SA (EchoMorpho-T2) and +/- of the fetal cardiac ultrasound between 18SA and 24SA (Gold standard) or, failing this, with the anatomopathological examination when it is available if a medical termination of pregnancy took place before the EchoMorpho-T2."
75907215|NCT04323436|Drug|Capmatinib|Film-coated tablet
75907216|NCT04323436|Drug|spartalizumab placebo|dextrose 5% in water (D5W) for infusion
75907217|NCT03694873|Drug|Tramadol Hydrochloride|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
75907218|NCT03694873|Drug|Celecoxib 200mg|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
75907219|NCT02188446|Behavioral|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
75907220|NCT02191020|Drug|Total glucosides of paeony & Acitretin Capsules|
76070720|NCT05915390|Dietary Supplement|walnuts|walnuts will provide 15% of the total energy
76070721|NCT05915390|Dietary Supplement|Habitual diet|continue with habitual diet and abstain from walnuts
75907221|NCT02191020|Drug|Acitretin Capsules|
75907222|NCT02832063|Biological|B244|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
75907223|NCT02832063|Biological|Placebo|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
75907224|NCT02188524|Other|Exercise|Tai Chi and Compensatory Stepping
75907225|NCT03694717|Drug|Saline Solution for Injection|The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
75907226|NCT02184234|Drug|Antistax film coated tablets|
76070722|NCT05914688|Drug|LY3209590 (Formulation 1)|Administered SC.
76070723|NCT05914688|Drug|LY3209590 (Formulation 2)|Administered SC.
76070724|NCT05912062|Drug|Trastuzumab (neoadjuvant)|Trastuzumab loading dose at 8mg/kg at day 1 followed by Trastuzumab at 6mg/kg in a 21-day cycle for six cycles
76070725|NCT05912062|Drug|Pertuzumab (neoadjuvant)|Pertuzumab loading dose at 840mg at day 1 followed by Pertuzumab at 420mg in a 21-day cycle for six cycles
75316061|NCT04046744|Procedure|Axillary brachial plexus block with a long-acting local anesthetic|axillary block with 15-30 ml Ropivacaine 0,5%.
75460959|NCT01846559|Biological|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
75460960|NCT01846559|Drug|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
75460961|NCT01846559|Drug|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
75460962|NCT01846585|Behavioral|Arousal Based Therapy for Insomnia|Intervention includes education about sleep and a desensitization technique to reduce sleep interfering arousal
75460963|NCT01846585|Behavioral|Cognitive Behavioral Therapy for Insomnia|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
75460964|NCT01846637|Procedure|laparoscopic sleeve gastrectomy|
75764957|NCT04253106|Genetic|Liquid biopsies (blood, gastric fluid).|Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.
75460965|NCT01846650|Drug|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
75460966|NCT01846650|Drug|XELODA|Single oral XELODA 2000mg qd
75764958|NCT04251416|Drug|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
75764959|NCT04236908|Drug|NSAIDS|Naproxen 500mg by mouth twice a day as needed.
76070726|NCT05912062|Drug|Paclitaxel (neoadjuvant)|Paclitaxel starting at day 8 at 80mg/m2, days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks
75316062|NCT04046744|Procedure|Axillary brachial plexus block with a short-acting local anesthetic + Analgesic block at the elbow with a long-acting local anesthetic|axillary block with 15-30 ml Lidocaine 1,5% + radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%.
75316063|NCT04046744|Drug|Ropivacaine|axillary block with 15-30 ml Ropivacaine 0,5%
75316064|NCT04046744|Drug|Ropivacaine|radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%
75460967|NCT01846676|Behavioral|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
75764960|NCT04236908|Device|Battlefield Acupuncture|"Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men).~Battlefield acupuncture utilizes up to 10 ASP acupuncture needles (5 in each ear). The Battlefield Acupuncture points include: cingulate gyrus, thalamus, omega-2, point zero, and shen men. The semi-permanent needles are left in place and typically stay in place for 2-7 days. Needles will usually fall out on their own, can be removed by the patient or the patient can call study staff and come in for removal if desired."
75460968|NCT01846676|Other|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
75460969|NCT01846689|Drug|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
75764961|NCT04236908|Device|GV26 with manual tonification|"Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle).~The protocol for using GV26 is as follows: With the patient in a seated position the acupuncturist places a 40mm needle in the acupuncture point GV26 (located on the philtrum, on the anterior midline, at the junction of the upper 1/3 and lower 2/3 of the distance from the nose to the margin of the upper lip). The acupuncturist then rapidly rotates the needle at the handle clockwise and counterclockwise (known as manual tonification) for 20-40 seconds at a time. The patient then stands up and assesses their pain. This will be performed up to 6 cycles. If a patient is unable to sit or stand, this may also be performed in a supine position with the patient attempting to sit or stand every 20-40 seconds."
76070727|NCT05905471|Other|Interview|Interview study
75614096|NCT04286061|Other|Assisted soft tissue mobilization|It will be done for 60 seconds, making a total of 30 strokes with the tool in the longitudinal direction to the muscle fibers. The physiotherapist will previously apply some massage cream to the area to be treated (adductor musculature) so that the tool slides at a 45º angle. Landslides will be made from the femoral condyle to the groin, and vice versa, exerting a pressure with the instrument of 3 over 10 on the analog visual scale that the subject feels
75614097|NCT02670499|Device|CPM|Used to aid in recovery from TKR
75614098|NCT02670499|Device|GAPFLEX|Used to aid in the recovery of TKR
75316065|NCT04046744|Drug|Lidocaine|axillary block with 15-30 ml Lidocaine 1,5%
75614099|NCT04180345|Other|Psychometric validation of the questionnaire|"Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)"
75614100|NCT03709017|Drug|Ponatinib|Iclusig 45mg, 15mg
75764962|NCT04231760|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
75764963|NCT04231760|Drug|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
76070728|NCT05904990|Device|High Intensity Laser|High Intensity Laser
75316066|NCT01792453|Other|Spring water|
75316067|NCT03025646|Other|Mental Health care services & home based training|"From day 0 of the study period we will initiate setting up the intervention in two schools, which will include two components:~Implementing mental health care services at schools targeting the mothers diagnosed as having depression who have consented to participate in the study (intervention mother).~Psychologists will provide counseling session over 4-6 months period. Every month a psychiatrist will visit each school for reviewing the records of the mothers and mothers will be referred to the National Institute of Mental Health (NIMH) if necessary~Organizing training sessions of the intervention mothers for supporting enhanced child care at home.~Organizing training of the intervention mothers by special educator through a parental training module in the schools. Special educator will conduct refresher training at home every month."
75614101|NCT02671903|Device|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
76070729|NCT05904236|Drug|Treatment with ICVB-1042 administered intravenously|Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
76070730|NCT05904028|Drug|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
76070731|NCT05904028|Device|Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule|Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
75460970|NCT01846715|Biological|Implantation of SRC|
75764964|NCT04225117|Drug|enfortumab vedotin|intravenous (IV) infusion
75764965|NCT04225117|Drug|pembrolizumab|IV infusion
75764968|NCT04200937|Device|Tactra Malleable|The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.
75764969|NCT04200937|Device|Spectra Penile Prothesis|The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.
75764970|NCT04200937|Device|AMS Ambicor|The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.
75907227|NCT03694639|Other|ganglion impar block|CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected
76070732|NCT05902234|Behavioral|interdiciplinary treatment|Normal interdiciplinary treatment path
75614102|NCT01167582|Biological|Red blood cell transfusion|Liberal versus restrictive transfusion
75614103|NCT03695445|Drug|Peripheral administration of Norepinephrine|Systematic follow-up of complications from peripheral administration of Norepinephrine
75907228|NCT03564327|Procedure|Wide antrum circle ablation|As standard hospital policy
75614104|NCT04204551|Behavioral|high-intensity interval training (HIIT)|Two 12-week HIIT cycles will be divided with 3 months of break. Each HIIT cycle will consist of three 1-hour training sessions weekly. Each 1-hour training session will consist of 10-minutes warm-up (at slow voluntary speed), 40-minutes of interval exercise and 10-minutes cool-down phase. The interval exercise part will consist of 10 sets of 4 minutes interval including 2-minutes cycling at ≥ 60 [rpm], but preferably at 80-90 [rpm] (fast phase of interval) and 2-minutes cycling at ≤ 60 [rpm] (slow phase of interval). The training will be performed on a stationary cycle ergometer (MONARK, Ergomedic 874E, Sweden). The heart rate (HR, [bpm]) will be measured by Polar system (Polar, Finland). The patients will pedal on the cycloergometer at 60%-80% of their individualized HRmax.
75907229|NCT03564327|Procedure|External electric cardioversion|Three attempts (200-250 joules)
76070733|NCT05900453|Other|Clinical decision support (CDS) tool|"The web-based clinical decision support (CDS) tool uses patient information (e.g., age, sex, BMI, perioperative status) to create personalized predictions of recovery following knee replacement. The CDS tool predicts range of motion, physical function, and pain recovery. Clinicians can use these predictions to (1) inform patients of their expected prognosis, (2) monitor patients' recovery against their predicted recovery, and (3) tailor treatments according to individual patients' needs.~Clinicians were provided with basic training for how to use the CDS tool, and were given examples of how to integrate it into clinical care. However, the CDS tool did not dictate any treatment decisions; clinicians were free to use the CDS tool at their discretion to inform decision making."
76072525|NCT01611883|Drug|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks.
76072526|NCT04170517|Diagnostic Test|Measurement of serum progesterone on the day of FET|Measurement of serum progesterone on the day of FET
75316068|NCT04750993|Diagnostic Test|musculoskeletal ultrasonography|The presence of subclinic synovitis findings in the hand joints was evaluated with musculoskeletal ultrasonography.
75316069|NCT01793857|Other|Data collection|Paper questionnaire
75316070|NCT01410890|Biological|alglucosidase alfa|Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
75316071|NCT01431950|Drug|fluticasone furoate|Inhaled corticosteroid
75316072|NCT01431950|Drug|albuterol/salbutamol|Provided as rescue relief of asthma symptoms
75460971|NCT01846767|Other|Oral glucose breath test|Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton & Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
75460972|NCT01846780|Procedure|PTA & stenting|PTA & stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
75460973|NCT01846806|Other|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
75460974|NCT01846832|Drug|TMC435|150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
75316073|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|0.1 mL, Intradermal (ID)
75316074|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|0.1 mL, Intradermal (ID)
75316075|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
75316076|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (High-dose)|0.5 mL, Intramuscular (IM)
75316077|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
75316078|NCT01431716|Drug|EFI/ACT-385781A|
75316079|NCT00550953|Drug|telmisartan+amlodipine|
75316080|NCT00550953|Drug|telmisartan|
75316081|NCT00322465|Drug|Tinidazole|2 gm single dose (4 tablets orally at 500 mg each).
75764971|NCT04199741|Drug|89Zr-DFO-SC16.56|Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
75907230|NCT05014854|Device|Usage of the SensoGrip-System comprised of the SensoGrip pen and a tablet app.|Intervention consists of the usage of the SensoGrip-System in at least 6 and up to 8 therapy session together with the participating child. It is assumed that the standard frequency of therapy sessions is once a week, resuming in a span of 6-8 weeks. 10 minutes of every therapy session during the intervention phase must involve the application of the SensoGrip-System. Sample exercises are made available, therapists can freely choose which exercises are used.
75614105|NCT04204551|Behavioral|conventional physical therapy|Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
75907231|NCT04476199|Combination Product|Venetoclax and Decitabine|The prognosis of acute myeloid leukemia (AML) patients aged over 60 years is poor and allogeneic stem cell transplantation (allo-SCT) is the only curative option.The association VEN-DEC is a promising combination therapy for AML elderly patients who are fit and eligible for allo-SCT.
75907232|NCT02188680|Other|Low FODMAPS diet|FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
75907233|NCT03702595|Other|Hip flexors stretching protocol|Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
75907234|NCT02191098|Drug|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
75460975|NCT01846832|Drug|Pegylated interferon alfa-2a (PegIFNα-2a)|180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
75907235|NCT04050319|Diagnostic Test|Screening and diagnosis if injured|physical therapy
75907236|NCT02188758|Other|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
75907237|NCT02030340|Procedure|lower urinary tract dysfunction|Urodynamic investigation with a double (two systems: air-charged and water filled) catheter system
75907238|NCT02191176|Drug|Dextromethorphan syrup - low dose|
75907239|NCT02191176|Drug|Dextromethorphan syrup - high dose|
75907240|NCT02191176|Drug|Placebo|
75907241|NCT02191254|Drug|Antistax®|
75907242|NCT02191254|Drug|Placebo|
75907243|NCT02184312|Drug|Nevirapine XR low dose|
75907244|NCT02184312|Drug|Nevirapine XR medium dose|
75614106|NCT04177303|Drug|Metformin|Participants will be randomized to metformin 2000 mg
75614107|NCT04177303|Drug|Placebo|Participants will be randomized to placebo
75614108|NCT04177225|Procedure|Trans thoracic Ultrasound Examination|Ultrasound examination of cardiac function before and after induction of general anesthesia.
75764972|NCT04199741|Drug|SC16.56, Phase I, Cohort 2|7.5mg
75764973|NCT04199741|Drug|SC16.56, Phase I, Cohort 3|22.5mg
75764974|NCT04199741|Drug|SC16.56, Phase II|Dose for Phase II will be determined by results from Phase I.
75907245|NCT02184312|Drug|Nevirapine XR high dose|
75907246|NCT02184312|Drug|Nevirapine (VIRAMUNE®)|
75907247|NCT02184390|Other|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
75316082|NCT00322465|Other|Placebo|Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.
75316083|NCT00322465|Drug|Doxycycline|100 mg orally, twice daily for 7 days.
75316084|NCT00322465|Drug|Azithromycin|1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
75460976|NCT01846832|Drug|Ribavirin (RBV)|1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is < 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is > or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
75460977|NCT01846845|Device|Conventional Prosthetic Transfemoral Socket System|Conventional transfemoral may include an ischial containment socket, a pin suspension socket, and/or suction suspension socket
75614109|NCT04177225|Other|Intravenous fluid administration|Intravenous fluids will be administered as a bolus in response to standard clinical indications
75614110|NCT01167426|Drug|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
75614111|NCT01167426|Drug|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
75614112|NCT04091035|Other|To describe the incidence of disease and evaluate risk factors|Se above
75764975|NCT04194437|Device|OCS Liver System|The OCS Liver System will be used to preserve, optimize and assess livers from DCD donors.
76072527|NCT01848457|Drug|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 & 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 & 2 of treatment Cycles 1 & 2 (Treatment Arms 1, 3) OR Cycles 3 & 4 (Treatment Arms 2, 4)
75907248|NCT02184468|Other|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
75907249|NCT02188914|Radiation|Positron emission tomography scan|
75907250|NCT02188914|Other|Magnetic resonance imaging|
75907251|NCT04050241|Device|Glidescope intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Glidescope videolaryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
75460978|NCT01846845|Device|Novel Prosthetic transfemoral socket system|Prosthetic socket that incorporates lower socket trim-lines and transfemoral vacuum suspension
76070734|NCT05897905|Behavioral|Personalised, holistic follow-up appointments underpinned by self determination theory|"Appointment 1 (two weeks after discharge):~Address participants knowledge gaps as regards their stroke, medication and secondary prevention.~Detailed biopsychosocial review.~Understand participant priorities and jointly set goals.~Agreeing onward referrals if needed.~Written summary sent to GP with copy to participant.~Appointment 2 (six weeks):~Review priorities identified in post stroke review checklist.~Review goals and plans from first appointment.~Address any new or persistent information gaps.~Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being.~Agreeing onward referrals and action plan.~Written summary and plan sent to GP."
76070735|NCT05897099|Behavioral|Comprehensive Tele-harm Reduction|Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
75460979|NCT01846910|Behavioral|Tooth Whitening|1. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
75460980|NCT01846910|Behavioral|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
75460981|NCT01846923|Biological|PCV13|
75460982|NCT01846936|Procedure|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
75460983|NCT01846936|Procedure|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation."
75460984|NCT01846936|Procedure|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
75460985|NCT01846962|Drug|Budesonide|The administered dose of topical steroid was 400mcg or 800mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
75614113|NCT04204785|Behavioral|Noise Reduction Education|OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
75614114|NCT04286919|Behavioral|A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students|A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
75764977|NCT04186221|Device|OCS Liver System|OCS Liver System for preserving and assessing donor livers for transplantation
75614115|NCT04090333|Other|Standard withdrawal therapy|All painkillers are abruptly stopped for a 2 months period.
75614116|NCT04089475|Device|Dermoscope|Dermoscopy is a noninvasive diagnostic tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic clinical dermatology and microscopic dermatopathology.
75614117|NCT02862873|Procedure|Spinal anaesthesia|
75614118|NCT02862873|Drug|Ondansetron|
76070736|NCT05897099|Behavioral|Off-site Linkage to HIV Prevention|The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
76070737|NCT05896878|Dietary Supplement|Root.Health Dietary Supplement|The Root.Health supplement is composed of six plant-based compounds with established roles in supporting innate physiological processes which are implicated in pain: tetrohydrocurcumin, ergothioneine, dihydroberberine, trans-resveratrol, ginger root extract, and methylcobalamin. Participants will take the provided supplement twice per day for the entire study duration in addition to pain management treatment protocols the participants currently follow.
76072528|NCT01848457|Drug|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
75614119|NCT02862873|Other|saline solution|
75764978|NCT04181359|Drug|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
75764979|NCT04181359|Drug|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
75907252|NCT04050241|Device|Mcintosh intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Mcintosh laryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
75907253|NCT02191332|Drug|Viramune|
75460986|NCT01846962|Drug|Fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
75316085|NCT00322777|Behavioral|Spirituality Teaching Program|The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
75460987|NCT01846962|Behavioral|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
75460988|NCT01846962|Drug|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1mg/day or 2mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
75460989|NCT01846975|Drug|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
75460990|NCT01847053|Other|cinnamon|Intervention will be both ground cinnamon and cinnamon extract.
75460991|NCT01847053|Other|Oatmeal|Oatmeal control, around 70g; without cinnamon
75907254|NCT03702361|Drug|VPRIV|VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
75907255|NCT02191410|Procedure|High Frequency Positive Pressure Ventilation|TV 2 mL kg-1 PBW, I:E ratio > 0.3, RR 60 breaths min-1 and a FGF of < 2 L min-1, using a second identical ventilator with low compliant internal circuit
75907256|NCT02191410|Procedure|Continuous Positive Airway Pressure|CPAP of 2 cm H2O
75460992|NCT01847066|Device|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
75907257|NCT03699085|Behavioral|ED-LINC|ED-LINC will include 1) A brief negotiated interview at the bedside with an emphasis on motivation to link to services 2) Pharmacotherapy including a discussion of opioid safety, take-home naloxone and initiation of buprenorphine from the ED for participants that are interested and eligible; 3) Longitudinal care management which will proceed for 3-months; and 4) Care plan in the Emergency Department Information Exchange (EDIE) system. This will be coupled with a study cell phone and a weekly supervisory case conference which is consistent with collaborative care principles.
76070738|NCT05893134|Other|Risk Assessment|A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest risk for dengue transmission in the study area
76070739|NCT05891821|Drug|Balstilimab|An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody
75460993|NCT01847066|Device|Erbium 2940 plus cosmetics|laser
75460994|NCT01847079|Other|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
75460995|NCT01847105|Other|RevitaLens|Multi-purpose disinfecting solution
75614120|NCT02671513|Drug|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
75460996|NCT01847105|Other|OptiFree PureMoist|Multi-purpose disinfecting solution
75460997|NCT01847118|Drug|Sevacizumab|
75460998|NCT01847144|Drug|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
75460999|NCT01847144|Drug|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
75614121|NCT04266951|Behavioral|Singstrong:|Group singing and breathing control training
75614122|NCT02671669|Behavioral|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
75907258|NCT02191644|Dietary Supplement|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
75907259|NCT02191644|Dietary Supplement|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
76070740|NCT05891353|Other|Cold Water Immersion|Cold Water Immersion task of hand
76070741|NCT05891353|Other|Pain Inducing Stretch|Moderately painful stretch of the neck
76070742|NCT05891353|Other|Pain Free Stretch|Pain free stretch of the neck
76070743|NCT05889104|Other|Randomization Program|The subjects in the Control Group will undergo twelve weeks of low impact Aerobics Training along with a health awareness program
76070744|NCT05889104|Other|Progressive Loading Protocol (PLP):|he subjects in the Progressive Loading Group will undergo 4-7 days of moderate to high impact loading activities per week.
76070745|NCT05886335|Drug|Cyclophosphamide|Time of administration
76070746|NCT05883488|Other|Robot-assisted upper extremity rehabilitation|The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes in addition to the conventional rehabilitation program. Participants will receive a total of 4 weeks of treatment.
75764980|NCT04168710|Drug|ESP block with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
75764981|NCT04168710|Other|Saline control/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
75764982|NCT04150380|Biological|Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)|See arm descriptions
75764983|NCT04150380|Other|Placebo|See arm descriptions
75764984|NCT04149210|Drug|Fluorometholone 0.1% Oph Susp|fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
75764985|NCT04149210|Drug|Artificial Tears|Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
75316086|NCT05439759|Behavioral|Condition 1: Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
75764986|NCT04106466|Device|Medtronic Summit RC+S DBS system|Open label active Deep Brain Stimulation (DBS)
75316087|NCT05439759|Behavioral|Condition 2: Training spatial integration|Spatial integration involves what the investigators refer to as mid-level vision. Spatial integration is a concern in developing a PRL since an area of the visual periphery that is best suited to discriminate a simple visual feature may not be appropriate to integrate information across objects, such as in reading or recognizing facial identity or expression. The investigators address this issue with a targeted spatial integration training approach developed by MPI Seitz and based on contour integration tasks used in previous PL studies to train mid-level visual processes. Target stimuli consist of contours formed by spaced Gabors. The difficulty is manipulated by varying orientation jitter of Gabors. Several optotypes will be included to promote generalization, including shapes and facial expressions.
75614123|NCT02671669|Behavioral|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
75764987|NCT04092192|Device|IVC filter removal|"In the clinic, it will be explained to patient that they are asked to participate in a study that would randomize them to one of two established techniques for IVC filter removal. It will be explained these are both techniques that are used by interventional radiologists normally used for IVC filter retrieval.~One technique would be the utilization of an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.~The other technique described will be the usage of a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed."
75764988|NCT04090619|Other|Questionnaire Administration|Complete questionnaires
75614124|NCT03814005|Drug|Azacitidine|Azacitidine subcutaneous or intravenous injection.
75614125|NCT03814005|Drug|Pevonedistat|Pevonedistat intravenous infusion.
75907260|NCT02189226|Device|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
76070747|NCT05883488|Other|Conventional rehabilitation|Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
75614126|NCT03814005|Drug|Docetaxel|Docetaxel intravenous infusion.
75614127|NCT03814005|Drug|Paclitaxel|Paclitaxel intravenous infusion.
75764989|NCT04086082|Device|Markerless Image Guidance|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
75764990|NCT04085887|Drug|Panitumumab-IRDye800|Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).
75764991|NCT04085887|Device|Pinpoint-IR9000 endoscopic/handheld device|"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
76070748|NCT05883137|Device|Optiflow Switch|High flow nasal oxygen with the Optiflow Switch device
75614128|NCT03814005|Drug|Carboplatin|Carboplatin intravenous infusion.
75614129|NCT02676115|Other|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
75764992|NCT04085887|Device|Explorer Air camera|"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
76070749|NCT05880446|Other|Bowel symptoms & QoL assessment|QoL and bowel symptoms questionnaires will be held to patients, anthropomorphic measurement, handgrip test, physical activity level and usual diet quality of the patient will be assessed.
75764993|NCT04085887|Device|PDE-NEO-II|"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
75764994|NCT04081779|Other|Survivorship Care Plan|Receive patient-generated SCP
75764995|NCT04081779|Other|Educational Intervention|Receive telephone-based educational counseling session
76070750|NCT05880394|Drug|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
75907261|NCT03698929|Other|Dietary Effect of Cholesterol - Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
75316088|NCT05439759|Behavioral|Condition 3: Training spatial attention|The investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red-circle appears in a series of other colored-circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.
75614130|NCT02676115|Other|Medipore Tape|"One layer of Medipore tape will be placed across the incision.~Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
75614131|NCT02863887|Behavioral|Weight loss intervention|The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
75764996|NCT04081779|Other|Questionnaire Administration|Ancillary studies
75764997|NCT04071236|Drug|Avelumab|Given IV
75764998|NCT04071236|Drug|Peposertib|Given PO
75764999|NCT04071236|Other|Quality-of-Life Assessment|Ancillary studies
75765000|NCT04071236|Other|Questionnaire Administration|Ancillary studies
76070751|NCT05880394|Drug|Copper-64 DOTATATE|Copper-64 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
75461000|NCT01847157|Device|tDCS|"Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current."
75316089|NCT05439759|Behavioral|Condition 4: Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision,Condition 4 combines the elements of Conditions 1-3.
75316090|NCT00558831|Drug|Benzoyl Peroxide|Benzoyl Peroxide 2.5%
75316091|NCT00558831|Drug|Moisturizing Lotion|
75316092|NCT01431638|Drug|Canakinumab 150mg in prefilled syringe|Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
75461001|NCT01847157|Drug|Epidermis anesthesia|"15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
75461002|NCT01847157|Drug|sham anesthesia|"15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
75765001|NCT04071236|Radiation|Radium Ra 223 Dichloride|Given IV
75765003|NCT04065009|Drug|Ropivacaine|Experimental drug will be administered intraperitoneally
75765004|NCT04065009|Drug|Saline Solution|Placebo will be administered intraperitoneally
75765005|NCT04064424|Other|Prevention video advertisement|Skin Cancer Prevention videos
75765006|NCT04064424|Other|Prevention images for advertisement|Skin Cancer Prevention images
75765007|NCT04064424|Other|No Advertisement|No skin cancer prevention videos or images were advertised.
75765008|NCT04049656|Device|HFVI|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
75461003|NCT01847157|Other|Repeated passive movement|"Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes."
75316093|NCT03021993|Drug|Nivolumab|Nivolumab will be administered on days 1, 15 and 29. If disease has progressed at day 29, the subject will proceed to surgery. If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
75461004|NCT01847157|Device|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
75765009|NCT04042701|Drug|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin. All participants will receive DS-8201a at the RDE in combination with pembrolizumab."
75765010|NCT04042701|Drug|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin."
75614132|NCT05552131|Device|T-wave coronary lithotripsy catheter system|Subjects who plan to receive possible interventional therapy meet all admission criteria and do not meet any exclusion criteria, and enter the screening stage of this clinical trial after signing informed consent. All subjects who sign the informed consent will be provided with a unique subject screening number. All subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled and lumen pretreated with a coronary shock catheter system followed by the implantation of drug-eluting stents.
75614133|NCT02668471|Procedure|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
76070752|NCT05880095|Other|Unrestricted Mediterranean diet|Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.
75614134|NCT02668471|Procedure|traditional method|Radial artery catheters will be placed by the palpation technique only.
75614135|NCT02668549|Other|DB review for Doctor/Pharmacy Shopping Behavior|Database review to evaluate of doctor/pharmacy shopping behaviors
75316094|NCT01392170|Drug|PEG-IFNá-2a|45 mcg given subcutaneously as a single weekly dose for 24 months.
75614136|NCT04175353|Dietary Supplement|Dairy snack|The effects of dairy snack are compared with orange juice.
75614137|NCT04175353|Dietary Supplement|Berry snack|The effects of two berry snacks are compared with berry soup.
75614138|NCT04175743|Drug|CT-044 HCl|CT-044 HCl is a reactive species decomposition accelerant
75765011|NCT04042701|Drug|Pembrolizumab|All participants will receive pembrolizumab (200 mg Q3W) via intravenous (IV) infusion prior to DS-8201a in Parts 1 and 2 of the study.
75614139|NCT04016233|Drug|Tenofovir douche|660 mg TFV in 125 mL hypo-osmolar solution
75616412|NCT02642419|Drug|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
76070753|NCT05880095|Other|Energy-reduced Mediterranean diet|Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.
76070754|NCT05880095|Other|Mediterranean diet with time-restricted eating|Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
76070755|NCT05876572|Drug|intradermal naloxone|One time 8 mg/0.1 mL dose of naloxone to be administered intradermally
75316095|NCT00558753|Drug|pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
76070756|NCT05876572|Device|microneedle injection|Intradermal delivery of naloxone using microneedle
76070757|NCT05875259|Drug|BR1019-1|Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
75461005|NCT01847170|Biological|Fecal Microbial Transplantation|
75461006|NCT01847183|Behavioral|Click City®: Alcohol|A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
75461007|NCT01847222|Biological|SANGUINATE™|PEG-bHb-CO
75461008|NCT01847222|Drug|Normal Saline Solution|Placebo
75461009|NCT01847235|Drug|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
75461010|NCT01847261|Dietary Supplement|Soy Dairy Protein Blend|
75461011|NCT01847261|Dietary Supplement|Positive Control (Dairy Whey Protein)|
75461012|NCT01847300|Behavioral|cSBI-M|In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.
75316096|NCT00558753|Drug|Placebo|Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
75316097|NCT01391546|Biological|ZOSTAVAX|1 dose 0.65 mL
75616413|NCT02642419|Drug|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
75907262|NCT03698929|Other|Dietary Effect of Cholesterol - Non-Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
76070758|NCT05875259|Drug|BR1019-2|Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
76070759|NCT05875259|Drug|BR1019-1 + BR1019-2|Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
76070760|NCT05874791|Behavioral|Goal Management training|metacognitive group intervention
76070761|NCT05871437|Drug|Huaier granule|Huaier Granules: oral administration, 10g once, 3 times a day, used for 1 year, or intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that they no longer benefit. If the patient experiences grade 3-5 (NCI CTC AE V5.0) adverse reactions related to Huai'er granules, and the adverse reactions do not recover after 2 weeks (returning to grade 1 or 2), it can be considered to reduce dosage or stop Huai'er granules treatment. If the medication is suspended for more than 2 weeks, the medication can be interrupted according to the judgment of the researcher. If the same adverse reaction occurs again, the Huaier granules will be permanently discontinued.
76070762|NCT05871320|Drug|[99mTc]Tc-TECANT1|only one arm - the administration of [99mTC]-Tc-TECANT1 in all patients included
75316098|NCT03025490|Device|Capnographic monitoring|Capnographic monitoring is used during the sedation.
75316099|NCT01410110|Behavioral|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
75316100|NCT01410110|Behavioral|Work Therapy|20 hours per week of work therapy
75461013|NCT01847339|Drug|bupivacaine|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
75316101|NCT05408871|Drug|adnectin 18F-BMS-986192 Head and Neck Cancer|Head and Neck Cancer: PET imaging will be performed after initial diagnosis and within 2 weeks of MRI or CT of the neck done as standard of care. MRI will include T1 weighted pre and post gadolinium spin echo, diffusion weighted imaging, and T2 weighted imaging. CT of the head and neck with contrast will be performed per standard clinical protocol. Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of [18F] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
75316102|NCT05408871|Drug|adnectin 18F-BMS-986192 Brain Metastases|Brain Metastases: Recruited patients will undergo standard clinical MRI within 2 weeks prior to PET, including T1 weighted pre- and post-gadolinium spin-echo and gradient-echo imaging, diffusion weighted imaging, susceptibility weighted imaging (2D SWI), T2 weighted imaging, 3D FLAIR, and combined DCE and dynamic susceptibility contrast (DSC) perfusion (DCE perfusion will be performed first, DSC perfusion will utilize T2 spin echo images). DCE perfusion will be processed on syngo Tissue 4D software (Siemens). DSC perfusion will be processed with syngo MR Perfusion Engine (Siemens). Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of [18F] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
75461014|NCT01847339|Other|saline solution|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure
75616414|NCT00901576|Drug|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
75616415|NCT00901576|Drug|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
75616416|NCT00901576|Drug|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
75616417|NCT00655837|Drug|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
75765014|NCT04029480|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, 1 tablet QD
75461015|NCT01847352|Drug|Intravenous administration of ferric carboxymaltose|Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
75461016|NCT01847352|Other|Subacute hypoxic exposures|Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
75461017|NCT01847365|Device|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
75765015|NCT04029480|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg, oral, 1 tablet QD
75765016|NCT04029480|Drug|Placebo to ertugliflozin 15 mg|Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
75765017|NCT04029480|Drug|Placebo to ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
75765018|NCT04029480|Biological|Insulin|The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.
75765019|NCT04029480|Drug|Metformin|Participants will receive stable dose of background metformin.
75907263|NCT02256774|Drug|BILR 355 BS|
75907264|NCT02256774|Drug|Combivir®|
75907265|NCT02256774|Drug|Ritonavir|
76070763|NCT05867056|Drug|IMC-I109V-101 Single Ascending Dose|Single dose administration of IMC-I109V-101
76070764|NCT05867056|Drug|IMC-I109V-101 Multiple Ascending Doses|Multidose administration of IMC-I109V-101
76070765|NCT05866471|Drug|Psilocybin|The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of botanically-derived psilocybin.
75461018|NCT01847378|Procedure|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
75461019|NCT01847391|Drug|GS-6615|GS-6615 tablet(s) administered orally once daily
75461020|NCT01847391|Drug|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
75316103|NCT01391000|Procedure|LASER CO2|The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2
75316104|NCT01391000|Procedure|TENS|"Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.~Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA."
75316105|NCT02275767|Device|50% cortical/50% cancellous FDBA|Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA
75765020|NCT04028843|Behavioral|Healthy Beginnings|The program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the smartphone application, personalized feedback from counselors and, evidence-based behavioral intervention delivered throughout pregnancy.
75765021|NCT04025710|Device|BIOMONITOR III and BIOMONITOR IIIm|"Insertion of BIOMONITOR III or BIOMONITOR IIIm~three scheduled in-office follow-ups~48-hour Holter ECG"
75765022|NCT04020029|Other|Mindset|Mindset Intervention will include watching three brief ~10-25 minute films
75765023|NCT04020029|Other|Reflection activities|Reflection activity include exercises to internalize the message
75765024|NCT04017819|Drug|18F-C-SNAT4|Radiotracer- Dose 10 mCi
75765025|NCT04017819|Procedure|Positron emission tomography (PET)/Computed tomography (CT) Scan|Positron emission tomography (PET)/Computed tomography (CT) Scan
75765026|NCT04016818|Drug|18F-FDG|Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
75461021|NCT01847404|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
75461022|NCT01847404|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
75461023|NCT01847404|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
75765027|NCT04016818|Device|Breast-dedicated PET camera|Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility
75765028|NCT04009213|Device|LiquiBand FIX8®|An n-butyl-2-cyanoacrylate adhesive monomer and D&C Violet #2 dye
75765029|NCT04009213|Device|AbsorbaTack™|An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D&C Violet No. 2.
75765030|NCT04002947|Drug|DA-EPOCH|Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
75765031|NCT04002947|Biological|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for 6 cycles.
75765032|NCT04002947|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m2 IV, Vincristine 1.4 mg/m2 (2 mg cap) IV are administered on Day 1 of each 21-day cycle for 6 cycles. Prednisone 40 mg/m2 PO is administered daily on Days 1-5 of each cycle.
75765033|NCT04002947|Drug|Acalabrutinib|Acalabrutinib is administered orally at 100 mg twice a day for 14 days during the window period. During combination therapy, acalabrutinib is administered 100 mg twice daily for the first 10 days for 6 cycles.
75765034|NCT04002297|Drug|zanubrutinib|Administered as two 80 mg capsules by mouth twice a day
75765035|NCT04002297|Drug|bendamustine|Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
75765036|NCT04002297|Drug|rituximab|Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
76072529|NCT01817725|Biological|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those <= 20 years old and 40μg in those > 20 years old.
75765041|NCT03977402|Other|Biological specimen collection|Collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.
75765042|NCT03967054|Drug|Ivermectin|Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
75316106|NCT02275767|Device|100% cortical FDBA|Ridge preservation after tooth extraction using 100% cortical FDBA
75316107|NCT02275767|Device|100% cancellous FDBA|Ridge preservation after tooth extraction using 100% cancellous FDBA
75316108|NCT05397717|Other|observational|Observational, without interfering the patient care of treating doctors
75316109|NCT00324259|Drug|Estradiol|
75316110|NCT04600141|Drug|Tocilizumab|Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.
75316111|NCT04600141|Drug|Heparin - Therapeutic dosage|Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
75461024|NCT01847404|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
75461025|NCT01847417|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
75765043|NCT03967054|Drug|Placebo oral tablet|placebo in the same size, color and shape at the ivermectin tablet
75765044|NCT03966261|Other|blood sample|we perform blood sample in healthy subject before and after a meal to measure incretins concentration
75907266|NCT04597164|Other|Artificial liver support system|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
75461026|NCT01847417|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
75907267|NCT02191722|Behavioral|reading comics booklet|
75765045|NCT03962894|Drug|Prednisolone|During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
75461027|NCT01847417|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
76070766|NCT05866471|Device|Transauricular Vagus Nerve Stimulation (taVNS)|For both the active and sham taVNS procedure, participants will apply electrodes to two left ear targets. After electrode placement, participants will connect the electrode wire to their taVNS system and will commence self-administered vagus stimulation. The stimulation systems, which allow double-blind administration of either active or sham taVNS will require a code to initiate stimulation, which will be securely sent to participants the morning of each taVNS treatment. Once participants receive the code, they will enter it into the system to receive their randomized stimulation session (active or sham).
75461028|NCT01847417|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
75461029|NCT01847456|Drug|human insulin as nasal spray|
75614140|NCT04175899|Other|Pharmacist-led Oral Chemo Care Program (POCCP)|"Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients."
75614141|NCT02671591|Behavioral|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
75461030|NCT01847456|Drug|Placebo|
75614142|NCT02671591|Behavioral|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
75765046|NCT03962855|Drug|Ifetroban Sodium|Ifetroban sodium 250 mg capsule once daily for 4 weeks
76072530|NCT01870999|Drug|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
75461031|NCT01847482|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest
75461032|NCT01847495|Drug|Irinotecan|40mg/m2 x 3-5 days
75765047|NCT03962855|Other|Placebo|Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
75765048|NCT03953443|Other|Not interventional|
75461033|NCT01847495|Radiation|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
75461034|NCT01847508|Device|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
75461035|NCT01847508|Device|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
75461036|NCT01847521|Dietary Supplement|Luteolin, Quercetin and Rutin combined in a capsule|
75461037|NCT01847534|Other|Supplemental PN|
75461038|NCT01847534|Other|Standard Care|
75614143|NCT02671747|Behavioral|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
75907268|NCT03693859|Behavioral|Cognitive enhancement program|The cognitive enhancement condition (BWL+GAMING) will both teach the behavioral skills necessary for weight loss and strengthen the executive functions that underlie these skills.
75907269|NCT03693859|Behavioral|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks.
75907270|NCT02256852|Biological|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
75907271|NCT02189304|Drug|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
75907272|NCT02189304|Drug|PT009|PT009 administered as 2 inhalations
75907273|NCT02189304|Drug|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
75907274|NCT02184858|Drug|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
75907275|NCT02191956|Behavioral|Behavioral Parent Training|Weekly clinic session, mid-week call, home practice
75907276|NCT02030652|Procedure|Intermittent nasal positive pressure positive ventilation.|
75907277|NCT02030652|Procedure|CPAP|Nasal continuous positive airway pressure
75907278|NCT03535662|Drug|Orvepitant|Single oral dose
75907279|NCT03535662|Drug|Itraconazole|Once daily dosing for 10 days
76072531|NCT01870999|Drug|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
75765049|NCT03949283|Diagnostic Test|ChemoID Assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
75765050|NCT03949283|Drug|Standard Chemotherapy|"Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
75765051|NCT03943173|Drug|Chemotherapy|Given standard chemotherapy
75765052|NCT03943173|Drug|Olaparib|Given PO
75907280|NCT02192034|Behavioral|Navigation|
75907281|NCT03702205|Dietary Supplement|Betaine supplementation|Group taking oral betaine supplementation
75907282|NCT03702205|Dietary Supplement|Placebo treatment|Group taking oral supplementation with placebo (starch) in a similar capsule form.
75907283|NCT03624829|Other|Shared care|The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
75907284|NCT02189538|Dietary Supplement|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
75907285|NCT02189538|Dietary Supplement|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
75907286|NCT03624751|Radiation|radioiodine|Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
75316112|NCT04600141|Drug|Heparin - Prophylactic dosage|Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
75907287|NCT02184936|Other|standard of care|
75765053|NCT03943173|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75765054|NCT03941782|Drug|Alpelisib|As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication.
75765055|NCT03933904|Drug|Sirolimus|Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.
76072532|NCT01870921|Drug|Ticagrelor|90mg/tablet, 1 tablet bid
75765056|NCT03932864|Biological|MGTA-145|MGTA-145 will be given in various doses intravenously
75614144|NCT04033471|Drug|midazolam|epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given
75614145|NCT02670421|Behavioral|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.
75765057|NCT03932864|Biological|plerixafor|240 µg/kg subcutaneously
75765058|NCT03932864|Biological|Placebo|Placebo will be given in various doses intravenously
75765059|NCT03911778|Other|Improvement of symptoms|Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
75765060|NCT03903289|Procedure|Automated red cell exchange|Erythrocytapheresis is an automated red cell exchange procedure that removes blood that contains HbS from the patient while simultaneously replacing that same volume with packed red cells free of HbS.
75765061|NCT03903289|Procedure|Manual red cell exchange|Active Comparator: Manual red cell exchange
75907288|NCT02192268|Other|PEP|
76072533|NCT00526474|Drug|Vorapaxar|2.5-mg tablet daily for at least 1 year
75614146|NCT02670421|Behavioral|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
75907289|NCT02192268|Other|HFOO|
75907290|NCT02192268|Other|Assisted Coughing|
75907291|NCT02185092|Dietary Supplement|Lactobacillus GG|probiotic supplement
75907292|NCT02185092|Other|Sugar pill|placebo
75907293|NCT02189616|Behavioral|SMS reminder|send weekly mobile phone short message reminders to the intervention group
75907294|NCT02189616|Other|SMS consultation|told patients to consult qualified asthma nurses by SMS when they need
75907295|NCT02189616|Other|regular care|patients are asked to fill in their paper asthma diary daily for 3 months
75907296|NCT03693703|Diagnostic Test|bi-parametric MRI|Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration
75907297|NCT03693703|Diagnostic Test|multi-parametric MRI|T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration
75907298|NCT02189694|Device|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
76072534|NCT00526474|Drug|Placebo|matching tablet daily for at least 1 year
75316113|NCT00324415|Biological|cetuximab|400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
75907299|NCT02189694|Device|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
75907300|NCT02189694|Device|Insulin pump therapy|Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
75907301|NCT02189772|Drug|Metadoxine extended release|MG01CI
75907302|NCT02189772|Drug|Placebo|Inactive drug
75907303|NCT02192346|Drug|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
75907304|NCT02192346|Drug|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
75907305|NCT02192346|Drug|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
75907306|NCT02192346|Drug|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
76070767|NCT05866471|Device|Sham taVNS|"For both the active and sham taVNS procedure, participants will apply electrodes to two left ear targets. After electrode placement, participants will connect the electrode wire to their taVNS system and will commence self-administered vagus stimulation. The stimulation systems, which allow double-blind administration of either active or sham taVNS will require a code to initiate stimulation, which will be sent to participants via HIPAA-compliant email the morning of each taVNS treatment. Once participants receive the code, they will enter it into the system to receive their randomized stimulation session (active or sham).~For sham taVNS intensity will be set at 0 mA."
75461039|NCT01847586|Procedure|Paired Associative Stimulation|PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
76070768|NCT05866471|Behavioral|Treatment as Usual (TAU)|Participants assigned to TAU will not receive taVNS post-psilocybin dosing but will instead undergo integration sessions at 1 day and 1-week post-psilocybin dosing. This is the typical treatment approach following psilocybin administration.
75316114|NCT00324415|Drug|cisplatin|75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
76070769|NCT05861349|Diagnostic Test|Nerve conduction study|Nerve conduction study of median and ulnar nerve together with sensory comparative methods on the affected side (sides).
76070770|NCT05861349|Diagnostic Test|Ultrasound|Ultrasound of the median nerve on the affected side (sides).
76070771|NCT05860673|Procedure|mini invasive scoliosis surgery|"The minimally invasive technique, involves two small median skin incisions that allow the deep structures to be exposed. The muscle fibers are separated from the bony insertion by the process of subperiosteal skeletonization. The Investigators then proceed with the arthrectomy of the levels to be instrumented and the infiltration of pedicle screw pairs of the appropriate caliber according to the free-hand technique. After amplioscopic control of proper screw placement, osteotomies of the posterior elements are performed to facilitate correction of the metameres."
75316115|NCT00324415|Drug|fluorouracil|1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
75316116|NCT00324415|Radiation|radiation therapy|Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy [5 weeks if given on schedule and without interruption], maximum 54.0 Gy [6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
75316117|NCT00390559|Drug|nicotine transdermal system|21 mg nicotine transdermal system
75461040|NCT01847586|Procedure|Paired Associative Stimulation-Control|PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
75907307|NCT02192346|Drug|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
75907308|NCT02192346|Drug|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
75907309|NCT02192346|Drug|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
75907310|NCT02192346|Drug|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
75907311|NCT02192346|Drug|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
75907312|NCT03698773|Other|Access to routine information|Access to routine pain-control information
75907313|NCT03698773|Other|Access to website|Access to informational website: thepainlesspush.com
75907314|NCT02185170|Procedure|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
75907315|NCT02185170|Device|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
75907316|NCT02185170|Device|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
75907317|NCT03693469|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
75907318|NCT02192424|Drug|Metformin alone|
75907319|NCT02192424|Drug|Metformin + Intermittent Insulin Therapy|
75907320|NCT04276597|Drug|177Lu-DOTATOC|177Lu labeled somatostatin receptors targeting ligand
75765062|NCT03903289|Procedure|Simple red cell transfusion|Active Comparator: Simple red cell transfusion
75765063|NCT03866798|Biological|Panzyga|Immune Globulin, intravenous, human-ifas
75907321|NCT02257008|Drug|BILR 355 BS|
75907322|NCT02257008|Other|Grapefruit juice|
75907323|NCT02257008|Drug|Nelfinavir|
75907324|NCT02257008|Drug|Atazanavir|
75907325|NCT02257008|Drug|Ritonavir|
75907326|NCT04432948|Other|PHQ-9 Depression Scale|It involves a 9-question scale that detects depression
75907327|NCT04432948|Other|GAD-7 General anxiety disorder scale|It involves a 7-question scale that detects general anxiety disorder
75907328|NCT04432948|Other|38-questions questionnaire|It involves a 38 question questionnaire that aims to detect any association between the Covid-19 pandemic, the psychological impllications and anaesthetic practice
75316118|NCT00390559|Drug|Nicotine transdermal system|Placebo nicotine patch
75316119|NCT00390559|Other|Nicotine containing cigarette|Nicotine containing cigarette
75316120|NCT00390559|Other|Placebo cigarette|Non nicotine containing cigarette
75765064|NCT03864146|Behavioral|Brief Behavioral Compliance Enhancement Treatment|This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
75316121|NCT04528459|Device|Stryker© ADAPT™ platform|The ADAPT system is a software platform that utilizes augmented reality to assist surgeons with implant alignment, lag screw length and positioning, and distal interlocking screw placement for cephalomedullary fixation of peritrochanteric femur fractures.
75316122|NCT04528459|Radiation|Traditional fluoroscopy|For patients in the control group, traditional fluoroscopy will be utilized for placement of the cephalomedullary nail.
75316123|NCT02107339|Drug|Methadone|Methadone 0.2 mg/kg administered at induction of anesthesia
75316124|NCT02107339|Drug|Hydromorphone|Hydromorphone 2 mg administered at the conclusion of anesthesia
75316125|NCT00390949|Behavioral|Peer education among commercial sex workers and clients|
75316126|NCT00390949|Behavioral|Condom distribution and promotion|
75461041|NCT01847599|Other|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
75461042|NCT01847612|Procedure|indocyanine green fluorescent cholangiography|
75461043|NCT01847612|Drug|methylene blue|
75461044|NCT01847651|Procedure|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
75461045|NCT01847651|Drug|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
75765065|NCT03860961|Other|Questionnaire Administration|Ancillary studies
75765066|NCT03860961|Other|Survivorship Care Plan (SCP)|Given survivorship care plan
75765067|NCT03860961|Other|Treatment Plan|Given treatment plan
75765068|NCT03820947|Device|VenaSeal™ Closure System|The VenaSeal™ closure system is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.
75765069|NCT03820947|Device|Endothermal Ablation (ETA)|"ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein.~Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice."
75765070|NCT03820947|Procedure|Surgical Stripping|Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.
75907329|NCT03693391|Drug|JNJ-64140284|Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
75907330|NCT03693391|Drug|Fluorine-18 Labeled [18F]-JNJ-64511070|An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) [18F]JNJ-64511070 will be administered.
75907331|NCT02185248|Behavioral|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
75907332|NCT04433806|Behavioral|Referral to weight loss program|16 weeks Diabetes Prevention Program based weight loss program at a local community partner
75907333|NCT03693313|Behavioral|CrossFit Kids exercise program|Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
75907334|NCT02189928|Device|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
75907335|NCT02189928|Other|Usual care|
75907336|NCT04433650|Device|Pictorial support in person-centred care for children (PicPecc)|"Phase A: The child has the protocol for methotrexate treatment, the healthcare professionals have one workshop that containing person-centred care, universal design, distress, symptom management and the digital reporting and communication tool.~Phase B: The child has everything in phase A. In addition, the child use the digital reporting and communication tool that has a thermometer (graded from zero (green) to ten (red)). The result of the assessment is visualized as a face (mimic and colour represents the intensity of the symptom and/or emotion (i.e., anxiety, appetite, fear/worries, how I´m feeling today, nausea, pain, sleep, and tiredness)). The digital reporting and communication tool has a body figure for location of pain, pictures for the type of pain, and an open question. There is an avatar and a gamification part, e.g., the child gets a pet after assessing the symptoms/emotions. The child reports in the app, and the child decides the frequency of assessments."
75907337|NCT02192580|Drug|Omega-3|Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
75907338|NCT02193594|Radiation|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
75907339|NCT02193594|Procedure|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
76070772|NCT05860673|Procedure|posterior spinal fusion technique|"The standard open technique involves a longitudinal incision along the midline extended along the entire thoracolumbar spine, the paravertebral muscles are incised and spread apart to expose the posterior vertebral structures, in a stretch extending more than 30 cm. The series of facetectomies are performed first, and then pairs of pedicle screws are infixed freehand.~After performing the osteotomies necessary to mobilize the vertebral metameres at the apex of the deformity, correction by derotation maneuvers is continued, and the obtained correction is fixed with pre-shaped bars that are then connected to the screws and tightened to the nuts by dynamometric technique. Almost all vertebral levels of the thoracolumbar tract are included in the arthrodesis"
76070773|NCT05857735|Other|Observational registry with no intervention.|No intervention
75907340|NCT02193594|Drug|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
75907341|NCT02185326|Drug|Growth hormone (Norditropin, Novo nordisk)|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
75907342|NCT02185482|Behavioral|Physician Supported Care|
76070774|NCT05857150|Diagnostic Test|Treadmill Test|Measurement of whole-body fitness level. Walking or running on a treadmill and breathing into a machine that measures oxygen level during test. Heart rhythm is continuously monitored during exercise using an electrocardiogram (ECG).
76070775|NCT05857150|Diagnostic Test|Strength Test|Measure the strength of leg muscles by kicking against a machine with resistance.
76070776|NCT05857150|Diagnostic Test|Dual-Energy X-Ray Absorptiometry|Body composition measurement.
76070777|NCT05857150|Procedure|Muscle Biopsy|Obtain a small piece of muscles from the upper part of the legs
76070778|NCT05857150|Procedure|Fat Biopsy|Fat sample taken from abdomen
75316127|NCT00390949|Procedure|Syndromic treatment of sexually transmitted infections|
76070779|NCT05857150|Diagnostic Test|Resting Energy Expenditure|Measured by indirect calorimetry. Measures how much energy the body uses at rest by placing a special plastic dome over the head while resting quietly for 30 minutes. Measures oxygen breathed in and carbon dioxide breathed out.
76070780|NCT05857150|Diagnostic Test|Magnetic resonance imaging|MRI on upper leg to look at fat and muscle
75614147|NCT02670421|Behavioral|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
75614148|NCT02671279|Dietary Supplement|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
76070781|NCT05857020|Device|Auricular Acupressure|"Auricular Acupressure (AA) utilizing all-natural vaccaria ear seeds will be applied to 5 designated sites on each participant's ear (total of 10 seeds placed per patient).~Participants will be asked if they consent to having their ear placement photographed after placement (optional) and audio recorded during interventionist ear seed placement (optional) in collaboration with the BAApress training fidelity study."
76070782|NCT05857007|Device|Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids|Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
75614149|NCT02671201|Other|Education|Different methods in education of emergency ultrasound
75614150|NCT02668081|Procedure|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
75614151|NCT02668081|Procedure|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
75614152|NCT00910351|Drug|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
76070783|NCT05854992|Drug|Acute migraine treatment with any prescribed triptans|Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.
75316128|NCT00390949|Procedure|Systemic counselling for STI patients|
75316129|NCT00392041|Drug|Eszopiclone|3mg qpm for 12 weeks
75316130|NCT00392041|Drug|placebo|1 pill qpm for 12 weeks
75316131|NCT01792765|Other|Ultrasound guidance|Patient will have intraoperative ultrasound .
75614153|NCT02671357|Procedure|ERAMIP|3D-LPD with stented umbrella-pancreaticogastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
75614154|NCT04175665|Drug|Semaglutide|Prescription for semaglutide as part of usual clinical practice
75614155|NCT02671123|Procedure|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
75316132|NCT01390844|Drug|Boceprevir (BOC)|200 mg capsules, 800 mg three times daily by mouth
75316133|NCT01390844|Drug|Placebo to boceprevir|200 mg placebo capsules, 800 mg three times daily by mouth
75614156|NCT02671123|Procedure|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
75616418|NCT00655837|Drug|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
75316134|NCT01390844|Drug|Peginterferon alfa-2b (PEG)|1.5 mcg/kg/week subcutaneously
75316135|NCT01390844|Drug|Ribavirin (RBV)|200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
75614157|NCT04174729|Device|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
75765071|NCT03809078|Drug|68Ga RM2|PET radiopharmaceutical
75907343|NCT02185482|Other|Usual care|
75765072|NCT03809078|Drug|68Ga-PSMA-11|PET radiopharmaceutical
75765073|NCT03809078|Device|Investigational PET scanner coils and software|GE Healthcare non-approved PET scanner coils and software
75765074|NCT03806257|Other|Enhanced Physical Therapy Protocol|A structured physical therapy protocol that requires subject to ambulate more frequently than the standard-of-care patient.
75765075|NCT03803774|Drug|Birinapant|Given IV
75907344|NCT03536364|Behavioral|Food Order|carbohydrate (ciabatta bread ) first, followed 10 minutes later by protein (grilled chicken) and vegetables
75907345|NCT03536364|Behavioral|Carbohydrate Last|protein and vegetables first, followed 10 minutes later by carbohydrate
75765076|NCT03803774|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRRT
75765077|NCT03793218|Device|Latera Device|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
75907346|NCT03536364|Behavioral|Vegetables first|vegetables first, followed 10 mins later by protein and carbohydrate.
75907347|NCT02192736|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
76070784|NCT05854992|Drug|Standard of care management of acute migraine without triptans|Any standard of care management without triptans
75614158|NCT04174729|Device|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
75614159|NCT04174729|Device|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
75614160|NCT04174729|Device|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
75614161|NCT04174729|Device|Linear Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
75765078|NCT03793218|Procedure|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
75765079|NCT03780062|Biological|S100B protein dosing|Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L
75765080|NCT03776071|Drug|Enzastaurin Hydrochloride|mg
75765081|NCT03776071|Other|Placebo|mg
75907348|NCT03535428|Diagnostic Test|VENOUS exploration|venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
75461046|NCT01847651|Other|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
75461047|NCT01847651|Other|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
75461048|NCT01847651|Other|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
75765082|NCT03776071|Drug|Temozolomide|mg/m^2
75765083|NCT03776071|Radiation|Radiotherapy|Gy
75765084|NCT03737214|Drug|Lucerastat|Administered in hard gelatin capsules containing 250 mg of lucerastat.
75765085|NCT03716869|Other|Universal Screening Arm|"Students with PHQ-9 score >10, corresponding to a positive MDD screen, will proceed through the same SAP triage process as students referred by traditional means.~SAP triage will determine MDD identification. As SAP triage is not diagnostic, MDD identification is based on SAP recommendations for MDD related school or community services.~Treatment engagement will be tracked per current SAP processes.~To immediately identify and address suicidal intent, the survey will flag a positive response to PHQ-9 question 9 in real time. A suicidal student would proceed directly to management through the school crisis plan.~Students in the intervention arm will also be tracked for behavior concerning for MDD at any point in the school year prompting SAP triage referral."
75765086|NCT03702517|Device|lateral stair walking exercise|15 minutes of lateral stair walking exercise
75765087|NCT03702517|Device|traditional physiotherapy|strengthening exercise, balance training and gait training
75765089|NCT03680144|Procedure|Dynamic Susceptibility Contrast-MRI (DSC-MRI)|Undergo DSC-MRI
75461049|NCT01847651|Other|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
75461050|NCT01847651|Other|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
75461051|NCT01847651|Other|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
75614162|NCT04174729|Device|Door Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
75765090|NCT03680144|Procedure|Magnetic Resonance Imaging (MRI)|Undergo diagnostic MRI
75765091|NCT03679312|Drug|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
75765092|NCT03679312|Drug|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
75765093|NCT03679299|Other|Observational - No intervention|See outcomes
75907349|NCT02192892|Dietary Supplement|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
75907350|NCT02192892|Dietary Supplement|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
75907351|NCT02192892|Dietary Supplement|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
75907352|NCT02192892|Dietary Supplement|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
75907353|NCT02192892|Dietary Supplement|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
75907354|NCT02192892|Dietary Supplement|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
75907355|NCT02192892|Dietary Supplement|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
75614163|NCT02670265|Dietary Supplement|Olimel Peri 2.5% ®|During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
75614164|NCT02670265|Dietary Supplement|Isotonic fluid (E153)|Controls received 1l of isotonic fluid daily by intravenous route.
75907356|NCT02192892|Dietary Supplement|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
75907357|NCT02192892|Dietary Supplement|Commercial porridge flour|Porridge from commercial porridge flour
75907358|NCT02192892|Dietary Supplement|Commercial porridge bar|Porridge from commercial porridge bar
75907359|NCT02192892|Dietary Supplement|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
75461052|NCT01847651|Other|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
75461053|NCT01847664|Drug|Rifamycin SV-MMX® 400 mg b.i.d.|
75614165|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
75316136|NCT01390844|Drug|Cross-Over Boceprevir Treatment|At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
76070785|NCT05853276|Behavioral|Brush DJ app|Brush DJ app is a mobile app which can be freely downloaded. This app was chosen as part of the intervention as it was recognized by the NHS to reduce the risk of gum disease and tooth decay among its users. This app was built around the info given in the public health England Delivering Better Oral Health Toolkit.
75461054|NCT01847664|Drug|Rifamycin SV-MMX® 600 mg t.i.d.|
75461055|NCT01847664|Drug|Rifamycin SV-MMX® Placebo|
75461056|NCT01847677|Drug|Bevacizumab|
75316137|NCT04036214|Device|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty Laser
75316138|NCT01430624|Behavioral|PPRS|Video including information psychoeducation and modeling of adaptive behavioral coping strategies for use post-assault. Shown at time of post assault medical exam.
75316139|NCT01430624|Behavioral|PIRI|Video containing pleasant imagery and relaxation instruction information. Shown at time of post assault medical exam.
75316140|NCT00395161|Drug|Metoclopramide|0.2 mg/kg/dose IV every 12 hours
75461057|NCT01847677|Drug|Paclitaxel|
75461058|NCT01847677|Drug|Carboplatin|
75461059|NCT01847690|Drug|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
75461060|NCT01847703|Procedure|Robotic surgery|Minimal invasive surgery performed with daVinci robotic system
75461061|NCT01847703|Procedure|Abdominal surgery|Current gold standard
75461062|NCT01847742|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|
75461063|NCT01847768|Biological|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
75461064|NCT01847768|Procedure|Bronchoalveolar Lavage|
75461065|NCT01847768|Drug|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
75461066|NCT01847768|Procedure|Nasal Lavage|
75461067|NCT01847768|Procedure|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
75614166|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 alone
75614167|NCT04175587|Drug|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
75614168|NCT02668159|Dietary Supplement|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
75614169|NCT02668159|Dietary Supplement|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
75614170|NCT02668159|Dietary Supplement|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
75614171|NCT02668159|Dietary Supplement|Placebo|7 tablets of placebos administered prior to one the OGTT
75614172|NCT02670109|Drug|Carmustine|300mg/m2, IV, in 3 hours, during day -4
75614173|NCT02670109|Drug|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
75614174|NCT02670109|Drug|Carboplatin|1400/m2, IV, in 1 hour, during day -3
75614175|NCT02670109|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
75614176|NCT02670109|Drug|Busulfan|16mg/kg, Oral, during day -4
75614177|NCT02670187|Biological|GLS-5300|
75614178|NCT00922636|Drug|LY2216684|Taken in tablet form QD po.
75907360|NCT04762212|Procedure|Mobilization with movement and stretching, stretching or control|The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.
75907361|NCT04412707|Drug|Melphalan|Peripheral versus central administration
75907362|NCT04412707|Drug|Dexamethasone|Oral tablets
75907363|NCT03534882|Other|Discontinuation of topical prostaglandin analogue therapy|Participants are asked to discontinue their prostaglandin analogue eye drops for the designated time period (42 days)
75907364|NCT02930850|Device|Rad-67 Pulse oximeter|Noninvasive pulse oximeter that measures hemoglobin
75907365|NCT02193672|Drug|[18F] Fluciclatide|[18F] Fluciclatide given by vein before PET/CT scan.
75907366|NCT02193672|Procedure|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
75907367|NCT02193672|Behavioral|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
75907368|NCT03698695|Drug|THN 201|THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
75907369|NCT03698695|Drug|Donepezil|Donepezil 5 mg/d and Mefloquine placebo
75907370|NCT03698695|Drug|Placebo|Donepezil placebo and Mefloquine placebo
75614179|NCT00922636|Drug|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
75614180|NCT00922636|Drug|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
75907371|NCT03693235|Procedure|bending angle of a lightwand|For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
75907372|NCT02030808|Drug|Muscle Relaxants (MR) group|patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
75907373|NCT02030808|Drug|Non- Muscle Relaxants (NMR) group|No cisatracurium® (Nimbex) will be administered
75316141|NCT00395161|Drug|Zinc|one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants < or equal to one year of age, and 20 mg/day elemental zinc for patients > 1 year of age)
75614181|NCT00922636|Drug|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
75907374|NCT03702049|Behavioral|Nurse-led Community Health Worker TBI (RN/CHW TBI) program|Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
75614182|NCT02667925|Drug|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
75614183|NCT02669719|Biological|chemotherapy followed dendritic cells|Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
75765094|NCT03645122|Procedure|Noninvasive neuromodulation via paired corticospinal-motoneuronal stimulation (PCMS)|This study is a novel approach to studying neuroplasticity after stroke. Previous work in humans with incomplete spinal cord injury demonstrates that the resulting plasticity transiently enhances motor output, indicating that there is also therapeutic potential. This study will attempt to induce bi-directional plasticity in corticospinal-motoneuronal synapses serving an intrinsic hand muscle of the hemiparetic limb. Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects.
75765095|NCT03642587|Other|There is no intervention in this study.|There is no intervention in this study.
75907375|NCT04729296|Drug|Golimumab|For participants ≥45 kg, 50 mg of golimumab will be administered subcutaneously For participants <45 kg, the dose of golimumab is 30 mg/m2 to maximum of 50 mg
75907376|NCT04729296|Drug|Placebo|Inactive Drug
75907377|NCT03698617|Drug|HSK3486|For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
75907378|NCT03698617|Drug|Propofol|For induction of general anesthesia
75907379|NCT02193750|Dietary Supplement|Placebo|1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
76070786|NCT05852145|Drug|Stevioside|"355 ml of tea lemon flavor added with 2.2 gr. of stevioside should be drunk~Salivary pH will be collected at 0, 5, 10, 15, 30, 45 and 60 minutes later.~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later.~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be determined at 0 and 120 minutes later.~Operative Taxonomic Units of dental biofilm will be analyzed at 0 and 120 minutes later."
76070787|NCT05850494|Drug|HFA MDI|"Dose formulation: MDI~Unit dose strength(s): Reference (propellant only)~Dosage Level: 4 inhalations, single dose~Route of administration: Oral inhalation~Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
75316142|NCT00395161|Dietary Supplement|Glutamine|one enteral dose daily of glutamine 0.3 gm/kg/day
75316143|NCT00395161|Drug|Selenium|one enteral dose daily of selenium (40 μg for infants < 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children > 13 years)
75907380|NCT02193750|Dietary Supplement|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
75907381|NCT02193750|Dietary Supplement|High Oligosaccharide Group|1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
75461068|NCT01847768|Procedure|Bronchial Brushings|
75461069|NCT01847768|Procedure|Lung Mucosal Biopsy|
75461070|NCT01847768|Procedure|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer & glycerol negative control.
75461071|NCT01847768|Procedure|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
75316144|NCT00395161|Other|saline|equivalent volume of intravenous saline
75316145|NCT00395161|Other|sterile water|equivalent volume of sterile water
75316146|NCT00395161|Other|selenium|equivalent volume of sterile water
75316147|NCT00395161|Dietary Supplement|whey-protein|one enteral dose daily of whey-protein
75316148|NCT01430468|Procedure|Glenoid Positioning System|Design and fabrication of patient specific instrument for placement of a guide pin to be used to aid in bone preparation for placement of a metaglene and its fixation screws or anatomic glenoid component
75461072|NCT01847768|Procedure|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
75461073|NCT01847768|Procedure|Spirometry|
75461074|NCT01847781|Biological|Prevenar13|
75316149|NCT02076776|Behavioral|Repetitive Task Practice (RTP)|This group will preform arm and hand therapy.
75614184|NCT02669719|Drug|pemetrexed and carboplatin|Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
75316150|NCT02076776|Behavioral|Voluntary cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
75461075|NCT01847794|Device|Cell Search® CTC epithelial kit|"Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
75614185|NCT00644761|Drug|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
75461076|NCT01847807|Drug|low dose Astragalus|
75461077|NCT01847807|Drug|high dose astagalus|
75461078|NCT01847820|Device|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
75461079|NCT01847833|Other|MRI scan|
75461080|NCT01847846|Device|CPAP mask - prototype|prototype mask, wore for all sleeps for 4 and 8 weeks (as randomly selected). Mask to be used in conjunction with participant's usual prescribed CPAP settings.
75461081|NCT01847872|Drug|IPV IM Needle|
75614186|NCT05330728|Other|Suggestions for lifestyle changes+ Abdominal massage|Suggestions for lifestyle changes+ abdominal massage will be applied. Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Abdominal massage will be applied 3 times a week for 4 weeks.
75765098|NCT03624478|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
76070788|NCT05850494|Drug|HFO MDI|"Dose formulation: MDI~Unit dose strength(s): Experimental (propellant only)~Dosage Level: 4 inhalations, single dose~Route of administration: Oral inhalation~Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
75316151|NCT02076776|Behavioral|Assisted cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
75316152|NCT01792843|Behavioral|data|"comparisons of clinical characteristics~comparisons of cognitive profiles~comparisons of grey matter density patterns~comparisons of EEG rhythms features"
75316153|NCT04052672|Other|Exercise and Nutritional Supplement|The intervention consists of exercise (a combination of supervised and in home) as well as a nutritional supplement (a combination of whey protein and creatine).
75316154|NCT01794013|Behavioral|Parent training|All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
75316155|NCT01794013|Behavioral|Routine care|routine care
75765099|NCT03616496|Drug|Neuraceq PET/CT imaging|PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated
75316156|NCT01409564|Drug|Cilostazol|Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
75316157|NCT01409564|Drug|Placebo|Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
75461082|NCT01847872|Drug|IPV ID Needle|
75461083|NCT01847872|Drug|IPV IM Device|
75461084|NCT01847872|Drug|IPV ID Device|
75461085|NCT01847898|Procedure|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
75461086|NCT01847898|Procedure|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
75461087|NCT01847911|Other|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
75461088|NCT01847911|Other|instructor training|a pre-validated OSCE neonatal resuscitation program
75461089|NCT01847924|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
75461090|NCT01847924|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
75614187|NCT05330728|Other|Suggestions for lifestyle changes+ Kinesio taping|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Kinesio taping will be applied 3 times a week for 4 weeks.
75614188|NCT05330728|Other|Suggestions for lifestyle changes|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once.
75765100|NCT03604978|Procedure|Biospecimen Collection|Undergo blood sample collection
75765101|NCT03604978|Procedure|Echocardiography|Undergo ECHO
75765102|NCT03604978|Biological|Ipilimumab|Given IV
75765103|NCT03604978|Procedure|Magnetic Resonance Imaging|Undergo brain MRI
75765104|NCT03604978|Biological|Nivolumab|Given IV
75765105|NCT03604978|Radiation|Stereotactic Radiosurgery|Undergo multi-fraction stereotactic radiosurgery
75765106|NCT03599752|Drug|Chemotherapy|Receive chemotherapy
75765107|NCT03599752|Procedure|Metastasectomy|Undergo pulmonary metastasectomy
75765108|NCT03593356|Behavioral|Monthly cash gift payments of $333|These subjects receive $333 each month for 76 months via debit card.
75765109|NCT03593356|Behavioral|Monthly cash gift payments of $20|These subjects receive $20 each month for 76 months via debit card.
75765110|NCT03576742|Diagnostic Test|potential biomarkers|facs analysis, microbiome analysis
75765111|NCT03568448|Other|Response monitoring (no intervention)|Response monitoring (no intervention)
75765112|NCT03501979|Drug|Tucatinib|Tucatinib study drug is given in tablet form and taken daily.
75765113|NCT03501979|Drug|Trastuzumab|Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.
75907382|NCT02193126|Other|Trauma Affect Regulation: Guide for Education and Therapy (TARGET)|The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
76070789|NCT05850351|Other|Virtual reality|Virtual reality is a simulated experience that creates a virtual environment to give the user the feeling of an immersive virtual world, using glasses and a handheld device that can track hand movements. Activities that will improve the functional and respiratory capacity of children with cystic fibrosis will be developed and integrated into the virtual reality game.
75316158|NCT01794091|Drug|Eplerenone|Eplerenone 25 mg daily for 6 months
75316159|NCT01794091|Drug|Placebo|
75316160|NCT01390298|Other|Observational|Observational study only
75316161|NCT01794169|Drug|Azacitidine|
75765114|NCT03501979|Drug|Capecitabine|Capecitabine is approved by the FDA and is available commercially as an oral drug.
75461091|NCT01847950|Dietary Supplement|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
75461092|NCT01847950|Dietary Supplement|Maltodextrin|
75461093|NCT01847963|Drug|Sindhuvallathy mezhugu ( SVM)|500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
75461094|NCT01847963|Drug|Kalladaippu Kudineer (KK) -|130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
75461095|NCT01847976|Drug|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
75765115|NCT03479138|Diagnostic Test|Induced sputum|Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome
75765116|NCT03478553|Other|Blood draw|Blood draw
76070790|NCT05850351|Other|Online|Online exercises are physical activities that are performed via a video-conferencing tool. Children will be at their home environment and exercises which will improve their functional and respiratory capacity will be instructed and supervised by a physiotherapist.
75316162|NCT01794169|Drug|DA|
75316163|NCT00396019|Drug|PEG-Intron|
75461096|NCT01847989|Drug|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
75461097|NCT01847989|Drug|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
75461098|NCT01848002|Drug|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
75461099|NCT01848002|Drug|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
75765117|NCT03478553|Other|Questionnaire|Pulmonary Fibrosis Questionnaire
75765118|NCT03474107|Drug|Enfortumab Vedotin|Intravenous infusion
75765119|NCT03474107|Drug|Docetaxel|Intravenous infusion
75765120|NCT03474107|Drug|Vinflunine|Intravenous infusion
75765121|NCT03474107|Drug|Paclitaxel|Intravenous infusion
75765122|NCT03456843|Drug|Antiandrogen Therapy|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
75765123|NCT03456843|Drug|Docetaxel|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
75765124|NCT03456843|Other|Laboratory Biomarker Analysis|Correlative studies
75765125|NCT03456843|Procedure|Quality-of-Life Assessment|Ancillary studies
75316164|NCT01390220|Drug|USL261|
75316165|NCT01390220|Drug|Placebo|
75316166|NCT00357331|Drug|potassium citrate|20 meq by mouth in capsule form twice daily
75316167|NCT04046042|Other|Conventional exercise|Virtual reality exercise performed during the first two hours of the hemodialysis session
75461100|NCT01848015|Other|detection of CTCs|
75765126|NCT03456843|Other|Questionnaire Administration|Ancillary studies
75765127|NCT03456843|Procedure|Radical Prostatectomy|Undergo cytoreductive radical prostatectomy
75765128|NCT03400332|Drug|BMS-986253|Specified dose on specified days
75461101|NCT01848080|Behavioral|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
75461102|NCT01848093|Other|sputum collection|collecting of spontaneous sputum from the patient
75461103|NCT01848106|Drug|pegnivacogin/anivamersen|
75461104|NCT01848106|Drug|Bivalirudin|
75461105|NCT01848119|Drug|Gabapentin|
75461106|NCT01848119|Drug|lactose|
75461107|NCT01848132|Drug|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
75765129|NCT03400332|Biological|Nivolumab|Specified dose on specified days
75765130|NCT03400332|Biological|Ipilimumab|Specified dose on specified days
75765131|NCT03400332|Other|Placebo|Specified dose on specified days
75765132|NCT03395184|Drug|PF-06651600 Placebo|12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks
75765133|NCT03395184|Drug|PF-06651600|200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
75765134|NCT03395184|Drug|Placebo PF-06700841|12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks
75765135|NCT03395184|Drug|PF-06700841|60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
75765136|NCT03377270|Behavioral|Respiratory Swallow Training|Training in the Optimal Respiratory Swallow Pattern and Lung Volume at Swallow Initiation
75765137|NCT03286699|Behavioral|Dietary Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
75316168|NCT04046042|Other|Exercise during the last two hours of the hemodialysis session|Virtual reality exercise performed during the last two hours of the hemodialysis session
75316169|NCT00357955|Behavioral|Behavioral counseling and peer support|Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
75614189|NCT00645073|Drug|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
75614190|NCT00645073|Drug|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
75907383|NCT02194374|Procedure|ROR1R-CAR-T Cell Infusion|"Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
75907384|NCT02194374|Drug|Fludarabine|"FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.~FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3."
75907385|NCT02194374|Drug|Cyclophosphamide|FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
75907386|NCT02194374|Drug|Rituximab|"FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.~BR Regimen: 375-500 mg/m2 by vein on Day -4."
75316170|NCT00357955|Behavioral|Interactive Education|interactive lectures with hands-on learning
75316171|NCT00357955|Behavioral|Role modeling|learning from peers with similar disease and problems
75461108|NCT01848132|Drug|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
75316172|NCT00357955|Procedure|Pharmacologic case management|provided by clinical pharmacists following pre-established algorithms
75461109|NCT01848132|Drug|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
75461110|NCT01848132|Drug|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
75461111|NCT01848132|Drug|Prednisone|Prednisone: oral, 100 mg, days 1-5
75316173|NCT00550173|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
75316174|NCT00550173|Drug|erlotinib|150 mg, orally, once daily until progression or unacceptable toxicity develops
75461112|NCT01848132|Drug|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
75461113|NCT01848197|Drug|paclitaxel|
75461114|NCT01848236|Dietary Supplement|Vitamin D2|Ergocalciferol vitamin D2
75461115|NCT01848236|Dietary Supplement|Vitamin D3|Cholecalciferol vitamin D2
75614191|NCT04259008|Other|Manganese omission|Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.
75614192|NCT04259008|Other|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."
75614193|NCT04258930|Other|Aluminum sulphate and calcium acetate drying soaks|Dilute one envelope of the powder in 500 ml of clean cold water and apply for 10 minutes every 8 hours until completely healed.
75614194|NCT04258930|Device|Topical sterile silicone gel for wounds|Apply a thick layer of silicone gel to all open areas every 8 hours until completely healed.
75614195|NCT04258930|Device|Hydrocolloid dressing|Apply enough hydrocolloid dressings to cover all open areas and change every 2 to 3 days once the dressing becomes saturated (starts to drain around the borders).
75614196|NCT02669875|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
75614197|NCT02669875|Drug|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
75614198|NCT04176289|Diagnostic Test|PPI measurement|The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
75614199|NCT02671045|Genetic|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
75614200|NCT02671045|Genetic|Genomic profile by other methods|Genomic profiling by other testing methods.
75616419|NCT00655837|Drug|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
75907387|NCT02194374|Drug|Bendamustine|"BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.~FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3."
75907388|NCT03693079|Procedure|Wet cupping therapy|"CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~Primary suction; cups are left attached to the skin for 5 minutes.~Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied"
75765138|NCT03286699|Behavioral|Physical Activity Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
75765139|NCT03248310|Behavioral|Quality of Life Assessments|Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
75765140|NCT03212170|Drug|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging|18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
75765141|NCT03207529|Drug|Alpelisib|Given PO
75765142|NCT03207529|Drug|Enzalutamide|Given PO
75461116|NCT01848262|Procedure|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
75765143|NCT03190941|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
75616420|NCT02634931|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
75616421|NCT05336422|Other|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
75765144|NCT03190941|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
75765145|NCT03190941|Biological|Anti-KRAS G12V mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
75765146|NCT03190941|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
75907389|NCT02193204|Behavioral|Personal Stress Imagery|"The stress imagery script will be based on participants' description of a recent personal event experienced as most stressful, and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions."
75907390|NCT02193204|Behavioral|Neutral Imagery|The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
75316175|NCT04163107|Drug|Hydroxychloroquine|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
75316176|NCT04163107|Drug|Carfilzomib Injection|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
75316177|NCT04163107|Drug|Dexamethasone|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
75316178|NCT01429298|Drug|Hydromorphone|2 mg IV hydromorphone over to 2-3 minutes
75765147|NCT03179085|Behavioral|Home-Based Kidney Care|All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
75316179|NCT01429298|Drug|Usual care|Attending administers IV opioid of his choosing
75316180|NCT00397579|Drug|DT388IL3|Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
75316181|NCT04141657|Other|Pharmacogenetic test|Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.
75765148|NCT03147937|Other|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online
75765149|NCT03147287|Drug|Palbociclib|Palbociclib is a drug that may stop cancer cells from growing
75765150|NCT03147287|Drug|Fulvestrant|Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
75765151|NCT03147287|Drug|Avelumab|Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
75765152|NCT03135275|Procedure|Staged complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
75765153|NCT03135275|Procedure|Immediate complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
76070791|NCT05846113|Diagnostic Test|Renasight|"The Renasight™ test is a next generation sequencing (NGS) gene mutation assay for patients with chronic kidney disease (CKD) which utilizes genomic DNA from patient blood or buccal swab samples to analyze over 380 genes that are associated with autosomal dominant, autosomal recessive and X-linked disorders.~Patients undergoing Renasight™ testing are offered optional genetic information sessions in addition to their test results.~RenasightTM is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
75316182|NCT01408706|Device|Miller Air tip|Miller Enema Air Tip is inserted into rectum prior to simulation and each radiation treatment.
75461117|NCT01848262|Procedure|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
75461118|NCT01848275|Device|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
75765154|NCT03135275|Device|Synergy™ stent|Bioabsorbable Polymer Drug-Eluting Stent
75907391|NCT03693001|Device|Intermittent Exposure to Oxygen via Oro-Nasal Mask|Patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ATA) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask for 40 treatments over a 2 month period.
75907392|NCT02193906|Other|Cognitive training|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
75907393|NCT02193906|Other|Placebo task|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
76070792|NCT05842512|Drug|ADI-PEG20|Treatment for NASH
76070793|NCT05842512|Other|Placebo|Treatment for NASH
76070794|NCT05839743|Other|Aerobic Exercise|The aerobic exercise program will be specially prepared for the participants and will aim to rhythmically exercise large muscle groups. The exercise will be performed twice a week for 6 weeks at 50-75% of maximum heart rate for 20-50 minutes per session. Each exercise will last 30-60 minutes in total, after adding 5 minutes of warm-up and 5 minutes of cool-down before and after the exercise. The participant's pulse will be monitored continuously during the exercise.
76070795|NCT05839743|Other|Balance Exercise|Balance exercises belonging to the Otago Exercise Program and other balance exercises used in the elderly will be prepared specifically for the participant and will be applied 2 days a week for 6 weeks in combination. Before and after the exercise, a 5-minute warm-up and 5-minute cool-down exercise will be performed.
75316183|NCT01408706|Device|Radiadyne Immobilizer|Radiadyne Immobilizer is inserted into rectum prior to simulation and each radiation treatment
75316184|NCT02988531|Other|PET/MR scan|Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
75316185|NCT04045886|Behavioral|Online Educational Modules (Videos)|5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
75316186|NCT04051502|Drug|Method 1: Indocyanine green dye|Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
75316187|NCT04051502|Drug|Method 2: Indocyanine green dye|"1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~Dorsal side of the IP ligament~Ventral side of the IP ligament~Dorsal side of the utero-ovarian ligament~Ventral side of the utero-ovarian ligament"
75316188|NCT04051502|Drug|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
75316189|NCT04051502|Drug|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.
75461119|NCT01848275|Device|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
75461120|NCT01848301|Device|Optical Coherence Tomography|OCT imaging of the LAD coronary artery
75461121|NCT01848301|Drug|Acetylcholine|Infusion in the coronary artery to study endothelial function
75765155|NCT03104569|Procedure|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
75765156|NCT03095248|Drug|Selumetinib|Continuous twice daily dosing; oral agent
75765157|NCT03068442|Drug|Imaging with flutemetamol F 18 PET/CT|All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
75765158|NCT03053141|Device|Rhythmia Mapping System|The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
75765159|NCT03049462|Drug|Mirabegron|Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.
75907394|NCT03692923|Other|virtual community|
76070796|NCT05839743|Other|Combined Exercise|In the combined exercise program, first balance exercises and then aerobic exercise program will be applied 2 days a week for 6 weeks.
76070797|NCT05839639|Drug|NrtIs|Subjects will receive NrtIs therapy for 24 weeks.
76070798|NCT05839639|Drug|HH-003|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.
76070799|NCT05839639|Drug|HH-003+NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.
76070800|NCT05839145|Other|Strength force measurment|The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)
76070801|NCT05839145|Other|Time tests|Lower and upper limb capacities of the patients will be measured during timed tests
75907395|NCT02193360|Drug|FFP104|Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
75907396|NCT03688321|Dietary Supplement|Probiotic capsule GR-1 and RC-14|Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
75316190|NCT01408628|Behavioral|Internet Insulin Education|"Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of < 7.0% using an established treat-to-target algorithm."
75316191|NCT01389752|Drug|LY2216684|Administered orally
75316192|NCT01389752|Drug|Activated Charcoal|Administered orally
75316193|NCT01428128|Drug|Arsenic Trioxide|IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
75316194|NCT01407926|Other|Nurse-Led Mental Health Promotion Intervention|The nurse-led intervention is a multi-faceted 6-month program led by a Registered Nurse that involves regular home visits, monthly case conferences, and evidence-based assessment and management of depression using an interprofessional approach.
75316195|NCT00358501|Drug|Defibrotide|Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
75461122|NCT01848301|Procedure|Brachial Artery Flow Mediated Dilation|Assess peripheral brachial artery endothelial function
75461123|NCT01848314|Procedure|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
75461124|NCT01848327|Dietary Supplement|Caprylic Triglyceride|Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
75461125|NCT01848327|Dietary Supplement|Placebo|Placebo (40 gram packet orally once a day for 90 days)
75461126|NCT01848340|Drug|GSK1265744B (sodium salt) containing 14C-GSK1265744B|A white to slightly colored nonsterile crystalline powder for oral solution
75461127|NCT01848340|Drug|150 mg GSK1265744B|This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
75461128|NCT01848340|Drug|Placebo|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
75461129|NCT01848379|Procedure|ADT+FD|
75461130|NCT01848379|Procedure|FD|
75907397|NCT03688321|Dietary Supplement|Placebo capsule|Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
75907398|NCT03692845|Procedure|Transforaminal Lumbar Interbody Fusion either open or minimally invasive|Spinal fusion procedure through the intervertebral foramen
75907399|NCT02194452|Radiation|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
75907400|NCT02194452|Procedure|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
76070802|NCT05839145|Other|Motor scales|Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)
76070803|NCT05839145|Other|Questionnaires|Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)
76070804|NCT05839145|Device|Accelerometry|Patients physical activity will be measured at home using accelerometer sensors
76070805|NCT05839145|Other|MNR|Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs
76070806|NCT05839145|Other|Bio-impedance analysis|The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)
76070807|NCT05837897|Drug|Vedolizumab IV|Vedolizumab IV infusion
76070808|NCT05837897|Drug|Placebo|Vedolizumab placebo-matching IV infusion
75316196|NCT01427972|Drug|LY2623091|Administered orally
75316197|NCT01427972|Drug|Eplerenone|Administered orally
75461131|NCT01848444|Other|Breastmilk|to measure levels of contaminants in human breastmilk samples
75461132|NCT01848470|Drug|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
75461133|NCT01848470|Drug|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
75461134|NCT01848470|Drug|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
75461135|NCT01848470|Drug|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
75461136|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
75461137|NCT01848470|Drug|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
75461138|NCT01848470|Drug|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
75461139|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
76070809|NCT05832801|Other|( Traditional dietary advice )|traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).
75461140|NCT01848496|Procedure|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
75614201|NCT04084327|Other|stastical analysis|1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results
75461141|NCT01848509|Device|With teletransmission|Teletransmission of alerts
75461142|NCT01848535|Dietary Supplement|GOS addition|GOS (2.5g 3x per day) supplemented during 12 days
76070810|NCT05832801|Other|(Pilates exercises)|Pilates exercises will be in the form of Swan, One leg up-down, Leg circles, Single leg stretch, Saw, Side kicks, The hundred,. Pelvic lift on the ball, Sit-ups with the ball, Stretching on the ball. exercise Dose will be First month (1st-8th session) 1 set of 8 repetitions Second month (8th-16th session) 2 sets of 10 repetitions
76070811|NCT05821868|Device|Dosivent|Dosivent® inhalation chamber is designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
76070812|NCT05821868|Device|Aerochamber Plus Flow Vu|Aerochamber Plus Flow Vu® inhalation chamber is also designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
76070813|NCT05817175|Procedure|pre-pectoral breast reconstruction|to prospectively evaluate the utilization of the pre-pectoral approach, and evaluate oncological and aesthetic outcomes related to each type of surgical technique and the use of postmastectomy radiation therapy
75316198|NCT00336323|Procedure|Laser Photocoagulation|Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart
75316199|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
75461143|NCT01848535|Dietary Supplement|Placebo|Maltodextrine(2.5g 3x per day) supplemented during 12 days
75461144|NCT01848548|Procedure|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
75461145|NCT01848574|Other|standardized multifaceted information procedure to improve patients' comprehension|
75614202|NCT01175135|Drug|PF-02545920|5 mg tablet every 12 hours for 28 days
75614203|NCT01175135|Drug|PF-02545920|15 mg tablet every 12 hours for 28 days
75614204|NCT01175135|Drug|Placebo|One tablet/capsule every 12 hours for 28 days
75614205|NCT01175135|Drug|Risperidone|3 mg capsule every 12 hours for 28 days
75765160|NCT03049462|Other|B Complex Plus Vitamin C Tablets|Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
75765161|NCT02990546|Drug|midodrine|Midodrine will be given to treatment arm as enteral medication
75316200|NCT00336323|Drug|Bevacizumab|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
75461146|NCT01848587|Other|acupuncture|
75461147|NCT01848587|Other|usual care|
75461148|NCT01848600|Behavioral|interpretation of the abstract|the intervention consist to interpret the results of the meta-analysis after reading the abstract.
75461149|NCT01848613|Drug|Vinorelbine|
75765162|NCT02990546|Other|Standard of Care|Patients in the control arm will receive standard of care for septic shock
75765163|NCT02965963|Drug|Dopamine|
75765164|NCT02965963|Drug|Metoclopramide|
75765165|NCT02965963|Drug|Placebos|
75765166|NCT02965963|Other|Rest|
75316201|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
75316202|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
75316203|NCT01427738|Drug|Gentian Violet|Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.
75316204|NCT01427738|Drug|Nystatin oral suspension|Participants were administered Nystatin oral suspension 4 times a day for 14 days.
75316205|NCT01426958|Drug|afatinib|standard therapeutic dose
75461150|NCT01848652|Drug|infusion of MYOCET|
75461151|NCT01848665|Drug|Indomethacin|
75461152|NCT01848665|Drug|Placebo|
75461153|NCT01848691|Other|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
75461154|NCT01848704|Behavioral|interpretation of the abstract|
75461155|NCT01848717|Device|MINTLIFT®|
75461156|NCT01848730|Drug|CNV2197944|
75461157|NCT01848730|Drug|Placebo|
75461158|NCT01848743|Drug|Tenofovir|
75461159|NCT01848743|Drug|lamivudine|
75614206|NCT02667613|Other|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
75614207|NCT02667613|Other|Control|Usual customary care
75614208|NCT00645541|Procedure|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
75765167|NCT02965963|Other|Exercise - 60%|60% of VO2max
75765168|NCT02965963|Other|Exercise - 85%|85% of VO2max
75765169|NCT02865135|Drug|DPX-E7 vaccine|Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A*02 positive patients.
75907401|NCT02194452|Procedure|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
75907402|NCT02194452|Other|laboratory biomarker analysis|Correlative studies
75765170|NCT02865135|Drug|Cyclophosphamide|Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
75765171|NCT02858310|Biological|E7 TCR cells|T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
75765172|NCT02858310|Drug|Aldesleukin|Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.
75907403|NCT04243213|Other|Vibration Plate|Vibration at 15° tilt, which means the patients partly use their own body weight (resistive vibration exercise).
75316206|NCT01426958|Drug|ritonavir + afatinib|simultaneous intake of ritonavir and afatinib on second treatment day
75907404|NCT04243213|Other|Tilt at 15°|To compare if a possible effect derives from the vibration or the tilting only, a second group was added who will only receive 10 min of 15° tilt without the vibration.
75316207|NCT01426958|Drug|ritonavir + afatinib|on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
75907405|NCT04243213|Other|Standard hospital mobilization|early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients
75461160|NCT01848769|Drug|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
75907406|NCT02193438|Other|Spices intake|Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.
75316208|NCT05266157|Other|Manual lymph drainage|Manual lymph drainage
75316209|NCT05266157|Other|Usual care|skin care, exercise and compression stocking
75316210|NCT00397813|Drug|Cyclosporine|Given PO
75316211|NCT00397813|Drug|Fludarabine Phosphate|Given IV
75316212|NCT00397813|Other|Laboratory Biomarker Analysis|Correlative studies
75316213|NCT00397813|Drug|Mycophenolate Mofetil|Given PO
75316214|NCT00397813|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
75461161|NCT01848769|Drug|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
75461162|NCT01848769|Drug|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
75461163|NCT01848782|Behavioral|interpretation of the abstract of the systematic review|
75461164|NCT01848795|Device|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
75461165|NCT01848795|Device|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
75461166|NCT01848808|Dietary Supplement|Wobenzym PS|
75461167|NCT01848808|Dietary Supplement|Placebo|
75461168|NCT01848860|Procedure|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
75461169|NCT01848860|Biological|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
75461170|NCT01848873|Drug|Amlodipine|amlodipine 5mg daily
75461171|NCT01848873|Drug|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
75461172|NCT01848873|Drug|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
75461173|NCT01848886|Procedure|Endoscopic radial artery harvest|Radial artery harvest is performed as an endoscopic procedure.
75616422|NCT00655915|Other|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
75765173|NCT02858310|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
75765174|NCT02858310|Drug|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
75316215|NCT00397813|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
75461174|NCT01848886|Procedure|Open radial artery harvest|Radial artery harvest is performed as an open procedure.
75765175|NCT02840942|Behavioral|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
75765176|NCT02840942|Behavioral|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
75765177|NCT02836600|Drug|LY3039478|Administered orally
75765178|NCT02811744|Drug|11C-acetate|Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
75907407|NCT02193438|Other|Placebo|Tomato juice intake
75907408|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
75907409|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
75907410|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
75907411|NCT02257164|Procedure|Femoral nerve block|2 mg/ml
75907412|NCT02257164|Procedure|obturator nerve block|
75907413|NCT02257164|Procedure|intraarticular injection|
75907414|NCT02193984|Behavioral|Peer support|
76070814|NCT05813132|Drug|BEAM Protocol|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
75316216|NCT00397813|Radiation|Total-Body Irradiation|Undergo TBI
75316217|NCT01791023|Other|Physical exercise|30 minutes of aerobic exercise on treadmill with moderate intensity.
75765179|NCT02769962|Drug|EP0057|"EP0057 IV Q 2weeks Day 1 and Day 15, administered in 28 day cycles, until disease progression or development of intolerable side effects~Plus olaparib (PO days 3-13* and days 17-26*) administered in 28 day cycles, until disease progression or development of intolerable side effects. P1: Dose Escalation P2: RP2D~(* On days 13 and 26, only one dose of olaparib will be administered in the morning)"
75765180|NCT02769962|Drug|olaparib|olaparib (PO days 3-13* and days 17-26* administered in 28 day cycles, until disease progression or development of intolerable side effects Plus EP0057 (IV Q 2weeks, Day 1 and Day 15) administered in 28 day cycles, until disease progression or development of intolerable side effects P1: Dose Escalation P2: RP2D (* On days 13 and 26, only one dose of olaparib will be administered in the morning)
75765181|NCT02753790|Radiation|Intensity Modulated Radiotherapy|"Whole brain radiation using IMRT: 60 Gy to gross disease (planning treatment volume [PTV] 60) or 45 Gy to gross disease (PTV 45) and 30 Gy to subclinical sites (PTV 30) over 15 fractions.~Patients will be treated Monday through Friday (5 days per week) for 3 weeks. Patients with either a single metastasis greater than 15 cubic centimeters (cm) or total volume of metastases greater than 26 cubic cm will receive the lower dose of 45 Gy to visible brain metastases. 45 Gy may also be prescribed per physician discretion.~Gross disease which has received prior radiosurgery will receive 30 Gy."
75765182|NCT02740634|Drug|F-18 AV 1451|Tau binding agent
75765183|NCT02740634|Drug|C-11 PiB|Amyloid binding agent
75765184|NCT02709720|Drug|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
75765185|NCT02709720|Drug|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
75765186|NCT02709720|Drug|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
75765187|NCT02709720|Drug|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
75765188|NCT02709720|Radiation|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
75765189|NCT02689466|Drug|[18F]FP-TZTP|radioligand
75765190|NCT02652260|Drug|Doravirine, Tenofovir, Lamivudine - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
75765191|NCT02652260|Drug|Doravirine, Tenofovir, Lamivudine - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.
76070815|NCT05813132|Drug|CEM protocol|CEM (Carboplatin, Etoposide, Melphalan)
75316218|NCT01791101|Drug|Eltrombopag|
75461175|NCT01848886|Procedure|Mammarioradial graft (Y-graft)|The radial artery is used as an composite graft positioned on the internal mammarian artery.
75461176|NCT01848886|Procedure|Aortoradial graft (Free RA)|The radial artery is used as an free graft positioned on the aorta.
75461177|NCT01848925|Biological|SANGUINATE™|40 mg/mL intravenous infusion.
75461178|NCT01848925|Drug|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
75461179|NCT01848964|Device|Clinical and instrumented measurements|"Clinical examination will include stump pain, wound, scar and unusual shape.~Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)~After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.~Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.~Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate."
75461180|NCT01849003|Drug|GS-6615|GS-6615 tablet(s) administered orally
75765192|NCT02652260|Drug|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
75316219|NCT00398983|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days
75316220|NCT01791179|Behavioral|Comprehensive substance abuse services|
75316221|NCT00358579|Drug|Adrenaline|1 mg
75316222|NCT00358579|Drug|Vasopressin|40 IU
75316223|NCT00338039|Drug|Cetuximab|500 mg/m^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.
75316224|NCT00338039|Drug|Gemcitabine|"Induction Therapy: 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.~Chemotherapy Maintenance: 1 gm/m^2/week over 100 minutes weekly for 3 weeks then 1 week off."
75461181|NCT01849016|Drug|N-Acetylcysteine|
75461182|NCT01849016|Drug|Placebo|
75616423|NCT02637271|Other|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
75765193|NCT02652260|Drug|Placebo to ATRIPLA™|A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
75765194|NCT02652260|Drug|Placebo to Doravirine, Tenofovir, Lamivudine|A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
75765195|NCT02635009|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo PCI using 3DCRT
75765196|NCT02635009|Other|Cognitive Assessment|Ancillary studies
75765197|NCT02635009|Radiation|Intensity-Modulated Radiation Therapy|Undergo PCI with HA using IMRT
75765198|NCT02635009|Other|Laboratory Biomarker Analysis|Correlative studies
75765199|NCT02635009|Other|Quality-of-Life Assessment|Ancillary studies
75765200|NCT02593526|Drug|Bumetanide|Diuretic
75765201|NCT02593526|Other|Cool Dialysate|Cool dialysate (35°C)
75765202|NCT02580981|Other|Acute Lymphobastic Leukemia (ALL) Treatment Options|Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
75765203|NCT02571725|Drug|Olaparib|Olaparib starts concomitantly with the first dose of Tremelimumab
75765204|NCT02571725|Drug|Tremelimumab|3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
75765205|NCT02535702|Other|In vivo MRS|1H MR spectroscopy to assess brain metabolites.
75765206|NCT02535702|Other|fMRI|Three fMRI sessions to assess test-retest reliability of functional connectivity (FC) measures at rest and during task performance.
75765207|NCT02535702|Other|EEG/EOG|Electroencephalography or electrooculography (EEG/ EOG) sessions to record electrical activity of the brain or measure corneo-retinal standing potentials.
75614209|NCT02667769|Other|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose <55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
75614210|NCT02667691|Dietary Supplement|SODB Dimpless|Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
75614211|NCT02667691|Dietary Supplement|Placebo|Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
75614212|NCT02667691|Other|caloric restriction|Caloric recommendation reduced by 20%
75765208|NCT02535702|Other|Stimulation tasks|To be used in the context of fMRI to study blood-oxygenation-level- dependent responses in the brain to sensory stimulation.
75765209|NCT02535702|Other|NSPRD|To be used in conjunction with pupillometry in the context of fMRI to study blood-oxygenation-level-dependent responses to selective neurostimulation of pain fibers.
75765210|NCT02535702|Other|Structural MRI|High spatial MRI and diffusion tensor imaging (DTI) to assess brain morphology and structural connectivity.
75765211|NCT02504905|Device|TMS|single TMS pulses at intensities in random order from 0 to 100% (increasing at 5% intervals) of stimulator output at a frequency of 0.1 Hz. Three pulses will be delivered at each intensity. MEPs will be recorded and their amplitudes will be plotted against the corresponding stimulation intensity. This curve will provide three significant parameters: (a) S50 intensity (intensity for which we get a MEP 50 % of its maximal size); (b) estimated resting motor threshold (RMT): the abscissa where the tangent to the slope crosses the x axis; and (c) the maximum MEP ( plateau value).
75907415|NCT02194608|Device|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
75907416|NCT02195856|Dietary Supplement|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
75907417|NCT02195856|Dietary Supplement|Placebo|
75907418|NCT02195934|Other|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
75907419|NCT02195934|Other|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
75316225|NCT00338039|Drug|Oxaliplatin|Induction Chemotherapy: 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.
75316226|NCT00338039|Drug|Capecitabine|Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
75316227|NCT00338039|Radiation|Radiotherapy|Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
75316228|NCT00358657|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplantation
75316229|NCT00358657|Drug|Cyclophosphamide|Given IV
75316230|NCT00358657|Drug|Fludarabine Phosphate|Given IV
75907420|NCT02194686|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
75907421|NCT02194686|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
75907422|NCT04633681|Dietary Supplement|Sweetener and sweetness enhancer consumption|Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
75907423|NCT03692767|Biological|Anti-CD22 CAR NK Cells|Anti-CD22 CAR NK Cells injection
75907424|NCT03535038|Diagnostic Test|Inferior vena cava (IVC) diameter using USG|IVC diameter is measured from the distal of right hepatic pain and inferior vena cava meeting point using Philips En Visor C USG.
75316231|NCT00358657|Other|Laboratory Biomarker Analysis|Correlative studies
75316232|NCT00358657|Drug|Mycophenolate Mofetil|Given PO
75316233|NCT00358657|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic bone marrow transplantation
75316234|NCT00358657|Drug|Sirolimus|Given PO
75316235|NCT00358657|Drug|Tacrolimus|Given IV or PO
75316236|NCT00358657|Radiation|Total-Body Irradiation|Undergo total-body irradiation
75316237|NCT00340379|Drug|Ziprasidone|Target dosage 120-160mg/day based on tolerance
75316238|NCT00340379|Drug|Sertraline|Target dosage 150-200mg/day based on tolerance.
75316239|NCT00340379|Drug|Haloperidol|Target dosage 6-8mg/day based on tolerance.
75316240|NCT02982811|Device|i-ACT|3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
75316241|NCT00342563|Drug|mecamylamine|mecamylamine 10mg/day
75316242|NCT00342563|Drug|Placebo|Placebo
75316243|NCT00358735|Device|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
75765212|NCT02501941|Drug|ketamine|Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
75765213|NCT02470299|Drug|Ketorolac|"Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds~Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:~Patients < 65 years of age: Daily dose of 30 mg for three doses.~Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
75316244|NCT00358735|Drug|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
75461183|NCT01849029|Behavioral|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
75461184|NCT01849042|Drug|Ebixa|add-on of Ebixa oral pump already receiving donepezil with stable dosage
75461185|NCT01849042|Drug|donepezil|
75461186|NCT01849081|Device|CPAP|Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
75614213|NCT05098561|Other|Music Treatment|The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
75765214|NCT02470299|Other|Placebo|"Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:~Patients < 65 years of age: Daily dose of 30 mg for three doses.~Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
75907425|NCT03535038|Diagnostic Test|Vascular pedicle width (VPW)|VPW is measured by drawing a line from the left subclavian artery exit point from aorta perpendicular to the point where superior vena cava crosses with right bronchi.
75907426|NCT04622995|Drug|Benzodiazepine|Benzodiazepine prescribing
75907427|NCT01341639|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
75614214|NCT02669641|Dietary Supplement|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
75616424|NCT02637271|Other|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
75616425|NCT02637349|Behavioral|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
75316245|NCT04053803|Drug|IMR-687|Oral administration of once daily IMR-687
75316246|NCT01793519|Drug|Etanercept|Subcutaneous
75316247|NCT01793519|Drug|Infliximab|Infusion
75316248|NCT01793519|Drug|Adalimumab|Subcutaneous
75316249|NCT01793519|Drug|Placebo|Matching Placebo
75316250|NCT00359203|Device|Dual chamber pacemeker|
75316251|NCT01795339|Drug|AZD3293|Oral solution
75316252|NCT01795339|Drug|Placebo|Oral solution
75316253|NCT02109419|Other|HHT-G|Helping Hands Technology global cognitive function assessment
75316254|NCT02109419|Other|HHT-D|Helping Hands Technology depression assessment
75316255|NCT02109419|Other|Geriatric Depression Scale (DGS)|Geriatric Depression Scale (DGS)
75316256|NCT02109419|Other|MMSE|Mini Mental State Exam
75316257|NCT02000011|Other|comprehensive geriatric assessment (CGA)|
75316258|NCT02000011|Other|Geriatric intervention plan (GIP)|
75316259|NCT04024007|Diagnostic Test|Citrate dosage|Patients are dialysed according to the standard of care. Biological variables are measured in pre-filter, post-filter and dialysate 30 minutes after the dialysis is initiated.
75316260|NCT01794325|Other|Trans-radial|Coronary angiography performed through trans-radial access
75765215|NCT02444338|Device|MitraClip|Implantation of the MitraClip System for patients with chronic heart failure.
75765216|NCT02444338|Other|standard of care|
75461187|NCT01849081|Behavioral|LIfestyle|Subjects will undergo 12 weeks of dietary counseling.
75316261|NCT01794325|Other|Trans-femoral|Coronary angiography performed through trans-femoral access
75616426|NCT02637349|Behavioral|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
75616427|NCT04162093|Procedure|uretero ileal anastomosis in single trough|
75316262|NCT04022603|Device|Cyclometer Ergometer|The measurements are carried out on a max effort of 12 minutes on a cyclometer ergometer with a constant load (Motomed viva2 light). A first effort is made with a Venturi type mask whose Inspired Fraction in Oxygen (FiO2) is set for a pulsated oxygen saturation (SpO2) greater than or equal to 85%, and then a second at 2h interval with high-throughput googles (Optiflow) with the corresponding FiO2.
75907428|NCT01341639|Biological|INFANRIX™ hexa|INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
75316263|NCT00359983|Biological|MenHibrix (Hib-MenCY-TT)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
75461188|NCT01849094|Drug|Milrinone 6mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
75461189|NCT01849094|Drug|milrinone 10mg ER|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
75461190|NCT01849094|Drug|milrinone 14mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
75461191|NCT01849107|Biological|Plasma citrulline|
75316264|NCT00359983|Biological|Hib conjugate vaccine (ActHIB)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
75316265|NCT03824249|Diagnostic Test|Indirect Calorimetry|Performance of indirect calorimetry in Canopy mode.
75461192|NCT01849120|Device|EQUANOX Advance 8004CB sensor|The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
75461193|NCT01849133|Radiation|external fractionated radiotherapy|conventional external beam radiotherapy
75461194|NCT01849133|Radiation|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
75616428|NCT02637193|Drug|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
75461195|NCT01849159|Biological|Mesenchymal stem cells|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
75461196|NCT01849159|Other|Reference therapy: 400 mL of 0.9% NaCl solution|
75461197|NCT01849185|Other|Food supplement|
75765222|NCT02364557|Radiation|Stereotactic Body Radiotherapy|"Patients receive 1, 3, or 5 fractions of radiation, beginning within 6 weeks of study entry.~For metastases in the peripheral lung, patients receive a single fraction of 30 Gy or 3 fractions for a total of 45 Gy.~For a single liver metastases, patients receive a single fraction of 30 Gy.~For metastases in the abdominal-pelvic or liver (>1), patients receive 3 fractions for a total of 45 Gy.~For metastases in the central lung or mediastinal/ cervical lymph nodes, patients receive 5 fractions for a total of 50 Gy.~For spinal metastases, patients receive 1 fraction of 20 Gy.~For non-spinal osseous metastases, patients receive 3 fractions for a total of 30 Gy.~For thoracic/cervical spine metastases, patients receive 5 fractions for a total of 35 Gy."
75907429|NCT01341639|Biological|RotaTeq|RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
75907430|NCT01341639|Biological|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
75907431|NCT01341639|Biological|ProQuad™|ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
75907432|NCT03534960|Device|High Flow Nasal Oxygen Therapy|Nasal cannula flows of 3 to 8 lpm via systems approved to provide increased humidification and warmth to inspired gas
75907433|NCT03534960|Device|Nasal CPAP|"Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O"
75907434|NCT02196012|Behavioral|Intervention group|
75907435|NCT02196012|Behavioral|attention control condition|
75907436|NCT02628028|Drug|LY3337641|Administered orally
75907437|NCT02628028|Drug|Placebo|Administered orally
75316266|NCT04388735|Behavioral|Questionnaire|Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
75316267|NCT00345371|Drug|Topiramate|
75316268|NCT00345371|Drug|Placebo Oral Tablet|
75316269|NCT03006276|Drug|DFN-15 Active|
75316270|NCT03006276|Other|DFN-15 Placebo|
75316271|NCT00350363|Drug|Zymar|zymar qid
75316272|NCT04801667|Biological|Coronavac|The CoronaVac is manufactured by Sinovac Life Sciences Co., Ltd. This vaccine contains the inactivated SARS-CoV-2 virus antigen and is administered intramuscularly.
75461198|NCT01849198|Device|accelerometry m. trapezius and m. adductor pollicis|
75461199|NCT01849211|Drug|rocuronium|
75461200|NCT01849224|Other|Pelvic and lower extremity exercise|
75461201|NCT01849237|Genetic|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).
75616429|NCT02637193|Drug|Moxifloxacin|400 mg single dose moxifloxacin
75616430|NCT02637193|Drug|Drug - placebo|Placebo administered for 16 days
75616431|NCT04163575|Biological|:Anti-CD22-CAR|Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
75616432|NCT00656773|Drug|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
75614215|NCT02886221|Procedure|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
75765223|NCT02364557|Procedure|Surgery|All surgical resections will be approached with intent of an R0 resection (rendering the patient with no evidence of measureable disease and pathologic negative margin) and must occur within 6 weeks of study entry. Approach to surgery will be based upon the treating surgeon. An open, laparoscopic, or thorascopic approach is acceptable.
75614216|NCT02669485|Drug|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
75765224|NCT02332668|Biological|Pembrolizumab|IV infusion
75614217|NCT02669485|Device|Fluorescence imaging|
75614218|NCT05658185|Behavioral|MIDITRA|"The psychological treatment protocol will be implemented over 10 group sessions of face-to-face psychological treatment with patients. The treatment sessions will have the following objectives and themes:~Adjustment to the disease:~Self-esteem/self-concept:~Coping with fear:~Emotional self-regulation:~Social area and enjoyment:~Decision making and problem solving:~Communication and listening skills:"
75907438|NCT03688087|Device|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
75907439|NCT03688087|Device|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
75907440|NCT02194764|Drug|Naltrexone and 2-butanol|50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
75614219|NCT00922480|Drug|Fimasartan|Fimasartan 60 ~ 120mg/po take one tablets once a day
75614220|NCT00922480|Drug|Losartan (Control)|Losartan 50 mg ~ 100 mg/po, take one tablets once a day
75765225|NCT02301182|Device|ADM X3-MoP Cup|
75765226|NCT02301182|Device|CoC Cup|
75907441|NCT02194764|Drug|2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)|a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
75907442|NCT03692689|Biological|SCT200|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
75907443|NCT02196090|Behavioral|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
75765227|NCT02245997|Radiation|External beam radiotherapy|
75316273|NCT02578992|Procedure|Head-lift position|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
75765228|NCT02245997|Radiation|proton beam RT|
75765229|NCT02225301|Other|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention.
75765230|NCT02179086|Radiation|3-dimensional conformal radiation therapy|Undergo standard-dose 3D-CRT
75765231|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo standard-dose IMRT
75765232|NCT02179086|Radiation|photon beam radiation therapy|Undergo dose-escalated and -intensified photon IMRT
75765233|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo dose-escalated and -intensified photon IMRT
75765234|NCT02179086|Radiation|proton beam radiation therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
75907444|NCT02196090|Device|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
75907445|NCT04619719|Device|Hyperbaric Oxygen Therapy (HBOT)|Patients assigned to the treatment arm will receive up to 5 treatments of hyperbaric oxygen therapy administered daily at 2.0 atmospheres for 90 minutes per session.
75316274|NCT02578992|Device|7cm high pillow|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
75316275|NCT00351299|Drug|Dexmedetomidine|dexmedetomidine infusion titrated to effect
75316276|NCT00351299|Other|Standard of Care|Standard of care per treating physician preference
75316277|NCT02909868|Device|BackBeat-PHC|A conductance catheter will be used to obtain PV loops prior to a Moderato pacemaker implant procedure.
75316278|NCT05341518|Procedure|Subscapularis repair|To complete reverse total shoulder arthroplasty, the surgeon must cut through the subscapularis muscle. In this arm of the study, the muscle will be repaired, rather than left to heal itself.
75316279|NCT04303416|Drug|Albumin solution|plasma exchange with albumin, one per week for one month, then one per month for 5 months
75316280|NCT05330286|Drug|LMI070|oral solution
75616433|NCT00656773|Drug|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
75616434|NCT04017559|Behavioral|Motivational Interviewing|A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
75616435|NCT04165525|Device|Ablation|comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
75616436|NCT04163263|Drug|BOS-356|topical gel
75616437|NCT04163263|Drug|Vehicle|topical gel
75765235|NCT02179086|Drug|temozolomide|Given PO
75765236|NCT02179086|Other|laboratory biomarker analysis|Correlative studies
75765237|NCT02105545|Other|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
75765238|NCT02088749|Behavioral|lifestyle intervention for obesity|
75765239|NCT02016924|Drug|ATV|Capsules administered once daily according to dosing recommendations per product monograph
75765240|NCT02016924|Drug|DRV|Tablets administered once daily according to dosing recommendations per product monograph
75765241|NCT02016924|Drug|Cobicistat|Tablets administered orally once daily with food
75765242|NCT02016924|Drug|BR|Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
75614221|NCT04174885|Procedure|epicardial ablation|"In general anesthesia and left lung ventilation, authors will access the right thorax by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be visualized by trans esophageal echocardiography before the ablation."
75765243|NCT02016924|Drug|F/TAF|Tablets administered orally once daily
75765244|NCT02016924|Drug|LPV/r|Solution administered orally
75765245|NCT02016924|Drug|Third Unboosted Drug|ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
75765246|NCT02016924|Drug|Cobicistat TOS|Tablets for oral suspension
75907446|NCT03534414|Dietary Supplement|Portfolio Dietary Pattern|"Portfolio Dietary Pattern consisting of 4 food components, including:~plant sterols (sterol-enriched margarine or supplement)~viscous soluble fibres (oats, barley, psyllium, eggplant, okra, etc)~plant protein (soy products and pulses), and~nuts (tree nuts and peanuts)"
75907447|NCT03534414|Dietary Supplement|NCEP Based Diet|A low saturated fat, low cholesterol diet.
75461202|NCT01849237|Drug|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
75461203|NCT01849302|Dietary Supplement|Beverages varying in macronutrient content on appetite|In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
75765247|NCT02016924|Drug|F/TAF TOS|Tablets for oral suspension
75765248|NCT01996865|Drug|Lenalidomide|
75907448|NCT03534336|Behavioral|Incentive for Education|"A $150 Incentive for Education is given to the participants for passing at least nine quizzes by the end of the program"
75907449|NCT03534336|Behavioral|Incentive for Weight Loss|"A $150 Incentive for Weight Loss is given to the participants for losing at least 5% of baseline weight by the end of the program"
75907450|NCT02967640|Drug|Ketalar|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
75907451|NCT02967640|Drug|NaCl 9%|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
75461204|NCT01849315|Behavioral|AKIDS II|Physically active intervention
75316281|NCT05330286|Drug|LMI070|Oral solution
75316282|NCT05330286|Drug|LMI070|Oral solution given in fasted state
75316283|NCT05330286|Drug|LMI070|Oral solution given in fed state
75461205|NCT01849341|Drug|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
75461206|NCT01849341|Drug|Roflumilast 500 mcg per day|
75461207|NCT01849367|Device|Eldith Neuroconn tDCS device|
75461208|NCT01849380|Drug|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
75461209|NCT01849380|Drug|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
75765249|NCT01996865|Drug|Rituximab|
75765250|NCT01774487|Drug|Pentoxifylline|20 mg/kg/day divided in 3 doses, given orally for 90 days
75765251|NCT01763645|Drug|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
75765252|NCT01763645|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
75765253|NCT01763645|Drug|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
75765254|NCT01740596|Device|C-Pulse® System Counterpulsation|The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
75765255|NCT01717131|Procedure|Surgery for standard axillary node dissection|
75765256|NCT01717131|Other|No axillary lymph node dissection|No surgery on axillary lymph node
75765257|NCT01704274|Other|Low Dose GTN 0.0285 mg/hr|Low Dose GTN
75765258|NCT01704274|Other|High Dose GTN 0.057 mg/hr|High Dose GTN
75765259|NCT01704274|Other|Placebo|Placebo
75765260|NCT01517100|Other|Nabilone|CB agonist
75907452|NCT03692533|Diagnostic Test|Immunohistochemistry|"Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case."
75907453|NCT02943928|Device|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
75907454|NCT02943928|Device|traditional method by experience|Operator inserted the double lumen tube by experience
75907455|NCT02194920|Procedure|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
75461210|NCT01849393|Other|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
76070816|NCT05812989|Behavioral|Social Engage Coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
75316284|NCT05532462|Procedure|Trans-nasal complete nasalabial cyst excision|The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.
75316285|NCT00352001|Drug|azacitidine|Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
75316286|NCT00352001|Drug|lenalidomide|Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
75316287|NCT00401401|Drug|zalutumumab|Eight weekly infusions
75614222|NCT02886143|Procedure|Active Voiding Trial|"Nursing protocol:~Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push~Clamp the Foley~Deflate the catheter balloon and remove the catheter from the bladder.~Record the amount of saline that was instilled into the bladder.~Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate~7. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter"
75614223|NCT02886143|Procedure|Passive Voiding Trial|"Nursing protocol:~Deflate the catheter balloon and remove the catheter from the bladder.~Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).~5. If the patient has not voided within 5 hours, assist the patient to try to void.~6. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.~7. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter"
75316288|NCT00401401|Drug|cisplatin|Infusions
75461211|NCT01849406|Drug|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
75461212|NCT01849406|Drug|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
75461213|NCT01849445|Procedure|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
75614224|NCT02670967|Dietary Supplement|Soluble Fibre|
75316289|NCT00401401|Procedure|Radiotherapy|Daily in the treatment period
75316290|NCT00352781|Drug|nicotine replacement therapy|nicotine transdermal patches as per product monograph
75316291|NCT00352781|Behavioral|behavioural intervention|Smoking cessation counselling and relapse prevention
75316292|NCT03587519|Procedure|Early|Early ileostomy closure
75316293|NCT03587519|Procedure|Late|Late ileostomy closure
75461214|NCT01849445|Other|Home physiotherapy exercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
75461215|NCT01849471|Other|questionnaires|patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
75461216|NCT01849484|Radiation|Radiation according to indication with hippocampal sparing|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
75616438|NCT02634697|Behavioral|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
75614225|NCT04258618|Behavioral|CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS|Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI. This includes weekly, one hour sessions addressing sleep for 6 weeks.
75765261|NCT01517100|Drug|CP-945,598|Cannabinoid Receptor 1 antagonist
75765262|NCT01517100|Other|hyperglycemic clamp|assesses beta cell response
75765263|NCT01517100|Other|euglycemic-hyperinsulinemic clamp|measures insulin sensitivity
75765264|NCT01517100|Other|Nabilone|cannabinoid receptor agonist
75614226|NCT04258618|Device|Repetitive Transcranial Magnetic Stimulation|Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment. This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression. Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
75614227|NCT02669563|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
75765265|NCT01087346|Behavioral|Reading Information|Reading information about risk factors for obesity among children
75765266|NCT00914719|Behavioral|Information only|
75614228|NCT02669563|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
75765267|NCT00914719|Behavioral|Sexual risk reduction intervention|
75765268|NCT00914719|Behavioral|sexual risk reduction + alcohol risk reduction component|
75765269|NCT00905645|Device|Silimed Gel-Filled Mammary Implant|
75907456|NCT04855552|Behavioral|Behavioral Weight-loss Program Via Telehealth|Investigators will use a manual based on the DPP, as adapted previously for the endometrial cancer population and now adapted for breast cancer survivors. Dr.Courtney McCuen-Wurst, has extensive experience in working with persons with overweight and obesity with medical comorbidities. She also has experience leading group interventions at our Center via telehealth. The content of the sessions addresses the domains associated with behavioral weight management including nutrition, exercise, stress and emotion management, and lifestyle modification strategies (to improve adherence to the diet and activity plan). Participants will monitor energy intake and physical activity daily to help them achieve recommended calorie and activity goals. Self-monitoring will be encouraged online with MyFitnessPal.com, which will be shared with the study staff to increase accountability and provide opportunity for feedback to participants.
75907457|NCT04855552|Behavioral|Behavioral Weight-Loss Program Via Telehealth - Weight Measures|Each participant will also be mailed a digital scale (Eat Smart) so they can weigh themselves each week and report their weight to the group leader; patients will be encouraged to take a picture of their weight on the scale after they step off (the number remains for 3-seconds) and send the picture to Dr. McCuen-Wurst. Participants will be encouraged to start with at least 1-minutes of moderately vigorous physical activity (e.g. brisk walking, swimming), at least five days per week, building up to at least 30-minutes per day (150-minutes per week) by week-6.
76070817|NCT05812989|Behavioral|Connect for Caregivers|Participants will complete an individual session with a coach who will use a digitized prioritization tool to help identify goals and an action plan for social connectedness.
75614229|NCT02669563|Drug|[13N]ammonia|IV injection of [13N]ammonia
76070818|NCT05811442|Drug|50561 high dose|study drug
76070819|NCT05811442|Drug|50561 low dose|study drug
75614230|NCT02669563|Drug|[11C]HED|IV injection of [11C]HED
75614231|NCT04963036|Other|Entropy and NOL-Guided Goal Directed Anesthesia|Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
75614232|NCT04963036|Other|Standard of Care Group (Entropy and blinded NOL)|"Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate…), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing)."
75614233|NCT02537119|Procedure|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
75614234|NCT02537119|Procedure|Massage therapy|Rubbing on hamstrings
75614235|NCT04255420|Procedure|SPG Block|A cotton-tipped applicator soaked in 1% lidocaine will be inserted into the nostril on the side of the headache. If the headache is bilateral, two cotton-tipped applicators will be inserted. The cotton-tipped applicators will be left in place for 15 minutes.
75614236|NCT04255420|Drug|Standard IV Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.
75765270|NCT00900198|Procedure|Biopsy|Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
75765271|NCT00754260|Behavioral|Caffeine reduction|patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
75765272|NCT00713492|Drug|Alcohol|human laboratory alcohol consumption.
75765273|NCT00684437|Behavioral|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
75765274|NCT00684437|Behavioral|Questionnaire|Questionnaires taking 15-30 minutes to complete.
75765276|NCT00469339|Behavioral|Family Health History|
75765277|NCT00250055|Procedure|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
75765278|NCT00237263|Drug|Entacapone|
75765281|NCT00001379|Biological|Interferon|For LYG Grade 1 and 2: Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond CR.
75765282|NCT00001379|Drug|Rituxan and EPOCH|For LYG Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituxan) every 3 weeks for 6 cycles.
75765283|NCT01095328|Other|screening|screening for Q-fever with a single blood sampling
75765284|NCT01023425|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
75765285|NCT00285584|Drug|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
75614237|NCT00973479|Drug|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
75765286|NCT00285584|Drug|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
75765287|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
75907458|NCT04855552|Behavioral|Validated Surveys of Patient-Reported Outcomes|"The following surveys will be completed by participants pre- and post-intervention:~COH-QOL Instrument - Breast Cancer Patient (QOL-BC)~International Physical Activity Questionnaire (IPAQ) Short Form~Patient Health Questionnaire (PHQ-9) (Depression)~Acceptability of Intervention Measure~The following survey will be completed post-intervention~• Exit interview regarding acceptability of the program.~The following measurements/clinical tests results will be collected and compared pre- and post-intervention:~Anthropometric measurements: height (self-report); weight (as measured on scale provided by study)~Mammographic breast density estimated in annual clinical mammogram"
75907459|NCT03701971|Other|evaluation of the intensity of pruritus|evaluation of the intensity of pruritus with various questionnaires
75907460|NCT02194140|Other|oral iodinated contrast material|diluted in water
75316294|NCT01794481|Procedure|Resistance Exercise Training (RET)|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
75316295|NCT02843568|Other|Laboratory Biomarker Analysis|Correlative studies
75316296|NCT02843568|Radiation|Standard fractionation|60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
75907461|NCT03534648|Drug|PF-06865571 administered Day 7-14|PF-06865571 administered Q12hr on Days 7-14
75316297|NCT02843568|Radiation|Stereotactic Body Radiation Therapy (SBRT)|40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
75461217|NCT01849484|Radiation|Radiation according to indication without hippocampal protection|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
75461218|NCT01849510|Radiation|hypofractionated 12x3 Gy + integrated boost 12x4 Gy|hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT & hfSRT
75461219|NCT01849510|Radiation|hypofractionated 10x3 Gy|hypofractionated, homogeneous radiation (10x3 Gy)
75614238|NCT00973479|Other|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
75461220|NCT01849523|Behavioral|Web-based information and support|
75461221|NCT01849536|Device|SENSIMED Triggerfish®|
75461222|NCT01849549|Behavioral|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
75461223|NCT01849549|Other|MRI|Anatomical, diffusion, and/or functional MRI
75614239|NCT00973479|Drug|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
75765288|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
75765289|NCT01026857|Drug|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
75461224|NCT01849601|Device|percutaneous transluminal angioplasty balloon catheter|
75765290|NCT03671447|Other|ICU Usual Care|The control condition delivered at ICU is usual care.
75765291|NCT03671447|Behavioral|Tele-ICU|The experimental complex intervention ERIC consists of daily tele-medicine based rounds at ICU. Tele-ICU is implemented after a blended learning program for ICU staff which will be completed prior to the site's crossover.
75907462|NCT03534648|Drug|PF-06865571 administered Day 1-14|PF-06865571 administered Q12hr on Day 7-14
75907463|NCT03534648|Drug|PF-05221304 administered Day 1-14|PF-05221304 administered Q12hr on Days 1-14
75907464|NCT03534648|Drug|PF-05221304 administered Day 7-14|PF-05221304 administered Q12hr Days 7-14
76070820|NCT05811442|Drug|Placebo|Non-active study drug
75765292|NCT03853655|Radiation|Post-operative adjuvant radiotherapy|"Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.~Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.~Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks~For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week."
75614240|NCT04082221|Other|no intervention|no intervention
75765293|NCT03807700|Drug|Experimental Denture Adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
75765294|NCT01583842|Drug|124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)|"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration & PET/CT scan 6 weeks later."
75316298|NCT02843568|Procedure|Four Dimensional Computed Tomographic Imaging (4DCT)|Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
75316299|NCT05242679|Other|Myofascial release technique along with conventional physiotherapy exercises|Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
75461225|NCT01849614|Other|Cardiac SPECT perfusion scan|A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
75461226|NCT01849640|Drug|DHA-piperaquine and Primaquine|Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
75461227|NCT01849666|Drug|phenprocoumon|6 mg oral single dose
75316300|NCT05242679|Other|Conventional physiotherapy exercises|Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
75316301|NCT04270981|Drug|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C|960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition
75316302|NCT01793675|Procedure|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
75461228|NCT01849666|Drug|vemurafenib|960 mg bid orally
75461229|NCT01849679|Other|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
75461230|NCT01849705|Other|No intervention|
75461231|NCT01849731|Other|Face-to-face|is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.
75461232|NCT01849731|Other|Face-to-face intervention plus telephone reinforcement|In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
75461233|NCT01849744|Drug|VS-4718|
75614241|NCT04174183|Device|Closed-incision Negative-pressure Therapy - Dry dressing|A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .
75614242|NCT04174495|Diagnostic Test|DXA and CT-scan|DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
75614243|NCT04315493|Drug|pyrotinib maleate fasted in P1, low-fat diet in P2|pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
75614244|NCT04315493|Drug|pyrotinib maleate low-fat diet in P1, fasted in P2|pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
75614245|NCT04173871|Device|Protac Myfit®|A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
75614246|NCT02862483|Drug|Tamsulosin 0.2mg|
75614247|NCT02862483|Drug|Tadalafil 5mg|
75614248|NCT02862483|Drug|Placebo for Tamsulosin|
75614249|NCT01173653|Other|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
75614250|NCT01173653|Other|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
75616439|NCT00882583|Drug|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
75616440|NCT00882583|Drug|Dasatinib|Oral Dasatinib Days 8 through 64.
75616441|NCT00882583|Drug|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
75765295|NCT01583842|Drug|124I-MIBG (carrier added)|"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration & PET/CT scan 6 weeks later."
75765296|NCT01583842|Procedure|Positron Emission Tomography (PET) /Computerized tomography (CT)|A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.
75765297|NCT01092754|Procedure|MRI|contrast enhanced MRI
75765298|NCT01092754|Procedure|MRI|contrast enhanced MRI
75765299|NCT01092754|Drug|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
75765300|NCT02530606|Procedure|Photoacoustic Imaging|Undergo PAI
75765301|NCT00291668|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
75765302|NCT00291668|Other|Placebo|"Active Substance: isotonic sodium chloride solution~Pharmaceutical Form: Solution for injection~Concentration: 1 mL~Route of Administration: Subcutaneous use"
75765303|NCT01095406|Device|S1 ventilation|Ventilation with a O2 and CO2 controller
75765304|NCT00458393|Drug|daily TDF/FTC|daily oral medication
75461234|NCT01849757|Other|prime crystalloid|used for priming the CPB circuit
75316303|NCT04345939|Diagnostic Test|Detection method|Different methods for pathogen diagnosis
75461235|NCT01849757|Other|Human Albumin|Used as a constituent for priming the CPB circuit
75461236|NCT01849757|Other|Voluven|Used as a constituent for priming the CPB circuit
75461237|NCT01849796|Device|tDCS|TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
75461238|NCT01849809|Procedure|Gamma Ventral Capsulotomy|
75765305|NCT00458393|Drug|Placebo|daily oral medication
75765306|NCT03955354|Drug|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
75765307|NCT03955354|Drug|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
75765308|NCT01095484|Drug|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
75461239|NCT01849835|Procedure|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
75461240|NCT01849835|Procedure|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
75616442|NCT00882583|Radiation|Radiation Therapy|Standard Radiation Therapy.
75616443|NCT00656149|Procedure|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
75616444|NCT00656149|Procedure|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
75616445|NCT00900562|Drug|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
75616446|NCT02634775|Other|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
75616447|NCT02636959|Other|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
75765309|NCT01063478|Drug|RAD001 (in addition to standard radiation and chemotherapy)|Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
75765310|NCT01327144|Drug|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
75765311|NCT01327144|Drug|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
75765312|NCT01026935|Device|Open inguinal hernia repair|Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
75316305|NCT03533465|Behavioral|Complicated Grief Therapy (CGT)|CGT is an evidence based 16 session targeted grief therapy delivered in individual one hour weekly sessions. Treatment will end at 16 sessions (offered over the course of 20 weeks)
75316306|NCT01793753|Drug|Propofol|
75316307|NCT00360685|Drug|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
75316308|NCT00360685|Drug|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
75316309|NCT05487456|Other|P4M3 CA35|Ad libitum use of P4M3 with CA35 cartridges
75316310|NCT05487456|Other|P4M3 CM35|Ad libitum use of P4M3 with CM35 cartridges
75316311|NCT05487456|Other|CIG|Ad libitum use of subject's own preferred brand of cigarettes
75316312|NCT05487456|Other|Smoking Abstinence|Abstention from cigarette smoking
75316313|NCT04270825|Behavioral|Group CBT with IPT|Group treatment designed to target relationships with both possessions and people.
75765313|NCT01566071|Other|Assessment of drive abilities|
75765314|NCT01323101|Drug|Doxycycline|Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
75765315|NCT01323101|Other|No doxycycline|
75907465|NCT03701893|Dietary Supplement|Lactobacillus PS11610|7 months and a half intervention study. A 6 months intervention period preceded by a period of sampling and analysis of vaginal, seminal and gland swabs of 6 weeks. During the 6 months of intervention the men participants will intake one capsule that contains 1*10E9 colony forming unit (CFU) of Lactobacillus PS11610 and the women participating will intake two capsules of the same product (each 12 hours). If the couple stay pregnant during the intervention the man will end the product intake and the woman will reduce the dose to one capsule with 1*10E9 CFU of Lactobacillus PS11610 per day during 12 additional weeks.
75765316|NCT00310856|Biological|MenACWY-CRM|Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
75907466|NCT00005584|Biological|bleomycin sulfate|
75907467|NCT00005584|Drug|ABVD regimen|
75907468|NCT00005584|Drug|BEACOPP regimen|
75316314|NCT03797209|Device|EUS-guided fistulization AXIOS|By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
75316315|NCT00558519|Drug|cyclophosphamide|
75316316|NCT00558519|Drug|cytarabine|
75316317|NCT00558519|Drug|daunorubicin hydrochloride|
75316318|NCT00558519|Drug|dexamethasone|
75614251|NCT02667535|Drug|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
75616448|NCT04510480|Other|Observational study without specific intervention|Observational study with standard cardiac arrest approach
75316319|NCT00558519|Drug|doxorubicin hydrochloride|
75316320|NCT00558519|Drug|mercaptopurine|
75316321|NCT00558519|Drug|methotrexate|
75316322|NCT00558519|Drug|pegaspargase|
75316323|NCT00558519|Drug|thioguanine|
75765317|NCT00310856|Biological|MenC-CRM|One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
75765318|NCT00310856|Biological|DTaP-Hib-IPV|
75765319|NCT00310856|Biological|PC7|One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
75765320|NCT00310856|Biological|MMR|
75907469|NCT00005584|Drug|epirubicin hydrochloride|
75907470|NCT00005584|Drug|prednisone|
75316324|NCT00558519|Drug|vincristine sulfate|
75316325|NCT00558519|Radiation|radiation therapy|
75316326|NCT03380195|Other|Watermelon juice|Subject drinks 355ml of watermelon juice 1 hour prior to submaximal exercise
75907471|NCT00005584|Drug|vinblastine sulfate|
75907472|NCT00005584|Radiation|radiation therapy|
75907473|NCT02194218|Drug|Nevirapine, low dose|50 mg
75907474|NCT02194218|Drug|Nevirapine, high dose|100 mg
75907475|NCT02194296|Drug|Ambroxol hydrochloride - lozenge|
75907476|NCT02194296|Drug|Ambroxol hydrochloride - syrup|
75907477|NCT04225572|Behavioral|Physical Therapy: Dependent on Patient's Needs|"Therapeutic exercise:~ROM: Begin with passive upper extremity ROM and progress to active ROM.~Strengthening: Progressive upper extremity resistive exercises starting with light weights.~Aerobic: Select a suitable, individual aerobic exercise program (walking, yoga, etc.) Manual therapy~Soft tissue mobilization, myofascial release, and stretching of identified tight and stiff tissue.~Lymphedema treatment~Manual lymph drainage: Gentle lymphatic massage to lymph nodes and vessels by PT for 1-2 weeks. Instruct patient in self MLD to perform 1-2×/day for 10 minutes during the remaining weeks.~Compression therapy: Gradient compression bandaging for daily wear with activities and exercise for 1-2 weeks. Instruct in self compression bandaging or issue a compression garment to wear with exercise or activity, or with worsening symptoms of AWS (i.e. cording extends down arm) or lymphedema."
75907478|NCT02195076|Other|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
75907479|NCT02196480|Biological|anti-TNF|Anti-tumor necrosis factor therapy
75907480|NCT03977701|Behavioral|Phonological treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.
75907481|NCT03977701|Behavioral|Morpheme treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of targeted morphemes following the methodology of Plante and colleagues. A minimum of 50 productions will be targeted per 1-hour session.
75907482|NCT04224220|Other|Adult Medical Care Coordination|Nurse-based support that includes a home visit and follow-up coaching telephone calls to monitor patient status and ability to self-manage symptoms.
75907483|NCT04224220|Other|Remote Patient Monitoring|Nurse-based support and coaching that incorporates the use of technology to monitor patient status and ability to self-manage symptoms.
75907484|NCT02197026|Drug|Hylan G-F 20|
75907485|NCT02197026|Drug|Standard treatment|Standard drug treatment at the discretion of the investigator
75316327|NCT03380195|Other|Sport drink|Subject drinks 355ml of Gatorade 1 hour prior to submaximal exercise
75316328|NCT03380195|Other|Sugar water|Subject drinks 355ml of sugar water (22.5g) 1 hour prior to submaximal exercise
75316329|NCT03380195|Other|Water|Subject drinks 355ml of water 1 hour prior to submaximal exercise
75316330|NCT04309110|Device|or geko™ X-T3|The geko™ X-T3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin.
75907486|NCT02197026|Procedure|Physiotherapy|
75765321|NCT00310856|Biological|Varicella|
75765322|NCT03995615|Procedure|scaling and root planing|"After initial clinical evaluation, supra gingival calculus removal will be done. GCF samples will be collected from the control and test groups (Baseline samples) using paper strips (ORAFLOW). ® Group III patients will undergo a through oral hygiene instructions, full mouth supra-gingival and sub- gingival scaling and root planing clinical parameters will be re-recorded 6 weeks later and a 2nd GCF samples will be collected from selected test site from each patients following periodontal intervention.~All the samples will be placed in eppendorf vials containing the buffer solution and samples will be stored at -800 c until the time of analysis by Enzyme -linked immune sorbent assay kit (ELISA) (GENX BIO) TM"
75765323|NCT03670355|Drug|Tenofovir (TFV) IVR|Contains 1.4 g TFV
75907487|NCT02197026|Procedure|Hydrotherapy|
75907488|NCT02197104|Drug|citocoline|Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
75907489|NCT03975595|Behavioral|Meditation Intervention A|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
75907490|NCT03975595|Behavioral|Meditation Intervention B|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
75907491|NCT02197182|Drug|LUXSOL copper containing cream|Active comparator arm
75907492|NCT02197182|Drug|Metronidazole gel|Active comparator for treatment of bacterial vaginosis
75907493|NCT03692455|Procedure|Roux-en-Y Gastric Bypass|The Roux-en-Y gastric bypass procedure involves creating a stomach pouch out of a small portion of the stomach and attaching it directly to the small intestine, bypassing a large part of the stomach and duodenum. Not only is the stomach pouch too small to hold large amounts of food, but by skipping the duodenum, fat absorption is substantially reduced.
75907494|NCT03692455|Procedure|Vertical Sleeve Gastrectomy|VSG surgery restricts food intake and decreases the amount of food used. Most of the stomach is removed during this surgery, which may decrease ghrelin, a hormone that prompts appetite. Lower amounts of ghrelin may reduce hunger more than other purely restrictive surgeries, such as AGB.
75907495|NCT02197260|Drug|3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days|Systemic antibiotics after sub gingival mechanical debridement
76070821|NCT05800834|Drug|Morphine Sulfate|"For the preparation of the gel formulated for the intervention, the proportion of an ampoule of dimorf® (morphine sulfate) in the injectable presentation of 10mg/ml will be used. Morphine sulfate is a strong, systemic opioid analgesic used for the relief of severe pain.~For the base of the compound, Curatec Hidrogel with Alginate® will be used. A transparent and viscous hydrogel, which provides a moist environment, preventing the dressing from adhering to the skin, preventing additional injuries generated by difficulty removing the dressing."
75316331|NCT04271137|Combination Product|3D printed PEEK onlay|3d computer-designed Orbital onlay
75316332|NCT04271137|Combination Product|Pre-bent orbital mesh|Pre-bent orbital mesh on 3d printed template
75316333|NCT01792271|Other|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
75316334|NCT00403117|Drug|Placebo + Inactive Marijuana (0% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
75614252|NCT04284735|Other|Quantitative ATX and LPA determination in plasma and sputum|"Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (cases) and in plasma and sputum from RA patients without ILD (controls) after sputum induction using hypertonic saline inhalation"
75616449|NCT04488094|Drug|[18F]FSPG|A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of [18F]FSPG.
75316335|NCT00403117|Drug|Placebo + Active Marijuana (3.27% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
75765324|NCT03670355|Drug|Placebo IVR|Contains placebo
75765325|NCT01068782|Drug|XL184|given orally as capsules
75765326|NCT03975998|Procedure|Mitral valve repair|Minimally invasive repair of severe organic mitral regurgiation
75765327|NCT01566227|Other|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
75765328|NCT02532062|Dietary Supplement|Cholecalciferol|4,000 IU, oral, once a day for one year
75765329|NCT02532062|Dietary Supplement|multivitamin|oral, once a day for one year
75765330|NCT02532062|Dietary Supplement|Placebo|oral, once a day for one year
75765331|NCT01566305|Dietary Supplement|Buttermilk without added egg-yolk|Buttermilk without added egg-yolk
75765332|NCT01566305|Dietary Supplement|Buttermilk with added egg yolk|Buttermilk with added egg yolk
75765333|NCT01566305|Dietary Supplement|Skimmed milk with added egg-yolk|Skimmed milk with added egg-yolk
75765334|NCT01566305|Dietary Supplement|Skimmed milk without added egg yolk|Skimmed milk without added egg yolk
75907496|NCT03688009|Behavioral|Mindfulness-Based Family Psycho-Education (MBFBE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
75907497|NCT03688009|Behavioral|Family Psycho-Education (FPE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
75907498|NCT02197338|Other|Bile Duct Cannulation|Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
75907499|NCT03687931|Drug|Dexamethasone|Drop
76070822|NCT05800834|Drug|Lidocaine Hcl 2% Jelly|The control group will receive lidocaine® in gel (2% sterile jelly lidocaine hydrochloride) alone. Because it is a homogeneous, transparent gel, free of lumps and impurities, it has similar characteristics to the hydrogel (Curatec Hidrogel with Alginate®) used in the preparation of morphine gel, guaranteeing the blinding of the study.
75765335|NCT01566383|Procedure|24-hr pH monitoring|"Visit 1~The following will be done:~A medical history including review of your current drugs;~Collection of demographic information;~A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~The catheter will be removed from your nose; and~You will return the recording device"
75765336|NCT00283712|Drug|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
75907500|NCT02814526|Behavioral|Aerobic exercise|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
75907501|NCT02814526|Behavioral|Stretching/balance/range of motion exercise|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
76070823|NCT05798325|Other|2MWT|Two minutes walk tests.
75614253|NCT05657951|Device|ArcScan Insight 100 very high-frequency digital ultrasound|The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
75765337|NCT00283712|Other|Placebo Comparator|Placebo administered in place of infliximab for control group
75907502|NCT04214574|Device|Parasagittal oblique technique (Ultrasound)|the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.
75907503|NCT04214574|Device|Paramedian tranverse technique (Ultrasound)|the transducer will be applied in the parasagittal plane, and after identification of the intervertebral level, the probe will be rotated 90 degrees into a transverse orientation and centered on the neuraxial midline in a way to align the beam with the interspinous and interlaminar space and thus to get a paramedian transverse interlaminar view. The needle will be inserted in plane from the lateral end of the ultrasound transducer with its tip directed towards the medial border of the articular process.
76070824|NCT05798325|Other|MFM32|Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.
76070825|NCT05798325|Other|MyoGrip|The MyoGrip is a dynamometer for measuring grip strength.
76070826|NCT05798325|Other|QOL-gNMD|"The Quality of Life in genetic Neuromuscular Disease questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage"
76070827|NCT05798325|Diagnostic Test|Spirometry|Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g. Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
75461241|NCT01849861|Drug|Methimazole|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~TSH and FT4~Questionnaire of Quality of life for older adults (WHOQOL-OLD)~Mini-Mental State Examination~Geriatric Depression Scale~Cardiopulmonary exercise testing - cardiopulmonary capacity"
76070828|NCT05798325|Device|Acceleromerty|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
76070829|NCT05798325|Other|10mWT|10 meters walking Test.
75461242|NCT01849887|Biological|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
75461243|NCT01849887|Drug|Placebo|Placebo
75765338|NCT03981536|Drug|AP-101|Administered by intravenous infusion (IV)
75765339|NCT00048724|Biological|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
75765340|NCT00449033|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
75765341|NCT00449033|Drug|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
75765342|NCT00449033|Drug|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m^2 IV
76070830|NCT05798325|Other|PUL|The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.
76070831|NCT05798325|Other|NSAA|The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.
76070832|NCT05798325|Other|NSAD|The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.
75316336|NCT00403117|Drug|Naltrexone 12 Mg+ Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
75765343|NCT00449033|Drug|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m^2 IV
75614254|NCT02667145|Other|Self care program focusing on the assistive device|self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
75765344|NCT01024127|Other|Laboratory Biomarker Analysis|Correlative studies
75765345|NCT01024205|Drug|sunitinib malate|
75907504|NCT02195154|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron.~The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
75907505|NCT02196636|Drug|Placebo|Matching placebo, administered orally with approximately 240 mL of buffer
75907506|NCT02196636|Drug|RO6806127|Administered orally with approximately 240 mL of buffer
75907507|NCT03534024|Dietary Supplement|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicelle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
75907508|NCT03534024|Dietary Supplement|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomcielle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
75907509|NCT04175574|Other|Music|The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
75316337|NCT00403117|Drug|Naltrexone 25 Mg + Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
75316338|NCT00403117|Drug|Naltrexone 50 Mg+ Active Marijuana (3.27% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
75316339|NCT00403117|Drug|Naltrexone 100 Mg+ Active Marijuana (3.27% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
75461244|NCT01849900|Other|Knowing your body|"Women will receive the Knowing your body kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits."
75765346|NCT01024205|Other|laboratory biomarker analysis|
75765347|NCT01024205|Procedure|adjuvant therapy|
75765348|NCT01024205|Procedure|neoadjuvant therapy|
75765349|NCT01024205|Procedure|therapeutic conventional surgery|
75765350|NCT00448019|Drug|Fludarabine|25 mg/m^2 IV over 30 minutes daily for 3 days
75765351|NCT00448019|Drug|Cyclophosphamide|250 mg/m^2 IV over 30 minutes daily for 3 days
75765352|NCT00448019|Drug|Rituximab|375 mg/m^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m^2 IV 30-minute infusion.
75765353|NCT00448019|Drug|Bevacizumab|10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
75765354|NCT01024361|Device|CPAP|CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
75765355|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
75765356|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
75765357|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
75765358|NCT00457691|Drug|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
75765359|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
75765360|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
75765361|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
75765362|NCT00457691|Drug|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
75765363|NCT00457301|Behavioral|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
75765364|NCT00456755|Drug|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
75765365|NCT00456755|Other|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
75765366|NCT03820271|Other|SuperMELD|"The population of this arm will consist of patients newly enrolled in the National Liver Transplantation Waiting List for decompensated cirrhosis, whose liver function and MELD score are assessed at enrollment and then routinely reassessed at least quarterly during the waiting phase.~Patients will be followed from their listing to transplantation or discharge or death."
75765367|NCT00447005|Drug|Axitinib (AG-013736)|AG-013736 5mg twice daily [BID]
75765368|NCT01024439|Procedure|transumbilical single incision laparoscopic appendicectomy|"Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.~Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done."
75765369|NCT01024439|Procedure|conventional laparoscopic appendicectomy|"Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.~Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings."
75614255|NCT04316819|Other|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
75765370|NCT01024517|Drug|GLPG0259 solution|single oral dose, GLPG0259, 50 mg oral solution
75765371|NCT01024517|Drug|GLPG0259|single oral dose, GLPG0259, 50 mg solid formulation
75907510|NCT02753686|Drug|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
75907511|NCT02753686|Drug|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
75614256|NCT04286841|Drug|Immunotherapy|Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
75765372|NCT01565759|Drug|Lithium Carbonate|"The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg."
75765373|NCT00446849|Drug|MMX Mesalamine|MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
75765374|NCT01565837|Drug|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
75765375|NCT01565837|Radiation|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
75907512|NCT02195388|Other|comprehensive cardiac rehabilitation|Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
75765376|NCT00446459|Drug|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
75765377|NCT00456599|Drug|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
75765378|NCT00456599|Drug|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
75765379|NCT00456599|Procedure|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
75765380|NCT00456521|Drug|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
76070833|NCT05798325|Other|TANS|This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).
75316340|NCT00403117|Drug|Naltrexone 12 Mg + Inactive Marijuana (0% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
75765381|NCT00456521|Drug|Placebo|
75765382|NCT00456521|Behavioral|Intensive group lifestyle modification counseling|
75765383|NCT00456365|Drug|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
75614257|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
75765384|NCT00456365|Drug|Placebo|Placebo daily
75765385|NCT03843047|Drug|3 mg/mL nicotine strength e-liquid|Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
75907513|NCT03534258|Device|Ceribell Rapid Response EEG, Survey|This trial will qualitatively examine how information from rapid response and conventional EEG data changes physicians' diagnostic suspicion or their treatment decisions and confidence levels. In addition, the results will examine the mean time to EEG lead placement, and ease of use.
75907514|NCT04216927|Drug|Nitric Oxide|gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
75316341|NCT00403117|Drug|Naltrexone 25 Mg + Inactive Marijuana (0% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
75316342|NCT00403117|Drug|Naltrexone 50 Mg + Inactive Marijuana (0% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
75765386|NCT03843047|Drug|6 mg/mL nicotine strength e-liquid|Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
75461245|NCT01849900|Behavioral|Healthy Lifestyle|Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
75461246|NCT01849913|Other|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
75461247|NCT01849913|Other|Placebo|"To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy)."
75461248|NCT01849926|Drug|Ibuprofen|
75461249|NCT01849926|Drug|Mecillinam|
75461250|NCT01849939|Drug|Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)|
75461251|NCT01849965|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
75765387|NCT03843047|Drug|12 mg/mL nicotine strength e-liquid|Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
75765388|NCT03843047|Drug|24 mg/mL nicotine strength e-liquid|Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
75765389|NCT01565915|Device|Perlane-L|Perlane-L Injection in the midface
75316343|NCT00403117|Drug|Naltrexone 100 Mg + Inactive Marijuana (0% THC)|One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
75765390|NCT01565915|Other|Non-treatment|Non-treatment Arm
75907515|NCT04216927|Drug|Oxygen|Oxygen alone will be entrained for placebo arm
75461252|NCT01849965|Drug|placebo vehicle gel|
75461253|NCT01849965|Drug|Standard of Care gel, Aquasite|
75316344|NCT00353795|Procedure|MR Imaging of the Coronary Arteries|
75907516|NCT02329834|Drug|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
76070834|NCT05798325|Other|MyoPinch|The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.
75316345|NCT04602299|Other|Set the minimum time of gastroscopy|This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.
75316346|NCT00558285|Drug|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
75316347|NCT00558285|Drug|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
75461254|NCT01849978|Behavioral|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
75461255|NCT01849978|Behavioral|Changing your habits brochure|"Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA."
75614258|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
75614259|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
75765391|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
75765392|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
75765393|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
75765394|NCT00455741|Drug|Estradiol infusion|Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
75765395|NCT00455741|Drug|Progesterone infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
75907517|NCT02329834|Drug|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
75907518|NCT02195466|Drug|Tipranavir (TPV)|500 mg bid on days 7-14
75907519|NCT02195466|Drug|Ritonavir (RTV)|200 mg bid on days 7-14
75907520|NCT02195466|Drug|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
76070835|NCT05798325|Other|MyoQuad|The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.
76070836|NCT05798325|Other|ACTIVLIM|Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.
76070837|NCT05798325|Other|PREM|This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.
75765396|NCT00445679|Drug|DVS SR|Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
75765397|NCT00445679|Drug|Paroxetine|20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
75461256|NCT01849978|Behavioral|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
75765398|NCT00455429|Drug|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram [mg]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
75765399|NCT00455429|Drug|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
75765400|NCT00455429|Drug|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
75765401|NCT00455429|Drug|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
75907521|NCT03692377|Device|Virtual Reality|Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
75907522|NCT02195544|Drug|Synvisc®|
75907523|NCT03687853|Device|Intrahepatic Arterial Infusion|Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
75907524|NCT02197494|Drug|Valsartan|320mg tablets
76070838|NCT05798325|Other|SF-MPQ|The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
76070839|NCT05798325|Other|FSS|The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living. The patient responds on a Likert-type scale ranging from 1 to 7.
75316348|NCT00558285|Drug|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
75316349|NCT00558285|Drug|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
75316350|NCT01792921|Behavioral|COG - FUN|
75316351|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
75461257|NCT01849978|Behavioral|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
75461258|NCT01849991|Biological|Lactobacillus reuteri|"Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.~The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily."
75461259|NCT01849991|Biological|Placebo|Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
75461260|NCT01850017|Drug|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
75461261|NCT01850056|Device|drug eluting balloon catheter (trade name: Orchid)|
75461262|NCT01850056|Device|common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)|
75461263|NCT01850095|Drug|treatment azelaic acid (azelan)|treatment for 6 months
75765402|NCT00455429|Drug|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
75765403|NCT00445601|Drug|gemcitabine hydrochloride|Given intravesically
76070840|NCT05798325|Other|IPAQ|This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.
76070841|NCT05798325|Other|Rang of motion|The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.
75461264|NCT01850095|Drug|dorspirenone/ethynil estradiol|
75765404|NCT00445601|Other|placebo|Given intravesically
75765405|NCT00444587|Drug|Second line chemotherapy|As prescribed
75765406|NCT00444587|Drug|trastuzumab [Herceptin]|6mg/kg iv every 3 weeks
75765407|NCT00455195|Biological|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
75765408|NCT00235716|Drug|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
76070842|NCT05798325|Device|Goniometry|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
75765409|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
75765410|NCT00235716|Drug|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
75765411|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
75765412|NCT00235716|Drug|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
75765413|NCT00274742|Biological|Blinatumomab (MT103)|Doses from 0.5 to 120 µg/m^2/24hours by continuous intravenous infusion
75765414|NCT03973398|Procedure|Quadratus Lumborum block|ultrasound guided Quadratus Lumborum block for postoperative pain
75765415|NCT03970044|Drug|Exenatide 2 MG|Glucagon-like peptide-1 receptor
75765416|NCT03970044|Drug|Dapagliflozin 10 MG|sodium-glucose co-transporter 2 (SGLT2) inhibitor
75765417|NCT00283400|Drug|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
75765418|NCT00444275|Drug|esomeprazole (Nexium®)|"This randomized study was conducted on parallel groups and included two phases:~One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
75765419|NCT00444275|Drug|Xolaam®|"This randomized study was conducted on parallel groups and included two phases:~One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
75907525|NCT02710474|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
75907526|NCT02710474|Behavioral|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
75907527|NCT03683017|Device|OrthoPulse 2.0|Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
75907528|NCT03683017|Device|OrthoPulse 2.1|Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
75907529|NCT03683017|Device|Invisalign 3.5 Day Wear|Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.
75316352|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
75316353|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
75316354|NCT02832323|Biological|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
75614260|NCT00645229|Drug|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
75614261|NCT01172873|Drug|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
75614262|NCT01172873|Behavioral|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
75614263|NCT02886299|Drug|Fenofibrate|
75614264|NCT02886299|Drug|Simvastatin|
75614265|NCT02667379|Other|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
75765420|NCT00454805|Drug|AZD2171|Oral tablet
75765421|NCT00454805|Drug|Fulvestrant|intramuscular injection
75765422|NCT00283244|Drug|erlotinib hydrochloride|given orally
75765423|NCT00283244|Drug|gemcitabine hydrochloride|given IV
75765424|NCT03975686|Other|neuromuscual realigning exercise|neuromuscular realigning exercise
75765425|NCT00282464|Drug|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
75316355|NCT04567277|Procedure|External ventricular drainage (EVD) conversion into ventriculo-peritoneal shunt (VPS)|EVD in high grade SAH patients were converted into VPS with 7-10 days of EVD insertion
75765426|NCT00282464|Drug|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
75765427|NCT01068938|Device|three different perimeters: HFA, Octopus, MATRIX|visual fields
75765428|NCT03976856|Drug|GB226|Geptanolimab, 210mg，q2w，ivgtt.
75765429|NCT03976856|Drug|Fruquintinib|Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
75765430|NCT00273182|Device|InSync Model 8040|Subjects with sucessful implants of InSync Model 8040.
75316356|NCT00558207|Drug|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
75316357|NCT00558207|Drug|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
75461265|NCT01850121|Drug|Infliximab|5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
75765431|NCT00273182|Device|InSync III Model 8042|Subjects with successful implants of InSync III Model 8042
75765432|NCT03976700|Drug|Bufei Jianpi granule|Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
75765433|NCT03976700|Drug|Placebo Bufei Jianpi granule|Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
75765434|NCT00209274|Device|Percutaneous mitral valve repair using MitraClip implant|MitraClip Implant
75765435|NCT00209274|Procedure|Mitral valve repair or replacement surgery|Repair or replacement of mitral valve
75765436|NCT03976778|Other|Training program for family physicians on well-child care for children under-5 years|The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
76070843|NCT05798325|Other|Video captured monitoring|"Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:~Upper limbs: hands to head~Lower limbs: Sit to stand with or without the help of a person~Self-defined important task: A task of the patient's choice, from a list of tasks, representative of his/her motor difficulties or hindrance to autonomy."
76070844|NCT05798325|Device|Activity monitoring|Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
75461266|NCT01850134|Other|Experimental Study Product|
75461267|NCT01850134|Other|Control Study Product|
75461268|NCT01850147|Drug|Sunitinib, chemotherapy|sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
75461269|NCT01850160|Drug|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
75461270|NCT01850160|Drug|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
75461271|NCT01850160|Drug|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
75765437|NCT03975764|Diagnostic Test|Collection of fecal sample|Analysis of fecal microbiome
75765438|NCT03841331|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
75765439|NCT03841331|Drug|Matching Placebo Tablets|Placebo Tablets
75765440|NCT01069016|Procedure|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
75765441|NCT01069016|Procedure|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
75765442|NCT01326156|Device|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
75765443|NCT03969966|Other|renal replacement therapy as clinically indicated|Continuous renal replacement therapy
75765444|NCT00262080|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
75765445|NCT00262080|Drug|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
75765446|NCT01073904|Drug|Levonorgestrel Emergency Pill (BAY86-5028)|Single dose of 1.5 mg coated tablet
75765447|NCT01073904|Drug|Postinor 2|Single dose of 1.5 mg tablet
75316358|NCT05343351|Other|Technique of injection method|"In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel."
75765448|NCT03969810|Behavioral|Rounding Summary|Written summary of rounds
75765449|NCT03973554|Other|pearl powder|natural product, support bone and joint health
75765450|NCT03973554|Drug|CPP-ACP|Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
75765451|NCT03973320|Other|Chart Review|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty patients.
75765452|NCT00282308|Drug|Rituximab|Rituximab was supplied in single-use vials.
75765453|NCT00282308|Drug|Methotrexate|
75765454|NCT00282308|Drug|Methylprednisone|Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
75765455|NCT00282308|Biological|C. albicans|Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
75765456|NCT00282308|Biological|Tetanus toxoid adsorbed booster vaccine|Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
75614266|NCT05261659|Behavioral|Exposure Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
75765457|NCT00282308|Biological|23-valent pneumococcal polysaccharide vaccine|Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
75614267|NCT05261659|Behavioral|Exposure Therapy|These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
75614268|NCT00925600|Biological|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
75614269|NCT00925600|Biological|Placebo|Prefilled syringe for subcutaneous (SC) injection
75614270|NCT00645307|Drug|Extended Release OROS® Paliperidone|
75765458|NCT00282308|Biological|Keyhole limpet hemocyanin|Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
75765459|NCT01072968|Drug|BF2.649|1 capsule per day in the morning before the breakfast
75765460|NCT01072968|Drug|Placebo|1 capsule per day in the morning before the breakfast
75765461|NCT03969732|Drug|1. amyloid PET；2. T807 PET|"Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)"
75765462|NCT03975608|Behavioral|"Adaptation of CALM"|"The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.~The sessions address the 4 dimensions of the original program designed for palliative cancer patients:~Symptom management and communication with healthcare providers~Changes in self and relations with each others~Spirituality, sense of meaning, and purpose~Thinking of the future, hope, and mortality~As an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control."
75765463|NCT00282152|Device|B-STN DBS|Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
75765464|NCT00282152|Drug|Optimal drug therapy|The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
75765465|NCT00281840|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
75316359|NCT00407485|Biological|ziv-aflibercept|Given IV
75316360|NCT00407485|Other|pharmacological study|Correlative studies
75461272|NCT01850173|Device|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
75461273|NCT01850186|Device|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
75461274|NCT01850186|Drug|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
75765466|NCT00281840|Drug|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
75316361|NCT00354887|Drug|Capecitabine|Oral capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m^2) on Days 1-14 in 21 Day Cycle.
75316362|NCT00354887|Drug|Oxaliplatin|130 mg/m^2 by vein Day 1 over 2 hours in 21 Day Cycle
75316363|NCT01794559|Device|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
75614271|NCT02666287|Drug|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
75316364|NCT02985320|Biological|Single-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
75316365|NCT02985320|Biological|Single-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
75316366|NCT02985320|Biological|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
75316367|NCT02985320|Biological|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
75316368|NCT02985320|Biological|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
75461275|NCT01850199|Other|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
75316369|NCT02985320|Biological|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
75614272|NCT02666287|Drug|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
75614273|NCT02666287|Drug|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
75614274|NCT02666287|Drug|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
75614275|NCT02666287|Drug|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
75614276|NCT02668861|Drug|Vitamin D|Vitamin D 4000IU/day for 8 weeks
75614277|NCT02668861|Drug|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
75614278|NCT02668861|Other|placebo|placebo for 8 weeks
75614279|NCT05330650|Drug|Coated Vicryl+|We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
75614280|NCT05330650|Drug|Vicryl|We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
75765467|NCT00281840|Procedure|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
75765468|NCT00281840|Radiation|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
75765469|NCT00281684|Drug|SB705498 400 mg|SB705498 400 mg
75461276|NCT01850199|Other|Usual management|Usual care will be provided, including face-to-face visits
75461277|NCT01850225|Device|Auditory brainstem implant|
75461278|NCT01850238|Biological|AADvac1|AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
75461279|NCT01850238|Other|Placebo|The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
75461280|NCT01850251|Dietary Supplement|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
75461281|NCT01850251|Dietary Supplement|Standard nutritional supplement|High protein, high calorie nutritional supplement.
75614281|NCT02668705|Other|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
75614282|NCT04879654|Procedure|endoscopic surgery|endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
75461282|NCT01850264|Device|Application of quadripolar / bipolar LV electrodes|
75614283|NCT04997005|Device|AMIStem-P|Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant
75614284|NCT04255888|Procedure|Laterally positioned flap in thick periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
75614285|NCT04255888|Procedure|Laterally positioned flap in thin periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
75765470|NCT00281684|Drug|SB705498 1000 mg|SB705498 1000 mg
75765471|NCT00281684|Drug|Placebo|Placebo
75765472|NCT00281684|Drug|Co-Codamol|Co-Codamol
75907530|NCT03683017|Device|Fixed Orthodontic Appliances (Braces)|Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
75614286|NCT02668627|Procedure|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
75765473|NCT03975452|Radiation|Reduced radiation volumes|Patient treated with reduced radiation volumes with the exclusion of elective pelvic nodal irradiation
75765474|NCT03976622|Biological|Blood samples|Blood samples: serum and PBMC
75765475|NCT03976622|Biological|Skin biopsies|These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
75765476|NCT00272792|Drug|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
75765477|NCT00272792|Drug|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
75765478|NCT01069094|Drug|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
75765479|NCT01069094|Drug|Progenta|25 mg, administered as a once daily oral dose for 90 days.
75765480|NCT01069094|Drug|Progenta|50 mg, administered as a once daily oral dose for 90 days.
75765481|NCT01069094|Drug|Lucron Depot|3.75 mg IM monthly
75765482|NCT01069094|Drug|Placebo|Administered as a once daily oral dose for 90 days.
75765483|NCT00048568|Drug|Abatacept|Intravenous (IV) Solution, - Weight Titered (500 mg < 60 kg); (750 mg 60-100 kg), )1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
75765484|NCT00048568|Drug|Methotrexate|Tablets, Oral, >= 15 mg, weekly, 1 year
76070845|NCT05797766|Behavioral|Fluid Distribution Timetable|a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
75316370|NCT02985320|Biological|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
75316371|NCT04537247|Procedure|partial nephrectomy for complex renal tumor|removal of tumor with sufficient safety margin with preservation of functioning renal unit (renal tissue with its collecting system, arterial supply and venous as well as lymphatic drainage).
75316372|NCT05338047|Drug|Pegfilgrastim|Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.
75316373|NCT04407884|Device|Soovu Labs Inc. Pain Relief System|Longnitual follow-up
75461283|NCT01850277|Drug|Amiodarone|The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.
75461284|NCT01850277|Procedure|External electrical cardioversion (EEC)|"The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.~If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented."
75461285|NCT01850277|Drug|Pharmacotherapy to slow and control ventricular rate|The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% >95%
75765485|NCT00048568|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
75765486|NCT00262002|Biological|MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
75765487|NCT00262002|Biological|MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
75765488|NCT00262002|Biological|MenACWY PS (MenACWY-CRM, polysaccharide vaccine)|MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
75765489|NCT00262002|Biological|HBV (Hepatitis B vaccine)|Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
75765490|NCT00262002|Biological|Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)|Prevnar was administered IM in the anterolateral area of the left thigh.
75765491|NCT00262002|Biological|MMR (Measles, Mumps and Rubella vaccine)|MMR at 12 month of age, administered in the left arm.
75765492|NCT00262002|Biological|DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)|DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
75765493|NCT00262002|Biological|Menjugate (Men C conjugated vaccine)|Menjugate was injected IM in the anterolateral area of the right thigh.
75765494|NCT01092988|Device|Exablate 2100|MR guided focused ultrasound
75765495|NCT03955120|Behavioral|Dayzz mobile sleep training|"The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study."
75765496|NCT03955120|Other|Treatment as usual|Standard medical care for specific sleep condition
75765497|NCT01583998|Behavioral|e-MBC|antidepressant treatment
75765498|NCT01584076|Drug|Donepezil|"Oral Donepezil Daily~Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.~Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds."
75461286|NCT01850277|Procedure|Atrioventricular junction ablation (AVJA)|The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
75765499|NCT01584076|Other|Patching|Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
75765500|NCT03954964|Behavioral|Education on disposal of opioids|Current class curriculum including education about pain management with additional education about the disposal of opioids.
75765501|NCT03956836|Diagnostic Test|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC
75765502|NCT01093144|Device|pelvic measurements using the LaborPro Device|pelvic measurements using the LaborPro Device,ultrasound non invasive measurements
75461287|NCT01850316|Radiation|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
75765503|NCT00281528|Drug|ABI-007 (Abraxane)|30 minute infusions
75765504|NCT00281528|Drug|bevacizumab|infusions
75765505|NCT01095640|Drug|adapalene 0.3% topical gel|once a day, 84 days
75765506|NCT03955276|Other|Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)|Biologically targeted matched treatment (chosen by treating physician)
75614287|NCT00968253|Drug|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
75765507|NCT01095718|Behavioral|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
75907531|NCT01340937|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
75907532|NCT01340937|Biological|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
75907533|NCT01340937|Biological|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
75907534|NCT01340937|Biological|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
75907535|NCT01340937|Biological|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
75907536|NCT02303470|Behavioral|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
75316374|NCT02111863|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
75316375|NCT02111863|Drug|Fludarabine|Fludarabine 25 mg/m^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
75316376|NCT02111863|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
75316377|NCT02111863|Biological|4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)|On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
75461288|NCT01850329|Other|computed-assisted information program|
75461289|NCT01850342|Procedure|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
75614288|NCT00968253|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
75614289|NCT00968253|Drug|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
75614290|NCT00968253|Drug|Doxorubicin|50 mg/m^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
75614291|NCT00968253|Drug|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
75614292|NCT00968253|Drug|Mesna|600 mg/m^2 IV continuous infusion daily for 24 hours days 1-3.
75614293|NCT00968253|Drug|Methotrexate|200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 IV over 22 hours day 1.
75614294|NCT00968253|Drug|Ara-C (Cytarabine)|3 gm/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
75614295|NCT00968253|Drug|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
75907537|NCT02303470|Behavioral|Moderate Exercise|
76070846|NCT05793905|Combination Product|Buffered lidocaine in inferior alveolar nerve block injection|Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars
75316378|NCT04031768|Other|Timing of rest prior to blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
75765508|NCT01095718|Behavioral|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
75765509|NCT01095718|Behavioral|Trial and Error|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
75765510|NCT00280748|Drug|pemetrexed disodium|500 mg/m2 once every 21 days up to 126 days
75765511|NCT00280748|Radiation|radiation therapy|Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
75765512|NCT00271856|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
76070847|NCT05793905|Drug|lidocaine 2% in inferior alveolar nerve block injection|Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
76072460|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
75765513|NCT00271856|Behavioral|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
75765514|NCT03975374|Drug|Tobramycin/dexamethasone opthalmic solution|To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
75765515|NCT03975374|Drug|Tobradex Opthalmic Solution|Tobradex Opthalmic Solution
75765516|NCT01070264|Dietary Supplement|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
75765517|NCT01070420|Other|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via Rt central femoral vein.
75765518|NCT01070420|Other|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via continuous peripheral vein.
75316379|NCT03832881|Diagnostic Test|ADAMTS13, VWF assay|
75316380|NCT02660411|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
75316381|NCT02660411|Drug|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
75316382|NCT02078492|Drug|10 mg of Ketorolac|Patients will receive 10 mg of Ketorolac for pain control.
75316383|NCT02078492|Drug|15 mg of Ketorolac|Patients will receive 15mg of Ketorolac for pain control.
75614296|NCT00968253|Drug|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
75614297|NCT04258540|Behavioral|Yoga group|The intervention group received yoga 2 times a week for 12 weeks (á 1.25 hr).
75614298|NCT04258540|Behavioral|yoga course|yoga course
75614299|NCT00646009|Drug|budesonide/formoterol|
75614300|NCT00646009|Drug|fluticasone/salmeterol|
75614301|NCT00646009|Drug|albuterol|
75614302|NCT04069663|Other|No interventional study|Retrospective data analysis
75614303|NCT00646087|Drug|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
75614304|NCT00646087|Drug|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
75614305|NCT04255576|Dietary Supplement|Dietary Supplement: Calcium/Vitamin D|All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
75614306|NCT02668315|Biological|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
75614307|NCT05309434|Behavioral|Coach|The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.
75614308|NCT04175197|Device|Drug Coated Balloon|Legflow Drug Coated Balloon
75614309|NCT02862405|Other|vision tests|
75765519|NCT00061048|Biological|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
75907538|NCT03692299|Drug|Saccharomyces Boulardii Oral Tablet|Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
76070848|NCT05793099|Other|Effect of aqueous propolis gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given aqueous propolis gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing aqueous propolis gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
75316384|NCT02078492|Drug|30 mg of Ketorolac|Patients will receive 30mg of Ketorolac for pain control.
75461290|NCT01850368|Radiation|Stereotactic ablative radiotherapy|"The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by >48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy."
75461291|NCT01850407|Behavioral|Education Counseling|
75614310|NCT04258696|Device|diode laser|using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
75614311|NCT04258696|Device|ultrapak Knitted retraction cord|using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
75614312|NCT05180565|Device|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
75765520|NCT01070498|Drug|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
75907539|NCT03692299|Drug|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months
76072461|NCT04146519|Biological|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
75316385|NCT04498949|Behavioral|UP|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
75461292|NCT01850420|Drug|IMC-1|
75461293|NCT01850433|Behavioral|Internet based CBT for body dysmorphic disorder|
75461294|NCT01850511|Procedure|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
75461295|NCT01850511|Drug|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
75765521|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 24 weeks.
75765522|NCT01581398|Drug|Pegasys|sc, qw, 24 weeks.
75765523|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
75765524|NCT01581398|Drug|Pegasys|sc, qw, 48 weeks.
75907540|NCT02197650|Drug|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
75907541|NCT02650648|Drug|cyclophosphamide|chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight<70kg) or 1500mg/m^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
75907542|NCT02650648|Biological|NK cells|Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.
75907543|NCT02650648|Biological|hu3F8|On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.68 mg/kg/day and infused over ~30-90 minutes
76072462|NCT04146519|Other|Placebo|Saline solution
76072463|NCT04022811|Drug|0.1% bromfenac|the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
75461296|NCT01850537|Device|treatment of degenerative disc disease using the PROW LIF|TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
75316386|NCT04498949|Other|Treatment as usual|Diagnostic test. Psychoeducation Supoortive care
75765525|NCT03957148|Behavioral|Sugar-sweetened beverage reduction education for preschool children|Participants in the SSB-IMB program will receive 10 weeks of SSB related nutrition education at their child's preschool. Each week a different lesson pertaining to parental information, motivation, or behavioral skills related to SSBs will be presented via an interactive display board. Twice a week, two student educators will stand by display boards for two hours and deliver the lessons that will last 5-10 minutes with each parent. These displays will include an activity for parents to apply knowledge and skills learned during the short lesson. Educators will also provide parents with informational handouts pertaining to each lesson to reinforce concepts learned. Display board education is flexible, so that if a parent arrives while another parent is receiving education, the second educator can begin the lesson with the new parent. Multiple parents can participate in a lesson at the same time. Groups of 2-3 parents can review the lesson together, learning from each other.
75765526|NCT03954808|Other|Motor Imagery Training|Motor imagery training will be designed for the individual basis with standard protocols
76072464|NCT04022889|Device|INTERCEPT Treated Platelets|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.
76072465|NCT04146129|Drug|CDX-0159|Single dose of one of four dosages of CDX-0159
75316387|NCT04528563|Drug|Ketorolac Tromethamine 10 MG/ML|Non-Steroidal-Anti-Inflammatory given intravenously.
75765527|NCT03954808|Other|Traditional physiotherapy|Traditional physiotherapy within a specific program
75316388|NCT04528563|Drug|Morphine Sulfate 10Mg/1mL Injection|Opioid commonly used for acute abdominal pain given intravenously.
75316389|NCT01405898|Dietary Supplement|beetroot juice|Beetroot juice 4 weeks 250ml daily
75316390|NCT01405898|Dietary Supplement|Nitrate-free beetroot juice|Nitrate-free beetroot juice 4 weeks 250ml daily
75316391|NCT03086317|Device|Standard Catheter-Directed Thrombolysis|Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
75316392|NCT03086317|Device|Ultrasound-Accelerated Thrombolysis|USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
75316393|NCT00355199|Drug|Rituximab-HDS|Rituximab-HDS
75316394|NCT00355199|Drug|Rituximab-CHOP|Rituximab-CHOP
75316395|NCT01389128|Other|Non-pharmacological resources|"A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm."
75461297|NCT01850576|Behavioral|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
75765528|NCT00270998|Behavioral|Behavioral Therapy|Pelvic muscle training and exercises
75316396|NCT01389128|Other|Routine care|Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
75316397|NCT04493567|Drug|BMS-986036|Specified dose on specified days
75316398|NCT01793987|Device|Coblation polypectomy|
75765529|NCT00270998|Device|Intravaginal Pessary|Intravaginal pessary
75907544|NCT02650648|Drug|rIL-2|On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10^5 U/m^2/day.
75316399|NCT01961531|Device|Accuboost APBI|28Gy delivered in 5 daily fractions
75316400|NCT00363805|Dietary Supplement|green tea|Given orally
75316401|NCT00363805|Drug|Polyphenon E|Given orally
75316402|NCT00363805|Other|placebo|Given orally
75316403|NCT01388816|Drug|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
75461298|NCT01850628|Drug|Paclitaxel|
75461299|NCT01850628|Biological|trastuzumab|
75461300|NCT01850628|Biological|pertuzumab|
75461301|NCT01850654|Genetic|LS tumor screening|All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
75765530|NCT00270998|Device|Pessary combined with behavioral therapy|Intravaginal pessary and behavioral therapy
75765531|NCT01070576|Other|no intervention|no intervention
75907545|NCT03682939|Biological|Bexsero® (meningitis B vaccine)|Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant
75907546|NCT03682939|Biological|Menveo® (meningitis ACWY vaccine)|Menveo® 0.5ml IM vaccine administered into dominant arm of participant
75907547|NCT02927184|Drug|VK2809|
75907548|NCT02927184|Drug|Placebo|
75907549|NCT02201992|Other|Clinical Observation|Undergo observation
75907550|NCT02201992|Drug|Crizotinib|Given PO
75907551|NCT02201992|Other|Laboratory Biomarker Analysis|Correlative studies
75907552|NCT03687775|Other|Stability assessment|Qualitative and quantitative stability assessment
75907553|NCT03534492|Drug|Durvalumab|Infusion
75907554|NCT03534492|Drug|Olaparib|P.O.
75907555|NCT03687697|Biological|Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media|A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
75907556|NCT03624283|Drug|Betahistine|Betahistine is used in the treatment of and vertigo.
75316404|NCT01665521|Other|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
75316405|NCT01791647|Drug|metformin 1500 mg|
75316406|NCT01791647|Drug|myoinositol 1500 mg|
75316407|NCT00363883|Drug|vorinostat|Given orally
75316408|NCT00363883|Other|laboratory biomarker analysis|Correlative studies
75316409|NCT00356057|Device|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
75316410|NCT00364819|Drug|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
75316411|NCT04524351|Drug|Posiphen|Solid oral dosage form, capsule
75316412|NCT04524351|Drug|Placebo|Solid oral dosage form, capsule
75461302|NCT01850654|Genetic|Genetic testing|"Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.~The following study participants will have free genetic testing:~CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors~CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results and they do not have methylation of the MLH1 promoter~CRC study participants diagnosed with CRC <50 years, regardless of tumor studies or family history~CRC study participants diagnosed with CRC ≥ 50 years with a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life, regardless of tumor studies.~At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing."
75765532|NCT01070654|Procedure|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
75765533|NCT01070654|Device|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
75765534|NCT01581632|Device|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
75461303|NCT01850654|Behavioral|Genetic Counseling|"The participants found to have LS or another type of hereditary cancer will have free genetic counseling.~At-risk relatives of the individuals found to have LS are eligible for free genetic counseling."
75614313|NCT04255498|Drug|Etanercept|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
75765535|NCT03741686|Dietary Supplement|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ [100kcal] of glucommanan)
75765536|NCT03741686|Dietary Supplement|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
75765537|NCT01582334|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
75765538|NCT00279812|Dietary Supplement|50ug selenium enriched yeast|Selenomethionine supplement (50ug/d Se) for 12 weeks
75316413|NCT02107157|Device|755nm Laser with Cap Array|
75316414|NCT04523961|Drug|2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion|Topical anesthetic used to numb the skin prior to laser procedures
75316415|NCT04523961|Drug|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion|Topical anesthetic used to numb the skin prior to laser procedures
75316416|NCT01792505|Biological|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
75316417|NCT01794221|Procedure|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
75461304|NCT01850654|Other|Biorepository|The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
75316418|NCT01794221|Procedure|stitches only|standard of care
75316419|NCT00365053|Drug|belinostat|Given IV
75316420|NCT00365053|Other|laboratory biomarker analysis|Correlative studies
75316421|NCT05309967|Other|GLUMA DESINSITIZER|GLUTARALDEHYDE
75316422|NCT05309967|Other|PLACEBO|DESTILLED WATER
75461305|NCT01850654|Behavioral|Questionnaire|
75765539|NCT00279812|Dietary Supplement|100ug selenium enriched yeast|Selenomethionine supplement (100ug/d Se) for 12 weeks
75765540|NCT00279812|Dietary Supplement|200ug selenium enriched yeast|Selenomethionine supplement (200ug/d Se) for 12 weeks
75765541|NCT00279812|Dietary Supplement|Control onion|3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
75316423|NCT03668561|Device|Caligaloc|15 days of wearing of the Caligaloc orthosis
75316424|NCT00555789|Drug|AEB071|200mg oral b.i.d.
75907557|NCT03624283|Behavioral|Exercise-based vestibular rehabilitation|Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
75907558|NCT03687619|Other|CO-OP|Interventions (from top to down) related to the development of fine-motor skills
75907559|NCT03687619|Other|Conductive Education|Interventions (from down to top) related to the development of fine-motor skills
75907560|NCT03687463|Drug|Decitabine|Decitabine for injection
75907561|NCT02197728|Device|Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy|
75907562|NCT03687385|Device|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
75316425|NCT00555789|Drug|mycophenolic plus tacrolimus|720mg b.i.d. 2yrs
75614314|NCT04255498|Drug|Mifepristone|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
75765542|NCT00279812|Dietary Supplement|Enriched onion|3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
75907563|NCT03687385|Device|low-flow nasal oxygenation (LFNO)|Active comparator LFNO: O2 flow 5L/min, FiO2 40%
75907564|NCT02031198|Drug|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
75907565|NCT03682861|Behavioral|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
75316426|NCT04288895|Drug|Vortioxetine|5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
75461306|NCT01850667|Radiation|Stereotactic body radiotherapy|"Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)"
75907566|NCT03682861|Behavioral|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
75907567|NCT03682783|Diagnostic Test|Fundus Image|Fundus image of optic nerve
75316427|NCT01792739|Drug|Lactobacillus casei variety rhamnosus granules|"Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
75316428|NCT01792739|Drug|Placebo|"Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
75316429|NCT05289765|Other|A natural neutral Ecological Extra Virgin Olive Oil based gel|A natural neutral Ecological Extra Virgin Olive Oil based gel will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline.
75614315|NCT00645775|Dietary Supplement|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
75614316|NCT02862249|Biological|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
75614317|NCT02862249|Biological|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
75765543|NCT00279812|Other|Placebo|Placebo supplement for 12 weeks
75765544|NCT01070732|Drug|Paracetamol|All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
75765545|NCT00207714|Drug|Golimumab|Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
75907568|NCT02196948|Other|Electrolysis Percutaneous Therapeutic (EPTE)|
75907569|NCT02196948|Other|Eccentric exercise|
75907570|NCT03692143|Drug|Teriparatide|subcutaneous injection of teriparatide(20 mg) once daily
75907571|NCT03692143|Procedure|PVP|With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously
75316430|NCT05289765|Other|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline
75765546|NCT00207714|Drug|MTX|Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
75765547|NCT00207714|Drug|Placebo|Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
75316431|NCT04110431|Procedure|Left bundle branch pacing|Successful LBBP was defined as (1) LBBP lead is located at 1.5-2cm from His-bundle towards right ventricular apex; (2) Paced QRS morphology of right bundle branch delay(CRBBD) in lead V1; (3) Stimulus to the peak of R wave in V5 and V6 QRS wave, which represents left ventricular activation time(Stim-LVAT), is less than 100ms and constant at high and low output pacing; (4) Unipolar pacing threshold<1.5V/0.5ms; (5) Recording P potential when narrow QRS escape rhythm or CRBBB escape rhythm(not essential).
75316432|NCT04110431|Procedure|Biventricular pacing|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
75316433|NCT00554385|Drug|ABT-089|Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
75316434|NCT00365209|Other|laboratory biomarker analysis|Correlative studies
75316435|NCT00365209|Other|pharmacological study|Correlative studies
75316436|NCT00365209|Drug|curcumin|Given orally
75907572|NCT03692143|Drug|Alendronate|Alendronate Sodium, oral, 70mg, once a week
75765548|NCT00207714|Drug|Infliximab|Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
75765549|NCT00207090|Drug|ixabepilone|ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
75765550|NCT00207090|Drug|Rifampin|rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
76070849|NCT05793099|Other|Effect of placebo gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given placebo gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing placebo gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
76070850|NCT05792046|Device|Visual field|test for detecting loss in visual function
76070851|NCT05786534|Dietary Supplement|Green Seaweed|400 mg per day
76070852|NCT05785819|Drug|VLX-1005|VLX-1005, a 12-LOX enzyme inhibitor
76070853|NCT05785819|Drug|Placebo|Placebo matching VLX-1005
76070854|NCT05784844|Drug|Meropenem|Carbapenem antibiotic
76070855|NCT05784844|Drug|Micafungin|Echinocandin antifungal
76070856|NCT05783661|Other|Conventional antibiotic strategies|Treatment according to the local guidelines of the Hospital Clinic de Barcelona.
75614318|NCT04258384|Other|survey application|Data collection tools used in the study; Demographic Data Form, Mcgill and Melzack Pain Questionnaire, Short Form-36 (SF-36), Vanderbilt Multidimensional Pain Coping Inventory (VMPCI), Pain Coping Inventory (PCI), Pain Coping Scale were used.
75461307|NCT01850680|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
75461308|NCT01850680|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
75614319|NCT02666209|Drug|Ulocuplumab|CXCR4 inhibitor given weekly on a 28 day cycle intravenously
75765551|NCT03969576|Procedure|DEB-TACE|"Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated on demand according to the radiological response."
75907573|NCT02201004|Drug|TOFOGLIFLOZIN CSG452|Pharmaceutical form:tablet Route of administration: oral
75907574|NCT02201004|Drug|insulin|Pharmaceutical form:solution Route of administration: subcutaneous
75907575|NCT02201004|Drug|placebo|Pharmaceutical form:tablet Route of administration: oral
75461309|NCT01850680|Drug|methotrexate|Pharmaceutical form:capsule Route of administration: oral
75461310|NCT01850680|Drug|folic acid|Pharmaceutical form:tablet Route of administration: oral
75461311|NCT01850719|Procedure|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
75614320|NCT02666209|Drug|Lenalidomide|immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
75614321|NCT02666209|Drug|Bortezomib|proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
75614322|NCT02666209|Drug|Dexamethasone|steroid given at physician discretion on a 28 day cycles
75614323|NCT00964743|Drug|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
75907576|NCT02197884|Drug|JNJ-54861911, 25 mg|JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
76070857|NCT05783661|Other|Regimens guided by epidemiological surveillance|Treatment according to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
76070858|NCT05782491|Procedure|Interscalene Block|It is an ultrasound guided brachial plexus nerve block at roots/trunks used to anesthetize the shoulder and upper arm. Goal is to spread local anesthetic around superior and middle trunks of brachial plexus, between the anterior and middle scalene muscles.
75614324|NCT00964743|Drug|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
75614325|NCT04258774|Other|Carbon Dioxide|The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
75907577|NCT02197884|Drug|Itraconazole 200 mg|Itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
75907578|NCT02197884|Drug|Clarithromycin 500 mg|Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
75907579|NCT02201082|Procedure|Airway clearance technique|
76070859|NCT05782491|Procedure|PECS II Block|PECS II block is comprised of two separate fascial plane blocks to anesthetize anterolateral chest wall using an ultrasound guided injection between the pectoralis major muscle and pectoralis minor muscle at third rib and a second ultrasound guided injection between pectoralis minor and serratus anterior. The goal is a high volume hydro dissection of the two fascial planes to anesthetize anterolateral chest wall and axilla.
75614326|NCT02537041|Procedure|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
75907580|NCT02201082|Drug|Amikacin nebulization|
76072466|NCT04146129|Drug|Normal saline|Single infusion of normal saline
75614327|NCT02537041|Procedure|MRI|
75614328|NCT02862327|Drug|intravenous dexamethasone|intravenous injection of dexamethasone
75614329|NCT02862327|Drug|intravenous placebo|intravenous injection of placebo
75614330|NCT02862327|Drug|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
75614331|NCT02862327|Other|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
75614332|NCT04945720|Procedure|Hepatic artery infusion chemotherapy（HAIC）|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
75765552|NCT03969576|Procedure|cTACE|"Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated on demand according to the radiological response."
75765553|NCT01071408|Other|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
75765554|NCT00059332|Drug|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
75765555|NCT00059332|Drug|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
75765556|NCT01095952|Device|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
75765557|NCT01096030|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
75765558|NCT00233454|Drug|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
75765559|NCT00047320|Drug|carboplatin|Given IV
75765560|NCT00047320|Drug|etoposide|Given IV
75316437|NCT01792895|Procedure|Manipulation|The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
75316438|NCT01792895|Procedure|Mobilization|The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
75765561|NCT00047320|Drug|ifosfamide|Given IV
75765562|NCT00047320|Drug|thiotepa|Given IV
75765563|NCT00047320|Procedure|adjuvant therapy|
75765564|NCT00047320|Procedure|conventional surgery|
75765565|NCT00047320|Procedure|neoadjuvant therapy|
75907581|NCT02201160|Dietary Supplement|omega 3|Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
76072467|NCT04022655|Other|ICU Care|No intervention
76072468|NCT04022577|Behavioral|Adherence Therapy|Motivational interviewing-based AT in this study was based on Gray et al.'s eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
75461312|NCT01850719|Other|Physical Therapy|"Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.~In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study."
75461313|NCT01850732|Other|Ultrasound of aorta|
75461314|NCT01850771|Procedure|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
75614333|NCT04945720|Drug|Durvalumab|Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
75461315|NCT01850771|Procedure|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
75614334|NCT02666365|Procedure|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
75614335|NCT02666365|Procedure|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
75614336|NCT03423303|Diagnostic Test|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
75765566|NCT00047320|Procedure|peripheral blood stem cell transplantation|
75765567|NCT00047320|Radiation|radiation therapy|craniospinal irradiation
75765568|NCT00233064|Biological|Lyophilized Palivizumab|Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
75765569|NCT00233064|Biological|Liquid Palivizumab|Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
76072469|NCT04022577|Behavioral|control group|The control group received routine care
75461316|NCT01850784|Dietary Supplement|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
75461317|NCT01850784|Dietary Supplement|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
75765570|NCT03973242|Device|Dual focus with narrow band imaging|dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
75907582|NCT03687229|Diagnostic Test|A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
75907583|NCT03687229|Diagnostic Test|A)fasting serum glucose, B)Fasting serum insulin|measure level of insulin resistance
75907584|NCT05085054|Drug|Osimertinib Mesylate|Participants will receive targeted therapy followed by salvage surgery
76072470|NCT04145583|Drug|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
75316439|NCT01792895|Procedure|Mobilization with movement|"This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.~For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions."
75316440|NCT05183919|Other|Digital Treatment|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
75461318|NCT01850810|Other|Experimental Study Product|
75461319|NCT01850810|Other|Control Study Product|
75461320|NCT01850836|Procedure|repetitive transcranial magnetic stimulation|
75461321|NCT01850849|Drug|LEO 39652 cream|
75907585|NCT03687151|Other|non intervention / observationnal|non intervention / observationnal
75907586|NCT02257320|Device|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
75907587|NCT03969121|Drug|Palbociclib|Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
75316441|NCT02109497|Drug|PBT2|PBT2 250 mg administered
75316442|NCT04350411|Device|Conventional diathermy|Abdominal free flap raise performed with conventional diathermy. Settings: cutting 40 Watt, coagulation 40 Watt.
75461322|NCT01850849|Drug|cream vehicle|
75461323|NCT01850862|Other|Collective group exercise program in patients with KOA|
75461324|NCT01850862|Other|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
75461325|NCT01850875|Behavioral|Eye-Movement-Desensitization-Reprocessing|
75461326|NCT01850901|Procedure|Renal sympathetic denervation|
75461327|NCT01850927|Procedure|Remote ischaemic preconditioning|
75461328|NCT01850927|Procedure|Control|
75461329|NCT01850940|Drug|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
75461330|NCT01850940|Other|conventional thearpy|conventional therapy with salt limitation ,et al
75461331|NCT01850953|Drug|Varenicline|This is an approved smoking cessation medication.
75907588|NCT03969121|Drug|Endocrine therapy|Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
75907589|NCT02201238|Drug|Diclofenac sodium|Diclofenac sodium
75907590|NCT02201238|Drug|Menthol|Menthol
75907591|NCT03682627|Procedure|Fenestration|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The peritoneal will not be sutured at the edges to keep the fenestration open. No interpositioning of the omentum will be performed.
75316443|NCT04350411|Device|PEAK PlasmaBlade™|Abdominal free flap raise performed with PEAK PlasmaBlade™ Settings: cutting 7 (35 Watt), coagulation 7 (35 Watt)
75316444|NCT00409825|Drug|17-OHPC|Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
75461332|NCT01850953|Drug|Placebo|
75461333|NCT01850966|Drug|Iguratimod|The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
75461334|NCT01850979|Drug|Tacrolimus|tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
75461335|NCT01850979|Drug|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
75461336|NCT01850992|Device|Active CPAP|Effective CPAP will be administered
75461337|NCT01850992|Device|Sham CPAP|This is placebo CPAP
75461338|NCT01851005|Drug|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
75461339|NCT01851005|Drug|Sevoflurane|Control Vol% to maintain BIS 40~45
75461340|NCT01851005|Drug|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40~45 and changes of vital signs within 20%.
75461341|NCT01851005|Drug|Normal saline|Use as placebo
75461342|NCT01851005|Drug|Rocuronium|0.8 mg/kg for induction
75461343|NCT01851031|Procedure|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
75765571|NCT03954730|Other|Eccentric Training|First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
75765572|NCT03954730|Other|Active Release Technique|Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
75765573|NCT03973086|Dietary Supplement|Citrus flavonone-O-glycosides- LD|Low Dose of 200 mg
75765574|NCT03973086|Dietary Supplement|Citrus flavonone-O-glycosides- HD|High Dose of 400 mg
75765575|NCT03973086|Dietary Supplement|Placebo|Placebo (Microcrystalline Cellulose) of 400 mg
75765576|NCT01071486|Drug|Hematological Stem Cell Transplantation|Oral or Intravenous Busulfan as part of the preparative protocol for transplantation
75907592|NCT03682627|Procedure|Fenestration and clipping|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The window edges will be clipped after fenestration using 8 metal clips.
75907593|NCT02257398|Drug|GSK2140944|GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
75907594|NCT02257398|Drug|GSK2140944 placebo|GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
75907595|NCT02257398|Drug|Moxifloxacin|Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
75907596|NCT02257398|Drug|Moxifloxacin placebo|Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
75907597|NCT03533868|Diagnostic Test|Point-of-care viral load monitoring test|For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
75461344|NCT01851044|Procedure|Platelet Rich Plasma|
75461345|NCT01851044|Procedure|Whole Blood Injection|
75461346|NCT01851044|Procedure|Saline Injection|
75907598|NCT02198742|Device|Miller blade|To participate in the study the subjects must have >500 intubations with the miller blade.
75461347|NCT01851057|Behavioral|STAR|Problem-solving and education intervention (8 total sessions)
75461348|NCT01851057|Behavioral|Education Only|Education around epilepsy (8 total sessions)
75461349|NCT01851070|Drug|Allogeneic Mesenchymal Precursor Cells|
75765577|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
75765578|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
75765579|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
75461350|NCT01851070|Drug|Normal Saline|
75461351|NCT01851096|Drug|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
75461352|NCT01851109|Behavioral|genetic counseling|"The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:~A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;~Discuss how the results - positive or negative - affect cancer risk~Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);~Discuss how the test is conducted and what the results might be (positive, negative, uncertain);~Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc."
75461353|NCT01851135|Other|Neuropsychological examination and quality of life measures|
75461354|NCT01851148|Other|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
75765580|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
75765581|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil monotherapy
75765582|NCT03974490|Other|Rhythmic auditory stimulation|Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
75765583|NCT01073046|Device|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
75614337|NCT04268433|Other|N/A - Non-interventional study|"Stages:~Patient information and written informed consent (3 Copies. To be carried out >24 hours after receiving the patient information sheet)~Physiological recording set up (ECG, BP, sensor and respiratory band)~Control period - no music played~Series of pieces of music without tempo control~Repeat series of pieces of music with tempo control~Participant leaves the study"
75765584|NCT00278954|Biological|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
75765585|NCT03973008|Radiation|Adjuvant Chemoradiotherapy|DT 45Gy/25F/5W, using IMRT technology, synchronous tegio single drug chemotherapy
75765586|NCT03973008|Drug|Adjuvant Chemotherapy|Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days
75765587|NCT00278564|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
75765588|NCT00278564|Drug|Cyclophosphamide|
75765589|NCT00278564|Drug|Mesna|
75765590|NCT00278564|Drug|ATG(rabbit)|
75316445|NCT00409825|Procedure|Blood Draws|10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
75461355|NCT01851148|Other|sham treatment|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence"
75461356|NCT01851148|Drug|triptans|administration of triptans drug treatment according to international guidelines
75461357|NCT01851161|Procedure|computed tomography|Undergo conventional CT scan in both supine and prone positioning
75461358|NCT01851161|Procedure|4-dimensional computed tomography|Undergo 4D CT scan in both supine and prone positioning
75461359|NCT01851161|Radiation|radiation therapy|Undergo radiation therapy
75461360|NCT01851187|Behavioral|antenatal psychological intervention|"emotion management included:~(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms."
75461361|NCT01851187|Behavioral|routine prenatal care|Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
75461362|NCT01851200|Drug|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
75765591|NCT00278564|Drug|Methylprednisolone|
75765592|NCT00278564|Drug|G-CSF|
75765593|NCT00278564|Drug|Rituxan|
75765594|NCT01071564|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
75765595|NCT01071564|Other|Laboratory Biomarker Analysis|Correlative studies
75765596|NCT01071564|Other|Pharmacogenomic Study|Correlative studies
75765597|NCT01071564|Other|Pharmacological Study|Correlative studies
75765598|NCT01071564|Drug|Vismodegib|Given PO
75765599|NCT03975296|Procedure|preoperative single-shot TMQLB|"The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
75765600|NCT03975296|Procedure|preoperative single-shot TPVB|The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
75765601|NCT03975296|Drug|patient controlled intravenous analgesia(PCIA)|at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
75765602|NCT03974256|Other|Training in the use of the automaton|2 days training on automaton use
75765603|NCT01073124|Procedure|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
75316446|NCT02104427|Drug|TG-0054 combined with G-CSF|
75316447|NCT03832803|Behavioral|Empty bladder|No drinking protocol.
75316448|NCT03832803|Behavioral|Full bladder|Followed drinking protocol
75765604|NCT00268346|Drug|ZD1839|ZD1839 treatment will be taken once a day PO, every day about the same time
75765605|NCT00203892|Biological|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
75765606|NCT00203892|Biological|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
76070860|NCT05782491|Procedure|Superficial Cervical Plexus Block|This block is a superficial injection to the deep cervical fascia between the investing layer of the deep cervical fascia and the prevertebral fascia in the neck. This block provides anesthesia of the skin of the anterolateral neck and the ante-auricular and retro-auricular areas, as well as the skin overlying and immediately inferior to the clavicle on the chest wall. This is an ultrasound guided injection with the goal of placing the needle tip in the fascial layer underneath the SCM adjacent to the cervical plexus, which is contained within the tissue space between the Cervical fascia and posterior sheath of the SCM.
76070861|NCT05782153|Device|Intervention A (hearing aid self-fitting with direct adjustment)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using a self-fitting strategy with direct adjustment. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete a hearing screening (at 500, 1000, 2000 and 4000 Hz) called Hearing Check on the Lexie smartphone application, which will be used to tune the hearing aids according to frequency and loudness level. Participants will be able to use two wheels to change the loudness and fine-tune the hearing aids. Participants will wear the hearing aids for four weeks.
75461363|NCT01851226|Procedure|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
75316449|NCT00410059|Drug|Erlotinib|150 mg by mouth daily x 28 days
75316450|NCT04749147|Other|Black and White Printed Survey|This survey will feature black and white text and graphics.
75316451|NCT04749147|Other|Red Printed Survey|This survey will feature red text and graphics.
75461364|NCT01851265|Drug|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
75461365|NCT01851265|Other|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
75461366|NCT01851265|Other|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
75461367|NCT01851265|Other|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
75461368|NCT01851278|Drug|Triamcinolone hexacetonide|High dose means 40mg or 2ml of triamcinolone hexacetonide
75461369|NCT01851278|Drug|Triamcinolone hexacetonide|Low dose means 20mg or 1 ml of triamcinolone hexacetonide
75461370|NCT01851304|Dietary Supplement|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
75461371|NCT01851304|Dietary Supplement|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
75461372|NCT01851343|Other|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
75461373|NCT01851408|Drug|sorafenib tosylate|Given orally
75461374|NCT01851408|Drug|temsirolimus|Given IV
75461375|NCT01851460|Device|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of >75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
75461376|NCT01851473|Drug|cocaine|25 mg IV on days 1, 5, and 10
75907599|NCT02198742|Device|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
76070862|NCT05782153|Device|Intervention B (hearing aid self-fitting with in-situ fitting)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using the in-situ audiometry fitting strategy. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete an in-situ audiogram on the Lexie app, which enables the measurement of hearing thresholds through the hearing aids (at 500, 1000, 2000 and 4000 Hz). The hearing aids will then be self-programmed according to the participant's in-situ audiogram with a proprietary fitting algorithm that is based on NAL-NL2. Participants will wear the hearing aids for four weeks.
75316452|NCT00310427|Drug|LY686017|50 mg administered orally on a daily basis
75316453|NCT00310427|Drug|Placebo|Administered on a daily basis
75316454|NCT01792999|Device|Contrast-enhanced KBCT|Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
75316455|NCT04749069|Diagnostic Test|Comparison of pain intensity rating scale|Comparison of numerical pain intensity rating scale Comparison of faces pain rating scale Comparison of consumption of total amount of remifentanil
76070863|NCT05781711|Drug|levodopa-carbidopa|levodopa-carbidopa is the standard therapy used in Parkinson's disease
76070864|NCT05781711|Drug|Metformin|Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production
75614338|NCT00645385|Other|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
75461377|NCT01851473|Drug|quinine|80 mg orally on days 7-10
76070865|NCT05778591|Drug|Placebo|Placebo.
75316456|NCT00411463|Behavioral|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|"IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms."
75461378|NCT01851473|Drug|acetazolamide|15 mg orally on days 2-5
75461379|NCT01851486|Drug|Clonidine|Clonidine 0.15 mg
75461380|NCT01851486|Drug|Naloxone|naloxone 0.15 mg/kg
75765607|NCT00203892|Biological|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
75765608|NCT00250718|Drug|Vincristine|Vincristine should be administered intravenously through a freely-running IV.
75461381|NCT01851486|Drug|placebo|
75765609|NCT00250718|Drug|VP-16|The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
75765610|NCT00250718|Drug|Rituximab|"The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.~Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.~Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses"
75461382|NCT01851486|Other|saline|
75461383|NCT01851499|Dietary Supplement|Ultramicronized PEA (Normast)|600 mg
75461384|NCT01851512|Drug|T-R (Test-Reference drug)|
75461385|NCT01851512|Drug|R-T (Reference-Test drug)|
75614339|NCT02862093|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
75765611|NCT00250718|Drug|Dexamethasone|Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
75765612|NCT00250718|Drug|Levofloxacin|Levofloxacin will be administered at 500 mg PO qd.
75765613|NCT00276614|Drug|bortezomib|
75765614|NCT00276458|Drug|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
75765615|NCT00276458|Drug|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
75765616|NCT00276458|Drug|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
75765617|NCT00276458|Drug|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
75765618|NCT00276380|Drug|EGb761|EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
75907600|NCT02198742|Device|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
75907601|NCT02201316|Drug|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
75907602|NCT02201316|Drug|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
75907603|NCT02201316|Drug|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
75907604|NCT03682549|Diagnostic Test|Oral microbiome analysis|Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.
75461386|NCT01851525|Device|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
75461387|NCT01851538|Other|Observational study; no intervention.|
75461388|NCT01851551|Drug|Vincristine Sulfate Liposome Injection plus rituximab|
75461389|NCT01851564|Device|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
75461390|NCT01851564|Other|Standard Therapy|Standard Medical and Endoscopic Therapy
75461391|NCT01851577|Behavioral|Family Foundations coparenting program|Family Foundations is a coparenting program for new mothers and fathers designed to teach them skills needed to parent together effectively and facilitate healthy child development. Family Foundations will be administered concurrently with home visiting.
75907605|NCT02197962|Device|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
76070866|NCT05778591|Drug|Buprenorphine 0.15 MG [Belbuca]|Buprenorphine
76070867|NCT05774678|Radiation|Group 1 (preoperative radiation hypofractionated)|radiation schedules/regimens before your scheduled breast surgery
75907606|NCT02197962|Device|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
75907607|NCT03533790|Drug|DEP-Ru|"Drug: ruxolitinib~Drug: doxorubicin~Drug: etoposide~Drug: methylprednisolone"
75316457|NCT00411463|Drug|Seroquel|"Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder."
75765619|NCT00276380|Drug|Placebo|Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
75765620|NCT00276380|Drug|Acetylsalicylic acid|Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
75765621|NCT03975218|Other|Patients With Stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
75316458|NCT03239015|Drug|Gefitinib|Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
75907608|NCT02198118|Other|Domiciliary exercises for the upper limbs|Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
75316459|NCT03239015|Drug|Erlotinib|Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
75316460|NCT03239015|Drug|Afatinib|Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
75316461|NCT03239015|Drug|Trastuzumab|Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
75614340|NCT02666443|Drug|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
75614341|NCT02666443|Drug|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
75765622|NCT02531984|Drug|Azithromycin|
75907609|NCT02201706|Procedure|Multi-electrocoagulation retinectomy|"a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.~All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.~Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process."
75907610|NCT02198196|Behavioral|Weight Talk-Mindfulness|
76070868|NCT05774678|Other|Group 2 (preoperative radiation conventionally fractionated)|radiation schedules/regimens before your scheduled breast surgery
75316462|NCT03239015|Drug|Oxazolidine|Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
75316463|NCT03239015|Drug|Olaparib|Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
75316464|NCT03239015|Drug|Everolimus|Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
75316465|NCT03239015|Drug|Cabozantinib|Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
75316466|NCT03239015|Drug|Vemurafenib|Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
75316467|NCT03239015|Drug|Dabrafenib|Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
75316468|NCT03239015|Drug|Palbociclib|Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
75316469|NCT03239015|Drug|PD-1/L1 inhibitor plus anti-angiogenic agent|PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
75316470|NCT00356993|Drug|Nicotine Replacement Therapy|transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
75614342|NCT02666443|Drug|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
75614343|NCT00925522|Device|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
75765623|NCT00267956|Drug|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
75907611|NCT02198820|Drug|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
75907612|NCT02198820|Drug|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
75907613|NCT02257476|Drug|Carfilzomib|Carfilzomib will be given as an IV infusion over 4 hours. Subjects will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib in Cycle 1 and following the dose on Cycle 2 Day 1. During these observation times, post dose IV hydration may be given at physician's discretion.
75907614|NCT02257476|Drug|Dexamethasone|Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
76070869|NCT05774353|Other|Patient questionnaire|Patients included in the study will complete an online questionnaire (LimeSurvey).
76070870|NCT05767762|Other|scale Idiopathic Clubfoot|The Dimeglo and the muscle activity scale will be performed at 3, 6 and 12 months with patient with idiopathic clubfoot
75765624|NCT00267956|Drug|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
75907615|NCT02202018|Other|Active KT intervention|"Provider & patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space~Educational white board presentations promoting home dialysis~Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial & national averages~A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.~Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic."
75907616|NCT02198898|Device|GUARDIX-SG|
75614344|NCT01130532|Drug|Tadalafil|Administer orally
75614345|NCT01130532|Drug|Placebo|Administer orally
76070871|NCT05766683|Drug|onabotulinumtoxinA at a depth of 2mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 2mm
75316471|NCT00356993|Behavioral|behavioural intervention|Smoking cessation counselling, relapse prevention strategies
75316472|NCT01793077|Drug|Depo-Eligard®|Subcutaneous
75316473|NCT00555477|Drug|anastrozole|1 mg tablet by mouth once a day
75316474|NCT04019249|Behavioral|Healthy Weight Coaching|Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
75765625|NCT01072292|Behavioral|CBT-I|CBT-I is a six week program designed to improve sleep quality in people with COPD.
75765626|NCT00267488|Drug|topotecan|
75907617|NCT03691753|Device|Fitaya Vena Cava Filter System|After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
75907618|NCT03691753|Device|Aegisy Vena Cava Filter|After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
75907619|NCT02198274|Drug|BIBH 1|100 mg/week
75316475|NCT02109731|Other|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
75316476|NCT00365599|Drug|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
75907620|NCT02202096|Other|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
75316477|NCT00365599|Drug|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
75316478|NCT00358007|Device|PTV Reduction|The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
75461392|NCT01851577|Behavioral|Home visiting|Home visiting is a child abuse prevention approach for new mothers designed to strengthen protective factors and mitigate risk factors in order to promote optimal child development.
75461393|NCT01851603|Device|AVL-3288|Drug
75461394|NCT01851603|Drug|Placebo|Identical diluent to that used for AVL-3288
75614346|NCT04258306|Dietary Supplement|Revifast|Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
75461395|NCT01851616|Dietary Supplement|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
75614347|NCT04258306|Dietary Supplement|pure resveratrol|resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
75614348|NCT04068961|Other|Genetic analyzes|Analysis by CGH array, homozygotic cartography and candidate gene sequencing
75614349|NCT04284501|Behavioral|Non|questionnaire
75461396|NCT01851616|Dietary Supplement|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
75461397|NCT01851629|Behavioral|Locomotor Training|Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.
75614350|NCT00646165|Drug|Forodesine|
75614351|NCT04253158|Behavioral|Educational standard|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs.
75614352|NCT04253158|Behavioral|Educational standard and Harm prevention|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs increasing intentions to use harm prevention strategies.
75614353|NCT04253158|Behavioral|Educational standard and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and shifting alcohol-related expectancies.
75765627|NCT01073696|Drug|granisetron IV|IV
75765628|NCT01073696|Drug|granisetron patch|patch
75765629|NCT00058552|Drug|Pertuzumab (rhuMAb 2C4)|
75765630|NCT03954496|Device|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
75765631|NCT03954496|Behavioral|Intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills the participant wants to regain.
75765632|NCT01093768|Drug|Oxytocin|
76070872|NCT05766683|Drug|onabotulinumtoxinA at a depth of 4mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 4mm
76070873|NCT05766488|Device|Continuous glucose monitor|A continuous glucose monitor will be provided in the experimental arm of this study for 6 months. This monitor will be a Freestyle Libre 2 device.
75614354|NCT04253158|Behavioral|Expectancies and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and shifting alcohol-related expectancies.
75765633|NCT01093768|Drug|Vasopressin|
75765634|NCT03954418|Dietary Supplement|Acesulfame K, cyclamate, saccharine, aspartame|Intervention group receives a combination of multiple artificial sweeteners
75765635|NCT03954340|Device|iRemember Neurofeedback (NFB)|"Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range."
75765636|NCT01096108|Behavioral|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
75765637|NCT01096108|Behavioral|Motivational and Problem-Solving|Counseling phone calls
75765638|NCT01096108|Behavioral|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
75614355|NCT04253158|Behavioral|Educational standard and Normative perceptions|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and correcting erroneous norms about alcohol use.
75765639|NCT03954028|Procedure|Gingival Punch Biopsy after healing of Gingival Soft Tissue Augmentation|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half. After 3 months of healing, a gingival punch biopsy will be performed in both sides to collect the tissues for analysis.
75765640|NCT00044512|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
75765641|NCT03956524|Biological|EuTCV|Single 0.5 mL dose of TCV of EuBiologics co., Ltd.
75765642|NCT03956524|Biological|Typbar-TCV™|Single 0.5 mL dose of TCV of Bharat Biotech
75765643|NCT03956524|Biological|Typhim Vi®|Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur
75765644|NCT03953638|Diagnostic Test|Next Generation Sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
75765645|NCT03805438|Drug|Chloroprocaine Hcl 3% Inj|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
75765646|NCT01584154|Procedure|cryoablation|cryoablation with an 8mm-tip catheter
75765647|NCT01584154|Procedure|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
75907621|NCT02202096|Other|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
75907622|NCT02202096|Other|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
75907623|NCT02202096|Other|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
76070874|NCT05766488|Device|Traditional glucometer|A traditional glucometer device will be assigned in the standard of care arm of this study for 6 months.
75461398|NCT01851629|Other|Cross-Sectional Testing (No Intervention)|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
75907624|NCT02202096|Other|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
76070875|NCT05766215|Behavioral|Therapeutic Education|It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program
76070876|NCT05761795|Drug|IVMED 85|Eye drop
76070877|NCT05761795|Drug|Placebo|Placebo eye drop
76070878|NCT05759260|Other|Observation|Observation
75461399|NCT01851681|Drug|Amoxicillin|
75461400|NCT01851707|Drug|IPI-145|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
75461401|NCT01851707|Drug|Placebo|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
75461402|NCT01851733|Device|MRI-guided Laser Heat Ablation (MLA)|
75461403|NCT01851733|Drug|Doxorubicin|
75461404|NCT01851733|Other|Blood draw - dendritic cells|"The second 10 patients enrolled to Arm B:~before MLA (up to 3 days before)~2 weeks after MLA~4 weeks after MLA~every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)"
75461405|NCT01851733|Device|Dynamic Susceptibility Contrast Magnetic Resonance Imaging|
75614356|NCT04253158|Behavioral|Normative perceptions and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and increasing intentions to harm prevention strategies.
75614357|NCT04253158|Behavioral|Educational standard, Normative Perceptions, and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs, correcting erroneous norms about alcohol use, and shifting alcohol-related expectancies.
75765648|NCT01096264|Other|SSI and SphygmoCor® evaluations|"SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived."
75907625|NCT02202096|Other|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
75907626|NCT02202096|Other|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|"Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline."
75316479|NCT02421133|Other|Transitional care program.|"During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.~The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.~During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit."
75614358|NCT04253158|Behavioral|Normative perceptions, Expectancies, and Harm Prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use, shifting alcohol-related expectancies, and increasing intentions to use harm prevention strategies.
75614359|NCT04068415|Other|Constipation risk assessment scale|questionnaires
75316480|NCT02421133|Other|standard care program|The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician…) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
75614360|NCT04912804|Other|Questionnaires|SF-12, GHQ-12 and HAQ
75614361|NCT02668237|Other|OptiPAC|Molecular and urinary tests.
75316481|NCT00554619|Drug|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
75614362|NCT02668237|Other|Usual care|Antibiotics for prevention.
75614363|NCT04856800|Dietary Supplement|Whey|20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)
75614364|NCT04856800|Dietary Supplement|Placebo|The placebo contains <1 kcal and 0 g protein
75614365|NCT00646711|Drug|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
75316482|NCT02104739|Drug|Exenatide|Single subcutaneous injection (10 mcg)
75461406|NCT01851759|Drug|cinepazide|"2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
75461407|NCT01851759|Drug|placebo|"2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
75614366|NCT00646711|Drug|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
75316483|NCT02104739|Drug|Saxagliptin|Single dose orally (5 mg)
75316484|NCT02104739|Drug|Exenatide extended-release (ER)|Subcutaneous injection (2mg) weekly for 6 weeks
75765649|NCT01096420|Procedure|acupuncture|"Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.~Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).~Sterile disposable and steel needle (3210) were used .~The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi."
75614367|NCT04255186|Device|Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
75907627|NCT02202096|Other|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
75614368|NCT04255186|Device|Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
75614369|NCT04255186|Device|Sham stimulation|a simulated stimulation protocol so that the device does not emit current
75614370|NCT00972777|Drug|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
75614371|NCT00972777|Drug|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
75614372|NCT04254874|Drug|Abidol hydrochloride|0.2g once, 3 times a day,two weeks
75614373|NCT04254874|Drug|Abidol Hydrochloride combined with Interferon atomization|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
75614374|NCT02667223|Biological|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
75614375|NCT02667223|Biological|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
75765650|NCT01096420|Drug|topiramate|"The patients were submitted to the topiramate treatment also for 12 consecutive weeks.~The study phase consists of a 4-week titration and a 8-week maintenance period.~All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).~Study drug was administered daily in equally divided twice daily doses."
75765651|NCT01096888|Behavioral|Enhanced WIC Program|Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
75765652|NCT06186258|Device|percutaneous pulmonary valve implantation (PPVI)|The only inclusion criterion is a successful PPVI to treat RVOT dysfunction. Procedural techniques were at each operator's discretion as well as post-procedure treatments and patient's follow-up. As we sought to assess IE incidence during follow-up, patients who underwent catheterization for intended PPVI but who did not had a successful valve implantation were not included. Successful PPVI was defined as patient discharged alive without valve surgery after successful valve implantation in the RVOT.
75765653|NCT06186245|Other|Early feeding with an oral diet|Participants in the treatment arm will be initiated on a clear liquid diet on day 1 of medical ICU admission. Diet will be progressed on day 2 to full liquid diet or diabetic diet as patient tolerates based on which diet the patient would prefer.
76070879|NCT05756582|Diagnostic Test|Prevalence of Latent Tuberculosis Infection|The prevalence of Latent Tuberculosis Infection [LTBI] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed [higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.
75316485|NCT02104739|Other|Placebo|Placebo tablets and Placebo (normal saline) injections
75907628|NCT02202096|Other|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
75316486|NCT00411619|Drug|Everolimus|Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
75461408|NCT01851785|Behavioral|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
75461409|NCT01851798|Other|Home sleep test administered to all enrolled subjects|
75461410|NCT01851824|Drug|acenocoumarol|4 mg single oral doses on Days 1 and 23
75461411|NCT01851824|Drug|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
75316487|NCT02277093|Drug|Pacritinib|
75765654|NCT06186206|Behavioral|Social media interventions for vaccine uptake|"Culturally Tailored Social Media Campaign: 4 communities receive a culturally tailored social media campaign via Facebook, focusing on geographical targeting. Content aligns with indigenous cultural norms and values, featuring educational materials, testimonials, and messaging addressing vaccine misconceptions on childhood routine and HPV vaccinations' importance and safety.~WhatsApp-Based Vaccine Training for CHW: 4 communities receive both the culturally tailored social media campaign and WhatsApp-based vaccine training for CHWs. Interactive training allows CHWs to engage in discussions, seek guidance, and enhance their ability to communicate effectively. This component targets vaccine hesitancy and boosts vaccine uptake rates."
75907629|NCT02202096|Other|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
76070880|NCT05755256|Dietary Supplement|Probiotic|After randomization, participants will consume the probiotic for 12 weeks.
76070881|NCT05755256|Dietary Supplement|Placebo|After randomization, participants will consume the placebo for 12 weeks.
75316488|NCT00412087|Drug|cholecalciferol (vitamin D3)|randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
75316489|NCT00412087|Drug|cholecalciferol|randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
75316490|NCT00412087|Drug|cholecalciferol|cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
75614376|NCT02667223|Biological|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
75614377|NCT02667223|Biological|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
76070882|NCT05754697|Other|Instrument assisted soft tissue mobilization in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
75316491|NCT00312923|Drug|Policosanol|20 mg of policosanol in capsular form daily
75316492|NCT00312923|Dietary Supplement|Placebo|Two capsules of 10 mg of microcrystalline cellulose daily
75461412|NCT01851837|Other|Exercise time|Continuous training, Interval training
75461413|NCT01851850|Drug|Opicapone|25mg or 50mg once per day
75461414|NCT01851915|Behavioral|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
75614378|NCT02667223|Biological|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
75907630|NCT02202096|Other|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
75316493|NCT01793155|Other|Inspiratory muscle training|Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.
75316494|NCT01793155|Other|Placebo comparator: standard physiotherapy|Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
75316495|NCT01794377|Behavioral|30 minutes of high intensity training|"This group will carry out a 5-min warm-up period on bicycle ergometer at an intensity corresponding to 50% of Vo2max before performed eight times the intermittent training exercise as follows:~30 sec at 120% of Vo2max,~1 min at 50% of Vo2max,~15 sec at 30-40 revolutions per minute of strength training at 100% of the maximal anaerobic power, which will be first determined by means of a force-velocity test on a Monark ergometer,~1 min at 50% of Vo2max.~The training session will be terminated by a 3-min cool-down period at 40% of Vo2max.~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
75316496|NCT01794377|Behavioral|40 of an endurance training|"The moderate-intensity continuous exercise group will carry out a 40-min session of continuous cycling at a moderate intensity (50 % of Vo2max).~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
75316497|NCT00412243|Drug|Clofarabine|40 mg/m^2 Daily for 3 Days
75316498|NCT00412243|Drug|Cyclophosphamide|Beginning dose 200 mg/m^2 every 12 hours for 3 days
75316499|NCT04317963|Biological|Bezlotoxumab|Bezlotoxumab 10 mg/kg IV infusion in addition to standard CDI treatment
75461415|NCT01851915|Behavioral|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
75461416|NCT01851941|Drug|mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
75461417|NCT01851954|Drug|Clarithromycin|IV clarithromycin infusion
75461418|NCT01851967|Other|MoodGYM|MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
75614379|NCT04240912|Device|CompuFlo Epidural Computer Controlled System|"The CompuFlo Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the physician to perform epidural anesthesia and epidural injections using standard methods. However, for the purpose of this study the instrument will be used only as a monitor to detect the occurrence of EPW.~The CompuFlo Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
75614380|NCT02883660|Genetic|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
75765655|NCT06186193|Behavioral|MyP|see above: attention exercise based on phone app
75765656|NCT06186180|Other|inspiratory muscle training|They will perform 5 sets of 10 repetitions with a 1-minute rest between sets, 5 days a week, using a specific respiratory muscle training device
75765657|NCT06186154|Dietary Supplement|Folinic acid (oral); Cyanocobalamin sublingual|"Vitamin B12 (also known as Cyanocobalamin) daily sublingual supplementation of 1000 mcg/day and folinic acid orally 1mg/day~Laboratory: Complete blood count, electrolytes, reticulocytes, creatinine, urea, alkaline phosphatase (ALP), alanine transaminase, ferritin, total homocysteine, lactate and hemoglobin A1c. Routine blood will be collected as regular standard of care with each visit. MMA will also be assessed. Peripheral serum values (CBC, B12) will serve as a representation of central micronutrient availability~Clinical Evaluation: the Newcastle mitochondrial disease adult scale (NMDAS)"
75765658|NCT06186141|Drug|Morphine|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
75614381|NCT02882724|Behavioral|Exercise|8-week aquatic exercise training program
75765659|NCT06186141|Drug|Oxycodone|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
75765660|NCT06186128|Behavioral|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
75614382|NCT02882724|Behavioral|Control|Control group did not do the exercise training.
75614383|NCT04173091|Diagnostic Test|No Intervention|No Intervention planed
75614384|NCT00918736|Drug|sodium hyaluronate|3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
75614385|NCT02666053|Drug|BMS-663068|BMS-663068
75765662|NCT06186102|Dietary Supplement|Spermidine|Spermidine capsule of 8 mg x 3 capsules daily.
75765663|NCT06186102|Other|Placebo|Placebo capsule. 3 capsules daily.
75765664|NCT06186089|Dietary Supplement|probiotics|patients undergoing total gastrectomy take probiotics qd for 3 months
75907631|NCT03946111|Drug|Naltrexone and Bupropion|Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.
75907632|NCT03946111|Other|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
75907633|NCT02202174|Device|Supraglottic Airway Device|
75907634|NCT03943927|Other|Guided Metoprolol Management|"CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient."
76070883|NCT05754697|Other|Positional release technique in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
76070884|NCT05754697|Other|Traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
75316500|NCT04317963|Drug|Standard CDI treatment|Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse
75316501|NCT02047591|Other|Relaxing-touch method|
75316502|NCT01426412|Drug|LY3015014 IV|Administered IV over 30-90 minutes
75316503|NCT01426412|Drug|Placebo IV|Administered IV only over 30-90 minutes
75614386|NCT04257838|Drug|Piperacillin/tazobactam or Meropenem|"The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~Just before the antibiotic infusion (T0)~In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels."
75614387|NCT01172639|Drug|Methotrexate|Methotrexate tablet
75614388|NCT01172639|Drug|Sulfasalazine|Sulfasalazine tablet
75614389|NCT01172639|Drug|Leflunomide|Leflunomide tablet
75614390|NCT01172639|Drug|Prednisone|Prednisone tablet
75614391|NCT01144182|Behavioral|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
75614392|NCT00646789|Drug|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
75316504|NCT01426412|Drug|LY3015014 SC|Administered SC
75765665|NCT06186076|Drug|TRX-221|TRX-221 oral dose as defined
75765666|NCT06186063|Other|Pramlintide|At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.
76070885|NCT05753878|Drug|HH-120 nasal spray, PartA cohort 1|A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
76070886|NCT05753878|Drug|HH-120 nasal spray, Part A cohort 2-7|A single dose of HH-120 nasal spray.
75316505|NCT01426412|Drug|Placebo SC|Administered SC
75614393|NCT01225562|Drug|Ticagrelor 90 mg|Oral dose twice a day
75614394|NCT01225562|Drug|Ticagrelor 60 mg|Oral dose twice a day
75614395|NCT01225562|Drug|Ticagrelor Placebo|Oral dose twice a day
75765667|NCT06186063|Other|Placebo (saline) infusion|At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 25 ml/h. The infusion will be terminated after 180 minutes.
75765668|NCT06186050|Dietary Supplement|Beetroot drink|Drink containing 10g of beetroot powder in 250 mL cold tap water
75765669|NCT06186050|Dietary Supplement|Placebo|Mio flavouring in 250 mL cold tap water. Trace amounts of sugar and sodium were added to match the content in the beetroot supplement
75765670|NCT06186050|Dietary Supplement|Control|Low-fat meal with cornflakes, greek yogurt, skim milk, and orange juice
75765671|NCT06186037|Drug|Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg|Oral administration once a day, taking it for 3 years
75765672|NCT06186037|Drug|Mono drug group of Rosuvastatin 20 mg|Oral administration once a day, taking it for 3 years
76070887|NCT05753878|Drug|HH-120 nasal spray, Part A cohort 8-9|Two doses of HH-120 nasal spray.
75316506|NCT00315341|Drug|Buprenorphine/naloxone|Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
75316507|NCT00315341|Drug|Methadone|Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
75316508|NCT02277249|Drug|Digoxin (transvaginal administration)|"Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
75614396|NCT04203628|Diagnostic Test|Xpert MTB/Rif Ultra on stool samples|"The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~Standard sucrose flotation method~Optimized sucrose flotation~Stool processing kit (SPK)~Simple One-step method (SOS)"
75614397|NCT04203628|Diagnostic Test|Xpert MTB/Rif Ultra on respiratory sample|The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
75765673|NCT06186024|Device|Bridge|Stent implantation
76070888|NCT05753878|Drug|HH-120 nasal spray, Part B|HH-120 nasal spray, 10 times daily for 7 consecutive days.
75765674|NCT06186011|Procedure|Wire-guided surgery|If assigned to the WGS, the marking will be performed by the radiologist on the day prior to the intervention.
75765675|NCT06186011|Procedure|Radioactive seed localization|If assigned to the RSL, the marking will be performed by the radiologist on the day prior to the intervention. The handling and traceability will be done by the nuclear medicine physician.
75907635|NCT03691675|Device|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
75907636|NCT03533166|Other|Chlorhexidine|0.03% Chlorhexidine + 0.05% CPC mouth rinse
75907637|NCT03533166|Other|Placebo|Placebo mouth rinse
75907638|NCT03937453|Diagnostic Test|MRI/MRCP|An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee
75907639|NCT03687073|Drug|Indole-3-Carbinol|Cohorts 2, 3, & 4: 400 mg PO BID
75907640|NCT03687073|Drug|Silibinin|Cohorts 1 & 4: 720mg
75907641|NCT03687073|Drug|Silibin|Cohort 3: 360mg
75907642|NCT03691597|Diagnostic Test|improved patient satisfaction ,marginal integrity, shade match and gingival health|"For both groups N.Awill make a recall visit after6 months and after 12 months:~Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~Images will be analyzed using imageJ software to measure marginal gap.~Gingival health will be measured using G"
75316509|NCT02277249|Drug|Digoxin (transabdominal administration)|"Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
75907643|NCT02199210|Other|Prompting forethought|Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
75907644|NCT03686917|Other|CHAT-P|Survey
75907645|NCT02031354|Dietary Supplement|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
76070889|NCT05753878|Other|Placebo nasal spray, Part B|Placebo nasal spray, 10 times daily for 7 consecutive days.
75316510|NCT04767620|Drug|Rugdenzengsheng No. 1 prescription|The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
75461419|NCT01851980|Other|CWS|Chest wall strapping to reduced vital capacity by 20% of its baseline value
75765676|NCT06186011|Procedure|Intraoperative ultrasound localization|If the patient is assigned to the Intraoperative ultrasound localization (IOUS), no further procedures will be necessary until surgery. Subsenquently, the primary surgery will be performed.
75907646|NCT03682471|Drug|Deoxycholic acid Injection|Solution for subcutaneous injection.
75907647|NCT03682471|Drug|Placebo|Placebo, 10 mM sodium phosphate, 0.9% [w/v] sodium chloride in water for subcutaneous injection.
75907648|NCT02198352|Drug|BIBN 4096 BS - in single rising doses|
75907649|NCT02198352|Drug|Placebo|
75907650|NCT03533088|Other|Hospitalized rehabilitation|Patients will recive a rehabilitation prgram at the clinic twice in a week until the post-operative 12. weeks
75907651|NCT03533088|Other|Home-based rehabilitation|Patients will recive a home program once in a two weeks until the 6. weeks of post-operative period. Then will start to recieve a rehabilitation program ar the clinic once in a week auntil the 12. week of the post-operative period.
75907652|NCT02202408|Drug|SKI2670|Oral, Single Dose
75907653|NCT02202408|Drug|Placebo|Same shape as the experimental drug
75907654|NCT02202486|Other|Brain MRI|Brain MRI with gadolinium contrast
75907655|NCT02202564|Procedure|LT|Orthotopic LT
75907656|NCT02202564|Drug|ADV-TK|
75907657|NCT02202564|Drug|ganciclovir|
75907658|NCT02202642|Procedure|collagenase|Cultured limbal stem cells transplantation
75907659|NCT02198508|Drug|DFX(Deferasirox)|
75907660|NCT02198508|Drug|DFP(Deferiprone)|
75907661|NCT03533634|Procedure|Open Reduction Internal Fixation superior plate|3.5mm superior reconstruction plate
75907662|NCT03533634|Procedure|Open Reduction Internal Fixation anteroinferior plate|3.5mm anteroinferior reconstruction plate
75907663|NCT02202720|Drug|Sevoflurane|Short term sedation with sevoflurane in ICU
75907664|NCT02206308|Biological|Chimeric anti-CD20 monoclonal antibody|
76070890|NCT05753787|Other|preservative-free solution of standard post-cataract eye drops|Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
76070891|NCT05752045|Device|Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device|Double ophthalmological imaging capture of eye fundus with different fundus camera to screen patient for various eye diseases.
76070892|NCT05750121|Behavioral|E-health enhanced motor-cognitive training|The intervention group will implement physical activity (aerobic exercise and resistance training) and cognitive training (CogniFit) intervention with the e-health components (persuasive technology). The intervention period will last for 12 weeks, with three 90 minutes sessions (60 minutes of physical activity and 30 minutes of cognitive training) per week.
76072471|NCT04145583|Drug|voriconazole +HSK3486|Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
75765677|NCT06185998|Device|low pressure tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
75765678|NCT06185998|Device|plated balloon tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
75765679|NCT06185972|Drug|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
75765680|NCT06185972|Device|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
75765681|NCT06185959|Behavioral|Psychoeducation and Process Group for Asian and Asian American Psychiatric Outpatients|Participants will be individuals enrolling in a 1.5 hour weekly therapy group lasting 12 weeks and will be invited to participate in research on group processes and outcomes. The psychoeducation and process group will be a 12-session weekly closed group with 10-15 participants per group (2-3 groups total) conducted via Zoom to enhance accessibility and reduce barriers to care. Groups will be co-led by licensed clinical psychologists with experience providing both group psychotherapy and culturally responsive services. Group sessions will include brief check-ins, collaborative agenda-setting, a mini-didactic, individual reflection, and group discussion. The didactics curriculum will include topics such as intergenerational trauma, cultural differences in emotional expression, the model minority myth, family dynamics, racism, and positive connections to culture.
75765682|NCT06185920|Other|Description of severe infection|Description of severe infections treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.
75765683|NCT06185907|Other|Surgery|We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.
75765684|NCT06185881|Procedure|restoration of cervical carious teeth|restoration of carious cervical lesions by glass ionomer
75907665|NCT03686839|Behavioral|SMR neurofeedback training to MCI|SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
75907666|NCT02202798|Device|Syringe device|
75907667|NCT02202876|Other|Oral Glucose Tolerance Test|1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
76072472|NCT04022421|Drug|Hydroxychloroquine|the drug will be taken by one group of the patients daily at a dose of 400mg
75316511|NCT02988765|Procedure|Groin ultrasound +/- fine needle aspiration|"Preoperative ultrasound morphometry (USM) of the inguino-femoral lymph nodes (IFLN).~The FNAC and/or FNAB is performed in case of suspicious nodes, if at least one of the selected criteria is relieved during ultrasound"
75316512|NCT04767542|Drug|Intravenous Infusion|analgesic
75316513|NCT04767542|Procedure|Local anesthesia|Local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally to transverses abdominis muscle
75316514|NCT00316355|Behavioral|Traditional CBT|CBT with EX/RP is a psychosocial treatment that incorporates exposure with ritual prevention.
75316515|NCT00316355|Behavioral|Stepped-Care CBT|In the CBT stepped-care program, patients are first provided with a less expensive, less intrusive, and more accessible option that resembles quality community care (e.g., self-administered EX/RP combined with counseling to address medication issues, life stress, and motivational enhancement). Patients who fail to respond to this initial treatment progress to a more intensive treatment (e.g., therapist-administered EX/RP).
75316516|NCT04265703|Procedure|Internal jugular vein catheterization|Catheterization of internal jugular vein with real-time (in-plane) method, with neutral neck position. Standard aseptic technique.
75316517|NCT04265703|Procedure|Subclavian vein catheterization|Catheterization of subclavian/axillary vein with infra-clavicular approach with real-time (in-plane) method, without shoulder retraction. Standard aseptic technique.
75316518|NCT04265703|Procedure|Innominate vein catheterization|Catheterization of innominate vein with supra-clavicular approach with real-time (in-plane) method, with neutral shoulder position and no shoulder retraction. Standard aseptic technique.
75316519|NCT01794533|Drug|Lidocaine with Epinephrine+ Normal saline|local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
75461420|NCT01851980|Drug|Furosemide|40 mg and 120 mg
75461421|NCT01851980|Drug|Placebo|0.9% saline
75461422|NCT01851993|Drug|Ondansetron|
75614398|NCT04067557|Diagnostic Test|molecuar test of BV|diagnosis of BV
75614399|NCT02665819|Other|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
75614400|NCT00925288|Biological|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
75461423|NCT01851993|Drug|Placebo|0.9% saline
75461424|NCT01852006|Device|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
75614401|NCT04174573|Other|GTO|"Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)"
75765685|NCT06185868|Other|No intervention measures|No intervention measures
75765686|NCT06185855|Other|Retrospective Ultrasonographic Data Analysis|The intervention involves a detailed retrospective analysis of ultrasonographic data from patients who underwent breast lesion surgery. The study focuses on developing a quantitative nomogram model, which integrates patient age and significant sonographic characteristics of breast lesions. The purpose is to differentiate breast lesions and assess their malignancy in a non-invasive, accurate manner. This analysis uses data collected from January 2020 to June 2023, including clinical and ultrasound examination records from patients who met the inclusion criteria. The intervention does not involve any direct patient interaction or new diagnostic procedures.
75765687|NCT06185842|Behavioral|breathing exercise, walking exercise and vaccination counseling|"Participants will perform diaphragmatic breathing exercises and pursed lip breathing exercises two days a week for eight weeks.~Participants will be asked to walk for 20-30 minutes every day for eight weeks. Monitoring will be done weekly.~Participants will be counseled about infectious diseases, modes of transmission and the importance of vaccination, and will be advised to receive influenza and pneumococcal vaccines recommended for this age group.~The 5A model guide will be used regarding behavioral change towards physical activity and vaccination."
75765688|NCT06185829|Drug|Neurloeptanalgesic treatment|Usual neuroleptanalgesic treatment
75765689|NCT06185829|Other|Hypnoanalgesia|Hypnoanalgesia
75765690|NCT06185816|Device|Active Treatment|The treatment is a non-invasive pulsed radio frequency current that emits a high frequency magnetic field. It has a pulse width of 0.2ms, a pulse rate of 2Hz and an intensity between 0 - 30ma. There is a 'beep' sound as the pulses occur. There are 2 electrodes used - one is the indifferent electrode that is placed on the skin at a suitable distance away from the active electrode and the other, an active electrode - is a probe that is applied to the target nerve to treat the mononeuropathy
75765691|NCT06185816|Device|Non-active Treatment|The placebo device will be inert with nil current emitted however the device will look and be used in exactly the same way. There will also be a 'beep' sound emitted and only the investigator will know the difference. The placebo device will not deliver any electrical stimulation.
75765692|NCT06185803|Procedure|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
75765693|NCT06185790|Other|LCHF diet|Low-carb high-fat (LCHF) diet
75765694|NCT06185777|Behavioral|Exercise oncology counseling and referal|Identification & brief consultation Screening: Needs assessment for exercise therapy Information / educational talk Consultation with the patient Risk assessment (with physician clearance) Consultation Referral to exercise therapy
75316520|NCT01794533|Drug|Lidocaine with Epinephrine + fentanyl|local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
75765695|NCT06185751|Biological|WS-CART-CS1|-Subject will be hospitalized for 7 days
75765696|NCT06185751|Drug|Lymphodepleting chemotherapy|"Cyclophosphamide 500 mg/m^2 IV on Days -5, -4, and -3~Fludarabine 30 mg/m^2 IV on Days -5, -4, and -3"
75765697|NCT06185738|Other|WCM app|WCM app evaluation at baseline, at completion of WCM program and 4 weeks after completion of WCM program, by completing PROMIS and Self Efficacy for managing disease scale questionnaires
75765698|NCT06185712|Behavioral|Nurse-led disease management education|Nurse-led disease management education was applied to the intervention group
75765699|NCT06185699|Diagnostic Test|standard superficial skin biopsy (SSSB)|standard superficial skin biopsy (SSSB) was applied to the face that was wiped with dry sterile gauze after dropping cyanoacrylate by marking 1 cm2 area on the slide that was wiped with dry sterile gauze from 3 areas of the face, right cheek, nose and the mid-forehead. After the slide was left for 60 seconds and slowly removed from the face, immersion oil was dripped onto the slide and covered with a coverslip, and Demodex mites were counted first under the light microscope at x10 and then x20 magnification (Demodex foliculorum and brevis were not differentiated). The process was repeated for each region.
75765700|NCT06185673|Genetic|BB-301: Dose escalation phase 1b cohort 1|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 short hairpin (sh)RNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 1 in the dose escalation phase of the study will receive a fixed number of intramuscular (IM) injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 1.2e13 vg/subject."
75765701|NCT06185673|Genetic|BB-301: Dose escalation phase 1b cohort 2|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 2 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 3.6e13 vg/subject."
75765702|NCT06185673|Genetic|BB-301: Dose escalation phase 1b cohort 3|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 3 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 5.4e13 vg/subject."
75907668|NCT02202876|Other|High Glycemic Index Meal|"isocaloric breakfasts - set the high glycemic index to 80~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
75907669|NCT02202876|Other|Low Glycemic Index Meal|"isocaloric breakfasts - set the low glycemic index to 30~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
75907670|NCT02202876|Other|Test Soda|Test soda containing 60% fructose and 40% glucose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams.
75907671|NCT02202876|Other|Fruit juice|Fruit juice containing a combination fructose, glucose, and sucrose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams
75907672|NCT03686761|Procedure|A Involvement with the osteotomy site of the surgery|A Involvement with the osteotomy site of the surgery
75907673|NCT02206386|Other|MHTraining-Net|See Arm Description for more details.
75316521|NCT00412867|Drug|Alteplase|0.6 mg/kg of Alteplase is intravenously administered
75614402|NCT04174573|Other|GT-tDCS|"Group therapy~Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks"
75765703|NCT06185673|Genetic|BB-301: Dose expansion phase 2a|Subjects in the dose expansion phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, at the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D).
75765704|NCT06185660|Drug|sodium zirconium cyclosilicate (SZC)|sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.
75765705|NCT06185621|Drug|100mg aspirin|Patients received oral 100mg aspirin, one tablet daily for 2 years
75765706|NCT06185608|Drug|0.25% ropivacaine|A total of 15 ml of 0.25% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
75765707|NCT06185608|Drug|0.5% ropivacaine|A total of 15 ml of 0.5% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
75765708|NCT06185608|Drug|1% ropivacaine|A total of 15 ml of 1% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
75765709|NCT06185595|Other|Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.|9.3 oz (273 ml) aliquot of one of the study beverages every 15 min for a total of 28 oz (828 ml) over a 45-min period, followed by 15 min of rest. Flavored water matched for sweetness, color. flavor, but cannot be matched for saltiness. All sodium-containing drinks will include a base blend of other electrolytes (potassium 15 mmol/L, magnesium 8 mmol/L, and calcium 5 mmol/L).
75765710|NCT06185582|Other|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
75907674|NCT02206386|Other|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
76072473|NCT04022031|Drug|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
76072474|NCT03947151|Drug|Degarelix injection(s)|1 or 2 degarelix injection(s)
75316522|NCT03641027|Other|Increased physical activity|"Preoperatively~Individual coaching by a physical therapist to:~increase physical activity 30 minutes/day (At least 150 min/week)~decrease time spent sitting/lying~Telephone follow up one week after the intervention starts~At the hospital~-Frequent mobilization~After discharge~A telephone follow up one week postoperatively with coaching by a physical therapist to:~increase physical activity 30 minutes/day (At least 150 min/week) until 8 weeks postoperatively~decrease time spent sitting/lying~The intervention includes a prescribed FaR (Fysisk aktivitet på recept) with frequency, duration and intensity of the activity corresponding 12-15 on the BORG-RPE scale."
75316523|NCT03641027|Other|Standard care|
75765711|NCT06185556|Procedure|Irreversible electroporation|Percutaneous (CT-guided) irreversible electroporation of 1-3 perivascular and peribiliary colorectal liver metastasis.
75765712|NCT06185556|Radiation|Stereotactic body radiotherapy|Stereotactic body radiotherapy (CT- or MRI-guided) of 1-3 perivascular and peribiliary colorectal liver metastases.
75765713|NCT06185530|Diagnostic Test|Detection of obstructive coronary disease|Detection of obstructive coronary disease
75316524|NCT01730833|Biological|pertuzumab|Given IV
75316525|NCT01730833|Biological|trastuzumab|Given IV
75316526|NCT01730833|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
75907675|NCT03028129|Drug|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
75316527|NCT01730833|Other|laboratory biomarker analysis|Optional correlative studies
75316528|NCT00413335|Drug|Rosiglitazone|2mg to begin then 4mg, twice daily for 4 months
75316529|NCT00413335|Drug|Placebo|Subject receives placebo.
75614403|NCT01143714|Drug|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
75907676|NCT03028129|Drug|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
75907677|NCT02202954|Other|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
76072475|NCT04145505|Procedure|COLORECTAL CANCER SURGERY|SENTINEL NODE DETECTION
75316530|NCT00414271|Drug|Docetaxel|Docetaxel 60 mg/m2 IV on day 1
75316531|NCT00414271|Drug|Capecitabine|Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
75316532|NCT02110147|Drug|uridine triacetate|
75614404|NCT01143714|Other|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
75765714|NCT06185517|Diagnostic Test|Questionnaire translation and validation|Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Validation of a French translation
75765715|NCT06185491|Other|HGI|Data collection from glucose monitoring systems and dosage of glycated hemoglobin and glycated albumin measured 3 times at 6-month intervals (+/- 3 months)
75316533|NCT00414817|Behavioral|Automated Phone-Based Refill Reminders|The BREATHE EASY Medication Reminder Program uses interactive voice recognition phone technology to offer timely reminders to patients to refill their ICS medication, educational messages about ICS, and may offer to transfer them to a refill line or to speak with a pharmacist if they have questions.
75765716|NCT06185478|Diagnostic Test|MRI scan|MRI scan
75765717|NCT06185465|Device|Prontosan Wound Irrigation Solution|After debridement surgery, the test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
75765718|NCT06185465|Device|Normal Saline|After debridement surgery, the test group is selected according to the randomization number of enrollment. For control group, normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
75765719|NCT06185413|Other|Participatory system dynamics approach|First, local health profiles of children will be collected and used to engage key leaders and stakeholders from intervention communities and municipal administrations in participatory processes. These will be used to develop a systems map of drivers of PA behaviour in schoolchildren aged 6-12 years in the local communities. Second, based on the systems map, stakeholders from the civic and private sectors will be involved in developing and implementing actions to promote healthy PA behaviour through system changes.
75765720|NCT06185400|Drug|Disitamab Vedotin|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC
75765721|NCT06185400|Drug|third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression
75765722|NCT06185400|Drug|pyrotinib|RC48+pyrotinib after EGFR-TKIs progression
75765723|NCT06185374|Behavioral|Text Message Instructions/Motivation|For instructional messages, earlier messages will remind patients of the colonoscopy appointment and later messages will help patients complete the bowel preparation process in real-time. Motivational messages will be sent along with instructional messages.
75765724|NCT06185361|Drug|Fluoxetine 20 MG|fluoxetine
75461425|NCT01852097|Behavioral|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|"The general approach to the intervention is the following:~Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.~Give feedback to individuals on their questionnaire responses.~Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.~Provide advice on overcoming practical barriers.~Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.~Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation."
75461426|NCT01852123|Device|High-sensitivity troponin I assay|
75461427|NCT01852136|Device|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
75614405|NCT04800757|Behavioral|individual -Brief Motivational Intervention (BMI)|"A baseline survey will be administered prior to the session.Sessions will be initiated by exploring working conditions and psychosocial factors that may influence risk for work related injuries. If the LDL is motivated to change the target behavior, a 'change plan' will be developed which involves identifying reasons for change, goals in making change, specific actions and timelines, and others who may help the person change. The final step will be the development of a personal safety plan to reduce work place risks and a discussion of the following topics: (a) how they will know if their plan is successful, (b) potential obstacles, and (c) what the worker can do if the plan does not work. Finally,each worker will be asked to write and sign a personal pledge (Mi Promesa) to implement his own safety plan.Follow-up surveys will be conducted 4 weeks after the baseline survey."
75765725|NCT06185361|Drug|Desmopressin|desmopressin
75765726|NCT06185335|Genetic|ANB-010, dose 1|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 1.
75765727|NCT06185335|Genetic|ANB-010, dose 2|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 2.
75765728|NCT06185335|Genetic|ANB-010, dose 3|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 3.
75765729|NCT06185322|Other|Physical therapy program with upper cross syndrome specific exercises|Ten physical therapy sessions consisting of electrotherapy and upper cross syndrome -specific exercise program.
75765730|NCT06185322|Other|Physical therapy program with conventional neck strengthening exercises|Ten physical therapy sessions consisting of electrotherapy and conventional neck strenthening exercises
75765731|NCT06185296|Device|Intelligent telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
75765732|NCT06185296|Device|Telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data
75461428|NCT01852136|Device|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
75907678|NCT03660384|Procedure|PPV/SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
75907679|NCT03660384|Procedure|PPV/C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
75907680|NCT02206464|Biological|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
75316534|NCT01795651|Procedure|identification of take-home message of lecture|
75316535|NCT00360971|Biological|palifermin|Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
75765733|NCT06185283|Diagnostic Test|panoramic x-ray|Long cone paralleling technique and a film holder designed specifically for implant imaging were used for intraoral radiograph. To maintain the same film- implant distance and cone implant distance, a modification were carried out for the film holder. This modification is a hole drilled exactly above the implant fixture so the distance were maintained during subsequent film exposures. Through this modification, standardized radiographs were achieved.
75765734|NCT06185270|Diagnostic Test|SPPB|Short Physical Performance Battery using the automated device (Andantefit)
75765735|NCT06185257|Device|EEG|"Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~Patients in remission~Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured"
75765736|NCT06185244|Behavioral|Therapist-supported internet-delivered trauma-focused CBT|12 weeks of therapist-supported internet-delivered trauma-focused CBT for both the youth and the care giver.
75765737|NCT06185244|Behavioral|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
75765738|NCT06185231|Other|Percussion Massage Group|In addition progressive exercise program, The Percussion massage group will receive percussion massage therapy for a total of 5 minutes for each muscle group. The application will be done to the Quadriceps and Hamstring muscle groups before exercise. Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.
75907681|NCT02206464|Biological|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
75316536|NCT00360971|Drug|cisplatin|Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
75316537|NCT00360971|Other|placebo|Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
75316538|NCT00360971|Procedure|neck dissection|A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
75316539|NCT00360971|Radiation|radiation therapy|A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
75316540|NCT01791881|Drug|Hugeltox|1.25U~2.5U/site, Maximum dosage 12.5U~60U/person
75461429|NCT01852136|Device|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
75461430|NCT01852149|Device|MPAS Implant|The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
75765739|NCT06185231|Other|Conventional Group|"Conventional group undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks.~Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes."
75765740|NCT06185218|Other|Intravesical Botulinum Toxin|Botulinum Toxin injections will be made into the bladder.
75765741|NCT06185192|Dietary Supplement|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
75765742|NCT06185127|Drug|Dexmedetomidine|Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
75765743|NCT06185127|Drug|Ketamine|A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.
75907682|NCT02203188|Procedure|Lid debridgement scaling|
75907683|NCT04059679|Drug|Rivaroxaban 2.5 Mg Oral Tablet|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
75907684|NCT04059679|Drug|Aspirin 81 mg|EC aspirin 81 mg qd
75907685|NCT02206542|Device|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
75907686|NCT02206542|Other|Physical therapy|
75907687|NCT02206542|Device|Electroacupuncture|
75907688|NCT03691363|Behavioral|M-STEP|Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes > MVPA at baseline with 2) HR>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR>140 (low end of MVPA). The intervention will be 6 weeks in duration.
75316541|NCT01791881|Drug|Botulinum Toxin Type A(Botox®)|1.25U~2.5U/site, Maximum dosage 12.5U~60U/person
75461431|NCT01852188|Other|Type of glove used for intrapartum vaginal exams|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
75461432|NCT01852253|Procedure|2% chlorhexidine|
76072476|NCT04022109|Device|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
76072477|NCT04022109|Procedure|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
75765744|NCT06185127|Drug|Midazolam|Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam were administered.
75765745|NCT06185127|Drug|Fentanyl|Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.
75765746|NCT06185101|Behavioral|STEP-UP|The STEP-UP chronic pain self-management intervention (Support, Training, and Education for Pain Self-Management - Using Podcasts) will feature an educational podcast series teaching core pain self-management skills. Podcasts will be supplemented by sessions with a Community Health Worker taking place at designated times over a 7-week period. The Community Health Worker will guide participants in a modified Patient Priorities of Care (PPC) approach to help them identify their values and priorities and develop goals that reflect these.
75765747|NCT06185088|Device|Coda® Balloon Catheters|A balloon device that will be introduced into participants' intestine over a guide wire to test the radial stretch of the small bowel.
75765748|NCT06185088|Device|Double Balloon Endoscope (DBE)|A balloon device that will be introduced retrograde through the ileostomy and the inter-balloon distance will be increased causing stretch on the intestine to test longitudinal stretch. The DBE will only be used if a participant tolerated the Coda® Balloon Catheter intervention.
75316542|NCT03636503|Drug|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatmen
75461433|NCT01852253|Procedure|0.12% chlorhexidine|
75765749|NCT06185049|Behavioral|PROCARE+ 2.0 two booster sessions.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include two booster sessions at 6 and 12 months into the intervention.
75765750|NCT06185049|Behavioral|PROCARE+ 2.0 one booster session.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include abooster sessions at 6 months into the intervention.
75907689|NCT02202330|Other|Video Arm|"5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
75907690|NCT03682315|Device|Biphasic phycogenic biomaterial|Maxillary sinus floor elevation and bone grafting with the use of biphasic phycogenic biomaterial combined with autogenous cortical bone
75907691|NCT03682315|Device|Xenograft bovine hydroxyapatite|Maxillary sinus floor elevation and bone grafting with the use of xenograft bovine hydroxyapatite combined with autogenous cortical bone
75461434|NCT01852266|Biological|RSV cps2 Vaccine|10^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
75461435|NCT01852266|Biological|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
75316543|NCT03636503|Drug|Utomilumab|Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
75316544|NCT03636503|Drug|Avelumab|Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
75461436|NCT01852279|Device|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
75316545|NCT03636503|Drug|PF04518600|In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
75316546|NCT00371293|Behavioral|Weight Loss Program|Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
75461437|NCT01852279|Device|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
75461438|NCT01852305|Other|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI>30) or moderate sleep apnea (AHI>15 to <30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI>5 to <15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
75461439|NCT01852305|Device|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
75461440|NCT01852318|Drug|pregabalin 75mg daily for 12 weeks|oral pregabalin 75mg daily for 12 weeks
75907692|NCT02257710|Device|Orsiro|
75316547|NCT00371293|Device|CPAP therapy|Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
75461441|NCT01852318|Drug|fexofenadine 60 mg daily for 12 weeks|fexofenadine 60 mg daily for 12 weeks
75461442|NCT01852318|Drug|placebo|
75765751|NCT06185049|Behavioral|PROCARE+ 2.0 without booster sessions|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors.
75765752|NCT06185023|Behavioral|Low-intensity physical exercise|As an active control intervention, a low-intensity non-aerobic exercise program was selected that mirrors more closely the standard-of-care physical therapy currently provided to stroke patients. This control intervention will offer the same level of participant involvement and type of exercises, but without the intensity element, i.e., it will not incorporate the cardiovascular and the strengthening components.
75765753|NCT06185023|Behavioral|High-intensity physical exercise|We have developed a new exercise program specifically designed for individuals with post-stroke aphasia, Aphasia Physical EXercise (APEX), to provide a safe, stroke- and aphasia-friendly physical exercise intervention to achieve optimal physical fitness and cognitive/language gains. This intervention, based on published research and clinical practice recommendations, is a high-intensity interval training full-body workout optimized to accommodate the range of motor abilities and general deconditioning observed in stroke survivors.
75765754|NCT06184997|Other|INTAKE OF ISOTONIC DRINK|Intake of natural isotonic drink based on 20% Atlantic sea water, mixed with lemon and stevia.
75316548|NCT05288101|Dietary Supplement|Proteinex and Enterex DBT Victus Laboratories|The supplement was provided five days per week. Three days a week, the supplement was given at the beginning of the HD session and the patients were instructed to consume it slowly during the next 3 hours. The remaining two days, the supplement was consumed at home and instructed to be consumed between meals. The ONS consisted of one can of polymeric formula (Enterex DBT, Victus Laboratories) and 5.6 g of a protein powder supplement (Proteinex, Victus Laboratories). The final mixture provided 240 kcal, 17 g protein, 8.1 g lipids, 25 g carbohydrates, 4 g dietary fiber, 201 mg sodium, 490 mg calcium, 356 mg phosphorus and 371 mg potassium
75316549|NCT05288101|Procedure|Dry weight adjustment through BIVA|Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.
75316550|NCT01791959|Dietary Supplement|synbiotic|2 symbiotics capsules per day for 28 weeks
75765755|NCT06184997|Other|PLACEBO|Intake of natural mineral water
75765756|NCT06184958|Drug|Lidocaine group|Group A: Lidocaine group( 25 patients) will receive 5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
75765757|NCT06184958|Drug|Ketamine group|Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
75765758|NCT06184958|Drug|Placebo group|Group C:placebo group (25 patients) will receive placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
75316551|NCT01791959|Other|placebo|2 Maltodexterin capsules as a placebo per day for 28 weeks
75765759|NCT06184932|Behavioral|HAHE|Participants will self-initiate rehabilitative activities through the HAHE program.
75765760|NCT06184932|Behavioral|Exergame|Participants will self-initiate rehabilitative activities through the Exergame program.
76070893|NCT05746871|Device|Agilik|The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.
75316552|NCT03448159|Drug|Fluoxetine Hydrochloride|Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).
75316553|NCT03448159|Other|Placebo|Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).
75316554|NCT03448159|Behavioral|Exercise Program|All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.
75316555|NCT00361439|Drug|Mometasone|2 puffs in each nostril once daily of nasal spray
75316556|NCT00361439|Drug|Placebo|2 puffs in each nostril once daily of nasal spray
75316557|NCT00361595|Drug|zoledronic acid|5 mg zoledronic acid administered in a single 15 minute IV
75765761|NCT06184906|Dietary Supplement|Weaning by Mediterranean Diet|Introduce solid foods typical of the Mediterranean Diet at weaning of infants
75765762|NCT06181838|Procedure|Lesion extraction|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
75765763|NCT06181838|Drug|Tretinoin|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
75765764|NCT06181097|Device|negative pressure wound therapy|The intervention group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The Smith & Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility.
76070894|NCT05746871|Other|standard care|Subjects will continue with their standard care for 5 weeks
76070895|NCT05745961|Radiation|TSPO PET scan (11C-PBR28)|PET scan
75765765|NCT06181097|Other|standard dressing|The standard dressing group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The same PICO dressing will be applied, but without the suction.
75765766|NCT06180889|Drug|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
75765767|NCT06180889|Drug|KN060 Low|Single dose of KN060 administered as intravenous infusion
75765768|NCT06180889|Drug|KN060 Middle|Single dose of KN060 administered as intravenous infusion
75765769|NCT06180889|Drug|KN060 Hight|Single dose of KN060 administered as intravenous infusion
76070896|NCT05743400|Drug|Thymoglobulin 25 milligrams (mg) Injection|Patients will receive thymoglobulin between 5 and 20 milligrams/kilograms (mg/kg) as an intravenous infusion over a period of 2 to 5 days depending on the dose and the transplant package chosen by the physician.
76070897|NCT05743400|Biological|blood test|"Thymoglobulin® serum levels~Time frame : samples will be drawn at the following points :~1 after each end of perfusion ;~1 though concentration before each perfusion ;~3 blood samples in 3 different days during the first week;~1 weekly for 2 weeks post HSCT."
75907693|NCT03682237|Device|Carbohydrate counting, automated bolus calculation|Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.
75907694|NCT03682237|Device|Flash glucose monitoring (FGM)|Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.
76070898|NCT05739422|Procedure|Neuropilates online exercise class|Online, remotely supervised neuropilates exercise class
76070899|NCT05739422|Procedure|Online generalised exercise class|Online, remotely supervised generalised exercise class
76070900|NCT05739422|Procedure|Unsupervised home exercise programme|Unsupervised, home based generalised exercise programme
75907695|NCT02203266|Device|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
75316558|NCT03438487|Biological|Flucelvax Trivalent Influenza Vaccine|"Flucelvax is a cell culture seasonal trivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage or B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
75316559|NCT03438487|Biological|Flucelvax Quadrivalent Influenza Vaccine|"Flucelvax Quadrivalent is a cell culture seasonal quadrivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage, 4) B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
75316560|NCT03458117|Genetic|Talimogene Laherparepvec (T-VEC)|a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)
75316561|NCT00417859|Device|Total knee arthroplasty: mobile bearing|Total knee arthroplasty: mobile bearing
75907696|NCT02203266|Behavioral|Education|Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
76070901|NCT05735587|Other|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
76070902|NCT05735587|Other|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
75316562|NCT01792037|Drug|Etomidate|
75316563|NCT01792037|Drug|Midazolam|
75461443|NCT01852331|Drug|PGD granules|The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
75765770|NCT06179303|Drug|Abemaciclib|Given PO
75765771|NCT06179303|Drug|Anastrozole|Given anastrozole
75316564|NCT01792037|Drug|methylprednisolone|
75765772|NCT06179303|Procedure|Biospecimen Collection|Correlative studies
75765773|NCT06179303|Procedure|Computed Tomography|Undergo PET/CT
75765774|NCT06179303|Procedure|Diagnostic Imaging|Undergo clinical imaging for tumor assessment
75765775|NCT06179303|Drug|Exemestane|Given exemestane
75907697|NCT03686527|Procedure|stenosis aortic valve|"The exams to be realized :~a clinical examination with blood pressure~a 12-lead surface electrocardiogram~a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)~Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)~a cardiac MRI looking for fibrosis myocardial"
76070903|NCT05734820|Diagnostic Test|HD- colonoscopy|HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.
76070904|NCT05734820|Diagnostic Test|HD-colonoscopy assisted by AI|HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.
76070905|NCT05734807|Drug|Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)|Subjects will receive NrtIs therapy for 24 weeks.
76070906|NCT05734807|Drug|HH-003 and NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.
76070907|NCT05734807|Drug|HH-003, NrtIs and PEG-IFN-α|Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
75765776|NCT06179303|Other|Fludeoxyglucose F-18|Given IV
75765777|NCT06179303|Drug|Fluorine F 18 Fluoro Furanyl Norprogesterone|Given IV
75765778|NCT06179303|Drug|Fulvestrant|Given fulvestrant
75765779|NCT06179303|Biological|Gonadotropin-releasing Hormone Analog|Given GnRH analog
75765780|NCT06179303|Drug|Letrozole|Given letrozole
75765781|NCT06179303|Procedure|Positron Emission Tomography|Undergo PET/CT
75765782|NCT06179303|Drug|Tamoxifen|Given tamoxifen
75316565|NCT00373399|Drug|Inactive Marijuana (0% THC)|Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
75316566|NCT00373399|Drug|Low THC marijuana (1.8 %THC)|Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
75461444|NCT01852331|Drug|Placebo|The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
75461445|NCT01852357|Other|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
75614406|NCT04800757|Behavioral|Group (Group Problem Solving)|Participants will be administered a baseline survey prior to session. The GPS intervention consists of a discussion between 2-5 LDLs and a trained group facilitator. The sessions will last 30-45 minutes and are intended to encourage and support Latino day laborers (LDL) to act to reduce work-related hazards and promote worksite safety. The intervention combines four participatory and group problem solving activities to engage in collaborative learning: an icebreaker, the risk identification, action planning, and Nuestra Promesa (Our Pledge). The last activity requires LDL to select a risk reduction behavior and then to fill out and sign a card detailing a pledge to implement a safety plan. Follow up surveys will be conducted four weeks post intervention, to assess participants' change in attitudes, beliefs, and risk reducing behavior and their implementation or their safety plan.
75765783|NCT06179303|Drug|Therapeutic Estradiol|Given PO
75765784|NCT06179238|Other|Education|Patients with urinary catheter insertion during the study periods will be identified and consent will be obtained for the study. In the first stage of the study, questionnaires will be applied face to face to the experimental group and the control group. Then, education and brochures will be given to the patients in the experimental group. Patients in the experimental group will be visited and evaluated every day until the urinary catheter is removed. After the urinary catheter is removed, the patients in the experimental group and urinary catheter self-care management scale will be applied to the control group.
75765785|NCT06179238|Other|without patient education|without patient education
75765786|NCT06179186|Device|Intense Pulsed Light|The axilla will be treated with intense pulsed light, being right or left, depending upon randomization.
75461446|NCT01852357|Other|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
75461447|NCT01852396|Procedure|Retroclavicular block|Retroclavicular approach ultrasound guided regional anesthesia
75765787|NCT06179186|Device|Diode Laser|The axilla will be treated with diode laser, being right or left, depending upon randomization.
75765788|NCT06178094|Behavioral|Video Training|The participants in the Training Group is to sent a total of eight episodes of the Diabetes Training Videos prepare by the researcher, twice a week, through smartphones after the first interview
75765789|NCT06177132|Behavioral|VIS-REHAB protocol|The VIS-REHAB protocol entails two essential components: postural stability (PS) and gaze stability (GS). Within the postural stability component of the VIS-REHAB protocol, there are static and dynamic balance exercises, along with general gross motor activities targeting core stability, agility, and bilateral coordination. The gaze stability part includes exercises enhancing oculomotor function such as smooth pursuit and saccadic movements, as well as VOR-exercises. Additionally, a general gross motor training program emphasizes gaze stability by including exercises that improve eye-foot and eye-hand coordination. Furthermore, each session includes counselling and the provision of background information on the exercises.
75907698|NCT03533556|Dietary Supplement|L-theanine|Oral administration of 2.5 mg/kg body weight of L-theanine dissolved in 100 ml of water
75907699|NCT03533556|Dietary Supplement|Caffeine|Oral administration of 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
75907700|NCT03533556|Dietary Supplement|L-theanine-Caffeine Combination|Oral administration of a combination of 2.5 mg/kg body weight of L-theanine and 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
75765790|NCT06177132|Behavioral|SHAM therapy protocol|Exercises on general gross motor training targeting core stability, agility, bilateral coordination, eye-foot and eye-hand coordination. Only gross motor skills are trained, without specific attention to the principles of vestibular rehabilitation (adaptation, substitution), without specific exercises that are characteristic for vestibular rehabilitation (improving postural and gaze stability) and with counselling only on the background of the gross motor exercises, without any information or focus on the vestibular issue.
75765791|NCT06177106|Other|Solar Simulated Light|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
75316567|NCT00373399|Drug|High THC marijuana (3.9% THC)|Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
75316568|NCT04271267|Other|No Intervention|
75316569|NCT00318929|Drug|Divalproex Sodium Extended-Release Tablets|Once a day dosing
75461448|NCT01852409|Drug|bevacizumab|
75765792|NCT06176703|Device|mobile application|using mobile application along with standard treatment of diabetes mellitus
75907701|NCT03533556|Other|Placebo|Oral administration of 100 ml of water
75461449|NCT01852435|Drug|R-CEOP-70|
75461450|NCT01852435|Drug|R-CEOP-90|
75461451|NCT01852435|Drug|R-CHOP-50|
75461452|NCT01852461|Drug|Beractant|Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
75461453|NCT01852461|Drug|Poractant alfa|porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
75765793|NCT06170632|Device|Biliary drainage|Biliary drainage with FC-SEMS Niti-S FLARE TYPE
75765794|NCT06169995|Drug|Remimazolam Tosilate|bolus dose: 5mg，IV supplemental dose: 2.5mg，IV
75316570|NCT00418015|Procedure|Blood Draw|Blood for OPRM1 analysis
75316571|NCT00362453|Behavioral|Tai Chi versus Attention Control|60 minutes, twice a week for 12 weeks.
75316572|NCT00418093|Drug|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
75765795|NCT06165991|Drug|Liposomal bupivacaine, Bupivacaine|"1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA"
75614407|NCT04800757|Behavioral|Standard of Care (OSHA 10 Safety Cards)|Participant will be administered a baseline survey prior to the session.Participants in this standard of care control group will receive four wallet size cards with information about risk reduction strategies to deal with the four hazards responsible for most workplace fatalities in Texas: falls, struck by, heat exposure and cuts. The laminated cards are adapted from OSHA's website publicly available materials in Spanish for workers with limited literacy.
75765796|NCT06165809|Drug|TQB3015 tablets|TQB3015 is a protein inhibitor
75316573|NCT00418093|Drug|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
75316574|NCT00418093|Drug|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
75765797|NCT06165653|Behavioral|5-Minute, Audio-Recorded Guided Mediation Practice|"Five different meditation practices will be provided, all of which have been validated in prior research.~The Body Scan practice consists of instruction in how to direct non-judgmental attention to different regions of the body~The Mindful Breathing practice consists of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations~The Mindfulness of Discomfort practice consists of instruction in how to zoom in to deconstruct discomfort and map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences~The Savoring practice consists of instruction in identifying and amplifying pleasant memories~The Loving-Kindness practice consists of instruction in cultivating feeling of warmth and compassion toward the self and others"
75765798|NCT06164925|Diagnostic Test|Nutrition screening and assessment|"The patient is interviewed for changes in body weight in the last six months and food intake in the last two weeks.~The investigator evaluates the patient's diet, symptoms related to their nutritional status, and functional capacity according to the Subjective Global Assessment (SGA). The SGA tool itself is completed by the researcher.~Height and weight of the patient are measured, if not yet recorded, and BMI is calculated.~The patient's muscle mass is measured using mid-upper arm circumference (MUAC), calf circumference (CC) and bioelectrical impedance (BIA), and their muscle function assessed using hand grip strength."
75765799|NCT06162949|Drug|Vonoprazan|an acid suppressor therapy that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner.
75316575|NCT00374335|Procedure|abdominal ultrasound|abdominal ultrasound to detect hepatic hemangiomas
75907702|NCT03691285|Procedure|Mandibular Overdenture|Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
75907703|NCT02206854|Drug|R-flurbiprofen|200 mg gelatine capsule once orally
75907704|NCT03624205|Device|paclitaxel-releasing coronary balloon (SeQuent® Please)|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
75907705|NCT02206932|Drug|Sofosbuvir + Simeprevir|
75907706|NCT03686449|Procedure|Non-cultured Autologous Keratinocyte Suspension|New method for treatment of post-burn raw area
75316576|NCT00374335|Other|Dermatologic Examination|Complete dermatologic examination
75316577|NCT05287789|Other|Squatting position by footstool|"Before the study, the height of the toilet bowls in the patient rooms was measured as 42 cm. The stools to be used for the study are manufactured by ordering laminated with white medium density fiberboard and synthetic resin resistant to harsh chemicals. Stools are made of high quality non-slip materials for patient safety.~After the first postoperative ambulation, stable patients whose bowel movements resumed met their initial defecation needs with the squatting position created using a stool at the appropriate height on the water closet type toilet.~The patients used footstools throughout a week after discharge at home and in the hospital for defecation."
75316578|NCT03855371|Drug|Decitabine|20mg/m2/d, intravenously, d1-d5, q4w
75316579|NCT03855371|Drug|Arsenic Trioxide|0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
75316580|NCT00554229|Drug|ZD4054|ZD4054 10 mg oral tablet once daily
75316581|NCT00554229|Drug|Placebo|Matching placebo oral tablet once daily
75316582|NCT03284723|Drug|PF-06804103|Dose Escalation Part - 1A Dose Expansion Part - 2A
75316583|NCT03284723|Drug|PF-06804103 + Palbociclib +Letrozole|Dose Escalation - Part 1B Dose Expansion - Part 2B
75461454|NCT01852474|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
75461455|NCT01852487|Dietary Supplement|400mg /day during 6 months|
75461456|NCT01852500|Other|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
75614408|NCT04257916|Other|Experimental|Myofascial technique intervention of the subastragalar joint, kinesiotape and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
75461457|NCT01852500|Other|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
75461458|NCT01852526|Device|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
75907707|NCT03686449|Procedure|Adipose-Derived Stem cell-Keratinocyte Suspension|New method for treatment of post-burn raw area
75907708|NCT03686449|Procedure|Split skin graft|Traditional method for treatment of post-burn raw area
75316584|NCT00374803|Drug|Mycophenolic Acid (Myfortic)|"Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day)."
75765800|NCT06162949|Drug|Amoxicillin|An antibiotic of penicillins antibiotic group
75907709|NCT02207010|Biological|AZD1775|All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
75907710|NCT03686293|Other|Standardized breakfast|One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
75765801|NCT06162949|Drug|Clarithromycin|An antibiotic of macrolide group
76070908|NCT05732077|Drug|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
75316585|NCT03854357|Procedure|Subscapularis Rehabilitation|Specific subscapularis rehabilitation exercises which are not included in the current, standard rehabilitation protocol assigned to total shoulder arthroplasty patients post-operatively.
75765802|NCT06162949|Drug|Esomeprazole|An acid suppressor therapy that blocks the proton pump.
75907711|NCT05261724|Diagnostic Test|MRI|In this study patients with suspected primary and secondary brain tumors, confirmed by routine MRI evaluation (T1, T2, T2*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation.
75316586|NCT03854357|Procedure|Standard Rehabilitation|Standard post-operative rehabiliation protocol assigned to all total shoulder arthroplasty patients postoperatively
75316587|NCT00418951|Drug|Voriconazole|400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
76070909|NCT05732077|Diagnostic Test|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
76070910|NCT05732077|Device|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
75316588|NCT00418951|Drug|Liposomal amphotericin B|3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
75316589|NCT00418951|Drug|Liposomal amphotericin B|9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
75907712|NCT03686137|Other|Data collection|Colelction of pre-operative, surgical and post-surgical data
75907713|NCT02203422|Drug|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
75316590|NCT00363077|Biological|GSK1247446A Group|Low dose influenza vaccine adjuvanted with AS03 compared
75316591|NCT00363077|Biological|Fluarix™|GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
75907714|NCT02203422|Drug|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
75907715|NCT03686059|Drug|Omega 3|daily intake of 250 mg
75907716|NCT03686059|Device|punctal plug|punctal plug will be inserted in inferior punctum
75907717|NCT03682159|Other|manual lymphatic drainage|The intervention group received the same conventional postoperative cares as the control group, but also underwent 5 sessions of manual lymphatic drainage (MLD)
75316592|NCT00550017|Drug|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
75316593|NCT00375973|Drug|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
75461459|NCT01852526|Device|Active Comparator: Plif|monosegmental PLIF
75461460|NCT01852539|Drug|dexmedetomidine|The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
75765803|NCT06162819|Drug|Amitriptyline|Amitriptyline will be used for prophylaxis of migraine, also used as antidepressant
75907718|NCT03532854|Drug|Valsartan|Valsartan P.O
75907719|NCT03532854|Drug|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin P.O
75907720|NCT03682003|Diagnostic Test|blood diagnostic tests|blood tests are performed to determine hepcidin, IL-6, CRP, PCT, serum iron, ferritin, transferrin and transferrin saturation
75907721|NCT03591822|Behavioral|A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot|Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
75907722|NCT03591822|Behavioral|B : Systemic evaluation of the pain|A systematic evaluation of the pain
76070911|NCT05731271|Drug|TST003|IV humanized anti-GREM1 monoclonal antibody
76070912|NCT05730192|Device|CADDIE|A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
76070913|NCT05725460|Procedure|dextrose 5% median nerve hydrodissection|planned to be a good alternative to steroid hydrodissection
75316594|NCT00375973|Drug|Placebo|Sugar pill dose comparable to duloxetine
75461461|NCT01852539|Drug|propofol|Propofol 2.0 mg/kg was administrated
75765804|NCT06162819|Drug|Flunarizine 5mg|Flunarizine will be used for prophylaxis of migraine,
75765805|NCT06159075|Behavioral|Video|A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
75765806|NCT06158451|Combination Product|Zinc oxide propolis|"Propolis liquid (Brazilian Green Bee Propolis Liquid Extract, Uniflora®) and Zinc oxide powder will be mixed on a glass slab with the help of a stainless -steel spatula.~• The mixing ratio of zinc oxide powder and Propolis liquid is 2:1 until a paste like consistency is reached."
75907723|NCT03690973|Drug|Alveolar socket preservation with graft and flap surgery|Alveolar socket preservation with xenogenic bone graft and flap surgery
75907724|NCT03690973|Device|Immediate implant placement with bone using flapless surgery|Immediate implant placement with xenogenic bone graft using flapless surgery
75907725|NCT03690973|Device|Immediate implant placement with bone using flap surgery|Immediate implant placement with xenogenic bone graft using flap surgery
75765807|NCT06158451|Combination Product|Modified triple antibiotic paste|"Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals, Egypt,), and clindamycin capsules 300 mg(Dalacin C™ Pfizer, Egypt).~After the removal of enteric coating of tablets with the help of blade, the drugs are pulverized into fine powder using sterilized mortar and pestle.~The same amount of each powdered drug (1:1:1) is mixed to form m-TAP powder which is mixed with one part of propylene glycol (P) and the same volume of macrogol (M) to form a paste like consistency"
76070914|NCT05722184|Diagnostic Test|BactInsight blood culture system|A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.
75765808|NCT06151535|Device|ELAPR002f Injectable Gel|Intradermal Injections
75765809|NCT06149104|Drug|sacubitril/valsartan|sacubiril/valsartan
75765810|NCT06148389|Drug|STSA-1301 subcutaneous injection|Subjects will receive the administration dose on Day 0 following protocol requirements.
75765811|NCT06148389|Drug|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements.
75765812|NCT06142019|Device|Controlled desaturation (hypoxemia)|Stable hypoxemia is created in healthy subjects by having them breathe hypoxic air mixtures
75765813|NCT06139900|Other|Assessment|No intervention will be applied to the participants. Postural stability will be evaluated in the virtual reality environment and real environment.
76070915|NCT05717062|Drug|Varespladib intravenous form|This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
76070916|NCT05717062|Drug|varespladib-methyl- oral form|Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
75765816|NCT06131827|Other|Neural mobilization|Neural mobilization will be performed with twenty oscillations per minute being repeated three sets of one minute respecting one minute interval of rest between each set for 4 days weekly for six week
75765817|NCT06131827|Other|Task based activities|Task based activities consisted of different types task which will be performed with the dosage of 45 minute session 5 days weekly for six week.
75765818|NCT06131762|Other|Active release technique|This include active release technique for 4 weeks
75765819|NCT06131762|Other|Positional release technique|This include positional release technique for 4 weeks
75765820|NCT06131658|Other|Functional motor control excercise|This include functional motor control thrice a week for six weeks
75765821|NCT06131658|Other|convectional excercise|This include convectional exercise thrice a week for six weeks
75316595|NCT03235817|Other|Spontaneous ventilation|The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.
75316596|NCT03235817|Device|Pressure support ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
75316597|NCT03235817|Device|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
75316598|NCT02110121|Device|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
75765822|NCT06124950|Behavioral|Gender-transformative intervention|The GTI intervention will be delivered by trained nurses and social workers throughout participants' fertility treatment cycle. The intervention components will equip couples with educational information on health and relationship and skills obtained from interactive activities designed with an explicit focus on challenging gender stereotypes, all of which could incite reflection on sociocultural norms and gender-related inequality.
75765823|NCT06124235|Combination Product|Coated Orthodontic Miniscrews with Chlorhexidine Hexametaphosphate Nanoparticles|"insertion:~According to the random number generated, the corresponding envelop for left and right side by chosen.~The patient will be asked to brush his/her teeth.~The patient will rinse his/her mouth with chlorhexidine mouth rinse (0.12%) just before surgery being at least half an hour after brushing.~The miniscrews used conical shaped, self-drilling, 1.6 mm in diameter, 8mm in length made of Ti.~The site of insertion determined from the x-ray by using stent that will be fabricated for accurate site for OMS.~Infiltration LA will be administered. Approximately 0.45 mL ,injected into the alveolar mucosa above the OMS placement site, in order to provides an acceptable anesthesia, while still allowing the patient feedback in case the OMS contacting the periodontal ligament (PDL).~OMS will be placed manually by screw driver on buccally at an angle 90 degrees and then adjusted to the appropriate angle.~x-ray will be taken to confirm OMS position."
75765824|NCT06124235|Combination Product|Uncoated Miniscrew with Chlorhexidine Hexametaphosphate Nanoparticles|Non-coated orthodontic miniscrews
75765825|NCT06121934|Drug|Carica Papaya Leaf Extract|Active drug: CPLE 500mg 2 capsule t.i.d for 5 dayseive CPLE or placebo once daily for 5 days.
75907726|NCT03690973|Drug|Alveolar socket preservation with graft and flapless surgery|Alveolar socket preservation with xenogenic bone graft and flapless surgery
75907727|NCT04059289|Other|Posterior chamber intraocular lens (IOL)|This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
75907728|NCT02203500|Drug|Lacidipine|
75907729|NCT02203500|Drug|Telmisartan|
76070917|NCT05717062|Drug|Placebo intravenous form|The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
76070918|NCT05717062|Drug|Placebo - oral form|Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
75316599|NCT02110121|Device|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
75316600|NCT00421603|Drug|Adderall-XR and Topiramate|Adderall-XR 60mg/day and Topiramate 300mg/day
75316601|NCT00421603|Drug|Placebo|Placebo
75316602|NCT01794611|Device|laryngoscopy|
75765826|NCT06121934|Drug|Placebo|Placebo: visually matched placebo 2 capsule t.i.d for 5 days
76070919|NCT05714943|Behavioral|DigiKnowIt News: Teen|Participants will interact with a multimedia educational website that will teach them about pediatric clinical trials, including topics such as participant rights and safety and different types of procedures used in trials, and will provide strategies for parent-teen shared decision-making about clinical trials.
75765827|NCT06120725|Drug|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
75765828|NCT06120725|Drug|Clopidogrel|Efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
75765829|NCT06094387|Diagnostic Test|Thrombin generation assay|Thrombin generation parameters in patients receiving central catheter insertion
75765830|NCT06086275|Drug|Buprenorphine|At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.
75765831|NCT06081530|Drug|BI 3802876|BI 3802876
75765832|NCT06081530|Drug|Placebo matching BI 3802876|Placebo matching BI 3802876
76072478|NCT04022109|Diagnostic Test|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
75461462|NCT01852539|Device|laryngeal mask airway (LMA)|The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
75765833|NCT06080503|Radiation|LT-SABR|42.5 Gy in 5 fractions Low-risk: twice/week Moderate-risk: weekly
75765834|NCT06080503|Radiation|IMRT|63 Gy in 28 fractions (T1) 65.25 Gy in 29 fractions (T2)
75765835|NCT06078488|Other|Individualized and Protocolized Nutritional Care Bundle|"Education on nutritional and wound care for patient/family based on the latest guidelines based on the The European Pressure Ulcer Advisory Panel, the National Pressure Injury Advisory Panel, and the Pan Pacific Pressure Injury Alliance Prevention and Treatment of Pressure Ulcers/Injuries: 2019 Clinical Practice Guideline. A dietetic consultation at baseline, week 4 and week 8 on optimizing nutritional intake to meet caloric/protein requirements, along with additional high protein high energy (HPHE) supplementation prescribed for those participants who do not meet nutritional requirements (25-35kcal/kg/d and 1.2-2.0g protein/kg/d). The dietetic consultation will be done via face-to-face home visits and/or telehealth. A specialised nutritional supplement containing 4.5 g Arginine, 156 mg Vitamin C, 40.9 mg alpha-tocopherol equivalents (Vitamin E), 30 kcal will be administered twice a day via oral ingestion or tube feeding (mixed in 100ml water) for 12 weeks."
75316603|NCT00376363|Device|Ahmed implant|placement of glaucoma drainage device to control intraocular pressure
75765836|NCT06078488|Other|Optimized Standard Care|Only receiving education and management from specialized nurses trained in nutritional management , with or without supplementation
75765837|NCT06074471|Procedure|ultrasound guided supraclavicular brachial plexus block|"Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 SN 6N-49005130 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))"
75765838|NCT06065865|Behavioral|Guidance document|"The main intervention of interest is the guidance document, which is explained under 'Arms'. Within the treatment trajectory, that is based on the guidance document, the participants can receive a combination of NIKA, and parent and child can both get EMDR-therapy. The therapies are combined in one treatment trajectory.~NIKA consists of 5 weekly sessions during which participants are videotaped by a trained therapist. The therapist will provide personalized feedback to the parent, which is focused on reducing disrupted parenting behavior and increasing sensitive parenting behavior. EMDR is a brief trauma therapy (in this trial a maximum of six 90-min sessions for the parent and a maximum of six 60-min sessions for the child) aimed at reducing the negative load of the memories of traumatic events. Both parent and child can receive this therapy. During the weekly sessions, the participant is asked to bring the traumatic event to mind while the therapist provides a distracting task."
75765839|NCT06065709|Behavioral|Breath awareness meditation|Breath awareness meditation
75461463|NCT01852552|Device|transcatheter aortic valve implantation|Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
75765840|NCT06060054|Diagnostic Test|Device measurements|Overnight device measurements
75765841|NCT06058598|Other|Exercise Training|6-months supervised exercise training + 6 months unsupervised exercise training
75765842|NCT06058598|Other|Lifestyle Counselling|12-months of lifestyle counselling
75316604|NCT00376363|Device|Baerveldt implant|placement of glaucoma drainage device to control intraocular press
75316605|NCT00363779|Drug|Cyclosporine|An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
75316606|NCT00363779|Genetic|Gene expression analysis|A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
75316607|NCT00363779|Genetic|Microarray analysis|Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
75907730|NCT03681925|Diagnostic Test|Nutrition Literacy Assessment Instrument (NLit)|The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
76070920|NCT05713890|Other|Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation|"Observation of a VR scenario depicting multiple repetitions of a specific upper limb motor task belonging to typical activities of daily living, followed by mental imagination of the action observed and then by the execution of the same task, using objects provided in a kit.~In each session, patients will watch 2 different videos and will perform the two corresponding actions. The time scheduled for observation, imagery and execution of each action will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes. New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
75765843|NCT06052527|Other|Autonomous Treatment System for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza Based on Machine Learning|A novel treatment recommendation system for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza, which is based on machine learning
75765844|NCT06047457|Biological|Botulinum toxin type A|"Dose A U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
76072479|NCT04022109|Diagnostic Test|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
75765845|NCT06047457|Biological|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
75765846|NCT06047457|Other|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
75316608|NCT00363779|Other|Laboratory biomarker analysis|Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
75461464|NCT01852552|Procedure|Aortic Valve Replacement|Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
75614409|NCT04257916|Other|Manual therapy group|Myofascial technique of the subastragalar joint and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
75614410|NCT04920682|Drug|Reversal of moderate neuromuscular blockade|Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)> 0.4
75614411|NCT04920682|Drug|Reversal of superficial neuromuscular blockade|Neostigmine 30 mcg/kg when TOF (T4 / T1)> 0.4
75614412|NCT04920682|Drug|Two-step reversal|Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)> 0.4
75765847|NCT06047457|Biological|Botulinum toxin type A|"Dose A U/I, IM on Week 24 and Week 36 with a total of 2 injections."
75907731|NCT03681847|Procedure|Normal saline|normal saline 0.9% 15 ml/kg over 15-20 minutes.
75907732|NCT03681847|Procedure|hydroxyethyl starch|hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
75907733|NCT03681847|Procedure|Hypertonic saline|hypertonic saline 3% (7ml/kg) over 15-20 minutes.
75907734|NCT03533478|Dietary Supplement|Oral treatment Alzer y Diamel|"Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year."
75907735|NCT03533478|Dietary Supplement|Placebo|Placebo treatment
75316609|NCT00376597|Other|quality of life assessment|Ancillary studies
75316610|NCT00376597|Other|educational intervention|Receive lymphedema educational materials
75316611|NCT00376597|Procedure|Physical therapy|Complete physical therapy-focused intervention
75316612|NCT01405820|Drug|natalizumab IV|natalizumab for IV Infusion
75316613|NCT01405820|Drug|natalizumab SC|natalizumab for Subcutaneous Injection
75316614|NCT01405820|Drug|IV Placebo|Intravenous placebo to natalizumab
75316615|NCT01405820|Drug|SC Placebo|Subcutaneous placebo to natalizumab
75461465|NCT01852565|Drug|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
75461466|NCT01852565|Drug|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
75461467|NCT01852578|Drug|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
75461468|NCT01852604|Drug|Samatasvir|Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
75614413|NCT04920682|Drug|Placebo|0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)> 0.4
75614414|NCT04174339|Drug|Camrelizumab|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
75614415|NCT04174339|Drug|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
75765848|NCT06047457|Biological|Botulinum toxin type A|"Dose B U/I, IM on Week 24 and Week 36 with a total of 2 injections."
75765849|NCT06047444|Biological|Botulinum toxin type A|"Dose A Unit/Injection (U/I), Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
75765850|NCT06047444|Biological|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
75765851|NCT06047444|Other|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
75765852|NCT06047444|Biological|Botulinum toxin type A|"Dose A U/I, IM at Week 24 and Week 36 with a total of 2 injections."
75765853|NCT06047444|Biological|Botulinum toxin type A|"Dose B U/I, IM at Week 24 and Week 36 with a total of 2 injections."
75765854|NCT06041802|Biological|MK-3475A|MK-3475A is a fixed-dose formulation of pembrolizumab and MK-5180 for SC administration.
75765855|NCT06035692|Drug|Ropivacaine|According to the results of the preliminary experiment, the BPB group was given ultrasound-guided BPB with 0.15% ropivacaine 20ml.The ropivacaine concentration was the 90% minimum effective concentration(MEC90) for preventing vasospasm during operation.
75765856|NCT06030804|Drug|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
75765857|NCT06030804|Drug|Placebo|Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
75765858|NCT06024551|Other|Telerehabilitation|Patients in this arm will be given telerehabilitation three times a week, for four weeks.
75765859|NCT06024551|Other|home exercise program|Patients in this arm will receive home exercise program for four weeks
75765860|NCT06010511|Other|3T MRI scan|Conventional (3T) brain MRI scans will be used to determine global and functional markers of cerebral SVD, like WMH volume and presence of lacunes, microbleeds and superficial siderosis (3D T1, 3D FLAIR, SWI, DWI), hemodynamics (arterial spin labelling & flow territory mapping) and white matter structural integrity (diffusion tensor imaging (DTI)). Furthermore, we want to measure structural integrity with a novel MR fingerprinting sequence and an inhomogeneous magnetization transfer (ihMT) MRI scan. We also want to apply a fMRI scan technique to measure CSF fluctuations in the 4th ventricle as a measure of brain glymphatics. Also the flow-territory mapping sequence is a non-standard sequence. Heart rate and respiratory signal will be measured during the scans (3T and 7T MRI) with standard vendor-supplied equipment.
75765861|NCT06010511|Other|7T MRI scan|Ultra-high field (7T) brain MRI scans will be used to determine WMH shape and other markers of cerebral SVD in or surrounding the WMH, like local enlarged perivascular spaces, (cortical) microinfarcts and microbleeds (T1, T2, FLAIR and T2*) and vascular pulsatility (phase contrast MRI). Moreover, a recently implemented MRI technique to measure glymphatic flow in perivascular spaces will be used.
75765862|NCT06010511|Behavioral|Neuropsychological assessment|"Mini-mental state examination~Clock drawing~15-Word Verbal Learning Test, immediate and delayed~Visual Association Test~Stroop Color Word Test, 40 item version~Trail Making Test A&B~Letter Digit Substitution Test~Animal fluency test~Hospital anxiety and depression scale~Informant Questionnaire on Cognitive Decline in the Elderly"
75907736|NCT02203656|Drug|Placebo|placebo supplement
75907737|NCT02203656|Dietary Supplement|Nutritional Supplement|protein supplement
75907738|NCT02203656|Behavioral|In-home exercise|In-home exercise program
76070921|NCT05713890|Other|Home-based landscape observation with virtual-reality for upper limb rehabilitation|"Observation of virtually explorable landscapes followed by rest with eyes closed without focusing on any thought in particular and then execution of the same actions requested to VR-AOT-group. In each session, patients will explore 2 different landscapes and perform 2 different actions. The time scheduled for observation, rest and action execution will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes.New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
75907739|NCT02203656|Drug|Testosterone|Testosterone injection
75907740|NCT04436146|Other|laryngeal manual therapies|The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
75907741|NCT02203734|Procedure|Moderate Pressure Massage|The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.
76070922|NCT05711251|Other|Physical Activity in Health Promotion|During the term, the participants in the study group took lessons on many subjects, from the benefits of physical activity to suggestions to increase physical activity at work and in daily life.
76070923|NCT05709548|Drug|Indocyanine green|Subjects with a diagnosis of acute cholecystitis who undergo urgent laparoscopic cholecystectomy with the preoperative administration of indocyanine green (between 1-2 hours prior to surgery).
76070924|NCT05709301|Drug|Donepezil Hydrochloride|Donepezil 10mg once daily
76070925|NCT05709301|Drug|Placebo|Matching placebo
76070926|NCT05704803|Diagnostic Test|Diagnostic Test: IN Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
76070927|NCT05694546|Behavioral|Community Health Worker Post-Discharge Intervention|Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
75461469|NCT01852604|Drug|Simeprevir|Simeprevir will be supplied as 75 and 150 mg oral capsules.
76070928|NCT05691686|Other|Finely milled whole wheat-legume bread|The intervention examines the effect of finely milled wheat-legume bread in subjects with normal body weight.
76070929|NCT05691686|Other|Less processed whole wheat-legume bread|The intervention examines the effect of less processed whole wheat-legume bread in subjects with normal body weight.
76070930|NCT05691686|Other|Less processed whole wheat bread|The intervention examines the effect of less processed whole wheat bread in subjects with normal body weight.
76070931|NCT05691686|Other|White wheat bread|The intervention examines the reference food product in subjects with normal body weight.
75907742|NCT02203734|Procedure|Light Pressure Massage|The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
75907743|NCT02203812|Drug|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
75907744|NCT02203812|Drug|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
75907745|NCT04431388|Device|ultrasound device|We performe a differnt analgesic techniques to know if some of then are better
75907746|NCT04431388|Drug|Levobupivacaine|using the same AL
75907747|NCT02199444|Drug|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
75614416|NCT04174339|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
75907748|NCT02199444|Drug|Placebo|
76070932|NCT05691595|Other|Online survey data collection|The data will be collected via a web-survey created with the SurveyMonkey® software. The web-survey will be distributed among nurses at IRCCS Policlinico San Donato (San Donato Milanese, Italy) and ASST Grande Ospedale Metropolitano Niguarda (Milan, Italy).
76070933|NCT05687279|Biological|RSVt Vaccine|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
75614417|NCT00972543|Biological|Efalizumab (Raptiva)|"Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks."
76070934|NCT05687279|Other|Control Group|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
76070935|NCT05683600|Biological|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
75614418|NCT00972543|Biological|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
76070936|NCT05683600|Biological|Placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
76070937|NCT05674448|Biological|HH-003 20mg/kg|HH-003 20mg/kg Q2W intravenously for 24 weeks
75461470|NCT01852604|Drug|Ribavirin (RBV)|Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
75461471|NCT01852604|Drug|TMC647055|TMC647055 will be supplied as 150 mg oral capsules.
75461472|NCT01852604|Drug|Ritonavir (RTV)|Ritonavir will be supplied as 80 mg/mL oral solution.
75461473|NCT01852604|Biological|Pegylated interferon (Peg-IFN)|Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
75461474|NCT01852604|Other|Samatasvir matching placebo|Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
75614419|NCT04173481|Other|Rood's Group|"ROOD'S sensory motor training~Brushing & strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy."
75614420|NCT04173481|Other|Conventional Physical Therapy Group|Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
75765863|NCT06010511|Other|General baseline data|"Baseline data, such as age, sex, psychiatric comorbidity and medication lists will be extracted from the patient files.~Age (Year of birth); Years of education; BMI (height & weight); Sex; Verhage scale (education); Smoking status; Blood values; Sleep habits; Waste-hip ratio; Blood pressure; Current/general cardiovascular health; Psychiatric comorbidity; medical history related to cardiovascular health."
75765864|NCT06008756|Drug|MK-0616|MK-0616 20 mg tablet taken by mouth.
75765865|NCT06008756|Drug|Placebo|Placebo tablet matched to MK-0616 taken by mouth.
75765866|NCT06005818|Drug|Pembrolizumab injection|PD-1 antibody
75907749|NCT02199522|Procedure|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
75907750|NCT03532698|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
75907751|NCT03532698|Drug|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
75907752|NCT03685981|Other|Incentives mailer|Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
76070938|NCT05674448|Biological|HH-003 3mg/kg|HH-003 3mg/kg Q2W intravenously for 24 weeks
76070939|NCT05665309|Procedure|3D anatomical model of aneurysm|Surgery prepared with 3D anatomical model of aneurysm
76070940|NCT05662202|Combination Product|BF-200 ALA and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT):~Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
75316616|NCT01405742|Drug|rF.VIII|40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
75316617|NCT00321269|Behavioral|Single Illness Management|8 week nursing intervention addressing Congestive Heart Failure
75907753|NCT02207790|Drug|E2609|
75765867|NCT06001372|Drug|Ketamine|"Ketamine, 0.5-1.2mg/kg, administered intramuscularly~Doses can range 0.5-1.2 mg/kg. Starting dose for all participants will be 0.5mg/kg.~Dose can be titrated up to maximum of 1.2 mg/kg or titrated down to 0.5 mg/kg based on response and clinical judgement.~Dose will be administered by injecting into large muscle mass (eg, deltoid, gluteal muscle, thigh)"
75765868|NCT06000865|Behavioral|Action video game training|20 sessions of AVG over 10 weeks (45 minutes per session, 2 sessions per week)
75765869|NCT06000865|Behavioral|Conventional physical training|20 sessions of physical training over 10 weeks (45 minutes per session, 2 sessions per week)
75765870|NCT05996627|Drug|Belumosudil|Given PO
75765871|NCT05996627|Procedure|Biospecimen Collection|Undergo blood sample collection
75765872|NCT05996627|Other|Electronic Health Record Review|Ancillary study
75765873|NCT05996627|Drug|Placebo Administration|Given PO
75765874|NCT05974020|Other|Control|No intervention will be applied to the control group, and information will be given on general foot care instructions and the use of appropriate shoes.
75765875|NCT05974020|Other|Intrinsic Muscle Training|"In addition to general foot care instructions and briefings on the use of appropriate shoes, intrinsic muscle training including alternating toe movement, toes picking up sheets, opening and closing the toes, pinching the toe separators, toe transitions and short foot exercises will be implemented.~Additionaly, warm-up exercises, ankle exercises and functional exercises will be included in the program."
75765876|NCT05974020|Other|Aerobic Exercise|In addition to general foot care instructions and information on the use of appropriate shoes, warm-up exercises, ankle exercises, functional exercises and intrinsic muscle training, the participants will be given a walking program for aerobic exercise.
75765877|NCT05972473|Drug|Aflibercept Ophthalmic|2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).
75765878|NCT05972473|Biological|IBI302|8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.
75765879|NCT05971251|Drug|Loncastuximab Tesirine and Acalabrutinib|Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
75907754|NCT02207790|Drug|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
75316618|NCT00321269|Behavioral|Comorbid Illness Management|8 week nursing intervention to address Congestive Heart Failure and emotional coping
75316619|NCT01794767|Drug|0,9% NaCl flush|Normal Saline solution
75316620|NCT01794767|Drug|Heparin 50U/ml|Heparin solution
75316621|NCT01425632|Drug|TAU-284|TAU-284 Low
75316622|NCT01425632|Drug|TAU-284|TAU-284 High
75316623|NCT01425632|Drug|Placebo|Placebo
75316624|NCT00321971|Behavioral|PST-MCI/AD Caregiving|The PST-based intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
75316625|NCT00321971|Behavioral|NT-MCI/AD Caregiving|The nutritional education program will be based on the new USSDA dietary recommendations. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
75907755|NCT03685903|Device|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
75907756|NCT02203968|Drug|Fibrinogen concentrate|Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
75316626|NCT02076152|Device|FMISO PET|
75461475|NCT01852617|Behavioral|Training in smoking cessation counseling|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
75461476|NCT01852630|Drug|cefepime + Albumin|cefepime + Albumin will be given for 2 days
75461477|NCT01852630|Drug|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
75461478|NCT01852643|Procedure|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
75461479|NCT01852643|Procedure|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
75907757|NCT02203968|Drug|Placebo Comparator|Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
75907758|NCT03690895|Other|Retrospective survival analysis|Kaplan-Meier model
75907759|NCT02010424|Other|control group|standard IVF protocol
75907760|NCT02010424|Device|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
75907761|NCT02204046|Drug|BIWA 4|
75907762|NCT03063346|Dietary Supplement|Protein hydrolysate high dose|
75907763|NCT03063346|Dietary Supplement|Protein hydrolysate low dose|
75907764|NCT03063346|Dietary Supplement|Placebo|
75907765|NCT03690817|Behavioral|RBANS-H, virtual Morris Water Maze|Cognitive tasks for respectively: general cognition and spatial cognition
75907766|NCT02208102|Procedure|Radio-frequency catheter ablation|
75765880|NCT05970419|Other|high power laser acupuncture (HPLA)|High power laser therapy A Zimmer Opton pro, integrated High-power class IV laser device (serial N: 15200013306 & REF: 4682, made in Germany, manufactured by Zimmer Medizin System). It emits radiation in the infrared range to deliver topical heating and raise tissue temperature. The simultaneous application of two wavelengths of laser light (810 and 980nm) provides the user with a huge variety of therapy options. The laser probe - with the small spacer (3.1cm2) , with parameters of 3 watts, 5Hz, 50% duty cycle, 20 joule/ point for 13 seconds with 6.4 j/cm2 . Although a maximum power of 8000 W was reported in two studies, the average power of the lasers used in t
75461480|NCT01852656|Behavioral|Postcard and IVR Reminder Group|"IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.~Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012."
75461481|NCT01852656|Behavioral|Postcard Only Reminder Group|Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
75765881|NCT05970419|Other|conventional treatment|"Superficial heat (hot packs). Will be applied 10 - 15 minutes. Guideline-endorsed treatment is to stay active, return to normal activity, and to exercise. Different exercise types are used in the treatment of CLBP such as strength and aerobic training on land as well as specific exercises such as motor control exercises (MCE).~General exercises activating the extensor (paraspinals) and flexor (abdominals) muscle groups will be used."
75765882|NCT05970419|Other|Sham laser|sham laser (Not active)
75907767|NCT03623971|Device|Cataract AI agent|An artificial intelligence to make comprehensive evaluation and treatment decision of different types of cataracts.
75907768|NCT03063268|Behavioral|Trust-Enhanced Messaging on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
75907769|NCT03063268|Behavioral|Interactive features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
75907770|NCT03063268|Behavioral|Standard E-Consent|Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
75461482|NCT01852656|Behavioral|IVR Only Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
75461483|NCT01852682|Drug|PA21|
75907771|NCT02208180|Behavioral|Return of genomic results on cardiovascular disease risk|"Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study."
75907772|NCT03690739|Drug|Carboplatin|Administration according to investigator's discretion
75907773|NCT03690739|Drug|Gemcitabine|Administration according to investigator's discretion
75907774|NCT03690739|Drug|Bevacizumab|Administration according to investigator's discretion
75614421|NCT00925132|Drug|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
75316627|NCT02076152|Device|MRI|"MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
75316628|NCT02076152|Drug|Bevacizumab|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
75614422|NCT02862015|Other|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
75614423|NCT02862015|Drug|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
75614424|NCT00646867|Device|Tetrix|Twice daily topical application
75614425|NCT00646867|Device|Placebo|Twice daily topical application
75614426|NCT02863653|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
75765883|NCT05959135|Device|Gastric ultrasonography|"It seems like the text you provided is already in Turkish and it appears to be written in an academic style. If you want this text to be translated to English in an academic language, it would be:~Ultrasonographic evaluation of gastric contents in Diabetic and Non-Diabetic term pregnancies"
75765884|NCT05952635|Procedure|Tip bendable suction ureteral access sheath|Patient use tip bendable suction ureteral access sheath during flexible ureteroscopy to see if flexible ureteroscopy with S-UAS offers the better treatment outcomes in terms of clinical effectiveness and post-operative complications.
75907775|NCT03690739|Drug|PLD|Administration according to investigator's discretion
75907776|NCT03690739|Drug|Paclitaxel|Administration according to investigator's discretion
75907777|NCT03690739|Drug|PLD|Administration 30 mg/m² q21
75907778|NCT03690739|Drug|Trabectedin|Administration 1.1 mg/m² q21
75765885|NCT05949996|Other|A nurse-led symptom distress screening program|Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
75765886|NCT05946408|Other|Supervised antenatal exercises|"Supervised antenatal exercises along with education twice a week. Protocol consists of warm up (10 min), Aerobic training (20 mins, 60-75% of max. HR), Strength training (25 minutes), followed by a cool down of 15 minutes.~The Interventions to be provided for a period of 12 weeks."
75765887|NCT05946408|Other|Antenatal Education|Antenatal education at 12th week of pregnancy. Which consists of education on Posture in pregnancy, Role of pelvic floor muscles, Labor and breathing and relaxation techniques.
75765888|NCT05939752|Other|ophthalmological examination|OCT-retinal angiography At inclusion, 3 months and 6 months
75765889|NCT05939752|Biological|blood test|"a 2-mL tube of blood will be taken to test for blood markers predisposing to cardiovascular complications.~At inclusion"
75907779|NCT03690739|Drug|Cisplatin|Administration according to investigator's discretion
75907780|NCT01983748|Biological|Autologous Dendritic Cells loaded with autologous Tumor RNA|
75907781|NCT02208258|Device|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
75907782|NCT03623815|Other|transcranial direct current stimulation|"Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered."
75907783|NCT02208336|Other|medical chart review|Ancillary studies
75461484|NCT01852695|Behavioral|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
75907784|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
75907785|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
75907786|NCT03921229|Behavioral|Tele-coaching|"Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s)."
75907787|NCT02199678|Drug|Placebo|placebo
75907788|NCT02199678|Drug|ketamine 25 mg|ketamine
75907789|NCT02199678|Drug|ketamine 35 mg|ketamine
75907790|NCT02199678|Drug|ketamine 50 mg|ketamine
75907791|NCT03681613|Other|NEMEX program combined with a CNS-focused protocol|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training."
75907792|NCT03681613|Other|NEMEX program|The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
75316629|NCT02076152|Drug|CCNU|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
75316630|NCT03025958|Drug|Nimotuzumab|
75316631|NCT03025958|Radiation|Radiation|
75316632|NCT00380029|Drug|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
75907793|NCT02199834|Behavioral|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
75316633|NCT00380029|Procedure|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
75316634|NCT01405508|Drug|Brivaracetam tablets|100 mg, intake twice daily (BID) for 7 days during Run-In Period
75316635|NCT01405508|Drug|Brivaracetam bolus|10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period
75316636|NCT01405508|Drug|Brivaracetam infusion|10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period
75316637|NCT01405508|Other|Placebo|100 mg twice daily (BID) for 7 days during Run-In Period
75316638|NCT00426283|Drug|Flovent|1760 mcg daily
75316639|NCT00426283|Other|Placebo|Placebo
75765890|NCT05929911|Behavioral|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in the ability to reflect and affective regulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
75765891|NCT05929807|Drug|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
75765892|NCT05916807|Other|Stabilization Exercises|It consists of 26 patients who will receive stabilization exercises which will be divided in three components in lying posture, sitting, standing, rolling and kneeling positions to treat posterior, inferior muscles of scapula for 35-45 min for 3 days a week for 4 weeks.
75765893|NCT05916807|Other|Posture Training|It consists of 26 patients who will receive postural training and breast-feeding patterns for the mother and child for 35-45 min in 3 days a week for 4 weeks.
75765894|NCT05907070|Other|Mandala group|Mandala group will participate in 2 sessions of individual mandala drawing art activity with the theme of 'Emotions' accompanied by classical or instrumental music. In each session, a mandala will be created.
75765895|NCT05907070|Other|Value clarification group|Value clarification groups will participate in the value clarification activity by writing 2 sessions individually with the theme of 'Emotions' accompanied by classical or instrumental music.
75765896|NCT05896150|Procedure|Cryoanalgesia AND single-injection paravertebral block|CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
75765897|NCT05896150|Procedure|Single-injection paravertebral block|Paravertebral block with Bupivacaine 0.5%
75765898|NCT05890729|Drug|XTMAB-16 or Placebo|Infusion
75765899|NCT05884840|Diagnostic Test|HELENA|"The current CV risk screening program in based using the REGICOR risk function, which is integrated in the primary care electronic health record. This risk function predicts the probability within 10 years of developing a coronary event. Those who are categorized as high risk, obtaining a 10% of probability, are candidates of receiving lipid lowering drugs and recommendations on healthy life habits.~What this intervention suggests is that, besides the REGICOR estimation, the electronic health records will also incorporate a new CV risk function, REASON. The model predicts the risk of holding a pathologic ABI score, in people aged 50-74 years old who are apparently free of CV. Patients who obtain a score ≥ 7 will undergo a PAD screening program with ABI test. If the value of the test is ≤0.9, the REGICOR, physicians will recommend indications of the Health Catalan Institute's CV and lipid Guidelines to the patients."
75765900|NCT05875142|Behavioral|Behavioral: Digital Tutorial Overview|Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 2 weeks.
75765901|NCT05875142|Behavioral|Behavioral: Training Materials|10 weeks post-tutorial access to additional digital training materials.
75765902|NCT05875142|Behavioral|Behavioral: Feedback and Coaching|10 weeks post-tutorial access to additional digital training materials and systematic feedback and coaching.
75316640|NCT00383071|Biological|H5N1 vaccine|Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
75316641|NCT00383071|Procedure|Apheresis|Once subjects achieved a high antibody titer (>1:160), they could begin apheresis to collect plasma.
75765903|NCT05869617|Other|Aquatic exercise|"Participants in the aquatic therapy group will receive aquatic therapy in a HydroWorx aquatic therapy pool at Hydrathletics.~In the aquatic therapy group the 20 minutes of aerobic exercise at each visit will involve walking on an underwater treadmill. The intensity of the walking will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on movement patterns that simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or increasing resistance."
75907794|NCT02199834|Behavioral|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
75907795|NCT03690583|Drug|Zinc sulfate|Zinc sulfate 10 mg for children younger than 1 year old, 20 mg for children older than 1 year old, will be diluted in 1 ml of sterile water and administered orally every day in the morning during hospitalization
75316642|NCT00322439|Drug|Etanercept|Observational study - no drug administered
75316643|NCT05287165|Drug|IM96 CAR-T cells|treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
75316644|NCT01795027|Drug|S-1 plus oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
75316645|NCT01795027|Drug|S-1 single|16 courses S-1 single after d D2 resection
75316646|NCT00365261|Drug|Eszopiclone|eszopiclone 2 to 3 mg po at bedtime
75316647|NCT00365261|Drug|Placebo|placebo 2 to 3 mg po at bedtime
75316648|NCT00426517|Drug|Campath 1H|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
75316649|NCT00426517|Drug|Busulfan|Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder
75316650|NCT00426517|Drug|Horse Anti-human Thymocyte Globulin (h-ATG)|Conditioning with h-ATG 40 mg/kg total dose over 4 days given intravenously
75316651|NCT00426517|Drug|Total Body Irradiation (TBI)|TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder
75316652|NCT00426517|Drug|Sirolimus or equivalent based on response|post Transplantation immunosuppressants
75316653|NCT00365417|Drug|Bevacizumab|15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
75765904|NCT05869617|Other|Land-based Exercise|"Traditional land-based training will take place the Hydrathletics gym with similar exercises provided to the aquatic therapy group.~The aerobic exercise for the land-based therapy group will be 20 minutes of treadmill walking. The intensity will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on similar movement patterns to the aquatic therapy group to simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or the resistance used for the exercise."
75765905|NCT05861986|Drug|risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
75614427|NCT04254718|Behavioral|Digital Storytelling|Creation of a digital story about the infant with video and music selected by parents
75765906|NCT05859776|Drug|AXT107 Low Dose|Single suprachoroidal injection of AXT107 (0.125 mg/eye)
75765907|NCT05859776|Drug|AXT107 Mid Dose|Single suprachoroidal injection of AXT107 (0.250 mg/eye)
75614428|NCT02664805|Drug|LEO 124249 ointment|Ointment
75765908|NCT05859776|Drug|AXT107 High Dose|Single suprachoroidal injection of AXT107 (0.500 mg/eye)
75765909|NCT05856019|Other|J Stroke Myofascial Release|Group A will receive J stroke myofascial release on planter fascia (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
75907796|NCT03690583|Other|Glucose|The placebo group will receive glucose diluted in 1 ml of sterile water orally every day during hospitalization
75907797|NCT03685513|Other|BioHPP PEEK-based single posterior crowns|BioHPP PEEK is 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymer for extreme durability especially for frameworks for fixed and removable dental prostheses. It has many advantages as low density, light weight, shock absorber, biocompatible and venerable with composite resin.
75765910|NCT05856019|Other|Ischemic Release on Gastrocnemius through Dry Cupping|Group B will ischemic release on gastrocnemius (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
75765911|NCT05849584|Other|Transperineal ultrasound|A 2D scan will be performed of one experienced clinician. The average of 3 2D levator hiatal anteroposterior measurements will be stored. Then, a 3D/4D ultrasound examination of the pelvic floor will be performed using a Voluson S10, E8 or E10 (GE healthcare, Zipf, Austria) device with a RAB 4-8 MHz curved array transducer with the acquisition angle set at 85 degrees. Offline analysis of the ultrasound volumes will be performed using the 4D view (GE Healthcare, Austria) software, blinded to all clinical data. Hiatal anteroposterior diameter will be measured in both 2D and 3D. Hiatal area and hiatal transverse diameter will be measured in the 3D volume
75765912|NCT05847478|Other|Auricular acupressure of traditional Chinese Medicine|"The participants will be randomly assigned to receive the auricular point patch therapy.~The selected acupoints include Shenmen, hungry point, endocrine, stomach, mouth and subcortical. The opaque patch with vaccaria seed is used for acupoint pressing. Pressing the acupoints once a day before and after eating, each time for 1 minute, lasting for 2-3 days, follow up visit once a week. The intervention period is 3 months."
75765913|NCT05847478|Behavioral|Intermittent low carbohydrate diet|"The participants will be randomly assigned to the intermittent low carbohydrate diet group.~The intermittent carbohydrate diet includes 7 days of low carbohydrate diet within 2 weeks (consecutive or nonconsecutive, carbohydrate intake be controlled as ≤ 50g per day). The study duration is 3 months, including 1-month intervention period and 2-month self-maintenance period."
75765914|NCT05847478|Behavioral|Health education|Health education is conducted once a week during 3-month intervention for all participants. Health education including the understanding of childhood obesity and cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
75316654|NCT00365417|Drug|Doxorubicin|60 mg/m^2 IV every 21 days x 4 cycles
75316655|NCT00365417|Drug|Cyclophosphamide|600 mg/m^2 IV every 21 days x 4 cycles
75765915|NCT05839392|Biological|Biological characterization of AML with MECOM or atypical 3q26 rearrangements|Peripheral blood and bone marrow withdrawal
75765916|NCT05824754|Other|Just-In-Time-Adaptive-Intervention (JITAI)|"Behavioral: MiWaves behavioral messages~Participants will be using the MiWaves mobile app for 30 days. When a participant is assigned to receive a message, a message will be randomly selected from a pool of intervention message sets. Messages are based in motivational interviewing and include affect management and behavioral economic strategies."
75765917|NCT05773599|Other|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. Laughter yoga will be applied one day apart to the experimental group with a low sleep quality score. After dasa, sleep quality and life satisfaction will be evaluated again with
75765918|NCT05763212|Other|Reverse Walking+Baseline treatment|Reverse Walking+Baseline treatment
75765919|NCT05763212|Other|Whole Body Vibration + Reverse Walking+Baseline treatment|Whole Body Vibration + Reverse Walking+Baseline treatment
75316656|NCT00365417|Drug|Capecitabine|Following clinical response assessment, 650 mg/m^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
75316657|NCT00365417|Drug|Docetaxel|Following clinical response assessment, 75 mg/m^2 IV every 21 days x 4 cycles
76070941|NCT05662202|Combination Product|Vehicle and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT):~Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
76070942|NCT05659602|Biological|HH-120 Nasal Spray|HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
75907798|NCT03685513|Other|Metal ceramic single posterior crowns|Standard metal coping veneered with glass ceramics
75907799|NCT03685435|Other|Bedside ultrasound|Checking for gastric content using bedside ultrasound
75316658|NCT00427297|Drug|AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|First line regimen
75316659|NCT00427297|Drug|d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|First line regimen
75614429|NCT02664805|Drug|LEO 124249 ointment vehicle|Ointment vehicle
75907800|NCT03533400|Device|Jamboxx Respiratory Therapy Device|Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece containing a breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
75907801|NCT03533400|Device|Jamboxx Musical Device|Jamboxx musical device is a hands free, breath controlled music device designed for people with quadriplegia. It resembles a common harmonica in that the user slides a mouthpiece along its horizontal axis to change the pitch of the instrument. The device connects to a personal computer via a mini USB to USB cable to interface with software that provides visual feedback for playing notes and sends the information to the computer speakers. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx musical device can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key
75316660|NCT00427297|Drug|AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|First line regimen
76070943|NCT05656898|Device|Piezocision+GaALAs diode laser|After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .
75907802|NCT03026257|Device|Lotrafilcon B contact lenses with added wetting agent|Silicone hydrogel contact lenses
76070944|NCT05656898|Device|Piezocision|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
76070945|NCT05656898|Device|Orthodontic fixed appliance|Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
75907803|NCT03026257|Device|Samfilcon A contact lenses|Habitual silicone hydrogel contact lenses
75907804|NCT03026257|Device|POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Multi-purpose disinfecting solution for contact lens care
76070946|NCT05655195|Device|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
75765920|NCT05759754|Drug|TCM+ Routine Therapy|"TCM：The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued."
75765921|NCT05759754|Drug|Routine Therapy|Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
75765922|NCT05758779|Behavioral|Visualization of coronary Imaging and oral description|The participants is allowed to see their coronary CT scan including oral description. The study will test the effect on smoking habit and changes in LDL-C in one year.
75907805|NCT03026257|Device|Hydrogen peroxide-based contact lens solution with added wetting agent|Solution for contact lens cleaning and disinfecting
75907806|NCT03026257|Device|Senofilcon C contact lenses|Habitual silicone hydrogel contact lenses
75907807|NCT03026257|Device|Senofilcon A contact lenses|Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks
75907808|NCT03026257|Device|Comfilcon A contact lenses|Habitual silicone hydrogel contact lenses
75907809|NCT03026257|Device|Habitual Multi-Purpose Solution (HMPS)|Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
76070947|NCT05655195|Device|GENUS device (sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
76070948|NCT05650320|Drug|0.3% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
76070949|NCT05650320|Drug|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
75316661|NCT00427297|Drug|d4T/3TC/ABC (stavudine/lamivudine/abacavir)|First line regimen For children who have anaemia(Hb of<8g/dl), AZT will be substituted for d4T.
75316662|NCT00427297|Drug|ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Second line regimen
75316663|NCT00427297|Drug|ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
75316664|NCT00427297|Drug|ABC/3TC/NVP (abacavir/lamivudine/nevirapine)|First line regimen
75316665|NCT00384241|Behavioral|Induced Stress|Participation in an active coping task by playing a video game against another participant.
75316666|NCT00384241|Procedure|Buccal Swab|One Buccal swab collected from each parent
75316667|NCT04271111|Behavioral|Online Treatment for Interpersonal Stress|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
75316668|NCT04271111|Behavioral|Physical Health Education Tool|Intervention designed to improve physical health through exercise, eating habits, and sleep
75765923|NCT05755087|Procedure|Biospecimen Collection|Undergo blood sample collection
75765924|NCT05755087|Procedure|Computed Tomography|Undergo CT
75765925|NCT05755087|Procedure|Positron Emission Tomography|Undergo PET scan
75765926|NCT05755087|Drug|Tegavivint|Given IV
75765927|NCT05743270|Biological|RP3|Genetically modified herpes simplex type 1 virus
75907810|NCT02199912|Procedure|Biopsy of adipose and muscular tissue|
75907811|NCT02199912|Other|Blood sampling|
76070950|NCT05650320|Other|0% OPA-15406 vehicle|Twice-daily administration for 4 weeks.
76070951|NCT05649059|Drug|Cannabidiol|Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
76070952|NCT05649059|Drug|Placebo|Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.
75907812|NCT02199912|Other|Calorimetry|
75907813|NCT02199912|Other|Impedance measure|Evaluation of physical composition (non-invasive method)
75907814|NCT02199912|Other|Evaluation of nutritional status|"Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia"
75907815|NCT02199912|Other|Evaluation of physical performance|"This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french"
75907816|NCT02199912|Other|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
75907817|NCT02199912|Other|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
76070953|NCT05648253|Device|Vaginal Dilator Therapy by Hyivy device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each use session consisting of: 10 minutes of heat (37-42ºC) and 10 minutes of dilation therapy
75907818|NCT02199912|Other|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
75907819|NCT03681457|Drug|LJN452|Dose A single dose
75614430|NCT04285593|Other|Bulgarian squats|The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
75907820|NCT02200068|Other|SANOIA Website|
76070954|NCT05643131|Device|Hyivy device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each use session consisting of: 10 minutes of heat (37-42ºC) and 10 minutes of dilation
75316669|NCT00427765|Drug|Busulfan|Test Dose = 32 mg/m^2 IV for 1 Day; 130 mg/m^2 IV for 4 Days
75316670|NCT00427765|Drug|Melphalan|70 mg/m^2 IV for 2 Days
75316671|NCT00366275|Procedure|Immunochemotherapy, in vivo purging and autrotransplant|2-4 courses every 3 weeks with rituximab 375 mg/m^2 on day 1, vincristine 1.4 mg/m^2 on day 2 and cyclophosphamide 400 mg/m^2 on days 2-6. Courses were started if granulocytes >1.5 · 10^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM [carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m^2 on days +14 and +21 after autotransplant.
75614431|NCT01143402|Drug|Dacarbazine|Given IV
75614432|NCT01143402|Other|Laboratory Biomarker Analysis|Correlative studies
75614433|NCT01143402|Other|Quality-of-Life Assessment|Ancillary studies
75614434|NCT01143402|Drug|Selumetinib|Given PO
75614435|NCT01143402|Drug|Temozolomide|Given PO
75614436|NCT00646945|Drug|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
75614437|NCT00646945|Drug|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
75614438|NCT01171625|Device|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
75907821|NCT04974502|Procedure|Nonsurgical periodontal treatment|Oral hygiene instructions, scaling and root planning.
75907822|NCT03690505|Behavioral|Interviews|informant-based questionnaire semi-structured individual interviews focus group interviews
75907823|NCT02200146|Drug|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
75907824|NCT02200146|Drug|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
75907825|NCT04974190|Device|Nasal Spray Device|A Nasal Spray apparatus containing a liquid
75907826|NCT03690349|Other|Skin test|Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
75907827|NCT02200224|Other|Rapid Testing|
75907828|NCT03685279|Behavioral|Nurtured Heart Approach|Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.
76070955|NCT05640167|Behavioral|Interdisciplinary Clinic|Interdisciplinary Clinic - assessment and recommendations by Nutrition, Pharmacy, Physical Therapy, and Speech Therapy and Educational Seminar - Parkinson's specific education and resources in group format
76070956|NCT05638620|Drug|stellate ganglion block with 0.5% bupivacaine|"The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty."
76070957|NCT05637606|Drug|Ephedrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started
75907829|NCT02208492|Drug|Levetiracetam|Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
75614439|NCT00629889|Drug|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
75614440|NCT00629889|Drug|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
75765928|NCT05743270|Other|CCRT(concurrent chemoradiation therapy)|CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
76070958|NCT05637606|Drug|Norepinephrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.
76070959|NCT05637606|Drug|Etilefrine Hydrochloride bolus|The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started
75765929|NCT05743270|Other|carboplatin and paclitaxel|chemotherapeutic agents
75765930|NCT05743270|Biological|nivolumab|anti-PD1 monoclonal antibody
75765931|NCT05697549|Behavioral|cognitive behavior language therapy|Cognitive behavior language therapy is an extensive form of Cognitive behavior therapy. and it is used in the management of speech-language related problems. It helps the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. and it also helps the individuals to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and Augmentative alternative communication.
75765932|NCT05695937|Dietary Supplement|phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
75765933|NCT05695937|Dietary Supplement|krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
75907830|NCT02208492|Drug|Carabamazepine|Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
75907831|NCT03685201|Dietary Supplement|Orange Juice1|100% Orange Juice
76070960|NCT05637606|Diagnostic Test|Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)|PPV, SVV and mini_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery
76070961|NCT05633160|Drug|64Cu-SAR-BBN|64Cu-SAR-BBN
76070962|NCT05633160|Drug|67Cu-SAR-BBN|67Cu-SAR-BBN
76070963|NCT05632640|Other|Standard of Care|Following the participants procedure, standard of care will be given in the recovery area.
76070964|NCT05632640|Device|Weighted blanket|Following the participants procedure once in the recovery area, the nursing staff will place a weighted blanket on the participants. Different weighted blanket sizes will be used based on participants weight.
76070965|NCT05626985|Diagnostic Test|GAMAD|Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.
76070966|NCT05626192|Other|Anatomical dissection and Immunohistochemical techniques|Anatomical dissection and description
76070967|NCT05623774|Drug|Imatinib Mesylate|400mg tablet
76070968|NCT05623774|Drug|IkT-001Pro|100mg or 400mg tablet
76070969|NCT05623059|Drug|Slow Release DHEA|DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.
76070970|NCT05622045|Behavioral|Voice data|Recorded response to a question about their participation in a weight loss study.
75316672|NCT04346017|Diagnostic Test|Cytokines dosage|Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).
75316673|NCT04346017|Diagnostic Test|Complement dosage|Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.
75316674|NCT00384865|Drug|Simvastatin|Simvastatin 40 mg, taken orally, once a day for 6 months
75316675|NCT00384865|Drug|Aspirin|Aspirin 81 mg, taken orally, once a day for 6 months
75316676|NCT00384865|Drug|Placebo|Placebo, taken orally, once a day for 6 months
75614441|NCT04898686|Biological|Probiotic chewables|chewables containing Lacticaseibacillus rhamnosus GG
75614442|NCT04898686|Biological|Placebo chewables|chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.
75614443|NCT04257604|Drug|Perampanel|Perampanel tablets.
75614444|NCT03381261|Drug|Botulinum toxin type A|Injection of Botulinum toxin type A in back of head
75614445|NCT05224752|Other|Online Survey|Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
75765934|NCT05695937|Other|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol
75765935|NCT05695937|Other|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil
75765936|NCT05686070|Drug|Asundexian (BAY2433334)|Once daily, oral
75765937|NCT05686070|Drug|Placebo|Placebo to asundexian, once daily, oral
75907832|NCT03685201|Dietary Supplement|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
75907833|NCT03685201|Dietary Supplement|Raw Orange|Raw Orange
75907834|NCT01670188|Device|Pneumatic SCD - VenaFlow System (DJO Global)|
75907835|NCT02208570|Other|PPV>14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
75907836|NCT02208570|Drug|Volume loading|Hydroxyethyl starch solution 6ml/kg iv injection
75907837|NCT02208570|Other|PPV<14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
75907838|NCT03685123|Behavioral|Physical activity recommendations|Participants in the PA-REC group will exercise at 550 MET min. per week in a supervised format
76070971|NCT05618678|Behavioral|DIGNITY|DIGNITY is a multi-component, multi-level intervention that guides shared decision-making in nursing homes to support person-centered dementia care. Based in theory, this intervention targets nursing home staff attitudes and behaviors around assessing and judging whether to engage in risk situations to support resident preferences for everyday living and care despite cognitive decline due to dementia. It includes a protocol manual, baseline training on how to implement the DIGNITY strategy, and six ECHO sessions to help frontline staff negotiate intrinsic and cultural factors in preference situations that carry a risk to residents' health and safety.
75907839|NCT03685123|Behavioral|Weight maintenance recommendations|Participants in the WM-REC group will exercise at 970 MET min. per week in a supervised format
76070972|NCT05618678|Behavioral|Infection Control|This is an attention control intervention with similar dose of educational content and attention from interventionist. It includes distribution of links to the CDC Infection Control Practice Guidelines for nursing homes, a baseline training on infection control practices for frontline workers, and six ECHO coaching sessions.
76070973|NCT05615415|Drug|PET Tracer|Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
76070974|NCT05615415|Drug|MRI Tracer|Injected via intravenous catheter during PET-MR scanning.
76070975|NCT05615415|Device|3T PET/MRI|Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.
75316677|NCT00323453|Device|Open appendectomy using Alexis Wound Retractor followed by standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
75461485|NCT01852721|Behavioral|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
75461486|NCT01852721|Behavioral|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
75461487|NCT01852734|Procedure|embolizations ,uterine fibroid|"26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop"
75614446|NCT04315259|Device|Diode laser|irrigation activated by diode laser versus soft tissue laser application therapy
75907840|NCT03685123|Behavioral|OPTIFAST weight loss|Participants will participant in an OPTIFAST medical weight loss program and exercise training
75907841|NCT04982536|Device|VMCore Biopsy System|Prostate Examine
75907842|NCT04982536|Device|Standard of Care Biopsy Needle|Prostate Examine
75316678|NCT00323453|Procedure|Open appendectomy with standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
75316679|NCT03599479|Device|Virtual reality group|Virtual reality group The study intervention is to provide acute pain management for the subject undergoing fluoroscopic pain intervention by using the virtual reality program provided by the collaborator through virtual reality device (headset, headphone, and smartphone) that are commercialized on the market.
75316680|NCT00428077|Biological|bcr-abl peptide vaccine|Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.
75461488|NCT01852734|Procedure|embolizations|comparison between the two microspheres
75614447|NCT04849936|Diagnostic Test|Testing Fecal Biomarkers In Comparison To Endoscopic Examination With Confocal Laser Endomicroscopy|Patients, who were examined during a routine diagnostics, should submit an extra morning stool sample up to two weeks before or after the gastroscopy and/or coloscopy to generate the data of the fecal biomarker mentioned above.
75614448|NCT00630045|Drug|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
75614449|NCT00630045|Procedure|resection of liver metastasis|surgery with the aim of R0 resection
75614450|NCT04315103|Combination Product|a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP|All the injections were done by the same experienced physician using aseptic procedures.
75614451|NCT02861859|Drug|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
75614452|NCT02861859|Drug|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
75907843|NCT02208726|Other|Sucrose pillules|Unmedicated sucrose pillules
75907844|NCT02208726|Other|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
75907845|NCT03690193|Behavioral|Ketogenic Diet|All participants will be assigned to the 3-month 1:1 ketogenic diet intervention (approximately 70% fat, <10% carbohydrate, and 20% protein).
75907846|NCT02208804|Device|Holmium-166-poly (L-lactic acid) microspheres|
75907847|NCT03684967|Drug|Fruquintinib|Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
75907848|NCT01933048|Drug|FluMist|FluMist Intranasal Vaccine
75614453|NCT00910507|Behavioral|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
75907849|NCT02258100|Other|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
75907850|NCT04059367|Drug|NNC9204-1177|Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
75907851|NCT04059367|Drug|Cocktail of 5 already approved drugs|5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
75907852|NCT02208882|Drug|BMS-986120|
75907853|NCT02208882|Drug|Placebo|
75907854|NCT02208882|Drug|Midazolam|
75907855|NCT04432246|Device|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
75316681|NCT00428077|Genetic|reverse transcriptase-polymerase chain reaction|"A baseline reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a baseline circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction."
75614454|NCT00910507|Behavioral|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
75614455|NCT05657795|Device|Closed-loop automated oxygen control (Oxygenie, SLE6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
75614456|NCT00910585|Behavioral|Coaching, providing social support|Active telephone and in person coaching
75614457|NCT04317209|Drug|SHR0410|administered intravenously
75614458|NCT04317209|Drug|Placebo|administered intravenously
75907856|NCT03681301|Other|virtual reality simulator|Additional self-directed learning and practice using virtual reality simulator
75907857|NCT02208960|Device|Neonatal Kit|"Contents of the neonatal kit:~Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~Sunflower oil emollient (50 mL)~ThermoSpot~Mylar infant sleeve~Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker."
75907858|NCT02208960|Behavioral|Neonatal Stimulation|"A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:~Eye contact and talking to children~Responsive feeding and caregiving~Singing songs, including those with gentle touch"
75907859|NCT04974112|Other|Apply SGA and NRS2002|Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information
75614459|NCT04255654|Other|Brief Intervention for Food Insecurity|2 item screening tool (brief intervention)
75316682|NCT01795729|Device|Stent|Coronary revascularization
75316683|NCT01795729|Drug|optimal medical therapy|Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
75316684|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
75316685|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
75316686|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
75614460|NCT00647023|Drug|metformin|1000 mg metformin x 2 daily during 8 months
75614461|NCT05657717|Drug|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
75907860|NCT03690115|Drug|Ponatinib 30 MG|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
75907861|NCT02209038|Behavioral|Expanded AD Choice|
75907862|NCT02209038|Behavioral|Expanded Life-sustaining Therapy Choice|
75907863|NCT03681067|Drug|GSK1070806|GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
75907864|NCT03681067|Drug|Placebo- sodium chloride|Placebo injectable solution will be delivered via intravenous infusion as a single infusion
75907865|NCT03061708|Drug|AZD2014|mTOR inhibitor
75316687|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
75907866|NCT03680989|Device|Bright Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver ~10,000 lux at 22."
75907867|NCT03680989|Device|Natural Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver ~500 lux at 22."
75907868|NCT03062410|Other|Electronic PRO in daily clinical practice|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
75907869|NCT02204202|Drug|[18F]FDG|10 millicuries (mCi) of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
75907870|NCT02204202|Drug|[18F]ISO-1|8 mCi of [18F]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
75907871|NCT01886794|Drug|Postmenopausal, topical vaginal estrogen cream|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
75907872|NCT01886794|Drug|Placebo Comparator: Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
75907873|NCT02209116|Other|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
75907874|NCT04982380|Drug|Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
75614462|NCT00924898|Drug|efavirenz, emtricitabine, and tenofovir|Once daily ART with emtricitabine, tenofovir DF and efavirenz
75461489|NCT01852747|Procedure|Multilevel Spinal fusion with Actifuse ABX®|Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
75907875|NCT04982380|Drug|Siliankang simulating tablets|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
76070976|NCT05611775|Device|Triaxial accelerometer|Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
75461490|NCT01852773|Procedure|Open repair of thoracic aorta injury|open surgical management of aortic injury
75614463|NCT01167192|Drug|Cisplatin|
75614464|NCT01167192|Drug|Carboplatin|
75614465|NCT01167192|Radiation|Radiation therapy|
75765938|NCT05679518|Behavioral|ConquerFear intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
75316688|NCT00367601|Drug|Erlotinib|Erlotinib 150 mg qd days 1-21
76070977|NCT05608707|Behavioral|Physical activity intervention|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
75316689|NCT00367601|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
75316690|NCT00385801|Drug|Risperidone|
75316691|NCT00385801|Drug|Placebo|
75316692|NCT01759901|Procedure|Pringle|Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
75316693|NCT00429403|Drug|Goserelin|3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
75316694|NCT05286931|Drug|Ciprofloxacin 500 mg|Ciprofloxacin 500 MG, taken once orally.
75316695|NCT00367679|Drug|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
75461491|NCT01852773|Procedure|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
75614466|NCT01167192|Procedure|Mastectomy (recommended but not mandatory)|
75614467|NCT00646321|Drug|budesonide/formoterol (Symbicort)|
75614468|NCT00646321|Drug|budesonide|
75614469|NCT00647101|Drug|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
75614470|NCT01166958|Drug|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
75614471|NCT01166958|Drug|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
75614472|NCT01170221|Drug|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
75765939|NCT05679518|Behavioral|CALM intervention|CALM is a semi-structured, manualized, individual psychotherapy intervention designed for patients with advanced cancer. It includes 3-6 individual therapy sessions, with each approximately lasts 45-60 minutes, delivered over 3-6 months. The sessions cover 4 domains: 1) symptom management and communication with health care providers; 2) changes in self and relations with close others; 3) sense of meaning and purpose; and 4) the future and mortality. All modules will be addressed with each patient, but the sequencing and time devoted to each domain can be varied, based on the concerns that are most relevant to each patient.
75765940|NCT05679518|Behavioral|Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
75907876|NCT02204358|Procedure|autologous bone marrow stem cells|"Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.~If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits."
75907877|NCT04973644|Device|Remote monitoring devices+Internet management platform|Remote monitoring devices collects blood glucose, total cholesterol, serum ketones and serum uric acid,then upload data to the platform.
75614473|NCT01170221|Drug|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
75614474|NCT04849624|Other|No Intervention|This is an observational study and involved no intervention
75907878|NCT02209194|Device|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
75907879|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
75614475|NCT04254640|Drug|Cladribine Injection|Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
75614476|NCT04254640|Drug|Aclarubicin|aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
75614477|NCT04254640|Drug|G-CSF|G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
75316696|NCT00368459|Drug|raloxifene|Raloxifene is a selective estrogen receptor modulator
75316697|NCT00368459|Drug|Placebo|Identical appearing placebo
75614478|NCT04254640|Drug|cytarabine|cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
75614479|NCT01166646|Drug|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
75316698|NCT01402700|Device|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
75316699|NCT00429949|Drug|Dasatinib|
75614480|NCT01166646|Drug|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
75461492|NCT01852786|Other|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
75461493|NCT01852786|Other|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
75461494|NCT01852864|Drug|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
75614481|NCT04203394|Other|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
75614482|NCT04203394|Other|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
75614483|NCT00647179|Procedure|Transsphenoidal adenomectomy|Surgery
75614484|NCT04909840|Other|Instructions oral hygiene with toothbrush plus dental floss|Instructions of oral hygiene with toothbrush plus dental floss
75614485|NCT04909840|Other|Instructions oral hygiene with toothbrush only|Instructions only with toothbrush
75614486|NCT04065763|Other|Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.
75614487|NCT01129284|Drug|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
75614488|NCT04065607|Procedure|Reopen the abdomen to check missed pathology or abdominal washouts|Re opening of the abdomen once the patient is stabilized after 24-48 hours to check the missed injury after damaged control surgery in trauma and to control the sepsis in fecal peritonitis due to abdominal tuberculosis or typhoid perforation
75614489|NCT00647257|Drug|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
75614490|NCT00647257|Drug|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
75614491|NCT04033393|Other|Game based dual-task training|Participants in the experimental group will receive game based dual-task training with a treadmill
75765941|NCT05673486|Combination Product|PENG Block|"With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer is then slid medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks.~Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 100 mg of ropivacaine is then deposited in this plane, lifting the psoas tendon."
75765942|NCT05673486|Combination Product|Multimodal analgesia|Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight <60kg; 3mg if patient's weight >60kg) + Paracetamol 1g/8h and Nefopam 20mg/8h. Frequency of morphine administration depends on the assessed pain.
75765943|NCT05668156|Other|Consensus Decision Making|Consensus-based decision-making process, where experts are asked to comment definitions of terms used for fasting interventions
75765944|NCT05654337|Other|Expert health counseling|Expert advice on dietary education, lifestyle change, and physical exercise schedule
75907880|NCT03680833|Procedure|Sentinel node detection in cervical cancer|The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
75907881|NCT02209350|Procedure|Aorta-femoral bypass|"Access to the femoral artery is performed through a lateral incision from the inguinal ligament. Operations technique on the abdominal aorta.~Aorta-femoral bypass. Proximal anastomosis between the prosthesis and aorta is applied in the sort of end-to-side in the reconstruction by shunting.~After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. In a case of preserved antegrade blood flow the femoral artery anastomosis applied in the sort of end-to-side. If antegrade flow is absent, anastomosis is formed in the sort of end to end."
75461495|NCT01852877|Behavioral|Corrections case management|Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
75461496|NCT01852903|Dietary Supplement|calcium ascorbate|
75907882|NCT02209350|Procedure|Recanalization and stenting of aorta-iliac segment|"Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.~Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter)."
75907883|NCT02209350|Drug|Therapy: aspirin and clopidogrel|prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
75316700|NCT05286775|Other|Clinical treatment and Knee educational program|"Three weekly medical interventions, according to the patient's need as observed at baseline.~3ml paraspinal infusion of 1% Lidocaine (segmental spinal level);~5,000 impulses of Radial Shockwave Therapy (pneumatic generator, 0.16mJ/mm² of energy and 20Hz of frequency) at the most painful spot of the knees;~*6,000 pulses of Focused Shockwave Therapy (electromagnetic generator) at four sites of the painful knee.~For those with knee pain of 7 or above in Visual Analogue Scale after the treatments above, the interventions below will be delivered in the order they appear:~Ultrasound guided genicular nerve block: infusion of up to 10ml 0.50% Levobupivacaine without vasoconstrictor;~Hydrodissection of superficial and deep plane nerves: infusion of 10ml 5% dextrose diluted in water (D5W);~Intra-articular Infusion of Hyaluronic Acid: ultrasound guided infusion of 2.5ml of sodium hyaluronate at the knee joint.~Four weekly applications."
75614492|NCT04033393|Other|Treadmill training|Participants in the control group will receive treadmill training
75461497|NCT01852903|Dietary Supplement|ascorbic acid|
75461498|NCT01852903|Other|placebo|
76070978|NCT05608707|Dietary Supplement|Personalised nutrition intervention|Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
75461499|NCT01852916|Device|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
75461500|NCT01852916|Device|NHFOV|Nasal High Frequency Oscillatory Ventilation
75461501|NCT01852929|Other|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
75614493|NCT01166568|Device|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
75614494|NCT02664727|Behavioral|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
75614495|NCT02664727|Behavioral|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
75614496|NCT02666989|Drug|placebo|2 placebo pills twice a day
75614497|NCT04742179|Other|Manteinance and care intervention on the green areas.|Manteinance and care intervention on the green areas.
75614498|NCT01166178|Drug|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
75614499|NCT01166178|Drug|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
75614500|NCT01166178|Dietary Supplement|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
75765945|NCT05651009|Procedure|TKA|Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation
75765946|NCT05640622|Other|Gait Outcomes Assessment List (GOAL)|Gait Outcomes Assessment List (GOAL) is a scale developed to contribute to the determination of treatment goals. This questionnaire includes the priorities, expectations, and goals of children with CP who can walk and reveals their walking characteristics.
75765947|NCT05638737|Drug|AZD4831|AZD4831
75765948|NCT05638737|Other|Placebo|Placebo
75765949|NCT05611879|Drug|Tislelizumab|Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles
75765950|NCT05611879|Drug|Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles.
75907884|NCT05263128|Other|Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome|To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey
75907885|NCT02204514|Procedure|Surgery for external snapping hip|
75907886|NCT03680599|Behavioral|Connection to Health for Smokers|Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.
75614501|NCT00646477|Device|titration night|"Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:~in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.~in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events."
75614502|NCT00924820|Drug|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
75907887|NCT03680599|Behavioral|Enhanced Standard of Care|Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators
75907888|NCT02209428|Drug|Temozolomide|75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
75907889|NCT03684733|Diagnostic Test|MRI|Clinical MRI breast screening examination
75907890|NCT03684577|Behavioral|Hypnotherapy for Agoraphobia|see description of the experimental arm
75461502|NCT01852981|Behavioral|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
75614503|NCT01225172|Drug|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
75614504|NCT01225172|Drug|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
75907891|NCT03684499|Other|fluid supplementation|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
75907892|NCT03684499|Other|breast feeding|The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.(Bandyopadhyay et al, 2017)
75614505|NCT02665039|Drug|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~280 mg/m2 in patients with GFR 40-60 ml/min~250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min"
75614506|NCT02665039|Drug|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
75614507|NCT02665039|Drug|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
75614508|NCT02665663|Device|medical device|
75765951|NCT05611879|Drug|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.
75765952|NCT05604170|Drug|Ganaxolone|GNX will be administered.
75765953|NCT05598840|Other|Care for today Mobile Application|"C4T (Care for Today) Education is a digital application (app) designed to offer quality educational materials.~The APP will be provided to the patients in the outpatient centre four months before surgery. Patients will be able to download the APP using a QR code that will be provided during the visit. They'll realize the download immediately or at home, in both cases a detailed explication of how to use the APP and its contents will be provided using an example version."
75765954|NCT05588466|Other|CDS Alone|The practices in the 'CDS alone' arm will receive an updated CDS for HTN management.
75765955|NCT05588466|Other|CDS plus practice facilitation|The practices in the 'CDS plus practice facilitation' arm will receive an updated CDS for HTN management plus practice facilitation to support the adoption of the CDS.
75765956|NCT05582356|Dietary Supplement|Carbohydrate group (Group OC)|Carbohydrate group (Group OC)
75907893|NCT02200848|Drug|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
75765957|NCT05582356|Dietary Supplement|Placebo group (Group OP|Placebo group (Group OP
75765958|NCT05574920|Diagnostic Test|Al18F-NOTA-FAPI-04 PET/CT scan|Patients enrolled underwent PET/CT after injection of Al18F-NOTA-FAPI-04 to image lesions of breast cancer.
75907894|NCT03684421|Diagnostic Test|Pregnancy Rate|The clinical pregnancy and live birth rate according to the protocol of COS
75907895|NCT02204670|Other|Acute release of irisin after a single exercise session.|We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
75316701|NCT05286775|Other|Knee educational program|"Three weekly 60-minute educational program sessions with the following services:~Stretching and strengthening exercises for specific muscle groups (hip flexors, extensors, and abductors; knee flexors and extensors; plantar flexors; and abdominal muscles), using one's own body and gravity resistance. Patients will be encouraged to practice them at home at least twice a week after the end of the sessions.~Nutritional guidance: Instructions on the importance of adequate weight management, healthy food consumption, and the adequate intake of nutrients.~Physical activities: Counseling on home-based physical activities, according to their physical capacities, to protect knee joints.~General health: psychology counseling, encouraging participants to apply strategies and self help conduct to improve their general health; Occupational Therapy: Activities of Daily Living strategies to protect knee joints; Nursing: Counseling on strategies for improving healthy sleeping habits."
75316702|NCT02078726|Drug|Glucagon|glucagon (hormone produced by the body)
75765959|NCT05574907|Diagnostic Test|68Ga-FAPI PET/CT scan|Patients with suspected breast cancer underwent 68Ga-FAPI PET/CT after an injection of 74-148 MBq (2-4 mCi) 68Ga-FAPI to image lesions of breast cancer.
75765960|NCT05571670|Drug|Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor|Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.
75316703|NCT04027010|Other|"Healthy U tablet application"|"There are seven modules in Healthy U: Puberty, Birth Control, Teen Pregnancy, HIV, STDs, Healthy Relationships, and Condom Negotiation. Each module has six sections: Introduction and Review, Narrative Teen Portrait, Information Film, Activity/Game, Dramatic Film, and Imagination Challenge. The Introduction and Review has videos lasting 1-2 minutes where the Healthy U host introduces each module. In the Narrative Teen Portrait for each module, a different teen discusses their experience with the topic for 1-3 minutes. The Information Film lasts 5-18 minutes per module and provides factual information. For each module, the Activity/Game includes multiple choice, true/false, or other games. The Dramatic Film lasts 5-17 minutes for each module and shows a fictional account of a teen experiencing the topic. Finally, the Imagination Challenge asks the youth to imagine a scenario, such as going to a health clinic to obtain free condoms."
75907896|NCT02204826|Drug|Korean Red Ginseng (KRG)|"The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks."
75316704|NCT00431041|Drug|solifenacin|Oral
75614509|NCT04844086|Biological|RPM CD19-mbIL15-CAR-T cells|"Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
75614510|NCT05329870|Other|SNP array|SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
75316705|NCT00431041|Drug|oxybutynin immediate release|Oral
75316706|NCT00390611|Drug|Sorafenib|
75316707|NCT00390611|Drug|Paclitaxel|Paclitaxel
75316708|NCT00390611|Drug|Carboplatin|Carboplatin
75461503|NCT01852981|Behavioral|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
75461504|NCT01852994|Drug|Testosterone replacement|Application quarterly of Testosterone Undecylate
75461505|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
75461506|NCT01853007|Behavioral|COACH Program|
75461507|NCT01853033|Biological|ABT-122|Injection
75461508|NCT01853033|Biological|Placebo|Placebo Injection
75614511|NCT01143324|Device|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
75765961|NCT05560386|Behavioral|Text messaging|text messaging content to support diabetes prevention.
75765962|NCT05560386|Behavioral|Virtual workshop|virtual workshop content to support diabetes prevention.
75765963|NCT05517330|Biological|Tislelizumab|200mg IV Q3W
75765964|NCT05517330|Drug|Afatinib|30mg PO QD
75765965|NCT05516589|Drug|Nab-paclitaxel|260mg/m^2 IV Q3W
75765966|NCT05516589|Drug|Cisplatin|75mg/m^2 IV Q3W
75765967|NCT05516589|Biological|Tislelizumab|200mg IV Q3W
75765968|NCT05516589|Drug|Afatinib|30mg PO QD
75765969|NCT05500391|Other|Oncological Follow-up|Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)
75907897|NCT02204826|Procedure|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
75907898|NCT02200926|Other|Loaded breathing training|7 days/weeks, for 8 weeks
75907899|NCT02200926|Other|Unloaded breathing training|7 days/week, for 8 weeks
75907900|NCT02200926|Other|Placebo|7 days/week, for 8 weeks
75907901|NCT03684031|Behavioral|Cognitive Control Training|A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
75907902|NCT03684031|Behavioral|Sham Cognitive Control Training Program|A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
75907903|NCT02751450|Device|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
75907904|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
75461509|NCT01853098|Behavioral|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
75461510|NCT01853111|Biological|Interleukin-2|
75461511|NCT01853124|Drug|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
75461512|NCT01853124|Drug|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
75461513|NCT01853150|Device|rTMS Motor cortex|
75907905|NCT03680443|Other|assembly in THA revision|A single-center continuous series of 62 patients receiving such an assembly in THA revision was assessed retrospectively at a minimum 5 years' follow-up. Failure due to aseptic loosening or instability and implant survival at last follow-up were analyzed.
76070979|NCT05601986|Other|Physiotherapy and Rehabilitation Program|"The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board."
75461514|NCT01853150|Device|rTMS Supplementary motor area|
75461515|NCT01853189|Other|OMT + Usual Care|patients from this group received 6 sessions of OMT
75461516|NCT01853189|Other|Usual Care|patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
75461517|NCT01853202|Behavioral|Supervised aerobic exercise training|
75461518|NCT01853241|Procedure|Single Balloon|All patients in this group will undergo single balloon enteroscopy
75614512|NCT04172935|Device|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance, astigmatism is corrected.
75614513|NCT04254016|Dietary Supplement|HIBISTEVER1|During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
75614514|NCT02665585|Procedure|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
75907906|NCT02204904|Genetic|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
75907907|NCT02209662|Device|APIC-PRP|APIC-PRP
75907908|NCT02209662|Other|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
75461519|NCT01853241|Procedure|Spirus|All patients in this group will undergo Spirus Enteroscopy
75461520|NCT01853267|Procedure|Intervention Group (Non-Packing)|The haemostatic pack placed in the perianal abscess cavity will be removed on discharge and the wound will be left to heal without packing in situ
75461521|NCT01853267|Procedure|Control group (Packing)|After the procedure the abscess cavity will be packed with a non-adherent dressing as per standard treatment and the packing changed at regular intervals in the community until healing by secondary intention is complete.
75461522|NCT01853293|Drug|Kudzu extract|
75461523|NCT01853293|Drug|Placebo|
75614515|NCT04252924|Other|lifestyle characteristics|Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
75614516|NCT02883816|Other|assessment of lung function|measurement of lung volumes and flow rates of bronchial
75765970|NCT05492591|Drug|Peginterferon α1b|Injecting different doses of the peginterferon α1b into different groups of subjects.
75765971|NCT05492591|Drug|Peginterferon α1b with valacyclovir|Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.
75765972|NCT05492591|Drug|Valacyclovir|Valacyclovir is a positive control drug.
75765973|NCT05467423|Dietary Supplement|Iron|4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.
75765974|NCT05462912|Device|custom foot orthotic|The goal of this study is to find out whether the use of software generated custom-made orthopedic foot orthoses improves pain in the long term.
75765975|NCT05461521|Other|Family members of patients admitted to the ICU|"At inclusion:~Collection of demographic data, Anxiety-Depression Scale (HADS), Insomnia Severity Index (ISI), Resilience Insomnia Severity Index (ISI), Resilience Scale (CD RISC 10), Peritraumatic Dissociation Peritraumatic Dissociation Experience Scale (PDEQ) and MEDEC questionnaire.~Venous blood sampling at 350 relatives~Upon discharge of the patient (alive or deceased): Resuscitation questionnaire, HADS, ISI and PDEQ.~3 months after discharge: Demographic questionnaire, Post Traumatic Stress Disorder questionnaire (PCL-5), THS Past Trauma Experience Questionnaire, HADS experiences, HADS, ISI, CD RISC 10, MEDEC and Who- assist questionnaire (Question 2) on the use of psychoactive substances.~6 months after patient discharge: PCL-5, HADS, ISI, CD RISC 10, MEDEC, Who-assist (Question 2) and Prolonged Grief disorder (PG-13) questionnaire on bereavement if patient died in the ICU."
75765976|NCT05461521|Other|Health care professionals|All professionals in all categories and in all participating departments will be asked to complete questionnaires to assess the level of conflict, work stress and burn out in the units : Masclach Burnout Inventory (MBI), Job Content Questionnaire (JCQ), Ethical Decision-Making Climate Questionnaire (EDMCQ), Professional Quality Of Life scale (ProQOL), Connor-Davidson Resilience scale (CD-RISC 10), Cultural Awareness Scale (CAS).
75765977|NCT05461521|Other|Patients|Inclusion (at D3 after admission to the ICU): collection of demographic data Discharge from the ICU: characteristics of the stay and outcome (alive/deceased)
75907909|NCT03689881|Device|Tomosynthesis of SI joints|"All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction."
75461524|NCT01853293|Behavioral|Medical Management|Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
75461525|NCT01853306|Drug|Veliparib|veliparib
75461526|NCT01853319|Drug|Regorafenib (Stivarga, BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
75765978|NCT05460767|Biological|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
75765979|NCT05446129|Drug|Ezabenlimab|Ezabenlimab
75765980|NCT05446129|Drug|BI 765063|BI 765063
75765981|NCT05446129|Drug|Pembrolizumab|Pembrolizumab
75765982|NCT05434741|Behavioral|Weekly Group Skills|The topics covered in group CBT sessions are: 1.) Domains of Healthy Aging; 2.) Stress and anxiety; 3.) Adherence and Engagement in Primary/Preventative Care; 4.) Depression and Distress; 5.) Physical Activity; 6.) Stigma/Self-Compassion; 7.) Substance Use; 8.) Acceptance of Uncertainty and Uncomfortable Emotions; 9.) Diet; 10.) Behavioral Activation; 11.) Frailty and Memory/Cognition; and 12.) Wrap-Up and Maintaining Gains.
75907910|NCT03689803|Procedure|sleeve gastrectomy|sleeve gastrectomy.
75907911|NCT03689803|Procedure|gastric bypass|gastric bypass
75907912|NCT02209740|Other|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
76070980|NCT05601986|Other|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
76070981|NCT05599503|Behavioral|Behavioral Interventions|Traditional SimpleC Wellness
76070982|NCT05599503|Behavioral|Robot Interventions|Robot interventions
76070983|NCT05598138|Biological|Biological Collection|A blood sample (10 ml) will be taken for each patient included in the study.
75907913|NCT02220582|Other|MRI|Magnetic Resonance Imaging
75907914|NCT02205138|Drug|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
76070984|NCT05591404|Behavioral|Trier Social Stress Test (TSST)|Participants randomized to the TSST arm will experience the Trier Social Stress Test.
75907915|NCT02257788|Biological|PRO 140|Humanized monoclonal antibody to CCR5
75907916|NCT02220660|Drug|BI 1744 CL|
76070985|NCT05589675|Other|Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program|The individuals eligible for the colorectal cancer screening program will receive at home an invitation letter to participate to the program along with a FIT test. The follow-up will be similar to the standard of care, i.e. reminder letters at 5 and 10 months if there is no participation, and reminders if no coloscopy after a positive FIT test
76070986|NCT05589675|Other|Sending of a prior notification to the new entrants of the national program|Dispatch of a notification, one month prior the dispatch of the screening test along the invitation letter. This intervention is among the new entrants to the national program
75907917|NCT02220660|Drug|BI 54903 XX|
75316709|NCT00432601|Behavioral|type of decision aid|We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
75316710|NCT01793389|Procedure|Subepithelial connective tissue graft|
75316711|NCT01793389|Procedure|Platelet Rich Fibrin|
75461527|NCT01853358|Biological|NK Cell infusion|"level 1: 1 x 10e6 NK cells /kg;~level 2: 5 x 10e6 NK cells /kg;~level 3: > 5.10e6 and ≤ 5.10e7 cellules NK/kg"
75765983|NCT05434741|Other|"One-time Trifold Brochure titled HIV: 50 Years or Older"|"Participants in the education only group will receive a one-time trifold brochure titled HIV: 50 Years or Older. This brochure contains information on the prevalence of HIV among people aged 50 and older, defines medication adherence and drug resistance, encourages physical activity and proper nutrition, and addresses the health risk behavior of tobacco-smoking for people living with HIV. Participants receive one brochure in the information-only group."
75461528|NCT01853410|Device|gekoTM|
75765984|NCT05422573|Behavioral|post-test cardiovascular genetic counseling with pre-test education by video|post-test cardiovascular genetic counseling with pre-test education by video
75765985|NCT05422573|Behavioral|required phone call with genetic counselor pre-test|REQUIRED phone call with genetic counselor pre-test.
75765986|NCT05422573|Behavioral|optional phone call with genetic counselor pre-test|OPTIONAL phone call with genetic counselor pre-test
75765987|NCT05413889|Behavioral|Epic 30-day unplanned readmission risk score|If a patient is identified as having a high risk of readmission defined as readmission risk >20%, a link to transitional and supportive care services (TSC) will be appear in the story board.
75765988|NCT05398328|Device|active metal appliance|fixed metal labial orthodontic appliance MBT 0.022'' slot
75765989|NCT05398328|Device|active esthetic appliance|fixed ceramic labial orthodontic appliance MBT 0.022'' slot
75765990|NCT05398328|Combination Product|retention fixed appliance|fixed lingual metal retention appliance
75765991|NCT05398328|Combination Product|retention removable appliance|removable clear termoplastic retention appliance
75765992|NCT05398172|Device|MorpheusV Applicator|Eligible subjects will receive 3 treatments 4 weeks apart with the MorpheusV Applicator according to the study protocol
75765993|NCT05381363|Drug|Inhaled Interferon α2b|Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day
75765994|NCT05381363|Other|Standard of Care|Standard of care treatment will be provided based on the New Coronavirus Pneumonia Prevention and Control guideline (9th edition), published by National Health Commission of China
75461529|NCT01853423|Drug|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
75461530|NCT01853436|Device|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
75461531|NCT01853449|Drug|Fentanyl Citrate|
75614517|NCT00647413|Behavioral|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
75614518|NCT00647491|Biological|adalimumab|20 mg sc eow
75614519|NCT00647491|Biological|adalimumab|40 mg sc eow
75614520|NCT00647491|Biological|adalimumab|80 mg sc eow
75765995|NCT05380648|Procedure|Total knee arthroplasty|Total knee arthroplasty surgery will be performed by different orthopedist.
75765996|NCT05371470|Device|Ellipsis Health Voice Application|Smartphone application that utilizes voice biomarkers to assess for potential presence and severity of depression and anxiety
75765997|NCT05369806|Behavioral|Interactive two-way SMS dialogue|This study uses Mobile WACh, a human-computer hybrid system that enables two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day. Women who experience pregnancy or infant loss will be enrolled into an infant loss track. The NLP model will be applied to incoming participant messages. Those flagged as urgent by the model will be flagged within the SMS system, allowing study nurses to triage and appropriately respond to those messages.
75765998|NCT05368285|Biological|barzolvolimab|Subcutaneous Administration
75316712|NCT00391079|Drug|Sativex|"Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg."
75316713|NCT00391079|Drug|Placebo|Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
75316714|NCT00387751|Biological|Bevacizumab|Given IV
75316715|NCT00387751|Other|Laboratory Biomarker Analysis|Correlative studies
75316716|NCT00387751|Other|Pharmacological Study|Correlative studies
75316717|NCT00387751|Drug|Sorafenib Tosylate|Given orally
75316718|NCT01795235|Drug|Saline|Saline s.c.
75316719|NCT01795235|Drug|Glucagon|Glucagon s.c.
75316720|NCT01795235|Drug|Placebo|Sugar Pill
75316721|NCT01795235|Drug|Atenolol|Beta-1 receptor antagonist
75614521|NCT00647491|Biological|placebo|placebo sc eow
75614522|NCT04253704|Combination Product|IDL lotion|IDL lotion is water-based (> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
75907918|NCT02220660|Drug|BI 1744 CL + BI 54903 XX FDC|
75907919|NCT02220660|Drug|Placebo|
75907920|NCT02209818|Radiation|Laser Irradiation One dose|
75614523|NCT04253704|Combination Product|Control lotion|Control lotion is water-based (> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
75614524|NCT04252456|Procedure|Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
75907921|NCT02209818|Radiation|Laser Irradiation Two doses|
75461532|NCT01853449|Other|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
75461533|NCT01853449|Drug|Placebo|0.9% saline
75461534|NCT01853488|Radiation|DXA|Osteodensitometry
75765999|NCT05368285|Drug|Matching Placebo|Subcutaneous Administration
75766000|NCT05365178|Drug|TQB3616 capsule|TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
75461535|NCT01853488|Radiation|pQCT|Osteodensitometry
75461536|NCT01853501|Procedure|Autologous fat grafting|ADSC ovary injection
75766001|NCT05365178|Drug|Placebo|It is a placebo
75461537|NCT01853540|Drug|Sildenafil|
75461538|NCT01853566|Drug|growth hormone|GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
75461539|NCT01853579|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
75766002|NCT05365178|Drug|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
75461540|NCT01853579|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
75461541|NCT01853657|Other|Virological monitoring|
75461542|NCT01853670|Radiation|concurrent chemo + IGRT|
75766003|NCT05351801|Drug|THC (Dronabinol)|Participants will receive a target dose of 10mg per day of THC (Dronabinol).
75766004|NCT05351801|Drug|CBD (Epidolex)|Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
75766005|NCT05351801|Drug|THC + CBD (Nabiximols)|Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).
75766006|NCT05351801|Drug|Placebo|Placebo
75907922|NCT02257944|Behavioral|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
75907923|NCT02257944|Other|Treatment as Usual|treatment as usual
75907924|NCT02220738|Drug|ABT-957|ABT-957 administered twice-daily for 7 days
75907925|NCT02220738|Other|Placebo for ABT-957|Placebo for ABT-957 administered twice-daily for 7 days
75907926|NCT03689725|Other|Music|Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
75907927|NCT04981990|Procedure|Single lung ventilation by double lumen endotracheal tube|Single lung ventilation using double lumen endotracheal tube and isolation of the operated lung during surgery to create ideal surgical field
75907928|NCT04981990|Procedure|Two lung ventilation by conventional single lumen endotracheal tube|Intermittent two lung ventilation so that no significant hypoxia occurs with creating optimum surgical field
75461543|NCT01853670|Radiation|neoadjuvant chemo + IGRT|
75461544|NCT01853683|Procedure|Conservative Management|
75461545|NCT01853683|Procedure|Operative Management|
75461546|NCT01853709|Behavioral|Education|
75461547|NCT01853709|Other|Fiber free diet|
75461548|NCT01853709|Dietary Supplement|Adjuvants|
75461549|NCT01853709|Drug|Polyethylene glycol (PEG)|
75461550|NCT01853709|Drug|Bisacodyl|
75614525|NCT01224158|Device|Experimental Power Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day with the experimental toothbrush and toothpaste provided) moving to the next quadrant of the mouth at 30-second intervals.
75766007|NCT05321264|Behavioral|Educational nursing intervention|Four weekly individualized intervention sessions, with a duration of 40 minutes.
75766008|NCT05316688|Procedure|Near Infrared Imaging|Undergo NIR imaging
75907929|NCT02205216|Device|Active tDCS|anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.
75907930|NCT02205216|Device|Sham tDCS|"anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary tingling sensation without effects on the brain."
76070987|NCT05585450|Device|Electroacupuncture|"BL32 and BL33 will be inserted by needles of 0.30×75mm size at an angle of 45°, inward and downward, to the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, to the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm to the depth of 25-30mm. The needles will be lifted, thrust, and twisted evenly three times after insertion to induce the sensation of deqi.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hertz (Hz) and an electric current of 2-6.5 milliampere (mA) for BL32, BL33 and BL35, and 0.5 mA-2mA for SP6."
76070988|NCT05585450|Device|Sham electroacupuncture|"The four pairs of acupoints will be inserted by needles of 0.30×25mm or 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hz and a minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on."
76070989|NCT05582538|Drug|Ceralasertib|240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
76070990|NCT05582538|Drug|Durvalumab|1500 mg i.v. day 1 (q28)
75614526|NCT01224158|Device|Flat trimmed Manual Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day using the toothbrush and toothpaste provided) in their usual manner.
75614527|NCT02665351|Drug|Peramivir|The two regimens of Peramivir were compared
75614528|NCT02666911|Procedure|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
75766009|NCT05316688|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75766010|NCT05316688|Drug|Tozuleristide|Given IV
75766011|NCT05294640|Drug|0.9% Bacteriostatic Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
75766012|NCT05294640|Drug|1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
76070991|NCT05582538|Drug|Nab-paclitaxel|100mg/m2 i.v. day 1,8,15 (q28)
76070992|NCT05580653|Other|Controlled feeding study of beef and/or pinto beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.
75766013|NCT05294640|Procedure|Eyelid Lesion Removal|Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.
75907931|NCT02205216|Behavioral|Rehabilitation Therapy|"All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:~cognitive training: attentional strategies (mental counting, mental obstacle)~transfer training: everyday activities~motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory)."
75907932|NCT03683953|Other|mesenchymal stem cells therapy|mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group
75907933|NCT03683953|Drug|0.9% sodium chloride|0.9% sodium chloride in control group
75461551|NCT01853761|Device|Exercise after|"Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
75461552|NCT01853761|Device|Exercise at same time|"Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
75461553|NCT01853761|Device|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
75461554|NCT01853761|Device|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
75461555|NCT01853761|Device|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
75461556|NCT01853761|Device|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
75461557|NCT01853787|Drug|Formoterol Fumarate|Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
75461558|NCT01853787|Drug|Salmeterol|Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
76070993|NCT05580653|Other|Controlled feeding study of eggs and/or black beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.
75461559|NCT01853800|Drug|Rivaroxaban (Xarelto, BAY59-7939)|
75461560|NCT01853813|Drug|Bevacizumab and FOLFIRI|"The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.~After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity"
75461561|NCT01853852|Drug|GR181413A/AT1001 solution|Powder for reconstitution
75461562|NCT01853852|Drug|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
75907934|NCT03061396|Other|Matching points PC6+CV12|Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
75766014|NCT05239741|Biological|Pembrolizumab|Intravenous (IV) infusion
76070994|NCT05578547|Other|combined Kendell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"• The combined exercise will be done as follow:~1) slowly pull the subject's neck to the head, thereby attaching the chin to the neck.~(2) the subject's eyes should be looking directly forward. (3) hold both hands on the back of the subject's head. (4) ask the subject to push his/her head backwards against the hands. (5) ask for the hands to be spread as wide as possible in order to stretch the pectoralis major.~Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
75907935|NCT03061396|Other|Single points PC6|Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
75907936|NCT02209896|Device|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
75907937|NCT05262894|Other|extreme hypercapnia induced by ventilation insufficiency|Re-breathing of gas by breathing into the simulated avalanche snow
75907938|NCT03689647|Device|Arm Swing Driven Assistive Apparatus|The investigators are testing a simple, custom built apparatus to determine if it can facilitate the use of the arms to swing the legs during walking. More specifically, the investigators will measure how this assistive apparatus affects the metabolic cost and biomechanics of walking.
75766015|NCT05239741|Drug|Oxaliplatin|85 mg/m^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
75461563|NCT01853852|Other|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
75461564|NCT01853852|Drug|Placebo capsule|Solution matched
75766016|NCT05239741|Drug|Leucovorin|400 mg/m^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
75766017|NCT05239741|Drug|5-fluorouracil|400 mg/m^2 given as an IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for a total dose of 2400 mg/m^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
75766018|NCT05239741|Drug|Irinotecan|180 mg/m^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
75907939|NCT04973722|Drug|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
75461565|NCT01853865|Other|Instruction in self-referral|
75461566|NCT01853891|Other|dim light at night|
75461567|NCT01853904|Procedure|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
75461568|NCT01853904|Procedure|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
75461569|NCT01853917|Other|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
75461570|NCT01853956|Drug|Alprazolam 0.25 mg|Reference product
75461571|NCT01853956|Drug|Alprazolam 0.25 mg|Test product
75461572|NCT01853969|Other|Typing assessment|
75461573|NCT01854008|Other|rehabilitation more the urban circuit|"included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called A PEU, FEM SALUT! Itineraris urbans per Mataró http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index"
75766019|NCT05239741|Biological|Bevacizumab|IV infusion
75766020|NCT05239741|Biological|Cetuximab|IV infusion
75907940|NCT04973722|Drug|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
76070995|NCT05578547|Other|ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
76070996|NCT05576610|Procedure|Standard preventive advice+ enzymatic mouth sprays ( Oral7 mouth spray)|"The following are advice that will be given face-to-face to parent and participant and a take home pamphlet would be provided:~Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~To not share toothbrushes.~To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~To store toothbrushes apart to prevent spread of diseases through the bristles.~To brush teeth at least twice a day, after meals and before bed.~To brush for as long as two to three minutes.~Parents would be advised told to supervise the participant's brushing.~Frequency of using the Mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
76070997|NCT05576610|Procedure|Standard Preventive Advice + placebo mouth spray ( normal saline mouth spray )|"The following are advice that will be given face-to-face to parent and participant and a take home pamphlet would be provided:~Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~To not share toothbrushes.~To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~To store toothbrushes apart to prevent spread of diseases through the bristles.~To brush teeth at least twice a day, after meals and before bed.~To brush for as long as two to three minutes.~Parents would be advised told to supervise the participant's brushing.~Frequency of using the mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
75614529|NCT02666911|Procedure|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
75614530|NCT04253860|Device|Transcutaneous electrical neurostimulation|Sessions of 30 minutes of TENS will be applied three times a week during 90 days
75461574|NCT01854008|Other|rehabilitation program but not given urbane circuits|Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
75461575|NCT01854021|Procedure|intravenous anesthesia|intravenous anesthesia
75461576|NCT01854021|Procedure|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
75614531|NCT01129128|Biological|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
75766021|NCT05221866|Behavioral|Empowering patient to steer their pain management after surgery|Prior to discharge from the hospital, patients will be approached regarding interest in the study with an introductory letter that describes the content and purpose of the study. Following informed consent, patients will be randomized to receive the consumer health informatics app (UControlPain) versus provision of an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or patients.
75766022|NCT05221866|Behavioral|Provider-facing prescription aid|Providers will be given information to inform a patient-centered post-discharge pain management plan.
75461577|NCT01854021|Procedure|inhalational anesthesia|inhalational anesthesia
76070998|NCT05575947|Device|da Vinci Surgical System|da Vinci Surgical System
75461578|NCT01854073|Drug|Hyoscine butyl bromide|
75461579|NCT01854073|Drug|Normal saline|
75461580|NCT01854086|Other|Questionnaires about compliance and persistence with bisphosphonates treatment|
75461581|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 1.
75461582|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 2.
75461583|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m^2 x 21 days) with group 3.
75766023|NCT05216094|Other|smart phone App|stroke subjects completed tasks-oriented program demoed in the smart phone app with affected upper limb or bilateral arm movement for 12 weeks
75766024|NCT05216094|Other|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program with smart phone app ,without task-oriented program demoed function, for 12 weeks
75461584|NCT01854125|Biological|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
75461585|NCT01854125|Biological|autologous bone marrow msenchymal stem cells transplantation|
75461586|NCT01854164|Dietary Supplement|HGE (hydrolyzed ginseng extract)|
75461587|NCT01854164|Dietary Supplement|Placebo|
75461588|NCT01854190|Device|WatchPAT|BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
75614532|NCT01129128|Biological|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
75766025|NCT05202223|Behavioral|Harmony at HOME (H@H)|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
75907941|NCT03284034|Device|CoolCurve|The right and left sides of the upper back fat will be randomly assigned to receive Cryolypolysis (CoolCurve + Advantage applicator) 35 minutes session, 3 sessions 30 days apart.
75907942|NCT03284034|Drug|ATX-101|The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
75907943|NCT01358175|Drug|Secukinumab (75 mg)|Secukinumab (75 mg)
75907944|NCT01358175|Drug|Secukinumab (150 mg)|Secukinumab (150 mg)
75907945|NCT01358175|Drug|Placebo|Placebo
75316722|NCT00391469|Other|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
75766026|NCT05195528|Drug|Vonoprazan|Orally via capsule
75907946|NCT03689569|Dietary Supplement|Resistant starch|Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
75907947|NCT03689569|Behavioral|Exercise|Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
75907948|NCT03689569|Behavioral|Starch|Patients will be given 30 grams of corn starch
75907949|NCT03683797|Other|Post-discharge call|Patients will receive a call 1-3 days after they were discharged from the hospital to make sure their healthcare needs are being met.
75907950|NCT02209974|Drug|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
76070999|NCT05575947|Procedure|laparoscopic bariatric surgery|laparoscopic bariatric surgery
75316723|NCT00391469|Drug|Rapid infusion of cold normal saline|
75316724|NCT00387829|Device|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
75766027|NCT05195528|Drug|Placebo|Orally via capsule
75907951|NCT02209974|Drug|Inhaled Placebo|
75907952|NCT03689413|Drug|Sugammadex 200 MG in 2 ML Injection|1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
75907953|NCT02220816|Behavioral|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
75907954|NCT02220816|Behavioral|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
75907955|NCT03683641|Device|Extracorporeal Shock Wave Therapy|Use ESWT on chronic insertional Achilles tendinopathy
75907956|NCT03683641|Device|Sham Control group|Use sham ESWT on chronic insertional Achilles tendinopathy
75907957|NCT05262816|Other|electroacupuncture|electroacupuncture at Sanyinjiao (SP6)
75907958|NCT03680209|Other|Simulation|pre-training observation training post training observation
75907959|NCT02207049|Behavioral|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
75907960|NCT02207049|Behavioral|No Snacking|Caloric needs will be provided to preschoolers within three meals
75907961|NCT02205372|Drug|MT-3995|
75907962|NCT02205372|Drug|Placebo|
75907963|NCT02678793|Drug|CNTX-4975|
75907964|NCT02210442|Behavioral|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
75907965|NCT02210442|Other|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
76071000|NCT05570305|Drug|Zibotentan|Zibotentan 1.5 mg once per day as a hard capsule.
76071001|NCT05570305|Drug|Dapagliflozin|Dapagliflozin 10 mg once per day as a tablet.
76071002|NCT05570305|Drug|Placebo|Matching placebo.
76071003|NCT05570305|Drug|Dapagliflozin and Zibotentan|Dapagliflozin 10 mg once per day as a tablet in combination with zibotentan 1.5 mg once per day as a hard capsule.
75907966|NCT04116229|Procedure|Oral glucose tolerance test|After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
76071004|NCT05568680|Biological|SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR|Autologous T cells Transduced with Mesothelin KIR-CAR
76071005|NCT05565716|Other|Support Person|"Prior to randomization, participants will select their preference of the type of support person if they are assigned to this arm 1) a person they have close relationship with, or 2) a Peer Mentor, an individual who has successfully monitored their blood pressure at home using the study's equipment and also has diabetes, kidney disease, and high blood pressure. The Peer Mentor works with the research study team.~This will be provided with the same weekly blood pressure feedback that the participants will receive. The support person is encouraged to reach out to the participant at least weekly."
75316725|NCT01512407|Procedure|Transarterial chemoembolisation using cisplatin-lipiodol mixture|Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
75316726|NCT00388453|Device|Dx-pH Probe|24 hour ph monitoring
75316727|NCT00388453|Procedure|Manometry|procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
76071006|NCT05565716|Other|Social Norms|Participants will receive weekly text messages that includes their individualize blood pressure performance statistics, included frequency of blood pressure monitoring and average blood pressure, and compare it to goals provided at the beginning of the study, as well as the week prior. Participants will also has access to a leaderboard that displays blood pressure performance information all people in the study in an anonymous fashion.
76071007|NCT05562518|Drug|Estrogen|1 vaginal ovule daily for three consecutive weeks, followed by 1 vaginal ovule 2 times per week
76071008|NCT05562518|Drug|dehydroepiandrosterone|1 vaginal ovule daily
76071009|NCT05562518|Drug|Estrogen + probiotics|2 vaginal ovules daily for 5 consecutive days, repeated every 4 weeks
76071010|NCT05562518|Drug|Moisturizer|1 vaginal ovule daily for 10 consecutive days, followed by 1 vaginal ovule every three days
76071011|NCT05556356|Drug|Acetaminophen|pre-operative acetaminophen (1000mg)
75766028|NCT05187065|Other|The mobile-based education and exercise program|Starting from the preoperative period, mobile-based patient education, progressive relaxation exercise and knee exercise program will be applied to the patient as a whole. Mobile-based education will include pre-operative and discharge education. The patient will be given a progressive relaxation exercise with the support of the mobile application and the exercises included in the knee exercise program that should be done after the surgery will be shown. Progressive relaxation exercises will be applied twice a day in the afternoon and evening. Postoperative knee exercises will be performed 3 to 5 times a day, depending on the type of exercise. These exercises will be continued regularly for up to 4 weeks after discharge.
75766029|NCT05158777|Biological|Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.|live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection
75766030|NCT05158777|Biological|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection
75766031|NCT05152212|Biological|LVGN7409|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
75766032|NCT05135156|Behavioral|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.
75907967|NCT04116229|Behavioral|Cognitive testing|For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
76071012|NCT05556356|Other|Placebo: Multivitamin|pre-operative Multivitamin
75461589|NCT01854203|Drug|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
76071013|NCT05553522|Combination Product|Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine|"SRS and oral tucatinib for 2 wk, followed by oral tucatinib, oral capecitabine, and intravenous (IV) trastuzumab maintenance during 21-d cycles until tumor progression, participant withdrawal, a severe adverse event deemed related to the study drug, or the treating physician discontinues the drug. There are three dosing levels of tucatinib (Dose Level 0, Dose Level -1, or Dose Level -2) using a dose de-escalation scheme. Dosing of capectabine (1000 mg/m2 BID Days 1-14) and trastuzumab (6 mg/kg once per 21 days; 8 mg/kg initial loading dose) per cycle will remain the same regardless of tucatinib dosing.~Dose Level 0: 300 mg twice a day (BID) continuously for 2 wk post SRS, then 300 mg BID continuously per cycle.~Dose Level -1: 250 mg twice a day (BID) continuously for 2 wk post SRS, then 250 mg BID continuously per cycle.~Dose Level -2: 200 mg twice a day (BID) continuously for 2 wk post SRS, then 200 mg BID continuously per cycle."
76071014|NCT05553132|Combination Product|Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier|Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip. There are not enough cartilage cells to fill the defect so cartilage cells need to be mixed with MSCs. MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair. MSCs can be found in bone marrow and in the fatty tissues (i.e., area under the skin of the belly or breast) of patients. Fibrin glue is a product made from the naturally occurring compounds in blood which cause clotting. This glue hardens into a gel-like substance into which cells such as cartilage cells (chondrons) and AMSCs can be placed.
75316728|NCT00392951|Drug|sirolimus|Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
75461590|NCT01854203|Drug|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
75461591|NCT01854216|Drug|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
75461592|NCT01854216|Drug|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
75461593|NCT01854216|Drug|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
75614533|NCT01129128|Biological|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
75614534|NCT04172389|Procedure|vesico-vaginal fistula robot assisted laparoscopic repair|realization of O'conor technique or extra-vesical technique for vaginal vesico fistula repair in robot assisted coelioscopy
75614535|NCT01222520|Drug|Telmisartan and amlodipine|Telmisartan 80 mg and amlodipine 5 mg once a daily
75614536|NCT01222520|Drug|Telmisartan|80 mg once a daily
75461594|NCT01854307|Procedure|Pneumoperitoneum and SVV/PPV|
75461595|NCT01854320|Behavioral|Acceptance-based treatment|
75614537|NCT04252222|Device|Videolaryngoscopy with VL3|Tracheal Intubation aided by VL3 Videolaryngoscope
75614538|NCT05312424|Dietary Supplement|Placebo|300 mg olive oil
75614539|NCT05312424|Dietary Supplement|Low GG|150 mg GG
75614540|NCT05312424|Dietary Supplement|High GG|300 mg GG
75614541|NCT02888210|Device|MD-15 Intraocular Lens|
75614542|NCT04172233|Biological|AK101|AK101 is an anti-IL-12/23p40 monoclonal antibody.
75614543|NCT04172233|Biological|placebo|matching placebo
75766033|NCT05135156|Behavioral|Publicly available transplant education resource (Attention Control)|Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.
76071015|NCT05550753|Behavioral|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies.4 BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
76071016|NCT05550753|Behavioral|No intervention - placebo control|No intervention - placebo control
76071017|NCT05549297|Drug|Tebentafusp|soluble gp100-specific T cell receptor with anti-CD3 scFV
75766034|NCT05125185|Other|The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation|To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
76071018|NCT05549297|Drug|Tebentafusp with Pembrolizumab|soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with Pembrolizumab
76071019|NCT05549297|Drug|Investigators Choice|Investigators choice of therapy
75766035|NCT05111951|Behavioral|Mobile health-delivered physical exercise and support for physical activity|Mobile health-delivered physical exercise sessions, prescription of an individual exercise-regime and support for physical activity through behavior change techniques.
76071020|NCT05547867|Procedure|Radial head prosthesis|Radial head arthroplasty in comminuted radial head fractures.
76071021|NCT05544734|Drug|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|5 mg/325 mg tablet
75766036|NCT05111951|Behavioral|Mobile health-delivered behavior change techniques.|Mobile health-delivered behavior change techniques following the core elements of the Swedish model for physical activity on prescription.
76071022|NCT05544734|Drug|Acetaminophen 1000mg|1000 mg tablet
75766037|NCT05082545|Drug|SHR-2002 and SHR-1316|Cohort study
75766038|NCT05062889|Drug|5-Fluorouracil continuous infusion FOLFOXIRI schedule|3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
76071023|NCT05544734|Drug|Ibuprofen 400 mg|400 mg tablet
75316729|NCT00389467|Device|Merci Retriever and Penumbra System|"The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).~The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2)."
76071024|NCT05542030|Diagnostic Test|EMR with CAD-Eye™|"Patients of group 1 undergoing Intervention 1 are subjected to an EMR with CAD-Eye™ to detect the remaining lesions immediately after the endoscopic procedure.~The suspected remaining lesions in the post-procedure defect detected with CAD-Eye™ are removed and sent to pathology to confirm the diagnosis."
75766039|NCT05062889|Drug|5-Fluorouracil bolus FOLFOX schedule|400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
75316730|NCT02982967|Other|Physical Activity|Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
75461596|NCT01854320|Behavioral|Standard behavioral treatment|
75461597|NCT01854333|Other|ADOS module 1-4 or ADI-R|
75614544|NCT01221350|Dietary Supplement|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
75766040|NCT05062889|Drug|5-Fluorouracil continuous infusion FOLFOX schedule|2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
76071025|NCT05542030|Diagnostic Test|EMR without CAD-Eye™|"Patients of group 2, undergoing intervention 2, subjected to an EMR alone. The immediate detection of remaining lesions is based on the visual impression of the expert.~The suspected remaining lesions in the post-procedure defect are removed and sent to pathology to confirm the diagnosis."
76071026|NCT05542030|Diagnostic Test|Follow-up colonoscopy with CAD-Eye™|"Patients undergoing Interventions 1 and 2, with a previous EMR, are assigned for a three-month follow-up using the CAD-Eye™ as a complementary procedure to detect remaining lesions.~For the detection of residual lesions, the colonoscope with the CAD-Eye™ assistance is used during the post-procedural scar evaluation. Suspicious lesions detected are removed and sent to pathology for final diagnosis."
76071027|NCT05539040|Procedure|Right Atrial ganglionated plexus ablation|"A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed).~All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs).~Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional."
76071028|NCT05539040|Diagnostic Test|Holter Monitor|"48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF.~These will be performed at 3, 6, 9, 12 months"
75614545|NCT01221350|Dietary Supplement|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
76071029|NCT05539040|Procedure|Pulmonary vein isolation|"Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy.~ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved."
75766041|NCT05062889|Drug|Oxaliplatin FOLFOX and FOLFOXIRI schedule|85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
76071030|NCT05539040|Procedure|Right cavo-tricuspid and left roof linear ablation|CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.
75766042|NCT05062889|Drug|Oxaliplatin CAPOX schedule|130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
75766043|NCT05062889|Drug|L-Leucovorin|200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
75766044|NCT05062889|Drug|Capecitabine|Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
75766045|NCT05062889|Drug|Irinotecan|165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.
75766046|NCT05062889|Drug|Trifluridine/Tipiracil|35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
75766047|NCT05062889|Drug|Trastuzumab|4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.
75766048|NCT05062889|Drug|Tucatinib|300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.
75766049|NCT05044910|Dietary Supplement|Ready to Use supplementary food (RUSF)|Children with malnutrition will be given RUSF
76071031|NCT05539040|Diagnostic Test|Personal ECG recordings|All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.
76071032|NCT05539040|Other|Quality of life questionnaire|A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.
75766050|NCT05037045|Drug|GLP-1 receptor agonist|GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM
75316731|NCT01424930|Drug|Abiraterone|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
75316732|NCT01424930|Drug|Prednisone|Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
75614546|NCT02665429|Behavioral|Individual prescribing data profile and self-assessment|Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
75766051|NCT05013788|Other|Social Media Enhanced Education|Along with usual asthma education received,participants will receive asthma education via various social media platforms ,Facebook, Twitter, Instagram, and/or Snapchat. Topics of education will include background on asthma and pathophysiology, asthma severity classification, asthma triggers, different medications and indications for when to take them, how to use an inhaler technique, and symptom monitoring.Online resources from the American Lung Association and the National Asthma Education and Prevention Program will also be posted.
75766052|NCT05013788|Other|Usual Asthma Education|For patients who are admitted to Children's Memorial Hermann for asthma exacerbation, asthma education is provided to patients and families on the day of discharge by the nurse and respiratory therapist on triggers, Signs & Symptoms, Medication Use, Medication Delivery, Peak Flow, Zones and how to respond to each, and Cleaning equipment.Nursing staff are responsible for printing out education sheets to give to patients and showing an education video that is 20 minutes long. An asthma action plan are given to families on discharge. Patients that are discharged from the emergency room are given the same educational materials by the nurses and/or respiratory therapists except for the asthma video. Patients receive a variable amount of asthma education when going to usual clinic visits. The education provided is dependent on the provider, and usually limited in length to the time of the visit
75907968|NCT04116229|Procedure|Magnetic resonance imaging|Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
75907969|NCT02210832|Behavioral|Best practices|
75907970|NCT02210832|Behavioral|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
75316733|NCT00389857|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
76025355|NCT05134181|Drug|sacroiliac joint injection|"Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied"
75766053|NCT04997993|Drug|Leflunomide|Leflunomide, 20-50mg PO daily
76071033|NCT05538000|Other|Face to face and telephonic interviews|"face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment~telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment"
75614547|NCT00646633|Procedure|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
76071034|NCT05537714|Behavioral|Qualitative interviews/focus groups|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
76071035|NCT05530694|Behavioral|Clinician communication training|The clinician training is a generic, skills- and attitude-based approach for clinicians to acknowledge their decision making conversations with patients that 1) there is more than one option, and 2) patient's views matter in deciding what to do next. This tools-free approach can be used on the spot when needed and is termed fostering choice awareness (FCA). The one-hour training consists of 4 parts: 1) a knowledge session on evidence and guidelines on effective conversations and SDM, 2) video-review of behaviors which foster or hinder choice awareness, 3) clinical simulations in which clinicians practice fostering choice awareness behaviors, and 4) a reminder card for use in future clinic visits. Video clips will be of patient-clinician conversations around treatment decision making to prompt and probe clinicians' experiences, improve understanding, and improve practice.
76071036|NCT05530694|Behavioral|Patient activation|"The patient activation component consists of three questions patients can ask their clinician to help them become more involved: 1. What are my options?; 2. What are the possible benefits and harms of those options?; 3. How likely are each of those benefits and harms to happen to me? These questions have been used in studies to promote improved communication in a number of conditions including cardiovascular disease, cancer, and women's health."
75316734|NCT00389857|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
75316735|NCT01424306|Other|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
75316736|NCT01424306|Other|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
75461598|NCT01854346|Behavioral|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
75614548|NCT00647569|Procedure|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
75766054|NCT04991779|Diagnostic Test|AI-assisted cEEG detection tool|"This study is an observational study to evaluate the accuracy of AI-assisted cEEG diagnostic tool with routine care. All patients from the cohort accept cEEG monitoring and AI-assisted cEEG detection tool.~The tool included a quantitive EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction.~The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association."
75316737|NCT01424306|Other|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
75316738|NCT02110381|Device|Device guided breathing RESPeRATE|"Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.~Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit."
75461599|NCT01854372|Drug|R-HCVAD and R-MC|
75461600|NCT01854398|Device|CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.
75614549|NCT00647569|Procedure|Conventional facial closure|The abdominal facia is closed with with continuous running suture
75766055|NCT04981483|Procedure|conservative surgery for uterus in placenta accreta|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle[outside in-in out then out in-in out] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
76071037|NCT05530694|Behavioral|RA Medication summary guide and RA Choice|RA Choice presents information on FDA-approved RA treatments in a set of cards, which can be used alone or in combination based on a patient's preference, values, and the clinician's experience. The RA medication summary guide describes options for medication, physical therapy, occupational therapy, and ways to stay healthy with diet and exercise. Tool development followed key principles of creating low literacy materials that featured icons, short phrases written in plain language, and included topics of interest to RA patients faced with a medication decision. For the proposed study, we will include a paper-based version of the tool, or a web-based version available for telephone or VA Video Connect (VVC) visits. The tools will be updated to include new FDA-approved therapies (e.g., JAK inhibitors).
75316739|NCT02110381|Device|Isometric hand grip Zona Plus|"Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.~Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit."
75461601|NCT01854398|Device|sham-CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
75461602|NCT01854411|Other|analgesic measure|ibuprofen and ketoprofen measured into breast milk
75316740|NCT05286463|Combination Product|bee venom gel phonophoresis|a noncontact low-frequency pulsed ultrasound delivered through Bee Venom previously prepared gel as topical application using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
75316741|NCT05286463|Device|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
75316742|NCT04271527|Procedure|cognitive fusion targeted biopsy|A novel three-dimensional matrix positioning based cognitive fusion targeted biopsy
75316743|NCT01795183|Drug|AMISULPRIDE|Pharmaceutical form: tablet Route of administration: oral
75316744|NCT01424228|Drug|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
75316745|NCT01424228|Drug|prucalopride|"Prucalopride 2 mg daily before breakfast~1 mg for subjects >65 years; in case of insufficient response 2 mg at week 2 or week 4"
75461603|NCT01854424|Other|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
75461604|NCT01854437|Drug|Mg Oxide|250 mg orally for 4 weeks
75461605|NCT01854450|Other|Asymmetrical Lateral Decubitus|"After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position"
75461606|NCT01854450|Other|control|usual obstetrical care
75461607|NCT01854463|Drug|Vitamin D3|2000IU per day
75461608|NCT01854463|Drug|placebo|elemental calcium 200mg per day per 24 weeks
75461609|NCT01854476|Device|pad-gauze with tranexamic acid (Hemostopan™)|The use of pad-gauze containing tranexamic acid (Hemostopan™)
75461610|NCT01854489|Drug|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days [Phase 1 ]
75614550|NCT00647647|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
75614551|NCT00647647|Drug|Lamisil® Tablets 250 mg|250mg, single dose fasting
75614552|NCT01221272|Drug|Ranolazine|"One 500 mg tablet in the evening on Day 1 of the period~One 500 mg tablet, twice daily on Days 2-3 of the period~Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)"
75614553|NCT01221272|Drug|Placebo to match ranolazine|Placebo to match ranolazine administered in the same form and frequency as the active drug.
75461611|NCT01854489|Drug|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
75461612|NCT01854489|Drug|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
75766056|NCT04975269|Drug|Acetazolamide|Target dose: 500 mg / day
75766057|NCT04975269|Drug|Placebo|Placebo
75907971|NCT04981600|Device|Radiofrequency ablation|Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.
75316746|NCT01795885|Behavioral|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show 16 and Pregnant once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show."
75766058|NCT04956666|Drug|Lyophilized S95014|"Each patient was administrated, over 1 to 2 hours, every 2 weeks Lyophilized S95014 intravenously at the dose of 1000, 2000 or 2500U/m2, as per investigator's judgement.~In total, 9 infusions of lyophilized S95014 were administrated (at week 7, 9, 11, 15, 17, 19, 23, 25 and 27).Patients received other backbone chemotherapy agents as per ALL-MB 2015."
75766059|NCT04942457|Behavioral|Fasting|Prolonged fasting for 7-10 days (caloric intake <500 kcal in liquid form)
75766060|NCT04942041|Other|Simulation based quality program|Stroke team simulation. Virtual reality task training simulation.
75766061|NCT04937972|Drug|SHR-1701 Combined With Fluazopalil|SHR-1701 +fluzoparib
75766062|NCT04931511|Drug|Compound betamethasone Injection(Gluteal muscle injection)|Gluteal muscle injection(Compound betamethasone 1ml + Sodium Chloride Injection 4ml) + Subacromial Ultrasound Guided injection(Sodium Chloride Injection 5ml)
75766063|NCT04931511|Drug|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|Gluteal muscle injection (Sodium Chloride Injection 5ml)+ Subacromial Ultrasound Guided injection (corticosteroid 1ml+Sodium Chloride Injection 4ml)
75766064|NCT04931511|Behavioral|Physical therapy|paticipant will be teached by the Physicaltherapist to reduce the shoulder pain at home
75766065|NCT04908774|Behavioral|Fasting Mimicking Diet|"The mobile application Salufast provides standardised fasting packages for 5 days of approx. 500 kcal and accompanies the participants during all fasting days."
75766066|NCT04883983|Drug|Open Label Placebo|Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.
75316747|NCT01795963|Behavioral|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress. Specifically, it teaches communication techniques and problem-solving skills that help couples to effectively deal with conflict. It also teaches couples how to enhance positive aspects of their relationship by fostering fun and friendship.
75461613|NCT01854502|Behavioral|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
75316748|NCT01795963|Behavioral|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz & Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite & Fincham, 2007; Braithwaite & Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
75461614|NCT01854502|Behavioral|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
75461615|NCT01854515|Drug|Budesonide|
75766067|NCT04883983|Drug|Patient medication as standardly prescribed|Pain medication will be prescribed per standard treatment for initial prescription. On request for additional pain medication, pain medication will be prescribed as per the standard protocol. Pain assessment surveys will be used at 2, 6, and 12 week followups.
75461616|NCT01854515|Drug|Dexamethasone acetate|
75461617|NCT01854567|Biological|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
75766068|NCT04861961|Procedure|DS vs. SADI-S vs. OAGBP|Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.
75766069|NCT04853485|Device|repetitive transcranial magnetic stimulation (rTMS)|All subjects with early psychosis will be divided into three subgroups determined by their psychotic symptoms and cognition. There are three rTMS strategies: (1) For subgroup 1, characterized by negative symptoms, iTBS over cerebellum and 1 Hz over right DLPFC; (2) For subgroup 2, characterized by cognition deficits, 20 Hz over the left inferior parietal cortex; (3) For subgroup 3, characterized by positive symptoms: 10 Hz over ACC. Ten to twenty sessions of rTMS will be delivered to each patients during the intervention period.
76025356|NCT05323175|Drug|Ropivacaine injection|Local anesthesia injected under ultrasound guidance
75461618|NCT01854567|Biological|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
75461619|NCT01854606|Drug|AEB071|a Protein Kinase C Inhibitor
75461620|NCT01854606|Drug|Everolimus|mTOR inhibitor
75461621|NCT01854619|Device|Photodisinfection (antimicrobial photodynamic therapy, aPDT)|A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
75461622|NCT01854619|Device|Saline irrigation|The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
75461623|NCT01854671|Other|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
75316749|NCT01796041|Drug|Indocyanine Green|
75461624|NCT01854723|Drug|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
75461625|NCT01854723|Drug|Continuation of insulin glargine|Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
76071038|NCT05528900|Diagnostic Test|allergy test|allergy test are oral food challenge , prick test and IgE blood rate
75461626|NCT01854736|Drug|Grazax|GRAZAX
75614554|NCT01221272|Procedure|SPECT MPI|Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
75614555|NCT01221272|Behavioral|Exercise|Treadmill stress test
75614556|NCT00647725|Procedure|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
75614557|NCT00647725|Procedure|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
75614558|NCT01220414|Drug|Naltrexone, then placebo|50 mg of naltrexone
76071039|NCT05521737|Procedure|Electroacupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. EA is applied for 20 minutes at an alternating frequency of 2 Hz. Acupunctural points are Zusanli (E36), Fenlong (E40), Yinlingquan (B9), Sanyinjiao (B6), Taichong (H3) and Zulinqi (VB41).
75766072|NCT04796337|Biological|Sotatercept|Sotatercept subcutaneous injection at a dose of 0.3 to 0.7 mg/kg.
75766073|NCT04784650|Other|Pre-dialysis population|Pre-dialysis population, consisting of both Diabetes Mellitus (DM) and non-DM patients
75766074|NCT04766788|Other|Wearable devices, saliva samples, survey measures|Provide a self-collected saliva sample, download and use the suite of apps (e.g., Fitbit, Social Rhythms, Roadmap 2.0), and answer online surveys.
75461627|NCT01854736|Other|Placebo|Placebo
75907972|NCT04981600|Device|Laser|"The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day."
75907973|NCT02212392|Drug|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
75316750|NCT03562975|Drug|Ocrelizumab|Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds
75461628|NCT01854749|Drug|S1 combined with cisplatin|
75461629|NCT01854762|Drug|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
75461630|NCT01854762|Drug|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
75461631|NCT01854788|Other|Autogenic drainage|It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
75461632|NCT01854788|Other|Slow expiration with glottis opened in lateral posture|It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
75614559|NCT01220414|Drug|Placebo, then Naltrexone|sugar pill
75614560|NCT01128894|Biological|albiglutide|albiglutide weekly subcutaneous injection
75766075|NCT04754087|Device|Vivacit-E and Longevity (HXLPE) Liners|This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.
75766076|NCT04742894|Behavioral|Visual Feedback Training|Participants will be trained to work with a computer setup to control the position of a visual cursor on the screen using their speech while their auditory feedback is altered. The goal of the training is to help improve speech production and motor control ability.
75766077|NCT04738318|Drug|Glucocorticoids|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
76071040|NCT05521737|Procedure|Sham Acupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. Sham acupuncture will be applied using a nonpuncture device without electrical stimulation at the same acupunctural points as in the EA group.
75766078|NCT04738318|Drug|Saline|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
75461633|NCT01854788|Other|Temporary-positive expiratory pressure|The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
75614561|NCT01128894|Drug|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
75907974|NCT02833077|Device|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.
75614562|NCT01128816|Device|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
75907975|NCT03679897|Drug|Ropivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution
75907976|NCT03679897|Drug|Levobupivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution
75907977|NCT03060070|Drug|Ketamine|Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
76071041|NCT05519150|Diagnostic Test|low dose radiation abdomen/pelvis CT scan (stone protocol)|Kidney donors who consent will undergo a low dose radiation abdominal CT scan to identify new kidney stones in the remaining kidney. The will come to an IU Health Hospital for a low dose radiation abdomen/pelvis CT scan (stone protocol).
76071042|NCT05519150|Procedure|Blood draw|To compare the changes changes in eGFR in evaluated kidney donors Blood will be draw by a trained phlebotomist.
75766079|NCT04733742|Drug|rhTNK-tPA|intravenous thrombolysis with rhTNK-tPA followed by endovascular treatment
75316751|NCT01796119|Procedure|Ridge Splitting|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
75316752|NCT01796119|Procedure|Implants placed using drilling technique|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
75316753|NCT04750681|Dietary Supplement|Placebo|Subjects orally ingested, with water, one capsule per day (in the evening)
75766080|NCT04733742|Other|Endovascular treatment|endovascular treatment
75766081|NCT04726709|Behavioral|Poised for Parkinson's|Lecture, demonstration, activities, and supplemental materials designed to improve self-awareness, situational awareness, and ability to make good choices for physical and emotional self-care, moment-to-moment.
75766082|NCT04724915|Procedure|Conventional Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with manual instrumentarium (jig-based).
75766083|NCT04724915|Procedure|Robot-Assisted Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with the help of a surgical robot.
75766084|NCT04721353|Drug|Prazosin Hydrochloride|prazosin hydrochloride oral 1-25 mg/day
76071043|NCT05519150|Other|24 hour urine collection|To compare the changes in metabolic kidney stone risk parameters in 24-hour urine assessments to pre-donation urine studies in evaluated kidney donors.
76071044|NCT05517200|Diagnostic Test|Machine Learning Test for Migraine|Resting EEG, and Visual and Auditory Stimulation
76071045|NCT05515939|Device|InPen Insulin Pen|The InPen is a reusable smart insulin pen for people living with diabetes. The device uses Bluetooth technology to send dose information to a mobile application. The InPen can be used to deliver insulin, help calculate insulin doses, and estimate carbohydrates for meals
76071046|NCT05515029|Combination Product|GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor|Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28
75461634|NCT01854801|Other|Individual medical Care|Individual medical care in occupational and environmental diseases centers
75461635|NCT01854801|Other|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
75461636|NCT01854853|Behavioral|STYLE Brazil|Multifamily group HIV/STI Prevention Intervention
75461637|NCT01854853|Behavioral|Health Promotion|Health promotion intervention
75614563|NCT01220180|Drug|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
75614564|NCT01220180|Drug|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
75766085|NCT04715217|Biological|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
75907978|NCT03060070|Drug|dexmedetomidine|dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
76071047|NCT05514483|Drug|Placebo|Single intravenous dose of 10 mL of sodium chloride (NaCl) 0.9% over 15 minutes.
75461638|NCT01854866|Other|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
75766086|NCT04714827|Biological|KQ-2003 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .
75766087|NCT04712175|Diagnostic Test|Nasopharyngeal sampling|Swabs will be taken of nasopharyngeal samples for RT-PCR
75766088|NCT04712175|Diagnostic Test|Saliva sampling|A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
75766089|NCT04704154|Drug|Regorafenib, (Stivarga, BAY73-4506)|"Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets)."
75907979|NCT03060070|Drug|control group|20ml of 0.25% bupivacaine will be injected in each side of the TAP block
75907980|NCT02212470|Device|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
76071048|NCT05514483|Drug|Ondansetron|Single intravenous dose of ondansetron hydrochloride dihydrate 0.15 mg/kg (maximum 16 mg) in 10 mL of NaCl 0.9% over 15 minutes.
76071049|NCT05511597|Behavioral|Split-belt treadmill training|Split-belt walking with various speed ratios between the two legs, applied with random-block practice
76071050|NCT05511597|Behavioral|Complex task practice|Overground gait flexibility training with added cognitive tasks
75316754|NCT04750681|Dietary Supplement|Saffron|Subjects orally ingested, with water, one capsule per day (in the evening)
75316755|NCT04750603|Drug|Fluticasone furoate (FF)/Vilanterol (VI)|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints
75316756|NCT04750603|Drug|Salbutamol|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints.
75316757|NCT01423916|Drug|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
75316758|NCT01423916|Drug|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
75316759|NCT01423916|Drug|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
75316760|NCT01423916|Drug|Placebo|OPC-34712 placebo
75461639|NCT01854892|Other|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
75766090|NCT04704154|Drug|Nivolumab (Opdivo)|480 mg administered on Day 1 of each treatment cycle.
75461640|NCT01854892|Other|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
75461641|NCT01854892|Other|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
75461642|NCT01854931|Behavioral|Tai Ji Quan|single aim intervention
75461643|NCT01854957|Biological|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
75461644|NCT01854970|Drug|esomeprazole|Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
75766091|NCT04684420|Drug|Glucophage® XR RM Test|Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.
75907981|NCT02212470|Device|Nitinol stenting|Nitinol stent deployment
75907982|NCT03683563|Other|4% sodium citrate|the catheter will be locked with 4% citrate solution after each dialysis session
75907983|NCT03683563|Other|30% sodium citrate|the catheter will be locked with 30% citrate solution after each dialysis session
76071051|NCT05511597|Behavioral|Static balance exercise|Mindfulness and breathing combined with static balance exercises
75316761|NCT00436969|Device|Orthovisc|Orthovisc injection
75316762|NCT00436969|Drug|Control|Celestone (betamethasone sodium phosphate and acetate) - 2 mL
75907984|NCT03563625|Procedure|Caudal block|Caudal block/bupivacaine 0.25%
76071052|NCT05508087|Diagnostic Test|electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan|We use electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan for the prediction of cardiovascular complications after high dose chemotherapy and hematopoietic cell transplantation in patients with haemoblasts.
75461645|NCT01854996|Drug|PF-05089771|450mg
75461646|NCT01854996|Drug|PF-05089771|450mg
75461647|NCT01854996|Drug|PF-05089771|450mg
75461648|NCT01855009|Dietary Supplement|MannaBears|Subjects will be administered 4 MannaBears daily
75461649|NCT01855009|Dietary Supplement|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
75461650|NCT01855009|Dietary Supplement|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
75461651|NCT01855009|Dietary Supplement|Vitamin D3|Subjects will be administered 800 IU vitamin D3
75461652|NCT01855022|Behavioral|MI + IVR|Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
75907985|NCT03563625|Procedure|Wound infiltration|Local anesthetic wound infiltration/bupivacaine 0.25%
75907986|NCT03563625|Drug|Bupivacaine|bupivacaine
75907987|NCT04973488|Other|Therapeutic plasma exchange|The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
75766092|NCT04684420|Drug|Glucophage® XR Reference|Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
75766093|NCT04674306|Biological|α-lactalbumin vaccine|"α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1c: 50 mcg~D1d: 50 mcg (D1d will only be utilized if D1c is deemed too toxic)"
75907988|NCT02213016|Device|Transcranial Magnetic Stimulation|
75316763|NCT00455689|Drug|Leuprolide acetate|"Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women."
75316764|NCT00394277|Drug|peginterferon alfa-2a|180 µg sc weekly for 48 weeks
75316765|NCT00394277|Drug|Ribavirin|1200 mg po daily for 48 weeks
75461653|NCT01855035|Other|prolonged ECG monitoring|10-day Holter ECG measurement
75316766|NCT00394277|Drug|peginterferon alfa-2a|360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
75614565|NCT01220180|Drug|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
75766094|NCT04674306|Biological|Zymosan|"Adjuvant used in vaccine preparation~DL1: 10 mcg~DL2: 100 mcg~DL3: 10 mcg~D1b: 10 mcg~D1c: 50 mcg~D1d: 30 mcg (D1d will only be utilized if D1c is deemed too toxic)"
75907989|NCT02213016|Device|Sham Transcranial Magnetic Stimulation|
75907990|NCT03683485|Procedure|long duration EPBD|An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.
75907991|NCT03683485|Procedure|EST|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
75316767|NCT00394277|Drug|Ribavirin|1400-1600 mg po daily for 48 weeks
75316768|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
75316769|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
75316770|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
75316771|NCT00395057|Drug|Ranibizumab 500µg|Ranibizumab 500µg injections at Day 1, Month 1, Month 2
75316772|NCT05287919|Other|Patients received the standard physical therapy (SPT) programme (passive mobilization) twice a day.|All participants have received standard physical therapy (SPT) sessions based on a passive range of motion mobilization protocol for the lower limbs. It consisted of a bilateral series of 10 repetitions of hip flexion, knee flexion and extension, and ankle flexion and extension. The procedure was performed twice a day: a morning (between 8am - 12pm) and an afternoon session (between 2pm - 6pm).
75461654|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
75461655|NCT01855061|Procedure|Biopsy|"Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity."
75461656|NCT01855061|Procedure|Blood samples|Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
75614566|NCT01220024|Drug|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
75614567|NCT01220024|Drug|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
75461657|NCT01855061|Procedure|Pharmacokinetics|Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
75461658|NCT01855061|Procedure|Midazolam clearance test|Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
75614568|NCT01128738|Drug|GSK1358820|Onabotulinum toxin type A
75461659|NCT01855100|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
75461660|NCT01855113|Device|Invisalign|
75614569|NCT01128738|Drug|Placebo|Placebo
75766095|NCT04634357|Drug|ET140203 T Cells|"Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct"
75766096|NCT04575025|Drug|Tabrecta tablets|There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.
75766097|NCT04558164|Device|Active Theta Burst Stimulation|Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80% of motor threshold (MT).
75766098|NCT04558164|Device|Sham Theta Burst Stimulation|Sham stimulation will be delivered at 10% of motor threshold (MT), with all other parameters matching the active TBS condition.
75907992|NCT04973878|Procedure|EGD first|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
75907993|NCT04973878|Procedure|Colonoscopy first|In this group, patients receiving a colonoscopy followed by EGD during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
75316773|NCT05287919|Other|Patients received the low-frequency neuromuscular electrical stimulation (NMES)|Electrical stimulation was performed twice a day after SPT. Two electrodes were attached to each thigh at the motor points of the quadriceps muscle. The point halfway between the anterior superior iliac spine and the base of the patella was used as reference and electrodes were placed 15 cm apart each other, 5 cm proximal and 10 cm distal from the reference point. After the first measurement, semi-permanent markers were used to indicate the position of electrodes. Electrical stimulation was performed using a 4-channels device (Sonopuls 492, series 4, Enraf-Nonius®, Rotterdam, Netherlands). The low-frequency protocol consisted of 100 Hz and 400 ms width pulses, delivered in trains of 5 s ON (ramp-up time: 1 s, plateau: 3 s, ramp-down time: 1 s) and 10 s OFF. Sessions had 20 min of duration (total of 40 min/day) and the current amplitude (mA) was adjusted to the identification of visible and palpable contractions and was rectified every 3 min to sustain the initial level of contraction.
75614570|NCT00625248|Drug|Antithrombotics|With or without or discontinuted use of Antithrombotics
75766099|NCT04557449|Drug|PF-07220060|CDK4 inhibitor
75766100|NCT04557449|Combination Product|Letrozole|Endocrine Therapy
75766101|NCT04557449|Combination Product|Fulvestrant|Endocrine Therapy
75461661|NCT01855139|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
75614571|NCT01143090|Drug|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
75614572|NCT05125146|Behavioral|e-CBTi|See arm/group description
75766102|NCT04557449|Drug|Midazolam|Benzodiazepine used for DDI
75766103|NCT04557449|Combination Product|Enzalutamide|Androgen Receptor inhibitor
75907994|NCT02258178|Biological|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
75461662|NCT01855152|Other|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
75461663|NCT01855152|Other|Treatment as usual|Treatment delivered as usual in the care home
75614573|NCT05125146|Drug|Trazodone|See arm/group edescription
75614574|NCT01165554|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
75614575|NCT01218308|Biological|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
75614576|NCT01218308|Biological|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
75614577|NCT02887976|Drug|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor
75614578|NCT02887976|Drug|Methylprednisolone|Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
75766104|NCT04551131|Drug|Ruxolitinib|Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks
75766105|NCT04551131|Drug|Dexamethasone|Given intravenously (IV) or orally (PO) twice a day for 8 weeks
75907995|NCT01355679|Device|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
75907996|NCT03062566|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
75907997|NCT02220972|Drug|Perampanel|
75907998|NCT02220972|Drug|Placebo|
75907999|NCT02205606|Drug|HGP0816 5mg|P.O.
75461664|NCT01855165|Behavioral|Advice on DDIs|
75461665|NCT01855178|Device|Emfit Movement Monitor|Factory settings
75461666|NCT01855204|Radiation|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
75461667|NCT01855217|Drug|Sugammadex|1 mg/kg total BW based sugammadex reversal of deep block
75614579|NCT01165320|Drug|Caspofungin|
75614580|NCT01217606|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
75766106|NCT04551131|Drug|Etoposide|Given intravenously (IV) once a week for 8 weeks
75766107|NCT04546438|Device|miraDry®|"MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands.~In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions)."
75766108|NCT04538352|Drug|Semaglutide|Medication for type 2 diabetes management
75766109|NCT04538352|Drug|Insulin Degludec|Medication for type 2 diabetes management
75766110|NCT04538352|Drug|Insulin aspart|Medication for type 2 diabetes management (rapid-acting)
75766111|NCT04449588|Drug|BDB-001 Injection|BDB-001 Injection+Conventional treatment
75766112|NCT04449588|Other|Conventional treatment|Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
75766113|NCT04438382|Biological|Infliximab|Given IV
75766114|NCT04438382|Biological|Intravenous Immunoglobulin Therapy|Given IV
75766115|NCT04438382|Drug|Prednisone|Given IV or PO
75766116|NCT04438382|Other|Quality-of-Life Assessment|Ancillary studies
75766117|NCT04438382|Other|Questionnaire Administration|Ancillary studies
75908000|NCT02205606|Drug|HGP0816 10mg|P.O.
75908001|NCT02205606|Drug|HGP0816 20mg|P.O.
75908002|NCT02205606|Drug|HCP1306 5/10mg|P.O.
75908003|NCT02205606|Drug|HCP1306 10/10mg|P.O.
75908004|NCT02205606|Drug|HCP1306 20/10mg|P.O.
75908005|NCT03629977|Device|CRRT|Continuous Renal Replacement Therapy
75766118|NCT04420923|Other|Observe and Plan|First the individual interval between the injections of anti-VEGF (vascular endothelial growth factor) is established by observing the time from the loading dose to recurrence of the disease. The patient will come to control every four weeks to establish this interval. Second, the patient will receive injections at intervals that are two weeks shorter than the observed period. 2-3 injections are given before the next control. The control should be no later than six months ahead.
75766119|NCT04420923|Other|Treat-and-Extend|"At the first control 4 weeks after the loading dose, the ophthalmologist assesses whether the macula is still wet or whether the macula is dry. In case of wet macula, the patient receives a new injection on the same day and a new control in 4 weeks. If the macula is dry, the patient will return in 2 weeks for the next injection, ie the injection interval is extended from 4 to 6 weeks.~Patients will be controlled every time they are to receive an intravitreal injection. If the macula is dry, the injection interval will be extended by 2 weeks and if the macula is wet the interval is shortened by 2 weeks. The shortest interval will be 4 weeks."
75766120|NCT04400331|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
75766121|NCT04352101|Drug|Bupropion XL|Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.
75766122|NCT04352101|Drug|Escitalopram|Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.
75766123|NCT04334083|Behavioral|Comparison of biomarkers of stress|Emergency will be followed during a night shift and the rest day et during a day shift and the rest day. They will be observed by a medical externship student. We will assess the role of expertise and habituation to stressful emergency situations.
75766124|NCT04324112|Drug|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
75766125|NCT04324112|Drug|Encorafenib|Encorafenib will be given orally at a dose of 450mg QD continuously for 28-day cycles with no resting period between cycles.
75766126|NCT04317872|Drug|High dose of peri-operative intravenous dexamethasone|25mg aacidexam is administered during induction followed by 10mg on the ward after 12 hours
75766127|NCT04317872|Drug|Low dose of peri-operative intravenous dexamethasone|10mg aacidexam is administered during induction followed by placebo on the ward after 12 hours
75766128|NCT04316182|Drug|Cabozantinib|Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.
75766129|NCT04309266|Device|Amadeo by Tyromotion|Distal upper extremity/hand robot for robot-assisted therapy
75766130|NCT04309266|Behavioral|Active Learning Protocol for Stroke|Metacognitive approach involving active problem solving for using the affected upper extremity in motoric activities. Also includes a home program.
75766131|NCT04304820|Drug|Eltrombopag|Between 12 and 17yo (adult dose of 150mg) Between 6 and 11yo (75 mg) Between 3 and 5 yo (2.5 mg/kg)
75766132|NCT04304820|Drug|Cyclosporine|Day 1 to start of h-ATG: 2mg/kg/day by mouth (All subjects) Start of h-ATG to Month 6: 3 mg/kg/dose by mouth administered every 12 hours (12yo and above) 6 mg/kg/dose by mouth administered every 12 hours (less than 12yo) Month 6 to Month 24: Dosing to be adjusted based on response
75614581|NCT01217606|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
75614582|NCT05463146|Other|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
76071053|NCT05500235|Behavioral|Smart phone based training|The study team will acquaint headmasters with the Tobacco Free Teachers-Tobacco Free Society (TFT-TFS) program and the smartphone training app. Headmasters will receive six monthly trainings on smartphones, including brief videos followed by quizzes with feedback, discussion forums to promote peer learning, demonstration of techniques, and the ability to review the content as needed. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) six group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
75461668|NCT01855217|Drug|Sugammadex|1 mg/kg ideal BW based sugammadex reversal of deep block
75614583|NCT05463146|Other|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
75614584|NCT05463146|Other|Deep breathing exercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
75766133|NCT04304820|Drug|Horse-Anti-thymocyte-Globulin|h-ATG at a dose of 40 mg/kg/day for 4 days (intravenously for approximately 4 hours daily) Note: Omitted in patients who have achieved a complete response at the initial NIH visit after initiating oral treatment remotely
75461669|NCT01855217|Drug|Placebo|0,9% NaCl
75461670|NCT01855230|Drug|ASM-024|ASM-024 b.i.d for 14 days
75461671|NCT01855230|Drug|Placebo|Placebo b.i.d. for 14 days
75461672|NCT01855256|Drug|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
75766134|NCT04244552|Biological|ATRC-101|ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.
75461673|NCT01855256|Drug|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
76071054|NCT05500235|Behavioral|In person training|Headmasters will receive three face-to-face trainings, each 60-75 minutes long and held at convenient locations. The study team will introduce headmasters to the TFT-TFS program and teach participants how to use paper-based materials. The trainings will encourage participants to discuss successes and come up with solutions to overcome challenges. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) 6 group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
76071055|NCT05499052|Drug|REKOVELLE®|"Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio."
75316774|NCT05287919|Other|Patients received the medium-frequency neuromuscular electrical stimulation (NMES)|Electrical stimulation was performed twice a day after SPT. Two electrodes were attached to each thigh at the motor points of the quadriceps muscle. The point halfway between the anterior superior iliac spine and the base of the patella was used as reference and electrodes were placed 15 cm apart each other, 5 cm proximal and 10 cm distal from the reference point. After the first measurement, semi-permanent markers were used to indicate the position of electrodes. Electrical stimulation was performed using a 4-channels device (Sonopuls 492, series 4, Enraf-Nonius®, Rotterdam, Netherlands).The medium-frequency protocol had similar parameters, but a carrier frequency of 2500 Hz and burst frequency of 100 Hz. Sessions had 20 min of duration (total of 40 min/day) and the current amplitude (mA) was adjusted to the identification of visible and palpable contractions and was rectified every 3 min to sustain the initial level of contraction.
76071056|NCT05497973|Behavioral|E-health ecosystem of stepped psychosocial care|"Screening and monitoring: weekly administration of an emotional state thermometer. If the score is >5, participants are asked to complete the HADS. If HADS' score >10, step 2 is assigned. The same procedure is followed for steps 3 & 4. Participants remain in each step for 2 weeks, and all level changes are preceded by a videoconference with a health professional~Online psychoeducation campus: displays co-constructed videos and posts developed by health professionals and patients about LC diagnosis and treatment aspects.~Online support community: anonymous survivors with LC diagnoses are included. Professionals and patient mentors supervise and foster debate, peer support, and resolve health Q&As.~Weekly online group psychotherapy led by a clinical psychologist and composed of eight 90-minute sessions. Eligible users are placed on a waiting list, starting when 5-6 users are available."
75316775|NCT00371267|Behavioral|Telephone-delivered Cognitive Behavior Therapy|Telephone-delivered cognitive behavior therapy for pain management
75316776|NCT00371267|Other|Telephone-delivered Patient Education|Telephone-delivered patient education regarding chronic pain
75316777|NCT00438451|Drug|Levetiracetam|LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
75461674|NCT01855269|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
75614585|NCT05460962|Other|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
75614586|NCT05460962|Other|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
75614587|NCT01128114|Drug|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
76071057|NCT05497973|Behavioral|Usual psychosocial care|Usual psychosocial care for cancer survivors at ICOHospitalet centre led by a clinical psychologist. Usual psychosocial care consists of 7 individual sessions of 45-60 minutes, with 2-3 weeks of space between sessions, based on Individual Meaning-Centered Psychotherapy (IMCP) for Patients With Advanced Cancer (Breitbart et al., 2012). Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled on a website open to all patients and relatives.
75766135|NCT04244552|Biological|Pembrolizumab|Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
75316778|NCT00438451|Drug|Carbamazepine|CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
75908006|NCT02832375|Drug|stannous fluoride|0.454% w/w stannous fluoride containing 1100ppm of fluoride
75316779|NCT00438451|Drug|Lamotrigine|LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
75316780|NCT00456547|Procedure|Blood Draw|Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
75316781|NCT00456625|Biological|Engerix™-B|Intramuscular injection, 1 dose
75461675|NCT01855269|Dietary Supplement|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
75461676|NCT01855269|Dietary Supplement|placebo sterile water|
75908007|NCT02832375|Drug|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
76071058|NCT05492695|Drug|Galcanezumab|Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
75316782|NCT00439465|Biological|Ex-vivo expanded effector cells|This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
75316783|NCT00457795|Drug|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
75461677|NCT01855282|Behavioral|Behavioral Intervention|Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
75614588|NCT05458544|Drug|[177Lu]Ludotadipep 3.7 GBq|"Phase 1:~Patients will receive a single dose of 3.7 GBq of [177Lu]Ludotadipep~Test article code/name: [177Lu]Ludotadipep~Administration route: intravenous injection~Total dose strength: 3.7 GBq~Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of [177Lu]Ludotadipep every 8 [±1] weeks (4 to 6 times)~Test article code/name: [177Lu]Ludotadipep~Administration route: intravenous injection~Total dose strength: 4 to 6 x 3.7 GBq~Dosage form: solution for injection"
76071059|NCT05492695|Other|Placebo|Galcanezumab' placebo. This is the same vehicle as the study intervention formulation but does not contain active galcanezumab-gnlm.
76071060|NCT05484557|Drug|Apixaban|treatment for 6 to 12 weeks
76071061|NCT05484557|Drug|Enoxaparin Sodium|treatment for 6 to 12 weeks
76071062|NCT05482854|Other|Analytical Treatment Interruption (ATI)|"Analytical Interruption of Treatment for 24-48 weeks~ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria"
76071063|NCT05482347|Other|Educational video|The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
75908008|NCT03059680|Other|High potassium diet|An increase in consumption of high potassium fruits and vegetables
76071064|NCT05480800|Biological|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose|3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).
76071065|NCT05480800|Biological|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose|3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
76071066|NCT05480800|Biological|Typhoid conjugate vaccine (TCV) low dose|3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
76071067|NCT05480800|Biological|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose|3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 Group in Stage 2 (Africa).
76071068|NCT05480800|Biological|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose|3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
75908009|NCT04964752|Device|continuous glucose-monitoring|Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.
76071069|NCT05480800|Biological|Typhoid conjugate vaccine (TCV) full dose|3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
76071070|NCT05480800|Biological|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
76071071|NCT05480800|Combination Product|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
76071072|NCT05480800|Combination Product|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
76071073|NCT05480800|Drug|Placebo|3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo_Step 1 and Placebo_Step 2 in Stage 1 (Europe).
75316784|NCT04749979|Drug|Agonist (decapeptyl )|giving agonist
75316785|NCT04749979|Drug|HCG ( eg. Choriomon )|giving HCG
75316786|NCT01423604|Drug|Capecitabine|Capecitabine starting dose - 2000 mg/m^2 (1000 mg/m^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
75316787|NCT01423604|Drug|Ruxolitinib|Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
75316788|NCT01423604|Drug|Placebo|Placebo matching ruxolitinib
75461678|NCT01855295|Dietary Supplement|Protein Supplement|During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
75316789|NCT00441259|Biological|ChimeriVax™-JE|One dose of 4.0 log10 PFU is given in a volume of 1 ml for children aged > 3 years and 0.5 ml to children and infants aged < 3 years administered subcutaneously
75614589|NCT01217060|Drug|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
75766136|NCT04244552|Drug|Pegylated liposomal doxorubicin (PLD)|Pegylated liposomal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis. PLD is doxorubicin HCL encapsulated in liposomes formulated with surface-bound methoxypolyethylene glycol
75461679|NCT01855308|Procedure|Single site robotic chole|Cholecystectomy
75766137|NCT04243499|Biological|IV ICT01|humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody
75766138|NCT04221555|Drug|Docetaxel, Oxaliplatin, S-1 and Durvalumab|"Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~Surgery~Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28 plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment."
75766139|NCT04221555|Drug|Durvalumab and Tremelimumab|"Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be administered every four weeks for three cycles.~Surgery~Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be administered every 4 weeks for 12 months as an adjuvant treatment."
75908010|NCT02205684|Other|Computer game skills training|Playing Nintendo Wii Sports
75908011|NCT02205684|Other|Physical activity|Aerobic High Intensity Training (HIT)
75908012|NCT03563781|Procedure|Sentinel node detection|Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
75908013|NCT03062332|Genetic|Faecal genome|Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
76071074|NCT05480800|Other|Saline|3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).
75461680|NCT01855308|Device|da Vinci Si Surgical System|minimally invasive robotic surgical system designed to facilitate complex procedures
75316790|NCT00441259|Biological|Japanese Encephalitis Inactivated Mouse Brain Vaccine|Two doses of 1 ml reconstituted JE-MBDV is given to subjects aged > 3 years and 0.5 ml is given to children and infants aged < 3 years administered subcutaneously
75316791|NCT04750057|Drug|Anifrolumab|Multi-centre, open-label, early access program (EAP) designed to provide access to intravenous (IV) treatment regimen of 300 mg anifrolumab (MEDI-546) every 4 weeks (Q4W) for eligible patients with moderate-to-severe active SLE while receiving standard therapy.
75316792|NCT01402544|Drug|ranibizumab|0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
75461681|NCT01855321|Drug|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
75614590|NCT01217060|Drug|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
75614591|NCT01217060|Radiation|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
75614592|NCT01217060|Procedure|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
75614593|NCT01217060|Drug|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
75614594|NCT04816669|Biological|BNT162b2|Intramuscular injection
75614595|NCT01165242|Biological|Meningococcal vaccine GSK 134612|One intramuscular injection
75614596|NCT01165242|Biological|Menactra®|One intramuscular injection
75908014|NCT02925403|Biological|R21/Matrix-M1|
75908015|NCT02925403|Other|Saline|
76071075|NCT05477823|Radiation|External beam radiation therapy|Standard of care EBRT
76071076|NCT05477823|Radiation|Prostate brachytherapy boost|Standard of care BTX
75316793|NCT01401842|Other|Lumbar ext. high intensity progressive resistance exercise|1 active set of 1 exercise, 1x/week, 11 weeks
75316794|NCT01401842|Other|Low intensity core stabilization exercise|1 set of 5 exercises, 1x/week, 11 weeks
75461682|NCT01855321|Drug|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
75461683|NCT01855334|Drug|Spironolactone|
75461684|NCT01855334|Dietary Supplement|L-arginine|
75461685|NCT01855334|Drug|Placebo|
75461686|NCT01855347|Device|Near Infrared Spectroscopy|NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
75614597|NCT01170065|Drug|BIBF 1120|Intermediate dose BIBF 1120 twice daily
75614598|NCT01170065|Drug|BIBF 1120|High dose BIBF 1120 twice daily
75614599|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 twice daily
75614600|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 once daily
75614601|NCT02885922|Drug|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
75908016|NCT02213640|Device|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
76071077|NCT05477823|Drug|Androgen deprivation therapy|Standard of care ADT
76071078|NCT05477823|Diagnostic Test|Positron emission tomography (PET)/magnetic resonance imaging (MRI)|Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
75908017|NCT02213640|Device|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
75908018|NCT05301387|Procedure|Ganglion Sphenopalatine Block|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL or Block performed with bilaterally inserted q-tips with isotone NaCl
75908019|NCT04973176|Device|Standard Bougie|Standard Bougie for endotracheal intubation
75908020|NCT04973176|Device|Flexi-tip Bougie (P3 Medical Bristol,UK)|Flexi-tip Bougie for endotracheal intubation
75908021|NCT04108741|Device|C-Mill augmented reality treadmill training|PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.
75316795|NCT00460525|Biological|FMP2.1/AS02A|3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
75461687|NCT01855373|Dietary Supplement|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
75908022|NCT02205918|Other|Active TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS."
75614602|NCT04174417|Procedure|systolic blood pressure (SBP)|"Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
75908023|NCT02205918|Other|Sham TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS."
75908024|NCT03059836|Dietary Supplement|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
75908025|NCT03059836|Dietary Supplement|Placebo|Organic Sunflower Oil 5000mg per day
75908026|NCT03679819|Device|HR-TRUS|Medical procedures to be performed in the study consist of subject preparation and prostate imaging. The HR-TRUS exam will be done with a transrectal probe either the day before surgery, or in the OR right before surgery. The exam will be done in the same manner as during a regular transrectal ultrasound exam and no invasive procedures will be associated.
75908027|NCT02626780|Device|GID SVF-2|Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.
75908028|NCT03683407|Other|Next-Genernation Sequence|Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease
75908029|NCT02221206|Device|Mini-Screw implant|Mini-screw implants (VectorTASTM8*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
75908030|NCT03683329|Other|Antibiotic de-escalation|"All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation."
75908031|NCT03683329|Other|Standard treatment|Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
75908032|NCT05262192|Other|nutrition education|Nutrition education will be given to the patients in the experimental group.
75316796|NCT00460525|Biological|Rabies Vaccine|White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
75316797|NCT00460993|Drug|Lunesta|"Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4."
75316798|NCT00441883|Drug|PF-03187207 and Latanoprost Vehicle|
75461688|NCT01855373|Dietary Supplement|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
75461689|NCT01855373|Dietary Supplement|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
75461690|NCT01855373|Other|Placebo|Placebo: 2 capsules twice daily on an empty stomach
75908033|NCT04981054|Procedure|Cystocele repair|Repair of endopelvic fascia and anterior colporrhaphy
75908034|NCT04972864|Other|Exercise training group|A regular advanced exercise program was given and followed.
75908035|NCT04972864|Other|Control training group|Basic exercises was given at the beginning and did the same exercises
75908036|NCT03677557|Drug|16,5% Cutaquig|Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
75908037|NCT01363401|Biological|HYNR-CS inj|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
75908038|NCT01363401|Other|Control group|No treatment of HYNR-CS inj
75908039|NCT03673020|Biological|ASV® AGEN2017 + QS-21 Stimulon® adjuvant|Neoantigen Vaccine
75908040|NCT04980508|Diagnostic Test|corpus cavernosum electromyography|Cc-EMG was performed by using the cc-EMG module of Ellipse 4 device (Andromeda, Germany), which comprises of a 2-channel electromyography amplifier with a row sampling rate of 16 kHz, filtered sampling rate of 166.67 Hz and a band width of 0.5-30 Hz with the speed of the thermo-writer paper set at 5 mm/s. Measurements of the electrical activity of the corpus cavernosum (EACC) were done for 10 minutes using coaxial needle electrodes during the flaccid state and after intracavernous papaverine (60 mg) injection.
75316799|NCT00441883|Drug|Latanoprost 0.005% and PF-03187207 Vehicle|
75316800|NCT00461773|Drug|Letrozole|Letrozole 2.5 mg po qd
75316801|NCT00461773|Drug|Bevacizumab|bevacizumab 10 mg/kg IV
75461691|NCT01855386|Other|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
76071079|NCT05474794|Diagnostic Test|DFI-EUS|"All patients enrolled having a confirmed histologic diagnosis of GIST or leiomyoma will undergo endoscopic ultrasound evaluation.~First, the expert endoscopist will perform EUS-DFI examination for the detection of slow flow vascularization in SELS. Microvascularization EUS-Doppler evaluation will last between three and five minutes."
76071080|NCT05474794|Diagnostic Test|CE-EUS|"Immediately, after the first approach, CE-EUS (using Sulphur hexafluoride ultrasound contrast agent) will be performed for diagnosis confirmation. Sonovue will be administered intravenously in one (2.4 mL) or two administrations (4.8 ml), according to physician´s criteria, followed by an injected flush of 5 mL of sodium chloride solution (9 mg/mL).~CE-EUS it will take around 5 minutes, with a total diagnostic approach around one hour."
75908041|NCT03679663|Device|Ultrasound|Use of ultrasound to identify pre-puncture site
75908042|NCT02218476|Drug|CoQ10|
75908043|NCT02218476|Drug|Placebo|
75908044|NCT03679507|Procedure|Low Intensity Ultrasound Therapy|Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
75908045|NCT03679507|Other|Enhancing CBD oil penetration into joints by sonophresis|High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
75461692|NCT01855386|Other|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
75908046|NCT04972708|Genetic|Cross-sectional genetics study|Cross-sectional genetics study
75908047|NCT02221440|Device|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
75908048|NCT02221440|Device|Low flow room air|Sham: oxygen will be administered by nasal catheter at a flow rate of 0 L/min.
75316802|NCT00461851|Drug|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
75316803|NCT00461851|Drug|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
75461693|NCT01855438|Behavioral|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
75461694|NCT01855490|Drug|Exenatide|
75461695|NCT01855503|Procedure|Core Biopsy|
75461696|NCT01855516|Drug|Heparin|
75461697|NCT01855529|Drug|Ropivacaine in one arm and placebo (NaCl) in the other arm|
75461698|NCT01855542|Other|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
75461699|NCT01855542|Other|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
75461700|NCT01855555|Drug|sedation with propofol|"When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported."
75766140|NCT04219163|Biological|CLL-1.CAR T cells|"Dose escalation study with 3 dose levels:~DL1: 1x10^7 cells/m2, DL2: 3x10^7 cells/m2, DL3: 1x10^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10^6 cells/m2"
75766141|NCT04208178|Drug|Alpelisib|Alpelisib orally taken - continuous once daily, in a 21-day cycle.
75766142|NCT04208178|Drug|Alpelisib matching Placebo|Alpelisib matching placebo orally taken - continuous once daily, in a 21-day cycle
75766143|NCT04208178|Drug|Trastuzumab|Trastuzumab 6mg/kg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
75908049|NCT04963582|Procedure|Acupuncture|LI4 is located on the dorsum of the hand, midway between the 1st and 2nd metacarpal bones, approximately in the middle of the 2nd metacarpal bone on the radial side. Acupuncture is practiced by using 0,25x25mm sized needles. LI4 point is punctured perpendicularly 2cm in the direction of the palm center.
75908050|NCT02218632|Other|lactose-free diet|standard diet
75908051|NCT02218632|Dietary Supplement|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
75908052|NCT02205996|Drug|Insulin (Humulin S)|Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
75908053|NCT02205996|Device|Euglycaemic Hypoglycaemic Insulin clamp|
76025357|NCT05323175|Other|Standard of care medications|Whatever the ED clinicians normally give for renal colic pain
76025358|NCT02673619|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
75316804|NCT00461851|Drug|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
75316805|NCT00442507|Drug|Erlotinib|
75316806|NCT00442507|Drug|Avastin|
75614603|NCT04174417|Procedure|mean blood pressure (MBP)|"For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory."
75766144|NCT04208178|Drug|Pertuzumab|Pertuzumab 420 mg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
75908054|NCT04980586|Diagnostic Test|CASA score protocol to Non-obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
75908055|NCT04980586|Diagnostic Test|CASA score protocol to Mild obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
76071081|NCT05473962|Diagnostic Test|assessment and quantification of symptoms related to post-traumatic stress.|Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
76071082|NCT05467072|Device|Annular closure|Lumbar discectomy patients treated with Annular Closure Device BARRICAID
75461701|NCT01855568|Procedure|Single-dose Methotrexate|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
75461702|NCT01855568|Procedure|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
75461703|NCT01855581|Drug|pediatric sedation (propofol, ketamine, etc)|"Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively."
75461704|NCT01855594|Drug|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
75614604|NCT02885844|Procedure|INVERTED VISION|The tasks will be performed either with normal or inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
75614605|NCT02885844|Procedure|NORMAL VISON|subject's field of view will be restricted by goggles without lenses in order to be equivalent to the inverted vision one.
75614606|NCT00966693|Drug|Dexamethasone|Given PO
75614607|NCT00966693|Drug|Lenalidomide|Given PO
75614608|NCT00966693|Drug|Thalidomide|Given PO
75461705|NCT01855594|Drug|Placebo|placebo tablet, 6 week course of oral administration
75461706|NCT01855646|Other|Structured Sign Out Form|
75461707|NCT01855672|Device|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
75461708|NCT01855698|Other|Observation|
75461709|NCT01855711|Drug|GR68755 (Alosetron hydrochloride) 1 mg tablet|1 tablet (1 mg) once a day
75461710|NCT01855724|Drug|Gemcitabine-Pazopanib|
75614609|NCT01215968|Biological|LY2189265|1.5 mg administered subcutaneously
75614610|NCT01215968|Drug|Placebo|Administered subcutaneously
75766145|NCT04208087|Drug|SI-722|SI-722 will be intravesically instilled.
75766146|NCT04208087|Drug|Placebo|Placebo will be intravesically instilled.
75766147|NCT04188743|Biological|Allogenic FMT|Transplantation of fecal microbiota from a donor into a recipient
75766148|NCT04188743|Biological|Autologous FMT|Transplantation of autologous fecal microbiota
75766149|NCT04187053|Procedure|Conventional mechanical therapy|Both experimental and sham arms will receive the Conventional mechanical therapy
75766150|NCT04187053|Drug|Saline|Sham group will receive saline as a sham for methylene blue
75766151|NCT04187053|Drug|Methylene Blue|Experimental arm will receive methylene blue
75766152|NCT04187053|Device|Light emitting laser|Experimental arm will receive Light emitting laser
75614611|NCT02663713|Drug|Ticagrelor|Ticagrelor 60mg twice daily
75614612|NCT02663713|Drug|Clopidogrel|Clopidogrel 75 mg once daily
75766153|NCT04187053|Device|Non-light emitting laser|Sham group will receive Non-light emitting laser
75766154|NCT04170556|Drug|Regorafenib|Regorafenib 160 mg/day 3 weeks on and 1 week off
75766155|NCT04170556|Drug|Nivolumab|Nivolumab at the dose of 1.5 mg/kg, 3 mg/kg or 240 mg/infusion every 2 weeks. Dose will be adjusted depending on the incidence of adverse events
75766156|NCT04159324|Other|optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation|the optimized treatment pathway includes coordinated transitions between rehabilitation phases and institutes using individual case management and portal solutions
75766157|NCT04140227|Drug|NOV03|100% Perfluorohexyloctane
75766158|NCT04135898|Drug|SIBP-04|3mg/kg, infusion in 90 minutes
75766159|NCT04135898|Drug|Bevacizumab|3mg/kg, infusion in 90 minutes
76071083|NCT05464784|Drug|MN-001|MN-001 is a novel, orally bioavailable small molecule compound
75766161|NCT03922724|Drug|ATL-RIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5mcg /kg/day subcutaneous on days -12, -8, and -4, ruxolitinib 45 mg/day from day -12 through day -2, and zidovudine 300mg orally three times a day from day -1 through day +50.
75766162|NCT03922724|Drug|mRIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, lowdose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous on days -12, -8, and -4.
75908056|NCT04980586|Diagnostic Test|CASA score protocol to Moderate obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
75908057|NCT04980586|Diagnostic Test|CASA score protocol to Severe obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
76071084|NCT05464784|Drug|MN-001 placebo|The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
76071085|NCT05464030|Drug|M9140|M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined.
75766163|NCT03922724|Procedure|allo HCT|Stem cell transplant
75461711|NCT01855737|Drug|Warfarin|Prescribe warfarin to the patients who are needed.
75461712|NCT01855763|Drug|Metformin|
75614613|NCT02664649|Drug|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].~- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
75614614|NCT02664649|Drug|Standard of care|VKA or Antiplatelet therapy
75614615|NCT02664493|Drug|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
75614616|NCT00963807|Drug|Cisplatin|Given IV
75614617|NCT00963807|Procedure|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
76071086|NCT05459701|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once daily for 24 weeks.
76071087|NCT05459701|Other|Placebo|Placebo
75614618|NCT00963807|Drug|Docetaxel|Given IV
75461713|NCT01855763|Drug|Insulin|
75461714|NCT01855776|Device|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
75461715|NCT01855776|Behavioral|Cash Incentives|Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
75461716|NCT01855776|Behavioral|Charitable Incentives|Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
75461717|NCT01855776|Other|Usual Care|"The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating."
75461718|NCT01855841|Drug|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
75461719|NCT01855841|Drug|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
75461720|NCT01855854|Drug|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
75614619|NCT00963807|Drug|FDG|Undergo FDG PET/CT
75614620|NCT00963807|Drug|FLT|Undergo FLT PET/CT
75766164|NCT03922724|Drug|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Pentostatin 4mg /m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally daily on days -11 through -4. Busulfan IV, pharmacokinetically dosed, on days -3 and -2.
75766165|NCT03922724|Drug|GVHD prophylaxis|"High-dose, post-transplantation cyclophosphamide (PTCy) on days +3~and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on~days +5 through +25."
75766166|NCT03922724|Drug|IOC|e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
75766167|NCT03899220|Behavioral|Project Matter|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
75766168|NCT03879694|Biological|Incomplete Freund's Adjuvant|Given SC
75766169|NCT03879694|Drug|Octreotide Acetate|Given IM
75766170|NCT03879694|Biological|Sargramostim|Given SC
75766171|NCT03879694|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
75766172|NCT03833479|Other|No Further Treatment|No further treatment
75766173|NCT03833479|Drug|TSR-042|Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
75766174|NCT03807102|Biological|Tumor Vaccine|NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
75908058|NCT03059914|Device|InterOss|Anorganic bovine bone mineral - Xenograft
75908059|NCT03059914|Device|Bio-oss|Anorganic bovine bone mineral ( Xenograft)
75908060|NCT04972474|Other|Smartphone app in-app components|Insightful notification text, data visualisation, research team contact details.
75766175|NCT03782259|Drug|dapagliflozin|Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
75766176|NCT03782259|Other|Placebo|Placebo
75766177|NCT03749460|Biological|Nivolumab|Given IV
75766178|NCT03749460|Biological|Ipilimumab|Given IV
75766179|NCT03749460|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75766180|NCT03743194|Drug|Exparel 266 MG Per 20 ML Injection|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
75461721|NCT01855893|Other|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
75908061|NCT02221518|Behavioral|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
75908062|NCT02206074|Dietary Supplement|Beetroot|
76071088|NCT05459389|Other|targeted antibiotics therapy|targeted antibiotics therapy guided by resistance genotyping (n=24)
75461722|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
75461723|NCT01855906|Procedure|Gap balanced surgical technique|Gap balanced surgical technique
75461724|NCT01855906|Procedure|Measured resection|Measured resection surgical technique
75908063|NCT04972084|Device|Powerscope group|Treatment of Class II malocclusions using Powerscope appliance
75908064|NCT04980742|Procedure|acute normovolemic hemodilution|acute normovolemic hemodilution
75908065|NCT02219802|Procedure|Treatment according arm|
75908066|NCT04980664|Other|Integrated intervention strategies|Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
75908067|NCT02206230|Radiation|Hypofractionated radiation therapy|
75908068|NCT02206230|Radiation|Standard radiation therapy|
76071089|NCT05458843|Procedure|Fluid replacement|Participants will drink Gatorade Zero ad libitum, up to 1 cup every 15 minutes.
75461725|NCT01855932|Behavioral|Technology Supported|All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
75614621|NCT00963807|Procedure|PET/CT|Undergo FDG PET/CT and FLT PET/CT
75614622|NCT00963807|Procedure|Surgery|Undergo surgery
75614623|NCT01142466|Drug|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
75614624|NCT02663635|Device|Safe'N'Sound|
75614625|NCT00648505|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
75614626|NCT00648505|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
75766181|NCT03743194|Drug|Placebo|Patients randomized to standard analgesia technique will be given pain medications.
75908069|NCT04972006|Behavioral|Remote, intensive intervention for injection phobia|The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.
75614627|NCT01215734|Biological|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
75766182|NCT03702244|Diagnostic Test|cCTA with selective FFRct|PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
75766183|NCT03645525|Drug|Human Umbilical Cord-derived Mesenchymal stem cell|The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
75766184|NCT03645525|Drug|placebo|saline
75766185|NCT03640624|Combination Product|Multidisciplinary treatment|"Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients."
75766186|NCT03640624|Combination Product|Treatment as usual|Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 - 6 months)
75766187|NCT03598608|Biological|pembrolizumab|Administered as an IV infusion every 3 weeks (Q3W)
75908070|NCT02220036|Dietary Supplement|Magnesium Oxide|Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
76071090|NCT05458843|Procedure|No fluid replacement|Participants will not be permitted to drink.
76071091|NCT05455281|Device|CHLOE|CHLOE is designed to automatically analyze events related to embryo development from Time Lapse Incubator (TLI) images and provide prediction on the likelihood of embryos developing to the blastocyst. This information can assist embryologists and IVF professionals in the selection of the most viable embryo for transfer or freezing, when there are multiple embryos deemed suitable.
75316807|NCT05286073|Procedure|Endodontic Root Canal Treatment|Root canal shaping procedures were performed. Irrigation was done after each three pecks of endodontic file. After instrumentation (Groups 1-3), the canals were dried with sterile paper points. The dentinal walls were then coated with Sealapex. For vertical root fracture resistance testing, sample preparation was done in acrylic blocks. Then roots were coated with polyvinylsiloxane impression material. After that roots were inserted again into acrylic resin blocks. The acrylic blocks with the vertically aligned roots were mounted in the Instron testing machine. 0.5 mm diameter round tip stainless-steel rod was fixed to the universal testing machine. The universal testing machine was adjusted and vertical compressive force was applied at a crosshead speed of 1mm/min. The Instron tester applied a slowly increasing force, until the root fractured. The maximum amount of force necessary to fracture every sample was recorded in Newton (N).
75614628|NCT01215734|Biological|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
75614629|NCT04172311|Other|Modified Atkins Diet|Modified Atkins diet is a type of ketogenic diet which is less restrictive
75766188|NCT03598608|Biological|Favezelimab|Administered as an IV infusion Q3W
75766189|NCT03562845|Other|NA-Observational only|NA-Observational only
75614630|NCT04172311|Drug|Levetiracetam|Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
75614631|NCT02863185|Drug|Pitavastatin|
75766190|NCT03534466|Device|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
76025359|NCT02673619|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2
75614632|NCT02863185|Drug|Atorvastatin|
75614633|NCT02666833|Device|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
75766191|NCT03534466|Behavioral|Conventional physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
75766192|NCT03527498|Device|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
75766193|NCT03527498|Behavioral|Physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
75766194|NCT03468959|Behavioral|Maternal Supplemental PUFA Intake|Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
75766195|NCT03461146|Drug|MT-6548|Oral tablet
75766196|NCT03460704|Drug|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d. dosing).~The 1 MIU/ml CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (11 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d. (morning and evening) over aperiod of 12 month.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g. salbutamol/albuterol), supplied by the Sponsor, could be taken to improve tolerability."
75766197|NCT03460704|Other|Placebo|1 mL saline solution 0.45%. The placebo was made up of identical empty glass vials to which the same saline solution diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to mantain the blind.
75766198|NCT03430843|Drug|Tislelizumab|200 mg administered intravenously (IV)
75766199|NCT03430843|Drug|Paclitaxel|135-175 mg /m² administered IV , or 80-100 mg/m^2 administered IV according to local guidelines for standard of care
75316808|NCT01401530|Biological|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
75316809|NCT01387022|Drug|Tenofovir, lamivudine and efavirenz|Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
75316810|NCT00395135|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
75316811|NCT00395135|Drug|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
75461726|NCT01855971|Dietary Supplement|EGCG|Life Extension, Mega Green Tea Extract Decaffeinated is a dietary supplement containing EGCG extract (45% EGCG). This extract contains 98% total polyphenols and 45% epigallocatechin-3-gallate (EGCG). EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.
75461727|NCT01855971|Dietary Supplement|Placebo|Same capsules containing rice flour. No active treatment is given.
75316812|NCT00395291|Drug|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
75316813|NCT00395291|Drug|Placebo|Placebo
75461728|NCT01855971|Other|Cognitive training|Feskits program 3 times per week (1 hour/session) Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention, attention/perception, working memory, auditory and visual memory, executive function and language.
75461729|NCT01855984|Dietary Supplement|Oral mixed tocotrienols|200mg per day
75461730|NCT01855984|Dietary Supplement|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
75461731|NCT01856010|Other|ECT treatment|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
75461732|NCT01856010|Other|Standard Care (Non-ECT group)|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
75614634|NCT01215422|Procedure|timed intubation|timed intubation
75614635|NCT04315025|Biological|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
75614636|NCT04315025|Biological|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
75614637|NCT02664571|Device|Pet scan with FBB|"Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself."
75614638|NCT02664571|Device|MRI scan|Subjects will have an MRI scan at inclusion.
75614639|NCT02664571|Biological|APO E genotyping|Subjects will have APO (apolipoprotein) E genotyping if not already known.
75614640|NCT00972153|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
75614641|NCT00972153|Device|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
75614642|NCT04736485|Drug|perioperative treatment|FLOT + Spartalizumab
75614643|NCT00647881|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
75766200|NCT03430843|Drug|Docetaxel|75 mg/m^2 administered IV or 70 mg/m^2 IV in Japan
75766201|NCT03430843|Drug|Irinotecan|125 mg/m^2 administered IV
75766202|NCT03422198|Radiation|Vaginal Cuff Brachytherapy|Undergo standard of care vaginal cuff brachytherapy
75766203|NCT03422198|Radiation|Short course vaginal cuff brachytherapy|Undergo short course vaginal cuff brachytherapy
75461733|NCT01856036|Procedure|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
75766204|NCT03382600|Biological|Pembrolizumab|200 mg Q3W on Day 1 by IV infusion
75908071|NCT02220114|Drug|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
75316814|NCT01386788|Other|There is no intervention planned (observational)|No intervention foreseen
75614644|NCT00647881|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fed
75766205|NCT03382600|Drug|Oxaliplatin|130 mg/m^2 Q3W on Day 1 by IV infusion
75766206|NCT03382600|Drug|TS-1|40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
75766207|NCT03382600|Drug|Cisplatin|60 mg/m^2 Q3W on Day 1 by IV infusion
75766208|NCT03288311|Other|Protocolized post-extubation respiratory support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
75908072|NCT04972240|Other|customization of abutment|we will customize abutment for every patient not ready made
75908073|NCT02221596|Dietary Supplement|vitamin D|50,000IU/wk of vitamin D3
75908074|NCT02221596|Other|aerobic training|7 days of treadmill training during the 13th week of study
75908075|NCT04971616|Other|Demographic data and range of motion.|The body parameters (BMI, age, gender), daily activities (daily steps, sedentary), work and rest time (sleep time, quality) were collected through wearable devices. The range of motion of neck and waist was collected through hand-held devices.
75316815|NCT00445315|Drug|PF-00868554|300 mg BID
75316816|NCT00445315|Drug|PF-00868554|450 mg BID
75908076|NCT02224794|Device|Ovation® Abdominal Stent Graft Platform|
75766209|NCT03288311|Other|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
75908077|NCT02221752|Dietary Supplement|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
75908078|NCT02221752|Dietary Supplement|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
75316817|NCT00445315|Drug|PF-00868554|100 mg BID
75316818|NCT00445315|Drug|PF-00868554|300 mg TID
75316819|NCT00445315|Drug|Placebo|Placebo
75316820|NCT03025412|Procedure|endoscopic surgery|Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
75461734|NCT01856062|Drug|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
75614645|NCT02861625|Behavioral|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
75766210|NCT03211416|Other|Laboratory Biomarker Analysis|Correlative studies
75766211|NCT03211416|Biological|Pembrolizumab|Given IV
75766212|NCT03211416|Drug|Sorafenib Tosylate|Given PO
75766213|NCT03209479|Drug|Glatiramer acetate|Copaxone subcutaneous injection syringe
75766214|NCT03207009|Genetic|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
75766215|NCT02836093|Behavioral|FACIT-Fatigue 52-point questionnaire|
75614646|NCT04174261|Drug|Ticagrelor|Preprocedural ticagrelor loading and standard dose thereafter
75614647|NCT04174261|Procedure|Remote Ischemic Preconditioning|Preprocedural remote ischemic preconditioning on the non-dominant arm
75766216|NCT02787369|Drug|ACY-1215|
75461735|NCT01856062|Drug|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
75461736|NCT01856088|Device|Inspiron Stent|stent implantation
75461737|NCT01856088|Device|Biomatrix Flex Stent|stent implantation
75614648|NCT04174261|Drug|Clopidogrel|Preprocedural clopidogrel loading and standard dose thereafter
75614649|NCT00971997|Drug|Lispro Mix 50/50|Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
75766217|NCT02787369|Drug|Ibrutinib|
75766218|NCT02787369|Drug|Idelalisib|
75766219|NCT02759861|Drug|harvoni|8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
75766220|NCT02566772|Drug|TAS3681|TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
75766221|NCT02551003|Drug|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
75766222|NCT02551003|Device|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
75766223|NCT02550054|Drug|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
75766224|NCT02550054|Drug|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
75766225|NCT02550028|Drug|Oral levetiracetam|Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
75766226|NCT02550028|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
75766227|NCT02520063|Drug|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
75766228|NCT02520063|Drug|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
75766229|NCT02520063|Drug|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
75766230|NCT02472314|Drug|1.3% Liposomal Bupivacaine|local tissue infiltration of Liposomal Bupivacaine during surgery
75766231|NCT02472314|Drug|0.125% Bupivacaine|Continues nerve block with Bupivacaine during surgery and postoperatively
75766232|NCT02262806|Drug|Metreleptin|A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.
75766233|NCT02224469|Device|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
75766234|NCT02158507|Drug|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
75766235|NCT02141074|Drug|nonacog beta pegol|For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
75766236|NCT01830712|Drug|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
75766237|NCT01659879|Behavioral|Multimedia information|
75766238|NCT01659879|Behavioral|verbal information|
75766239|NCT01561391|Drug|activated recombinant human factor VII|Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
75766240|NCT01561391|Drug|activated recombinant human factor VII|Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
75766241|NCT01561391|Other|factor IX|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
75766242|NCT01561391|Drug|factor VIII|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
75766243|NCT01524705|Drug|Insulin Glargine|Glargine-injectable, variable, once daily (QD), 6 months
75461738|NCT01856101|Drug|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
75766244|NCT01524705|Drug|Metformin|Metformin-oral, up to 1000mg, twice daily (BID), 6 months
75766245|NCT01524705|Drug|Prandial insulin|Aspart or glulisine or lispro
75766246|NCT01524705|Drug|Exenatide|Injectable, 5mcg, twice daily (BID), 6 months
75766247|NCT01455805|Device|Minuteman Fusion Implant|The Minuteman™ interspinous interlaminar fusion device consists of a central threaded portion that has a two-part wing plate hinged near its proximal end, with spikes on the extended distal end of the wing plate, and a multi-spiked end cap plate that is located at the distal end of the device and is retained and tightened in place with a locking hex nut. Compression between the spiked wing plate and the spiked end cap plate serves to fix the spinous processes in place and to facilitate fusion, together with bone graft fusion material placed within the device. The threaded external body has been designed to provide ease of distraction and insertion via a minimally invasive surgical procedure.
75766248|NCT01455805|Procedure|surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis
75766249|NCT01072539|Drug|tigecycline|As prescribed by physician in usual clinical practice
75766250|NCT00846313|Other|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
75766251|NCT00715611|Procedure|Pleurectomy/Decortication|Pleurectomy/decortication will be performed as per standard technique
75766252|NCT00715611|Drug|pemetrexed and cisplatin or carboplatin|The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
75766253|NCT00715611|Radiation|Intensity Modulated Radiation Therapy|IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
75766254|NCT00667043|Drug|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
75766255|NCT00667043|Drug|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
75766256|NCT00218998|Behavioral|exercise training|
75766257|NCT00218868|Procedure|Skin scrape|scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
75766258|NCT03953716|Device|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes * 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
75316821|NCT03025412|Behavioral|physiotherapy and exercise|Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
75766259|NCT03953716|Drug|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
75766260|NCT03953716|Drug|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
75766261|NCT03953716|Drug|Marvelon|Marvelon 1 pill QD*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) *3 menstrual cycle
75766262|NCT01096498|Drug|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of one 0.75 mg coated tablet
75908079|NCT04971382|Drug|Curcumin|Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
75461739|NCT01856127|Drug|Vilazodone|Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
75766263|NCT01096498|Drug|Levonorgestrel (Postday)|Single dose of one 0.75 mg tablet
75766264|NCT01096576|Drug|balapiravir [RO4588161]|sequential cohorts receiving doses orally twice daily for 5 days
75461740|NCT01856127|Drug|Sertraline|Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
75766265|NCT01096576|Drug|placebo|orally twice daily for 5 days
75766266|NCT01097122|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups
75461741|NCT01856153|Dietary Supplement|Before meal|
75461742|NCT01856153|Dietary Supplement|With Meal|
75461743|NCT01856153|Dietary Supplement|After meal|
75461744|NCT01856166|Device|Release analgesia by CADD SMITHS PCEA pump|Analgesia will be release by continuous manner with an automatic pump
75766267|NCT00147537|Drug|CP-751,871|"Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles"
75908080|NCT02220192|Procedure|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
75908081|NCT04728906|Device|Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells|heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)
75461745|NCT01856166|Device|Release analgesia by CADD SMITHS PIEB pump|Analgesia will be release by bolus with an automatic pump
75461746|NCT01856166|Drug|Levobupivacaine|
75461747|NCT01856166|Drug|Sufentanil|
75461748|NCT01856179|Dietary Supplement|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
75461749|NCT01856205|Drug|Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]|"IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate."
75908082|NCT02220270|Device|ASD and PDA closure|
75461750|NCT01856231|Behavioral|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
75461751|NCT01856244|Behavioral|treadmill walking|
75461752|NCT01856244|Device|Treadmill|
75461753|NCT01856283|Drug|Nilotinib 300mg BID|Nilotinib
75614650|NCT04171609|Behavioral|Expressive writing|During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
75766268|NCT00147537|Drug|paclitaxel|"Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles"
75766269|NCT00147537|Drug|carboplatin|"Phase 2 Arm A:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles"
75766270|NCT00147537|Drug|CP-751,871|Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
75908083|NCT03061162|Radiation|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
75908084|NCT02220348|Drug|linaclotide|
76071092|NCT05453292|Procedure|Endoscopic ultrasound guided radiofrequency ablation|Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.
75614651|NCT00910741|Drug|Nanoplatin (NC-6004) and Gemcitabine|
75614652|NCT02863731|Other|Alternating working postures, first day|On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
75614653|NCT02863731|Other|Alternating working postures, second day|On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
75614654|NCT02863497|Behavioral|Mindfulness-based Sex Therapy|These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
75461754|NCT01856296|Procedure|Biopsy|
76071093|NCT05453097|Diagnostic Test|Selvester QRS Score with Preoperative ECG|Selvester QRS score will be calculated with the preoperative ECG of the patients.
75461755|NCT01856335|Other|Patient Education|
75461756|NCT01856335|Other|exercise: increase physical activity/goal setting|
75461757|NCT01856348|Drug|Vitamin D|
75461758|NCT01856374|Device|Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
75461759|NCT01856374|Device|Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
75614655|NCT00647959|Drug|Doxycycline Tablets, 150mg|150mg, single dose fasting
75614656|NCT00647959|Drug|Adoxa Tablets 150 mg|150mg, single dose fasting
75614657|NCT00648583|Drug|Ondansetron Tablets 24 mg|24mg, single dose fed
75766271|NCT00147537|Drug|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
75766272|NCT00147537|Drug|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
75766273|NCT00147537|Drug|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
75766274|NCT01326507|Biological|Dosage de l'h-FABP|Dosage de l'h-FABP
75766275|NCT00222729|Drug|Pemetrexed|500 mg/m2 day 1 q 21 days
75766276|NCT00222729|Drug|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
75766277|NCT00147225|Drug|AMG 531|"Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).~1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)"
75766278|NCT00147225|Drug|Carboplatin|AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
75766279|NCT00147225|Drug|Adriamycin|75-90 mg/m^2 IV
75908085|NCT04151680|Drug|Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive intermittent treatment with a novel oral anticoagulant drug
75908086|NCT04151680|Drug|Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive chronic treatment with a novel oral anticoagulant drug
75908087|NCT02221830|Drug|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
75766280|NCT00147225|Drug|Ifosfamide|10 gm/m^2 IV; OR, High dose ifosfamide = 14 gm/m^2.
75766281|NCT00222105|Drug|Doxil|Doxil 40 mg/m2 IV day 1
75908088|NCT02221830|Drug|Placebo|This intervention utilizes a Placebo Camparator
75908089|NCT02221908|Device|Mespere Venus 1000 CVP System|
75766282|NCT00222105|Drug|Thalidomide|50-100 mg day 1-28
75766283|NCT00222105|Drug|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
75766284|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|100 U/kg every week
75614658|NCT00648583|Drug|Zofran® Tablets 24 mg|24mg, single dose fed
75766285|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|200 U/kg every week (Week 26 onwards)
75766286|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Biventricular pacing
75766287|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Right ventricular pacing
75766288|NCT00247676|Drug|Sunitinib (SU011248)|Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
75614659|NCT04284579|Device|IV cannula|We measure the time duration needed for IV cannulation
75766289|NCT01073774|Behavioral|Side by side|
75908090|NCT04151446|Device|Laser Scleral Microporation|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
75614660|NCT02882334|Device|Finger Force Manipulandum|
75766290|NCT01073774|Behavioral|couples control condition|
75766291|NCT00267020|Drug|enzastaurin|1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles
75908091|NCT02224950|Device|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
75908092|NCT02224950|Other|Non-medicated Emollient plus Cotton Sleeve|
75908093|NCT02224950|Other|Placebo Sleeve|
75614661|NCT02882334|Other|Conventional physiotherapy|
75614662|NCT02664259|Procedure|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
75614663|NCT02664259|Procedure|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
75614664|NCT02664259|Procedure|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
75614665|NCT04285749|Drug|Fluvastatin|Fluvastatin PO 80mg QD for 2 weeks
75766292|NCT00267020|Drug|gemcitabine|1000 milligrams/square meter (mg/m^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
75766293|NCT03975062|Drug|dabigatran etexilate|150 mg twice daily (BID)
75766294|NCT03970772|Drug|Glucagon Injection|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
75766295|NCT03970772|Other|Glucose Tablets|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
75766296|NCT03970928|Device|PVI|A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
75766297|NCT03970850|Diagnostic Test|NeuMoDx CT/NG Assay|NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System
75766298|NCT03970850|Diagnostic Test|FDA-cleared NAATs|Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs
75766299|NCT00242216|Drug|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
75766300|NCT00242216|Drug|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
75766301|NCT00240110|Drug|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
75766302|NCT00240110|Drug|Placebo|Control arm
75908094|NCT04970524|Procedure|Comparison of conventional free gingival graft versus partial free gingival graft|"Conventional free gingival graft was applied to the area of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
75908095|NCT04970524|Procedure|Comparison of conventional free gingival graft versus partial free gingival graft|"Partially de-epithelialized free gingival graft was applied to the other region of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
75908096|NCT04970758|Other||no intervention
75908097|NCT03039114|Drug|Parsaclisib|Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.
75614666|NCT04285749|Other|RNA-sequencing|RNA-sequencing will be completed on the original diagnostic biopsy and the final melanoma excision
75614667|NCT04285749|Other|Gene expression profiling|Gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision
75614668|NCT02660125|Procedure|Endometrial scratch injury|midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
75614669|NCT03809481|Drug|Danaparoid Sodium|inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
75614670|NCT03809481|Drug|Argatroban|Synthetic direct thrombin inhibitor
75614671|NCT00649129|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
75614672|NCT00649129|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
75614673|NCT01127646|Drug|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
75766303|NCT00240110|Drug|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
75766304|NCT00239720|Drug|hOKT3gamma1(Ala-Ala)|Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle
75766305|NCT00239720|Drug|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
75766306|NCT02532140|Drug|WCK 5107 250 mg to 2000 mg|
75766307|NCT02532140|Drug|Cefepime 2000 mg|
75766308|NCT02532140|Drug|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
75766309|NCT02532140|Drug|Placebo|
75766310|NCT00266864|Drug|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
75766311|NCT00266708|Drug|Risedronate|risedronate 35 mg weekly
75766312|NCT00266708|Drug|Placebo|Risedronate Placebo 35 mg weekly
75766313|NCT00266630|Drug|olanzapine|oral, daily
75766314|NCT00266630|Drug|lithium|Dose adjusted according to local package insert
75614674|NCT01127646|Drug|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
75766315|NCT00266630|Drug|valproate|Dose adjusted according to local package insert
75766316|NCT00266630|Drug|carbamazepine|Dose adjusted according to local package insert
76071094|NCT05452850|Diagnostic Test|Left and Right Ventricular Global Strain Imaging|Two-dimensional, color Doppler, spectral Doppler, and 3D digital echocardiographic image recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
75614675|NCT01127646|Drug|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
75614676|NCT04284423|Diagnostic Test|joint fluid lactate|Analysis of lactate level in joint fluid to determine presence of septic joint
75766317|NCT02531672|Drug|11C-choline|
76071095|NCT05452200|Behavioral|Solicitation for lung cancer screening|3 levels of solicitation will be cumulated. First : a Simple collective solicitation of all staff via internal media 4 months later : Personalized indirect solicitation of at-risk groups with information posted in identified areas 4 months later : Personalized direct solicitation of at-risk groups
75614677|NCT02660047|Drug|Liraglutide|"Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
76071096|NCT05452200|Other|added exams to the usual lung cancer screening|"spirometry examination~Questionnaires~Blood samples and breath samples to find biomarkers"
75766318|NCT02531672|Device|PET/CT Scan|
75766319|NCT00129129|Biological|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
75614678|NCT02660047|Drug|Liraglutide - Placebo|"Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
75766320|NCT00129129|Biological|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
75766321|NCT00129129|Biological|Pediarix|Primary phase: 3 IM doses
75766322|NCT00129129|Biological|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
75766323|NCT00129129|Biological|Menomune|Primary phase: 1 SC dose
75766324|NCT00221403|Drug|Risperidone oral solution|liquid, BID dosing.
75766325|NCT00221403|Drug|Valproate Oral Solution|liquid, BID dosing.
75766326|NCT00221403|Other|Placebo|liquid, BID dosing.
75766327|NCT00145977|Drug|Alendronate|alendronate 70 mg once weekly
75766328|NCT00145977|Dietary Supplement|Calcium Citrate|600 mg of calcium citrate
75766329|NCT00145977|Dietary Supplement|Vitamin D|500 mg of Vitamin D consumed with the evening meal.
75766330|NCT00238238|Biological|rituximab|Given IV
75766331|NCT00238238|Drug|lenalidomide|Given orally
75766332|NCT03970460|Device|Primary TKA with cemented modular metal-backed tibial implant|Tibial implant will be done with a cemented implant
75766333|NCT03970460|Device|Primary TKA with uncemented trabecular metal|Tibial implant will be done with a uncemented implant
75766334|NCT03970148|Procedure|Nd: YAG laser|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
75766335|NCT01073852|Drug|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
75766336|NCT01073852|Drug|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
75316822|NCT00395993|Drug|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
75316823|NCT00395993|Drug|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
75766337|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040) and Valsartan|Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
75766338|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040)|Nifedipine 60mg, Once daily
75766339|NCT01071122|Drug|Valsartan|Valsartan 160mg, Once daily
75614679|NCT04285437|Behavioral|infant massage|Mother will be trained how to massage their babies by International Association of Infant Massage (IAIM) Certified Infant Massage Instructor, and then their babies will be massaged by themselves during the first 2 months after birth.
75614680|NCT00648661|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
75614681|NCT00648661|Drug|Lexapro® Tablets 20 mg|20mg, single dose fed
76071097|NCT05448716|Diagnostic Test|Left Atrial Strain Imaging|Two-dimensional, color Doppler, spectral Doppler recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
76071098|NCT05448716|Diagnostic Test|Electrocardiography|Electrocardiography will be taken at baseline and the follow-up periods
75766340|NCT03973190|Procedure|Immediate alveolar regeneration after exodontia|The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
75766341|NCT03973190|Procedure|installation of dental implant and collection of biological material|The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
76071099|NCT05445375|Other|PAD education video|20-min online multi-media video
75908098|NCT03039114|Drug|Hexal|Bendamustine 90 mg/m^2 administered intravenously at protocol-defined timepoints.
76071100|NCT05444712|Procedure|Chemotherapy + follow up|"Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
76071101|NCT05444712|Procedure|Chemotherapy + ASCT + follow up|"Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~The fifth or sixth cycles should be used as stem-cell mobilizing chemotherapy for patients with ASCT strategy~A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~Patients with in Complete Response after 6 cycles will receive a High Dose Therapy as conditioning regimen before transplantation~A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
75614682|NCT05367414|Other|aromatherapy massage (diluted tea tree oil)|massage with diluted tea tree oil was applied
75908099|NCT03039114|Drug|Gazyvaro|Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
75908100|NCT04970602|Drug|Methylene Blue|Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
76071102|NCT05444244|Other|Relational Research Recruitment and Engagement Intervention|"Specified recruiter/point of contact~Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)~Resource matching (financial, transportation constraints)"
75316824|NCT03542513|Device|Colli-Pee|Urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium).
75316825|NCT03542513|Device|Qvintip|Vaginal self-samples will be collected with the Qvintip (Aprovix AB, Uppsala, Sweden).
75908101|NCT02221986|Behavioral|Interdisciplinary rehabilitation|
76071103|NCT05430828|Drug|Repatha (evolocumab); Praluent (alirocumab)|Dosage form: Injection
76071104|NCT05430191|Other|Cascade Screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
75316826|NCT04388137|Other|No intervention.|No intervention.
75316827|NCT00374231|Drug|tacrolimus|Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
75316828|NCT00374231|Drug|mycophenolate mofetil|Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
75316829|NCT00374231|Drug|Prednisone|Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
75316830|NCT00400205|Drug|Docetaxel|Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
75614683|NCT05367414|Other|aromatherapy massage (sweet almond oil)|massage with sweet almond oil was applied
75614684|NCT04284111|Device|Orthokeratology lenses|Orthokeratology lenses
75614685|NCT04171687|Drug|Clopidogrel 75mg|Clopidogrel 75 mg tablet
75614686|NCT04171687|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
75614687|NCT04171687|Drug|RAPA113|RAPA113 tablet
75614688|NCT03556215|Device|Eustachian tube dilatation device|Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
75614689|NCT03556215|Procedure|Myringotomy|Myringotomy will be performed using a standard procedure.
75614690|NCT00648817|Drug|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
75766342|NCT03973190|Device|ISQ analysis|The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
75461760|NCT01856374|Drug|Pravastatin 20mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
75614691|NCT00648817|Drug|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
76071105|NCT05428631|Device|Implantation of the CARDIOMEMS™ HF device|The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
76071106|NCT05428488|Drug|Abatacept (W12-W48)|"The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study."
76071107|NCT05428488|Drug|TNF Inhibitor (W12-W48)|In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
76071108|NCT05428488|Drug|TNF Inhibitor (W0-W12)|All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
76071109|NCT05428007|Drug|Sarilumab|Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.
75908102|NCT02225028|Behavioral|Physical Activity Counseling|Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
76071110|NCT05428007|Drug|Ipilimumab Injection|Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.
75908103|NCT04963114|Behavioral|art therapy|guided art tour and workshop
75908104|NCT04963348|Other|convolutional neural networks (CNNs)|CNN architecture named U-Net architecture
75908105|NCT02831673|Drug|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
75316831|NCT00400205|Drug|Cisplatin|Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
75316832|NCT00400205|Drug|5-fluorouracil|5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
75316833|NCT00445705|Drug|placebo|Part A: Placebo every 12 hours for 4 weeks
75316834|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 3 mg every 12 hours for 4 weeks
75316835|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 20 mg every 12 hours for 4 weeks
75316836|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 60 mg every 12 hours for 4 weeks
75614692|NCT02664025|Procedure|vaginal examination simulator|
75614693|NCT04284033|Device|Extended Wear Infusion Set|For two of the 4 weeks, the Extended Wear insulin infusion set will be used
75614694|NCT04284033|Device|Standard Infusion Set|For two of the 4 weeks, the standard insulin infusion set will be used
75316837|NCT01386554|Drug|Repository Corticotropin Injection|Acthar given SC for 6 months
75316838|NCT01386554|Drug|Placebo|"Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week)."
75316839|NCT00400439|Drug|dalcetrapib (RO4607381)|900mg po daily for 24 weeks
75614695|NCT02663479|Dietary Supplement|Cardiopressin|
75614696|NCT02663479|Dietary Supplement|Placebo|
75614697|NCT02663401|Behavioral|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
75614698|NCT02862561|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
75614699|NCT02862561|Biological|Precision Cells|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
75614700|NCT02663323|Device|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
75766343|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 1 under fasting conditions
75766344|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 2 under fasting conditions
75766345|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Plain Tablet under fasting conditions
75766346|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Dry Granules under fasting conditions
75766347|NCT00128661|Biological|human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
75766348|NCT00128661|Biological|hepatitis A inactivated virus vaccine|Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
75908106|NCT02831673|Drug|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
75316840|NCT00400439|Drug|placebo|po daily for 24 weeks
75316841|NCT00448201|Biological|anti-thymocyte globulin|0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)
75316842|NCT00448201|Biological|sargramostim|GM-CSF 500 ug everyday (QD) subcutaneously will be given to recipients who remain with an Absolute neutrophil count (ANC) < 1000/microliter (uL) past day 20
75614701|NCT01215188|Biological|V114 Aluminum-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
75614702|NCT01215188|Biological|V114 Non-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.
75614703|NCT01215188|Biological|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
75614704|NCT04285281|Drug|Gabapentin oral capsules|Oral capsule pharmaceutical treatment.
75614705|NCT02663245|Other|Intervention 1|"Diabetes specific consultation~Basic training in clinical guidelines~Platform of communication for professionals~Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
75766349|NCT03975140|Procedure|Hypersensitive acupoint group|The first five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
75766350|NCT03975140|Procedure|Hyposensitive acupoint group|The last five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
75766351|NCT01072760|Procedure|K wire|Mallet finger treatment
75766352|NCT00145509|Drug|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
75766353|NCT00145509|Drug|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
75766354|NCT03965871|Drug|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
75766355|NCT03965871|Drug|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
75766356|NCT03965871|Drug|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
75766357|NCT03965871|Drug|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
75766358|NCT03965949|Drug|Hormone Replacement cycle 1|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
75766359|NCT03965949|Drug|Hormone Replacement cycle 2|Hormone Replacement cycle with GnRHa suppression
75766360|NCT00220779|Drug|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
75766361|NCT00220779|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|
75316843|NCT00448201|Biological|therapeutic allogeneic lymphocytes|A minimum total cluster of differentiation 34 (CD34)+ cell dose of 3 x 10^6 cells/kg and a maximum 8 x 10^6 cells/kg will be infused on day 0
75316844|NCT00448201|Drug|busulfan|6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
75316845|NCT00448201|Drug|fludarabine phosphate|fludarabine 30 mg/m^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3
75316846|NCT00448201|Drug|methotrexate|Methotrexate 5 mg/m^2 per day on days +1, +3 and +6
75316847|NCT00448201|Drug|tacrolimus|Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
75461761|NCT01856374|Drug|Atorvastatin 40mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
75461762|NCT01856387|Biological|high neutrophil to lymphocyte ratio|
75461763|NCT01856387|Other|normal neutrophil-to Lymphocyte ratio|
76071111|NCT05428007|Drug|Nivolumab/Relatlimab|The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
76071112|NCT05423119|Behavioral|conventional therapy|upper limb rehabilitation with and without technologies
75316848|NCT00448201|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
75316849|NCT00448201|Procedure|peripheral blood stem cell transplantation|Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
75316850|NCT05287607|Diagnostic Test|Urine sample for carbonic anydrase (I) levels|Point of care diagnostic device used routinely for non-invasive estimation of serum bilrubin level.
75316851|NCT01386008|Device|senfilcon A contact lens|senofilcon A spherical contact lens worn in a daily wear modality
76071113|NCT05419934|Behavioral|EMDR therapy|"Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~History of the patient (collection of anamnesis)~Securing the patient, preparing for the desensitization phases~Desensitization phases, to be repeated for each traumatic event to be desensitized:~Evaluation of the target to be treated~Desensitization~Installation of positive beliefs~Body scanner (verification of body non-response)~Closure, verification that the patient is in a stable emotional state allowing him to leave the session~Reassessment phase, to be repeated for each traumatic event that has been desensitized:~Reassessment of the traumatic target, verification of complete desensitization."
76071114|NCT05419934|Behavioral|Routine Care|Children in the routine care group receive psychological monitoring administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P). The proposed treatment is a psychological follow-up associated with relational support psychotherapy
76071115|NCT05415722|Drug|TERN-501|Investigational drug
76071116|NCT05415722|Drug|TERN-101|Investigational drug
76071117|NCT05415722|Other|Placebo|Matching placebo
75316852|NCT01386008|Device|investigational enfilcon A|investigational enfilcon A, worn daily wear modality
75316853|NCT00375167|Behavioral|Recovery Workbook Training (psychoeducational training)|The Recovery Workbook uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning, build personal support, and develop goals and plans of action. The intervention period of 30 weekly sessions recommended by Spaniol and colleagues was shortened to 12 weekly sessions to accommodate for clinical and participant commitment. No workbook content was excluded, and all practice exercises were covered.
75461764|NCT01856413|Drug|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
75461765|NCT01856426|Drug|EDP239|
75461766|NCT01856426|Drug|Placebo|
75461767|NCT01856452|Device|the mixture including indocyanine green|Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation
75461768|NCT01856452|Device|radioisotope|Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation
75461769|NCT01856517|Drug|Clonidine|
75461770|NCT01856517|Drug|Placebo|
75316854|NCT00375167|Behavioral|ACT as usual|Assertive Community Treatment services provided as per established and evidence-based fidelity standards.
75316855|NCT00375713|Drug|Levocetirizine|1 Levocetirizine 5mg tablet per day before bedtime for 14 days
75316856|NCT00375713|Drug|Cetirizine|1 Cetirizine 10mg tablet per day before bedtime for 14 days.
75316857|NCT00375713|Drug|Placebo-Levocetirizine|1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
75316858|NCT00375713|Drug|Placebo-Cetirizine|1 Placebo-Cetirizine tablet per day before bedtime for 14 days
75316859|NCT00375713|Drug|Standard topical steroid (1% hydrocortisone) ointment|1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
75316860|NCT00465595|Drug|psilocybin|The dose of psilocybin received in the two sessions will range anywhere from low to high.
75461771|NCT01856556|Drug|NRX-1074|Single IV or PO administration
75461772|NCT01856556|Drug|Placebo|Single IV or PO placebo administration
75461773|NCT01856621|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
75461774|NCT01856621|Drug|Seretide Diskus|2 inhalations as a single dose
75461775|NCT01856621|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
75461776|NCT01856621|Drug|SF Easyhaler|2 inhalations as a single dose
75461777|NCT01856634|Drug|100 mg Delamanid|100 mg Delamanid BID for 10 days
75461778|NCT01856634|Drug|50 mg Delamanid|50 mg Delamanid BID for 10 days
75461779|NCT01856634|Drug|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 10 days
75461780|NCT01856634|Drug|10 mg Delamanid Pediatric Formulation|Patients > 10 kg will receive DPF 10 mg BID for 10 days
75461781|NCT01856634|Drug|5 mg Delamanid Pediatric Formulation|"Patients > 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days"
75461782|NCT01856634|Drug|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
75766362|NCT00207740|Drug|CNTO148|Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
75316861|NCT05285995|Other|Music Intervention|Before the operation, subjects were asked to choose their favorite music to listen so as to reduce the anxiety before the operation and before the induction of anesthesia.
75766363|NCT00207740|Drug|Placebo|Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
75908107|NCT02831673|Drug|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
75908108|NCT04962802|Behavioral|Manhood 2.0|Manhood 2.0 engages young men in questioning, challenging, and transforming harmful gender norms, with the goal of reducing intimate partner and sexual violence and unintended teen pregnancy. Manhood 2.0 is a male-only group-level intervention, based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Activities include group discussion, role playing, knowledge sharing, and skill-building; their purpose is to challenge young men to think critically about social expectations and restrictive norms, engage in dialogue about these gender norms, and then assess the way rigid norms affect their attitudes and behaviors toward key issues, including intimate relationships, gender-based violence, substance abuse, sexually transmitted infections, and early pregnancy. Sessions are two hours long and occur once a week for seven weeks.
76071118|NCT05412407|Other|Questionnaire|description of analgesic self-medication in the context of acute pain using a questionnaire evaluating the drug taken, the dosage, the duration of treatment, the type of pain, its intensity, the origin of the drug, the source of information consulted and the factors that prompted the patient to self-medicate
75461783|NCT01856647|Procedure|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (~3 ml) will be obtained from the lower abdomen following local anesthesia.
75461784|NCT01856660|Behavioral|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to > 40 min per day, 5 times/week.
76071119|NCT05409131|Device|Omnipod 5 System|Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.
76071120|NCT05406453|Other|Whole Genome Sequencing testing|Whole Genome Sequencing testing, community-based contact tracing
76071121|NCT05405738|Procedure|2 flap palatoplasty technique|cleft palate repair by 2 flap palatoplasty technique
75316862|NCT05285995|Other|The animation intervention|Before surgery, subjects were asked to choose their favorite cartoons to watch to reduce anxiety before surgery and induction of anesthesia.
75461785|NCT01856660|Behavioral|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
75461786|NCT01856725|Procedure|Hemodynamic measurements for CRT device programming|
75461787|NCT01856725|Device|CRT device implant with MultiPoint Pacing|
75461788|NCT01856738|Drug|Rivastigmine|Capsule. Dose 3,0 - 6,0 mg BID
75461789|NCT01856738|Drug|Placebo (for rivastigmine)|Capsule. Dose 3,0 - 6,0 mg BID
75461790|NCT01856777|Device|Semi-quantitative panel test|
75461791|NCT01856777|Device|High sensitivity urine pregnancy test|
75614706|NCT02663245|Other|Intervention 2|"7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~Basic training in clinical guidelines.~Platform of communication for professionals.~Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
76071122|NCT05405738|Other|normal group|control normal group
75316863|NCT00376805|Drug|Fludarabine|administered intravenously 25 mg/m^2 times 5 doses
75316864|NCT00376805|Drug|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
75316865|NCT00376805|Radiation|Total body irradiation|200 cGy (gray) on day -1
75316866|NCT00376805|Other|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
75316867|NCT00376805|Biological|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
75461792|NCT01856803|Drug|anti thymoglobulin|
75461793|NCT01856816|Other|Meal Pattern Treatment A|"In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
75614707|NCT00629733|Drug|RO-14|
75614708|NCT02659657|Drug|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
75766364|NCT00265382|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
76071123|NCT05405738|Procedure|Furlow with buccinator technique|cleft palate repair by Furlow with buccinator technique
75614709|NCT02861547|Other|death|
75766365|NCT03969602|Behavioral|Cognitive-behavioral Therapy|The biopsychosocial approach of CBT focuses on the complex interaction between psychological, social and biological factors. The biopsychosocial model assumes that health problems are hardly ever limited to just one domain of human experience but by multiple domains of human experience. CBT helps patients understand thoughts and feelings that influence behaviors. It consists of a cognitive aspect and a behavioral aspect. The cognitive aspect is based on Becks cognitive model: the way that individuals perceive a situation is more closely connected to their reaction than the situation itself. A person's cognition has impact on their mood and emotions, their bodily reactions and their behavior. The second part of cognitive behavior therapy focuses on the actual behaviors that are contributing to the problem. The goal of CBT is to identify maladaptive thoughts and change them into more realistic and constructive thoughts to modify feelings and behavior and thereby the experience of pain.
75766366|NCT03969602|Other|Biomedical and surgery-specific education|Biomedical and surgery-specific education preoperatively and an exercise manual postoperatively.
75766367|NCT03974984|Procedure|Colon Resection|All patients undergo laparoscopic colon cancer resection.
75766368|NCT03974984|Procedure|Epidural anesthesia|Epidural inserted preoperatively and kept for 1 day postoperatively
75766369|NCT03974984|Drug|NSAID|NSAID administered according to standard operating procedure postoperatively
75766370|NCT00206726|Drug|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
75908109|NCT04962802|Behavioral|Post-High School Readiness|Post-High School Readiness program helps young men prepare for life after high school. This includes helping them prepare resumes, learning how to apply to jobs or colleges, providing interview prep, and other life skills. It is a male-only group-level program that includes discussion, feedback, knowledge sharing, and skill-building; their purpose is to prepare young men for life after high school. Sessions are two hours long and occur once a week for seven weeks.
75316868|NCT05285839|Drug|Dupixent|dupilumab 300mg
75316869|NCT01793363|Procedure|Tracheotomy|
75316870|NCT05287139|Other|Quality of Life|Assessment of patients' quality of life using the EORTC QLQ-C30 and EORTC-QLQ-BR 23 questionnaires
75766371|NCT00237692|Behavioral|Nurse Behavioral intervention with Home BP Telemonitoring|Nurse-administered behavior intervention
75766372|NCT00237692|Behavioral|Nurse Medication Management with Home BP Telemonitoring|Nurse administer medication management according to hypertension decision support
75766373|NCT00237692|Behavioral|Nurse Combined intervention with Home BP Telemonitoring|Combination of the nurse administered tailored behavioral & medication management
75766374|NCT00237458|Drug|Lacosamide|"Dosage: Lacosamide up to 400 mg/day;~Dosage form: Film-coated tablets;~Dosage Frequency and Duration: Two times per day; 9.5 years"
75766375|NCT01581788|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
75766376|NCT03973346|Other|Risk screening tool exposure|Risk screening tool is available to providers
75766377|NCT00265148|Drug|Rosiglitazone|Extended Release Tablets
75766378|NCT00265148|Other|Placebo|Placebo dummy to match
75766379|NCT01072838|Radiation|APBI (Dose Escalation)|"Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each."
75908110|NCT02220504|Other|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients.
75908111|NCT02220504|Other|Maintenance antipsychotic treatment|Maintenance antipsychotic medication to stabilized patients.
75908112|NCT04962958|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
75908113|NCT04962958|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
75316871|NCT00448357|Biological|rabbit anti-thymocyte globulin (ATG)|.5 mg/kg on day -3 and 2.5 mg/kg on day -2
75316872|NCT00448357|Biological|therapeutic allogeneic lymphocytes|minimum total cluster of differentiation (CD34+) cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on day 0
75316873|NCT00448357|Drug|busulfan|PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
75316874|NCT00448357|Drug|fludarabine phosphate|30 mg/m^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3
75316875|NCT00448357|Drug|tacrolimus|The suggested starting dose is 0.03 mg/kg po bid starting on day -1
75316876|NCT00448357|Procedure|allogeneic hematopoietic stem cell transplantation|A minimum total CD34+ cell dose of 3 x 10^6 cells/kg and maximum of 8 x 10^6 cells/kg will be infused on day 0
75316877|NCT00448357|Procedure|peripheral blood stem cell transplantation|minimum total CD34+ cell dose of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on day 0
75316878|NCT00448357|Drug|methotrexate|5 mg/m^2 on days +1, +3 and +6
75316879|NCT00450073|Drug|ergocalciferol (vitamin D2)|50,000 IU weekly
75316880|NCT00450073|Device|Sperti Del Sol Lamp|5 times a week for 12 weeks
75316881|NCT00450073|Drug|Vitamin D3|50,000 IU weekly
75316882|NCT00467077|Biological|PEG-interferon alfa-2b|PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks
75614710|NCT02659891|Biological|IVIg|
75614711|NCT02659891|Other|Placebo|
75614712|NCT02863341|Other|Team-care deprescribing with deprescribing guide|Beers criteria 2015, STOPP criteria 2014, drug interaction
75614713|NCT02659735|Drug|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
75614714|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
75614715|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
75766380|NCT01072838|Device|Contura MLB Breast Brachytherapy Catheter|
75766381|NCT03973424|Behavioral|Simple|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
75316883|NCT00467077|Drug|gefitinib|ZD1839 will be administered at a dose of 250 mg orally once daily,
75766382|NCT03973424|Behavioral|Standard|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
75766383|NCT00043186|Drug|Placebo|Placebo subcutaneous injection
75766384|NCT00043186|Drug|Denosumab|Denosumab for subcutaneous injection
75461794|NCT01856816|Other|Meal Pattern Treatment B|"In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
75461795|NCT01856816|Other|Meal Pattern Treatment C|"In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
75766385|NCT00043186|Drug|Alendronate|Alendronate 70 mg tablets
75766386|NCT00041470|Drug|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
75908114|NCT04962958|Drug|Donafenib|administration of Donafenib
75908115|NCT02031510|Drug|placebo|transversus abdominis plane block with saline 0.9%
75908116|NCT02031510|Drug|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
75908117|NCT02031510|Drug|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
75908118|NCT03059758|Other|fMRI|All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
75461796|NCT01856829|Dietary Supplement|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
75461797|NCT01856829|Other|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
75461798|NCT01856842|Procedure|Angiography and embolotherapy|
75461799|NCT01856881|Drug|AMG 876|Ascending multiple doses of study drug administered SC
75614716|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
75614717|NCT04283799|Dietary Supplement|A new human milk fortifier|Contents of protein, protein/energy ratio, moderate hydrolysis of whey protein, medium-chain fatty acid are increased in the new HMF
75614718|NCT04286763|Diagnostic Test|Biliary RMI and CT scan.|"For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients."
75614719|NCT00648193|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
75614720|NCT00648193|Drug|Paxil® 40 mg Table|40mg, single dose fasting
75614721|NCT04283721|Other|Educational video|Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.
75614722|NCT01215032|Drug|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
75766387|NCT00041470|Drug|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
75766388|NCT00041470|Drug|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
75766389|NCT00041470|Drug|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
75316884|NCT00400829|Drug|eribulin mesylate|Given IV
75908119|NCT02230878|Drug|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
75908120|NCT02230878|Drug|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
75908121|NCT02230878|Drug|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
75908122|NCT02230878|Drug|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
75908123|NCT02230878|Drug|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
75908124|NCT03059602|Other|No specific treatment based intervention-health measurement instrument|Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
75316885|NCT04388371|Drug|Glutamine|Glutamine will be administered by IV injection prior to PET imaging.
75316886|NCT01995929|Procedure|transnasal functional endoscopy|
75316887|NCT00467389|Drug|Donepezil, 5 mg daily|This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
75908125|NCT02222064|Behavioral|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
75908126|NCT04961788|Drug|Gemox combimed PD1 antibody|"Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
75908127|NCT02222142|Drug|Isoflurane|Comparison between isoflurane and propofol, Retrospective study
75316888|NCT00467389|Other|Oral Placebo|Inactive Comparator with Similar Appearance to Active Medication
75766390|NCT03953950|Drug|Spironolactone|Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep< 140/90 mmHg, but avoid hypotension <90/60 mmHg), and serum potassium level (<5.5 milliequivalent /liter)
75766391|NCT03953950|Drug|Losartan|Losartan Starting dose: 50 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep< 140/90 mmHg, but avoid hypotension <90/60 mmHg), and serum potassium level (<5.5 milliequivalent /liter)
75766392|NCT00206102|Drug|quetiapine fumarate|flexible dose oral
75766393|NCT00206102|Drug|risperidone|flexible dose oral
75766394|NCT03954262|Behavioral|observation of propofol ANS response|received an induction bolus or TCI infusion of propofol
75908128|NCT04961710|Drug|Hetrombopag Olamine|Hetrombopag Olamine; once daily
75908129|NCT04961710|Drug|Placebo|Placebo; once daily
75908130|NCT02225262|Radiation|CyberKnife Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
75908131|NCT04961866|Dietary Supplement|parenteral protein 1 g/kg|patients received 1 g/ kg of protein
75908132|NCT04961866|Dietary Supplement|Parenteral nutrition 2 g/kg|Patients received 2 g/ kg of protein
76071124|NCT05400031|Biological|propolis|"After obtaining written consent, oral identification of all participants will be performed prior to randomization. Oral diagnosis of children receiving chemotherapy will be repeated on day 0, day 5, and day 10, and the difference between the Oral Mucositis Rating Scale mean scores of the children in the groups will be examined.~Oral Mucositis Assessment: Oral Mucositis Rating Scale will be used. The oral mucosa of children will be evaluated using the World Health Organization Oral Mucositis Classification."
75461800|NCT01856920|Biological|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
75461801|NCT01856946|Dietary Supplement|4,000 IU vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
75461802|NCT01856959|Drug|Magnesium Sulfate|2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
75461803|NCT01856959|Drug|magnesium sulfate & albuterol|0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
75461804|NCT01856959|Drug|Albuterol|0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
75614723|NCT02659579|Behavioral|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
75614724|NCT02659579|Behavioral|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
75614725|NCT00962247|Device|Television reduction device|A TV allowance helps turn off the television when the time limits have been met.
75614726|NCT02659423|Behavioral|BIC 1|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
75614727|NCT02659423|Behavioral|BIC 2|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
75766395|NCT00041080|Drug|tamoxifen citrate|Given orally
75766396|NCT00041080|Drug|thalidomide|Given orally
75766397|NCT00041080|Other|laboratory biomarker analysis|Correlative studies
75766398|NCT00205712|Drug|Ketamine|Ketamine without dexmedetomidine
75766399|NCT00205712|Drug|Dexmedetomidine|Ketamine plus dexmedetomidine
75766400|NCT01097200|Device|Elevate mesh|The correction of the prolapse can be made by this new technique.
75766401|NCT01097200|Device|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
75766402|NCT03953404|Diagnostic Test|SPLA2-IIA|bedside blood test
75766403|NCT03953794|Device|Fitbit Charge 3|Smart watch monitoring activity and movement, heart rate, sleep, and more
75766404|NCT03969524|Device|MRI|Patients will undergo magnetic resonance imaging (MRI) at baseline (T0) (before NAC) and after the 2nd cycle of neoadjuvant chemotherapy(T2). Histopathological examination (gold standard) of the surgical specimen will be done for each patient and Compared to the results of MRI.
75766405|NCT03969758|Drug|Ciprofloxacin|will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively.
75766406|NCT03969758|Drug|Cefixime|will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively.
75766407|NCT03974672|Procedure|Re-laparotomy|
75766408|NCT00203294|Drug|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
75766409|NCT00203294|Drug|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
75766410|NCT01074086|Drug|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
76071125|NCT05400031|Biological|Placebo|Placebo
76071126|NCT05398380|Other|Liver transplantation|Liver transplantation
76071127|NCT05396885|Biological|CART-ddBCMA|BCMA-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain
76071128|NCT05394831|Drug|JIN-A02|PO, QD
76071129|NCT05393674|Drug|Fedratinib Oral Capsule [Inrebic]|400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
76071130|NCT05393674|Drug|Nivolumab|240 mg every 2 weeks i.v. from cycle 2-n
76071131|NCT05393284|Drug|OPL-0401 Dose 1|Pharmaceutical Form: Capsule; Route of Administration: Oral
75908133|NCT04426084|Other|Hypertension|Exposure : Any registered diagnosis of I10 within 15 years or a registered pick-up of a prescription of antihypertensive treatment (ATC C02CA, C02DB02, C03, C07, C08, C09) within one year before index date in the Swedish prescribed drug register (exluding those with a registered diagnosis of other indications for betablocker (heart failure, atrial fibrillation) or ACE-inhibitor, ARB(heart failure) ) Exposures will be compared between cases and controls and between cases with different outcomes and controls
75766411|NCT01074320|Other|Other|Observational study
75766412|NCT02531828|Device|Application of dressings for surgical correction.|Dressing for surgical correction
75908134|NCT04426084|Other|Diabetes type 2|"Exposure: Any registered diagnosis of E11 within 15 years or a registered pick-up of a prescription with any antidiabetic treatment (ATC A10) within one year before index date in the Swedish prescribed drug register.~Exposures will be compared between cases and controls and between cases with different outcomes and controls"
75908135|NCT04426084|Other|Obesity|Exposure: Diagnosis ICD E66 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes and controls
76071132|NCT05393284|Drug|Placebo|Pharmaceutical Form: Capsule; Route of Administration: Oral
76071133|NCT05392803|Device|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy; then sham treatment after a 7-day washout period"
76071134|NCT05392803|Device|Sham then Active Treatment|"Application of 30 days of sham treatment; then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy after a 7-day washout period"
76071135|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
76071136|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase)
75766413|NCT02531828|Device|POLYSHAFT®|
75766414|NCT00264290|Drug|Valganciclovir|900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
76071137|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase)
75908136|NCT04426084|Drug|Antihypertensive Agents|"Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date.~Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls"
76071138|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
76071139|NCT05383352|Drug|Folinic Acid|LV 400 mg/m2 intravenously over 30 minutes, on Day 1 and Day 15 of every 28-day cycle
76071140|NCT05383352|Drug|5-Fluorouracil|5-FU 2,400 mg/m2 intravenously over 46 hours, on Day 1 and Day 15 every 28-day cycle
75316891|NCT00377741|Drug|valganciclovir [Valcyte]|900mg po
75614728|NCT02659423|Behavioral|BIC 3|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
75614729|NCT02663089|Drug|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of [14C]-GSK961081 (approximately 6.2 kilobecquerel [kBq]) intravenously as a single dose over 1 hour.
75614730|NCT02663089|Drug|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of [14C]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
75766415|NCT00264290|Drug|Placebo|Placebo designed to resemble Valganciclovir
75766416|NCT00234494|Drug|Cisplatin|Cisplatin 70 mg/m2, day 1
75766417|NCT00234494|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, day 1 and 8
75766418|NCT00234494|Drug|Bevacizumab|Bevacizumab 15mg/kg, day 1
75766419|NCT00234104|Drug|OPC-41061(Tolvaptan)|
75908137|NCT04426084|Drug|Statins (Cardiovascular Agents)|Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.
75908138|NCT04426084|Other|Chronic kidney disease|Exposure: Diagnosis ICD N18 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes (mechanical ventilation, continuous renal replacement therapy mortality) and controls. Exposures will thereafter be compared in subgroups by BMI at ICU-admission and in subgroups matched by history of type 2 diabetes.
76071141|NCT05381961|Device|Bioimpedance spectroscopy (BIS) measurement, SOZO device|All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.
76071142|NCT05380427|Drug|CU-40101|CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
76071143|NCT05379790|Drug|Irinotecan|3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.
76071144|NCT05379790|Drug|CAPOX|Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
76071145|NCT05379023|Behavioral|Face-to-face evaluation (FF)|The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
76071146|NCT05379023|Behavioral|TeleNP evaluation|The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
76071147|NCT05374538|Drug|VIC-1911|VIC-1911 tablets for oral administration
76071148|NCT05374538|Drug|sotorasib|Sotorasib tablets for oral administration
76071149|NCT05373264|Drug|Hydrochlorothiazide 25 mg|An oral capsule containing 25mg of hydrochlorothiazide
75766420|NCT01582568|Drug|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
75766421|NCT00263666|Biological|Rotarix|Oral vaccination
75766422|NCT00263666|Biological|Placebo|Oral administration
75766423|NCT00263666|Biological|Tritanrix-HB+Hib|Concomitant routine vaccination, IM administration
75766424|NCT00263666|Biological|Polio Sabin|Oral administration, concomitant routine vaccination
75766425|NCT00195338|Drug|etanercept|
75908139|NCT02830893|Device|LARA|Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
75908140|NCT02830893|Behavioral|Standard|Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
75908141|NCT02231112|Radiation|Whole breast RT on prone position|
75908142|NCT04425382|Drug|Darunavir/Cobicistat|Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily
75908143|NCT04425382|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily
75908144|NCT02231190|Drug|GSK1278863|GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
75461805|NCT01856972|Procedure|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
75908145|NCT02231190|Drug|Placebo|GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
75908146|NCT03563937|Drug|Phenprocoumon|Follow the physician's prescription.
75908147|NCT03563937|Drug|Apixaban|2.5 mg or 5 mg, twice daily
75908148|NCT03563937|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg or 20 mg, once daily
75908149|NCT03563937|Drug|Edoxaban|30 mg or 60 mg, once daily
75908150|NCT04424992|Other|Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.|Describe the natural history and clinical evolution of hospitalized patients over time affected by SARS-COV-2 infection, understand the pathogenesis of the disease and improve the aids and therapeutic procedures.
75908151|NCT02231268|Drug|Gladem|
75461806|NCT01856972|Procedure|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
75614731|NCT02663089|Drug|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
75614732|NCT02663167|Behavioral|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
75614733|NCT02664103|Drug|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
75766426|NCT01096654|Other|Ct-scan or adrenal vein sampling|Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
75908152|NCT04961476|Dietary Supplement|1-MNA|1-MNA supplementation
75908153|NCT02231346|Drug|Berodual® Respimat® - inhaler|
75908154|NCT02225418|Drug|Ropivacaine|
75908155|NCT02225418|Drug|saline|
75908156|NCT04431856|Behavioral|Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.
75908157|NCT04431856|Behavioral|SHG|Brochure that details techniques for coping with stress.
75908158|NCT03679429|Device|NBI Function|In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
75908159|NCT02231424|Drug|Drug: Berodual®|
76071150|NCT05373264|Drug|Placebo|A matching oral capsule containing placebo
76071151|NCT05370521|Drug|Tildacerfont|Oral tablet formulation taken once daily.
76071152|NCT05370521|Drug|Placebo|Non-active dosage form taken once daily.
75766427|NCT00035932|Drug|Atazanavir + ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
75766428|NCT00035932|Drug|Atazanavir + saquinavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
75766429|NCT00035932|Drug|Lopinavir/ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
75766430|NCT03953248|Drug|L-Carnitine|
75766431|NCT02530372|Device|UriCap-F|non-invasive urine collection device for women
75908160|NCT04960852|Other|a single shade structurally colored universal resin composite|Omnichroma is a single shade composite that is claimed to have blending effect with the tooth color, thus eliminate shade matching procedures during restorative treatment
76071153|NCT05370040|Biological|AAHI-SC2 Vaccine|AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine
76071154|NCT05370040|Biological|AAHI-SC3 Vaccine|AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine
76071155|NCT05370040|Biological|EUA or approved vaccine|Janssen or Pfizer vaccines (control arm)
75766432|NCT03953326|Behavioral|HeartPhone app|Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
75908161|NCT04431934|Dietary Supplement|PROBIOTIC|"Participants assigned to the probiotic arm will receive 2 sachets of Vivomixx® dissolved in 50 L of warm water (according to the manufacturer indications) every 12 h orally or through a nasogastric tube (in this case the tube will be flushed with 50 mL of water after the administration). The probiotic will be started 24 h after the last dose of NAA and will be administered for 14 consecutive days. Each sachet of Vivomixx® contains a combination of 4 Lactobacillus (L. paracasei 24733, L. acidophilus 24735, L. delbrueckii ssp bulgaricus 24734, L. plantarum 24730), 3 Bifidobacteria (B. brief 24732, B. longum 24736, B. infantis 24737), and Streptococcus thermophilus 24731 at a concentration of 450 billion (45x1010) live lyophilized bacteria per sachet."
75766433|NCT03953326|Drug|Acetylcholine|Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
75766434|NCT03953326|Drug|Sodium Nitroprusside|Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
75766435|NCT03953326|Drug|L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester|This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
75766436|NCT01097278|Dietary Supplement|cholecalciferol|Given orally
75908162|NCT04431934|Dietary Supplement|FMT REGIMEN|The FMT preparation will be administered as 2 doses, once a week, of 14-17 capsules per dose. Each dose (14-17 capsules) will contain the fecal microbiota equivalent to 50 gr of stools from a healthy donor. If the patient is carrying a nasogastric tube, the content of capsules will be decapsulized (~27 gr of powder), diluted in 50 mL of water and passed through it, followed by the administration of 50 mL of water to flush the tube. The first dose will be administered 24 h after the last dose of NAA and the second dose one week later. Whenever possible, the two doses of FMT will be originated from the same donor. According to our data done by flow cytometry and bacterial culture in three replicates, each absorbate capsule contains approximately 1.12x1010 live bacteria.
75908163|NCT04717128|Other|Breastfeeding Skills Workshop|Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
75908164|NCT02231502|Other|Vegetable-based convenience food|
75908165|NCT02231502|Other|Vegetable meal|
75908166|NCT04960774|Other|Observational study, no intervention|Observational study, no intervention
75908167|NCT02225496|Procedure|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.
75908168|NCT02225496|Procedure|Modified Barium Swallow (MBS)|MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.
75908169|NCT02225496|Behavioral|Questionnaires|Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
75316892|NCT05287061|Behavioral|Multicomponent Psychological Program (MPP)|"Patients will receive health pills during hospital admission. This intervention will be brief for individual application, but without specific content for each person, protocolized in its content and tools, and with a cognitive-behavioral orientation. Its therapeutic objective is to provide the patient with immediate control strategies for negative emotions and some pattern of active and positive coping. Two months after hospital discharge, the patients will also receive a multicomponent psychological program of a group nature. Based on motivational interviewing and positive psychology, with two blocks: emotions and consolidation of intentions. Two individual sessions will be carried out at the beginning to be able to do individual orientation, plan the intervention protocol, determine the objectives, the group intervention, and the specific action packages that the patient will receive."
75316893|NCT00379145|Drug|trabectedin|
75614734|NCT02663011|Other|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|"To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation."
75614735|NCT02659345|Behavioral|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
75766437|NCT01097278|Other|placebo|Given orally
75766438|NCT01096732|Drug|GDC-0449|Gelatine capsules of 150mg.Taken O.D. for 14 days.
75766439|NCT01097356|Dietary Supplement|probiotic drinkers|HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
75766440|NCT01100788|Dietary Supplement|Short chain fructo-oligosaccharide (scFOS) 5 g|"Dietary Supplement: scFOS 5 g~Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew."
75766441|NCT01100788|Other|Placebo|Treatment without scFOS fiber
75766442|NCT01100788|Dietary Supplement|Short chain fructooligosaccharide (scFOS) 8 g|Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
75908170|NCT04960696|Diagnostic Test|OSDI|Change of OSDI in distance education
75908171|NCT04960696|Diagnostic Test|tear break up time|Change of tear break up time in distance education
75908172|NCT04960696|Diagnostic Test|schirmer|Change of schirmer in distance education
75908173|NCT05057130|Drug|Doxorubicin, Cisplatin, Methotrexate|IV
75908174|NCT05057130|Drug|Doxorubicin, Cisplatin|IV
75908175|NCT04961008|Other|Bottle-PEP|A device that gives positive pressure from a bottle with the help of a non deflating tube
75908176|NCT04961008|Other|Routine physiotherapy|Routine pulmonary physiotherapy
75908177|NCT03677479|Procedure|socket preservation procedure|socket preservation of post extraction site using bone xenografts
75316894|NCT00382031|Drug|Zalutumumab|Individual dose titration weekly i.v doses
75316895|NCT00382031|Other|Control|Best Supportive Care
75766443|NCT01097434|Device|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
75766444|NCT01097434|Device|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
75766445|NCT00022516|Drug|Cyclophosphamide|50 mg/day orally continuously for 1 year
75766446|NCT00022516|Drug|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
75766447|NCT03953092|Drug|YG1699|YG1699 at Multiple Doses
75766448|NCT03953092|Drug|Placebos|Placebos
75766449|NCT01097512|Drug|AS703569/gemcitabine|"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
75766450|NCT01097512|Drug|AS703569/gemcitabine|"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
75766451|NCT01100866|Dietary Supplement|POMELLA™ (pomegranate extract)|in a capsule form, 2 x 500mg once daily
75766452|NCT01100866|Other|Placebo|placebo capsules
75766453|NCT01097590|Device|Active TLA Gut™ column|Five consecutive treatment sessions. The therapy will be administrated every second day.
75766454|NCT01097590|Device|Placebo|Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
75908178|NCT02222220|Drug|Metoclopramide|30 mg/day during 4 weeks
75908179|NCT02222220|Drug|placebo|
75316896|NCT04270799|Diagnostic Test|Machine Learning Classification|Patient's scans will be used as input into in-house software to extract multiple radiomics features. These features will be used to develop a risk-signature which can predict malignancy risk. Patient scans will also be used as input into deep learning/convolutional neural network models to perform automated imaging classification.
75316897|NCT00382265|Drug|tamsulosin|tamsulosin 0.4mg po qd for 28 days
75908180|NCT03059290|Device|neolix file|first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
75908181|NCT03677323|Device|Virtual reality|"The patient will have the choice between different environments and the use of this device will remain under the control of the medical team.~The patient will wear the virtual reality device at the time of the completion of the ankle block and will remove it once the nerve puncture is complete."
75316898|NCT00382265|Other|Placebo|placebo po qd for 28 days
75316899|NCT05286905|Device|Osteosynthesis cephalomedullary nail|Osteosynthesis of reverse oblique peritrochanteric fractures with cephalomedullary nail
75461807|NCT01856972|Other|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
75614736|NCT02659345|Behavioral|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
75908182|NCT03677323|Drug|Droleptan|Venous administration of 1.25 mg of Droleptan
75908183|NCT03677323|Drug|Propofol|Venous administration of 20 mg of Propofol
75908184|NCT03677323|Drug|Sufentanyl|Venous administration of 5 μg of Sufentanyl.
76071156|NCT05369962|Device|Ultrasound|Ultrasound measurements of the Qcsa
75316900|NCT05286905|Device|Osteosynthesis proximal femur locking plate|Osteosynthesis of reverse oblique peritrochanteric fractures with proximal femur locking plate
75316901|NCT01795001|Other|No intervention|
75461808|NCT01856985|Drug|Misoprostol|
75614737|NCT00918580|Biological|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
75614738|NCT02662855|Other|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
75614739|NCT02662855|Drug|Favipiravir|oral administration of Favipiravir tablets
75614740|NCT00648271|Drug|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
75316902|NCT00383747|Drug|transdermal nicotine patch|14mg transdermal nicotine application
75316903|NCT00383747|Drug|Transdermal Nicotine Patch|14mg transdermal nicotine application
75461809|NCT01856985|Drug|Mifepristone|
75461810|NCT01856998|Drug|Propofol|
75461811|NCT01856998|Drug|Diprivan|
75461812|NCT01857011|Drug|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
75461813|NCT01857011|Drug|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
75614741|NCT00648271|Drug|Lopressor® Tablets 50 mg|1x50mg, single dose fed
75614742|NCT04170127|Procedure|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
75614743|NCT00648349|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
75614744|NCT00648349|Drug|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
75614745|NCT04253938|Other|Education|Subjects will be provided education about AAP approved feeding practices for infants 1 to 12 months of age.
75614746|NCT00649207|Drug|ABT-888|Oral Capsules
75614747|NCT00649207|Radiation|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
75614748|NCT02662621|Other|blood samples|
75614749|NCT02662621|Other|Urine samples|
75766455|NCT00033514|Biological|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
75766456|NCT00033514|Drug|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
75766457|NCT00006916|Biological|bleomycin|
75766458|NCT00006916|Device|Ommaya reservoir|
75766459|NCT00006916|Radiation|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
75766460|NCT03952858|Other|Telerehabilitation Group|The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.
75766461|NCT02530138|Dietary Supplement|synbiotic|2 symbiotics capsules per day for 28 weeks
75766462|NCT02530138|Dietary Supplement|Placebo|2 placebo capsules per day for 28 weeks
75766463|NCT02529982|Dietary Supplement|Curcumin|
75766464|NCT02529982|Dietary Supplement|Placebo|
75766465|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel [200 milligram/square meter (mg/m^2)] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram*minute/milliliter (mg*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
75766466|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
75766467|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
75614750|NCT02663947|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
75614751|NCT00920686|Drug|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
75766468|NCT00454649|Drug|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
76071157|NCT05368649|Other|Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
75614752|NCT00920686|Drug|placebo|administered as 3 placebo hard gelatin capsules
75614753|NCT00920686|Drug|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
75614754|NCT00648427|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
75614755|NCT00648427|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
75766469|NCT00454649|Drug|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
75766470|NCT00454649|Drug|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m^2) 60-minute infusion on Day 1 of each cycle.
75766471|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
76071158|NCT05368376|Drug|Labetalol Hydrochloride Oral Tablet|Labetalol 200 mg
76071159|NCT05368376|Drug|Metoprolol Tartrate Oral Tablet|Metoprolol 100 mg
76071160|NCT05366751|Drug|SAGE-324|SAGE-324 oral tablets
75614756|NCT02656225|Drug|Ejiao compound|20ml,twice daily, orally after breakfast Duration:4 weeks
75614757|NCT02656225|Drug|Niferex|one tablet,once daily, orally after breakfast Duration:4 weeks
75614758|NCT04253470|Other|embryo transfer|Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
75766472|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
75766473|NCT00454649|Drug|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m^2) infusion on Day 1 of each cycle.
75766474|NCT00454649|Drug|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m^2) 10-minute infusion followed by cisplatin (75 mg/m^2) infusion on Day 1 of each cycle.
75766475|NCT00454571|Drug|pazopanib hydrochloride|Given PO
75908185|NCT02225574|Drug|MEK-162|"Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
75614759|NCT04170751|Drug|16 mcg / cc of norepinephrine(group N)|In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
75908186|NCT02225574|Drug|Nilotinib|"Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle."
76071161|NCT05364463|Procedure|Methods for cannulating the radial artery in a cardiac catheterization|The puncture will be performed in each participant according to the method has been assigned randomly: ultrasound and hyperemia, ultrasound only, hyperemia only, palpation.
76071162|NCT05360680|Drug|CUE-102|CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
75316904|NCT01421342|Drug|Switching: Bupropion-SR|Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
75908187|NCT02225574|Behavioral|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
75908188|NCT02625922|Drug|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
75316905|NCT01421342|Drug|Augmenting: Antidepressant + Bupropion-SR|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.~And~Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
75316906|NCT01421342|Drug|Augmenting: Antidepressant + Aripiprazole|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.~And~Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
75316907|NCT00403403|Drug|Bevacizumab|Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
75316908|NCT00403403|Drug|Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve [AUC]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
75614760|NCT04170751|Drug|0.4 unit / cc of vasopressin(group V)|In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
75908189|NCT02625922|Drug|Placebo|Matching placebo i.v infusion
75908190|NCT03679273|Dietary Supplement|Abound|Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
76071163|NCT05358171|Other|HIgh UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
75614761|NCT04865536|Drug|1800 mg TBI-223|3 x 600 mg SR1 tablets
75614762|NCT04865536|Drug|2400mg TBI-223|3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
75766476|NCT00454571|Drug|leuprolide acetate|
75766477|NCT00454571|Drug|goserelin acetate|
75908191|NCT02259192|Device|MED-EL Maestro Cochlear Implant|cochlear implant
75908192|NCT03619291|Other|Aerobic Exercise|walking on a treadmill at moderate intensity, total duration 15 minutes
75766478|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
75766479|NCT01323257|Drug|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
75766480|NCT01323257|Drug|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
75614763|NCT04865536|Drug|3000mg TBI-223|4 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
75908193|NCT03619291|Other|High-intensity functional training|functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes
75316909|NCT00403403|Drug|Placebo|Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
75316910|NCT03025568|Other|PEEK|PEEK (poly-ether-ether-ketone) has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth. Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
75316911|NCT03025568|Other|Bre.flex|In the recent time thermoplastic materials (breflex) become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus.
75461814|NCT01857024|Drug|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
75461815|NCT01857037|Other|Histoscanning™ and multiparametric MRI|Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
75461816|NCT01857076|Procedure|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
75461817|NCT01857076|Procedure|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
75461818|NCT01857076|Other|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
75461819|NCT01857089|Device|Orthotest CE|"Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.~Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.~Pressure measurement"
75461820|NCT01857128|Device|Drawtex dressing|
75461821|NCT01857128|Device|Negative Pressure Wound Therapy|
75461822|NCT01857141|Drug|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
75461823|NCT01857141|Drug|normal saline|patients in the control groups received the equivalent volume of normal saline.
75614764|NCT04865536|Drug|TBI-223 Placebo|3 x Placebo tablets
75614765|NCT04865536|Drug|TBI-223 Placebo|4 x Placebo tablets
75614766|NCT04865536|Drug|TBI-223 Placebo|5 x Placebo tablets
75614767|NCT02662465|Procedure|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
75614768|NCT02659111|Other|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
75614769|NCT02659111|Other|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
75766481|NCT01323257|Drug|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
75766482|NCT01323257|Drug|TMC435|50 mg capsule once daily for 7 days (Trt F)
75766483|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
75766484|NCT03837743|Drug|DUR-928 Topical Solution|Topical solution containing active drug
75766485|NCT03837743|Drug|Vehicle Topical Solution|Topical solution containing no active drug
75766486|NCT01323335|Drug|IV Uric Acid|
75766487|NCT01323335|Drug|IV Rasburicase|
75766488|NCT03836729|Drug|Tenofovir alafenamide/emtricitabine|TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.
75766489|NCT03836729|Drug|GSK3640254|GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
75766490|NCT01027481|Drug|Lucentis|intravitreally administration of 0.05 ml Lucentis
75766491|NCT00443729|Drug|Comparator: raltegravir|raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
75766492|NCT00443729|Drug|Comparator: placebo|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
75766493|NCT00443729|Drug|Comparator: lopinavir (+) ritonavir|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
75766494|NCT00443729|Drug|Comparator: placebo|raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
75908194|NCT03619291|Other|control|physical inactivity, reading sports science literature, total duration 15 minutes
75908195|NCT02259270|Other|Record review|Record review. No intervention with patient or physician. No effect on outcome.
75908196|NCT02259270|Other|AST-history|Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
75908197|NCT03059212|Device|rTMS|High frequency rTMS for 3 to 10 min to increase the excitability of cortex.
75908198|NCT03059212|Behavioral|Cognitive training program|A rehabilitation protocol that facilitates attention, memory, execution.
75908199|NCT03688477|Device|iovera°|iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
76071164|NCT05358171|Other|No UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
76071165|NCT05357144|Behavioral|Loyalty card program at drug shops & supply of HIVST and SRH products|"Consenting drug shops will receive:~training on Malkia Klabu implementation;~HIVST training (same as comparison drug shops);~procedures for referring to youth-friendly HIV/SRH services;~a monthly supply of HIVST reserved for free distribution to AGYW, with free price stickers and pre-packaged with referral information; and~reimbursement for SRH products given to AGYW (e.g., birth control pills)."
76071166|NCT05357144|Behavioral|Comparison drug shops|Consenting drug shops in the comparison arm catchment areas will have access to the Maisha Meds inventory management application system for offline digital recording of HIVST, HIVST kits earmarked for free to AGYW, guidance on HIV care referral plan to facilitate linkage to nearby health facilities for AGYW. These control drug shops will not participate in Malkia Klabu (Queen Club) program implementation.
76071167|NCT05356962|Behavioral|StOP?-protocol|The StOP?-protocol is an intra-operative briefing initiated by the responsible surgeon. When performing a StOP?-protocol, the surgeons inform the team present in the operating room about the Status (St) of the operation, the Objectives (O) of the operations, the potential problems (P) they may meet and encourage the team to ask questions or voice concerns (?). The responsible surgeon announces at the team timeout when they plan to perform the StOP-protocol(s).
75461824|NCT01857154|Dietary Supplement|Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate."
75766495|NCT00443651|Drug|Rituximab|Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
76071168|NCT05348317|Behavioral|VetReach|Telehealth-delivered MI-CBT substance use disorder care model
76071169|NCT05343130|Device|Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation activated by the brain-computer interface based on hand movement intention.
76071170|NCT05343130|Device|Sham Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation which activation will be independent of the brain-computer interface based on hand movement intention.
76071171|NCT05342402|Other|Somatosensory Rehabilitation Program|Somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
76071172|NCT05342402|Other|Educational Pain Management Program|Educational Pain Management Program includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
76071173|NCT05337228|Drug|IN-C006 Peri inj.|IN-C006 peri inj. will be injected continuously for 3 days.
75461825|NCT01857154|Dietary Supplement|Non-Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate."
75614770|NCT02656147|Biological|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
75614771|NCT04170049|Behavioral|Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )|Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
75766496|NCT00443651|Drug|Anti-inflammatory drugs|Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
75908200|NCT02225652|Drug|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
76071174|NCT05337228|Drug|RPN301|RPN301 will be injected continuously for 3 days.
76071175|NCT05329506|Other|patient population|questionnaires, standard of care
76071176|NCT05328076|Drug|Indocyanine green|Indocyanine green is used to perform intraoperative angiography.
75766497|NCT01027637|Other|5 mm vessel clips|evenly placed vessel clips placed at surgery and tracked by ultrasound
75766498|NCT03616067|Drug|Botox® injection|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars)
75766499|NCT03616067|Drug|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear.
75461826|NCT01857154|Dietary Supplement|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
75461827|NCT01857167|Dietary Supplement|Fish Oil Supplementation|
75461828|NCT01857167|Dietary Supplement|Flaxseed Oil Supplementation|
75766500|NCT01027247|Device|Ologen TM|
75766501|NCT01027715|Other|EEG monitoring and treatment of EEG seizures|Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
75766502|NCT01027325|Other|Dietary Intervention|Starch digestibility and carbohydrate quantity
75766503|NCT03029195|Device|Nasoalveolar molding therapy|Presurgical infant orthopedics
75766504|NCT00443261|Drug|Azacitidine|SC azacitidine
75766505|NCT00443261|Drug|Cisplatin|cisplatin 75 mg/m^2 day 8 every 28 days
75766506|NCT00439517|Drug|UFOX + Cetuximab|"Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)~Oxaliplatin infusion (85mg/m^2) on days 1 and 15 (every 2 weeks)~Oral UFT® (250mg/m^2 tegafur + 560 mg/m^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21~Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21"
75766507|NCT00439517|Drug|FOLFOX4 + Cetuximab|"Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)~Oxaliplatin infusion (85 mg/m^2) on days 1 and 15 (every 2 weeks)~5-FU bolus + infusions (400 mg/m^2) on days 1, 2, 15 and 16~Folinic Acid infusions (200 mg/m^2) on days 1, 2, 15 and 16"
75766508|NCT01031147|Other|Examination|3D-TOF-MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
75766509|NCT01031225|Drug|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
75461829|NCT01857167|Dietary Supplement|placebo|
75766510|NCT01028105|Other|Preoperative MRSA screening|MRSA preoperative screening and post operative infection rate, 30 days post operative
75766511|NCT01028261|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
75908201|NCT02222298|Procedure|Video assisted ablation of pilonidal sinus|A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.
75766512|NCT01031303|Biological|DTacP-IPV combined vaccine (TETRAXIM™)|0.5 mL, Intramuscular
75766513|NCT01028339|Drug|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
75766514|NCT01028339|Drug|Mannitol|Mannitol
75766515|NCT01028417|Device|Platinum microcoil|Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
75766516|NCT04700501|Other|Enjoy Your Bump - CBT life skills learning programme|Antenatal use of an online Cognitive Behavioural Therapy life skills learning programme to improve maternal feelings of anxiety and low mood.
75766517|NCT04695119|Other|Exposure is septic shock (defined according to Sepsis-III) and standard treatment according to departmental protocols.|Collection of data, biomarker and echocardiography analysis will be centralized and blinded. Assessment of endpoints will be blinded.
75908202|NCT02222298|Procedure|Bascom Cleft lift procedure|
75908203|NCT03059368|Device|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
75766518|NCT01031459|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
75766519|NCT03495791|Other|YouTube Video|Educational Video
75908204|NCT03461653|Other|Telemedicine counselling|women on web counselling
75908205|NCT04960462|Procedure|nerve root sleeve reinforcement|treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement
75908206|NCT02222376|Drug|Pirfenidone|Twice a day topical application
75908207|NCT02222376|Procedure|Debridement|Weekly ulcer debridement
76071177|NCT05328076|Device|SPY Portable Handheld Imaging (SPY-PHI)|The device is used to perform intraoperative angiography.
76071178|NCT05327270|Drug|Nivolumab|Given by IT
76071179|NCT05317806|Drug|Metformin Extended Release Oral Tablet|daily metformin treatment vs. no treatment with metformin
75766520|NCT00438815|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
75766521|NCT00438659|Drug|mometasone furoate|Applied to treatment area
75766522|NCT00438659|Other|placebo|Applied to treatment area
75766523|NCT01028495|Drug|RX-0201 plus Gemcitabine|RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
75766524|NCT00437645|Drug|Valsartan 160 mg capsules|
75766525|NCT00437645|Drug|Amlodipine 5 mg capsules|
75766526|NCT00437645|Drug|placebo|capsules
75461830|NCT01857180|Other|Curriculum|
75461831|NCT01857193|Drug|ribociclib (LEE011)|LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
75461832|NCT01857193|Drug|Exemestane|Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
75461833|NCT01857193|Drug|Everolimus (RAD001)|Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
75461834|NCT01857219|Behavioral|Tai chi|
75461835|NCT01857245|Other|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
75461836|NCT01857284|Drug|Tauroursodeoxycholic Acid Capsules|250mg.tid.po
75461837|NCT01857284|Drug|Ursodeoxycholic Acid Capsules|250mg.tid.po
75461838|NCT01857336|Other|infusion of G-CSF mobilized peripheral harvest|
75614772|NCT02659267|Behavioral|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
75908208|NCT03672799|Behavioral|Rehabilitation Planning Consult (RPC)|"Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC."
75908209|NCT03672799|Other|Wait list control (WLC)|"Participants who are allocated to WLC will complete a 12 week waiting period. At the end of the waiting period, participants will crossover to the RPC group.~Participants will be assessed at four time points, 1) Baseline assessment, 1 week prior to waiting period, 2) post-waiting period assessment, 1 week after waiting period, 3) post-intervention assessment, 1 week after RPC, and 4) follow-up assessment,13 weeks after RPC."
75908210|NCT04960540|Other|MRI,|"In this project, multi-modal brain imaging methods, such as resting-state functional MRI, task-state functional MRI, structural MRI and diffusion tensor imaging, will be used to analyze brain structure, gray matter morphology, white matter fibrous brain functional activation mode and brain functional connectivity network, and other dimensions.~In particular, combined with the brain functional activities of ALS patients in the cognitive processing task of language understanding and language use, the brain network damage of ALS patients in motor and executive function was compared, and the neural activities and network mechanism of specific changes in language cognitive processing in ALS patients were investigated. Combined with the clinical neuropsychological behavior evaluation data"
75908211|NCT02231658|Drug|Liraglutide|
75908212|NCT02231658|Drug|Lixisenatide|
76071180|NCT05317299|Other|3 different type of exercise|Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
75614773|NCT02659033|Drug|ceftriaxone|ceftriaxone (1 gram per day)
76071181|NCT05316142|Procedure|AGV implantation|This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world
76071182|NCT05309928|Drug|Amoxicillin|medication administration
76071183|NCT05309421|Drug|EVX-01|Investigational drug given in combination with standard of care
76071184|NCT05309421|Drug|Pembrolizumab 25 MG/ML|Standard of care
76071185|NCT05306925|Dietary Supplement|Arginine|The intervention infants will receive either parenteral nutrition which contains additional arginine (up to 18% arginine content) or a separate arginine infusion to provide up to 18% arginine. This is in comparison to standard parenteral nutrition which has an arginine content of 6.3%.
76071186|NCT05301036|Device|Diadem prototype|Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
76071187|NCT05300568|Other|No Intervention|This is a non-product related survey.
76071188|NCT05299099|Drug|IN-C006 inj.|IN-C006 will be injected continuously for 3 days.
76071189|NCT05299099|Drug|RCN301|RCN301 will be injected continuously for 3 days.
76071190|NCT05295056|Device|AFGen1 Device Wear Test|Participant wears the device for 7 days
76071191|NCT05295056|Device|AFGen 1 Device Single Use|Participant wears the device in conjunction with a standard ECG
76071192|NCT05293392|Behavioral|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|This is a multi-component intervention to increase COVID-19 vaccine uptake among youth that was co-created with community partners and refined with qualitative feedback from Black and Latino youth and parents. The intervention consists of culturally-tailored educational materials to increase awareness about the COVID-19 vaccine, culturally-sensitive communication strategies employed by pediatric primary care providers and community health workers, and strategies to facilitate and standardize access to the COVID-19 vaccine in the primary care clinic.
76071193|NCT05293392|Behavioral|Standard Care|Standard care includes routine offer of the COVID-19 vaccine and counseling about the COVID-19 vaccine by pediatric primary care providers.
75316912|NCT00405353|Drug|Androgel 10 grams of gel containing 100 mg of testosterone|testosterone gel
75316913|NCT01384760|Behavioral|Lifestyle modification|During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
75461839|NCT01857349|Other|Chlora Prep|Surgical Scrub skin preparation
75461840|NCT01857349|Other|Dura Prep|Surgical Scrub skin preparation
75614774|NCT02659033|Drug|Cefotaxime|cefotaxime (1 gram every 8 hours)
75316914|NCT01384760|Behavioral|Simple lifestyle advice|Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
75316915|NCT00406133|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor
75316916|NCT01384292|Drug|NKTR-118|12.5 mg oral tablet once daily
75316917|NCT01384292|Drug|NKTR-118|25 mg oral tablet once daily
75461841|NCT01857375|Device|Insulin Pen Device|Insulin pen was compared to administration of insulin using standard syringes.
75461842|NCT01857388|Behavioral|ParentCorps|
75461843|NCT01857401|Other|No intervention, observational study only|No intervention. We are collecting blood for an ex vivo study
75908213|NCT03677167|Other|walking on a treadmill|Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
75908214|NCT04959682|Other|Music Intervention|After rating levels of fatigue and relaxation, the professional health care musicians will play 30 minutes of patient-tailored, pleasant instrumental music with a combination of relaxing (on average 60-80 bpm) and lively, slightly more up-beat tempo to regulate arousal-levels
75908215|NCT04542408|Drug|Anticoagulation Agents (Edoxaban and/or high dose LMWH)|In-hospital (ICU & normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until
75908216|NCT04542408|Drug|Low dose Low molecular weight heparin or Placebo|In-hospital (ICU & normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
75908217|NCT03623581|Biological|GB226|3mg/kg treat every 2 weeks
75316918|NCT01384292|Drug|Placebo|Oral treatment
75316919|NCT02982707|Drug|BMS-986177|Single oral dose
75316920|NCT00450463|Drug|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
75316921|NCT00450463|Drug|Flutamide (Eulexin)|Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
75461844|NCT01857453|Drug|carboplatine|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
75461845|NCT01857453|Drug|Etoposide|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
76071194|NCT05291611|Behavioral|Online-based Cognitive-behavioral Therapy for OCD|26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
76071195|NCT05290727|Other|Aquoral Lipo (Esteve)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
75461846|NCT01857453|Radiation|radiation therapy|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
75908218|NCT03059134|Drug|Mirabegron 25mg|We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
75908219|NCT04959136|Device|Ambulatory Monitoring Solution|Aim is to evaluate PR; RR; NIBP, cNIBP, SpO2 and arterial blood pressure with investigational Ambulatory Monitoring Solution (AMS)
75908220|NCT04959214|Behavioral|progressive relaxation egzersize|Performing exercises in a quiet environment for 45 minutes with the Turkish Psychologists Association CD. Filling the PSQI and FSS before and 1 month after the application
75461847|NCT01857466|Procedure|Floseal|
75461848|NCT01857466|Procedure|Bipolar coagulation|
75461849|NCT01857479|Drug|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
75614775|NCT04170595|Biological|GB221,2 mg/kg|Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
75614776|NCT04170595|Biological|GB221,6 mg/kg|Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
75614777|NCT04170595|Biological|Herceptin,6 mg/kg|Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
75614778|NCT04170595|Biological|GB221,8mg/kg|Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes
75766529|NCT03477383|Diagnostic Test|donor-derived cell-free DNA (dd-cfDNA)|Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
75766530|NCT03465371|Other|CSC OnDemand Training Intervention|"Level 1: Readiness~Online readiness tool~Level 2: Core Knowledge~Week 1-self-paced core curriculum, totaling 8 hours of instruction~Level 3: Going Deeper~Week 2-instructor-led, role-specific, and advanced topics, totaling 12 hours of instruction~Level 4: Sustainability~9 months of online community of practice support; a discussion forum; open office hours with experts; multisite case conferencing; access to online materials"
75908221|NCT03672721|Drug|IA Carbo+ Radiation|combination of intraarterial carboplatin + radiation in dose escalation
75908222|NCT02225808|Behavioral|CBT for anxiety in autism|
75908223|NCT04959370|Device|internal fixation implantation of dynamic hip screw|Dynamic hip screws (DHS) are a femoral head-sparing orthopedic device used to treat femoral neck fractures.
75908224|NCT04959370|Device|internal fixation implantation of cannulated compression screw|Cannulated Screw is designed to provide a minimally invasive method of anatomical fixation.
76071196|NCT05290727|Other|Hyabak (Thea)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
75316922|NCT00450463|Biological|PROSTVAC-F/ TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.
75316923|NCT00450463|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
75908225|NCT02941237|Device|Pulse oximeter|"Time taken to measure oxygen saturation.~Completion of usability questionnaire"
75908226|NCT02222454|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
75908227|NCT04959292|Diagnostic Test|arthroscopy|arthroscopy
75908228|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
75908229|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
75908230|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
75908231|NCT04958980|Behavioral|Specific and educational guidelines on care for pathology (diabetes mellitus) according to each profession involved in the research|"Physician: Guidance on pathology, sequelae and treatment, as well as guidance on the importance of medical monitoring.~Dental surgeon: guidance on oral health, demonstration of brushing techniques and daily flossing and periodontal changes resulting from diabetes mellitus.~Nurse: Guidance on pathology prioritizing pathophysiology, self-care and skin care and wound prevention (vascular sequelae).~Nutritionist: nutritional guidelines on diabetes mellitus and healthy eating habits.~Physiotherapist: guidance on prevention of falls and injuries and health promotion.~Physical educator: guidance on the importance of practicing physical activities for general health, encouraging self-care and body awareness and demonstrating basic physical activities that can be performed at home."
75908232|NCT02222532|Drug|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
75908233|NCT02222532|Drug|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
75908234|NCT04959058|Device|Volunteer|An ultrasound machine will be used to calculate the elastographic value of the brachial plexus in three different positions.
75461850|NCT01857479|Drug|Inhaled amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].~The first dose will be administered under direct supervision."
75461851|NCT01857492|Device|tDCS|
75461852|NCT01857492|Behavioral|Meditation|Both Active and SHAM groups will receive Meditation.
75614779|NCT04170595|Biological|GB221:2mg/kg and Capecitabi:1000mg/kg|GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
75766531|NCT03465371|Other|InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
75766532|NCT03465371|Other|Virtual InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of virtual (via Zoom) in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of virtual (via Zoom) in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
75766533|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
75766534|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
75766535|NCT01028573|Drug|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
75766536|NCT01028573|Drug|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
75766537|NCT01028573|Drug|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
75766538|NCT01028573|Drug|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
75908235|NCT04958590|Radiation|whole spine X-ray|Group 1 underwent whole spine X-ray in standing and sitting positions.
75908236|NCT04958824|Diagnostic Test|Pharmacogenetic test|Pharmacogenetic test results for Cytochrome P450 genes are examined for markers of variant metabolism.
75908237|NCT02226042|Behavioral|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
76071197|NCT05290402|Other|JEEVA (new digital health navigator app)|An app can be used on a mobile phone or tablet.
75766539|NCT04683575|Drug|Selenium Yeast|oral medication
76071198|NCT05285202|Other|Active TB case finding with linkage to preventive therapy (ACF/TPT)|ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative for eligible for TPT (interested after counseling and either positive tuberculin skin test or known HIV infection).
76071199|NCT05283252|Device|3-D printed Guide|Guided Endodontic micro-surgery
75766540|NCT04683575|Drug|Placebo|oral medication
75766541|NCT01031615|Behavioral|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
75614780|NCT04170595|Biological|Herceptin:2mg/kg and Capecitabin:1000mg/kg|Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
75766542|NCT01031615|Behavioral|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
75766543|NCT00442559|Drug|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
75908238|NCT03672565|Behavioral|Phase One: Standardized Brief Intensive ERP|Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
75614781|NCT04511533|Drug|Dacomitinib|Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
75766544|NCT00442559|Drug|inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
75766545|NCT01031693|Device|Transcranial Magnetic Stimulation|daily sessions for 5 days
76071200|NCT05283252|Other|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
76071201|NCT05282953|Drug|KIO-301|KIO-301 intravitreal injection at ascending doses
76071202|NCT05278663|Drug|E6742|E6742 tablet.
76071203|NCT05278663|Other|Placebo|E6742-matching placebo tablet.
76071204|NCT05271604|Biological|Ozuriftamab Vedotin|Conditionally active biologic anti-ROR2 antibody drug conjugate
76071205|NCT05271604|Biological|PD-1 inhibitor|PD-1 inhibitor
76071206|NCT05270408|Device|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.
76071207|NCT05270408|Device|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.
75766546|NCT01323491|Drug|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
76071208|NCT05270408|Device|Sham Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
76071209|NCT05266079|Drug|Intervention Group|Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction
76071210|NCT05266079|Drug|Control Group|Er-Xian decoction
75316924|NCT00407381|Drug|Ranibizumab|Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
75316925|NCT00407381|Procedure|Laser photocoagulation|Laser photocoagulation in either focal or grid pattern as determined by investigator.
75766547|NCT00441701|Drug|Navarixin 1 mg|Navarixin 1 mg capsules
75766548|NCT00441701|Drug|Navarixin 10 mg|Navarixin 10 mg capsules
75766549|NCT00441701|Drug|Placebo to match navarixin|Placebo to navarixin capsules
75766550|NCT00441701|Drug|Rescue medication|Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
75766551|NCT00441545|Drug|Fosrenol (Lanthanum Carbonate)|The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.
76071211|NCT05265351|Diagnostic Test|Transdiaphragmatic pressure measurement|Ultrafast ultrasound imaging of the diaphragm during artificially evoked responses
76071212|NCT05265351|Diagnostic Test|EMG|Surface electromyography of the diaphragm for phrenic nerve conduction study
76071213|NCT05261646|Drug|Hetrombopag|"Stage 1： Hetrombopag lower dose； Hetrombopag higher dose~Stage 2:~Hetrombopag X mg (dose to be determined based on Stage 1 results)"
75316926|NCT00384449|Drug|Ranibizumab|Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
75316927|NCT01401062|Drug|Fresolimumab|
75316928|NCT01401062|Radiation|Radiation Therapy|
75316929|NCT00452335|Drug|Lubiprostone|12 mcg capsule once daily (QD)
75316930|NCT00452335|Drug|Lubiprostone|12 mcg capsule twice daily (BID)
75316931|NCT00452335|Drug|Lubiprostone|24 mcg capsule twice daily (BID)
76071214|NCT05261646|Drug|Matching placebo|Matching placebo（Stage 1；Stage 2）
75766552|NCT00441545|Drug|Sevelamer hydrochloride|The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
75316932|NCT00386243|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
75766553|NCT03995381|Other|Decision aids|Shared decision making with decision aids
75766554|NCT01031849|Drug|Kaletra|Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
75766555|NCT00436553|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 (Standard Fluence rate) or 25 J/cm^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
75908239|NCT03672565|Behavioral|Phase Two: Flexible Patient Driven Intensive ERP|"Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially)."
76071215|NCT05257278|Device|MonoPlus®|MonoPlus® is indicated for use in general soft tissue approximation, specially in cases where extended wound support of more than 4 weeks is desirable
76071216|NCT05255302|Drug|Pembrolizumab before randomization|Pembrolizumab 200 mg every 3 weeks before randomization
76071217|NCT05255302|Drug|Chemotherapy|Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
75316933|NCT00386243|Behavioral|Pain self-management program|The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
76071218|NCT05255302|Drug|Pemetrexed|Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
75316934|NCT00386243|Drug|Co-Analgesic Therapy|"Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram"
75316935|NCT00386243|Drug|Opioid Analgesics|Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
75316936|NCT01400516|Drug|Teriparatide|20 μg, subcutaneous injection, 1 injection per day
75316937|NCT01400516|Drug|calcium citrate|1000 mg of calcium citrate
75461853|NCT01857518|Other|-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI|"Visit V1: Diagnostic and clinical assessments~Visit V2: psycho-behavioral assessment and neuroimaging~Visit V3: Diagnostic and clinical assessments~Visit V4: psycho-behavioral assessment and neuroimaging"
75316938|NCT01400516|Drug|Vitamin D|800 IU of Vitamin D
75614782|NCT02662231|Procedure|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
75316939|NCT01400516|Drug|TNF antagonist|TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
75614783|NCT00648973|Drug|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
75316940|NCT01796275|Behavioral|Core intervention program|
75461854|NCT01857544|Drug|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
75614784|NCT00648973|Drug|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
75614785|NCT00648973|Drug|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
75614786|NCT02662309|Drug|MPDL3280A|Intravenous infusion
76071219|NCT05255302|Drug|Pembrolizumab after randomization|Pembrolizumab 200 mg every 3 weeks after randomization
75461855|NCT01857557|Other|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
75461856|NCT01857570|Radiation|Volume Computed Tomography of the wrist and carpus|
75461857|NCT01857596|Drug|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
75461858|NCT01857609|Drug|Metformin|
75461859|NCT01857609|Drug|Metformin and Pantoprazole|
75766556|NCT00436553|Drug|Ranibizumab|Ranibizumab 0.5 mg administered as an intravitreal injection.
75766557|NCT00436553|Drug|Verteporfin Placebo|To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
75766558|NCT00436553|Drug|Ranibizumab Placebo|To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
76071220|NCT05249387|Drug|A-967079 and BAM8-22 application|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
75614787|NCT02658955|Procedure|Short stitch|Surgeons will receive instructions to change the technique of abdominal wall closure
75316941|NCT01796275|Behavioral|Booster session|
75614788|NCT02655835|Behavioral|Internet Mindfulness Meditation|
75766559|NCT00441467|Drug|Glufosfamide|5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
75908240|NCT03672565|Behavioral|Follow-Up Phase: Booster Calls|Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
75908241|NCT02258646|Behavioral|Exercise training at home|
75316942|NCT01796275|Behavioral|Control only (Tea gathering)|
75614789|NCT02655835|Behavioral|Access|
75908242|NCT02258646|Behavioral|Telemonitoring and education/self-management|
75908243|NCT02919163|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
75908244|NCT02231970|Procedure|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
75908245|NCT02855814|Other|Body Composition|No intervention. This is an observational, normative study of body composition variation in preterm infants
75908246|NCT03623425|Drug|68Ga-PSMA-11 PET|a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
75908247|NCT03623425|Drug|18F-FCH PET|a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
75908248|NCT02232048|Other|Transthoracic Echocardiogram|
75908249|NCT04958512|Drug|Yangxue Qingnao pill|The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
75908250|NCT04958512|Drug|Hydergotoxine mesylate tablets|The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
76071221|NCT05249387|Drug|A-967079 and BAM8-22 application after 5 minutes.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
76071222|NCT05249387|Drug|A-967079 application.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
75316943|NCT01796431|Drug|Eviplera®|
75316944|NCT01383356|Drug|Metformin Single Tablet|Metformin medium doseTablet
75316945|NCT01383356|Drug|Linagliptin/Metformin Combo|Fixed dose combination
75316946|NCT01383356|Drug|Linagliptin Single Tablet|Linagliptin Single medium dose Tablet
75316947|NCT02111447|Drug|Propofol|Propofol infusion with nasal oxygen
75316948|NCT02111447|Drug|Propofol|Propofol infusion with an LMA
75316949|NCT02111447|Drug|Sevoflurane|Sevoflurane with an LMA
75316950|NCT02111447|Drug|Isoflurane|Isoflurane with an LMA
75461860|NCT01857609|Drug|Metformin and Rabeprazole|
75908251|NCT04958512|Other|blank control group|There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
75908252|NCT03672409|Behavioral|Intervention in knowledge|"The knowledge intervention will be done through four group learning sessions with the objective of significantly increasing diabetes knowledge in health professionals.~The learning sessions will be carried out weekly in a period of 4 weeks, with a duration of 60 minutes per session. In addition, two sessions will be held for the evaluation of pre and post intervention knowledge. The learning sessions consist in the diagnosis, evaluation, complications and comorbidities, pharmacological treatment and nutrition in type 2 diabetes."
75316951|NCT01796821|Drug|Vehicle gel|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application <1,500 mg gel per day."
75316952|NCT01796821|Drug|SR-T100 gel with 1.0 % SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application <1,500 mg gel per day."
75316953|NCT01796821|Drug|SR-T100 gel with 2.3% SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application <1,500 mg gel per day."
75316954|NCT05966545|Procedure|pars plana vitrectomy and intraocular foreign body removal|removal of vitreous body and attachment to foreign body then extraction of foreign body
75316955|NCT05966493|Drug|lufepirsen|Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
75316956|NCT05966493|Drug|Vehicle|Matching vehicle without lufepirsen.
75316957|NCT05966454|Drug|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
75316958|NCT05966454|Drug|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
75461861|NCT01857648|Other|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
75461862|NCT01857661|Device|sound generator|hearing aid with an integrated sound generator
75461863|NCT01857661|Device|hearing aids with only amplification|
75461864|NCT01857700|Other|Compensation for transport cost|
75461865|NCT01857700|Other|Compensation for lost wages|
75461866|NCT01857700|Other|Compensation for transport cost and lost wages|
75461867|NCT01857700|Other|Standard of Care|Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
75461868|NCT01857726|Drug|Doxorubicin|Transarterial chemoembolization (TACE) with adriamycin
75766560|NCT01028729|Drug|Endostar|7.5mg/m2/day, iv, from day 1 to day 14
75766561|NCT01028729|Drug|Gemcitabine-Cisplatin chemotherapy|Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
75908253|NCT02222766|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 sessions offered weekly
76071223|NCT05249387|Drug|Vehicle and BAM8-22 application.|Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
75908254|NCT02222766|Behavioral|Control|Minimal attention control- 9 weekly mailed information on general child development
75908255|NCT04957888|Other|none intervention|none intervention.
76071224|NCT05249322|Other|Follow-up alternating between face-to-face consultation and teleconsultation every three months.|"The intervention will be an alternate follow-up every three months with:~A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine.~An usual in-hospital consult of about 1h30 with paramedical and medical consult."
76071225|NCT05248269|Procedure|Radiofrequency thermocoagulation|The 2 pertinent contacts connect to Radiofrequency thermocoagulation lesion-generator equipment (Cosman G4 with Ad-tech electrodes), expressly modified for use with SEEG electrodes. The following parameters will be adopted: current power 3 W within 180 seconds and current intensity (usually approximately 25 mA) variable according to impedance.
75908256|NCT03678961|Behavioral|external rotation of leg|external rotation of leg by 45 degrees
76071226|NCT05243550|Drug|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
75908257|NCT03678961|Behavioral|hip flexion and knee flexion|hip flexion by 15/45 degrees and knee flexion by 15/45 degrees
75908258|NCT04957576|Behavioral|Visuo-tactile stimulation|The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.
75316959|NCT05966441|Dietary Supplement|Curcumin|"The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders.~Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress.~Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily"
75614790|NCT02662075|Device|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
75461869|NCT01857726|Drug|Cisplatin|transarterial chemoinfusion with cisplatin 50-100 mg
75461870|NCT01857752|Drug|Temozolomide|
75614791|NCT02661919|Device|Emfit mattress sensor|Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
75766562|NCT03357419|Drug|Cephalexin|"The subjects will be randomized, at the operation day, to one of two treatment groups:~group 1: prophylactic antibiotic~group 2: placebo oral capsule~Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
75766563|NCT03357419|Drug|Placebo oral capsule|"The subjects will be randomized, at the operation day, to one of two treatment groups:~group 1: prophylactic antibiotic~group 2: placebo~Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
75766564|NCT01031927|Drug|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
75766565|NCT01028807|Other|Early feeding|after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
75766566|NCT01028807|Other|5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
75766567|NCT01028885|Procedure|radiation therapy treatment planning/simulation|
75316960|NCT05966441|Drug|Paclitaxel|"Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV..~Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV."
75461871|NCT01857765|Behavioral|Rehabilitation|Range of motion stretching exercises
75461872|NCT01857765|Behavioral|Follow-up|Follow-up with surgeon's clinic
75461873|NCT01857791|Behavioral|multidisciplinary, behavior modification|
75461874|NCT01857804|Drug|Amoxicillin|In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
75461875|NCT01857804|Drug|Chlorhexidine gluconate|The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
75461876|NCT01857804|Drug|Saline|The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
75614792|NCT04032691|Drug|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
75766568|NCT01028885|Procedure|intensity-modulated radiation therapy|
75614793|NCT02658799|Drug|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
75766569|NCT01028885|Procedure|image-guided radiation therapy|
75766570|NCT01028885|Procedure|magnetic resonance imaging|
75766571|NCT01028885|Procedure|computed tomography|
75908259|NCT03672253|Drug|CAR-T Re-treatment|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
75908260|NCT04957810|Behavioral|WeChat Mini Program|Through the WeChat applet, it provides services such as visit content configuration, self-image configuration, self-image measurement configuration, and visit reminders.
75766572|NCT01032005|Other|double fortified salt|Refined salt of particle size < 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
75766573|NCT01032083|Drug|Citalopram|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
75766574|NCT01032083|Drug|Placebo|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
75766575|NCT00436163|Drug|Peginterferon alfa-2a|180 mcg subcutaneously once per week for 48 weeks.
76071227|NCT05243290|Dietary Supplement|Nicotinamide Riboside|The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.
76071228|NCT05243290|Dietary Supplement|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.
76071229|NCT05240599|Procedure|Exercise Training|Exercise training will be applied in sets of 10x3, 3 times a day for 8 weeks.
76071230|NCT05239546|Drug|Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years
76071231|NCT05236517|Drug|Semaglutide D Dose 1|Tablet given orally
75316961|NCT05966428|Other|Conventional Exercises|"This conventional exercises included stretching and strengthening, balance-coordination, mobility and range of motion exercises.~The control group received conventional therapy 3 days a week for 8 weeks. Each therapy session a day lasted 45 minutes in control group."
75316962|NCT05966428|Other|Sensory Integration Therapy|"The Sensory Integration Therapy was applied to the intervention group in addition to the conventional exercise program. Sensory Integration Therapy included tactile, proprioceptive, and vestibular activities. The tactile sensory activities consisted of materials such as stepping stones, tactile box, brushing, fabric walking path. The vestibular sensory activities consisted of materials such as hammock swings, trampolines, rope nets, rock walls, river stones. Proprioceptive sensory activities consisted of materials such as weight bearing activities, heavy lifting, deep pressure, big ball activities, tug of war and ball pits.~The intervention group underwent each session 45 minute conventional therapy and 15 minutes SIT. The therapy program continued 3 days a week for 8 weeks in intervention group."
75316963|NCT05966415|Dietary Supplement|Endocalyx Pro|4 capsules once daily OR 2 capsules twice daily.
75766576|NCT01029041|Other|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
75766577|NCT01029041|Other|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
75461877|NCT01857817|Drug|VT-122|The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
75614794|NCT02658799|Drug|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
75766578|NCT00006604|Drug|ATV|Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
75908261|NCT02226354|Dietary Supplement|Ahiflower oil|9.73 ml per day for 28 days
75908262|NCT02226354|Dietary Supplement|Flaxseed oil|9.73ml per day for 28 days
76071232|NCT05236517|Drug|Semaglutide D Dose 2|Tablet given orally
76071233|NCT05236517|Drug|Semaglutide D Dose 3|Tablet given orally
76071234|NCT05236517|Drug|Semaglutide C Dose 4|Tablet given orally
76071235|NCT05236517|Drug|Semaglutide C Dose 5 (50 mg)|Tablet given orally
76071236|NCT05236517|Drug|Placebo (Semaglutide C)|Tablet given orally
76071237|NCT05236517|Drug|Placebo ( Semaglutide D)|Tablet given orally
76071238|NCT05236127|Other|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
75316964|NCT05966415|Other|placebo|4 capsules once daily OR 2 capsules twice daily
75316965|NCT05966402|Other|Virtual Reality|Immersion in Virtual Reality
75316966|NCT05966389|Other|No interventions|No interventions
75316967|NCT05966363|Radiation|Nanodot|Radiation measurements using nanodots placed on the eyes, ears, neck and lower abdomen during an imaging examination.
75614795|NCT02536885|Procedure|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
75316968|NCT05966350|Diagnostic Test|Diagnosis of sensitive neuronopathy - phase 1|Search of positivity with anti-AGO antibodies test
75316969|NCT05966350|Diagnostic Test|Diagnosis of sensitive neuronopathy - phase 2|Title of anti-AGO antibodies
75316970|NCT05966350|Other|Comparison with Chi2 method|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a Chi2 method for qualitative data.
75614796|NCT02536885|Procedure|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
75766579|NCT00006604|Drug|Ritonavir|Administered as 100 mg capsules or oral solution.
75766580|NCT03951376|Behavioral|UPRIGHT intervention|The UPRIGHT intervention design consists of two different phases consecutively implemented in two school years: intensive phase and follow-up phase. During the intensive phase, all stakeholders are trained in the UPRIGHT WELL-BEING FOR US programme (18 skills). The follow-up phase (WELL-BEING FOR ALL) intends not only to maintain the effect of the intensive training in youths, but also to boost the positive mental health atmosphere created in the whole school. To do so, different collective activities will be organized at school level such as celebration of thematic days, activities with the community, and outdoor/indoor activities.
75766581|NCT01097902|Drug|Ibuprofen|800 mg oral one time only
75908263|NCT04957654|Other|VST with collagen plug soaked in blood|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with collagen plug soaked in blood
75908264|NCT04957654|Other|VST with Allograft Demineralized bone matrix Grafton|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with Allograft Demineralized bone matrix Grafton
75316971|NCT05966350|Other|Comparison of data with parametric Test (T-test)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography, evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a parametric test (T-test).
75316972|NCT05966350|Other|Comparison of data with non-parametric test (ANNOVA)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a non-parametric (ANNOVA).
75316973|NCT05966337|Procedure|CPAP|Use of non-invasive ventilation in patients in group 2 with CPAP.
75316974|NCT05966337|Procedure|BIPAP|Use of non-invasive ventilation in patients in group 3 with BIPAP.
75316975|NCT05966337|Procedure|Usual care in phisicaltherapy|Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol
75316976|NCT05966207|Behavioral|Individual Cognitive Stimulation|"The Individual Cognitive Stimulation will be conducted by caregivers, with support by the research team. The intervention will span 12 weeks, consisting of three weekly sessions (30 minutes each session), totaling 36 sessions. Caregivers in this study will utilize a previously translated and validated version of Making a Difference 3 - Individual Intervention of Cognitive Stimulation - A manual for caregivers, specifically adapted for the European Portuguese population."
75461878|NCT01857817|Drug|Placebo|The placebo capsules will be prepared to match the active drug.
75461879|NCT01857830|Behavioral|Meditation Retreat|The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
75461880|NCT01857830|Behavioral|Active Comparator Relaxation Group|Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
75461881|NCT01857843|Device|Zotalolimus Eluting Stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1."
75614797|NCT02655757|Drug|Sitagliptin|5 mg, 1 tablet per day for 12 months
75614798|NCT02655757|Drug|Placebo|Placebo,1 tablet per day for 12 months
75766582|NCT01097902|Drug|Placebo tablet|Placebo tablet oral one time only
75766583|NCT00436007|Biological|GSK 257049|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
75766584|NCT00436007|Biological|Tritanrix™ HepB/Hib|GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
75316977|NCT05966181|Behavioral|experimental group|"Experimental Group-Repetitive Simulation~First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation."
75908265|NCT04957654|Other|VST with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles
75908266|NCT02223000|Drug|BIBV 308 SE solution|
76071239|NCT05236127|Other|Intermittent Fasting|The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
76071240|NCT05230251|Drug|177Lu-PNT2002|Men randomized to receive 177Lu-PSMA will receive 1 cycle of 177Lu-PSMA at a dose of 6.8MBq administered intravenously 2 weeks prior to the planned HDR administration in the Department of Nuclear Medicine as per local practice for the administration of therapeutic radiopharmaceuticals and consistent with good practices.
76071241|NCT05230251|Radiation|High Dose Radiation|HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.
75316978|NCT05966064|Drug|Denosumab 120 Mg/1.7 Ml Inj|Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label
75614799|NCT02661841|Other|LI-Guided Therapy|Preemptive treatment according to LI monitoring
75316979|NCT05966064|Drug|Placebo|placebo randomized at baseline and after 3 months
75908267|NCT02223000|Drug|BIBV 308 SE capsule 1|
75908268|NCT02223000|Drug|BIBV 308 SE capsule 2|
75316980|NCT05966012|Drug|Tranexamic acid|Recent data suggests that antifibrinolytics like tranexamic acid (TXA) might be able to lessen the inflammation of the nervous system caused by surgery and CPB through the inhibition of plasmin production, thereby stabilising the blood brain barrier.
75316981|NCT05965999|Device|EsoCheck|EsoCheck® (EC) is an FDA 510(k) cleared device that is indicated for use in the collection and retrieval of surface cells of the esophagus in the general population 12 years of age and older.
75316982|NCT05965986|Other|Experimental: PREPS only|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative."
75461882|NCT01857843|Device|Everolimus eluting stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1."
75766585|NCT00436007|Biological|Rouvax™|Aventis Pasteur's attenuated measles vaccine.
75614800|NCT02661841|Other|Heart Failure Guidelines|Treatment according to clinical signs
75614801|NCT01214720|Drug|bevacizumab [Avastin]|Intervenous repeating dose
75614802|NCT02655991|Behavioral|Telephone Case Monitoring|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
75614803|NCT02655991|Behavioral|Treatment as Usual|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
75766586|NCT00436007|Biological|Stamaril™|Aventis Pasteur's attenuated yellow fever vaccine.
75766587|NCT00436007|Biological|Polio Sabin™|GSK Biologicals' oral polio virus vaccine
75766588|NCT01032317|Device|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
75908269|NCT04957420|Drug|Neupro|Rotigotine Patches
75908270|NCT03350035|Drug|IV Ganaxolone active|IV
75908271|NCT03350035|Drug|IV Placebo, non-active|IV
75908272|NCT02223078|Biological|G17DT|
75461883|NCT01857843|Drug|Ezetimibe 10mg & Simvastatin 40mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~Pravastatin 20mg (mevalotin®, BMS)"
75766589|NCT01029197|Behavioral|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
75614804|NCT02655913|Drug|vitamin C|Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
75614805|NCT02655913|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
75766590|NCT01029197|Other|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
75614806|NCT02655913|Other|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
75766591|NCT01032395|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
75766592|NCT01032395|Biological|Fluad®|15 ug of HA antigen; adjuvanted; trivalent
75766593|NCT01032395|Biological|Begrivac®|15 ug of antigen; non-adjuvanted; trivalent
75908273|NCT02223078|Biological|Placebo Comparator|
75908274|NCT04957108|Other|Device identification using Xray.|PMIDa and CRMD-f applications were used to identify CIED
75908275|NCT02905188|Genetic|GLYCAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10^7/m2~DL2: 3x10^7/m2~DL3: 1x10^8/m2~DL4: 3x10^8/m2~DL5: 1x10^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
76071242|NCT05222685|Behavioral|Better Together Physician Coaching|Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
76071243|NCT05213806|Other|Withholding feeds around transfusion|Withholding enteral feeds for preterm infants (<30 weeks) around the time of blood transfusions to determine if any impact on the development and/or severity of Necrotizing Enterocolitis.
76071244|NCT05213806|Other|Continued feeds around transfusion|Continued enteral feeds
75461884|NCT01857843|Drug|Pravastatin 20mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~Pravastatin 20mg (mevalotin®, BMS)"
75614807|NCT00649285|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
75766594|NCT00435461|Drug|Fluticasone furoate and fexofenadine|Fluticasone furoate and fexofenadine
76071245|NCT05213559|Other|wheat biscuit enriched with plant proteins|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins
75461885|NCT01857856|Drug|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
75461886|NCT01857895|Drug|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
75614808|NCT00649285|Drug|Macrobid® Capsules 100 mg|100mg, single dose fed
75614809|NCT04318574|Other|Balance, Agility, Strengthening Exercise (BASE) Class|The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
75614810|NCT02661685|Biological|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
75614811|NCT04169269|Drug|Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters|anticoagulant, subcutaneous injection
75614812|NCT04169269|Drug|Rivaroxaban 10 milligram Oral Tablet|anticoagulant, oral
75766595|NCT01097980|Drug|Trazodone|50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained
75766596|NCT01097980|Drug|Placebo|Placebo
75766597|NCT01029275|Drug|Pre-treatment with octreotide|Pre-treatment with octreotide
75766598|NCT01098058|Other|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
75766599|NCT01098058|Other|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
75766600|NCT03994445|Behavioral|Mobile Phone-Based Intervention|"We propose our intervention based on social cognitive behavior theories and the stages of the change model.~The program will be carried out using the word Mettle, it will help ex-smokers stay off cigarettes through advices generated to promote the health from religious concepts and culture perspectives ."
75908276|NCT02905188|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
75908277|NCT02905188|Drug|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
75908278|NCT03676933|Drug|DS107E|
75908279|NCT03676933|Drug|Vehicle|
75908280|NCT03676933|Drug|Hydrocortisone Butyrate 0.1% Cream|Steroid taken topically once a day
76071246|NCT05213559|Other|common wheat biscuit|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
76071247|NCT05210751|Other|Physical and psychosocial assessments|Dual Task Test, 6 min Walking Test, the Baecke Habitual Physical Activity Questionnaire, Multidimensional Fatigue Inventory-20, Tracking Test, General Self-Efficacy Scale the Toronto Alexithymia Scale, the Revised FM Impact Questionnaire, the Social Support Scale.
75908281|NCT04957030|Diagnostic Test|ULDCT group|underwent ultralow-dose chest CT
75908282|NCT02232204|Behavioral|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
75766601|NCT01029431|Device|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted & the evaluation described below will be conducted. The first LMA will then be removed & the other device inserted & assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment & before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, & inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
75766602|NCT00434759|Behavioral|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
75908283|NCT03671941|Drug|D578|D578 Tab.1T single oral administration under fasting condition
75908284|NCT03671941|Drug|CKD-357|CKD-357 Tab.1T single oral administration under fasting condition
75908285|NCT03058900|Drug|Fecal microbiota transplantation (FMT)|One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
75908286|NCT03058900|Other|Drug: Placebo (saline)|One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
75908287|NCT03058900|Drug|Methotrexate (MTX)|Weekly methotrexate in maximum tolerable dosis
75908288|NCT02226510|Drug|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
75908289|NCT02226510|Drug|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
75908290|NCT03676855|Procedure|bladder dissection|Comparison between bladder dissection at the beginning of cesarean section For morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy
76071248|NCT05200702|Device|Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland)|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
76071249|NCT05199246|Device|Lower-limb powered dermoskeleton|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
76071250|NCT05193552|Drug|Hizentra|subjects level of IGRT will be adjusted for bioavailability as per manufacturer's instructions
76071251|NCT05190081|Other|TASK TRAINING|A special program including motor and cognitive tasks was prepared. Both lower and upper extremity motor tasks and verbal, arithmetic, auditory, and visual cognitive tasks were planned based on evidence. The dual-task and single-task training were held 2 days a week, 40 minutes, for a total of 10 sessions for 5 weeks. A patient-appropriate task was selected for each cognitive task each week.
76071252|NCT05188703|Behavioral|Patient Navigation|Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.
76071253|NCT05187819|Diagnostic Test|predictive value of a blood test|Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.
75316983|NCT05965986|Other|Experimental: PREPS and therapy|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative. In addition, participants will have a therapist call on week 2 and 4 of the program and then one week after surgery to check in and ensure the patient is meeting all milestones and answer any questions."
75461887|NCT01857921|Drug|Pravastatin 20mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~Test group:~Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~Control group:~Pravastatin 20mg daily for 12 months after randomization"
75614813|NCT02655367|Other|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
75614814|NCT02655367|Other|Milled oats|Test meal consisting of 264g porridge made with milled oats
75614815|NCT02661529|Procedure|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
75908291|NCT04956874|Behavioral|FL-REACH|The FL REACH intervention is a 6-session intervention designed to facilitate transition to care following delivery of a memory disorders diagnosis by a MDC team. The intervention focused on an approach that used a toolbox of strategies to tailor skills-based learning, knowledge transmission, and self-care strategies to dementia caregivers. This pilot study focuses on adapting the established REACH II intervention for translation to the clinical setting, with a focus not only on implementation of the key components of the program, but also on feasibility and sustainability. This is part of a stepped-care model that is being developed at the AdventHealth-Orlando MDC. Caregivers of patients will be referred to the FL REACH intervention for foundational training and skills-development.
75908292|NCT02225886|Drug|Ascorbic Acid|300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
75908293|NCT04956328|Drug|Obeticholic Acid Tablets|Obeticholic Acid：Once a day (QD) by mouth (PO).
75908294|NCT04956328|Drug|UDCA|UDCA：continue prestudy dose
75908295|NCT04956328|Drug|Placebo|Placebo
75316984|NCT05965973|Other|Low fat diet|During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat
75316985|NCT05965973|Other|High fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat
75316986|NCT05965947|Behavioral|Medical Nutrition Therapy|One-on-one nutrition assessment, education, and counseling with a Registered Dietitian.
75614816|NCT02661529|Procedure|Transthoracic Echocardiogram (TTE)|"An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.~Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall."
75614817|NCT02661529|Other|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
75766603|NCT00434759|Behavioral|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
75766604|NCT01029509|Drug|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
75766605|NCT04829903|Drug|Dulaglutide|Dulaglutide injections
75766606|NCT04829903|Drug|Liraglutide|Liraglutide injections
75766607|NCT01032551|Behavioral|Vascular Access Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
75766608|NCT00440999|Drug|Pyronaridine artesunate|
75766609|NCT00440999|Drug|Chloroquine|
75766610|NCT00434213|Drug|Daytrana|Methylphenidate Transdermal System (MTS)
75766611|NCT01029743|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
75766612|NCT01029743|Drug|Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)|Daily dose, dosage frequency and duration will be decided by physicians
75766613|NCT01032785|Device|no interventions|no interventions
75766614|NCT01029821|Drug|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
75908296|NCT02223234|Behavioral|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
75908297|NCT02223234|Behavioral|Control|Monthly emails on child health
75908298|NCT02223234|Behavioral|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
75316987|NCT05965934|Drug|Direct Sodium Removal Infusate 2.0|Direct Sodium Removal via peritoneal ultrafiltration using Infusate 2.0 (30% icodextrin, 10% dextrose). Patients (if not yet on SGLT-2 inhibitors) will receive SGLT-2 inhibitors.
75908299|NCT03671863|Other|Invasive analysis (caryotype, CGH array)|Invasive analysis (caryotype, CGH array)
75908300|NCT03671863|Other|Prenatal management|Prenatal management
75316988|NCT05965830|Device|Diaphragm ultrasound|A single, simultaneous assessment of the diaphragm muscle functioning through dEMG and dUS at the time of spontaneous breathing.
75316989|NCT05965804|Diagnostic Test|McMurray knee examination test|The McMurray test will be performed in different knee flexion and rotation angles.
75316990|NCT05965791|Diagnostic Test|Phalen's wrist flexion test|The Phalen's test will be performed at different wrist flexion angles from 0 to 90 degrees.
75316991|NCT05965778|Device|T2769|T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle.
75614818|NCT02661529|Other|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
75766615|NCT00006184|Drug|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
75614819|NCT02661373|Drug|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
75908301|NCT02223312|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
75908302|NCT03676699|Diagnostic Test|Ultrasound chest|Ultrasound detection of extravascular lung water
75908303|NCT04426656|Behavioral|Phone application|"The mini-app (used in Part 2) has four main functions:~a knowledge center that contains a series of HIV-, sexual health-, and PrEP-related educational articles in Chinese;~an HIV self-test toolkit ordering system that allows users to order a finger-prick HIV rapid test toolkit and shipped to home for free (one piece at a time);~an asynchronous message function that allows users to chat with a study staff (C.Li); and~a user profile page where users can manage all HIV test orders."
75908304|NCT04955782|Behavioral|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability|"The volume will be measured by weighing the sample in the container in which it has been collected, it will be a pre-weighed container. The volume will be assessed by aspirating the sample using a non-toxic pre scaled surgical pipette.~The samples will be liquified in an incubator at 37 C. Complete ejaculate liquefaction is normally achieved within 15-30 minutes at room temperature (WHO2010).~pH will be analyzed 30 minutes after collection. pH test strips in range of 6.0-10.0 will be used. A value under 7.0 will indicate lack of alkaline seminal vesicular fluid (pH-Fix 0-14 from Macherey-Nagell,Germany).~The samples concentration and motility will be analyzed in laboratory by Neubauer chamber, morphology will be assessed by RAL Diff-Quik kit (3x0.5L) from RAL Diagnostics, France as per the manufacturers' recommendation.~Vitality will be analyzed by Vital screen, FertiPro N.V. Belgium,as per guidelines of manufacturer"
75908305|NCT03058822|Drug|BMS-931699|BMS-931699 single subcutaneous dose on Day 1
75461888|NCT01857921|Drug|Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~Test group:~Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~Control group:~Pravastatin 20mg daily for 12 months after randomization"
75614820|NCT02661373|Drug|Cobicistat|Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
75316992|NCT05965778|Device|Vismed® Multi|Hyaluronic acid
75316993|NCT05965765|Diagnostic Test|Total knee arthroplasty|who got total knee arthroplasty because of osteoarthritis
75316994|NCT05965765|Diagnostic Test|osteoarthritis without surgery|who has osteoarthritis and didn't get any surgery
75316995|NCT05965765|Diagnostic Test|control group|healthy people
75461889|NCT01857947|Other|AECOPD Mr proADM|
75316996|NCT05965713|Device|Neurolutions IpsiHand System|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
75316997|NCT05965713|Other|Standard of Care - Home Exercise Program for Upper Extremity|Subjects will receive a customized home range of motion exercise program. Subjects will be recommended to complete their exercises daily, 5 out of 7 days per week for 12 weeks
75614821|NCT00649051|Drug|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
75316998|NCT05965674|Procedure|Sacral Erector Spinae Plane Block|The transducer will be placed 3-4 cm laterally to the second medial sacral crest in order to visualize the intermediate sacral crest. In the interfascial plane, a total of 20 mL of local anesthetic solution (comprised of 10 mL bupivacaine 0.5%, 5 mL lidocaine 2%, and 5 mL normal saline) will be injected between the erector spinae muscles and the intermediate sacral crest. The same procedure will be performed on the contralateral side.
75461890|NCT01857960|Behavioral|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
75614822|NCT00649051|Drug|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
75614823|NCT02536573|Other|Radlink Surgical Positioning Software|
75614824|NCT02655289|Device|Modulated TENS|"Frequency: 100 Hz~Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~Mode: intensity modulation (40% decrease every 0.5 seconds)~TENS device: ARTROSTIM® SELECT~Channels: 2~Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)"
75614825|NCT02655289|Device|Placebo TENS|"Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~Mode: continuous~TENS device: ARTROSTIM® SELECT~Channels: 2~Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)"
75461891|NCT01857999|Drug|Losartan|
75461892|NCT01857999|Drug|Placebo|
75461893|NCT01858025|Radiation|Pencil Beam scanning Radiation|
75461894|NCT01858025|Drug|5-fluorouracil|
75461895|NCT01858025|Drug|Mitomycin-C|
75461896|NCT01858038|Device|Fraxel Repair - Fractional Laser treatment|An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
75461897|NCT01858051|Dietary Supplement|Cholecalciferol|
75766616|NCT00006184|Drug|Bortezomib|Induction chemotherapy: 1.3 mg/m^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
75908306|NCT04955704|Device|InferRead CT Pneumonia.AI|InferRead CT Pneumonia.AI reads chest CT DICOM images from medical imaging storage devices and triages cases by detecting pneumonia lesions and then flagging suspected cases in the study list. InferRead CT Pneumonia.AI is a tool to assist clinicians and it does not replace the interpretation and diagnosis by clinicians.
75908307|NCT03671707|Behavioral|Brief AWARD advice|"Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~Ask: smokers will be asked about their smoking behaviour~Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~Refer smokers to smoking cessation services if they agree.~Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline"
75614826|NCT04169971|Other|Music|Played through headphones during the operation under spinal anaesthesia
75614827|NCT02661607|Procedure|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
75614828|NCT02661607|Device|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
75908308|NCT03671707|Drug|Nicotine replacement therapy sampling|Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
75908309|NCT03671707|Behavioral|Active referral|Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
75908310|NCT03671707|Behavioral|Very brief advice|Subjects will receive general advice to quit
75908311|NCT03671707|Behavioral|Leaflet|Subjects will receive a standard leaflet on perinatal smoking by Department of Health
75908312|NCT02226588|Drug|Misoprostol|
75908313|NCT04955548|Procedure|arthroscopic micro-fracture with autologous adipose gel|Fully cut the adipose tissue taken out under the arthroscopy, transfer the cut adipose tissue to a syringe connected with a double pass, push back and forth through the syringe to physically emulsify the adipose, and centrifuge to obtain the autologous adipose gel, and inject it into the lesion
75908314|NCT04955548|Procedure|arthroscopic micro-fracture|Surgeons routinely perform international standard micro-fracture surgery to repair cartilage damage
75908315|NCT03676621|Drug|Misoprostol|buccal tablets
75614829|NCT02661607|Procedure|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
75316999|NCT05965661|Other|virtual reality upper limb hand training|The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.
75317000|NCT05965661|Other|virtual reality control training|The PD patients randomized in the control group will receive virtual reality control training.
75461898|NCT01858051|Dietary Supplement|Placebo|
75614830|NCT04170829|Biological|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
75614831|NCT02655211|Procedure|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
75766617|NCT00006184|Drug|Cyclophosphamide|Induction chemotherapy: 600 mg/m^2 day 4 Transplant: 1200 mg/m^2 intravenous x 4 days (days -6, -5, -4, -3)
75461899|NCT01858064|Drug|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
75461900|NCT01858077|Device|ABSORB BVS™|Bioresorbable scaffold
75461901|NCT01858077|Device|XIENCE™|Drug eluting metallic stent
75461902|NCT01858090|Drug|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
75461903|NCT01858090|Drug|Group Fentanyl|
75461904|NCT01858090|Drug|Group sufentanil|
75461905|NCT01858090|Drug|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to <100 mmHg, fluid loading and ephedrine (5 mg) were administered.
75461906|NCT01858090|Drug|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
75461907|NCT01858090|Drug|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
75461908|NCT01858090|Drug|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
75461909|NCT01858090|Drug|Diphenhydramine|for severe pruritus
75461910|NCT01858090|Drug|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
75614832|NCT02655211|Procedure|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
75614833|NCT02655211|Other|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
75614834|NCT02655445|Procedure|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
75614835|NCT02655445|Procedure|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
75614836|NCT02655445|Procedure|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
75614837|NCT00649987|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
75614838|NCT00649987|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
75766618|NCT00006184|Drug|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
75766619|NCT00006184|Drug|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m^2 day continuous intravenous (CIV) days 1-3
75766620|NCT00006184|Drug|Etoposide|Induction chemotherapy: 50 mg/m^2 day continuous intravenous days 1-3
75766621|NCT00006184|Drug|Fludarabine phosphate|Induction chemotherapy: 25 mg/m^2 day intravenous days 1-3 Transplant: 30 mg/m^2 day x 4 days (days -6, -5, -4, -3 )
75766622|NCT00006184|Drug|Prednisone|60 mg/m^2 day 1-4
75766623|NCT00006184|Drug|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m^2 day continuous intravenous days 1-3
75461911|NCT01858090|Drug|Diclofenac sodium|as additional analgesic among cases in which VAS>3(Postoperatively)
75461912|NCT01858103|Drug|BMN 110|
75461913|NCT01858116|Drug|[68Ga]ABY-025|Intravenous injection followed by PET imaging
75766624|NCT00006184|Drug|Methotrexate|Transplant: 5 mg/m^2 intravenous on days +1, +3, +6, +11
75766625|NCT00006184|Biological|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m^2 subcutaneously every day, days 1-4
75766626|NCT00006184|Biological|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) > 1000/ul x 2 days
75317001|NCT05965648|Behavioral|Families FORWARD (Focusing on Relationships, Well-being, and Responsibility aheaD)|Families FORWARD aims to engage families in planning for adulthood earlier and more actively. Program skills include communication and problem-solving; guided practice in setting realistic goals, breaking down goals into incremental action steps, and problem-solving barriers to goal attainment; repeated engagement in future-oriented communication; and training on how to navigate transition-related and adult services. Parents/caregivers will participate in six or seven telehealth sessions (60-75 minutes each). Youth on the autism spectrum will have the option of participating in up to three program sessions to increase collaborative planning within the family. Families will identify and work toward individualized transition planning goals that may fall within any area of planning or functioning (e.g., housing, education, guardianship).
75317002|NCT05965635|Other|Ixodus scapularis nymphs|Tick challenge
75461914|NCT01858129|Drug|Experimental group: Budicort by Inhalation|Inhaled Budicort twice daily
75614839|NCT04169035|Device|The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.|The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.
75461915|NCT01858129|Drug|placebo|
75614840|NCT04169035|Procedure|forceps or ventouse|"The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body."
75766627|NCT00434057|Device|MelaFind(R)|Biopsy ratio comparison
75766628|NCT01098136|Other|Chiropractic|Manual treatment of musculoskeletal complaints
75766629|NCT01098136|Other|Conventional medical intervention|Medical, physiotherapy
75461916|NCT01858142|Behavioral|Parental presence decision tool|
75461917|NCT01858142|Behavioral|Standard preparation|
75461918|NCT01858155|Drug|Melatonin|
75461919|NCT01858168|Drug|Olaparib|Tablets to be taken on an empty stomach twice a day.
75461920|NCT01858168|Drug|Temozolomide|Tablets to be taken on an empty stomach before bedtime.
75461921|NCT01858168|Drug|Irinotecan|Administered via IV
75461922|NCT01858181|Biological|ocaratuzumab|
75614841|NCT01142232|Drug|Lenalidomide plus Melphalan during autologous stem cell transplantation|Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
75614842|NCT01142232|Drug|Lenalidomide maintenance|Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
75766630|NCT01098136|Other|Conventional and alternative intervention|Medical and alternative methods for treatment of pelvic pain syndromes
75766631|NCT00433199|Drug|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
75766632|NCT00433199|Drug|Placebo|Placebo Control
75766633|NCT03950986|Other|Modified clinical reminders|Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
75908316|NCT03676621|Drug|Oxytocin|intravenous drip
75908317|NCT02226666|Drug|MRI with Multihance|Patients will have Multihance used as an IV contrast agent for their scan.
75908318|NCT02226666|Drug|MRI with Eovist|Patients will have Eovist used as an IV contrast agent for their scan.
75461923|NCT01858207|Procedure|Transcatheter Arterial Chemoembolization|traditional TACE, conventional TACE
75461924|NCT01858207|Procedure|Radiofrequency ablation|simultaneous multiple electrodes and switching RF controller
75461925|NCT01858207|Drug|Doxorubicin|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
75461926|NCT01858233|Behavioral|Intensive Behavioral Modification|Intensive dietary counseling, increased physical activity, lactation counseling
75461927|NCT01858246|Device|Bonebridge|
75461928|NCT01858246|Device|Bone Anchored Hearing Aid|
75461929|NCT01858272|Drug|H5.020CMV.PDGF-b and limb compression bandage|
75461930|NCT01858298|Other|Conservative treatment: pulpectomy and composite resin crown|
75461931|NCT01858298|Other|Non-conservative treatment: Tooth extraction|
75461932|NCT01858311|Dietary Supplement|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
75461933|NCT01858311|Other|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
75461934|NCT01858324|Other|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
75461935|NCT01858337|Other|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
75908319|NCT04419454|Device|BodyTite|retrospectively evaluate this novel treatment approach to improve the appearance of cellulite on the thighs and buttocks by tightening the SFS using RFAL.
76071254|NCT05187585|Diagnostic Test|radiograph interpretation without the support of the RAYVOLVE app|"Phase 1 does not involve any intervention: residents, emergency physicians, and radiologists will interpret the x-rays without the support of the RAYVOLVE application.~The emergency physician interprets the x-ray and manage the case as per protocol, all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated."
75461936|NCT01858337|Other|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
75614843|NCT04169659|Device|Kyphoplasty with insertion of Sctructured Titanium Microspheres|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.
75317003|NCT05965622|Behavioral|Attachment Based Family Therapy (ABFT) + Treatment As Usual (TAU)|"Attachment Based Family Therapy (ABFT): ABFT is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Therefore, ABFT focuses on strengthening parent-child attachment bonds to create a protective and secure base for young adult development. Sessions are scheduled weekly, and the intervention lasts on average 16 weeks.~The participants in the ABFT condition will also receive treatment as usual (TAU)."
75317004|NCT05965622|Behavioral|Treatment As Usual (TAU)|The participants in the treatment as usual (TAU) condition will only receive regular existing care to treat suicidality in young adults.
75766634|NCT03226379|Other|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~Health system strengthening~Delivery of a co-designed education program tailored to frontline healthcare workers~Implementation of an algorithm for HIV-related meningoencephalitis~Infectious diseases/AHD mentorship and laboratory capacity building"
75766635|NCT01030055|Drug|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
75317005|NCT05965596|Other|a psycho educational intervention program|The program was developed by the researcher herself based on recommendations derived from a systematic review of psychoeducational interventions to improve the quality of Life and psychological outcomes in gynecological cancer patients. Also guided by the program adopted by chow et all in 2014(28) to test the feasibility of implementing a psychoeducational intervention program for gynecological cancer patients.
75461937|NCT01858337|Other|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
75461938|NCT01858337|Other|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
75614844|NCT04169659|Device|Kyphoplasty with Polimethylmetacrilate (convetional surgery)|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
75614845|NCT02655133|Drug|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
75614846|NCT02655133|Drug|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
75614847|NCT02536807|Drug|Hyaluronan|HA gel injection
75614848|NCT02883738|Other|tremor|evaluation of the intensity of the tremor
75766636|NCT03994991|Device|active TMS|Transcranial magnetic stimulation
75908320|NCT03678649|Drug|Capecitabine|1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
75614849|NCT04395547|Dietary Supplement|JointAlive™|Combination herbal extract
75908321|NCT04955860|Other|Dental model analysis|No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.
76071255|NCT05187585|Diagnostic Test|radiograph interpretation with the support of the RAYVOLVE app|The residents interpret the X-ray with the RAYVOLVE application's support and indicate the presence or not of a fracture without sharing it with the senior emergency physician. A senior emergency physician manages the case as usual, and all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated
76071256|NCT05183113|Other|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
75766637|NCT03994991|Device|sham TMS|Sham transcranial magnetic stimulation
75461939|NCT01858350|Other|Active Music Therapy|
75614850|NCT04395547|Dietary Supplement|Placebo|Combination placebo product
75614851|NCT02660671|Behavioral|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
75614852|NCT02660671|Behavioral|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
75908322|NCT02886156|Device|CPAP|CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
75461940|NCT01858350|Other|Passive Music Therapy|
75614853|NCT02660671|Behavioral|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
75614854|NCT02536495|Drug|Docetaxel|Given IV
75461941|NCT01858350|Other|Distraction Therapy|
75461942|NCT01858402|Drug|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
75908323|NCT02886156|Dietary Supplement|BSC|BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
75614855|NCT02536495|Other|Laboratory Biomarker Analysis|Correlative studies
75766638|NCT03994757|Behavioral|MRBI|The activities content is designed according to the children's daily routine and goals. It mainly involves bathing activities, eating activities, dressing activities, game activities, social and communication activities, and according to the needs of parents. In the treatment room, after the therapist and parents discuss the intervention methods and suggestions, they will demonstrate the intervention strategies and methods, and let the parents practice the practice, and the therapist will guide them. After discussing with parents, the therapist will give parents a homework related to children's daily routine, let the parents implement at home, and discuss with parents and record before each intervention.
75908324|NCT03678571|Other|Latrunculin A supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Latrunculin A
75614856|NCT02536495|Other|Pharmacological Study|Correlative studies
75766639|NCT03994757|Behavioral|Control|Traditional treatment was directly performed for children in the treatment room by the therapist. The activity content was designed according to the children's goals. After each end of treatment, therapist will give parents a homework related to traditional treatments, let the parents perform at home, and know the parents' performance at home and record before each treatment begins.
75766640|NCT01098448|Other|scaling and root planing|scaling and root planing as a single therapy
75766641|NCT01098448|Drug|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm
75766642|NCT01098448|Drug|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
75908325|NCT04955392|Other|Osteopathic treatment protocol|"The intervention protocol consists of 4 techniques that will be performed according to the following order:~Inhibition of the suboccipital muscles.~Parietal Lift.~Sutherland Technique of Sphenobasilar Synchondrosis.~Compression technique of the fourth ventricle (CV4)."
75614857|NCT02536495|Drug|Selinexor|Given PO
76071257|NCT05177289|Device|Theradome® LH80 pro|The Theradome LH80 pro is a wearable laser helmet device, which uses red laser light to stop hair loss, thicken existing hair and stimulate the growth of new hair.
75908326|NCT04955392|Other|Sham technique|Sham technique that consists of placing the hands on top of the skull without any therapeutic intention for five minutes.
75614858|NCT02536417|Drug|Melatonin|To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
75614859|NCT02536417|Drug|Sugar pill|To determine if placebo effect plays a part in preventing the development of delirium
75614860|NCT01140906|Drug|Placebo|capsules, daily, orally
75614861|NCT01140906|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
75614862|NCT01140906|Drug|Duloxetine|encapsulated capsules, daily, orally
75614863|NCT00650065|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
75317006|NCT05965596|Other|the routine care|the routine care provided for all gynecological cancer patients in the study setting
75766643|NCT01098448|Other|surgery|periodontal surgery in residual pockets of >4mm
75766644|NCT01098448|Drug|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
75766645|NCT01098448|Other|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm and periodontal surgery in residual pockets of >4mm
75766646|NCT01098448|Other|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets >4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
75908327|NCT02226744|Behavioral|Focused Breathing|
75908328|NCT03671629|Other|Enhanced clinical pharmacist service|The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
75908329|NCT04954768|Other||This is a observational study, and there is no interventions.
75908330|NCT02845297|Drug|pembrolizumab|Intravenous pembrolizumab
76071258|NCT05177289|Device|Scalp cooling|Scalp cooling is a standard treatment that is applied to prevent hair loss during chemotherapy.
75317007|NCT05965453|Device|the Castor single branch stent graft|Participants who received thoracic endovascular aortic repair by meant of the Castor single branch stent graft from June 2018 to June 2022 were enrolled in our study.
75317008|NCT05965388|Drug|nucleoside analogues or interferon|ETV、TDF、TAF、TAF、IFN-a-2b
75766647|NCT01098448|Other|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets >4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets >5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
75766648|NCT01098526|Drug|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
75908331|NCT02845297|Drug|Azacitadine|Intravenous or subcutaneous
75908332|NCT04954534|Biological|human umbilical cord blood derived mesenchymal stem cells|High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
76071259|NCT05177263|Other|Placebo|Sterile Water
76071260|NCT05177263|Drug|10% Oral Dextrose Solution|10% Oral Dextrose Solution
76071261|NCT05177263|Drug|20% Oral Dextrose Solution|20% Oral Dextrose Solution
76071262|NCT05177263|Drug|30% Oral Dextrose Solution|30% Oral Dextrose Solution
75614864|NCT00650065|Drug|Zyrtec® Tablets 10 mg|10mg, single dose fasting
75614865|NCT02654821|Biological|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
75766649|NCT01098526|Drug|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
75317009|NCT05965375|Other|Observational; No Interventions were given.|Observational; No Interventions were given.
75317010|NCT05965323|Behavioral|Health Education|Health education with comic books and videos
75317011|NCT05965310|Behavioral|Virtual Psychological Intervention: Cognitive Behavioral Therapy|An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
75317012|NCT05965297|Device|DeltaFil|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using DeltaFil conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (DeltaFil). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
75766650|NCT01030211|Procedure|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
75766651|NCT01030211|Other|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
75461943|NCT01858402|Drug|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
75461944|NCT01858415|Device|TriPollar|
75766652|NCT01030367|Drug|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
75766653|NCT01032941|Drug|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
75766654|NCT00005908|Drug|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m^2 intravenous day 1
75461945|NCT01858441|Drug|Abiraterone Acetate|
75766655|NCT00005908|Drug|Anastrozole|1 mg orally daily for five years
75766656|NCT00005908|Drug|cyclophosphamide|600 mg/m^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
75766657|NCT00005908|Drug|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m^2 intravenous day 1
75766658|NCT00005908|Drug|Doxorubicin hydrochloride|60 mg/m^2 will be administered as a slow intravenous push on day 1
75766659|NCT00005908|Drug|Tamoxifen Citrate|20 mg/day orally for five years
75766660|NCT00005908|Drug|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m^2 orally twice daily day 2-15
75766661|NCT00005908|Drug|Capecitabine - Dose A|capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
75908333|NCT03678415|Behavioral|Community-Based Primary Mental Health Care (CBPMHC) package|According to the intervention package, after receiving training, the service providers will start providing service according to learning to the enrolled mothers. The intervention package has developed in many maternal and psychosocial supports like psycho-educational communication about pregnancy complications, danger signs, birth preparedness; psycho-social support including information about psycho-education, graded activities and different types of alternative thoughts. Besides, in this regard the investigators included anxiety and depression disorders symptoms, postpartum mood disorders like postpartum blue, postpartum psychosis, etc. The primary healthcare service provider's provide intervention along with their daily routine and investigators follow it up by their visits.
75461946|NCT01858454|Procedure|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
75766662|NCT00432965|Device|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
75766663|NCT00432965|Device|VAC Therapy|VAC Therapy
75766664|NCT01098604|Device|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
75908334|NCT04954612|Other|Questionnaire study (Cross-sectional analytical clinical research)|Questionnaire study (Cross-sectional analytical clinical research)
75317013|NCT05965297|Device|Riva Self Cure HV|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using Riva conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (Riva Self Cure HV). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
75317014|NCT05965284|Drug|Azathioprine|All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
75461947|NCT01858454|Procedure|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere [Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.].
75461948|NCT01858467|Device|Endotracheal intubation|Portex endotracheal tube 6.5mm or 7.0mm internal diameter
75461949|NCT01858467|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
75461950|NCT01858480|Drug|D-ribose|D-ribose powder for oral solution and D-ribose for injection.
75461951|NCT01858480|Other|Placebo|Placebo dosage form designed to mock active.
75461952|NCT01858493|Behavioral|Continence promotion group education workshop|Interactive group education workshop promoting continence
75461953|NCT01858493|Behavioral|Sham health lecture|Interactive group education workshop about general health
75766665|NCT01098604|Device|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
75766666|NCT00440297|Biological|Comparator: modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
75766667|NCT00440297|Biological|Comparator: ENGERIX-B™|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
75766668|NCT00432809|Procedure|Gastric bypass|Roux-en-Y gastric bypass
75766669|NCT00432809|Procedure|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
75766670|NCT00431951|Drug|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
75766671|NCT00431951|Drug|Placebo|Capsules to match experimental drug
75766672|NCT00004978|Drug|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
75766673|NCT01030601|Drug|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
75766674|NCT01030679|Drug|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
76071263|NCT05176665|Drug|EMB-01|EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses). All patients will be premedicated with a histamine-1 (H1) receptor antagonist diphenhydramine (25 or 50 mg) intravenously 30-60 minutes prior to dosing in the first two cycles. Premedication for subsequent treatment cycles will depend on whether the patient develops infusion-related reactions (IRR), at the discretion of the investigator.
76071264|NCT05174832|Drug|Cisplatin|75 mg/m2 IV days 1 of each 21-day cycle
76071265|NCT05174832|Drug|Nab-paclitaxel|125 mg/m2 IV days 1 and 8 of each 21-day cycle
76071266|NCT05174832|Drug|Pembrolizumab|200 mg IV every 21 days
76071267|NCT05174832|Drug|Olaparib|300 mg PO BID
75317015|NCT05965284|Drug|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months
75614866|NCT02654821|Procedure|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
76071268|NCT05173922|Behavioral|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
75317016|NCT05965245|Behavioral|Suubi-Mhealth|Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
75317017|NCT05965232|Diagnostic Test|Fibroscan|"Performing FibroScan :~The patient is positioned supine, with the right arm in maximum abduction to clear the intercostal spaces.The measurement itself is performed on the right lobe of the liver via the intercostal (intersection of the mid-axillary line and the xiphoid process) using a dedicated probe (3.5 MHz) after application of a conduction gel to the skin. FibroScan® examinations are carried out by personnel trained in the use of the device.This training is specific and validated by the device's manufacturer manufacturer, EchosensTM (Paris). Ten valid measurements at the same measurement point in the right liver must be be performed, with an interquartile range/median ratio ≤ 30 (required only if the elastometry value is > 7.1 KPa."
76071269|NCT05166369|Behavioral|Communication skills training|"This intervention consists of a course on communication skills for healthcare professionals.~It will be done remotely via the internet and will include: communication skills training and optimal management of acute non-complicated RTI and delayed antibiotic prescription. Training modules will be delivered via a specific website password protected. Healthcare professionals will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
75317018|NCT05965206|Behavioral|Follow-up phone interview|Follow-up phone interview within 7 business days after receiving intravenous chemotherapy
75461954|NCT01858506|Procedure|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
75461955|NCT01858506|Procedure|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
75461956|NCT01858571|Drug|Low dose chemotherapy|"Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Etoposide (50 mg/m2/d)~Cycle B~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
75614867|NCT02654821|Procedure|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
75614868|NCT02882412|Other|observational|
75614869|NCT04170439|Drug|Clomiphene plus metformin plus N acetyle cysteine in arm number 1|oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium
75614870|NCT04170439|Drug|Clomiphene citrate plus metformin with chromium|oral adminstration of clomiphene citrate plus metformin and chromium
75614871|NCT04170439|Drug|clomiphene citrate plus metformin|oral adminstration of clomiphene citrate plus metformin
75766675|NCT01030679|Drug|CKD-501 1mg|1 mg/tablet, orally, 1 tablet once daily for 8 weeks
75766676|NCT01030679|Drug|CKD-501 2mg|2 mg/tablet, orally, 1 tablet once daily for 8 weeks
75766677|NCT01030679|Drug|Placebo|orally, 1 tablet once daily for 8 weeks
75766678|NCT00430937|Drug|Daptomycin|4 mg/kg intravenous once daily
75766679|NCT00430937|Drug|Vancomycin|1 g intravenous twice daily
75766680|NCT00430937|Drug|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
75766681|NCT01101412|Drug|Edetate Calcium Disodium|Given through CVC or PVC.
75766682|NCT01101412|Drug|Ethanol|Given through CVC or PVC
75766683|NCT01101412|Drug|Trimethoprim-sulfamethoxazole|Given through CVC or PVC
75766684|NCT01101412|Other|Hypertonic Saline|Given through CVC or PVC
75908335|NCT04954924|Other|standardized physiotherapy program and Kinesio tape|
75766685|NCT00004888|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
75908336|NCT04954378|Diagnostic Test|radiomics|
75908337|NCT03676387|Other|ultrasound guided|"Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation [ETT OD=0.55*(subglottic diameter)+1.16] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes."
75908338|NCT02226900|Procedure|Hybrid Revascularization|Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
76071270|NCT05166369|Behavioral|Mobile phone application on RTI|"This intervention involves the use of a mobile phone application by parents and caregivers.~The mobile app will provide information, education and interactive tools about acute noncomplicated respiratory tract infections.~PC centres allocated to this group will display posters and flyers to inform parents and caregivers about the mobile app. Healthcare staff will also promote the use of this app by parents and caregivers.~The app information will be useful before the consultation, and will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making.~Importantly, the app will allow tailoring the guidance provided according to the type of infection or the number of days with symptoms.~Healthcare professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
76071271|NCT05165056|Device|Intimleds|INTIMILEDS® is a photobiomodulation device designed for intravaginal use. It's design permits an irradiation of the whole vaginal wall, the vulva, and the cervix, with a constant intensity.
75461957|NCT01858584|Drug|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
75614872|NCT05188092|Other|Lung ultrasound guided deresuscitation|"With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours."
75766686|NCT00004888|Drug|docetaxel|Given IV
75766687|NCT00004888|Biological|trastuzumab|Given IV
75766688|NCT00004888|Other|laboratory biomarker analysis|Correlative studies
75766689|NCT03951220|Other|Diffusion Weighted Magnetic Resonance Imaging (DWMRI)|Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy.
75908339|NCT02226900|Procedure|Conventional Coronary Artery Bypass Surgery|On pump coronary artery by-pass surgery
76071272|NCT05163717|Combination Product|INP105|A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery [POD®]-olanzapine)
76071273|NCT05163717|Combination Product|Placebo|A single dose of POD-placebo (Precision Olfactory Delivery [POD®]-placebo)
76071274|NCT05158140|Biological|V110|Single intramuscular (IM) dose of 0.5 mL V110 a pneumococcal polysaccharide vaccine containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
76071275|NCT05158140|Biological|V114|Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F
76071276|NCT05158140|Biological|mRNA-1273|Single IM dose of 50 μg/0.25 mL mRNA-1273
76071277|NCT05158140|Biological|Placebo for V110|Single IM dose of 0.5 mL placebo for V110
76071278|NCT05158140|Biological|Placebo for V114|Single IM dose of 0.5 mL placebo for V114
76071279|NCT05157243|Drug|Nitazoxanide|Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
76071280|NCT05157243|Dietary Supplement|Vitamin Super-B Complex|Vitamin Super B-Complex administered orally twice daily for 5 days to maintain the blind
76071281|NCT05157243|Drug|Placebo|Two matching placebo tablets administered orally with food twice daily for 5 days
76071282|NCT05157243|Other|Standard of Care|Local standard of care for COVID-19
76071283|NCT05156125|Drug|VTX002|Dose A tablet administered orally once daily
76071284|NCT05156125|Drug|VTX002|Dose B Tablet administered orally once daily
76071285|NCT05156125|Drug|Placebo|Placebo Tablet for VTX002 administered orally once daily
76071286|NCT05154214|Procedure|Adenotonsillectomy|Removal of tonsils and adenoids
75766690|NCT03951220|Other|DXA scan|Used to assess bone density
76071287|NCT05154214|Procedure|Drug-induced sleep endoscopy directed surgery|Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
75766691|NCT03951220|Other|Bloods and urine|Samples will be taken to assess bone biomarkers
75908340|NCT04954456|Drug|QLS31901|QLS31901 is a bispecific antibody specifically targeting PD-L1 and TGF-β.In part 1,the QLS31901 will be administered in sequential cohorts on day 1 of every 21-day cycle (3 weeks) via IV infusion.In part 2,the QLS31901 will be administered in parallel cohorts(selected dose and dosing frequency ) on day 1 of every 2week or every 3week via IV infusion
76071288|NCT05153434|Drug|ARD-101|Twice Daily, Oral Administration
76071289|NCT05137132|Dietary Supplement|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
75317019|NCT05965154|Drug|Carrilizumab, bevacizumab,capecitabine|"Carrilizumab: 200mg/ cycle, three weeks as a treatment cycle, the first day of each cycle, intravenous drip;~Bevacizumab: 7.5mg/kg, intravenous infusion on the first day of each cycle, every 3 weeks for 1 cycle (Q3W);~Capecitabine: 1250mg/m2, three weeks as a treatment cycle, oral twice a day (once in the morning and once in the evening; Stop the drug for 1 week after 2 weeks of treatment."
76071290|NCT05137132|Dietary Supplement|Placebo|MCT oil
75317020|NCT05965141|Drug|Aribulin;carboplatin;bevacizumab|Aribulin combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive recurrent ovarian cancer.
75317021|NCT05965102|Drug|Tirelizumab；Chemotherapy monotherapy|Tirelizumab combined with chemotherapy in first-line treatment of relapsed/metastatic non-small cell lung cancer with ECOG PS score of 2
75614873|NCT02660515|Procedure|Additional wrist arthroscopy|
75908341|NCT02232360|Drug|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
75908342|NCT02232360|Drug|Rosuvastatin alone|Rosuvastatin 10mg per day
76071291|NCT05136820|Device|Atrial Flow Regulator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
76071292|NCT05136820|Device|Sham Comparator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
76071293|NCT05128630|Drug|Durvalumab|Patients will receive 1500 mg durvalumab via IV infusion q3w concomitant with chemotherapy (Cisplatin/carboplatin plus etoposide) for up to a maximum of 3 cycles, then via IV infusion at the same interval during sequential radiotherapy and then every 4 weeks for up to a maximum of 12 months or until confirmed disease progression, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
76071294|NCT05123612|Behavioral|Fiber|Additional 20 grams of fiber/day.
75317022|NCT05965076|Procedure|Glycine Perio Flow|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss and glycine perio-flow.
75317023|NCT05965076|Behavioral|Angled Toothbrush|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and an angled toothbrush.
76071295|NCT05123612|Behavioral|Fermented Foods|6 servings of fermented foods/day
75317024|NCT05965076|Procedure|Standard Professional Oral Hygiene|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss.
75317025|NCT05965076|Behavioral|Standard Domiciliary Oral Hygiene|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and a standard toothbrush.
75461958|NCT01858584|Dietary Supplement|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
75461959|NCT01858610|Drug|Irbeasartan/hydrochlorothiazide|
75461960|NCT01858610|Drug|Irbesartan|
75614874|NCT02660515|Procedure|ORIF|
75614875|NCT02883504|Procedure|Echo-Doppler examination and left heart catheterization|
75614876|NCT02660593|Dietary Supplement|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
75461961|NCT01858610|Drug|Hydrochlorothiazide|
75461962|NCT01858623|Drug|Losartan/hydrochlorothiazide|
75461963|NCT01858623|Drug|Losartan|
75461964|NCT01858623|Drug|Hydrochlorothiazide|
75461965|NCT01858649|Procedure|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
75461966|NCT01858649|Drug|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
75614877|NCT00962091|Drug|Alisertib|Alisertib OS Alisertib PIC Alisertib PIC
75766692|NCT00004732|Procedure|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
75908343|NCT03676309|Drug|Nutriceutical Oral Capsule,|nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks
75908344|NCT03676309|Drug|Placebo Oral Tablet|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
75908345|NCT04954144|Device|Leap Motion Sensor|As a virtual reality treatment method, leap motion sensor was integrated with laptop computer and participants played object capture, firefly, bee-batting games to improve performance based hand skills.
75614878|NCT02660437|Other|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; ~30min).
75614879|NCT02536651|Procedure|Ankle surgery|Plastic or orthopedic surgery of the ankle
75614880|NCT00649363|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
75614881|NCT00649363|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
75614882|NCT04285203|Other|Educational Video Intervention|Educational videos
75766693|NCT00004732|Device|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
75614883|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
75766694|NCT01098760|Drug|Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment|Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
75766695|NCT03952390|Other|control|
75766696|NCT03952390|Other|sepsis|
75766697|NCT00430781|Drug|pazopanib (GW786034)|
75614884|NCT02654899|Other|Placebo|Placebo
75766698|NCT00430781|Drug|lapatinib (GW572016)|
75766699|NCT01033097|Drug|DNK333 5 mg|5 mg oral
75766700|NCT01033097|Drug|Placebo to 5 mg|5 mg placebo oral
75766701|NCT01033097|Drug|DNK333 25 mg|25 mg oral
75766702|NCT01033097|Drug|Placebo to 25 mg|25 mg placebo oral
75614885|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
75614886|NCT02654743|Dietary Supplement|Sulforaphane|Children with ASD will receive Sulforaphane in this study
75317026|NCT05965050|Diagnostic Test|Myofascial Release Technique|myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
75317027|NCT05965050|Other|Ultrasound Therapy|Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
75766703|NCT01033097|Drug|DNK333 100 mg|100 mg oral
75766704|NCT01033097|Drug|Placebo to 100 mg|100 mg placebo oral
75614887|NCT04314258|Dietary Supplement|Moringa oleifera tea|4 grams of Moringa oleifera tea twice daily
75614888|NCT02862795|Procedure|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
75614889|NCT04168723|Drug|MD1003|Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
75614890|NCT04168723|Drug|Moxifloxacin 400mg|Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
75614891|NCT04168723|Drug|Placebo for MD1003|Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
75614892|NCT04168723|Drug|Placebo for moxifloxacin|Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
75614893|NCT04168801|Dietary Supplement|early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
75614894|NCT00649441|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
75614895|NCT00649441|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
75614896|NCT01122576|Device|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
75614897|NCT01122576|Device|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
75614898|NCT01122576|Device|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
75766705|NCT01033097|Drug|Betamethasone 4 mg|4 mg oral
75766706|NCT01033097|Drug|DNK333 1mg|1 mg oral
75766707|NCT01033097|Drug|Placebo to 1mg|1 mg placebo oral
75766708|NCT01323725|Behavioral|Team-based financial incentives|Team-based financial incentives for smoking cessation at 6 month post-quit date.
75766709|NCT01033721|Drug|Palomid 529|comparison of different dosages of drug
75766710|NCT00429299|Drug|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
75766711|NCT00429299|Biological|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
75766712|NCT00429299|Drug|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
75766713|NCT00429299|Drug|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
75766714|NCT00429299|Drug|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
75766715|NCT00429299|Drug|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
75766716|NCT01033799|Other|Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
75766717|NCT01033799|Other|Non fermented dairy product (control)|
75766718|NCT01033877|Biological|TdaP vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
75908346|NCT04954144|Other|Neurodevelopmental Treatment Approach|It is a method that tries to control sensorimotor components of muscle tone, reflexes, abnormal movement patterns, postural control, sensory-perception and memory problems with special techniques.
75908347|NCT02232438|Behavioral|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
75908348|NCT03678337|Other|observational cohort with plasma samples|plasma samples
76071296|NCT05122663|Behavioral|Vestibular Rehabilitation|Vestibular Rehabilitation refers to the specific interventions that physical therapists provide to patients with dizziness and vertigo symptoms. These interventions can involve repositioning maneuvers, habituation exercises, gaze stabilization, and/or balance training exercises, depending on the specific etiology of dizziness and vertigo per an established clinical protocol utilizing a patient's history and exam findings. Physical therapists instruct patients in how to perform these exercises at home and provide instructions and referral for patients to follow-up with an outpatient physical therapist for further care.
75908349|NCT04953676|Procedure|round tunnel technique|Both the femoral tunnel and tibial tunnel were drilled by 8-mm cannulated drill
75908350|NCT04953676|Procedure|flat tunnel technique|Both the femoral tunnel and tibial tunnel were dimension of 5×11-mm rounded-rectangular, which was created by initially drilling a round tunnel with a 5-mm cannulated drill and reshaped by use of a bone rasp and custom-made dilator.
75908351|NCT02226978|Drug|Tipranavir|
75908352|NCT02226978|Drug|Ritonavir|
75908353|NCT02226978|Drug|Valaciclovir|
75317028|NCT05965037|Device|FLUYDO NC percutaneous transluminal coronary angioplasty balloon catheter|The FLUYDO NC is a rapid exchange percutaneous transluminal non-compliant coronary angioplasty balloon catheter. It is a single use only medical device, non-implantable, non-pyrogenic and sterilized with ethylene oxide and CO2 mixture. The distal portion has a hydrophilic coating and consists of two lumens: one for balloon inflation and deflation, the other for guidewire advancement and retraction. The product is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.
75908354|NCT02831959|Device|NovoTTF-200M device|
75317029|NCT05964985|Drug|Normal saline|After the induction of anesthesia, normal saline is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
75317030|NCT05964985|Drug|Ropivacaine|After the induction of anesthesia, 0.375% ropivacaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
75614899|NCT02660203|Procedure|Forced expiration|"Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.~The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed"
75614900|NCT02654665|Behavioral|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
75614901|NCT02654665|Drug|Liraglutide|GLP-1 agonist
75614902|NCT02654509|Biological|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
75317031|NCT05964985|Drug|Compound lidocaine|After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
75614903|NCT04168333|Biological|T101 Group|"Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15."
75614904|NCT04168333|Biological|Placebo Group|"Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15."
75614905|NCT02654431|Procedure|Breast Cancer patient|Samples
75614906|NCT02654431|Procedure|Cancer patients|Samples
75614907|NCT04167865|Other|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
75614908|NCT02658643|Procedure|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
75908355|NCT02831959|Other|Best Standard of Care|
75908356|NCT04953832|Behavioral|Cognitive Training|Participants are asked to remember a series of items while solving puzzles.
75317032|NCT05964985|Drug|Esketamine|After the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral quadratus lumborum block
75317033|NCT05964959|Other|Mouth Educational Program|The Mouth Educational Program is a nurse-led patient education program for dry mouth in patients with a life-limiting condition or frailty.
75317034|NCT05964959|Other|Care as Usual|Care as usual is defined as the standard dry mouth care as provided by participants' own treating physicians.
75908357|NCT04953520|Procedure|ultrasound-CT fusion imaging|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
75908358|NCT04953520|Procedure|pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
75908359|NCT04359030|Diagnostic Test|Multislice CT scanning for aortic wall calcification|Multislice CT scanning for aortic wall calcification
75908360|NCT04359030|Diagnostic Test|Transthoracic stress echocardiography|Transthoracic stress echocardiography
75908361|NCT04953988|Procedure|Robotic TKA|Robotic TKA
75908362|NCT04953988|Procedure|Manual operation|Manual operation
75908363|NCT01358331|Drug|MK-8353|Administered orally twice daily for 28 days for each cycle
75908364|NCT04953598|Diagnostic Test|Ultrasonography|Patient undergoes diagnostic ultrasound examination
75908365|NCT03676231|Drug|SGM-1019|Active
75908366|NCT03676231|Drug|Placebo|Inactive
75908367|NCT04937010|Procedure|Occipital nerve stimulator implant|Implantation of occipital nerve stimulator and different stimulation parameters
75908368|NCT04952818|Diagnostic Test|RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)|Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
76071297|NCT05122663|Other|Usual Care|Usual Care refers to any combination of diagnostic testing, medications, and patient education or counseling provided by a patient's treating ED physician.
75766719|NCT01033877|Biological|Td vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d)
75317035|NCT05964933|Procedure|Complete Pulpotomy|"Complete caries removal and excision of the entire coronal pulp to the level of the root canal orifices will be performed. After haemostasis, the pulp chamber will be filled with Biodentine® and a final direct restoration placed in 1 or 2 visits.~If there is no bleeding from the exposed pulp, pulpectomy and root canal treatment will be performed instead, and the patient will be excluded from the study."
75766720|NCT00428597|Drug|sunitinib malate|"sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~Dose may be decreased to 25 mg daily in case of adverse events.~It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination."
75766721|NCT00428597|Drug|Placebo|Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
75766722|NCT01033955|Drug|Rosuvastatin|Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
75317036|NCT05964933|Procedure|Pulpectomy and Root Canal Treatment|After complete caries removal and pulp exposure, Pulpectomy will be performed to remove all pulp tissues. Conventional root canal treatment will be performed using rotary instrumentation followed by obturation with gutta percha and traditional sealers in 1 or 2 visits. A final restoration will be placed to ensure a good coronal seal, and this may include full coronal coverage restorations if clinically indicated.
75317037|NCT05964894|Other|ergonomic training|ergonomic education & exercise training
75766723|NCT01033955|Drug|Placebo|identical appearing encapsulated placebo.
75766724|NCT00428441|Drug|Warfarin|tablets, based on INR levels, according to D-dimer levels
75317038|NCT05964842|Behavioral|SMS|Participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
75317039|NCT05964842|Behavioral|Phone call|Participants in this arm will receive three phone call reminders. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
75461967|NCT01858649|Drug|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
75766725|NCT01033175|Procedure|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
75908369|NCT03623503|Other|Observational study|
75908370|NCT02227056|Drug|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
75908371|NCT05708157|Drug|concomitant intranasal antihistamine and corticosteroid|concomitant intranasal administration with antihistamine and corticosteroid
75317040|NCT05964842|Behavioral|Mobile money incentive|Once participants in the study arms with mobile money complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money.
75461968|NCT01858649|Drug|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
75461969|NCT01858649|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
75461970|NCT01858662|Procedure|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
75461971|NCT01858662|Drug|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
75614909|NCT02658643|Procedure|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
75908372|NCT04952662|Genetic|Genetic variants|COL1A1 rs1800012, COL1A2 rs412777, COL5A1 rs12722, ACTN3 rs1815739, ACE rs1799752, ESR1 rs2234693, MMP3 rs679620, VDR rs2228570 and GDF5 rs143383
76071298|NCT05119660|Device|Intermittent Theta Burst Stimulation|iTBS
75461972|NCT01858662|Drug|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
75461973|NCT01858662|Drug|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
75614910|NCT02658721|Drug|Lidocaine|
75614911|NCT02658721|Drug|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
75614912|NCT02658721|Drug|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
75614913|NCT02658721|Drug|Fentanyl|If the patient had a VAS score of >4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
75614914|NCT02658721|Drug|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.~In case of bradycardia (HR <50/min), 0.5 mg intravenous atropine was administered."
76071299|NCT05111587|Other|Questionnaire|Participant must complete a questionnaire about injury during climbing practice in an artificial structure
76071300|NCT05109429|Behavioral|Neutral Cue-induced Craving|For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
75766726|NCT01033175|Procedure|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
76071301|NCT05109429|Behavioral|Visual Opioid Cue-induced Craving|For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
75766727|NCT01033253|Behavioral|Health in Motion|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
75766728|NCT00144339|Drug|tiotropium|
75766729|NCT00144339|Drug|placebo|
75766730|NCT03967665|Drug|N-acetyl-L-cysteine|NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
75766731|NCT02531607|Other|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
75766732|NCT00144027|Behavioral|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
75766733|NCT00127803|Biological|Placebo (vaccine diluent)|0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
75317041|NCT05964803|Diagnostic Test|Questionnaires|MLWH and control groups were asked to complete the following questionnaires: International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), ICIQ-Short Form (ICIQ-SF), International Prostate Symptom Score (IPSS), King's Healthcare Questionnaire (KHQ), 8-item Overactive Bladder Questionnaire (OAB-V8), Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7).
75317042|NCT05964790|Drug|HS-10380|Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days
75317043|NCT05964790|Drug|Placebo|Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days
75461974|NCT01858662|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
75461975|NCT01858662|Drug|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
75461976|NCT01858675|Other|Biomarkers, red blood cells and plasma assessment|
75461977|NCT01858714|Behavioral|Behavior Therapy for Weight Loss|Standard behavioral treatment for weight loss and weight loss maintenance.
75461978|NCT01858714|Behavioral|Behavior Therapy + Environment|Standard behavioral therapy with an emphasis on environmental strategies.
75461979|NCT01858714|Behavioral|Acceptance-based Behavior Therapy + Environment|Behavioral therapy with acceptance-based and environmental strategies.
75461980|NCT01858727|Other|forced air warming group|30 minutes before the preoperative will use forced air warming
75461981|NCT01858727|Other|control group|do not heating group
75614915|NCT02658721|Drug|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
75614916|NCT02658721|Drug|Diclofenac sodium|The patients with a VAS score of >4 were administered with 75 mg diclofenac sodium via intramuscular route.
75614917|NCT02658721|Drug|Ephedrine|In the event of hypotension (systolic arterial pressure <90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
75614918|NCT02658721|Drug|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
75614919|NCT00965523|Drug|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
75614920|NCT02652013|Other|cognitive evaluation|
75614921|NCT00629967|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
75614922|NCT00629967|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
75766734|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
75766735|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
75766736|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
75908373|NCT03671317|Behavioral|Medical Clowning|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
75766737|NCT03967431|Other|Narrative Enhancement and Cognitive Therapy (NECT)|Narrative Enhancement and Cognitive Therapy includes two introduction meetings, three psychoeducation meetings, seven cognitive restructuring meetings, seven narrative enhancement meetings and one summing up meeting.
75766738|NCT03967509|Behavioral|Comet|
75766739|NCT01077999|Drug|Carboplatin|Carboplatin AUC = 2 , weekly.
75766740|NCT01077999|Drug|Paclitaxel|Paclitaxel 50 mg/m2, weekly
75766741|NCT01077999|Drug|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
75766742|NCT01077999|Radiation|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
75766743|NCT00127413|Behavioral|Cognitive Behavioral Therapy - Pain|Pain treatment
76071302|NCT05109429|Behavioral|Visual and Tactile Opioid Cue-induced Craving|For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
76071303|NCT05094401|Device|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
75317044|NCT05964777|Device|Repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation|with the rapid development of neuroregulatory technology, rTMS and tACS have a profound impact on cognitive impairment. The damaged neural circuit of DLPFC-DACC may lead to impaired cognitive function in bipolar disorder.We used DTI imaging technology to calculate the DLPFC cortical region corresponding to the strongest point of dlpfc and DACC fiber connection as the stimulus site.Using high-frequency rTMS and high-precision tACS stimulation,thus affect the nerve ring pathway , thereby rapidly, effectively and safely improving cognitive impairment with bipolar disorder in remission.
75461982|NCT01858779|Behavioral|Measurement of peripheral pulse|All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.
75614923|NCT02654587|Drug|OSE2101|
75614924|NCT02654587|Drug|Docetaxel|
75614925|NCT02654587|Drug|Pemetrexed|
75317045|NCT05964751|Diagnostic Test|lipid profile|measuerments of lipid profile parameters to detect hyperlipidemia
75317046|NCT05964751|Diagnostic Test|fasting blood suger|measurment of fasting blood suger to detect hyprerglicemia
75317047|NCT05964738|Drug|Diuretics withdrawal|Diuretics that not have been demonstrated improve survival in chronic HFrEF are withdrawn
75614926|NCT04283643|Other|Transcranial Focused Ultrasound|Non-invasive brain stimulation technique
75614927|NCT04283643|Other|Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
75614928|NCT02861703|Behavioral|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
75614929|NCT02861313|Device|CM LOC attachment|CM LOC attachment
75614930|NCT02861313|Device|ball attachment|Ball attachment
75614931|NCT02654353|Procedure|Ablation|In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
75614932|NCT01122264|Drug|Tadalafil|Administered orally for 24 weeks.
75614933|NCT01122264|Drug|Sildenafil Citrate|Administered orally for 24 weeks.
75614934|NCT04311294|Drug|ANS-6637 Low Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
75614935|NCT04311294|Drug|ANS-6637 High Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
75614936|NCT04311294|Drug|Matched Placebo|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
75766744|NCT00127413|Behavioral|Cognitive Behavioral Therapy-Integrated|Integrated treatment
75766745|NCT00127413|Behavioral|Cognitive Processing Therapy - PTSD|Cognitive processing therapy
75766746|NCT00127413|Behavioral|Treat as Usual|Treatment as usual
75766747|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^7 CFU in 10 mL phosphate-buffered saline
75766748|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^8 CFU in 10 mL phosphate-buffered saline
75317048|NCT05964738|Drug|Diuretics maintenance|Any diuretic could be used
75317049|NCT05964712|Procedure|Medical surgery therapy|De novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment.
75461983|NCT01858779|Device|72h holter ECG|All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
75461984|NCT01858792|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
75461985|NCT01858792|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
75766749|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^9 CFU in 10 mL phosphate-buffered saline
75908374|NCT04350840|Behavioral|feedback|feedback of optical diagnosis performance per 3 month
75908375|NCT03058744|Drug|IDP-118 Lotion|Lotion
75908376|NCT03058744|Drug|HP Monad Lotion|Lotion
75908377|NCT03058744|Drug|Ultravate Cream|Cream
75908378|NCT03058744|Drug|Tazorac Cream|Cream
75908379|NCT02734537|Drug|Cisplatin|Given IV
75908380|NCT02734537|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75908381|NCT02734537|Other|Laboratory Biomarker Analysis|Correlative studies
75908382|NCT03059056|Drug|Empagliflozin 25mg|Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
75908383|NCT02227134|Procedure|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
75614937|NCT04265131|Other|art therapy|Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
75908384|NCT00951639|Dietary Supplement|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
75908385|NCT00951639|Procedure|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
75317050|NCT05964634|Diagnostic Test|OCT imaging|Image J or Spectralis OCT built-in software package was used to manually locate and measure the area and width of the temporal parapapillary atrophy.
75614938|NCT00920218|Biological|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
75614939|NCT00920218|Biological|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
75766750|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^10 CFU in 10 mL phosphate-buffered saline
75908386|NCT00951639|Dietary Supplement|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
75614940|NCT02861235|Other|Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary|with gamma-camera and D.SPECT camera
75614941|NCT02861235|Other|Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Toulouse centre
75614942|NCT02861235|Other|Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Nancy centre
75614943|NCT02861235|Other|stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days|with gamma-camera and D.SPECT camera, in Paris centre
75614944|NCT02861235|Other|Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera|rest thallium-201 tomoscintigraphy for myocardial viability assessment
75614945|NCT02861235|Other|Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera|rest technetium-99m tomoscintigraphy for myocardial viability assessment
75908387|NCT03058666|Drug|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
75908388|NCT03058666|Device|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
75908389|NCT02223624|Other|walking and light weights|
75908390|NCT02223624|Other|eccentric aerobic exercise|
75908391|NCT02223624|Other|concentric aerobic exercise|
75908392|NCT03563547|Behavioral|Dietary counseling (fat modifed diet)|Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
75908393|NCT03563547|Behavioral|Dietary Counseling (fat modified + soy enriched diet)|"Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
75908394|NCT03058510|Procedure|Frequency domain optical coherence tomography|OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
75461986|NCT01858792|Other|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
75461987|NCT01858805|Procedure|esophagectomy|
75461988|NCT01858831|Drug|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
75461989|NCT01858831|Drug|Atovaquone|Atovaquone
75766751|NCT03971565|Biological|Blood sample 5 milliliter|The blood of the patients will be collected during their hospitalization of the hematology department participating in the research
75766752|NCT01037465|Drug|N-acetylcysteine|N-acetylcysteine
75766753|NCT01037465|Drug|Placebo|Placebo
75766754|NCT03971331|Device|PAC catheter and critical care ultrasound examination|Patients in study group were placed the PAC and performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately
75766755|NCT01582425|Drug|Isavuconazole|oral
75766756|NCT01582425|Drug|Methadone|oral
75766757|NCT00143403|Drug|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
75766758|NCT00143403|Drug|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
75766759|NCT00220701|Drug|Lexapro (escitalopram)|antidepressant drug selective serotonin reuptake inhibitor (SSRI)
75766760|NCT00127101|Drug|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
75766761|NCT00127101|Drug|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
75908395|NCT02227212|Drug|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75317051|NCT05964608|Behavioral|Behavioral Therapy|"Structured interviews, consisting of a total of 6 sessions, were held once every two weeks for men with premature ejaculation problems. Behavioral therapy took place once every two weeks for a total of six 45-minute sessions. The stop-start technique was the therapy used. Behavioral therapy interviews were conducted at the urology outpatient clinic of the hospital. Post-tests were administered to men with premature ejaculation (PEDT) and their spouses (FSFI and SQOL-F) immediately after the 6th session was completed."
75614946|NCT00649519|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
75461990|NCT01858844|Other|CHEST COMPRESSION TECHNIQUE (CCT)|The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.
75461991|NCT01858870|Drug|lacosamide|routine clinical practice
75461992|NCT01858909|Drug|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
75461993|NCT01858935|Drug|ND-L02-s0201 Injection|Single IV infusion.
75614947|NCT00649519|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
75614948|NCT00629811|Drug|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
75614949|NCT00629811|Drug|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
75908396|NCT00303849|Drug|Carboplatin|Given IA
75908397|NCT00303849|Drug|Etoposide|Given IV
75908398|NCT00303849|Drug|Etoposide Phosphate|Given IV
75614950|NCT02654275|Other|Proprioceptive Intervention|
75614951|NCT02882256|Other|Video discharge instructions|Discharge instructions provided in video form
75614952|NCT02652091|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
75614953|NCT02652091|Device|BETACONNECT device|Used to apply Betaseron.
75614954|NCT00625560|Drug|Entecavir|entecavir 1.0 mg QD
75614955|NCT00625560|Drug|Lamivudine|lamivudine 100 mg QD
75614956|NCT02651857|Device|Fuse® Colonoscope|Endoscopic diagnostic procedures for lower GI tract
75614957|NCT02651857|Device|Fuse® Gastroscope|Endoscopic diagnostic procedures for upper GI tract
75614958|NCT04167709|Other|Education in clinical competence in detecting signs of postpartum depression in immigrant mothers|Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
75766762|NCT03967119|Device|Patient monitoring|Arterial blood pressure, pulse oxygen saturation, and cardiac output/stroke volume are monitored with invasive arterial catheter, pulse oxymetry, and esophageal doppler in all participants. Some dynamic variables including SVV and PPV are automatically calculated in each monitor. PWV is manually calculated in a printed plethysmographic waveform. Plethysmographic waveform amplitude (PW) is measured on a beat-to-beat basis as the vertical distance between peaks and preceding valley troughs in the waveform. The maximum PW (PWmax) and minimum PW (PWmin) are determined manually over the same respiratory cycle, and PWV is calculated. PWV=(PWmax-PWmin)/[(PWmax+PWmin)/2].
75766763|NCT00126555|Drug|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
75908399|NCT00303849|Other|Laboratory Biomarker Analysis|Correlative studies
75908400|NCT00303849|Drug|Mannitol|Given IA
75461994|NCT01858935|Drug|Placebo|Single IV infusion.
75461995|NCT01858961|Drug|BI 201335|Once a day
75461996|NCT01858961|Drug|ribavirin|Twice a day
75461997|NCT01858961|Drug|BI 207127|Twice a day
75461998|NCT01858961|Drug|Telaprevir|Three times a day
75461999|NCT01858961|Drug|ribavirin|Twice a day
75462000|NCT01858961|Drug|Pegylated Interferon|Once a week
75462001|NCT01858987|Procedure|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
75462002|NCT01858987|Procedure|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
75462003|NCT01858987|Device|Ligasure|
75462004|NCT01858987|Other|vascular staple|
75908401|NCT00303849|Drug|Melphalan|Given IA
75908402|NCT00303849|Other|Quality-of-Life Assessment|Ancillary studies
75908403|NCT00303849|Drug|Sodium Thiosulfate|Given IV
75908404|NCT04863846|Other|No intervention, observational study|Exposure of interest: clinical implementation of an algorithm
75908405|NCT03058432|Radiation|Radiotherapy alone|
76071304|NCT05094115|Behavioral|Psychological Flexibility Training (PFT)|"A 2-day workshop lasting approximately 8 hours per day. Day 1: an overview of the training and to describe the posture or stance that prepares one to respond to challenging situations in a psychologically flexible manner.~Day 2: identifies common coping strategies that typically fail or even backfire over the long term and to practice skills that promote psychological flexibility. Experiential exercises will be integrated throughout the training.~Following the PFT, 4 optional, monthly, one-hour booster sessions to supply refresher information.~An experiential exercise to highlight one or more process/concept that was introduced during the 2-day training.~Questions from the attendees about applying the concepts in their lives.~Comments and questions from the booster session facilitators to encourage application of the concepts."
75614959|NCT04310982|Device|The G-Walk sensor system (G-Walk)|The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
76071305|NCT05092750|Device|FerroTraceTM|A magnetic
75614960|NCT02651935|Device|Intellivent ASV|Automated Invasive mechanical ventilation and weaning strategy
75614961|NCT04311138|Other|community-based reablement service|Experimental group receive a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour.
75614962|NCT04311138|Other|multicomponent training|control group receive a 10-wk multicomponent training including 1.5-hr group intervention (group exercise, cognitive training, and health education) and 1.0-hr placebo intervention.
75614963|NCT00650455|Drug|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
75766764|NCT00126555|Radiation|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
75766765|NCT00126555|Procedure|Conventional surgery|Undergo surgery
75766766|NCT00126555|Other|laboratory biomarker analysis|Correlative studies
76071306|NCT05092750|Drug|indocyanine green (ICG)|Given by SC injection
76071307|NCT05091489|Other|Qualitative assessment about PrEP acceptability|Qualitative research among key-populations, community and healthcare workers, and decision and policy makers, including focus group and semi-directive interviews
76071308|NCT05087082|Other|Virtual Hospital at Home - Home admission of epidemic patients|Admitting COVID-19 patients at home
75317052|NCT05964556|Other|Functional Movement Screen (FMS)|FMS is an analysis system that evaluates muscle strength imbalance and functional performances on the dominant-non-dominant side in athletes. It aims to detect stability and mobility that can be ignored in the asymptomatic active population and athletes. It consists of 7 basic parameters determined by Gray Cook (Deep Squat, Hurdle Step, -In-line Lunge, Shoulder Mobility, Active Straight Leg Raise, Trunk Stability, Rotatory Stability). The athletes were evaluated after giving verbal instructions to the athletes about the head, trunk, knee and foot positions. For each parameter, the athletes were given points between 0-3 values. The total score was determined as 21 points. Completing the movement completely and without compensation was given 3 points, and 2 or 1 points were given according to the activation of the compensation mechanism and balance disorders. In case of any pain during or at the end of the movement in the evaluated parameter, 0 points were given to the athletes.
75317053|NCT05964556|Other|Isokinetic Muscle Evulation of Knee Muscles|The isokinetic knee flexor and extensor group muscle strengths of the athletes participating in the study were measured on the dominant and non-dominant sides. Measurements were performed with an ISOMED 2000 (D&R Ferstl GmbH, Hemau, Germany) isokinetic measuring device. The test protocol was adjusted to be concentric/concentric. Measurements were made at angular velocities of 60°/sec and 180°/sec. At an angular speed of 60°/sec, the athlete was asked to perform 10 repetitions of voluntary knee flexion/extension at maximum strength. Then, after resting for 30 seconds, 30 repetitions of knee flexion/extension were performed at an angular velocity of 180°/sec. Before starting the test in both angular speeds, 3 repetitive attempts were made to learn the movement. The following parameters were evaluated at 60°/sec and 180°/sec angular speed.
75317054|NCT05964543|Drug|Q-1802 Injection,Oxaliplatin Injection,Capecitabine|Q-1802：A dose Q-1802 will be administered intravenously Q2W. XELOX（oxaliplatin，capecitabin）: 21 days as a cycle Oxaliplatin will be administered 130mg/m2 as a 2-hour IV infusion,administer once on the first day, with 21 days as a cycle Capecitabine will be administered 1000mg/m2 orally twice daily (D1-D14),21ds is one cycle.
75614964|NCT00650455|Drug|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
75614965|NCT00650455|Drug|placebo|placebo tablet every morning and capsule every evening for 12 weeks
75614966|NCT02654041|Drug|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
75614967|NCT02651779|Procedure|Open reduction and internal plate fixation|
75766767|NCT00004228|Drug|asparaginase|Given IV
75766768|NCT00004228|Drug|cyclophosphamide|Given IV
75766769|NCT00004228|Drug|cytarabine|Given IV
75766770|NCT00004228|Drug|daunorubicin hydrochloride|Given IV
75766771|NCT00004228|Drug|dexamethasone|Given IV
75766772|NCT00004228|Drug|doxorubicin hydrochloride|Given IV
76071309|NCT05082142|Drug|Tranexamic acid|Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
75766773|NCT00004228|Drug|leucovorin calcium|Given IV
75766774|NCT00004228|Drug|mercaptopurine|Given IV
75766775|NCT00004228|Drug|methotrexate|Given IV
75766776|NCT00004228|Drug|prednisone|Given IV
75766777|NCT00004228|Drug|thioguanine|Given PO
75766778|NCT00004228|Drug|vincristine sulfate|Given IV
75766779|NCT00004228|Radiation|radiation therapy|
75766780|NCT01101568|Drug|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
75766781|NCT01101568|Drug|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
75766782|NCT01101568|Drug|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
76071310|NCT05080803|Drug|intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone|intravitreal administration
75614968|NCT02651779|Other|Closed reduction and plasterimmobilisation|
75614969|NCT02658409|Biological|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
75766783|NCT01098838|Drug|LCL161|
75766784|NCT01098916|Radiation|Home X-rays|X-rays examinations performed at home
75766785|NCT01098916|Radiation|X-rays in hospital|
75614970|NCT02658409|Biological|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
75766786|NCT01087840|Drug|Raltegravir|"Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.~Arms: Raltegravir/Truvada Other Names: Isentress/Truvada"
75614971|NCT02653885|Other|Red red cell distribution width|Results from hemogram
75766787|NCT01098994|Dietary Supplement|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
75766788|NCT01098994|Other|Dummy pills|Daily placebo administration for 8 weeks
75766789|NCT01099072|Drug|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
75766790|NCT01099072|Drug|methylphenidate+carnitine|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
75766791|NCT00003526|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75766792|NCT00195260|Drug|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
75908406|NCT03058432|Radiation|Concurrent chemoradiotherapy|
75766793|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
75766794|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
75766795|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
75766796|NCT00031486|Drug|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
75766797|NCT00031486|Drug|Placebo|Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
75766798|NCT01099150|Dietary Supplement|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~900 mg of total flavan-3-ols and procyanidins.
75908407|NCT04649112|Genetic|PBCAR19B|Single dose of Allogeneic Anti-CD19 CAR T cells will be injected/infused
75908408|NCT04952740|Procedure|IPC+PCI|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
75766799|NCT01099150|Dietary Supplement|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~400 mg total flavan-3-ols and procyanidins.
75908409|NCT04952740|Procedure|No IPC|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.
75908410|NCT04316832|Behavioral|Mindfulness based cognitive training|The mindfulness based cognitive training will include three short mindfulness exercises: a) a breathing exercise, b) a body scan exercise, and c) a mindfulness attention exercise.
75908411|NCT04316832|Other|Control exercise|Participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
75908412|NCT02828241|Drug|DFD-04 Ointment|
75908413|NCT02828241|Other|Placebo Ointment|
75317055|NCT05964530|Procedure|Surgery|Surgery procedures include LAR+ anal preservation or APR
75317056|NCT05964491|Other|No intervention|No intervention studied
75614972|NCT02653807|Other|mobilization with movement|manual therapy intervention
75614973|NCT02653807|Other|osteopathic mobilization|manual therapy intervention
75614974|NCT01121562|Drug|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
75614975|NCT04169425|Procedure|elective diverting ileostomy|
75614976|NCT02658253|Biological|PRIMVAC|3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
75614977|NCT02658253|Biological|GLA-SE|2.56 µg of GLA content
75614978|NCT02658253|Biological|Alhydrogel|0.85 mg og Aluminium content
75614979|NCT02658253|Biological|Placebo|0.9% Na cl
75614980|NCT04311060|Diagnostic Test|Molecular panel|"Detection of CBF rearrangements using PCR: CBFB-MYH11 [inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22).~NGS panel to detect classic mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT"
75614981|NCT02651623|Drug|Sertraline|Multiple doses of sertraline for 14 days
75766800|NCT01099150|Dietary Supplement|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
75766801|NCT00003508|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75766802|NCT01088074|Device|Histoacryl Tissue Adhesive|
75908414|NCT04308642|Other|blood test for renal biomarkers|blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)
75908415|NCT04308642|Other|urine test for renal biomarkers|urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)
75908416|NCT04952428|Behavioral|"Re-examination visit (today visit)"|"Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom & Richmond test will be conducted."
75908417|NCT04641858|Biological|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
76071311|NCT05080491|Diagnostic Test|immuno analysis and neuropsychological tests|"A venous blood sample will be taken for assay in immuno-analysis including and for assay in chromatography with mass spectrometry. Patients will participate in computer neuropsychological tests: .~Venous blood collection and the administration : the tubes are transported to the biochemistry laboratory of the University Hospital Center of Nice (CHU Nice) which prepares five aliquots (4 for assays in immuno-analysis including 2 on site, and one for assay in chromatography with mass spectrometry.~Administration of two neuropsychological tests on computer(Attention Network Task and Tower of London)."
76071312|NCT05072665|Device|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
76071313|NCT05072067|Procedure|the sleeve gastroplasty with the endoscopic system Overstich SX|the sleeve gastroplasty with the endoscopic system Overstich SX
76071314|NCT05065970|Drug|Felzartamab|anti-CD38+ monoclonal antibody
76071315|NCT05065970|Other|Placebo|Placebo comparator
76071316|NCT05065801|Combination Product|GABRINOX|Patients in the experimental arm received sequential treatment: 3 cycles of GEMBRAX followed by 2 cycles of FOLFIRINOX
76071317|NCT05065801|Combination Product|FOLFIRINOX|Patients in this arm received reatment: 3 cycles of FOLFIRINOX
76071318|NCT05064943|Diagnostic Test|2-minute step test|"The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg."
76071319|NCT05061693|Drug|INCB054707|Oral; Tablet
75317057|NCT05964439|Device|HoloUS app for ultrasound visualization|Study participants will wear HoloLens see-through glasses and use the HoloUS app for ultrasound visualization in the conduct of a vascular access procedure in a phantom.
75317058|NCT05964426|Other|Turkey Health Literacy Scale (TSOY-32)|A survey will be conducted.
75462005|NCT01859000|Other|Multidimensional Family Therapy|MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.
75462006|NCT01859000|Other|Group CBT|Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
75462007|NCT01859039|Biological|Administration of Live attenuated influenza vaccine|
75462008|NCT01859052|Other|Low carbohydrate diet|Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.
75462009|NCT01859052|Other|Low calorie low fat diet|The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet
76071320|NCT05061693|Drug|Placebo|Oral; Tablet
75317059|NCT05964023|Device|pBFS rTMS|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
75317060|NCT05964023|Device|5-cm rTMS|"Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be localized by 5-cm rule."
75317061|NCT05963269|Other|Computer assisted intramuscular learning game|It is an educational game that can only be opened from the computer, with questions and answers and cases. The game is currently under development by the developers. The researcher will be able to see how many times the students entered the game and how many points they got.
75317062|NCT05961644|Drug|Cladribine Subcutaneous Injection|Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)
75462010|NCT01859052|Other|AHA diet recommendations|given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
75462011|NCT01859065|Behavioral|Intensified anticipatory guidance|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
75462012|NCT01859065|Behavioral|Routine|Routine anticipatory guidance (control)
75462013|NCT01859091|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
75766803|NCT01088074|Device|Dermabond|
75766804|NCT01088074|Device|Staples|
75766805|NCT01088074|Device|Monocryl 4-0|
75766806|NCT03952000|Behavioral|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
75908418|NCT04641858|Biological|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.
76071321|NCT05057754|Behavioral|Cooling|Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C
76071322|NCT05057754|Behavioral|Heating|A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.
75908419|NCT03835143|Procedure|subinguinal varicocelectomy|varicocele ligation done at the level of subinguinal region
75908420|NCT03563703|Device|Ultrasound|Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.
76071323|NCT05057754|Behavioral|Exercising|Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.
76071324|NCT05057754|Behavioral|Typing|All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.
76071325|NCT05057754|Behavioral|Using a mouse|"Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software."
76071326|NCT05057754|Behavioral|Cooking|Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
76071327|NCT05055830|Drug|The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.|The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.
76071328|NCT05053971|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
76071329|NCT05053971|Procedure|Core Biopsy|Undergo core needle biopsy
76071330|NCT05053971|Drug|Entinostat|Given PO
76071331|NCT05053412|Diagnostic Test|Helio Liver Test|A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
76071332|NCT05048069|Drug|Mucosta®SR Tablets 150mg(Rebamipide)|adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.
75317063|NCT05961644|Drug|0.9% Chloride Injection Sodium|0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
75317064|NCT05961631|Other|Bio-electrical Impedance Analysis|Variable measured: Fluid accumulation (FA), volume excess (VE), total body weight (TBW), extracellular water (ECW), intracellular water (ICW)
75317065|NCT05961033|Device|Virtual Reality based exercises|Play VR games
75317066|NCT05960240|Drug|AB-101|AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.
75462014|NCT01859104|Behavioral|Use of smartphone app|
75462015|NCT01859117|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
75462016|NCT01859117|Biological|10 x 10^6 cells|10 x 10^6 cells administered on Study Days 1 and 8
75908421|NCT03563703|Device|Near Infrared Light|Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
75908422|NCT04952272|Combination Product|CpG-ODN|CAR-T cells secreting scFv against OX40
75908423|NCT04295928|Behavioral|PPP|Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation
75908424|NCT04952116|Other|Eyelid reconstruction|Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
75908425|NCT02227524|Other|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
75908426|NCT02227524|Device|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
75908427|NCT02227524|Device|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
75908428|NCT02227524|Device|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
75317067|NCT05960240|Drug|Placebo|A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.
75317068|NCT05960240|Drug|Nucleos(t)ide Analogue|Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
76071333|NCT05046496|Diagnostic Test|Intra-arterial digital subtraction angiography|Invasive intra-arterial angiography, with intra-arterial stent placement if a stenosis is confirmed
75317069|NCT05958433|Behavioral|Rehabilitation with stoma appliance|The rehabilitation group will receive preoperative stoma education in addition, a water-filled ostomy appliance (50-100 ml) will be attached 48 hours before surgery. These pouches will not be removed until surgery, and the EST nurse will teach the patients preoperatively how to manage the ostomy appliance with similar standards as described in the usual postoperative stoma care.
75908429|NCT04951960|Other|Higher PEEP setting|PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
75766807|NCT03951922|Behavioral|Horticultural activity|Therapeutic horticulture activities are plant-related activities that include but not limited to digging, watering, planting, weeding, trimming, fertilizing, mulching, harvesting, learning about organic farming, and exploring options to incorporate horticulture into daily activities
75766808|NCT03961594|Other|expansion volémique|cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
75766809|NCT02530060|Drug|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
76071334|NCT05044195|Biological|aQIV|Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1
76071335|NCT05044195|Biological|Comparator QIV|Participants receive a 0.5-mL intramuscular dose of Comparator QIV on Day 1
76071336|NCT05041166|Drug|Hyperpolarized [13C] Pyruvate|Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
76071337|NCT05038150|Drug|SGN1|SGN1, will be administered as an IV infusion, via an IV catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.
75462017|NCT01859117|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
75462018|NCT01859117|Biological|100 x 10^6 cells|100 x 10^6 cells administered on Study Days 1 and 8
75614982|NCT02651623|Drug|Moxifloxacin|A single dose of 400 mg Moxifloxacin
75614983|NCT02651623|Drug|Drug - Placebo|Placebo administered for 14 days
75614984|NCT02651701|Procedure|MR-PET|whole body MR-PET with dedicated liver+rectal protocol
75908430|NCT04951960|Other|Lower PEEP setting|PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
75908431|NCT02223780|Other|early palliative care|the patients will benefit from an early palliative care consultation
75908432|NCT04951882|Biological|human derived umbilical cord derived mesenchymal stem cells|intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
75614985|NCT04167475|Dietary Supplement|Probiotic capsule|Each probiotic capsule contains 1 x 10^9 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsules will be supplied by PrecisionBiotics Ltd.
75614986|NCT04167475|Dietary Supplement|Placebo capsule|Each placebo capsule contains corn starch and magnesium stearate. The placebo capsules will be supplied by PrecisionBiotics Ltd.
75614987|NCT01121484|Drug|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
75614988|NCT01121484|Drug|placebo|Placebo tablets taken orally once daily.
75614989|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release oral tablet
75614990|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release tablet
75614991|NCT01169675|Drug|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
75614992|NCT01169675|Drug|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
75614993|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
75614994|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
75614995|NCT01169675|Drug|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
75614996|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
75614997|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
75908433|NCT01355523|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|6 mg oral melatonin daily 1 hour before bedtime
75908434|NCT01355523|Drug|Placebo|6 mg oral placebo daily 1 hour before bedtime
75908435|NCT02223936|Other|group exposed|Assessment by Brunet Lezine scale
75908436|NCT02223936|Other|Control|Not exposed group
75908437|NCT04952038|Behavioral|sleep disorder|ALS patients with or without sleep disorder
75908438|NCT02227602|Drug|Mango polyphenolics|Frozen mango pack will be provided (200~400g per day).
75908439|NCT04951414|Diagnostic Test|ICF core set|KOA rehabilitation regimen based on the complete core combination of ICF was accepted
76071338|NCT05029063|Drug|Rivaroxaban 10 MG|Identical comparator drug
76071339|NCT05027503|Other|Exercise with hippotherapy simulator|30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
75614998|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
75614999|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
75615000|NCT01169675|Drug|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
75615001|NCT01169675|Drug|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
76071340|NCT05027503|Other|Respiratory Physiotherapy|Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
75615002|NCT01169675|Drug|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
75615003|NCT00650533|Drug|Glimepiride Tablets 1 mg|1mg, single dose fed
75615004|NCT00650533|Drug|Amaryl® Tablets 1 mg|1mg, single dose fed
76071341|NCT05024591|Device|Lunit INSIGHT MMG CADe/x for medical imaging|• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis
75615005|NCT02653729|Behavioral|cognitive behaviour therapy|
75766810|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
75766811|NCT01101646|Drug|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
75766812|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
75766813|NCT02530216|Other|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|"AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint."
75766814|NCT01101724|Behavioral|Mandated Rest, Intervention|"In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury."
75908440|NCT02227680|Other|Music Therapy|Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
75615006|NCT02653729|Drug|Espidone|
75615007|NCT02653729|Drug|Olepra|
75317070|NCT05958355|Other|Functional postural control training|All participants will receive functional postural control training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
75317071|NCT05958355|Other|Treadmill training|All participants will receive treadmill training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
75317072|NCT05955066|Drug|Baricitinib 4 MG|1 capsule (4mg) daily for 24 weeks
75615008|NCT02653729|Drug|Donu|
75615009|NCT02881866|Drug|Furosemide|
75317073|NCT05955066|Drug|Placebo|1 capsule daily
75317074|NCT05954507|Diagnostic Test|PET/MRI|PET/MRI is a new-generation hybrid camera capable of simultaneously performing FDG positron emission tomography and gadolinium-injected MRI. PET/MRI could be a relevant prognostic marker of progression, and could significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis.
75317075|NCT05939245|Procedure|Furosemide Injection|Continuous infusion of furosemide is administered starting at 2 mg/hour and can be titrated until the target urine output of 1-2 cc/kg/hour is achieved for 48 hours. In case of hypotension (MAP <65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
75462019|NCT01859169|Procedure|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
75462020|NCT01859182|Drug|selumetinib|Given PO
75462021|NCT01859182|Drug|Akt inhibitor MK2206|Given PO
75462022|NCT01859182|Other|laboratory biomarker analysis|Correlative studies
75462023|NCT01859182|Other|pharmacogenomic studies|Correlative studies
75462024|NCT01859182|Procedure|quality-of-life assessment|Ancillary studies
75615010|NCT02881866|Drug|Saline|
75615011|NCT00924664|Biological|Tanezumab 20 mg|Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
75615012|NCT00924664|Biological|Tanezumab 10 mg|Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
75615013|NCT04314869|Procedure|Uterus transplantation|Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.
75766815|NCT01584700|Procedure|Renal Artery Denervation|Radiofrequency ablation of the renal artery sympathetic outflow tract.
75766816|NCT01101802|Drug|Mycophenolate mofetil|Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
75766817|NCT01101802|Drug|sugar pill|Arm 2 patients were given 2 sugar pills bd for 8 weeks
75766818|NCT01099228|Other|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
75766819|NCT01099228|Other|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
75908441|NCT02227680|Other|Massage Therapy|Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
75908442|NCT04951648|Drug|Almonertinib|Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
75908443|NCT04951648|Drug|chemotherapy|Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
76071342|NCT05018611|Behavioral|LifeSkills Mobile|A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
75462025|NCT01859234|Drug|89Zr-bevacizumab|89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
76071343|NCT05009394|Procedure|Targeted Muscle Reinnervation (TMR)|Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.
75615014|NCT05252611|Other|Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8)|The aim of this study is to test the validity of the Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8).
75615015|NCT02653651|Drug|Ketamine|Ketamine infused at 0.1 mg/kg/hour
75766820|NCT00003472|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
75766821|NCT01099306|Other|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
75766822|NCT01088152|Behavioral|Celiac school|Structured education of adult celiac patients at 10 sessions.
75766823|NCT01088152|Behavioral|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
75766824|NCT01099384|Behavioral|Written self-help materials|Written materials to help adolescents stop tobacco use
75766825|NCT01099384|Behavioral|Group behavioral counseling|group behavioral counseling (2 day weekend program)
75766826|NCT01088230|Other|Botox®|the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
75766827|NCT01088230|Other|saline solution|the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
75766828|NCT01099462|Drug|Ibuprofen|Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
76071344|NCT05009394|Procedure|Regenerative Peripheral Nerve Interface (RPNI)|Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.
76071345|NCT05009394|Procedure|Standard neuroma treatment, neuroma excision, and muscle burying|Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
76071346|NCT05004298|Other|Animal Assited therapy|The intervention will be structured in 10 group sessions, with a weekly frequency and one hour duration.
75615016|NCT02653651|Drug|Lidocaine|Lidocaine infused at 1 mg/kg/hour
75615017|NCT02653651|Drug|Placebo|An equal volume of saline
75615018|NCT02653573|Behavioral|Coaching|Self-management education
75766829|NCT01088308|Procedure|High rate atrial and vetricular stimulation|The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
75766830|NCT01088308|Procedure|Ventricular Tachycardia induction|A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
76071347|NCT04999839|Drug|NDI-034858 study drug|NDI-034858 2 mg oral capsules.
76071348|NCT04999839|Drug|NDI-034858 study drug|NDI-034858 5 mg oral capsules.
75615019|NCT02887469|Drug|3% hypertonic saline|The same as above
75766831|NCT01099540|Drug|Pazopanib|Pazopanib 800 mg qd daily
75766832|NCT00003298|Drug|cisplatin|Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
75766833|NCT00003298|Drug|fluorouracil|Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
75766834|NCT00003298|Drug|leucovorin calcium|Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
75766835|NCT00003298|Drug|paclitaxel|Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
75766836|NCT00003298|Procedure|surgery|"The surgical procedure performed involved a radical subtotal or total gastrectomy.~A complete surgical resection was required"
75462026|NCT01859260|Device|CPAP/autopap|
75462027|NCT01859273|Behavioral|mHealth|mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
75615020|NCT02651233|Other|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
75615021|NCT05376839|Drug|Cedirogant|Capsule, Oral
75615022|NCT02651311|Other|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
75317076|NCT05939245|Procedure|Placebo Injection|Continuous infusion of placebo fluid is administered at a rate of 2 mL/hour. In case of hypotension (MAP <65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
75766837|NCT00003298|Radiation|radiation therapy|Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
75766838|NCT01327456|Behavioral|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
75766839|NCT01099696|Dietary Supplement|B. infantis 35624|B. infantis 35624 in white capsules
75766840|NCT01099696|Dietary Supplement|placebo|white placebo capsules
75317077|NCT05937451|Other|PRIME solution|The investigators will apply an AKI prediction model (PRIME solution) based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician.
76071349|NCT04999839|Drug|NDI-034858 study drug|NDI-034858 15 mg oral capsules.
75317078|NCT05934877|Behavioral|PrEP navigation + text messaging|Using a client-centered approach, the PrEP navigator works to link participants into SUD treatment and other ancillary behavioral health and support services, according to their unique barriers, with the ultimate goal of PrEP initiation, adherence, and persistence; services may include mental healthcare, counseling for intimate partner violence, food insecurity, housing instability, hormone therapy. Text-messaging support includes once weekly text message.
75317079|NCT05934877|Behavioral|Standard of Care|The SOC arm provides PrEP education, information, and referrals. Those randomized to the SOC arm receive an approximate 20-30-minute educational session on PrEP, and will be given a PrEP pamphlet and list of clinics that provide PrEP in LAC.
75462028|NCT01859286|Other|standardized sign out process|The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
75462029|NCT01859338|Radiation|cone-beam computed tomography|Undergo CBCT
75462030|NCT01859338|Radiation|magnetic resonance imaging|Undergo MRI
75766841|NCT03961282|Other|Doorway Width Test|The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.
75462031|NCT01859338|Radiation|computed tomography|Undergo fan beam computed tomography
75615023|NCT02651311|Drug|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
75766842|NCT03961282|Other|Door Frame Color Test|The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).
75766843|NCT03950908|Other|Single bite biopsy technique|During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.
75766844|NCT03950908|Other|Double bite biopsy technique|During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
75766845|NCT03951844|Device|BRIDGE/EMPATIA exoskeleton|The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
75908444|NCT04185246|Drug|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
75908445|NCT04185246|Diagnostic Test|Echocardiogram|Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
75908446|NCT04164888|Drug|CIVI 007|hypercholesterolemia agent
76071350|NCT04999839|Drug|NDI-034858 study drug|NDI-034858 30 mg (2*15 mg) oral capsules.
75462032|NCT01859351|Drug|WX-037|
75462033|NCT01859351|Drug|WX-554|
75462034|NCT01859377|Drug|V0498 - A mg|Single oromucosal administration
75462035|NCT01859377|Drug|Ibuprofen|Single oral administration
76071351|NCT04999839|Other|Placebo|Placebo matched to NDI-034858 oral capsules.
76071352|NCT04994808|Drug|Clofarabine|Given IV
76071353|NCT04994808|Drug|Fludarabine|Given IV
76071354|NCT04994808|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
75615024|NCT02651311|Drug|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
75615025|NCT04168177|Procedure|PCA|Patient controlled analgesia
75615026|NCT04168177|Procedure|ESP|erector spinae plane block
75615027|NCT02653261|Drug|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
75615028|NCT02653261|Drug|Placebo|An equal volume of saline
75615029|NCT04252378|Procedure|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
75766846|NCT03960970|Drug|Azithromycin 500 mg|Additional IV Azithromycin 500 mg to Standard Prophylaxis
75766847|NCT03960970|Drug|Mefoxin 2g|Standard Prophylaxis
75615030|NCT04252378|Procedure|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
75766848|NCT00002842|Drug|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
75766849|NCT00002842|Drug|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
75462036|NCT01859416|Dietary Supplement|Oral nutritional supplement|
75462037|NCT01859429|Other|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
75766850|NCT00002842|Drug|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
75766851|NCT00002842|Procedure|adjuvant therapy|Chemotherapy given after hepatic resection
75766852|NCT00002842|Procedure|conventional surgery|Hepatic resection
75766853|NCT01099930|Other|immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|"Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.~Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant"
75766854|NCT01099930|Other|Standard Therapy|Patient will receive standard therapy as decided upon by their treating neurologist.
75766855|NCT03950596|Other|Acute resistant load exercises|"Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises"
75766856|NCT03950596|Behavioral|Background Questionnaire|Background questionnaire will be filled out by participants
75766857|NCT03950596|Other|Pain Questionnaire|Pain questionnaire regarding pain in the knee during previous 3 months
75766858|NCT03950596|Genetic|DNA and RNA test|DNA and RNA tests will be sent to a genetic laboratory for analysis
75908447|NCT04951258|Other|Multicomponent exercise|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Multicomponent exercise included strengthening, balance training, aerobic dance, and stretching
75317080|NCT05934877|Behavioral|Contingency Management|Non-responders in the ASK-PrEP arm will be stepped and re-randomized (1:1) to Contingency Management (CM), either in concert with ASK-PrEP or alone. CM is a progressive contingency schedule. Participants submit a thrice weekly urine sample. Participants will receive a voucher-based escalating reinforcement schedule. Successive urine samples that are nonreactive for the metabolites of their identified SUD will escalate their voucher point value. Each three consecutive nonreactive urine samples will receive bonus voucher points. A reactive urine sample will place the participant at the initial voucher point value; however, a rapid reset procedure allows participants to return to their place in the escalating schedule following three consecutive nonreactive urine samples. Voucher points can be redeemed at any time during the study for goods or services that promote a pro-social and healthy lifestyle.
75462038|NCT01859442|Procedure|Structured responsive interval exercise training programme|
75462039|NCT01859442|Other|Sham group|NO intervention in this group, only standard care (no exercise programme)
75615031|NCT02657941|Behavioral|Motivational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines"
75908448|NCT04951258|Other|Video home exercise group|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Video home exercise included four limbs mobility exercise, stretching, strengthening, and aerobic exercise
75908449|NCT02227914|Drug|Oprozomib|Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
75908450|NCT02227914|Drug|Sorafenib|Study subjects will receive sorafenib tablets twice a day for Days 1-28
75908451|NCT04161456|Drug|Apremilast|Apremilast twice daily 30 mg
75908452|NCT04951024|Procedure|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
76071355|NCT04994808|Radiation|Total-Body Irradiation|Undergo TBI
76071356|NCT04994808|Drug|Treosulfan|Given IV
75462040|NCT01859455|Drug|LGT209 50 mg|Active experimental drug
75462041|NCT01859455|Drug|LGT209 300 mg|Active experimental drug
75766859|NCT03950596|Diagnostic Test|Ultrasound|Ultrasound of the knee joint and the quadriceps muscle and the pica tendon
75766860|NCT03950596|Diagnostic Test|Percutaneous Needle Core Biopsy|Core Biopsy will be taken from the quadriceps femoris muscle
75766861|NCT01100008|Procedure|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
75766862|NCT01584310|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
75766863|NCT01584310|Other|No STAMP using|No intervention
75766864|NCT03951688|Other|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
75766865|NCT00143247|Drug|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
75766866|NCT00125853|Drug|Nebivolol|Nebivolol 2.5mg daily
75766867|NCT00125853|Drug|Atenolol|Atenolol 25mg daily
75766868|NCT00219141|Drug|Aliskiren 150/300 mg|Aliskiren 150 mg tablets
75908453|NCT04951024|Procedure|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance.
75908454|NCT04110054|Drug|S-600918|Tablets for oral administration
75908455|NCT04110054|Drug|Placebo to S-600918|Tablets for oral administration
75908456|NCT04950790|Drug|Shuxinin injection|Shuxuening injection : 5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
75908457|NCT04950790|Drug|Basic treatment|Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
75908458|NCT04950790|Drug|Placebo|sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
76071357|NCT04992598|Other|Hypnosis session|Hypnosis session will precede therapeutic strategies and reduction
75317081|NCT05934578|Other|Exercise training|Aerobic and light muscle resistance exercise by online cardiovascular rehabilitation
75766869|NCT00219141|Drug|Losartan 50/100 mg|Losartan 50 or 100 mg capsules
75908459|NCT04951180|Other|Demographic data and MRI images extraction|The data were retrospectively extracted pre- and postoperatively after hip arthroscopy. The prognosis of the surgery was evaluated through MRI images.
75462042|NCT01859455|Drug|Placebo|Placebo comparator
75462043|NCT01859455|Drug|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
75462044|NCT01859468|Dietary Supplement|Amorphous calcium carbonate|
75462045|NCT01859468|Other|Placebo|
75615032|NCT02657941|Behavioral|educational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions"
75615033|NCT02653339|Drug|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
75462046|NCT01859481|Drug|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
75908460|NCT04950478|Other|Virtual Reality|5 minutes before the procedure, they were recorded on 'Child and Parent Information Form', State-Trait Anxiety Inventory for Children and FPS-R. Their heart rate and oxygen saturation values were read and recorded. Children wore the virtual reality headset and game was started one minute before the venipuncture. As soon as the injector inserted, the researcher turned on a stopwatch and read and recorded heart rate and oxygen saturation values. When the injector was removed, the researcher stopped the stopwatch and recorded the duration of the procedure.When the injector was removed, the stopwatch was stopped and heart rate and oxygen saturation were recorded. The children took off the virtual reality headset and were asked to evaluate their pain level through FPS-R and their responses were recorded.
76071358|NCT04992598|Procedure|Reduction|All dislocation would be reduced Under adequate analgesia and sufficient sedation. All methods for reduction can be used.
76071359|NCT04991402|Device|Dolutegravir-based antiretroviral therapy|"This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care."
75615034|NCT02653339|Drug|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
75766870|NCT00219141|Drug|Aliskiren placebo|Aliskiren 150 mg placebo tablet
75766871|NCT00219141|Drug|Losartan 50/100 mg placebo|Losartan 50/100 mg placebo capsules
75766872|NCT03971487|Behavioral|Psychosis and cognitive assessments|Administration of MINI, PANSS and Quality of Living scales
75766873|NCT03971487|Behavioral|Physical and neuro-cognitive evaluations|Physical, neurological and cognitive evaluations.
76071360|NCT04991311|Drug|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
75317082|NCT05925439|Device|Tuohy needle group|Ultrasound-guided S1 transforaminal epidural block with Touhy needle
75317083|NCT05925439|Device|Quincke needle group|Ultrasound-guided S1 transforaminal epidural block with Quincke needle
75317084|NCT05910164|Device|PELGRAZ prefilled syringe or PELGRAZ prefilled pen|PELGRAZ prefilled syringe or PELGRAZ prefilled pen https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz
75317085|NCT05899933|Procedure|Non-surgical peri-implant therapy|"2 weeks after baseline examination, non surgical therapy will be applied in implants diagnosed with peri-implantitis prior to enrollment in surgical therapy.~Firstly, participants will be instructed in oral hygiene. Professional supragingival and subgingival debridement of implants/ teeth, including the selected for the study implants, will be performed. Local anesthesia will be performed, when needed. Targeted implants will be treated with PEEK-coating ultrasonic tips (Instrument PI; EMS), titanium curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), rubber cup and polishing paste. Possible adjustments to implant-borne prostheses will be considered, whenever possible. Re-evaluation of non-surgical therapy will be performed after 6 weeks.~At the 6-week reevaluation, participants with peri-implant probing pocket depth ≥5 mm and bleeding on probing and/or suppuration in patients with full mouth plaque score ≤20% will proceed to surgical therapy."
75766874|NCT03971487|Diagnostic Test|Safety labs and electrocardiogram|Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
75766875|NCT03971487|Biological|Ocrelizumab infusion|Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
75908461|NCT04950556|Other|Exercise|Pelvic floor muscle exercise will be given to the exercise group
75908462|NCT04950556|Other|Control|No intervention
76071361|NCT04990401|Behavioral|Behavioral Activation Teletherapy|A total of 10 teletherapy sessions to be delivered over 12-14 weeks, designed to increase physical activity among depressed individuals.
76071362|NCT04986865|Drug|ATG-101|ATG-101 will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
75615035|NCT04169503|Drug|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
76071363|NCT04974008|Drug|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
75462047|NCT01859481|Drug|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
75462048|NCT01859481|Drug|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
75615036|NCT00649597|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
75908463|NCT02224014|Drug|Lendormin D tablets|
75462049|NCT01859520|Procedure|swim-up, density gradient sperm preparation techniques|Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
75462050|NCT01859533|Device|Neopuff|"Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).~Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010)."
75462051|NCT01859546|Behavioral|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
75462052|NCT01859559|Procedure|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
75908464|NCT02224092|Dietary Supplement|multivitamin multimineral with phytonutrient supplementation|"The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo."
75462053|NCT01859559|Procedure|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
75462054|NCT01859585|Drug|Parecoxib|Parecoxib 40 mg intravenous
75462055|NCT01859585|Drug|Ketorolac|Ketorolac 30 mg intravenous
75462056|NCT01859624|Drug|Albuterol|Albuterol 4 mg
75462057|NCT01859650|Other|MR and CT imaging|
75908465|NCT03671161|Device|Insulin Pump and flash glucose monitoring|Adults with type 1 diabetes, HbA1c >9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.
75908466|NCT02258802|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
76071364|NCT04956744|Biological|IMS001|IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).
75462058|NCT01859689|Radiation|brachytherapy|Undergo image-guided HDR brachytherapy
75462059|NCT01859689|Radiation|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
75462060|NCT01859689|Other|laboratory biomarker analysis|Correlative studies
75615037|NCT00649597|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
76071365|NCT04954781|Drug|Tislelizumab|Tislelizumab will be initiated on day 14 after the first TACE session. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
76071366|NCT04954781|Combination Product|TACE|TACE is performed by using drug-eluting beads. TACE treatment starts on day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator's decision.
76071367|NCT04948502|Device|SaExten vena cava filter system|Subjects will undergo intervention, be implanted with a SaExten filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
75317086|NCT05899933|Procedure|Implantoplasty|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy) and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implantoplasty will be applied using tungsten carbide burs of various shapes and sizes (Peri-implantitis Kit; Meisinger) followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
76071368|NCT04948502|Device|Denali inferior vena cava filter|Subjects will undergo intervention, be implanted with a Denali filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
75615038|NCT02653105|Biological|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
76071369|NCT04942405|Biological|TURCOVAC|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28
76071370|NCT04942405|Biological|CoronaVac|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
76071371|NCT04940598|Other|high intensity interval exercise|HIIT training will be delivered two times per week for 16 weeks (32 sessions). Each session will be separated by at least 24-hrs. Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule. The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test. HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.
76071372|NCT04940598|Other|No-exercise control group|No-exercise control group
75462061|NCT01859728|Drug|Irinotecan|"Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
75766876|NCT00142935|Behavioral|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
75908467|NCT03671083|Device|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
76072409|NCT00499083|Other|laboratory biomarker analysis|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
75462062|NCT01859728|Drug|Cisplatin|"Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
75462063|NCT01859728|Drug|Cisplatin|"Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics."
75462064|NCT01859728|Drug|Gemcitabine|"Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
75908468|NCT04950088|Other|Hand-held video game device|
75908469|NCT03675997|Other|HAD (Hospital Anxiety and Depression) scale|HAD (Hospital Anxiety and Depression) scale will be completed and reported by patients the first day of conditioning and then weekly from day 0 corresponding to the autograft, until their last day in the hematological department.
75462065|NCT01859754|Biological|Octagam 5%|Intravenous immunoglobulin 5%
75462066|NCT01859754|Biological|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
75462067|NCT01859767|Drug|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
75462068|NCT01859780|Other|Visual distractor|
75462069|NCT01859806|Procedure|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
75615039|NCT02657785|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
75615040|NCT02653027|Drug|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
75615041|NCT02653027|Other|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
75908470|NCT04950400|Drug|Carrelizumab + chemotherapy + apatinib|Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
75908471|NCT02228070|Device|strabismus video goggles|
75908472|NCT02625220|Device|Prototype toric lens senofilcon A|Investigational prototype
76071373|NCT04938258|Behavioral|Intensive Case Management|Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes. This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition. The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
75908473|NCT03623269|Procedure|posterior approach to total shoulder arthroplasty|The posterior approach to total shoulder arthroplasty approaches the patient from the back of the shoulder and spares the rotator cuff.
75908474|NCT04046484|Drug|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
75908475|NCT04046484|Drug|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
75908476|NCT03670927|Other|Environmental, occupational and lifestyle-related exposures|A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
75908477|NCT04949932|Other|Mixed powder of Lens culinaris, Curcuma longa, Mentha arvensis, Azadirachta indica, and Trigonella foenumgraecum.|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
75908478|NCT04949932|Other|Cicer arietinum powder|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
75908479|NCT02826603|Drug|Secukinumab|300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
75908480|NCT02826603|Drug|Ustekinumab|Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
76071374|NCT04936685|Biological|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Liquid solution for injection Intramuscular
76071375|NCT04936061|Device|CoolStat active device|The CoolStat active device will administer a therapeutic flow of dry air into the nostril.
76071376|NCT04936061|Device|CoolStat sham device|The CoolStat sham device will administer a sham flow of ambient air into the nostril.
76071377|NCT04934098|Device|Adjustable Compression Wrap|The material will be delivered, adapted, and oriented for the daily use of the adjustable compression wrap (Ready Wrap®). The wrap allows for easy use because it is the pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compression properties, it can be used as a therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)). The institutional protocol for the control of the lymphedema phase will be respected, in which the orthosis is used at home for the longest period possible, with the only removal for bathing and sleeping; in addition, skincare and therapeutic exercises for the upper limbs should be performed daily.
75462070|NCT01859806|Procedure|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
76071378|NCT04934098|Device|Compression Bandage|Evaluation, skincare, compression bandaging, and guidance on therapeutic exercises for upper limbs. The material used for binding is tubular mesh, foam, elastic compression bandage. Therapy will be followed according to the institutional protocol for the lymphedema reduction phase, in which it will be reassessed twice a week for 30 days.
76071379|NCT04930367|Behavioral|Radio Ads|Engaging radio mini shows that address community stigma and medical literacy through busting common myths with humor and building empathy with heartfelt storytelling.
75462071|NCT01859832|Other|Cylex ImmuKnow Assay|This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
75615042|NCT04168255|Procedure|Double tamponade|Double tamponade procedure in retinal detachment with PVR and inferior breaks
75615043|NCT02650765|Other|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
75615044|NCT02652793|Drug|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
75615045|NCT02652793|Drug|Lamivudine|Lamivudine 300 mg once dailly
76071380|NCT04930367|Behavioral|Community Sensitization Campaign|Large-scale, infographic billboards and posters located in public areas and secondary schools to address stigma, medical literacy and promote community support for AYAHIV.
75317087|NCT05899933|Procedure|Erythritol Air-abrasive device|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implant surface decontamination with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS) will be applied followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
75766877|NCT00142935|Behavioral|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
75462072|NCT01859845|Other|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
75766878|NCT00142935|Behavioral|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
75766879|NCT03967041|Diagnostic Test|radiological defined sarcopenia|Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height
75766880|NCT00233948|Drug|nelfinavir mesylate|Given orally
76071381|NCT04930367|Behavioral|Informational Posters|Large-scale, infographic posters located in clinic waiting areas to normalize HIV and build confidence in treatment.
75317088|NCT05899933|Procedure|Prophylaxis|Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
75462073|NCT01859871|Behavioral|Website Intervention|Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
75615046|NCT02650687|Procedure|Processed EEG|In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
75766881|NCT00233948|Procedure|biopsy|Correlative studies
75766882|NCT00233948|Other|laboratory biomarker analysis|Correlative studies
75766883|NCT00233948|Other|pharmacological study|Correlative studies
76071382|NCT04930367|Behavioral|Motivation Walls|Interactive, patient-generated posters located in the consultation room where patients can post words and phrases about themselves and their futures.
76071383|NCT04930367|Other|Pill Container|A discreet pill container to support ART adherence.
75615047|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
75766884|NCT00233948|Genetic|gene expression analysis|Correlative studies
75766885|NCT00233948|Genetic|western blotting|Correlative studies
75766886|NCT00233948|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
75766887|NCT00233948|Other|immunoenzyme technique|Correlative studies
76071384|NCT04930367|Other|CombinADO-specific training for healthcare workers|Comprehensive in-service training for healthcare workers focused on the needs of adolescents and young adults living with HIV
75766888|NCT00233480|Drug|atorvastatin|atorvastatin 10mg PO QD
75766889|NCT00233480|Drug|placebo|matched placebo Qd x 3 months
75766890|NCT01072994|Dietary Supplement|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
75766891|NCT03801928|Drug|Inflectra|The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.
75766892|NCT02530918|Drug|DS-7080a|1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
75766893|NCT02530918|Drug|Ranibizumab|0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
76071385|NCT04930367|Other|One Stop Shop Model of Care|Model of care that allows adolescents and young adults living with HIV to access a complete set of services, including HIV care, in one central location.
76071386|NCT04930367|Other|Treatment Toolkit|A guide to clinic visits and discussions on ART and viral load monitoring to help healthcare workers better communicate with patients.
75908481|NCT02224170|Drug|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
76071387|NCT04930367|Other|Self-reflection Kit|A simple handout for healthcare workers to help patients reflect on their ART progress and understand the concept of viral load as a measure of ART success.
76071388|NCT04930367|Behavioral|Peer Support|Peer exposure to examples of adolescents and young adults openly living with HIV (AYAHIV) and; opportunities to share their experiences with HIV in one-on-one interactions with other AYAHIV during clinic visits.
76071389|NCT04930367|Behavioral|Informational and motivational Video|An informational and motivational video that in simple language with engaging graphics that a) demystifies and simplifies HIV, ART, and viral load and; b) emphasizes that people can live long, healthy lives.
75317089|NCT05890417|Other|questionnaire|Female Sexual Function Index (FSFI) and WHO Quality of Life-BREF (WHOQOL-BREF) questionnaires at baseline and 6 months after starting hormone replacement therapy
75462074|NCT01859884|Behavioral|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
75766894|NCT01584622|Device|CADence System|Non-invasive detection of > or equal to 50% stenosis in any of the major coronary arteries.
75766895|NCT03950518|Drug|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules, 12mg/d
75317090|NCT05888246|Diagnostic Test|Magnetocardiogram|Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
75462075|NCT01859910|Procedure|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
75766896|NCT03950518|Drug|Arginine hydrochloride|AHC,12mg/d AH,40g/d
75766897|NCT03950518|Drug|levamisole|AHC,12mg/d AH,40mg/d LM,150mg/d
76071390|NCT04930367|Behavioral|Support groups- caregivers of adolescents and young adults living with HIV|A learning, support, and empowerment group for caregivers of adolescents and young adults living with HIV (AYAHIV). Through monthly gatherings, the program aims to foster confidence, and equip caregivers with strategies to support AYAHIV adherence journey.
76071391|NCT04930367|Behavioral|Support groups- adolescents and young adults living with HIV|A peer-to-peer learning, support, and empowerment group to address loss of hope and improve medical literacy. Through biweekly gatherings, the program aims to foster belonging and confidence, equipping young people and caregivers with strategies to navigate the adherence journey.
75317091|NCT05884814|Behavioral|Morning exercise|Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
75317092|NCT05884814|Behavioral|Afternoon exercise|Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
75317093|NCT05884814|Behavioral|Habitual physical activity levels|Participants will be asked to maintain their normal activity levels
75317094|NCT05878925|Other|Aroma|The study intervention is an olfactory stimulation with vanilla or strawberry aroma. The aroma will be applied to the inner surface of the nCPAP mask of preterm infants using designated scent pens every 3-4 hours over a period of 12 hours. The two aromas will be applied in blocks of 5 consecutive infants (5 infants vanilla, 5 infants strawberry, and so forth).
75462076|NCT01859910|Procedure|routine preparation for cataract|
75766898|NCT01102036|Other|Cultura L casei F19, acidophilus La5 , B lactis Bb 12|2 weeks consumption,250 ml/day
75766899|NCT01102036|Other|Yoghurt without probiotics|Yoghurt without probiotics
75766900|NCT01100164|Drug|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
75766901|NCT01100164|Drug|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
75766902|NCT03950284|Device|immediate loading with all on four technique in FFF|All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
75766903|NCT01102114|Biological|NicVAX Vaccine|NicVAX vaccine given 6 times over 6 months
75766904|NCT01102114|Biological|Placebo Vaccine|Placebo vaccine given 6 times over 6 months
75766905|NCT01327222|Drug|Bevacizumab|1.25 mg intravitreal bevacizumab
75766906|NCT03950362|Drug|Avelumab|Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)
75766907|NCT03950362|Device|Radiotherapy|60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
75766908|NCT00263588|Drug|lapatinib|tyrosine kinase inhibitor
75766909|NCT00213135|Drug|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
75908482|NCT02224170|Drug|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
75908483|NCT03058120|Other|Deferral of admission for stress test|Early discharge; admission and stress test are deferred.
75908484|NCT02224248|Behavioral|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
75766910|NCT00213135|Drug|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
75766911|NCT00213135|Other|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
75908485|NCT02224248|Behavioral|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
75908486|NCT03670771|Diagnostic Test|Harrahill method for measuring of intraabdominal pressure|IAP obtained by using patient own urine as the transducing medium. One clamps the Foley catheter just above the urine collection bag. The tubing is then held at a position of 30-40 cm above the symphysis pubis and the clamp is released. The IAP is indicated by the height (in cm) of the urine column from the pubic bone. The meniscus should show respiratory variations.
75766912|NCT00077974|Drug|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
75908487|NCT02228148|Device|NFS|Cochlear Nucleus Fitting Software
75908488|NCT02228148|Device|CSS|Cochlear Nucleus Custom SoundTM Suite
75908489|NCT04949698|Device|plasma exchange|Plasma exchange was performed daily for five times or until platelet level returned to normal
75908490|NCT02258568|Behavioral|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
75908491|NCT05956847|Procedure|gastroscopy|When performing gastroscopy, the endoscopist will perform a biopsy based on the condition of gastric mucosal lesions, with one specimen retained and the remaining specimens subjected to pathological examination
75908492|NCT05956782|Behavioral|Breathe Easier|See Intervention Group (IG) description.
75908493|NCT05956743|Other|progressive relaxation exercise sessions|"Intervention Group: A total of 6 weeks of planning will be made with the working group.~week: Patients included in the study group and meeting the research criteria will be informed about the research. Pre-test data forms for each patient who accepted to participate in the study, Patient Identification Form, Pittsburgh Sleep Quality Index (PUKI) within 30 minutes will be collected.~,3.,4.,5. week: Patients will practice a total of 12 progressive relaxation exercise sessions for 30 minutes, 3 times a week (Monday, Wednesday, Friday) for 4 weeks, accompanied by the training booklet and music player.~6. week: In the last week of the application, individuals will be called to the hospital and in the Diabetes Polyclinic training room. A final test will be made by the researcher. The Pittsburgh Sleep Quality Index (PUKI) will be reapplied."
75462077|NCT01859936|Device|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
75908494|NCT05956743|Other|Sham|"1. week: After informing Sham group patients about the research at the first interview, Patient Information Form, Pittsburgh Sleep Quality Index (PUKI) will be applied.~6. week: In the 6th week of the study, individuals will be called to the hospital and the post-test Pittsburgh Sleep Quality Index (PUKI) will be re-administered by the researcher in the diabetes outpatient training room. Since the study was terminated after the 6th week, a booklet and music player will be given to the patients. In addition, progressive relaxation exercise training will be given to the patients and the importance of using it in their lives will be explained."
75908495|NCT05956717|Device|Orthokeratology|The experimental group wore orthokeratology lenses
75908496|NCT05956704|Device|Orthokeratology with aspheric wide inversion zone design in the optical zone|An orthokeratology lens with an altered optical zone design is designed for an aspherical wide inversion arc in the optical zone
75908497|NCT05956704|Device|Orthokeratology with traditional spherical design in the optical zone|Subjects wore the orthokeratology with traditional spherical design in the optical zone
75908498|NCT05956678|Behavioral|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
75615048|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
75766913|NCT00124917|Radiation|Radiation|Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 centigray (cGy) in 180 cGy daily fractions.[1]
75462078|NCT01860014|Drug|Poractant alfa|Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
75462079|NCT01860014|Drug|Beractant|Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
75462080|NCT01860053|Behavioral|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
75766914|NCT03967353|Behavioral|New management mode intervention|"Patients in routine treatment group use TB assistant APP. Medical staff strengthen health promotion of the patients,including, infection control, doctor-patient communication, etc."
75462081|NCT01860066|Drug|QVA149|QVA149 via inhaler twice a day
75462082|NCT01860066|Drug|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
75462083|NCT01860105|Drug|MDCO-157|intravenous administration
75615049|NCT00600067|Drug|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
75615050|NCT00600067|Drug|Placebo|Oral placebo capsules, once daily, 28 weeks
75908499|NCT05956678|Behavioral|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
75615051|NCT02650609|Drug|Methylprednisolone|
75766915|NCT01100398|Procedure|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
75908500|NCT05956652|Device|Hydra Transcatheter Aortic Valve System|The Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
75908501|NCT05956639|Drug|6-month course of antiandrogen drugs|6-month course of Rezvilutamide and ADT + chemotherapy
75317095|NCT05878925|Other|Placebo|During the control intervention, identically looking placebo pens will be used to apply a colored carrier solution (without aroma) to the inner surface of the nCPAP mask of preterm infants in the same manner.
75766916|NCT01102348|Other|PEP-uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
75766917|NCT00141921|Drug|Etanercept|Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
75766918|NCT00029146|Procedure|extracranial-intracranial bypass surgery|Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy
75766919|NCT00029146|Drug|best medical therapy|best current practice medical therapy
75766920|NCT01079793|Drug|ixabepilone|
75766921|NCT01079793|Procedure|adjuvant therapy|
75908502|NCT05956639|Drug|Long-term course of antiandrogen drugs|Long-term course of Rezvilutamide and ADT + chemotherapy
75908503|NCT05956613|Procedure|Partial pulpotomy|Use of newly introduced bioceramic putty in partial pulpotomy
75317096|NCT05878730|Diagnostic Test|urine collection|"Urine collection will be made on a 12 hours period (20h00-8h00), the night before V2~at V2 : 2 mL urinal sample for measure of 6-SMT concentration (ng/mL) and creatinin (mg/mL)~Measure of 6-SMT will be made by a validated radio-immunology assay"
75317097|NCT05878730|Diagnostic Test|Level of Protein 14.3.3|"blood sample at V2 (2x7mL ACD tubes)~measured by ELISA"
75462084|NCT01860105|Drug|PLAVIX|oral administration
75462085|NCT01860131|Behavioral|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
75908504|NCT05956600|Drug|Amisulpride 50 MG|Amisulpride 50 mg titrated to dose range of 50 to 1200 mg
75908505|NCT05956574|Behavioral|Nutrigenomix, personalized dietary plan|Personalized dietary plan.
75908506|NCT05956574|Behavioral|Physical Activity|Participate in an exercise program to work up to 300 min/week of moderate-intensity activity.
75908507|NCT05956574|Behavioral|Behavioral counseling|Review behavioral counseling videos and participate in worksheets to assist with behavioral change.
75908508|NCT05956574|Behavioral|Standard Dietary plan|Receive a standard dietary plan
75908509|NCT05956561|Other|dental implants were placed for all cases while assessing vitamin D levels|vitamin D assessment with measuring implant stability and clinical finding of early failure
75908510|NCT05956548|Procedure|external securement of scs leads during the scs trial period|two groups- one group will have an anchor device used alone to secure the leads, the second group will have an anchor device with a suture to secure the leads
75908511|NCT05956522|Drug|Test Empagliflozin And Linagliptin Tablets|specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd
75908512|NCT05956522|Drug|Reference Empagliflozin And Linagliptin tablets|specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH & Co. KG
75908513|NCT05956470|Behavioral|Meditation and breathing program : Sudarshan Kriya Yoga (SKY)|The SKY sessions (3x1,5 h on consecutive days) included online instruction in gentle stretches ('office yoga' in a sitting position), specific breathing exercises and meditation, and discussion of cognitive/behavioral coping skills. After the 3-day program, participants asked to practice the techniques once a day for about 30 min. In addition, there were weekly group exercise sessions of 1 hour where all participants were asked to join.
75462086|NCT01860144|Drug|Bevacizumab|
75317098|NCT05878730|Diagnostic Test|Level of miR-451|"blood sample at V2 (2.5mL PAX-gene tube)~measured by quantitative RT-PCR"
75317099|NCT05860660|Behavioral|survey|questionnaires
75462087|NCT01860157|Device|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
75615052|NCT02650609|Drug|Placebo|
75615053|NCT02652871|Drug|LY2510924|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase."
75615054|NCT02652871|Drug|Idarubicin|"Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days."
75766922|NCT01079793|Radiation|intensity-modulated radiation therapy|
75766923|NCT03950206|Other|Indocyanine green angiography|Intravenous ICG (PULSION Medical Systems SE, Feldkirchen, Germany) will be used for the intraoperative evaluation of ureteral vascularization. Twenty-five milligrams of indocyanine green will be diluted in 10 ml of soluble water, and a bolus of 0.25 mg/Kg will be injected through a peripheral vein. During laparoscopy, a NIR camera-head (KARL STORZ Gesellschaft Mit Beschränkter Haftung&amp; Co., Tuttlingen, Germany) will be used to visualize the ureteral vascularization.
75908514|NCT05956470|Behavioral|Stress management education|This control intervention included viewing of educational videos on stress management and group discussions, where the sessions were equal in length to the SKY intervention. There were also weekly follow-up sessions as in the SKY group where the educational points were reviewed and experiences of the subjects during the previous week was discussed.
75615055|NCT02652871|Drug|Cytarabine|"Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
75766924|NCT01088620|Drug|Panitumumab|"Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression."
75615056|NCT00650299|Drug|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
75766925|NCT01088620|Drug|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
75766926|NCT01088620|Drug|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
75908515|NCT05956457|Behavioral|Digital Health Coaching Program|Digital health intervention consisting of weekly calls from a Health Advisor to a participant, accompanied by delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
75908516|NCT05956457|Device|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
75908517|NCT05956444|Other|Neurodevelopmental Therapy (NDT)|In the treatment program; vestibular and proprioceptive training on the balance board; dynamic balance training in sitting with eyes open and closed, kneeling upright and standing; balance exercises in front of the mirror; standing on one leg with eyes open and closed to increase proprioceptive input; vestibular and proprioceptive training on exercise balls of the appropriate size; balance training on the trampoline; footpad sensory stimulation with different materials; weight-bearing training in sitting, crawling, kneeling and standing positions; functional reaching and throwing-holding exercises in different positions; multitasking pieces of training; gait exercises in various ways and training for climbing and descending stairs appropriate to the child's situation (assisted, unaided, symmetrical, reciprocal) took place.
75908518|NCT05956444|Other|Conventional Physiotherapy|Classical physiotherapy applications for balance.
75615057|NCT00650299|Drug|Xanax XR® Tablets 3 mg|3mg, single dose fed
75908519|NCT05956431|Drug|Levosimendan Injection|The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
75615058|NCT00970593|Drug|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
75615059|NCT00970593|Drug|placebo comparator|Group 1 & 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
75766927|NCT00026494|Drug|temozolomide|
75908520|NCT05956431|Drug|physiological saline|The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
75908521|NCT05956418|Drug|Centhaquine|Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p<0.0001), lactate levels (p=0.0012) and base-deficit (p<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
75908522|NCT05956392|Behavioral|Screen-use reduction + Sleep extension|60 minutes of a participants' daily screen-use time on school days will be repurposed for more sleep time.
75615060|NCT04167553|Drug|HM15136|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.
75615061|NCT04167553|Drug|Placebo|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.
75615062|NCT02657395|Device|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
75615063|NCT04168411|Procedure|Symptomatic Treatment|Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
75766928|NCT00026494|Drug|vinorelbine tartrate|
75766929|NCT03950128|Behavioral|Mindfulness-Based Skills Training (MBST)|"This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well."
75766930|NCT03950128|Behavioral|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
75317100|NCT05858463|Other|Modality of exercise training|muscle adaptations following intermittent high intensity interval exercise training and continuous low intensity exercise training
75615064|NCT02861469|Other|Semi-structured interviews|individual semi-structured interviews with general practitioners and family members
75615065|NCT04168099|Drug|Cefotaxime|Cefotaxime IV
75615066|NCT04168099|Drug|Gemifloxacin|Gemifloxacin oral
75766931|NCT03950050|Drug|Ambroxol|"Ambroxol Hydrochloride therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
75908523|NCT05956379|Other|exercise|Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, >=3 cardio workouts per week. The form of aerobic exercise can be carried out in the form of treadmill walking, walking, jogging, cycling, aerobic dance, ball games, swimming, rope skipping, stepping exercises, etc. When the exercise reaches the target intensity, we will adjust the training intensity process according to personal ability. The physical therapist will again adjust the content of the aerobic exercise program at week 12 based on the reassessment of the exercise capacity.
75317101|NCT05834790|Other|Mobile Augmented Reality (MAR) for oral health education program|MAR application named MAKAR will be available to download and use for smartphones and tablets. Participants will need to scan QR code to access the content of oral health education program
75615067|NCT04283877|Drug|Methylphenidate|3 x 10 mg oral tablets. Single acute dose for all participants
75615068|NCT04283877|Drug|Placebo oral tablet|3 x 10 mg oral lactose tablet for all participants
75766932|NCT01100476|Device|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
75766933|NCT01102504|Drug|Placebo|Placebo
75766934|NCT01102504|Dietary Supplement|Ateronon|Tomato extract containing 28 mg lycopene/ day
75766935|NCT01088698|Radiation|UVB-311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
75766936|NCT01088776|Dietary Supplement|n-3 Fatty Acid supplement|"Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.~Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules."
76071392|NCT04930367|Behavioral|Mental health screening and linkage to adolescent-focused mental health support|HCWs will be trained in the use of a brief mental health screening tool focusing on depression, anxiety, and post-traumatic stress disorder. Mental health service providers at each facility will be trained and supported to provide diagnostic and mental health support to youth with positive screens who agree to further evaluation.
75317102|NCT05834790|Other|Lecture-based oral health education program|The oral health education program that will be delivered by traditional lecture-based process
75317103|NCT05824078|Procedure|Arthroscopic surgery|Arthroscopic approach involves smaller incision, offering less traumatic procedures and faster healing, but due to the limited space in this closed field with significant vasculature and nerve distribution, scoping has increased risk for iatrogenic injuries.
75317104|NCT05824078|Procedure|Open Surgery|The open approach requires dissection of capsuloligamentous structures, which can lead to stiffness of the joint due to capsular scarring as it heals. However, it offers good visual field when treating the injury, allowing maneuverability to avoid iatrogenic soft tissue injuries.
75317105|NCT05815537|Other|Low-Reverberation|The exposure to low-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., small classroom.
75615069|NCT02650453|Procedure|Deep venous reconstruction|PTA & stenting with/without endophlebectomy and/or arteriovenous fistula creation
75615070|NCT00962013|Device|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
75615071|NCT02650375|Drug|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
75615072|NCT02652715|Other|Laboratory Biomarker Analysis|Correlative studies
75615073|NCT02652715|Other|Quality-of-Life Assessment|Ancillary studies
75766937|NCT01088776|Dietary Supplement|Placebo|The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
75766938|NCT00023764|Drug|bortezomib|Given IV
75766939|NCT01088854|Device|CPAP|unique session of 30-minute of continuous airway positive pressure
75317106|NCT05815537|Other|High-Reverberation|The exposure to high-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., large lecture hall/auditorium.
75615074|NCT02652715|Other|Questionnaire Administration|Ancillary studies
75615075|NCT02652715|Dietary Supplement|Salvia hispanica Seed|Given PO
75766940|NCT03961126|Drug|Injection of autologous fatty tissue associated with autologous platelet-rich plasma.|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
75766941|NCT03961126|Drug|Corticosteroids (clobetasol 0.05%)|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
75615076|NCT04283487|Dietary Supplement|Fructans|500ml 0.9% normal saline containing 40g fructans
75615077|NCT04283487|Dietary Supplement|Glucose|500ml 0.9% normal saline containing 40g glucose
75615078|NCT04283487|Dietary Supplement|Saline|500ml 0.9% normal saline
75766942|NCT03949816|Other|medical consultation: different doctor-patient-centered style of communication|Different doctor-patient communication
75908524|NCT05956366|Behavioral|Family-based treatment|Open-end family therapy ad modum The Maudsley model
76071393|NCT04923568|Device|EaseVRx|Participants will experience 2 sessions of the EaseVRx device for chronic pain
75908525|NCT05956301|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through Nasal catheter
76071394|NCT04921371|Other|Colgate® Cavity Protection Toothpaste|Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
75766943|NCT03949816|Other|information letter / no medical consultation|In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
75766944|NCT01584778|Other|eosinophil cationic protein|Serum eosinophil cationic protein levels
76071395|NCT04921371|Other|Listerine® Cool Mint®|Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
75317107|NCT05808686|Other|Ischemic Conditioning|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
75766945|NCT00189488|Drug|Palifermin|Administered as an intravenous (IV) bolus.
75766946|NCT00189488|Drug|Placebo|Administered as an intravenous (IV) bolus.
75766947|NCT00189488|Other|Conditioning Regimen|"Each participant received 1 of the following conditioning regimens:~Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~TBI/VP-16~Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie > 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~Busulfan (Bu)/Cy~Bu/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])~Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])"
75766948|NCT00189488|Procedure|Allogeneic stem cell transplant|Allogeneic marrow/peripheral blood progenitor cell transplantation
75908526|NCT05956301|Device|High-flow nasal oxygen|High Flow Nasal Cannula will be administered
75908527|NCT05956301|Device|Supraglottic jet oxygenation and ventilation|Nasal jet tube will be administered
75908528|NCT05956288|Device|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.
75908529|NCT05956275|Drug|Tramadol|ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
76071396|NCT04921371|Other|Concept Curve Winter Series Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
76071397|NCT04921371|Other|5% Hydroalcohol Mouthrinse|Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
76071398|NCT04921371|Other|Mouthrinse Prototype 1|Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
76071399|NCT04921371|Other|Mouthrinse Prototype 2|Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
76071400|NCT04920123|Device|Neuro-World|Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.
76071401|NCT04911491|Device|IMST|Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
76071402|NCT04911491|Device|Sham Training|Repeated inhalations against a low resistance will be performed using a handheld device.
75908530|NCT05956275|Drug|Morfin|No block was applied to the patients in control
75908531|NCT05956262|Device|AR-toothbrush machine|Student in AR group received a two-time repeated AR-based training for 30 minutes at two-week intervals. The AR-based training system (PVIX Oral, EPED) digitized the steps of the toothbrushing technique applying optical tracking technology to enable the participants to obtain immediate scoring after the completion of practice. The scoring depends on the level of removing simulated dental plaque. The AR system was equipped with an optical tracking unit, a 3D training head model, and a wireless toothbrush. The toothbrushing practice time for the upper and lower jaw is 3 minutes, respectively. A tooth-brushing song played while the students implemented.
76071403|NCT04911465|Device|Flashback CRI T1 Tablet|Collect continuous data on the compensatory reserve index, a measurement of a patient's central volume status.
76071404|NCT04909970|Other|Self-hypnosis|Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
75766949|NCT00189488|Drug|Methotrexate|
75908532|NCT05956262|Behavioral|Teach proper brushing skills|Students in the traditional group received a two-time repeated 10-minute lesson regarding proper toothbrushing skills in the classroom at two-week intervals. The students were taught by a well-trained dental hygienist using teaching aids (such as dental models, and toothbrushes).
76071405|NCT04909970|Other|Control (Waiting list)|Usual practice during the first 16 weeks. At the end of study, the participant will practice Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
76071406|NCT04899245|Diagnostic Test|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
76071407|NCT04895215|Drug|AB-2004|Taken 3 times daily with food
76071408|NCT04895215|Drug|Placebo|Take 3 times daily with food
76071409|NCT04893096|Drug|MOR202|Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
75908533|NCT05956249|Other|Online group therapy|Online group therapy for the treatment of depression, anxiety and improvement of emotional well-being.The intervention will be carried out in 6 groups of 6 participants.
75908534|NCT05956249|Other|Control Group|Without intervention at the first moment, but the control group will receive the intervention after the reassessment of the scales by the scholarship holder was done.
75908535|NCT05956210|Device|Evaluation of implementation regarding Philips Healthdot as monitoring device of hospitalized patients at one surgical ward|Hospitalized patients at one surgical ward will receive a Healthdot as monitoring device which will be used as primary monitoring after 3 months of preparation with education of hospital staff, improving infrastructure and training with application, activation and interpretation
75908536|NCT05956197|Other|No intervention|No intervention. This is a cohort study
75908537|NCT05956145|Drug|Colchicine 0.5 MG|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
75908538|NCT05956145|Other|Placebo|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
75908539|NCT05956132|Other|retrospective study|data collection from clinical history and medical records
75908540|NCT05956080|Diagnostic Test|Allergy testing|University Medicine Greifswald
75908541|NCT05956067|Other|Green Light stimulation|A portable battery-operated ganzfeld light stimulation device will be used to deliver green light for 2 hours per day for 5 consecutive days.
75908542|NCT05956067|Other|Equal Energy White stimulation|A portable battery-operated ganzfeld light stimulation device will be used to deliver white light for 2 hours per day for 5 consecutive days.
75908543|NCT05956067|Other|S-cone modulating white light|A portable battery-operated ganzfeld light stimulation device will be used to deliver S-cone modulating light for 2 hours per day for 5 consecutive days.
75908544|NCT05956054|Other|needle type|straight or curved
75908545|NCT05956028|Procedure|Ultrasound guided SCV cannulation|receive ultrasound guided SCV cannulation
75908546|NCT05956028|Procedure|Ultrasound guided IJV cannulation|receive ultrasound guided IJV cannulation
75908547|NCT05955989|Other|soft lining of complete denture processed by 3 different techniques.|soft lining for complete denture
75908548|NCT05955963|Other|Abdominal auscultation|spectral analysis of Bowel sounds
75908549|NCT05955950|Behavioral|Gratitude list|Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.
75462088|NCT01860157|Device|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
75615079|NCT02657317|Behavioral|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
75908550|NCT05955950|Behavioral|List of any event|Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
75462089|NCT01860183|Drug|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
75908551|NCT05955833|Diagnostic Test|89Zr-DFO*-trastuzumab PET scan|Patients will be administered 37 MBq 89Zr-DFO*-trastuzumab and undergo 3 PET scans on the total body PET scanner at day 1, day 2 and day 4 post-injection (p.i.). The first 3 patients will undergo an additional PET 1-2 h p.i. for dosimetry purposes. Three scans are needed for PK modelling and day 4 p.i. is chosen because it is the same time point as in historical controls. Blood samples for (radioactive) PK analysis will be taken at 10 min, 30 min, 1 h and 2 h p.i., and at every PET scan.
75462090|NCT01860196|Drug|Meditoxin|
75462091|NCT01860196|Drug|Normal saline|
75908552|NCT05955820|Device|Suspension system|Participants will be tested by four exercises designed for impingement syndrome using the suspension system
75908553|NCT05955820|Device|Dumbbells|Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
76071410|NCT04889183|Drug|Semaglutide|Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
76071411|NCT04889183|Drug|Placebo|Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
76071412|NCT04888741|Drug|Thymoglobulin|GVHD prophylaxis
76071413|NCT04888741|Drug|Cyclophosphamide|Post transplant cyclophosphamide strategy for GVHD prophylaxis
76071414|NCT04888741|Drug|Cyclosporine|immunosuppressant
75462092|NCT01860209|Procedure|Hemodialysis|Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
75462093|NCT01860222|Procedure|SR|
75462094|NCT01860222|Procedure|PLAT|
75462095|NCT01860235|Drug|EMLA|% eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
75462096|NCT01860235|Drug|Injectable anesthesia|Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
75462097|NCT01860235|Drug|2% Benzocaine|Topical anesthetic - 200mg/g of 2% benzocaine
75462098|NCT01860235|Drug|Placebo|Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
75615080|NCT02657317|Other|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
75462099|NCT01860248|Drug|Vapocoolant spray|The Vapocoolant spray containing alkane is applied for 20 seconds.
75462100|NCT01860248|Drug|Water spray|This spray is covered so the patient and the investigator can not find the spray type out.
76071415|NCT04888741|Drug|Sirolimus|immunosuppressant
75766950|NCT03974906|Other|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO）|Applying continuous hemodynamic monitoring system ( LiDCO) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
75766951|NCT03969290|Device|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
75766952|NCT03969290|Device|Etafilcon A contact lenses|Daily disposable contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
75766953|NCT00233402|Drug|Hexvix|Single Instillation, Transurethral Resection of the Bladder
75766954|NCT00233402|Procedure|Standard white light cystoscopy|
75908554|NCT05955794|Other|voice recordings|"Experimental treatment/procedure:~The first recording will be made in the laboratory. The lab will have sound insulation (the sound-to-noise ratio of the room should be at least 30dB) to record the voice samples. Similar to the recordings made in the lab, parents/caregivers will be instructed on how to collect voice recordings at home several times during the day using a smartphone. Parents/caregivers will be asked to note down the patient's emotional state during each recording in a predefined protocol.~All patients will undergo paediatric, morphological, neurocognitive and behavioural assessment, hearing and ENT evaluation, perceptual and acoustic voice analysis.~Perceptual assessment will be done blind.The vowel recordings will be analysed by two software tools: Biovoice [1] and Praat [2]."
75908555|NCT05955781|Procedure|Spinal Mobilization With Leg Movement|spinal mobilization with leg movement is the intervention given to experimental group. This technique involves applying pressure to the relevant spinous process while the patient moves their limb through the previously restricted range of motion. It is assumed that the restriction of movement is due to a spinal issue but it does not always indicate nerve damage as spinal movement is necessary for limb movement beyond a certain point. The goal is to address any spinal mechanical limitations and there may also be potential effects on the nerves.
75615081|NCT04283331|Drug|Proparacaine Ophthalmic|Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
75766955|NCT00233324|Drug|Surfactant|Intubation and administration of surfactant by 1 hour of age.
75908556|NCT05955781|Procedure|Spinal Mobilization|The patients will be given Spinal mobilization transverse glide(kaltenborn glide) on the effected spinous process. The total time duration will be 25-30 minutes.
75908557|NCT05955781|Procedure|Conventional treatment|Participants will be given Hot pack for 15 minutes, TENS for 10 minutes
75908558|NCT05955742|Device|Control|The operator prepared the glide path using a #15K-type stainless-steel hand file.
75908559|NCT05955742|Device|ProGlider|The operator prepared the glide path using the ProGlider file.
75462101|NCT01860274|Device|External Mesh for vein grafts|
75908560|NCT05955742|Device|WaveOne Gold Glider|The operator prepared the glide path using the WaveOne Gold Glider file.
75908561|NCT05955716|Device|Virtual reality glasses|Virtual reality glasses are a device suitable for every mobile phone. It is used to watch the 360 degree video selected from the Youtube program.
75908562|NCT05955703|Behavioral|ppm based training|The training program based on the precede proceed model was applied to hemodialysis patients for 8 sessions. Eight sessions of training were given to the experimental group within the scope of the model, a booklet was developed in line with the trainings and posters were prepared.
76071416|NCT04888741|Drug|Mycophenolate Mofetil|immunosuppressant
76071417|NCT04886388|Device|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
75462102|NCT01860300|Drug|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
76071418|NCT04886388|Other|Physician-guided Standard of Care for type 2 diabetes|Current ADA Standard of Care Guidelines for type 2 diabetes
76071419|NCT04883814|Diagnostic Test|18F-fluoroestradiol PET/CT|Estrogen receptor targeted imaging
76071420|NCT04883554|Other|Olfactory therapeutic|The sessions of the olfactory sensory therapy group take place according to the care framework at a frequency of one session of 45 minutes per week
76071421|NCT04883554|Other|Body therapy|very specific stages at a weekly frequency and lasts 1 hour. Kinesic time or time to set the body in motion (20 min) Kinesthetic time: time of slow movements (20 min) Talk time (20 min)
75462103|NCT01860300|Drug|placebo|
75462104|NCT01860313|Behavioral|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
75462105|NCT01860313|Behavioral|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
75462106|NCT01860326|Drug|Alisporivir|Capsules supplied as open labeled bulk medication in 10-unit blister packages
75462107|NCT01860352|Dietary Supplement|Fish OIl|
75615082|NCT02657473|Drug|tobramycin inhalation solution|
75615083|NCT02657473|Drug|Saline 0.9% inhalation solution|
75615084|NCT04281459|Other|HIV Treatment Satisfaction Questionnaire status|Administration of pseudoanonymous HIV-TSQs (translated into Italian) to all included patients.
75615085|NCT02652637|Drug|neomycin, metronidazole, polyethylene glycol (PEG)|
75615086|NCT02861079|Device|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
75615087|NCT02861079|Drug|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
75766956|NCT00233324|Device|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
75766957|NCT00233324|Drug|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
75766958|NCT00233324|Drug|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
75908563|NCT05955677|Drug|[68Ga]Ga-PSMA-D5|Each subject receive a single intravenous injection of [68Ga]Ga-PSMA-D5, and undergo PET/CT imaging within the specificed time.
75766959|NCT00023452|Drug|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons > 50.0 kg. For persons < 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if > 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT)."
75766960|NCT00023452|Drug|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
75766961|NCT03974516|Drug|Careseng 1370|Careseng 1370 should be taken around 1 hour before meal.
75615088|NCT02652403|Device|Complete conventional dentures|"The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments."
75317108|NCT05803343|Behavioral|Regulating Together-Canine|RT-C is an animal assisted, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. RT-C meets for 1.5 hours, twice weekly for five weeks with concurrent youth and caregiver groups. The children progress through skills including relaxation training, arousal ratings, problem size, mindfulness, problem solving, and cognitive flexibility. The caregivers learn crisis management, reward systems, and coaching strategies for topics taught to the children. Homework is utilized to reinforce use of skills outside the group. The canines are present throughout as both a calming presence and teaching assistant. Children will be able to interact with the dog when practicing relaxation at the beginning of each session and throughout the session. Additionally, the dog will help to emphasize certain curriculum concepts.
75462108|NCT01860365|Other|Complementary medicine consultation and treatment|Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.
75462109|NCT01860365|Other|Patients receiving conventional supportive care|Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
75615089|NCT02652403|Device|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
75766962|NCT03972878|Other|control snack|dry fruit snack (200 kcal) + 250 ml water
75462110|NCT01860378|Other|Full price|Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
75462111|NCT01860378|Other|$5 off|Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
75462112|NCT01860391|Device|Diammine Silver Fluoride|Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
75615090|NCT02861157|Behavioral|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
75615091|NCT00649675|Drug|Meloxicam Tablets 15 mg|15mg, single dose fed
75615092|NCT00649675|Drug|Mobic® Tablets 15 mg|15mg, single dose fed
75615093|NCT04283565|Other|Systematic screening of AOMI by BPI measurement.|The strategies will be associated according to a 2*2 factorial design in order to obtain 4 arms
75766963|NCT03972878|Other|control cream|commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water
75766964|NCT03972878|Other|cream version 1|commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
75766965|NCT03972878|Other|cream version 2|commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water
75766966|NCT03972878|Other|cream version 3|commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water
75908564|NCT05955677|Drug|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of [68Ga]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
75766967|NCT03972878|Other|control chocolate bar|commercial chocolate bar (200 kcal)+ 250 ml water
75766968|NCT03972878|Other|chocolate bar version 1|commercial chocolate bar (200 kcal), version 1+ 250 ml water
75766969|NCT01073072|Procedure|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
75766970|NCT01073072|Procedure|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
75766971|NCT01088932|Drug|SRX246|capsules
75908565|NCT05955664|Diagnostic Test|MRI indlcuding DTI|A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.
75908566|NCT05955664|Diagnostic Test|Pelvic floor ultrasound.|"The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US."
75766972|NCT01100554|Device|Sleep endoscopy|Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
75766973|NCT03961048|Drug|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally|Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
75908567|NCT05955599|Other|ACL Injury Prevention Training|Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
75766974|NCT03961048|Drug|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally|Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
75908568|NCT05955599|Other|Control - Shoulder Injury Prevention Training|Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
75908569|NCT05955560|Device|PureWick Male External Catheter|The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.
75908570|NCT05955560|Device|Sage PrimoFit|The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
76071422|NCT04881604|Device|Adjustable Compression Wrap|"Delivery, adaptation and guidance for daily use of the Adjustable Compression Wrap. (Ready Wrap® allows for easy use because to be pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compressive properties, it can be used as therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
75317109|NCT05803343|Behavioral|Regulating Together-Standard|RT-S an established, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
75615094|NCT04283565|Other|Management of CVRF by a motivationnal interviewing.|The strategies will be associated according to a 2*2 factorial design in order to obtain 4 arms
75615095|NCT02652559|Device|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
75766975|NCT01100632|Dietary Supplement|Ginseng, vitamins, minerals|2 capsules per day
75766976|NCT01100632|Other|Placebo - Gelatin capsule|2 capsules per day
75766977|NCT03949426|Drug|KPG-818|KPG-818 Capsules (1 mg, 5 mg and 20 mg) for oral administration is the drug substance powder filled in capsule (PIC) dosage form. KPG-818 Capsules and placebo capsules are packaged in HDPE bottle capped with HDPE cap.
75766978|NCT03949348|Procedure|Mid-urethral sling placement using autologous rectus fascia|Mid-urethral sling placement using autologous rectus fascia
75766979|NCT03949348|Procedure|Mid-urethral sling placement using synthetic mesh|Mid-urethral sling placement using synthetic mesh
76071423|NCT04881604|Device|Compression Sleeve|"Delivery, adaptation and guidance for daily use of the Compression sleeve. (Compression Sleeve is a mesh in the shape of a glove that provides compression on the fabrics needed to help control the volume of the limbs. Traditionally used for stage 2 of compressive therapy. The composition of the material is: 64% Nylon, 36% Elastane (Spandex) ).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
76071424|NCT04870515|Other|Best Practice|Receive standard lifestyle recommendations
76071425|NCT04870515|Other|Dietary Intervention|Receive dietary instructions
75462113|NCT01860417|Biological|Allogenic Mesenchymal Stromal Cells|
75462114|NCT01860417|Drug|Mepivacaine|
75462115|NCT01860443|Other|Telepsychiatry collaborative program|"The intervention includes:~Online training for the health staff~Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression~Online supervision in a web platform by specialists~Telephone monitoring"
75462116|NCT01860443|Other|Usual care|"Online training for the health staff~Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression"
75462117|NCT01860469|Procedure|vancomycin-soaked mesh|
75462118|NCT01860469|Procedure|plain mesh|
75462119|NCT01860482|Drug|Newrabell® Tablet 10mg|
75615096|NCT02652559|Device|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
75615097|NCT02652559|Device|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
75766980|NCT03949582|Other|Test food containing different types of dietary protein|"The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum"
75908571|NCT05955547|Other|Prognosis Scoring|To determine the prognosis of patients admitted to ICU with a scoring system that includes inflammation and nutritional status
75766981|NCT00022672|Drug|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
75908572|NCT05955521|Procedure|exosome and ctDNA evaluation|Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.
75908573|NCT05955404|Other|Kangaroo mother care|This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
75908574|NCT05955391|Drug|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
75766982|NCT00022672|Drug|anastrazole (Arimidex®)|1 mg tablet taken orally daily
75908575|NCT05955378|Device|DSR Ankle|This is the experimental ankle component used in the overall prosthetic intervention.
75908576|NCT05955378|Device|Predicate Ankle|This is the participant's prescribed ankle/foot complex used in the overall prosthetic intervention.
75908577|NCT05955313|Drug|Naltrexone Hydrochloride|treatment of vulvodynia
76071426|NCT04870515|Other|Exercise Intervention|Complete aerobic and strength/resistance exercises
76071427|NCT04870515|Other|Quality-of-Life Assessment|Ancillary studies
75317110|NCT05783921|Drug|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"TQB2618 injection is an Anti TIM-3 (T-cell immunoglobulin and mucin domain-3) monoclonal antibody.~Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
75317111|NCT05783921|Drug|Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
75317112|NCT05775042|Biological|CM338|CM338 injection
75317113|NCT05745298|Device|Xcite Clinical Station|The abdominal functional electrical stimulation (AFES) will be conducted using the Xcite system. This is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education. The electrical stimulation will be applied to the abdominal and back muscles. In addition, participants will receive two specific respiratory muscle training exercises performed 3 days per week.
75317114|NCT05741372|Drug|Rosuvastatin|Rosuvastatin
75766983|NCT05626036|Device|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
75766984|NCT05626036|Device|Synthes Fibulink|High-tensile strength suture syndesmosis repair
75766985|NCT00076804|Behavioral|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
75766986|NCT00141453|Drug|olmesartan medoxomil|Tablets 10, 20, or 40 mg
75766987|NCT00141453|Drug|Placebo Tablets|Matching placebo tablets
75766988|NCT00076570|Drug|Sirolimus|
75766989|NCT00076570|Drug|Tacrolimus|
75766990|NCT01079871|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
75908578|NCT05955287|Behavioral|Telemonitoring|Text messages of encouragement will be sent to patients and partners. No more than 2 messages will be sent per week to prevent respondent fatigue.
75908579|NCT05955287|Behavioral|Peer Based|Patients and partners will attend OSA virtual support groups led by an African American patient with long-standing OSA and their bed partner. Peer-motivator couples will be trained and certified as competent prior to interacting with study participants. They will share their experiences with managing OSA including coping strategies to maximize CPAP adherence.
75908580|NCT05955287|Behavioral|CPAP Education|Patients with OSA and their bed partners will participate in two 1-hour video support groups at 2 weeks and 2 months ran by patients with OSA and their bed partners
75908581|NCT05955287|Behavioral|Usual Care|Participants will receive OSA education and CPAP training from providers trained in OSA management.
76071428|NCT04870515|Other|Questionnaire Administration|Ancillary studies
75317115|NCT05741372|Drug|Digoxin|Digoxin
75317116|NCT05741372|Drug|Metformin hydrochlorid|Metformin hydrochloride
75766991|NCT03966963|Behavioral|Eye Movement Desensitization Reprocessing (EMDR)|Trauma-Focused Therapy
75766992|NCT00124449|Drug|Abatacept|"solution, intravenous injection, monthly, 169 days~weight based:~<60 kg = 500 mg~60 to 100 kg = 750 mg~>100 kg = 1 g"
75766993|NCT00124449|Drug|placebo|solution, intravenous injection, 0 mg, monthly, 169 days
75766994|NCT00076336|Drug|Telbivudine|600mg/day oral tablet for 104 weeks
75766995|NCT00076336|Drug|Lamivudine|100mg/day oral tablet for 104 weeks
75766996|NCT00076336|Drug|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
75766997|NCT05626504|Device|Pipeline Embolization Device with Vantage Technology|Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.
75766998|NCT00185588|Drug|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
76071429|NCT04869358|Drug|Ofatumumab|Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
76071430|NCT04868214|Device|coagulation measurements|peak and trough coagulation measurements of patients treated with Xarelto, Eliquis, or Lixiana and coagulation measurements of healthy proband blood spiked with eiter Xarelto, Eliquis or Lixiana.
76071431|NCT04866576|Dietary Supplement|Q CAN PLUS|Active powder with fermented soy, 2 pouches per day, each pouch contains 12-15 gms of fermented soy
75615098|NCT02652559|Other|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
75766999|NCT00185588|Drug|Gemcitabine|850 mg/m2
75767000|NCT01074398|Genetic|gene expression analysis|
75317117|NCT05741372|Drug|Furosemide|Furosemide
75767001|NCT01074398|Genetic|polymorphism analysis|
75615099|NCT02652559|Other|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
75767002|NCT01074398|Genetic|protein expression analysis|
75615100|NCT02860923|Drug|Exenatide|
75615101|NCT02860923|Drug|Placebo|
75767003|NCT01074398|Other|immunohistochemistry staining method|
75767004|NCT01074398|Other|laboratory biomarker analysis|
75615102|NCT04166461|Other|Not application, observational study|Not application, observational study
75767005|NCT01074476|Dietary Supplement|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
75767006|NCT01074476|Other|Placebo|Placebo tablets, twice per day for 3 months
75908582|NCT05955274|Behavioral|Mobile Behavioral Parent Training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
75908583|NCT05955274|Behavioral|Just-in-time intervention: Parenting Strategies|Parents will receive prompts via phone that provide parenting suggestions and parenting feedback when they are interacting with their child.
75908584|NCT05955248|Dietary Supplement|Mixed-nutriend supplement (NUT)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the active multi-nutrient supplement made of whey protein + leucine + vitamin D doses pre-mixed in unlabeled packets prepared by Gruppo Nutrition to dilute in a cup (250 mL) of water. In addition, participants will ingest 15 mL of fruit-flavored fish oil, provided as a liquid oil. They will receive a dosing cup, pre-marked to 15 mL, for a total dose providing 2120 mg eicosapentaenoic acid (EPA) and 1320 mg docosahexaenoic acid (DHA).
75908585|NCT05955248|Other|Multimodal Prehabilitation (MM)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the NUT intervention + structured exercise training prescribed by a kinesiologist (1. 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2. 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps). Training will be performed for 4 weeks prior to surgery (1x/week supervised by kinesiologist at hospital, 2x/week at alone at home)
75317118|NCT05740098|Behavioral|Best Practices|Five As plus referral to a quit line
75317119|NCT05740098|Behavioral|Financial Incentives|Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.
75767007|NCT00232544|Device|Telecommunications system|The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.
75767008|NCT00232544|Other|TLC-Control|A TLC system for providing general health education
75767009|NCT03974126|Other|40 grams of starch|40 grams of starch in form of white bread to be consumed within 15 minutes
75767010|NCT03974126|Other|80 grams of starch|80 grams of starch in form of white bread to be consumed within 15 minutes
75767011|NCT00231842|Drug|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
75767012|NCT00231842|Device|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
75767013|NCT00231842|Drug|Cisplatin|dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
75767014|NCT01073150|Drug|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
75767015|NCT00076102|Drug|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
75767016|NCT03968588|Drug|Tacrolimus(reduced), Mycophenolate mofetil(standard)|tacrolimus target trough blood level: 3~8ng/mL MMF dose: 1.5~2g/d
75767017|NCT03968588|Drug|Tacrolimus(standard), Mycophenolate mofetil(reduced)|tacrolimus target trough blood level: 5~15ng/mL MMF dose: 0.5~1g/d
75767018|NCT05625880|Device|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place
75317120|NCT05740098|Drug|Nicotine Replacement Therapy|Nicotine patches and gum/lozenge provided together for dual therapy
75317121|NCT05730413|Drug|Bisoprolol|Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.
75317122|NCT05730413|Drug|Bisoprolol|Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
75317123|NCT05725213|Drug|Metvix® 160 mg/g Creme|Patients are treated with Metvix creme and exposed to artificial daylight
75317124|NCT05720455|Drug|Fexofenadine HCL and pseudoephedrine HCL|Extended-Release Tablets
75615103|NCT02861001|Device|conventional bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
75615104|NCT02861001|Device|VivaSight-SL tube|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
75615105|NCT04168021|Behavioral|Leg ischemia|potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
75615106|NCT04032769|Other|MODS (MOdified Diagnostic Strategy)|"Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)"
75767019|NCT03974282|Behavioral|Psychological task|Participants will complete a psychological task that evokes antisocially- and prosocially-motivated empathic responding
75908586|NCT05955248|Dietary Supplement|Placebo Control (CTRL)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive a placebo dietary supplement made of maltodextrin and sunflower oil.
75908587|NCT05955209|Drug|Disitamab Vedotin（RC48-ADC）|Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death.
75462120|NCT01860495|Procedure|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
75462121|NCT01860495|Procedure|G2|tradetional occlusive collagen membrane
75908588|NCT05955196|Procedure|BLOOD AND TUMOR|sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece
75908589|NCT05955144|Device|Picterus JP|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is placed.
75908590|NCT05955131|Other|Nutritional acute postprandial intervention: Control bread|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of control bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination
75908591|NCT05955131|Other|Nutritional acute postprandial intervention: bread suppelmented with Chilean beans|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of supplemented bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination.
75908592|NCT05955131|Other|Nutritional acute postprandial intervention: Control glucose|Volunteers will arrive at fasting and capillary blood samples will be obtained before (0 min) and after the intake an amount of control glucose containing 50g of this monosscharide (10 min of intake), capillary slood will be also obtained at 15, 30, 60, 90 and 120 postprandial for glycemia determination.
75908593|NCT05955118|Device|Hydrus Microstent|Hydrus Microstent placed at the time of cataract surgery
75908594|NCT05955105|Drug|ILB-2109|ILB-2109 tablets will be administered by mouth every day in 21-day cycles
75908595|NCT05955105|Drug|Toripalimab|Toripalimab injection will be administered via IV every 21 days.
75908596|NCT05955079|Other|Whole blood|3 samples (before, after surgery and before chemotherapy)
75908597|NCT05955027|Drug|ZX-7101A|a drug to treat influenza, oral
75908598|NCT05955027|Drug|Placebo|placebo control, oral
76071432|NCT04866576|Dietary Supplement|Placebo|Maltodextrin powder with Whey protein and flavor (provided by BESO Biological Research, Inc.)
76071433|NCT04840797|Device|HeartStart HS1|Automated External Defibrillator
76071434|NCT04825223|Drug|Multicomponent Meningococcal B Vaccine|Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
75462122|NCT01860508|Drug|pemetrexed /carboplatin|
75462123|NCT01860547|Dietary Supplement|Bilberries|Frozen bilberries, 100 g/d
75462124|NCT01860547|Dietary Supplement|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
75462125|NCT01860547|Dietary Supplement|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
75462126|NCT01860547|Dietary Supplement|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
75767020|NCT01582646|Drug|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
75767021|NCT03741452|Other|transversalis fascia plane block|patient controlled analgesia devices with tramadol
75767022|NCT00231062|Device|Sinuplasty|
75317125|NCT05711576|Other|Non surgical peri-implant mucositis therapy with one-stage full-mouth scaling|Patients were treated with full mouth non surgical peri-implant mucositis therapy performed with only full mouth scaling and root planing
75462127|NCT01860599|Behavioral|Exercise|150 minutes of moderate exercise per week
75462128|NCT01860599|Behavioral|Without exercise|Pre-study activity level (i.e. no exercise)
75462129|NCT01860625|Drug|Donepezil patch|
75462130|NCT01860625|Drug|placebo|
75462131|NCT01860638|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
75462132|NCT01860638|Drug|Lomustine|Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m^2 PO Q6W, with a cap of 200 mg per dose.
75767023|NCT03974360|Drug|AMG 334|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
75767024|NCT00184028|Drug|Taxotere|Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
75317126|NCT05711576|Other|Non surgical peri-implant mucositis therapy with one-stage full-mouth scaling and chlorexidine|Patients were treated with full mouth non surgical peri-implant mucositis therapy performed with only full mouth scaling and root planing and chlorexidine
75317127|NCT05709314|Drug|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
75317128|NCT05702450|Biological|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
75767025|NCT00184028|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
75767026|NCT00183872|Drug|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
75317129|NCT05679557|Other|Perioperative geriatric assessment and intervention|The intervention will comprise a preoperative, thorough geriatric, multidisciplinary assessment (CGA) and tailored interventions, focused on optimizing health issues of expected importance in further course of surgery. Furthermore, postoperative ward rounds by a geriatric team will be conducted. Thus, the course of treatment for each patient will be a close interdisciplinary collaboration.
75767027|NCT03815175|Device|XIENCE|Subjects who received XIENCE family stent systems will be included.
75767028|NCT03815175|Drug|DAPT (aspirin and/or P2Y12 receptor inhibitor)|"1-month clear subjects (pooled from Xience 28 USA study and Xience 28 Global study) will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for > 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up."
75767029|NCT01076127|Behavioral|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
75908599|NCT05954728|Behavioral|Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|CBT-AR is a four-stage modular treatment for ARFID delivered by a mental health clinician. The four stages include: 1) Psychoeducation and early change; 2) Treatment planning; 3) Addressing maintaining mechanisms; and 4) Relapse prevention. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
76071435|NCT04825223|Drug|Meningococcal Group B Vaccine MenB|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
75317130|NCT05648955|Dietary Supplement|an enriched high protein and high energy oral nutrition supplement (ONS)|NA (see intervention name)
75317131|NCT05645003|Device|High-frequency real-time rTMS protocol|It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
75767030|NCT01076127|Behavioral|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
75767031|NCT01080027|Drug|Rebif® New Formulation|The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
75317132|NCT05645003|Device|Sham rTMS Protocol|It was planned to apply a to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
75317133|NCT05641753|Drug|Evolocumab Cartridge|Injectable PCSK9 inhibitor.
75462133|NCT01860638|Drug|Placebo|Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
75462134|NCT01860638|Radiation|Radiotherapy|Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
75767032|NCT00262028|Biological|MenACWY-CRM Vaccine|
75767033|NCT00262028|Biological|MenACWY-PS Vaccine|
75767034|NCT00183248|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
75767035|NCT00183248|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
75767036|NCT00183248|Drug|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
75908600|NCT05954728|Behavioral|Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder|Nutrition counseling will be provided by skilled registered dietitians at the MGH Translational and Clinical Research Center (TCRC). Sessions focus on the foods necessary for a healthy diet, how to meet nutritional needs, how to incorporate healthy exercise, and support for making these changes. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
76071436|NCT04825223|Drug|Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
76071437|NCT04825223|Drug|Placebo|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
75317134|NCT05641753|Drug|Atorvastatin Calcium Tablets|HMG-CoA reductase inhibitor for oral use.
75317135|NCT05641753|Drug|Ezetimibe Tablets|Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
76071438|NCT04825223|Drug|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
75317136|NCT05641753|Drug|18F-FDG|Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
75462135|NCT01860638|Drug|Temozolomide|Temozolomide will be administered orally (PO) as 75 mg/m^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m^2 per day for the first 5 days of Cycle 1, then 200 mg/m^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
75462136|NCT01860638|Drug|SOC Agent|The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
75767037|NCT00183248|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
75767038|NCT00183248|Procedure|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
75767039|NCT00183248|Procedure|Kidney transplant|Occurs at study entry
75767040|NCT00183170|Drug|Alcohol|Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.
75462137|NCT01860664|Drug|hydrocortisone ophthalmic ointment 0.5%|"Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~Study medication dosing details:~0.05 grams hydrocortisone per gram of combination product~each application equal to 1/20th of a gram~total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone"
76071439|NCT04822649|Diagnostic Test|Adenosine stress echocardiography with the evaluation of coronary artery blood flow|"The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove.~In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1 kilohertz (kHz), 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5 kHz, 50 kHz, 250 kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg).~By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis."
76071440|NCT04819386|Other|Active vision therapy sessions with the NEIVATECH Virtual Reality-based system|The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
76071441|NCT04815096|Drug|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|[18F]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
76071442|NCT04813055|Procedure|Therapeutic EUS|"EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~EUS-guided pancreatic duct drainage"
75317137|NCT05641753|Device|Angiocatheter 20IV|Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.
75767041|NCT00183170|Other|Placebo|Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.
75767042|NCT00230282|Drug|Alemtuzumab|3 to 30 mg, IV
75767043|NCT00230282|Drug|Fludarabine|[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid
75767044|NCT00230282|Drug|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
75317138|NCT05641753|Device|J-Wire|Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.
75462138|NCT01860664|Drug|placebo|Mineral oil and white petrolatum
75462139|NCT01860690|Drug|Methotrexate|50 mg / meter squer Intramuscular (IM) MTX.
75767045|NCT00261950|Drug|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
75767046|NCT01071434|Procedure|MR Imaging|
75767047|NCT00230048|Behavioral|Brief computer-delivered intervention|Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
75767048|NCT00229658|Drug|pramlintide acetate|Subcutaneous injection prior to each major meal
75767049|NCT00182078|Drug|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
75908601|NCT05954663|Other|Basic demographic information|"Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism~Clinical examination carried out 1 month after the operation and more than 6 months after the operation~Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation"
75908602|NCT05952440|Other|Tapering and/or discontinuation of treatment based on AI-guidance|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on AI-guidance
75908603|NCT05952440|Other|No tapering and/or discontinuation of treatment based on AI-guidance|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on AI-guidance
75908604|NCT05952440|Other|Tapering and/or discontinuation of treatment based on standard of care|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on standard of care
75317139|NCT05641753|Device|GlycoCheck Glycocalyx Measurement Software|Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
75615107|NCT00970359|Biological|AZD6244|"Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
75615108|NCT01121406|Drug|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
75615109|NCT01121406|Drug|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
75767050|NCT00182078|Drug|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
75767051|NCT03968510|Procedure|parathyroidectomy|routine parathyroidectomy will be done for the treatment of adenoma
75767052|NCT00181844|Drug|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children <12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
75767053|NCT00181766|Drug|Strattera (atomoxetine)|Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
75767054|NCT00180674|Drug|Warfarin|
75767055|NCT01074632|Drug|Lurasidone HCl|
75767056|NCT00076024|Drug|Placebo|5 mg twice daily [bid] continuous dosing
75908605|NCT05952440|Other|No tapering and/or discontinuation of treatment based on standard of care|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on standard of care
75908606|NCT05952349|Drug|OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)|44 Patients with PCOS receiving olive oil 5ML/5MG (BD) nutritional sachet 2100MG (BD
75908607|NCT05952349|Drug|Metformin (1000 mg Twice a day)|44 Patients with PCOS receiving Metformin 1000mg (BD)
75908608|NCT05952310|Other|Natural Killer (NK) cells (a new immunotherapy)|"It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease.~The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands.~The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect.~In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells."
75908609|NCT05951920|Procedure|Lymph node aspiration / Blood sampling|Lymph node aspiration / Blood sampling
75908610|NCT05951504|Drug|Methylprednisolone|Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
75317140|NCT05627700|Device|AVL200 IOL|The AVL200 is an intraocular lens surgically implanted in the eye after cataract surgery.
75615110|NCT01121406|Drug|Topotecan|Patients receive topotecan in 3 or 4 week schedule
75615111|NCT01121406|Drug|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
75615112|NCT01121406|Drug|BI 6727|Patients receive BI 6727 infusion every 3 weeks
75615113|NCT02650141|Drug|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
75615114|NCT02650141|Drug|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
75615115|NCT02657239|Behavioral|MOVE UP|Weight management behavioral program
75767057|NCT00076024|Drug|Docetaxel|Standard of care drug administration
75767058|NCT00076024|Drug|AG-013736 (axitinib)|5mg twice daily [bid] continuous dosing
75767059|NCT00076024|Drug|Docetaxel|Standard of care drug administration
75767060|NCT05626426|Device|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
75767061|NCT01103050|Drug|QAV680 + Cetirizine Placebo|
75767062|NCT01103050|Drug|QAV680 + Cetirizine|
75767063|NCT01103050|Drug|Cetirizine + QAV680 Placebo|
75767064|NCT01103050|Drug|QAV680 Placebo + Cetirizine Placebo|
75767065|NCT01102816|Other|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
75615116|NCT02652325|Drug|Saline|
75767066|NCT01102816|Other|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
75767067|NCT00075478|Procedure|Total-Body Irradiation|Undergo TBI
75767068|NCT00075478|Drug|Fludarabine Phosphate|Given IV
75908611|NCT05951348|Procedure|Delayed cord clamping for 30 seconds|waiting for 30 seconds after delivery of the fetus or milking of the cord in the direction of the fetus 10 times in time frame 10-15 seconds
75908612|NCT05950386|Other|Lead exposure|The lead-acid battery factory workers will exposure to lead via Inhalation of lead particles, ingestion of lead-contaminated dust and water.
75908613|NCT05950178|Diagnostic Test|Apnea test under high-flow oxygenation|Apnea test under high-flow oxygenation in patients with a confirmed clinical brain death by a standard apnea test (under standard oxygen therapy)
75908614|NCT05946200|Procedure|Low flow technique in general anesthesia|It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.
75908615|NCT05944601|Behavioral|Virtual and computer-based cognitive remediation training|Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).
75908616|NCT05940688|Behavioral|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
75908617|NCT05940688|Behavioral|Community Health Worker|Health care information delivered via CHW.
75908618|NCT05940688|Behavioral|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
75908619|NCT05939297|Other|Heart Health Self-efficacy and Self-Management Scale|In order to measure the self-management and self-efficacy levels of the individuals, patients will be administered the Heart Health Self-efficacy and Self-Management Scale.
76071443|NCT04813055|Procedure|Percutaneous Procedures|Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)
75317141|NCT05626621|Drug|Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray|Participants will follow this medication regimen for 6 months.
75615117|NCT02652325|Drug|Povidone-Iodine|
75615118|NCT02652325|Drug|5% Povidone-Iodine USP swabs|
75615119|NCT00960687|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
75767069|NCT00075478|Drug|Mycophenolate Mofetil|Given PO
75767070|NCT00075478|Drug|Cyclosporine|Given PO
75767071|NCT00075478|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
75767072|NCT00175916|Drug|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
75767073|NCT01089088|Drug|cisplatin|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
75908620|NCT05939297|Other|Self-Care Management Scale in chronic diseases|For the external construct validity statistical method, the self-management level of the individuals will also be determined with the Self-Care Management in Chronic Diseases Scale, which has been previously validated and reliable in Turkish.
75908621|NCT05939297|Other|general self-efficacy scale|For the external construct validity statistical method, the self-efficacy level of the individuals will also be determined with the general self-efficacy scale, which has been previously validated and reliable in Turkish.
75908622|NCT05937477|Other|Fitbit smartwatch|Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
75317142|NCT05626621|Drug|Mometasone Nasal Irrigation (1 mg capsule)|Participants will follow this medication regimen for 6 months.
75615120|NCT00960687|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
75615121|NCT00920140|Drug|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
75767074|NCT01089088|Drug|gemcitabine hydrochloride|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
75908623|NCT05932758|Procedure|Vacuum-assisted excisional biopsy|at least 4g of tissue sampled (excisional biopsy)
75908624|NCT05932758|Procedure|Not excisional biopsy|biopsy with less than 4 g of tissue sampled
75908625|NCT05927753|Device|Deseyne Daily Disposable Contact Lens (Test Device)|Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
75317143|NCT05626621|Drug|Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation|Participants will follow this medication regimen for 6 months.
75615122|NCT00920140|Drug|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
75615123|NCT00649753|Procedure|Category II Pelvic Blocking|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
75767075|NCT01089088|Drug|sunitinib malate|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
75767076|NCT03968432|Behavioral|MIAS&Q|There were two interventions compared in this study: 1) Be Sweet to Babies Videos and Pamphlet; and 2) Be Sweet to Babies Videos, pamphlet, and MIAS&Q. The Be Sweet to Babies vaccination pain management videos and pamphlet were provided to all participants as this information is publicly available, and demonstrates the effectiveness of the evidence-based recommended vaccination pain management strategies for infants. In addition, a pamphlet was used which was developed in partnership with CHEO and Ottawa Public Health as a knowledge translation tool. Those in the intervention arm were also given MIAS&Q included five questions and statements based on the MI approach consisted of four scaled questions and two open-ended questions, aimed to present brief informative and affirmative questions and statements to help the parents reflect on their own thoughts and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
75317144|NCT05624931|Behavioral|Brief CBT-Based Intervention|"Aims 1 (n=30) and 2 (n=18) will inform the Aim 3 intervention. We anticipate that the intervention will be comprised of four treatment sessions. These sessions will likely target two pathways to PrEP adherence and persistence: (1) decreased withdrawal and avoidance and (2) behavioral skill building to increase self-care/health behaviors. To decrease withdrawal and avoidance, we will likely include CBT-based exercises that improve distress tolerance and coping. To help participants build new behavioral skills, we will likely incorporate behavioral activation and problem-solving. Behavioral activation is a CBT strategy that promotes scheduling activities that align with an individual's values, which will also break maladaptive patterns of withdrawal and avoidance. Problem-solving is an empirically-supported treatment for depression; training patients to problem-solve adaptively will help them approach PrEP use by navigating barriers."
75615124|NCT00649753|Procedure|Category II Pelvic Blocking and Cranial|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
75317145|NCT05624931|Other|Enhanced Treatment as Usual|This is the control intervention. Participants will receive antenatal care as usual, which is monthly visits to the MOU, information about using PrEP during pregnancy (information sheet or pamphlet), and a psychological services referral.
75317146|NCT05602740|Device|Harmony|Passive recording of the head pulse
75317147|NCT05593094|Drug|ZN-A-1041 50mg BID|twice a day (BID) via oral administration
75317148|NCT05593094|Drug|ZN-A-1041 100mg BID|twice a day (BID) via oral administration
75317149|NCT05593094|Drug|ZN-A-1041 200mg BID|twice a day (BID) via oral administration
75615125|NCT00649753|Procedure|Cranial Only|Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
75615126|NCT01120782|Device|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
75615127|NCT01120782|Device|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
75615128|NCT02650297|Other|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
75615129|NCT02650297|Device|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
75615130|NCT04203862|Drug|NPC-22|Single administration of low dose NPC-22
75767077|NCT03968432|Behavioral|Be Sweet to Babies Videos and Pamphlet|The Be Sweet to Babies vaccination pain management videos and pamphlet will be provided to all participants. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of sweet solution during vaccination, will be used. This pamphlet is a knowledge translation tool previously developed in partnership with the Children Hospital of Eastern Ontario (CHEO) and Ottawa Public Health and has been publicly available on the Ottawa Public Health Website since June 2013. The content presented about pain management for infants during vaccination is the same information as the video.
75317150|NCT05593094|Drug|ZN-A-1041 400mg BID|twice a day (BID) via oral administration
75317151|NCT05593094|Drug|ZN-A-1041 600mg BID|twice a day (BID) via oral administration
75767078|NCT00075400|Drug|imatinib mesylate|Given PO
75317152|NCT05593094|Drug|ZN-A-1041 800mg BID|twice a day (BID) via oral administration
75767079|NCT00075400|Other|laboratory biomarker analysis|Correlative studies
75317153|NCT05593094|Drug|ZN-A-1041 1000mg BID|twice a day (BID) via oral administration
75317154|NCT05593094|Drug|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b|ZN-A-1041: twice a day (BID) via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
75462140|NCT01860716|Drug|Melatonin|Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
75462141|NCT01860716|Drug|Placebo|
75462142|NCT01860729|Drug|Anacetrapib|
75462143|NCT01860729|Drug|Placebo|
75462144|NCT01860742|Drug|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
75462145|NCT01860742|Drug|177Lu-DOTATATE|177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
75462146|NCT01860755|Other|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
75462147|NCT01860755|Other|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
75908626|NCT05925166|Drug|rhTNFR-Fc|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
75908627|NCT05925166|Drug|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
76071444|NCT04813055|Procedure|Surgical Interventions|Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)
76071445|NCT04813055|Procedure|non-EUS-based endoscopic procedures|Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
75317155|NCT05593094|Drug|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b|ZN-A-1041: twice a day (BID) via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
75317156|NCT05593094|Drug|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b|ZN-A-1041: twice a day (BID) via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
75317157|NCT05593094|Drug|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c|ZN-A-1041: twice a day (BID) via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
75615131|NCT04203862|Drug|NPC-22|Single administration of low/middle dose NPC-22
75615132|NCT04203862|Drug|NPC-22|Single administration of middle dose NPC-22
75615133|NCT04203862|Drug|NPC-22|Single administration of middle/high dose NPC-22
75615134|NCT04203862|Drug|NPC-22|Single administration of high dose NPC-22
75615135|NCT04203862|Drug|NPC-22 Placebo|Single administration of NPC-22 Placebo
75615136|NCT01120626|Drug|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
75615137|NCT01120626|Drug|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
75615138|NCT04252534|Combination Product|PRP combined Magnovision|The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection
76071446|NCT04812678|Procedure|Fasciatherapy|Fasciatherapy, with manual therapy and/or gestual therapy.
75317158|NCT05593094|Drug|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c|ZN-A-1041: twice a day (BID) via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
75615139|NCT04252534|Biological|PRP|Fresh autologous platelet rich plasma, injected subtenon space.
75615140|NCT00650377|Drug|Finasteride Tablets 5 mg|5mg, single dose fed
75615141|NCT00650377|Drug|Proscar® Tablets 5 mg|5mg, single dose fed
75615142|NCT05115370|Other|Semi-structured qualitative interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
75615143|NCT02649985|Drug|[F-18]PBR06|PET radiopharmaceutical
76071447|NCT04812678|Procedure|Physiotherapy|Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
76071448|NCT04810052|Behavioral|Behavioral Intervention|Perform 1 nice thing
76071449|NCT04810052|Behavioral|Behavioral Intervention|Write a letter or note of gratitude
75615144|NCT02649985|Drug|[C-11]PBR28|PET radiopharmaceutical
75615145|NCT02650063|Drug|DE-117|
75615146|NCT02649751|Drug|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
75615147|NCT02649751|Drug|Placebo|The placebo treatment is lactose capsule.
76071450|NCT04810052|Behavioral|Behavioral Intervention|Track daily activities
76071451|NCT04810052|Other|Interview|Ancillary studies
76071452|NCT04810052|Other|Quality-of-Life Assessment|Ancillary studies
75615148|NCT04252300|Drug|Rosuvastatin|Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
75615149|NCT04252300|Drug|Rosuvastatin + BAY1817080|A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
75615150|NCT02649595|Other|Red Cross Respite care|See detailed description.
75615151|NCT04256746|Other|Boiled Rice|
75615152|NCT04256746|Other|Boiled Rice+0.37 gr mulberry fruit powdered extract|
75615153|NCT04256746|Other|Boiled Rice+0.75 gr mulberry fruit powdered extract|
75615154|NCT04256746|Other|Boiled Rice+1.12 gr mulberry fruit powdered extract|
75615155|NCT04256746|Other|Boiled Rice+1.50 gr mulberry fruit powdered extract|
75615156|NCT04256746|Other|Rice Porridge|
75615157|NCT04256746|Other|Rice porridge+1.50 gr mulberry fruit powdered extract|
75615158|NCT04167319|Other|QST and PRO measurements during treatment|We will observe the natural course of CIPN using multiple measurements
75767080|NCT03972722|Drug|GLS-010|Patients will be given 240mg GLS-010 every treatment.
75767081|NCT03972644|Procedure|Aortic valve replacement|Open heart surgery or transcatheter surgery
75767082|NCT01103206|Drug|cinacalcet|Intake of a single tablet of cinacalcet
75767083|NCT01103206|Drug|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
75767084|NCT01103206|Drug|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
75767085|NCT00228566|Drug|Armodafinil|
75767086|NCT01105468|Device|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
76071453|NCT04810052|Other|Questionnaire Administration|Ancillary studies
76071454|NCT04792970|Drug|Talc|All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
76071455|NCT04778501|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
75767087|NCT01105468|Device|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
75767088|NCT03949114|Behavioral|Evaluation|Evaluate a weak debilitating phenotype screening on the patients before surgery;
75767089|NCT03949114|Behavioral|nursing care|Traditional post-operative nursing care
76071456|NCT04755309|Behavioral|Rhythmic intervention|"The rhythmic intervention consists in an ecological and non-invasive intervention based on enriched auditory and musical active experience. It is based on the most recent scientific evidence in the field and provides exposure to and active synchronization with complex musical rhythms. It is thought to promote the infant's ability to recognize and process the complex rhythms of spoken language. Importantly, it taps into and empowers early auditory processing skills. The intervention includes several tasks described in the literature, for example tapping and bouncing at the beat of complex musical rhythms.~The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks."
75767090|NCT03949114|Behavioral|rehabilitation|"Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days."
75767091|NCT01105546|Drug|recombinant activated factor VII|90 µg/kg/day i.v.
75767092|NCT01105546|Drug|recombinant activated factor VII|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
75908628|NCT05917795|Procedure|Endoscopic Sleeve Gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope (GIF-H190/GIF-HQ190; Olympus Medical Systems Corp., Tokyo, Japan) will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch. The final effect of ESG is the creation of a gastric tubule thus reducing the volume of the stomach. After the procedure, the final shape will be evaluated, to examine any gaps that would require additional closure, and to exclude bleedings and/or other complications.
75767093|NCT00074152|Drug|chemotherapy|Given within 10 weeks after surgery.
75767094|NCT00074152|Radiation|radiation therapy|Given within 6 months after surgery
75908629|NCT05916404|Other|Upper extremity high-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate.~In case of desaturation (<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient."
75908630|NCT05916404|Other|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
75908631|NCT05914155|Drug|Rituximab (genetical recombination)|Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
75908632|NCT05914155|Drug|Placebo|Administer placebo IV infusion every two weeks for two doses in double-blind phase.
76071457|NCT04755309|Behavioral|Passive auditory stimulation|The same auditory stimulation is provided to infants, but no active tasks are proposed. Children and caregiver are entertained with motor and cognitive tasks not related to the auditory stimuli presented. The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks.
76071458|NCT04753372|Drug|Rivaroxaban 2.5 MG [Xarelto]|rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD
76071459|NCT04748042|Drug|Abiraterone|Abiraterone 1000 mg by mouth per day for approximately 6 months.
75462148|NCT01860781|Drug|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
75615159|NCT04256668|Diagnostic Test|Obtaining one or semen samples|Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
75767095|NCT00261846|Drug|Bosutinib|"Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.~Part 2, 500 mg oral, continuous, daily dosing."
75767096|NCT00169442|Biological|Tritanrix™-HepB/Hiberix™ Kft.|GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
76071460|NCT04748042|Drug|Prednisone|Prednisone 5 mg by mouth per day for approximately 6 months.
75462149|NCT01860794|Drug|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
75462150|NCT01860820|Device|Geko device|
75615160|NCT02649517|Procedure|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
75615161|NCT00924508|Device|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
75317159|NCT05593094|Drug|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c|ZN-A-1041: twice a day (BID) via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion
75615162|NCT00924508|Drug|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
75615163|NCT00650923|Drug|ziv-aflibercept|Given IV
75767097|NCT00169442|Biological|Tritanrix™-HepB/Hiberix™|GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
75767098|NCT00169442|Biological|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
75317160|NCT05591118|Drug|Anticoagulant Therapy|All subjects will receive anticoagulation for a minimum of 3 months.
75317161|NCT05591118|Device|Catheter-Directed Therapy|The endovascular physician can choose to use either mechanical thrombectomy (MT) using a device cleared by the FDA to treat PE or catheter-directed thrombolysis (CDL) using an infusion catheter cleared by the FDA to administer thrombolytic drugs for the treatment of PE
75615164|NCT00650923|Procedure|radiation therapy|Undergo RT
75908633|NCT05914155|Drug|Rituximab (genetical recombination)|Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
75908634|NCT05910463|Other|AXOMOVE Therapy Medical Device|Personalized exercise programs for the self-rehabilitation of low back pain patients
75908635|NCT05907395|Drug|PF-07293893|PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
75908636|NCT05907395|Drug|Placebo|Matching placebo will be prepared as an oral suspension given in each cohort.
75908637|NCT05896293|Drug|kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
75908638|NCT05896293|Drug|GnRH|SC administration of GnRH for approximately six days (pulsatile, every 120 minutes)
75615165|NCT00650923|Drug|temozolomide|Given PO
75908639|NCT05887388|Behavioral|Connect-Home Plus|Connect-Home Plus will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Plus Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home Plus care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses,therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the illness and functional needs. In Step 2, a dementia caregiving specialist will call the patient's home three times within 30 days of discharge. Both intervention steps will focus on key care needs, such as 1) home safety; 2) care of symptoms of ADRD; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
75317162|NCT05590403|Biological|RSVPreF3 OA investigational vaccine|One dose administered intramuscularly at Day 1.
75317163|NCT05590403|Drug|Placebo|One dose administered intramuscularly at Day 1.
75317164|NCT05577728|Drug|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
75615166|NCT00650923|Procedure|pharmacological study|Correlative studies
75615167|NCT00650923|Procedure|laboratory biomarker analysis|Correlative studies
75615168|NCT04241926|Diagnostic Test|transpolmonary thermodilution|Thermodilution was attempted via PICC and via CICC in the same patient
75615169|NCT02649205|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
75615170|NCT04256590|Diagnostic Test|Ultrasonography imaging|This study aimed to measure the tongue surface areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue surface areas.
75615171|NCT00637858|Dietary Supplement|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
75615172|NCT00637858|Dietary Supplement|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
75317165|NCT05577728|Drug|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)"|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference."
75615173|NCT00637858|Dietary Supplement|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
75615174|NCT00637858|Dietary Supplement|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
75767099|NCT00169442|Biological|Polyribosil-Ribitol-Phosphate (PRP) vaccine|plain PRP polysaccharide vaccine
75767100|NCT00169442|Biological|Tritanrix™-HepB Kft|GSK Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
75767101|NCT02530762|Other|Novel Fiber|novel fiber supplemented beverage provided in one serving
75615175|NCT00637858|Other|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
75767102|NCT02530762|Other|Positive Fiber control|positive control fiber supplemented beverage provided in one serving
75767103|NCT02530762|Other|Negative Control|No added fiber beverage
75767104|NCT00261716|Behavioral|IPS|Individual Placement and Support Evidence based supported employment
75767105|NCT00261716|Behavioral|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
76071461|NCT04748042|Radiation|External Beam Radiotherapy|External beam radiotherapy, dose will depend on lesion location. Completed within 40 days of study start.
75767106|NCT00261716|Behavioral|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
76071462|NCT04748042|Biological|Androgen Deprivation Therapy (ADT)|ADT by luteinizing hormone-releasing hormone (LHRH) agonist or antagonist for 6 months.
75767107|NCT01089166|Drug|Metformin|
75767108|NCT03809104|Other|Virtual reality-based rehabilitation programs|A virtual reality (VR)-based rehabilitation program that lasts for 12 weeks, twice per week, 30 minutes per time. The program was combined with progressive resistant training and functional movement of dominant upper (UE) limb. The device of the VR including one computer, one oculus headset, and one hand-hold sensor. The rehabilitation secession contains 4 different VR games in total, including (1) Leap Motion Blocks (2) Slum Ball VR Tournament (3) VR Super Sports 10th Edition- Basketball (4) VR Super Sports 10th Edition- Soccer.
76071463|NCT04748042|Drug|Olaparib|Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.
75767109|NCT00203502|Drug|Bevacizumab|IV 15mg/kg 21 days
76071464|NCT04743492|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.
76071465|NCT04742374|Biological|Blood sampling|Blood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis
75767110|NCT00203502|Drug|Cyclophosphamide|500mg per meter squared, IV every 21 days
75767111|NCT00203502|Drug|Docetaxel|60 mg per meter squared, IV every 21 days
75767112|NCT03799198|Other|Weight Management Program (WMP)|As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
75317166|NCT05577156|Behavioral|Self-questionnaires and semi-structured interview|Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions
75462151|NCT01860833|Drug|Ibuprofen|time of treatment 14 days
75462152|NCT01860833|Drug|Celecoxib|time of treatment 14 days
75615176|NCT04167241|Diagnostic Test|Echocardiography|Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
75767113|NCT03799198|Drug|Medication for chronic weight management (Rx)|"Following listed 5 drugs will be administered as prescribed by the study doctor:~1) Orlistat (Xenical® pills, per os [p.o.; by mouth]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously [under the skin])."
75767114|NCT01105780|Drug|Placebo|Matching placebo
75767115|NCT01105780|Drug|JNJ-41443532|250mg tablet once daily for 1 day
76071466|NCT04741516|Drug|Foquest|The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®). Foquest® is a novel formulation of MPH developed by Purdue Pharma (Canada) and is approved in Canada for the treatment of ADHD in patients six years of age and older. Foquest® is the first methylphenidate product approved in Canada with an onset of action within one hour and a duration of action up to and including 16 hours (Wigal et al.2016). Foquest® is an ADHD treatment option for patients who require a rapid onset of action and extended duration of action
76071467|NCT04741282|Other|Pulmonary telerehabilitation|pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise
76071468|NCT04741282|Other|progressive muscle relaxation training|summarized Jacobson progressive muscle relaxation training method
76071469|NCT04733040|Drug|MOR202|5 or 2 doses of MOR202 will be administered as an intravenous infusion
76071470|NCT04730609|Drug|Dexmedetomidine|Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
76071471|NCT04726215|Drug|[18F]F AraG|PET imaging agent specific to activated T cells
76071472|NCT04717869|Diagnostic Test|Ultrasound|2D ultrasound image collection
76071473|NCT04717869|Diagnostic Test|Biomarker Analysis|Inflammatory and nutritional biomarker analysis
76071474|NCT04717869|Other|Frailty Index|A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
76071475|NCT04713176|Drug|DWJ1248 with Remdesivir|1 tablet of DWJ1248 TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
76071476|NCT04713176|Drug|Placebo with Remdesivir|1 tablet of placebo TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
75462153|NCT01860833|Drug|Diclofenac|time of treatment 14 days
75462154|NCT01860859|Procedure|Closure of the hysterotomy at the time of primary cesarean|
75462155|NCT01860911|Drug|Insulin|
75462156|NCT01860911|Drug|NG-monomethyl-L-arginine|
75462157|NCT01860924|Behavioral|exercise|vigorous intensity exercise
75615177|NCT02649127|Behavioral|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
75615178|NCT02649127|Behavioral|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity [i. e., >60% of oxygen uptake reserve (VO2R)], and a time of 20-25 minutes each bout of training
75615179|NCT02649127|Behavioral|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
76071477|NCT04710303|Biological|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 [E1-, E2b-, E3-] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
75462158|NCT01860924|Behavioral|health education|education
75462159|NCT01860963|Procedure|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
75767116|NCT01103518|Drug|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
75767117|NCT03947086|Device|Transcranial Direct Current Stimulation (TDCS)- Active|A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
75767118|NCT03947086|Device|Transcranial Direct Current Stimulation (TDCS)- Sham|The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.
75767119|NCT03947086|Behavioral|Cognitive Training|"Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, & Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao & Maurer, 2009; Dillon, Kannan, Dean, Spelke, & Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved."
75615180|NCT04251598|Behavioral|I Am Protecting My Child from the Sun|"The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband."
76071478|NCT04703647|Other|Administration of questionnaires for prospective group|Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .
75767120|NCT04924504|Other|No interventions|No interventions
75767121|NCT03947008|Other|Intuitive Eating Program|"A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions."
75767122|NCT03946852|Device|Abdominal Regional Perfusion|Abdominal Regional Perfusion
75767123|NCT03948802|Diagnostic Test|Interleukine 33 test in blood plasma|ELISA test for Interleukin 33
75767124|NCT01103674|Device|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
75767125|NCT01089322|Drug|inhaled corticosteroid plus LABA plus oral corticosteroid|formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
75615181|NCT04251598|Behavioral|SMS for sun protection|While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
75767126|NCT01327534|Drug|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
75767127|NCT01327534|Drug|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
75767128|NCT05625568|Drug|VYNT-0126|Liquid for oral administration once daily
75767129|NCT05625568|Drug|Placebo|Liquid for oral administration once daily
75767130|NCT03741166|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
75908640|NCT05886777|Biological|Combination [RSVpreF+BNTb162b2]|Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
75908641|NCT05886777|Biological|Bivalent BNT162b2 (original/Omi BA.4/BA.5)|Bivalent BNT162b2 given as an intramuscular injection
75908642|NCT05886777|Biological|RSVpreF|RSVpreF given as an intramuscular injection
75908643|NCT05886777|Biological|QIV|Licensed QIV given as an intramuscular injection
76071479|NCT04703647|Other|Blood samples for prospective group|Blood samples at T0,T1,T2 and T3.
75462160|NCT01861015|Drug|Epinephrine|
75462161|NCT01861015|Drug|Vasopressin|
75462162|NCT01861041|Drug|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
75615182|NCT02657161|Biological|RABIPUR®|Biological rabies vaccine
75615183|NCT02657161|Biological|PIKA rabies vaccine|Biological rabies vaccine
75615184|NCT02657161|Biological|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
75462163|NCT01861041|Drug|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
75462164|NCT01861067|Procedure|LESS-TLH|
75615185|NCT01139580|Drug|Calcipotriene Foam|Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
75615186|NCT01139580|Drug|Vehicle Foam|Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
75462165|NCT01861067|Procedure|LESS-LAVH|
75462166|NCT01861119|Drug|Silicone gel Kelo-cort™;|
75462167|NCT01861119|Drug|Onion extract gel Contractubex™|
75462168|NCT01861145|Device|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
75908644|NCT05886777|Biological|Normal Saline Placebo|Normal saline (0.9% sodium chloride solution for injection)
75908645|NCT05886374|Drug|HMPL-415S1|HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
75615187|NCT02657083|Device|DreaMed Substance Administration Device|"2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision."
75615188|NCT02657083|Device|Sensor Augmented Pump (SAP)|"2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise"
75615189|NCT04686760|Drug|Nitroglycerin|2 mg/ml solution of nitroglycerin used for nebulization four hourly
75615190|NCT04312698|Drug|D013, D326, D337|Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
75767131|NCT03960736|Other|ESP block (Group A)|US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.
75908646|NCT05882006|Other|gallstones|fellow up if the patients have gallstones
75908647|NCT05881928|Drug|Sodium Valproate 500 Mg Prolonged-Release Oral Tablet|sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :
76071480|NCT04703647|Other|Blood samples for control group|Blood samples just one time
75462169|NCT01861145|Drug|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
75462170|NCT01861158|Behavioral|Parenting Wisely|Computer-based, online, interactive parenting intervention
75615191|NCT04312698|Drug|placebo of D013, D326, D337|Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
75615192|NCT04312698|Drug|D013, placebo of D326, placebo of D337|Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
75615193|NCT04251832|Drug|Sodium Thiosulfate|Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
75615194|NCT04312464|Other|non|no intervention
75615195|NCT02656927|Behavioral|Yoga Condition|
75615196|NCT04251988|Device|Oculus Go VR|virtual reality headset
75615197|NCT04312776|Other|none intervention|
75615198|NCT02656849|Drug|BAY 1000394|
75908648|NCT05881928|Drug|Lamotrigine|lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .
75908649|NCT05881928|Device|E.E.G|device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
75908650|NCT05872893|Drug|Ondansetron|Patients will receive age-adjusted doses of ondansetron 5mg/m2
75908651|NCT05872893|Drug|Dexamethasone|Patients will receive dexamethasone 4mg/m2
75908652|NCT05869747|Behavioral|Blood Donation|Participants asked to donate whole blood at a donation facility from a list provided by the study.
75462171|NCT01861171|Dietary Supplement|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
75908653|NCT05869747|Behavioral|Plasma Donation|Participants asked to donate plasma at a donation facility from a list provided by the study.
75908654|NCT05869747|Behavioral|Zone 2 Training|Participants asked to work out in their custom Zone 2 heart range 4 times a week for 45 to 60 minutes.
75908655|NCT05869747|Behavioral|Intermittent Fasting|Participants asked to engage in an intermittent fasting routine of a 16 hour fast followed by an 8 hour eating period at least 4 times a week.
75908656|NCT05869747|Behavioral|Surveys|Participants were asked to complete surveys throughout the study to monitor intervention progress and to collect baseline and end-of-study data.
76071481|NCT04703621|Drug|Daratumumab Injection|subcutaneious daratumumab administration
76071482|NCT04703569|Procedure|Dressing with monolayer high compression elastic bandage|The nurse will be apply the therapy high compression elastic bandage once a week, during 26 weeks
76071483|NCT04703569|Procedure|Dressing with Unna boot|The nurse will be apply the therapy Unna Boot once a week, during 26 weeks.
76071484|NCT04702139|Device|shoulder arthroplastis|- Group (Treatment): Placement of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
75462172|NCT01861197|Drug|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
75462173|NCT01861210|Behavioral|Couples Voluntary HIV Counseling and Testing|
75462174|NCT01861210|Behavioral|Individual Counseling and Testing|
75462175|NCT01861223|Drug|afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)|
75908657|NCT05869539|Drug|Combination of Tumor-infiltrating lymphocyte transfer with ANV419|"The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10^9 and up to 2x 10^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419."
75908658|NCT05863026|Behavioral|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
75908659|NCT05858359|Behavioral|ImPACT program|"During the ImPACT program, the brain cancer survivor and a carer collaborate on:~Becoming aware of the patient's core strengths and difficulties~Helping the patient to be optimally responsive to the guidance of the carer, and~Creating compensatory strategies to respond to real-world manifestations of the patient's difficulties and helping the patient implement these strategies at home."
75908660|NCT05855226|Other|OTHER-intervention (Occupational Therapy at Home E-Rehabilitation)|The occupational therapist will use activity monitoring and coaching techniques with videoconference during OTHER.
75908661|NCT05826288|Other|BioIntelliSense BioButton Rechargable|This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.
75908662|NCT05826288|Other|Memora Health two-way patient engagement platform provided by RC|The Memora Health platform is designed to automate complex care workflows, making them simple for patients and clinicians to navigate. It utilizes a multi-modal communications system that primarily relies on two-way text messaging and artificial intelligence.
75908663|NCT05826275|Drug|TGN-S11|Small Molecule
75908664|NCT05826275|Drug|Pembrolizumab|PD-1 checkpoint blockade
75908665|NCT05824637|Device|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
75908666|NCT05824637|Diagnostic Test|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
75908667|NCT05818345|Behavioral|Pricing intervention|Participants will be provided with a menu with manipulated prices for products with lower kilocalories
75908668|NCT05804227|Drug|Ulixertinib|Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
75908669|NCT05790343|Behavioral|BAPHYC|Nine weekly peer led group meetings
76071485|NCT04702139|Device|shoulder arthroplastis|- Group (Control): Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
76071486|NCT04702113|Diagnostic Test|Cipherome Lighthouse Pilot|Preemptive pharmacogenomic testing
75615199|NCT04313010|Other|PRF|A sample of whole venous blood was drawn from the patient's forearm. The blood sample was transferred into a tube without anticoagulant and centrifuged immediately using a centrifuge.
75615200|NCT04313010|Other|BC|According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
75908670|NCT05774249|Procedure|Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine|while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.
75908671|NCT05774249|Procedure|Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline|Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
75908672|NCT05767398|Drug|Zanubrutinib|Administered as a tablet or capsule
75908673|NCT05759819|Device|Standard stenting|The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
75908674|NCT05756855|Behavioral|adapted behavioral intervention|cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis
75908675|NCT05754541|Device|WeFlow-Tribranch Aortic Arch Stent Graft System|Endovascular treament in patients with aortic arch dissection and aneurysm by WeFlow-Tribranch Aortic Arch Stent Graft System
75908676|NCT05742438|Drug|Lidocaine IV|Continuous intravenous infusion of lidocaine
75908677|NCT05742438|Drug|Dexmedetomidine IV|Continuous intravenous infusion of dexmedetomidine
75908678|NCT05742438|Drug|intrathecal morphine|intrathecal morphine injection
76071487|NCT04701723|Other|cardiac coherence|standard care associated to cardiac coherence training during 3 months
76071488|NCT04697784|Device|TREO Abdominal Stent-Graft System|The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.
75615201|NCT05252260|Procedure|Diode Laser|Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
76071489|NCT04696146|Drug|Berinert|Intrarenal dose of 500 U of Berinert
76071490|NCT04696146|Drug|Placebo|Normal Saline placebo
76071491|NCT04693676|Biological|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
76071492|NCT04685486|Other|Virtual Reality|Immersive and interactive game played through a portable head-mounted display as a distraction mechanism
76071493|NCT04684719|Biological|low titer whole blood|low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site
76071494|NCT04684719|Biological|Standard Care|crystalloid infusion or blood component transfusion resuscitation
76071495|NCT04681248|Drug|DKN-01|Administered by IV infusion
76071496|NCT04680897|Behavioral|Early restriction release|Participants will no longer have restrictions on vaginal penetration 2 weeks after surgery.
75615202|NCT05252260|Procedure|Conventional Surgery|A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.
75767132|NCT03960736|Other|TEA group (Group B)|Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
75767133|NCT02530840|Behavioral|medical team|Lowering HbA1c by behavioral changes in meetings with the medical team.
75615203|NCT05252260|Other|Low level laser therapy (LLLT)|Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
75767134|NCT02530840|Behavioral|peers group|Lowering HbA1c by behavioral changes in meetings with the peers group.
75767135|NCT02530840|Behavioral|SMS notification|Lowering HbA1c by behavioral changes in meetings with the SMS notification
75767136|NCT01106170|Drug|Provex CV|dietary supplement, 2 capsules per day by mouth
75767137|NCT01106170|Other|placebo|corn starch, 2 capsules per day by mouth
75767138|NCT01103752|Other|no intervention, descriptive study|no intervention, descriptive study
76071497|NCT04680897|Behavioral|Standard restriction recommendation|Participants will return to intercourse after 6 weeks
76071498|NCT04680026|Drug|HBI-3000|Small molecule, multi-ion channel blocker
76071499|NCT04680026|Drug|Placebo|Normal saline
75317167|NCT05575817|Behavioral|Web Based Patient Tutorial on Prolonged Grief Disorder Therapy|"The patient tutorial will contain 9 modules, each designed to be used flexibly in conjunction with Prolonged Grief Disorder Therapy (PGDT) telehealth sessions with the therapist. Each module takes about 15-30 minutes to complete. The patient tutorial consists of information about grief and adaptation to loss, including a description of seven healing milestones that are the focus of PGDT and an explanation of prolonged grief and how to understand it. In addition, the tutorial has descriptions of the procedure, goals and rationale for a series of in-session therapeutic exercises to be undertaken with the therapist, as well as descriptions and encouragement to participate in interim therapeutic activities (i.e., homework) assigned by the therapist after each treatment session. The tutorial also contains a self-assessment component for each module that can be completed by the patient and shared with the therapist."
75317168|NCT05563506|Behavioral|Healthy Kids +|Three times a week for 30 weeks.
75767139|NCT00232596|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
75767140|NCT00232596|Drug|Placebo|Oral tablet.
75767141|NCT04771936|Other|Physiotherapy Exercises|All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.
75767142|NCT00073918|Drug|cyclophosphamide|Given IV
75767143|NCT00073918|Drug|etoposide|Given IV
75767144|NCT00073918|Radiation|iodine I 131 tositumomab|Given IV
76071500|NCT04669665|Drug|SLS-002|Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
76071501|NCT04669665|Drug|Placebo|Intranasal placebo
76071502|NCT04669665|Other|Standard of care|Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
75317169|NCT05549999|Diagnostic Test|North Star Ambulatory Assessment|North Star Ambulatory Assessment is an ambulatory assessment developed specifically for Duchenne Muscular Dystrophy.
75317170|NCT05543096|Device|Adroit Guiding Catheter, Cordis Transradial Access Devices, Cordis Diagnostic Catheters, Cordis Guidewires|Observation
75317171|NCT05541276|Drug|Melatonin|Melatonin for injection 1 mg/mL
75317172|NCT05541276|Drug|Isotonic sodium chloride solution|Sodium chloride 0.9 % for injection
75615204|NCT02536729|Drug|Oral Sodium Phosphate - Normal preparation|
75767145|NCT00073918|Procedure|quality-of-life assessment|Ancillary study
75767146|NCT00073918|Procedure|peripheral blood stem cell transplantation|Undergo ASCT given via central catheter
75767147|NCT01071642|Drug|stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure|ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
76071503|NCT04669665|Device|Intranasal device|Device to deliver intranasal solution
76071504|NCT04661007|Drug|tafasitamab|tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
76071505|NCT04661007|Drug|lenalidomide|lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
76071506|NCT04661007|Drug|parsaclisib|parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
76071507|NCT04661007|Drug|R-CHOP|R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
75908679|NCT05732792|Other|CIPS Survey|"The survey is endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) and will be distributed from February 2023 onwards to its members for a period of 3 months.~Each anesthesiologist's participation to the survey will be voluntary and anonymous individual consent will be implied by the person's willingness to complete the survey.~The survey will also mention this.~All surveys will be administered via SurveyMonkey. Surveymonkey allows to build Health Insurance Portability and Accountability Act (HIPAA) compliant surveys that follow strict rules around the protection of health information.~Of note, Surveymonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored on the surveymonkey database. The access to the result database is held by a password that only the authors can use to analyze the data yielded at the end of the survey period."
75615205|NCT02536729|Drug|Oral sodium phosphate - Modified Preparation|
75615206|NCT02536729|Drug|polyethylene glycol + Electrolytes|
75908680|NCT05730751|Procedure|spinal anesthesia|spinal anesthesia
76071508|NCT04660396|Device|BVA-100|"The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin (a commonly used tag is 131I, resulting in 131I -HSA). Data inputs to the software come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and transudation rate are reported, with statistics showing the quality of the results. The subject blood samples and calibration standards are measured in a gamma counter, whose output is automatically, or manually, input to this calculation program."
76071509|NCT04658940|Device|AcQBlate® Force Sensing Ablation System|Percutaneous catheter ablation of the cavotricuspid isthmus
75615207|NCT02656771|Device|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
75317173|NCT05541159|Drug|TNO155|Single oral dose of TNO155 on Day 1
75317174|NCT05517174|Biological|High-Dose Quadrivalent Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used as the active comparator.
75317175|NCT05517174|Biological|Standard-Dose Quadrivalent Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the Danish governmental influenza vaccine program may be used.
75462176|NCT01861236|Drug|Firmagon® (degarelix)|Monthly subcutaneous injections
75615208|NCT02883582|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
75767148|NCT01071642|Drug|ACE/ARB stopped 24 hours before procedure and start immediately after|ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
75462177|NCT01861262|Device|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
75615209|NCT02883582|Device|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
75615210|NCT02656537|Device|EnSite™ HD Grid Catheter mapping system|
75615211|NCT00917644|Drug|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
75615212|NCT00917644|Genetic|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
75615213|NCT02649283|Device|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
75615214|NCT02649283|Procedure|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
75767149|NCT00231894|Drug|Pioglitazone|pioglitazone 30-45 mg/day
75908681|NCT05730751|Procedure|caesarean section|LSCS
75908682|NCT05726188|Procedure|Colonic resection|Elective or urgent colonic resection; minimally-invasive or open surgery; completion surgery for endoscopically resected pT1 colon cancer with high risk features
75908683|NCT05725005|Drug|ASN51|ASN51 formulation for oral capsule
75615215|NCT01137786|Drug|Non ionic contrast media comparator|One time administration for PCI
75615216|NCT01137786|Drug|Non ionic contrast media comparator|one time administration for PCI
75615217|NCT00631774|Dietary Supplement|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
75767150|NCT00231894|Behavioral|Life style diet group|life style diet education group 1x/week
75767151|NCT00231894|Other|Placebo|placebo comparator capsules
75767152|NCT00203424|Drug|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
75767153|NCT00203268|Drug|dihydroergotamine mesylate|1.0 mg. intramuscularly
75767154|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
75767155|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
75767156|NCT00168818|Drug|enoxaparin|40 mg once daily
75767157|NCT00260832|Drug|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
75767158|NCT00260832|Drug|Dacogen (decitabine) only|20mg/m^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
75462178|NCT01861275|Device|Nasal CPAP|Nasal CPAP treatment for obstructive sleep apnoea
75462179|NCT01861327|Drug|CO2|carbon dioxide (CO2) as arterial contrast media
75462180|NCT01861327|Drug|Iodine contrast media|Iodine as arterial contrast media
75767159|NCT00168038|Biological|Immunoglobulin Intravenous (Human)|A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
75767160|NCT00167414|Procedure|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
75767161|NCT00167414|Radiation|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
75908684|NCT05719844|Diagnostic Test|Neuropsychological tests|"List of neuropsychological tests:~Matrix reasoning~D2-R~Coding~Symbol search~Digit span~Alertness (computerized TAP battery)~Divided Attention (computerized TAP battery)~Go / No go (computerized TAP battery)~Incompatibility (computerized TAP battery)~Working memory (computerized TAP battery)~16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (< 17 years old)~complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (< 17 years old)"
75908685|NCT05717647|Other|Observational study: neuromonitoring|collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
75908686|NCT05715138|Procedure|GPi-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into the posteroventral part of bilateral GPi nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
75908687|NCT05715138|Procedure|STN-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
75317176|NCT05498493|Behavioral|Cognitive Rehabilitation|The virtual small group format will include two to five participants and one facilitator per group. The three individual sessions are distributed at the beginning, middle, and towards the end of the training program. Individual Session 1 occurs after Group Session 1. It covers orientation to the training program, including orientation to and clarification of the Participant Handbook. Individual Session 2 occurs after Group Session 5 and involves review and implementation of training strategies. Individual Session 3 occurs after Group Session 9 and covers review of learned strategies, implementation of training strategies in daily life, and review of execution, obstacles, and adjustments required for individual projects.
75317177|NCT05498493|Behavioral|Brain Health Education Program|The active control group will control for non-specific effects inherent to supervised CR. Participants will receive a manualized brain health education (BHE) training program, matched with the adapted CR intervention for therapist time and homework. Once these participants complete the 12 weeks of the control intervention and undergo the post-intervention assessments, participants will be offered the 12 weeks active intervention to ensure that all study participants have the potential of benefitting from CR.
75462181|NCT01861340|Drug|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
75462182|NCT01861366|Other|A one year multifaceted implementation strategy|
75462183|NCT01861366|Other|A three hour lecture about the guidelines|
75462184|NCT01861379|Procedure|Ghost Ileostomy|At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
75462185|NCT01861392|Procedure|sensorio-motor training|
75462186|NCT01861405|Behavioral|neuropsychological testing and quality of life assessments|
75462187|NCT01861405|Radiation|Standard of Care WBRT or SRS|
75462188|NCT01861405|Device|Functional magnetic resonance imaging|
75615218|NCT05367258|Other|Patients satisfaction after medical and surgical treatment for umbilical endometriosis|It is a retrospectively evaluation of cases of umbilical endometriosis in our clinic over the last 30 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.
75615219|NCT05252104|Diagnostic Test|CORE-TOS diagnostic tool|Collection of clinical findings from clinical examination, subdivided into 5 sub-categories. Positivity in 4 or 5 of these subcategories is considered diagnostic for thoracic outlet syndrome (TOS).
75615220|NCT00625170|Drug|olanzapine|olanzapine 10 mg/day for 8 days
75615221|NCT00625170|Drug|Haloperidol|haloperidol 3 mg/day for 8 days
75615222|NCT00599755|Radiation|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
75615223|NCT00599755|Drug|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
75615224|NCT04251364|Drug|Acetazolamide|Daily acetazolamide pill intake
75615225|NCT04251364|Drug|Atorvastatin|Daily atorvastatin pill intake
75615226|NCT04251364|Drug|Placebo oral tablet|Daily placebo pill intake
75767162|NCT00166712|Drug|Tacrolimus (TAC)|Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
75767163|NCT00166712|Drug|Sirolimus|Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
75767164|NCT00166712|Drug|Alemtuzumab|Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
75767165|NCT00166712|Drug|Mycophenolate mofetil (MMF)|MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
75767166|NCT03972566|Drug|INOMAX|INOMAX + PBM
75615227|NCT00637260|Device|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
75767167|NCT03973034|Diagnostic Test|Low depth whole genome sequencing|Low depth whole genome sequencing of the peripheral blood samples from different groups.
75767168|NCT02531750|Other|Immobilization due to an Achilles tendon rupture|
75615228|NCT00637260|Device|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
75317178|NCT05493761|Drug|Denosumab|60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
75767169|NCT01073306|Biological|Investigational Vaccine for Dengue Virus Subtype 2|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
75767170|NCT01073306|Other|Placebo|Subcutaneous injection of placebo
75767171|NCT03974438|Procedure|Superficial dry needling / Acupunture|Se arm-description.
75767172|NCT03972410|Behavioral|EMDR|2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
75767173|NCT03972410|Behavioral|SEDP|2-4 sessions individual 60-min-long treatment sessions of SEDP
75767174|NCT01074710|Drug|[2-13C] uracil|po, in the form of semi-solid meal, granules, once a period
75767175|NCT01074710|Drug|[2-13C] uracil, placebo|po, in the form of semi-solid meal, granules, once a period
75908688|NCT05715138|Device|GPi-DBS devices|"DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China);~Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
75317179|NCT05493761|Drug|Alendronate Sodium|70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
75317180|NCT05492994|Diagnostic Test|Spirometry|Pulmonary function test
75317181|NCT05492994|Diagnostic Test|Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Pulmonary function test
75317182|NCT05492994|Diagnostic Test|Magnetic Resonance Imaging|Magnetic Resonance Imaging
75615229|NCT02648425|Drug|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
75317183|NCT05492994|Diagnostic Test|Chest Computer Tomography|Chest Computer Tomography
75615230|NCT02648425|Drug|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
75317184|NCT05492994|Diagnostic Test|Blood biomarker analysis|Blood biomarker analysis
75317185|NCT05490030|Drug|TNO155|Single oral dose of TNO155 on Day 1
75615231|NCT02648425|Drug|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
75615232|NCT00637338|Biological|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
75615233|NCT00637338|Biological|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
75615234|NCT00625482|Biological|OPV|
75615235|NCT00625482|Biological|OPV plus BCG|
75767176|NCT01074788|Behavioral|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
75767177|NCT00073528|Drug|Lapatinib|1500 mg orally once a day
75767178|NCT00073528|Drug|Letrozole|2.5 mg orally once a day
75767179|NCT00073528|Drug|Placebo|Placebo (which matched with lapatinib tablet)
75767180|NCT01585012|Device|Cervical cap (Focus Touch™ Conception System)|Cervical cap
75767181|NCT01585090|Other|doing strengthening exercises of pelvic floor muscles|
75767182|NCT03801148|Drug|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
75767183|NCT03801148|Drug|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
75767184|NCT03801148|Drug|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
75767185|NCT03801148|Drug|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
75767186|NCT03960814|Drug|Insulin detemir|No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
75767187|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
75767188|NCT01103830|Drug|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
75767189|NCT01103830|Other|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning."
75767190|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
75767191|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
75767192|NCT01103830|Other|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning."
75767193|NCT01106482|Other|Serology blood draw|Blood draw only, no vaccine
75767194|NCT01103908|Device|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
75767195|NCT01106560|Procedure|Minimally Invasive Anterior Approach|Anterior minimally invasive surgery (AMIS)
75767196|NCT01106560|Procedure|Standard postero-lateral approach|
75767197|NCT01106638|Behavioral|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
75767198|NCT01106638|Behavioral|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
75767199|NCT05532670|Device|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
75767200|NCT02530684|Other|insole|Insoles available on the market without prescription
75908689|NCT05715138|Device|STN-DBS devices|"DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China);~Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
76071510|NCT04652154|Other|Transitioning young patients' health care trajectories|New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
76071511|NCT04650256|Other|Complementary and alternative medicine (CAM)|CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
75317186|NCT05487664|Device|Transcutaneous Auricular Neruostimulation (tAN)|The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
75317187|NCT05480228|Drug|NRD135SE.1|The double-blind treatment phase is up to 13 weeks.
75317188|NCT05480228|Other|Placebo|A matching placebo will be taken for up to 13 weeks.
75317189|NCT05474339|Other|Cardiac rehabilitation|Using Cardiac rehabilitation for patients after coronary artery bypass graft
75767201|NCT00072280|Biological|dactinomycin|Given Slow intravenous (IV) push over 1-5 minutes, dose < 1yr 0.025 mg/kg > or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64
75615236|NCT00625482|Biological|OPV|
75767202|NCT00072280|Drug|cyclophosphamide|Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
75767203|NCT00072280|Drug|etoposide|Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
75767204|NCT00072280|Drug|ifosfamide|Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
75767205|NCT00072280|Drug|vincristine sulfate|Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
75767206|NCT00072280|Procedure|Conventional Surgery|"Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections."
75767207|NCT00072280|Biological|MESNA (mercaptoethane sulfonate)|Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.
75767208|NCT00072280|Biological|Filgrastim|Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
75767209|NCT03948412|Device|Closed Incision Negative Pressure Wound Therapy (Prevena)|Closed Incision Negative Pressure Wound Device (Prevena) applied to closed wound at completion of operation.
75767210|NCT03948412|Other|Control - Standard Dressings|Standard wound dressings applied to closed wound at completion of operation.
75615237|NCT00625482|Biological|OPV plus BCG|
75615238|NCT02648503|Drug|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
75615239|NCT02648503|Drug|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
75615240|NCT04787614|Other|No intervention|No intervention
75615241|NCT04250896|Other|Control group|Standard child care in health unit plus exposure to EsIAN
75615242|NCT04250896|Behavioral|SMS´s sending by cell phone for behavior change|SMS messages sent through a cell pone through the RapidPro platform on practices related to the prevention of infant malnutrition to primary caregivers and the strengthening of counseling for the prevention of infant malnutrition with health providers.
75615243|NCT05253508|Drug|Lidocaine 2% Injectable Solution|A digital nerve block by injections to the base of the finger
75767211|NCT03946696|Other|Interactions with therapy-animals|How people interact with humans and non-humans animals during and outside visits from therapy-animal teams.
75767212|NCT01103986|Behavioral|Motivational/health literacy education (Test group)|"Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick."
75767213|NCT04597606|Other|Exercise with spontaneous ventilation.|"Patients will perform 10 minutes, constant load, exercise in a cycloergometer. To set the load, a baseline incremental effort test will be performed previously (VISIT 1).~Then, in a separate day (VISIT 2), the subject will perform 10 minutes cycling at the 75% load of that determined as maximum in VISIT 1, at a constant rate of 30 to 35 pedal revolutions per minute, in spontaneous breathing, with low flow oxygen through conventional nasal cannula adjusted to achieve SpO2 between 92to 94%"
75908690|NCT05709535|Diagnostic Test|[18F]-PSMA-1007|[18F]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of [18F]PSMA-1007 for PET scan.
75767214|NCT04597606|Device|Exercise with NIV|VISIT 2 Non invasive mask ventilation: parameters will be titrated during a free cycling period at the end of the spontaneous breathing exercise. Then, in a separate day (VISIT 3), with the same constant load, cycling cadence and under NIV, the patient will perform 10 min of cycling.
75908691|NCT05703282|Drug|AD-104-A|PO, Single-Dose, AD-104-A
75908692|NCT05688059|Other|Absorbable Suture and Permanent Suture|Absorbable Suture and Permanent Suture
75908693|NCT05678582|Diagnostic Test|Liver biopsy|liver biopsy were taken then evaluated by histopathological examination
75908694|NCT05678491|Other|Endoscopic mucosal band ligation|The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
75908695|NCT05673668|Device|Endovascular Denervation System (Netrod)|The Netrod system is a percutaneous, catheter- based device which uses radiofrequency energy to denervate the sympathetic nerves surrounding the arteries
75908697|NCT05650281|Other|NO INTERVENTION|NO INTERVENTION
75767215|NCT04597606|Device|Exercise with HFNC|With constant flows of 50 lpm and with FiO2 adjusted according to SPO2, to obtain a constant saturation between 92 and 94%. The same pedaling load and frequency will be maintained, with similar variables collected.
75317192|NCT05463796|Other|Samples|"Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues"
75767216|NCT01104064|Device|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
75908698|NCT05635812|Other|Neuropsychological assessment|neuropsychological assessment and clinical scales duration: 3 hours
75908699|NCT05635812|Other|EEG experimentation|duration: 1 hour
75908700|NCT05635812|Other|Oculometry experimentation|duration: 30 minutes
75317193|NCT05455827|Other|fMRI neurofeedback (A)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to enhance differences between the self-blame and other-blame conditions
75615244|NCT04524130|Drug|Lidocaine Hydrochloride|lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.
75317194|NCT05455827|Other|fMRI neurofeedback (B)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to minimise differences between the self-blame and other-blame conditions
75317195|NCT05451641|Behavioral|Blood flow restriction resistance training|The participants will receive a 2-week exercise training program (3 times per week). Each training session will consist of 3 resistance training exercises with two blood flow restriction devices (wide-rigid cuff and narrow-elastic band). For both arms, the participants will perform the same exercise with different BFR devices.
75317196|NCT05439057|Drug|Remimazolam|Remimazolam is infused at a rate of 0.3 mg/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
75317197|NCT05439057|Drug|Control|Normal saline is infused at a rate of 0.3 ml/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
75615245|NCT04524130|Drug|Ketamine|Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.
75317198|NCT05434663|Drug|SUSTOL|SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles.
75615246|NCT04524130|Drug|Placebo|Normal saline will be given with the same rate of lidocaine or ketamine.
75615247|NCT00600613|Radiation|cone beam imaging|All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
75615248|NCT00649831|Drug|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
75767217|NCT01104064|Device|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
75767218|NCT04593394|Diagnostic Test|Continous laryngoscopy exercise test|Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored
75908701|NCT05634174|Drug|Mirabegron|Single dose, 100mg oral mirabegron
75908702|NCT05632354|Drug|open-label GBT021601|open-label GBT021601
75908703|NCT05619705|Behavioral|Healthy for Two-Health Coaching (H42)|The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.
75908704|NCT05619705|Behavioral|Maintain Healthy in Pregnancy and Postpartum(mHIPP)|A brief video on maternal warning signs that is available in English or Spanish.
75908705|NCT05604859|Drug|Methylprednisolone|Methylprednisolone:1-2mg/kg/d(or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d),ivgtt,3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (methylprednisolone > 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone > 2mg/kg/d) was continued for another 3-5 days.
75767219|NCT04593394|Diagnostic Test|Overnight respiratory polygraphy|Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea
75767220|NCT01106716|Drug|Placebo|Placebo IV Infusion
75767221|NCT01106716|Drug|KAI-1678|KAI-1678 IV Infusion
75767222|NCT01106716|Drug|Lidocaine|Lidocaine
75767223|NCT00071812|Drug|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
75767224|NCT00071812|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
75767225|NCT00071812|Drug|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
75767226|NCT00071812|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
75908706|NCT05604859|Drug|intravenous immunoglobulin|intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was continued for another 3-5 days.
75908707|NCT05604859|Drug|Tocilizumab|Tocilizumab:4mg/kg, once
75908708|NCT05604859|Drug|Low molecular weight heparin|Low molecular weight heparin:100U/kg, qd or q 12h,IH,4-7 days
75908709|NCT05604859|Other|conventional treatment|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
76071512|NCT04644055|Diagnostic Test|EUS- share wave of the liver|Evaluation of the right and left hepatic lobe with EUS-guided share wave
76071513|NCT04642443|Device|SENSE Device|The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
75615249|NCT00649831|Drug|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
75615250|NCT05251870|Drug|autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70|Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.
75615251|NCT05117944|Other|"drama-supported patient role experience"|The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
75615252|NCT02648659|Drug|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
76071514|NCT04640441|Other|Sit-to-stand care|"Passive range of motion(ROM) exercise of lower legs, active ROM exercise of lower legs, and sitting balance exercise, 20~30 min, once daily.~Anti-gravity ROM exercise of lower leg, resistance exercise of low leg, and sitting balance exercise, 20~30min, once daily.~Stepping exercise and sit-to-stand exercise, 20~30min, once daily."
75615253|NCT02648659|Drug|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
75615254|NCT02648659|Drug|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
76071515|NCT04631770|Procedure|Systemic mediastinal lymph node dissection|Systematic hilar and mediastinal lymph node dissection.
76071516|NCT04631770|Procedure|Spared mediastinal lymph node dissection|Mediastinal lymph node is spared in this group.
75317199|NCT05434351|Other|vaginal dehydroepiandrosterone|the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated
75317200|NCT05418478|Behavioral|Intervention transtheoretical model group|"The Transtheoretical Model is a conscious behavior modification model that focuses on individual decision making and planning processes. It is the only model that examines behavior change as a dynamic process rather than an outcome, and considers behavioral strategies that include the individual's cognitive and behavioral processes in this process.~In the model, it is stated that behavior change is a process and develops gradually. It is reported that the change in the behavior of individuals consists of six stages: 1) not thinking, 2) thinking, 3) preparation, 4) taking action, 5) maintaining and 6) terminating. This model consists of four main constructs called change stages (time-related dimension), change processes/behavior modification methods (independent variable dimension), self-efficacy (levels of change) and decision-making balance (perceptions of harm and benefit of change)."
75615255|NCT02648659|Drug|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
75615256|NCT04567888|Behavioral|Happify Teens|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
75615257|NCT01125930|Drug|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
75908710|NCT05595486|Other|Baby2Home Mobile Application|Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.
75908711|NCT05590234|Drug|Dexmedetomidine injection|1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%
75767227|NCT00071110|Procedure|Electroacupuncture|For subjects randomized to EA, needles were placed at points GV-20-on the crown of the head and yin tang-on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
75767228|NCT00071110|Procedure|Sham|For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
75767229|NCT03960346|Procedure|Ablation with cryoenergy|Esophageal temperature-guided ablation using cryoengery and an esophageal temperature probe.
75767230|NCT01104142|Device|CGM|Continuous Glucose Monitoring System
75317201|NCT05408468|Behavioral|FAMCOPE-ICU|(1) FAMCOPE-ICU is a digital eHealth emotion regulation and coping intervention. FAMCOPE-ICU contains three digital modules representing the three interventional doses. Corresponding with Gross's Extended Process Model of Emotion Regulation, the three respective doses entail assessments, adaptive feedback, and interactive activities pertaining to understanding their affective experiences, learning strategies to regulate emotions and stress, and practicing these skills in a virtual decision-making task. Each dose of the intervention is expected to last 10-15 minutes
75317202|NCT05405673|Diagnostic Test|Fecal immunochemical test (FIT)|A kind of stool test
75908712|NCT05590234|Drug|Bupivacaine 0.25% Injectable Solution|20 ml of bupivacaine 0.25%,
75317203|NCT05405257|Drug|Oxytocin|IV 1IU Oxytocin in 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
75615258|NCT01125930|Drug|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
75767231|NCT01327924|Drug|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
75908713|NCT05590234|Drug|normal saline|20 ml of normal saline 0.9%.
75908714|NCT05584332|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)|0.5 ml injection in 3 dosing regimen
75908715|NCT05584332|Biological|Placebo|0.5 ml injection in 3 dosing regimen
75317204|NCT05405257|Other|Placebo|IV, 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
75615259|NCT02656615|Drug|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
75767232|NCT03946384|Other|data collection|data collection on the history of the disease, hemophilia
75908716|NCT05572749|Dietary Supplement|Crocus Kozanis|In this study, intervention will be the administration of Crocus Kozanis dietary supplement. Crocus Kozanis is a herb which is cultivated in Kozani, Greece.
75908717|NCT05572749|Dietary Supplement|Placebo of Crocus Kozanis|Placebo of Crocus Kozanis
75317205|NCT05401292|Drug|Hibiclens|antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing
75615260|NCT05253430|Procedure|Lymphadenectomy type|D1 vs D2 lymph node dissection
75767233|NCT01104298|Drug|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
75767234|NCT01104298|Drug|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
75767235|NCT01106872|Drug|Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid|
75767236|NCT00071032|Biological|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
75908718|NCT05572749|Drug|Metformin|Metformin will be administered in a dosage of 1000mg per day. Metformin is a formally approved therapy for children with diabetes in Europe.
75908719|NCT05564208|Drug|elafibranor|Oral Tablet
75908720|NCT05564208|Drug|elafibranor|Oral Tablet
75908721|NCT05562635|Combination Product|5% polymer gel with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
75908722|NCT05562635|Combination Product|10% polymer gel with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
75908723|NCT05562635|Combination Product|Placebo intervention|Application of placebo without CBD
75908724|NCT05552547|Device|Home Blood Pressure Machine|Participants will be asked to measure blood pressure twice daily for three days in a row at home.
75908725|NCT05552547|Device|24-Hour Blood Pressure Machine|Participants will be asked to wear the machine for 24 hours.
75908726|NCT05540444|Device|RadConnect|"The study will be performed in a clinical setting at the department of radiology of LUMC, meaning that we aim to test the hypothesis that (RadConnect) can reduce the number of phone calls from a select set of extension used by technologists (the Sending Extensions) to another select set of extensions manned by radiologists (Receiving Extensions)."
75317206|NCT05401292|Drug|Isopropyl Alcohol 70% Topical Application Solution|First aid antiseptic
75317207|NCT05394545|Device|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
75908727|NCT05540223|Device|DREAMS 3G RMS|Subject undergoes implantation of DREAMS 3G RMS
75908728|NCT05540223|Device|Xience DES|Subject undergoes implantation of Xience DES
75908729|NCT05508230|Other|Hyaluronic Nasal Spray|Health care product - nasal application
75615261|NCT03946579|Other|self questionnaires|FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
75767237|NCT00071032|Biological|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
75615262|NCT05031988|Other|No intervention will be used.|Determinants of physical activity and mental health among the students during Covid-19 lockdown will be assessed.
75615263|NCT00651235|Drug|Losartan and Atenolol or Propranolol|"50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.~Losartan is 100 mg/day for adult and 50 mg/day for children."
75767238|NCT03960268|Drug|Brodalumab|interleukin 17 receptor A antagonist
75767239|NCT05485480|Drug|conventional opioid-based group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
75767240|NCT05485480|Drug|opioid-sparing group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
75767241|NCT03960502|Drug|AG-881|Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of [14C]AG-881.
75317208|NCT05381740|Device|Novel rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. High-frequency rTMS (5Hz) will be delivered using 42 10 second trains of 50 pulses each (total 2100 pulses) for a period of 22 minutes. Immediately after the completion of rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
75767242|NCT03960502|Drug|[13C315N3]AG-881|Single IV microdose of approximately 100 μg.
75767243|NCT01107028|Other|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
75767244|NCT05470270|Drug|Hydroxycarbamide|Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
75767245|NCT05372926|Device|high flow nasal canulae|high flow nasal canulae is a oxygen therapy technic which allows the administration of warmed and humidified oxygen with a flow up to 50L/Min and a monitored FiO2. Physiological previous studies reported various effects of this technic especially on work of breathing. In our study the investigators aim to test this physiological property during exercise.
75767246|NCT05372926|Device|Ventury mask|Ventury mask is a oxygen therapy technic which allows the administration with a mask of oxygen with a flow up to 15L/Min and a monitored FiO2.
75767247|NCT03945994|Other|Connecting People Intervention|Improve the resourcefulness of social networks of people with mental health problems
75317209|NCT05381740|Device|Sham rTMS Approach|Participants in this arm will receive sham rTMS given over the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. Immediately after the completion of sham rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
75317210|NCT05375630|Dietary Supplement|Placebo|Placebo
75317211|NCT05375630|Dietary Supplement|Vitamin K2|Vitamin K2
75615264|NCT00651235|Drug|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
75615265|NCT02656459|Other|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
75615266|NCT04015219|Device|Self retained cryopreserved amniotic membrane|PROKERA SLIM
75615267|NCT04015219|Other|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
75615268|NCT02648269|Drug|SEL-110|
75615269|NCT02648269|Biological|SEL-212|
75615270|NCT02648269|Biological|SEL-037|
75615271|NCT00918346|Drug|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
75615272|NCT02649361|Drug|Anlotinib|Anlotinib p.o. qd
75615273|NCT02649361|Drug|Placebo|Placebo p.o. qd
75615274|NCT02648815|Procedure|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
75615275|NCT02648815|Procedure|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
75767248|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
75767249|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
75767250|NCT01107184|Procedure|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
75767251|NCT01107184|Procedure|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
75767252|NCT00259610|Drug|methotrexate|varies
75767253|NCT00259610|Drug|sulfasalazine|varies
75767254|NCT00259610|Drug|hydroxychloroquine|varies
75767255|NCT00259610|Drug|etanercept|varies
75767256|NCT01090258|Device|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate [RR], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
75767257|NCT01090258|Other|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
75767258|NCT01074866|Device|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
75767259|NCT04460482|Device|Near-infrared spectroscopy (NIRS)|NIRS-guided PCI
75908730|NCT05496829|Behavioral|Multicomponent Adherence Intervention|The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
75908731|NCT05496829|Other|Usual Care|Receipt of usual care from providers
75908732|NCT05477238|Procedure|walking tasks|The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
75908733|NCT05476172|Drug|Dienogest Pill|The effect of dienogest on endometriosis pain symptoms.
75908734|NCT05476172|Drug|Norethindrone Acetate|The effect of Norethindrone Acetateon endometriosis pain symptoms.
75908735|NCT05444985|Other|Pain Management|Regional anesthetic techniques for peri-operative pain management after surgery.
75908736|NCT05444062|Behavioral|Educational material and treatment recommendations for patients, general practitioners and pharmacists|Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.
75908737|NCT05433155|Device|Nasotracheal intubation|Nontracheal intubation using clinical standard videolaryngoscopy or direct laryngoscopy
75908738|NCT05432518|Drug|Afatinib|Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
75908739|NCT05432518|Drug|Dasatinib|Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
75908740|NCT05432518|Drug|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
75908741|NCT05432518|Drug|Everolimus|Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
75908742|NCT05432518|Drug|Olaparib|Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
75908743|NCT05428709|Behavioral|Acute Exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
75317212|NCT05364476|Behavioral|16 weeks digital intervention|"Participants will be enrolled into a 16-week program which consist of an online and offline support from health coaches and dietitian. Participants will be given diet and exercise recommendations and lesson plans on a weekly basis by the health coaches, and supported by the dietitian.~Participants will be required to log in their blood sugar levels, weight and steps daily using connected device, including glucometer, smart band and body fat weighing scale provided into the daily report card. They will also be required to manually record their meals and exercise daily in the daily report card provided upon enrollment into study. Reviews of log will be done on a weekly/biweekly interval by the health coaches."
75317213|NCT05364281|Other|Intracuff pressure measurement|The intracuff pressures were measured and noted after each position (neck extension and placement of mouth gag), at every 5th minute while the operation and before the extubating.
75462189|NCT01861418|Other|Lumbopelvic Manipulation|Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
75615276|NCT00913978|Device|Group 1: VitaHeat|Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
75615277|NCT00913978|Device|Group 2: Bair Hugger|Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
75615278|NCT02648893|Other|Multiple biofortified food crops (MBFC-Exp)|Meals from three biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.
75615279|NCT02648893|Other|Commercially available non-fortified food crops (MBFC-C)|This arm will consume meals based on three commercially available (non-biofortified) food crops three times per day, six days per week, for 9 months.
75615280|NCT02649049|Other|there is no intervention|
75767260|NCT04460482|Device|Angiography|Angiography guided PCI
75767261|NCT00165776|Drug|BOTULINUM TOXIN TYPE B|
75767262|NCT04389112|Other|biopsy|Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
75908744|NCT05426759|Device|Pulsed Field Ablation of epicardial Ganglionated Plexi.|Using Pulsed Field Ablation (PFA), delivered via an epicardial catheter, to selectively ablate the ganglionated plexi (GP) on the epicardial surface of the heart.
75908745|NCT05422976|Device|EVI-01|High molecular weight Hyaluronic Acid
76072410|NCT00499083|Procedure|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
75615281|NCT04687540|Drug|Tocilizumab|Baseline: Tocilizumab (infusion of 8 mg/kg bodyweight or a maximum of 800 mg) will be infused over 60 minutes at the end for the study day, therefore study visit 1 (study day 1) measurements are baseline.
75908746|NCT05413096|Combination Product|Combination of diclofenac potassium and propolis|Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel
75908747|NCT05413096|Other|placebo|placebo
75908748|NCT05407987|Drug|Ferric derisomaltose|Ferric Derisomaltose is a solution based iron supplement provided in 100 mg elemental iron/mL. Patients randomized to Iron Therapy Arm will with a bodyweight <50kg will receive 500mg of Ferric Derisomaltose, and patients with a bodyweight >50kg will receive 1000mg of Ferric Derisomaltose, to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg. Patients will receive a single infusion between 21 and 90 days preceding surgical intervention.
75908749|NCT05407987|Drug|Placebo|Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.
75908750|NCT05391061|Drug|Abrocitinib|Tablets
75908751|NCT05375994|Drug|avutometinib (VS-6766) and adagrasib|The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion
75908752|NCT05346523|Device|Isabel Pro - The DDx generator (CDDS)|Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
75908753|NCT05338320|Procedure|Ultrasound Guided Erector Spinae Plane Block|General anesthesia and Ultrasound Guided Erector Spinae Plane Block
75317214|NCT05358535|Drug|Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
75317215|NCT05358535|Drug|Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
75908754|NCT05338320|Drug|Intrathecal morphine|General anesthesia and intrathecal morphine
75908755|NCT05338320|Other|General anesthesia using intravenous fentanyl (1µg/kg)|General anesthesia using intravenous fentanyl (1µg/kg)
75908756|NCT05327465|Other|Aerobic and resistance exercise|Perform exercise at home with virtual supervision, including aerobic exercise (e.g.,cycling), which can improve cardiovascular (heart) and lung function, and resistance exercise (e.g., dumbbell lifting and using resistance band. The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer
75908757|NCT05327465|Other|Usual Care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise (aerobic and resistance exercise) program after 16 weeks.
75908758|NCT05309109|Other|Hemodialysis sessions|Patients will receive thrice weekly 4 hours hemodialysis sessions during 12 months.
75908759|NCT05302973|Other|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
76072411|NCT00499083|Procedure|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
75615282|NCT04687540|Drug|Saline 0.9%|Participants are under influence of tocilizumab since the effect of the drug will last for 4 weeks. Participants will be infused with saline at study visit 2 (study day 21). Placebo to tocilizumab will be saline (NaCl 0.9%) as tocilizumab is a colorless solution and has to be diluted with NaCl 0.9% prior to administration
75615283|NCT01137474|Drug|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
75615284|NCT01137474|Drug|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
75615285|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
75615286|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
75767263|NCT03945838|Other|Complete Decongestion Therapy|"It is given in two phases. First phase includes intensive therapy which aims to reduce the volume of the extremity. Second phase aims to preserve these reductions of volume.~All patients were prescribed lymphedema specific exercises and were advised to walk (for 30 minutes everyday) daywhile taking complete decongestive therapy. They were specifically informed that exercise does not aggravate the severity of their lymphedema.~Short stretch bandages were applied to the patients with self manual lymphatic drainage. Intensive phase was given 5 days a week, and short stretch bandages applied for 23 hours a day with 1 hour interval. To increase the local pressure on the areas required, foams were added. Patients were screened with arm circumferential measurements once a week. After gaining a plateau in the volumes, patients were prescribed compression garments."
75767264|NCT05337748|Device|Lexie Self Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
75767265|NCT05337748|Device|Lexie Professional Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
75767266|NCT00165698|Drug|menatetranone|15 mg three times a day orally for 12 months
75767267|NCT00165698|Drug|alfacalcidol|0.25 μg twice a day orally for 12 months
75767268|NCT05331196|Diagnostic Test|Preoperative cardiopulmonary exercise tetsing|Patients underwent a cardiopulmonary exercise test prior to surgery.
75767269|NCT01075022|Drug|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
75908760|NCT05302973|Other|Aerobic exercise|30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
75317216|NCT05349188|Dietary Supplement|Melatonin 3 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills.
75908761|NCT05277077|Other|Pain neuroscience education|The experimental group will follow a PNE protocol based on previous procedure for a whole period of 6 weeks in addition the conventional treatment.
75462190|NCT01861418|Other|Sham manipulation|Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
75462191|NCT01861431|Behavioral|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
75462192|NCT01861431|Behavioral|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
75317217|NCT05349188|Dietary Supplement|Melatonin 0.5 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills.
75317218|NCT05349188|Other|Cellulose placebo pill|Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills.
75462193|NCT01861509|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
75462194|NCT01861535|Drug|Imiquimod|
75462195|NCT01861535|Procedure|Surgery|
75615287|NCT04791436|Diagnostic Test|Gustatory and olfactory function test|The gustatory and olfactory function will be tested by using the combined Burghart Screening 12 test containing smelling sticks and taste strips (Fa. MediSense, Groningen, Netherlands). Evaluation of taste and smell is performed by offering the sticks/strips and demand a forced multiple choice.
75615288|NCT04791436|Diagnostic Test|Molecular assessment of saliva|Saliva samples will be taken for molecular biological determination of the oral microbiome. The microbiome is determined at the Institute for Medical Microbiology by 16s-rRNA gene analysis with Next Generation Sequencing and bioinformatics.
75767270|NCT01075022|Drug|Placebo|Placebo Capsule, Single Dose
75908762|NCT05277077|Other|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (30 treatment sessions, five a week, for 90min duration).
75317219|NCT05317819|Drug|ADI-PEG20|Treatment for hepatocellular carcinoma
75317220|NCT05317819|Other|Placebo|Treatment for hepatocellular carcinoma
75317221|NCT05307627|Drug|low-dose naltrexone|LDN doses <20 mg/day
75317222|NCT05298306|Drug|LAT8881|"In Part A, LAT8881 will be given as a single intravenous infusion at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, a single intravenous infusion of LAT8881 will be given, the dose to be determined by the results in Part A"
75317223|NCT05298306|Drug|Placebo|Matching placebo'given as a single intravenous infusion at all dose levels
75317224|NCT05291338|Drug|Doxorubicin|no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size
75462196|NCT01861561|Drug|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
75462197|NCT01861561|Drug|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
75462198|NCT01861600|Other|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
75462199|NCT01861600|Other|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
75767271|NCT03946150|Diagnostic Test|P/FP Ratio|PaO2/Fio2 X PEEP
75908763|NCT05276063|Drug|Linsitinib|Study medication taken twice daily by mouth
75908764|NCT05276063|Drug|Placebo|Placebo taken twice daily by mouth
75462200|NCT01861600|Other|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
75615289|NCT04790188|Dietary Supplement|Nootropic|10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.
75615290|NCT04790188|Dietary Supplement|Placebo|10g of maltodextrin lemon flavor (HSN®).
75767272|NCT03944824|Other|Exercise Plan using resistance bands|Exercise under the guidance of an exercise physiologist using elastic resistance bands and weekly meeting with an exercise physiologist for 12 weeks
75767273|NCT03944824|Diagnostic Test|Modified Fried Frailty Scale|Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.
75767274|NCT00225758|Drug|Lapatinib|1500 mg po daily for 26 weeks or longer
75767275|NCT03944746|Other|Education Curriculum|Different educational curriculums were applied to each cohort
75767276|NCT03972332|Diagnostic Test|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
75767277|NCT05330260|Diagnostic Test|neurocognitive test battery|Assessment of the incidence of late postoperative cognitive decline (LPOCD)
75767278|NCT03968354|Biological|"Collection of additional blood tubes; Biobanking (plasma, liver tissue)."|"Preservation of liver tissue obtain by liver biopsy, constitution of a collection~Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research"
75767279|NCT03947944|Procedure|SMILE using manifest refraction planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
75908765|NCT05270460|Drug|PCS12852|PCS12852 oral tablet administered once daily
75908766|NCT05270460|Drug|Placebo|Placebo comparator oral tablet administered once daily
75908767|NCT05269862|Device|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted in-clinic (not using the Virtual Clinic feature).
75908768|NCT05269862|Device|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted using Virtual Clinic or in-clinic as appropriate.
75908769|NCT05260918|Other|Float-REST|Participants will utilize sensory deprivation tanks.
75908770|NCT05260918|Other|Nappod|Participants will utilize nappod.
75908771|NCT05260801|Other|Bright Lighting|The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.
76071517|NCT04629066|Behavioral|Remote Cardiac Rehabilitation (CR)|"Patients randomized to remote CR will be asked to use an app for cardiac rehabilitation a minimum of 3 times a week. Patients will be given an exercise prescription provided by a certified exercise physiologist.~The exercise prescription will change each week based on refreshed data from the prior week.~Instructional videos for each exercise are provided in the app. Patients will not be told to perform the exercise at a particular time. Instead they will be asked to complete a certain amount of exercise per week at whatever time is convenient for them. Patients randomized to remote CR will also receive App based reminders to take their medications, resources to guide healthy eating habits, and other behavioral health advice as is done as standard of care in both remote based and clinic based CR."
75462201|NCT01861600|Other|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
75462202|NCT01861600|Other|Human Milk|Human Milk
75462203|NCT01861613|Biological|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
75462204|NCT01861626|Drug|V0057 - A mg|Single oral administration
75462205|NCT01861626|Drug|Isotretinoin|Single oral administration
75462206|NCT01861639|Device|ineffective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
75767280|NCT03947944|Procedure|SMILE using vector planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
75908772|NCT05260801|Other|Placebo Lighting|The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.
75908773|NCT05260073|Drug|Tirbanibulin (Klisyri®)|Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days
75908774|NCT05250713|Device|Transcranial stimulation|Patients will receive either direct current stimulation or alternate stimulation.
75908775|NCT05249192|Device|Immediate urinary catheter removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
75908776|NCT05249192|Device|Early urinary catheter removal|urinary catheter removal on the first postoperative day (6 a.m)
75908777|NCT05232565|Procedure|Percutaneous Transluminal Coronary Angioplasty|Angioplasty intervention of coronary vessels or coronary bypass graft stenosis
75908778|NCT05230199|Behavioral|SENSE multisensory program|In order to support parent's ability to implement the daily SENSE program they will be provided with an educational manual reviewing the program, weekly meetings with a therapist, and logs to report their visitation schedule and activities. Parents are able to choose different types of each sensory exposure. All options address the same key principles for that behavior and only include those that have evidence to support their use and are appropriate at each PMA.
75615291|NCT02648737|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch & Craske, 2009; Craske, 2010).
75908779|NCT05230199|Behavioral|Monitored standard of care|Infants who receive sensory exposures only as standard of care but do not recieve the SENSE program
75908780|NCT05224609|Drug|Lorlatinib|Single 100mg oral dose anti-cancer agent
75908781|NCT05214287|Drug|Hypoxic Gas Mixture|Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
75767281|NCT01104532|Drug|ASP1941|oral tablet
75767282|NCT01104532|Drug|sitagliptin|oral tablet
75462207|NCT01861639|Device|active TBS|A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
75908782|NCT05183282|Device|Tarsus Patch|The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
75908783|NCT05182931|Drug|Dabrafenib 75 MG|Refer arm description
75908784|NCT05182931|Drug|Trametinib 2 MG|Refer arm description
75908785|NCT05163067|Behavioral|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
75908786|NCT05157165|Biological|Convalescent plasma|Hyperimmune plasma from convalescent COVID-19 donors with titre 1:80 or more
75908787|NCT05156476|Procedure|Genicular nerve block-iPACK group|Group 1: Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
75908788|NCT05156476|Procedure|Femoral triangle block-iPACK group|Group 2: Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
75908789|NCT05156476|Procedure|Local infiltration analgesia|Group 3: LIA (performed by surgeon) Method: Blind injection Drug: a total of 200ml of 0.2% ropivacaine will be used (400mg). Of this, 150ml of ropivacaine 0.2% will be mixed with 1mg of adrenaline.
75767283|NCT03945916|Dietary Supplement|Dark chocolate|180 g/d dark chocolate for 15 days followed by exercise testing
75767284|NCT03945916|Dietary Supplement|Placebo|Placebo: 180 g/d imitation dark chocolate for 15 days followed by exercise testing
75908790|NCT05154370|Drug|Intravenous steroid|This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
75908791|NCT05139680|Drug|tafamidis|80 or 61 milligrams (mg)
75462208|NCT01861639|Device|Sham TBS|A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
75462209|NCT01861639|Device|fMRI|Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2*-weighted echo-planar imaging sequence
75462210|NCT01861639|Device|EEG|EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
75615292|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
75615293|NCT02645305|Biological|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
75767285|NCT03945682|Other|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
75767286|NCT01107574|Drug|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
75767287|NCT01107574|Procedure|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
75767288|NCT01107574|Other|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
75767289|NCT01104610|Device|Breas Vivo 40|The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
75767290|NCT03971500|Drug|AntiPlatelet therapy|AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
76071518|NCT04626050|Behavioral|Medical Music|Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks
76071519|NCT04626050|Behavioral|Narrative Writing|Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks
76071520|NCT04626050|Behavioral|Prolonged Exposure Therapy|Psychotherapy including imaginal exposure for PTSD
75317225|NCT05291338|Drug|Lipiodol|Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.
75317226|NCT05289596|Behavioral|Sleep Healthy Using the Internet (SHUT-i)|SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
75615294|NCT04609696|Drug|Danicopan: Powder-In-Capsule 1|Danicopan (200 milligrams) will be administered orally on Day 1.
75615295|NCT04609696|Drug|Danicopan: Powder-In-Capsule 2|Danicopan (200 milligrams) will be administered orally on Day 1.
75615296|NCT04609696|Drug|Danicopan: Tablet|Danicopan (200 milligrams) will be administered orally on Day 1.
75615297|NCT01168973|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
75615298|NCT01168973|Drug|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
75615299|NCT01168973|Drug|Docetaxel|75 milligrams per square meter (mg/m^2) (60 mg/m^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
75615300|NCT00631462|Drug|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
75767291|NCT03971500|Procedure|Percutaneous coronary intervention|PCI with DES implantation
75767292|NCT00259298|Drug|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
75767293|NCT01108744|Drug|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
75615301|NCT03918109|Drug|OTO-313|single intratympanic injection of gacyclidine
75615302|NCT03918109|Drug|Placebo|single intratympanic injection of placebo
75767294|NCT01108744|Drug|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
75767295|NCT01581866|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
75767296|NCT01075334|Dietary Supplement|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
75767297|NCT01075334|Dietary Supplement|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
76071521|NCT04626050|Behavioral|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning
76071522|NCT04625023|Other|Observational|Retrospective cohorts and Prospective observation of standard clinical practice
75767298|NCT01107808|Drug|Calcium and Vit D|ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
75767299|NCT01107808|Drug|Metformin, Vit D and Calcium|ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
75767300|NCT03947554|Dietary Supplement|HRG80 Panax ginseng|Panax ginseng containing 63.4 mg ginsenosides
75767301|NCT03947554|Dietary Supplement|Panax ginseng|Panax ginseng containing 19.6 mg ginsenosides
75767302|NCT03947554|Dietary Supplement|Placebo|800 mg excipient
75767303|NCT01104844|Drug|Full Dose Strength|Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
75767304|NCT01104844|Drug|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
76071523|NCT04624074|Behavioral|Teen Marijuana Check Up|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
76071524|NCT04623710|Drug|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
75767305|NCT01104844|Drug|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
75767306|NCT01104844|Drug|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
75767307|NCT01104844|Drug|Ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
75767308|NCT01104844|Drug|Ibuprofen high dose|Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
76071525|NCT04618757|Behavioral|Hedonic Reward|A reimbursement credit for hedonic expenses worth up to $50 will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
76071526|NCT04618757|Behavioral|Cash Reward|A reimbursement credit for $50 in cash will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
76071527|NCT04618757|Device|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
76071528|NCT04606459|Device|Coronary sinus reducer|The Reducer System comprises the Reducer device (Reducer) pre-mounted on the Reducer Balloon Catheter. The Reducer System is available in one model size. The Reducer is a sterile, single-use, implantable device designed to establish a narrowing in the coronary sinus (CS) and is intended to improve perfusion to ischemic myocardium in the presence of reversible ischemic heart disease to alleviate the symptoms of refractory angina. The device is implanted percutaneously through the right internal jugular vein into the CS. The Reducer is pre-mounted (crimped) on the Reducer Balloon Catheter which, after inflation, causes device expansion and apposition with the vessel wall. The balloon catheter is then deflated and removed from the CS, leaving the device permanently implanted.
76071529|NCT04606459|Other|Optimal medical therapy|Guideline-directed medical therapy
75317227|NCT05268237|Drug|Liraglutide|Sublingual or subcutaneous liraglutide
75317228|NCT05268237|Drug|Placebo|Sublingual placebo
75317229|NCT05265923|Drug|CM310|IL-4Rα monoclonal antibody
75317230|NCT05265923|Other|Placebo|Placebo
75317231|NCT05249062|Device|SHAPES app|Participants will be asked to use the app and connected devices daily for 3 months.
75317232|NCT05228873|Drug|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
75317233|NCT05227092|Device|3D OPTIMIZED WMN MPRAGE|"At the cervical level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 2D Sagittal PSIR / 3D MPRAGE and the 3D OPTIMIZED MPRAGE WMN data set with sagittal and axial acquisition.~At the thoracic level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 3D MPRAGE and the 3D Sagittal OPTIMIZED MPRAGE WMN data set."
75462211|NCT01861639|Device|Effective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
75462212|NCT01861652|Device|Venous Health Systems Vasculaire Leg Compression Device|Leg (calf) compression device used to alleviate symptoms of restless legs
75462213|NCT01861678|Procedure|High tie of IMA|Conventional technique
75462214|NCT01861678|Procedure|Low tie of IMA|Technique for preserving left colic arterial perfusion
75462215|NCT01861691|Procedure|Open surgery|Conventional technique
75615303|NCT04187430|Behavioral|Retrospective|Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
75615304|NCT04187430|Behavioral|Prospective|After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
75462216|NCT01861691|Procedure|Laparoscopic surgery|New minimum invasive technique
75615305|NCT02648035|Biological|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
75615306|NCT04311372|Behavioral|Educational Sesssion+Material+Videos|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
75615307|NCT04311372|Behavioral|Educational Sesssion+Material ONLY|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
75767309|NCT01104844|Drug|Placebo|2 placebo tablets
75767310|NCT03945526|Drug|Astaxanthine|
75767311|NCT03945526|Drug|Placebo Oral Tablet|
75767312|NCT01105078|Procedure|Flow rate|Different flow rate during cardiopulmonary bypass
75767313|NCT01105156|Behavioral|VEW Questionnaire|Patient Self reported questionnaire filled in.
75767314|NCT03750136|Drug|Hypertonic saline|high dose furosemide with hypertonic saline 3x daily
75767315|NCT03750136|Drug|Furosemide Injection|high dose furosemide
75767316|NCT03947476|Device|thoracic band|Thoracic band fixation
75767317|NCT03945058|Device|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
75767318|NCT03945058|Device|SHAM|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
75767319|NCT01108042|Drug|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
75767320|NCT01105234|Drug|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
76071530|NCT04601363|Device|Patient Specific Rod|Posterior spinal fusion rod
75462217|NCT01861730|Biological|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
75767321|NCT01108198|Drug|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
75908792|NCT05135728|Behavioral|Unstuck and On Target: Preschool|Unstuck & On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
75908793|NCT05128734|Drug|Temozolomide|Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.
75908794|NCT05128734|Drug|Olaparib|Olaparib will be administered orally twice daily in treatment arm 2.
75908795|NCT05128383|Drug|Dupilumab|Dupilumab a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits interleukin (IL)-4 and IL-13 signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes.
76071531|NCT04598269|Drug|ATI-1777|ATI-1777 topical solution 2.0% w/w
76071532|NCT04598269|Drug|Vehicle|Vehicle topical solution containing no ATI-1777
76071533|NCT04593407|Procedure|Endoscopic mucosal resection (EMR)|"Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional lift-and-cut procedure or an underwater technique"
76071534|NCT04593407|Procedure|Endoscopic submucosal dissection (ESD)|"Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.~The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation."
75615308|NCT04744012|Procedure|Modified Periostal Pocket Flap Technique|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
75615309|NCT02644993|Radiation|Proton therapy|
76071535|NCT04593212|Diagnostic Test|Optical Coherence Tomography Angiography|Evaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA)
75462218|NCT01861730|Biological|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
75462219|NCT01861743|Other|Multimodal Analgesia|Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.
75462220|NCT01861743|Other|Patient controlled analgesia|Subjects will be treated with patient controlled narcotic analgesia for pain management.
75615310|NCT04117438|Other|no intervention|There is no intervention. We are just asking breast cancer patients what their food story is.
75615311|NCT00652561|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
75615312|NCT01168427|Device|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
75615313|NCT00653497|Behavioral|Aquatic exercise|"Arthritis Foundation Aquatics Program~community-based aquatic exercise program~participants asked to attend 2 classes per week for 20 weeks~each class 45-60 minutes in duration"
75615314|NCT05251168|Procedure|PET Guided Bone Marrow Biopsy|"The results of PET/CT images were discussed with the referring physician. PET/CT targeted metabolic marrow biopsy was planned two hours after the whole body diagnostic imaging or on a subsequent day one hour after injecting 2-3 mCi of FDG to minimize the radiation exposure burden to the interventionist.~Society of Interventional Consensus guidelines was followed for image-guided biopsy.~The bone marrow biopsy was done under the PET/CT guidance using the same PET/CT scanner with the help of an automated robotic arm (ARA) workstation"
75615315|NCT05251168|Procedure|Trephine Bone Marrow Biopsy|All the participants underwent trephine bone marrow biopsies from the bilateral posterior superior iliac spine before treatment planning.
75615316|NCT03206437|Behavioral|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
75767322|NCT01108198|Drug|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
75767323|NCT05237674|Behavioral|The TEACHOUT intervention|"The core component of the Intervention is a two-day training course on EOtC given to elementary school teachers followed by the teachers committing to apply EOtC for at least five hours a week, delivered in 1-2 weekly sessions for one school year (in this study, August 2022 to June 2023).~In the training course knowledge and understanding of the practice and theory of EOtC is facilitated in presentations and talks supplemented by illustrative examples in workshops and plenum discussions on local implementation. The 1-2 weekly EOtC sessions during the school year 2022-2023 may be delivered by one or more teachers simultaneously in various school subjects, at various places outside the school buildings."
75767324|NCT03947710|Other|High-protein meals|Patients on maintenance hemodialysis will consume high protein meals during dialysis for one week (3 dialysis sessions)
75462221|NCT01861769|Other|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
75767325|NCT03947710|Other|Low- protein meals|Patients on maintenance hemodialysis will consume low protein meals during dialysis for one week (3 dialysis sessions)
75767326|NCT03947710|Other|No meals|Patients on maintenance hemodialysis will not consume meals during dialysis for one week (3 dialysis sessions)
75767327|NCT03945370|Dietary Supplement|β-hydroxybuturate esters|Oral dietary supplement product containing β-hydroxybuturate esters
75767328|NCT03945370|Dietary Supplement|Placebo drink|Oral placebo drink
75767329|NCT01108276|Device|Convatec engenex negative pressure wound therapy|ConvaTec Engenex® is a negative pressure wound therapy that stimulates wound healing and promotes granulation tissue formation, removal of wound exudate and infectious materials by the application of negative pressure to wounds. It utilizes Bio-Dome™ Dressing technology to effectively control infection, drainage and odor while promoting granulation and wound healing at 75mmHg pressure.
75615317|NCT03206437|Behavioral|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
75767330|NCT01108900|Drug|sildenafil|tables, 25,50,100 mg, on demand, 1 month
75615318|NCT01124916|Procedure|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
75767331|NCT01105390|Biological|rilotumumab|Given IV
75767332|NCT01105390|Drug|cisplatin|Given IV
75767333|NCT01105390|Drug|pemetrexed disodium|Given IV
75908796|NCT05126836|Drug|Cilostazol 100Mg Tab|Cilostazol Twice a Day
75908797|NCT05126836|Drug|Placebo|Placebo
75908798|NCT05109338|Device|Ben-Guard Garment|Wearable device designed to secure CVCs and gastrointestinal feeding tubes. The Ben-Guard Catheter Securement Device was designed specifically to better secure and conceal CVC tubing, protecting the patient by keeping tubing closer to the body.
75908799|NCT05090995|Behavioral|Behavioral Self-Management and Feedback|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, active self-monitoring of health and behavior using daily diaries, and the provision of personalized health feedback and advice.
75908800|NCT05090995|Behavioral|Behavioral Self-Management|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, and active self-monitoring of health and behavior using daily diaries.
75767334|NCT01105390|Other|laboratory biomarker analysis|Correlative studies
76071536|NCT04591015|Behavioral|Hospital: DD-CA|In the DD-CA group, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with educational, motivational and medication adherence messaging that is currently an arm of our parent DD-ME grant with added COVID support messages that provide information addressing identified barriers in Hispanic underserved communities (e.g. obtaining testing supplies and medications, accessing routine medical care, and completing other important diabetes self-management behaviors such as healthful eating, exercise, social distancing, quarantine, and stay-at-home/lockdown guidelines).
75615319|NCT01124916|Procedure|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
75615320|NCT00631618|Drug|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
75767335|NCT04250662|Device|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
75767336|NCT04250662|Device|Active tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Active tDCS arm alone without guided imagery, will have 20 minutes of tDCS stimulation without guided imagery.
75908801|NCT05089227|Drug|"treatment intervention"|for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban
75908802|NCT05089227|Drug|"treatment standard"|during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
75908803|NCT05089227|Biological|biological assessment|CBC, reticulocytes, haptoglobin, LDH, bilirubin
75908804|NCT05081024|Procedure|Biopsy|Undergo biopsy
75908805|NCT05081024|Procedure|Biospecimen Collection|Undergo collection of blood and/or tissue samples
75908806|NCT05081024|Other|Electronic Health Record Review|Medical records are reviewed
76071537|NCT04591015|Behavioral|Hospital: Usual Care (UC)|In the UC group, participants will not receive the added COVID support messages, both groups will have a referral placed to the Diabetes Transitions Service (DTS) at the time of discharge as part of usual care. Participants will be contacted by a peer health coach following protocol to coordinate care with outpatient health and other community resources.
76071538|NCT04588233|Dietary Supplement|Melatonin|Each subject will receive 3mg of melatonin 1 hour prior to bedtime for 12 consecutive nights
76071539|NCT04588233|Other|Placebo|Each subject will receive a placebo 1 hour prior to bedtime for 12 consecutive nights
75615321|NCT02647801|Behavioral|Mindfulness intervention|"Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation)."
75615322|NCT04627090|Other|Data collection|Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
75615323|NCT04777630|Diagnostic Test|None, neuroimaging|Observation only to observe differences in neuroimaging
75615324|NCT04714060|Biological|UB-621|mAb by SC administration
75767337|NCT04250662|Device|Sham tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus sham tDCS arm will have 30 seconds of tDCS stimulation with 25 minutes of guided imagery.
75767338|NCT04250662|Device|Sham tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Sham tDCS alone arm will have 30 seconds of tDCS stimulation without guided imagery.
75767339|NCT05164120|Drug|Belnacasan|Oral administration
75767340|NCT05164120|Drug|Placebo|Tablet containing 0mg of API
75767341|NCT03945136|Behavioral|Dynamic Interpersonal Therapy|Dynamic Interpersonal Therapy is a time-limited, manualized, interpersonal and affect-focused psychodynamic treatment that is frequently used to target depression and anxiety.
75462222|NCT01861769|Other|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
75462223|NCT01861782|Other|Dead Sea Solar and Water Treatment|
75908807|NCT05075005|Other|Treatment Cohort|Subjects will walk on a specified University of Florida Natural Area Teaching Laboratory's (NATL) nature trail for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Time, distance, and GPS walking route will be recorded utilizing the MapMyRun smartphone application, which is free to download and easy to use. The study team will assist each subject with downloading the application onto their smartphone and provide a brief training on app use at their pre-trial visit. Subjects will be asked to save each training session within the app to report to the study team upon completion of the 8-week training protocol. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
75908808|NCT05075005|Other|Control Cohort|Subjects will walk on hardscapes (e.g. sidewalk, asphalt, track, etc) for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Similarly to the treatment group, subjects will be asked to utilize the MapMyRun smartphone application to record their training sessions. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
76071540|NCT04583891|Behavioral|IntelliCare|IntelliCare is a self-guided, fully automated suite of 6 apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
75462224|NCT01861782|Other|Sulfur Pool & Medicinal Mud|
75462225|NCT01861795|Other|Preterm Neonates|Preterm Neonates
75462226|NCT01861808|Other|Lumbar puncture|The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
75462227|NCT01861821|Device|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication
75462228|NCT01861821|Device|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication
75767342|NCT04162366|Drug|Aprocitentan 25 mg|Tablet, oral use once daily
75767343|NCT04162366|Drug|Placebo|Matching placebo tablet, oral use once daily
75767344|NCT03947242|Drug|Pyrotinib and Trastuzumab plus Vinorelbine|Pyrotinib:400mg orally daily Trastuzumab:8mg/kg ivgtt load followed by 6mg/kg ivgtt 3-weekly for a total of 4 cycles Vinorelbine :25mg/m2 ivgtt 3-weekly for a total of 4 cycles,d1 d8
75767345|NCT03944980|Drug|Docetaxel|Docetaxel injection
75767346|NCT03944980|Biological|PD1-T cells|PD1-T cells injection
75767347|NCT05094700|Other|Non-marketed Cosmetic Facial Cleanser|Participants will apply non-marketed cosmetic facial cleanser on cleanse facial skin, twice daily for 4 weeks.
75462229|NCT01861834|Drug|Omegaven 10%|"Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.~Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN"
75462230|NCT01861860|Device|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain > 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
75462231|NCT01861873|Other|measuring liver function by 18-FDGal PET/CT|
75767348|NCT01108432|Other|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
75767349|NCT03576664|Drug|Carvedilol 25mg|Cross-over, randomized, placebo-controlled study.
75615325|NCT04431778|Drug|Ethosuximide|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
75767350|NCT03576664|Drug|Placebo oral capsule|Cross-over, randomized, placebo-controlled study.
75767351|NCT03502408|Procedure|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
75767352|NCT03502408|Procedure|Endovascular Thrombectomy|Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
75767353|NCT02529826|Procedure|Testicular Biopsy|An open testicular biopsy will be performed by an attending urologist under general anesthesia.
75767354|NCT01108978|Drug|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
75767355|NCT01108978|Drug|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
75767356|NCT01109134|Drug|tirofiban intracoronary bolus-only|administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
75908809|NCT05050357|Device|Hormonal intrauterine device|insertion of hormonal IUD during menstrual period
76071541|NCT04583891|Behavioral|Psychoeducation|The Patient Education app will contain content relevant for general distress management. This includes information about thoughts/worries, prevalence of mood symptoms, CBT strategies for coping with negative affect, and other information typical of education-based mental health apps. The structure of this app will closely mirror patient education websites and apps which mimic the form and structure of apps that target cancer survivors and that primarily provide educational information about cancer and related symptoms.
76071542|NCT04583891|Behavioral|Coaching|The randomization of added coaching vs. no added coaching after 1 week will only be carried out in the IntelliCare group. Coaching is a human supported approach to optimizing the use and benefit of the IntelliCare apps.
75615326|NCT04431778|Drug|Placebo|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
75615327|NCT05252650|Behavioral|pain|postoperative pain
75767357|NCT01109134|Drug|tirofiban intravenous bolus plus infusion|administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
75767358|NCT01108588|Drug|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
75767359|NCT01108588|Drug|Aspirin|Aspirin 300 mg daily
75767360|NCT01108588|Drug|Clopidogrel|Clopidogrel 75 mg daily
75767361|NCT01108588|Drug|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
75767362|NCT01208740|Drug|Metformin|500 mg three times daily
75767363|NCT01208740|Drug|Placebo|1 pill three times daily
75767364|NCT01208818|Drug|Cyclophosphamide + Bortezomib + Dexamethasone regimen|"Dosing regimen (21 day-cycle):~Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect."
75767365|NCT01208818|Drug|Bortezomib +Dexamethasone regimen|"Dosing regimen (21 day-cycle):~Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect."
75767366|NCT01208818|Device|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
75908810|NCT05050357|Drug|Progestins Norethindrone|oral ethisteron twice daily for three months
75908811|NCT05032430|Behavioral|CCC|A mix of mindfulness-based stress reduction, mindful eating, and mindful parenting strategies.
75908812|NCT05032430|Behavioral|Enhanced Usual Care|Consists of strategies meant to enhance health and well-being (e.g., health education, strategies to get more physical activity) but does not include mindfulness as an active ingredient.
75908813|NCT05008809|Drug|mFOLFOX6|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
75615328|NCT05252572|Biological|CLL1 CAR T-cells|Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection
75615329|NCT00631384|Behavioral|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
75767367|NCT01208818|Device|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient > 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
75767368|NCT05067712|Procedure|Open Surgical Exposure Technique|"A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~Follicular tissue is removed from the exposed crown area~The flap is repositioned back and sutured~The area over the exposed canine crown is excised leaving a window with the crown uncovered.~If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances."
75908814|NCT05008809|Drug|mFOLFOXIRI|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
75767369|NCT05067712|Procedure|Closed Surgical Exposure Technique|"A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~Follicular tissue is removed from the exposed crown area.~An attachment with a chain is bonded to the exposed canine crown.~The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~The extraction of the primary canine (if present) made before or in connection with the surgical exposure~Ten to fifteen days later the sutures are removed.~Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch."
75462232|NCT01861886|Device|ESS505 (BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
75462233|NCT01861899|Device|SI-LOK|Sacro-iliac joint fusion
75767370|NCT03947320|Drug|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
75767371|NCT01111630|Drug|recomon (Epoetin Beta)|administer once weekly
75767372|NCT01111630|Drug|recomon (Epoetin Beta)|administer three times weekly
75767373|NCT01208896|Drug|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
75767374|NCT03944278|Device|Thulium Laser|Thulium laser for skin resurfacing procedures
75767375|NCT01327768|Procedure|Olfactory ensheathing cells|Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
75767376|NCT03942796|Drug|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
75908815|NCT04986917|Device|Hernia repair surgery using the Su2ura® approximation device|. The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.
75908816|NCT04986917|Diagnostic Test|Physical Examination|All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.
75908817|NCT04986917|Diagnostic Test|Vital Signs|Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).
75908818|NCT04986917|Diagnostic Test|Blood Tests|"All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides).~5 ml of blood (equals to 1 spoon) will be taken for each test."
75908819|NCT04986917|Diagnostic Test|Urine Pregnancy Test|Urine pregnancy test will be performed during the screening visit (for WOCBP).
75908820|NCT04986917|Diagnostic Test|Abdominal Ultrasound imaging|All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.
75908821|NCT04986917|Other|EuraHS-QoL|patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort
75908822|NCT04986917|Other|Visual Analouge Scale (VAS)|A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.
75908823|NCT04986917|Diagnostic Test|Clinical evaluation for hernia recurrence and clinical bulging|"The procedure includes:~Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT.~SAE's and SADE's evaluation of the seroma.~Taking a photograph of the surgery area without disclosing the subject's identity."
75908824|NCT04976179|Drug|Ferric carboxymaltose|Ferric carboxymaltose to be given as an intravenous infusion
75908825|NCT04976179|Drug|Ferrous sulfate|Ferrous sulphate tablet to be taken orally
75462234|NCT01861912|Device|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities
75615330|NCT00631384|Behavioral|Individual VCT|Women to receive individual VCT
75908826|NCT04975334|Drug|kisspeptin, GnRH, naloxone|Six IV doses of kisspeptin 112-121
75908827|NCT04975334|Drug|GnRH|Two IV doses of GnRH
75908828|NCT04975334|Drug|Naloxone|One bolus and one infusion of naloxone
75908829|NCT04966104|Behavioral|ODYSSEE-vCHAT|Automated digital counselling program with social network support
75908830|NCT04964843|Drug|N-acetylcysteine|N-acetylcysteine is an FDA approved medication that is used to treat acetaminophen overdose.
75908831|NCT04964843|Drug|Placebo|Placebo
75908832|NCT04962776|Drug|Low-concentration carbohydrate and nitrates|Patients in the CHON group will be given 400 mL of a clear carbohydrate drink (12.5 g/100 mL maltodextrin, 50 kcal/100 mL) and 2 capsules of beet root extract 1 gm on the evening before surgery (8 hours) and another 200 mL of the carbohydrate drink and 1 capsule of beet root extract 1 gm on the day of surgery, 2 h before anesthesia induction.
75908833|NCT04962776|Drug|Low-concentration carbohydrate|Patients in the CHO group will be given the same carbohydrate drink in the CHON group with 2 placebo capsules with the evening drink and one with the morning drink.
75767377|NCT03942796|Procedure|pulsed radiofrequency ablation of the dorsal root ganglion under fluroscopic guidance/ radiofrequency neurolysis/ radiofrequency denervation device name: Neuro Therm TM 1100|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion using the following settings: 2-Hz frequency, 20-ms pulses in a 1 second cycle, 120 second duration and 42°C temperature. Impedance ranges between 150 and 400 Ohms at all levels under fluroscopic guidance. For each pulsed RF application, the procedure will be repeated 4 times, for a total duration of 8 minutes
75767378|NCT01114282|Drug|velcade|
75615331|NCT05252494|Other|animal assisted therapy|In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
75317234|NCT05216302|Behavioral|Group-based Nordic Walking Exercise Program|An exercise intervention based on nordic walking and health education of one hour and 15 minutes per session. Each session includes 10 min of health education followed by 15 minutes of warm-up exercises, 30 minutes of nordic walking and finally 15 min to cool-down. The intervention is meant to last during two months (last round of chemotherapy and one month pre-surgery), twice weekly for approximately a total of 16 sessions.
75317235|NCT05177887|Device|Traumacel PULVIS, Traumacel ENDO Applicator|Haemostatic plant polysaccharide powder made of the oxidized cellulose with flexible applicator (38 cm).
75615332|NCT02691130|Biological|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
75615333|NCT02691130|Biological|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
75615334|NCT02691130|Biological|Saline|0.9% NaCl in double distilled water
75615335|NCT00916006|Drug|PEP005 Gel|0.015%, three day treatment
75615336|NCT00916006|Drug|Vehicle gel|Vehicle gel, three day treatment
75615337|NCT04606186|Dietary Supplement|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
75615338|NCT04606186|Dietary Supplement|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia)
75767379|NCT01114282|Drug|Pralatrexate|
75767380|NCT01111708|Procedure|Close Rectal Dissection - IPAA|Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
75767381|NCT03944122|Device|ultrasound|therapeutical ultrasound were applied to the patients
75767382|NCT01109212|Drug|Bindarit|dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks
75767383|NCT01109212|Drug|Placebo|dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
75908834|NCT04962776|Other|Water with placebo capsules|Patients in the W group will be given equivalent volume of drinking water with placebo capsules by evening and in the morning of surgery.
75908836|NCT04950803|Dietary Supplement|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 20 billion CFU daily)
75908837|NCT04950803|Dietary Supplement|Active placebo|Active placebo contains active vitamin
75615339|NCT04701814|Other|biomechanical scapular mobilization with movement and motor learning|the therapist applied posterior tilt and exteral rotation with upward rotation mobilization to scapula and therapist also warp bilt around GH joint to applied inferior and posterior glid then ask patient to elevate his arm. then we applied motor learning approach by asking patient to elevate his arm with maintaining of external rotation with posterior glid of scapula.
75615340|NCT04589572|Procedure|XLIF|the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
75615341|NCT04589572|Procedure|PLIF|open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
75767384|NCT01111864|Dietary Supplement|fortification with iron and micronutrients|Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
75767385|NCT01111864|Dietary Supplement|Sprinkles|Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
75767386|NCT01211782|Drug|caprylic triglyceride|oral, 20 gm, daily x 6 months
75767387|NCT01211782|Drug|long-chain triglyceride|oral, 14 gm, daily x 6 months
75908838|NCT04946825|Drug|Nicotine replacement therapy patch|The nicotine patch is attached to the participant's skin and provides a slight constant stream of nicotine. The smaller dose is meant to reduce nicotine dependence.
75908839|NCT04946825|Drug|Nicotine replacement therapy lozenge|The nicotine lozenge contains small amounts of nicotine, which a participant slowly dissolves in their mouth. Like the patch, the smaller dose is meant to reduce nicotine dependence.
75908840|NCT04946825|Behavioral|Quit electronic cigarettes|Participants will receive instruction and text message support to quit electronic cigarettes when they quit combustible cigarettes.
75317236|NCT05177796|Drug|Carboplatin|Given IV
75317237|NCT05177796|Drug|Cyclophosphamide|Given IV
75317238|NCT05177796|Drug|Doxorubicin|Given IV
75317239|NCT05177796|Drug|Paclitaxel|Given IV
75317240|NCT05177796|Biological|Panitumumab|Given IV
75317241|NCT05177796|Biological|Pembrolizumab|Given IV
75317242|NCT05170048|Drug|EG-301|The investigation drug, EG-301 Tablets 150mg, is for oral use.
75317243|NCT05170048|Dietary Supplement|AREDS2 supplements|AREDS2 supplement is the stand of care
75767388|NCT01111942|Other|radiation combined with weekly carboplatin|"recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;~Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.~Induction Triple Therapy Treatment with TPF:~Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta* 6 mg SC Day 5 (*Neupogen may be substituted at the investigator's discretion)"
75767389|NCT01111942|Procedure|conservation surgery|Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
75767390|NCT01112020|Device|CHG Catheter Dressing Patch|2% CHG dressing applied to 7 sites
75767391|NCT01112020|Device|Biopatch|Biopatch applied to 7 sites
75767392|NCT01112020|Device|Tegaderm CHG|Tegaderm CHG IV Securement Dressing applied to 7 sites
75767393|NCT03944200|Drug|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
75462235|NCT01861912|Drug|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.
75767394|NCT03944200|Drug|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
75317244|NCT05165524|Device|QS Nd:YAG laser|Patients will be treated with Quality-switched (QS) Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (MedLite® C6) operating at a wavelength of 1064 nm, fluence range from 2.1 J/cm2 to 8.1 J/cm2 with a 4-6mm spot size.
75767395|NCT03940534|Device|TAD|TAD is a device used to aid medication adherence.
75767396|NCT03942640|Other|subctaneous perineural injection|"Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection"
75908841|NCT04946825|Behavioral|Continue electronic cigarettes|Participants will receive instruction and text message support to continue using electronic cigarettes after they quit combustible cigarettes.
75908842|NCT04908579|Drug|bupivacaine(intraperitoneally) and ketamine (intraperitoneally)|"40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~10 ml normal saline 0.9% will be given intravenous."
75908843|NCT04908579|Drug|bupivacaine(intraperitoneally) and ketamine (intravenously)|"40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites."
75908844|NCT04908579|Drug|bupivacaine(intraperitoneally)|"40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~10 ml normal saline 0.9% will be given intravenous."
75908845|NCT04907656|Behavioral|dCBT|As per arm of the same name
75908846|NCT04901390|Dietary Supplement|Yogurt with B. lactis and added cane sugar|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with cane sugar twice daily for 14 days.
75908847|NCT04898387|Combination Product|Bimatoprost Timolol (T4030)|Eye drop
75908848|NCT04898387|Combination Product|Bimatoprost Timolol (Ganfort)|Eye drop
75908849|NCT04874532|Other|Community Paramedic Program|Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.
75908850|NCT04874532|Other|Education Material|Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
75908851|NCT04869189|Device|JJVC Marketed Contact Lens|Acuvue Oasys® 1-Day
75908852|NCT04848753|Combination Product|Toripalimab combined with cisplatin and paclitaxel|Specified doses on specified days.
75908853|NCT04848753|Combination Product|Placebo combined with cisplatin and paclitaxel|Specified doses on specified days.
75317245|NCT05165524|Drug|Triple cream|Patients will be treated with a triple brightening cream (Pigmanorm®), applied daily, three times per week for 12 weeks on the lesion. Interruption for 4 days will be adopted in case of irritation/redness. 50+ sun protection cream will be used as well during the treatment period.
75317246|NCT05163899|Procedure|Release of filum terminale|Surgery will be offered to section the filum terminale
75462236|NCT01861912|Drug|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
75908854|NCT04833816|Drug|Administration of drug|Administration of ketamin during the 48h after trauma
75317247|NCT05160168|Drug|THE-630|Oral THE-630 administered once daily in a continuous regimen
75462237|NCT01861912|Drug|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
75908855|NCT04825561|Drug|AD-208|PO, Once daily(QD), 24weeks
75908856|NCT04825561|Drug|AD-2081|PO, Once daily(QD), 24weeks
75908857|NCT04825561|Drug|placebo of AD-208|PO, Once daily(QD), 24weeks
75615342|NCT04669132|Drug|Olanzapine|- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
75615343|NCT04669132|Drug|Netupitant|- Netupitanto 300 mg, once daily, on chemotherapy day;
75615344|NCT04669132|Drug|Palonesetron|- Palonosetron 0.56 mg, once daily, on chemotherapy day;
75908858|NCT04825561|Drug|placebo of AD-2081|PO, Once daily(QD), 24weeks
75908859|NCT04823247|Drug|Tildrakizumab|As provided in real world clinical practice.
75908860|NCT04814329|Other|genetic characteristic|the underlying genetic characteristics that prodicting response
75908861|NCT04795830|Combination Product|Bioceramic root repair material as pulp dressing in pulpotomy in primary molars|BC RRM-F, a novel premixed bioceramic-based putty, can be used as a pulp dressing to promote pulp healing and repair with an added convenience for the pediatric patient. The aim of the present study is to evaluate the efficacy of a bioceramic root repair material as pulp dressing in pulpotomy in primary molars. The success of this material as pulpotomy dressing in primary molars will be evaluated clinically and radiographically in comparison to mineral trioxide aggregate pulpotomy. Both materials will be compared in terms of ease of handling, time to perform procedure and convenience of application. Each material's success will be evaluated by comparing its performance with or without the added peripheral seal of a stainless steel crown.
75908862|NCT04795830|Combination Product|Mineral Trioxide Aggregate as pulp dressing in primary molars (MTA)|MTA's sealing ability, biocompatibility, ability to stimulate hard tissue formation and its regenerative ability when used in contact with pulp tissues has made MTA pulpotomy the new gold standard as opposed to formocresol pulpotomy in treating the amputated pulp stumps of primary molars.
75908863|NCT04793373|Device|Syringe|A syringe will be used to detect the loss of resistance and needle's entry of epidural space.
75908864|NCT04772222|Drug|Dexmedetomidine Hydrochloride|Potent α2-adrenergic receptor agonist that provides sedation, analgesia, and prevents shivering but does not suppress ventilation.
75767397|NCT03942640|Other|deep prolotherapy|The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
75767398|NCT01112098|Behavioral|Patient Pamphlet|letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
76071543|NCT04582994|Behavioral|Beta tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)
76071544|NCT04582994|Behavioral|Alfa tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)
75462238|NCT01861938|Biological|Melanoma vaccine modified to express HLA A2/4-1BB ligand|
75462239|NCT01861951|Drug|Pazopanib|
75462240|NCT01861951|Drug|Doxorubicin|
75462241|NCT01861964|Dietary Supplement|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
75462242|NCT01861964|Dietary Supplement|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
75462243|NCT01861964|Dietary Supplement|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
75462244|NCT01861977|Behavioral|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
75615345|NCT04701346|Other|Low SAA diet|Diet with low content of methionine and cysteine
75767399|NCT01211860|Drug|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
75615346|NCT04701346|Other|High SAA diet|Diet with high content of methionine and cysteine
75615347|NCT01168349|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
75615348|NCT00915772|Drug|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
75615349|NCT00915772|Drug|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
75615350|NCT00915772|Drug|Metformin|Metformin 1000 mg tablet bid
75615351|NCT03571828|Drug|AMG 562|AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
75615352|NCT04363606|Other|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
75615353|NCT04363606|Biological|blood test|complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
75615354|NCT04363606|Other|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
75615355|NCT04363606|Device|actigraphy|assessment of sleep quality
75615356|NCT04363606|Device|Neuromuscular evaluation|"The maximum isometric force produced by the knee extensors will be measured on the ergometer~the intensity of muscular electrical activity recorded by surface electromyography~Peripheral nerve stimulation~Transcranial magnetic stimulation~Magnetic resonance imaging"
75615357|NCT04363606|Other|stool analysis|analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
75615358|NCT04363606|Other|food diary|3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
75615359|NCT00632086|Drug|PA32540|
75615360|NCT00632086|Drug|aspirin component of PA32540|The 325 mg aspirin component of PA32540
75615361|NCT00632086|Drug|Ecotrin|325 mg Ecotrin
75615362|NCT00912964|Drug|Mirabegron|Mirabegron tablets
75615363|NCT00912964|Drug|Placebo|Matching mirabegron placebo tablets.
75767400|NCT01112176|Procedure|Increase in paced heart rate|The pacing rate will be increased by 10 bps at every stage
75767401|NCT01589536|Other|interval-rehabilitation|The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
75767402|NCT01211938|Radiation|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
75767403|NCT01211938|Radiation|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
75767404|NCT02947438|Drug|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
75615364|NCT02647957|Procedure|Code Stroke|Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
75767405|NCT02947438|Drug|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
75767406|NCT03940768|Dietary Supplement|Lactobacillus plantarum 299v|Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
75767407|NCT03940768|Dietary Supplement|Placebo|Administration of placebo in cancer patients who receive home enteral nutrition.
75767408|NCT01209052|Drug|GSK1325756|Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
76071545|NCT04582994|Behavioral|Sham|participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
76071546|NCT04570943|Combination Product|Gabrinox|"Regimen: GEMBRAX~Other Names:~Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²~Regimen: FOLFIRINOX~Other Names:~Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²~Gembrax + Folfirinox = GABRINOX"
75462245|NCT01861977|Behavioral|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
75462246|NCT01861990|Drug|Valproic Acid|All participants enrolled on valproic acid arm.
75615365|NCT02641639|Drug|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
75615366|NCT02641639|Drug|Placebo|Saline for infusion
75615367|NCT02647723|Dietary Supplement|DHA|2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
75615368|NCT02647723|Dietary Supplement|Sugar pill|2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
75615369|NCT02647567|Other|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
75615370|NCT02647567|Other|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
75615371|NCT00651469|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
75615372|NCT00651469|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
75615373|NCT02647489|Biological|PAMVAC|
75615374|NCT02647489|Biological|Alhydrogel|
75615375|NCT02647489|Biological|GLA-SE|
75615376|NCT02647489|Biological|GLA-LSQ|
75767409|NCT01209052|Other|Placebo|Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
75767410|NCT01209130|Drug|DCDT2980S|Intravenous repeating dose
75767411|NCT01209130|Drug|rituximab|Intravenous repeating dose
75767412|NCT01209208|Drug|Budesonide|9 mg per day
75767413|NCT01209208|Drug|Mesalamine|3 g per day
75767414|NCT01209208|Other|Placebo|0 g per day
75462247|NCT01862003|Drug|AZD8931|160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
75462248|NCT01862003|Drug|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
75462249|NCT01862003|Drug|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
75767415|NCT03940612|Dietary Supplement|STP4 (product with probiotics)|STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.
75615377|NCT02647489|Other|Placebo|
75767416|NCT03940612|Dietary Supplement|Placebo (product without probiotics)|Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
76071547|NCT04570943|Radiation|MRI-GUIDED STEREOTACTIC RADIOTHERAPY|"Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox.~Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended."
75908865|NCT04772222|Drug|Morphine Sulfate|Opioid agonist that provides analgesia, pain management and sedation and may suppress ventilation.
75317248|NCT05158218|Behavioral|Robotic Exoskeleton Gait Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will be completed in a 60-minute sessions with rests as needed. The key components of the therapy will include: 1) optimally challenging activities of variable intensity that emphasize motor planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints, 2) task specific overground movements that promote building a repertoire of mobility strategies that can be utilized in the community, and 3) motor tasks requiring active control that increase participant therapeutic engagement. An overhead body weight support system or a gait-belt may be used for some individuals during the robotic exoskeleton gait training blocks.
75615378|NCT00653575|Behavioral|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
75615379|NCT00653575|Behavioral|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
75615380|NCT02641171|Other|Specimen sampling|exhaled air samples blood samples fecal samples
75615381|NCT00910897|Drug|Velcade-Dexamethasone|
75615382|NCT00910897|Drug|Velcade-Thalidomide-Dexamethasone|
75908866|NCT04766021|Drug|Mirabegron|Dose-response effect on thermogenesis
75908867|NCT04766021|Drug|Placebo|Placebo control condition
75908868|NCT04764370|Device|WeFlow-Ach Moduler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
76071548|NCT04568226|Other|ConquerFear Intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
75615383|NCT00913744|Drug|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
75317249|NCT05158218|Behavioral|Physical Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. An overhead body weight support system or a gait-belt may be used for some individuals during the gait training blocks
75462250|NCT01862003|Drug|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
75462251|NCT01862003|Drug|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
75615384|NCT00913744|Drug|Sham injection|Sham injection
75615385|NCT00651547|Drug|budesonide/formoterol|
75615386|NCT00651547|Drug|budesonide|
75462252|NCT01862016|Procedure|APRV|Pressure ventilation mode allowing early spontaneous breathing
75462253|NCT01862016|Biological|arterial blood gas measurement each morning|
75615387|NCT00651547|Drug|formoterol|
75615388|NCT04202848|Diagnostic Test|Flora analysis|diversity and abundance of bacteria in patients who received malignant tumors
75615389|NCT04589260|Drug|TD-1058|Study drug to be administered by oral inhalation
75615390|NCT04589260|Drug|Placebo|Placebo to be administered by oral inhalation
75615391|NCT02641327|Device|EarlySense (Passive monitoring)|Passive contact-free monitoring
75615392|NCT02644759|Biological|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
75615393|NCT00912808|Drug|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
75615394|NCT00912808|Drug|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
75908869|NCT04752644|Biological|MVA-mBN294B|MVA-BN-RSV (nominal titre 5 x10*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.
75908870|NCT04752644|Drug|Placebo|TBS (Placebo) as intramuscular injections (0.5ml)
75908871|NCT04749511|Behavioral|Extrambulatory digital PROMs detection|The aim of the study is to investigate the validity of an alternative method of evaluating PROMs in which the questionnaire will be administered to the patient digitally (Google Forms) in an out-of-patient setting.
75908872|NCT04748380|Other|CRC decision aid pamphlet|A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise
75767417|NCT01112254|Procedure|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
75908873|NCT04748380|Other|Home Safety Pamphlet|The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
75908874|NCT04730336|Device|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
75908875|NCT04728360|Drug|BAT2206|45 mg/0.5 mL
75908876|NCT04728360|Drug|Stelara (EU-sourced)|45 mg/0.5 mL
75317250|NCT05154162|Diagnostic Test|PSMA PET/CT|PSMA PET/CT (limited to the pelvis)
75317251|NCT05154162|Procedure|Transperineal template prostate biopsy|Transperineal template prostate biopsies will be performed as per treating urologist's usual practice. No specific template for biopsy is prescribed for the purposes of the study. However, template sampling of the prostate is required, with a minimum of 12 cores, dependent on prostate volume. MRI will be available for any additional targeted biopsies required. Transperineal template biopsies must be labelled appropriately and sent for histopathological analysis.
75317252|NCT05154162|Procedure|Transperineal targeted prostate biopsy|If the PSMA PET/CT is normal, transperineal prostate biopsy would be omitted If the PSMA PET/CT is abnormal, transperineal prostate biopsies would be performed targeting the MRI (done prior to study) and PSMA PET/CT images
75317253|NCT05151341|Diagnostic Test|Urine collection (150ml)|Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)
75317254|NCT05151341|Other|Blood sample (20 ml)|"Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research."
75317255|NCT05140174|Other|Radical Healing and Internalized Stigma (RHIS) Training|8-hour RHIS training includes, readings that discuss radical healing and internalized stigma, access to didactic information regarding radical healing and internalized stigma. Therapists will role play certain scenarios that may involve minority stress experiences and discuss with the trainers different types of responses that could be therapeutic. The training will focus on the most up to date research regarding transgender mental health, minority stress, radical healing, and role-plays that focus on these processes.
75317256|NCT05136989|Behavioral|Individual and collective semi-structured interviews|Individual and collective semi-structured interviews will be performed with professionals to identify levers (practices, knowledge, tools, regulations) which, at the level of services and establishments, enable the development of a policy of less recourse to coercion
75317257|NCT05136989|Behavioral|Individual semi-structured interviews with ex-patients|Individual semi-structured interviews will be performed with ex-patients in order to gather their experiences in the seven institutions concerned and to better understand the impact of their hospitalization in these institutions on their lives
75317258|NCT05136989|Behavioral|Observations out in the services|Observations will be carried out in the services in order to measure the gap between rhetoric and practice, and to observe the effective implementation of lesser use practices
75317259|NCT05129449|Device|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) conducted with motorized PowerSpiral in subjects presenting with surgically altered GI anatomy indicated for ERCP with biliary indication.
75462254|NCT01862042|Other|Follow-up diary and questionnaire|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
75462255|NCT01862068|Other|Blood samples and clinical data|Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
75767418|NCT03940846|Diagnostic Test|Virtual biopsy|Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
75767419|NCT01112332|Device|SmartStep insole|Smart StepTM is an innovative biofeedback and monitoring system designed to help clinicians effectively guide patients with compromised lower limb function due to orthopedic or neurological trauma towards optimal gait performance. It records and analyzes key gait parameters and provides instantaneous and accurate audio and visual feedback.
75767420|NCT01112410|Other|Hypertonic saline|"Hypertonic saline (6%) nebulised twice a day for 4 weeks.~(Randomised crossover trial)"
75908877|NCT04724499|Behavioral|High-Intensity Intervals Training|16 week exercise program with stationary bike.
75908878|NCT04724499|Other|Attention Control|16 week stretching program.
76072412|NCT00499083|Procedure|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
75317260|NCT05106127|Drug|EG-007|A Repurposed Drug
75462256|NCT01862068|Other|Blood sample|Blood sample will be performed at inclusion from all healthy patients
75462257|NCT01862081|Drug|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
75462258|NCT01862081|Drug|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
75462259|NCT01862081|Drug|Paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
75462260|NCT01862120|Drug|Dose D1 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
75615395|NCT02647333|Dietary Supplement|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
75615396|NCT02647333|Dietary Supplement|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
75767421|NCT01112410|Other|Isotonic saline|Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.
75767422|NCT01114750|Drug|Insulin in dextran matrix capsule (and placebo)|Single dose capsule (and placebo)
75767423|NCT01328470|Drug|Clopidogrel, cilostazol|Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
75767424|NCT01109446|Biological|Platelet Rich Plasma|27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
75767425|NCT01109446|Procedure|Isotonic Saline Solutions|3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
75767426|NCT01109446|Drug|Triamcinolonacetonid|Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
75767427|NCT03940378|Drug|Levamisole Hydrochloride|Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
75767428|NCT03940378|Drug|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
75767429|NCT01112488|Other|Patient Engagement Programme|Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
75767430|NCT03940222|Device|Interactive Binocular Treatment|The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
75767431|NCT03940222|Procedure|Patching Therapy|Patching of the dominant eye with better best corrected visual acuity
75767432|NCT01115062|Drug|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
75767433|NCT01115062|Drug|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
75767434|NCT01115062|Drug|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
75767435|NCT01115140|Drug|metformin plus placebo|metformin 850 mg cp, 2 cps daily
75767436|NCT01115140|Drug|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
75767437|NCT01115140|Drug|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
75767438|NCT01115140|Drug|placebo alone|placebo cp, 2 cps daily
75767439|NCT01112644|Drug|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
75767440|NCT01112644|Other|Placebo (PLA)|Different daily doses; intake every 12 hours
75908879|NCT04682925|Other|skin care arm of where evidence-based practices in the implementation guide|"The nasal mucosa and nasal skin under the nasogastric tube will be cleaned and dried twice a day with a pH-compatible cleanser.~A water-based moisturizing cream will be applied to the nasal skin under the nasogastric tube twice a day, after care with a pH-compatible cleanser.~Spray skin barrier will be applied twice a day after applying water-based moisturizing cream to the nasal skin under the nasogastric tube.~The nasal mucosa and nasal skin under the nasogastric tube will be evaluated twice daily for signs of pressure-related injury. All these care interventions applied to the skin care arm will be applied together with the doctor and nurse responsible for the treatment and care of the patient."
75908880|NCT04682925|Device|hydrocolloid (Convatec Granuflex-extra thin) dressing|The nasal skin of the patients and the surrounding skin will be cleaned with a pH-compatible cleaner, dried and a new hydrocolloid cover will be applied once a day. All these care interventions applied to the hydrocolloid dressing arm will be applied together with the physician and nurse responsible for the treatment and care of the patient.
75908881|NCT04682925|Other|control|In routine care, the skin under the nasogastric tube is evaluated once a day for redness and wound formation by the nurse responsible for the patient's care and is cleaned and dried with appropriate cleaners.
75317261|NCT05106127|Drug|Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
75615397|NCT02641405|Device|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
75767441|NCT01112722|Biological|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
75767442|NCT01112722|Biological|histamine|imitates pain and erythema of honeybee venom
75767443|NCT01209676|Drug|IMCgp100 injection|a monoclonal T cell receptor anti-CD3scFv fusion protein
75767444|NCT03941938|Procedure|Cyanoacrylate reinforcement|Anastomosis Reinforcement with with nebulization of 1cc of glue on the anastomosis line
75767445|NCT03941938|Procedure|No reinforcement|Nothing applied on the anastomosis line
75767446|NCT01015222|Drug|Dasatinib|Starting dose of 50 mg daily PO for 28 day cycle
75767447|NCT01015222|Drug|Bevacizumab|Starting dose 5 mg/kg IV Day 1 and 15
75767448|NCT01015222|Drug|Paclitaxel|Starting dose 40 mg/m2 IV Day 1, 8 and 15
75767449|NCT01115218|Procedure|Trabeculectomy|Trabeculectomy with mitomycin C
75767450|NCT01207336|Device|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
75908882|NCT04678167|Diagnostic Test|Caloric test|Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
75908883|NCT04678167|Diagnostic Test|Measurement of the speed of Nystagmus|A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
75908884|NCT04678167|Diagnostic Test|Angle of deviation at Fukuda|The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
75908885|NCT04678167|Diagnostic Test|Alexander's degree of nystagmus|"there are 3 degrees:~Degree I: nystagmus that exists only when the eyes are turned to the right.~Degree II: also exists when the eyes are to the right or to the front.~Degree Ill: exists when the eyes are on the right, front, or left"
75908886|NCT04678167|Other|EHTEV questionnaire|Handicap Scale for Balance Disorders and Vertigo
75908887|NCT04678167|Other|EEV questionnaire|European Vertigo Assessment Questionnaire
75908888|NCT04678167|Other|anxiety VAS|visual analog scale of anxiety
75908889|NCT04648969|Drug|kisspeptin 112-121|20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
75908890|NCT04648969|Drug|GnRH|1 intravenous dose of GnRH
75317262|NCT05106127|Drug|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.
75615398|NCT02641405|Device|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
75317263|NCT05104489|Biological|AdimrSC-2f|IM injection
75317264|NCT05088278|Procedure|Anatomical single bundle ACL reconstruction with hamstrings|Anatomical ACL reconstruction with quadruple-bundle hamstrings graft
75317265|NCT05088278|Procedure|Anatomical single bundle ACL reconstruction with patellar tendon|Anatomical single bundle ACL reconstruction with patellar tendon
75317266|NCT05088278|Procedure|ACL reconstruction with over the top plus lateral plasty technique|Non-anatomical ACL reconstruction, the hamstrings' tibial insertion is preserved; a double-bundle hamstring graft is passed intra-articularly, fixed in over the top position on the lateral femoral condyle, and then passed extra-articularly deeply to ileo-tibial band up to the tibia, where it is fixed at the level of Gerdy's tubercle.
75615399|NCT02647255|Procedure|Plasma Exchange (PE)|PE treatment>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
75767451|NCT01115296|Dietary Supplement|L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri dose of 1x108 CFU.
75767452|NCT01115296|Other|Placebo|Placebo
75767453|NCT03940456|Other|Questionnaire|Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
75908891|NCT04622592|Biological|Instramuscular vaccine|On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
75908892|NCT04604093|Device|SMBG Meter|Self Monitoring Blood Glucose Meter
75317267|NCT05081791|Behavioral|Exercise Training|12-week exercise training program including a combination of endurance and resistance training for 45 minutes, twice a week.
75317268|NCT05077215|Drug|EG-007|A Repurposed Drug
75317269|NCT05077215|Drug|Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
75317270|NCT05077215|Drug|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
75615400|NCT02647255|Drug|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
75615401|NCT04415086|Biological|convalescent plasma|The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
75615402|NCT04329442|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|30 day supply of 200mg tablets
75767454|NCT01115374|Procedure|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
75767455|NCT01115374|Device|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
75767456|NCT01209910|Other|Water|Subjects in this arm will be able to drink water with some conditions.
75767457|NCT01212250|Drug|carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
75767458|NCT01212250|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
75767459|NCT01209988|Drug|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
75767460|NCT01209988|Other|No medication|No medication
75767461|NCT02529748|Other|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
75908893|NCT04604093|Device|FreeStyle Libre 2 System|The Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System
75908894|NCT04558775|Other|Observational|no intervention
75767462|NCT02529748|Other|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
75767463|NCT02529748|Other|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
75767464|NCT03943186|Device|Ectoin Lozenges Honey Lemon|application of Ectoin Lozenges (EHT02) in accordance with the instructions for use
75767465|NCT03943186|Device|Hyaluronic Acid/Icelandic moss Lozenges|application of the lozenges in accordance with the instructions for use
75462261|NCT01862120|Drug|placebo|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
75462262|NCT01862120|Drug|Dose D2 of Interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
75767466|NCT01210066|Drug|Fentanyl|IV fentanyl 1mcg/kg
75767467|NCT01210066|Other|Cold pressor test|Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes
75767468|NCT01210066|Other|Fentanyl plus cold pressor test|fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
75767469|NCT01115530|Other|Resistance exercise|Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks
75908895|NCT04545866|Drug|budesonide (Pulmicort nebulizing suspension).|The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.
75908896|NCT04545866|Drug|surfactant (poractant alfa;Curosurf)|The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
75908897|NCT04529993|Procedure|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
76072413|NCT00499083|Procedure|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
75908898|NCT04523220|Drug|BAY1213790 (Osocimab)|Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
75908899|NCT04523220|Drug|Placebo|Subcutaneous administration in the same manner as Osocimab.
75908900|NCT04503265|Drug|AMXI-5001:Dose Escalation Phase I|Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
75317271|NCT05064306|Drug|131I-omburtamab|50 mCi 131I-omburtamab
75317272|NCT05047692|Biological|AdCLD-CoV19-1|Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein
75317273|NCT05028829|Drug|Atorvastatin 20mg|Oral administration of atorvastatin 20 mg
75462263|NCT01862120|Drug|Dose D3 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
75462264|NCT01862146|Procedure|smoke expose|
75462265|NCT01862172|Other|Additional MRI|
75462266|NCT01862185|Other|semi-quantitative procalcitonin|
75767470|NCT01115530|Dietary Supplement|Protein and HMB (see below) supplement|Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
75767471|NCT03942172|Device|SpotOn balance glasses|SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
75767472|NCT01212328|Other|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
75767473|NCT01212328|Other|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
75767474|NCT03939988|Radiation|Photobiomodulation|Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
75767475|NCT03939988|Radiation|Placebo photobiomodulation|In the placebo group, the same procedures will be made, but the laser will be turned off.
75317274|NCT05028829|Drug|Placebo|Oral administration of placebo
75317275|NCT05012163|Behavioral|Reminder|Letter, short message service (SMS) text, phone, and/or email
75317276|NCT05012163|Behavioral|Financial incentive|Letter, SMS, phone, and/or email
75317277|NCT05012163|Behavioral|Lottery|Letter, SMS, phone, and/or email
75317278|NCT05009251|Behavioral|Reminder|Mailed letter, short message service (SMS) text, and/or patient portal message
75317279|NCT05009251|Behavioral|Risk reduction|Mailed letter, SMS, and/or patient portal message
75317280|NCT05009251|Behavioral|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
75317281|NCT05009251|Behavioral|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
75317282|NCT05005975|Drug|MT-7117|MT-7117
75317283|NCT04939610|Drug|68Ga-FAP-2286|68Ga-FAP-2286 IV administered as imaging agent for PET scan.
75317284|NCT04939610|Drug|177Lu-FAP-2286|Patients with positive uptake of 68Ga-FAP-2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).
75767476|NCT01112878|Drug|Sugar pill|"Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
75317285|NCT04939610|Drug|177Lu-FAP-2286|Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D and schedule determined in Phase 1 dose escalation.
75317286|NCT04912505|Drug|Aspirin|Run-in phase during one week with daily aspirin intake at 8 AM; visit 1: blood sampling at H24 and H2; intermediate phase (two weeks): daily aspirin intake at 8 PM; visit 2: blood sampling at H12; then daily intake of aspirin at the time preferred by the patient and study end visit 2 weeks after visit 2
75317287|NCT04882813|Drug|Dapagliflozin|Dapagliflozin dispensing claim is used as the exposure group.
75908901|NCT04503265|Drug|AMXI-5001:Dose Expansion Phase II|Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
75615403|NCT04414228|Device|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
75615404|NCT04414228|Device|ProAQT in guiding goal-directed hemodynamic therapy|If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If mean arterial pressure is < 70 mmHg and/or cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of < 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
75908902|NCT04468906|Procedure|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat LHBT lesions.
75908903|NCT04468906|Procedure|"Self-locking T Tenotomy"|"Self-locking T Tenotomy describes the surgical procedure that will be performed to treat LHBT lesions."
75908904|NCT04446260|Drug|SHR-A1811|be administered via intravenous (IV) infusion
75615405|NCT00960531|Biological|ACC-001+ QS21 (3mcg)|ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
75615406|NCT00960531|Biological|ACC-001 (10 mcg) + QS-21|ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
75615407|NCT00960531|Biological|ACC-001+QS-21 (30mcg)|ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
75767477|NCT01112878|Drug|Gabapentin|"Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
75767478|NCT01112878|Drug|Clonidine|"Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
75767479|NCT01109680|Drug|Neramexane|Multiple dose Neramexane followed by single dose 14C Neramexane
75908905|NCT04409080|Drug|REGN7257|Single dose will be administered by intravenous IV infusion
75908906|NCT04407442|Drug|Azacitidine|Given IV
76072414|NCT00499083|Radiation|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
75317288|NCT04882813|Drug|Sitagliptin|Sitagliptin dispensing claim is used as the reference group.
75317289|NCT04879407|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
75317290|NCT04879407|Drug|Warfarin|Any warfarin dispensing claim is used as the reference group
75317291|NCT04849520|Device|High flow nasal cannula|Oxygen supplement via high flow nasal cannula at a rate of 2 liters/kg/min
75317292|NCT04849520|Device|Buccal oxygenation|Oxygen supplement intra-orally via oral Ring-Adair-Elwyn endotracheal tube connected to oxygen at a rate of 0.5 liters/kg/min
75317293|NCT04846764|Other|Neuropsychological tests|"Scales and tests to evaluate:~laterality~anxiety~depression~professional level~education level~pre-morbid level~memory disorders~Experimental procedure"
75908907|NCT04407442|Biological|Daratumumab|Given SC
75317294|NCT04846712|Other|Collect data of medical record|Collect data of medical record: initial physical examination, ultrasound (US), Magnetic Resonance Imaging (MRI), physical examination at 30 days, physical examination at 3 months, physical examination at 6 months and final examination at 12 months.
75317295|NCT04840979|Drug|11C-ER176|11C-ER176 is a novel TSPO radioligand that was developed because of its relative insensitivity to the rs6971 polymorphism. Increased TSPO signal on PET is associated with activation of microglia in the brain. The radioligand will be administered in tracer doses at activity of up to 20 mCi (740 MBq), IV, total of one injection. A single dose of radioligand will be injected over 1 minute.
75317296|NCT04840979|Drug|18F-florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.
75615408|NCT04280367|Diagnostic Test|Standardised semi-structured talk|Comprehensive assessment of at-risk mental states (CAARMS) will be used.
75615409|NCT04280367|Diagnostic Test|Autistic spectre disorder screening|Autism-spectrum quotient (AQ) auto-questionnaire will be used.
75615410|NCT04280367|Diagnostic Test|Anxiety measuring|An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
75615411|NCT02859909|Biological|BT595|
75615412|NCT00652639|Drug|Clonazepam|Tablets, 1 mg, single-dose
75615413|NCT00652639|Drug|Klonopin|tablets, 1 mg, single-dose
75615414|NCT02858271|Drug|AKB-9778 subcutaneous injection|
75908908|NCT04407442|Drug|Dexamethasone|Given IV or PO
75317297|NCT04839692|Drug|Hyaluronic acid filler|Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.
75767480|NCT01115608|Other|Pharmacist follow-up|Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
75767481|NCT01212406|Drug|Vitamin D|Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
75767482|NCT03939910|Device|Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.|Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
75767483|NCT01109758|Drug|Fenofibrate|145 mg
75767484|NCT01115686|Drug|Branched-chain aminoacids|"Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks."
75767485|NCT01115686|Drug|Placebo|"Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks."
75615415|NCT02644681|Procedure|Aortic Aneurysm, Thoracic surgery|
75615416|NCT02859987|Procedure|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
75615417|NCT02859987|Procedure|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
75767486|NCT03939754|Behavioral|Dedalo project|Physical activity, healthy food, socialization and mental activity promotion
75767487|NCT01328236|Drug|Bortezomib|"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
75767488|NCT01328236|Drug|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
75767489|NCT01328236|Drug|Dexamethasone|"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
75767490|NCT03939832|Other|Fraction of inspired oxygen level|A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
75767491|NCT01328392|Drug|Dexlansoprazole|30mg a day, 3 months
75767492|NCT01113034|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
75767493|NCT01113034|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
75767494|NCT01212562|Procedure|Immunocryosurgery|Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
75767495|NCT01115842|Drug|Vitamin D|Vitamin D 4000IU per day for 5 days
75767496|NCT01115920|Drug|MTP-131 (Bendavia™)|Single 4 hour intravenous infusion
75317298|NCT04796545|Device|SING IMT(TM) System, model NG SI IMT 3X|The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
75317299|NCT04788069|Dietary Supplement|Wholemeal bread|180g wholemeal bread/day + fixed portion at test day
75317300|NCT04788069|Dietary Supplement|Sourdough bread|180g sourdough bread/day + fixed portion at test day
75317301|NCT04788069|Dietary Supplement|Bread with sourdough|180g bread with sourdough/day + fixed portion at test day
75462267|NCT01862198|Device|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
75462268|NCT01862211|Other|blood sampling|A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
75462269|NCT01862237|Other|Intervention|"blood collection~Completion of a pre-operative cardiac MRI.~Completion of a coronary angiography examination~Completion during the surgery d'une myocardial biopsy,~Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~Completion of a cardiac MRI 1 year after surgery."
75462270|NCT01862263|Drug|Vildagliptin|Orally active and highly selective inhibitor of DPP-4
75615418|NCT02859987|Device|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
75615419|NCT02644915|Drug|Edaravone|Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
75615420|NCT02644915|Drug|0.9%%NaCl solution|"100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg"
75767497|NCT01116076|Behavioral|Decision+ program (to improve optimal drug prescription for ARI)|DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
75767498|NCT01210378|Drug|Nitroglycerin patch|Nitroglycerin patch
76072415|NCT00418886|Drug|Vandetanib|oral once daily tablet
76072416|NCT00418886|Drug|Pemetrexed|intravenous infusion
76072417|NCT00284726|Device|Celsior Cold Storage Solution|
76071549|NCT04568226|Other|Active control: Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
76071550|NCT04567615|Biological|Nivolumab|Specified dose on specified days
76071551|NCT04567615|Biological|Relatlimab|Specified dose on specified days
75767499|NCT01109836|Behavioral|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
75317302|NCT04769466|Other|LifeBio Memory|LifeBio Memory is a digital reminiscence therapy platform designed to collect the life stories of older adults to generate personalized life storybooks that capture their unique narratives and social histories. Life story booklets, summaries, and materials are also developed as mechanisms for sharing this story and for staff to provide enhanced person-centered care.
75317303|NCT04766502|Other|Blood sample (20 ml) and EORTC QLQC30 survey|"Blood sample (20ml) will be taken before and 24h after PIPAC procedure~EORTC QLQC30 during pre operative consultation and at each post operative consultations"
75317304|NCT04760795|Other|PTSD Check List (PCL) scale|PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.
75317305|NCT04760795|Other|Brief COPE scale|Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.
75317306|NCT04760795|Other|GAD-7 (Generalized Anxiety Disorder) scale (during containment)|GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
75317307|NCT04760795|Other|Analog scale|Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
75767500|NCT01116154|Drug|lenalidomide|Given orally
75767501|NCT01116154|Drug|vorinostat|Given orally
75317308|NCT04760795|Other|GAD-7 (Generalized Anxiety Disorder) scale (post containment)|GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.
75317309|NCT04760795|Other|Big Five Inventory (BFI) scale|Big Five Inventory (BFI) will be realized to evaluated personality.
75317310|NCT04760795|Other|Relationship Scales Questionnaire (RSQ)|Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.
75317311|NCT04744077|Behavioral|Influencer Instagram account|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
75462271|NCT01862263|Drug|Insulin|Long- acting human insulin analog indicated to improve glycemic control
75462272|NCT01862263|Drug|Placebo|Matching placebo of vildagliptin
75462273|NCT01862289|Other|Diagnostic of chronic hyperventilation syndrome|Nijmegen questionnaire, Hyperventilation challenge and blood gases
75615421|NCT00960375|Behavioral|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
75767502|NCT01116154|Other|laboratory biomarker analysis|Correlative studies
75767503|NCT01113190|Behavioral|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed."
75462274|NCT01862302|Drug|Haloperidol|1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
75462275|NCT01862302|Drug|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
75462276|NCT01862341|Dietary Supplement|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
75462277|NCT01862354|Procedure|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
75462278|NCT01862354|Procedure|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
75767504|NCT01113190|Behavioral|Intervener-delivered Brief Intervention (IBI)|"IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller & Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions."
75767505|NCT01113190|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
75908909|NCT04372615|Drug|Inebilizumab|"RCP: Blinded treatment on Day 1, Day 15,~Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care)."
75908910|NCT04372615|Drug|Placebo|The placebo group will receive IV matching placebo on Day 1 and Day 15,
75908911|NCT04348448|Drug|Canakinumab 150 MG/ML [Ilaris]|COVID-19
76071552|NCT04566692|Biological|IGSC 20%|SC infusion pump.
76071553|NCT04564183|Other|Sample collection|Blood, Urine, Nail, Hair, Saliva, optional Stool
75615422|NCT00960375|Behavioral|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
75908912|NCT04345796|Drug|Carvedilol+Empagliflozin|Group A
75908913|NCT04345796|Drug|Carvedilol|Group B
75908914|NCT04345796|Drug|Empagliflozin|Group C
75908915|NCT04345796|Drug|Placebo|Group D
75908916|NCT04336306|Other|virtual reality-based therapy (VRBT)|"The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist."
75908917|NCT04310267|Device|Petit typeface mask|(Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
75908918|NCT04288479|Behavioral|Single high-intensity interval training session|10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
76071554|NCT04564183|Other|Questionnaires|SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire
76071555|NCT04564183|Radiation|High resolution CT scan of the chest|Upon enrollment, all participants will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.
76071556|NCT04564183|Diagnostic Test|Pulmonary Function Test|All recruited participants will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.
76071557|NCT04548063|Other|6,000 word consent form|Mock consent form with consistent content in approximately 6,000 word length.
76071558|NCT04548063|Other|4,000 word consent form|Mock consent form with consistent content in approximately 4,000 word length.
76071559|NCT04548063|Other|2,000 word consent form|Mock consent form with consistent content in approximately 2,000 word length.
76071560|NCT04548050|Other|Nurses training|"Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~Presentation to all staff of a service protocol for early colostrum donation."
76071561|NCT04547010|Dietary Supplement|Soy Isoflavone supplement|Participants received 60 mg of soy-isoflavone supplement per day.
76071562|NCT04538378|Drug|Olaparib|Olaparib tablet will be administered at a total daily dose of 600 mg orally in two divided doses, approximately 12 hours apart.
75615423|NCT00651703|Biological|CYT004-MelQbG10 + Montanide|
75615424|NCT00651703|Biological|CYT004-MelQbG10 + Montanide + Imiquimod|
75615425|NCT00651703|Biological|CYT004-MelQbG10 + Imiquimod|
75615426|NCT00651703|Biological|CYT004-MelQbG10 intra nodal injection|
75615427|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
75615428|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
75615429|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
75317312|NCT04744077|Behavioral|Research study Instagram account|Intervention arms will deliver the same exercise-related content on the same schedule on the intervention Instagram accounts. The arms will deliver 13-weeks worth of content which goes through the last possible day of the intervention. The structure was based on feedback from stakeholders in a formative focus group. All of the content delivered through the accounts is evidence-based and referenced from reputation organizations/agencies such as the American College of Sports Medicine, American Heart Association, Center for Disease Control, and World Health Organization. Each Co-PI will post videos to answer participant questions. To ensure that the content between both groups is the same, the Co-PIs will meet to determine which questions to answer and draft the response.
75908919|NCT04265612|Procedure|"Pico® negative pressure dressing"|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy.The dressing will remain on for 7 days without waking up, unless it is saturated, in which case only the dressing will be changed"
75908920|NCT04265612|Procedure|"Aquacel Surgical® hydrogel dressing"|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
75908921|NCT04258319|Diagnostic Test|Ultrasound Procedure|Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
75317313|NCT04742166|Procedure|Reconstruction|Lateral gastrojejunal Terminolateral gastrojejunal
75317314|NCT04740424|Drug|FS222|Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
75462279|NCT01862367|Drug|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
75462280|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
75462281|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
75462282|NCT01862393|Device|400 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
75615430|NCT00632242|Drug|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
75767506|NCT01113190|Behavioral|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
75767507|NCT01210456|Drug|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|"All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure."
75908922|NCT04257877|Procedure|Blood sampling|Blood samples for proteomic analysis in plasma of both groups
75908923|NCT04233671|Behavioral|Mindfulness based relapse prevention and peer mentoring|"Importantly, the treatment will utilize a group format. Group process can serve as a vital agent in breaking down client denial about drug abuse problems. Groups have also been shown to be suitable for treating problems commonly associated with substance abuse, including depression, isolation, and shame.~Additionally, groups intrinsically have many rewarding benefits, including reducing isolation and enabling members to witness the recovery of others. The eight-week group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, then followed by group sessions led by peer mentors for an additional four weeks."
76071563|NCT04538378|Drug|Durvalumab|Durvalumab will be administered IV into a peripheral or central vein on Day 1 of every cycle at a flat dose of 1,500 mg.
76071564|NCT04536857|Other|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.
76072418|NCT00230659|Other|Blood sample to be taken.|Blood sample to be taken.
75462283|NCT01862393|Device|700 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
75317315|NCT04736420|Drug|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure group
75317316|NCT04736420|Drug|Warfarin|Warfarin dispensing claim is used as the reference group
75317317|NCT04718896|Drug|bimekizumab|Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
75462284|NCT01862393|Device|1000 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
75462285|NCT01862406|Other|Label|Participants were presented with either a generic label or a brand-name label
75462286|NCT01862432|Other|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
75462287|NCT01862458|Biological|tPA alone|
75462288|NCT01862458|Biological|tPA plus dornase|
75462289|NCT01862471|Device|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
75462290|NCT01862471|Device|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
75462291|NCT01862497|Drug|Carvedilol vs. Prazosin|
75908924|NCT04227145|Behavioral|SexHealth Mobile|"It will integrate two existing services in our community: a mobile medical unit (MMU) operated by Swope Health Services, and SexHealth a point-of-care contraception counseling service that our research team developed for Children's Mercy Hospital's emergency department (ED). Using a menu of adaptive services, SexHealth Mobile will bring contraceptive care to women with SUD (including a subset of women with OUD), if they wish to receive it, at targeted recovery sites Swope currently partners with."
75767508|NCT01210612|Device|five-toed socks|five-toed socks usage
75615431|NCT00632242|Drug|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
75767509|NCT01207804|Device|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
75908925|NCT04222088|Drug|Arthemeter-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to <16kg); 2 tablets (15 to <25kg); 3 tablets (25 to <35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old)"
75615432|NCT02644837|Device|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
75908926|NCT04222088|Drug|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
76071565|NCT04536142|Diagnostic Test|MRI|A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.
76071566|NCT04536142|Diagnostic Test|neuropsychological tests and qualitative assessment|"Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe"
76071567|NCT04534153|Drug|Fexofenadine Hydrochloride without sodium lauryl sulfate|without sodium lauryl sulfate
75462292|NCT01862523|Biological|Capsaicin|Thirty-three* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
76071568|NCT04534153|Drug|Fexofenadine Hydrochloride with sodium lauryl sulfate|with sodium lauryl sulfate
76072419|NCT00089024|Drug|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 & 2; Repeat one 3-week cycle starting day 22
75462293|NCT01862523|Biological|diluent|diluent
75462294|NCT01862549|Behavioral|Dialectical Behavior Therapy for children|
75462295|NCT01862549|Behavioral|Treatment as Usual|
75462296|NCT01862562|Procedure|Open surgery|Conventional technique
75615433|NCT02644837|Device|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
75615434|NCT02644837|Device|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
75615435|NCT02644837|Device|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
75767510|NCT01116310|Drug|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
75767511|NCT01116310|Drug|Placebo|Bottles containing 60 capsules.
75767512|NCT01210846|Drug|tivozanib|1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
75462297|NCT01862562|Procedure|Laparoscopic surgery|New minimum invasive technique
75462298|NCT01862601|Device|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
75462299|NCT01862627|Procedure|Optical coherence tomography|
75462300|NCT01862653|Device|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
75462301|NCT01862679|Other|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
75767513|NCT01116388|Other|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
75462302|NCT01862679|Procedure|Haemodiafiltration|"During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood."
75767514|NCT01116388|Other|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
75767515|NCT01109914|Biological|Dukoral|"Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*~Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*~Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*~Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria*~Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)"
75767516|NCT01110070|Device|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
75767517|NCT01110070|Device|ChonDux|single use device
75908927|NCT04222088|Drug|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
75908928|NCT04196543|Other|écho-doppler with ultrasonar Sonovue® injection|"During this unique visit they will benefit from 2 imaging exams performed by two different operators:~Echo-doppler without standard method contrast injection (common practice)~An echo-doppler with Sonovue® ultrasound injection Ultra_evar method (2.5 ml bolus 2-3 seconds) During this examination, the endoprosthesis and the aneurysm sac will be scanned according to the 4 incidences described above in order to objective whether or not there is a endoleak.~The patient then performs the control CT-scan prior to discharge from hospital.~The results of the medical imaging exams will be communicated to them before the hospital discharge, once the CT-scan has been performed.~A cross-review of the studies will be performed later."
75908929|NCT04187950|Dietary Supplement|Yogurt with B. lactis and added honey|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.
75908930|NCT04187950|Dietary Supplement|Yogurt with heat-inactivated B. lactis and added cane sugar|The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
75908931|NCT04136340|Other|In-person in clinic follow-up visit|Patient will be seen in-person (i.e. an IR/NV or AFX visit) in the clinic by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks. Any patients randomized to the in-person group who experience an extraordinary burden and/or are physically unable to attend their in-person visits will be able to be seen by their Supportive Care Service clinician via a home telemedicine visit (patients will return to their original group assignment if possible).
75908932|NCT04136340|Other|Telemedicine follow-up visit|"i. Patients will be seen by video telemedicine at home by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks.~ii. Patients will have access to a clickable link that will initiate a video telemedicine call to the clinician's office. The clinical team will be responsible for answering such calls and for ensuring the clinician and the patient connect and begin the actual visit."
75615436|NCT02644837|Device|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
75615437|NCT02644837|Device|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
75615438|NCT02644837|Device|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
75615439|NCT02644837|Device|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
75615440|NCT02964585|Drug|Canagliflozin|100 mg
75908933|NCT04105777|Device|Parenteral Nutrition Bag Eurotube|7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.
75908934|NCT04105777|Device|Parenteral Nutrition 2/3 chamber Bag|Premixed 2/3-chamber bags which are eventually completed with other supplements shortly before administration by infusion into the bag.
75615441|NCT02964585|Drug|Placebo|1 tablet daily for 16 weeks
75615442|NCT00637936|Drug|Oxygen|Inspiratory fraction during anaesthesia
75615443|NCT02644603|Procedure|Enhanced Recovery After Surgery|"Before operation:~Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.~In operation:~Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.~After operation:~Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization."
75908935|NCT04104945|Radiation|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
76072420|NCT00089024|Drug|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 & 2; Repeat one 3-week cycle starting day 22
75615444|NCT02640703|Biological|Infanrix + Prevenar 13|Different time of application
75615445|NCT00630279|Drug|Placebo|Placebo
75615446|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
75615447|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
75615448|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
75767518|NCT03941626|Biological|CAR-T/TCR-T cells immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
75767519|NCT01211002|Radiation|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
75908936|NCT04063722|Procedure|modified Benelli procedure|use of modified Benelli procedure for surgical treatment of gynecomastia
75908937|NCT04020458|Procedure|dental intervention|"Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
75908938|NCT03978520|Drug|Elsubrutinib|Capsule; Oral
75908939|NCT03978520|Drug|Placebo for elsubrutinib|Capsule; Oral
75908940|NCT03978520|Drug|Upadacitinib|Film-coated tablet; Oral
75908941|NCT03978520|Drug|Placebo for upadacitinib|Film-coated tablet; Oral
75908942|NCT03968328|Other|Interview|Take part in interview
75908943|NCT03968328|Other|Survey Administration|Respond to survey
75908944|NCT03962127|Other|no intervention|no intervention
75908945|NCT03947957|Diagnostic Test|collection of expectoration, stools and blood|collection of expectoration, stools and blood
75908946|NCT03941743|Drug|Fingolimod|Given PO
76071569|NCT04533412|Behavioral|Self-management barrier support|For the intervention, community health workers will assess barriers to good self-management behaviors that lie within 4 domains: 1) social context, 2) physical health and functioning, 3) cognitive factors, and 4) psychological factors. They will work with participants for 6 months to help them work through their barriers to self-management of COPD. Participants can also participate in home-based pulmonary rehabilitation and can receive emergency pack/action pack medication for COPD exacerbations.
75908947|NCT03941743|Drug|Fingolimod Hydrochloride|Given PO
76072421|NCT00089024|Drug|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
75317318|NCT04717726|Dietary Supplement|Milk Thistle (MT)|Participants in the MT and EX + MT groups will be provided 900 mg of standardized milk thistle extract daily (300 mg three times per day before meals) over the 12-week regimen. We will use the standardized Jarrow Formulas Milk Thistle Veggie Caps containing 30:1 extract that is standardized to contain 80% total Milk Thistle seed flavonoids (polyphenols), including the critical Silymarin fractions isosilybinins A and B, silybinins A and B, silychristin and silydianin that is active against suppressing the UGT1A1 enzyme increasing plasma bilirubin. The capsules are free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Rationale for using this brand: There have been inconsistencies with previous studies that did not use a standardized silymarin extract, which may have contained low levels of the active polyphenolic flavonoids in the milk thistle plant, which varies in the plant's stems, leaves, roots, and flowers.
75462303|NCT01862692|Behavioral|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
75615449|NCT03850522|Biological|PD-L1 peptide|PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
75908948|NCT03941743|Other|Questionnaire Administration|Ancillary studies
76072422|NCT00089024|Drug|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
75615450|NCT02640781|Procedure|self-expandable metal stent insertion(covered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
75908949|NCT03929393|Behavioral|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
75908950|NCT03929393|Other|Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
75908951|NCT03899259|Drug|Baricitinib|Administered orally
75908952|NCT03899259|Drug|Placebo|Administered orally
75908953|NCT03896685|Drug|Bedaquiline 100 MG|Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
75908954|NCT03896685|Drug|Delamanid 50 MG Oral Tablet|Delamanid: 100 mg BID
75908955|NCT03896685|Drug|Clofazimine 100 MG Oral Capsule|Clofazimine: 100 mg QD
75908956|NCT03896685|Drug|Linezolid 600Mg Tab|Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
75908957|NCT03896685|Drug|Control arm MDR-TB regimen, designed according to latest WHO guidelines|Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
75908958|NCT03874715|Drug|Insulin Aspart SAR341402|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
75767520|NCT01211002|Drug|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 ~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
75767521|NCT01211080|Drug|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
75908959|NCT03874715|Drug|Insulin Aspart|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
75908960|NCT03874715|Drug|Insulin glargine U100|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
75908961|NCT03801863|Procedure|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
75908962|NCT03801863|Drug|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
75908963|NCT03801356|Drug|Selective Nerve Root Block|Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
75908964|NCT03786003|Procedure|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
75908965|NCT03786003|Procedure|Thoracotomy|Standard thoracotomy
75908966|NCT03664037|Drug|Dexamethasone phosphate|each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline [NS]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
76072423|NCT00089024|Procedure|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
75317319|NCT04717726|Dietary Supplement|Lactobacillus Gasseri (LAC)|Participants in the LAC and LAC + EX groups will receive two doses of 3 billion CFU of lactobacillus gasseri per day for a total of 6 billion CFU, the recommended upper level for supplementation of probiotic cultures. We will use Swanson brand Lactobacillus gasseri, whose capsules are also free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Importantly, this brand uses acid-resistant designed release capsules to improve the viability of the lactobacillus in the human stomach.
75767522|NCT01116700|Drug|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
75767523|NCT01113346|Drug|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
75767524|NCT01113346|Drug|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
75767525|NCT01113424|Drug|Nicotine|Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
75908967|NCT03664037|Drug|Placebo|each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
75908968|NCT03659981|Other|MRI 7T|The imaging parameters will come from the 7 Tesla Siemens MRI
75317320|NCT04717726|Behavioral|Exercise (EX)|Participants in the EX, EX + MT, and EX + LAC groups will complete five weekly exercise sessions on their own, expending roughly 600 kcal per session. Participants will be provided a Polar A-300 heart rate monitor programmed for their individual attributes (height, weight, age, training status, gender), which gives a real-time estimate of energy expenditure during exercise. Participants will report to the lab once per week to download the exercise sessions and verify compliance. If participants are not compliant (defined as completing 85% of their assigned exercise sessions per month), they will be disqualified. This intervention has been successfully used by Dr. Flack in multiple studies to produce significant weight loss without dietary intervention in this population with a retention rate of over 90%
75462304|NCT01862692|Behavioral|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
75462305|NCT01862705|Other|Thoracic spine manipulation|TSM thrust or non-thrust
75462306|NCT01862822|Other|upright position|
75462307|NCT01862835|Drug|Degarelix|
75767526|NCT01113424|Drug|Nicorette® (Nicotine Gum)|Single-dose of marketed nicotine gum 2 mg or 4 mg
75767527|NCT01211158|Drug|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
75908969|NCT03600779|Device|inhomogeneous Magnetisation Transfer (ihMT) sequence|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
75908970|NCT03600779|Device|inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
75767528|NCT01211158|Drug|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
75767529|NCT03943108|Diagnostic Test|Gait analysis|Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.
75767530|NCT01116778|Biological|eN-Lac®|One capsule with 2x10^9 colony forming unit (cfu) LP GMNL-32, once daily, po
75767531|NCT01116778|Other|Placebo|One placebo capsule, once daily, po
75767532|NCT01110148|Other|video-based informed consent for skin biopsies|video-based informed consent for punch and shave biopsies
75767533|NCT01110148|Other|traditional informed consent|traditional informed consent (standard of care) from physicians for shave and punch biopsies
75767534|NCT01116856|Other|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
75767535|NCT01110226|Drug|KML-001|"KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off."
75767536|NCT01110226|Drug|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
75767537|NCT01211236|Other|application of wound dressing made of bio-bags (vitapads) containing maggots|
75767538|NCT01211236|Other|application of classical hydrogel/alginate wound dressing|
75767539|NCT03789292|Biological|CT-P17 SC|Subcutaneous injection of Adalimumab 40mg every two weeks
76071570|NCT04533412|Behavioral|Basic COPD Education|"The attention control will consist of 4 visits by a COPD educator to the home to review the COPD education booklet. During the first visit, this COPD educator will review the COPD 1-2-3 booklet in its entirety with the patient. During visits 2 and 3, the COPD educator will make a visit to check in with the patient, ask how they are doing with their respiratory symptoms, and review any sections of the COPD 1-2-3 booklet the patient chooses. The COPD educator will recommend visits every 2 months but the patient and COPD educator may choose to modify the interval as needed. If the patient appears to be experiencing worsening respiratory symptoms during any visit, the COPD educator will notify the patient's physician."
76071571|NCT04525014|Drug|RRx-001|RRx-001 will be administered every 3 weeks via intravenous infusion at three dose levels: 0.5 mg/m2 (Max 1 mg), 1 mg/m2 (Max 2 mg), and 2 mg/m2 (Max 4 mg).
76071572|NCT04525014|Drug|Temozolomide|100 mg/m2 (children ≥0.5 m2) or 3 mg/kg (children <0.5 m2) daily for 5 days beginning on day 1 of each cycle
75767540|NCT03789292|Biological|Humira SC|Subcutaneous injection of Adalimumab 40mg every two weeks
75908971|NCT03567356|Other|"MAT-PLUS Helping Hands"|"1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
75908972|NCT03538457|Drug|Paracetamol|Patients are tested for their normal prescription paracetamol medication
75908973|NCT03535376|Drug|Valsartan|Patients are tested for their normal prescription valsartan medication
75908974|NCT03514485|Behavioral|Yes We Can Children's Asthma Program|The Yes We Can Children's Asthma Program intervention is a medical-social model based on a chronic care approach, including risk stratification, clinical care management, social care coordination by a community health worker, and primary care physician asthma champions. This intervention includes asthma education, trigger reduction visits and care coordination. There will be five clinic visits and four home visits over 12 months implemented by the primary care CHW who is integrated into the primary care practice.
76071573|NCT04525014|Drug|Irinotecan|90 mg/m2 taken orally daily for 5 days administered 1 hour after temozolomide
76071574|NCT04524611|Drug|Risankizumab|Intravenous (IV) Infusion
76071575|NCT04524611|Drug|Risankizumab|Subcutaneous (SC) Injection
76071576|NCT04524611|Drug|Ustekinumab|Intravenous (IV) infusion
76071577|NCT04524611|Drug|Ustekinumab|Subcutaneous (SC) injection
76071578|NCT04519580|Diagnostic Test|PET/CT|FDG-PET/CT at baseline, week 8 and week 10.
75317321|NCT04717726|Dietary Supplement|Control (CON)|Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.
75462308|NCT01862835|Drug|Testosterone|
75767541|NCT01212718|Drug|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
75767542|NCT01212718|Drug|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
75767543|NCT01211314|Drug|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
75767544|NCT01113814|Device|FibroScan|
75767545|NCT01113814|Device|Acoustic Radiation Force Impulse (ARFI)- Imaging|
75767546|NCT01211392|Other|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
75767547|NCT01110304|Other|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
75462309|NCT01862835|Drug|Anastrozole|
75767548|NCT01110304|Device|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
75767549|NCT01207960|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
75767550|NCT03942874|Behavioral|Group Reward Retraining|Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated
75767551|NCT02529514|Drug|Baclofen|25 mg for 7 days at 10 pm every day
75767552|NCT02529514|Drug|Placebo|Placebo for 7 days at 10 pm every day
75767553|NCT01208116|Other|Cardiovascular events|"Coronary intervention~Infarction~Congestive heart failure~Stroke~Cardiac death"
75767554|NCT03941002|Diagnostic Test|Assesment of diaphragm function|Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation
75767555|NCT03939130|Dietary Supplement|Fructose|Consumption of 1.0g / kg of body mass / day of fructose.
75767556|NCT03939130|Dietary Supplement|Glucose|Consumption of 1.0g / kg of body mass / day of glucose.
75767557|NCT03939130|Other|Fructose and exercise|Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
75908975|NCT03514485|Behavioral|School-Based Asthma Therapy|School-Based Asthma Therapy includes enhanced care coordination for prescribed daily controller medication. The school nurse will coordinate with teachers and the school CHW to schedule daily controller asthma medication administration. The school CHW will assist in obtaining a current asthma care plan and medication administration form from the primary care provider.
75317322|NCT04715646|Drug|Brivaracetam|"Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses.~Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral~Oral solution Concentration: 10 mg/ml Route of administration: oral"
75462310|NCT01862835|Drug|Estrogen patch|
75767558|NCT01113970|Drug|Indibulin|Indibulin given orally once a day for 5 days followed by a 9 day rest
75767559|NCT01211470|Drug|Daptomycin|Active Comparator: Daptomycin.
76071579|NCT04515147|Biological|CVnCoV 6 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
75317323|NCT04691817|Drug|Atezolizumab|1200mg infusion
75317324|NCT04691817|Drug|Tocilizumab|Tocilizumab 6mg/kg or 4mg/kg infusion
75317325|NCT04673942|Biological|AdAPT-001|Oncolytic virus administered by intratumoral injection
75317326|NCT04673942|Drug|Checkpoint Inhibitor, Immune|Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
75317327|NCT04671485|Other|Standard care|Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
75462311|NCT01862887|Drug|PH-797804|Tablet, 24 mg, single dose
75767560|NCT01211470|Drug|PMX-30063-investigational drug|Experimental: PMX-30063
75767561|NCT01114048|Drug|Thalidomide, cyclophosphamide, dexamethasone, bortezomib|"Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1~28 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D 1~4, 15-18 Repeated every 28 days~Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days~Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration"
75317328|NCT04671485|Other|Autohypnosis|"The patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
75462312|NCT01862887|Drug|Moxifloxacin|Tablet, 400 mg, single dose
75767562|NCT01211548|Other|contrast CTA of the CAP|CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
75767563|NCT01208194|Drug|MGN1703|solution, 60 mg, twice a week, until progression
75462313|NCT01862887|Drug|Placebo|Tablet, PH-797804 matched placebo, single dose
75462314|NCT01862900|Biological|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
75767564|NCT01208194|Drug|Placebo|solution, 60 mg, twice a week, until progression
75767565|NCT01208272|Behavioral|Cognitive Behavioral Therapy (CBT)|
75767566|NCT01208272|Behavioral|Interpersonal Therapy (IPT)|
75767567|NCT01114126|Drug|Neu-P11|comparison of different dosages of drug
75767568|NCT01114126|Drug|Neu-P11 placebo|comparison of different dosages
75767569|NCT03939052|Dietary Supplement|Free amino acids intake|Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
75767570|NCT01208350|Behavioral|No intervention|Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
75767571|NCT01208350|Behavioral|Group-based payout|Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
75767572|NCT01208350|Behavioral|Individual payout|Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
75767573|NCT03939208|Behavioral|BRISC|
75767574|NCT03939208|Behavioral|SAU|
75767575|NCT01213030|Drug|[F-18] FMISO|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
75767576|NCT01213030|Drug|[F-18] HX4|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
75767577|NCT01208428|Behavioral|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
75767578|NCT01208428|Behavioral|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
75767579|NCT01211626|Drug|ANA773|ANA773 Tosylate Capsule
75767580|NCT01211626|Drug|Placebo|Matching Placebo Capsule
75767581|NCT01211704|Drug|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
75767582|NCT01211704|Drug|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
75317329|NCT04671485|Other|Musicotherapy|"the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
75317330|NCT04646668|Combination Product|E-cigarette and Heat not burn|Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
75317331|NCT04641351|Drug|Zilretta Injectable Product or Placebo|The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
75317332|NCT04622293|Drug|Solriamfetol Oral Tablet [Sunosi]|Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
75317333|NCT04622293|Drug|Placebo|A placebo encapsulated to look the same as the experimental drug will be given to the control group.
75317334|NCT04603300|Drug|INT301|INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
75317335|NCT04603300|Drug|Placebo|Fully functional toothpaste containing no immunotherapy agents
75767583|NCT02529670|Procedure|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
75767584|NCT02529670|Procedure|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
75317336|NCT04594811|Drug|NT-I7|Administered by intramuscular (IM) injection.
75317337|NCT04594811|Drug|Nivolumab|Administered by intravenous (IV) injection.
75317338|NCT04593056|Drug|Warfarin|Warfarin dispensing claim is used as the reference
75767585|NCT02529670|Procedure|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
75767586|NCT03939286|Other|Clinical-neurological and neuropsychological tests|The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
75767587|NCT03939286|Diagnostic Test|Blood sampling|Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.
75767588|NCT03939286|Other|Assessment of physical activity via fitness tracker/diary|All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.
75317339|NCT04593056|Drug|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure
75317340|NCT04588051|Drug|Cabozantinib|60mg daily
75767589|NCT03939286|Other|MRI-examinations|Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
75767590|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
75767591|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
75767592|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
75767593|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
75767594|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
75767595|NCT01208506|Drug|placebo|A single dose of NNC0114-0000-0005 placebo.
75767596|NCT03938896|Other|platelet rich plasma|Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged
75767597|NCT03938896|Other|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
75767598|NCT01208584|Other|fMRI, DTI|functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
75767599|NCT01213108|Behavioral|Örebro prevention program|6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth
75767600|NCT01213108|Behavioral|Business as usual|Regular alcohol prevention activities and curricula in Swedish schools
75767601|NCT03938818|Behavioral|Tu'Washindi intervention|"The intervention includes the following components:~PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders."
75767602|NCT03938818|Other|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
75767603|NCT03938506|Other|cuff pressure of the endotracheal tube|The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
75767604|NCT01117636|Drug|Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter [mL]) between 14 hours post dental surgery.
75767605|NCT01117636|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
75767606|NCT01117636|Drug|Placebo|Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
75767607|NCT03938740|Drug|HDV-Insulin Lispro and Insulin Degludec (-40%)|HDV-Insulin Lispro and Insulin Degludec (-40%)
75908976|NCT03514485|Behavioral|Open Airways for School Plus|"Open Airways for Schools Plus was designed to improve the asthma self-management skills in children and enhance control of asthma in the school. The school intervention includes:~Open Airways for Schools curriculum for all students with asthma. Classes will be conducted by the school CHW once each semester.~Environmental classroom assessments conducted by school CHWs for students enrolled in the study. These teachers will receive classroom supplies to create a more asthma-friendly classroom environment.~Asthma education for school staff/personnel at the start of each school year.~School facility walk-through assessments to detect potential environmental asthma triggers will be conducted by the School District of Philadelphia."
75908977|NCT03502200|Device|JUUL|Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.
75908978|NCT03502200|Other|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.
75908979|NCT03336242|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
75908980|NCT03334435|Drug|Baricitinib|Administered orally
75908981|NCT03334435|Drug|Placebo|Administered orally
75908982|NCT03333395|Drug|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
76071580|NCT04515147|Biological|CVnCoV 12 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
76071581|NCT04515147|Biological|Hepatitis A vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
76071582|NCT04515147|Biological|Pneumococcal vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
76071583|NCT04515147|Biological|CVnCoV 12μg|Participants will receive an intramuscular injection by needle in the deltoid area.
75767608|NCT03938740|Drug|HDV-Insulin Lispro and Insulin Degludec (-10%)|HDV-Insulin Lispro and Insulin Degludec (-10%)
75767609|NCT01213186|Drug|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5*10E6/kg for 48 weeks.
75767610|NCT01213186|Drug|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5*10E6/kg for 48 weeks.
76071584|NCT04511494|Dietary Supplement|Peanut (bamba)|OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
75767611|NCT01117714|Procedure|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
75767612|NCT01110616|Drug|MK3134|MK3134, 25 mg tablets (5 x 5 mg capsule), orally
75767613|NCT01110616|Drug|Comparator: Lorazepam|Lorazepam, 2 mg (2 x 1 mg tablet), orally
75767614|NCT01110616|Drug|Comparator: Placebo|Placebo, to match MK3134, and placebo to match Lorazepam
75317341|NCT04566380|Drug|ONO-4538|IV infusion over 30 minutes
75317342|NCT04566380|Drug|oxaliplatin|IV infusion over 2 hours
75317343|NCT04566380|Drug|S-1|Administered orally twice daily
75317344|NCT04566380|Drug|capecitabine|Administered orally twice daily
75615451|NCT02640781|Procedure|self-expandable metal stent insertion(uncovered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
75615452|NCT02963025|Procedure|PEEP level|
75615453|NCT02963025|Procedure|Use of recruitment maneuvers|
75317345|NCT04566380|Drug|bevacizumab|IV infusion over 30 minutes
75317346|NCT04566380|Drug|temozolomide|Administered orally once daily for 5 days every 28 days
75615454|NCT00651781|Drug|Bortezomib|2 times per week of Velcade administration.
75615455|NCT04166617|Other|Conventional therapy|conventional physcial therapy rehabilitation for the upper limb
75317347|NCT04561180|Drug|EG-009A|Administered as an Intramuscular injection
75317348|NCT04561180|Drug|EG-009A Placebo|Administered as an Intramuscular injection
75317349|NCT04561180|Drug|Standard of Care|Standard of Care Treatment for COVID-19 Infection
75462315|NCT01862913|Other|Computer-assisted cognitive-behavioral therapy|The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
75462316|NCT01862913|Other|Usual care treatment|The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
75615456|NCT04166617|Other|Leap motion plus conventional therapya|leap motion plus conventional physcial therapy rehabilitation for the upper limb
75615457|NCT02646787|Behavioral|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
75615458|NCT02646787|Behavioral|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
75615459|NCT02646865|Behavioral|Self-Compassion Enhanced Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
75615460|NCT02646865|Behavioral|Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol
75615461|NCT00957801|Drug|Testosterone injection|100 mg single IM injection
75615462|NCT00957801|Drug|Testosterone gel|Testosterone gel 10 mg. administered topically daily for seven days
75615463|NCT00957801|Drug|Medrol|Medrol 6 day dose pack with an additional 4mg dose on day 7
75615464|NCT02640469|Other|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
75615465|NCT02640469|Other|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
75767615|NCT01117246|Device|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
75767616|NCT03938662|Dietary Supplement|formulation containing S-Adenosyl methionine and choline|Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.
75767617|NCT03938662|Dietary Supplement|Placebo|Placebo of same appearance, colour and taste,
75908983|NCT03333395|Drug|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
75317350|NCT04561180|Drug|Dexamethasone|The comparator, Administered as an Intravenous infusion
75317351|NCT04560023|Other|Exposition to multimedia content|Video and images watched on a tablet. Patient could decide which information want to watch.
75317352|NCT04546555|Device|Dual chamber pacemaker|Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.
75462317|NCT01862926|Drug|Rituximab|
75462318|NCT01862926|Drug|Cyclophosphamide|
75462319|NCT01862939|Drug|DS-7309|1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
75317353|NCT04546555|Other|Accelerated Physiologic Pacing|The lower rate limit will be programmed to an individualized heart rate.
75317354|NCT04546555|Other|Nocturnal Pacing|In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.
75462320|NCT01862939|Drug|placebo|placebo to match part 2 DS-7309
75462321|NCT01862965|Drug|PredEver|Firstline treatment with prednisone and Everolimus
75462322|NCT01862978|Drug|Heparin|
75462323|NCT01862978|Drug|Nadroparin|
75462324|NCT01862978|Drug|Placebo|
75462325|NCT01863004|Drug|Bortezomib|
75462326|NCT01863069|Drug|Interferon beta 1a|
75462327|NCT01863069|Drug|(IM) AVONEX®|
75462328|NCT01863082|Other|exercise|practice of physical exercise
75462329|NCT01863095|Behavioral|Personalized Feedback and Exercise|
75462330|NCT01863108|Biological|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
75615466|NCT02640469|Other|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
75767618|NCT01110772|Device|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
75767619|NCT01110772|Device|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
75767620|NCT01213420|Other|Nivea Cream for scar hydration|3 applications per day during 6 months
75767621|NCT01213420|Other|Aloë Vera FORMULA F-BC-096 for scar hydration|3 applications per day during 6 months.
75767622|NCT01213420|Other|Eucerin Calming cream for scar hydration|3 applications per day during 6 months
75767623|NCT01213420|Other|Aloë Vera with modified preservative for scar hydration|3 applications per day during 6 months
75767624|NCT01117402|Radiation|Radiotherapy|"Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.~Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions."
75767625|NCT01118104|Other|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
75767626|NCT03938428|Other|Survey|Patients who are eligible for this study will have been previously identified as part of the PREFACES project. The pharmacist who has conducted the clinical medication review will obtain verbal permission from the patient to be contacted by the research study team. This will be documented on the referral outcome document that is returned to the YAS clinical team. A member of YAS clinical staff from the PREFACES project will forward the name and residential address of patients who have agreed to be contacted to the research paramedic for this study. A covering letter, participant information sheet, questionnaire and consent form, will be posted to potential participants. A stamped addressed envelope will be included to enable return of the completed booklet at no costs to participants.
75767627|NCT01110928|Drug|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
75767628|NCT01213498|Drug|Atorvastatin|Zarator, 80 mg pr. day for 5 days
75767629|NCT01213498|Drug|Unikalk|1 tablet Unikalk pr day for 5. days
75767630|NCT01213342|Dietary Supplement|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~EPA (Eicosapentaenoic Acid) 1300mg~DHA (Docosahexaenoic Acid) 900 mg~Other Omega-3's 360mg~Total Omega 3's 2560 mg"
75767631|NCT01213342|Dietary Supplement|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
76071585|NCT04493411|Procedure|WBMRI|"WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~Baseline: (before or after 1-2 cycles of induction therapy)~Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~Between Week 24 - 36 (before starting maintenance therapy)~Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
75317355|NCT04504396|Drug|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
75317356|NCT04504396|Drug|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
75317357|NCT04504370|Drug|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
75317358|NCT04504370|Drug|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
75317359|NCT04500665|Drug|Colchicine|Colchicine
75317360|NCT04500665|Drug|Placebo|Placebo
75317361|NCT04500223|Other|Cervical Cranioflexion exercise plus cardiopulmonary exercise|Intervention:Cervical Cranioflexion exercise plus cardiopulmonary exercise
75317362|NCT04500223|Other|Cervical stretch exercise plus cardiopulmonary rehabilitation|control:Cervical stretch exercise plus cardiopulmonary rehabilitation
75615467|NCT02640391|Other|colonoscopy|
75615468|NCT02646709|Drug|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
75615469|NCT02646709|Drug|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
75615470|NCT02646709|Drug|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
75615471|NCT02646709|Drug|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
75615472|NCT00651859|Drug|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
75317363|NCT04495881|Drug|Sitagliptin 100mg|Sitagliptin 100mg Qd
75615473|NCT00651859|Drug|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
75908984|NCT03328104|Drug|Everolimus|Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.
75908985|NCT03328104|Drug|Nelarabine|650 mg/m2 IV daily x Day 1-5
75317364|NCT04486625|Drug|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
75317365|NCT04486625|Drug|Aztreonam-Avibactam|675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours
75317366|NCT04479423|Procedure|Soda-water instead of pure water to observe gastric filling|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of 2L polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at hospital in the morning after an over night fast (>8hours). Then they would be randomly assigned to controll group or soda group. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg simethicone. During the period, patients were asked to have a proper walk to wash out bubbles. An additional 900ml pure water or 400ml soda-water was drunk to obtain good vision before undergoing MCE examination.
75317367|NCT04476017|Drug|SAGE-718|Oral tablets.
75767632|NCT01111006|Device|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
75767633|NCT01121614|Device|LOTUS|Device used to seal blood vessel
75767634|NCT01121614|Device|Ethicon Harmonic Scalpel|
75767635|NCT01121614|Device|LigaSure bipolar vessel sealing device|
75767636|NCT01111084|Drug|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
75767637|NCT01121692|Behavioral|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
75767638|NCT01121692|Behavioral|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
75767639|NCT01121692|Behavioral|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
75767640|NCT01213810|Biological|Zostavax|Biological/Vaccine
75767641|NCT01215760|Other|Training with a mirror|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
75908986|NCT03328104|Drug|Cyclophosphamide|440 mg/m2 IV x Day 1-5
75908987|NCT03328104|Drug|Etoposide|100 mg/m2 IV x Day 1-5
75908988|NCT03327519|Behavioral|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
75615474|NCT00651859|Drug|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
75767642|NCT01215760|Other|No mirror therapy|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
75767643|NCT03937492|Other|GMI protocol|"This group follow GMI program split in 3 step:~left/right descrimination~visual motor imagery~mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
75767644|NCT03937492|Other|Standard Rehabilitation Protocol|"This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
75767645|NCT02529592|Biological|Endotoxin|
75908989|NCT03327519|Behavioral|Emmi|The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
75908990|NCT03300284|Behavioral|Questionnaires|Quality of Life Questionnaires
75908991|NCT03260400|Device|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
75908992|NCT03239496|Biological|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
75908993|NCT03239496|Biological|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
75908994|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
75767646|NCT02529592|Biological|Placebo|
75317368|NCT04453917|Biological|Collection of blood and urine|Collection of blood (47 mL) and urine (5 mL) at PML diagnosis and 1, 3 and 6 months after, for analysis of immune checkpoint molecules expression, detection of antiviral immune responses and virological analyses.
76071586|NCT04493411|Procedure|Positron Emission Tomography/Computed Tomography (PET/CT)|"PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~Baseline: (before or after 1-2 cycles of induction therapy)~Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~Between Week 24 - 36 (before starting maintenance therapy)~Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
76071587|NCT04493177|Behavioral|Educational intervention|Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.
75767647|NCT01118260|Procedure|total intravenous anaesthesia|propofol and remifentanil
75767648|NCT01118260|Procedure|spinal anaesthesia|bupivacaine and fentanyl
75767649|NCT01121770|Drug|fondaparinux sodium injection|1.5mg subcutaneously every day
75317369|NCT04453917|Biological|Spinal tap|Spinal tap for monitoring of JC viral load at PML diagnosis and 1, 3 and 6 months after, and collection of CSF (2 mL) for virological analyses.
75615475|NCT02962557|Device|NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake|The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
75317370|NCT04453917|Diagnostic Test|Brain MRI|Brain MRI at at PML diagnosis and 3 and 6 months after
75317371|NCT04453917|Biological|Neurological evaluation|Neurological evaluation at PML diagnosis and 1, 3 and 6 months after
75317372|NCT04444765|Other|Collection of clinical and biological data during renal replacement therapy sessions|Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).
75462331|NCT01863147|Drug|Sitagliptin and acarbose|Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
75615476|NCT02955823|Drug|Rituximab-Dexamethasone-Lenalidomide|"st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~if <PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~if <PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
75615477|NCT02644447|Biological|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
75767650|NCT01118416|Behavioral|HIV prevention intervention randomized control trial|Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
75767651|NCT01121848|Drug|Leucovorin|"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:"
75767652|NCT01121848|Drug|OXALIPLATIN|"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:"
75767653|NCT01121848|Drug|5-Fluorouracil|"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:"
75767654|NCT01122004|Drug|Pregabalin|
76071588|NCT04493177|Other|Conventional treatment Guia de Practica Clinica IMSS-029-08|Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.
75462332|NCT01863160|Drug|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (0.1%)~Left arm, single treatment area - Placebo cream"
75767655|NCT01122004|Drug|Pregabalin|
76071589|NCT04491877|Biological|RSV vaccine formulation 1|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
76071590|NCT04491877|Biological|RSV vaccine formulation 2|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
76071591|NCT04491877|Biological|Placebo|Pharmaceutical form: Suspension Route of administration: Intranasal
76071592|NCT04479618|Device|Usual Practice|A saline soaked piece of gauze, conformed to the size of the open ulcer area, will be placed over the ulcer and held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
75317373|NCT04433234|Drug|DS-5141b|Administered via subcutaneous injection once weekly
75317374|NCT04422639|Radiation|SRS/SRT|Comparing pre-operative SRS/SRT to post-operative SRS/SRT
75615478|NCT02644447|Biological|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
75615479|NCT02646631|Other|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
75767656|NCT03933982|Drug|Pyrotinib Plus Vinorelbine|Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
75767657|NCT01118572|Drug|YM177|oral
75767658|NCT01118572|Drug|etodolac|oral
75767659|NCT01118572|Drug|Placebo|oral
75767660|NCT03937648|Drug|COL-144 50mg|COL-144 50mg
75317375|NCT04384107|Biological|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in PCV13 plus 2 additional serotypes (22F, 33F) in each subcutaneous 0.5 mL single dose.
75317376|NCT04384107|Biological|PCV13|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each subcutaneous 0.5 mL single dose.
75462333|NCT01863160|Drug|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream"
75615480|NCT02646631|Behavioral|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
75615481|NCT02646631|Behavioral|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
75767661|NCT03937648|Drug|COL-144 100mg|COL-144 100mg
75462334|NCT01863173|Drug|metoprolol|using B blocker in patient group
75462335|NCT01863173|Drug|placebo|placebo to control group
75462336|NCT01863199|Drug|Lucentis (Treat and extend)|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
75462337|NCT01863199|Drug|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
75462338|NCT01863199|Drug|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
75462339|NCT01863212|Procedure|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
75767662|NCT03937648|Drug|COL-144 200mg|COL-144 200mg
75767663|NCT03937648|Drug|COL-144 400mg|COL-144 400mg
75767664|NCT03937648|Drug|Placebo|Placebo
75767665|NCT01219036|Drug|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
75767666|NCT01124500|Drug|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
75767667|NCT01216306|Behavioral|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
75615482|NCT02646631|Other|Educational Materials|Printed educational materials on the management of epilepsy
75615483|NCT02535793|Other|blood test (four dry tubes 7ml) and prick tests|
75615484|NCT00957723|Device|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
75615485|NCT02646397|Drug|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
75767668|NCT03937414|Device|The OSNA assay|SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
76071593|NCT04479618|Device|Improvised dressing|A piece of a new food-grade plastic bag, cut slightly larger than the ulcer, will be placed over the ulcer, sealed at the edges with an emollient to create an occlusive dressing. The dressing will be gently conformed to the ulcer contours to eliminate dead space, and a slit will be cut in the center to allow excess fluid to escape into a clean absorbent material placed over the slit. The device will be held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
76071594|NCT04479618|Device|Advanced dressing|A piece of polymeric membrane dressing, cut to extend at least 0.5cm beyond the open ulcer edges, will be placed over the ulcer and held in place with a wrap of stretch gauze. The approximate wound edges will be marked on the back of the dressing. Dressing changes will consist only of removing the dressing when the saturation level, visible through the wound backing, reaches the mark indicating the dressing edges and applying a new cut dressing. Changes will be conducted by the patient after they master the procedure.
76071595|NCT04476238|Dietary Supplement|Inosine|2 grams of inosine dissolved in 250 ml water taken by mouth
75767669|NCT01118884|Drug|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
75767670|NCT01216384|Drug|BI 671800|In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
75767671|NCT01216384|Drug|placebo|Subjects will receive according to the dose group matching number of placebo tablets
75767672|NCT01122082|Behavioral|food preloads|Subjects will eat in the morning during breakfast 300g cottage cheese (627kJ - 147kcal; 13.2g carbohydrate, 0.3g fat, 23g protein) plus, according to the situations, either: 90g sucrose, HCB); 6g aspartame; 40g vegetable oil; 40g paraffin oil. Therefore two breakfast will have the same energy content (2072kJ - 495kcal), as did the other two(565 kJ - 135kcal).
75767673|NCT03933592|Procedure|Serratus anterior block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
75767674|NCT03933592|Procedure|thoracic epidural|In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
75615486|NCT02646397|Drug|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
75767675|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21 every 28 days a cycle
75767676|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21, every 28days a cyce.
75767677|NCT01219192|Drug|M2ES|M2ES 45mg IV D1,8,15,22 28days a cycle
75767678|NCT01219192|Drug|M2ES 60mg|M2ES 60mg IV D1,8,15,22 every 28days a cycle
75317377|NCT04382521|Behavioral|Text Message Intervention|Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
75462340|NCT01863212|Behavioral|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
75767679|NCT01119196|Other|Icodextrin dialysate|use of alternate SOC dialysate
76071596|NCT04476238|Other|Placebo|250 ml water taken by mouth
76071597|NCT04476043|Drug|INCB054707|Oral; Tablet
75462341|NCT01863212|Other|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
75462342|NCT01863225|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
75462343|NCT01863225|Drug|Rosuvastatin|20 mg daily, 28-42 days
75462344|NCT01863225|Drug|Atorvastatin|40 mg daily, 28-42 days
75462345|NCT01863225|Drug|Rosuvastatin|40 mg daily, 28-42 days
75462346|NCT01863225|Drug|Atorvastatin|80 mg daily, 28-42 days
75462347|NCT01863238|Other|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
75462348|NCT01863238|Drug|Ivacaftor Exposed|
75462349|NCT01863251|Drug|Atomoxetine|
75615487|NCT02646397|Drug|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
75615488|NCT00653731|Behavioral|Snoezelen ©|Nursing individual intervention one time a week for 20 minutes
75615489|NCT00653731|Behavioral|structured reminiscence therapy|Individual nursing intervention: one time a week 20 minutes
75767680|NCT01119274|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
75767681|NCT01119274|Other|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
75767682|NCT01119352|Drug|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
75767683|NCT01119352|Drug|Placebo|Oral suspension, once daily. Totally 8 doses
75767684|NCT03935776|Behavioral|Risk Factors Modification Programme|12- week supervised risk factor modification programme derived from the Euroaction study standards
75767685|NCT03935776|Behavioral|Standard Healthcare|Patients are advised to adjust lifestyle without the support of the structured supervised programme
76071598|NCT04476043|Drug|Placebo|Oral; Tablet
76071599|NCT04473534|Behavioral|web based cognitive-behavioral therapy|one web session of psycho-education about sleep
75615490|NCT00653731|Behavioral|10-minutes activation|Individual nursing intervention: two times a week for 10 minutes
75615491|NCT00653731|Behavioral|Unstructured verbal communication|Individual nursing intervention: one time a week for 20 minutes
75615492|NCT02646553|Other|Children refered to the obesity clinic|Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
75615493|NCT04204395|Device|Peanut Ball|The participants in the experimental group will use the peanut ball at least every 2 hours, 30-minute usage for each time. More frequency will be available. Then, the participants will stop using the peanut ball when cervical os is dilated and effaced, may be ready to push.
75767686|NCT01213888|Drug|Trientine Hydrochloride|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
75317378|NCT04334278|Behavioral|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
75767687|NCT01213888|Drug|Oral placebo capsules|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
75615494|NCT02640079|Behavioral|Cognitive behavioral therapy|
75767688|NCT01119430|Drug|DU125530|20mg/twice a day
75767689|NCT01119430|Drug|Placebo|Similar pill as active comparator twice a day
75767690|NCT03781336|Behavioral|Mindfulness-based self care|Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
75767691|NCT02529124|Dietary Supplement|CONTROL|Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
75767692|NCT02529124|Dietary Supplement|PROTEIN|The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
75767693|NCT02529124|Behavioral|PHYSICAL ACTIVITY|A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
75908995|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
75908996|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
75908997|NCT03183037|Procedure|Acupuncture|The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
75908998|NCT03183037|Procedure|Sham Acupuncture|Subjects in this group will receive the sham acupuncture procedure on the same schedule as subjects in the real acupuncture group. In both groups, patients' eyes will be covered with patches so they cannot observe the treatment procedure. To improve incentive to join and stay in the study, we will unblind all patients at Week 12, and offer those randomized to the Sham group 8 weeks of Acu (real) treatment. All points used will be documented.
75908999|NCT03183037|Other|Usual Care Group|Patients go to clinic three times during the study, at Baseline, Week 8, and Week 12 to undergo QST and CPM tests. Patients will complete all questionnaires (CIPN severity by 0-10 11-point numeric rating scale, FACT/GOG-Ntx-11, NPS) and their pain medication use at these time points. Week 4 questionnaires can be completed over the phone. As an incentive for patients to join the study - and for those randomized to control to stay in the study - controls will be offered 8 weeks of Acu (real) treatment once they have completed Week 12 assessments.
76071600|NCT04471844|Device|Optune®|"Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~The study treatment plan will continue for 24 months, if no tumor progression."
75317379|NCT04334278|Behavioral|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth.
75317380|NCT04329728|Drug|AVM0703|Intravenous infusion over ~1 hours
75462350|NCT01863264|Other|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
75462351|NCT01863277|Drug|Melatonin|
75615495|NCT02859831|Other|water samples|
75615496|NCT04279353|Other|Mindfulness Based Intervention|this intervention is a 4 weeks program with logbook and follow up during intervention
75462352|NCT01863277|Drug|placebo|
75462353|NCT01863290|Other|Primary care redesign|Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
75462354|NCT01863316|Device|I gel|
75462355|NCT01863316|Device|LMA Supreme|
75462356|NCT01863329|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
75462357|NCT01863342|Procedure|CSI score < 40|
75462358|NCT01863342|Procedure|CSI score ≥ 40|
75615497|NCT02859753|Other|Percutaneous Radiofrequency Ablation|
75767694|NCT03780400|Behavioral|Osteoarthritis Physical Activity Care Pathway|The intervention includes brief physical activity (PA) counseling delivered via phone by a PA Counselor trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA counselor will assess readiness for change in PA and will utilize appropriate PA counseling components to assess participant's PA preferences/needs, as well as referral to PA resources and goal setting. Approximately two weeks after the initial call, the PA counselor will contact participants to check in on whether they have successfully connected with PA programs or resources discussed, review progress toward PA goals and set new goals. Participants will be provided with linkage to PA programs and resources to include: self-directed, group classes/community, physical therapy and other clinical/supervised programs. Three months after the initial call, the PA counselor will call participants to assess PA and stage of change using appropriate PA counseling components and goal setting.
75767695|NCT03780244|Device|Sculptra Aesthetic 8ml|Treatment of nasolabial folds
75767696|NCT03780244|Device|Sculptra Aesthetic 5ml|Treatment of nasolabial folds
75767697|NCT03937336|Behavioral|Bike Intervention Group|A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
75767698|NCT01119586|Genetic|DNA analysis|
75767699|NCT01119586|Genetic|genetic linkage analysis|
75767700|NCT01119586|Genetic|microarray analysis|
75767701|NCT01119586|Genetic|nucleic acid sequencing|
75767702|NCT01119586|Genetic|polymerase chain reaction|
75767703|NCT01119586|Genetic|polymorphism analysis|
75767704|NCT01119586|Other|laboratory biomarker analysis|
75767705|NCT01119664|Drug|SCH 721015|
75767706|NCT01216618|Device|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
76071601|NCT04471818|Drug|Ketamine|Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
75462359|NCT01863355|Drug|B0 group: bolus 0.6mcg/kg without background infusion|
75615498|NCT02859753|Other|Percutaneous Microwave Ablation|
76071602|NCT04471818|Other|Placebo|Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
75462360|NCT01863355|Drug|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
75615499|NCT04282863|Procedure|RM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.
75462361|NCT01863355|Drug|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
75462362|NCT01863381|Device|Tympanic membrane displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.~Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device."
75767707|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
75767708|NCT01119742|Drug|Butenafine Hydrochloride 1% B|Twice daily application for 7 days
75767709|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
75767710|NCT01119742|Drug|Vehicle A|Twice daily application for 7 days
75767711|NCT01119742|Drug|Vehicle B|Twice daily application for 7 days
75767712|NCT01119820|Other|Tissue Donation|Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
75767713|NCT01219348|Biological|IDO peptide vaccination|Vaccination every second week
75767714|NCT01216696|Drug|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
75767715|NCT01119976|Behavioral|Reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
75767716|NCT01119976|Behavioral|Different reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
75767717|NCT01216774|Other|Strength training|"Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM"
75767718|NCT03935386|Procedure|Standard Multi-layered Compression dressing|Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration
75767719|NCT03935386|Procedure|Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)|Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
75767720|NCT03937258|Drug|PF-04965842|Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions
76072424|NCT00089024|Procedure|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 [negative margins] or R1 [positive microscopic margins]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
75317381|NCT04298697|Drug|TDF/FTC Dose Schedule for Arm A|TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on Study Day 1, then one pill per day on Study Days 2 and 3. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
75462363|NCT01863381|Device|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
75462364|NCT01863394|Other|Screening by mothers|
75767721|NCT03937258|Drug|Probenecid|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
75767722|NCT01124656|Drug|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
75767723|NCT01122472|Drug|Lenalidomide|Daily for 3 weeks every 4 weeks for 24 months
75767724|NCT01122472|Drug|Placebo|Daily for 3 weeks every 4 weeks for 24 months
75767725|NCT01214122|Drug|AZD9668|60 mg orally twice daily for 11 days
75767726|NCT01214122|Drug|Warfarin|10 x 2.5 (25) mg orally once daily on day 1 and on day 14
75462365|NCT01863394|Other|Active comparator: Screening by community health workers|
75767727|NCT03935152|Drug|Dydrogesterone|dydrogesterone capsule
75767728|NCT03935152|Drug|placebo|placebo capsule
75767729|NCT01216852|Drug|Losartan Potassium|100 mg tablet
75767730|NCT03936868|Procedure|Tendon transfer|flexor carpi radialis transfer in most of patients and boye-transfer in very few
75767731|NCT03936946|Behavioral|Audio Content 1|~30 minute daily audio recordings of content 1 for 28 days
75767732|NCT03936946|Behavioral|Audio Content 2|~30 minute daily audio recordings of content 2 for 28 days
75767733|NCT01124812|Other|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|"Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:~Cohorts 1, 2 & 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 & 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 & 3. Treatment cycles will be repeated every 28 days.~Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.~Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).~Total treatment duration is 8-16 weeks"
75767734|NCT01328860|Biological|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
75767735|NCT01216930|Other|Observation|Observation
75767736|NCT01124968|Other|eConsulta|It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
75767737|NCT03933748|Drug|Teicoplanin-PMMA|Therapeutic drug monitoring of teicoplanin
75767738|NCT01120132|Drug|CsA high dose|Solution of Cyclosporine (high dose) administered during 28 days
75462366|NCT01863407|Drug|DAM|composed of dexamethasone, allantoin and metronidazole
75462367|NCT01863407|Drug|Normal Saline|Normal Saline 250ml
75462368|NCT01863420|Radiation|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
75767739|NCT01120132|Drug|CsA low dose|Solution of Cyclosporine (low dose) administered during 28 days
75767740|NCT01120132|Drug|PA|Suspension of Prednisolone Acetate administered during 28 days
75767741|NCT01120132|Drug|Placebo|Placebo solution administered during 28 days
75767742|NCT01120288|Drug|EZN-2968|
75462369|NCT01863459|Drug|Lisdexamfetamine Dimesylate|
75462370|NCT01863459|Drug|placebo|
75462371|NCT01863472|Device|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
75462372|NCT01863472|Device|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
75462373|NCT01863485|Drug|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
75462374|NCT01863511|Drug|loop diuretic|
75462375|NCT01863511|Drug|tolvaptan|
75767743|NCT01214278|Drug|rTG|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
75767744|NCT01214278|Drug|GArTG|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
75767745|NCT01214278|Drug|EE|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
75317382|NCT04298697|Drug|TDF/FTC Dose Schedule for Arm B|TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will be on a weekly dosing schedule of 2 pills on the first day, followed by one pill per day for the next two days. They will follow this dosing schedule for four weeks. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
75462376|NCT01863511|Procedure|ultrafiltration|
75462377|NCT01863537|Behavioral|Multimedia Connect|
75462378|NCT01863537|Behavioral|Traditional Connect|
75462379|NCT01863576|Dietary Supplement|Omega-3|The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.
75767746|NCT01214278|Drug|KPL|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
75767747|NCT01217008|Biological|GRNOPC1|One injection of 2 million GRNOPC1 cells.
75767748|NCT01120366|Drug|Tocilizumab plus methotrexate|Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
76071603|NCT04464434|Procedure|Upfront autologous HSCT|"HSCT comprises the following consecutive steps:~Mobilisation~Infusions of CYC 2g/m2 on 1 day.~Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10^6 CD34+ cells per kilogram body weight.~Conditioning~CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10^6/kg."
75317383|NCT04291651|Other|Survey|There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.
75767749|NCT01120366|Drug|Tocilizumab|tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
75462380|NCT01863576|Dietary Supplement|Placebo Comparator|The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.
75462381|NCT01863589|Drug|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
75462382|NCT01863602|Drug|Lamotrigine tablets|Administered for long-term according to the prescribing information in the locally approved label by the authorities.
75767750|NCT01219426|Other|Filling of three questionnaires|The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
75767751|NCT01217086|Drug|Infliximab|Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
75767752|NCT01217164|Dietary Supplement|no intervention|received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
75767753|NCT03933436|Other|Iodine swabs.|Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
75767754|NCT03933436|Other|Saline flush.|Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
75767755|NCT01120444|Device|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
75767756|NCT01120444|Device|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
75767757|NCT03934996|Other|Runners with educational training|"Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics"
75767758|NCT01214512|Other|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
76071604|NCT04463914|Behavioral|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
76071605|NCT04463914|Behavioral|Behavioral Activation Therapy app + EHR|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. The participant's primary care provider at MUSC will be provided access to a Moodivate provider portal that was developed by study team. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
75317384|NCT04275089|Device|Reia Vaginal Pessary|Reia Vaginal Pessary
75462383|NCT01863615|Drug|Isotretinoin 40 mg|Roaccutan 2 capsules of 20 mg; reference drug
75462384|NCT01863615|Drug|Isotretinoin 40 mg|Oratane 2 capsules of 20 mg; test drug
75615500|NCT04282863|Procedure|LM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
75317385|NCT04260698|Biological|omidubicel|hematopoietic stem cell transplant
75462385|NCT01863628|Other|aerobic exercise|
75462386|NCT01863628|Other|psychoeducation|
75462387|NCT01863641|Drug|calcitriol|Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
75462388|NCT01863641|Drug|placebo|Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
75462389|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Reference product
75462390|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Test product
75615501|NCT00652795|Drug|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
75615502|NCT00652795|Drug|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
75462391|NCT01863706|Drug|Misoprostol|400µg oral misoprostol
75615503|NCT03778021|Behavioral|Behavioral Gardening Exposure|Assistance provided with planting and maintaining the school garden
75767759|NCT01217320|Dietary Supplement|creatine|5g/d throughout 12 weeks
75767760|NCT01217320|Dietary Supplement|placebo (dextrose)|5g/d throughout 12 weeks
75615504|NCT03778021|Behavioral|Healthy Eating and Gardening Curriculum|14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
75767761|NCT03936712|Dietary Supplement|Energy Drink|Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.
75767762|NCT03936712|Dietary Supplement|Placebo Drink|The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
75767763|NCT01214590|Device|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
75767764|NCT02529046|Dietary Supplement|CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
75767765|NCT02529046|Behavioral|Placebo|Placebo group received 4 g/day of olive oil. Aerobic exercise
75767766|NCT01217398|Biological|bevacizumab|
75462392|NCT01863706|Drug|Oxytocin|20 IU Oxytocin
75462393|NCT01863719|Drug|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
75462394|NCT01863719|Drug|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
75462395|NCT01863784|Drug|JNJ-38518168|All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
75767767|NCT01217398|Drug|temozolomide|
75462396|NCT01863797|Other|Early induction|
75767768|NCT01217398|Genetic|polymorphism analysis|
75767769|NCT01217398|Other|pharmacogenomic studies|
75767770|NCT01125124|Drug|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
75767771|NCT01214746|Drug|Placebo|1 tablet Unikalk 1 time pr day for 5 days
75767772|NCT01214746|Drug|Atorvastatin|Zarator, 80 mg pr day for 5 days
75767773|NCT03935074|Drug|intra-arterial administration of melphalan|
75462397|NCT01863797|Other|Expectant mamagement|
75767774|NCT01120522|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
75767775|NCT01125280|Procedure|Conservative treatment versus surgical treatment|Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
75767776|NCT01217632|Drug|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
75767777|NCT01217632|Drug|Placebo|Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
75767778|NCT01217632|Drug|Entecavir|
75767779|NCT01122628|Device|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
76071606|NCT04463914|Behavioral|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
76071607|NCT04454658|Drug|ABBV-744|Tablet; Oral
75462398|NCT01863810|Drug|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
75462399|NCT01863810|Drug|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
75462400|NCT01863810|Drug|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
75615505|NCT00911170|Drug|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
75615506|NCT00911170|Drug|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
75615507|NCT00911170|Biological|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
75615508|NCT00911170|Drug|Standard Chemotherapy|"Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil."
75909000|NCT03183037|Behavioral|questionnaires|FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
76071608|NCT04454658|Drug|Navitoclax|Tablet; Oral
75462401|NCT01863810|Drug|Placebo of KW21052|Oral,once a day, for 8 weeks
75462402|NCT01863810|Drug|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
75462403|NCT01863823|Drug|Amoxicillin and Tetracyclines|202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
75462404|NCT01863823|Drug|Mouth washing|Two time washing mouth per day
75462405|NCT01863836|Procedure|Fluoroscopy|
75462406|NCT01863836|Procedure|Radial EBUS-guided biopsy|
75767780|NCT01217710|Behavioral|Activity monitor/smartphone health coaching|Initial health coaching at enrollment will involve the collaborative creation of an action plan with personally relevant, specific actions for increasing physical activity. The short term goals will be rated for self-efficacy and modified to maximize likelihood of success. Health coaches will discuss important mediators of physical activity (e.g., self-efficacy, enjoyment, social support, problem-solving). Weekly coaching calls will involve discussion of progress toward goals and problem-solving of barriers utilizing a motivational interviewing approach. Motivational messages will also be developed and sent daily to participants via the smartphone. These messages will indicate the percentage of steps related to their daily goal.
75767781|NCT03933280|Drug|Nalbuphine|i.v. nalbuphine bolus of 50 μg/kg.
75767782|NCT03933280|Drug|Propofol|A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min
75767783|NCT03933280|Drug|Dexmedetomidine|i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.
75767784|NCT03933280|Drug|Benoxinate Hydrochloride 0.4% Eye Drops|Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
75767785|NCT01217788|Drug|PH94B intranasal spray|Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
75767786|NCT03933514|Other|Plaque control|Children were instructed about the hygiene procedures
75767787|NCT03936556|Drug|Marketed toothpaste|Marketed stannous fluoride (0.454%) toothpaste
75767788|NCT03936556|Drug|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
75767789|NCT01120912|Drug|Oshadi Oral Insulin|Oral insulin single administration
75767790|NCT01217866|Procedure|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
75767791|NCT01122706|Other|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
75767792|NCT03785548|Other|Usage of a mirror|using a mirror during the pelvic examination
75767793|NCT01219582|Drug|Glucobay M (Acarbose/Metformin, BAY81-9783)|Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
75767794|NCT03934918|Other|Treatment|Patients for IOL are sent home after placement of intracervical balloon
75767795|NCT03933358|Other|Thyroid hormone levels|This is an observational study. Exposure: Different thyroid hormone levels.
75767796|NCT01121068|Other|Blood samplings|About 3.5ml of blood will be drawn from the participants monthly.
75767797|NCT01122940|Drug|Epamin: Reference Drug|Single dose of 75 mg (10 ml in suspension) of Epamin
75767798|NCT01122940|Drug|Phenytoin: Study Drug|Single dose of 75 mg (10 ml in suspension) of Phenytoin
75767799|NCT01214902|Device|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
75767800|NCT01214902|Behavioral|play|play which encourages the use of the hemiplegic hand
75767801|NCT03934762|Biological|Placebo|A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.
75767802|NCT03934762|Biological|Natural Aloe Vera|Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
75767803|NCT03934762|Biological|Aloe vera soup|Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
75767804|NCT01219816|Drug|Epratuzumab|Combination of chemotherapy + Epratuzumab
76071609|NCT04454658|Drug|Ruxolitinib|Tablet; Oral
76071610|NCT04452526|Other|Best Practice|Receive usual care
76071611|NCT04452526|Other|Educational Intervention|Receive educational materials
75767805|NCT01219816|Drug|Epratuzumab|Vincristine + Dexamethasone + Epratuzumab
75767806|NCT01121302|Drug|AZD5213|0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
75767807|NCT01121302|Drug|Placebo|
75767808|NCT01121380|Drug|BL-1021|"BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 & 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results."
75767809|NCT01121380|Drug|1021|1021
75767810|NCT01123096|Procedure|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
75767811|NCT01123096|Other|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
75767812|NCT01125592|Device|IonCLeanse Footbath|Application of an ionic footbath for 30 minutes per week for 4 weeks
75767813|NCT01218022|Drug|Losartan Potassium Tablets|
75767814|NCT01123174|Behavioral|ALGOS algorithm of case management|"If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt."
75767815|NCT01121458|Drug|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP< 80 mmHg), hypertension (SBP>150 mmHg), tachycardia (120 beats per minute), bradycardia (<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
76071612|NCT04452526|Other|Questionnaire Administration|Ancillary studies
76071613|NCT04452526|Other|Reminder|Receive reminder letter
76071614|NCT04434482|Drug|IMP4297(senaparib)|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
75767816|NCT03936322|Device|Minimally invasive fetoscopic repair of MMC|Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
75767817|NCT01215214|Drug|midazolam|midazolam: 3mg iv
75767818|NCT03936166|Drug|CRN01941 Oral Solution|Investigational drug
75615509|NCT02644213|Other|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~simulated road march using a virtual reality environment without additional load~simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~without physical or cognitive load (without march, waiting between performance evaluations) as control."
75767819|NCT03936166|Drug|CRN01941 Oral Capsule|Investigational drug
75767820|NCT03936166|Drug|Placebo Oral Solution|Placebo
75767821|NCT03936166|Drug|Placebo Oral Capsule|Placebo
75615510|NCT00910975|Drug|Peg-interferon-alfa2a (Pegasys)|Peg-interferon-alfa2a 180 µg per week
75767822|NCT01215370|Other|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
75767823|NCT01215370|Other|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
76071615|NCT04433091|Drug|2-Hydroxybenzylamine|2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.
75767824|NCT01215370|Other|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
75317386|NCT04243577|Device|Tele-EaT Sensors|Several iterations of a wearable surface EMG sensors patch and a wearable intra-oral lingual press device that we will develop, will be tested against commercially available wired devices. The wearable sensor patch will be an ultrathin patch with a honeycomb-inspired design that includes sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The wearable intra-oral device will integrate a wireless intraoral sensor system that will allow simultaneous recording of lingual pressure and movement during swallows and lingual tasks in a wireless fashion. Participants will perform standardized swallow tasks with both devices.
75317387|NCT04243577|Device|Conventional Sensors|Conventional sensors will include snap-on wired electrodes and the use of the Iowa Oral Performance Instrument as the control conditions. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
75615511|NCT00910975|Drug|Ribavirin (Copegus)|Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
75615512|NCT04165057|Other|Optimal muscle tension management|including TOF monitor and reversal of neuromuscular blockade agent : sugammadex
75615513|NCT00653887|Other|Biofeedback|4 sessions of biofeedback one session each week
75767825|NCT01215370|Other|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
75767826|NCT01215370|Other|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
75767827|NCT01123252|Dietary Supplement|Lactobacillus casei Shirota (LcS)|Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
75767828|NCT01123252|Dietary Supplement|Placebo|Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).
75767829|NCT01218178|Drug|Sodium bicarbonate plus NAC|154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
75767830|NCT01218178|Drug|Saline hydration plus NAC|0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
75767831|NCT01215448|Dietary Supplement|Wheatgrass juice|110 CC daily od frozen wheatgrass juice in the intervention arm
75767832|NCT03936400|Behavioral|Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy|Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
76071616|NCT04433091|Other|Placebo|Placebo will be given TID for seven days prior to ablation and 28 days post ablation.
76071617|NCT04431518|Drug|JULUCA 50Mg-25Mg Tablet|One dose of JULUCA will be taken daily for up to 14 days
76071618|NCT04419909|Drug|CD19 redirected autologous T cells (CTL019 or CTL119 cells)|Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
75317388|NCT04241601|Drug|Interleukin-2 [IL-2]|Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function
75462407|NCT01863862|Radiation|Radiochemotherapy or radiotherapy|"50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision."
75462408|NCT01863888|Drug|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
75462409|NCT01863888|Drug|cholestyramine|Pharmaceutical form:powder Route of administration: oral
75615514|NCT00653887|Other|Placebo|4 sessions, one each week, of discussion about anorectal disease
75615515|NCT01167881|Drug|BI 10773|Medium dose once daily
75317389|NCT04241601|Other|Placebo Dextrose 5% solution|Placebo Comparator: Dextrose 5% solution
75317390|NCT04200651|Drug|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
75767833|NCT03740854|Other|Pressure Controlled Ventilation|Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
75767834|NCT03740854|Other|Volume Controlled Ventilation|Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
75767835|NCT01125670|Drug|YM150|oral
75767836|NCT03934528|Device|Virtual environment activity|Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
75462410|NCT01863888|Drug|charcoal|Pharmaceutical form:granule Route of administration: oral
75462411|NCT01863914|Drug|Rosuvastatin|Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
75462412|NCT01863927|Other|Research intervention|After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
75767837|NCT01218256|Other|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
75909001|NCT03170258|Device|Neurofeedback (from fMRI and/or EEG)|During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired ~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
76071619|NCT04419831|Diagnostic Test|Yale Stress Pain Test (YSPT)|Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion
75462413|NCT01863966|Other|hot water drinking therapy|Drink 200ml hot water 3min before and after a meal. Swallow food with hot water and drink 200ml hot water before sleep
75462414|NCT01863966|Procedure|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation under endoscope
75462415|NCT01864057|Drug|thiamine hydrochloride 100 mg|
75462416|NCT01864070|Other|TheraSphere|TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
75462417|NCT01864070|Drug|Everolimus|"Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.~Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort."
75462418|NCT01864070|Other|Phone Call|At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
75615516|NCT01167881|Drug|Glimepiride|1-4 mg once daily
75767838|NCT03934450|Drug|RPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
75615517|NCT01167881|Drug|Placebo|Placebo matching BI 10773
75615518|NCT01167881|Drug|Placebo|Placebo matching Glimepiride
75615519|NCT02646085|Drug|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
75767839|NCT03934450|Drug|SPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
75767840|NCT03934450|Drug|Primaquine Phosphate|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
75767841|NCT03934450|Drug|Placebo|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
75767842|NCT01215682|Dietary Supplement|vitamin D|2000 IU/day of vitamin D3 as a once-daily dose
75767843|NCT01215682|Dietary Supplement|placebo|sweetened water
75767844|NCT01222156|Procedure|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
76071620|NCT04419649|Drug|KER-050|KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
76071621|NCT04418843|Procedure|Standard Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
76071622|NCT04418843|Procedure|Cold Snare Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
75462419|NCT01864083|Procedure|Positron Emission Tomography (PET)|
75462420|NCT01864083|Drug|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
75462421|NCT01864083|Procedure|Positron emission mammography (PEM) When available|
75462422|NCT01864083|Procedure|MR|
75462423|NCT01864135|Device|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
75462424|NCT01864135|Device|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
75462425|NCT01864161|Drug|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
75462426|NCT01864161|Drug|Liposomal iron|Sideral forte 30 mg/die
75462427|NCT01864187|Drug|Dexmedetomidine|The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
75767845|NCT01222156|Device|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
75767846|NCT03932188|Behavioral|Mental Health Assessments and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
75767847|NCT03932188|Device|MRI scan|Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
75767848|NCT03932344|Drug|Anakinra|Anakinra according to prescription
75767849|NCT01220050|Drug|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
75767850|NCT01220050|Drug|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
75767851|NCT01123330|Behavioral|Motivational Interviewing|
75909002|NCT03151083|Behavioral|Internet-based Self-help Insomnia Intervention|The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
76071623|NCT04418765|Drug|Eptinezumab|Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)
75317391|NCT04200651|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
75462428|NCT01864213|Drug|Ametop cream|
76071624|NCT04418765|Drug|Placebo|concentrate for solution for infusion, intravenously
75317392|NCT04182113|Device|1 Hz rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
75767852|NCT01123408|Drug|Clozapine|500 mg/day
75767853|NCT01123408|Drug|Olanzapine|20 mg/day
75767854|NCT01123408|Drug|Haloperidol|20 mg/day
76071625|NCT04418167|Drug|JSI-1187|JSI-1187 capsules for oral administration
76071626|NCT04418167|Drug|Dabrafenib|Dabrafenib capsules for oral administration
75317393|NCT04182113|Device|Sham rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
75317394|NCT04162015|Drug|Nivolumab|nivolumab 360 mg
75317395|NCT04162015|Drug|Pemetrexed|500 mg/m^2
75317396|NCT04162015|Drug|Cisplatin or Carboplatin|cisplatin 75 mg/m2 or carboplatin AUC=5
75462429|NCT01864226|Drug|RO5545965|Multiple ascending doses
75462430|NCT01864226|Drug|placebo|Multiple ascending doses
75462431|NCT01864239|Other|Medicines Advice Service|"The intervention consists of:~Telephone consultations with a pharmacist~Follow-up tailored written information~A medicine reminder chart"
75462432|NCT01864252|Other|Remote ischaemic preconditioning|3 cycles of 5 minutes to arm and legs
75462433|NCT01864252|Drug|IV Normal saline|Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.
75462434|NCT01864252|Drug|IV Glyceryl trinitrate 2-5ml/h|IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
75615520|NCT02639767|Drug|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m^2 for pemetrexed in combination with 75 mg/m^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
75615521|NCT02639767|Radiation|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
75615522|NCT02639767|Device|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
75767855|NCT00141297|Drug|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
75767856|NCT01123486|Drug|hydromorphone|hydromorphone 0.02 mg/kg
75767857|NCT01123564|Drug|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
75767858|NCT01123564|Radiation|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
75767859|NCT01220206|Drug|Placebo|2 placebo capsules daily
75767860|NCT01220206|Drug|One POMx capsule daily|One POMx capsule, one placebo capsule daily
75767861|NCT01220206|Drug|2 POMx Capsules|2 POMx Capsules daily
75767862|NCT01222312|Drug|Cisplatin|75 mg/m2, d1 every 3 weeks
75767863|NCT01222312|Drug|Oxaliplatin|85 mg/m², d1 every 2 weeks
75767864|NCT01222312|Drug|Docetaxel|75 mg/m2, d1 every 3 weeks
75767865|NCT01222312|Drug|Docetaxel|50mg/m2, d1 every 2 weeks
75767866|NCT01218334|Device|12 Lead Glove|Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
75767867|NCT03932266|Drug|Endostar|Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
75767868|NCT03932266|Drug|Cisplatin|Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
75767869|NCT03932266|Drug|Docetaxel|Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
75767870|NCT03932266|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
75615523|NCT04296136|Other|Advance Care Planning Discussion|Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
75767871|NCT03933046|Diagnostic Test|PSG|polysomnography and urine analaysis for protein levels
75767872|NCT03932110|Diagnostic Test|omentin, visfatin|diagnostic blood test
75767873|NCT00141219|Drug|pregabalin|150-600mg/day, BID
75767874|NCT00141219|Drug|Placebo|Placebo
75767875|NCT01123798|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
75767876|NCT01222468|Drug|nabilone 0.5 mg|nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
75767877|NCT01222468|Drug|placebo|placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
76071627|NCT04417634|Diagnostic Test|RFR|Measurement of resting flow ratio
75767878|NCT03931798|Diagnostic Test|Visual Scanning Test|The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
75767879|NCT01222546|Drug|CH5132799|
75767880|NCT01222624|Drug|PankoMab-GEX™|
76071628|NCT04417634|Diagnostic Test|FFR|Measurement of fractional flow reserve
76071629|NCT04416321|Device|Surgery with the Keos Lumbar Interbody Fusion Device|All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis
75767881|NCT03931720|Biological|BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
75767882|NCT01218412|Behavioral|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
75767883|NCT03934060|Other|Exercise|specific strength training
75767884|NCT01220284|Drug|Satraplatin in combo with vinorelbine|"Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks."
76071630|NCT04413461|Other|TENS|Transcutaneous Electro Neuro Stimulation
75615524|NCT02646241|Procedure|unroofing biopsy|Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
75767885|NCT01127464|Drug|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
75767886|NCT01127464|Drug|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
75767887|NCT01127464|Drug|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
75767888|NCT01222780|Drug|Marqibo|Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
76071631|NCT04413461|Other|TENS Sham|placebo of Transcutaneous Electro Neuro Stimulation : similar device without electro stimulation
75615525|NCT02646241|Procedure|EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)|EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB & unroofing biopsy.
75615526|NCT02639689|Device|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
75767889|NCT03931876|Drug|Placebos|Single ascending dose administration
75767890|NCT03931876|Drug|AV-006|Single ascending dose administration
75767891|NCT01222858|Behavioral|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
76071632|NCT04399252|Dietary Supplement|Lactobacillus rhamnosus GG|Participants will take 2 capsules per day of either LGG or placebo.
76071633|NCT04399252|Dietary Supplement|Lactobacillus rhamnosus GG Placebo|Participants will take 2 capsules per day of LGG placebo
76071634|NCT04387227|Drug|Carboplatin|Given IV
76071635|NCT04387227|Biological|Pembrolizumab|Given IV
76071636|NCT04379687|Other|Virtual reality|Use of virtual reality glasses for balance work
76071637|NCT04379687|Other|Control group|Balance treatment with according to Bayouk physiotherapy
75615527|NCT04829344|Drug|AG-920|AG-920 Sterile Topical Ophthalmic Solution
75615528|NCT04829344|Drug|Placebo|Placebo Topical Ophthalmic Solution
75615529|NCT04166305|Genetic|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
75615530|NCT04522960|Diagnostic Test|MEG+hdEEG+MRI|"We will perform several tests:~Neuropsychological testing to evaluate evolution of cognition during our study.~Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls"
75767892|NCT01222858|Behavioral|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
75767893|NCT01222936|Drug|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
75767894|NCT01223014|Drug|AZD2423|AZD2423
75767895|NCT01125904|Drug|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
75767896|NCT01125982|Drug|Propofol|Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
75767897|NCT01125982|Drug|Desflurane|Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
75767898|NCT01220362|Drug|Bupivacain 0.125%|Bupivacain 0.125%
75767899|NCT01220362|Drug|Bupivacain 0.125%/Fentanyl 2mcg/ml|Bupivacain 0.125%/Fentanyl 2mcg/ml
75767900|NCT01220440|Drug|Methylphenidate|Methylphenidate:10mg x 3 for one week
75767901|NCT01220440|Drug|Placebo|Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
75767902|NCT01220440|Drug|Dextroamphetamine|Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
75767903|NCT01123876|Drug|Veliparib|Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
75767904|NCT01123954|Biological|Seasonal flu vaccine|This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
75767905|NCT01124032|Drug|methylphenidate|a capsule containing 20 mg
75767906|NCT03934294|Other|Specific acupuncture group|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G."
75767907|NCT03934294|Drug|Metoclopramide 10mg|Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.
75767908|NCT03934294|Other|Non-specific acupuncture group|Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related conditions, and are not reported to improve digestive function.
75767909|NCT01218490|Procedure|ovarian cancer surgery|
75767910|NCT01124110|Behavioral|Tobacco Tactics Web-Based Intervention|The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
75767911|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
75767912|NCT01223170|Behavioral|Tailored content|Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
75767913|NCT01223170|Behavioral|Generic Internet-based information|Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
75767914|NCT01223170|Behavioral|Discussion forum|Access to a discussion forum for Cardiovascular Disease Rehabilitation.
75767915|NCT01223170|Behavioral|Behavioral monitoring|Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
76071638|NCT04378699|Other|SMR (12-15 Hz)|SMR training sessions (12-15 Hz) C4 unipolar placement, central region
76071639|NCT04378699|Other|alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
75615531|NCT00960063|Drug|Temozolomide|
75615532|NCT00960063|Drug|Vincristine|
75767916|NCT01218568|Drug|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
75767917|NCT01218568|Drug|Lactulose|Lactulose 30-60 ml in two or three divided doses.
75909003|NCT03058588|Genetic|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
75909004|NCT02919449|Biological|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
75909005|NCT02919449|Biological|Atezolizumab|Atezolizumab will be administered every 3 weeks
75909006|NCT02904291|Drug|Amlodipine|Patients are tested for their normal prescription amlodipine medication
75909007|NCT02874573|Drug|Tocilizumab|Investigational agent
75767918|NCT02529280|Behavioral|Intervention|Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
76071640|NCT04378023|Drug|Neoadjuvant Chemo-radiotherapy|Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
75767919|NCT01127542|Drug|Lenalidomide|Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
75767920|NCT01127620|Drug|Bilastine|20 mg encapsulated tablets
75767921|NCT01127620|Drug|Cetirizine|10 mg encapsulated tablets
75767922|NCT01127620|Drug|Placebo|encapsulated tablets
75767923|NCT01220518|Drug|Infliximab|Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
75767924|NCT01328938|Biological|GCPGC 3.6mg|Stage I:Single blinded
75767925|NCT01328938|Biological|GCPGC 6mg|Stage I: Single blinded;
75909008|NCT02874573|Drug|Normal saline|Placebo
75909009|NCT02811094|Other|polymerase chain reaction (PCR) technique of blood transcriptome analysis|this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
75317397|NCT04154345|Other|Exercise therapy (exercising into pain)|The intervention consists of 12 weeks of progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, in which the pain allowed ranges between 4 and 7 on a verbal NPRS for 9 weeks, then pain ratings are 0-2 for the remaining 3 weeks. Every physiotherapy session includes also 15 minutes of manual therapy.
76071641|NCT04378023|Procedure|Liver Transplantation|If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
75317399|NCT04150965|Drug|Elotuzumab, pomalidomide, dexamethasone|Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
75462435|NCT01864265|Drug|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
75317400|NCT04150965|Drug|Anti-LAG-3|"Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long."
75317401|NCT04150965|Drug|Anti-LAG-3 + Pomalidimide + Dexamethasone|Patients with Relapsed & Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
75615533|NCT00960063|Drug|Ifosfamide|
75317402|NCT04150965|Drug|Anti-TIGIT|"Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days."
75462436|NCT01864265|Drug|Placebo|Placebo will be administered according to the label of the biological
75462437|NCT01864278|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
75462438|NCT01864317|Device|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
75462439|NCT01864317|Other|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
75462440|NCT01864317|Other|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
75615534|NCT00960063|Drug|Irinotecan|
75615535|NCT00960063|Biological|Robatumumab|
75615536|NCT00960063|Drug|Doxorubicin|
75615537|NCT00960063|Drug|Cyclophosphamide|
75615538|NCT00960063|Drug|Etoposide|
75615539|NCT02646319|Other|Laboratory Biomarker Analysis|Correlative studies
75615540|NCT02646319|Drug|Nanoparticle Albumin-Bound Rapamycin|Given IV
75615541|NCT02646319|Other|Quality-of-Life Assessment|Ancillary studies
75615542|NCT00653965|Drug|Rosuvastatin|
75615543|NCT00653965|Drug|Atorvastatin|
75767926|NCT01328938|Biological|Neulasta (pegfilgrastim) 6mg|Stage II: Active comparator, double blinded
75767927|NCT01328938|Biological|GCPGC 6mg|Experimental: Stage II
75767928|NCT01220596|Drug|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
75909010|NCT02806570|Device|Mitral valve repair|
75909011|NCT02796859|Drug|Siltuximab|Investigational agent
75909012|NCT02796859|Drug|normal saline|Placebo
75909013|NCT02769832|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
75909014|NCT02769832|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
75462441|NCT01864317|Other|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
75462442|NCT01864317|Other|Humphrey Perimetry|Visual Field Testing
75767929|NCT01220596|Drug|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
75767930|NCT01218724|Drug|Losartan Potassium and Hydrochlorothiazide Tablets|
75767931|NCT01126216|Drug|Paclitaxel/Cisplatin|Experimental: Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32,
75767932|NCT01126216|Radiation|Reduced RT|Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
75909015|NCT02735252|Other|Systemic therapy|Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.
75909016|NCT02735252|Device|StrataNGS|CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added
75909017|NCT02706704|Drug|Adalimumab|
75909018|NCT02591472|Procedure|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
75909019|NCT02591472|Procedure|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
75909020|NCT02591472|Other|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
75462443|NCT01864317|Other|Applanation Tonometry|Measurement of Intraocular Pressure
75615544|NCT02646163|Drug|REP 2055|"(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks."
75462444|NCT01864330|Device|Thealoz Duo®|Eye Drops
75462445|NCT01864330|Device|Hyabak®|Eye Drops
75462446|NCT01864330|Device|Hydrabak®|Eye Drops
75462447|NCT01864343|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
75462448|NCT01864356|Drug|NT100|
75462449|NCT01864356|Drug|Placebo|
75462450|NCT01864369|Behavioral|eCounseling + Usual Care|"This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12."
75462451|NCT01864382|Other|Core stability|Core stability 5 days a week during 5 weeks
75462452|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
75615545|NCT00959907|Drug|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~Dysport®: 4 units will be injected in the left or right forehead side.~Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
75615546|NCT00912340|Drug|Everolimus|
75615547|NCT00912340|Biological|Trastuzumab|
75615548|NCT01167257|Drug|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
75462453|NCT01864395|Procedure|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
75462454|NCT01864395|Procedure|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
75615549|NCT01167257|Drug|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
75767933|NCT01126216|Drug|5-FU/Cisplatin|Active Comparator: 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33
75767934|NCT01126216|Radiation|Standard RT|Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
75767935|NCT01329016|Drug|Glyburide|Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
75767936|NCT01329016|Drug|Metformin|Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
75767937|NCT01329016|Drug|Glyburide-Metformin combination|Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
75767938|NCT01223326|Drug|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
75767939|NCT01223326|Drug|Saline|Na Cl 0.9% infusion
75767940|NCT03934138|Other|Educational movie on placebo mechanisms|"Educational movie on placebo mechanisms : animated video, duration : 12 minutes.~It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment)"
75767941|NCT03934138|Other|Informative movie on hand washing|Animated video, duration : 11 minutes. It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment).
75767942|NCT01124266|Procedure|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
75767943|NCT01124266|Procedure|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
75767944|NCT01223560|Drug|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
75462455|NCT01864395|Procedure|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
75767945|NCT01223560|Other|Exercise|Exercise on tread mill
75767946|NCT01223560|Dietary Supplement|Carbohydrate|Carbohydrate intake
75615550|NCT01119846|Drug|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
75615551|NCT01119846|Drug|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
75615552|NCT01119846|Drug|Sitagliptin|"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."
75615553|NCT03775525|Drug|GZ17-6.02|Super enhancer Inhibition
75615554|NCT03775525|Drug|Capecitabine|antimetabolite
75615555|NCT00654043|Drug|Torsemide|tablets, 20 Mg, single-dose
75615556|NCT00654043|Drug|Demadex|Tablets, 20 mg, single-dose
75615557|NCT02816632|Other|mRI|Neural bases of feedbacks' influence on decision making processes
75616450|NCT02634619|Procedure|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
75767947|NCT01223638|Other|Audiometry|Audiometry
75767948|NCT01127776|Device|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
75767949|NCT01127776|Other|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
75767950|NCT03932890|Device|Patient controlled fluid device administering high volume thirst guided fluid bolus|The administration of a 200ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose & 0.18% sodium chloride
75767951|NCT03932890|Device|Patient controlled fluid device administering low volume thirst guided fluid bolus|The administration of a 50ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose & 0.18% sodium chloride
75317403|NCT04150965|Drug|Anti-TIGIT + Pomalidimide + Dexamethasone|Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
75462456|NCT01864408|Other|"Usual practice counseling"|
75462457|NCT01864408|Other|"Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad)."|"After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling."
75462458|NCT01864447|Behavioral|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
75767952|NCT03933124|Device|Virtual Reality|The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
75767953|NCT01126294|Dietary Supplement|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
75767954|NCT01126294|Dietary Supplement|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
75767955|NCT01126294|Dietary Supplement|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
75317404|NCT04136353|Drug|Darolutamide|2 x 300mg oral tablets twice daily for 96 weeks
75317405|NCT04136353|Drug|Placebo oral tablet|2 oral tablets twice daily for 96 weeks
75317406|NCT04136353|Drug|Luteinizing Hormone-Releasing Hormone Analog|All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.
75767956|NCT01124344|Drug|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
75767957|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
75767958|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
75767959|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
75767960|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
75462459|NCT01864473|Other|Kshar Sutra|The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
75767961|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
75767962|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
75767963|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
75767964|NCT01218880|Drug|M2ES 7.5mg|M2ES Dosage：7.5mg/m2
75767965|NCT01218880|Drug|M2ES 15mg|M2ES Dosage：15mg/m2
75767966|NCT01218880|Drug|M2ES 30mg|M2ES Dosage：30mg/m2
75767967|NCT01218880|Drug|M2ES 45mg|M2ES Dosage：45mg/m2
75462460|NCT01864486|Device|Intelligent Retinal Implant System|
75909021|NCT02591472|Other|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
75317407|NCT04136353|Radiation|External Beam Radiotherapy|All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
75616451|NCT02634619|Procedure|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
75767968|NCT00162266|Drug|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
75767969|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
75767970|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
75767971|NCT00162266|Drug|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
75767972|NCT01223716|Behavioral|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
75767973|NCT01223716|Behavioral|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
75767974|NCT01223716|Behavioral|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
75909022|NCT02591472|Other|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
75767975|NCT03931018|Other|Alcohol|Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
75909023|NCT02591472|Other|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
75317408|NCT04107129|Procedure|Endometrial Biopsy|An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers
75317409|NCT04107129|Other|Euploid embryo transfer|Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.
75317410|NCT04107129|Diagnostic Test|Blood sample|Estradiol and Progesterone levels in the blood will be checked
75317411|NCT04096326|Drug|AGN-151586|AGN-151586 solution for injection.
75317412|NCT04096326|Drug|Placebo|Placebo solution for injection.
75616452|NCT04481308|Drug|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
75767976|NCT03928444|Procedure|intradermal injection of adipose derived stem cells to one side of the face|"Lipoaspiration for preparation of ADSC will be done according to the following technique:~Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of (50 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe.~Autologous adipose tissue derived stem cells (At-ADSCs) will be separated from the lipo-aspirate using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Viability of collected cells will be checked using trypan blue stain. Characterization of the isolated ADSCs population will be performed by flow cytometry."
75767977|NCT03928444|Procedure|intradermal injection of saline to one side of the face|intradermal injection of saline to one side of the face
75767978|NCT01126450|Drug|lenalidomide|Given orally
75767979|NCT01126450|Biological|cetuximab|Given IV
75767980|NCT01126450|Other|mutation analysis|Correlative studies
75767981|NCT01126450|Other|polymerase chain reaction|Correlative studies
75767982|NCT01126450|Genetic|polymorphism analysis|Correlative studies
75767983|NCT03930940|Device|remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
75767984|NCT03930940|Other|Regular treatment|Regular treatment is based on associated guidelines for ICH.
75767985|NCT03931096|Other|Quality of life questionnaire|Self and proxy PedsQL 4.0 questionnaires.
75767986|NCT01225978|Device|GeneInsight Clinic (GIC)|"GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing."
75767987|NCT01223872|Other|interview|"Standard Interview (2-15 years from last treatment)~Demographic data interview (pre-initial study interview)"
75767988|NCT01223872|Other|clinic visit and interview|"REACH Clinic Visit(initial or regular)~Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~Demographic data interview(pre-initial study interview)"
75909024|NCT02591472|Other|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
75909025|NCT02591472|Other|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
75909026|NCT02591472|Other|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
75909027|NCT02591472|Other|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
75909028|NCT02418156|Device|CorMatrix ECM for Vascular Repair|Standard femoral arterial interventional procedure using CorMatrix ECM for vascular repair.
75909029|NCT02345005|Device|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
75909030|NCT02326311|Drug|imatinib|Tyrosin kinase inhibitor
75909031|NCT02326311|Drug|nilotinib|Tyrosin kinase inhibitor
76072425|NCT00089024|Procedure|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
75616453|NCT02634541|Drug|Adalimumab|Biologic drug
75616454|NCT02634541|Other|PET/CT imaging|PET/CT imaging
75616455|NCT04475848|Drug|RO6953958|"Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD)."
75909032|NCT02326311|Drug|dasatinib|Tyrosin kinase inhibitor
75909033|NCT02324543|Drug|Gemcitabine|IV on days 4 and 11 of a 21 day cycle
75909034|NCT02324543|Drug|Taxotere|IV on days 4 and 11 of a 21 day cycle
75909035|NCT02324543|Drug|Xeloda|Twice a day orally on days 1 through 14 of a 21 day cycle
75909036|NCT02324543|Drug|Cisplatin|IV on days 4 and 11 of a 21 day cycle
75909037|NCT02324543|Drug|Irinotecan|IV on days 4 and 11 of a 21 day cycle
75616456|NCT04475848|Drug|Placebo|"Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg."
75767989|NCT01223872|Other|interviews and clinic visit|"Pre-REACH Clinic Interview(2-15 yrs from last treatment)~REACH Clinic Visit(initial or regular)~Post-REACH Clinic Interview(1mo from initial clinic visit)~Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~Demographic data interview(pre-initial study interview)"
75909038|NCT02279979|Device|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
75909039|NCT02215265|Drug|Cisplatin|Chemotherapy
75909040|NCT02215265|Radiation|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
75317413|NCT04072822|Drug|Anakinra and Zinc|Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
75462461|NCT01864499|Procedure|ultrasound measurement of variations in the diameter of the sheath of the optic nerve|pre-and postoperative optic nerve and J2 and J5 for all patients
75317414|NCT04072822|Drug|Prednisone|Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
75462462|NCT01864551|Drug|Lamotrigine|
75462463|NCT01864551|Drug|Olanzapine|
75462464|NCT01864577|Other|Negative Pleural Suction at -20 cm H2O|
75462465|NCT01864577|Other|Water seal|
75462466|NCT01864590|Device|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
75462467|NCT01864590|Device|Double Sylo Bag - Mesh Protocol|"double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure"
75462468|NCT01864616|Dietary Supplement|Vitamin D3|
75462469|NCT01864629|Behavioral|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
75462470|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|
75767990|NCT01220830|Device|Cytotron|Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
75767991|NCT01073384|Drug|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
75767992|NCT01126528|Dietary Supplement|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
75767993|NCT01126528|Dietary Supplement|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
75767994|NCT01329172|Other|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
75767995|NCT01329172|Other|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
75767996|NCT00225212|Drug|Rituximab 375 mg/m2|
75767997|NCT03853330|Device|Ultrasound|Ultrasound-guided Thoracic Epidural Analgesia and Erector spinae plane block.
75767998|NCT03853330|Drug|Bupivacaine HCl Inj 0.25%|Bupivacaine HCl Inj 0.25% will be used in both blocks by the same dose of 7.5-12 ml
75767999|NCT03853330|Drug|Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution|infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h will be used in both blocks and also for breakthrough pain after both blocks as a bolus of 5-10 ml.
75909041|NCT02055638|Drug|SRX246|capsules
75909042|NCT02055638|Drug|Placebo|
75909043|NCT01887938|Biological|HGT-1110|Participants will receive IT injection of HGT-1110.
75909044|NCT01850524|Drug|Ixazomib|IXAZOMIB capsules.
75909045|NCT01850524|Drug|Placebo|IXAZOMIB matching-placebo capsules.
75317415|NCT04072822|Drug|Placebos|Matching placebo
75462471|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
75462472|NCT01864655|Drug|saracatinib|oral drug given to experimental group
75462473|NCT01864655|Drug|Placebo|Placebo given to placebo group
75462474|NCT01864681|Drug|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
75462475|NCT01864681|Drug|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
75462476|NCT01864694|Behavioral|TLC-Diet|Participants receive diet intervention through an automated telephone system
75462477|NCT01864694|Behavioral|WEB-Diet|Participants receive diet intervention through a web-based system
75462478|NCT01864694|Other|Assessment-only control|Assessment-only control
75462479|NCT01864707|Other|Usual care + acupuncture|Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
75462480|NCT01864707|Other|usual care+mbsr|Patients of this group receive mindfulness based stress reduction in addition to usual care
75909046|NCT01850524|Drug|Dexamethasone|Dexamethasone tablets.
75909047|NCT01850524|Drug|Lenalidomide|Lenalidomide capsules.
75909048|NCT01816256|Procedure|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
75909049|NCT01775085|Behavioral|manualized group intervention|MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts & Sources of Meaning; 2) Identity, Cancer Survivorship, & Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present & Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity & Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, & Humor; and 8) Transitions: Reflections & Hopes for the Future.
75909050|NCT01775085|Behavioral|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
75768000|NCT01581944|Drug|2 Doses Goserelin|3.6mg administered monthly for 2 months prior to myomectomy
75909051|NCT01671696|Other|Cardiac MRI|Cardiac MRI
75909052|NCT01664910|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BM transplant
75317416|NCT04072783|Diagnostic Test|MRI,DTI, functional MRI|"Patients will undergo testing with Pre- and and post-surgical MRI. The protocol will be Sagittal T1, Axial inversion recovery, T2, fluid-attenuated inversion recovery, susceptibility weighted image, diffusion weighted images, diffusion tensor imaging, resting state fMRI, sagittal 3D GRE / FFE or 3D T1 VIBE and tractography.~Once patients are identified, surgery is planned.The standard of care procedures fall into two categories based on age of presentation, clinician judgement and family preference all other things being equal. Both the endoscopic-assisted craniectomy and open CVR are standard of care procedures. Patients self-select into these groups. None of the surgery nor any aspect of it is experimental.~Patients are routinely examined for neurodevelopment pre- and post-operatively as part of American Cleft Palate Craniofacial Association guidelines.The Vineland Adaptive Behavior Scales are used up to and including age 4."
75616457|NCT04475848|Drug|Midazolam|Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
75909053|NCT01664910|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or BM transplant
75909054|NCT01664910|Biological|Anti-Thymocyte Globulin|Given IV
75909055|NCT01664910|Drug|Bendamustine Hydrochloride|Given IV
76071642|NCT04373837|Behavioral|Prismatic googles inducing prismatic adaptation (PA) associated to Virtual Reality (VR)|"The experimental condition consists of PA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward shift of the visual field (experimental condition). After lenses removal, a leftward shift of spatial attention will be produced.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
76071643|NCT04373837|Other|Neutral googles inducing no-adaptation (NA) associated to Virtual Reality (VR)|"The sham condition of this study consists of NA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with neutral goggles (control condition), which should not induce a shift of the visual field and of spatial attention.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
76071644|NCT04371666|Drug|Pamrevlumab|Pamrevlumab per dose and schedule specified in the arm description
75616458|NCT04653142|Drug|BI 765063|BI 765063
75768001|NCT01581944|Drug|3 Doses Goserelin|3.6mg administered monthly for 3 months prior to myomectomy
75768002|NCT01226056|Drug|RAD001 in combination with sorafenib|"Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks."
75909056|NCT01664910|Drug|Fludarabine Phosphate|Given IV
75909057|NCT01664910|Biological|Inotuzumab Ozogamicin|Given IV
75909058|NCT01664910|Drug|Methotrexate|Given IV
75616459|NCT04653142|Drug|BI 754091|BI 754091
75616460|NCT00599521|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
75616461|NCT00599521|Drug|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
75909059|NCT01664910|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
75909060|NCT01664910|Biological|Rituximab|Given IV
75909061|NCT01664910|Drug|Tacrolimus|Given IV or PO
75909062|NCT01654159|Procedure|Monofocal IOL|Monofocal Intraocular lens will be implanted
75909063|NCT01654159|Procedure|Multifocal IOL|Multifocal IOL will be implanted
75909064|NCT01654159|Procedure|Toric IOL|Toric IOLS will be implanted
75909065|NCT01609842|Other|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
75909066|NCT01594580|Other|Antimicrobial impregnated scrubs|Scrubs are impregnated with an antimicrobial product
75909067|NCT01594580|Other|Non-impregnated scrubs|
75909068|NCT01569594|Device|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
75909069|NCT01121107|Device|Left Atrial Pressure Monitoring System|Left atrial lead is placed for ambulatory monitoring of left atrial pressure
75909070|NCT01121107|Device|Patient Advisory Module|Handheld device that provides medication reminders
75768003|NCT01127932|Behavioral|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
75615558|NCT02816632|Other|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
75768004|NCT01127932|Behavioral|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
75768005|NCT00162032|Drug|Sestamibi|Sestamibi
75768006|NCT01226134|Drug|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
75768007|NCT01226134|Drug|Placebo|placebo capsules,thrice a day for four weeks
75768008|NCT01126606|Drug|Dermacid Silver (Lactic acid)|Liquid soap, daily use
75768009|NCT01126606|Drug|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
75768010|NCT01329406|Drug|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
76071645|NCT04371666|Drug|Placebo|Matching placebo per schedule specified in the arm description
76071646|NCT04371666|Drug|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
75615559|NCT04167007|Drug|Gemcitabine|Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days
76071647|NCT04367506|Behavioral|BecomeAnEX|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
76071648|NCT04367506|Behavioral|Usual Care|Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
76071649|NCT04364776|Drug|Durvalumab|In this observational study, durvalumab will be administered according to current indications (PACIFIC phase III trial).
76071650|NCT04362059|Device|COVSurf Drug Delivery System|Device introduces surfactant to the patients lungs
76071651|NCT04362059|Other|Standard of Care|Standard of care treatment for respiratory illness
76071652|NCT04357288|Other|Patient Decision Aid|The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
76071653|NCT04357288|Other|Encounter Decision Aid|The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
76071654|NCT04340596|Biological|N-803 (IL-15 Superagonist)|Administered by subcutaneous (SQ) injection
76071655|NCT04340596|Biological|VRC07-523LS|Administered by intravenous (IV) infusion
76071656|NCT04340596|Biological|10-1074|Administered by intravenous (IV) infusion
76071657|NCT04338529|Drug|Binosto 70Mg Effervescent Tablet|As discussed in group descriptions
76071658|NCT04337684|Drug|Long Term Follow-Up|"Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up."
75768011|NCT01329406|Drug|Placebo|1 tablet by mouth twice daily for 28 days
75768012|NCT00258674|Other|Medicare Claims Feedback|Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
75768013|NCT00258674|Other|Medical Record Review|Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
75768014|NCT00258674|Other|Diabetes Resource Nurse|Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
75768015|NCT01126684|Drug|Atorvastatin|10 mg of atorvastatin once daily for six months
75768016|NCT01126684|Drug|Placebo|placebo once daily for six months
75768017|NCT01224028|Drug|Tacrolimus|oral
75768018|NCT01224028|Drug|Placebo|oral
75768019|NCT01226212|Dietary Supplement|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
75768020|NCT01226212|Dietary Supplement|Placebo|maltodextrose
75768021|NCT01075490|Drug|clonidine|addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
75768022|NCT01075490|Drug|clonidine|equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
75768023|NCT01126138|Drug|Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
75615560|NCT04167007|Drug|FOLFOX|Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
75909071|NCT00769782|Procedure|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
75615561|NCT01167179|Behavioral|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
75909072|NCT00764595|Drug|imatinib mesylate|Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
75909073|NCT00628745|Other|None. Observational Study.|
75615562|NCT04345120|Drug|SY-008|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
75317417|NCT04070989|Device|THA|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
75317418|NCT04052581|Procedure|POEM-TIF|Transoral Incisionless Fundoplication (TIF) following Per oral Endoscopic Myotomy (POEM) in the same session
75615563|NCT04345120|Drug|SY-008 matching placebo|SY-008 matching placebo
75768024|NCT01126138|Drug|Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine|"Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.~Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity"
75768025|NCT03930706|Other|Longer administration of estradiol (Progynova®)|All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
75768026|NCT03930862|Device|Locator Attachment (positioner)|intra oral attachment
75768027|NCT01224184|Behavioral|Young Women's CoOp|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
75909074|NCT00593840|Radiation|Intensity modulated radiation therapy|
75909075|NCT00576979|Drug|cyclophosphamide|Given IV
75909076|NCT00576979|Drug|etoposide|Given IV
75909077|NCT00576979|Procedure|allogeneic bone marrow transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
75909078|NCT00576979|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
75317419|NCT04031846|Drug|Rotarix™|Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)
75317420|NCT04031846|Drug|Infanrix™ hexa|Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)
75317421|NCT04031846|Drug|V114|15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevenar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,
75462481|NCT01864707|Other|usual care|Patients in this group will follow the same treatment for fatigue they received at study entry
75462482|NCT01864733|Other|Physical rehabilitation (exercise).|
75462483|NCT01864759|Biological|ICOVIR-5|
75462484|NCT01864785|Procedure|Fixation Combined With Fusion|Articular process fusion with bone graft was carried out after screw fixation
75462485|NCT01864785|Procedure|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
75462486|NCT01864798|Drug|Denosumab|
75615564|NCT02951455|Behavioral|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
75317422|NCT04031846|Drug|Prevenar 13™|13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.
75317423|NCT04022850|Behavioral|Intuitive de-implementation|A set of de-implementation strategies targeting automatic cognition to alter the clinical decision making of physicians regarding the CVD primary prevention practice to be performed with hypercholesterolemic patients aged 40-75 years old without ischemic heart disease or diagnosed cardiovascular disease and with low CVD risk (<5%)
75317424|NCT04022850|Behavioral|Reflexive de-implementation|A set of de-implementation strategies targeting reflexive cognition to alter the clinical decision making of physicians regarding the CVD primary prevention practice to be performed with hypercholesterolemic patients aged 40-75 years old without ischemic heart disease or diagnosed cardiovascular disease and with low CVD risk (<5%)
75462487|NCT01864811|Behavioral|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
75462488|NCT01864811|Behavioral|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
75462489|NCT01864824|Drug|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
75462490|NCT01864824|Drug|Placebo|Placebo
75462491|NCT01864863|Drug|HGP1206|One Bosentan 125 mg tablet
75768028|NCT01224184|Behavioral|Staying Healthy and Eating Well|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
75768029|NCT03932578|Drug|Atropine sulfate|Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
75768030|NCT03932578|Drug|Metoclopramide|Patients will receive IV metoclopramide 10 mg in 2 ml
75768031|NCT01126762|Behavioral|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
75768032|NCT01126762|Behavioral|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
75768033|NCT00258440|Drug|Weekly procrit dosing|The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
75768034|NCT00258440|Drug|Interval Dosing|The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
75768035|NCT01075568|Dietary Supplement|Nutrigal Okara - 100|
75768036|NCT01226368|Other|Biological Sample collection|Cervix cells
75768037|NCT01220986|Procedure|Liver biopsy|0, 30, 60, 90 min post inflow-division
75768038|NCT01329250|Drug|Moxifloxacin|Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
75909079|NCT00576979|Procedure|peripheral blood stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
76071659|NCT04329767|Device|IRIS 1.0|Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
76071660|NCT04307212|Other|50% heart rate reserve (HRR) low intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)
75909080|NCT00576979|Radiation|intensity-modulated radiation therapy|Undergo IMRT
75909081|NCT00576979|Radiation|tomotherapy|Undergo IMRT using helical tomotherapy
75462492|NCT01864863|Drug|Traclear|Two Bosentan 62.5 mg tablets
75615565|NCT02951455|Behavioral|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
75615566|NCT02951455|Behavioral|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
75615567|NCT02951455|Behavioral|PF|Whether the intervention is delivered by a peer facilitator.
75615568|NCT02951455|Behavioral|LC|Whether the intervention is delivered by a licensed clinician.
75615569|NCT02639611|Other|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
75615570|NCT02639611|Other|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
75909082|NCT04949230|Other|No Intervention Used|There is no intervention in this study
76071661|NCT04307212|Other|75% HRR moderate intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
76071662|NCT04307212|Other|Control no exercise|Trained and untrained participants will have a no exercise control day
76071663|NCT04300205|Device|High intensity LED light device|Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
75462493|NCT01864876|Biological|GLA-AF|Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
75462494|NCT01864876|Biological|GLA-SE|Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
75768039|NCT00224120|Drug|Silodosin|8 mg daily for 12 weeks
75768040|NCT00224120|Other|Placebo|One capsule daily for 12 weeks
76071664|NCT04300205|Device|Sham LED light device|Participants have the light treatment moved off their wound after masking
75462495|NCT01864876|Biological|EM060G (SE)|The same stable oil-in-water emulsion (SE), but without GLA.
75462496|NCT01864889|Biological|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
75462497|NCT01864902|Biological|CART33 cells|genetically modified lymphocyte therapy
75462498|NCT01864902|Biological|anti-CD33 CART|
75462499|NCT01864902|Biological|anti-CD33 CAR T cells|
75462500|NCT01864915|Drug|Prucalopride|Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
75462501|NCT01864915|Procedure|Colon Capsule|Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
75462502|NCT01864941|Procedure|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
75462503|NCT01864941|Device|Catheter venography with balloon venoplasty and balloon|
75462504|NCT01864954|Behavioral|Web+phone|We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
75615571|NCT01167023|Drug|Prasugrel|Administered orally, once daily for 30 days.
75317425|NCT04022850|Behavioral|Passive dissemination|Usual procedures of dissemination of clinical practice guidelines, focused in the distribution of materials, support tools and training in the reference group.
75317426|NCT03943030|Other|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
75317427|NCT03893448|Biological|V114|V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.
75462505|NCT01864980|Procedure|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
75462506|NCT01864980|Procedure|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
75462507|NCT01864993|Dietary Supplement|gluten|The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme
75462508|NCT01864993|Dietary Supplement|Placebo|Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
75462509|NCT01865019|Device|mechanical ventilation|
75462510|NCT01865071|Procedure|loop ileostomi|
75615572|NCT01167023|Drug|Placebo|Administered orally, once daily for 30 days.
75615573|NCT04273126|Behavioral|Adapted Family Resilience Intervention|The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
75317428|NCT03893448|Biological|Prevnar 13™|Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
75462511|NCT01865097|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
75462512|NCT01865097|Behavioral|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
75462513|NCT01865123|Behavioral|Transcendental Meditation|A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
75615574|NCT00654121|Drug|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
75615575|NCT04336852|Procedure|Flow mediated dilation (brachial and femoral arteries)|Assessment of vascular function of the brachial and femoral arteries.
75768041|NCT01224340|Behavioral|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
75768042|NCT01224340|Behavioral|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
75768043|NCT01224340|Other|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
75768044|NCT01226446|Drug|vitamin D|Vitamin D on top of the standard treatment
75768045|NCT01224418|Drug|Tacrolimus|oral
75768046|NCT00257660|Biological|Botulinum toxin type A|500 units
75768047|NCT00257660|Drug|Placebo|500 units
75768048|NCT01221064|Procedure|Early drainage removal|Drainage will be removed in postoperative day 1
75768049|NCT01221064|Procedure|Late drainage removal|Drains will be kept until daily drainage is 30ml and then removed
75768050|NCT01129180|Drug|azacitidine|Given SC
75768051|NCT01129180|Drug|bortezomib|Given IV
75768052|NCT01129180|Procedure|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
75768053|NCT03972020|Behavioral|Mindfulness Based Intervention|"The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on:~(1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a window of tolerance in order to maximize the clinical utility of the intervention and tailor it to breast cancer patients."
75768054|NCT03972020|Behavioral|Cognitive Behavioral Therapy|Cognitive behavior therapies will include cognitive restructuring, relaxation, skills training, and visual imagery, among other modalities.
75615576|NCT04336852|Procedure|Cerebral vascular reactivity to carbon dioxide (CO2)|Cerebral blood flow responses to increasing partial pressure of CO2
75768055|NCT01221142|Device|"Cincinnati Sub-Zero, Blanketrol III"|
75768056|NCT01128166|Device|COGNIS CRT-D|"Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion."
75615577|NCT04336852|Procedure|Cerebral vascular function test|Cerebral blood flow responses to a reactive hyperemia stimulus
75768057|NCT00224042|Drug|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
75768058|NCT00224042|Drug|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
75768059|NCT01129258|Drug|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
75768060|NCT01129258|Drug|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
75317429|NCT03893448|Biological|RotaTeq™|A total of 3 RotaTeq™ 2 mL oral dosings at ~2, ~4, and ~6 months of age.
75768061|NCT01224496|Drug|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
75768062|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program|Six-month, family-based, group, behavioral weight control program
75768063|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes|Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
75317430|NCT03893448|Biological|Pentacel™|A total of 3 Pentacel™ 0.5 mL IM dosings at ~2, ~4, and ~6 months of age.
75615578|NCT03484117|Behavioral|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
75615579|NCT01166945|Drug|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
75615580|NCT01166945|Drug|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
75615581|NCT02639533|Drug|Pregabalin|Pregabalin 150 mg PO, single dose.
75768064|NCT01226524|Drug|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
75768065|NCT01221376|Drug|Imatinib Mesylate|Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
75768066|NCT03928132|Behavioral|CPD Workshop on Depression and Diabetes|2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
75317431|NCT03893448|Biological|RECOMBIVAX HB™|A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at ~2, ~4, and ~6 months of age.
75317432|NCT03893448|Biological|VAQTA™|One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
75317433|NCT03893448|Biological|MMR II™|One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
75317434|NCT03893448|Biological|VARIVAX™|One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
75317435|NCT03893448|Biological|HIBERIX™|One HIBERIX™ 0.5 mL IM dosing at Visit 5.
75768067|NCT01224652|Drug|Paclitaxel|Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
75909083|NCT03563469|Other|Salivary bacterial and pH level|"Saliva sample will be collection ask the patient to stop eating and drinking for one hour before collecting the sample,(2) Give the patient distilled water and ask them to rinse their mouth well for 1 min,five minutes after this oral rinse, ask the patient to spit into 50ml sterile tube, collect 5ml of saliva and return to the laboratory within an hour.~The dental caries of all patients will also be recorded using dental mirror and explorer. The caries experience will be recorded in diagnostic chart using the World Health Organization (WHO) criteria for deciduous teeth and dmft caries index."
75909084|NCT02228538|Device|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system & off-the-shelf standard knee implant system from various manufacturers
75909085|NCT03058042|Other|Exercises of the pelvic floor muscle at home|Patients will perform pelvic floor exercises at home.
75909086|NCT03058042|Other|Exercises of the pelvic floor muscle in the outpatient|Patients will perform pelvic floor exercises in the outpatient.
75909087|NCT03563391|Other|New Infant Formula|New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
75317436|NCT03868670|Device|responsive neurostimulation|The RNS® System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to continuously monitor brain electrical activity, detect abnormal electrical activity and respond by delivering imperceptible levels of electrical stimulation to normalize that activity before an individual experiences seizures. This is an Early Feasibility Study determining the safety and efficacy of NAc-RNS in the treatment of LOC eating in treatment-refractory obesity.
75909088|NCT04003974|Drug|Losmapimod|This study includes a 48 week treatment period. Patients will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.
75909089|NCT04003974|Drug|Placebo oral tablet|This study includes a 48 week treatment period. Patients will receive Placebo twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily. The placebo tablets are identical to the Losmapimod tablets. Placebo should be taken with food and the date and time of each dose taken recorded in the subject diary.
75909090|NCT04949386|Drug|S-1226 (8%)|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.
75909091|NCT04949386|Other|Placebo|Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
75909092|NCT05139693|Device|Respiree|The aim of this project is to test the accuracy of pulse oximeters during mild, moderate and severe hypoxia. This is done by comparing the reading of the pulse oximeter during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a laboratory hemoximeter). The data obtained is submitted by pulse oximeter manufacturers to the FDA for device approval
75317437|NCT03848455|Diagnostic Test|genetic diagnosis|The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
75462514|NCT01865123|Behavioral|Prolonged Exposure|Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
75615582|NCT02639533|Other|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
75317438|NCT03730948|Biological|DC vaccine|DC vaccine for colorectal cancer
75615583|NCT02885987|Device|AmplifEYE|AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
75615584|NCT02646007|Biological|BM-MSC transplantation|Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
75615585|NCT02885675|Other|blood sampling|sample no more than 3ml
75317439|NCT03730818|Other|Water-based Exercise Group|The intervention consist will of a water-based exercise protocol
75615586|NCT02639377|Drug|Chlorhexidine gluconate|
75317440|NCT03730818|Other|Land-based Exercise Group|The intervention will consist of a land-based exercise protocol
75462515|NCT01865123|Behavioral|Educational control|This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
75462516|NCT01865136|Other|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
75615587|NCT02639377|Drug|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
75615588|NCT02639455|Behavioral|Exercise|Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
75615589|NCT00910000|Drug|Vorinostat|
75615590|NCT00910000|Drug|Carboplatin|
75615591|NCT00910000|Drug|Gemcitabine|
75615592|NCT02885909|Device|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
75615593|NCT02885909|Procedure|Insulin protocal|Using insulin protocal based on glucose monitor
75768068|NCT01224652|Drug|Irinotecan|irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
75768069|NCT00160706|Biological|Certolizumab Pegol (CDP870)|"Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.~Up to 84 months of therapy in this study."
75768070|NCT01226602|Drug|AZD6140|P2Y12 receptor antagonist
75768071|NCT01226602|Drug|Placebo|
75768072|NCT01221454|Procedure|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
75615594|NCT02700945|Device|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
75768073|NCT01221454|Drug|Conserved therapy|Oral or intravenous administration
75462517|NCT01865149|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
75768074|NCT01224730|Drug|perifosine|100 mg daily
75615595|NCT05657171|Drug|cyproterone Acetate/Ethinyl Estradiol Combination|cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
75768075|NCT03930784|Other|Nil intervention|
75768076|NCT01224808|Biological|Biostate|Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
75768077|NCT03927976|Behavioral|Path2Quit - culturally specific text message intervention|SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
75768078|NCT01221532|Behavioral|SHHE Peridischarge Intervention|"Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care."
75768079|NCT01226680|Drug|Tasocitinib|0.005% QD for 12 weeks
75615596|NCT00652873|Drug|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
75615597|NCT00652873|Drug|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
75768080|NCT01226680|Drug|Tasocitinib|0.003% QD for 12 weeks
75768081|NCT01226680|Drug|vehicle for Tasocitinib|vehicle QD for 12 weeks
75768082|NCT03930394|Diagnostic Test|Contrast ultrasound perfusion imaging|Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.
75768083|NCT00257192|Drug|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
75768084|NCT00257192|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
75768085|NCT01226758|Biological|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
75768086|NCT01226758|Biological|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
75768087|NCT03927898|Drug|Toripalimab|Participants receive Toripalimab (240mg)/q3w till progression of disease after SBRT
75462518|NCT01865175|Drug|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
75615598|NCT02887235|Other|Home Delivered, Medically Tailored Meals (HDTM)|
75615599|NCT00652171|Drug|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
75462519|NCT01865175|Drug|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
75615600|NCT00652171|Dietary Supplement|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
75462520|NCT01865188|Drug|LCZ696|Experimental monotherapy doses
75462521|NCT01865188|Drug|Amlodipine|Active comparator monotherapy doses
75462522|NCT01865188|Drug|LCZ696 and amlodipine combination|Experimental combination doses
75615601|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
75615602|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
75615603|NCT04281303|Procedure|Endoscopic vertical gastroplasty|endoscopic vertical gastroplasty + lifestyle modification
75615604|NCT02885831|Device|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
75462523|NCT01865188|Drug|Placebo|Placebo comparator dose
75462524|NCT01865201|Drug|Edaravone|Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
75768088|NCT03927898|Radiation|Stereotactic Body Radiotherapy|Participants receive SBRT (BED>80Gy) to oligometastatic lesions followed by Toripalimab (240mg)/q3w
75768089|NCT01224964|Drug|Montelukast|Montelukast, 10 mg
75768090|NCT01224964|Drug|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
75909093|NCT05133063|Behavioral|Gratitude letter|"Participants are given the following instructions:~Think of someone in your life who you feel like you have never fully or properly thanked for something meaningful or important that they did for you. . . . In the space provided below, please write a note to this person that describes why you feel like you never properly thanked them and letting them know why you feel thankful for something important that they did for you. Though this letter will not actually be sent to this person and is simply an exercise for you, please use this as an opportunity to really explore those feelings surrounding how you feel about what they have done for you and write honestly and openly from your heart. You have ten minutes."
75909094|NCT05133063|Behavioral|Control intervention|"Participants receive the following instructions:~Think of the room you are in…. In the space below, please provide a description of the room you are in. Try to focus on the specific elements in the room, the colours of the wall or objects in the room. Use this writing session as an opportunity to paint a detailed picture of this room and include as much specific information as you can. You have ten minutes."
75909095|NCT03508765|Diagnostic Test|Structural Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= ~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
75909096|NCT03508765|Diagnostic Test|Functional Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= ~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
75909097|NCT03508765|Behavioral|Digit Span subtest|Evaluates auditory attention and working memory
75909098|NCT03508765|Behavioral|Brief Test of Attention|Assesses selective auditory attention
75909099|NCT03508765|Behavioral|Trail Making Test (Parts A & B)|Assesses visual scanning, graphomotor speed, and setshifting
75909100|NCT03508765|Behavioral|Auditory Consonant Trigrams Test|Assesses attention and susceptibility to interference
75909101|NCT03508765|Behavioral|Controlled Oral Word Association Test|A timed test of verbal fluency.
75909102|NCT03508765|Behavioral|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall.
75317441|NCT03692871|Biological|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
75462525|NCT01865201|Other|Common fundamental management|common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
75909103|NCT03508765|Behavioral|The Center for Epidemiological Study-Depression|assesses perceived depression
75462526|NCT01865227|Behavioral|Group Counseling|
75462527|NCT01865240|Device|Renal Denervation|Renal Denervation Catheter
75462528|NCT01865253|Device|Renal Denervation|Renal Denervation
75462529|NCT01865266|Drug|Ulinaststin for injection|
75615605|NCT02859363|Genetic|26 common Fabry mutation types in Taiwan|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
75615606|NCT02656953|Other|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
75615607|NCT02656953|Other|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
75909104|NCT03508765|Behavioral|The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4|A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue
75909105|NCT03508765|Other|Blood draw|Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
75317442|NCT03692871|Biological|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 ml dose
75317443|NCT03667846|Drug|Topiramate|Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.
75462530|NCT01865266|Drug|placebo|
75462531|NCT01865279|Drug|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
75462532|NCT01865279|Drug|placebo|Ascending single doses - 5 dose levels
75317444|NCT03667846|Other|Placebo|Placebo tablets will be encapsulated in identical capsules.
75317445|NCT03658447|Drug|Pembrolizumab|200mg Pembrolizumab given 3 weekly for upto 35 cycles
75462533|NCT01865279|Drug|insulin degludec|A single dose corresponding to that of isophane human insulin
75615608|NCT02645929|Behavioral|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
75768091|NCT03932734|Other|survey|Face-Q conversion table
75768092|NCT01126918|Behavioral|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
75768093|NCT00256724|Device|Impedance Threshold Device|Active impedance threshold device
75768094|NCT00256724|Device|sham ITD|sham impedance threshold device
75768095|NCT03928054|Other|Kinesio Taping and therapeutic alliance|bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance
75768096|NCT03930550|Procedure|Tracheal intubation by endoscopy with flexible bronchoscope|A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
75768097|NCT03967964|Drug|Dehydroepiandrosterone 2.2 g|Vaginal ring with 2.2 grams DHEA.
75768098|NCT03967964|Drug|Dehydroepiandrosterone 1.5 g/Testosterone 25 mg|Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
75768099|NCT03967964|Drug|Testosterone|Vaginal ring with 35 mg testosterone.
75768100|NCT03967964|Drug|Testosterone Topical Gel|Gel containing 1% testosterone.
75768101|NCT03967964|Drug|Dehydroepiandrosterone Oral Capsule|Capsule containing 25 mg DHEA
75768102|NCT01129414|Drug|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
75768103|NCT01129414|Drug|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
75768104|NCT01129414|Drug|Omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration: oral"
75768105|NCT03967730|Combination Product|Sonodynamic therapy(SDT)|Sonodynamic Therapy (SDT) Sinoporphyrin Sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection(0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15 min of each lesion. Ultrasound parameters included intensity of 2.1W/cm2 for each lesion, resonance frequency: 1.0 MHz and duty factor: 30%.
75768106|NCT03930238|Behavioral|VA MapTrek|The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
75768107|NCT03930238|Behavioral|Fitbit Only|Fitbit Only
75768108|NCT03967886|Drug|YYD601 20mg|Patients should take drugs an hour before breakfast.
75615609|NCT01165307|Drug|Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
75768109|NCT03967886|Drug|Nexium 20mg|Patients should take drugs an hour before breakfast.
75768110|NCT03967886|Drug|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
75768111|NCT01129492|Device|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
75909106|NCT03563235|Drug|Xulin Jiangu granules|Xulin Jiangu granules tablets
75909107|NCT03563235|Drug|Calcitriol capsules|Calcitriol capsules tablets
75317446|NCT03658447|Drug|177Lu-PSMA|6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
75317447|NCT03638895|Device|ECAL Indirect Calorimeter|The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).
75462534|NCT01865279|Drug|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
75462535|NCT01865292|Drug|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
75462536|NCT01865292|Drug|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
75615610|NCT01165307|Drug|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
75462537|NCT01865305|Drug|insulin degludec/insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
75615611|NCT01165307|Device|NovaSure® Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
75615612|NCT02639143|Drug|ticagrelor|
75768112|NCT03968042|Drug|Nerve Growth Factor|Intramuscular injection for 2 weeks
75768113|NCT03968042|Drug|Edaravone|Intravenous injection for 2 weeks
75768114|NCT03968042|Drug|Combination of vitamin B1, B6, C, E and mecobalamine|Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
75768115|NCT01225042|Dietary Supplement|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
75768116|NCT01225042|Dietary Supplement|placebo|placebo consisting of carrier material powder of identical appearance
75768117|NCT01128322|Drug|S-Amlodipine, Telmisartan|
75768118|NCT01128322|Drug|S-Amlodipine|
75768119|NCT01128322|Drug|Telmisartan|
75768120|NCT01128322|Drug|Placebo|
75768121|NCT00157820|Device|Single Chamber Implantable Cardioverter Defibrillator|Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD
75768122|NCT00157820|Device|Dual Chamber implantable cardioverter defibrilator|Dual chamber ICD implantation: Jewel AF & GemIII AT as DC ICDs (DC true and SC sim arms)
75768123|NCT01126996|Procedure|Venepuncture|"Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~A booster dose of a MenC conjugate vaccine (optional)."
75909108|NCT01329900|Drug|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
75909109|NCT01329900|Drug|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
75909110|NCT01329900|Drug|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
75909111|NCT01329900|Drug|Mesna|"2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose."
75768124|NCT01129570|Drug|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
75768125|NCT00223808|Other|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
75768126|NCT00223808|Other|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
75768127|NCT00223808|Other|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
75768128|NCT03740620|Procedure|Bevel facing the cephalad direction of the patient|The bevel of the nasotracheal tube facing cephalad direction of the patient
75768129|NCT03740620|Procedure|Bevel facing leftward of the patient|The bevel of the nasotracheal tube facing the left side of the patient
75768130|NCT03971942|Behavioral|Neutral ABMT|In the neutral attention bias, there are 108 pairs of neutral-negative words, 54 pairs of which are used in the training group and 54 pairs of which are used in the placebo group. The word pairs in each group are repeated 4 times, with a total of 216 trial. Participants received 8 sessions over 2 weeks (1 session every other day).In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position.
75768131|NCT03971942|Behavioral|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 8 sessions over 2 weeks (1 session every other day). In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
75615613|NCT02639143|Drug|Clopidogrel|
75768132|NCT01221610|Device|Passeo-18 Lux DRB|
75768133|NCT01221610|Device|Standard PTA (POBA)|
75768134|NCT01073540|Drug|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
75768135|NCT01073540|Drug|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
75768136|NCT03930472|Behavioral|Market vouchers|Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.
75768137|NCT03741608|Behavioral|High blood pressure management education|The 7-part education series includes 5 sessions focused on mindfulness and breathing techniques for stress reduction. One session will focus on choosing healthy, low salt foods and will provide resources for smoking cessation. The final session will include a grocery store tour to teach participants how to read food labels and to purchase healthy food.
75768138|NCT03741608|Behavioral|Home blood pressure measurement|Participants will be taught to use an automated blood pressure cuff and will be asked to provide monthly blood pressure readings to study staff.
75768139|NCT03930160|Other|Logistic Organ Dysfunction System Score|Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
75768140|NCT01075724|Device|Patient Warming with Forced Air|Forced Air warming via BairHugger
75317448|NCT03638895|Behavioral|Diet, exercise & behaviour modification therapy|Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
75768141|NCT01075724|Device|Resistive Warming|Resistive Warming via HotDog device
75768142|NCT01225120|Other|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
75768143|NCT03740386|Drug|Phentolamine Mesylate 0.235 MG/ML [OraVerse]|compare effect of phentolamine mesylate in three arms
75768144|NCT01226836|Other|LWWCOPD for Pulmonary Rehabilitation|As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
75768145|NCT03927352|Biological|SCT630|Administered by subcutaneous injection
75768146|NCT03927352|Biological|Adalimumab|Administered by subcutaneous injection
75317449|NCT03610516|Drug|CFZ533|multiple doses of CFZ533 intravenous infusion
75317450|NCT03610516|Drug|Placebo|multiple doses of placebo intravenous infusion
75317451|NCT03565900|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose.
75462538|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
75615614|NCT02536027|Procedure|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
75615615|NCT02645773|Device|non-ablative laser|non-abaltive laser pre, immediate and post wounding
75615616|NCT02644057|Drug|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
75768147|NCT03929770|Procedure|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
75768148|NCT03929770|Procedure|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
75909112|NCT01329900|Drug|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
75909113|NCT01329900|Procedure|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
76072426|NCT00089024|Radiation|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
75317452|NCT03565900|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
75317453|NCT03565900|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
75317454|NCT03531762|Drug|Tepotinib|Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.
75317455|NCT03531762|Drug|Omeprazole|Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.
75317456|NCT03485924|Diagnostic Test|EUS-FNA with ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
75462539|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
75462540|NCT01865305|Drug|insulin degludec|Single dose administrated subcutaneously (s.c., under the skin).
75615617|NCT02644057|Drug|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
75317457|NCT03485924|Diagnostic Test|EUS-FNB without ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
75462541|NCT01865305|Drug|insulin aspart|Single dose administrated subcutaneously (s.c., under the skin).
75462542|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin) as comparator.
75615618|NCT00960999|Radiation|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
75768149|NCT01225198|Dietary Supplement|Multi-Vitamin/Mineral Supplement|A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
75768150|NCT01225198|Other|Liquid Placebo|The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
75768151|NCT03929848|Procedure|Cuff pressure|observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery
75768152|NCT01226992|Drug|Vancomycin|"Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
75909114|NCT03677635|Behavioral|Guided Autobiographical Memory Recall|Participants are asked to recall positive autobiographical memories with the assistance of prompts to promote specificity, generalisability and links to the future. The participants will also view a 5min psychoeducation video on the subject of memory specificity and motivation.
75909115|NCT03834597|Device|conventional Macintosh laryngoscope|After closure of surgical, anesthesiologist will perform the conventional Macintosh laryngoscope to assess post-thyroidectomy vocal cord mobility.
75909116|NCT03834597|Device|GlideScope®|Patient will be left for a while until hemodynamic stabilization then examination with GlideScope® will be commenced to assess postthyroidectomy vocal cord mobility by another experienced anesthesiologist
75909117|NCT04948216|Other|No intervention|No intervention
75909118|NCT05127993|Device|Passive Talaris Demonstrator|"The amputee will walk with the passive Talaris Demonstrator, a novel prosthetic foot, designed and built by Axiles Bionics."
75909119|NCT03997812|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
75909120|NCT03997812|Drug|Placebo|IV infusion of 0 mg of VVZ-149
75909121|NCT02825043|Device|High-Flow Nasal Cannula|This is a humidified oxygen delivery system.
76072427|NCT00081809|Drug|autologous human tumor-derived HSPPC-96|
75317458|NCT03464344|Other|neurological, neuropsychological and MRI evaluation|neurological, neuropsychological and MRI evaluation
75317459|NCT03464045|Drug|empagliflozin|drug
75317460|NCT03464045|Drug|DPP-4 inhibitors|drug
75317461|NCT03464045|Drug|SGLT-2 inhibitors|drug
75317462|NCT03462459|Drug|Vancomycin|Vancomycin capsule, 125 mg
75462543|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
75462544|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
75462545|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
75768153|NCT01226992|Biological|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
75768154|NCT01127074|Biological|KS24.22 cells|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
75768155|NCT01127152|Procedure|Measure of arterial pressure|Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.
75317463|NCT03462459|Drug|Placebo|Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
75768156|NCT03927586|Other|cognitive training|We will be using commercialized cognitive-based training programs in order to facilitate several cognitive functions. We will be targeting attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance different types of cognitive functions. Cognitive program difficulty will be adjusted automatically and continuously based on each participant's level of performance.
75768157|NCT03927586|Other|physical exercise training|The physical exercise programs will involve balance or strength training or aerobic exercises. These may include (but not limited to) stepping, walking, dancing, ball kicking and throwing, and etc. The exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period. The exercise intensity will be progressed as the participants improve their performance throughout practice. To prevent exercise-induced injuries, vital signs and the Borg Perceived Exertion Scale will be monitored and recorded in each training session. If the training therapist observed that the exercise may be too intense for the participants, he/she will immediately reduce the training intensity.
75768158|NCT01128478|Procedure|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
75317464|NCT03443869|Drug|Letermovir|LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks
75317465|NCT03443869|Drug|Valganciclovir|900 mg VGCV tablet orally, once daily for 28 weeks
75768159|NCT01128556|Drug|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
75768160|NCT01128556|Drug|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
75768161|NCT03927664|Other|Radiological assessment|Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
75768162|NCT01129726|Device|Transillumination-guided Fiberoptic Intubation|Light guided, Non-invasive
75768163|NCT01225432|Other|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
75317466|NCT03443869|Drug|Acyclovir (ACV)|400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks
75768164|NCT03929692|Behavioral|Multi-layer health promotion program|
75768165|NCT03929692|Other|Standard health education|
75768166|NCT03740464|Drug|long-acting granulocyte colony stimulating factor|A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
75768167|NCT03740464|Drug|Short-term granulocyte colony stimulating factor|Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
75317467|NCT03443869|Drug|Placebo to ACV|Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks
75317468|NCT03443869|Drug|Placebo to LET|Placebo to LET tablet orally, once daily for 28 weeks
75317469|NCT03443869|Drug|Placebo to VGCV|Placebo to VGCV tablet orally, once daily for 28 weeks
75317470|NCT03433898|Drug|BI 754091|Solution for infusion
75462546|NCT01865318|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin)
75462547|NCT01865331|Drug|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
75615619|NCT00960999|Radiation|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
75615620|NCT00654277|Drug|Ondansetron|ODT, 8 mg, single-dose
75317471|NCT03433898|Drug|BI 754111|Solution for infusion
75317472|NCT03418987|Other|Medical File data analysis|Analysis of the 2D/3D spine images (performed with the sterEOS software and the MATLAB software)
75317473|NCT03395210|Drug|PRN1008|BTK inhibitor
75317474|NCT03369587|Behavioral|Handwriting Practice|Self-directed home handwriting practice daily for 6 weeks
75317475|NCT03321630|Drug|Lenvatinib|Lenvatinib 20 mg orally each day on days 1-7
75462548|NCT01865331|Drug|placebo|Administered subcutaneously (s.c., under the skin)
75462549|NCT01865331|Drug|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
75462550|NCT01865357|Other|Brain MRI - Clinical and cognitive evaluation|"Clinical evaluation (EDSS, MSFC)~Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI"
75462551|NCT01865357|Other|Eye movement|Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
75615621|NCT00654277|Drug|Zofran|ODT, 8 mg, fasting conditions
75615622|NCT01124838|Drug|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
75615623|NCT01124838|Drug|Prednisone|Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
75768168|NCT03928990|Device|ActiGraph accelerometer|ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
75768169|NCT03927118|Procedure|intravitreal dexamethasone implant application|Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.
75768170|NCT03929380|Other|Squat protocol|60% of 1RM weight for 100 squat reps
75317476|NCT03321630|Drug|Pembrolizumab|Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
75768171|NCT01128634|Drug|GSK573719|13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
75768172|NCT01128634|Drug|GW573719/GW573719|13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
75768173|NCT03932422|Diagnostic Test|Evaluate if the individuals are resistant hypertensive patients|Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
75768174|NCT01227148|Other|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
75768175|NCT01227148|Other|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
75768176|NCT01227226|Drug|Artificial tears|Instill one drop of artificial tears
75768177|NCT01127308|Drug|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of [14C]ertugliflozin
75768178|NCT01128712|Drug|Pregabalin|150 mg /day
75768179|NCT01128712|Drug|Pregabalin|450 mg/day
75768180|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
75768181|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
75768182|NCT01227304|Device|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
75768183|NCT01127386|Drug|Lenalidomide|25mg od, dose reduction according to toxicity
75317477|NCT03284541|Behavioral|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
75317478|NCT03284541|Behavioral|Existing Public Health Practice|HIV testing, medication adherence, HIV risk reduction
75317479|NCT03260140|Behavioral|behavioral lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention
75462552|NCT01865370|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
75615624|NCT01124838|Drug|Placebo|Administered by subcutaneous injection
75615625|NCT02639221|Drug|PXT002331|
75615626|NCT00959751|Drug|NXN-188|200 mg capsules, 600 mg, PRN
75615627|NCT00959751|Drug|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
75615628|NCT00630435|Drug|Premarin®/MPA formulation A|
75768184|NCT01127386|Drug|Lenalidomide|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
75768185|NCT01127386|Other|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)|twice during study
75768186|NCT03927196|Behavioral|extended counseling|Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
75768187|NCT01221844|Dietary Supplement|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
75768188|NCT01221844|Drug|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
75768189|NCT01128790|Other|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
75768190|NCT01128790|Other|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
75768191|NCT01128868|Device|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
75317480|NCT03253796|Biological|Golimumab|Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.
75317481|NCT03253796|Biological|Placebo|Injections of matching placebo for golimumab.
75317482|NCT03241940|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
75317483|NCT03241940|Drug|Cyclophosphamide|Given IV
75462553|NCT01865370|Dietary Supplement|Placebo|Placebo (34.5g/day)
75462554|NCT01865383|Behavioral|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
75462555|NCT01865409|Behavioral|Kangaroo Care|Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
75615629|NCT00630435|Drug|Premarin®/MPA formulation B|
75615630|NCT00630435|Drug|Premarin®/MPA formulation C|
75615631|NCT00630435|Drug|Premarin®/MPA currently marketed product|
75317484|NCT03241940|Drug|Fludarabine Phosphate|Given IV
75317485|NCT03241940|Other|Laboratory Biomarker Analysis|Correlative studies
75317486|NCT03241940|Other|Questionnaire Administration|Ancillary studies
75615632|NCT02858193|Drug|1.35 g SCMC- lys powder|1.35 g SCMC- lys powder for oral solution
75768192|NCT01128868|Device|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
75768193|NCT01130194|Other|Combination of treatment modalities|"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."
75768194|NCT03928834|Behavioral|Adapted Nzira Itsva|Adolescents will be provided an enhanced adherence package consisting of VL testing using DBS, including the NI intervention and low-cost genotyping and drug resistance monitoring. Participants receiving the intervention will have their first session after recruitment and enrollment, and will schedule up to 4 additional booster sessions at a time convenient for them spaced approximately 1 month apart. This may be modified after the formative assessment.
75768195|NCT01221922|Device|RevLite Q-Switched Nd:YAG Laser|Laser treatment once every 2 weeks for a total of 10 treatments.
75768196|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
75768197|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
75909122|NCT04948372|Drug|Terlipressin treatment|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
75768198|NCT01227538|Other|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
75909123|NCT04948372|Drug|Usual care|Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
75909124|NCT03960606|Combination Product|PUR1900|PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
75909125|NCT03960606|Combination Product|Placebo|PUR1900 placebo
76071665|NCT04283942|Behavioral|Intermittent calorie restriction (ICR)|"Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
75317487|NCT03233854|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22 CAR T cells IV
75317488|NCT03233854|Drug|Cyclophosphamide|Given IV
75909126|NCT04947748|Other|Oral versus intravenous administration of antibacterial treatment|Mode of administration of antibacterial treatment
75317489|NCT03233854|Drug|Fludarabine Phosphate|Given IV
75317490|NCT03233854|Other|Laboratory Biomarker Analysis|Correlative studies
75317491|NCT03233854|Other|Questionnaire Administration|Ancillary studies
75317492|NCT03233854|Drug|NKTR-255|Given IV
75317493|NCT03132116|Drug|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
75317494|NCT03132116|Drug|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
75317495|NCT03073733|Biological|human retinal progenitor cells|live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
75615633|NCT02858193|Drug|Fluifort® syrup|SCMC-lys Syrup 90 mg/ml
75615634|NCT02858115|Other|Fluid challenge|100 ml of crystalloid was infused over 1-min
75615635|NCT02858115|Other|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
75615636|NCT00630591|Behavioral|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
75615637|NCT00630591|Behavioral|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
75615638|NCT00630591|Behavioral|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
75317496|NCT03073733|Other|Mock injection|pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection
75317497|NCT03029143|Drug|Vedolizumab IV|Vedolizumab intravenous infusion.
75317498|NCT02971137|Behavioral|Smoking Cessation plus CBI|proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
75768199|NCT03927040|Device|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.
75909127|NCT05184543|Other|Routine Exercise Program|8 weeks of routine basketball training will be done. Dynamic stretching exercises, in which large muscle groups are exercised, can be applied for 20 minutes.
75317499|NCT02971137|Behavioral|Smoking Cessation Standard|standard telephone-based smoking cessation intervention
75317500|NCT02959164|Drug|Decitabine|"Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~*Starting Dose Level"
75909128|NCT05184543|Other|Core Stability Exercise Program|In addition to the 8-week routine basketball training, 20 min core stability exercises will be given to the Core Group. Core stability exercises will be performed on the stable surface for the first 4 weeks, and core stability exercises will be performed on unstable surfaces for the next 4 weeks.
75909129|NCT05184543|Other|Body Weight Neuromuscular Warm-Up Program|Each 20-minute program consists of 5 different parts. The beginning of the program consists of low-speed running exercises with the ball. The running track for each exercise will include 4 basketball court areas. The second part consists of active stretching exercises. The third part consists of exercises focusing on general strength. The fourth part consists of plyometric, balance, and jump exercises. The final section consists of a sprint with sudden changes of direction and basketball movements.
75909130|NCT04947826|Procedure|HAIC (Hepatic arterial infusion chemotherapy)|For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
75317501|NCT02959164|Drug|Gemcitabine|"Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~*Starting Dose Level"
75317502|NCT02953262|Behavioral|My HealtheVet Brochure|Participants will receive a mailed brochure with basic My HealtheVet content.
75317503|NCT02953262|Behavioral|My HealtheVet Training Guide for Veterans Living with Diabetes|Participants will be mailed a bound My HealtheVet training guide with step by step instructions on how to register, upgrade to Premium account, refill prescriptions, use secure messaging, download their Blue Button reports, and other features
75317504|NCT02953262|Behavioral|My HealtheVet Group Training|Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes
75462556|NCT01865422|Other|parent-proxy QoL chronic cough specific questionnaire (PC-QOL)|
75615639|NCT02859675|Other|triangular test|metabolic state, impedance measurement, potential flavours evoked by sucrose,
75615640|NCT02859675|Biological|blood sampling|sampling of 2 mL
75768200|NCT03925012|Behavioral|Intervention|
75768201|NCT03928756|Behavioral|Push Notifications with Tailored Intervention Content|Participants will receive a push notification with a therapeutic message (e.g., about stress, mood, substance use motives, tools to reduce risky substance use) tailored to their recent daily or weekly survey responses. Messages include visual (memes, images, videos) and written content.
75768202|NCT03928756|Behavioral|Push Notifications with Engaging, Non-therapeutic Content|Participants will receive a push notification with an engaging, non-therapeutic message (e.g., fun facts).
75317505|NCT02953262|Behavioral|My HealtheVet Individual Training|Participants will be invited to participate in a one-on-one training to learn how to use My HealtheVet to help manage their diabetes at a time of their convenience.
75317506|NCT02924116|Device|Bioboosti|Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
75317507|NCT02904863|Biological|Extra blood draw samples|
75317508|NCT02899598|Biological|Extra blood draw samples|NEVER STARTED
75462557|NCT01865435|Genetic|cord blood sample|
75462558|NCT01865474|Drug|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
75462559|NCT01865474|Drug|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
75462560|NCT01865500|Drug|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
75462561|NCT01865500|Drug|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
75462562|NCT01865500|Drug|Metil prednisolone|
75615641|NCT02859675|Other|Questionnaires|Stunkard, PrefQuest
75615642|NCT02581215|Drug|mFOLFIRINOX|"mFOLFIRINOX:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
75615643|NCT02581215|Drug|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
75615644|NCT02581215|Other|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
75768203|NCT03928756|Behavioral|No Push Notifications|Participants will not receive a push notification.
75768204|NCT01225744|Drug|Cetuximab|"Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.~Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA > 2 m2 ."
75768205|NCT01225744|Drug|Irinotecan|Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
75768206|NCT01225744|Drug|Oxaliplatin|Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
75909131|NCT04947826|Drug|HLX10 (PD-1 antibody)|PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
75909132|NCT04947826|Drug|HLX04 (VEGF antibody)|Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
75909133|NCT04947826|Drug|Placebo|Placebo
75317509|NCT02899598|Biological|extra amniotic fluid samples|NEVER STARTED
75317510|NCT02899039|Biological|extra blood draw samples|
75462563|NCT01865526|Dietary Supplement|Six point diet|"The 6-point diet is a list of six items indicating how to modify their dietary habits:~Do not add salt at table and for cooking;~Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;~Replace noodle or bread with special no-protein food;~The second course (meat, fish and eggs) are allowed once a day in the usual quantity;~4-5 servings/day of fruits or vegetables are suggested;~Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables."
75317511|NCT02877706|Other|no specific intervention|
75317512|NCT02870517|Other|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have <60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
75615645|NCT04282941|Drug|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
75909134|NCT04947982|Other|carbon dioxide|carbon dioxide insufflation pressure
75909135|NCT03563079|Other|Instrument Assisted Soft Tissue Mobilization|Soft Tissue Mobilization
75909136|NCT03563079|Other|Manual Myofascial Release|Myofascial Release Technique
75909137|NCT02228616|Drug|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
75909138|NCT02228616|Drug|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
75909139|NCT02228616|Drug|Lactulose|Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
75615646|NCT04282941|Drug|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
75615647|NCT04280913|Other|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19.
75615648|NCT04282707|Procedure|Endoscopic closure of ESD defect|Closure of ESD defect would be performed with clip loop purse string technique
75615649|NCT04282707|Other|Gastric ESD without closure of ESD defect|Historical control with patients undergoing ESD without closure of ESD defect
75909140|NCT04759950|Behavioral|Multicomponent Physical Activity Program|The proposed physical exercise intervention follows the American College of Sports Medicine (ACSM, 2017) and the American Stroke Association (Billinger et al., 2014) recommendations for stroke patients. The five weekly 45-minute sessions are divided into (1) three sessions guided and supervised telematically by a physical exercise specialist and a physiotherapist; (2) and two autonomous exercise sessions. The supervised sessions include exercises to work aerobic capacity, muscle strength and endurance, flexibility, agility, and balance. The intensity of these exercises is prescribed individually according to each participant's initial level and are gradually increased as the program progresses. Participants are encouraged to walk at a similar intensity on autonomous physical exercise days as performed in the guided sessions (moderate intensity), based on the Borg scale of perceived exertion (Borg, 1982).
75317513|NCT02870517|Other|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
75317514|NCT02838303|Other|Organophosphate|Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
75317515|NCT02838303|Other|Placebo|Multineem, WHO Class U: Unlikely to present acute hazard in normal use
75317516|NCT02815696|Device|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
75317517|NCT02803502|Device|Chronometric method|Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)
75317518|NCT02803502|Device|Chromogenic method|"Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)"
75615650|NCT00910858|Drug|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
75768207|NCT01225744|Drug|UFT|UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
75768208|NCT01585636|Drug|SQ109|Single oral dose
75768209|NCT03926806|Other|Plain yoghurt|cups of 200 g yoghurt
75768210|NCT03926806|Other|Vitamin B yoghurt|cups of 200 g yoghurt
75462564|NCT01865526|Dietary Supplement|Low protein diet|Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
75768211|NCT03926962|Drug|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
75768212|NCT03926962|Drug|Placebo Oral Tablet|Visually matching placebo
75768213|NCT01131208|Genetic|gene expression analysis|
75768214|NCT01131208|Other|laboratory biomarker analysis|
75768215|NCT03926884|Dietary Supplement|Three-seeds mixture|mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
75909141|NCT04759950|Behavioral|Mindfulness-Based Stress Reduction Program|This intervention follows an adaptation of the scheme and instructions of the official Mindfulness-Based Stress Reduction (MBSR) program designed by Jon Kabat-Zinn. It includes body scanning, sitting meditation, and gentle hatha yoga techniques. An accredited mindfulness instructor leads the 12-week online program, which comprises a presentation session, followed by eight intervention sessions (once a week, lasting 2.5 hours) and an intensive practice session interspersed between sessions six and seven. Apart from the supervised session, the therapist asks participants to carry out some independent practice daily.
76072428|NCT01819129|Drug|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
75462565|NCT01865578|Device|tDCS|Transcranial direct current stimulation involves the application of weak electric currents to the brain.
75317519|NCT02803502|Device|Thrombin generation test (TGT)|"Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used."
75615651|NCT00910858|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
75317520|NCT02763579|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab intravenous infusion was administered at a dose of 1200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
75462566|NCT01865578|Device|Sham Stimulation|no electrical stimulation
75462567|NCT01865591|Device|Ultrasound-based Renal Denervation|
75462568|NCT01865604|Device|Anodal tDCS|
75462569|NCT01865604|Device|Cathodal tDCS|
75768216|NCT03926884|Dietary Supplement|Control|warm water with negligible amount of the three-seeds mixture
75768217|NCT01227694|Other|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
75462570|NCT01865604|Device|sham tDCS|
75462571|NCT01865630|Drug|Etanercept|Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
75462572|NCT01865643|Device|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
75462573|NCT01865656|Other|Skills training|Refresher training on Basic Emergency Obstetric and Newborn care
75462574|NCT01865656|Other|Emergency obstetric drills|Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
75615652|NCT02859285|Other|Placebo vulvar cream|
75615653|NCT02859285|Other|Estradiol vulvar cream|
75615654|NCT04260412|Device|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
75768218|NCT03740308|Device|Locally Made Zirconia Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. Locally Made Zirconia Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
75768219|NCT03740308|Device|ZR Zirconia Crwons NuSmile ® Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. ZR Zirconia Crwons NuSmile ® Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
75768220|NCT01227772|Biological|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
75768221|NCT02528578|Device|thermal stimulation delivered by a thermode.|Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
75768222|NCT02528578|Other|functional MRI|MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
75768223|NCT03926650|Device|Masimo Sedline Monitor Patient State Index|Masimo Sedline Monitor shows frontal electromyography and patient state index, Train of four monitor shows muscle strength on adductor pollicis muscle
75768224|NCT03919786|Procedure|topical local anesthesia of pulmonary vein combined with vagus nerve block|"Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex."
75768225|NCT03920020|Other|the concentric isokinetic exercise group|concentric isokinetic exercises
75768226|NCT03920020|Other|the eccentric isokinetic exercise group|eccentric isokinetic exercises
75768227|NCT03920020|Other|the control group|conventional physiotherapy and standard therapeutic exercises predetermined by us
75768228|NCT01132066|Other|tDCS|tDCS will lead to an increase in cortical excitability
75768229|NCT01132066|Other|Sham|Sham will provide identical subjective sensation as tDCS
75768230|NCT03924544|Drug|Decorin|Antifibrotic agent
75768231|NCT03924544|Drug|Mitomycin c|Antifibrotic agent
75768232|NCT01131364|Drug|F16IL2 in combination with doxorubicin|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
75768233|NCT02529202|Drug|Dexmedetomidine|Dexmedetomidine infusion
75768234|NCT00154310|Drug|Everolimus|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
75768235|NCT00154310|Drug|Cyclosporine|Tablets orally twice a day to maintain protocol specific target blood levels
75909142|NCT04759950|Behavioral|Computerized Cognitive Training|An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
75909143|NCT05086965|Other|Playing the virtual game simulation|The virtual game simulation developed by the researchers and designed by the researchers will be played on the computer for the students of the intervention group. Virtual game simulations are virtual games developed by researchers, specific to a clinical scenario, and prepared by transferring the videos taken with an action camera to the computer environment and displaying them in two dimensions.
75317521|NCT02763579|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
75317522|NCT02763579|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
75317523|NCT02763579|Drug|Placebo|Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
75615655|NCT04260412|Dietary Supplement|Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
75768236|NCT00154310|Drug|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
75768237|NCT00154310|Drug|Corticosteroids|Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
75768238|NCT03771352|Device|RxSight RxLAL|The patients will be assessed for 6 months
75768239|NCT03770728|Drug|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
75768240|NCT03770728|Drug|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
75317524|NCT02737748|Drug|TWB-103 Group|Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
75317525|NCT02737748|Drug|Placebo Group|Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
75317526|NCT02730299|Drug|NiCord® (omidubicel)|
75317527|NCT02730299|Other|Cord Blood Unit|Cord blood unit
75615656|NCT04260412|Dietary Supplement|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
75768241|NCT03770728|Drug|Background therapy: Metformin alone or in combination with SU|Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
75768242|NCT01130428|Device|Juvent 1000 Vibration Platform|"As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading [38]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes."
75768243|NCT01228396|Drug|Hyperimmune caprine serum against HIV lysate|1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
75768244|NCT02529358|Behavioral|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
75768245|NCT02529358|Behavioral|Personalized text messages|Patients write their own messages
75768246|NCT02529358|Behavioral|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
75768247|NCT01228474|Other|Select the Number of embryos to transfer|Select the Number of embryos to transfer
75768248|NCT01132222|Drug|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
75768249|NCT03926182|Drug|AST2818 Tablets|AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
75768250|NCT03926182|Drug|AST2818 Tablets|AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
75768251|NCT01132300|Device|Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)|Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
75768252|NCT03926416|Biological|CodaVax-H1N1|Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
75768253|NCT03926416|Biological|Fluzone quadrivalent|Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
75768254|NCT01130506|Drug|Cytarabine|Given IV
75768255|NCT01130506|Drug|Decitabine|Given IV
75768256|NCT01130506|Other|Laboratory Biomarker Analysis|Correlative studies
75317528|NCT02633644|Device|Harmony System|Percutaneous neuromodulation of the aortic wall
75317529|NCT02623699|Drug|Tofersen|Administered as specified in the treatment arm.
75317530|NCT02623699|Drug|Placebo|Administered as specified in the treatment arm.
75462575|NCT01865656|Other|Revised Case Sheets|Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
75909144|NCT04947280|Radiation|Fractionated Stereotatic Radiation Therapy|Participants prescribed to receive 9 Gy x 3 or 10 Gy x3 image-guided fractionated stereotatic radiation therapy.
75909145|NCT03834675|Diagnostic Test|transpulmonary thermodilution|Thermodilution was attempted via PICC and via CICC
75317531|NCT02618577|Drug|Edoxaban|"Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
75462576|NCT01865656|Other|Supportive supervision|Quarterly supportive supervision visits each of the intervention first referral units.
75462577|NCT01865656|Other|Referral strengthening|To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
75462578|NCT01865669|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
75462579|NCT01865695|Drug|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
76072429|NCT01819129|Drug|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
75768257|NCT01130506|Other|Pharmacological Study|Correlative studies
75462580|NCT01865695|Other|Placebo|
75462581|NCT01865721|Drug|Entonox|Entonox will be used according to the allocated method
75768258|NCT01130506|Drug|Vorinostat|Given PO
75768259|NCT01130584|Other|Pyruvate kinase isoform M2|
75768260|NCT01130662|Drug|combination therapy using decitabine and midostaurin|"Cohort 1:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.~Cohort 2:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.~Cohort 3:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle."
75768261|NCT01228006|Dietary Supplement|NatusGerin|1 capsule, 2 times a day.
75768262|NCT01228006|Other|Placebo capsules|1 capsule, 2 times a day
75768263|NCT01132456|Device|Drug eluting stent treatment|Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
75768264|NCT03924388|Device|Epidural spinal cord stimulation|The measurements will be obtained in 2 positions of supine and ~ 70° upright adjusted by the tilt-up table.
75768265|NCT03924388|Device|Trnascutaneous electrical spinal cord stimulation.|The measurements will be obtained in 2 positions of supine and ~ 70° upright adjusted by the tilt-up table.
75768266|NCT03925948|Behavioral|PLAN 4 Success-Diabetes|The study intervention-PLAN 4 Success-Diabetes-consisted of four 1 to 1 ½-hour weekly health literacy training and disease knowledge education sessions for four weeks (4 in-person sessions), followed by two home visits and monthly phone counseling for over 6 months (5 phone sessions). The intervention is theory-driven and builds on von Wagner's model to incorporate key elements such as health literacy, disease knowledge, and self-efficacy for better glucose outcomes.
75909146|NCT03830541|Other|Oral care delivery analysis in participants with ASD|The analysis of oral health status, tooth loss, oral rehabilitation, characteristics of routine dental treatment and treatment in general anaesthesia in persons with ASD
76072430|NCT01819129|Drug|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
76072431|NCT04147065|Drug|Duration of eradication regimen|14 day eradication regimen
76072432|NCT04024137|Drug|ZSP1273 200 mg|1 X 200-mg tablet taken orally
76072433|NCT04024137|Drug|Placebo|2 tablets taken orally
75317532|NCT02618577|Drug|ASA|ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripherial or coronary artery disease, a prior myocardial infarction, or a prior stroke.
75768267|NCT03919630|Other|Thrust Mobilization|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine
75768268|NCT03919630|Other|Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
75768269|NCT03925792|Behavioral|Lifestyle Medicine|diet, sleep, exercise and mindfulness
75768270|NCT03925714|Other|life style|life sryle control only
75768271|NCT03925714|Drug|Metformin|metformin twice daily
75768272|NCT03925714|Drug|Nigetella salivata|NS twice daily
75768273|NCT03919240|Biological|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
75768274|NCT01228552|Drug|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
75768275|NCT01228552|Other|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
76072434|NCT04024137|Drug|ZSP1273-400 mg|2 X 200-mg tablet taken orally
75768276|NCT03924076|Dietary Supplement|UHT Milk + Lactobacillus plantarum IS-10506|125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
75768277|NCT03924076|Dietary Supplement|UHT Milk|125 ml UHT milk given to placebo group
75317533|NCT02572791|Drug|Chlorhexidine|
75317534|NCT02572791|Drug|Mupirocin|
75768278|NCT03925558|Dietary Supplement|Probiotics|
75768279|NCT03925558|Dietary Supplement|Placebo|
75768280|NCT01228162|Procedure|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
75317535|NCT02572791|Behavioral|Household cleaning|
75317536|NCT02501642|Behavioral|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
75317537|NCT02501642|Other|Treatment as usual|Treatment as usual
75317538|NCT02475954|Behavioral|TH-CBT|The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via Video-to-Home (V2H).
75317539|NCT02475954|Other|Standard Care|Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable anti-depressant medications, established psychotherapy, clinical monitoring).
75317540|NCT02459587|Behavioral|Crisis Line Facilitation (CLF)|This single session therapist-delivered intervention addresses Veterans' perceived barriers and facilitators of crisis line use during periods of suicidal crisis. The CLF session culminates with the Veteran calling the Crisis Line with the therapist in the room as a way for the Veteran to practice the logistics of making the call and to have direct experiences that may counter any negative beliefs about Crisis Line use.
75768281|NCT03919084|Other|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
75909147|NCT04946890|Drug|MRX2843|MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
75317541|NCT02459587|Behavioral|Enhanced Usual Care (EUC)|Those in the EUC condition received the same promotional items and information about the Veterans Crisis Line (VCL) as the CLF condition. Participants were encouraged to seek help via a provider or the VCL if they felt suicidal in the future. Research staff briefly explained key information about the VCL to those in the EUC condition (e.g., the links between the VCL and the VA, the 24/7/365 availability, etc.).
75317542|NCT02307747|Other|blood samples|Blood samples will be collected every 4 hours during 24 h
75317543|NCT02281084|Drug|Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
75317544|NCT02281084|Drug|Durvalumab|Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
75909148|NCT04413604|Other|Young children's milk (1-<3)|young children's milk containing protein, energy and fat and micronutrients, in accordance with global and local nutritional recommendations for ages 1-3.
75909149|NCT02228772|Drug|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
76072435|NCT04024137|Drug|Placebo|1 tablet taken orally
76072436|NCT04024137|Drug|ZSP1273-600 mg|3 X 200-mg tablet taken orally
75317545|NCT02189018|Other|Active Exercise|Active exercise on a treadmill
75317546|NCT02189018|Other|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
76071666|NCT04283942|Behavioral|Continuous calorie restriction (CCR)|"Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × [height (cm) - 100] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
75317547|NCT02189018|Other|Weight loss and active exercise|Weight loss and active exercise on a treadmill
75768282|NCT03919084|Other|Pharmacy Care Program services|Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
75768283|NCT03919084|Other|Patient Navigation Services|In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
75768284|NCT03919084|Other|Motivational Interviewing|Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
75768285|NCT03919084|Other|Linkage to Community Partner Organization|The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
75317548|NCT02189018|Other|Ad lib activity at home|Ad lib activity at home
75317549|NCT02038361|Genetic|blood draw|
76071667|NCT04283019|Drug|CBD|CBD will be orally ingested
75615660|NCT02859051|Device|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
75615661|NCT04476550|Drug|Filgrastim|5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
75317550|NCT02013505|Other|Educational video|An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
75317551|NCT01991249|Other|blood draw|
75317552|NCT01973972|Behavioral|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
75615662|NCT00598975|Drug|NKTR-102 100 mg/m2|"NKTR-102 100 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
75615663|NCT00598975|Drug|NKTR-102 125 mg/m2|"NKTR-102 125 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
75615664|NCT00598975|Drug|Cetuximab|Cetuximab was administered once weekly via a 2-hour IV infusion at a starting dose of 400 mg/m2 on Day 1 and subsequently administered weekly at 250 mg/m2 via a 1-hour infusion thereafter.
75615665|NCT00957021|Device|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
75615666|NCT01124604|Drug|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
75909150|NCT02228772|Drug|Vincristine|Standard chemotherapy dosage and duration
75909151|NCT02228772|Drug|Cytarabine|Standard chemotherapy dosage and duration
76071668|NCT04283019|Drug|THC|THC will be orally ingested
76072437|NCT04024137|Drug|Placebo|3 tablets taken orally
75317553|NCT01973972|Behavioral|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
75317554|NCT01966120|Drug|BF-200 ALA gel|BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.
75462582|NCT01865734|Other|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
75768286|NCT03919318|Other|Root Canal Filling Sealers|Root Canal Obturation
75768287|NCT01329484|Behavioral|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
75768288|NCT01329484|Behavioral|Cognitive training|Cognitive training using a computerized system
75615667|NCT01124604|Drug|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
75615668|NCT00909844|Drug|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
75768289|NCT01329484|Other|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
75768290|NCT03923842|Drug|Denosumab Inj 120 MG/1.7ML|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
75768291|NCT03923842|Drug|Chemotherapy as clinical standard of care|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
75768292|NCT01130818|Drug|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
75317555|NCT01966120|Drug|Placebo to BF-200 ALA gel|The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
75615669|NCT02645695|Device|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
75615670|NCT02645695|Device|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
75615671|NCT02882568|Biological|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
75615672|NCT04232020|Diagnostic Test|Mismatch repair|MSI testing using Biocartis Idylla and MMR immunohistochemistry
75462583|NCT01865734|Other|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
75462584|NCT01865760|Dietary Supplement|Oral Glucose tolerance test (OGGT)|At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes
75615673|NCT00654433|Biological|ALD-101|A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
75615674|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
75768293|NCT01130818|Drug|placebo|single dose, oral solution
75768294|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), fasting
75768295|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), after high fat breakfast
75768296|NCT03924154|Drug|RVT-1201|RVT-1201 600 mg immediate-release tablet
75768297|NCT03924154|Drug|Placebo|Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
76071669|NCT04281992|Biological|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
75462585|NCT01865760|Dietary Supplement|Liquid mixed meal|At baseline subject will consume the liquid mixed meal in 10 minutes
75615675|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
75768298|NCT03923998|Drug|Neoadjuvant chemotherapy|Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
75768299|NCT03923998|Radiation|Neoadjuvant radiotherapy|Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
75317556|NCT01966120|Procedure|Photodynamic therapy with BF-RhodoLED|After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
75317557|NCT01908725|Drug|Lamazym|ERT, i.v. infusions weekly
75768300|NCT03923998|Procedure|Resection and reconstruction|Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
75768301|NCT03923764|Dietary Supplement|High protein and energy diet|Intervention group receives nutritional counseling to increase protein and energy in their diet to reach their estimated protein need (1.3 g/kg). Kontrol group continues their usual diet.
75768302|NCT03923764|Other|Habitual Diet|Patients continue their usual diet
75768303|NCT01229956|Genetic|DNA methylation analysis|
75768304|NCT01229956|Genetic|gene expression analysis|
75768305|NCT01229956|Genetic|microarray analysis|
75768306|NCT01229956|Genetic|reverse transcriptase-polymerase chain reaction|
75768307|NCT01229956|Other|laboratory biomarker analysis|
75768308|NCT03919006|Other|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
75768309|NCT03919006|Other|Gingival crevicular fluid, saliva and serum collection|GCF with filter paper using the intracrevicular method, saliva and serum collection
76072438|NCT04024137|Drug|Placebo|Subjects will receive matching placebo of ZSP1273
75909152|NCT02228772|Drug|Doxorubicin|Standard chemotherapy dosage and duration
75909153|NCT02228772|Drug|Mercaptopurine|Standard chemotherapy dosage and duration
75909154|NCT02228772|Drug|Cyclophosphamide|Standard chemotherapy dosage and duration
76071670|NCT04275973|Device|Lower limb prostheses|"Standard commercially available prostheses for participants with lower-limb amputation.~Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA)."
76071671|NCT04275973|Device|Orthoses for Drop-foot|Standard commercially-available orthoses or standard-of-care custom orthoses as well as standard commercially-available electrical stimulation neuro-orthoses.
75317558|NCT01798589|Drug|Ethylenediamine dihydrochloride allergen patch|1 allergen panel containing 2 allergen and 2 control patches
76071672|NCT04275973|Device|Footwear|Different footwear will be used.
75462586|NCT01865760|Drug|Octreotide|At baseline subjects will receive Octreotid 100 µg subcutaneous
75462587|NCT01865773|Procedure|HFR dialysis|HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
75462588|NCT01865825|Radiation|Esophageal Barium Xray|"•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day."
75462589|NCT01865838|Device|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
75768310|NCT01132768|Drug|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
75768311|NCT01132768|Drug|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
75768312|NCT01230034|Drug|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
75768313|NCT01230034|Drug|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
75768314|NCT03918616|Drug|Memantine, Dopamine receptor-agonists|The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
75768315|NCT03925168|Behavioral|Music therapy|Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
75768316|NCT03918694|Dietary Supplement|Vitamin C|Daily use of Vit C tablets
75768317|NCT03918694|Dietary Supplement|Placebo|Daily use of placebo tablets
75768318|NCT03923608|Diagnostic Test|Maximal muscle strength Test|1RM test performed in 5 different tools (Elastic Band, Pulley, halter, digital dynamometer and isokinetic dynamometer)
75768319|NCT03923608|Diagnostic Test|Exhaustion test|Test performed until individual exhaustion in 5 different tools (Elastic Band, Pulley, halter and isokinetic dynamometer)
75909155|NCT02228772|Drug|Methotrexate|Standard chemotherapy dosage and duration
75768320|NCT01228630|Drug|Cloratadd-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
75768321|NCT01228630|Drug|Allegra-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
75909156|NCT03833037|Other|Soft tissue sarcomas in adults|Adult sinovial sarcoma
75317559|NCT01693796|Other|blood and urine samples ; Echography|
75768322|NCT05402644|Procedure|hepatectomy|Liver resection
75768323|NCT03918538|Behavioral|Home rehabilitation exercise program|After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual. The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers.
75768324|NCT01230190|Dietary Supplement|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1*10^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
75768325|NCT01230190|Dietary Supplement|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
75909157|NCT03638466|Diagnostic Test|Functional Magnetic Resonance Imaging (fMRI)|Neural brain activity measured by fMRI
75909158|NCT03638466|Diagnostic Test|Magnetic Resonance Spectroscopy (MRS)|Glutamate and GABA levels measured by MRS
75909159|NCT03638466|Behavioral|Point Subtraction Aggression Paradigm (PSAP) Task|Aggression score measured by the PSAP task
75909160|NCT03638466|Drug|SPN-810|Treatment of SPN-810 36 mg on neuronal brain activity, GABA and Glutamate levels and on the aggression score
75909161|NCT03638466|Drug|Placebo|Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
76071673|NCT04273672|Diagnostic Test|Cognitive Battery|Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
76071674|NCT04273672|Behavioral|Voice, Speech and Language Analysis|Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
76072439|NCT04146831|Drug|Sintilimab|Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
75768326|NCT01228708|Other|Active implementation of a guideline for chronic disease|"Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD"
75768327|NCT05402488|Behavioral|Auditory stimulation|Auditory stimulation during sleep
75768328|NCT03923062|Device|chemicalpeeling|"Cleansing and degreasing the face with alcohol .~The patients must be sitting at an angle of 45.~A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~We then will wait for a few minutes and will observe the frost developing.~The patient will be then allowed to wash her face."
75768329|NCT03923062|Device|cryopeeling|Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
75909162|NCT03630588|Combination Product|Surimi intervention|"The bioactive compounds used to obtain the surimi product are:~Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.~EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States.~Probiotic BPL1~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi."
75909163|NCT03630588|Combination Product|Placebo|"Conventional surimi~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi."
75909164|NCT02228850|Drug|Alprostadil|
75909165|NCT02228850|Other|Placebo|
75317560|NCT01511614|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).
75462590|NCT01865851|Device|Classic Face Mask and NuMask|
75462591|NCT01865916|Drug|Polyethylene Glycol (PEG) and 15 mg Bisacodyl|Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl
75615676|NCT02643745|Procedure|Nephrology Intervention|"pre-operative study:~Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~optimise the patient' s overall condition with a pre-operative strategy:~Obesity control~Control protein, caloric, salt intake~Stop smoking~Good glycemic control~Start ACEI/ARA II if there is proteinuria~Start additional antihypertensive drug if required~Start hypolipemic treatment if required~Start hyperuricemia treatment if required~Start AAS, clopidogrel if it is necessary (prophylaxis)~Phosphate control~Anemia control~Metabolic acidosis correction"
75615677|NCT02638909|Drug|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
75615678|NCT01124292|Procedure|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
75909166|NCT02232828|Procedure|Selective removal|Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
76071675|NCT04273672|Behavioral|Questionnaires and Clinical Assessments|Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
76071676|NCT04273672|Genetic|DNA Analysis|Participants will have their blood drawn for DNA analysis.
75462592|NCT01865916|Drug|Polyethylene Glycol (PEG) + ascorbic acid|Subjects will be asked to take split dose of 2L PEG and vitamin C
75462593|NCT01865929|Device|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
75462594|NCT01865929|Procedure|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
75462595|NCT01865942|Procedure|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
75462596|NCT01865942|Procedure|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
75462597|NCT01865955|Procedure|Ultrasound|Ultrasound applied to the lumbar region to determine spinal needle placement.
75462598|NCT01865955|Device|The spinal needle|
75768330|NCT03923062|Combination Product|microneedling|"Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions"
75768331|NCT03918226|Procedure|exploratory laparotomy|Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
75768332|NCT01230268|Other|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
75768333|NCT01134406|Device|Hydros Joint Therapy|Single intra-articular injection.
75768334|NCT01134406|Device|Hydros-TA Joint Therapy|Single intra-articular injection
75768335|NCT01134406|Device|Synvisc-One|Single intra-articular injection.
75768336|NCT01231828|Drug|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
75768337|NCT01231828|Drug|Lactulose|Lactulose (30-60 ml per day)
75909167|NCT02232828|Procedure|Stepwise removal|"Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.~If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described."
75909168|NCT02232906|Drug|intravenous ferric carboxymaltose|Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation >20%)
75909169|NCT03563001|Drug|Budesonide(160ug) and Formoterol(4.5ug) bid|For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
75317561|NCT01511614|Device|sham|Sham Comparator
75317562|NCT00977860|Radiation|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
75317563|NCT00840944|Drug|somatropin|somatropin 0.050 mg/kg/day
75462599|NCT01865968|Biological|Inactivated HAV vaccine|Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.
75768338|NCT03923218|Other|LL-37 levels in Gingival crevicular fluid|Collected gingival crevicular fluid
75768339|NCT03923218|Other|Serum Vitamin D3 levels|Collected serum
75768340|NCT03923218|Other|Clinical parameters|Recorded plague index, gingival index, probing depth, clinical attachment level
75768341|NCT03923140|Drug|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
75768342|NCT05402410|Diagnostic Test|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
75768343|NCT05402176|Other|Whole Lung Lavage|Whole Lung Lavage (WLL) is performed as standard of care. Outcome following WLL is observed.
75768344|NCT01133080|Drug|Minocycline|minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
75768345|NCT01133080|Drug|placebo|"placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses."
75768346|NCT05402098|Procedure|Endodontic treatment using traditional access|Endodontic treatment will be carried out following complete removal of pulp chamber roof and achieving straight line access
75909170|NCT02228928|Drug|CAPNP, 50 ug/cm2 capsaicin patch|
75909171|NCT02228928|Drug|CAPNP, 100 ug/cm2 capsaicin patch|
75909172|NCT02228928|Drug|0.075% capsaicin cream|
75909173|NCT02228928|Other|Placebo patch|
75909174|NCT03888378|Drug|0.3% Topical Minocycline Ointment|0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
75909175|NCT03888378|Drug|1% Topical Minocycline Ointment|1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
75317564|NCT00840944|Drug|triptorelin|triptorelin 3.75 mg each month
75317565|NCT00579566|Other|Specimen protocol|The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
75317566|NCT00085930|Biological|EBV specific CTLs|CTLs: 2x10e7 cells/m2
75317567|NCT00386477|Procedure|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
75317568|NCT04024046|Dietary Supplement|Uqora|Participants will receive 1 Placebo Drink-Mix and 2 Placebo Capsules Daily
75317569|NCT04024046|Dietary Supplement|Group1|Participants will receive 1 Uqora Drink-Mix and 2 Placebo Capsules Daily
75317570|NCT04024046|Dietary Supplement|Group 2|Participants will receive 1 Uqora Drink-Mix and 2 Uqora Capsules Daily
75317571|NCT00453193|Drug|Pentostatin|4 mg/m^2 IV weekly for 4 weeks then every 2 weeks
75317572|NCT00453193|Drug|Alemtuzumab|30 mg IV three times weekly
75462600|NCT01865968|Biological|Live attenuated HAV vaccine|Live attenuated hepatitis A vaccine, 6.50 lgCCID50 per dose per 0.5 millilitre. Vaccines will be administered with one-dose regimen in the deltoid muscle.
75462601|NCT01866007|Drug|Guselkumab (lyophilized formulation)|Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
75462602|NCT01866007|Drug|Guselkumab (liquid formulation with PFS-U)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
75909176|NCT03888378|Other|Topical Vehicle Ointment|Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction
75909177|NCT03603288|Drug|idebenone 150 mg film-coated tablets|900 mg idebenone/day
75768347|NCT05402098|Procedure|Endodontic treatment using conservative access|Endodontic treatment will be carried out following partial removal of pulp chamber roof, extended only to the extent which helps to locate all the orifices with no efforts will be made to achieve straight line access
75768348|NCT01133236|Dietary Supplement|Salt and fluid restriction|"I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction."
75768349|NCT01230580|Drug|Protease Inhibitor|Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
75768350|NCT01230580|Drug|Standard-of-care Antiretroviral therapy|Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
75768351|NCT05401942|Other|Tele-monitoring through mobile application|Tele-monitoring of Patient reported outcomes
75768352|NCT01585792|Drug|TAK-875|
75768353|NCT01585792|Drug|TAK-875|
75768354|NCT01585792|Drug|Glimepiride|
75768355|NCT01585792|Drug|Placebo|
75768356|NCT03922672|Behavioral|Group piano training|The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
75768357|NCT01134484|Drug|Velcade|"INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)"
75768358|NCT01134484|Drug|Thalidomide|"INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70"
75909178|NCT03597360|Radiation|CT scan|Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
75909179|NCT02229006|Radiation|18F-NaF PET-CT|
75909180|NCT03576534|Other|Use of prebypass ultrafiltration (PBUF)|In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.
76071677|NCT04266795|Drug|Pevonedistat|Pevonedistat IV infusion.
76071678|NCT04266795|Drug|Venetoclax|Venetoclax tablets.
75317573|NCT00387023|Drug|Rituximab|250 mg/m^2 IV over 4-6 hours for 2 weeks.
75317574|NCT00387023|Drug|Zevalin|5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
75317575|NCT02985476|Other|Health reports|Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
75462603|NCT01866007|Drug|Guselkumab (liquid formulation with PFS FID)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
75909181|NCT03556956|Drug|Masitinib|Tyrosine kinase inhibitor
76071679|NCT04266795|Drug|Azacitidine|Azacitidine IV or SC injection.
76071680|NCT04265586|Behavioral|Education|"Sleep hygiene education is either face-to-face appointment or video-meeting with trained nurse."
75317576|NCT00472849|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.
76071681|NCT04265586|Behavioral|Web-based Cognitive Behavioural Therapy (iCBT)|iCBT is a web-based programme (7-16 weeks) designed to treat the symptoms of insomnia.
75317577|NCT00472849|Drug|Fludarabine|Fludarabine 30 mg/m^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.
75317578|NCT00472849|Drug|Cytarabine|Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.
75317579|NCT00472849|Drug|Rituximab|Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses).
75462604|NCT01866007|Drug|Guselkumab (liquid formulation)|Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
75462605|NCT01866033|Drug|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
75462606|NCT01866033|Drug|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
75462607|NCT01866033|Drug|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
75768359|NCT01134484|Drug|Dexamethasone|"INDUCTION THERAPY~VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)"
75768360|NCT01134484|Procedure|Peripheral Blood Stem Cell (PBSC) collection|"Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection"
75768361|NCT01134484|Procedure|First Autologous Transplantation|"HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days"
76071682|NCT04262466|Drug|IMC-F106C|IMC-F106C weekly IV infusions or SC injections
75909182|NCT02750592|Drug|Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.|Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
75768362|NCT01134484|Procedure|Second Autologous Transplantation|"HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days"
75768363|NCT03922906|Device|Pure-Vu System|Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g. blood.
75317580|NCT00472849|Drug|Pegfilgrastim|6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
75317581|NCT01399736|Procedure|FFR-guided revascularisation strategy|FFR-guided revascularisation strategy
75615679|NCT01124292|Device|Usability assessment|"Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.~Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions."
75615680|NCT02645539|Device|intravascular ventricular assist system (iVAS)|A mechanical circulatory support device using the principles of counterpulsation.
75615681|NCT02638675|Behavioral|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
75615682|NCT02638675|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
75909183|NCT03857646|Drug|Intralipid, 20% Intravenous Emulsion|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
75909184|NCT03857646|Drug|SMOF lipid|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
75909185|NCT03844074|Biological|bevacizumab|1.25 mg, intravitreal injection
75909186|NCT03844074|Biological|ranibizumab|0.5mg, intravitreal injection
75909187|NCT02624986|Drug|Idasanutlin|Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing.
75909188|NCT02624986|Drug|Obinutuzumab|Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months.
75615683|NCT02638675|Behavioral|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
75615684|NCT02638753|Other|education|Patients will be educated about pain neurophysiology.
75768364|NCT03918148|Drug|SGLT-2i|Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
75317582|NCT01399736|Procedure|randomised to guidelines group|Staged revascularisation by proven ischemia or persistence of symptoms of angina
75317583|NCT00453895|Drug|Sunitinib|50mg Sunitinib
75317584|NCT04481425|Other|SMS intervention|SMS intervention
75317585|NCT05365646|Device|Hearing aids equipped with motion sensing abilities|Participants will wear hearing aids that will assess their movement, and fall risk.
75768365|NCT03918148|Drug|DPP-4i|Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
75909189|NCT02624986|Drug|Rituximab|Participants received a fixed dose of rituximab, 375 mg/m^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants was to be given at a dose of 375 mg/m^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
75909190|NCT04412200|Device|Hyperbaric oxygen chamber (HBOC)|HBOC group will receive 100% oxygen at 2 ATA for 90 min with 5 min air breaks every 20 min at each session. Intensive management period includes 60 daily sessions, 5 days per week within 12 weeks,
76071683|NCT04262466|Drug|IMC-F106C and atezolizumab and pembrolizumab|IMC-F106C weekly IV infusions and atezolizumab Q3W IV infusion and pembrolizumab Q6W IV infusion
75317586|NCT00528541|Biological|botulinum toxin type A|200 Units at Visit 1 (Day 1)
75615685|NCT02638753|Other|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
75317587|NCT00528541|Biological|botulinum toxin type A|750 Units at Visit 1 (Day 1)
75317588|NCT00409565|Drug|Cetuximab|"Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"
75317589|NCT00409565|Drug|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
75317590|NCT00475501|Drug|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
75317591|NCT00475501|Drug|Finasteride|5 mg, oral, once/day, for 52 weeks
75317592|NCT00475501|Other|Placebo|Placebo
75317593|NCT04750421|Device|Transillumination Venolux®|Transillumination Venolux® method was used on the other half of the face before injections to visualize veins.
75615686|NCT02643589|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
75768366|NCT03917680|Diagnostic Test|Factor XII dosage|Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.
75768367|NCT03917680|Genetic|p.Thr328Lys mutation detection|Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.
75768368|NCT03917680|Diagnostic Test|Videocapillaroscopy|It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.
75768369|NCT03740074|Behavioral|PAI|"Consenting subjects will be given a Mio Slice, along with instructions on how to utilize the device.~They will register on line with PAI Health, and will be asked to sync their device at least once every 7 days. They will be encouraged to look at the device app on their smart phone at least once daily.~After 1 week of obtaining baseline data, subjects will be encouraged to try to obtain a PAI score of at least 30 initially. Once they obtain a score of 30 consistently, they will be encouraged to increase the score toward 50. If they consistently obtain 50, they can increase their goal sequentially toward a maximum goal of 100. The duration of the study will be 12 weeks."
75768370|NCT01133470|Drug|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
75768371|NCT01134718|Drug|TMC435 (G006)|one morning dose of 150 mg
75768372|NCT01134718|Drug|TMC435 (F021)|one morning dose of 150 mg
75768373|NCT01134718|Drug|TMC435 (G007)|one morning dose of 150 mg
75768374|NCT03922360|Behavioral|Smartphone-based Financial Incentives|"Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples < 6 ppm will be considered negative and those > 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test."
75768375|NCT03922360|Behavioral|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
75768376|NCT01228864|Procedure|quality of life|survey
75768377|NCT01228864|Procedure|Quality of life|
75768378|NCT03917758|Drug|SGLT2 inhibitor|Start of the treatment with SGLT2i.
75768379|NCT05206474|Device|IRADYN|"One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2 ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
75909191|NCT03058198|Diagnostic Test|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
75909192|NCT04946578|Dietary Supplement|Prebiotic|6 weeks of prebiotic supplementation twice a day
75909193|NCT04946578|Other|Placebo|6 weeks of maltodextrin supplementation twice a day
75909194|NCT04946422|Procedure|Arthroscopy|Discharge diagnosis of patients with sports injury-related injuries
75909195|NCT04945954|Other|Drug: Cyclophosphamide|"Administer 14.5mg/kg of Cyclophosphamide once a day for 4days. (intravenously)~Blood sampling of pharmacokinetics(PK) of cyclophosphamide will be performed in all patients who have taken the investigational drug for at least 4 days (For 2 days, It will be administered for pretreatment of transplant, for the other 2 days, It will be administered for Post-transplant treatment for the prevention of GVHD)"
75909196|NCT04946188|Device|Opuz NICGM|A wearable and non-invasive prototype device that allows for measurement of bioimpedance data with the aim to help develop a mathematical model to predict blood glucose levels.
75909197|NCT04945564|Procedure|Oxygen therapy and physical therapy|Patients receive oxygen therapy and physical therapy
75909198|NCT04945564|Device|Oxygen therapy|Patients receive oxygen therapy
75615687|NCT02643901|Biological|GW003|single SC injection
75909199|NCT04945252|Diagnostic Test|Signpost caries|Identify carious lesion according to ICCMS visual criteria
75909200|NCT04945096|Drug|decitabine|Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)
75909201|NCT04945096|Drug|Acetylcysteine|Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.
75615688|NCT02645383|Device|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
75317594|NCT00529555|Drug|minocycline HCl 2.1%|Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
75317595|NCT00529555|Procedure|Scaling and root planing|scaling and root planing
75317596|NCT00387335|Drug|sunitinib malate|Given orally
75317597|NCT01797757|Dietary Supplement|Fish oil enriched with EPA|
75317598|NCT01797757|Dietary Supplement|MAG-EPA oil|
75317599|NCT01797757|Drug|Orlistat|
75462608|NCT01866033|Drug|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
75462609|NCT01866046|Behavioral|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
75462610|NCT01866059|Device|Calcium silicate cement|Calcium silicate cement
75768380|NCT01134874|Behavioral|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
75768381|NCT01134874|Behavioral|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
75768382|NCT01134874|Behavioral|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
75909202|NCT04945096|Drug|Semustine|Semustine: 250 mg/m2/day on day -9.
75909203|NCT04945096|Drug|Cytarabine|Cytarabine: 2 g/m2 every 12 hours on day -8.
75615689|NCT02645383|Device|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
75317600|NCT04388423|Other|simulated puncture training|The residents are trained of simulated puncture : 1.the location puncture; 2. finding fixed-point needle on the model for 5 times, each time for 30 minutes.
75317601|NCT04388423|Other|traditional bedside teaching|The residents are trained by traditional bedside teaching
75462611|NCT01866059|Device|Glass Ionomer Cement|Glass Ionomer Cement
75615690|NCT02881944|Behavioral|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
75615691|NCT02881944|Behavioral|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
75768383|NCT01230736|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
75768384|NCT05401552|Other|Meal|Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives
75768385|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an application Site Rotation
75768386|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an a combination of Application sites
75768387|NCT03917368|Other|Ultrasound scan of the internal jugular veins|Participants, lying at their hospital bed, will maintain their head in a fixed position on the longitudinal axis, while an operator gently places a linear probe L12-RS (7.5-11 MHz), smeared with gel, on one side of the neck, at the middle level. A 15-sec video clip of the ultrasound images will be recorded. This procedure will be repeated on the other side of the neck. In addition, three electrodes will be placed on participants' chests and connected to the ultrasound system for simultaneously measuring the ECG signal.
75909204|NCT04945096|Drug|Busulfan|Busulfan: 3.2mg/kg/day on day -7 to -5.
75909205|NCT04945096|Drug|Cyclophosphamide|Cyclophosphamide: 1.8g/m2/day on day -4 to -3.
75909206|NCT04945096|Drug|Cyclosporin A|Cyclosporin A: 3mg/kg/d from day -8.
75317602|NCT01796899|Other|Brivaracetam 10 mg oral tablet|
75317603|NCT01796899|Other|Brivaracetam 50 mg oral tablet|
75317604|NCT01796899|Other|Brivaracetam 75 mg oral tablet|
75909207|NCT04945096|Drug|Anti-thymocyte globulin|Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.
75909208|NCT04945096|Drug|Mycophenolate|Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.
75909209|NCT04944394|Other|online questionnaire|"Administration of an online questionnaire (Limesurvey platform) at M0~- This questionnaire includes a characterization of the professional (center, profession, usual department and department during the health crisis, family situation). Generic stress factors, the traumatic impact of the crisis and collective and individual coping strategies are also collected."
76071684|NCT04262466|Drug|IMC-F106C and chemotherapy|IMC-F106C weekly IV infusions and chemotherapy Q1-3W IV infusion
75317605|NCT01796899|Other|Brivaracetam 100 mg oral tablet|
75615692|NCT00652405|Dietary Supplement|alcohol|250 ml of white wine (13% vol; ~25 gram of alcohol per day)
75909210|NCT04944394|Other|questionnaire survey|A questionnaire survey of the chief physician of the intensive care unit of each hospital will make it possible to characterize the support provided by the institution and how it changed over time
76071685|NCT04262466|Drug|IMC-F106C and tebentafusp|IMC-F106C weekly IV infusions and tebentafusp weekly IV infusions
75317606|NCT01796899|Other|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
75317607|NCT00477451|Drug|Inhaled placebo|Inhaled Staccato Alprazolam Placebo
75317608|NCT00477451|Drug|Inhaled alprazolam 1 mg|Inhaled Staccato Alprazolam 1 mg
75317609|NCT00477451|Drug|Inhaled alprazolam 2 mg|Inhaled Staccato Alprazolam 2 mg
75317610|NCT00477451|Drug|IV doxapram|0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
75317611|NCT00477685|Device|OculusGen Biodegradable Collagen Matrix Implant|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
75317612|NCT00530803|Drug|EMLA Cream|60 minutes x1
75317613|NCT00530803|Combination Product|Synera Patch|20 minutes x1
75317614|NCT04372927|Drug|Cisplatin|Given IV
75317615|NCT04372927|Biological|Durvalumab|Given IV
75317616|NCT04372927|Drug|Etoposide|Given IV
75317617|NCT04372927|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75462612|NCT01866059|Device|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
75462613|NCT01866085|Procedure|AdVance® sling procedure|
75462614|NCT01866085|Procedure|ARGUS Sling procedure|
75462615|NCT01866124|Other|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
75462616|NCT01866176|Device|Stabilizing Knee Brace|Brace with no valgus action
75462617|NCT01866176|Device|Valgus Knee Brace|Valgus brace with traditional three point bending system
75768388|NCT03922438|Procedure|usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.|Under general anesthesia, preparation of lip and palatal flaps will be done and then cleft margin flap which is designed to be inferiorly based will be used with anterior palatal closure in an attempt to decrease the incidence rate of naso-alveolar fistula (defect) that is usually occur and remain in those patients post-operatively.
75768389|NCT03922516|Diagnostic Test|ULDCT|Ultra-Low-Dose-CT (ULDCT) of the chest using tin filters with third-generation dual-energy CT devices. The projected dose used will be approximately 0.2 mSv per ULDCT of the chest.
75768390|NCT01135030|Procedure|Total knee|Primary Total knee
75768391|NCT05401474|Device|High Flow Nasal Cannula at 30L/min|Flow will be set at 30L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
75768392|NCT05401474|Device|High Flow Nasal Cannula at 45L/min|Flow will be set at 45L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
75909211|NCT04823806|Dietary Supplement|Spermidine (spermidineLIFE ®) OR Placebo|21 day of 6mg spermidine OR Placebo supplementation per day
75909212|NCT04944238|Device|Ankoris|Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
75909213|NCT04944628|Dietary Supplement|Probiotic|Probiotic in liquid format (oil suspension) administered 10 drops once daily for 2 weeks (2x10^9 cfu/day)
75317618|NCT04372927|Drug|Pemetrexed|Given IV
75615693|NCT00652405|Dietary Supplement|Placebo|250 ml of mineral water (Brand name: Vittel)
75615694|NCT02881710|Other|contrast product used to assess biomarkers variations|
75615695|NCT02643823|Biological|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
75768393|NCT05401474|Device|High Flow Nasal Cannula at 60L/min|Flow will be set at 60L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
75768394|NCT03917602|Procedure|human amniotic membrane plug with vitrectomy|using human amniotic membrane plug with vitrectomy to try to close large macular hole
75317619|NCT01381874|Drug|Exemestane|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
75615696|NCT02643823|Drug|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
75615697|NCT02638831|Drug|Ketorolac Tromethamine|Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
75768395|NCT03922282|Procedure|Gasless BABA|BABA robotic-thyroidectomy that is using elevation of flap instead of using carbon dioxide.
75768396|NCT03922282|Procedure|Classic BABA|BABA robotic-thyroidectomy that is using carbon dioxide.
75768397|NCT01135108|Drug|Placebo|Placebo IV Infusion
75768398|NCT01135108|Drug|KAI-1678|KAI-1678 IV Infusion
75909214|NCT04411108|Other|Kaia Back Pain App|The Kaia Back Pain App provides instructions on exercise execution to participants for one week
75909215|NCT04411108|Other|Physiotherapist Exercise Instructions and written handouts|Participants will be instructed by physiotherapists in exercise execution and receive handouts and exercise for one week
75909216|NCT04944472|Behavioral|HDKQ questionnaire|Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
75909217|NCT04944082|Drug|Ivermectin|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
75909218|NCT04944004|Other|CogniPlus|The CBCT programmes proposed in this study is called CogniPlus. This software package offers training of scientifically proven trainable cognitive functions. According to the user manual, the lifelike interactive system and its automatic adaptability to client's ability level made CogniPlus feasible in community settings.
75909219|NCT04944004|Other|Training As Usual (TAU)|Training As Usual (TAU)
75909220|NCT04943692|Drug|Metformin glycinate|1050 mg, tablets Administered orally, twice a day, for 12 months.
75317620|NCT01381874|Drug|Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
75317621|NCT01381874|Drug|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
75317622|NCT01399190|Biological|Bevacizumab|Bevacizumab administered according to prescribing information and normal clinical practice.
75317623|NCT01399190|Biological|Capecitabine|Capecitabine administered according to prescribing information and normal clinical practice.
75317624|NCT01399190|Drug|Oxaliplatin|Capecitabine administered according to prescribing information and normal clinical practice.
75615698|NCT02638831|Drug|Ketoprofen|Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
75615699|NCT01136772|Drug|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
75615700|NCT01136772|Drug|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
75615701|NCT00909532|Drug|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
75615702|NCT00909532|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
75768399|NCT01135264|Behavioral|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
75909221|NCT04943692|Drug|Metformin Hydrochloride|850 mg, tablets. Administered orally, twice a day, for 12 months.
75909222|NCT02587598|Drug|INCB053914|"Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth."
75909223|NCT02587598|Drug|I-DAC (Intermediate dose cytarabine)|Cytarabine dose will be 1 g/m^2. Cytarabine will be administered as an intravenous (IV) infusion.
75462618|NCT01866176|Device|New Knee Brace|Brace with new mechanism to decrease the knee loading.
75615703|NCT02756845|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
75615704|NCT02882490|Behavioral|Parent Training|
75615705|NCT02882490|Other|Supportive Therapy|
75615706|NCT04312308|Other|Sample collection|".Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.~.Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)~3. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)~4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.~4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional."
75615707|NCT02377570|Device|THERANOVA 400 dialyzer prototype AA|Hemodialysis
75615708|NCT02377570|Device|THERANOVA 400 dialyzer prototype BB|Hemodialysis
75615709|NCT02377570|Device|THERNOVA 400 dialyzer prototype CC|Hemodialysis
75615710|NCT02377570|Device|FX CorDiax 80 dialyzer|Hemodialysis
75615711|NCT01136382|Drug|budesonide|pMDI, inhalation, bid, 6 weeks
75615712|NCT01136382|Drug|placebo|pMDI, inhalation, bid, 6 weeks
75615713|NCT04772326|Other|Questionnaire|Questionnaire
75768400|NCT01135264|Behavioral|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
75768401|NCT03917212|Other|No intervention|No intervention, observational study with metabolic characterisation
75768402|NCT05201092|Drug|[14C]-Lu AG06466|[14C]-Lu AG06466 will be administered per schedule specified in the arm description.
75768403|NCT03917290|Behavioral|Neuromuscular training|Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
75909224|NCT02587598|Drug|Azacitidine|Azacitidine dose will be 75 mg/m^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).
75909225|NCT02587598|Drug|Ruxolitinib|Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.
75768404|NCT01230970|Drug|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
75768405|NCT01135576|Dietary Supplement|non-fortified fruit juices consumed as part of the usual diet|
75909226|NCT04942990|Other|calisthenic exercises|these exercises are a kind of exercise for increasing cardiovascular endurance
75615714|NCT00912028|Device|senofilcon A|contact lens
75768406|NCT01135576|Dietary Supplement|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
75768407|NCT01133782|Procedure|Access to diagnostic test|Randomization to receive a result of diagostic procedure the following day.
75909227|NCT04943146|Drug|Prednisone 10 MG+aspirin 100MG|Discontinue medication based on early pregnancy outcome
75909228|NCT04942444|Other|Dry needling|One-hour weekly session of DN in the 18th tender points during 6 weeks in the DNG, apart from continuing their medical treatment. The CG continue with the habitual medical treatment.
75909229|NCT02485574|Procedure|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.
75909230|NCT04942834|Drug|Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone|Class I or III antiarrhythmic drug, including sotalol
75909231|NCT04942834|Device|cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
75462619|NCT01866189|Other|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
75462620|NCT01866215|Other|exercise|cycling at 100W during 60 min
75462621|NCT01866215|Dietary Supplement|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
75462622|NCT01866215|Dietary Supplement|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
75615715|NCT00912028|Device|lotrafilcon B|contact lens
75615716|NCT00912028|Device|balafilcon A|contact lens
75615717|NCT00912028|Device|methafilcon A|contact lens
75615718|NCT00912028|Device|vifilcon A|contact lens
75615719|NCT00632008|Drug|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
75615720|NCT00632008|Drug|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
75615721|NCT04071730|Dietary Supplement|Immulina Dietary Supplementation|Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
75615722|NCT02731729|Drug|ipilimumab|
75615723|NCT02731729|Drug|nivolumab|
75768408|NCT02528890|Other|vaginal/anal swab for GBS from all participants|All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
75768409|NCT01228942|Device|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
75768410|NCT03917134|Drug|cephalosporin + Metronidazole Vaginal|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
75768411|NCT03917134|Drug|cephalosporin + Placebos|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
75768412|NCT03916900|Procedure|Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
75768413|NCT03916900|Procedure|Root canal treatment|Root canal treatment is an often straightforward procedure to relieve dental pain and save teeth. Patients typically need a root canal when there is inflammation or infection in the roots of a tooth. During root canal treatment, an endodontist who specializes in such treatment carefully removes the pulp inside the tooth, cleans, disinfects and shapes the root canals, and places a filling to seal the space.
75768414|NCT03917056|Procedure|Cap-assisted endoscopic sclerotherapy using long needle|Participants were treated with CAES using long needle.
75615724|NCT02645461|Drug|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
75909232|NCT03484286|Device|OPTILOGG|"OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer and a wirelessly connected weight scale. The system will have some patient specific information regarding the flexible (loop-) diuretics scheme.~The patient will be asked to step on the weight scale daily, and will be shown to some brief information on how to live better with HF, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in HF status, the patient is encouraged to contact his/her health care provider via telephone."
75615725|NCT02645461|Drug|Riluzole|Riluzole 50 mg twice daily
75615726|NCT00654589|Drug|Deferasirox|
75615727|NCT02645227|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
75768415|NCT03917056|Procedure|Cap-assisted endoscopic sclerotherapy using short needle|Participants were treated with CAES using short needle.
75909233|NCT03484286|Other|Standard care|Patients in the control group will be subject to standard heart failure care.
75615728|NCT02645227|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
75768416|NCT03916822|Diagnostic Test|Alloantigen-specific B-cells|Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry
75768417|NCT02528656|Device|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
75768418|NCT02528656|Device|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
75768419|NCT03921892|Behavioral|Parenting Education|Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
75768420|NCT01229020|Other|Observational study - no intervention|Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
76071686|NCT04259944|Drug|CAPOX|"DAY 1~OXA 130 mg/m2 administered as intravenous infusion over 2 hours in 250 mL dextrose 5%~CAPE 1000 mg/m2 administrated per os twice daily~DAY 2-14~• CAPE 1000 mg/m2 os twice daily~Cycle length is 3 weeks comprising 2 hours of oxaliplatin infusion every 21 days, 14 days of oral capecitabine and 7 days of resting."
75615729|NCT02645227|Procedure|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
75768421|NCT01232140|Other|CRP-guided antibiotic treatment|If CRP> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
75317625|NCT00531661|Device|HF Pressure Measurement System|A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
75317626|NCT01381718|Drug|modafinil|Given PO
75317627|NCT01381718|Other|placebo|Given PO
75615730|NCT00652483|Drug|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
75615731|NCT00652483|Drug|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
75317628|NCT00410189|Drug|ZD6474|300 mg by mouth daily for 28 Days.
75317629|NCT00479089|Drug|Docetaxel|25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
75317630|NCT00479089|Drug|ZD1839|250 mg by mouth daily, without break.
75462623|NCT01866228|Other|Consultation Recording|
75462624|NCT01866241|Drug|Misoprostol|Is a prostaglandin
75462625|NCT01866254|Drug|Hydromorphone|Injection of 100 mcg hydromorphone into the intrathecal space
75462626|NCT01866254|Drug|Morphine|Injection of 200 mcg of intrathecal morphine
75462627|NCT01866267|Drug|Maraviroc|HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
75615732|NCT01119066|Radiation|total body irradiation|dose of 1375-1500 cGy
75615733|NCT01119066|Drug|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
75768422|NCT05401162|Other|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
75768423|NCT01135654|Other|Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment|"We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much."
75909234|NCT04942756|Device|Continuous Glucose Monitoring|"FSL2 is an integrated continuous glucose monitoring (CGM) system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts. It is composed by a sensor and a reader. The Sensor, to apply on the back of the arm, continuously measures glucose concentration in interstitial fluid and has an 8-hour memory capacity. The Sensor is factory calibrated, does not require finger stick calibration and can be worn for up to 14 days.~The reader is a small handheld device that monitors glucose values in real-time to provide alerts and alarms which, when enabled, warn the user of Low Glucose, High Glucose or Signal Loss and prompt the user to scan the Sensor.~The FSL 2 System is CE mark, it is commercially available and in the current study it is being used in accordance with approved labeling. No modifications of FSL2 System have been performed for the utilization in the current study."
76071687|NCT04259944|Drug|Capecitabine|"DAY 1-14~• CAPE 1250 mg/m2 os twice daily~Cycle length is 3 weeks comprising 14 days of oral capecitabine and 7 days of resting."
76071688|NCT04259944|Drug|FOLFIRI|"Day 1:~IRI, 180 mg/m2 administered as iv infusion over 30-90 minutes in 250 mL dextrose 5%, concurrently (via a Y-connector) with~LV, 400 mg/m2 administered as an iv infusion over 2 hours, in 250 mL dextrose 5%, followed by~5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours.~Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest."
76071689|NCT04256941|Drug|Abemaciclib|Given PO
76071690|NCT04256941|Drug|Anastrozole|Given PO
76071691|NCT04256941|Drug|Fulvestrant|Given IM
75615734|NCT01119066|Drug|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
75615735|NCT01119066|Drug|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
75615736|NCT01119066|Drug|Melphalan|70mg/m2/day x 2
75615737|NCT01119066|Drug|Fludarabine|25mg/m2/ day x 5
75615738|NCT01119066|Drug|Clofarabine|20mg/m2/ day x 5 (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
75462628|NCT01866280|Behavioral|Normal sleep|Normal sleep= sleep 2300-0700
76071692|NCT04256941|Drug|Letrozole|Given PO
76071693|NCT04256941|Drug|Palbociclib|Given PO
76071694|NCT04256941|Drug|Ribociclib|Given PO
76071695|NCT04254692|Drug|Liposomal bupivacaine|Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
75615739|NCT01119066|Procedure|(CliniMACS) T-cell depleted PBSC Transplant|
75615740|NCT00910624|Drug|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
75615741|NCT00910624|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
76071696|NCT04254692|Other|Standard of care|Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
76071697|NCT04250857|Device|HeartStart FRX|Automated External Defibrillator
76071698|NCT04240808|Biological|UCD19 CAR T Cells|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes)
76071699|NCT04238676|Drug|PP353|active administered by intradiscal injection
75462629|NCT01866280|Behavioral|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
75615742|NCT00910624|Drug|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
75615743|NCT00654667|Drug|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
75615744|NCT00654667|Drug|Resveratrol|
75615745|NCT04164511|Dietary Supplement|2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)|The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
75615746|NCT04066738|Diagnostic Test|Cardiac MRI with gadolinium contrast|Imaging of left ventricular scar and coronary sinus venous system
75615747|NCT04066738|Diagnostic Test|3D reconstruction and location of coronary sinus venous system relative to myocardial scar|Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
75615748|NCT04066738|Diagnostic Test|Acute haemodynamic measurements during CRT implant|Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
76071700|NCT04238676|Other|Placebo|Sham injection
75462630|NCT01866280|Behavioral|Late sleep|Late sleep=sleep at 0230-1030 hours
75462631|NCT01866280|Behavioral|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
75462632|NCT01866332|Other|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
75615749|NCT05095428|Behavioral|PARTS Program|The PARTS Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
75768424|NCT01231126|Drug|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
76071701|NCT04236154|Other|Pedometer|Participants will wear a pedometer for 4 days at baseline, and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
75462633|NCT01866332|Device|Kinesio Tex Gold ( Kinesiotaping )|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
75768425|NCT01232218|Other|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
75768426|NCT01232218|Other|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
75768427|NCT01135732|Procedure|brush cytology|brush cytology during ERCP
75768428|NCT01135810|Behavioral|Hypnosis|
75768429|NCT01135810|Behavioral|Meditation|
75768430|NCT03769090|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
75768431|NCT03769090|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
75909235|NCT04942756|Device|Standard Care|"The control group is represented by the usual standard way for blood glucose (BG) monitoring. The control group will use a lancing device for finger samples for collection of blood drop to be put in the test strips to be read in the Glucose meter. Lancing devices, lancets and test strips used in the comparison groups are CE marked and are used according to the user's instructions.~Monitoring and/or self-monitoring of blood glucose using glucose meters and test strips provides quantitative measurements of fingerstick blood glucose at a single point in time for patients and their healthcare providers to monitor the effectiveness of glycemic control and make more immediate treatment with the right dosage of insulin. The usual standard routine for blood glucose monitoring in patients with DM and with insulin therapy is represented by at least three finger pricks/die according to the usual standards routine of each center."
75909236|NCT03484052|Other|Jugular ultrasound|Performing a jugular ultrasound by 2 operators before and after transfusion
75317631|NCT00479089|Drug|Dexamethasone|"Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment."
75317632|NCT01398956|Drug|Levetiracetam|"formulation: tablet or dry syrup~strength: 250 mg tablet, 500 mg tablet, dry syrup 50%~dosage: Sb ≥16 years and ≥4 and <16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and <16 years (<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day~frequency: twice daily"
75462634|NCT01866345|Procedure|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
75462635|NCT01866345|Procedure|Conventional orthodontic treatment|Conventional orthodontic Procedure
75462636|NCT01866358|Procedure|Intraosseous infusion|Using intraosseous infusion for resustation in this group
75462637|NCT01866358|Procedure|Umbilical vein infusion|Using umbilical vein infusion for resustation in this group
75615750|NCT05095428|Behavioral|NBSR-T Program|The NBSR-T Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
75768432|NCT03769090|Drug|Albuterol sulfate metered-dose inhaler 180 μg|Albuterol sulfate inhalation aerosol
75768433|NCT01135888|Device|Skin cooling devices|Cooling vest and cooling bandana
75768434|NCT03921736|Drug|Perindopril|4 mg/day p.o. for 12 months
75768435|NCT03921736|Drug|Hydrochlorothiazide|hydrochlorothiazide 25 mg/day p.o. for 12 months
75768436|NCT03921736|Drug|Estracomb TTS|Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months
75768437|NCT01231204|Procedure|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
75768438|NCT01231204|Procedure|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
75768439|NCT05401006|Drug|Acitretin 25Mg Cap|Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients
75768440|NCT05401006|Radiation|Narrowband ultraviolet B|Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months
75317633|NCT00410423|Drug|Bortezomib with mitoxantrone, etoposide and cytarabine|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
75768441|NCT01134094|Procedure|Open reduction internal fixation of the ankle|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
75768442|NCT01134094|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
76071702|NCT04236154|Other|Actigraph|Participants will wear a Actigraph for 4 days at baseline and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
76071703|NCT04236154|Other|Perturbation Treadmill|Participants will walk on an instrumented treadmill while wearing a safety harness at baseline and 4-6 weeks later. The perturbation treadmill will assess an individual's risk for falling. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
75615751|NCT04063150|Biological|fIPV (0.1 mL) ID|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.
75615752|NCT04063150|Biological|fIPV (0.1mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
75615753|NCT04063150|Biological|fIPV (0.2mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
75615754|NCT04063150|Biological|IPV|Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
75615755|NCT02645071|Behavioral|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
75615756|NCT04165681|Other|Limbix Spark|5-week, self-guided mobile + VR CBT-based program for adolescent depression
76071704|NCT04234113|Drug|SO-C101|SO-C101
76071705|NCT04234113|Drug|pembrolizumab|pembrolizumab
76071706|NCT04230590|Other|Observational|"Participants will not receive any study intervention.~During the 24-week study period, participants will complete five assessment visits and passive digital data from participant's smartphone and study-provided wrist wearable device will be collected."
75317634|NCT00410423|Drug|Bortezomib 1.0mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
75317635|NCT00410423|Drug|Bortezomib 1.3mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
75615757|NCT01123980|Drug|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
75615758|NCT01123980|Drug|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."
75615759|NCT01123980|Drug|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."
75768443|NCT01135966|Behavioral|Conventional resistance training program|Conventional resistance training program is followed.
75317636|NCT00387959|Biological|filgrastim|
75317637|NCT00387959|Biological|rituximab|
75317638|NCT00387959|Drug|cyclophosphamide|
75317639|NCT00387959|Drug|cyclosporine|
75317640|NCT00387959|Drug|fludarabine phosphate|
75317641|NCT00387959|Drug|mycophenolate mofetil|
75317642|NCT00387959|Procedure|allogeneic hematopoietic stem cell transplantation|
75317643|NCT00387959|Procedure|umbilical cord blood transplantation|
75462638|NCT01866384|Procedure|mild induced hypothermia|Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
75462639|NCT01866384|Other|Normal Temperature|In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
75615760|NCT01123980|Drug|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
75615761|NCT04037800|Procedure|SFUR-RARP|Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)
75615762|NCT04037800|Procedure|Standard RARP|Robotic-assisted radical prostatectomy with conventional RARP procedures.
75768444|NCT01135966|Behavioral|Whole body vibration resistance training program|WBV training on FITVIBE
75317644|NCT00387959|Radiation|total-body irradiation|
75317645|NCT00410891|Drug|gatifloxacin|
75317646|NCT01795157|Device|CCADSS|Questionnaire is transferred wireless to the physician's PC
75317647|NCT01795157|Device|pen-paper|Questionnaire completed and transferred to the physician using standard methods
75768445|NCT01136044|Other|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
75768446|NCT05400928|Device|Pulsed Field Ablation|pulmonary vein isolation will be performed with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
75615763|NCT02676973|Procedure|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
75615764|NCT02676973|Procedure|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
75768447|NCT01231282|Other|diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
75909237|NCT04942366|Other|High intensity interval training|HIIT using treadmill four sets of 4 minute interval session (at 90%-95% of the individual HR max calculated by using the karvonen method) and each set will be followed by three minute of moderate intensity exercise (at 70% of individual HR max).
75909238|NCT04942366|Other|Strength training|Strength training will be performed thrice a week, each session will consist of eight dynamic drills.
75909239|NCT04942132|Behavioral|Cognitive-behavioral (CBT)|Treatment includes a smartphone-delivered CBT program designed to improve the quality of life of individuals with chronic pain. The treatment is condensed in nine weeks, and contains the following modules or units of treatment: sleep quality, anxiety management, pain coping, medication use, physical conditioning, mood regulation, problem solving, decision-making and relationships with others. All the content and settings are written in Spanish.
75909240|NCT04941976|Drug|0.3% benzydamine hydrochloride spray oromucosal solution|"Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
76071707|NCT04225585|Behavioral|CST-PSP|skills training and experiential learning exercises
75909241|NCT04941976|Drug|Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)|"Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
75909242|NCT04942288|Other|The first group is acupressure and massage, the second group is massage|In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.
75909243|NCT02624284|Device|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
76071708|NCT04225585|Behavioral|General health education|general health education intervention that focuses on improving overall health
75909244|NCT02738450|Biological|ACI-24 low dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
76071709|NCT04222257|Drug|Antibiotics|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
75317648|NCT04750187|Other|Hypo-pressive abdominal exercise intervention|An 8-week hypo-pressive abdominal exercise program
75317649|NCT04749875|Other|blood sample|sampling of blood for research during routine care
75317650|NCT01381562|Drug|Drug: GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
75317651|NCT01381562|Drug|Meropenem|Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
75615765|NCT02676973|Procedure|Uphold™ LITE|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
75615766|NCT04015648|Biological|ChAdOx1 Zika|Single dose of ChAdOx1 Zika at different concentrations: 5 x 10^9 vp, 2.5 x 10^10 vp, 5 x 10^10 vp
75615767|NCT02638441|Other|hospital anxiety and depression scale|Detection of infertility effect on emotional status
75909245|NCT02738450|Biological|ACI-24 high dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
76071710|NCT04222257|Drug|Antibiotics|Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
76071711|NCT04216472|Drug|Alpelisib|Given PO
76071712|NCT04216472|Drug|Nab-paclitaxel|Given IV
76071713|NCT04212364|Behavioral|Peer Education|In this intervention, people who use opiates will be trained to be peer educators.
76071714|NCT04212364|Drug|Narcan Nasal Product|All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
76071715|NCT04212169|Drug|MEDI3506|multiple doses
76071716|NCT04212169|Drug|Placebo|multiple doses
76071717|NCT04207255|Drug|Opaganib|500mg of Opaganib orally twice a day continuously.
76071718|NCT04207255|Drug|Abiraterone|IV as directed by SOC
76071719|NCT04207255|Drug|Enzalutamide|IV as directed by SOC
76071720|NCT04207255|Drug|Opaganib|250mg of Opaganib orally twice a day continuously.
75768448|NCT01231360|Other|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
75768449|NCT01231360|Other|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
75768450|NCT01229098|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
75768451|NCT01136122|Device|CPAP Treatment|Effective CPAP treatment for one month
75768452|NCT01232374|Drug|Nimotuzumab|200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
75768453|NCT01232374|Drug|Placebo|4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
75768454|NCT01232374|Drug|cisplatin|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
75768455|NCT01232374|Radiation|Radiotherapy|"A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)"
75768456|NCT01231438|Drug|Renvela|800mg t.i.d. over 2 weeks
75768457|NCT01231438|Drug|Etalpha|0.25ug o.d. for 2 weeks
75317652|NCT01381562|Other|Placebo|saline placebo
75317653|NCT04749953|Procedure|Maxillary sinus floor augmentation|The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla
75615768|NCT02643511|Radiation|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
75615769|NCT02859207|Drug|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
75615770|NCT05090748|Device|Echocardiographic.|Echocardiographic test.
75615771|NCT02859129|Drug|rosuvastatin 40 mg tablet|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
75615772|NCT02859129|Drug|Epanova™ QD (2 x 1 g capsules)|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
75768458|NCT01131754|Other|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
75615773|NCT02859129|Drug|Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
76071721|NCT04205643|Biological|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
76071722|NCT04205643|Other|Placebo SC|Subcutaneous injection of Placebo SC
75317654|NCT00411749|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
75317655|NCT00411749|Biological|Comparator: Placebo (unspecified)|Placebo 0.5 ml injection in 3 dosing regimen
75615774|NCT02859129|Drug|Multiple (20) oral doses of 2 g Vascepa® every 12 hours|Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
75909246|NCT02738450|Biological|Placebo|Placebo is a standard PBS sterile solution administrated via s.c. injection.
75909247|NCT04941820|Other|clinical pharmacist intervention|clinical pharmacist intervention
76071723|NCT04195945|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
76071724|NCT04195945|Drug|Cladribine|Given IV
76071725|NCT04195945|Drug|Cytarabine|Given IV
76071726|NCT04195945|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
76071727|NCT04195945|Drug|Mitoxantrone|Given IV
76071728|NCT04195945|Other|Questionnaire Administration|Ancillary studies
76071729|NCT04195945|Other|Quality-of-Life Assessment|Ancillary studies
75317656|NCT01381016|Drug|Estradiol|Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
75317657|NCT01381016|Drug|Gonadotropin-releasing hormone (GnRH)|Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.
76071730|NCT04193072|Behavioral|Assessment of imagery ability|Movement imagery, kinesthetic imagery, and visual imagery ability assessed.
76071731|NCT04184050|Drug|HPN217|HPN217 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains
75768459|NCT05608330|Other|PETRUSHKA tool|In the experimental arm, the PETRUSHKA tool will automatically select the antidepressants that have the best profile in terms of efficacy and acceptability for each individual participant (based on their baseline demographic and clinical characteristics) and then ask the participant to provide their preferences about common (and non-serious) adverse events. Based on patient's preferences and their individual characteristics, the PETRUSHKA tool will then identify the three best antidepressants for the participant. The clinician and the participant will be presented with an overall recommendation (in the format of a pictogram) showing how strongly each antidepressant is recommended for that individual patient. Via a shared decision-making process, the participant and the clinician will then agree on which antidepressant to choose from the shortlist.
75768460|NCT05608330|Other|Usual Care|Any antidepressant prescribed by clinician based upon their clinical judgement.
75615775|NCT04164823|Device|Medical taping|For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
75768461|NCT01136200|Other|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
75768462|NCT02528968|Behavioral|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
75615776|NCT04164823|Drug|Analgesic self-medication (OTC)|Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
75615777|NCT03976336|Dietary Supplement|Berberine|500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
75615778|NCT03976336|Other|Identical Placebo|500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
75768463|NCT05402800|Other|FSFI questionnaire|The FSFI is a reliable test for the assessment of sexual function in women. The Arabic version of this test, was used. The FSFI is comprised of six domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) with score ranges of 0 (or 1) to 5. The total FSFI score ranges from 2.0 to 36. The translated version of the FSFI test was used in this study. All questions in the FSFI questionnaire were explained by the physician one by one, and they were filled in a suitable and silent environment where patients could comfortably share such intimate information
75768464|NCT01231594|Drug|GSK2118436|Study Drug
75768465|NCT01231594|Drug|GSK1120212|Study Drug
75768466|NCT01231594|Drug|Other approved anti-cancer agent|Study Drug
75909248|NCT04941352|Behavioral|6-session Interpersonal Relations Theory-based Motivational Interviews and 3 month follow-up.|6-session Interpersonal Relations Theory-based Motivational Interviews were applied to the individuals in the study group. All sessions were conducted face-to-face in the form of individual interviews. Each interview lasted an average of 30-40 minutes. With this intervention, it was aimed to increase treatment cooperation and motivation in individuals with schizophrenia, to increase insight, to improve adherence to treatment, daily living skills and social functionality.Study data were collected using a personal information form, the Functional Remission of General Schizophrenia Scale (FROGS) and the Scale for Assessing the Three Components of Insight (SAI). The data were analyzed on the basis of pre-intervention, post-intervention and 3 months after the intervention.
75317658|NCT01381016|Drug|Progesterone|Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.
75317659|NCT00412451|Drug|ocriplasmin|Intravitreal injection, single administration
76071732|NCT04176120|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
75317660|NCT00412451|Other|Sham injection|Sham intravitreal injection
75317661|NCT01398410|Drug|Rabeprazole|Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
75317662|NCT01398410|Drug|Rabeprazole|Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
75317663|NCT00412529|Drug|Entecavir|Entecavir 0.5 mg once daily for 12 weeks.
75462640|NCT01866397|Other|Cidofovir pharmacokinetics|Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
75462641|NCT01866436|Other|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
75615779|NCT04164589|Device|SCENAR 1NT-02.2|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
75615780|NCT02857959|Drug|Benzathine Penicillin G|
75615781|NCT00632398|Behavioral|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
75768467|NCT01231672|Biological|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
75317664|NCT00412529|Drug|Telbivudine|Telbivudine 600 mg once daily for 12 weeks.
75317665|NCT00412841|Drug|Atorvastatin|Atorvastatin 40mg vs placebo 40mg daily
75462642|NCT01866436|Other|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
75462643|NCT01866449|Drug|Cabazitaxel|
75615782|NCT00632398|Behavioral|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
75615783|NCT00654979|Device|SafeFlo IVC Filter|SafeFlo IVC Filter
75768468|NCT01136278|Drug|3,4-Methylenedioxymethamphetamine|125 mg, single dose
75768469|NCT01136278|Drug|Clonidine|150 μg per os
75768470|NCT01136278|Drug|placebo|capsules identical to MDMA or clonidine
75615784|NCT04231786|Procedure|Breast ultrasonography findings|Breast ultrasonography findings in patients over 30 years of age diagnosed with polycystic ovary syndrome.
75768471|NCT05402722|Drug|Eribulin|Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
76072440|NCT04025775|Device|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~Glooko/Diasend cloud upload system to monitor CGM/insulin data."
75615785|NCT02643433|Biological|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
75462644|NCT01866462|Other|NM504|NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
75615786|NCT02643433|Biological|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
75615787|NCT00632476|Other|Placebo|Placebo capsule once a day
75615788|NCT00632476|Dietary Supplement|Vitamin C|A 500-mg vitamin C capsule once a day
75615789|NCT04164745|Drug|Anlotinib, oral capsule|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
75615790|NCT04164745|Biological|Pembrolizumab|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
75615791|NCT00655213|Device|Symphony D 2450|
75615792|NCT00655213|Device|Symphony DR 2550|
75462645|NCT01866475|Device|EZ-IO|To have an EZ-IO placed up to 48 hours
75615793|NCT01198522|Drug|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
75615794|NCT02638285|Drug|LH|
75615795|NCT02638285|Drug|HCG|
75615796|NCT02638285|Drug|Clomiphene|
75615797|NCT04201210|Other|TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|Haploidentical 5+/10 HSCT from a relative, α/β T-depleted
75615798|NCT04201210|Other|Matched sibling donor transplantation|10/10 HSCT - matched family donor
75768472|NCT05402722|Drug|anti-PD-1 antibody|Sintilimab Injection，Intravenous infusion，200mg，3-week cycle
75615799|NCT01134250|Drug|F16IL2 in combination with paclitaxel|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
75615800|NCT03751774|Behavioral|MAMAACT|Post graduate training and health education materials
76072441|NCT04025775|Other|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
75462646|NCT01866488|Drug|Misoprostol|
75462647|NCT01866488|Other|Placebo|
75615801|NCT03414268|Other|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
75768473|NCT03921268|Drug|AZD1402|AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
75768474|NCT01232608|Behavioral|Exercise|12 months of exercise training
75768475|NCT05597332|Other|Care bundle for AKI|To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
75768476|NCT03921346|Device|Mobile device app (PedAMINES™) 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
75768477|NCT03921346|Device|Mobile device app (PedAMINES™) 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
75462648|NCT01866501|Procedure|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
75462649|NCT01866501|Device|EZ-IO|
75768478|NCT03921346|Device|Mobile device app (PedAMINES™) 3rd drug|To prepare 4 mL/kg dextrose 10%
75768479|NCT03921346|Device|Mobile device app (PedAMINES™) 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
75768480|NCT03921346|Device|Conventional method 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
75768481|NCT03921346|Device|Conventional method 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
75768482|NCT03921346|Device|Conventional method 3rd drug|To prepare 4 mL/kg dextrose 10%
75768483|NCT03921346|Device|Conventional method 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
75768484|NCT01137448|Behavioral|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
75768485|NCT05480488|Drug|Midazolam|Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).
75768486|NCT05480488|Drug|Warfarin|Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).
75768487|NCT05480488|Drug|Daridorexant|Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.
75768488|NCT03921112|Device|lung ultrasound|bedside lung ultrasound will be done for patients
75768489|NCT03921112|Other|routine tools|chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
75768490|NCT01229332|Drug|Saline|Continuous 24 h administration
75768491|NCT01229332|Drug|Carbidopa|Continuous 24 h administration
75768492|NCT03921034|Drug|Ropivacaine|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
75768493|NCT03921034|Drug|Saline|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
75768494|NCT01136590|Drug|Tranexamic Acid|A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.
75462650|NCT01866514|Procedure|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
75615802|NCT03414268|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
75768495|NCT01136590|Drug|fisiologic serum|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
75768496|NCT03920956|Other|ABPM service by Pharmacists|Patients will receive ABPM services provided by a pharmacist and complete a patient satisfaction survey
75768497|NCT01229488|Device|Intervention|Project was withdrawn before starting. There were no interventions
75768498|NCT01137760|Dietary Supplement|Sucrose|5 g of sucrose daily for 8 weeks
75768499|NCT01137760|Dietary Supplement|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
75615803|NCT01118520|Drug|perindopril arginine|10mgs orally daily for the duration of the trial
75615804|NCT01118520|Drug|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
75615805|NCT01118520|Drug|placebo|one daily
75768500|NCT01137760|Dietary Supplement|Galactooligosaccharide|5.0 g galactooligosaccharide daily for 8 weeks
75768501|NCT01233388|Other|Text message surveillance|Text message surveillance for vaccine adverse events
75615806|NCT04226638|Diagnostic Test|Dynamic ultrasound|Diagnosis was based on clinic suspicion and positive ultrasonography dynamic maneuvers by reproducing pain and slipping rib exam
75615807|NCT03744832|Diagnostic Test|Alere i™ Strep A assay|Point of care (POC) molecular-based, nucleic acid amplification test (NAAT). This isothermal molecular assay is CLIA waived (Clinical Laboratory Improvement Amendments) and Health Canada licensed for POC use, and is anticipated to have approval for use without need for back up culture testing.
75615808|NCT03744832|Diagnostic Test|Throat culture|Standard bacterial throat culture.
75615809|NCT01135992|Drug|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
75615810|NCT01135992|Drug|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
75615811|NCT03734770|Drug|Subcutaneous Progesterone|Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
75615812|NCT03734770|Drug|Vaginal progesterone|Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
75768502|NCT03920878|Drug|Aflibercept injected Pre- and Post-operatively|Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
75768503|NCT03920878|Drug|Aflibercept injected intraoperatively|Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
75768504|NCT01136824|Other|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic & health Trait anxiety Quality of life Nausea Expectations Anxiety & total mood disturbance Nausea & vomiting Multiple symptoms"
75768505|NCT03920644|Drug|Scopolamine Transdermal Patch [Transderm Scop]|Current Motion Sickness treatment, 1 patch behind the ear.
75317666|NCT00412841|Procedure|MRI, Venipuncture|MRIs done baseline, four and nine months
75317667|NCT00412841|Drug|Placebo|Tablets identical to atorvastatin 40mg
75317668|NCT01796483|Device|Clonidine (Catapressan)|Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
75317669|NCT01796483|Device|Placebo 90 minutes before EEG|Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
75615813|NCT00959049|Biological|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
75615814|NCT00959049|Biological|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
75317670|NCT00414167|Drug|bupropion|300 mg per day for 8 weeks
75317671|NCT00414167|Other|Placebo|Placebo
75317672|NCT00414635|Drug|Intermitent Dosing|"Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. ."
75462651|NCT01866514|Drug|2% preservative-free lidocaine|
75462652|NCT01866514|Device|EZ-IO|
75462653|NCT01866553|Drug|Nilotinib|300 mg capsule BID oral use
75462654|NCT01866553|Drug|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
75462655|NCT01866566|Biological|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
75462656|NCT01866566|Biological|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
75615815|NCT00956943|Drug|Nicoderm CQ transdermal nicotine|Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
75615816|NCT00956943|Drug|placebo|placebo patch
75768506|NCT03920644|Drug|Scopolamine|IND, up to 6 administration of intranasal gel.
75768507|NCT03920644|Drug|Placebo Patch|Placebo Patch, 1 patch behind the ear.
75768508|NCT03920644|Drug|Placebo Gel|Placebo Gel,up to 6 administration of intranasal gel.
75768509|NCT01131832|Dietary Supplement|Plant sterol|
75768510|NCT01131832|Dietary Supplement|Placebo|
75317673|NCT00531817|Drug|Tocilizumab|Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
75317674|NCT00531817|Drug|Placebo|Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
75317675|NCT00531817|Drug|Permitted DMARDs|As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
75317676|NCT00415493|Other|Cold-dry air provocation|15 minute exposure to cold-dry air by nasal mask
75317677|NCT00415493|Other|Warm-moist air provocation|15 minute exposure to warm-moist air by nasal mask
75317678|NCT01380782|Drug|BIBF 1120|200 mg BID oral for 28 day cycle
75317679|NCT01793441|Drug|Placebo|Placebo will be administered in different stages of the study for 12 weeks.
75317680|NCT01793441|Drug|RG7314|RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
75317681|NCT01398176|Dietary Supplement|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
75317682|NCT01398176|Dietary Supplement|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
75317683|NCT01796561|Dietary Supplement|Olive leaf extract liquid|Commercially available polyphenol-rich olive leaf extract liquid
75317684|NCT04355689|Drug|NPI-001|oral tablet
75317685|NCT04355689|Other|Placebo|Placebo tablets
75317686|NCT00455663|Behavioral|Cognitive Adaptation Training|Environmental supports for all independent living skills
75317687|NCT00455663|Behavioral|Pharm-Cognitive Adaptation Training|Environmental supports for medication and appointment adherence
75317688|NCT00455663|Other|Treatment as usual|Medication follow-up and limited case management provided by local community mental health authority
75317689|NCT00534001|Drug|bupropion hydrochloride|Given orally
75317690|NCT00534001|Other|placebo|Given orally
75317691|NCT00481351|Drug|Simvastatin 20mg plus ezetimibe 10mg|simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
75462657|NCT01866566|Biological|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
75462658|NCT01866566|Biological|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
75615817|NCT00958893|Drug|25 mg Proellex|one 25 mg capsules
75768511|NCT01137916|Drug|Imatinib|800 mg
75768512|NCT01233544|Procedure|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
75768513|NCT01137994|Drug|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
75768514|NCT01137994|Biological|Trastuzumab|monoclonal antibody directed to HER2 receptor
75768515|NCT01137994|Drug|Docetaxel|Taxane chemotherapy
75768516|NCT01137994|Drug|Paclitaxel|Taxane chemotherapy
75768517|NCT01137994|Drug|Vinorelbine|Vinka alkaloid
75768518|NCT05434390|Behavioral|Estoy PrEParado/ I am PrEPared intervention|Participants will receive an Information, Motivation, and Behavioral skills model PrEP intervention tailored for mixed immigrant status Latino men who have sex with men
75768519|NCT05434390|Behavioral|Usual Care|Participants will be offered PrEP navigation services as part of usual care at the study site.
75768520|NCT01138072|Drug|GSK2248761|200mg once daily
75768521|NCT01138072|Drug|Simvastatin|20 mg Simvastatin single dose
75768522|NCT01138072|Drug|Atorvastatin|20 mg atorvastatin single dose
75768523|NCT01138072|Drug|Rosuvastatin|10 mg rosuvastatin single dose
75768524|NCT01136902|Dietary Supplement|Oral Glucose Tolerance Test (OGTT)|75 g of glucose dissolved in 250 mL water.
75768525|NCT01229566|Drug|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
75317692|NCT00481351|Drug|ezetimibe|ezetimiba 10mg once a day
75768526|NCT01232686|Other|Online disease surveillance data access|In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
75768527|NCT01138306|Genetic|gene expression analysis|
75768528|NCT01138306|Genetic|mutation analysis|
75317693|NCT00481351|Drug|simvastatin 20mg|simvastatin 20mg once a day
75768529|NCT01138306|Other|flow cytometry|
75768530|NCT01138306|Other|laboratory biomarker analysis|
75768531|NCT01131910|Biological|TBE-vaccine|Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
75768532|NCT01131910|Biological|TBE-vaccine|Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
75768533|NCT01131910|Biological|Vaccination against TBE|0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
75768534|NCT03739606|Biological|Anti-CD123/CD3 Monoclonal Antibody MGD006|Given IV
75768535|NCT01232764|Other|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
75768536|NCT01136980|Device|TIF Transoral Fundoplication|A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
75768537|NCT01136980|Other|Sham placebo procedure|The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
75317694|NCT00481351|Drug|Simvastatin 80mg|simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
75317695|NCT00481507|Other|Kefir|The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
75317696|NCT00481507|Other|Placebo|The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
75768538|NCT01137058|Device|U-healthcare service|Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.
75768539|NCT01137058|Device|SMBG group|Glucose control with self monitoring of blood glucose.
75768540|NCT01233622|Drug|Vildagliptin|
75768541|NCT01233622|Drug|Placebo|
75768542|NCT01137214|Device|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
75768543|NCT01232842|Genetic|cytogenetic analysis|
75768544|NCT01232842|Other|HUMARA assay|
75615818|NCT01135914|Drug|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
75768545|NCT01232842|Other|fluorescence activated cell sorting|
75615819|NCT01135914|Procedure|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
75768546|NCT01232842|Other|laboratory biomarker analysis|
75768547|NCT01138462|Other|intervention|"5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation."
75768548|NCT05513014|Drug|Secukinumab|Patients with Psoriasis who initiated Secukinumab
75768549|NCT01138540|Other|lateral-Trendelenburg position|lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
75768550|NCT01138618|Device|Venous blod sample|Regular venous blood sample withdrawn from the laboratory
75615820|NCT04281927|Device|Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)|Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
75615821|NCT02858973|Drug|Q203|
75615822|NCT02858973|Drug|Placebo|
75615823|NCT04282005|Procedure|Metabolic/Bariatric surgery|Patients will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
75768551|NCT01138618|Device|CHEMPAQ|Capillary blood sample analyzed by CHEMPAQ
75768552|NCT01138774|Dietary Supplement|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
75317697|NCT01397786|Drug|OPC-34712|"Phase A: 1-2 mgs/day by mouth, max of 4 wks.~Phase B: 1-4 mgs/day by mouth, up to 52 weeks"
75615824|NCT04282005|Other|Lifestyle and Diet|Patients will be provided with a lifestyle interventions including dietary counselling choosing between a Low-Calorie Diet or a Meal Replacement Diet.
75615825|NCT04280679|Device|Sonovein 2|Patient are treated with the HIFU device and the pysician is doing a compressive bandage
75615826|NCT00907738|Drug|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
75615827|NCT04282161|Device|Axys EX device|Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
75615828|NCT01123356|Drug|Ofatumumab|"Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~Treatment to be administered for up to 6 cycles"
75615829|NCT01123356|Drug|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
75615830|NCT00630357|Drug|Levetiracetam (Keppra)|
75615831|NCT02858817|Drug|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
75615832|NCT02858817|Biological|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
75768553|NCT01131988|Drug|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
75768554|NCT01229800|Drug|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
75909249|NCT01291004|Drug|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
75317698|NCT00455975|Drug|Bevacizumab|Bevacizumab
75317699|NCT04016012|Dietary Supplement|Local Zambian Foods|Each week, participants in the intervention group will collect a pack of foodstuffs to last a week from the research site. The packs will be adjusted according to the weight of the participant and daily recommended allowances. Packaging of foodstuffs will be done in the food service lab at the Mukuba University. Instructions on how to prepare and use the food will be given to the participants. All food Items will be labelled diabetic food to avoid intra-household sharing.
75317700|NCT05366192|Drug|Nirmatrelvir and ritonavir stage 1|Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
75317701|NCT05366192|Drug|Nirmatrelvir and ritonavir stage 2|Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
75615833|NCT02858817|Other|NaCl 0,9%|0.9% NaCl solution for injection
75615834|NCT02883192|Drug|Ondansetron|Zofran 4 mg.
75615835|NCT02883192|Drug|Placebo|Placebo
75615836|NCT04280835|Behavioral|Group Psychoeducation that Focused on Social Skill Development|Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
75615837|NCT02883270|Device|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
75768555|NCT01229800|Drug|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
75768556|NCT05497258|Device|Artificial intelligence assistant system|The AI-assisted diagnosis system can provide the direction of disease diagnosis in real time and assist the doctor to give the final diagnosis
75768557|NCT01234558|Drug|GLYX-13|single IV dose
75909250|NCT01291004|Drug|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
75909251|NCT01291004|Drug|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
75909252|NCT04941118|Drug|Injection of dextrose, local anesthetic and saline to the myofascial trigger point|An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.
75909253|NCT04941118|Drug|Local anesthetic and saline injection to the myofascial trigger point|A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.
75317702|NCT05368922|Device|Virtual reality rehabilitation|"The virtual reality rehabilitation protocol will be based on two perceptual-motor tasks (e.g., visuomotor tracking task and pointing task) in a 3D environment. The visuomotor tracking task will consist in tracking a virtual target moving with an effector manipulated by a remote controller. The pointing task will consist in tapping targets that are in a cube as quickly as possible with an effector manipulated by a remote controller. Both tasks will be performed in a 3D virtual playful environment.~The rehabilitation protocol will follow a progression through the manipulation of the virtual environment and the constraints of the tasks."
75317703|NCT04013672|Drug|Pembrolizumab|200 mg IV every 3 weeks
75317704|NCT04013672|Drug|SurVaxM|500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
75615838|NCT02883270|Other|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
75317705|NCT04013672|Drug|Sargramostim|100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
75317706|NCT04013672|Drug|Montanide ISA 51|1 ml per dose dosed every two weeks for 4 doses and then every 3 months
75615839|NCT02860455|Device|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
75615840|NCT02860455|Device|CO-oximeter|"COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
75317707|NCT02078882|Biological|abatacept|125 mg subcutaneously each week for 24 weeks
75909254|NCT05136716|Other|Traditional Physical Therapy|Stretching for tight muscles, strengthening for weak muscles, postural reactions training, proprioceptive training, and walking training were all part of the neurodevelopmental treatment plan.
75909255|NCT05136716|Device|Hyperbaric oxygen therapy|HBO2 therapy at a pressure of 1.7 atm For 60 minutes, participants breathed 100% O2.
75909256|NCT05388344|Other|Booklet reading|Submission of the questionnaire before and after booklet reading
75317708|NCT00458237|Drug|Everolimus|Everolimus is being administered orally 7 days per week.
75317709|NCT00458237|Drug|Trastuzumab|Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.
75317710|NCT04344938|Other|questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality|Many critical ethical questions arise in pandemic covid 19planning, preparedness and response. These include: Who will get priority access to medications, vaccines and intensive care unit beds, given the potential shortage of these essential resources? In the face of a pandemic, what obligations do health-care workers have to work notwithstanding risks to their own health and the health of their families? How can surveillance, isolation, quarantine and social-distancing measures be undertaken in a way that respects ethical norms? What obligations do countries have to one another with respect to pandemic covid 19 planning and response efforts?
75317711|NCT05264909|Device|Multi-channel Transcranial direct current stimulation|A medical grade tDCS device will be use in this study (Star Stim TES, Neuroelectrics, Spain). The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
75462659|NCT01866605|Drug|Midazolam|Intravenous midazolam 0.3 mg/kg
75462660|NCT01866605|Drug|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
75462661|NCT01866605|Device|Bair Hugger|Forced air warming
75462662|NCT01866644|Drug|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
75462663|NCT01866644|Drug|Saline|Bath saline transplanted liver
75462664|NCT01866670|Behavioral|spiritual support|-Spiritual Support: deep breathing + guided image + meditation
75462665|NCT01866670|Behavioral|relaxation therapy|Relaxation Therapy: deep breathing
75462666|NCT01866683|Behavioral|1 month respiratory training|Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
75462667|NCT01866683|Behavioral|1 month waiting period|waiting or detraining period
75768558|NCT04797364|Diagnostic Test|Pharmacogenetic Testing|Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
75909257|NCT03483974|Diagnostic Test|hyperspectral imaging|using hyperspectral detector for evaluation excreta pattern
75909258|NCT04940962|Procedure|Sampling of adipose tissue|Removal of less than 1 cm3 of adipose tissue during visceral surgery
75909259|NCT03480854|Other|Quality Improvement|Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
75909260|NCT04940416|Device|Neurofit (oculometric testing)|The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.
75909261|NCT03483818|Procedure|Assessment & Treatment of HCV infection with oral antivirals|This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
75909262|NCT04940728|Other|Creative thinking techniques intervention program|The intervention program based on creative thinking techniques was designed to consist of four stages: preparation, theoretical briefing, skill development and evaluation. In the first stage of the program, acquaintance and information meeting, in the second stage, the theoretical part lasts for two weeks, in the third stage, various creative thinking techniques are applied for four weeks to gain creative thinking skills.
75909263|NCT00374660|Drug|Oxaliplatin|Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 40 to 80 mg/m^2 by dose escalations in 10 mg/m2 increments if no dose-limiting toxicity.
75317712|NCT05362838|Procedure|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
75615841|NCT00908596|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
75615842|NCT05143593|Diagnostic Test|SSBD(PCR-CRISPR/Cas12a)|Based on 1791 microorganism genomes of 232 species from the public database, we identified species-specific DNA-tags for 12 common pathogenic bacteria, which allowed us to design our Cas12a system for using the trans-cleavage activity and judging whether bacterium infects the patient or not by fluorescence value.
75615843|NCT02860689|Other|using questionnaires - International Index Erectile Function|using questionnaires
75615844|NCT02590120|Dietary Supplement|Enteral nutrition|
75615845|NCT02860533|Device|cuff device|Measurement of blood pressure during stress testing with cuff device
75768559|NCT01138852|Drug|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
75768560|NCT01138852|Drug|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
75768561|NCT01138930|Drug|Berberine|1.5g daily for 3 month
75768562|NCT01138930|Drug|Placebo|placebo daily
75768563|NCT01233154|Dietary Supplement|probiotic|
75909264|NCT00374660|Drug|Irofulven|Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered as a 30-minute infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 0.30 to 0.40 mg/kg if no dose-limiting toxicity.
75909265|NCT04940494|Other|collection of data|collection of data for all Obstetrical Anal Sphincter Injury women (score of quality of life, experimenting anal incontinence...)
75909266|NCT04940260|Diagnostic Test|Renal function|measure eGFR at one year post partum
75462668|NCT01866696|Device|oral implants|"For all cases, the following surgical and prosthetic protocol was followed.:~Clinical examination~Radiological examination~Guided oral implants insertion~Immediate Prosthetic loading~Follow-up"
75462669|NCT01866722|Behavioral|Usual care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
75462670|NCT01866722|Behavioral|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
75615846|NCT02860533|Device|iphone|Measurement of blood pressure during stress testing with iPhone
75615847|NCT01118052|Other|Laboratory Biomarker Analysis|Correlative studies
75768564|NCT01233154|Dietary Supplement|probiotic|
75768565|NCT01139242|Behavioral|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
75909267|NCT04940260|Diagnostic Test|proteinuria|measure urine protein creatinine ratio at one year postpartum
75909268|NCT04463108|Other|No Intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
75909269|NCT02624050|Drug|Methohexital|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
75768566|NCT01139242|Behavioral|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
75768567|NCT04764994|Device|Armeo®Spring ((Task-oriented upper extremity rehabilitation system)|Armeo®Spring is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The Armeo Spring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury or other neurological diseases and injuries. It combines an adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
75768568|NCT04764994|Other|Conventional Physical Therapy Program|This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.
75615848|NCT01118052|Biological|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given intraperitoneally
75768569|NCT01585870|Drug|Sorafenib (Nexavar, BAY43-9006)|"Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort."
75615849|NCT02860377|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
75317713|NCT05362838|Procedure|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
75317714|NCT00418457|Drug|General anesthesia and opioids|General anesthesia, usually with sevoflurane, and opioid analgesia
75317715|NCT00418457|Drug|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
75317716|NCT05365568|Procedure|Left Bundle Branch Area Pacing (LBBAP)|Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy
75317717|NCT05365568|Procedure|Biventricular pacing (BiV)|Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)
75317718|NCT00482911|Drug|cyclophosphamide|25-50 mg by mouth once daily on days 1-28.
75615850|NCT02860377|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
75768570|NCT01585870|Drug|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
75768571|NCT01234636|Dietary Supplement|Placebo oil|Placebo oil of 4g/day
75768572|NCT04746820|Other|single-center prospective pilot study|"fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~The cerebral response to an auditory stimulus is measured by fNIRS and AEP"
75768573|NCT05222464|Other|Standard of care treatments|Interventions will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
75909270|NCT02624050|Drug|Propofol|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
75909271|NCT03486470|Diagnostic Test|Ultrasound examination of radial arteries|Measuring the diameter and the depth of two radial segments on both arms
75909272|NCT05152160|Biological|Umbilical Cord Mesenchymal Stem Cell Therapy|Umbilical Cord Mesenchymal Stem Cell Therapy
75909273|NCT03483740|Behavioral|CRGT|Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 8 weekly 3-hour sessions.
75317719|NCT00482911|Drug|lenalidomide|10 mg by mouth once daily on days 1-28.
75317720|NCT00482911|Drug|sunitinib malate|12.5 - 25 mg by mouth once daily on days 1-28.
75317721|NCT01397162|Drug|Fluticasone propionate|Fluticasone propionate
75317722|NCT01397162|Drug|Placebo|Placebo matching fluticasone propionate HFA MDI
75317723|NCT01397162|Drug|BI 54903|BI 54903
75317724|NCT00460421|Drug|Palifermin|Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
75317725|NCT00460421|Radiation|Total Body irradiation|
75615851|NCT03394534|Other|CGA group|CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
75615852|NCT04277949|Device|Erbium:YAG|Treatment with Erbium:YAG laser
75615853|NCT04277949|Drug|UV endonuclease from Micrococcus luteus|Application of topical DNA repair enzymes
75615854|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for three months|period of treatment
75768574|NCT03738436|Other|Physical therapy traditional neuromuscular training, NMT|The NMT program includes re-position exercise using Swiss ball roll squat, strengthening and stretching exercises in various positions or combined using Swiss ball, Thera-Band or suspension system (Redcord), balance exercise on wobble board, proper landing strategy practices, and etc.
75768575|NCT03738436|Other|Physical therapy modified visual feedback, MVF|traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles
75768576|NCT01139320|Genetic|DNA analysis|
75768577|NCT01139320|Genetic|polymerase chain reaction|
75768578|NCT01139320|Other|laboratory biomarker analysis|
76071733|NCT04176120|Other|Standard Care|"Standard care is defined in this protocol to consist of the following:~Debridement;~Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~Appropriate use of systemic antibiotics."
75317726|NCT00460421|Drug|Chemotherapy|High dose etoposide, Cyclophosphamide
75317727|NCT00483223|Drug|Cisplatin|Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
75317728|NCT00483223|Drug|carboplatin|Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
75317729|NCT01397084|Drug|esomeprazole 20 mg|esomeprazole 20 mg once daily for 8 weeks
75317730|NCT00419315|Behavioral|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
75317731|NCT00419315|Behavioral|Usual Care|Usual care included a referral to a specialty addiction treatment program.
75317732|NCT00420017|Drug|Amiodarone|Intravenous amiodarone continuous infusion x 4 days
75317733|NCT00420017|Other|Control|No amiodarone
75317734|NCT00484393|Drug|tetracaine 4% gel|tetracaine applied prior to 1 injection
75317735|NCT00484393|Drug|Placebo|placebo applied prior to 1 injection
75615855|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for six months|period of therapy
75615856|NCT01123200|Device|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
75615857|NCT02857803|Procedure|Virtual Reality|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
75615858|NCT02857803|Procedure|Paper and Pencil|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
75615859|NCT02857803|Procedure|Conventional Therapy|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
75768579|NCT01139320|Other|pharmacological study|
75768580|NCT05210140|Drug|Escitalopram|"Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is commercially known as ELORYQA®, Elicea®, Escital®,PRAMES® or Lata® in Serbia. The recommended dose for Major depressive disorder is 10mg/day. Based on the individual response, dose can be adjusted and the maximum dose is 20 mg/day; 5 mg/day dose is also available. Escitalopram is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia) and Panic disorder (with or without agoraphobia) by Medicines and Medical Devices Agency of Serbia.~In known CYP2C19 poor metabolizers, initial dose should be 5mg/day during first 2 weeks, and based on the individual response it can be increased up to maximum of 10 mg of escitalopram per day, according to the guidelines of Medicines and Medical Devices Agency of Serbia."
75768581|NCT01142986|Behavioral|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
75909274|NCT03483740|Behavioral|HIV group therapy|These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 8 weekly 3-hour sessions.
75909275|NCT04940104|Drug|Botox Injectable Product|Botox is a well known neurotoxin that is derived from the bacterium clostridium botulinium. Its therapeutic applications are variable and well documented, alongside its cosmetic applications. There are seven known serotypes of Botox, from A to G, but only two types; A &B, are available for medical and cosmetic uses.
75909276|NCT03483428|Behavioral|Interventionist training and supervision|"Online and in-person training and weekly supervision with licensed clinical social worker while delivering the Family Check-Up to 5 families."
75909277|NCT03483428|Behavioral|Behavioral parent training|"Up to 6 sessions of the Family Check-Up program, involving discussions, assessments, feedback, and skills training with a parent coach."
76071734|NCT04169282|Device|nPEP (non-invasive positive expiratory pressure) mask|Positive end expiratory pressure (PEEP) mask
76071735|NCT04166604|Drug|Trifluridine/Tipiracil|"After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery"
75317736|NCT00485485|Drug|Imatinib Mesylate|400 mg by mouth daily
75317737|NCT00485485|Drug|Docetaxel|60 mg/m^2 by vein (IV) over 1 hour every 3 weeks
75317738|NCT00422201|Drug|Mifepristone|Singe dose
75317739|NCT01396148|Drug|sunitinib malate dose escalation|sunitinib starting dose will be 15mg/m^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
75317740|NCT01396148|Drug|sunitinib malate|sunitinib 50mg daily on Schedule 4/2
75768582|NCT01142986|Behavioral|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
75768583|NCT01329718|Other|Blood Sample|Blood sample collection
75768584|NCT01139398|Dietary Supplement|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
75768585|NCT01233934|Drug|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
75768586|NCT01233934|Drug|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
75768587|NCT01236508|Radiation|PET/CT imaging with F-18 fluorodeoxyglucose|Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
75768588|NCT05195944|Drug|Semaglutide Treatment|"The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day."
75768589|NCT05195944|Drug|Sitagliptin 100mg|"participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period"
75768590|NCT05185882|Other|Single leg squat|Single leg squat exercise in different circumstances
75768591|NCT04678726|Diagnostic Test|Lung ultrasound assessment for ruling out pneumothorax|Patients who have undergone heart surgery and have decided to enroll in our study, will have the standard chest x-ray and an additional lung ultrasound. Within a maximum of two hours of the chest tube removal, the standard chest x-ray will be performed, and then a different nurse will perform the lung ultrasound to check for pneumothorax.
75768592|NCT01236586|Drug|RO4929097|
75768593|NCT01236586|Drug|Dexamethasone|
75768594|NCT03559270|Drug|Baricitinib|Administered orally
75768595|NCT05136586|Other|Biofeedback|"6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instruction."
75768596|NCT05136586|Other|Meditation|"6 minutes of listening an audio tape made for the study that inspire mindfulness like meditation associated with psychological stimulation (positive encouragement) just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instructions."
75768597|NCT05136586|Other|Control and biofeedback post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer"
75768598|NCT05136586|Other|Control and control post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of of free activity where the participants will not be given any instruction."
75768599|NCT01234792|Drug|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
75909278|NCT03057886|Device|Comparative thermometers to compare with a new device|The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
75909279|NCT03131882|Drug|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
75909280|NCT03131882|Drug|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
75909281|NCT04938934|Behavioral|Lipids infusion|Lipids infusion via intestinal tube
75909282|NCT04938934|Behavioral|Sham infusion|Sham infusion via intestinal tube
75615860|NCT05054088|Device|T-Detect COVID test|• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
75909283|NCT04460534|Diagnostic Test|diagnostic|The principle of this study is to propose to patients in whom a COVID-19 infection is suspected and who are screened for the disease, the joint search for the virus in the semen.
75909284|NCT04938700|Drug|probiotics|Probiotics as granules can be used for infants and adolescents
75909285|NCT04938700|Drug|conventional medical treatment|Treatment for allergic diseases includes anti-allergic drugs, nasal spray hormones, inhaled hormones, external hormones, etc
75909286|NCT04837508|Drug|MRG002|Administrated intravenously
75615861|NCT03335722|Behavioral|Metronome-timed speech|Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
75768600|NCT01234792|Drug|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
75768601|NCT01234792|Drug|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
75768602|NCT01143220|Other|No specific interventions|Observational investigation, only procedures according to local hospital standard.
75768603|NCT03467932|Drug|Cohort A: ORMD-0801|"Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
75768604|NCT03467932|Drug|Placebo oral capsule|Placebo provided QHS, BID, TID
75768605|NCT03467932|Drug|Cohort B: ORMD-0801|"Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
75768606|NCT01234012|Biological|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
75768607|NCT01236664|Behavioral|Memory training|The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.
75768608|NCT01236664|Behavioral|Control Workshop|The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.
75768609|NCT01143298|Drug|LEO 27847 oral solution|
75768610|NCT01143376|Behavioral|High intensity training|high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
75768611|NCT01143376|Behavioral|short springs|short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
75768612|NCT01143376|Behavioral|Moderate intensity exercise|
75768613|NCT03318172|Device|Spinal Cord Stimulator|Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
75768614|NCT04618822|Behavioral|Teaching involving whole-body movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve whole-body movements and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
75768615|NCT04618822|Behavioral|Teaching involving hand movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve movements using hands and arms and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
75909287|NCT04938622|Other|Sedentary Control|Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
75317741|NCT00485953|Drug|risedronate|risedronate 35 mg per week
75768616|NCT04618822|Behavioral|Teaching involving minimal motor movements (control)|The control condition consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in groups of app. twelve children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities are completed seated on a chair using paper and pencil.
75768617|NCT01139788|Drug|LY2624587|"6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.~If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
75768618|NCT03250390|Device|Collection of volatile organic compounds during exhalation|"The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)"
75768619|NCT01139944|Genetic|DNA methylation analysis|
75768620|NCT01139944|Genetic|polymerase chain reaction|
75768621|NCT01139944|Other|laboratory biomarker analysis|
75909288|NCT04938622|Other|Exercising control|Exercise: Participants engaged in supervised exercise training in Noll Laboratory Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
75317742|NCT00422279|Device|Nobel Replace Tapered Groovy|Bone inductive implant placed in supralveoral position or extraction site
75768622|NCT05632666|Other|Inspiratory and expiratory muscle training at a therapeutic intensity|"The active treatment group will receive inspiratory muscle training starting at a therapeutic intensity of 30% of maximum inspiratory mouth pressure (PImax) and expiratory muscle training starting at a therapeutic intensity of 30% of maximum expiratory mouth pressure (PEmax) for 4 months.~In the active treatment group, the inspiratory and expiratory threshold (intensity) will be adjusted to the perceived exertion (measured with a Borg scale)."
75317743|NCT05222399|Drug|LY3871801|Administered orally.
75768623|NCT05632666|Other|Inspiratory and expiratory muscle training at a non-therapeutic intensity|The sham-control group will receive the same training protocol as the active treatment group but with a low (10% of PImax and PEmax) and stable non-therapeutic intensity.
75317744|NCT00486031|Drug|Balsalazide Disodium|
75317745|NCT04019834|Drug|regional nerve block with local anesthesia of bupivacaine with steroid|Patient will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes for either pectoral, serratus, or erector spinae nerve blocks. A block needle will be passed into the fascial plane and injectate will be deposited. The injectate in the active arm will contain a combination of bupivacaine, epinephrine and dexamethasone.
75768624|NCT01140022|Other|CT Screening|Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
75768625|NCT01140100|Drug|propofol|
75768626|NCT01140100|Drug|thiopental,propofol|
75768627|NCT01141036|Drug|propofol|Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
75768628|NCT01141036|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
75768629|NCT01235026|Dietary Supplement|Synbiotic|"5g of the prebiotic Oligofructose + 1 g of the probiotic Bifidobacterium animalis subsp. lactis Bb12 (4x10^10 CFU/g), twice a day, for 6 weeks."
75768630|NCT01235026|Dietary Supplement|Placebo|6g of maltodextrin, twice a day for 6 weeks.
75768631|NCT01141114|Other|Patient navigation|Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
75317746|NCT04019834|Other|Placebo regional nerveblock with normal saline|Patients who are randomized to placebo will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue .
75768632|NCT01141114|Other|Usual care|Usual care
75768633|NCT04977856|Behavioral|Behavioral activation (BA)|The main goal of the BA is to increase engagement in values-based activities and decrease avoidant behaviors that serve to maintain depression. The adolescent will learn about depression, how behavioral activations works, monitor their own activities, plan and do more values-based activities and deal with obstacles to getting in touch with positive reinforcement, such as avoidance behaviors.
75768634|NCT04977856|Other|Regular care within primary or secondary mental health care for children|Regular care (supportive therapy, waitlist, psychological treatments, drugs, or a combination of different interventions)
75768635|NCT04971850|Other|Sleep study|"Procedures added by research during PSG :~SDB screening questionnaires~Electromyography (EMG) of accessory and abdominal muscles~Cerebral oxygenation~Mandibular movements~Sleep headband (pre-teens and teens) or other connected device~Automatic PSG analyzes~Psychological and neuropsychological assessment The recordings of the study will be repeated at one year if the patient needs a treatment (surgery or noninvasive ventilation) following the results of the PSG."
75768636|NCT04948060|Other|Enhanced lung cancer screening services|A theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings
75768637|NCT01140178|Drug|HPPH|Given IV
75768638|NCT01235104|Procedure|Total nephrectomy|Total nephrectomy
75768639|NCT01236898|Drug|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
75768640|NCT04906720|Drug|Colchicine|colchicine 0.6mg oral twice daily for 7 days
76071736|NCT04166097|Other|Heart Smart Interventional Program|6-week program consisting of weekly didactic sessions that follow the steps outlined in the book.
75317748|NCT04017962|Drug|Letermovir Pill|Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A). The maximum duration of LTV administration will be 14 weeks. Patients receiving oral medication will be administered a pill diary for drug compliance purposes. This will be administered and reconciled in clinic.
75768641|NCT01140334|Behavioral|Voucher Reinforcement|Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
75768642|NCT01140334|Behavioral|Standard Control|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
75768643|NCT01141192|Dietary Supplement|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
75909289|NCT04938622|Other|15 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 15 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
76071737|NCT04157361|Diagnostic Test|Collection of breath condensate|Breath condensate will be collected from the patients involved in study.
76071738|NCT04145440|Drug|MOR202|Patients will receive 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing will occur weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
76071739|NCT04144751|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
76071740|NCT04144179|Biological|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
76071741|NCT04144179|Biological|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
76071742|NCT04144179|Biological|Quadrivalent RIV with H3 strain 3|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
75768644|NCT01141192|Dietary Supplement|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
75768645|NCT01144000|Drug|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
75768646|NCT01144078|Behavioral|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
75768647|NCT01144078|Behavioral|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
75768648|NCT01140412|Drug|Maraviroc|maraviroc 300 mg BID x 5 days
75768649|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
75768650|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
75768651|NCT01140412|Drug|Maraviroc|maraviroc 300 mg QD x 5 days
75768652|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
75768653|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
75768654|NCT02615860|Other|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
75909290|NCT04938622|Other|30 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 30 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
75909291|NCT04938622|Other|30 percent energy deficit (15/15)|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 15 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
75909292|NCT04938622|Other|60 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 30 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
76071743|NCT04144179|Biological|Quadrivalent RIV with H3 strain 4|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
76071744|NCT04144179|Biological|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
75768655|NCT02615860|Procedure|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
75768656|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
75768657|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
75909293|NCT04709822|Behavioral|Visuospatial Interference|"Two remote intervention sessions with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) alongside accompanying information.~Participants are instructed that they may continue using the technique self-guided after the first intervention session, and they may opt for additional intervention sessions with remote researcher support (maximum 6 intervention sessions)."
75909294|NCT04938310|Procedure|sleeve gastrectomy|sleeve gastrectomy
75909295|NCT04938310|Device|support garment|A custom made support garment
75909296|NCT03483350|Drug|Granisetron|Ampoule
75909297|NCT03483350|Drug|Midazolam|Ampoule
75909298|NCT03057730|Biological|Acellular Dermal Matrix|ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
75909299|NCT03480308|Drug|Fentanyl|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
75909300|NCT03480308|Drug|Dexamethasone|Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
75909301|NCT03480308|Drug|Bupivacaine|Bupivacaine
75909302|NCT03057418|Drug|Aurixim|Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
75909303|NCT03480230|Drug|Compound 121564|Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
75909304|NCT04938076|Device|Transcranial direct current stimulation|Transcranial direct current stimulation on motor cortex
75909305|NCT04937842|Biological|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
75909306|NCT05151614|Drug|Colchicine 0.5 MG|Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).
76071745|NCT04127227|Drug|sintilimab,pegaspargase,gemcitabine,oxaliplatin|"All patients enrolled in the study will accept sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimens their first-line therapy.~Patients with CR or PR will receive sintilimab maintenance therapy"
76071746|NCT04120935|Other|Observation|Prospective Observation of standard clinical practice.
76071747|NCT04111705|Drug|Lorlatinib|100 mg once daily
76071748|NCT04110353|Other|Wound dressings: Conservative dressings|Conservative dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
76071749|NCT04110353|Other|Wound dressings: Prevena dressings|Prevena dressing to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
76071750|NCT04110353|Other|Wound dressings: ciVAC dressings|Closed incision VAC dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
76071751|NCT04109313|Drug|LOU064|Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
75615862|NCT03335722|Device|Active tDCS|1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
76071752|NCT04106219|Drug|LY3295668 Erbumine|Administered orally.
76071753|NCT04106219|Drug|Topotecan|Administered IV.
76071754|NCT04106219|Drug|Cyclophosphamide|Administered IV.
75615863|NCT03335722|Device|Sham tDCS|Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
75615864|NCT04310670|Other|Psychotherapy|The patient will be treated according to Lacanian psychoanalytic ethics, which allows to adequately respond to the patient's request for healing but who at the same time does not ignore the progress of scientific research in the neurological field
75615865|NCT04310670|Behavioral|Physiotherapy|Physiotherapy treatment will be articulated through the use of techniques designed to qualify the functionality of the subject divided by symptom: weakness, dystonic attitudes of the limbs, walking disorders, tremor.
75769449|NCT03909256|Other|NUTRI-HAB|"The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian."
75909307|NCT03483194|Device|Virtual Reality|Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy
76071755|NCT04103580|Behavioral|Photo elicitation|Caregivers are taught to use photos to illustrate various feelings and meanings
76071756|NCT04099940|Behavioral|Virtual Reality Avatar Therapy (VRAT)|The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
76071757|NCT04099940|Behavioral|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
76071758|NCT04097418|Behavioral|Aerobic training compared to conventional motor training|"Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks."
76071759|NCT04096625|Device|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
76071760|NCT04096625|Behavioral|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.
76071761|NCT04096625|Device|Sham tDCS|Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
76071762|NCT04089865|Drug|Tranexamic Acid|Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.
76071763|NCT04088773|Diagnostic Test|blood biomarkers|biomarkers to distinguish fibrotic vs non-fibrotic CD lesions
76071764|NCT04088773|Diagnostic Test|stool biomarkers|fecal biomarkers of inflammation, mucosal inflammation
75909308|NCT03483194|Drug|Kalinox|Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
75909309|NCT04937530|Drug|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
76071765|NCT04088773|Diagnostic Test|MRI imaging|MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel
75317749|NCT04017962|Other|blood draw|Collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180.
75317750|NCT01396070|Drug|Brentuximab vedotin|"1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10."
75317751|NCT05366504|Combination Product|LiST + PRP intracorporeal injection|12 LiST sessions (2 sessions per week) plus PRP (2 intracorporeal injections 3 weeks apart, after the 1st and the 7th LiST sessions) ( 30 patients).
75615866|NCT04310670|Other|Non-Invasive Brain Stimulation (NIBS)|"Diversified transcranial electrical maneuver protocols with an on-line or off-line approach may be applied for therapeutic purposes. This will include: transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), random noise stimulation (tRNS)."
75615867|NCT00955617|Other|Contrast-enhanced MRA - Imaging examination|Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
75615868|NCT05462860|Other|Suprathel®|Application of standard of care dressing.®
75615869|NCT04277871|Behavioral|Pelvic floor muscles training (PFMT) combined with yoga|All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
75615870|NCT05331898|Behavioral|Education|the education given increased the rational drug use of the parents.
75615871|NCT03082209|Drug|ABBV-621|Intravenous (IV)
75615872|NCT03082209|Drug|Venetoclax|tablet, oral
75615873|NCT03082209|Drug|Bevacizumab|IV infusion
75615874|NCT03082209|Drug|FOLFIRI|IV infusion
75615875|NCT05423860|Other|no interventions will be performed (observational)|Not applicable. (no interventions will be performed with this observational study
75615876|NCT02224144|Drug|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
75768658|NCT04885192|Other|Stepped-Care Model|"Step 0: Screening via Manage My Pain (MMP) App. Patients using MMP will be prompted to complete questionnaires on pain catastrophizing, depressive symptoms, anxiety, suicide risk and opioid risk. Those scoring above clinical risk cut-offs will be referred to Step 1.~Step 1: Acceptance and Commitment Therapy (ACT) Workshop. Patients will be offered a virtual ACT workshop focusing on practical coping skills for dealing with pain, emotional dysregulation, and disability, while maximizing functioning and quality of life with chronic pain. Thirty days later, patients will be prompted to complete all questionnaires through MMP again; those who score above clinical risk cut-offs will be referred to Step 2.~Step 2: Dialectic Behavior Therapy (DBT) group. A 6-week DBT-based skills group will cover topics such as self-compassion, radical acceptance, distress tolerance, and mindfulness, among others. Thirty days later, patients will be prompted to complete questionnaires through MMP."
75768659|NCT01236976|Device|Therastride Treadmill System|This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It is registered with the FDA (Regulation Number 890.5380).
75768660|NCT01236976|Device|FES-assisted cycling|This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD).
75615877|NCT02224144|Drug|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
75768661|NCT01236976|Other|Trunk and upper and lower limb exercises|This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality.
75909310|NCT04937530|Drug|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
75909311|NCT04937608|Diagnostic Test|Sperm analysis|Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
75768662|NCT01236976|Other|Upper body strength and fitness program|This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
75769450|NCT01253278|Drug|LY2393910|as capsules, administered orally once daily for two weeks
75769451|NCT01253278|Drug|Placebo|as capsules, administered orally once daily for two weeks
75909312|NCT04937218|Behavioral|Egg demand creation campaign|Egg demand creation campaign including 14 months of above-the-line and below-the-line messaging.
75909313|NCT04937140|Diagnostic Test|14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients|assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)
75909314|NCT04409548|Other|All of the spatial and Temporal Gait parameters|
75909315|NCT04649840|Diagnostic Test|Humoral and cellular immunity|Humoral (IgG) and cellular (antigen-specific cells) immunity
75909316|NCT03482960|Drug|Hyperpolarized Xenon gas|"Hyperpolarized Xenon gas~Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~Administration: By mouthpiece attached to a single use Tedlar bag.~Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~Frequency: 10-minute interval between doses."
76071766|NCT04075305|Radiation|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
76071767|NCT04074993|Drug|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
76071768|NCT04074512|Drug|Copper Histidinate|Restoring Copper Histidinate levels normally found in the blood to assist in the maintenance of copper homeostasis.
75768663|NCT02334124|Other|Home|The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
75768664|NCT02334124|Other|Ward|Admission to a hospital based ward
75768665|NCT02334124|Drug|ceftriaxone|50mg/kg once daily
75909317|NCT03482960|Drug|PFP|"Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
75909318|NCT05259644|Device|laparoscopic sleeve gastrectomy|Surgical procedure - laparoscopic sleeve gastrectomy.
75317752|NCT05366504|Combination Product|LiST + Placebo(normal saline intracorporeal injection)|All subjects of this group will receive 12 sessions (V3-V14) of LiST with session frequency 2/week and 2 normal saline injections with 3 weeks treatment interval (V3 and V9), 10 ml of normal saline will be injected at each session.
75615878|NCT02224144|Drug|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
75909319|NCT05259644|Other|conservative treatment of obesity|Diet and exercise
75909320|NCT05259644|Device|endoscopic gastric plication|Endoscopic procedure - endoscopic gastric plication
75909321|NCT05151224|Diagnostic Test|microRNA 21|"Plasma microRNA 21 5p expression, by real-time polymerase chain reaction, before and after neoadjuvant systemic therapy.~Blood sample will be taken by a trained nurse, amount of blood will be 3 ml, and will be taken twice, one time before the start of the neoadjuvant systemic treatment , second time by the end of the neoadjuvant systemic treatment."
75909322|NCT04936672|Behavioral|Brisk walking and Tai Chi Chuan|This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.
75909323|NCT05259488|Dietary Supplement|immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
75909324|NCT03479996|Drug|Marcaine 0.5 % Injectable Solution|Intra -operative injection into obturator membrane
76071769|NCT04062708|Drug|Durvalumab|"Preoperative Treatment:~Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles."
75615879|NCT00958347|Device|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
75615880|NCT05419180|Drug|Stiripentol|Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
75615881|NCT04281615|Other|Generic Message|Exposed to four sets of promotional materials hypothesized to increase perceptions of self-efficacy to meet Guidelines.
75317753|NCT02108171|Drug|Dexmedetomidine|intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
75768666|NCT02334124|Drug|flucloxacillin|50mg/kg 6 hourly
75768667|NCT01140490|Procedure|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
75768668|NCT02528812|Device|TheraBand Roller Massager|The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
75768669|NCT02528812|Other|Manual Massage|A massage therapist massaged the participant
75768670|NCT01141270|Drug|AFOLIA|single sc injection, 225 IU
75768671|NCT01141270|Drug|Gonal-f|single sc injection, 225IU
75768672|NCT01141348|Behavioral|Special Intervention|16 week behavioral weight loss intervention included 2 hour weekly group sessions
75768673|NCT01141348|Behavioral|Delayed Intervention|During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
75768674|NCT01144156|Drug|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
75768675|NCT04860934|Behavioral|Dual Task Training Program Group|Fifteen patients will receive Dual Task Training Program. Total Period: 8 Weeks.
75768676|NCT04860934|Behavioral|Control Group|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
75768677|NCT01141504|Dietary Supplement|PeakATP 250|The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
75768678|NCT01141504|Dietary Supplement|Placebo|Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
75317754|NCT02108171|Drug|placebo|0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
75317755|NCT01395914|Drug|Anamorelin HCl|
75317756|NCT01395914|Drug|Placebo|
75317757|NCT00534235|Procedure|Decompression|Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain
75317758|NCT00534235|Device|Posterolateral Fusion and Implantation of Pedicle Screws|
75317759|NCT00534235|Device|Implantation of coflex Interlaminar Technology|
75317760|NCT04766840|Drug|CAR-T cells|Drug: IM73 CAR-T Cells Drug: Fludarabine Two days before cell infusion, patient will be treated with fludarabine for 3 days Drug: Cyclophosphamide: Two days before cell infusion, patient will be treated with Cyclophosphamide for 3 days
75317761|NCT03025178|Procedure|4Fr central venous catheter insertion|The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
75317762|NCT04011176|Procedure|Standard treatment + placebo|Placebo microcurrent
75317763|NCT04011176|Procedure|Standard treatment + Microcurrent Therapy|Actual microcurrent
75615882|NCT02857647|Behavioral|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
75615883|NCT02067052|Procedure|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
75615884|NCT02067052|Procedure|Surgery|Vulvectomy & lymphadenectomy
75768679|NCT01141504|Dietary Supplement|PeakATP 400|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
75768680|NCT01141504|Dietary Supplement|PeakATP 400 plus proprietary blend|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
75768681|NCT05632432|Procedure|Epicardial AAMs-patch transplantation|Perioperative assembly of an AAMs patch with epicardial transplantation at the end of CABG surgery
75768682|NCT05632432|Diagnostic Test|RNA-stabilized whole blood sampling|Collection (preoperative and at 6-month-follow-up) of TEMPUS(TM) stabilizing whole blood for epitranscriptomics-oriented measurements
75768683|NCT05632432|Diagnostic Test|Plasma sampling|Collection (preoperative and at 6-month follow-up) of blood-derived both RNA-stabilized and non-stabilized plasma aliquots for epitranscriptomic-oriented and other CVD biomarker oriented measurements, respectively
75768684|NCT05632432|Diagnostic Test|Transthoracic echocardiography|To assess cardiac structure and function both pre- and postoperatively (at both 3- and 6-month of follow-up)
75768685|NCT05632432|Diagnostic Test|Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI)|To assess detailed cardiac structure (i.e. interstitial fibrosis) and function both preoperatively and at 6-month follow-up postoperatively.
75768686|NCT05632432|Other|Symptom-scaling|Standardised evaluation of IHD and HF-related angina pectoris (CCS) and dyspnea (NYHA) and life quality (RAND36) pre- and postoperatively (at both 3- and 6-month follow-up).
75768687|NCT05632432|Other|6-minute walking test (6MWT)|Standardised assessment of physcial capacity pre- and postoperatively (at 6-month follow-up)
75768688|NCT05632432|Diagnostic Test|Blood sampling (NT-proBNP)|Collection of a blood sample measurement of NT-proBNP by an accredited hospital laboratory pre- and postoperatively (at both 3- and 6-month follow-up).
75768689|NCT05632432|Diagnostic Test|Transesophageal echocardiography|Performed by the perfusion-anesthesiologist at the beginning of the CABG surgery to evaluate both LAA and RAA for blood flow velocities, anatomy, possible sludge and thrombus.
75768690|NCT01235260|Other|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
75768691|NCT01235260|Drug|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
75615885|NCT05418712|Drug|Placebo|Placebo matched to VX-150 for oral administration.
75615886|NCT05418712|Drug|VX-150|Solution or Suspension for oral administration.
75768692|NCT05396950|Device|CPAP|CPAP in conjunction with radiotherapy
75768693|NCT01144858|Other|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
75768694|NCT01144234|Behavioral|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
75768695|NCT01144234|Behavioral|Information letter|In this arm the pregnant women got an information letter
76071770|NCT04062708|Procedure|Surgery|Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.
76071771|NCT04062708|Radiation|Radiotherapy|4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.
75317764|NCT00534937|Procedure|Compression wrapping|Short-stretch compression wrap will be applied at least once a week.
75317765|NCT00534937|Procedure|Flexitouch compression pump|In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
75317766|NCT03940807|Drug|11.25mg GnRH agonist|"Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
75768696|NCT01144312|Drug|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
75768697|NCT05395780|Drug|MAX-40279|MAX-40279 capsule will be administered orally
75768698|NCT01237288|Drug|Z-521|
75768699|NCT01238068|Device|gamma nail stryker|for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
75769452|NCT03899818|Device|drug-eluting balloon|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
75768700|NCT01237366|Behavioral|Resilient Affective Processing Therapy (RAPT)|Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
75768701|NCT01144390|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
75615887|NCT04280289|Drug|cannabidiol extract|"The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials"
75768702|NCT01144390|Drug|methadone maintenance treatment|methadone maintenance treatment
75768703|NCT01144936|Drug|VX-985 or matching placebo|low dose
75615888|NCT03302728|Drug|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
75615889|NCT03302728|Drug|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
75768704|NCT01144936|Drug|VX-985 or matching placebo|high dose
75768705|NCT01144936|Drug|VX-985 or matching placebo|dose TBD
75768706|NCT01144546|Procedure|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
75768707|NCT05350540|Other|ICG dye|Patients assigned to the intervention group will undergo surgery guided by tissue perfusion as directed by the ICG imaging
75317767|NCT03940807|Drug|0.1 mg GnRH agonist|"Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
75317768|NCT03940807|Drug|25 µg transdermal oestradiol|Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
75317769|NCT00461045|Drug|MRZ 0.5 mg/m^2|NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
75615890|NCT05331742|Drug|Vaccine|patients who have received vaccine against coronavirus disease infection
75615891|NCT03863236|Dietary Supplement|regular diet|The control group (group 1) will continue their regular diet.
75615892|NCT03863236|Dietary Supplement|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
75615893|NCT00958191|Device|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
75615894|NCT05322382|Procedure|A-line|Subjects breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia.
75615895|NCT03832972|Other|estrogen level|Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen
75615896|NCT03051477|Drug|Helixor® M|3-hour IV infusion on Monday, Wednesday, and Friday of each week.
75317770|NCT00535873|Drug|Lenalidomide|Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
75615897|NCT03125356|Other|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
75615898|NCT05314114|Procedure|No axillary surgery|No axillary surgery
75615899|NCT02860299|Drug|citrate 4%|
75615900|NCT02860299|Drug|unfractionated heparin|
75615901|NCT02860299|Biological|blood sample|
75615902|NCT02858739|Device|BIOFREEDOM STENT|
75615903|NCT02858505|Drug|27 mg elemental iron|
75615904|NCT02858505|Drug|54 mg elemental iron|
75615905|NCT05313100|Drug|sugammadex|At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
75615906|NCT00960843|Device|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
75768708|NCT01145014|Drug|BI 660848|2 mg oral drinking solution
75768709|NCT01145014|Drug|BI 660848|10 mg oral drinking solution
75768710|NCT01145014|Drug|BI 660848|20 mg oral drinking solution
75768711|NCT01145014|Drug|BI 660848|50 mg oral drinking solution
75768712|NCT01145014|Drug|BI 660848|100 mg oral drinking solution
75768713|NCT01145014|Drug|BI 660848|150 mg oral drinking solution
75768714|NCT01145014|Drug|BI 660848|200 mg oral drinking solution
75768715|NCT01145014|Drug|BI 660848|400 mg oral drinking solution
75768716|NCT01145014|Drug|BI 660848|600 mg oral drinking solution
75768717|NCT01145014|Drug|BI 660848|10,0 mg immediate release tablet
75768718|NCT01145014|Drug|BI 660848|50,0 mg immediate release tablet
75768719|NCT01145014|Drug|Placebo|matching placebo (oral drinking solution and IR tablets)
75769453|NCT03899818|Device|drug-eluting stent|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
76071772|NCT04059185|Other|Triple P-Level 2|Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.
75615907|NCT00960843|Other|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
75768720|NCT01329640|Device|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|"Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks"
75768721|NCT05335018|Drug|Glofitamab, Poseltinib, Lenalidomide|"Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
75768722|NCT00114777|Drug|Cyclosporin A|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
75768723|NCT00114777|Drug|Belatacept Less Intensive Regimen (LI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
75768724|NCT00114777|Drug|Belatacept More Intensive Regimen (MI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
75615908|NCT04281693|Diagnostic Test|Standard screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
75615909|NCT04281693|Diagnostic Test|New screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
75615910|NCT02860221|Drug|Tranexamic acid (TXA)|IV and topical administration
75615911|NCT02860221|Drug|Epinephrine|
75768725|NCT00139737|Drug|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
75768726|NCT03965559|Procedure|plasmapheresis|"Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).[Wikipedia]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. [Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.]"
75768727|NCT03965793|Device|Automated management of hypotension|Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
75768728|NCT00122187|Device|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
75768729|NCT00139659|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
75768730|NCT00139659|Drug|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
75768731|NCT00137631|Behavioral|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
75768732|NCT01582815|Drug|JNJ-40411813|Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
75768733|NCT01582815|Drug|Placebo|Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
75768734|NCT01076439|Drug|Fluticasone Furoate Nasal Spray|Fluticasone Furoate Nasal Spray: 110mcg QD
75768735|NCT01076439|Drug|Olopatadine Nasal Spray|Olopatadine Nasal Spray: 2660mcg BID
75768736|NCT01076439|Drug|Saline Nasal Spray|Placebo
75768737|NCT01078701|Biological|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
75768738|NCT01078701|Biological|Placebo|SPGN buffer
75768739|NCT01582893|Device|HCO1100|Dialysis
75768740|NCT01582893|Device|P210H|Dialysis
75615912|NCT02860065|Drug|CPC-201|solifenacin and donepezil
75615913|NCT02860065|Other|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
75615914|NCT04274829|Procedure|Thyroidecomt and lymphectomy|Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
75615915|NCT02857881|Procedure|De-epithelization and therapeutic photokeratectomy|
75615916|NCT02857569|Drug|Ipilimumab IT|
75615917|NCT02857569|Drug|Ipilimumab IV|
75615918|NCT02857569|Drug|Nivolumab IV|
75615919|NCT02638363|Behavioral|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
75615920|NCT04164667|Behavioral|Directed instruction of the combined intervention of physical activity and mindfulness meditation|By using the VA's ANNIE text messaging systems, the participant's will receive detailed guidance on the exercise and mindfulness session.
75462671|NCT01866722|Behavioral|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
75615921|NCT04164667|Behavioral|Self-guided practice of the combined intervention of physical activity and mindfulness meditation|The participants will receive the same goals about exercise and mindfulness practice, but without the added text messages where explicit instruction will be provided
75615922|NCT04164355|Drug|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
75615923|NCT01605253|Drug|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
75615924|NCT01605253|Drug|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
75615925|NCT04164433|Device|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
75615926|NCT00655135|Drug|LDP-02|Each patient in arms 2 & 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
75615927|NCT00655135|Drug|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
75615928|NCT02643121|Other|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
75615929|NCT04163965|Device|Capacitive ECG|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology.
75615930|NCT02643277|Behavioral|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
75615931|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
75615932|NCT02635945|Drug|PBF-680|
75615933|NCT02635945|Drug|Placebo|
75615934|NCT04059991|Biological|Influenza Vaccination|Only subjects vaccinated against influenza will be enrolled. The study itself is observational
75615935|NCT04162249|Other|Conventional LSI/AI-guided pulmonary veins ablation.|Conventional (low-power and long-duration) radiofrequency application.
75462672|NCT01866735|Other|Standardized Rehabilitation Therapy|
75462673|NCT01866748|Drug|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
75615936|NCT04162249|Other|High-power pulmonary veins ablation.|Experimental (high-power and short-duration) radiofrequency application.
75615937|NCT04162249|Other|Esophageal temperature monitoring|Two probes were simultaneously used: a deflectable one and a non-deflectable one.
75615938|NCT04162249|Diagnostic Test|Esophageal endoscopy|Esophageal endoscopy for acute detection of esophageal thermal lesions <72 hours after ablation.
75615939|NCT04164043|Behavioral|Wellness Recovery Program|12-week community-based recreation therapy
75615940|NCT00955305|Biological|Bevacizumab|Given IV
75615941|NCT00955305|Drug|Carboplatin|Given IV
75615942|NCT00955305|Biological|Cixutumumab|Given IV
75615943|NCT00955305|Drug|Paclitaxel|Given IV
75615944|NCT02635789|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
75615945|NCT02635789|Drug|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
75615946|NCT02635711|Behavioral|Adapted Taekwondo training|Adapted Taekwondo training for beginners
75317771|NCT00461513|Behavioral|Intervention|Disease management has emerged as a promising strategy to improve the outcomes of patients with CHF. Disease management in this study will use a multidisciplinary collaborative care, leveraging health information technology, and focusing on patient self-care.Collaborative care is the use of multidisciplinary teams to deliver evidence-based treatment to a defined population of patients with chronic illness.
75462674|NCT01866748|Drug|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
75615947|NCT02635711|Behavioral|Control|Daily jogging
75615948|NCT00655291|Drug|XP20B|
75615949|NCT00655291|Drug|Placebo|
75615950|NCT02857725|Drug|BAY 987517|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
75615951|NCT02857725|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
75768741|NCT03965715|Device|3D printing AFO, anterior AFO, off-the-shelf AFO|Subjects wear different AFOs and performed gait analysis.
75768742|NCT03965637|Drug|vitamin C|water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
75768743|NCT01078779|Drug|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
75462675|NCT01866748|Drug|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
76071773|NCT04059185|Other|Play Nicely|"Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes."
75909325|NCT05151068|Behavioral|traditional nursing method|"①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support."
75768744|NCT01078779|Drug|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
75768745|NCT00114231|Drug|capecitabine|
75462676|NCT01866748|Drug|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
75462677|NCT01866761|Procedure|Periodontal treatment|
75462678|NCT01866774|Other|Fecal calprotectin level|
75768746|NCT00114231|Drug|oxaliplatin|Given IV
75768747|NCT00114231|Procedure|neoadjuvant therapy|Undergo surgery
75768748|NCT00114231|Radiation|radiation therapy|Undergo radiotherapy
75768749|NCT00113919|Drug|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin* 10 mg/m, Continuous infusion 1-4 Adriamycin** 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
75768750|NCT00113841|Drug|Curcumin|2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
75768751|NCT00113841|Drug|Bioperine|5 mg (Tablets) orally twice daily
75768752|NCT00113607|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
75768753|NCT00113607|Drug|DOXIL|Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
75909326|NCT05151068|Behavioral|Precise acupoint application combined with ear acupoint embedding nursing program|On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.
75909327|NCT02524184|Drug|sildenafil|sildenafil 100 mg per day for 7 days.
75909328|NCT02524184|Drug|placebo|an identical placebo per day for 7 days
75462679|NCT01866800|Device|Renal Guard|Renal Guard
75462680|NCT01866800|Drug|Conventional Treatment|Saline and N-acetylcysteine
75909329|NCT03486236|Drug|VX-440|VX-440 was administered in TC with TEZ and IVA.
75462681|NCT01866813|Behavioral|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
75462682|NCT01866878|Device|equipment rehabilitation stereognosis|
75462683|NCT01866878|Device|TENS|
75462684|NCT01866891|Other|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
75462685|NCT01866969|Other|questionnaire administration|Ancillary studies
75462686|NCT01866969|Procedure|quality-of-life assessment|Ancillary studies
75462687|NCT01866982|Procedure|Umbilical Cord Milking|Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
75462688|NCT01866982|Procedure|Delayed Cord Clamping|Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
75462689|NCT01866995|Drug|"Raylis"|"Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)"
75768754|NCT00113607|Drug|Dexamethasone|Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
75769454|NCT03899662|Other|Cognitive Training|Cognitive training included memory, attention, velocity, intelligence
75769455|NCT03899662|Other|Physical Training|Physical training included aerobic, strength, flexibility and balance.
75462690|NCT01866995|Other|standard prostatostasis therapy|
75462691|NCT01867034|Other|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
75462692|NCT01867034|Other|Bare Metal Stent|
75462693|NCT01867060|Device|Automated Cardiac Event Recorder|Automated Cardiac Event Recorder to be worn continuously for one week.
75462694|NCT01867060|Device|Personal Heart Rhythm Monitor|Personal Heart Rhythm Monitor to be used twice-daily for three months.
75462695|NCT01867073|Other|Biomarker|
75462696|NCT01867112|Behavioral|Physical Activity|Physical activity either by individualized program or general guidelines
76071774|NCT04059185|Other|Usual care|"Our usual care control group participants receive a resource and referral list for local social services"
76071775|NCT04057131|Drug|Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
75909330|NCT03486236|Drug|TEZ|TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
75909331|NCT03486236|Drug|IVA|IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
75909332|NCT03486236|Drug|Matched Placebos|Placebos matched to VX-440, TEZ, and IVA.
75909333|NCT04935892|Behavioral|Slippers|Patients in the intervention group wear slippers when out of bed
75909334|NCT03486158|Device|CalproSmart™ system|Home test kit for measurement of calprotectin in fecal samples. A new clinical tool for monitoring patients with inflammatory bowel disease, enabling measurement of calprotectin level of rapid test through a specially developed Smartphone application (platforms such as Android o Iphone)
75909335|NCT03479918|Drug|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
75615952|NCT00656695|Drug|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
75615953|NCT00656695|Drug|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
75615954|NCT02858427|Behavioral|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
75615955|NCT02858427|Behavioral|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
75768755|NCT01080105|Behavioral|AIM Web based intervention + surveillance|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
75768756|NCT01080105|Behavioral|AIM web based intervention|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
75768757|NCT01080105|Behavioral|Educational website|Participants will receive access to a static educational website for 12 weeks.
75768758|NCT01076517|Device|Therasphere|Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
75768759|NCT00113529|Drug|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
75909336|NCT03479918|Drug|R-BL-M-04|R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
75909337|NCT03479918|Drug|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
76071776|NCT04050709|Biological|PD-L1 t-haNK|PD-L1 t-haNK Suspension for Infusion
75768760|NCT01078857|Other|Skin biopsy|A 3-mm-diameter skin biopsy punch was taken at the lateral side of the distal leg and fixed in 4% paraformaldehyde overnight. Sections of 50 m perpendicular to the dermis were cut on a sliding microtome, quenched with 1% H2O2 in methanol, and blocked with 5% normal goat serum. Sections were incubated with rabbit antiserum to protein gene product 9.5 (PGP 9.5, UltraClone, Isle of Wight, UK, 1:1000) overnight. PGP 9.5 is a ubiquitin carboxyl hydrolase, which labels myelinated and unmyelinated nerve fibers in the peripheral nervous system. Sections were then incubated with biotinylated goat anti-rabbit immunoglobulin G (Vector, Burlingame, CA) for 1 h and the avidin-biotin complex (Vector) for another hour. The reaction product was demonstrated using chromogen SG (Vector).
76071777|NCT04047992|Device|Indego™ Exoskeleton|The Indego® is a powered exoskeleton that can be used as a mode of therapy in an institutional setting. Proper walking in this device requires the user to manipulate their center of gravity and balance by postural trunk excursions in order for the legs to take steps.
76071778|NCT04046445|Drug|ATP128|5-6 SC injections
76071779|NCT04046445|Drug|BI 754091|≥ 7 IV infusions
76071780|NCT04046445|Drug|VSV-GP128|1 single IV injection
75768761|NCT01078935|Dietary Supplement|probiotics|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
75768762|NCT01078935|Dietary Supplement|placebo|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
75768763|NCT01079013|Drug|treosulfan|12 g/m2 x 3 days
75909338|NCT03479918|Drug|R-BL-M-04 + auto-SCT|R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
75909339|NCT04936048|Behavioral|Music Therapy|Music therapy will use rhythmic cues, music instruments (piano, drums, djembe, xylophone, harmonica), songs, and stories accompanied by songs or musical instruments to target common goals.
75909340|NCT04936048|Behavioral|Play therapy|Play therapy is designed as a play-based active comparison condition to control for factors such as support, therapist attention, positive expectancies, and emotional engagement. It will use verbal interaction, toys (Lego, finger puppets, Play Doh, puzzles), and the same stories as in MT, but without a musical component, to target common goals.
76071781|NCT04036435|Drug|BMS-986165|Specified dose on specified days
75615956|NCT02858427|Behavioral|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
75615957|NCT02858427|Behavioral|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
75615958|NCT02642887|Procedure|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
75768764|NCT00134901|Drug|Memantine|Memantine
75768765|NCT00134901|Drug|placebo|placebo
75768766|NCT01076595|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
75909341|NCT03482804|Other|Questionnaires|"Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.~The questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password."
75615959|NCT04204083|Device|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose in a 5-mL glass syringe.
75615960|NCT04271865|Other|Nutritional Education|Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status
75615961|NCT04271865|Other|model nutrition kitchen|Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.
75615962|NCT04271865|Other|recipe book|3) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
75615963|NCT04271865|Other|Provision of Dates|"Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females"
75768767|NCT00122109|Behavioral|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
75768768|NCT03965325|Other|Use of a standardized set to collect clinical and patient-centered data, to assess the trend of the Global Health Status overtime in colorectal cancer patients|Patients' data (baseline characteristics, clinical and PROMs outcomes) will be collected according to patient-centered standardized set regarding ICHOM recommendations. Data collection and the follow-up schedule are carried out at : baseline (before any treatment or surgery), 1- and 6-month follow-up and then once a year.
75768769|NCT01326663|Drug|Medication Trial|
75768770|NCT00113373|Drug|lapatinib ditosylate|Given orally
75768771|NCT00113373|Other|laboratory biomarker analysis|Correlative studies
75768772|NCT01079091|Device|ADVOS (Hepa Wash)|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
75768773|NCT01079091|Procedure|Standard Medical Therapy|Standard of care treatment
75769456|NCT01150006|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
75769457|NCT01253356|Device|IABP|Insertion of intra-aortic balloon < or = 3 hours before noncardiac surgery and maintained > or = 12-24 hours after surgery
75909342|NCT04935970|Diagnostic Test|diagnostic blood test|vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
75909343|NCT04935970|Diagnostic Test|neuropsychological test|neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
75909344|NCT03479840|Procedure|PCI|treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
75909345|NCT03482726|Behavioral|Cycling Cadence Modulation|6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.
75909346|NCT04935346|Other|no intervention group|The awareness of medical and nursing students were evaluated. there is no intervention
75768774|NCT01326351|Procedure|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
75615964|NCT00598585|Drug|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
75615965|NCT00598585|Drug|Placebo|Placebo pills 3X/day for 6 weeks
75615966|NCT04271553|Other|Video|In addition to standard workflow, participants will also receive the PFO bundle which consists of: 1) A cartoon video of about 6 minutes duration illustrating the events occurring during admission, anaesthesia and surgery and 2) Sets of activity sheets which have been tailored for different age groups. Families would be encouraged to complete activity sheets together.
75615967|NCT00175201|Procedure|Proactive care and rehabilitation|
75615968|NCT00653107|Procedure|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
75615969|NCT00653107|Radiation|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
75615970|NCT00653107|Radiation|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
75615971|NCT02635243|Drug|SAR438544|"Pharmaceutical form:solution~Route of administration: subcutaneous"
75615972|NCT02635243|Drug|r-glucagon|"Pharmaceutical form:solution~Route of administration: subcutaneous"
75615973|NCT02635243|Drug|insulin|"Pharmaceutical form:solution~Route of administration: intravenous"
75615974|NCT00953667|Drug|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
75615975|NCT04274439|Other|Internet-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.
75768775|NCT01326351|Procedure|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
75768776|NCT01326351|Behavioral|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
75768777|NCT01079169|Dietary Supplement|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
75768778|NCT00113295|Drug|Continued Paroxetine CR|
75768779|NCT00113295|Drug|Quetiapine|
75909347|NCT04935502|Other|Home based exercises with postural and ergonomic training|Group A will be treated with stretching and strenghtening exercises for 40 minutes along with postural and ergonomic training for 15 minutes session 3 days/week for 4 week.
75768780|NCT00113295|Drug|Placebo|
75909348|NCT04935502|Other|Home based exercises|Group B will be given stretching and strengthening exercises for 40 minutes, every alternate day (3 days per week) for 4 weeks.
75909349|NCT03482648|Drug|BBT-401-1S, Single dose|Single dose of BBT-401-1S, 7 dose levels, oral capsule
75768781|NCT00112905|Drug|sorafenib tosylate|Given PO
75909350|NCT03482648|Drug|BBT-401-1S, Multiple doses|Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
75909351|NCT03482648|Drug|Placebo|Placebo matched to BBT-401-1S, oral capsule
75909352|NCT04935190|Diagnostic Test|Vitalpercept|Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography
75909353|NCT05150834|Other|This is observational study|We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
75909354|NCT04934644|Procedure|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment 90 min from start to start of decompression. The chamber is pressurized to 2,4 ATA and the patients will be breathing 100% oxygen. Treatments will be given once daily, five days a week (no treatments on weekends and holidays).
75909355|NCT03486080|Drug|Dutogliptin Tartrate|Active treatment
75909356|NCT03486080|Drug|Filgrastim Injectable Product|Active treatment
75909357|NCT03486080|Drug|Placebos|placebo control
75768782|NCT00112905|Other|laboratory biomarker analysis|Optional correlative studies
75768783|NCT03964857|Other|Refined olive oil (ROO)|Consumption of chicken dishes made with ROO for a period of 8 weeks
75768784|NCT03964857|Other|Blended Oil 1 (BO1)|Consumption of chicken dishes made with BO1 for a period of 8 weeks
75768785|NCT03964857|Other|Blended Oil 2 (BO2)|Consumption of chicken dishes made with BO2 for a period of 8 weeks
75768786|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
75909358|NCT04934878|Biological|Referral information|first visit to our hospital/transfer from another hospital
75909359|NCT03131258|Procedure|Donor Nephrectomy|48 Donor Nephrectomy Patients
75909360|NCT03057262|Device|Repositioning splint|Application of repositioning splint in the study group.
75462697|NCT01867125|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
75615976|NCT04274439|Other|Online Booklet|An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
75615977|NCT02812173|Device|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
75615978|NCT02812173|Device|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
75615979|NCT02812173|Device|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
75615980|NCT00630669|Procedure|Rubber band ligation|placing rubber bands around the internal hemorrhoids
75615981|NCT00630669|Procedure|Bipolar coagulation|using electricity to cauterize
75615982|NCT02857335|Behavioral|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
75615983|NCT02857491|Drug|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
75615984|NCT02857491|Drug|sham|sham intravitreal injection before vitrectomy
75615985|NCT02857491|Procedure|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
75615986|NCT02857179|Procedure|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,…)
75615987|NCT00883129|Drug|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
75615988|NCT00883129|Drug|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
75615989|NCT00883129|Drug|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
75768787|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered on day 1
75462698|NCT01867125|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
75462699|NCT01867138|Drug|Cefazolin|
75615990|NCT02856867|Drug|Nintedanib|
75615991|NCT02856867|Drug|Fluorouracil|
75615992|NCT02856867|Drug|Leucovorin|
75615993|NCT02856867|Drug|Oxaliplatin|
75909361|NCT03479450|Drug|surfactant|surfactant is given when neonatal respiratory distress syndrome is diagnosed
75615994|NCT02856867|Drug|Placebo|
75615995|NCT00630513|Drug|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
75615996|NCT00630513|Drug|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
75909362|NCT03477344|Drug|Dexmedetomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
75909363|NCT03477344|Drug|Sodium chloride 0.9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
75909364|NCT04933864|Drug|Methylene Blue and Photodynamic Therapy|"Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm^2 energy dose.~For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm^2 energy dose were performed."
75909365|NCT03477266|Drug|Mosapride|Intake mouthly dissolving mosapride tablets in immediate post cesarean section
75909366|NCT03477266|Drug|Placebo Oral Tablet|Dummy identical tablets to mouthly dissolving mosapride tablets
75909367|NCT04933318|Other|TENS|Transcutaneus electrical nerve stimulation (TENS)- analgesic current therapy
75462700|NCT01867138|Drug|Vancomycin|
75462701|NCT01867138|Drug|Amikacin|
75462702|NCT01867151|Dietary Supplement|Gluten Free Diet|
75462703|NCT01867151|Dietary Supplement|Normal Diet|
75615997|NCT04059211|Diagnostic Test|Urinary dipstick|Sensitivity and specificity of urinary dipstick for proteinuria in emergency departments
75615998|NCT01278927|Behavioral|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
75615999|NCT01278927|Behavioral|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
75616000|NCT01278927|Behavioral|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
75616001|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
75768788|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
75768789|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
75768790|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
75768791|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered 3-4 years after dose 1
75768792|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
75768793|NCT02459327|Behavioral|Video Interaction Project|VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).
75616002|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
75909368|NCT04933318|Other|shamTENS|shamTranscutaneus electrical nerve stimulation (shamTENS)- analgesic current therapy
75909369|NCT04933318|Other|IFC|Interferential current therapy (IFC)- analgesic current therapy
75909370|NCT04933318|Other|shamIFC|shamInterferential current therapy (shamIFC)- analgesic current therapy
76072442|NCT03926481|Behavioral|Evaluate Healthy Lifestyle Program on cognitive outcomes|The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
76072443|NCT04028193|Dietary Supplement|Calogen|Polyunsaturated liquid fat supplement
75616003|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
76072444|NCT04028193|Dietary Supplement|Resource Energy|Carbohydrate Supplement
75616004|NCT04162483|Device|Neuroform Atlas Stent System|Stenting Assisted coiling procedure
75768794|NCT02459327|Behavioral|Family Check Up|FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
75768795|NCT01034189|Drug|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
75768796|NCT01034189|Drug|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
75768797|NCT01034189|Drug|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
75768798|NCT01034189|Radiation|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
75768799|NCT00425945|Drug|Pine Bark Extract (Flavangenol®)|"Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks."
75768800|NCT00416195|Drug|E2007|
75768801|NCT00416195|Drug|Placebo|
75768802|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term [ST], 42 months long term [LT])
75768803|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
75768804|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
75616005|NCT04270773|Biological|Human Papillomavirus 9-valent Vaccine, Recombinant|Vaccine administrated
75768805|NCT00121641|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
75768806|NCT00121641|Drug|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
75768807|NCT00121641|Drug|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
75909371|NCT03479372|Drug|PAN-90806 Ophthalmic Suspension|PAN-90806 provided in single-use dropper bottles for topical ocular administration
75616006|NCT00905632|Drug|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
75616007|NCT00905632|Drug|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
75616008|NCT00905632|Drug|Placebo + SOC|Placebo tid +SOC
75616009|NCT00905632|Drug|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
75909372|NCT03131336|Drug|PeproStat|solution for local application
75909373|NCT03131336|Drug|Saline|solution for local application
75616010|NCT01213732|Other|Isolated inferior limb perfusion|Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
75768808|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
75768809|NCT00121641|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
75768810|NCT00425555|Drug|Panobinostat|
75768811|NCT00424775|Drug|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
75768812|NCT01034267|Drug|F2695 SR|Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
75768813|NCT01323881|Device|Intermittent theta burst stimulation|Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
75768814|NCT00121485|Device|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
75768815|NCT01034345|Drug|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
75909374|NCT03057340|Biological|Dribble vaccine|DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
75909375|NCT02523950|Procedure|Staged phacoemulsification and DMEK|"Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.~Stage 2. DMEK is performed secondarily according to the corneal status of patients."
76072445|NCT04406181|Behavioral|HADS|Hospital Anxiety and Depression Scale
75768816|NCT01034345|Drug|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
75768817|NCT01763866|Biological|Evolocumab|Administered by subcutaneous injection
75768818|NCT01763866|Drug|Ezetimibe|Administered orally once a day
75768819|NCT01763866|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
75768820|NCT01763866|Drug|Placebo to Ezetimibe|Administered orally once a day
76071782|NCT04035447|Behavioral|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
76071783|NCT04033211|Device|Novosyn® CHD for fascia and skin closure|Experimental
76071784|NCT04033211|Device|Novosyn® for fascia and skin closure|Comparator
75616011|NCT05287360|Drug|Rivoceranib|Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
75462704|NCT01867177|Other|HIV testing|"HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; teachable moments during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable next steps with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention."
75616012|NCT05333770|Device|High-frequency repetitive transcranial magnetic stimulation|TMS is an investigational device that provides a way to test the function of a specific part of the brain that is devoted to moving my affected upper limbs by directing a low electrical current to that part of the brain through the scalp.
75616013|NCT05333380|Device|ECG/PPG monitoring|"The enrolled patients will wear an ECG patch and watch at the same time to collect ECG and PPG data respectively. The data collection time is from the day of hospitalization to before the ablation operation, and from 2 hours after the removal of ECG monitoring equipment to before leaving the hospital. The monitoring duration of each patient shall not be less than 18 hours."
75616014|NCT00954447|Drug|Placebo|Placebo, identical to Linagliptin tablet
75616015|NCT00954447|Drug|Linagliptin|intended final marketed dose
75616016|NCT05195320|Behavioral|Reinvention with MS|A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
75462705|NCT01867177|Other|standard of HIV care|Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
75616017|NCT05186584|Other|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|"Group A will receive the 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set (total 75 oscillations) for AP mobilizations at most symptomatic segment, with 10 seconds rest between sets. Most symptomatic segment is that segment of cervical spine at which patient will feel greatest pain by palpation.~For AP mobilizations, patient will lye supine and therapist will stand by his head. Therapist will make broad contact with the thumb, at the costal process of the vertebrae to be mobilized and spread fingers around adjacent neck for stability. Shoulder will be positioned above the joint being treated. Gentle oscillatory Anteroposterior pressure will be performed by the therapist's arm and trunk."
75616018|NCT05186584|Other|MAITLAND'S LATERAL MOBILIZATION|Group B will receive the same sets (i.e. 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set) for lateral mobilizations at most symptomatic segment, with 10 sec rest between each set. For lateral mobilization, patient will lye supine and therapist will stand by his head. Therapist will place the anterolateral aspect 2nd metacarpophalangeal joint over the lateral aspect of transverse process of most symptomatic segment. Gentle lateral oscillations towards the asymptomatic side will be provided by the therapist.
75768821|NCT01763866|Drug|Atorvastatin|Administered orally once a day
75768822|NCT01763866|Drug|Rosuvastatin|Administered orally once a day
75768823|NCT01763866|Drug|Simvastatin|Administered orally once a day
75768824|NCT01324037|Other|diagnostic algorithm|diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
75768825|NCT01034423|Dietary Supplement|Omega-3|Capsules with omega-3 fatty acids.
75768826|NCT01034423|Dietary Supplement|sun flower oil|Capsules with sun flower oil.
75768827|NCT00132873|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution
75768828|NCT01034501|Device|sham procedure|non activated laser tip
75768829|NCT01034501|Device|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
75768830|NCT01037543|Drug|HM10460A or placebo or Neulasta|Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
75768831|NCT00120627|Behavioral|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
75768832|NCT00120627|Other|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
75616019|NCT04735744|Other|Patients recovering from COVID19 receive usual care by allied health professionals|We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
75616020|NCT00903760|Drug|Decitabine|Decitabine 20 mg/m^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
75616021|NCT00903760|Drug|Clofarabine|Clofarabine 10 mg/m^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
75616022|NCT02969512|Other|HIPPER|Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.
75768833|NCT01588925|Device|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
75768834|NCT01588925|Drug|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
75768835|NCT01588925|Drug|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
75768836|NCT01589003|Other|Low Glycaemic index growing up milk|Low Glycaemic index growing up milk
75768837|NCT01589003|Other|High GI growing up milk|High glycaemic index growing up milk
75768838|NCT05332756|Other|Conservative management|Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
75768839|NCT01238146|Drug|bendamustine hydrochloride|Given IV
75768840|NCT01238146|Drug|obatoclax mesylate|Given IV
75768841|NCT01238146|Biological|rituximab|Given IV
75768842|NCT05292196|Drug|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
75768843|NCT05292196|Drug|TQC3721 suspension placebo for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
75768844|NCT01141894|Other|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
76071785|NCT04033107|Drug|Vitamin C|Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
76071786|NCT04033107|Drug|Metformin|Participants will orally take metformin 4g daily.
75768845|NCT01141894|Other|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
75768846|NCT02528422|Drug|Acyl-Ghrelin|
75768847|NCT01238224|Drug|Tadalafil|This is an acute study. Tadalafil 20 mg administered prior to a meal
75768848|NCT01237444|Drug|lopinavir/ritonavir plus one nucleoside|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
76071787|NCT04030312|Dietary Supplement|Bottle Supplementation--Commercially-Sterilized Donor Human Milk|Supplementation by bottle with 20-calorie-per-ounce commercially-sterilized donor human milk (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
75462706|NCT01867177|Behavioral|HIV care utilization|Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS), Community Health Worker (CHW) Program, case management/support services linking people to continuous, coordinated care after HIV dx. Another site will do Motivational Enhancement Intervention (MEI) sessions with quality of ife workshops and support groups. Health Educators recruit clients, make appointments, escort to test sites, intake, review. Additional components can include food security support, social and group support, drop in centers, text messaging and social media, depending on sites. All sites focus on approaches to reach community members and facilitate their supportive linkage to care with behavioral and structural supports.
75462707|NCT01867190|Biological|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
75462708|NCT01867203|Other|Genotyping|DNA extraction from blood
75462709|NCT01867229|Other|observational|standard of care fore patients with non metastatic breast cancer
75768849|NCT01237444|Drug|lopinavir /ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."
75768850|NCT01145092|Behavioral|exercise training, endurance training|The endurance training group exercised on a cycle ergometer (90% of power output determined at the respiratory compensation point = RCP). The duration of each training unit was increased with time. The resistance group trained on 8 weight machines where the workload gradually increased every 2-3 weeks. At week 13 an additional physical examination, OGTT and spiro-ergometry for adjusting the training were performed.
75768851|NCT01145170|Radiation|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
75768852|NCT01145170|Biological|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
75909376|NCT02523950|Procedure|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
75909377|NCT02523950|Device|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
75909378|NCT03482570|Device|ActiGraph|Activity behaviours will be objectively assessed by 7-day triaxial accelerometer assessment (ActiGraph GT3X+ Pensacola, FL, USA). Participants will be asked to wear an accelerometer around their waist, 24 hours a day for 7 days.
75317772|NCT00487669|Drug|paclitaxel poliglumex, pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
75462710|NCT01867255|Drug|venlafaxine ER (extended-release) 75 mg|A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
75616023|NCT02969512|Other|OASIS Online Educational Webinars|2-hour online educational large group sessions
75616024|NCT05177614|Dietary Supplement|Upper-level multiple micronutrient-fortified bouillon cube|80 µg/g Folic acid 1.2 µg/g Vitamin B12 3 mg/g Zinc (ZnO) 4 mg/g Iron (FePP/citric acid/trisodium citrate) 200 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
75616025|NCT05177614|Dietary Supplement|Lower-level multiple micronutrient-fortified bouillon cube|28.8 µg/g Folic acid 0.288 µg/g Vitamin B12 1.68 mg/g Zinc (ZnO) 1.3 mg/g Iron (FePP/citric acid/trisodium citrate) 96 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
75616026|NCT05177614|Dietary Supplement|Iodine-fortified bouillon cube|30 µg/g Iodine (KIO3)
75616027|NCT04165603|Procedure|Preoperative Infusion of Indocyanine Green|preoperatively infuse indocyanine green through peripheral vein
75768853|NCT01145248|Device|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
75768854|NCT01145248|Device|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
75768855|NCT03762616|Diagnostic Test|Micro-ultrasound targeted biopsy|Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
75909379|NCT03477188|Behavioral|Somatosensorial and Vestibular Exercises|In the experimental group, the subjects who were taken to the somatosensorial and vestibular exercises program after pre- treatment evaluations. The subjects in this group were given classical physiotherapy and somatosensorial combined with vestibular exercise performed 5-7 days a week, 1 set of 10 times with physiotherapist control. In the content of the training, in addition to the general physiotherapy program applied for Brunnstrom and Bobath exercises and spasticity inhibition according to in-bed mobility, Flask and spasticity conditions in the experimental group, a mutual study program was prepared with Cawthorne-Cooksey and Frenkel exercises in the bed, then balance and walking will be performed with the exercises
75768856|NCT03762616|Diagnostic Test|mpMRI targeted biopsy|Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
75462711|NCT01867268|Drug|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
76072446|NCT04406181|Behavioral|a survey|made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak
75317773|NCT00488059|Drug|enfuvirtide [Fuzeon]|90 mg SC twice daily
75462712|NCT01867268|Other|prone positioning|prone positioning the patient for 10 days following the surgery
75616028|NCT02846272|Procedure|Observation|Observation of MRI changes in subjects
75616029|NCT04202536|Drug|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
75317774|NCT00488059|Drug|Optimized background ARV|As prescribed
75317775|NCT00488059|Drug|Integrase inhibitor|As prescribed
75462713|NCT01867268|Other|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
75462714|NCT01867281|Drug|aspirin|
75462715|NCT01867437|Drug|Placebo|Sterile solution (vehicle) for subcutaneous infusion
75616030|NCT04202536|Drug|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily Other Name: VIREAD®
75616031|NCT02817880|Device|rTMS|
75616032|NCT02817880|Device|tDCS|
75616033|NCT02817880|Device|tsDCS|
75616034|NCT02794402|Drug|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
75616035|NCT02794402|Behavioral|Placebo|Placebo once weekly injections sc
75616036|NCT00883051|Drug|Lasmiditan|Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
75616037|NCT00883051|Drug|Placebo|Placebo
75462716|NCT01867437|Drug|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
75616038|NCT02637739|Device|hysteroscope|Women of PUL with β-hCG > 1000 IU/L or abnormal β-hCG trend (increase < 66% or decrease < 15%) were offered HSC.
75616039|NCT00655525|Dietary Supplement|fish oil|2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
75616040|NCT00655525|Dietary Supplement|placebo|placebo administered orally every day for 3 months
75616041|NCT03395587|Biological|Autologous, tumor lysate-loaded, mature dendritic cells (DC)|Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
75768857|NCT01141972|Dietary Supplement|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
75768858|NCT01141972|Other|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
75317776|NCT00488059|Drug|enfuvirtide [Fuzeon]|180 mg SC once daily
75317777|NCT02124889|Behavioral|Weekly Internet surveys|Subjects will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
75462717|NCT01867463|Biological|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
75462718|NCT01867463|Biological|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
75616042|NCT03395587|Drug|standard therapy|temozolomide, fractionated radiochemotherapy
75616043|NCT00903682|Drug|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
75616044|NCT00903682|Drug|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
75616045|NCT00655603|Other|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
75616046|NCT01117428|Drug|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
75616047|NCT05223322|Behavioral|Taking Charge during Treatment (TCT) Intervention|CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
75616048|NCT04162405|Behavioral|Tinnitus Handicap Inventory Test|A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
75616049|NCT02637661|Other|earlobe crease positive|
75616050|NCT02637661|Other|earlobe crease negative|
75616051|NCT02715466|Drug|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
75616052|NCT02715466|Drug|Balanced electrolyte solution|Sterofundin ISO
75616053|NCT00655681|Drug|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children < 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
75616054|NCT00655681|Other|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
75616055|NCT04187586|Other|Extracorporeal shock wave therapy|ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
75616056|NCT02345356|Genetic|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
75616057|NCT02345356|Other|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
75616058|NCT02635477|Behavioral|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
75616059|NCT02635477|Behavioral|Control|Behavioral: actigraphy device, step count measurement only
75768859|NCT01142050|Biological|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
75768860|NCT04316806|Dietary Supplement|Probiotic|Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)
75768861|NCT04316806|Drug|Rifaximin|Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
75317778|NCT02319967|Behavioral|CAPE|Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers
75317779|NCT02319967|Behavioral|CHW home visits|Home visits by community health workers (CHW) to assist children and their caregivers to implement the CAPE and other guideline-recommended competencies.
75317780|NCT02120443|Device|ivWatch Model 400|The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
75317781|NCT00536341|Drug|lenalidomide|2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
75317782|NCT00536341|Drug|Rituximab|375 mg/m2 Cycle 1 (split over Day 1 & Day 2); 500 mg/m2 Day 1 of Cycles 2-6
75317783|NCT00536341|Drug|Fludarabine|25 mg/m2 on Days 1, 2, and 3
75768862|NCT01145326|Drug|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
75768863|NCT01145326|Drug|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
75909380|NCT03477188|Behavioral|Conventional Group|In the control group, The subjects who were taken into the study were taken to the classical physiotherapy based on Bobath and Brunnstrom will be applied to increase the mobilization and spasticity up to the discharge stage known as 5-7 days a week
75909381|NCT03482492|Drug|Tramadol|Tramadol iv
75317784|NCT02122471|Drug|Plecanatide|
75616060|NCT05139550|Device|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises~ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises~bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities~Lift can, Lift pencil, Lift paper clip, Stack checkers,Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
75616061|NCT04221568|Drug|Bupivacaine-fentanyl|local anathetic&analgesic drugs
75616062|NCT04221568|Drug|levobupivacaine-fentanyl|local anathetic&analgesic drugs
75616063|NCT02635087|Device|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
75616064|NCT02707198|Drug|kefir|4 ounces of kefir 3 times a day, with or without food.
75616065|NCT04163497|Device|ICU Diaries|To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
75616066|NCT02635165|Device|Thoracic osteosyntheses with Stracos|
75616067|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
75616068|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
75616069|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
75616070|NCT04165447|Behavioral|Front-of-pack labeling strategy|We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
75616071|NCT00948675|Drug|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
75616072|NCT00948675|Drug|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 [maximum possible dose of 900 milligrams (mg)] intravenously infused over 30 minutes.
75616073|NCT00948675|Drug|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
75768864|NCT01144702|Drug|artesunate & mefloquine combination|A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
75768865|NCT01145404|Drug|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
75768866|NCT01145404|Drug|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
75909382|NCT03482492|Drug|Paracetamol|Paracetamol iv
75909383|NCT03477032|Biological|Faecal Microbiota Transplantation|Faeces acquired from a healthy donor
75909384|NCT03874286|Diagnostic Test|Liver Transplant|Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsies are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.
75909385|NCT03482414|Other|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
75462719|NCT01867463|Biological|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
75909386|NCT03482414|Other|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
75462720|NCT01867476|Other|Automated Adherence Monitoring System|
75317785|NCT02122471|Drug|Placebo|
75317786|NCT00461591|Drug|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
75317787|NCT00461591|Drug|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
75317788|NCT00461591|Procedure|TURBT|TransUrethral Resection of the Bladder Tumor
75317789|NCT02982733|Other|ABS|Ankaferd Blood Stopper
75317790|NCT02982733|Device|TR Band|Transradial band
75317791|NCT02982733|Other|CS|Sterile Gauze
75462721|NCT01867489|Other|No intervention|
75768867|NCT01237522|Drug|Metformin|A single dose study with one tablet of metformin 500 mg, time frame 24 hours
75768868|NCT02528344|Behavioral|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
75768869|NCT01238302|Procedure|Conventional arthroscopic rotator cuff repair|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4-5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repair of full thickness rotator cuff tear was done with suture anchors.~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound."
75616074|NCT00948675|Biological|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
75616075|NCT02850172|Behavioral|Walk, Eat, & Breathe|"Walking exercise: 3 times per week, 20~30 mins per section~Eat: nutritional assessment and advice weekly~Inspiratory muscle training: twice every day, 7 days a week, 6~8 weeks before surgery"
75768870|NCT01238302|Procedure|Arthroscopic rotator cuff repair with PRP|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4-5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repair of full thickness rotator cuff tear was done with suture anchors.~After tying sutures of the medial row, PRP gels were applied on the repair site.~The lateral row was secured using suture anchors.~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound."
75768871|NCT01235416|Drug|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
75768872|NCT04246996|Drug|gentamicin sulfate|Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
75909387|NCT03482414|Other|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
75768873|NCT04246996|Other|Catheter clamping only|Subjects in the control arm will have their standard-of-care transurethral catheter clamped for 1 hour post-placement to maintain subject masking to study arm.
76071788|NCT04030312|Dietary Supplement|Bottle Supplementation--Standard Infant Formula|Supplementation by bottle with 20-calorie-per-ounce standard infant formula (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
76071789|NCT04029129|Other|Air filtration and building envelop modifications|Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
76071790|NCT04028492|Drug|Tradipitant|BID
75616076|NCT02642497|Drug|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
75768874|NCT01238380|Other|patient care pathway|"Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 & IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change."
75768875|NCT00424463|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
75909388|NCT03476954|Other|Respiratory Impedance (RI)|A non-invasive respiratory device is employed to generate resistance during the inspiratory phase of respiration.
75909389|NCT04356794|Other|Acupuncture needle with electrical stimulation|EA is treated for 4 weeks, 3 times per week.
76071791|NCT04028492|Drug|Placebo|BID
76071792|NCT04028310|Other|Phonological|"Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~Phase 2: intervention with targeted daily training~Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~Phase 3: stopping training sessions for 8 weeks"
75616077|NCT02642497|Drug|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
76071793|NCT04028310|Other|Visual-attention|"Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~Phase 2: intervention with targeted daily training~Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~Phase 3: stopping training sessions for 8 weeks"
76071794|NCT04025957|Drug|SHR-1501|Administered subcutaneously
75909390|NCT04356794|Other|Sham electroacupuncture|Sham EA is treated for 4 weeks, 3 times per week.
75909391|NCT03479294|Drug|Shenlingcao Oral Liquid|Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
76071795|NCT04021316|Other|dCELL® Human Dermis (decellularised dermal skin allograft - DCD)|DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
75768876|NCT00424463|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
75616078|NCT02642497|Drug|systemic administration of ketamine|intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
75768877|NCT01324115|Drug|NG-nitro-L-arginine|
75768878|NCT01324115|Other|laboratory biomarker analysis|
75909392|NCT03482336|Other|Four FOP label designs|"Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a healthy level while the second unhealthy. Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables."
75909393|NCT03476720|Device|Pad positioning according to a manufacturer's diagram|Placement of defibrillation pads according to the diagram
75909394|NCT03482258|Dietary Supplement|Prebiotic|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).
75909395|NCT03482258|Dietary Supplement|Maltodextrin|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
75909396|NCT05259098|Drug|Sufentanil Sublingual Tablet System|Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
76071796|NCT04021316|Other|Compression bandaging therapy|Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
75616079|NCT00911131|Device|Capsule endoscopy (PillCam ESO)|The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
75616080|NCT00911131|Procedure|EGD|Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
75616081|NCT00911131|Device|Capsule endoscopy (PillCam ESO) with abdominal binder|An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
75616082|NCT02857257|Biological|ACHIM|After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM
75616083|NCT00903370|Procedure|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
75616084|NCT00903370|Device|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
75616085|NCT04273581|Drug|placebo|100mg/d，qn，for 14 days.
75616086|NCT04273581|Drug|Thalidomide|100mg/d，qn，for 14 days.
75616087|NCT01110408|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
75616088|NCT01110408|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
75616089|NCT01110408|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
75616090|NCT01110408|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
75768879|NCT01324115|Other|pharmacological study|
75768880|NCT01324115|Procedure|computed tomography|
75768881|NCT01324115|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
75768882|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
75768883|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
75768884|NCT01034735|Biological|r-hGH freeze-dried|Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
75768885|NCT01037621|Drug|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
75768886|NCT00424385|Drug|Gleevec + Sorafenib|400 mg Sorafenib every day (QD) 300mg Gleevec QD
75768887|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
75909397|NCT05259098|Drug|Intravenous Patient-Controlled Analgesia with morfine|Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
76071797|NCT04017832|Drug|Oral semaglutide|Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
75909398|NCT05259020|Combination Product|ID140009|Combination Product: ID140009 Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg/ Amlodipine 10mg/ Valsartan 160mg
75909399|NCT05259020|Combination Product|ID1803+ID1805|(Amlodipine 10mg/Valsartan 160mg)+(Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg)
75616091|NCT01110408|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
75909400|NCT03482180|Drug|KI1106 4g, QD|KI1106 4 Capsules
76071798|NCT04017832|Drug|Sitagliptin|Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
75317792|NCT00462449|Device|Functional Electrical Stimulation (FES) through the Ness H200|Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
75462722|NCT01867502|Drug|MET + Vildagliptin Group|"Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator."
75462723|NCT01867502|Drug|MET + Glibenclamide Group|"The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator."
75462724|NCT01867528|Procedure|Laparoscopic adhesiolysis|
75462725|NCT01867528|Procedure|Open adhesiolysis|
75462726|NCT01867554|Genetic|gene analysis|gene analysis
75462727|NCT01867567|Procedure|abdominal bandage|
75462728|NCT01867593|Device|C-11 methionine PET|
75616092|NCT02850328|Other|examination of muscle function and MVC in weightlessness|"MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~Rate of force development~Electromyographic activity~Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~Maximum voluntary activation capacity (%VA): %VA = (1-[torque superimposed twitch/torque resting twitch])*100%."
75616093|NCT00953043|Drug|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
75616094|NCT00953043|Drug|Placebo|Placebo medication given for three days
75616095|NCT00953043|Other|Bowel preparation|Polyethylene glycol-based bowel preparation
75616096|NCT02850484|Drug|Budesonide|Inhaled corticosteroid
75616097|NCT02850484|Drug|Formoterol|Long Acting Beta Agonist (LABA)
75768888|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
75768889|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
75768890|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
75768891|NCT00423917|Biological|bevacizumab|
75768892|NCT00423917|Drug|fulvestrant|
75768893|NCT00845026|Drug|LY2140023|80 milligram (mg), oral tablets, twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40 mg or a maximum of 160 mg.
75909401|NCT03482180|Drug|Atorvastatin Calcium 20mg, QD|Atorvastatin Calcium 20mg
75909402|NCT04459442|Procedure|Umbilical cord clamping at birth.|Umbilical cord clamping after delivery.
75909403|NCT04689932|Drug|Triferic AVNU|Ferric Pyrophosphate Citrate
75909404|NCT03479060|Procedure|Wet Cupping|cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Bloodletting and secondary suction and Removing and dressing
75909405|NCT03478748|Other|Dental health education|Anticipatory guidance given to mothers to promote their children's oral health.
75909406|NCT03481946|Drug|BAY1093884|0.3 mg/kg given intravenously
75909407|NCT03481946|Drug|BAY1093884|1 mg/kg given intravenously
75317793|NCT00534209|Biological|Allogeneic B7.1/HLA-A1|Dose: At least 4x10^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
75317794|NCT00534209|Other|Placebo|Given intradermally
75317795|NCT00534365|Device|tension-free vaginal tape|Retropubic mid-urethral sling
75317796|NCT00534365|Device|TVT-SECUR device|Mid-urethral mini-sling
75317797|NCT00423683|Drug|Arixtra alone|Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
75317798|NCT00423683|Device|Arixtra + filter|Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
75317799|NCT00424619|Drug|Vitamin D2|50 000 IU vitamin D2, one time bolus dose
75462729|NCT01867645|Drug|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
75909408|NCT04334408|Drug|Fremanezumab|Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
75909409|NCT04334408|Drug|Placebo|Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
75909410|NCT04294550|Other|Naloxegol|28 days of therapy with 25 mg/day of Naloxegol on cancer patients using opioids and suffering for opioids induced constipation not relieved by first-line laxatives.
75909411|NCT02523560|Other|home-based telerehabilitation|Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
75909412|NCT03476564|Drug|pentoxifylline|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
76071799|NCT04017832|Drug|Placebo (oral semaglutide)|Placebo tablet to be taken first thing in the morning
76071800|NCT04017832|Drug|Placebo (sitagliptin)|Placebo tablet to be taken 30 minutes after oral semaglutide
75768894|NCT00845026|Drug|aripiprazole|10 mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20 mg, 2-10 mg oral tablets, once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 30 mg (3-10 mg oral tablets).
75768895|NCT00845026|Drug|olanzapine|10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).
75768896|NCT00845026|Drug|risperidone|2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets).
75768897|NCT01145716|Procedure|Arthroscopy, surgery|Ulno-volar wrist approach to the TFCC
75768898|NCT01238458|Drug|[18F]AV-45 PET amyloid binding imaging|"This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
75768899|NCT01145794|Behavioral|smoking hygiene intervention|The intervention, SHI, will address SHS and quitting. It will include behavioral counseling to address health hazards of SHS for children, brief advice to quit and to adopt a no smoking policy around children and self-help materials (related to second hand smoking).
75768900|NCT02445131|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
75768901|NCT02445131|Drug|GA101|"Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg~Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg."
75768902|NCT02445131|Drug|CAL-101|"Induction: Cycle 2-6: d1-28: 150 mg p.o.~Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o."
75768903|NCT01235572|Procedure|standard follow-up care|Undergo early discharge and standard outpatient care
75768904|NCT01235572|Other|medical chart review|Undergo early discharge and standard outpatient care
75768905|NCT01235572|Procedure|quality-of-life assessment|Ancillary studies
75768906|NCT00691678|Drug|Chondroitin|400mg chondroitin three times a day (TID) for twenty-four weeks
75768907|NCT00691678|Drug|Glucosamine|500mg glucosamine TID for twenty-four weeks
75768908|NCT00423605|Drug|Xyrem®|flexible dosing
75768909|NCT01237600|Procedure|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
75768910|NCT01237756|Device|measurement of left and right lung ventilation|Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
75768911|NCT01142206|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
75768912|NCT01142206|Behavioral|Physical Activity|All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
75768913|NCT01142206|Behavioral|TV Watching + Physical Activity|The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
75768914|NCT03994289|Behavioral|Motor-assisted cycling|Participants will perform the motor-assisted cycling exercise using a physical therapy bike (RECK; Betzenweiler, Germany). Participants will perform 3×10-min bouts of motor-assisted cycling at the highest tolerable cadence. Before each bout, participants will perform 1-2 minutes of motor-assisted cycling at 5-10 rpm as a warm-up.
75768915|NCT03994289|Behavioral|FES cycling|"The testing procedures will be identical to that in the motor-assisted cycling visit except for the exercise type. Participants will wear FES cuffs on the upper and lower legs, bilaterally.~. The FES cycling will be performed on the motor-assisted bike using the wearable FES equipment. The purpose of motor-assisted cycling is to provide constant cadence. The Bioness L300 Plus system (Bioness, Valencia, CA) will be worn on the upper and lower legs to stimulates the quadriceps and dorsiflexors muscles during the motor-driven cycling exercise. An embedded gyroscope of the cuff can detect the motion of the lower leg so that the electrical stimulations will be generated at appropriate timing to activate leg muscles during the cycling exercise."
75768916|NCT01238614|Other|CHICA PSF plus JIT|
75768917|NCT01238614|Other|CHICA maternal depression PSF|
75768918|NCT01238614|Other|Control|
75768919|NCT05258188|Other|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is used for a mechanical benefit for the therapist providing deeper approach and braces remodeling of connective tissues through dissolution of extravagant fibrosis, while provoking repair and reconstructing forwarded by the recruitment of fibroblast.
75768920|NCT05258188|Other|Compressive Myofascial Release Technique|Compressive Myofascial Release Technique is a technique of soft tissue stretching that uses compression and sustained myofascial stretches to create a releasing force in the targeted area
75768921|NCT01145872|Behavioral|Mindfulness Based Cognitive Therapy|
75768922|NCT01145872|Behavioral|Health Enhancement Program|
75909413|NCT03476564|Drug|Vit E|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
75909414|NCT05258708|Biological|mRNA-1273 COVID-19 vaccine|two doses of mRNA-1273 vaccine at 28-day intervals
75909415|NCT05258552|Procedure|enema|preoperative enema
75317800|NCT00424619|Drug|Vitamin D2|100 000 IU vitamin D2, one time bolus dose
75317801|NCT00424619|Drug|Placebo|Placebo, 1 time bolus dose
75317802|NCT00425477|Biological|sargramostim|
75317803|NCT00425477|Drug|bexarotene|
75317804|NCT00425477|Genetic|cytogenetic analysis|
75317805|NCT00425477|Genetic|fluorescence in situ hybridization|
75317806|NCT00425477|Other|flow cytometry|
75317807|NCT00425477|Other|laboratory biomarker analysis|
75317808|NCT00425477|Procedure|biopsy|
75317809|NCT00427037|Drug|Cholecalciferol|50,000 IU weekly by mouth
75317810|NCT00427037|Drug|Placebo|identical placebo pill orally by mouth
75768923|NCT05400772|Other|electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
75909416|NCT05258474|Drug|controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)|single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
75909417|NCT05258474|Drug|Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
75909418|NCT05258474|Drug|Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)|single- and multiple-ascending dose (SAD/MAD)
75909419|NCT05258474|Drug|Placebo Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
75317811|NCT02113241|Drug|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
75317812|NCT02113241|Drug|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
75317813|NCT00427661|Other|Busulfan; Fludarabine; cyclosporine A and MMF|Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
75462730|NCT01867645|Drug|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
75462731|NCT01867684|Other|Psychotherapy|
75462732|NCT01867697|Drug|Cetuximab|
75462733|NCT01867697|Drug|Irinotecan|
75462734|NCT01867697|Drug|Oxaliplatin|
75462735|NCT01867697|Drug|Folinic Acid|
75616098|NCT01135134|Drug|Mometasone furoate|"The study drug is MFNS (50 μg spray device) and the dose will be:~5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
75616099|NCT01135134|Drug|Placebo|"MF Placebo nasal spray and administration will be as follows:~5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
75768924|NCT05214586|Procedure|Follow up of the clinical stage|Pain, Swelling, Infection, Patient satisfaction and recurrence of the disease will be measured
75768925|NCT01142362|Biological|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
75909420|NCT05258396|Other|MRI without injection of contrast product|MRI without injection of contrast product
75909421|NCT03478436|Drug|Doxycycline|Doxycycline 40 mg capsules
75317814|NCT00427973|Drug|cediranib maleate|Given orally
75317815|NCT00427973|Other|laboratory biomarker analysis|Peripheral blood was obtained from all patients enrolled for studies of early changes in circulating proangiogenic and proinflammatory molecules and cells. Blood samples were collected in EDTA-containing tubes before and after cediranib therapy on days 1 and 14 of cycle 1. Circulating VEGF, placental growth factor (PlGF), sVEGFR1, basic fibroblast growth factor (bFGF), interleukin (IL)-6, IL-8, transforming growth factor a ((TNF-a), gamma interferon (IFN-g) were measured using multiplex ELISA plates from Meso-Scale Discovery. Hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), sVEGFR2, angiopoietin 2 (Ang-2), sTie2, soluble c-KIT, carbon anhydrase 9 (CAIX), and stromal cell-derived factor-1a (SDF1a) were measured using ELISA kits from R&D Systems.
75462736|NCT01867697|Drug|Calcium Carbonate|
75462737|NCT01867723|Other|Internet communication application|Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
75462738|NCT01867736|Device|Passeo-18 Lux DRB|
75462739|NCT01867736|Device|Standard PTA (POBA)|
75462740|NCT01867749|Behavioral|Group Interpersonal Psychotherapy (IPT-G)|
75909422|NCT03476486|Procedure|Thread carpal tunnel release|Ultrasound-guided percutaneous minimally invasive thread carpal tunnel release using a looped thread technique
75909423|NCT01338987|Procedure|First Allogeneic Bone Marrow Transplant (BMT)|First Allogeneic Bone Marrow Transplant
75909424|NCT01338987|Drug|Leuprolide|Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients <18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients > 18 years and as a 3 month injection (adult preparation) for patients < 18 years
75462741|NCT01867749|Behavioral|Coping with Depression (CWD)|
75462742|NCT01867775|Drug|Mirtazapine|Mirtazapine 15 mg, at night, once a day for 14 days
75462743|NCT01867814|Procedure|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
75462744|NCT01867827|Other|Neurofeedback and Physical Exercise|
75462745|NCT01867827|Other|Physical Exercise|
75462746|NCT01867853|Device|PLR|passive leg raising test was done before and at the end of SBT
75462747|NCT01867866|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
75462748|NCT01867866|Drug|Trifluridine|35 mg/m2, orally, single dose
75462749|NCT01867879|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
75462750|NCT01867879|Drug|Placebo|Placebo tablets, orally, single dose.
75462751|NCT01867892|Drug|ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT|oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
75462752|NCT01867892|Drug|ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT|Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
75462753|NCT01867918|Procedure|Radiofrequency ablation, microwave, radiation therapy|Radiofrequency ablation Microwave ablation Radiation therapy
75768926|NCT01235806|Radiation|MRI|MRI of the scaphoid bone fracture suspicion
75768927|NCT02528266|Device|Nerve Capping Device|
75768928|NCT01238770|Drug|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
75768929|NCT01145950|Drug|LBEC0101|Etanercept 25mg, single dose
75768930|NCT01145950|Drug|Enbrel|Etanercept 25mg, single dose
75768931|NCT01243606|Behavioral|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
75768932|NCT01243606|Behavioral|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
75768933|NCT01238926|Dietary Supplement|PD vitamin supplementation|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
75768934|NCT01238926|Other|PD exercise intervention|Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
75768935|NCT01238926|Other|PD vitamin + exercise|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
75909425|NCT01338987|Drug|18F FLT|For the first 23 patients undergoing 1st bone marrow transplant (BMT):[18F]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
75909426|NCT01338987|Drug|Cyclophosphamide|Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults > 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric </= 22 years)
75909427|NCT01338987|Drug|Methotrexate|Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
75909428|NCT01338987|Drug|Tacrolimus|Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
75616100|NCT02850094|Behavioral|Financial Bonuses|Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
75909429|NCT01338987|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
75909430|NCT01338987|Drug|Busulfan|Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
75909431|NCT01338987|Drug|Fludarabine|Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
75909432|NCT01338987|Procedure|Second Allogeneic Bone Marrow Transplantation|Second Allogeneic Bone Marrow Transplantation
76071801|NCT04006262|Drug|Nivolumab 10 MG/ML|"Neo-adjuvant treatment : 240 mg intravenous (I.V.) in 30 minutes - every 2 weeks - 6 cycles~- Adjuvant treatment : 480mg I.V. in 30 minutes - every 4 weeks - 9 cycles"
76071802|NCT04006262|Drug|Ipilimumab 200 MG in 40 ML Injection|Neo-adjuvant treatment : 1mg/kg over 30 minutes every 6 cycles - 2 cycles
75616101|NCT00948441|Drug|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
75317816|NCT00427973|Procedure|computed tomography|computed tomography (CT) every 8 weeks to evaluate response and progression.
75317817|NCT00427973|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Magnetic resonance imaging (MRI) every 8 weeks to evaluate response and progression.
75317818|NCT00427973|Other|pharmacological study|Blood samples to characterize the steady-state PK of cediranib were drawn from a peripheral vein shortly before patients received the dose on days 8 and 15 of cycle 1 and at the following times relative to dosing on day 1 of cycle 2: 5 min and 1, 2, 4, 6, 8, and 24 hours, with the last sample collected before taking the next daily dose.
75317819|NCT01795703|Drug|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
75768936|NCT05137990|Behavioral|HIIT Exercise Intervention|Exercise trainers will provide encouragement and supervision for exercise prescription adherence and youth will select an age-appropriate music playlist from Spotify to enhance enjoyment throughout each session. Each exercise session consists of a 5-minute warm-up (10% HRmax), followed by a 20-minute HIIT protocol. The 20-minute HIIT protocol consists of seven bouts of 1-min high intensity exercise (90% HRmax) followed by 2-min of active recovery (10% HRmax). Participants will be encouraged to complete each exercise session with at least 24 hours of rest between each session.
75909433|NCT04234100|Other|Orange juice rich in hesperidin and narirutin|The product is a concentrated orange juice provided by the CITRUS Department of Florida (USA: www.FloridaCitrus.org).
75909434|NCT03476408|Other|Correlation / Observational|correlation between Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia
75909435|NCT03131180|Other|Rapid Learning Healthcare System|The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
75909436|NCT03478280|Drug|Brodalumab|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
76071803|NCT04005378|Other|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
76071804|NCT04005378|Other|Usual Care|Usual Care provided by CSC center
76071805|NCT03999515|Drug|Abiraterone Acetate|Given PO
76071806|NCT03999515|Drug|Enzalutamide|Given PO
76071807|NCT03999515|Drug|Erdafitinib|Given PO
76071808|NCT03995472|Drug|SHR-1501|Administered subcutaneously
75768937|NCT05137990|Behavioral|Stretching Intervention|This group will perform a home-based program of the same stretches utilized in the exercise group. The stretching protocol consists of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. As flexibility exercises are low-intensity, low-impact and low-volume, minimal caloric expenditure is expected to be incurred. To increase compliance and aid in the standardization of the home-based stretching, participants will be provided a booklet of the flexibility exercises. Participants will be shown how to use the booklet and instructed in the stretching exercises by an exercise trainer prior to the intervention.
75768938|NCT01239004|Drug|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
75768939|NCT01239004|Drug|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
75768940|NCT05171998|Procedure|venous blood sample|Phlebotomy procedure for a venous blood draw.
75768941|NCT01235884|Dietary Supplement|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
75909437|NCT03478280|Drug|Placebos|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
75616102|NCT00948441|Other|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
75909438|NCT04856007|Drug|Dapagliflozin/metformin XR FDC 5/500 mg|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
76071809|NCT03995472|Drug|SHR-1316|Administered intravenously
76071810|NCT03994952|Device|Sway Balance Application|Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
76071811|NCT03994952|Device|Balance Tracking Systems|This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
76071812|NCT03994627|Drug|Olaratumab|Administered intravenously (IV)
76071813|NCT03981978|Behavioral|Physical Activity|Self-report questionnaires assessing physical activity level.
76071814|NCT03980626|Behavioral|Walking|The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
75616103|NCT02849860|Drug|IDP-121 Lotion|Lotion
75616104|NCT02849782|Drug|Fampridine|Oral intake of 10 mg twice daily
75616105|NCT00630903|Drug|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
75616106|NCT00630903|Drug|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
75768942|NCT01235884|Dietary Supplement|Placebo|5 drops daily for 28 days
75768943|NCT01142440|Behavioral|behavioral intervention|"Dietary instructions~Oral hygiene instructions: GC plaque indicator kit~Antibacterial therapy: medident sol. one week a month, for 6 months~Fluorides: VOCO Profluorid varnish, once every 3 month~Restoration~Follow ups"
75768944|NCT01245322|Drug|lactobacilli|women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
75768945|NCT03789994|Behavioral|Affective touch|The affective touch comprises of two elements, namely the signal of care, love and acceptance, and stimulation of CT afferent of the skin. Caregivers will be trained to perform light stroking on stroke survivor's forearm while reviewing happy events with the use of photos.
75768946|NCT03789994|Other|Fine motor exercise|Fine motor exercises that are commonly used for rehabilitation.
75768947|NCT01142518|Drug|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
75768948|NCT03711994|Other|Alkantis|cold therapy pack placed on the wound post operatively
75317820|NCT01795703|Drug|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
75317821|NCT00429143|Radiation|Total Body Irradiation (TBI)|TBI twice daily days 6-9 prior to transplant (HSCT)
75768949|NCT00423449|Drug|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
75768950|NCT00423449|Drug|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
75768951|NCT00423449|Drug|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
75768952|NCT00423293|Drug|fluorouracil|1000 mg/m^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
75768953|NCT00423293|Drug|mitomycin C|10 mg/m^2 intravenous therapy on day 1 and day 29 of radiation therapy.
75768954|NCT00423293|Radiation|Intensity-modulated radiation therapy|"Prescription dose depends on tumor staging.~T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.~T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.~For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes > 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx."
75768955|NCT00423137|Drug|BIBW 2948 BS|Capsule
75768956|NCT00423137|Drug|Placebo|Capsule
75768957|NCT00422903|Drug|lapatinib|1500 mg administered orally daily
75909439|NCT04856007|Drug|Dapagliflozin/metformin XR FDC 10/1000 mg|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
75909440|NCT04856007|Drug|Dapagliflozin 5 mg + Metformin 500 mg XR|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
75909441|NCT04856007|Drug|Dapagliflozin 10 mg + Metformin 1000 mg XR|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
75317822|NCT00429143|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
75909442|NCT04936906|Behavioral|Extra Care (EC) Intervention|The EC intervention includes pre- and post- procedure calls from the surgeon, written educational material, personalized music during the operation, post-procedure skin cancer protection education, and are allowed to bring a guest into the procedure room.
75317823|NCT00429143|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
75317824|NCT00429143|Drug|Tacrolimus|Tacrolimus given one day prior to transplant (HSCT).
75317825|NCT00429143|Drug|Mycophenolate Mofetil (MMF)|MMF given one day prior to transplant (HSCT).
75317826|NCT00429143|Biological|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
75317827|NCT00430625|Biological|VPRIV ®,|Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
75317828|NCT00432341|Biological|botulinum toxin type A|200 Units at Visit 1 (Day 1)
75317829|NCT00432341|Biological|botulinum toxin type A|500 Units at Visit 1 (Day 1)
75317830|NCT00433745|Drug|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
75317831|NCT01395758|Drug|ARQ 197 plus erlotinib|Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
75616107|NCT02883426|Biological|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
75616108|NCT02883426|Biological|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
75317832|NCT01395758|Drug|Pemetrexed, docetaxel or gemcitabine|Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.
75317833|NCT00462605|Drug|entinostat|Given PO
75317834|NCT00462605|Drug|sargramostim|Given SC
75317835|NCT03025022|Drug|14C-JNJ-42847922 40 mg|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
75317836|NCT03024944|Drug|18F-THK-5351|Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
75317837|NCT02120287|Drug|Bevacizumab|Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
75317838|NCT02120287|Procedure|Magnetic Resonance Spectroscopy (MRS)|Subjects will have MRS prior to BZ-SRS.
75317839|NCT02120287|Procedure|Border Zone Stereotactic Radiosurgery (BZ-SRS)|The 'border zone' of the tumor will be targeted by SRS in a single session.
75616109|NCT02883426|Biological|Placebo|Administered by nasal spray
75616110|NCT01238289|Behavioral|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
75616111|NCT01238289|Behavioral|Control|This group continues with standard care at the community health center
75616112|NCT02849314|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
75768958|NCT00422903|Drug|letrozole|2.5 mg administered orally daily
75768959|NCT00422903|Other|placebo|1500 mg administered orally daily
75616113|NCT02849314|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
75768960|NCT00422669|Device|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
76071815|NCT03980262|Behavioral|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
76071816|NCT03980262|Behavioral|Money Smart|Money Smart is a financial literacy education program developed by the Federal Deposit Insurance Corporation (FDIC). Curricula are available for both adults and children.
76071817|NCT03978611|Drug|Relatlimab|Specified dose on specified days
76071818|NCT03978611|Drug|Ipilimumab|Specified dose on specified days
75317840|NCT00534833|Biological|DTaP-HB-PRP~T vaccine|0.5 mL, Intramuscular
75317841|NCT00534833|Biological|Tritanrix-HepB/Hib™|0.5 mL, Intramuscular
75317842|NCT00534833|Biological|Oral Polio Vaccine|0.5 mL, Oral
75317843|NCT00462839|Procedure|blood loss estimation|Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
75616114|NCT05171478|Diagnostic Test|Full-field optical coherence tomography|Sample obtained during bronchoscopy will be imaged using full-field optical coherence tomography
75616115|NCT02857101|Other|dosage of calprotectin|
75616116|NCT02849392|Other|Pistachio added 20% of kcals to diet|Pistachio added 20% of kcals to diet
75616117|NCT02857023|Behavioral|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
75768961|NCT00422669|Device|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
75768962|NCT00422591|Drug|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
75768963|NCT00422591|Drug|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
75317844|NCT00535301|Device|grafted anterior prolapse repair|anterior vaginal prolapse repair with graft
75768964|NCT00422513|Drug|methoxy polyethylene glycol-epoetin beta|120-360 micrograms intravenous (iv) monthly, starting dose
75317845|NCT00535301|Procedure|sutured anterior vaginal prolapse repair|anterior vaginal prolapse repair with suture
75462754|NCT01867918|Drug|Standard Chemotherapy|
75462755|NCT01867944|Behavioral|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
75462756|NCT01867944|Behavioral|Educational Control|Education on conventional treatment options for chronic constipation.
75462757|NCT01867957|Biological|Low-dose GC1109|50ug/dose
75462758|NCT01867957|Biological|High-dose GC1109|100ug/dose
75462759|NCT01867957|Biological|Low-dose Placebo|0.9% Saline 0.5 mL
75462760|NCT01867957|Biological|High-dose Placebo|0.9% Saline 1.0 mL
75462761|NCT01867970|Device|Tool|"The It's LiFe! tool consists of three different elements:~the 3D accelerometer (Figure 7-8);~the application (app) on a Samsung Smartphone (Figure 6);~a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription."
75768965|NCT00422513|Drug|Epoetin alfa|As prescribed, iv, 3 times weekly
75768966|NCT00202878|Drug|ezetimibe/simvastatin|Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
75909443|NCT04936906|Other|Usual Care (UC)|Standard of care pre and post surgery management provided to patients undergoing Mohs Surgery.
75909444|NCT02523794|Other|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
75909445|NCT02523794|Other|Placebo|Purified Drinking Water
75909446|NCT04736979|Drug|amoxicillin clavulanate|dosage according to Shariff score and creatinine clearance
75909447|NCT03706430|Device|Pulse CO-Oximeter sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb), Pulse Rate (PR), Perfusion Index (Pi), Methemoglobin (SpMet), Pleth Variability Index (PVi), RPVi, etc.
75909448|NCT03651050|Behavioral|Faith Based Outreach (FBO)|Faith base outreach groups will be trained in P-MHDT
75909449|NCT03651050|Behavioral|community-health-workers (CHW)|COmmon health workers will be trained in P-MHDT
75909450|NCT03562923|Drug|Test Product|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
75909451|NCT03562923|Drug|Reference Product|ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
75909452|NCT03562923|Drug|Placebo|Placebo Product
76071819|NCT03973333|Drug|IMC-C103C|Weekly IV infusions
76071820|NCT03973333|Drug|Atezolizumab|IV infusions every 3 weeks
76071821|NCT03973333|Drug|IMC-C103C|Weekly subcutaneous Injection
75768967|NCT00202878|Drug|simvastatin|Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
75768968|NCT00202878|Drug|Placebo for simvastatin 40 mg|one or two tablets orally daily
75768969|NCT00202878|Drug|Placebo for ezetimibe 10 mg/simvastatin 40 mg combination|one tablet orally daily.
75768970|NCT00414011|Drug|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
75768971|NCT00414011|Drug|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
75768972|NCT03994133|Other|Measurement of the hydration state by bio-impedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.~The measurement will be done in pre-dialytic"
75768973|NCT00231816|Biological|ZOSTAVAX™ (concomitant)|a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
75768974|NCT00231816|Biological|Comparator: Influenza Vaccine|a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
75768975|NCT00231816|Biological|ZOSTAVAX™ (Nonconcomitant)|Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
75768976|NCT00260208|Drug|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
75909453|NCT03476252|Diagnostic Test|pentraxin 3|serum pentraxin 3 level will be assessed using ELISA kits
75317846|NCT00434993|Drug|Albuterol Sulfate|"Albuterol sulfate, USP, solution for inhalation will be diluted as follows:~The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.~The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
75616118|NCT01207479|Device|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
75768977|NCT00260208|Drug|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
75768978|NCT00202644|Drug|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
76071822|NCT03969654|Device|PERSONA Total Knee|Primary Total Knee Arthroplasty
76071823|NCT03969654|Device|Vanguard Total Knee|Primary Total Knee Arthroplasty
75317847|NCT00434993|Procedure|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
75462762|NCT01867970|Behavioral|Self-management Support Program|Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
75909454|NCT03593252|Drug|Senna|Laxative,used for bowel preparation
75909455|NCT03593252|Drug|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Laxative used for bowel preparation
75909456|NCT03593252|Drug|Metronidazole Oral|Oral antibiotic
75909457|NCT03593252|Drug|Neomycin|Oral non-absorbable antibiotic
75909458|NCT03593252|Drug|Cefazolin|Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
75909459|NCT03593252|Drug|Metronidazole|Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
75909460|NCT03593252|Other|Nil per os|Fasting orders according to anesthesia prior to surgery: No solid for >=8 hours, no formula milk/full liquids >= 4hours; no breast milk or clear fluids >=2hours.
76071824|NCT03969654|Device|NexGen Total Knee|Primary Total Knee Arthroplasty
75616119|NCT02849236|Drug|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles"
75616120|NCT02849236|Drug|Placebo|20 mL saline 0.9%
75616121|NCT02856789|Other|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
75616122|NCT02856789|Other|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
75616123|NCT02856789|Other|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
75616124|NCT02856789|Other|Specialized hemostasis tests|Coagulation factors
75768979|NCT00202644|Drug|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
75768980|NCT01235962|Drug|pazopanib|Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
75768981|NCT01235962|Drug|placebo|Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
75768982|NCT01235962|Drug|pazopanib|Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
75768983|NCT01235962|Drug|placebo|placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
75768984|NCT00259740|Drug|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
75768985|NCT00201006|Behavioral|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
75317848|NCT00434993|Drug|Placebo|"Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
75317849|NCT01395524|Drug|NKTR-118|12.5 mg oral tablet once daily
75909461|NCT03593252|Other|Clear fluids the day before surgery|As part of bowel preparation, participants will be asked to stick to clear fluids following breakfast the day before surgery. Breast milk is allowed if applicable.
75317850|NCT01395524|Drug|NKTR-118|25 mg oral tablet once daily
75462763|NCT01867983|Behavioral|Weight gain prevention and smoking cessation|"The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls."
75616125|NCT02856711|Behavioral|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
75462764|NCT01867983|Behavioral|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
75616126|NCT02848924|Other|No intervention|
75616127|NCT04368676|Other|Sudarshan Kriya Yoga (SKY)|The SKY program is a standardized, easy to learn sequential breathing yoga consisting of regulated breathing techniques followed by a timed rhythmic breathing practice. Participants will learn various exercises including rhythmic breathing, gentle yoga, and guided meditation.
75768986|NCT00201006|Behavioral|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
75909462|NCT03476174|Drug|Pembrolizumab|Subjects will receive 200 mg pembrolizumab every 3 weeks for two cycles. Cycle length is 21 days (i.e., 3 weeks). On the last day of Cycle 2 (+/- 3 days), disease status will be assessed via imaging.
75768987|NCT00201006|Other|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
75909463|NCT03476174|Drug|Interleukin-2|Following the pembrolizumab treatment, HD IL-2 treatment will commence. After completing the 2 cycles of pembrolizumab, High Dose Interleukin-2 (HD IL-2) will be administered. This will require a hospital stay of at least 5 days for each treatment cycle. Established guidelines will be followed for safely administering HD-IL-2 and managing toxicities from this treatment. Two treatment cycles will be administered, Cycle 2 being separated from Cycle 1 by approximately 9 days after completion (assuming subject has recovered from Cycle 1 adequately to proceed with Cycle 2). Four weeks after completion of the 2 cycles (called a course of HD IL-2 therapy), disease status will be monitored via CT of the chest and abdomen/pelvis using revised RECIST guidelines
75909464|NCT04725045|Device|Boston Scientific: Study tool computer|compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
75909465|NCT03478202|Dietary Supplement|GOLO RELEASE|GOLO RELEASE plus Diet
75909466|NCT02259933|Drug|KUC 7483 CL|
75909467|NCT02259933|Drug|Placebo|
75317851|NCT01395524|Drug|Placebo|Oral tablet intake once daily
75462765|NCT01867996|Drug|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
75462766|NCT01867996|Drug|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
75462767|NCT01868048|Drug|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
75317852|NCT05366348|Other|Recreational activity|Horse-back riding
75462768|NCT01868048|Drug|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
75462769|NCT01868061|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
75462770|NCT01868061|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
75462771|NCT01868087|Dietary Supplement|Boost Plus®|
75768988|NCT00200850|Biological|House Dust Mite SLIT|low dose SLIT 143 Allergen Units(AU)/ml daily
75768989|NCT00200850|Biological|High dose SLIT|House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily
75768990|NCT00200850|Biological|Placebo SLIT|Placebo SLIT daily
75768991|NCT01073202|Drug|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
75616128|NCT04368676|Other|Health Enhancement Program|HEP is a structured group program designed to help participants with information and instruction how to lead a healthier life. Participants will be provided psychoeducation and support regarding healthy active living using techniques like music therapy, diet control, exercise, and monitoring these via journaling.
75317853|NCT04011020|Combination Product|Stem Cell Educator therapy|Patients with T1D will be evaluated by the study principal investigator or co-investigators. Informed consent will be obtained at the initial screening visit. The initial screening visit will occur within 30 days of initiation of SCE therapy. The second screening visit will occur within 7 days of therapy. Subjects who meet all criteria will be scheduled for treatment. All enrolled subjects will receive treatment with the SCE system consisting of a single session of mononuclear cells (MNC) collection by apheresis where 10 L of blood will be processed on day -1. The MNC product will then be exposed over to the SCE and on day 0 the product will be infused intravenously back to the patient.
75462772|NCT01868087|Dietary Supplement|Impact Advanced Recovery®|
75616129|NCT01117350|Drug|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
75616130|NCT01117350|Drug|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
75768992|NCT01073202|Drug|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
75768993|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2590066A|Intramuscular injection, two doses
75768994|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2592984A|Intramuscular injection, two doses
75768995|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340274A|Intramuscular injection, two doses
75768996|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340273A|Intramuscular injection, two doses
75768997|NCT01236040|Other|Placebo|Intramuscular injection, two doses
75768998|NCT03812224|Drug|Erenumab|Administered by subcutaneous injection once a month
75768999|NCT03812224|Drug|Placebo|Administered by subcutaneous injection once a month
75769000|NCT01146730|Behavioral|Workcoping and IPS|Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
75769001|NCT01146730|Behavioral|Ordinary care by GP or NAV|Ordinary care by the participants physician or the local Labour and Welfare Administration
75462773|NCT01868100|Other|self-completion questionnaire|
75769002|NCT01146028|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
75769003|NCT00231114|Device|Alair System|Treatment of airways with the Alair System
75909468|NCT05258318|Procedure|DK crush|Double Kissing Crush (DK-Crush) technique in patients with Unprotected Left Main Bifurcation lesions (ULMb).
75769004|NCT00231114|Device|Alair System|Sham treatment of airways with the Alair System
75769005|NCT03613480|Other|Motivational Interviewing|Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
75769006|NCT03543046|Device|Tortle Midliner|The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
75769007|NCT03530800|Drug|Dronabinol|Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)
75909469|NCT05258318|Procedure|DR crush|Double Rewire crush technique (DR-Crush) in patients with Unprotected Left Main Bifurcation lesions (ULMb).
75462774|NCT01868113|Drug|Inhaled corticosteroid|Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
75462775|NCT01868113|Other|Placebo|Placebo to be administered 12hourly
75462776|NCT01868126|Drug|DE-117 ophthalmic solution|
75462777|NCT01868126|Drug|latanoprost ophthalmic solution|
75909470|NCT03562689|Other|Delirium and with septic encephalopathy.|Delirium or septic encephalopathy survivors will be analized in the same way: Cognitive tests, EEG and MRI.
75317854|NCT01394978|Other|Control|Standard surgical techniques including staples and sutures.
75462778|NCT01868126|Other|Placebo|
75462779|NCT01868178|Device|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
75462780|NCT01868191|Drug|Benfotiamine|Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
75462781|NCT01868191|Drug|Placebo for benfotiamine|Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
75462782|NCT01868256|Other|early discharge (<72 h)|
75769008|NCT03530800|Drug|Placebo|Placebo for 10 weeks
75769009|NCT03479008|Diagnostic Test|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
75769010|NCT04982146|Drug|Bromelin|0.5mg per mL of total tumor volume calculated, administered percutaneously
75769011|NCT04982146|Drug|N-Acetylcysteine|20mg per mL of total tumor volume calculated, administered percutaneously
75769012|NCT04958746|Drug|Ciprofol|intravenous bolus
75769013|NCT04958746|Drug|Propofol|intravenous bolus
75769014|NCT01146106|Drug|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
75769015|NCT05631340|Other|Discharge education|Researcher's newly prepared discharge education supported by a booklet and mobile app
75769016|NCT03431584|Drug|infiltration of corticosteroids|infiltration of corticosteroids
75769017|NCT03431584|Drug|infiltration of corticosteroids and hyaluronic acid|infiltration of corticosteroids and hyaluronic acid
75769018|NCT00259272|Drug|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
75769019|NCT01239706|Drug|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
75317855|NCT01394978|Device|ProGEL Pleural Air Leak Sealant with standard surgical closure|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
75317856|NCT01394978|Device|ProGEL Pleural Air Leak Sealant without standard surgical closure|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
75317857|NCT04338698|Drug|Hydroxychloroquine|Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)
75616131|NCT01117350|Drug|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
75616132|NCT00952731|Drug|oral placebo|Oral placebo taken daily for 4-10 weeks.
75616133|NCT00952731|Drug|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
75462783|NCT01868256|Other|Conventional discharge|
75616134|NCT00952731|Drug|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
75462784|NCT01868282|Procedure|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
75769020|NCT01239784|Behavioral|Home-based neurodevelopmental rehabilitation programme|Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
75769021|NCT01246570|Behavioral|Exercise training|The patients will meet for organized exercise training once monthly and also exercise testing every third month.
75909471|NCT05258162|Other|Mobilization|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~Elbow flexion and extension~Wrist flexion and extension~Forearm supination and pronation~Lock and key exercises.~Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~Elbow flexion and extension~Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Mobilisations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~3 days per week for 3 weeks. Oscillations for 2 minutes at 2-3 oscillations per second."
75616135|NCT00952731|Drug|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
75616136|NCT04202224|Drug|Ibuprofen 400 mg and Acetaminophen 500 mg|Analgesia.
75769022|NCT01246570|Other|Control|The patients will receive the usual care provided by the hospitals and the community health services
75769023|NCT01239862|Other|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
75769024|NCT03106324|Drug|Revlimid (lenalidomide)|Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
75769025|NCT01147276|Drug|Vildagliptin|Vildagliptin (50 mg BID) in four weeks
75769026|NCT01250782|Drug|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
75769027|NCT01250782|Drug|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
75769028|NCT03913624|Other|Neuromuscular electrical stimulation|
75769458|NCT03908944|Drug|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
75317858|NCT04338698|Drug|Oseltamivir|Oseltamivir (75 mg orally twice a day for 5 days)
75317859|NCT04338698|Drug|Azithromycin|Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
75317860|NCT00435539|Drug|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
75317861|NCT00435539|Drug|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
75317862|NCT00435539|Drug|Sham Comparator|Intravitreal sham injection
75317863|NCT00462917|Behavioral|Pleiotropic info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session."
75317864|NCT00462917|Behavioral|AD-only info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
75317865|NCT00462917|Behavioral|Pleiotropic info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session."
75317866|NCT00462917|Behavioral|AD-only info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
75769029|NCT05153122|Device|SenseGuard|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
75769030|NCT01239940|Device|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
75616137|NCT04202224|Drug|Glucose|Placebo.
75769031|NCT01239940|Device|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
75769032|NCT03090412|Drug|HPPH|Given IV
75769033|NCT03090412|Other|Laboratory Biomarker Analysis|Correlative studies
75769034|NCT03090412|Drug|Photodynamic Therapy|Undergo PDT
75769035|NCT03090412|Other|Quality-of-Life Assessment|Ancillary studies
75909472|NCT05258162|Other|Muscle Energy Technique|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~Elbow flexion and extension~Wrist flexion and extension~Forearm supination and pronation~Lock and key exercises.~Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~Elbow flexion and extension~Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.~3 days per week for 3 weeks."
75317867|NCT04407416|Procedure|Breath sampling|The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography
75462785|NCT01868282|Procedure|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
75462786|NCT01868282|Procedure|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
75616138|NCT04202224|Other|No drug|Standard surgical procedure without any preoperative medication.
75616139|NCT02848690|Behavioral|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
75769036|NCT03090412|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
75769037|NCT01146886|Drug|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
75769038|NCT01146886|Drug|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
75769039|NCT01250860|Other|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
75769040|NCT01250860|Behavioral|Sham therapy|
75769041|NCT02782390|Other|Dental Restoration with Stainless Crown|Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans & Innes, 2010).
75769042|NCT02782390|Other|Dental Restoration with Composite Resin|"Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 15 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions."
75769043|NCT04877314|Other|Intermittent fasting|30 overweight male volunteers who will have 3 weeks intermittent fasting which has 16 hours fasting and 8 hours eating in a day period.
75769044|NCT01146184|Device|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
75769045|NCT01247896|Drug|PF-05190457|Single Dose 2 mg
75769046|NCT01247896|Drug|PF-05190457|Single Dose 10 mg
75769047|NCT01247896|Drug|PF-05190457|Single Dose 30 mg
75769048|NCT01247896|Drug|PF-05190457|Single Dose 100 mg
75317868|NCT05366036|Other|No Intervention|This is a non-interventional study.
75317869|NCT00464711|Drug|Escitalopram|Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
75769049|NCT01247896|Drug|PF-05190457|Single Dose 300 mg
75769050|NCT01247896|Drug|PF-05190457|Single Dose 600 mg
75769051|NCT01247896|Drug|PF-05190457|Single Dose - to be determined with food
75769052|NCT01247896|Drug|PF-05190457|Single Dose - to be determined
75769053|NCT01247896|Drug|Placebo|Single Dose Placebo
75769054|NCT02526004|Drug|Ceftazidime|
75769055|NCT02526004|Drug|Tobramycin|
75769056|NCT01146262|Other|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
75769057|NCT01146262|Procedure|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
75769058|NCT00421889|Drug|belinostat|
75769059|NCT00421889|Drug|Paclitaxel|
75769060|NCT00421889|Drug|Carboplatin|
75769061|NCT01146964|Procedure|MSSICS|Manual super small incision cataract surgery
75769062|NCT01146964|Procedure|Phacoemulsification|cataract surgery with Phacoemulsification
75769063|NCT01440010|Radiation|IORT with 50 kV x-rays, 20 Gy|Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
75769064|NCT01146340|Radiation|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
75769065|NCT03913468|Drug|Intravenous Ascorbic Acid|1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
75769066|NCT03913312|Biological|Unrelated cord blood|Unrelated cord blood comes from Shandong cord blood bank. TNC>1.5*107/kg;HLA 4-5/6
75769067|NCT03913546|Procedure|Spinal manipulative therapy|Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.
75769068|NCT03913546|Other|Sham spinal manipulative therapy|Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
75769069|NCT01147354|Dietary Supplement|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
75769070|NCT01147354|Other|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
75769071|NCT01435408|Other|Conventional primary PCI|Conventional primary PCI in STEMI with implantation of DES.
75769072|NCT01435408|Other|Ischemic postconditioning.|Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.
75769073|NCT01435408|Other|Deferred stenting in primary PCI.|In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.
75769074|NCT03916666|Procedure|Epiduroscopy|Endoscopic intervention
75317870|NCT01796015|Other|ONSD ultrasound|"Description of the ONSD ultrasound: ONSD is measured 3 mm behind the globe and perpendicularly to the optic nerve axis (2 dimensions mode).~For each optic nerve, 2 measures are performed: 1 sagittal and 1 transverse. The patient is positioned in 30° dorsal elevation. Gel is applied on the eyelid and a 7,5 MHz probe is used.~At the same time and on the same side, a transcranial Doppler is performed using a 2 MHz probe placed on the temple. Are measured: systolic velocity, mean velocity, diastolic velocity, resistance index and pulsatility index.~As ONSD measures cannot be done blinded (regarding ICP monitoring), a centralised evaluation (by 2 experts) of the recorded sonograms is planned."
75317871|NCT02078180|Drug|generic bupropion|We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
75769075|NCT01248286|Other|Whole grain rice|Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
75769076|NCT01248286|Other|Refined grain rice|Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
75616140|NCT02848690|Other|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
75616141|NCT00947427|Drug|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
75616142|NCT00947427|Drug|Placebo|Placebo subcutaneous injections
75616143|NCT02848612|Drug|anticoagulation by unfractionated heparin|anticoagulation by unfractionated heparin
75769077|NCT04744480|Procedure|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
75769078|NCT03916588|Behavioral|Individualized Care Plan|Medical, neuropsychological, and social assessment of patient's cognitive, behavioral, medical, and environmental needs with a focus on improving quality of life, reducing health care utilization, and improving staff/family caregiving burden along with a specific plan to address and monitor identified patient and staff/facility needs
75769079|NCT03913780|Other|Aerobic exercise more force|The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.
75769080|NCT01147432|Drug|PF-04427429|Single dose IV infusion up to 300mg
75769081|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
75769082|NCT01147432|Drug|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
75769083|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
75769084|NCT01147432|Other|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
75769085|NCT01147510|Drug|Combination of low ICS and montelukast|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
75769086|NCT01147510|Drug|Monotherapy of medium dose ICS|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
75769087|NCT03916432|Device|HELIOS biodegradable polymer sirolimus-eluting stents|HELIOS biodegradable polymer sirolimus-eluting stents
75317872|NCT00535613|Drug|Propofol|IV, single bolus at completion of anesthetic, 0.1 ml/kg
75616144|NCT04811404|Drug|Ethyl Eicosapentaenoic Acid|Treatment will be for six weeks
75616145|NCT01116882|Procedure|PCI|
75769088|NCT00421733|Drug|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
75616146|NCT02054013|Procedure|Prostatic artery embolization|
75616147|NCT02054013|Procedure|monopolar transurethral prostatectomy|
75769089|NCT00421733|Drug|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
75909473|NCT04459520|Behavioral|Positive COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested positive (PCR) for an active COVID-19 infection and that their physician has clinically diagnosed them with COVID-19.
75317873|NCT04010552|Drug|NALRINOX combination|NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
75616148|NCT02848846|Device|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand."
75462787|NCT01868295|Behavioral|Sleeping with denture|Sleeping with denture at night
75462788|NCT01868347|Other|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
75462789|NCT01868347|Other|control|PEEP after pneumoperitoneum and trendelenburg
75616149|NCT02850562|Behavioral|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
75616150|NCT02850562|Behavioral|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
75616151|NCT02856477|Biological|urine analysis|a sample of urine is collected during 8 hours.
75769090|NCT00421733|Drug|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
75769091|NCT01249378|Other|All subjects receive three sequences of a standard breakfast|"All subjects receive three sequences of a standard breakfast containing :~10 g non emulsified~or 40 g non emulsified~or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions"
75769092|NCT00421343|Drug|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
75769093|NCT00421343|Drug|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
75769094|NCT00421343|Behavioral|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
75769095|NCT03915808|Dietary Supplement|Conjugated linoleic acid group|supplementation of 3.2 g/day conjugated linoleic acid in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
75317874|NCT04010240|Other|Retrospective cohort|Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.
75317875|NCT00535769|Device|Electronic + no text message|Electronic monitor is attached but no text-messages are sent through cellular phones
75317876|NCT00535769|Device|Electronic monitor + text messages|Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
75317877|NCT05363696|Procedure|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting surgery procedure
75317878|NCT05363696|Procedure|Heart valve surgery|Heart valve surgery procedure
75317879|NCT03595670|Other|standardized questionnaires|standardized questionnaires concerning the perception
75462790|NCT01868360|Drug|Subconjunctival aflibercept|subconjunctival aflibercept injection
75462791|NCT01868360|Other|Placebo: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
75462792|NCT01868386|Radiation|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
75769096|NCT03915808|Dietary Supplement|Sunflower oil group|supplementation of equivalent sunflower oil in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
75769097|NCT03915730|Other|Initial periodontal therapy|Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
75769098|NCT01147588|Drug|lansoprazole|60 mg (2x30-mg capsule), once daily
75769099|NCT01147588|Drug|omeprazole|80 mg (2x40-mg capsule), once daily
75462793|NCT01868412|Device|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
75462794|NCT01868412|Device|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
75769100|NCT01147588|Drug|esomeprazole|40 mg (1x40-mg capsule), once daily
75769101|NCT01147588|Drug|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
75769102|NCT03908710|Other|Treatment of hypertension using blood pressure self-measurement at home|The primary aim of the present study is to investigate whether home blood pressure recording via Bluetooth and continuous communication between doctor and patient will give improved blood pressure values when comparing the initial values with the blood pressure values recorded after 3 months. Secondary examinations include treatment of hypotension and adverse events, the patient's experience, the user's potential problems with the blood pressure cuff, app downloading, problems with history issues or problems with technical
75769103|NCT03915886|Drug|JNJ-0440|JNJ-0440 tablets will be administered orally.
75769104|NCT03915886|Drug|Placebo|Matching placebo tablets will be administered orally.
75909474|NCT04459520|Behavioral|Negative COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested negative (PCR) for an active COVID-19 infection.
75909475|NCT04459520|Behavioral|Unavailable COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that testing is not available for active COVID-19 infections but that their physician has clinically diagnosed them with COVID-19.
75909476|NCT04459754|Drug|Fuzheng Yiliu Formulation|"The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption."
75909477|NCT03481868|Biological|Collection of blood and bone marrow|Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment
75909478|NCT02523638|Drug|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
75909479|NCT03478124|Behavioral|Cognitive evaluation|An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
75462795|NCT01868464|Biological|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10^6 cfu, 4x10^6 cfu, 8x10^6 cfu and 16x10^6 cfu, respectively.
75462796|NCT01868490|Drug|cytokine induced killer cells|at least 10*9 CIK cells, IV on day 0, 14, 28
75462797|NCT01868529|Drug|insulin degludec|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
75616152|NCT04235062|Drug|Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution|A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
75616153|NCT04235062|Drug|Intravenous Bolus Furosemide|Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
75769105|NCT01253434|Drug|E2022|E2022 Type A patch
75769106|NCT01253434|Drug|E2022|E2022 Type B patch
75769107|NCT01253434|Drug|E2022|E2022 Type C patch
75769108|NCT01253434|Drug|E2022|E2022 Type D patch
75769109|NCT01253434|Drug|E2022|E2022 Type E patch
75769110|NCT03916120|Genetic|Genetic analysis|Collect 2ml intravenous blood from patients after anaesthesia.
75769111|NCT03908164|Biological|Pertussis containing vaccine|Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
75909480|NCT03478046|Other|Weight loss|Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
75909481|NCT05257148|Drug|Zofenopril 30 mg|Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
75909482|NCT05257148|Drug|Nebivolol 5 mg|Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
75909483|NCT05257148|Drug|Zofenopril 30 mg + Nebivolol 5 mg|Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
75616154|NCT02848534|Biological|neutrophil to lymphocyte ratio|value of the neutrophil to lymphocyte ratio in the diagnosis of bacterial infections
75616155|NCT02848768|Drug|Sunitinib|
75769112|NCT01147120|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
75909484|NCT03481790|Drug|Lactoferrin|(Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.
75909485|NCT03481790|Drug|ferrous sulphate + folic acid (vitamin B9)|(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.
76071825|NCT03966781|Procedure|ESWL|ESWL will be conducted under epidural anesthesia. For epidural anesthesia, bupivacaine will be used to block the T6-T12 spinal segments. The patient's eyes will be lightly covered all along the procedure. Once epidural anesthesia is achieved, the patient will be given a light sedation and ESWL will be performed using a Dornier dual focus lithotripsy system providing a maximum of 5000 at the rate of 90 shocks per minute in over 1-2 days.
76071826|NCT03966781|Procedure|ERCP|Once ESWL is over, an endoscopic pancreatic sphincterotomy will be performed and complete stone removal will be attempted with subsequent stenting of the pancreatic duct in the presence of a pancreatic stricture (not detected on MRCP prior to enrolment) or in case of incomplete stone removal
75616156|NCT02848456|Procedure|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
75616157|NCT02848456|Procedure|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
75616158|NCT02848456|Procedure|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
75769459|NCT03908944|Drug|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
75909486|NCT03475862|Drug|PTI-821 capsule Manipulated|PTI-821 (oxycodone) 40 mg extended release capsule
75909487|NCT03475862|Drug|PTI-821 Non-manipulated|PTI-821 (oxycodone) 40 mg capsule extended release capsule
75909488|NCT03475862|Drug|OxyContin|Crushed OxyContin (oxycodone) extended-release 40 mg tablet
75909489|NCT03475862|Other|Placebo|Matching placebos for PTI-821 and oxycodone IR
75909490|NCT03475862|Drug|Oxycodone|Crushed oxycodone 40 mg immediate release tablet
75909491|NCT03481712|Diagnostic Test|Diagnostic tests|"Head-to-head comparison between:~CADScor and Diamond-Foster score~Rb PET and 3T CMRI~QFR and ICA-FFR"
75909492|NCT03477968|Other|Plasma sampling|Additional blood draw or additional volume during blood draw
76071827|NCT03966781|Procedure|Sham ESWL|In the sham/control group, patients will be given a transient superficial pin-prick sensation to give the feel of epidural anesthesia. After that the lithotripsy machine the will be switched on, without establishing any form of contact with the patients body.
75462798|NCT01868529|Drug|insulin glargine|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
75616159|NCT02283255|Other|Aerobic Exercise Training|Supervised aerobic and light muscle resistance exercise training
75616160|NCT02283255|Other|Inspiratory Muscle Training|Inspiratory muscle training with POWERbreathe device
75616161|NCT02283255|Other|No Exercise Training|Usual care
75616162|NCT02848144|Other|blood samples|
75616163|NCT02848144|Other|Collection of nosocomial infections|
75909493|NCT03430934|Combination Product|NAVI mapping with Indocyanine green|Moh's tumor imaging with Indocyanine green
76071828|NCT03966781|Procedure|Sham ERCP|Following sham ESWL patientswill be subjected to sham ERCP to examine the papillary area, but no pancreatic ductal intervention will be performed.
76071829|NCT03952806|Drug|Verdiperstat|300mg 2 oral tablets, twice daily
76071830|NCT03952806|Drug|Placebo|Matching placebo
76071831|NCT03944876|Drug|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
75462799|NCT01868555|Drug|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
75462800|NCT01868555|Drug|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
75616164|NCT02848300|Drug|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
75616165|NCT02848300|Drug|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
75616166|NCT00953745|Drug|Escitalopram|All subjects will begin on escitalopram and placebo for 8 weeks
75616167|NCT00953745|Drug|Aripiprazole|Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.
75616168|NCT00953745|Drug|Placebo Capsule|All subjects will begin on escitalopram and placebo capsule for 8 weeks.
75616169|NCT00953745|Drug|Placebo Tablet|After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.
75616170|NCT02847910|Procedure|the disposable tissue suction set|Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
75769460|NCT03897010|Device|Socket Graft|5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
75769461|NCT01257178|Drug|LY2624803|Administered orally
75616171|NCT02847910|Procedure|traditional metal instruments of abortion|Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
75616172|NCT02848066|Procedure|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
75616173|NCT04202380|Drug|Azithromycin|Patients will receive Azithromycin orally 1000 mg
75616174|NCT04202380|Drug|Ampicillin|All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
75616175|NCT04202380|Drug|Azithromycin|Azithromycin 500 mg orally once
75616176|NCT04202380|Drug|Azithromycin|Azithromycin 250 mg orally daily for 4 days
75462801|NCT01868555|Drug|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
75462802|NCT01868555|Drug|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
75616177|NCT04067674|Biological|Blood sampling|Blood sampling for biomarker measurement
76071832|NCT03944876|Drug|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
75616178|NCT02847988|Device|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
75616179|NCT02847988|Device|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
75616180|NCT02847832|Other|Standardized transvaginal ultrasound examination|
75616181|NCT02167048|Drug|Psychostimulants|"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."
75616182|NCT02847754|Other|Isometric resistance training|"Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band"
75616183|NCT02075710|Other|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
75616184|NCT02075710|Other|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
75616185|NCT02075710|Other|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
75616186|NCT02075710|Other|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
75769113|NCT01147120|Procedure|Clinical Massage Therapy (CMT)|PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
75769114|NCT03908242|Drug|salvianolic acid A|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
75769115|NCT03908242|Drug|Placebo|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
75769116|NCT00230178|Drug|Rasburicase (SR29142)|30-min IV infusion
75462803|NCT01868568|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin).
75616187|NCT02075710|Other|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
75616188|NCT02075710|Other|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
75616189|NCT02847442|Drug|BIA 9-1067|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
75616190|NCT02847442|Drug|levodopa/dopa decarboxylase inhibitor|OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
75462804|NCT01868568|Drug|insulin degludec/insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
75616191|NCT04736602|Drug|Triptorelin pamoate 15mg|Intramuscular injection (IM)
75616192|NCT02847520|Behavioral|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
75616193|NCT01698658|Other|ultrasound tomography|Undergo ultrasound tomography using SoftVue
75769117|NCT00230178|Drug|Allopurinol|Oral administration
75769118|NCT03908008|Drug|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
75909494|NCT03477812|Device|Polysomnography (Full sleep registration)|For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
75909495|NCT03475784|Drug|Restrictive fluid therapy|This group will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2 mL/Kg/hour.
75462805|NCT01868568|Drug|insulin degludec/insulin aspart 40|A single dose administered subcutaneously (s.c., under the skin).
75462806|NCT01868568|Drug|insulin degludec/insulin aspart 45|A single dose administered subcutaneously (s.c., under the skin).
75462807|NCT01868568|Drug|insulin degludec/insulin aspart 55|A single dose administered subcutaneously (s.c., under the skin).
75462808|NCT01868568|Drug|insulin aspart|A single dose administered subcutaneously (s.c., under the skin).
75462809|NCT01868568|Drug|biphasic insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
75463367|NCT05852600|Behavioral|Parents and Adolescents Talking about Healthy Sexuality (PATHS)|"PATHS is an intervention delivered to parents of AMSM that aims to increase parent communication about sexuality and HIV, as well as other parent behaviors supportive of sexual risk reduction. PATHS can all be accessed online, is self-paced, and typically takes parents 40-60 minutes to complete. The toolkit is comprised of 7 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. One month later parents complete a refresher module that queries them about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact."
75616617|NCT04161625|Behavioral|Digital exercise program with support|"The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis&Svettis)"
75616618|NCT02641951|Other|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
75616619|NCT02641951|Other|Pecs II block|Ultrasound guided Pecs II block
75616620|NCT04163029|Procedure|Preoperative oral care|tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
75616621|NCT04161703|Procedure|focused ultrasound, diet and exercise|"Focused Ultra Sound using a device of Mabel6 DUO Ultra Cavitation Technology produced by DAEYANG MEDICAL CO., KOREA applied on the abdominal region which extending bilaterally from the line extending from mid-axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crests below.~an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity a weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction"
75616622|NCT04161703|Procedure|diet and exercise|weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction. All subjects in both groups (A & B) followed an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity (moderate intensity = 12-14 according to Borg Scale). The beginning period will be 15 mints and increased gradually until reaching 30 mints per time.
75616623|NCT02636491|Device|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
75616624|NCT02636491|Device|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
76072535|NCT01848145|Drug|Ofatumumab|The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of >= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE >= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
76088818|NCT04745130|Drug|KRAS BRAF mutant Sintilimab + regafinil|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
75616625|NCT00657007|Biological|belimumab|"1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
75616626|NCT00657007|Biological|belimumab|"4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
75616627|NCT00657007|Biological|belimumab|"10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
75616628|NCT00657007|Biological|belimumab|"20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
75616629|NCT00657007|Biological|Placebo|"IV (in the vein) on Day 0 (Cohorts 1-4).~IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
75616630|NCT04318652|Drug|Methylprednisolone eyedrops|instillation of methylprednisolone eye drops
75616631|NCT04161547|Drug|CSPCHA115 100 mg; Matching placebo 100 mg|CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
76088819|NCT02462616|Other|not intervention|This is a cross-sectional study, no intervention was performed.
75463368|NCT05852600|Behavioral|Lead with Love (LWL)|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance. One month after watching LWL, parents return to the website to review refresher materials that summarize the most important lessons from the film."
75463369|NCT05851118|Behavioral|Quantified analysis of walking during a crossing task between two walkers|Functional test that reproduce a task of daily living.
75463370|NCT05851066|Drug|VSA003|sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
75463371|NCT05851066|Drug|0.9% NaCl|placebo
75463372|NCT05850819|Drug|Colloidal silver gelatin sponge|Augment the extraction socket with Gelatamp
75463373|NCT05850819|Drug|Sterile gauze pack|Extraction socket allowed to heal without augmentation with any material
75463374|NCT05850429|Dietary Supplement|Seaweed protein|Novel protein extracted from seaweed
75463375|NCT05850156|Procedure|basal blood collection|blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
75463376|NCT05850156|Procedure|blood collection M6|6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
75463377|NCT05850156|Procedure|blood collection M12|12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
75463378|NCT05846347|Drug|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.
75463379|NCT05845684|Other|Physiotherapy application|massage, oral and intraoral tactile stimuli and non-nutritive sucking will be performed to stimulate sucking, and massage applications and neurodevelopmental therapy for motor development.
75463380|NCT05845684|Other|Control Group|standard daily applications will be performed on patients
75463381|NCT05845489|Drug|Clopidogrel treatment group|Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
75463382|NCT05845489|Other|No antiplatelet or anticoagulant group|Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.
75463383|NCT05834894|Other|exposure(s) of interest : intensive care unit|Low muscle mass is highly prevalent at hospital admission, and muscle mass generally decreases during hospital stay, especially in critically-ill patients. We would like to mesure muscle mas in critically ill patients and determine the association between outcomes.
75463384|NCT05834166|Other|Upper back strengthening and Postural correction|The treatment protocol will involve upper back strengthening exercises and postural correction exercises 3 times a week for 10 to 15 minutes. Upper back strengthening will involve exercises with light-to-moderate load of free weights (body weight or resistance bands) or with a stability ball. Postural correction will involve maintaining the correct posture.
75463385|NCT05833074|Behavioral|Couples HIV testing and counseling|Couples HIV testing follows a CDC published protocol for delivery of HIV testing to relationship partners. HIV test results are obtained from Oraquick (FDA approved for at home HIV testing)
75463386|NCT05833074|Behavioral|Individual HIV testing and counseling|Individual HIV testing and counseling uses a counseling protocol based on the standard of care for routine HIV pre- and post-test counseling. HIV test results are obtained from Oraquick (FDA approved for at home testing)
75463387|NCT05830084|Drug|regorafenib tablet|"Regorafenib will be escalated/de-escalated, starting at DL0:~DL1: 82 mg/m^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~DL0 (starting dose): 66 mg/m^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~DL-1: 50 mg/m^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)"
75463388|NCT05826873|Behavioral|Discharge antibiotic stewardship intervention|Hospitalists will be provided with group-level, quarterly feedback reports illustrating the number of prescriptions that had the appropriate antibiotic duration and appropriate antibiotic choice for each of the three conditions.
75463389|NCT05818072|Procedure|One biopsy|To do one biopsy at the proximal part of the longest columnar-lined esophagus.
75463390|NCT05818072|Procedure|Three biopsy|To do three biopsy at the proximal, middle and distal part of the longest columnar-lined esophagus.
75463391|NCT05818072|Procedure|Seattle protocol|To do 4-quadrant biopsy every 1-2 cm at the esophagogastric junction. Seattle protocol has been considered as the gold standard biopsy protocol for patients with suspected Barrett's Esophagus.
75463392|NCT05818072|Device|Endoscopy|The participants will receive meticulous endoscopic examination with narrow-band imaging.
75463393|NCT05815602|Drug|Ebastine|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
75463394|NCT05815602|Drug|Duspatalin|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
75616632|NCT04161547|Drug|CSPCHA115 200 mg; Matching placebo 200 mg|CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
75616633|NCT04161547|Drug|CSPCHA115 400 mg; Matching placebo 400 mg|CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
75616634|NCT04161547|Drug|CSPCHA115 600 mg; Matching placebo 600 mg|CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
75616635|NCT02887898|Device|Automated bolus calculator|
75616636|NCT02887898|Other|Education|
76072536|NCT01847755|Drug|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
75463395|NCT05810246|Diagnostic Test|68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory)|"68Ga-NY104 PET/CT is expected to be completed within 21 days following screening. Participants will be administered a single, intravenous bolus of 68Ga-NY104 (1.8-2.2 MBq per kilogram bodyweight). PET/CT scanning will occur at 45 -75 minutes following injection of 68Ga-NY104.~Conventional imaging should be performed within one month from 68Ga-NY104 PET/CT. It includes contrast-enhanced MRI of brain and contrast-enhanced CT of abdomen and pelvis.~68Ga-NODAGA-LM3 PET/CT is optional in patients with evidence of or in suspicion of pheochromocytoma, paraganglioma, or pancreatic neuroendocrine tumor. They are encouraged to undergo exploratory 68Ga-NODAGA-LM3 PET/CT for better evaluation of neuroendocrine tumors. The decision, however, is up to the participants. 68Ga-NODAGA-LM3 PET/CT should be performed within one month after 68Ga-NY104 PET/CT. The details of 68Ga-NODAGA-LM3 PET/CT are similar to 68Ga-NY104 PET/CT."
76072537|NCT00527566|Biological|Mepolizumab|IV mepolizumab, 750 mg
75463396|NCT05807568|Other|NCAEM EM-SART Pre-Screen|Participants will be verbally asked the 3 participant questions on the NCAEM EM-SART Pre-Screen either directly or with support of hospital approved telephonic interpreters. Answers will be documented by the investigator digitally. Participants will be interviewed one time for a duration of approximately 15 minutes. No further action will be taken on study participants with negative elder mistreatment screens, unless findings concerning for emotional distress are identified by the investigator. If emotional distress is identified, these observations will be communicated to Geriatric Medicine team in person or via secure/encrypted email, with recommendations to follow-up with the participant about the results and take appropriate care actions. Study participants with positive elder mistreatment will have results shared with the study participant directly and with the Geriatric Medicine primary team via secure/encrypted email.
75463397|NCT05806606|Other|Dyadic empowerment based heart failure management program|The 16-week De-HF Program is delivered on a dyadic basis, The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.
75463398|NCT05806606|Other|Dyadic education program|The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
75463399|NCT05790369|Behavioral|Resistance training (New ankle machine training)|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
75463400|NCT05790369|Behavioral|Resistance training (Elastic band training )|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
75463401|NCT05784727|Device|Earswitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
75463402|NCT05784675|Device|MOBI-CPR game|Participants use MOBI-CPR game at home environment.
75463403|NCT05778318|Drug|The group of patients who received Lianhua Qingwen orally|Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
75463404|NCT05778318|Other|The group of patients who did not receive Lianhua Qingwen orally|The group of patients who did not receive Lianhua Qingwen orally.
75463405|NCT05777317|Device|10 kHz SCS|Spinal cord stimulation programmed to a frequency of 10 kHz
75463406|NCT05777317|Other|CMM alone|Conventional medical management alone
75463407|NCT05771636|Behavioral|Mental Imagery|"Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done."
75463408|NCT05771636|Behavioral|Control condition (activity planification)|The participant identifies 4 activities that he plans to do in the course of the next 2 weeks.
75463409|NCT05767554|Behavioral|Brief modified behavioral activation|The clinician will deliver psychoeducation about the nature of depression and the rationale behind the behavioral activation model (i.e. increasing level of activation can jumpstart a positive feedback cycle of reward and improvements in mood state). Participants will be encouraged to add new, enjoyable activities to their daily schedules. Clinicians will emphasize the importance of novelty and increased engagement with the surrounding environment in the psychoeducational portion and in activity scheduling.
75651585|NCT00694629|Drug|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
75651586|NCT00694629|Drug|rifapentine|20 mg/kg, daily, 8 weeks
75463410|NCT05758441|Behavioral|Mentoring to be Active plus Family|Ten, structured peer mentoring sessions (once a week) covering new content each week and guided skill-building and practice. The MPBA sessions target increasing daily physical activity and replacing sugary drinks with water for hydration. Mentoring sessions are conducted virtually. A 6-month family reinforcement program follows with a reinforcement packet sent to child participants' homes once a month.
75616637|NCT02633995|Procedure|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
75616638|NCT02633917|Behavioral|Motor control exercises|exercises to strength the lumbar musculature and control the posture
75616639|NCT02633917|Behavioral|Standard exercises|general exercises
75616640|NCT02633683|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
75616641|NCT01211522|Drug|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
75616642|NCT01211522|Drug|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
75616643|NCT01211522|Drug|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
75616644|NCT04161469|Procedure|Laser closure of the anal fistula tract (FiLaC)|The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s
75616645|NCT04161469|Procedure|Internal orifice closure|Closure of internal orifice with a purse-string suture using 2-0 polyglactin suture material.
75616646|NCT01211288|Device|Astra implants|Root form OsseoSpeed TX Astra Tech Implant System
76072538|NCT00527644|Device|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
75317925|NCT03595046|Procedure|thoracic paravertebral block(10 mL 0.25% ropivacaine with dexamethasone 5mg)|2) In group P, an appropriate thoracic spinous precess is located by positioning the probe in the transverse plane. Then the probe is moved laterally to locate the transverse process. The probe is manipulated slightly caudad or cephala to locate the intercostal space. The transverse process is visualized medially with the pleura dipping under the inferolateral aspect. The internal intercostal membrane, which is contiguous with the superior costotransverse ligament, was generally seen as a thin, radiopaque line extending from the transverse process, creating a wedge-shaped pocket, which represents the thoracic paravertebral space. A 22-gauge, facet-tip needle is advanced, in plane, from the lateral aspect of the ultrasound probe. When the needle pierced the internal intercostal membrane, and after aspiration demonstrated the absence of air or blood, 10 mL 0.25% ropivacaine with dexamethasone 5mg deposited in 5-mL increments.
75317926|NCT00217022|Other|Placebo|Placebo, 3 tablets daily
75616647|NCT02641795|Device|Minimally invasive robotic cochlear implantation|
75616648|NCT05404724|Drug|itraconazole、 SHR0302 tablets|Itraconazole 7 times and SHR0302 tablets twice. On the 8th day of this, itraconazole and SHR0302 tablets were taken simultaneously.
75616649|NCT02636257|Procedure|Recessive Spherical Headed Silicone Intubation|Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.
75616650|NCT02636257|Procedure|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
75616651|NCT00656461|Drug|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
75616652|NCT02633761|Drug|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
75616653|NCT02633761|Drug|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
75616654|NCT02633761|Drug|Misoprostol 200mcg|Buccal misoprostol 200mcg
75463411|NCT05758441|Behavioral|Tracking Health and Fitness|10 self-guided, self-paced modules mailed to child participants home.
75463412|NCT05755737|Drug|Ondansetron|Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)
75463413|NCT05755737|Drug|Placebo|Matching placebo identical in appearance.
75616655|NCT04161313|Other|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test.
76088820|NCT04703244|Procedure|chemotherapy or endocrine therapy for breast cancer|Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.
75616656|NCT04161313|Other|pulmonary function test|It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
75616657|NCT04161313|Other|Functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
75616658|NCT04161313|Other|Peripheral muscle strength|Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
75616659|NCT04161313|Other|Respiratory muscle strength|Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
75616660|NCT02633605|Device|First Sense Medical®|
75616661|NCT00883753|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
75616662|NCT02641717|Other|vaginal swab|
75616663|NCT04162639|Biological|Skin allograft|Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
75616664|NCT01210664|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10^8 cells. The second cohort will receive 0.4 x10^8 cells. The third cohort will receive 3.2 x10^8 cells. The fourth cohort will receive 26 x10^8 cells.
75616665|NCT02633839|Drug|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
75616666|NCT02633839|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
75616667|NCT02636335|Device|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
75616668|NCT02632903|Drug|Zoledronic acid|
75616669|NCT00657397|Drug|Methadone|Methadone sirup once daily
75616670|NCT04160611|Drug|Midazolam 7.5mg|The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
75616671|NCT04160299|Behavioral|Dance-based exergaming|Dance sessions
75616672|NCT02535559|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
75616673|NCT04161001|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
75616674|NCT04161001|Drug|Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
75317927|NCT00217022|Drug|Budesonide|9 mg daily (three tablets)
75616675|NCT04161001|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
75616676|NCT02636413|Drug|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
75616677|NCT02636413|Dietary Supplement|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
75616678|NCT04160767|Drug|Probiotic Vivomixx|VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
75317928|NCT03997994|Device|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter coated with a proprietary coating containing the drug and carriers.
75616679|NCT04160767|Behavioral|Gluten free diet|Gluten free diet will be encouraged in both arms
75317929|NCT00538759|Device|External beam radiation therapy|Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
75317930|NCT00538759|Other|Sham Control|
75317931|NCT05369312|Drug|BPI-442096|Subjects will receive BPI-442096 until disease progression
75317932|NCT03594968|Diagnostic Test|polycystic ovary syndrome|3 to 5th day of the women's normal cycle, we will perform a routine gynecological examination, a basic vaginal ultrasound, a basal hormone profile evaluation
75317933|NCT00538915|Biological|Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]|Nabi-IGIV 10% [Immune Globulin Intravenous (Human), 10%] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
75317934|NCT03997604|Device|Full Dentures created by additive manufacturing|Full dentures created by Additive manufacturing (Carbon Printers)
75317935|NCT03598946|Device|Urinary test|Women use a home urinary test themselves
75317936|NCT03594812|Device|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45º. The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis.
75317937|NCT03594812|Device|Radiofrequency without power|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45ºC (Celsius degrees). The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis. In this group, the radiofrequency device was switched off.
75317938|NCT03594812|Device|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
75616680|NCT04160767|Other|Placebo|Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
75341277|NCT05363228|Behavioral|Therapy by Dance and Movement|Therapy by dance and movement is based on the principals of movement-analysis by Rudolf Laban and Irmgard Bartenieff. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
75616681|NCT02633449|Behavioral|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
75798311|NCT01281774|Biological|Placebo|Normal saline (0.9%)
75317939|NCT00490009|Drug|Bexxar|"Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.~Bexxar will be administered to provide the following patient-specific radiotherapy:~Platelet count of 150,000/mm³ = 75 cGy~Platelet count ≥ 100,000/mm³ but < 150,000/mm³ = 65 cGy"
75463414|NCT05754554|Procedure|Atlas occipital decompression lateral joint release combined with occipital-neck fusion|A. Chiari malformation combined with type II Basilar invagination showed that the slope spinal canal angle decreased, and the position of the dentition moved up. The yellow fusion device in the picture is C1/2 lateral inter-articular Cage (the patent granted by the applicant for this project); B. After atlanto-occipital decompression, C1/2 lateral inter-articular release is performed, and a fusion device is implanted to move down the position of the tip of the tooth process to reduce the compression of the cervical medulla oblongata; C. Implantation of the posterior neck nail rod system; D. Improve the angle of the sloped spinal canal by posterior compression rod technique (Cantilever) to further reduce the compression on the superior cervical medulla oblongata.
75463415|NCT05746364|Behavioral|Brief CAT-Informed Intervention for Young People experiencing Difficulties with Eating|The therapy draws upon the principles of Cognitive Analytic Therapy (CAT), focussing on collaboratively identifying relational patterns (relationships with self and others) that young people experience difficulties with. The young person will be invited to attend 5 weekly sessions, each lasting 30-50 minutes. It will be delivered within a seven-week window (allowing for cancellations/missed sessions). Researchers will follow the RIDE manual treatment guide, which was developed by Clinical Psychologists, CAT accredited therapists and researchers.
75463416|NCT05741957|Behavioral|Once-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve one session weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 75 min. Participants will exercise with an exercising heart rate at 6-7 metabolic equivalents (METs). Health information provided to the usual care control group will be made available to the participants in this group.
75317940|NCT00490009|Drug|Acetaminophen|As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
75317941|NCT00490009|Drug|Diphenhydramine|As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions
75317942|NCT00490009|Drug|Potassium Iodide (KI)|Administered to prevent thyroid blockage 130 mg orally 3 times a day,
75463417|NCT05741957|Behavioral|Thrice-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve three sessions weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 25 min. Participants will exercise with an exercising heart rate at 6-7 METs. Health information provided to the usual care control group will be made available to the participants in this group.
75463418|NCT05741957|Other|Usual Care Control|Participants in this group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to general health and NAFLD, such as non-communicable diseases, infectious diseases, and a healthy lifestyle.
75463419|NCT05736952|Drug|Oral Topotecan Combined With Anlotinib|Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.；Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.
75463420|NCT05732506|Drug|Edoxaban|There are not intervention.
75463421|NCT05719779|Device|Ronco-Onco and MAD|Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.
75463422|NCT05719155|Drug|CKD-379|1 tablet administration under fed condition
75463423|NCT05719155|Drug|D759+D745+D150|3 tablet coadministration under fed condition
75463424|NCT05694442|Other|Lipmatte K|Lipmatte K contain ingredients that may hydrate and brighten the lip
75463425|NCT05694429|Other|Product K cleanser and moisturizer|Product K cleanser and moisturizer contain ingredients that may improve skin hydration and elasticity
75463426|NCT05686967|Dietary Supplement|MitoQ|MitoQ is a biochemically modified form of ubiquinol
75463427|NCT05686967|Dietary Supplement|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
75463428|NCT05686967|Behavioral|Aerobic exercise|Moderate intensity aerobic exercise on the treadmill
75463429|NCT05685043|Device|perfusion CT|Patients are selected for thrombectomy based on perfusion CT criteria. When the results from the perfusion CT scan (analyzed by RAPID software) indicate a core infarct volume exceeding 70 ml in patients < 80 years or 55 ml in patients > 80 years, then treatment is limited to best medical treatment (intravenous fibrinolysis if applicable) and no mechanical thrombectomy will be performed. This is the current standard of care for patients treated more than 6 hour after onset.
75463430|NCT05678075|Behavioral|Whole-food plant-based nutrition education|Participants will receive an educational intervention regarding the benefits of a whole food plant-based diet and how to incorporate more plant-based foods into their diets. The intervention will last 6 weeks.
75463431|NCT05674656|Drug|Dolutegravir/Rilpivirine FDC|Dolutegravir/Rilpivirine will be administered.
75463432|NCT05671354|Device|the auto-wrapping commode chair|The auto-wrapping commode chairs will seal off the excretions in a plastic bag when a button is pressed, and then prepare a new bag for next excretions. The sealed excretions will then be disposed of as usual garbage. The same staff, who are responsible for disposing of the excretions from the commodes in the pre-test, will dispose of the excretions from the auto-wrapping commode chairs during the trial.
75463433|NCT05664854|Device|Nerve cuff electrodes for spatially selective vagus nerve stimulation and electrical impedance tomography|Vagus nerve electrode cuffs will be placed on the exposed human vagus nerve during routine vagal nerve stimulator implantation surgery. These cuffs will then be used for spatially selective vagus nerve stimulation, with physiological readout, and electrical impedance tomography for the functional imaging of organ-specific regions in the nerve at cervical level.
75798312|NCT01170078|Drug|Epoetin Hospira|IV dose 3 times a week.
75616682|NCT02633449|Device|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
75463434|NCT05658328|Behavioral|SHARP - Physical and social activity|Technology-enabled neighborhood walking 3x/week for 16 weeks with conversational reminiscence
75616683|NCT02633449|Device|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
75616684|NCT02535637|Other|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
75616685|NCT04162717|Behavioral|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
75616686|NCT00911209|Behavioral|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
75616687|NCT00881569|Drug|CS-7017|CS-7017 administered orally, twice daily continuously for 6 weeks
75616688|NCT04017481|Other|Repetitive transcranial magnetic stimulation (rTMS)|The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
75616689|NCT04017481|Other|EEG guided Neurofeedback (NFB)|The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
75616690|NCT04160143|Procedure|Surgical resection and stereotactic body radiation therapy (SBRT)|Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
75616691|NCT02636179|Other|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
75616692|NCT00657163|Drug|fluoxetine|fluoxetine per os 20 mg daily
75616693|NCT00657163|Drug|placebo|placebo per os daily
75616694|NCT02636101|Drug|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
75616695|NCT04032457|Device|Phase A - olifilcon B with Tangible Coatings|Daily disposable silicone hydrogel contact lens
75616696|NCT04032457|Device|Phase B - etafilcon A with Tangible Coatings|Daily disposable hydrogel contact lens
75317943|NCT03769532|Drug|Pembrolizumab|Pembrolizumab (IMP): 200mg i.v. (fixed dose), every 3 weeks (Q3W), 8 doses
75317944|NCT03769532|Drug|Azacitidine|Azacitidine (SOC): 75 mg/m2 s.c., day 1-7 every 4 weeks (Q4W), 6 cycles
75463435|NCT05651633|Drug|lidocaine hydrochloride 5mg/g|1-2 drops up to six times daily for a maximum of 7 days
75463436|NCT05648448|Drug|Drug: Oseltamivir|Oral oseltamivir 75mg BD for 5/7
75463437|NCT05648448|Drug|Drug: Favipiravir|Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
75616697|NCT00657475|Drug|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
75616698|NCT00657475|Drug|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
75616699|NCT02636023|Device|SPhENo-Cardiograph|SPhENo-Cardiograph
75616700|NCT02632981|Other|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
76072539|NCT00527722|Device|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
75317945|NCT00490477|Device|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
75463438|NCT05648448|Drug|Drug: Zanamivir|Inhaled zanamivir 10mg BD for 5/7
75317946|NCT00491491|Drug|ibritumomab tiuxetan|0.4 mCi/kg
75317947|NCT00491491|Procedure|BEAM chemotherapy and autologous stem-cell transplantation|
75317948|NCT00492583|Drug|Bifidobacterium lactis (BB-12)|The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
75463439|NCT05648448|Drug|Drug: Baloxavir|"Oral baloxavir:~<80kg- single dose of 40mg on D0~≥80kg- single dose of 80mg on D0"
75463440|NCT05648448|Drug|Drug: Molnupiravir|Oral molnupiravir 800mg BD for 5/7
75463441|NCT05648448|Drug|Drug: Peramivir|Intravenous peramivir 600mg once only
75463442|NCT05648448|Drug|Drug: Laninamivir|Inhaled laninamivir 40mg once only
75616701|NCT02632981|Other|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
76072540|NCT00527722|Other|No lung plug|Standard lung biopsy without placement of the plug.
76072541|NCT01847443|Drug|Nicotine (2 mg)|2 mg nicotine gum in two formulations
76072542|NCT01847443|Drug|Nicotine (4 mg)|4 mg nicotine gum in two formulations
75616702|NCT04160689|Biological|implantology|placing of implant
75616703|NCT02631889|Device|Transcollation technology|The use transcollation technology for dissection during lung surgery
75616704|NCT02631889|Device|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
75616705|NCT00657319|Drug|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
75616706|NCT00881335|Device|flutter mucus clearance device|five minutes every sessions, three sessions per day
75616707|NCT02632825|Device|Nasal High Flow|Nasal High Flow Therapy
75616708|NCT00657631|Behavioral|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, & Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl & Wilson, 1999)."
75616709|NCT04159597|Drug|Upadacitinib|Upadacitinib will be administered as oral tablet.
75616710|NCT00661219|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
75616711|NCT00661219|Drug|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
75616712|NCT00665665|Drug|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
75616713|NCT00665665|Drug|placebo|Placebo for s.c. injection
75616714|NCT00665665|Drug|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
75616715|NCT00665665|Drug|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
75616716|NCT00665665|Drug|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
75616717|NCT00665743|Drug|PN400|naproxen 500 mg /esomeprazole 20 mg
75616718|NCT00665743|Drug|naproxen|naproxen 500 mg tablet
75616719|NCT00665743|Drug|naproxen|naproxen 500 mg
75616720|NCT04156711|Procedure|Remote Ischemic Preconditioning (RIPC)|Cycles of forearm ischemia and reperfusion by the inflation of a blood-pressure cuff over the systemic blood pressure for brief periods
75616721|NCT02357992|Radiation|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
75616722|NCT00661297|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil to be taken 1 h prior to sexual attempt
75463443|NCT05647616|Other|Strengthening exercises|Participants in group A will be required to complete 12 sessions in 4 to 6 weeks. Resistance-Bands will be used to do ankle plantar flexion and eversion (3 sets of 10 repetitions). Participants will have to be seated on the floor with the knee extended and instructed to perform the movement at the ankle joint without allowing extraneous movement at hip and knee. The resistance band will be doubled and securely attached to the base of a table. The training resistance will be determined by calculating 70% of the resting length of the resistance band and adding this distance to the resting length of the resistance band. Using this calculated distance, the examiner will place a mark to which the resistance band will be stretched during exercise performance on the floor. Each week a study investigator will track each participant's completion. Participants will be instructed to move through their entire range of motion for the direction of each exercise.
75616723|NCT00661297|Drug|Placebo|Matching placebo
75616724|NCT00665821|Behavioral|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
75616725|NCT00665821|Behavioral|General health education|General health education: a booklet describing general norms for maintaining good health
75317949|NCT00492583|Drug|Placebo|The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
75616726|NCT02842762|Device|Right ventricular epicardial pacing|The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.
75317950|NCT00492973|Drug|methylprednisolone acetate|Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate
75317951|NCT00492973|Drug|active comparator|bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline
75317952|NCT03594656|Drug|Ganoderma|0.8g twice daily
75616727|NCT02842762|Procedure|cardiac surgery|Elective cardiac surgery, with use of cardiopulmonary bypass.
75616728|NCT02842762|Device|3D TEE|Intraoperatively, all patients will be monitored by means of TEE
75616729|NCT02842762|Device|Pacemaker lead|All patients will have a epicardial pacemaker lead in situ.
75616730|NCT02690896|Behavioral|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
75616731|NCT02690896|Behavioral|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
75798313|NCT01170078|Drug|Epogen|IV dose 3 times a week
75317953|NCT03594656|Drug|Placebos|0.8g twice daily
75317954|NCT00494143|Device|CESR Prosthetic Foot|a novel prosthetic foot that is designed to store energy and release it at a predetermined time in the gait cycle
75616732|NCT00879775|Drug|Caffeine|Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
75616733|NCT00879775|Drug|Normal saline|Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
75616734|NCT02840344|Behavioral|Couples MBSR|Both members of the couple will be asked to participate in the weekly video sessions and activities.
75616735|NCT02840344|Behavioral|Individual MBSR|Only the young breast cancer survivor will participate in the weekly video sessions and activities.
75616736|NCT00665899|Behavioral|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
75616737|NCT00665899|Behavioral|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
75909655|NCT04932772|Other|Abdominal Exercises|Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
75909656|NCT04932304|Device|Transcranial direct current stimulation (tDCS)|
75909657|NCT04932304|Device|Sham Transcranial direct current stimulation (tDCS)|Sham Transcranial direct current stimulation (tDCS)
75616738|NCT00894790|Drug|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
75616739|NCT00894790|Drug|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
75616740|NCT04156867|Device|Dynesys|discectomy with Dynesys
75616741|NCT04156477|Dietary Supplement|Ketone ester|Intake of weight adjusted drink of a ketone ester
75616742|NCT04156477|Dietary Supplement|Glucose|Isocaloric and - volumetric taste adjusted drink
75616743|NCT04156477|Dietary Supplement|Tap water|Isovolumetric taste adjusted tap water (placebo)
75616744|NCT02840110|Other|ACTR T Cell Product|
75616745|NCT00665977|Drug|Thermosmart & placebo|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
75616746|NCT00665977|Drug|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
75909658|NCT01354353|Drug|LY2140023|Administered orally
75909659|NCT01354353|Drug|Aripiprazole|Administered orally
75909660|NCT04932538|Other|Kİnesio Taping|Kinesio Taping® (KT) is used for pediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception
75909661|NCT02622568|Drug|Veregen only|Topical application of Veregen 15% ointment on affected areas twice daily
75909662|NCT02622568|Procedure|Cryotherapy and Veregen|Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
75463444|NCT05645055|Other|treat these patients with biologics|treat these patients with biologics
75616747|NCT00665977|Device|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
75909663|NCT04932460|Procedure|CEUS|CEUS is performed before neoadjuvant treatment and surgery to evaluate the status of axillary lymph node and locate the sentinel lymph node.
75317955|NCT00494143|Device|typical prosthetic foot|patients will wear the prosthetic foot that they were prescribed by the care providers in the clinical team
75317956|NCT00494143|Device|standardized prosthetic foot|a standard foot that has had weights applied to match the mass of the CESR foot
75317957|NCT03595202|Drug|TS-143|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
75317958|NCT03595202|Drug|Placebo|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
75317959|NCT03596684|Dietary Supplement|citrulline supplementation|2.5 g per os of citrulline on the morning and the evening (5 g/ jour) during 4 weeks.
75616748|NCT02840500|Other|No intervention|No intervention
75909664|NCT04932460|Procedure|blue dye|Before operation, blue dye is injected for sentinel lymph node mapping.
75909665|NCT04932070|Dietary Supplement|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
75909666|NCT03070899|Drug|OBE2109|OBE2109 100mg tablets for oral administration once daily
75909667|NCT03070899|Drug|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
75616749|NCT02631811|Other|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
75909668|NCT03070899|Drug|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
75909669|NCT03070899|Drug|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
75616750|NCT00666055|Drug|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
75463447|NCT05641064|Drug|Placebo|Continuous infusion of saline starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
75463448|NCT05641064|Drug|Dexmedetomidine 0.5mcg/kg/h|Continuous infusion of dexmedetomidine in 0.5mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
75463449|NCT05641064|Drug|Dexmedetomidine 1 mcg/kg/h|Continuous infusion of dexmedetomidine in 1mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
75463450|NCT05634967|Other|Kesimpta|Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
75616751|NCT02840734|Other|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
75616752|NCT02839954|Biological|anti-MUC1 CAR-pNK cells|
75909670|NCT04931680|Other|Data collection|During the follow-up consultation, six weeks after inclusion (S6), data will be collected using a standardized digital questionnaire, including clinical features, economic, social and cultural characteristics, housing conditions and therapeutic details (type of environmental decontamination and treatment received). Data will then be compared between patients with therapeutic success or failure. A urine test strip will also be used during the S6 consultation to screen for proteinuria. The prevalence of post-streptococcal glomerulonephritis will be extrapolated from that of proteinuria.
75909671|NCT04931992|Other|No intervention|Retrospective analysis
75909672|NCT04931524|Drug|carbon-14-[14C]-ANG-3777|Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
75909673|NCT04431310|Other|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic|The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
75909674|NCT04931446|Procedure|Biopsy/surgical tissue and peripheral blood|Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens
75909675|NCT03562611|Drug|Nalbuphine|Nalbuphine administration during surgery
75463451|NCT05627570|Dietary Supplement|Healthy, balanced Diet A|Healthy, balanced diet following Eatwell Guide recommendations
75909676|NCT03562611|Drug|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
75317960|NCT03596684|Dietary Supplement|placebo supplementation|2.5 g of the product in the morning and in the evening during 4 weeks.
75463452|NCT05627570|Dietary Supplement|Healthy, balanced Diet B|Healthy, balanced diet following Eatwell Guide recommendations
75463453|NCT05627570|Behavioral|Behavioural support intervention|Participants will work with a behavioural scientist to create a personal plan to eat a healthier diet and be more physically active. This support will last for 6 months, with ongoing monthly telephone/video calls with the research team.
75463454|NCT05623800|Other|PREM-Kit|The PREM-Kit, which was created based on the Information-Motivation-Behavioral Skills model, is used in a series of HIV education sessions as part of the intervention. Over the course of three sessions, there will be a total of six weeks (one session for every two weeks). Three sub-modules, namely HIV facts and information, motivation for HIV preventive behavior, and behavioral skills for HIV prevention, will be emphasized in each session to the participants via flip chart and health educational videos. Additionally, participants will receive a QR code that gives them access to the PREM-Kit's e-flip chart, which they can see at a later time.
75651587|NCT02868125|Radiation|X ray radiography|All studied patients will undergo an x-ray radiography of the operated hip. This protocol is a part of the investigators' common practice policy regardless of the study.
75909677|NCT03562611|Drug|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
75909678|NCT04930120|Other|Inter ICU long distance patient transfer|Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
75909679|NCT04930276|Other|Diet intervention|Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.
75909680|NCT04442763|Device|Densah Burs|osseodensification method
75317961|NCT03596684|Procedure|glucose tolerance test|2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
75317962|NCT03832868|Behavioral|Pre-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
75909681|NCT04442763|Device|Standard drills|conventional drilling
75616753|NCT04159285|Behavioral|EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients|Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
75909682|NCT03057574|Drug|Follitropin Alfa|Patients must be prescribed Follitropin Alfa (Gonapure®)
75317963|NCT03832868|Behavioral|Post-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
75616754|NCT04159285|Other|Treatment as usual|Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
75616755|NCT02690662|Behavioral|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
75616756|NCT02631655|Other|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
75616757|NCT02840188|Other|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
75616758|NCT00661375|Drug|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
75616759|NCT04250974|Other|electroacupuncture|acupuncture with electricity
75616760|NCT00911287|Drug|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
75616761|NCT04154527|Other|Pelvic Floor and Abdominal Exercises|two repetitions of each exercise, during exhalation phase
75616762|NCT02837848|Procedure|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
75616763|NCT02837848|Procedure|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
75616764|NCT02631031|Drug|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
75616765|NCT02839564|Procedure|Laparoscopic adhesiolysis|After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
75616766|NCT02839564|Procedure|Diagnostic laparoscopy|After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
75616767|NCT00911365|Biological|autologous mesenchymal stem cells|"4*107 stem cell (100ml) Intra arterial infusion/ one time, then 4*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-> Total four times"
75616768|NCT00911365|Biological|normal saline|saline
75616769|NCT04250272|Procedure|Thoracoscopic lobectomy|Thoracoscopic lobectomy was performed for lung cancer
75616770|NCT02838160|Behavioral|Routine Care|After baseline measurement, Group 1 did not receive any intervention or education.
75616771|NCT02838160|Behavioral|Routine care Plus the designed booklet|Group 2 received only the designed booklet without any participation in the oral presentation.
75317964|NCT05630534|Drug|Minocycline|Minocycline is a tetracycline antibiotic routinely used in clinical practice for the treatment of bacterial infection and acne.
75616772|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations|Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
75616773|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside|The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
75463455|NCT05618093|Device|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds. If two finger probes are available, measurements will alternate between fingers.
75616774|NCT02839408|Dietary Supplement|Lactobacillus rhamnosus SP1|Sachet containing Lactobacillus rhamnosus SP1
75616775|NCT02839408|Drug|Azithromycin|Tablet containing 500mg Azithromicyn
75616776|NCT02839408|Other|Talc powder|Sachet containing talc powder and tablet containing talc powder
75616777|NCT02839408|Procedure|Periodontal treatment Scaling and root planning|
75909683|NCT04929964|Procedure|MRM , Toilet Mastectomy , BCS|MRM , modified radical mastectomy : removing breast and axilla toilet mastectomy : palliative removal of tumor load BCS ,Breast conservative surgery
75909684|NCT03056950|Device|DELFI PTS ii portable tourniquet|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
75317965|NCT05630534|Other|starch|Use starch capsules as placebo
75317966|NCT05630456|Other|Receving feedback|Receving regular feedback from a health provider
75317967|NCT05630456|Other|No regular feedback|No regular feedback from a health provider
75909685|NCT03057028|Drug|Anakinra|
75317968|NCT03594578|Behavioral|Episodic future thinking|Prospective thinking intervention
75317969|NCT03594578|Behavioral|Episodic recent thinking|Sham episodic thinking
75616778|NCT02838082|Behavioral|Sleep Hygiene Protocol|Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
75463456|NCT05612685|Behavioral|Healthcare provider referral to a tax filing app|Healthcare providers offer a referral to a tax filing app and briefly describe the potential benefits of tax credit receipt
75616779|NCT02838082|Behavioral|Standard of Care|All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
75616780|NCT02838004|Device|IOL MINI WELL READY|IOL MINI WELL READY
76072543|NCT00527878|Drug|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
75616781|NCT05334082|Other|FIFA 11+|15 progressive exercise drills for training preparation (warm-up)
75616782|NCT02837614|Drug|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
75616783|NCT02837614|Drug|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
75616784|NCT02837614|Procedure|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
75463457|NCT05606510|Other|Mindful exercise|In this study, a modified mindful exercise (ME) program based on mindful standing yoga refers to a type of exercise that aims to harmonize the body and mind through the effect of mindfulness meditation and stretching-awareness to carry on the actual moment through body movement and surroundings without any judgement.
75463458|NCT05606510|Other|usual care|Routine medicine and nursing care; as well as hospital-recommended movements (physical stretching).
75463459|NCT05603923|Behavioral|Lumen Coached PST Intervention.|Lumen Intervention Orientation. Participants in the Lumen intervention arm attend a Lumen orientation visit (60 minutes) during which they will be given a Lumen intervention tutorial and receive a study iPad, configured to limit access to only the Lumen intervention enabled on the device. Before leaving, participants are scheduled for the first PST session with Coach Lumen. At the end of each PST session, participants are prompted to schedule their next session with Coach Lumen. They receive automated reminder notifications 1 day prior to their next session, on the session day, and have the opportunity to make up missed sessions. As needed, Lumen intervention orientations can be done remotely.
75463460|NCT05603923|Behavioral|Human Coached PST Intervention.|Participants in the human coached PST arm will serve as active treatment controls given the demonstrated efficacy of human coached PST in depression and anxiety. They will complete 8 PST sessions with a human coach; first session in-person and remaining sessions via videoconferencing (i.e., Zoom preferred; with phone calls allowed) on the same 4 weekly and then 4 biweekly schedule as that for Lumen participants. Participants will receive a study iPad to use for their PST sessions via zoom. Participants also complete the PHQ-9 and GAD-7 during each session. Participants will receive a certificate of completion.
75463461|NCT05603923|Behavioral|Optional (delayed) Lumen Coached PST (Waitlist control).|Waitlist control participants will only complete assessments during the 18-week trial period. At the end of their 18-week assessment, they will have the option to complete 8 PST sessions on their assigned iPads.
75463462|NCT05594706|Other|Measurement of blood levels of 1,5-anhydroglucitol|Measurement of blood levels of 1,5-anhydroglucitol
75616785|NCT02837614|Drug|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
75616786|NCT02839486|Other|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
75616787|NCT02839486|Other|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
75651588|NCT00912639|Drug|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
76072544|NCT00527878|Drug|Placebo|
76072545|NCT01847209|Procedure|Video-Assisted Thoracic Surgery (VATS) wedge resection|
75317970|NCT00495079|Drug|Marqibo® (vincristine sulfate liposomes injection)|Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
75317971|NCT03024242|Device|Tight vaginoscope|
75317972|NCT00495157|Behavioral|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
75317973|NCT00495157|Behavioral|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
75616788|NCT05333536|Other|Experimental: Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of Upper Limb and Lower Limb with theraband ,10 reps each.Upper Limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower limb : Flexors of hip, Extensors of hip,Plantar flexors.
75616789|NCT05333536|Other|No Intervention: Control group|control only participates in their yearly swimming trainings.
75616790|NCT00879229|Drug|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
75616791|NCT00879229|Drug|Placebo|Placebo to match ambrisentan administered orally once daily.
75463463|NCT05592639|Procedure|Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy|Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.
75616792|NCT02837692|Drug|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
75463464|NCT05589077|Behavioral|Education on Female Athlete Nutritional Concerns|Visual and audio information presented within the Qualtrics system will cover topics on the Female Athlete Triad, Relative Energy Deficiency in Sport, and eating disorders.
75317974|NCT00495157|Behavioral|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
75317975|NCT03595748|Behavioral|Peer mentorship|Participants randomized to this arm of the study will speak with their dialysis peer mentor once a week about fluid intake and adherence to dialysis.
75463465|NCT05581160|Diagnostic Test|Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)|"Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form).~During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to:~Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices.~Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs.~The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique.~A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C."
75463466|NCT05578755|Behavioral|FutureU|"FutureU is based on the assumption that future orientation can be strengthened by increasing the extent to which people identify with their future self. People who identify more with their future self appear to be more inclined to make more altruistic choices favoring their future self and foregoing immediate gratification. The intervention provides psychoeducation and exposure to and interaction with the future self. Participants interact with a digitally aged version of themselves, i.e., their 'future self', using a smartphone application (app) or through immersive virtual reality (VR).~The app consists of three week-long modules. Participants interact with the app on a daily basis for about 5 minutes a day for 21 consecutive days.~The VR consists of three sessions, each lasting about 30 minutes. Each VR session is guided by a trained researcher."
75463467|NCT05578755|Behavioral|Goal-setting|In the control condition participants set goals (as in the intervention conditions), but receive no further guidance.
75463468|NCT05573620|Behavioral|ACT|"Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included 'The dreamed professional exercise' -variation on 'imagine your funeral exercise'-, Ship's captain metaphor, Imaginal exposure, Physicalizing exercise, and Watching thoughts as graffiti."
75463469|NCT05573620|Behavioral|In vivo exposure:|The audience was made up of university students. Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)
75616793|NCT02837692|Drug|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
75616794|NCT02837692|Drug|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
75616795|NCT02837692|Drug|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
75616796|NCT04249960|Behavioral|Managed transition|Young people, their family and clinicians will receive transition guidelines and will be asked to follow them as much as possible.
75616797|NCT04249570|Other|Povidone iodine|
75616798|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
75616799|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
75798314|NCT01283490|Device|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
75798315|NCT01283490|Device|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
75798316|NCT01283646|Drug|Apevitin BC|3.5 to 5 ml 3 times a daily
75798317|NCT01283646|Drug|Vitamin B Complex + Vitamin C|3.5 to 5 ml 3 times a daily
75341278|NCT05363228|Behavioral|Tai Chi|Tai Chi is based on somatic approach. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
75341279|NCT05547620|Device|LIFUS Online Real|Stimulation using NeuroFUS device while standing
75341280|NCT05547620|Device|LIFUS Online Sham|Stimulation using NeuroFUS device while standing
75798318|NCT01283724|Drug|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
75317976|NCT00539539|Other|Laerdal Q-CPR /technology|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
75616800|NCT02837770|Drug|Oral Diclofenac|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
75616801|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
75616802|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
75616803|NCT02837770|Drug|Artificial Tears|One drop Artificial Tears will be instilled 45' prior to the IVI.
75616804|NCT02837458|Device|High-Frequency|high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
75616805|NCT02837458|Device|Sham Stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
75616806|NCT00878995|Drug|Placebo Testosterone|Placebo (Saline) Testosterone given IM once per week.
75616807|NCT00878995|Drug|Testosterone Enanthate 100 MG/ML|Testosterone Enanthate 100mg/ml given once per week IM.
75616808|NCT02837536|Other|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
75909686|NCT04406961|Procedure|Endoscopic transpapillary antegrade sphincterotomy developed by Dr. Dovbenko.|Sph. Oddi consists of a longitudinal and circular smooth muscle layers. Circular muscle fibers form the pancreatic and duodenal parts. Anatomical justification was cutting of only the circular layer of sph Oddi by special sphincterotome. Papillary stenosis and stenosis terminal part of common bile duct due to damage only circular layer sph Oddi. Anterograde direction and hooked form of sphincterotome (endoscopic antegrade sphincterotomy- ASD) allows to capture only need layer and control depth. Also ASD was performed patient with SOD (I-III) with preservation of the longitudinal muscular layer sph Oddi and septum of papilla.
75936644|NCT03178604|Other|Classic massage|It involves applying the classic massage techniques: effleurage (gliding or sliding movement over the skin with a smooth continuous motion following the direction of the muscle fibers of the superficial muscles in a distal to proximal direction); petrissage (lifting, wringing, or squeezing of soft tissues in a kneading motion, or pressing or rolling of the tissues under or between the hands); tapotement (various parts of the hand striking the tissues at a fairly rapid rate). The general objective is to improve extensibility of muscle, tendon, fascia, joint capsule, and ligamentous structures.
75317977|NCT03596138|Other|Evaluate the reliability and reproductibility of the automated angular measurement by the Gazelab|Compare the results of the Gazelab to the alternate occlusion by prism bar (standard gold) examiners.
75463470|NCT05573620|Behavioral|Virtual Reality|"Virtual reality was delivered through Psious platform distributed in Spain by TEA and through a Virtual Reality equipment that included a Samsung S7 mobile and Samsung Gear VR glasses.~Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)"
75463471|NCT05572372|Behavioral|Acceptance and Commitment Therapy|The aim of the intervention was to increase psychological flexibility. Therapeutic methods focused on values clarification, cognitive defusion, self-as-context, acceptance, commited action and flexible attention to present moment.
75616809|NCT02837536|Other|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
75616810|NCT04250584|Device|iSlpr™|mandibular advancement device
75616811|NCT04250584|Device|SomnoDent® Classic|mandibular advancement device
75616812|NCT02837146|Biological|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
75616813|NCT02837146|Drug|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
75616814|NCT02837068|Device|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
75616815|NCT02837068|Device|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
75317978|NCT03977168|Procedure|Application of circumferential pelvic compression (CPC) device|Application of circumferential pelvic compression (CPC) device used at any time within 24 hours of injury
75616816|NCT02630875|Drug|A4250|A4250
75317979|NCT02982655|Procedure|Individualized BP lowering|
75317980|NCT03594188|Procedure|anesthetic methods|Patients will receive standard GA or LA for RF surgery.
75341281|NCT05547620|Device|LIFUS Offline|Stimulation using NeuroFUS device prior to standing
75341282|NCT05533580|Drug|Remimazolam|The experimental group was sedated with remimazolam.
75616817|NCT02837224|Device|The Situate Detection System|The Situate Detection System for locating surgical sponges
75616818|NCT00657865|Drug|ramipril|oral intake
75616819|NCT00657865|Drug|placebo|placebo
75616820|NCT00661765|Drug|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
75616821|NCT00661765|Drug|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
75616822|NCT02839252|Behavioral|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
75616823|NCT00657943|Drug|metformin|metformin tablets 2 g x 2
75616824|NCT00657943|Drug|insulin detemir|insulin as requested
75616825|NCT00657943|Drug|insulin aspart + insulin aspart protamin|insulin as requested
75616826|NCT00657943|Drug|Insulin aspart|insulin as requested
75616827|NCT02837380|Drug|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
75616828|NCT02837380|Drug|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
75616829|NCT02837302|Drug|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
75616830|NCT04249804|Drug|Magnesium Sulfate 1000 MG|intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
75616831|NCT02630797|Dietary Supplement|Blueberry Baseline|Before the study beginning, eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. A total of 150 days will be required for the equilibration of tracer in the body i.e. elimination from soft tissue and deposition in the bone. After equilibration, a baseline period of 42 days will occur, during which no blueberry products will be provided.
75616832|NCT02630797|Dietary Supplement|Blueberry Low|One food or beverage product containing freeze-dried blueberry powder equivalent to 0.75 cups of fresh blueberries will be provided daily for 42 days.
75616833|NCT02630797|Dietary Supplement|Blueberry Medium|Two food or beverage products containing freeze-dried blueberry powder equivalent to 1.5 cups of fresh blueberries will be provided daily for 42 days.
75616834|NCT02630797|Dietary Supplement|Blueberry High|Four food or beverage products containing freeze-dried blueberry powder equivalent to 3 cups of fresh blueberries will be provided daily for 42 days.
75616835|NCT02836834|Biological|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
75616836|NCT02631109|Drug|Pegaspargase|2000U/m2 day5
75616837|NCT02631109|Drug|doxorubicin|25mg/m2 day1
75463472|NCT05569018|Behavioral|Blended group transversal protocol (BLGr-TP)|It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,…) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
75463473|NCT05569018|Behavioral|Face-to-face group transversal protocol (FFGr-TP)|It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
75616838|NCT02631109|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
75616839|NCT02631109|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
75909687|NCT04406961|Device|The antegrade sphincterotome developed by Dr. Dovbenko.|A device is represented by a teflon catheter in the distal part of which a double tube of variable shape is created. The proximal part of the ASD sphincterotome consists of a handle, and a metal wire is located inside the teflon catheter for connection to an electrosurgical unit. On the distal part, the teflon catheter is formed of a double tube length is 10 to 35 mm. The metal wire exits the catheter at a distance 10 to 35 mm from the tip and enters into the tip the second teflon tube. The distal part of the knife is formed shape a hook. A metal cutting wire is located between two tubes. Moving the handle the metal wire is shifted. Pushing the metal wire or approaching in the distal part the second tube sets the depth of cut. The incision is made by moving on guidewire in bile duct. The power settings vary.
75936645|NCT03178604|Other|Sham massage|This group received a placebo intervention at the same time as the other group, maintaining only soft touch with the participant without exerting any mechanical pressure.
75936646|NCT03044249|Drug|MP-101|Capsules
75616840|NCT02839096|Drug|Placebo|Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
75616841|NCT02839096|Drug|Ferrous Sulfate|Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
75616842|NCT04156321|Dietary Supplement|Moringa fry|"School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm ."
75616843|NCT02838784|Other|Artacent Human Amniotic Membrane|Double layer dehydrated amnion product
75616844|NCT02838784|Procedure|Standard of Care|Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
75651589|NCT02866409|Procedure|scalp block|"In this group following nerves were blocked-~Supra-orbital nerve~Supra-trochlear nerve~Zygomatico-temporal nerve~Auriculo-temporal nerve~Posterior auricular branches of the greater auricular Nerve~The greater, lesser, and third occipital nerves"
75651590|NCT02866409|Procedure|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
75798319|NCT01586442|Drug|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
75616845|NCT02630485|Behavioral|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
75936647|NCT03044249|Drug|Placebo|Capsules
75936648|NCT02427308|Drug|Miltefosine|target dose = 2.5 mg/kg/day for 28 days
75936649|NCT03178292|Drug|Levofloxacin|Levofloxacin 500Mg daily for 5 days
75616846|NCT02630485|Dietary Supplement|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
75463474|NCT05563558|Drug|Pembrolizumab|Included in arm/group description
75463475|NCT05563558|Drug|Carboplatin|Included in arm/group description
75616847|NCT02630485|Drug|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
75616848|NCT00666133|Device|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
75616849|NCT04159363|Other|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
75616850|NCT02632513|Device|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
75616851|NCT00661843|Other|Integrated Yoga style practice|Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
75616852|NCT00879697|Behavioral|Walking Training|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
75616853|NCT00879697|Behavioral|Strength Training|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
75616854|NCT00894556|Drug|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
75616855|NCT00894556|Drug|Comparator: Placebo|Placebo to Rizatriptan
75616856|NCT00894556|Drug|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
75616857|NCT00666367|Drug|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
75616858|NCT00666367|Drug|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
75616859|NCT01210352|Drug|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
75616860|NCT00661921|Biological|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
75798320|NCT01586442|Drug|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
75463476|NCT05563558|Drug|Cabazitaxel|Included in arm/group description
75463477|NCT05557890|Behavioral|System Constellation VR-Seminar|individual-centered intervention in a group VR-setting, duration 2 to 3 days
75463478|NCT05557097|Diagnostic Test|Intrapartum sonography|Intrapartum ultrasound performed as an adjunct to clinical examination to assess fetal occiput position prior to performing vacuum delivery
75798321|NCT01587066|Drug|Quetiapine fumarate|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
75798322|NCT01587066|Drug|Divalproex sodium|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
75798323|NCT03873948|Other|Evaluation of arginine serum level|correlation of serum arginine level with periodontal and cardiovascular disease
75936650|NCT03178292|Drug|Placebo|Placebo Oral Tablet daily for 5 days
75341283|NCT05533580|Drug|Propofol|The control group was sedated with propofol.
75341284|NCT02998892|Behavioral|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
75341285|NCT02998892|Behavioral|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
75463479|NCT05545735|Drug|Standard of Care Antibiotic Therapy|Antibiotics will be administered as per the standard of care orally via tablet
75769632|NCT03885700|Behavioral|Educational program for 2 months|"The intervention was suggested based on the recommendations for adolescents' healthy diet and physical activity, it was derived from the 2008 Physical Activity Guidelines for Americans and Dietary Guidelines for Americans, 2010 by the U.S. HHS, Physical activity guidelines for children and adolescents by CPS 2012. The Food Guide Pyramid by the USDA, Nutrition &Healthy Eating by Mayo clinic & CDC website. The program was modified according to the age of the child. This plan was typically pursued in a School-based Intervention to Promote Healthy Lifestyles in Sousse, Tunisia, by Harrabi et al. The 1st month covered the healthy diet & the 2nd month covered the physical activity as follow:~1st & 5th week: A 60-minutesession in health education.~2nd & 6th week: Group counselling.~3rd & 7th week: Students were divided into 8 groups & each group was asked to make presentation about a task related to the topic.~4th & 8th week: Discussing the presentation."
75317981|NCT04407182|Dietary Supplement|Viusid and Asbrip|"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours plus standard care. Viusid and Asbrip will be administered orally.~Treatment duration: 21 days."
75616861|NCT00661921|Biological|Placebo|AMG 108 volume matching placebo
75317982|NCT04407338|Device|B-DYN|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
75616862|NCT04250506|Drug|Daridorexant|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
75616863|NCT04250506|Drug|Placebo|Placebo administered as tablets for oral use.
75616864|NCT04250506|Drug|Moxifloxacin|Moxifloxacin administered as film-coated tablets for oral use.
75769633|NCT01262170|Dietary Supplement|CigRx Lozenge|lozenge made of dietary supplements
75317983|NCT04407338|Device|Conventional Bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
75317984|NCT00539695|Biological|IL-2|"IL2 Administration:~Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT. If the patient has not developed >grade I side effects to IL-2 and has not developed >grade I GVHD then the patient may continue the IL-2 for 6 additional weeks. Time will be measured as 'week beginning with first IL-2 injection."
75317985|NCT03593954|Drug|JNJ-61393215|Participants will receive 2 oral administrations of 2 mg JNJ-61393215 as oral suspension.
75317986|NCT03593954|Drug|Ritonavir|Participants will receive 100 mg of ritonavir tablet orally.
75317987|NCT03593642|Drug|Continuous infusion of ropivacain in ESP catheter|administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
75317988|NCT03593642|Drug|Continuous infusion of Iso Saline in ESP catheter|administration of Iso Saline in ESP catheter to be the control group
75317989|NCT03590210|Drug|Trabectedin|Cycle 1 to 16 1.5mg/m² IV over 24 hours, q3w
75317990|NCT03590210|Drug|Nivolumab|Cycle 2 to 16 240 mg IV over 30 minutes, q3w
75341286|NCT05362604|Procedure|scheduled delivery at a tertiary center|Neonatal units in French hospitals are classified in three levels. The intention is for infants requiring high level care to receive it in a tertiary neonatal unit within the same network when appropriate. In case of known fetal gastro-intestinal artesia, the prenatal care includes obstetric consultation and level 3 ultrasound scheduled every four weeks at our unit until the end of the pregnancy, antenatal consultations with a specialized multidisciplinary team, and an antenatal visit of the birth center to reduce the parental anxiety.
75463480|NCT05544305|Other|Digital Home Based Care pathway|The digital version of the pathway includes an integrated data platform with an automated patient flow management system, digitised patient-reported outcome on web-based patient portal, and AI-based automated reporting for clinical decision support.
75463481|NCT05531994|Drug|Montelukast sodium oral thin films with water (T)|Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL
75769634|NCT01262170|Other|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
75769635|NCT00224874|Drug|Etanercept|Etanercept [25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks].
75769636|NCT00224874|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) [20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks].
75463482|NCT05531994|Drug|Montelukast sodium chewable tablets with water (R)|Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
75616865|NCT02836912|Other|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
75616866|NCT04158973|Other|Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge|At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
75616867|NCT04158973|Other|Routine VTE prophylaxis in hospital|Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
75616868|NCT02836678|Biological|Ridge splitting, immediate implant, Nanobone with PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~Alloplast bone graft material (Nanobone)~PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
75616869|NCT02836678|Biological|Ridge splitting, immediate implantand PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
75616870|NCT00662077|Drug|Ibandronate|Ibandronate endovenous 3 mg every 3 months
75616871|NCT00662077|Behavioral|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
75616872|NCT04250428|Behavioral|Demand intervention|"Women in the demand intervention arm will receive a home visit by a study nurse who will highlight the importance of supplementation and prophyllaxis to women. During this session, women will also be informed regarding side effects and the ideal timing of supplementation (after meals)."
75616873|NCT04250428|Behavioral|Supply intervention|In order to directly test the importance of access barriers, we will deliver supplements as well as malaria chemo- prophyllaxis directly to women through home visits by study nurses.
75616874|NCT01210118|Behavioral|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
75616875|NCT01210118|Behavioral|Higher intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
75616876|NCT00658099|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
75616877|NCT00658099|Drug|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
75616878|NCT00658177|Drug|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
75616879|NCT00658177|Drug|Placebo|Matching placebo
75616880|NCT02691104|Device|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
75909688|NCT04406961|Procedure|Endoscopic sphincterotomy.|Endoscopic standard sphincterotomy aims at opening bile duct or pancreatic duct by cutting the papilla and sphincter muscles. After deep bile duct cannulation, the standard sphincterotome is retracted until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary. The extent of the sphincterotomy is limited by the length of the intraduodenal portion of the common bile duct.
75909689|NCT04406961|Device|The standard sphincterotome.|"The standard sphincterotome, the Erlangen pull-type model, consists of a catheter containing a cautery wire exposed 15 to 25 mm near the tip of the instrument. The leading tip distal to the wire, the nose, is 5 to 10 mm in diameter. After deep bile duct cannulation, the sphincterotome is retracted slowly, until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made by lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary."
75769637|NCT00224874|Drug|Denileukin Diftitox|Denileukin Diftitox (ONTAK®) [9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19].
75769638|NCT00224874|Drug|Pentostatin|Pentostatin [1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
75616881|NCT02691104|Device|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
75463483|NCT05530148|Behavioral|Martial Arts Training Group|Participants in the experimental intervention group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, they will be instructed in the three exercises practiced in the experimental group, known as hubud, chi sau and padwork. Hubud is a turn-based, partnered, coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Chi Sau is a simultaneous contact drill from Chinese Kung Fu, specifically the Wing Chun school. Padwork is an amalgam of punching and kicking combinations used against focus pads or padded sticks to improve coordination, most commonly seen in kickboxing and Muay Thai. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of these exercises by the end of their participation in this intervention.
75616882|NCT00658255|Drug|budesonide/formoterol|
75769639|NCT03892330|Drug|Vincristine|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
75769640|NCT03892330|Drug|Oxytetracycline/ Cyclophosphamide|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
75769641|NCT03892330|Drug|Liposomal doxorubicin|The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
75769642|NCT03892330|Drug|Doxorubicin|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
75616883|NCT00658255|Drug|formoterol|
75651591|NCT02866409|Drug|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
75769643|NCT03892330|Drug|Pharmorubicin|The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
75769644|NCT03892330|Drug|Pirarubicin|The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
75317991|NCT03599960|Drug|Chemotherapy|"Idarubicin 12mg/m2 IV at D1~Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):~Patients <65y and albuminemia >35 g/l and CrCl (MDRD)>60 ml/min: 3000 mg/m²~Patients <65y and albuminemia <35 g/l and/or CrCl (MDRD) <60 ml/min: 1000 mg/m² IV~Patients ≥65y and albuminemia >35 g/l and CrCl (MDRD) > 60 ml/min : 1000 mg/m²~Patients ≥ 65y and albuminemia < 35 g/l and/or CrCl (MDRD) < 60 ml/min : 500 mg/m²~L-asparaginase (SPECTRILA) : 5000 units/m² IV at D2, 5, 8, 11 (switch to Erwinia asparaginase/Cirsantaspase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)"
75616884|NCT04158661|Procedure|thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)|preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
75317992|NCT03596372|Drug|BAY1834942|"Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part."
75317993|NCT05632328|Drug|AGEN1423|via IV, dosage per protocol, once every 2 weeks for up to 8 weeks
75616885|NCT04158661|Procedure|thymectomy by means of median sternotomy (transsternal)|with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
75616886|NCT04158661|Procedure|no thymectomy (control)|routine medical care
75616887|NCT01208870|Behavioral|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
75616888|NCT01208870|Behavioral|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
75616889|NCT02836210|Device|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
75769645|NCT03888118|Device|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
75616890|NCT04249102|Device|Guardian Connect, Medtronic|Guardian Connect is real-time continuous glucose sensor systems which provide glucose information updated every 5 minutes
75651592|NCT02866409|Drug|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
75769646|NCT00186186|Drug|Depakote ER|Depakote ER
75769647|NCT03892408|Device|Optiflow ™|supply of 100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) plus standard oxygen supply through rigid bronchoscope during apnea period.
75769648|NCT03969108|Drug|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
75769649|NCT03973944|Device|Cardiac resynchronization therapy|Atrio-biventricular pacing to shorten the prolonged PR interval
75317994|NCT05632328|Drug|Balstilimab|via IV, dosage per protocol, once evert 2 weeks, up to 2 years
75769650|NCT03885544|Other|Controlled Lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian (LOV) diet for 3 weeks. All foods will be provided to subjects during the intervention. Each subject's energy requirement will be estimated using sex-specific equations published by the Institute of Medicine for weight maintenance during the intervention.
75317995|NCT05632328|Drug|Gemcitabine|per standard care
75317996|NCT05632328|Drug|Nab-paclitaxel|per standard care
75463484|NCT05530148|Behavioral|Flexing, Toning and Balance|Participants in the active comparator group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, participants will start with a 5-minute warmup of basic joint mobilization exercises and dynamic stretching techniques. After this, participants will engage in a mild intensity circuit of exercises using resistance bands, bodyweight exercises and stability/balance exercises for approximately 50 minutes. The last 5 minutes of the session will be left for cooldown exercises and light stretching. Heartrate will be monitored regularly in order to prevent these exercises exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
75463485|NCT05528718|Drug|Nitrous oxide gas for inhalation|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
75769651|NCT03885544|Other|Controlled Unprocessed red meat diet|The unprocessed red meat diet will be the same as the LOV diet except that one 3-ounce portion of unprocessed red meat per day, 7 days per week (21 oz/wk) will be included. The unprocessed red meat will include beef tenderloin and pork loin. All foods will be provided to subjects during the intervention.
75769652|NCT03885544|Other|Controlled processed red meat diet|The processed red meat diet will be the same as the LOV diet except that one 3-ounce portion of processed red meat per day, 7 days per week (21 oz/wk) will be included. The processed red meat will include a variety of beef and pork luncheon meats with different methods of preservation. All foods will be provided to subjects during the intervention.
75769653|NCT00185640|Drug|Cyclosporine|Starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
75769654|NCT00185640|Drug|Anti-thymocyte globulin (ATG)|1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
75769655|NCT00185640|Drug|Mycophenolate mofetil (MMF)|Begins on day 0 after HCT at a dose of 15 mg/kg. Transplant recipients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
75769656|NCT00185640|Drug|Filgrastim|"Donors mobilized with 16 µg/kg/day filgrastim.~As needed, myelosuppression in transplant recipients will be managed with subcutaneous filgrastim 5 µg/kg/day"
75317997|NCT05632016|Procedure|erector spinae block (ESP)|the erector spinae plane block will be performed bilaterally using a high-frequency-curved ultrasound transducer (Mindray 35C50EB, China) placed in a longitudinal orientation 3 cm lateral to the spinous process at two different levels, one above the angle of kyphosis at T8- T10 and another below the angle of kyphosis at L3. An 8- cm 22-gauge block needle (EchoStim; Benlan Inc, Oakville, Canada) is inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane below erector spinae muscle, the block will be performed by injection of 10 mL of bupivacaine at each point.A total volume of 40 ml of diluted bupivacaine with a total dose of 3mg/kg with variable concentrations according to body weight will be given for each patient.
75616891|NCT04249102|Device|Abbott Diabetes Care|Abbott Diabetes Care is a Flash Glucose Monitoring system that provides up to 8 hours of retrospective continuous glucose monitoring data to users when the monitor is waved in proximity with the sensor.
75317998|NCT03593174|Device|Ossur Rigid Dressing|Removable Rigid Dressing
75317999|NCT03593174|Device|Elastic Bandage|Usual modality: Elastic bandage
75616892|NCT00658489|Behavioral|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
75341287|NCT05473286|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75616893|NCT02836288|Drug|Ketamine|Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.
75616894|NCT02836288|Other|Placebo|Placebo syrup will be given by mouth once a day for 12 weeks.
75616895|NCT02632435|Device|PICC|Participants will be randomized to a PICC for vascular access during chemotherapy.
75616896|NCT02632435|Device|PORT|Participants will be randomized to a PORT for vascular access during chemotherapy
75616897|NCT00658645|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
75616898|NCT00658645|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
75616899|NCT00658645|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
75616900|NCT02836132|Behavioral|Weight Watchers Online|
75616901|NCT02836132|Behavioral|Experience Success Virtual Reality Platform|
75616902|NCT01208402|Drug|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
75616903|NCT00633334|Other|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
75616904|NCT04248946|Other|Transcranial direct current stimulation|tDCS alters neural excitability in a polarity-specific manner via a weak direct electric current delivered through electrodes placed on the scalp. There are 3 types of stimulation: anodal, cathodal, and sham. In anodal tDCS, the positive electrode is placed over the target brain area to increase neuronal excitability. In cathodal tDCS, the negative electrode is placed over the target brain area to decrease neuronal excitability. Sham tDCS emulates the physical sensations of active (anodal/cathodal) tDCS but current is only delivered for a short period of time and is not enough to cause any neuromodulations
75616905|NCT01208324|Drug|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
75616906|NCT01208324|Drug|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
75616907|NCT01208324|Drug|Placebo Patch|placebo
75616908|NCT01208324|Drug|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
75651593|NCT04136925|Other|questionnaire|questionnaire before and after race
75769657|NCT00185640|Radiation|Total Lymphoid Irradiation (TLI)|0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
75769658|NCT03885388|Drug|MTX|multicourse methotrexate chemotherapy
75769659|NCT03885388|Drug|MTX+ACTD|combination use of methotrexate and actinomycin
75769660|NCT03973788|Procedure|repetitive transcranial magnetic stimulation (rTMS)|A single section of rTMS (2,000 pulses)
75769661|NCT03884686|Other|Web-based education resource|Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
75769662|NCT01152346|Drug|Azacitidine for Injection|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
75769663|NCT01152346|Drug|Vidaza®|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
75769664|NCT01260610|Drug|Tenofovir|300 mg of Tenofovir daily
75769665|NCT01260610|Drug|Telbivudine|600 mg of Telbivudine daily
75769666|NCT01260610|Drug|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
75463486|NCT05528718|Drug|Midazolam injection|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
75318000|NCT05631782|Drug|Shenkang decoction|Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
75318001|NCT03599882|Device|Fibroscan|Fibroscan with controlled attenuation parameter and transient elastography
75463487|NCT05528198|Drug|Montelukast sodium oral thin films without water (A)|Single-dose montelukast sodium oral thin film 5mg under fasted condition without water
75463488|NCT05528198|Drug|Montelukast sodium oral thin films with water (B)|Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL
75616909|NCT05333848|Behavioral|Internet-based storytelling programs with interactivity and stigma content|Participants viewed an interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
75616910|NCT05333848|Behavioral|Internet-based storytelling programs with stigma content only|Participants viewed a non-interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
75616911|NCT05333848|Behavioral|Internet-based storytelling programs with interactivity only|Participants viewed an interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
75769667|NCT01155622|Procedure|Endovascular Cooling|Infusion of <8°C cold saline followed by the implantation of the Icy 9.3F 38-cm catheter (ZOLL Medical Corporation, Chelmsford, MA) placed in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). Cooling was set at a maximum rate with a target temperature of 32°C or 34°C according to randomization.
75769668|NCT03885076|Procedure|Blood collection and bone marrow aspirate|Blood and bone marrow samples will be collected for the trial alongside routine tests.
75769669|NCT05477836|Device|MiWEndo-assisted colonoscopy|"All colonoscopies will be performed with high-definition technology. The MiWEndo System (MiWEndo Solutions, Barcelona) will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System.~At the beginning of the extubation, the MiWEndo System will be turned on. During extubation, each segment will be carefully examined with both white light and MiWEndo. In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
75798324|NCT01587144|Drug|Lucanthone|Lucanthone will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
75909690|NCT04929652|Drug|Surufatinib,Camrelizumab,Irinotecan,GM-CSF|"Dose climbing stage design (n=12) :~Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed > DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with > developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~Dose expansion phase design(n=36):~Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~Irinotecan: 200mg/㎡, iv, D1, 3w;~GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w."
75909691|NCT04929574|Diagnostic Test|Echocardiogram and Hematological Analysis|Echocardiogram and Hematological Analysis
75463489|NCT05528198|Drug|Montelukast sodium chewable tablets with water (C)|Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL
75463490|NCT05518474|Other|Self-proning|Rotating between lying flat with the chest down, on one's side or sitting up every 30 minutes to 2 hours when lying down during the day or while sleeping at night.
75909692|NCT04394949|Behavioral|Center for Independent Living SEEKS Team|Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
75909693|NCT04394949|Other|Usual Care|Consumers will get same CIL services they would get if they were not enrolled in the study.
75909694|NCT04929418|Other|10 km continuous running|Trial participants will perform a 10 km continuous running exercise
75463491|NCT05510596|Other|Magnetic Resonance Imaging with contrast injection|Magnetic Resonance Imaging with contrast injection
75463492|NCT05510596|Other|Blood withdrawal|Blood withdrawal : serum, plasma, cytokine assay
75463493|NCT05510596|Other|Neuropsychological tests|Neuropsychological tests
75463494|NCT05510206|Device|Leveling and alignment|"Polishing, Bonding of appliance, placement of the first arch wire for Super elastic NiTi group then the second wire after two months taking study model each month during the study For Smartarch Group placing experimental arch wire for 4 months , taking impression each month.~For both groups peri-apical X-Ray to lower anterior teeth is taken prior to treatment and 4 months later, also visual pain analogue scale is taken for 7 days after placing archwires"
75463495|NCT05498519|Drug|SY-4798|FGFR4 selective inhibitor
75616912|NCT05333848|Behavioral|Internet-based storytelling programs with no interactivity and no stigma content|Participants viewed a non-interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
75616913|NCT02838940|Procedure|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
75616914|NCT02838940|Drug|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
75318002|NCT03599726|Drug|Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
75318003|NCT03599726|Drug|Placebo|Placebo 5 mg per day for week 1-2 or 5-6
75616915|NCT00880399|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
75616916|NCT00880399|Other|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
75909695|NCT04929418|Other|1.5 km continuous swimming|Trial participants will perform a 1.5 km continuous swimming exercise.
75909696|NCT04929340|Other|Probiotic bacteria|The children are randomly allocated to a test or a control group with aid of computer-generated numbers at the time of consent. After the treatment, children in the test group are given 5 drops per day containing probiotic bacteria (Lactobacillus reuteri Protectis DSM 17938, Biogaia AB, Sweden) before bedtime. One dose consists of a minimum of 100 million live bacteria. Children in control group are given 5 drops per day (containing no bacteria).
75909697|NCT04929340|Other|Placebo|Children in control group are given 5 drops per day (containing no bacteria).
75318004|NCT03593096|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
75318005|NCT03593096|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
75463496|NCT05493605|Procedure|Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope|The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
75463497|NCT05471011|Other|Blood and nasal swab sampling|Blood and nasal swab sampling
75616917|NCT02835898|Other|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
75616918|NCT02835976|Drug|Olesoxime|Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
75769670|NCT03884764|Procedure|pulsed radiofrequency|patients with chronic pelvic pain due to chronic prostatitis will receive pulsed radiofrequency on sacral root number 3 and ganglion impar denervation and the patients will be followed for 6 months to assess pain severity radiofrequency procedure: patients will positioned prone on the operating table and under x-ray guidence sacral foramen number 3 will be identified and through it radiofrequency needle will be advanced to target the sacral root ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
75769671|NCT03884764|Procedure|ganglion impar denervation|patients with chronic pelvic pain due to chronic prostatitis will receive ganglion impar denervationand and the patients will be followed for 6 months to assess pain severity ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
75909698|NCT04929106|Device|mHealth support tool|The final app is named Active Leisure and consists of an advanced activity planner based on the platform developed by the ideal company Smart Cognition AS. The app offers different interface options (symbols only, easy to read text, plain text, and read aloud). The activity planner will mostly be used by the individual with IDs and a support person (caregiver or health care provider). After completing an activity, a simple reward is available (e.g., a smiling face or to share a picture with other users of the app). The use of tailored communication through personalization: the use of individuals first name in the activity planner, adaptation: individually chosen activities, adjusted communication (symbols, easy-to-read text or plain text), preparation and planning, and feedback: rewarding and positive feedback (after activities have been performed) is expected to increase motivation, and thereby lead to higher levels of PA.
75909699|NCT01353963|Drug|desvenlafaxine succinate|50 mg tablet once daily
75318006|NCT03592940|Dietary Supplement|Mediterranean diet|We aim to determine the effects of the traditional Mediterranean Diet on neuroendocrine tumours
75318007|NCT03592862|Drug|HTL0018318|Oral capsule
75616919|NCT02838706|Procedure|Surgery for hip fracture|
75616920|NCT02836054|Procedure|lumbar puncture (LP)|
75616921|NCT02836054|Procedure|brain MRI|
75616922|NCT02835742|Drug|Sargramostim|
75616923|NCT02835742|Drug|Placebo|
75616924|NCT05326360|Drug|Ramosetron Hydrochloride|we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
75616925|NCT00666523|Dietary Supplement|phytalgic|3/day
75616926|NCT00666523|Dietary Supplement|placebo|3/Day
75651594|NCT02867969|Other|Motor training|The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
75318008|NCT03592862|Drug|Placebo|Oral capsule
75318009|NCT03599570|Behavioral|STOP-HPV performance feedback intervention|This intervention will be the addition of performance feedback (in the presence of communication skills).
75318010|NCT03592784|Behavioral|Food Order Therapy|Instructing patient to, whenever possible, eat carbohydrates at the end of their meal.
75341288|NCT02129426|Drug|Ketamine|Sedation medication
75909700|NCT04928404|Procedure|tongue base suspension using barbed suture|all patients will undergo multi-level surgeries .Therefor, Anterolateral advancement pharyngeoplasty (ALA) or Barbed Reposition Pharyngoplasty (BRP) will be applied to improve retro-palatal obstruction and tongue base suspension using barbed suture for retro-lingual obstruction.
75909701|NCT04927936|Biological|Vaccination once with Janssen vaccine (only priming)|Vaccination (priming) with janssen vaccine. There is no boosting.
75909702|NCT04927936|Biological|Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.
75909703|NCT04927936|Biological|Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.
75909704|NCT04927936|Biological|Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.
75909705|NCT04928248|Other|Diabetes Dashboard integrated with Disease Manager App|The Diabetes Dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface. The Diabetes Dashboard is integrated within the diabetes module of the EHR-integrated Disease Manager App, which uses key information from the Diabetes Dashboard and provides a link to the Diabetes Dashboard.
75909706|NCT04167813|Drug|Ondansetron 8mg or matched placebo tablets|"Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase"
75769672|NCT03884842|Biological|Dupilumab/Dupixent|a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
75769673|NCT03884842|Biological|Placebo|Matched placebo
75769674|NCT01155700|Drug|omalizumab|
75909707|NCT04928638|Behavioral|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
75909708|NCT04928638|Behavioral|Written educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
75909709|NCT04928716|Other|voiding phase evaluation|Assessment of voiding phase in multiple sclerosis patients
75909710|NCT04928560|Diagnostic Test|SMI|ULTRASOUND
75318011|NCT03592784|Behavioral|Medical Nutrition Therapy|Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.
75318012|NCT00466817|Other|Placebo|9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
75318013|NCT00466817|Drug|Valganciclovir|Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
75318014|NCT03592706|Biological|IKC (Immune Killer Cells)|
75318015|NCT03592706|Procedure|TACE (Transcatheter Arterial Chemoembolization)|
75341289|NCT02129426|Drug|Midazolam|Sedation medication
75341290|NCT02129426|Drug|Dexmedetomidine|Sedation medication
75616927|NCT02838550|Behavioral|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
75341291|NCT01523821|Drug|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia] at various levels over different days
75341292|NCT01523899|Device|Xpert MRSA/SA SSTI|Use of Xpert MRSA/SA SSTI assay
75769675|NCT03892252|Other|No intervention|No intervention
75769676|NCT03887884|Drug|CVT-301|Levodopa Inhalation Powder
75769677|NCT03887884|Drug|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
75769678|NCT03887962|Device|Virtual Environment Biofeedback|Treadmill walking. Modified available technology for gait capture. Tailored software for virtual environment rendering and immersive qualities
75769679|NCT03887962|Device|Treadmill walking with no Virtual Environment Biofeedback|Treadmill walking. Flat screen / no virtual environment to act as attentional control.
75769680|NCT03892096|Diagnostic Test|Blood-based cell-free cfDNA qPCR assay|Up to 30mL of blood via venipuncture
75341293|NCT01523899|Diagnostic Test|Standard culture|
75616928|NCT02838550|Behavioral|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
75769681|NCT03892174|Other|Treatment protocol with adsorption|Adsorption while patients are in the OR on the extracorporeal circuit
75769682|NCT01262326|Other|Calorie and Carbohydrate Restriction|Carbohydrate Restriction = <20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
75769683|NCT01154530|Other|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
75769684|NCT03887572|Other|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
75909711|NCT03562533|Drug|pegylated liposomal doxorubicin (PLD) + carboplatin (CD)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
75909712|NCT03562533|Drug|carboplatin + paclitaxel (CP)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
75909713|NCT04927858|Drug|Empagliflozin|Empagliflozin
75616929|NCT00666601|Drug|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
75616930|NCT00666601|Drug|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
75616931|NCT01207388|Drug|Blinatumomab|Continuous intravenous infusion
75616932|NCT02835664|Dietary Supplement|Nicotinamide Riboside (Niagen)|
75909714|NCT03821727|Procedure|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive
75909715|NCT04927624|Procedure|transversus abdominis plane block|The transversus abdominis plane (TAP) block was first introduced by Rafi et al. in 2001 as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle. Since the thoracolumbar nerves originating from the T6 to L1 spinal roots run into this plane and supply sensory nerves to the anterolateral abdominal wall , the local anesthetic spread in this plane can block the neural afferents and provide analgesia to the anterolateral abdominal wall.
75909716|NCT04927624|Procedure|quoadratus lumborum block|quoadratus lumborum block
75909717|NCT02820597|Device|ClariFix device|
75909718|NCT04927546|Behavioral|Exercise|Thirty minutes of aerobic exercise in a treadmill.
75909719|NCT04927468|Procedure|supramaximal rectus recession|inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus
75909720|NCT04927468|Procedure|normal rectus recession|inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus
75909721|NCT03056716|Procedure|Silastic vs conventional drain in thoracic surgery|Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
75463498|NCT05460663|Behavioral|Stress Management and Resilience Training (SMART)|The Stress Management and Resilience Training (SMART) program was developed by Dr. Amit Sood. SMART focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. The SMART program incorporates practices that focus on six individual factors that have been found to promote individual-level resilience: positive coping, positive affect, positive thinking, realism, behavioral control, and altruism. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) or in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks.
75463499|NCT05458375|Drug|Estradiol vaginal cream|Insert pea-sized amount of vaginal estradiol cream into vagina nightly for first two weeks and then twice weekly thereafter.
75463500|NCT05446064|Behavioral|Stigma-reduction intervention|The intervention is modularized into four weekly 1-hour group sessions, led by a trained facilitator who provides psychoeducation to promote awareness and understanding of HIV stigma and teach CBT-based coping skills. Each group session will last 45-60 minutes. Participants are introduced to the general CBT model of HIV stigma and encouraged to track thoughts, feelings, and behavioral responses when encountering external stigma or adverse events. The participants further learn to differentiate effective and ineffective coping strategies and practice applying new coping skills to reduce internalized HIV stigma. The interventionist will follow the intervention manual to deliver the intervention and assign homework for group members to practice on their own. In the following sessions, the interventionist will review progress with participants, guide participants through exercises, and identify additional problems to be addressed in subsequent sessions.
75616933|NCT02835664|Dietary Supplement|Placebo|
75616934|NCT00666913|Other|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
75616935|NCT02838472|Drug|Ascorbic Acid|Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
75616936|NCT00666991|Drug|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
75616937|NCT02835430|Procedure|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
75769685|NCT05077852|Diagnostic Test|Urethrocystoscopy|Patients diagnosed with a primary bladder cancer at the base, trigone or neck of the bladder with USG in the urology clinic will be evaluated with urethrocystoscopy. With urethrocystoscopy, patients definitive diagnosed with bladder cancer and IPP.
75769686|NCT03887416|Drug|Dapagliflozin 10 MG Oral Tablet [Farxiga]|"The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
75769687|NCT03887416|Drug|Placebo Oral Tablet|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
75769688|NCT01260766|Device|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
75769689|NCT01260766|Device|Placebo Patch|same as active patch
75909722|NCT03056560|Behavioral|TakeCARE (video bystander program)|brief video encouraging active responses to high-risk situations for campus violence
75909723|NCT04927000|Drug|Tofacitinib|in tofacitinib treatment group，we added tofacitinib 5mg/BID in the basic treatment in all subjects.
75909724|NCT02822235|Other|No Intervention|
75909725|NCT04927078|Other|Observation of breathing pattern|Observations will be collected using a remote vision based patient monitoring and management system.
75909726|NCT04926532|Drug|Toripalimab|Toripalimab is a humanized anti-PD-1 monoclonal antibody
75769690|NCT01155856|Other|Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital|For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
75463501|NCT05444725|Other|Stage of Decision Making|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
75616938|NCT02835430|Procedure|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
75616939|NCT02835508|Drug|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
75616940|NCT02835508|Drug|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
75616941|NCT02835508|Drug|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
75909727|NCT04926532|Drug|Sorafenib|Sorafenib is a multi-kinase inhibitor
75909728|NCT04925674|Drug|HEC53856|"The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting."
75909729|NCT04925596|Behavioral|ePrimaPrescribe online educational program|online training program aiming to change general practitioners' benzodiazepine prescription
75909730|NCT04925596|Behavioral|ComunicaSaudeMental online educational program|online training program aiming to improve general practitioners' communication with mentally ill patients
75909731|NCT02035995|Other|Pregnant volunteers with GDM|
75909732|NCT04925518|Device|Closed Loop Mechanical Ventilation|Closed loop ventilation mode (Intellivent-ASV+®). Intellivent-ASV+® was initiated by activating the controllers for minute volume, PEEP (range 5 to 18 cmH2O) and fraction of inspired oxygen (FiO2) (range 21 to 100 %). The target shift ranges for CO2-management were set between -2.5 and +2.5 kPa, and for O2-management between -2 and +2 %.
75463502|NCT05444725|Other|Choice framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
75616942|NCT02838394|Procedure|Dry needling|Acupuncture filiform needles are inserted into myofascial trigger points
75616943|NCT02838394|Other|Sham dry needling|Blunted needles will be pressed against the skin, but no actual penetration will occur
75769691|NCT03891940|Procedure|patients recieving anterior cervical spine surgery|Anterior cervical discectomy with fusion, or ACDF, is a surgery designed to relieve spinal cord or nerve root pressure in the neck by removing all or part of a damaged disc
75463503|NCT05444725|Other|Opportunity Framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
75463504|NCT05420584|Procedure|Arterial chemoembolization|The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.
75463505|NCT05420584|Drug|Tislelizumab Injection|Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.
75463506|NCT05420584|Drug|XELOX|Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.
75769692|NCT01260844|Drug|briakinumab|single dose briakinumab and 2 doses of CYP substrates
75769693|NCT03891472|Drug|Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.|mFOLFIRINOX > SBRT > mFOLFIRINOX > Surgical Intervention
75616944|NCT00667147|Drug|Weekly Abraxane and Daily Vandetanib|Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
75616945|NCT00667147|Drug|Abraxane every three weeks and daily vandetanib|Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
75616946|NCT02835586|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
75651595|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3"
75651596|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3"
75651597|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6"
75769694|NCT03887494|Device|Implantation|Implantation of Y-Strut + cementoplasty in the femoral neck
75769695|NCT01154608|Drug|Creon|
75318016|NCT04406870|Drug|Sirolimus Oral Product|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks <30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
75341294|NCT05409716|Procedure|Compressive Elastic dressing for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, compressive elastic dressing, standardized as 13 threads gauze overlapped, opened, longitudinally pleated once and wrapped, making a 5-cm long cylinder, 1-cm in height, fixed with elastic crepe bandage was used to achieve hemostasis.
75616947|NCT04154215|Diagnostic Test|PET-CT FDG brain scan|"Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated."
75616948|NCT00911521|Drug|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
75616949|NCT02835352|Other|Essential oils massages|
75616950|NCT02835352|Other|Oil massages|
75616951|NCT02630407|Biological|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
75616952|NCT02630407|Other|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
75616953|NCT04248790|Behavioral|mobile app to improve adherence to PrEP self-management|Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
75463507|NCT05420584|Diagnostic Test|Pelvic MRI|Pelvic MRI to evaluate efficacy
75463508|NCT05420584|Procedure|Laparoscopic radical resection of rectal cancer|Surgical treatment for patients who meet the surgical conditions
75463509|NCT05416580|Drug|UDCA (Ursodeoxycholic acid)|UDCA is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
75463510|NCT05416580|Drug|Placebo|Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
75463511|NCT05416580|Drug|Metformin|Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.
75463512|NCT05414318|Device|Conformable GORE® TAG® Thoracic Endoprosthesis|Thoracic Endoprosthesis
75463513|NCT05414071|Device|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
75463514|NCT05413629|Other|Web-based patient education for the intrauterine insemination (IUI) treatment process|Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.
75616954|NCT00667303|Other|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
75616955|NCT00667303|Other|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
75616956|NCT00667303|Other|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
75616957|NCT02838238|Drug|Capecitabine|
75616958|NCT02838238|Drug|Placebo|
75616959|NCT00667537|Drug|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
75769696|NCT01154608|Other|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
75769697|NCT01262482|Drug|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
75769698|NCT01262482|Drug|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
75769699|NCT01261078|Drug|Placebo|intrathecal 8 mg of bupivacaine only
75463515|NCT05412511|Behavioral|MB-TB|Training exercises with throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
75463516|NCT05412511|Behavioral|MB-NTB|Training exercises without throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
75769700|NCT01261078|Drug|epinephrine 25|intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
75616960|NCT02835040|Other|New model of service delivery|Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
75463517|NCT05401578|Drug|Canakinumab|Canakinumab (Ilaris®, Novartis Switzerland) will be used in the recommended standard dose of 150 mg subcutaneously once. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
75769701|NCT01261078|Drug|Epinephrine 50|intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
75318017|NCT04406870|Drug|propranolol|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks <30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
75616961|NCT02835040|Other|Current practice|Interventions as determined by the treating General Medical team consistent with current usual practice.
75616962|NCT00667771|Drug|Naltrexone|
75616963|NCT01206764|Drug|RAD001|
75616964|NCT04248400|Other|Tai Chi training|A 24 weeks Tai Chi training with three 1-hour section per week
75616965|NCT04248400|Other|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
75616966|NCT00667927|Drug|Busulfan|See Detailed Description section for description of treatment plan.
75616967|NCT00667927|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
75616968|NCT00667927|Drug|Mesna|See Detailed Description section for description of treatment plan.
75616969|NCT02835118|Drug|Surotomycin|Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
75616970|NCT02835118|Drug|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
75616971|NCT00668005|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
75769702|NCT01261078|Drug|epinephrine 100|intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
75769703|NCT01261078|Drug|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
75769704|NCT03884218|Other|Infra red thermal imaging|thermal image using a non-touch, non-ionising, thermal camera system
75463518|NCT05401578|Drug|Placebo (0.9% NaCl)|1 ml 0.9 % saline solution s.c. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
75318018|NCT03592628|Other|Visual Aid|The visual aid was a one-sheet diagram with illustrations of important features of post-cesarean wound care.
75318019|NCT03592628|Other|Standard Instructions|Standard discharge instructions WITHOUT supplement of visual aid.
75318020|NCT03592550|Device|Ultrasound imaging|Abdominal ultrasound imaging of the liver
75318021|NCT03592394|Device|Immersive Virtual Reality (Gear VR)|Immersing the user in a total visual environment.
75318022|NCT03985514|Drug|Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).|Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
75318023|NCT03985514|Other|Active observation|In-hospital observation without antibiotics
75616972|NCT00668005|Drug|Placebo|Matching placebo
75616973|NCT02835196|Device|Optical Elastography|To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.
75616974|NCT02835196|Other|Visual Assessment|Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness
75616975|NCT05333692|Dietary Supplement|Fresubin® Protein Energy DRINK|1-2 bottles of Fresubin® Protein Energy DRINK per day
75616976|NCT05333692|Dietary Supplement|NEPRO® , Abbott|2-4 cans NEPRO® per day
75616977|NCT04154137|Other|Questionnaire|Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
75616978|NCT00668161|Behavioral|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
75616979|NCT00668239|Drug|intravitreous triamcinolone|Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent
75616980|NCT00668239|Procedure|laser therapy|pan fotocoaglulation by laser therapy
75769705|NCT01155934|Drug|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
75769706|NCT03891628|Behavioral|Modified Attachment and Biobehavioral Catch-up|Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
75769707|NCT03891628|Behavioral|Modified Developmental Education for Families|Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
75769708|NCT03891550|Drug|Epclusa|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks for all HCV genotype patients with and without hepatic decompensation
75616981|NCT00658801|Radiation|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:~Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.~Group 2: 5cm <Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
75463519|NCT05391542|Other|aligning archwires|At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.
75909733|NCT04925518|Device|Conventional Mechanical Ventilation|Mechanical ventilation with a conventional mode, usually either biphasic positive airway pressure ventilation (DuoPAP®) or adaptive support ventilation (ASV®)
75616982|NCT04156009|Other|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
75318024|NCT00540007|Drug|Lenalidomide|
75616983|NCT04156009|Other|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
75318025|NCT03592316|Other|Lower Extremity Amputation Pathway|"Pre-operatively: Subjects will meet with social work/case management, physical therapy, anesthesiology, and the prosthetist for the following: discuss expectations and rehabilitation; pain control options and consideration for epidural or nerve block; prosthetic treatment and care timeline.~Post-operatively: Physical therapy will begin on post-op day 1 with increasing complexity through post-op day 3. On post-op day 3 the wound will be examined by the surgeon and subjects will be cleared for discharge.~Quality of life surveys will be given at several time points during post-operative care."
75318026|NCT02982889|Drug|LIQ865A bupivacaine formulation|single subcutaneous injection in medial calf
75463520|NCT05391334|Device|Qumea|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
75463521|NCT05387161|Other|Nutritional intervention|The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative ungrammatical daily diet plan, which must be followed for the entire period of intervention (6 months).
75463522|NCT05385406|Diagnostic Test|HPV genotyping|Genotyping will be obtained by the Xpert system which uses 5 color channels containing primers and probes for the detection of specific genotypes or pooled results as follows: i) HPV 16, ii) HPV 18/45 in pooled result, iii) HPV types 31, 33, 35 52, or 58, in pooled result, iv) HPV types 51 or 59, in pooled result, and v) HPV types 39, 56, 66 or 68 in pooled result.
75616984|NCT02631499|Procedure|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
75616985|NCT02631499|Drug|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
75616986|NCT02631499|Drug|lipiodol|lipiodol is a kind of embolization material used in TACE
75616987|NCT00662233|Drug|cyclophosphamide|
75616988|NCT00662233|Drug|doxorubicin hydrochloride|
75616989|NCT00662233|Drug|etoposide|
75616990|NCT00662233|Drug|ifosfamide|
75616991|NCT00662233|Drug|vincristine sulfate|
75616992|NCT00662233|Procedure|adjuvant therapy|
75616993|NCT00662233|Procedure|neoadjuvant therapy|
75616994|NCT00662233|Procedure|therapeutic conventional surgery|
75616995|NCT00662233|Radiation|brachytherapy|
75616996|NCT00662233|Radiation|intraoperative radiation therapy|
75616997|NCT00662233|Radiation|radiation therapy|
75616998|NCT04156243|Biological|CD19 CARvac T cells|CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
75616999|NCT00668629|Drug|Lactic acid (Dermacid)|
75617000|NCT02630173|Procedure|Scaling and root planing|Scaling and root planing was done in both the groups
75617001|NCT02630173|Other|Endodontic treatment|In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
75617002|NCT02632357|Other|Spinal Manipulation|
75617003|NCT00658957|Drug|gentamicin-collagen sponge|5 × 5 cm sponge
75617004|NCT00658957|Drug|placebo collagen sponge|5 × 5 cm sponge
75617005|NCT00662467|Drug|aspirin + clopidogrel|Dual therapy
75769709|NCT01152658|Biological|PRGF|enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
75769710|NCT01152658|Other|NACL|Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
75769711|NCT01261156|Drug|E5555 100 mg and diltiazem|E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
75769712|NCT01261156|Drug|E5555 300 mg and diltiazem|E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
75769713|NCT03884530|Drug|Ticagrelor (Brilique) 90|Drug name Brilique 90 ml Drug form tablet
75769714|NCT03884530|Drug|Aspirin 75mg|Drug name Aspirin 75 ml Drug form tablet
75617006|NCT00662467|Drug|aspirin + clopidogrel + warfarin|Triple therapy
75617007|NCT00668941|Drug|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
75617008|NCT00668941|Drug|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
75617009|NCT00668941|Dietary Supplement|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
75909734|NCT04925362|Other|Biological specimens|"Biological specimens are collected to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis :~added for the research : blood, urine, stools~collected for the research : liver tissue sample, if a liver biopsy is indicated for clinical reasons (standard of care)"
75318027|NCT02982889|Drug|LIQ865B bupivacaine formulation|single subcutaneous injection in medial calf
75909735|NCT04925362|Other|Additional visit|Visits if possible during standard care, otherwise added by the research (If necessary the annual visit will be added by research for the collection of biological samples)
75909736|NCT04924894|Other|no intervention|no intervention
75909737|NCT03842709|Drug|Pramipexole Oral Tablet|Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
75318028|NCT02982889|Drug|Diluent for LIQ865|Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
75318029|NCT02982889|Drug|0.5% bupivacaine hydrochoride|single subcutaneous injection
75318030|NCT03599258|Device|Skylife|Newly FDA approved device
75318031|NCT03599258|Device|Standard Therapy|Both devices are considered standard therapy
75463523|NCT05385406|Diagnostic Test|Visual inspection after application of acetic acid|"After application of acetic acid and Lugol's iodine, the cervix will be assessed using simplified ABCD criteria (A= acetowhite lesion within the transformation zone, B = spontaneous bleeding or upon slight touch, C (optional) = Lugol-positive coloring of acetowhite lesions, D = diameter > 5mm of acetowhite lesion)."
75463524|NCT05377463|Behavioral|Peer support to promote uptake and persistence of medication assisted treatment (MAT)|Participants will be assigned to receive peer support to promote uptake of MAT and persistence. This component will consist of two informational sessions, a tailored recovery plan, and on-going support from a peer for the first 6 months.
75463525|NCT05377463|Behavioral|Behavioral Activation Treatment (BAT) to reduce depression|Participants will be assigned to receive BAT treatment for depression. This component will consist of 8 sessions where participants will identify short and long-term goals, values, and the activities unrelated to substance use that were previously enjoyed or are likely to increase a feeling of well-being. This intervention component focuses on making a plan to troubleshoot barriers to re-engage in these activities. Sessions are delivered weekly. The content includes psycho-education about what depression is, the intervention rationale, and the activities and monitoring of activities, building social contracts to engage networks, and discussion of potential barriers to following through with activities.
75463526|NCT05377463|Behavioral|Patient Navigation to promote linkage and engagement in HIV care|Participants will be assigned to receive patient navigation services. A patient navigator will provide information about the process of obtaining HIV care and provide instrumental support to access care as needed for six months. The navigator will assist with obtaining government sponsored insurance if the participant does not have employer sponsored insurance, including processing needed documents, monetary resources, transportation and clerical support to obtain required documents, such as state ID and birth certificates. Navigators will meet with participants to go over what to expect during their clinic appointment and explain in lay terms medical terminology likely to be discussed by providers to facilitate patient-provider interaction. Other instrumental support provided will be scheduling appointments, providing clean clothing, a place to shower, and transportation to attend medical appointments.
75463527|NCT05377463|Behavioral|Life Steps educational and skill building session to promote adherence to HIV medication|Participants assigned to this component will participate in a single session that includes one follow-up phone-call or visit. Participants will be exposed to cognitive-behavioral techniques and will learn about the importance of HIV treatment and the strategies and skills needed to take HIV treatment as prescribed. The session consists of strategies for problem solving transportation barriers, skills to improve communication with providers, strategies for dealing with side-effects, reminder cues, and managing lapses.
75463528|NCT05365815|Behavioral|Melanated Group Midwifery Care|Racially concordant maternity care Group prenatal care Racially concordant nursing care coordination Postpartum doula support
75617010|NCT00668941|Dietary Supplement|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
75617011|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
75617012|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
75617013|NCT00894322|Other|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
75769715|NCT05477680|Device|Navigation-guided surgery|Surgeon removes brain lesions and assesses brain shift with neuronavigation
75769716|NCT03887338|Other|Transnasal Fiberoptic Laryngoscopy|Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.
75769717|NCT03884062|Drug|DAAs|lab, U/S, Fibroscan & CT if needed
75769718|NCT03891316|Diagnostic Test|HFIP and Sevoflurane are measured after 3 consecutive days of work.|Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography
75769719|NCT03887260|Drug|Morphine PCA pump|Morphine given postoperatively.
75769720|NCT03887260|Procedure|ESP block|Regional anaesthesia technique performed under ultrasound guidance before surgery
75318032|NCT03599180|Device|microdialysis|Use microdialysis skill to collect dialyzate at sensitization acupoints
75318033|NCT03984344|Device|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
75318034|NCT03984344|Device|Continuous Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
75318035|NCT03984344|Device|Sham Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
75318036|NCT03592160|Other|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
75318037|NCT04194164|Other|Fluid intake app|Monitor fluid intake and interdialytic weight gain in patients using the fluid app
75318038|NCT00499447|Procedure|radiofrequency ablation|
75463529|NCT05365607|Device|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
75463530|NCT05365607|Device|Sham NightWare|NightWare device will not deliver an intervention (i.e., no vibration)
75909738|NCT03842709|Other|Placebo|Administration of placebo
75909739|NCT04924816|Procedure|Awake prone position|The prone position in awake patients consists of asking the patient to voluntarily change to prone position, in a swimmer's posture
75909740|NCT05707533|Procedure|TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique|The Transvaginal mesh procedure with Vaginal Adventitia Reserved and Anatomical Implant Technique for the treatment of POP. The Cefoxitin Injection Solution was used for Prophylactic antibiotics
75909741|NCT03056482|Drug|Ondansetron 8mg|Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
75909742|NCT03056482|Drug|Haloperidol 0.05mg/kg|Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
76072546|NCT05558878|Drug|Ambroxol Oral Product|"Drug: Ambroxol (75 mg capsule)~Ambroxol is a mucolytic and expectorant drug. Ambroxol has been approved as lozenges for topical analgesia of sore throat in pharyngitis owing to its local anesthetic properties. Anti-inflammatory properties of ambroxol were confirmed by numerous studies. Ambroxol affect neuronal transduction by blocking (TTX)-resistant Na+ channels (Nav1.8) in small (pain-sensing) dorsal root ganglion neurons more potently than TTX-sensitive channels."
75463531|NCT05361980|Device|Pediatric orthopaedic implant|Patient receives a pediatric orthopaedic implant as a part of standard clinical care.
75463532|NCT05360849|Behavioral|Practice Facilitation|Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs
76072547|NCT01846741|Device|M106 VNS Therapy System|
76072548|NCT05621590|Drug|MLC 901|MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
75318039|NCT00499447|Radiation|radiation therapy|
75769721|NCT03887260|Drug|Fentanyl|Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
75769722|NCT03891004|Procedure|Subcuticular Skin Closure|We will only close the subcuticular layer with suture
75318040|NCT03592082|Drug|Bismuth Subsalicylate|BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
75769723|NCT03891004|Device|Tissue Adhesives|No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
75769724|NCT03891082|Procedure|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
75318041|NCT03592082|Drug|standard antibiotic therapy|antibiotic therapy administered per standard protocol
75318042|NCT03592004|Other|neoadjuvant chemotherapy|neoadjuvant chemotherapy
75909743|NCT03056482|Drug|Haloperidol 0.1mg/kg|Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
75909744|NCT02817555|Drug|Epoetin Alfa|"The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin > 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
75318043|NCT00499915|Behavioral|Secondhand Smoke Reduction and Smoking Cessation Counseling|A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
75909745|NCT02817555|Drug|Darbepoetin alfa|"The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin >150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
76072549|NCT05621590|Drug|Placebo|placebo capsules filled with stevia sweetened powder
75318044|NCT00499915|Behavioral|Asthma Education|Asthma education will be provided at NICU discharge.
75318045|NCT03591926|Drug|SM04646|"Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week."
75318046|NCT03250195|Diagnostic Test|PET/MRI|PET/MRI scan
75463533|NCT05357547|Drug|Buspirone 20mg|Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism
75463534|NCT05357547|Drug|Placebo comparator|Lactose-sucrose tablets in opaque capsule
75463535|NCT05344833|Drug|Isatuximab|Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.
75463536|NCT05344833|Drug|Lenalidomide|Lenalidomide 15mg PO Days 1-28 Cycle 4 and can continue until disease progression.
75463537|NCT05342090|Other|Structured Counselling Tool|Participants will be administered a Structured Counselling Tool that addresses the following themes: outside influences, conflicting emotions, uncertainty, sexual changes and stability, normalization, self-image
75463538|NCT05339100|Drug|Anifrolumab|Participants will receive SC doses anifrolumab via AI or APFS.
75463539|NCT05339100|Device|Autoinjector|Autoinjector will be use to administer single SC dose of anifrolumab.
75463540|NCT05339100|Device|Accessorized Pre-Filled Syringe|Accessorized Pre-filled syringe will be use to administer single SC dose of anifrolumab.
75909746|NCT04924738|Behavioral|Monitoring and lifestyle|Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
76072550|NCT05554042|Diagnostic Test|Kintsugi Voice Device|The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
75463541|NCT05337514|Behavioral|Enhanced Engagement|EngAGE will allow care partners send older adults encouragement which will be read aloud to the older adult through the EngAGE app.
75463542|NCT05337514|Behavioral|Standard Engagement|Care partners can encourage their older adult partner using traditional / existing communication mechanisms.
75463543|NCT05327153|Behavioral|Acceptance and Commitment Therapy|The theoretical foundation of ACT is Relational Frame Theory (RFT) based on the functional contextualism philosophy, which suggests that the main psychological problem derived verbal and cognitive interaction with environment, leading to behaviors contrary to long-term values and psychological inflexibility. The psychopathological model of ACT includes six core parts: experiential avoidance, cognitive fusion, attachment to the conceptualized self, conceptualized past and feared future, lack of value clarity, inaction.
75617014|NCT02631265|Other|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
75617015|NCT02631265|Other|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
75617016|NCT02631265|Other|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
75617017|NCT00662623|Behavioral|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
75617018|NCT00662623|Behavioral|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
75617019|NCT00669097|Drug|TKI258|
75617020|NCT00633412|Drug|Esomeprazole|20mg oral daily
75617021|NCT00633412|Drug|Ranitidine|150mg oral twice daily
75617022|NCT00633412|Drug|Esomeprazole|40mg oral tablet daily
75769725|NCT03891082|Procedure|BALLOON INSERTION|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
75769726|NCT01154686|Behavioral|Cogmed|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. Training is implemented with a software program (RoboMemo©). It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
75769727|NCT03883984|Drug|Cysteamine Bitartrate|Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
75769728|NCT03883984|Drug|Placebo Oral Tablet|Placebo administered for 8 weeks. 125mg tablet QID.
75909747|NCT04924192|Drug|TQB3616 capsules|A CDK4/6 kinase inhibitor
75463544|NCT05323838|Behavioral|Subjective quality of live|The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.
75463545|NCT05323838|Procedure|Blood extraction|Blood collection by qualified personnel.
75617023|NCT00596635|Dietary Supplement|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
75617024|NCT00596635|Dietary Supplement|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
75617025|NCT00659113|Drug|cisplatin|
75617026|NCT00659113|Drug|tegafur-gimeracil-oteracil potassium|
75909748|NCT04924192|Drug|Anlotinib Hydrochloride capsules|A multi-target receptor tyrosine kinase inhibitor
75617027|NCT00659113|Other|cytology specimen collection procedure|
75909749|NCT04924192|Drug|Irinotecan Hydrochloride for Injection|An inhibitor of DNA topoisomerase Ⅰ
75909750|NCT02036073|Drug|recombinant human erythropoietin|rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
75617028|NCT00659113|Procedure|endoscopic biopsy|
75617029|NCT00662701|Procedure|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
75617030|NCT00662701|Procedure|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
75909751|NCT03793803|Behavioral|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
75909752|NCT04924426|Procedure|TTC immersion|TTC immersion
75909753|NCT02036229|Drug|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
75909754|NCT03056404|Other|additional blood sample|
75617031|NCT04159051|Device|Regional Hyperthermia|Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
75617032|NCT00662779|Drug|arformoterol|15 mcg arformoterol nebulizer
75909755|NCT03056404|Other|respiratory functional exploration|
75909756|NCT02817087|Device|repetitive Transcranial Magnetic Stimulation -On|Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain
75909757|NCT02817087|Device|repetitive Transcranial Magnetic Stimulation -Off|Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.
75909758|NCT02036307|Dietary Supplement|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
75909759|NCT02036307|Dietary Supplement|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
75909760|NCT03056326|Drug|CHF6333 (Part 1 - SAD)|Single doses of CHF6333 at each period
75909761|NCT03056326|Drug|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6333 at each period
75769729|NCT03886870|Behavioral|Lifestyle and work intervention|"The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes."
76072551|NCT05621434|Drug|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
76072552|NCT05621356|Other|A nasal fluid Basophil Activation Test (BAT)|a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
76072553|NCT01870843|Drug|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
75463546|NCT05323838|Behavioral|Accelerometry|To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique
75463547|NCT05323838|Dietary Supplement|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
75909762|NCT03056326|Drug|CHF6333 (Part 2 - MAD)|once daily multiple doses of CHF6333 for 14 days
75909763|NCT03056326|Drug|Placebo (Part 2 - MAD)|once daily multiple doses of placebo matching CHF6333 for 14 days
75909764|NCT03056170|Device|real tDCS|"In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code."
75463548|NCT05302999|Drug|Gabapentin|Generic gabapentin
75463549|NCT05302999|Drug|Placebo|Inert cellulose
75617033|NCT00662779|Drug|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
75909765|NCT04923022|Other|Vegan Diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
75617034|NCT00662779|Drug|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
75617035|NCT00669253|Procedure|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
75617036|NCT00669253|Procedure|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
75909766|NCT04923022|Other|Therapeutic exercise|Individuals in the therapeutic exercise group will perform therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
76072554|NCT01797952|Drug|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
76072555|NCT01797952|Other|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
75909767|NCT04923490|Behavioral|state and trait anxiety scale levels|"While the STAI-I anxiety level is scored as (1) never, (2) somewhat, (3) frequently, and (4) almost always, the scoring options in STAI-II are (1) almost never, (2) sometimes, (3) most of the time, and (4) almost always."
75909768|NCT02813577|Device|Lutonix® 035 Drug Coated Balloon PTA Catheter|Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
75909769|NCT04922788|Biological|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant
75909770|NCT04922788|Biological|Placebo|0,5 mg Aluminum adjuvant
75617037|NCT00669253|Procedure|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
75617038|NCT02630329|Procedure|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
75617039|NCT02630329|Procedure|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
75617040|NCT00911599|Diagnostic Test|Blood metal ion levels|Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
75617041|NCT00662935|Procedure|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
75617042|NCT02630095|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
75617043|NCT02630095|Device|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
75617044|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
75617045|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
75617046|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
75617047|NCT00669565|Drug|Bavituximab|Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
75617048|NCT00669643|Drug|PB 6 doses - Rifampicin and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone"
75617049|NCT00669643|Drug|PB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
75617050|NCT00669643|Drug|MB 12 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
75617051|NCT00669643|Drug|MB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
75617052|NCT00669721|Drug|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
75617053|NCT00669721|Drug|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
75617054|NCT00669799|Drug|gentamyacin|topical internasal
75617055|NCT00669799|Drug|gentamyacin|intranasal
75617056|NCT04158505|Other|non-interventional|This prospective, observational study will be conducted according to each site's routine clinical practice
75909771|NCT02815293|Drug|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
75909772|NCT02815293|Drug|Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
75909773|NCT04922398|Biological|platelet rich plasma|blood will be withdrawn from the patient then separation of the platelet rich layer and then injection in the ovary
75318047|NCT03591848|Behavioral|Online support decision tool|Online support decision tool, in addition of the standard oral information
75318048|NCT03591848|Behavioral|standard oral information|standard oral information
75318049|NCT03599102|Behavioral|LOVED Intervention|
75318050|NCT03598868|Drug|Vortioxetine|Augmentation : Vortioxetine 10 mg p.o. for week 1, Vortioxetine 5-20 mg p.o. for week 2,4,6.
75318051|NCT03598868|Drug|Placebo|Augmentation : Placebo for week 1,2,4,6
75318052|NCT03591692|Procedure|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
75909774|NCT04922398|Drug|Normal saline|0.9% normal saline will be injected in each ovary
75936295|NCT03186092|Other|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
75936296|NCT03186092|Other|sham muscle training|sham comparator
75909775|NCT04922086|Procedure|Conventional aesthetic crown lengthening surgery|The demarcation of the gingival zenith final position will be done on the teeth using a periodontal probe. This demarcation will be done through visual examination based on the crown length/width ratio and the position of the cemento-enamel junction (CEJ). The gingival margin of the central and canine incisors will be positioned at similar heights and a more coronal gingival contour will be determined for the lateral incisors. An internal bevel incision will be made with a blade on each tooth, preserving the interdental papillae. The incised gingival tissue will be removed using a periodontal curette in both groups. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). Carbide drills and manual chisels will be used for bone resection to obtained a CEJ-BC distance of 3 mm. Simple interproximal interrupted sutures will be performed.
75769730|NCT03886870|Behavioral|Lifestyle intervention|"The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home."
75769731|NCT03890926|Radiation|radioactive Iodine-125 seed implantation under the guidance of 3D template|3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
75769732|NCT03883672|Behavioral|Personality and transactional factors|"Pre-admission transplant questionnaire: given and collected by the transplant physician during the pre-graft consultation before entering hospitalization (approximatively 15 days before). To be completed by the patient on site (approximately 45 minutes to complete the questionnaire)~Transplant admission questionnaire: given during the first days of hospitalization. To be completed within 6 days and returned to the transplant physician (approximately 30 minutes to complete the questionnaire)~Post-transplant follow-up questionnaire: given in consultation at 6 months by the transplant physician (between 30 and 45 minutes to complete the questionnaire in consultation)"
75769733|NCT01586494|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
75769734|NCT01586494|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
75769735|NCT03886948|Drug|LY3074828|Administered subcutaneously (SC)
75769736|NCT03886948|Device|PFS|PFS used to administer LY3074828
75617057|NCT00659347|Drug|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
75909776|NCT04922086|Procedure|Guided dual aesthetic crown lengthening surgery|The double guide will be positioned and an internal bevel incision on each tooth will be made following the guide demarcation. After the initial incision, the incised gingival tissue will be removed using a periodontal curette. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). The dual guide will be positioned again and the bone tissue will be removed using carbide drills and manual chisels following the double guide. No interproximal crestal bone will be removed. Simple interproximal interrupted sutures will be performed to stabilize the flap.
75909777|NCT02813421|Device|CGM Informed|
75909778|NCT04922008|Drug|capecitabine and trastuzumab|In IRIS-C cohort, patients who met the inclusion criteria(ER and PR<10%, T≤2cm or ER and/or PR ≥10% 1cm<T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
75909779|NCT04922008|Drug|vinorelbine and trastuzumab|In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR<10%, T≤2cm or ER and/or PR ≥10% 1cm<T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
75617058|NCT00659347|Drug|Placebo|Capsules,25 mg,BID,6weeks
75617059|NCT00894166|Drug|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
75617060|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
75651598|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6"
75769737|NCT03886948|Device|AI|AI used to administer LY3074828
75769738|NCT02527330|Other|MR T2* imaging|Cardiac magnetic resonance imaging with T2* imaging
75769739|NCT01259362|Procedure|Transcranial Magnetic Stimulation|5 Hz, 120 % motor threshold, intertrain interval 20s, number of pulses in train 50.
75769740|NCT01259362|Procedure|Transcranial Magnetic Stimulation|Cocaine addicted will receive 20 sham TMSr
75769741|NCT03886792|Behavioral|Triggered reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
75463550|NCT05298865|Behavioral|Positive imagination stimulation|The intervention messages aim to generate participants' positive mental image toward their life and also to relieve parental stress by shifting their attention to positive life events. The positive affect cues will be developed based on qualitative interviews with 30 parents from our previous study during pandemic and also extended literatures on positive psychology. Our previous qualitative interview aimed to understand parental concerns on flu and COVID-19 vaccination, parental life stressors throughout the pandemic were also explored. The positive cues will be discussed and evaluated by the research team with an aim to cover major positive life events that are personal relevant to parents, including positive social support (friendship), positive family support (family gathering), qualified time spent with children (here we will also embed a gratitude practice to elicit strong positive feelings), and cultivate positive self by imagining achieving personal goals in the future.
75617061|NCT00894166|Drug|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
75617062|NCT00894166|Drug|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
75617063|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
75769742|NCT03886792|Behavioral|Social interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
75909780|NCT03056092|Drug|Intravitreal ranibizumab|Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done
75909781|NCT04921852|Procedure|costoclavicular brachial plexus block|A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.
75909782|NCT04921852|Procedure|lateral sagittal infraclavicular block|A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
75909783|NCT04921540|Procedure|Ingrown toenails with surgery with chemical cauterisation|Removal of the ingrown lateral part of the toenail and chemical cauterisation
75909784|NCT04921540|Procedure|Ingrown toenails with only surgery|Removal of the ingrown lateral part of the toenail with directed Healing pad
75909785|NCT04921306|Drug|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
75909786|NCT04921306|Drug|Placebo|Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
75909787|NCT04921462|Procedure|Septoplasty surgery|septoplasty procedures were performed by a single surgeon using the same technique among all patients. The procedures were conducted under general anesthesia according to the standard preoperative care used in our institution.
75769743|NCT03684070|Behavioral|Self-Monitoring, peer support and motivational prompts|The intervention compares the effect of technologically delivered motivational messages, and peer support upon daily step counts.
75909788|NCT04921150|Other|standardization management|Apply standardization management to improve the outcomes of pregnancy
75909789|NCT04920760|Dietary Supplement|Vitamin A supplement|The supplementation protocol will be the additional care established by World Health Organization (WHO) and the United Nations International Children ʹs Fund (UNICEF) for measles (1998)(i.e. of 200,000 IU, or 50,000-100,000 IU for children > 1 or for infants of < 1 year of age, respectively).
75909790|NCT03056248|Drug|Placebo oral capsule|On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
75909791|NCT03056248|Drug|Lithium Carbonate|On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
75909792|NCT04920604|Other|Face-to-face anesthesia consultation|The anesthesia consultation is carried out in person in accordance with the usual management.
75909793|NCT04920604|Other|Remote anesthesia consultation|"Anesthesia consultation is carried out in teleconsultation via the Téléo web application (audio and video) at the patient's home on a computer or smartphone. This application allows sending and receiving documents identical to those during the face-to-face consultation."
75463551|NCT05298865|Behavioral|Neutral recall message|The control message aims to equate time and attention as in the intervention group. Therefore, a recall task will be assigned to participants. Brief texts will be provided to guide participants to memorize their life senarios but not to induce emotions. Messages include the following: recall the breakfast and lunch you had yesterday; recall the clothes and shoes you wore yesterday; recall the kitchen in your home; recall one of the chairs in your home; recall the routes to the nearest supermarket and subway of your house.
75463552|NCT05298150|Other|Dynamic cycling|The dynamic cycling involves smart bike that changes according to participants' performance.
75909794|NCT04920526|Drug|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|No intervention will be administered
75769744|NCT03684070|Behavioral|Self-monitoring|Self-monitoring of data from wearable step count tracker
75769745|NCT03891238|Drug|Avelumab|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
75909795|NCT04920448|Drug|N-Acetyl cysteine|Administered as specified in the treatment arm
75909796|NCT04969900|Other|Placebo oil|The placebo group will receive placebo oil.
75909797|NCT04969900|Other|Lavender oil.|Investigational Product. This group will receive Lavender oil.
75909798|NCT04969666|Drug|IPED2015|Active treatment
75909799|NCT04969666|Drug|Placebo|Placebo
75463553|NCT05298150|Other|Forced cycling|The same smart bike as used for dynamic cycling, but its adaptive capacity will be disabled. In this case, the bike will behave as standard exercise stationary bike. It will not change its performance according to participants' response.
75318053|NCT03591692|Procedure|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
75318054|NCT00501631|Drug|VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
75463554|NCT05297500|Device|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-12)
75769746|NCT01261234|Drug|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
75769747|NCT01152736|Drug|Nicotine|2 mg Single-dose
75463555|NCT05295797|Behavioral|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
75463556|NCT05291520|Biological|VH3810109|VH3810109 will be administered.
75463557|NCT05291520|Biological|rHuPH20|rHuPH20 will be administered.
75769748|NCT01262794|Biological|CDP6038|100 mg/mL solution for injection, single dose
75769749|NCT01262794|Biological|Placebo|0.9% sodium chloride for injection Single-dose
75909800|NCT04969744|Device|ICE|Intermittent Cooling Exposure using cooling garment for 1-2 hours
75909801|NCT04969588|Diagnostic Test|Microsoft Azure Kinect Developer Kit|3D images and 3D joint coordinates are obtained.
75909802|NCT04969588|Diagnostic Test|Bioelectrical impedance analyzer|Fat mass, fat-free mass and percentage body fat in total body and body segments are estimated.
75463558|NCT05285306|Behavioral|PEACE Program|This pilot will consist of 3 individual telemedicine sessions to teach cognitive behavioral coping skills and provide education related to gynecologic cancer surveillance and psychological distress.
75617064|NCT00894166|Drug|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
75617065|NCT00894166|Drug|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
75617066|NCT00880165|Device|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
75769750|NCT03883438|Procedure|Modified coronally advanced flap and acellular dermal matrix graft|Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
75769751|NCT01261468|Device|Active SCS|SCS IPG activated
75769752|NCT01261468|Device|Deactivated|SCS IPG deactivated
75318055|NCT00501631|Drug|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
75318056|NCT05631704|Drug|VH4524184|VH4524184 will be administered.
75318057|NCT05631704|Drug|Midazolam|Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
75318058|NCT05631704|Drug|Placebo|Placebo will be administered.
75318059|NCT01887067|Procedure|Renal denervation therapy|
75617067|NCT02834650|Other|Cardiac MRI with contrast|Cardiac MRI
75617068|NCT02834650|Other|Cardiac MRI without contrast|Cardiac MRI
75617069|NCT02834650|Other|Blood Test|Hematocrit, Creatinine, Troponin, BNP
75617070|NCT02834650|Other|Heart Rate|Holter Monitor
75769753|NCT01262950|Other|portable motion detector|
75318060|NCT03591536|Other|Pentoxifylline|400 mg pentoxifylline oral tablet from 3 days before surgery and on the day of surgery
75318061|NCT03591536|Other|Placebo|oral placebo tablets from 3 days before surgery and on the day of surgery
75617071|NCT02834650|Other|Pulmonary Function Test|Pulmonary Function Test
75617072|NCT02834650|Other|Genetic Testing|Genetic Testing
75617073|NCT02834650|Other|Repeat MRI scan|Repeat MRI scan
75617074|NCT04032223|Procedure|Implant placemet in the mandibular canine regions|Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
75617075|NCT00659503|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
75617076|NCT00659503|Drug|Placebo|placebo
75909803|NCT04969588|Diagnostic Test|Dual Energy X-ray Absorptiometry|Skeletal length and body composition are estimated.
75909804|NCT04432168|Procedure|Fetoscopic Laser Surgery|Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.
75769754|NCT03890848|Behavioral|Wechat application reminder intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
75909805|NCT04432168|Other|Standard Treatment|"In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease.~Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week.~IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia.~PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia.~Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation."
75909806|NCT04969354|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.
75909807|NCT04969432|Other|Client-centered|Rehabilitation
75909808|NCT04969042|Device|Pins Medical G122 RS|G122RS model implanted spinal cord stimulation device, which could give closed-loop functional stimulation in the epidural space
75463559|NCT05271006|Behavioral|Exercise|The mHealth platform to be used by the exercise group is Down Dog, which has a suite of apps for yoga, HIIT, barre, and running workouts. Down Dog has agreed to provide free memberships for one year to all participants in the study. To ensure participant de-identification on the Down Dog platform, each participant will receive a Participant ID which will be pre-registered by the study coordinator on the Down Dog platform. Randomized participants will be provided instructions for downloading the apps onto their phone or a link to the website to be used on their computer. Following randomization, participants in the exercise group will be asked to engage in physical activity (using any if the Down Dog apps), 4 days a week for 20 minutes a day for 12 weeks.
75463560|NCT05265806|Drug|Intranasal oxytocin|Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).
75463561|NCT05265806|Drug|Oral oxytocin|Each subject will be assigned to administration of oxytocin lingual spray (24 IU).
75909809|NCT04968730|Other|Postoperative rehabilitation nursing|Make postoperative rehabilitation plan according to nursing experience for group A Develop rehabilitation process according to the activity plan for group B
75909810|NCT04968262|Other|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis and sedation. Blood and urine samples were collected at the intensive care unit from this patient group at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. 24 patients were documented without sepsis and acute kidney injury as a control group.
75909811|NCT04968262|Other|Sepsis-related acute kidney injury therapy|Patient management of sepsis and sepsis-related acute kidney injury followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis, sedation and renal replacement therapy (if needed). In this patient group, blood and urine sampling was performed at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up.
75909812|NCT03061006|Drug|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL > 15 to 30 mL/min); Assessment of kidney function every 6 months.
75909813|NCT03061006|Drug|Warfarin|Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
75909814|NCT03060928|Procedure|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
75909815|NCT03060928|Procedure|Micro-perforations|Biological stimulation with micro-perforations
75909816|NCT03060928|Procedure|Artelon®|Biological stimulation with Artelon® Tissue Reinforcement
75909817|NCT03061240|Device|Smart pain assessment tool|We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
75463562|NCT05265806|Drug|Placebo|An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
75617077|NCT04248556|Other|Health care product|Health care product (gel) - to be applied on the participant's skin
75617078|NCT00663013|Other|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
75617079|NCT02834728|Behavioral|telephone interview|
75617080|NCT04158193|Other|acupuncture|Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
75769755|NCT03890848|Behavioral|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
75769756|NCT03890692|Procedure|flexible nasoendoscopy|"nasopharyngeal endoscopy : After washing nasal cavities with a sterile physiologic solution to remove secretions or scabs, and decongesting them with an oxymetazoline solution in the subjects with turbinate hypertrophy,~Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\ septum\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists"
75769757|NCT01259518|Drug|TRIN2755|In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
75769758|NCT01259518|Drug|TRIN2755|In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
75769759|NCT01156168|Genetic|DNA analysis|
75769760|NCT01156168|Genetic|gene expression analysis|
75909818|NCT03055702|Other|Mobile phone text message reminder|an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
75909819|NCT04980274|Other|Intervention focused on identified organ dysfunction(s)|Intervention focused on identified organ dysfunction(s)
75909820|NCT04920214|Diagnostic Test|SonoVue|CEUS examination was performed and corresponding image information of liver lesions was obtained.
75463563|NCT05256238|Other|comprehensive supervised exercise program (CSEP)|"The CSEP starts as soon as possible after cancer diagnosis and lasts for 12 weeks:~week 1-6 (during cancer treatment): 2 supervised sessions at the exercise room of the University Hospital Leuven in connection to the radiotherapy treatment session and one additional session at home. Patients will receive equipment to perform the program at home, e.g. weights, therabands,…~week 7-12 (after cancer treatment): 1 supervised session at the exercise room of University Hospital Leuven in connection to the follow-up consultations (once a week) with the oncologist and two additional sessions at home~maintenance program (from week 13), patients will exercise at home with a monthly teleconsultation"
75909821|NCT04919902|Procedure|Electric cardioversion|Electric cardioversion in short sedation according to established clinical practice and indications
75463564|NCT05255081|Device|Adspray|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
75617081|NCT04158193|Other|sham acupuncture|"Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks."
75769761|NCT01156168|Genetic|polymorphism analysis|
75909822|NCT04967794|Other|Teleorientation and Tooth Brushing Orientation|Guide children in toothbrushing with a preventive purpose during the COVID-19 pandemic
75909823|NCT04967638|Procedure|tumor resection and mandible reconstruction|The patients who underwent primary ablative tumor resection with segmental mandibulectomy and immediate VFF reconstruction were retrieved from the database
75909824|NCT04919746|Other|Systemic acupuncture|Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.
75909825|NCT04980196|Diagnostic Test|urodynaemic studies|The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
75463565|NCT05255081|Procedure|Placebo-control|Spray with saline would be applied to organs under incision
75463566|NCT05243017|Genetic|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
75463567|NCT05242419|Drug|Sodium Chloride Injection|0.9% Sodium Chloride Injection
75463568|NCT05242419|Drug|Huperzine A Injection|Huperzine A Injection
75617082|NCT02834572|Behavioral|All About Me|Assessment and algorithm to determine recommended HIV testing approach
75617083|NCT02834572|Behavioral|Control|HIV testing information
75769762|NCT01156168|Genetic|protein expression analysis|
75769763|NCT01156168|Other|immunohistochemistry staining method|
75769764|NCT01156168|Other|laboratory biomarker analysis|
75769765|NCT01261546|Drug|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~Ranitidine 5 mg/kg IV, q.d. for 2 days~Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
75769766|NCT01261546|Drug|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~Ranitidine 5 mg/kg IV, q.d. for 2 days.~Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
75769767|NCT03883360|Drug|Cannabidiol (CBD)|Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
75769768|NCT03883360|Drug|Placebo|Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
75769769|NCT01261702|Drug|Placebo|Normal saline IV
75463569|NCT05241301|Other|one to one interviews|one to one interviews to explore the perspective of family carers of older adults of Turkish and Moroccan origin in Flanders and Brussels, Belgium, concerning advance care planning (ACP)
75463570|NCT05232227|Drug|Primaquine double dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets
75463571|NCT05232227|Drug|Primaquine single dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US
75617084|NCT04158115|Other|Entire Spine Mobilization|8 sessions of Following: -Entire Spinal Mobilization of all spinal segment from C0 to C1 to L5 to S1 (10 reps × 3 sets), - Moist heat: 10 to 15 minutes, - Soft tissue Mobilization, - Exercises : (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
75769770|NCT01261702|Drug|magnesium sulphate|The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
75769771|NCT01156246|Drug|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
75769772|NCT03890770|Drug|BMS-986165|Oral administration
75909826|NCT04980118|Behavioral|Control group|A nutritional intervention program that consisted of two individual nutritional consults.
75909827|NCT04980118|Behavioral|Nutrition and physical activity group|A nutritional and physical activity intervention program that consisted of two individual nutritional consults and five nutritional group lectures.
75909828|NCT03672188|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
75909829|NCT03672188|Drug|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection
75909830|NCT04980352|Other|real world treatment by doctors|real world treatment by doctors
75909831|NCT04919668|Behavioral|Simulated grocery shopping exercise|Participants will click a link and simulate an online grocery shopping experience by selecting items for 12 grocery categories.
75909832|NCT04919434|Other|IRECO|During 5 days, women included in the study will have to only use personal care product distributed by the research team.
75909833|NCT03060694|Other|diabetes|"a history of diabetes and using anti-diabetic medicines.~fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%."
75909834|NCT03239990|Behavioral|Incredible Years, Parent group supported by home visiting|Parents are taught to use positive and consistent strategies in reducing child misbehavior
75909835|NCT03060850|Drug|AC0010MA|Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
75909836|NCT04432558|Diagnostic Test|Spielberger's State-Trait Anxiety Inventory|Patients will be wanted to fill the Spielberger's State-Trait Anxiety Inventory the night before the surgery.
75909837|NCT04432558|Other|Visual analog scale, Ramsay's sedation scale|The analgesic consumption of the patients will be recorded by evaluating the pain with VAS (Visual analog scale) and sedation status with Ramsay's sedation scale in the 1st, 4th, 12th and 24th hour of postoperative period.
75909838|NCT04432558|Drug|Tramadol, paracetamol, diclofenac sodium|The analgesic consumption of the patients will be recorded
75909839|NCT04770428|Drug|MEDI7352|A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.
75909840|NCT04770428|Drug|Placebo|Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
75909841|NCT04919278|Procedure|Chiropractic adjustments|Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body's physical function.
75909842|NCT04979650|Drug|Methylprednisolone succinate|1 gram of methylprednisolone succinate within 500 ccs of normal saline
75909843|NCT04979650|Drug|Normal saline|500 g of normal saline without methylprednisolone succinate
75909844|NCT04919044|Other|Motor Imagery Training|The number of imagined contractions were 34 trials, each trial was 10 seconds with 5seconds rest between each trial and 2 minutes' rest was given after first 17 trials.
75909845|NCT04919200|Diagnostic Test|the single-breath helium dilution method and Whole-body plethysmography|The patients with obstructive lung disease simultaneously subjected to the single-breath helium dilution method and Whole-body plethysmography tests.
75909846|NCT04967716|Other|basic information|Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
75909847|NCT04967716|Other|venous blood test|The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation. No fasting is required before blood draw, and there is no time limit. Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital. The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
75909848|NCT04703738|Procedure|Soft tissue flap + Connective Tissue Graft|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.
75909849|NCT04703738|Device|Soft tissue flap + Geistlich Fibro-Gide®|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.
75909850|NCT04967404|Dietary Supplement|Phosphatidylserine|800 mg per day for 10 days
75936297|NCT03522285|Other|investigation: erythrocyte sedimentation rate|investigations will be done to detect presence of infection and x-ray also for detection of infection or loosing of hip components
75463572|NCT05225363|Biological|Chimeric Antigen Receptor T-cells|Receive TAG72-CAR T cells IP
75617085|NCT04158115|Other|Segmental Mobilization|"8 sessions of following -Segmental Mobilization: All lumbar segment from L1 to L2 to L5 to S1 (10 reps × 3 sets) - Moist heat: (10 to 15 minutes), -Soft tissue Mobilization~- Exercises: (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)"
75463573|NCT05225363|Drug|Cyclophosphamide|Given IV
75463574|NCT05225363|Drug|Fludarabine|Given IV
75463575|NCT05221229|Drug|Liraglutide plus upstream risk factors modification advice and consultation|Patients will be on treatment with daily injections of Liraglutide for a total of 65 weeks. During initial consultation for AF ablation, patients' BMI, risk factors status and baseline blood tests were performed and reviewed. Then the patients were discussed and encouraged to achieve optimal goal of risk factors modifications by non pharmacological and pharmacological measures.
75769773|NCT03890302|Drug|FB704A|Administered by IV infusion
75769774|NCT03890302|Drug|Placebo|Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
75769775|NCT03886480|Device|SaeboVR|Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
75769776|NCT01261858|Device|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
75769777|NCT03886636|Other|neuroscience pain education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week, before an MT session. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, one-on-one sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
75769778|NCT03886636|Other|manual therapy|In our study, Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
75769779|NCT03886636|Other|home exercises|All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
75769780|NCT03886402|Device|GID SVF-2|Treatment of erectile dysfunction with the subjects own cells
75769781|NCT03883204|Drug|Aripiprazole|Initial dose: 10 mg.
75769782|NCT03883204|Drug|Risperidone|Initial dose: 2 mg.
75769783|NCT03890380|Device|Magneto Wire|Patients will be treated with Magneto Wire
75769784|NCT03890458|Drug|DEVIT-3|The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
75909851|NCT04650152|Drug|Tricor (fenofibrate), 145 mg, film-coated tablet|Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
75909852|NCT04967950|Drug|Secukinumab 300 MG|Secukinumab 150 mg s.c. with loading dose at baseline, week 1,2,3,4 and then every 4 weeks from week 5 up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, Secukinumab 150 mg will be with a switch to 300 mg.
75909853|NCT04967950|Drug|Secukinumab 150 MG|Methotrexate 15 mg po. every week up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, methotrexate with a switch to Secukinumab 150 mg at 12 weeks.
75909854|NCT04967950|Drug|Methotrexate|methotrexate
75909855|NCT04967326|Drug|Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)|
75909856|NCT03145142|Procedure|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
75909857|NCT03145142|Procedure|Delayed Cord Clamping|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
75909858|NCT03062176|Drug|Anakinra|Anakinra (Kineret)
75909859|NCT03472820|Other|Diet Recommendations|Specific dietary guidelines will be outlined for participants.
75909860|NCT03472820|Other|Lifestyle Recommendations|Participants are encouraged to average a minimum of 7 hours of sleep per night.
75909861|NCT03472820|Other|Exercise Recommendations|Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
75909862|NCT03472820|Other|Stress Management Recommendations|Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
75909863|NCT03472820|Other|PhytoGanix (tropical fruit flavor)|Organic Superfruits & Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
75936298|NCT02436278|Other|4MGS|Usual walking speed measured over 4 metres
75769785|NCT01156324|Behavioral|Online Stress Management Group (Upliv)|Personalized online stress management program
75769786|NCT01156324|Behavioral|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
75769787|NCT01155076|Dietary Supplement|Vitality Product|Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
75769788|NCT01155076|Dietary Supplement|Placebo|Placebo taken twice a day for 8 weeks
75769789|NCT01263418|Drug|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
75769790|NCT03882814|Drug|pethidine|Pethidine 50 mg intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. Opioid analgesia (pethidine HCl - 50 mg I.M.) was given following amniotomy.
75769791|NCT03882814|Drug|Placebo - Concentrate|Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
75909864|NCT03472820|Other|UltraFlora Intensive Care|Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
75909865|NCT04967014|Drug|HIP2101|Test drug
75463576|NCT05215587|Device|TEVAR|A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
75909866|NCT04967014|Drug|RLD2101|Reference drug
75909867|NCT03055286|Drug|CWP232291|"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
75909868|NCT03470948|Other|Observe postoperative complications|The aim of this study is to confirm the utility of a 10-point Surgical Apgar Score to rate surgical outcomes in Whipples procedure in patients with pancreatic cancer.
75909869|NCT04918498|Behavioral|early physiotherapy programs|establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy
75909870|NCT04918498|Behavioral|routine treatment|provide routine nursing and rehabilitation program
75463577|NCT05211700|Other|This is an observational study, there is no intervention in this study.|There is no intervention in this study
75769792|NCT03886558|Other|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months.|The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
75769793|NCT01156402|Behavioral|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
75909871|NCT02915432|Biological|3 mg/kg anti-PD-1 mAb JS001 Q2W|"This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment."
75909872|NCT02915432|Biological|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
75318062|NCT03598712|Device|Compression by chest bandage urgo K2®|"- Installation of a short stretch belt (urgo K2® kit)~- Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~- Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device"
75769794|NCT03890224|Device|home ventilators|The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
75769795|NCT03889990|Device|IQOS|"Smoke IQOS"
75909873|NCT02915432|Biological|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
75318063|NCT03598712|Procedure|punctures|Every 7 days after the second puncture of a volume > 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
75318064|NCT00501943|Drug|Avonex (Interferon beta 1a)|
75318065|NCT00501943|Drug|Riluzole|
75318066|NCT00501943|Drug|Placebo|
75617086|NCT00670189|Drug|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
75651599|NCT05834010|Biological|Fecal Microbiome Transplant|Fecal matter from healthy age/sex matched established and screened donors, recruited from the Danish Blood-donor system
75318067|NCT03598634|Procedure|administration of riboflavin for epi-off cross-linking|riboflavin 0.1% in 20% dextran solution
75463578|NCT05211063|Dietary Supplement|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
75463579|NCT05211063|Dietary Supplement|Placebo|Daily intake of one tablet for 42 days.
75463580|NCT05210231|Other|Transcranial Direct Current Stimulation|The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
75463581|NCT05203120|Radiation|Proton therapy|All patients will receive proton therapy 67.5Gy/15fx
75909874|NCT03062098|Device|ultrasound imaging|Ultrasound imaging during embryo transfer using a small vaginal probe.
75909875|NCT02178332|Other|Yhteispeli, whole school programme|
75909876|NCT02178332|Other|Two theoretical lectures|
75909877|NCT02620384|Drug|Experimental: Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
75909878|NCT02620384|Drug|Experimental: Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
75909879|NCT03470870|Other|Comparative analysis of the characteristics|"Predictive nomogram of short-term hospitalization (less than two days after surgery)~Factors influencing the variations of average stay lenght~Morbidity of the ERAS program"
75909880|NCT04918576|Drug|Tranexamic acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
75909881|NCT04918576|Drug|Normal Saline|40 mL topical of 0.9% normal saline
75909882|NCT04214756|Procedure|Acute Pancreatitis|All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
75909883|NCT04403308|Biological|ONO-7913|ONO-7913 will be administered by intravenous continuous infusion during the designated time.
75909884|NCT02523170|Device|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
75909885|NCT03472508|Drug|Folic Acid|Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
75909886|NCT03472508|Drug|Enalapril Maleate and Folic Acid Tablets (Yiye)|Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
75909887|NCT03472508|Drug|Enalapril|Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
75909888|NCT04966780|Procedure|acute abdominal surgery|Acute surgery for acute abdominal disease
75617087|NCT00663091|Drug|Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
75617088|NCT00663091|Drug|WPP-201 Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
75909889|NCT03470792|Device|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
75909890|NCT04966936|Other|questionnaires for clinical assessments|Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)
75909891|NCT04966936|Other|2 minute walking test|the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).
75909892|NCT04966936|Other|The gait analysis at the motion analysis laboratory.|Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared
75909893|NCT04966312|Other|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
75909894|NCT04966312|Other|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
75909895|NCT03472430|Device|Transcutaneous electrical nerve stimulation|The TENS machine used in the study will be the Endomed 482 that delivers biphasic pulsed currents using pulse duration of 400 µs and pulse frequencies between 80-100 pulses.
75909896|NCT03472430|Device|TENS machine with electrodes not emitting any impulses.|TENS machine with electrodes not emitting any impulses.
75909897|NCT04966234|Drug|Posaconazole 100 MG [Noxafil]|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
75909898|NCT04966234|Drug|Posaconazole 40 MG/ML|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
75909899|NCT03472352|Biological|An anticancer medication (A01) and immune cells (IC01)|The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
75909900|NCT04018820|Other|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
75909901|NCT04979026|Device|active ankle pumping with a regular watch alarm|In addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge.
75617089|NCT00663091|Drug|Bacteriophages|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
75909902|NCT04979026|Device|intermittent pneumatic compression|In this group, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
75909903|NCT03927794|Other|Self-Assembling Peptide P11-4|Self-Assembling Peptide P11-4 promotes subsurface biomimetic remineralization of enamel. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix is formed. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.
75909904|NCT04966468|Device|Virtual Reality|The Lenovo Mirage Solo Headset will be kept at home by the patient for the duration of the study (4 days). The VR headset will be equipped with 10 non-interactive videos and a short interactive game. The videos and the game are characterized by relaxing scenarios. The game will require the active interaction of the patient. At the end of the observational period, the investigator will download the usage data to detect information about the patient's use. Before and after each use of the VR headset, the patient will be asked to fulfil the Edmonton Symptom Assessment Scale (ESAS). On T0, the patient will be asked to wear a wearable device, the Empatica E4 wristband measuring physiological parameters. On day T1, the patient will return the VR headset and the wristband to the investigator and will fulfil again the HADS and BPI questionnaires.
75909905|NCT04966468|Other|Control|"The investigator will illustrate to the patient how to use the tablet for watching videos, suggesting using it especially in moments of psycho-physical discomfort. The tablet will be given to the patient for the duration of the study (four days). The tablet will be equipped with 10 non-interactive 2D videos characterized by relaxing settings with natural or artistic scenarios, giving a passive use to the patient. Before and after each use of the tablet, patient has to fullfil the ESAS digitally inserted into the tablet. Patient can answer by selecting the answer on the touchscreen. Without filling the scale, the patient will not be able to access the videos inserted in the tablet. On day T1, patient will return the tablet to the investigator and fill out the HADS and BPI questionnaires."
75909906|NCT03130946|Device|Cryo-assisted core needle biopsy|Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
75909907|NCT03130946|Device|FNA|FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
75909908|NCT04978714|Procedure|Cystocele repair|Fascial repair for endopelvic fascia and anterior colporrhaphy
75909909|NCT03061942|Other|Arthroscopic rotator cuff repair without synovectomy|30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.
75909910|NCT03061942|Other|Arthroscopic rotator cuff repair with synovectomy|30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
75909911|NCT03915860|Drug|Trifarotene|Topical Cream
76072556|NCT04725838|Device|Medtronic Intellis™ and Vanta™|Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems
75617090|NCT00670345|Drug|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
75617091|NCT00670345|Drug|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
75617092|NCT04153981|Drug|Insulin Glargine|Administered SC
75617093|NCT02631343|Behavioral|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
75769796|NCT01153048|Other|Intensification of education|The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
75769797|NCT03647566|Diagnostic Test|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
75909912|NCT04965922|Behavioral|Multimodal intervention|"The intervention consists of identifying the individual needs of each caregiver and patient and identifying sources of improvement in the management of daily life, including the optimization of social support. This optimization requires the involvement of people in the environment (family, friends, neighbours) who can provide help, support of any kind, recurrent or punctual, minimizing negative family interactions and maximizing positive contributions by each in supporting and supporting the individual.~The intervention is personalized in the sense that the content of each session seeks to adapt itself to the specificities of the couple situation and its surroundings.~interviews/meetings involving a psychologist social worker."
76072557|NCT01816477|Device|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
75463582|NCT05195840|Behavioral|Personalized Treatment for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.
75769798|NCT03647566|Diagnostic Test|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
75769799|NCT03647566|Diagnostic Test|Aortic MRI|Aortic MRI to assess aortic morphology and contextualise PET scan
75769800|NCT03591952|Procedure|Suction-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
75769801|NCT03591952|Procedure|Gravity-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
75769802|NCT03882502|Other|anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation|anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
75769803|NCT01156636|Drug|Sildenafil|50 mg 3 times/day for 1 year
75463583|NCT05195840|Behavioral|Cognitive Behavioral Therapy for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.
75769804|NCT01156636|Drug|Placebo|
75769805|NCT01259674|Device|AboMeg-B-09|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
75769806|NCT01259674|Other|Placebo|Placebo syrup: 5ml to be taken 4 times a day during the entire study period
75617094|NCT02631343|Other|Essential newborn care|
75617095|NCT04153903|Other|OCT, coronary angiography, FFR|Coronary images by OCT and angiography and FFR values will be registered.
75617096|NCT01165229|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
75617097|NCT01165229|Biological|Placebo|Intramuscular injection.
75617098|NCT00596011|Drug|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
75769807|NCT03881722|Dietary Supplement|Mg alginate|Mg alginate after feedings
75769808|NCT03889678|Diagnostic Test|Color flow doppler|Color flow doppler proximal to vein insertion site to document flow
75769809|NCT01153126|Behavioral|Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
75617099|NCT00596011|Drug|Placebo|Matching placebo BID
75617100|NCT00670423|Drug|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
75617101|NCT00670423|Drug|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
75617102|NCT00670423|Drug|Bortezomib|"Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:~Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3~Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3~Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3"
75617103|NCT04153825|Device|Transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
75909913|NCT03470714|Other|Force Irradiation|For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
75909914|NCT03470714|Other|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
75909915|NCT04170998|Drug|Evogliptin 5mg|Participants receive Evogliptin 5mg orally once a day
75909916|NCT04170998|Drug|Evogliptin Placebo|Participants receive placebo to match Evogliptin 5mg orally once a day
75909917|NCT04170998|Drug|Dapagliflozin 10mg|Participants receive Dapagliflozin orally once a day
75909918|NCT04170998|Drug|Metformin ≥ 1000mg|Metformin are administered at the same dose and formulation.
75909919|NCT04458740|Other|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
75909920|NCT03055780|Device|CT-FFR. CTA. FFR|Study is to compare results of CT FFR against CTA and interventional FFR
75909921|NCT03130868|Other|Characterizing changes in the microbiome|Analyzing the microbial content from stool samples
75909922|NCT04966078|Procedure|liposuction|suction-assisted liposuction
75769810|NCT03889288|Device|Medical device - electronic-pain killer|Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.
75909923|NCT04966078|Procedure|surgical excision|periareolar surgical excision
75909924|NCT04965532|Drug|sevoflurane anesthesia|Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
75909925|NCT04965532|Drug|Propofol Injection|Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
75909926|NCT04965610|Other|Preoxygenation with High Flow Nasal Cannula|Preoxygenation for 5 minutes via High Flow Nasal Cannula. After induction of anaesthesia apnoeic oxygenation with HFNC
75909927|NCT04965610|Other|Preoxygenation via face mask|Preoxygenation for 5 minutes via face mask. After induction of anaesthesia apnoeic oxygenation with tight fitting face mask
75617104|NCT04153825|Device|Interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
75769811|NCT01153204|Behavioral|Group Psychotherapy|
75617105|NCT04153825|Other|Hydrocollator hot-pack|The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
75617106|NCT04153825|Device|Sham transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
75617107|NCT04153825|Device|Sham interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
75769812|NCT01153204|Other|Group Psychotherapy plus Sildenafil citrate|
75769813|NCT01153204|Drug|Sildenafil citrate|
75769814|NCT03760666|Drug|Brequinar/Brequinar + Ribavirin|The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
75769815|NCT03760510|Device|Tube Fastener|Endotrachel tube secured with tube fastener
75769816|NCT03760510|Device|Adhesive Tape|Endotracheal tube secured with adhesive tape.
75909928|NCT03055546|Drug|Oxytocin|intranasal administration of oxytocin
75909929|NCT03055546|Drug|Placebo|intranasal administration of placebo
75909930|NCT04918264|Drug|Fluoropyrimidine treatment (5-FU or capecitabine) and dosage|In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
75909931|NCT04918264|Other|Uracil dosage|For each patient, uracil concentration will be evaluate and patients will be compared based on 16 ng/mL as threshold.
75769817|NCT03882112|Drug|HIP1601 40mg|Single dosing of HIP1601 40mg, orally
75909932|NCT04918264|Behavioral|Overall survival|For each group of patient, on 16 ng/mL as threshold for uracil concentration, overall survival will be compared betwen the two groups of patients (Uracil <16 vs Uracil ≥16).
75909933|NCT04978558|Other|Continuous assessment of cerebrovascular autoregulation with NIRS and TCD|Continuous monitoring of MAP, cerebral oxygenation, and cerebral blood flow velocity before, during, and after surgery to calculate two cerebrovascular autoregulation indices Cox and Mx.
75909934|NCT04917718|Drug|Conversion from IR Tacrolimus to XR Tacrolimus|All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus
75909935|NCT04917952|Device|Blood Flow Restriction (BFR)|"Exercise: Bilateral knee extension at range 90ο-0ο~Load: 30% 1RM~BFR: Yes, 80% at both legs~Sets: 4~Reps: 30-15-15-15~Rest: 30'' between sets~Tempo: 2-0-2-0~Participants of the intervention group will receive an exercise protocol with blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Blood flow restriction will be applied at 80% by using pressure cuffs. The cuffs will be applied to the proximal thigh. Cuff pressure needed for a 100% vascular occlusion will be determined for each individual at a seated and relaxed position."
76072558|NCT01816477|Drug|Epidural (ropivicaine 0.25%)|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
75617108|NCT02632201|Biological|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
75617109|NCT02632201|Biological|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
75617110|NCT00659659|Drug|MEDI-563|1.0 mg/kg IV: MEDI-563
76072559|NCT01846507|Drug|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
75463584|NCT05194800|Other|Virtual Mirror Therapy|Subjects will be offered the use of a Virtual Reality headset therapy game. Fiducial markers will be placed on the residual limb for tracking via front facing cameras on the Oculus Quest 2 and the sound limb movements will be duplicated (flipped for chirality) and mapped onto the residual limb to provide the appearance of their residual limb. The software will direct the subjects through a series of guided movements, stretches, and visualization exercises which last a total of 15 minutes. Afterwards the subjects will be given 5 minutes of unstructured time in the program to perform any of exercises or movements they desire in order to attempt to relieve their phantom limb pain.
75617111|NCT00659659|Drug|MEDI-563|100 mg, 200 mg SC
75617112|NCT00659659|Other|Placebo Comp.|Placebo SC
75617113|NCT00659659|Other|Placebo|Placebo as a single IV infusion (Certain number of subjects)
75617114|NCT00670501|Drug|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
75617115|NCT00670501|Drug|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
75617116|NCT00670501|Drug|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
75617117|NCT00670501|Drug|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
75617118|NCT00670501|Drug|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
75617119|NCT02631421|Procedure|Blood Sampling|
75617120|NCT02631421|Other|Cardiac MRI|
75617121|NCT05657093|Dietary Supplement|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
75617122|NCT05657093|Combination Product|Placebo|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
75769818|NCT01263574|Drug|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
75769819|NCT03882190|Drug|GnRHa|patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
75769820|NCT03882346|Combination Product|LifeLiver|LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
75769821|NCT03464734|Drug|Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel|At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
75769822|NCT01156870|Drug|SAR566658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
75769823|NCT01156948|Drug|misoprostol|400ug vaginally the day before surgery
75769824|NCT01156948|Drug|oral misoprostol|400ug misoprostol orally the day before the surgery
75769825|NCT03881956|Behavioral|Health-promoting lifestyle education program|The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
75769826|NCT01157104|Drug|IDX320|IDX320 400 mg in tablets (8x50 mg) administered orally once daily
75769827|NCT01157104|Drug|IDX184|IDX184 100 mg in capsules (2x50 mg) administered orally once daily
75769828|NCT01157104|Drug|IDX184 placebo|IDX184 matching placebo in capsules administered orally once daily
76072560|NCT05615038|Procedure|Contact aspiration Thrombectomy|Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.
75617123|NCT04153669|Behavioral|Exercise-NMES|Exercise-NMES
75617124|NCT04153669|Behavioral|Exercise-No NMES|Exercise-No NMES
75617125|NCT00663247|Device|Mesalazine|3 grams daily for 3 months
75617126|NCT00663247|Drug|Placebo|3 grams daily for 3 months
75617127|NCT02629939|Behavioral|course for learning CPR|
75617128|NCT04158271|Device|Prone Position|In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position
75617129|NCT04158271|Device|Laryngeal tube|In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube
75909936|NCT04917952|Device|Sham Blood Flow Restriction (sham BFR)|"Exercise: Bilateral knee extension at range 90ο-0ο~Load: 30% 1RM~BFR: Yes, Sham BFR, 10mm Hg at both legs~Sets: 4~Reps: 30-15-15-15~Rest: 30'' between sets~Tempo: 2-0-2-0~Participants of the control group will receive an exercise protocol with sham blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Sham technique for blood flow restriction will be applied by using pressure cuffs inflated at 10mm Hg. The cuffs will be applied to the proximal thigh. Cuff pressure will be applied for each individual at a seated and relaxed position."
75909937|NCT03060538|Drug|BFKB8488A|Administered subcutaneously starting on Day 1 and according to dosing schedule.
75909938|NCT03060538|Other|Placebo|Administered subcutaneously starting on Day 1 and according to dosing schedule.
75909939|NCT06016595|Diagnostic Test|Chronic prostatitis/chronic pelvic pain syndrome|Chronic prostatitis/chronic pelvic pain syndrome UPOINT
75617130|NCT04158271|Device|Endotracheal tube Leackage|In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
75909940|NCT06016569|Diagnostic Test|Exhaled breath condensate sampling|Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed.
75909941|NCT06016569|Diagnostic Test|Blood sampling|A venous blood sample will be taken for further biomarker analysis.
75463585|NCT05189106|Drug|Baricitinib|Each participant will be treated with open-label baricitinib for 24 weeks. Participants will receive 2 mg baricitinib by mouth daily for the first 8 weeks and 4 mg baricitinib by mouth daily for the remaining 16 weeks.
75463586|NCT05184842|Drug|Venetoclax|Venetoclax 400 mg po on days 1, 8, 15 and 28 of each cycle (28day cycle)
75617131|NCT01163747|Biological|tocilizumab|Intravenous repeating dose
75617132|NCT01163747|Drug|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
75463587|NCT05184842|Drug|Decitabine|Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)
75769829|NCT01157104|Drug|IDX320 placebo|IDX320 matching placebo in tablets administered orally once daily
75769830|NCT01157260|Drug|Kremezin|AST-120 2g three times a day
75769831|NCT01157026|Dietary Supplement|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
75463588|NCT05149976|Diagnostic Test|Voice recording before and after dietary intake|"A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test."
75463589|NCT05140018|Procedure|Kidney Transplantation|All participants will receive a kidney transplantation from a living donor or deceased donor
75769832|NCT01157026|Other|placebo plus tamoxifen|20mg tamoxifen daily
75463590|NCT05140018|Combination Product|Immunosuppression|All participants will receive immunosuppresive drugs to prevent rejection of de kidney transplant graft.
75463591|NCT05140018|Procedure|Nephrectomy (kidney donation)|All kidney donors will receive a nephrectomy for kidney donation
75463592|NCT05135650|Other|Questionnaire Administration|Ancillary studies
75463593|NCT05135650|Biological|Sotrovimab|Given IV
75463594|NCT05135650|Procedure|Biospecimen Collection|Undergo blood and nasal swab sample collection
75617133|NCT01163747|Biological|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
75617134|NCT01163747|Biological|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
75617135|NCT00663325|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
75617136|NCT00659893|Drug|PEP005 Topical gel|0.05%, two day dose
75617137|NCT02629783|Other|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
75617138|NCT02629783|Other|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
75617139|NCT02629783|Drug|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
75769833|NCT01263652|Drug|Diclofenac hydroxyethylpyrrolidine|IM/PO
75769834|NCT01263652|Drug|orphenadrine|IM/PO orphenadrine
75769835|NCT01263652|Drug|Tramadol|IM/PO tramadol
75769836|NCT01263652|Drug|Dipyrone|PO/IM Dipyrone
75769837|NCT01259752|Device|compression stockings|compression stockings
75769838|NCT01259752|Other|standard non compressive stockings|standard non compressive stockings
75769839|NCT03881644|Drug|Imigran|All patients will undergo this intervention on one of two study days
75769840|NCT03881644|Other|Isotonic Saline|All patients will undergo this intervention on one of two study days
75769841|NCT03881644|Other|Pituitary adenylate cyclase-activating peptide-38|All patients will undergo this intervention on both study days
75769842|NCT01263730|Behavioral|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
75769843|NCT01265368|Biological|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
75909942|NCT06016569|Procedure|LDCT|LDCT scan will be performed.
75909943|NCT06016569|Diagnostic Test|Vital signs|Blood pressure, weight, height, pulse, oxygen saturation will be measured.
75909944|NCT06016569|Diagnostic Test|Spirometry|Spirometry will be performed.
75463595|NCT05121688|Other|Physiotherapy|A Tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.
75909945|NCT06016530|Behavioral|Sleep Deprivation|During a sleep deprivation period lasting over 36 hours, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant while adhering to a standardized diet. To achieve this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs).
75909946|NCT06016530|Drug|Dexamethasone Supplementation|"Dexamethasone belongs to the drug class of corticosteroids. It is a synthetic glucocorticoid that activates glucocorticoid receptor (GR) and the hypothalamic-pituitary-adrenal (HPA) axis selectively.~Following the administration of 1 mg of dexamethasone as a pharmacological stressor, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant under a standardized diet. To facilitate this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs)."
75909947|NCT06016517|Drug|Adalimumab|40 mg subcutaneously every 2 weeks with oral placebo once daily
75909948|NCT06016517|Drug|Sarilumab|200 mg subcutaneously every 2 weeks with oral placebo once daily
75909949|NCT06016517|Drug|Upadacitinib|15 mg orally once daily with subcutaneous placebo injection every 2 weeks
75909950|NCT06016504|Behavioral|Health Education|Participate in an adaptive virtual consultation
76072561|NCT05615038|Procedure|Stent retriever thrombectomy|Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.
76072562|NCT05613790|Device|Active High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
76072563|NCT05613790|Device|Sham High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
76072564|NCT01846039|Device|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
75463596|NCT05111834|Behavioral|Supervised resistance training plus nutritional endorsement|resistance training 2x per week, nutritional endorsement/therapy based on individual needs
75463597|NCT05111834|Behavioral|Nutritional endorsement|nutritional endorsement/therapy based on individual needs
75463598|NCT05104892|Drug|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
75617140|NCT01163279|Behavioral|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
75617141|NCT01163279|Behavioral|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
75769844|NCT01259830|Drug|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
75769845|NCT01259830|Drug|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
75769846|NCT01157338|Procedure|diagnostic cardiac catheterization|coronary intervention: angiography
75769847|NCT01157338|Procedure|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
75769848|NCT03881878|Drug|TAHP and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Tastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (420mg, IV)"
75769849|NCT03881878|Drug|TAHP plus AC and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Tastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
75769850|NCT01159522|Drug|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
75769851|NCT00224484|Biological|GSK208141|3 intramuscular doses
75769852|NCT00224484|Biological|Havrix (investigational formulation)|3 intramuscular doses
75769853|NCT00224484|Biological|Placebo|3 intramuscular doses
75769854|NCT01265602|Drug|LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
75769855|NCT01265602|Drug|LASW1510|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
76072565|NCT01610167|Device|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
75463599|NCT05104892|Drug|placebo|Pharmaceutical form: Tablet Route of administration: Oral
75769856|NCT01265602|Drug|vehicle of LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
75769857|NCT01265680|Drug|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
75909951|NCT06016504|Behavioral|Health Education|Participate in a non-adaptive virtual consultation
75909952|NCT06016504|Other|Informational Intervention|Given information-only
75909953|NCT06016504|Other|Survey Administration|Ancillary studies
75909954|NCT06016491|Behavioral|acupressure|Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each woman, and then the person were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks.
75909955|NCT06016491|Behavioral|Sham acupressure|Compression was applied on the bone region where the meridians did not pass, parallel to the KD1 and SP6 points (approximately 1-1.5 cm away). Similar to the acupressure group, the sham group was treated with symmetrical extremities and for similar durati
75909956|NCT06016426|Other|Mass closure vs layer by layer closure of transverse laparotomy incisions in children and infants.|the transverse laparotomy incision in infants and children will be either closed as single layer included the peritoneum, posterior rectus sheath and anterior rectus sheath wit muscle sparing, or the laparotomy will be closed in layer by layer in which the peritoneum and posterior rectus sheath are closed as a layer and the anterior rectus sheath is closed as a seprate layer.
75909957|NCT06016413|Drug|Nab paclitaxel|All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
75909958|NCT06016413|Drug|Carboplatin|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
75909959|NCT06016413|Drug|adelbelimumab|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
75909960|NCT06016400|Drug|Alfacalcidol Oral Solution|Alfacalcidol Oral Solution 1ug a day
75617142|NCT04155931|Other|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
75769858|NCT01157494|Other|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
75769859|NCT03879148|Other|Erector spinae plane block|Erector spinae plane block was performed to the patients under aseptic conditions
75909961|NCT06016400|Drug|Placebo|Placebo
75909962|NCT06016374|Other|telerehabilitation|"During this study, the patient will be asked to use the TeleRé programme at least 5 times a week for 30 minutes for one month. Through the programme, they will have access to exercises in video format and thus self-rehabilitation as well as serious therapeutic games. The self-education games and videos target the functional and motor recovery of the upper limb. In addition, cognitive functions (attention, memory, etc.) will also be stimulated via the programme. Therapeutic education modules and PROMS assessments will also be available."
75909963|NCT06016361|Other|VS-200Cr|Topical cream with moisturizing factors.
75909964|NCT06016361|Other|Standard of care|AAD recommended course of care.
75909965|NCT06016309|Other|There is no intervention.|There is no intervention.
75909966|NCT06016296|Other|Combined Movement and Storytelling Intervention|The 40-minute sessions will include three moments: (i) warm-up (5 minutes), which consists of joint mobility exercises and introduction to the motor story of the week; (ii) main part (25 minutes), which incorporates the narration of the motor story by the educator initially, as well as the participation of the children, through their own corporeality with movements based mainly on FMS (locomotion skills and object control) and two way verbal interaction based on questions allusive to the narration delivered by the educator or direct verbal participation cast by each child and; (iii) cool down (10 minutes), where space is provided for the children to gradually return to calm, together with feedback on the contents addressed during the session.
75909967|NCT06016244|Other|Oxygen saturation threshold|Oxygen saturation threshold on which supplemental oxygen is decided
75769860|NCT01265758|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
75909968|NCT06016231|Device|Light Adjustable Lens|The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
75909969|NCT06016166|Device|Eye mask|The 3D eye mask with the ability to adjust for different faces and eliminate light
75909970|NCT06016153|Other|Software based feedback|Feedback is given by the data of a software built in Ambu Man C Torso (Ambu A/S, Copenhagen, Denmark).
75909971|NCT06016153|Other|Instructor feedback|Feedback is given by the opinion and observation of an experienced instructor.
75617143|NCT02629705|Dietary Supplement|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
75617144|NCT02629705|Dietary Supplement|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
75617145|NCT00670657|Drug|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
75617146|NCT01162499|Drug|Exendin-(9-39)|IV infusion of exendin-(9-39) for 5 hours
75769861|NCT01263808|Drug|Indacaterol 150 µg|Once daily (QD) via single-dose dry powder inhaler (SDDPI)
75769862|NCT01263808|Drug|Indacaterol 300 µg|QD via SDDPI
75769863|NCT01263808|Drug|Indacaterol 600 µg|QD via SDDPI
75769864|NCT01263808|Drug|Placebo|QD via SDDPI
75769865|NCT01263808|Drug|Placebo/moxifloxacin|Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
75463600|NCT05096936|Other|Pilates|"The solo Pilates method will be applied twice a week for 12 weeks using the following exercises:~20 Breaths, Double leg stretch, Single leg stretch, Leg circles, Hip lift on ball, Abdominal tightening on ball, Alternating two supports, Side bend, Side kick - side kick, Side kicks, Shell and Swan and Neck pull stretches; in the tenth session, we evolved some exercises: The saw, Swan dive, Book close series, Hip lift on the ball and Front pulls; in the eighteenth session we changed again some exercises for: Leg pull back, Rolling like a Ball, Swimming, Roll over and Leg pull front."
75463601|NCT05096936|Other|Photobiomodulation|Applications of FBM or placebo (MR4 ACTIVet PRO Laser Shower Portable, MRM, USA) will last for 115s and will deliver 60 J at each point. The mode of application, with the patient supine on a stretcher, with the grouping probe held stationary in contact with the skin, at a 90-degree angle, in the pubic mound and in the perineum region.
75463602|NCT05092100|Behavioral|Visual stimulus similarity|Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.
75463603|NCT05092100|Other|fMRI|fMRI will be used to measure patterns of BOLD activity during learning.
75463604|NCT05092100|Other|Eye tracking|Eye tracking will be used to measure patterns of eye movements when viewing images.
75617147|NCT01162499|Other|Vehicle|Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
75617148|NCT04153513|Drug|Lanolin|Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
75617149|NCT04153513|Other|Mother's milk|After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
75617150|NCT00659971|Drug|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
75617151|NCT05657015|Drug|Lepidium Sativum|2 ml of LS in situ gel at baseline
75617152|NCT05657015|Drug|Simvastatin|1.2% of SMV in situ gel at baseline
75617153|NCT04314479|Behavioral|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
75617154|NCT02887313|Drug|mFOLFOX6|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
75617155|NCT02887313|Radiation|Radiotherapy|Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
75617156|NCT01206140|Other|Laboratory Biomarker Analysis|Correlative studies
75617157|NCT01206140|Drug|Selumetinib|Given PO
75617158|NCT01206140|Drug|Temsirolimus|Given IV
75617159|NCT01162421|Biological|adalimumab|Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
75617160|NCT01162421|Drug|Methotrexate|Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
75617161|NCT05366387|Device|intrapulmonary percussive ventilation|Intrapulmonary percussive ventilation is a non invasive ventilation technique where small boli or air are delivered, at adjustable frequency and pressure, to the upper airways though a mouthpiece. IPV is currently used in the clinic to aid with airway clearance in neuromuscular and airway diseases.
75617162|NCT05366387|Radiation|delivery of 99mTc-DTPA aerosol|A 99mTc-DTPA aerosol (500 MBq+/-20%, 3 ml volume) is generated with a jet nebuliser (MMAD 4 µm). The aerosol is inhaled by the study subject and lung deposition is imaged by SPECT
75769866|NCT01159678|Behavioral|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:~Important of sexuality to quality of life. & Definitions of sexual desire and arousal.~Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.~Sexual beliefs.~Mindfulness.~Genital anatomy and physiology.~Body Image.~Relationship satisfaction and communication.~Body-oriented mindfulness exercises (focusing and self-observation).~Using Thought records.~Mindfulness and the thought stream.~Sexual aids to boost arousal.~Moving on.~In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
75769867|NCT01159756|Drug|Travacom|Travacom ophthalmic solution (1 drop per day)
75617163|NCT02885519|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment"
75617164|NCT02885519|Behavioral|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
75617165|NCT02885441|Drug|Ketorolac|Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
75318068|NCT03598634|Procedure|administration of riboflavin for epi-on cross-linking|riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid
75318069|NCT04008134|Behavioral|CHoBI7 health facility program|The CHoBI7 health facility program focuses on promoting handwashing with soap and water treatment to diarrhea patients and their household members during the one-week period after the patient is admitted to the health facility, when their household is at highest risk for diarrheal diseases. The CHoBI7 program includes: (1) a WASH pictorial module delivered by a health worker bedside to diarrhea patient and their household members in a health facility on handwashing with soap, water treatment, and safe water storage; and (2) a diarrhea prevention package containing chlorine tablets for water treatment, a soapy water bottle (water and detergent powder), a handwashing station, and a water vessel with a lid and tap for safe drinking water storage. Households are instructed to boil their water once their supply of chlorine tablets is completed.
75341295|NCT05409716|Procedure|Wristband TR band for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, hemostatic wristband TR BandR (Terumo Corporation, Tokyo, Japan) was utilized was used to achieve hemostasis.
75463605|NCT05090163|Other|PREP Plus|Group based exercise in addition to PREP exercises
75341296|NCT01565551|Other|N/A (Observational Study)|No Interventions: Observational Study
75463606|NCT05090163|Other|PREP|Group based exercise
75617166|NCT04314791|Device|Ultrasound evaluation, with grayscale and color Doppler imaging|In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
75617167|NCT02885597|Drug|Juanbi pill|4g, twice a day, 3month, oral
75617168|NCT02885597|Drug|Juanbi pill placebo|4g, twice a day, 3month, oral
75769868|NCT01071876|Drug|BF2.649|1 capsule in the morning before breakfast
75769869|NCT01071876|Drug|Placebo|1 capsule in the morning before breakfast
75769870|NCT01161706|Other|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
75463607|NCT05082844|Radiation|MRI assessment|Evaluation of the clinical-radiological results from the case series of patients surgically treated for cuff rotator lesions from 2009 to 2020 at the Shoulder-Elbow Department . At 12 months the result is considered stabilized, so we will proceed to collect all case histories that have passed this follow-up period.
75463608|NCT05073822|Drug|Tacrolimus|reduction of both standard Tacrolimus & Mycophenolate mofetil does in one arm
75617169|NCT02885597|Drug|Methotrexate|5mg, once a week, 3 month, oral
75617170|NCT01188551|Drug|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
75617171|NCT01188551|Drug|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
75617172|NCT01188551|Drug|Midazolam|Sedative given pre-op.
75617173|NCT04316429|Other|Egg included vegan phase|: Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets. Participants will also receive instructions to preserve an isocaloric condition with the addition of 2 eggs in their diets. Counseling of the study participants will be based on the U.S. Department of Agriculture (USDA) healthy vegetarian meal plans, with modifications to exclude dairy products. [21] Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet (with the exception of including eggs) will also be provided.
75617174|NCT04316429|Other|Vegan Phase|The participants will consume a vegan diet for 6 weeks. The study dietitian will provide counseling and sample meal plans based on the USDA healthy vegetarian dietary pattern, with modifications to exclude eggs and dairy products. Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet will also be provided.
75617175|NCT05293379|Other|Connected teleconsultation booth|15-minutes assessment in a connected teleconsultation booth.
75617176|NCT01161407|Dietary Supplement|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
75617177|NCT01161407|Dietary Supplement|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
75617178|NCT01161173|Drug|Erlotinib|Erlotinib was provided in the retail versions of the product.
75617179|NCT01159769|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
75617180|NCT02885207|Biological|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:~Crisis with clinical symptoms indicating focal seizure~& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~No argument for metabolic or neurodegenerative genetic epilepsy.~Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
75617181|NCT05280119|Device|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
75769871|NCT01581996|Drug|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
75769872|NCT01157572|Drug|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
75769873|NCT01157572|Drug|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
75769874|NCT01074372|Drug|REGN727|4 cohorts (dose 1, 2, 3, 4)
75769875|NCT01074372|Drug|Placebo|4 cohorts (dose 1, 2, 3, 4)
75909974|NCT06016101|Other|100 Patients|"For patients and professionals: retrieval of socio-demographic data~For patients :~Pill counting~Morisky questionnaire"
75909975|NCT06016101|Other|Healthcare professionals (20 doctors, 20 pharmacists and 20 nurses)|"For patients and professionals: retrieval of socio-demographic data~For healthcare professionals :~Evaluation of user experience~Evaluation of the report produced by the application"
75909976|NCT06016062|Drug|RC148|RC148 is a bispecific antibody, targeting programmed death-1(PD-1) and Vascular endothelial growth factor(VEGF).
75617182|NCT05280119|Device|Ultrasound device routinely used in the department.|Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
75769876|NCT01161784|Dietary Supplement|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
75909977|NCT06016049|Other|EMLA® adjuvant|cutaneous forearm deafferentation
75909978|NCT06016049|Behavioral|Sensory training|Sensibility training of the median nerve
75909979|NCT06016036|Drug|SAL-0951|"SAL-0951：~initial phase：4mg QD for 8 weeks~subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
75909980|NCT06016036|Drug|Placebo|"SAL-0951 placebo：~initial phase：4mg QD for 8 weeks~subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
75909981|NCT06015984|Behavioral|Traning|In order to participate in the training module, a user name and password will be given to the initiative group, the link to be used in the self-managed and asynchronous training platform will be shared, and it will be ensured that it participates in the web-based nurse training, and the training will last for eight weeks.
75909982|NCT06015971|Dietary Supplement|omega-3|Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet
75909983|NCT06015971|Dietary Supplement|Standard|Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet
75909984|NCT06015958|Other|Streptococcus salivarius M18 toothpaste (1 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
75909985|NCT06015958|Other|Streptococcus salivarius M18 toothpaste (10 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
75909986|NCT06015932|Behavioral|Cognitive Behavior Therapy|Participate in CBCSM group sessions
75909987|NCT06015932|Other|Questionnaire Administration|Complete questionnaires
75909988|NCT06015919|Behavioral|dash diet|"Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs."
75909989|NCT06015919|Device|Acupuncture|acupuncture
75909990|NCT06015854|Biological|Vvax001 therapeutic cancer vaccine|Patients will receive three immunizations, with an interval of 3 weeks between each immunization at weeks 0, 3 and 6. Each vaccination will be given as two injections; 1 injection in each leg. The injections will be administered intramuscularly in the upper legs, preferably in the m. vastus lateralis.
75909991|NCT06015828|Dietary Supplement|bovine lactoferrin|Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.
75909992|NCT06015802|Other|diagnosed and treated reasonably according to the clinical guidelines and clinical pathways|The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
75909993|NCT06015776|Other|Gender|Differences between men and women will be observed
75909994|NCT06015763|Procedure|Endoscopy|Endoscopic biopsy
75617183|NCT05280119|Procedure|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
75617184|NCT04123691|Device|pulse oximetry monitoring|pulse oximetry monitoring as per routine clinical practice
75617185|NCT01157897|Biological|VMP001|Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
75769877|NCT01161784|Dietary Supplement|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
75769878|NCT03881254|Other|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
75769879|NCT03881254|Other|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
75909995|NCT06015711|Drug|Maxigesic administration|Preoperative Maxigesic IV administration
75909996|NCT06015698|Procedure|Laparoscopic tubal disconnection|"The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~Then, the tube is severed in the middle of the burn area with laparoscopic scissors~Ensure adequate hemostasis"
76072566|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
75769880|NCT03881254|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
75463609|NCT05047952|Drug|Vortioxetine|"Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician."
75769881|NCT03881254|Other|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
75769882|NCT01265914|Biological|FP-01.1|Ascending doses of FP-01.1 will be administered
75769883|NCT01265914|Biological|placebo|
75769884|NCT01263964|Procedure|coronary angiogram|coronary angiogram
75769885|NCT01267942|Drug|Enhancin|"Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm."
75769886|NCT02527252|Other|Craniosacral therapy|
75769887|NCT02527252|Other|Classic Massage|
75617186|NCT01157897|Other|P. vivax sporozoite challenge|P. vivax sporozoite challenge
75617187|NCT04316507|Procedure|Genetic Counselling and Testing|Oncologist-initiated brief genetic counselling and testing
75617188|NCT01185821|Drug|BAF312|BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
75769888|NCT00254982|Biological|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
75769889|NCT01264042|Dietary Supplement|Ferrous Sulfate|60 mg with 200 mL water, single administration
76072567|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
75463610|NCT05047952|Drug|Placebo|A placebo pill will be taken once daily.
75463611|NCT05028660|Diagnostic Test|GAG score|blood and urine samples to determine GAG scores
75617189|NCT02885285|Behavioral|Spinning Class|Spinning Class twice a week for six weeks.
75769890|NCT01074528|Behavioral|mindfulness based stress reduction program|8-week mindfulness training program
75769891|NCT01268020|Drug|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
75769892|NCT03968796|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|
75769893|NCT03968796|Other|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
75769894|NCT03968796|Other|Kinesio Taping|
75769895|NCT03968796|Other|Sham Kinesio Taping|
75769896|NCT03879226|Device|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for the applications during the training and/or detraining periods will be 30 Joules (J) per site (510 J per lower limb). PBMT will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
75769897|NCT03879226|Device|Placebo|Placebo will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
75769898|NCT03968718|Behavioral|Systematic ePROMs Assessment|"Depending on the care setting, eligible patients will be asked to fill in one of the following e-PROMs assessment:~Edmonton symptom assessment scale (ESAS-r) (outpatients)~Distress Thermometer (inpatients)~An ad hoc questionnaire adapted from the Bench-Can and EURACAN projects plus the institutional customer satisfaction survey (patients followed by multidisciplinary teams)"
75909997|NCT06015698|Procedure|Laparoscopic salpingectomy|"The tube will be removed from its anatomical attachements by progressive bipolar coagulation~Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~Removal of the tube through one of the ancillary ports using artery forceps~Ensure adequate hemostasis"
75909998|NCT06015633|Other|No intervention|Observational only
75909999|NCT06015594|Drug|Metformin|Patients treated with metformin
75617190|NCT02885285|Behavioral|Yoga Class|Yoga Class twice a week for six weeks.
75617191|NCT02885285|Behavioral|Dance Class|Dance Class twice a week for six weeks.
75617192|NCT02885285|Other|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
75617193|NCT00893464|Drug|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
75617194|NCT05318326|Drug|placebo group|placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
75617195|NCT05318326|Drug|Yogliptin 400mg group|Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
75617196|NCT05318326|Drug|Yogliptin 200mg group|Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
75617197|NCT02834962|Procedure|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
75617198|NCT02834962|Procedure|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
75910000|NCT06015568|Drug|MCLA-129: 1500mg or 2000mg IV Q2W|Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
75910001|NCT06015568|Drug|Befotertinib: 75 mg or 100 mg Po QD|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD.~Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs."
75910002|NCT06015555|Behavioral|TAMO|TAMO therapy
75910003|NCT06015555|Behavioral|Postural Control exercises|Postural Control exercises
75910004|NCT06015542|Drug|Elranatamab|Elranatamab will be administered as monotherapy for six cycles of 28 days. Elranatamab 76 mg will be administered QW with a 2-step-up priming dose regimen administered during the first week (12 mg D1 and 32 mg D4).
75910005|NCT06015503|Drug|PLB1004|PLB1004 is a capsule in the form of 80mg and 40mg.
75910006|NCT06015477|Drug|Ticagrelor monotherapy|starting dose of ticagrelor was a single loading dose of 180mg (90mg x 2 tablets) and thereafter 1 tablet (90mg) each time, twice daily.
75910007|NCT06015477|Drug|Dual Antiplatelet Therapy|Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.
75910008|NCT06015464|Drug|Orelabrutinib|Addition of novel BTK inhibitor, Orelabrutinib，150 mg qd, to standard treatment regimens, which include R-CHOP and Pola-R-CHP
75910009|NCT06015451|Other|Sub-symptom threshold exercise|Aerob exercise at an intensity just below the intensity that provokes symptom exacerbation.
75910010|NCT06015412|Diagnostic Test|Radiographic classification|disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system
75463612|NCT05009680|Drug|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
75463613|NCT05009680|Drug|Placebo|Placebo is administered orally twice a day
75463614|NCT05001828|Drug|ADI-PEG 20|ADI-PEG 20 in combination with venetoclax and azacitidine
75617199|NCT04205110|Diagnostic Test|PET-CT|PET-CT compared to intravascular imaging for assessment of atherosclerotic plaques in stable angina patients
75617200|NCT02834182|Behavioral|IRMf|
75617201|NCT02834182|Behavioral|Mini International Neuropsychiatric Interview|
75617202|NCT02834182|Behavioral|Positive And Negative Syndrom Scale|
75769899|NCT01264120|Behavioral|Health Psychology Intervention|The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
75769900|NCT01582698|Biological|FSME-IMMUN 0.5 ml|Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
75769901|NCT01586572|Drug|mOPV1|Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
75769902|NCT01586572|Drug|bOPV 1,3|The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
75769903|NCT03971916|Drug|HBM9161(HL161BKN)|Subcutaneous injection; Single dose on Day 1
75910011|NCT06015399|Procedure|Implementation of closed insufflation technique during segmentectomy|After the identification the targeted segmental bronchus during the operation,ligating the proximal end of the targeted bronchus. Put the vessel separation forceps in the distal bronchial space to avoid the accidental damage of the vessels. Use a 50ml syringe to inject air into the distal bronchus (about 100ml is expected) until the intersegmental plane is satisfactory. Divide the target bronchus using the cutting and closing device.
75910012|NCT06015399|Procedure|Implementation of dilatation and collapse technique during segmentectomy|Divide the target bronchus using the cutting and closing device. Ask the anesthesiologist to inflate the lung completely from pure oxygen to the affected side and then change to single lung ventilation. Wait for the intersegmental plane to appear(usually about 15 minutes).
75910013|NCT06015386|Other|inclined plane|2 parallel groups one treated with clear aligner and other treated using inclined plane
75910014|NCT06015386|Other|clear aligner|2 parallel groups one treated with clear aligner and other treated using inclined plane
75910015|NCT06015373|Drug|supress the night dose of carvedilol|already described
75910016|NCT06015334|Procedure|cataract surgery with implantation of intraocular lens|Cataract surgery with implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.
75769904|NCT03971916|Drug|Placebo|Subcutaneous injection; Single dose on Day 1
75617203|NCT02834182|Behavioral|Young Mania Rating Scale|
75769905|NCT03759340|Drug|ATI 502 0.46% Topical Solution|apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)
75617204|NCT02834182|Behavioral|Hamilton Depression Scale|
75617205|NCT00891904|Biological|cetuximab|Given IV
75617206|NCT00891904|Radiation|stereotactic body radiation therapy|Undergoing Radiotherapy
75617207|NCT02834338|Device|activity tracking for autofeedback|The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.
75617208|NCT02837926|Other|questionnaire|
75617209|NCT02837926|Biological|Gardasil vaccine|
75617210|NCT02837926|Biological|Cervarix®|
75617211|NCT02834260|Drug|Dexamethasone implant OZURDEX|
75617212|NCT02834416|Behavioral|Supervised Group Exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
75617213|NCT02834416|Behavioral|Home Based Exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
75463615|NCT05000866|Behavioral|Communication skills training video|The communication skills training video component is designed to be self-delivered. Four couples are depicted in separate scenes discussing HIV testing, drug use, sexual agreements, and drug use during sex. Each scene is viewed twice. In the initial viewing, the couple in the video makes one or more communication errors. The scene is subsequently viewed a second time and the couple utilizes more effective communication skills, resulting in a more adaptive resolution. Each scene is introduced by a narrator who points out communication errors and orients viewers to skills utilized in adaptive versions of each scene.
75463616|NCT05000866|Behavioral|Drug use module|The substance use module is administered after step 5 of CHTC and prior to the delivery of rapid HIV-test results. The couple was first asked to fill in a calendar for the past 30 days, indicating each day on which either member used drugs or consumed alcohol. Completion of the calendar is done through an ACCESS database to facilitate remote intervention delivery. After completion of the calendar, the HIV tester asked a series of debriefing questions designed to elicit the couples' perspective on their use, establish the couple's goals and limits for drug use, and make plans to achieve these goals.
75463617|NCT04998734|Diagnostic Test|ASI-SR|Psychometric properties of ASI-SR
75617214|NCT02831608|Biological|Influenza vaccine|
75617215|NCT02831608|Biological|Placebo|
75617216|NCT01157351|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
75617217|NCT01157351|Drug|risperidone|flexible dosing as prescribed by the study doctor for 15 months
75617218|NCT01157351|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
75617219|NCT01157351|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
75617220|NCT01157351|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
75617221|NCT01157351|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
75617222|NCT01157351|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
75617223|NCT01157351|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
75617224|NCT02834494|Procedure|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
75617225|NCT02834494|Biological|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
75617226|NCT02831686|Drug|Selinexor|
75617227|NCT02831686|Drug|Ixazomib|
75617228|NCT02831686|Drug|Dexamethasone|
75617229|NCT02831530|Drug|Abemaciclib|
75617230|NCT04248478|Other|Eating Behaviours|Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
75617231|NCT04248478|Other|Health Status|The effect of fibromyalgia on the daily life of the patients will be questioned with Fibromyalgia Impact Questionnaire (FIQ). The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week.
75617232|NCT00633490|Drug|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
75617233|NCT04247932|Behavioral|Active labor market intervention|Behavior change intervention
75617234|NCT02834026|Other|Cicloergometry training|
75617235|NCT02834026|Other|No Cicloergometry training|
75617236|NCT02831452|Other|pelvic floor muscle strength evaluation|
75617237|NCT02831374|Drug|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
75617238|NCT02831374|Procedure|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
75617239|NCT02831374|Biological|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
75617240|NCT02831374|Procedure|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
75617241|NCT02831374|Procedure|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
75769906|NCT03881176|Device|PoNS Treatment|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
75769907|NCT03877042|Device|Cruciate-retaining (CR) prostheses|One leg is conducted TKA with Cruciate-retaining (CR) prostheses.
75769908|NCT03877042|Device|Posterior-stabilized (PS) prostheses|One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
75769909|NCT00224016|Drug|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
75769910|NCT00224016|Drug|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
75769911|NCT03878680|Other|Study questionnaires|"Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~Core questionnaire on wheezing.~Core questionnaire on rhinitis.~Core questionnaire on atopic dermatitis."
75769912|NCT01266226|Device|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
75769913|NCT01266226|Device|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
75769914|NCT03881410|Procedure|different types of ultrasound technique|Shear-wave elastography-guided or Convention ultrasound-guided
75769915|NCT02527174|Drug|Volasertib|Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
75769916|NCT02527174|Drug|Idarubicin|Given IV daily on Days 1-3 of treatment protocol.
75769917|NCT02527174|Drug|Cytarabine|Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
75769918|NCT01264198|Behavioral|Resistance Training|Supervised Resistance Training
75910017|NCT06015321|Drug|Enzalutamide|enzalutamide 160 mg PO daily
75910018|NCT06015295|Diagnostic Test|18F-Fluciclovine (Axumin)|Given by Injection
75910019|NCT06015295|Diagnostic Test|Pet Scan|Scans
75910020|NCT06015269|Drug|DC cells|At a single arm, 1x107cells dose
75910021|NCT06015243|Drug|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
75910022|NCT06015230|Biological|low dose GR1603 in phase Ⅰb|6 subjects in GR1603 low dose，2 subjects in placebo
75910023|NCT06015230|Biological|high dose GR1603 in phaseⅠb|6 subjects in GR1603 high dose，2 subjects in placebo
75910024|NCT06015230|Biological|low dose GR1603 in phase Ⅱ|low dose GR1603 monthly
75769919|NCT03880942|Other|Informative story book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
75910025|NCT06015230|Biological|high dose GR1603 in phase Ⅱ|high dose GR1603 monthly
75910026|NCT06015230|Biological|Placebo in phase Ⅱ|Placebo
75910027|NCT06015217|Drug|"Cetaphil Healing Ointment"|"Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change"
75769920|NCT03880942|Other|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
75769921|NCT02526940|Procedure|rectal biopsies|6 rectal biopsies
75769922|NCT02526940|Other|Blood samples|Blood samples
75769923|NCT01161940|Drug|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
75769924|NCT01161940|Drug|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
75910028|NCT06015152|Drug|Tazarotene 0.045% Topical Application Lotion [ARAZLO]|[ARAZLO]
75910029|NCT06015139|Device|cotton roll-coated viscoelastic polymer pads|relton-hall frame cotton roll-coated viscoelastic polymer pads
75910030|NCT06015139|Device|viscoelastic polymer pads|relton-hall frame viscoelastic polymer pads
75910031|NCT06015126|Drug|metronomic oral vinorelbine plus anlotinib|To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer
75910032|NCT06015113|Drug|Disitamab Vedotin plus pyrotinib or naratinib|"Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days."
75910033|NCT06015100|Drug|Inetetamab plus pyrotiniband and capecitabine|Inetetamab plus pyrotiniband and capecitabine
75910034|NCT06015074|Drug|Propofol|patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.
75463618|NCT04997577|Behavioral|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. A short-term memory component, in which listeners are asked to remember what a designated speaker said two sentences prior, was added to the auditory training paradigm to make the task more challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
75617242|NCT02831374|Drug|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
75617243|NCT02833870|Behavioral|Musical intervention|
75617244|NCT02833870|Behavioral|Non-musical (cooking) intervention|
75617245|NCT02833870|Behavioral|Control with no intervention|
75617246|NCT02833558|Device|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
75617247|NCT02833558|Procedure|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
75910035|NCT06015074|Drug|Ciprofol|patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.
75910036|NCT06015061|Diagnostic Test|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.
75617248|NCT02831218|Procedure|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
75617249|NCT02831218|Procedure|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
75910037|NCT06015048|Drug|SHR-A1811 combined with Pyrotinib.|SHR-A1811 combined with Pyrotinib
75617250|NCT02831218|Procedure|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
75617251|NCT02831218|Procedure|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
75617252|NCT02831140|Behavioral|Early exercises|"In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
75617253|NCT02831140|Behavioral|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
75617254|NCT02831140|Behavioral|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
75617255|NCT02831140|Behavioral|commun interventions|"In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~, preservation of Serratus anterior and the front part of Latissimus Dorsi ).~In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
75617256|NCT02833480|Drug|Fluticasone group|
75318070|NCT04008134|Behavioral|CHoBI7 mHealth program|The CHoBI7 mHealth (mobile health) program targets five key behaviors: (1) preparing soapy water using water and detergent powder; (2) handwashing with soap at food and stool related events; (3) treating household drinking water using chlorine tablets during the one week high risk period after the diarrhea patient in the household was admitted to the health facility; (4) safe drinking water storage in a water vessel with a lid and tap; and (5) heating of household drinking water until it reaches a rolling boil after the one week high risk period. Participant households receive bi-weekly voice and text messages from the CHoBI7 mHealth program over a 12-month period. These mobile messages are sent using the VIAMO platform (www.viamo.io).
75318071|NCT04008134|Behavioral|CHoBI7 home visit program|The CHoBI7 home visit program involves two, 30-minute home visits conducted during the week after the index diarrhea patient was recruited at the health facility. A health worker reinforces the content of the CHoBI7 health facility program in the participant's home.
75617257|NCT02833480|Drug|Budesonide group|
75617258|NCT02833480|Drug|Formoterol group|
75617259|NCT04248166|Device|Photoacoustic imaging|"Photoacoustic image of thyroid nodule is obtained by using probe of photoacoustic imaging equipment and image data and data are stored in the device.~The patient's examination is the same as the general ultrasound, and the patient is asked to hold his breath for about 3-4 seconds to get the photoacoustic image."
75617260|NCT02833636|Procedure|ACEF score|
75617261|NCT04201054|Drug|Fluconazole|50 mg of fluconazole administered orally in a single dose.
75617262|NCT04247854|Dietary Supplement|Bacillus subtilis probiotic|Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.
75617263|NCT04247854|Other|Placebo|Over 5 days of interventional period, the patient receives 1 placebo tablet per day
75617264|NCT01157117|Biological|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
75617265|NCT01157117|Biological|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
75617266|NCT01157117|Drug|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
75910038|NCT06015048|Drug|SHR-A1811 combined with other antitumor therapies|SHR-A1811 combined with other antitumor therapies
75910039|NCT06015035|Drug|Sintilimab and anlotinib in combination with chemotherapy|Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
75910040|NCT06014255|Drug|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
75617267|NCT04247386|Drug|PEG-Mizone|"The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water."
75910041|NCT06014255|Other|Standard of Care|Radical prostatectomy within 4-8 weeks of randomization.
75463619|NCT04997577|Behavioral|Auditory training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
75910042|NCT06014177|Behavioral|STIckER|"STIckER is an interactive and personalized intervention based on the principles of SDM that has been designed with input from the AYA ED patients and providers. STIckER guides AYA patients through a series of steps, beginning with scanning your STIckER. Participants complete risk assessments, SDM modules, and conclude with an anonymous final digital infographic that informs an SDM conversation with the medical provider. This decision aid seamlessly integrates into the ED workflow, recommending appropriate STI testing for high-risk individuals and using SDM concepts for those at intermediate risk."
75463620|NCT04991792|Other|Intervention Group 1: Infant Formula with synbiotics|Infants will receive infant formula during the first 6 months of life
75910043|NCT06014177|Other|Control|"After enrollment but before the start of their clinical visit, AYA participants assigned to a provider in the control arm will scan a QR code. They will receive a prompt stating, If you would like to be tested for a sexually transmitted infection today, please tell your medical doctor."
75617268|NCT04247386|Drug|PEG-ELS|The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
75769925|NCT01157650|Other|Autologous mesenchymal stem cells|"The trial is divided in three phases:~I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.~II.- Treatment phase includes:~Liposuction procedure to obtain adipose tissue.~Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)~ASCs implant~III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant."
75769926|NCT01266382|Device|AposTherapy|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
75769927|NCT03880864|Radiation|Ultrasound|Lung ultrasound
75910044|NCT06014060|Procedure|24 Months DAPT|All subjects will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 12 months after randomization.
75910045|NCT06014060|Procedure|12 Months DAPT|All subjects will receive aspirin (100 mg/day) monotherapy without co-administration of clopidogrel for 12 months after randomization.
75910046|NCT06013280|Other|Progresive Muscle Relaxation and Breathing Exercise|"Intervention protocol contains 40 minuntes sessions, which involved tensing and relaxing the body along with deep breathing.~Protocol consisted with; Warm-up (5 minutes breathing exercise) Progressive Muscle Relaxation Exercises (The participants performed PMR for each body part in a particular order, beginning with the face muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet. This muscle tensing and relaxing procedures were performed in accompaniment with deep breathing.) Cool-down (5 minutes breathing exercise)"
75910047|NCT06013267|Other|Chin tuck against resistance exercise|The experimental group will receive a four-week CTAR protocol and regular dysphagia care, while the control group will only receive routine dysphagia care. The routine dysphagia care is including dysphagia education, dietary precautions, oral hygiene, and swallowing training, etc. The CTAR protocol is first, the study nurses face-to-face teach dysphagia patients to perform CTAR exercises once, then the patient perform CTAR exercises three times a day, five days a week, and for four weeks. The CTAR exercise is to tighten a rubber ball which placed between the chin and the sternum, and to perform 3 cycles of isometric exercise and isotonic exercise.
75463621|NCT04991792|Other|Intervention Group 2: Infant Formula with prebiotics|Infants will receive infant formula during the first 6 months of life
75617269|NCT02833246|Other|SMS/MMS text messaging|text messaging reminders on oral chemotherapy medication adherence
75617270|NCT02833246|Other|usual care|
75617271|NCT02885051|Procedure|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
75617272|NCT02833324|Behavioral|Education regarding ambulation|The participants will be educated on the importance of postoperative ambulation during the recovery period.
75617273|NCT02833324|Behavioral|Ambulation reminder alarms|Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
75318072|NCT03591302|Biological|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from living donor.
75318073|NCT03591302|Radiation|Total Lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
75318074|NCT03598556|Dietary Supplement|Vitamin D3|180,000IU Vitamin D3 oral emulsion
75318075|NCT03598556|Other|Placebo|Placebo
75318076|NCT03024476|Behavioral|Behavioral intensification|"Suggested algorithm for behavioral intensification:~If frequency of BP measurement ≤5 in a week, send a texting message~If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse~Target range of home-systolic blood pressure: 110 - 135~If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)~If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management"
75463622|NCT04991792|Other|Control Group 1 and 2: Infant Formula without synbiotics|Infants will receive infant formula during the first 6 months of life
75463623|NCT04989881|Device|da Vinci Simulator|Single training session
75463624|NCT04989881|Device|Laparascopic training box|Single training session
75617274|NCT02833324|Other|Fitbit|Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
75910048|NCT06013202|Other|Nigella Sativa Oil Mouth Rinse|Nigella Sativa Oil Mouth Rinse
75617275|NCT04248088|Behavioral|Gentle Stretching and Education|60 minutes of gentle stretching twice weekly for 6 months
75617276|NCT02833090|Procedure|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
75769928|NCT01162018|Procedure|acupuncture|The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.
75769929|NCT01162018|Other|placebo|
75769930|NCT01162174|Dietary Supplement|Oligonol|
75769931|NCT01159990|Biological|rAd5 Gag-Pol Env A/B/C|1×10^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
75769932|NCT01159990|Biological|rAd5 Gag-Pol|5×10^9 PU rAd5 Gag-Pol delivered via intramuscular injection
75910049|NCT06013202|Other|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)
75769933|NCT03880630|Other|Inspiratory muscle training|Patients will perform 3 inspiratory loading tests (15%, 30%, and 50% of maximum inspiratory pressures) on 3 separate days with the sequence will be randomized. Patient will then be trained with individualized IMT program based on the results of 3 inspiratory loading tests.
75769934|NCT01160068|Drug|Metformin|Metformin Tablets 1000 mg
75769935|NCT01160068|Drug|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
75769936|NCT01266616|Biological|Profectus HIV MAG pDNA vaccine|3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
75910050|NCT06010550|Radiation|Magnetic resonance imaging|Brain magnetic resonance imaging
75910051|NCT06005766|Behavioral|Metacognitive Skills Training (MCT)|The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
75910052|NCT06005766|Other|Treatment as usual|Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
75617277|NCT02833012|Drug|Caprylic Triglyceride Oil|10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
75617278|NCT02833012|Drug|AC-1202|60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
75617279|NCT02833012|Drug|Axona|40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
75617280|NCT02833012|Drug|AC-1204|40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
75651600|NCT05833997|Procedure|Monopolar Transurethral resection of bladder tumor|"Patients randomized to Monopolar TURBT will be operated using a 26F continuous-flow resectoscope sheaths and a single-pole working element to exclusive use of the resection. The power will be set to cut in 80w and 60w. The technique that will be performed will be the classic endoscopic resection from the top of the tumor until reaching the base, taking a sample from the base of the lesion (muscle layer). Fragments will be removed through an Ellik evacuator, and the solution used will be 3% glycine. After the procedure, the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation.~After 30-60 days of the first procedure, all patients diagnosed with a lamina propria invasion in the uro-pathology analysis (T1) will be submitted to a new monopolar TURBT."
75769937|NCT01266616|Biological|IL-12|Administered at Weeks 0, 4, and 12
75769938|NCT01266616|Other|Placebo|Saline injections at Weeks 0, 4, and 12
75769939|NCT01162252|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
75769940|NCT01162252|Behavioral|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
75769941|NCT01162330|Other|Screening urine and saliva tests for congenital Cytomegalovirus|With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
75910053|NCT06004102|Other|reminder text message|The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
75910054|NCT05999773|Drug|SGLT2 inhibitor|Start of SGLT-2 inhibitors to treat diabetes according diabetology indications.
75910055|NCT05995678|Behavioral|STEP-Home-SP|This group will meet for ~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.
75910056|NCT05995678|Behavioral|Transition Assistance Program|Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
76072568|NCT04478500|Drug|Minocycline|"Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase."
75617281|NCT00891202|Drug|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 [active moiety of ET in plasma] trough plasma concentration >=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration <5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
75617282|NCT00891202|Drug|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
75617283|NCT02831062|Other|low protein diet + ketosteril|Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
75617284|NCT02830906|Drug|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
75617285|NCT02830906|Drug|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
75617286|NCT02832778|Drug|Efavirenz|Efavirenz 400mg
75617287|NCT02832778|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
75617288|NCT02832778|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
75617289|NCT02832778|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
75617290|NCT02832778|Drug|Rifinah or local generics|Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)
75617291|NCT01185509|Drug|trastuzumab|
75617292|NCT01185509|Drug|vinorelbine|
75341297|NCT05356598|Other|Authority-delivered Health promotion video|A video delivered by a US Army Lieutenant Colonel (authority figure) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
75341298|NCT05356598|Other|Peer-delivered Health Promotion Video|A video delivered by a US Army ROTC cadet (peer) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
75341299|NCT05356598|Other|Control Group Video|Video of a US Army First Lieutenant squatting, bench pressing, and deadlifting with voiceover. No mention of musculoskeletal injuries or help-seeking behavior.
75617293|NCT02830984|Procedure|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
75617294|NCT02830984|Procedure|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
75617295|NCT02833168|Other|patient-filled questionnaires|All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
75617296|NCT02833168|Device|spiromanometry|Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
75617297|NCT04247230|Drug|Tetracaine|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
75617298|NCT04247230|Other|Matching placebo (PET500)|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
75617299|NCT04247230|Drug|STUD100|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
75769942|NCT01157806|Radiation|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
75769943|NCT01266694|Drug|Colchicines|oral form, 1 mg, once a day during 14 days
75769944|NCT01266694|Drug|Placebo|oral form, placebo
75769945|NCT03878836|Other|Routine assessments|Routine assessments, no specific intervention
75769946|NCT03876886|Drug|Epirubicin|Epirubicin 90mg/m2 iv d1 or divide into two days
75769947|NCT03876886|Drug|Cyclophosphamide|cyclophosphamide600mg/m2 iv d1,q14d*4cycles;with G-CSF support: 3ug/kg ih
75769948|NCT03876886|Drug|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d*4cycles
75769949|NCT03876886|Drug|Carboplatin|carboplatin AUC=3 iv d2, q14d*8cycles;with G-CSF support: 3ug/kg ih
75769950|NCT03876886|Drug|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d*8cycles
75769951|NCT03878992|Drug|Genotropin miniquick 0.5 mg, injection|GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
75769952|NCT01266772|Drug|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
75463625|NCT04985422|Behavioral|Smartphone-based Daily Ecological Momentary Intervention|Interventions are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted 6 random times a day over the set intervention period (4 weeks) to complete brief EMA and EMI intervention actions) across contexts in daily lives for the reduction of depressive symptoms, as well as rumination distress, and improve functioning.
75769953|NCT01266772|Drug|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
75769954|NCT01264354|Drug|Clevudine 30mg|Clevudine 30mg
75341300|NCT05395910|Drug|Paclitaxel|This is a prospective, two armed phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC/ePIPAC using paclitaxel in patients with peritoneal carcinomatosis.
75341301|NCT01566331|Device|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
75463626|NCT04985422|Behavioral|Smartphone-based Weekly-delivered Information|Information with simple actions for reducing depressive symptoms are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted weekly with a new set of information, together with a 5-min assessment. The information includes intervention actions provided in the EMI group.
75463627|NCT04970953|Procedure|Right heart catheterization|Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.
75769955|NCT01264354|Drug|Clevudine 20mg+Adefovir dipivoxil 10mg|Clevudine 20mg+ Adefovir 10mg
75769956|NCT01264354|Drug|Clevudine 20mg|Clevudine 20mg
75769957|NCT01264432|Other|Laboratory Biomarker Analysis|Correlative studies
75910057|NCT05995678|Behavioral|VA Solid Start|VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
75910058|NCT05994339|Drug|Almonertinib|Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.
75910059|NCT05993338|Diagnostic Test|right heart catheterization (RHC).|Assessment of pulmonary artery pressure in COVID-19 survivors using right heart catheterization (RHC).
75463628|NCT04965454|Combination Product|Fluorine-18 fluorocholine|18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.
75769958|NCT01264432|Other|Quality-of-Life Assessment|Ancillary studies
75769959|NCT01264432|Radiation|Radiation Therapy|Undergo LDFWAR
75769960|NCT01264432|Drug|Veliparib|Given PO
75769961|NCT03880318|Procedure|Joint Preserving Surgery in spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies
75769962|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 1|• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
75769963|NCT02527096|Drug|lamivudine (Epivir®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
75769964|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
75769965|NCT01160224|Drug|GW766944|Drug: GW766944 (Active Drug Treatment)
75769966|NCT01160224|Other|Placebo|This is placebo to match.
75769967|NCT03876730|Other|ICF CP Core Set|Core set
75769968|NCT01162564|Device|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
75769969|NCT01162642|Dietary Supplement|Green Tea|Green Tea 4 cups daily
75769970|NCT01162642|Other|Placebo|4 cups placebo tea for 6 weeks
75769971|NCT01266928|Drug|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
75769972|NCT01157962|Procedure|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
75769973|NCT03879928|Drug|Single ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
75769974|NCT03879928|Drug|Multiple ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
75769975|NCT03879928|Drug|Food effects of FM101|The study drug (FM101) will be administered orally under fasted condition and fed condition.
75769976|NCT01160302|Drug|Microgranular Curcumin C3 Complex®|4 grams twice daily for 21-28 days
75769977|NCT01162720|Procedure|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
75769978|NCT01162720|Procedure|Short duration tourniquet|Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
75769979|NCT01268176|Dietary Supplement|cholecalciferol|50,000 IU once per month for 3 months
75769980|NCT03878290|Behavioral|Resilience, Stress, and Ethnicity (RiSE)|Group based stress reduction program focused on helping minorities develop coping and empowerment skills
75910060|NCT05978986|Diagnostic Test|Determining of the clinical class of chronic venous disorders by artificial intelligence|The doctor takes pictures of the lower extremities and uploads them to the IVENUS application, which automatically determines the clinical class according to CEAP. Further, the doctor independently determines the clinical class according to CEAP and enters the data into the register.
75769981|NCT01264588|Other|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
75769982|NCT01267006|Drug|GSK1325756|GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
75769983|NCT01267006|Drug|Placebo tablet|Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
75769984|NCT01268332|Drug|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
75769985|NCT01162798|Other|infant formula|test infant formula fed to infants until 6 months corrected gestational age
75769986|NCT01162798|Other|control infant formula|commercially available infant formula
75769987|NCT01158196|Device|infra-red diode laser|"laser treatment of scar after keloid excision~laser treatment of surgery scar"
75769988|NCT01162876|Drug|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
75910061|NCT05978804|Other|Computerized Cognitive Training via BrainHQ|Computerized Cognitive training (BrainHQ)
75318077|NCT03024476|Drug|Pharmacological intensification based on olmesartan|"Study drug will be provided from the roll-in period.~Step I:~Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days~Use olmesartan 40 mg if mean systolic blood pressure >150 during the immediate past 2 days~Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg~Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg~Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg~If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.~Use of beta-blockers is permitted if clinically indicated.~At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule."
75463629|NCT04941924|Procedure|Intraductal Radio-Frequency Ablation|"The electrode employed in this study is the STARmed ELRA™ (Endo Luminal Radiofrequency Ablation) electrode; this is a CE marked device. The selected electrode will be connected to the VIVA™ Combo generator (also a CE marked device) and advanced over the guide wire.~The power of the generator should be set at either 7 or 10 W depending on the electrode used per manufacturer instructions. An ablation should then be applied at a temperature of 70 to 80℃ for 2 minutes. For longer length strictures or stent occlusions, the RFA probe is withdrawn from proximal to distal in a step by step fashion in respect to the access method used."
75910062|NCT05978804|Device|Active tDCS (tDCS) on DLPFC|Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
75463630|NCT04941924|Device|Biliary Stent Placement|Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
75463631|NCT04939454|Procedure|quadricipital biopsy|The primary endpoint will be evaluated by histological examination only. The technique of percutaneous biopsy using the modified Bergström needle technique is currently considered the best alternative in the context of research, as it allows sufficient material to be obtained for various analyses and is much less invasive than the reference technique (surgical biopsy). Indeed, unlike surgical biopsy which requires an operating room and is a relatively heavy procedure (two suture planes, skin incision of several centimeters, resting for 48 hours after the procedure...), percutaneous biopsy by the modified Bergström technique can be performed in a consultation room, requires only one stitch, and allows resumption of walking 30 minutes after the end of the procedure.
75769989|NCT03877588|Dietary Supplement|Oral Nutritional Support|Preoperative oral nutritional support is provided according to malnutrition grade
75769990|NCT05666908|Device|HFNO|After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) > 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.
75769991|NCT03876418|Diagnostic Test|Intra-abdominal Pressure|Aggressive screening, prevention and treatment of intra-abdominal hypertension
75769992|NCT01158274|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
75769993|NCT01158274|Drug|capecitabine|Given orally
75769994|NCT01158274|Other|laboratory biomarker analysis|Correlative studies
75318078|NCT03024476|Device|Bluetooth-equipped sphygmomanometer|"Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)"
75318079|NCT03024086|Drug|DWJ1252|DWJ1252 and Placebo of Gasmotin
75910063|NCT05965869|Other|diabetes program|CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
75910064|NCT05963932|Drug|BMS-986419 DR Capsule|Specified dose on specified days
75769995|NCT05666830|Device|Lando® artificial dermal regeneration matrix|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
75769996|NCT03876496|Device|SensableCare System|"The Sensable®Care Mattress has sensors embedded in it. Sensable®Care System is able to identify if the subject is stirring in bed, sitting up from the bed, attempting to leave the bed, or being out of the bed. If the subject is found to be in any of these four scenarios, four different types of alerts/notifications will warn clinicians: Stirring Notification, Sitting Up Notification, Bed Leaving Alert, Out of Bed Alert, will be generated by Sensable®Care System respectively.~Once these four alerts/notifications are generated, designated attending nurses or caregivers equipped with a mobile app will receive audible, vibratory, and/or visual alerts from the Dashboard with subject's room number and type of alert displayed mobile app. Thus, interventions/assistance can be carried out presumably early. Harm to patient safety may be prevented."
75769997|NCT01267084|Drug|Trabectedin|Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
75769998|NCT01267084|Drug|Ketoconazole|Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
75769999|NCT01267084|Drug|Dexamethasone or equivalent steroid|Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
75770000|NCT01158352|Dietary Supplement|Nutritional supplementation formula|Nutritional supplementation formula
75770001|NCT01158352|Dietary Supplement|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
75770002|NCT01162954|Drug|DA-6034|
75770003|NCT01162954|Drug|Placebo|
75770004|NCT01264666|Dietary Supplement|Chinese tea flavor liquor|60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
75463632|NCT04937998|Procedure|Autologous PRP injection|Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis
75463633|NCT04937998|Procedure|HA injection|Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis
75770005|NCT01264666|Dietary Supplement|Chinese Meijiao liquor|
75770006|NCT01264666|Dietary Supplement|Water control|
75617300|NCT02832934|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
75770007|NCT01160692|Dietary Supplement|Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months
75770008|NCT01160692|Other|Placebo|Daily oral intake of matching placebo tablets for 3 months
75617301|NCT02832934|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
75617302|NCT04247776|Combination Product|Prehab|Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing
75770009|NCT01158430|Behavioral|ACT group therapy|Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours
75770010|NCT01264822|Drug|Rabeprazole Sodium|"The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg."
75463634|NCT04937309|Device|non invasive auricular vagal stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles
75617303|NCT04247776|Other|ERAS|Enhanced Recovery After Surgery guidelines are applied.
75770011|NCT03880006|Behavioral|Case management|Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
75770012|NCT01161004|Drug|Sugammadex - Nacl 9/00|"Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~Nacl 9/00: same volume as Sugammadex"
75770013|NCT01161004|Drug|Nacl 9/00 - sugammadex|"Nacl 9/00: same volume as Sugammadex~Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses."
75463635|NCT04937309|Drug|usual medical treatment|Standard anti emetic treatments to prevent emesis due to chemotherapy
75770014|NCT03876340|Other|Treatment algorithm|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.
75910065|NCT05963932|Drug|BMS-986419 IR Tablet|Specified dose on specified days
75910066|NCT05949437|Other|Yuga|Traditional yoga body posture for 15 minutes, yoga breathing exercises for 30 minutes and meditation for 5 minutes for 12 weeks
75770015|NCT03876340|Other|Current treatment|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
75770016|NCT01163110|Dietary Supplement|Realbuild|Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
75910067|NCT05949437|Other|Aerobic exercises|in form of treadmill according to the target exercise heart rate for 12 weeks
75910068|NCT05942781|Device|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period.
75770017|NCT01264900|Behavioral|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
75770018|NCT01264978|Device|Repetitive magnetic stimulation of the quadriceps muscle|"During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions."
75910069|NCT05942781|Device|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
75463636|NCT04937309|Device|sham stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles, with a sham device
75463637|NCT04933552|Other|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod, that have started before inclusion of the patient into the study will be enrolled.
75463638|NCT04924985|Other|Non-Physiological Feedback CPR|Non-physiologically guided CPR using AV feedback (integrated into defibrillators)
75463639|NCT04924985|Other|Physiological Feedback CPR|Physiological feedback CPR using an optimal regional O2 Saturation (rSO2), End-tidal CO2 (ETCO2) or combined (rSO2/ETCO2) target
75463640|NCT04917484|Drug|Lu-177-DOTA-Octreotide|Lu-177-DOTATOC in standard doses or individualized doses.
75463641|NCT04916613|Drug|Darolutamide 300 mg|600 mg po, b.i.d.
75463642|NCT04916613|Drug|Placebo|po, b.i.d.
75463643|NCT04916613|Drug|Androgen deprivation therapy|Use according to local standard of care
75463644|NCT04916314|Behavioral|Low Carbohydrate diet|Second Nature is a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), encouraging adoption of a low energy, low-carbohydrate diet, peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application; each participant additionally receives an instructional handbook, and recipe book (+/-wireless weighing and activity tracking technology).
75463645|NCT04893525|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.
75463646|NCT04878679|Other|Strenght training combined with WB-EMS|Bodyweight exercise training combined with WB-EMS (2 times/week) with a 85Hz electrical impulse
75910070|NCT05930418|Diagnostic Test|Cardiac MRI|Cardiac Magnetic Resonance provides more sensitive measure of ventricular volume and ejection fraction as well as novel markers of tissue characterization and edema assessment.
75910071|NCT05924360|Other|conventional exercise program|The conventional treatment program will be applied to all participants included in the study, consisting of wand, codman, active and passive stretching exercises. This program will be administered to all patients five days a week. Wand exercises will be applied in the directions of flexion, abduction, extension, internal and external rotation, and will consist of 10 repetitions. Codman exercises will be applied in the directions of flexion, abduction, and circular, and will also consist of 10 repetitions. Active and passive stretching exercises will be applied in the directions of flexion, abduction, and external rotation, and will consist of 10 repetitions.
75910072|NCT05924360|Other|Mulligan application|The mobilization with movement technique, a part of Mulligan applications, will be performed twice a week in the directions of flexion, abduction, and external rotation.
75910073|NCT05924360|Other|Maitland application|Maitland Group: The Maitland application will be applied in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be administered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
75318080|NCT03024086|Drug|Gasmotin|Gasmotin and Placebo of DWJ1252
75463647|NCT04878679|Other|Cardiovascular training with WB-EMS|Cardiovascular training , using the rowing machine, combined with WB-EMS (2 times/week) with a 7Hz electrical impulse
75463648|NCT04878679|Other|Control group|No physical activity
75617304|NCT04247776|Behavioral|Fitbit|Fitbit is worn to monitor step counts.
75617305|NCT02830750|Procedure|Ablation|
75318081|NCT04407104|Diagnostic Test|skin prick-test|retrospective study on data already collected
75318082|NCT03598400|Behavioral|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
75318083|NCT03598400|Behavioral|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
75318084|NCT03598322|Procedure|Dextrose 1mL injection|Dextrose 1mL injection and hydrodissection for CTS
75318085|NCT03598322|Procedure|Dextrose 2mL injection|Dextrose 2mL injection
75617306|NCT02832700|Dietary Supplement|Casein glycomacropeptide|
75617307|NCT02832700|Dietary Supplement|Placebo|
75617308|NCT02832466|Other|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
75617309|NCT05223790|Device|Pain measurement during care procedures in neonatal reanimation|Pain measurement during care procedures in neonatal reanimation
75770019|NCT03876574|Procedure|DSA-guided implantation of hepatic artery infusion pump|Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.
75910074|NCT05924360|Device|TENS|TENS application will be administered for 20 minutes at 100Hz
75936299|NCT03522207|Diagnostic Test|polysomnography|BASELINE PSG Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
75770020|NCT03876574|Drug|Gemcitabine|Given intra-arterially for 30 minutes
75770021|NCT03876574|Drug|Floxuridine|Given intra-arterially continuously for 14 days
75770022|NCT03876574|Drug|dexamethasone|Given intra-arterially continuously with 5-FUDR
75770023|NCT01158508|Procedure|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
75770024|NCT01268722|Device|Balloon angioplasty|This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
75770025|NCT01268722|Device|Primary stenting|This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
75770026|NCT01161082|Drug|REGN727(SAR236553)|subcutaneous
75770027|NCT01158586|Drug|Levobupivacaine|patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
75770028|NCT01158742|Other|Glomerular Filtration Rate with Iothalamate|used to determine kidney function
75770029|NCT01158742|Other|Glomerular Filtration Rate with Iohexol|used to determine kidney function
75770030|NCT01267396|Drug|Sertraline|Sertraline Hydrochloride Tablets 100 mg
75463649|NCT04878445|Procedure|Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.|Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.
75463650|NCT04877327|Procedure|Ablation|Cryotherapy and radiofrequency
75770031|NCT05018884|Procedure|Observation of surgical site infections|No intervention is done, only observation of routine clinical practice
75770032|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
75770033|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
75770034|NCT01158898|Drug|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
75936300|NCT03522207|Drug|Trazodone|100 mg trazodone or placebo given once 30 minutes prior to 2nd PSG
75936301|NCT03522207|Drug|Placebos|placebo per os 30 minutes prior to 2nd PSG
75318086|NCT03598322|Procedure|Dextrose 4mL injection|Dextrose 4mL injection
75318087|NCT05631314|Procedure|operative treatment|Operative treatment can consist of open reduction and volar and/or dorsal plating or closed reduction and fixation with K-wires, external fixateur.
75318088|NCT05631314|Procedure|non-operative treatment|Non-operative treatment will consist of immobilization in a below the elbow cast for 4-6 weeks with or without prior closed reduction.
75318089|NCT04009070|Device|Acupuncture Pres Needle: 0.22x1.5 mm needle|Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.
75463651|NCT04875130|Diagnostic Test|blood samples|Taking blood samples (plasma, serum) and measure the level of Adrenomedullin
75463652|NCT04865848|Procedure|Dental local anesthesia|Dental local anesthesia
75463653|NCT04864808|Behavioral|Behavioral Parent Training|Parents will receive sessions of behavioral parent training with components specifically targeted toward parents with ADHD. The number of sessions will be informed based on stakeholder feedback. Treatment will be delivered via telehealth.
75617310|NCT02832232|Other|translational dorsal glide mobilization technique grade III|"Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
75770035|NCT02527018|Device|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
75770036|NCT01161238|Other|Monitored for limb volume|Subjects are monitored for limb volume change using bioimpedance analysis
75770037|NCT01267474|Other|Nutritional education|"A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts."
75770038|NCT01267474|Other|Control|The control group received only three one-hour general sessions on health issues.
75770039|NCT01267552|Procedure|Non drains will be placed during operation|Non drains will be placed during operation
75770040|NCT01267552|Procedure|Closed suction drainage|Closed suction drainage will be placed during operation
75770041|NCT01159132|Drug|raltegravir|12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
75770042|NCT01161316|Drug|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|"Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
75770043|NCT01161316|Drug|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.|"Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
75770044|NCT01161550|Drug|Granulocyte colony-stimulating factor (G-CSF)|
75770045|NCT01161550|Drug|Cladribine|
75770046|NCT01161550|Drug|Cytarabine|
75770047|NCT01161550|Drug|All-Trans Retinoic Acid (ATRA)|
75463654|NCT04859322|Drug|Glucagon|Pancreatic clamp
75770048|NCT01161550|Drug|Midostaurin|
75770049|NCT01159210|Biological|Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)|Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.
75770050|NCT03877198|Device|Automated oxygen control by the CLiO2 algorithm|Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period
75770051|NCT03877198|Device|Automated oxygen control by the Oxygenie algorithm|Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
75770052|NCT01159288|Biological|Dex2|"Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.~Induction immunotherapyIntradermal injections of Dex once a week during 4 consecutive weeks.(Peptides pulsed onto DC, sources of Dex: PRS pan-DR, MAGE-3 DP04, MAGE-1 A2, MAGE-3 A2, NY-ESO-1 A2 et MART-1 A2)~Continuation Immunotherapy: Intradermal injections of Dex every two weeks during 6 weeks."
75770053|NCT03879460|Drug|Naltrexone Hydrochloride|50 mg per os naltrexone hydrochloride
75770054|NCT03877120|Drug|Dexmedetomidine 0.004 MG/ML|Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.
75770055|NCT03877120|Drug|Diazepam Injectable Solution|diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.
75770056|NCT01159366|Procedure|percutaneous coronary intervention|early timing
75910075|NCT05920226|Device|pacemakers implantation and assessment of cardiac function and cardiac fibrosis|"150 patients will be implanted with pacemakers. In addition to the echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers, the tests described above will be repeated at 1 (V1), 12 (V2), 24 (V3) months after inclusion. Echocardiography and peripheral venous blood sampling for myocardial fibrosis markers detection will be repeated to all patients before pacemakers implantation and after 6,12 and 24 months of observation period. Contrast-enhanced cardiac magnetic resonance imaging (MRI) will be performed before pacemaker implantation and 6 months after surgery.~In addition, pacemakers programming data will be evaluated after 1, 12, 24 months after inclusion in the study (atrioventricular delay, percentage of ventricular stimulation, episodes of high atrial frequency, fibrillation/atrial flutter, ventricular tachycardia)."
75910076|NCT05920226|Diagnostic Test|assessment of cardiac function and cardiac fibrosis|The patients who do not require a pacemaker placement will undergo diagnostic testing such as echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers.
75463655|NCT04846647|Behavioral|unexplained hypophoshatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
75770057|NCT01267786|Procedure|Liver surgery|hepatectomy
75770058|NCT03879382|Biological|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
75770059|NCT03879382|Drug|Fludarabine|30mg/m2/d
75770060|NCT03879382|Drug|Cyclophosphamide|300mg/m2/d
75770061|NCT03874780|Device|Vibe Delivery system|delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system
75770062|NCT03874390|Other|ozone|gaseous ozone was applied on periodontal pocket two times in one week.
75770063|NCT01265290|Device|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
75770064|NCT01265290|Device|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
75770065|NCT01166932|Drug|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
75770066|NCT01166932|Drug|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
75770067|NCT01167010|Drug|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
75770068|NCT01167010|Drug|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
75770069|NCT01167010|Drug|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
75770070|NCT01280188|Drug|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
75770071|NCT01280188|Drug|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
75770072|NCT01269502|Device|"Temp Touch Diabetica Solutions inc."|Daily measurement of skin temperature on feet for one year
75770073|NCT01269502|Other|Inspection|Inspection of feet daily for one year
75770074|NCT03872050|Diagnostic Test|No intervention apart from tests, including interview|No interventions
75770075|NCT01167088|Drug|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
75770076|NCT01167088|Drug|Placebo|Placebo
75318090|NCT04008602|Device|Quick icing|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
75770077|NCT03871972|Drug|Umbilical Cord Blood Unit|3 infusions of umbilical cord blood (UCB) unit (TNC > 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
75770078|NCT01164982|Device|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
75770079|NCT01165060|Drug|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
75910077|NCT05918406|Combination Product|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
75910078|NCT05916092|Device|TransLoc 3D|TransLoc 3D SI Joint Fusion System
75910079|NCT05903820|Drug|Estradiol patch|Transdermal patch of estradiol
75910080|NCT05903820|Drug|Progesterone|Oral progesterone capsules 100mg/day
75910081|NCT05901675|Other|Lifestyle Management Program|The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.
76072569|NCT01816243|Drug|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
76072570|NCT01816243|Drug|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
75318091|NCT04008602|Device|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the decreased nerve conduction velocity.
75463656|NCT04846374|Device|PowerPort|The study will compare pheresis sessions with the old system versus pheresis sessions with one of two new configurations.
75463657|NCT04839666|Drug|Propofol|Perioperatively propofol administration
75617311|NCT02832232|Other|pressure maintained suboccipital Inhibition technique|"Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
75617312|NCT02832232|Other|Control Group|Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
75617313|NCT02830828|Other|Investigation of precision pinch grip control|
75318092|NCT04008524|Biological|CAR-T cells|Chimeric Antigen Receptor-T cells
75617314|NCT02830516|Other|Measurement of lung elastance by two methods|Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
75770080|NCT01280578|Device|Transcatheter PFO Closure|Transcatheter PFO Closure
75318093|NCT05631158|Diagnostic Test|MRI|"The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.~All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.~For future proving the value of our study, we will also collect and store blood samples at the initial visit."
75770081|NCT01165294|Drug|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
75770082|NCT01165294|Drug|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
75770083|NCT03871738|Other|Proprioceptive training|"The intervention to the experimental group will consist of the application of the protocol of proprioception exercises. Before the exercises of the protocol, a warm-up will be carried out that will last 3 minutes and consists of exercises of joint mobility and jumping rope.~The protocol consists in carrying out two exercises per session, of 10 minutes each. A minute of rest will be implemented between the warm-up and the completion of the protocol, in addition to one minute between the two proprioception exercises in each session. The exercises will vary from week to week, and all the protocol exercises should be done barefoot. The exercise protocol proposed in this study consists of a total of 7 exercises: of unipodal and bipodal support, with unstable surfaces and postural changes."
75318094|NCT05631080|Procedure|Anatomical Endoscpic enucleation of the Prostate|Transurethral endoscopic enucleation of the prostate adenoma
75463658|NCT04838262|Other|Acute Stressors|Sympathetic nervous system activity and blood pressure will be measured before, during, and after several acute laboratory-based cognitive (Stroop Color Word Test), emotional (International Affective Picture System), and physiological (Cold Pressor Test) stressors.
75463659|NCT04831957|Diagnostic Test|Assesment of thyroïd function|Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample
75770084|NCT01165372|Drug|Artesunate or dihydroartemisinin-piperaquine|artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
75770085|NCT03871660|Device|FreeStyle Libre Pro|Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
75770086|NCT03871582|Other|No intervention|Cross-sectional
75770087|NCT01167322|Drug|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
75318095|NCT03591224|Other|Pharmacogenomic Testing|pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism
75318096|NCT03591224|Other|Pharmacist Standard of Care|Pharmacist providing standard of care as per usual practice
75770088|NCT01269814|Procedure|Gastroscopy|Gastroscopy
75770089|NCT01280734|Drug|Circadin (R) 2 mg|One 2 mg tablet at 23:00
75770090|NCT01280734|Drug|Stilnox (R) 10 mg|One 10 mg encapsulated tablet at 23:00
75770091|NCT01280734|Drug|Placebo|One tablet or encapsulated tablet at 23:00
75770092|NCT03871504|Other|Submaximal isometric exercise|The exercise is a submaximal isometric contraction
75770093|NCT01269892|Dietary Supplement|lactose-free milk|a milk without lactose
75770094|NCT01269892|Dietary Supplement|conventional milk|a milk with lactose
75770095|NCT01280890|Behavioral|Staff training using VIPS|Staff training using the VIPS framework
75770096|NCT01280890|Behavioral|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
75770097|NCT01280890|Behavioral|Control group|Filmed traditional Lectures will be given to care staff
75770098|NCT01269970|Other|18-FDG-PET-CT|
75770099|NCT01587430|Drug|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
75770100|NCT01587430|Drug|standard dose ARA-C|
75463660|NCT04827420|Behavioral|Mi Quit Care|Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.
75463661|NCT04825106|Other|Diagnostic context|A life-threatening situation occurs in 3 different contexts
75463662|NCT04824846|Behavioral|Integrated back pain module (IBPM)|All Ambulance drivers will be screening with the Proforma to determine their low back pain symptoms. Those workers who are diagnosed with mechanical back pain during the 12 months fulfill a self-report quality of life questionnaire (SF-36). Then Integrated back pain module (IBPM) will be delivered to them after the introduction course conducted for 1 day and then the intervention will last for 6 months. Research staff will explain how to operate and use the module. Subjects must comply with all the care and prevention guidelines of the research module so that it achieves the expected results. They also need to complete the checklist provided in the Edmodo software via their respective smartphones.
75770101|NCT03874000|Biological|Sintilimab|Given IV
75770102|NCT03874000|Drug|Metformin Hydrochloride|Given PO
75910082|NCT05901675|Other|Post-stroke Optimization of Walking using Explosive Resistance|POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
75910083|NCT05888402|Drug|Toripalimab|Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.
75910084|NCT05888402|Radiation|Concurrent chemoradiation therapy and consolidation immunotherapy|Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.
75910085|NCT05888207|Drug|Savolitinib|Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
75770103|NCT01165528|Procedure|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
75770104|NCT01167400|Behavioral|Cybercycling|exercising on a videogame-enhanced interactive 3D stationary bicycle for 3 months, 3-5x/wk
75318097|NCT03590990|Diagnostic Test|Ultrasonsography, mammography, biopsy|Ultrasonsography of lump in breast Mammography of patents above 35 years Biopsy if indicated
75318098|NCT05631002|Diagnostic Test|Chemical shift encoding-based water-fat MRI|Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
75318099|NCT03590912|Drug|Mometasone 50 Mcg/Inh Nasal Spray|One spray in each nostril once daily for one month
75770105|NCT01167400|Behavioral|Traditional exercise|exercising on a traditional stationary bike for 3 months, 3-5x/wk
75770106|NCT03757234|Drug|Omadacycline|po tablets
75770107|NCT03757234|Drug|Levofloxacin|iv solution/po tablets
75770108|NCT03757234|Drug|Omadacycline|iv solution
75770109|NCT03756766|Diagnostic Test|RSV point of care testing|Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
75770110|NCT03874156|Drug|Atorvastatin 40mg|Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
75770111|NCT03874156|Drug|Placebo Oral Tablet|Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
75770112|NCT01165606|Procedure|Chest physiotherapy|
75770113|NCT01586650|Other|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
75770114|NCT01586650|Other|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
75770115|NCT01586728|Other|Air - oxygen|"his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)~nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%."
75770116|NCT01586728|Other|Oxygen - Air|"nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%."
75770117|NCT01167478|Dietary Supplement|Caffeine|After ingestion of 6 mg.kg-1 of body mass of caffeine, subjects will perform the one exercise trial.
75770118|NCT01167478|Dietary Supplement|Caffeine|6 mg/kg of body mass of caffeine will be ingested by subjects before exercise.
75770119|NCT01281358|Other|HOP-ON|A programme of activities which promote motor development
75770120|NCT01281358|Other|SMILES|Details are provided on ways for parents to interact with their premature infants
75770121|NCT01281436|Other|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
75770122|NCT01281436|Other|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
75770123|NCT01587196|Drug|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
75770124|NCT01281514|Drug|everolimus|Given PO
75910086|NCT05888207|Drug|Fluvoxamine|Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
75617315|NCT04247152|Other|Intraoperative Aberrometry vs preoperative biometry|Hypothesis: Intraoperative aberrometry measures lower levels of astigmatism more accurately than preoperative biometry in patients undergoing cataract surgery.
75770125|NCT01281514|Drug|carboplatin|Given IV
75770126|NCT01281514|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
75770127|NCT01281514|Other|laboratory biomarker analysis|Correlative studies
75910087|NCT05887843|Drug|Mometasone + Azelastine|Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril
75617316|NCT02832310|Procedure|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
75770128|NCT00223080|Biological|ALVAC-HIV vCP1521 + AIDSVAX|Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL
75770129|NCT00223080|Other|ALVAC Placebo + AIDSVAX Placebo|ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection
75770130|NCT03871192|Diagnostic Test|FACET JOINT UNDER CT GUIDANCE|injection of triamcinolone in the facet joint under CT guidance
75910088|NCT05887843|Drug|Mometasone Furoate|Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril
75770131|NCT03871192|Diagnostic Test|NERVE BLOCK UNDER CT GUIDANCE|injection of triamcinolone around the dorsal ramus under CT guidance
75910089|NCT05887843|Drug|Azelastine Hydrochloride|Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril
75910090|NCT05883163|Device|Stimit Activator 1|The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.
75463663|NCT04824846|Other|Health Educational Pamphlet.|In Health Educational Pamphlet (HEP) sessions, Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
75770132|NCT03871192|Diagnostic Test|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone in the facet joint under fluoroscopy guidance
75770133|NCT03871192|Diagnostic Test|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone around the dorsal ramus under fluoroscopy guidance
75770134|NCT03871192|Diagnostic Test|FACET JOINT UNDER ULTRASOUND GUIDANCE|injection of triamcinolone in the facet joint under ultrasound guidance
75770135|NCT03871192|Diagnostic Test|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|injection of triamcinolone around the dorsal ramus under ultrasound guidance
75463664|NCT04820257|Behavioral|Home based exercise|Exercise at home and behavioural change to increase daily exercise
75463665|NCT04818502|Device|Tendyne™ Mitral Valve System|Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.
75463666|NCT04814888|Other|intubation with a cuffed ETT by a printed 3D airway model|Two anaesthesiologists unaware of patient's demographic data such as patient's height, weight, and age predicted and recorded ETT size by inserting various sized cuffed-ETTs (MallinckrodtTM Hi-Lo tracheal tube, Covidien, Ireland) to a printed 3D airway model. If the diameter of trachea undersized, air leak around ETT can occur. In that case, we can use that ETT after inflating the pilot balloon with small amount of air. Standard monitoring (non-invasive blood pressure measurement, electrocardiogram, and pulse oximetry) was applied to pediatric patients in the operating room and general anesthesia was induced with ketamine 1 mg/kg and rocuronium 0.6 mg/kg and maintained with sevoflurane. After intubation with a cuffed ETT by a printed 3D airway model was finished, an air leak test was performed by one of three anaesthesiologists dedicated to pediatric cardiac anesthesia.
75617317|NCT02831920|Other|CEUS and targeted biopsies|
75617318|NCT02831920|Other|MRI and targeted biopsies|
75617319|NCT02830672|Procedure|Surgical release A1 pulley for Trigger finger of the hand|
75617320|NCT02832076|Procedure|Subcutaneous negative suction drain for 10 days|
75617321|NCT02832076|Procedure|No subcutaneous drain|
75770136|NCT02526784|Drug|degarelix|
75770137|NCT03971682|Behavioral|PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP program is a structured individualized program for detained youth based on Compassion Focused Therapy, aimed to develop a compassionate motivation in these youth.~Treatment As Usual Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation."
75770138|NCT03971682|Other|Treatment As Usual - TAU|Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
75770139|NCT02526706|Other|VisionBlue|VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
75770140|NCT01281592|Drug|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
75770141|NCT03971604|Drug|Vitamin A|treated with Vitamin A
75910091|NCT05880784|Other|Reinforcement of Peer coaching and clinical audit|The goal of the proposed research study is to test the effectiveness and feasibility of an intervention to enhance peer coaching and clinic audit activities to facilitate the implementation of the Package of Essential Non- Communicable Diseases (PEN) in Nepal.
75318100|NCT03590912|Drug|Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)|Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks
75910092|NCT05880784|Other|Continuation of usual practice without intervention|No intervention will be carried out, instead usual practice will be evaluated at the start and the end of the study period.
75617322|NCT02831842|Drug|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
75910095|NCT05878405|Other|Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Given PO
75910096|NCT05878405|Other|Methylene Blue Oral Rinse|Given PO
76072571|NCT05484778|Procedure|Dual tasking paradigm|The dual task methodology is a testing model that requires one person to perform two tasks at the same time. The dual task is divided into two as motor-motor or motor-cognitive. Dual tasks provide an opportunity to examine the attention demands of both tasks and allow possible interference to be observed. The idea behind this design is that central processing capacity has a limit and must be distributed among concurrent tasks.
75318101|NCT03590912|Drug|Steroid Drug (prednisolone)|This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.
75770142|NCT03971604|Drug|Vitamin E|treated with Vitamin E
75318102|NCT03598010|Device|Actitan-F (7dd)|1 sack every 4 hours, maximum 4 sacks/day for 7 days.
75617323|NCT02831842|Drug|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
75617324|NCT02831842|Drug|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
75770143|NCT02531490|Drug|Labetalol|
75770144|NCT02531490|Drug|Nifedipine|
75318103|NCT03598010|Device|Actitan-F (28dd)|1 sack every 4 hours, maximum 4 sacks/day for 28 days.
75318104|NCT00503113|Drug|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) injection every 3 months
75617325|NCT00891046|Drug|Canakinumab|Canakinumab
75617326|NCT02830282|Other|Blood Collection|
75617327|NCT04245982|Procedure|Gingival biopsy|Two gingival biopsies from each participant were collected.
75617328|NCT02830048|Drug|Glibenclamide|
75617329|NCT02830126|Other|Anesthesiology Control Tower Feedback|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
75617330|NCT04245358|Device|Ainara|1g of gel per administration
75770145|NCT02531490|Drug|Methyldopa|
75770146|NCT02526472|Procedure|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
75770147|NCT02526472|Procedure|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
75770148|NCT03871114|Drug|Triamcinolone Acetonide in orabase|treatment of OLP with topical steroid
75770149|NCT01272622|Radiation|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
75463667|NCT04805216|Procedure|Blood test|"Participants will have blood tests at baseline (nearest 30 day incremental time point after 2nd dose of Covid-19 vaccine, +/- 7 days):~T, B & NK cells~Full Blood Count and differential~Serum Immunoglobulins~Antibodies against VZV, CMV, Rubella~Quantiferon assay (T-Cell response)~Covid antibody assay (LIAISON® SARS-CoV-2 S1/S2 IgG quantitative assay)~Participants will have blood tests during follow up (after second dose of Covid-19 vaccine) with a window of +/- 7 days:~Blood test 2 - performed at the next 30 day time point (Covid antibody assay)~Blood test 3 - performed at the next 30 day time point (Covid antibody assay and quantiferon* if final blood test)~Blood test 4 (optional) - performed at the next 30 day time point (Covid antibody assay)~Blood test 5 (optional) - performed at the next 30 day time point (Covid antibody assay and quantiferon* if final blood test)~Quantiferon assay will be only be performed where possible."
75770150|NCT01272622|Other|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
75770151|NCT01281670|Other|vibration|8 week vibration
75770152|NCT01281748|Drug|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
75770153|NCT01281748|Other|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
75770154|NCT03873610|Behavioral|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
75770155|NCT03873610|Behavioral|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
75770156|NCT00220740|Drug|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
75770157|NCT00220740|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
75770158|NCT03870958|Procedure|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
75770159|NCT03870958|Procedure|Control|Children allocated to this group will receive the same dietary advices and brushing instructions.
75770160|NCT01167556|Behavioral|Family Motivational Intervention|A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
75770161|NCT01074606|Device|AcrySof Toric Intraocular Lens|Implantation of the AcrySof Toric Intraocular Lens (IOL)
75770162|NCT01273402|Drug|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
75770163|NCT01273714|Procedure|thyroid resection|bilateral subtotal versus total thyroidectomy
75770164|NCT03873688|Other|expiratory muscle training|The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
75770165|NCT01167790|Procedure|buccal cavity examination|autofluorescence examination
75770166|NCT03873454|Device|Sennheiser non-occlusive headphones|Patients listened to music of their choice using non-occlusive headphones
75770167|NCT03873454|Device|Sennheiser non-occlusive headphones without music|Patients wore non-occlusive headphones but had no music playing
75770168|NCT03873454|Other|No Sennheiser non-occlusive headphones|Patients did not wear non-occlusive headphones and did not listen to music
75463668|NCT04804007|Drug|Etoposide|etoposide will be provided with prescription for etoposide 50mg orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.
75617331|NCT02829892|Device|Light therapy|14-days exposure with an innovative ambient light
75617332|NCT02828800|Other|Cartography of allodynic and hypoasthetic territories|The cartography of allodynic and hypoasthetic territories will be performed by applying a tactile stimulation of an application force of 15g (for allodynia) or 0.7g (for hypoesthesia). Tracings will be plotted on tracing paper layer that will then be evaluated by the VISITRAK® tool (Smith & Nephew), validated method reproducible and standardized, enabling accurate measurement of the area concerned .
75617333|NCT02829970|Behavioral|SUCCEEDS Program|Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention & Alcohol Disorders (BAAAD).
75617334|NCT02829970|Behavioral|Living a Healthy College Lifestyle|Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
75617335|NCT02828722|Other|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
75770169|NCT01274728|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
75770170|NCT03873298|Drug|Inhaled nitric oxide|Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
75318105|NCT00503113|Drug|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) infusion every 3 months
75318106|NCT00503113|Drug|Alendronate|70mg per oral (po) weekly
75463669|NCT04801381|Procedure|Aquablation therapy|Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA
75463670|NCT04801381|Procedure|Transurethral laser enucleation|Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).
75617336|NCT02828722|Other|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
75910097|NCT05871385|Device|rTMS group|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises
75463671|NCT04799665|Diagnostic Test|Breast CT|This is a cross-sectional clinical study to determine the feasibility of breast CT for breast density assessment and association of CT-derived density measures with metabolic syndrome in overweight/obese Mexican-origin women in Southern Arizona. There is no intervention.
75463672|NCT04782180|Drug|Descovy 200Mg 25Mg Tablet|daily Descovy tab by mouth
75617337|NCT04245592|Dietary Supplement|Extra Virgin Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of organic EVOO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
75617338|NCT04245592|Dietary Supplement|Refined Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of ROO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
75617339|NCT02828332|Other|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
75617340|NCT02828332|Other|Quality of life|Evaluation of the quality of life and comorbidities
75617341|NCT02828566|Drug|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
75463673|NCT04782180|Behavioral|PrEP|PrEP will be provided in a community setting by community-based harm reduction program.
75463674|NCT04763499|Other|freeze dried strawberry powder|approximately 24 strawberries that have been freeze dried into a powder
75770171|NCT00184002|Drug|Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone|"Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~1 cycle = 21 days.~Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
75770172|NCT01167868|Drug|FosD|oral tablet
75910098|NCT05871385|Device|placebo rTMS group|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo placebo rTMS plus designed vestibular rehabilitation exercises.
75318107|NCT00542971|Drug|Idarubicin|12 mg/m^2 IV over 1 hour daily (days 1-3)
75463675|NCT04762017|Drug|OCS-05 IV administration|Multiple Dose of OCS-05 IV administration for 5 consecutive days
75463676|NCT04762017|Other|Placebo IV administration|Placebo IV administration for 5 consecutive days
75617342|NCT02828566|Drug|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
75617343|NCT02828566|Drug|IN saline 0.9%|Intranasal 0.9% normal saline
75617344|NCT02828566|Drug|IV saline 0.9%|Intravenous 0.9% normal saline
75617345|NCT04245046|Drug|Candesartan, Amlodipine, Atorvastatin|compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
75617346|NCT02828176|Procedure|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.~these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
75617347|NCT02828176|Procedure|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
75617348|NCT02828176|Procedure|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
75617349|NCT02828176|Procedure|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
75617350|NCT02829580|Procedure|Echocardiography|Measures by Doppler and study of endothelial function
75617351|NCT02828410|Dietary Supplement|SBI|Serum bovine immunoglobulin protein isolate 10 g twice per day
75770173|NCT01167868|Drug|Placebo|oral tablet
75910099|NCT05866367|Drug|Low dose Regular Insulin|Regular insulin administered intranasally at either 40 IU
75318108|NCT00542971|Drug|Sorafenib|Starting dose 400 mg by mouth for 7 days
75318109|NCT00542971|Drug|Ara-C|1.5 g/m^2 IV over 24 hours daily (days 1-4)
75341302|NCT01566409|Drug|Polyethylene glycol 3350|Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
75463677|NCT04757584|Drug|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On [A] vs Off [B]) with 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
75770174|NCT01167946|Drug|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
75463678|NCT04756791|Procedure|SAPB|local anesthetic is injected between the serratus anterior and latissimus dorsi muscles.
75463679|NCT04756791|Procedure|Local Injection Anesthesia|Anesthesia is injected directly into the tissue that is will be numbing.
75463680|NCT04752475|Drug|Furosemide|Furosemide 20 mg pill taken daily for 5 days
75770175|NCT01167946|Drug|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
75770176|NCT01167946|Drug|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
75770177|NCT01326234|Behavioral|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
75770178|NCT01326234|Behavioral|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
75770179|NCT01072110|Procedure|Colonoscopy|Patients will undergo colonoscopy for evaluation of their symptoms.
75463681|NCT04752475|Other|Placebo|Identical-appearing placebo pill taken daily for 5 days
75770180|NCT01072110|Procedure|Confocal Laser Endomicroscopy|Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
75910100|NCT05866367|Drug|High dose Regular insulin|Regular insulin administered intranasally at either 80 IU
75463682|NCT04748289|Device|ICU Cockpit software testing|"the ICU Cockpit Software Platform is intended to be used for monitoring of patient characteristics and vital physiological parameters in patients at the Neurointensive Care Unit of the University Hospital Zurich.~Furthermore, three different applications for prognostication and prediction of complications will be tested:~ICU Cockpit COVID-19 for remote monitoring of isolated patients,~ICU Cockpit Stable State for a comprehensive visualization of vital parameters and as additional aid in early detection of imminent critical complications~ICU Cockpit Cerebral Ischemia for the prediction of delayed DCI in patients with subarachnoid hemorrhage (SAH)."
75463683|NCT04746586|Other|Circulating MiRNA indentification|Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS
76072572|NCT05576896|Drug|Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab|"Prior to starting therapy, patients will have a pretreatment cross-sectional scan. Patients will then begin with encorafenib 300 mg daily starting with Cycle 1 day 1; then patients will receive IV cetuximab weekly, with 400 mg/m2 on C1D1 as a loading dose and 250 mg/m2 on all other days.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
76072573|NCT01845805|Drug|oral azacitidine|
75770181|NCT01166074|Biological|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
75770182|NCT03971292|Genetic|RNA sequencing|Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
75770183|NCT01275508|Drug|FITC-Adalimumab|The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
75770184|NCT01073670|Drug|Indomethacin|Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
75770185|NCT01073670|Drug|Acetaminophen & Indomethacin|Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
75770186|NCT01073670|Drug|Acetaminophen|Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
75770187|NCT01166152|Behavioral|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
75910101|NCT05859347|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
75910102|NCT05859191|Biological|Blood sample|Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
76072574|NCT01845805|Other|Observation|
76072575|NCT05575804|Drug|GQ1001+pyrotinib|GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.
76072576|NCT05575804|Drug|pyrotinib+capecitabine|pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
75463684|NCT04740801|Device|Ablation procedure|Catheter ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav StablePoint ablation catheter
75318110|NCT00504751|Drug|bortezomib, dexamethasone, ifosfamide|"VIPER chemotherapy will be administered every 28 days at the following doses:~Dexamethasone 40 mg IV days 1-4~Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~Cisplatin 25 mg IV days 1-4~Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~VELCADE 1.5 mg/m2 on days 2 and 5"
75318111|NCT00504751|Drug|mesna, cisplatin, etoposide, rituximab|"VIPER chemotherapy will be administered every 28 days at the following doses:~Dexamethasone 40 mg IV days 1-4~Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~Cisplatin 25 mg IV days 1-4~Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~VELCADE 1.5 mg/m2 on days 2 and 5"
75318112|NCT03994484|Drug|HA121-28 tablets|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
75770188|NCT01582464|Behavioral|Social Marketing for protective headgear|"Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.~To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), & a demographic & functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes."
75770189|NCT01168180|Other|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
75770190|NCT01168180|Other|Ultrasound therapy and hot pack|
75770191|NCT03971370|Biological|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
75770192|NCT03971370|Biological|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Zagreb post-exposure immunization schedule at day 0,7,21.
75770193|NCT03971370|Biological|Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
75770194|NCT03873142|Behavioral|Mindful Parenting|The mindful parenting intervention is an adaption for parents of the Mindfulness-Based Cognitive Therapy (MBCT) for depression (Kabat-Zinn, 1990), and the Mindful-Based Stress Reduction program (MBSR; Kabat-Zinn, 1990). The mindful parenting intervention will follow the manual developed by Bögels and Restifo (2014). The intervention consists of 9x3hour sessions. Eight of these sessions are run on consecutive weeks and the final session is run eight weeks after the eighth session. These groups involve group discussions around parenting, meditation exercises, and yoga, amongst other things.
75770195|NCT01168336|Drug|Betahistine standard formulation|betahistine 24 mg tablets
75463685|NCT04739267|Device|CardioFlux|Not an intervention
75463688|NCT04735731|Diagnostic Test|Echography|Echography of diaphragma and other respiratory muscles
75463689|NCT04720885|Procedure|kind of surgery|hysteroscopy, curettage, other
75770196|NCT01168336|Drug|Betahistine Extended Release formulation|betahistine 32 mg tablets
75770197|NCT01168336|Drug|Placebo|matching placebo
75770198|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 5 mg: once daily orally for 4 weeks
75770199|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 10 mg: once daily orally for 4 weeks
75770200|NCT01166308|Radiation|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
75770201|NCT01166308|Radiation|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
75770202|NCT01168414|Drug|Ganfort|Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)
75770203|NCT01168414|Drug|Duotrav|Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
75770204|NCT00180414|Device|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
75770205|NCT01277224|Behavioral|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
75798325|NCT01587144|Drug|Temozolomide (TMZ)|"TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
75936302|NCT03522207|Diagnostic Test|polysomnography|2nd psg, done 1 week after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
75463690|NCT04720326|Drug|Tacrolimus Pill|Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
75463691|NCT04720326|Drug|Tacrolimus capsule|Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
75770206|NCT03870646|Combination Product|Hypertonic saline of NaCl (7%) in combination with hyaluronic acid|Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
75770207|NCT03870646|Combination Product|Isotonic saline of NaCl (0,9%)|Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
75770208|NCT03968484|Biological|platelet transfusion|Transfusion of platelets
75770209|NCT03873220|Device|Wrist Actigraphy Devices|A watch-like wearable sensor
75770210|NCT03873220|Device|Sleep Monitor|Remote Sensor
75463692|NCT04719078|Diagnostic Test|MRI of the chest|The study participants will obtain a MRI of the thorax with one of the institutions MR machines (Philips Achieva 1.5T, GE Discovery 3T, MRI Siemens Skyra 3T, and GE SIGNA Artist 1.5T). The study participant will be asked to lie in the MR scanner for about 30 minutes while the images will be acquired. The image acquisition with the above-mentioned MR machines is authorised in Switzerland and the application is done according to the product information.
75770211|NCT03873220|Device|Polysomnography|Sleep Monitor
75770212|NCT03873220|Device|Videography|Thermal Camera
75770213|NCT01166464|Behavioral|text messaging for smoking cessation|A 7-week program of daily text messages
75463693|NCT04717362|Drug|Natesto Nasal Product|Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
75770214|NCT01166464|Behavioral|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
75463694|NCT04706273|Device|GORE® VIABAHN® Endoprosthesis|On Day 1, Participants will receive the GORE® VIABAHN® Endoprosthesis
75463695|NCT04701177|Diagnostic Test|AltoidaML|Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML). ClinicalTrials.gov Identifier: NCT02843529
75463696|NCT04700917|Behavioral|Cognitive Behavioural Therapy|Internet-Based CBT
75463697|NCT04700826|Drug|Direct Oral Anticoagulants|choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
75463698|NCT04700189|Device|ab interno canaloplasty|A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.
75463699|NCT04693949|Other|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
75770215|NCT01281904|Behavioral|Relaxation Acupressure|Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
75770216|NCT01281904|Behavioral|Stimulating Acupressure|Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
75463700|NCT04693949|Other|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
75463701|NCT04689256|Device|MR-010|MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat.
75463702|NCT04688528|Radiation|Dose de-escalation and / or Volume de-escalation|The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.
75463703|NCT04687917|Behavioral|The facilitation, training, feedback, and consultation (FTFC) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, and consultation
75463704|NCT04687917|Behavioral|The facilitation, training, feedback, consultation, and pay-for-performance (FTFC+PFP) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, consultation, and pay-for-performance.
75463705|NCT04678453|Biological|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
75770217|NCT01168492|Drug|ketamine|0.5mg/kg ketamine iv
75770218|NCT03870490|Drug|VNRX-5133 + cefepime|IV infusion (3 doses)
75770219|NCT00174252|Drug|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
75770220|NCT01278082|Drug|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
75770221|NCT01278082|Drug|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
75770222|NCT03870256|Drug|misoprostol|Patient receive 600mic gm sublingual misoprostol
75770223|NCT03870256|Drug|Carbetocin|Patient receive 100 mic gm carbetocin IV
75770224|NCT03870256|Drug|TA|The patient receives 1gm oral tranexamic acid
75770225|NCT01166542|Biological|REOLYSIN|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
75770226|NCT01166542|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
75770227|NCT01166542|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
75770228|NCT01166542|Drug|Placebo|Placebo
75770229|NCT00169104|Drug|G-CSF|5 mcgm/kg daily Monday through Friday weeks 3-14
75770230|NCT00169104|Drug|trastuzumab|4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
75617354|NCT04245124|Other|Strategic Memory Advanced Reasoning Training|SMART focuses on three metacognitive strategies: Strategic Attention, Integrated Reasoning and Innovation.
75318113|NCT03994484|Drug|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 50 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
75770231|NCT00169104|Drug|vinorelbine|25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
75770232|NCT00169104|Drug|G-CSF|5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
75770233|NCT00169104|Drug|saline placebo|Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
75770234|NCT03870412|Drug|PEG-rhG-CSF|The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
75770235|NCT03872674|Biological|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
75770236|NCT01168648|Behavioral|Yoga as stress management|Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
75770237|NCT01168648|Other|Rest without using any relaxation technique|The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
75770238|NCT03872986|Device|SDF|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI)
75770239|NCT03872986|Device|Giomer|Beautifil II dental restorative material
75770240|NCT03872986|Device|GIC|Equia forte dental restorative material
75463706|NCT04647032|Device|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4
75463707|NCT04646486|Behavioral|Video debriefing|Obstetric teams will review their own performance on video in a debriefing session to improve future performance.
75617355|NCT04245124|Other|Traditional Cognitive Rehabilitation|Participants randomized to the TCR condition will participate in a clinician-directed intervention that provides manualized, traditional clinician-directed cognitive rehabilitation that was developed for the SCORE trial (Cooper et al., 2017)
75770241|NCT03872830|Drug|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
75936303|NCT03522207|Drug|Trazodone|100 mg trazodone per os 30 minutes prior to 3rd PSG
75318114|NCT03994484|Drug|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
75463708|NCT04611191|Other|Team Sports|The intervention involves team sports in sports clubs in local municipalities
75463709|NCT04611191|Other|Control|The intervention involves a control condition with participants continuing their normal way of living
75463710|NCT04608214|Drug|Alisporivir|Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).
75770242|NCT03872830|Drug|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
75770243|NCT02526316|Biological|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
75770244|NCT02526316|Biological|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
75318115|NCT03994484|Drug|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 200 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
75318116|NCT03994484|Drug|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 300 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
75463711|NCT04608214|Other|Standard of care (SOC)|Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)
75463712|NCT04601727|Diagnostic Test|16srRNA pyrosequencing analysis of microbiota of saliva and faeces|No intervention in this study
75463713|NCT04571762|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT (a fraction dose adapted to the OAR geometry-of-the-day, 5 fractions) performed on the MR-Linac
75617356|NCT04246450|Device|Implantable Cardioverter Defibrillator (ICD) insertion|Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF <35%. In patients in the LVEF <35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
75770245|NCT03872596|Drug|Seroquel IR 300mg|Administered during Part A, administered orally BID with water, over 5 days.
75936304|NCT03522207|Drug|placebos|100 mg placebo per os 30 minutes prior to 3rd PSG
75318117|NCT03994484|Drug|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 450 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
75318118|NCT03994484|Drug|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 600 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
75463714|NCT04553289|Other|exercising into pain|the intervention consists in 4 strength exercises: one will be performed into pain (ranging between 4 and 7 on NPRS scale) and the rest between 0 adn 2 on a NPRS scale
75617357|NCT04244812|Other|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
75617358|NCT04244812|Device|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
75910103|NCT05852613|Device|high power laser therapy (HPLT)|high power laser therapy (HPLT) will be produced by A LEVELASER EZ1 EASYONE device which produces a Ga Al As CW diode laser with pulsed emission 980 nm and maximum average power 5 W with a high level of energy penetration. While the patient is in a prone position and the head slightly bends to the front, The treatment will be performed at a distance of 60-70 cm, perpendicular to the cervical region, in a pulsed mode of 4 Hz, wavelength = 980 nm, radiation power density P = 4 W in the scan phase and 2 W in the acupuncture phase and energy 840 J. Patients will receive pulsed HPLT laser treatment for 8 minutes. Scanning will be performed transversely and longitudinally to the bilateral paraspinal muscles, inter-scapular area, upper trapezius and the neck region for 6 minutes followed by 2 minutes acupuncture. Protective goggles will be used to prevent direct eye contact of the laser beam.
75617359|NCT02827864|Behavioral|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
75617360|NCT02827864|Behavioral|apply tDCS concurrently|Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
75617361|NCT02827864|Behavioral|MT with sham tDCS|The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
75617362|NCT00633568|Drug|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
75617363|NCT00633568|Drug|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
75910104|NCT05852613|Combination Product|selected physical therapy program|hot pack, US for 5 min, exercise for 20 min.
75936305|NCT03522207|Diagnostic Test|polysomnography|3rd PSG, done 2 weeks after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
75770246|NCT03872596|Drug|Seroquel IR 25mg|Administered during Part B, as a single, 25mg dose taken with water.
75770247|NCT03872596|Drug|Quetiapine Formulation A 300mg|Administered during Part A, administered orally BID with water, over 5 days.
75463715|NCT04553289|Other|exercising with no/slight pain|the intervention consists in 4 strength exercises and all of them will be performed in no pain/slight pain (between 0 and 2 on NPRS scale)
75463716|NCT04552717|Other|My Grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains four main sections: Learning, Self-assessment, Manage symptoms and Find support.
75463717|NCT04549207|Drug|Bone modifying agent|Use of bone modifying agent
75770248|NCT03872596|Drug|Quetiapine Formulation B 300mg|Administered during Part A, administered orally BID with water, over 5 days.
75770249|NCT03872596|Drug|Quetiapine Formulation 25mg|Administered during Part B, as a single, 25mg dose taken with water.
75770250|NCT00163020|Drug|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
75770251|NCT00163020|Drug|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
75318119|NCT03994484|Drug|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
75318120|NCT01013779|Drug|Carboplatin|"During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1."
75318121|NCT01013779|Drug|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
75463718|NCT04537195|Behavioral|ADSMP-C|A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)
75318122|NCT01013779|Radiation|Radiotherapy|"Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions"
75463719|NCT04535492|Behavioral|Decision Making Support Tool|Primary care practices randomized in a stepped wedge cluster design will implement a newly developed predictive model and analytic tool to improve shared decision-making for patients.
75318123|NCT05630846|Biological|Investigational MMRV(H)NS vaccine|1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.
75463720|NCT04535193|Drug|18F-mFBG for intravenous administration|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
75617364|NCT04246294|Device|Continuous Positive Airway Pressure (CPAP)|"CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care."
75617365|NCT02829658|Behavioral|Psychologic test|Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
75617366|NCT02829658|Other|No intervention|No intervention
75617367|NCT02827630|Other|Proteus Discover|FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application
75617368|NCT02827630|Other|Usual Care|Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
75910105|NCT05852314|Behavioral|Culturally Adapted Manual Assisted Therapy (CMAP-SI)|C-MAP has been adapted from a self-help guide called Life After Self-Harm based on the principles of CBT. It is a brief problem-solving therapy comprising have 4 sessions weekly and then 4 fortnightly and last about 50 minutes each. The manual has been translated to Urdu giving special consideration to cultural adaptation of phrases and concepts to reflect Pakistani culture. Additionally, culturally appropriate case scenarios were incorporated and a consensual view to addressing cultural factors such as gender role, family conflicts and financial difficulties was taken. The culturally adapted intervention consists of the following components: evaluation of self-harm attempt, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships, and relapse prevention strategies. Participants will receive sessions according to adapted CMAP-SI manual.
75463721|NCT04526444|Device|Fitness tracker|Fitness tracker Mi Smart Band 5 with the computational algorithm PAI
75463722|NCT04526444|Other|Online training|Les Mills On Demand
75463723|NCT04526444|Other|Peer support via social media|Facebook group
75463724|NCT04506437|Behavioral|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
75463725|NCT04506437|Behavioral|Standard of care engagement practices|Standard of care engagement practices and services-as-usual
75617369|NCT05216692|Procedure|La Tour Hospital Foot Strengthening Protocol|"First exercise : NMES forward lean doming. Doming exercise assisted by NMES placed on the IFM. 8 sec of contraction (6 sec rest) moving the trunk forward. 12 repetitions, 3 sets. Progressive increase of the intensity of NEMS during 4 weeks and increase of body load while decreasing the number of repetitions.~Second exercise : MTP joint flexion. Isometric MTP joint flexion contractions. 4 contractions of 5 sec (10 sec rest), 3 sets. Progressive increase of the number of MVIC during 4 weeks and of increase body load while keeping the same intensity.~Third exercise : Foot-ankle rebound. Multiple jumps with only plantar flexion. Keeping the knee stiff and straight and pushing off the ground with only ankle and MTP plantar flexion by a forefoot contact with the ground. 10 seconds of jump (1 min of rest) during 5 sets. Progressive increase of body load while keeping the same intensity."
75770252|NCT03870100|Drug|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous
75770253|NCT03870100|Drug|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous
75463726|NCT04505345|Behavioral|Cognitive training using the Systemic Lisbon Battery|The Systemic Lisbon Battery comprises exercises for cognitive rehabilitation developed to describe diverse activities of daily living.
75463727|NCT04505345|Behavioral|Treatment-as-usual|Treatment as usual for alcohol use disorder from Casa de Saúde do Telhal is delivered according to the Minnesota Model.
75463728|NCT04494711|Behavioral|Physical Functional Literacy for Adults|A 5 week physical literacy for program focused on virtual knowledge translation strategies to improve function and mobility for adults with multiple chronic conditions. This is a population -based approach to rehabilitation
75463729|NCT04457622|Other|Auditory perception tasks in healthy participants|"The participants complete auditory perception tasks while EEG, and MEG record brain signals (primary outcome measure). The tasks acquire behavioral responses with button presses (secondary outcome measure).~All analyses are intra-subject (no analyses are between-subject)."
75770254|NCT03870178|Device|Transcranial direct current stimulation (tDCS)|The noninvasive and nonpharmacological weak electrical current applied to the scalp to modulate cortical excitability.
75770255|NCT01166698|Drug|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
75770256|NCT01166698|Drug|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
75770257|NCT01166698|Drug|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
75318124|NCT05630846|Biological|Investigational MM(H)RVNS vaccine|1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.
75318125|NCT05630846|Biological|Investigational M(L)M(L)R(L)V(L)NS vaccine|1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.
75463730|NCT04439734|Device|Electromyostimulation|WB-EMS once per week 20 min for 16 weeks
75463731|NCT04438083|Biological|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
75617370|NCT05216692|Procedure|Standard Literature Foot Strengthening Protocol|"During the 1st week, the participants will perform the Short foot exercise (SFE) during 3 series of 10 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 2nd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 3rd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing bipedal position. 1 minute of rest will be give between series.~During the 4th week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing unipedal position. 1 minute of rest will be give between series.~The progression of the exercise during the protocol will be based on passing from a sitting position to a unipedal standing position."
75463732|NCT04420611|Other|Session 1 (day 1)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
75617371|NCT04245826|Other|Change in LCSBs Intake|Effect of changing LCSBs intake
75770258|NCT01168804|Drug|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
75617372|NCT04245826|Other|Substitute LCSBs for SSBs or Water|Effect of substituting LCSBs for SSBs or Water
75770259|NCT01168882|Drug|RGB-286638|The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
75770260|NCT03872362|Diagnostic Test|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
75318126|NCT05630846|Biological|Marketed MMRV_Lot 1 and Lot 2 vaccine|1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.
75617373|NCT02829736|Procedure|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
75770261|NCT01168960|Behavioral|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
75770262|NCT01169116|Radiation|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
75770263|NCT01278940|Biological|Dendritic Cells (DC) malignant melanoma|The patients were assigned to intradermal or intranodal DC vaccination
75910106|NCT05847647|Other|Retrograde Filling Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect.
75910107|NCT05847647|Other|Retrograde Filling+L-PRF Group|2. Group: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect (
75318127|NCT03590756|Other|16 weeks mango intake|Participants will be provided fresh frozen Ataulfo mangoes.
75318128|NCT04407494|Biological|Reporting of anosmia, ageusia and other clinical symptoms|Reporting of anosmia, ageusia and other clinical symptoms related to COVID-19 - CODA test - SARS-CoV2 RT-PCR and ELISA
75318129|NCT00557947|Device|Suture|intradermal and topical suturing
75318130|NCT00557947|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
75318131|NCT03590600|Drug|BTZ-043|Powder and solvent for oral suspension
75318132|NCT03590600|Drug|Placebo|Matching placebo: powder and solvent for oral suspension
75617374|NCT02829736|Procedure|Standard post-operative chest tube|A regular chest tube is left in the pleura.
75617375|NCT02829736|Procedure|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
75770264|NCT01278940|Procedure|IL-2|IL-2 were administrated by intranodal injection
75770265|NCT01282450|Radiation|Radiotherapy|Radiotherapy
75770266|NCT03873532|Drug|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 21-day treatment cycle).
75770267|NCT03873532|Drug|Capecitabine|Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
75770268|NCT01282528|Biological|infliximab|3mg/kg, at week 0, 2, 6, 14, 22
75770269|NCT01166854|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy
75770270|NCT01169272|Device|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
75770271|NCT01169428|Behavioral|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
75798326|NCT01587144|Radiation|Radiation|60 Gy administered in 30 fractions for 42 days in the concomitant phase.
75798327|NCT01587144|Drug|Placebo|Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
75770272|NCT01169428|Behavioral|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors [e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information & education]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
75770273|NCT01169506|Device|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
75770274|NCT01169740|Procedure|Measurement of bilirubin in blood and skin color|Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
75318133|NCT03024788|Device|syringe, fundus camera etc|Physical examination, fundus examination, blood and urine samples collection
75910108|NCT05847647|Other|(Orthograde Filling Group / OG Group).|3. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect
75910109|NCT05847647|Other|(Orthograde Filling+L-PRF Group|4. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect
75910110|NCT05838482|Device|CT Photon-Counting|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
76072577|NCT04415125|Diagnostic Test|Applying on-ice and off-ice performance tests|The subjects were given a written description of study procedures and potential risks.The athletes'history of injury including previous injury site, type, number, date, surgical status, time to return to the field after the injury and the mechanism of injury were recorded. The subjects completed off-ice performance measures followed by on-ice testing with time allotted for warm-up before both the off-ice and on-ice testing.
76072578|NCT04371094|Device|a device to facilitate endotracheal intubation|a device to facilitate endotracheal intubation
76072579|NCT01845025|Drug|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
76072580|NCT01845025|Drug|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
76072581|NCT01845025|Drug|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
75318134|NCT00506155|Drug|Avastin|10 mg/kg by vein over 90 minutes
75318135|NCT00506155|Drug|Cisplatin|70 mg/m^2 by vein over 4 hours
75463733|NCT04420611|Other|Session 2 (day 3)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
75318136|NCT00506155|Drug|Doxorubicin|30 mg/m^2 by vein over 15 minutes
75318137|NCT00506155|Drug|Methotrexate|30 mg/m^2 by vein over 30 minutes
75318138|NCT00506155|Drug|Vinblastine Sulfate|3 mg/m^2 by vein over 30 minutes
75318139|NCT03590522|Genetic|Ryanodine Receptor 2 gene expression|Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
75318140|NCT03597542|Other|Eggs and Carbohydrates|Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.
75617376|NCT02829346|Drug|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
76072582|NCT01845025|Drug|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
75617377|NCT02829346|Drug|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
76072583|NCT01845025|Drug|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
76072584|NCT03830632|Other|Plyometric Training|
75617378|NCT05210764|Drug|propofol|General anesthesia is induced and maintained mainly with propofol.
76072585|NCT03830632|Other|Traditional Training|
76088821|NCT04490226|Dietary Supplement|Beta-Hydroxybutyrate as Ca-Mg-salt, active|24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
75617379|NCT05210764|Drug|sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
75617380|NCT05210764|Drug|S-ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
75617381|NCT00889720|Drug|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
75617382|NCT04244500|Procedure|swab sampling|Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
75617383|NCT02827786|Device|Electromagnetic Acoustic Imaging|Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
75617384|NCT02827552|Other|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
75770275|NCT01169584|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10^6 pfu/kg to 3 x 10^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
75463734|NCT04420611|Other|Session 3 (day 15)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to drink or eat caffeinated food/drinks 24 hours prior to night-time urine collection (at least one cup of coffee or a can of Coca-Cola®).~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
75770276|NCT01282684|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
75318141|NCT03590444|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution|"Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution"
75463735|NCT04420611|Other|Session 4 (day 30)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
75463736|NCT04418453|Other|Integration of telemedicine for MOUD in primary care|Patients with opioid use disorder in rural primary care settings may be referred to receive telemedicine for medication treatment for opioid use disorder
75463737|NCT04345211|Other|Group1, walking group|The walking group includes a weekly walking goal of 75 minutes.
75463738|NCT04345211|Other|Group 2, Walking plus manual therapy|Walking plus self-administered thorax manual therapy
75770277|NCT01282684|Drug|Placebo|Matching placebo for PLX5622.
75318142|NCT00506857|Drug|Busulfan|Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.
75463739|NCT04345211|Other|Group 3; Walking plus exercises with Theraband|Walking plus thorax exercises with Theraband
75463740|NCT04340531|Other|Best Practice|Receive usual care
75617385|NCT04244734|Other|Usual care treatment|"All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
75770278|NCT01169818|Drug|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target"
75770279|NCT01282762|Biological|HEPLISAV|"0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.~HEPLISAV booster injection = one dose of 0.5 mL volume when needed."
75770280|NCT01282762|Biological|Engerix-B|"2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.~Engerix-B booster injection = one dose of 2.0 mL volume when needed"
75770281|NCT01169662|Dietary Supplement|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
75770282|NCT01169662|Dietary Supplement|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
75770283|NCT01282840|Drug|Tolterodine SR|Tolterodine SR 4 mg qd
75318143|NCT00506857|Drug|Fludarabine|30 mg/m^2 by vein daily x 4 days.
75318144|NCT04006496|Behavioral|Expressive Writing Coaching|For the intervention group, a trained expressive writing expert/coach will introduce the expressive writing concept to consented patients during the first visit, followed by an introduction of the first expressive writing exercise and prompt. The expert/coach will introduce new writing prompts at each subsequent visit. A script containing each visit's writing prompt and instructions will also be left with the patients for future use and/or reference. The trained clinician will collect, read, and analyze the writing sample using a health coaching technique by: 1) summarizing what the patient wrote, 2) evoking double-sided reflection by reading back the writing sample to the patient, and 3) developing a metaphor and review with the patient. Patients will also have the opportunity to ask the trained clinician questions and receive guidance.
75770284|NCT01282918|Device|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
75318145|NCT03590132|Behavioral|Strong African American Families Program|SAAF is a 7 session family skills training program
75318146|NCT03590132|Behavioral|Strong African American Families--Teen Program|SAAF-T is a 5 session family skills training program
75318147|NCT03024632|Procedure|Trial of labor|trial of labor after 3 or more previous cesarean deliveries
75318148|NCT03024554|Device|Implantation of the Bifurcated Multilayer Flow Modulator|
75318149|NCT04005170|Drug|Toripalimab|Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
75463741|NCT04340531|Other|Survey Administration|Ancillary studies
75463742|NCT04340531|Other|Tobacco Cessation Counseling|Receive referred to counseling session
75463743|NCT04340531|Other|Tobacco Cessation Counseling|Receive phone counseling
75463744|NCT04340531|Other|Training|Undergo training
75463745|NCT04335214|Other|one to one interview|one to one interviews with older people from moroccon origin in Belgium
75463746|NCT04328038|Other|Survey|Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue
75770285|NCT01282918|Device|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
75770286|NCT01282996|Other|Abdominal surgery|to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery
75770287|NCT01172548|Drug|imatinib mesylate|
75770288|NCT01283230|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
75318150|NCT04005170|Drug|Paclitaxel/Cisplatin|Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.
75463747|NCT04325815|Device|CADDIE- Computer Aided (AI) Device used in Endoscopy|"CADDIE assisted polyp detection~CADDIE assisted polyp characterisation"
75770289|NCT01172626|Drug|valproate sodium|oral administration,15-30mg/kg,daily
75770290|NCT01172626|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
75770291|NCT01172626|Other|Pharmacokinetic analysis|laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
75770292|NCT01169974|Other|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 & 3 minutes
75770293|NCT02526082|Other|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
75770294|NCT03869242|Device|NovoTTF-200A|newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.
75463748|NCT04319328|Drug|Cefazolin|Non-interventional pharmacokinetic evaluation
75770295|NCT01283308|Behavioral|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
75770296|NCT01283308|Behavioral|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
75770297|NCT01172704|Behavioral|Skills Building - Motivational Interviewing|"SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values."
75770298|NCT01172782|Drug|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
75770299|NCT01172860|Device|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
75770300|NCT03866746|Drug|Aflibercept Injection|Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.
75798328|NCT03870984|Dietary Supplement|wNUTS, low-caloric diet plus nuts|15g of nuts and 15g of hazelnuts in association with low caloric diet
75798329|NCT03870984|Other|w/oNUTS, low-caloric diet without nuts|low caloric diet
75318151|NCT04005170|Radiation|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
75318152|NCT04766528|Other|3 maximal aerobic tests|Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet
75318153|NCT03597308|Drug|5mg of Oxycodone every 6 hours as needed for pain|5mg of Oxycodone every 6 hours as needed for pain
75318154|NCT03597308|Drug|600mg of Ibuprofen every 6 hours as needed for pain|600mg of Ibuprofen every 6 hours as needed for pain
75463749|NCT04319328|Drug|Ceftazidime|Non-interventional pharmacokinetic evaluation
75463750|NCT04319328|Drug|Ciprofloxacin|Non-interventional pharmacokinetic evaluation
75463751|NCT04317326|Procedure|"Lifestyle modifications group (Control)"|It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 <55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.
75770301|NCT03866746|Other|micropulsed yellow laser|Micropulse yellow IQ 577nm laser (Iridex Corporation, Mountain View, CA, USA) was employed. The Area Centralis lens (laser spot size magnification 0.94) was utilized with 400 mw power, 200μm spot size and 200 ms pulse duration with 5% duty cycle after micropulse mode activation. Laser was applied on clinically visible thickened macula with different number of confluent non- spacing shots in 7x7 grids. Care was taken to begin treatment outside the foveal avascular zone and not to treat the fovea when there was no visible reaction. If there was any visible reaction; treatment was stopped and the power was reduced until there was no visible reaction.
75770302|NCT03869320|Drug|ACT-1004-1239|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg. For the ADME subpart, a single oral dose of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given simultaneously with the ACT-1004-1239 capsule. For the absolute bioavailability subpart, a single intravenous dose of a maximum of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given at the expected tmax after the administration of the ACT-1004-1239 capsule.
75770303|NCT03869320|Other|Placebo|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
75770304|NCT03869320|Drug|ACT-1004-1239 (Food-effect subpart)|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg.
75910111|NCT05836272|Drug|Norepinephrine Bitartrate|"The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.~Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion."
75910112|NCT05836272|Other|Placebo|For the control group placebo: 250 ml of 5% glucose will be prepared and will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour.
75910113|NCT05835024|Device|Acorai Sensor Data Collection (ASDC) system 1.0|"A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.~A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation."
75318155|NCT03597308|Drug|500mg of Acetaminophen every 6 hours as needed for pain|500mg of Acetaminophen every 6 hours as needed for pain
75318156|NCT03597230|Other|Dye|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions At the beginning of the surgical procedure, 1 ml of blue patent will be injected in the normal remaining part of the pancreas. The diffusion of the dye among all lymph node areas will be noticed by the surgeon.
75318157|NCT03762122|Drug|Rogaratinib|Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.
75318158|NCT03596996|Dietary Supplement|Ferrous Sulfate|Ferrous sulfate dosed by WHO guidelines by age for the prevention of iron deficiency and anemia.
75617386|NCT04244734|Other|New Treatment Protocol-MotoMED®|"Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
75617387|NCT02880306|Other|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
75617388|NCT02827318|Dietary Supplement|Isomaltulose|75g Isomaltulose (low glycaemic load intervention)
75617389|NCT02827318|Dietary Supplement|Glucose|75g Glucose (high glycaemic load intervention)
75770305|NCT03869320|Other|Placebo (Food-effect subpart)|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
75770306|NCT03869398|Dietary Supplement|Tums|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
75770307|NCT03869398|Dietary Supplement|Calcitriol|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
75910114|NCT05821387|Drug|Lucid-21-302|A small molecule inhibitor of hypercitrullination
75910115|NCT05821387|Drug|Placebo|Product containing excipients with no active ingredients
75910116|NCT05814198|Diagnostic Test|HALP score|we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
75318159|NCT03596996|Dietary Supplement|Placebo|Placebo with identical appearance comparison intervention arm
75318160|NCT00507559|Device|Aptus Endovascular AAA Repair System|EVAR (endovascular aneurysm repair)
75318161|NCT00508105|Procedure|subscapularis peel|"Detachment of the subscapularis tendon from its insertion on the lesser tuberosity the peel."
75318162|NCT00508105|Procedure|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
75318163|NCT04750135|Drug|metformin 500 mg TID Oral Tablet|biguanides derivatives
75318164|NCT04750135|Drug|Placebo|Placebo
75617390|NCT02827318|Dietary Supplement|Sweetened water|Sweetened water will be used as a control
75617391|NCT04309968|Drug|Drug: SYHA1801|Drug: SYHA1801 administered orally
75770308|NCT01170052|Drug|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
75770309|NCT01170052|Drug|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
75463752|NCT04317326|Procedure|Automatic NIV|In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.
75910117|NCT05795504|Other|resistive exercise|They will perform combined upper and lower resistive exercises, 30 min, 3 sessions / week for 12 weeks in addition to calcium and vitamin D supplements.
75910118|NCT05795504|Other|high intensity interval training|They will perform HIIT for three sessions/ week for 12 weeks, 30 minutes/ session in addition to calcium and vitamin D supplements.,
75770310|NCT01170052|Drug|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
75770311|NCT01283620|Behavioral|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
75770312|NCT01283620|Other|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
75770313|NCT01284478|Drug|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
75463753|NCT04317326|Procedure|CPAP treatment group|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.
75318165|NCT04003922|Other|Adalimumab treatment|Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.
75318166|NCT03598088|Device|Ovaprene|non-hormonal contraceptive ring
75770314|NCT00252720|Drug|candesartan|32 mg oral tablet
75318167|NCT00558571|Drug|BI 10773 low dose|
75770315|NCT01283698|Drug|Experimental: LAS 41004 dosage 1|dosage 1, once daily
75318168|NCT00558571|Drug|placebo to BI 10773|
75318169|NCT00558571|Drug|BI 10773 medium dose|
75463754|NCT04317326|Procedure|NIV treatment groups|In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
75463755|NCT04283903|Diagnostic Test|PICF|PICF collection from 4 sites
75770316|NCT01283698|Drug|Experimental: LAS 41004 dosage 2|LAS 41004 dosage 2, once daily
75463756|NCT04255160|Drug|Estradiol (mylan or vivelle dot patch)|Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
75770317|NCT01283698|Drug|Experimental: LAS 41004 dosage 3|dosage 3, once daily
75770318|NCT01283698|Drug|Placebo Comparator: placebo|once daily
75770319|NCT01283698|Drug|Reference|Active Comparator,once daily
75770320|NCT03869164|Device|ValveClamp|ValveClamp is an easy-to-operate transcatheter edge-to-edge mitral valve repair system with larger coaptation width
75770321|NCT00167778|Device|Transverse plane rotation adaptor pylon|Potential future practice
75770322|NCT00167778|Device|Rigid pylon|Current clinical practice
75770323|NCT01284556|Drug|Phenobarbital|tablet
75770324|NCT01284556|Drug|Placebo tablet|tablet
75318170|NCT00558571|Drug|BI 10773 high dose|
75318171|NCT03970382|Biological|NeoTCR-P1 adoptive cell therapy|The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.
75318172|NCT03970382|Biological|nivolumab|Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody
75318173|NCT03970382|Biological|IL-2|IL-2 is a biologic response modifier. It is a type of protein called a cytokine.
75318174|NCT03978728|Device|Extra-corporeal membrane oxygenation|Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.
75318175|NCT00508183|Procedure|single row|This method involves using a single row of anchor(s) to reattach the cuff to the bone.
75770325|NCT03869086|Other|Freeze dried blueberry powder|36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
75770326|NCT03869086|Other|Anthocyanin free, sugar-matched placebo|36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
75910119|NCT05795504|Dietary Supplement|calcium and vitamin D|they will receive calcium and vitamin D supplements only.
75936651|NCT02427386|Drug|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
75770327|NCT01170130|Drug|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
75463757|NCT04255160|Other|Placebo|A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
75910120|NCT05780008|Behavioral|Eat My ABCs|"The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home."
75910121|NCT05777798|Device|Hyalistil Bio PF|Moisturizing and lubricating ophthalmic solution
75910122|NCT05772663|Other|Personalized program of rehabilitation|"D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20*20). At D119, the person returns the accelerometric writbands."
75910123|NCT05772663|Other|Routine program of rehabilitation|"Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20*20). At D119, the person returns the accelerometric writbands."
75463758|NCT04254562|Behavioral|Weekly Meetings with a Supported Employment/Supported Education Specialist|Participants will receive intervention for 12 months which includes weekly meetings with a Supported Employment/Supported Education Specialist (HYPE Specialist). During the weekly meetings, the HYPE Specialist will review each participant's education and employment goals, and deliver individualized support relevant to those goals which include use of structured HYPE tools and worksheets as needed.
75910124|NCT05760274|Diagnostic Test|multichannel intraluminal impedance and pH monitoring (MII/pH)|A pH-MII probe is inserted nasally into the esophagus, and the position verified by chest radiograph. pH-MII data are evaluated using manufacturer's software, and each tracing is manually reviewed and validated.
75936652|NCT02427386|Drug|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
75318176|NCT00508183|Procedure|double row fixation|"This technique, double row fixation, involves adding an extra anchor(s) over the number used for single row fixation. This extra anchor(s) is placed further inside the bone and may help to increase the fixation strength of the repair."
75318177|NCT03593798|Other|Lifestyle|Lifestyle intervention an effect on weight and physical capacity
75318178|NCT01797133|Procedure|ID fellow-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
75318179|NCT01797133|Procedure|Pharmacist-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
75463759|NCT04254562|Behavioral|Focused Skill and Strategy Training (FSST)|Participants receive a 12 week Focused Skill and Strategy Training (FSST), a structured cognitive remediation intervention.
75463760|NCT04254562|Behavioral|Enhanced Services as Usual|One hour meetings every semester to review individual academic needs and review list of available on campus resources to best meet the student's needs.
75617392|NCT04244578|Device|Active tDCS|Active tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
75617393|NCT04244578|Device|Sham tDCS|Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
75770328|NCT02526238|Device|TMS and trunk rotation|TMS and trunk rotation
75770329|NCT02526238|Device|Sham TMS and trunk rotation|Sham TMS and trunk rotation
75770330|NCT00167310|Drug|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
75770331|NCT00167310|Drug|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
75770332|NCT02525770|Device|radiostereometric analysis (RSA)|
75770333|NCT03973476|Other|Phone care support by midwife|Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
75770334|NCT03754582|Drug|Perampanel|Oral tablets.
75770335|NCT03754582|Drug|Perampanel|Intravenous infusion.
75318180|NCT05632874|Behavioral|relaxing breathing exercise|"Kumbhaka Pranayama, Sama Vritti Pranayama and box breathing breathing techniques will be applied to the patients."
75770336|NCT03866824|Drug|injection of Platelet Enhanced Plasma(PRP)|intra-articular injection
76072586|NCT04257760|Behavioral|Palliative Care consultation outside standard of care|The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.
75318181|NCT01797913|Drug|gemcitabine|gemcitabine，1000mg/m2，ivgtt，DAY1&DAY8
75770337|NCT03866824|Drug|injection of corticosteroids|intra-articular injection
75770338|NCT03866824|Device|RMI|A CONTROL RMI at 1 year follow-up.
75770339|NCT03869008|Device|gammaCore Sapphire|"gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation."
75463761|NCT04243512|Behavioral|Time-restricted eating|Restrict food and beverage intake (except water) to a 10-hour window
75463762|NCT04225156|Biological|efgartigimod|Intravenous infusion of efgartigimod
75318182|NCT03596294|Drug|Clazosentan|Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h
75318183|NCT03596294|Drug|Rifampicin|Single i.v. dose of 600 mg rifampicin for 30 min
75318184|NCT03596294|Other|Saline (0.9% sodium chloride)|Single i.v infusion of 500 mL saline for 30 min
75463763|NCT04199182|Behavioral|Exercise Training|A multi-component group exercise intervention that emphasizes functional training. Duration is 6 months, and frequency is 3x per week.
75617394|NCT02828878|Biological|Allogeneic MPBC transplantation from matched related donor|
75617395|NCT05183464|Biological|saliva samples|Collection of salivary a-amylase during the day (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm) with Salivette.
75318185|NCT00537407|Drug|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
75617396|NCT05183464|Behavioral|Stanford sleepiness scale|"The Stanford Sleepiness Scale evaluates sleepiness at the time of the evaluation. The subjects have to choose the statement best representing their level of sleepiness on a scale ranging from 1 to 7: the higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
75617397|NCT05183464|Behavioral|Karolinska Sleepiness Scale|"The Karolinska Sleepiness Scale assesses the perceived level of sleepiness at the time of the evaluation on a 9-points scale. The higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
75617398|NCT05183464|Behavioral|Epworth Sleepiness Scale|"The Adapted Epworth Sleepiness Scale for children in which the item falling asleep while in a car stopped in traffic was replaced by falling asleep at school assesses the risk of falling asleep in 8 daily-life situations estimated on a 4-point Likert scale. The total score is the sum of the scores for the 8 items: a higher score represents greater sleepiness and the pathological threshold is higher than 10.~This scale will be submitted to the children one time, at the onset of the hospitalization."
75770340|NCT03869008|Device|Sham Device|The Sham device delivers no electrical stimulations but subjects randomized to the Sham device will received the same instructions to use the Sham device to stimulate 2 minutes on each side of the neck, twice a day, every day for the first 4 weeks after randomization.
75318186|NCT00537407|Drug|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
75770341|NCT00161616|Drug|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
75770342|NCT03868852|Drug|Apatinib mesylate tablets|Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)
75318187|NCT00537407|Drug|Ribavirin|Ribavirin supplied as 200 mg tablets
75341303|NCT01566409|Other|Placebo|Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
75463764|NCT04199182|Other|Healthy Aging Attention Control (HA-ATC)|"Participants in the HA-ATC group will receive a health education program modeled on the 10 Keys to Healthy Aging curriculum and the National Council on Aging's Aging Mastery Program. HA-ATC will include an 8-week face-to-face group program followed by bi-weekly sessions for the remaining 4 months."
75463765|NCT04184687|Procedure|Nanofractures|anterior cruciate ligament reconstruction will be performed in combination with the nanofractures for the treatment of cartilaginous lesions
75463766|NCT04184687|Procedure|no treatment cartilaginous lesions|patient undergoing to the anterior cruciate ligament reconstruction without treatment of the cartilaginous lesions
75463767|NCT04179123|Device|Customised PAP interfaces|Customised PAP interfaces
75463768|NCT04138433|Device|Real tDCS|Anodal tDCS 2 ma
75463769|NCT04138433|Device|Sham tDCS|Sham tDCS 2 ma
75770343|NCT03868852|Radiation|Three-dimensional conformal intensity modulation|Three-dimensional conformal intensity modulation (IMRT) technique was used for post-operative radiotherapy. The radiation dose was 45-54 Gy.
75770344|NCT01283776|Drug|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
75936653|NCT05520827|Drug|BI 1584862|BI 1584862
75936654|NCT05520827|Drug|Placebo|Placebo
75936655|NCT03181802|Drug|Botox|single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
75936656|NCT03181802|Drug|Placebos|4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
75936657|NCT04518137|Drug|ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle|48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
75770345|NCT01163422|Device|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
75770346|NCT01170286|Biological|Whole peanut extract|Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
75770347|NCT01170286|Biological|Placebo formulation|Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
75770348|NCT01284712|Biological|blood sample|blood sample coming from therapeutic bleeding in hospital
75770349|NCT01163500|Dietary Supplement|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
75770350|NCT01163500|Other|Placebo|Placebo controlled (dextrin)
75770351|NCT01173094|Device|Percutaneous Transluminal Angioplasty|Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
75910125|NCT05757128|Behavioral|Optimal Health Program|The OHP intervention will comprise a psychosocial management program that will be adapted to the CHR population and will be accompanied by a structured workbook, all accessed virtually through a web based digital portal. Sessions are approximately 1 hour in duration and held weekly for 6 weeks, and every two weeks for the remaining 6 weeks. The OHP has three components: 1) assessment and engagement; 2) therapy sessions, and 3) maintenance integration.
75910126|NCT05748184|Device|ULDCT PACS prototype|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
75318188|NCT05632796|Procedure|Adjusting the Pfannenstiel skin incision according to the occipitofrontal diameter (OFD) of the fetal head.|All women will be subjected to regional spinal anesthesia. Pfannenstiel incision will be made according to the fetal occiputofrontal diameter, marked on the skin (Pfannenstiel incison with Kaya modification) Following blunt entry to the abdominal cavity, the uterine lower segment Kerr incision will be performed. Folllowing delivery of the baby, umblical cord will be cut and an arterial umblical cord blood sample will be taken. Placenta will be removed. 1st and 5th min. Apgar scores will be noted. Uterine incison will be sutured double-layer with 1 polyglactin 910 suture . Peritoneum and fascia, will be closed with 2-0 and 1 polyglactin 910 suture respectively. Skin incision will be sutured with continuous 3-0 rapid polyglactin 910 suture and measured with flexible ruler in centimeters following completing the skin incision closure.
75318189|NCT00214916|Drug|intensive insulin therapy (Actrapid IV to normoglycemia)|intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
75318190|NCT00214916|Drug|conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)|conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
75318191|NCT00469391|Device|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
75318192|NCT00469391|Procedure|Sham Procedure|Weight loss
75617399|NCT05183464|Behavioral|BLAST test|"The BLAST (Bron/Lyon Attention Stability Test) is a computerized attention test evaluating brief lapses of attention with 4 measures: reaction times, errors and two composite measures (Stability and Intensity). The subjects have to detect the presence or the absence of a specific stimulus during approximatively 60 trials for 3 minutes. Normative data are available for both children and adults.~This test is part of the neuropsychological evaluation, conducted the afternoon of the first day of hospitalization. The test is realized at 4:00pm."
75617400|NCT04244422|Other|PIEZOSURGERY VERSUS CONVENTIONAL SURGERY|Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
75770352|NCT01173094|Device|below-knee arterial bypass|Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
75770353|NCT01284790|Device|Cochlear implants|
75770354|NCT01283854|Behavioral|Supervised home-based exercise|"Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard)."
75617401|NCT02827474|Other|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
75770355|NCT01173250|Procedure|adding diverting ileostomy|
75770356|NCT01173250|Procedure|omitting diverting ileostomy|
75770357|NCT01163734|Drug|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
75910127|NCT05748184|Device|PACS viewer prototype|A PACS system mimicking the clinical PACS system used in LUMC.
75910128|NCT05748184|Device|Optimized ULDCT viewer prototype version(s)|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images. Optimized version(s) of previous version.
75318193|NCT00438971|Drug|Duloxetine|Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
75770358|NCT01163734|Other|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
75770359|NCT01284868|Drug|mirabegron|oral
75770360|NCT01284868|Drug|Bisoprolol|oral
75770361|NCT01284868|Drug|propranolol|oral
75770362|NCT01284868|Drug|placebo|oral
75770363|NCT01163812|Procedure|Laparoscopic D2 distal gastrectomy|"Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved."
75770364|NCT01170442|Drug|vitamin D3 2000 IU|vitamin D3 2000 IU orally, daily for 6 months
75770365|NCT01170442|Drug|vitamin D3 5000 IU|vitamin D3 5000 IU orally, daily for 6 months
75770366|NCT01170442|Drug|Placebo|placebo orally, daily for six months
75463770|NCT04135586|Other|Exercise training|Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training. The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.
75463771|NCT04135586|Other|Control|Yoga + educational program
75463772|NCT04132128|Other|carbohydrate counting|taught how to count carbohydrates in their diet with their personal tool
75463773|NCT04131491|Procedure|Lumbar puncture|Lumbar puncture for AD biomarker fluid analysis
75463774|NCT04103346|Other|air filtration with air purifier with hepa filter|long-term (4 week) air filtration with the Holmes HAP8650B-NU-1 air purifier in the residence of low-income seniors impacted by roadway pollutants.
75770367|NCT03866356|Behavioral|intervention group|The women in the intervention group were provided care according to SICP
75463775|NCT04103346|Other|sham|air purifier running with air filter removed
75770368|NCT01173328|Behavioral|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
75770369|NCT01173328|Behavioral|Normal Breathing|
75770370|NCT01170520|Device|repetitive transcranial Stimulation|rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
75770371|NCT03868696|Procedure|MUA with sham ultrasound|Standard MUA with sham ultrasound
75770372|NCT03868696|Procedure|MUA with active ultrasound|Standard MUA guided by ultrasound
75770373|NCT01170676|Behavioral|Puff City GA|Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.
75770374|NCT01170676|Behavioral|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
75770375|NCT03876184|Other|Aesthetic archwires|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
75770376|NCT03876184|Other|Control group|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
75770377|NCT01173406|Behavioral|CPAP education|Standard CPAP education plus an session and one telephone follow up
75770378|NCT01163890|Behavioral|Work and Health Initiative|Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
76088822|NCT04490226|Dietary Supplement|ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active|24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
75463776|NCT04101669|Device|EndoBarrier Liner|The EndoBarrier System is provided as a single-use, sterile device and consists of an EndoBarrier Liner preloaded, packaged and sterilized within the EndoBarrier Delivery System. The EndoBarrier Delivery System is utilized to deliver the EndoBarrier Liner to the proximal small intestine. The EndoBarrier Liner is removed using the EndoBarrier Retrieval System. The EndoBarrier System incorporates no pharmacological, biological tissue or blood products.
75463777|NCT04101669|Other|Sham|Patient receives upper endoscopy but no treatment
75463778|NCT04099485|Other|Electronic Health Record Best Practice Advisory|The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
75463779|NCT04099173|Behavioral|Brief Mindfulness Based Intervention|This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
75770379|NCT01163890|Behavioral|Usual Medical or Behavioral Intervention|Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
75770380|NCT00252564|Drug|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
75770381|NCT00252564|Drug|Oxaliplatin|85 mg/m2 on Days 1 and 15
75770382|NCT00252564|Drug|Leucovorin|400 mg/m2 on Days 1 and 15
75770383|NCT00252564|Drug|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
75770384|NCT00252564|Drug|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
75910129|NCT05747846|Procedure|Carpal tunnel release, WALANT technique|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.
75910130|NCT05747846|Procedure|Carpal tunnel release using a tourniquet|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
75318194|NCT04388267|Drug|Fluid challenge|"All patients who met the inclusion criteria will receive a standardised bolus of 250 ml of crystalloid in 5 minutes administered by hand with a 50 ml syringe.~During the study period, hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected for 20 minutes prior to the intervention (fluid challenge), during the fluid challenge and 25 minutes after completion.~The total duration of the intervention (fluid loading) is 5 min. The total duration of hemodynamic parameters recording is 60 min."
75318195|NCT00219284|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
75617402|NCT02827474|Other|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
75910131|NCT05738811|Other|TENS treatment protocol|The 2 sets of electrodes of TENS were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot.
75463780|NCT04092387|Other|Cigarettes with varying nicotine content|1) Altering the nicotine content of the tobacco research cigarettes
75910132|NCT05738811|Other|EMS treatment protocol|The electrodes were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot. A portable comfy EMS channel was used to apply EMS protocol to set at threshold of muscle contraction level.
75318196|NCT00509041|Drug|dasatinib|50 mg PO bid
75463781|NCT04092387|Other|E-Cigarettes|1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig conditions
75463782|NCT04082416|Biological|Placebo plus standard therapy|"Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )"
75463783|NCT04082416|Biological|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
75318197|NCT00470717|Procedure|Weekly telephone call|Details of feeding and health/sickness will be obtained
75463784|NCT04070781|Drug|Itacitinib|"Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles"
75617403|NCT02827396|Behavioral|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
75617404|NCT04243954|Drug|PCA IV Hydromorphone (continuous dose = 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
75770385|NCT03868462|Device|Optos P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
75770386|NCT03868462|Device|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
75770387|NCT01284946|Drug|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
75770388|NCT01173562|Drug|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
75770389|NCT01170910|Procedure|Static incubation|"Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.~."
75770390|NCT01170910|Procedure|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
75770391|NCT00166296|Drug|Escitalopram|15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
75770392|NCT00166296|Drug|Placebo|Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
75770393|NCT01173640|Drug|Midazolam|2 mg oral dose
75770394|NCT01173640|Dietary Supplement|resveratrol (single dose)|1 g oral dose
75770395|NCT01173640|Dietary Supplement|resveratrol (multiple dose)|1 g oral dose for 8 days
75770396|NCT03868774|Procedure|repetitive transcranial magnetic stimulation|rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.
75910133|NCT05738811|Other|Exercises|Patient were given 30 minutes treatment session, 10 minutes of supported walking 10 minutes of BWS treadmill training 10 minutes of Task-specific over ground locomotor training (LT) There was rest of 2 minutes The frequency of the sessions was five times a week for 12 weeks.
75910134|NCT05738135|Drug|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
75463785|NCT04070781|Drug|Tocilizumab|"Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles"
75318198|NCT03035851|Behavioral|Aerobic exercise|
75910135|NCT05738135|Drug|normal saline|Patients will receive 50 ml normal saline over 30 minutes.
75910136|NCT05734261|Procedure|Airway Oscillation System|After each methacholine dose administred, respiratory function will be measured by forced oscillation
75910137|NCT05732259|Other|Percussion therapy|Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.
75910138|NCT05732259|Other|Manual Myofascial Release technique|Manual myofascial release technique for 90 sec continuous.
75910139|NCT05732246|Other|First rib mobilization with balloon breathing exercises|Patient was in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation.
75910140|NCT05730595|Procedure|lymph node dissection|The extent of lymph node dissection varies between groups
75910141|NCT05724797|Drug|NRS-033|A single dose of NRS-033 will be administered
75910142|NCT05724797|Drug|Placebo|A single dose of matching placebo will be administered
75910143|NCT05719311|Drug|adrulipase|Enteric microgranule formulation of adrulipase.
75910144|NCT05716815|Diagnostic Test|CT scans 2D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
75936658|NCT03181178|Dietary Supplement|Macro-micronutrient complementary food supplement|This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
75318199|NCT03035851|Behavioral|Stretch and Strength|
75318200|NCT00439673|Drug|5-Azacytidine|
75318201|NCT00439673|Drug|Valproic Acid|
75463786|NCT04067765|Behavioral|Alcohol cue|Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of alcohol beverages (beer, wine, or liquor)
75318202|NCT00439673|Drug|ATRA|
75318203|NCT03596060|Drug|Fentanyl|Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.
75770397|NCT00252174|Drug|Stage 1 Active Methylenedioxymethamphetamine|"Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
75770398|NCT00252174|Drug|Stage 1 Low dose Methylenedioxymethamphetamine|"Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg."
75318204|NCT03596060|Drug|Propofol|Propofol will be used for introduction in general anesthesia.
75318205|NCT03596060|Drug|Rocuronium|Rocuronium will be used for introduction in general anesthesia.
75318206|NCT03596060|Drug|Chirochaine|Chirochaine 0.5% will be used in regional anesthesia.
75770399|NCT00252174|Behavioral|Psychotherapy|Psychotherapy conducted with low or active dose MDMA
75770400|NCT00252174|Drug|Stage 2 Active Methylenedioxymethamphetamine|"Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
75770401|NCT01170988|Procedure|T-Graft|T-Graft
75798330|NCT01170156|Device|Hi-Lo Evac tube (Mallinckrodt Inc, USA) (Instilled blue dye)|The cuff pressure will be first checked and reset at 30 cm H2O if needed. Next, blue dye will be instilled just above the cuff through the lumen ending in the subglottic area of the Hi-Lo Evac tube. Then a suctioning manoeuvre will be performed with a suction pressure of - 400 mbar through a 16 French suction catheter. Thereafter, a fiberoptic bronchoscopy will be performed, looking for the presence of blue dye in the trachea and/or the bronchi.
75798331|NCT01587222|Drug|Albumin|Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.
75770402|NCT03868306|Other|CBC , Iron study and Haemoglobin electrophoresis .|The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
75770403|NCT01077180|Device|Implantation of the Rheos System|Open label
75770404|NCT01077180|Other|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
75770405|NCT01171066|Device|Tasman CPAP system|Participants will trial the Tasman CPAP system for a duration of 1 week in place of their current CPAP system.
75770406|NCT01164046|Drug|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
75617405|NCT04243954|Drug|PCA IV Hydromorphone (continuous dose ≠ 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
75910145|NCT05716815|Diagnostic Test|CT scans 2D plus 3D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
75910146|NCT05708625|Drug|Intralesional Sodium stibogluconate|Sessions will be held once weekly for a maximum of 6 weeks
75318207|NCT03596060|Drug|Morphine|Morphine will be administered bolus iv in General anesthesia group postoperatively before patients leave OR.
75318208|NCT00473837|Drug|Chloroquine|This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
75770407|NCT01164046|Drug|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
75770408|NCT01074762|Behavioral|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
75770409|NCT01075464|Drug|MEGF0444A|Intravenous escalating dose
75910147|NCT05708625|Procedure|Intralesional Cryotherapy|Intralesional Cryotherapy. Sessions will be held every two weeks
76072587|NCT04242940|Device|Fitting of Ponto 4|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting one/two bone-anchored sound processors (Ponto 4) to patients that are already implanted with abutments.
75617406|NCT04243954|Drug|Oral morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
75617407|NCT04244344|Other|fall prevention measures|High fall risk signage, information sheet, High fall risk bracelet, verbal instructions
75617408|NCT02827240|Other|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
75770410|NCT01075464|Drug|bevacizumab|Intravenous repeating dose
75770411|NCT01075464|Drug|paclitaxel|Intravenous repeating dose
75318209|NCT00473837|Drug|Placebo|The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
75910148|NCT05708625|Drug|Intralesional Voriconazole|Weekly intralesional Voriconazole
75910149|NCT05708625|Drug|Oral doxycycline|200 mg daily for 6 weeks or till complete cure
75318210|NCT02122549|Device|HWD1000|Wearable cardioverter-defibrillator designed for inpatient use
75341304|NCT04388696|Behavioral|Sisterhood 2.0|The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
75341305|NCT02184416|Other|observational|The study is non interventional. All drugs will be prescribed
75936659|NCT03181178|Dietary Supplement|A micronutrient powder|This intervention provided a 1 g micronutrient powder with nutrition education
75936660|NCT03181178|Behavioral|Nutrition education|This intervention provided nutrition education sessions
75910150|NCT05698602|Device|NivolisMonitor|"NivolisMonitor comprises a sensing element and controller to measure respiratory values, such as pressure and flow optionnally temperature, relative humidity and oxygen concentration, of a patient being treated with a respiratory therapy devices NIV, CPAP or HDN.~NivolisMonitor is inserted between the respiratory assistance device and the mask or cannula inline with the standard patient circuit used routinely with the respiratory assistance device.~NivolisMonitor functions are:~measure the respiratory values from the builtin sensor (Pressure, Flow, Temperature, Humidity, Oxygen fraction),~store the measurements in the embedded memory~extract from the measurement basic respiratory markers:~detect if and when a patient is using the respiratory assist device,~calculate leakage~calculate respiratory frequency~transmit the measured values via the NivolisBox component to NivolisPortal"
75910151|NCT05698602|Device|NivolisAnton|"NivolisAnton device enables wireless and remote communication from tcPCO2 monitors which measure transcuteanously CO2 and O2 partial pressures in the blood (tcPCO2 & tcPO2) .~NivolisAnton device connects to the serial port of tcPCO2 monitor, detects if the monitor is actively measuring blood gas values, collects the measurements from the monitor by following manufacturer's communication protocol and stores the collected values in its internal memory. When applicable per the manufacturer recommendations, NivolisAnton collects the values to apply the drift correction as per the manufacturer recommendations.~NivolisAnton transmits the collected data to external receiving devices, such as Medical Devices (NivolisMonitor or another Medical Device that is granted approved data access by Vivardis) via Bluetooth or data servers (NivolisBox as an example) via WIFI. This data is thereafter transmitted by previously mentioned devices to the NivolisPortal server for archiving."
75910152|NCT05697276|Drug|Lidocaine|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
75617409|NCT02827942|Drug|vonoprazan 20 mg bid|Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
75617410|NCT02827942|Drug|Amoxicillin 500 mg tid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
75617411|NCT02827942|Drug|Amoxicillin 750 mg bid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
75910153|NCT05697276|Drug|Bupivacain|Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
75910154|NCT05690204|Drug|SAP001|Test the efficacy and safety of SAP 001 versus placebo
75910155|NCT05674955|Diagnostic Test|Circuit weight versus aerobic training|"Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C."
75936661|NCT04541537|Diagnostic Test|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry
75936662|NCT04541537|Diagnostic Test|Dog Detection|Analysed by the dogs of Curie Institute at the training centers
75936663|NCT02420522|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
75463787|NCT04067765|Behavioral|Neutral cue|Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of neutral beverages (water).
75463788|NCT04066166|Diagnostic Test|Palpation|All healthy subjects palpated
75463789|NCT04064164|Behavioral|Speeko for Elderspeak|Speeko for Elderspeak is a communication feedback IOS application.
75770412|NCT01285180|Drug|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
75341306|NCT04387838|Diagnostic Test|Anti-SARS-CoV2 Serology|A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
75770413|NCT01075542|Device|AcrySof Toric intraocular lens, model SN60TT|The lens is made of foldable acrylic material and is implanted in the capsular bag
75770414|NCT01075542|Device|AcrySof Monofocal IOL, model SN60AT|The lens is made of foldable acrylic material and is implanted in the capsular bag
75770415|NCT01075620|Device|PFC-Sigma RP|Posterior stabilizing rotating platform total knee components
75770416|NCT01075620|Device|LPS RP|non-posterior stabilized rotating platform design
75798332|NCT01587222|Drug|Midodrine|"Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
75341307|NCT04387838|Other|Questionnaire|"Data concerning personal exposure factors are collected in a questionnaire:~Socio-demographic factors: sex, age~Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital~Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures"
75463790|NCT04063709|Diagnostic Test|Acoustic Radiation Force Impulse (ARFI) ultrasound|ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
75617412|NCT02827942|Drug|Clarithromycin 200 mg bid|Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
75617413|NCT02827942|Drug|Metronidazole 250 mg bid|Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
75463791|NCT04062656|Drug|Nivolumab|Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes
75617414|NCT00880087|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
75770417|NCT03968250|Behavioral|Cognitive Behavioral Therapy for Treating Fatigue|"The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.~The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed."
75770418|NCT01074840|Other|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
75463792|NCT04062656|Drug|relatlimab|relatlimab (80mg flat dose) administered IV over 60 min
75770419|NCT01077492|Other|Virtual Bronchoscopy Navigation|Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
75770420|NCT01074918|Drug|Potassium, Magnesium, Citrate|Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
75770421|NCT01074918|Drug|Potassium Chloride|Potassium Chloride
75770422|NCT01074996|Drug|S-1|40-60mg bid , days 1-14, every 3 weeks
75936664|NCT02420522|Device|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
75936665|NCT04540757|Procedure|Surgery|Participants will be randomised to receive surgery as part of multi-modality treatment
75318211|NCT03024008|Biological|BonoFill-II|"Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion.~A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed.~internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union."
75463793|NCT04062656|Drug|Oxaliplatin|Oxaliplatin 85mg/m² IV over 1 h
75463794|NCT04062656|Drug|Docetaxel|Docetaxel 50mg/m² IV over 1 h
75463795|NCT04062656|Drug|5-Fluorouracil (5-FU)|5-fluorouracil 2600mg/m² IV over 24h
75463796|NCT04062656|Drug|Folic acid (FA)|Folic acid 200mg/m² IV over 30 min
75463797|NCT04041050|Drug|Navitoclax|Tablet; Oral
75463798|NCT04041050|Drug|Ruxolitinib|Tablet; Oral
75318212|NCT00509197|Drug|Placebo (sham inhaler)|
75617415|NCT00880087|Procedure|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
75617416|NCT02827084|Device|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
75463799|NCT04041050|Drug|Celecoxib|Capsule; Oral
75463800|NCT04035369|Procedure|Tap and Inject (TAI)|"Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL"
75617417|NCT02827084|Device|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
75617418|NCT00889252|Device|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
75617419|NCT00889252|Device|contact lens|Placebo contact lens
75617420|NCT00670813|Drug|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
75770423|NCT01074996|Drug|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
75318213|NCT00509197|Drug|Fluticasone|Fluticasone 250mcg bid for one month
75463801|NCT04035369|Procedure|Pars Plana Vitrectomy (PPV)|Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
75463802|NCT04018313|Biological|CT-P39|150 mg/mL, Solution for injection in PFS
75463803|NCT04018313|Biological|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
75463804|NCT04018313|Biological|CT-P39|150 mg/mL, Solution for injection in PFS
75770424|NCT00160524|Biological|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
75770425|NCT01077570|Drug|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
75770426|NCT01075698|Drug|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
75770427|NCT01075698|Drug|ARB (Telmisartan)|Telmisartan 20-80 mg/day
75910156|NCT05674500|Other|Educational Training on standardized coaching language|The faculty trainer participants in training groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The training video will demonstrate the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction).
75936666|NCT04540757|Procedure|No surgery|Participants will be randomised to receive no surgery as part of multi-modality treatment
75318214|NCT00442013|Drug|Lansoprazole|Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
75318215|NCT00442013|Drug|Matching placebo|Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
75463805|NCT04018313|Biological|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
75318216|NCT03981302|Other|Family nursing conversations|"The intervention is based on the concept family systems nursing developed by Wright & Maureen. Family nursing aims to change restricting beliefs and alleviate illness suffering. The Illness Beliefs model and Calgarymodels are essential components. The illness beliefs model illuminates the family's different beliefs about their problems. The Calgary models consist of the Calgary family assessment model and the Calgary intervention model and aim to support change and help the family to find new ways to handle the illness. The use of the components cannot be standardised but must be tailored to match the needs of the specific family. The family nursing conversations in this intervention will last 1,5 hour. Every family will be offered three family nursing conversations with roughly three weeks interval. If the family after three conversations express a need for follow-up, they will be offered the fourth conversation."
75318217|NCT02121067|Drug|Levonorgestrel Intrauterine System (LNG-IUS)|The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
75463806|NCT04018313|Biological|US-licensed Xolair|150 mg/mL, Solution for injection in PFS
75463807|NCT04011332|Other|Integrated Care Model|The patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led integrated care model for three months. The model constitutes a bundle of interventions that are commonly known as key elements in COPD management. In addition, the ANP-Team (Advanced Nursing Practice-Team) will coordinate the different health professionals within the hospital and across transitions within the three months.
75463808|NCT04006405|Diagnostic Test|GAG score|blood and urine samples to determine GAG scores
75463809|NCT03976518|Drug|Atezolizumab|Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).
75617421|NCT00670813|Drug|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
75617422|NCT01110330|Drug|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
75770428|NCT03966300|Other|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
75770429|NCT00159822|Drug|Voriconazole|"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"
75770430|NCT01164124|Dietary Supplement|Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
76072588|NCT04233424|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
75463810|NCT03974412|Diagnostic Test|Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT [protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes]"
75463811|NCT03974412|Device|Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
75463812|NCT03973203|Dietary Supplement|Niacin|The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.
75463813|NCT03930823|Other|Interview|One to one interview
75617423|NCT01110330|Drug|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
75617424|NCT01110330|Drug|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
75617425|NCT00663481|Drug|CoFactor|
75617426|NCT00663481|Drug|Leucovorin|
75617427|NCT04308954|Drug|[18F]flumazenil|[18F]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
75617428|NCT05016778|Drug|GPRC5D-CAR-T|After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
75617429|NCT02881398|Device|mHealth|After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
75617430|NCT02881398|Other|Standard-Care|After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
75617431|NCT04243564|Device|Supraglottic device (SGD)|Positioning of SGD as temporary ventilatory device before tracheal intubation
75617432|NCT05010460|Drug|Roxadustat|orally 100mg every other day for 5-8 days prior to CABG
75617433|NCT05010460|Drug|Placebo|orally 100mg every other day for 5-8 days prior to CABG
75617434|NCT00596947|Drug|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
75617435|NCT00596947|Drug|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
75910157|NCT05674500|Other|Educational Training on goal setting|The faculty trainer participants in the control groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The video will be a 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices.
75936306|NCT03186248|Procedure|Per oral endoscopic myotomy|General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
75318218|NCT03595826|Drug|Neurostimulant pharmaceutical drugs|The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
75770431|NCT01164124|Other|Placebo|routine feedings
75770432|NCT01171144|Other|Epidemiologic Surveillance System of the Ministry of Health of Panama|Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
76072589|NCT04233424|Other|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
75770433|NCT01171144|Other|Mortality database of the Contraloria General de la Republica|Reviewing the Mortality database of the Contraloria General de la Republica
76072590|NCT04185610|Other|Qi Gong|Guided Qi Gong class
76088823|NCT04490226|Dietary Supplement|fasting, active|36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
75463814|NCT03916926|Device|"A simple medical strategy consisting of silver diamine fluoride (SDF)"|Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)
75318219|NCT00509587|Drug|pazopanib hydrochloride|Given orally
75770434|NCT01171144|Other|Hospital discharge records|Reviewing the hospital discharge records
75318220|NCT00509587|Procedure|pharmacological study|Correlative studies
75770435|NCT01285258|Procedure|hysterectomy|excluding the uterus with saving ovaries
75318221|NCT00509587|Procedure|laboratory biomarker analysis|Correlative studies
75463815|NCT03916926|Device|"B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)"|GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
75463816|NCT03906370|Diagnostic Test|Diagnostic criteria for MS|The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
75463817|NCT03899857|Drug|Pembrolizumab|Pembrolizumab will be added to standard of care
75463818|NCT03871491|Drug|Azithromycin|The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
75770436|NCT00158262|Drug|Propranolol|Propranolol short-acting or long-acting capsule
75770437|NCT00158262|Drug|Placebo|Placebo-matching propranolol short-acting or long-acting capsule
75770438|NCT03868072|Drug|XELJANZ 5Mg Tablet|XELJANZ 5Mg Tablet 1T single oral administration under fasting
75617436|NCT00596947|Drug|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
75910158|NCT05672784|Procedure|genicular nerve block plus standard analgesia|In supine position with a pillow under the popliteal fossa, a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) will be placed parallel to the shaft of long bones of the legs. The target points will be next to superior lateral, superior medial, and inferior medial genicular arteries to block the superior lateral, superior medial, and inferior medial branches of genicular nerve. Identification will be done using color Doppler near the periosteal areas (the junctions of the epicondyle and the shafts of the femur and tibia, accordingly). The needle will be inserted in the plane of the ultrasound probe in the long-axis view. After confirming the placement of the needle-tip next to the genicular arteries, a 2.5 mL of bupivacaine (5%) will be injected at each target points.
75910159|NCT05672784|Procedure|genicular nerve block plus infiltration Between Popliteal Artery and Capsule of Posterior Knee plus standard analgesia|IPACK block will be performed in supine position with flexion of the knee in 45o. low frequency transducer at a depth of 3.5-4 cm will be placed transversely over the medial aspect of the knee, 2-3 cm above the patella, with sliding the transducer proximally and distally to identify the distal part of the shaft of the femur and the popliteal artery ( If the two femoral condyles appear first, proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared). Advance the needle in plane toward the space between the popliteal artery and the femur then 15 ml of bupivacaine 0.5% will be injected plus genicular nerve block
75910160|NCT05672784|Drug|standard analgesia (paracetamol and meloxicam)|(paracetamol 1 gm thrice daily and meloxicam (15 mg) every 24).
75910161|NCT05661253|Drug|25 ml of bupivacaine 0.25% via serratus anterior block|patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,
75910162|NCT05661253|Drug|25 ml of bupivacaine 0.25% via modified serratus anterior palne block|patients will receive modified serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia.
75910163|NCT05656001|Other|Real-time functional magnetic resonance imaging Neurofeedback and Real-time Biofeedback|Participants will take part in three runs of real-time functional magnetic resonance imaging feedback (rt-fMRI-NF) training with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive biofeedback will take part in three runs of biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
75936307|NCT03528057|Device|Hemostat|Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
75318222|NCT00509665|Drug|doxorubicin hydrochloride|given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
75617437|NCT00596947|Drug|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
75617438|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
75770439|NCT03868072|Drug|Chong Kun Dang Tofacitinib Tablet|Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting
75770440|NCT02526394|Biological|Meningococcal vaccine|Meningococcal vaccination
75770441|NCT02526394|Drug|Pertussis containing vaccine|Pertussis containing vaccination
75770442|NCT00157950|Biological|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
75770443|NCT00157950|Biological|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
75770444|NCT01283932|Drug|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
75318223|NCT00509665|Drug|gemcitabine hydrochloride|given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
75770445|NCT05666752|Dietary Supplement|Allium Cepa L. Peel Heated Water Extract|4 capsules/day after meal(1,200 mg/day) for 8 weeks
75770446|NCT05666752|Dietary Supplement|Placebo|4 capsules/day after meal(1,200 mg/day) for 8 weeks
75770447|NCT03966144|Device|RoboHear Device|Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words
75770448|NCT01171300|Other|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
75318224|NCT00513799|Drug|Mupirocin ointment|Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.
75318225|NCT00513799|Genetic|Chlorhexidine showers|Apply Clorhexidine wash to entire body once daily for 5 days.
75318226|NCT00513799|Procedure|Bleach baths (dilute)|Pour 2 ounces of bleach into water-filled bath tub. Soak in bath for 15 minutes. Apply once daily for 5 days.
75318227|NCT00513799|Behavioral|Intensive education on personal hygiene|Repeat hygiene methods for 5 days.
75770449|NCT01171300|Other|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
75770450|NCT03964896|Other|Survey|Complete survey
75770451|NCT03964896|Other|Survey Administration|Ancillary studies
75770452|NCT03964896|Behavioral|Telephone-Based Intervention|Receive telephone calls
75770453|NCT01171378|Drug|Ofatumumab|"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"
75770454|NCT01164280|Other|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
75770455|NCT03875560|Biological|IC14|recombinant chimeric anti-human CD14 monoclonal antibody
75770456|NCT03875560|Drug|Placebo|Inactive
75770457|NCT02526862|Device|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
75770458|NCT02526862|Device|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
75770459|NCT02526862|Device|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
75318228|NCT00514501|Drug|Iodofiltic acid I 123|
75318229|NCT00561145|Other|Energy restriction period|The experiment can be divided in 3 phases, namely (1) run-in phase, (2) energy restriction phase and (3) ad libitum food intake phase. Thus, for all participants the experiment consists of three subsequent phases.
75318230|NCT00442169|Biological|ChimeriVax-WN02 Low Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
75463819|NCT03871491|Drug|Placebo|Identical appearing placebo, administered as a single oral dose directly after randomization.
75463820|NCT03853902|Behavioral|Mindfulness Program|Mindfulness Program
75617439|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
75617440|NCT04155697|Drug|2% Chlorohexidine Gluconate soap|Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
75617441|NCT04155697|Drug|62% ethyl alcohol-based hand sanitizer|Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
75617442|NCT00663559|Drug|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
75617443|NCT04158349|Drug|Oxaliplatin|Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
75617444|NCT04158349|Drug|mFOLFIRI|mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
75617445|NCT00670891|Procedure|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~Air or Gas Embolus~Decompression Illness~Carbon Monoxide poising~Clostridial Myonecrosis (Gas Gangrene)~Necrotizing Fasciitis~Crush Injury (Compartment syndromes)~Selected Problem Wounds~Compromised Skin Flaps or Grafts~Refractory Osteomyelitis~Exceptional Anemia due to Blood loss~Osteoradionecrosis~Thermal Burns and Radiation Tissue Damage~Diabetic Wounds~Intra-Cranial Abscess~Brain Injury and other Head Trauma~Cerebral Palsy~High Altitude Sickness~Lyme disease"
75770460|NCT01171456|Drug|Metformin|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
75770461|NCT01171456|Drug|Placebo|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
75770462|NCT03865888|Drug|Cyclosporins|Cyclosporins eye drops to be administered in dry eyes
75770463|NCT03865888|Drug|Tacrolimus|Tacrolimus eye drops to be administered in dry eyes
75770464|NCT01173796|Procedure|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
75770465|NCT01173796|Procedure|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
75770466|NCT03865966|Other||No intervention
75770467|NCT03866122|Device|NTM Monitoring|NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.
75936308|NCT03527979|Procedure|IVF/ICSI|IVF/ICSI
75318231|NCT00442169|Biological|ChimeriVax-WN02 Medium Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
75318232|NCT00442169|Biological|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
75318233|NCT00442169|Biological|0.9% Saline solution|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
75463821|NCT03847324|Other|Pain Neuroscience Education|"This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors."
75463822|NCT03847324|Other|Multimodal Physiotherapy|This intervention will be divided in pain neuroscience education, orthopedic manual therapy and therapeutic exercise.
75770468|NCT03875404|Diagnostic Test|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
75770469|NCT01284010|Genetic|DNA analysis|
75770470|NCT01284010|Genetic|fluorescence in situ hybridization|
75770471|NCT01284010|Genetic|gene expression analysis|
75770472|NCT01284010|Genetic|microarray analysis|
75770473|NCT01284010|Genetic|mutation analysis|
75770474|NCT01284010|Genetic|polymerase chain reaction|
75770475|NCT01284010|Other|laboratory biomarker analysis|
75770476|NCT01285336|Genetic||
75910164|NCT05656001|Other|Sham functional magnetic resonance imaging neurofeedback and sham biofeedback|Participants will take part in three runs of sham neurofeedback with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive sham biofeedback will take part in three runs of sham biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
75463823|NCT03847324|Other|Usual Care|Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
75463824|NCT03846947|Device|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
75617446|NCT00888940|Drug|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
75617447|NCT00888940|Drug|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
75463825|NCT03840967|Drug|Niraparib|Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
75463826|NCT03839914|Drug|Vancomycin powder|For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
75770477|NCT01171846|Other|Pelvic Floor Muscle training|"Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).~Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation."
75910165|NCT05639192|Biological|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
75910166|NCT05639192|Other|Placebo|Placebo will be administered once per week as an i.v. infusion
75617448|NCT00595621|Device|Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)|Multi-Channel Phased Gastric Pacemaker (MGP-1)
75617449|NCT02826070|Drug|Telbivudine|Telbivudine, 600mg, oral, daily
75770478|NCT01284088|Device|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
75770479|NCT01284088|Procedure|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
75770480|NCT01284166|Drug|dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution|1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
75770481|NCT01164514|Biological|CPG 7909|CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
75770482|NCT01164514|Biological|J5-OMP Vaccine|J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
75770483|NCT01164514|Drug|Placebo|Normal saline.
75770484|NCT01164592|Device|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
75770485|NCT01285414|Drug|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide & Radiation Therapy
75770486|NCT01285414|Drug|Temozolomide & Radiation Therapy|Temozolomide & Radiation Therapy
75617450|NCT02826070|Drug|Adefovir dipivoxil|Adefovir dipivoxil 10mg, oral, daily
75617451|NCT02826070|Other|off-treatment follow-up|
75617452|NCT00663637|Device|CAM (Complete Airway Management) Catheters|Prior to extubation, endotracheal tube lumen secretions are mechanically removed using CAM Rescue Cath followed by CAM Endotrach Cath.
75617453|NCT05090488|Behavioral|Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
75770487|NCT03875248|Device|Blood pressure measurement|Measure optically the blood pressure through the use of a smartphone
75770488|NCT03875014|Device|surgery with implant for hip fracture|hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
75770489|NCT03875170|Other|Experimental|The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility. The subject will be asked to perform an isometric contraction, with a series of 3 seconds for sustained contraction and a rest between contraction of 2 to 3 seconds after activating the Golgi apparatus, making an inhibition of the stimulus and bringing the joint and muscle to the highest possible range of motion without pain.
75910167|NCT05620576|Drug|LY3857210|Administered orally
75910168|NCT05620576|Drug|Placebo|Administered orally
75463827|NCT03838263|Drug|Nivolumab|2 nivolumab infusion (240 mg IV) 2 weeks apart (on day 1 and day 15) followed by standard chemoradiation.
75910169|NCT05619081|Behavioral|POWERNAP|POWERNAP of max 30min while participants ly down comfortably
75910170|NCT05617885|Drug|Darolutamide|Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
75910171|NCT05617885|Drug|Abemaciclib|"Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing."
75910172|NCT05617885|Drug|GNRH-A Leuprolide Acetate|Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
75770490|NCT03875170|Other|Control|The active stretching technique will be performed for the hip, quadriceps and hamstring flexors with a voluntary antagonist activation to relax the agonist muscle, holding the movement to be performed for 30 seconds to stimulate the neuromuscular spindle and produce a relaxation of the muscle fibers.
75910173|NCT05617885|Drug|GNRH-A Goserelin|Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
76072591|NCT05534932|Device|Remote Patient Monitoring|Subjects in this group will receive RPM therapy through the University of Chicago Heart Failure program. This therapy consist of a bluetooth tablet, blood pressure cuff and a health scale for subjects to bring home and take thier measurements on a daily bases up to their 3 month clinic visit. This data will then be transmitted to EPIC where the study team will retrieve the data.
75617454|NCT00663715|Other|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
75617455|NCT02826226|Device|multiple-breath-washout test|
75463828|NCT03838263|Radiation|Chemoradiation|Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7
75463829|NCT03808051|Procedure|Physiological-based cord clamping|See Arm description.
75463830|NCT03808051|Procedure|Time-based cord clamping|See Arm description.
75617456|NCT02826226|Drug|Bronchodilator Agents|
75770491|NCT01172002|Drug|Leflunomide|"Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
75770492|NCT01172002|Drug|Azathioprine|"Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
75463831|NCT03801642|Drug|Dapagliflozin|10 mg oral tablets taken once daily for 12 weeks
75463832|NCT03801642|Other|Placebo|Placebo tablet (matched in size and color to active tablet) taken once daily for 12 weeks
75463833|NCT03790657|Behavioral|practice of a complex walking task|walking over obstacles
75463834|NCT03790657|Device|Dosage A: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
75617457|NCT00671047|Other|non-interventional|SLE nature history observational
75617458|NCT00671125|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
75617459|NCT00671125|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
75770493|NCT03867994|Drug|Atorvastatin|
75463835|NCT03790657|Device|Dosage B: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
75463836|NCT03724396|Behavioral|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
75463837|NCT03724396|Behavioral|Novel Executive Function Training - NEXT|Modifies programs like CogSMART and cognitive remediation training to help participants improve executive functioning to adhere to recommendations from BWL.
75617460|NCT00671125|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
75617461|NCT00671203|Procedure|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
75770494|NCT03867994|Drug|Carvedilol|
75770495|NCT03867994|Drug|saline|
75910174|NCT05617885|Drug|Degarelix|Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
75910175|NCT05616338|Other|Blood sample|"A blood sample and a nasal brush for each participant. The nasal brushing will allow the isolation of epithelial cells that will serve as a comparison for the bronchial tissue produced from blood-derived iPS.~A blood sample of approximately 14 ml will be taken for isolation and freezing of the blood mononuclear cells allowing the generation of iPS."
75910176|NCT05614570|Device|SSVEP Device|Non-invasive, non-interventional SSVEP sensor device
75910177|NCT05614570|Other|SCAT5|The Sport Concussion Assessment Tool version 5
75910178|NCT05603832|Drug|F14|625 mg intra-articular sustained-release celecoxib
75910179|NCT05603832|Drug|0.25 % Bupivacaine HCl|Local anesthetic
75910180|NCT05603832|Drug|Acetaminophen|Analgesic
75910181|NCT05603832|Drug|Methocarbamol|Muscle relaxant
75910182|NCT05601271|Drug|Allopurinol|Allopurinol 100 to 300 mg a day for 3 months
75463838|NCT03713645|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant|Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients
75463839|NCT03705507|Drug|Selumetinib|Selumetinib is a small molecule inhibitor of the MEK protein
75463840|NCT03705507|Drug|Dexamethasone|Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
75463841|NCT03695848|Device|MRI scan|Before decompresssion surgery, DTI and fMRI will be recorded by a FDA approved 3T MRI scanner (Philips Achieva)
75617462|NCT04157803|Diagnostic Test|Acetic acid % spray|"If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly."
75617463|NCT04157959|Drug|SHR4640 dose1|Tablet,dose1,QD
75617464|NCT04157959|Drug|Febuxostat dose2|Tablet,dose2,QD
75617465|NCT04243408|Other|Autologous umbilical cord blood transfusion|single dose of an autologous umbilical cord blood transfusion
75770496|NCT01172080|Other|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
75770497|NCT03867604|Procedure|Sham injection|Injection to the subcutaneous layer at upper trapezium level
75770498|NCT03867604|Procedure|Fascia injection|Injection to the fascia below upper trapezium muscle
75770499|NCT01285570|Drug|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
75770500|NCT01285570|Drug|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
75770501|NCT01285570|Drug|5% dextrose in water|Placebo
75770502|NCT01164748|Radiation|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
75770503|NCT01172236|Drug|Lactoferrin|"Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.~Control group: newborns (group B) will receive only standard therapy and they will be used as controls."
75770504|NCT01172236|Drug|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
75770505|NCT02525926|Procedure|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
75770506|NCT02525926|Procedure|sham procedure|"Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
75770507|NCT02525848|Drug|dexamethasone|dexamethasone 8 mg iv 2 minutes before induction of anesthesia
75770508|NCT02525848|Drug|Gabapentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
75910183|NCT05593198|Procedure|Khoury technique|the bone block will be used following the principles of the Khoury technique to augment the bone volume.
75910184|NCT05593198|Procedure|Guided bone regeneration|the membrane and the bone granules will be used to perform the guided bone regeneration technique.
75463842|NCT03686410|Behavioral|Web-based Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
75463843|NCT03686410|Other|Conventional Treatment|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
75463844|NCT03675308|Biological|Placebo|Placebo for risankizumab administered by subcutaneous injection
75463845|NCT03675308|Biological|Risankizumab|Risankizumab administered by subcutaneous injection
75617466|NCT04243408|Other|placebo|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
75617467|NCT00660283|Drug|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
75617468|NCT02826148|Other|RAADS-R scale|This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
75617469|NCT00663949|Drug|Captopril|25 mg captopril tablet q8h
75617470|NCT00663949|Drug|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
75617471|NCT00660439|Behavioral|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
75770509|NCT02525848|Drug|Aprepitant|oral aprepitan 80mg 1 hour before induction of anesthesia.
76072592|NCT05367856|Drug|Chidamide combined with BEAM|Chidamide: 30mg po D-7,D-4,D-1 and D+3 Carmustine: 300mg/m2 ivgtt D-7 Etoposide: 100mg/m2/d ivgtt q12h D-6-D-3 Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3 Melphalan: 140mg/m2 ivgtt D-2
75617472|NCT02825758|Dietary Supplement|ZestiVits|"The study product is a low-carbohydrate, orange flavour, vitamin, mineral and trace element (micronutrient) supplement for use in ketogenic and restricted therapeutic diets, for children aged from 11 years of age and adults.~The recommended dosage of the study product for each subject will be determined and prescribed by a dietitian. This will be based on individual requirements for micronutrient supplementation."
75770510|NCT03865576|Diagnostic Test|Non-invasive ICP measurement|Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
75770511|NCT01172314|Dietary Supplement|EAA+LEU vs total AA|15 g as a bolus
75770512|NCT01172314|Dietary Supplement|Total AA vs EAA+LEU|15 g as a bolus
75770513|NCT01269112|Device|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
75770514|NCT01269112|Device|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
75770515|NCT01174420|Device|Use of ologen Collagen Matrix in trabeculectomy|After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
75770516|NCT01174420|Drug|Use of Mitomycin-C in trabeculectomy|After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
75770517|NCT01164826|Drug|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
75770518|NCT01164826|Drug|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
75770519|NCT03867292|Other|Myofascial|"The aim of the application of the crossed hands technique is to produce a deep fascial release, placing the subject in prone position, while the standing physiotherapist will contact with one hand on the spine at the level of the thoracolumbar hinge and with the other hand on the sacrum, so that the hands are crisscrossed. The crossed hands technique will be performed between 90 seconds and 5 minutes.~The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally."
75617473|NCT00888238|Drug|sitagliptin|Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
75463846|NCT03667807|Device|Repetitive transcranial magnetic stimulation|Non invasive brain stimulation
75770520|NCT03867292|Other|Electrotherapy|The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.
75770521|NCT01174498|Device|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
75936309|NCT03627377|Behavioral|Multi-component Intervention for Diabetes in Adults with Serious Mental Illness|Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
75936310|NCT02707952|Drug|ABT-493/ABT-530|Co-formulated tablet
75318234|NCT00442169|Biological|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
75318235|NCT00442169|Biological|0.9 % NaCl solution|Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
75318236|NCT00515203|Drug|Placebo|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
75318237|NCT00515203|Drug|AMG 531|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
75463847|NCT03664687|Drug|Zoledronate|Administered intravenously (IV)
75463848|NCT03663504|Other|No Preparation|No preparation before surgery
75463849|NCT03663504|Drug|Neomycin and Flagyl|Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
75617474|NCT00888238|Drug|Comparator: Placebo|Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
75617475|NCT05660356|Drug|Growth Hormone|Pfizer provided GH therapy
75617476|NCT05660356|Drug|Placebo|Pfizer provided placebo
75617477|NCT00595465|Biological|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
75617478|NCT02825914|Dietary Supplement|Casein glycomacropeptide (CGMP)|
75617479|NCT02825914|Dietary Supplement|Placebo|
75617480|NCT00671281|Drug|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
75318238|NCT00216476|Drug|Aripiprazole|10-30 mg oral once daily for 104 weeks
75463850|NCT03654066|Drug|Botulinum toxin type A|Botox injection in the LES
75463851|NCT03654066|Device|Endoscope balloon dilator|Distal esophageal dilation
75463852|NCT03654066|Other|Patient reported outcomes|Subjects will complete two patient reported outcome measures (Eckardt and MADS).
75617481|NCT00671281|Drug|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
75617482|NCT01205438|Drug|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
75617483|NCT01205438|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
75617484|NCT01205438|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
75770522|NCT01174498|Device|t-VNS Sham stimulation|t-VNS Sham stimulation
75770523|NCT01284322|Drug|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
75936311|NCT02707952|Drug|OBV/PTV/r|Co-formulated tablet
75910185|NCT05584059|Behavioral|Focused Acceptance and Commitment Therapy|This is an individual-based FACT counselling programme which composes of 4-6 sessions on a weekly basis (45-60mins/session). All the sessions are delivered by a trained FACT interventionist via either video-conferencing (e.g., Zoom or Windows Teams) or face-to-face format. The programme aims to increase the psychological flexibility of the parent, so that he/she is able to (i) experience the present moment and take perspective on self (i.e., Awareness); (ii) detach the distressing private experiences and associated rules and to take a non-judgemental, accepting stance toward the painful experiences (i.e., Openness) and (iii) exhibits strong connection with values and commit to values-consistent actions. The trained interventionist will use different ACT strategies in these sessions, including ACT metaphors, experiential exercises, guided mindfulness exercises, guided imagery exercises and values clarification exercises to reinforce the above principles.
75617485|NCT04155229|Other|Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)|"For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg."
75617486|NCT04944316|Behavioral|Dietary intervention|Low-fat, plant-based diet
76088824|NCT04490226|Dietary Supplement|fasting, inactive|"36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later."
75463853|NCT03654066|Diagnostic Test|Barium esophagram|Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
75463854|NCT03653650|Combination Product|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
75463855|NCT03653650|Combination Product|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
75617487|NCT04944316|Behavioral|Dietary intervention|Portion-controlled diet (compliant with ADA guidelines)
75617488|NCT00664183|Drug|Vitreosolve|Intravitreal injection
75770524|NCT01284400|Other|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
75770525|NCT01285648|Procedure|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
75770526|NCT01172392|Drug|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
75770527|NCT01172392|Drug|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
75770528|NCT01164904|Drug|Amg 181|Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
75770529|NCT03865186|Behavioral|Psychoeducation Program|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
75770530|NCT03865186|Behavioral|no intervention|
75770531|NCT03863938|Drug|Tegoprazan 50mg|K-CAB
75770532|NCT01175044|Procedure|Betadine Lavage|Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation
76088825|NCT02464800|Procedure|Vitrectomy for proliferative diabetic retinopathy|25-gauge vitrectomy
75318239|NCT00216476|Drug|Risperidone Long Acting Injectable (LAI)|25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
75318240|NCT00216476|Drug|Quetiapine|Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
75318241|NCT00561457|Device|Bard Luminexx Iliac Stent and Delivery System|Iliac Stenting
75318242|NCT00515437|Biological|Botulinum Toxin Type B (Myobloc)|
75318243|NCT00515437|Biological|Matched placebo to Myobloc|
75318244|NCT00474617|Drug|Sugammadex|
75318245|NCT00474617|Drug|Rocurium|intravenous (IV) single bolus dose of 0.6 mg.kg-1
75318246|NCT00562315|Drug|FACBC|Anti-3-[18F]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
75463856|NCT03653650|Combination Product|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
75463857|NCT03590691|Other|Vietnam National Hypertension Program|A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
75617489|NCT00671359|Drug|TR-701 600mg|TR-701 600mg
75617490|NCT04153201|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg daily for patients weighing < 60 kg, hydroxychloroquine 400 mg daily for patients weighing >= 60 kg
75617491|NCT05660278|Other|Milk containing A1 and A2 beta-casein|Single dose of milk
75617492|NCT05660278|Other|Milk containing only A2 beta-casein|Single dose of milk
75770533|NCT01175044|Procedure|Saline Lavage|Following revision knee surgery, 2000ml sterile saline lavage prior to closure
75770534|NCT03864016|Drug|Induction and maintenance of anesthesia|The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
75770535|NCT03864016|Drug|Adaptation of sufentanil doses according to the usual protocol|At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
75770536|NCT03864016|Drug|Adjustment of sufentanil doses according to pupillometry|At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
75910186|NCT05565495|Drug|Hydromorphone|Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
75463858|NCT03590691|Other|Expanded community health worker services|A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
75910187|NCT05561400|Device|tDCS|5x5 saline-soaked sponge electrodes will be used with the cathode placed over the right cerebellar hemisphere; 1cm under and 4cm lateral of the inion targeting lobule VII and the anode will be placed on the right shoulder. The electrode placement will be the same across both conditions.
75910188|NCT05561400|Other|Placebo|sham tDCS to the right cerebellum
75910189|NCT05557825|Radiation|Photobiomodulation Therapy|Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
75910190|NCT05547503|Drug|AFA-281|Part 1: AFA-281 will be administered as a single dose at 5 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 days at 3 dose levels (TBD)
75910191|NCT05542394|Dietary Supplement|Curcumin|"water soluble version of turmeric extract standardized to 10% curcuminoids~."
75910192|NCT05539742|Dietary Supplement|Coconut oil|Coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
75910193|NCT05539742|Dietary Supplement|Palm oil|Palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
75910194|NCT05531734|Device|NaoX Intra-Auricular Device (IAD) monitoring EEG data|Intrauaricular measurement tool developed by NaoX Technology to retrieve EEG type data.
75910195|NCT05531734|Behavioral|Simple psychometric tests|Associated with simple and self-managed psychometric tests.
75910196|NCT05522023|Procedure|group treated with aromatic solution|The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
75910197|NCT05522023|Procedure|group treated with drinking water|In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
75770537|NCT03860662|Diagnostic Test|Nociceptor flexor reflex|The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
75910198|NCT05519579|Drug|Methotrexate|Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
75910199|NCT05519579|Drug|Blinatumomab|Blinatumomab 28ug/day continuous infusion for 4 weeks
75910200|NCT05508971|Procedure|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
75910201|NCT05508971|Procedure|Adenotonsillectomy|Tonsil and adenoid removal
75770538|NCT03860662|Drug|Botox|botox
75770539|NCT03860662|Drug|Baclofen|baclofen
75770540|NCT01177696|Behavioral|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
75770541|NCT01177852|Drug|diphenhydramine + dropropizine + pseudoephedrine|"Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml"
75910202|NCT05485142|Procedure|prolotherapy|5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.
75910203|NCT05470608|Drug|SL-1002|SL-1002 injectable solution
75910204|NCT05470608|Drug|Placebo|Matching placebo injectable solution
75463859|NCT03590691|Behavioral|Storytelling intervention|The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
75463860|NCT03590691|Behavioral|Home blood pressure self-monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
75463861|NCT03582488|Drug|18F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
75617493|NCT00664261|Behavioral|smoking cessation intervention|
75617494|NCT00664261|Other|cancer prevention|
75617495|NCT00664261|Other|counseling intervention|
75617496|NCT00664261|Other|educational intervention|
75617497|NCT00664261|Other|laboratory biomarker analysis|
75617498|NCT00664261|Other|questionnaire administration|
75617499|NCT00664261|Other|survey administration|
75617500|NCT00664261|Procedure|study of high risk factors|
75617501|NCT04153123|Drug|Epinephrine|
75770542|NCT01177852|Drug|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|"Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml"
75910205|NCT05470517|Drug|Ceftriaxone|"Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed."
75463862|NCT03580057|Behavioral|Breastfeeding promotion intervention|Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.
75910206|NCT05470517|Procedure|Intra-peritoneal Fluid Aspiration|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
75463863|NCT03580057|Behavioral|Diet and weight loss intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
75910207|NCT05465122|Procedure|Carotid Endarterectomy|This is the standard proven therapy for carotid stenosis that involves an arterotomy followed by removal of plaque and reconstruction of the vessel.
75910208|NCT05465122|Procedure|FDA-approved carotid stents|This is the standard proven therapy for carotid stenosis that involves an arterotomy followed by removal of plaque and reconstruction of the vessel.
75463864|NCT03568552|Behavioral|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
76072593|NCT02124304|Device|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
75463865|NCT03553810|Drug|Entresto|Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
75463866|NCT03553810|Drug|Valsartan|Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
75463867|NCT03546699|Diagnostic Test|Estimation of hospital-wide incidence of ARDS|"Estimation of hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification.~To describe clinical characteristics and outcomes for these patients.~To analyze the prognosis and time course of patients who initially meet criteria for Kigali-defined ARDS and subsequently progress to Berlin-defined ARDS.~For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans."
75463868|NCT03543865|Behavioral|New Hope (NH)|New Hope will be implemented over 1 visit (2-4 hours) in a youth-preferred setting after Emergency Department (ED) discharge for a suicide attempt, and in the past few years has been updated to also target suicide ideation and binge behavior. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by with Native actors, vignettes specific to this community, and Elders speaking in Apache (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life.Youth will be encouraged to choose a support person from his/her family to take part in the intervention.
75617502|NCT02825524|Device|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
75617503|NCT00671593|Biological|House Dust Mite|"Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,~1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml"
75617504|NCT00671593|Biological|Diluent|Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
75617505|NCT01104870|Drug|UT-15C|oral
75617506|NCT02887664|Procedure|Blood test|Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
75617507|NCT02825368|Biological|MMR|0.5 mL, subcutaneous
75617508|NCT02825368|Biological|Tdap|0.5 mL, intramuscular
75617509|NCT02825368|Other|Diphtherinum®|
75770543|NCT01285726|Other|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
75770544|NCT01288144|Other|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
75617510|NCT02825368|Other|Pertussinum®|
75617511|NCT02825368|Other|Tetanotxicum®|
75617512|NCT02825368|Other|Morbilinum®|
75617513|NCT02825368|Other|Ourlianum®|
75770545|NCT01285804|Other|Cuffed ETT|Kimberly Clark
75770546|NCT01285804|Other|Uncuffed ETT|Kimberly Clark
75770547|NCT01178008|Procedure|Active acupuncture|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.
75910209|NCT05465122|Other|Intensive Medical Management|INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
75910210|NCT05460494|Behavioral|RELOAD-C|RELOAD-C is a web-based platform that centralizes 6 brief videos of our MCP expert (Dr. Applebaum) discussing sources of meaning, links to virtual group meetings facilitated by a social worker trained in MCP to promote discussion of MCP concepts, and written content providing guidance on homework and exercises referenced in the MCP videos
75318247|NCT00562315|Other|ProstaScinct|ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
75770548|NCT01178008|Procedure|Placebo acupuncture|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
75770549|NCT01288222|Other|KIR genotype|KIR genotype data from unrelated donor are collected
75770550|NCT01175122|Biological|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
75910211|NCT05449119|Biological|Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data|at T0, T3 months, T6 months, T9 months and T12 months
75318248|NCT00216086|Drug|Capecitabine|"Capecitabine 1000* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~*For calculated creatinine clearance of 30-50 mL/min or patients > 70 years old, capecitabine starting dose is 825 mg/m2 po bid"
75318249|NCT00216086|Drug|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
75463869|NCT03543865|Behavioral|Elders Resilience (ER)|Elders' Resiliency is a monthly manualized curriculum taught by Elders in the community intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength. Each lesson introduces youth to cultural knowledge, stories, and songs with an emphasis on respect and the sacredness of each life. Our community-based Apache staff will select Elders who both express an interest in the current project and have demonstrated affinity and skill for teaching the current curriculum in the schools. After this group of Elders is recruited and agree to participate, they will be paired with our paraprofessional Apache study staff.
75463870|NCT03543865|Other|Case Management (CM)|Research Program Assistants, who are trained Surveillance System Staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the Suicide Ideation Questionnaire (SIQ) to assess imminent risk, and if youth report not yet having connected to services, referral to Apache Behavioral Health Services (ABHS), the local community mental health center. At CM visits, the Research Program Assistants will also monitor participants' completion of the study battery, which will be self-administered using tablets. In addition, Research Program Assistants will score the SIQ before leaving the youth. If the SIQ reveals the participant is at imminent risk, Research Program Assistants will employ a protocol for rescue services, which involves triaging youth immediately to the ED for further assessment and care.
75617514|NCT02825368|Other|Sterile saline|0.5 mL, intramuscular
75463871|NCT03516513|Behavioral|Problem Solving Therapy as Usual|Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.
75617515|NCT02825368|Other|Sugar pellets|
75617516|NCT02632279|Dietary Supplement|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
75617517|NCT02632279|Dietary Supplement|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
75617518|NCT02632279|Device|Stimulator ON|Participants will be tested while their stimulator is turned ON
75770551|NCT03863392|Drug|Misoprostol|induction of labor
75318250|NCT00216086|Procedure|EUS|biopsy per EUS
75770552|NCT01175200|Drug|Clopidogrel|antiplatelet agent
75770553|NCT01175200|Drug|Prasugrel|antiplatelet agent
75910212|NCT05449119|Other|Body Mass Index (BMI)|Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months
75318251|NCT00216086|Drug|Neoadjuvant Chemotherapy|"Irinotecan 200 mg/m2 IV, day 1~Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles"
75318252|NCT00216086|Procedure|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
75318253|NCT00216086|Procedure|Surgery|Surgery within 8 weeks following chemoradiotherapy
75318254|NCT00216086|Procedure|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
75617519|NCT02632279|Device|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
75617520|NCT02631187|Device|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
75617521|NCT02881476|Other|Biological: Cell-based therapy|Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
75617522|NCT00664339|Biological|Flu Vaccine|Single dose of Flu vaccine by year (1)
75770554|NCT01175200|Drug|Lansoprazole|proton pum inhibitor
75770555|NCT01175200|Drug|Placebo|placebo comparator similar to lansoprazole
75770556|NCT01288300|Behavioral|Picture good health/Imaginate una buena salud|Diabetes education, self-empowerment training, exercise, patient navigator
75770557|NCT01288300|Behavioral|Diabetes lecture|Diabetes self-management lecture
75770558|NCT03865108|Procedure|Ultrasound imaging|This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
75770559|NCT03865108|Procedure|Cervical speculum examination|This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
75770560|NCT01178164|Genetic|Blood sampling for biological and genetic analysis|"Clinical examination~Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females."
75463872|NCT03516513|Behavioral|Assisted Problem Solving Therapy|Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
75463873|NCT03483766|Device|Robotic Functional Rehabilitation system|The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
75463874|NCT03467165|Device|MRgFUS treatment|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
75318255|NCT00474851|Drug|Norethindrone acetate + estrogens|Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
75318256|NCT00474851|Drug|norethindrone acetate + placebo|norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
75463875|NCT03467165|Device|MRgFUS treatment|MRgFUS treatment of pain caused by hip OA
75463876|NCT03453372|Device|MRgFUS Treatment|Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
75463877|NCT03453372|Other|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
75463878|NCT03421782|Behavioral|Cognitive Behavior Therapy|Undergo PROSPECT internet-based CBT
75617523|NCT00664339|Other|Conventional medical therapy for heart failure|According with the international guidelines
75617524|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
75617525|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
75770561|NCT03860350|Dietary Supplement|Aged Garlic Extract|
75770562|NCT03860350|Dietary Supplement|Placebo|
75770563|NCT01174654|Behavioral|Contingency management|A 12-week contingency management intervention
75770564|NCT01175278|Procedure|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
75770565|NCT01175278|Other|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
75463879|NCT03421782|Behavioral|Exercise Intervention|Undergo POWER exercise intervention
75463880|NCT03407560|Device|SintLife|"Patients will be treated for degenerative diseases of the spine, such as lumbar stenosis, spondylolysis and spondylolisthesis, degenerative disc disease.~The fusion technique used will be the posterolateral arthrodesis of one or more vertebral levels included in the lumbosacral region (L1-S1), obtained by screws and bars, together with a preparation of the transverse processes treated with bone substitute in order to Sintlife obtain new bone formation and then spinal fusion. It is also possible to associate interbody fusion with the use of a cage."
75617526|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
75617527|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
75617528|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
75617529|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
75617530|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
75770566|NCT01286350|Behavioral|FL3X: Flexible Lifestyle Empowering Change|The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
75798333|NCT01587222|Drug|Octreotide|"Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
75798334|NCT01170234|Device|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
75910213|NCT05449119|Other|24-hour food and beverage record|at T0, T3 months, T6 months, T9 months and T12 months
75910214|NCT05449119|Other|Mini Nutritional assessment (MNA)|at T0, T3 months, T6 months, T9 months and T12 months
75318257|NCT00545623|Procedure|Acupuncture|acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
75318258|NCT00545623|Behavioral|Relaxation Response|listening to CDs with verbal instructions of techniques to elicit relaxation response
75318259|NCT00545623|Other|sham acupuncture|sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
75318260|NCT00215150|Drug|Ziprasidone|Sertraline augmentation with ziprasidone
75770567|NCT01285882|Other|Representations|"A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.~To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :~1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.~2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.~Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation."
75318261|NCT00215150|Drug|Sertraline|Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
75463881|NCT03405129|Behavioral|Phoenix|Phoenix cessation app
75910215|NCT05449119|Other|Measurement of muscle mass by bioelectrical impedance analysis|at T0, T3 months, T6 months, T9 months and T12 months
75463882|NCT03405129|Behavioral|NRT order button|Ability to order NRT through smartphone app
75910216|NCT05449119|Other|Measurement of sensorimotor functions|at T0, T3 months, T6 months, T9 months and T12 months
75910217|NCT05449119|Other|Measurement of cognitive functions|at T0, T3 months, T6 months, T9 months and T12 months
75910218|NCT05448144|Other|Collect stool and blood samples from patients|Collect stool and blood samples from patients
75463883|NCT03405129|Behavioral|Factoid|Factoid app
75463884|NCT03404596|Drug|Nicotine Patch|Nicotine patches and thorough education of the indications for the patch will be provided to all participants.
75463885|NCT03404596|Behavioral|Counseling|Brief counseling sessions, 10-15 minutes each.
75910219|NCT05442359|Drug|Nano-bio fusion gingival gel|Thin coat applied to cover the palate after free gingival graft harvest. A stent will be placed to retain its effect. Patients will receive the gel to be used at home twice daily till 3rd week and once in the 4th week
75910220|NCT05442359|Device|stent|Applied as a palatal stent for palatal wound
75910221|NCT05428566|Dietary Supplement|Pulse-based diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine and chickpeas) will be used."
76072594|NCT02124460|Behavioral|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
75463886|NCT03404596|Behavioral|Smartphone|Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.
75463887|NCT03404596|Other|AutoSense|Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
75463888|NCT03400605|Other|Infant feeding questionnaire|Prospective infant feeding questionnaire administered over the telephone or in-person at 2 weeks and at 2, 4 and 6 months postpartum
75463889|NCT03355456|Procedure|Radiofrequency ablation|Ablation procedure to eliminate atrial fibrillation
75617531|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
75617532|NCT00664417|Biological|Physiological saline|0.5 mL, IM, 2 injections
75617533|NCT04031755|Drug|Minocycline|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
76088826|NCT02462304|Procedure|End-Point-Management grid laser|
75617534|NCT04031755|Drug|Placebos|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
75617535|NCT01104792|Drug|Cariprazine|Cariprazine was supplied in capsules.
75318262|NCT04192994|Drug|Intravitreal Antibiotic Injection|Intravitreal Antibiotic Injection
75318263|NCT04192994|Procedure|Pars Plana Vitrectomy|Pars Plana Vitrectomy
75318264|NCT04199234|Dietary Supplement|Experimental product consumption|Consumption of an encapsulated iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
75318265|NCT04199234|Dietary Supplement|Comparator product consumption (Iron sulphate)|Consumption of iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
75318266|NCT04198844|Drug|warfarin|warfarin user
75463890|NCT03340220|Drug|XPF-008|Capsule filled with XEN1101
75463891|NCT03340220|Drug|Microcrystalline Cellulose|Placebo capsule
75463892|NCT03340220|Drug|XPF-010|Capsule filled with XEN1101
75463893|NCT03340220|Drug|Itraconazole 400mg|Oral
75463894|NCT03324529|Device|Tako Breath|Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (<10 breaths/min) with prolonged exhalation.
75463895|NCT03317158|Drug|Durvalumab (Cohort 1-3)|Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
75463896|NCT03317158|Radiation|External Beam Radiotherapy (EBRT)|EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
75463897|NCT03317158|Biological|Bacillus Calmette-Guérin (BCG)|"Dose level 0 (starting dose) = Full-dose~Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US."
75463898|NCT03317158|Drug|Gemcitabine|Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses
75617536|NCT01205126|Drug|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
75617537|NCT01205126|Drug|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
75617538|NCT01205126|Drug|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
75617539|NCT04155307|Device|Anal EndoFLIP®|Anal EndoFLIP® measure to evaluate anal compliance
75617540|NCT04155307|Diagnostic Test|Anal Manometry|Anal Manometry done in standard care
75617541|NCT04155307|Diagnostic Test|Defecography|Defecographydone in standard care
75617542|NCT04155307|Diagnostic Test|Electromyogram|Electromyogram done in standard care
75770568|NCT03863626|Other|Frusemide IV shots|"giving frusemide by IV shots~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade comparing its administration timed 60 minutes prior to the morning Frusemide shot versus given after. (This will be in a second level of randomization)"
75770569|NCT03863626|Other|Frusemide IV infusion|"giving frusemide by continuous IV infusion~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade"
75770570|NCT01178242|Procedure|Salivary Gland and Labial Mucous Membrane Transplantation|"Minor salivary glands (SG) will be obtain en block from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures"
75770571|NCT03860116|Behavioral|APP-based case management service|The intervention consists of 4 parts, educational articles, online communication with case managers, supportive service information and visit reminder. Educational articles are both delivered automatically and retrieved by participants. Online communication can also be initiated by participants and case managers. Case managers are request to respond to questions from participants as well as care about medication taking behaviors of each patients during the first month. Supportive service information, which include time, location and charges of service providers will be retrieved by participants, with reminders of available service information scheduled at the beginning of every month. Visit reminders are scheduled at one week before due date.
75770572|NCT03860116|Behavioral|Standard-of-care followup service|When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.
75770573|NCT03864874|Diagnostic Test|Intraoperative intracavitary lung ultrasonography|Ultrasonography on the deflated lung for detection of lung nodules
75770574|NCT03860194|Dietary Supplement|Protison with High Protein 51(Original Flavor)|Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
75770575|NCT01178320|Drug|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
75770576|NCT03864718|Procedure|photodynamic therapy|Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
75770577|NCT01175512|Drug|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
75770578|NCT01175512|Drug|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
75770579|NCT01178476|Device|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
76088827|NCT02462304|Drug|ranibizumab|
76088828|NCT02462304|Drug|Bevacizumab|
75463899|NCT03317158|Drug|Docetaxel|Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.
75463900|NCT03317158|Biological|Tremelimumab|Tremelimumab 75 mg intravenously Day 1 (+/- 2 days) every 28 days x 4 cycles.
75617543|NCT00664495|Behavioral|Diet Weight Loss|
75617544|NCT00664495|Behavioral|Exercise Weight Loss|
75617545|NCT00664495|Behavioral|Exercise Without Weight Loss|
75617546|NCT00624494|Device|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
75617547|NCT00624494|Device|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
75617548|NCT05137314|Drug|PLG0206|PLG0206 is an engineered antibacterial peptide (EAP)
75617549|NCT02629627|Dietary Supplement|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
75617550|NCT02629627|Drug|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
75770580|NCT03864484|Device|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.
75770581|NCT03864484|Behavioral|Usual rehabilitation|The control group receives usual rehabilitation.
75770582|NCT03859570|Drug|Pentoxifylline|Pentoxifylline (PTX) is a methylxanthine derivative that is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). This enzyme, which has at least 5 subtypes, is responsible for inactivation of the important second messengers, Cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP)
75770583|NCT03859570|Drug|Placebos|Placebo
75770584|NCT01178554|Behavioral|psychotherapy|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
75770585|NCT01178554|Behavioral|evidence-based treatment|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
75318267|NCT04198844|Drug|apixaban|apixaban user
75318268|NCT04198610|Procedure|Non surgical periodontal therapy|Procedure/Surgery: non surgical periodontal therapy and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
75318269|NCT03023852|Drug|JNJ-63623872|Participants will receive JNJ-63623872 600 mg (2*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
75318270|NCT03023852|Drug|Oseltamivir|Participants will receive Oseltamivir 75 mg (1*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
75318271|NCT00214136|Radiation|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
75318272|NCT00213980|Drug|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
75463901|NCT03317158|Drug|Durvalumab (Cohort 4/5)|Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.
75463902|NCT03317158|Other|To be determined|Other regimens to be determined
75463903|NCT03311997|Procedure|Surgical reattachment of hamstring tendons|operatively reattachment of the tendons using suture anchor
75463904|NCT03304223|Diagnostic Test|[18F]FB-IL2 PET scan|[18F]FB-IL2 PET scan procedure
75463905|NCT03293056|Other|High-intensity interval Hydrogynmastics|The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.
75617551|NCT02629627|Dietary Supplement|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
75617552|NCT02629627|Other|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
75770586|NCT01178554|Behavioral|modular evidence-based treatment|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita & Weisz, 2004)
75463906|NCT03293056|Other|Hydrogynmastics Continuous Moderate|For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
75463907|NCT03287583|Behavioral|SBIRT for Gambing|The SBIRT intervention uses a brief gambling screening assessment to determine whether or not a participant is at risk for problem gambling. This is followed by a structured short brief intervention to assist people in better understanding their risk for gambling and what they can do to limit that risk.
75617553|NCT00664729|Behavioral|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
75617554|NCT00664729|Behavioral|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
75617555|NCT00664729|Behavioral|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
75617556|NCT00946647|Drug|Panobinostat (LBH589)|Panobinostat was supplied by Novartis as immediate-release hard gelatin capsules in strengths of 5 mg, 10 mg, and 20 mg packaged in high density polyethylene bottles.
75617557|NCT00946647|Drug|5-Azacytidine|
75617558|NCT04310514|Dietary Supplement|Fructose/glucose/xylitol/saccharose|"Intervention: rehydration with glucose solution. Glucose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~Intervention: rehydration with fructose solution. Fructose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~Intervention: rehydration with xylitol solution. Xylitol will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~Intervention: rehydration with sucrose solution Saccharose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m."
75617559|NCT00671827|Behavioral|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
75617560|NCT05117736|Drug|Sacubitril / Valsartan Oral Tablet|For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.
75617561|NCT05117736|Drug|Placebo|Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
75617562|NCT00671905|Procedure|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
75617563|NCT00671905|Procedure|PV isolation|Circumferential PV isolation
75617564|NCT02631967|Procedure|Kono anastomosis|Kono anastomosis
75770587|NCT03859882|Other|Sleep deprivation|40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
75770588|NCT03859726|Diagnostic Test|NIRS|Near-infrared spectroscopy (NIRS) offers non-invasive, in-vivo, real-time monitoring of tissue oxygenation. Changes in regional tissue oxygenation as detected by NIRS may reflect the delicate balance between oxygen delivery and consumption.
75770589|NCT03859726|Diagnostic Test|Sublingual microcirculation|The sidestream dark field (SDF) imaging devices provide high contrast images of the microvasculature.
75318273|NCT04190498|Diagnostic Test|Nocturnal oximetry|Diagnosis of OSA will be based on the 3% Oxygen Desaturation Index (IDO) obtained by home nocturnal oximetry. The oximetry recordings will be centralized in sleep laboratory of the University Hospital of Grenoble Alpes. Oximetry data will be analyzed by a technician from the sleep laboratory of the University Hospital of Grenoble Alpes
75463908|NCT03287583|Other|Enhanced Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
75463909|NCT03274960|Combination Product|Griess,|Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
75318274|NCT00516217|Biological|galiximab|
75463910|NCT03274882|Drug|S95005|The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
75770590|NCT03745768|Device|Intermittent Theta Burst Stimulation|Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
75770591|NCT03745768|Device|sham stimulation|Sham stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
75318275|NCT04001504|Biological|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV (30µg Hemagglutinin)
75463911|NCT03263247|Behavioral|Memory Training|
75463912|NCT03263247|Behavioral|Psychoeducation|
75463913|NCT03263247|Behavioral|Alphabet search|
75463914|NCT03246841|Other|Genetic testing|A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
75463915|NCT03241693|Other|blended-learning in ethics|"Experimental group followed clinical practices in hospital centers during 8 months.~In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used."
75463916|NCT03241693|Other|control group|"Control group followed clinical practices in hospital centers during 8 months as usual.~In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out."
75463917|NCT03171064|Behavioral|Resistance and Endurance Exercise|Machine-based, 2x/week endurance and resistance training for 12 weeks
75463918|NCT03171012|Other|Lower limbs CRT|cycle ergometer for lower limbs
75463919|NCT03171012|Other|Upper limbs CRT|cycle ergometer for upper limbs
75463920|NCT03171012|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
75463921|NCT03171012|Other|respiration|respiration
75617565|NCT02631967|Procedure|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
75617566|NCT04157491|Drug|anlotinib and anti PD-1 antibody|Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
75617567|NCT04157647|Device|CytoSorb|The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
75770592|NCT03745222|Drug|Tislelizumab|PD-1 inhibitor (monoclonal antibody against PD-1)
75770593|NCT03745222|Drug|Concurrent chemoradiotherapy (cCRT)|Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
75770594|NCT03745222|Other|Placebo|Placebo
75770595|NCT01286584|Drug|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
75770596|NCT01286584|Drug|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
75318276|NCT04001504|Biological|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV (15µg Hemagglutinin)
75318277|NCT04198532|Other|Contrast bath|Contrast bath (hot and cold therapy)
75617568|NCT04157647|Device|Control|No hemadsorption filter or other treatment will be included in the CPB circuit
75318278|NCT00564265|Other|Observation|Not applied
75617569|NCT00671983|Procedure|Neurocognitive Testing|
75770597|NCT03863314|Device|Virtual Simulation|Virtual simulation of workplace-related scenarios of pre-recorded videos using the same actors
75770598|NCT03863314|Other|In-person Simulation|In-person simulation of workplace-related scenarios with live actors
75770599|NCT03743038|Drug|FMX101 vehicle|FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
75910222|NCT05428566|Dietary Supplement|TLC diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber."
75910223|NCT05427799|Dietary Supplement|Honey|A mixed flora honey that will be obtained from local producers. and will be consumed by a daily dose of 0.5 g/kg body weight of honey by each participant and will be divided into two doses.
75463922|NCT03161860|Behavioral|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
75318279|NCT04198298|Drug|EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
75318280|NCT04198298|Drug|ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
75318281|NCT04198298|Drug|Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
75318282|NCT04199936|Device|Electrical Muscle stimulation|Electrical muscle stimulation
75318283|NCT00516919|Drug|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
75463923|NCT03147859|Biological|Vedolizumab (brand name Entyvio)|IV infusion
75463924|NCT03131219|Biological|Ravulizumab|Participant received weight-based dosages for 26 weeks during the Initial Evaluation Period. Participants received a loading dose on Day 1, followed by maintenance dosing on Day 15 and once every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing < 20 kg.
75910224|NCT05427799|Dietary Supplement|Other carbohydrate alternatives such as jell-o|A daily dose of 0.5 g/kg body weight of Jell-O will be consumed by each participant and will be divided into two doses. Jell-O was selected as a source of sucrose with negligible phenolic capacity.
75910225|NCT05419635|Drug|Asundexian (BAY2433334)|Study intervention BAY2433334 will be administered as tablet taken orally.
75463925|NCT03103789|Diagnostic Test|single catheter mucosal impedance testing|
75463926|NCT03103789|Diagnostic Test|balloon assembly mucosal impedance testing|
75463927|NCT03063463|Procedure|pneumatic dilation|Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.
75463928|NCT03063463|Procedure|surgical myotomy|This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.
75617570|NCT02629471|Behavioral|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
75617571|NCT00946101|Biological|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
75770600|NCT03743038|Other|Hydro-alcohol solution|Hydro-alcohol solution based vehicle (Test Article B)
75770601|NCT03864250|Drug|Tacrolimus|The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.
75910226|NCT05402384|Drug|AVTX-801|Medical grade D-galactose
75910227|NCT05402384|Drug|Placebo|Placebo
76072595|NCT04148872|Other|Neuromuscular Retraining Therapy (4 months)|Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.
75318284|NCT00516919|Behavioral|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
75318285|NCT04199858|Behavioral|Baseline pain stimulations|During baseline pain stimulations, a comparison block will include 6 high- and 2 moderate-pain stimulations.
75318286|NCT04199858|Behavioral|Conditioning|"During nocebo induction trials, the conditioned stimulus (i.e., a sham medical gel that can increase pain sensitivity, named TDA and contained in either a brown or a blue jar) is paired to unconditioned high-pain stimuli (nocebo trials). Lower 'baseline' pain is paired with no gel application (control trials)."
75318287|NCT04199858|Behavioral|Evocation|"During nocebo evocation, lower pain stimulations are administered both after the administration of the conditioned stimulus (i.e., a sham medical gel TDA) and the control stimulus (no medical gel), in order to evoke nocebo responses to the sham hyperalgesic medication."
75463929|NCT03055208|Radiation|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
75463930|NCT02948725|Other|Cross-education + standard rehabilitation|
75463931|NCT02914613|Drug|SF0166 Topical Ophthalmic Solution|
75617572|NCT00946101|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
75617573|NCT00664885|Other|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
75617574|NCT00672061|Drug|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
75617575|NCT00672217|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
75770602|NCT03864250|Drug|Prednisone|The initial dose of prednisone is 0.5 mg/kg/d orally (maximum dose 40 mg/d), and after 8-12 weeks, the dose was gradually reduced until discontinuation. TAC treatment is given at the same time (the treatment plan is the same as the experimental group).
75770603|NCT01175746|Drug|Nicardipine|
75770604|NCT01175746|Drug|remifentanil|0.1-0.5 ugkg/min during hypotensive anesthesia
75463932|NCT02908984|Behavioral|Specific neck rehabilitation|Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and vestibular rehabilitation, included oculomotor function if indicated, and general exercises
75463933|NCT02908984|Other|Standard primary health care|The treatment may include pharmacological medication, chiropractic and physiotherapy or no active treatment
75770605|NCT01174810|Drug|Exenatide|Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
75463934|NCT02793726|Procedure|NMR|NMR
75463935|NCT02781857|Other|No intervention|
75770606|NCT01288690|Behavioral|Narrative Exposure Therapy|3, 1-1/2 hour sessions, individual, meeting weekly.
75770607|NCT01178632|Drug|Passiflora|01 tablet Passiflora p.o., b.i.d.
75770608|NCT01178632|Drug|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
75463936|NCT02753335|Behavioral|GMI and Desensitization|"Graded Motor Imagery (GMI) is used to treat chronic pain conditions and movement problems related to alterations in the nervous system such as CRPS, postamputation limb pain and back pain. The patient is trained in monitored steps. The three treatment components include left/right discrimination training, motor imagery exercises and mirror observations of the unaffected limb, appearing as the affected limb. They are performed sequentially, but require a flexible approach to suit the individual patient. The imagined movements have been demonstrated to activate motor cortical areas similar to those activated in the actual execution of that movement.~Desensitization (D) is used to decrease hyperalgesia by repeated tactile stimulation of the affected area with various materials."
75463937|NCT02753335|Behavioral|Desensitization|Desensitization (D) is used to decrease hyperalgesia and allodynia by repeated tactile stimulation of the affected area with various materials.
75463938|NCT02723474|Device|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
75463939|NCT02713945|Drug|Simvastatin|Experimental drug administrated orally
75617576|NCT00672217|Behavioral|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
75617577|NCT00660751|Drug|Duloxetine|SNRIs
75617578|NCT00664963|Device|Implantation of YUKON Sirolimus-eluting Stent|Implantation of YUKON Sirolimus-eluting Stent
75617579|NCT00664963|Device|Implantation of YUKON Stent (uncoated)|Implantation of YUKON Stent (uncoated)
75617580|NCT00672295|Drug|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
75617581|NCT04155073|Behavioral|smoking cessation, early COPD detection, electronic visit|electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)
75617582|NCT04155073|Other|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
75617583|NCT04154995|Diagnostic Test|Venipuncture|Blood testing at 3, 6 and 12 months
75770609|NCT01178710|Drug|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
76072596|NCT04148872|Drug|Chemodenervation (4 months)|A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
75463940|NCT02713945|Drug|Placebo|Treatment for the control group
75617584|NCT04154995|Diagnostic Test|Ultrasound Quadriceps Muscles|Ultrasound measurement of quadriceps muscle mass and health
75617585|NCT00665041|Drug|Quinagolide|"• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral."
75617586|NCT04153045|Device|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
75617587|NCT04152655|Drug|Idebenone|30mg tablets three times a day
75463941|NCT02686229|Other|no interventions|
75463942|NCT02685605|Procedure|Standard surgery|
75770610|NCT03864328|Drug|RVT-1601|Inhaled RVT-1601 administered TID via eFlow nebulizer
75770611|NCT03864328|Drug|Placebo|Inhaled Placebo administered TID via eFlow nebulizer
75770612|NCT01174888|Drug|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
75770613|NCT01174888|Drug|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
75770614|NCT01174888|Drug|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
75770615|NCT01174888|Drug|etoposide|Patients receive etoposide IV over 1 hour
75770616|NCT01174888|Drug|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
75770617|NCT01178788|Drug|17 alpha-hydroxy progesterone caproate|weekly injection of 17 P
75910228|NCT05394506|Procedure|Skin Biopsy|The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
75463943|NCT02685605|Radiation|Intraoperative radiotherapy|Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.
75463944|NCT02685605|Radiation|Radiochemotherapy|EBRT to 60 Gy plus 75 mg/m2/d temozolomide
75617588|NCT04152655|Drug|Placebo oral tablet|placebo tablets three times a day
75770618|NCT01178788|Drug|micronized Progesterone|daily administration of vaginal progesterone
75463945|NCT02685605|Drug|Temozolomide|Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
75770619|NCT01178788|Procedure|Control|
75463946|NCT02664935|Drug|AZD4547|FGFR Inhibitor
75463947|NCT02664935|Drug|Vistusertib|MTORC1/2 Inhibitor
75770620|NCT00153816|Drug|Calcium Carbonate|3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
75770621|NCT00153816|Drug|Vitamin D3|1000 IU/daily; two tablets per day; 500 IU per tablet
75910229|NCT05394506|Procedure|Muscle biopsy|The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
75910230|NCT05393219|Other|Cardiac biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on emWave Pro software on a computer just before entering the examination circuit
75910231|NCT05393219|Other|Mindfulness|6 minutes of a guided video tape made for the study that inspires mindfulness like meditation associated just before entering the examination circuit.
75318288|NCT04199858|Other|Electroencephalography (EEG)|In the single group of participants, EEG recordings will be conducted during baseline, during a first resting-state of 5-minutes, during induction/evocation of nocebo responses, and during a second resting-state of 5-minutes.
75318289|NCT00547105|Drug|Erlotinib|Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
75318290|NCT00547105|Radiation|SBRT|SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body
75318291|NCT04198064|Procedure|Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/~2 cups of % 0.9 saline solution) during the insertion of the cystocopy tube during their cystocopy."
75318292|NCT04198064|Procedure|No Bag Squeeze|Participants will receive a standard cystocopy procedure as per standard of care.
75318293|NCT03969368|Device|rPMS device|Pelvic floor muscle contractions will be induced by the rPMS device.
75318294|NCT03969368|Procedure|Pelvic floor muscle training|Control group will undergo a pelvic floor muscle training
75318295|NCT04388215|Drug|CKD-828|orally, 1 tablet once a day for 8 weeks
75463948|NCT02664935|Drug|Palbociclib|CDK4/6 Inhibitor
75463949|NCT02664935|Drug|Crizotinib|ALK/MET/ROS1 Inhibitor
75463950|NCT02664935|Drug|Selumetinib|MEK Inhibitor
75463951|NCT02664935|Drug|Docetaxel|Taxane, anti-mitotic cytotoxic chemotherapy
75463952|NCT02664935|Drug|AZD5363|AKT Inhibitor
75617589|NCT00672373|Drug|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
75617590|NCT00672373|Drug|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
75463953|NCT02664935|Drug|Osimertinib|EGFRm+ T790M+ Inhibitor
75318296|NCT04388215|Drug|CKD-828(placebo)|orally, 1 tablet once a day for 8 weeks
75318297|NCT04388215|Drug|D326|orally, 1 tablet once a day for 8 weeks
75318298|NCT04388215|Drug|D326(placebo)|orally, 1 tablet once a day for 8 weeks
75318299|NCT04388215|Drug|D337|orally, 1 tablet once a day for 8 weeks
75318300|NCT04388215|Drug|D337(placebo)|orally, 1 tablet once a day for 8 weeks
75463954|NCT02664935|Drug|Durvalumab|Anti-PDL1
75463955|NCT02664935|Drug|Sitravatinib|VEGFR Inhibitor
75463956|NCT02664935|Drug|AZD6738|ATR inhibitor
75463957|NCT02658474|Behavioral|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
75617591|NCT01109940|Biological|AIN457A|
75617592|NCT00595309|Biological|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
75617593|NCT00665119|Drug|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
75617594|NCT00665119|Drug|placebo|NaCl 0.9 %
75770622|NCT00153816|Drug|placebo|placebo; two tablets per day
75770623|NCT02525146|Other|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
75770624|NCT02525224|Dietary Supplement|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
75770625|NCT03966222|Device|Endoscopic vein harvest|An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision.
75770626|NCT03966222|Other|Open vein harvest|Open vein harvest
75770627|NCT03862846|Drug|REN001|Once daily
75463958|NCT02610179|Dietary Supplement|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
75463959|NCT02610179|Dietary Supplement|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
75463960|NCT02586207|Drug|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
75617595|NCT05113212|Device|Macular surgery with NGENUITY surgical display system|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon
75463961|NCT02586207|Drug|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
75463962|NCT02586207|Radiation|Radiation|70 Gy fractionated over 35 days
75617596|NCT05113212|Device|Macular surgery with standard operating microscope|Patient undergoes VR surgery with visualization using standard operating microscope
75617597|NCT00665197|Radiation|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
75617598|NCT00665197|Radiation|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
75617599|NCT04309890|Other|Arabic version of the Overactive Bladder Symptom Score Questionnaire|All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
75463963|NCT02573324|Drug|Temozolomide|Oral Capsule
75617600|NCT00672529|Dietary Supplement|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
75617601|NCT02629549|Drug|OTL38|Infusion of OTL38 prior to surgery
75617602|NCT00672607|Drug|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
75617603|NCT00672607|Drug|Placebo|Placebo
75617604|NCT00665509|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
75617605|NCT00672685|Dietary Supplement|omega-3|V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
75617606|NCT00672685|Behavioral|multi-domain intervention|multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
75617607|NCT00672685|Drug|Placebo|OMEGA-3 placebo
75617608|NCT00595075|Drug|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
75617609|NCT00595075|Drug|placebo|placebo identical in appearance to active experimental drug x 1 dose
75617610|NCT00887224|Drug|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
75617611|NCT00887224|Drug|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
75617612|NCT00887224|Drug|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
75770628|NCT01077648|Drug|Trastuzumab or Lapatinib|Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
75770629|NCT03863002|Biological|Mesenchymal Stem Cell|Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks
75770630|NCT00151476|Drug|Celecoxib|800 mg total daily dosing
75770631|NCT00151476|Other|Routine Medical Care|
75318301|NCT04388215|Drug|D013|orally, 1 tablet once a day for 8 weeks
75318302|NCT04388215|Drug|D013(placebo)|orally, 1 tablet once a day for 8 weeks
75318303|NCT04195100|Drug|Pilocarpine Ophthalmic Solution|"low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day"
75318304|NCT04199546|Other|Chewing and swallowing rehabilitation|A home based chewing and swallowing training program (CST) will be applied by an experienced physical therapist. The Functional Chewing Training will be used to improve chewing function which has five steps including positioning the child and food, sensory stimulation, chewing training and adjustment of food consistency to improve chewing function. To support hyolaryngeal elevation, laryngeal mobilization will be performed. Hyolaryngeal mobilization will be performed by moving hyolaryngeal complex in right, left and up directions manually.
75318305|NCT06069479|Procedure|craniofacial surgery|Surgical treatment, either stripcraniectomy or fronto-orbital advancement
75463964|NCT02573324|Drug|Depatuxizumab mafodotin|Intravenous (IV) Infusion
75463965|NCT02573324|Radiation|Radiation|
75463966|NCT02573324|Drug|Placebo for ABT-414|IV Infusion (IV)
75463967|NCT02572557|Device|TruFreeze Spray CryoTherapy|TruFreeze Spray CryoTherapy using liquid nitrogen
75463968|NCT02572557|Drug|Liquid nitrogen|TruFreeze Spray CryoTherapy using liquid nitrogen
75617613|NCT00672763|Drug|Colecalciferol D3 (Vigantol Oil)|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
75770632|NCT03859804|Procedure|Standard transrectal 12 core biopsy|TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
75770633|NCT03859804|Procedure|MRI- US fusion prostate biopsy (FPB)|FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
75770634|NCT01077726|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
75318306|NCT06069453|Device|Hyaluronic Acid (HA) sodium salt and Hydeal-D|intravesical solution containing Hyaluronic Acid (HA) sodium salt and Hydeal-D
75463969|NCT02553642|Drug|Nivolumab|"Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit"
75617614|NCT00672763|Drug|Medium chain triglycerides|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~Migliol Oil 5ml oral fortnightly (2 doses)"
75318307|NCT06069440|Other|Swimming Fatigue Task|Swim freestyle at a steady, controlled pace until mechanical failure (i.e., inability to maintain the predetermined speed) is reached.
75617615|NCT04154449|Drug|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
75463970|NCT02553642|Drug|Nivolumab plus Ipilimumab|"Combination Treatment~Ipilimumab 3 mg/kg~Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses"
75770635|NCT01286116|Device|Parachute Implant|Mechanical ventricular partitioning
75318308|NCT06069388|Procedure|diaphragm technique|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
75910232|NCT05393219|Other|Resources mobilization|6 minutes of a guided video tape that purpose to mobilize inner resources and strength of the student just before entering the examination circuit.
76072597|NCT04148872|Other|Neuromuscular Retraining + Chemodenervation|Participants will receive both interventions for the last 4 months of their time on study.
75463971|NCT02523092|Drug|Acthar gel|Acthar gel given IM or SQ as per package insert
75463972|NCT02482350|Behavioral|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
75463973|NCT02450773|Drug|Furosemide|40 mg furosemide on postpartum day 1-6
75463974|NCT02450773|Drug|Potassium chloride|20 meq potassium chloride on postpartum day 1-6
75463975|NCT02450773|Drug|Placebo #1|Placebo (for furosemide)
75463976|NCT02450773|Drug|Placebo #2|Placebo (for KCl)
75617616|NCT02629081|Other|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
75617617|NCT00661063|Drug|ketamine|ketamine 150 mcg/g bid
75617618|NCT00661063|Drug|vehicle gel|bid - 12 weeks
75617619|NCT00661063|Drug|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
75318309|NCT06069388|Procedure|conventional therapy|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
75341308|NCT01567891|Biological|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
75341309|NCT05354336|Drug|SHR6390(100mg)|SHR6390 at a single oral dose of 100 mg.
75463977|NCT02445248|Biological|Tisagenlecleucel|A single infusion of 5 x 10^8 viable CTL019 transduced cells, which will be administered via intravenous infusion.
75617620|NCT00661063|Drug|clonidine gel 1%|bid 12 weeks
75617621|NCT00665587|Procedure|Cox-MAZE III|Maze procedure according to standards of the department
75617622|NCT02629237|Other|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
75617623|NCT02825446|Procedure|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
75770636|NCT01179100|Drug|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
75770637|NCT03864172|Dietary Supplement|Usual intake + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice
75770638|NCT03864172|Dietary Supplement|Usual intake+SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
75770639|NCT03864172|Dietary Supplement|Adequate calcium + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
75770640|NCT03864172|Dietary Supplement|Adequate calcium+ SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
75770641|NCT02525302|Drug|HT-100|HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
75770642|NCT01286194|Drug|Rabeprazole sodium|Rabeprazole sodium 10 mg orally every day for 14 days
75770643|NCT01179256|Dietary Supplement|CURCUMIN|oral supplementation of curcumin 2000mg
75770644|NCT01179256|Other|no intervention other than stopping study|no intervention other than stopping study
75770645|NCT03858088|Procedure|Liver transplantation|Liver transplantation from deceased donors
75770646|NCT03859180|Behavioral|Focused breathing|Focused breathing is a series of focused, controlled breaths that aid in relaxation. Each participation in this group will be taught how to do focused breathing by the study investigator. Once determined to be able to perform focused breathing, participants will be asked to practice it for 4 minutes, twice a day, for 6 weeks. If they choose to do so, they may practice focused breathing if they become anxious at other times. They will be asked to keep a diary of each time they practice and/or use focused breathing.
75770647|NCT01179412|Drug|2% povidone-iodine|apply 4 times a day for one week
75910233|NCT05393219|Other|Control|6 minutes of standardized neutral video on general topics that generates no modification of affects just before entering the examination circuit.
75910234|NCT05390515|Drug|Tildrakizumab Prefilled Syringe|IL-23 inhibitor
75770648|NCT01179412|Drug|2% povidone-iodine|apply 2% povidone-iodine 4 times per day for one week
75910235|NCT05387980|Drug|CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
75910236|NCT05381675|Other|Tele-rehabillitation|"Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
75910237|NCT05381675|Other|Prescribed Exercise Program|"The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
75910238|NCT05378243|Device|Robotic Gait Training|Use of a walker adapted with robotic components to promote proper walking gait
75910239|NCT05378243|Behavioral|Functional Clinical Therapy|Personalized program of physical therapy targeted to improving walking gait
75910240|NCT05377593|Device|eminoplasty with patient specific Zirconium dioxide onlay implant|Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants
75910241|NCT05372588|Drug|NVX-CoV2515|Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
75910242|NCT05372588|Drug|NVX-Cov2373|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
75910243|NCT05372588|Drug|NVX-CoV2373 + NVX-CoV2515|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
75910244|NCT05372588|Drug|NVX-CoV2540|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
75770649|NCT03862690|Drug|BIAsp 30|Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
75910245|NCT05372588|Drug|NVX-CoV2373 + NVX-CoV2540|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
75318310|NCT06069362|Other|Manual physiotherapy and neurodynamic exercises|"Cervical passive mobilisation techniques and techniques of the anatomical structures surrounding the nerve. These techniques aim to open the nerve root foramen. They are gentle traction techniques and contralateral lateral glide mobilisation techniques. Interface techniques for scalenes will also be included.~Home exercises for cervical mobility and neurodynamic sliders of the upper extremity: Patients will be taught progressive upper extremity neurodynamic sliders, starting with gentle movement and progressing to exercises involving more movement based on the patient's irritability."
75770650|NCT03863548|Other|complication|collection of post-operative bleeding complications
75910246|NCT05363267|Dietary Supplement|curcumin, high phenolic extra virgin olive oil (HP-EVOO)|"identical for all participants with the exception of the curcumin dose level~Dose 1: 1000 mg Curcumin daily dose with 1 capsule of 25 ml HP-EVOO volume at morning and night Dose 1: 2000 mg Curcumin daily dose with 2 capsules of 25 ml HP-EVOO volume at morning and night Dose 3: 4000 mg Curcumin daily dose with 4 capsules of 25 ml HP-EVOO volume at morning and night"
75770651|NCT03862768|Procedure|surgery|Surgery requires at least removal of all drug-resistant lesions.
75910247|NCT05352776|Device|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
75910248|NCT05338593|Other|Outcome|Mortality rate of prolonged therapy.
76072598|NCT04129294|Drug|NS-089/NCNP-02|"NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~[Part 1] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks [Part 2] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks."
75770652|NCT03862768|Drug|Imatinib 400 MG|Imatinib 400 MG/d should be taken once the patients resume oral diet
75770653|NCT03862768|Drug|Imatinib escalation|Imatinib 600 MG/d
75770654|NCT03862768|Drug|Sunitinib|Sunitinib 37.5 MG/d
75770655|NCT03862456|Other|Azithromycin|azithromycin (500 mg/24h/3 days)
75770656|NCT03862456|Other|Metronidazole|metronidazole (500 mg/8h/7 days)
75770657|NCT03859102|Dietary Supplement|Pre-operative Carbohydrate PreLoad drink|Pre-operative Carbohydrate PreLoad drink, 1 sachet given the night before surgery. One sachet given 2-4hours before surgery.
75910249|NCT05335798|Device|Bodyweight augment system|Motorized cables will be providing downward force on the participant's pelvis
75910250|NCT05335798|Device|Smart insole|Insole provided auditory feedback when heel strike or toe-off events happen
75910251|NCT05335434|Device|THOR LX2.3 with LED Lollipop|The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration
75910252|NCT05330312|Device|Digital cognitive behavioral therapy|Therapy for patients with pulmonary fibrosis
75910253|NCT05329649|Biological|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
76072599|NCT05310994|Dietary Supplement|Placebo drink|consume 1 bottle per day
75770658|NCT03859102|Drug|Oral Gabapentin pre-op|One dose of Gabapentin pre-operatively, 300mg orally.
75910254|NCT05326633|Combination Product|MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
75910255|NCT05326412|Drug|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
75910256|NCT05297747|Diagnostic Test|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patients.
75910257|NCT05297747|Diagnostic Test|Chronic periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
75910258|NCT05282797|Drug|ANEB-001|Experimental Treatment
75770659|NCT03859102|Drug|Oral Lansoprazole pre-op|One dose of Lansoprazole pre-operatively, 30mg orally.
75910259|NCT05282797|Drug|Placebo|Placebo comparator
75910260|NCT05281952|Procedure|endoscopic ligation|the surgical ligation of one or both sphenopalatine arteries by endoscopic way.
75910261|NCT05281952|Procedure|Supra-selective embolization|occlusion of the terminal branches of the nasal external carotid artery.
75910262|NCT05276492|Drug|Abiraterone Oral Tablet|Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
75910263|NCT05276492|Drug|Prednisone tablet|Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
75910264|NCT05276492|Other|Drug Dairy/Log|A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.
75463978|NCT02445248|Drug|Lymphodepleting chemotherapy|Prior to CTL019 cell infusion, an additional lymphodepleting chemotherapy cycle is planned. The use of any additional chemotherapy prior to the recommended lymphodepleting chemotherapy will be at the discretion of the investigator and dependent on the patient's disease burden. Lymphodepleting chemotherapy should be started 14 to 5 days before CTL019 infusion (D1) to allow for at least 48 hours from last dose of lymphodepleting chemotherapy to CTL019 infusion. The proposed lymphodepleting regimen is: Fludarabine (25 mg/m2 intravenously [i.v.] daily for 3 doses) and cyclophosphamide (250 mg/m2 i.v. daily for 3 doses starting with the first dose of fludarabine).
75770660|NCT03859102|Drug|Intravenous Paracetamol intra-operatively|One dose of Paracetamol intra-operatively, 1gram intravenous infusion.
75910265|NCT05276492|Drug|Low-fat meal|"A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff."
75910266|NCT05269732|Behavioral|Group Cognitive Behavioural Therapy (CBT)|The 9-week group Cognitive Behavioural Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists. This intervention was developed by Dr. Van Lieshout (Principal Investigator) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced each week. The first half of each session is devoted to core CBT content, including cognitive restructuring. The second half is devoted to group discussions co-led by participants on topics relevant to mothers with PPD (e.g., sleep, supports, role transitions). Homework is assigned at each session.
75910267|NCT05268731|Procedure|External plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external plastic endoprosthesis if the duodenum or jejunum cannot be accessed by a guide wire
75910268|NCT05268731|Procedure|Combined external internal plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external/internal plastic endoprosthesis if the duodenum or jejunum can be accessed by a guide wire. No definitive drainage intended in initial procedure.
75910269|NCT05268731|Procedure|Primary metal stent|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of a self-expanding metal stent if the duodenum or jejunum can be accessed by a guide wire. A definitive drainage is intended in the initial procedure, for example in patients with malign bile duct obstruction
75318311|NCT06069323|Device|repetitive Transcranial Magnetic Stimulation|Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.
75318312|NCT06069310|Drug|Mepolizumab 100 MG|Monthly administartion of mepolizumab 100mg
75341310|NCT05354336|Drug|SHR6390(125mg)|SHR6390 at a single oral dose of 125 mg.
75341311|NCT05354336|Drug|SHR6390(150mg)|SHR6390 at a single oral dose of 150 mg.
75341312|NCT05564923|Drug|there is no intervention|there is no intervention
75341313|NCT05349110|Device|Computer-aided diagnosis (CADx) systems|"AI4CRP (artificial intelligence for colorectal polyps), a CNN based computer-aided diagnosis system for diagnosis of colorectal polyps (COMET-OPTICAL research group);~CAD EYE, a computer-aided diagnosis system for diagnosis of colorectal polyps (Fujifilm® Corporation, Tokyo, Japan)."
75770661|NCT03859102|Drug|Intravenous Dexamethasone intra-operatively|One dose of Dexamethasone intra-operatively as an anti-emetic, 8mg intravenous.
75770662|NCT03859102|Drug|Intravenous Ondansetron intra-operatively|One dose of Ondansetron intra-operatively as an anti-emetic, 4mg intravenous
75770663|NCT03859102|Drug|Infiltration of surgical wounds with local anaesthetic|Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.
75770664|NCT03859102|Drug|Intravenous Magnesium intra-operatively|One infusion of intravenous Magnesium Sulphate intra-operatively as an analgesic, 50mg/kg given over 30minutes.
75770665|NCT03859102|Drug|Post-operative Gabapentin analgesia|Post-operative oral Gabapentin 300mg, three times daily as an analgesic.
75770666|NCT03859102|Drug|Post-operative oral Paracetamol analgesia|Post-operative Paracetamol as an analgesic. Initially intravenously, then orally. One gram four times daily.
75770667|NCT03859102|Drug|Post-operative Ondansetron anti-emesis|Intravenous Ondansetron administered post-operatively as prophylactic anti-emesis. 4mg three times daily, for 24 hours. Then as required.
75770668|NCT03859102|Procedure|Early extubation|Removal of the endotracheal tube in the Intensive Care Unit as soon as is safe.
75910270|NCT05255887|Other|Informing Patients With Video|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. (The content of the training to be done with the video is stated in the appendix) In the study, no attempt will be made to the control group patients other than the routine practice of the institution before the surgery. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in both the experimental and control groups by face-to-face interview method.
75770669|NCT03859102|Procedure|Early mobilisation/physiotherapy|Mobilisation (active and passive limb movements, deep breathing) with the assistance of nurse/physiotherapist to occur as soon as possible post-operatively.
75463979|NCT02420548|Behavioral|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
75463980|NCT02420548|Behavioral|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
75910271|NCT05238415|Diagnostic Test|Psychological and Physiological Assessments|About N = 60 patients admitted to the study receive a 3-day assessment (a further examination) at the Kiliani-Klinik Bad Windsheim which considers physical and psychological parameters relevant for the diagnosis of a Post-/ Long-COVID Syndrom.
75910272|NCT05216029|Other|Best Practice|Receive standard of care
75910273|NCT05216029|Other|Informational Intervention|View oncology dashboard
75463981|NCT02412566|Drug|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
75341314|NCT01568827|Dietary Supplement|Blackraspberry Slurry|Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
75341315|NCT05245370|Behavioral|Control video|Control group 1 will see a control video consisting of basic information about the different types of psychotherapy that are covered by insurance in Germany and the process of applying for psychotherapy with the insurance. The control video is matched in duration (10 minutes), set-up and the overall topic (psychotherapy) to the intervention video testimonials.
75463982|NCT02397226|Procedure|Radiofrequency ablation|
75463983|NCT02397226|Procedure|High ligation/stripping|
75463984|NCT02397226|Device|Radiofrequency ablation catheter|
75463985|NCT02397226|Procedure|Tumescent anesthesia|
75463986|NCT02397226|Procedure|General anesthesia|
75463987|NCT02397226|Device|Vein stripping catheter|
75463988|NCT02396277|Procedure|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
75463989|NCT02308878|Behavioral|Mobile health cognitive stimulation|
75463990|NCT02296684|Biological|MK-3475 (neoadjuvant)|
75463991|NCT02296684|Procedure|Surgery|Standard of care
75463992|NCT02296684|Radiation|Intensity modulated radiation therapy|Recommended, standard of care
75770670|NCT03859102|Other|Encourage early oral food intake|Patients will be encouraged to start eating as soon as possible post-operatively
75770671|NCT02525068|Drug|AZD5363|Until confirmed disease progression.
75770672|NCT02525068|Drug|Enzalutamide|Until confirmed disease progression.
75463993|NCT02296684|Radiation|Image-guided radiation therapy|Recommended, standard of care
75463994|NCT02296684|Drug|Cisplatin|Standard of care
75463995|NCT02296684|Biological|MK-3475 (adjuvant)|
75463996|NCT02296684|Procedure|Peripheral blood|-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery
75463997|NCT02107261|Drug|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
75463998|NCT02107261|Drug|Placebo|matching placebo
75910274|NCT05216029|Other|Questionnaire Administration|Ancillary studies
75910275|NCT05190315|Drug|Chlorpromazine|"Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide."
75910276|NCT05190315|Drug|Temozolomide|"Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events > grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle."
75910277|NCT05190315|Radiation|Radiation Therapy|Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
75910278|NCT05177575|Procedure|Thoracotomy application|The chronic pain findings of the patients who underwent thoracotomy will be questioned at the postoperative 3rd and 6th months.
75770673|NCT02524678|Drug|Placebo|
75770674|NCT02524678|Drug|URC102|
75770675|NCT01181206|Procedure|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
75770676|NCT05274880|Drug|CKD-393|PO, QD
75770677|NCT00149994|Drug|Cyclosporine A|
75770678|NCT00149994|Drug|Tacrolimus|
75910279|NCT05160961|Procedure|Serratus anterior plane block|Serratus anterior plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
75617624|NCT02825446|Procedure|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
75617625|NCT04242706|Device|ETTEvac|Endotracheal tube with evacuation lumen without noble metal coating
75617626|NCT04242706|Device|BIP ETTEvac|Endotracheal tube with evacuation lumen with noble metal coating
75318313|NCT06069297|Other|Multimodal Prehabilitation|Preoperative multimodal intervention including exercise training, nutritional therapy and anxiety reducing techniques, aimed at preventing or attenuating surgery-driven functional decline. A personalized intervention program will be prescribed based on specific physical, nutritional and psychological conditions recognized during the multimodal assessment. Patients will follow a two to three-day per week training for 4 weeks. Exercise modalities will be adapted to personal preference and patient conditions. Based on dietary habits, medical conditions and nutritional status, a certified nutritionist will provide a comprehensive diet management program. A food-based intervention with a balanced macronutrient composition coupled with oral nutritional supplements will be prescribed to achieve the estimated daily energy and protein requirements. Participants will be instructed by psychology-trained personnel on how to reduce anxiety.
75318314|NCT06069284|Other|No intervention|No intervention
75463999|NCT02098265|Device|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
75617627|NCT00672919|Drug|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
75617628|NCT01109316|Drug|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
75770679|NCT00149994|Drug|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
75770680|NCT00149994|Drug|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
75910280|NCT05160961|Procedure|Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
75910281|NCT05157789|Other|SMS|In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
75318315|NCT06069271|Other|Kettlebell swing|The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
75318316|NCT06069245|Dietary Supplement|MitoQ|80mg of MitoQ taken in one dose on one occasion.
75318317|NCT06069245|Dietary Supplement|Placebo|Gelatin capsules
75464000|NCT02098265|Behavioral|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
75341316|NCT05245370|Behavioral|Rationale video|The active control group 2 will see a short rationale and the control video. The rationale is a 2:45 minute-long animated video (designed via the visual communication platform powtoon, https://powtoon.com/) explaining some of the underlying mechanisms of depression.
75464001|NCT02098265|Other|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
75464002|NCT02098265|Other|EEG|EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
75617629|NCT01109316|Drug|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
75617630|NCT01109316|Drug|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
75617631|NCT02825290|Drug|Choriogonadotropin alfa|
75617632|NCT02825290|Drug|Triptorelin acetate|
75617633|NCT00675961|Behavioral|Brief Counseling Intervention (BCI)|Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
75770681|NCT00149994|Drug|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
75770682|NCT01179646|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
75770683|NCT01075776|Drug|C-type natriuretic peptide (CNP)|360 pmol/min for 15 minutes intra-arterially
75770684|NCT01075776|Drug|Saline|Sodium Chloride 0.9% intra-arterially 0.5ml/min
75770685|NCT01075776|Drug|Acetylcholine|2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
75770686|NCT01288768|Procedure|Knee arthroscopy|Knee arthroscopy within 4 weeks.
75770687|NCT01079910|Drug|isopropylmethylphenol and Fluoride|0.1% isopropylmethylphenol and 1150ppm fluoride
75617634|NCT00675961|Drug|Naltrexone|Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
75910282|NCT05145153|Procedure|Thoracic surgery application|The chronic pain findings of the patients who underwent thoracic surgery will be questioned at the postoperative 3rd and 6th months.
75318318|NCT06069219|Drug|Epidural administration of sufentanil|The epidural cannulations were placed by anesthesiologists before general anesthesia. Correct positioning of the catheters were tested and confirmed by negative aspiration and injection of 3 mL of 2% Lidocaine. The epidural infusion (solution of 0.2 % ropivacaine 5 ml with 25 to 50 mcg sufentanil in 50 ml of 0,9% NaCl) was started with bolus of 5 ml over 5 minutes and then continuous infusion was maintained was throughout the surgery at 3-12 mL/h and 2-12 mL/h after the surgery. Single dose of sufentanil was given when needed.
75318319|NCT06069167|Other|Collection of data related to bowel urgency|Data will be extracted from the patient's medical record and patients will be interviewed to collect data specific to the research
75464003|NCT02098265|Other|RecoveriX|RecoveriX is a brain driven rehabilitation system for stroke patients that pairs mental activities with motor functions.
75910283|NCT05143840|Drug|Asciminib|Potent tyrosine kinase inhibitor that displays anti-tumor activity by specifically targeting the ABL myristate-binding pocket (STAMP).
75910284|NCT05143840|Drug|Ascimininb + Nilotinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of nilotinib 300mg, once daily, with the goal of attaining MR4.5.
75910285|NCT05143840|Drug|Asciminib + Imatinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of imatinib 300mg, once daily, with the goal of attaining MR4.5.
75910286|NCT05143840|Drug|Asciminib + Dasatinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of dasatinib 50mg, once daily, with the goal of attaining MR4.5.
75910287|NCT05142059|Diagnostic Test|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A|The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
75910288|NCT05134974|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
76072600|NCT05310994|Dietary Supplement|Wasabi Leaf Extract Drink|consume 1 bottle per day
76072601|NCT05272306|Other|Number of attempts for successful transesophageal echocardiography|Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.
75318320|NCT06069141|Drug|Benzathine Penicillin G|Benzathine Penicillin G (2.4 MU intramuscularly once)
75318321|NCT06069141|Drug|Doxycycline Capsule|doxycycline (100 mg orally twice daily for 7 days)
75318322|NCT06069128|Device|Neurotrigger Basic. eye blinking stimulator|NeuroTrigger Basic is intended to stimulate healthy muscles in order to improve or facilitate muscle performance for maintaining/increasing muscle range of motion and for the prevention or retardation of disuse atrophy.
75318323|NCT06069115|Radiation|Radiation therapy protocol for Breast cancer|Conformal 3D radiation therapy will be performed 4-12 weeks after surgical treatment of breast cancer on Electa Axesse linear gas pedal with 6 MeV energy in traditional fractionation mode. Different RT schemes will be used depending on the stage of the disease, type of surgical treatment, and morphological variant of the tumor. In organ-preserving surgeries the remaining breast will be irradiated with a single focal dose (FD) of 2 Gy, up to the total focal dose (TFD) of 50 Gy. In the presence of risk factors, irradiation of lymphatic outflow pathways will be performed: axillary, sub/adclavicular and parasternal lymph nodes areas (FD 2 Gy, up to TFD 44-46 Gy). In radical breast resection we'll use irradiation of the anterior chest wall in 2 Gy FD, up to 50 Gy FD, irradiation of lymphatic outflow pathways: axillary, sub/adclavicular and parasternal lymph nodes (2 Gy FD, up to 44-46 Gy FD).
75318324|NCT06069115|Diagnostic Test|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
75318325|NCT06069115|Diagnostic Test|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
75464004|NCT02098265|Other|Delay|10 week delay before intervention
75464005|NCT02098265|Device|BCI-FES|
75464006|NCT02014597|Device|HOCD|feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma
75464007|NCT01962324|Radiation|SIB Dose-Escalation Radiotherapy|
75464008|NCT01942954|Other|Mobile health cognitive stimulation|
75464009|NCT01939275|Radiation|copper Cu 64-DOTA-trastuzumab|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
75464010|NCT01939275|Device|positron emission tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
75464011|NCT01939275|Other|laboratory biomarker analysis|Correlative studies
75464012|NCT01939275|Procedure|Computed Tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
75617635|NCT00675961|Other|BCI + Naltrexone|Combination of the two previous interventions
75617636|NCT00675961|Behavioral|Treatment as Usual|Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
75617637|NCT00887068|Drug|Azacitidine|32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
75617638|NCT00941031|Drug|AIN457|
75318326|NCT06069115|Diagnostic Test|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
75318327|NCT06069115|Diagnostic Test|SF-36 Quality of Life Questionnaire|Standard questionnaire for assessment quality of patient's life https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
75910289|NCT05134974|Drug|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
75770688|NCT01079910|Drug|Fluoride and Silica|NaF/Silica toothpaste containing 1150ppm fluoride
75464013|NCT01900574|Drug|Golimumab|Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
75617639|NCT00941031|Drug|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
75770689|NCT01286896|Drug|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
75617640|NCT00941031|Drug|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
75910290|NCT05134922|Drug|Gedatolisib|Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.
75910291|NCT05109442|Drug|AFM24|intravenous infusion
75910292|NCT05109442|Drug|Atezolizumab 840 MG in 14 ML Injection|intravenous infusion
75318328|NCT06069115|Diagnostic Test|Demographic and anthropometric measures|Age, sex, height. weight, body mass index (BMI)
75318329|NCT06069115|Other|Indicators characterizing the severity of the underlying disease|Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease) Medications taken.
75617641|NCT00941031|Drug|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
75617642|NCT04310436|Behavioral|Modifying saccades by looking down to naval.|Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
75770690|NCT03965988|Drug|DHA|Docosahexaenoic acid
75770691|NCT03965988|Drug|Placebo|Placebo
75770692|NCT01286974|Drug|[14C]linifanib|[14C]linifanib, single administration, oral liquid
75910293|NCT05108870|Drug|HB-201|A anti-cancer vaccine that treats HPV-related cancers.
75617643|NCT04310436|Behavioral|Modifying saccades by looking in air.|Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
75910294|NCT05108870|Drug|HB-202|A anti-cancer vaccine that treats HPV-related cancers.
75318330|NCT06069089|Radiation|Dexa scan|No intervention
75617644|NCT00886834|Drug|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
75318331|NCT06069050|Procedure|sequential adolesent left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
75318332|NCT06069037|Procedure|sequential adult left lateral lobe liver transplantation (SALT)|SALT for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
75910295|NCT05108870|Drug|Carboplatin|Chemotherapy drug.
75318333|NCT06069011|Other|Interdisciplinary management|assessment and treatment in an interdisciplinary model
76072602|NCT05272306|Diagnostic Test|A questionnaire for cardiologist satisfaction|A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
75318334|NCT06069011|Other|usual care|assessment and treatment in usual care model
75318335|NCT06068985|Drug|PHESGO|Subcutaneous formulation with pertuzumab and trastuzumab.
75617645|NCT00886834|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
75910296|NCT05108870|Drug|Paclitaxel|Chemotherapy drug.
75910297|NCT05108870|Procedure|Transoral Robotic Surgery|Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.
76072603|NCT05272306|Diagnostic Test|A questionnaire for patient satisfaction|A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
76072604|NCT04997668|Device|SOLTIVE Thulium Fiber Laser|Patients randomized to Arm A will undergo surgery to remove their kidney stone with FDA approved SOLTIVE Thulium Fiber Laser.
76072605|NCT04997668|Device|Ho:YAG Laser|Patients randomized to Arm B will undergo surgery to remove their kidney stone with FDA approved Ho:YAG laser.
75464014|NCT01582204|Drug|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd & pelvis), 124I-cG250-PET/CT & Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan & 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, & pelvis with contrast after cycles 2, 3, 4 & 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline & week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, & serial blood sampling, following the lst inj of 124I-cG250.
75318336|NCT06068972|Device|MolecuLight|Point-of-care fluorescence imaging of high bacterial loads
75770693|NCT01286974|Drug|ABT-869, linifanib|linifanib once a day (QD), oral tablet
75910298|NCT05107401|Behavioral|Digital Crowdsourced Intervention to Reduce HIV Stigma among Adolescents and Young Adults|Adolescents and young adults will participate in a crowdsourcing contest to create digital materials to reduce HIV stigma in order to increase HIV testing. Entries will be judged by a community judging panel and expert judging panel. Winning entries will be selected for the digital intervention and presented to participants in the intervention arm.
75464015|NCT01558999|Drug|High concentration SI-614|1 drop in each eye 4 times a day
75770694|NCT03857854|Drug|Pirfenidone|treatment group
75770695|NCT03857854|Drug|Placebos|placebo group
75318337|NCT06068946|Biological|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist
75910299|NCT05099276|Drug|Tranexamic Acid Pill|1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
75910300|NCT05099276|Drug|Placebo|Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
75910301|NCT05096481|Biological|PEP-CMV|The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
76072606|NCT05246488|Diagnostic Test|American Orthopedic Foot and Ankle Association Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analog Scale (VAS)|All participants will receive two assessments, 7 days apart. After the demographic data of the patients are recorded with the form prepared by us, they will be evaluated with the AOFAS Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analogue Scale (VAS).
76072607|NCT04907188|Biological|HB-adMSCs|The subject will receive 6 autologous HB-adMSCs intravenous infusion of 200 million (2 x 10^8 cells) cells approximately every 28 days.
75318338|NCT06068946|Biological|Placebo|Placebo comparator
75464016|NCT01558999|Drug|Low concentration SI-614|1 drop in each eye 4 times a day
75464017|NCT01558999|Drug|Vehicle|1 drop in each eye 4 times a day
75464018|NCT01491568|Device|rhBMP-2/CRM/CD HORIZON® Spinal System|rhBMP-2/CRM with the CD HORIZON® SpinalSystem
75318339|NCT06068920|Other|Distress evaluation|To evaluate the effects of psychological distress caused by living with a chronic disease such as rheumatoid arthritis.
75318340|NCT06068894|Dietary Supplement|"Humanized galacto-oligosaccharides (hGOS)"|10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage
75318341|NCT06068894|Dietary Supplement|Galacto-oligosaccharides (GOS)|10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage.
75318342|NCT06068894|Other|Matching Placebo|10-15 g/day powdered corn syrup comprised of fructose, glucose, and an inert cellulose material that matches the consistency, color sweetness, and taste of the prebiotics, that can be added to any non-alcoholic beverage.
75318343|NCT06068829|Drug|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inebilizumab was given after IVMP.
75318344|NCT06068829|Drug|Rituximab(RTX)|RTX: 500mg IV on Day 1 and Day15. The first dose of RTX was given after IVMP.
75318345|NCT06068816|Dietary Supplement|Nutrient-dense drink|a nutrient-dense drink developed by FrieslandCampina in line with the European Society for Clinical Nutrition and Metabolism guidelines for the dietary management of older malnourished patients
75318346|NCT06068803|Dietary Supplement|Ketone drink|Participants will consume three daily ketone monoester (KME) drinks (0.282g KME/kg body weight/ serving) for 4 weeks.
75464019|NCT01342367|Drug|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
75464020|NCT01342367|Drug|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
75770696|NCT03858946|Procedure|Simple trapeziectomy|A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch
75318347|NCT06068803|Dietary Supplement|Placebo|Participants will consume three daily taste-matched calorie-free placebo drinks for 4 weeks.
75318348|NCT06068790|Procedure|HoLEP Surgery|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
75798335|NCT01167660|Device|The Thrombo-Monitor (ThM)|Non-invasive measurement of coagulation status and comparison to standard blood coagulation tests. In healthy neonates - immediately after birth, before the administration of vitamin K. Coagulation tests will be done on an umbilical cord blood sample. In sick neonates, coagulation studies will be done according to the medical condition.
75318349|NCT06068777|Drug|Rosmary|inhale two drops of rosemary oil, from a gauze, for 3 minutes before the procedure of extraction of a primary molar
75318350|NCT06068777|Drug|Lemongrass Oil|inhale two drops of lemongrass oil, from a gauze, for three minutes before the procedure of extraction.
75318351|NCT06068751|Other|Aerobic Exercise|The initial group will receive instructions to increase their moderate to high-intensity physical activity frequency to at least 60 minutes per day (in episodes exceeding 10 minutes) by 50%, with a minimum of three days per week. They will be encouraged to engage in enjoyable and age-appropriate activities, including jogging, brisk walking, swimming, dancing, cycling, as well as sports like basketball, football, and tennis.
75318352|NCT06068751|Other|Neck Exercises|The second group, focused on neck exercises, will receive guidance from an experienced physiotherapist and their families. The physiotherapist will demonstrate a series of stretching and isometric strengthening exercises for specific muscle groups: upper trapezius, levator scapula, sternocleidomastoid, cervical flexors, and extensors, which have been associated with migraines in prior studies. Each patient will perform 3 sets of 10-15 repetitions for both stretching and isometric strengthening exercises per muscle group, with a 1-minute break between sets. Patients will be advised to maintain a gentle stretch during stretching exercises, avoiding excessive force to prevent discomfort. Static stretching and isometric strengthening exercises will involve holding each position for 5-10 seconds. In the initial week, a reduced set of 5 repetitions will be allowed for adaptation. Throughout the intervention, participants will follow this exercise regimen for 3 days weekly.
75464021|NCT01342367|Drug|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
75617646|NCT00880009|Drug|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
75617647|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
75617648|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
75617649|NCT04242472|Behavioral|SMS-based Mobile Health intervention|Nutritional related SMS text message mobile health intervention will be provided to Tuberculosis patients.
75617650|NCT02827006|Procedure|corrective osteotomy distal radius|Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
75617651|NCT00676039|Drug|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
75617652|NCT00676039|Drug|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
75617653|NCT00676039|Drug|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
75770697|NCT03858946|Procedure|Weilby|The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
75798336|NCT03871140|Other|diagnosis|therre is no intervention diagnosis or treatment for patients
75910302|NCT05096481|Drug|Temozolomide|Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
75910303|NCT05096481|Biological|Tetanus Diphtheria Vaccine|Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
75318353|NCT06068725|Behavioral|Training videos|After determining the application and control groups in the research, the purpose of the research was explained to both groups. The mobile phone usage skills of the individuals who will be included in the application group were evaluated with the Digital Literacy Scale. Training videos for 15 people each (30 minutes in total) regarding symptom management were shared on the phones of the patients/relatives in the application groups, and the patients and their relatives were informed and watched the training video. Data collection forms would be filled out before the application (Z0), on the 30th day of the application (Z1), and on the 90th day of the application (Z2).
75318354|NCT06068712|Behavioral|Attentional Cue Type|Positive cue (target), negative cue (distractor), or neutral cue (baseline)
75464022|NCT01342367|Radiation|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
75464023|NCT01220908|Device|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
75464024|NCT01220908|Device|Coils|Lung Volume Reduction Coil(s)
75617654|NCT00676039|Drug|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
75617655|NCT01104636|Drug|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
75617656|NCT04268511|Procedure|Caudal epidural block group|The linear probe of ultrasound was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone. A 22 Gauge 50 mm echogenic block needle was advanced
75617657|NCT04268511|Procedure|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
75617658|NCT04931602|Diagnostic Test|Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan|investigations for secondary causes of osteoporosis
75617659|NCT04157023|Device|Simulator-based Training of Direct Ophthalmoscopy|A digital simulator is used to teach the skills of direct ophthalmoscopy
75617660|NCT04157257|Drug|TDF tablet|TDF tablet 300mg QD
75617661|NCT04157257|Drug|Entecavir Tablet|Entecavir tablet 0.5mg QD
75617662|NCT04157257|Drug|QL-007|QL-007 tablets 200mg BID
75770698|NCT01287052|Drug|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
75770699|NCT01288924|Drug|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
75318355|NCT06068699|Other|Postcard|Participants received a postcard asking them to address non-adherence to remote monitoring.
76072608|NCT04847440|Drug|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
75617663|NCT04243174|Behavioral|SMS Messaging|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
75617664|NCT02852421|Procedure|Single injection paravertebral block|"The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections"
75617665|NCT02852421|Procedure|Multiple injection paravertebral blocks|"Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
75617666|NCT02825134|Device|Transcatheter aortic valve replacement|Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
75617667|NCT02825134|Device|Surgical aortic valve replacement|Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
75617668|NCT04152811|Behavioral|Cooking Matters for Diabetes|Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.
75617669|NCT04152811|Other|Usual Diabetes Care|Usual Diabetes Care
75617670|NCT04152889|Drug|Camrelizumab|Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
75617671|NCT04152889|Drug|S-1|Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
75770700|NCT01288924|Other|Control|NSS 2 ml intravenous before surgery and every 12 hours for two days.
75770701|NCT03857932|Procedure|Participants receive SLNB as well as non SLNs resection|Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
75770702|NCT01181362|Procedure|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
75770703|NCT01179724|Drug|high dose proton pump inhibitor|IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
75798337|NCT01167738|Drug|capecitabine|1250 mg/mq days 1-28 every 4 weeks
75910304|NCT05095948|Procedure|Discussion|Undergo audio recording of clinic conversations
75910305|NCT05095948|Other|Electronic Health Record Review|Review of medical records
75910306|NCT05095948|Other|Questionnaire Administration|Complete questionnaires
75910307|NCT05093855|Drug|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
75910308|NCT05083832|Procedure|Continuous Erector Spina Plane Block vs Continuous Serratus Anterior Plane Block|Two different catheter techniques with same doses local anesthetic infusion
75910309|NCT05080439|Other|Diacutaneous Fibrolysis|Application of diacutaneous fibrolysis in teres major
75910310|NCT05080439|Other|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
75910311|NCT05070650|Drug|Acetylcysteine|200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
75910312|NCT05070650|Drug|Paracetamol|500 mg/10 mg granules for oral solution: one sachet three times per day
75910313|NCT05070650|Drug|Phenylephrine|500 mg/10 mg granules for oral solution
75318356|NCT06068686|Drug|Vildagliptin 50 MG|vildagliptin plus their metformin.
75318357|NCT06068686|Drug|Glimepiride 3 Mg Oral Tablet|glimepiride plus their metformin
75341317|NCT05245370|Behavioral|Clinician testimonial|This group will see the rationale video first, followed by testimonial of a professional clinician/psychotherapist.
75341318|NCT05245370|Behavioral|Patient testimonial|This group will see the rationale video first, followed by testimonial of a patient who is being treated for depression with psychotherapy.
75341319|NCT01568905|Other|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
75341320|NCT01568905|Other|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
75910314|NCT05056766|Behavioral|questionnaires: Epworth Sleepiness Scale; Pichot fatigue questionnaire.|"Each patient will undergo 3 to 7 polygraphy recordings according usual practice of titration At the same time, Self-questionnaires will be conducted by the patient in order to evaluate Oral appliance efficacy.~Optimal titration of oral appliance will be done according subjectives parameters. (sleepeness Reduction and fatigue Reduction).~Neither the investigator nor the patient will know the polygraphy results (apnea-hypopnea index)"
75910315|NCT05056324|Device|Online vestibular rehabilitation tool|For those randomized to the intervention group, a 6 weeks duration vestibular rehabilitation will be delivered using an online tool (YrselTräning)
75910316|NCT05056324|Other|Standard care (written instructions leaflet)|For those randomized to the control group, a 6 weeks duration standard vestibular rehabilitation will be delivered using a written instructions leaflet
75910317|NCT05047211|Drug|Ferrous sulfate|one tablet 325 milligrams three times a day
75617672|NCT04152889|Drug|Docetaxel|Docetaxel: 40 mg/m^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
75617673|NCT00602511|Drug|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
75910318|NCT05047211|Drug|Iron dextran|1000 mg intravenous infusion
75318358|NCT06068647|Diagnostic Test|Lung ultrasound, computed tomographic scan and patch-based cardio-respiratory evaluations|"Ultrasonographic findings will be obtained with machines supplied with clinical Units. Additionally, US scans as acquired with open research platform will also be gathered. For both scanners, ultrasonographic scans will be performed and videos will be recorded and stored in each landmark. Metal cutaneous landmarks will be positioned and left during computed tomographic (CT) scans, indicating the areas of ultrasonographic assessment.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. Within the scope of this study, sensors will be applied to the upper chest. The following information will be collected by each sensor: electrocardiography, respiratory effort, respiratory flow, activity, position, and sound pressure level."
75910319|NCT05040893|Behavioral|Physiotherapy|"Interventions will include:~Education and self-management strategies, including the use of wearable activity and real-time heart rate monitors, to safely guide pacing and activity.~Breathing pattern education and retraining (including diaphragmatic, relaxed, and paced breathing exercises).~Return-to-activity exercise programming (e.g., postural, aerobic, and whole-body strengthening exercises)."
75617674|NCT00602511|Drug|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
75617675|NCT02826616|Drug|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
75910320|NCT04977310|Device|CardioMEMS|Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery
75910321|NCT04958642|Drug|Adrabetadex|Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.
76072609|NCT04847440|Drug|Viread|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
76072610|NCT04847440|Drug|AB-729|AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
75770704|NCT01179724|Drug|H2RB|IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
75341321|NCT01568905|Other|High level nicotine cigarette|smoke the study cigarette exclusively for one week
75617676|NCT00676117|Drug|Esomeprazole (D961H)|20mg
75910322|NCT04956432|Drug|SHR4640|SHR4640 Dose 1 ,tablets, QD
76072611|NCT04812106|Other|No Intervention|No Intervention
76072612|NCT04807660|Other|middle ear fluid sample|middle ear fluid sample for each enrrolled children
75617677|NCT00676117|Drug|Loxoprofen|60mg tablet
75617678|NCT05042986|Drug|.[14C]-SKI-O-703|Single oral dose of 200 mg (100 μCi in 200 mg salt [0.5 μCi/mg as salt], equivalent to 100 μCi in 142 mg active [0.7 μCi/mg as active]) of [14C]-SKI-O-703 containing approximately 100 μCi of [14C]-SKI-O-703 per capsule after an overnight fast.
75910323|NCT04956432|Drug|Allopurinol|Allopurinol 300mg, tablets, QD
75936667|NCT02427230|Behavioral|Pelvic floor muscle training|"The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks."
76072613|NCT03692572|Dietary Supplement|Nitrate supplementation|Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.
76072614|NCT03692572|Dietary Supplement|placebo|Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
76072615|NCT03516760|Drug|GEM333|infusion of GEM333; administered intravenously and continuously over 10 days
76072616|NCT01870297|Drug|LY3025876|Administered SQ
76072617|NCT01870297|Drug|Placebo|Administered SQ
75341322|NCT05322980|Diagnostic Test|Microcephaly|Those with a z score of birth head circumference < -2 (primary microcephaly) are classified into the Microcephaly group.
75617679|NCT02852187|Device|SIGNUS MOBIS PEEK Cage|Lumbar Interbody Fusion
75617680|NCT02852187|Device|SIGNUS MOBIS II ST Cage|Lumbar Interbody Fusion
75617681|NCT00676273|Device|TVT-Obturator (TVT-O)|sub urethral sling
75617682|NCT00676273|Device|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
75770705|NCT01176136|Behavioral|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
75798338|NCT01167738|Drug|cisplatin|30 mg/mq on days 1 and 15 every 4 weeks
75617683|NCT01104558|Drug|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
75617684|NCT04242160|Other|Modified Clamshell Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
75910324|NCT04950010|Behavioral|High-Intensity Interval Training|HIIT is a type of training in which short periods of high-intensity anaerobic exercise (1-4 minutes at 80-95% of VO2peak) are alternated with less intense aerobic recovery periods (1-3 minutes at 50-60% VO2peak). Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise (i.e., number and intensity of intervals) increases across weeks. Intervals will progress from a heart rate corresponding with 75% VO2peak in Week 1 to 90-95% VO2peak in Weeks 5-8. Sessions will be ~30 minutes in length. Indoor cycling is the primary mode of exercise.
75617685|NCT04242160|Other|Left Anterolateral Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
75617686|NCT00602589|Drug|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
75617687|NCT00911755|Procedure|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
75770706|NCT03862612|Procedure|regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block|Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
75910325|NCT04950010|Behavioral|Moderate-Intensity Exercise|Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Indoor cycling is the primary mode of exercise. Sessions will include moderate-intensity cycling that progresses from a heart rate corresponding with 55-60% VO2peak for 30 minutes in Week 1 to 65-70% VO2peak for 45-50 minutes in Weeks 5-8.
75910326|NCT04935762|Drug|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
75910327|NCT04920084|Other|Plant based meals|For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
75910328|NCT04914832|Biological|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.
75910329|NCT04912492|Behavioral|RealConsent1.0|A web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors.
75910330|NCT04912492|Behavioral|RealConsent2.0|A revised and updated web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors, but also integrates new program segments into RealConsent 1.0 specific to how alcohol use can inhibit SV intervention at multiple steps of the decision-making process.
76072618|NCT01870297|Drug|Liraglutide|Administered SQ
76072619|NCT01814761|Drug|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
76072620|NCT05141110|Drug|NVP-1705|NVP-1705
75318359|NCT06068621|Drug|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"Azacytidine (75 mg/m2/day, days 1 to 7).~Cytarabine (75-100 mg/m2 bid, days 1 to 5).~Aclacinomycin(20 mg/day, days 1,3,5).~Chidamide (30 mg/day , days 1,4,8,11).~Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
75617688|NCT00911755|Procedure|Endotracheal Intubation|
75617689|NCT02826850|Procedure|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
75617690|NCT02826850|Procedure|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
75318360|NCT06068621|Drug|"3+7"|"IA regimen:~Idarubicin (8-10 mg/m2) for 3 days .~Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~Daunorubicin(60 mg/m2) for 3 days.~Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."
75617691|NCT04270071|Drug|Yangxin Shengmai|Yangxin Shengmai Granules
75617692|NCT04270071|Drug|Yangxin Shengmai placebo|Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.
75617693|NCT04270071|Drug|nitroglycerin tablets|Be used when angina attack
75617694|NCT04152733|Device|High flow nasal cannula|Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
75770707|NCT03862534|Procedure|CAF|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession
75770708|NCT03862534|Procedure|CAF + CTG|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
75798339|NCT01167738|Drug|epirubicin|30 mg/mq on days 1 and 15 every 4 weeks
75798340|NCT01167738|Drug|gemcitabine|800 mg/mq on days 1 and 15 every 4 weeks
75798341|NCT01167738|Drug|metformin|2 g days 1-28 every 4 weeks
76072621|NCT05141110|Drug|NVP-1705-R|NVP-1705-R
76072622|NCT01843933|Device|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
75798342|NCT01272726|Behavioral|Education|Education on the genetics of ADHD and treatment options for ADHD
75617695|NCT02826538|Device|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
75617696|NCT02826538|Device|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
75910331|NCT04912492|Behavioral|Stress Management|A web-based multimedia program designed to help individuals recognize the symptoms and sources of stress and provide them with a wide variety of powerful tools for managing stress.
75770709|NCT03857698|Other|Conservative Physical Therapy|"Patients who were discharged from the hospital and received the sutures will be supervised 2 days a week for 8 weeks. Exercise programs will be promoted individually.~Ice application for pain, edema control~Patellar mobilization~Three-way straight leg lifting exercises~Isometric exercises around the hips and knees~Active assisted, active, resistant knee range of motion exercises~Heel shift exercises in supine and sitting~Hip abduction on the side lying~Stretching exercises for patients with gastrosoleus, hamstring, hip flexor muscles~Neuromuscular Electrical Stimulation (NMES) for quadriceps muscle of patients will be applied. The isometric quadriceps contraction observed during the procedure will be required to actively participate in the patients."
75798343|NCT01167816|Drug|Vidaza|Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
75910332|NCT04912492|Behavioral|Alcohol intoxication|Men assigned to moderate alcohol dose condition (target BrAC .08%) with NIAAA approved alcohol administration procedures
75318361|NCT06068608|Drug|TNM005|single,intramuscular injection
75910333|NCT04912492|Behavioral|No-Alcohol Placebo|Men assigned to an no-alcohol placebo control condition.
75318362|NCT06068608|Drug|Placebo|single,intramuscular injection
75318363|NCT06068608|Drug|VariZIG|a single dose of VARIZIG 625 IU,intramuscular injection
75318364|NCT06068595|Other|musculoskeletal ultrasound|After clinical examination and medical interrogation, The investigating physician gives her decisions in the e-CRF according to the 5 axes: diagnosis (I), therapy (II), patient referral (III), prescription of additional tests (IV) and follow-up (V). The investigator performs the targeted musculoskeletal ultrasound with his personal ultrasound machine, following his usual operating procedure and give/keep the final diagnostic.
75464025|NCT01185171|Drug|ZD 1839 500mg|"Optional Induction chemotherapy:~Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance [CC] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.~Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle."
75910334|NCT04906278|Device|Foley catheter balloon|A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix
75910335|NCT04906278|Procedure|Amniotomy|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip. Care should be taken to protect maternal vaginal tissues from the forceps. Once the forceps reach the amniotic sac, the tip is pushed up against the sac with the index or middle finger of the internal hand to pierce the membranes. The nature of amniotic fluid will be checked.
75318365|NCT06068569|Biological|GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)|Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed. 1st injection - component I, 2nd injection - component II.
75318366|NCT06068556|Biological|GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition|Two intramuscular injections of GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition will be performed. 1st injection - component I, 2nd injection - component II.
75341323|NCT01569451|Drug|Rituximab|intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
75464026|NCT01106261|Procedure|Metastasectomy|Pulmonary Metastasectomy
75910336|NCT04906278|Drug|Oxytocin|The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
75910337|NCT04895670|Behavioral|Empowering Youth Aging out of Foster Care|App that allows storage of health information, and access to reputable health information and community resources.
75910338|NCT04895475|Behavioral|SARS-CoV-2 vaccine|Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit. Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
76072623|NCT01798030|Other|Vitamin D|N/A, frozen specimen study
75341324|NCT01569451|Drug|Glatiramer Acetate|20 mg injected subcutaneously daily
75617697|NCT04152577|Drug|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
75798344|NCT01167894|Drug|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
75341325|NCT01569451|Other|Placebo|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
75910339|NCT04895202|Other|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
75318367|NCT06068491|Other|I-VCALD|I-VCALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
75770710|NCT03857698|Other|Body Stabilization Exercise|"In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~Consecutive shoulder flexion and extension in supine~Building a bridge~Lower body and hip flip~Single leg extension with bilateral arm elevation~Resilient leg stretch with bilateral arm elevation~Hip external rotation in lateral hospitalization~Side-lying arm opening~Shoulder girdle retraction on ball, horizantal abduction and extension"
75770711|NCT01287130|Drug|Cetuximab|Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
75770712|NCT01287130|Drug|AZD6244|Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
75770713|NCT00149214|Drug|pemetrexed|500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
75770714|NCT00149214|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
75770715|NCT00149214|Drug|doxorubicin|60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
75770716|NCT00149214|Drug|docetaxel|100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)
75770717|NCT03034018|Drug|suvorexant|10-20 mg taken at bedtime for four weeks
75770718|NCT03034018|Drug|placebo|placebo taken at bedtime for four weeks
75770719|NCT02524990|Behavioral|Home-based follow-up with SQPT|Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
75318368|NCT06068465|Drug|pimavanserin tartrate|pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks
75318369|NCT06068465|Drug|placebo|placebo, capsule, once daily by mouth for 6 weeks
75318370|NCT06068439|Drug|Acetylsalicylic Acid|aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
75770720|NCT03965910|Other|Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data|"Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic."
75770721|NCT02525458|Device|QAMS-containing PMMA|Wear retainer with QMAS-containing PMMA on one side of retainer
75770722|NCT02525458|Device|QAMS-free PMMA|Wear retainer with QMAS-free PMMA on other side of retainer
75770723|NCT03967782|Behavioral|CON|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75910340|NCT04878458|Procedure|phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
75910341|NCT04878458|Procedure|phacoemulsification with intraocular lens implantation combined with trabeculectomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
75910342|NCT04864587|Diagnostic Test|Artificial intelligence used for image recognition in pouchoscopy|The aim of this study is to develop an image recognition algorithm that reliably detects the different graduations of pouch inflammation and neoplasms in the pouch
75318371|NCT06068439|Drug|Placebo|Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
75318372|NCT06068426|Diagnostic Test|Transabdominal ultrasound Shear wave elastography|TUS SWE will be performed using a Canon Aplio i800 ultrasound system and a curved 1-6 MHz transducer. 2D SWE will be performed with measurement of shear wave speed in the head, body and tail of the pancreas.
75318373|NCT06068413|Device|CT image-assisted detection software|CT image-assisted detection software can help doctor to diagnosis the focal liver lesion
75318374|NCT06068400|Biological|BCMA/GPRC5D double CAR-T|BCMA/GPRC5D double CAR-T is a new type CAR-T cells therapy for patients with Multiple Myeloma.
75318375|NCT06068374|Other|Break of sedentary behavior with dual task|Patients will interrupt sedentary behavior performing walking and cognitive activities simultaneously
76072624|NCT03329950|Drug|CDX-1140|CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
75318376|NCT06068374|Other|Break of sedentary behavior with walking|Patients will interrupt sedentary behavior performing walking
75318377|NCT06068361|Diagnostic Test|EEG|32-electrode EEG (resting state, passive auditory and active visual task)
75464027|NCT01106261|Procedure|Active monitoring|Active monitoring
75770724|NCT03967782|Behavioral|EX-MEAL|Condition with an acute exercise set right before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right before ad ad libitum lunch meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75770725|NCT03967782|Behavioral|MEAL-EX|. condition with an acute exercise set right after lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right after an ad libitul buffet meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
75770726|NCT03858556|Procedure|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
75770727|NCT03858556|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
75770728|NCT03858556|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
75617698|NCT04152577|Drug|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
75770729|NCT03858556|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
75770730|NCT03858556|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75770731|NCT03858556|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75770732|NCT03858556|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
75770733|NCT03858556|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
75770734|NCT03857776|Other|Open dialogue about complementary alternative medicine|1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
75770735|NCT03857776|Other|Standard care|Standard care including referral to a homepage about CAM
75770736|NCT02555254|Procedure|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
75770737|NCT02555254|Procedure|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
75770738|NCT01179802|Other|Strenuous Endurance exercise|"Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters."
75770739|NCT01179880|Drug|E6005|Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
75770740|NCT01179880|Drug|Placebo|Matching placebo for each step
75770741|NCT03862222|Other|Retinal Imaging|Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
75910343|NCT04845399|Drug|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
75910344|NCT04841317|Combination Product|Mobile technology intervention|Home blood pressure cuff used by patients twice a week, with blood pressures transmitted to providers remotely
75910345|NCT04826614|Other|optimized treatment|early adjust dose or change drug
75910346|NCT04807374|Device|Control IQ|We aim to conduct a non-randomized prospective interrupted time series pilot study to investigate the effect of HCL insulin delivery on glycemic control in underserved adolescents with poorly controlled T1D.
75318378|NCT06068296|Diagnostic Test|short term memory assessment|"Aphasia group: The Dutch verbal STM assessment tool will be administered over a time span of maximum two consecutive days depending on how fatigued the patient is during testing.~Healthy control group: the Dutch verbal STM assessment tool will be administered."
75617699|NCT02856087|Drug|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
75617700|NCT02856087|Drug|Naloxone|naloxone infusion
75617701|NCT02856087|Drug|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
75770742|NCT03862222|Other|Pupillometry|Participants will complete a task studying pupillary response to light
75770743|NCT03862222|Other|Contrast Sensitivity|Participants will complete a task evaluating contrast sensitivity
75770744|NCT03862222|Diagnostic Test|Neuropsychological Evaluation|Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
75770745|NCT03862222|Genetic|APOE genotyping|APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
75318379|NCT06068296|Diagnostic Test|Oxford cognitive screen|Evaluation of the cognitive abilities of the patients with aphasia.
75318380|NCT06068296|Diagnostic Test|Token Test|Evaluation of the severity of the aphasia in patients with aphasia.
75318381|NCT06068296|Diagnostic Test|Montreal cognitive assessment|Evaluation of cognitive dysfunction in the group of healthy volunteers.
75910347|NCT04799106|Behavioral|Community Based Strategies for Early Detection of Melanoma|"The main procedures of this study include educational sessions about melanoma and how to detect it at its earliest stages with the help of a community health worker, conducting a self-skin examination every three months, helping to perform a skin examination every three months for a family member or friend who would be selected as a partner, and completing short questionnaires at the beginning of the study, at month three during the study, and at completion of the study."
75770746|NCT03862222|Other|blood draw|Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
75770747|NCT03862222|Other|Gait Assessment|Gait assessment will be conducted by trained researcher
75770748|NCT03862222|Other|Actigraphy|Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
75770749|NCT01181440|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
75770750|NCT01181440|Other|Conventional care|Weekly application of conventional care
75770751|NCT01289626|Drug|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
75617702|NCT02856087|Drug|Normal Saline|normal saline infusion
75770752|NCT01289626|Drug|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
75910348|NCT04766853|Drug|Dexamethasone|Dexamethasone 5mg/ml
75910349|NCT04766853|Drug|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
75617703|NCT02881632|Device|Structured Light Plethysmography (SLP) - Pneumscan|Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
75617704|NCT02855931|Procedure|Middle turbinate resection|
75617705|NCT00676429|Drug|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
75770753|NCT01176214|Procedure|Early tracheostomy|"Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset."
75770754|NCT01176214|Procedure|Late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
75770755|NCT01179958|Behavioral|aerobic training|24 weeks of aerobic training, 4X/week
75770756|NCT01179958|Behavioral|stretching/toning|stretches and toning exercises designed to promote flexibility and improved core strength
75910350|NCT04765605|Device|WeFlow-Tbranch Stent Graft System|The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
75910351|NCT04755218|Other|Vaginal Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States"
75910352|NCT04755218|Other|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current labor induction protocol
75770757|NCT00114972|Device|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
75910353|NCT04732845|Biological|Fully human anti CD19 CAR-T Cell Dose|"Level -1 (1 x 10^5 cells/kg) Level 1 [Starting Dose] (5 x 10^5 cells/kg) Level 2 (1 x 10^6 cells/kg) Level 3 (2 x 10^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes."
75910354|NCT04732845|Drug|Fludarabine|25 mg/m2 daily from day -5 to -3
75617706|NCT00676429|Drug|Placebo|Placebo as oral solution, individually titrated
75617707|NCT02880072|Dietary Supplement|phosphate orally|4 different preparations of phosphate
75770758|NCT00114972|Procedure|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
75770759|NCT02444728|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg BID for 12 months
75770760|NCT02444728|Drug|Cyclophosphamide|Cyclophosphamide 1000mg intravenous infusion every month for 6 months
75318382|NCT06068283|Behavioral|LOTUS mHealth Intervention Group|A mobile, WebApp-based intervention comprised of tips for HIV prevention, a community wall for peer interaction and support, HIV prevention monitoring and reminders, guided discussions with a health care professional, a resource database, and a personalized profile. Intervention components are designed to promote HIV prevention service use, reduce stigma and improve social support, coping strategies, and positive affect.
75318383|NCT06068283|Behavioral|LOTUS Control Group|Access to an information-only website with content on HIV transmission, PrEP, harm reduction, and resources for women.
75318384|NCT06068244|Other|3D printed crowns|3D printed crowns
75318385|NCT06068244|Other|Zirconia crowns|Nu smile zirconia crowns
75770761|NCT02444728|Drug|Azathioprine|After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
75770762|NCT02444728|Drug|Methylprednisolone|Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
75770763|NCT03858790|Device|PINS Spinal Cord Stimulator|Subjects will be implanted with PINS spinal cord stimulator
75910355|NCT04732845|Drug|Cyclophosphamide|60mg/Kg on day -6
75318386|NCT06068231|Device|Temporary Crown|Implants were loaded with temporary restorations 6 to 8 weeks after implantation and had occlusal contact with opposing dentition.
75318387|NCT06068231|Device|Permanent Crown|Implants were loaded with permanent restorations at least 3 months after implantation and had occlusal contact with opposing dentition.
75770764|NCT01180114|Behavioral|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
75770765|NCT01180114|Other|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
75910356|NCT04693715|Drug|RNS60|RNS60 injection solution
75910357|NCT04693715|Drug|Placebo|Placebo injection solution
75910358|NCT04693585|Behavioral|MESSSSAGE - live|mHealth education and social support intervention, synchronous via call
75910359|NCT04693585|Behavioral|MESSSSAGE - asynchronous|mHealth education and social support intervention, asynchronous via text
75910360|NCT04670536|Device|PASS LP implants|Thoraco lumbar arthrodesis
75910361|NCT04670536|Device|PASS DEGEN|Thoraco lumbar arthrodesis
75910362|NCT04670536|Device|PASS TULIP PRIME|Thoraco lumbar arthrodesis
75910363|NCT04634435|Combination Product|CIML NK Cells plus KP1237 and low dose IL-2|Single dose infusion of CIML NK Cells plus KP1237 followed by low dose IL-2
75910364|NCT04614610|Drug|Lidocaine Iv|Lidocaine 1.5mg/kg (Max dose: 200mg) in Dextrose 5% 100mL over 10 minutes
75318388|NCT06068205|Diagnostic Test|Blood test - atomic force microscopy in the force spectroscopy mode|A single blood test to be analysed through atomic force microscopy in the force spectroscopy mode
75318389|NCT06068179|Drug|Mycophenolate Mofetil, Oral, 250 Mg|Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy
75617708|NCT02856165|Device|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 > 94%.
75910365|NCT04614610|Drug|Placebo|Dextrose 5% 100mL over 10 minutes
75910366|NCT04613453|Drug|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
75910367|NCT04613453|Drug|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
75318390|NCT06068179|Drug|methimazole, oral, 10mg|Methimazole 15-30mg daily initially then titrate to maintenance dose.
75318391|NCT06068166|Combination Product|TEA plus GDMT|Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures. Since 1995, Professor Liu Fengqi has pioneered the use of TEA to treat end-stage HFrEF and achieved surprising results. TEA could reduce the enlarged heart cavity, halt and reverse cardiac remodeling, and improve cardiac systolic and diastolic function. Currently, thousands of HFrEF patients have received TEA procedure. All the patients received maximally tolerated guideline-directed medical therapy (GDMT).
75318392|NCT06068166|Drug|GDMT|All the patients received maximally tolerated guideline-directed medical therapy (GDMT) alone.
75910368|NCT04562740|Device|ABLUMINUS DES drug eluting stent|Following successful plain balloon angioplasty of the arterial lesion, (defined as <30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), the ABLUMINUS stent will be deployed at the lesion as per Instructions for Use (IFU) after appropriate sizing using the diameter of the plain balloon angioplasty. After deployment of the ABLUMINUS stent, further balloon angioplasty of the stent will be performed, using the same diameter standard balloon catheter at 2 minutes inflation, to ensure adequate moulding and expansion of the stent.
75910369|NCT04535219|Other|Exercise|60 minutes of moderate-intensity treadmill exercise (70% of maximal heart rate determined from the maximal graded exercise test)
75910370|NCT04535219|Other|Supervised Total Sleep Deprivation|Laboratory-monitored total sleep deprivation
75910371|NCT04511234|Device|MagicTouch PTA sirolimus drug coated balloon (DCB)|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as <30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
75910372|NCT04511234|Device|POBA standard balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
75910373|NCT04499924|Drug|tucatinib|300 mg given twice daily orally
75318393|NCT06068101|Diagnostic Test|Secreening test for primary aldosteronism and Confirmatory Testing|Serum aldosterone and plasma direct renin concentrations were measured by a chemiluminescent immunoassay. A positive PA screening was defined by aldosterone > or = 10 ng/dL and aldosterone to renin ratio > or = 2 ng/dL/uUI/mL
75318394|NCT06068088|Behavioral|Self-administered survey at hospital|Self-administered survey on the food practices of the patient Completion before the beginning of chemoradiotherapy
75617709|NCT02856165|Device|Low-flow oxygen therapy with standard nasal canula|flow adjusted to SpO2 > 94% (up to a maximum of 2l/min).
75617710|NCT02629315|Other|Carnoy's solution|
75617711|NCT02629315|Other|10% neutral buffered formaldehyde|
75617712|NCT04310046|Procedure|PCI before TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
75617713|NCT04310046|Procedure|PCI after TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
75617714|NCT02855853|Other|serious game et virtual reality|
75318395|NCT06068088|Biological|Blood sample for nutritional assessment|15 ml of blood sampled during nutritional examination before the beginning and during the month following the end of chemoradiotherapy
75617715|NCT02855853|Other|Nintendo Wii|
75770766|NCT01289704|Other|TreSPE|"treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~Proprioceptive and postural kinesitherapy according to the Perfetti method.~Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls."
75770767|NCT01289704|Other|SPE|"Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.~Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.~Proprioceptive and postural kinesitherapy according to the neurocognitive method.~Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls."
75770768|NCT00129402|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
75770769|NCT00129402|Drug|simvastatin|Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
75910374|NCT04499924|Drug|trastuzumab|6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
75910375|NCT04499924|Drug|ramucirumab|8 mg/kg will be administered IV on Days 1 and 15 of each cycle
75910376|NCT04499924|Drug|paclitaxel|60 or 80 mg/m^2 IV on Days 1, 8, and 15 of each cycle
75910377|NCT04499924|Other|tucatinib placebo|Given twice daily orally
75464028|NCT00987532|Behavioral|parent-focused intervention|The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
75318396|NCT06068088|Other|Consultation with nutritionist doctor and dietician|Before the beginning and during the month following the end of chemoradiotherapy Consultation of approximatively one hour
75464029|NCT00987532|Behavioral|twice weekly gym lessons|twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
75464030|NCT00896493|Drug|anti-thymocyte globulin|ATG will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg
75464031|NCT00896493|Drug|cyclosporine|5 mg/kg PO or IV
75464032|NCT00896493|Radiation|Lymphoid radiation|TLI is administered ten times in 80c- 120c Gy fractions on day -11 through day -7 and day -4 through day -1
75464033|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 1|Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
75464034|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 2|Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
75464035|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 3|Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
75341326|NCT01569529|Behavioral|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
75341327|NCT01569607|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Training sessions for 5 days in a row
75341328|NCT01569607|Device|Sham stimulation|Sham stimulation
75464036|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 4|Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
75464037|NCT00695552|Behavioral|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
75910378|NCT04499924|Other|trastuzumab placebo|IV on Days 1 and 15 of each cycle
75910379|NCT04481555|Drug|Azithromycin|Prophylactic azithromycin treatment 250 mg three times weekly vs placebo
75910380|NCT04481555|Drug|ICS|All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
75910381|NCT04453020|Device|DBS of the LHA|Deep Brain Stimulation of the Lateral Hypothalamic Area
75910382|NCT04439357|Drug|Trametinib Dimethyl Sulfoxide|Given PO
75910383|NCT04437511|Drug|Donanemab|Given IV
75910384|NCT04437511|Drug|Placebo|Given IV
75910385|NCT04434768|Biological|UMSC01|There will be one dose of IV administration in patients with acute ischemic stroke, or one dose of IV administration followed by low or high doses of IA infusion for acute ischemic stroke with or without bridging therapy (i.e. Intravenous rt-PA thrombolysis or intraarterial thrombectomy) with 12 months of follow up after the first treatment.
75910386|NCT04370587|Biological|T3011|T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
75910387|NCT04370587|Combination Product|T3011 + pembrolizumab|T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
75910388|NCT04357353|Biological|Platelet rich plasma|PRP will be used in the experimental arm.
75910389|NCT04357353|Other|Placebo Sham Injection|sham injection
75910390|NCT04347447|Other|Exercise training|All groups will complete a supervised 12-week resistance training protocol, 3 days per week.
75910391|NCT04321343|Drug|PXL065|PXL065 oral tablet
75910392|NCT04321343|Drug|Placebo oral tablet|Placebo oral tablet
75910393|NCT04318938|Drug|Brigatinib|Treatment with Brigatinib
75910394|NCT04318938|Drug|Tyrosine kinase inhibitor|Treatment with any TKI
75910395|NCT04311723|Procedure|Anesthesia Procedure|Receive anesthesia using laryngeal mask
75910396|NCT04311723|Procedure|Anesthesia Procedure|Receive anesthesia using endotracheal tube
75910397|NCT04311723|Procedure|Bronchoscopy|Undergo standard of care bronchoscopy
75910398|NCT04298255|Other|Round Spermatid Injection (ROSI)|In Vitro Fertilization using Round Spermatid Injection (ROSI)
75910399|NCT04298255|Other|Half ROSI-half Sperm Donor Fertilization|Half ROSI-half Sperm Donor Fertilization
75910400|NCT04292717|Behavioral|Gait training|All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.
75910401|NCT04274153|Biological|Gardasil9|Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
75910402|NCT04238754|Drug|Epidiolex|Epidiolex 100 mg/mL Oral Solution
75464038|NCT00695552|Behavioral|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
75464039|NCT00598026|Other|Tele- follow-up|Remote transmission to the implantation centre every 3 months
75617716|NCT00676507|Biological|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
75617717|NCT00676507|Other|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
75617718|NCT02880150|Other|Stress test|
75770770|NCT01180192|Drug|oxygen|either 8 L/minute O2 via face mask for 2 hours
75910403|NCT04238754|Drug|Placebo|Cherry syrup oral solution
75910404|NCT04232358|Drug|Corticosteroid injection|Corticosteroid injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
75910405|NCT04232358|Drug|Local anesthesia injections|Local anesthesia injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
75910406|NCT04225234|Other|Financial incentives|"Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes."
75910407|NCT04223570|Device|Portable Apple Smart Phone Protoporphyrin IX Spectrometer Camera|This is a portable device that uses a camera to non-invasively and efficiently measure the level of protoporphyrin IX in various areas skin. This camera will be used in all participants to measure the level of protoporphyrin IX in various areas of skin as detailed in the study description.
75910408|NCT04220190|Biological|RAPA-501 Autologous T cells|TREG/Th2 cells
75910409|NCT04213820|Device|Transcranial magnetic stimulation|TMS (theta burst) will be administered consisting of bursts containing 3 pulses at 50 Hz and an intensity of 80% motor threshold repeated at 200 ms intervals (i.e., at 5 Hz) and a 10 s between burst triplet interval for a total for 190 s (600 pulses). The intervention will be given daily 5 times/week during 4 weeks.
75910410|NCT04213820|Behavioral|Body Image Intervention|Body image interventions delivered directly after TMS will include body exercises that target disturbed body image and psychoeducation about the body. Together with a therapist the participants with anorexia nervosa will explore and estimate their body size through feedback.
75910411|NCT04213820|Behavioral|Treatment as usual|Treatment as usual at the eating disorder unit, Child and adolescent psychiatric clinic and Psychiatric clinic is delivered during 4 weeks
75910412|NCT04212143|Other|there is no intervention|There is no intervention in this study. It is observational only.
75910413|NCT04208958|Biological|VE800|VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.
75910414|NCT04208958|Drug|Nivolumab|Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
75910415|NCT04208958|Drug|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection.
75464040|NCT00598026|Other|Conventional follow-up|Visits at the implantation centre every 3 months
75617719|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
75617720|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
75617721|NCT01204658|Biological|Synflorix|Intramuscular injection
75617722|NCT01204658|Biological|Prevenar 13|Intramuscular injection
75617723|NCT01204658|Biological|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
75770771|NCT01181830|Drug|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
75770772|NCT01181830|Drug|placebo|administration of 8.1 mmol bid of placebo
75770773|NCT03739528|Drug|Levofloxacin + dexamethasone followed by dexamethasone|Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
75770774|NCT03739528|Drug|Tobramycin + Dexamethasone|Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
75770775|NCT03857386|Procedure|PECS group|Pecs block performed using ultrasound guidance
75341329|NCT05564845|Diagnostic Test|MR scan of the brain|Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
75617724|NCT00951483|Drug|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
75617725|NCT01104246|Drug|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
75910416|NCT04205955|Other|Best Practice|Receive healthy living education via phone call
75910417|NCT04205955|Dietary Supplement|Dietary Intervention|Receive diet modification coaching via phone call
75910418|NCT04205955|Other|Message|Receive motivational messages via email and/or text message
75910419|NCT04205955|Other|Quality-of-Life Assessment|Ancillary studies
75910420|NCT04205955|Other|Questionnaire Administration|Ancillary studies
75910421|NCT04186832|Device|FitBit|Wear FitBit
75910422|NCT04186832|Device|Pedometer|Wear pedometer
75910423|NCT04186832|Other|Quality-of-Life Assessment|Ancillary studies
75910424|NCT04186832|Other|Questionnaire Administration|Ancillary studies
75910425|NCT04183179|Behavioral|Happy Family, Healthy Kids Program|"The 14-week healthy eating program activities including four components:~A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
75910426|NCT04175444|Diagnostic Test|VisuALL Field Analyzer|Each participant will conduct a visual field test with the visuaALL headset.
75617726|NCT00676741|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75617727|NCT00676741|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75617728|NCT00676741|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75617729|NCT01103778|Drug|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
75770776|NCT03857386|Procedure|Control group|Local infiltration anesthesia performed during the operation
75770777|NCT01587586|Biological|PEGASYS 180 µg Q1W|48 doses, solution, 48 weeks
75770778|NCT01587586|Biological|P1101 180 µg Q1W, 48 doses|48 doses, solution, 48 weeks
75770779|NCT01587586|Biological|P1101 270µg Q1W, 48 doses|48 doses, solution, 48 weeks
75770780|NCT01587586|Biological|P1101 450µg Q2W, 24 doses|24 doses, solution, 48 weeks
75910427|NCT04175444|Diagnostic Test|Humphrey Field Analyzer|Each participant will conduct a standard of care Humphrey Visual Field.
75770781|NCT01181908|Drug|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
75910428|NCT04150068|Drug|Oral Lenacapavir|Tablets administered without regard to food
75617730|NCT02855619|Procedure|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
75910429|NCT04150068|Drug|Oral Lenacapavir Placebo|Tablets administered without regard to food
75910430|NCT04150068|Drug|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
75910431|NCT04150068|Drug|Failing ARV Regimen|Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
75910432|NCT04150068|Drug|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
75910433|NCT04144153|Combination Product|Opioid Free Total Intravenous Anesthesia|Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride
75910434|NCT04144153|Combination Product|Total Intravenous anesthesia with opioid|Total Intravenous anesthesia with opioid
76072625|NCT03329950|Drug|CDX-301|CDX-301 will be injected once a day for five days before Cycles 1 and 2.
75770782|NCT01289236|Drug|milnacipran|1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
75770783|NCT01289236|Drug|Milnacipran|1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
75770784|NCT01289236|Drug|Placebo|1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
75770785|NCT01287286|Dietary Supplement|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
75770786|NCT01287286|Dietary Supplement|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
75910435|NCT04130022|Device|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
75910436|NCT04128995|Procedure|Advanced Medical Therapy and Bariatric Surgery|Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
76072626|NCT03329950|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
76072627|NCT03329950|Drug|Chemotherapy|Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
75770787|NCT01289860|Dietary Supplement|Flavonoids|475g of anthocyanidins in 300ml of blueberry drink.
76072628|NCT01814371|Drug|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
75318397|NCT06068062|Other|modification of OSCE using TBL format|Modification of Team-based learning format and implementing OSCE using that modified format to teach clinical skills to medical students.To teach clinical skills this structure of TBL was modified and with use of OSCE following strategy was planned as intervention. First of all, the students were provided with the resource material regarding the skills to be taught. Then a formative OSCE session was organized where students were divided into groups each with 5 students. They were rotated in two OSCE stations. First each student one by one was supposed to perform the task that was clearly documented and was evaluated by peers and facilitator. Immediate feedback from peers and facilitators was given to each student. Students were also instructed to discuss among themselves and designate roles also to make a plan and act like team in performing task on OSCE station 2.
75318398|NCT06068036|Behavioral|Telehealth intervention: HEARTS technical package + activity monitor (Smartwatch Mi Band 7®)|Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
75617731|NCT02855619|Procedure|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
75464041|NCT00585065|Device|CRT device implant|The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
75464042|NCT00444093|Drug|Opii normata treatment|"After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day."
75617732|NCT02855619|Procedure|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
75617733|NCT00673621|Drug|Technosphere Insulin Inhalation Powder|3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
75617734|NCT00673621|Drug|Salbutamol (Albuterol)|2 puff = 200 mcg total dose
75617735|NCT00673621|Drug|Methacholine chloride|5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
75617736|NCT01103466|Device|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
75617737|NCT01103466|Device|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
75770788|NCT01289860|Dietary Supplement|Control|29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
75770789|NCT03858478|Drug|Biktarvy arm|BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
75770790|NCT01289938|Drug|Diphenhydramine|Diphenhydramine 50 mg oral once
75770791|NCT01289938|Drug|Metoclopramide|10 mg i.v. metoclopramide once
75770792|NCT00114738|Drug|Rituximab (R)|Rituximab is given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.
75770793|NCT00114738|Biological|EPOCH|EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
75770794|NCT00114738|Drug|Bortezomib (B)|Bortezomib is given alone for one cycle.
75318399|NCT06068036|Behavioral|Telehealth intervention: HEARTS technical package|The same intervention as the experimental group, but without the additional use of the physical activity monitor (Smartwatch Mi Band 7®).
75341330|NCT05564845|Diagnostic Test|Blood work|Lab work for current lab values and biobanking
75341331|NCT05564845|Diagnostic Test|Neurological examination|Classical neurological examination
75770795|NCT00114738|Drug|Bortezomib|Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.
75770796|NCT00114738|Drug|Bortezomib or observation|At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
75770797|NCT01180348|Drug|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
75770798|NCT01180348|Drug|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
75770799|NCT01180426|Drug|CHR-2797|120mg once daily oral for 48 weeks
75770800|NCT01289314|Procedure|TLH|Total laparoscopic hysterectomy (TLH)
75770801|NCT01289314|Procedure|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
75770802|NCT02524756|Procedure|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
75318400|NCT06068023|Drug|Folfirinox|"Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study.~The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice."
75770803|NCT02524756|Procedure|laparoscopic radical hysterectomy (type III/C2).|
75910437|NCT04128995|Drug|Advanced Medical Therapy|Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
75910438|NCT04128995|Procedure|Bariatric Surgery|Vertical Sleeve Gastrectomy for youth without type 2 diabetes
75910439|NCT04126577|Biological|blood samples|4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
75910440|NCT04114175|Other|Exercise BE|Basic exercises related to amputation will be applied
75910441|NCT04114175|Other|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
75910442|NCT04106154|Behavioral|Kinesiology Support|12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
75910444|NCT04056247|Other|Plasma sample collection|Collect at least two plasma samples
75318401|NCT06068023|Drug|Capox|or 8 CAPOX cycles (Arm 1) every 3 weeks.
75318402|NCT06067997|Diagnostic Test|pulmonary embolism diagnosis|"The diagnosis of pulmonary embolism will be made using the diagnostic algorithm suggested by the 2019 European guidelines . The pre-test clinical probability of pulmonary embolism will be defined based on the simplified Wells score. In patients with a low pre-test clinical probability and a D-dimer level below the threshold value the diagnosis of pulmonary embolism will be excluded. The D-dimer level will be measured using the quantitative assay routinely used in each participating center; the threshold value for a positive result compared to a negative result is 500 μg per milliliter for patients under 50 years of age. For each additional decade of age, the exclusion cutoff will increase by 100 μg per milliliter.~The criterion for the presence of pulmonary embolism is the detection of an intraluminal filling defect on CT."
75617738|NCT01103466|Device|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
75617739|NCT02627053|Drug|rivaroxaban|
75617740|NCT00945945|Drug|Duloxetine (DLX)|dose daily by mouth
75617741|NCT00945945|Drug|Placebo (PLA)|Placebo Comparator daily by mouth
75617742|NCT01203956|Device|SmartFlex|Device used with smartflex engaged.
75617743|NCT01203956|Device|Standard|
75617744|NCT04150627|Other|deep breathing|Deep breathing maneuver to increase parasympathetic nerve activity
75617745|NCT01103232|Procedure|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
75770804|NCT01180504|Radiation|intensity-modulated whole-abdominal radiotherapy|Consolidation intensity-modulated whole-abdominal radiotherapy using helical tomotherapy to a total dose of 30 Gy in 1.5 Gy fractions
75770805|NCT01290016|Behavioral|2 servings dairy + exercise|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
75770806|NCT01290016|Behavioral|4 servings dairy + exercise|Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.
75770807|NCT01290016|Behavioral|Control|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
75770808|NCT01287442|Procedure|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
75910445|NCT04045184|Other|Food assistance|This is an observational study of an existing community program. No intervention is provided beyond food assistance in the community program.
75910446|NCT04003896|Drug|Abemaciclib|"Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc."
75910447|NCT03996005|Procedure|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
75910448|NCT03952156|Genetic|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
75910449|NCT03952156|Genetic|HMI-102|"Control subjects will generally have the same assessments as treated subjects.~Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102."
76072629|NCT01814371|Other|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
75770809|NCT00148122|Drug|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
75910450|NCT03925675|Drug|PET/CT with F-Fluciclovine (Axumin)|Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
75910451|NCT03920293|Biological|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams [mg]/milliliter [mL]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
75910452|NCT03920293|Drug|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
75910453|NCT03912376|Diagnostic Test|Quest Hyperspectral Imaging System|In this camera 3 sensors are combined for optimal spectral imaging. For 2D reference, and to facilitate annotating the data, a high resolution (full HD) color image, recorded with an RGB-sensor, is included with each hyperspectral dataset.
75910454|NCT03910387|Drug|Gemcitabine|Given gemcitabine/nab-paclitaxel combination therapy
75910455|NCT03910387|Drug|Nab-paclitaxel|Given gemcitabine/nab-paclitaxel combination therapy
75910456|NCT03910387|Drug|Telotristat Ethyl|Given PO
75910457|NCT03882229|Device|MED-EL CI systems|• Cochlear Implant (CI) and external audio processor
75910458|NCT03871712|Behavioral|Motivational interview|The participants will be called twice with 2-4 weeks interval after the randomisation. This will be after 8 weeks of sick leave.
75910459|NCT03871712|Behavioral|Stratified vocational advice|The participants will be called after the randomisation. The amount of calls/meetings will be decided after each call, but with a maximum of 4 for the high risk group. This may include physical meetings.
75318403|NCT06067984|Device|Study App|An investigational prescription digital therapeutic in the form of a smartphone app.
75910460|NCT03851445|Drug|Screening Platform|The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
75910461|NCT03844815|Drug|Decitabine|"Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle"
75910462|NCT03844815|Drug|Venetoclax|Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
75910463|NCT03841669|Behavioral|Aerobic Exercise Group|Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
75910464|NCT03841669|Behavioral|Physical Activity & Health Information Group|This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits.
75910465|NCT03838445|Device|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
75910466|NCT03837899|Drug|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
75910467|NCT03820830|Drug|Palbociclib 125mg|Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
75910468|NCT03820830|Drug|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
75910469|NCT03791619|Device|Higher Cylinder Toric IOL|Symfony Toric models ZXT300 and ZXT375 IOL
75910470|NCT03791619|Device|Lower Cylinder Toric IOL|Symfony Toric model ZXT150 IOL
75318404|NCT06067971|Device|Laparoscopic surgery with augmented reality device|Gynecological laparoscopic surgery with augmented reality device.
75318405|NCT06067945|Other|microleakage|prevention of microleakage and secondary carries
75318406|NCT06067906|Other|Hypocaloric diet|Hypocaloric diet
75318407|NCT06067906|Other|Dissociated diet|Dissociated diet
75318408|NCT06067893|Drug|Dexmedetomidine|Patient receives dexmedetomidine for 48 hours post-operatively
75318409|NCT06067893|Drug|Normal Saline|Patient receives normal saline for 48 hours post-operatively
75318410|NCT06067880|Other|Cancer-related Unilateral|This group included patients who have used only contraction type LVs.
75318411|NCT06067880|Other|Normal + Ectasis LVs|This group included patients who had only non- contraction type LVs.
75318412|NCT06067867|Other|Data extraction from medical files|Data extraction from medical files
75318413|NCT06067854|Procedure|the standard procedure - without regional anaesthesia|the standard procedure - without regional anaesthesia
75464043|NCT00444093|Drug|Loperamid Treatment|"All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day."
75770810|NCT00148122|Drug|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
75770811|NCT03857308|Behavioral|Mindfulness Training|"This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
75770812|NCT03857308|Behavioral|Reappraisal Training|"This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
75770813|NCT01182142|Drug|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
75770814|NCT01180582|Device|Triathlon Periapatite (PA)-coated Tibial Component|Triathlon Periapatite (PA)-coated Total Knee Arthroplasty Tibial Component for uncemented fixation
75770815|NCT03858166|Drug|PEG-rhG-CSF|6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
75770816|NCT01180738|Behavioral|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
75770817|NCT01180738|Behavioral|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
75770818|NCT01587742|Drug|CCB use|Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
75770819|NCT01180816|Drug|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
75910471|NCT03791567|Biological|Donislecel (allogeneic islets of Langerhans for transplant)|Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).
75318414|NCT06067854|Procedure|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
75318415|NCT06067789|Procedure|neuraxial anesthesia|Intervention arm participants will be allocated to neuraxial anesthesia.
75770820|NCT01587664|Device|NewBreez ILP|NewBreez ILP implantation
75770821|NCT01287598|Drug|Regorafenib (Stivarga, BAY73-4506)|BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
75464044|NCT00316290|Behavioral|Integrated Parent Training|Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
75464045|NCT00316290|Behavioral|Behavioral Parent Training|Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
75464046|NCT00003042|Biological|filgrastim|
75464047|NCT00003042|Drug|cisplatin|
75910472|NCT03773393|Biological|CK0801|CK0801 (a Cord blood-derived T-regulatory cell product)
75910473|NCT03770572|Genetic|Low dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at low dose
75464048|NCT00003042|Drug|cyclophosphamide|
75910474|NCT03770572|Genetic|High dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at high dose
75318416|NCT06067776|Biological|Cetuximab|Given IV
75464049|NCT00003042|Drug|doxorubicin hydrochloride|
75318417|NCT06067776|Drug|Osimertinib|Given PO
75464050|NCT00003042|Drug|melphalan|
75910475|NCT03756792|Behavioral|Normal Education Material|Patients will receive standard educational material about Mohs micrographic surgery.
75910476|NCT03756792|Behavioral|Vignette|Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
75910477|NCT03696433|Dietary Supplement|Low-salt diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
75318418|NCT06067776|Drug|Tucatinib|Given PO
75318419|NCT06067750|Diagnostic Test|Narcotrend compared to Cerebral Function Analysing Monitor (CFAM)|All patients will receive Narcotrend and CFAM monitoring in this observational study
75464051|NCT00003042|Drug|mesna|
75464052|NCT00003042|Drug|paclitaxel|
75464053|NCT00003042|Drug|tamoxifen citrate|
75464054|NCT00003042|Procedure|bone marrow ablation with stem cell support|
75464055|NCT00003042|Procedure|conventional surgery|
75464056|NCT00003042|Procedure|peripheral blood stem cell transplantation|
75464057|NCT01873118|Other|RN-RHDS protocol|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
75318420|NCT06067724|Other|Pelvic and trunk control exercises|Patients in this group will be treated by the traditional physical therapy program in addition to a 18 sessions of pelvic control exercises for 40 min included pelvic tilting exercises and pelvic stabilization exercises from different positions. Pelvic tilting exercises included anterior, posterior and lateral pelvic tilting. Pelvic stabilization exercises include bridging, planking, clamshell and quadribed exercises. In addition to trunk control exercise which consist of lifting the pelvis with crock-lying, unilateral pelvic bridge, upper trunk flexion rotation, and lower trunk flexion rotation, flexion extension of the lower trunk, upper trunk lateral flexion, lower trunk lateral flexion, upper trunk rotation, lower trunk rotation, forward reach, and lateral reach.
75770822|NCT01287598|Drug|Warfarin|CYP 2C9 (warfarin) at Cycle 1
75770823|NCT01287598|Drug|Omeprazole|CYP 2C19 (omeprazole) at Cycle 1
75770824|NCT01287598|Drug|Midazolam|CYP 3A4 (midazolam) at Cycle 1
75464058|NCT01873118|Other|RN-RHDS+PT-RHDS protocol|The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
75910478|NCT03696433|Dietary Supplement|High-salt diet|The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
75770825|NCT01287598|Drug|Rosiglitazone|CYP2C8 (rosiglitazone) at Cycle 1
75770826|NCT03855514|Other|NuShield|NuShield® is a dehydrated placental allograft.
75770827|NCT01182532|Other|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
75770828|NCT01182532|Drug|TCM Syndrome Differentiation and Treatment|"Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction.~Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction."
75910479|NCT03672331|Other|Mammogram|Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
75910480|NCT03672331|Other|Ultrasound|As required according to the national/regional guidelines or personalised schedule according to risk assessment
75910481|NCT03672331|Other|MRI|As required according to the national/regional guidelines or personalised schedule according to risk assessment
75910482|NCT03672331|Other|Tomosynthesis|As required according to the national/regional guidelines or personalised schedule according to risk assessment
75910483|NCT03659565|Behavioral|Enhanced Pre-Visit Consultation|The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
75770829|NCT01182532|Other|Western therapy plus TCM treatment|"Symptomatic treatment using the same treatment methods in western therapy group;~Syndrome differentiation and treatment adopting the same methods in TCM treatment group."
75770830|NCT03862144|Drug|Netupitant/Palonosetron|
75910484|NCT03659565|Behavioral|Usual Care Control|Caregivers and patients will participate in usual pre-visit process.
75910485|NCT03546049|Procedure|US-guided percutaneous biliary drainage|"Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed).~Length: 6-10 cm. Diameter: 8-10 mm."
75910486|NCT03546049|Procedure|EUS-guided biliary drainage|"Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access.~Length: 6-10 cm. Diameter: 8-10 mm."
75910487|NCT03530189|Drug|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
76072630|NCT01814371|Behavioral|Hygiene Protocol|"Follow key hygiene tips:~Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~Use liquid(pour or pump) soaps instead of bar soaps.~Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~Do not share personal care items such as razors, brushes, or deodorant.~Wash all sheets and towels in hot water. Wash sheets every week.~Use towels and wash cloths only once before washing and do not share."
75464059|NCT01873118|Other|RN-RHDS + PT-RHDS + NIAF|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
75464060|NCT01873144|Drug|Epinephrine 1/1000|Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
75464061|NCT01873144|Drug|HSS 3%|Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
75464062|NCT01873144|Device|HHHFNC|Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age
75464063|NCT01873144|Drug|NS (0.9%)|Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
75617746|NCT01103232|Procedure|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
75910488|NCT03530189|Drug|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
75910489|NCT03485391|Behavioral|Prolonged Exposure|Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
75770831|NCT03857152|Diagnostic Test|Contrast enhanced spectral mammography (CESM)|"Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice.~CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram.~The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging)."
75910490|NCT03438747|Device|P-15L Bone Graft|The investigational group will be treated with P-15L in an instrumented TLIF
75910491|NCT03438747|Other|Local autologous bone in a TLIF with Instrumentation|The active control group will be treated local autologous bone in an instrumented TLIF
75318421|NCT06067685|Other|Observation|Prospective Observation only. Will record serum triglyceride, fingerstick blood triglyceride measurements, cord c-peptide, and neonatal body fat composition measurements in the first 6 months.
75617747|NCT02627287|Device|FlexPen®|For subcutaneously (s.c. under the skin) injection.
75910492|NCT03434769|Drug|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
75770832|NCT01290172|Drug|Administration of Somatostatin|"6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days."
75910493|NCT03434769|Drug|Fludarabine|Fludarabine 25mg/m^2 IV on days -5 to -3
75910494|NCT03434769|Biological|CAR-T Cells|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 [Starting dose] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
75910495|NCT03425500|Procedure|Bridging Rotator Cuff Reconstruction|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft
75910496|NCT03425500|Procedure|Superior Capsular Reconstruction|Superior Capsular Reconstruction of massive rotator cuff tear
75910497|NCT03425500|Device|GRAFTJACKET™ allograft|The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
75910498|NCT03404492|Other|Stress echocardiography|A stress echocardiography will be performed in addition to the traditional patient care
75910499|NCT03398070|Other|Standard of Care|"The standard of care interventions for Functional Neurological Disorders (FND) include:~delivery of a rule-in diagnosis~providing educational materials~referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~referring to FND-related cognitive behavioral therapy (CBT)~psychotropic medication management based on standard psychiatric care"
75910500|NCT03331198|Biological|JCAR017 (lisocabtagene maraleucel)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
75910501|NCT03331198|Biological|JCAR017 (lisocabtagene maraleucel) + ibrutinib|Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
75318422|NCT06067672|Other|Observations to investigate the current practices of communication and decision-making during Nurse-patient consultations|No intervention
75617748|NCT02627287|Device|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
75318423|NCT06067646|Behavioral|Semistructured interview|Semistructured interview and validated quality of life assesment using EQ5-DL
75318424|NCT06067633|Other|Triple-Masked|Eligible manuscripts in the triple-masked editorial process arm will be masked electronically before being entered in the trial by the editorial assistant
75318425|NCT06067633|Other|Usual Procedures|Articles will be processed by the editors with identifiable/unmasking content of cover page and letters.
75617749|NCT02627287|Drug|placebo|For subcutaneously (s.c. under the skin) injection
75770833|NCT01290172|Drug|Administration of placebo|"The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy."
75770834|NCT03861598|Drug|Carvedilol|Carvedilol orally starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
75318426|NCT06067620|Procedure|Robotic right hemicolectomy|Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section, using the Da Vinci Xi.
75318427|NCT06067620|Procedure|Laparoscopic right hemicolectomy|Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline.
75318428|NCT06067607|Other|eye gaze technology|eye gaze technology and software activities
75318429|NCT06067581|Biological|SENL103|Patients will be treated with BCMA CAR-T cells
75910502|NCT03331198|Biological|JCAR017 (lisocabtagene maraleucel) + venetoclax|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
75770835|NCT01184482|Drug|cetuximab and lapatinib|"Cetuximab: 400 mg/m2 on Day 1 then 250 mg/m2 weekly~Lapatinib: Start once daily on Day 1. Dose escalating cohorts:~750 mg (3 tabs)~1000 mg (4 tabs)~1250 mg (5 tabs)"
75464064|NCT01873157|Drug|Bortezomib|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
75770836|NCT03855124|Device|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle actitity, reduce musculoskeletal pain and discomfort.
75910503|NCT03326310|Drug|Azacitidine|"Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression"
75617750|NCT02853669|Procedure|Ultrasound-guided Lumber Plexus Block|(30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
75617751|NCT02853669|Procedure|adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
76072631|NCT05124652|Device|Auto Adjusting Prosthesis|Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
75318430|NCT06067529|Drug|hormone replacement therapy|hormone replacement therapy
75318431|NCT06067490|Drug|RC1416(SAD)|RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
75318432|NCT06067490|Drug|Placebo(SAD)|Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.
75318433|NCT06067477|Dietary Supplement|Vitamin D Supplement|Vitamin D Supplement
75318434|NCT06065800|Device|STEELEX® Sternum Set|Sternal Closure with stainless steel suture (STEELEX®) in patients undergoing cardiac surgery
75318435|NCT06065215|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that uses powerful magnets and radio waves to generate detailed images of the body's internal structures. The MRI intervention includes using a specialized MRI machine and lung imaging protocol.
75617752|NCT00673699|Procedure|Gastric mucosal biopsy|Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
75770837|NCT01184560|Drug|Sibutramine|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
75318436|NCT06065215|Diagnostic Test|Echocardiogram|"An echocardiogram, often called an echo, is a non-invasive medical test that uses high-frequency sound waves (ultrasound) to create real-time images of the heart's structure and function. It provides valuable information about the heart's size, shape, and function."
75464065|NCT01873157|Drug|Placebo|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
75617753|NCT01112982|Other|Magnetic Resonance Imaging|An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
75318437|NCT06065215|Diagnostic Test|Lung ultrasound|Lung ultrasound is a non-invasive imaging technique that employs high-frequency sound waves (ultrasound) to visualize the structures and conditions of the lungs. It is particularly valuable for diagnosing and monitoring lung-related conditions, such as pneumonia, pleural effusions, and pulmonary edema. The lung ultrasound intervention involves using an ultrasound machine equipped with a specialized probe gently placed on the chest to capture detailed images of the lungs and adjacent structures.
75770838|NCT01184560|Drug|Orlistat|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
75770839|NCT03861832|Dietary Supplement|KB220Z|Acts to enhance dopamine
75770840|NCT03861832|Dietary Supplement|Placebo|A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
75770841|NCT01290250|Other|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
75770842|NCT03861520|Device|Midtrimester anomaly scan|A detailed anomaly scan to detect soft markers at 16 to 24 weeks pregnancy
75464066|NCT01873183|Other|Goal directed fluid therapy|
75464067|NCT01873196|Behavioral|Receive extra oil|
75318438|NCT06065163|Other|Diuretic de/escalation based on ultrasound findings (VExUS Score)|Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)
75318439|NCT06065163|Other|Diuretic de/escalation based on clinical findings (CCS Score)|Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)
75770843|NCT03861520|Genetic|Fetal Karyotyping|Fetal karyotyping after birth to confirm chromosomal anomaly diagnosed clinically
75770844|NCT01184638|Drug|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
75770845|NCT01184638|Drug|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
75770846|NCT01290328|Drug|Epoetin Alfa|150 units/kg/weekly
75770847|NCT01184716|Other|Vitamin D fortification|Bread and milk fortified with vitamin D3
75318440|NCT06064643|Other|Online Survey|All participants will be asked to complete an online survey
75318441|NCT06064643|Other|Qualitative Interview|30 survey participants will take part in a single one-hour qualitative interview.
75770848|NCT01184794|Drug|levobupivacaine|40 ml over 48 hours
75770849|NCT01587508|Drug|meloxicam/cyclobenzaprine hydrochloride|two oral capsules a day during approximately 07 days
75770850|NCT01587508|Drug|meloxicam - Movatec®|two oral tablet a day during approximately 07 days
75770851|NCT01587508|Drug|cyclobenzaprine - Miosan®|two oral tablet a day during approximately 07 days
75770852|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 6 weeks
75770853|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 15 mg BID for 6 weeks
75770854|NCT00147498|Drug|CP-690,550|30 mg BID for 6 weeks
75770855|NCT00147498|Other|Placebo|Placebo tablets
75770856|NCT05267704|Device|Samsung Gear Virtual Reality Headset|VR headset displaying preselected game during renal biopsy
75770857|NCT02974036|Other|Patient education for osteoarthritis|Group sessions and optional supervised exercise.
76072632|NCT03232138|Dietary Supplement|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
75318442|NCT06064643|Other|Bleed Diary|50 participants will complete a 30 day bleed diary
75318443|NCT06064058|Dietary Supplement|Ghazwan program|6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction.
75318444|NCT06064058|Drug|Standard management|Standard care with NSAIDs and acetaminophen for pain management
75318445|NCT06063382|Behavioral|Exam|Academic exam based on the Brazilian National High School Exam (ENEM).
75464068|NCT01873196|Behavioral|Receives behavior changed messages on CSB package|
75464069|NCT01873222|Device|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI~Assessment by OFDI at a 8-month follow-up"
75464070|NCT01873222|Device|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI~Assessment by OFDI at a 8-month follow-up"
75464071|NCT01873248|Drug|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
75464072|NCT01873274|Dietary Supplement|MK-7 containing capsule|
75464073|NCT01873274|Dietary Supplement|basic yogurt enriched with MK-7|
75464074|NCT01873274|Dietary Supplement|nutrient-enriched yogurt with MK-7|
75464075|NCT01873300|Procedure|Endoscopic Esophageal Myotomy|Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
75464076|NCT01873313|Drug|Ropivacaine|
75770858|NCT03856762|Dietary Supplement|traditional Jiangnan diet|traditional Jiangnan diet supplement from Monday to Friday for six months
75770859|NCT03856762|Dietary Supplement|Mediterranean diet|Mediterranean diet supplement from Monday to Friday for six months
75770860|NCT03856762|Dietary Supplement|Current Shanghai diet|current Shanghai diet supplement from Monday to Friday for six months
75770861|NCT01176760|Drug|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
75770862|NCT01176760|Other|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
75770863|NCT01080066|Other|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
75770864|NCT01185184|Drug|CP-690,550|Single doses separated by a minimum of 72 hour washout between treatments
75770865|NCT01077882|Behavioral|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
75770866|NCT01077882|Behavioral|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
75770867|NCT01077882|Behavioral|Lifestyle factors and psycho-education|by dietician and psychiatrist
75770868|NCT01077882|Other|no educational program|standard care without educational program
76072633|NCT03232138|Drug|Placebo|Inactive ingredients
75464077|NCT01873339|Drug|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
75770869|NCT03856606|Behavioral|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
75770870|NCT03856606|Behavioral|Prolonged sitting with interval exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
75770871|NCT04988464|Behavioral|Sleep Scholar|A single-session, internet-based insomnia intervention for college students
75770872|NCT04988464|Behavioral|Building Healthy Habits|A single-session, self-guided, internet-based intervention focused on healthy eating and exercise
75770873|NCT03861754|Behavioral|Lifestyle modification|
75617754|NCT01112982|Drug|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is > 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
75617755|NCT01112982|Drug|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
75770874|NCT00113568|Drug|Tranexamic acid tablets (XP12B)|Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
75770875|NCT05266768|Drug|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
75770876|NCT03856372|Radiation|Hypofractionated|daily fractions, five fractions per week.
75910504|NCT03326310|Drug|Selumetinib|"Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression."
75910505|NCT03317496|Drug|Avelumab 800 mg in combination with pemetrexed / carboplatin|Avelumab Pemetrexed Carboplatin
75464078|NCT01873339|Drug|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
75770877|NCT03856372|Radiation|Conventional|daily fractions, five fractions per week.
75617756|NCT01203878|Drug|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
75770878|NCT01185262|Drug|Lenalidomida and Rituximab|"Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.~Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).~In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.~If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).~In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1."
75770879|NCT03855358|Drug|TQB2450 Injection and Anlotinib Hydrochioride Capsules|TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
75464079|NCT01873352|Procedure|catheter ablation|Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.
75770880|NCT01291030|Dietary Supplement|magnesium supplementation|The supplementation starts with 450 mg of magnesium oxide daily, up to a maximum of 3 times 450 mg daily, while aiming at a serum magnesium level of > 1,9 mg/dl.
75617757|NCT01203878|Drug|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
75617758|NCT02853825|Behavioral|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
75617759|NCT00676819|Drug|insulin aspart|
75910506|NCT03317496|Drug|Avelumab 800 mg in combination with gemcitabine / cisplatin.|Avelumab Gemcitabine Cisplatin
75910507|NCT03317496|Drug|Avelumab 1200 mg in combination with pemetrexed/carboplatin|Avelumab Pemetrexed Carboplatin
75617760|NCT00676819|Drug|human insulin|
75910508|NCT03317496|Drug|Avelumab 1200 mg in combination with gemcitabine/cisplatin|Avelumab Gemcitabine Cisplatin
75910509|NCT03314688|Behavioral|Dietary/Physical Activity intervention|Motivational counseling to follow established dietary and exercise guidelines.
75910510|NCT03314688|Behavioral|Usual Care|Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
75910511|NCT03308474|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
75617761|NCT02851953|Device|Aqueduct-100|
75617762|NCT04151797|Other|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~Data collection on comorbidities, medication and laboratory results.~A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~A detailed feedback to the geriatrician.~A written report addressed to the attending physician"
75770881|NCT00113490|Biological|motavizumab (MEDI-524)|Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
75910512|NCT03301506|Drug|Seladelpar 5 mg Capsule|Subjects will be assigned to a treatment group if tolerability issues noted in the previous study.
75617763|NCT01112514|Drug|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
75770882|NCT00113490|Biological|palivizumab 15 mg/kg|Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
75770883|NCT01182922|Behavioral|Invitation letter|Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
75770884|NCT02524522|Device|INTELLiVENT-ASV mode|Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
75770885|NCT02524522|Device|SIMV mode|Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
75617764|NCT02629003|Drug|[11C]Cimbi-36|
75617765|NCT02629003|Drug|[11C]Cimbi-36-5|
75617766|NCT00625794|Drug|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
75770886|NCT01326624|Device|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
75770887|NCT01176994|Device|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
75770888|NCT00146640|Drug|MR Prednisone|Participants will receive tablets containing MR prednisone (to achieve the appropriate dose of 3-10 milligrams [mg] prednisone per day) at bed time.
75617767|NCT00625794|Behavioral|Smoking cessation counseling|8 weeks or counseling
75617768|NCT02853981|Device|Harmonic scalpel|a method for liver parenchymal transection
75770889|NCT00146640|Drug|IR Prednisone|Participants will receive tablets containing IR prednisone (to achieve the appropriate dose of 3-10 mg prednisone per day) in the morning.
75617769|NCT02853981|Device|Kelly clamp crush technique|a method for liver parenchymal transection
75770890|NCT00146640|Drug|Placebo - MR Prednisone|Participants will receive placebo matching to MR prednisone tablet at bed time.
75770891|NCT00146640|Drug|Placebo - IR Prednisone|Participants will receive placebo matching to IR prednisone tablet in the morning.
75770892|NCT01183000|Procedure|Closure of the peritoneum at cs|Injection of 5 mg Marcaine (anesthetic solution) to the leg
75770893|NCT01185418|Drug|risperidone|
75770894|NCT01185418|Drug|aripiprazole|
75770895|NCT01185418|Drug|haloperidol|
75770896|NCT01185418|Drug|amisulpride|
75770897|NCT01185418|Drug|lactose|
75910513|NCT03301506|Drug|Seladelpar 10 mg Capsule|Subjects will be assigned to a treatment group unless there are tolerability issues.
75910514|NCT03242174|Other|Health Behavior Questionnaire Packet|Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
75910515|NCT03236441|Device|RIPC|Remote ischemic preconditioning
75910516|NCT03236441|Device|Sham-RIPC|Control
75617770|NCT00911911|Procedure|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
75617771|NCT00911911|Procedure|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
75617772|NCT00911911|Procedure|SURGERY|Surgery after neoadjuvant chemotherapy
75617773|NCT01203098|Drug|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
75617774|NCT01203098|Drug|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
75617775|NCT01203098|Drug|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
75617776|NCT05032794|Other|Unrestricted diet before colonoscopy|Free diet, without restrictions
75770898|NCT03856450|Device|DTS|Subjects undergo wrist imaging using DTS.
75770899|NCT03856450|Device|X-ray|Subjects undergo wrist imaging using standard X-ray imaging.
75770900|NCT03856450|Device|MRI or CT|Subjects may undergo wrist imaging using MRI or CT.
75770901|NCT01183156|Behavioral|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
75770902|NCT01183156|Behavioral|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
75770903|NCT01185574|Dietary Supplement|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
75770904|NCT03861364|Drug|Propofol|2,4 mg/kg
75770905|NCT03861364|Drug|Propofol|1,4 mg/kg
75770906|NCT01177072|Other|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
75770907|NCT01177072|Other|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
75770908|NCT01177150|Drug|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
75770909|NCT01177150|Drug|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
75770910|NCT05250466|Procedure|Radiofrequency technology|The vulva and vagina were routinely disinfected with iodophor, the negative plate was placed on the patient's waist and abdomen, and the vulva module was selected for treatment for 10 minutes per side, for a total of 20 minutes. Parameters: power 10-20W, temperature 38-42C°, once every 10 days, 5 times in total
75770911|NCT05250466|Procedure|Electrical stimulation|Routine vulvovaginal disinfection with iodophor, vaginal probes are placed in channel A, electrode pads are placed in channels B\C\D respectively, the frequency of electrical stimulation (the most comfortable amount) is adjusted, 10 times is a course of treatment, and mild lesions are treated for 1-2 courses of treatment , 2 to 3 courses of treatment for moderate to severe lesions.
75770912|NCT01185730|Procedure|Right Heart Catheterization|all patients of the all centers will have Right Heart Catheterization at the diagnosis
75770913|NCT03855202|Biological|CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
75770914|NCT03855202|Biological|PS+CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
75770915|NCT03855202|Biological|PS|PS,dose is 70mg/kg
75770916|NCT03855202|Other|Placeo|0.9% sodium chloride installation after 24 hours
75770917|NCT01185808|Biological|Vitamin D|Vitamin D 5000IU/day for 6 weeks
75770918|NCT01183624|Other|Herbal Patch|1 herbal patch applied for approximately 8 hours per day for 14 days
75910517|NCT03228667|Drug|N-803 + Pembrolizumab|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
75910518|NCT03228667|Drug|N-803 + Nivolumab|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
75910519|NCT03228667|Drug|N-803 + Atezolizumab|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
75910520|NCT03228667|Drug|N-803 + Avelumab|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
75910521|NCT03228667|Drug|N-803 + Durvalumab|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
75910522|NCT03228667|Drug|N-803 + Pembrolizumab + PD-L1 t-haNK|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
75910523|NCT03228667|Drug|N-803 + Nivolumab + PD-L1 t-haNK|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
75617777|NCT05032794|Other|1-day low residue diet|To follow a diet low in residues / fiber. the day before the colonoscopy.
75617778|NCT05032794|Drug|Bisacodyl 5 MG|If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
75617779|NCT00676975|Drug|Traditional Chinese Medicine|"A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale"
75617780|NCT00676975|Drug|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
75617781|NCT00945555|Drug|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
75617782|NCT04318184|Procedure|Aerobic exercise|The aerobic exercise protocol was performed 3 times a week for 3 months on the treadmill. Loading periods were performed according to the heart rate maximum using the Karvonen formula (%60-80 Heart rate maximum)
75617783|NCT00673777|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
75770919|NCT01183624|Other|Placebo Patch|Control patch with no herbal ingredients
75770920|NCT01291186|Drug|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
75770921|NCT01291186|Drug|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
75770922|NCT01291186|Drug|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
75770923|NCT01291186|Drug|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
75770924|NCT01291186|Drug|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
75770925|NCT01291186|Drug|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
75770926|NCT01291186|Drug|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
75770927|NCT01291186|Drug|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
75770928|NCT01291186|Drug|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
75770929|NCT01291186|Drug|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
75770930|NCT01291186|Drug|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
75910524|NCT03228667|Drug|N-803 + Atezolizumab + PD-L1 t-haNK|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
75910525|NCT03228667|Drug|N-803 + Avelumab + PD-L1 t-haNK|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
75910526|NCT03228667|Drug|N-803 + Durvalumab + PD-L1 t-haNK|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
75617784|NCT01108458|Drug|Pertuzumab|iv, 840 mg, 420 mg
75910527|NCT03212404|Drug|CK-301 (cosibelimab)|CK-301 will be administered in periods of 28-day cycles.
75464080|NCT01873352|Procedure|renal sympathetic denervation|Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
75464081|NCT01873365|Other|Data collection|Case report forms (CRFs), logbooks and booklets.
75464082|NCT01873378|Drug|Triptorelin 3.75 mg|
75464083|NCT01873391|Procedure|Diagnostic hysteroscopy|
75464084|NCT01873430|Drug|Melatonin|
75464085|NCT01873443|Drug|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10~25mg/week Folic acid at least 5mg/week
75617785|NCT01108458|Drug|Erlotinib|PO, 150 mg
75770931|NCT01291186|Drug|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
75910528|NCT03206736|Other|Loop DS surgery|these patients will receive a loop DS bariatric procedure
75910529|NCT03181048|Procedure|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
75910530|NCT03181048|Procedure|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
75910531|NCT03127215|Drug|Olaparib|Olaparib 150 mg tablet
75464086|NCT01873469|Radiation|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
75617786|NCT00633646|Dietary Supplement|diets contained different levels of protein|diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
75617787|NCT04318262|Biological|Determination of the clinical and biological characteristics|"clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis…), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications…~biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP…"
75910532|NCT03127215|Drug|Physician's choice|treatment according to current guidelines
75464087|NCT01873482|Behavioral|Movement to rhythm|Movement to rhythm
75464088|NCT01873508|Drug|RO4917523|Fast release MR capsule, single dose
75464089|NCT01873508|Drug|RO4917523|Target release MR capsule, single dose
75464090|NCT01873508|Drug|RO4917523|Slow release MR capsule, single dose
75617788|NCT04318262|Biological|Description of the antibiotic resistance profile|Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique
75617789|NCT04318262|Biological|Molecular epidemiology of S. lugdunensis infections|Genome sequencing (Illumina technique)
75617790|NCT00680485|Drug|GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)|
75617791|NCT02851641|Procedure|"pushed mono-canaliculonasal intubation"|
75464091|NCT01873508|Drug|RO4917523|[13C]-labeled tracer dose i.v.
75464092|NCT01873521|Procedure|Non invasive ventilation|
75464093|NCT01873547|Biological|cell therapy|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
75464094|NCT01873547|Other|rehabilitation|Patients only receive rehabilitation of limb function.
75464095|NCT01873573|Procedure|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
75770932|NCT04979338|Other|Ultrasound guided Continuous Infraclavicular Brachial Plexus Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op [administered by anesthesiologist]
75770933|NCT04979338|Other|Ultrasound guided Continuous Femoral Nerve Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op [administered by anesthesiologist]
75770934|NCT04979338|Other|Ultrasound guided Pudendal Nerve Block|20-40cc of 0.25% bupivacaine + 1:200K epinephrine [administered by anesthesiologist, pre-incision]
75770935|NCT04979338|Drug|Bupivacaine|0.25% or 0.5% with or without 1:200K epinephrine
75770936|NCT04979338|Other|Bilateral ultrasound guided Transversus Abdominis Plane Block|40-60cc of 0.25% bupivacaine + 1:200K epinephrine [administered by anesthesiologist post-op or at end of surgery]
75770937|NCT04979338|Other|Bilateral spermatic cord block|10cc per spermatic cord of 0.5% bupivacaine [administered by surgeon @ intraop]
75770938|NCT04979338|Other|Pecs I & II Block|0.25% bupivacaine: 15-30mL per side for Pecs I-III
75770939|NCT04979338|Other|Local anesthetic|0.25% or 0.5% bupivacaine into the appropriate surgical site
75770940|NCT01177306|Drug|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
75770941|NCT03856294|Drug|Rikkunshito|Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
75770942|NCT03856294|Drug|Placebos|Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
75910533|NCT03127215|Drug|Trabectedin|Trabectedin 1.1mg/m² infusional solution
75910534|NCT03125811|Other|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
75464096|NCT01873573|Other|Triamcinolone Injection|Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
75464097|NCT01873573|Procedure|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
75464098|NCT01873599|Behavioral|Positive Affect Journaling|
75770943|NCT01183702|Procedure|LASIK surgery|Participants have received LASIK surgery and their eyes are healthy.
75770944|NCT01183702|Other|No Intervention|Participant has healthy eyes not altered by LASIK surgery.
75770945|NCT03854968|Other|Quality control|The performance of the home mechanical ventilator of all patients in the study will be evaluated with a portable device
75770946|NCT01185886|Genetic|gene expression analysis|
75770947|NCT01185886|Genetic|mutation analysis|
75770948|NCT01185886|Genetic|polymorphism analysis|
75770949|NCT01185886|Other|biologic sample preservation procedure|
75770950|NCT01185886|Other|laboratory biomarker analysis|
75770951|NCT01185886|Other|pharmacogenomic studies|
75770952|NCT01290406|Drug|BEZ235|
75770953|NCT03854890|Drug|Indocyanine Green|Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
75770954|NCT03854812|Drug|Magnesium Sulphate|a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
75770955|NCT03854812|Drug|Fentanyl|loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
75770956|NCT03854812|Drug|Propofol|0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
75770957|NCT03860896|Drug|GB004|GB0004 high dose
75770958|NCT03860896|Drug|Placebo|Placebo
75770959|NCT03860896|Drug|GB004|GB004 low dose
75770960|NCT01183936|Procedure|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
75770961|NCT01183936|Procedure|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
75770962|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
75770963|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
75770964|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
75770965|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
75910535|NCT03125811|Drug|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
75910536|NCT03087396|Device|Treatment of insufficiency fractures|Filling of micro fractures or insufficiency fractures with a bone substitute material
75464099|NCT01873612|Procedure|Hypoxic ventilatory response|
75464100|NCT01873612|Procedure|Hypercapnic ventilatory response|
75464101|NCT01873625|Biological|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
75770966|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
75770967|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
75770968|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
75770969|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
75770970|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
75770971|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
75770972|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
75770973|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
75770974|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
75770975|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
75464102|NCT01873625|Biological|placebo|
75770976|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
75910537|NCT03085524|Diagnostic Test|Platelet function testing|The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
75910538|NCT03085524|Diagnostic Test|Vascular ultrasonography|The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
76072634|NCT02131402|Device|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
75318446|NCT06062394|Behavioral|Penn Med Healthy Heart Program|Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
75318447|NCT06062225|Procedure|Kamikawa|Kamikawa reconstruction after proximal gastrectomy
75464103|NCT01873638|Procedure|Cholecystectomy|
75464104|NCT01873651|Device|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
75318448|NCT06062225|Procedure|STJI|Single-Tract Jejunal Interposition(STJI) reconstruction after proximal gastrectomy
75318449|NCT06062225|Procedure|SOFY|SOFY reconstruction after proximal gastrectomy
75770977|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
75318450|NCT06058338|Behavioral|Produce Prescription|Produce prescriptions mitigate health and food access inequities by partnering with healthcare providers to prescribe fruits and vegetables via financial incentives to patients experiencing food insecurity, low income, and/or chronic disease(s) risk.
75464105|NCT01873664|Behavioral|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
75464106|NCT01873690|Drug|Ciprofloxacin|Once, 400 mg IV
75464107|NCT01873690|Drug|Placebo|5% Dextrose in water
75464108|NCT01873716|Drug|Indocyanine green|Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
75464109|NCT01873768|Drug|Tranexamic Acid (TXA)|1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
75318451|NCT06055491|Drug|Vitamin D3 or Saline injection at ipsilateral deltoid muscle|study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection
75318452|NCT06054503|Device|prototype of sensor|The investigational device is composed of a sensor placed on the respiratory line of the ventilated patients and connected to a ventilation measure unit which records the ventilation parameters
75617792|NCT04242316|Behavioral|Mirror Therapy|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.
75770978|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
76072635|NCT02131402|Device|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
75464110|NCT01873768|Drug|ε-Aminocaproic Acid (EACA)|7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
75464111|NCT01873781|Drug|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
75770979|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
75770980|NCT01186120|Device|Biolimus A9-eluting stent|drug-eluting stent
75464112|NCT01873794|Device|Bright white light|
75464113|NCT01873794|Device|Dim red light|
75770981|NCT01186120|Device|Everolimus-eluting stent|drug-eluting stent
75770982|NCT01184170|Behavioral|overfeeding|Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
75770983|NCT01287910|Other|Cardiac MRI|Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
75464114|NCT01873807|Drug|IDA|Idarubicin: 15mg/m2/d: -8->-6d
75464115|NCT01873807|Radiation|TBI|TBI: 4.5 Gy/d, -5d, -4d
75464116|NCT01873807|Drug|CTX|CY:60mg/kg/d, -3d, -2d
75464117|NCT01873807|Drug|VP-16|VP-16: 15mg/kg, -2d, -1d
75464118|NCT01873820|Dietary Supplement|Calcium ascorbate|
75464119|NCT01873820|Dietary Supplement|Ascorbic acid|
75464120|NCT01873872|Dietary Supplement|Theralac probiotic|
75464121|NCT01873872|Dietary Supplement|Culturelle probiotic|
75464122|NCT01873872|Other|placebo|
75464123|NCT01873885|Drug|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
75318453|NCT06053255|Device|High-intensity focused ultrasound for Sacroiliitis using the Neurolyser XR|HIFU is delivered via a non-invasive ultrasonic transducer, through a gel pad for acoustic coupling, into the patients body in a precise manner focused on the lateral sacral branch nerves.
75318454|NCT06052449|Behavioral|Social determinants of health screening assessment and referral process|Unite Us is an electronic SDoH screening and referral tool assessing: (1) financial resource strain; (2) housing stability; (3) transportation needs; and (4) food insecurity. Upon completion, the Unite Us platform identifies a list of geographically-tailored resources to connect the individual in need. A staff member will administer the SDoH screening and referral tool, review the results with the participant, and use the geographically-tailored resources to make SDoH-related referrals.
75617793|NCT04242316|Behavioral|Bilateral arm training|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
75617794|NCT00680563|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
75464124|NCT01873885|Drug|Experimental: Single IV Infusion Vasomera (PB1046)|
75464125|NCT01873898|Device|Rex Medical Closer™ Vascular Closure System|The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
75464126|NCT01873937|Radiation|Red LED|Phototherapy with red LED on temporomandibular area
75617795|NCT02887508|Behavioral|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
75617796|NCT02887508|Behavioral|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
75617797|NCT02851719|Other|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
75617798|NCT02851719|Other|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
75617799|NCT01108068|Drug|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
75617800|NCT02851875|Other|Registry|
75617801|NCT00680641|Drug|Simvastatin|40mg of Simvastatin once daily
75617802|NCT00680641|Drug|Placebo|40mg of placebo once daily
75617803|NCT01201850|Drug|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
75617804|NCT05660122|Drug|Fexuprazan Hydrochloride|Fexuclue Tablet 40mg
75617805|NCT04980144|Drug|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
75617806|NCT04980144|Drug|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
75617807|NCT00951171|Procedure|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
75617808|NCT00951171|Procedure|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
75617809|NCT00677131|Other|Reading the package insert of the drug|package insert of the drug
75617810|NCT00677131|Other|Reading the education information provided by the Pharmacy of NTUH|education information
75617811|NCT00677131|Other|Oral education provided by the pharmacist|Oral education provided by the pharmacist
75617812|NCT02825056|Drug|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
75617813|NCT02825056|Drug|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
75617814|NCT02628691|Other|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
75617815|NCT02826772|Drug|GT0918|anti-tumor activity
75617816|NCT00677209|Biological|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
75617817|NCT02824744|Device|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)|
75617818|NCT02824744|Device|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)|
75617819|NCT00674011|Drug|Bevacizumab|Given as part of standard of care or another research protocol
75617820|NCT02824900|Device|Vibration stimuli to neck muscles|
75617821|NCT02824900|Device|Vibration stimuli to hand|
75617822|NCT02824900|Behavioral|conventional physiotherapy|
75617823|NCT00674089|Dietary Supplement|Vitamin A|Vitamin A 50,000 IU
75617824|NCT00674089|Dietary Supplement|Placebo|Vitamin A Placebo
75617825|NCT01200992|Biological|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
75617826|NCT01200992|Biological|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
75910539|NCT03081195|Behavioral|MFG|The MFG is a series of weekly meetings guided by a protocol.Over the course of 16 weeks, groups are held weekly and are facilitated by trained and supervised group leaders (in this case either parent peers or community health outreach workers). Groups can consist of up to 20 families involving adult caregivers and all children over six years of age in the family. The protocols have been designed to provide opportunities during each session to directly apply content to the realities of family life, emergent cultural and values perspectives, as well as tailor messages to age of child. Redundancy for missed appointments and opportunities for reinforcement is built in. We aim for families to attend at least 8 meetings or more (out of 16 sessions in total), as findings suggests this dose is needed to reduce child conduct problems and the majority of families reach this goal.
75770984|NCT05666674|Other|TSA algorithms|Our study will be composed of an experimental and an active comparator (i.e., control) arm. Both arms will perform a postural tremor test (PTT) to elicit parkinsonian tremors. The PTT is where subjects stabilize their backs against a wall and position their hands in the air against gravity for two minutes. The experimental arm will receive VR plus activated Tremor Stabilization Algorithms (TSA-ON) while the active comparator arm will receive VR only (TSA-OFF). Thus, subjects in the experimental arm will not see their digital arms tremor while those in the active comparator arm will. Our primary outcome is the severity of PTT elicited tremors. Tremors will be recorded by VR motion-capture controllers.
75318455|NCT06052449|Behavioral|Current practice - Community-based lunch cancer screening (LungTalk)|The current practice during community events is to offer LungTalk. LungTalk is a novel theoretically grounded health educational tool that will be delivered via iPad and is an interactive computer-based program that includes audio, video and animation segments with scripts presented from a master content library in consideration of different ways people like to learn. Informed by our prior research, LungTalk tailors its content based on smoking status and perceived barriers. In prior work, LungTalk more than doubled LCS knowledge and health beliefs (p < 0.01), and was associated with a significant increase in deciding to screen for lung cancer compared to control group; OR 1.99; 95% Confidence Interval (CI), 1.03, 3.85, p = 0.03.
75318456|NCT06040281|Behavioral|intensive individual support in nutrition and exercise|"Intensive care for nutrition and exercise adapted to the social context. Individualised exercise and nutrition recommendations.~three weeks of inpatient rehabilitation with an individual plan of treatment, which includes medical care, sports therapy, physiotherapy, ergotherapy, nutritional education and psychological care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)"
75770985|NCT03860506|Drug|PSI-697|
75464127|NCT01873937|Radiation|INFRARED LED|Phototherapy with infrared LED on temporomandibular area
75464128|NCT01873937|Radiation|LASER|Phototherapy with LASER INFRARED on temporomandibular area
75770986|NCT03860506|Drug|Placebo|
75910540|NCT02962401|Drug|Obinutuzumab|"6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1"
75910541|NCT02962401|Drug|Idelalisib|"6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
75910542|NCT02920996|Drug|Merestinib|Oral, predetermined dosage per protocol, once daily per 28 day treatment cycle
75910543|NCT02898181|Device|Neuromodulation|Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation Parasym neuromodulation system with electrodes attached to the ear. Neuromodulation will be applied continuously for 2 hours daily.
75464129|NCT01874002|Device|Combo stent|Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
75464130|NCT01874015|Biological|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
75464131|NCT01874015|Biological|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
75464132|NCT01874028|Drug|trientine dihydrochloride|Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
75770987|NCT01186354|Behavioral|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
75770988|NCT01290562|Radiation|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
75770989|NCT01186432|Drug|PDS 1.0|
75770990|NCT03855826|Drug|Nifekalant hydrochloride|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
75910544|NCT02880319|Drug|Stereotactic Body Radiation Therapy (SBRT)|
75910545|NCT02880319|Device|Stereotactic Linear Accelerator|
75910546|NCT02836249|Drug|TAF|TAF 25 mg tablet administered orally once daily
75910547|NCT02836249|Drug|TDF|TDF 300 mg tablet administered orally once daily
75910548|NCT02836249|Drug|TAF Placebo|TAF placebo tablet administered orally once daily
75910549|NCT02836249|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
75464133|NCT01874041|Other|Massage|
75464134|NCT01874041|Other|Occlusal splint|
75464135|NCT01874080|Drug|Saxagliptin/Metformin|
75770991|NCT03855826|Drug|Amiodarone|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
75770992|NCT01184248|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
75770993|NCT01588288|Procedure|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
75910550|NCT02827344|Biological|blood sample collection for CTC and MDSC analysis|"Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
75770994|NCT02355418|Procedure|Mitral valve repair|Standard mitral valve repair surgery
75770995|NCT01186510|Procedure|lung perfusion|see literature of proceeding
75770996|NCT01186510|Procedure|no lung perfusion|see literature of proceeding
75770997|NCT01287988|Drug|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
75617827|NCT02824666|Drug|ATI-9242|"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
75770998|NCT01287988|Drug|placebo|Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
75318457|NCT06040281|Behavioral|Usual Care|Usual care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
75770999|NCT03860818|Other|Health services delivery|Technology-enabled pharmacist intervention
75771000|NCT01184404|Drug|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
75771001|NCT02525380|Procedure|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
75771002|NCT02524366|Device|Artificial Urinary Sphincter|
75771003|NCT02524600|Device|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
75771004|NCT02524600|Device|scintigraphic imaging|
75318458|NCT06036121|Drug|ADRX-0706|Antibody drug conjugate targeting Nectin-4
75318459|NCT06028477|Device|Stanford Glove|The non-invasive neuromodulation hardware system comprises two wireless controllers/battery packs which are fastened to the top of each hand via an adjustable elastic strap. Each controller is equipped with four vibrotactile fingertip stimulators, also known as tappers. There is a total of eight tappers (for index, middle, ring and pinkie of each hand) per system.
75464136|NCT01874093|Device|The Ischemic Stroke System|SPG stimulation and standard of care
75464137|NCT01874093|Device|Sham control|Sham stimulation and standard of care
75464138|NCT01874106|Other|Diet Therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
75464139|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
75464140|NCT01874171|Drug|Cisplatin|
75464141|NCT01874171|Drug|Cetuximab|
75617828|NCT02824666|Radiation|[18F]Fallypride Imaging|Subjects will be injected with approximately 250 MBq or 6.75 mCi of [18F]Fallypride [5-6 mCi being the typical range of injected dose].
75617829|NCT00674167|Drug|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
75617830|NCT00674167|Drug|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
75771005|NCT01186588|Drug|Canagliflozin|One 300-mg dose of canagliflozin on Day 1
75771006|NCT03854266|Drug|Low dose alteplase|Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours
75771007|NCT03854266|Drug|Unfractionated heparin|Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.
75771008|NCT03854266|Device|Infusion catheter|A sidehole catheter (Unifuse, AngioDynamics, US) catheter will be advanced to the pulmonary arteries to facilitate the catheter directed thrombolysis
75771009|NCT01187992|Drug|Atorvastatin|80 mg/day
75771010|NCT03854422|Device|left position|colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy
75771011|NCT03854422|Device|left supine position|Colonoscopy in the Left supine position
75771012|NCT03854422|Device|dynamic position|Colonoscopy in the Dynamic position
75771013|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
75771014|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
75771015|NCT01293604|Other|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
75910551|NCT02769416|Other|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
75318460|NCT06021626|Drug|CRD3874|"Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI.~Cohort CRD3874-SI Dose level (mg/kg)~0.1~0.3~0.9~1.8~2.7~4.05"
75464142|NCT01874184|Other|counseling intervention|Take part in weekly group counseling sessions
75910552|NCT02700841|Drug|Melphalan|Given IV
75910553|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Undergo autologous CD34 HSCT
75771016|NCT03849976|Behavioral|Therapeutic communication|Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
75771017|NCT01191034|Drug|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|"The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.~This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod."
75318461|NCT06016543|Procedure|osteopathic manipulative treatment (OMT)|Osteopathic manipulative treatment provided at the discretion of the treating physician and based on the patient's response to previous treatments.
75318462|NCT06015360|Procedure|Fat Graft|Fat grafting
75464143|NCT01874184|Behavioral|behavioral dietary intervention|Set goals for changing dietary habits
75771018|NCT03852940|Other|Parenteral nutrition|
75771019|NCT03852940|Other|Enteral Nutrition|
75771020|NCT01191112|Other|Peptide based enteral formula|Sole source nutrition as per HCP
75771021|NCT01186822|Device|Lung Flute|Used twice daily
75318463|NCT06014502|Drug|IMGS-001|Every 2 weeks
75771022|NCT01186900|Procedure|ultrasound-guided needle aspiration|one time drainage at time of randomization
75771023|NCT03853018|Device|CWAT intervention|Participant in the intervention group will wear an activity tracker for 12 weeks.
75318464|NCT06004050|Drug|Delgocitinib|Topical administration
75318465|NCT06004050|Other|Vehicle cream|Topical administration
75318466|NCT06003569|Behavioral|BACK-S|"BACK = Better Asthma Control for Kids:~The BACK -Standard package includes a tailor-and-adapt to context strategy of approaches necessary to implement BACK in schools based on our past work, operationalized as an implementation blueprint to coordinate with partner roles of child/family, schools, healthcare teams and community resource agencies. This includes a facilitation strategy to support problem-solving through regular learning collaborative meetings for asthma navigators (bi-weekly), school nurses (monthly to bi-monthly) and health care champions (quarterly)."
75464144|NCT01874184|Behavioral|exercise intervention|Attend group exercise activities
75464145|NCT01874184|Other|questionnaire administration|Ancillary studies
75464146|NCT01874184|Other|laboratory biomarker analysis|Correlative studies
75464147|NCT01874197|Device|B-TEVAR device|Creation and implantation of the Branched Thorcoabdominal aortic anerysm device
75464148|NCT01874236|Drug|0.75% bupivacaine|Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block
75464149|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine
75617831|NCT00674167|Drug|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
75617832|NCT02824588|Behavioral|Working Memory Training|Training mental flexibility
75617833|NCT02824588|Behavioral|Internet use|Used as control for time spent on computer
75617834|NCT00680719|Behavioral|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
75617835|NCT00680719|Behavioral|IBFT|Integrated Behavioral and Family Therapy (IBFT).
75617836|NCT04150471|Other|RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis|Conventional Q-RT-PCR every 3 months
75617837|NCT00912145|Drug|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
75771024|NCT03853018|Device|CWAT + motivation intervention group|Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
75771025|NCT01187056|Behavioral|Training programme|2 x 2 hours of training (workshops)
75771026|NCT01188070|Behavioral|Usual Care|Educational materials
75771027|NCT01188070|Behavioral|Psycho-education|Educational group sessions
75771028|NCT01188070|Behavioral|Psycho-education plus physical exercise|Psychoeducation intervention plus an individualized exercise program
75771029|NCT01293760|Other|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
75771030|NCT01293760|Other|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
75771031|NCT01188148|Drug|Memantine|5 mg per day of memantine
75771032|NCT01188148|Drug|Placebo|
75771033|NCT01187134|Behavioral|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
75771034|NCT01187212|Drug|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
75771035|NCT01187212|Drug|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
75771036|NCT01588600|Other|Dietary Fiber|Fiber added to breakfast
75771037|NCT03849508|Drug|Norepinephrine|"Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
75771038|NCT03849508|Drug|Phenylephrine|"Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
75771039|NCT03849664|Drug|Cytoflavin® solution|Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
75771040|NCT03849664|Drug|Cytoflavin® enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
75771041|NCT03849664|Drug|Placebo solution|Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
75464150|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
75617838|NCT00680875|Behavioral|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
75771042|NCT03849664|Drug|Placebo enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
75771043|NCT01291732|Drug|Matching placebo|single dose of matching placebo
75771044|NCT01291732|Drug|BI 135585 XX|single dose of low, medium or high dose of BI 135585 XX
75771045|NCT03849742|Other|Quality-of-Life Assessment|Ancillary studies
75771046|NCT03849742|Other|Questionnaire Administration|Ancillary studies
75771047|NCT03849742|Procedure|Supportive Care|Receive Uber rides
75771048|NCT05671432|Biological|CM326|CM326 injection
75318467|NCT06003569|Behavioral|BACK-E|The BACK-Enhanced package includes the BACK-Standard package plus an Enhanced strategy to develop interrelationships with students/family, schools, and community agencies providing resources to address social determinants of health.
75318468|NCT06003244|Other|6-minute walk distance (6MWD) test|6-minute walk distance (6MWD) test will be performed according to clinical standards
75771049|NCT05671432|Other|Placebo|Placebo
75771050|NCT01291810|Biological|TNF Kinoid|TNF Kinoid
75318469|NCT06003244|Other|6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (3l/min, nasal)
75318470|NCT06003101|Biological|Bone marrow aspirate concentrate (BMAC)|Bone marrow aspiration from the body of the ilium will be performed through one of the arthroscopic portals.
75771051|NCT01291810|Biological|WFI|WFI
75318471|NCT06003101|Procedure|Control|Standard of care hip arthroscopy without bone marrow aspiration will be performed in these patients.
75318472|NCT06002074|Behavioral|Stress Management and Resilience Training Program|One-on-one stress management and resilience consultation by a certified SMART trainer followed by self-guided on-line training consisting of 4 modules.
75464151|NCT01874249|Other|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
75464152|NCT01874249|Other|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
75617839|NCT04243252|Behavioral|Healthy Pantry Program|Food pantries will receive the Healthy Pantry Program online training, which will be completed by at least one pantry staff member and teaches pantry staff a novel traffic-light nutrition labeling system, a multilingual healthy recipe database, and how to use those and other behavioral economic strategies to implement simple interventions in the food pantry to promote client selection of healthier options. Onsite support by a registered dietitian is included.
75771052|NCT03854188|Procedure|Acupuncture|Use acupuncture therapy in the treatment of chronic pelvic pain.
75771053|NCT03853720|Procedure|balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices|"Catheterization of the left renal vein and the inferior diaphragmatic vein and occlusion with a balloon placed in the distal portion of this vein.~Endoscopic access to the gastric cavity, gastric varices identification and flow measurement, including velocity, by endoscopic Doppler ultrasound (US). The balloon in the draining vein will be inflated and the velocity will be reassessed. Endoscopic puncture of the varices will be done and the embolization will be conducted under balloon-occlusive conditions (Injection of Cyanoacrylate: Lipiodol mixture 1:1 slowly and gradually). Balloon will be kept inflated and a microcatheter will be used through its lumen inside the variceal bed to inject occlusive agent (cyanoacrylate) mixed with Lipiodol.~At the end of the procedure an occlusion device (plug amplatzer 2) will be placed."
75771054|NCT01187290|Radiation|neoadjuvant chemoradiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
75464153|NCT01874249|Other|Transient elastography|Transient elastography values greater than 8 kPa
75464154|NCT01874301|Other|High quantity probiotic|The intervention type is food product
75464155|NCT01874301|Other|Low quantity probiotic|The intervention type is food product
75464156|NCT01874301|Other|placebo|
75464157|NCT01874314|Drug|SQ109|300mg or 450mg of SQ109 administered orally, once daily for 7 days.
75464158|NCT01874314|Other|SQ109 Placebo|Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
75464159|NCT01874314|Drug|Moxifloxacin|400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
75771055|NCT01293838|Drug|Cipralex®|"Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~10 mg tablets: 28~20 mg tablets: 84~Total for 30 participants:~10 mg tablets: 840~20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~*20 mg tablets: 1512"
75771056|NCT01188304|Drug|aleglitazar|repeated daily doses
75771057|NCT01188304|Drug|aspirin|repeated daily doses
75771058|NCT01188304|Drug|placebo|repeated daily doses
75771059|NCT01188382|Procedure|CSF dynamic investigation|
75771060|NCT02524444|Drug|Mefloquine|Tabs Mefloquine 250mg
75771061|NCT02524444|Drug|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
75771062|NCT01293916|Other|Spica casting|single versus double leg spica casting
75771063|NCT01291966|Behavioral|Motivational interview|
75771064|NCT03852238|Other|Blood test and self-administrated questionnaires|
75771065|NCT03853408|Procedure|Cholecystectomy|Cholecystectomy (removal of the gallbladder) for acute cholecystitis
75910554|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--AHSCT|Undergo AHSCT
75910555|NCT02700841|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo autologous CD34 HSCT
75464160|NCT01874327|Behavioral|Baby JASPER|Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
75617840|NCT04243252|Other|Waitlist Control|Normal food pantry use for duration of the 9-month study period. Control pantries will have access to the Healthy Pantry Program after study is completed.
75910556|NCT02700841|Biological|Tetanus Toxoid Vaccine|Given IM
75910557|NCT02688985|Drug|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
75617841|NCT04242004|Drug|Docosahexaenoic acid (DHA) capsules|Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).
75617842|NCT04242004|Dietary Supplement|Soy oil capsules|The placebo was identical looking capsules that contained soy oil
75910558|NCT02688985|Procedure|Lumbar Puncture|Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
75617843|NCT04150237|Other|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
75617844|NCT02824510|Other|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
75617845|NCT02824510|Other|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
75771066|NCT01188616|Behavioral|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
75910559|NCT02688985|Drug|Methyloprednisolone|Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
75910560|NCT02688985|Drug|Antihistamine|Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
75910561|NCT02672826|Procedure|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
75910562|NCT02669186|Drug|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
75910563|NCT02669186|Drug|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
75910564|NCT02602145|Other|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.
75910565|NCT02568566|Other|Laboratory Biomarker Analysis|Correlative studies
75910566|NCT02568566|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
75910567|NCT02548104|Other|ACB|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
75910568|NCT02548104|Other|ACB + iPACK|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
75464161|NCT01874327|Behavioral|Standard Baby Classroom|Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
75617846|NCT02824510|Drug|Insulin aspart, glargine and detemir|
75617847|NCT00674245|Drug|Pantoprazole|40 mg once daily for 4 weeks
75771067|NCT01291576|Procedure|Rectal/colorectal segmental resection|Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
75771068|NCT01291576|Procedure|Rectal nodule excision|Either full thickness excision or rectal shaving
75771069|NCT03853642|Other|Blood sampling|Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
75771070|NCT01292044|Other|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
75464162|NCT01874366|Drug|P11187|"Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval."
75464163|NCT01874366|Drug|Placebo|"Placebo capsules will be matching in appearance with the active drug capsules of P11187.~In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo"
75464164|NCT01874379|Other|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
75617848|NCT00674245|Drug|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
75617849|NCT00674245|Drug|placebo|40 mg once daily for 4 weeks
75617850|NCT04194190|Drug|Individual Patient TCR-Transduced PBL|
75617851|NCT04242082|Diagnostic Test|GLUT 1 gene expression|"GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment."
75617852|NCT00878215|Device|Explorer Liver Image Guided System|
75617853|NCT00878215|Device|Explorer Liver Passive Tracking|
75617854|NCT00878215|Procedure|Liver surgery|-Standard of care
75617855|NCT00878215|Procedure|Liver abalation|-Standard of care
75910569|NCT02536365|Behavioral|Sensory Integration Therapy|Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
75464165|NCT01874379|Other|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
75318473|NCT06001801|Behavioral|Diabetes Prevention Program|"The DPP group is led by the Community Health and Social Services Center (CHASS) community health workers (CHWs). For this study, the workers will deliver 16 weekly sessions (core phase) followed by two monthly sessions (maintenance phase). Each session lasts one hour plus the time required to weigh each participant and review food and activity logs.~This program will help participants make healthy lifestyle changes. Examples are improvements in eating and physical activity. The goal is that participants lose some weight and eat healthier food.~Sessions will be offered in-person in a room with video capacity to allow attendance of participants that cannot attend in person. For those participating virtually, the CHWs will briefly review with them what participants logged.~Participation in this project should last approximately 6-months."
75318474|NCT06001801|Behavioral|INSPIRA|"This intervention will include the DPP plus additional interventions. The additional interventions include: participants to stay for an extra 30 minutes following the regular DPP sessions. In these INSPIRA sessions, participants will be trained in providing mutual peer support, be matched with a peer partner and asked to talk at least once a week, receive vouchers or gift cards, discuss participants action plans with the peer partner, and share challenges, successes, and tips from the CHW and others in the session.~CHWs will provide brief trainings on autonomy-supportive peer support approaches over the first three weeks of sessions.~Participation in this project should last approximately 6-months."
75464166|NCT01874379|Other|Standard of Care|Normal Procedures, no complementary medicine intervention.
75617856|NCT04243018|Behavioral|Acceptance and Commitment Therapy Group Treatment|The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
75318475|NCT05999526|Other|Reconnection to mechanical ventilation for 1 hour|As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
75617857|NCT04243018|Behavioral|Peer Support Group|The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
75617858|NCT02628847|Drug|sildenafil citrate|
75771071|NCT01191346|Other|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
75771072|NCT01191424|Drug|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
75771073|NCT01191424|Drug|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
75771074|NCT04956718|Other|Cold Pressor Test (CPT)|Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.
75771075|NCT04956718|Other|Placebo NaCl Nasal spray|placebo nasal spray containing NaCl solution
75464167|NCT01874418|Other|Biomarker|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
75464168|NCT01874444|Device|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
75318476|NCT05999526|Other|Direct extubation|The participant will be extubated immediately after the spontaneous breathing trial.
75464169|NCT01874444|Device|2|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
75617859|NCT02628847|Drug|Placebo|
75617860|NCT04241770|Other|no intervention|no intervention
75617861|NCT00677287|Biological|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
75771076|NCT01187680|Device|Spraygel|
75771077|NCT01187680|Device|Control|Good surgical technique, no adhesion barrier
75771078|NCT01291654|Drug|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
75771079|NCT01291654|Drug|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
75771080|NCT01291654|Drug|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
75771081|NCT03853174|Other|Endurance Training ET|Endurance training were prformed. Intensity was gradually increased.
75771082|NCT03853174|Other|Resistance Training RT|Resistance training were prformed. Intensity was gradually increased.
75771083|NCT01187758|Behavioral|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
75771084|NCT03853096|Drug|Cefazolin|Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
75771085|NCT05671276|Drug|aspirin and clopidogrel|DAPT (until 6 months) + ASA
75771086|NCT05671276|Drug|Rivaroxaban|half-dose NOAC
75464170|NCT01874444|Device|3|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
75771087|NCT03848026|Other|Middle ear fluid viscosity|The patients were subdivided into two groups according to median viscosity level
75910570|NCT02536365|Behavioral|Applied Behavioral Analysis|Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
75910571|NCT02536183|Device|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
75910572|NCT02536183|Drug|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
75318477|NCT05998577|Device|ESM and Traqq|Two telephone applications: ESM is a psychosocial diary and Traqq is a food diary to measure abdominal pain as well as possible triggerfactors (i.e. diet, stress, anxiety)
75318478|NCT05987904|Device|LynxPatch|Measurements with the LynxPatch device are conducted.
75318479|NCT05987527|Diagnostic Test|Urine sample|Routine procedures
75617862|NCT05660902|Other|ROM Exercises|The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
75617863|NCT00674401|Procedure|Radiofrequency catheter ablation|"In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~Empirical pulmonary vein antrum circumferential isolation, or~High frequency sites ablation in the LA~In case of Persistent AF, patients will be randomized into one of 2 in the study:~Empirical circumferential PV antrum isolation w/out roof line, or~A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
75771088|NCT03848026|Other|Tympanostomy tube extrusion time|Tympanostomy tube extrusion time of the all patients recorded prospectively.
75771089|NCT03852160|Drug|Esketamine 28 mg|Participants will receive 28 mg esketamine as nasal spray (Initial dose for elderly participants with 65-74 years of age on Day 1 and then uptitrated to 56 mg on Day 4).
75318480|NCT05987527|Diagnostic Test|Blood sample|Routine procedures
75318481|NCT05987527|Other|Lifestyle questionnaire|Lifestyle questionnaire
75617864|NCT02824120|Other|Comedy|patients will watch comedy film
75617865|NCT02824120|Other|Documentary|patients will watch a documentary film
75617866|NCT00677443|Drug|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
75318482|NCT05970107|Procedure|Axillary Lymph Node Dissection|"ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest."
75318483|NCT05970107|Procedure|Axillary Reverse Mapping|Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND
75318484|NCT05970107|Procedure|Lymphaticovenous Bypass|Lymphaticovenous bypass/anastomosis (LVB/LVA) involves supramicrosurgery in which the blocked lymphatic vessel of an affected limb is connected to a nearby vein with the aid of ultra-fine instruments and a powerful operating microscope.
75318485|NCT05942859|Diagnostic Test|Artificial Intelligence and Machine Learning technology|Artificial Intelligence describes computer software designed to mimic human cognitive function. Machine learning is a type of artificial intelligence in which the model created is exposed to data, identifies patterns, and recognises relationships between features seen in the data and the 'ground truth'. This technology will be applied to participants ECGs.
75318486|NCT05940545|Drug|Favipiravir|Small molecule antiviral
75771090|NCT03852160|Drug|Esketamine 56 mg|Participants will receive 56 mg esketamine as nasal spray (Initial dose for participants with 18-64 years of age) on Day 1. The dose may be increased/may remain same based on the efficacy and tolerability. Participants with 65 to 74 years of age will receive esketamine 56 mg from Day 4 onwards.
75771091|NCT03852160|Drug|Esketamine 84 mg|Participants may receive 84 mg (maximum uptitrated esketamine dose). The dose may be decreased/may remain same based on the efficacy and tolerability.
75771092|NCT03852160|Drug|Placebo|Participants will receive matching placebo as nasal spray.
75771093|NCT03852160|Drug|Escitalopram|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
75318487|NCT05940545|Drug|Ribavirin|Small molecule antiviral
75464171|NCT01874444|Device|4|"Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
75464172|NCT01874457|Biological|MMR (Mumps, Measles and Rubella)|MMR (Mumps, Measles and Rubella)
75464173|NCT01874470|Device|renal denervation|
75464174|NCT01874470|Other|standard medication|
75464175|NCT01874483|Drug|Placebo|placebo
75464176|NCT01874483|Drug|BI 187004|BI 187004, dose 2
75771094|NCT03852160|Drug|Sertraline|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
75771095|NCT03852160|Drug|Duloxetine|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
75771096|NCT03852160|Drug|Mirtazapine|Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
75318488|NCT05936684|Behavioral|Breathing with prolonged exhalation (ProlEx) during risky decision-making|20 min divided in 3 blocks of slow, 0.1 Hz breathing (6 cycles per minute) with an inhalation-to-exhalation ratio of 2:8. Cue-assisted breathing (same across participants) and performance of a risky decision-making task (Tom et al., 2007) in the magnetic resonance imaging (MRI) scanner with simultaneous acquisition of physiological and pupil data.
75771097|NCT03852160|Drug|Agomelatine|Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
75318489|NCT05936684|Behavioral|Normal breathing (Eupnea/Control) during risky decision-making|20 min divided in 3 blocks of normal breathing (expected range: 0.16-0.33 Hz, i.e., 10-20 per min), Cue-assisted breathing (individually adapted) and performance of a risky decision-making task (Tom et al., 2007) in the MRI scanner with simultaneous acquisition of physiological and pupil data.
75771098|NCT03852160|Drug|Bupropion|Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
75771099|NCT03852160|Drug|Trazodone Prolonged Release|Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
75771100|NCT01193998|Other|Treatment as per model probability|Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
75771101|NCT01193998|Other|Treatment as per usual care|Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
75771102|NCT03849352|Behavioral|Lifestyle changes with the support of health technology|Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
75771103|NCT01294540|Drug|Drug: E2609|E2609 orally at varying ascending doses
75771104|NCT01294540|Drug|Placebo|Matching Placebo
75771105|NCT01292122|Device|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
75771106|NCT01194076|Behavioral|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
75771107|NCT02524210|Drug|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
75771108|NCT02524210|Drug|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
75771109|NCT02524210|Drug|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
75771110|NCT01292200|Behavioral|watch DVD and small group discussion|Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
75771111|NCT01292200|Behavioral|watch DVD|Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
75318490|NCT05935488|Other|EVOCs emulsion|Continuous breath sampling directly into SIFT-MS equipment. The instrument is equipped with a mouthpiece connected to the SIFT inlet where the subject blows in and the breath is analyzed in real-time
75464177|NCT01874483|Drug|BI 187004|BI 187004, dose 4
75617867|NCT00677443|Drug|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
75617868|NCT04913584|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
75617869|NCT00674557|Drug|SOD1 inhibitor ATN-224|
75617870|NCT00674557|Drug|exemestane|
75617871|NCT00674557|Genetic|protein expression analysis|
75617872|NCT00674557|Genetic|proteomic profiling|
75617873|NCT00674557|Other|laboratory biomarker analysis|
75617874|NCT00674557|Other|pharmacological study|
75617875|NCT04259242|Procedure|SRP|scaling and root planing with ultrasonic scaler and manual instruments
75464178|NCT01874483|Drug|BI 187004|BI 187004, dose 5
75464179|NCT01874483|Drug|BI 187004|BI 187004, dose 6
75464180|NCT01874483|Drug|BI 187004|BI 187004, dose 7
75464181|NCT01874483|Drug|BI 187004|BI 187004, dose 1
75464182|NCT01874483|Drug|BI 187004|BI 187004, dose 3
75464183|NCT01874496|Dietary Supplement|GDS, no meal|GDS, no meal
75464184|NCT01874496|Dietary Supplement|GDS, meal|GDS, meal
75464185|NCT01874496|Dietary Supplement|control, no meal|control, no meal
75464186|NCT01874496|Dietary Supplement|control, meal|control, meal
75771112|NCT03847792|Drug|Group DB/Dexamethasone-Bupivacaine|The patient were received an intra-articular injection of 18ml bupivacaine 0.25% added to 8mg dexamethasone.
75910573|NCT02365766|Drug|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
75910574|NCT02365766|Drug|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
75910575|NCT02365766|Drug|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
75910576|NCT02365766|Procedure|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
75910577|NCT02317874|Drug|Carboplatin|Given IV
75910578|NCT02317874|Drug|Paclitaxel|Given IV
75910579|NCT02317874|Drug|Talazoparib|Given PO
75617876|NCT04150003|Behavioral|Pulmonary Rehabilitation program|Structured rehabilitation program of directed exercises
75617877|NCT04150003|Other|Usual care|Usual care for patients who had suffered a Pulmonary Embolism
75318491|NCT05933005|Device|D-kit/EF1|"D-kit/EF1 delivers interventions through online platforms and can be downloaded to smart devices through the iOS App store or Google Play Store. Games are specifically designed to assist children with delayed cognitive development in the acquisition of foundational cognitive skills.~The core technology of the D-kit/EF1 is the 'reinforcement technique', a technology used in traditional behavioral therapy. Specifically, D-kit incorporates the Discrete Trial Training (DTT) approach into its instructional content to facilitate the acquisition of basic cognitive skills."
75318492|NCT05933005|Device|Sham group program|The sham program was designed to provide a similar experience as the experimental group by replacing the content within the same app. The control group uses the same mobile tablet device and accesses the app with the provided control group account. When accessing the app with the control group account, instead of the Adaptive Learning Lesson reflecting the principles of D-kit, educational animations created for educational purposes are provided.
75464187|NCT01874509|Behavioral|Check Your Drinking|
75464188|NCT01874509|Behavioral|Alcohol Help Centre|
75617878|NCT05660824|Device|Stromal Vascular Fraction infiltration|Procedure to prepare SVF: In the operations room and after aseptic technic, local anesthesia is applied in the liposuction incision site with lidocaine 1% without epinephrine subcutaneously. 60 ml of tumescent solution are injected. After 15-20 minutes waiting, 15 ml of lipoaspiration per side are recollected into a double syringe. This is centrifuged for 4 minutes at 2.500 rpm and the remaining fat is separated from the other fractions. Two 1.4 mm GEMS syringes are attached together, and fat is transferred at least 30 times from one syringe to the other. Syringe content is again centrifugated for 4 minutes. The oil is discarded and approximately 1.5ml SVF fraction remains.
75771113|NCT03847792|Drug|Group FB /Fentanyl-Bupivacaine|The patient were received an intra-articular injection of 1 ug/kg fentanyl added to 18ml of 0.25% bupivacaine.
75910580|NCT02255383|Device|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
75910581|NCT02253251|Genetic|KRAS-variant and microRNA binding site mutation testing|Participant in these studies will be tested for the KRAS-variant
75771114|NCT03847792|Drug|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2ml isotonic saline added to 18ml of 0.25% bupivacaine.
75771115|NCT01294618|Drug|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
75464189|NCT01874522|Drug|TAS-102 tablets|"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."
75464190|NCT01874522|Drug|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
75464191|NCT01874561|Drug|Custirsen|Custirsen will be administered iv using an infusion pump over a 2-hour period.
75464192|NCT01874561|Drug|Placebo|Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
75771116|NCT01188850|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
75910582|NCT02221999|Drug|Paclitaxel|
75910583|NCT02221999|Drug|Cisplatin|
75910584|NCT02221999|Drug|Gonadotropin-releasing hormone agonist|Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
75910585|NCT02221999|Drug|Letrozole|
75910586|NCT02038140|Device|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
75910587|NCT01849562|Drug|Sovaprevir|Nonstructural protein 3/4A protease inhibitor.
75910588|NCT01849562|Drug|ACH-3102|Nonstructural protein 5A inhibitor.
75910589|NCT01849562|Drug|Ribavirin|
75910590|NCT01849562|Drug|Placebo|
75910591|NCT01700179|Drug|ACH-0143102|
75910592|NCT01700179|Drug|Ribavirin|
75910593|NCT01659606|Biological|alemtuzumab|Conditioning: alemtuzumab 0.2 mg/kg/dose IV/SC x 5 doses
75910594|NCT01659606|Drug|Fludarabine|fludarabine 30 mg/m2/dose IV x 6 doses
75910595|NCT01659606|Drug|Cyclosporins|
75910596|NCT01659606|Drug|Mycophenolate mofetil|
75910597|NCT01659606|Drug|Tacrolimus|
75910598|NCT01474200|Device|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
76072636|NCT02131402|Device|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
75910599|NCT01474200|Drug|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
75910600|NCT01171131|Other|Blood/saliva sampling|one-time blood sample (~ 1 TBS) and saliva sample (~ 1 tsp)
75464193|NCT01874561|Drug|Moxifloxacin|Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
75464194|NCT01874574|Drug|Hylan G-F 20|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
75464195|NCT01874574|Drug|Corticosteroid|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
75771117|NCT01194232|Drug|Sildenafil|8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
75771118|NCT01296334|Drug|morphine LO|intravenous infusion, 10 mg, once, 4 hours
75464196|NCT01874587|Radiation|adaptative radiotherapy|weekly replanning
75464197|NCT01874600|Device|Brain Sentinel Seizure Detection Device and Warning System|The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
75464198|NCT01874613|Device|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
75771119|NCT01296334|Drug|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
75771120|NCT01296334|Drug|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
75464199|NCT01874613|Device|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
75464200|NCT01874639|Device|standard bipolar coagulation|
75464201|NCT01874639|Device|Aquamantys® probe for liver hemostasis|
75464202|NCT01874652|Device|Light Weight Breast Implants|Light Weight Breast Implants
75464203|NCT01874678|Drug|TS-1/Cisplatin|
75464204|NCT01874704|Behavioral|Comparison of biomarkers of stress|
75464205|NCT01874717|Other|Conscious sedation for dental care|
75464206|NCT01874717|Drug|midazolam|
75464207|NCT01874730|Other|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
75464208|NCT01874730|Drug|Volulyte® (6% HES 130/0.4 in balanced solution)|"For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg."
75464209|NCT01874730|Other|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
75464210|NCT01874743|Drug|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
75464211|NCT01874769|Other|Blood collection|"5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.~10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen~5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria."
75464212|NCT01874769|Other|Skin biopsies|"A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.~During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients"
75771121|NCT01296334|Drug|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
75771122|NCT01296334|Other|saline|intravenous infusion, 0.9% saline, once, 4 hours
75771123|NCT03851770|Other|Characterization of Vagus nerve stimulation|Characterization of Vagus nerve stimulation induced larynx evoked motor potential. Patients participating in the study will be asked to come to perform the experiment (duration maximum 1 hour) at the Neurophysiology Department of Saint Luc .
75771124|NCT03847558|Diagnostic Test|FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
75771125|NCT01194310|Procedure|phaco|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone
75464213|NCT01874782|Device|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
75771126|NCT01194310|Procedure|phaco-ELT|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus excimer laser trabeculotomy (ELT)
75771127|NCT01194310|Procedure|phaco-Trabectome|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus Trabectome
76072637|NCT01814137|Drug|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
75464214|NCT01874795|Device|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
75464215|NCT01874795|Device|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
75464216|NCT01874821|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
75771128|NCT01189006|Drug|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
75771129|NCT01294774|Drug|KRP203 - 1.2mg|
75464217|NCT01874821|Other|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
75464218|NCT01874834|Other|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
75617879|NCT05660824|Procedure|Plattelet Rich Plasma infiltration|Procedure to prepare PRP: 15 cm of peripheral blood obtained by venipuncture are centrifugated at 5000 RPM during 5 minutes. Using PRP Arthrex kit platelets poor plasma is discarded and 1-3 mm of PRP are ready to be injected
75617880|NCT04150159|Dietary Supplement|FMD Arm|ProLon Fasting Mimicking Diet Plan
75771130|NCT01294774|Drug|Placebo to KRP203 - 1.2 mg|
75771131|NCT01292356|Drug|cetuximab|
75464219|NCT01874847|Dietary Supplement|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
75464220|NCT01874847|Dietary Supplement|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
75464221|NCT01874873|Drug|Anlotinib|
75464222|NCT01874899|Device|RestoreSensor Neurostimulation|
75318493|NCT05931146|Other|MyNetDiary app group|MyNetDiary will be used to track calories, and exercise while motivating for living a healthier life each day.The intervention period would last for three months. Total energy expenditure (TEE) of every participant enrolled into the study would be calculated at the start of the study and an exercise and diet plan with a calorie deficit of around 1000 kcal per week would be provided to the participant. The diet and exercise plan would be modified according to the new TEE of the participant. MyNetDiary app has built-in food and exercise activities with their respective calories' count. Moreover, customized foods and exercises can also be added into the application
75771132|NCT01194388|Device|MicroFx™ PGLA COILS|. This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
75464223|NCT01874964|Behavioral|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
75464224|NCT01874964|Behavioral|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
75771133|NCT01294852|Other|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]).
75771134|NCT03851848|Other|Joint mobilization (JM)|Joint mobilization (JM) is a manual therapy to move the joint in a desired direction. It is commonly used for improving the joints' ROM and pain intensity, and to overcome joint restriction.
75464225|NCT01874977|Behavioral|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
75464226|NCT01874977|Behavioral|Educational materials|"Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment."
75617881|NCT00677521|Drug|Acarbose|50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
75617882|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
75617883|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|27g placebo chocolate bar to be consumed for 365 days.
75771135|NCT03851848|Other|Myofascial release (MFR)|Myofascial release (MFR) is a technique in which a slow, sustained pressure is applied to the restricted soft tissue in order to restore optimal length, reduce pain and improve function.
75771136|NCT01292434|Behavioral|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
75771137|NCT03847246|Drug|Baraclude® tablets,1.0 mg|oral,once,under fasting condition
75464227|NCT01874977|Behavioral|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
75464228|NCT01874990|Dietary Supplement|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
75464229|NCT01874990|Dietary Supplement|low-salt diet|
75464230|NCT01875003|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at high or low dose Q4W.
75464231|NCT01875003|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection Q4W.
75617884|NCT02826304|Procedure|Vaginal hysterectomy|"All the cases were performed by the same surgical team~Incision is made at the anterior cervical lip below the bladder reflection~Anterior peritoneal entry .~Douglas pouch entry.~The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~Uterine artery clamping division and ligation~After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~Hemostasis~The vaginal vault is closed after insertion of intraperitoneal drain and"
75617885|NCT02826304|Procedure|Laparoscopic assisted vaginal hysterectomy|"Uterine manipulator was inserted through the cervix to mobilize the uterus~Veress needle was inserted through the base of the umbilicus~creation of pneumoperitoneum~Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~The round and the utero-ovarian ligament are coagulated and divided.~Dissection through the vesico-uterine space to displace bladder away from the cervix.~Uterine artery was coagulated and divided laparoscopically~anterior colpotomy over the cup of the uterine elevator.~Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis."
75617886|NCT00674713|Other|Acupuncture|
75617887|NCT00674713|Drug|Ondansetron|
75617888|NCT00674713|Drug|Physiological saline solution|
75617889|NCT00674713|Other|Sham acupuncture|
75771138|NCT03847246|Drug|Entecavir tablets,1.0 mg|oral,once,under fasting condition
75771139|NCT01292512|Other|Prognostic screening for complicated grief|Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
75617890|NCT00674713|Drug|Ondansetron|
75464232|NCT01875003|Drug|Standard of Care|Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists [LABAs], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
75464233|NCT01875016|Procedure|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
75617891|NCT00674713|Other|Acupuncture at P6 point|
75617892|NCT00674713|Drug|Physiological saline solution|
75617893|NCT00674713|Other|Sham acupuncture|
75617894|NCT04241380|Drug|Anticoagulant Solutions|Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
75617895|NCT04241380|Other|No anticoagulant solutions|They will receive non-coagulant or coagulant treatment according to clinical conditions.
75617896|NCT04241380|Drug|Anticoagulant management|"Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months."
75617897|NCT00677677|Biological|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
75617898|NCT00674791|Biological|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
75617899|NCT02824354|Drug|Nalmefene (Selincro®) 18 mg tablet|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
75617900|NCT02824354|Drug|placebo|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
75318494|NCT05931146|Other|Paper diary group|Paper Diary will be used to track calories and exercise. The nutritional intake and exercise would be recorded for three months. The diet and exercise plans would be modified according to the new Total Energy Expenditure of the participants.
75318495|NCT05926544|Behavioral|Standard implementation webinar and online training|"The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, booster eligibility, mechanisms of action, and outcomes.~The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients."
75464234|NCT01875029|Device|sham-tDCS + back school|sham tDCS + back school
75464235|NCT01875029|Device|real-tDCS + back school|real tDCS + back school
75617901|NCT00674869|Other|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
75771140|NCT05282914|Drug|administration of UI058|Test
75771141|NCT05282914|Drug|administration of UIC202004|Reference
75464236|NCT01875042|Device|TENS|Transcutaneous electrical nerve stimulation
75464237|NCT01875042|Device|Sham TENS|Sham Transcutaneous electrical nerve stimulation
75771142|NCT01296490|Other|Stress test|Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
75771143|NCT01294930|Other|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
75771144|NCT01292590|Other|High fat meal|40 grams saturated fat
75771145|NCT03849196|Drug|2L PEG-Asc|PEG-Asc powder
75771146|NCT03849196|Drug|Bisacodyl 10Mg Suppository|bisacodyl 10 mg suppository
75771147|NCT03849196|Drug|1L PEG-Asc|PEG-Asc powder
75617902|NCT04150315|Diagnostic Test|Proteome analysis|Evaluation of specific protein levels in tissue and plasma.
75771148|NCT05282836|Device|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
75771149|NCT01292668|Drug|methyl-5-aminolevulinate hydrochloride cream|Applied topically
75771150|NCT01292668|Drug|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
75771151|NCT01292668|Procedure|laser therapy|Undergo laser light photodynamic therapy
75771152|NCT01189084|Biological|Observational|Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
75771153|NCT03851692|Other|Intravenous Cannulation (iv placement)|The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.
75771154|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
75771155|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
75771156|NCT01296802|Drug|dexfenfluramine|oral, 40 mg to 60 mg, single application as a challenge
75910601|NCT00913471|Other|blood samples|"Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy."
75617903|NCT02823496|Other|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
75771157|NCT01189162|Device|NIMV with SLE ventilator vs HFNC via Vapotherm|Nasal respiratory support for RDS
75318496|NCT05926544|Behavioral|Virtual facilitation|This intervention involves a 30-minute virtual facilitation site visit and 8 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
75771158|NCT03851536|Procedure|Transvaginal Ultrasound Guided ET|Use of TVUS to guide ET
75771159|NCT03851536|Procedure|Transabdominal Ultrasound Guided ET|Use of TAUS to guide ET
75464238|NCT01875055|Device|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
75464239|NCT01875055|Device|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
75771160|NCT01296958|Drug|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
75910602|NCT00698854|Device|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
75910603|NCT00698854|Device|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
75910604|NCT00665223|Drug|ACR16|Capsules will be swallowed whole with water.
75910605|NCT00665223|Drug|Placebo|Capsules will be swallowed whole with water.
75464240|NCT01875068|Behavioral|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
75617904|NCT02823496|Other|Untreated skin|One site is patched without treatment as control
75617905|NCT00677755|Drug|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
75617906|NCT00677755|Drug|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
75910606|NCT00500123|Procedure|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
75464241|NCT01875068|Behavioral|versus NPs and PAs who are not required to discuss patient referrals (control group).|
75617907|NCT00674947|Drug|BIIB015|IV infusion once every 3 weeks until disease progression or unacceptable toxicity
75771161|NCT01296958|Behavioral|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
75771162|NCT01191580|Behavioral|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
75910607|NCT00178659|Other|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
75318497|NCT05924789|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
75617908|NCT02628457|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
75771163|NCT01191580|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
75910608|NCT03060226|Diagnostic Test|blood sample|Search of blood predictive marker (s)
75910609|NCT03786380|Drug|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily.
75910610|NCT03055234|Drug|Oral Treprostinil|Extended-release oral tablet for TID administration
75464242|NCT01875081|Biological|Livercellgram|"Livercellgram~Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20~25℃~Injection Method: Directly inject into liver through hepatic artery"
75464243|NCT01875094|Other|Self-Management / MTM using Health IT|
75910611|NCT03055234|Drug|Placebo|Matching placebo for TID administration
75318498|NCT05923970|Diagnostic Test|Serology for antibody levels - Baseline|Measurement of rubella IgG antibody levels at baseline
75318499|NCT05923970|Diagnostic Test|Serology to assess cell mediated immune (CMI) response - Baseline|Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.
75318500|NCT05923970|Diagnostic Test|Serology for antibody levels - Post third dose of MMR vaccine|Measurement of rubella IgG antibody levels post third dose of MMR vaccine
75464244|NCT01875107|Drug|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
75464245|NCT01875133|Other|altitude exposure|stay at different altitudes: 490, 1630, 2590 m
75464246|NCT01875146|Other|4x4 min HIT|Conventional 4x4 min high-intensity interval training
75617909|NCT02823418|Procedure|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
75617910|NCT02823418|Procedure|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
75617911|NCT04149379|Drug|Hyperbaric oxygen|20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
75617912|NCT02824042|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
75617913|NCT02824042|Drug|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
75910612|NCT03055312|Drug|TPC|"Conventional chemotherapy(choose a):~TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.~GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 & days 8)every 3 weeks.~GC:(Gemcitabine 1000mg/m2 on days 1 & days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 & days 8) every 3 weeks"
75318501|NCT05923970|Diagnostic Test|Serology to assess CMI - Post third dose of MMR vaccine|Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.
75318502|NCT05912829|Device|IOL Master 700|Biometry using the IOL Master 700
75318503|NCT05912829|Device|Casia-2|Anterior segment-OCT to evaluate lens tilt
75617914|NCT02628925|Device|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
75910613|NCT03055312|Drug|Bicalutamide 150 mg|Bicalutamide 150mg/day,every 28 days
75910614|NCT03055468|Behavioral|Peer support|Peer support and antidepressant medications
75910615|NCT04977544|Device|vert|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
76072638|NCT01814137|Drug|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
75318504|NCT05912829|Device|MS-39|Corneal Topography using the MS-39
75318505|NCT05912829|Device|OSIRIS|Abberometry using the OSIRIS-Abberometer
75318506|NCT05912829|Device|Autorefractor|Evaluation of Refraction using an Autorefractor
75318507|NCT05912829|Diagnostic Test|Subjective Refraction|Refraction performed by experienced staff
75318508|NCT05912829|Diagnostic Test|Biomicroscopy|Slit Lamp Examination
75318509|NCT05907213|Drug|Ketamine (Ketalar) Dose Level 1|Loading Dose: 0.05 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
75318510|NCT05907213|Drug|Ketamine (Ketalar) Dose Level 2|Loading Dose: 0.08 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
75318511|NCT05907213|Drug|Ketamine (Ketalar) Dose Level 3|Loading Dose: 0.12 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
75318512|NCT05907213|Drug|Ketamine (Ketalar) Dose Level 4|Loading Dose: 0.18 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
75464247|NCT01875146|Other|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
75464248|NCT01875146|Other|4x4 min HIT + (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
75464249|NCT01875146|Other|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
75464250|NCT01875172|Drug|Bupropion SR|Comparison of bupropion SR or placebo + smoking cessation counseling
75464251|NCT01875172|Drug|placebo|
75771164|NCT01191580|Behavioral|Brief Supportive Psychotherapy|"The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures."
75617915|NCT02628301|Dietary Supplement|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
75617916|NCT02628301|Other|Normocaloric diet|Normocaloric diet
75910616|NCT04977544|Drug|Sertraline|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
75617917|NCT00675181|Drug|Melatonin|5mg per os
75910617|NCT04917640|Radiation|Radiation Therapy|Either SBRT or IMRT radiation therapy
75910618|NCT03470636|Device|HeartLight X3|Pulmonary vein isolation
75910619|NCT05157074|Behavioral|Group Drumming Music Therapy|"All 24 Armstrong Rhythm Cycle™ sessions is conducted in a circle to ensure maximum line of sight for each participant. A variety of diverse percussion instruments ranging from hand drums, stick drums, shakers, and rhythm sticks are available as well as adaptive measures to address limited physical functioning. Instrument choice is dependent on ease of use for the level of the physical ability, skill development needs, and personal choice. Participants are informed that they are free to use the same instrument for the duration of each session or to switch instruments at any time.~Utilizing the five components of The Armstrong Rhythm Method, this protocol guides participants through three phases to achieve rhythmic skill development and group cohesion for their therapeutic benefit."
75617918|NCT00675181|Drug|Placebo|per os
75910620|NCT02626000|Drug|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.
75617919|NCT04241458|Drug|BI 703621|BI 703621
75771165|NCT01295086|Drug|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
75910621|NCT02626000|Biological|Pembrolizumab|Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W
75910622|NCT03769376|Device|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction.
75910623|NCT03769376|Device|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction.
75910624|NCT03060460|Diagnostic Test|Ultrasound guided sheath insertion|ultrasound is used routinely for sheath insertion
75617920|NCT04241458|Drug|Placebo|Placebo
75617921|NCT04241458|Drug|Midazolam|Midazolam
75617922|NCT02823808|Drug|NESINA ACT TAB. 25/15mg|Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
75617923|NCT02823808|Drug|AMARYL-M TAB. 2/500mg|Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
75617924|NCT04241302|Diagnostic Test|Pure Tone Audiogram|A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).
75617925|NCT04151719|Drug|Methylnaltrexone bromide (MNTX)|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
75771166|NCT01295086|Drug|Oxaliplatin|100 mg/m² day 1 every 3. week
75771167|NCT01295086|Drug|Capecitabine|1250 mg/² continuously
75771168|NCT01295086|Drug|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
75771169|NCT03847012|Other|exercise|The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
75910625|NCT03744494|Procedure|Bilateral simple orchidectomy (BSO)|
75910626|NCT03744494|Procedure|Bilateral Subcapsular Orchidectomy|
75910627|NCT03744494|Procedure|Bilateral Epididymal-sparing Orchidectomy|
75910628|NCT03060382|Device|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.
75910629|NCT03060382|Biological|total knee arthroplasty|Total knee arthroplasty was conducted for the patients of control group
75910630|NCT05156450|Drug|TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone|Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
75910631|NCT03060304|Drug|Tamoxifen|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.
75910632|NCT03060304|Drug|estradiol valerate|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
75910633|NCT03665636|Drug|Triheptanoin|This is an open-label study. The UX007 (triheptanoin) starting dose will be 0.25 - 0.5 g/kg and titrated to a maximum of 2.5g/kg depending the on the subject's tolerance. The dose may be reduced if not tolerated. The compound will be administered 3-4 times per day, either at the end of a meal or with a snack. It should be given at least 2 hours apart from any cornstarch dose to allow each to act independent of one another, and to prevent the risk of increased gastrointestinal side effects. The doses may be held during episodes of gastroenteritis or diarrhea.
76072639|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
75318513|NCT05907161|Device|SRP+LASER (Dentsply Sirona - SIROLaser Blue)|adjunct irradiation with a diode laser (Dentsply Sirona - SIROLaser Blue) intrasulcularly to all sites with PD ≥ 4mm
75318514|NCT05907161|Device|SRP+HA|adjunct hyaluronic acid (Regedent, HyaDENT Cross linked hyaluronic intrasulcularly to all sites with PD ≥ 4mm
75771170|NCT03851224|Procedure|control group|immediate implant with immediate loading using no graft
75771171|NCT03851224|Procedure|study group|immediate implant with immediate loading using autogenous bone graft
75771172|NCT03851224|Procedure|study group 2|immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
75771173|NCT01194700|Drug|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
75771174|NCT01194700|Drug|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
75771175|NCT01194700|Drug|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
75771176|NCT01194700|Drug|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
75771177|NCT01189318|Drug|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4~28 50~150mg (increments and deduction of 50mg are allowed)
75771178|NCT01194778|Dietary Supplement|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
75318515|NCT05907161|Device|SRP|non-surgical periodontal therapy (SRP) with utrasonic device and curretes
75318516|NCT05899244|Other|muscle streching exercice|"For this exercice the participant will have to place the foot of the stretched leg on a step while maintaining his knee in extension.~From this starting position the patient will have to do a pelvic anterior tilt while keeping is back straight and his gaze horizontal until the movement induce a feeling of stretching in the posterior part of the thigh."
75318517|NCT05899244|Other|Slider|"In order to define the starting position for a slider, the participant will be positioned in lateral decubitus with the knee extended and will perform a hip flexion until a sensation of pain or stretching feeling appears on the posterior part of the thigh or of the knee. If the hip flexion does not induce a stretching sensation or pain, a dorsal ankle flexion is added. Once this position is defined the patient slightly reduces the amount of hip flexion until the stretching/pain sensation disappears.~From this starting position, to perform the slider: the subject performs a hip flexion movement and simultaneously a cervical extension movement, this corresponds to the outward movement. For the return movement the patient performs a hip extension and at the same time a cervical flexion. The slider technique must be pain free."
75318518|NCT05899244|Other|Tensioner|"The participant will be positioned in lateral decubitus with the knee extended and the hip, the cervical, thoracic and lumbar spine placed in neutral position.~For the outward movement, the participant will perform a hip flexion associated with a simultaneous movement of cervical extension until a sensation of pain or a stretching feeling appears on the posterior part of the thigh or of the knee.If this combined movements do not induce a stretching sensation or pain, a dorsal flexion of the ankle is added.~For the return movement, the participant will realize a hip extension simultaneously associated to a movement of extension of the cervical spine. If the dorsal flexion of the ankle was used during the outward movement, a movement plantar flexion of the ankle must be used in association to the movement of hip extension."
75910634|NCT04432402|Drug|Lenalidomide|Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
75318519|NCT05890950|Drug|K-757 and K-833|Both administered orally
75617926|NCT02823886|Other|MRI at D7|The infarct size measured on MRI at 7 days.
75617927|NCT02823886|Biological|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
75617928|NCT05299255|Drug|Utidelone|Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer
75617929|NCT05299255|Drug|Placebo|the placebo as control group.
75318520|NCT05890950|Drug|Matching placebo to K-757 and K-833|Both administered orally
75318521|NCT05890352|Procedure|Biospecimen Collection|Undergo optional collection of blood
75318522|NCT05890352|Procedure|Computed Tomography|Undergo PET/CT and CT
75318523|NCT05890352|Drug|Lenalidomide|Given PO
75318524|NCT05890352|Procedure|Magnetic Resonance Imaging|Undergo MRI
75318525|NCT05890352|Procedure|Positron Emission Tomography|Undergo PET/CT
75318526|NCT05890352|Other|Quality-of-Life Assessment|Ancillary studies
75318527|NCT05890352|Other|Questionnaire Administration|Ancillary studies
75318528|NCT05890352|Biological|Tafasitamab|Given IV
75318529|NCT05890352|Drug|Tazemetostat|Given PO
75318530|NCT05890352|Drug|Zanubrutinib|Given PO
75318531|NCT05886673|Other|experimental cream|experimental cream
75318532|NCT05886673|Other|standard of care|standard of care
75318533|NCT05866640|Device|F2 filter and delivery system|Placement of F2 device in aorta to cover great cerebral vessels
75318534|NCT05856487|Drug|NVP-2203|Take it once daily for 8 weeks orally.
75318535|NCT05856487|Drug|NVP-2203-R1|Take it once daily for 8 weeks orally.
75318536|NCT05856487|Drug|NVP-2203-R2|Take it once daily for 8 weeks orally.
75318537|NCT05856487|Drug|NVP-2203-R3|Take it once daily for 8 weeks orally.
75318538|NCT05856487|Drug|NVP-2203 Placebo|Take it once daily for 8 weeks orally.
75318539|NCT05856487|Drug|NVP-2203-R1 Placebo|Take it once daily for 8 weeks orally.
75318540|NCT05856487|Drug|NVP-2203-R2 Placebo|Take it once daily for 8 weeks orally.
75318541|NCT05856487|Drug|NVP-2203-R3 Placebo|Take it once daily for 8 weeks orally.
75464252|NCT01875172|Behavioral|smoking cessation counseling|
75464253|NCT01875185|Drug|Aspirin 81 mg|Aspirin 81 mg orally daily for 7 days
75464254|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy with Splenectomy|
75464255|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
75464256|NCT01875224|Drug|Belatacept|
75464257|NCT01875224|Drug|Tacrolimus|Standard administration of tacrolimus
75464258|NCT01875263|Drug|Cloxacilin|2g/4 hours i.v., 5 days
75464259|NCT01875263|Drug|Cloxacillin|2g/4h 14 days Standard therapy
75464260|NCT01875263|Drug|Levofloxacin|500 mg v.o./24h, 9 days
75617930|NCT02823340|Device|Fractional microneedle RF(United, Peninsula Medical, China)|
75617931|NCT00677911|Behavioral|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
75771179|NCT01194778|Dietary Supplement|vitamin K1|15 µg vitamin K1 per day during 12 weeks
75910635|NCT03663764|Drug|Thymosin a1|All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
76072640|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
75910636|NCT03663764|Radiation|hypofractionated radiotherapy|HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.
75464261|NCT01875289|Procedure|obturator nerve block|
75617932|NCT02823184|Biological|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
75771180|NCT01194778|Dietary Supplement|vitamin K2|15 µg vitamin K2 per day during 12 weeks
75771181|NCT01194778|Dietary Supplement|vitamin K2|30 µg vitamin K2 per day during 12 weeks
75771182|NCT01194778|Dietary Supplement|vitamin K2|45 µg vitamin K2 per day during 12 weeks
75771183|NCT01194934|Drug|NOX-A12|4 mg/kg daily IV for 5 days
75771184|NCT01194934|Drug|NOX-A12|2 mg/kg daily IV for 5 days
75771185|NCT01194934|Drug|Filgrastim|5 µg/kg SC daily for 5 days
75771186|NCT01194934|Drug|NOX-A12 in combination with Filgrastim|Safe and efficacious dose regimen according to results of groups A and B
75771187|NCT01353118|Biological|gastric bypass|Optimise glucose control within 3 months before operation
75771188|NCT03849040|Procedure|Endobronchial Ultrasound|All patients will undergo EBUS-TBNA as per routine care, except for the one difference where the procedures will be video-recorded so that they can be used for computer analysis at a later time. Static images will be obtained from EBUS videos in order to perform segmentation. Segmentation will be conducted by both an experienced endoscopist and NeuralSeg.
75771189|NCT01189474|Device|Blephasteam|Eye lid warming goggles
75771190|NCT01297036|Drug|Donepezil, ODT 10 mg|Test- Donepezil Hydrochloride 10 mg Tablet single dose
75771191|NCT01297036|Drug|Donepezil, 10 mg tablet|Reference: Donepezil Hydrochloride 10 mg Tablet
75771192|NCT01189552|Behavioral|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
75771193|NCT01189552|Behavioral|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
75771194|NCT01297114|Drug|Florbetaben|This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
75771195|NCT01292824|Drug|ITX 5061|ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
75464262|NCT01875315|Other|Diagnostic Cardiac Imaging|
75318542|NCT05840380|Device|instrumental soft tissue mobilization|Individual supine for application will be deposited. The Graston instrument glides over the tissues of the individual. cream will be applied to make it easier, then the physiotherapist will will stand on its side at the level and graston for 5 minutes. superficially on the thoracolumbal fascia between the sacrum and T12. will be applied
75318543|NCT05826808|Diagnostic Test|Polysomnography|The polysomnographic recordings include electroencephalogram (EEG), electrooculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), pulse oximetry, transcutaneous capnography, nasal airflow and thoracic and abdominal respiratory effort.
75318544|NCT05820854|Other|Self-assess and reporting self-care self-efficacy levels|Patients will have to self-report the self-care self-efficacy levels they experienced in managing the OAC therapy.
75464263|NCT01875328|Other|Telemedicine|Post stroke follow up in home using telemedicine.
75464264|NCT01875328|Other|Clinic|Post stroke clinic group follow up
75464265|NCT01875341|Device|NCPAP; Nasal continuous positive airway pressure.|Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
75464266|NCT01875341|Device|NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group|In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
75464267|NCT01875354|Dietary Supplement|Dietary Supplements and TR90 Eating Plan|Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
75464268|NCT01875354|Dietary Supplement|Placebo and Low Fat Eating Plan|
75464269|NCT01875380|Drug|Regorafenib|
75464270|NCT01875393|Drug|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
75617933|NCT00677989|Procedure|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
75617934|NCT00677989|Procedure|Open appendectomy|open appendectomy: did appendectomy by laparotomy
75617935|NCT02822482|Drug|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
75617936|NCT02822482|Drug|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
75617937|NCT00678067|Dietary Supplement|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
75910637|NCT03663764|Drug|concurrent chemoradiotherapy|All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
75464271|NCT01875406|Other|diagnostic exercises|
75771196|NCT01292902|Other|inspiratory muscle exercise|To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 < 88%.
75771197|NCT01292902|Other|inspiratory muscle exercise|Equal to the group with chronic heart failure.
75910638|NCT03060148|Device|Medtronic neurostimulation system|Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
75910639|NCT04432324|Biological|Intravenous Immune Globulin|IVIG Intravenous infusion
75910640|NCT04432324|Drug|Standard Medical Treatment|SMT
75910641|NCT02736890|Drug|Botulinum Toxin A|Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
75910642|NCT02736890|Drug|Placebo|Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
75910643|NCT04977388|Drug|Droxidopa|Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.
75910644|NCT04977388|Other|Placebo|Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.
75464272|NCT01875419|Device|Transcranial direct current stimulation (tDCS)|"Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between."
75464273|NCT01875419|Behavioral|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
75910645|NCT04965376|Procedure|Glenohumeral joint steroid injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
75910646|NCT04965376|Procedure|Suprascapular nerve block steroid injection|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
75910647|NCT03472196|Device|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
75464274|NCT01875497|Dietary Supplement|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
75464275|NCT01875523|Drug|Serelaxin|
75617938|NCT00678067|Dietary Supplement|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
75771198|NCT01195012|Behavioral|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
75771199|NCT03846700|Device|aquablation|"minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet"
75464276|NCT01875536|Device|rTMS|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
75771200|NCT03846700|Device|holep|holmium laser enucleation of prostate
75318545|NCT05814614|Other|pelvic physical therapy|Pelvic floor muscle exercises, biofeedback, bladder training
75464277|NCT01875536|Behavioral|conventional physical therapy|The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
75464278|NCT01875549|Device|stent insertion|to use a LCD stent at an unilateral or bilateral stent insertion
75617939|NCT00678067|Dietary Supplement|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
75617940|NCT00678067|Other|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake <30% of total calories, Saturated fat intake <10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
75910648|NCT03470480|Device|Real Repetitive transcranial magnetic stimulation|A real magnet will be used during rTMS treatments, which will look identical to the sham magnet. The participants and treatment facilitator will be blinded to which magnet will be used. High frequency repetitive transmagnetic stimulation (rTMS) will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
75771201|NCT03846700|Device|pvp|photoselectivevaporization of prostate
75771202|NCT01295164|Device|classic aberrometer and aberrometer AOVIS-1|"Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer."
75910649|NCT03470480|Device|Sham Repetitive transcranial magnetic stimulation|A sham magnet will be used during rTMS treatments, which will look identical to the real magnet. The participants and treatment facilitator will be blinded to which magnet will be used. The sham rTMS treatments will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
75910650|NCT03470480|Behavioral|Methamphetamine visual cues|Just before each rTMS session, participants will be shown methamphetamine-related pictures
75910651|NCT03470480|Behavioral|Neutral visual cues|Just before each rTMS session, participants will be shown neutral pictures
75910652|NCT04958018|Dietary Supplement|Almonds|almond (Prunus dulcis) consumption
75910653|NCT04958018|Dietary Supplement|Snack bars|324 calories/day, Nutri-Grain cereal bars, 120 kcal each
75910654|NCT04976998|Diagnostic Test|imaging|imaging by ultrasonography and nerve conduction studies will be done for both grups
75936312|NCT05706155|Behavioral|Control Diet|Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
75318546|NCT05814029|Other|Mobilization with movement for Ankle|The participant will assume a lunge position on a rigid serving table with the relevant extremity in a weight-bearing stance and the foot in a neutral position. An inelastic belt will be placed around the clinician's waist, flush with the lower edge of the medial malleolus, around the distal tibia and fibula. The clinician will stabilize the talus and forefoot with the web spacing of the hands and pressure dimensions on the talus and forefoot, and maintain posterior to anterior sliding of the tibia over the talus using the arch. The clinician will continue to apply pressure while the person is reporting discomfort and/or while the lunge moves, which will continue until the end of the range of motion. Mobilization will be performed as a set of 10 repetitions.
75464279|NCT01875549|Procedure|Endoscopic retrograde cholangiopancreatoscopy(ERCP)|to use ERCP for a stent insertion in an obstructive biliary tract
75464280|NCT01875562|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
75464281|NCT01875575|Dietary Supplement|Placebo|
75464282|NCT01875575|Dietary Supplement|Glucose 25g|
75464283|NCT01875575|Dietary Supplement|Glucose 10g|
75464284|NCT01875627|Dietary Supplement|Konjac noodles|Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
75464285|NCT01875627|Dietary Supplement|Carbohydrate and Konjac Noodles|
75464286|NCT01875627|Dietary Supplement|Carbohydrate noodles|
75464287|NCT01875653|Biological|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
75464288|NCT01875653|Biological|Autologous PBMCs in GM-CSF (MC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
75464289|NCT01875666|Drug|Trastuzumab|8 mg/kg IV, single dose
75464290|NCT01875666|Drug|pertuzumab|840 mg IV single dose
75464291|NCT01875666|Drug|lapatinib|1000 mg daily for 7 days
75464292|NCT01875679|Other|Comprehensive Surgical Coaching|
75464293|NCT01875679|Other|Conventional Surgical Training|Surgical training as per participant's residency program
75771203|NCT01295164|Device|Aberrometer AOVIS-I|Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
75464294|NCT01875705|Drug|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
75464295|NCT01875705|Drug|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
75464296|NCT01875718|Drug|UC1010|
75464297|NCT01875718|Drug|Placebo|
75464298|NCT01875744|Drug|Polyethylene glycol 4000|
75464299|NCT01875757|Drug|Vitamin D3|
75464300|NCT01875757|Drug|Placebo|
75464301|NCT01875796|Behavioral|Cognitive-Behavioral Therapy|
75464302|NCT01875796|Behavioral|Motivation Enhancement Therapy|
75464303|NCT01875796|Behavioral|Integrated Cannabis and Anxiety Reduction Treatment|
75464304|NCT01875796|Behavioral|False Safety Behavior Elimination Therapy|
75464305|NCT01875822|Dietary Supplement|Super-Curcumin|The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
75464306|NCT01875835|Device|Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)|
75617941|NCT04239898|Other|Red cabbage microgreens|2 cups per day
75617942|NCT04239898|Other|Red beet microgreens|2 cups per day
75617943|NCT02822326|Biological|CD19-CAR-T2 Cells|
75617944|NCT00675337|Procedure|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
75617945|NCT00675337|Procedure|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
75617946|NCT04152265|Procedure|colonoscopy|colonoscopy
75464307|NCT01875835|Device|Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)|
75464308|NCT01875887|Procedure|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
75617947|NCT04152265|Other|questionnaires|complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
75617948|NCT04152265|Other|demographic data collections|completing the demographic questionnaire
75617949|NCT04152265|Other|anthropometric data collections|For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
75910655|NCT05156294|Device|NovoMatrix|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Consecutively, 4 to 6 mm height healing abutments and the allogenic membrane (NovoMatrix®, BioHorizon) folded in two on top of the implant (secured with the healing abutment), will be placed. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
75910656|NCT05156294|Other|Control|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
75910657|NCT03469856|Drug|Prasugrel monotherapy|A multicenter, single arm, open-label trial of in patients with chronic stable angina
75617950|NCT04152265|Procedure|Collecte the biological samples|blood and faeces collections
75771204|NCT03848806|Drug|HAT1|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
75771205|NCT03848806|Drug|Calcipotriol|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
75771206|NCT03848884|Behavioral|Adherence monitoring and education|Standardized medication counseling and education combined with individual patient customized guidance and counseling - administered monthly.
75771207|NCT03850990|Behavioral|Placebo pill and no placebo pill|The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.
76072641|NCT04084288|Other|Acupuncture|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
75464309|NCT01875900|Other|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
75771208|NCT00867802|Behavioral|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
75464310|NCT01875900|Other|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
75771209|NCT01189864|Drug|Ciprofloxicin or Vigamox or other.|Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
75771210|NCT01189864|Drug|Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
75771211|NCT01189864|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
75464311|NCT01875913|Behavioral|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
75464312|NCT01875913|Behavioral|Standard Message|"Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online)."
75464313|NCT01875926|Biological|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
75464314|NCT01875926|Biological|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
75464315|NCT01875926|Biological|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
75617951|NCT02822404|Dietary Supplement|Urinary and blood sample for Cystatine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
75617952|NCT02822248|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-64-R84-070)
75617953|NCT00675493|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
75771212|NCT01195246|Biological|HEPLISAV|Intramuscular (IM) injection on Day1
75771213|NCT01195246|Biological|Engerix-B|Intramuscular (IM) injection on Day 1
75910658|NCT04153786|Other|Temporary changes in an already-implanted medical device (biventricular pacemaker)|"During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits."
75910659|NCT04912232|Device|Detection of Occult Hemorrhage in Trauma Patients|Non-invasive monitoring of trauma patients
75464316|NCT01875939|Drug|Oral WCK2349|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
75464317|NCT01875939|Drug|IV WCK771|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
75910660|NCT04917016|Diagnostic Test|Plasma B-HCG levels|Blood sample
75910661|NCT04917250|Drug|Gemcitabine|1000mg/㎡，d1,4 ivdrip
75617954|NCT04240990|Other|Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.|"The diagnostic strategy will include an initial clinical, radiographic and bacteriological evaluation of all enrolled children:~TB contact history~Suggestive TB symptoms in the previous 4 weeks~Physical examination~Clinical, anthropometric and biochemical assessment of malnutrition~Clinical assessment for other non-dietary causes of malnutrition~Digitalized CXR~Ultra performed on NPA and stool samples, and one gastric aspirate (GA)~Mycobacterial culture performed on two GAs~Abdominal ultrasonography~QuantiFERON®-TB Gold IGRA~Monocyte-to-Lymphocyte Ratio (MLR)~C-Reactive Protein (CRP)~TB diagnosis will be made according to national TB guidelines."
75464318|NCT01875952|Drug|Isoniazid|Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
75464319|NCT01876004|Drug|Methotrexate|50 mg/m2, IM (intramuscularly), single dose
75617955|NCT02627131|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
75771214|NCT01195246|Biological|Fendrix|Intramuscular (IM) injection on Day 1
75771215|NCT01292980|Device|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
75910662|NCT04917250|Drug|Pegaspargase|2500IU/㎡, maximum dose less than 3750IU
75318547|NCT05804461|Behavioral|Motivational Interviewing|Upon refinement from Formative Research (Aim 1), a three-session, individual-level intervention to increase Pre-Exposure Prophylaxis (PrEP) uptake among men who have sex with men (MSM) in Puerto Rico will be implemented. The facilitator will use Motivational Interviewing techniques to guide the sessions. The intervention's design and content will be the same for each study group; the only difference will be the modality of implementation; one group of participants will receive a face-to-face intervention, while another group will receive an online intervention.A total of 170 participants will be randomized in a 1:1 ratio into each of the two intervention modalities (n=85 face-to-face and n=85 online) while a control group will be recruited following a 3:1 ratio of intervention vs. control. In addition to baseline assessment, participants will be asked to complete a post test at the end of the third session (60 days) and a follow-up post-test at the 150-day mark, separately.
75318548|NCT05803655|Other|36-hour duration between ovulation triggering and oocyte pick-up procedure|36-hour duration between ovulation triggering and oocyte pick-up procedure
75318549|NCT05803655|Other|38-hour duration between ovulation triggering and oocyte pick-up procedure|38-hour duration between ovulation triggering and oocyte pick-up procedure
75318550|NCT05799612|Drug|Paclitaxel|Given by IV (vein)
75318551|NCT05799612|Biological|mRNA plus Lysate-loaded Dendritic Cell Vaccine|Given by IV (vein)
75318552|NCT05799612|Drug|PEGYLATED-INTERFERON ALPHA-2A|Given by IV (vein)
75318553|NCT05799612|Drug|Filgrastim|Given by IV (vein)
75318554|NCT05791617|Diagnostic Test|cardiac PET/MRI|Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
75318555|NCT05791617|Diagnostic Test|Inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
75318556|NCT05791617|Diagnostic Test|Diagnostic Test: NT-proBNP|NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
75464320|NCT01876004|Drug|Placebo|Prescribed Placebo IM (intramuscularly), single dose
75464321|NCT01876017|Biological|Intravenous transfer of Autologous (BMMNCs)|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
75464322|NCT01876030|Device|FES|
75464323|NCT01876056|Behavioral|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
75464324|NCT01876069|Device|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
75617956|NCT02821936|Procedure|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
75771216|NCT03846856|Other|Biopsy|Biopsy taken during surgical procedure
75771217|NCT03846934|Device|Ultrasonography thoracic|Thoracic ultrasonography will be performed as soon as possible after admission to the ED, without delaying the start of treatment and in addition to routine thoracic radiography.
75771218|NCT05671120|Procedure|Transcutaneous levator recession|recession of the upper and lower eyelid retractors can improve the upper eyelid contour if the patient has lateral flare (common in TED). The choice of procedure depends on severity of lid retraction and associated features like proptosis, status of extraocular muscles, and corneal condition
75464325|NCT01876069|Device|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
75771219|NCT01191814|Procedure|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
75771220|NCT01191814|Procedure|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
75910663|NCT04917250|Drug|Etoposide|100mg/㎡，d1-3 ivdrip
75910664|NCT04917250|Drug|Dexamethasone|20mg/d d1-4 ivdrip
75617957|NCT04239664|Other|Acceptance Based Telephone Support (ABS+UC)|Support based on Acceptance and Committment Therapy (Hayes, 1999)
75910665|NCT05156138|Other|no interventions as it is a case control observational study|no interventions as it is a case control observational study
75910666|NCT05155748|Other|Continuous education and knowledge exchange|The intervention is educational and directed at the complete nursing home care team.
75910667|NCT04977076|Other|Uninterrupted NOAC use|Continuing NOAC use in advance of elective CAG or PCI.
75910668|NCT04977076|Other|Interrupted NOAC use|Usual care, interruption of NOAC prior to procedure.
75910669|NCT03469778|Device|Robotic Therapy|Robotic Therapy
75910670|NCT04976764|Other||
75910671|NCT04859582|Biological|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
75910672|NCT04859582|Drug|Cisplatin|Administered as an IV infusion on Day 1 Q3W
75910673|NCT04859582|Drug|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
75910674|NCT04859582|Drug|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
75910675|NCT04859582|Drug|Capecitabine|Administered orally BID on Days 1 to 14 Q3W
75910676|NCT04859582|Drug|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
75910677|NCT03469700|Other|general anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr
75910678|NCT03469700|Other|Paravertebral block|Bilateral paravertebral block guided by a nerve stimulator will be performed by injecting local anesthetic mixture from levels T11 to T6. Each 20 ml of the mixture will contain: 6 ml lidocaine 2%; 6 ml lidocaine 2% with adrenaline 5 μg /ml; 5 ml bupivacaine 0.5%; 50μg fentanyl (1 ml); and 2 ml saline 0.9%
75617958|NCT04240834|Drug|Aspirin|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
75617959|NCT04240834|Drug|Ticagrelor|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
75617960|NCT01200758|Drug|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
75617961|NCT01200758|Drug|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
75617962|NCT01200758|Drug|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m^2 IV) administered every 3 weeks.
75771221|NCT03850834|Drug|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
75771222|NCT03850834|Drug|placebo enteric-coated tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
75771223|NCT01191892|Drug|carboplatin|
75910679|NCT03469700|Other|Placebo PVB|Placebo bilateral paravertebral block guided by a nerve stimulator will be performed by injecting normal saline from levels T11 to T6.
75910680|NCT03062020|Device|QUIPP|Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
75910681|NCT03469622|Device|EndoRings|EndoRings-assisted colonoscopy
75910682|NCT03469622|Device|Standard colonoscopy|Standard colonoscopy without any additional devices
75910683|NCT04912726|Drug|Sildenafil Injectable Product|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
75910684|NCT03130712|Drug|GPC3-CART cells|Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
75910685|NCT04912882|Diagnostic Test|Circulating tumor cell|detecting circulating tumor cell pre- and post operatively
75910686|NCT03472118|Device|Nasal High Flow Oxygen|Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
75617963|NCT01200758|Drug|Doxorubicin|Eight cycles of doxorubicin (50 mg/m^2 IV) administered every 3 weeks.
75617964|NCT01200758|Drug|Vincristine|Eight cycles of doxorubicin (1.4 mg/m^2 IV) administered every 3 weeks.
75771224|NCT01191892|Drug|gemcitabine hydrochloride|
75771225|NCT01191892|Drug|vandetanib|
75910687|NCT04976842|Device|OFA|Anesthesiology technique based on Mulier protocol. Before induction, loading dose of dexmedetomidine 0,25mcg/kg (max 20mcg). Induction with dexmedetomidine 0,1mcg/kg, lidocaine 1mg/kg, ketamine 0,1mg/kg plus propofol 2mg/kg plus rocuronium1mg/kg IBW (if required). Maintenance with dexmedetomidine 0,1mcg/kg/h, lidocaine 1mg/kg/h, ketamine 0,1mg/kg/h and propofol infusion adjusted according to bispectral index indication ( BIS maintained 40-60). 15 minutes prior to end of surgery, the dose of drugs is reduced to dexmedetomidine 0,05mcg/kg/h, lidocaine 0,5mg/kg/h, ketamine 0,05mg/kg/h.
75771226|NCT01191892|Drug|Placebo|Placebo of vandetanib tablet
75771227|NCT05596474|Dietary Supplement|Beet-root juice|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.
75771228|NCT05596474|Radiation|red-light therapy|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.
75617965|NCT01200758|Drug|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
75771229|NCT05596474|Dietary Supplement|Placebo|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.
75771230|NCT05596474|Radiation|sham light|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
75771231|NCT01189942|Drug|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
75771232|NCT01293058|Drug|Intranasal naloxone|spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
75771233|NCT01293058|Drug|Intravenous|Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
75771234|NCT05671042|Other|Patients with Upper excretory tract tumors|Standard of care for patients with Sezary Syndrome
75771235|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
75617966|NCT02823106|Drug|Verapamil and Citicoline|Single dosing strategy will be used.
75771236|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
75771237|NCT05565898|Device|positron emission tomography for exclusion of bone marrow infiltration in lymphoma|compare the diagnostic accuracy of PET/CT scan against Bone Marrow Biopsy in detection of bone marrow involvement for staging of lymphoma
75771238|NCT01195402|Procedure|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
75771239|NCT01192360|Procedure|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
75771240|NCT01192360|Procedure|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
75771241|NCT01190332|Procedure|endoscopic sphincterotomy by conventional method|
75771242|NCT01190332|Procedure|endoscopic sphincterotomy by rendezvous method|
75771243|NCT01190488|Behavioral|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
75771244|NCT01190488|Behavioral|Active Comparator|TAU
75771245|NCT05668390|Drug|STALORAL® Birch 300 IR|2 treatment periods will consist of 2 steps: an escalation phase, where the treatment dose will gradually increase, followed by a maintenance phase.
75771246|NCT01192438|Procedure|Laser-based thermotherapy|MRI-guided transperineal placement of a laser probe into the prostate
75771247|NCT03846466|Drug|KHK4323 IV/S|IV / Single administration
75771248|NCT03846466|Drug|KHK4323 SC/S|SC / Single administration
75617967|NCT02823106|Other|Placebo|Single matching dosing strategy will be used.
75617968|NCT02821858|Drug|Odalasvir (ODV)|ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.
75617969|NCT02821858|Drug|AL-335|AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.
75617970|NCT02821858|Drug|Placebo|Matching placebo will be administered.
75617971|NCT04240600|Dietary Supplement|Experimental group|2 cans or bottles (200ml)per day, orally
75617972|NCT04240600|Dietary Supplement|Control group|2 cans or bottles (200ml)per day, orally
75617973|NCT00876343|Drug|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
75617974|NCT00876343|Drug|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
75617975|NCT00876343|Drug|Placebo|administered orally once daily, 6 weeks
75617976|NCT02822014|Other|FDG-PET/CT|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
75464326|NCT01876095|Procedure|Multidisciplinary medication review|"Consists of the following steps:~1. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.~2. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.~3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.~5. Execution of pharmaceutical care plan according to agreed schedule."
75464327|NCT01876108|Drug|H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
75318557|NCT05783466|Other|Low-fat dairy products|3-month intervention
75318558|NCT05783466|Other|Whole-fat dairy products|3-month intervention
75617977|NCT04151641|Dietary Supplement|MNGDPF|Standardized mangosteen extract in dry powder form
75318559|NCT05783466|Other|Milk polar lipid enriched whole-fat dairy products|3-month intervention
75910688|NCT04976842|Drug|OBA|Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
75318560|NCT05780931|Behavioral|Study-specific rehabilitation (SSR) procedures|Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.
75318561|NCT05779501|Behavioral|Internet-delivered strengths use intervention|"The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution."
75318562|NCT05779501|Behavioral|Waiting-list|"The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program."
75617978|NCT04151641|Dietary Supplement|MNGEF|Standardized mangosteen extract in encapsulated form
75617979|NCT02627989|Drug|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
75771249|NCT03846466|Drug|KHK4323 IV/M|IV / Multiple administration
75771250|NCT03846466|Drug|Placebo IV/S|IV / Single administration
75771251|NCT03846466|Drug|Placebo IV/M|IV / Multiple administration
75771252|NCT03846466|Drug|Placebo SC/S|SC / Single administration
75910689|NCT02779556|Other|ACP Living with Diabetes Guide|American Colleges of Physicians (ACP) Living Well with Diabetes Guide
75910690|NCT02779556|Other|ADA Living Well with Diabetes Workbook|American Diabetes Association (ADA) Living Well with Diabetes Workbook
76072642|NCT04084288|Device|Peripheral Nerve Stimulator|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
75318563|NCT05779319|Device|non contact measurement with the IOL Master 700|postoerpative we will perform non contact measurement with the IOL Master 700
75771253|NCT01293136|Procedure|Femoral nerve block|Ropivacaine
75617980|NCT02627989|Drug|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
75617981|NCT02822170|Other|IV amino acids and in-bed cycle ergometry|IV amino acids and in-bed cycle ergometry
75617982|NCT02627209|Other|spectrophotometric assay|measurement of enzyme activity in the serum
75617983|NCT02627209|Other|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
75617984|NCT00675649|Biological|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
75617985|NCT00675649|Biological|placebo|placebo sc injection every 4 weeks from week 0 to week 20
75771254|NCT01293136|Drug|Intravenous opioids|Whatever opioids prescribed
75771255|NCT01195480|Genetic|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10^8/m2
75771256|NCT01195480|Biological|Irradiated donor-derived Lymphoblastoid Cell Line|"The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in > 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion."
75771257|NCT01295398|Device|nebulisations|
75771258|NCT01293292|Drug|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
75910691|NCT05133206|Other|Advice on fasting before the procedure|Patients are allowed to eat and drink freely up to the point of transfer to the Catheter Laboratory.
75910692|NCT05106998|Device|nailfold capillaroscopy|Nailfold capillaroscopy (NFC) is a non-invasive easily repeatable technique and the best method for morphological analysis of nutritional capillaries in the nailfold area
75936313|NCT05706155|Behavioral|Plant-based Diet|Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
75318564|NCT05775562|Diagnostic Test|Pre and post dive examinations|"Performing pre-dive examinations:~- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~Portable Spirometry~Pulmonary ultrasound~Cardiac ultrasound~Measurement of circulating bubbles~ECG~Venous blood sampling (biological collection)~Water balance (Δweight/water intake)~EFR by plethysmography cabin~Weight measurement~Realization of the examinations the day after the dive:~Venous blood sample (biological collection)~Portable Spirometry~Pulmonary ultrasound~Cardiac ultrasound~Weight measurement"
75910693|NCT03470402|Other|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
75910694|NCT03470402|Other|BNAV|BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.
75910695|NCT03470402|Other|iNYP|Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
75910696|NCT03470402|Other|Standard Educational Material|Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
75910697|NCT03470402|Other|High-Risk Message|Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
75910698|NCT02603900|Drug|ropivacaine|15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
75910699|NCT02603900|Drug|bupivacaine|20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
75910700|NCT02603900|Device|Sham Adductor Canal Catheter|Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
75910701|NCT02603900|Device|Adductor Canal Catheter|Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
75910702|NCT01669798|Drug|BIBF 1120|PO 200mg BID
75910703|NCT03055078|Biological|mesenchymal stem cells|Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
75910704|NCT02334722|Drug|Levetiracetam|
75936314|NCT05552573|Biological|low-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
75936315|NCT05552573|Biological|Recombinant COVID-19 Vaccine (CHO Cell)|This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.
75936316|NCT05552573|Biological|high-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
75318565|NCT05752006|Other|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
75464328|NCT01876121|Drug|Celecoxib|oral
75464329|NCT01876160|Other|Transcutaneous electrical nerve stimulation|
75464330|NCT01876173|Behavioral|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
75464331|NCT01876186|Drug|Solifenacin for 12 weeks|Solifenacin 5 mg one a day for 12 weeks
75771259|NCT01295476|Genetic|gene expression analysis|
75771260|NCT01295476|Genetic|microarray analysis|
75771261|NCT01295476|Other|laboratory biomarker analysis|
75771262|NCT01195558|Other|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
75771263|NCT01195714|Drug|Ofatumumab|solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
75464332|NCT01876186|Drug|Solifenacin for 24 weeks|Solifenacin 5 mg once a day for 24 weeks
75464333|NCT01876199|Behavioral|intense follow up|
75464334|NCT01876225|Behavioral|Forced coughing during cervical punch biopsy|
75464335|NCT01876238|Other|T-PAT|
75464336|NCT01876238|Other|Surveys|Pre-test and posttest surveys and questionnaires
75771264|NCT01195792|Drug|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
75771265|NCT01195792|Drug|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
75771266|NCT01295554|Other|NCE MRA and CE MRA|"Each patient will receive on the same day:~NCE MRA~CE MRA usually performed in the clinical routine~After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images."
75771267|NCT05668468|Dietary Supplement|Bifidobacterium adolescentis IVS-1 capsule|Daily Bifidobacterium adolescentis IVS-1 capsule containing up to 6x10 ninth cfu per capsule or daily cellulose capsule
75771268|NCT05668468|Other|Placebo cellulose capsule|Daily cellulose capsule
75910705|NCT04916626|Behavioral|OPUS YOUNG|OPUS YOUNG is a two year out-patient specialized early intervention service for children and adolescents with a first episode psychosis. The OPUS YOUNG treatment consists of the following elements: modified assertive community treatment, low patients to case manager ratio, cognitive-behavioural case management (CBCM), psycho-educational family treatment including multiple family groups(MFG) and psychoeducational siblings groups, Social Cognition and Interaction Training (SCIT), possible individual Cognitive Behavioural Therapy (CBT) in addition to CBCM, and manual based psychopharmacologic treatment. Additional, special transition support, individual school/employment support, and prevention and treatment of substance abuse.
75318566|NCT05744557|Other|num Vapocoolant|Spray will be administered for 4 to 6 seconds from a distance of 3 to 6 inches to desired sites of skin
75318567|NCT05743049|Other|Obtaining blood for analysis of various circulating biomarkers|4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
75910706|NCT04916626|Behavioral|Treatment as Usual|The patients allocated to TAU will be offered non-manualized treatment following national Danish guidelines and local guidelines. Treatment is provided by a multidisciplinary team and consists of case-management (no defined upper case load), family support and psychoeducation, in addition to psychopharmacological treatment. In some cases, social skills training and CBT may be offered. In general, office visits take place in outpatient clinics.
75910707|NCT05035784|Drug|Fecal supernatant|Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .
75910708|NCT05035784|Drug|Placebo|a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.
75910709|NCT04976062|Diagnostic Test|Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS)|The NIRS-IVUS technique is an intravascular imaging technique, combining morphological information derived from intravascular ultrasound (IVUS) and molecular information on plaque composition, namely its respective lipid-core burden, using spectral differences between cholesterol and collagen, detected by near-infrared spectroscopy (NIRS). A combined NIRS-IVUS pullback results in a color-coded map indicating the probability of lipid-rich plaque presence in yellow, co-registered to the corresponding IVUS cross-sections.
75318568|NCT05741346|Drug|BCX9930|Taken orally at 400 mg twice daily (BID)
75318569|NCT05728476|Procedure|Vitrectomy combined with ILM peeling|Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.
75318570|NCT05728476|Drug|Conbercept intravitreal injection|Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
75771269|NCT01192594|Behavioral|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
75771270|NCT01192594|Behavioral|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
75771271|NCT03848494|Procedure|Surgery|Laparoscopic floppy Nissen, laparoscopic-left thoracoscopic Collis-Nissen, laparoscopic gastric fundus wrapped around the stomach
75910710|NCT04534400|Radiation|thoracic CT-scan|Automated measurement
75910711|NCT04458116|Dietary Supplement|Curcumin|Participants will receive 1.5 grams of turmeric 95% curcumin for 1 month (3 capsules / day containing 500mg each for 4 weeks).
76072643|NCT01813435|Drug|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
75910712|NCT04975984|Diagnostic Test|qualitative hCG levels and ultrasound criteria|detect upper limit of qualitative hCG levels associated with successful expectant management of ectopic pregnancy
75910713|NCT03469544|Other|complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction|"complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
75910714|NCT02204462|Drug|FBnTP|A PET imaging radiotracer
75318571|NCT05728411|Other|Remote foot temperature monitoring system|"Remote temperature monitoring involves a thermometric mat that can detect hot spots on the plantar surface of the foot. The mat has embedded cellular connectivity so that data can be transmitted from the patient's home to the company, where the temperature data can be analyzed. The company has a team of health coaches that work with patients and providers to detect signs of damage early in order to prevent ulceration."
75464337|NCT01876264|Procedure|Extended resection|
75464338|NCT01876264|Procedure|Conventional resection|
75464339|NCT01876290|Drug|Dexamethasone and Ondansetron|Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
75464340|NCT01876290|Drug|Placebo|Placebo
75464341|NCT01876303|Other|laboratory biomarker analysis|Correlative studies
75464342|NCT01876303|Other|questionnaire administration|Ancillary studies
75910715|NCT03062254|Drug|radium-223 dichloride|6 doses of Radium-223
75936317|NCT03189056|Diagnostic Test|Chagas serology|IFI + ELISA method if no biological confirmation of chagas disease is in our possession
76072644|NCT01813435|Drug|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
75318572|NCT05728411|Other|Enhanced usual care|"Usual care is based on the VA's amputation prevention program (PAVE - Preventing Amputation in Veterans Everywhere - VHA Directive 1410), which provides a model of care for patients at risk for amputation as well as patients who have already undergone an amputation.~Usual care will be enhanced by providing resources (e.g., information through written newsletters) relevant to a population of Veterans with diabetes, including information on nutrition and cooking, physical activities, and whole health opportunities"
75318573|NCT05726370|Drug|Pembrolizumab|Immunoglobulin G4 monoclonal antibody, via IV infusion
75464343|NCT01876316|Drug|Moxifloxacin|single oral administration of 400mg of moxifloxacin
75617986|NCT00633724|Biological|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
75617987|NCT01107912|Drug|prasugrel|administered orally, daily for 12 days
75617988|NCT01107912|Drug|clopidogrel|Administered orally, daily for 12 days
75771272|NCT03850132|Behavioral|FAM-SOTC-PL|"The adapted FAM-SOTC-PL intervention was delivered at the home of the participants and focuses on supporting the effective, cognitive, and behavioural domains of the bereaved family caregivers experience by targeting concerns/issues in these categories. The FAM-SOTC-PL comprises of the following five components:~Drawing forward narratives about the pre- and post-loss experience.~Asking therapeutic/interventive questions, emphasising on the most pressing concerns also assessing health issues.~Validating/acknowledging emotional responses.~Assessing the need for specific information and recommendations regarding bereavement.~The use of commendation/commending strengths, by focusing on and affirming the strengths of the family caregiver."
75771273|NCT01190722|Drug|etoricoxib|120 mg once daily for the 1st 6 postoperative days
75771274|NCT01190722|Drug|Diclofenac|50 mg oral 3 times daily the 1st 6 postoperative days
75771275|NCT01192672|Behavioral|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
75771276|NCT01192672|Behavioral|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
75771277|NCT01192750|Other|immunohistochemistry staining method|
75771278|NCT01192750|Other|laboratory biomarker analysis|
75771279|NCT01192750|Other|medical chart review|
75771280|NCT01196260|Drug|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin will be under the NSCLC guideline
75936318|NCT03189056|Biological|Creatinina|Plasmatic single mesure after consultation 1, to evaluate renal function
75318574|NCT05726370|Drug|CISPLATIN|Platinum agent, via IV infusion
75318575|NCT05726370|Drug|Carboplatin|Platinum agent, via IV infusion
75318576|NCT05726370|Drug|Docetaxel|Antineoplastic agent, via IV infusion.
75318577|NCT05720065|Drug|Botulinum toxin type A|Randomized double-blind administration
75464344|NCT01876316|Drug|Placebo|single oral administration of 400mg of placebo
75464345|NCT01876342|Procedure|open repair|2-0 sutures
75464346|NCT01876342|Procedure|endoscopic TEP repair|mesh
75617989|NCT01200524|Drug|AZD2423|20 mg tablet
75617990|NCT01200524|Drug|AZD2423|50 mg tablet
75617991|NCT01200524|Drug|Placebo|Placebo
75617992|NCT00678145|Drug|naloxone|Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
75617993|NCT00678145|Dietary Supplement|fructose|Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
75617994|NCT00678145|Behavioral|exercise|Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
75617995|NCT00678145|Drug|Morphine sulfate|Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
75617996|NCT00678145|Drug|Epinephrine|Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
75617997|NCT04239742|Diagnostic Test|F18-fluciclovine PET/CT|370 MBq ±10% 18F-Fluciclovin + low-dose CT scan, from skull base to pelvis.
75617998|NCT04239742|Diagnostic Test|F18-PSMA-1007 PET/CT|4 MBq/kg ±10% F18-PSMA + low-dose CT scan, from skull base to pelvis
75617999|NCT05010642|Device|Use of Eko DUO electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
75618000|NCT02626741|Dietary Supplement|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
75618001|NCT02626741|Behavioral|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
75618002|NCT04317950|Other|Vojta|Reflex locomotion stimulus
75618003|NCT04317950|Other|Sham|sham stimulus
75618004|NCT02879916|Drug|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
75618005|NCT02879916|Drug|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
75618006|NCT02690506|Drug|Placebo|
75618007|NCT02690506|Drug|Pregabalin|
75318578|NCT05720065|Drug|Isotonic saline 0,9%|Randomized double-blind administration
75318579|NCT05717504|Device|Implantable Loop Recorder|Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
75464347|NCT01876394|Other|Coconut Oil|Shake with 50 g Coconut oil
75464348|NCT01876394|Other|Canola Oil|Shake with 50 g Canola oil
75464349|NCT01876394|Other|Grapeseed Oil|Shake with 50 g Grapeseed oil
75464350|NCT01876394|Other|Chia Oil|Shake with 50 g Chia oil
75464351|NCT01876394|Other|Butter|Shake with 50 g Butter
75464352|NCT01876407|Device|Low intensity laser for oral mucositis|
75618008|NCT04310280|Drug|Insulin Glargine|Half of the wound surface is injected daily with topical glargine insulin
75618009|NCT04310280|Drug|Saline|Half of the wound surface is injected daily with topical saline solution
75318580|NCT05717504|Other|Quality of life survey|A quality of life survey will be performed at the end of the follow-up period. The survey will be done over the phone or in person if the follow-up visit is in person.
75318581|NCT05714618|Diagnostic Test|Gadolinium-enhanced cardiac MRI|Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.
75318582|NCT05714618|Diagnostic Test|B Natriuretic Peptide|Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.
75318583|NCT05714618|Diagnostic Test|Systemic inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.
75910716|NCT02125136|Drug|Gem/nab-Pac|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle"
75771281|NCT01196338|Behavioral|Early weight-bearing and range of motion exercises|"0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;~At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;~After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis."
75771282|NCT01196338|Behavioral|non-weight bearing, no range of motion|"0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;~At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;~After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis."
75771283|NCT03850210|Device|Short Splint|Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.
75771284|NCT03850210|Device|Traditional Long Splint|Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
75771285|NCT01293526|Device|Control|Patients who respond will have leads will be placed using standard procedures.
75771286|NCT01293526|Device|Experimental|Patients who respond will have their leads placed based on study measurements.
75910717|NCT02125136|Drug|FOLFIFINOX|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle."
75910718|NCT04912258|Drug|Trans arterial chemoembolization with Irinotecan Drug-eluting Beads|preoperative chemoembolization with Irinotecan Drug-eluting Beads
75910719|NCT01952288|Drug|simvastatin|simvastatin 40 mg/day for 12 months
75910720|NCT01952288|Drug|Placebo Oral Tablet|placebo comparator
75910721|NCT04912414|Behavioral|Brief Family Therapy (BFT)|Patients transferred to the hospital for the treatment of psychosomatic symptoms was randomized (1:1) to receive either Brief Family Therapy (BFT) or a control treatment. Some participants randomized to the BFT arm receive a combination of chemotherapy and BFT and others receive only BFT. BFT comprises 10 sessions using a generic model of problem formation and resolution. This psychotherapy is useful for treating individual, couple, and family problems. Its broad applicability is based on its view that the client's complaint is the problem, not a symptom of something else BFT views behavior, especially a client's problematic behavior, as a function of interaction with other people. After randomization, all participants were asked to complete questionnaires about their psychosomatic symptoms and health at baseline, at the end of the intervention (at 4 months).
75910722|NCT03054532|Drug|Durvalumab|Durvalumab intravenous 1500 mg
75910723|NCT03054532|Drug|Lenali|Lenalidomide oral 20 mg/day
75318586|NCT05706272|Other|Comprehensive geriatric assessment (CGA)|The intervention includes a holistic comprehensive geriatric assessment using the PASTEL assessment tool that includes medical, psychiatric, functional and social aspects. Physical tests will include function, risk of falling, hand muscle strength, Timed up and Go (TUG), chair-stand test, blood pressure, saturation and BMI. A proactive person centered care plan will be established based on identified needs and the patients own priorities. A nurse will coordinate the care in the elderly team at the intervention practice with access to rehabilitation staff such as physiotherapist and occupational therapist. Follow-ups at the primary care practices will be carried out in accordance with the study plan. To strengthen care coordination, contact will be taken with other health care providers before the follow-ups.
75318587|NCT05706272|Other|Care as usual|The control group will receive care as usual at the matched control primary care centers
75464353|NCT01876407|Device|Low intensity laser for oral mucositis switch off|Low intensity laser for oral mucositis switch off
75464354|NCT01876433|Drug|Mirabegron|
75464355|NCT01876433|Drug|Placebo|
75464356|NCT01876459|Other|MRI|
75464357|NCT01876459|Procedure|lumbar puncture|
75464358|NCT01876459|Behavioral|neuropsychological tests|
75464359|NCT01876472|Behavioral|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
75464360|NCT01876498|Procedure|Xiaflex surgery|Xiaflex surgery
75464361|NCT01876537|Device|Hardware wound healing|
75464362|NCT01876537|Device|Usual Surgery|
75464363|NCT01876550|Drug|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
75464364|NCT01876550|Drug|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
75910724|NCT04975360|Dietary Supplement|Caffeine|The 160 mg caffeine pulsatile-release formulation was manufactured using a drug layering process. Caffeine and the excipients are dispersed in the coating media and then sprayed onto inert microcrystalline cellulose spheres using a fluid bed through a Wurster tube with continuous inlet air that dries the liquid in the dispersion, to obtain various layers consisting of caffeine and release-controlling polymers. The applied release-controlling polymeric system is based on methacrylate copolymers, which control the release of caffeine in pH-dependent and pH-independent manner. The release mechanism of the polymeric system is mainly driven by the swellability and permeability of the copolymers. The final micropellets are then encapsulated into hydroxypropylmethylcellulose capsules.
75318588|NCT05699967|Other|data collection|Participants wear a wristband with a Photoplethysmography (PPG), heart rate and respiratory rate sensor continuously for 3 days. Once gateway and device are linked, all data will be transmitted continuously via Bluetooth to an in-house database. The Device Hub allows to control data availability and signal quality of the wearables, but no scores will be calculated and visualized. The data obtained for calculating the NEWS2 is solely observational and for the study staff. It has no clinical consequence on the treatment of the patient. It is analyzed whether the score with values form the wearables and Electronic Health Record (EHR) corresponds to the conventionally calculated NEWS2 score with values coming only from the EHR.
75318589|NCT05681468|Other|Keto-SAT|"Nutrition counselling focused on Keto diet (saturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
75318590|NCT05681468|Other|Keto-CAN|"Nutrition counselling focused on Keto diet (unsaturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
75318591|NCT05681468|Other|LFD|"Nutrition counselling focused on low-fat diet.~30% total energy (TE) as fat, 50% TE as carbohydrates (primarily whole grains) and 17-20% TE protein (mainly lean sources)."
75318592|NCT05680519|Other|theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention|The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.
75618010|NCT04151407|Drug|Drug 601|Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
75771287|NCT01293526|Device|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
75771288|NCT01192984|Biological|KW-0761|Intravenously 8 times at 1-week intervals
75771289|NCT01196728|Drug|CM3.1-AC100|SAD study with single ascending subcutaneous doses
75910725|NCT04975360|Other|Placebo|Identical hydroxypropylmethylcellulose capsules without containing caffeine micropellets.
75910726|NCT00812708|Device|Morcher iris diaphragm implantation|Surgical implantation of Morcher iris device(s)
75771290|NCT01193062|Drug|PF-04995274|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
75318593|NCT05680519|Other|Control group|The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. In addition, the research assistant will send regular SMS messages to the participants at a similar frequency to the intervention group, but these messages will contain only general health advice.
75771291|NCT01193062|Drug|PF-04995274|Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
75771292|NCT01196494|Procedure|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
75771293|NCT04890574|Device|CellMist™ System|Open Label, Safety and Feasibility
75771294|NCT01196572|Procedure|Internal Urethrotomy|surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
75771295|NCT01196650|Drug|IN 10 003 formulation A|
75771296|NCT01196650|Drug|IN 10 003 formulation B|
75771297|NCT01196650|Drug|Placebo capsules|
75771298|NCT03846154|Behavioral|Comprehensive family intervention including individual sessions of FORNET|"A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~Access to schools and school material~Family visits~Their parents received training regarding agriculture and microcredit projects, and financial assistance~FORNET if affected by trauma-related symptoms, and/or acting aggressive~If needed medical assistance /.) If needed, legal assistance"
75771299|NCT01193296|Drug|Vildagliptin|
75910727|NCT03054454|Procedure|Podiatry|Podiatry treatments and care from the multidisciplinary team.
75618011|NCT04824118|Diagnostic Test|Thromboelastometry|Point of Care Test for clotting parameters (ClotPro device)
75618012|NCT04824118|Diagnostic Test|Clotting Studies|"Standard laboratory tests for clotting:~International normalised ratio (INR)~Prothrombin time (PT)~adjusted partial thromboplastin time (aPTT)~fibrinogen"
75618013|NCT04824118|Diagnostic Test|Full Blood Count|For platelet count
75618014|NCT04824118|Diagnostic Test|Quantitative hCG|Serum human chorionic gonadotrophin
75618015|NCT04824118|Diagnostic Test|Pregnancy Test|Point of care urinary pregnancy test
75618016|NCT02627911|Device|Diabeloop System|Insulin delivery
75771300|NCT01193296|Drug|Sitagliptin|
75771301|NCT03845998|Procedure|use the three-finger method|The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.
75771302|NCT03845998|Procedure|use the weight-related method|The size of the laryngeal mask airway was determined by the patient's weight.
75771303|NCT01193374|Behavioral|Clinician enhanced screening and counseling prompts|PDA based health risk screening for well child issues and obesity risks
75771304|NCT01193374|Behavioral|Tailored education and motivational materials|Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.
75771305|NCT01193374|Behavioral|basic educational brochure|Booklet by ADA sent x 1.
75771306|NCT04888156|Other|Unchanged treatment|Treatment is the same pre- and post self-tonometry
75771307|NCT04888156|Other|Changed treatment|Treatment is changed post self-tonometry
75771308|NCT01196962|Device|Central venous catheter|Central venous catheter insertion to subclavian vein
75771309|NCT01197040|Drug|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
75771310|NCT01197040|Drug|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
75771311|NCT05387824|Device|Magnetic stimulation -Armchair type MS • NovaMag NT-60|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
75771312|NCT05387824|Device|Electrical Stimulation- TTNS|TTNS were performed 2 days a week, for 30 min a day, for a total of 12 sessions for 6 weeks.
75618017|NCT02627911|Device|Continuous Glucose Monitoring|
75618018|NCT02627911|Device|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
75618019|NCT02627911|Dietary Supplement|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
75771313|NCT05387824|Behavioral|Bladder Training|"Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.~BT, consisting of four stages, did not contain any PFMT programs in two groups."
75771314|NCT05436340|Device|The Effect Of Heel Protector In Intensive Care Units|In the experimental group, foot joint opening and heel pressure sore formation will be observed by using heel protector pad.
75771315|NCT05436340|Device|Control group|Heel pads will not be used in the control group. Routine maintenance will be applied
75771316|NCT03848338|Procedure|Electrocochleography|Electrocochleography measurement Intra-operatively and Post-operatively at follow-up appointments along with correlative measurements (Impedance, eCAP, PTA, Speech)
75771317|NCT01193452|Drug|S-1, Leucovorin|"S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week."
75771318|NCT01193452|Drug|leucovorin, 5-fluorouracil|"leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks"
75771319|NCT05670886|Procedure|uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.
75618020|NCT04239586|Drug|Sulfonylurea|Starting treatment with sulfonylurea class of drug
75318594|NCT05679908|Drug|TNX-1900|Patients will spray TNX-1900 once into each nostril.
75464365|NCT01876550|Drug|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
75318595|NCT05679908|Drug|Placebo Nasal Spray|Patients will spray placebo nasal spray once into each nostril.
75318596|NCT05674851|Other|MRI|collection of MRI scans for mathematical model development
75318597|NCT05673382|Behavioral|Internet-based cognitive behavioral therapy|The intervention (the treatment) within this study is based on cognitive behavioral therapy principles and adapted to target psychological symptoms related to life crises. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
75318598|NCT05672992|Other|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
75910728|NCT00563576|Drug|Femring®|"Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months."
75910729|NCT00563576|Drug|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
75464366|NCT01876563|Dietary Supplement|vitamin D|one tab 4000 IU/day vitamin D
75464367|NCT01876563|Dietary Supplement|placebo|one tab per day placebo
75464368|NCT01876576|Other|Clear liquids|Clear liquids
75464369|NCT01876576|Other|Low residue breakfast and lunch|Low residue
75464370|NCT01876589|Device|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
75464371|NCT01876589|Device|Xience Prime|Drug eluting metallic stent
75464372|NCT01876602|Behavioral|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
75618021|NCT02628613|Drug|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
75618022|NCT02628613|Drug|Paclitaxel plus Epirubicin|standard neoadjuvant chemotherapy
75771320|NCT03845608|Combination Product|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation
75910730|NCT04911946|Other|Questionnaire|After signing the informed consent form agreeing to participate in the study, the participants answered the questionnaire about diagnostic and therapeutic questions related to a clinical case of osteoporotic fracture in 4 scenarios: the initial care in the emergency room, at the time of discharge from hospital, during their outpatient return in 3 and 6 months.
75910731|NCT04912102|Device|high flow nasal oxygen device (HFNO)|it is a novel technique by which heated humidified oxygen is supplied via nasal prongs at flow rates ranging from 40 to 70 L/minute. The Fio2 ranges from 0.21 to 1.0.
75910732|NCT04390178|Biological|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection
75910733|NCT04911218|Device|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
75910734|NCT04911218|Device|Conventional 5Fr arterial sheath|Placement of conventional 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
75910735|NCT04904744|Other|Low tailored message|2 low tailored text or phone message reminders that child is overdue for well child check visit
75910736|NCT04904744|Other|No message|No reminders are sent
75910737|NCT04904744|Other|Low tailored message plus COVID-19 vaccine message|2 low tailored text or phone message reminders that child is overdue for well child check visit and that COVID-19 vaccine is available
75910738|NCT04342286|Genetic|Organoid culture|Organoid culture
75910739|NCT04975282|Device|Bottle feeding|Bottle was used as an alternative oral feeding method for preterm infants.
75318599|NCT05672927|Biological|9-valent HPV vaccine, 2 doses alternate timing|Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
75464373|NCT01876615|Drug|YH4808|experimental drug
75464374|NCT01876615|Drug|Diclofenac|Depain tablet 25mg
75771321|NCT01197118|Radiation|sequence chemoradiotherapy|"Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: see arm 2"
75464375|NCT01876615|Drug|YH4808+Diclofenac|
75618023|NCT04239352|Diagnostic Test|Pentraxin 3 ; new biomarker|"Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component."
75771322|NCT01197118|Drug|chemotherapy alone following radical resection|Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1~5, i.v.; leucovorin, 200 mg/m2/day on day 1~5, i.v.; every 21 days repeated, for 6 cycles.
75318600|NCT05672927|Biological|9-valent HPV vaccine, 3 doses standard timing|This will be the comparison group for the 2-dose group.
75318601|NCT05672225|Drug|Dexmedetomidine|Dexmedetomidine 0.2mcg/kg/hr (2ml/hr) administration via continuous channel in the experimental group
75318602|NCT05672225|Drug|Control|Normal saline 2ml/hr administration via continuous channel in the experimental group
75910740|NCT04975282|Device|Cup feeding|Cup was used as an alternative oral feeding method for preterm infants.
75910741|NCT03109574|Device|BioFlo DuraMax Chronic Hemodialysis Catheter|
75910742|NCT03109574|Device|Standard of Care Catheter|
75318603|NCT05665712|Procedure|enhanced recovery|bundle of factors that have been shown to help with recovery in other surgical services such as good pain control, early ambulation, early nutrition
75910743|NCT04911712|Dietary Supplement|a hospital formula of normal protein liquid diet supplementation|group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)
75910744|NCT04911712|Dietary Supplement|a hospital formula of high protein liquid food supplementation|group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
75910745|NCT03469466|Diagnostic Test|bedside ultrasound|bedside ultrasound imaging of the lungs
75910746|NCT04975126|Other|CatInfo tool|Presentation about cataract surgery
75910747|NCT04316156|Device|Uincare Homeplus|Interactive digital healthcare system
75910748|NCT04316156|Other|Brochure|Brochure
75936319|NCT03189056|Procedure|Urodynamic exploration|With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
75318604|NCT05659459|Drug|KIN001|Oral tablet
75318605|NCT05659459|Drug|KIN001-Placebo|Comparator - Oral tablet with same appearance of KIN001
75318606|NCT05657483|Diagnostic Test|Venous blood sample|Blood chemistry tests: neutrophil; lymphocyte; monocyte; platelet counts.
75318607|NCT05657483|Other|Surgical staging of endometrial cancer|Endometrial, adnexal, and lymphoid tissue samples.
75464376|NCT01876641|Drug|Vemurafenib + Cobimetinib, Decitabine|
75464377|NCT01876654|Device|TruMatch® patient specific cutting guide|
75618024|NCT04239352|Diagnostic Test|Lipoprotein-associated phospholipase A2 ; new biomarker|Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.
75618025|NCT02627833|Other|observation|Record lung function, Lung clearance index, inflammatory status
75618026|NCT01100034|Drug|Etanercept|Expected duration of 24 weeks as one course
75771323|NCT03845764|Diagnostic Test|Rapid on-site evaluation|Specimens obtained with endoscopic sampling procedures are stained with a rapid method (i.e., Diff Qui) and submitted to on-site cytologic review
75618027|NCT00675727|Biological|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
75318608|NCT05656430|Behavioral|Internet-based Cognitive Behavioral Therapy|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
75910749|NCT04975750|Behavioral|Problem solving intervention|The intervention focuses on the individual employee and his/her work situation and work-private life balance. The following steps are implemented: inventory and prioritization of problems; brainstorming options and solutions; formulation of an action plan; evaluation, and follow-up. The intervention is carried out in about 3 planned meetings (30 - 45 min) between the manager and the employee. However, given the lack of research regarding the intervention delivered to this specific population and which dose that should be considered as beneficial as well as the complexities of the identified problems, the number of meetings is not specified
75910750|NCT04975750|Behavioral|Care as usual|The managers and the employee have meetings regarding the employee and his/her work situation and work-private life balance. However, the managers are not educated in and do not use the problem solving intervention. They are instead instructed to use their usual procedures.
75910751|NCT05161052|Device|Corvis ST (dynamic Scheimpflug technology)|"Measurement of corneal stiffness parameters { Deformation Amlitude (DAR1), Integrated radius, Stress parameter (SP A1), Stress strain index (SSI) and Corvis biomechanical index (CBI) } in keratoconic corneas before and after 3 and 6 months CXL using Corvis ST.~Measurement of demarcation line depth using anterior segment OCT and correlate between corneal stiffness following CXL and demarcation line depth"
75618028|NCT02822560|Device|pEVAR|percutaneous femoral access using a suture-mediated closure device
75318609|NCT05652153|Other|Single-/paired-pulse transcranial magnetic stimulation|Single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) is a technique for noninvasive assessment of brain physiology by delivering single or paired magnetic stimuli to the scalp with an electromagnetic coil. This results in transient induction of cortical electrical activity, which can be measured as evoked potentials by electromyography (EMG) and electroencephalography (EEG). Note that sp/ppTMS is used for neurophysiologic measurements; it is distinct from other TMS applications such as repetitive TMS, which can be used as interventions.
75771324|NCT01197196|Behavioral|Behavioral Weight Loss Intervention|Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
75910752|NCT03061864|Behavioral|Periviable Birth Plan|
75910753|NCT05160818|Radiation|Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiotherapy radiosurgery (SRS)|intervention description see above
75910754|NCT04915222|Other|Natural apophyseal glides|Patients received conventional therapy and NAGS with 2-3 hertz (less than 6 repetitions) in 3 sets for 3 weeks. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
75910755|NCT04915222|Other|Cervical manual traction|Patients received cervical manual traction (CMT) along with traditional therapy. Treatment frequency was 3 sessions per week for total three weeks duration. CMT applied was intermittent type traction.8 to 10 kg force was applied at an angle of 20 to 25 degree from horizontal. 5sets of cervical traction are performed. In every set traction is given for 1 minute with rest period of 20 seconds. The total time of traction session was 10 minute. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
75910756|NCT03471962|Other|surgery|Indirect measurement of RQ was performed by anesthesia ventilator and compared to marker of anaerobic metabolism (arterial lactate, venoarterial PCO2 gradient, venoarterial PCO2 gradient/ arteriovenous O2 content difference, ScVO2) at different time of the srugery (every hours). In post-operative time, complications and hospital's length of stay were recorded.
75910757|NCT04911556|Dietary Supplement|Bifidobacterium longum|types of intestinal flora
75910758|NCT04911556|Dietary Supplement|A placebo made of starch|placebo
75910759|NCT04583150|Procedure|Bariatric surgery|Bariatric surgery : sleeve gastrectomy or Roux-en-Y gastric bypass (RYGB)
75910760|NCT03470324|Device|[standard STN]|standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
75910761|NCT03470324|Device|[STN+SNr]|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
75910762|NCT03470324|Behavioral|Swallowing therapy|Swallowing therapy with speech therapist
75910763|NCT03470246|Behavioral|PACO intervention for CABG patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from coronary artery bypass grafting (CABG). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
75618029|NCT02822560|Procedure|open femoral access|cutdown to femoral artery and surgical closure
75618030|NCT00675805|Device|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
75618031|NCT00675805|Device|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
75618032|NCT02880930|Dietary Supplement|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
75910764|NCT03470246|Behavioral|PACO intervention for AVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from aortic valve replacement (AVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
75771325|NCT01197196|Other|Migraine Education|Participants assigned to this condition (Healthy Living for Migraine Relief [HLMR]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
75771326|NCT03848572|Diagnostic Test|Repetitive assessment of PRECISE-DAPT score|The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
75910765|NCT03470246|Behavioral|PACO intervention for MVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from mitral valve repair (MVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
75910766|NCT04915066|Other|Medical data collection|Collection of medical data from patients'medical records
75910767|NCT04911010|Behavioral|Prolonged Exposure|In the intervention condition, patients are treated with prolonged exposure in 16 hours of individual therapy immediately after the baseline measurement. The 16 individual therapeutic sessions take place 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapeutic sessions are recorded on video with camera focus on the therapist. Parts of the prolonged exposure procedure (reliving the traumatic memory) are recorded on tape (via the patient's personal smartphone) so that the patient can listen to the recording as homework at home. The patients then take part in a post-treatment study diagnosis (T1).
75464378|NCT01876667|Other|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
75464379|NCT01876667|Other|Placebo|Usual Care
75318610|NCT05649358|Device|Lactate sensor (Lactisense)|Non-invasive monitoring of interstitial lactate levels during and after exercise.
75464380|NCT01876680|Other|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
75771327|NCT01295632|Drug|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
75464381|NCT01876680|Other|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
75910768|NCT03998540|Diagnostic Test|Western blot|Western-blot analysis of a giant protein, with specific antibodies directed against C-ter and N-Ter of the protein
75910769|NCT03998540|Other|Protein interaction studies|Analyses of several interacting proteins by specific Western-blot and in-vitro tests.
75910770|NCT03782636|Drug|Aldesleukin|"PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion"
75910771|NCT03782636|Other|Placebo|sterile diluent used for the aldesleukin preparation and 5% glucose
75910772|NCT04911244|Diagnostic Test|bronchoalveolar lavage|endobronchial sampling through bronchoscopy
75910773|NCT04910620|Drug|Placebo|Placebo only
75910774|NCT04910620|Drug|TCI378|TCI378 (Lactobacillus plantarum TCI378)
75464382|NCT01876693|Procedure|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
75771328|NCT01295632|Drug|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
75771329|NCT01295632|Drug|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
75910775|NCT04910620|Drug|TCI507|TCI507 (Lactobacillus plantarum TCI507)
75910776|NCT03761810|Drug|S6G5T-3|Once a day topical cream
75910777|NCT03761810|Drug|S6G5T-8|Once a day topical cream
75910778|NCT04915456|Drug|Systemic Steroid (Prednisolone)|Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS
75910779|NCT04915456|Other|Placebo|Placebo additive to topical steroids in a postoperative setting after FESS
75910780|NCT04575740|Device|PAP|Positive airway pressure to treat sleep apnea
75910781|NCT04853836|Combination Product|co-ultraPEALut|Olfactory rehab 10 minutes twice a day for all the observation period + co-ultraPEALut (700 PEA + 70 Luteolin) 1 dose daily.
75910782|NCT04853836|Procedure|Olfactory Rehab|Olfactory Rehabilitation10 minutes twice a day for all the observation period
75910783|NCT04853836|Drug|PEA-LUT 1 sachet|Only 1 sachet day of PEA-LUT no olfactory training
75910784|NCT04853836|Drug|PEA-LUT 2 sachet day|2 sachets day of PEA-LUT no olfactory training
75910785|NCT04498130|Behavioral|12-Week Home Exercise Group|12 week home-based program consisting of: weekly Zoom group chats; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page
75618033|NCT04770766|Other|Non-medical practitioners|All observational research activity in each cohort is related to the exposure of non-medical practitioners in the Emergency Department or Urgent Treatment Centre
75618034|NCT04148833|Drug|LDE-Paclitaxel|LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
75318611|NCT05634226|Device|Hands-free oral-positive pressure device (oPEP)|This is a pilot study using a novel, minimal risk, portable, hands-free oral-positive pressure device (oPEP) in patients with Fontan palliation that will examine whether using this device in both the acute and chronic phase will alter Fontan hemodynamics and create pulsatility in the Fontan circuit and thereby increasing cardiac output. This device is easy to use and poses no significant risk to human subjects. We will measure this through echocardiographic measures including pulsatility in different aspects of the Fontan circuit including IVC, hepatic veins, the Fontan conduit, and pulmonary arteries and aortic blood flow measurements. After demonstration of how to use the device appropriately, we will have patients use the device after their clinical echocardiogram for their clinic appointment. We will ask them to use the device at home 3-4 times a day for 10-15 mins and have them return in approximately 4 weeks to have another echocardiogram done with the same measurements.
75464383|NCT01876745|Drug|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
75464384|NCT01876758|Behavioral|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
75618035|NCT04148833|Drug|LDE-Placebo|LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
75771330|NCT05416450|Device|intravaginal electrical stimulation added to bladder training|BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.
75464385|NCT01876758|Behavioral|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
75771331|NCT03845530|Diagnostic Test|Blood Test|Blood test taken and sent for laboratory analysis
75771332|NCT03844594|Drug|Eptifibatide Injection|Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
75771333|NCT03848650|Device|OpSens Medical OptoWire|"The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries."
75910786|NCT04498130|Behavioral|Education Comparison Group|12 week home-based program consisting of: weekly check-in phone calls; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page.
75910787|NCT04841668|Drug|Metformin|Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
75910788|NCT03469388|Diagnostic Test|Pulse wave analyses; central blood presaure parameters|Pulse wave analyses; central blood presaure parameters
75910789|NCT04492904|Other|Home-use Test and Follow-up Questionnaire|Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
75910790|NCT03469310|Drug|Acetaminophen 500Mg Cap|non-narcotic medication first with narcotic as second choice
75910791|NCT03469310|Drug|Tylenol #3 Oral Tablet|Narcotic medication first
75910792|NCT03469310|Drug|Tramadol|non-narcotic medication first with narcotic as second choice
75910793|NCT04910854|Drug|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), The curative effect was evaluated every 8 weeks.
75910794|NCT04839874|Other|No intervention|Semi-structured qualitative interviews
75910795|NCT03469232|Drug|Huanglian-Jiedu Decoction|Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
75464386|NCT01876797|Drug|ticagrelor/prasugrel|
75464387|NCT01876836|Device|i-gel|i-gel placed after induction
75464388|NCT01876836|Device|C-LMA|placed after induction
75618036|NCT04926246|Drug|R1: Reference Product X|under fasted conditions
75618037|NCT04926246|Drug|T1: Test Product M|under fasted conditions
75618038|NCT04926246|Drug|T2: Test Product N|under fasted conditions
75618039|NCT04926246|Drug|T3: Test Product O|under fasted conditions
75618040|NCT04926246|Drug|T4: Test Product O|under fed conditions
75910796|NCT04904224|Device|Panintestinal video capsule endoscopy|Performing a video capsule endoscopy using the Pill Cam Crohn's capsule from Medtronic
75910797|NCT04904224|Device|Colonoscopy|Performing a standard colonoscopy using the colonoscope available in the study center
75618041|NCT04926246|Drug|R2: Reference Product Y|under fasted conditions
75618042|NCT04926246|Drug|T5: Test Product P|under fasted conditions
75618043|NCT04926246|Drug|T6: Test Product P|under fed conditions
75618044|NCT04926246|Drug|T7: Test Product Q|under fasted conditions
75771334|NCT03848650|Procedure|FFR|A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
75771335|NCT03848182|Drug|Gemcitabine|Gemcitabine will be administered on days 1, 8, 15 every 28 days
75618045|NCT04926246|Drug|R3: Reference Product Z|under fasted conditions
75318612|NCT05626816|Device|Genital Nerve Stimulation|Electrical stimulation applied to the genital nerve with surface electrodes using an off the shelf TENS unit (Ultima Plus). First, an amplitude threshold for the pudendo-anal reflex responses will be determined. Then, sham (1-2 Hz) and effective stimulation (20 Hz) will be briefly applied to record responses. Then, stimulation will be applied in random presentation order to record any changes in anorectal manometry outcomes due to both sham and effective stimulation.
75771336|NCT03848182|Biological|TT vaccine booster|One human TT childhood vaccine booster will be administered on day 8
75771337|NCT03845920|Combination Product|tdcs (sham/anodal) + drug (placebo/tyrosine)|"tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.~Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols."
75618046|NCT04926246|Drug|T8: Test Product S|under fasted conditions
75910798|NCT03527186|Drug|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
75910799|NCT05159882|Drug|THR-1442 and Dapagliflozin placebo|THR-1442 tablets 20mg and Dapagliflozin tablets placebo
75318613|NCT05626816|Diagnostic Test|Clinical exam|Examination by physician determines the presence of pelvic reflexes (pudendo-anal and bulbocavernosus) which are essential for GNS to have an effect.
75318614|NCT05626816|Diagnostic Test|Collection of SCI common data elements|Data regarding participant demographics, history of injury, and medical history will be collected.
75318615|NCT05626816|Diagnostic Test|Bowel function survey completion|Two surveys will be conducted to assess the bowel function of the participant. The International SCI Bowel Function Basic Data Set (ISCI BF BDS v2.1) and the SCI Qulaity of Life Bowel Management Difficulties (SCI-QoL BMD) survey scales collect data on overall bowel function and how any difficulties impact the participants quality of life.
75318616|NCT05626816|Diagnostic Test|International Standard for Neurological Classification of SCI (ISNCSCI)|The physician will conduct the ISNCSCI to determine the level and severity of injury to the spinal cord. This is done by determining the ability to detect light touch and pinprick stimulation. Outcomes will be a Spinal Injury Association Impairment Scale (AIS) grade of A-D.
75464389|NCT01876849|Drug|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
75464390|NCT01876862|Other|Antiretroviral treatment interruption|pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
75618047|NCT04926246|Drug|T9: Test Product S|under fed conditions
75618048|NCT04926246|Drug|T10: Test Product U|under fasted conditions
75910800|NCT05159882|Drug|Dapagliflozin 10mg and THR1442 placebo|Dapagliflozin tablets 10mg and THR-1442 tablets placebo
75910801|NCT04910698|Drug|Antibiotic|Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
75910802|NCT04461236|Dietary Supplement|Oral Supplement|Supplement provided in capsules. Half the capsules to be taken with lunch and the other half with dinner. All supplements are commercially available.
75318617|NCT05626816|Diagnostic Test|Response to genital nerve stimulation (GNS)|GNS will be applied to determine if there is a response in the participant. If the participant has no response to the stimulation they will be excluded from the second visit as it is dependent on the ability to respond to GNS.
75318618|NCT05626816|Diagnostic Test|Anorectal Manometry testing (ARM)|"The participant will be instrumented for ARM testing. This requires a special balloon catheter to be inserted into the anus and secured, surface electrode pads being applied to the anal sphincter, and electrode pads being applied to the genital nerve stimulation sites.~Once instrumented, the participant will be tested with the London Classification procedure. This procedure asks the participant to perform several actions (squeeze to withhold a bowel movement, push to have a bowel movement, and cough) as well as inflating the balloon on the catheter to determine reflex thresholds (RAIR, retroanal inhibitory reflex which relaxes the anal sphincter in response to rectal distension) and sensory thresholds (first senstation,"
75318619|NCT05618886|Other|Education|The education about urinary incontinence, PFM and PFMT together with lifestyle behavior modifications such as using the knack, maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure will be provided along with the PFMT instruction.
75618049|NCT02821546|Drug|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
75618050|NCT02821702|Device|Vaginal ultrasound|
75618051|NCT02821702|Biological|Blood sample|
75618052|NCT00876265|Device|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
75910803|NCT04461236|Dietary Supplement|Placebo|Placebo
75618053|NCT00876265|Device|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
75910804|NCT04914442|Diagnostic Test|Microscopic examination|All the studies cases are microscopically examined using the ordinary stains (hematoxylin and eosin) then the eosinophilic infiltration are counted in 10 high power field manually
75318620|NCT05618886|Other|Education and PFMT|Along with education twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant's will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participant's will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary.
75771338|NCT01197274|Device|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
75618054|NCT04308018|Procedure|S2alar-iliac screws|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
75618055|NCT04308018|Procedure|S1 screws|Caudal end of the instrumentation at S1
75771339|NCT00146328|Drug|Tipranavir|
75771340|NCT01197352|Behavioral|Motivational and Normative Feedback|Weekly feedback based on their frequency and degree of at-risk drinking behavior using normative, educational and motivational feedback
75771341|NCT01197352|Behavioral|Self-Awareness|Weekly queries to raise awareness and allow self-reflection about drinking habits
75771342|NCT04918030|Procedure|In-hospital staged PCI|After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).
75771343|NCT04918030|Procedure|Out-hospital staged PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.
75771344|NCT04916938|Behavioral|Interaction Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
75771345|NCT04916938|Behavioral|Mother's child psychotherapeutic session|Mother's representation of the event, mother's representation of the relation to her child, maternal emotions.
75771346|NCT04916938|Behavioral|Interview|History and perception of the mother's issues.
75771347|NCT04916938|Behavioral|Self-rated questionnaires|Parental Self-Questionnaire to assess the perception of the evolution of the father, mother and child
75771348|NCT01295788|Device|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
75771349|NCT01295788|Device|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
75771350|NCT01197430|Other|exercise training|
75771351|NCT01295866|Device|nasal nitric oxide|
75771352|NCT03848104|Other|bone and joint infection treated with cefoxitin|the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
75771353|NCT03844516|Other|Peak oxygen uptake test with pacing|Peak oxygen uptake test with paced heart rate
75771354|NCT03844516|Other|Peak oxygen uptake test without pacing|Peak oxygen uptake test without paced heart rate
75771355|NCT03844126|Other|Transition classes|90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
75771356|NCT03844204|Device|Thermal servo-controlled system|All patients will be positioned under the infant warmer. In the treatment group, a probe positioned on the skin of the neonate will guide the thermal exposure in a servo-controlled modality. In the control group, thermal exposure will be determined manually by setting the power of the heater at the maximum output.
75771357|NCT05670808|Drug|Epinephrine injection|Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
75618056|NCT02690350|Drug|U3-1784|Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
75771358|NCT01197664|Drug|paricalcitol|Given PO
75771359|NCT01197664|Radiation|radiation therapy|Undergo radiotherapy
75771360|NCT01197664|Other|laboratory biomarker analysis|Correlative studies
75771361|NCT01197664|Drug|fluorouracil|Given PO
75771362|NCT01199458|Drug|alfentanil|20 mikrogr/kg
75618057|NCT02879838|Other|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
75618058|NCT02821468|Drug|Droglican|Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
75618059|NCT02821468|Drug|Paracetamol or oral NSAIDs excluding COX2 inhibitors|
75771363|NCT01199458|Drug|saline|The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
75771364|NCT03733444|Drug|GLPG1690|GLPG1690, film-coated tablets for oral use.
75771365|NCT03733444|Drug|Placebo|Matching placebo, film-coated tablets for oral use.
75618060|NCT04964622|Drug|nurofen|tablet
75618061|NCT04769050|Drug|Docetaxel combined with Trastuzumab±Pertuzumab|Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
75771366|NCT01199614|Drug|open-label PTH(1-84)|open label PTH(1-84) at either 25mcg every other day, 25mcg every day, 50mcg daily, 75mcg daily, or 100mcg daily
75771367|NCT01296100|Behavioral|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
75318621|NCT05597618|Other|Training Program to be Developed for Empowering New Graduated Nurses|"The training program, which will be prepared based on structural and psychological empowerment theories, will consist of two parts: face-to-face theoretical training and online training.~Theoretical Education Part In the theoretical part, empowerment based on structural and psychological empowerment theories, effective communication, problem-solving and decision-making, time management, stress management, and nursing legislation will occur. In addition, the subject related to the institution's promotion (organizational chart, vision, mission, values, etc.) will be included.~Online Education Part In the online part; Videos of theoretical education subjects, institutional information, and documents (institutional instructions and procedures, institution vision-mission-values, management chart, etc.), nursing-related legislation (nursing law, nursing regulation), nursing ethical codes and case studies of sample subjects are included."
75318622|NCT05594784|Drug|Olverembatinib|a third-generation TKI
75771368|NCT01296100|Behavioral|Lifestyle intervention (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
75771369|NCT01197820|Device|MRI|"Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.~In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.~Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed"
75771370|NCT01586104|Radiation|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
75318623|NCT05594784|Drug|Venetoclax|a selective inhibitor of B-cell lymphoma 2 (Bcl-2)
75318624|NCT05594784|Drug|prednisone|Glucocorticoids
75618062|NCT04769050|Drug|T-DM1 or Capecitabine combined with Pyrotinib regimen.|T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
75618063|NCT04309656|Drug|Pretomanid|"Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~Treatment C (test) = single 50-mg dispersible tablet, orally administered.~Treatment D (test) = single 10-mg dispersible tablet, orally administered."
75618064|NCT02821624|Drug|G1T38 (CDK 4/6 Inhibitor)|CDK 4/6 Inhibitor
75618065|NCT02821624|Drug|Placebo|Placebo
75318625|NCT05594784|Drug|Vincristine|Anti-tumor alkaloids
75318626|NCT05583864|Device|CONDUIT Porous Titanium Spinal Cage|Already included in arm/group descriptions.
75618066|NCT02879058|Procedure|Intraoperative contact ultrasonography|In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
75618067|NCT02881164|Other|Low glycemic index|Subjects intake a low glycemic index breakfast
75618068|NCT02881164|Other|High glycemic index|Subjects intake a high glycemic index breakfast
75618069|NCT02821390|Drug|Nepafenac Eye Drops|One drop instilled to the eye's cul de sac prior to the intravitreal injection.
75771371|NCT04871854|Drug|Tocilizumab|patients treated with Tocilizumab for Covid-19 infection
75771372|NCT04871854|Drug|traditional Covid -19 therapy|patients treated with traditional therapy for Covid-19 infection
75771373|NCT01588522|Drug|compound 31543 Calcitriol|topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
75771374|NCT04834336|Device|inspiratory muscle training device|Inspiratory muscle training will be performed with an inspiratory muscle training device.
75771375|NCT04834336|Other|Physical training|Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
75771376|NCT01296178|Drug|IDARUBICINE|"Administration of chemotherapy induction~Idarubicin IV Dose of 12 mg/m2/day days 1 to 3"
75318627|NCT05583864|Device|PROTI 360 Titanium-Coated PEEK Spinal Cage|Already included in arm/group descriptions.
75318628|NCT05573009|Behavioral|cognitive behavioral approach-based stress reduction program|"Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~Session main topics are:~Session 1 - Introducing the purpose and content of the program - Stress Psychoeducation Session 2 - Cognitive restructuring Session 3 -Behavioral coping Session 4 - Problem solving training Session 5-Upcoming parenthood"
75618070|NCT02821390|Drug|Placebo (Artificial Tears)|One drop instilled to the eye's cul de sac prior to the intravitreal injection
75618071|NCT02821312|Drug|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
75318629|NCT05559749|Behavioral|collaborative care|a 24-week neurology based collaborative care program consisting of: 1. a series of every 2 weeks care management calls by the care manager to evaluate anxiety, depression, seizures and side effects and deliver brief therapy interventions to the participant, and 2. collaborative care conferences including a psychiatrist to generate expert recommendations for anxiety and depression management and communication of recommendations between the care manger, psychiatrist and neurologist.
75771377|NCT01296178|Drug|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
75318630|NCT05559749|Behavioral|usual neurology care|ongoing usual neurology care, without the addition of the collaborative care program
75771378|NCT03845686|Diagnostic Test|Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)|The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.
75910805|NCT04904146|Diagnostic Test|Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.|The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.
75910806|NCT04455464|Drug|Midodrine Oral Tablet|Midodrine will be given 10 mg for one time only.
75771379|NCT05670652|Other|clinical examination|Clinical examination with optimal (Lighting, using a disposable mouth mirror and a millimeter-ruler) will be performed, in addition to an upper and lower arch impression will be made and a study cast will be prepared.
75910807|NCT04914598|Drug|ENDOSTAR，cisplatin|After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment
75910808|NCT04914598|Drug|Placebo , cisplatin|Placebo , cisplatin
75910809|NCT04312256|Device|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin (ECG) electrodes.
75910810|NCT04903990|Other|Blood sample|As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
75910811|NCT03470168|Device|Hyperbaric Oxygenation Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
75910812|NCT03470168|Device|Normobaric Oxygenation therapy|Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
75910813|NCT04904380|Other|Active peer learning|HMS, HBS and peer learning in combination with AIR and PRISMS
75910814|NCT04913974|Procedure|Uni-condylar knee arthroplasty|Surgical replacement of medial compartment of arthritic knee with an implant
75910815|NCT03099746|Behavioral|INVOLVE|Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.
75910816|NCT03099746|Behavioral|Informational Support|Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
75910817|NCT03099746|Behavioral|Usual Care|Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
75910818|NCT04903912|Diagnostic Test|Vascular ultrasound or other imaging methods according to current guidelines|Peripheral vascular ultrasound / ankle/brachial index / CT angiography / MR angiography / angiography
75910819|NCT04903912|Diagnostic Test|Laboratory tests|Metabolic profile and platelet reactivity
75910820|NCT04903912|Drug|Medical treatment according to current guidelines|Antithrombotic drugs, lipid-lowering drugs, antihypertensive drugs, and pharmacotherapy to increase walking capacity according to current guidelines
75910821|NCT04903912|Procedure|Endovascular od surgical peripheral revascularizations|Endovascular od surgical peripheral revascularizations according to current guidelines
75910822|NCT03054220|Drug|Dextromethorphan 5 MG|
75910823|NCT03054220|Drug|Tramadol 10 mg|
75910824|NCT03054220|Drug|Duloxetine 60mg|
75910825|NCT03054220|Drug|Paroxetine 20 mg|
75910826|NCT05388188|Drug|sublingual sufentanil|Dsuvia in patients with SCD VOC as a bridging medication.
75910827|NCT04903834|Diagnostic Test|Soton hyperinflammation score|Score for hyperinflammation defined by blood parameters and other physiological measurements
75910828|NCT04903834|Diagnostic Test|HScore|Score for secondary haemophagocytic lymphohistiocytosis validated in prior publications
75910829|NCT03470090|Behavioral|Neuromuscular Exercises|In the experimental group, the subjects who were taken into the study were taken to the neuromuscular exercise (NME) program after the pre-treatment evaluations. The subjects in this group were given classical physiotherapy and NME performed 6 days a week, 1 set of 10 times physiotherapist control. NME was including warming, neuromuscular exercises (balance, muscle strengthening, proprioception, sensorimotor system training, joint stabilization and postural control exercises) and cooling periods.
75910830|NCT03470090|Behavioral|Conventional Group|In the control group, the subjects who were taken into the study were taken to the classical physiotherapy (hotpack (HP), ultrasound (US), transcutaneous electrical stimulation (TENS)) and conventional exercises program after the pre-treatment evaluations.
75910831|NCT03053908|Procedure|Actigraphy|Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
75910832|NCT03053908|Procedure|Nocturnal Polysomnograpahy (NPSG)|N1 habituation and N2 data collection
75910833|NCT04203836|Drug|LEO 152020 Tablet|film-coated tablet
75910834|NCT04118036|Drug|Pembrolizumab|intravenously over 30 minutes every 21 days (+/- 3 days)
75910835|NCT04118036|Drug|Abemaciclib|Oral 2 times a day
75910836|NCT05159336|Device|tACS for auditory hallucinations via single arm|a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol
75618072|NCT02821312|Drug|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
75910837|NCT04914130|Other|Study specific testing procedures|Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc
75910838|NCT05159258|Other||
75910839|NCT04903600|Dietary Supplement|Probiotics fruit vegetable fiber powder product|Eat 16 g for once, and twice a day
75910840|NCT04903600|Dietary Supplement|Placebo|Eat 16 g for once, and twice a day
75318631|NCT05556902|Device|Permanent Epidural Spinal Cord Stimulation|Permanent Spinal Cord Stimulation implanted in participants undergoing routine care for management of chronic neuropathic pain.
75910841|NCT03471884|Procedure|Nonintubated thoracoscopic lobectomy|Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.
75910842|NCT03471884|Procedure|Intubated thoracoscopic lobectomy|Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
75910843|NCT04909918|Drug|Dexamethasone|Baseline laboratory & clinical data will be taken before and after the study drugs according to our protocol.Intravenous dexamethasone 8 mg/day given for 7 days
75910844|NCT04909918|Drug|Methylprednisolone|Baseline laboratory & clinical data will be taken before and after the study drugs according to our protocol. Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
75910845|NCT04903444|Device|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system .
75910846|NCT03054688|Device|Somnotouch NIBP|Somnotouch NIBP in addition to standard blood pressure measurement
75910847|NCT04903678|Drug|Melphalan|Melphalan is performed for intrathecal chemotherapy
75910848|NCT04903366|Drug|Timolol Maleate|timolol maleate 0.5% gel-forming solution
75910849|NCT03054610|Drug|Betamethason Sodium Phosphate|
75910850|NCT03054610|Drug|Ropivacaine|
75910851|NCT03054610|Drug|Botulinum Toxins, Type A|
75910852|NCT03053752|Procedure|Transcutaneous Electric Nerve Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
75910853|NCT04909762|Other|Early Rehabilitation and Mobilisation (ERM)|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package. It is provided by health professionals from multiple disciplines and care-givers within intensive care settings.
75910854|NCT04902742|Procedure|Fluoroscopy-guided ganglion impar block|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Being most commonly used technic, transsacrococcygeal technique, a 22-gauge, 1.5-inch spinal needle is advanced through the sacrococcygeal disk and positioned carefully anterior to the sacrococcygeal junction. Injection of contrast results in a classical comma sign. A mixture of steroid and local anesthetic is given.
75936320|NCT03189368|Device|Activation of multi-site pacing capability on CRT devices|"Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed sculpting of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.~Programming features:~Interpolar distance for the first left ventricular pulse >30mm (i.e. non-sequential poles used)~Nearly simultaneous (Δt=5msec) second left ventricular pulse and~Threshold of ≤3.5V@0.5msec"
75618073|NCT02821078|Other|4D flow imaging sequence|4D flow imaging sequence
75318632|NCT05555342|Procedure|Irreversible electroporation (IRE) ablation|IRE will be performed using the NanoKnife or Aliya System. CT or cone-beam CT will be used to direct electrode placement.
75618074|NCT04240132|Other|Adherence to Hand Hygiene|determine the colonization of microorganisms due to microbial reproduction on the external surface of the distal end of the enteral feeding tube (EFT), hub of the EFT and other feeding system components and assess the relation between the colonization and adherence to hand hygiene practices by nurses and other healthcare workers
75318633|NCT05555342|Radiation|Radiation Therapy|Moderate-dose radiation therapy to the target tumor(s) in 1 fraction.
75318634|NCT05551481|Procedure|To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 2 years.|resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)
75618075|NCT02821156|Drug||Inhaled Nitric Oxide with monitoring by EZ-KINOX device
75618076|NCT02821234|Other|MRI|
75618077|NCT02820922|Procedure|Orthopedic|anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
75618078|NCT02822638|Other|STEMI PATIENT Cohort|PCI
75618079|NCT00633958|Drug|18F-FLT|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
75618080|NCT00633958|Radiation|PET Imaging|
75618081|NCT02820688|Drug|Bupivacaine 0.25%|
75618082|NCT02820688|Drug|Prilocaine 1%|
75618083|NCT02820688|Procedure|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
75618084|NCT02820688|Drug|Bupivacaine 0.167%|
75618085|NCT02820688|Drug|Bupivacaine 0.125%|
75771380|NCT01193764|Dietary Supplement|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
75771381|NCT01193764|Dietary Supplement|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
75771382|NCT04793620|Other|TQL1055|Semisynthetic saponin adjuvant
75771383|NCT04793620|Biological|Acellular pertussis vaccine|Acellular pertussis vaccine
75771384|NCT01296256|Drug|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
75771385|NCT01197976|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
75910855|NCT04902742|Procedure|Fluoroscopy-guided caudal epidural steroid injection|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. An 18-gauge epidural needle (Tuohy) is advanced at an angle of 45° to the skin until a 'give-way' sensation is felt and position of the needle is confirmed by lateral and anteroposterior fluoroscopic images. Then 5 ml of iohexol solution is injected through it to confirm the position. A properly placed needle would produce a classical 'inverted fern tree' appearance in anteroposterior view after dye injection or a 'filling defect'. The needle is introduced up to S3 level for proper spread of the drug. A mixture of steroid and local anesthetics is given.
75771386|NCT01197976|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
75910856|NCT03053986|Dietary Supplement|Apple polyphenols|1 tablet per day at evening before sleeping
75910857|NCT03053986|Other|Placebo|1 tablet per day at evening before sleeping
75910858|NCT03053830|Drug|Ketamine|0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
75910859|NCT04913740|Other|Ointment and dressing for external use|"pay attention to the protection of exposed skin, so that it is local dry.~Do a good job of facial moisturizing work before work use moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~After work, avoid using irritants to clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
75910860|NCT04913896|Drug|PD-1 inhibitor|SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery
75910861|NCT04913662|Procedure|Pressurized Intraperitoneal Aerosol Chemotherapy|Aerosolization of chemotherapic agent for intraperitoneal chemotherapy
75910862|NCT04913506|Other|Group Mirror|For 30 minutes, ROM exercises will be applied to the solid upper extremity in all directions in front of a real mirror by the practitioner. (3 weeks, 5 days a week, 15 sessions in total)
75910863|NCT04913506|Device|Group NMES|NMES will be applied to the hemiplegic arm(deltoid, elbow extensors and forearm) for 30 minutes by the practitioner (3 weeks, 5 days a week, 15 sessions in total)
75936321|NCT02291211|Drug|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
75618086|NCT02820688|Drug|Prilocaine 0.66%|
75618087|NCT02820688|Drug|Prilocaine 0.5%|
75618088|NCT02820688|Device|Ultrasound|All nerve blocks will be performed with ultrasound guidance
75618089|NCT02818816|Drug|brimonidine tartrate 0.2%|Alpha adrenergic receptor agonist
75771387|NCT04781062|Diagnostic Test|Blood and urine molecular analysis (Timing 0)|peripheral blood and urine sample collection
75771388|NCT04781062|Diagnostic Test|Blood and urine molecular analysis (Timing 1)|peripheral blood and urine sample collection
75771389|NCT03731182|Biological|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
75771390|NCT03731182|Biological|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
75771391|NCT05339308|Other|Magnesium oil (BetterYou) dermal application|10 sprays (200 mg) of magnesium oil (BetterYou) will be applied to skin covering knee extensor muscles. The magnesium oil will be applied only once
75618090|NCT02818816|Other|Carboxymethylcellulose Eye Drops|Ocular lubricants
75618091|NCT02820610|Drug|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
75618092|NCT02820610|Drug|Magnesium Sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
75618093|NCT02820610|Drug|Normal saline 0.9 %|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
75618094|NCT04751266|Procedure|minimally invasive repair of pectus excavatum|substernal insertion of a metal bar
75910864|NCT04913506|Other|Group Mirror+NMES|The practitioner will be synchronized with visual or auditory stimuli, and ROM exercises in all directions in front of the real mirror for 30 minutes, and NMES therapy for 30 minutes on the paretic upper extremity will be applied together. (3 weeks, 5 days a week, 15 sessions in total)
75910865|NCT04913428|Other|Interdigital exercise|Patient asked to sit in upright position interlocking their fingers with inhaling deeply bringing the arms up and exhaling through mouth while bring the arm down.
75618095|NCT02820532|Device|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
75618096|NCT04745728|Drug|Prednisone|1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.
75618097|NCT04745728|Drug|Cyclophosphamide|1-2mg/kg/d p.o. with a target accumulated dose of 12g.
75771392|NCT05339308|Other|Placebo Control|Natural mineral-free oil (10 sprays) will be applied as the control condition. This will be done only once
75910866|NCT04913428|Other|Blow-Bottle technique|For blow bottle 20cm of bottle filled with 10cm of water in which a tube of length 35- 40cm inserted with the inner diameter of ≥8mm(21).Patient is asked to form bubbles in bottle by exhaling in bottle performing Forced Expiratory Techniques.
75771393|NCT03730012|Drug|gilteritinib|Oral tablet
75771394|NCT03730012|Drug|atezolizumab|Intravenous infusion
75910867|NCT04902586|Device|TTFields|The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
75910868|NCT03053674|Other|Oral and written explanation|Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
75910869|NCT03053674|Other|Follow-up questionnaire|Follow-up questionnaire to determine whether participants have receive post-partum vaccination
75910870|NCT03053596|Device|DEB-TACE using anthracyclin loaded LifePearl™|The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.
75910871|NCT03053284|Drug|Pasireotide 0.6Mg Solution for Injection|Pasireotide 0.6Mg Solution for Injection will be given once per study visit
75910872|NCT03053284|Drug|Saline Solution|Saline Solution injection will be given once per study visit
75910873|NCT04894318|Behavioral|Low-fat and low-cholesterol diet|Low-fat (<30% of total energy) and low-cholesterol (<200mg/day) diet total of 12 weeks
75910874|NCT03053128|Device|Cardiac shock wave therapy|Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
75910875|NCT03053128|Other|Sham cardiac shock wave (Control group)|Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
75910876|NCT03053206|Drug|ADE Protocol|"ADE chemotherapy~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
75910877|NCT04893928|Other|QUECOMIICAT survey|IBD-related knowledge. It will be assessed using the recently validated QUECOMIICAT (Qüestionari Coneixements Malaltia Inflamatòria Intestinal Catalunya) questionnaire (27) originally developed in Spanish. Compared with the most well-known CCKNOW (Eaden JA et al in 1999)(28), it incorporates IBD updated data (29).
75910878|NCT04893928|Other|Self-Efficacy for Appropriate Medication Use Scale|Treatment adherence and compliance. It will be assessed using the Self-Efficacy for Appropriate Medication Use Scale (SEAMS), a 13-item self-administered scale previously translated into Spanish and validated by Bozada-Gutiérrez K et al on a Mexican population (3). According to 13 situations asked by the items, patients stratify the level of confidence about correctly taking their medications: 1, not at all confident; 2, somewhat confident; 3, very confident. The sum of results ranges from 13 to 39 points, where higher scores indicate optimal self-efficacy for taking the pharmacological treatment.
75618098|NCT04745728|Drug|Rituximab|1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count>5/ul.
75618099|NCT02818660|Drug|Synachten|To stimulate the adrenals to increase the cortisol Production as much as possible
75618100|NCT05659186|Drug|Tislelizumab|200mg IV Q3W
75618101|NCT05659186|Drug|Anlotinib|12mg PO QD
75618102|NCT05659186|Radiation|Radiotherapy|Multimodal Radiotherapy
75618103|NCT01107444|Drug|Docetaxel|Administered intravenously
75936322|NCT03189290|Procedure|posterior Quadratus Lumborum Block (QLB)|Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
75618104|NCT01107444|Drug|LY2181308|Administered intravenously
75618105|NCT04238806|Drug|Desflurane Inhalational agent|Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.
75771395|NCT03728140|Procedure|Self-spent Culture Medium|Replace embryo transfer solution with Self-spent culture medium in IVF-ET.
75771396|NCT03842332|Behavioral|Life Skills and Resilience Program|The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
75771397|NCT05288842|Biological|Lumbar puncture|5 mL of CSF
75771398|NCT05288842|Biological|blood sample|6x5 mL of blood sample collected :1 dry tube, 2 EDTA tubes, 1 fluoride tube, and 2 polypropylene tubes
75771399|NCT03844360|Drug|Bortezomib|bortezomib was administered follow the doctor's advice.
75771400|NCT03844360|Drug|Eltrombopag|eltrombopag was administered follow the doctor's advice.
75771401|NCT03844360|Drug|Imatinib|imatinib was administered follow the doctor's advice.
75771402|NCT03844360|Drug|dasatinib|dasatinib was administered follow the doctor's advice.
75771403|NCT03844360|Drug|Pegaspargase|pegaspargase was administered follow the doctor's advice.
75910879|NCT04893928|Other|ICTs preferences and barriers survey|"Information and communication technologies (ICTs) preferences and barriers. It will be assessed using an ad-hoc inventory designed by the authorship. It has 45 questions mainly answered through a 5-points Likert scale. This inventory was inspired by the surveys used by Mauer M et al on an international population with urticaria (11), and those used by Reich J et al (30) and Chowdhary TS et al (31) on American patients with IBD. Survey approaches aspects related to:~Frequency of use of ten different ICTs for personal purposes;~Frequency of use of ten different ICTs for IBD-related purposes;~A free question about others ICTs that the patient uses for IBD-related purposes;~Eight specific IBD-related purposes ICTs are used to;~Assessment of ICTs for eight IBD-related purposes;~Eight Features an IBD-related App must comprehend."
75910880|NCT04893928|Other|Focus group and IBD mobile App for health support (MAHS) development and validation|In stage II, a qualitative study will be performed using focus group discussion to explore the experiences and perceptions of patients with IBD using ICTs for health support in different contexts. Focus groups will be established following the Krueger and Casey guidelines (32). Collected data will address the development of an IBD MASH. The developed IBD MASH will be validated on a randomised pilot study along stage III. Methodology and ethical aspects of stage II and III will be defined in another proposal, after stage I preliminary findings.
75771404|NCT03844360|Drug|Anti-Infective Drugs|anti-infective drugs was administered follow the doctor's advice.
75910881|NCT04908982|Drug|Aspirin 81mg|81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
75771405|NCT03844360|Drug|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor|pegaspargase was administered follow the doctor's advice.
75318635|NCT05550402|Drug|Salbutamol|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
75771406|NCT01198054|Drug|Lenalidomide|"Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease"
75910882|NCT04909294|Radiation|Stereotactic Radiotherapy with Linac MRI|"38 Gy in 4 fractions of 9.5 Gy over the entire prostate,~+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI."
76072645|NCT01813435|Drug|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
75618106|NCT02820454|Drug|AGuIX|A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
76072646|NCT05037526|Device|Dexcom G System|Continuous glucose monitoring system
76072647|NCT05037526|Device|Self monitoring blood glucose|Standard Care
76072648|NCT04008160|Device|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
76072649|NCT01798498|Device|Princess® VOLUME|
75318636|NCT05550402|Drug|Ipratropium Bromide|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
75318637|NCT05550402|Drug|Salbutamol plus Ipratropium Bromide|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
75618107|NCT02820454|Radiation|whole brain radiation therapy|30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
75618108|NCT05659108|Behavioral|CPR|HIGH QUALITY CPR
75618109|NCT02878824|Other|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek & Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr & Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
75771407|NCT01199770|Other|Control, small|control pasta, small portion
75771408|NCT01199770|Other|Experimental B, small|experimental pasta, small portion
75771409|NCT01199770|Other|Experimental pasta C, small|experimental pasta C, small portion
75771410|NCT01199770|Other|control, medium|control pasta, medium portion
75771411|NCT01199770|Other|experimental pasta B, medium|experimental pasta B, medium portion
75771412|NCT01199770|Other|experimental pasta C, medium|experimental pasta C, medium portion
75771413|NCT01199770|Other|NL|no pasta, water only
75464391|NCT01876875|Dietary Supplement|Energy-restricted, n-3 polysaturated fatty acids-rich diet|The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
75910883|NCT04893850|Behavioral|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to improve parent well-being and promote supportive parenting practices. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target parental mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
75910884|NCT04893850|Behavioral|Community Services as Usual Clinical Referral list|The community services as usual clinical referral list provides information on accessing psychological and family support services in Winnipeg. This resource is used to locate: crisis, distress, and support phone lines, counselling and peer-support resources, and free apps relating to mindfulness and meditation.
76072650|NCT02554708|Device|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
76072651|NCT01813357|Drug|Rosuvastatin|encapsulated tablet 20mg daily
76072652|NCT01813357|Other|Placebo|Placebo arm included to maintain blinding
75318638|NCT05550402|Other|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
75910885|NCT02811159|Drug|Telapristone acetate|Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.
75910886|NCT04901650|Diagnostic Test|Survey|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
75318639|NCT05549258|Drug|Inebilizumab|Inebilizumab administered intravenously (IV) over a total of 28 weeks.
75910887|NCT04412356|Procedure|Tracheotomy|Surgical procedure to secure airway
75318640|NCT05547347|Procedure|Magnetic Resonance Imaging|Undergo MRI
75318641|NCT05547347|Procedure|Mammogram|Undergo a mammogram
75464392|NCT01876875|Dietary Supplement|Usual diet|The patients of this group were randomized to continue their usual diet
75464393|NCT01876927|Other|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
75464394|NCT01876927|Other|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
75464395|NCT01876940|Device|air-Q, followed by fiberoptic intubation|
75464396|NCT01876940|Device|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
75464397|NCT01876966|Drug|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
75464398|NCT01876966|Drug|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
75464399|NCT01876966|Drug|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets [20/120 mg] at 0, 8, 24, 36, 48, and 60 hours)
75464400|NCT01877005|Drug|Ruxolitinib|
75910888|NCT04893304|Device|co2 laser|types of laser
75318642|NCT05547347|Procedure|Ultrasound|Undergo a breast ultrasound
75318643|NCT05547347|Procedure|Ultrasound-Guided Biopsy|Undergo a percutaneous ultrasound-guided breast clip placement
75318644|NCT05518838|Drug|OKN-007|OKN-007 is an intravenously administrated drug being developed as a novel anti-cancer therapy against gliomas.
75464401|NCT01877018|Behavioral|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
75464402|NCT01877031|Device|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
75464403|NCT01877031|Device|Ultrasound|Standard of Care - Ultrasound guided intervention
75910889|NCT04901026|Other|An in-house manikin|Participants obtain an in-house manikin
75910890|NCT04892992|Behavioral|DFG|
75910891|NCT04430998|Drug|Zinc L-Carnosine|Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
75910892|NCT04430998|Drug|Chlorhexidine|Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
75910893|NCT04430998|Other|Water|Rinse mouth with 10 ml of water, retain for 3 minutes, 3 times daily
76072653|NCT01812655|Device|Virtual Reality|
76072654|NCT01812655|Other|Passive Distraction|
76072655|NCT02346526|Procedure|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
76072656|NCT02346526|Procedure|CT scan|Standard CT scans will be carried out prior to treatment, week 9, and week 25.
76072657|NCT02346526|Procedure|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
76072658|NCT02346526|Drug|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
76072659|NCT02346526|Procedure|bone scan|Standard bone scans will be carried out prior to treatment, week 9, and week 25.
75771414|NCT01202032|Drug|Association of Bevacizumab (BVC)+ Pazopanib (PZP)|"Treatment is administered in 28-day cycles, during which patients received BVC intravenously every 2 weeks and oral PZP once daily from days 1 to 28. For the first cycle, PZP is administered alone from days 1 to 14.~The starting dose for dose escalation is BVC at 7.5 mg/kg in combination with PZP 400 mg (level 1).~The therapy regimens for each dose level are respectively:~BVC 7.5 mg/kg + PZP 600 mg (level 2) BVC 10 mg/kg + PZP 600 mg (level 3) BVC 10 mg/kg + PZP 800 mg (level 4). Patients who experience grades 3 to 4 adverse events have dose adjustments to one or both drugs. Dose reductions affect in priority the administration of PZP. Doses reductions to PZP are made in 200-mg decrements and to BVC to 2.5-mg/kg decrements.~Patients with toxicities that warrant reductions at either PZP 400 mg or BVC 7.5 mg/kg are withdrawn from the study."
75771415|NCT05266300|Genetic|DPYD genotype|"The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G>A) rs67376798(c.2846A>T) rs55886062(c.1679T>G) rs56038477(75017182)/(c.1236G>A)"
75910894|NCT03052894|Device|Hydraulic Monitoring Device|"The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.~This will be compared to measurements using a current monitoring device in the same patient."
75771416|NCT03844984|Drug|ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
75771417|NCT03844984|Drug|Midazolam|This group will receive midazolam 0.05 mg/Kg
75771418|NCT03844984|Drug|Normal saline|This group will receive normal saline 10 mL
75771419|NCT03844984|Drug|ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
75771420|NCT03844984|Drug|Lidocaine|This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
75771421|NCT03842176|Procedure|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
75318645|NCT05518786|Other|Exposure of interest: critical illness|Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae
75464404|NCT01877044|Dietary Supplement|NAXUS|
75771422|NCT03842176|Procedure|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
75318646|NCT05516576|Device|endomina®|Endoscopic gastroplasty
75464405|NCT01877044|Dietary Supplement|Placebo|
75771423|NCT03842020|Other|Blood pharmacokinetic samples|1 or 3 sample(s) will be taken in the following time windows: [H0-H3]; [H5-H9] and just before the next set [H24], depending if the child is or is not admitted to hospital
75771424|NCT03843658|Other|There is no intervention, but a diagnosis.|Cohorts will be determined by the primary rheumatology diagnosis.
75318647|NCT05514405|Drug|Remimazolam (Byfavo)|Remimazolam is continuously infused based on bispectral index (within 40-60).
75318648|NCT05514405|Drug|Propofol|Propofol is continuously infused based on bispectral index (within 40-60).
75318649|NCT05509647|Drug|Unfractionated heparin|Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
75464406|NCT01877057|Dietary Supplement|Saturn|
75464407|NCT01877096|Behavioral|Motivational Interviewing|A brief motivational interviewing session
75464408|NCT01877096|Behavioral|Attention Control|Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
75464409|NCT01877122|Device|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
75464410|NCT01877122|Device|Marlex® Mesh Implant|
75464411|NCT01877174|Device|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
75464412|NCT01877174|Procedure|transcarotid stenting|
75464413|NCT01877200|Other|No treatment given|Patients will fill out a questionnaire by interview.
75464414|NCT01877213|Behavioral|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
75464415|NCT01877226|Drug|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
75464416|NCT01877252|Procedure|Surgical revascularization|
75464417|NCT01877252|Procedure|Endovascular revascularization|
75464418|NCT01877252|Other|No vascular intervention|
75464419|NCT01877304|Device|AKITA|
75771425|NCT03843814|Procedure|APT MRI|
75771426|NCT01200004|Drug|Azacitidine|75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
75771427|NCT01200004|Drug|Lenalidomide|Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
75771428|NCT01200004|Drug|Grifola Frondosa|3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
75771429|NCT01198210|Drug|saline|local peritonsillar infiltration of 2 ml saline,
75771430|NCT01198210|Drug|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
75771431|NCT01198210|Drug|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
75771432|NCT01198210|Drug|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
75910895|NCT03052894|Device|Standard EMG Monitoring Device|"Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.~This will be used as the clinical monitoring device and as a comparator."
75910896|NCT03051958|Behavioral|Internet mindfulness&exposure treatment|"See description under Arm."
75771433|NCT03843736|Behavioral|Lifestyle intervention|"Balance the diet;~Limit high-calorie and high-fat food intake, reduce eating out, and establish regular eating habits;~Monitor body weight, avoid sedentary, get more sun and regular activities;~Mental health regulation."
75771434|NCT03843736|Drug|Probiotic Agent|Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
75771435|NCT03843736|Drug|Oral contraceptive|The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.
75771436|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
75771437|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
75771438|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
75771439|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
75771440|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
75771441|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
75771442|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
75771443|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
75771444|NCT03841630|Drug|LY3437943|Administered subcutaneously (SC)
75771445|NCT03841630|Drug|Placebo|Administered SC
75771446|NCT05668234|Other|interview|semi-directive interview
75771447|NCT04088578|Other|Training|Controlling movement of an object on computer screen by adjusting muscle activity.
75771448|NCT04088578|Other|Vagus Nerve Stimulation|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
75771449|NCT04088578|Other|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
75771450|NCT01198288|Other|domiciliary rehabilitation|a respiratory rehabilitation programme at the patient home
75771451|NCT01198288|Other|Standard Care|As describe in the standard care arm
75771452|NCT03841942|Other|clinically-based spacing strategy|All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI < 150 for CD, Partial Mayo score < 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.
75318650|NCT05490979|Behavioral|Contemplative dyad meditation|Participants take part in a 3-hour group meditation training led by a professional meditation teacher. They receive detailed instructions and also practice contemplative dyad meditation for at least 30 minutes with another participant. During the 2 weeks following the training, participants meet in supervised group settings to practice the meditation method with alternating partners for up to 6 times.
75464420|NCT01877317|Device|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
75464421|NCT01877330|Procedure|Interscalene block for shoulder arthroscopy|
75318651|NCT05490979|Behavioral|Fast friends|During 2 weeks, participants meet in supervised group settings to practice the 'fast friends' exercise with alternating partners for up to 6 times.
75318652|NCT05489510|Combination Product|Pulsed or continuous lighting|The cross-linking procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UVA light source and riboflavin solution).
75464422|NCT01877356|Procedure|bilateral spinal anesthesia|prilocaine plain 2% 50 mg
75464423|NCT01877356|Procedure|unilateral spinal anesthesia|prilocaine 2% hyperbaric 30 mg
75318653|NCT05469269|Behavioral|Passive Education|Education: QR codes will be posted at each barber's station within a barber shop, as well as on other study materials located within the shop. The QR code recruitment mechanism will encourage potential participants to complete a Prostate Cancer Knowledge and Risk Assessment questionnaire (ie. Screener) which acts as a screener for study eligibility. The screener can be completed by scanning the QR code with a cell phone while in the barbershop. Barbers will encourage their clients to complete the Screener.
75771453|NCT03841942|Other|Trough level-based strategy|"patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI < 150 for CD, Partial Mayo score < 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level < 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study."
75771454|NCT01200316|Procedure|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
75771455|NCT01200316|Procedure|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
75771456|NCT01200316|Behavioral|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
75771457|NCT05670574|Procedure|Surgery with extended (D3) mesenterectomy for small bowel tumors|
75771458|NCT01200472|Drug|Apremilast|Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
75771459|NCT01200472|Drug|Placebo|Placebo capsules identical to apremilast
75771460|NCT04087486|Diagnostic Test|Implementation of a behavioural test for patients with TBI|"The following data will be collected: (1) sociodemographic variables (2); clinical and psychological data; (3) functional tests (neuropsychological testing, TEM version CRR and TEM-PRO).~On day one, patients will undergo standard neuropsychological tests and questionnaires listed hereafter, which are commonly used in the clinical practice at the CRR.~The Patient Competency Rating Scale (PCRS)~TEM (Multiple errands test)~GREFEX~5 POINTS TEST~TAP 2.3~Behavioral Assessment of the Dysexecutives Syndrome (BADS)~On day two, the patients will perform the TEM-PRO test ambulatory in our vocation rehabilitation unit.~Predictors variables will be collected before testing: Sociodemographic: age, sex, education, marital status, mother language, time since TBI, severity of the TBI (moderate or severe), type of lesion (contusion, diffuse axonal injury grade 1-3, ischemic or other complications), history of TBI, stroke or meningitis."
75771461|NCT01200628|Behavioral|DEPITAC|heteroevaluation scale by a nurse during hospitalization
75771462|NCT04638790|Drug|Doxorubicin|25 mg/m2 i.v. day 1,15 for ABVD/AVD
75910897|NCT03051958|Other|Treatment as usual|Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
75771463|NCT04638790|Drug|Bleomycin|10,000 units/m2 i.v. days 1,15 for ABVD
75771464|NCT04638790|Drug|Vinblastine|6 mg/m2 i.v. days 1,15 for ABVD/AVD
75771465|NCT04638790|Drug|Dacarbazine|375 mg/m2 i.v. days 1,15 for ABVD/AVD
75771466|NCT04638790|Drug|Etoposide|100 mg/m2 i.v. days 1-3
75771467|NCT04638790|Drug|Doxorubicin|50 mg/m2 i.v. day 1 for EACODD-14
75771468|NCT04638790|Drug|Cyclophosphamide|650 mg/m2 i.v. day 1
75771469|NCT04638790|Drug|Vincristine|1,4 mg/m2 i.v. day 8
75318654|NCT05469269|Behavioral|Education by Community Navigator|A community navigator will be onsite to assist in information delivery, navigation to resources, and encourage the completion of the Screener through the QR code. Participants can opt to connect with the community navigator if they have questions, need assistance in scheduling a PSA screening, or if they have other resource needs. The community navigator will help participants connect with a primary care provider to continue with all preventive healthcare recommendations.
75771470|NCT04638790|Drug|Dexamethasone|20 mg i.v. days 1-3
75318655|NCT05469269|Behavioral|Education at Community Outreach Screening Event|The Community Navigator will set up PSA screening events at specific barber shops for participants who wish to move forward with screenings.
75464424|NCT01877382|Drug|Milademetan|DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
75464425|NCT01877382|Drug|Milademetan|Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
75771471|NCT04638790|Drug|Dacarbazine|375 mg/m2 i.v. day 1 for EACODD-14
75771472|NCT05212402|Dietary Supplement|Cannabinol|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
75771473|NCT05212402|Other|Placebo|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
75771474|NCT04606498|Other|Observational|Observational study only - no intervention
75771475|NCT05282602|Other|baseline physical therapy treatment along with Wii Fit based exercises|Group A performed Wii Fit based exercises for 6 weeks. Group A will be treated with Wii Fit based exercises (40 mins session, 3 days/week, Penguin slide, soccer heading, tilt table, tightrope walking)
75771476|NCT05282602|Other|Proprioceptive exercises|Group B will be treated with Proprioceptive training (40 min session, 3 days/week, toe walking, heel walking, cross-body leg swings right and left sides, partial squat, ). In both groups pre and post-test measurements of Balance and Fall of risk will be assessed through Berg Balance scale, STAR excursion, Modified Fall Efficacy scale, and Timed Up and Go (TUG). Evaluation will be done before session start and at the end of 6th Week.
75771477|NCT01200706|Drug|Amoxicillin|amoxicillin 50mg/kg/day given in two different administration schemes
75771478|NCT01200784|Drug|Nicotinamide|dosage
75771479|NCT01200862|Drug|Investigational new drug company code: BGS649|
75771480|NCT01200862|Drug|Placebo|
75771481|NCT03843502|Drug|Kava Dietary Supplement|Participants will be given three 75mg kava capsules.
75771482|NCT01200940|Other|Sucralose|sucralose will be given at doses of 68 mg (equivalent to one 12 oz soda) 170 mg (equivalent to two and one-half 12 oz sodas, and 250 mg (equal to 100% of the FDA s acceptable daily intake for a 50kg individual).
75771483|NCT01200940|Other|Aspartame|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
75771484|NCT01200940|Other|Acesulfame-Potassium|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
75771485|NCT01200940|Other|Control|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
75910898|NCT04908124|Device|Lubricant A|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
75910899|NCT04908124|Device|Lubricant B|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
75910900|NCT04908124|Device|Lubricant C|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
75618110|NCT02878824|Other|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray & Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
75771486|NCT01201018|Drug|Oshadi D, Oshadi R|Oral administration
75618111|NCT04627558|Other|stroke patients, balance assessment|validity relability dubousset functional test
75464426|NCT01877434|Procedure|Reversed shoulder arthroplasty|
75771487|NCT03841552|Device|Augmented Feedback|An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
75771488|NCT03841552|Other|Control Group|Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
75464427|NCT01877447|Device|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
75618112|NCT02820376|Other|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
75771489|NCT05667844|Behavioral|interoceptive mind-body exercise|A interoceptive mind-body exercise program in a patient with Generalized Anxiety Disorder and Major Depressive Disorder based on a Multidimensional Assessment of Interoceptive Awareness. Each session of the body-mind intervention lasts 80 minutes and is supervised by physical education professionals. The intervention is divided in 4 parts, that are: Preparatory phase (reception) the subjects will be welcomed through subjective analyzes of the researcher; Initial phase (preliminares) Mindfulness, grounding, sensory stimulation and joint warm-up exercises are performed; main phase (exercises) stretching, mobility, posture and balance exercises are performed with full attention and listening after each exercise; Final phase (relaxation) breathing exercises, stretching exercises, body scanning and relaxation are performed.
75771490|NCT03841396|Drug|Sodium chloride|All participants received a single dose of sodium chloride as placebo
75771491|NCT03844438|Drug|LPM3480226|The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
75771492|NCT03841474|Drug|Psychiatric treatment with sertraline|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
75771493|NCT03841474|Drug|Psychiatric treatment with escitalopram|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
76088829|NCT04489602|Other|ObsQoR-10F Questionnaire|The ObsQoR-10F questionnaire consists of 10 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. It takes two minutes to complete all the items. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. If the patient has returned home with her child, she can be contacted by phone to complete the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
75771494|NCT04507594|Procedure|Lung lobectomy OR esophagus cancer resection|Lunge lobectomy (total) Resection of esophagus cancer
75771495|NCT03843112|Drug|Vivag Plus|Contains two lactobacilli strains; l. gasseri and l. rhamnosus
75771496|NCT03843112|Drug|Placebo - Cap|Vaginal supplements
75771497|NCT01198444|Drug|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
75771498|NCT05670184|Drug|LSD|Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.
75771499|NCT05670184|Drug|Ethanol|Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
75910901|NCT04908124|Device|Lubricant D|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
75910902|NCT04908124|Device|Lubricant E|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
75464428|NCT01877460|Other|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
75464429|NCT01877473|Procedure|Ablation|
75618113|NCT00876187|Biological|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
75618114|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
75318659|NCT05457972|Drug|Estradiol|Imvexxy is an FDA-approved drug produced by TherapeuticsMD.
75318660|NCT05457972|Device|Vaginal Moisturizer|Ingredients include hydrogenated coconut and palm oils and natural-source vitamin E (d-alpha tocopheryl acetate and tocopherols).
75318661|NCT05453929|Drug|Rocuronium for deep NMB|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
75318662|NCT05453929|Drug|Rocuronium for moderate NMB|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
75464430|NCT01877486|Procedure|Ablation|Pulmonary vein isolation following dofetilide
75618115|NCT00876187|Biological|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
75618116|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
75618117|NCT00876187|Biological|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
75318663|NCT05449145|Dietary Supplement|Vitamin D|1st week: Vitamin D 82285.71 IU per day (total dose: 576000IU per week); 2th to 4th week: Vitamin D 41142.86 IU per day (total dose: 288000IU per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
75318664|NCT05449145|Dietary Supplement|Non-Vitamin D|1st week: 95% MCT oil 5.71 ml per day (total dose: 40 ml per week); 2th to 4th week: 95% MCT oil 2.86 ml per day (total dose: 20 ml per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
75318665|NCT05437562|Other|Ewing Amputation|All patients will receive Ewing Amputation to test feasibility.
75318666|NCT05435586|Other|Web Based Breastfeeding Education and Counseling with Digital Game Support|The educational content prepared by the researcher on the web page will be integrated into the game program designed with the gamification technique. In this designed program, users will be notified at appropriate times to enter the system and play games from the link sent via e-mail. After the users have finished the game, they will fill the scale in the relevant week and will only be able to exit the system in that way.
75318667|NCT05434052|Other|Turkish Validity and Reliability of The CIQ-R Scale|The aim of this study is to adapt the Community Integration Questionnaire-Revised (CIQ-R)scale to Turkish society and to make its validity and reliability in Turkish. It has 18 questions. This study will be conducted with stroke patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
75618118|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
75618119|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
75618120|NCT00876187|Drug|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
75618121|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
75618122|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
75618123|NCT04238884|Drug|Voriconazole preemptive genotyping strategy|The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
75618124|NCT04238884|Drug|Voriconazole clinical practice|The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
75771500|NCT04467814|Behavioral|Better Together|"Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.~Caregiver participants in the intervention group will receive up to six telephone or video calls with the research assistant or Clinical Resource Therapist. Sessions will review the knowledge translation (KT) product with family members (~15 minutes), art goals, brainstorm strategies, and discuss setbacks. The calls with the caregiver may occur 1 to 2 times in the hospital, within one week of going home, and then in Months 2 and 3."
75771501|NCT04467814|Behavioral|Usual Care|Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.
75771502|NCT01198678|Dietary Supplement|Boost Nutritional Supplement|Boost- Nutritional Supplement
75771503|NCT01201096|Radiation|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
75771504|NCT01201096|Procedure|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
75771505|NCT03842800|Other|MRI|Patients and volunteers will receive an MRI.
75771506|NCT03842800|Drug|Ketamine|Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
75771507|NCT01201174|Other|fermented papaya preparation (FPP)|Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
75771508|NCT04415788|Device|Test of Incremental Respiratory Endurance - IMT|The TIRE training regimen will involve the use of a tablet provided to assigned subjects with the training software installed and a PrO2® device through which they will train. The software allows subjects to track their inspiratory muscle performance via real-time graphic representations of their efforts as training progresses.
75771509|NCT04415788|Device|Threshold - IMT|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
75771510|NCT04415788|Device|Sham IMT (Low resistence)|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
75618125|NCT01102374|Drug|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
75618126|NCT01102374|Drug|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
75618127|NCT01102374|Drug|Placebo|Placebo monthly
75771511|NCT01201252|Procedure|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
75771512|NCT03841006|Device|MRI|dynamic MRI pelvis
75771513|NCT01202422|Drug|Pregabalin controlled release, 165 mg|Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
75771514|NCT01202422|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for four days.
75771515|NCT01202422|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for four days
76088830|NCT03501576|Biological|Inactivated Influenza Vaccine|Given seasonal inactivated influenza vaccine IM
75618128|NCT01102374|Dietary Supplement|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
75618129|NCT05658640|Drug|Trametinib|Oral
75618130|NCT05658640|Drug|Dexamethasone|Oral/ Intravenous
75618131|NCT05658640|Drug|Cyclophosphamide|Intravenous
75618132|NCT05658640|Drug|Cytarabine|Intravenous
75618133|NCT05658640|Drug|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
75618134|NCT04238572|Device|Audiovisual distraction device|Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption
75910903|NCT04430764|Procedure|non-surgical periodontal treatment|Non-surgical periodontal treatment program was as following: First, motivation and oral hygiene instructions were given to all participants with periodontitis. The modified-Bass tooth brushing technique with a given dentifrice and toothbrush twice a day, and dental flossing/ interdental brushing once a day was advised to all patients with periodontitis. Second, scaling using an ultrasonic device and root planning by hand instruments under local anesthesia was performed.
75771516|NCT03840694|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours.
75464431|NCT01877499|Other|Optimization of HDF key parameters|"First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~Treatment time (up to 4 hours per session);~Blood flow rate (up to 400 mL/min;~Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits."
75464432|NCT01877512|Drug|Change in daily dosage of Growth Hormone|
75464433|NCT01877525|Procedure|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
75318668|NCT05426681|Drug|GlyBURIDE Oral Tablet|"Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide"
75318669|NCT05424900|Behavioral|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
75318670|NCT05418296|Device|A novel digital health device|A videogame-generated virtual world designed for the AD/ADRD care dyad.
75910904|NCT04892836|Other|Training|Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)
75910905|NCT04901182|Diagnostic Test|the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)|the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
75464434|NCT01877577|Dietary Supplement|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
75464435|NCT01877590|Drug|alpha-lipoic acid|
75910906|NCT04900948|Drug|Pimecrolimus cream 1%|Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
75910907|NCT04900948|Drug|cream 0.1% methylprednisolone aceponate|Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
75464436|NCT01877616|Other|diagnostic test|Polysomnography
75910908|NCT04892368|Other|Home-based supervised exercise program|Combination of aerobic and strength training exercises, in addition to home exercise instructions issued during preoperative physiotherapy education.
75464437|NCT01877616|Other|Diagnostic test|overnight polysomnography
75464438|NCT01877629|Drug|ACT-129968 500 mg tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
75464439|NCT01877629|Drug|ACT-129968 250 mg capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
75464440|NCT01877681|Procedure|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
75464441|NCT01877681|Procedure|Active comparator|Usual care as specified in the PU practice guideline
75464442|NCT01877694|Drug|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
75464443|NCT01877694|Drug|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
75464444|NCT01877707|Other|home monitoring|Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
75464445|NCT01877733|Other|Maximal strength training|
75618135|NCT04238572|Device|Analgesia nociception index|ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
75618136|NCT02880696|Behavioral|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
75771517|NCT03840694|Other|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.
75771518|NCT03892018|Drug|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
75318671|NCT05417347|Other|Low-fat dairy products|Milk: low fat (less than 2% M.F.) Yogurt: less than 2% M.F. Cheese: less than 20% M.F.
75318672|NCT05417347|Other|Full-fat dairy products|Milk: full-fat milk Yogurt: 2% and more M.F. Cheese: Regular cheese products
75771519|NCT03842644|Device|Tension reduction device|Continue using this device for 3 months post surgery.
75771520|NCT01201564|Procedure|intraperitoneal onlay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
75771521|NCT01201564|Procedure|sublay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
75771522|NCT05018104|Other|This is not an interventional study|This study utilizes data from the St. Paul's Hospital Peripheral Nerve Block Database.
75771523|NCT03725722|Drug|Delgocitinib cream|Cream for topical application
75771524|NCT03725722|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
75771525|NCT01198912|Drug|placebo|during 56 days
75771526|NCT01198912|Drug|doxycycline 100 mg|during 56 days
75771527|NCT03842488|Drug|Experimental: RAL QD|Prescription of 2x RAL 600mg (1200MG) once daily
75771528|NCT03842488|Drug|Active comparator: DRV/cb|Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
75771529|NCT03842254|Drug|Erythropoietin|Subcutaneous injection of erythropoietin 10,000 units
75771530|NCT01202500|Procedure|reducing treatment to 3 months|The treatment will be stopped after 3 months
75910909|NCT04901104|Drug|Thymosin Alpha1|Drug interventions have been done in previous clinical studies
75771531|NCT01202500|Procedure|registered length of treatment|The treatment procedure will follow the actual recommandation
75771532|NCT04223050|Drug|Oxygen gas|Administering oxygen to achieve the desired peripheral oxygen saturation
75910910|NCT04900324|Device|MRI guidance|Injections of botulinum toxin performed using MRI guidance
75910911|NCT04900324|Device|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
75910912|NCT04892680|Behavioral|Online Diabetes Self-Management Education and Support (DSMES) Program|Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.
75464446|NCT01877746|Drug|Combination of prednisone and azathioprine|"Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
75318673|NCT05406726|Dietary Supplement|palmitoylethanolamide|palmitoylethanolamide is an lipid based endocannabinoid naturally made by the body and is present in several common foods such as eggs
75618137|NCT02880696|Behavioral|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
75618138|NCT02880696|Device|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
75618139|NCT04693702|Device|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
75618140|NCT02818504|Other|Wize Mirror|Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
75318674|NCT05406726|Dietary Supplement|Placebo|a capsule filled only with maltodextrin will be used as a placebo
75618141|NCT02818270|Drug|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
75618142|NCT02818270|Drug|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
75618143|NCT02879760|Biological|Ad-MAGEA3|Intramuscular injection
75618144|NCT02879760|Biological|MG1-MAGEA3|Intravenous infusion
75771533|NCT01198990|Behavioral|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
75318675|NCT05403736|Other|Cardiac Aggressive Risk MitigAtion Plan|Cardio-oncology consultation along with long-term collaborative cancer care visits during standard of care radiation therapy that will occur weekly for up to 6 weeks followed by 6-week and 3-month follow-up visits. Health will be monitored with biosensor monitoring devices.
75464447|NCT01877746|Drug|Combination of prednisone and azathioprine|"Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
75464448|NCT01877746|Other|No intervention|No intervention, only standard medical therapy
75771534|NCT01198990|Behavioral|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
75771535|NCT01201642|Drug|Prednisolone|Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
75771536|NCT01201642|Device|acupuncture|The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
75910913|NCT04907812|Drug|Tranexamic acid|Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery
76088831|NCT05142462|Device|Hip arthroplasty|Hip prosthesis surgical implantation
75771537|NCT01201642|Other|other treatment|common medicine or other physical treatment which are different from those 5 Arms Previously.
75771538|NCT05004064|Drug|Acalabrutinib|Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.
75771539|NCT05004064|Drug|Rituximab|Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
75771540|NCT03842410|Device|Single-Incision Sling|Solyx Single-Incision Sling for correction of stress urinary incontinence done in the office.
75771541|NCT03798418|Behavioral|elastic band strengthening exercise|2-3days per week(150min per week)
75771542|NCT03798418|Dietary Supplement|diet counseling|each patients in this group will receive4-5times diet counseling
75771543|NCT04982692|Drug|intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
75771544|NCT04982692|Drug|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
75318676|NCT05402657|Procedure|Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy|UBRUL-FP involves ultrabrief right unilateral ECT delivered using a novel frontoparietal montage, where the anterior electrode is shifted frontally to a position above the midpoint of the right eye to avoid temporal lobe stimulation (and reduce memory side effects). UBRUL-FP will be delivered using standard ECT devices.
75318677|NCT05402657|Procedure|Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy|UBRUL-TP is the standard form of ultrabrief right unilateral ECT, using the conventional temporoparietal (d'Elia) electrode placement, where the anterior electrode is placed over the right temporal lobe. UBRUL-TP will be delivered using standard ECT devices.
75771545|NCT01202734|Drug|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
75771546|NCT01201720|Procedure|Plasma exchange with albumin|Realization of 6 plasma exchange with albumin in 11 days
75771547|NCT01201954|Drug|sucrose|oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
75771548|NCT03037684|Diagnostic Test|neurophysiology|electrophysiologic measurements of peripheral nerves
75318678|NCT05402527|Dietary Supplement|Fish nutrients|Intake of fish protein, omega-3 fatty acids, and vitamin D
75318679|NCT05402527|Dietary Supplement|Whey protein|Intake of whey protein
75318680|NCT05402527|Dietary Supplement|Maltodextrin|Intake of maltodextrin
75318681|NCT05399407|Other|Health e-coaching|Management of overweight / obesity
75318682|NCT05396963|Dietary Supplement|Egg white|Intake of egg white
75318683|NCT05396963|Dietary Supplement|Whey protein|Intake of whey protein
75318684|NCT05396963|Dietary Supplement|Maltodextrin|Intake of maltodextrin
75318685|NCT05386264|Other|Expanded autologous T regulatory cells|A 3+3 dose escalation design with expanded T regulatory cells administered on Day 1 and Day 15
75464449|NCT01877759|Biological|Mesenchymal stem cell|Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow & umbilical cord , IN 6 divided doses , at interval of 1 week .
75618145|NCT02879760|Biological|Pembrolizumab|Intravenous infusion
75771549|NCT01202812|Dietary Supplement|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
75771550|NCT01202812|Other|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
75771551|NCT03840850|Other|Personalized Risk Communication for People with Type 2 Diabetes|The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy. These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
75771552|NCT01203748|Procedure|PVI + Lines ablation|Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
75771553|NCT01203748|Procedure|PVI|Pulmonary vein antrum isolation
75771554|NCT01203748|Procedure|PVI + CFE ablation|Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
75771555|NCT02966314|Drug|Omalizumab|Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
75771556|NCT02966314|Drug|Placebos|Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
76088832|NCT05140200|Biological|GSK3511294|GSK3511294 will be administered.
75318686|NCT05369468|Drug|dexmedetomidine as adjuvant with bupivacaine|to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
75464450|NCT01877785|Drug|MHAA4549A|Single-ascending dose of MHAA4549A
75464451|NCT01877785|Drug|Placebo|Placebo to MHAA4549A
75464452|NCT01877798|Procedure|volume resuscitation, vasoactive drug|
75618146|NCT02818348|Drug|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
75618147|NCT02818348|Drug|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
75618148|NCT04308876|Other|Manual therapy|Manual therapy includes techniques applied to elbow joints and surrounding tissues
75618149|NCT04308876|Other|Strengthening exercises|Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
75618150|NCT00634192|Drug|tobramycin|1x300mg/d inhaled
75618151|NCT00634192|Drug|tobramycin|2x300mg/d inhaled
75618152|NCT02626897|Device|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
75618153|NCT02626897|Device|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
75771557|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 5mg/day for one year
75771558|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 40mg/day for one year
75771559|NCT04938154|Device|DBS ON|The DBS system will be turned on and the patient will be left on their best setting for 3 months.
75771560|NCT04938154|Device|DBS OFF|The DBS system will be turned off, and will be left off for 3 months.
75771561|NCT01204060|Other|Nasal allergen challenge|Subjects will receive a nasal spray containing an allergen to which they are allergic
75771562|NCT01204060|Other|Nasal placebo challenge|Subjects will receive a nasal spray with allergen diluent
76088833|NCT05133102|Other|Sample collection|Collection of saliva sample
76088834|NCT03369210|Drug|red blood cell transfusion trigger|patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
75771563|NCT01202890|Drug|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
75771564|NCT01202890|Drug|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
75771565|NCT03118804|Diagnostic Test|Assessment of Lung Tidal Distribution With EIT|Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
75771566|NCT01199224|Drug|veliparib|veliparib formulation A
75464453|NCT01877811|Drug|RXDX-105|"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
75771567|NCT01199224|Drug|veliparib|veliparib formulation B
75910914|NCT04907812|Procedure|Surgery|This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints <50 contracture ii. PIP joints <40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints >50 degree contracture ii. PIP Joints >40 degrees contracture b. >2 fingers involved
75464454|NCT01877824|Other|Fast-track training|
75771568|NCT01199224|Drug|veliparib|veliparib formulation C
75464455|NCT01877850|Procedure|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
75464456|NCT01877863|Other|exercise|12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
75464457|NCT01877889|Drug|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 [treatment period 2] or Sequence 2 [treatment period 1]).
75464458|NCT01877889|Drug|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 [treatment period 1] or Sequence 2 [treatment period 2]).
75618154|NCT02879214|Radiation|Simultaneous boost along with chemo|Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
75618155|NCT04238182|Other|wet cupping|This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.
75318687|NCT05369468|Drug|Bupivacain only|to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
75771569|NCT01199224|Drug|veliparib|veliparib formulation C
75771570|NCT03840304|Other|Yoga@work|Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
75771571|NCT03839056|Device|IC+PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~This intervention is included in the clinical practice routine"
75910915|NCT04907734|Other|Caliper|Description of the sample adipose tissue and skinfolds using different calipers.
75318688|NCT05368623|Diagnostic Test|Color fundus photograph|Subjects will undergo color fundus photography before and after pharmacological dilation of pupils.
75318689|NCT05368623|Diagnostic Test|Optical Coherence Tomography (OCT) of the retina|Subjects will undergo OCT of the retina after pharmacological dilation of pupils.
75318690|NCT05368623|Drug|Mydriatic Agent|Pharmacological dilation of pupils will be done by instilling mydriatic agent in eyes of Subjects
75318691|NCT05367362|Drug|Minocyclin|200 mg intravenous/oral minocycline hydrochloride for a total of 21 days
75618156|NCT04238182|Other|dry cupping|The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
75771572|NCT03839056|Device|PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
75771573|NCT03839056|Device|PIEB+PCEA standar flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
75771574|NCT01204138|Drug|Apremilast|Apremilast 30mg BID
75771575|NCT01204138|Drug|Placebo|Placebo BID
75771576|NCT03840538|Drug|Probiotic Product - Cap|probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
75771577|NCT05668078|Diagnostic Test|Rapid Antigen Testing (RAT) for COVID-19|COVID-19 RAT intervention done among the school students to see if RAT test can play a role in reducing absenteeism. School type-1-only for symptomatic participants, School type-2-Serial testing at three days interval for all participants and School type-3 got no testing.
75771578|NCT01206088|Drug|nilotinib|administration of nilotinib as 2nd line
75910916|NCT04892290|Other|Conservative Treatment for Postdural Puncture Headache|The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.
75910917|NCT01889186|Drug|ABT-199 (Main Cohort)|Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
75618157|NCT02627755|Device|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
75464459|NCT01877928|Device|Boussignac CPAP device|Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.
75318692|NCT05366140|Other|Prospective follow-up of patients who have received instrumented lumbar arthrodesis supplemented the Implanet Jazz System(TM)|To assess the clinical outcomes of patients receiving standard of care Implanet Jazz System(TM) at the time of their instrumented lumbar arthrodesis.
75318693|NCT05352789|Other|Non validated Survey|Overall inclusion of metabolic and nutritional parameters in prehabilitation practices will be assessed as the proportion of each parameter conducted from the mandatory queries presents as yes/no/unsure responses for each centre. Intervention or process details for included parameters will be described based on the response variable. The survey presents 4 question formats; free text (thematic qualitative analysis), 5 and 6 point likert scales (proportional response), categorical data (proportional response) and yes/no/unsure response sets (Binary response (no and unsure - grouped). All categorical data versions are parameter dependent and response variables can be requested from the research team.
75464460|NCT01877928|Device|standard CPAP|Standard of care postoperative treatment for OSA.
75318694|NCT05350449|Behavioral|Loving-kindness Meditation|Loving-kindness meditation is a type of mindfulness practice where the focus is on love/compassion and kindness for self and others. The guided meditation will be provided via recording device. The intervention is 4 week long.
75464461|NCT01877954|Drug|Extra-fine hydrofluoroalkane beclometasone dipropionate|
75464462|NCT01877954|Drug|Fluticasone propionate|
75464463|NCT01877967|Dietary Supplement|VSL#3|The intervention group will be asked to ingest two sachets (2x4.4g) of the food supplement (VSL#3) each day for 12 weeks, either both at the same time, or one in the morning and one in the evening. This food supplement is in powder form and can be ingested with either cold food or any non-carbonated cold drink. The control group will be given a placebo, although as it is a double-blind intervention, will not know it is a placebo. They will similarly to the intervention group be asked to take two sachets (2x4.4g) of a powder rach day for 12 weeks, either both at the same time, or one in the morning and one in the evening.
75618158|NCT02627755|Device|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
75771579|NCT01202968|Procedure|Transcutaneous neuro-muscular electrical stimulation|Neuro-muscular electrical stimulation with two pairs of surface electrodes was applied to submental area. One paired electrodes to be placed horizontally was attached on the anterior half of area between mandible and hyoid bone. The other was affixed to posterior half of the same area far laterally. Bipolar electrical stimulation with pulse rate of 80-Hz, duration of 700 µs and intensity to evoke visible muscle contraction was performed for 60 minutes a day until one day before extubation.
75318695|NCT05348837|Procedure|Deep brain stimulation|Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.
75910918|NCT01889186|Drug|ABT-199 (Safety Expansion Cohort)|Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
75910919|NCT04900558|Procedure|Radical Cystectomy|All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc...
75910920|NCT04892212|Drug|Sirolimus|The daily dose of sirolimus is divided twice.
75910921|NCT04892056|Other|Friction Mechanics|anterior segment retraction using elastomeric power chains
75910922|NCT04892056|Other|Frictionless Mechanics|anterior segment retraction using closing loops
75910923|NCT03052582|Other|Milk type|
75618159|NCT02817724|Device|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
75910924|NCT01510184|Drug|Zevalin|Zevalin administered intravenous infusion.
75910925|NCT01510184|Drug|Y-90-Zevalin|Y-90-Zevalin administered by intravenous infusion.
75618160|NCT02817724|Other|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
75910926|NCT01510184|Drug|Rituximab|Rituximab administered by intravenous infusion.
75910927|NCT01510184|Drug|In-111 Zevalin|In-111-Zevalin administered by intravenously.
75910928|NCT04907422|Diagnostic Test|CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction|new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
75910929|NCT04907422|Diagnostic Test|non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction|conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
75910930|NCT04900090|Other|Epidemiological study|"Clinical phenotypic assessment and neurosensory measures~Biological, genetic and metabolomic evaluation~Questionnaires (quality of life, gout, life habit, comorbidities)~Morphological evaluation by Dual-energy CT scan"
75318696|NCT05340569|Diagnostic Test|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
75318697|NCT05307991|Drug|PrEP|HIV pre-exposure prophylaxis (or PrEP) will include the Malawi-approved PrEP regimen at time of study enrollment. At time of submission, the only Malawi-approved regimen includes Tenofovir/emtricitabine (TDF/FTC) containing 300 mg of TDF and 200 mg of FTC. If additional PrEP regimens become available in Malawi during the study recruitment or follow-up, participants will be able to choose from any regimen that they are eligible to receive per Malawi PrEP guidelines.
75618161|NCT00681421|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
75771580|NCT05281900|Diagnostic Test|Clinical Tests|Shoulder impingement and instability tests and shoulder normal range of motion measurement.
75910931|NCT04906954|Other|NMES|Standardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.
75910932|NCT04907344|Drug|Camrelizumab|IV infusion
75910933|NCT04907344|Drug|Nab-Paclitaxel|IV infusion
75910934|NCT04907344|Drug|Carboplatin|IV infusion
75910935|NCT03877484|Device|ALLEVYN Gentle border|ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
75910936|NCT04907266|Other|Structured Questionnaire|A structured proforma to assess outcome
75910937|NCT04906876|Drug|Gemcitabine|Gemcitabine as a 90-minute IV infusion
75910938|NCT04906876|Drug|Docetaxel|Docetaxel as a 60-minute IV infusion
75910939|NCT04906876|Drug|9-ING-41|9-ING-41 as an IV infusion over 1-4 hours twice weekly
75464464|NCT01877967|Dietary Supplement|placebo|
75464465|NCT01878058|Other|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
75464466|NCT01878110|Behavioral|COMB|
75464467|NCT01878123|Biological|AMP-110|Dose levels 1 through 7: Single intravenous infusion on Day 0
75464468|NCT01878123|Other|Placebo|Dose levels 4 through 7: Single intravenous infusion on Day 0
75464469|NCT01878136|Drug|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
75910940|NCT00858728|Behavioral|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
75464470|NCT01878188|Drug|BC-819/PEI|Intravesical instillation
75910941|NCT00858728|Behavioral|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
75910942|NCT04906798|Drug|CKD-385|Test Drug
75910943|NCT04906798|Drug|D744|Reference Drug
75910944|NCT05039138|Other|NEUROMUSCULAR TRAINING EXERCISE|patients will receive neuromuscular training exercises in group II
75618162|NCT00684463|Drug|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
75910945|NCT05039138|Other|traditional training exerises|traditional strength training exercises in group I
75464471|NCT01878188|Drug|BCG Vaccine|intravesical instillations
75618163|NCT02817490|Other|patient education program|"The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session."
75618164|NCT02817568|Other|Drawing Blood|Drawing Blood for genetic analysis
75618165|NCT00678457|Drug|Ondansetron|ondansetron (4 μg/kg b.i.d.)
75618166|NCT00678457|Drug|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
75771581|NCT05281900|Other|MVIC measurements|For the normalization of muscle activation during exercises, muscle activation levels during maximum voluntary isometric contraction (MVIC) of the dominant side Upper Trapezius, Middle Trapezius, Lower Trapezius, Serratus Anterior, Biceps Brachii, Triceps Brachii and Infraspinatus muscles will be recorded. Participants will be asked to stop for 10 seconds at the point where they show resistance. A total of three measurements will be taken and the highest value recorded. The areas where the electrodes will be placed will be prepared by shaving and cleaning with alcohol. The electrode placement will be made parallel to the muscle fibers. A rest period of at least 2 minutes will be allowed between measurements.
75771582|NCT05281900|Other|Exercises|"Activation of the scapula and shoulder girdle muscles will be measured during variations of the plank exercise.~In the tests, participants will be asked to stay in this position for 10 seconds after providing the standardized stance in the plank position. During the test, a video will be taken and incorrect attempts will be repeated.~Determined plank variations will be done in mixed order. Each exercise will be repeated 3 times and the average of the repetitions will be recorded as the result. A 2 minute rest period will be given between exercises.~After each exercise, the perceived effort level will be questioned with the BORG scale.~4 assisted exercises:~Low plank~Low plank w/ isometric shoulder external rotation~High plank~High plank plus~Bear plank~3 assisted exercises:~Low plank w/ front reach~High plank w/ shoulder taps~High plank w/ toe touch~2 assisted exercises:~Low plank bird dog~High side plank"
75910946|NCT03785912|Behavioral|Internet-based self-help|Eight cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of adjustment problems after having an accident.
75910947|NCT04891744|Drug|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
75618167|NCT00678457|Drug|Placebo|placebo
75618168|NCT02817646|Other|Computed tomography scan made for clinical reasons|Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)
75618169|NCT02817646|Dietary Supplement|Nutrition as per hospital protocol|Patients received enteral and/or parenteral nutrition as per usual hospital protocol
75910948|NCT04891744|Drug|Thalidomide|100mg/d, Po. on day1-28
75910949|NCT04891744|Drug|Dexamethasone|20 mg/d Po. on day 1, 2,8,9,15,16,22,23
75464472|NCT01878201|Drug|Fimasartan|Fimasartan 30 mg
75464473|NCT01878201|Drug|Valsartan|Valsartan 80 mg
75464474|NCT01878227|Drug|Coenzyme A|Coenzyme A 400mg per day
75464475|NCT01878227|Drug|Fenofibrate 200mg|Fenofibrate 200mg per day
75464476|NCT01878240|Procedure|EVAR without coils embolization/ Coils embolization during EVAR|
75464477|NCT01878266|Radiation|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
75618170|NCT00678613|Drug|Probiotics and Placebo|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
75618171|NCT00678613|Drug|Probiotics and Norfloxacin|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
75618172|NCT02817334|Drug|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
75618173|NCT02626429|Dietary Supplement|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
75618174|NCT02817412|Behavioral|Go/No-Training|
75910950|NCT04891900|Drug|TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine|"Initial treatment (6 cycles)：~TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle"
75910951|NCT03687320|Device|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
75771583|NCT01204372|Drug|Gemcitabine - Trastuzumab - Erlotinib|"Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~Erlotinib: oral route 100 mg/day from C1D1."
75771584|NCT01567228|Other|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
75771585|NCT01204450|Drug|Temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
75771586|NCT01204450|Drug|Valproic Acid|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
75618175|NCT02817412|Behavioral|Stop-Signal Training|
75618176|NCT02817412|Behavioral|Dot-Probe Paradigm|
75618177|NCT02817412|Behavioral|Generic Response Training|
75771587|NCT03835780|Other|No intervention|A observation of outcomes in usual practice
75771588|NCT03834454|Drug|Bupivacaine|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
75771589|NCT03834454|Drug|Bupivacaine|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
75910952|NCT03687320|Device|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
75771590|NCT02428270|Drug|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
75771591|NCT02428270|Drug|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
75771592|NCT01204528|Drug|Zemplar|Vitamin D receptor activator (VDRA)
75771593|NCT02299492|Other|Person Centered Care Planning|PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
75771594|NCT02178046|Device|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
75771595|NCT01566916|Procedure|Total Hip Arthroplasty|
75771596|NCT01566994|Behavioral|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
75771597|NCT01566994|Behavioral|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
75910953|NCT04891588|Drug|Switching the preserved prostaglandin analog-timolol FC to Fixalpost (preservative free prostaglandin analog-timolol FC)|"switching preserved prostaglandin analog- timolol FC (fixed combination) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC (Fixalpost).~form: preservative free latanoprost - timolol fix combination (50 micrograms/ml latanoprost + 5 mg/ml timolol), ocular solution dosage: once daily, at 8.00 p.m. duration: 3 months"
75910954|NCT04900012|Procedure|Distal pancreatectomy|We are going to collect all cases
75910955|NCT03050866|Drug|Cabazitaxel|25mg/m2 q3w
75318698|NCT05307991|Device|STI testing|Urine specimens will be tested for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) using GeneXpert® (Cepheid, Sunnyvale, CA) Xpert® CT/GC platform and cartridge and syphilis RPR titer (BD Macro-VUE™, Becton, Dickinson and Company, Franklin Lakes, NJ [FDA approved]) with confirmatory Treponema pallidum particle agglutination (TP-PA) (Serodia Fujirebio Inc, Malvern, PA [CE mark]) if RPR is positive.
75618178|NCT04579432|Other|Education|With the training module prepared according to the ADDIE model, the intervention group will be trained on reproductive health and sexual health.
75618179|NCT00678769|Drug|Cixutumumab|Given IV
75771598|NCT01566994|Behavioral|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
75618180|NCT00678769|Other|Laboratory Biomarker Analysis|Correlative studies
75618181|NCT00678769|Other|Pharmacological Study|Correlative studies
75618182|NCT00678769|Drug|Temsirolimus|Given IV
75618183|NCT02817022|Other|developmentally supportive care|DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
75618184|NCT04146883|Drug|Antibiotics|Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
75618185|NCT02817256|Dietary Supplement|Vitamins and Minerals|Multivitamins and Minerals supplementation
75618186|NCT00681577|Biological|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
75771599|NCT01203124|Drug|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
75771600|NCT01203124|Drug|Placebo|Placebo
75771601|NCT05281822|Other|The stress management training|The women in the experimental group were provided with stress management training to help cope with stress conditions how to use positive coping in conditions in case of stress and tension.
75318699|NCT05307991|Behavioral|Assisted partner notification|"Participants will be asked to provide the name and locator information for all sexual partners in the preceding 6 months. Participants will be asked to refer sexual partners to the clinic and will be provided with cards to distribute to partners. Each card will request that the recipient report to the STI clinic with the card and will contain a linking number that links them back to the index participant.~Sexual Partner Tracing: In accordance with the contract referral approach, if the named partners do not present to an STI clinic within 7-14 days, community outreach workers will contact the partners and counsel them to visit the clinic. Contact may be made through telephone, text message, or in person, as needed and will not disclose the name or identify of the index patient."
75618187|NCT02817100|Drug|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
75910956|NCT03050866|Other|Antihistamine|As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
75771602|NCT03829930|Drug|Entinostat|"Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly."
75910957|NCT03050866|Other|Corticosteroid|As intravenous premedication (dexamethasone 8 mg or equivalent)
75910958|NCT03050866|Other|H2 antagonist|As intravenous premedication (ranitidine or equivalent)
75910959|NCT03050866|Other|Antiemetic|Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
75910960|NCT03471806|Behavioral|Food reward at baseline|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.
75910961|NCT03471806|Behavioral|Food reward after treatment|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
75771603|NCT03829930|Drug|Enzalutamide|Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
75910962|NCT04455308|Diagnostic Test|Biological sample collection|10mL blood sample
75910963|NCT03051880|Drug|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
75910964|NCT03051880|Drug|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
75910965|NCT04891276|Other|Data collection|Data collection on the national PMSI database
75910966|NCT05390996|Other|dental implant placement|dental implant placement by using a different drilling techniques
75910967|NCT05163236|Diagnostic Test|Positive fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
75618188|NCT02817100|Drug|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food [Continental breakfast])
75318700|NCT05307991|Diagnostic Test|Acute HIV testing|Persons initiating or re-initiating PrEP will also be screened for acute HIV infection (AHI) using Abbott RealTime HIV-1 Assay (Abbott Laboratories, Chicago, IL) or Xpert® HIV-1 Viral Load (GeneXpert, Cepheid, Sunnyvale, CA).
75618189|NCT02817100|Drug|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
75618190|NCT00684697|Dietary Supplement|iron|High, intermediate and low iron dosage orally for 2 months
75618191|NCT02816944|Procedure|EUS-guided laser ablation for refractory neoplasms|
75771604|NCT01203202|Drug|Clomipramine|15mg and 30mg on demand
75771605|NCT03829384|Biological|mRNA-1944|mRNA encoding Chikungunya antibody
75771606|NCT03829384|Other|Placebo|Saline
75910968|NCT05163236|Diagnostic Test|Negative fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
75910969|NCT05163236|Diagnostic Test|Fecal immunochemical test (FIT) not performed|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
75910970|NCT04899466|Device|ActiGraft|Whole blood clot (WBC) gel
75910971|NCT05163002|Behavioral|Nutritional education & carbohydrate counting|Nutrition Education with a multidisciplinary team
75910972|NCT03052660|Drug|Midazolam|Oral administration preoperatively
75910973|NCT03052660|Drug|Placebo oral capsule|Oral administration preoperatively
75910974|NCT05159180|Device|cardioz mapping|Patients will be submitted to mapping of both voltage and tissue impedance.
75910975|NCT04891120|Diagnostic Test|Treadmill test (Bruce protocol)|Treadmill test performed with and without a mask.
75910976|NCT05006456|Device|Catheter ablation|Subjects will undergo catheter ablation using the new technologies, including THERMOCOOL SMARTTOUCH® SF catheter with Visitag SURPOINT, QDOT catheter and HELIOSTAR catheter when they are used in conjunction with Carto system for AF ablations.
75910977|NCT04958174|Device|web-application|web application for monitoring children's development
75910978|NCT04753814|Diagnostic Test|Diagostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.
75464478|NCT01878266|Radiation|Hypofractionated Arm (2)|The total dose to 4500 cGy in 15 fractions in 3 weeks
75464479|NCT01878266|Radiation|Conventional Arm (3)|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
75464480|NCT01878279|Other|Underlying medical illness|
75618192|NCT00678847|Device|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
75618193|NCT00678847|Device|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
75910979|NCT04412278|Other|Online Survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
75618194|NCT02816866|Other|empowered primary care model|mode of survivorship care
75910980|NCT05162612|Diagnostic Test|abtominal CT|standard basic Abdominal Ct scan
75910981|NCT05162534|Other|effect of COVID-19 exposure|effect of COVID-19 exposure
75910982|NCT04890808|Dietary Supplement|Inosine|Patients will be dosed with two 500 mg capsules of Inosine twice daily for 36 months
75910983|NCT04890808|Dietary Supplement|IP6|Patients will be dosed with two 500 mg capsules of IP6 twice daily for 36 months
75910984|NCT05162456|Diagnostic Test|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
75910985|NCT05162456|Diagnostic Test|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
75910986|NCT04890964|Device|Transcranial Direct Current Stimulation (tDCS)|A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
75910987|NCT04890886|Diagnostic Test|Thermal imaging|Use of a thermal imaging cameral to measure brown and white adipose tissue function
75318701|NCT05304481|Biological|ATL administration|Subjects have ATL administration using intravenous infusion
75318702|NCT05272462|Drug|Minoxidil|Minoxidil is an antihypertensive vasodilator medication commonly used for the treatment of high blood pressure and pattern hair loss.
75318703|NCT05253482|Procedure|wet cupping therapy|Vacuum cups will used on different acupuncture points to perform WCT: The one on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra was DU 14 (Dazhui) point; the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra interscapulum region were UB 42 (Pohu) bilateral points; and the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 7th thoracic vertebra were UB 46 (Geguan) bilateral points and additionally the patient's trigger points which we detect during the examination. There will be 5-7 points in total. The technique used will be triple S (Sucking, Scarification, Sucking) in all sessions.
75464481|NCT01878305|Device|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
75464482|NCT01878318|Drug|methotrexate|stable dose
75464483|NCT01878318|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 24 weeks
75464484|NCT01878357|Drug|dihydroartemisinin-piperaquine|Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).
75464485|NCT01878357|Drug|primaquine|One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
75618195|NCT02816866|Other|specialty survivor clinic|mode of survivorship care
75618196|NCT00684853|Drug|bevacizumab|1.25 mg of bevacizumab intravitreal
75618197|NCT00684853|Drug|vetaporfin|full fluence of vetaporfin
75618198|NCT02816554|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
75618199|NCT02816554|Biological|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
75618200|NCT02816554|Biological|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
75618201|NCT02816554|Biological|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
75910988|NCT04890886|Diagnostic Test|Echocardiogram|Echocardiographic imaging of the fetal heart to assess ventricular function
75910989|NCT04890886|Diagnostic Test|ECG|ECG of the fetus and the neonate to look at the cardiac electrical activity
75910990|NCT04890886|Diagnostic Test|MRI scan|MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function
75618202|NCT02816476|Drug|Daratumumab|
75618203|NCT00678925|Dietary Supplement|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
75618204|NCT00678925|Dietary Supplement|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
75618205|NCT00875485|Procedure|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
75618206|NCT00875485|Biological|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
75618207|NCT04572802|Procedure|Coronary angiography|Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
75618208|NCT04237870|Device|Active cTBS|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS will be repeated twice with 15 min interval. The cTBS sessions last for 4 weeks, 5 times a week. Treatment will be applied to central suleus.
75618209|NCT04237870|Device|Sham|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
75910991|NCT04890886|Diagnostic Test|Serum blood markers|Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
75910992|NCT03469154|Other|Dyad training method|The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.
75910993|NCT03469154|Other|Instructor led training method|The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
75910994|NCT04080700|Procedure|Distal radial approach|Operator puncture the distal radial artery with open needle or venipuncture catheter needle for coronary angiography and percutaneous coronary intervention.
75618210|NCT00684931|Other|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
75910995|NCT04906252|Diagnostic Test|Echocardiography|Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution
75910996|NCT04906252|Diagnostic Test|Electrocardiogram (ECG)|Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution
75910997|NCT05137886|Drug|PD-1 inhibitor|decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.
75318704|NCT05248256|Other|Evidence-based radiation dose limitation to the vertebral bone marrow|The only intervention that will occur during the radiation treatment planning process will be the application of evidence-based radiation dose limitations to the vertebral bone marrow during treatment plan optimization in order to attempt to limit Grade 3 Lymphopenia (G3L) toxicity.
75318705|NCT05240794|Device|ABM-01|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)
75318706|NCT05240794|Device|Digital Control|Placebo control for ABM-01
75464486|NCT01878370|Other|High risk|"Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.~Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches."
75464487|NCT01878370|Other|Best Practice|"Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.~Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices."
75464488|NCT01878396|Drug|Anti-B-RAF|
75618211|NCT04238104|Other|no intervention|it's only observational study. No interventions.
75618212|NCT04147117|Device|Cervical pessary|Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.
75618213|NCT00679003|Behavioral|SLCBT|Social learning and cognitive behavioral therapy
75464489|NCT01878422|Drug|Arm A: FOLFIRI or FOLFOX + Bevacizumab|Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
75464490|NCT01878422|Drug|Arm B: FOLFIRI or FOLFOX|Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
75464491|NCT01878422|Drug|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
75464492|NCT01878422|Drug|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
75618214|NCT00679003|Behavioral|ES|Education and support (information about nutrition and gastrointestinal system)
75618215|NCT04547140|Biological|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion 120 mg/kg
75318707|NCT05232799|Other|Care Anywhere with Community Paramedics program|Outpatient management with supportive services provided by the community paramedic team.
75318708|NCT05230134|Procedure|Cervical sympathetic block|All participants will get the cervical sympathetic block and catheter under ultrasound guidance.
75318709|NCT05228821|Drug|Voxelotor Oral Tablet|During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
75318710|NCT05222152|Drug|Chronocort|Hydrocortisone modified-release hard gelatin capsules for oral administration - 5mg and 10mg
75318711|NCT05222152|Drug|Plenadren|Hydrocortisone modified-release tablets for oral administration - 5mg and 20mg
75318712|NCT05200572|Behavioral|Dyadic Life Review (DLR)|DLR will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes. Each session will facilitate a recall of each phase of life: childhood, adolescence, young adulthood, mid-life, earlier later life, and later life. While together, the patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life.
75318713|NCT05188027|Other|Aerobic Exercise|Walking at 60% of maximal aerobic capacity on a treadmill
75464493|NCT01878448|Drug|Anlotinib|
75464494|NCT01878474|Drug|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
75464495|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
75618216|NCT04547140|Drug|Placebo|Intravenous infusion
75771607|NCT01203280|Other|icing massage|The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
75910998|NCT04905394|Procedure|subchondroplasty|subchondroplasty is an innovative percutaneous procedure in which calcium phosphate, biocompatible material similar to the native bone apatite with osteoinductive properties, is injected inside BML areas. The purpose of subchondroplasty is the patient's symptoms relief, improving the mechanical strength of subchondral bone, stimulating bone remodeling to avoid bone sagging, and slow down the arthritic degenerative process to postpone arthroplasty.
75464496|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
75910999|NCT05135624|Drug|SP16 (6mg)|SP16 will be administered as 2 concurrent, separate 2 mL s.c injections of 3mg/mL SP16
75911000|NCT05135624|Other|Placebo|Placebo will be administered as 2 concurrent, separate 2 mL s.c. injections of sterile water
75318714|NCT05188027|Other|Resistance Exercise|Performing one set of 10 repetitions of 10 different weight-lifting exercises
75318715|NCT05188027|Other|No exercise|Participants will rest in a supine position for 30 minutes.
75464497|NCT01878474|Drug|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
75318716|NCT05188014|Behavioral|Luteal Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer during the last week of active pill consumption.
75464498|NCT01878474|Drug|Placebo|Single ascending dose in Caucasian men
75911001|NCT05135624|Drug|SP16 (12 mg)|SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
75318717|NCT05188014|Behavioral|Follicular Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer within 5 days of starting their menses.
75318718|NCT05159297|Other|Reference values|Normative reference values of coordination tests will be obtained
75318719|NCT05141526|Other|Non-restrictive satiating intervention|Diet group containing satiating foods
75318720|NCT05141526|Other|Conventional restrictive intervention + non-restrictive satiating intervention|Diet group with a calorie deficit during the first phase followed by a diet containing satiating foods in the second phase
75318721|NCT05141526|Other|Control group|This group will receive minimal healthy guidelines
75318722|NCT05137262|Other|Abiraterone acetate|Given by IV
75318723|NCT05137262|Drug|Durvalumab|Given by IV
75318724|NCT05137262|Drug|Methotrexate|Given by IV
75318725|NCT05137262|Drug|Vinblastine|Given by IV
75318726|NCT05137262|Drug|Doxorubicin Hydrochloride|Given by IV
75318727|NCT05137262|Drug|Cisplatin|Given by IV
75464499|NCT01878474|Drug|Placebo|Age-effect in Caucasian men
75464500|NCT01878474|Drug|Placebo|Gender-effect in Caucasian women
75464501|NCT01878474|Drug|Placebo|Single ascending dose in Japanese men
75464502|NCT01878487|Device|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|"There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~At baseline~After thrombus aspiration with a thrombus extraction catheter~After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such."
75464503|NCT01878513|Drug|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
75618217|NCT04547140|Drug|Standard Medical Treatment|SMT
75618218|NCT00679159|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
75618219|NCT00679159|Biological|Prevenar|Streptococcus pneumoniae vaccine
75618220|NCT04237714|Behavioral|Smiling is fun|"Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador."
75464504|NCT01878539|Device|coagulometer|
75464505|NCT01878539|Behavioral|training programme|
75618221|NCT04146103|Drug|Novex|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
75911002|NCT03469076|Other|YUN ACN Cream|YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
75911003|NCT04905472|Device|Vestibular prosthesis/implant|The intervention is a vestibular prosthesis which our collaborators at the University of Geneva are implanting into the inner ear in deaf patients without vestibular function who are receiving a cochlear implant. The vestibular implant (VI) has three rate sensors and senses angular head velocity in three dimensions and provides this information to the brain by stimulation the afferent nerves innervating the three semicircular canals. Our goal is to use the VI to better understand how the brain processes this prosthetic information and uses it to generate meaningful behavioral responses including eye movements, postural control, and perception.
75911004|NCT04905472|Device|Vestibular Implant Stimulation|VI subjects will be studied before the implant is activated (pre) and then after it is turned on (acute On); this will take about 2 hrs. Then they will have 8 hours of motion-modulated VI stimulation while they actively explore the hospital environment, after studies will be repeated (chronic On). Each set of outcome experiments will be performed twice, once with and once without low-levels of stochastic noise added to the VI stimulation provided for the 8-hour period. The noise amplitude is tailored to each patient to maximize stochastic resonance so extraction & integration of spatial signal provided by the VI will always be the first experiment, but the order of the subsequent outcome sessions (active/passive head rotations, tilt/translation motion discrimination and VOR behavioral changes & postural control) will be randomized. VI subjects will participate in 4 full-day sessions, each separated by at least a month.
75911005|NCT04905550|Drug|Almonertinib|Almonertinib 110mg p.o qd. Treatment with Almonertinib will continue until progression or unacceptable toxicity.
75318728|NCT05132556|Other|Acute Beetroot Juice|Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness
75464506|NCT01878565|Drug|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
75911006|NCT04905550|Radiation|Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)|Image guided, 24-15 Gy*1F was recommended if use SRS. 9-12 Gy*3F/1W or 6Gy×5F/1W was recommended if use SRT. 30Gy/10F/2W for WBRT, large residual lesions will be treated with a local dose (≤DT 45Gy/15F).
75464507|NCT01878565|Drug|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
75911007|NCT04667000|Other|Forced Air Warming|We will use Forced Air Warming for cesarean patient
75911008|NCT04890418|Drug|Ketalar, 5 mg/mL Injectable Solution|The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.
75911009|NCT04890418|Other|Placebo|The patients will receive 10 mL of 0.9% saline. This injection is also performed after the realization of PNB but before tourniquet set up and before start of surgery.
75911010|NCT04890184|Dietary Supplement|grape juice|grape juice
75911011|NCT04890184|Other|control|no intervention
75911012|NCT03051802|Device|Navigated Endoscopy|Navigated endoscopy used to guide the placement of HDR applicators in the esophagus or lung as a replacement to current standard of practice using fluoroscopic imaging.
75618222|NCT05654038|Biological|Anti-CD19 UCAR-NK cells|"The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set three different dose levels of UCAR-NK cells:Dose level one: 5-10×10^6/kg; Dose level two:1-2×10^7/kg; Dose level three:2-5×10^7/kg."
75911013|NCT04905238|Device|Continuous positive airway pressure|Continuous positive airway pressure
75618223|NCT00685009|Drug|Estrogen hormone therapy|Estrogen pill daily
75618224|NCT00685009|Drug|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
75618225|NCT00685009|Drug|Placebo|Placebo pill daily
75911014|NCT04349150|Device|Virtual reality|Intervention consists of providing virtual reality in place of standard sedatives and narcotics for a portion or the duration of the colonoscopy
75911015|NCT03051724|Other|Telematic follow up|Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
75911016|NCT04456010|Other|Questionnaire|Eligible patients will be selected from our electronical database and invited via email to participate.
75911017|NCT04905004|Procedure|Canine retraction|Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.
75911018|NCT04455932|Diagnostic Test|Abbreviated non-contrast MRI of the liver|every 6 months
75911019|NCT04455932|Diagnostic Test|Ultrasound surveillance|every 6 months
75911020|NCT04455932|Diagnostic Test|Multiphase contrast-enhanced liver MRI|screening
75911021|NCT04899154|Other|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.
75911022|NCT04899154|Other|stool sampling|Participants will provide one stool sample at inclusion
75911023|NCT04905160|Other|COMPASSION Digital Biomarker|Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
75318729|NCT05129475|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
75318730|NCT05129475|Drug|Ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to PF-07321332/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours after PF-07321332/ritonavir dosing.
75318731|NCT05123742|Diagnostic Test|COVID-19 Testing|Testing for the SARS-CoV-2 virus
75464508|NCT01878578|Drug|Eslicarbazepine acetate|Tablets containing ESL 600 mg
75464509|NCT01878578|Drug|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
75464510|NCT01878578|Drug|Placebo|Tablets containing matching placebo
75464511|NCT01878630|Device|Remote Patient Management|"Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~weighing scale (Seca 861 with bluetooth, seca gmbh & co. kg.)~blood pressure device (UA767PBT with bluetooth, A&D Ltd.)~ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~- electronic patient record (eHealth connect 2.0, T-Systems International)"
75464512|NCT01878630|Other|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
75771608|NCT01204606|Procedure|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4 or 5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repaired of rotator cuff tear was done with suture anchors.~Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound.~Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
75911024|NCT04890548|Drug|AZD3427|Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
75911025|NCT04904848|Other|Survey evaluation|examine the convergent validity and reliability of a Turkish version
75464513|NCT01878643|Drug|vancomycin or gentamicin|Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
75911026|NCT03050944|Other|Lifestyle behaviour and dietary habits assessment|Lifestyle behaviour and dietary habits assessment
76072660|NCT01812109|Device|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy|Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes ~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
75911027|NCT05053958|Other|superimposition of DICOM file from CBCT and STL file of Intraoral scanner|These files will be imported in implant planning software,and virtual implant planning will be performed.
76072661|NCT01811953|Drug|Empagliflozin|medium dose oral administration
75464514|NCT01878643|Drug|Placebo|normal saline administered to patient via nebulization
76072662|NCT01811953|Drug|Metformin|oral administration
75911028|NCT04898998|Device|Transcutaneous electrical nerve stimulation (TENS)|Surgical patients under general anesthesia were recruited from a medical center. Each patient was randomly assigned to the experimental group (TENS) or control group (routine care).
75318732|NCT05119777|Device|HArmonyCa Injectable Gel|Subdermal or deep dermal injection
75318733|NCT05111977|Device|Vibrant capsule|A capsule delivering mechanical vibrations
75464515|NCT01878695|Drug|IV/oral n-acetylcysteine|
75464516|NCT01878708|Drug|PEG-L-asparaginase|
75464517|NCT01878708|Drug|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
75618226|NCT02816086|Other|Interdisciplinary collaboration structure|A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
75618227|NCT00679237|Behavioral|smoking cessation|NRT and varenicline
75618228|NCT00679237|Drug|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
75618229|NCT00679237|Drug|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
75618230|NCT00679237|Behavioral|training|daily walking
76072663|NCT01811953|Drug|Empagliflozin|low dose of Empagliflozin oral administration
76072664|NCT01811953|Drug|Empagliflozin/Metformin|low dose of Empagliflozin
75318734|NCT05106465|Device|Konectom platform|Administered as specified in the treatment arm.
75318735|NCT05086315|Drug|SAR443579|Powder for solution for infusion; by IV infusion
75318736|NCT05086289|Drug|LY3526318|Administered orally
75318737|NCT05086289|Drug|Placebo|Administered orally
75318738|NCT05082012|Device|Treatment of Hallux Valgus|Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.
75318739|NCT05062031|Device|Defocus Incorporated Multiple Segments® (DIMS®) lenses|Daily wear for 24 months. Lenses have a central monofocal optical zone correcting spherical or spherocylindrical ametropia, surrounded by a ring made up of 300 defocusing pellets. This lens geometry reduces the phenomenon of blurred image projected in the retinal periphery, encountered when myopic eyes are corrected with monofocal lenses.
75618231|NCT00679237|Biological|influenza vaccine|vaccine (FLuarix, Influvac etc)
75618232|NCT00679237|Drug|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
75618233|NCT00679237|Behavioral|weight reduction|diet tips
75618234|NCT02816164|Drug|Neupogen|Subcutaneous injections
75318740|NCT05062031|Drug|Atropine 0.05% eyedrops|One drop each evening in both eyes for 24 months.
75318741|NCT05062031|Device|Monofocal lenses|Daily wear for 24 months
75464518|NCT01878721|Radiation|PET/CT|positron emission tomography/computed tomography
75618235|NCT02816320|Other|Hospitalization|Patients who were hospitalized in acute care
75618236|NCT00681733|Drug|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
76072665|NCT01811953|Drug|Metformin|oral administration
76072666|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
76072667|NCT01811953|Drug|Empagliflozin|medium dose oral administration
75911029|NCT04898998|Other|routine care|routine care
75911030|NCT03051022|Drug|Dexamethasone 8 mg|Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
75911031|NCT03051022|Drug|Morphine 2 mg|Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
75911032|NCT03052504|Other|Registration of complications|Prospective registration
75911033|NCT04648826|Device|AeroEclipse II Breath Actuated Nebulizer|Patients will receive AZA via commercial device, AeroEclipse II Breath Actuated Nebulizer.
75911034|NCT04648826|Drug|Bintrafusp alfa|Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W [once every 3 weeks]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.
75464519|NCT01878734|Dietary Supplement|Micronutrient Powders|Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
75911035|NCT04648826|Drug|Azacytidine|Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.
75911036|NCT03052270|Drug|Arabin Pessary|Insertion of Arabin pessary for the prevention of preterm delivery
75911037|NCT04898842|Other|Dietary intervention|To determine whether a 4 stage bowel obstruction diet as a means of managing oral intake in patients symptomatic with malignant sub-acute bowel obstruction (SBO) is deliverable and effective in clinical practice.
75464520|NCT01878747|Behavioral|Provider Tailored Intervention for Perioperative Stress|Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
75911038|NCT05390762|Other|Common phase|A common face to face day hospital combining physical therapies with psychotherapeutic support such as Cognitive Behavioral Therapy to combat kinesiophobia.
75911039|NCT05390762|Other|Telecare rehabilitation|A Second phase of 5 weeks of telecare rehabilitation of the reconditioning type of 15 sessions.
75911040|NCT05390762|Other|Care in Face to Face|A Second phase of 5 weeks of care in face to face day hospital of the reconditioning type of 15 sessions.
75911041|NCT03052348|Other|Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
75911042|NCT03052348|Other|Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
75911043|NCT04172480|Other|Blood sampling|Peripheral blood sampling on EDTA
75464521|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|"Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~--------------------------------------------------------------------------------"
75618237|NCT00681733|Drug|Pioglitazone|30 mg OD
75318742|NCT05046301|Procedure|Biospecimen Collection|Correlative studies
75464522|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
75618238|NCT00681733|Drug|Pentoxifylline|1200 mg/d
75618239|NCT02816008|Behavioral|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
75618240|NCT02816008|Behavioral|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
75618241|NCT04151329|Biological|BAT1306 and BAT8001 2.4mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
75618242|NCT04151329|Biological|BAT1306 and BAT8001 3.6mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
75911044|NCT04890340|Diagnostic Test|ARNA Breast|Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method
75318743|NCT05046301|Other|Contrast Agent|Given IV
75318744|NCT05046301|Procedure|Contrast-Enhanced Mammography|Undergo contrast-enhanced mammography
75318745|NCT05046301|Other|Questionnaire Administration|Ancillary studies
75318746|NCT05045144|Combination Product|RSVPreF3(120 μg)|A single dose of RSVPreF3(120 μg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 μg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.
75318747|NCT05045144|Combination Product|Flu Quadrivalent influenza vaccine (15 μg HA)|A single dose of Flu Quadrivalent influenza (15 μg HA) vaccine was administrated intramuscular (IM).
75318748|NCT05045144|Combination Product|Placebo|One dose of placebo, administered intramuscularly in the deltoid region of the right arm, at Day 1.
75318749|NCT05040776|Drug|EP-7041 Injection|EP-7041 infusion
75318750|NCT05037292|Other|PAUSE Intervention|Standardized frailty screening and utilization of a frailty review board (PAUSE Board)
76072668|NCT01811953|Drug|Metformin|oral administration
76072669|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
75464523|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
75464524|NCT01878864|Drug|Bupivacaine lozenge|
75618243|NCT02815774|Drug|SP2086|all subjects were given SP2086 50mg only one time.
75618244|NCT00679315|Drug|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
75618245|NCT00679315|Drug|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
75618246|NCT04049773|Procedure|haemodialysis|haemodialysis, thrice weekly in-center
75618247|NCT02626351|Other|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: [1] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; [2] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; [3] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; [4] Follow up.
75911045|NCT05018234|Device|Noval Oral Appliance|A scan of the mouth will be performed to make the oral device. The device will be 3D printed with Asiga UV Max printer using FDA 510(k) cleared VeriSplint OS Resin.Subjects will be will be asked to wear the oral device at night for 3 nights and fill out a survey reviewing their experience wearing the device.
75911046|NCT05015114|Other|Sarcopenia Assessment|Sarcopenia Assessment
75318751|NCT05022524|Dietary Supplement|Acetate (Apple Cider Vinegar)|Consumer-grade apple cider vinegar (ACV) capsules will have extra enteric coating applied for delivery further into the GI tract.
75318752|NCT05017363|Procedure|ENGAGE|Goal-setting approach and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS), which is established goal setting tools for children aged 5-9. Administration of the Canadian Occupational Performance Measure (COPM), the most widely used goal-setting tool in paediatric rehabilitation that has been used with children as young as seven years. Introducing simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
75318753|NCT05016765|Device|Active, self-directed electrical stimulation of the median nerve|Electrical stimulation of the median nerve (12 Hz, pulse width 200µs), initially at the threshold needed to see movement of the right thumb with stimulation. After initial training with the device and education in the rationale for suprathreshold stimulation, participants will choose timing and intensity of stimulation based on their momentary symptom severity and their experience with the treatment since the beginning of the study. Participant can choose right or left median nerve (we will suggest their nondominant hand to minimize interference with daily activities).
75318754|NCT05014295|Other|Accessing personal medical records online via online portals|The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
75464525|NCT01878864|Drug|Lidocaine-adrenalin injection|
75318755|NCT05000944|Other|breakfast omission (BO)|this group will not be provided with a breakfast until lunch time (at 12:30).
75318756|NCT05000944|Other|early-morning breakfast consumption (EM-BC)|this group will be provided with an early morning breakfast (at 08:30).
75464526|NCT01878903|Other|Electronic VAS|Post-opearive pain patients will be assessed using electional VAS and verbal NRS
75618248|NCT02626351|Other|Baseline data collection (active comparator)|Endpoint data collection only
75618249|NCT05652400|Other|Exposure to antiretroviral therapy|Outcomes will be compared with regard to current or previous exposure to antiretroviral therapy.
75618250|NCT00679393|Procedure|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
75618251|NCT00679393|Procedure|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
75618252|NCT02815852|Other|Women under 40 years old with histological diagnosis of breast cancer|Evaluation of imaging characteristics (ultrasound, mammography and mammary MRI if available) of breast cancer with the corresponding histological reports and assess whether in women <40 years the typical imaging presentation pattern of malignancies observed in women> 40 years are confirmed.
75618253|NCT02816242|Other|concept map teaching|teaching anatomy using concept map to improve critical thinking
75618254|NCT02816242|Other|traditional teaching|teaching anatomy using lecture
75618255|NCT04692298|Other|pulses|kidney beans, pinto beans, lentil, black-eyed pea and chickpea
75618256|NCT02815930|Other|HCU Status|Total healthcare expenditures in the top 5% of Ontarians
75618257|NCT04238962|Drug|Semaglutide (administered by DV3396 pen-injector)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks
75618258|NCT04238962|Drug|Semaglutide (administered by PDS290 pen-injector)|Increasing doses of semaglutide given sc in the stomach for 7 weeks
75911047|NCT05390684|Other|audit of complications, prospective data collection|Prospective colecction of data will be performed to create a predictive model of leak and major complication
75464527|NCT01878929|Drug|Allergen(Tree, Grass, Weeds)|Greer is manufacture of all allergen extract used in this study.
75464528|NCT01878942|Drug|Placebo|"Capsules containing mannitol looking identical to LSD~per os"
75911048|NCT04889482|Other|No intervention|No intervention
75911049|NCT03963518|Drug|Immune checkpoint inhibitor|Immune checkpoint inhibitor
75911050|NCT04885114|Genetic|Intraparenchymal rAAV1 - (mi)RNA HTT|Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
75618259|NCT01098474|Biological|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
75911051|NCT04889170|Other|Intervention|"Intervention: After recording the patient characteristics and the baseline dysphagia characteristics, the intervention begins. The intervention lasts 3 weeks, by extended stay it lasts 5 or 7 weeks.~The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and an SLT watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training or a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.~Allocation to the Groups will be done by a randomization software"
75464529|NCT01878942|Drug|LSD|200µg per os, single dose
75318757|NCT05000944|Other|mid-morning breakfast consumption (MM-BC)|this group will be provided with a mid (late) morning breakfast (at 10:30).
75464530|NCT01878955|Genetic|AMH level difference between patient with PCOS and multicystic ovaries.|
75318758|NCT05000723|Other|Standard of care|"Standard of care consisting of~clearance of infection~treatment with antibiotics (antisuppressive, DAIR) or surgery (1 stage, 2 stage Girdlestone)~Radiology: X-ray pelvis and hip, X-ray pelvis with kingmark, CT scan pelvis/hip"
75911052|NCT04526912|Drug|VIB7734|Single subcutaneous dose
75911053|NCT04526912|Drug|Placebo|Intravenous single dose matched to VIB7734.
75911054|NCT04884646|Other|VR with Routine physical therapy and Virtual reality|VR group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
75911055|NCT04884646|Other|Motor Imagery with Routine physical therapy|MI group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
75911056|NCT04884646|Other|Routine physical therapy|Group A will be given routine physical therapy in 40-min sessions and 20 min of walking and cycling with a short period of rest, every alternate day (3 days per week) for 12 weeks
75911057|NCT05013476|Combination Product|Butterfly handheld ultrasound machine|Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education
75464531|NCT01878968|Other|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
75618260|NCT01098474|Biological|Tritanrix™ HB+Hib|Intramuscular, 3 doses
75618261|NCT01098474|Biological|Prevnar™|Intramuscular, 3 doses
75318759|NCT04988685|Device|Sirolimus Eluting Balloon|PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
75771609|NCT01204606|Procedure|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4 or 5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repaired of rotator cuff tear was done with suture anchors.~43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound.~Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
75318760|NCT04987645|Procedure|Water-only infusion technique|During a routine colonoscopy, a resident in the study will use water only infusion technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
75318761|NCT04987645|Procedure|Water infusion and air insufflation|During a routine colonoscopy, a resident in the study will use water infusion and air insufflation technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
75318762|NCT04983875|Behavioral|BAC-Enhanced Letter|The BAC-Enhanced Letter intervention includes enhancing the standard mammography results letter with a few additional lines of text informing patients of their personal BAC status.
75464532|NCT01878994|Behavioral|Counselling group|
75464533|NCT01878994|Behavioral|Nereu group|
75464534|NCT01879007|Drug|Factive® Tab / Factive IV|
75618262|NCT01098474|Biological|Polio Sabin™|Oral, 3 doses
75464535|NCT01879020|Drug|TA-8995|Drug: TA-8995 1mg
75618263|NCT01098474|Biological|Menjugate™|Intramuscular, 3 doses
75618264|NCT04238026|Procedure|Distal radial artery approach|Use of distal radial artery approach in coronary angiography and angioplasty
75618265|NCT00633802|Drug|Risperidone|1 mg/d risperidone for 10 weeks or placebo
75911058|NCT04406896|Drug|Selatogrel|A single subcutaneous injection of 16 mg.
75911059|NCT04454996|Drug|tong-jiang granules|This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
75464536|NCT01879020|Drug|TA-8995|Drug: TA-8995 2.5mg
75464537|NCT01879020|Drug|TA-8995|Drug: TA-8995 5mg
75464538|NCT01879020|Drug|TA-8995|Drug: TA-8995 10mg
75464539|NCT01879020|Drug|TA-8995|Drug: TA-8995 25mg
75464540|NCT01879020|Drug|Placebo|Placebo (TA-8995 1mg)
75464541|NCT01879020|Drug|Placebo|Placebo (TA-8995 2.5mg)
75911060|NCT04454996|Drug|Chang 'an II Recipe|This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
75911061|NCT04454996|Drug|The placebo of tong-jiang granules|This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
75911062|NCT04454996|Drug|The placebo of Chang 'an II Recipe|This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
75911063|NCT04297124|Drug|CC-90009|0.6 mg [ 14C]-CC-90009 administered IV as a single dose
75911064|NCT04297124|Radiation|[14C]|A single dose of [ 14C]-CC-90009 will contain approximately 2 µCi of radioactivity.
75911065|NCT04888780|Other|The web-based Watson's Human Care Theory oriented training|Video calls were held every 15 days via the skype program with complete adherence to the schedule. In these interviews, the clinical picture of diabetes and the psychosocial status of adolescents were discussed. A total of 14 interviews with 15-day intervals were made with each adolescent. All video interviews were carried out by the first researcher and they were all recorded.
75911066|NCT04101890|Drug|Diaper care with Theraworx|Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
75911067|NCT04898218|Other|Exercise|The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
75318763|NCT04983875|Behavioral|Waitlist Control|Patients randomized to this group will receive a standard post-mammography results letter which does not include any information about their personal BAC status. However, participants randomized to this group will be informed of their personal BAC findings at the end of their study participation (approximately 6 months after mammography).
76072670|NCT03926728|Biological|CTH522-CAF01 IM|On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
75911068|NCT04456712|Drug|Ciprofloxacin 400 MG/200 ML Intravenous Solution|antibiotic
76072671|NCT03926728|Biological|CTH522-CAF09b IM|On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
75911069|NCT04456712|Drug|Levofloxacin 750 MG|antibiotic
75911070|NCT04889014|Genetic|Personal genomic educational testing (PGET)|PGET consisted of a panel of pharmacogenomic variants
75911071|NCT04889014|Genetic|No personal genomic educational testing (NPGET)|Lack of pharmacogenomic testing
75911072|NCT04456868|Behavioral|Electroencephalogram|Electroencephalogram will be done for P300 wave assessment
75911073|NCT04456868|Behavioral|walking test|8-Meter walking test will be done for gait parameter assessment
75911074|NCT04456868|Behavioral|Quality of life questionnaire|Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn & Yahr
75911075|NCT04456868|Procedure|Position emission tomography|Position emission tomography will be done for
75911076|NCT04884490|Drug|Co-trimoxazole|Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
75911077|NCT04884490|Drug|Placebo|Placebo thrice (8 hourly) daily for 7 days orally.
75911078|NCT04898530|Other|NO INTERVENTION|There is no intervention for this study.
75911079|NCT03962036|Device|Bispectral index monitor|BIS monitor is a novel measure of the level of consciousness by algorithmic analysis of a patient's electroencephalogram during general anesthesia.
75911080|NCT04883866|Behavioral|Telephone Breastfeeding Support Program|On the 3rd day after discharge, a reminder messages will be sent to the mothers in the inter vention group. Throughout the program, 21 reminder messages will be sent to mothers in the first month after discharge to support the mother and encourage breast milk via a messaging application (whatsapp, bip, telegram, etc.). In addition, a total of seven phone calls, once a week in the first month after discharge and once a month in the eighth, twelfth and sixteenth weeks, will be made to check personalized information about individual breastfeeding questions of mothers.
75911081|NCT04883866|Behavioral|Sending a breastfeeding guide for premature babies to the phone of mothers in addition to the routine discharge procedure|In addition to the routine discharge procedure, a breastfeeding guide for premature babies will be sent to the mothers' phone.
75911082|NCT03681392|Dietary Supplement|Dr. Pyke's Supplement for Stream (S4S)|Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
76072672|NCT03926728|Biological|CTH522 ID|24 microgram CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 ml syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
75318764|NCT04982029|Drug|Cannabidiol 100 MG/ML [Epidiolex]|600mg
75618266|NCT04460248|Drug|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|"Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21;~Lenalidomide, 25 mg qd, po, day 2-11;~Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years."
75618267|NCT02819986|Behavioral|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
75618268|NCT05658874|Drug|Multimodal Bundle Drugs|multimodal pain therapy
75771610|NCT03833518|Other|Rehabilitation using motorized glove for stroke and spinal cord injury|Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.
75771611|NCT03833518|Other|Functional MRI for stroke and spinal cord injury|All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.
75318765|NCT04982029|Drug|Placebo|Matching placebo
75318766|NCT04966715|Procedure|Epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of colorectal carcinomatosis by this way
75318767|NCT04964674|Behavioral|Behavioral Measurement|Take measurements of behavioral performance
75771612|NCT03833518|Other|Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury|Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
75464542|NCT01879020|Drug|Placebo|Placebo (TA-8995 5mg)
76072673|NCT03926728|Biological|CTH522 TO|24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
75464543|NCT01879020|Drug|Placebo|Placebo (TA-8995 10mg)
75618269|NCT05658874|Procedure|Operative Cystoscopy|Evaluate bladder and treat Hunner lesions with kenalog or fulguration as appropriate
75911083|NCT04888546|Drug|Anlotinib hydrochloride capsules＋ TQB2450 injection|"Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
75911084|NCT05390294|Procedure|Surgical intervention with or without postoperative adjuvant therapy|Surgical intervention with or without postoperative adjuvant therapy
75911085|NCT04888234|Drug|Ru-Yi-Jin-Huang Powder|Ru-Yi-Jin-Huang Powder is the most common TCM topical drug for skin diseases. It is often used to treat skin ulcers, sprain of joint with swelling, and other inflammatory diseases.
76072674|NCT03926728|Biological|Placebo (Saline)|Placebo only given as IM, ID and TO
75771613|NCT01774552|Device|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
75771614|NCT01298284|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
75911086|NCT04454762|Drug|Cabozantinib|oral administration (40 mg daily, reduced dose 20 mg daily)
75318768|NCT04961905|Drug|NVP-2002-R1+NVP-2002-R2|NVP-2002-R1 1 tablet, once daily and NVP-2002-R2 1 tablet, once daily
75771615|NCT01204840|Drug|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
75771616|NCT01204840|Drug|Patch protocol|"Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped."
75771617|NCT01203358|Drug|Exosurf|Infants received up to four intratracheal doses of the surfactant.
75618270|NCT05658874|Behavioral|Behavioral health consultation/therapy|Patient to see behavioral health/psychiatric care
75618271|NCT05658874|Other|Pelvic floor physical therapy|Patient to have evaluation and treatment by a trained pelvic floor physical therapist
75771618|NCT01203358|Drug|Survanta|Infants received up to four intratracheal doses of the surfactant.
75911087|NCT03050788|Device|Smartphone confocal microscopy|Imaging of skin lesion using the smartphone confocal microscopy
75911088|NCT04897984|Biological|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
75318769|NCT04961905|Drug|NVP-2002|NVP-2002 is a combination of NVP-2002-R1 and NVP-2002_R2 NVP-2002, 1 tablet, once daily
75318770|NCT04953130|Biological|Gardasil® HPV vaccine|Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).
75318771|NCT04932759|Behavioral|music listening|music listening during dental treatment
75318772|NCT04926974|Behavioral|Low Vision Rehabilitation|Smart phone App
75464544|NCT01879020|Drug|Placebo|Placebo (TA-8995 25mg)
75464545|NCT01879033|Other|Reactive hyperemia peripheral artery tonometry (Rh-PAT)|Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
75618272|NCT05658874|Other|Usual Urogynecologic care|Usual care from practicing academic Urogynecologist
75618273|NCT05658874|Drug|Bladder Instillation|Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin
75618274|NCT05658874|Drug|Vaginal estrogen|Topical vaginal estradiol application
75618275|NCT05658874|Drug|Methenamine|UTI prevention/bladder therapeutic
75618276|NCT05658874|Drug|Amitriptyline/Gabapentin|Part of multimodal pain therapy
75618277|NCT02878902|Other|Post implementation|Patient group whose care course was organized by the nurse coordinator of chronic renal failure
75618278|NCT02819830|Behavioral|Exercise Intervention|Combined strength and aerobic exercise
75618279|NCT02820064|Procedure|duodenal biopsy during gastroduodenal endoscopy|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
75911089|NCT04456088|Combination Product|150 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.
75911090|NCT04456088|Combination Product|80 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.
75911091|NCT04897828|Device|Covered Stent placement|Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients
75911092|NCT04455698|Behavioral|Remote Telegenetic Counseling by Phone|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor by Telephone.
75318773|NCT04925505|Procedure|Interscalene brachial plexus blocks with ultrasound guidance under general anesthesia|Ultrasound-guidance, interscalene brachial plexus blocks, in-plane technique, perineural injection, 0.5% ropivacaine 12.5ml and 0.2% lidocaine 12.5ml
75318774|NCT04922216|Behavioral|Core|Behavioral weight loss core includes behavioral lessons, activity tracker, daily self-weighing, weekly tailored feedback summary.
75911093|NCT04455698|Behavioral|Remote Telegenetic Counseling by Videoconferencing|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor using Videoconferencing Technology.
75318775|NCT04922216|Behavioral|Standard Diet Monitoring|Standard monitoring using smartphone tracking of all calorie intake.
75618280|NCT04425538|Drug|Infliximab|Either infliximab or infliximab-abda will be used at the discretion of the investigator
75618281|NCT04309344|Device|WEREWOLF COBLATION System|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage; fibrillations were removed and the surface was smoothed. This low energy and low suction setting minimizes damage to healthy chondrocytes surrounding and is therefore the preferred setting for the removal of articular cartilage.
75771619|NCT01203436|Procedure|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
75771620|NCT01203436|Procedure|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
75318776|NCT04922216|Behavioral|Simplified Diet Monitoring|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
75318777|NCT04922216|Behavioral|Adaptive Activity Goals (Daily)|Physical activity goals that adapt once each day using the participants' data derived from activity tracker.
75318778|NCT04922216|Behavioral|Adaptive Activity Goals (Weekly)|Physical activity goals that adapt once each week using the participants' data derived from activity tracker.
75318779|NCT04922216|Behavioral|Message Decision Points (Fixed)|Message timing is fixed and evaluated at specific times each day to determine message eligibility.
75318780|NCT04922216|Behavioral|Message Decision Points (Adaptive)|Message timing is adaptive and derived from individual user data to determine message eligibility.
75318781|NCT04922216|Behavioral|Message Decision Rules (Standard)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.
75318782|NCT04922216|Behavioral|Message Decision Rules (Adaptive)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.
75318783|NCT04922216|Behavioral|Message Choice (No)|Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision
75318784|NCT04922216|Behavioral|Message Choice (Yes)|Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.
75771621|NCT01485484|Device|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
75618282|NCT04309344|Procedure|control|mechanical debridement
75618283|NCT02879526|Drug|C-CPT|Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
75771622|NCT03832426|Drug|Narlaprevir|100 mg film-coated tablets
75771623|NCT03832426|Drug|Ritonavir|100 mg film-coated tablets
75771624|NCT03840070|Device|Potenfill|Maximum: 22ml
75771625|NCT03312010|Device|Spinal Cord Stimulator HF|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
75771626|NCT03312010|Device|Spinal Cord Stimulator Sham|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
75911094|NCT04455698|Behavioral|Usual Care Arm|Participants in the usual care arm will receive usual care services depending on which referral method they choose and if they initiate services. After a 6 month status survey, if they have not had genetic services through usual care they will be offered services and re-randomized to ARM A/ARM B.
75318785|NCT04903431|Behavioral|Crisis Response Planning for Suicide Risk|Crisis Response Planning is focused on creating personalized set of steps for individuals to follow in case of a crisis and includes individuals' personal warning signs of distress, behavioral coping strategies, reasons for living, social supports to contact, and contact information for professional services, including emergency services. Personalization of the Crisis Response Plan is encouraged, and individuals are instructed to handwrite each step of the Crisis Response Plan on an index card to review.
75911095|NCT04883710|Other|Gene therapy|This is a prospective patient registry.
75911096|NCT04454840|Biological|Plasma from healthy young people treatment + Riluzole|Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.
75911097|NCT04454840|Drug|Riluzole|The basic treatment is Riluzole 25~50mg twice daily
75911098|NCT03050710|Device|Princess® VOLUME Lidocaine|Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
76072675|NCT03895762|Drug|Abstral Oral Disintegrating Tablet (ODT)|Opioid(Fentanyl)
76072676|NCT01811563|Device|Zimmer|
75911099|NCT03051568|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
75618284|NCT02815306|Device|Polyaxial brace|The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
75618285|NCT04309032|Procedure|retrograde bladder filling with 0.9% normal saline 250cc prior to removal of foley catheter|0.9% NS 250cc was introduced before foley catheter removed for discharge
76072677|NCT01811563|Device|Stryker|
75618286|NCT04690582|Behavioral|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
76072678|NCT01033552|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
76072679|NCT01033552|Drug|Fludarabine|40 mg/m^2/day intravenously on Days -6, -5, -4, -3 and -2.
75464546|NCT01879033|Other|Blood levels for glucose, insulin, lipids and adipocytokines|A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
75464547|NCT01879046|Procedure|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
75464548|NCT01879111|Other|patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
75618287|NCT04690582|Behavioral|Crisis Response Plan (CRP)|The crisis response plan (CRP) is a collaborative, patient-centered intervention that is typically handwritten on an index cards and focuses on several key components: (1) warning signs, (2) self-regulatory strategies, (3) reasons for living, (4) sources of social support, and (5) professional and crisis services.
75618288|NCT04690582|Behavioral|Safety Planning Intervention (SPI)|The safety planning intervention (SPI) is a suicide-focused intervention typically handwritten on a pre-printed form that includes the following sections: (1) warning signs, (2) internal coping strategies, (3) people and social settings that provide distraction, (4) people who can offer help, (5) professionals or agencies they can contact during a crisis, and (6) making the environment safe.
75771627|NCT01203514|Drug|Erythropoietin|Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.
75464549|NCT01879150|Device|Cyclaplex bone anchor|Device implantation
75771628|NCT01203514|Other|Sham Comparator|Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
75771629|NCT03723070|Device|The Cryterion Cardiac Cryoablation System|Cryoablation System that includes a Balloon Catheter, Circular Mapping Catheter, Steerable Sheath and Cryoablation Console. In combination, components of the System will be inserted into the left atrium and a thermal injury at the PV ostium will be created to electrically isolate the veins
75771630|NCT01473784|Procedure|transoral robotic surgery|Undergo TORS using the Da Vinci Robotic Surgical System
75771631|NCT01473784|Procedure|quality of life assessment|After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
75771632|NCT00842764|Procedure|Holmium: YAG laser|Minimally Invasive Holmium:YAG laser Blepharoplasty
75771633|NCT01204996|Drug|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
75771634|NCT01204996|Drug|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
75771635|NCT01204996|Drug|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
75771636|NCT01204996|Drug|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
75771637|NCT03831022|Other|Capillary refill time and skin mottling score measurement at the admission to the emergency department|Patients who meet the inclusion criteria and none of the non-inclusion criteria will benefit from capillary refill time and skin mottling score measurement at the admission to the emergency department (ED) and followed during their hospital stay to precise the destination after ED (home, ICU, ward) and 30- and 90-days mortality after hospital admission.
76072680|NCT01033552|Drug|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
76072681|NCT01033552|Drug|Cyclosporine A|Days -3 to 100+ to maintain a level of >200 ng/ml; initial dose 2.5 mg/kg over 2 hours every 8-12 hours for children.
76072682|NCT01033552|Drug|Mycophenolate mofetil|15 mg/kg intravenous twice per day on days -3 through 30.
76072683|NCT01033552|Procedure|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
75318786|NCT04899167|Other|MRI 1.5T and 3.0T|Magnetic Resonance Imaging for Renal Fibrosis
75318787|NCT04897867|Device|CoolSculpting® Elite System with CoolSculpting® Elite applicators|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
75618289|NCT04690582|Behavioral|Narrative Assessment|"The narrative assessment is a patient-centered assessment approach in which the clinician invites the patient to share the story of a recent crisis or period of intense emotional distress. Patients are asked to identify the thoughts, emotions, and physical sensations experienced in the time leading up to this crisis, as well as the contextual and environmental characteristics surrounding the crisis. Information obtained from the narrative assessment is then used to help formulate a crisis response plan."
75318788|NCT04896918|Behavioral|Tobacco use|
75618290|NCT02878980|Behavioral|Exercise Intervention|Undergo supervised 1-on-1 exercise sessions
75618291|NCT02878980|Other|Laboratory Biomarker Analysis|Correlative studies
75771638|NCT01297192|Drug|solifenacin succinate|Oral
75771639|NCT01297192|Drug|mirabegron|Oral
75771640|NCT01205074|Device|13C Methacetin Breath Test|
75911100|NCT04981964|Procedure|Exercise training|both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
75911101|NCT04888390|Behavioral|Muti-model exercise intervention|The Muti-model exercise intervention include aerobic exercise training by ergometer or treadmill, resistance exercise by using elastic band and flexibility exercise by active stretch. The total training program takes for 60 minutes, 2-3 times per week for 3 months.
75911102|NCT04888390|Behavioral|Disease and exercise suggestion|The participants will be provided by educational program about heart failure self-care and home-based exercise approach.
75911103|NCT03993314|Drug|Chloroprocaine|Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
75911104|NCT03993314|Drug|Bupivacaine|1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
75911105|NCT04888078|Procedure|Bassini hernia repair|Non-mesh tissue inguinal hernia repairs
75318789|NCT04896151|Diagnostic Test|Minnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental|The MMPI-2-RF-EX is a broadband, self-report measure of personality and psychopathology was developed for research purposes in order to develop the MMPI-3 (Ben-Porath & Tellegen, 2020), which is comprised of a subset of MMPI-2-RF-EX items.
75318790|NCT04883671|Other|Standard of Care|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
75618292|NCT02878980|Other|Quality-of-Life Assessment|Ancillary studies
75618293|NCT02878980|Other|Questionnaire Administration|Ancillary studies
75318791|NCT04883671|Radiation|SBRT|SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer
75318792|NCT04860466|Drug|CC-96673|IV Infusion
75318793|NCT04846504|Behavioral|MMBFM program with clinician coach support|Clinician-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed.
75318794|NCT04846504|Behavioral|MMBFM program with peer coach support|Peer-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed. Peers will be women with lived experience of perinatal depression who are trained on the coaching protocol.
75318795|NCT04846504|Behavioral|Patient facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
75464550|NCT01879163|Biological|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
75464551|NCT01879163|Biological|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
75771641|NCT01205074|Dietary Supplement|Grape fruit juice|
75771642|NCT01205074|Drug|Non selective beta blocker - Propranolol|
75771643|NCT01205074|Dietary Supplement|Ethanol|
75771644|NCT03722524|Drug|amlodipine / indapamide / perindopril arginine FDC|CCB / diuretic / ACE inhibitor
75771645|NCT03722446|Device|Arrow Catheter Kit.|The group will be randomized to receive this labor analgesia kit.
75771646|NCT03722446|Device|B.Braun Catheter Kit|The group will be randomized to receive this labor analgesia kit.
75911106|NCT04887532|Drug|HR19042 capsule|phase 1 :8mg; phase 2:12mg; phase 3:16mg
75464552|NCT01879189|Behavioral|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
75911107|NCT03889340|Device|IQool|Subjects will undergo hypothermia therapy with the IQool system
75464553|NCT01879202|Drug|Methylphenidate modified release|Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.
75464554|NCT01879202|Drug|Maltodextrin|Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
75464555|NCT01879215|Procedure|Intramedullary nailing of the tibia|Standard care surgery
75464556|NCT01879254|Device|Deep Brain Stimulation|
75464557|NCT01879267|Behavioral|Exercise training|6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
75464558|NCT01878162|Other|Exercise|
75771647|NCT05667220|Drug|Sitagliptin|Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.
75771648|NCT05667220|Drug|Sitagliptin combined with Beidougen capsule|Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
75771649|NCT01205308|Dietary Supplement|Vegetable oil based margarine with plant stanol ester enrichment|3 g plant stanols/ day
75771650|NCT01298830|Drug|GLP-1 CellBeads|GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
75771651|NCT01203592|Drug|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
75771652|NCT05669326|Other|NODDI TRACT|"Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without contrast injection will be performed, lasting approximately 40 minutes (including installation and deinstallation).~The operative time, surgical procedures and postoperative follow-up are not modified in this study."
75771653|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
75771654|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
75771655|NCT01203670|Dietary Supplement|Phytalgic|Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
75771656|NCT03829150|Drug|Dexlan|Dexlansoprazole MR 60 mg qd for 7 days
75618294|NCT04420156|Other|No intervention administered.|Eye exams are standard of care and would be performed regardless of participation in this study.
75618295|NCT02627521|Procedure|PRU guided CABG|Coronary Artery Bypass Surgery
75771657|NCT03829150|Drug|Amoxicillin|Amoxicillin (Amolin) 1 g bid. for 7 days
75318796|NCT04846504|Behavioral|Patient facing plus clinic facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams, plus recommendation of / referral to the Mindful Mood Balance for Moms study by OB clinicians at the 4 study sites. OB clinicians will choose from printed materials (e.g., flyers, posters in exam rooms and waiting rooms, prescription pads) and electronic medical record prompts (e.g., smart lists, dot phrases) to facilitate engagement in the Mindful Mood Balance for Moms course. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
75318797|NCT04841265|Dietary Supplement|Vitamin D3|The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.
75618296|NCT02627521|Procedure|CABG per standard of care|Coronary Artery Bypass Surgery
75618297|NCT02627521|Device|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
75618298|NCT02627521|Drug|Ticagrelor|Ticagrelor administration prior to randomization
75618299|NCT02627599|Device|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
75618300|NCT02815228|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-034)
75618301|NCT00681967|Drug|Gefitinib|250 mg; oral
75618302|NCT00681967|Drug|Gefitinib|250mg; oral
75618303|NCT00685321|Device|H1 deep TMS coil|20 daily deep rTMS treatment
75618304|NCT00685321|Device|Sham|inactive treatment
75618305|NCT04239118|Combination Product|Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets|Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
75618306|NCT04239118|Procedure|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
75618307|NCT04139941|Diagnostic Test|Test for HCV antibodies with an RDT|Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
75618308|NCT02815150|Dietary Supplement|preoperative oral carbohydrate drink|5% glucose solution 250ml 2-3 hours before surgery
75771658|NCT03829150|Drug|Clarithromycin 500mg|clarithromycin (Klaricid) 500 mg bid for 7 days
75771659|NCT03829150|Drug|Metronidazole|Metronidazole (Flagyl) 500 mg bid daily for 7 days
75771660|NCT03820804|Other|Diet|A specific dietary treatment for patients with Phenylketonuria.
75771661|NCT03820804|Drug|Sapropterin|A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
75771662|NCT01205386|Device|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
75771663|NCT01205464|Drug|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
75771664|NCT01205464|Drug|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
75771665|NCT01205542|Behavioral|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
75771666|NCT01205542|Behavioral|Reference|Health check and advice to continue ordinary physical activity
75318798|NCT04832594|Other|AI selection for supplemental breast MRI|An AI tool will generate scores used to determine eligibility. Women randomized to MRI will be examined in an MRI scanner.
75618309|NCT02814994|Behavioral|tidal volume guided by respiratory system compliance|ventilated with tidal volume guided by respiratory system compliance
75618310|NCT02814994|Behavioral|low tidal volume|ventilation ventilated with low tidal volume
75771667|NCT01205620|Device|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
75771668|NCT01205620|Other|No intervention|No intervention will be performed in the control group
75464559|NCT01879098|Dietary Supplement|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
75464560|NCT01879098|Dietary Supplement|Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
75771669|NCT03828838|Drug|Lu-177 PSMA-617|Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)
75911108|NCT03050632|Behavioral|N-back|The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).
75911109|NCT03050632|Behavioral|White Bear Task|For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
75911110|NCT04920890|Device|Radiofrequency therapy with manual therapy|Monopolar Capacitive Resistive Radio Frequency at 448 kHz (INDIBA®) (RFMCR) with manual therapy.
75318799|NCT04829240|Behavioral|Veterans Anxiety Skills Training Intervention|Modular anxiety intervention designed for Primary Care-Mental Health Integration settings, including up to six 30-minute sessions occurring approximately every 2 weeks, in which Veterans select modules of interest to them to complete, with an emphasis on psychoeducation and cognitive-behavioral coping strategies for self management of anxiety symptoms
75318800|NCT04829240|Behavioral|PCMHI Usual Care|Appointment with Primary Care-Mental Health Integration provider at local primary care clinic for anxiety treatment; provider delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PCMHI care
75318801|NCT04798196|Behavioral|ElderTree on laptop (ET- LT)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-LT arm will access ET on Laptop (ET- LT)"
75464561|NCT01879098|Dietary Supplement|Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
75464562|NCT01879098|Dietary Supplement|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
75464563|NCT01879280|Procedure|Traditional pterional craniotomy|In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
75464564|NCT01879280|Procedure|Osteoplastic craniotomy|"In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity."
75464565|NCT01879293|Drug|Metformin|
75618311|NCT00875017|Drug|Lanthanum Carbonate|1 x 1000mg tablet
75464566|NCT01879293|Drug|placebo|
75618312|NCT00875017|Drug|Sevelamer|3 x 800mg tablets
75618313|NCT02819362|Device|MRI|The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
75618314|NCT00679705|Drug|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
75618315|NCT00679705|Drug|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
75771670|NCT01205698|Other|Nutritional drink|
75771671|NCT03828526|Other|High Fidelity Simulation|Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.
75771672|NCT03828526|Other|Traditional teaching strategy|Classroom-based strategy
75771673|NCT01297660|Other|Video-urodynamic examination|
75771674|NCT01297738|Other|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
75771675|NCT01297738|Other|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
75771676|NCT01297738|Other|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
75911111|NCT04920890|Device|Placebo without radiofrequency.|The device will be used without turning on the patient, thus administering a placebo treatment.
75464567|NCT01879358|Device|Drug-eluting stent|
75464568|NCT01879384|Device|CMA 70 catheter directly positioned in bone tissue|At the end of the surgery the CMA microdialysis catheter is placed inside the bone
75618316|NCT00679705|Drug|Placebo|Glucose 5%, IV
75911112|NCT04920890|Other|Manual therapy.|Common manual therapy administered for said pathology by traditional physiotherapy.
75911113|NCT04883164|Other|Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples|Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.
75771677|NCT01297738|Other|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
75911114|NCT02809833|Drug|Tocilizumab|Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
75771678|NCT03819010|Drug|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25
75771679|NCT03819010|Drug|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
75771680|NCT05099536|Drug|3D011-08|participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).
75771681|NCT03818932|Drug|Celecoxib|Post-Operative Non Opioid Pain Protocol
75771682|NCT03818932|Drug|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
75771683|NCT03818932|Drug|Ketorolac|Post-Operative Non Opioid Pain Protocol
75771684|NCT03818932|Drug|Gabapentin|Post-Operative Non Opioid Pain Protocol
75771685|NCT03818932|Drug|Acetaminophen|Post-Operative Non Opioid Pain Protocol
75771686|NCT03818932|Drug|Diazepam|Post-Operative Non Opioid Pain Protocol
75464569|NCT01879397|Device|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam~ARFI based images of the carotid artery and plaque~Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
75464570|NCT01879423|Drug|Lamotrigine Dispersible/Chewable tablets 5mg*5|Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
75771687|NCT03830554|Other|Organic Atlas cedar wood essential oil (Cedrus Atantica)|At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
75771688|NCT01205854|Device|Ultrasonography|Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
75318802|NCT04798196|Behavioral|ElderTree on smart system (ET- SS)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support.~ElderTree on smart system (ET- SS) will use voice-activated smart speakers connected to the Internet. Because they are used by talking and listening rather than typing and reading, many barriers associated with laptop use can be avoided."
75464571|NCT01879423|Drug|Lamotrigine Compressed tablet 25mg|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
75464572|NCT01879462|Drug|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
75464573|NCT01879462|Drug|Placebo|Visually matching GSK2878175
75771689|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
75771690|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
75771691|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
75771692|NCT01205932|Drug|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
75911115|NCT03788642|Procedure|Control LED shoe arm|Patients with DFU will wear LED shoe 30 minutes once daily
75911116|NCT03788642|Procedure|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes once daily
75911117|NCT04897126|Drug|MUSK Pill|On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.
75318803|NCT04798196|Behavioral|Treatment as usual (TAU)|Treatment as usual (TAU)
75318804|NCT04780867|Behavioral|Delayed vaccination|First and second hepatitis B vaccinations will be delayed by 1 month in the interventional group to establish whether changes in psychosocial and lifestyle factors during training impact immune health.
75318805|NCT04765696|Other|No intervention is administered|No intervention is administered, the cohort is followed in order to evaluate the impact of housing and relocation on active ageing outcomes.
75464574|NCT01879475|Device|032-11|Topical haemostat
75464575|NCT01879475|Device|Floseal (R)|Topical haemostat
75464576|NCT01879488|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
75911118|NCT04897126|Drug|Placebo|Placebo
75464577|NCT01879488|Device|Vibrating-mesh nebulizer|
75464578|NCT01879488|Other|Gamma scintigraphy|
75464579|NCT01879488|Other|Preoperative spirometry|
75464580|NCT01879501|Behavioral|Low Vision Self-Management Program|The program has been describe above.
75771693|NCT01300780|Drug|Etoricoxib|Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
75771694|NCT01300780|Other|Placebo|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
75771695|NCT01297816|Drug|placebo|100mg,BD, fo three month
75911119|NCT03161054|Drug|Prednisone|"Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast)."
75911120|NCT03161054|Drug|Vinorelbine|"Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast)."
75771696|NCT01297816|Drug|Minocycline|100mg
75771697|NCT01206634|Procedure|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
75911121|NCT03161054|Drug|Etoposide|Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
75771698|NCT01206634|Behavioral|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
75771699|NCT01297894|Drug|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
75771700|NCT01297894|Drug|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
75911122|NCT03161054|Drug|Cyclophosphamide|"Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner)."
75911123|NCT03161054|Drug|Rituximab|Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
75911124|NCT03050554|Drug|Avelumab|Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
75771701|NCT03830008|Behavioral|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
75771702|NCT01298908|Procedure|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
75771703|NCT01298908|Procedure|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
75911125|NCT03050554|Radiation|SBRT|SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
75911126|NCT04909112|Other|Evaluation of olfactory function|Evaluation of olfactory function using olfactory detection thresholds
75911127|NCT04909112|Other|Evaluation of taste function|Evaluation of taste function using taste detection thresholds
75911128|NCT04909112|Other|Evaluation of (intra-nasal and oral) trigeminal functions|Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.
75911129|NCT03050164|Drug|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
75911130|NCT03050164|Drug|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
75911131|NCT02037087|Behavioral|Good household prenatal practice|Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
75911132|NCT02037087|Behavioral|Care seeking|"Danger-sign recognition~Reminders for government projects"
75318806|NCT04763109|Other|Whole-body Magnetic Resonance Imaging|Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
75318807|NCT04760678|Other|Observational study|No intervention (observational study in human participants)
75771704|NCT01298908|Procedure|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
75911133|NCT02037087|Behavioral|Full bank of SMS|"Danger-sign recognition~Reminders for government projects~Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression"
75911134|NCT02797262|Device|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
75911135|NCT03049930|Drug|Ketamine|Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
75911136|NCT03049930|Drug|Sodium chloride|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
75911137|NCT02036463|Drug|Prednisone|
75911138|NCT02036463|Drug|Placebo|
75318808|NCT04753788|Diagnostic Test|PCR|qPCR for T.pallidum
75318809|NCT04753788|Diagnostic Test|LAMP|LAMP assay for T.pallidum
75771705|NCT05666362|Drug|benoxinate hydrochloride 0.4% group|They will receive benoxinate hydrochloride 0.4% immediately before fundus
75318812|NCT04731714|Device|Rhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected ~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
75771706|NCT05666362|Drug|saline 0.9% .|They will receive saline 0.9% before fundus examination in each eye .
75771707|NCT01206010|Drug|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
75911139|NCT04887844|Drug|Lidocaine injection|Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
75771708|NCT01206010|Drug|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
75771709|NCT01206010|Drug|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
75771710|NCT01297972|Biological|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
75318813|NCT04731714|Device|Arrhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected ~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
75771711|NCT01298050|Procedure|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
75911140|NCT04887844|Drug|Corticosteroid injection|Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
75911141|NCT04887844|Other|Conventional Physical therapy|The study participants underwent a physiotherapy program that included a one-time 15-minute cold therapy using ice packs and closed-kinetic chain quadriceps strengthening program as follows; isometric quadriceps exercise, isokinetic concentric, and eccentric quadriceps exercises with heel slides and squads. These exercises were repeated ten times a day, seven days per week, for eight weeks in total
75318814|NCT04730037|Drug|Edoxaban|- Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
75318815|NCT04730037|Drug|Warfarin Potassium|- Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)
75464581|NCT01879514|Drug|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
75464582|NCT01879514|Drug|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
75464583|NCT01879527|Drug|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
75464584|NCT01879527|Drug|Sugar pill|containing placebo
75771712|NCT05621824|Device|Endoscopic ultrasound|Use endoscopic ultrasound to examine the pancreatic lesions.
75771713|NCT05621824|Procedure|EUS-Fine needle aspiration|If solid mass of pancreas was found during EUS, EUS-FNA shall be conducted for diagnosis.
75771714|NCT05665582|Other|Family program|A 4-day psychoeducational family program.
75771715|NCT01298986|Procedure|Pulmonary vein isolation ablation procedure for atrial fibrillation|The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
75318816|NCT04730037|Drug|Warfarin Potassium placebo|- Warfarin K 1 mg placebo tablets once daily
75318817|NCT04730037|Drug|Edoxaban placebo|- Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
75464585|NCT01879566|Other|No intervention will be done. The study is observational|
75464586|NCT01879605|Drug|Docusate natrium and sorbitol|
75464587|NCT01879605|Drug|Bisacodyl|
75464588|NCT01879631|Procedure|radial keratotomy|
75464589|NCT01879644|Behavioral|NF|
75464590|NCT01879644|Behavioral|SM|
75464591|NCT01879644|Behavioral|PE|
75464592|NCT01879644|Behavioral|SU|
75464593|NCT01879670|Device|CircuLite Synergy left ventricular assist device|
75464594|NCT01879696|Device|ECSPRESS catheter with active vacuum|
75911142|NCT05390138|Behavioral|Smart Sleep Apnea Self-management Support Programme (4S)|The experimental group will receive usual care and Smart Sleep Apnea Self-management Support Programme (4S). The 4S includes two interview sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to self-management. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
75771716|NCT01298986|Procedure|Hybrid procedure for ablation of atrial fibrillation|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
75771717|NCT01298986|Procedure|The Cox Maze Procedure for Ablation of Atrial Fibrillation|A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
75771718|NCT01298986|Procedure|Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
75771719|NCT05665114|Drug|QN-030a|NK cell therapy
75911143|NCT05390138|Behavioral|General Hygiene Information (GH)|The control group will receive usual care and general hygiene information (GH). The GH includes two GH sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to general hygiene information. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
75464595|NCT01879709|Behavioral|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
75464596|NCT01879709|Behavioral|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
75464597|NCT01879709|Other|Treatment as Usual|"Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided"
75464598|NCT01879748|Drug|Rasagiline|"Each subject will be enrolled into 1 of 4 cohorts:~cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~placebo (8 Japanese and 8 Caucasian subjects)"
75771720|NCT05665114|Drug|Cyclophosphamid|Lympho-conditioning Agent
75911144|NCT04897204|Procedure|Catheter ablation and left atrial appendage occlusion|The patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion.
75318818|NCT04719221|Drug|Evolocumab|The maximum dose of combined cholesterol therapy (Statin + Ezetimibe) is prescribed for 2 months, and a cholesterol test is performed in an outpatient clinic to ensure that LDL-Cholesterol <70mg/dL is met. Patients who do not meet the criteria are randomized to maintain current treatment or receive additional Evolocumab according to randomization.
75318819|NCT04719221|Device|NIRS IVUS|near-infrared spectroscopy
75318820|NCT04712669|Drug|rodatristat ethyl 300 mg tablet BID|rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care
75318821|NCT04712669|Drug|rodatristat ethyl 600 mg BID|2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care
75318822|NCT04712669|Drug|Placebo|2 matching placebo tablets on top of standard of care
75318823|NCT04709757|Device|Intermittent Dosing HF10 30/90|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 120 seconds OFF
75318824|NCT04709757|Device|Intermittent Dosing HF10 30/360|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 360 seconds OFF
75318825|NCT04696575|Biological|Atezolizumab|Given IV
75911145|NCT04897204|Procedure|Additional left atrial appendage electrical isolation combined with catheter ablation and left atrial appendage occlusion|These patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion, combined with additional left atrial appendage occlusion.
75771721|NCT05665114|Drug|Fludarabine|Lympho-conditioning Agent
75771722|NCT05665114|Drug|Cytarabine|Lympho-conditioning Agent
75911146|NCT03686228|Procedure|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and wound care and pain killer drug
75911147|NCT03686228|Drug|No-PB-MNC therapy|Patients will receive ASA 81 mg once daily and wound care and pain killer drug
75911148|NCT03049696|Behavioral|ENCOURAGEING START|16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
75911149|NCT04430608|Device|Dexcom G6|"The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC."
75318826|NCT04696575|Drug|Carboplatin|Given IV
75464599|NCT01879748|Drug|Placebo|"Each subject will be enrolled into 1 of 4 cohorts:~cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~placebo (8 Japanese and 8 Caucasian subjects)"
75464600|NCT01879787|Other|tDCS|tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
75464601|NCT01879813|Dietary Supplement|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
75771723|NCT05665114|Drug|VP-16|Lympho-conditioning Agent
75464602|NCT01879813|Dietary Supplement|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
75464603|NCT01879839|Dietary Supplement|Diet|Patients receive special diet 4 days prior to contrast-agent administration.
75911150|NCT02595320|Drug|Capecitabine|"Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7)."
75911151|NCT04887376|Device|Mirror frame|Combined Mirror and NMES therapy
75464604|NCT01879865|Other|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
75911152|NCT04887376|Device|Control|Only NMES therapy
75771724|NCT01206790|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
75771725|NCT03814486|Other|descriptive|evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted
75771726|NCT03814798|Biological|IGSC 20% daily push versus every 2 weeks pump|IGSC 20% syringe daily push dosing for 16 weeks followed by every 2 weeks pump dosing for 16 weeks or the reverse sequence
76072684|NCT01033552|Radiation|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
75771727|NCT03814798|Biological|IGSC 20% daily push versus once a week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by once weekly ambulatory pump administration dosing for 16 weeks or the reverse sequence
75771728|NCT03814798|Biological|IGSC 20% daily push versus 2 times per week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by 2 times/week ambulatory pump administration on preselected days (eg, Monday and Thursday) not less than 3 days apart for 16 weeks or the reverse sequence
75771729|NCT03814798|Biological|IGSC 20% 150 mg/kg|loading dose of IGSC 20% consisting of 5 consecutive daily doses of 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of IGSC 20% 150 mg/kg starting Week 1 (Day 8) through Week 32 using an infusion SC pump
75318827|NCT04696575|Drug|Etoposide|Given IV
75318828|NCT04696575|Drug|Lamivudine|Given PO
75318829|NCT04694638|Other|Body position change|combined use of prone positioning and high-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) can reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.
75318830|NCT04688866|Other|Sequencing|This is an observational study, since the assignment of the medical intervention (e.g. cerclage or pessary) is not at the discretion of the investigator. However, cervical samples collected from both groups are subjected to amplicon sequencing for taxonomic classification of microorganisms.
75318831|NCT04688788|Drug|Rituximab|Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.
75318832|NCT04688788|Drug|Ocrelizumab|Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.
75318833|NCT04688788|Drug|Fexofenadine|Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
75318834|NCT04688788|Drug|Paracetamol|Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
75464605|NCT01879865|Other|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
75911153|NCT04666766|Device|Microwave scanning of the head|A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.
75618317|NCT04672486|Behavioral|POD Adventures|"Participants in the intervention arm will receive information about local services/national helplines and a brief problem-solving intervention that is delivered through a smartphone app with telephone guidance from a lay counsellor. The intervention is grounded in stress-coping theory, with a technical focus on practical problem solving. The emphasis on problem solving reflects the primacy of psychosocial stressors in adolescent help-seeking. Moreover, problem-solving is among the most commonly used practice elements in evidence-based psychological interventions for children and adolescents globally.~The content of the app comprises two sections: 'Adventures' which teaches problem-solving concepts and methods through contextually-appropriate games; and 'My POD' which scaffolds the student through the application of step-by-step problem-solving procedures to their own prioritized problems."
75911154|NCT02809053|Biological|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
75911155|NCT02809053|Biological|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
75911156|NCT04396756|Drug|PLN-74809|PLN-74809
75911157|NCT04396756|Drug|Placebo|Placebo
75911158|NCT05390060|Device|Neuromonitoring|Multimodal neuromonitoring encompassing intracranial pressure, brain tissue oxygenation, microdialysis and cerebral blood flow monitoring
75771730|NCT03814408|Biological|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
75771731|NCT05618704|Dietary Supplement|Hydrolyzed protein infant formula|The subjects will take the formula for 16 weeks
75771732|NCT01299142|Drug|FGI-101-1A6|anti-TSG101 human monoclonal antibody, single dose
75771733|NCT05281120|Device|Low-level mechanical vibrations WITH vertical sinusoidal acceleration|Small platform designed to induce vertical, sinusoidal acceleration.
75318835|NCT04688788|Drug|Methylprednisolone|Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
75318836|NCT04683679|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses
75464606|NCT01879878|Dietary Supplement|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
75618318|NCT00685555|Behavioral|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
75771734|NCT05281120|Device|Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration|Small platform designed to NOT induce vertical, sinusoidal acceleration
75318837|NCT04683679|Drug|Olaparib|Olaparib will be administered twice daily continuously without breaks on a 21-day (3 week) cycle length, for a total of 2 cycles. Olaparib tablets will be administered bid (2 x 150 mg tablets twice daily; total 600 mg daily) on continuous days without interruption for 2 cycles. Each 3 week period constitutes one cycle.
75318838|NCT04683679|Radiation|Radiation|The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.
75318839|NCT04671329|Device|Affirm Contrast Biopsy procedure|Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.
75464607|NCT01879878|Dietary Supplement|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
75771735|NCT00146172|Drug|neratinib|HKI-272
75771736|NCT01206868|Procedure|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
75771737|NCT01206868|Procedure|Control|Standard kidney transplantation
75771738|NCT03814642|Drug|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
75911159|NCT04887142|Other|Standard of health care|The patients in this observational study will be exposed to the standard health care interventions according to the hospital diagnostic and treatment protocols and procedures and clinical judgment of the treating physicians.
75911160|NCT04666688|Drug|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
75911161|NCT04666688|Drug|Tislelizumab|anti-PD-1 monoclonal antibody
75911162|NCT04666688|Drug|Gemcitabine/nab-paclitaxel|chemotherapy
75618319|NCT00685555|Behavioral|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
75911163|NCT04548986|Device|Aktiia.product|The participants wear Aktiia.bracelet for the duration of the cardiac rehabilitation program. The device is initialized once per week.
75618320|NCT02815072|Other|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
75771739|NCT03814642|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
75464608|NCT01879891|Other|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
75464609|NCT01879904|Procedure|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
75911164|NCT05701839|Procedure|face mask ventilation|In participants with face mask ventilation, oxygen inhaled through face mask at a flow rate of 5 L/min.
75911165|NCT05701839|Procedure|nasopharyngeal tube ventilation|In participants with nasopharyngeal tube ventilation, oxygen inhaled through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min.
75464610|NCT01879917|Drug|Liraglutide|
75318840|NCT04665921|Drug|SGN-STNV|Given into the vein (IV; intravenously)
75318841|NCT04661995|Combination Product|Hearing Aid and Notched Noise Therapy|Notched Noise Therapy involves presenting wide-band sound with the tinnitus frequency region notched out, referred to as notched noise, or notch therapy. This procedure may distribute lateral inhibition into the notched frequency region, suppressing tinnitus neural activity believed to be occurring there. This type of therapy is provided through a sound file that is streamed through hearing aids.
75318842|NCT04661995|Combination Product|Hearing Aid and Broadband Noise|"Broadband Noise, or white noise, is a common tinnitus sound therapy treatment option. It is also commonly used as a masker noise for individuals with tinnitus that like to enrich their environment with sound."
75771740|NCT03814642|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg tablet
75771741|NCT01299220|Drug|Acitretin|Acitretin 10 mg by mouth daily
75318843|NCT04661995|Device|Hearing Aid|A-O groups will use ear-level, self-contained devices (hearing aids) that (1) are capable of streaming shapeable broadband noise between 1-10 kHz; (2) allow for normal conversation; and (3) are comfortable, easy to use, and discrete. These criteria describe a behind-the-ear hearing aid with the capability of streaming custom sounds. Hearing aids are used to provide amplification to those with hearing loss and are fit by licensed audiologists. Sometimes, hearing aids can provide benefit to those with bothersome tinnitus.
75464611|NCT01879917|Drug|Placebo|Saline
75464612|NCT01879930|Drug|doxycycline|"Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100"
75464613|NCT01879930|Drug|placebo|"Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group"
75464614|NCT01879943|Device|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
75771742|NCT03814330|Diagnostic Test|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
75771743|NCT03814330|Diagnostic Test|Quality of Recovery Score|Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
75771744|NCT03814330|Other|Sedation/Analgesia|Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.
75911166|NCT05701839|Device|oxygen saturation monitoring|In participants with oxygen saturation monitoring, assist ventilation through face mask will be performed when oxygen saturation drops to 95%, it lasts for another 10 seconds when oxygen saturation restores to 100%.
75911167|NCT05701839|Device|oxygen reserve index monitoring|In participants with oxygen reserve index monitoring, assist ventilation through face mask will be performed when oxygen reserve index drops to 0.1, it lasts for another 10 seconds when oxygen reserve index restores to 0.1.
75911168|NCT04882618|Drug|Indocyanine green|indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy
75318844|NCT04644965|Diagnostic Test|CombynTM Function & Spaces ECG|Multi-frequency impedance measurement to assess the muscle and fat mass
75911169|NCT03462290|Drug|botulinum toxin type A|Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide
75911170|NCT03462290|Drug|placebo|solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
75911171|NCT04879394|Other|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
75911172|NCT03108638|Behavioral|R3 Supervisor Implementation Strategy|Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
75911173|NCT04896424|Procedure|cryoballoon-based pulmonary veins isolation|A cryoballoon is introduced to the LA via a steerable sheath following a single transseptal puncture. The balloon is advanced toward the PV ostium and inflated. PV occlusion is documented by the injection of contrast. Optimal vessel occlusion is assumed when the PV showes complete contrast retention without any backflow to the atrium. The freezing time is chosen between 180 and 240s and left at the operator's discretion, along with a decision if to follow with a bonus-freeze cycle. The application is aborted and the cryoballoon is repositioned in the case of ineffective cooling or when the nadir temperature decreases < -60°C, to avoid excessive cooling. In cases where a real-time recording of PV potentials is available a short time-to-isolation<60s resultes in a single 180s freeze cycle. CBA always startes from the left upper PV (LUPV) followed by the left lower PV (LLPV).
75911174|NCT03732339|Device|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
75911175|NCT03468842|Biological|Probiotic|Already described
75911176|NCT03468842|Biological|Placebo|Placebo
75911177|NCT02047539|Drug|Aspirin|1000 mg/day of aspirin 1000 mg/day of sugar pill
75911178|NCT02047539|Drug|Placebo|
75911179|NCT05389748|Other|Placebo|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to placebo in association with standard of care
75911180|NCT05389748|Biological|dodecafluoropentane emulsion (DDFPe)|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to DDFPe in association with standard of care
75618321|NCT04140019|Diagnostic Test|CMR|Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
75318845|NCT04644965|Diagnostic Test|Blood Taking|Sampling of blood of the finger pad to assess liver function
75318846|NCT04644965|Diagnostic Test|Spiroergometry|Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level
75318847|NCT04644965|Diagnostic Test|Dordel Koch Test (DKT)|Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run
75318848|NCT04644965|Diagnostic Test|Ultrasound|Ultrasound for abdominal wall muscles
75318849|NCT04644965|Diagnostic Test|Stance and gait analyses|Stance and gait analyses for measuring the core stability
75771745|NCT03814330|Device|Laryngeal Mask Airway|Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
75318850|NCT04643795|Drug|MGL-3196|Once daily oral dose for 6 days
75464615|NCT01879943|Procedure|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
75464616|NCT01879956|Other|Craft Activities|There is no intervention method used to perform the task.
75464617|NCT01879956|Behavioral|OGI Method|metacognitive approach to assess executive functions.
75464618|NCT01879969|Procedure|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
75464619|NCT01879969|Procedure|computer assisted orthognathic planning and surgery of asymmetric patients|
75464620|NCT01879995|Procedure||
75464621|NCT01880034|Other|Lipid Emulsion Survey|
75618322|NCT04237948|Device|transcranial direct current stimulation (tDCS)|cerebellar tDCS consists in the application of a low intensity (1-2 mA) steady current through a surface scalp electrode over the cerebellum
75771746|NCT03813784|Drug|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
75771747|NCT03813784|Drug|Capecitabine|1000 mg/m^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
75771748|NCT03813784|Drug|Oxaliplatin|130 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle.
75618323|NCT04237948|Behavioral|Physical therapy|Hospitalized patients will undergo a 60 minutes physical treatment improving gait and postural instability for four weeks of time
75618324|NCT00685633|Drug|bicalutamide|Given orally
75618325|NCT00685633|Drug|enzastaurin hydrochloride|Given orally
75618326|NCT04206670|Device|In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
75771749|NCT03813784|Drug|Apatinib|250 mg administered as continuous oral once daily (QD) of each 3-week cycle.
75771750|NCT03818542|Drug|ABBV-181|intravenous infusion
75771751|NCT03818542|Drug|ABBV-368|intravenous infusion
75771752|NCT03818542|Drug|ABBV-927|intravenous infusion
75771753|NCT03818542|Drug|ABBV-927|intratumoral injection
75771754|NCT03818308|Drug|Sofosbuvir and Velpatasvir|All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.
75771755|NCT03827044|Drug|Avelumab|Avelumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
75911181|NCT02047617|Device|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
75911182|NCT02047617|Device|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
75911183|NCT04896190|Other|Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position|Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.
75911184|NCT02522858|Drug|Atropine|"To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.~During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group."
75911185|NCT02522858|Drug|Dexmedetomidine|Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
75911186|NCT02522858|Drug|Ephedrine|Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
75318851|NCT04641286|Other|Body motion categorisation|All patients will receive passive motion categorisation monitoring
75318852|NCT04632381|Drug|Zotatifin|Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).
75911187|NCT04455542|Other|LMND-ALS|in line with LMND -ALS inclusion criteria, and CMAP amplitude of peripheral motor nerves (CMAP amplitude of the 10 peripheral motor nerves with the most obvious CMAP amplitude decline was selected as the CMAP amplitude for grouping of the patients) was less than the median of CMAP amplitude of LMND -ALS group.
75911188|NCT04455542|Other|UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
75911189|NCT04455542|Other|FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.
75911190|NCT02036697|Drug|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
75618327|NCT04206670|Device|Waiting Control In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
75911191|NCT02036697|Drug|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
75911192|NCT02036697|Drug|Morphine|morphine 150 mcg.
75911193|NCT02036697|Drug|Fentanyl|15 mcg
75911194|NCT04882462|Drug|Nimotuzumab|Nimotuzumab, 400mg, intravenously every 3 weeks, for at least 18 weeks
75618328|NCT00685711|Biological|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
75771756|NCT03814096|Diagnostic Test|Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)|Syphilis Health Check (SHC) POC-test is a treponemal POC-test based on 3d generation enzyme immunoassay (EIA) method detecting both Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies.
75771757|NCT05659030|Other|Education|In order to develop the training material, first of all, a literature review will be made and a training booklet will be prepared. The training booklet will be submitted to expert opinion and a pilot application will be made by giving its final form. The training content is based on Pender's Health Promotion Model, which consists of 3 components.
75911195|NCT04882462|Drug|Sintilimab|Sintilimab, 200mg, intravenously every 3 weeks, for at least 18 weeks;
75911196|NCT04882462|Drug|Chemotherapy drug|Chemotherapy drugs were selected by the investigator, every 3 weeks, for 18 weeks
75911197|NCT03106688|Diagnostic Test|fMRI imaging|Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
75911198|NCT03106688|Diagnostic Test|[11C]carfentanil PET scan|[11C]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
75911199|NCT03106688|Diagnostic Test|[18F]FMPEP-d2 PET scan|[18F]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
75911200|NCT03106688|Diagnostic Test|[18F]-FDG PET scan|Brain and body insuin stimulated glucose uptake is measured with radioligand [18F]-FDG.
75911201|NCT03106688|Diagnostic Test|Physical activity measures and fitness tests|Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
75911202|NCT03106688|Diagnostic Test|Laboratory measurements|Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
75318853|NCT04632381|Drug|Placebo|5% dextrose injection, USP
75318854|NCT04627428|Biological|RPESC-RPE-4W|RPESC-RPE-4W
75318855|NCT04623775|Biological|Nivolumab|Specified dose on specified days
75318856|NCT04623775|Biological|Relatlimab|Specified dose on specified days
75318857|NCT04623775|Drug|Carboplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
75318858|NCT04623775|Drug|Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
75318859|NCT04623775|Drug|Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
75618329|NCT04371952|Drug|Doxycycline|comparison of doxycycline 200 mg/day to placebo
75318860|NCT04623775|Drug|Nab-Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
75618330|NCT04371952|Drug|Placebo|Placebo : lactose, 380 mg/gélule
75911203|NCT03106688|Diagnostic Test|Questionnaires|All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
75911204|NCT03106688|Diagnostic Test|Hyperinsulinemic euglycemic clamp|Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
75318861|NCT04623775|Drug|Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
75318862|NCT04621916|Drug|FVIII|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
75318863|NCT04621916|Drug|Emicizumab|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
75318864|NCT04607590|Other|Best Practice|Receive usual care
75318865|NCT04607590|Procedure|Quality-of-Life Assessment|Ancillary studies
75318866|NCT04607590|Other|Questionnaire Administration|Ancillary studies
75318867|NCT04607590|Procedure|Yoga|Participate in yoga sessions
75618331|NCT00682123|Dietary Supplement|19-norandrostendione|"Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.~The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects."
75618332|NCT04145089|Device|Glidescope video laryngoscopy/ C-MAC video laryngoscopy|usage of said devices according to manual
75618333|NCT00679861|Behavioral|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
75618334|NCT00679861|Behavioral|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
75618335|NCT02814760|Other|training of emergency professionals to acute stroke management|"The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization)."
75618336|NCT00875797|Dietary Supplement|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
75618337|NCT00875797|Dietary Supplement|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
75618338|NCT04144621|Procedure|ICSI|Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
75911205|NCT04882228|Drug|Entelon Tab.150mg|twice daily for 8 weeks
76072685|NCT01033552|Procedure|Bone marrow or umbilical cord blood (UCG) stem cell transplantation|Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
76072686|NCT00997906|Drug|carboplatin,|Given IV
76072687|NCT00997906|Drug|cisplatin|Given IV
75318868|NCT04586062|Drug|Plasminogen|Human Plasminogen
75318869|NCT04578938|Drug|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
75318870|NCT04578938|Behavioral|Cognitive training|8 sessions of computer-based cognitive training
75318871|NCT04578938|Behavioral|Sham Training|8 sessions of computer-based sham training
75318872|NCT04578574|Other|Bodily Illusions (BI) Procedure|Each sessions will consists of two types of illusions that are 15 min each, the rubber hand illusion (RHI) and the walking illusion (WI) that involve both arms and legs.
75464622|NCT01880112|Drug|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
75464623|NCT01880125|Drug|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
75464624|NCT01880138|Other|watching animated cartoon before general anesthesia|
75464625|NCT01880138|Other|not watching animated cartoon beofre general anaesthesia|
75464626|NCT01880151|Device|EEG|EEG recorded during a resting condition and during an episodic memory task condition
75464627|NCT01880190|Other|Ringer's Lactate|
75464628|NCT01880190|Other|HES 130/0.4 and Ringer's Lactate|
75464629|NCT01880203|Procedure|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
75911206|NCT04882228|Drug|Venitol Tab.|twice daily for 8 weeks
75911207|NCT04882228|Drug|Placebo of Venitol Tab.|twice daily for 8 weeks (with Entelon Tab.150mg. It is for the masking.)
75911208|NCT04882228|Drug|Placebo of Entelon Tab.150mg|twice daily for 8 weeks(with Venitol Tab. It is for the masking.)
75318873|NCT04578574|Device|Transcranial direct electrical stimulation (tDCS)|Each sessions will consists of electrical current delivered from a battery-driven, constant current stimulator using saline-soaked surface sponge electrodes. One electrode will be placed on your scalp on the right side and the other electrode over the left eye on your forehead. A weak current will be applied for 30 min at the same time as the BI.
75318874|NCT04578574|Other|Sham Transcranial Direct Electrical Stimulation (tDCS)|Each session of the Sham tDCS will be applied for 30 min at the same time as the BI.
75911209|NCT02037009|Other|Health care organization (anesthetic surveillance)|
75911210|NCT04882306|Device|Bilateral MARIA scan|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to determine their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® patient bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts, and array are brought into contact with the breast. Depending on the patient's breast size, one or more cup inserts may be placed in the array to ensure a good but non-compressing fit between the breast and the system interface. The scan sequence will then be performed, this takes a couple of minutes.
75911211|NCT02047383|Other|Respiratory infection|An assessment of the patients included in the study will be conducted
75318875|NCT04575948|Drug|Moringa Oleifera|Non toxic Moringa extract with antibacterial and antiplaque effect will be used
75318876|NCT04575948|Drug|Chlorhexidine mouthwash|Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.
75318877|NCT04575948|Drug|Base formula|Base formula is a negative control
75318878|NCT04571242|Device|DTM Programming|DTM-SCS programming
75318879|NCT04571242|Device|Conventional SCS programming|Conventional SCS programming
75618339|NCT04337476|Device|The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention|Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.
75618340|NCT02626195|Dietary Supplement|nutritional support program|"Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~Calories: 30-35Kg, via enteral or parenteral~Protein: 1.2-1.5g/Kg~Lipid : 1-1.5g/Kg~Mineral and vitamins supply~Blood glucose control~Daily monitoring by dietician and specialized nurse"
75618341|NCT02814214|Device|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
75618342|NCT00685789|Device|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
75618343|NCT00685789|Device|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
75618344|NCT04329832|Drug|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min). For patients < 45kg, doses will be halved. For patients with GFR<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
75771758|NCT00145626|Drug|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
75771759|NCT00145626|Device|Miltenyi Biotec CliniMACS|Stem cell selection device
75771760|NCT00145626|Procedure|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
75771761|NCT01206946|Drug|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
75771762|NCT01206946|Other|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
75771763|NCT01207024|Other|knee MRI|knee MRI before surgery (inclusion) and one year after
75771764|NCT03813940|Biological|HPV Vaccine,135μg/0.5ml|HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
75911212|NCT04886674|Dietary Supplement|bovine colostrum|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for < 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
75911213|NCT02260011|Drug|Ipratropium bromide HFA-134a inhalation aerosol|
75911214|NCT02260011|Drug|Atrovent® CFC inhalation aerosol|
75911215|NCT02260011|Drug|Placebo|
75911216|NCT02047773|Other|Duration|If bacterial load checked on day 7 is less than 10^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
75911217|NCT02047773|Drug|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
75911218|NCT02047773|Drug|Meropenem|
75911219|NCT03562299|Device|OrthoPure™ XT|A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
76072688|NCT00997906|Drug|gemcitabine hydrochloride|Given IV
75318880|NCT04540380|Drug|Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab|Conditioning regimen .Patients will receive Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Thymoglobulin
75911220|NCT04886830|Procedure|laparoscopic appendectomy using a single endoloop for appendiceal stump closure|laparoscopic appendectomy using a single endoloop for appendiceal stump closure before resecting the appendix
75911221|NCT04886830|Procedure|laparoscopic appendectomy using two endoloops for appendiceal stump closure|laparoscopic appendectomy using a two endoloops for appendiceal stump closure before resecting the appendix
75911222|NCT04886830|Procedure|laparoscopic appendectomy using a clip for appendiceal stump closure|laparoscopic appendectomy using an endoclip for appendiceal stump closure before resecting the appendix
75771765|NCT03813940|Biological|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
75771766|NCT03967938|Drug|Olaparib Oral Capsule|Olaparib tablets 300mg twice daily
75771767|NCT03817918|Procedure|Lung ultrasonography|Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
75771768|NCT03817996|Other|Fluid challenge|250ml of saline in Responders (those who increased >10% their cardiac output after a passive leg raising maneuver).
75771769|NCT01299298|Drug|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
75771770|NCT01299298|Drug|placebo|50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
75771771|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
75318881|NCT04540380|Procedure|Combined bone marrow and kidney transplant|Recipients will receive a conditioning regimen that includes rituximab on study days -7 and -2, fludarabine 10mg/m2/day on days -6 to -3 (4 doses), cyclophosphamide (22.5mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumabon days -1, 0, and +1. Combined kidney and bone marrow transplant will be performed on study day 0. Methylprednisolone will be started at 250 mg/day on day 0 and tapered to prednisone 20mg by day 10 after which it will be continued until day 20. Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 52 weeks following transplantation. The proportion of patients successfully weaned off immunosuppression without chimerism transition syndrome (CTS) will be assessed.
75464630|NCT01880216|Drug|Bemiparin sodium|subcutaneous application daily for 7±2 days
75771772|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
75771773|NCT00153062|Drug|Clopidogrel placebo|placebo
75771774|NCT00153062|Drug|Clopidogrel placebo|placebo
75771775|NCT00153062|Drug|Micardis|80 mg micardis
75771776|NCT00153062|Drug|Micardis|80 mg micardis
75771777|NCT00153062|Drug|Aggrenox placebo|placebo
75771778|NCT00153062|Drug|Aggrenox placebo|placebo
75771779|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
75771780|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
75771781|NCT00153062|Drug|Micardis placebo|placebo
75771782|NCT00153062|Drug|Micardis placebo|placebo
75771783|NCT01207180|Other|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
75771784|NCT01207180|Other|Satisfaction survey|Patients will be given a satisfaction survey.
75771785|NCT01207180|Other|Control group --- no intervention|Control group
75771786|NCT03813550|Diagnostic Test|Fecal and blood samples|Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
75771787|NCT00145470|Drug|Asenapine|Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
75911223|NCT04886752|Dietary Supplement|vitamin C without liposome|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
75911224|NCT04886752|Dietary Supplement|liposomal process A vitamin C|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
76072689|NCT00997906|Drug|paclitaxel|Given IV
76072690|NCT00997906|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
76072691|NCT01811485|Drug|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
75771788|NCT00145470|Drug|Placebo|Placebo fast dissolving SL tablets, BID
75771789|NCT03813706|Procedure|lymph node dissection|The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
75771790|NCT03813628|Other|polished celtra press full coverage crown|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
75771791|NCT03813628|Other|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
75771792|NCT03813628|Other|contralateral natural teeth|the polished and glazed all ceramic crowns will be compared by the contralateral natural teeth
75771793|NCT03813394|Drug|pembrolizumab|-Pembrolizumab in Solution for Injection
75911225|NCT04886752|Dietary Supplement|liposomal process B vitamin C (Double Nutri™)|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
75911226|NCT02047851|Other|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
75911227|NCT03051490|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
75911228|NCT03051490|Drug|porcine PERT|oral, enterically-coated, pig-derived, pancreatic enzyme replacement
75464631|NCT01880216|Drug|Enoxaparin sodium|subcutaneous for 7±2 days
75771794|NCT03813394|Drug|bevacizumab|"Bevacizumab in Concentrate for Solution~Bevacizumab in Concentrate for Solution"
75771795|NCT03813316|Drug|DPP-4 inhibitor|Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
75911229|NCT03816813|Other|blood and saliva sampling|blood and saliva sampling
75911230|NCT04895800|Dietary Supplement|Phytovive|Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
75911231|NCT04895800|Dietary Supplement|Placebo|Natural Flavors [Chocolate, Caramel, Vanilla Cream], Silica, Inulin, Sucralose)
75911232|NCT04895800|Dietary Supplement|Caffeine|Caffeine (Green tea caffeine extract (170 mg; to deliver 34 mg caffeine [20% natural caf-feine])
75911233|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment|Compound level meeting
75318882|NCT04531722|Procedure|Intraoperative brain microdialysis|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe.
75318883|NCT04521166|Device|Hearing aid|Settings in a wearable hearing aid will be adjusted within a clinically-relevant range for two features. The features include wide dynamic range compression and microphone directionality.
75911234|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
75911235|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
75911236|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
75911237|NCT04886362|Drug|Ivermectin|Treatment with Ivermectin in the first 7 days from symptoms onset.
75618345|NCT04329832|Drug|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
75771796|NCT03813316|Drug|SGLT2 inhibitor|Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
75771797|NCT03813316|Drug|SGLT2 inhibitor and DPP-4 inhibitor|Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
75771798|NCT03813004|Diagnostic Test|Reaction for gait perturbation|"Participants were subjected to four different perturbation types while walking on the treadmill:~left treadmill belt deceleration for right leg toe off~right treadmill belt deceleration for left leg toe off~left treadmill belt acceleration for right leg heel strike~right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait."
75464632|NCT01880255|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
75464633|NCT01880268|Device|BCI-controlled neurorehabilitation device|"Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)"
75464634|NCT01880268|Behavioral|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
75771799|NCT03817840|Procedure|Treatment of Cushing's|Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism
75464635|NCT01880281|Other|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
75464636|NCT01880294|Drug|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
75464637|NCT01880307|Drug|Azathioprine|
75464638|NCT01880307|Drug|Infliximab|
75464639|NCT01880307|Drug|Prednisolon|
75911238|NCT04886362|Drug|Placebo|Treatment with Placebo in the first 7 days from symptoms onset.
75618346|NCT02626273|Radiation|weight loss|
75618347|NCT04237246|Drug|Tacrolimus|"24 hour long acting advegraf"
75618348|NCT00680095|Drug|AN2690|AN2690 Solution, 2.5%, Daily for up to 21 days
75618349|NCT00680095|Drug|AN2690|AN2690 Solution, 7.5%, Daily for up to 21 days
75618350|NCT00680095|Drug|AN2690|AN2690 Solution, 5.0%, Daily for up to 21 days
75618351|NCT00680095|Other|AN2690 Solution, Vehicle|AN2690 Solution, Vehicle, Daily for up to 21 days
75618352|NCT00680095|Other|Sodium Lauryl Sulfate, 0.5%|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
75911239|NCT02050035|Other|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
75911240|NCT04886206|Biological|DLI|the patients will receive the injection of donor lymphocytes from haplo-identical donor (the son or daughter or possibly nephew or niece of the patient). No immunosuppressive drugs will be used. The HLI dose levels are 1) 1x107 CD3+/kg 2) 5x107 CD3+/kg 3) 7.5x107 CD3+/kg 4) 1x108 CD3+/kg.The CRM method (Continual Reassessment Method) was chosen to specify the dose of cells to be injected, each patient being assigned a dose that is believed to be associated with the target toxicity corresponding to the maximum tolerated dose (MTD). The dose-toxicity curve will be readjusted after assessing the toxicity of each patient.
75911241|NCT02048007|Drug|Azithromycin|Biannual mass oral azithromycin to children
75911242|NCT02048007|Drug|Placebo|Biannual mass oral placebo to children
75911243|NCT04881994|Drug|Finerenone (BAY94-8862)|Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
75911244|NCT02048085|Drug|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
75911245|NCT02048085|Drug|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
75911246|NCT04430374|Other|No interverntion|No intervention will be done, registry only
75911247|NCT03051412|Other|No Intervention|No intervention
75318884|NCT04515784|Behavioral|Safety Aid Reduction Treatment for PTSD|START-PTSD includes many of the key elements found in empirically supported treatments for PTSD including: a) psychoeducation regarding the development and maintenance of PTSD; and b) exposure to internal sensations and external situations that are connected to one's fear/distress response via identification and elimination of safety aids. Known safety aids to be covered include: cognitive avoidance (e.g., using mental distractions to avoid trauma-related images); situational avoidance (e.g., avoiding crowded market places); checking behaviors (e.g., checking doors, windows, locks, and perimeters more often than necessary); reassurance seeking (e.g., excessively watching the news); other compulsive behaviors (e.g., checking the location of exits); use of companions (e.g., relying on someone to attend a social gathering); and use of alcohol and certain substances (e.g., consuming alcohol to reduce anxiety).
75318885|NCT04510662|Drug|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
75318886|NCT04508348|Other|Human Milk|Exclusive Human Milk diet
75771800|NCT01301170|Procedure|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
75771801|NCT01207258|Behavioral|Motivational Enhancement Therapy|20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
75318887|NCT04508348|Other|Standard of Care|This diet will include mother's milk and/or formula
75318888|NCT04506944|Other|No intervention|No specific exposure is explored.
75318889|NCT04494256|Drug|BIIB105|Administered as specified in the treatment arm.
75464640|NCT01880333|Other|Modified Atkin Diet|Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
75464641|NCT01880346|Dietary Supplement|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
75464642|NCT01880346|Dietary Supplement|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
75464643|NCT01880372|Dietary Supplement|Alpha Lipoic Acid|Same as Arm description
75464644|NCT01880385|Biological|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
75618353|NCT04237168|Diagnostic Test|IgNGS from circulating tumor DNA|3 longitudinal plasma samples will be evaluated at three different time points per patient: 0 (pre-treatment), end of treatment, and at 6 months after treatment.
75618354|NCT00685867|Other|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
75618355|NCT00685867|Behavioral|Hand hygiene promotion|"Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~Isolation precautions according to the hospitals' capacity and strategy~Additional basic infection control interventions (if necessary)"
75771802|NCT05624086|Behavioral|exercise|Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
75318890|NCT04494256|Drug|Placebo|Administered as specified in the treatment arm.
75318891|NCT04465370|Device|Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight|A Swan-Ganz catheter, FloTrac transducer, ClearSight finger cuff and ForeSight Elite sensors will be placed prior to the start of the catheterization procedure. Intermittent cardiac output and other hemodynamic parameters will be collected throughout the duration of the procedure and analyzed according to the Statistical Analysis Plan.
75771803|NCT03817450|Behavioral|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention nursing homes.
75771804|NCT01301248|Other|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
75464645|NCT01880385|Drug|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
75464646|NCT01880385|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
75464647|NCT01880385|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
75464648|NCT01880385|Drug|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
75464649|NCT01880385|Biological|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
75618356|NCT02814604|Other|Nutrition Rating Systems|Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
75618357|NCT00686023|Procedure|internal fixation (DHS - richard nail)|internal fixation
75771805|NCT01301248|Other|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
75771806|NCT03817684|Drug|BPN14770|Drug BPN14770
75618358|NCT00686023|Procedure|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
75618359|NCT02814136|Procedure|Ablation|
75618360|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
75911248|NCT03051334|Other|diagnosed as bicuspid aortic valve|
75318892|NCT04463654|Device|Zero Self-Harm app|Safety plan app for smartphones
75318893|NCT04446468|Behavioral|PEACE|The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide.
75318894|NCT04446468|Other|Standard Psychiatric Hospital Discharge Care|Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
75318895|NCT04428437|Drug|Lenvatinib|Prescribed by physician.
75318896|NCT04415008|Drug|HAD induction with intermediate dose cytarabine|daunorubicin,cytarabine,homoharringtonine
75318897|NCT04412629|Drug|Cabozantinib|Cabozantinib should be taken on an empty stomach (at least 1 hour before or 2 hours after eating) at the same time every day.
75618361|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
75618362|NCT00680173|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
75618363|NCT04293016|Behavioral|Support as usual|this group receives current best practice which includes participation in ICU support groups and provision of community support resources
75318898|NCT04412629|Procedure|Blood for plasma biomarkers|Baseline, cycle 1 day 8, cycle 1 day 15, and day 1 of every cycle thereafter
75464650|NCT01880398|Other|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
75464651|NCT01880411|Biological|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
75464652|NCT01880450|Behavioral|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
75618364|NCT04293016|Behavioral|problem solving therapy|This group will receive one on one therapy based on identifying stressors and solutions to those stressors
75618365|NCT04293016|Behavioral|ICU diary|This group will provided with a structured written diary that includes identification of stressors and development of solutions to those stressors
75771807|NCT03817684|Drug|Placebo|Placebo
75771808|NCT03817372|Device|Anterior-posterior electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-posterior electrode position
75771809|NCT03817372|Device|Anterior-lateral electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-lateral electrode position
75771810|NCT01301326|Device|subthreshold and threshold laser treatment|subthreshold laser treatment
75771811|NCT01301326|Device|Threshold laser treatment|threshold laser treatment
75771812|NCT01302028|Drug|ASP1941|Oral
75911249|NCT02808975|Drug|Placebo|Subcutaneous injections administered as described in arm description
75771813|NCT01302106|Drug|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
75771814|NCT00152516|Drug|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
75911250|NCT02808975|Drug|Adalimumab|Subcutaneous injections administered as described in arm description
75911251|NCT04881136|Device|Reveal LINQ™|The physical device is the Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data that will be used for gait analysis.
75911252|NCT04885738|Other|no intervention|"For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD."
75911253|NCT02050191|Behavioral|www.princetonlivingwell.com|
75318899|NCT04412629|Procedure|Tissue biopsy|Baseline, before start of cycle 2, and time of progression
75318900|NCT04406857|Drug|Capecitabine|Given PO
75318901|NCT04406857|Radiation|Radiation Therapy|Undergo radiation therapy
75318902|NCT04406857|Drug|Ropidoxuridine|Given PO
75464653|NCT01880450|Behavioral|TEEN|Control condition the promote communication, decision-making skills etc.
75464654|NCT01880463|Drug|Omega-3 fatty acids (fish oil)|
75464655|NCT01880463|Dietary Supplement|Vitamin D3|
75464656|NCT01880463|Dietary Supplement|Vitamin D3 placebo|
75464657|NCT01880463|Drug|Fish oil placebo|
75464658|NCT01880476|Other|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
75771815|NCT00145158|Biological|8 HLA-A2-restricted peptides and Montanide ISA51|
75771816|NCT00145158|Biological|8 HLA-A2-restricted peptides and CpG 7909|
75618366|NCT00682279|Drug|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
75618367|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
75911254|NCT02976038|Drug|elamipretide|40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
75771817|NCT03813082|Behavioral|Prolonged wakefulness|40 hours of prolonged wakefulness
75911255|NCT02669511|Drug|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
75911256|NCT04885894|Drug|Zeposia|Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
75911257|NCT04885660|Drug|compound lisinopril tablet|The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
75911258|NCT04885660|Drug|compound lisinopril tablet(Lisonorm®)|The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
75911259|NCT02050269|Drug|Iohexol|Iohexol, 300 mg/mL
75911260|NCT03468764|Procedure|Vigileo monitoring during lung recruitment maneuver|"Standard monitoring parameters, invasive blood pressure and hemodynamic values (SVV and CO, through Vigileo device) will be monitored. With the patient in a supine position and as SVV reaches a value of 12-15%, a LRM is performed, consisting in the application of 30 cm H2O continuous positive airway pressure for 30 seconds.~The alterations in the above mentioned parameters will be registered before and after the maneuver.~The same procedure will be performed after a 8 ml/kg crystalloids fluid challenge, as soon as SVV reaches the value of 10%."
75911261|NCT02037633|Drug|Fentanyl|Fentanyl IV
75911262|NCT02037633|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block using ropivacaine
75464659|NCT01880489|Behavioral|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
75464660|NCT01880502|Drug|Belviq 10mg|Belviq 10mg single dose administration
75464661|NCT01880502|Drug|Belviq 20mg|Belviq 20mg single dose administration
75464662|NCT01880502|Drug|Placebo|Placebo single dose administration
75771818|NCT03812926|Device|Compuflo assited procedure|number of needle entry required to identify the ligamentum flavum
75464663|NCT01880606|Procedure|colonoscopy with endomicroscopy|Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
75464664|NCT01880619|Drug|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
75464665|NCT01880619|Drug|Solifenacin|Patients in the arm will receive Solifenacin
75464666|NCT01880619|Drug|Control|Patients in this are will receive placebo
75464667|NCT01880632|Drug|XELOX|"Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
75771819|NCT01302184|Device|Lokomat®|"Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks"
75911263|NCT02037633|Drug|ropivacaine|
75911264|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
75911265|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound.
75911266|NCT05106218|Device|SurroundScope|The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
75911267|NCT05106218|Device|Standard Laparoscope|The procedure will be performed according to the institution's standard of care, using the Standard laparoscope for visualization.
75911268|NCT05684211|Drug|Ametumumab|A recombinant fully human anti-EGFR monoclonal antibody
75911269|NCT05684211|Drug|Anti-PD-1 monoclonal antibody|Toripalimab 3 mg/kg，Intravenous titration，Q2W
75911270|NCT05684211|Drug|Cetuximab|Cetuximab 500 mg/m2 ，Intravenous titration，Q2W
75911271|NCT05684211|Drug|FOLFIRI|Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
75911272|NCT04894942|Other|American Orthopaedic Foot and Ankle Society Score (AOFASS)|calculation of the score AOFASS before and after the surgery
75618368|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
75618369|NCT02811484|Drug|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c>8%
75771820|NCT01302184|Device|Treadmill|"Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks."
75318903|NCT04393454|Drug|Sirolimus 2Mg Tab|Sirolimus (oral) will be started at 2 mg daily. Sirolimus dosing will be titrated to meet serum trough levels of >8 ng/ml, assayed at 7 days after starting a new dose, by chromatography/nmass spectrometry. Once adequate serum levels are met (≥8 ng/ml), the same dosing will be continued until progression of disease as evidenced by imaging, or unacceptable toxicity.
75771821|NCT03812458|Behavioral|website and brochure|website and brochure
75771822|NCT05624008|Other|Bioceramic glass ionomer restoration|bioactive glass ionomer with unique biocompatibility and biological regenerative properties
75771823|NCT05624008|Other|Resin modified glass ionomer restoration|A hybrid of glass ionomer and composite resin with acid-base and polymerizable components
75318904|NCT04385381|Device|URECA CTO device|facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature with the URECA CTO device.
75618370|NCT02811484|Behavioral|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
75771824|NCT03817216|Device|Prostatic Urethral Lift (PUL)|PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
75771825|NCT05623930|Device|laser acupuncture|In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
75771826|NCT05623930|Other|wet cupping|in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
75771827|NCT05623852|Dietary Supplement|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
75771828|NCT03812692|Device|MATRx plus|The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
75771829|NCT03812536|Other|No Void|Currently the protocol at The Ohio State University Hospital requires voiding spontaneously prior to discharge from the PACU. Our intervention group will be discharged home without having to void spontaneously as a discharge criteria.
75618371|NCT00686179|Drug|AZD3480|Capsule, oral, single dose, 6 days
75618372|NCT00686179|Drug|Moxifloxacin|Capsule(encapsulated), oral, single dose
75618373|NCT00686179|Drug|PLACEBO|Capsule, oral, single dose
75618374|NCT04139707|Device|Caring4Dementia|A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
75618375|NCT04139707|Other|White Paper|The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
75618376|NCT02813902|Drug|Heliocare with Fernblock PLE technology|240 mg taken orally daily over the course of 1 year
75771830|NCT03817294|Other|Comparison of exercise training modalities|As above
75771831|NCT03817060|Procedure|cryopreservation of embryos at cleavage stage|cryopreservation of embryos at cleavage stage (day 3) of embryo development
75771832|NCT03817060|Procedure|cryopreservation of embryos at blastocyst stage|cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
76072692|NCT01811485|Drug|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
75318905|NCT04373629|Behavioral|attentional modulation|Attentional instructions when viewing faces will be given
75318906|NCT04373629|Other|perceptual modulation|Faces will be presented of varying durations
75318907|NCT04373629|Other|naturalistic viewing|Faces will be viewed without specific instructions
75318908|NCT04367051|Drug|Withdrawal of Spironolactone|Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
75318909|NCT04367051|Drug|Continuation of spironolactone|Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
75318910|NCT04350229|Drug|Drug omission|Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
75318911|NCT04350229|Other|Control group|No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.
75318912|NCT04335708|Dietary Supplement|Postibiotic formulation|5 mL daily of edible gel with intracellular content of Lactobacillus casei CRL-431
75318913|NCT04335708|Dietary Supplement|Placebo formulation|5 mL daily of edible gel without intracellular content of Lactobacillus casei CRL-431
75618377|NCT02813902|Other|Sugar Pill|A pill that appears similar to the supplement
75771833|NCT03817138|Other|Exposures: Markers of disease progression|From early phases of the study, it is expected that six main domains will be assessed which will include over N=100 potential markers reflecting different markers of dementia disease progression identifiable from patients' primary care EHR.
75771834|NCT05623696|Device|Sham or actual non-invasive (Magnetic) brain stimulation|5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC
75464668|NCT01880645|Procedure|Fine Needle Aspiration (FNA)|If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
75771835|NCT01302340|Drug|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
75771836|NCT01302340|Drug|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
75464669|NCT01880645|Procedure|Ultrasound|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
75618378|NCT00922597|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
75771837|NCT01302340|Drug|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
75318914|NCT04318587|Diagnostic Test|Allosure|Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.
75771838|NCT00150800|Drug|Brivaracetam|"Active Substance: Brivaracetam~Pharmaceutical Form: Tablet~Concentration: 10 mg and 25 mg~Route of Administration: Oral"
75911273|NCT03130634|Drug|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
75911274|NCT02050425|Device|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
75911275|NCT02050425|Device|CPAP|Patients continue therapeutic CPAP therapy
75318915|NCT04316975|Other|Study Driven Procurement of Biopsies|Four research biopsies collected at the midpoint of current BE or IMC at Baseline and after reaching CEIM. Biopsies will be used to calculate ML scores both pre and post EET.
75618379|NCT02811172|Other|BEhavior of biomarkers during pregnanCy and lactatiOn|
75618380|NCT04151173|Procedure|laparoscopic aspiration/electrocoagulation|laparoscopic aspiration/electrocoagulation of ovarian endometrioma
75618381|NCT04151173|Procedure|laparoscopic cystectomy|laparoscopic cystectomy of ovarian endometrioma
75618382|NCT02627365|Behavioral|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
75618383|NCT02813746|Dietary Supplement|Fitness program|
75618384|NCT02813746|Behavioral|Stop smoking|
75618385|NCT02813746|Procedure|Endometrial fluid collection|
75618386|NCT00874939|Drug|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
75771839|NCT03812770|Drug|Sorafenib|Oral Sorafenib, 400mg, Bid
75771840|NCT03812770|Drug|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
75771841|NCT03812770|Drug|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
75771842|NCT00144300|Drug|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
75771843|NCT00144300|Drug|Requip|Standard marketed product dispensed according to manufacturer's guidelines
75771844|NCT03812068|Behavioral|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
75771845|NCT03812068|Behavioral|Developmental behavioral intervention|Parent-mediated developmental behavioral intervention
75771846|NCT01582724|Procedure|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
75911276|NCT04885582|Other|HLA antigen results|HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.
75911277|NCT02124824|Drug|BQ-123|Endothelin subtype A antagonist
75911278|NCT04895020|Biological|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
75911279|NCT04880746|Drug|BEAC|Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
76072693|NCT01811485|Drug|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
75618387|NCT00874939|Drug|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
75618388|NCT00874939|Drug|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
75771847|NCT00149630|Drug|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
75771848|NCT00149630|Drug|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
76072694|NCT05246644|Drug|acetaminophen|we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
75618389|NCT00874939|Drug|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
75771849|NCT00149630|Behavioral|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
75771850|NCT00149630|Other|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
75771851|NCT01302496|Biological|TriMix-DC and ipilimumab|Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
75771852|NCT00127842|Drug|Etanercept|Administered according to the product monograph by subcutaneous (SC) injection
75771853|NCT03720652|Behavioral|8-Week Mindful Self-Compassion (MSC)|"The 8-week MSC is a course of eight 2.5 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 8-session program that integrates SC and mindfulness.~It includes the following components:~Discovering Mindful Self-Compassion~Practicing Mindfulness~Practicing Lovingkindness~Discovering your Compassionate Voice~Living Deeply~Meeting Difficult Emotions~Exploring Challenging Relationships~Embracing Your Life"
75771854|NCT03720652|Behavioral|6-Week Mindful Self-Compassion (MSC)|"The 6-week MSC is a course of six 1 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 6-session program that integrates SC and mindfulness.~It includes the following components:~What is Self-Compassion~Practicing Self-Compassion~Discovering your Compassionate Voice~Self-Compassion and Resilience~Self-Compassion and Burnout~Going Forward This program is a shortened version of the 8-week program, specifically created for the needs of health care staff."
75771855|NCT03968016|Device|SYSMEX HLSCL|Diagnostic device
75771856|NCT03964740|Other|Mobile App intervention|The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
75771857|NCT00112866|Drug|cilengitide|Given IV
75771858|NCT00112866|Procedure|therapeutic conventional surgery|Undergo tumor resection
75911280|NCT04880746|Drug|Cladribine combined with BEAC|Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
75771859|NCT00112866|Other|pharmacological study|Correlative studies
75771860|NCT00112866|Other|laboratory biomarker analysis|Correlative studies
75911281|NCT03050086|Drug|BPX-04 1% minocycline topical gel|once daily administration of topical minocycline gel to face
75911282|NCT03050086|Drug|BPX-04 2% minocycline topical gel|once daily administration of topical minocycline gel to face
75911283|NCT03050086|Drug|BPX-04 vehicle topical gel|once daily administration of topical minocycline gel to face
76072695|NCT03832036|Diagnostic Test|Paraspinal Mapping and Quantitative Sensory Pain Test|Participants will be tested at baseline.
76072696|NCT01798888|Procedure|Implantation of Deep Brain Stimulation|
76072697|NCT01810939|Drug|Patiromer|
76072698|NCT01810939|Drug|Placebo|
76072699|NCT01798576|Drug|Pegylated Interferon alfa-2a|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
75318916|NCT04314219|Drug|Cyclophosphamide 50mg|Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5
75318917|NCT04314219|Drug|Methotrexate|Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6
75318918|NCT04292925|Other|New treatment protocol|The new treatment protocol focuses on training of executive processes using remedial strategies and on promoting the use of meta-cognitive strategies. Goal directed activities are used to improve the underlying cognitive process and transfer of the learned skill to everyday function will be encouraged.
75318919|NCT04292925|Other|Conventional therapy|conventional therapy
75464670|NCT01880645|Procedure|Breast Surgery + Lymph Node Removal|Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
75464671|NCT01880658|Drug|Capecitabine|Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
75464672|NCT01880671|Device|Inactive Migraine Medical Device|
75464673|NCT01880671|Device|Migraine Medical Device|
75464674|NCT01880749|Drug|RAD001|
75464675|NCT01880775|Drug|Prilocaine|experimental
75464676|NCT01880775|Drug|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
75618390|NCT00874939|Drug|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
75618391|NCT04268836|Device|Optimal Acuity Clear-K® Low Vision Aid System treatment|The treatment involves irradiation of the cornea with low energy light in a treatment pattern that produces corneal shape change.
75618392|NCT00634348|Drug|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
75618393|NCT00634348|Drug|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
75318920|NCT04291391|Other|North American-type diet|All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)
75911284|NCT04885348|Behavioral|Intervention Group (Dental Home Visits + Dental Home Education Leaflets)|No drugs were given in the Intervention. The intervention group received Dental Home Visits consisted of 6 monthly home visits by oral health therapists/dental home visitors where they deliver dental care advice to the parents for durations of approximately 30 minutes until follow-up at two years. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion. These messages included information on daily tooth brushing with fluoride toothpaste, controlling dietary sugar intake, and the need for regular dental check-ups. The families were also be provided with information about local dental services available in their vicinity and how to access these services.
75618394|NCT00680329|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
75911285|NCT04885348|Behavioral|Control Group (Dental Home Education Leaflets)|Only Dental Home Education Leaflets were provided every six months for 2 years.
75911286|NCT03050242|Drug|Glycopyrrolate|Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery
75911287|NCT04894630|Other|antimicrobial treatment|Detailed history taking and all clinical findings were collected. Corneal scrapings were obtained from patients and subjected to staining and culture for bacterial and fungal pathogens; Bacterial and fungal growth were identified by standard laboratory procedures.
75911288|NCT04880902|Procedure|sleeve gastrectomy|Laparoscopic sleeve gastrectomy had evident therapeutic effects on preexisting obesity-related comorbidities. All patients were referred for abdominal MSCT with a volumetric assessment of gastric pouch within 1 month of surgery and 1 year postoperatively
76072700|NCT01798576|Drug|Ribavirin|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
75318921|NCT04287413|Behavioral|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination.~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
75318922|NCT04287413|Behavioral|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
75318923|NCT04282720|Device|SurgiMend Mesh|Following placement of SurgiMend mesh during laparoscopic hiatal hernia repair, patient will be scheduled for follow up using an upper GI series to check for recurrence of the hiatal hernia. Follow up upper GIs will be performed at 6 months post-surgery. Subjects will also complete a QOL survey to assess other GI associated symptoms before and after surgical repair. The QOL survey can be administered by phone by study team members
75318924|NCT04277598|Biological|APO-2|APO-2: dose adjusted gel for topical administration.
75318925|NCT04277598|Other|Placebo|Placebo gel for topical administration.
75618395|NCT00680329|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
75318926|NCT04265430|Other|Contrast Agent|Given IV
75318927|NCT04265430|Procedure|Magnetic Resonance Imaging|Undergo MRI
75318928|NCT04265430|Other|Quality-of-Life Assessment|Ancillary studies
75618396|NCT02811016|Drug|Budesonide 200|200 µg inhaled at 7:00 a.m. and 7 p.m.
75618397|NCT02811016|Drug|Budesonide 800|800 µg inhaled at 7:00 a.m. and 7 p.m.
75618398|NCT02811016|Drug|Placebo|Placebo Inhalation at 7:00 a.m. and 7 p.m.
75618399|NCT00686413|Drug|AZD3480|single dose, oral
75618400|NCT00686413|Radiation|2-[18F]-F-A85380|Single dose, IV
75618401|NCT02810860|Procedure|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
75618402|NCT04144309|Procedure|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
75771861|NCT03824626|Diagnostic Test|TEVAR patients|Computed Tomography Angiography (CTA) will be performed using a 16-slice unit before and after intravenous administration of 100 mL of iodinated contrast material. Phase contrast-Magnetic Resonance (pc-MRI) will be performed using a 1.5-T unit with 40-mT/m gradient power and a four-channel cardio-thoracic coil. ECG-triggered, free-breathing through plane, and in-plane pc-MRI sequences will be performed for phase-velocity mapping of aortic and branches flow. Ad hoc processing of preoperative CTAs, based on 3D multiplanar reconstruction, will be performed with 3Mensio Vascular software 8.0® (3Mensio Medical Imaging B.V.), which provides specific functions for automatic measurements.
75771862|NCT00127608|Procedure|Collection of clinical samples|"The following samples were obtained from each subject:~Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~Papule swabs (PS) from four papules~Crusts from two lesions~One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique."
75911289|NCT04894552|Procedure|Laparoscopic Hysterectomy and Sentinel Lymph Node Biopsy for Endometrial Carcinoma|Patients with endometrial carcinoma will undergo laparoscopic hysterectomy and sentinel lymph node biopsy. The patient will be positioned in a modified lithotomy position with the hips flexed 30 degrees. Blue dye is injected at the cervix. The round ligament will be transected. Sentinel lymph nodes will be detected, dissected and isolated. Then standard lymphadenectomy will be done. Then the infundibulopelvic ligament will be transected. Ligation of the uterine vessels. The cardinal ligaments will be transected, and the vaginal fornices will be opened laparoscopically. The whole specimen will be removed through the vagina. The vaginal cuff will be then closed trans-vaginally. Intraoperative and early postoperative complications will be assessed. The isolated sentinel lymph node will be sent for pathological study as well as the standard lymphadenectomy specimens. Both specimens will be compared to assess the diagnostic reliability and sensitivity of the sentinel lymph node.
76072701|NCT00565084|Drug|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
75318929|NCT04265430|Other|Questionnaire Administration|Ancillary studies
75771863|NCT00149396|Drug|NV1020|NV1020 dose levels: 3x10^6, 1x10^7, 3x10^7, and 1x10^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
75771864|NCT03816904|Other|Blood samples|Blood samples before the introduction of chemotherapy
75771865|NCT03741348|Procedure|Erector Spinae Plane Block|In (ES) group After skin sterilization, ESPB was performed in sitting position at the level of T9 linear ultrasound (US) transducer (Phillips-Saronno Italy) was placed vertically 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between the two transverse processes. After local infiltration of needle insertion site with 2-3ml of 2% lidocaine, a 22-gauge Short bevel needle (Spinocan, B.Braun Melsungen AG, Germany) was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles. Then, up to 20 ml of bupivacaine 0.5% was injected. The procedure was repeated following the same steps on the other side of back.
75771866|NCT03741348|Procedure|control|in control group, Erector Spinae Plane Block will not be done
75771867|NCT05080504|Device|Eko DUO|"Each subject will take an Eko DUO device home and take DUO recordings immediately before or after their prescribed CardioMEMS measurements.~The DUO recordings will be taken at 3 predefined chest locations: the right upper sternal border, left upper sternal border, and right anterolateral. Each DUO recording lasts about 15 seconds. The total time per recording session is expected to be 2-4 minutes, which allows for time between recordings and any potential repeat recordings. Study participation will last for 90 days."
75771868|NCT01075802|Drug|Tamoxifen|Dose escalation
75771869|NCT03967314|Other|TLIP block group (group T)|In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).
75771870|NCT03967314|Other|Wound infiltration group (group W)|In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
75771871|NCT03816592|Procedure|Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
75771872|NCT03816592|Procedure|Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
75771873|NCT01078038|Device|Cypher|Sirolimus-eluting stent implantation
75911290|NCT04880356|Other|collection of data|collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
75318930|NCT04230408|Drug|Durvalumab|Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation
75318931|NCT04222712|Drug|TRS01 eye drops|Dosed four times a day (QID)
75318932|NCT04222712|Drug|TRS01 eye drops|Dosed four times a day (QID)
75464677|NCT01880814|Behavioral|Cognitive Behavioral Therapy (CBT)|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
75318933|NCT04205487|Behavioral|Motivational Interviewing (MI)|Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
75771874|NCT01078038|Device|Xience V|Everolimus-eluting Stent implantation
75771875|NCT00223496|Drug|Aripiprazole|Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
75771876|NCT05623618|Behavioral|PACE labelling|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
75771877|NCT02531412|Drug|Spironolactone|After a major surgery event a time 0, 24h and 48h
75771878|NCT02531412|Drug|Placebo|After a major surgery event a time 0, 24h and 48h
75911291|NCT04880512|Drug|SYHX 1901 tablets|SYHX 1901, oral tablets, in fasted state
76072702|NCT00565084|Drug|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
76072703|NCT01810783|Drug|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
75318934|NCT04205487|Behavioral|Contingency Management (CM)|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
75318935|NCT04196114|Device|STIMO-2 device implantation|Implantation of SCS lead in epidural space and implantation of neurostimulator in abdominal region
75771879|NCT00255944|Behavioral|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
75318936|NCT04195698|Drug|Upadacitinib|Upadacitinib will be administered oral as tablet
75771880|NCT00255944|Behavioral|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
75771881|NCT03811990|Behavioral|Cleveland Clinic Stress Free Now Meditations For Healers|Phone-based meditation application
75771882|NCT01071824|Procedure|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
75771883|NCT01071824|Procedure|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
75771884|NCT03823456|Other|Self-acupressure|We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
75771885|NCT03823456|Other|Sham Self-acupressure|We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
75771886|NCT00143598|Device|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
75318937|NCT04185363|Drug|Maralixibat|All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) twice daily
75771887|NCT00143598|Device|Knee-length, placebo stocking|Worn daily for two years
75771888|NCT03971240|Procedure|evacuation of traumatic acute subdural hematoma|craniotomy will be done with evacuation of the hematoma
75771889|NCT03816826|Other|physical therapy|both are physical therapy intervention technique used to treat the soft tissue acute injuries
75318938|NCT04178122|Genetic|Result disclosure|Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
75618403|NCT04144309|Procedure|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
75771890|NCT01080144|Other|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
75771891|NCT01299844|Behavioral|Diabetes Peer Counseling|16 Home visits from a bilingual/bicultural diabetes peer counselor.
75318939|NCT04161157|Behavioral|Pathways|Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (~30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.
75318940|NCT04152161|Biological|BCG vaccine SSI|Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.
75618404|NCT05592262|Drug|SHR2554|On an empty stomach - after meals
75618405|NCT05592262|Drug|SHR2554|After meals - on an empty stomach
75618406|NCT00690313|Drug|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
75618407|NCT02810938|Device|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
75618408|NCT02626585|Procedure|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
75618409|NCT04237480|Diagnostic Test|serum value 1,25(OH)2 vitamin D|statistical evaluation of the serum values
75618410|NCT04144543|Other|White Noise|The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.
75771892|NCT01301404|Dietary Supplement|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
75771893|NCT03816670|Drug|Corifollitropin Alfa|late start (day 4) vs. corifollitropin-alfa standard start (day 2)
75771894|NCT03816514|Procedure|SpHb monitoring|Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring
75771895|NCT03816514|Procedure|Conventional management|Conventional management without SpHb monitoring
75771898|NCT00126672|Drug|Rapamycin|
75771899|NCT01302574|Dietary Supplement|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
75771900|NCT01080378|Procedure|Dietary and Exercise Intervention|Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
75618411|NCT04144543|Other|Facilitated Tucking|The baby's arms and legs were held in flexed positions close to the midline of the torso in sidelying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.
75618412|NCT04144543|Other|White Noise+Facilitated Tucking|The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position.
75771901|NCT03811678|Drug|Kangdaprevir Sodium Tablet|Tablet，administered orally once daily
75771902|NCT03811678|Drug|placebo|Tablet，administered orally once daily
75771903|NCT00145574|Drug|colesevelam HCl|Tablets
75318941|NCT04152161|Biological|Placebo|Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
75771904|NCT00145574|Drug|placebo|Matching Tablets
75771905|NCT05660668|Other|Transbond LR|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond LR will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
75771906|NCT05660668|Other|Transbond XT|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond XT will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
75771907|NCT04984486|Device|dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level~After a period of osseointegration of the implant, a transgingival healing screw is placed to allow the healing of soft tissues. After this healing phase, the final prosthesis will be loaded on the implant."
75771908|NCT05034562|Procedure|Computed Tomography|Undergo PET/CT
75771909|NCT05034562|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
75911292|NCT04880512|Drug|Placebo|Matching placebo, oral tablets, in fasted state
75911293|NCT04885270|Drug|cisplatin i.p.|paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1
75318942|NCT04121949|Device|CADScor®System|The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
75318943|NCT04106193|Other|Blended Facilitation|Blended facilitation consists of an External Facilitator and Internal Facilitator to support adoption of intimate partner violence screening practices for WVs treated in primary care.
75618413|NCT04237324|Procedure|Treatment one side BLE by NAFL|One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.
75771910|NCT05034562|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
76072704|NCT00565864|Drug|L-thyroxine (L-T4)|L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
75618414|NCT04237324|Procedure|Treatment another side BLE by FMR|One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
75771911|NCT05034562|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MRI
75771912|NCT00145496|Drug|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
75771913|NCT00145496|Drug|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
75771914|NCT01299922|Drug|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
75771915|NCT01299922|Drug|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
75618415|NCT02813434|Biological|florbetapir|18F-AV-45 or 18F-Florbetapir
75618416|NCT04139863|Diagnostic Test|aMMP-8 chairside test|No test
75771916|NCT03967574|Device|Transcranial direct current stimulation|"The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped."
75911294|NCT03048994|Dietary Supplement|Glutamine|"Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.~IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.~An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration."
75618417|NCT02810782|Drug|Phenobarbital|Phenobarbital per os
75618418|NCT02810782|Drug|Chlorpromazine|Chlorpromazine per os
75618419|NCT02810782|Drug|Morphine|Morphine per os
75318944|NCT04106193|Other|Implementation as usual|Implementation as usual refers to traditional, site-initiated support for screening practices to detect intimate partner violence among WVs treated in primary care.
75771917|NCT05030818|Drug|Polypill of acetylsalicylic acid, ramipril and atorvastatin|Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
75771918|NCT05030818|Drug|Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin|Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
75771919|NCT01582022|Drug|Bupivacaine|local application for 5 minutes
75318945|NCT04106193|Other|Toolkit|All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.
75318946|NCT04097340|Device|Attentional Bias Retraining (ABR)|Participants randomized to this intervention will receive 2 weeks of ABR for opioids delivered via a mobile device.
75318947|NCT04097340|Device|Control Training|Participants randomized to this intervention will receive 2 weeks of training without ABR, delivered via a mobile device.
75318948|NCT04057287|Other|No intervention|No intervention
75318949|NCT04052776|Drug|Buspirone|40mg
75318950|NCT04052776|Drug|Levodopa-Carbidopa|400mg/100mg
75464678|NCT01880814|Behavioral|Caregiver-Child Treatment|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
75911295|NCT03048994|Dietary Supplement|Placebo|"Nutritional support will be continued as per managing ICU team discretion.~Management of severe sepsis will be continued as per managing ICU team discretion.~Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.~To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out."
75911296|NCT04885426|Drug|low-dose metformin|Metformin Pill 250mg/day
75911297|NCT04885426|Drug|high-dose metformin|Metformin Pill 500mg/day
75464679|NCT01879241|Drug|Rasagiline|
75464680|NCT01879241|Drug|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
75771920|NCT01582022|Drug|normal saline|local application for 5 minutes
75771921|NCT03967418|Behavioral|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychiatric and addictive comorbidities)
75911298|NCT04885426|Drug|Placebo|Placebo
75911299|NCT04879888|Biological|Peptide pulsed Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
75318951|NCT04052776|Drug|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
75318952|NCT04052776|Drug|Placebo oral tablet|Non-active metabolite
75464681|NCT01880827|Procedure|Roux-en-Y|Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.
75618420|NCT02626117|Device|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
75771922|NCT01301482|Device|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
75771923|NCT01582412|Drug|Isavuconazole|oral
75771924|NCT01582412|Drug|digoxin|oral
75771925|NCT01300000|Other|Human Milk|ad lib
75911300|NCT03048682|Device|Foley catheter - Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator."
75911301|NCT03048682|Device|Foley catheter - Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice"
75318953|NCT04035187|Drug|fast itraconazole tablet|100mg dose
75318954|NCT04035187|Drug|medium itraconazole tablet|100mg dose
75318955|NCT04035187|Drug|slow itraconazole tablet|100mg dose
75318956|NCT04035187|Drug|oral itraconazole solution|100mg dose
75318957|NCT04002037|Drug|Triamcinolone Acetonide 40mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
75318958|NCT04002037|Drug|Triamcinolone Acetonide 10mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
75464682|NCT01880827|Drug|GIP-infusion|Blood flow and volume during infusion
75464683|NCT01880827|Drug|GLP-1|Blood flow and volume during infusion
75464684|NCT01880827|Drug|MMS|Blood flow and volume after meal solution
75464685|NCT01880827|Procedure|Sleeve gastrectomy|as in RYGS group
75464686|NCT01880853|Other|mammography|participants were screened by mammography alone every year
75464687|NCT01880853|Other|ultrasound|participants were screened by ultrasound alone every year
75911302|NCT04880122|Diagnostic Test|Dried blood spot and venous blood collection|A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).
75464688|NCT01880853|Other|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
75771926|NCT01300000|Other|Investigational infant formula|ad lib
75771927|NCT01300000|Other|Milk based standard infant formula|ad lib
75771928|NCT03816436|Other|Follow- up (FU) assessment|Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
75771929|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
75771930|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
75771931|NCT00255164|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
75771932|NCT03811444|Device|Haemolance Plus safety lancet|Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
75771933|NCT03811444|Device|Prolance safety lancet|Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
75911303|NCT04879576|Other|Treatment|Telerehabilitation including pulmonary rehabilitation and posture exercises at 8 weeks in total with 2 sessions per week
75911304|NCT02808819|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
75911305|NCT02808819|Biological|Benralizumab|Benralizumab administered subcutaneously every 8 weeks
75911306|NCT04879108|Other|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
76072705|NCT01808209|Device|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
75464689|NCT01880866|Drug|(-)-Epicatechin|A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
75464690|NCT01880879|Device|helios stent|the group with helios stent implanted
75464691|NCT01880905|Procedure|Measure of uteroovarian ligament length during gynecological surgery|
75464692|NCT01880931|Drug|Remifentanil|The effect site concentration of remifentanil
75464693|NCT01880944|Other|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
75771934|NCT03811444|Device|MediSafe Solo safety lancet|MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
75464694|NCT01880970|Other|starter infant formula with pro and prebiotics|
75464695|NCT01880970|Other|Placebo comparator|
75464696|NCT01880996|Other|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
75464697|NCT01881022|Behavioral|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
75464698|NCT01881035|Procedure|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
75771935|NCT02915614|Procedure|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
75771936|NCT03967652|Diagnostic Test|Nanomaterial-based sensors|Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
75771937|NCT01300078|Drug|MF101|MF101 10 g/day MF101 15 g/day
75771938|NCT03816280|Procedure|Elective cardiopulmonary bypass (CPB)|All groups undergo elective cardiopulmonary bypass (CPB)
75771939|NCT03816280|Procedure|Alpha-stat acid-base management|Acid-base status during CPB will be maintained using the alpha-stat regime
75771940|NCT03816280|Procedure|pH-stat acid-base management|Acid-base status during CPB will be maintained using the pH-stat regime
75771941|NCT05578690|Behavioral|Diet|An initial 8 weeks of low-calorie diet including meal replacements (total of 800 kcal/day) will be initiated with the objective to lose at least 10% of initial body weight. From week 8 until week 12, an individual food-reintroduction plan will take place with partial meal product substitution. At week 12 and until pregnancy dieticians will ensure sustained compliance with diet aligned with the general recommendations for women seeking pregnancy (low-fat diet, rich in protein and carbohydrates and in some individuals slightly carbohydrate-reduced diet (prediabetes or family disposition to diabetes) with focus on carbohydrate quality (more fiber and whole grain). Consultations with a dietician for mapping diet and eating patterns and regular follow-up with a dietitian to maintain diet changes and modify diets if needed.
75911307|NCT04879108|Other|Physiotherapy Rehabilitation|"Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
75464699|NCT01881074|Drug|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
75911308|NCT04884880|Drug|Luo-Fu-Shan Plaster|Luo-Fu-Shan Plaster 10g，once daily，4 weeks
75464700|NCT01881074|Drug|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
75911309|NCT04884880|Drug|The placebo 10g|Placebo 10g，once daily，4 weeks
75911310|NCT04872244|Device|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele for postmenstrual spotting and do not have desire for fertility
75911311|NCT04872244|Drug|Levonorgestrel Drug Implant Product|intrauterine administration
75911312|NCT04872322|Drug|Ropivacaine 0.5% Injectable Solution|Participants will receive the nerve block preoperatively using 0.5% ropivacaine
75464701|NCT01880710|Procedure|Subtotal hysterectomy|Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.
75464702|NCT01880710|Procedure|Total Hysterectomy|total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
75911313|NCT04872322|Drug|Ropivacaine 0.25% Injectable Solution|Participants will receive the nerve block preoperatively using 0.25% ropivacaine
75911314|NCT04872322|Drug|Percocet Pill|After surgery participants will be given a prescription for Percocet to be taken as needed for pain
75318959|NCT04002037|Drug|Dexamethasone 4 mg/ml|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
75318960|NCT03985384|Drug|Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Semaglutide 2 MG/1.5 ML Subcutaneous Solution
75318961|NCT03985384|Drug|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
75618421|NCT02626117|Device|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
75618422|NCT02810626|Device|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
75911315|NCT04872322|Drug|Norco Pill|After surgery participants will be given a prescription for Norco to be taken as needed for pain
75911316|NCT04872322|Procedure|Foot/Ankle Surgery|Participant will undergo foot or ankle surgery and receive a popliteal nerve block
75911317|NCT04879264|Diagnostic Test|self-rating scale for severity of sleep disorders|Participants report the severity of their sleep disorders on a self-rating scale form 0-10 (0=no sleep disorders, 10= maximum sleep disorders).
75911318|NCT04879264|Diagnostic Test|self-rating scale for distress caused by sleep disorders|Participants report their distress caused by sleep disorders on a self-rating scale form 0-10 (0=no distress, 10= maximum distress).
75911319|NCT04871932|Biological|Recently Vaccination|
75911320|NCT03048526|Device|NovaTears®|Topical eye drops for lubrication of the ocular surface
75318962|NCT03976245|Drug|Etanercept|injection
75318963|NCT03976245|Drug|tofacitinib|tablet
75318964|NCT03967704|Procedure|Life quality evaluation|As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss > 2 cm and/or pain.
75318965|NCT03929640|Drug|Acetaminophen|Acetaminophen 650 mg tablet every 6 hours
75318966|NCT03929640|Drug|Placebo|Placebo oral tablet every 6 hours
75911321|NCT03048526|Device|Hydrabak®|Eye drops
75911322|NCT04871620|Diagnostic Test|>15% SV increase during fluid challenge|The stroke volume will be measured before and after 15 minutes fluid challenge with crystalloids
75318967|NCT03929640|Drug|Ibuprofen|Ibuprofen 600 mg tablet every 6 hours
75318968|NCT03919370|Other|No intervention|there will be NO intervention
75911323|NCT04879186|Procedure|Peripheral endovascular angioplasty|Peripheral endovascular angioplasty - using endovascular techniques to treat peripheral artery occlusive lesions.
75911324|NCT04879030|Drug|Beta-Lactams|The patient was randomized to use beta-lactams antibiotic
75911325|NCT04879030|Drug|Fluoroquinolone|The patient was indicated to use a combination of beta-lactams and fluoroquinolones
75911326|NCT04871386|Behavioral|Acceptance and commitment therapy (ACT) exercises|The ACT group received 14 (partially succeeding) daily exercises, with each of the following categories being focused twice: Acceptance, contact with the present moment, cognitive defusion, self as context, personal values and committed action. The exercises consisted of metaphors and questions for self-reflection, explanations about emotions and thoughts with techniques to handle them differently, as well as a body scan.
75771942|NCT05578690|Behavioral|Exercise|After an initial 8-week ramp-up phase (during the initial low-calorie diet), the women will be encouraged to attend supervised exercise sessions on the study location (combination of vigorous-intensity, interval-based indoor cycling, and circuit training) twice weekly and to perform additional moderate-to vigorous-intensity exercise to obtain at least 150 min per week of moderate-intensity or 75 min per week of vigorous-intensity physical activity or a combination. The plan will include individual exercise and/or group exercise. Exercise watches with heart-rate monitors will be worn at each exercise session to determine whether the requirement regarding weekly time spent at moderate or vigorous intensity will be met. Regular follow-up with the women to maintain exercise changes and modify the exercise plan if needed.
75771943|NCT05578690|Behavioral|Mentorship|"Women are offered an individualized plan to successfully fulfil the multifactorial lifestyle intervention and the women will be offered both individual and/or group sessions with a mentor. After 8 weeks of the intervention, the women will be invited to another meeting where the choice of mentor will be evaluated, and the women will be offered to join a pre-parents-group. Group sessions will include conversational sessions, cooking classes and exercise classes with focus on changing lifestyle and maintaining a healthy lifestyle change. At the time of pregnancy groups will be reconsidered and the women will be offered participation in pregnancy-groups."
75911327|NCT04871386|Behavioral|Positive psychology (PP) exercises|The PP group received 14 daily exercises that were derived from positive psychology interventions that have been proven effective in alleviating clinical symptoms and increasing subjective well-being. In detail, these were: Identifying positive emotions and ways to increase them; Enhancing pleasure from daily activities; Writing a gratitude letter; Identifying and appreciating three personal traits; Receiving a letter of support from one's future self; Taking different perspectives on one's current situation; Envisioning a perfect day; Identifying energy boosters and drainers; Identifying 3 character strengths and using one in a new way; Life review: Writing a legacy; Identifying the positive relationships in one's life; Doing an act of kindness; Three good things; and Coping with failure.
75911328|NCT04878796|Diagnostic Test|Serum collection, adverse events collection|Measuring Abs variation at different timepoints compared to baseline. LIAISON SARS-Cov-2 TrimericS IgG and Elecsys anti-SARS-Cov-2 tests will be adopted. The level of Abs will be evaluated at baseline and 30(±7), 180(±7),365(±7)days after the 2nd dose of vaccine
75911329|NCT04870996|Device|tDCS|tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.
75318969|NCT03899090|Behavioral|Float pool|Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
75911330|NCT04870996|Behavioral|Cognitive Training|All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.
75911331|NCT04871230|Diagnostic Test|3G DBS|Collection of capillary blood samples for the 3G q-PCR test
75618423|NCT00875563|Device|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
75618424|NCT02810548|Procedure|OFD alone|Periodontal surgical cleaning procedure
75911332|NCT04871230|Diagnostic Test|Sputum Test|Collection of sputum for test culture, microscopy, GeneXpert
75911333|NCT04871230|Diagnostic Test|3G Veinous Blood|Collection liquid veinous blood for the 3G q-PCR test
75911334|NCT04582318|Biological|NGM621|NGM621 will be administered via IV infusion
75911335|NCT04582318|Biological|Placebo|Placebo will be administered via IV infusion
75318970|NCT03899090|Behavioral|Float chair|Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
75318971|NCT03887988|Procedure|"Primary early reconstruction"|Primary surgical reconstruction of the fracture within 3 weeks after injury
75318972|NCT03887988|Other|Nonsurgical|Nonsurgical treatment of fracture
75318973|NCT03887988|Procedure|"Primary delayed reconstruction"|Primary surgical reconstruction of the fracture more than 3 weeks after injury
75618425|NCT02810548|Drug|Platelet rich Fibrin|Natural platelet concentrate rich in growth factors
75618426|NCT02810548|Drug|Nanohydroxyapatite|Synthetic bone graft
75618427|NCT01155869|Drug|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
75618428|NCT01155869|Drug|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
75618429|NCT05635006|Other||No special intervention, randomly classify the subjects
75771944|NCT01300156|Drug|Oxaliplatin-based chemotherapy (ESHAOx)|"Etoposide 40 mg/m2, D1-4~Methylprednisolone 500mg, D1-5~Cytarabine 2 g/m2, D5~Oxaliplatin 130 mg/m2, D1"
75771945|NCT03811522|Other|carbon dioxide insufflation|Receives CO2 insufflation
75911336|NCT04878718|Biological|Fecal Microbiota Transplant; Vancomycin|Subject will be treated with vancomycin followed by fecal microbiota transplant
75618430|NCT02810470|Dietary Supplement|Fortimel Compact Protein|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
75911337|NCT03048916|Other|general swallowing therapy|including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
75618431|NCT02810470|Dietary Supplement|Fortimel Cream|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
76072706|NCT01808209|Device|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
75618432|NCT00690469|Other|Laboratory Biomarker Analysis|Correlative studies
75771946|NCT03811522|Other|Air insufflation|Receives air insufflation
75771947|NCT03811288|Other|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
75771948|NCT00126594|Drug|Sorafenib Tosylate|Given orally 400 mg orally (PO) every 12 hours
75771949|NCT00126594|Biological|Recombinant Interferon Alfa-2b|Given subcutaneously (SC) 0.5 million with +/- 5 % variance (0.475 MU - 0.525 MU); Dose level 0: 0.5 X 10^6 international units twice daily
75771950|NCT00126594|Other|Laboratory Biomarker Analysis|Correlative studies
75771951|NCT01080456|Drug|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
75771952|NCT03822052|Other|Lactated ringers|IV fluid
75618433|NCT00690469|Other|Questionnaire Administration|Ancillary studies
75618434|NCT02810314|Behavioral|neuropsychological battery|neuropsychological battery including cognitive and behavioural tests
75618435|NCT02810314|Other|resting state functional magnetic resonance image (rs-fMRI)|rs-fMRI
75618436|NCT02625493|Other|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
75618437|NCT02813590|Other|Ascitic fluid puncture|
75618438|NCT02813590|Other|Skin swaps from puncture side|
75618439|NCT02813590|Other|Stool samples|
75618440|NCT00690547|Other|muscle activation|activation of the muscle quadriceps femoris
75771953|NCT03822052|Other|5% dextrose lactated ringers|IV fluid
75771954|NCT03811054|Drug|Apatinib（250mg/d） combined with EGFR-TKI|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
75771955|NCT00126438|Drug|123I-mIBG (meta-iodobenzylguanidine)|Single Dose
75771956|NCT03821818|Behavioral|Food Allergy Elimination + Willis Exercise|Food Allergy Elimination + Willis Exercise (performing a 2-minute Aerobic-surge exercise > 75% max heart rate, 5/day)
75771957|NCT01075854|Drug|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
75771958|NCT03967392|Drug|Xylocaine|TREATMENT
75771959|NCT03821116|Other|Milk|Swedish milk from cow.
75771960|NCT03821116|Other|Soured milk (filmjölk)|Swedish soured milk (from cow milk).
75771961|NCT00142584|Drug|Nebivolol (NEB)|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
75771962|NCT00142584|Drug|Metoprolol (MET)|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
75771963|NCT04848064|Drug|Cyclophosphamide|Given IV
75771964|NCT04848064|Drug|Fludarabine|Given IV
75911338|NCT03048916|Other|NMES therapy|he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
75911339|NCT04878250|Drug|Bintrafusp alfa|4 doses of bintrafusp alfa (1200mg flat dose) administered intravenously at 14 day intervals before undergoing radical cystectomy.
75911340|NCT04877938|Behavioral|Echolgical physical activity Intervention|'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV).
75318974|NCT03887988|Procedure|Secondary reconstruction|Second surgical reconstruction of the fracture after a primary reconstruction.
75318975|NCT03883711|Other|Database|Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
75318976|NCT03876860|Device|Silicone Dilator|Addition of silicone band to standard vaginal dilator
75318977|NCT03876860|Device|Standard Dilator|Standard vaginal dilator
75318978|NCT03873545|Procedure|Cryopreserved Osteochondral Allograft|This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.
75771965|NCT04848064|Biological|Mogamulizumab|Given IV
75771966|NCT04848064|Biological|Natural Killer Cell Therapy|Given via infusion
75771967|NCT04848064|Other|Quality-of-Life Assessment|Ancillary studies
75464703|NCT01881100|Other|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
75771968|NCT04848064|Other|Questionnaire Administration|Ancillary studies
75771969|NCT00126126|Other|EBAR Program|Evidence Based Amputee Rehabilitation Program
75911341|NCT04877548|Other|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
75464704|NCT01881100|Other|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
75464705|NCT01881139|Behavioral|exercise training|
75464706|NCT01881152|Other|Educational campaign|Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
75771970|NCT03816046|Drug|botulinum toxin A|injection in hair bearing area of armpits
75911342|NCT04877548|Other|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
75618441|NCT02809924|Other|Simulation-based just-in-time training|Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
75618442|NCT02809924|Other|Video training|Video describing endotracheal intubation
75911343|NCT04877548|Other|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
75911344|NCT04878016|Biological|ZKAB001|Patients will receive ZKAB001 5mg/kg administered by IV infusion every 21days，
75618443|NCT00690625|Drug|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
75318979|NCT03872349|Other|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
75318980|NCT03872349|Other|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
75318981|NCT03852719|Drug|Bulevirtide|Administered via SC injections
75771971|NCT00125268|Device|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
75771972|NCT00125268|Device|Sham Device|The sham device is non-active but otherwise identical to the study device.
75771973|NCT03816124|Procedure|radiofrequency ablation|radiofrequency ablation of the genicular nerves
75318982|NCT03795493|Behavioral|Short-term diet and exercise intervention|Participants assigned to the intervention group will perform both the diet and acute exercise interventions. The interventions will be applied prior to up to six chemotherapy cycles of a consistent protocol. The total number of treatments of a given protocol received prior to treatment conclusion is dependent on patient condition and oncologic care preferences.
75318983|NCT03785145|Drug|MT10109L|MT10109L will be injected into the LCL.
75771974|NCT03815968|Other|low sodium diet|included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
75771975|NCT03964662|Device|WeReha|Rehabilitation of stroke patients with the device WeReha
75911345|NCT04878016|Drug|Placebo|Patients will receive placebo administered by IV infusion every 21days.
76072707|NCT05246332|Device|Grounding|The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.
76072708|NCT04585009|Drug|GSK3923868|GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
76072709|NCT04585009|Drug|Matching placebo|Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
75464707|NCT01881152|Other|Usual care|Information on stroke usually delivered at the community level.
75464708|NCT01881165|Drug|Cranberry|
75464709|NCT01881165|Drug|Placebo|
75464710|NCT01881178|Dietary Supplement|NOPALEA|
75464711|NCT01881191|Other|MRI|
75464712|NCT01881204|Dietary Supplement|Hesperidin and Calcilock|Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
75464713|NCT01881204|Dietary Supplement|Hesperidin|Hesperidin (552mg) will be administered in the form of cookies (biscuit).
75464714|NCT01881204|Dietary Supplement|Control|Cookies without Hesperidin or Calcilock added.
75464715|NCT01881217|Drug|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
75618444|NCT00690625|Drug|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
75618445|NCT02813512|Drug|ADSCs|Autologous ADSCs
75618446|NCT00687037|Drug|Cetylpyridinium chloride|
75618447|NCT02810002|Device|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
75618448|NCT02810002|Device|Control infantry boot|Training: infantry basic training in the control boots
75618449|NCT02625415|Device|Vitamin B6 cream|Topical Vitamin B6 cream
75618450|NCT02625415|Device|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
75618451|NCT02809768|Drug|Avatrombopag|
76072710|NCT04585009|Device|Monodose RS01|Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
75771976|NCT01080534|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
75771977|NCT01301560|Radiation|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
75771978|NCT01301560|Radiation|Observation|No local treatment
75911346|NCT04878016|Drug|Carboplatin|Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
75911347|NCT04878016|Drug|Etoposide|"Etoposide (100 mg/m^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy."
75911348|NCT04871152|Drug|OnabotulinumtoxinA|To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.
75911349|NCT02808429|Drug|Placebo|Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
75618452|NCT02809768|Drug|Fluconazole|
75618453|NCT02809768|Drug|Itraconazole|
75618454|NCT02809768|Drug|Rifampin|
75911350|NCT02808429|Drug|Atacicept 25 mg|Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
75911351|NCT02808429|Drug|Atacicept 75 mg|Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
75911352|NCT03047200|Biological|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
76072711|NCT05246176|Device|nephrostomy set|insertion of the nephrostomy set through the skin to obtaining good external drainage of bile in case of malignant obstructive jaundice.
75318984|NCT03785145|Drug|Placebo|Placebo will be injected into the LCL.
75618455|NCT02813278|Dietary Supplement|simo decoction|Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
76072712|NCT03698032|Dietary Supplement|Water|Participants will consume water only
75911353|NCT04870372|Drug|Selegiline|Subjects will receive one Selegiline tablet (5 mg) per day administered at breakfast. The initial dose of Selegiline is 5 mg/day and be up-titrated in 2-week intervals in increments of 5 mg up to 10 mg (which can be taken at breakfast or divided doses of 5 mg each taken at breakfast and lunch) according to the investigator's judgment, based on individual clinical response and tolerability.
75911354|NCT02048319|Drug|Pasireotide LAR 60 mg|Pasireotide long acting release, intramuscular injection
76072713|NCT03698032|Dietary Supplement|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
75318985|NCT03764969|Behavioral|standard smoking cessation program (SCP)|Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra & Buchkremer 2004), and will be carried out by a qualified therapist.
75318986|NCT03764969|Behavioral|Cognitive remediation treatment (CRT)|Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).
75464716|NCT01881282|Drug|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
75464717|NCT01881282|Drug|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
75464718|NCT01881295|Dietary Supplement|Placebo control|
75464719|NCT01881295|Dietary Supplement|Low dose potassium gluconate|
75464720|NCT01881295|Dietary Supplement|Medium dose potassium gluconate|
75464721|NCT01881295|Dietary Supplement|High dose potassium gluconate|
75464722|NCT01881295|Dietary Supplement|Low dose potato|
75464723|NCT01881295|Dietary Supplement|Medium dose potato|
75464724|NCT01881295|Dietary Supplement|High dose potato|
75464725|NCT01881295|Dietary Supplement|High dose French fries|
75464726|NCT01881295|Dietary Supplement|Basal diet control|
75464727|NCT01881321|Behavioral|Counseling Intervention|20-40 minute contraceptive counseling session based on the principles of motivational interviewing
75464728|NCT01881347|Dietary Supplement|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
75618456|NCT02813278|Other|gum chewing|Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra & Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
75618457|NCT04138849|Drug|BBT-877 single dose|Oral capsule, single dose.
75618458|NCT04138849|Drug|Placebo single dose|Oral capsule, single dose.
75618459|NCT00690703|Device|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
75618460|NCT04237090|Drug|Diphenhydramine|Drug identification number : 02369567
75618461|NCT04237090|Drug|Cetirizine|Drug identification number : 02231603
75618462|NCT04237090|Drug|Lactose pill|Natural product number : 00501190
75618463|NCT04237090|Drug|Sodium chloride 0.9%|Drug identification number : 00037796
75318987|NCT03764969|Behavioral|Implicit computer-based habit-modifying training (ICHT)|Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
75911355|NCT02048319|Procedure|Aspiration sclerotherapy|Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
75911356|NCT02048319|Drug|Placebo|Saline solution, injected as placebo
75318988|NCT03758326|Other|Body App|Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.
75464729|NCT01881347|Dietary Supplement|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
75464730|NCT01881360|Other|Gluten-free diet|A diet that is free of the gluten component
75618464|NCT00690781|Dietary Supplement|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
75771979|NCT03819946|Device|esophageal cooling device (Attune Medical, Chicago, IL)|The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.
75464731|NCT01881360|Other|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
75911357|NCT01594762|Drug|Topical pexiganan cream 0.8%|14 days of treatment
75464732|NCT01881386|Device|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
75911358|NCT01594762|Drug|Topical placebo cream|14 days of treatment
75911359|NCT01594762|Other|Standard wound care|14 days of treatment
75911360|NCT03561987|Procedure|Bariatric surgery|There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
75911361|NCT02048397|Other|Pulmonary Rehabilitation|
75911362|NCT02048397|Dietary Supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate|
76072714|NCT03698032|Dietary Supplement|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
75318989|NCT03756597|Device|ReCIVA|The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.
75318990|NCT03756597|Device|CASPER|Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line
75318991|NCT03743610|Other|Simulated altitude|Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
75464733|NCT01881399|Device|Fluorescence cholangiography (da Vinci surgical system)|Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
75464734|NCT01881399|Other|Virtual cholangiography|Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
75464735|NCT01881399|Procedure|Conventional IOC|Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
75464736|NCT01881464|Device|Endopath from Itamar medical - FDA approved device.|endothelial function assessment by Endopath device
75464737|NCT01881464|Drug|Anti TNF Alfa.|This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
75464738|NCT01881477|Procedure|kinetics modalities|"The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.~The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.~Additionally, it promotes the adoption and sitting positions long and short legged and walk."
75464739|NCT01881490|Device|MRE|Developing the Pediatric Crohn's Disease Intestinal Damage Score (pMEDIC score) and the Pediatric MRE-Based Activity Index (PICMI)
75464740|NCT01881503|Biological|HBOC-201|HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
75618465|NCT00690781|Dietary Supplement|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
75911363|NCT03935308|Radiation|MR guided Linear Accelerator|The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
75911364|NCT02048475|Other|desflurane|changing concentration
75464741|NCT01881516|Device|acupuncture|once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
75911365|NCT02048553|Device|Tablet-guided ventriculostomy|"In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand )."
75464742|NCT01881516|Device|sham acupuncture|the same acupoints and time as in acupuncture arm, but use a Park Sham Device
75464743|NCT01881555|Procedure|invasive coronary angiography|
75911366|NCT02048553|Procedure|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
75464744|NCT01881555|Procedure|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
75464745|NCT01881568|Drug|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
75911367|NCT03046888|Procedure|Robot assisted pyelolithotomy|A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
75911368|NCT03046498|Behavioral|Evidence-Based Program|DSMP and DPP
75318992|NCT03743610|Other|Placebo simulated altitude|Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
75911369|NCT03046576|Diagnostic Test|plasma DPP4 activity|DPP4a was determined by enzymatic assays.
75771980|NCT03819946|Other|Standard esophageal temperature probe|If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
75911370|NCT03049384|Other|Traditional Exercise|The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
75911371|NCT03049384|Other|Tailored Exercise|The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
75911372|NCT03561909|Other|Platelet transfusion|Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.
75911373|NCT03562143|Dietary Supplement|Ferrous Sulfate|Patients will take iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) on alternate day for 6 weeks.
75911374|NCT03562143|Dietary Supplement|Ferrous Sulfate|Patients will take iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) daily for 6 weeks.
75318993|NCT03740256|Biological|CAdVEC|The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells. Testing each element separately would not be beneficial or informative, since the combination therapy is anticipated to have unique profiles of both therapeutic benefit and potential toxicities.
75464746|NCT01881568|Drug|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
75464747|NCT01881581|Biological|Saline Solution|Saline Solution is used as control in all arms.
75464748|NCT01881581|Biological|D-GPEi|D-GPEi is used in Arm A,B,C,G and H.
75464749|NCT01881581|Biological|M-GPE|M-GPE is used in Arm D,E,F,G and H
75464750|NCT01881594|Procedure|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
75464751|NCT01881607|Behavioral|RESPIRNET Program|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
75464752|NCT01881633|Drug|ISU302|
75318994|NCT03724175|Drug|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks for UC pouchitis patients
75318995|NCT03709459|Drug|Doxycycline|Participants will be asked to take Doxycycline 100mg/day for 12months duration
75771981|NCT05623384|Procedure|Stellate ganglion block|A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）
75911375|NCT03049228|Diagnostic Test|31P-MRS scan and cardiac MRI scan|"31P-MRS measurement of the heart: Phosphorous magnetic resonance spectroscopy (31P-MRS) will be used for the determination of the energy status of the heart in vivo. The localization of phosphorus energy metabolites in the heart will be performed by one-dimensional spectroscopic imaging, resulting in spectra from slices through the heart of 1 cm thickness. The peaks of PCr and ATP will be fitted in order to calculate the ATP/PCr ratio.~The measurement of cardiac function is a standardised protocol. In the 4 chamber view setting a T1 mapping sequence will be performed for the detection of fibrosis. Hereafter patients will receive contrast for T2 mapping and late enhancement studies for determining extracellular volume and ischemia."
75911376|NCT03049228|Diagnostic Test|Atrial biopsy for high-resolution respirometry|Mitochondrial respiration rates are ex vivo measured in tissue homogenates under exposure of different substrates, stimulating different complexes of the electron transport chain of the mitochondria.
75771982|NCT05623384|Procedure|Facial and glossopharyngeal nerve blocks|The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. （mecobalamin injection 1mg；lidocaine 20mg； dexamethasone 10mg ；Physiological saline 2ml）
75771983|NCT05623384|Drug|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
75911377|NCT03049228|Diagnostic Test|Blood analysis|To determine blood glucose metabolism and renal function.
75911378|NCT03049228|Diagnostic Test|Body composition|This device uses air displacement plethysmography for determining percent fat and fat-free mass in adults and children. The 5-minute test consists of measuring the subject's mass (weight) using a very accurate electronic scale, and volume, which is determined by sitting inside the BOD POD chamber. From these two measurements, the subject's body composition is calculated.
75911379|NCT03049228|Diagnostic Test|Indirect Calorimetry|As basal energy metabolism might be related to cardiac metabolism and mitochondrial function, and basal metabolic rate shows inter-individual variance, it is an important subject characteristic of the patients. Resting substrate oxidation rates are measured with indirect calorimetry for 30 minutes. A ventilated hood is connected to indirect calorimetry equipment, which measures concentrations of oxygen consumption and CO2 production. From these parameters, the respiratory quotient (RQ), as well as energy expenditure and substrate metabolism will be computed. During this measurement, every 10 minutes (so 4 times) one tube of blood (10ml) will be drawn for the analysis of lipid and glucose metabolites.
75911380|NCT02615470|Behavioral|Enhanced immunization delivery model|Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
75911381|NCT02615470|Other|Immunization update|Basic immunization update online webinar will summarize changes in immunization schedules.
75911382|NCT05674227|Procedure|Robotic surgery|Surgical treatment of operable lung cancers using robotic systems
75911383|NCT05674227|Procedure|Video-assisted thoracoscopy|Surgical treatment of operable lung cancers using a video-assisted thoracoscopy approach (VAT)
75911384|NCT05674227|Procedure|Open surgery|Surgical treatment of operable lung cancers using open surgery
75911385|NCT03046654|Diagnostic Test|Trans vaginal sonography|Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os'.
75911386|NCT03046654|Diagnostic Test|Vaginal examination|Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.
75771984|NCT00125190|Drug|rhIGF-1 (mecasermin) for a period of 86 weeks|Once a day rhIGF-1 injections
75911387|NCT03046654|Diagnostic Test|Speculum examination|Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
75911388|NCT02048709|Drug|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
75911389|NCT03048448|Drug|Fevipiprant|Single 450mg dose
75911390|NCT02050815|Drug|MEK162|
75911391|NCT02048787|Drug|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
75318996|NCT03690986|Biological|VX15/2503|Given IV
75911392|NCT04374448|Procedure|Sinonasal Benign or Malignant Tumor Resection|During sinus tumor resection, margins will initially be estimated with the naked eye. Then the dye, Indocyanine Green (ICG), will be injected through the intravenous line to identify tumor margins and be compared to estimated margins.
75318997|NCT03690986|Biological|Ipilimumab|Given IV
75318998|NCT03690986|Biological|Nivolumab|Given IV
75464753|NCT01881633|Drug|Placebo|
75464754|NCT01881646|Radiation|Positron emission tomography (PET) using [11C]PBR28|
75464755|NCT01881698|Other|Platelet function during pregnancy Multiple Electrode Aggregometry (Multiplate@) device|Observation of platelet function in pregnancy
75911393|NCT04374448|Procedure|Skull Base Surgery (Assessment of Nasoseptal Flap)|In this surgery, a piece of individuals septum will be used for the reconstruction. The amount of time for the flap to fluoresce Indocyanine Green (ICG) will be measured. It will be ensured that the it is still lighting up at the end of the surgery, indicating it is still receiving a good supply and ensures longevity of the flap.
75771985|NCT03810820|Device|mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)|A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
75911394|NCT04374448|Procedure|Endoscopic Sinus Surgery|During the surgery, the timing of Indocyanine Green (ICG) administration to fluorescence of anterior and posterior ethmoidal artery and of the internal carotid artery will be measured.
75618466|NCT00690781|Dietary Supplement|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
75464756|NCT01881711|Device|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
75618467|NCT00690781|Dietary Supplement|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
75464757|NCT01881711|Device|Imaging|Imaging of ventricle size
75618468|NCT04187794|Other|Interview patient|to investigate an association between literacy level and medication adherence in patients with rheumatic diseases.
75618469|NCT00682669|Behavioral|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
75618470|NCT00682669|Behavioral|HLC|An 8-week program consisting of lectures and discussion of health-related topics.
75464758|NCT01881724|Behavioral|Sleep education|
75618471|NCT05631184|Behavioral|Self-administered acupressure group|Self-administered acupressure treatment group was developed on the basis of previous systematic reviews and clinical studies of acupuncture and acupressure for depression. It has robust theoretical basis of TCM. The acupoints selected are commonly used for depression according to a recent systematic review and recommended by other clinical practice guidelines.
75771986|NCT03810664|Drug|Somatrogon|A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).
75771987|NCT03810586|Device|Non-invasive measurement of blood pressure|Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
75771988|NCT00141726|Drug|Etanercept|Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
75771989|NCT03967548|Drug|Germinal peptide eye drops|Germinal peptide eye drops of 0.004%
75771990|NCT03819868|Procedure|High cost|Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
75911395|NCT04374448|Procedure|Posterior Epistaxis Management (SPA Ligation)|During surgery timing of Indocyanin Green (ICG) administration to fluorescence of the sphenopalatine artery will be measured.
75911396|NCT02048865|Drug|Apixaban|Apixaban 2.5 mg tablets BID for 6 months
75911397|NCT02048865|Drug|Placebo drug|placebo drug 2.5mg BID for 6 months
75911398|NCT03663946|Other|Non-Interventional|Non-Interventional
75911399|NCT02048943|Drug|dovitinib lactate|Given PO
75618472|NCT05631184|Behavioral|Mental health education group|Mental health education training group was developed based on the materials regarding depression and mental health from the Centre of Health Protection, Department of Health, the Government of Hong Kong SAR and reviewed by a clinical psychologist.
75911400|NCT02048943|Drug|gemcitabine hydrochloride|Given IV
75911401|NCT02048943|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
75911402|NCT02048943|Other|pharmacological study|Correlative studies
75911403|NCT02048943|Other|laboratory biomarker analysis|Correlative studies
75464759|NCT01881815|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
75464760|NCT01881841|Behavioral|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
75464761|NCT01881880|Device|Bilateral mammography with Tomosynthesis|no intervention pre specified to be administered to participants
75464762|NCT01881893|Behavioral|ACHD-CARE Program|The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
75464763|NCT01881906|Other|Usual care|
75464764|NCT01881906|Other|Exercise|
75464765|NCT01881919|Dietary Supplement|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
75911404|NCT02049021|Device|MECTA SPECTRUM 5000Q ECT|
75911405|NCT02049021|Procedure|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
75911406|NCT04430296|Procedure|Cyclophotocoagulation|"High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU): parameters: 21 MHz frequency, 2.45 W acoustic power, with the activation of each transducer lasting 6 seconds MicroPulse cyclophotocoagulation (MP-CPC):Laser settings of 2 Watts (W) will be applied for a 90 seconds treatment time for each 180 degrees, with a duty cycle of 31.3%, which consists of 0.5ms on time and 1.1 ms off-time and delivering a total of 112,7 Joules Continuous Wave cyclophotocoagulation (CW-CPC): The laser settings used will be 1.250 W, 4s exposure time per burn, 22-24 burns per eye."
75318999|NCT03665909|Other|Remote activity monitoring system|The home-based sensor technology of eNeighbor relies on multiple, non-invasive and safe remote monitors (up to 6 sensors) that can alert family caregivers and/or health professionals to potentially negative situations that lead to adverse outcomes (e.g., wandering, falls, incomplete activity of daily living tasks). The technology platform of eNeighbor relies on wireless infrastructure that allows for remote monitoring via alerts that are communicated to the family caregiver's or nurse care manager's personal computers or handheld devices. The Alerts that are generated from the sensors detected abnormal motion or activity are sent to the family caregiver as well as a nurse care manager that monitors the real-time information generated by the eNeighbor sensors.
75319000|NCT03623100|Behavioral|Speech Production Treatment.|Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.
75771991|NCT03819868|Procedure|Low Cost|Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
75319001|NCT03623100|Behavioral|Speech Production + Speech Perception Treatment.|This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
75319002|NCT03616184|Drug|Ruxolitinib|Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.
75319003|NCT03615690|Other|Fasting Mimicking Diet|5 day reduced calorie diet
75771992|NCT01301716|Drug|GDC-0980|Oral escalating dose
75771993|NCT01301716|Drug|bevacizumab|Intravenous repeating dose
75771994|NCT01301716|Drug|carboplatin|Intravenous repeating dose
75771995|NCT01301716|Drug|cisplatin|intravenous repeating dose
75911407|NCT02050893|Drug|sedatives(Midazolam and Propofol)|
75319004|NCT03615690|Other|Regular Diet|Regular Diet
75464766|NCT01881919|Dietary Supplement|Control|Address: Fagron GmbH&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
75464767|NCT01881945|Other|Non-invasive physiological signal recording on healthy volunteer|
75464768|NCT01881958|Drug|DiaPep277®|
75464769|NCT01881971|Drug|Placebo|suger pill manufactured to mimic crestor pills
75464770|NCT01881971|Drug|Rouvastatin calcium|
75464771|NCT01881997|Drug|Fentanyl|Fentanyl Intramuscular (IM), 1ugm/kg, x1
75771996|NCT01301716|Drug|paclitaxel|Intravenous repeating dose
75771997|NCT01301716|Drug|pemetrexed|intravenous repeating dose
75464772|NCT01881997|Drug|Normal Saline|IM normal saline
75464773|NCT01882010|Drug|sargramostim|"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"
75464774|NCT01882010|Drug|placebo|saline solution daily subcutaneous injection 56 days
75771998|NCT01075932|Dietary Supplement|DHA-rich fish oil|Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
75771999|NCT01075932|Dietary Supplement|Placebo|2 g placebo (olive oil) taken daily for 12 weeks
75772000|NCT01303042|Drug|Insulin lispro mix 50/50|Insulin lispro mix 50/50 t.i.d : six months
75772001|NCT03810430|Behavioral|health promotion|health promotion on water, sanitation and hygiene and child feeding along with hygiene kits were delivered to the mothers in the intervention arm
75772002|NCT03810118|Diagnostic Test|fluid challenge|4 ml/kg fluid challenge infused over in either 10 or 20 minutes
75772003|NCT01300312|Drug|Eperisone hydrochloride and Diclofenac sodium|Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
75772004|NCT01300312|Drug|Eperisone hydrochloride|eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
75911408|NCT02050971|Biological|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
75911409|NCT02050971|Biological|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
75772005|NCT01567384|Drug|OSI-906 and Pemetrexed|"Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1."
75911410|NCT05257330|Diagnostic Test|CSF Examination|Lumbar puncture for CSF Examination
75464775|NCT01882010|Diagnostic Test|Sham Comparator: Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
75464776|NCT01882049|Device|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
75618473|NCT00682747|Drug|Hyperbaric oxygen|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
75618474|NCT00682825|Behavioral|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
75772006|NCT00111228|Device|Guardian RT|
75464777|NCT01882075|Drug|Open loop|
75772007|NCT00111228|Device|SMBG only|SMBG only
75464778|NCT01882075|Device|Closed-loop|
75464779|NCT01882101|Procedure|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
75772008|NCT04742842|Biological|COVIGEN C19 0.8 mg ID or Placebo ID|2 doses of COVIGEN C19 0.8 mg ID or Placebo ID will be given at Day 1 and Day 29.
75772009|NCT04742842|Biological|COVIGEN C19 2.0 mg IM or Placebo IM|2 doses of COVIGEN C19 2.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
75772010|NCT04742842|Biological|COVIGEN C19 4.0 mg IM or Placebo IM|2 doses of COVIGEN C19 4.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
75464780|NCT01882101|Procedure|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
75464781|NCT01882127|Drug|All-Trans Retinoid Acid(ATRA)|patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
75464782|NCT01882127|Drug|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
75464783|NCT01882140|Other|Electrical Stimulation by Capacitive Field|
75618475|NCT00682825|Behavioral|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
75772011|NCT04742842|Biological|COVIGEN C20 1.0mg vaccine ID|COVIGEN C20 1.0mg ID vaccine will be given at Day 1
75772012|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
75772013|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
75772014|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
75772015|NCT01080612|Drug|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
75772016|NCT03810274|Device|3DV+TPS；VARIAN TPS；FonicsPlan|
75772017|NCT03810040|Device|140 microns denuding pipette|the degranulated needle size was 140 microns
75772018|NCT03810040|Device|150 microns denuding pipette|the degranulated needle size was 150 microns
75772019|NCT01301794|Dietary Supplement|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
75772020|NCT03819790|Drug|Basal insulin glargine and lixisenatide|Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)
75772021|NCT03819790|Drug|Basal insulin Basaglar/Lantus + gliclazide MR|basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD
75772022|NCT03819790|Drug|Metformin|Patients can be administered with most tolerant dose of metformin
75772023|NCT01301872|Other|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
75772024|NCT01560364|Other|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
75772025|NCT01560442|Drug|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
75772026|NCT05623150|Diagnostic Test|Liver biopsy|Liver biopsy planned as part of routine care. Clinical-biological characterisation with bio collections.
75772027|NCT03807934|Other|Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems|Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
75772028|NCT01300468|Drug|PHA-848125AC|
75464784|NCT01882140|Other|Electrical Stimulation by Capacitive Field Placebo Sham|
75464785|NCT01882166|Drug|fostimon|
75464786|NCT01882166|Drug|puregon|
75464787|NCT01882179|Drug|Mineralocorticoid receptor antagonist potassium-canrenoate|
75464788|NCT01882179|Drug|placebo|
75618476|NCT02809612|Behavioral|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
75618477|NCT00682903|Device|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
75618478|NCT00912379|Biological|hemoglobin determination|laboratory and non invasive hemoglobin determinations
75464789|NCT01882192|Behavioral|Family physical activity planning|"This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting."
75319005|NCT03610451|Behavioral|Floatation-REST plus usual care|Individuals will receive Floatation-REST plus usual care. Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms are lightproof and soundproof. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin.
75319006|NCT03610451|Behavioral|Usual care|Individuals will receive usual care on the inpatient unit of the Laureate Eating Disorders Program.
75319007|NCT03608059|Drug|ATG/PTCy|low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
75911411|NCT03551782|Drug|Cetrelimab 480 mg|Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
75772029|NCT01303120|Drug|Femoral Nerve Block|Preoperative Bupivacaine 0.5%, perineurally as single shot
75772030|NCT01303120|Drug|Combined nerve blocks|Preoperative Bupivacaine 0.5%, perineurally as single shot
75464790|NCT01882205|Device|Virtual chromoendoscopy|
75464791|NCT01882205|Procedure|Chromoendoscopy|Panchromocolonoscopy with methyleen blue 0.1%
75464792|NCT01882218|Drug|Galactose|After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
75464793|NCT01882218|Drug|Standard Treatment|Standard liver surgery.
75618479|NCT02809378|Drug|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
75618480|NCT02809378|Drug|sevoflurane|Inhalational anesthetics Halogenated.
75618481|NCT02809378|Drug|remifentanil|ultra-short acting opioid anesthetics
75772031|NCT01303120|Drug|Patient-controlled analgesia|Patient controlled analgesia with morphine
75772032|NCT00110994|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21
75618482|NCT02809378|Drug|pentothal sodium|intra-venous anesthetics for anesthesia induction
75772033|NCT00110994|Drug|Placebo|Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
75772034|NCT00110994|Drug|Dacarbazine|Dacarbazine, 1000 mg/m^2 intravenous on Study Day 1
75772035|NCT01078194|Device|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
75772036|NCT04435990|Biological|10,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL
75618483|NCT02809378|Drug|propofol|intra-venous anesthetics for anesthesia induction and maintenance
75618484|NCT00683059|Drug|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
75618485|NCT02813122|Device|x-ray|x-ray for the detection of leaks and bleeding
75618486|NCT01185353|Drug|LY3009104|Administered orally
75618487|NCT01185353|Drug|Placebo|Administered orally
75618488|NCT01185353|Drug|Methotrexate|Administered orally as background therapy
75618489|NCT02809300|Biological|blood collection|
75618490|NCT04237402|Other|Hair follicles sampling|The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
75772037|NCT04435990|Biological|30,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL
75772038|NCT04435990|Biological|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
75911412|NCT03551782|Drug|Apalutamide 240 mg|Apalutamide 240 mg (4*60 mg) tablets per day will be administered orally.
75911413|NCT02806947|Drug|Sirolimus|Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
75319008|NCT03608059|Drug|standard ATG|in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
75464794|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
75618491|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
75618492|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
75618493|NCT00683137|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
75618494|NCT02809456|Drug|Nicorandil|oral intake
75911414|NCT02806947|Drug|Prednisone|Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
75911415|NCT03046732|Other|"Implementing Explore Transplant Education"|"The Explore Transplant Ontario (ETO) education program"
75772039|NCT01560052|Drug|methylprednisolone|"Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
75772040|NCT01560052|Drug|Placebo|"Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
75772041|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
75772042|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
75618495|NCT05576740|Procedure|Determination of hormone level concentrations|Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.
75772043|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
75772044|NCT05515588|Drug|BI 690517 (C-14)|BI 690517 (C-14)
75772045|NCT05515588|Drug|BI 690517|BI 690517
75772046|NCT01303198|Device|APAP - Therapy|automatic positive pressure therapy
75772047|NCT01303354|Procedure|Lumbar Transforaminal Epidural Steroid Injection|
75772048|NCT03804970|Behavioral|cash rewards for the fellow up|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
75772049|NCT03804970|Behavioral|Showing retinal photos to participants|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
75464795|NCT01882244|Behavioral|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
75618496|NCT05576740|Procedure|Jump height determination|by Chronojump contact mat, determine five types of jump in centimeters: Squat jump without additional weight, Squat jump with 50% of body weight, Countermovement jump, Abalakov jump, and Drop jump, during the early follicular phase, late follicular phase, and mid-luteal phase.
75772050|NCT03804970|Behavioral|SMS reminders for participants and their family|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
75772051|NCT03804970|Behavioral|Watching brief video and basic explanation for disease|This basic explanation will be offered by professional doctors or nurses.
75772052|NCT03804970|Behavioral|Having the Diabetic Club|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
75772053|NCT05622994|Drug|Rimonabant|Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
75911416|NCT03442114|Behavioral|Hydroxyurea SDM Toolkit|Implementation tools and visit decision aids
75319009|NCT03608059|Drug|standard PTCy|post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell
75319010|NCT03597581|Drug|RGX-202-01|RGX-202-01 is a small molecule inhibitor of the creatine transporter, SLC6a8.
75618497|NCT05576740|Procedure|Grip strength determination|measuring of changes in muscle strength by handgrip dynamometer in the hand to be tested (handgrip test) during the early follicular phase, late follicular phase, and mid-luteal phase. Three attempts on each hand.
75319011|NCT03597581|Drug|FOLFIRI|FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
75319012|NCT03597581|Drug|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor.
75464796|NCT01882244|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
75772054|NCT01303432|Dietary Supplement|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
75464797|NCT01882283|Dietary Supplement|Tea Treatment Group|This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms
75772055|NCT01303432|Dietary Supplement|Yogurt|One yogurt (125mL) per day
75464798|NCT01882283|Dietary Supplement|Placebo|
75618498|NCT05576740|Procedure|Flexibility determination|measurement of changes in the range of motion of the hamstring musculature, by sit and reach test (cm), during the early follicular phase, late follicular phase, and mid-luteal phase. Three tries.
75772056|NCT05622916|Drug|Topical Ethanol Extract (Piper crocatum)|Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section
75772057|NCT05622916|Drug|Trichloroacetic Acid Topical|Trichloroacetic acid topical 90%
75911417|NCT03442114|Behavioral|Clinician Pocket Guide|current hydroxyurea protocol and ASH pocket guide
75911418|NCT03562065|Biological|mesenchymal stem cells|"Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~1.10^6 CSM / kg~2.10^6 CSM / kg~4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
76072715|NCT05246020|Procedure|HIPEC|Docetaxel (60-75mg/m2) perfusion solution will be infused into the peritoneal cavity through the tubes within 24 hours after the laparoscopic evaluation. Then, perfusate containing cisplatin (75 mg/m2) will be infused 24 hours later. NHIPEC will be administered at 43°C for a duration of 60min. Saline solution (3000mL) will be used to dissolve the drug, and it will be heated and circulated at a flow rate of 300-500 mL/min.
75772058|NCT03815032|Device|Drift assessment of OptoWire Deux FFR wire (1)|Simultaneous data of two different OptoWire DeuxTM guidewires (group 1) to assess a single coronary stenosis and detect any difference if any.
75772059|NCT03815032|Device|Drift assessment of OptoWire Deux FFR wire (2)|Simultaneous data of one Optowire Deux TM guide wires and one VERRATA-TM FFR wire (group 2) to assess a single coronary stenosis and detect any difference if any.
75772060|NCT04285606|Behavioral|Patient-led rehab with short immobilization|Short immobilization followed by patient-led shoulder rehab
75464799|NCT01882296|Drug|AGSPT_10|AGSPT 10mg for 7days administration
75464800|NCT01882296|Drug|AGSPT_20|AGSPT 20mg for 7days administration
75464801|NCT01882296|Drug|AGSPT_40|AGSPT 20mg x 2tablet for 7days administration
75618499|NCT05576740|Procedure|Indirect maximum oxygen consumption determination|by the Course Navette test, the indirect oxygen consumption is calculated using the formula: VO2max = (6xFA) - 27,4 (FA = Speed of the last stage of the test completed. It takes place during the early follicular phase, late follicular phase, and mid-luteal phase.
75618500|NCT05576740|Device|Sensory and pain threshold determination|by electrical muscle stimulator (Digitimer DS7A), during the early follicular phase, late follicular phase, and mid-luteal phase.
75618501|NCT05576740|Other|Physical and mental symptoms associated with the menstrual cycle|By The Daily Record of Severity of Problems (DRSP) questionnaire, during a full menstrual cycle.
75772061|NCT03819556|Other|Milk protein in fresh milk|Milk protein in increasing doses.
75772062|NCT03804034|Device|Block of resin|
75772063|NCT03804034|Device|Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire|
75772064|NCT03819244|Device|940 nm Gallium Aluminum Arsenide Diode Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.
75772065|NCT03819244|Device|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
75772066|NCT01303588|Behavioral|Yoga|24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months
75772067|NCT01303588|Behavioral|Qigong|12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
75772068|NCT01303666|Procedure|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
75772069|NCT01303666|Procedure|TI of the knee|"This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles."
75772070|NCT03819166|Device|with deep touch pressure application|The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.
75772071|NCT03819166|Device|without deep touch pressure application|The deep touch pressure will not be applied.
75464802|NCT01882296|Drug|Pantoprazole_20|Pantoprazole 20mg for 7days administration
75464803|NCT01882296|Drug|Pantoprazole_40|Pantoprazole 40mg for 7days administration
75464804|NCT01882322|Drug|Prograf|oral
75464805|NCT01882322|Drug|Advagraf|oral
75464806|NCT01882335|Behavioral|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
75464807|NCT01882348|Behavioral|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)-including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
75911419|NCT04870684|Other|thromboelastometry test|This study does not modify the usual care of the patient. Only 5 citrated tubes (maximum 15 mL of blood) are collected in addition to the initial emergency department sample (routine care). The patient's care follows the classic thrombolysis alert pathway. There is no additional complementary examination or additional neurological evaluation. Clot formation kinetics will be evaluated by thromboelastometry to determine the predictive parameters of revascularization. Clot formation and lysis parameters as well as revascularization according to thrombo-inflammation processes will be studied.
75911420|NCT02037399|Drug|intravenous dexamethasone|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
75464808|NCT01882361|Drug|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
75464809|NCT01882361|Drug|placebo comparator|this placebo has no specific pharmacological activity
75464810|NCT01882374|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
75911421|NCT02037399|Drug|intravenous normal saline|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
75464811|NCT01882387|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
75319013|NCT03574610|Device|Transcranial Rotating Permanent Magnet Stimulator (TRPMS)|"TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller."
75319014|NCT03569085|Drug|Sevoflurane|The patient will receive Sevoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
75772072|NCT01304446|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
75618502|NCT05576740|Device|Daily activity|by accelerometer (GENEActiv) during a full menstrual cylcle: Wrist-worn device measuring accelerations as a measure of daily activity, in cpm, counts per minute.
75319015|NCT03569085|Drug|Isoflurane|The patient will receive isoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
75464812|NCT01882400|Drug|Bisphosphonate treatment|Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
75464813|NCT01882426|Other|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
75464814|NCT01882426|Other|Usual Care|usual step care practice
75464815|NCT01882452|Behavioral|Memory Specificity Training|This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
75618503|NCT05576740|Procedure|Biochemical parameters determination|Determination of concentration of iron (μg/dL), ferritin (ng/mL), and transferrin (mg/dL), during the early follicular phase, late follicular phase, and mid-luteal phase.
75618504|NCT05576740|Procedure|Blood count determination|Determination of concentration of hemoglobin (g/dL), red blood cells (10^6/μL), hematocrit (%), white blood cells (10^3/μl), platelets (10^3/μl), during the early follicular phase, late follicular phase, and mid-luteal phase.
75319016|NCT03528044|Procedure|Bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
75319017|NCT03500744|Procedure|Erector spinae plane block|Ropivacaine 0.5% 20 mL at each site of ESPB
75911422|NCT03561753|Drug|Group A (the standard 2HRZE/4HR regimen）|The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
75911423|NCT03561753|Drug|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
75911424|NCT02260089|Drug|Low dose of telmisartan|
75911425|NCT02260089|Drug|High dose of telmisartan|
75911426|NCT02260089|Drug|Placebo|
75618505|NCT05576740|Procedure|Body composition parameters determination|Determination of weight (kg), total body water (L), proteins (kg), minerals (kg), body fat mass (kg), body mass index (BMI) (kg/m2), basal metabolic rate (kcal) by Bioelectrical Impedance Analysis, during the early follicular phase, late follicular phase, and mid-luteal phase.
75772073|NCT03801460|Other|Remotely administered physiological reconditioning program|Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
75911427|NCT03805815|Device|tunable crack sensor|blood pressure monitoring via crack sensor
75319018|NCT03500744|Procedure|Sham block|Skin infiltration only
75772074|NCT04246762|Drug|Olokizumab|Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
75772075|NCT04246762|Drug|Omeprazole|Tablets, 20 mg, oral
75772076|NCT04246762|Drug|Caffeine|Tablets, 100 mg, oral
75911428|NCT02049255|Drug|Chloroprocaine|"The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia"
75911429|NCT02049255|Drug|Marcaine|"The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia"
75911430|NCT02049333|Procedure|Phacoemulsification|
75319019|NCT03483753|Drug|Vasopressin|"Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement.~Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min"
75319020|NCT03483753|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.
75319021|NCT03452891|Other|Methylcellulose|Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
75319022|NCT03452891|Drug|Simvastatin-Methylcellulose|Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
75618506|NCT05576740|Procedure|Vital signs|Determination of blood pressure (mmHg) and heart rate (bpm) at baseline, one minute and three minutes after the Course Navette test
75618507|NCT05576740|Other|Checking for correct use of contraceptive methods|Pre-test questions about possible forgetfulness or mishandling of the method
75772077|NCT04246762|Drug|Warfarin+ Vitamin K|Warfarin -Tablets 10 mg, oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule
75772078|NCT04246762|Drug|Midazolam|Syrup, 2 mg/mL, oral
75618508|NCT05576740|Procedure|Urinary LH determination|Urine LH test strips are performed from day 8 of the cycle until positive.
75772079|NCT03796624|Device|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted"
75772080|NCT03796624|Device|PODEYE|"Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3."
75911431|NCT02049333|Procedure|Endoscopic Cycloplasty (ECPL)|
75911432|NCT02806713|Drug|Phenazopyridine|
75911433|NCT02806713|Other|no Phenazopyridine|Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided
75911434|NCT02037711|Drug|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
75911435|NCT02037711|Drug|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
75911436|NCT03561675|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
75911437|NCT03561675|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
75911438|NCT02049411|Drug|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
75911439|NCT02049411|Drug|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
75911440|NCT02807493|Device|Occlusal Support Device|Bite plate
75911441|NCT02807493|Other|Control|Control group
75911442|NCT02051127|Other|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
75618509|NCT04139473|Procedure|Hepaticojejunostomy / Duct-to-duct anastomosis|
75772081|NCT03799978|Drug|ACT-541468|ACT-541468 50 mg film-coated tablets
75772082|NCT03799510|Biological|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
75772083|NCT03799510|Drug|GLA-SE solution|The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.
75911443|NCT02049489|Biological|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
75911444|NCT02051751|Drug|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
75911445|NCT02051751|Drug|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
75772084|NCT03799120|Drug|Tamsulosin BID|comparison of once daily versus twice daily tamsulosin
75464816|NCT01882452|Behavioral|Education and Support|The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
75772085|NCT03799120|Other|Placebo|Placebo
75772086|NCT03796312|Behavioral|Tub Bathing|The infant's face was washed and dried while still wrapped before being immersed. The water level in the tub was set at approximately 9-12 cm or deep enough to cover the baby's shoulders. A folded cloth towel was placed into the tub before bathing. The temperature of the bath water was controlled using a special water thermometer and adjusted to 37-38°C. The infant was held securely; the head and neck were supported on the researcher's forearm, and the shoulder was grasped using the researcher's thumb and finger. Cleaning was performed using a soft cloth and baby skin cleaner. The front and back areas were cleaned without turning the infant. The newborn was safely removed from the water and wrapped in a clean towel.
75772087|NCT03796312|Behavioral|Sponge Bathing|Sponge bathing is routine care of the clinic
75772088|NCT03792724|Drug|Urelumab + Nivolumab|Treatment with intratumoral urelumab after which Nivolumab will be given.
75911446|NCT02049567|Device|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
75911447|NCT02049567|Procedure|Cataract Surgery|Performed using standard microsurgical techniques
75911448|NCT02051829|Other|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
75464817|NCT01882491|Drug|Placebo|Solution for subcutaneous injection
75464818|NCT01882491|Drug|gevokizumab|Solution for subcutaneous injection
75464819|NCT01882504|Drug|gevokizumab|
75464820|NCT01882517|Dietary Supplement|Yogurt that contains plant stanol esters|
75464821|NCT01882517|Dietary Supplement|Placebo yogurt|
75464822|NCT01882530|Drug|Paracetamol|
75464823|NCT01882530|Drug|Nefopam|
75911449|NCT02051907|Device|KAM1403 Gel|
75911450|NCT02051907|Device|aloevera gel|
75911451|NCT02049801|Drug|MEK inhibitor MEK162|Given PO
75911452|NCT02049801|Drug|idarubicin|Given IV
75911453|NCT02049801|Drug|cytarabine|Given IV
75911454|NCT02049801|Other|pharmacological study|Correlative studies
75911455|NCT02049801|Other|laboratory biomarker analysis|Correlative studies
75911456|NCT02049879|Drug|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
75911457|NCT02051283|Other|RFA|RFA
75319023|NCT03450850|Device|NOVOTTF-200A|NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate >= 75% (>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.
75464824|NCT01882530|Drug|Ketoprofen|
75911458|NCT02053311|Drug|Orteronel|300mg orteronel
75911459|NCT02053311|Drug|Placebo|Placebo
75319024|NCT03408353|Procedure|Biospecimen Collection|Undergo collection of blood samples
75319025|NCT03408353|Procedure|Mammography|Undergo standard of care mammography
75319026|NCT03408353|Other|Questionnaire Administration|Complete questionnaires
75319027|NCT03367962|Drug|[18F]F-Ara-G|the [18F]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
75319028|NCT03320330|Other|Laboratory Biomarker Analysis|Correlative studies
75464825|NCT01882530|Drug|Morphine|
75464826|NCT01882556|Drug|onabotulinumtoxinA|
75911460|NCT02051439|Procedure|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava 3 times before balloon assisted Valsava 3 times. The second group performed balloon assisted Valsava 3 times before conventional Valsava 3 times for venous reflux examination by duplex scan.
75911461|NCT02807259|Behavioral|Multi-level intervention|At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
76072716|NCT05246020|Procedure|intravenous chemotherapy|Patients in the control group will receive three cycles of intravenous NACT. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin AUC 5 for a 21-day cycle.
75319029|NCT03320330|Biological|Pepinemab|Given IV
75319030|NCT03320330|Other|Pharmacological Study|Correlative studies
75319031|NCT03310424|Other|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
75319032|NCT03301038|Drug|Rifampin|Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
75464827|NCT01882556|Drug|Placebo|
75464828|NCT01882595|Other|Nebulization through the tracheostomy|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
75911462|NCT02053389|Behavioral|DVD Decision Aid|"The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation."
75911463|NCT02053389|Behavioral|Written decision aid|"A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer."
75911464|NCT03805893|Procedure|Moderate heat pain|To apply a sensory challenge that can be applied over longer periods required for PET imaging and that is also compatible with high magnetic fields during MRI scanning, we will use a well-established thermal challenge of the lower extremity. To apply mildly painful heat to the patient, the right leg (from the foot up to the knee) will be wrapped in a blanket that incorporates a network of small-diameter plastic tubing through which hot water (45 - 55 oC) is circulated from a temperature-controlled reservoir.
75911465|NCT02053467|Other|Champlain BASE eConsult Service|After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
75464829|NCT01882595|Other|Nebulization through the mouth|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
75618510|NCT04139629|Diagnostic Test|antichlamydial antibody test|At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
75772089|NCT03792646|Dietary Supplement|Whey protein|Exercise training + 20g whey protein
75772090|NCT03792646|Other|Exercise training|Strength exercise
75772091|NCT00499330|Procedure|lobectomy|
75772092|NCT00499330|Procedure|segmentectomy or wedge resection|
75772093|NCT00144170|Drug|Tipranavir (with low dose ritonavir)|
75772094|NCT00144170|Drug|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
75772095|NCT03799042|Device|Virtual Reality|Subjects will wear a 3D glass and watch 3D pictures (or video) of landscapes or tourist sites in Hong Kong.
75772096|NCT03799042|Behavioral|Inter-generation interaction|Secondary school student will play games and chats with secondary school students. Games involve identifying famous landscapes or tourist sites in Hong Kong
75772097|NCT03798886|Other|natural cycle|When follicle is ready for ovulation, we will use this injection by intra-dermal route
75618511|NCT04139629|Drug|treatment of infertility with ART|COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
75618512|NCT04222894|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
75772098|NCT03798886|Other|modified natural cycle|we will use that drug in the natural modified transfer group after embryo transfer
76072717|NCT01807117|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
76072718|NCT01807117|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
75618513|NCT04222894|Other|Control Diet|Participants will be asked to continue their usual diets for the 12-week study period.
75618514|NCT00687349|Behavioral|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
75618515|NCT02813044|Drug|total intravenous anesthesia (TIVA)|In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
75772099|NCT03798886|Other|embryo transfer|we will do transfer when the endometrium is ready
75772100|NCT03798808|Other|Consumption of fruits, vegetables and dairy products|Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
75772101|NCT03798730|Behavioral|Solid Model|"Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)"
75772102|NCT03798730|Behavioral|Liquid Model|"Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages."
75772103|NCT03798652|Device|Research CMR scan|CMR scanning at a 3Tesla scanner at King's College London
75772104|NCT03798652|Device|Research 3D transthoracic echocardiogram|The scan is required to assess left ventricular systolic function
75772105|NCT03798652|Other|6-minute walk test|Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
75772106|NCT03796390|Biological|CD123 CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
75772107|NCT03796234|Other|Dietary and physiotherapy|3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
75772108|NCT03796234|Other|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
75319033|NCT03300258|Device|Robotic therapy|"The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour."
75319034|NCT03300258|Device|Aerobic therapy|The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
75319035|NCT03296956|Dietary Supplement|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.
75319036|NCT03296956|Other|Placebo|Matching placebo for appearance, taste
75911466|NCT02053545|Drug|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF"
75911467|NCT02051985|Other|Aerobic exercise training|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).~Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).~Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
75911468|NCT02051985|Other|Standard physical therapy|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
75772109|NCT04186468|Other|ICU follow-up clinic|The intervention aims at improving health-related quality of life and will contain three components: information, consultation and networking. More information will be available for the participants from the intensive care stay onwards, e.g. an information brochure, and during the entire follow-up period, e.g. by contacting the outpatient clinic via telephone. Participants will be invited to visit the ICU follow-up clinic at least once during the first six months after discharge from ICU. During the visits, participants will be screened for symptoms of PICS and, if required, referred to specialists for further treatment. The aim of the networking part is to improve the exchange between the health sectors and disciplines, e.g. through a special referral letter from the ICU follow-up clinic, and thus to provide a network of outpatient care providers for the former ICU patients.
75911469|NCT02802345|Drug|Nintedanib|
75911470|NCT02802345|Drug|Placebo|
75911471|NCT02802345|Drug|Sildenafil|
75911472|NCT02052063|Device|stapled transanal rectal resection|transanal rectal resection using staple will be done for rectocele
75319037|NCT03296033|Drug|Enoxaparin|The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.
75464830|NCT01882608|Other|Mental Health Telemetry (MHT)|Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
75911473|NCT02052063|Device|Anal compliance measure with Endoflip system|Anal compliance will be measured using Endoflip system
75772110|NCT03798496|Procedure|Open reduction and internal fixation|Open reduction of the Galeazzi fracture dislocation with a plate.
75911474|NCT02053779|Drug|Triptorelin 0.1mg|Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
75911475|NCT02801877|Behavioral|IntelliCare|
75911476|NCT02801877|Behavioral|Hub App with the Recommender System|
75911477|NCT02801877|Behavioral|Coaching|
75464831|NCT01882621|Drug|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
75464832|NCT01882621|Drug|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
75618516|NCT02813044|Drug|inhalation anesthesia group|In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
75618517|NCT02625883|Other|Interview|Interview by validated Quality-of-life-questionnaire
75618518|NCT04236778|Drug|VE303|The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
75618519|NCT04236778|Drug|Oral Vancomycin|Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
75911478|NCT02056041|Procedure|Hepatectomy|
75911479|NCT02053857|Dietary Supplement|RUTF|
75911480|NCT02053857|Dietary Supplement|RUTF-P|
75911481|NCT02053857|Drug|Amoxicillin|
75319038|NCT03296033|Drug|Enoxaparin|This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
75319039|NCT03295981|Drug|Zoledronic Acid|4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
75319040|NCT03284788|Behavioral|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
75319041|NCT03203603|Other|No active intervention|This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
75319042|NCT03199365|Behavioral|Behavioral Dietary Intervention|Undergo TSSC intervention sessions
75911482|NCT02053935|Drug|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
75911483|NCT02037867|Device|Fibrosis Biomarkers|Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
75911484|NCT02054091|Dietary Supplement|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
75911485|NCT02056197|Other|Placebo|Shortwave
75911486|NCT02056197|Other|Stable surface exercises|Stable surface exercises
75911487|NCT02056197|Other|Unstable surface exercises|
75911488|NCT02056275|Other|Nutrition supplement + dietary counseling|Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
75911489|NCT02056275|Other|Dietary Counseling|Dietary counseling provided at each study visit by study dietitian.
75464833|NCT01882634|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
75464834|NCT01882673|Behavioral|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivated tobacco quitline use
75911490|NCT02038101|Behavioral|Education and Feedback|"Formal Rounds on AUC for TTE~Appropriate Use for TTE Application for Smartphone~Individualized Feedback Reports provided by email"
75911491|NCT02056353|Device|LOGIC-Insulin algorithm|
75911492|NCT02056353|Device|Paper protocol|
75911493|NCT03636633|Other|Standard respiratory physiotherapy|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques.
75911494|NCT03636633|Other|Standard respiratory physiotherapy and inspiratory muscle training|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques. Addition to that, threshold IMT device will be used for the training. Training intensity will set at 40% of the maximum inspiratory pressure.
75911495|NCT03603951|Drug|SHR2554|SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
75618520|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|"Group A:~Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.~Treatment will focus on the patient's needs and in accordance with the physicians requests.~Three months post initial treatment re-assessment will be conducted."
75772111|NCT03798340|Other|Vibratory perturbed task-specific movement training|The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.
75911496|NCT02052219|Drug|Blisibimod|Blisibimod administered subcutaneously
75772112|NCT03798340|Other|Traditional task-oriented facilitation|Reach-to-grasp training and hand release training
75772113|NCT03798340|Other|Sensorimotor training|Targeted to goals that are relevant to the sensorimotor facilitation of the patient
75911497|NCT02052219|Drug|Placebo|Placebo administered subcutaneously
75911498|NCT03561519|Other|Fecal Microbiota Transplantation (FMT)|Fecal suspension administered in colonoscopy into the cecum of the patient.
75772114|NCT00255086|Drug|Memantine|10mg Memantine
75911499|NCT03561519|Other|Placebo|As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
76072719|NCT01807117|Procedure|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
75618521|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
75319043|NCT03199365|Behavioral|Behavioral Intervention|Undergo TSSC intervention sessions
75319044|NCT03098576|Other|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
75319045|NCT03098576|Other|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
75464835|NCT01882673|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
75911500|NCT02056587|Drug|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
75464836|NCT01882686|Other|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
75464837|NCT01882712|Drug|CD07805/47 Gel 0.5%|
75772115|NCT00255086|Drug|Placebo pill|10mg placebo pill
75911501|NCT02038335|Drug|DMPA|Depot medroxyprogesterone acetate
75911502|NCT02038335|Drug|NET-EN|Norethisterone enantate
75911503|NCT02038335|Drug|MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
75911504|NCT02038335|Device|LNG-I|Levonorgestrel subdermal implant
75911505|NCT02038335|Device|ENG-I|Etonogestrel subdermal implant
75911506|NCT02038335|Device|Cu-IUD|Copper IUD
75772116|NCT00110214|Drug|docetaxel|Given IV
75772117|NCT00110214|Other|placebo|Given IV
75772118|NCT00110214|Drug|prednisone|Given orally
75772119|NCT00110214|Biological|bevacizumab|Given IV
75772120|NCT00110214|Other|laboratory biomarker analysis|Correlative studies
75772121|NCT04176172|Drug|Varenicline|Participants will receive open-label varenicline for 12 weeks.
75772122|NCT04176172|Drug|Nicotine patch|Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)
75772123|NCT04176172|Behavioral|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.
75772124|NCT04176172|Behavioral|Standard treatment + Managed Problem Solving (MAPS) adherence intervention|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
75911507|NCT02056665|Drug|MINOCYCLINE|Pill Minocycline 50 mg capsule
75911508|NCT02056665|Drug|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
75911509|NCT02056743|Drug|CYP cocktail|Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
75464838|NCT01882712|Drug|CD07805/47 Gel Placebo|
75464839|NCT01882777|Behavioral|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
75618522|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
75618523|NCT01098240|Drug|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
75772125|NCT03798262|Other|Gluten|Tereos
75772126|NCT03798262|Other|Placebo|Whey protein from Nestlé Healthy Science
75618524|NCT01098240|Other|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
75911510|NCT02056743|Drug|Fexofenadine 30mg|Each group administered Fexofenadine 30mg under fasting conditions.
75618525|NCT02812888|Drug|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
75911511|NCT02056743|Dietary Supplement|Red ginseng|During 4~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
75911512|NCT02056743|Dietary Supplement|Fermented-red ginseng|During 4~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
75911513|NCT02805309|Behavioral|Exercise|Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
75911514|NCT02805309|Behavioral|Cognitive behavioral interventions|The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
75911515|NCT02805309|Behavioral|Attention control education program|A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
75911516|NCT02804763|Drug|Placebo|Solution for infusion, 0,9% saline
75772127|NCT01078272|Other|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
75911517|NCT02804763|Drug|Dapirolizumab pegol (DZP)|Solution for infusion
75772128|NCT01078272|Other|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
75772129|NCT03795844|Procedure|liver retraction Nathanson retractor|liver retractor will be used for the retraction of left lobe of liver
75772130|NCT03795844|Procedure|liver retraction snake retractor|liver retractor will be used for the retraction of left lobe of liver
75911518|NCT02052297|Other|GSK2634673F|GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
75911519|NCT02052375|Drug|ASP2408|subcutaneous injection
75911520|NCT02052375|Drug|Placebo|subcutaneous injection
75911521|NCT03561363|Behavioral|High-fat diet|The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
75911522|NCT02054559|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
75911523|NCT02054559|Radiation|Radiotherapy|
75464840|NCT01882842|Procedure|Endometrial biopsy|Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
75618526|NCT00922675|Procedure|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
75772131|NCT03795844|Procedure|liver retraction fan retractor|liver retractor will be used for the retraction of left lobe of liver
75618527|NCT00922675|Procedure|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
75772132|NCT03795844|Procedure|liver retraction laparoscopic grasper|laparoscopic grasper without any special tools
75618528|NCT04149028|Procedure|PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml|intraovarian injection of 2 mml of PRP by laparoscopic guide
75618529|NCT02809222|Other|Samples|Blood samples
75772133|NCT03792802|Procedure|laparoscopic appendectomy port sites|one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port
75911524|NCT02054637|Drug|Lanreotide|
75911525|NCT02056977|Other|Titration|Individualized PEEP according to PEEP titration monitored by EIT
75911526|NCT02056977|Other|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
75911527|NCT02057055|Other|Soap 300000027003|
75911528|NCT02057055|Other|Soap 300000029240|
75911529|NCT02057211|Biological|autologous mesenchymal stem cell transplantation|
75911530|NCT02057211|Procedure|sham transplantation of mesenchymal stem cells|Placebo control for transplantation of mesenchymal stem cells
75911531|NCT02052531|Drug|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
75911532|NCT02052531|Other|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
75911533|NCT02054793|Drug|Itraconazole|100 mg 200 mg 300 mg
75911534|NCT02054793|Drug|Orteronel|300 mg
75911535|NCT02052687|Drug|LFX453 H1|LFX453 high dose cream 1
75911536|NCT02052687|Drug|LFX453 L1|LFX453 low dose cream 1
75911537|NCT02052687|Drug|LFX453 H2|LFX453 high dose cream 2
75911538|NCT02052687|Drug|LFX453 L2|LFX453 low dose cream 2
75911539|NCT02052687|Drug|Imiquimod|Imiquimod cream
75618530|NCT02809222|Other|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
75911540|NCT02052687|Drug|Placebo 1|Placebo cream 1
75911541|NCT02052687|Drug|Placebo 2|Placebo cream 2
75911542|NCT02052765|Device|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
75911543|NCT02057289|Drug|Micafungin|Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
75911544|NCT02057367|Drug|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
75911545|NCT02057367|Drug|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
75911546|NCT02057445|Drug|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
76072720|NCT01807117|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
75464841|NCT01882842|Device|Transvaginal ultrasound|A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
75464842|NCT01882881|Other|Healthy American Control Diet|The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
75772134|NCT05669170|Behavioral|Psychosocial intervention|"The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~Review and adjustment of the patient and caregiver supportive care plans~Emotional support and the opportunity to ventilate feelings~Counseling regarding specific caregiving skills~Assistance with problem-solving of specific issues that the caregiver brings to the sessions~Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours."
75464843|NCT01882881|Other|Dark Chocolate/Cocoa Diet|The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide ~33% of calories from fat. The SFA (~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (~9g).
75618531|NCT04139785|Other|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
75618532|NCT02812966|Device|Lutonix|Drug Coated Balloons
75911547|NCT02057445|Other|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
75618533|NCT02812966|Device|IN.PACT|Drug Coated Balloons
75618534|NCT00687661|Drug|Bisphosphonate|35mg given orally once weekly for 24 months
75772135|NCT05669170|Drug|Methylphenidate|norepinephrine and dopamine reuptake inhibitor
75772136|NCT03792568|Other|ALK Inhibitor|Any ALK inhibitor like crizotinib, alectinib and so on.
75772137|NCT01303822|Behavioral|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
75772138|NCT03798184|Procedure|Non-carious cervical lesion restoration|Restoration of non-carious cervical lesions with Prime&Bond Active in self-etch or selective-etch mode with or without bioglass
75772139|NCT03798028|Biological|UC-MSCs|The UC-MSCs will be administrated by intravenous injection at the dose of 1×10^6 cells/kg.
75772140|NCT03799822|Drug|Rivaroxaban 10 MG Oral Tablet|replacement of warfarin by rivaroxaban
75772141|NCT03799822|Dietary Supplement|MK-7 2000µg thrice weekly|dietary supplement of vitamin K2 MK-7 2000µg thrice weekly
75772142|NCT03799822|Drug|Vitamin K Antagonist - Drug|treatment with a vitamin K antagonist
75772143|NCT03795766|Procedure|Surgeries for gynecologic disease|All patients accept surgeries for gynecologic disease.
75772144|NCT03799900|Drug|Rapastinel|During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
75772145|NCT03799900|Drug|Ketamine|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
75772146|NCT03799900|Drug|Placebo|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
75772147|NCT03795688|Other|Pregnancy|Peripartum transition from pregnant to postpartum state
75772148|NCT03795532|Procedure|SWL|Shock wave lithotripsy
75911548|NCT02054871|Procedure|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
75911549|NCT02054949|Drug|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
75618535|NCT00687661|Drug|Placebo|identical placebo pill once weekly for 24 months
75772149|NCT05625022|Drug|Lianhua Qingke tablets|Lianhua Qingke tablets: 4 tablets once, three times daily
75772150|NCT03792178|Other|Bulk fill composite|Composite resin dental material
75772151|NCT03792178|Other|Nano resin composite|Dental composite material
75772152|NCT01303978|Drug|APD421|Single dose
75772153|NCT03994900|Diagnostic Test|Blood sampling for HbNO assessment|Blood sampling
75772154|NCT01304056|Device|Ventilatory therapy|
75772155|NCT03799666|Other|Pulmonary Rehabilitation|Patients will be treated with daily medication prescribed by the physician. Additionally patients will participate in a 12-w.eek community-based pulmonary rehabilitation programme, with two exercise training sessions per week and six psycho-education sessions, managed by a multidisciplinary team, once every two weeks. Patient's families will be invited to participate in the psychoeducational component
75618536|NCT02809534|Drug|Anlotinib|Anlotinib p.o. qd
75772156|NCT03799666|Other|Daily medication|Patients will be treated with daily medication prescribed by the physician and will continue to receive the standard care from the primary care centre team.
75772157|NCT01304602|Drug|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
75772158|NCT01304602|Drug|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
75911550|NCT02748057|Drug|Ezetimibe|
75911551|NCT02748057|Drug|Rosuvastatin|
75772159|NCT01304134|Drug|Oxycodone|dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
75772160|NCT01304134|Drug|Morphine|dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
75772161|NCT00124020|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days
75911552|NCT02057601|Drug|Levobupivacaine infiltration group|The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
75911553|NCT02052843|Behavioral|Steps to Success|
75911554|NCT02052843|Behavioral|Traditional Healthy Families|
75464844|NCT01882881|Other|Almond Diet|The Almond Diet will include 1.5 oz of almonds daily and provide ~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing ~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
75464845|NCT01882881|Other|Dark Chocolate/Cocoa + Almond Diet|This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at ~34-35% and the SFA will match that of the Almond Diet at ~8-9%. The fiber content of this diet will be highest (~35g); cholesterol will remain ≤200 mg/day.
75618537|NCT00687817|Drug|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
75618538|NCT02809144|Procedure|Nerve block|Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
75911555|NCT02055027|Other|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
75618539|NCT02808988|Procedure|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
75911556|NCT02057679|Drug|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
75911557|NCT02057679|Drug|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
75911558|NCT02055105|Procedure|miRNA in Sepsis|miRNA in Sepsis
75911559|NCT02038491|Procedure|regional anesthesia|Spinal, epidural, combined spinal epidural, nerve blocks
75911560|NCT02055183|Drug|BAT|Noninterventional, retrospective, observational phase 4 patient Registry
75911561|NCT02055261|Device|Low frequency DBS of the pedunculopontine nucleus|
75319046|NCT03089840|Device|OrganOx metra|Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
75319047|NCT03082612|Behavioral|Faith-Based African American Cancer Survivorship Storytelling Intervention|The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research
75319048|NCT03068819|Drug|CIML NK Cell Infusion|-Day 0
75618540|NCT02808988|Procedure|gingival crevicular fluid collection|gingival crevicular fluid collection by periopapers
75618541|NCT02808988|Other|zoledronic acid|5 mg/year zoledronic acid (i.v.)
75772162|NCT00124020|Drug|Vancomycin|Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
75772163|NCT01080690|Procedure|EGD|In this arm EGD will be performed before EUS.
75772164|NCT01080690|Procedure|EUS|In this arm EUS will be performed before EGD.
75911562|NCT02055339|Device|Fisher & Paykel heated humidified high flow nasal cannula|
75911563|NCT02055339|Device|InfantFlow/RAM nasal continuous positive airway pressure|
75911564|NCT02052921|Procedure|Rectal resection|Surgical rectal resection
75911565|NCT02052921|Other|Observation|
75911566|NCT02055417|Behavioral|Personal Approaches to Treatment Choices for HIV|
75911567|NCT02055417|Behavioral|Stress Reduction Skills Program|
75911568|NCT02052999|Drug|PAC-14028 cream 1%|Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
75911569|NCT02052999|Other|Vehicle|Participants received topical Vehicle twice daily for 8 weeks
75911570|NCT02052999|Drug|Rozex gel 0.75%|Participants received topical Rozex gel 0.75% twice daily for 8 weeks
75911571|NCT02055573|Other|Ready To Learn (RTL)|See arm description
75911572|NCT02055573|Other|All Babies Cry (ABC)|See arm description
75911573|NCT03561285|Diagnostic Test|antiphospholipid Abs|Laboratory test
75911574|NCT02055651|Behavioral|Examination and survey|Routine medical examination as required by law and follow-up for lifestyle change program
75464846|NCT01882894|Device|Custom PFO|PFO made out of thermoplastic material molded to the patient's foot
75464847|NCT01882894|Other|Faux orthosis|Foam cut out
75464848|NCT01882920|Drug|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) <2.5 l/min/m2, stroke volume index (SVI) < 35 SVI ml/m2 and stroke volume variation (SVV)> 15%. In the case of CI <2.5 l/min/m2 and SVI <35 ml/m2 with SVV < 15%, an infusion with dopamine was initiated.
75464849|NCT01882920|Drug|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
75464850|NCT01882946|Biological|DCVax-Direct|Autologous, activated dendritic cells for intratumoral injection
75464851|NCT01882959|Other|Radiofrequncy Denervation|
75464852|NCT01882972|Behavioral|Exercise|
75618542|NCT02625805|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
75618543|NCT02625805|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
75618544|NCT02625805|Drug|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
75772165|NCT05626270|Device|LunulaLaser OTC|The LunulaLaser™ OTC is a nonthermal and non-invasive procedure designed to restore the growth of clear, healthy nails in clients with onychomycosis.
75772166|NCT01080846|Drug|Misoprostol|600 mcg of sublingual misoprostol
75772167|NCT03792412|Other|Usability Questionnaire|Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
75772168|NCT01076322|Drug|Meptin® Swinghaler|"Meptin® Swinghaler®~Ingredient: Procaterol HCL~Dosage form: 10g/puff~Dose(s): 10g~Dosing schedule: 20g (total 20g)"
75772169|NCT01076322|Drug|Ventolin® MDI|"Ventolin® MDI~Ingredient: Salbutamol sulfate~Dosage form: 100g/puff~Dose(s): 100g~Dosing schedule: 200g (total 200g)"
75772170|NCT03795064|Procedure|Foam sclerotherapy|Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
75772171|NCT03795064|Procedure|Endothermal ablation|Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
75772172|NCT01078350|Procedure|tumor tissue aspiration|
75772173|NCT01078350|Procedure|phlebotomy|
75772174|NCT03966066|Drug|erythromycin|3-5mg/kg.d orally for 6 months
75772175|NCT03792100|Drug|SmofKabiven emulsion for infusion|Total Parenteral Nutrition
75464853|NCT01882972|Behavioral|Meditation|
75464854|NCT01882998|Behavioral|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
75464855|NCT01883011|Drug|Piracetam|
75464856|NCT01883011|Other|Placebo|
75464857|NCT01883037|Other|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
75464858|NCT01883050|Device|Self Monitoring Software Application|Computer Software application to track health progress after interventional surgery
75618545|NCT00687895|Procedure|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm~The content of the package included~description of signs and symptoms of malaria disease~history taking relevant to malaria and physical examination~identification of danger signs and severe illness for referral~appropriate treatment~counseling patients on the use of drugs.~Malaria microscopy. contents~make thick blood smears from patients with fever and stain with Giemsa~identify and count malaria parasites~maintain the microscope and store blood slides."
75618546|NCT02808910|Behavioral|Nudged to eat less added salt and more other seasonings|
75618547|NCT02808910|Behavioral|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
75772176|NCT03792100|Drug|"Hospital compounded All in one emulsion"|Total Parenteral Nutrition
75772177|NCT00215540|Drug|Lucinactant 175 mg/kg|Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
75772178|NCT00215540|Drug|Lucinactant 90 mg/kg|Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
75772179|NCT00215540|Drug|Placebo|Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
75464859|NCT01883063|Device|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
75464860|NCT01883063|Device|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
75464861|NCT01883076|Biological|autologous cell-based delivery|"autologous cells (derived from self)"
75464862|NCT01883089|Behavioral|Motivational Enhancement Therapy|
75464863|NCT01883102|Drug|Capsaicin 0.1%|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
75464864|NCT01883102|Drug|Placebo|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
75464865|NCT01883128|Device|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
75772180|NCT03966846|Dietary Supplement|Kefir|
75772181|NCT03966846|Dietary Supplement|Milk|
75911575|NCT02057913|Drug|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
75911576|NCT02055729|Biological|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
75911577|NCT02055729|Biological|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 & 28)
75772182|NCT03791944|Device|3DV+TPS/VARIAN|Use imported 3DV+TPS to map targets and develop treatment plans
75911578|NCT02055729|Biological|Stool sample|Stool samples will be collected on days 0 and 28.
75911579|NCT02055729|Biological|Urine sample|Urine samples will be collected on days 0 and 28.
75911580|NCT02057991|Other|educational intervention|Watch an educational video
75911581|NCT02057991|Procedure|CAM exercise therapy|Watch a mindfulness exercise video
75772183|NCT03791944|Device|TPS / VARIAN|Use imported TPS to map targets and develop treatment plans
75911582|NCT02057991|Other|caregiver-related intervention or procedure|Watch mindfulness exercise video and/or educational video
75911583|NCT02057991|Other|questionnaire administration|Ancillary studies
75911584|NCT02057991|Other|laboratory biomarker analysis|Correlative studies
75464866|NCT01883128|Procedure|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
75911585|NCT02053155|Behavioral|Computer based patient education|
75464867|NCT01883128|Procedure|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
75319049|NCT03068819|Procedure|CD3+ T Cell Product Infusion|-Day -1
75319050|NCT03021330|Drug|Daunomycin and Cytarabine (DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
75464868|NCT01883167|Drug|RDEA3170 10 mg|RDEA3170 10 mg once daily (qd)
75464869|NCT01883167|Drug|Febuxostat 40 mg|Febuxostat 40 mg qd
75772184|NCT03791944|Device|3DV + TPS / Domestic Accelerator|Use domestic 3DV+TPS to delineate target areas and develop treatment plans
75772185|NCT03791944|Device|TPS / Domestic Accelerator|Use domestic TPS to map targets and develop treatment plans
75772186|NCT03797950|Behavioral|Voice Reminder (Group A)|Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.
75911586|NCT02055807|Other|PEEP and recruitment maneuvers|
75319051|NCT03021330|Drug|Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-4 and 1g/㎡/d on day 5-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
75319052|NCT03019081|Drug|Isoproterenol|The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.
75319053|NCT03019081|Other|placebo|placebo
75319054|NCT03018418|Radiation|Proton therapy|Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
75464870|NCT01883167|Drug|placebo|placebo qd
75464871|NCT01883180|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
75464872|NCT01883193|Dietary Supplement|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
75464873|NCT01883219|Drug|TKIs|Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
75464874|NCT01883232|Device|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4%
75618548|NCT02808910|Behavioral|Nudged to eat more vegetables|
75618549|NCT02808910|Behavioral|Nudged to eat smaller portions|
75618550|NCT02808910|Behavioral|Nudged to eat less calorie-dense food|
75618551|NCT00688051|Other|My Life with CF game|Play the game My Life with CF
75772187|NCT03797950|Behavioral|Cash Incentive (Group B)|Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
75911587|NCT02055807|Other|ZEEP (no PEEP nor recruitment maneuver)|
75911588|NCT02260167|Other|A mix of natural treatments and medications|
75911589|NCT02748213|Drug|Xeloda|Participants will receive oral Xeloda, 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle.
75911590|NCT02748213|Drug|Taxotere|Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
75911591|NCT02748213|Drug|Herceptin|Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
75911592|NCT05257096|Behavioral|Medical clown|The medical clown will meet the children in the waiting room for 15-30 minutes and will accompany them through the whole investigation, up to one hour.
75772188|NCT03797716|Device|Little Journey app|"The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery."
75911593|NCT03804099|Drug|Aflibercept Injection [Eylea]|After instillation of topical anesthetic, sterilization of the eyelid, and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) is injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions
75911594|NCT03048604|Device|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
75319055|NCT03018418|Drug|Chemotherapy|5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
75911595|NCT02058303|Drug|Exparel Forearm block|20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
75911596|NCT02058303|Drug|Bupivacaine supraclavicular block|20-30mL 0.5% bupivacaine
75911597|NCT05256862|Other|Data collection|"Data collection~on the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) comparing the time period before implementation (01/2017-01/2020) and after implementation (02/2020-06/2022)~on the performance of three novel tests as triage tool in the screening algorithm, QG-MPH, Prevo-check® and PT Monitor®"
75911598|NCT02058381|Drug|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
75911599|NCT02058381|Drug|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
75911600|NCT02053233|Device|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
75911601|NCT02053233|Device|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
75911602|NCT04147156|Procedure|Epley's Maneuver|Treatment with Epley's Maneuver in the ROTUNDUM-chair
75911603|NCT04147156|Procedure|Semont Maneuver|Treatment with the Semont Maneuver in the ROTUNDUM-chair
75911604|NCT04147156|Procedure|360 degree vertical rotation|Treatment with 360 degree vertical rotation in the ROTUNDUM-chair
75911605|NCT04869904|Procedure|dental and plaque sampling|sampling of dental plaque and saliva during the treatment
75911606|NCT04870060|Drug|Curcumin Lozenges|Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
75464875|NCT01883232|Device|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine administered with a syringe prior to the procedure
75911607|NCT04870294|Device|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material.
76072721|NCT02804854|Drug|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
75464876|NCT01883245|Device|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
75319056|NCT02960087|Radiation|Low dose rate brachytherapy|I-125 to a total dose of 144 Gy
75319057|NCT02960087|Radiation|High dose rate brachytherapy|27 Gy in 2 fractions
75319058|NCT02951598|Drug|Florbetapir F 18 PET Scan|Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
75319059|NCT02947386|Other|Laboratory Biomarker Analysis|Correlative studies
75464877|NCT01883245|Device|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
75319060|NCT02947386|Biological|Nimotuzumab|Given IV
75319061|NCT02947386|Biological|Nivolumab|Given IV
75319062|NCT02874404|Drug|Ibrutinib|Given PO
75464878|NCT01883258|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
75464879|NCT01883258|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
75911608|NCT04870294|Device|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
75319063|NCT02874404|Other|Laboratory Biomarker Analysis|Correlative markers
75319064|NCT02874404|Drug|PI3K-delta Inhibitor TGR-1202|Given PO
75464880|NCT01883271|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
75911609|NCT02613910|Drug|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
75464881|NCT01883271|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
75618552|NCT00688129|Behavioral|KITS Program|This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
75911610|NCT02613910|Drug|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
75618553|NCT00688207|Drug|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
75618554|NCT02880462|Dietary Supplement|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
75618555|NCT02880462|Other|placebo|Placebo is made of starch
75618556|NCT00688285|Other|automated clinical alerts|automated clinical alerts in the electronic medical record
75911611|NCT02613910|Drug|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
75319065|NCT02866669|Behavioral|Practice Facilitation|ractices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
75618557|NCT00688285|Other|provider education|PCP education session on CKD
75618558|NCT00688363|Procedure|weekly blood glucose profile|once daily self-control of urinary-glucose
75618559|NCT00688363|Procedure|three-monthly haemoglobin A1c|once daily self-control of urinary-glucose
75772189|NCT01304212|Drug|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
75772190|NCT01304212|Drug|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
75772191|NCT01304212|Drug|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
75772192|NCT01304212|Drug|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
75911612|NCT02613910|Drug|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
75319066|NCT02866669|Behavioral|Peer Coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
75618560|NCT00688363|Procedure|no blood-glucose self-control|once daily self-control of urinary-glucose
75618561|NCT02812654|Drug|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
75911613|NCT02802735|Drug|Apremilast|Tablet for oral administration
75911614|NCT02802735|Drug|Placebo|Tablet for oral administration
75936668|NCT02427230|Behavioral|Pelvic floor muscle training|"The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.~Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks."
75319067|NCT02866669|Behavioral|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
75618562|NCT02812654|Drug|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
75319068|NCT02824627|Drug|Oxytocin|A growing body of data shows that intra-nasal administration of oxytocin has promise for treating a host of psychiatric disorders. Considerable data indicates that oxytocin reduces amygdala response to negative stimuli in patients with generalized anxiety disorder, borderline personality disorder, and post-traumatic stress disorder. Given that one of the potential underlying neurobiological mechanisms of irritability and emotional dysregulation in pediatric population with disruptive behavior and mood disorder is the hyperactivity of amygdala to negative emotional stimuli, and that oxytocin reduces this, it is critical to determine the extent to which this intervention improves irritability and emotional dysregulation in children and adolescents with disruptive behavior and mood disorders.
75464882|NCT01883284|Other|Tests in vitro after sampling nasal cells of CF patients or controls|Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
75772193|NCT03797638|Device|Finger Force Manipuladum (FFM)|Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
75772194|NCT01560520|Behavioral|Physical activity|Observation only
75464883|NCT01883310|Device|sham tDCS + TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
75618563|NCT02812654|Radiation|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
75772195|NCT00143390|Drug|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
75772196|NCT00143390|Drug|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
75772197|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
75618564|NCT02809066|Other|Sufficient dietary calcium intake in premenstrual syndrome|"Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;~50 gr kashkaval cheese,~400 ml milk and~150 gr yogurt for each day."
75772198|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
75772199|NCT03238534|Device|Neobianacid®|Oral administrations of Neobianacid® (30' after meals and on demand)
75772200|NCT03238534|Drug|Omeprazole 20mg|Daily administration Omeprazole 20mg (per os, 30' before breakfast).
75772201|NCT03238534|Other|Neobianacid® placebo|Oral administrations of Neobianacid® placebo (30' after meals and on demand)
75772202|NCT03238534|Other|Omeprazole placebo|Daily administration Omeprazole placebo (per os, 30' before breakfast).
75772203|NCT05624476|Diagnostic Test|mNGS of urine cell-free DNA|Metagenomic sequencing of urine cell-free DNA
75772204|NCT03792022|Behavioral|Adherence to timely vaccine uptake|Adherence to timely vaccine uptake
75772205|NCT05624242|Procedure|cardiac magnetic resonance imaging|all patients had magnetic resonance imaging at baseline and during follow-up.
75772206|NCT01304290|Other|Hyperinsulinemic/normoglycemic clamp|"Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours."
75772207|NCT03797248|Combination Product|Chinese herbal medicine|All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
75772208|NCT01304368|Procedure|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
75618565|NCT01097694|Drug|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
75618566|NCT01097694|Drug|Placebo|Placebo
75772209|NCT00141102|Drug|Celecoxib|Participants are assigned to one of two groups in parallel for the duration of the study
75772210|NCT00141102|Drug|Diclofenac + Omeprazole|Participants are assigned to one of two groups in parallel for the duration of the study
75772211|NCT03663712|Biological|Talimogene Laherparepvec|TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells
75772212|NCT03797092|Biological|Allogeneic adipose-derived stromal cells (CSCC_ASC)|Active group
75772213|NCT03797092|Other|Control group|No treatment
75936669|NCT02427230|Drug|vaginal electrical stimulator (CefarPeristim Pro)|electrical stimulation
75936670|NCT05478551|Drug|Botulinum Toxin|We will be comparing botulinum toxin following the biopsies to placebo injection. We will then compare photos of each biopsy site at set intervals following the procedure.
75772214|NCT03796936|Behavioral|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy|a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)
75319069|NCT02824627|Drug|Placebo|Inactive substance administered in volume equivalent to volume administered in active treatment arm.
75319070|NCT02743611|Biological|BPX-701|autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch
75319071|NCT02743611|Drug|Rimiducid|dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
75319072|NCT02705196|Genetic|delolimogene mupadenorepvec|oncolytic virus encoding TMZ-CD40L and 4-1BBL
75319073|NCT02705196|Drug|gemcitabine|chemotherapy
75319074|NCT02705196|Drug|nab-paclitaxel|chemotherapy
75319075|NCT02705196|Biological|atezolizumab|anti-PD-L1 antibody
75319076|NCT02689440|Drug|Dasatinib|Given PO
75319077|NCT02689440|Other|Laboratory Biomarker Analysis|Correlative studies
75319078|NCT02689440|Drug|Venetoclax|Given PO
75319079|NCT02668666|Drug|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
75464884|NCT01883310|Device|real tDCS +TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
75618567|NCT02808754|Procedure|Remote Ischemic Preconditioning|Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic > 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
75464885|NCT01883323|Drug|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
75319080|NCT02668666|Drug|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
75319081|NCT02508363|Behavioral|questionnaires|
75618568|NCT00688831|Drug|AZD1305|Solution for iv infusion , single dose
75618569|NCT00688831|Drug|Placebo|NaCl solution for iv infusion, single dose
75618570|NCT02808832|Behavioral|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
75618571|NCT00688987|Drug|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
75618572|NCT00688987|Dietary Supplement|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
75618573|NCT02808676|Dietary Supplement|Vitamin D3|Dose: 10000 IU, three times per week, orally.
75772215|NCT03796780|Dietary Supplement|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks
75772216|NCT03796780|Dietary Supplement|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks
75772217|NCT01080924|Device|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
75772218|NCT03573856|Behavioral|Active Living|Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.
75772219|NCT03573856|Other|Health and Safety|Participants will be provided with education related to general health and safety topics.
75772220|NCT01078428|Other|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
75772221|NCT01078428|Other|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
75772222|NCT01081002|Drug|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
75936671|NCT05478551|Drug|Normal saline|Normal saline will serve as the placebo control on the contralateral side of the back.
75936672|NCT03180788|Procedure|Traction assisted ESD|A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
75936673|NCT03180788|Procedure|Traditional ESD|Endoscopic submucosa dissection
75936674|NCT02420444|Biological|BCG SSI|The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
75936675|NCT02420444|Biological|Placebo|This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
75319082|NCT02364713|Biological|Bevacizumab|Given IV
75319083|NCT02364713|Drug|Gemcitabine Hydrochloride|Given IV
75319084|NCT02364713|Other|Laboratory Biomarker Analysis|Correlative studies
75319085|NCT02364713|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
75319086|NCT02364713|Drug|Paclitaxel|Given IV
75319087|NCT02364713|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75319088|NCT02364713|Other|Quality-of-Life Assessment|Ancillary studies
75319089|NCT02364713|Drug|Topotecan Hydrochloride|Given IV
75319090|NCT02186600|Drug|Calcium Carbonate|Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
75319091|NCT02186600|Drug|Vitamin D3|Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
75319092|NCT02186600|Drug|Risedronate|Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
75319093|NCT02186600|Behavioral|Bone-loading exercises|Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.
75319094|NCT02105259|Behavioral|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for patients social anxiety disorder
75319095|NCT02105259|Other|Waiting list|Waiting list, where participants wait for delayed treatment
75772223|NCT01081002|Drug|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
75772224|NCT03789136|Other|Not applicable, observational study|Not applicable, observational study
75319096|NCT01907789|Other|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
75464886|NCT01883323|Drug|Fludarabine|i.v., 25mg/m2 per day for 5 days
75464887|NCT01883323|Biological|Tumor-Infiltrating Lymphocytes|i.v., 1x10^10 - 1.6x10^11 cells
75618574|NCT02808676|Other|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
75772225|NCT03789058|Drug|Ibuprofen 400 mg|Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
75772226|NCT03788902|Drug|Ritalin|Single dose of Ritalin IR 0.3-0.5 mg/kg OR placebo
75772227|NCT05669092|Drug|Toripalimab|3mg/Kg iv d1q2w
75772228|NCT05669092|Radiation|CRT|IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
75772229|NCT05669092|Radiation|SCRT|25Gy/5fx
75772230|NCT05669092|Drug|XELIRI|Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
75772231|NCT05669092|Drug|FOLFRINOX|Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
75772232|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
75772233|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
75772234|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
75772235|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
75772236|NCT01306240|Procedure|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
75319097|NCT01907789|Procedure|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
75464888|NCT01883323|Biological|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
75464889|NCT01883349|Procedure|Kidney Transplant|Kidney Transplant Surgery
75464890|NCT01883375|Behavioral|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
75772237|NCT01306240|Procedure|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
75772238|NCT03714022|Drug|Abatacept|Participants will receive abatacept at a single dose 750 mg as IV infusion.
75772239|NCT05624164|Procedure|Lateralised microfracture|making microfracture(4 holes with 2mm diameter) at the lateral side of the footprint right after arthroscopy rotator repair.
75772240|NCT00143312|Drug|voriconazole|Voriconazole is given to patients at least 48 hours after chemotherapy
75772241|NCT03967028|Procedure|cesarean section|lower segment cesarean section either elective or emergency
75772242|NCT03791866|Other|Nutrition|Enteral nutrition
75772243|NCT03967262|Behavioral|Brief Motivational Intervention|The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
75772244|NCT04833946|Other|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
75772245|NCT04833946|Other|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
75772246|NCT01077206|Drug|Simvastatin|80mg daily versus 40mg daily, for 21 days.
75772247|NCT03791710|Procedure|autologous fat grafting|regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound
75772248|NCT03791710|Drug|Topical Cream|serial dressing with topical agents e.g Silver Sulphadiazine
75772249|NCT03791710|Procedure|split thickness skin grafting|depridment and split thickness skin grafting
75319098|NCT01907789|Procedure|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
75319099|NCT01907789|Behavioral|Questionnaire|"Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery."
75319100|NCT01907789|Procedure|Transvaginal Ultrasound|"Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline."
75319101|NCT01907789|Behavioral|Phone Call|"Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly."
75319102|NCT01873833|Drug|capecitabine|Given PO
75319103|NCT01873833|Drug|cyclophosphamide|Given PO
75319104|NCT01873833|Drug|lapatinib ditosylate|Given PO
75772250|NCT05623540|Drug|Bisphosphonates, Combinations|
75772251|NCT05622838|Diagnostic Test|Alpha1 -Antitrypsin level|measuring alpha1 -antitrypsin level in pregnant women
75772252|NCT01305694|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
75772253|NCT03791476|Drug|rhC1INH|C1 esterase inhibitor
75772254|NCT03791476|Other|Saline Solution|saline solution
75772255|NCT03791632|Other|classical lecture style presentation|classical lecture style presentation
75772256|NCT03791632|Other|an intervention in the form of fun workshops|an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
75772257|NCT03791632|Other|digital media intervention|digital media intervention
75772258|NCT03791554|Procedure|Group A (Lateral closed tunnel subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the adjacent teeth to treating gingival recession with edges of the recession sutured together after placing connective tissue graft
75772259|NCT03791554|Procedure|Group B (Tunnel procedure with subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
75772260|NCT05620732|Biological|Claudin18.2 CAR-T cells|patients treated with Claudin18.2 CAR-T cells
75772261|NCT01306318|Drug|eperisone hydrochloride plus diclofenac sodium capsule|Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
75772262|NCT01306318|Drug|eperisone hydrochloride tablet and diclofenac sodium tablet|Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
75772263|NCT03191656|Device|IASD Implant|Implantation of the IASD device using trans-septal puncture and the IASD system
75772264|NCT03788668|Procedure|Hyoid suspension|Hyoid suspension will be done with barbed reposition pharyngoplasty
75772265|NCT00254540|Drug|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
75772266|NCT05380492|Biological|VOY-101|Intravitreal injection of VOY-101
75772267|NCT03973658|Device|Hearing aids|Fitting of hearing aids (for the first time)
75772268|NCT01077440|Genetic|DNA analysis|DNA analysis will be performed on samples collected.
75772269|NCT01077440|Genetic|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
75772270|NCT01077440|Other|flow cytometry|Flow cytometry will be done on the samples collected.
75319105|NCT01873833|Biological|trastuzumab|Given IV
75319106|NCT01873833|Other|laboratory biomarker analysis|Correlative studies
75319107|NCT01567800|Other|18F-Fluoroazomycin Arabinoside (18F-FAZA)|PET scan with the radiolabelled tracer 18F-FAZA
75772271|NCT01077440|Other|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
75772272|NCT03791320|Diagnostic Test|Vessel Fractional Flow Reserve|FFR measurement based on coronary angiography
75772273|NCT01326494|Drug|Arm 1 Oral Cortico Steroids|"Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )"
75772274|NCT03794674|Other|No intervention.|No intervention, since this is a validation study
75772275|NCT01306396|Behavioral|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
75772276|NCT03794830|Other|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
75319108|NCT01446744|Radiation|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
75464891|NCT01883375|Behavioral|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
75464892|NCT01883401|Dietary Supplement|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
75464893|NCT01883401|Dietary Supplement|Dietary fiber|4g or 8g dietary fiber blended in water
75319109|NCT01446744|Radiation|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"
75618575|NCT02808676|Other|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
75618576|NCT02808676|Other|placebo D3|matching placebo for Vitamin D3
75618577|NCT02808676|Other|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
75772277|NCT03794830|Other|electrotheraphy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions)
75772278|NCT05297188|Device|ergonomic sleep mask|Ergonomic sleep mask; It is a material that covers the eye and ear completely and can be adjusted according to the patient, can be washed and reused at 30 degrees after use, 95% cotton, 5% polyester structure and 100% light proof properties.
75772279|NCT01306552|Behavioral|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
75772280|NCT01306552|Behavioral|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
75618578|NCT02808676|Other|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
75772281|NCT01306552|Behavioral|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
75772282|NCT03791242|Device|Cpap and ketogenic diet|Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks
75772283|NCT03791164|Behavioral|The Pain Toolkit|the Pain Toolkit is a leaflet that encourages self management techniques for patients with chronic pain
75772284|NCT03791164|Behavioral|the Back Book|The Back Book is a patient information leaflet that offers information and advice about back pain
75772285|NCT03790930|Diagnostic Test|deep learning|manually labeled samples will be used to train, validate and test deep learning algorithm, and then realize automatic classification.
75772286|NCT01305850|Drug|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
75772287|NCT01305850|Drug|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
75936676|NCT02420444|Biological|AERAS-404|AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
75936677|NCT04328909|Device|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
75936678|NCT04328909|Other|Control Group|Usual care - No E-Care app will be provided
75319110|NCT01431209|Other|Laboratory Biomarker Analysis|Correlative studies
75319111|NCT01431209|Drug|Ruxolitinib Phosphate|Given PO
75618579|NCT04138459|Other|Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services|"Explore recovery orientation of mental health services in a municipality through:~Qualitative, in-depth interviews with service users and mental health professionals and~Observational fieldwork"
75618580|NCT02878746|Device|Robotic mirror therapy|2-dimensional
75618581|NCT02878746|Device|Conventional mirror therapy|2- and 3-dimensional
75319112|NCT01393795|Drug|Qutenza|8% patch
75319113|NCT01393795|Drug|Tegaderm|No active drug
75319114|NCT01389089|Behavioral|ice gel pack|ice gel pack combined with elevation
75618582|NCT00683371|Procedure|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
75772288|NCT01305850|Drug|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
75772289|NCT01305850|Drug|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
75911615|NCT04869748|Other|Perfetti method|"Participant was blindfolded, while lying flat in a quiet and comfortable room.~Participants received a 15-minute session of Perfetti method on affected elbow flexor.~Participants were asked to concentrate on the position of their elbows.~Protocol has 4 steps of training starting from 2 positions; full flexion and full extension 3 positions; full flexion, elbow flexion 90 degree and full extension 4 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 45-60 degree and full extension 5 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 90 degree, elbow flexion 45-60 degree and full extension of elbow.~After therapist passively moved elbow joint to a position, participant guessed the position of his/her elbow. If the answers were correct consecutively for 10 times, the therapist increased the number of positions according to the protocol."
75911616|NCT04869748|Other|passive stretching|"Participant was blindfolded, while lying flat in a quiet and comfortable room.~Each participant received gentle passive stretching of elbow flexor and maintained in full elbow extension position for 15 minutes."
75772290|NCT03790696|Device|Cognitive Training Program|"The cognitive training program has been designed by Dr. Sylvester. It is a simple computer game looking at some shapes and faces on a computer screen and pressing a button when a target shape appears.~This is the first study to use this exact computer training regimen for testing in its ability to reduce symptoms of anxiety in children with anxiety disorders. Each session of the computer game takes approximately 45-60 minutes and subjects complete 8 total sessions over one month. The computer game involves paying attention to parts of the screen while distracting square boxes appear at other locations. A target X appears at the location that participants are paying attention to and the subjects press a button when it appears."
75772291|NCT03790774|Behavioral|Neurofeedback|Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
75772292|NCT01306630|Drug|tivozanib (AV-951) and capecitabine (Xeloda®)|Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
75911617|NCT03048214|Procedure|Infraclavicular nerve block|Infraclavicular nerve block is a relatively safe and straightforward brachial plexus nerve block that can be used to provide intraoperative regional anaesthesia for upper limb surgeries from the elbow to fingers.
75911618|NCT03048214|Procedure|General anaesthesia|Usual practice for upper limb surgeries.
75911619|NCT02058615|Behavioral|Male Spouse Transition Toolkit|
75911620|NCT02058927|Drug|Measles vaccine|measles revaccination administered at 12 months from start of ART
75319115|NCT01389089|Other|Multi-layer compression bandage|Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
75319116|NCT01389089|Device|A-V Impulse compression|A-V Impulse compression dosage: 130mmHg exerted to the sole of the foot for one second, every twenty second.
75618583|NCT00683371|Procedure|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
75618584|NCT04308798|Procedure|Surgical glove changing|Changing surgical glove after draping and before cementation during total knee arthroplasty
75618585|NCT04138693|Device|G-PUR® 2x 2.0 g oral suspension|Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake
75911621|NCT02059083|Behavioral|Heart rate variability biofeedback|
75911622|NCT02059083|Behavioral|CBT|
75911623|NCT02060955|Biological|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
75911624|NCT02060955|Drug|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
75911625|NCT02273362|Drug|Erlotinib|Given PO
75911626|NCT02273362|Drug|Erlotinib Hydrochloride|Given PO
75911627|NCT02273362|Other|Laboratory Biomarker Analysis|Correlative studies
75319117|NCT01198067|Drug|Pomalidomide|Given PO
75618586|NCT04138693|Device|G-PUR® 1x 2.0 g oral suspension|Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake
75618587|NCT04138693|Device|Placebo oral suspension|Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
75618588|NCT02812498|Other|Teleconsultation|The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
75618589|NCT02812498|Other|Standard|Group of patients followed in a traditional way
75618590|NCT00689065|Drug|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
75618591|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
75911628|NCT02273362|Other|Quality-of-Life Assessment|Ancillary studies
75911629|NCT02059317|Other|Flexion-extension in the sagittal plane|The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
75911630|NCT02059317|Other|Rotation in a transverse plane|The movement required of the subject is a rotational movement where the subject alternately touches with his/her left and right hands two targets. The latter are positioned horizontally on either side of the subject at shoulder height and at arm's length. The movement is repeated 30 times at a frequency of 0.28 Hz.
75319118|NCT01181375|Other|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
75319119|NCT00928525|Drug|Imatinib Mesylate|800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
75319120|NCT00826020|Drug|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
75319121|NCT00818025|Behavioral|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
75464894|NCT01883414|Device|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
75464895|NCT01883466|Other|Forearm venous occlusion plethysmography study|Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
75772293|NCT01306708|Drug|amitriptyline|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
75319122|NCT00816114|Other|Chart Review|Investigator review of MDACC CML patient charts.
75319123|NCT00754208|Drug|methylphenidate|Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
75772294|NCT03794518|Drug|Pioglitazone Plus dapaglifliozin|Pioglitazone Plus dapaglifliozin
75464896|NCT01883479|Behavioral|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
75618592|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
75618593|NCT00690937|Drug|Colesevelam Cholestagel|Drug comparator
75618594|NCT00690937|Drug|Placebo|Placebo
75618595|NCT00690937|Drug|Placebo|Placebo
75772295|NCT03794518|Drug|Placebo|(Beta blockers, ACEI, ARB, and aldosterone )
75772296|NCT05566288|Drug|Cytisinicline|compressed film-coated tablet containing 3 mg cytisinicline
75772297|NCT05566288|Drug|Placebo|Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline
75618596|NCT01102140|Drug|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
75772298|NCT05566288|Drug|Moxifloxacin|400 mg tablets
75772299|NCT03788278|Device|BioBeat|The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.
75772300|NCT03790540|Device|DentalVibe|It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients
75772301|NCT03790540|Drug|Topical Benzocaine 20%|Topical benzocaine 20% gel on the mucosal injection site prior to injection
75911631|NCT02059317|Other|Complex movement in three dimensions|The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
75936679|NCT03180866|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
75618597|NCT01102140|Drug|Sugar Pill|Matching sugar pill
75618598|NCT02690116|Other|Qigong/Tai Chi Easy|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
75618599|NCT02690116|Other|Sham Qigong|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
75618600|NCT02690116|Other|Educational Support|Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60-minute class per week for the 8 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
75618601|NCT00689143|Drug|sargramostim|
75618602|NCT02812810|Device|active rTMS|
75618603|NCT02812810|Device|sham rTMS|
75772302|NCT03794596|Drug|Avelumab|Colourless odourless aqueous solution for infusion at dose of 10mg/kg
75319124|NCT00579423|Biological|QS21|"Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
75319125|NCT00505245|Other|Interview|Complete interview
75911632|NCT04429906|Device|Huami smart wearable device|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
75319126|NCT00505245|Other|Quality-of-Life Assessment|Complete quality of life assessment
75319127|NCT00505245|Other|Questionnaire Administration|Complete questionnaires
75772303|NCT03794596|Drug|Aspirin|300mg tablets
75911633|NCT03561129|Other|Embryo transfer|all the fresh embryo transfers, performed between January 1997 and December 2016 at Humanitas Fertility Center after IVF-ICSI cycles, divided per operator
75319128|NCT00290160|Behavioral|Protein supplementation|
75772304|NCT03794596|Drug|Lansoprazole (Proton Pump Inhibitor)|300mg capsule
75772305|NCT01306786|Drug|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
75772306|NCT01306786|Drug|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
75772307|NCT03788590|Device|Jenscare TAVI|Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
75772308|NCT03788200|Procedure|Bracing|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
75772309|NCT03788200|Procedure|posterior C1-C2 instrumented fusion|Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
75772310|NCT01304758|Device|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
75772311|NCT05571748|Dietary Supplement|Alpha-lipoic acid|A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.
75911634|NCT02060175|Device|Cilotax drug-eluting stents implantation|
75911635|NCT02060175|Device|DESyne drug-eluting stents implantation|
75911636|NCT03048760|Other|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans & 1 after approx. 2 weeks of radiotherapy treatment.
75911637|NCT01027858|Behavioral|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
75911638|NCT01027858|Behavioral|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
75911639|NCT02059473|Procedure|Rotator cuff repair|Physiotherapy & Surgery
75911640|NCT02059473|Procedure|Physiotherapy|
75319129|NCT04199390|Procedure|total hip arthroplasty|each patient is expected to undergo an anterior total hip arthroplasty procedure and some sort of physical therapy postoperatively
75319130|NCT04193774|Diagnostic Test|Conjunctival swab|Swab of the conjunctival fornices of both eyes
75464897|NCT01883479|Behavioral|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
75464898|NCT01883518|Biological|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
75464899|NCT01883531|Drug|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
75772312|NCT05571748|Other|Placebo|A trial of acute exercise before and after 4 weeks of placebo supplementation.
75772313|NCT03788356|Device|Inspiratory muscle training|Inspiratory muscle training with a device
75772314|NCT03788356|Other|Diaphragmatic breathing|Diaphragmatic breathing exercise
75772315|NCT05695144|Device|tDCS active stimulation combined with rTMS sham stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
75911641|NCT03048838|Behavioral|Risk reduction behavioral intervention|
75911642|NCT03048838|Behavioral|Wellness Promotion Intervention|
75464900|NCT01883531|Drug|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
75464901|NCT01883544|Drug|ALXN1007|
75464902|NCT01883570|Other|training in visual search strategy|
75319131|NCT04193774|Drug|Oxybuprocaine Hydrochloride 0.4% Eye Drops|One drop of topical anesthesia in one eye
75319132|NCT04193774|Drug|artificial tears|One drop of artificial tears in the other eye
75319133|NCT03023540|Drug|PXT3003|Liquid oral solution, 5 mL (Dose 1 or Dose 2) bid OR 10 mL (Dose 1) bid
75618604|NCT02879370|Procedure|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
75464903|NCT01883570|Other|access to a library of chest x-rays without search strategy|
75618605|NCT04139239|Diagnostic Test|Coma Recovery Scale-revision|Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
75618606|NCT02808442|Biological|UCART19|
75618607|NCT00683527|Drug|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
75618608|NCT02808598|Behavioral|Breast Cancer Clinical Trials Education Program|The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
75618609|NCT00634426|Procedure|Surgical excision of the metastatic process|Surgical excision of the metastatic process
75618610|NCT00634426|Radiation|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
75618611|NCT00683683|Behavioral|Knowledge Translation|The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
75618612|NCT00683761|Drug|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
75618613|NCT02812732|Behavioral|DOSE HPV|"The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3&4. Action Plans are developed in Session 5. Sessions 6&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles."
75618614|NCT00912457|Drug|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
75618615|NCT00912457|Drug|placebo|placebo 1 p/day for 28 days
75911643|NCT03046810|Device|Wellness toileting system|This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
75319134|NCT04197674|Other|Dialysis modality|This is a observational cohort study, and there is no intervention for all participants. Our aim is to evaluate dialysis modality (PD and HD) on patient survival
75319135|NCT00547729|Device|HeartPOD™ System|HeartPOD™ device with DynamicRx® automatically measures left heart pressures throughout the day.
75464904|NCT01883583|Device|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
75319136|NCT04199312|Device|The ZELTIQ System|The MMS device will be used to perform the treatments.
75319137|NCT00518089|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
75319138|NCT00518089|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
75319139|NCT02985242|Drug|Empagliflozin|Empagliflozin film-coated tablet
75319140|NCT02985242|Drug|Glimepiride|Glimepiride tablet
75319141|NCT02985242|Drug|Empagliflozin placebo|Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
75319142|NCT02985242|Drug|Glimepiride placebo|Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
75464905|NCT01883596|Drug|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
75464906|NCT01883596|Drug|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
75464907|NCT01883609|Biological|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
75464908|NCT01883609|Biological|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
75464909|NCT01883609|Biological|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
75464910|NCT01883648|Drug|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
75464911|NCT01883648|Other|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
75464912|NCT01883661|Biological|BMMNC|Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
75911644|NCT02059629|Device|Eluna pacemaker family|"New pacemaker generation with new functions, like wandless RF telemetry SafeSync"
75319143|NCT04197518|Diagnostic Test|neuro trax system and a neurology test.|"the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving."
75319144|NCT04197440|Drug|BAM8-22 2mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
75319145|NCT04197440|Drug|BAM8-22 1mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
75319146|NCT04197440|Drug|BAM8-22 0.5 mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
75319147|NCT04197440|Drug|Placebo|20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop
75319148|NCT04197440|Drug|BAM8-22 with 1 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop
75319149|NCT04197440|Drug|BAM8-22 with 5 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop
75618616|NCT02808286|Behavioral|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
75618617|NCT02808286|Behavioral|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
75618618|NCT04139161|Procedure|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion >12, indicating a transition to moderate physical activity, or 3) self-reported pain >5.
75618619|NCT04093492|Other|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
75618620|NCT04093492|Other|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
75618621|NCT04139083|Procedure|LSC mesh suspension|Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.
75772316|NCT05695144|Device|rTMS active stimulation combined with tDCS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
75319150|NCT04197440|Drug|BAM8-22 with 25 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop
75618622|NCT04139083|Procedure|TVM|Transvaginal mesh kit is delivered into the pelvis via vagina route.
75772317|NCT05695144|Device|tDCS active stimulation combined with rTMS active stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
75319151|NCT04197440|Drug|BAM8-22 with inactivate cowhage spicules|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
75911645|NCT02059629|Device|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
75911646|NCT03046420|Other|Chart review|This is a retrospective chart review study. The charts of patients who meet the inclusion criteria will be abstracted into a standardized electronic case report form, as described in Section 5. A standardized case report form for each patient will be created so as to collect uniform data. Charts data for one year back to the start date of data abstraction will be included in the study
75319152|NCT03023774|Drug|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
75319153|NCT04021160|Device|High frequency repetitive transcranial magnetic stimulation (rTMS)|10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
75772318|NCT05695144|Device|tDCS sham stimulation combined with rTMS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
75464913|NCT01883674|Other|Resistance training|All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
75464914|NCT01883687|Procedure|Septoplasty|
75464915|NCT01883700|Other|Boiled Pasta|
75618623|NCT04200586|Drug|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
75618624|NCT02807974|Drug|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
75618625|NCT02807818|Behavioral|Home visiting Program for Young Pregnant Women|
75618626|NCT04120168|Genetic|Laboratory Tests|"Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication."
75618627|NCT00874549|Biological|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
75618628|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75618629|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
75618630|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75618631|NCT04116814|Diagnostic Test|wall-to-lumen ratio measurement|wall-to-lumen ratio measurement in patients with renal insufficiency
75618632|NCT02807740|Other|Virtual reality|Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
75618633|NCT02807740|Other|Conventional rehabilitation program|In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
75618634|NCT02812108|Device|intracranial stent, flow diverter and coils|
75618635|NCT02807896|Other||This study is cohort.
75618636|NCT02812264|Behavioral|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
75618637|NCT02812264|Behavioral|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
75618638|NCT02812264|Behavioral|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
75618639|NCT02812264|Behavioral|scale|Connected scale that will transfer weight information to app
75618640|NCT04236700|Other|Oral clinical exam|Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
75618641|NCT02812030|Other|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
75618642|NCT02625103|Procedure|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
75618643|NCT02625103|Drug|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
75618644|NCT02807662|Behavioral|Adapted Seeking Safety Intervention|Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
75618645|NCT01155479|Drug|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
75618646|NCT01155479|Drug|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
75618647|NCT01155479|Drug|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
75618648|NCT01155479|Drug|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
75618649|NCT01155479|Drug|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
75618650|NCT01155479|Drug|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
75618651|NCT04138303|Other|Exercise Protocol|The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.
75772319|NCT03790618|Drug|3,4-Methylenedioxymethamphetamine|Participants will be given 0.75mg/kg of 1.5mg/kg MDMA
75772320|NCT03790618|Drug|methamphetamine|Please see above.
75464916|NCT01883700|Other|Boiled Chickpeas with Oil|
75464917|NCT01883700|Other|Instant Mashed Potatoes|
75464918|NCT01883700|Other|Instant Mashed Potatoes with Egg Whites|
75464919|NCT01883713|Device|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
75464920|NCT01883726|Device|Grayson's presurgical nasoalveolar molding|Grayson NAM
75464921|NCT01883726|Device|Figueroa's presurgical nasoalveolar molding|Figueroa NAM
75464922|NCT01883739|Other|Parental Presence at Handover Rounds|
75464923|NCT01883752|Procedure|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
75618652|NCT04138303|Other|Calorie-Restrictive Low Carbohydrate Diet (CR-LC)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).
75618653|NCT04138303|Other|Ancestral Diet (AD)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
75618654|NCT02807584|Device|ELECT|
75618655|NCT04031131|Drug|Instillagel|Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.
75618656|NCT04031131|Other|KY Gel|Lubricant Gel
75618657|NCT00683839|Behavioral|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
75618658|NCT02807272|Drug|Tipifarnib|Oral tablet
75618659|NCT02811796|Other|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
75618660|NCT04138771|Device|An artificial intelligence system for postoperative management of cataract patients|This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
75772321|NCT03790228|Drug|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
75772322|NCT01304836|Drug|Advagraf|oral
75772323|NCT01304836|Drug|Mycophenolate Mofetil|oral
75772324|NCT01304836|Drug|Simulect|IV
75772325|NCT01304836|Drug|Corticosteroids|IV & oral
75319154|NCT04021160|Device|Sham stimulation|A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
75319155|NCT03023618|Device|FloTrac|Stroke Volume has been maintained at 90% of the maximal Stroke Volume as in NICE protocol 2011
75319156|NCT04020614|Other|Survey|A survey with 13 questions will be applied to the patients
75464924|NCT01883765|Behavioral|Neurofeedback active|
75618661|NCT01155323|Device|etafilcon A|1-day soft contact lens
75618662|NCT01155323|Device|omafilcon A|1-day soft contact lens
75618663|NCT02807194|Other|spinal anesthesia|
75772326|NCT01306864|Device|Hemospray Kit|Hemostasis of Arterial GI Bleeding
75911647|NCT04877626|Drug|Artemeter plus lumefantrina vs artesunato plus amodiquina|"Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)"
75464925|NCT01883765|Behavioral|Neurofeedback sham|
75464926|NCT01883765|Behavioral|Metacognitive Training|
75618664|NCT02807194|Other|general anesthesia|
75618665|NCT02807194|Procedure|lumbar disc herniation|
75618666|NCT00912535|Drug|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
75618667|NCT00912535|Drug|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
75618668|NCT02811718|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
75618669|NCT02811718|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
75618670|NCT04313777|Behavioral|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
75618671|NCT04313777|Device|Virtual therapeutic support|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.
75618672|NCT04313777|Behavioral|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
75772327|NCT03788122|Other|In-depth interview|The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
75464927|NCT01883791|Behavioral|SBIRT|See above Arm description.
75464928|NCT01883791|Behavioral|Health Education|See Arm Description.
75464929|NCT01883830|Device|gaming therapy (Xbox)|
75464930|NCT01883830|Device|Dynamic balance platform (Biodex)|
75772328|NCT01307176|Behavioral|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
75772329|NCT01307254|Procedure|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
75772330|NCT01307332|Drug|MabCampath-1h|Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
75772331|NCT03790462|Other|Music intervention|"A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes & data collected."
75772332|NCT01305928|Other|Warm Hand-off|"Warm Hand-Off~Staff brief intervention and warm hand-off (5 min):~Assess withdrawal, need for medication change~Describe warm hand-off process~Provide 2-page flyer~Perform call, leave room~Notify patients' nurse patient is talking to quitline~Quitline session (20 min):~Collect minimum data set~Explore thoughts/feelings toward quitting~Provide medication education~Build plan to stay quit~Schedule next call~Staff check-back (5 min):~Ask patient how session went~Ask if patient requests cessation medication script on discharge"
75618673|NCT02811874|Behavioral|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
75772333|NCT01305928|Other|Fax|"Fax~Staff standard in-patient session: (30 minutes):~Assess withdrawal, need for medication change~Conduct assessment of smoking history, interest in quitting~Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting~Provide 2-page flyer~Provide medication education~Build plan to stay quit~Describe fax-referral process~Ask if patient requests cessation medication script on discharge"
75772334|NCT03790384|Drug|Mitomycin|Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
75772335|NCT05694910|Other|Reiki|Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
75772336|NCT04915924|Device|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
75772337|NCT03787732|Drug|Fluid Bolus|500 milliliters of an intravenous crystalloid solution of the operator's choosing
75772338|NCT03787732|Other|No Fluid Bolus|No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation
75772339|NCT01307488|Drug|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
75772340|NCT01307488|Drug|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
75618674|NCT02811874|Behavioral|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
75618675|NCT02625727|Other|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
75772341|NCT03790072|Biological|OmnImmune®|infusion of OmnImmune® (expanded gamma delta T lymphocytes)
75772342|NCT01306006|Biological|Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine|Normal measles vaccines licensed for distribution through the national EPI program
75772343|NCT01304992|Dietary Supplement|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
75772344|NCT01304992|Dietary Supplement|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
75772345|NCT03787342|Procedure|Double Flap Incision|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
75618676|NCT02625727|Other|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
75618677|NCT02884739|Other|Data collection|
75618678|NCT04313699|Drug|Antiretroviral treatment|The cohort will recruit HIV infected participants who are on antiretroviral treatment
75618679|NCT01155167|Drug|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
75618680|NCT01155167|Other|Placebo|Placebo
75618681|NCT02807038|Procedure|Lung function test|Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
75618682|NCT04141111|Device|Continuous Glucose Monitoring (CGM)|"On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review."
75618683|NCT02811406|Procedure|Receives IV albumin infusion|"IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
75618684|NCT02811406|Biological|Do not receive IV albumin infusion|"No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
75618685|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|Low Dose- 70g bar
75618686|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|High Dose- 100g bar
75618687|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|Low Dose- 70g bar
75618688|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|High dose: 100g bar
75618689|NCT00691249|Dietary Supplement|Shredded Wheat|70g bar
75618690|NCT05238155|Drug|antimetabolite|When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
75618691|NCT01106586|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
75618692|NCT01106586|Drug|ATV|Atazanavir 300 mg capsule administered orally once daily
75618693|NCT01106586|Drug|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
75618694|NCT01106586|Drug|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
75618695|NCT01106586|Drug|Stribild Placebo|Placebo to match Stribild administered orally once daily
75618696|NCT01106586|Drug|ATV Placebo|Placebo to match ATV administered orally once daily
75618697|NCT01106586|Drug|RTV Placebo|Placebo to match RTV administered orally once daily
75772346|NCT03787342|Procedure|Modified Periosteal Releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
75911648|NCT03046030|Other|Real acupuncture|Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
75618698|NCT01106586|Drug|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
75618699|NCT02884583|Other|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
75618700|NCT00683995|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
75618701|NCT02806882|Drug|Ceftaroline fosamil|600mg IV infusion
75772347|NCT03787342|Procedure|Coronally Advanced Lingual Flap|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
75772348|NCT03787342|Procedure|Periosteal releasing incision|
75772349|NCT05694754|Device|Theta Burst Transcranial Magnetic Stimulation|Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill
75772350|NCT03794128|Procedure|Blood collection for research (next-generation sequencing [NGS])|Participants will have whole blood collected for next-generation sequencing (NGS).
75772351|NCT03794128|Procedure|Blood collection for research (HLA typing)|Participants will have whole blood collected for HLA typing.
75464931|NCT01883843|Device|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
75464932|NCT01883843|Device|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
75772352|NCT03794440|Drug|Sintilimab|200mg IV d1， Q3W
75772353|NCT03794440|Drug|IBI305|15mg/kg IV d1， Q3W
75772354|NCT03794440|Drug|Sorafenib|400mg PO BID
75464933|NCT01883869|Drug|ticagrelor|
75618702|NCT02884817|Drug|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
75772355|NCT05534542|Other|exercıse|ıntradıalıtıc core stabılızatıon
75772356|NCT05089552|Other|1-WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale|WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale The WHOQOL-BREF is composed of 26 self-administered items. Using a 5-point Likert response scale ranging from 1 (very dissatisfied/very poor) to 5 (very satisfied/very good), family caregivers were asked to rank each item accordingly. Caregivers were asked to respond to the items indicating their assessment of QOL during the preceding 2 weeks, Ohaeri and Awadalla developed and tested the Arabic version of the WHOQOL-BREF among an Arab population in Kuwait. The translated Arabic WHOQOL-BREF has considerable reliability and validity indices . As reported in the Kuwaiti study, a satisfactory (≥0.7) Cronbach's alpha was reported for the full questionnaire and the domains
75772357|NCT05089552|Other|SCL-90-R(Symptoms Checklist-90-Revised) Arabic version scale|"developed by Derogatis et al. and El-Behairy. established the validity and reliability of the Arabic version.SCL-90-R is a 90-item self-report symptom inventory, and reflect the psychologic symptom pattern of psychiatric and medical patients. Each item of the 90 is rated on a five-point scale of distress (0-4), ranging from not at all to extremely.Under usual circumstances, SCL-90-R requires between 12 and 15 minutes to be completed.SCL-90-R is a measure of the current psychologic symptom status. It is not a measure of personality, except indirectly, in that certain personality disorders may manifest a characteristic profile on the primary symptom dimensions."
75772358|NCT05089552|Other|addiction severity index|a semi-structured interview that takes approximately 45 minute. developed to evaluate treatment outcome in substance abusers. The instrument focuses on seven areas that are typically affected in the lives of substance abusers: medical status, employment, drug use, alcohol use, legal status, family/social status, and psychiatric status. Information regarding frequency, duration, and severity of problems in these seven areas is collected for both lifetime and recent (past 30 days) history. The ASI provides two types of scores: severity and subjective ratings of the client's need for treatment, and composite scores of problem severity during the prior 30 days. Specific alcohol-related questions include total lifetime years of use, money spent on alcohol, and number of days that alcohol problems are experienced.
75772359|NCT03789682|Drug|Adjuvant chemotherapy|adjuvant chemotherapy using Gemcitabine plus Cisplatin
75618703|NCT02884817|Other|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
75618704|NCT02884817|Other|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
75772360|NCT05527522|Combination Product|nutritional and educational intervention|individualized diet plus educational intervention with/without nutritional supplements
75772361|NCT05527522|Other|standard practice|The patients received the usual treatment and clinical practice
75772362|NCT05694598|Genetic|VGR-R01|CYP4v2-coding gene delivered by AAV vector
75772363|NCT01307566|Device|Continuous Positive Airway Pressure CPAP|CPAP treatment
75772364|NCT00139776|Drug|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed."
75464934|NCT01883869|Drug|placebo|placebo
75464935|NCT01883882|Behavioral|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
75464936|NCT01883921|Other|Immunoglobulin Therapy|
75618705|NCT02806804|Biological|one dose test vaccine|
75618706|NCT02806804|Biological|one dose commercially available trivalent influenza vaccine|
75319157|NCT04026698|Behavioral|Resident and Family Engagement Intervention|"The leadership coaching component targets managers, administrators/ directors of care in long-term care settings. These sessions involve selecting a subset of relevant performance outcomes from the quality improvement plan that align with leadership vision and priorities for staff performance which leaders can monitor, reinforce and encourage.~The education component involves a one-day in-person training session for staff and managers on communication strategies and ways to engage family and residents in care planning, and includes follow-up visits.~The huddle component involves a series of resident and family led huddles (brief, 15 minute meetings) to discuss a care related topic with staff to foster proactive communication and information sharing. Resident-family dyads will participate in the huddles, along with the staff and management team who received the training. The huddles will be scheduled for 15 minutes once/month for up to 3 months."
75319158|NCT04029818|Biological|Bifidobacterium BSL_PS404|Each participant will consume 1 capsule daily at lunch for 8 weeks.
75618707|NCT02806804|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
75618708|NCT04138537|Other|OB volume|The mean OB volume was calculated in cubic millimeters and compared between the two groups.
75618709|NCT04138537|Other|CCCRC test|CCCRC test was done for olfactory function assessment and compared between the two groups.
75618710|NCT02811562|Device|manikin|
75618711|NCT02811562|Device|fiberoptic bronchoscope|
75618712|NCT02811562|Device|pentax-airwayscope|
75618713|NCT04137991|Device|Nol-Index guided analgesia|Monitor that indicates the level of nociception-antinociception balance
75618714|NCT04137991|Other|Standard Analgesia|Administration of remifentanil based guided by heart rate, blood pressure, and experience
75618715|NCT04031365|Procedure|Acupuncture|Use of sterile, disposable needles in acupuncture
75618716|NCT04031365|Behavioral|Cognitive Behavioral Therapy|psychotherapy
75618717|NCT01155011|Behavioral|Physical Activity|"MIPARC will focus on 3 physical activity goals:~increasing walking behavior through gradually increasing step goals~increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,~reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months."
75618718|NCT01155011|Behavioral|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
75618719|NCT01155011|Behavioral|Phone counseling call|"To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:~health check~step goal check~barrier identification~problem solving~specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring."
75772365|NCT00139776|Drug|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed."
75319159|NCT04029818|Biological|Placebo|Each participant will consume 1 capsule daily at lunch for 8 weeks.
75464937|NCT01883934|Other|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
75464938|NCT01883934|Other|Control|
75464939|NCT01883947|Procedure|Touch massage|Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
75464940|NCT01883947|Other|non-TENS|Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
75464941|NCT01884012|Procedure|long term oxygen therapy|
75618720|NCT01155011|Behavioral|Peer Mentoring|"Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.~The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity."
75618721|NCT01155011|Behavioral|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
75772366|NCT03787186|Drug|GLPG1690 film-coated tablets|a single oral dose of GLPG1690
75772367|NCT03787186|Drug|[14C]-GLPG1690 solution for infusion|a 15-minute IV infusion [14C]-GLPG1690
75772368|NCT03787186|Drug|[14C]-GLPG1690 capsules|single oral dose of [14C]-GLPG1690
75772369|NCT03787420|Other|communication system|"We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale."
75319160|NCT04196426|Behavioral|Nutrition education intervention about osteoporosis and calcium|The intervention is designed and developed based on the Intervention Mapping Process and the Health Belief Model. Topics of the intervention include: the importance of osteoporosis and risk factors, role of calcium in bone health and controlling the disease, calcium recommendations and sources, role of vitamin D and physical activity in calcium absorption and bone health, and how to identify calcium-rich foods in the locality and prepare meals with local calcium-rich foods. A recipe booklet containing recipes using local calcium-rich foods will be given to the participants after the end of the two nutrition lessons. Interactive activities are incorporated in each lesson to encourage the participation of participants.
75464942|NCT01884090|Behavioral|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
75464943|NCT01884116|Drug|NSAID patch|
75618722|NCT01155011|Behavioral|Support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
75618723|NCT01155011|Behavioral|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
75618724|NCT01155011|Behavioral|Group educational sessions|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
75618725|NCT01155011|Behavioral|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
75772370|NCT00413699|Drug|CP-690,550|5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
75772371|NCT00413699|Drug|CP-690,550|10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
75772372|NCT01037855|Other|Non-intervention observational study|Non-intervention observational study
75772373|NCT03713320|Drug|Cobomarsen|At least weekly doses of cobomarsen (282 mg) throughout study treatment period
75772374|NCT03713320|Drug|Vorinostat|Daily doses of vorinostat throughout study treatment period
75772375|NCT03712930|Drug|Pamiparib|60 mg orally twice daily (BID)
75772376|NCT00420407|Drug|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
75772377|NCT00420407|Drug|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
75772378|NCT03793972|Other|Triage with referral to primary care|During intervention weekends(and holidays) a nurse will triage patients using a newly developped extended Manchester Triage System (eMTS). Patients appropriate for primary care will be referred to the general practitioner on call.We will inform patients about the nature of the intervention using leaflets and broadcasting in the waiting room of the Emergency Department.
75772379|NCT03793972|Other|Usual care|During a control weekend (and holidays), all data registration and collection will be the same as during intervention weekends but patents will not be informed about their allocation advice. The emergency physician will see all patients deciding to stay at the ED, without influence of the triage advice. As in standard clinical care, patients will have the right to change their mind and go spontaneously to the general practitioner. . During control weekends, we will only inform about triage in general but no about the general practioner or the intervention.
75772380|NCT01037933|Other|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
75772381|NCT01037933|Other|Non-humor intervention (distraction)|"A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player"
75911649|NCT03046030|Other|Sham acupuncture|Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles [20, 35, 104-106]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling [20, 35, 104]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
75772382|NCT01038011|Drug|drug treatment|
75772383|NCT03787108|Other|Magnetic resonance spectroscopy measurement|Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.
75772384|NCT03789448|Other|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines
75772385|NCT03789370|Drug|Propofol|Maintanance of general anaesthesia with propofol
75772386|NCT03789370|Drug|Sevoflurane|Maintainance of general anaesthesia with sevoflurane.
75772387|NCT00420095|Drug|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
75772388|NCT00420095|Drug|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
75772389|NCT03789526|Procedure|ultrasound guidance|ultrasound guidance of tendon injection
75319161|NCT04196582|Device|Comparison of LMA Gastro Airway® and Gastro-Laryngeal Tube in patients who will undergo biliopancreatic procedures.|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
75319162|NCT03832478|Device|Virtual Reality Headset Given|Samsung Gear VR Headset with guided mindfulness meditation app
75618726|NCT01155011|Behavioral|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
75618727|NCT00689689|Device|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
75618728|NCT00689689|Device|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
75618729|NCT02879292|Other|Spinal anesthesia|Spinal Anesthesia
75319163|NCT00518713|Drug|Clobazam Low Dose|0.25 mg/kg/day; tablets; orally; for 15-18 weeks
75464944|NCT01884116|Drug|NSAID patch + transcutaneous electric nerve stimulation|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
75319164|NCT00518713|Drug|Clobazam Medium Dose|0.5 mg/kg/day; tablets; orally; for 15-18 weeks
75618730|NCT00689767|Device|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
75618731|NCT00689767|Device|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
75618732|NCT04313465|Other|Immediate discharge|Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
75618733|NCT02806648|Drug|Palbociclib|Palbociclib
75618734|NCT04138147|Procedure|Superficial cervical plexus with auriculotemporal nerve blocks|Superficial cervical plexus block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
75618735|NCT04138147|Procedure|Cervical retrolaminar with auriculotemporal nerve blocks|Cervical retrolaminar block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
75772390|NCT01038089|Dietary Supplement|Resveratrol|Resveratrol
75772391|NCT01305070|Device|Admiral Xtreme|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
75772392|NCT01305070|Device|In.Pact Admiral|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
76072722|NCT05245630|Procedure|Robotic arm assisted PET/CT guided biopsy|"After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done."
75319165|NCT00518713|Drug|Clobazam High Dose|1.0 mg/kg/day; tablets; orally; for 15-18 weeks
75618736|NCT04071808|Diagnostic Test|ELISA Test|The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
75618737|NCT04307784|Dietary Supplement|VD3|VD3 (50.000 IU/week) for 8 weeks
75618738|NCT04307784|Dietary Supplement|Omega-3FA|Omaga-3FA (300 mg/day) for 8 weeks
75618739|NCT04307784|Dietary Supplement|VD3 and Omega-3FA|VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks
75618740|NCT04307784|Other|Control|No intervention is given
75618741|NCT00689845|Biological|bleomycin sulfate|Given IV
75618742|NCT00689845|Biological|filgrastim|Given subcutaneously
75319166|NCT00518713|Drug|Placebo|tablets; orally; daily for 15-18 weeks
75618743|NCT00689845|Biological|rituximab|given IV
75772393|NCT00419393|Drug|Keppra XR (Levetiracetam XR)|500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
75772394|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
75772395|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
75319167|NCT03948464|Drug|Slow release oral morphine (SROM)|Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.
75464945|NCT01884116|Drug|NSAID patch + heating pad|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
75618744|NCT00689845|Drug|cyclophosphamide|Given IV
75772396|NCT01038167|Drug|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
75772397|NCT01038167|Drug|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
75618745|NCT00689845|Drug|cytarabine|Given subcutaneously
75618746|NCT00689845|Drug|doxorubicin hydrochloride|Given IV
75618747|NCT00689845|Drug|etoposide phosphate|Given IV
75618748|NCT00689845|Drug|ifosfamide|Given IV
75618749|NCT00689845|Drug|methotrexate|Given IV
75618750|NCT00689845|Drug|prednisolone|Given orally
75618751|NCT00689845|Drug|prednisone|Given orally
75618752|NCT00689845|Drug|vincristine sulfate|Given IV
75618753|NCT00689845|Drug|vindesine|Given IV
75618754|NCT00624767|Drug|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
75618755|NCT00624767|Drug|NovoLog|NovoLog at doses up to 30 IU
75618756|NCT04200820|Diagnostic Test|Trampoline|During trampoline training that participants undergo constant change of vestibular stimulation. This triggers deep proprioception as well as other sensory inputs. This trigger might affect strength, body stability, muscle coordinative responses, joint movement amplitudes and spatial integration
75772398|NCT01038167|Drug|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
75772399|NCT01038167|Drug|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
75618757|NCT04205981|Other|Aerobic exercise|8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
75618758|NCT02806492|Other|50-100ug phenylephrine before CPB|In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP <60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
75618759|NCT02806492|Other|50-100ug phenylephrine during CPB|In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
75772400|NCT01307722|Other|left atrial distensibility-guiding prescription of heart failure drugs|This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
75772401|NCT03787030|Drug|Vitamin E Acetate ointment|Application of 1 ml of ointment to the distal anal canal, every 12 hours for an 8-week period.
75911650|NCT03046030|Other|VGAIT|In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
75911651|NCT03046030|Other|VGAIT control|The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
75911652|NCT02059707|Device|LARIAT RS Suture Delivery Device|LARIAT RS Suture Delivery Device
75911653|NCT05255848|Drug|Unfractionated heparin|Patients will be given the same standard of care treatment plus nebulized heparin 5000IU every 8 hours started 24 hours after randomization, using a compressed air nebulizer, and will be continued for one week. In case of any complication, if the attending physician feels it necessary intervention treatment will be stopped
75911654|NCT04877704|Other|Symprove (probiotic)|Symprove's unique water-based formula is packed full of live, active bacteria. It is a probiotic, not a drug.
75911655|NCT04877704|Other|Placebo|Matched placebo to Symprove probiotic
75911656|NCT04430062|Procedure|Surgical procedures performed under general anesthesia|Surgical procedures performed under general anesthesia in patients with perioperative SARS-CoV-2 infection
75911657|NCT02799381|Drug|Optimized antiparkinsonian treatment|Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
76072723|NCT05245630|Procedure|PET fused CT-Fluoroscopy guided biopsy|CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
76072724|NCT05363410|Dietary Supplement|MagnéVie B6®|micronutrient supplement
75772402|NCT03787030|Drug|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
75319168|NCT03948464|Drug|Methadone|Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.
75772403|NCT03993977|Diagnostic Test|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
75772404|NCT03993977|Other|Conventional treatment|Clinical judgement and conventional coagulation tests
75772405|NCT03786874|Other|Identify work interruptions|estimate baseline characteristics of the collaborative working model (proportion expressed as a percentage)
75772406|NCT03786874|Other|Understand work interruptions|Team-review of the results of the task interruption and professional representations, identify activities to protect from task interruption
75772407|NCT03786874|Other|Act to limited work interruptions|Adaptation of organizations; Awareness raising and Coaching for change
75772408|NCT03786562|Drug|Intrathecal Morphine|Group 1
75772409|NCT03786562|Drug|Intrathecal Morphine + Intravenous Nalbuphine|Group 2
75464946|NCT01884116|Drug|NSAID patch + topical capsaicin|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
75464947|NCT01884142|Other|Aerobic Exercise Training|
75464948|NCT01884155|Procedure|Allogeneic umbilical cord blood therapy|
75464949|NCT01884168|Biological|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
75464950|NCT01884207|Other|MRI|
75464951|NCT01884220|Other|There are no interventions in this study.|
75772410|NCT02173613|Other|procalcitonine|"The recommendations will be based on the level of PCT: 4 levels of advice will be given:~It is highly recommended to stop antibiotics if PCT <0.1ng/ml, and the recommended stop if 0.1ng/ml <PCT <0.25 ng / ml.~It is recommended to continue treatment if 0.25 ng / ml <PCT ng / ml.~Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level."
75772411|NCT02639728|Other|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
75772412|NCT02639728|Other|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
75772413|NCT02639728|Other|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
75772414|NCT01038401|Procedure|GI endoscopy and GALT biopsies|This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
75772415|NCT01038401|Biological|A sample of venous blood will also be collected|These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
75772416|NCT03793894|Behavioral|Smoking Cessation Counseling|All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
75772417|NCT03793894|Behavioral|Decision Aid|"The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)"
75772418|NCT03793894|Behavioral|Shared decision making (SDM)|"During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare & Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context."
75772419|NCT03793894|Behavioral|CHW Navigation|The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
75772420|NCT03786328|Behavioral|Standard Psychiatric Treatment|Standard psychiatric treatment is offered individuals identified with a clinical mental disorder. Treatment will follow golden standard treatment in the psychiatric clinic, meaning a combination of therapy and psychopharmacological treatment.
75772421|NCT03786328|Behavioral|Preventive Psychological Treatment|Preventive Psychological Treatment is offered individuals identified with a sub-clinical mental condition. Treatment consists of 8 sessions of cognitive-behavioural therapy.
75772422|NCT01305148|Device|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
75772423|NCT01305226|Drug|THR-100|THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
75772424|NCT01305226|Drug|Streptokinase|Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
75772425|NCT03786250|Procedure|Geriatric Assessment|Systematic screening of delirium, prevention of delirium, early treatment, pain management with scales adapted to chronicity, conciliation of medication to emergency discharge, among others.
75772426|NCT05694208|Behavioral|Education Group|In the first pre-operative interview at the gynecological oncology outpatient clinic of the relevant hospital, the purpose of the research will be explained to the patients and an informed consent form will be filled. The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
75772427|NCT01308268|Drug|Ivermectin + Albendazole|Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (>= 2 years old) single dose, PO
75772428|NCT03785938|Dietary Supplement|Probiotic|Liquid probiotic supplied by the company Symprove
75772429|NCT03785938|Other|Placebo|Placebo made of maltdextrin. Will be similar in taste and consistency
75772430|NCT01305304|Other|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
75772431|NCT01305304|Other|Other|No history of endurance sports activity
75772432|NCT01308346|Device|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
75464952|NCT01884233|Behavioral|Standard Care|Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
75772433|NCT01308346|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
75772434|NCT03785704|Drug|Xinmailong Injection|Xinmailong injection is extracted, separated, purified and refined from Periplaneta americana. It is the second class of new drugs and the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China) for the prevention and treatment of heart failure. Its main constituents include complex nucleoside bases and binding amino acids.
75772435|NCT05694130|Drug|Prednisolone|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
75772436|NCT05694130|Drug|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
75772437|NCT01308112|Dietary Supplement|iron|Daily supplementation with iron (60 mg) as ferrous sulphate
75772438|NCT03786172|Behavioral|Smoking cessation Intervention|"A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange)~A motivational gadget distributed to the patients~Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients"
75464953|NCT01884233|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
75618760|NCT02806492|Other|decreasing CPB flow|With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.
75618761|NCT02806492|Other|Decreasing CPB flow AND 50-100ug phenylephrine|In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.
75319169|NCT04020692|Behavioral|EOPC Intervention|"The issue of drug continuity after hospital discharge has become a major issue in recent years. When patients return home, the drugs taken do not correspond to the treatments prescribed at the end of the hospitalization. This is due to appropriate or inappropriate initiatives of the patients (or their relatives) and/or the physicians accompanying them. Prescribed medications, on the other hand, are almost always dispensed by community pharmacists.~The scope chosen in this project is that the intervention of an operational clinical pharmacy team (EOPC), targeting both patient and health care professionals (inpatient and outpatient), will maintain, in outpatient care, the drugs treatments that have been optimized during hospitalization."
75618762|NCT02806492|Other|Increasing CPB flow|In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
75618763|NCT02884895|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction Disposable
75618764|NCT02884895|Device|Direct Laryngoscopy|Direct Laryngoscopy
75618765|NCT02806258|Radiation|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
75618766|NCT02806258|Drug|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
75618767|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
75618768|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
75618769|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
75772439|NCT03786172|Behavioral|Usual care|A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident
75772440|NCT03793816|Device|BiZactTM Open Sealer/Divider|The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
75772441|NCT03793582|Diagnostic Test|ApneaLink Type III portable sleep study|Type III portable sleep study
75911658|NCT02799381|Drug|Levodopa-Carbidopa Intestinal Gel (LCIG)|Dose levels were individually optimized.
75911659|NCT02799381|Device|CADD-Legacy ambulatory infusion pump|(manufactured by Smiths Medical)
75911660|NCT02799381|Device|Percutaneous endoscopic gastrostomy tube|(PEG tube)
75911661|NCT02799381|Device|Jejunal extension tube|(J-tube)
75319170|NCT04196270|Drug|Ropivacaine injection|In a dose finding study the total volume of ropivacaine changes according to the biased coin up-and-down sequential design
75319171|NCT05560633|Other|No intervention|No intervention
75319172|NCT04020380|Drug|Azithromycin 250Mg Capsule|250 mg OD
75618770|NCT00691405|Drug|Placebo|Placebo inhalation solution BID
75618771|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
75911662|NCT04877158|Behavioral|Self-Blame and Perspective-Taking Intervention|The intervention is a group therapy that consists of experiential art tasks followed by psychoeducation about social behaviors with weekly homework. There are four sessions, each one week apart.
75319173|NCT00521989|Drug|CRx-102 (2.7/90)|CRx-102 dose 1
75618772|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
75618773|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
75618774|NCT00691405|Drug|Placebo|Placebo inhalation solution QD
75911663|NCT04387942|Drug|IL-2|For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
75618775|NCT01106430|Drug|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
75618776|NCT01106430|Drug|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
75618777|NCT02804698|Behavioral|Education intervention|13-week educational and physical activity intervention
75911664|NCT04877002|Diagnostic Test|Sona Saliva C-19 Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
76072725|NCT05363410|Other|Placebo|placebo supplement
75319174|NCT00521989|Drug|Prednisolone|Prednisolone
75911665|NCT01333059|Drug|Midazolam|
75911666|NCT01333059|Drug|Normal saline|
75911667|NCT01333059|Drug|Fentanyl|
75911668|NCT03046186|Diagnostic Test|Mixed meal test with double tracer technique|
75319175|NCT00521989|Drug|Placebo|Placebo
75772442|NCT05567302|Other|Manual therapy|"In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~A rotational maneuver will be performed from the posterior side of the articular pillar part of the superior vertebra, on the opposite side of the side where the movement restriction is present."
75772443|NCT05567302|Other|myofascial release|The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
75319176|NCT00521989|Drug|CRx-102 (2.7/180)|CRx-102 dose 2
75464954|NCT01884246|Behavioral|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
75464955|NCT01884246|Other|Referral to primary care provider for CVD risk management|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
75464956|NCT01884272|Drug|lesinurad 400 mg|
75464957|NCT01884272|Drug|naproxen 250 mg|
75464958|NCT01884272|Drug|indomethacin 25 mg|
75772444|NCT00419159|Drug|Everolimus (RAD001)|Everolimus was supplied in 5 mg tablets in blister packs.
75464959|NCT01884285|Drug|Part A: AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
75319177|NCT00521989|Drug|CRx-102 (2.7/360)|CRx-102 dose 3
75464960|NCT01884285|Drug|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
75464961|NCT01884285|Drug|Part C1: Abiraterone acetate combination with AZD8186|Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
75772445|NCT05693896|Behavioral|Centering Appetite|A digital treatment of Appetite Awareness Treatment (AAT) and behavioral weight loss treatment (BWL) over 6 months, delivered remotely using Zoom. The goal of AAT is to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants diagnosed with Binge Eating Disorder (BED) and bulimia nervosa reduce binge eating, overeating, urges to eat in response to non-appetite stimuli, and prevent weight gain.
75772446|NCT03785782|Device|Ultrasound|Breast ultrasound
75911669|NCT02060253|Drug|ganetespib|Given IV
75911670|NCT02060253|Drug|paclitaxel|Given IV
75911671|NCT02060253|Biological|trastuzumab|Given IV
75319178|NCT04029350|Drug|Anlotinib Combined With Osimertinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Osimertinib：80 mg/tablet， per os (p.o.) daily. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
75319179|NCT04029506|Other||this is an obsevational study which needs no interventions
75319180|NCT04196036|Procedure|Day of vitrification|Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5
75319181|NCT00548041|Other|HIV test by oral swab|Eligible subjects underwent rapid HIV testing by oral swab.
75319182|NCT04020770|Other|Vibrating ball|Parameters: 5 30-sec bouts of 68Hz vibration followed by a 1-minute rest.
75319183|NCT05560321|Other|Sani24|Disinfectant
75319184|NCT05560321|Other|Routine Disinfection|Routine disinfection at the study hospital
75464962|NCT01884285|Drug|Part D1: AZD2014 combination with AZD8186|Dose & schedule finding of AZD8186 in combination with AZD2014
75464963|NCT01884285|Drug|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
75464964|NCT01884285|Drug|Part C2: Abiraterone acetate combination with AZD8186|Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
75464965|NCT01884298|Drug|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
75464966|NCT01884298|Drug|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
75464967|NCT01884324|Other|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
75464968|NCT01884363|Other|Once ounce per day of walnuts|
75911672|NCT02060253|Biological|pertuzumab|Given IV
75911673|NCT03560973|Drug|Gemcitabine|ramucirumab/ placebo was added to gemcitabine
75911674|NCT03560973|Drug|Ramucirumab|ramucirumab/ placebo was added to gemcitabine
75464969|NCT01884376|Device|Neuromaix|
75464970|NCT01884389|Other|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
75464971|NCT01884402|Drug|Peginterferon alfa-2a|Treatment as usual clinical practice
75464972|NCT01884402|Drug|Ribavirin|Treatment as usual clinical practice
75464973|NCT01884415|Biological|HBV vaccine|Patients receive a second cycle of vaccination
75464974|NCT01884415|Biological|HBV vaccine|Patients receive vaccination according to the guidelines.
75464975|NCT01884428|Drug|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
75464976|NCT01884428|Drug|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
75464977|NCT01884428|Drug|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
75319185|NCT04020302|Behavioral|Self-monitoring shopping intervention|Intervention will occur once per week for a duration of 8 weeks. The intervention format will alternate between individual and group sessions, so that the first week of intervention will be provided in a group format, the second week will be provided in an individual format, and so forth. Sessions will be 90 minutes in duration. Data will be collected during individual sessions, which will occur every other week. During individual sessions, each participant will meet at the facility for the first 15 minutes, will travel to a local grocery store for 45 minutes, and then reconvene at the facility for the final 30 minutes. Group sessions will follow the same structure; however, all ten participants will be present. Each of the 8 sessions will consist of the following: awareness training; facilitation of strategy generation; facilitation of error detection; reinforcement of self-monitoring techniques; and opportunity for participants to practice self-monitoring techniques.
75618778|NCT01154231|Drug|Nonacog Alfa (Genetical Recombination)|"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less."
75618779|NCT02806180|Procedure|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
75618780|NCT02806180|Procedure|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
75772447|NCT05693662|Behavioral|Mindfulness-Based Self-Compassion Education|An education booklet created within the scope of ASD diagnosis will be presented to the parents of children with ASD. The booklet will be prepared in line with the relevant literature, including the development of the child with ASD, activities of daily living, social communication skills, and the processes of awareness-based self-compassion education in an 8-session interview with parents. The booklet will be presented to the parents participating in the research at the first session of the Mindfulness-Based Self-Compassion Training. During the creation of the training booklet, the final form of the booklet will be given by taking the opinions of the experts and in line with the relevant suggestions.
75772448|NCT03717064|Drug|RO7049389|RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
75618781|NCT02804776|Drug|Gefitinib|250mg oral daily for 4 weeks
75618782|NCT01154153|Drug|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
75618783|NCT01154153|Drug|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).~For children who were >=2 to <6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~For children who were >=6 yrs to <12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase."
75618784|NCT01154153|Drug|Placebo nasal spray|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).~For children who were >=2 to <6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~For children who were >= 6 yrs to <12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase."
75618785|NCT01154153|Drug|Claritin® Syrup|Children's Claritin® Syrup [5 mg of loratadine per 5 mL] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
75618786|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
75618787|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
75618788|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
75772449|NCT03717064|Drug|Pitavastatin|Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.
75772450|NCT03716050|Drug|Nitroglycerin|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
75772451|NCT03716050|Device|Negative Pressure Wound Therapy/ Wound VAC|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 3,4,7,and 8 will receive iVAC therapy.
75772452|NCT03716050|Other|Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg)|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 5,6,7,and 8 will receive angiography.
75911675|NCT02059785|Drug|Pinocembrin for Injection|
75911676|NCT04383574|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd..Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (600SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
75319186|NCT04195724|Other|mNGS for pathogen detection|mNGS for pathogen detection and metabonomics (ascites, fecal,venous blood from superior mesenteric vein, hepatic vein and peripheral vein, respectively)
75772453|NCT03716050|Other|No treatment|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 1 will include no treatment.
76072726|NCT01613131|Drug|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
76072727|NCT01613131|Drug|Estradiol|Topical, .06%, Applied once daily for 50 days.
76072728|NCT01613131|Drug|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
76072729|NCT01798342|Dietary Supplement|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
75319187|NCT00548197|Drug|Bevacizumab|one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
75772454|NCT05693584|Other|distraction|diverting the patient's attention with virtual reality glasses
75772455|NCT03782038|Device|MCD|Micro coring skin removal with automated coring device
75772456|NCT02069860|Device|Bone Anchored Port System (BAP)|The port body will be implanted onto the petrous bone and a sealing cap, a twofold valve system and a catheter are connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation.
75772457|NCT01310920|Other|observation|genotyping
75772458|NCT03785860|Other|Dietary Fiber|Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
75772459|NCT03785860|Other|Placebo|Placebo will be given in a powder form to mix with a beverage of one's choice.
75319188|NCT04029272|Drug|Metformin|500 mg tid for 12 weeks
75772460|NCT00413231|Device|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
75772461|NCT01988584|Biological|umbilical cord blood (hUCB) cells|Autologous umbilical cord blood banked with the Cord Blood Registry.
75772462|NCT01988584|Drug|Saline Infusion (Placebo)|A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.
75319189|NCT04029272|Drug|Exenatide 2 MG|Exenatide injection once weekly for 12 weeks
75618789|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
75618790|NCT00691561|Behavioral|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
75772463|NCT01988584|Biological|bone marrow derived mononuclear cells (BMMNCs)|Autologous stem cells from bone marrow harvest.
75618791|NCT00684229|Procedure|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
75618792|NCT00684229|Drug|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
75772464|NCT02113163|Drug|Metformin Eicosapentaenoate|
75772465|NCT02113163|Drug|Metformin HCl and Vascepa|
75772466|NCT00413153|Drug|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
75911677|NCT04383574|Biological|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd..Two doses of high dosage (1200SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (1200SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
75319190|NCT02985164|Radiation|PDSa|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).
75319191|NCT02985164|Radiation|PDSb|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
75319192|NCT00548431|Drug|6-mercaptopurine|Standard dose 25 mg/m^2/day. Can be increased up to 75 mg/m^2/day if the myelosuppression is acceptable (ANC>0.5 T-count >50)
75618793|NCT02887001|Other|Pharmacist consultation|
75772467|NCT00413153|Drug|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
75772468|NCT01308502|Device|Dx-pH probe|Dx-pH probe with 24 hour recording
75772469|NCT01310998|Behavioral|High intensity exercise|4x4 intervals
75772470|NCT02107937|Biological|DCVAC/OvCa with Standard of Care|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
75772471|NCT02107937|Biological|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
75772472|NCT02107937|Drug|Standard of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
75772473|NCT03781882|Procedure|Platelet rich plasma infiltration in the wound edges|platelet rich plasma will be injected in the wound edges
75772474|NCT03781882|Procedure|Closure of wound without platelet rich plasma infiltration|No infiltration of platelet rich plasma is done
75772475|NCT01038479|Dietary Supplement|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
75772476|NCT01038479|Behavioral|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
75772477|NCT03793192|Other|PACE2 Intervention|Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
75772478|NCT01035125|Behavioral|Self-management program|Participants will receive a one week inpatient self-management program
75772479|NCT03793270|Diagnostic Test|for patients and healthy donors|"Detection of (CD19, CD24, CD38 & CD27) markers in peripheral blood samples by Flow Cytometry~Determine the serum level of IL 10 using ELISA plate"
75772480|NCT03781648|Diagnostic Test|NBI withdrawal method|The newly available second generation of NBI using the 290 system (290-NBI) provides an at least twofold brighter image compared with the previous version
75772481|NCT01312090|Biological|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (-30°Cand-60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
75911678|NCT04383574|Biological|Two doses of placebo at the schedule of day 0,28|The placebo was manufactured by Sinovac Research & Development Co., Ltd., Two doses of placebo at the schedule of day 0,28,and one dose of booster immunization with placebo 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
75911679|NCT04383574|Biological|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd..Two doses of low dosage (300SU/0.5ml)experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with low dosage (300SU/0.5ml) experimental vaccine 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
75911680|NCT04876768|Procedure|Use of different concentrations of oxygen during ERCP|The endoscopic intervention will be conducted in the endoscopy suite located at UK Albert B. Chandler Hospital in Lexington, Kentucky. ERCP/EUS uses an endoscope which is a long flexible narrow tube with a camera at the end is passed through the mouth, esophagus, stomach and the first part of the duodenum. The goal is to access a small elevation in the duodenum called the papilla of Vater. This papilla drains the biliary and pancreatic ducts which brings digestive juices from the liver, gallbladder and the pancreas. The endoscopist will inject contrast dye through the papilla into the ducts and takes X-rays to show lesions such as stones, strictures or blockages. If appropriate these can be treated by passing instruments through a port in the endoscope. Immediately following the endoscopic intervention; complications (bleeding, aspiration, perforation) will be recorded by study personnel as either yes or no, which will be used to assess the overall success of the procedure.
75319193|NCT04195412|Device|tDCS + upper limb rehabilitation|Stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. Stimulation intensity will be 2 mA with current ramping up and down of 10 seconds each. The stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
75464978|NCT01884428|Drug|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
75464979|NCT01884428|Drug|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
75618794|NCT04236622|Other|Periodontal clinical exam|"The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis."
75618795|NCT04313387|Diagnostic Test|Corneal tomography multivariate index derived from a support vector machine (CTMVI).|MATHEMATICAL ALGORITHM: To build the equation extracted from SVM, 58 variables were used, some of them were extracted from the spreadsheet.. After the construction of these 58 feature vectors (FV), an SVM-derived index was created, which was called the corneal tomography multivariate index derived from a support vector machine (CTMVI). Considering that each patient represents a point on a cartesian plane with 58 dimensions (each coordinate representing one of the 58 FV), the role of SVM is to find the hyperplane that best separates the CG, KCG, and VAE-NT G subjects. A hyperplane is algebraically described by a linear equation; in this case, there are 59 coefficients, 58 of which are related to the FV and one independent coefficient representing the bias (which is a possible parallel dislocation of a given hyperplane).
75618796|NCT02804620|Behavioral|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
75618797|NCT00690079|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol*h/L
75618798|NCT00690079|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
75618799|NCT05251415|Biological|Blood sampling|Blood will be taken in larger quantity.
75618800|NCT02805712|Other|Verbal Information and Discussion|Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.
75618801|NCT02805712|Other|Control|The control group will receive usual written care material and a palliative care consult if ordered by physician.
75772482|NCT01312090|Behavioral|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
75618802|NCT00874237|Drug|Inhaled loxapine|Inhaled Staccato Loxapine 10 mg single dose
75772483|NCT01312402|Drug|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
75772484|NCT01312402|Drug|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
75464980|NCT01884441|Drug|Bendamustine|"Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles"
75464981|NCT01884441|Drug|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
75464982|NCT01884441|Drug|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
75464983|NCT01884454|Behavioral|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
75464984|NCT01884467|Drug|Gentamicin|Comparison of Gentamicin versus placebo
75464985|NCT01884467|Drug|Placebo|
75618803|NCT00874237|Drug|Inhaled placebo|Inhaled Staccato placebo single dose
75618804|NCT00874237|Drug|Oral moxifloxacin|Oral moxifloxacin 400 mg
75464986|NCT01884493|Device|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
75464987|NCT01884493|Device|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
75772485|NCT01312480|Other|5A's Model|"The smoking cessation intervention is based on the 5A's model, which includes the following elements:~Ask if the patient smokes.~Advise every patient to quit.~Assess readiness to quit.~Assist in quitting and finding services.~Arrange for cessation services and follow-up."
75911681|NCT03046108|Device|blind injection of Morton neuroma|Introduction of a needle based in anatomical landmark
75464988|NCT01884506|Dietary Supplement|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
75464989|NCT01884506|Dietary Supplement|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
75464990|NCT01884532|Device|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
75464991|NCT01884558|Drug|isavuconazole|oral
75464992|NCT01884558|Drug|metformin|oral
75464993|NCT01884584|Drug|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
75464994|NCT01884623|Drug|Cetuximab|
75464995|NCT01884623|Drug|Methotrexate|
75464996|NCT01884636|Drug|isavuconazole|oral
75464997|NCT01884636|Drug|methotrexate|oral
75464998|NCT01884662|Behavioral|Virtual walking|"As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking."
75464999|NCT01884662|Behavioral|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
75465000|NCT01884701|Device|ENABLER-P Catheter System|
75465001|NCT01884714|Other|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
75465002|NCT01884727|Dietary Supplement|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
75465003|NCT01884727|Dietary Supplement|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
75465004|NCT01884792|Other|Sitting OGTT|
75465005|NCT01884792|Other|Standing OGTT|
75465006|NCT01884792|Other|Sitting CGM|
75465007|NCT01884792|Other|Standing CGM|
75465008|NCT01884805|Device|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
75465009|NCT01884818|Other|Manipulation vs. TNS thoracic pain|
75465010|NCT01884831|Biological|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions|
75465011|NCT01884857|Drug|Metoprolol Succinate ER Tablets 50 mg|1* 50 mg tablet once a day
75465012|NCT01884857|Drug|'TOPROL-XL®' ER Tablets 50 mg|1 * 50 mg tablet per day
75465013|NCT01884870|Procedure|Surgical Treatment|Surgical Treatment - open, endoscopic or laparoscopic
75465014|NCT01884883|Device|PROTEOR Internal unicompartmental knee brace|
75465015|NCT01884896|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
75465016|NCT01884896|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
75465017|NCT01884909|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
75465018|NCT01884909|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
75465019|NCT01884935|Biological|Natalizumab|As specified in the treatment arm
75465020|NCT01884948|Drug|Omegaven™|
75465021|NCT01884961|Other|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
75465022|NCT01884974|Other|myeloproliferative disease|Echocardiogram, demographic data, St George respiratory questioner
75465023|NCT01884987|Drug|GM1|This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
75465024|NCT01885013|Drug|Metformin + Myocet + Cyclophosphamide|"Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
75465025|NCT01885013|Drug|Myocet + Cyclophosphamide|"Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles"
75465026|NCT01885026|Behavioral|eScreen|Access to the eScreen platform offering assessment of alcohol and drug use, with automated feedback on problematic or non-problematic use. Follow-up over time based on user needs.
75911682|NCT03046108|Drug|blind injection of Mepivacaine|blind injection of 1 cc of Mepivacaine Normon 2% ®
75465027|NCT01885026|Behavioral|Assessment only of alcohol and drug use.|Assessment of alcohol and drug use at baseline and follow-up.
75618805|NCT00874237|Drug|Oral placebo|Oral placebo similar in appearance to moxifloxacin 400 mg
75618806|NCT02805946|Drug|posaconazole|iv versus oral
75618807|NCT05544604|Device|Transcranial direct current stimulation|tDCS will be delivered with current strength of 2 mA for 20 min . Current will be applied through two concentric electrodes target electrode; return electrode. First we will fill the electrode cage with an electroconductive gel, and then position the electrodes, with the target electrode over the FDI hotspot, and finally we fasten the electrodes with a tubular net-shaped elastic bandage in mesh tissue, making sure that it will not push the electrode forward or backward. This procedure will aim at reducing contact impedance and at creating a uniform adherence between the whole surface of the electrodes and the scalp, avoiding uneven distribution of the current (Fertonani, 2015). We will position the central electrode (anode) according to the study group over C3 or C4 , the stimulating electrode will be placed on the scalp at T7 or T8 for the insular cortex per the 10-20 (EEG) system.
75618808|NCT04139005|Behavioral|Awareness|The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
75618809|NCT04139005|Behavioral|Connection|The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
75618810|NCT04139005|Behavioral|Insight|The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
75618811|NCT01153841|Biological|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
75618812|NCT01153841|Biological|Infanrix hexa™|Intramuscular, 3 doses
75618813|NCT02804386|Drug|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
75618814|NCT02805868|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
75618815|NCT02805868|Other|Laboratory Biomarker Analysis|Correlative studies
75618816|NCT02805868|Biological|Siltuximab|Given IV
75618817|NCT00691639|Other|Blood Collection Only|Blood Collection Only
75618818|NCT02805634|Other|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
75618819|NCT02805634|Device|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
75618820|NCT00684385|Drug|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H&NC will take two tablets at each dose administration.
75618821|NCT02690038|Drug|Intravenous immunoglobulin (IVIG)|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization"
75618822|NCT02690038|Drug|Normal Saline|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization"
75618823|NCT00691795|Drug|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
75618824|NCT04136821|Dietary Supplement|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
75772486|NCT01312480|Other|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
75465028|NCT01885026|Behavioral|Internet-based treatment for depression or anxiety|Internet-based treatment for primary diagnoses of depression, panic anxiety or social phobia.
75618825|NCT04136821|Other|Resistance Training|6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
75911683|NCT03046108|Drug|blind injection of Triamcinolone|blind injection of 40 mg of triamcinolone (trigon depot ®)
75618826|NCT02805556|Drug|BMS-663068|Single oral dose of BMS-663068
75618827|NCT02805556|Drug|BMS-626529|Single intravenous dose of [13C]BMS 626529
75465029|NCT01885052|Behavioral|QuitTXT Study|Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.
75465030|NCT01885052|Behavioral|Low Contact|
75465031|NCT01885065|Other|Gel-based artificial saliva|"Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.~Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks."
75618828|NCT04136977|Device|Eustachian tube dilation|Unilateral or bilateral balloon dilation of the Eustachian tube using the FDA-cleared XprESS ENT Dilation System
75618829|NCT00694291|Drug|Sorafenib|400 mg orally twice daily
75618830|NCT00694291|Drug|Placebo|Matching Placebo
75618831|NCT04100902|Drug|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
75465032|NCT01885091|Other|Kinerase|
75465033|NCT01885143|Radiation|Digital Breast Tomosynthesis|
75772487|NCT00412607|Device|NAVISTAR® THERMOCOOL® Catheter|The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
75772488|NCT03785392|Procedure|Group 1 In-plane|"Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block."
75911684|NCT03046108|Device|ultrasound guided injection|Introduction of a needle based guided by ultrasound
75618832|NCT04100902|Drug|Placebo sublingual tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
75618833|NCT01153763|Drug|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
75618834|NCT00691873|Drug|Placebo|placebo
75618835|NCT00691873|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
75618836|NCT02805322|Device|ARC InstaTemp MD|Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
75618837|NCT02805322|Device|Covidien Genius 2 Tympanic Thermometer|Measurement of Tympanic Temperature using a standard approved method - Control arm.
75618838|NCT02805322|Device|Welch Allen SureTemp Plus Sublingual Thermometer|Measurement of Sublingual Temperature using a standard approved method - Control arm.
75772489|NCT03785392|Procedure|Group 2 out of plane|Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
75772490|NCT01035203|Behavioral|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
75772491|NCT01035203|Behavioral|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
75772492|NCT05693428|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 5-6 mg/kg/h intravenously on a perfusor.
75772493|NCT05693428|Drug|Isoflurane|isoflurane was used as anaesthetice of - 1.1-1.2 MAC.
75772494|NCT05693428|Drug|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
75772495|NCT01035281|Drug|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
75772496|NCT05693350|Diagnostic Test|DUS|Duplex ultrasound
75772497|NCT01035359|Procedure|External fixation|Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
75618839|NCT05538052|Drug|Tramadol hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
75618840|NCT05538052|Drug|Lidocaine Hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
75618841|NCT05298475|Drug|Statin|Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
75772498|NCT01035359|Procedure|Volar plate|Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
75772499|NCT01561066|Procedure|Autologous platelet-rich fibrin glue (PRFG)|"Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.~PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings."
75772500|NCT01561066|Drug|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
75772501|NCT03793036|Dietary Supplement|preoperative nutrition|The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
75772502|NCT00419003|Drug|Lamotrigine|anticonvulsant medication
75772503|NCT00419003|Drug|Ketamine|subanesthetic dose of NMDAR antagonist
75772504|NCT00419003|Drug|Riluzole|glutamate release inhibitor
75772505|NCT03793348|Device|MCD|Micro coring skin removal with automated coring device
75772506|NCT01035437|Drug|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
75772507|NCT00418691|Drug|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
75911685|NCT03046108|Drug|guided injection of mepivacaine|ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
75618842|NCT05298475|Drug|PCSK9 inhibitor|1 injection of PCSK9 inhibitor once a month SC
75618843|NCT05298475|Drug|PCSK9 inhibitor|1 injection of PCSK9 inhibitor twice a month SC
75618844|NCT02884505|Device|Pupillometry|Measures pupillary dynamics in darkness and light conditions
75618845|NCT02884505|Behavioral|Psychomotor Vigilance Task|Response time task measuring neurobehavioral alertness
75618846|NCT02884505|Other|Auditory Evoked Potential|Measure of electroencephalographic response to standardized auditory tones
75618847|NCT02884505|Behavioral|Hypersomnia Severity Index|Self-report measure of hypersomnolence
75618848|NCT02805400|Other|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
75618849|NCT00691951|Drug|budesonide and budesonide/formoterol|
75319194|NCT04195412|Device|Sham tDCS + upper limb rehabilitation|Sham stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each sham stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. The anode will be placed to the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off automatically after 30 seconds. The sham stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
75618850|NCT05355233|Other|bebo concept|techniques to remove urinary incontinence
75772508|NCT00418691|Drug|Modafinil|200 mg PO Once Daily x 4 Weeks
75319195|NCT04195646|Device|EndoVigilant CAD Software|The CAD software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the CAD software is installed on a computer system unit that utilizes an an operating system.
75772509|NCT00418691|Drug|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
75772510|NCT03777592|Procedure|erector spinae plane block|local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces
75772511|NCT03781258|Drug|Warfarin|Anti-thrombotic monotherapy (ASA)-Warfarin withdrawal.
75319196|NCT04020224|Device|Amustaline/GSH pathogen reduction technology|Whole blood treated with pathogen reduction technology
75319197|NCT04020224|Device|Standard of Care|Red Blood Cell Component or whole blood
75319198|NCT00522925|Drug|PS433540|200mg capsule, once daily for 28 days
75465034|NCT01885169|Biological|Flumist®|The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
75465035|NCT01885221|Behavioral|Multimedia Support Intervention|
75618851|NCT05355233|Other|diaphragmatic breathing|techniques to remove urinary incontinence
75772512|NCT03781102|Behavioral|16-Week Diabetes Prevention Program for Mothers and Children|The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
75772513|NCT05397340|Device|Deep brain stimulation|active DBS with optimal stimulating parameters
75772514|NCT00412373|Drug|Placebo|for 6 weeks
75772515|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
75772516|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
75772517|NCT05357170|Other|Human feces collection|Human feces collection and blood sampling
75772518|NCT05692726|Other|Patients|Patients will get study-specific measurements within first 5 days of standard of care treatment of hyponatremia or until discharge
75319199|NCT00522925|Drug|placebo|placebo capsule, once daily for 28 days
75319200|NCT00522925|Drug|PS433540|500mg capsule, once daily for 28 days
75319201|NCT04028882|Other|Signaling, metabolomic and transcriptomic analysis|Signaling, metabolomic and transcriptomic analysis
75319202|NCT04028726|Other|Back-squat exercise|Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.
75319203|NCT04028804|Procedure|FDG PET|Each patient will receive a single intravenous injection of FDG (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FDG are being drawn up or radioactive decay has reduced the amount of available.
75465036|NCT01885234|Other|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
75465037|NCT01885234|Other|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
75465038|NCT01885273|Procedure|Pressurized irrigation method|The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.
75618852|NCT02805166|Drug|PEG-rhG-CSF|
75618853|NCT02621671|Behavioral|Cognitive interview|
75618854|NCT02621671|Other|Survey|
75618855|NCT04316351|Drug|Toripalimab + Pemetrexed + Anlotinib|"Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).~If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit."
75618856|NCT02805244|Drug|JTZ-951, 14C-JTZ-951|
75618857|NCT00694447|Procedure|Acupuncture|
75618858|NCT02884349|Procedure|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
75618859|NCT02625337|Drug|Pembrolizumab|
75618860|NCT02625337|Drug|Dabrafenib|
75618861|NCT02625337|Drug|Trametinib|
75618862|NCT02625337|Procedure|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
75618863|NCT02625337|Procedure|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
75319204|NCT04028804|Procedure|FLT PET|The FLT PET scan will be performed 1-5 days after FDG PET in order to ensure consistency between imaging findings. Each patient will receive a single intravenous injection of FLT (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FLT are being drawn up or radioactive decay has reduced the amount of available.
75319205|NCT04020146|Other|Gingival biopsies|Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.
75319206|NCT00524017|Biological|cetuximab|given IV
75319207|NCT02985554|Drug|Nivolumab|Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
75618864|NCT04236310|Drug|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment for 4 cycles
75618865|NCT04236310|Drug|Anastrozole|Anastrozole 1md, orally once daily for 16 weeks (For premenopausal women, ovarian suppression may be considered)
75319208|NCT05560165|Procedure|F-18 sodium fluoride PET/CT guided robotic arm assisted injection of combination of local anesthetic and steroids|A surgical aseptic approach will be followed for the procedure. Local anesthesia of the skin and soft tissue at the entry site will be achieved by 1% lignocaine. A 23G lumbar puncture needle will be introduced and the real-time final placement of the needle will be confirmed with low dose CT (40 mA) fused with pre-procedure PET images. After confirming the real-time position, the local anesthetic and steroid injection (0.5ml of 0.5% Bupivacaine per joint and a total dose of 80mg of Methylprednisolone acetate divided equally based on the number of joints to be injected) will be injected intraarticularly and periarticularly around the target joint through the lumbar puncture needle. The skin entry site will be compressed manually to achieve hemostasis. The same procedure will be repeated if multiple joints are to be injected. After the procedure, patient vitals will be observed for thirty minutes in the recovery area and discharged in stable condition.
75618866|NCT04236310|Drug|Pyrotinib|Pyrotinib 400mg once daily for 16 weeks
75618867|NCT04236310|Drug|Trastuzumab|Trastuzumab 6mg/kg (loading dose, 8mg/kg), infusion once every 3-week cycle for 5 cycles.
75618868|NCT02805478|Other|There is no intervention|This is a prospective observational cohort study without any intervention
75618869|NCT04134949|Behavioral|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
75618870|NCT04134949|Behavioral|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
75319209|NCT04028258|Dietary Supplement|Mixture of fibers + Placebo|Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)
75319210|NCT04028258|Dietary Supplement|Placebo + Mixture of fibers|Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)
75319211|NCT00525421|Drug|Curcuminoids|Curcuminoids tablets 2000mg three times per day for 12 days
75618871|NCT02804308|Behavioral|Combined Training|
75618872|NCT02805088|Other|Electroencephalographic recordings|
75618873|NCT02805088|Other|neuropsychological evaluation|
75618874|NCT02805088|Other|clinical evaluation of symptoms|
75319212|NCT00525421|Drug|Placebo|
75319213|NCT04195022|Procedure|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
75618875|NCT02621515|Drug|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
75772519|NCT01308658|Drug|Darunavir (DRV)|2x400-mg DRV tablet or 800-mg tablet
75319214|NCT04195022|Procedure|Dental Restoration with Bulk fill resin composite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with bulk fill resin composite.
75618876|NCT00912613|Other|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
75618877|NCT02803918|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75618878|NCT02803918|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75618879|NCT02803918|Drug|Basal Insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75618880|NCT02803918|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
75772520|NCT01308658|Drug|ritonavir|on Day 3
75772521|NCT03785314|Other|thoracic epidural catheterization|thoracic epidural catheterization with different posture
75772522|NCT03785002|Other|Strength training|24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
75618881|NCT04138069|Other|PLB+Aerobic Bicycling|"Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes"
75618882|NCT04138069|Other|Aerobic Bicycling|"Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes"
75618883|NCT04022356|Device|Feetme Connected Soles|"Walk for 10 meters (and 30meters):~By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely."
75618884|NCT02621593|Device|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
75772523|NCT03785002|Other|Protein intake|Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
75772524|NCT03781024|Combination Product|Footwash|footbath/footwash can help cleanse the wound, remove dead tissue, increase circulation and puts the wound in direct contact with medication to promote faster healing.
75618885|NCT04236466|Device|hyrax appliance|Hyrax will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines.
75319215|NCT02128867|Other|Assisted Autogenic Drainage (AAD)|
75319216|NCT02128867|Other|bouncing and AAD|
75319217|NCT02128867|Other|bouncing|
75319218|NCT03965702|Device|Use of a decision support system on the EV1000 monitoring (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
75465039|NCT01885273|Procedure|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
75465040|NCT01885286|Procedure|circumcision with simple circumcision device|Circumcision performed with the device in the operating room using local anesthesia
75618886|NCT04236466|Device|haas appliance|Haas will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines. Acrylic part will be added on palate
75465041|NCT01885312|Behavioral|Adaptive Tailored Intervention|Adaptive
75618887|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
75772525|NCT03780946|Procedure|Magnetic anastomosis for pancreaticojejunostomy|Magnetic anastomosis for pancreaticojejunostomy
75465042|NCT01885312|Behavioral|Consequence-based Intervention|Loss Framed
75772526|NCT03780946|Procedure|Traditional hand-sewn anastomosis|Traditional manual anastomosis for pancreaticojejunostomy
75772527|NCT03777514|Drug|Ferumoxytol|treatment of iron deficiency anemia with IV iron.
75618888|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
75465043|NCT01885312|Behavioral|Tailored, not adaptive, based Intervention|Baseline tailored not adaptive
75465044|NCT01885312|Other|Assessment only|EMA only
75465045|NCT01885325|Other|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
75465046|NCT01885338|Drug|N-acetylcysteine (NAC)|
75465047|NCT01885338|Drug|Inactive placebo capsule|
75465048|NCT01885351|Behavioral|MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
75618889|NCT02805010|Drug|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
75618890|NCT02805010|Other|Placebo|On Day 1, subjects will receive a single SC dose of placebo
75618891|NCT02621437|Other|Osteopathy sessions|- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
75618892|NCT02621437|Other|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~pain questionnaire with digital scale,~quality of life survey: SF-12~HAD (Hospital and Anxiety Depression) questionnaire"
75618893|NCT02621281|Device|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
75772528|NCT03777514|Drug|Ferrous sulfate|treatment of iron deficiency anemia with oral iron
75772529|NCT03777514|Other|Oral vitamin C|Oral vitamin C to be used as a placebo for participants receiving IV iron
75772530|NCT03777514|Other|Intravenous normal saline|Intravenous normal saline will be used as placebo for participants receiving oral iron
75772531|NCT03777124|Drug|SHR-1210|Subjects receive SHR-1210 intravenous every 2 weeks
75772532|NCT03777124|Drug|Apatinib|Subjects receive Apatinib orally every day
75772533|NCT03777124|Drug|Pemetrexed|Subjects receive Pemetrexed intravenous every 3 weeks
75772534|NCT03777124|Drug|Carboplatin|subjects receive carboplatin intravenous every 3 weeks
75772535|NCT00418379|Drug|300 IR (4M)|300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
75772536|NCT00418379|Drug|300 IR (2M)|300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
75772537|NCT00418379|Drug|Placebo|Placebo tablet
75772538|NCT03780556|Drug|Lornoxicam and mepridine|compare the effect of each to control pain
75772539|NCT01038791|Device|heated humidification|temperature 35°
75772540|NCT01038791|Device|heat and moisture exchanger|single patient device
75772541|NCT01038791|Device|usual mechanical ventilation without humidification|mechanical ventilation with usual parameters
75772542|NCT03780868|Procedure|external dacryocystorhinostomy|external DCR under general anesthesia with standard sterilization procedures.
75772543|NCT03780868|Procedure|canalicular silicone intubation with MMC|canalicular silicone intubation with MMC under general anesthesia with standard sterilization procedures.
75772544|NCT00418145|Drug|megadose oral methylprednisolone|1400 mg qd/5 days
75772545|NCT00418145|Drug|IV methylprednisolone|1000 mg/qd/5 days
75772546|NCT03780634|Procedure|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
75772547|NCT03780634|Drug|PD-1 antibody|200mg intravenously every 3 weeks
75772548|NCT03780634|Drug|Sorafenib|400 mg Bid Po
75772549|NCT03780478|Drug|Nerve block|0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
75772550|NCT03780478|Drug|Placebo Saline Injection|Saline injection, total volume 2ml
75772551|NCT03785080|Other|restart NOAC very early|withhold NOAC less than 24 hours Post OGD
75772552|NCT03785080|Other|restart NOAC early|withhold NOAC for 72 to 84 hours Post OGD
75772553|NCT03777358|Device|3D-TVS|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then hysteroscopy will be performed
75772554|NCT03777280|Device|peek framework RPD|it is a polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base made by injecting technique and have several advantages regarding strength and esthetics
75772555|NCT03777280|Device|cobalt chromium framework RPD|standard framework device
75772556|NCT00417989|Device|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
75772557|NCT03784768|Other|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
75911686|NCT03046108|Drug|guided injection of Triamcinolone|ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
75911687|NCT01370733|Device|NEST-1 (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.
75319219|NCT03965702|Other|Manual application of the GDFT protocol (standard of care)|Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
75465049|NCT01885351|Behavioral|MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
75465050|NCT01885364|Drug|Normal saline|intravenous injection with normal saline before injection of propofol
75465051|NCT01885364|Drug|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
75465052|NCT01885364|Drug|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
75465053|NCT01885364|Drug|propofol|intravenous injection after pretreatment
75465054|NCT01885390|Device|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
75465055|NCT01885403|Device|non-invasive respiratory parameter measurements|
75465056|NCT01885416|Other|consumption of test meal based on dairy products|
75465057|NCT01885416|Other|consumption of high fat test meal without dairy products|
75465058|NCT01885416|Other|consumption of high fat test meal with dairy products|
75465059|NCT01885429|Dietary Supplement|Positive Control|Subject consumes 25g of whey protein following unilateral exercise
75465060|NCT01885429|Dietary Supplement|Negative Control|Subject consumes 6.25g of whey protein following unilateral exercise
75465061|NCT01885429|Dietary Supplement|Low Protein Low Leucine Spike|Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
75465062|NCT01885429|Dietary Supplement|Low Protein High Leucine Spike|Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
75465063|NCT01885429|Dietary Supplement|Low Protein + High Leucine + BCAA Spike|Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
75465064|NCT01885442|Device|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
75618894|NCT02621281|Device|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
75618895|NCT02803996|Drug|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
75618896|NCT02803996|Drug|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
75319220|NCT04194866|Other|receiving operation during the day or at night|120 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and in the Night Group (18:00-22:00)
75319221|NCT00525733|Drug|darunavir 800 mg|darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
75618897|NCT04136431|Other|Programed cryotherapy and continuous passive motion|The intervention group started to use a CPM machine and applied programed cryotherapy intermittently within one hour while returning to the ward on the day of surgery.
75618898|NCT04136431|Other|Unrogramed cryotherapy and continuous passive motion|A CPM machine and cryotherapy were not applied on the day of surgery while returning to the ward
75618899|NCT02800954|Biological|blood samples|
75618900|NCT02800954|Biological|Bone marow samples|
75618901|NCT00694681|Behavioral|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
75772558|NCT03784768|Other|Control Group|Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
75319222|NCT00525733|Drug|FTC 200 mg/TDF 300mg|Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
75772559|NCT03780712|Other|Non applicable|No intervention as it is an observational study
75772560|NCT01038947|Biological|Uricase-PEG 20|Intramuscular injection of Uricase-PEG 20 without premedication
75319223|NCT00525733|Drug|Maraviroc|Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
75465065|NCT01885455|Other|Usual Care|Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
75772561|NCT03777046|Behavioral|Standard of Care (SOC)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
75772562|NCT03777046|Behavioral|SOC with Psychology Therapy (CBT)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
75772563|NCT03780166|Drug|Parsaclisib|Parsaclisib administered orally once daily at the cohort-specified dose level.
75772564|NCT02043587|Drug|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
75772565|NCT02043587|Drug|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages >50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
75772566|NCT02043587|Drug|PEG-asp|2,000 IU/m2 IV for ages </= 50, age > 50, 1000 IU/m2 IV Day 16, Courses 1A & 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
75772567|NCT02043587|Drug|CTX|750 mg/m2 IV, days 1 &15 for subjects <40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 & 16 for subjects < 40 years of age if day 14 bone marrow M2 or M3; Courses 1A & 2A
75772568|NCT02043587|Drug|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A & 2A; Maintenance: Monthly, days 1-5
75772569|NCT02043587|Drug|Liposomal AraC|25 mg intrathecal (IT), on days 1 & 15 during Courses 1A & 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
75772570|NCT02043587|Drug|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B & 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
75772571|NCT02043587|Drug|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B & 2B
75772572|NCT02043587|Drug|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C & 2C
75772573|NCT02043587|Drug|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C & 2C
75772574|NCT02043587|Drug|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
75772575|NCT02043587|Drug|Rituximab|375 mg/m2 IV once daily on days 1 & 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C & 2A
75772576|NCT02043587|Drug|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
75319224|NCT00525733|Drug|Raltegravir|Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
75772577|NCT01561222|Drug|Calcitriol|0.25 ug per day for one year
75772578|NCT01561222|Drug|placebo|one pill per day
75772579|NCT05289154|Other|self- applied acupressure plus Qigong course plus advice literature|daily self applied acupressure over 20min plus 2 times per week online live Qigong course of each 45min- both over 8 weeks.
75772580|NCT05289154|Behavioral|advice literature with naturopathy|advice literature with naturopathic remedies will be handed out and application will be supported with dairies and phone calls
75319225|NCT00525733|Drug|Ritonavir 100 mg|one tablet of ritonavir is taken with darunavir daily
75465066|NCT01885455|Other|Intervention Arm|The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
75772581|NCT01035515|Drug|Placebo|Single dose oral capsule placebo comparator
75772582|NCT01035515|Drug|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
75772583|NCT01035515|Drug|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
75772584|NCT01308892|Dietary Supplement|High flavanol chocolate|chocolate high in flavanols
75772585|NCT01308892|Dietary Supplement|Low flavanol chocolate|chocolate low in flavanols
75319226|NCT04028336|Other|TITRATION|PEP titration pulmonary opening (PEP-OP) was performed in all patients followed by new LUS and Peso measurement.
75319227|NCT00526123|Device|Symmetric Tip Catheter|Dialysis catheter
75319228|NCT00526123|Device|Conventional Split-tip Catheter|Dialysis Catheter
75319229|NCT04406324|Other|No intervention|No Intervention. The study consists in a prospective clinical longitudinal follow-up
75772586|NCT01308892|Dietary Supplement|High fat challenge|Milkshake with 95g fat
75772587|NCT01039025|Drug|Topotecan|After stem cells are collected, Topotecan 3.5 mg/m^2 intravenously given over 30 minutes on Days 1 - 5.
75772588|NCT01039025|Drug|Cyclophosphamide|After stem cells are collected, Cyclophosphamide 1 g/m^2/day intravenously given over 2 hours on Days 1 - 3.
75772589|NCT01039025|Drug|Melphalan|After stem cells are collected, Melphalan 70 mg/m^2/day intravenously given on Days 4 and 5.
75772590|NCT01039025|Other|Peripheral Blood Stem Cells|On Day 7, some or all of the stem cells will be reinfused.
75618902|NCT02800564|Behavioral|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
75618903|NCT02800564|Behavioral|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
75618904|NCT04236232|Diagnostic Test|Thyroid function|Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery
75618905|NCT02803762|Drug|Pacritinib|400 mg [14C]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
75618906|NCT00871741|Biological|GSK2202083A vaccine|Intramuscular, three doses
75618907|NCT00871741|Biological|Infanrix hexa|Intramuscular, three doses
75618908|NCT00871741|Biological|Menjugate|Intramuscular, two doses
75618909|NCT02800408|Other|Whole grain high-BCX maize|The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
75618910|NCT02800408|Other|Refined grain high-BCX maize|The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
75618911|NCT02800408|Other|Whole grain white maize|The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
75618912|NCT02800720|Behavioral|Meditation Awareness Training|8 Week Meditation Intervention
75618913|NCT02800720|Behavioral|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
75772591|NCT01308970|Behavioral|Stress Management Group 1|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
75772592|NCT01308970|Behavioral|Stress Management Group 2|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
75772593|NCT01308970|Behavioral|Stress Management Group 3|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
75772594|NCT03776968|Drug|HC1119|oral
75772595|NCT03779776|Other|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at 1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
75911688|NCT01370733|Device|SHAM|The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
75911689|NCT03048292|Other|Acute Endovascular Stroke Treatment|
75911690|NCT02061189|Other|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
75911691|NCT02613364|Behavioral|Behavioral Intervention|Undergo yoga intervention
75911692|NCT02613364|Other|Cognitive Intervention|Undergo CBT-I intervention
75911693|NCT02613364|Other|Educational Intervention|Receive health education
75911694|NCT02613364|Other|Laboratory Biomarker Analysis|Correlative studies
75319230|NCT04194710|Biological|Autologous Cytokine Rich Serum|"Proteins, called cytokines, released from blood platelets and leukocytes, play an important role in the repair and regeneration of the injured tissue that causes lateral epicondylitis.~Autologous Cytokine Rich Serum is prepared by the medical devise Q-Cytokine (CE MED31489) from patient's blood. The company Tecnologia Regenerativa Qrem S.L., with licence number 7096-PS from Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), is the manufacturer of this product. Q-Cytokine is a lab-in-a-box devise, and consist of an automatic centrifuge and a sterile disposable kit. After 9 steps of centrifugation, that take place in 36 minutes, Cytokine Rich Serum is obtained. This Cytokine Rich Serum is then injected to the epicondyle.~Patients randomized to this treatment will receive 1 injections of Autologous Cytokine Rich Serum right after randomization and another one after 15 days.~This process will take place at outpatient clinics."
75465067|NCT01885481|Drug|Dexamethasone|epidural steroid injection using dexamethasone
75465068|NCT01885481|Drug|Betamethasone|epidural steroid injection using betamethasone
75465069|NCT01885507|Other|Pass recommendations on ventilation factors and extubation|"the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
75465070|NCT01885520|Dietary Supplement|fasting condition|eperisone SR tablet 75mg administrated under fasting
75465071|NCT01885520|Dietary Supplement|fed condition|eperisone SR tablet 75mg administrated fed condition
75465072|NCT01885546|Device|AgaMatrix Blood Glucose Monitor|
75465073|NCT01885572|Device|TiLOOP Bra|Titaniferously coated polypropylene mesh
75465074|NCT01885585|Drug|Apixaban|
75465075|NCT01885598|Drug|Apixaban|
75465076|NCT01885611|Other|Multi-Drug Therapy (Novartis Ⓡ)|The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
75911695|NCT02613364|Device|Monitoring Device|Correlative studies
75911696|NCT02613364|Other|Quality-of-Life Assessment|Ancillary studies
75911697|NCT02061267|Dietary Supplement|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
75911698|NCT02061267|Dietary Supplement|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
75772596|NCT03779776|Other|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
75772597|NCT00412217|Drug|Placebo|Participants will receive placebo tablets (matched to erlotinib) once daily.
75465077|NCT01885611|Dietary Supplement|Virgin Coconut Oil|cold-processed VCO
75465078|NCT01885624|Biological|TAB08|monoclonal antibody
75772598|NCT00412217|Drug|Erlotinib|Erlotinib will be given as 150 mg PO once daily.
75772599|NCT00412217|Other|Standard of care|Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.
75772600|NCT05510440|Dietary Supplement|Alpha-amino acid derivatives|Alpha-amino acid derivatives mainly citrulline will be used as a supplement to reduce kidneys and other internal organs damage
75772601|NCT01312558|Behavioral|Prudent diet group|
75772602|NCT01312558|Behavioral|Mediterranean diet group|
75465079|NCT01885650|Other|Airway Clearance Techniques|
75465080|NCT01885663|Procedure|Umbilical cord blood therapy|Intravascular umbilical cord blood therapy
75465081|NCT01885676|Device|PRGF-Endoret|PRGF-Endoret mesotherapy micro injection.
75465082|NCT01885676|Other|Saline Solution|Saline Solution mesotherapy micro injection
75465083|NCT01885715|Drug|Injection of neostigmine|"At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms."
75465084|NCT01885728|Dietary Supplement|An arginine rich nutritional supplement|Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
75618914|NCT02625025|Procedure|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
75772603|NCT01035593|Procedure|plasmapheresis and IVIG|Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
75772604|NCT01035593|Drug|recombinant C1 inhibitor|100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
75772605|NCT03784534|Other|Imaging|high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan
75772606|NCT03784534|Behavioral|Clinical and behavioral testing : Motor recovery progress|NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth
75772607|NCT03784534|Behavioral|Clinical and behavioral testing : Motor skills|the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
75618915|NCT02625025|Procedure|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
75772608|NCT03776734|Other|Cryotherapy application|Effects of 5-10- 20 minutes cold application on quadriceps muscle
75772609|NCT01317784|Device|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
75772610|NCT01317784|Device|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
75772611|NCT01317784|Device|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
76072730|NCT01798342|Dietary Supplement|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
75465085|NCT01885741|Device|IPBS|
75465086|NCT01885780|Device|Laser-assisted Astigmatic keratotomy|Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
75465087|NCT01885793|Device|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
75618916|NCT02625025|Procedure|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
75618917|NCT00692263|Drug|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
75618918|NCT00692263|Drug|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
75618919|NCT00692263|Drug|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
75618920|NCT00694759|Drug|pioglitazone|30 mg for 2 weeks, then 45 mg daily
75618921|NCT00694759|Drug|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
75618922|NCT00694759|Drug|placebo|capsule twice daily
75618923|NCT02803840|Radiation|Low-dose radiotherapy|2 x 2 Gy on symptomatic sites only
75772612|NCT01317784|Device|HIV only|Choice of 4 different tests for HIV only.
75772613|NCT01318330|Drug|Homeo-GH|Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
75772614|NCT03780088|Behavioral|mTranS-C|mobile health
75772615|NCT03779698|Other|BiodentineTM|In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
75772616|NCT03779698|Drug|Formocresol|In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
75772617|NCT03779542|Procedure|cataract surgery|phacoemulsification and intraocular lens implantation
75772618|NCT03779464|Drug|S1 or Gemcitabine|Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area < 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area >1.5 m²; D1-14, q3w)
76072731|NCT04410835|Diagnostic Test|Online Survey|Psychological questionnaires
75772619|NCT05489380|Device|AccuMeasure|intracolonoscopy measurement of polyps using a laser-based device
75772620|NCT03776578|Procedure|swallow fuction and swallow training|nasogastric tube dependence rate
75772621|NCT01314820|Other|normal saline injection|20 cc normal saline injection into knee joint
75618924|NCT00694837|Drug|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
75772622|NCT01314820|Other|sham injection|no saline injection
75772623|NCT03784690|Other|Individualized intraoperative BP management|"In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).~Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status."
75772624|NCT03784690|Other|Standard intraoperative BP management|Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.
75772625|NCT05091502|Diagnostic Test|Personalised musculoskeletal modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop personalised musculoskeletal models
75618925|NCT02800252|Drug|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
75772626|NCT01309048|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
75319231|NCT04194710|Procedure|Arthroscopic Resection|"Surgical treatment of resection by arthroscopy is the standard treatment for chronic epicondylitis. The surgery is performed in the operating room under local anesthesia and lasts approximately 30 minutes. During the surgery, the doctor accesses the tendon by arthroscopy to perform an exeresis of the degenerated tendon. After the operation, the patient is directed to the recovery room where the responsible doctor will perform a physical examination and examination before leaving the center.~This process will take place at the major ambulatory surgery center of the investigator's hospital."
75319232|NCT04026854|Behavioral|Quality of live at work|The judging criteria will be collected using two questionnaires: a questionnaire sent to the local referent of each center and a questionnaire for each nurse. Because the study is longitudinal (two collections of data), the questionnaires will be completed twice to twelve months apart by the same nurses.
75618926|NCT02800252|Drug|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
75618927|NCT02800252|Drug|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
75618928|NCT02621359|Drug|Nitazoxanide|Nitazoxanide 500 mg twice daily
75772627|NCT01309126|Biological|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
75772628|NCT01309126|Drug|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
75772629|NCT03784378|Drug|RXDX-105|RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
75772630|NCT03784456|Dietary Supplement|25% protein|Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
75772631|NCT03784456|Dietary Supplement|15% protein|Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
75772632|NCT01314898|Drug|3 mg PF-03882845|3 mg PF-03882845, single oral dose
75772633|NCT01314898|Drug|10 mg PF-03882845|10 mg PF-03882845, single oral dose
76072732|NCT05363098|Other|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
75772634|NCT01314898|Drug|30 mg PF-03882845|30 mg PF-03882845, single oral dose
75319233|NCT04027790|Diagnostic Test|Epi proColon|Analysis of DNA methylation status for Septin9 and additional biomarkers
75319234|NCT04028024|Drug|Ulinastatin|Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta
75772635|NCT01314898|Drug|100 mg PF-03882845|100 mg PF-03882845, single oral dose
75772636|NCT01314898|Drug|Spironolactone|100 mg spironolactone, single oral dose
75772637|NCT03779386|Other|music|music during labor and delivery
75319235|NCT00444821|Device|AneuRx AAA stent graft / Talent AAA stent graft|Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
75618929|NCT02621359|Drug|Levofloxacin|Levofloxacin 500 mg once daily
75618930|NCT02621359|Drug|Doxycyclin|Doxycyclin 100 mg twice daily
75618931|NCT02621359|Drug|Omeprazole|Omeprazole 40 mg twice daily
75618932|NCT02800018|Other|risk factors|investigators will analyze if certain risk factors will influence the progression of the encephalopathy
75618933|NCT01152437|Drug|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
75618934|NCT01152437|Drug|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
75772638|NCT03779308|Device|whole body vibration therapy|The study participants will receive the WBVT when standing still on a vibration platform independently or with own hand support on the platform rail. The vibration protocol is modified from the study by Gusso et al (2016). The WBVT training is of 20 Hertz, a peak-to-peak amplitude of 2 mm and peak acceleration of 15.79m/s or 1.61g. The sessions will be 18 minutes in length, 4 days per week for 4 weeks. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the desired parameters.
75618935|NCT02800174|Device|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
75618936|NCT02800174|Drug|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
75772639|NCT03776422|Behavioral|Mobile self-help intervention|Participants receive several apps on their phone including IntelliCare apps, which are based on principles of cognitive-behavioral therapy. Participants also receive the Pocket Helper app, which has been designed for this study. The tools within the Pocket Helper app include a crisis text line that is available 24/7, the Illinois Warm Line which is available Monday through Friday from 8am to 5pm, directions to call 911 in the case of an emergency, the Koko web app that provides crowdsourced emotional support, brief cognitive-behavioral interventions, daily tips, and daily surveys. Phones will also include the StreetLight Chicago app, which provides homeless individuals with up-to-date information on shelters, health clinics, emergency contacts, mental health services, and more.
75772640|NCT03778918|Other|inflammatory bowel disease|blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP
75772641|NCT03778918|Other|IBS or Normal Control|blood based biomarker compared normal control with IBD
75772642|NCT03784144|Diagnostic Test|Biering-Sorensen Test and Prone Plank Test|All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.
75772643|NCT01560676|Behavioral|HEALTH[e]TEEN|8 lessons over 6-8 weeks
75772644|NCT01560676|Behavioral|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
75772645|NCT01315366|Dietary Supplement|Euro D and Ci-CalD|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
75772646|NCT01315366|Dietary Supplement|Euro D, Ci-CalD|Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
75772647|NCT03778762|Procedure|Blind tracheal intubation through AirQ|underwent blind intubation with correction manoeuvres
75772648|NCT03778762|Procedure|Fiberscopic tracheal intubation through AirQ|: underwent fibreoptic guided intubation
75772649|NCT01315756|Device|Use of Few Touch Application (FTA)|"The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user."
75911699|NCT02061267|Dietary Supplement|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
75911700|NCT02061267|Dietary Supplement|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
75319236|NCT04027634|Other|Baduanjin program|This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
75618937|NCT04137913|Behavioral|Musical arts intervention|A 6-week group music class that incorporates listening, theory, performance, and creation of music.
75618938|NCT02800330|Drug|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
75319237|NCT00526591|Drug|Everolimus|Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
75319238|NCT00526591|Procedure|conventional surgery|Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
75319239|NCT04027478|Dietary Supplement|FMD|fasting mimicking diet
75319240|NCT05559775|Drug|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
75618939|NCT02800330|Drug|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
75618940|NCT02800330|Drug|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
75618941|NCT02799862|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
75911701|NCT02060409|Genetic|spliceosome|spliceosome mutations
75911702|NCT01370655|Drug|MK-7145|
75911703|NCT01370655|Drug|Hydrochlorothiazide (HCTZ)|
75911704|NCT01370655|Drug|Placebo to MK-7145|
75911705|NCT01370655|Drug|Placebo to HCTZ|
75911706|NCT02059863|Behavioral|SPRING|SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
75911707|NCT02612194|Drug|Crizotinib|Crizotinib was administered orally at 250mg twice daily
75319241|NCT04027400|Behavioral|computer-assisted rehabilitation|Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.
75319242|NCT05559619|Drug|Calcium carbonate|1000 mg of natural calcium carbonate once daily for 12 weeks
75618942|NCT02799862|Drug|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
75618943|NCT01151579|Drug|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
75618944|NCT01151579|Drug|Albuterol|Nebulized albuterol 2.5mg
75618945|NCT00694915|Biological|Mycobacterium w|Immunomodulator
75618946|NCT00694915|Biological|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
75618947|NCT02800096|Behavioral|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
75618948|NCT02800096|Behavioral|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
75618949|NCT00694993|Drug|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
75618950|NCT00694993|Drug|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
75618951|NCT02803450|Procedure|Epidural needle|Medication administration via epidural needle.
75618952|NCT02803450|Procedure|Catheter Administration|Medication administration via epidural catheter.
75618953|NCT02803450|Procedure|Standard of Care Epidural Administration|Medication administered at higher concentration, lower volume via epidural catheter.
75618954|NCT00692497|Behavioral|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
75618955|NCT02803528|Drug|Biodentine|Biodentine is going to be used as the direct pulp capping material
75618956|NCT02803528|Drug|MTA|MTA is going to be used as the direct pulp capping material in the second group
75618957|NCT04136041|Device|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
75618958|NCT01097616|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
75618959|NCT01097616|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
75618960|NCT01097616|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
75618961|NCT02799628|Behavioral|intervention|intervention with recommendation and therapist introduction
75618962|NCT02799628|Other|placebo|low back pain education, and physical therapy 3 times per week
75618963|NCT00695071|Drug|Itraconazole|Oral
75618964|NCT04047823|Device|a digital Infrared thermography (FLIR E5 Serial No.63985976）|Measurements were taken during radiation and additionally two weeks after radiotherapy weekly. Temperature change was measured by thermal infrared imager (FLIR) for 4 test areas within the supraclavicular radiation field and on an opposite non-irradiated area, which was outlined using a specific software package (FLIR Systems 6.3.17227.1001).
75618965|NCT02799550|Biological|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
75618966|NCT00695149|Procedure|Transplantation of bone marrow stromal cell|
75319243|NCT05559619|Drug|Vitamin D3|1000 IU vitamin D3 once daily for 12 weeks
75618967|NCT04137679|Radiation|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
75618968|NCT04137679|Procedure|Neoadjuvant Radiochemotherapy followed by surgery|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
75618969|NCT04939428|Drug|Molnupiravir|Four molnupiravir 200 mg capsules taken by mouth.
75618970|NCT04939428|Drug|Placebo|Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
75618971|NCT02621125|Dietary Supplement|Fertilix|daily supplementation
75618972|NCT02621125|Other|Placebo|Placebo
75618973|NCT00695227|Diagnostic Test|Screening for Barrett's Esophagus|
75618974|NCT02799394|Other|Activity modification, exercises and gradual return to sport|
75618975|NCT00692575|Behavioral|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
75618976|NCT00692575|Other|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
75618977|NCT02803294|Procedure|transcatheter aortic valve replacement|
75618978|NCT00871429|Other|Lindi skin care products|"Subjects will then be instructed to apply all three products daily for 1 month.~The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C)."
75618979|NCT02803216|Drug|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
75618980|NCT02803216|Drug|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
75618981|NCT02803216|Drug|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
75319244|NCT05559619|Device|laser acupuncture therapy|The patient was in crock lying for stimulation of acupoints in abdomen and lower limbs then asked to be in side lying for stimulation of acupoints in the back. After disinfection of the skin and careful localization of the acupoints, low level laser therapy (LLLT) (model: Lis 1050, SN: EM 13481014, manufactured by EME srl, Italy) was applied bilaterally on Dazhu (BL 11), Ganshu(BL 18), Pishu (BL20), Shenshu (BL23), Zusanli (ST 36), Sanyinjiao (Sp6), Jingmen(GB25), Yanglingquan (GB34) andXuanzhong (GB39) acupoints, while it was applied in the midline on Guanyuan (CV4) andMingmen (GV4) acupoints. Each acupoint was irradiated for 60 sec, with total duration of 20 min, wave length of 905 nm, average radiant power output of 12 mW, energy density of 2 J/cm2, pulse radiation of 200 ms and pulse frequency of 5000 Hz
75465088|NCT01885806|Device|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
75319245|NCT04194320|Procedure|Ultrasound (US) guided supraclavicular brachial plexus block|Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block
75465089|NCT01885806|Device|Sham Magnetic Stimulator|"This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10"
75465090|NCT01885819|Biological|Autologous stromal vascular fraction cells|
75465091|NCT01885832|Biological|Autologous adipose tissue stromal vascular fraction|
75618982|NCT02624635|Other|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
75618983|NCT02624635|Other|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ [1.0278 - (0.0278 x number of repetitions)] as was used by (Shirazi et al., 2007).
75618984|NCT04308408|Behavioral|Guideline Daily Amounts|All food items displayed the corresponding GDA label in the lower left corner of the front of the package.
75618985|NCT04308408|Behavioral|Multiple Traffic Light|All food items displayed the corresponding MTL label in the lower left corner of the front of the package.
75772650|NCT01315756|Device|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
75465092|NCT01885845|Device|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
75465093|NCT01885845|Other|Indirect weight assesment of blood loss|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
75618986|NCT04308408|Behavioral|Warning Labels|"Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL."
75618987|NCT04308408|Behavioral|Video|Participants viewed a short (less than 1 min) video explaining how to interpret the label.
75618988|NCT02799316|Other|HBV core antibodies testing. • Real time PCR testing.|"HBV core antibodies testing in HBV surface antigen negative patients.~Real time PCR testing for those having positive HBc antibodies."
75618989|NCT04015999|Dietary Supplement|Microbiota Directed Complementary Food (MDCF)|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
75618990|NCT04015999|Dietary Supplement|Ready to Use Supplementary Food (RUSF)|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
75618991|NCT04936932|Device|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
75618992|NCT04936932|Device|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
75618993|NCT02803372|Other|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
75618994|NCT02803372|Other|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
75618995|NCT00695383|Behavioral|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
75618996|NCT00695383|Behavioral|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
75618997|NCT04933890|Device|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
75465094|NCT01885858|Behavioral|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
75618998|NCT02803684|Other|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
75618999|NCT00625950|Procedure|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
75319246|NCT05559307|Drug|Xingnaojing injection|Xingnaojing injection 20 ml+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 7 days.
75319247|NCT04194242|Drug|HEC96719 tablets|0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1
75465095|NCT01885858|Behavioral|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
75465096|NCT01885884|Behavioral|Embedded Supportive Care|
75465097|NCT01885923|Device|ITAREPS|Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
75619000|NCT02620969|Other|Blood and dialysate sampling|Blood and dialysate sampling
75619001|NCT02799238|Biological|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
75619002|NCT02799238|Radiation|Radiotherapy|Radiotherapy 5 days/week for 6 weeks
75619003|NCT02799238|Drug|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
75619004|NCT00692653|Behavioral|P4|Tailored online decision support system for prostate cancer treatment decision making
75619005|NCT02798926|Device|polyethylene bag|The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
75619006|NCT02620813|Drug|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
75619007|NCT02620813|Drug|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
75619008|NCT02803060|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formaulation number- SR15-62 -Z15-038).
75619009|NCT00695461|Dietary Supplement|Lactobacillus plantarum 299v in oatmeal drink|Bacteria in a concentration of 10(9) CFU/ml
75619010|NCT00695461|Dietary Supplement|Oatmeal drink|Oatmeal drink as in arm 1 but without bacteria added.
75619011|NCT02798848|Device|Tablet computer|iPad
75619012|NCT00692731|Dietary Supplement|500 mL/day of a beverage providing approximately 625 mg catechins|Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
75619013|NCT00692731|Other|Control beverage matched for energy and caffeine content|500 mL/day of a control beverage
75619014|NCT02624401|Drug|Dexmedetomidine|Intravenous infusion
75619015|NCT02624401|Drug|Propofol|Intravenous infusion
75319248|NCT04194242|Drug|Placebo tablet|0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
75319249|NCT04893499|Behavioral|Chios mastic water|Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
75319250|NCT04893499|Behavioral|Placebo water|Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
75619016|NCT02624401|Drug|S-ketamine|Intravenous infusion
75319251|NCT04893499|Behavioral|Chios mastic fruit juice|Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
75619017|NCT02624401|Drug|Sevoflurane|Inhalation
75319252|NCT04893499|Behavioral|Placebo fruit juice|Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
75319253|NCT04194086|Drug|posaconazole oral suspensions|posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
75319254|NCT04023266|Drug|Intravenous N-Acetylcysteine|Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
75319255|NCT00475085|Drug|aprepitant|Given orally or IV
75319256|NCT00475085|Drug|dexamethasone|Given orally or IV
75619018|NCT02624401|Drug|Placebo|Intravenous infusion of saline (Ringer's Acetate)
75619019|NCT02624557|Drug|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
75319257|NCT00475085|Drug|granisetron hydrochloride|Given orally or IV
75619020|NCT02802748|Drug|Oral Vinorelbine|Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
75619021|NCT02802748|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
75619022|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
75619023|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
75619024|NCT02798614|Device|10-day cast|Removal of plaster cast fixation 10 days after reduction
75619025|NCT02620891|Device|helium oxygen mixture|
75619026|NCT02798692|Biological|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
75619027|NCT02798692|Biological|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
75772651|NCT01319656|Behavioral|Support, management, educational, counselling, follow-up|The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
75772652|NCT03778684|Diagnostic Test|Visceral fat thickness|An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.
75772653|NCT03778684|Diagnostic Test|Body mass index|Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.
75772654|NCT01315912|Drug|Letrozole|2.5 mg /day for 5 days
75619028|NCT02798692|Biological|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
75619029|NCT02798692|Biological|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
75619030|NCT02620735|Device|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
75619031|NCT02620735|Behavioral|Exercise Only|12 week exercise program
75619032|NCT02620735|Behavioral|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
75619033|NCT02620735|Behavioral|Health Coaching|10 over the phone health coaching sessions.
75619034|NCT02798770|Other|No Intervention Foreseen|
75619035|NCT04235452|Diagnostic Test|Somatosensory evoked potential|"Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out."
75619036|NCT01151345|Drug|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
75619037|NCT01151345|Drug|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
75619038|NCT02802904|Other|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
75772655|NCT03784222|Drug|Blonanserin|patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
75319258|NCT00475085|Drug|palonosetron hydrochloride|Given orally or IV
75319259|NCT00475085|Drug|prochlorperazine|Given orally or IV
75319260|NCT00475085|Drug|placebo|Given orally
75319261|NCT00551707|Drug|CRx-102 (2.7/180)|prednisolone 2.7 mg plus dipyridamole 180 mg
75319262|NCT00551707|Drug|prednisolone|prednisolone (2.7 mg)
75465098|NCT01885962|Behavioral|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
75319263|NCT00551707|Drug|dipyridamole|dipyridamole 360 mg
75319264|NCT00551707|Drug|placebo|placebo
75319265|NCT00551707|Drug|CRx-102 (2.7/360)|Prednisolone 2.7 mg plus Dipyridamole 360 mg
75319266|NCT04193930|Drug|Letrozole|Oral tablet letrozole 2,5 mg/twice daily for 5 days
75319267|NCT04193930|Drug|Menotropins|150 IU of highly purified menotropins intramuscular
75319268|NCT04193930|Drug|recombinant Follicular stimulating hormone|recombinant Follicular stimulating hormone 300- 400 IU
75319269|NCT00445211|Drug|Heparin|Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
75319270|NCT00445211|Other|Without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin.
75319271|NCT04193852|Drug|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Coated Tablets
75772656|NCT03784222|Other|MRI and serum BDNF|60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
75465099|NCT01885988|Drug|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
75319272|NCT04193852|Drug|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Coated Tablets
75319273|NCT03023072|Other|Incontinence Detection System|
75319274|NCT00552409|Dietary Supplement|Cholecalciferol|2000 IU by mouth daily for one year
75319275|NCT00552409|Dietary Supplement|Placebo|One softgel daily for one year
75319276|NCT04028180|Other|p-Menthane,3-8-diol (PMD) Topical Repellent|"p-Menthane,3-8-diol (PMD) is a recommended active ingredient, which has been evaluated for safe use by the U.S. Environmental Protection Agency (USEPA)1. According to the USEPA laboratory exposure of animals to the active ingredient, PMD, this resulted in no adverse effects except eye irritation. The eye irritation potential of the finished product formulation has not been studied; therefore as a precaution, the products will be handled in the same way as the active ingredient. The researcher and participant must wear eye protection during application of the product and the potential for eye irritation is described in the Participant Information Sheet. . Participants will be excluded if they have a known allergy to any of the product ingredients, or any skin condition, which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
75319277|NCT04028180|Other|Picaridin Topical Repellent|"Icaridin (trade names include Picaridin) is a known mosquito and midge repellent active ingredient. The active ingredient, Picaridin, has been classified as potentially mildly irritating/uncomfortable to the eyes - participants and researcher will wear safety glasses during handling of the products and the participants will be warned about the potential for irritation during the Informed Consent Procedure. Participants will also be excluded if they have a known allergy to any of the product ingredients, or any skin condition which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
75319278|NCT05559229|Procedure|laparoscopic whole-layer cholecystectomy|laparoscopic whole-layer cholecystectomy.
75465100|NCT01885988|Drug|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
75465101|NCT01886001|Drug|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
75465102|NCT01886001|Drug|Chlorhexidine|Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
75465103|NCT01886001|Drug|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
75465104|NCT01886001|Other|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
75772657|NCT01319890|Procedure|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
75772658|NCT03783910|Drug|GRT9906|One prolonged-release tablet containing 40 mg of GRT9906
75319279|NCT03830918|Biological|Atezolizumab|Given IV
75319280|NCT03830918|Drug|Niraparib|Given PO
75319281|NCT03830918|Other|Quality-of-Life Assessment|Ancillary studies
75319282|NCT03830918|Other|Questionnaire Administration|Ancillary studies
75465105|NCT01886014|Drug|Oxytocin|
75465106|NCT01886014|Other|placebo|
75465107|NCT01886027|Behavioral|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
75772659|NCT03783910|Drug|Placebo|Placebo matching GRT9906 tablets
75911708|NCT03044860|Procedure|Double-balloon enteroscopy (DBE) with biopsy retrieval|With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every ~30 cm of the small intestine and specific locations in the large intestine
75319283|NCT03830918|Drug|Temozolomide|Given PO
75319284|NCT03830515|Device|microMend|Wound closure product consisting of tan array of tiny metal Microstaples affixed to adhesive backing. The device is the size and shape of a butterfly closure and intended for closure of skin wounds.
75465108|NCT01886027|Behavioral|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
75465109|NCT01886053|Drug|Faropenem（high dose group）|dosage form: Injection dosage:2400 mg frequency: Three times a day
75465110|NCT01886053|Drug|Faropenem（low-dose group)|dosage form: Injection dosage:2400 mg frequency: twice a day
75465111|NCT01886053|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
75619039|NCT02802904|Other|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
75772660|NCT03778450|Drug|Analgesics, Opioid|"Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients."
75772661|NCT03778450|Drug|Non-Opioid Analgesic|Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
75319285|NCT05559151|Procedure|Remimazolam Benzenesulfonate|"In the experimental group, remazolam 6-12mg/kg/h, atracurium cisphenylate 0.1-0.3 mg/kg and sufentanil 0.3-0.5 μg/kg were infused by micropump for anesthesia induction, and the BIS value was controlled at 50±5 before tracheal intubation.~Anesthesia maintenance: intravenous infusion of remifentanil 0.1-0.3 μg/kg/min, target controlled infusion of remifentanil in experimental group (group R), BIS value was controlled at 50±5, intermittent addition of atracurium cisphenylate to maintain muscle relaxation."
75319286|NCT04193618|Procedure|Conservative surgery for placenta accretta|Uterine devasculrization and transverse compressing sutures before placental delivery
75319287|NCT00553735|Drug|Cyclosporine A 0.05%|Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
75319288|NCT00553735|Drug|Arificial Tear|Artificial Tear - three times a day for 18 months.
75319289|NCT04023968|Behavioral|YESplus workshop|"See description in Arms section."
75319290|NCT04023968|Behavioral|WOW! workshop|"See description in Arms section."
75319291|NCT00523237|Drug|Raltegravir|400 mg Twice daily for 24 weeks
75319292|NCT04027166|Drug|Methadone|Methadone will be administered before study procedures
75619040|NCT02802904|Other|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
75772662|NCT03776500|Drug|PBTZ169|PBTZ169 crystalline supplied as powder for oral solution
75772663|NCT03776500|Drug|Placebo|matching placebo supplied as powder for oral solution
75772664|NCT01319968|Drug|Estriol 0.1% vaginal cream|Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
75772665|NCT05000164|Device|Bausch + Lomb Ultra® Multifocal for Astigmatism|Study Lens
75772666|NCT03778528|Procedure|cataract surgery|tissue collection.
75772667|NCT03776110|Drug|GRT9906 PR tablet|40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)
75772668|NCT03776110|Drug|Placebo|Placebo tablet matching 40 mg GRT9906 PR tablet
75772669|NCT03778216|Behavioral|Family Based Treatment|
75772670|NCT05616130|Other|Data Collection|Researcher will collect data from subject's medical records: information regarding your medical history, trauma injury, heart rate, blood pressure, temperature (vital signs), use of antibiotics (medications used to treat infection) and other medications, development of infection, and treatment results will be recorded and kept with your research records. Demographic information (such as name, address, phone number, gender, race, height and weight, age and birth date), medical record notes (including but not limited to history and physical exam notes, progress notes, consultation reports, laboratory test results, operative reports, information relating to acquired immunodeficiency virus (HIV) infection, radiologic (x-ray studies) results, and blood samples)
75772671|NCT05616130|Procedure|Bone marrow collection and blood collection|At time of scheduled surgery, researcher will collect a 20ml (approximately 4 teaspoons) sample of bone marrow while you are in the operating room receiving surgery for your orthopedic (bone) injuries or elective hip repair. Blood collection will occur at time of surgery, day 14 on study or discharge from hospital and at 3 and 6 months. Up to 58 ml (about 4 tablespoons) sample of blood will be collected from an existing intravenous line or peripheral needle stick.
75772672|NCT05616130|Other|Serial interviews to complete surveys and questionnaires|Participants will be asked to complete questionnaires and surveys that assess your health, quality of life, daily living activities, and mobility. These activities occur at enrollment, day 14 in hospital or discharge, and at the 3, 6, and 12-month visits.
75319293|NCT04027166|Drug|Methadone|Methadone will be delayed (4 hours) until the end of the procedures
75319294|NCT05559073|Procedure|Radiofrequency ablation|pulmonary vein isolation using radiofrequency ablation.
75465112|NCT01886066|Biological|Indocyanine Green (ICG)|ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. One 25 mg vial of ICG will be reconstituted in 10 mL of aqueous solvent (2.5 mg/mL). The solution will be injected at the 3 and 9 o'clock positions of the cervical stroma. 0.5 mL is injected superficially (submucosa) and 0.5 mL is injected deep (~8mm) in the cervical stroma for a total injection volume of 2 mL.
75465113|NCT01886079|Drug|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
75465114|NCT01886079|Drug|Saline|0.4 mcg/kg/h, IV
75465115|NCT01886092|Device|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
75319295|NCT04027088|Dietary Supplement|Immunonutrition|It is a hypercaloric and hyperproteic dietary supplement formulated with immunonutrients: Arginin, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
75911709|NCT03044626|Drug|Radiotherapy|"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
75911710|NCT03044626|Drug|Nivolumab|Nivolumab 240 mg fixed dose (q2w)
75619041|NCT02798302|Other|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
75911711|NCT04875832|Behavioral|Eye Movement Desensitization and Reprocessing - EMDR|"EMDR is a comprehensive psychotherapy approach, originally developed to treat the victims of trauma. EMDR is guided by an information processing model known as the Adaptive Information Processing (AIP) model. One of the key assumptions of the AIP model is that dysfunctionally stored (disturbing) memories are the cause of several mental pathologies. EMDR is therefore used to address a range of complaints that follow distressing life experiences and it~is characterized by an eight-phase psychotherapy approach. The intervention is based on the use of bilateral stimulation (e.g., taps, tones, or eye movements), which aims to stimulate the information processing system of the brain in combination with other methods of established psychotherapies. EMDR is widely recognized as an empirically supported treatment for post-traumatic stress disorder (PTSD) and it is one of the best psychological treatment focused on the ri-processing of recent traumatic experiences"
75619042|NCT02798146|Other|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
75619043|NCT02802670|Drug|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of [14C]-labeled GDC-0810 on Day 1.
75319296|NCT04027088|Dietary Supplement|Standard|It is a hypercaloric and hyperproteic dietary supplement formulated without immunonutrients
75619044|NCT02802826|Behavioral|Tailored Exercise Prescription|The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
75619045|NCT02798068|Drug|Solu-medrol or placebo administration|patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
75619046|NCT02802358|Procedure|Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)|
75619047|NCT02802436|Procedure|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
75619048|NCT02797912|Other|No intervention|
75619049|NCT02802280|Other|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
75619050|NCT04235842|Other|Physical Exercise|Moderate-intensity continuous exercise training performed at cycle ergometer.
75772673|NCT05616130|Other|Telephone follow up call|The study team will contact you at 12 months to complete a telephone interview to learn about your health and well being.
75772674|NCT03776266|Procedure|No intervention is required due to retrospective observational study|Red blood cell transfusion on or after percutaneous coronary intervention
75772675|NCT03776344|Device|Virtual Reality intervention - Oculus Rift HD|During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
75772676|NCT03783988|Combination Product|DHEA and TRIAC|The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)
75772677|NCT03778138|Drug|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
75772678|NCT03777670|Diagnostic Test|Blood test|Drop of blood for RNA and metabolic analysis
75772679|NCT03777748|Device|dental implants and stud attachments|
75772680|NCT03783754|Drug|telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg|low-dose combination therapy
75772681|NCT03783754|Drug|Placebo oral capsule|matched placebo
75772682|NCT03783832|Other|OCT ANGIOGRAPHY DATA|Follow-up of diabetic macular edema treated by Aflibercept (EYLEA®) with OCT angiography
75772683|NCT01309438|Drug|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
75319297|NCT00543101|Drug|Darunavir (DRV/r)|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
75319298|NCT00543101|Drug|continue on current dual boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
75319299|NCT00553969|Drug|carvedilol phosphate|Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
75319300|NCT00553969|Drug|lisinopril|tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
75319301|NCT00553969|Drug|carvedilol phosphate and lisinopril|carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
75619051|NCT04235842|Other|High-intensity interval training performed at cycle ergometer.|High-intensity interval training performed at cycle ergometer.
75619052|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
75319302|NCT00553969|Drug|placebo and placebo|capsule once daily for 9 months; dosage unknown
75619053|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
75619054|NCT02797834|Procedure|Endometrial fluid collection|
75619055|NCT02797756|Procedure|Esophago-gastro-duodenoscopy (EGD) with biopsy|
75619056|NCT02797756|Procedure|Esophageal Impedance Monitoring (EIM)|
75465116|NCT01886092|Device|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
75619057|NCT02797600|Behavioral|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
75619058|NCT02797600|Other|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
75619059|NCT04135105|Other|Normal hearing group|Observational
75619060|NCT02797444|Other|semi-structured interviews|
75619061|NCT04136119|Other|questionnaire|survey exploring practice of vitamin and micronutrient supplementation
75619062|NCT02797366|Radiation|Proton radiotherapy|
75619063|NCT00692887|Device|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
75619064|NCT02801890|Biological|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
75619065|NCT02801812|Device|nailfold capillaroscopy|Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment
75619066|NCT00695851|Drug|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
75619067|NCT00695851|Drug|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
75772684|NCT01309438|Drug|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
76072733|NCT05362942|Drug|Venetoclax, Decitabine, Azacytidine, Cytarabine|Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
76072734|NCT01868893|Drug|Obinutuzumab|
76072735|NCT01868893|Drug|Chlorambucil|
75465117|NCT01886092|Device|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
75465118|NCT01886092|Device|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
75619068|NCT02797210|Device|Continuous theta-burst stimulation|
75619069|NCT02624323|Procedure|Real-time ultrasound-guided central vein catheterization.|
75619070|NCT02796820|Drug|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
75619071|NCT04135885|Drug|Folic Acid|The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0~20 points, and the score ≥10 points is defined as the recovery period).
75619072|NCT04135885|Drug|Placebos|Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0~20 points, and the score ≥10 points is defined as the recovery period).
75619073|NCT02801968|Procedure|Tap block|
75619074|NCT02801968|Other|intravenous analgesia|
75619075|NCT00696865|Drug|AZD2624|oral suspension, 3 doses
75619076|NCT00696865|Drug|Placebo|
75619077|NCT02802046|Radiation|Computed tomographic angiography of coronary artery|
75619078|NCT02620657|Other|Non interventional study|Non interventional study
75619079|NCT02801734|Other|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
75619080|NCT02624011|Behavioral|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
75619081|NCT02796898|Drug|SM88 (Cohort 1)|"Tyrosine Isomers - 230 mg qd~Phenytoin - 50 mg qd.~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd"
75619082|NCT02796898|Drug|SM88 (Cohort 2)|"Tyrosine Isomers - 460 mg (230 mg bid)~Phenytoin - 50 mg qd~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd"
75619083|NCT00693043|Drug|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
75619084|NCT00695929|Drug|Levosimendan|Intravenous injection
75619085|NCT00695929|Drug|Milrinone|Intravenous injection
75619086|NCT04235296|Biological|epidermal growth factor|Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
75619087|NCT04235296|Biological|mesenchymal stem cell conditioned medium-derived pleiotropic factor|Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
75619088|NCT02624167|Drug|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
75619089|NCT02624167|Drug|Placebo|Patients will be given oral dose of matching Placebo
75619090|NCT02796976|Other|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
75619091|NCT02620501|Drug|Lidocaine|topical lidocaine
75319303|NCT03963986|Device|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
75319304|NCT00475241|Behavioral|Prolonged Exposure therapy for PTSD|exposure-based treatment for PTSD
75619092|NCT02620501|Drug|Placebo|0.45% Normal Saline
75619093|NCT02796742|Other|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
75619094|NCT00693121|Drug|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
75619095|NCT00693121|Drug|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
75619096|NCT02796586|Other|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
75319305|NCT00475241|Behavioral|Present centered therapy for PTSD|present focused coping and problem solving for PTSD
75319306|NCT04724005|Other|No drug|No drug used
75619097|NCT04134793|Procedure|radiofrequency ablation|bipolar radiofrequency ablation by ablation forceps
75619098|NCT02801500|Device|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
75619099|NCT02801500|Procedure|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
75619100|NCT02801344|Dietary Supplement|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
75619101|NCT02801344|Dietary Supplement|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
75619102|NCT02801344|Dietary Supplement|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
75619103|NCT02801344|Other|Controlled-diet|the diet containing 0.8 g protein /kg/day
75619104|NCT02620423|Biological|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
75619105|NCT02620423|Drug|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
75619106|NCT02620423|Drug|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
75619107|NCT02620423|Drug|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
75619108|NCT02620423|Drug|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
75619109|NCT02620423|Drug|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
75619110|NCT02620423|Drug|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
75619111|NCT02796430|Other|Time needed to start indirect calorimetry measurement|Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
75619112|NCT02796430|Other|Indirect calorimetry measurement|Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
75619113|NCT00696007|Drug|Gemcitabine and cisplatin|"Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²"
75619114|NCT00696007|Other|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
75619115|NCT02796508|Behavioral|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
75465119|NCT01886118|Procedure|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
75619116|NCT02796508|Behavioral|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
75619117|NCT02624089|Drug|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
75619118|NCT02624089|Drug|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
75619119|NCT02801422|Other|fMRI|
75619120|NCT02624245|Other|Conventional Physical Therapy|
75619121|NCT02796196|Other|Medical Chart Review|Review of medical chart
75619122|NCT02796196|Device|Monitoring Device|Wearable physical activity monitoring device
75619123|NCT02796196|Procedure|Physical Therapy|Undergo primarily self-directed physical therapy
75619124|NCT00696943|Drug|([18F]-ML-10)|[18F]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of [18F]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
75319307|NCT05533567|Drug|Remimazolam|The experimental group was sedated with remimazolam.
75465120|NCT01886118|Other|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
75465121|NCT01886118|Other|Conventional media culture|embryos are cultured in conventional media
75465122|NCT01886131|Other|Synchronised video-polysomnography|"We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task."
75619125|NCT02796040|Device|MRI|
75619126|NCT00693199|Drug|amlodipine|amlodipine 5mg once daily for 28 days
75619127|NCT00693199|Drug|terazosin|terazosin 2 mg once daily for 28 days
75619128|NCT00693199|Drug|amlodipine plus terazosin|amlodipine 5 mg plus terazosin 2 mg once daily for 28days
75619129|NCT02795962|Other|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
75619130|NCT02623777|Dietary Supplement|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
75619131|NCT02623777|Dietary Supplement|Short chain fatty acids|Short chain fatty acids administered
75619132|NCT04135651|Procedure|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
75619133|NCT04135651|Procedure|Cricoid pressure|To apply cricoid pressure, the crocoid cartilage was compressed with a single-handed three-finger maneuvre towards the vertebral bodies.
75619134|NCT02796118|Drug|ASP2151|Oral
75319308|NCT05533567|Drug|Propofol|The control group was sedated with propofol.
75319309|NCT03022604|Dietary Supplement|C4/Generation 4|12 grams of C4/Generation 4
75319310|NCT03022604|Dietary Supplement|C450X|12 grams of C450X
75319311|NCT03022604|Dietary Supplement|Placebo|12 grams of flavored dextrose
75319312|NCT04193540|Other|ACE questionnaire|Regardless of the result of the ACE questionnaire, physician, resident and nurse in charge of the patient will be asked their clinical opinion on decision-making capacity of the patient, based on a 4 steps Lickert scale and blindly of ACE result.
75319313|NCT04026464|Drug|Intravenous Ibuprofen|The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.
75465123|NCT01886144|Device|Knee OA Brace|
75619135|NCT02796118|Drug|Placebo|Oral
75619136|NCT02795884|Drug|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
75619137|NCT02795884|Drug|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
75619138|NCT02795728|Other|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
75619139|NCT02795728|Other|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
75619140|NCT02800798|Other|Preeclampsia positive|
75619141|NCT02795572|Dietary Supplement|Vitamin D|Vitamin D 2000 IU oral once daily
75619142|NCT02795572|Dietary Supplement|Vitamin B6|Vitamin B6 100 mg oral once daily
75319314|NCT04026464|Drug|Intravenous Ibuprofen + Oral Acetaminophen|The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen [160 mg/5ml concentration] every 6 hours for a total of 12 doses.
75619143|NCT02795572|Dietary Supplement|Vitamin B12|Vitamin B12 100 mcg oral once daily
75619144|NCT02795572|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
75619145|NCT02795650|Drug|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
75619146|NCT02795650|Drug|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
75911712|NCT04865692|Other|BFRT|Patients of Interventional group were treated with routine physiotherapy program combined with LI-BFR consist of 10 minutes' session 3 per week for 12 weeks. In order to determine the training load 20% of 1RM, participants had performed knee extension in full range with a challenging weight. After each test, participants rated their perceived exertion level on (RPE) scale to determine the difficulty of the resistance. The derived 1RM was used to determine the 20% 1RM load used for low-load training. Blood flow restriction proximal to the working muscles achieved through using pressure cuffs. The cuff was applied to the proximal thigh. During week 1 the inflation pressure was 100mmHg. Final exercise pressure based the week of the training. Quadriceps size was measured by tape measures thigh
75619147|NCT02800876|Other|CT-acquisition|
75619148|NCT02795494|Behavioral|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
75619149|NCT02795494|Behavioral|ASK-P questionnaire at baseline|Patient-reported activity level score
75619150|NCT02795494|Behavioral|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
75619151|NCT02801188|Drug|Bupivacaine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
75619152|NCT02801188|Drug|Mixture of bupivacaine and dexmedetomidine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
75619153|NCT04236076|Device|PulseHaler|PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.
75619154|NCT04236076|Device|Sham - control|Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
75619155|NCT04235920|Diagnostic Test|Montreal Cognitive Assessment (MoCA)|This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
75619156|NCT02795260|Biological|Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
75619157|NCT02795260|Biological|placebo of Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
75619158|NCT02801032|Drug|Tadalafil|"Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
75772685|NCT01309438|Drug|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
75319315|NCT00554671|Other|Algorithm driven medication titration|Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
75772686|NCT01309438|Drug|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
75319316|NCT00554671|Behavioral|Monitoring|Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
75319317|NCT00554671|Behavioral|Group support|Peer support are provided in the group setting
75319318|NCT00554671|Behavioral|Self efficacy|Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
75319319|NCT04192838|Procedure|Laparoscopic incisional ventral hernia repair|Laparoscopic repair of incisional ventral hernias (5-15 cm) with adouble-layer polypropylene- expanded polytetrafluoroethylene (ePTFE) mesh.
75465124|NCT01886157|Procedure|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
75465125|NCT01886157|Procedure|Corticosteroid injection|Standard trigger finger corticosteroid injection.
75465126|NCT01886170|Other|Phase II of the Study: Information regarding Current Diabetes Control|Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
75465127|NCT01886183|Other|Virtual Reality Training|The participants of the study will be trained 8 balance games during 14 sessions
75465128|NCT01886183|Other|Physical Therapy|Patients of the control group will be trained with balance exercises.
75465129|NCT01886196|Drug|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
75772687|NCT03776032|Drug|Darbepoetin alfa|Administered by subcutaneous injection once a week
75772688|NCT03776032|Drug|Placebo|Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
75772689|NCT03775798|Drug|Direct antiviral agents for hepatitis C|Direct-acting antivirals for hepatitis C
75772690|NCT01309516|Behavioral|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
75319320|NCT04192838|Procedure|Open incisional ventral hernia repair|Standard polypropylene mesh was positioned as an inlay, or as an onlay over the external oblique fascia (i.e., subcutaneously), as preferred by the operating team. The mesh was fixed with absorbable stitches. Drains were usually placed.
75619159|NCT02801032|Drug|Placebo|"Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
75619160|NCT05442190|Drug|Hypericin|SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment.
75319321|NCT00554749|Behavioral|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
75619161|NCT05442190|Drug|Placebo|Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
75619162|NCT02795416|Drug|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
75619163|NCT02790658|Dietary Supplement|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
75619164|NCT02795026|Procedure|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
75619165|NCT02795026|Procedure|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
75619166|NCT02689960|Drug|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
75619167|NCT01150097|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
75619168|NCT01150097|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
75772691|NCT03775876|Procedure|Shoulder Arthroscopy|patients in both groups are programmed for an elective shoulder arthroscopy surgery
75911713|NCT04865692|Other|Routine Physical Therapy|knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
75319322|NCT03022214|Dietary Supplement|Placebo|Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
75319323|NCT03022214|Dietary Supplement|Intervention|"Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~EnduraCell broccoli sprout powder: 3 capsules~Bulk Powders Green tea extract: 1 capsule~Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal"
75619169|NCT01150097|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
75619170|NCT01150097|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
75619171|NCT01150097|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
75772692|NCT03775876|Procedure|Regional Block|patients in both groups received regional block for anesthesia: brachial plexus blockade was performed using the interscalene approach under ultrasound combined to nerve stimulation. 20 ml ropivacaine 0.375% were injected.
75772693|NCT03775876|Drug|Propofol|propofol 10mg/ml was used for sedation as described in the arms section
75772694|NCT03775876|Drug|Dexmedetomidine|Dexmedetomidine was diluted to 4mcg/ml and used for sedation as described in the arms section
75911714|NCT03045952|Procedure|microwave ablation device|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
75911715|NCT03045796|Device|Oxygen Saturation measured by WristOx|Patients will be hooked up to finger cuffs as well as ECGs to monitor oxygen saturations in different part of the body.
76072736|NCT03459898|Device|AlignRT system (VisionRT Ltd., London, UK)|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
75319324|NCT04192916|Drug|DOACs|Direct Oral Anticoagulants
75619172|NCT01150097|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
75319325|NCT01797991|Drug|Dexamethasone per os|
75319326|NCT01797991|Drug|Matching placebo for dexamethasone IV|
75619173|NCT02790190|Other|Radiotherapy dose|
75619174|NCT02794948|Other|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province
75619175|NCT02794948|Dietary Supplement|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province.
75619176|NCT01149863|Drug|Plerixafor|Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
75619177|NCT02794792|Drug|Ipragliflozin L-proline|Oral
75619178|NCT02794792|Drug|Metformin|Oral
75619179|NCT02794792|Drug|Placebo|Oral
75619180|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
75619181|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
75619182|NCT02790268|Procedure|Lens Subluxation Surgery|Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
75619183|NCT00872989|Drug|docetaxel|Given IV
75619184|NCT00872989|Drug|vandetanib|Given orally
75619185|NCT02794714|Drug|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
75619186|NCT02794714|Drug|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
75619187|NCT02790112|Other|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty."
75772695|NCT03775876|Diagnostic Test|BIS|sedation level was monitored using bispectral index to achieve values described in the arms group
75772696|NCT01320514|Drug|Fibrin Sealant (Artiss)|
75772697|NCT03773536|Drug|Artesunate-amodiaquine given with single low dose primaquine|Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
75911716|NCT04876144|Device|Kogito|"Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~CBT - vicious circle, progressive muscle relaxation, peer support content~Cognitive distortions, relaxation in imagination, peer support content~Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks"
75911717|NCT04875598|Procedure|Ultrasound assisted - Laparoscopy assisted Transversus Abdominis Plane Block|Ultrasound assisted TAPB application will be applied by an anesthesiology and reanimation specialist and Laparoscopy assisted TAPB application will be applied by the surgeon performing the operation.
75911718|NCT04865224|Diagnostic Test|hemoglobin estimation|In this method, in which different deep learning models are used together, the age range is intended to be as wide as possible to provide a quick solution with a high accuracy and low error values.
75319327|NCT01797991|Drug|Dexamethasone IV|
75319328|NCT01797991|Drug|Matching placebo for dexamethasone per os|
75319329|NCT05499247|Other|SkinQ Glow Bright Wonder Mask|"Mode of Usage:~Cleanse and dry face. Apply 1 tsp or 5g of the product. Apply with clean finger or brush to full face. Leave to dry for 15 minutes. Wipe with wet cotton or rinse with cool water.~Route of Administration: Topical"
75319330|NCT00475319|Drug|placebo|comparison of different dosages of drug
75319331|NCT00475319|Drug|1% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
75772698|NCT03773848|Procedure|Open Reduction Internal Fixation (ORIF)|Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate & tightrope
75319332|NCT00475319|Drug|2% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
75319333|NCT04026074|Drug|Fentanyl|Weight adapted drug application
75319334|NCT04026074|Drug|Remifentanil|Weight adapted drug application
75319335|NCT04026074|Drug|Clonidine|Weight adapted drug application
75319336|NCT04026074|Drug|EMLA Cream|Salve application on the body part where the regional anaesthesia will be administered
75319337|NCT04026074|Drug|Placebo iv|i.v. administration of 0,9% NaCl
75319338|NCT04026074|Drug|Placebo salve|Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
75465130|NCT01886196|Other|placebo|placebo designed to mimic experimental drug (ibuprofen)
75465131|NCT01886196|Behavioral|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
75465132|NCT01886196|Behavioral|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
75465133|NCT01886209|Drug|Prednisone|
75465134|NCT01886209|Drug|VX-509|
75465135|NCT01886209|Drug|Methylprednisolone|
75772699|NCT01320592|Drug|PD0332991|
75772700|NCT01320592|Drug|Paclitaxel|
75911719|NCT04865380|Drug|Tranexamic Acid 100 MG/ML|1g IV x 1 dose of Tranexamic Acid administered preoperatively.
75911720|NCT04865068|Diagnostic Test|Echocardiography measures on SSA participants|"Upon SSA Subject is admitted to the hospital for an echocardiography,~Information about this study process,~Participants will receive an information note ;~Administration of a medical history questionnaire, collection of cardiovascular risk factors, weight toe (all of which are routinely collected before an echocardiographic examination is performed);~Performing and recording the echocardiographic examination according to routine protocol~delivery of the results according to the usual management;~deferred analysis of the recordings on workstation with classification of the data (normal-pathological) according to the different standards"
75911721|NCT04869046|Drug|Instillation of levobupivacaine in surgical wound|Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
75911722|NCT04430530|Biological|Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
75911723|NCT04875910|Other|Home-based exercise program|"The exercise program will include task specific training to improve balance and the training will progress every two weeks. A Physical therapist will be following up and monitoring the participants adherence to the training by audio or video call.~The exercise program for Week 1: Sit to Stand 5 times, Steps forward, backward and to the sides 5 times, 10 meters walk. 45 minutes session /3 times per week. Week 2: Sit to stand 10 times, Steps forward, backward and to the sides 5 times , Sit and reach 5 min for each hand and walk for 15 meters. 45 minutes session, 3 times per week. Week3 Sit to stand 10 times, Step on bench 5 times, Stand and reach 5 and walk for 15 meters. 45 minutes session, 3 times per week. Week 4 Stand and reach 5 times, Step on bench 10 times, climbing stairs (5 steps flight stairs up and down) and walk for 20 meters. 50 minutes session, 3 times per week."
75911724|NCT04385680|Drug|Chlorhexidine Gluconate vaginal solution 0.05%|preoperative vaginal preparation
75911725|NCT04864756|Other|Simulation based learning|Learning for medical students using simulation based techniques including scenario execution as a complement to conventional teaching methodologies
75772701|NCT03773692|Behavioral|Passive feedback and JITAI|"Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA."
75911726|NCT04868422|Device|Telemonitoring via wireless internet-based system|
75465136|NCT01886222|Other|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
75465137|NCT01886222|Other|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
75465138|NCT01886248|Drug|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
75465139|NCT01886274|Device|Transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
75465140|NCT01886326|Other|Consumption of 42 grams of peanuts daily|Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
75465141|NCT01886339|Other|SNIF test (Sniff Nasal Inspiratory Force)|
75619188|NCT04234750|Biological|mesenchymal stem cell conditioned medium-derived pleiotropic factor|After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
75619189|NCT01148771|Drug|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
75619190|NCT01148771|Drug|ertapenem|1 gram 30 minute infusion q24h for 3 days
75772702|NCT03783676|Drug|Remifentanil|Receive remifentanil bolus and infusion guided by an algorithm.
75772703|NCT03783676|Drug|Normal saline|Receive normal saline bolus and infusion guided by the remifentanil algorithm.
75465142|NCT01886352|Drug|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
75465143|NCT01886352|Drug|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
75465144|NCT01886352|Drug|Intraperitoneal atomization of levobupivacaine.|"Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~Each subdiaphragmatic area 0.05 ml/kg~Dome of abdomen then settling onto bowel 0.05 ml/kg~Surgical dissection site 0.05 ml/kg~At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg."
75465145|NCT01886365|Device|Space GlucoseControl System, B. Braun, Melsungen, Germany|Computerized algorithmic application of insulin
75619191|NCT05429008|Drug|HMPL-A83 injection|Day 1,8,15,22 dose; 28 day treatment cycles.
75619192|NCT01148693|Drug|gentamicin|10mg per 10ml of contrast media
75619193|NCT01148693|Drug|Placebo|Distilled water
75772704|NCT03783598|Behavioral|Person centered, occupation based intervention support with problem solving therapy|This program that was developed from the occupational therapy perspective which is person centered and occupation based for T2D intervention was designed as 6 modules. The intervention group received person centered, occupation based intervention support with problem solving therapy as 6 modules. The control group had not any intervention, just had a education about effect of diabetes on life.
75772705|NCT01309594|Procedure|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
75619194|NCT00693355|Other|Sodium butyrate|sodium butyrate
75772706|NCT01320748|Behavioral|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
75772707|NCT01320748|Behavioral|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
75772708|NCT03775642|Behavioral|Intervention video|The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
75465146|NCT01886365|Other|Conventional therapy with a fixed insulin dosing scheme|Routine care
75772709|NCT03775642|Behavioral|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
75772710|NCT04422886|Device|active transcranial direct current stimulation (tDCS)|20 minutes at 2.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines)
75772711|NCT04422886|Behavioral|Physiotherapy|motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
75911727|NCT02798211|Drug|Secukinumab 300 mg|150 mg x 2 s.c. injection
75911728|NCT02798211|Drug|Secukinumab 150 mg|150 mg s.c. injection
75465147|NCT01886430|Other|Functional electrical stimulation|Functional electrical stimulation for 10 days
75465148|NCT01886430|Other|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
75465149|NCT01886443|Drug|Antithrombin-III|
75465150|NCT01886443|Drug|Infliximab|
75465151|NCT01886443|Drug|Apotransferrin|
75772712|NCT04422886|Device|sham transcranial direct current stimulation (sham)|1 minutes at 1.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines) and 19 minutes with unit shut off and electrodes remaining on the scalp
75772713|NCT03783520|Device|Er,Cr:YSGG Laser|Er,Cr:YSGG Laser is used for disinfection of the root canals.
75772714|NCT03783520|Other|Sodium hypochlorite|Sodium hypochlorite is used for disinfection of the root canals
75772715|NCT05582200|Diagnostic Test|Positron Emission Tomography (PET) using two PET tracer under IND|Positron Emission Tomography
75772716|NCT03775720|Behavioral|Dietary advice|Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
75911729|NCT02798211|Other|Placebo|Placebo
75911730|NCT04874896|Dietary Supplement|Microbiota autotransplantation|Patients received microbiota autotransplantation in capsules (1g per day) for 6 months
75911731|NCT04874896|Dietary Supplement|Control|Patients will not received microbiota autotransplantation in capsules and will received usual medical care
75911732|NCT04868344|Drug|MRG003|Administered intravenously
75911733|NCT03045640|Other|FSI ECD|The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
75911734|NCT04868266|Other|end tidal carbon dioxide monitoring|We will monitor end tidal carbon dioxide with capnography during minimal sedation
76072737|NCT01868503|Drug|lapatinib ditosylate|Given PO
76072738|NCT01868503|Radiation|radiation therapy|Undergo radiation therapy
76072739|NCT01868503|Other|laboratory biomarker analysis|Correlative studies
75465152|NCT01886443|Drug|Human recombinant erythropoietin|
75465153|NCT01886443|Drug|C1-Inhibitor|
75465154|NCT01886443|Drug|Glutathione|
75465155|NCT01886443|Drug|Alfa-tocopherol|
75465156|NCT01886443|Drug|Melatonin|
75465157|NCT01886443|Drug|Epoprostenol|
75465158|NCT01886456|Device|Laser trabeculoplasty|
75465159|NCT01886469|Drug|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
75465160|NCT01886469|Drug|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
75619195|NCT00693355|Other|NaCl|NaCl
75619196|NCT04114552|Other|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
75619197|NCT02620111|Dietary Supplement|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
75619198|NCT02620111|Dietary Supplement|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
75465161|NCT01886469|Drug|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
75465162|NCT01886482|Other|nutrition intervention|high protein diet
75619199|NCT02883959|Other|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
75619200|NCT00696085|Behavioral|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
75619201|NCT02794558|Device|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
75619202|NCT00693433|Drug|dexamethasone|Given orally
75619203|NCT00693433|Drug|temsirolimus|Given IV
75619204|NCT00693433|Other|laboratory biomarker analysis|Correlative studies
75619205|NCT02794090|Behavioral|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
75911735|NCT03045718|Behavioral|Horticultural Therapy|The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
75465163|NCT01886495|Other|nutrition intervention|
75465164|NCT01886508|Procedure|Nerve-spring radical hysterectomy|Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
75465165|NCT01886508|Procedure|radical hysterectomy|Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
75465166|NCT01886521|Procedure|Lumbar drain|
75465167|NCT01886521|Procedure|Ventricular drain|
75465168|NCT01886534|Other|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
75911736|NCT02060019|Drug|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
75465169|NCT01886534|Behavioral|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
75465170|NCT01886534|Other|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
75465171|NCT01886534|Other|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
75465172|NCT01886534|Other|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
75465173|NCT01886547|Other|Prostate health screening|
75465174|NCT01886560|Drug|Doxycycline|Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
75465175|NCT01886560|Drug|Placebo|Tablets placebo one PO per day for 12 weeks
75465176|NCT01886573|Drug|Azacitidine|Given SC
75465177|NCT01886573|Drug|Entinostat|Given PO
75465178|NCT01886573|Other|Laboratory Biomarker Analysis|Correlative studies
75465179|NCT01886573|Other|Pharmacological Study|Correlative studies
75619206|NCT02794090|Behavioral|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
75619207|NCT05414422|Drug|PCN-101|Concentrate for solution for infusion
75465180|NCT01886573|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75465181|NCT01886586|Behavioral|Problem Solving Therapy|6-12 sessions of Problem Solving Therapy (both members of dyad)
75465182|NCT01886586|Behavioral|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
75619208|NCT05414422|Drug|Placebo|Concentrate for solution for infusion
75619209|NCT00872599|Drug|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
75619210|NCT00872599|Drug|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
75465183|NCT01886586|Other|Enhanced Usual Care|Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
75619211|NCT04233658|Drug|Placebo|3x2 capsules / day
75772717|NCT01320904|Procedure|NMES|"We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation."
75911737|NCT04864600|Other|Candle C|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
75911738|NCT04864600|Other|Candle 1|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
75911739|NCT02061501|Other|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
75911740|NCT02061501|Other|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
75319339|NCT04026152|Behavioral|Resistance training|Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
75465184|NCT01886599|Drug|Asunaprevir|
75465185|NCT01886612|Device|Duo-STIM neuromuscular electrical stimulator|
75465186|NCT01886612|Device|AV Impulse System Model 6000|
75465187|NCT01886625|Procedure|unilateral single-port VATS sympathicotomy|
75465188|NCT01886638|Drug|Abacavir|
75465189|NCT01886664|Drug|sevoflurane|
75465190|NCT01886664|Drug|Desflurane|
75465191|NCT01886677|Behavioral|Immediate diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
75911741|NCT05654415|Other|Melatonin|Each enrolled patient will be subjected to two nap EEG recordings receiving in one occasion the melatonin-based solution under study at a dosage of 5 mg
75911742|NCT05654415|Other|Deprivation|Each enrolled patient will be subjected to two nap EEG recordings,in one they will be subjected to sleep deprivation
76072740|NCT05362708|Device|Clinical - Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort during a port-a-cath procedure.
75465192|NCT01886677|Behavioral|Delayed diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
75465193|NCT01886703|Behavioral|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
75465194|NCT01886729|Other|transcranial direct current stimulation (tDCS)|
75465195|NCT01886742|Drug|Standard Dose Group|The standard dose of Cefazolin will be administered intravenously.
75465196|NCT01886742|Drug|Weight Based Group|The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
75465197|NCT01886755|Dietary Supplement|ORS rehydration solution|
75465198|NCT01886755|Dietary Supplement|placebo|
75465199|NCT01886768|Device|Double pledget nasal anesthesia (DPNA)|By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.
75465200|NCT01886768|Device|Single pledget nasal anesthesia (SPNA)|Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
75465201|NCT01886820|Drug|[18F]NAV4694|
75465202|NCT01886898|Other|Infant formula|infant formula
75465203|NCT01886898|Other|Breastfeeding|
75465204|NCT01886911|Other|Attention Training Intervention Game|
75465205|NCT01886911|Other|Prosocial Training Intervention Game|
75465206|NCT01886911|Other|Control for Attention Intervention|
75465207|NCT01886911|Other|Control for Prosocial Intervention|
75465208|NCT01886924|Behavioral|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
75465209|NCT01886924|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
75465210|NCT01886976|Biological|CART-138 cells|
75465211|NCT01886989|Dietary Supplement|Cocoa polyphenols|Cocoa polyphenols (960mg) reconstituted in water
75619212|NCT04233658|Drug|Cynara Scolymus|3x2 capsules / day
75465212|NCT01887015|Device|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
75319340|NCT04026152|Behavioral|Unified Protocol|This intervention consists four weekly sessions adapted from the Unified Protocol. The first module is Psychoeducation and Motivational Interviewing. During this module, participants will develop an understanding of their own pattern of emotional responding to exercise as well as increasing participants' readiness and motivation for behaviour change.The second module is Cognitive Flexibility, during which participants will learn about how automatic negative interpretations can influence their emotional reactions and prevent them from considering alternative explanations. The third module is Countering Emotion-Driven Behaviours during which participants will identify and counter behaviours used to dampen strong emotions, particularly those associated with exercise. Lastly, module four will use Exposure to external and internal emotional triggers to increase participants' tolerance to the emotions that arise in exercise environments.
75319341|NCT00555997|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
75619213|NCT05411302|Other|Mental health supportive text messages|Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
75319342|NCT00555997|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
75465213|NCT01887054|Device|Tower of Hanoi|
75619214|NCT00693511|Behavioral|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
75619215|NCT00693511|Behavioral|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
75619216|NCT02623621|Drug|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
75619217|NCT00693589|Drug|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
75619218|NCT04233736|Procedure|Bilateral lumbar erector spinae plane block|Bilateral lumbar erector spinae plane blocks performed under ultrasound guidance
75319343|NCT00555997|Drug|Placebo|"0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo"
75465214|NCT01887054|Other|Placebo group - non use of Tower of Hanoi|
75619219|NCT02620267|Device|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
75619220|NCT02794168|Drug|VAS203|Treatment
75772718|NCT01320904|Procedure|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
75772719|NCT03775564|Other|REMEDRUGBY PROGRAM|"1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~12th General Debriefing session Including : - 3 tournaments~8 hours of Touch Rugby"
75772720|NCT03775564|Other|TOUCH RUGBY PROGRAM|Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
75465215|NCT01887080|Other|Exercise|"This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
75619221|NCT02794168|Drug|Saline|Placebo
75772721|NCT03775564|Other|TAU|Treatment as usual
75772722|NCT01320982|Drug|minocycline|minocycline 100 mg/bid
75772723|NCT01320982|Drug|pramipexole|pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
75772724|NCT01320982|Drug|acetylsalicylic acid|acetylsalicylic acid 500mg/ bid
75772725|NCT01320982|Drug|placebo|placebo bid
75772726|NCT04431232|Device|Endoscopic Band Ligation|Band ligation of the gastric body for weight loss
75465216|NCT01887080|Device|Microcurrent|"This group had the exercise program after electrolipolysis, thrice a week for eight weeks.~The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).~Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
75911743|NCT03044548|Other|Supportive supervision|" Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.~Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.~Receivers: nurses working at HC level with children with malnutrition.~Reference guidelines:~• Current National IMAM guidelines~Attitude and philosophy:~• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle ."
75465217|NCT01887080|Other|Cardiovascular Risk Factors|It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
75465218|NCT01887093|Behavioral|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
75319344|NCT00475787|Procedure|Spinal Manipulation|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
75465219|NCT01887106|Drug|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
75465220|NCT01887106|Drug|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
75772727|NCT01321060|Procedure|Aspiration|
75772728|NCT01321060|Procedure|Catheter drainage|
75772729|NCT01321060|Drug|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
75772730|NCT03773224|Procedure|Irrigation|upon closure of the peritoneum gentamicin-saline solution (160 mg of gentamicin in 400 ml of normal saline 0.9%) will be used for irrigation of every layer of the wound before its closure
75772731|NCT03783208|Drug|G-CSF|Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
75911744|NCT03044938|Drug|salbutamol|Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
75911745|NCT03044938|Drug|Placebo|Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
75911746|NCT03045484|Drug|Controlled-release oxycodone|CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
75911747|NCT03045484|Other|Chemoradiotherapy|Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
75911748|NCT04874506|Drug|MBM-02|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
75911749|NCT04867876|Behavioral|Physical Therapy|Management of urinary incontinence by a physical therapist will include but is not limited to biofeedback, dietary management, alleviation of constipation, and neuromuscular re-education.
75911750|NCT04429672|Behavioral|The Right to your Sexual Health|which is of a socio-educational type and is made up of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Behavior and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of opening, development and closing phase
75911751|NCT04429672|Behavioral|Friendly sexual health services and reproductive for adolescents|consists of six sessions (one a week) lasting 50 minutes each, using illustrative material through official flipcharts of the secretary of health on reproductive health, sexually transmitted diseases and sexual violence
75319345|NCT00475787|Procedure|Detuned Ultrasound|"US machine is turned on and set at 0 w/cm2"
75319346|NCT04407026|Biological|biofluids|Gingival crevicular fluid, saliva and serum samples were obtained.
75319347|NCT04406012|Procedure|paravertebral block|paravertebral block group
75319348|NCT00446147|Drug|Pyridoxine|100mg BID/daily, Per oral
75319349|NCT00446147|Drug|Placebo|placebo 100mg BID/daily, Per oral
75319350|NCT04406168|Procedure|urinary diversion|follow up outcomes of urinary diversion
75319351|NCT04345471|Drug|Desvenlafaxine 100 mg|once daily dosing for 8 weeks
75319352|NCT04345471|Drug|Desvenlafaxine 50 mg|once daily dosing for 8 weeks
75465221|NCT01887106|Drug|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
75465222|NCT01887106|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
75465223|NCT01887119|Drug|Eplerenone|
75465224|NCT01887119|Other|Placebo|Eplerenone-matched placebo
75465225|NCT01887145|Procedure|Endoscopic surgery|Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
75772732|NCT03783208|Other|Saline|Slow infusion of saline into the endometrial cavity using a soft embryo transfer catheter.
75772733|NCT03773068|Drug|BAY1817080 - Formulation A|Formulation A
75772734|NCT03773068|Drug|BAY1817080 - Formulation B|Formulation B
75772735|NCT03773068|Drug|[13C715N]-BAY 181708 stable isotope label (SIL)|0.1 mg [13C715N]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
75465226|NCT01887145|Procedure|Open surgery|Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
75619222|NCT02793934|Other|Scales|"For stroke patients there are used scales:~Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia~For patients after THR:~The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
75619223|NCT02793934|Other|New model of rehabilitation|
75619224|NCT02793934|Other|Old model of rehabilitation|
75619225|NCT02793934|Other|ICF reader|
75619226|NCT01148537|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 * 20 mcg/h.
75619227|NCT01148537|Drug|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 * 20.
75619228|NCT01148537|Drug|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
75619229|NCT02794324|Procedure|Voluntary deep-inspiratory breath hold|Patients undergoing scanning in v_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
75619230|NCT02794324|Procedure|Active-breathing-controlled deep-inspiratory breathhold|Patients undergoing scanning in ABC_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC_DIBH, CT images will be obtained.
75772736|NCT04893382|Procedure|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
75772737|NCT04893382|Procedure|Ringer's Lactate for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
75772738|NCT01321138|Procedure|Femoral nerve block|The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
75772739|NCT01321138|Procedure|PCA morphine|Postoperative analgesia with self-administration iv morphine
75772740|NCT01320046|Other|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|"Patients will undergo the following evaluation:~Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~Medical history.~Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours."
75772741|NCT05540782|Behavioral|PROMIS-SF v2.0 -Cognitive Function 8a|Patient-Reported Outcomes (PROs)
75772742|NCT01309750|Radiation|Small Bowel Transit Study|Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
75772743|NCT03772756|Procedure|Endoscopic ultrasound guided radiofrequency ablation|Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
75772744|NCT03772756|Radiation|chemoradiotherapy|Receive chemoradiotherapy
75465227|NCT01887158|Drug|Polyethylene glycol|
75619231|NCT02794324|Procedure|Prone treatment|Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
75911752|NCT04874428|Drug|Rivaroxaban 10 mg Oral Tablet|Administration of one single dose of rivaroxaban (10 mg) in tablet form.
75911753|NCT04874428|Drug|Apixaban 2.5 mg Oral Tablet|Administration of one single dose of apixaban (2.5 mg) in tablet form.
75319353|NCT04345471|Drug|Placebo|once daily dosing for 8 weeks
75319354|NCT00476021|Device|Levonorgestrel-releasing IUD (Mirena)|levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
75319355|NCT02704364|Biological|NGM282|
75319356|NCT02704364|Other|Placebo|
75319357|NCT05457049|Diagnostic Test|Molecular residual disease test|OncoMRD Lung
75319358|NCT00447083|Device|UVB|UVB exposure by a tanning bed
75319359|NCT00447083|Procedure|Non-UVB|Non-UVB exposure by a tanning bed
75319360|NCT04192682|Drug|Anlotinib Hydrochloride|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
75465228|NCT01887158|Drug|Bisacodyl|
75465229|NCT01887184|Drug|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranassaly
75465230|NCT01887197|Other|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
75465231|NCT01887197|Drug|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
75465232|NCT01887197|Drug|mannitol inhalation powder|mannitol inhalation powder
75619232|NCT02794324|Device|Active-breathing-controlled deep-inspiratory breathhold|The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
75619233|NCT02789722|Other|Yerba Mate Extract|Yerba Mate extract capsules 750 mg
75619234|NCT02789722|Other|Placebo|Take 3 capsules, 3 times daily for 28 days.
75619235|NCT02793778|Drug|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
75619236|NCT02793778|Drug|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
75619237|NCT02793544|Drug|Fludarabine|"Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
75619238|NCT02793544|Drug|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
75619239|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy on Day -1|"200 cGy TBI is administered in a single fraction on Day -1.~Radiation sources, dose rates, and shielding follow institutional practice."
75619240|NCT02793544|Procedure|Infusion of non-T-cell depleted bone marrow on Day 0|"On Day 0, the harvested bone marrow is infused.~Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
75619241|NCT02793544|Drug|Busulfan|"Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM*min (Perkins et al., 2012))~Busulfan dosing is based on adjusted IBW (Appendix K)"
75619242|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
75619243|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
75772745|NCT03775252|Dietary Supplement|Ketogenic diet|Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
75772746|NCT04664998|Diagnostic Test|Diagnostic test for NG/CT|All participants will receive diagnostic testing for NG/CT at each quarterly visit.
75772747|NCT04664998|Diagnostic Test|HIV testing|All participants will receive diagnostic testing for NG/CT at each quarterly visit.
75772748|NCT03772678|Drug|LSALT peptide|novel 16 amino acid peptide
75772749|NCT03772678|Other|0.9% Saline|saline
75772750|NCT04628572|Drug|Ceftazidime-avibactam|Non-Interventional Study
75772751|NCT03772912|Device|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
75319361|NCT00556543|Device|U-plate fracture repair system|All subjects meeting inclusion criteria will undergo surgery for the repair of their fractured rib/s using the U-plate device. Subjects will be monitored daily during the entire course of their hospitalization for adverse experiences. Subjects will be contacted by phone to complete the MPQ and SF-36 Health Survey. Subjects will be asked if and when they have returned to work or to their previous level of functioning. Subjects will be asked if they had any complications or problems associated with their surgery.
75319362|NCT04192292|Drug|Sulfonylurea|Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
75319363|NCT04192292|Drug|DPP4 Inhibitor|Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.
75319364|NCT04025762|Device|Hybrid closed-loop system (CamAPS FX)|Hybrid closed-loop system
75319365|NCT04025762|Device|Sensor augmented pump therapy|Sensor augmented pump therapy
75319366|NCT00448175|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
75319367|NCT00448175|Drug|Tolterodine|
75319368|NCT04176835|Drug|Oxytocin nasal spray|Single-dose oxytocin will be administered intranasally
75619244|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"200cGy TBI is administered in twice daily on Days -3, -2, and -1.~Radiation sources, dose rates, and shielding follow institutional practice."
75619245|NCT02793544|Drug|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
75619246|NCT02793544|Drug|Sirolimus|"Sirolimus dosing is based on adjusted IBW (Appendix K).~Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects < 18 years old:~A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
75619247|NCT02793544|Drug|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
75619248|NCT02793544|Drug|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted."
75619249|NCT02793544|Drug|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
75911754|NCT04863976|Other|Dynamic stretching|Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)
75619250|NCT02793544|Drug|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
75619251|NCT02793544|Drug|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
75619252|NCT02793544|Drug|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
75619253|NCT02793388|Drug|Supervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.
75772752|NCT03772990|Drug|Calcium Chloride|Calcium Chloride
75772753|NCT03772990|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride
75772755|NCT03782896|Other|acute postoperative pain|All patients assessed postoperative pain score in the recovery room and postoperative 2 month
75772756|NCT03775018|Procedure|Transversus abdominis plane blockade|Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.
75772757|NCT03775018|Drug|Intravenous analgesia|Acetaminophen 1g/6h iv will be administered
75772758|NCT03773458|Device|An artificial system for the screening of scoliosis|An artificial intelligence to make evaluation of scoliosis using back images
75772759|NCT03782662|Drug|Itraconazole|Itraconazole capsules
75772760|NCT03782662|Drug|Verapamil|Verapamil tablets
75772761|NCT03782662|Drug|Rifampicin|Rifampicin capsules
75772762|NCT03782662|Drug|Midazolam|Midazolam oromucosal solution
75772763|NCT03782662|Drug|Placebo for RV521|Placebo for RV521 capsules
75772764|NCT03782662|Drug|RV521|RV521 capsules
75772765|NCT01309984|Drug|Lusedra|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
75772766|NCT01309984|Drug|Propofol|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
75772767|NCT03772132|Biological|mutation and signal pathway activation status analysis Drug: FORFIRINOX|Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
75772768|NCT03772054|Drug|Sevoflurane|Inhalation anesthetic agent
75772769|NCT03772054|Drug|Propofol|Intravenous anesthetic agent
75465233|NCT01887223|Procedure|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
75465234|NCT01887223|Drug|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
75772770|NCT03771820|Drug|NC-6004|NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
75619254|NCT02793388|Drug|Unsupervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
75465235|NCT01887236|Behavioral|Step physical activity program|Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
75465236|NCT01887236|Behavioral|Stability Ball Program|Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
75465237|NCT01887249|Drug|Clarithromycin|
75619255|NCT02793310|Procedure|DMEK|The intervention group will receive cornea transplantation by DMEK
75465238|NCT01887249|Drug|metronidazole|
75619256|NCT02793310|Procedure|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
75465239|NCT01887249|Drug|esomeprazole|
75619257|NCT02689882|Dietary Supplement|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
75619258|NCT02789644|Drug|Ursodeoxycholic Acid|Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
75619259|NCT04234594|Drug|QL1203|6 mg/kg intravenous (IV) infusion only once，on the first day.
75619260|NCT04234594|Drug|Vectibix®|6 mg/kg intravenous (IV) infusion only once，on the first day.
75619261|NCT02789488|Dietary Supplement|Fenugreek seeds extract 500 mg|Furocyst one caps BID
75619262|NCT02793076|Other|Bollywood Dance|8 week Bollywood Dance Program
75772771|NCT03771820|Drug|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
75772772|NCT03771742|Procedure|transverse scan, in-plane, posterior-anterior TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
75619263|NCT03806608|Procedure|Crestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
75619264|NCT03806608|Procedure|Subcrestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
75619265|NCT01148459|Biological|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
75619266|NCT01148459|Biological|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly"
75772773|NCT03771742|Procedure|paramedian sagittal scan, in-plane, caudal-cranial TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the paramedic sagittal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
75772774|NCT03774940|Diagnostic Test|peripheric blood count|preoperative peripheric blood count
75772775|NCT03771976|Procedure|Cesarean section|Risk of cesarean section between the cohorts
75772776|NCT03771976|Procedure|No cesarean section|Vaginal birth rate between the cohorts
75772777|NCT01320358|Drug|ECMPS-IEM|ECMPS-IEM
75772778|NCT05531890|Drug|GTX-102 medium dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
75772779|NCT05531890|Drug|GTX-102 medium dose slow Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
75772780|NCT05531890|Drug|GTX-102 high dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
75772781|NCT05531890|Drug|GTX-102 low dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
75772782|NCT05531890|Drug|Betamethasone solution as intramuscular injection Period 1 and Period 2|reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
75911755|NCT04863976|Other|Passive stretching|passive stretching of the quadriceps muscle
75911756|NCT04863976|Other|Self-stretching|Self-stretching of the quadriceps muscle
75911757|NCT04864288|Device|Shear Wave Elastography|is a quantitative method in which the probe generates acoustic impulses through the tissue to create molecular vibration. These vibrations create shear waves so that elasticity might be calculated, because it is proportional to the speed of the waves
75465240|NCT01887262|Device|BCM-guided fluid management|
75465241|NCT01887262|Procedure|Fluid management based on the clinical information alone|
75772783|NCT05531890|Drug|Betamethasone Oral Solution Period 1 and Period 2|Comparator product 0.1 mg/kg betamethasone oral drops solution
75772784|NCT03782584|Other|modified pilates exercise|modified exercises from original pilates exercises.
75619267|NCT01148459|Biological|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly."
75619268|NCT02789254|Biological|FLYSYN|"Cohort 1:~Patient 1-3: FLYSYN 0.5 mg/m² BSA* day 1~Cohort 2:~Patient 4-6: FLYSYN 0.5 mg/m² BSA day 1 FLYSYN 1.0 mg/m² BSA day 2~Cohort 3:~Patient 7-9: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 4.5 mg/m² BSA day 2~Cohort 4:~Patient 10-12 and 13-18: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2~Cohort 5:~Patient 19-21: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 44.5 mg/m² BSA day 2~Cohort 6:~Patient 22-24 and 25-31: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2, FLYSYN 15 mg/m² BSA day 15, FLYSYN 15 mg/m² BSA day 29~* The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03."
75772785|NCT03782584|Other|daily life advises|they will be given daily life advises to prevent neck pain
75772786|NCT03782428|Dietary Supplement|Probiotic|30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129
75772787|NCT03782428|Other|Placebo|Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
75772788|NCT00123474|Drug|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
75772789|NCT00123474|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
75772790|NCT00123474|Drug|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
75772791|NCT00123474|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
75772792|NCT00142298|Drug|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
75772793|NCT03774628|Biological|Chengdu Kanghua (one booster shot)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0
75772794|NCT03774628|Biological|Chengdu Kanghua (two booster shots)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
75772795|NCT03774706|Drug|Misoprostol|two tablets misoprostol 400 μg sublingual
75772796|NCT03774706|Drug|Tranexamic Acid|two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline
75911758|NCT04867720|Drug|Everolimus|- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~8mg/mL.
75911759|NCT02799069|Drug|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
75911760|NCT02799069|Drug|MAL Cream|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
75911761|NCT02799069|Drug|Vehicle|topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
75911762|NCT01669174|Drug|Placebo|
75911763|NCT01669174|Drug|BYM338|BYM338
75911764|NCT02060097|Dietary Supplement|Cocoa flavanol beverage|
75911765|NCT02060097|Dietary Supplement|Placebo beverage|
75772797|NCT03774706|Drug|placebo to tranexamic acid|placebo to tranexamic acid (110 ml saline)
75772798|NCT03967496|Procedure|Types of Anesthesia|"General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively."
75772799|NCT03967496|Procedure|Access of Surgery|Type of surgical access
75772800|NCT03967496|Other|Comorbidities|A patient may have more than one comorbidity
75772801|NCT03967496|Drug|Preoperative Medication|Preoperative medications
75772802|NCT03967496|Diagnostic Test|Routine blood test|Preoperative and Intraoperative Investigations
75911766|NCT03045562|Drug|Normal saline|Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
75772803|NCT03709654|Biological|NB01|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01
75911767|NCT03045562|Drug|Salvianolate injection|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
75911768|NCT02062047|Procedure|FMSRP|FMSRP in a maximum of 24 hours.
75911769|NCT02062047|Drug|Chlorhexidine|Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
75911770|NCT02062047|Procedure|PMSRP|Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
75911771|NCT02062047|Other|Placebo|Application and irrigation of placebo, rinsing placebo solution during 60 days
75911772|NCT03047902|Other|Group 1 - Parents will be present for the Questionnaire.|"In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them."
75911773|NCT03047902|Other|Group 2- Parents will not be present for the Questionnaire|
75911774|NCT03045406|Drug|Apixaban|Tablets
75911775|NCT03045406|Drug|Dalteparin|Injections
75772804|NCT03709654|Other|Vehicle Control|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control
75911776|NCT02798835|Drug|Adductor canal block|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
75911777|NCT02798835|Drug|Adductor canal block with dexamethasone|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
75911778|NCT02798835|Drug|Adductor canal catheter|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
75911779|NCT02798835|Drug|Bupivacaine|Used in spinal anesthetic
75911780|NCT02798835|Drug|Fentanyl|May or may not be used in spinal anesthetic
75911781|NCT02798835|Drug|Ropivacaine 0.5% Injectable Solution|Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
75911782|NCT02798835|Drug|Dexamethasone|To be given intravenously at time of nerve block to one of the study arms.
75911783|NCT03044236|Procedure|Stretching|The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
75911784|NCT02061579|Behavioral|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
75319369|NCT04176835|Drug|Placebo|
75319370|NCT00476645|Drug|Fulvestrant|Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
75319371|NCT01846195|Device|CM 1500|
75319372|NCT04406402|Behavioral|Acute dietary protocols and lifestyle modification|The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).
75619269|NCT03913234|Drug|Ribociclib, Trastuzumab, Letrozole|Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
75619270|NCT02792842|Drug|ART-123 (3-day ART)|ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
75619271|NCT02792842|Drug|ART-123 (1-day ART)|ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
75619272|NCT02792842|Drug|Placebo|Placebo infusion once daily on days 1-3 in each cycle
75911785|NCT03044470|Other|cryotherapy|Role of cryotherapy in reduction of post operative pain
75911786|NCT02061657|Drug|Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation
75465242|NCT01887275|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
75465243|NCT01887275|Drug|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
75465244|NCT01887314|Dietary Supplement|Standardized Ginger extract|
75465245|NCT01887340|Drug|Carboplatin|"- carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
75619273|NCT02792998|Drug|IW-1701|IW-1701 Tablet
75619274|NCT02792998|Drug|Placebo|Matching Placebo Tablet
75619275|NCT02792920|Device|CoCr-EES|
75619276|NCT02792608|Behavioral|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
75619277|NCT02792686|Drug|ABX464|Single Administration
75772805|NCT00412061|Drug|Octreotide|Octreotide 30 mg intramuscularly (i.m.) every 28 days.
75772806|NCT00412061|Drug|Placebo|A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
75319373|NCT00477191|Drug|Etanercept|TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
75319374|NCT04025918|Device|Vasopressor automated delivery system|"Novel closed-loop system incorporating:~Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm."
75465246|NCT01887340|Drug|Etoposide|100 mg/m2 D1 to D5
75619278|NCT02792374|Other|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
75619279|NCT02792530|Other|Dietary consultation|Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
75772807|NCT00412061|Drug|Everolimus|A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
75465247|NCT01887340|Drug|Cisplatin|20 mg/m2 de D1 to D5
75772808|NCT03964350|Drug|Ethanol|"The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol."
75772809|NCT03964350|Other|Placebo|The placebo comparator will be individual servings of back cheery sugar-free jello.
75772810|NCT01310452|Drug|insulin detemir|insulin detemir once daily with metformin
75772811|NCT01310452|Drug|neutral protamine insulin|neutral protamine insulin once daily with metformin
75619280|NCT02792296|Other|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
75619281|NCT02791984|Device|Fluid challenge with 250 ml of Ringer Lactate|"Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge"
75772812|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
75772813|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
75772814|NCT01035671|Drug|placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
75465248|NCT01887379|Drug|GRDF furosemide|The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
75619282|NCT02789332|Drug|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
75772815|NCT03966534|Other|Blood diversion|Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
75772816|NCT03771196|Other|Bioactive Restorative Material|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth
75772817|NCT03771196|Other|Resin-modified glass ionomer|Enhanced glass ionomer with acceptable mechanical properties and esthtic properties
75772818|NCT03770962|Behavioral|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will assist her."
75772819|NCT04560868|Device|Control mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence.
75772820|NCT04560868|Device|Experimental mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence. Experimental participants also receive additional content designed to motivate smoking reduction/quitting and provide skills training.
75772821|NCT04560868|Drug|Nicotine patch|Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.
75619283|NCT02789332|Drug|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
75619284|NCT02789332|Drug|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
75619285|NCT02789332|Procedure|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
75772822|NCT03769636|Device|GaitUp Physilog 5|"The primary outcomes are measured by the Physilog 5 (physical activity) at four different periods (T1-T4). Physilog 5 is worn for 4 weeks in total.~The secondary outcomes are fatigue, measured by FSMC (fatigue scale for motor and cognitive functions questionnaire), self-rated health-related quality of life, measured by the EQ-5D (health-questionnaire) and self-rated walking capacity, measured by the MSWS-12 (Twelve Item MS Walking Scale)."
75772823|NCT05479084|Other|Kinesiotaping|Kinesio taping will be applied on the lower part of the trapezius.
75772824|NCT03769558|Other|Non-Interventional|Non-Interventional
75772825|NCT03769480|Other|Muscle strength evaluation and Respiratory function Tests|Muscle strength evaluation and Respiratory function Tests
75772826|NCT03769402|Drug|Citric acid|Citric acid ph1, 50% concentration solution
75772827|NCT03769402|Drug|Control Test|Control group, xenograft was used to fill infrabony defects without treating bone surface
75772828|NCT04466410|Biological|XT-150|Single bolus intrathecal injection
75772829|NCT04466410|Biological|Placebo|Placebo is a sterile phosphate-buffered saline
75772830|NCT04444180|Diagnostic Test|Virtual hand illusion (VHI)|Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
75772831|NCT01321294|Procedure|laparoscopic anti-reflux surgery|
75772832|NCT00411671|Drug|Sorafenib|400 mg By Mouth Twice Daily for 28 Days.
75772833|NCT04419688|Drug|STT-5058|Monoclonal Antibody STT-5058
75772834|NCT04419688|Drug|Placebo|Matching placebo to STT-5058
75619286|NCT02789332|Other|Stratification|Hormone-receptor status (HR+ vs HR-) Age < 40 years vs >= 40 years
75619287|NCT02792140|Drug|Naltrexone|one week
75619288|NCT02792140|Other|Placebo|one week
75619289|NCT04234282|Procedure|Manual Physical Therapy|Orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment.
75619290|NCT02791594|Drug|Pembrolizumab|
75619291|NCT02791750|Other|questionnary of quality of life|
75619292|NCT04234516|Drug|Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film|3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
75619293|NCT04234516|Drug|Morphine Sulfate 30 mg|oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
75772835|NCT03770806|Procedure|Femoral Nerve Block|Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
75319375|NCT04025918|Drug|Phenylephrine|Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
75772836|NCT03770806|Procedure|Adductor Nerve Block|Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
75772837|NCT03770806|Other|No Block|routine iv and oral pain medication alone-observation only
75772838|NCT01039103|Drug|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
75772839|NCT01039103|Drug|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
75772840|NCT01036061|Drug|GSK618334 Low Dose|GSK618334 low dose
75772841|NCT01036061|Drug|GSK618334 PET subjects|PET subjects
75772842|NCT01036061|Drug|GSK618334 Medium Dose|Medium Dose
75772843|NCT01036061|Drug|GSK618334 High Dose|GSK618334 High Dose
75772844|NCT03770104|Procedure|ETT insertion depth using Spanish recommendations|Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
75772845|NCT03770104|Procedure|ETT insertion depth using international recommendations|Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
75772846|NCT01039181|Drug|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
75911787|NCT02061657|Drug|Placebo( for misoprostol)|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
75619294|NCT02791672|Behavioral|Discharge within 24 hours|If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
75619295|NCT02789566|Drug|Primaquine|Primaquine 30 mg taken after meal in the morning.
75772847|NCT01036139|Drug|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
75772848|NCT03770026|Drug|clomiphene citrate|Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.
75772849|NCT03770026|Drug|Saline cervical flushing|Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
75772850|NCT03770026|Biological|Intrauterine Autologous platelet-rich plasma|Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.
75772851|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
75772852|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
75772853|NCT03769870|Drug|Teneligliptin 20mg/day|cross-over
75772854|NCT03769870|Drug|Atorvastatin 40mg/Day|cross-over
75772855|NCT03769870|Drug|Teneligliptin 20mg/day + Atorvastatin 40mg/day|cross-over
75772856|NCT03769792|Diagnostic Test|Blood and faeces tests|During V0 - Laboratory tests, particularly for calprotectin concentration assessment
75772857|NCT03769792|Device|Impedance spectroscopy test|During V1 - the electrical impedance of pelvic floor muscles will be measured
75772858|NCT03769792|Diagnostic Test|Full gynecological and proctological examination|During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
75772859|NCT03769792|Diagnostic Test|Transanal ultrasonography|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
75911788|NCT03048136|Drug|Nivolumab|Specified dose on specified days
75319376|NCT04025918|Drug|Ephedrine|Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
75619296|NCT03889522|Diagnostic Test|Bioelectrical Impedance Analysis|BIA is a radiation-free and clinically accessible measure of body composition [47, 49]. An electrode is placed on the youth's extremities and they are asked to sit for 10 minutes. The youth's height and weight is manually inputted and the measure is obtained (approx. 90 seconds to complete). BIA sends a low level of electrical current through the body and measures the impedance to the current based on fat, muscle, bones providing a measure of body composition.
75911789|NCT03048136|Drug|Ipilimumab|Specified dose on specified days
75911790|NCT03797859|Procedure|Apneic ventilation|Ventilation by THRIVE
75911791|NCT02062203|Drug|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
75911792|NCT02062203|Drug|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
75911793|NCT02062203|Drug|Placebo|Single oral dose of placebo
75911794|NCT02062203|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
75772860|NCT03769792|Diagnostic Test|Anorectal manometry|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
75319377|NCT04025918|Device|Manual vasopressor delivery system|"Manual dosing system consisting:~Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm."
75319378|NCT04406246|Drug|Nitazoxanide 500Mg Oral Tablet|Health workers affected by SARS-CoV-2 will receive the next doses of nitazoxanide: 500 mg every 6 hour for two days and then every 12 hours for four days.
75619297|NCT03889522|Diagnostic Test|Total Body Dual-energy X-ray Absorptiometry|The DXA total body scan provides measurements of percent body fat, lean and fat free mass throughout the body. Youth lay on a table while the machine moves around them. The process takes about 3 minutes and 20 seconds.
75465249|NCT01887392|Other|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
75319379|NCT02115347|Drug|Ertugliflozin 15 mg|Tablet
75619298|NCT03889522|Diagnostic Test|Blood draw|Blood will be drawn to assess the following labs: HbA1c, leptin, lipid panel and comprehensive metabolic panel.
75619299|NCT02791360|Other|Brain MRI|
75911795|NCT04863820|Diagnostic Test|cutaneous silent period|form of Nerve conduction studies
75911796|NCT04863742|Drug|Dextenza 0.4Mg Ophthalmic Insert|sustained released dexamethasone, 0.4mg
75319380|NCT01798147|Procedure|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
75619300|NCT00872521|Drug|PAD induction|"Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 & 11), Doxorubicin 20 mg/m2 i.v. (D1 & 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 & 12)"
75619301|NCT04234438|Device|SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)|Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
75619302|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
75619303|NCT02791126|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
75619304|NCT02791126|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
75619305|NCT04048213|Other|questionnaire|questionnaire send to the parents
75619306|NCT02790814|Device|Moyo strap-on|Continous measurements
75619307|NCT02790814|Device|Hand-held fetoscope|Intermittent measurements
75772861|NCT01321918|Other|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
75772862|NCT01321918|Other|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
75772863|NCT03769324|Diagnostic Test|Osmolarity Test|Osmolarity Test
75772864|NCT03769246|Device|Upright Go Device|Participants will be asked to use the Upright device everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
75911797|NCT04863742|Drug|Prednisolone Acetate|Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
75319381|NCT01798147|Procedure|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
75319382|NCT04025450|Drug|Chidamide+VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
75319383|NCT04025450|Drug|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
75319384|NCT05622643|Other|MRI|Comparison between groups
75319385|NCT04024982|Other|Sequence of teaching (Lecture first followed by Simulation)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
75319386|NCT04024982|Other|Sequence of teaching (Simulation first followed by Lecture)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
75319387|NCT02115581|Drug|Coenzyme Q10|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
75319388|NCT02115581|Drug|Placebo|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
75619308|NCT00693667|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
75619309|NCT02791048|Behavioral|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
75619310|NCT00697021|Drug|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
75619311|NCT00697021|Drug|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
75619312|NCT02790892|Behavioral|Art therapy - pre and post test measures|12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
75465250|NCT01887405|Drug|Adrenaline auto-injector|"Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water"
75619313|NCT02620345|Drug|Dydrogesterone M ( case 1 )|"Dydrogesterone Multivitamin nature~Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~1tablet/24 hours/day (to 4 weeks after postpartum)"
75619314|NCT02620345|Drug|Dydrogesterone M ( case 2 )|"Dydrogesterone Multivitamin nature~Fibroids/ Women of Reproductive age ( discovered fibroids )~1tablet/24 hours/day ( from discovered fibroids through 6 months)"
75619315|NCT02790970|Device|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
75619316|NCT02790970|Other|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
75619317|NCT02623543|Device|OrthoK|
75619318|NCT00696163|Drug|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
75619319|NCT02790502|Device|Food Photography Application©|Group testing RFPM as method of recording plate waste
75619320|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide + sunitinib|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
75619321|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
75619322|NCT00693823|Procedure|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
75619323|NCT00693823|Device|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
75619324|NCT02788864|Drug|Arterakine (DHA/piperaquine)|"Stage 1: Parasite Clearance~Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
75619325|NCT02788864|Drug|Placebo|"Stage 1: Parasite Clearance~Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
75619326|NCT05298787|Drug|RLS-0071|RLS-0071 is administered as an IV infusion
75619327|NCT05298787|Drug|Saline Placebo|Placebo is administered as an IV infusion
75619328|NCT04137055|Drug|ZSP0678-10mg|ZSP0678 tablet administered orally under fasted condition
75319389|NCT04192058|Device|Sham transcranial direct current stimulation (tDCS)|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
75319390|NCT04192058|Device|Active transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) it is a therapeutic method that modulates membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively. The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min.
75619329|NCT04137055|Drug|ZSP0678-30mg|ZSP0678 tablets administered orally under fasted condition
75772865|NCT03769246|Other|Ergonomic Handout|Participants will be asked to use the ergonomic handout everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
75772866|NCT03769012|Dietary Supplement|Beta-Glucan|95% beta-glucan sourced from whole cell Euglena Gracilis
75772867|NCT03769012|Dietary Supplement|Placebo|microcrystalline cellulose
75465251|NCT01887431|Other|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
75465252|NCT01887431|Other|Conventional therapy|3-month routine clinic visits
75319391|NCT04191902|Behavioral|orientation|patients will be oriented
75772868|NCT03835481|Drug|BI 730357|Film-coated tablet
75772869|NCT03835481|Drug|Placebo to match BI 730357|Film-coated tablet
75772870|NCT03768934|Other|1X airtime incentive|An incentive given in the form of airtime.
75772871|NCT03768934|Other|2X airtime Incentive|An incentive given in the form of airtime.
75772872|NCT03768934|Other|Lottery airtime incentive|An incentive given in the form of airtime.
75465253|NCT01887444|Dietary Supplement|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
75619330|NCT04137055|Drug|ZSP0678-60mg|ZSP0678 tablets administered orally under fasted condition
75772873|NCT03768778|Procedure|Debridement and dural repair|
75772874|NCT02680366|Device|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
75772875|NCT02680366|Device|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
75772876|NCT00708695|Behavioral|Nurse Home Visiting|Visits from nurses from mid-pregnancy to child age 2 years.
75772877|NCT01567540|Drug|Sitagliptin|100 mg Sitagliptin daily for 15 weeks
75772878|NCT01039259|Device|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
75772879|NCT01039337|Other|Hip School|The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
75772880|NCT01039337|Other|Hip School and Manual Treatment|Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
75772881|NCT01039337|Other|Minimal control intervention|As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
75772882|NCT01885637|Other|Transition program|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
75772883|NCT01036841|Drug|desmopressin tablet|Administration of desmopressine tablet
75772884|NCT01036841|Drug|desmopressin MELT formulation|Administration of desmopressine MELT formulation
75772885|NCT03709576|Drug|Pevonedistat|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
75465254|NCT01887444|Other|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
75465255|NCT01887457|Drug|VFEND|voriconazole will be administered in iv form
75465256|NCT01887483|Dietary Supplement|Vetal Laban active|Dairy product with probiotic
75465257|NCT01887483|Dietary Supplement|Placebo|Dairy product without probiotic
75619331|NCT04137055|Drug|ZSP0678-120mg|ZSP0678 tablets administered orally under fasted condition
75619332|NCT04137055|Drug|ZSP0678-180mg|ZSP0678 tablets administered orally under fasted condition
75619333|NCT04137055|Drug|ZSP0678-240mg|ZSP0678 tablets administered orally under fasted condition
75619334|NCT04137055|Drug|ZSP0678-320mg|ZSP0678 tablets administered orally under fasted condition
75619335|NCT04137055|Drug|ZSP0678|ZSP0678 tablets administered orally under fasted or fed condition
75619336|NCT04137055|Drug|ZSP0678-Dose 1|ZSP0678 tablets administered orally once daily for 14 Days
75619337|NCT04137055|Drug|ZSP0678-Dose 2|ZSP0678 tablets administered orally once daily for 14 Days
75619338|NCT04137055|Drug|ZSP0678-Dose 3|ZSP0678 tablets administered orally once daily for 14 Days
75619339|NCT04137055|Drug|ZSP0678 Placebo|Participants will receive placebo matching to ZSP0678 orally.
75619340|NCT02788786|Drug|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
75619341|NCT02788786|Drug|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
75619342|NCT02788786|Drug|Salt and Water|salt and water mix oral rinse
75465258|NCT01887509|Device|Probe-based confocal laser endomicroscopy|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE~Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well.~After all procedures are complete, a second assessment of pCLE images by a third party will be performed."
75772886|NCT03709576|Procedure|transplant|Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.
75772887|NCT03709576|Drug|Azacitidine|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
75772888|NCT01039571|Procedure|double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair
75772889|NCT00122460|Drug|Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Subjects in will receive initial dose of 400 mg/m^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
75772890|NCT00122460|Drug|Platinum (Cisplatin or Carboplatin) + 5-FU|All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
75772891|NCT03768466|Drug|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
75772892|NCT03768388|Drug|levoketoconazole|food effect
76088835|NCT02466048|Procedure|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
75465259|NCT01887509|Procedure|Rectoscopy|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Both healthy and tumor tissue will be examined."
75465260|NCT01887509|Procedure|EUS|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view."
75619343|NCT00693901|Behavioral|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
75619344|NCT00693901|Behavioral|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
75619345|NCT03668236|Drug|Isotonic crystalloids|"Types of fluid to be used in both intervention groups:~IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~Fluids used for dehydration: Water or isotonic glucose should be used~Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy"
75619346|NCT02623465|Drug|Insulin Lispro|Administered subcutaneously (SC)
75772893|NCT03763396|Drug|Ketoconazole (KCZ)|Oral Tablet
75772894|NCT03763396|Drug|Posaconazole (PCZ)|Delayed Release Oral Tablet
75772895|NCT01320436|Dietary Supplement|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
75772896|NCT01320436|Drug|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
75772897|NCT04794088|Drug|Imatinib Mesylate intravenous solution|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).
75772898|NCT04794088|Drug|Placebo|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
75772899|NCT03763084|Drug|Acetaminophen|For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
75772900|NCT03763084|Drug|Sufentanil|For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
75619347|NCT00693979|Device|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
75319392|NCT04191980|Other|Comparison of prostate multi-zone segmentation obtained with an automatic deep learning-based algorithm and two expert radiologists|"The algorithm is used to perform a multizone segmentation of the prostate including delineation of : the whole prostate contours, the transition zone contours, the anterior fibromuscular stroma.~The contours is independently corrected by 2 radiologists. The corrected contours of the different zones will be stored and for each zone 6 different metrics will be used to evaluate the difference between the initial and corrected contours:~Mean Mesh Distance: Average Boundary Distance (ABD) for each point of the reference segmentation. The distance to the closest point of the compared segmentation is first computed. Then the average of all these distances is computed and gives the ABD~General Hausdorff distance (HD)~95% percentile (P) of the HD and the 95th (P) of the asymmetric HD distribution~95% HD modified (HD95_1): different approach by first computing the 95th (P) of the asymmetric HD then taking the maximum~Dice coefficient~Difference in volumes"
75319393|NCT00477659|Drug|Donepezil hydrochloride|Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks
75465261|NCT01887509|Procedure|Biopsy and resection|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE~Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well."
75619348|NCT04232800|Drug|Riboflavin|The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
75619349|NCT04232800|Other|Placebo|An inert, standard placebo in identical capsules to primary intervention.
75619350|NCT01148225|Drug|adalimumab|Adalimumab, pre-filled syringe, administered by SC injection
76088836|NCT02466048|Device|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
75619351|NCT02623387|Procedure|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
75619352|NCT02788240|Drug|Peg GCSF|
75619353|NCT02788240|Biological|20% Albumin|
75619354|NCT02788240|Dietary Supplement|Nutrition|
75619355|NCT02788240|Other|Bowel wash|
75619356|NCT02788240|Drug|Terlipressin 1- 4mg,if indicated|
75619357|NCT02788240|Drug|Meropenem or Imepenem, if indicated|
75619358|NCT02788240|Drug|Placebo|
75619359|NCT02788162|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - X71-144)
75619360|NCT04134715|Drug|PF-06826647|100 mg tablet
75619361|NCT04134715|Drug|Oral Contraceptive (OC)|OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
75619362|NCT04136899|Other|Dukes scale|collection of questionnaires
75619363|NCT02788006|Drug|Regorafenib 160 mg|
75619364|NCT00694057|Drug|HE3286|HE3286 10 mg per day (5 mg BID)
75619365|NCT00694057|Drug|Placebo|Placebo capsules BID
75619366|NCT02884115|Drug|benzathine penicillin|
75772901|NCT03763006|Procedure|Eyelid cleaning|This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.
75619367|NCT00696319|Other|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
75619368|NCT00696319|Other|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
75465262|NCT01887535|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as an oral suspension formulation.
75465263|NCT01887535|Drug|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as an oral suspension formulation.
75619369|NCT01190891|Procedure|Manual Physical Therapy|Same as arm description
75619370|NCT01190891|Procedure|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
75619371|NCT00871975|Device|Urodynamics + TETRA - NIRS|Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
75772902|NCT01567618|Drug|Docetaxel|"Docetaxel 50mg/m2 iv drip, repeat every two weeks;~Efficacy will be evaluated every three cycles."
75772903|NCT01567618|Drug|Fluorouracil|Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
75772904|NCT03768154|Procedure|Supine + spontaneous effort|without muscle paralysis in supine position
75772905|NCT03768154|Procedure|Supine + paralysis|administer muscle paralysis in supine position
75772906|NCT03768154|Procedure|Prone + paralysis|change the patient position from supine to prone with muscle paralysis
75319394|NCT04033627|Procedure|In Vitro T cells depletion using CliniMCAS system|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
75319395|NCT04191278|Drug|Varenicline|All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84
75319396|NCT04191278|Device|Mobile phone application|Participants randomized to 2 of the 3 study groups will receive a mobile phone application designed to improve adherence to medication. The app has a number of functions, including: a) reminders to take medication; b) information about coping strategies for dealing with side effects and withdrawal symptoms; c) provision of a personalized graphical display of treatment progress (e.g., adherence, side effects); d) camera-based verification of having taken medication.
75619372|NCT00694213|Biological|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
75619373|NCT00694213|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
75619374|NCT00694213|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
75619375|NCT00694213|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
75619376|NCT04134403|Drug|STASIS|Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
75619377|NCT01190813|Drug|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
75619378|NCT01190813|Drug|Placebo|Oral placebo tid
75619379|NCT01190813|Other|Patching|Two hours of daily patching
75619380|NCT03641326|Drug|Sunitinib|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.
75619381|NCT03641326|Device|wGT3x-BT|Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
75619382|NCT03721510|Biological|PGT121 + VRC07-523LS|PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously
75619383|NCT03721510|Biological|PGT121 + VRC07-523LS + PGDM1400|PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
75619384|NCT02788942|Procedure|Removing from Epigastric port|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
75619385|NCT04313309|Other|Integrative Yoga Therapy|Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
75465264|NCT01887535|Drug|JNJ-54861911 30 mg|JNJ-54861911 30 mg will be administered as an oral suspension formulation.
75465265|NCT01887535|Drug|JNJ-54861911 80 mg|JNJ-54861911 80 mg will be administered as an oral suspension formulation.
75465266|NCT01887535|Drug|JNJ-54861911 25 mg|JNJ-54861911 25 mg will be administered as a solid dose formulation.
75465267|NCT01887535|Drug|Placebo|Matching placebo will be administered as an oral suspension formulation.
75911798|NCT02611882|Drug|Ga-68 labeled HBED-CC PSMA|The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 μg Ga-68 HBED-CC PSMA.
75465268|NCT01887548|Other|Personality Traits Questionnaires|Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
75465269|NCT01887561|Drug|dasatinib|
75619386|NCT00870727|Drug|Aripiprazole oral product|Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
75619387|NCT00870727|Drug|Placebo oral capsule|Placebo will be identical in size and appearance to study drug.
75619388|NCT02787928|Drug|Intrathecal hydromorphone|Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
75619389|NCT02617069|Biological|botulinum toxin injection|
75619390|NCT02617069|Biological|0.9% normal saline injection|
75619391|NCT02617069|Device|Implantable loop recorder|
75772907|NCT03768154|Procedure|Prone + spontaneous breathing|cease the paralysis in supine position
75772908|NCT04771078|Biological|Nonconforming idecabtagene vicleucel|Nonconforming idecabtagene vicleucel is to be administered to participants after lymphodepleting chemotherapy
75772909|NCT03762928|Drug|PF-06651600|200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
75772910|NCT03762928|Drug|midazolam|single administration of midazolam 2 mg oral solution
75772911|NCT03762928|Drug|efavirenz|single administration of efavirenz 50 mg capsule
75772912|NCT01561456|Drug|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
75772913|NCT01561456|Drug|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
75772914|NCT01321996|Procedure|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
76088837|NCT02465970|Device|STARSTIM|"Multifocal transcranial direct current stimulation.~CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~The stimulation is applied during a 60 min session"
76088838|NCT02465970|Device|sham TDCS|
76088839|NCT04662372|Other|Description|description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
75319397|NCT04191278|Behavioral|Contingency management|Participants randomized to 1 of the 3 study groups will receive monetary reinforcement contingent upon verified medication adherence behaviors. Participants in the other 2 groups will be yoked to a participant in the CM group so that they also have a chance of earning monetary reinforcers, though not contingent upon their own behaviors.
75319398|NCT04750031|Procedure|Liver Biopsy|Liver biopsy is a procedure to obtain small amount of liver by a needle.
75319399|NCT04141046|Device|XCSITE100 Stimulator - Individualized theta-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
75465270|NCT01887574|Other|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
75619392|NCT02788630|Behavioral|Sleep hygiene counseling|The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
75619393|NCT02619877|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
75911799|NCT02611882|Device|Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective
75911800|NCT02611882|Device|Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.
75619394|NCT02619877|Other|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
75619395|NCT02788552|Drug|Thiamine Hydrochloride|Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
75619396|NCT04135339|Other|Eccentric exercise|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.
75619397|NCT04135339|Other|Concentric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.
75619398|NCT04135339|Other|Isometric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
75619399|NCT01147055|Drug|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
75619400|NCT01147055|Drug|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
75619401|NCT01147055|Drug|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
75619402|NCT03705754|Device|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
75911801|NCT02060877|Other|observational study: use of patient questionnaires|observational study, there is no study intervention, only patient questionnaires
75911802|NCT02062281|Biological|23-valent pneumococcal polysaccharide vaccine|Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
75319400|NCT04141046|Device|XCSITE100 Stimulator - Individualized alpha-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
75319401|NCT04141046|Device|XCSITE100 Stimulator - Active Sham|20 seconds of ramp-in to 40 seconds of 10 Hz tACS with a ramp out of 20 seconds for a total of 80 seconds of stimulation
75319402|NCT04148534|Drug|Rocroniom, Non Depolarizing Muscle Relaxant|compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
75465271|NCT01887613|Drug|Regnite|oral
75465272|NCT01887626|Drug|Ticagrelor 90 mg whole tablet|Ticagrelor 90 mg whole tablet administered as a single oral dose
75465273|NCT01887626|Drug|Ticagrelor 90 mg tablet crushed|Ticagrelor 90 mg crushed and suspended in water
75465274|NCT01887626|Drug|Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube|Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
75465275|NCT01887665|Behavioral|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
75465276|NCT01887691|Drug|eszopiclone|Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
75465277|NCT01887704|Device|Rotablator|Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.
75319403|NCT04388527|Biological|COVID-19 Convalescent Plasma|Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.
75319404|NCT04747964|Drug|STSP-0601 for Injection|Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements
75772915|NCT00137436|Drug|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
75911803|NCT02062281|Biological|trivalent influenza vaccine|Single 0.5ml trivalent influenza vaccine was administered IM
75911804|NCT02062281|Biological|23vPPV+TIV|Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
75319405|NCT04747964|Drug|STSP-0601 for Injection|Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements
75911805|NCT03047824|Device|Intravascular continuous monitoring|Bedside usual insulin therapy guided by continuous glucose monitoring
75319406|NCT04747964|Drug|STSP-0601 for Injection|Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements
75465278|NCT01887704|Procedure|conventional angioplasty|Conventional angioplasty was used in both arms.
75465279|NCT01887704|Procedure|stenting|Stenting was implanted in both arms.
75465280|NCT01887704|Device|Cutting balloon|Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
75465281|NCT01887704|Drug|Aspirin|Aspirin will be administrated in participants in both arms.
75465282|NCT01887704|Drug|Clopidogrel|Clopidogrel will be administrated to participants in both arms.
75465283|NCT01887704|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be used in both arms.
75465284|NCT01887704|Device|zotarolimus-eluting stent|Zotarolimus-eluting stent will be implanted in participants in both arms.
75465285|NCT01887704|Device|Everolimus-eluting stent|Everolimus-eluting stent will be used in both arms.
75619403|NCT02623231|Drug|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
75619404|NCT02623231|Drug|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
75772916|NCT00137436|Drug|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
75772917|NCT00137436|Drug|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
75772918|NCT03762772|Drug|TAF/EVG Vaginal Insert|1 combination vaginal insert (20mg TAF/16mg EVG)
75772919|NCT03762538|Drug|Propofol|Patients will be induced to unconsciousness using propofol intravenously.
75465286|NCT01887704|Device|Sirolimus-eluting stent|Sirolimus-eluting stent will be used in both arms.
75465287|NCT01887730|Behavioral|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
75619405|NCT04232878|Drug|CVL-936|CVL-936
75619406|NCT04232878|Drug|Matching Placebo|Placebo matching CVL-936
75772920|NCT03762382|Drug|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
75772921|NCT03762382|Drug|TFV IVR|TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
75911806|NCT03047824|Other|Standard of care|Bedside usual insulin therapy guided by intemittent glucose monitoring
75911807|NCT05654571|Diagnostic Test|mammography|All patients are checked for mammography every year after surgery.
75319407|NCT04747964|Drug|STSP-0601 for Injection|Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements
75319408|NCT04747964|Drug|STSP-0601 for Injection|Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
75319409|NCT04190966|Behavioral|Integrated Behavioural therapy|Integrated smoking cessation behavioural therapy
75319410|NCT04190966|Drug|Integrated Pharmacotherapy|Integrated smoking cessation pharmacotherapy including choice of combination nicotine replacement therapy, varenicline or electronic cigarettes
75319411|NCT04190966|Device|Integrated Web-based application|Integrated smoking cessation web-based application
75465288|NCT01887730|Behavioral|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
75465289|NCT01887730|Behavioral|Control|
75465290|NCT01887743|Drug|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
75465291|NCT01887756|Device|Tele Rehabilitation|
75465292|NCT01887782|Device|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
75465293|NCT01887782|Device|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
75465294|NCT01887795|Drug|Erlotinib|
75465295|NCT01887795|Drug|WBRT|
75465296|NCT01887821|Drug|Chloroquine|
75465297|NCT01887821|Drug|Dihydroartemisinin/Piperaquine|
75465298|NCT01887834|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|
75465299|NCT01887834|Dietary Supplement|Kyodophilus Matching Placebo Capsules|
75465300|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
75465301|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
75465302|NCT01887873|Device|Hyaluronan Thiomer i.o. implant|
75619407|NCT02623153|Drug|Oxaliplatin|oxaliplatin 130 mg/m2
75619408|NCT02623153|Drug|capecitabine|capecitabine of 1000 mg/m2
75619409|NCT02623153|Drug|S1|S1 of 40 mg/m2
75619410|NCT02623153|Drug|Docetaxel|docetaxel 40 mg/m2
75619411|NCT04316195|Diagnostic Test|Assessment of the bulbocavernosus reflex|"According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA."
75619412|NCT02616913|Other|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
75619413|NCT02616913|Other|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
75619414|NCT02616913|Other|Placebo|Each subject consumes placebo in one of 3 treatment periods
75619415|NCT02884037|Drug|Rifaximin group 1|Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
75772922|NCT03762382|Drug|Placebo IVR|Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
75772923|NCT03767998|Other|Respiratory muscle training for IMST|2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
75619416|NCT04233502|Drug|Melatonin|prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
75772924|NCT03767998|Other|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
75772925|NCT03767998|Other|Respiratory muscle training for EMST|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
75772926|NCT03767920|Drug|bupivacaine|TAP block with 20 ml of 0.25% bupivacaine bilaterally
75772927|NCT03767920|Drug|dexamethasone|TAP block with 4 mg dexamethasone bilaterally
75772928|NCT03767920|Drug|placebo to dexamethasone|TAP block with 4 mg placebo to dexamethasone bilaterally
75772929|NCT03834623|Drug|CC-122|Oral CC-122 at 2 mg daily, 5 days out of 7
75772930|NCT03834623|Drug|Nivolumab|240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle
75772931|NCT03767842|Device|Visor System|Subjects are monitored one time with the Visor System.
75772932|NCT03767764|Diagnostic Test|Test Yliver|Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique
75465303|NCT01887899|Device|transcranial direct current stimulation|
75465304|NCT01887899|Device|sham stimulation|
75619417|NCT04233502|Drug|Placebo|Placebo melatonin
75772933|NCT03993743|Biological|CD147-CART|Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
75772934|NCT03773926|Device|Neuro-feedback therapy|The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
75772935|NCT03762304|Other|Household blood pressure screening with care encouragement|"During the household survey visit, survey enumerators collected two measurements of the respondent's blood pressure. If either of the measurements exceeded 140 mmHg systolic or 90 mmHg diastolic, enumerators told participants: Your blood pressure readings are higher than normal. High blood pressure is dangerous because it makes the heart work too hard. High blood pressure increases the risk of heart disease and stroke. High blood pressure can also cause other problems, such as heart failure, kidney disease, and blindness. You can control high blood pressure by taking action. Then the enumerators recommend that an individual seek medical care within 2 months."
75772936|NCT01039727|Other|care as usual + 5 specific CDs|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
75772937|NCT01039727|Other|care as usual + email assistance + AurelisOnLine (AoL) + CDs|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
75772938|NCT03762226|Drug|Anti-VEGF|Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
75772939|NCT03993899|Device|FineHearing strategy or HDCIS strategy|Cochlear implant with FineHearing strategy or HDCIS strategy
75465305|NCT01887951|Drug|Penthrox Inhaler|
75772940|NCT03762148|Dietary Supplement|ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
75772941|NCT03762148|Dietary Supplement|ferrous sulphate|nutritional iron (14 mg) supplement in form of ferrous sulphate
75772942|NCT03762148|Dietary Supplement|ferric pyrophosphate|nutritional iron (14 mg) supplement in form of ferric pyrophosphate
75772943|NCT03762148|Dietary Supplement|ferrous fumarate + 3.5 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)
75772944|NCT03762148|Dietary Supplement|ferrous fumarate + 7 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)
75772945|NCT03762148|Dietary Supplement|ferrous sulphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)
75772946|NCT03762148|Dietary Supplement|ferrous fumarate + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C
75911808|NCT04873804|Other|Transcranial Direct Current Stimulation|The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
75772947|NCT03762148|Dietary Supplement|ferric pyrophosphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)
75772948|NCT03762148|Dietary Supplement|ferrous fumarate + 7 g GOS + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
75465306|NCT01887951|Drug|Tramadol Injection|
75465307|NCT01887964|Other|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
75465308|NCT01887964|Other|Control flour|Wheat flour without resistant starch (type-4)
75772949|NCT01589159|Drug|Capecitabine|Drug:capecitabine 700mg/m2, twice daily on days 1-14.
75772950|NCT01589159|Drug|Etoposide|Etoposide 30mg/m2, once daily on days 1-7.
75772951|NCT03762070|Device|CL Detect™ Rapid Test|Observational study of a FDA cleared device, the CL Detect™ Rapid Test.
75619418|NCT01146665|Behavioral|Computer-based PAF|This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
75619419|NCT01146665|Behavioral|Computer-based Sham|This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
75619420|NCT00696475|Drug|Diazoxide choline|
75465309|NCT01887977|Other|MRI examination|The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
75619421|NCT00696475|Drug|Diazoxide choline|
75619422|NCT00696475|Drug|Diazoxide choline|
75619423|NCT00696475|Drug|Placebo|
75619424|NCT03628066|Drug|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
75911809|NCT03795363|Drug|Orkambi|Orkambi is a novel approved therapy for use in people homozygous for the F508del mutation in the CFTR gene. It is a combination of lumacaftor (VX-809) and ivacaftor( VX-770) that addresses both the processing and gating defects of the F508del mutation. The small-molecule corrector lumacaftor corrects the F508del processing defect and increases epithelial delivery of CFTR protein1. Ivacaftor is a CFTR potentiator that increases the channel open probability in F508del-mutant CFTRs that undergo epithelial delivery in vitro and has an additive effect with lumacaftor on chloride transport (2,3,4,5).
75465310|NCT01888016|Other|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
75619425|NCT03628066|Drug|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
75619426|NCT03628066|Drug|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
75619427|NCT03628066|Diagnostic Test|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
75619428|NCT02616757|Device|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
75619429|NCT00625079|Drug|sildenafil|the dose of sildenafil will be 20mg three times per day (orally)
75619430|NCT02788318|Other|Brain samples|Collected in patients died
75619431|NCT02788318|Other|Skin samples|Collected in patients died
75772952|NCT03711292|Behavioral|Antibiotic Stewardship|For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
75911810|NCT03045172|Biological|Platelet Rich Plasma|PRP
75911811|NCT03045172|Drug|Placebo|Saline
75911812|NCT03560583|Drug|Metoclopramide|Metoclopramide 10 mg BID
75911813|NCT03560583|Drug|Placebo Oral Tablet|Placebo 10 mg BID
75465311|NCT01888016|Other|standard physiotherapies treatment|"10 standard treatments in 2 weeks~Deltoid and infraspinatus muscles electrotherapy~Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~Scar massage~Upper limb, cervical spine and scapula massages~Passive and assisted/active shoulder mobilization exercises~Scapula micro-mobilizations~Gleno-humeral decoaptation~Elbow, wrist and hand active mobilization~Proprioceptive exercise with and without the aid of the mirror"
75465312|NCT01888029|Device|transcranial direct current stimulation|
75619432|NCT02619721|Device|PINS SNS|
75619433|NCT04133389|Other|Growth mindset of personality educational intervention|This is a brief online educational intervention that teaches growth mindset of personality. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
75619434|NCT04133389|Other|Growth mindset of athletic ability educational intervention|This is a brief online educational intervention that teaches growth mindset of athletic ability. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
75619435|NCT02787616|Genetic|buccal swab|cheek swab for DNA sampling
75619436|NCT02787772|Procedure|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
75619437|NCT02616835|Device|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
75619438|NCT02616835|Device|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
75619439|NCT01145885|Drug|BI 6727|PLK-1 inhibitor
75619440|NCT02787538|Behavioral|US-ANSWER-2 decision aid|US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
75619441|NCT02787538|Behavioral|Control group (Online medication guide)|Standard online medication guide.
75465313|NCT01888029|Device|sham stimulation|
75465314|NCT01888042|Drug|Everolimus|10 mg (1 tablet of 10 mg)
75465315|NCT01888055|Device|transcranial direct current stimulation|
75465316|NCT01888055|Device|sham stimulation|
75465317|NCT01887652|Other|conventional ovarian stimulation|a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.
75319412|NCT03988387|Behavioral|Peer Support (PS)|Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.
75772953|NCT03937895|Biological|'SMT-NK' Inj (allogeneic Natural Killer cell)|In 120 mL, 3x10^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.
75772954|NCT03937895|Drug|Pembrolizumab Injection [Keytruda]|Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).
75772955|NCT03761992|Dietary Supplement|Gingko Baloba|Tablets
75772956|NCT03761992|Other|Placebo|Tablets
75772957|NCT03761836|Device|ShangRing|The ShangRing™ is a device for male circumcision that was invented by Jian Zhong Shang and has been on the Chinese market since 2005. It consists of a sterile device with two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. It currently holds a European Conformity (CE) mark, an EN ISO certificate, and is FDA approved. Clinical data from ShangRing studies in Africa were reviewed by the WHO Technical Advisory Group (TAG) on Innovations in Male Circumcision in January 2013 and were found to meet its clinical requirements. The ShangRing manufacturer was accepted by the WHO Prequalification Programme for Male Circumcision Devices in 2015.
75772958|NCT03767452|Drug|Xiaflex® 0.58 mg|0.25 mL injections.
75772959|NCT04731142|Device|Huma|V. Digital remote patient monitoring using blood pressure and blood sugar devices in combination with a smartphone application ('the Huma app'). Participants are provided with home monitoring devices and download the Huma app. Participants are shown how to use the devices, how to input measurements into a smart phone and how to set personal goals. Data recorded via the Huma app is self-reported and includes activity data, diet information, blood glucose measurements, blood pressure measurements, weight, and the Diabetes Distress Scale (a self-reported questionnaire used to measure distress related to living with diabetes).
75772960|NCT04731142|Behavioral|Video group consultations|"Each patient is invited to attend a total of three VGCs during the 12-weeks lasting approximately one hour and 15 minutes each. Each session is facilitated by a Practice Nurse (PN) and consists of 6-10 people with T2DM. The self-reported Huma app (see below) and patient EPR data are used to populate a Discussion Dashboard which is used in each VGC to facilitate discussion. During the first VGC session, patient goals are discussed and adjusted in a group setting with topics relevant to their condition covered by the PN. Between each VGC session, patients spend time working on their goals and continuing to enter self-reported metrics into the Huma app. During the second and third VGC sessions, each patient is discussed, along with their performance against agreed goals. The PN also uses pre-prepared content to discuss topics relevant to managing diabetes (e.g., staying motivated, low carb diets)."
75772961|NCT04731142|Behavioral|KNOW Diabetes|Each patient is signed up to a series of educational email campaigns to complement the VGC sessions and provide broader education around diabetes management. Patients receive two emails per week during the 12-week service on a variety of topics.
75772962|NCT04731142|Other|Standard of care|Normal primary care service provided to matched control group.
75772963|NCT03767374|Procedure|Inguinal swab sample|Inguinal samples using swab at cross-sectional visit
75465318|NCT01887652|Other|individualized ovarian stimulation|After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.
75619442|NCT02616991|Procedure|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
75465319|NCT01888081|Drug|A-dmDT390-bisFv(UCHT1) (Resimmune®)|
75465320|NCT01888081|Radiation|Ionizing Radiation|
75465321|NCT01888094|Other|Ultrasound-guided cannulation and examination|
75465322|NCT01888107|Drug|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
75465323|NCT01888107|Drug|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
75465324|NCT01888107|Drug|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
75619443|NCT02786992|Drug|Misoprostol|
75619444|NCT02786992|Drug|Oxytocin|
75619445|NCT02786992|Drug|Carbetocin|
75619446|NCT02786992|Drug|Placebo|
75619447|NCT02617303|Procedure|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 6 weeks (2 sessions per week) and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
75465325|NCT01888120|Drug|Ziconotide|
75619448|NCT02617303|Procedure|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
75619449|NCT02884193|Procedure|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
75619450|NCT02884193|Procedure|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
75619451|NCT02884193|Procedure|Sham Ice Bag|"Placebo application through an ice bag empty."
75619452|NCT02787460|Behavioral|Behavioral Text Messages|
75319413|NCT03988387|Behavioral|Reminder and Resource Transfer (RRT)|"Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points."
75619453|NCT04232644|Drug|ADAIR 10mg IR capsules|manipulated ADAIR IR 3x10 mg capsules
75619454|NCT04232644|Drug|Crushed d-amphetamine sulfate IR tablets|crushed d-amphetamine sulfate IR 6 x 5 mg tablets
75619455|NCT02622529|Other|Screening through questionnaires|Distribution of Questionnaires to every participant within the single existent Arm at three times.
75619456|NCT03557788|Drug|Rifaximin Oral Tablet|PO 550mg TDS for 2 weeks
75619457|NCT04133155|Drug|nab paclitaxel plus gemcitabine|Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
75619458|NCT01190267|Drug|asenapine|asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
75619459|NCT02622763|Biological|Tolerogenic Dendritic Cells|Intralesional administration
75619460|NCT02787382|Device|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
75619461|NCT03279874|Other|Interviews|Semi-structured one-on-one interviews
75619462|NCT00869089|Drug|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
75619463|NCT01190189|Biological|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
75619464|NCT04232488|Procedure|coronary angiography using distal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using distal radial artery ('snuff box'); color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
75619465|NCT04232488|Procedure|coronary angiography using proximal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using proximal radial artery; color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
75619466|NCT02616367|Drug|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
75619467|NCT02616367|Drug|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
75619468|NCT05347264|Other|gun massager|15 to 20 minutes along with hot pack.
75619469|NCT05347264|Other|transverse friction massage|15 to 20 minutes along with hot pack.
75619470|NCT04200118|Other|Observational|non intervention
75619471|NCT04200040|Biological|OrienX010 injection|"OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd."
75465326|NCT01888133|Behavioral|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
75465327|NCT01888133|Behavioral|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
75465328|NCT01888146|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
75465329|NCT01887028|Device|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
75619472|NCT04200040|Drug|Dacarbazine (DTIC)|Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
75619473|NCT00871117|Biological|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
75619474|NCT00871117|Biological|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
75619475|NCT00871117|Biological|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
75619476|NCT04232722|Drug|Arsenicals|As4 S4
75619477|NCT02787070|Drug|PQ supervised|
75619478|NCT02787070|Drug|PQ unsupervised|
75619479|NCT02622685|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
75619480|NCT02622685|Drug|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
75619481|NCT02622685|Drug|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
75619482|NCT02622685|Drug|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
75619483|NCT02622607|Drug|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
75619484|NCT02622841|Procedure|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
75772964|NCT03767374|Procedure|Anal swab sample|Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
75772965|NCT03767374|Procedure|Fecal sample|Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
75772966|NCT03767374|Other|Risk factor assessment|Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
76088840|NCT02465892|Behavioral|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
75772967|NCT03767296|Drug|Ephedrine Hydrochloride 3 MG/ML|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease < 20%)"
75619485|NCT02622451|Behavioral|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
75619486|NCT02622451|Behavioral|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
75619487|NCT02619565|Other|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
75911814|NCT04873882|Device|Acoustic ventilation|"Placement and removal of the esophageal stethoscope~Connection of a microphone to the esophageal stethoscope outside of and removed from the patient's body at the location on the figure above Connection fo monaural earpiece.~Digital breath sound real-time monitoring will be collected as .wav files from the device with no identifiable elements and the data from the device will be downloaded onto a desktop and we will keep and store the data on a secure departmental server.~Additional monitoring schedule includes evaluation of breath sounds with a conventional stethoscope every 30 minutes intraoperatively, at the start of one-lung ventilation, at the return to two-lung ventilation and prior to extubation and during any changes on the digital breath sounds recording monitor."
75619488|NCT03181750|Behavioral|Patient Navigator Intervention Group|Bicultural, bilingual navigators conducting home visits with patients and caregivers.
75619489|NCT02616445|Drug|UE2343|"UE2343~10mg, 20, 35mg~twice daily for 9 days"
75619490|NCT02616445|Drug|Placebo|"10mg, 20, 35mg~twice daily for 9 days"
75619491|NCT02616445|Drug|Placebo|"Cross-over study~single dose administered twice (on day 1 and day 8)~study duration 17 days"
75619492|NCT02616445|Drug|UE2343|"Cross-over study~UE2343~single dose administered twice (on day 1 and day 8)~study duration 17 days"
75619493|NCT02616445|Drug|UE2343|"UE2343~twice daily for 3 days~single dose on day 4"
75619494|NCT02622373|Device|PEA POD Infant Body Composition System|The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
75772968|NCT03767296|Drug|Phenylephrine|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease < 20%)"
75772969|NCT03761758|Device|Spectacle lenses|Spectacle lenses with clear central apertures
75772970|NCT03761602|Other|Not applicable (for observational studies)|This study is an observational study. No intervention will be administered for research purposes.
75772971|NCT03761524|Procedure|Customized V plate fixation|(CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .
75911815|NCT03560427|Drug|Duloxetine 60mg|"Patients will receive duloxetine, 60 mg tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
76088841|NCT02465814|Drug|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
76088842|NCT02465814|Drug|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
76088843|NCT02465814|Drug|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
76088844|NCT02465814|Drug|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
76088845|NCT02465814|Drug|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
75319414|NCT03988387|Drug|daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]|All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF] for the first month of enrollment.
75319415|NCT04145414|Device|MRI|Reproductibility test assessed with MRI for cerebrospinal fluid movements
75319416|NCT03748082|Drug|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
75465330|NCT01888159|Procedure|Bilateral Salpingectomy|
75465331|NCT01888159|Procedure|Tubal sterilization with bipolar energy|
75465332|NCT01888172|Behavioral|Weight Watchers Online Program|Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.
75465333|NCT01888172|Device|Philips ActiveLink|Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.
75465334|NCT01888172|Behavioral|Eating and Activity Newsletter|General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
75465335|NCT01888211|Dietary Supplement|Omega 3 fatty acid supplementation|2 grams Omacor daily
75465336|NCT01888211|Dietary Supplement|Olive Oil|2 grams olive oil daily
75465337|NCT01888224|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
75772972|NCT03761524|Procedure|Conventional miniplates fixation|Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
75772973|NCT00410813|Drug|dasatinib|given orally
76088846|NCT02465814|Drug|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
75319417|NCT03748082|Diagnostic Test|Reactive Hyperemia Index|Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.
75465338|NCT01888237|Drug|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
75465339|NCT01888237|Drug|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
75465340|NCT01888250|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
75465341|NCT01888263|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
75465342|NCT01888276|Other|evaluation of word generation and of motivation|"Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~The test of Stroop that assesses selective attention~During the session 2:~The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~The task of the casino (Iowa Gambling Test)~The task of landing~The test of Stroop"
75465343|NCT01888289|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
75465344|NCT01888302|Drug|Cisplatin|Given IV
75619495|NCT02787226|Drug|Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
75465345|NCT01888302|Drug|Gemcitabine Hydrochloride|Given IV
75465346|NCT01888302|Other|Quality-of-Life Assessment|Ancillary studies
75319418|NCT03748082|Procedure|Endothelial Cells Collection|Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.
75619496|NCT02787226|Drug|Continuous Perineural Ropivicaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
75772974|NCT02366572|Other|Control|Non pulse extruded cereal
75772975|NCT02366572|Other|Pea protein|Pulse extruded cereal
75772976|NCT02366572|Other|Pea starch|Pulse extruded cereal
75772977|NCT02366572|Other|Pea fibre + pea starch|Pulse extruded cereal
75772978|NCT02366572|Other|Pea protein + pea starch|Pulse extruded cereal
75772979|NCT02366572|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
75772980|NCT03767140|Procedure|acupuncture|The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture
75772981|NCT03760978|Drug|Dexmedetomidine|
75772982|NCT03760900|Combination Product|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, within 24 hours after birth
75772983|NCT03766984|Drug|Diclofenac sodium 25 mg|Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
76088847|NCT02465814|Drug|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
76088848|NCT04645212|Biological|ADVM-022|Long term follow-up of subjects that received ADVM-022
75319419|NCT00478361|Drug|Gemcitabine hydrochloride|Gemcitabine 900 mg/m^2 IV over 90 minutes repeat every 14 days.
75319420|NCT00478361|Drug|Paclitaxel|135 mg/m^2 IV over 1 hour
75319421|NCT00478361|Drug|Doxorubicin hydrochloride|Doxorubicin 40 mg/m^2 IV over 20 minutes
75319422|NCT00478361|Drug|Pegfilgrastim|Subcutaneously injection on day 1.
75319423|NCT02129725|Drug|Sildenafil citrate|Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months
75319424|NCT02129725|Drug|Placebo Oral Capsule|placebo capsules, 1 capsule po three times a day for 3 months
75319425|NCT04766372|Other|Behaviour change|Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.
75465347|NCT01888302|Drug|Sirolimus|Given PO
75772984|NCT03766984|Drug|Tramadol hydrochloride 25 mg|Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
76088849|NCT05093244|Device|SeQuent Please ReX|The SeQuent Please ReX is a conventional rapid exchange balloon tip catheter with a drug-coated balloon (DCB). The surface of the SeQuent Please ReX balloon is coated with paclitaxel, embedded in a soluble matrix (resveratrol).
75319426|NCT05622487|Other|Neural Therapy|Neural therapy is a form of treatment that aims to act on the autonomic nervous system, by injecting local anesthetics into certain parts of the body.
75465348|NCT01888315|Device|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
75465349|NCT01888315|Device|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
75465350|NCT01888315|Device|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
75465351|NCT01888315|Device|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
75619497|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
75619498|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
75619499|NCT02787148|Behavioral|Cognitive behavioral therapy|
75772985|NCT03766984|Drug|Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg|Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
75772986|NCT03758872|Diagnostic Test|cuff assisted colonoscopy(with cuff use of endocuff vision second generation)|this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
75772987|NCT00405821|Drug|Acyclovir|400mg twice daily for 24 months
75619500|NCT02616289|Other|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
75911816|NCT03560427|Drug|placebo|"Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
75772988|NCT00405821|Drug|Placebo|Placebo tablet twice daily for 24 months
75911817|NCT04873648|Behavioral|caloric reduced -intermitted fasting diet|obese women with food addiction and binge eating follow intermittent calorie restriction diet ( time-restricted eating - typically 16 -hour fasting and 8-hour eating)
75911818|NCT04873648|Behavioral|Daily calorie restriction|obese women with food addiction and binge eating disorder follow a Daily calorie restriction diet
75465352|NCT01888328|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
75465353|NCT01888341|Drug|Isotretinoin|Isotretinoin Capsules,20 mg
75772989|NCT03766828|Procedure|inside-out-access technique with inside-out access device (Surfacer (R))|inside-out-access technique with (Surfacer (R)) with a new CE certified device (Surfacer (R), Bluegrass Vascular)
75911819|NCT04873648|Behavioral|Control group|obese women without food addiction and binge eating disorder follow a Daily calorie restriction diet
75911820|NCT02796963|Behavioral|Crowdsourced intervention|The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.
75911821|NCT02796963|Behavioral|Traditional intervention campaign|The pre-intervention period will include conventional HIV testing campaigns organized by local CDC, Community-Based Organization (CBO), and partners. These are typically designed by experts and social marketing companies.
75772990|NCT03766828|Procedure|access technique including Sharp recanalization|access technique with Sharp recanalization via interventional radiology
75911822|NCT04429828|Other|COVID-19 e-package: Psychological wellbeing for healthcare workers|All healthcare students have access to a COVID-19 educational learning package around psychological wellbeing (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.
75911823|NCT04873180|Diagnostic Test|sectioning and staining of renal neoplasms after nephrectomy operation|nephrectomy operations will be done to patients diagnosed as having renel tumors
75911824|NCT04867330|Other|Toxicities reduced treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
75911825|NCT03560505|Diagnostic Test|Ultrasound protocol|High-resolution ultrasound protocol at pre-defined sites bilaterally. Pre-defined sites: Sciatic nerve (proximal and distal), tibial nerve (proximal and distal), common fibular nerve (proximal and distal), superficial fibular nerve (proximal and distal) and sural nerve (proximal and distal).
75911826|NCT04867564|Diagnostic Test|Echocardiography|Traditional echocardiography and speckle tracking echocardiography (STE) before and 1, 6, and 12 months after RT
75911827|NCT03797547|Other|AFLIBERCEPT|Patients will be treated following a real life protocol and according to the French recommendation
75465354|NCT01888354|Drug|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
75772991|NCT03928600|Combination Product|Cervical Foley combined with Misoprostol|Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
75911828|NCT04867252|Drug|Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day)|51 Patients with PCOS receiving Resveratrol and Myoinositol 1000mg and 1000mg BD daily respectively
75911829|NCT04867252|Drug|Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)|51 Patients with PCOS receiving Metformin and Pioglitazone 500 mg and 15 mg BD daily respectively
75911830|NCT03560271|Drug|Cyclo-Z|Cyclo (His-Pro) and zinc
75911831|NCT03560271|Other|Placebo|Matching placebo
76088850|NCT05093244|Device|Plain old balloon angioplasty (POBA)|Any commercially available semi-compliant PTCA balloon may be used per the investigator's discretion.
75465355|NCT01888380|Procedure|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
75465356|NCT01888380|Procedure|Conventional autopsy|
75465357|NCT01888393|Drug|lumacaftor 200 mg q12h + ivacaftor 250 mg q12h|
75465358|NCT01888406|Behavioral|Guided Self-Help|
75465359|NCT01888406|Behavioral|Pure Self-Help|
75465360|NCT01888419|Other|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
75465361|NCT01888445|Drug|roxadustat|oral
75772992|NCT03928600|Drug|Dinoprostone 10mg insert OR|Application for 24h of Dinoprostone 10mg insert
75772993|NCT03928600|Drug|Misoprostol|Application of vaginal misoprostol 25ug 4/4h until 150ug
75465362|NCT01888445|Drug|darbepoetin alfa|iv
75465363|NCT01888458|Drug|Micafungin|All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
75911832|NCT04863274|Drug|atorvastatin|"Profound patients' consultations (different from standard practice) on the importance of primary prevention of cardiovascular diseases, including preventive administration of statins.~Subjects in profound consultation group will receive regular reminders (2 times a month) via SMS and phone calls to check following the doctor's recommendations and remind about follow-up visit to study centre."
75911833|NCT02062515|Drug|icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
75465364|NCT01888471|Procedure|Blood sample|Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.
75319427|NCT05622487|Other|Kinesio taping|Kinesiotape is used for injury prevention, rehabilitation and performance enhancement. It has been shown to be clinically effective in increasing joint movements, increasing muscle activity, inducing muscle maximum torque earlier, and improving functional performance
75319428|NCT04024592|Device|Biodex System 4|Reliability and validity of isokinetic strength measurement of the knee, hip and ankle in typically developing children.
75319429|NCT03901183|Other|Plant-based Diet|Patients are guided to change their nutrition to a plant-based diet.
75319430|NCT04024748|Device|PET/CT imaging|Subjects will be have a PET/CT scan with PCD-1000A following their scheduled routine PET/CT scan. There will be no additional administration of radiopharmaceutical for the study.
75319431|NCT04024826|Behavioral|EFP|This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
75619501|NCT03421756|Drug|Alemtuzumab|Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
75619502|NCT03421756|Radiation|Total Body Irradiation|300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
75619503|NCT03421756|Drug|Sirolimus|Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
75772994|NCT01322152|Drug|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
75911834|NCT04873414|Biological|Convalescent plasma treatment|Convalescent Plasma collected from patients who recover from COVID-19 and have been discharged from the hospital for at least 14 days.
75911835|NCT02063373|Other|Hyaluronic acid|treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.
75911836|NCT02063451|Dietary Supplement|Very Low Calorie Diet (VLCD)|Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
75465365|NCT01888471|Other|Vaginal swab sample|Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.
75911837|NCT02062671|Procedure|renal denervation|
75772995|NCT05414344|Behavioral|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
75911838|NCT04863196|Other|Laser therapy Treatment Group|laser in gastric mucosa lesion
75911839|NCT04863196|Other|Barrier Dust Treatment Group|barrier powder in gastric mucosa lesion
75319432|NCT04024826|Behavioral|LFP|This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.
75465366|NCT01888510|Procedure|computed tomography|Undergo conventional free breathing CT
75319433|NCT04024826|Behavioral|ELP|This group will perform the Resistance training intervention on the day 18 of the menstrual cycle, which corresponds to the mid of early luteal phase
75319434|NCT04024826|Behavioral|LLP|This group will perform the Resistance training intervention on day 21 of the menstrual cycle, which corresponds to the mid of late luteal phase
75319435|NCT00483509|Drug|NGR-hTNF|iv q3W 0.8 mcg/sqm NGR-hTNF
75319436|NCT00483509|Drug|Doxorubicin|iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
75319437|NCT03049553|Device|Cobas HPV-DNA test|"Cobas HPV-DNA testing device from Roche is already in standard use in the Danish screening program for purpose of triage and primary screening of women 60+. It has four signals; HPV-negative, HPV-16, HPV-18 and other"
75319438|NCT03864211|Procedure|Thermal ablation|Radiofrequency ablation or microwave ablation is performed under CT or ultrasound guidance for one to five target lesions.
75319439|NCT03864211|Drug|Toripalimab|"Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation."
75465367|NCT01888510|Procedure|4-dimensional computed tomography|Undergo 4D CT
75465368|NCT01888510|Procedure|computed tomography|Undergo ABC CT
75619504|NCT00870103|Drug|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
75619505|NCT02619487|Other|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
75619506|NCT02619487|Other|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
75911840|NCT04429594|Other|blood sampling|blood sampling at J0, M6, M12, M24, M36, M48, M60
75465369|NCT01888510|Procedure|cone-beam computed tomography|Undergo ABC CBCT
75319440|NCT02938403|Behavioral|In vivo counseling|Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.
75619507|NCT03365752|Drug|Chloroprocaine|A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
75911841|NCT02062749|Drug|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
75465370|NCT01888510|Procedure|cone-beam computed tomography|Undergo free breathing CBCT
75619508|NCT03365752|Drug|Mepivacaine|A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
75619509|NCT03365752|Drug|General Anesthetics|General anesthetics will be administered intravenously
75619510|NCT02622217|Behavioral|Sleep deprivation|
75619511|NCT04133467|Other|scalp block|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
75619512|NCT02619643|Device|Transcranial Magnetic Stimulation (Magstim)|
75619513|NCT04232410|Diagnostic Test|Drug induced sleep endoscopy|DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
75772996|NCT05414344|Behavioral|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
75772997|NCT05414344|Behavioral|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
75772998|NCT01446016|Drug|Paclitaxel|Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
75772999|NCT01446016|Drug|Docetaxel|Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks
75773000|NCT01446016|Drug|Abraxane|Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
75773001|NCT01446016|Drug|Ixabepilone|Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
75773002|NCT00137046|Drug|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
75911842|NCT04866940|Other|Sequences test|the realization of preliminary acquisitions to validate the feasibility of clinical or cognitive research protocols
75773003|NCT00137046|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
75773004|NCT03760354|Drug|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
75773005|NCT03760354|Other|Placebo|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
75319441|NCT02938403|Behavioral|Standard Smoking Cessation Counseling|Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
75319442|NCT03842839|Drug|Tiotropium Inhalation Powder [Spiriva] 0.018mg|Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.
75319443|NCT03842839|Drug|Salbutamol sulphate aerosol (Ventolin) 0.01mg|As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
75773006|NCT01322230|Other|Control|Multimedia Control
75911843|NCT04872946|Dietary Supplement|Tea|Ashwagandha(Withania somnifera) root and leaf extract (32% Withania Oligosaccharides, 10% Withanolide Glycosides, 0.5% Withaferin A) 125 mg Saffron(Crocus Sativus) stigmas extract (3.48% Crocin and 0.03% Safranal) 28mg
75911844|NCT04872946|Other|Serum|Aqua/Water/Eau, Glycerin, Propanediol, Diheptyl Succinate, Caprylic/Capric Triglyceride, Lactococcus Ferment Lysate, Sorbitol, Dimethicone, Steareth-21, Octyldodecyl Neopentanoate, Sodium Polyacrylate, Steareth-2, Caprylyl Glycol, Hydrogenated Polydecene, Trideceth-6, Octyldodecanol, Panthenol, Sodium PCA, Azelaic Acid, Bisabolol, Capryloyl Glycerin/Sebacic Acid Copolymer, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Caprylhydroxamic Acid, Phytic Acid, Aminomethyl Propanol, Lactic Acid, Sodium Chloride, Phenoxyethanol, Sodium Benzoate.
75319444|NCT04190576|Device|Low Level Laser Therapy|Hydroxyapatite bone graft with collagen
75319445|NCT00450983|Biological|muromonab-CD3|
75319446|NCT00450983|Biological|natural killer cell therapy|
75319447|NCT00450983|Drug|fludarabine phosphate|
75465371|NCT01888523|Behavioral|Expressive writing|log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
75465372|NCT01888523|Behavioral|Everyday experiences writing|log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
75465373|NCT01888536|Drug|Limaprost|
75465374|NCT01888536|Drug|Pregabalin|
75465375|NCT01888536|Drug|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
75465376|NCT01888536|Drug|Placebo(for Limaprost)|mimic Limaprost tablet
75465377|NCT01888549|Drug|High-dose PPI|:40mg, po(per oral) 2times.day, 8weeks
75619514|NCT04232410|Diagnostic Test|Measurement of critical closing pressure of the uppper airway|After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
75619515|NCT02616133|Other|chart abstraction|abstraction of breast cancer patients with de-identified data
75911845|NCT04872946|Other|Moisturizer|Aqua/Water/Eau, Glycerin, Diisopropyl Dimer Dilinoleate, Coco-Caprylate, Lactococcus Ferment Lysate, Myristyl Myristate, Dimethicone, Propanediol, Behenyl Alcohol, Glyceryl Stearate SE, Potassium Cetyl Phosphate, Palmitic Acid, Ammonium Acryloyldimethyltaurate/Beheneth-25 Methacrylate Crosspolymer, Myristyl Laurate, Caprylyl Glycol, Hydroxyethylcellulose, Myristic Acid, Tocopherol, Ethylhexylglycerin, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Helianthus Annuus (Sunflower) Seed Oil, Trisodium Ethylenediamine Disuccinate, Lactic Acid, Sodium Hydroxide, Sodium Phosphate, Disodium Phosphate, Sodium Chloride, t-Butyl Alcohol, Phenoxyethanol, Sodium Benzoate.
76088851|NCT04617132|Behavioral|MBCT/MBSR|This intervention teaches the practice of mindfulness - being aware of the present moment without judgement - to help reduce the emotional reactivity to thoughts and bodily sensations, which prevents downward spirals into depression, anxiety, or fear.
75619516|NCT02785666|Drug|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
75619517|NCT02785666|Behavioral|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
75619518|NCT01145417|Drug|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
75619519|NCT02622139|Device|Multispectral Optoacoustic Tomography (MSOT)|MSOT for the evaluation of disease activity in IBD patients
75619520|NCT04232332|Drug|Recombinant human nerve growth factor injection,experimental|Intramuscular injection once on the first day according to dose requirements
75619521|NCT04232332|Drug|Recombinant human nerve growth factor injection,single dose|Intramuscular injection once on the first day according to dose requirements
75619522|NCT04232332|Drug|Recombinant human nerve growth factor injection,multiple dose|Intramuscular injection once daily for 7 days according to dose requirements
75619523|NCT04135183|Procedure|changes of Pneumonia Severity Score|assessing effectiveness of CAP treatment by using continuous pneumonia severity score
75773007|NCT01322230|Other|WISEMD Original|Current WISEMD
75773008|NCT01322230|Other|Social Networking|Social networking feature
75773009|NCT01322230|Other|Social Networking plus Emotional Design|social networking features plus user interface enhancements
75773010|NCT03760276|Drug|Voriconazole Oral Product (Vfend®)|To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
75773011|NCT03766594|Drug|Sildenafil Citrate|Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period
75319448|NCT00450983|Drug|methotrexate|
75319449|NCT00450983|Drug|thiotepa|
75319450|NCT00450983|Genetic|gene expression analysis|
75319451|NCT00450983|Other|flow cytometry|
75465378|NCT01888549|Drug|standard PPI|: 40mg, po(per oral) 1times.day, 8weeks
75465379|NCT01888549|Drug|placebo|
75773012|NCT03766594|Drug|Folic Acid|Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
75773013|NCT03766594|Drug|Placebo Oral Tablet|Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
75319452|NCT00450983|Other|immunologic technique|
75319453|NCT00450983|Procedure|allogeneic hematopoietic stem cell transplantation|
75319454|NCT00450983|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75319455|NCT00450983|Radiation|total-body irradiation|
75319456|NCT05295043|Drug|(CDK)4/6 inhibitor|CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
75465380|NCT01888562|Drug|Ponatinib|Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
75465381|NCT01888575|Drug|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
75465382|NCT01888588|Drug|Risk of symptomatic peptic ulcer|Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
75465383|NCT01888627|Other|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
75465384|NCT01888679|Procedure|Head movement|Head movement in extension, flexion, right and left rotation
75465385|NCT01888718|Drug|Fexofenadine Hydrochloride|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
75465386|NCT01888731|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
75465387|NCT01888744|Drug|GnRH agonist|
75465388|NCT01888744|Drug|GnRH antagonist|
75465389|NCT01888744|Drug|hP-hMG|
75465390|NCT01888744|Drug|Human chorionic gonadotropin|induction of final oocyte maturation
75465391|NCT01888744|Drug|Progesterone|
75465392|NCT01888757|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
75465393|NCT01888783|Other|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
75465394|NCT01888796|Drug|Linagliptin|
75465395|NCT01888796|Drug|placebo|
75465396|NCT01888809|Behavioral|Comprehensive preventive services|Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
75465397|NCT01888809|Behavioral|Screening and referral|
75619524|NCT02785276|Device|AutoFuser Pain Pump|Closed loop local anaesthetic infusion system
76088852|NCT04489446|Drug|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
75465398|NCT01888822|Drug|Ciprofloxacin|Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy
75465399|NCT01888822|Drug|Ampicillin-sulbactam|Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy
75619525|NCT02785276|Drug|Ropivacaine|Commonly used local anaesthetic drug
75619526|NCT02785276|Other|Normal Saline (0.9%)|Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
75619527|NCT00696553|Other|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
75619528|NCT00696553|Behavioral|Nutrition plus Exercise|Nutrition plus Exercise
75619529|NCT04316039|Drug|Temozolomide|Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.
75619530|NCT04316039|Radiation|intensity modulated radiation therapy|The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).
75619531|NCT04199416|Device|mRehab app|The mRehab app will be an interactive system with a user-friendly graphical user interface to provide multiple motivational functions that engage individuals in their prescribed home exercises. The app will contain video-based lower limb strengthening and aerobic exercise materials, health information, and motivational functions to increase their access to rehabilitation and care resources to augment their self-management ability.
75619532|NCT04199416|Device|Sham app|The sham app will only contain educational components and text-based exercise recommendations.
75619533|NCT00697645|Device|Deep TMS (Transcranial magnetic stimulation)|All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
75619534|NCT00697645|Device|Brainsway Deep TMS|Deep TMS applied over the motor strip
75619535|NCT02786680|Behavioral|stroop test in condition DBS off|Patients were evaluated in DBS Off
75619536|NCT02786680|Behavioral|stroop test in condition DBS on|Patients were evaluated in DBS On
75619537|NCT00697723|Procedure|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
75619538|NCT01144715|Device|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
75619539|NCT01144715|Device|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
75619540|NCT00696631|Drug|Dronedarone (SR33589)|oral administration
75619541|NCT00696631|Drug|Placebo|oral administration
75465400|NCT01888822|Drug|Placebo|Prophylactic placebo infusion before elective laparoscopic cholecystectomy
75619542|NCT04198324|Procedure|Closure of the uterus with endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed with suturing the endometrium.
75619543|NCT04198324|Procedure|Closure of the uterus without endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed without suturing the endometrium.
75619544|NCT02615977|Behavioral|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
75773014|NCT03758794|Other|interactive lecture|an interactive lecture will be given to a group of dental interns students on child abuse recognition and reporting
75773015|NCT03758794|Other|online education|an online educational module will be sent to a group of dental interns students on child abuse recognition and reporting
75773016|NCT03766360|Behavioral|Functional Analytical Psychotherapy (FAP)|The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
75465401|NCT01888835|Drug|Mirtazapine|
75465402|NCT01888835|Drug|Placebo|
75465403|NCT01888848|Dietary Supplement|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
75465404|NCT01888848|Dietary Supplement|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
75465405|NCT01888861|Dietary Supplement|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
75465406|NCT01888861|Drug|placebo|the patients in this arm were received 900mg placebo through NG tube.
75465407|NCT01888939|Other|Walking on a Treadmill|
75465408|NCT01888939|Other|Sedendary Activities Only|
75465409|NCT01888978|Drug|Gem-OX|
75465410|NCT01888978|Drug|Gem-5FU|
75465411|NCT01888978|Drug|Gem-Tax|
75911846|NCT04863040|Behavioral|MOVI intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 10 at high intensity (85-90% of HR max) followed by 20 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities. To increase the workload, and after evaluation of cardiorespiratory capacity, after 12 weeks of program, the HIIT protocol will be changed to 20 of high intensity work alternating with 10 of recovery."
75619545|NCT02615977|Behavioral|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
75619546|NCT01189487|Drug|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
75773017|NCT00122382|Drug|Abatacept|abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
75465412|NCT01888978|Drug|Modified FOLFOX-6|
75619547|NCT02786602|Genetic|pyrosequencing|
75773018|NCT00122382|Drug|placebo|placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
75773019|NCT00122382|Drug|methotrexate|Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
75465413|NCT01888978|Drug|Ox-Tax|
75773020|NCT01028716|Drug|Cyclophosphamide|Given IV
75773021|NCT01028716|Biological|Filgrastim|Given SQ
75911847|NCT02796651|Drug|Formoterol fumarate (6 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
75911848|NCT02796651|Drug|Formoterol furmarate (20 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
75465414|NCT01888978|Drug|FOLFIRI|
75465415|NCT01888978|Drug|Tax-Iri|
75911849|NCT02796651|Drug|Placebo for formoterol fumarate|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
75911850|NCT02796651|Drug|Formoterol fumarate (12 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
75465416|NCT01888991|Other|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
75465417|NCT01889004|Drug|Dexmedetomidine|Escalating concentrations until loss of responsiveness
75773022|NCT01028716|Drug|Fludarabine Phosphate|Given IV
75773023|NCT01028716|Drug|Mycophenolate Mofetil|Given PO
75773024|NCT01028716|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
75773025|NCT01028716|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
75773026|NCT01028716|Drug|Tacrolimus|Given IV or PO
75465418|NCT01889004|Drug|Propofol|Escalating concentrations until loss of responsiveness
75773027|NCT01028716|Radiation|Total-Body Irradiation|Undergo total-body irradiation (TBI)
75465419|NCT01889017|Other|patient questionnaire (tablet pc based)|
75465420|NCT01889056|Drug|Erythropoietin (Epoetin beta)|
75465421|NCT01889056|Drug|Placebo|0.9% sodium chloride solution
75465422|NCT01889082|Behavioral|Behavioral Weight Loss Intervention for Young Adults|
75465423|NCT01889095|Drug|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
75465424|NCT01889095|Drug|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
75465425|NCT01889121|Behavioral|Structured psychosocial intervention|This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
75465426|NCT01889134|Drug|Sedron (alendronate)|
75465427|NCT01889134|Procedure|Parathyroidectomy|
75465428|NCT01889147|Biological|hRESCAP|one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
75465429|NCT01889147|Biological|Placebo|
75465430|NCT01889160|Drug|AZD4721 Solution|1-9 mg/mL liquid solution
75465431|NCT01889160|Drug|AZD4721 Placebo|Liquid solution
75465432|NCT01889160|Drug|AZD4721 Suspension|9 mg/g liquid suspension
75773028|NCT02531724|Drug|Levosimendan|
75773029|NCT02531724|Drug|Placebo|Sodium chloride
75773030|NCT03758482|Other|Probe meal|The probe meal (total caloric content 750 Kcal) will be ingested at a standard rate in 10 min.
75773031|NCT03760198|Drug|Meditoxin|50U of MEDITOXIN is injected intradermally to each axilla
75773032|NCT03760198|Other|Placebo|normal saline is injected intradermally to each axilla
75773033|NCT03760042|Drug|Within-Subject Active vs Placebo Topical Applications|Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
75773034|NCT03760042|Drug|Within-Subject Active vs. Placebo Topical Applications|Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
75773035|NCT03759964|Drug|Ferric carboxymaltose|1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
75773036|NCT03759964|Drug|Placebo|100 mL of IV isotonic serum saline at day 1 following surgery
75773037|NCT00106704|Drug|Comparator: Sitagliptin|sitagliptin 10 mg tablet, once daily for 54 weeks
75773038|NCT00106704|Drug|Comparator: Placebo|Placebo oral tablet once daily for 24 weeks
75773039|NCT00106704|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg tablet once daily for 30 weeks
75911851|NCT02796651|Drug|Formoterol fumarate (40 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
75319457|NCT04190732|Behavioral|Physician phone call|Often, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team.
75619548|NCT02621905|Drug|Sporanox|At least 2 capsules twice a day for 3 weeks
75619549|NCT02621905|Drug|Lozanoc|At least 2 capsules twice a day for 3 weeks
75319458|NCT03839563|Behavioral|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
75465433|NCT01889173|Drug|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
75465434|NCT01889173|Drug|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
75619550|NCT02785198|Device|Passive knee extensor machine|The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
75619551|NCT04134247|Drug|PD-1 combined with chemotherapy|"PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
75619552|NCT04134247|Drug|chemotherapy|"Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
75911852|NCT03044080|Drug|IncobotulinumtoxinA|Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
75319459|NCT01796405|Drug|Clofarabine|
75619553|NCT04232098|Other|Heat to ankle|Heat administered via hot water to ankle level
75619554|NCT04232098|Other|Heat to calf|Heat administered via hot water to calf level
75619555|NCT01106352|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
75619556|NCT01106352|Drug|Docetaxel|Docetaxel (75 mg/m^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
75319460|NCT04190810|Behavioral|Inhibition|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
75319461|NCT04190810|Behavioral|Classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
75319462|NCT04190810|Behavioral|Control|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
75773040|NCT03759886|Drug|Paromomycin Sulfate Powder|The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
75773041|NCT03965364|Device|INCRAFT|Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
75773042|NCT03766282|Device|ECMO|Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
75465435|NCT01889173|Drug|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
75465436|NCT01889173|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
75319463|NCT04190654|Drug|KW-6356|Single oral dose of KW-6356
75319464|NCT04190264|Device|Thermal Rehabilitation Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
75465437|NCT01889212|Other|11C-erlotinib PET/CT|
75465438|NCT01889264|Other|Observational|Observational, Translational non-treatment study
75465439|NCT01889277|Drug|MT-3995-Low|
75465440|NCT01889277|Drug|MT-3995-High|
75911853|NCT03044080|Drug|OnabotulinumtoxinA|ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
75319465|NCT04190264|Other|Cold Water Immersion|Whole-body immersion in cold water.
75319466|NCT03649321|Drug|Bemcentinib|200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
75319467|NCT03649321|Drug|Nab-paclitaxel|25 mg/m^2 Day 1 /8 every 21 days or 28 days.
75319468|NCT03649321|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days or 28 days
75319469|NCT03649321|Drug|Cisplatin|Cisplatin 25 mg/m^2 Day 1 /8 every 21 days
75465441|NCT01889277|Drug|Placebo|
75465442|NCT01889290|Drug|Methylnaltrexone|Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
75911854|NCT03047668|Dietary Supplement|diet with/without supplementation|diet with/without supplementation with PUFAs
75911855|NCT04429282|Drug|ibuprofen|Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.
75911856|NCT04429282|Drug|Placebo|Placebo
75619557|NCT01144403|Drug|Cyclophosphamide|as prescribed, 6 cycles
75619558|NCT01144403|Drug|Fludarabine|as prescribed, 6 cycles
75619559|NCT01144403|Drug|Mitoxantrone|as prescribed, 6 cycles
75619560|NCT01144403|Drug|Rituximab|375 mg/m^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
75619561|NCT03071926|Drug|Pegylated Liposomal Doxorubicin|20 mg, qw, first 6 weeks ,every 8 weeks
75619562|NCT02619331|Procedure|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
75773043|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
75911857|NCT02063529|Drug|FOLFOXIRI + Cetuximab|Cetuximab 500mg/m² + irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
75619563|NCT03061552|Diagnostic Test|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
75619564|NCT02883647|Drug|Entecavir or Tenofovir|Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
75911858|NCT02063529|Drug|FOLFOXIRI|Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
75911859|NCT02063607|Biological|Peginterferon lambda|
75465443|NCT01889316|Device|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
75619565|NCT02621827|Other|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
75619566|NCT02615899|Other|Matched: Targeted (specific) balance exercise interventions|
75773044|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
75773045|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days."
75911860|NCT02062983|Drug|Herceptin|"Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression."
75911861|NCT02613208|Drug|Bevacizumab|Bevacizumab will be administered as per local clinical practice and local labeling.
75465444|NCT01889316|Device|AN24|
75465445|NCT01889342|Behavioral|Metacognitive therapy|
75465446|NCT01889342|Behavioral|Cognitive behavioral therapy|
75465447|NCT01889368|Dietary Supplement|Grape Seed Extract|300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
75619567|NCT02615899|Other|Mismatched: Untargeted (non-specific) balance exercise interventions|
75619568|NCT02703922|Other|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
75465448|NCT01889368|Dietary Supplement|Placebo|300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
75619569|NCT00625157|Drug|ASF 1096 0.5 % cream|
75911862|NCT02613208|Drug|Paclitaxel|Paclitaxel will be administered as per local clinical practice and local labeling.
75911863|NCT02063841|Device|lead-free protective drape containing bismuth and antimony (RADPAD®)|
75911864|NCT02063841|Device|sterile identical sham drape|
75911865|NCT02063919|Other|the mucosal microbiome in the biopsy specimen was analysed|
75911866|NCT03045250|Device|Corneal confocal microscopy|Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
75911867|NCT03045250|Procedure|Skin biopsy|Skin biopsy will be used to assess the appearance of nerve fibers in subjects with type 1 diabetes.
75619570|NCT00625157|Drug|ASF 1096 placebo cream|
75619571|NCT01143389|Drug|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
75619572|NCT01143389|Device|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
75619573|NCT00868231|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
75619574|NCT00868231|Drug|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
75619575|NCT00868231|Drug|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
75619576|NCT04231864|Biological|Durvalumab|Given intravenously (IV)
75619577|NCT04231864|Drug|Epacadostat|Given orally (PO)
75911868|NCT03045250|Procedure|Nerve conduction study|Nerve conduction studies will be use to assess for neuropathy.
75619578|NCT02786524|Behavioral|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
75773046|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days."
75773047|NCT00105066|Drug|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
75773048|NCT00105066|Drug|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
75619579|NCT02883803|Biological|Injection of mesenchymal stem cells|Injection of mesenchymal stem cells
75619580|NCT02883803|Biological|Injection of albumin alone|Injection of albumin alone
75773049|NCT01322308|Drug|pioglitazone|30 mg tablet QD (taken once daily)
75773050|NCT01322308|Drug|placebo|tablet taken once a day
75773051|NCT05208268|Drug|Pariet|Pariet Tablets.
75773052|NCT03766048|Procedure|Single-Anterior-Mesh, SAM|laparoscopic sacropexy is only performed with the anterior mes
75773053|NCT03766048|Procedure|Double-Mesh, DM|laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space
75773054|NCT00104520|Drug|AZLI 75 mg two times a day (BID)/three times a day (TID)|
75773055|NCT00104520|Drug|Placebo two times a day (BID)/three times a day (TID)|
75773056|NCT03759652|Behavioral|before-after study|The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
75773057|NCT03963882|Drug|Two cycles of neoadjuvant chemotherapy|Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
75773058|NCT03963882|Diagnostic Test|First imaging evaluation|First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)
75911869|NCT03045250|Other|Blood draw|Subjects will undergo a one time blood draw for biomarkers.
75911870|NCT02064075|Drug|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
75319470|NCT04190108|Diagnostic Test|Fecal calprotectin assay|FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.
75319471|NCT04149704|Behavioral|ACP video decision aid|10 minute video decision aid describing the goals-of-care options
75619581|NCT00698347|Device|M2a-Magnum™ Hip System|
75773059|NCT03963882|Diagnostic Test|Second imaging evaluation|Second imaging evaluation consists of pelvic magnetic resonance imaging
75773060|NCT03963882|Drug|The third cycles of neoadjuvant chemotherapy|The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
75773061|NCT03963882|Procedure|RH|Radical hysterectomy
75773062|NCT03963882|Radiation|Radiochemotherapy|Concurrent radiochemotherapy
75773063|NCT03963882|Diagnostic Test|Pathologic evaluation|Pathologic evaluation for RH patients
75773064|NCT05180188|Behavioral|Training|In the 8-week training period, participants will have three training sessions with a duration of 30 minutes at 70% of VO2peak per week.
75773065|NCT01081314|Behavioral|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
75773066|NCT01081314|Behavioral|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
75911871|NCT02064075|Drug|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
75911872|NCT02064153|Procedure|Cool dialysate|Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.
75911873|NCT02064153|Procedure|Warm dialysate|All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
75911874|NCT04866628|Dietary Supplement|Helichrysum italicum infusion|Comparison of metabolic syndrome components before and after four weeks of daily consumption of Helichrysum italicum infusion.
75911875|NCT04866628|Dietary Supplement|Helichrysum arenarium|Comparison of metabolic syndrome components before and after four weeks of daily consumption of Helichrysum arenarium infusion.
75911876|NCT04866394|Radiation|SBRT|Patients will be planned with the aim of delivering 30 Gy in 5 fractions.
75911877|NCT03789747|Other|As a observational study, there is no intervention.|As a observational study, there is no intervention.
75319472|NCT04149704|Other|Usual Care-|Verbal description of the three types of care
75319473|NCT03347071|Behavioral|Prevention Course Group|The undergraduate prevention course is structured around Eat Breathe Thrive Program curriculum. The course aims to teach somatic practices, provide healthy tools for emotional regulation, allow for the creation of community-based networks of support, foster a sense of meaning and purpose through service activities, and practice these learned skills through yoga.
75319474|NCT04190888|Other|No intervention|No intervention - observational study
75319475|NCT04149938|Drug|Lidocaine topical system 1.8%|
75465449|NCT01889394|Procedure|secondary wound healing|secondary wound healing
75465450|NCT01889394|Procedure|primary wound closure using a limberg flap|primary wound closure using a limberg flap
75465451|NCT01889407|Drug|Idarubicin|8 mg/m2, iv drip on days 1-3
75465452|NCT01889433|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
75465453|NCT01889433|Drug|Pegasys|180 µg subcutaneously, once a week
75465454|NCT01889446|Dietary Supplement|Calcium propionate|
75465455|NCT01889472|Device|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
75619582|NCT04130581|Other|Transcranial Magnetic Stimulation (TMS)|TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
75319476|NCT04149938|Drug|Lidocaine patch 5%|
75911878|NCT04862884|Drug|HRS4800 tablets|"Drug: HRS4800 tablets Low-dose group, single oral administration~Drug: HRS4800 tablets Low-medium dose group, single oral administration~Drug: HRS4800 tablets medium -dose group, single oral administration~Drug: HRS4800 tablets Medium and high dose group, single oral administration~Drug: HRS4800 tablets High-dose group, single oral administration"
75911879|NCT04862884|Drug|placebo|"Drug: placebo Low-dose group, single oral administration~Drug: placebo Low-medium dose group, single oral administration~Drug: placebo medium -dose group, single oral administration~Drug: placebo Medium and high dose group, single oral administration~Drug: placebo High-dose group, single oral administration"
75319477|NCT01797601|Drug|Human Insulin|160 U of insulin
75319478|NCT01797601|Drug|Placebo|Insulin dilution medium without insulin
75319479|NCT02984930|Drug|Administration of study drug (esomeprazole, mosapride)|Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.
75619583|NCT02784886|Biological|Women at high risk of MAP|Blood sample
75619584|NCT02614573|Device|CoagucheckXSR Capillary INR measures|"We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.~If capillary INR is <2 or >3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.~If capillary INR is > 4, then verification by venous measure and refer to general practitioner."
75619585|NCT02614495|Drug|Surufatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
75619586|NCT01143077|Drug|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
75619587|NCT02786446|Drug|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
75619588|NCT02786446|Drug|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
75619589|NCT02786446|Drug|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
75619590|NCT02618941|Biological|AFFITOPE® PD01A|s.c. injection
75619591|NCT02784964|Biological|Elixcyte 8 ml|ADSC 6.4*10^7 cells, allogeneic injection
75619592|NCT02784964|Device|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
75619593|NCT02784964|Biological|Elixcyte 4 ml|ADSC 3.2*10^7 cells, allogeneic injection
75619594|NCT02784964|Biological|Elixcyte 2 ml|ADSC 1.6*10^7 cells, allogeneic injection
75619595|NCT02619019|Drug|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
75619596|NCT02619019|Drug|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
75619597|NCT02619019|Drug|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
75619598|NCT02615587|Drug|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
75773067|NCT03114046|Behavioral|Lower extremity Constraint-induced movement therapy(LE-CIMT)|"Both phases (A and B) will last 10 weekdays, and during baseline and treatment phases, the data will be collected on 5 different odd days. Considering the long period of data collection. During the baseline phase, no assessment will be administered on even days. The treatment will be delivered daily, along 10 weekdays, 3.5 hours per day. The motor training will be delivered during 3 hours and 30 minutes will be allocated to the administration of the TP.~Both caregivers and participants will be individually interviewed before and after treatment."
75773068|NCT05145322|Device|Composite with 90 degree cavosurface angle|Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the preparation will be restored with a bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
75319480|NCT02984930|Drug|Administration of study drug (esomeprazole, placebo tablet)|Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.
75319481|NCT02984930|Procedure|upper endoscopy, scintigraphy|After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
75319482|NCT04149548|Diagnostic Test|ultrasound|Obstetric ultrasound to pregnant women
75911880|NCT02063061|Device|Sham treatment|Patients will receive simulated treatment, with the same ESWT unit as in other arm. Placebo gel-pad is design to prevent shockwaves emission. Looks identical as active gel-pad.
75319483|NCT02123017|Drug|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses
75619599|NCT02786368|Behavioral|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
75319484|NCT02123017|Drug|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
75619600|NCT02786368|Behavioral|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
75319485|NCT02123017|Drug|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses
75319486|NCT04149626|Drug|Dexmedetomidine|Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)
75319487|NCT04149626|Drug|Midazolam|Sedation using midazolam (initial bolus dose followed by continuous infusion)
75319488|NCT04149626|Drug|Remifentanil|Sedation using remifentanil (initial bolus dose followed by continuous infusion)
75465456|NCT01889498|Drug|Acetazolamide|"Acetazolamide twice a day, at 12 hour intervals:~250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery~One tablet to take two hours before surgery~500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours."
75465457|NCT01889511|Behavioral|Intervention group - texts|"Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes."
75619601|NCT02615821|Behavioral|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
75619602|NCT04307160|Procedure|Bilateral lateral rectus recession|All patients will undergo bilateral lateral rectus recession according to standard tables. In the younger age group, the amount of lateral rectus recession will be reduced by 0.5 mm. in those with inferior oblique overaction, inferior oblique recession will be performed
75619603|NCT02956798|Radiation|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
75619604|NCT02947516|Procedure|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
75619605|NCT02947516|Procedure|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
75619606|NCT01096446|Drug|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
75619607|NCT00864721|Drug|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
75619608|NCT05308420|Procedure|Pericapsular nerve group (PENG) block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
75773069|NCT05145322|Device|Composite with wide bevel|Lesion-specific cavity design with wide bevel throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the cavity will be restored in with a pre-warmed (using Bioclear Heatsync Kit) bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
75773070|NCT03759262|Drug|Cholecalciferol|A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
75773071|NCT03765658|Drug|GRT0151Y dose escalation|Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)
75319489|NCT04149392|Device|Continuous Glucose Monitor|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge. The participants will go home with the device and keep it for 6-14 days until they return to clinic for follow up visit. At this time the device will be removed, the information regarding glucose levels during those days will be downloaded and based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
75619609|NCT05308420|Procedure|Spinal anesthesia|Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally
75619610|NCT05308420|Drug|Intrathecal morphine|100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
75773072|NCT03765658|Drug|Matching placebo|Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
75773073|NCT00135330|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
75911881|NCT02063061|Device|ESWT treatment|ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
75773074|NCT00135330|Drug|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
75773075|NCT05128318|Procedure|Nissen Fundoplication, cholecystectomy|Collection of adipose tissue pieces in the context of programmed abdominal surgery to treat to treat hiatal hernia, gastroesophageal reflux or vesicular lithiasis. During the surgery treatment, adipose tissue of 1-2 cm3 will be collected for the protocol by laparoscopy by the surgeon in charge of the procedures.
75773076|NCT03765580|Dietary Supplement|Fish|Lunch containing fish
75619611|NCT05308420|Procedure|Sham PENG block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
75465458|NCT01889524|Other|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
75773077|NCT03765580|Other|Control|Lunch containing no fish
75911882|NCT03044002|Device|Biotronik 4 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
75773078|NCT03765424|Diagnostic Test|Ultrasound|Ultraosund of temporal, carotid and axillary arteries
75911883|NCT03044002|Device|6 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
75911884|NCT04862728|Other|- Strong kids screening tool - Stamp screening tool - PYMS screening tool|Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP) evaluates patient's clinical diagnosis, nutritional intake during hospitalization and anthropometric measurements, developing a care plan based on the child's overall malnutrition risk (low, medium or high).Screening Tool for Impaired Nutritional Status and Growth (STRONG kids). It consists of four items: subjective clinical assessment, high-risk diseases, nutritional intake and losses, weight loss or poor weight gain. Patients classified at high nutritional risk have a longer hospitalization and a negative standard deviation score (SDS) for weight-for-height (WFH), which indicated a state of acute malnutrition.The Pediatric Yorkhill Malnutrition Score (PYMS) is adopted among medical and surgical patients between 1 and 16 years of age. The PYMS assesses four items: BMI, history of recent weight loss,
75911885|NCT03043846|Other|Follow-up every 3 months during 1 year (data collection in eCRF)|
75911886|NCT03043846|Other|Follow-up every month to follow the pre-defined strategy|
75619612|NCT05308420|Drug|Intrathecal placebo|0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
75619613|NCT02615665|Procedure|Hepatic resection|Removal of a part of the liver during surgery
75319490|NCT00486863|Drug|Praziquantel|60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.
75319491|NCT00486863|Other|Placebo|Made with the same color coded gelatin capsules with the inert compound dextrose.
75319492|NCT02123329|Behavioral|Pharmacist delivered smoking cessation program|"The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.~To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.~• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems"
75619614|NCT02897050|Drug|Docetaxel|Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1
75619615|NCT02897050|Drug|Capecitabine|Capecitabine 1200mg/m2/d, po, d1-d21
75619616|NCT02897050|Drug|Cyclophosphamide (tablet)|Cyclophosphamide 50 mg/d, po, d1-d21
75619617|NCT02897050|Drug|Fluorouracil|Fluorouracil 500mg/m2, iv, d1
75619618|NCT02897050|Drug|Epirubicin|Epirubicin 100mg/m2, iv, d1
75619619|NCT02897050|Drug|Cyclophosphamide (injection)|Cyclophosphamide 500mg/m2, iv, d1
75619620|NCT02619097|Drug|Pegol-sihematide injection|single dose
75773079|NCT01076478|Drug|Cilostazol|100 mg, 200mg tablet Cilostazol
75773080|NCT01076556|Drug|Alvocidib Hydrochloride|Given IV
75773081|NCT01076556|Drug|Cyclophosphamide|Given IV
75773082|NCT01076556|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
75773083|NCT01076556|Other|Pharmacological Study|Correlative studies
75619621|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
75619622|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
75619623|NCT01095666|Drug|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
75619624|NCT01095666|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
75619625|NCT01095666|Drug|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
75619626|NCT04132765|Other|Drooling Impact Scale|A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.
75773084|NCT01076556|Biological|Rituximab|Given IV
75773085|NCT00134784|Drug|[123I]B-CIT SPECT imaging|To assess [123I]B-CIT SPECT imaging
75773086|NCT03965442|Drug|Control|Patients who underwent mastectomy under standard general anesthesia
75773087|NCT03965442|Drug|Esmolol|Patients who underwent mastectomy under general anesthesia with esmolol infusion
75773088|NCT00134082|Biological|KGEL vaccine|Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10^8 cells per dose. The first dose was given on Day +1.
75773089|NCT00134082|Biological|Filgrastim|5 mcg/kg/day starting on Day +6 until ANC is >= 1000/mcL.
75773090|NCT00134082|Biological|Rituximab|375 mg/m^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
75911887|NCT04862806|Diagnostic Test|COVID-19 serology|Immune response to BNT162b2 mRNA vaccine is assessed on the basis of anti covid19 IgG levels. A centralized assessment of the serological response for 4 medical centers is performed on serum samples stored at -60 °C using Abbott-SARS-CoV-2 IgG quant (Positive value > 151; range 0-40.000). The other 4 medical centers performed the test locally using DiaSorins-LAISISON SARS-CoV S1/S2 IgG test (positive value >15 range 15-400). In the central virus laboratory at the Chaim Sheba Medical center the test was done by Elisa-RDB (positive value >1.1; range 1.1-10).
75773091|NCT00134082|Drug|Cyclophosphamide|50 mg/kg/day on Day -3, -2, -1, and 0.
75911888|NCT04862494|Other|clinical surveillance|regular clinical follow up including chest X-rays, pulmonary investigations, etc...
75619627|NCT04132765|Other|Drooling Frequency and Severity Scale|In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)
75911889|NCT04862494|Procedure|diaphragmatic plication|plication of a hemidiaphragm, performed via laparoscopy, thoracoscopy (including robot-assisted surgery), or classical thoracotomy
75465459|NCT01889524|Other|Jet nebulizer|"The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a T piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL."
75619628|NCT04132765|Other|The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)|A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').
75619629|NCT04132765|Other|Drooling Quotient (DQ)|DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.
75911890|NCT04872634|Biological|SNK01 (Super Natural Killer Cells 01)|Investigational Product : SNK01 (Super Natural Killer Cells 01) Principal Component : Autologous Natural Killer Cell To induce anti-tumor immunity in Locally advanced or Metastatic Non-small Cell Lung Cancer Patients who have failed prior TKI therapy for EGFR, ALK, or ROS1 Gene Mutation and to strengthen the Antibody-Dependent Cellular Cytotoxicity (ADCC) of Cetuximab, 4x10^9 or 6x10^9 cells are infused through the veins of the subjects within 45 minutes (±15 minutes) per 100 mL total 8 times at intervals of one week.
75911891|NCT04872634|Drug|GC|"Gemcitabine; 1000mg/m2, Day 1, Day 8, 4-cycle administration, Mixed with normal saline 50ml and administered into a vein for 30 min.~Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour."
75911892|NCT04872634|Biological|Cetuximab|"First administration: 400mg/m2 Subsequent administration: 250mg/m2 (Premedication before administration*) Weekly Administration continues until the disease progresses or unacceptable toxicity develops.~400mg/m2: Administered into a vein for 120 minutes 250mg/m2: Administered into a vein for 60 minutes"
75911893|NCT04862182|Diagnostic Test|Trans-perineal ultrasound|Intrapartum trans-perineal ultrasound in predicting the mode of delivery.
76088853|NCT04489446|Drug|Placebo|Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
75619630|NCT04132765|Other|Patient and caregiver visual analog scale (VAS) for drooling|Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)
75619631|NCT04132765|Other|Functional Oral Intake Scale (FOIS)|Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.
75619632|NCT04132765|Other|number of bibs daily used|Parents will be asked their children's number of bibs daily used.
75619633|NCT04132765|Other|number of hospital admissions per year related to respiratory infections|Parents will be asked their children's number of hospital admissions per year related to respiratory infections.
75619634|NCT04132765|Other|Gross Motor Function Classification System (GMFCS)|The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.
75619635|NCT04132765|Other|Manual Ability Classification System (MACS)|The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.
75619636|NCT04132765|Other|Communication Function Classification System (CFCS)|The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.
75619637|NCT04132765|Other|Eating and Drinking Ability Classification System (EDACS)|EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.
75773092|NCT01081392|Biological|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
75773093|NCT03765346|Drug|Oxycodone IR ADF|Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
75773094|NCT03765346|Drug|Oxycodone API powder|Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
75773095|NCT03765346|Drug|Placebo to match oxycodone API powder|Placebo to match oxycodone API powder (mass of 30 mg).
75773096|NCT03765346|Drug|Placebo to match manipulated oxycodone IR ADF.|Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
75619638|NCT04231474|Device|Urodynamic testing|All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
75773097|NCT01078818|Drug|IV trivalent saccharose hydroxide ferrous|"Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up~1 month 1 oral placebo /24h"
75619639|NCT02615431|Other|MitraClip Intervention|
75619640|NCT05338840|Other|MULLIGAN ROTATIONAL MOVEMENT|12 sessions over 6 weeks
75911894|NCT04862104|Behavioral|Intervention group|In addition to the routine care they received, the patients in the intervention groups were given discharge training developed in the pre-discharge period. Discharge training consisted of a verbal and written information booklet containing instructions for the patient and the patient's caregiver on pain management, nutrition management, incision site care, strengthening self-care, returning to daily life activities, and colostomy care. Discharge training was given in the service after evaluating the surgical recovery status of the patient before discharge. The average duration of each training was 30-45 minutes. The patients were evaluated in terms of surgical recovery by calling by phone 2 weeks after discharge, 4 weeks and 8 weeks later. The developed education booklet was given to the patient and it was ensured that he could benefit from the information at home.
75911895|NCT04872556|Device|Laser acupuncture device|The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
75911896|NCT04872556|Device|Pseudo-laser acupuncture|The experiment group would arrange Pseudo-laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
75911897|NCT03047356|Behavioral|"If-then plans"|"If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)"
75911898|NCT03047356|Other|Control|Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
75465460|NCT01889524|Other|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
75619641|NCT05338840|Other|Medial gapping technique|12 sessions over 6 weeks
75911899|NCT03047590|Behavioral|Choice-based Exercise Intensity|Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.
75619642|NCT02618863|Device|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
75619643|NCT05302180|Other|Pain neuroscience education|"The online pain neuroscience education program will be based on the model proposed by the Pain Research Group, available in http://pesquisaemdor.com.br, which presents the Path of Recovery. In our program we will hold 10 meetings: (1) conversation with the group, (2) acceptance and pain education, (3) continuation about pain education, (4) sleep hygiene, (5) pharmacological assistance, (6) recognizing stress and negative emotions, (7) increasing positive coping in lifestyle, (8) exercises, (9) communication, and (10) prevention of recurrence. The program will be offered by synchronous meetings; asynchronous (videos) and e-book."
75773098|NCT01078818|Drug|Oral ferrous fumarate|"200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)~Postoperative Period:~200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet"
75773099|NCT01078818|Drug|Oral and intravenous Placebo|Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
75773100|NCT03964038|Drug|gilteritinib|oral
75773101|NCT03964038|Drug|gilteritinib mini tablet|oral
75911900|NCT03047590|Behavioral|Positive Affect Focus|Participants are instructed to focus on feeling good while exercising.
75911901|NCT03047590|Behavioral|Heart rate-based Exercise Intensity|Participants are instructed to regulate their exercise intensity based on their heart rate.
75911902|NCT01668784|Biological|Nivolumab|
75911903|NCT01668784|Drug|Everolimus|
75319493|NCT02123329|Other|Control arm (i.e: regular care)|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
75319494|NCT04148924|Other|Questionnaire|"Patients complete a questionnaire for assess their symptoms like anxiety and depression.~These questionnaires contains:~socio-demographic characteristics : sex, age, type and stage of cancer, performans status~ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms~HADS - A : Hospital Anxiety and Depression scale includes 2 subscales which assess anxiety (HADS-A) and depression (HADS-D)~BEDS : Brief Edimburg depression Scale is s a relevant scale for assess depression in palliative care patients.~Questions on the assessment, the treatment and difficulties in management of anxious and depressive symptoms.~The evaluation will be realized in the first days of hospitalization (72 hours)."
75465461|NCT01889537|Behavioral|Virtual Reality|The patient will receive virtual reality during a burn care procedure
75773102|NCT01326390|Device|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
75773103|NCT01326390|Procedure|DSA arteriogram- hepatic arteries|Standard of care
75773104|NCT01326390|Procedure|CO2 aortogram|Standard of care
75773105|NCT01079052|Drug|Famotidine|Tablets
75911904|NCT04866238|Device|Vestibular fixed appliances|The fixed appliances will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
75911905|NCT04866238|Device|Clear aligners|The clear aligners will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
75911906|NCT02750514|Biological|Nivolumab|Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
75911907|NCT02750514|Drug|Dasatinib|
75619644|NCT05302180|Other|Usual care|All participants will receive usual care in one of the five physiotherapy clinics accredited to SUS, according to availability of scheduling in the services. The usual care consists of 10 sessions of physical therapy, that is mainly composed by kinesiotherapy and electrothermophototherapy.
75619645|NCT01100658|Drug|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
75773106|NCT01326468|Drug|Temsirolimus|All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.
75773107|NCT01326468|Drug|Cetuximab|"All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.~Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy."
75911908|NCT02750514|Biological|Relatlimab|
75911909|NCT02750514|Biological|Ipilimumab|
75911910|NCT02750514|Drug|BMS-986205|Specified dose on specified days
75911911|NCT02229240|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
75911912|NCT02229240|Drug|Matching albiglutide placebo|Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
75911913|NCT04611750|Drug|AD036|AD036 will be given for 14 days
75911914|NCT04611750|Drug|Placebo|Placebo will be given for 14 days
75465462|NCT01889550|Behavioral|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
75465463|NCT01889550|Behavioral|Access to the website www.ouh.dk|Access to the usual information from the hospital website
75465464|NCT01889576|Dietary Supplement|Magnesium Oxide|
75465465|NCT01889589|Other|Surveillance|
75911915|NCT02820714|Drug|BLI801 Laxative|BLI801 Laxative
75911916|NCT02259426|Drug|Dihydroartemisinin-piperaquine combination (Artekin)|
75911917|NCT02259426|Drug|Primaquine|Single-dose 0.25mg/kg
75911918|NCT02229630|Radiation|Pregnant women with intra-uterine growth restricted Foetuses|Diffusion-weighted cerebral MRI before 32 weeks of gestation
75911919|NCT03742518|Drug|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
75911920|NCT03742518|Drug|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
75465466|NCT01889615|Other|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
75465467|NCT01889628|Dietary Supplement|Liquid-based Nutritional Formulae and liquid glucose|
75465468|NCT01889654|Other|Venous blood sampling|
75465469|NCT01889680|Drug|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
75465470|NCT01889680|Drug|LV|400 mg/m2 IV day 1 every 14 days until disease progression
75465471|NCT01889680|Drug|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
75465472|NCT01889680|Drug|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
75465473|NCT01889719|Biological|MVA-CMDR|injections of MVA-CMDR vaccine
75465474|NCT01889732|Device|ROTEM|
75773108|NCT01326468|Drug|Cisplatin|All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.
75773109|NCT01326468|Device|Radiation Therapy|Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
75911921|NCT03742518|Drug|Topical vehicle solution|Vehicle solution application will be performed by the individual subject at approximately the same time each day.
75911922|NCT03412890|Drug|Relugolix|Relugolix 40-mg tablet administered orally once daily
75911923|NCT03412890|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
75911924|NCT02229708|Behavioral|Healthy Lifestyle Group|
75465475|NCT01889745|Drug|HX-1171|Anti-oxidatant, Anti-inflamation
75465476|NCT01889758|Drug|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
75465477|NCT01889758|Drug|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
75465478|NCT01889758|Drug|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
75619646|NCT01100658|Drug|Placebo|1 capsule per day for 1 week.
75619647|NCT02618785|Procedure|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
75619648|NCT02618707|Other|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
75465479|NCT01889771|Drug|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
75619649|NCT05276908|Procedure|Thoracolumbar interfascial plane block (TLIP)Technique|A curvilinear array ultrasound probe (Siemens ACUSON X300 Ultrasound System) will be placed at the targeted lumbar level.The corresponding spinous process and interspinal muscles will be identified, and the probe will be slided laterally to identify the longissimus muscle and iliocostalis muscle. Under ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a medial to lateral orientation through the belly of longissimus muscle toward the iliocostalis muscle. Hydro-dissection with 2-3 ml of isotonic saline solution will confirm the correct needle tip position and, after negative aspiration, 0.25 % bupivacaine will be injected slowly whilst carefully monitoring the spread of local anesthetic into the fascial plane between the longissimus and iliocostalis muscles. The same procedure will be repeated on the contralateral side.
75465480|NCT01889784|Device|Phototherapy through light emitting diode (LED) - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
75619650|NCT05276908|Procedure|Anesthetic Management|"Induction:~Induction of general anesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of atracurium.~Maintenance:~Anesthesia will be maintained with inhaled isoflurane 0.8% in oxygen enriched air (FiO2=0.5). Maintenance doses of 0.1 m\kg atracurium will be provided every 30 minutes. Then the patient will be placed in prone position."
75911925|NCT03371082|Biological|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
75619651|NCT05276908|Drug|Bupivacaine Injection 10ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
75911926|NCT03371082|Biological|Lantus®|Route of administration: subcutaneous injection
75911927|NCT02258880|Drug|SUN13837|
75619652|NCT05276908|Drug|Bupivacaine Injection 20ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
75619653|NCT02785978|Drug|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring"
75619654|NCT02785978|Other|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)"
75619655|NCT02785978|Other|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
75619656|NCT02785978|Device|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
75619657|NCT02785978|Other|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
75619658|NCT02786056|Other|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
75619659|NCT02786212|Drug|Dexmedetomidine|
75619660|NCT02786212|Drug|Normal Saline|
75619661|NCT05273710|Other|Regular toast and juice|Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.
75619662|NCT05273710|Other|High phytate toast and juice|Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.
75773110|NCT03703336|Biological|ROTAVIN (liquid formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10^6 plaque forming units (PFU) of strain G1P[8] per dose of 2 mL.
75773111|NCT03703336|Biological|ROTAVIN-M1 (frozen formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10^6 PFU of strain G1P[8] per dose of 2 mL.
75773112|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
75773113|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
75773114|NCT03702166|Behavioral|Cognitive Processing Therapy (CPT)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. CPT is delivered in three phases: education, processing, and challenging.
75773115|NCT00132678|Drug|Risperdal Consta|12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
75911928|NCT02258880|Drug|placebo|
75911929|NCT03340974|Drug|GC4419|90 mg Avasopasem (GC4419) per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
75911930|NCT03340974|Drug|Placebo|Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
75911931|NCT03340974|Radiation|Stereotactic Radiation Therapy (SBRT) 50 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
75773116|NCT00132678|Drug|Placebo|Matching placebo intramuscular (IM) injection every 2 weeks
75773117|NCT01081548|Drug|atorvastatin|20 mg
75773118|NCT01081548|Drug|atorvastatin|20 mg
75911932|NCT03340974|Radiation|Stereotactic Radiation Therapy (SBRT) 55 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
75911933|NCT03731052|Drug|188-0551 Spray|Topical Spray containing active drug
75911934|NCT03731052|Drug|Vehicle Spray|Topical Spray containing no active drug
75911935|NCT02229786|Drug|Buscopan® plus|
75911936|NCT02229786|Drug|Buscopan®|
75911937|NCT02229786|Drug|Paracetamol|
75619663|NCT05273710|Other|Regular toast and juice, with folic acid|Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
75619664|NCT02784808|Drug|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
75619665|NCT02784808|Drug|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
75619666|NCT02784652|Drug|Zoledronic acid|Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
75619667|NCT02784652|Radiation|Radiotherapy|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions,
75619668|NCT04231630|Other|Prolacta|Will receive outpatient supplementation with donor human milk product added to mother's own milk
75619669|NCT02784730|Procedure|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
75619670|NCT02784730|Procedure|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
75619671|NCT02786290|Device|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
75619672|NCT04231552|Drug|Camrelizumab|Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
75773119|NCT00101868|Device|Discharge communication software|Computerized physician order entry software used by discharging physician
75619673|NCT02785744|Other|Gaucher disease DNA mutation analysis|
75619674|NCT01100502|Drug|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
75619675|NCT01100502|Drug|placebo|Every 21 days by IV infusion
75619676|NCT02784418|Procedure|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
75619677|NCT02784418|Procedure|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
75773120|NCT00101868|Other|Usual care discharge process|Handwritten
75773121|NCT00101400|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
75911938|NCT02229786|Drug|Placebo|
75619678|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone IV drip
75619679|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
75619680|NCT02784340|Drug|Saline (IV fluids)|IV fluids 500 cc saline infusion
75619681|NCT02784340|Drug|Bupivicaine and Fentany|
75619682|NCT02784340|Device|25G spinal needles|
75619683|NCT02785822|Drug|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
75619684|NCT02785822|Drug|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
75911939|NCT02612428|Biological|ELAD System|An extracorporeal human hepatic cell-based liver treatment
75911940|NCT02612428|Other|Standard of Care (Control)|Standard medical treatment as defined by the protocol
75911941|NCT03287232|Drug|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
75911942|NCT03287232|Drug|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
75911943|NCT03281382|Biological|Ad5-yCD/mutTKSR39rep-hIL12|Oncolytic adenovirus expressing two suicide genes and human IL-12
75911944|NCT03047434|Other||
75911945|NCT02229942|Drug|Rituximab|"Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months."
75911946|NCT02229942|Drug|Placebo|Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
75911947|NCT03047512|Behavioral|Experimental: Internet-based program|"Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered."
75911948|NCT03280056|Biological|NurOwn® (MSC-NTF cells)|Autologous transplantation of bone marrow derived mesenchymal stem cells propagated ex vivo and induced to secrete neurotrophic factors
75911949|NCT03280056|Other|Placebo|Placebo
75911950|NCT03280056|Other|Bone Marrow aspiration|Bone Marrow aspiration
75619685|NCT02878512|Procedure|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
75619686|NCT02878512|Procedure|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
75619687|NCT04302246|Genetic|Biological testing on sequential blood sample|Biological characterization of various immune function and blood circulating leukocytes phenotyping before liver transplantation and therafter at day-3, -7, -14 postoperatively and if septic complication occurs.
75911951|NCT03047278|Procedure|Serial Blood Samples|Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
75911952|NCT03047278|Procedure|Serial Urine Samples|Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
75319495|NCT04148924|Other|Medical staff questionnaire|"Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~socio-demographic characteristics : sex, age, type and stage of cancer, performans status~ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms"
75465481|NCT01889784|Device|Placebo phototherapy - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
75465482|NCT01889784|Device|Phototherapy through light emitting diode (LED) - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
75619688|NCT03677986|Behavioral|Video DOT+|Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
75619689|NCT04847856|Behavioral|Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.|The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
75619690|NCT04306614|Procedure|Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration|Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
75619691|NCT04231006|Radiation|High dose rate brachytherapy|High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
75619692|NCT01094886|Drug|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
75619693|NCT04231240|Device|Measure of ACT with IStat|Measure of ACT with a point of care device named IStat
75619694|NCT02784028|Other|SGM-101|Administration of SGM-101 prior surgery
75619695|NCT02782234|Behavioral|Contract management|
75619696|NCT01094808|Drug|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
75619697|NCT01094808|Drug|Placebo|Placebo capsules
75619698|NCT01094808|Other|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
75619699|NCT00864253|Drug|ABI-007|Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
75619700|NCT00864253|Drug|Dacarbazine|Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
75773122|NCT03821064|Other|Patient Navigation|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
75619701|NCT02782312|Drug|ICS+LABA|Seretide is inhaled for one year
75619702|NCT02782312|Other|routine therapy|routine therapy for one year
75619703|NCT01094730|Device|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
75619704|NCT01094730|Device|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
75619705|NCT04229758|Drug|Anticoagulants|DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
75619706|NCT04307706|Behavioral|Acceptance and Commitment Therapy|The Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in six sessions. The duration of each session lasted on average 60-90 minutes. A session was held for each parent once a week.
75619707|NCT04230538|Device|DJO Walker|
75619708|NCT04230538|Device|Traditional plaster cast|
75619709|NCT02783794|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
75911953|NCT03047278|Drug|Gabapentin 300 mg|All patients were treated with oral single dose of gabapentin 300 mg.
75911954|NCT03047278|Drug|Cetirizine Hydrochloride 10 mg|Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
75911955|NCT03047044|Other|Optimizing basal infusion (B.I)|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: ~ 8 hr: 2 - 4 ml, 8-24 hr: 1 - 3 ml, 24 hours ~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 0.5 ml).
75619710|NCT02783794|Drug|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
75911956|NCT03047044|Other|Conventional PCA mode|Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
75911957|NCT03045016|Drug|Prazosin, ALPRESS® LP 2,5 et 5 mg|"Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days."
75911958|NCT04849858|Drug|Bupivacaine|Participants in this group will receive a TAP block using the drug Bupivacaine.
75911959|NCT04849858|Drug|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine.
75619711|NCT00698425|Other|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
75911960|NCT04849858|Drug|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine followed by a re-dosing during their hospitalization
75911961|NCT04429360|Procedure|pelvic reconstructive surgery|Pelvic reconstructive surgery
75619712|NCT00698425|Drug|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
75619713|NCT02614417|Other|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
75619714|NCT05342506|Drug|Toripalimab + ScTIL|Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10^9 intravenous reinfusion.
75619715|NCT05242198|Procedure|Robotic prostatectomy|patients who will undergo robotic prostatectomy
75619716|NCT04230616|Procedure|total knee arthroplasty|total knee arthroplasty
75619717|NCT04230616|Radiation|CT scan|The first 52 participants will recieve a pre- and postoperative CT scan of the hip, knee and ankle.
75619718|NCT04230850|Other|Static Cupping|Two cups will be applied unilaterally to the lumbar paraspinals. The skin will be elevated to 1.5 cm ensuring standardized pressure. Cups will remain on the treatment area statically for 4 minutes prior to removal. Another 4 minute bout of identical treatment to the contralateral side will follow. (Participants will be equally dispersed into three treatment groups via stratified randomization).
75773123|NCT03963726|Radiation|stereotactic radiotherapy|The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
75619719|NCT04230850|Other|Dynamic Cupping|One cup will be applied ipsilaterally, raising skin to 1.2 cm of standard pressure. The cup will be continuously moved in a sweeping motion between L1 and L5 within a defined width. This process will be repeated on the other side. Each side will be treated for 4 minutes dynamically for a total treatment duration of 8 minutes. (Participants will be equally dispersed into three treatment groups via stratified randomization).
75619720|NCT04230850|Other|Stretching|The stretching program performed will involve a double knee to chest stretch, cat stretch, camel stretch, and pelvic tilts. Participants will receive a 30 second rest break between each of the four stretches. (Participants will be equally dispersed into three treatment groups via stratified randomization).
75619721|NCT00638092|Drug|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
75619722|NCT00638092|Drug|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
75619723|NCT04230772|Procedure|Natural Orifice Specimen Extraction Surgery|In the experimental group, patients will be performed robotic colorectal resection with natural orifice specimen extraction.
75619724|NCT04230772|Procedure|Traditional Robotic-assisted Surgery|In the active comparator group, patients will be performed traditional robotic-assisted colorectal resection.
75773124|NCT03963726|Other|microwave alabation|The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
75773125|NCT03966456|Drug|Chemotherapy|compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
75773126|NCT01076712|Other|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
75911962|NCT04861402|Device|The ICP monitoring will be performed in a non-invasive method developed by Brain4Care|"The ICP monitoring will be performed in a non-invasive way through the cranial deformation method developed by Brain4Care Inc.~The selected patients will be monitored until 1h/day for 7 sequential days or even discharge. The clinical outcomes such as ventilatory status will be noted (if the subject is under oxygen supplementation, using non-invasive mechanical ventilation or intubated), the ventilatory parameters during the monitorization will be analyzed in the intubated group (or those from a non-intubated group who was intubated during the seven days of hospitalization) including IFO2, CV, PEEP, driving pressure, and pressure plate as well as ventilatory asynchronies. Some changes in ventilatory parameters during monitorization will be noted. These procedures will be applied to all groups, excepted to the healthy group. This last group will be monitored only once for 30 minutes at the Federal University of São Carlos (UFSCar)."
75773127|NCT01076712|Other|Education Classes|Education Classes
75619725|NCT05342272|Drug|Betaine taurine PVP gel|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
75619726|NCT05342272|Drug|Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
75619727|NCT04230460|Drug|Cannabis (THC) (Inhaled) Placebo|Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
75619728|NCT04230460|Drug|Cannabis (High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
75619729|NCT04230460|Drug|Cannabis (Very High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
75619730|NCT04230460|Drug|Alcohol (oral)|Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
75619731|NCT02783638|Drug|YHD1119|2 by 2
75619732|NCT02783638|Drug|Lyrica|2 by 2
75911963|NCT03043690|Dietary Supplement|Ammonium succinate|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
75911964|NCT03043690|Other|Placebo|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
75911965|NCT03044782|Other|53-Item Survey|
75619733|NCT04229524|Procedure|Fluorescence angiography|After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least> 30.
75619734|NCT02783326|Other|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
75619735|NCT02782000|Other|lessons,long-term supervision and message|
75619736|NCT02782000|Other|lessons,short-term supervision and message|
75619737|NCT04230070|Drug|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Bioequivalence
75619738|NCT04230070|Drug|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Bioequivalence
75619739|NCT02782078|Biological|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
75619740|NCT01293682|Drug|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
75619741|NCT02782156|Other|Process evaluation|Adherence to screening and action algorithm
75619742|NCT05342116|Other|Nestle Preload|1 sachet of Preload (50g) diluted with 400ml of water, to be consumed 2 to 4 hours prior to the endoscopy.
75773128|NCT01076790|Drug|Dexmedetomidine|Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
75911966|NCT04858984|Device|Virtual Reality|A portable, standalone VR headset called Oculus Go (Facebook Technologies, LLC. 1601 Willow Road, Menlo Park, CA 940250) with a head-mounted display with built in audio drivers was used. Disposable hygiene masks and a surgical cap were used as an underlay below the headset an
75319496|NCT05622175|Drug|F8IL10|"The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular.~Patients with arthritis flare(s) in large joints (shoulders, elbows, knees and ankles, with the exception of hip) and small joints (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per 2010 Rheumatoid Arthritis Classification Criteria [1] will be treated with increasing dose of F8IL10 according to the schedule detailed below:~Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10"
75619743|NCT05342116|Other|Water|400ml of water to be consumed 2 to 4 hours prior to the endoscopy.
75773129|NCT01076790|Drug|Saline|Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
75773130|NCT01582932|Drug|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
75773131|NCT03965520|Behavioral|exercise rehabilitation by near-infrared spectrometer|We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
75773132|NCT03965286|Drug|DAAs|Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) 12 weeks Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) 12weeks
75619744|NCT02782936|Other|measurement of the work of breathing|"We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).~Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses."
75773133|NCT02531334|Dietary Supplement|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
75773134|NCT02531178|Biological|ABBV-257|subcutaneous injection
75773135|NCT02531178|Biological|Placebo|Placebo for ABBV-257
75773136|NCT01079208|Other|test starter infant formula|infants are fed for 6 months with this starter formula
75773137|NCT01079208|Other|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
75773138|NCT01079208|Other|control standard formula|infant are fed 6 months with this formula
75773139|NCT01079286|Drug|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
75773140|NCT01081704|Drug|ustekinumab|Single dose of 45 mg subcutaneous injection
75773141|NCT01081704|Drug|ustekinumab|Single dose of 90 mg subcutaneous injection
75773142|NCT00141518|Drug|Levodopa-carbidopa intestinal gel (LCIG)|
75773143|NCT00141518|Device|CADD-Legacy® 1400 ambulatory infusion pump|
75773144|NCT00141518|Device|percutaneous endoscopic gastrostomy tube (PEG tube)|
75773145|NCT00141518|Device|jejunal extension tube (J-tube)|
75773146|NCT03973736|Other|application of a diagnostic and therapeutic protocol (multidisciplinary discussion and radiological CT review)|Since the introduction of the new protocol in 2012, a single central multidisciplinary team has been formalized, with weekly discussion of cases, including different specialists from all the provincial hospitals. CT scans of discussed cases are reviewed by one of two experienced radiologists based on pre-defined criteria.
75773147|NCT02531360|Drug|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an [18F]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo [18F]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
75773148|NCT00253448|Radiation|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
75773149|NCT00253448|Radiation|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
75773150|NCT01075880|Drug|Rebif (Interferon beta-1a)|The treatment to be administered is interferon beta-1a on prescription, used as per SmPC, i.e. both doses 22 and 44 mcg s.c. tiw, and the titration pack 8.8 mcg and 22 mcg s.c. tiw when initiating the therapy.
75319497|NCT01798069|Behavioral|reflective writing|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
75319498|NCT01798069|Behavioral|reading medical publication workshops|
75319499|NCT04149158|Dietary Supplement|Placebo|
75619745|NCT02782936|Device|Gas mask|During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
75319500|NCT04149158|Dietary Supplement|Sinetrol® Xpur|
75319501|NCT04149080|Procedure|SIM + polypropylene membrane|After tooth extraction the socket will be filled with 1.2% simvastatin gel and covered with polypropylene membrane, which will be intentionally exposed.
75619746|NCT02782858|Drug|GNbAC1|Monthly IV repeated dose
75619747|NCT02782858|Drug|Placebo|Monthly IV repeated dose
75619748|NCT00864097|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 16)
75773151|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
75773152|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
75773153|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
75773154|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
75911967|NCT04429204|Procedure|Biospecimen Collection|Undergo collection of tissue
75911968|NCT04429204|Procedure|Cryosurgery|Undergo cryoablation
75319502|NCT04149080|Procedure|Placebo|After tooth extraction the socket will be filled with gel and covered with polypropylene membrane, which will be intentionally exposed.
75773155|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
75773156|NCT00130520|Drug|bevacizumab|10mg/kg every two weeks IV-bevacizumab
75773157|NCT00130520|Drug|erlotinib|150mg daily by mouth-erlotinib
75773158|NCT00132132|Behavioral|Behavioral education program|Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
75773159|NCT00130442|Drug|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
75773160|NCT00130442|Drug|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
75773161|NCT00130208|Drug|Sulodexide|100 mg sulodexide gelcaps
75773162|NCT00130208|Drug|Placebo|0 mg gelcap
75773163|NCT00253370|Drug|BAY 43-9006|Given orally
75773164|NCT00253370|Drug|docetaxel|Given IV
75773165|NCT00253370|Drug|cisplatin|Given IV
75911969|NCT03679884|Drug|Daridorexant 10 mg|Daridorexant 10 mg film-coated tablets
75773166|NCT01071980|Other|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
75619749|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
75619750|NCT00864097|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 16)
75619751|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
75619752|NCT00864097|Biological|tanezumab|IV tanezumab 2.5 mg every 8 weeks (through Week 16)
75619753|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
75773167|NCT03966482|Behavioral|Group before-after|The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
75773168|NCT03966170|Drug|Citicoline|Citicoline as neuroprotector
75911970|NCT03679884|Drug|Daridorexant 25 mg|Daridorexant 25 mg film-coated tablets
75911971|NCT03679884|Drug|Daridorexant 50 mg|Daridorexant 50 mg film-coated tablets
75465483|NCT01889784|Device|Placebo phototherapy - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
75465484|NCT01889823|Other|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
75465485|NCT01889823|Other|Hyperoxia|Subjects will be breathing 100% oxygen
75465486|NCT01889836|Biological|'MenCC-Bio'|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
75465487|NCT01889836|Biological|MENJUGATE|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.
75619754|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
75619755|NCT00864097|Other|IV placebo|IV placebo to match tanezumab every 8 weeks (through Week 16)
75619756|NCT04230226|Dietary Supplement|Pre-workout plus and protein recovery plus|Study products consumed prior and after exercise
75619757|NCT04230226|Other|Placebo|Placebo product consumed prior and after exercise
75619758|NCT02782624|Drug|Empagliflozin|5 days of treatment with 5 mg BI 10773 bid until steady state
75619759|NCT02782624|Drug|Empagliflozin|5 days of treatment with 10 mg BI 10773 qd until steady state
75773169|NCT03966170|Drug|Placebo oral tablet|placebo drug
75773170|NCT01076426|Drug|Pro-biotics|Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
75773171|NCT01076426|Dietary Supplement|Oligosaccharide|oligosaccharide one pack per day
75773172|NCT00140426|Drug|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
75773173|NCT00140426|Drug|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
75773174|NCT03966560|Drug|Brimonidine Tartrate|Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months
75911972|NCT03679884|Drug|Placebo|Matching placebo film-coated tablets
75619760|NCT02781766|Other|Thrombin generation measurement.|
75619761|NCT02781688|Behavioral|Physical Activity|"Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.~Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.~Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.)."
75619762|NCT00887536|Drug|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
75619763|NCT00887536|Drug|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
75619764|NCT00887536|Drug|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
75619765|NCT00887536|Drug|cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles"
75619766|NCT00887536|Drug|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles [filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.]
75619767|NCT02614339|Drug|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
75619768|NCT02614339|Drug|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
75911973|NCT04861480|Biological|C-4-29 Cells|Drug: C-4-29 Cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
75911974|NCT04849702|Procedure|No intervention was compared|No intervention was compared
75911975|NCT02230020|Device|Nasal High Flow|
75911976|NCT03043612|Device|Cook Sof-Flex® Double Pigtail Ureteral Stent coextruded with doxazosin|Placement of drug-coated ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
75619769|NCT00697333|Procedure|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
75619770|NCT04132687|Procedure|autologous blood patch therapy|use autologous blood as blood patch therapy in persistent air leak
75619771|NCT02618395|Drug|SPARC001A|
75911977|NCT03043612|Device|Cook Sof-Flex® Double Pigtail Ureteral Stent|Placement of a commercially available ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
75911978|NCT04861168|Procedure|driving pressure guided ventilation|driving pressure guided ventilation
75911979|NCT04861168|Procedure|Conventional protective lung strategy|Conventional protective lung strategy
75911980|NCT02233062|Dietary Supplement|Exclusive Enteral Nutrition Therapy|
75911981|NCT04861012|Device|Ultrasound|All subjects initially will be subjected to abdominal ultrasound, and if fatty liver is detected fibroscan will be done
75465488|NCT01889849|Drug|BIP 48|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
75619772|NCT02618395|Drug|SPARC001B|
75319503|NCT04148768|Device|Inferential therapy|Interferential therapy(IFT) utilises two of these medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross & they literally interfere with each other - hence another term that has been used in the past but appears to be out of favour at the moment - Interference Current Therapy. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation.
75773175|NCT03966560|Drug|Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops|Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months
75773176|NCT03966560|Drug|Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension|Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months
75911982|NCT02230098|Other|Remote Ischemic Conditioning|
75773177|NCT03966560|Drug|Travoprost and Timolol|Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months
75911983|NCT02230176|Drug|Sunitinib|
75911984|NCT02230176|Drug|177Lu-DOTA0-Tyr3-Octreotate|
75911985|NCT03042208|Other|Self guided handout|Written handout with basic weight management strategies
75319504|NCT04148768|Device|short wave diathermy|SWD: Technical specification of Generator frequency: 27.12 MHz, ± 0.6% Output power: continuous High-Frequency max. 400 W, pulsed High-Frequency max. 1000 W (peak) Pulse duration: ca. 400 µs Pulse repetition frequency: 15-200 Hz adjustable in 10 steps Mains supply: 230-240 V / 50 Hz Mains voltage variation: approx. ± 10% Current consumption: approx. 6 Ampere (at 230 V)
75465489|NCT01889849|Drug|Pegasys|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
75465490|NCT01889875|Drug|"ALK Grazax 75,000 SQ-T Phleum pratense"|
75465491|NCT01889875|Drug|"ALK AluTard 225 Phleum pratense"|
75465492|NCT01889888|Other|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
75465493|NCT01889914|Drug|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
75465494|NCT01889927|Other|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
75619773|NCT02618395|Drug|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
75619774|NCT01183013|Drug|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
75619775|NCT01183013|Drug|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
75619776|NCT01183013|Drug|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
75619777|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
75619778|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
75619779|NCT01183013|Drug|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
75773178|NCT03966560|Drug|Bimatoprost and Timolol|Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months
75773179|NCT03966560|Drug|Latanoprost|Latanoprost 0.005% 1 eye drop, every day for 6 months
75773180|NCT01072058|Drug|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
75773181|NCT01072214|Drug|pazopanib|gw786034
75773182|NCT01072214|Drug|pazopanib|gw786034
75773183|NCT01072214|Drug|pazopanib|gw786034
75773184|NCT01072214|Drug|Placebo|placebo
75911986|NCT03042208|Behavioral|Weight Watchers|Access to Weight Watchers in-person meetings and online tools
75911987|NCT02232516|Drug|romidepsin|Given IV
75911988|NCT02232516|Drug|lenalidomide|Given PO
75911989|NCT02232516|Other|laboratory biomarker analysis|Correlative studies
75911990|NCT03042130|Other|Standard of care|standard of care
75911991|NCT03042130|Drug|Iron Carboxymaltose|Two IV doses
75911992|NCT04849468|Drug|Declofenac|evaluating the preemptive effect of intramuscular declofenac on postoperative analgesia in patients undergoing perianal surgeries under saddle block
75911993|NCT04849468|Drug|saline|evaluating the preemptive effect of intramuscular saline on postoperative analgesia in patients undergoing perianal surgeries under saddle block as control
75911994|NCT02232594|Drug|Berodual®|
75773185|NCT00121134|Drug|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
75911995|NCT04848922|Other|Hot shower intervention|Intervention group took a shower in a standing position at a water temperature of 37-41°C for 10-20 minutes between 6 and 12 hours after vaginally birth.
75319505|NCT04023500|Behavioral|Motivational interview vs. prevailing education|"In intervention group dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients.~In control croup dental hygienist defined patients educational needs and gave direct instructions how to change behaviour and self-care."
75465495|NCT01889940|Behavioral|Training for professionals (Spinal Cord Injury Unit staff).|"Prior to the training, separate focus groups for professionals, patients & families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period."
75465496|NCT01889953|Other|EUS-guided biliary drainage|"Based on the patient's condition, the will receive:~Rendezvous technique~Direct transluminal access transesophageal technique~Direct transluminal access transduodenal technique~or direct transluminal access using transgastric approach"
75465497|NCT01889966|Drug|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
75465498|NCT01889979|Drug|Tramadol|100 mg of Tramadol was applied in the forearm SC (single dose).
75619780|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
75773186|NCT00121134|Drug|Cyclophosphamide|Once a day for 6 months
75773187|NCT00121134|Drug|Methotrexate|Twice daily for the first two days of every week for 6 months
75465499|NCT01889979|Drug|Placebo|2 ml of a sterile solution was applied in the forearm SC (single dose).
75465500|NCT01890018|Behavioral|Electronic Pill Bottle tracking|All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications
75619781|NCT04129801|Other|Isokinetic Dynamometer|Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
75619782|NCT04129801|Other|Bioimpedance|Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
75619783|NCT02618629|Drug|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
75619784|NCT04132609|Behavioral|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
75619785|NCT04132609|Behavioral|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
75319506|NCT02123485|Device|Low frequency (1 hz) rTMS, as add-on to ECT|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
75773188|NCT00121134|Drug|Capecitabine|"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"
75319507|NCT02123485|Device|Sham-rTMS|Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
75465501|NCT01890018|Behavioral|Adherence Messaging|Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.
75465502|NCT01890018|Behavioral|Social Influence|Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
75773189|NCT03966690|Device|Isokinetic leg extension/-flexion on a legpress device|Maximum strength and rate of leg-flexion /-extension during legpress exercise
75773190|NCT03966690|Device|Isokinetic leg extension/-flexion on a legcurl device|Maximum strength and rate of leg-flexion /-extension during legcurl exercise
75773191|NCT03966378|Other|Grape seeds extract|Grape seeds extract powder
75773192|NCT03966378|Other|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste
75465503|NCT01890278|Radiation|Whole Brain IMRT|
75465504|NCT01890278|Radiation|Conventional Whole Brain RT|
75911996|NCT04858906|Device|McGrath laryngoscope|The patients in this group will be evaluated and intubated with McGrath laryngoscope (angulated videolaryngoscope).
75911997|NCT04858906|Device|C-MAC D-blade laryngoscope|The patients in this group will be evaluated and intubated with C-MAC D-blade laryngoscope (hyperangulated videolaryngoscope).
75911998|NCT04858438|Procedure|Insufflation during surgery|This is the amount of insufflation using during the surgical procedure.
75911999|NCT03175068|Behavioral|CBT|CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
75319508|NCT04023344|Drug|Humalog Mix25|Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
75319509|NCT04023344|Drug|Insulin Lispro Biphasic 25|"Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses"
75619786|NCT04132531|Procedure|Bariatric (weight loss) surgery|Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
75912000|NCT03175068|Behavioral|ST|Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
75912001|NCT04858516|Drug|palbociclib and exemestane plus trastuzumab and pyrotinib|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer
75912002|NCT03148860|Drug|Methotrexate|subjects will receive once weekly 15 mg (3 capsules) MTX
75912003|NCT03148860|Drug|Ustekinumab|subject will receive Ustekinumab open-label over a treatment period of 52 weeks
75319510|NCT03932552|Other|Exercise|aerobic exercise program during 2 + 12 weeks, highly monitored and tailored to individual physical capacity.
75319511|NCT03932552|Other|nutritional therapy|individualised nutritional intervention
75319512|NCT00452387|Drug|Mitoxantrone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Mitoxantrone 9mg/m2~Dose Level -1 Mitoxantrone 12mg/m2~Dose Level 1 Mitoxantrone 12mg/m2"
75619787|NCT02615197|Behavioral|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
75619788|NCT02615197|Behavioral|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
75912004|NCT03148860|Other|Placebo|subjects will receive once weekly 3 capsules PLC to MTX
75912005|NCT03043300|Other|Screening Criteria Review|"The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States."
75319513|NCT00452387|Drug|Prednisone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Prednisone 5mg bid~Dose Level -1 Prednisone 5mg bid~Dose Level 1 Prednisone 5mg bid"
75319514|NCT00452387|Drug|Sorafenib|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Sorafenib 400 mg QD~Dose Level -1 Sorafenib 400 mg QD~Dose Level 1 Sorafenib 400 mg bid"
75319515|NCT03931616|Procedure|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
75319516|NCT03931616|Procedure|Regular care|A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
75319517|NCT02761837|Behavioral|IVR call/text|For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
75319518|NCT02761837|Behavioral|Email|Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
75319519|NCT00452543|Drug|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
75619789|NCT04229212|Device|hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)|In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
75773193|NCT03758248|Genetic|CYP2C19|The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19*17 carriers) or higher (CYP2C19*2 carriers) risk of major adverse cardiovascular events.
75773194|NCT00119262|Drug|doxorubicin hydrochloride|Given IV
75773195|NCT00119262|Drug|cyclophosphamide|Given IV
75773196|NCT00119262|Biological|bevacizumab|Given IV
75773197|NCT00119262|Drug|paclitaxel|Given IV
75912006|NCT03043300|Other|Pre-Travel Questionnaire|"The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States."
75912007|NCT03043300|Other|Pre-Travel Stool Specimen Collection|"The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
75773198|NCT00119262|Biological|filgrastim|Given SC
75773199|NCT00119262|Biological|pegfilgrastim|Given SC
75773200|NCT00119262|Radiation|radiation therapy|Undergo radiation therapy
75773201|NCT00119262|Drug|tamoxifen citrate|Given orally
75773202|NCT00119262|Drug|aromatase inhibition therapy|Receive aromatase inhibition therapy
75465505|NCT01890317|Procedure|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
75619790|NCT02618473|Other|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
75319520|NCT00452543|Drug|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
75773203|NCT01077102|Other|Eccentric exercise training|The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
75773204|NCT03703882|Drug|Edasalonexent|100 mg/kg/day
75319521|NCT00452543|Behavioral|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
75773205|NCT03703882|Drug|Placebo|Placebo
75773206|NCT00131664|Drug|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
75773207|NCT00131664|Drug|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
75319522|NCT00452543|Drug|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
75773208|NCT00131664|Drug|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
75912008|NCT03043300|Other|Short-Term Post-Travel Questionnaire|"The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel."
75912009|NCT03043300|Other|Short-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
75912010|NCT03043300|Other|Long-Term Post-Travel Questionnaire|"The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel."
75619791|NCT00634660|Drug|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
75319523|NCT04148690|Other|Group antenatal care (GANC)|Group antenatal care (GANC) is a service delivery model where women with pregnancies of similar gestational age are brought together for antenatal care (ANC), incorporating information sharing and peer support.
75319524|NCT04148690|Other|Standard antenatal care|Routine antenatal care as recommended by th Ministry of Health of Tanzania
75619792|NCT02886767|Other|skin to skin contact|The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
75912011|NCT03043300|Other|Long-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
75319525|NCT05621785|Device|Lung Ultrasonografi|All babies under 32 weeks of gestation will be included in the study. All data of postnatal corticosteroid users will be recorded using lung USG
75319526|NCT04990375|Device|tDCS|5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)
75465506|NCT01890330|Other|Canola Oil 25 g/d|Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
75465507|NCT01890330|Other|Non-Canola Oil Mixture 25 g/d|Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
75465508|NCT01890538|Drug|Administration of 100 mg dimenhydrinate intravenous|
75465509|NCT01890538|Drug|2 g piracetam intravenous|
75465510|NCT01890681|Behavioral|Baby NAP SACC|
75465511|NCT01890681|Behavioral|Back to Sleep|
75465512|NCT01891123|Device|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
75465513|NCT01891123|Drug|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
75773209|NCT03765268|Procedure|Neurectomy in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve
75773210|NCT03765268|Procedure|nerve sparing in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve
75773211|NCT03765190|Combination Product|Radiation: Proton Therapy+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
75465514|NCT01891279|Other|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
75465515|NCT01891279|Other|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
75465516|NCT01891292|Drug|Enalapril|0.25-0.35 mg/kg/day
75773212|NCT03765112|Device|Optical coherence tomography angiography|Multiple scans of the retina will be recorded to evaluate microvascular changes.
75912012|NCT02230488|Other|Intensive Diabetes Case Management|"A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE~--------------------------------------------------------------------------------"
75912013|NCT04860622|Diagnostic Test|Serum thyroid function tests|At the first hospital visit, the blood tests will be made for TSH, FT4, FT3, and beta HCG concentration measurement
75912014|NCT03131154|Drug|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
75619793|NCT00922753|Other|VS|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
75619794|NCT00922753|Other|AI-4/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
75619795|NCT00922753|Other|AI-6/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
75773213|NCT00131508|Drug|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
75912015|NCT03131154|Drug|Vehicle of ADX-102 Ophthalmic Solution|Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
75912016|NCT03120702|Device|Investigational Rainbow SpHb sensor|Investigational Rainbow SpHb sensor
75912017|NCT03040648|Device|DSA|DSA was used for detection of intravascular injection
75912018|NCT03040648|Device|RTF|RTF was used for detection of intravascular injection
75912019|NCT02232672|Device|Choline PET/CT and MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
75912020|NCT04858282|Other|mobile application (BC-SDM)|"The mobile application (BC-SDM)includes four functions to support SDM activity: Understanding breast cancer, Surgical approach, Choose the right breast cancer knowledge, and Let's make a decision for myself. Patients first read the information in Understanding breast cancer and Surgical approach to receive a tailored education in breast cancer"
75912021|NCT04857892|Drug|GSK3640254|GSK3640254 will be administered via oral route.
75912022|NCT04857892|Drug|DTG|DTG will be administered via oral route.
75912023|NCT04857892|Drug|GSK3640254/DTG|GSK3640254/DTG will be administered via oral route.
75912024|NCT05072262|Drug|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml
75912025|NCT05072262|Drug|Dexamethasone Ophthalmic|Topical dexamethasone 1 mg/ml (Spersadex)
75912026|NCT04857970|Other|Electronic HRQoL questionnaires with feedback to physicians|Use of the CHES software for HRQoL collection and graphical display of the patients' HRQoL scores to physicians
75912027|NCT04857970|Other|Paper-pencil HRQoL questionnaires w.o. feedback to physicians|Use of paper-pencil HRQoL questionnaires, the results of which are not presented to physicians
75912028|NCT02230644|Other|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
75912029|NCT02230644|Other|Other distraction|Such as newspaper, magazine or the news on television
75912030|NCT04858048|Procedure|Anesthesia|2 types of anesthesia (general and WALANT) performed during the surgery
75912031|NCT02233140|Device|Extra-corporeal pulsed-activated therapy or shockwave therapy|
75912032|NCT05629650|Behavioral|Tai Chi for memory|The adapted form of TCM will be provided at 60 minutes per session, twice a week for 12 weeks by a certified Tai Chi instructor who had experience in teaching older adults with cognitive impairments.
75912033|NCT04857268|Device|wearable continuous ECG monitoring patch, ATP-C120|"ATP-C120 is a novel, single-lead ECG monitoring device which can continuously monitor the ECG signal as long as 14 days (11 days if the device is connected to the smartphone via Bluetooth) when attached to skin adjacent to the heart of patients. It weighs about 8.3 g, with a size of 84 × 39 × 8.3 mm.~When the device is attached to the patient, several predefined methods were utilized to prevent the occurrence of noise or signal loss. First, the skin was cleansed and disinfected using a 70% ethanol solution. Skin hair was removed if needed. Then the protection film was removed from the patient-side surface of the device. The device is placed at the left 3rd intercostal space 45 degrees tilted toward the inside."
75912034|NCT02230722|Behavioral|Motivational Interviewing|
75912035|NCT02230722|Behavioral|Attention Control|
75912036|NCT03043456|Device|Thermoplastic complete denture|A device used to substitute the teeth for edentulous patients made of thermoplastic resin
75619796|NCT05141500|Device|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|"Reprocessed noninvasive pulse oximeters~1859 & 2329~MAX-A & MAX-N"
75619797|NCT04312373|Other|Ankle Foot Orthosis|"According to the SCED methodology, patients were fitted with ankle foot orthosis intermittently, during 4 phases, in the following order : without orthosis (A1), with orthosis (B1), again without orthosis (A2) and again with orthosis (B2).~All the phases were carried out over one day."
75619798|NCT02618239|Dietary Supplement|Bimuno Galacto-oligo-saccharide|
75619799|NCT05341102|Drug|LY3556050|Administered orally.
75619800|NCT05341102|Drug|Placebo|Administered orally.
75619801|NCT02615041|Drug|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
75773214|NCT00131508|Drug|Placebo|Placebo
75773215|NCT03765034|Behavioral|Constrain-induced Movement Therapy|8-week therapy program utilizing constraint of the unaffected arm
75773216|NCT03765034|Behavioral|Usual Occupational Therapy|8-week therapy program without constraint of the unaffected arm
75773217|NCT01321684|Other|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
75773218|NCT01321684|Other|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
75773219|NCT05088772|Device|Hyperbaric Oxygen Therapy|"Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 air breaks, typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference."
75773220|NCT05050318|Biological|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
75773221|NCT05050318|Biological|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
75465517|NCT01891292|Drug|N-Acetylcysteine|N-Acetylcysteine 0.5 mmol/kg
75773222|NCT03764956|Other|Low glycemic Index Therapy (LGIT)|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.
75319527|NCT04023032|Behavioral|multicomponent cognitive intervention|"The intervention takes place in groups of 6-10 participants and is leaded by one occupational therapist. It includes 16 sessions, 90 minutes each.~The first part of each session starts with a 15-minute review of previous homework or relaxation. The second part, which lasts 35 minutes, involves structured training with activity-sheets, board games, role-playing and computerized games. The third part, which lasts 30 minutes, is the lifestyle interventions. The instructor explains the generalization of the previous activities toward daily life, and introduces healthy lifestyles. Through group discussions, the therapist guides participants to develop solutions and strategies for their memory or cognition-related problems and application to daily life. The last 10 minutes are used to suggest homework."
75619802|NCT02615041|Drug|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
75465518|NCT01891448|Other|WebCONSORT tool|Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
75773223|NCT03764956|Other|Modified Atkins Diet (MAD)|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.
75773224|NCT03778996|Drug|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)|Daily oral combination therapy for cancer
75773225|NCT03764722|Drug|Levosimendan|"The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP <90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months."
75773226|NCT03756610|Device|Active tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
75773227|NCT03756610|Device|Sham tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
75773228|NCT03756610|Device|Active boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.
75912037|NCT03043456|Device|Conventional acrylic resin complete denture|A device used to substitute the teeth for edentulous patients made of acrylic resin
75912038|NCT05628402|Other|Semi-structured interview|The semi-structured interview will take place during a standard follow-up appointment with the therapist already treating the patient after the patient has agreed to participate in the study.
75465519|NCT01891448|Other|Modified WebCONSORT tool|Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
75465520|NCT01891487|Drug|Track A|Bimatoprost 0.03% solution applied to eyebrow
75465521|NCT01891487|Drug|Track B|Refresh Tears applied to eyebrows
75619803|NCT02615041|Drug|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
75619804|NCT04229602|Drug|Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
75619805|NCT04229602|Drug|EFEXOR® XR|EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
75619806|NCT05298163|Drug|Calcitriol capsules|Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
75619807|NCT05298163|Drug|Placebo|One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
75773229|NCT03756610|Device|Sham boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
75773230|NCT05024734|Drug|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
75319528|NCT04961359|Biological|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
75319529|NCT04961359|Biological|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
75619808|NCT05133232|Device|SynPhNe physio-neuro platform|"The SynPhNe device training protocol lasting approximately 60 mins:~Preparation for setup (~5 mins)~Instruction video led warm up with active single and multi-joint movements - (~20 mins): • Wrist extension and flexion• Fingers extension and flexion• Arm pronation and supination• Open grasp and close grasp • Open pinch and close pinch• Pronate and close grasp/ supinate and open grasp~Rest break - (~5 mins)~Video led task practice as per the tasks below (any 4 tasks only) - (~30 mins) • Grasp, lift and transfer water bottle using cylindrical grasp• Grasp lift and transfer pen using pinch grip• Flip pages of a book using lateral pinch grip• Use chopsticks to lift, transfer and place a small object• grasp doorknob and turn clockwise/anticlockwise, spoon scoop to pick up macaroni, open/ close a cylindrical jar, put object in pouch while holding it open and close it, fold/crease/tear a A4 size paper or fold handkerchief, reach a basket at different heights with an object."
75619809|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
75619810|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
75619811|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
75619812|NCT05340946|Procedure|general anaesthesia|intraoperative general anaesthesia followed by postoperative IV patient analgesia
75619813|NCT05340946|Procedure|spinal anaesthesia|patient received spinal followed by continuous ultrasound guided femoral never block.
75773231|NCT05024734|Drug|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
75773232|NCT05024734|Drug|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
75773233|NCT05024734|Drug|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
75773234|NCT03699124|Biological|FD MVA-BN|Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)
75773235|NCT05461066|Behavioral|CESAR training|Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.
75319530|NCT04022642|Other|High-Intensity Interval Training|"The program will be applied in the first 10-15 minutes of each PE class, twice a week, including a brief warm-up, ranged from 14 to 20 intervals, adopting a 2:1 work to rest ratio (ie, 30-s work, followed by 30-s rest)~A cut-point of >=90% of maximal heart rate was used as our criterion for satisfactory compliance to high-intensity exercise~In order to estimate effort, fatigue and training load, a subjective effort scale will be used throughout each session. The heart rate will be monitored throughout the session in real time through Bluetooth technology.~Actigraph accelerometers (wGT3X-BT), randomly distributed by the students in each session, will be used to characterize the intensity of the sessions."
75319531|NCT05621707|Drug|chemotherapy combined with PD-1 inhibitors|Induction chemotherapy combined with PD-1 inhibitors followed with standard concurrent chemoradiotherapy
75319532|NCT04022720|Procedure|Platelet Rich Fibrin Application|Platelet Rich Fibrin application at first post-op visit.
75319533|NCT04906057|Behavioral|Forced Aerobic Exercise (FE)|High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer
75319534|NCT04906057|Behavioral|Voluntary Aerobic Exercise (VE)|Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer
75319535|NCT03832088|Diagnostic Test|Berg Balance Scale|Berg Balance Scale performed for balance disorder
75619814|NCT00863707|Drug|Regadenoson|IV
75619815|NCT00863707|Drug|Placebo|IV
75319536|NCT03832088|Diagnostic Test|Timed Up and Go Test|Timed Up and Go Test for walking speed
75619816|NCT05340634|Dietary Supplement|Metionac|Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
75619817|NCT05340634|Drug|Oral contraceptive|Drospirenone 4 mg once a day
75619818|NCT02886689|Drug|TNF-alpha antagonist and other biotherapy|
75619819|NCT04181086|Procedure|surgical excision of intracranial cavernoma|microvascular excision of intracranial cavernoma
75619820|NCT05367479|Drug|Antibiotic|Peri-operative, intravenous antibiotic for surgical site infection
75619821|NCT02614105|Procedure|Pelvic floor muscle training|16 weeks of group-based exercise
75619822|NCT02614105|Procedure|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
75773236|NCT03764644|Behavioral|Combined ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Each session, participants see 160 trials of which 128 trials include one neutral and one threatening stimulus. The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
75319537|NCT03832088|Diagnostic Test|Jamar hand dynamometer|Jamar hand dynamometer for grip strength which correlates with muscle strength of patient
75773237|NCT03764644|Behavioral|Combined Sham ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Of the 160 trials, the probe appears with equal frequency on the location of the neutral and threatening stimulus (128 trials). The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
75773238|NCT03764566|Behavioral|Questionnaires|The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
75773239|NCT05002972|Behavioral|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
75773240|NCT05460910|Other|core stability exercises with treadmill|swiss ball use patient is lying in supine position with 15 repitations and 3 sets.
75773241|NCT05460910|Other|core stability exercise without treadmill|technique used to improve stability
75773242|NCT03756220|Drug|Combination therapy of vitamin C and thiamine|Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
75319538|NCT03832088|Diagnostic Test|Calf circumference|Calf circumference for muscle mass evaluation. Calf circumference is an anthropometric measurement which correlates with muscle mass.
75773243|NCT03756220|Drug|Normal saline solution|Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
75319539|NCT04765904|Procedure|SDF|1)Dry with cotton to affected tooth surfaces 2) Apply the SDF material 3)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
75619823|NCT02614105|Other|Control|Brief information only
75773244|NCT04651114|Behavioral|Decision-making tool|"Women will be directed to a secure website to download a copy of the decision making tool and worksheets (they can download as many copies as they wish to). The women will use the tool and worksheets at their own pace for the pilot study period.~The decision making tool is a 23-page tool and set of 9 downloadable worksheets. The tool covers topics relevant to women with disabilities in considering or planning a pregnancy: 1) Overview of Pregnancy: 2) Knowing what is important; 3) Partners, family and important relationships; 4) Physical function and independence; 5) Health and wellbeing; 6) Caring for an infant; 7) Financial resources & insurance; 8) How to find reliable information and resources; 9) Connecting with other women with physical disabilities; 10) Dealing with reactions of others, stigma and bias, pressure; and 11) Reaching a decision."
75773245|NCT03764410|Procedure|Non-surgical periodontal treatment|all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
75319540|NCT04765904|Procedure|Hall technique|Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up
75619824|NCT02780830|Drug|AZD2014|AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
75619825|NCT02780830|Drug|Ibrutinib|Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
75319541|NCT00565045|Device|Neuromuscular electrical stimulator|"Intervention Characteristics Common to Both Groups~• 6-week intervention~Home exercise, daily~Exercise (at home) 2 sessions/day~A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~Lab therapy, 2x/week~Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible)."
75465522|NCT01892033|Behavioral|Aerobic Exercise|12 weeks of brisk walking
75465523|NCT01892280|Behavioral|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
75465524|NCT01892280|Behavioral|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
75465525|NCT01892319|Drug|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
75465526|NCT01892319|Drug|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
75619826|NCT04187807|Drug|Melatonin 5 mg|Placebo
75619827|NCT02780752|Drug|hymecromone|Oral Hymecromone
75619828|NCT02781298|Dietary Supplement|New Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
75773246|NCT03764332|Device|Stabilometry|To evaluate the static balance of subjects when barefoot and when using three types of footwear with their eyes closed or open.
75319542|NCT04022798|Other|Exercise, manual therapy|"Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists."
75619829|NCT02781298|Dietary Supplement|Multicereals Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
75619830|NCT04132297|Behavioral|Asthma Academy|The Asthma Academy is a one hour virtual training that includes providing information about asthma, asthma medications, communicating with healthcare providers and navigating healthcare resources.
75773247|NCT04980040|Drug|Alogliptin Benzoate|Alogliptin benzoate tablets
75773248|NCT00131352|Device|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
75773249|NCT00131352|Other|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
75773250|NCT03756142|Diagnostic Test|Motion Analysis|Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system
75773251|NCT04633642|Procedure|Ultrasound group|Every week during a six-week treatment period
75773252|NCT04633642|Procedure|Surgical group|Every week during a six-week treatment period
75773253|NCT00136916|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
75773254|NCT00136916|Drug|Subcutaneous insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
75319543|NCT04022330|Other|Blood sampling|The blood sampling will be done just before surgery
75319544|NCT05621551|Drug|Dapagliflozin|The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
75619831|NCT04132297|Behavioral|Telehealth Visit|The telehealth Visit will be conduct by a trained Doctor of Nurse Practice (DNP) student via a scheduled meeting through zoom on the participant's smart phone or computer. The visit will last about one hour wherein participant will be asked about their asthma knowledge and will be given information about asthma.
75619832|NCT01094184|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
75619833|NCT01094184|Drug|Paclitaxel|Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
75773255|NCT04633564|Biological|Bevacizumab as MYL-1402O|Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
75773256|NCT04633564|Biological|Bevacizumab as Avastin|Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
75773257|NCT04960228|Behavioral|Altruism Video|The video provides three vignettes about a diverse set of people who may be more vulnerable to serious health consequences from COVID-19. In each of the stories, high vaccine uptake of those around these vulnerable individuals serves to protect them. This communicates that getting the COVID-19 vaccine can be done for prosocial reasons and to foster a sense of community, as it provides protection not only to oneself, but also to others.
75773258|NCT04960228|Behavioral|COVID-19 Informational Text|The topics included in the text are how COVID-19 spreads, hygiene, physical distancing, and travel restrictions. Participants will complete three comprehension questions, one after each of the following sections: hygiene, physical distancing, and travel restrictions.
75773259|NCT03756064|Drug|Pyrotinib|Pyrotinib: 400mg orally daily
75773260|NCT03756064|Drug|Trastuzumab|Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;
75773261|NCT03756064|Drug|Docetaxel|Docetaxel: 75mg/m2 for a total of 6 cycles
75773262|NCT03756064|Drug|Carboplatin|Carboplatin: AUC=5 for a total of 6 cycles
75319545|NCT04022486|Other|Incidence, management and risk factors of seizure|Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
75619834|NCT01094184|Drug|Docetaxel|Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
75773263|NCT03756064|Drug|Placebo Oral Tablet|Placebo Oral Tablet: 400mg orally daily
75773264|NCT03755986|Device|ATOMO Diagnostic Test|The ATOMO diagnostic test device is the only intervention used in this study.
75319546|NCT00565669|Drug|Cyclosporin A Restasis®|
75773265|NCT04619992|Device|Currently marketed Hydrophillic Intermittent Catheter|Currently marketed Hollister standard with tip hydrophilic intermittent catheter
75319547|NCT00565669|Drug|Blink tears|blink tears to be used twice a day
75319548|NCT00565669|Drug|Systane|systane to be used twice a day
75319549|NCT00453479|Drug|GSK233705B|
75773266|NCT04619992|Device|Test Hydrophilic Intermittent Catheter|Hollister standard with tip hydrophilic intermittent catheter with design enhancements
75773267|NCT00136604|Biological|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
75773268|NCT00136604|Biological|Mencevax ACWY|GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine
75773269|NCT00136604|Biological|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
75773270|NCT00136604|Biological|Meningitec|Wyeth's MenC CRM197 conjugated vaccine, Meningitec
75319550|NCT04148378|Other|No intervention|There is no intervention for this study.
75773271|NCT03764176|Procedure|Conventional impressions|"In the conventional group, a polyether impression (ImpregumTM, 3M ESPE, Seefeld, Germany) will be taken with a customized tray (Diatray Top, Dental Kontor, Stockelsdorf, Germany). The impression will be poured with Gypsum IV Class Scale 5° (T6, Techim, Techim Group s.r.l., Arese, Italy) and then, the models mounted in a fully adjustable articulator (Protar Evo 7, KaVo Dental, Biberach, Germany). Afterwards, a dental wax-up will be made accordingly to the functional and esthetic requirements. Finally, master model and wax-up will be digitalized by using a lab scanner.~A surgical template will be derived from the mounted casts (conventional group) and used to place the implants using guided surgery."
75773272|NCT03764176|Procedure|Digital impressions|"Patients will be randomly assigned to undergo intraoral digital impression (digital group) or conventional impression (conventional group). In the digital group, a digital impression will be taken using CS 3600 intraoral scanner (Carestream Dental LLC, Atlanta, GA, USA). The digital data (STL, STereo Lithography interface format) will be imported in a 3D design software to realize a virtual wax-up according to the functional and esthetic requirements.~A surgical template will be derived from the virtual plane (digital group) and used to place the implants using guided surgery."
75319551|NCT04165135|Drug|Standard of Care for Haemophilia A|There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
75773273|NCT03764020|Drug|Placebo oral capsule/placebo comparator|3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline
75619835|NCT00697879|Drug|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
75319552|NCT02132533|Drug|Nifedipine|Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
75619836|NCT02780908|Other|Graded exercise testing|All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
75773274|NCT03764020|Drug|Melatonin/experimental|Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
75773275|NCT00135512|Drug|bupropion hydrochloride|Study drug
75773276|NCT00130728|Drug|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
75773277|NCT00130728|Drug|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
75773278|NCT00130728|Drug|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
75773279|NCT00129974|Drug|pemetrexed and gemcitabine|
75773280|NCT04947436|Device|High Frequency Chest Wall Oscillation|The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.
75773281|NCT04947436|Device|Mechanical insufflation/exsufflation|A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.
75773282|NCT03966326|Drug|sevoflurane and fentanil|Patients will receive standard general anesthesia
75773283|NCT03966326|Drug|sevoflurane and fentanil plus PECS II block|Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block
75773284|NCT02531256|Device|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
75773285|NCT01321840|Procedure|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
75773286|NCT00119106|Drug|Tenofovir disoproxil|Antiretroviral
75319553|NCT02132533|Drug|Placebo|Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
75319554|NCT02132533|Other|Usual care|Usual evaluation, monitoring and care for women with preterm labor.
75319555|NCT03927482|Behavioral|CARES mobile smart phone app|The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support
75319556|NCT03927482|Behavioral|Check Your Drinking|Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
75619837|NCT02780908|Other|Resting testing|The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
75619838|NCT01134731|Drug|paliperidone|1-5 mg daily (QD)
75619839|NCT01134731|Drug|lithium|300-1500mg QD
75619840|NCT01134731|Drug|Placebo|1-5 placebo capsules
75773287|NCT00119106|Drug|Placebo|Placebo
75773288|NCT03755908|Device|Forced oscillation technique (FOT)|FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
75773289|NCT05460598|Other|beddings with cooling effects|beddings with cooling effects (mattress topper and bed linen)
75773290|NCT05460598|Other|commonly used bedding|commonly used bedding
75773291|NCT03758014|Drug|Chlorogenic acid for Injection|Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation.
75619841|NCT04132063|Drug|Generic levetiracetam|Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
75619842|NCT05340556|Genetic|Blood sample|Blood sample of 12 ml EDTA plasma.
75619843|NCT05340556|Genetic|Swap test|receive swab tests for collecting cells from the oral mucosa
75773292|NCT03758014|Drug|Lomustine|Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use.
75773293|NCT04925908|Diagnostic Test|RT-PCR for SARS-Cov-2|Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction
75773294|NCT00135356|Drug|Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)|Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
75773295|NCT00135356|Drug|continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)|Protease inhibitor [PI] combination + 2 NRTIs
75773296|NCT00118716|Drug|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol
75773297|NCT00118716|Drug|Fluticasone Propionate|Fluticasone Propionate
75773298|NCT04584346|Dietary Supplement|Liquigen MCT oil|MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values
75773299|NCT04584346|Other|Standard American Diet|Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
75773300|NCT01079858|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
75773301|NCT03755830|Other|Skin biopsy|Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
75773302|NCT05124782|Other|Rheumatoid Arthritis Impact of Disease questionnaire|Rheumatoid Arthritis Impact of Disease questionnaire
75773303|NCT05039788|Other|Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements|"Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements At D30 and D90~Measurement of systolic and diastolic blood pressure, impedancemetry, weight, 3 times a week between D30 and D90 post-transplant,"
75773304|NCT00118482|Drug|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
75773305|NCT03966950|Dietary Supplement|melatonin|melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.
75619844|NCT04127071|Procedure|Ultrasound-guided Needle Aspiration Procedure|The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.
75619845|NCT04127071|Procedure|Incision and Drainage (I&D)|The current standard procedure to drain an abscess of purulent material.
75619846|NCT01141205|Biological|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
75619847|NCT01141205|Drug|Saline|1.2 ml saline intramuscularly
75619848|NCT02618317|Drug|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
75773306|NCT03966950|Drug|Placebo oral tablet|placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
75773307|NCT03755752|Procedure|Phacoemulsification with and without Trypan Blue capsule staining|Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.
75773308|NCT03755674|Procedure|CHRONOTYPE-ADJUSTED DIET|Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
75773309|NCT01076582|Drug|EE20/DRSP (YAZ, BAY86-5300)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
75773310|NCT01076582|Drug|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
75773311|NCT01081938|Drug|INSULIN GLARGINE|"Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine"
75773312|NCT01081938|Drug|INSULIN GLULISINE|"Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"
75773313|NCT01082796|Drug|Glipizide|Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
75773314|NCT03763786|Drug|Cetrorelix Acetate|Used a standard
75773315|NCT03965936|Procedure|lipofilling|Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.
75912039|NCT03043222|Device|UroLift as artifical device for prostatic urethral lift.|UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
75912040|NCT03043222|Device|Embospheres Microspheres as embolic agents for prostate artery embolization|Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
75912041|NCT03043144|Other|Worsening of olfaction from enrollment visit to 6 months|Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
75619849|NCT02618317|Drug|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
75773316|NCT03965936|Procedure|lipofilling enriched with adipose tissue derived stem cells|"Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region."
75912042|NCT03043144|Other|Worsening of taste from enrollment visit to 6 months|Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
75912043|NCT03043144|Other|Serum Zinc|Serum zinc will be evaluated for association with taste and/or smell impairment
75912044|NCT03043144|Other|Chronic rhinosinusitis|Chronic rhinosinusitis will be evaluated for association with smell impairment
75912045|NCT03043144|Other|Dialysis adequacy|Dialysis adequacy will be evaluated for association with taste and/or smell impairment
75912046|NCT03043144|Other|Decayed missing filled teeth index (DMFT)|DMFT will be evaluated for association with taste impairment
75319557|NCT04022408|Diagnostic Test|Liquid based cytology|Liquid based cytology
75319558|NCT04022408|Diagnostic Test|Conventional cytology|Conventional cytology
75773317|NCT01079364|Drug|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
75773318|NCT01079364|Drug|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
75912047|NCT02234466|Drug|Oral dexamethasone|Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.
75773319|NCT01079364|Drug|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
75773320|NCT01077752|Drug|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
75912048|NCT02234466|Drug|Ondansetron|Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.
75912049|NCT02234466|Other|Gelatin capsule|Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule
75773321|NCT01077752|Drug|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
75912050|NCT03042832|Behavioral|LOCI|Leadership development with coaching and organizational change support
75912051|NCT03042832|Behavioral|Internet Based Webinar Leadership Training|Internet Based Webinar Leadership Training
75912052|NCT02230800|Drug|Tocovid SupraBio plus pentoxifylline|
75619850|NCT02618317|Drug|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
75773322|NCT01077752|Drug|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
75773323|NCT01077752|Drug|NaCl|NaCl
75912053|NCT02230800|Drug|Matching placebos|
75912054|NCT02234544|Drug|Ezetimibe|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection [25(OH)D, PTH, calcium, albumin]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
75912055|NCT02234544|Drug|Cholecalciferol|All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
75912056|NCT02234544|Other|Placebo|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection [25(OH)D, PTH, calcium, albumin]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
75912057|NCT04860544|Procedure|RED BLOOD CELLS TRANFUSION|
75619851|NCT02781376|Other|CHICA OSA|Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
75619852|NCT02781376|Other|Snoring Identification Only|Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
75619853|NCT02614963|Drug|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
75619854|NCT02614963|Drug|placebo|Irritable bowel syndrome patients treated with placebo
76088854|NCT03198234|Biological|T-allo10|The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
75619855|NCT01140503|Drug|Apremilast|Apremilast 20mg PO BID
75319559|NCT05621473|Device|PICC|Tunnel PICC puncture technology is a perfect combination of ultrasound-guided puncture, ECG lead technology, PICC and subcutaneous tunnel. The valve conduction PICC is equipped with an integrated ECG lead Doppler ultrasound machine. Before the catheter is placed, in the yellow area, in the ultrasound mode, evaluate the blood vessel condition, measure the blood flow velocity, and correctly select the puncture site. When the catheter is pushed close to the superior vena cava, the electrocardiograph mode is switched to complete the precise positioning of the catheter according to the principle of ECG positioning technology. A subcutaneous tunnel was prepared in the green area, and the PICC at the puncture site in the yellow area was introduced to the green area and carefully bandaged. Whole-process integrated operation, simple and efficient operation.
75319560|NCT04022174|Behavioral|Moderate dosage training of action Observation and Motor imagery|Motor imagery and action observation of orofacial exercises with moderate dosage
75319561|NCT04022174|Behavioral|Intensive dosage training of action observation and motor imagery|Motor imagery and action observation of the orofacial exercises with intensive dosage
75319562|NCT04022174|Biological|Intensive dosage orofacial exercises|Orofacial exercises with high intensity
75319563|NCT04022174|Behavioral|Moderate dosage orofacial exercises|Orofacial exercises with moderate intensity
75619856|NCT02689726|Drug|GTL001+|
75619857|NCT02689726|Drug|Aldara|5% imiquimod cream
75619858|NCT00863317|Drug|montelukast sodium|4mg granules daily for 14 days
75619859|NCT00863317|Other|sucrose|table sugar as placebo daily for 14 days
75619860|NCT02883413|Behavioral|CRT + Teach the Parent|CRT sessions will occur for 45-60 minutes every day (excluding weekends) for 6-8 days while adolescents are in hospital. Adolescents will be given homework and asked to practice tasks each day.
75619861|NCT02883413|Behavioral|CRT + Contact Control|Adolescents will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). Adolescents will be able to choose 2 tasks from a list and be asked to engage in those tasks with their parents.
75619862|NCT01200368|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
75619863|NCT01200368|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
75619864|NCT01200368|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
75773324|NCT03763630|Drug|House dust-mite SLIT|received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day. Normal saline was administered to the placebo group. 11 µg of HDM allergen (equal parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered twice daily as oral drops.
75773325|NCT03763630|Drug|Normal saline|Normal saline administered in same frequency and manner as intervention
75619865|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
75619866|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
75619867|NCT00697957|Behavioral|Exercise|Progressive impact exercise
75619868|NCT02878668|Procedure|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
75619869|NCT04125121|Drug|Sevoflurane-propofol|General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
75773326|NCT01082016|Other|Sleep Enhancement Program (SEP)|Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
75773327|NCT03964844|Other|No intervention|No intervention
75773328|NCT01079442|Other|Postoperative coffee|"schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):~08:00 100mL beverage~12:00 100mL beverage~16:00 100mL beverage"
76088855|NCT02717832|Drug|hyperinsulinemic-euglycemic clamp|
75319564|NCT04022252|Device|Cheese dental laser|810 nm GaAlAs diode laser device
75619870|NCT02618083|Device|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
75619871|NCT01079130|Drug|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
75619872|NCT01079130|Drug|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
75619873|NCT01079130|Drug|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
75619874|NCT01079130|Drug|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
75619875|NCT05341570|Drug|BPI-21668|Subjects will receive BPI-21668 until disease progression
75619876|NCT02689414|Procedure|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
75619877|NCT02689414|Procedure|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
75619878|NCT01078974|Drug|pomalidomide|Taken orally once a day
75619879|NCT01078974|Drug|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
75619880|NCT01078974|Drug|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
75619881|NCT04307082|Drug|[14C]-Ibrexafungerp|Radio-labeled Ibrexafungerp, single dose.
75619882|NCT02877576|Procedure|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
75773329|NCT01079442|Other|water|"The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:~08:00 100mL beverage~12:00 100mL beverage~16:00 100mL beverage"
75912058|NCT02259036|Other|Ecological Momentary Treatment Enhancement|Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
75912059|NCT04860388|Procedure|closed eruption technique|The impacted teeth treated with closed eruption technique firstly. Orthodontic traction started a week later the sutures were removed. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch using double-arch technique. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, and keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The measurements compared with the contralateral canines that served as control teeth.
75773330|NCT03755596|Drug|Z. officinale extract|Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
75912060|NCT03043066|Procedure|Scaling and root planing|subjects underwent full mouth supragingival and subgingival scaling
75912061|NCT03043066|Drug|scaling and root planing along with antibiotic intervention|subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
75912062|NCT04860310|Procedure|Endometrial biopsy|Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.
76088856|NCT02717754|Drug|Oseltamivir|Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
76088857|NCT02717754|Drug|Placebo|Oseltamivir matched placebo will be administered intravenous for 5 days.
75465527|NCT01892579|Behavioral|Tailored Activity Program|TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).
75465528|NCT01892579|Other|Home Safety and Education Program|The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
75465529|NCT01892800|Procedure|Lung resection|
75619883|NCT02877576|Behavioral|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter…). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
75619884|NCT02877576|Behavioral|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
75319565|NCT04022252|Device|OrthoPulse|850 nm LED (light emitting diode)
75319566|NCT04022252|Other|Placebo|810 nm GaAlAs diode laser device
75319567|NCT03926702|Drug|Radiopharmaceuticals|All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
75619885|NCT02878200|Biological|dihydroartemisinin-piperaquine|A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
75619886|NCT05340088|Procedure|Retrograde intrarenal surgery after DJ stent placement|Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
75773331|NCT00129272|Drug|Bupropion-SR|150mg tablets taken orally twice daily for 9 weeks.
75773332|NCT00129272|Other|Placebo|Matching placebo (to Buproion-SR) twice daily for 9 weeks.
75319568|NCT00567229|Biological|rituximab|
75319569|NCT00567229|Drug|lenalidomide|
75319570|NCT00567229|Genetic|microarray analysis|
75319571|NCT00567229|Other|flow cytometry|
75319572|NCT00567229|Other|laboratory biomarker analysis|
75319573|NCT04148846|Drug|Dypirone|Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
75465530|NCT01893008|Other|Inspiratory Muscle Training (IMT)|"The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.~Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.~Training will be started after the chemoradiation period (if applicable)."
75773333|NCT03963804|Device|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
75465531|NCT01893112|Behavioral|Unity Workshop|The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training & Education Center for health).
75465532|NCT01893112|Behavioral|Breast Cancer Screening|
75773334|NCT01326338|Drug|Nitazoxanide|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
75773335|NCT03963648|Diagnostic Test|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
75465533|NCT01893229|Drug|Lithium|Lithium is used as a mood stabiliser
75912063|NCT04848532|Behavioral|Weight loss treatment|The intervention will consist of group-based, weekly or biweekly weight loss coaching (75 minutes per session), which will occur via Zoom videoconferencing software. This intervention is designed to facilitate a 5-10% weight loss and engagement in up to 250 min/week of moderate-to-vigorous physical activity, which is the standard recommendation in lifestyle modification programs for adolescents. Participants will also be asked to download and utilize the smartphone app, Fitbit, to track eating behavior. Weight loss coaches will be experts in lifestyle modification who have graduate degrees in psychology or a related field. Participants will be given guidance on how to reduce your calorie intake (using a balanced deficit diet) and gradually increase your physical activity. Participants will learn to set goals for diet, weight, and physical activity.
75319574|NCT04148846|Procedure|Sphenopalatine block|The sphenopalatine block will be performed with the patient in the supine position, with neck extended. Following topical anesthesia of the nasal vestibules with one application of 10% lidocaine spray and one application of 2% lidocaine gel in each nostril, two long cotton swab applicators embedded in 2% lidocaine jelly, one in each nostril, will be introduced. They will be advanced at a 45-degree angle to the floor of the nose until resistance is encountered, indicating that the swab is in the posterior nasopharyngeal wall, superior to the middle nasal concha. It will be held in this position for 5 minutes and then removed. Thereafter, a 14 gauge, non-cutting, teflon blunt catheter will be introduced into each nostril at a 45 ° angle to the hard palate until it touches the posterior wall of the nasopharynx. For it will be applied 2ml of 0.375% Ropivacaine, on each side, slowly.
75465534|NCT01893229|Drug|Valproate|Valproate is used as a mood stabiliser
75465535|NCT01893229|Drug|Oxcarbazepine|Oxcarbazepine is used as a mood stabiliser
75465536|NCT01893229|Drug|Quetiapine|Quetiapine is used as a mood stabiliser
75465537|NCT01893229|Drug|Olanzapine|Olanzapine is used as a mood stabiliser.
75465538|NCT01893229|Drug|Ziprasidone|Ziprasidone is used as a mood stabiliser
75619887|NCT04302012|Procedure|Color fundus photography|Subjects will undergo fundus photography before and/or after administration of mydriatic agent
75619888|NCT04302012|Drug|Mydriatic Agent|Subjects may be administered mydriatic medication to dilate their pupils.
75619889|NCT02780518|Device|Airvo|Applying high flow nasal oxygen
75619890|NCT04306770|Other|OPTIMUM programme|"OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content."
75619891|NCT00869557|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
75619892|NCT00869557|Drug|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
75619893|NCT02878356|Behavioral|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
75619894|NCT02878356|Behavioral|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
75773336|NCT01326416|Dietary Supplement|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
75465539|NCT01893645|Device|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
75619895|NCT02878356|Behavioral|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
75619896|NCT02780596|Other|Item1|Does CHILD NAME often wake one or more times during the night?
75619897|NCT02780596|Other|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
75619898|NCT02780596|Other|Item3|Do you think CHILD'S SLEEP is a problem?
75619899|NCT02780596|Other|Item4|Do you think CHILD NAME has a sleep problem?
75619900|NCT02780596|Other|Item5|Do you have any concerns about CHILD NAME'S sleep?
75773337|NCT01326416|Other|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
75773338|NCT02531282|Behavioral|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
75773339|NCT02531282|Behavioral|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
75773340|NCT04899232|Drug|Antithrombin III|Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).
75773341|NCT03757936|Drug|HLX04|Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
75773342|NCT03757936|Drug|HLX10|Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
75773343|NCT04574908|Device|ViSi device|Mobile patient monitoring system for vital signs.
75773344|NCT04559698|Behavioral|LGBTQ-affirmative CBT training|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.
75319575|NCT04148846|Drug|Ketoprofen|Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
75319576|NCT04148846|Drug|Gabapentin|Gabapentin 300 mg 8 / 8h for 7 days orally
75319577|NCT04148846|Drug|Dexamethasone|Dexamethasone 4mg 8 / 8h for 48h orally
75319578|NCT04148846|Drug|Theophylline|Theophylline 200mg, 12 / 12h, for 5 days, orally
75912064|NCT04857346|Drug|Indocyanine green|Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.
75319579|NCT04148846|Dietary Supplement|Espresso coffee|Espresso coffee 20ml, 5x / day, for 7 days
75773345|NCT03963258|Device|whole-body vibration training|The subjects were exposed to alternating vertical sinusoidal vibration using a Galileo tilting table system.The frequency of WBV ranged from 5 to 20 Hz, and the amplitude ranged from 1 to 6 mm.The subjects were kneeled on the ground, both shoulders flexed at 90 degrees, elbows slightly flexed, their trunk bent in this position and contacted on the platform board with their palms equidistant from the midpoint of the board
75773346|NCT03963258|Other|conventional upper limb training|compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
75319580|NCT00567307|Drug|Red Heart Pill 2b (Polypill)|Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
75773347|NCT01079520|Procedure|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
75912065|NCT03040570|Procedure|Conservative oxygenation target|Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
75912066|NCT03040570|Procedure|Liberal oxygenation target|Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining >94%.
75319581|NCT00567307|Other|Standard Practice|Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
75319582|NCT00487565|Device|Total knee arthroplasty|Total knee arthroplasty using a posterior stabilized implant
75319583|NCT04069741|Other|Decision Aid|A website that contains information about de Quervain's tenosynovitis and the options for treatment
75319584|NCT04069741|Behavioral|Toolkit for de Quervain's|A website that offers 4 sessions of mind-body skills to help manage pain from de Quervain's tenosynovitis
75773348|NCT01079520|Procedure|Mediastinoscopy|Traditional surgical method to stage lung cancers
75912067|NCT03041974|Procedure|Red Blood Cell transfusion|
75319585|NCT04146662|Diagnostic Test|Faecal immunochemical test|Faecal immunochemical test (FIT) and urine volatile organic compounds (VOC) analysis.
75319586|NCT04406480|Genetic|CGH-array and exome sequencing|A blood sample will be used for CGH-array and exome sequencing
75319587|NCT00568087|Drug|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
75319588|NCT00568087|Drug|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
75619901|NCT02877420|Other|Non-Technical Skills Training Curriculum|
75619902|NCT02877420|Other|Conventional Simulation Training Group|
75619903|NCT01200290|Drug|LY2127399|120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
75619904|NCT02781142|Other|Motor imagery training|The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
75619905|NCT04131985|Procedure|Erector Spina Block|After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
75619906|NCT05052372|Drug|Balversa|BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery
75773349|NCT03763474|Combination Product|Euglyca application|'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
75773350|NCT01082094|Biological|ACRX-100|Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
75773351|NCT03753568|Device|Electronic medicine reminder system|Electronic surveillance device is attached to the participants push through pill sheet and the smart phone application reminds the participants to take their medicine if they are about to take their daily dosage.
75773352|NCT01082172|Device|Implant Thoracic Stent Graft|Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
75619907|NCT02618005|Dietary Supplement|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
75619908|NCT02781064|Drug|Atorvastatin 20mg|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
75773353|NCT03757858|Device|Thermotron RF-8|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.
75773354|NCT03757858|Biological|Adoptive cellular Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.
75319589|NCT00487721|Drug|Silibin-Phytosome|Subjects will take Silibin-Phytosome for 2-10 weeks. The dose of Silibin-Phytosome is 13 grams daily, in three divided doses. Patients will be asked to mix 1 level teaspoon and 1 heaping ¼ teaspoon of Silybin-Phytosome powder into 6 tablespoons of applesauce for each dose.
75619909|NCT02781064|Drug|Placebo|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
75619910|NCT04205682|Drug|Cannabidiol|CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
75773355|NCT03757858|Drug|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
75912068|NCT03041974|Procedure|Microparticles quantification|Flow cytometric quantification of microparticles in transfused blood
75319590|NCT04021940|Procedure|ULOD|ULOD
75319591|NCT04148612|Diagnostic Test|Opti-Me|Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
75319592|NCT00568633|Procedure|Allogeneic HSCT|Allogeneic, 5+ of 6 HLA-matched PBSC transplant from sibling, mobilized to target of 5 x 10e6 CD34+ cells/kg and < 7 x 10e8 CD3+ cells/kg.
75319593|NCT00568633|Drug|Anti-thymocyte globulin (ATG)|1.5 mg/kg for 5 days by IV
75319594|NCT00568633|Drug|Cyclosporine (CSP)|6.25 mg/kg twice daily oral
75319595|NCT00568633|Drug|Mycophenolate mofetil (MMF)|15 mg/kg twice daily oral
75319596|NCT00568633|Radiation|Total lymphoid irradiation (TLI)|80 cGy/fraction radiotherapy in 10 fractions.
75619911|NCT04205682|Drug|Placebo|Placebo capsules administered BD for 5 days
75619912|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
75619913|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
75773356|NCT03757858|Drug|Chemotherapy|Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
75912069|NCT03042520|Other|Observation only|
75912070|NCT03042442|Diagnostic Test|Point-of care biomarkers|Point-of care biomarkers(Activin,Midkine) assessed by WB and IHC
75912071|NCT03042442|Other|Clinical, venous blood samples, pancreatic tissue|Clinical evaluation, venous blood samples and pancreatic tissue needed for determining point-of-care biomarkers.
75912072|NCT03042442|Other|Follow-up|Participants will be assessed (by telephone) over a period of 2 years
75319597|NCT00568633|Drug|Methylprednisolone sodium succinate|1.0 mg/kg for 5 days by IV
75619914|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
75619915|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
75619916|NCT01134263|Biological|Placebo: NaCl 0.9%|0.5 ml, SC
75619917|NCT00626184|Drug|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
75912073|NCT04848766|Drug|De-escalation Treatment Strategy of dual antiplatelet therapy|Patients receive de-escalation treatment of dual antiplatelet therapy after percutaneous coronary intervention
75912074|NCT04860076|Drug|Pembrolizumab|Standard of care
75319598|NCT00568633|Drug|Best standard care|"Intervention consist of:~Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~Autologous transplantation~Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~Umbilical cord blood transplantation~Haploidentical transplantation"
75619918|NCT00634738|Procedure|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
75619919|NCT02780440|Behavioral|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
75619920|NCT02780440|Behavioral|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
75619921|NCT02780440|Behavioral|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
75773357|NCT01079676|Drug|Filgrastim (Eurofarma)|Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
75619922|NCT01199822|Biological|Olaratumab|Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
75619923|NCT05158816|Procedure|ECMO|Patients undergoing extracorporeal membrane oxygenation
75319599|NCT03022838|Drug|Caffeine|From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
75912075|NCT04856878|Drug|Vancomycin|The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.
75319600|NCT03021980|Behavioral|SuperFIT|Behavioural intervention with two components. One component will consist of social and physical environmental changes at the preschools and the other component consists of a family educational program.
75619924|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
75619925|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
75619926|NCT01096056|Biological|Fluarix|Intramuscular administration, 1 dose
75619927|NCT00866359|Drug|Apremilast (CC-10004)|"Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)"
75619928|NCT00866359|Drug|Placebo|"Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)"
75619929|NCT00634816|Radiation|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
75651601|NCT05833997|Procedure|Holmium Laser resection of bladder tumor (HoLEBT)|"It will be used a 24-26F continuous-flow resectoscope sheath with a specific working element to use with a 600µm fiber to Laser Holmium.~Patients will be operated with the Megapulse 70w (Richard Wolf) and laser will be set to deliver the energy of 0,5J and 30-40Hz frequency, 15-20W of final energy. The solution used will be 0,9% saline solution. The resection will start from the base of the lesion, reaching the muscle layer to obtain a sample and resection of the whole tumor, without fragmentation. After this, the morcellation will be performed in the apex of tumor sparing the base with a long nephroscope, and the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation. The morcellated product will be sent to the pathology lab for detailed analysis."
75773358|NCT01079676|Drug|Filgrastim (Granulokine, Amgen)|Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
75912076|NCT04848376|Device|(1) SmartLoc (2) SmartLoc Evo (3) Winloc(4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L|As long as there are patients using the above device, conduct questionnaire interview.
75912077|NCT04847830|Device|Er:YAG laser (Waterlase)|The WaterLase iPlus tissue cutting system is a unique device with diverse, hard- and soft-tissue dental applications. It utilizes advanced laser and water atomization technologies to safely and effectively cut, shave, contour, roughen, etch, and resect oral hard-tissue, and direct laser energy to perform oral soft-tissue removal, incision, excision, ablation and coagulation.
75912078|NCT04847830|Procedure|root surface dbridement|root surface debridement under local anaesthesia
75319601|NCT05363449|Drug|UHE-103 Cream|UHE-103 is an investigational combinational therapy containing keratolytic and antifungal
75319602|NCT05363449|Drug|Naftin (naftifine hydrochloride) Cream|Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug
75319603|NCT04146506|Other|Muscle stretching exercises|Muscle stretching exercises consisting of static stretching exercises of the knee flexors
75465540|NCT01893749|Behavioral|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
75773359|NCT03753256|Device|Transbond XT|"Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants."
75773360|NCT03753256|Device|Protecto®CaF2Nano|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
75773361|NCT03753256|Device|Pro Seal®|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
75619930|NCT02780986|Behavioral|Female entertainment worker intervention group|"The following summarises the content of each session:~Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.~Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.~Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.~Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms."
75773362|NCT03753256|Device|Opal®Seal|"Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
75773363|NCT01082250|Drug|Lurasidone HCl|120mg dose. 3-way cross-over for 21 days
75773364|NCT05460286|Other|Chiropractic Manipulation|20 participants with low back pain existing more than 3 months was included in the CSMT group. Lumbar region chiropractic HVLA (High Velocity, Low Amplitude) spinal manipulation and/or sacroiliac joint chiropractic HVLA manipulation were applied to participants. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
75773365|NCT05460286|Other|Spinal Decompression Device Treatment|20 participants with low back pain existing more than 3 months was included in the SD group. Lumbar region spinal decompression (traction) device therapy was applied to participants, and as a standard of treatment was given a hot pack for 15 minutes before applying and a cold pack for 10 minutes after applying. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
75319604|NCT00489281|Drug|Cyclophosphamide|Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
75619931|NCT02780986|Behavioral|Heterosexual men intervention group|"This will be delivered via 3 main activities:~Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.~Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.~Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants"
75619932|NCT01199198|Drug|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
75773366|NCT01082406|Drug|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
75773367|NCT01082406|Drug|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
75773368|NCT03755362|Procedure|Standard Treatment|Dental evaluation at baseline, 3, 6, and 9 months.
75773369|NCT03755362|Procedure|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
75912079|NCT04856644|Drug|4-month rifapentine-based regimen|8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin
75465541|NCT01893775|Biological|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
75319605|NCT00489281|Drug|Fludarabine|Fludarabine 30 mg/m^2/day IV on Days -6, -5, -4, -3, and -2.
75319606|NCT00489281|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.
75319607|NCT00489281|Drug|Sirolimus|The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.
75319608|NCT00489281|Procedure|Allogeneic bone marrow transplant|An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
75465542|NCT01894269|Drug|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
75465543|NCT01894347|Other|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
75465544|NCT01894789|Drug|Ticagrelor|Blinded administration of ticagrelor for 10 days
75465545|NCT01894789|Drug|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
75465546|NCT01894815|Drug|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
75912080|NCT01329978|Drug|Sofosbuvir|Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
75319609|NCT00489281|Radiation|Total body irradiation - 200|200 centigray (cGy) in one fraction on Day -1.
75319610|NCT00489281|Drug|Levetiracetam|Given at 500 mg PO twice daily from Day -6 to Day +365.
75619933|NCT01199198|Drug|Placebo|Placebo by mouth once a day for 14 days.
75465547|NCT01894815|Device|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
75465548|NCT01894815|Other|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
75619934|NCT01095978|Drug|Clarithromycin (Klacid SR)|Klacid SR in a dose of 1000 mg once daily
75619935|NCT01134107|Drug|Insulin Lispro 6 Day (6D)|Administered by infusion pump for 12 week treatment period
75619936|NCT01134107|Drug|Insulin Aspart 6 Day (6D)|Administered by infusion pump for 12 week treatment period
75619937|NCT01199042|Device|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
75619938|NCT02780674|Biological|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
75619939|NCT02780674|Biological|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
75619940|NCT05339620|Procedure|implant driver facilitated micro-osteoperforations|"3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention ."
75619941|NCT01198574|Dietary Supplement|Iron group|Ferrous fumarate, 60 mg, weekly dose
75619942|NCT01198574|Dietary Supplement|Vitamin A group|Retinol, weekly dose, 15,000 IU
75619943|NCT01198574|Dietary Supplement|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
75619944|NCT01198574|Dietary Supplement|Placebo group|folic acid only as placebo group
75619945|NCT01198028|Drug|Erlotinib|Given PO
75619946|NCT02780362|Drug|Prodactariv|1 tablet contains 60 mg Daclatasvir
75319611|NCT00489281|Biological|Anti-thymocyte globulin|Test dose of 0.5 mg/kg IV given on Day -9, then 2 mg/kg/day IV on Day -8 and -7.
75319612|NCT00489281|Radiation|Total body irradiation - 400|400 centigray (cGy) in one fraction on Day -1.
75319613|NCT05362669|Behavioral|SMS invitation|Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.
75465549|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus|
75465550|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus|
75619947|NCT02780362|Drug|Clatazev|1 tablet contains 60 mg Daclatasvir
75619948|NCT01197950|Device|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
75619949|NCT01197950|Device|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
75619950|NCT01092780|Drug|MK-7288|one or two 10 mg capsules, orally, single dose
75619951|NCT01092780|Drug|Placebo to MK-7288|one or two capsules, orally, single dose
75619952|NCT01092780|Drug|Modafinil|two 100 mg tablets, orally, single dose
75619953|NCT01092780|Drug|Placebo to modafinil|two 100 mg tablets, orally, single dose
75619954|NCT05338138|Device|ultrasound guided central venous catheter insertion|Prospective comparative randomized controlled clinical study.
75619955|NCT04228744|Device|DBS system|"The DBS device utilized in the present study includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead contains four stimulating contacts. The length of each contact is 1.5 mm, and the spacing between contacts is 1.5 mm.~The participants will receive stepwise surgery. The electrodes will be implanted firstly which will be externalized for several days and then the IPG will be implanted. During externalization, the experimenters will record the local field potential and electroencephalography in resting or task-based state with conditions of sham-stimulation or active-stimulation."
75619956|NCT05338684|Device|Colour doppler,MSCT,MRI|ultrasound/color duplex at Jugular veins & carotid and vertebral arteries first ,then MSCT/CTA mainly with relation of neck & Bain arteries to the bone of the skull in 6 mm cuts and/or MRI/MRA/MRV by standardized multi-parametric MR protocol will be implemented for all patients. All sequences will be acquired on a 1.5T MR scanner.
75619957|NCT04306302|Biological|ExPEC10V|Participants will receive a single IM injection of ExPEC10V.
75619958|NCT04306302|Biological|Placebo|Participants will receive single IM injection of matching placebo.
75773370|NCT03755284|Other|Sacral Massage|● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
75773371|NCT00133952|Drug|Ruboxistaurin|Administered orally
75773372|NCT00133952|Drug|Placebo|Administered orally
75773373|NCT03755050|Other|general and specific data|General and specific data collected
75773374|NCT00118092|Drug|tanespimycin|Given IV
75319614|NCT05362669|Behavioral|Phone call invitation|Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.
75619959|NCT05338606|Drug|Bimatoprost Sustained Release Implant|Intraocular Implant
75773375|NCT00118092|Other|laboratory biomarker analysis|Correlative studies
75465551|NCT01895751|Procedure|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
75465552|NCT01896024|Behavioral|Psychiatric Management|
75619960|NCT01092546|Drug|[18F]Flutemetamol|All subjects will receive an IV dose of [18F]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 MBq.
75619961|NCT02779348|Drug|BIA 3-202|Nebicapone tablets 200 mg
75619962|NCT02779348|Drug|warfarin|Varfine® 5 mg (warfarin 5 mg) tablets
75619963|NCT02877264|Drug|vapendavir 132 mg capsule|
75773376|NCT01083108|Other|Roux-en-Y Gastric Bypass|The surgical group will be studied before and 6 days after bariatric surgery.
75773377|NCT01083108|Other|Caloric Restriction|The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
75773378|NCT04555096|Drug|GC4419|180 Minute IV Infusion
75773379|NCT04555096|Drug|Placebo|180 Minute IV Infusion
75773380|NCT00097500|Drug|exenatide|subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
75773381|NCT00097500|Drug|Insulin glargine|subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
75773382|NCT00097500|Drug|Metformin|Patients usual dosage
75773383|NCT01082484|Drug|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
75912081|NCT01329978|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
75912082|NCT01329978|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
75912083|NCT03041818|Behavioral|Horseback riding therapy|Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
75912084|NCT04859686|Behavioral|Mindfulness-Based Stress Reduction|The MBSR program included weekly 2.5-hour sessions in a group format over eight weeks, plus a 1-day retreat. Formal practices included several types of meditation, such as mindful breathing, sitting meditation, walking meditation, gentle hatha yoga, body scan, and mindful awareness. Participants were asked to practice at home for 20 minutes daily, six days a week.
75465553|NCT01896024|Behavioral|Motive-oriented therapeutic relationship/Plan Analysis|
75465554|NCT01896570|Procedure|Catheter ablation of subsequent atrial tachycardia|
75773384|NCT01082484|Drug|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
75465555|NCT01896622|Drug|Ritonavir|Impact on dabigatran PK/PD
75465556|NCT01896622|Drug|Cobicistat|Impact on dabigatran PK/PD
75465557|NCT01897051|Drug|Rifaximin + propranolol|"Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
75619964|NCT02877264|Drug|vapendavir 264 mg tablet|
75619965|NCT02877264|Drug|vapendavir 24 mg/mL oral suspension|
75773385|NCT01082484|Drug|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
75773386|NCT04551898|Drug|BGB-DXP593|Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
75773387|NCT04551898|Drug|Placebo|Placebo to match BGB-DXP593 administered as specified in the treatment arm
75773388|NCT03757780|Other|Questionaire|A questionaire will be made to pregnant ladies who take caffeine during pregnancy
75773389|NCT04849780|Device|ACUVUE Oasys 1-Day|TEST
75773390|NCT04849780|Device|Habitual Lens|Subjects' own Habitual Lenses
75773391|NCT03757702|Other|Evaluation|Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
75773392|NCT03757624|Procedure|shrinkage|shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
75773393|NCT03754894|Device|ready made plastic stent application|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
75773394|NCT03754894|Procedure|simple interrupted sutures|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement and securing the flap with simple interrupted sutures
75619966|NCT02779582|Drug|Oral Micronized Progesterone|The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
75619967|NCT02779582|Drug|Placebo|pill with no effect
75619968|NCT01197794|Drug|AZD1981|AZD1981 twice daily
75619969|NCT01197794|Drug|AZD1981|AZD1981 once daily
75619970|NCT01197794|Drug|Placebo|Placebo to match AZD1981
75651602|NCT05833984|Drug|IMM01|IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
75651603|NCT05833984|Drug|Tislelizumab|Tislelizumab 200mg Q3W IV
75773395|NCT04823494|Device|Hearing aids|Earbud style hearing aids fit to both ears
75773396|NCT05384392|Other|Recorded interview|A recorded clinical interview, transcribed verbatim and blinded analyzed
75619971|NCT04307316|Other|ACBT group|"ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization"
75773397|NCT05384392|Other|Clinical scales|Answering to clinical scales : PANSS (Positive and Negative Syndrome Scale); BPRS (Brief Psychiatric Rating Scale); CDSS (Calgary Depression Scale for Schizophrenia); MADRS (Montgomery-Åsberg Depression Rating Scale); Altman; YMRS (Young Mania Rating Scale); GAF (Global Assessment of Functioning); SF-36 (36-Item Short Form Survey); CGI-S (Clinical Global Impression Scale) et CGI-I (CGI-Improvement)
75773398|NCT05384392|Biological|Blood sample|Blood collection of inflammatory markers (IL-1, sIL-2R, IL-4, IL-6, IL-8 and TNF levels) and 2 EDTA tubes and 2 dry tubes for biological collection (plasma bank and serum bank). This blood sample will be taken during routine sampling.
75912085|NCT04859686|Procedure|Acupuncture Treatment|"Participants received two treatments per week over eight weeks, 35-40 minutes each.~At each treatment, participants were treated with 10 body and two ear points: seven major points on either the front or back of the body. The treatment position alternated between sessions, such that the first session was on the back, with the next session on the front, unless a physical limitation prevented alternation."
75465558|NCT01897051|Drug|Propranolol + Placebo|"Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
75465559|NCT01897090|Other|Elimination Diet|
75912086|NCT04847518|Drug|Kan Jang capsules|"One capsule contains a fixed combination of proprietary~Andrographis paniculata Nees. herb, native extract, DER native 4,5-8,0 :1 260 mg (Diterpene lactones andrographolide and 14-deoxy, 11,12- didehydroadnrograholide) 15-20 mg~Eleutherococcus senticosus (Rupr. et Maxim) Harms, root, native extract DER native 17-30:1 : 11.4 mg and other inactive excipients (Polycristalline cellulose, Magnesium stearate)."
75912087|NCT04847518|Other|Placebo capsules|Inactive excipients
75912088|NCT04984278|Drug|Nabiximols|oromucosal spray
75912089|NCT04984278|Drug|Placebo|oromucosal spray
75912090|NCT04859998|Behavioral|dog-assisted therapy|It will consist of 20 sessions conducted twice a week in the facilities of the association. It will involve different activities and physical exercises facilitated by the dogs. The program will be conducted in two associations (12 participants in each one, 6 belonging to the experimental and 6 belonging to the control group in each association) and in groups of three participants.
75465560|NCT01897090|Other|Dietary Guidelines for Americans|
75465561|NCT01897142|Biological|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
75465562|NCT01897142|Drug|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
75465563|NCT01897142|Biological|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
75465564|NCT01897142|Drug|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
75465565|NCT01897142|Biological|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
75465566|NCT01897142|Drug|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
75465567|NCT01897142|Biological|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
75465568|NCT01897142|Drug|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
75619972|NCT04307316|Other|Conventional Physical therapy|Chest percussion, deep breathing, Huff and cough. Early mobilization
75773399|NCT05384392|Other|MRI scans of the brain|The MRI scans of the brain will be performed. This exam is performed in routine care in the context of this pathology
75912091|NCT04978740|Other|Ophthalmological examination|"Eye examination :~Ocular tonometry to determine intraocular pressure Refraction assessment Retina examination Slit lamp examination Visual acuity Schirmer's test Corneal topography Funduscopic examination Optical coherence tomography"
75465569|NCT01897142|Biological|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
75465570|NCT01897142|Drug|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
75465571|NCT01897142|Biological|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
75619973|NCT02779426|Behavioral|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
75619974|NCT04228198|Procedure|Radical cystectomy|Procedure/Surgery: Radical cystectomy. Removal of urinary bladder with three different approaches: i) Robotic-assisted, ii) Laparoscopic, and iii) Open Surgery
75619975|NCT04317638|Other|Lipid profile|3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
75651604|NCT05833971|Drug|cadonilimab+chemotherapy|cadonilimab plus cisplatin and Nab-PTX, Q3W
75465572|NCT01897142|Drug|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
75465573|NCT01897298|Behavioral|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
75465574|NCT01897649|Dietary Supplement|NUTRIOSE FB06|15g/day NUTRIOSE FB06
75465575|NCT01897649|Dietary Supplement|GLUCIDEX 21|15g/day GLUCIDEX 21
75465576|NCT01897662|Dietary Supplement|NUTRIOSE FB06|14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day
75465577|NCT01897662|Dietary Supplement|GLUCIIDEX 21|7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
75465578|NCT01897740|Drug|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
75465579|NCT01897753|Drug|growth hormone|36 months
75619976|NCT04307472|Behavioral|Clinician Nudge|Active choice intervention in the electronic health record and peer comparison messaging on performance
75619977|NCT04307472|Behavioral|Patient Nudge|Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
75619978|NCT02780050|Other|core muscle activation using physical fitness|"2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression."
75619979|NCT00634894|Drug|Femara|2.5 mg by mouth daily x 12 weeks
75619980|NCT00634894|Drug|Placebo|Placebo capsule by mouth daily x 12 weeks
75619981|NCT04228120|Behavioral|self-regulation programme|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
75619982|NCT02779270|Drug|BAY987518|"Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104"
75619983|NCT02779270|Drug|Sunscreen Lotion (U77-030 Control)|Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
75619984|NCT02779894|Other|Remote control of patients|Diagnosis outside the hospital (3 Home PR) CPAP (if needed) titration at home REmote control of patient's during 3 months by video or phonoconference
75619985|NCT04228900|Dietary Supplement|Individualized plan for improvement of nutrition|For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,
75619986|NCT04228900|Drug|Systematic drug review|Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
75619987|NCT01078662|Drug|olaparib|Tablets Oral BID
75619988|NCT04227886|Radiation|Radiation|Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.
75619989|NCT04227886|Drug|Capecitabine-Irinotecan Combination|The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1*1*1 or 65mg/m2 for UGT1A1*1*28 weekly, followed by a cycle of XELIRI.
75619990|NCT02200978|Drug|ATO|Given IV
75319615|NCT04146584|Device|Sofwave Treatments|The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.
75619991|NCT02200978|Drug|RIF|Given orally
75619992|NCT02200978|Drug|ATRA|Given orally
75619993|NCT02200978|Drug|mitoxantrone|Given IV
75619994|NCT02200978|Drug|Ara-C|Given IV
75619995|NCT02200978|Drug|MTX|Given orally
75619996|NCT02200978|Drug|6MP|Given orally
75619997|NCT02200978|Other|intrathecal injection|Ara-C and dexamethasone
75619998|NCT02779192|Drug|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
75619999|NCT02779192|Drug|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
75620000|NCT02779192|Drug|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
75620001|NCT05020210|Drug|Sivelestat sodium|Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
75620002|NCT04227808|Drug|Lenvima 4 mg Oral Capsule|The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
75319616|NCT05362513|Drug|Ivermectin Tablets|Group B received a single dose of oral ivermectin 200 mcg per kg
75620003|NCT04963426|Behavioral|Behavioral interventions targeting multiple risk behaviors as well as protective factors|Depending on the baseline data and prioritization of actions, behavioral interventions related to the following topics will be implemented: alcohol use, dietary behaviors, drug use, hygiene, mental health, physical activity, protective factors, sexual behaviors, tobacco use, violence and unintentional injury.
75319617|NCT05362513|Drug|Permethrin Cream|Group A received Permethrin 5% twice with a one-week interval.
75319618|NCT04148222|Other|No intervention|There is no intervention for this study
75319619|NCT04147910|Drug|KW-6356|Single oral dose of KW-6356
75319620|NCT02117999|Device|Cross-linking with iontophoresis|The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.
75319621|NCT02117999|Device|Standard corneal cross-linking|In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
75319622|NCT05362357|Behavioral|iSTART Web-app|30-day substance prevention web-app for students at a Hispanic Serving Institution.
75465580|NCT01897870|Behavioral|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
75620004|NCT04963426|Other|School-level interventions targeting the school environment and system|Depending on the baseline data and prioritization of actions, and based on the Global Standards for Health Promoting Schools, school-level interventions related to the following will be implemented: school policies and resources, school governance and leadership, school and community partnerships, school curriculum, school social-emotional environment, school physical environment, school health services
75319623|NCT04457297|Drug|trifluridine and tipiracil|Trifluridine and tipiracil will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
75319624|NCT04457297|Drug|Placebo|Placebo will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
75319625|NCT05362279|Other|Training|"One month after the pre-test, the post-test will be administered to the nurses who will be in the control group.~Nurses who will be in the experimental group will be given training after the pre-test. A post-test will be administered one month after the training."
75465581|NCT01897961|Other|Anticorps anti-PLA2R1|
75465582|NCT01898065|Drug|18-F-MISO|PET scan with the 18 Fluoro Misonidazole
75465583|NCT01898221|Drug|Ethanol|We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a ~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
75465584|NCT01898221|Procedure|Ablation|The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
75465585|NCT01898338|Drug|Fosfomycin 2gr/6h iv|
75465586|NCT01898338|Drug|Daptomycin 10mg/kg/24h iv|
75465587|NCT01898572|Other|Standard care|Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
75465588|NCT01898897|Procedure|epidural catheter insertion|A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
75465589|NCT01898897|Procedure|robot assisted laparoscopic urogenital surgery|The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
75465590|NCT01898936|Procedure|Pretreatment with CO2 laser before photodynamic therapy|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.~The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours."
75465591|NCT01898936|Device|Only photodynamic therapy|
75465592|NCT01899001|Behavioral|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
75465593|NCT01899001|Behavioral|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
75465594|NCT01899105|Drug|lumacaftor|
75465595|NCT01899105|Drug|ivacaftor|
75465596|NCT01899456|Device|Catheter-based renal denervation|
75465597|NCT01899469|Procedure|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
75620005|NCT01091454|Drug|brostallicin|Given IV
75620006|NCT01091454|Drug|cisplatin|Given IV
75620007|NCT01140347|Biological|Placebo|8 mg/kg IV every 2 weeks
75620008|NCT01140347|Biological|Ramucirumab DP (IMC-1121B)|8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
75620009|NCT01140347|Other|BSC|Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
75319626|NCT04146116|Drug|intranasal povidone-iodine|povidone-iodine USP, 10% w/w antiseptic
75620010|NCT02779114|Drug|Control group|Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
75912092|NCT03042364|Other|Pipelle de Cornier|RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day
75620011|NCT02779114|Other|Reduction group 1|Dose reduction of 50% for 12 months of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
75620012|NCT02779114|Other|Reduction group 2|Dose reduction of 50% of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®) for 6 months and if they are still in remission therapy will be discontinued.
75620013|NCT04227964|Device|Enamel matrix derivative, bone replacement graft, barrier membrane|
75620014|NCT04227964|Procedure|Tooth extraction and replacement|
75620015|NCT02779036|Procedure|Task-oriented home exercise|Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
75620016|NCT02779036|Procedure|Usual Physiotherapy Care|Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
75620017|NCT02878278|Drug|Chidamide BIW|Chidamide is given 30mg, twice a week
75620018|NCT02878278|Drug|Chidamide QD|Chidamide is given 10mg,QD
75620019|NCT02883101|Behavioral|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
75620020|NCT05209126|Dietary Supplement|Beetroot juice|Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
75620021|NCT05224739|Procedure|Minimally Invasive Liver Resection|laparoscopic and robotic liver resections
75620022|NCT04227652|Drug|Ibuprofen administration|Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
75620023|NCT02883569|Procedure|open or endoscopic discectomy|FDA approved surgical procedures
75620024|NCT02883569|Procedure|epidural block|epidural block
75620025|NCT02883569|Other|exercise|educated exercise
75620026|NCT02883569|Drug|ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac|FDA approved medication such as ibuprofen, naxoprofen etc.
75620027|NCT02883569|Procedure|decompression|FDA approved surgical procedure such as lamiectom and, laminotomy
75465598|NCT01899469|Procedure|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
75465599|NCT01899469|Procedure|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
75620028|NCT02883569|Procedure|instrumentation and fusion|FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
75620029|NCT02883569|Drug|codeine, oxycontine, IRcodone, Tramadol|FDA approved opioid drug such as codeine, oxycontin, IRcodon
75620030|NCT02883569|Procedure|epidural adhesiolysis|FDA approved epidural adhesiolysis with catheter or endoscope
75620031|NCT04306224|Biological|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
75620032|NCT02883023|Other|Electrosclerotherapy|Combination of intralesional bleomycin sclerotherapy and electroporation
75620033|NCT02883023|Drug|Intralesional bleomycin injection|Local intralesional injections with bleomycin
75620034|NCT02778958|Drug|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
75620035|NCT02778958|Drug|ibuprofen|"iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
75620036|NCT01197560|Drug|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
75620037|NCT01197560|Drug|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m^2 IV days 1 and 15 every 28 days for 6 Cycles
75620038|NCT01197560|Drug|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m^2 IV day 1 for 21 days for 6 Cycles
75620039|NCT01197560|Drug|Rituximab|Suggested starting dose for Rituximab is 375 mg/m^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
75651605|NCT05833932|Drug|Suhexiang Pill|Suhexiang Pill is an approved traditional Chinese patent medicine.
75912093|NCT02233218|Drug|Telmisartan|
75912094|NCT02233218|Drug|Amlodipine|
75912095|NCT02233218|Drug|Rosuvastatin|
75912096|NCT03042598|Device|Biphasic Cuirass Ventilation|The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.
75912097|NCT02259504|Other|PHASE 1- HyperSoft® 3D and HyperSoft® Helical Coils|Framing with HyperSoft® 3D or any FDA-approved bare platinum coil. Must fill and finish the the aneurysm with HyperSoft® 3D and/or HyperSoft® helical coils.
75912098|NCT02259504|Other|PHASE 2 - HydroSoft® 3D and HydroSoft® Helical Coils|Framing with HydroFrame® or HydroSoft® 3D coils. Must fill the aneurysm with HydroFrame®, HydroSoft® (3D and/or Helical), and/or HydroFill® Coils and finish with HydroSoft® (3D and/or Helical) Coils.
75912099|NCT04429438|Biological|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after conventional chemotherapy will be treated with multiple 4SCAR gene-engineered T cells
75620040|NCT01197560|Drug|Etoposide|"Suggested starting doses for Etoposide are:~100 mg/m^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-10 every 28 days for 6 Cycles"
75620041|NCT04227418|Device|12 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
75620042|NCT04227418|Device|6 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
75620043|NCT04227418|Device|Hand held ECG monitoring|Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.
75620044|NCT04228666|Biological|HB-adMSCs|Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
75620045|NCT04196140|Device|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
75620046|NCT05199142|Drug|SDI-118|SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
75620047|NCT05199142|Drug|Placebo|The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
75620048|NCT05320978|Device|Hand grip test, computed tomography|A hand grip test, abdominal computed tomography are performed before surgery.
75620049|NCT05315362|Device|solid microneedle skin patch|intradermal vaccination with a skin patch
75620050|NCT05315362|Biological|mRNA-1273|administration of mRNA-1273 vaccine
75620051|NCT05315362|Device|standard needle|intramuscular vaccination with a standard needle
75620052|NCT02778568|Behavioral|Resistance training|Resistance training exercises
75620053|NCT02778568|Behavioral|Control|Stretching exercises
75620054|NCT04227496|Device|Auditory disturbances|A sound will be played from a portable device (smartphone) during movement
75773400|NCT05459974|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg once daily for 30 days after the atrial fibrillation ablation
75773401|NCT05459974|Drug|Placebo|Placebo pill once daily for 30 days after the atrial fibrillation ablation
75620055|NCT01133405|Drug|LY2886721|Oral capsules
75620056|NCT01133405|Drug|Placebo|Oral capsules
75620057|NCT02779816|Device|Pen device|Adaptive pen device
75620058|NCT01196078|Drug|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
75620059|NCT01196078|Drug|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
75620060|NCT05314660|Drug|38 % silver diamine fluoride|Application of 38% SDF on carious dentine lesions.
75620061|NCT05314660|Procedure|Atraumatic restorative technique|Hand excavation of carious dentine followed by application of Glass ionomer
75620062|NCT05314660|Procedure|Ultra conservative dentistry|Removal of soft dentine and enlarging of cavity to control bio film
75620063|NCT05314036|Other|Standardized test meal|During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal.
75773402|NCT03754816|Procedure|PECS II and parasternal block|10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
75773403|NCT03754816|Drug|Levobupivacaine|Levobupivacaine
75773404|NCT04542694|Drug|Favipiravir|200 mg coated tablets
75773405|NCT04542694|Drug|Standard of care|"Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc."
75912100|NCT02262546|Drug|Pramipexole extended-release (ER) tablets|
75912101|NCT02262546|Drug|Pramipexole immediate-release (IR) tablets|
75912102|NCT02262546|Drug|Moxifloxacin|
75912103|NCT02262546|Drug|Pramipexole Placebo|
75912104|NCT02262546|Drug|Moxifloxacin Placebo|
75912105|NCT05626608|Device|Classical ring stimulation|Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
75912106|NCT05626608|Device|Stimulation in directional mode|Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
75912107|NCT05623878|Drug|68Ga-labeled NY108|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY108.
75912108|NCT04859374|Behavioral|Mindfullness|Behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
75912109|NCT04859374|Drug|treatment as usual (TAU) (pharmacological)|Any pharmacological therapy used for managing chronic pain or chronic migraine
75620064|NCT01133171|Behavioral|Nurse Alone|Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
75620065|NCT01133171|Behavioral|Dashboard Plus Nurse|Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
75620066|NCT01195844|Biological|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children < 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
75773406|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
75620067|NCT02883725|Other|data collection|
75620068|NCT04920292|Drug|Oxfendazole|Oxfendazole is a benzimidazole anthelminthic drug.
75620069|NCT04920292|Drug|Placebo|The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
75620070|NCT02779972|Other|Echo stress test|Echo stress test
75620071|NCT04312685|Device|Prometra II Programmable Pump system - Flowonix Medical|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
75773407|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
75773408|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
75773409|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
75912110|NCT03042052|Drug|detrusor infection of Botulinum toxin|detrusor injection
75912111|NCT01338012|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
75912112|NCT04856098|Drug|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 2 capsules
75912113|NCT04856098|Drug|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 1 capsule
75912114|NCT04856098|Drug|Indacaterol maleate and glycopyrronium bromide|Batch B Ultibro Breezhaler 85/43 μg 2 capsules
75620072|NCT02779738|Drug|Merestinib|Administered orally
75620073|NCT04227262|Other|MIRROR THERAPY|The children were instructed to sitting on chair and a mirror is placed in midsagittal plane of the child, with the normal limb in front of mirror and the affected limb is blocked so the patient see only the reflected movement of the sound limb (non affected).
75620074|NCT01132547|Drug|cyproheptadine hydrochloride|Given orally
75773410|NCT01589328|Other|Early Palliative care integrated with usual oncologic care|"Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
75773411|NCT03965208|Drug|Bivalirudin|titrated continuous infusion
75773412|NCT03965208|Drug|Unfractionated heparin|titrated continuous infusion
75773413|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
75773414|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
75773415|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
75773416|NCT01083342|Drug|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
75773417|NCT00129116|Biological|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
75773418|NCT00129116|Biological|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
75912115|NCT04856098|Drug|Ultibro Breezhaler with oral charcoal|Activated charcoal suspension, granules 50 g / bottle
75912116|NCT05611554|Behavioral|ACT|Psychological intervention focused on (a) values clarification, (b) defusion strategies, (c) training in flexible attention to the present moment (mindfulness), and (d) committed action and psychological acceptance through metaphors and experiential exercises.
75912117|NCT04856254|Procedure|Trial of labor after cesarean section|The pregnant females with history of previous cesarean section will be classified according to clinical and ultrasound score as patient suitable to undergo trial of labor after CS [TOLAC]or not suitable for [TOLAC] so undergo from the beginning to elective repeated cesarean section.
75912118|NCT03041584|Procedure|Guided placement|implant placement with use of guide
75912119|NCT03041584|Procedure|Non-guided placement|conventional implant placement
75912120|NCT03041584|Device|Astra Tech TX implant|
75620075|NCT01132547|Other|placebo|Given orally
75620076|NCT01194830|Drug|Linagliptin|Active drug 1 tablet PO QD
75620077|NCT01194830|Drug|Placebo|1 Tablet PO QD
75620078|NCT05074888|Drug|Prospekta|Oral administration.
75620079|NCT05074888|Drug|Placebo|Oral administration.
75773419|NCT00129116|Biological|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
75773420|NCT00129116|Biological|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
75773421|NCT00129116|Biological|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
75773422|NCT00117156|Drug|Fludarabine|
75620080|NCT04228510|Procedure|2D speckle tracking echocardiography|"Global and segmental strain and strain rate in longitudinal and circumferential directions will be detected after PPCI; before discharge. The LV circumferential strains and strain rates will be determined from the short-axis views at the basal, middle, and apical levels, and longitudinal strains and strain rates will be determined from the apical 2-, 3-, and 4-chamber views of the LV.~Segmental longitudinal strains equal to -15% or closer to 0 will be considered abnormal (injured segments). The average segmental longitudinal strain and strain rate of the abnormal segments is defined as the injury longitudinal strain (InjLS) and injury longitudinal systolic strain rate (InjLSRs)."
75620081|NCT02778334|Other|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~patients who return home and~patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3)."
75620082|NCT02778178|Drug|ropivacaine plus clonidine|20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
75620083|NCT02778178|Drug|Placebo|20 mL saline 0.9%, per side
75620084|NCT02778178|Device|ultrasound|
75620086|NCT04228432|Other|Dedicated and coordinated monitoring|"Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6."
75620087|NCT01194440|Drug|letrozole|Given orally
75620088|NCT01194440|Drug|zoledronic acid|Given IV
75620089|NCT04228588|Drug|Mepolizumab 100 MG [Nucala]|Mepolizumab 100mg, SC, every 4 weeks
75620090|NCT04823052|Drug|Sulindac (HLX-0201), dose strength 1|Sulindac (HLX-0201) Capsule
75620091|NCT04823052|Drug|Sulindac (HLX-0201), dose strength 2|Sulindac (HLX-0201) Capsule
75620092|NCT04823052|Drug|Placebo|Placebo Capsule
75620093|NCT04823052|Drug|Gaboxadol (HLX-0206)|Gaboxadol (HLX-0206) Capsule
75620094|NCT05048992|Other|ELDOA method|group A will receive
75620095|NCT05048992|Other|Post-facilitation stretching|Group B will receive
75620096|NCT04114474|Diagnostic Test|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
75620097|NCT05258500|Other|Ghostly app|For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
75620098|NCT05258500|Other|Blood flow restriction|Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
75620099|NCT05258500|Other|Leaflet|This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
75620100|NCT00951015|Drug|GSK1349572|investigational HIV-1 integrase inhibitor
75620101|NCT00951015|Drug|efavirenz|approved therapy for HIV-1 infection, used as an internal study control
75620102|NCT01139021|Biological|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
75620103|NCT02777866|Drug|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
75773423|NCT00117156|Drug|Rituximab|
75773424|NCT01083420|Drug|Minocycline|Minocycline 0.2% mouthwash
75773425|NCT01083420|Drug|Dexamethasone|Dexamethasone 0.01% mouthwash
75773426|NCT01083498|Device|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
75620104|NCT02777866|Drug|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
75620105|NCT00626262|Drug|Esomeprazole|Oral and Intravenous
75620106|NCT02876796|Drug|GS-0976|Capsule(s) administered orally
75620107|NCT02876796|Drug|Placebo|Capsule(s) administered orally
75620108|NCT02876796|Other|1-13C acetate|10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
75620109|NCT02876796|Other|Fructose solution|Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
75620110|NCT04980820|Other|No mask|The participant is asked to wear no mask for 10 minutes.
75620111|NCT04980820|Device|Filtering face mask 2 (FFP2)|The participant is asked to wear a FFP2 mask for 1 hour during work.
75912121|NCT04905498|Behavioral|Commercial Advertising Literacy Training|"Children were shown food commercials and in between those commercials they saw and heard statements such as These foods won't make you happy and Those foods are so unhealthy."
75912122|NCT04905498|Behavioral|Control|Children were shown food commercials that were the same length as the other group but did not receive any information about whether the content was truthful.
75912123|NCT04859452|Drug|DBPR108 tablets|Drug: DBPR108, tablet, oral
75912124|NCT04859452|Drug|Metformin hydrochloride tablets|Drug: Metformin hydrochloride, tablet, oral
75620112|NCT04980820|Device|Filtering face mask 3 (FFP3)|The participant is asked to wear a FFP3 mask for 1 hour during work.
75620113|NCT02876562|Procedure|root coverage with collagen matrix|the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
75620114|NCT02779660|Procedure|Remote ischemic preconditioning (RIPC)|RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
75620115|NCT02779660|Procedure|sham-intervention|In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
75620116|NCT01193660|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells > 3x10^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
75620117|NCT01193660|Drug|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
75620118|NCT01193660|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
75620119|NCT01193660|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
75620120|NCT01193660|Other|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
75620121|NCT04298814|Other|severe covid-19 pneumonia with ET|severe covid-19 pneumonia undergoing endotracheal intubation
75773427|NCT00096954|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of > 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
75773428|NCT00096954|Drug|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
75773429|NCT00096486|Drug|everolimus|
75773430|NCT00096486|Drug|gefitinib|
75773431|NCT00116844|Drug|Valaciclovir|Valtrex 1g once daily
75773432|NCT00116844|Drug|Placebo|placebo
75773433|NCT03963336|Drug|LMWH|Subcutaneous LMWH 1mg/kg/day for 2 weeks
75773434|NCT03963336|Drug|acetazolamide|Carbonic anhydrase inhibitor 1-2g/day for 6 months
75773435|NCT00128492|Drug|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
75773436|NCT03966794|Device|Epidural Electrical Stimulation|Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
75773437|NCT03966794|Combination Product|Functional scaffold & Epidural Electrical Stimulation|Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
75773438|NCT00132314|Drug|IM risperidone|long-acting injectable risperidone
75773439|NCT00132314|Drug|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
75773440|NCT04539262|Drug|Remdesivir (RDV)|Administered as an aerosolized solution
75773441|NCT04539262|Drug|Placebo|Administered as an aerosolized solution
75773442|NCT03754738|Device|Balloon guide catheter|Use a balloon guide catheter in the mechanical thrombectomy
75773443|NCT03754738|Device|Non-balloon guide catheter|Use a non-balloon guide catheter in the mechanical thrombectomy
75912125|NCT04859452|Drug|Glibenclamide tablets|Drug: Glibenclamide, tablet, oral
75912126|NCT04859452|Drug|Valsartan Capsules|Drug: Valsartan, capsule, oral
75912127|NCT04859452|Drug|Simvastatin tablets|Drug: Simvastatin, tablet, oral
75912128|NCT04859140|Other|Psychometric ratings (Likert-scale)|Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)
75912129|NCT04859140|Behavioral|Range of motion measures|Sit-and-reach and toe touch tests
75912130|NCT04859140|Behavioral|Mental calculation task|Iterated substractions (for 2 minutes)
75912131|NCT04859140|Device|Resting-state electroencephalography|Alpha and beta oscillation power (4 minutes recordings)
75912132|NCT04859140|Device|Resting-state galvanic skin resistance measures|Skin conductance during the resting state period
75912133|NCT04881162|Device|NOVIS Transcarotid Neuroprotection System (NPS)|The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
75912134|NCT02262624|Drug|Telmisartan|
75620122|NCT02778022|Behavioral|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
75465600|NCT01899547|Procedure|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
75620123|NCT04306068|Other|Plyometric protocol|"Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets."
75620124|NCT02777788|Drug|JinFuKang|treated with chemotherapy
75620125|NCT02777788|Drug|XingZaoRuanJian|treated with chemotherapy
75620126|NCT02777788|Drug|pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin|
75620127|NCT02856009|Other|completion of a quality of life questionnaire|
75620128|NCT01076166|Drug|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
75620129|NCT00631059|Other|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
75620130|NCT02777710|Drug|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
75773444|NCT03702010|Device|spinal cord stimulation conventional|If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.
75773445|NCT03702010|Device|spinal cord stimulation experimental|If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.
75773446|NCT04538170|Behavioral|pain after surgery|
75912135|NCT02262624|Drug|Hydrochlorthiazide (HCTZ)|
75465601|NCT01899547|Procedure|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
75773447|NCT04537234|Biological|High-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
75773448|NCT04537234|Biological|Standard-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
75773449|NCT04537078|Drug|Duphaston|will be used for pituitary suppression in the first arm:20 mg/day will be started from the first day of the ovulation induction in the follicular phase and in the luteal phase will be started the next day after oocyte pickup at 20 mg/day.
75773450|NCT04537078|Drug|Gonadotropin|will be used for controlled ovarian hyperstimulation in both arms
75773451|NCT04537078|Drug|Cetrotide Injectable Product|will used in the second arm for pituitary suppression in the second group daily when the biggest oocyte reaches size 14 mm till ovulation triggering
75773452|NCT04537078|Drug|Decapeptyl|will be used for ovulation triggering.in the first arm:in a dose of 2 ampules of 0.2 mg will be administered when leading follicle >18 mm in diameter. in the second arm:in a dose of 2 ampules 0.2 mg will be administered when leading follicle >18 mm in diameter in the first cycle only.
75912136|NCT02262624|Drug|Telmisartan/HCTZ fixed combination|
75912137|NCT02605044|Drug|Masitinib (AB1010)|
75912138|NCT02605044|Drug|FOLFIRI|
75912139|NCT04856410|Other|Spaceflight|Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.
75912140|NCT04856410|Other|Controls|No intervention
75912141|NCT04757298|Behavioral|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
75465602|NCT01899599|Drug|PankoMab-GEX|start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
75465603|NCT01899599|Drug|Placebo|start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
75465604|NCT01899664|Procedure|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
75620131|NCT02777710|Drug|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
75620132|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~4 doses starting from 121 to < 212 days of age"
75773453|NCT04537078|Drug|Chorionic Gonadotropin|will be used in the second cycle of the second arm for ovulation triggering in a dose of 10,000 IU when the leading follicle >18 mm in diameter.
75773454|NCT04537078|Drug|Combined Oral Contraceptive|luteal phase priming from day 21 of the cycle before controlled ovarian stimulation for one week .
75620133|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~3 doses starting from 212 days to < 12 months of age"
75620134|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~2 doses starting from 12 months to < 24 months of age"
75620135|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~1 dose starting from 24 months to < 72 months of age"
75620136|NCT00602901|Other|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
75773455|NCT04537078|Drug|Cyclo-Progynova|Starting from cycle Day 3 of the intented cycle for thawed embryo transfer, patients will receive the white tablets of Cyclo-Progynova daily. From Day 10 onwards, endometrium growth will be monitored by transvaginal ultrasound.
75773456|NCT04537078|Drug|progesterone|in the intended cycle of embryo transfer when endometrial thickness ≥ 7 mm. Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after embryo transfer and in pregnant cases will continued till the 12 weeks of gestation.
75773457|NCT04532164|Drug|Butenafine HCl 1% (BAY1896425) - Induction Phase|To each of two test sites, approximately 20 μl/cm^2 of the Butenafine HCl 1% was applied directly to the skin and covered with a 25 mm Hilltop chamber with a Webril pad (2 cm in diameter, within an area of approximately 3 cm^2), and tape was applied over the chamber to secure the occlusive patch to the skin. On the next day, the chambers were removed and both test sites were lightly wiped. Approximately 2 μl/cm^2 of Butenafine HCl 1% was reapplied directly to the skin and lightly spread over the treated irradiated test site. The treated non-irradiated test site did not receive a similar reapplication. Between 5 and 15 minutes after application, the treated irradiated test site was irradiated with two times the subject's Minimal Erythema Dose (MED). Evaluation of the test sites occurred two days after the irradiation. This procedure was repeated two times per week for three consecutive weeks for a total of 6 induction exposures per test site.
75773458|NCT04532164|Drug|Butenafine HCl 1% (BAY1896425) - Challenge Phase|5 μl/cm^2 of the Butenafine HCl 1% was applied directly to each of the two virgin sites (treated sites) adjacent to the induction patch sites and covered with Hilltop chambers with Webril pad and tape was applied over the chambers to secure the occlusive patches to the skin. Two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Sites were at least 2.5 cm apart. The patches were removed 24 hours later and the sites were lightly wiped. Test sites were evaluated. Butenafine HCl 1% (2 μl/cm^2) was applied to the treated irradiated site. After 15 minutes, the treated irradiated site and the untreated irradiated site were irradiated with 0.5 MED of UVA/UVB irradiation followed by 10 Joules/cm^2 of UVA from a xenon arc solar simulator equipped with a Schott WG345 to eliminate UVB radiation. The remaining sites served as the treated non-irradiated site and untreated non-irradiated site.
75773459|NCT01561924|Drug|eptacog alfa (activated)|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
75773460|NCT00116688|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
75773461|NCT04531540|Drug|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.
75773462|NCT04799782|Drug|Mirtazapine|15 mg dose before bed-time
75773463|NCT04799782|Drug|Placebo|One placebo pill before bed-time
75773464|NCT04790812|Drug|Celecoxib|Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
75773465|NCT04790812|Drug|Acetaminophen|Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
75912142|NCT04757298|Behavioral|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
75620137|NCT00602901|Other|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
75620138|NCT00602901|Drug|Usual medical care|Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
75773466|NCT04790812|Drug|Placebo|A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
75620139|NCT04874350|Drug|LPCN 1148|LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
75773467|NCT03754504|Dietary Supplement|Cranberry powder|3 capsules /day of whole cranberry powder (500mg/each)
75912143|NCT04757298|Behavioral|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
75620140|NCT04874350|Drug|Placebo|Oral matching placebo capsule
75620141|NCT00945477|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
75319627|NCT05362201|Procedure|therapeutic position of the anterior repositioning splints|the ADDWR paricipants will be allocated into 2 grounps and treated with anterior repositioning splints determined by traditional and digitial method respectively.
75465605|NCT01899716|Other|Exercise|
75773468|NCT03754504|Dietary Supplement|Placebo|3 capsules/day of a placebo comparator
75620142|NCT02777398|Procedure|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
75773469|NCT03697252|Drug|Xanomeline and Trospium Chloride Capsules|Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
75773470|NCT03697252|Drug|Placebo Capsules|Placebo Capsules
75465606|NCT01900015|Drug|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
75465607|NCT01900015|Drug|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
75773471|NCT03701074|Drug|Ibuprofen and acetaminophen|Intravenous ibuprofen given concomitantly with oral acetaminophen
75773472|NCT03701074|Drug|Ibuprofen and placebo|Intravenous ibuprofen given concomitantly with oral placebo
75773473|NCT03757468|Device|orthodontic - maxillary expansion|After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
75912144|NCT04757298|Behavioral|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.
75912145|NCT04428892|Behavioral|Pedagogyc Strategy|Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.
75912146|NCT04712526|Device|AEON Endostapler|Surgery with AEON Endostapler
75912147|NCT02607280|Drug|DS-5565|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
75319628|NCT02119871|Procedure|Bilateral Open Pleurae|Both pleurae are opened Right pulmonary vein drainage
75319629|NCT02119871|Procedure|Right Pleura Open|Right pleura open Left ventricular apical drainage
75319630|NCT04147598|Other|LFD|Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.
75319631|NCT04147598|Other|SAD|Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
75465608|NCT01900028|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
75620143|NCT02777398|Procedure|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
75465609|NCT01900028|Drug|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
75465610|NCT01900028|Drug|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
75465611|NCT01900041|Drug|Pantovigar|1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
75465612|NCT01900041|Drug|Minoxidil 2% only|1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
75465613|NCT01900080|Other|Same-Day HIV testing and ART initiation|Same-day HIV testing and ART initiation
75465614|NCT01900080|Other|Standard ART Initiation|Standard ART Initiation
75465615|NCT01900080|Other|Sub-Study: Same-Day ART, CD4 Count >500|Same-day CD4 count and ART initiation for patients with CD4 count >500 cells/mm3 (CD4 count within 7 days of HIV test)
75620144|NCT01135719|Procedure|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
75620145|NCT01076088|Drug|Sitagliptin 50 mg|Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
75620146|NCT01076088|Drug|Metformin 500 mg|Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
75620147|NCT01076088|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
75620148|NCT01076088|Drug|Placebo|Matching placebo tablets to sitagliptin or metformin for 24 weeks.
75773474|NCT03754348|Radiation|PET scan with tracer injection [18F] DPA-714|the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
75773475|NCT01322620|Other|No treatment given|No treatment given. Participants are to complete a questionnarie in the study.
75620149|NCT01076088|Drug|Metformin 850 mg|Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
75773476|NCT03754192|Radiation|perfusion Computed Tomography|Will be carried before liver surgery
75912148|NCT02233374|Other|Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI & ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
75912149|NCT02233374|Other|Late MRI and PET/CT 6 weeks post chemo/RT|Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI & ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
75912150|NCT02233452|Drug|Methadone|The solution of methadone was prepared by mixing 10 ml of methadone (10 mg/ml) and 90 ml of saline 0.9% (Baxter, São Paulo, Brazil)
75620150|NCT05021458|Other|Gong's mobilization|Ten patients will be treated with Gong's mobilization.
75773477|NCT03757390|Drug|Exforge® tab 5/160mg, Crestor® tab 10mg|co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
75773478|NCT03757390|Drug|CJ-30060 5/160/10mg|Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
75912151|NCT02233452|Drug|Ketamine|The solution of ketamine was prepared by mixing 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 80 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 10 mg/ml of ketamine.
75912152|NCT02233452|Drug|Methadone plus Ketamine|the solution of methadone, ketamine was prepared by mixing 10 ml of methadone hydrochloride (10 mg/ml, Cristália®, São Paulo, Brazil), 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 70 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 1 mg/ml of methadone and 10 mg/ml of ketamine.
75319632|NCT02130583|Behavioral|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
75319633|NCT02130583|Behavioral|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
75319634|NCT04145804|Device|Medtronic Minimed 670G insulin pump|It is an insulin pump to deliver insulin to the patient and associated with a sensor to monitor the glucose levels of the patient. The new feature in this device is the automode algorithm which regulates insulin delivery to the patient automatically to keep glucose levels within target.
75319635|NCT02120261|Drug|Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
75620151|NCT05021458|Other|SNAG|: Ten patients will be treated with SNAGs
75620152|NCT02776462|Device|EyeBox CNS|
75620153|NCT02776384|Other|Observational study|
75620154|NCT02777632|Procedure|Living donor liver transplantation|
75620155|NCT02777320|Drug|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
75773479|NCT01322698|Biological|Tests for candidiasis|Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
75620156|NCT02777320|Drug|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
75620157|NCT04226560|Device|41% Silicone Hydrogel Soft Contact Lenses(SHSCL)|Silicone Hydrogel
75620158|NCT04226560|Device|ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens|Senofilcon C (USFDA Device License #K160212)
75620159|NCT04226560|Other|Contact Lens Care Product|Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
75620160|NCT04226560|Other|Contact Lens Case|"Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)"
75773480|NCT03753958|Procedure|Conventional treatment|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
75620161|NCT01193348|Drug|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
75620162|NCT00945321|Drug|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
75773481|NCT03753958|Radiation|aPDT|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
75773482|NCT03753880|Device|HEMOPATCH Sealing Hemostat|Hemopatch sealing hemostat used after LR to cover the resection surface
75773483|NCT05458804|Device|VR training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different paces and intensities of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
75773484|NCT03753802|Other|Chest Physiotherapy|During sessions, the child is lying on the back, he should not have eaten within two hours prior to the sessions. An extended slow expiration handling is performed on 3 respiratory cycles consecutive, this session is repeated for 10 minutes. Breaks are made regularly during the treatment to have approximately 5 to 6 minutes of handling and 4-5 minutes of rest on the total 10 minutes of treatment. Induced cough handlings will be conducted at five minutes and at ten minutes if the child has not coughed during the movements of chest physiotherapy. These are performed by a brief pressure above the jugular (suprasternal) notch of the patient. Only two consecutive trials of the induced cough handling are allowed, even if the handlings are unsuccessful the physiotherapist does not insist. The following 5 minutes of the session are 5 minutes of rest. During the sessions the physiotherapist wears a mask and respects the usual rules of hygiene.
75773485|NCT03753802|Other|Surveillance|The session is only a surveillance session with the physiotherapist. The physiotherapist is only watching over the child. The parents of the child wait in the waiting room during the physiotherapy session. They don't know which treatment (chest physiotherapy or no treatment) is applied to their child.
75773486|NCT03757156|Other|Withdrawal of aspirin|People who are taking aspirin stop to taking aspirin.
75620163|NCT00945321|Drug|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
75773487|NCT05401240|Behavioral|information reveal|the experimental group will be informed that there will be an important examination about his/her cardiopulmonary fitness condition at the outpatient department (OPD)
75773488|NCT04728802|Drug|Proxalutamide|Proxalutamide 300mg q.d
75773489|NCT04728802|Drug|Placebo|Placebo pill
75773490|NCT03757078|Drug|Relief Pro cream|Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.
75773491|NCT03757078|Drug|Relief Pro rectal suppositories|Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
75773492|NCT03750916|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
75773493|NCT05322148|Drug|Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free|A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.
75773494|NCT03750760|Drug|Alirocumab|PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
75773495|NCT03750760|Drug|Atorvastatin 80mg|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
75773496|NCT03750760|Drug|Ezetimibe 10mg|Cholesterol absorption inhibitor
75773497|NCT01076894|Procedure|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
75912153|NCT04846660|Other|Production pressure|Participant exposed to production pressure
75912154|NCT02262702|Drug|Paracetamol 665 mg|Paracetamol 665 mg tablet
75912155|NCT02262702|Drug|Paracetamol 500 mg|Paracetamol 500 mg tablet
75912156|NCT04846894|Diagnostic Test|Ga-68 PSMA-11 PET/CT imaging|Sequential PET/CT imaging using analog and digital PET/CT scanners after single intravenous injection of Ga-68 PSMA-11
75465616|NCT01900080|Other|Sub-Study: Standard Pre-ART Care, CD4 Count >500|Standard pre-ART care for patients with CD4 count >500 cells/mm3
75465617|NCT01900093|Drug|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
75465618|NCT01900106|Drug|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
75465619|NCT01900106|Drug|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
75465620|NCT01900158|Drug|Amphinex, Gemcitabine and Cisplatin|Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, for up to a total of eight cycles. Either one or two PCI treatments (Amphinex, Gemcitabine and intraluminal laser light of 652nm) during the 8 cycles of chemotherapy
75465621|NCT01900171|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
75620164|NCT00945321|Drug|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
75620165|NCT00945321|Drug|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
75620166|NCT02776228|Drug|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
75620167|NCT02776228|Drug|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
75620168|NCT04990492|Diagnostic Test|Paper GAD 7|The paper based GAD 7 that is commonly accepted at clinics
75620169|NCT04990492|Diagnostic Test|Voice Administered GAD 7|This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
75620170|NCT00631215|Procedure|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
75620175|NCT00945243|Device|Zero-P|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
75620176|NCT01192412|Procedure|Intervention is blood pressure management approach|1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is >105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP <100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
75773498|NCT01076894|Procedure|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
75319636|NCT02120261|Drug|Lidocaine Hydrochloride|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
75319637|NCT02120261|Drug|Triamcinolone acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
75773499|NCT04715932|Drug|Hesperidin|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
75319638|NCT00492089|Drug|bevacizumab|Given IV
75319639|NCT00492089|Drug|placebo|Given IV
75319640|NCT00492089|Procedure|magnetic resonance imaging|
75319641|NCT00492089|Procedure|quality-of-life assessment|
75319642|NCT04319783|Drug|Darolutamide|Darolutamide alone
75319643|NCT04319783|Radiation|Radiotherapy|Darolutamide + Consolidation Radiotherapy
75465622|NCT01900171|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
75465623|NCT01900184|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
75465624|NCT01900184|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
75465625|NCT01900197|Drug|10% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
75465626|NCT01900210|Behavioral|WaySafe|
75465627|NCT01900236|Behavioral|Based on behavioral motivational interviewing (MI) technique|In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
75620177|NCT01192412|Procedure|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is <80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is >85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
75620178|NCT04226092|Device|GPSkin Barrier Pro|This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).
75773500|NCT04715932|Drug|Placebo|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
75773501|NCT00130832|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
75465628|NCT01895179|Other|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
75773502|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV)|Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
75773503|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV) (staggered)|Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
75773504|NCT00096018|Drug|fludarabine phosphate|Given IV
75773505|NCT00096018|Drug|thalidomide|Orally
75773506|NCT04713748|Device|Tasso-SST on Demand|Participants will collect a small blood sample using the Tasso-SST OnDemand device during a serology blood draw visit already scheduled for the MURDOCK C3PI Study (Pro00105703). Participants will be provided a kit that includes written, step-by-step instructions that include pictures. Participants will also have the option to watch a brief video on using the device, available online, prior to collection. Both blood samples will be spun and processed for serum. Serum will be frozen and shipped to the lab at Duke for antibody testing. Antibody results will be compared between the two methods.
75773507|NCT04713748|Other|Regular Phlebotomy|Participants will have a small blood sample collected via regular venipuncture.
75773508|NCT01079754|Drug|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
75773509|NCT01079754|Drug|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
75773510|NCT03757000|Drug|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
75773511|NCT03750604|Diagnostic Test|visceral fat obesity (surface area and function)|"WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein"
75773512|NCT04702984|Device|LID021201 contact lenses|Investigational silicone hydrogel sphere contact lenses for frequent replacement daily wear
75912157|NCT05571696|Behavioral|Immune Strength|Immune Strength is a 12 week online program that provides content, strategies, and guidance on how to improve your immune system and increase your mental wellbeing, with a focus on stress, sleep, nutrition, and exercise. In addition to the online program, each participant will be paired with a Cleveland Clinic Coach who will communicate with the participant via email. The Coach will help guide the participant throughout the program and provide encouragement and guidance for making behavior changes for making a more resilient immune system.
75912158|NCT03041662|Diagnostic Test|MR/MRCP|MR/MRCP
75773513|NCT04702984|Device|OPTI-FREE multipurpose solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
75773514|NCT04701658|Drug|Bamlanivimab|Administered intravenously.
75773515|NCT03750526|Behavioral|rTMS and AR|rTMS performs 1Hz,15 minutes real rTMS. AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
75912159|NCT04846192|Other|Nutritional evaluation|Collecting existing data on pre operative nutritional status and outcomes after surgery
75319644|NCT01798537|Drug|Neomycin Colistin Nystatin Vancomycin|All participating study arm patients will receive SDD from admission to discharge
75773516|NCT03750526|Behavioral|Sham rTMS and AR|Sham rTMS applies 1Hz, 15 minutes sham rTMS. AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
75773517|NCT03750526|Behavioral|AR|AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.
75773518|NCT03750526|Behavioral|Conventional physiotherapy|Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
75773519|NCT03756922|Drug|FDL169|CFTR corrector
75773520|NCT03756922|Drug|FDL176|CFTR potentiator
75773521|NCT01322776|Drug|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m^2 i.v. on days 1~3 of each 28-day cycle cyclophosphamide i.v. on days 1~2 of each 28-day cycle
75465629|NCT01895179|Other|Grazing|Grazing involves eating meals spread out over the course of the day.
75465630|NCT01900262|Other|Strengthening|Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.
75465631|NCT01900262|Other|Balance Training|Participants will be asked to compete 8 weeks of functional balance training at home.
75465632|NCT01900262|Other|Stretching|Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
75465633|NCT01900275|Other|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
75465634|NCT01900288|Behavioral|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
75773522|NCT03756844|Behavioral|Just Right Challenge Food Club|Systematic desensitization, positive reinforcement and escape extinction at a level of just right challenge.
75912160|NCT04477044|Other|Study Group|GoPro Hero4 to be mounted on the participant's forehead while performing intubation on a manikin.
75912161|NCT04840576|Other|Regular waterproof sterile dressing.|Waterproof sterile dressing OPSITE Post-Op Visible, Smith & Nephew, UK
75912162|NCT04840576|Other|Prophylactic Negative Pressure Dressing|Negative wound pressure dressing: PICO-7, Smith & Nephew, UK
75620179|NCT04226092|Device|Aquaflux AF200|This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).
75620180|NCT04868578|Dietary Supplement|study treatment PPI|patient take PPI every day during 12 months
75620181|NCT04868578|Dietary Supplement|Placebo comparator|patient take PPI placebo every day during 12 months
75620182|NCT02777164|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
75620183|NCT01192178|Drug|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
75620184|NCT01192178|Drug|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
75620185|NCT02777008|Drug|CTP-543|
75620186|NCT02777008|Drug|Placebo for CTP-543|
75620187|NCT02855775|Other|additional blood sample|blood sample every 3 weeks
75620188|NCT02775994|Drug|Canakinumab|interleukin beta (IL-1) antagonist
75620189|NCT01192100|Behavioral|Breakfast Skipping|Participants will continue to skip breakfast each morning.
75620190|NCT01192100|Behavioral|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
75620191|NCT01192100|Behavioral|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
75319648|NCT04765826|Procedure|Autologous mini punch grafting|"All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included.~. Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local inﬁltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site"
75465635|NCT01900288|Behavioral|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
75465636|NCT01900301|Drug|Scopolamine|Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
75620192|NCT04193566|Drug|Forxiga|"Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin."
75620193|NCT00869401|Drug|dasatinib|Given orally
75620194|NCT00869401|Drug|temozolomide|Given orally
75620195|NCT00869401|Other|placebo|Given orally
75620196|NCT00869401|Radiation|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
75620197|NCT04226482|Device|New Device|Laparoscopic appendectomy using new ultrasonic shears.
75620198|NCT04226482|Device|Used Device|Laparoscopic appendectomy using reprocessed ultrasonic shears.
75620199|NCT04823104|Other|Home visitation|Home visitation for pregnancy follow-up
75620200|NCT01076010|Drug|Tivozanib|Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
75620201|NCT01076010|Drug|Sorafenib|Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
75620202|NCT02775838|Drug|Indocyanine green|perioperative application of Indocyanine green (ICG)
75620203|NCT04122391|Other|sound level volume|Noise level during cardiac arrest
75912163|NCT04476498|Procedure|Pull-PEG with Gastropexy|Additionally to a conventional pull-PEG a gastropexy will be performed.
75465637|NCT01900301|Drug|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
75465638|NCT01900327|Radiation|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
75620204|NCT02776852|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number: SR15-43-Y65-158)
75620205|NCT02775604|Behavioral|Video based/Therapists' rating of comprehensive-home-fall-hazard-checklist (vt-CHFHC)|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
75620206|NCT02775604|Behavioral|Paper based/Patient self-rating of comprehensive-home-fall-hazard-checklist (pp-CHFHC)|A paper version of CHFHC and other self-reported documents will be completed by the participants in their homes based on standardized verbal instruction provided by the research staff.
75620207|NCT04305990|Device|Demand-driven delivery method|The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.
75620208|NCT04305990|Device|Free-flow delivery method|The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
75912164|NCT04840420|Other|social prescribing|as above
75620209|NCT02614651|Procedure|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
75773523|NCT03750214|Device|Biop Colposcopy System|"The procedure stages:~Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~A questionnaire completed by the user after the Biop procedure, with regards to system usage~Image Registration analysis"
75773524|NCT04877470|Other|Consultation at spine-centre|All patients who visited the spine-centre for the first time in 2019 are included in this group.
75773525|NCT00128102|Drug|Vorinostat|Vorinostat 100 mg oral capsules
75773526|NCT00128102|Drug|Placebo|Vorinostat-matching placebo oral capsules
75773527|NCT03965858|Drug|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
75319650|NCT03692221|Drug|MSC Treatment group 1 (low dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
75465639|NCT01900327|Drug|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
75465640|NCT01900327|Procedure|Surgery|Upfront pancreato-duodenectomy
75773528|NCT03965858|Drug|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
75773529|NCT03965858|Drug|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
75465641|NCT01900327|Drug|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
75773530|NCT03965858|Drug|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
75773531|NCT03965780|Other|SPIN-SSLED Program|"The SPIN-SSLED Program is a 3-month-long (13 sessions) group training program designed to be delivered via videoconferencing to provide information and skills to improve leader support group leaders' confidence and self-efficacy to carry out their leadership roles and reduce the burden on them of leading a support group. Each session is about 90 minutes long and covers one of the 13 modules of the program.~Module topics includes: (1) The Leader's Role; (2) Starting a Support Group; (3) Structuring a Support Group Meeting; (4) Scleroderma 101; (5) Successful Support Group Culture; (6) Managing Support Group Dynamics; (7) Loss and Grief: The support group leader; (8) Loss and Grief in Scleroderma: Supporting group members; (9) Advertising and Recruitment for the Support Group; (10) The Continuity of the Group; (11) Supporting Yourself as a Leader; (12) Remote Support Groups; and (13) Transitions in Support Groups."
75773532|NCT04668274|Drug|200 mg resveratrol as JOTROL|Low (first) dose of single ascending dose study
75773533|NCT04668274|Drug|500 mg resveratrol as JOTROL|Second (intermediate) dose of single ascending dose study
75773534|NCT04668274|Drug|700 mg resveratrol as JOTROL|Third (highest) dose of single ascending dose study
75773535|NCT04668274|Drug|500 mg resveratrol as JOTROL administered to assess influence of food|500 mg resveratrol as JOTROL administered to assess influence of food
75773536|NCT01077908|Biological|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
75465642|NCT01900340|Dietary Supplement|Saline|Intravenous saline infusion and intraduodenal administration of saline via feeding tube
75773537|NCT01077908|Drug|Best available antiviral drug therapy|"Intravenous ganciclovir 5mg/kg twice daily~Oral valganciclovir 900mg twice daily~Intravenous foscarnet 90 mg/kg twice daily"
75773538|NCT03750058|Device|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
75912165|NCT04840420|Other|usual care|as above
75912166|NCT04845880|Diagnostic Test|Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2|Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
75912167|NCT04600752|Drug|Augmentin (ES)-600|Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.
75912168|NCT04840810|Procedure|In-plane Axis|"In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis."
75319651|NCT03692221|Drug|MSC Treatment group 2 (high dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
75319652|NCT03692221|Other|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
75319653|NCT04140422|Other|Hyperosmolar eye drops|Application of one preservative-free hyperosmolar eye drop, when waking up and one eye drop 30 min later to one eye by the investigators
75319654|NCT04140422|Other|Placebo|Application of one preservative-free lubricating eye drop, when waking up and one eye drop 30 min later to the fellow eye by the investigators
75319655|NCT01797809|Drug|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
75319656|NCT04145882|Procedure|additional osteotomies|varisation osteotomy, supination osteotomy or both
75319657|NCT01797341|Drug|Tacrolimus|
75319658|NCT01797341|Drug|Tacrolimus|
75319659|NCT04145570|Drug|Erlotinib HCl 150 mg|"Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.~dosing in each period."
75319660|NCT04145570|Drug|Tarceva®|Tarceva® 150 mg
75465643|NCT01900340|Drug|Exendin 9-39|IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
75773539|NCT04406194|Drug|FAVICOVIR 200 mg Film Tablet|FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.
75773540|NCT04406194|Drug|AVIGAN 200 mg Film Tablets|AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
75620210|NCT02614651|Procedure|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
75773541|NCT03822884|Drug|Epoetin Alfa 40000 UNT/ML|40.000 UI subcutaneous single dose
75773542|NCT03822416|Drug|Nicotine patch|Nicotine patch (dose based on number of cigarettes per day) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
75773543|NCT03822416|Drug|Nicotine lozenge|Nicotine lozenge (2 or 4 mg if less or greater than 30 minutes to first cigarette in the morning respectively) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
75773544|NCT03822416|Behavioral|Therapy|In-person meeting at baseline, 6 phone counseling sessions with participants over 8 weeks after initial in-person meeting, possible additional phone counseling (3 phone calls) from 8 weeks to 6 months after initial in-person meeting, and possible text messages when agreed to by participants during the 8 week to 6 month phase
75773545|NCT03822416|Other|Information|Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
75773546|NCT04405570|Drug|Molnupiravir 200 mg|Oral capsule of molnupiravir
75620211|NCT02614651|Procedure|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
75773547|NCT04405570|Drug|Molnupiravir 400 mg|Oral capsule of molnupiravir
75773548|NCT04405570|Drug|Molnupiravir 800 mg|Oral capsule of molnupiravir
75319661|NCT05353387|Other|Motivational Interviewing|Motivational Interviewing will be carried out in 3 different sessions, each to be conducted one week apart. 6 weeks after the last interview, first follow up would be conducted through phone communication and 6 weeks after the first follow up, a face-to-face interview would be conducted for the scales to be applied to the participants again.
75465644|NCT01900340|Dietary Supplement|Saline|IV saline infusion and intraduodenal administration of nutrients
75773549|NCT04405570|Drug|Placebo (PBO)|placebo oral capsule
75773550|NCT01080092|Behavioral|breathing technique|breathing technique as a stress management technique, reinforced by biofeedback
75773551|NCT01080092|Behavioral|behavioral strategies|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
75773552|NCT00127712|Drug|Amiodarone|
75319662|NCT04145492|Drug|Vitamin K2|Patients will take 90 ug of vitamin K2
75319663|NCT04145492|Drug|Cholecalciferol (inactive vitamin D)|Patients will take 10 ug of vitamin inactive vitamin D
75465645|NCT01900340|Drug|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
75319664|NCT04145492|Drug|Vitamin K2 and Cholecalciferol|Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D
75465646|NCT01900353|Other|brushing methods|
75773553|NCT01322854|Radiation|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
75773554|NCT01082744|Drug|Ropivacaine + Sufentanil|Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
75465647|NCT01900366|Procedure|Fat Biopsy|Fat biopsy
75465648|NCT01900379|Procedure|CPAP treatment|This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
75773555|NCT01082744|Drug|Ropivacaine|Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
75773556|NCT04404010|Other|Immersive Virtual Reality|Participants randomized to the iVR simulator utilizes a head-mounted display producing 3D visuals with haptic controllers for an immersive operating room experience. The module produced consists of the key steps in performing a reverse shoulder arthroplasty using virtual versions of the equipment used in the real procedure. Prior to initiation, participants will be provided with a safety and training demonstration on the use of the VR module by study personnel. Participants will be provided as much time as they require to watch the video, including repetition if desired, which they will be timed for completion.
75773557|NCT04404010|Other|Surgical Technical Instructional Video|Participants will be provided as much time as they require to watch the instructional video, including repetition if desired, which they will be timed for completion.
75773558|NCT03748030|Radiation|Confirmed Left-Sided Breast Cancer|Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
75319665|NCT05352217|Device|Mobile app ovarian cancer followup (ePRO)|The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.
75319666|NCT00548171|Biological|Boostrix™|Intramuscular injection, 1 dose
75319667|NCT04147754|Procedure|Epidural anesthesia|Preoperative epidural anesthesia at physician discretion
75319668|NCT04147754|Procedure|Intrathecal morphine|Preoperative intrathecal morphine at physician discretion
75465649|NCT01900379|Other|Sham CPAP treatment|This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
75465650|NCT01900405|Drug|Dexmedetomidine|
75465651|NCT01900418|Behavioral|Walk with Ease|An evidence-based walking program
75465652|NCT01900457|Other|electromyography|
75465653|NCT01900457|Other|electroencephalography|
75465654|NCT01900457|Other|approaches from psychophysics|
75620212|NCT02614651|Procedure|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
75620213|NCT02614651|Device|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
75319669|NCT04147754|Procedure|Erector spinae block|Preoperative erector spinae block at physician discretion
75620214|NCT04225780|Drug|Low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.
75620215|NCT04045171|Drug|Tacrolimus|Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months
76072741|NCT04602169|Procedure|PVI|PV re-isolation will be conducted according to the CLOSE-protocol. Point-by-point radiofrequency (RF) delivery will be performed aiming for a contiguous circle enclosing all PVs. RF will be delivered in a power-controlled mode (without ramping) using 35-40 Watt. The irrigation rate will be set at 30 ml/min. RF will be delivered until an ablation index (AI) of ≥400 is reached at the posterior wall and ≥550 at the anterior wall. In case of dislocation, a new RF application reaching the AI target will be applied. Maximal intertag distance between two neighboring lesions is 6 mm. In case of intra-esophageal temperature (T°) rise >38.5°C during posterior LA wall ablation, RF delivery will stopped at an AI of 300. In the absence of first pass isolation, touch-up ablation was applied until PVI. In case of reconnection during the waiting time or during the adenosine test, the site of reconnection will be located and treated with touch-up ablation until adenosine proof PVI is reached.
75319670|NCT01798381|Dietary Supplement|Essential fatty acids|
76072742|NCT04602169|Procedure|PVI + SVC|Patients in this group receive PVI according to the CLOSE protocol. In addition, they will receive an SVC isolation. The circular mapping catheter will be introduced in the superior vena cava to determine baseline electrical activity and to confirm definite entrance and exit block after ablation. Ablation will be performed proximally to the SVC/right atrial junction with the contact force-catheter using circular point-by-point radiofrequency delivery with a power setting of 35W, targeting an AI ≥400. High output (25 mA) pacing will be applied before each RF application to check for phrenic nerve stimulation. In areas of phrenic nerve capture ablation will be avoided even in case of incomplete isolation.
75319671|NCT04765748|Device|Cytosorb|Cytokine filter, which can be used intraoperatively while using a heart lung machine
75620216|NCT04816864|Diagnostic Test|extracardiac vagal nerve stimulation (ECANS) + EPS|"The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing."
75620217|NCT02877966|Dietary Supplement|Amixea|Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
75620218|NCT02877966|Other|Placebo|
75319672|NCT05348473|Device|Alpha type|Tips of the seton will be tied as alpha-shaped.
75319673|NCT05348473|Device|Beta type|Tips of the seton in this group will be overlapped and tied
75620219|NCT04226014|Procedure|Endoscopic ultrasound|Echo-endoscopy ultrasound is an examination that presents little risk. However, any medical act, exploration, intervention even conducted under conditions of competence and safety in accordance with current data of medicine and the regulations in force, conceals a risk of complications. In particular, esophageal perforations can occur. They are often favored by underlying lesions (tumor, diverticulum, anatomical variants ...). Other complications are possible such as cardiovascular, respiratory or infectious disorders, as with any anesthesia.
75620220|NCT02618161|Radiation|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
75620221|NCT02618161|Radiation|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
75620222|NCT04226404|Other|CSD1905-11|Flavor variant CSD1905-11 of a 4.8% nicotine ENDS product
75620223|NCT04226404|Other|CSD1905-12|Flavor variant CSD1905-12 of a 4.8% nicotine ENDS product
75319674|NCT05348473|Device|Comfort type|Knotless seton will be applied
75319675|NCT00492401|Drug|decitabine|Given IV
75319676|NCT00492401|Other|laboratory biomarker analysis|Correlative studies
75319677|NCT00492401|Other|pharmacological study|Correlative studies
75319678|NCT00492401|Other|high performance liquid chromatography|Correlative studies
75319679|NCT00492401|Genetic|microarray analysis|Correlative studies
75319680|NCT00492401|Genetic|RNA analysis|Correlative studies
75319681|NCT00492401|Other|mass spectrometry|Correlative studies
75319682|NCT00492401|Genetic|DNA methylation analysis|Correlative studies
75319683|NCT00492401|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
75319684|NCT04143464|Behavioral|Kyphosis-specific exercise class and kyphosis-specific exercise videos|"The kyphosis-specific exercise is based on the protocol published by Katzman and team in 2016. It includes warm-up, back muscle strength training, spine mobility training, spine alignment training, and stretching. The class will last around 60 minutes.~The exercise videos have the same content as the kyphosis-specific exercise class. The participants are asked to practice everyday at home following the videos."
75319685|NCT05400811|Biological|MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for subcutaneous administration.
75319686|NCT05400811|Biological|MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for sublingual administration.
75319687|NCT05400811|Biological|MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 9.000 UTm/mL for sublingual administration.
75319688|NCT05400811|Biological|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
75319689|NCT05400811|Biological|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
75319690|NCT04149002|Behavioral|Intervention Arm Weekly IP3 text messages|Subjects will be provided with a pre and post intervention survey, in addition to a narrated Powerpoint presentation focusing on the logistics of their IP3. Subjects will also receive weekly automated text messages to encourage adherence to the need for their IP3.
75319691|NCT04149002|Other|Active Control Arm General pregnancy text messages|Subjects will be given pre and post pre questionnaires, in addition to a narrated Powerpoint presentation about the Clinic. Subjects will also be sent weekly text messages with general pregnancy information.
75319692|NCT03674827|Biological|PF-06936308|PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
75319693|NCT04147286|Drug|Atorvastatin 40mg|12 weeks of 40 mg atorvastatin therapy per os
75620224|NCT04226404|Other|CSD1905-13|Flavor variant CSD1905-13 of a 4.8% nicotine ENDS product
75620225|NCT04226404|Other|CSD1905-14|Flavor variant CSD1905-14 of a 4.8% nicotine ENDS product
75620226|NCT04226404|Other|CSD1905-15|Flavor variant CSD1905-15 of a 4.8% nicotine ENDS product
75620227|NCT04226404|Other|CSD1905-16|Flavor variant CSD1905-16 of a 4.8% nicotine ENDS product
75620228|NCT04226404|Other|CSD1905-17|Flavor variant CSD1905-17 of a 4.8% nicotine ENDS product
75620229|NCT00698113|Procedure|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
75620230|NCT00698113|Other|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
75620231|NCT01075152|Drug|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
75620232|NCT01075152|Biological|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
75620233|NCT02775526|Procedure|TOT|70 patients
75620234|NCT02775526|Procedure|TVT|70 patients
75620235|NCT02775526|Procedure|Burch Colposuspension|70 patients
75620236|NCT04134637|Device|ultrasound|in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
75319694|NCT04147286|Drug|Placebo oral tablet|Identical placebo
75319695|NCT00493181|Drug|Interleukin-11 (IL-11 or Neumega)|10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
75620237|NCT04134637|Drug|Bupivacaine Hydrochloride 5 MG/ML|twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
75620238|NCT04133857|Other|aerobic exercise|aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
75620239|NCT02877186|Other|commercially-available diet soda|Subjects are asked to consume diet soda three times daily for one week.
75620240|NCT02877186|Other|carbonated water (control)|Subjects are asked to consume carbonated water three times daily for one week.
75620241|NCT04225858|Procedure|Omission of sentinel lymph node biopsy|No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
75620242|NCT02617849|Drug|Pembrolizumab|200 mg IV every 3 weeks
75620243|NCT02617849|Drug|Carboplatin|AUC=6, every 3 weeks x 4
75620244|NCT02617849|Drug|Paclitaxel|175 mg/m2, every 3 weeks x 4
75912169|NCT04840810|Procedure|Out of plane Axis|"In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis."
75620245|NCT02775448|Drug|Carduus marianus 6cH|
75620246|NCT02775448|Drug|Carduus marianus 12cH|
75620247|NCT02775448|Drug|Carduus marianus 30cH|
75620248|NCT02775448|Drug|Placebo|
75620249|NCT02775448|Behavioral|Exercise|aerobic exercise, 30 minutes, daily
75620250|NCT02775448|Other|Diet|1600 calories
75620251|NCT00950859|Drug|GSK1349572 (Cohort I)|50 mg once daily
75620252|NCT00950859|Drug|GSK1349572 (Cohort II)|50 mg twice daily
75620253|NCT02775292|Biological|Aldesleukin|Given SC
75620254|NCT02775292|Drug|Cyclophosphamide|Given IV
75620255|NCT02775292|Drug|Fludarabine Phosphate|Given IV
75620256|NCT02775292|Other|Laboratory Biomarker Analysis|Correlative studies
75620257|NCT02775292|Biological|Nivolumab|Given IV
75912170|NCT05565066|Device|FNB group|Fine-needle-biopsy (Echotip ProCore Needle)
75912171|NCT05565066|Device|FNA group|Fine-needle-aspiration (Echotip Needle)
75620258|NCT02775292|Biological|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
75620259|NCT02775292|Biological|NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Given ID
75620260|NCT02775292|Procedure|Positron Emission Tomography|Correlative studies
75620261|NCT00862849|Drug|Insulin Lispro|
75620262|NCT00862849|Drug|Regular Human Insulin|
75620263|NCT00862849|Drug|rHuPH20|
75319696|NCT04143659|Biological|levonorgestrel butanoate (LB) injection|"The initial formulation of the investigational product (IP) is LB Injectable Suspension at a concentration of 40 mg/2 mL (20 mg/mL). Each vial contains 2 mL at 20mg/mL for a total of 40 mg. This formulation will only be used for dosing groups A and B with the injections completed as 40 mg IM (2 mL) or 40 mg SQ (2 mL).~The second formulation of the investigational product (IP) is LB Injectable Suspension is a concentration of 140 mg/2 mL (70 mg/mL). Each vial contains 2 mL at 70 mg/mL for a total of 140 mg. This formulation will only be used for dosing groups B2, C, and D with the injections completed as 40 mg SQ (0.57 mL), 50 mg SQ (0.71 mL), and 60 mg SQ (0.86 mL)."
75620264|NCT01090050|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
75912172|NCT04840186|Procedure|Liver-resection or ablation|Liver-resection of colorectal liver metastasis. Ablation can be used as adjunct to surgery.
75912173|NCT04840186|Drug|2nd line chemotherapy|2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist
75912174|NCT04476810|Device|kahook dual blade|Combined Phacoemulsification and Excisional Goniotomy with the Kahook Dual Blade
76072743|NCT05204368|Drug|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection
75319697|NCT04388059|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy at 2 and 5 cm from the pylorus on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
75319698|NCT04147364|Other|no intervention|only retrospective reviews for medical records
75319699|NCT04147520|Behavioral|Brief Motivational Interview|Single (60 min) session discussion of alcohol use and associated experiences.
75319700|NCT03588962|Biological|In-stent restenosis|Patch tests for the metals applicated in each of the patients
75620265|NCT01090050|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
75620266|NCT02776618|Procedure|running subcuticular closure of excisional defect|Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
75620267|NCT00944229|Drug|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
75620268|NCT00944229|Drug|Placebo|4 capsules of placebo every 24 hours
75620269|NCT02775370|Drug|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
75620270|NCT00698893|Biological|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
75620271|NCT04225468|Behavioral|ACL Opioid Exposure Reduction Program|Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
75620272|NCT02855307|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
75620273|NCT02855307|Device|Insulin pump|Patient's insulin pump will be used to infuse insulin.
75620274|NCT02855307|Device|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
75620275|NCT02855307|Drug|Insulin|Patient's usual fast-acting insulin analog will be used.
75912175|NCT03041506|Drug|Lidocaine|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
75912176|NCT03041506|Procedure|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
75912177|NCT03041506|Drug|Midazolam|IV administration up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 seconds) for sedation and pain relief.
75912178|NCT03041506|Drug|Ketamine|IV administration up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds) for sedation and pain relief.
75912179|NCT02586792|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
75912180|NCT04428970|Procedure|Invasive ICP monitoring|Insertion of a parenchymal pressure measuring probe
75912181|NCT04590144|Device|INVICTA lead|The implant or the attempt to implant an INVICTA lead
75912182|NCT04845724|Other|Standard Diet|
75912183|NCT04845724|Other|Modified Diet|
75912184|NCT02580708|Drug|Rociletinib|
75912185|NCT02580708|Drug|Trametinib|
75912186|NCT03041428|Device|Ultraprotective ventilation|Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
76072744|NCT05204368|Drug|Meropenem|Meropenem 1g for injection
76072745|NCT03394846|Behavioral|Test of Existing MI Products|Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
75620276|NCT02855307|Other|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
75620277|NCT01077960|Biological|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
75620278|NCT04269369|Drug|5-Fluorouracil|"The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature."
75620279|NCT02776696|Device|Advanced Hybrid Closed Loop System|
75912187|NCT04845802|Other|Inspiratory muscle training(high-IMT group)|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training. Training intensity will set at 60% of the maximum inspiratory pressure.
75319701|NCT03595891|Other|Non-Interventional|Non-Interventional
75912188|NCT04845802|Other|Inspiratory muscle training(low-IMT group)|Dancers will be perform at a load setting of level 1 (corresponding to ~10% baseline MIP), using the same device as the training group.
75319702|NCT00493805|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization"
75465655|NCT01900470|Behavioral|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
75465656|NCT01900496|Biological|Brentuximab vedotin|Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.
75620280|NCT02776696|Device|Hybrid Closed Loop System|
75620281|NCT02776540|Drug|Clopidogrel|there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
75620282|NCT02776540|Drug|Aspirin|there's another group will receive 400 mg Aspirin
75773559|NCT03749824|Dietary Supplement|Omega-3|Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
75912189|NCT03041350|Other|Smartphone video-assisted ALS(advanced life support)|As an preparation for this study, personnel training in mock advanced life support (ALS) simulation including the smartphone video call methodology was conducted. The smartphones were not separately purchased or produced; commercially available smartphones already owned by the emergency medical service (EMS) personnel and medical directors were used. To facilitate the smartphone video call between the medical director and the EMS personnel and to prevent the caregivers or others nearby from hearing the conversation, Bluetooth earphone sets were used. Data were collected using the cardiopulmonary resuscitation (CPR) recording form uploaded in SNS which consisted of EMS personnel and medical directors, and the quality of CPR was evaluated
75912190|NCT04845646|Drug|ASC41|5mg/tablet
75912191|NCT04845646|Drug|Itraconazole|200mg/capsule
75912192|NCT04845646|Drug|Phenytoin|300mg/capsule
75912193|NCT03041194|Other|dietary affects|Dietary affects on urine pH in relation to Interstitial cystitis symptoms
75912194|NCT02234778|Device|TGI SVF material via intramuscular injection|Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
75319703|NCT00493805|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
75319704|NCT04145102|Other|hesperidine|used for antibacterial and reminerlization assesment
75319705|NCT04145102|Other|propolis|used for antibacterial and reminerlization assesment
75620283|NCT00944697|Drug|Oxycodone Naloxone|Oxycodone Naloxone tablets
75620284|NCT00944697|Drug|Placebo tablets|Placebo Oxycodone Naloxone tablets
75620285|NCT02772796|Drug|SENS-218|Oral Administration
75620286|NCT00626652|Drug|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
75465657|NCT01900496|Biological|Rituximab|Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m^2 IV. Additional doses are given at three and six months post week 27.
75773560|NCT03749824|Dietary Supplement|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
75465658|NCT01900509|Drug|Bendamustine|Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
75465659|NCT01900509|Drug|Clofarabine|Route of administration: IV days 1-5.
75912195|NCT03038776|Biological|Recombinant influenza hemagglutinin|Avian H7N9 influenza vaccine
75319706|NCT04145102|Other|silver diamine fluoride|used for antibacterial and reminerlization assesment
75319707|NCT03588650|Drug|HLX20|a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein
75319708|NCT00494585|Drug|CEP-701|80 mg orally twice a day for 30 days
75319709|NCT05589428|Dietary Supplement|Low sodium bread|Bread low in sodium
75465660|NCT01900509|Drug|Etoposide|Route of administration: IV days 1-5.
75465661|NCT01900509|Drug|Etoposide phosphate|Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
75465662|NCT01900509|Drug|Dexamethasone|Route of administration: three times daily orally (by mouth), days 1-5.
75465663|NCT01900522|Drug|ITI-214 Dose A|ITI-214 Dose A Oral Solution
75319710|NCT05589428|Other|Placebo|Normal bread from bakery
75319711|NCT00494975|Device|Narrow band UVB phototherapy , long wave UVA phototherapy|A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
75465664|NCT01900522|Drug|ITI-214 Dose B|ITI-214 Oral Solution Dose B
75465665|NCT01900522|Drug|ITI-214 Dose C|ITI-214 Dose C Oral Solution
75465666|NCT01900522|Drug|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
75465667|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
75465668|NCT01900522|Drug|ITI-214 Dose E|ITI-214 Dose E Oral Solution
75620287|NCT02775136|Device|HS-1000 recording|
75620288|NCT02878122|Procedure|Cancer treatment|Chemotherapy and laparoscopic surgery
75773561|NCT04401202|Dietary Supplement|Nigella sativa oil|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
75773562|NCT00096356|Dietary Supplement|CoQ10 & Vitamin E|
75773563|NCT00096356|Dietary Supplement|Placebo & Vitamin E|
75773564|NCT03747952|Procedure|Tibiotalocalcaneal arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
75773565|NCT03747952|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
75773566|NCT03747874|Diagnostic Test|ventilatory polygraphy|we put a ventilatory polygraphy device on the patient in the evening, they come back home to sleep while the device is recording ventilatory parameters and they come back the morrow to give the device back
75465669|NCT01900522|Drug|ITI-214 Dose F|ITI-214 Dose F Oral Solution
75465670|NCT01900522|Drug|ITI-214 Dose G|ITI-214 Dose G Oral Solution
75465671|NCT01900522|Drug|ITI-214 Dose H|ITI-214 Dose H Oral Solution
75465672|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
75465673|NCT01900548|Dietary Supplement|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
75465674|NCT01900548|Dietary Supplement|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
75465675|NCT01900548|Dietary Supplement|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
75465676|NCT01900548|Other|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
75465677|NCT01900587|Drug|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
75465678|NCT01900587|Drug|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
75465679|NCT01900600|Other|Cardiopulmonary exercise test|All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
75620289|NCT04878172|Device|TempSure Firm|The TempSure firm will be used on the abdomen for non-invasive lipolysis.
75620290|NCT04306926|Drug|TQB2450|TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
75620291|NCT04306926|Radiation|SBRT|Give according to the location of the lesion and clinical condition.
75620292|NCT04807348|Drug|Chiglitazar 32mg|Administrated once daily
75620293|NCT04807348|Drug|Chiglitazar 48mg|Administrated once daily
75620294|NCT04807348|Drug|Placebo|Placebo of Chiglitazar
75620295|NCT04807348|Drug|Metformin Hydrochloride|most tolerable dose
75620296|NCT01075074|Procedure|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
75620297|NCT04224922|Drug|Paclitaxel|
75773567|NCT03749590|Drug|Magnesium Sulfate|Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
75773568|NCT03749590|Drug|Placebo (NaCl 0,9%)|Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
75773569|NCT03749512|Diagnostic Test|Complete blood count|During routine preoperative blood test complete blood count is taken.
75773570|NCT03749512|Other|Histopathological examination|Routine postoperative histopathological examination of lung tumor.
75912196|NCT02570490|Drug|sodium fusidate|
75912197|NCT02570490|Drug|linezolid|
75773571|NCT01076816|Drug|dexmedetomidine|"dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
75319712|NCT03590353|Device|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
75912198|NCT04839640|Other|Bredent denture teeth|composite resin denture teeth
75912199|NCT04845334|Behavioral|RR intervention|"The short psychological intervention consists of a narrative interview and a psychocorporeal intervention. Narrative interview: this is an interview aimed at exploring the experience and awareness of illness. The sharing of the dimension of pain and suffering, the verbalization of emotions, the narration of the history of illness, expectations and fears related to the intervention will be aimed at an emotional and cognitive restructuring of the experience of illness, improving the perception of internal resources and resilience.~Psycho-corporeal intervention:it is a training to the psychophysiological technique of the Relaxation Response (R.R.) of Hebert Benson (Mind-Body Medical Institute of Havard), aimed at stress management and consequently at reducing the perception of pain"
75912200|NCT02565732|Biological|Botulinum toxin type A|Botulinum toxin type A, Dose A, Topical
75465680|NCT01900600|Other|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
75465681|NCT01900613|Behavioral|Ninos Sanos Familia Sana|
75465682|NCT01900639|Behavioral|change time of intake of aspirin|
75465683|NCT01900678|Device|VytronUS Ablation System|Pulmonary vein isolation.
75465684|NCT01900717|Drug|LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified|
75465685|NCT01900717|Drug|LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks|
75912201|NCT02565732|Biological|Botulinum toxin type A|Botulinum toxin type A, Dose B, Topical
75912202|NCT02565732|Biological|Placebo comparator|Placebo, Dose C, Topical
75912203|NCT04839094|Diagnostic Test|rapid antigen testing versus RT-PCR|Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients.
75465686|NCT01900743|Drug|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
75912204|NCT04845412|Diagnostic Test|Hearing screening tests|"Our study was conducted in accordance with the National Hearing Screening Test Protocol. The newborns had transient evoked otoacoustic emissions (TEOAE) with click stimulus as a hearing screening test in the first three days after birth, using Otometrics Madsen Accuscreen S/N: 36484 (USA) device."
75465687|NCT01900743|Drug|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
75465688|NCT01900756|Behavioral|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
75465689|NCT01900769|Drug|Blood Volume Dilution|
75773572|NCT01076816|Procedure|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
75773573|NCT01076816|Procedure|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
75773574|NCT03718156|Other|PREPARED Trial Intervention|Nursing staff members will be trained to adjust the therapeutic nursing plans (TNP) for residents enrolled in the study, as follows: 1) by providing optimal stimulation (surveying the use of eyeglasses and hearing aids, the room lighting and space organization; orienting the resident to time and space; and stimulating the resident using familiar objects, photos, and life histories); and 2) by assessing the presence of 4 modifiable delirium risk factors (antipsychotic use, sensory impairment, restraint use, and dehydration) and taking specific actions once a given risk factor is identified. For instance, if physical restraints are used, the TNP will require that they are to be removed during care when a caregiver is present (nail care, feeding, and wound care).
75773575|NCT03747796|Other|Supine position|The children will be placed in the supine position after ingestion of a standard volume of clear fluid
75773576|NCT03747796|Other|Semi-sitting position|The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
75773577|NCT03749356|Drug|TacroBell SR cap.|"Orally, once-daily in the morning~After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~12ng/ml for 0 to 3months and then at 3~8ng/ml for 3 to 6months of study treatment."
75912205|NCT02234856|Procedure|Laparoscopic Hysterectomy trainer|In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
75465690|NCT01900782|Biological|Intervention A|Prefilled syringe.
75465691|NCT01900782|Biological|Intervention B|Prefilled syringe.
75465692|NCT01900782|Biological|Placebo|Prefilled syringe to match experimental drug and active comparator.
75465693|NCT01900795|Drug|V117957|V117957 4.5 mg suspension taken orally after surgery.
75912206|NCT04855084|Other|Monolithic FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
75620298|NCT04224922|Drug|Carboplatinum|
75773578|NCT01562470|Other|Cellulite reduction cream|1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
75465694|NCT01900795|Drug|Ibuprofen|Ibuprofen 400 mg tablets taken orally after surgery.
75465695|NCT01900795|Drug|Placebo|Placebo taken orally after surgery.
75465696|NCT01900808|Device|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
75773579|NCT01562158|Procedure|standard therapy|Standard treatment of bleeding
75773580|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
75912207|NCT04855084|Other|Monolithic FDPs: after adjustment|After the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
75773581|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
75912208|NCT04855084|Other|Metal fused porcelain FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
75319713|NCT03590353|Device|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
75319714|NCT05581628|Diagnostic Test|Pain location inventory (PLI)|PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28
75319715|NCT05581628|Diagnostic Test|Symptom Impact Questionnaire (SIQR)|The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score
75465697|NCT01900808|Device|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
75465698|NCT01900808|Device|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
75465699|NCT01900834|Other|No treatment given|The participants will not receive any treatment
75465700|NCT01900860|Dietary Supplement|Vitamin D|Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
75465701|NCT01900873|Device|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
75773582|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
75773583|NCT01562158|Drug|placebo|Placebo
75319716|NCT05581628|Diagnostic Test|Fibromyalgia Impact Questionnaire (FIQ)|FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
75319717|NCT03558373|Drug|Immunosuppressive|Immunosuppressive therapies
75319718|NCT04064957|Biological|HB-adMSCs|
75319719|NCT05581550|Radiation|FDG-PET|Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
75319720|NCT05581550|Radiation|Galium-68 DOTATATE|200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
75620299|NCT04224922|Drug|Epirubicin|
75620300|NCT04224922|Drug|Cyclophosphamide|
75620301|NCT00626418|Drug|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
75620302|NCT00626418|Drug|Placebo|Placebo tablets
75620303|NCT02877030|Other|Video game|The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
75620304|NCT02877888|Drug|fluoride varnish 22600ppm|topical application on teeth every 6months
75773584|NCT03749200|Other|Obemat2.0 therapy|
75773585|NCT03749200|Other|Regular practise in primary care|
75773586|NCT03612232|Drug|Cabozantinib-s-malate|oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously
75773587|NCT05297110|Drug|atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
75319721|NCT05183191|Other|Controlled hypoglycaemic state while driving with a driving simulator|Participants arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants drive on a designated circuit using a driving simulator. Initially, a euglycaemic state (5.0-8.0 mmol/L) is kept stable and blood glucose is then progressively declined targeting at a level between 3.0-3.5 mmol/L by administering insulin. Blood glucose is kept stable in the hypoglycaemic range for 30 minutes. Thereafter, blood glucose is raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, the investigators analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression are recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively. Participants are blinded to the blood glucose values during the procedure and have to rate their symptoms and their driving performance on a 0-6 scale every 15 minutes.
75620305|NCT02772640|Drug|Rosuvastatin and Ezetimibe morning or evening administration|"Timing of the drug administration:~morning -> evening evening -> morning"
75620306|NCT02877342|Other|Pre-hospital notification|Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
75620307|NCT02877810|Other|Telemedicine|Telemedicine is a live, interactive, audiovisual teleconferencing system.
75319722|NCT03588494|Combination Product|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
75773588|NCT04315246|Biological|radiolabeled DPTA-omburtamab|Biological, radiolabeled DPTA-omburtamab
75773589|NCT04358068|Drug|Hydroxychloroquine (HCQ)|Administered orally
75773590|NCT04358068|Drug|Azithromycin (Azithro)|Administered orally
75773591|NCT04358068|Drug|Placebo for Hydroxychloroquine|Administered orally
75773592|NCT04358068|Drug|Placebo for Azithromycin|Administered orally
75773593|NCT03694210|Device|EndoRotor Therapy|To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
75319723|NCT03588494|Drug|Endostar for one cycle|Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
75465702|NCT01900873|Device|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
75773594|NCT04339972|Device|LIFUP|Low Intensity Focused Ultrasound Pulsation (LIFUP) is an interesting new form of brain stimulation that may be possible to stimulate non-invasively, safely, deep in the brain with focal precision.
75773595|NCT04339972|Device|Sham LIFUP|The same as LIFUP but the device is not turned on and the subject does not receive any ultrasound.
75912209|NCT04855084|Other|Metal fused porcelain FDPs: after adjustment|After the occlusal adjustment, digital occlusal relationship recording was done of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
75912210|NCT02561442|Drug|ceftriaxone|
75465703|NCT01900886|Other|Peginterferon alfa-2a|Treatment as usual clinical practice
75465704|NCT01900886|Drug|Ribavirin|Treatment as usual clinical practice
75465705|NCT01900912|Other|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
75912211|NCT02262858|Drug|Telmisartan and HCTZ|
75912212|NCT02262858|Drug|Telmisartan|
75912213|NCT02262858|Drug|HCTZ|
75620308|NCT02877810|Other|Telephone|Consultations will be given over telephone.
75620309|NCT02772484|Device|HS-1000|
75620310|NCT02876952|Other|HIGH VOLUME (HV) Supervised exercise|"Supervised exercise two nonconsecutive days per week (day 1-on the treadmill, day 2-on the bike) for 16 weeks. High-intensity interval training (HIIT) protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. 1-4 min cool-down at moderate-intensity.~HIIT protocol on the bike: 5 to 10-min warm-up at moderate intensity. After that, 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 16 repetitions in HV-HIIT week by week. 5-10 min cool-down at moderate-intensity"
75773596|NCT00096278|Biological|Bevacizumab|Given IV
75773597|NCT00096278|Drug|Fluorouracil|Given IV
75773598|NCT00096278|Drug|Leucovorin Calcium|Given IV
75773599|NCT00096278|Drug|Oxaliplatin|Given IV
75773600|NCT03748732|Procedure|sclerectomy|scleral flap
75773601|NCT03748654|Diagnostic Test|Visual Field Testing|Visual field test using the protocol 24-2 Threshold Test
75912214|NCT04845100|Other|Animal Assisted Activity Program|"Animal Assisted Activity Program (HayDAP)~st week (Pre-test, introduction-introduction)~nd week (Information about cats)~th (Cat story reading)~th week (Teaching songs, poems, rhymes about cat)~th week (Making / decorating a cat house)~th week (Participation in the rehabilitation program with the treatment animal)~th week (Evaluation and closing, last test)"
75912215|NCT04476732|Other|Paraben-free skincare product|Paraben-free lotion will be applied twice a day for one week.
75912216|NCT04476732|Other|Paraben-containing skincare product|Paraben-containing lotion will be applied twice a day for one week.
75773602|NCT00095940|Drug|lapatinib ditosylate|Given orally
75319724|NCT03588494|Drug|Endostar for two cycles|Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
75620311|NCT02876952|Other|Mediterranean Diet Recommendations|"Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction."
75620312|NCT02876952|Other|Physical Activity Recommendations|Participants will be advised to perform, without supervision, moderate to high-intensity dynamic aerobic exercise (walking, jogging, cycling or swimming) 3-5 days per week, following an adequate warm-up of 5-15 min, at moderate to high intensity (below the ischemic threshold) for a period of 20 to 40 min (not including warm-up and cool-down) followed by a cool-down period of 5-10min. Participants will receive information related to heart rate values regarding moderate and high exercise intensity domains for the self monitoring of exercise intensity.
75319725|NCT00550277|Drug|LBH589|LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
75319726|NCT05581394|Device|BabySat V3|Evaluation of Accuracy of BabySat V3
75620313|NCT02876952|Other|LOW VOLUME (LW) Supervised exercise|Supervised exercise two nonconsecutive days per week (one day on the treadmill, and the second one on the bike) for 16 weeks. HIIT protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. The training session will end with a 1-4 min cool-down period at moderate-intensity. Total exercise time of 20min HIIT protocol on the bike: 10-min warm-up at moderate intensity. After that, participants will cycle for 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 8 repetitions in LV-HIIT week by week. The training session will end with a 5-10 min cool-down period at moderate-intensity.
75319727|NCT03518983|Device|Dornier Aries2 device|The Dornier Aries2 device and will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft and the 2 crura(two sites).
75620314|NCT02772406|Device|Linked Color Imaging|
75620315|NCT02772406|Device|white light imaging|
75620316|NCT02772718|Drug|XOMA 358 single dose level A|XOMA 358 single dose level A administered by intravenous infusion
75620317|NCT02772718|Drug|XOMA 358 single dose level B|XOMA 358 single dose level B administered by an intravenous infusion
75319728|NCT03518983|Device|Dornier Aries2 device (sham probe)|The Dornier Aries2 device and will be used for the purpose of the study but the active probe will be replaced by an identical sham probe.
75465706|NCT01900925|Procedure|Prescriptive Hip Exercises and Manual Therapy techniques|1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
75319729|NCT05581316|Diagnostic Test|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center.|This patients who were included in this study were assessed for four weeks from the first day of hospitalization and taken to the treatment program. All patients who use peripheral venous catheters in this group.
75319730|NCT00550589|Drug|cidofovir|1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.
75319731|NCT00550589|Genetic|DNA methylation analysis|formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation
75319732|NCT00550589|Genetic|gene expression analysis|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
75620318|NCT02772718|Drug|XOMA 358 single dose level C|XOMA 358 single dose level C administered by an intravenous infusion
75620319|NCT02772718|Drug|XOMA 358 multiple dose level 1|XOMA 358 multiple dose level 1 administered by an intravenous infusion
75773603|NCT00095940|Procedure|therapeutic conventional surgery|Undergo surgery
75773604|NCT00095940|Other|laboratory biomarker analysis|Correlative studies
75773605|NCT00095940|Other|pharmacological study|Correlative studies
75773606|NCT00095940|Procedure|positron emission tomography|Correlative studies
75319733|NCT00550589|Genetic|polymerase chain reaction|performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
75773607|NCT00095940|Procedure|magnetic resonance imaging|Correlative studies
75912217|NCT02235012|Drug|Ketamine|"KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~Initial rapid infusion of 0,23 mg/kg~Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
75912218|NCT02235012|Drug|Placebo|"CHLORURE DE SODIUM 0,9 % MACOPHARMA :~Initial rapid infusion of 0,23 mg/kg~Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
75319734|NCT00550589|Procedure|biopsy|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
75465707|NCT01900925|Procedure|Pragmatic low back pain treatment|"advise to stay active,~discourage bed rest,~appropriate medication use,~reassurance.~Short term use of manipulation/medication,~supervised exercise,~cognitive behavioral therapy,~multidisciplinary treatment,~termination of use of modalities."
75465708|NCT01900938|Procedure|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
75773608|NCT00114218|Drug|Gemcitabine Hydrochloride|Given IV
75773609|NCT00114218|Drug|Docetaxel|Given IV
75773610|NCT00095628|Drug|ispinesib|Given IV
75620320|NCT00866281|Drug|midostaurin|Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
75620321|NCT02772016|Drug|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
75620322|NCT04225000|Other|Exercise Group|Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.
75620323|NCT04225000|Other|Mobilization Group|"Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week."
75620324|NCT04121611|Drug|Unfractionated heparin|"Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)"
75912219|NCT02235090|Other|Direct current stimulation of cervical spinal cord|10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
75912220|NCT04854928|Drug|LTX-109 gel, 3%|A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
75912221|NCT04854928|Drug|Placebo gel|A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
75620325|NCT04121611|Drug|Acetylsalicylic Acid (ASA)|"Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose < 2 hours of EVT completion~ASA 81mg PO OD maintenance dose"
75319735|NCT00550589|Procedure|histopathologic examination|Evaluated at baseline and 6 weeks after treatment discontinuation
75319736|NCT05103319|Other|Data collection for statistical analysis to identify patterns of treatment response/ non-response|All data are restricted from the patient physical and electronic record of the Pain Management-Unit of the University Hospital Basel. No external data sources will be used. Records will be screened from 2012- May 2021. Variables collected are e.g. demography, medical diagnosis, psychological diagnosis, infusion therapy, medication, pain.
75319737|NCT04144712|Drug|Caffeine Citrate|study rate of occurrence of Apnea of Prematurity between the 2 groups
75620326|NCT02617615|Drug|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
75319738|NCT05099653|Other|physical activity|physical activity
75620327|NCT02617615|Drug|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
75620328|NCT02772250|Behavioral|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by one investigator at 15:00-17:00 on the day before colonoscopy.
75773611|NCT00095628|Other|laboratory biomarker analysis|Correlative studies
75773612|NCT00095628|Other|pharmacological study|Correlative studies
75773613|NCT01077986|Drug|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
75773614|NCT01077986|Drug|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
75773615|NCT01077986|Drug|Everolimus|Everolimus will be administered daily, starting on day 1.
75773616|NCT01082562|Drug|BMS-844421|"Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
75773617|NCT01082562|Drug|0.9% sodium chloride injection solution|"Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
75912222|NCT05412966|Device|PEAR-002B|PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder
75912223|NCT05412966|Device|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
75912224|NCT02262936|Drug|Desmopressin|
75319739|NCT03588338|Drug|Perfalgan|For postoperative pain
75319740|NCT03588338|Drug|Control|For postoperative nausea and vomiting
75465709|NCT01900938|Procedure|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
75912225|NCT02262936|Drug|Fesoterodine|
75912226|NCT04838704|Drug|Ruxolitinib+Calcineurin +Methotrexate|low-dose ruxolitinib combine with calcineurin and short course of methotrexate.
75912227|NCT04838704|Drug|Calcineurin +Methotrexate+Mycophenolate mofetil|calcineurin and short course of methotrexate and mycophenolate mofetil
75912228|NCT04844632|Biological|Vaccine anti-Covid19|Vaccination with AstraZeneca or Pfizer-Biontech anti-Covid19 vaccine
75912229|NCT04844710|Combination Product|acupuncture and standard care|manual acupuncture in acupoint LI4, LI11, ST36 every 2 days for 6 times standard care
75912230|NCT04844710|Drug|standard care|standard care only
75912231|NCT02235168|Procedure|six minute walking test|
75465710|NCT01900938|Drug|Midazolam|
75465711|NCT01900938|Drug|Propofol|
75465712|NCT01900951|Drug|Temozolomide|
75465713|NCT01900964|Procedure|PTFE membrane|The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
75620329|NCT02772250|Behavioral|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
75620330|NCT02614885|Device|RFA|Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
75620331|NCT02772172|Device|Surgical Template|
75773618|NCT01086930|Device|ReJoyce Workstation|The device has two parts. A muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff and an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. As well as a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association.
75620332|NCT02772094|Biological|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
75912232|NCT04844398|Other|Clown visits by RED NOSES Clowndoctors Austria|Participants will receive one clown visit per week over four weeks in a group setting. The visits will take place in at least two different wards of each participating psychiatric care facility. In each ward, max. 10 participants will be targeted. The visits are carried out routinely by two professional clown artists from RED NOSES Clowndoctors Austria. The duration of the visits and the specific artistic sequences will take place according to internally organized routines. The essence of the clown visit is to catch the patient's attention proactively and reach the highest level of engagement possible. The specific artistic sequences are implemented spontaneously according to the situational atmosphere and current mood of participants. One clown visit will last between 1 and 2 hours depending on age and number of participants. Each participant will be engaged between 5 and 10 minutes by the clown. The clown artists are not involved in any study-related research activities.
76072746|NCT05362240|Procedure|Four corner fusion|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denuded the articulating surfaces between lunate , capitate , hamate and triquetrum . Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones
75319741|NCT05099185|Biological|Water-soluble vitamins and trace elements measures|We would like to measure water-soluble vitamins (B1, B6, B9, B12, C) and trace elements (zinc, selenium) in blood and dialysate for the patients treated by online post-dilution hemodiafiltration patients. There measures on blood are done systematically during the half-yearly report of our patients in our hemodialysis center. Only results are collect for the study.
75319742|NCT04144634|Other|Strengthening exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of progressive resistance training based around the movement of standing up/sitting down.
75319743|NCT04144634|Other|Stretching exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of gentle stretching of upper limbs and lower limbs.
75319744|NCT05068609|Biological|Nivolumab|Participants in this study are being treated with nivolumab for SCCHN
75620333|NCT02771860|Drug|denosumab|60mg sc
75620334|NCT02771860|Drug|Placebo|identical syringe
75620335|NCT02771860|Dietary Supplement|Calcium/Vit D supplementation|Daily dosage Calcium 1000mg / Vit D 880 IU
75620336|NCT02771782|Biological|BCG vaccine (SSI)|
75620337|NCT02771782|Biological|TDaP-IPV vaccine|
75620338|NCT02771392|Drug|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
75620339|NCT02771392|Other|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
75620340|NCT02771470|Drug|Probiotics|Microbial composition using probiotic
75620341|NCT02771470|Drug|placebo|Microbiota modulation using placebo
75620342|NCT02696746|Other|Observation|No intervention
75620343|NCT02771704|Other|Silver Diamine fluoride|
75620344|NCT02771704|Other|Potassium iodide|
75620345|NCT02771704|Other|Chlorhexidine|
75620346|NCT02771704|Other|Silver diamine fluoride and potassium iodide|
75773619|NCT01086930|Other|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
75773620|NCT03748576|Behavioral|telemedicine: management through WeChat group chat|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care
75773621|NCT03963180|Other|coffee|All patients were asked to drink the entire 150-mL amounts within 20 minutes under the supervision of a nurse or doctor. Patients were free to drink any amount of water but no more coffee, black tea, or other forms of caffeine, such as soda. Coffee and hot water were prepared with a conventional coffee machine (Nescafe Alegria; 100 g caffeine; Nestlé. Gatwick, United Kingdom).
75773622|NCT03963024|Drug|"Conditioning treatment Treosulfan-TMI"|Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)
75319745|NCT00496379|Drug|ZK219477|Given intravenously over approximately 30 minutes once every 3 weeks
75465714|NCT01900964|Procedure|Collagen membrane|A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
75465715|NCT01900990|Device|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
75465716|NCT01901003|Drug|Lorazepam|
75465717|NCT01901003|Other|no premedication|
75465718|NCT01901003|Drug|Placebo (microcrystalline celluloses)|
75620347|NCT02771704|Other|Physiological saline|
75620348|NCT02771548|Procedure|Anterior Cruciate Ligament Reconstruction|
75773623|NCT03963024|Procedure|SCT|Stem Cell Transplant
75912233|NCT02259660|Device|Respiratory muscle strength training|Inspiratory and expiratory muscle strength training occur when subjects are required to breath in (as with inspiratory training) or out (as with expiratory training) through a pressure threshold device. This device features a spring-loaded one way valve which will only open if the subject is able to generate sufficient air pressure to overcome a predetermined pressure threshold. This threshold is typically set at 75% of the subject's maximum capacity. Repeatedly overcoming this threshold during training produces a strengthening effect in most people.
75912234|NCT02259660|Device|Sham respiratory muscle strength training|The placebo / sham intervention will mimic the active intervention(s) in every respect except the devices used will be rendered neutral via removal of the pressure threshold spring inside the devices.
75465719|NCT01901016|Behavioral|Jacobson progressive muscular relaxation|PMR involves learning to identify the tension in specific muscle groups by tightening and relaxing each muscle group. It includes three different exercises: 1) contraction-relaxation of 12 large muscle groups in the arms, legs, and trunk; 2) identification and relaxation of tensions without the need for movement or contractions; and 3) contraction-relaxation of 12 small muscle groups in the neck, eyes, and mouth
75465720|NCT01901016|Behavioral|Schultz's autogenic training|AT is a relaxation technique that is based on body attitude, reduction of exterior stimulation, inner concentration, and mental repetition of verbal formulas [28]. These formulas are organized into six exercises: 1) heaviness; 2) warmth; 3) calm and regular heart function; 4) self-regulation of respiration; 5) warmth in the upper abdominal area; and 6) agreeable cooling of the forehead.
75912235|NCT04844320|Diagnostic Test|Cobb angle measurements|PA Chest x-rays will be taken in all patients in the preoperative, postoperative 1st year and 2nd year
75465721|NCT01901042|Dietary Supplement|Symbiotic|Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
75465722|NCT01901042|Dietary Supplement|Maltodextrin|Control patients will receive sachets containing maltodextrin
75912236|NCT02263092|Behavioral|Physical exercise|The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
75465723|NCT01901068|Device|MonoMax|Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
75620349|NCT02771314|Drug|AZD9291|AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
75319746|NCT05581238|Other|TRACK-TCT|An extra variable will be added to an existing prediction model. It is hypothesized that the predictive ability will improve and that better distinction could be made between patients with an increased risk for receiving blood transfusions.
75912237|NCT02263092|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn, Germany) using a pair of saline-soaked sponge electrodes (surface 35 and 36cm²). tDCS will be applied to Cz and Oz according to International 10-20 EEG system. In the anodal tDCS, the anode will be placed in Cz and cathode in Oz. In the cathodal tDCS the inverse position will be done. Parameters of current intensity and duration (dose) used were 2 mA stimulation intensity for 20 minutes with current ramping up and down of 10 seconds each.For sham, the same position of anodal tDCS will be assumed, however, current duration is only 30 seconds, with current ramping up and down of 10 seconds each. Moreover, the electrostimulation device is automatically turned off without patient's perception. Thus, patients experience early sensations (mild to moderate tingling) in stimulation site without inducing effect. Moreover, after each tDCS session, patients will answer adverse effects questionnaire.
75912238|NCT02263092|Behavioral|Rest|15 or 30 minutes seat without move the legs
75912239|NCT03038542|Behavioral|Gain-framed text messages|
75912240|NCT03038542|Behavioral|Standard care text messages|
75319747|NCT05068375|Diagnostic Test|Thrombophilia screening|Genetic thrombophilia and acquired thrombophilia screening
75319748|NCT03020420|Other|Cicatricell Cream|Cream to be applied 2 times a day for 8weeks to 6 months
75620350|NCT02771002|Device|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
75620351|NCT02771158|Drug|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
75620352|NCT02771158|Drug|placebo|placebo will be administered to double blind the study
75620353|NCT02771080|Procedure|Cardiac surgery|
75773624|NCT03963024|Drug|GvHD prophylaxis|Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)
75773625|NCT01082718|Drug|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
75773626|NCT02531100|Device|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
75773627|NCT02531100|Other|SOC treatment only|Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
75773628|NCT01583010|Device|ANV(R)|"Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group"
75773629|NCT04380142|Drug|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
75773630|NCT04380142|Drug|Placebo for Levodopa/Carbidopa (LD/CD)|Oral capsule
75773631|NCT04380142|Drug|Levodopa/Carbidopa (LD/CD)|Oral encapsulated tablet
75773632|NCT04380142|Drug|Placebo for ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
75773633|NCT04375696|Drug|Polyglucosamine L112|Polyglucosamine; Ascorbic Acid; Tartaric Acid
75912241|NCT03038464|Diagnostic Test|Synovial biopsy|Biopsy of jint prior reimplantation of new joint prosthesis
75319750|NCT03895736|Biological|blood sampling|Sampling of 15 ml of blood during a blood test at Day 0, Day 1 and Day 3
75319751|NCT02124863|Device|Intrapulmonary Percussive Ventilation|20 min IPV freq 300/min, p 10cmH2O
75620354|NCT02770924|Device|AT LISA TRI TORIC|phacoemulsification with IOL implantation
75620355|NCT02770924|Device|AT LISA TRI|phacoemulsification with IOL implantation
75912242|NCT02259738|Drug|Human Urinary Kallidinogenase|
75912243|NCT02259738|Drug|Shuxuening injection|
75773634|NCT04375696|Other|Placebo|Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide
75620356|NCT02770534|Procedure|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
75620357|NCT02770768|Drug|Flibanserin|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
75620358|NCT02770768|Drug|Placebo|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
75319752|NCT04144244|Other|MicroFluidic Sperm Sorting Chips|sperm selection of IUI treatment
75319753|NCT04144244|Other|Gradient-Density Centrifugation|sperm selection of IUI treatment
75620359|NCT02770690|Drug|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
75620360|NCT02770690|Drug|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
75620361|NCT02770690|Drug|placebo|apply normal saline before propofol iv injection
75620362|NCT02770378|Drug|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
75620363|NCT02770378|Drug|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
76072747|NCT05362240|Procedure|three corner fusion without triquetrum excision|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denude the articulating surfaces between lunate , capitate , hamate and don not include triquetrum. Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones.
75620364|NCT02770378|Drug|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
75620365|NCT02770378|Drug|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
75620366|NCT02770378|Drug|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
75620367|NCT02770378|Drug|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
75620368|NCT02770378|Drug|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
75773635|NCT03748498|Device|laser|Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
75773636|NCT04336228|Drug|Escitalopram|20mg daily for 3-4 weeks.
75773637|NCT04336228|Drug|Placebo oral tablet|20mg placebo tablet daily for 3-4 weeks.
75773638|NCT03937180|Behavioral|Blended care|An interactive e-learning programme delivered through a secured web-based platform for patients and general practitioners (GPs), blended with face-to-face contacts between the involved GP and patient.
75912244|NCT04854460|Drug|Revemact|1 tablet contains 6 mg Ivermecin
75912245|NCT04854460|Drug|Stromectol (first dose)|2 tablet contain 6 mg Ivermecin
75912246|NCT04854460|Drug|Stromectol (second dose)|2 tablet contain 6 mg Ivermecin
75912247|NCT04854538|Drug|Ekmasonid|1 extended release tablet contains 9 mg Budesonide
75912248|NCT04854538|Drug|Uceris (first dose)|1 extended release tablet contains 9 mg Budesonide
75912249|NCT04854538|Drug|Uceris (second dose)|1 extended release tablet contains 9 mg Budesonide
75912250|NCT05331690|Drug|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml starter the day before surgery
75912251|NCT05331690|Drug|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
75912252|NCT05331690|Drug|Dexamethasone Ophthalmic|Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
75912253|NCT04373668|Behavioral|Hypnotic Medication Review|A training programme focused providing guidance on the review and withdrawal process of hypnotic drugs.
75912254|NCT04373668|Behavioral|Structured Sleep Hygiene|Training module on the principle of good sleep hygiene
75319754|NCT04144478|Other|Web based education|Web based education
75319755|NCT04998409|Device|Monofocal lens|not applicable as patients are already implanted with the monofocal lens
75319756|NCT00497081|Drug|mirtazapine|mirtazapine 30 mg daily for 3 months
75319757|NCT00497081|Drug|placebo|placebo 30 mg daily for 3 months
75319758|NCT04144400|Behavioral|Direction Check App|Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.
75319759|NCT04144400|Behavioral|Direction Check App (Time Management Version)|Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
75319760|NCT03906656|Device|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
75319761|NCT03906656|Device|KAFO/SCO|Current knee ankle foot orthosis that the subject was wearing at baseline
75319762|NCT01796951|Drug|Aspirin 325 mg daily|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
75319763|NCT01796951|Drug|Celecoxib 200 mg BID|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
75319764|NCT03281239|Diagnostic Test|Laser doppler, blood tests, and holter ECG|"Diagnostic tests :~laser doppler~blood tests~Holter ECG. No drug and no placebo were used in this arm."
75319765|NCT03588104|Device|POWER2DM system|This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care
75912255|NCT04373668|Behavioral|Night Time Care Activities Programme|Training and support package to assist in the development of a personalised night time care plan and support the implementation and dissemination of information within the care home environment
76072748|NCT02132572|Device|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
75319766|NCT03588104|Other|Usual care|Usual care as given to diabetes patients by the patient's diabetes care team.
75319767|NCT04838041|Drug|Asciminib|40 mg by mouth (PO) twice a day (BID).
75319768|NCT04838041|Drug|Imatinib|400 mg by mouth (PO) once daily
75620369|NCT02770378|Drug|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
75912256|NCT02556372|Drug|JKB-122|Orally administered capsules of JKB-122 which will be taken once daily with dose escalation from 5mg up to 40mg depending on the monthly response.
75319769|NCT03106285|Dietary Supplement|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10^8 CFU L retueri DSM17938
75319770|NCT03106285|Dietary Supplement|Placebo|5 drops of placebo drops
75319771|NCT03588026|Drug|rVA576|6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
75319772|NCT03588026|Other|Standard of care (SOC)|6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
75319773|NCT03587948|Diagnostic Test|Diabetes mellitus|Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
75319774|NCT04766060|Other|Fluorescent Imaging|Fluorescense imaging used to evaluate blood perfusion
75319775|NCT03587792|Procedure|stapedectomy|Stapedectomy as described in literature with stapes removal, Carbon Dioxide (CO2) laser platinectomy and placement of a prothesis(piston) between the incus long process and the stapes footplate
75319776|NCT04143620|Procedure|Procedure|Triple procedure
75319777|NCT04143854|Drug|MBA-P01(Botulinum toxin A)|Intramuscular injection; Dose varies by group
75319778|NCT04143854|Drug|Placebo|Intramuscular injection; normal saline
75319779|NCT04765670|Other|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
75620370|NCT02770378|Drug|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
75912257|NCT04854226|Dietary Supplement|Macronutrients_CARB|Breast milk 150 to 170 mL/d; Target fortification: 9.0 g/100mL COH, 3.0 g/100mL protein, 4.0 g/100mL fat, 86.4 kcal/100mL
75912258|NCT04854226|Dietary Supplement|Macronutrient_FAT|Breast milk 150 to 170 mL/d; Target fortification: 5.5 g/100mL COH, 3.0 g/100mL protein, 5.5 g/100mL fat, 86 kcal/100mL
75912259|NCT02202434|Device|Lotus Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
75319780|NCT04765670|Other|Kinesiotape Application|Bilateral Kinesiotape application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
75319781|NCT03587714|Diagnostic Test|HCV RT-PCR|HCV ribonucleic acid by reverse transcriptase polymerase chain reaction (RT-PCR)
75319782|NCT03022058|Device|Ear-EEG system|Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
75319783|NCT03587558|Drug|Carvedilol|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
75319784|NCT03587558|Drug|Flecainide|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
75319785|NCT03021512|Procedure|Phaco with Restor|Phacoemulsification with bilateral bifocal intraocular lenses implantation
75319786|NCT03021512|Procedure|Phaco with Panoptix|Phacoemulsification with bilateral trifocal intraocular lenses implantation
75319787|NCT02943265|Other|Care Coordination Strategies|Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
75319788|NCT03895346|Behavioral|Mindfulness|Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e. breath or body sensations)
75319789|NCT03895346|Behavioral|Brain Games and Puzzles|Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
75319790|NCT04415905|Drug|Propofol|The participants in the group P are anesthetized with propofol
75319791|NCT04415905|Drug|Sevoflurane|The participants in the group S are anesthetized with sevoflurane.
75319792|NCT03021356|Device|Aortic xenograft|After randomization, the aortic xenograft is implanted in the standard fashion
75620371|NCT02770378|Drug|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
75620372|NCT02770456|Dietary Supplement|High dose fish oil|Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
75912260|NCT02202434|Device|CoreValve/Evolut R Transcatheter Aortic Valve Replacement System|Procedure: Transcatheter aortic valve replacement (TAVR)
75620373|NCT02770456|Dietary Supplement|Low dose fish oil|Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
75319793|NCT02979704|Drug|Rosuvastatin|45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
75465724|NCT01901081|Device|IMES|"Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months."
75912261|NCT02202434|Device|LOTUS Edge Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
75912262|NCT05330598|Device|Connected Catheter|The Connected Catheter System is a replaceable wireless urinary prosthesis that is indicated for bladder emptying in male patients who have impaired bladder emptying due to chronic Urinary Retention. The Connected Catheter resides fully internally in the male lower urinary tract (urethra and bladder neck) and remains in place for up to 7 days before removal.
75465725|NCT01901107|Drug|Kiklin capsules|oral
75620374|NCT02770456|Dietary Supplement|Olive oil|Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
76072749|NCT01868035|Drug|tositumomab and iodine I-131 tositumomab|"Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass."
75465726|NCT01901120|Drug|Betanis|oral
76072750|NCT05162482|Biological|BIBP (CNBG, Sinopharm) WIV|BIBP (CNBG, Sinopharm) WIV (Whole Inactivated Virus in a single dose, prefilled syringe with a storage temperature of 2-8°C)
76072751|NCT05162482|Biological|CanSinoBIO|CanSinoBIO (Viral Vector in a single dose, prefilled syringe with a storage temperature of 2-8°C)
75465727|NCT01901133|Drug|MDV3100|Oral
75465728|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (tablet)
75465729|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (capsule)
75465730|NCT01901172|Drug|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
75465731|NCT01901172|Drug|RO5503781|Daily for 5 days followed by 23 days rest per cycle
75620375|NCT02770222|Drug|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
75620376|NCT02770222|Drug|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
75620377|NCT02770222|Drug|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
75620378|NCT02770144|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
75620379|NCT02770144|Behavioral|Access to Referral to Social Services|
75620380|NCT00943917|Other|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
75620381|NCT00943917|Drug|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
75620382|NCT00943917|Other|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
75620383|NCT04780620|Other|Parent Intervention Group|Parents will be involved in 8 weekly sessions.
76072752|NCT05162482|Biological|AstraZeneca ChAdOx|AstraZeneca ChAdOx (Viral Vector in a multi-dose vial consisting of 10 doses with a storage temperature of 2-8°C)
75620384|NCT02876250|Drug|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
75620385|NCT02876250|Drug|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
75620386|NCT02769910|Drug|Capsaicin 24 Hours|Dermal patches for transdermal application of Capsaicin, applied for 24 hours
75319794|NCT02979704|Drug|Atorvastatin|45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
75319795|NCT05580224|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
75319796|NCT05580146|Dietary Supplement|Zynamite® 15% 150mg|leaves of the mango food plant
75319797|NCT05580146|Dietary Supplement|Zynamite® 15% 300mg|leaves of the mango food plant
75773639|NCT03937180|Behavioral|Usual care|"General practitioners offering usual care are expected to follow the Belgian guidelines as described in the most recent online version of Anxiety, stress and sleeping problems A toolbox for general practitioners. or Sleeping pills and sedatives. How to assist your patients in the search for other solutions? which are both available in French and Dutch."
75912263|NCT03038386|Other|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
75912264|NCT04373200|Biological|Blood samples collection|Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients
75912265|NCT04373200|Other|Saliva collection|Saliva collection at Month 4 for 25 survivors COVID-19 patients
75912266|NCT02263170|Other|MRI (magnetic resonance imaging)|Assessment of the sphincter morphology
75912267|NCT02263170|Other|US (ultra sound)|Assessment of the sphincter morphology
75912268|NCT02263170|Other|FLIP (functional luminal imaging probe)|Assessment of the biomechanical properties of the sphincter region
75620387|NCT02769910|Drug|Capsaicin 1 Hour|Dermal patches for transdermal application of Capsaicin, applied for 1 hour
75620388|NCT02769910|Other|Qutenza Demo Patch|Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
75912269|NCT02263170|Other|HRAM (high resolution anal manometry)|Assessment of the biomechanical properties of the sphincter region
75912270|NCT03040258|Other|Health-E-PALS-Pilot|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
75912271|NCT03038152|Procedure|Axillary Lymph Node Dissection|Undergo targeted axillary lymph node dissection
75319798|NCT05580146|Dietary Supplement|Zynamite® 15% 600mg|leaves of the mango food plant
75465732|NCT01901172|Drug|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
75773640|NCT03917446|Drug|Propofol bolus|Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.
75465733|NCT01901172|Drug|RO5503781|Single doses Days 1 and 11
75465734|NCT01901172|Drug|posaconazole|Multiple doses Days 8-14
75465735|NCT01901198|Biological|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
75465736|NCT01901198|Biological|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
75773641|NCT04335136|Drug|RhACE2 APN01|Patients will be treated with APN01 intravenously twice daily (BID).
75620389|NCT02876484|Drug|Colesevelam|
75773642|NCT04335136|Drug|Physiological saline solution|Patients will be treated with placebo intravenously twice daily (BID).
75773643|NCT03748108|Drug|lidocaine|a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
75912272|NCT03038152|Procedure|Localization|Undergo axillary lymph node localization
75912273|NCT03038152|Device|Medical Device|Receive Magseed via ultrasound guided injection
75912274|NCT05284890|Drug|CC-99677|Specified dose on specified days
75912275|NCT03038230|Drug|MCLA-117 bispecific antibody|MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
75912276|NCT04853758|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.
75912277|NCT04853758|Drug|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.
75912278|NCT02784288|Procedure|Neck Dissection|All patients will undergo neck dissection of the cervical lymph nodes
75912279|NCT02784288|Procedure|Standard-of-Care (SOC) Transoral Surgery of Primary Site|Patients with a single lymph node that measures less than six centimeters, have no extracapsular extension in the lymph node, and have no perineural or perivascular invasion of the primary biopsy will undergo transoral surgery of the primary site.
75912280|NCT02784288|Radiation|SOC Radiation|Patients who have 2 positive nodes with no extracapsular extension, or have perineural or perivascular invasion of the primary biopsy will undergo radiation.
75319799|NCT05580146|Dietary Supplement|Placebo|Sunflower oil matched for appearance
75319800|NCT03021044|Other|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
75319801|NCT03021044|Other|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
75319802|NCT01797679|Other|Strength Training|
75319803|NCT01797679|Other|Aerobic Exercise|
75620390|NCT02876484|Drug|Chenodeoxycholic Acid|
75620391|NCT02876484|Other|Water|
75620392|NCT02851485|Drug|GLPG1972 600 mg oral solution fasted|dosing after overnight fasting
75620393|NCT02851485|Drug|GLPG1972 600 mg oral tablet fasted|dosing after overnight fasting
75620394|NCT02851485|Drug|GLPG1972 600 mg oral tablet fed|dosing after high-fat high-calorie breakfast
75620395|NCT04779372|Behavioral|smartphone-based dCBT-I from a Wechat applet|Participants will receive 6-week smartphone-based dCBT-I from a Wechat applet.
75620396|NCT04779372|Behavioral|sleep education|Participants will receive sleep education like the advices getting from common sleep clinic.
75620397|NCT02696668|Other|modified FaME|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.
75620398|NCT02696668|Other|Multisensory|"Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:~Limits of stability training with eyes open / eyes closed~Self induced movement strategies with eyes open / eyes closed~Gaze stability exercises in sitting / standing / walking~Sensory integration~Habituation exercises"
75620399|NCT04297722|Other|Dairy products|Dairy consumption including total dairy, full-fat dairy, low-fat dairy, total milk, full-fat milk, low-fat milk, total yogurt, full-fat yogurt, low-fat yogurt, total cheese, hard cheese and fresh cheese
75620400|NCT02769598|Device|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
75620401|NCT04297644|Other|There is no intervention|There is no intervention
75620402|NCT02769676|Other|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
75620403|NCT02769676|Other|usual care|Participants in the usual care arm will receive no additional interventions.
75620404|NCT02876094|Drug|celecoxib|dose-response
75620405|NCT00603135|Drug|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
75620406|NCT02769754|Device|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
75620407|NCT02769754|Other|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
75620408|NCT02769286|Drug|Osimertinib|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
75620409|NCT02855073|Biological|ReJoinTM|adipose derived mesenchymal progeinitor cells
75620410|NCT02855073|Drug|Sodium Hyaluronate|Sodium Hyaluronate Injection
75620411|NCT01077024|Other|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
75773644|NCT03748108|Drug|Placebo|a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
75773645|NCT04171414|Biological|CT-P17 SC AI (adalimumab)|Subcutaneous Injection of Adalimumab 40mg once every two weeks
75773646|NCT04167670|Drug|Vonoprazan|Over-encapsulated tablets administered orally.
76088858|NCT04550676|Behavioral|HIIT (intervention)|Following a 5-minute warm-up, high and moderate-intensity exercise bouts will alternate: a five bouts of 4-minute high-intensity exercise (90% VO2peak) will alternate with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8. This is followed by a 5-minute cool-down. The total exercise time will be 42 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
75319804|NCT03587324|Drug|Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).|"To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)"
75319805|NCT00604045|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
75620412|NCT02769130|Drug|Losartan|Losartan is given for 12 months
75620413|NCT02768896|Behavioral|Baseline|Patients will walk naturally with EEG measuring brain waves
75620414|NCT02768896|Behavioral|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
75620415|NCT02768896|Behavioral|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
75620416|NCT02768896|Behavioral|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
75773647|NCT04167670|Drug|Amoxicillin|Capsules administered orally.
75773648|NCT04167670|Drug|Clarithromycin|Tablets administered orally.
75773649|NCT04167670|Drug|Lansoprazole|Over-encapsulated capsules administered orally.
75773650|NCT03747406|Procedure|Erector spinae plane block|the level between T9 and T10 will be identified using ultrasound as well as transverse processes depth. An array probe will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge Tuohy needle will be advanced inplane until it made contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration was confirmed. The same procedure will be repeated in the contralateral side.
75319806|NCT00604045|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
75773651|NCT03747406|Procedure|TAP block|a linear array transducer 5-12 MHz will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge needle will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
75773652|NCT03747250|Device|Videolaryngoscopy|In experimental group (interventional group), patients will be intubated with the videolaryngoscope
75773653|NCT03747250|Device|Direct laryngoscopy|In control group (active comparator group), patients will be intubated with the direct laryngoscope
75912281|NCT02784288|Drug|SOC Carboplatin|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
75912282|NCT02784288|Drug|SOC Paclitaxel|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
75912283|NCT02784288|Procedure|Videofluoroscopy|All patients undergo a videofluoroscopy procedure one year after completion of therapy to assess swallowing function.
75620417|NCT02853357|Other|Manipulation|"Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust."
75465737|NCT01901237|Behavioral|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
75912284|NCT03040180|Drug|Electrochemotherapy with bleomycin|Systemic injection, once only treatment
75912285|NCT03040180|Device|EndoVE|Electroporation using an endoscopic electroporation device
75912286|NCT04454606|Device|Fit test|"Bitrex Fit Test The Bitrex test uses a person's ability to test a bitter solution to determine whether a respirator fits properly[11]. Each subject was given a taste-threshold screening test prior to each fit test to ensure that he or she could taste. This process was done without subject wearing a respirator. After passing the sensitivity test, the subject will process to 7 steps of fit test as following~Breathe normally~Breathe deeply~Head side to side~Head up and down~Bent over wrist, jogging~Talking~Breath normally Each step took 60 seconds and the Bitrex solution was refilled into the hood every 30 seconds with half dosage of the amount of the previously test. We asked the participant if he / she could taste the solution during each steps of the test . The test was considered a failure, otherwise, a pass."
75912287|NCT04454606|Device|Filtration Test|"Respirator Performance~The real time respirator performance test method was developed using MT-05U machine (SIBATA model, Saitama, Japan), which measure particle concentrations of diameter 0.03 - 0.06 µm using and particle generator laser beam scattering particle counter that measure particles outside and inside the mask. The ratio between these two values reflected % leak as following:~leak=((Paticle inside the filter))/((Paticle inside the filter)) x 100 And calculate % filter performance = 100 - % leak We tested at the airflow rate of 40L/min which is 3-4 times higher than normal physiology, assuming that there should be no leakage through the filter. We tested 2 types of filter is CareStar and SafeStar that was incorporated with the silicone mask. CareStar is limited for 24 hour usage and SafeStar is for 72 hour duration.~Study protocol"
75912288|NCT02235246|Drug|Magnesium Sulfate|magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
75912289|NCT02235246|Drug|Normal saline|Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
75912290|NCT03037996|Other|patients' response|patients' satisfaction to anesthesia services
75319807|NCT05582954|Behavioral|EsteemUp|EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.
75773654|NCT00113516|Drug|carboplatin|AUC of 6 mg*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
75465738|NCT01901263|Behavioral|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
75465739|NCT01901276|Drug|Omeprazole 40 mg bid|As above.
75465740|NCT01901315|Procedure|Online consultation|Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
75465741|NCT01901315|Procedure|Face-to-face consultation|Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
75620418|NCT02853357|Other|Sham Manipulation|The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
75465742|NCT01901354|Other|Low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
75465743|NCT01901354|Other|Airway Pressure Release Ventilation (APRV)|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
75620419|NCT02853357|Other|Core Strengthening Exercises|Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
75620420|NCT04858698|Device|Ultrasound / Echocardiography|Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
75620421|NCT02769208|Device|Central air handling unit air purification technologies|As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
75620422|NCT02769052|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
75620423|NCT02768740|Drug|Hydrocortisone hemisuccinate|In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
75620424|NCT01089582|Other|No intervention|
75620425|NCT00603213|Procedure|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.~Echocardiogram is an ultrasound of the heart."
75620426|NCT02768974|Drug|OPRX-106|Oral delivery, once daily.
75773655|NCT00113516|Drug|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
75773656|NCT00113516|Drug|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
75773657|NCT03251326|Drug|Nabilone|Nabilone capsules (4 mg)
75773658|NCT03251326|Drug|Cannabis|Cigarettes (0.0 and 5.6% THC)
75773659|NCT03251326|Drug|Propranolol|Propranolol capsules (40mg)
75773660|NCT03251326|Drug|Placebo|Placebo capsules
75912291|NCT02135276|Drug|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
75465744|NCT01901367|Dietary Supplement|nutritional intervention|Receive nutritional intervention
75465745|NCT01901367|Behavioral|exercise intervention|Receive exercise intervention
75465746|NCT01901367|Other|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
75465747|NCT01901367|Behavioral|counseling intervention|Receive phone counseling with a trained health coach
75465748|NCT01901367|Other|quality-of-life assessment|Ancillary studies
75620427|NCT02851095|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
75620428|NCT02851095|Drug|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
75620429|NCT02851095|Drug|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
75620430|NCT04224532|Procedure|Pneumoperitoneum Timing (Before Positioning)|Before Reverse Trendelenburg Position
75620431|NCT04224532|Procedure|Pneumoperitoneum Timing (After Positioning)|After Reverse Trendelenburg Position
75620432|NCT02876874|Drug|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
75773661|NCT04140292|Drug|Photodynamic therapy (PDT)|"PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered."
75773662|NCT04140292|Drug|Vitamin D3|"D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment~Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result"
75912292|NCT02235324|Biological|ziv-aflibercept|Given IV
75912293|NCT02235324|Drug|leucovorin calcium|Given IV
75912294|NCT02235324|Drug|fluorouracil|Given IV
75912295|NCT02235324|Other|laboratory biomarker analysis|Correlative studies
75465749|NCT01901367|Other|laboratory biomarker analysis|Correlative studies
75465750|NCT01901367|Other|questionnaire administration|Ancillary studies
75465751|NCT01901380|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|
75912296|NCT04843696|Device|cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy)|the hospital-based NPV once per week in the maintenance program at least three times per month. The ventilator is set to the control model with a frequency of 12~15 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot), and delivery of negative pressures ranging from -20 to -35 cm H2O.
75912297|NCT04843696|Behavioral|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)
75912298|NCT01230242|Device|Levonorgestrel Intrauterine Device|levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
75912299|NCT02263248|Drug|venlafaxine|slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
75465752|NCT01901432|Drug|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~50 mg b.i.d.,~100 mg b.i.d.;~150 mg b.i.d.,~200 mg b.i.d.;~150 mg t.i.d.;~200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
75465753|NCT01901445|Behavioral|Educational action with focal group|
76072753|NCT04414969|Drug|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1, PEG-ASP 2500U/m2 im d1, Chidamide, 30mg, po, on d1，d5，d8，d12，d15，d19. The regimen was repeated every 3 weeks for 4 cycles followed by involved-field radiotherapy after got CR and PR (patients with efficacy of SD and PD withdrew from the study). Intensity-modulated radiation treatment was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 54-56 Gy. During the radiotherapy, the anti-PD-1 antibody is administrated (200mg ivdrip, every 3 weeks) for 2 cycles. After the completion of radiotherapy, the subsequent 2 cycles of anti-PD-1 antibody + Peg-Asparaginase + Chidamide are administrated. After the end of all the above induction treatments , anti-PD-1 antibody (200mg ivdrip, every 3 weeks for up to 9 cycles) is given as maintenance therapy for 6 months (the total cycles of anti-PD-1 antibody is 17）.
76072754|NCT04817098|Behavioral|Journey of Life|The concept underlying the JoL intervention is that caregivers and community members can support each other and their children through reflection, dialogue, and action. JoL addresses children's and adolescents' ecologies by working with caregivers, educators, and community members to understand the importance of their support in protecting children.
76072755|NCT01609933|Drug|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
76072756|NCT01609933|Drug|ABT-267|ABT-267 (tablets)
75620433|NCT02768818|Dietary Supplement|Probiotic VIVOMIXX™|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
76072757|NCT01609933|Drug|pegylated interferon alpha-2a (pegIFN)|pegIFN alpha-2a (syringe)
76072758|NCT01609933|Drug|Ribavirin (RBV)|Ribavirin (tablets)
76072759|NCT03255928|Diagnostic Test|PAS assay, TGT|Evaluation of platelet function
75620434|NCT02768818|Dietary Supplement|Placebo|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
76072760|NCT03241420|Device|lung clearance index (LCI)|Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
75319808|NCT05582954|Behavioral|EsteemUp-G|The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program
75319809|NCT05246683|Other|observational|registry
75319810|NCT03587246|Diagnostic Test|3DTVUS : Uterine peristaltic frequencies|Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
75319811|NCT01798459|Drug|Methylphenidate|
75620435|NCT02876016|Device|functional MRI|locate the cerebral bases in functional imaging
75620436|NCT00862459|Drug|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
75620437|NCT00862459|Drug|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
75912300|NCT02263248|Drug|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
75912301|NCT02263248|Drug|placebo|patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
75319812|NCT03587090|Diagnostic Test|echocardiography|echocardiography by subcostal and transhepatic views
75319813|NCT04143308|Other|Simultaneous training of walking and cognitive group|"Device:~SWATCH system (App & controller)~Wearable technology Fitness wristband & APP"
75465754|NCT01901458|Device|Spectra Optia® IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
75912302|NCT04838860|Drug|Siltuximab|Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
76072761|NCT01843777|Behavioral|Standard-of-Care|the standard of care in audiologic practice
76072762|NCT01843777|Behavioral|Treatment|motivational interviewing
76072763|NCT05361772|Drug|colchicine|colchicine 0.5mg per day for 24 months
76072764|NCT05361772|Drug|Placebo|placebo 0.5mg per day for 24 months
76072765|NCT05360368|Drug|HLX07|A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
75319814|NCT04143308|Other|Cognitive training group|"Device:~SWATCH system (App)~Wearable technology Fitness wristband & APP"
75620438|NCT00862459|Drug|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
75620439|NCT00862459|Drug|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
75620440|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
75620441|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
75620442|NCT02768428|Other|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
75620443|NCT00603369|Behavioral|group intervention|13-session intervention
75620444|NCT00603369|Behavioral|group intervention|2-session intervention
75620445|NCT02853279|Behavioral|Interval exercise training|"Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗_peak- 〖WR〗_LT )+ 〖WR〗_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week."
75620446|NCT02853279|Behavioral|Continuous exercise training (CON)|Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
75620447|NCT02768116|Procedure|Sirolimus Drug-eluting Stent via Active Transfer of Plaque|
75620448|NCT02768116|Procedure|Sirolimus Drug-eluting Stent implantation via Provisional T Stenting|
75620449|NCT02768272|Device|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
75620450|NCT02768272|Procedure|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
75620451|NCT04269681|Device|High Flow Nasal Cannula|"Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher & Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature.~The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea.~The HFNC should be offered to the patient in ARF as follows:~Initial parameters: Flow 45 ml / L, FiO2 50%, AIRVO 37oC temperature;~Titrate the flow up to 60ml / L or up to the maximum tolerated;~Titrate FiO2 to maintain SatO2 between 92% to 98%, starting with 50%;~Keep the AIRVO temperature at 37oC, if not possible, acceptable down to 34oC."
75620452|NCT04269681|Other|Standard respiratory support|The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea. For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team. NIPPV will be performed with the patient in a supine position at 45 degrees. The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage. A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort. The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
75620453|NCT00635284|Drug|ABI-009|nab-rapamycin
75620454|NCT02854839|Biological|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
75620455|NCT02768350|Procedure|Ventilator hyperinflation technique|"Hyperinflation using a ventilator or ventilator hyperinflation technique (VHI) was developed from the manual hyperinflation (MHI) technique. There is no need to disconnect the patient when using the VHI technique and consequently there is no loss of PEEP and little or no risk of the adverse effects associated with MHI."
75319815|NCT04143308|Other|Treatment as usual group|Keep treatment as usual
75319816|NCT00555321|Drug|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term [ST]), in accordance with local practice and the package insert, 4 years (Long-Term Extension [LTE])
75319817|NCT00555321|Drug|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
75620456|NCT02768350|Procedure|Conventional treatment|Conventional treatments are the routine treatment that patients were received from the physical therapist who take care them. The routine treatments are consist of chest physical therapy techniques (i.e. vibration, positioning, etc.) and others treatment (i.e. passive movement).
75912303|NCT04839016|Drug|SHR-1314|SHR-1314
76072766|NCT05355376|Procedure|Bundle of measures to decreased SSI|
76072767|NCT04810702|Other|no intervention|no intervention
76072768|NCT01842607|Biological|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
75319818|NCT00555321|Drug|Belatacept More Intensive (MI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension [LTE])"
75319819|NCT00555321|Drug|Belatacept Less Intensive (LI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
75620457|NCT04131595|Biological|MVA-BN-WEV Dose 1|1 x 10^7 Inf.U MVA-BN-WEV vaccine
75620458|NCT04131595|Biological|MVA-BN-WEV Dose 2|1 x 10^8 Inf.U MVA-BN-WEV vaccine
75912304|NCT04839016|Drug|Placebo|Placebo
75912305|NCT05166278|Behavioral|De-escalation training|The intervention will include training on verbal and nonverbal de-escalation techniques. The training will be prepared according to the recommendations of the Beta Project of the American Association for Emergency Psychiatry, the World Health Organization Quality Rights training to act, unite and empower for mental health and a handbook for the use of de-escalation skills in a hospital setting by Amdur E. The first part of the education is based on theoretical backgrounds: aggressive behavior in a psychiatric patient, risk factors, focusing on factors that can be modified, communication, de-escalation. The second part is a practical workshop. The training will be 16 hour duration in total. A short handbook and a list of verbal and non-verbal approaches will be prepared for all staff members involved in the training.
75912306|NCT03037918|Dietary Supplement|Yakult light|A fermented milk drink containing the probiotic Lactobacillus casei Shirota
75319820|NCT00555321|Drug|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term [ST]), ≤ 1 g/day, 4 years (Long-term extension [LTE])
75319821|NCT05583500|Other|Experimental: Single group: excentric exercise protocol|Excentric exercise protocol will be performed for all subjets, consisted of 10 sets of 20 repetitions of squats, jumping from a height of 50 cm
75620459|NCT04131595|Biological|MVA-BN-WEV Dose 3|2 x 10^8 Inf.U MVA-BN-WEV vaccine.
75620460|NCT00699049|Drug|Alpha blocker|oral
75620461|NCT00699049|Drug|placebo|oral
75620462|NCT00699049|Drug|solifenacin|oral
75620463|NCT04131283|Drug|Epinephrine|Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
75620464|NCT02768038|Other|Observational|Blood, stool ja biopsy specimens
75620465|NCT04224454|Other|Questionnaire|"Questionnaire was adapted from questionnaires used by the French national agency Institut de Veille Sanitaire to study vaccination coverage and were completed with the assistance of one fellow to limit missing data."
75620466|NCT02614027|Other|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
75620467|NCT02614027|Other|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
75620468|NCT02617693|Behavioral|lifestyle intervention|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
75620469|NCT02617693|Other|standard antenatal care|Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
75620470|NCT02696980|Device|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
75620471|NCT02767648|Other|proteomic urine analysis|proteomic urine analysis
75620472|NCT00943761|Drug|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
75620473|NCT00943761|Drug|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
75620474|NCT00943761|Drug|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
75620475|NCT00943761|Drug|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (<75 kg or ≥75 kg, respectively), for 48 weeks
75620476|NCT02617771|Drug|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
75620477|NCT02696590|Dietary Supplement|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
75620478|NCT02617459|Drug|Levobetaxolol eye drops|one drop per time; twice daily
75319822|NCT03587012|Other|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
75319823|NCT03587012|Other|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
75620479|NCT02617459|Drug|Betaxolol eye drops|one drop per time; twice daily
75620480|NCT02854995|Procedure|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
75620481|NCT02854995|Procedure|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.[5] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
75912307|NCT04324554|Diagnostic Test|MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
75912308|NCT04838392|Device|RIGHTEST Continuous Glucose Monitoring System|RIGHTEST Continuous Glucose Monitoring System
75319824|NCT03904316|Biological|Biodesign Otologic graft|Acellular matrix derived from porcine small intestine submucosa
75319825|NCT03904316|Other|Autologous temporalis fascia|An autologous graft for tympanic membrane repair
76072769|NCT04794478|Device|Dexcom Continuous Glucose Monitoring System|Dexcom Continuous Glucose Monitoring System
75319826|NCT02133235|Procedure|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
75620482|NCT04192786|Other|Standard physiotherapy program+50 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
75620483|NCT04192786|Other|Standard physiotherapy program+100 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
75912309|NCT04454294|Other|Control|"Common Process Steps:~Informed consent forms will be signed by those who wish to take part in the research.~The form in which individual characteristics are questioned will be filled.~Hands will be washed, gloves will be worn.~Before the procedure, body temperature, heart rate, respiratory rate, blood pressure, oxygen saturation and bleeding amount will be recorded.~Drains will be kept parallel to the ground and upright.~Drainage hoses will not be bent and in-bed position will be provided in accordance with gravity.~It will be ensured that all connections between the chest tubes and drainage unit are tight and secure.~Dressings of the chest and mediastinum drains will be fixed on the patient's skin, so as not to interfere with drainage.~To prevent the tubes from coming out, they will be fixed to the patient bed.~Vital signs, Sp02 and bleeding amount will be recorded every hour for 6 hours after surgery"
75620484|NCT04192786|Other|Standard physiotherapy program|Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
75936323|NCT03627143|Other|KTI activities|"The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~Selection of one or more local physician champions from both the ED as well as the cardiology group;~Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~Development of local action plan addressing local barriers to implementation;~Provision of the free Smartphone App to be developed for the guidelines;~Regular reminders provided by the local research staff;~Audit and feedback charts of site compliance"
75620485|NCT02767726|Device|non-invasive multimodal imaging|
75620486|NCT02696512|Drug|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
75620487|NCT02696512|Device|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
75620488|NCT02696512|Dietary Supplement|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
75620489|NCT02696512|Other|Standard of Care|Standard of Care treatment
75620490|NCT00949533|Drug|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
75620491|NCT02767414|Device|Respirio Flu Test|The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
75620492|NCT02767414|Device|eLab Flu Test|The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
75620493|NCT02767414|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
75773663|NCT04138810|Other|VCE|Videoconference conducted according to a standard script which reviews the following key aspects of post-operative care: bowel functions, voiding functions, presence of vaginal bleeding, pain control, diet status, ambulatory status and any additional concerns. Standard post-operative instructions and precautions are reviewed as well.
75773664|NCT04138810|Other|Survey|Measure of satisfaction regarding post-op visit.
75773665|NCT00127166|Drug|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
75773666|NCT00127166|Drug|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
75319827|NCT02133235|Procedure|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
75319828|NCT05583266|Drug|Pentoxifylline sustained-release tablets|a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets
75319829|NCT05583266|Drug|Pentoxifylline sustained-release tablets placebo|Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
75620494|NCT02767258|Device|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
75620495|NCT02767258|Device|VIDISIC® GEL|Carbomer based gel, used in the treatment of dry eye.
75620496|NCT04224376|Device|App based Serious Gaming with the Genu Sport knee trainer|The Genu Sport knee trainer has a strength monitoring unit with three integrated sensors which is placed in the popliteal area and a tablet with the application which allows to transfer the raised force into the game modus. Each training session in our study takes around 5 minutes and is performed autonomously by the patient in his bed with 45° degrees of upper body evaluation while the patient holds the tablet in both hands. By simply pushing his knee downward onto the measuring unit the patient can apply the force.
75773667|NCT00127166|Drug|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
75773668|NCT00127166|Drug|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
75773669|NCT00127166|Drug|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
75773670|NCT00125138|Drug|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
75620497|NCT02854761|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
75620498|NCT00866047|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
75773671|NCT00125138|Drug|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
75773672|NCT00125138|Drug|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
75773673|NCT00125138|Drug|Placebo|Syrup formulation
75773674|NCT04132336|Drug|Naproxen sodium/Caffeine (BAY2880376)|Tablet, oral, single dose
75773675|NCT04132336|Drug|Naproxen sodium (Aleve)|Tablet, oral, single dose
75773676|NCT04132336|Drug|Caffeine|Tablet, oral, single dose
75936324|NCT05392101|Drug|Deferasirox 360 MG|Deferasirox 360 MG p.o. once daily
75936325|NCT04951739|Procedure|Peroral endoscopic myotomy|Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.
75620499|NCT01706692|Biological|Adalimumab|all dosages, frequencies and durations prescribed
75620500|NCT01706692|Biological|Etanercept|all dosages, frequencies and durations prescribed
75620501|NCT01706692|Biological|Infliximab|all dosages, frequencies and durations prescribed
75620502|NCT01706692|Biological|Ustekinumab|all dosages, frequencies and durations prescribed
75620503|NCT01706692|Drug|Cyclosporine A|all dosages, frequencies and durations prescribed
75773677|NCT04132336|Drug|Placebo|Tablet, oral, single dose
75773678|NCT04131556|Drug|Maribavir|Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
75773679|NCT04315636|Drug|Surfactant nebulisation|200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
75773680|NCT04295356|Biological|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks
75773681|NCT04295356|Biological|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks
75773682|NCT03691948|Other|Responsible Opioid Prescriber Education (ROPES)|The ROPEs intervention is a self-guided, web-based continuing dental education intervention. Consistent with ADA recommendations, ROPEs consists of seven modules of active content: (1) Overview; (2) Background on the Opioid Epidemic; (3) Dental Pain Management and the Role of Opioids; (4) Universal Precautions Approach; (5) Screening, Monitoring, and PDMP use; (6) Providing Patient Education; and, (7) Case Vignettes. All key intervention content is delivered via video-based platform and includes downloadable practice aides and resources.
75319830|NCT04405856|Device|Intra Aortic Balloon Pump|Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.
75620504|NCT01706692|Drug|Fumaric acids|all dosages, frequencies and durations prescribed
75620505|NCT01706692|Drug|Methotrexate|all dosages, frequencies and durations prescribed
75620506|NCT01706692|Drug|Other anti-psoriatic systemic treatments|all dosages, frequencies and durations prescribed
75620507|NCT02767336|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
75620508|NCT02617537|Drug|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
75773683|NCT03691948|Other|Active Comparator Control|An online PDF version of the Center for Disease Control Guideline for Prescribing Opioids for Chronic Pain.
75773684|NCT04126174|Device|femtosecond laser system arcuate corneal incision|Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
75773685|NCT04126174|Other|Manual LRI|Manual LRI
75773686|NCT04124926|Drug|Vonoprazan|Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
75773687|NCT04124926|Drug|Lansoprazole|Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
75773688|NCT03746158|Dietary Supplement|curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
75773689|NCT05321056|Device|masks (surgical mask, respirator)|The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model in the procedure room for measuring droplet exposure.
75773690|NCT03753100|Other|Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint|The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
75773691|NCT03747094|Drug|Fentanyl|0.5 mic/kg fentanyl will be given immediately before the procedure
75773692|NCT03747094|Drug|Ketamine|0.25 mg ketamine will be administered immediately before the procedure
75620509|NCT02617537|Drug|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
75773693|NCT04274686|Device|Tegaderm placement|Placement of perforated Tegaderm bandage over lower face, with diamond-shaped hole aligned with the patient's mouth, for use during bag-mask ventilation
75773694|NCT04274686|Other|No Tegaderm|Bag-mask ventilation performed in ordinary fashion, without use of Tegaderm bandage
75773695|NCT03753022|Other|Group G5|Submitted to peep 5
75773696|NCT03753022|Other|Group G10|Submitted to peep 10
75773697|NCT03753022|Other|Group G15|Submitted to peep 15
75773698|NCT03752944|Procedure|lefort I osteotomy for maxillary advancement|fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.
75620510|NCT04719442|Behavioral|Building Healthy Families|Building Healthy Families (BHF) is a family based obesity treatment program which includes key behavior change strategies including goal setting for both behavior change and weight loss, self-monitoring, rewards/contingency management, role modeling, and stimulus control/ modifying the environment. BHF includes a minimum of 32 contact hours consisting of three main program components: nutrition education, behavior modification, and physical activity. Participants and parents are expected to attend 12 continuous weeks of education (2 hours/session) followed by 12 weeks of relapse prevention refresher courses. Relapse prevention refresher sessions are every three weeks for one hour to re-evaluate goals, discuss rewards/contingency management and changes in stimulus control with seasonal changes and holidays. A final follow-up check-in session is conducted at 12 months for approximately 1 hour.
75773699|NCT03752788|Behavioral|Dual-task Training Fixed Priority|"Dual-task training fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
75773700|NCT03752788|Behavioral|Dual-task Training Variable Priority|"Dual-task training variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
75773701|NCT04113694|Device|Extended Infusion Set|Each subject is asked to wear each Extended Wear Infusion Set for at least 174 hours.
75773702|NCT03745846|Biological|Composite Gel Containing Black Raspberry|Composite Gel Containing Black Raspberry 3,000/preparation
75773703|NCT03745846|Biological|placebo|Composite Gel Containing Black Raspberry-placebo
75912310|NCT04454294|Other|Experimental Group (Absorption Group)|"Common process steps~Appropriate negative pressure monitoring system of the patient, who is admitted to the intensive care unit with underwater drainage system, will be established.~The suction control room combined with the vacuum regulator will be filled with sterile distilled water up to the specified level (20 cm H2O).~From the vacuum regulator, the drain or drains will be connected tightly and by preventing the crimping, from the aspirator receptor hoses.~Suction will begin with a low level and gradually increase the suction until a slight bubble is noticed in the suction control room.~Suction pressure will be maintained between 5 and 15 kPa (kilopascals) or 10-20 cm H20.~The application will continue without interruption until the patient's drain need and the doctor's request is ended.~During the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
75912311|NCT04454294|Other|Experimental Group (Milking Group)|"Common process steps will be applied~Operation will start from the area near the drain entrance point~Latex tube will be folded into 12 cm long pieces and will be gripped with two hands~The procedure will be repeated 3 times by compressing the parts gripped by the nurse hand.~This process will be repeated in the distal part.~After the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
75912312|NCT02782806|Device|Masimo Rad-67 Pulse Oximeter|Noninvasive pulse oximeter
75912313|NCT05389358|Behavioral|Asiphephe health worker training|Lay health workers are already employed by the Department of Health and are trained in-service (30 hours) and receive monthly supervision (total of approximately 6 one-on-one hours; 15 group hours).
76072770|NCT04760938|Behavioral|Outdoor Behavioral Healthcare (OBH)|Participants in this intervention will participate in one of 7 programs that have been accredited by the Outdoor Behavioral Healthcare Council that specializes in 13-17 year old adolescents experiencing behavioral healthcare issues. Each program works in a unique wilderness setting in various United States National Forests and Parks (e.g., Washington, Oregon, New Mexico, Wisconsin, Utah). The average length of stay in an OBH wilderness program is 90 days, which is a total standard care time of 1,056 hours. All of the OBH programs have been accredited by the Association for Experiential Education Accreditation for Outdoor Behavioral Healthcare programs.
75620511|NCT00869323|Biological|rituximab|375 mg/m^2 intravenously on Days 1,8, 15 and 22
75620512|NCT00869323|Drug|bortezomib|1.3 mg/m^2 intravenous bolus days 1, 8, 15 and 22
75620513|NCT02775058|Device|synergoss Pxx|dental grafting
76072771|NCT04760938|Behavioral|Cognitive Behavioral Therapy (CBT)|The 12-week treatment period will consist of 15 90-minute sessions that will be administered individually. Homework (including reading assignments) are given to encourage your child to practice the techniques learned during the weekly sessions. The total standard of care time for CBT is 22.5 hours of direct treatment hours not including time spent on homework over these twelve weeks. Those therapists that are selected to deliver treatment for the CBT group will be certified by a nationally recognized CBT organization and licensed to work as a therapist in the state where they are providing treatment. Therapy will be delivered in an outpatient setting or through Telehealth.
75620514|NCT02774980|Behavioral|Recurrent depression|
75620515|NCT02767102|Other|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
76072772|NCT01803607|Drug|odanacatib|odanacatib 50 mg oral tablet
76072773|NCT01803607|Other|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
75319831|NCT00607243|Biological|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
75620516|NCT02767102|Other|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
75620517|NCT02774902|Drug|TAK-438|TAK-438 tablets
75620518|NCT02774902|Drug|Clarithromycin|Clarithromycin tablets
75620519|NCT04662970|Device|Device programming|Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
75620520|NCT02766946|Device|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
75465755|NCT01901458|Device|Spectra Optia® Collection Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
75465756|NCT01901471|Drug|Single bolus of Placebo of CicloMulsion® (Neurovive).|"The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
75620521|NCT02766946|Device|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
75620522|NCT02766946|Other|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
75620523|NCT02766946|Other|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
75620524|NCT02766868|Drug|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
75620525|NCT02774434|Device|JM-105|Measurement of TcB via the JM-105 device
75620526|NCT02767024|Drug|Sodium nitroprusside|Sodium nitroprusside is a medication used to lower blood pressure.
75620527|NCT02767024|Drug|Dobutamine|Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ÃŸ receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.
75620528|NCT02767024|Drug|Furosemide|Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
75620529|NCT02766790|Dietary Supplement|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
75620530|NCT02766790|Other|Placebo|Placebo, an inactive formulation
75620531|NCT02774200|Drug|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
75620532|NCT02766712|Procedure|Pace During 1st Half of Lesion|
75620533|NCT02766712|Procedure|Pace During 2nd Half of Lesion|
75620534|NCT01192022|Biological|TachoSil®|Intraoperative application as secondary hemostatic treatment
75620535|NCT01192022|Device|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
75319832|NCT04143074|Behavioral|multidisciplinary behavioral intervention|behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
75319833|NCT04142918|Other|Immunostaining|Immunostaining of oral mucosa/gingiva samples
75319834|NCT00607321|Device|Medtronic Bifurcation Stent System|Percutaneous Coronary Stenting
75620536|NCT02766634|Biological|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
75620537|NCT02766634|Biological|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
75620538|NCT04857190|Device|Parker Flex-it Directional Stylet|Parker Flex-it Directional Stylet
75620539|NCT04857190|Device|Conventional Malleable Stylet|Conventional Malleable Stylet
75620540|NCT02774044|Drug|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
75620541|NCT02774044|Drug|Survanta|
75620542|NCT00635206|Device|BiPap auto with Fi Flex|"MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)~MaxIPAP = 25 cm H2O~MinPS = 2 cm H2O (cannot be adjusted)~MaxPS = 8 cm H2O~Bi-Flex setting of 3"
75620543|NCT00635206|Device|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)
75620544|NCT02766556|Drug|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
75620545|NCT02766556|Procedure|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
75620546|NCT02766556|Drug|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
75620547|NCT01191944|Drug|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
75620548|NCT01191944|Drug|pramipexole extended release tablet|0.375mg-4.5mg, once a day
75620549|NCT02774512|Drug|Nilotinib|Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
75620550|NCT04224844|Other|Erector spinae plane block|The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.
75620551|NCT04224844|Other|Control group|Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.
75319835|NCT04142840|Drug|Dexmedetomidine|a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia
75319836|NCT04142840|Drug|Propofol|a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
75465757|NCT01901471|Drug|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|"The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).~Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.~CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.~CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
75465758|NCT01901484|Drug|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
75465759|NCT01901497|Device|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
75465760|NCT01901510|Drug|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
75465761|NCT01901510|Other|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
75620552|NCT02773888|Device|HS-1000|
75465762|NCT01901523|Behavioral|Reporting of discrepancy to journal|
76072774|NCT02958514|Device|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of *500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
75620553|NCT04223908|Other|observational : questionnaries for assessment of health burden|The French IN-FOCUS study was designed to capture current and retrospective data in FCS or MCS. Patients were called by the participating centers and were proposed to answer a paper questionnaire or to connect to a web-based questionnaire The questionnaire was divided into sections specifically assessing various domains of their experience: demographic data, signs, symptoms and complications of the disease, healthcare circuit, management, relationship with healthcare providers, and burden of the disease on daily life. (Details are available as supplementary material S1). The questionnaire focused on symptoms because the interest of quality of life assessment tools is debated in rare diseases with episodic manifestations. Indeed, most of these tools refer to a limited recall period.
75620554|NCT01191788|Behavioral|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
75620555|NCT01191788|Behavioral|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
76072775|NCT02958514|Drug|Tobramycin and Dexamethasone Ophthalmic Ointment|
76072776|NCT04388722|Device|Pulse CO-Oximeter Sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
76072777|NCT04667260|Procedure|Maxillary sinus membrane elevation|Maxillary sinus membrane elevation with blood coagulum
76072778|NCT04667260|Procedure|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
75319837|NCT04142762|Drug|ABI-H2158|ABI-H2158 tablets
75319838|NCT04142762|Drug|Itraconazole|Itraconazole capsules
75620556|NCT00940875|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle
75620557|NCT00940875|Drug|gemcitabine|1250mg/m2/day on days 1 and 8 of each 4 week cycle
75620558|NCT00940875|Drug|gemcitabine|1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
75620559|NCT02766322|Other|Oral Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
75620560|NCT02766322|Other|Oral Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
75620561|NCT02766322|Other|Intravenous Alcohol Challenge Test (Clamp)|Subjects will be evaluated with an alcohol clamp (i.e. alcohol will be infused intravenously until reaching 60mg/dl and this blood alcohol concentration will be kept constant for two hours). We will record subjective responses to alcohol throughout different times of the clamp.
76072779|NCT05290168|Diagnostic Test|abdominal Doppler|"Inferior vena cava diameter and distensibility~Hepatic vein Doppler~Portal vein Doppler~Splenic artery and vein Doppler~Renal artery and vein Doppler"
75319839|NCT04142762|Drug|Rifampin|Rifampin capsules
75319840|NCT04142762|Drug|Midazolam|Midazolam syrup
75319841|NCT04142762|Drug|Ethinyl Estradiol / Levonorgestrel|Ethinyl Estradiol / Levonorgestrel tablets
75319842|NCT04142762|Drug|Esomeprazole|Esomeprazole capsules
75319843|NCT04142762|Drug|Placebo matching oral contraceptive|Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
75319844|NCT00607867|Other|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
75319845|NCT00607867|Other|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
75319846|NCT03020264|Device|glycemic sensor FREESTYLE Libre Pro|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
75319847|NCT03445520|Behavioral|Intervention Coaching Group|Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
75319848|NCT03586778|Other|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
75319849|NCT03586778|Other|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
75620562|NCT02766322|Other|Intravenous Alcohol Self-administration Test|"Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit."
75319850|NCT03586778|Other|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
75620563|NCT00624572|Drug|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
75620564|NCT02774122|Device|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
75319851|NCT04142528|Device|ParkinPal|Wear and periodic recording of motion data during daily wear
75319852|NCT02138227|Behavioral|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
75319853|NCT02138227|Behavioral|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
75319854|NCT03586700|Drug|Xiao zhong fang granules|Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.
75319855|NCT03586700|Radiation|Short wave infrared radiation|Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
75319856|NCT03586700|Drug|Placebo Xiao zhong fang granules|Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
75319857|NCT02275923|Device|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
75319858|NCT02139007|Drug|Alendronate|
75465763|NCT01901536|Behavioral|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
75465764|NCT01901549|Procedure|Renal denervation|The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
75773704|NCT04105972|Drug|ELX/TEZ/IVA|FDC tablet for oral administration.
75319859|NCT03833115|Other|vaginal gel containing or not sodium lauryl sulfate|Prevention
75319860|NCT04142138|Other|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
75465765|NCT01901549|Drug|Metoprolol|Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
75319861|NCT01590277|Drug|Active Ethanol|Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
75465766|NCT01901549|Drug|Lisinopril|ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
75620565|NCT02774122|Device|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
75773705|NCT04105972|Drug|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
75773706|NCT04105972|Drug|IVA|Mono tablet for oral administration.
75773707|NCT04102540|Other|Infographic intervention|Information visualizations (infographics) will be used to teach participants about HIV during study visits immediately following their normal clinic visits.
75773708|NCT00124982|Drug|Abatacept|IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
75912314|NCT05389358|Behavioral|Asiphephe therapeutic sessions|Asiphephe sessions are manualized using illustrated job aids, a participant workbook, session checklists, and an intervention manual. The model is informed by problem-solving therapy (Lund, 2018), trauma-informed coping (Sikkema, 2018) and safety planning (Garcia-Moreno, forthcoming) and was piloted with 12 health workers with input from 3 global mental health experts.
75620566|NCT02851017|Other|Exercise|This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
75773709|NCT00124982|Drug|Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)|During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
75773710|NCT00124982|Drug|Anti-Tumor Necrosing Factor (TNF) Therapy|Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
75319862|NCT01590277|Drug|Active Iomazenil|Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.
75465767|NCT01901601|Procedure|LALAK|"A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
75620567|NCT05656274|Drug|JS1-1-01|Oral tables
75620568|NCT05656274|Drug|Placebo|Oral tables
75620569|NCT02773810|Other|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
75773711|NCT04263142|Drug|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
75773712|NCT04263142|Drug|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
75773713|NCT04095286|Drug|AMB new formulation (1 mg)|AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
75912315|NCT05389358|Other|IPV assessment|IPV intensity as measured by WHO Multicountry Study Instrument at a cut-off of any past-year physical/sexual/psychological violence exposure vs. none
75912316|NCT05389358|Other|Referral for IPV or Mental Health|Study staff are trained to recognize signs or symptoms of distress and to make appropriate referrals to appropriate community-based services, if necessary. Experienced mental health professionals on the investigative can be consulted or referred to should a participant exhibit severe symptom of mental distress.
75465768|NCT01901601|Procedure|IEK|"A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
76072780|NCT01867021|Biological|Fluvirin(TIVf)|
75319863|NCT01590277|Drug|Placebo|Control: no alcohol, administered for a total of 90 minutes.
75319864|NCT01590277|Drug|Placebo|Control: no iomazenil, administered for a total of 10 minutes
75319865|NCT03586622|Dietary Supplement|Low FODMAP diet (LFD)|The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
75620570|NCT05656118|Device|Genoss® DCB|Paclitaxel coated balloon with a shellac plus vitamin E excipient
75620571|NCT02766010|Device|TensorTip|Non Invasive screening of various physiological and hematological parameters.
75773714|NCT04095286|Drug|Reference AMB (5 mg)|AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
75773715|NCT04093414|Device|Select Secure pacing lead|A Select Secure pacing lead is placed in the bundle of His or Left bundle branch area based upon randomization
75773716|NCT04093258|Device|Dailies Total 1® Multifocal Contact Lenses|TEST
75773717|NCT04093258|Device|Air Optix® Multifocal Contact Lenses Plus HydraGlyde®|CONTROL
75773718|NCT04253236|Drug|RVT-1401 680 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
75773719|NCT04253236|Drug|RVT-1401 340 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
75773720|NCT04087720|Biological|Pegloticase|intravenous (IV) infusion
75773721|NCT03747016|Dietary Supplement|high-energy digestible food E2|The women undergoing Cesarean section are given high energy digestible food 300ml before surgery
75912317|NCT04853680|Device|Anti-adhesion barrier (Collarbarrier)|Collagen derived anti-adhesion barrier
75912318|NCT04853524|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
75912319|NCT04853524|Drug|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)|A combination of BIC, FTC and TAF will be administered orally.
75912320|NCT04853134|Drug|Proxalutamide|200 mg q.d.
76072781|NCT01867021|Biological|Agriflu (TIV)|
76072782|NCT01866709|Drug|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
75912321|NCT04853134|Other|Standard of Care|Standard of care as determined by the PI
75912322|NCT05389202|Other|Perfusion CT scanning|Abdominopelvic CT scan with perfusion and spectral analysis performed 7 days (± 5 days) before prostate embolization.
75912323|NCT04852900|Other|Decompression with 30%|"Hot Pack for 10 mins Soft Tissue Mobilization~Muscle Strengthening~Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
75912324|NCT04852900|Other|Decompression with 40%|"Hot Pack for 10 mins Soft Tissue Mobilization~Muscle Strengthening~Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
75319866|NCT03586622|Dietary Supplement|VSL#3®|VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum* BL03, B. infantis* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus** BD08; *Recently reclassified as B. animalis subsp. lactis ** Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
75912325|NCT04852900|Other|Decompression with 50%|"Hot Pack for 10 mins Soft Tissue Mobilization~Muscle Strengthening~Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
75620572|NCT04317560|Procedure|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
75912326|NCT05164328|Other|No intervention|No intervention
75912327|NCT04852744|Other|Brain MRI|"Anatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min).~The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner & Friston, 2000]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups."
75620573|NCT04317560|Procedure|injectable platelet rich fibrin injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
75465769|NCT01901601|Drug|Retrobulbar Block or General Anesthesia|
75912328|NCT03040882|Other|cotton sock|Application of a cotton sock in the immediate postoperative period before applied the Walker
75773722|NCT03747016|Dietary Supplement|glucose injection G2|The women undergoing Cesarean section are given glucose injection 300ml before surgery
75912329|NCT03040882|Other|Elastic Compression Wraps|Application of an Elastic Compression Wraps in the lower limb in the immediate postoperative period before applied the Walker (standard care)
75319867|NCT03586466|Device|BupreCare|"Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device."
75465770|NCT01901601|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.
75773723|NCT03747016|Dietary Supplement|normal saline N2|The women undergoing Cesarean section are given normal saline 300ml before surgery
75773724|NCT03747016|Dietary Supplement|high-energy digestible food E1|The women in delivery room are given high energy digestible food 300ml.
75912330|NCT03037762|Procedure|Flexible Endoscopic Evaluation of Swallowing|
75912331|NCT04843540|Drug|CTP-543|Rifampin as oral capsule
75465771|NCT01901601|Drug|Topical Anesthesia|
75465772|NCT01901601|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
75773725|NCT03747016|Dietary Supplement|glucose injection G1|The women in delivery room are given glucose injection 300ml.
75773726|NCT03747016|Dietary Supplement|normal saline N1|The women in delivery room are given normal saline 300ml.
75773727|NCT04086472|Biological|Clesrovimab|Single dose of clesrovimab administered via IV infusion.
75773728|NCT04086472|Other|Placebo|Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.
75912332|NCT04838470|Other|cardiac rehabilitation|multidisciplinary disease management program
75912333|NCT05380622|Diagnostic Test|Coronary CT angiography|"Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge.~Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab."
75912334|NCT04838548|Drug|MRG003|Administered intravenously
75912335|NCT05379062|Behavioral|Active Singing Group|The participants of the Active Singing Group take part in a weekly 45-minute singing activity in a group over a period of 3 months. In total the investigators expect 12 choir rehearsals. The rehearsals will take place between 2pm and 3.30pm in the church of the Wehrle-Diakonissen Private Clinic in Salzburg. The group will be led by a professional and experienced choir director.
75773729|NCT04086472|Biological|RSV-A Memphis 37b|Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
75773730|NCT03752632|Device|Veinplicity with tourniquet|Veinplicity will be used with a tourniquet
75620574|NCT04192708|Procedure|intercostal nerve block under direct vision|When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
75319868|NCT03586466|Drug|Buprenorphine/naloxone|Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
75773731|NCT03752632|Device|Tourniquet|A tourniquet alone will be used.
75773732|NCT03752554|Procedure|segmental resection|All cases will undergo surgery under general anesthesia. The mandibular lesion will be segmentally resected. The cuts will be performed with the aid of the prefabricated digital template. The neurovascular bundle will be separated and protected. Then reconstruction will be performed
75912336|NCT05379062|Behavioral|Receptive Music Group|The participants of the Receptive Music Group will individually listen to the already researched CD for Parkinson's patients (Bernatzky, Wendtner, Volc, 2012) at home at the same time on one weekday.
75620575|NCT04192708|Procedure|intercostal nerve block under ultrasound guidance|After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
75773733|NCT04249336|Drug|Fluoro-Calcium-Phospho-Silicate based dentifrices|Bio-Active glass based formulation
75773734|NCT04249336|Drug|8% Arginine based dentifrices|Tubular occluding formulation
75773735|NCT04249336|Drug|8% Strontium Acetate|Tubular occluding formulation
75773736|NCT04249336|Drug|Sodium Fluoride|No claim of relieving Dentin Hypersensitivity
75773737|NCT03752476|Procedure|number of Beta lactam class prescription for the same infection|Each number of Beta lactam prescription without interruption are compared
75912337|NCT04838158|Diagnostic Test|Isokinetic measurements|Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).
75912338|NCT05216198|Other|Check of the different exams performed at the emergencies|Check of the different exams performed at the emergencies
75773738|NCT04245202|Device|HFNCOT|The patient will receive a high flow nasal of humidified oxygen, set between 2 to 25 l/min. The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation >92%.
75773739|NCT04245202|Other|St-FMOT|The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation >92%.
75912339|NCT04852510|Drug|Metformin Versus a combination of Metformin and Thymoquinone (TQ)|Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
75773740|NCT03979924|Behavioral|Trismus rehabilitation|"The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,…) in order to strengthen the stretching."
75319869|NCT03586466|Other|MEMS|Subjects will receive their medication in a MEMS pill bottle.
75319870|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
75319871|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
75319872|NCT00570349|Drug|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
75465773|NCT01901640|Drug|DA-8159 (Udenafil)|
75465774|NCT01901666|Drug|Growth Hormone|"All GH deficient patients with bone age <14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.~Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy"
75465775|NCT01901692|Radiation|TACE+External beam RT|Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
75465776|NCT01901692|Drug|Sorafenib|Sorafenib 800 mg/day orally
75773741|NCT03752164|Behavioral|Yoga and Mindfulness Skills|Single brief session in which children are taught yoga and skills in mindfulness
75773742|NCT04079842|Device|INVSENSOR00029|Noninvasive pulse oximeter sensor
75773743|NCT03745534|Other|eABR|eABR
75465777|NCT01901705|Drug|Indigo naturalis ointment|The Indigo naturalis ointment was composed of a 1:10 mixture of Indigo naturalis powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio)
75465778|NCT01901705|Drug|Placebo|The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake [Blue #32] and 45.2% Allura Red AC aluminum lake [Red #40] powders), Vaseline, microcrystalline wax, and olive oil.
75620576|NCT04192708|Procedure|paravertebral block under ultrasound guidance|"Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist"
75620577|NCT05655728|Drug|Metformin|The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose [maximum: 1500 mg/day]).
75319873|NCT03586388|Other|Oral immunotherapy protocol|"In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk."
75620578|NCT05655728|Other|Placebo|The participants will receive treatment of placebo.
75465779|NCT01901731|Procedure|transjugular coil embolisation of pelvic veins|
75465780|NCT01901731|Procedure|endovenous treatment of leg varicose veins|
75912340|NCT05204810|Other|Anticoagulation strategy|For each session of this cross-over study, a different anticoagulation therapy is used: either 1 dose of anticoagulant or 2 doses of anticoagulant
75465781|NCT01901744|Procedure|Cataract Surgery|
75912341|NCT05204810|Other|Blood sampling|During the study sessions, blood sampling is performed from the arterial blood line at different time points (5min, 60min, 240min and at the dialysis end)
75912342|NCT05204810|Other|Scanning of hemodialyzer with micro-computed tomography|After the study sessions, the used hemodialyzers are scanned using a gold standard micro computed tomography technique.
75912343|NCT04843384|Other|Reiki|Reiki was performed according to the need of each patient and lasted an average of 20-25 minutes. After the procedure, the patients were left to rest for ten minutes. The researcher was focused in a neutral way on the sessions without the intention of healing. After the session, the patients were allowed to rest for ten minutes.
75319874|NCT04141826|Dietary Supplement|Hydrolysed whey|500 mL solution of 25 gram hydrolysed whey per day during 4 weeks
75319875|NCT04141826|Dietary Supplement|Intact whey|500 mL solution of 25 gram intact whey per day during 4 weeks
75465782|NCT01901757|Drug|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
75773744|NCT04078126|Combination Product|BFF|Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
75773745|NCT04078126|Combination Product|Symbicort Turbuhaler|Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
75319876|NCT04141826|Dietary Supplement|Caseinate|500 mL solution of 25 gram casein ate per day during 4 weeks
75465783|NCT01901757|Drug|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
75465784|NCT01901783|Procedure|With primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
75465785|NCT01901783|Procedure|Without primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
75773746|NCT04073368|Dietary Supplement|AXA1957|Amino acids, food study
75773747|NCT04073368|Dietary Supplement|AXA1125|Amino acids, food study
75773748|NCT04073368|Dietary Supplement|Placebo|Amino acids, food study
75773749|NCT03745456|Diagnostic Test|Blood samples for ROTEM and platelet function.|Thormoboelastometry is based on the measurement of elasticity of blood by continuous graphical logging of the firmness of a blood clot during clot formation and subsequent fibrinolysis
75773750|NCT04380688|Drug|Acalabrutinib|Acalabrutinib administered orally
75773751|NCT00124748|Drug|Imatinib mesylate|Imatinib is packaged in bottles as 100mg and 400mg tablets
75465786|NCT01901796|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
75465787|NCT01901822|Procedure|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
75465788|NCT01901822|Procedure|Sutured separately|The soft tissue and the allograft will be sutured separately using a continuous sling suture.
75465789|NCT01901835|Procedure|mind-body intervention procedure|Participate in media diversion with humorous and non-humorous movies
75773752|NCT04070326|Drug|Lanadelumab|Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
75912344|NCT04843384|Other|Sham reiki|With the Sham Reiki patients, a nurse without reiki training performed Sham Reiki randomly for approximately 20-25 minutes, following a protocol which did not include the body's energy centers or chakras.
75465790|NCT01901835|Other|survey administration|Ancillary studies
75465791|NCT01901835|Procedure|quality-of-life assessment|Ancillary studies
75465792|NCT01901887|Drug|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
75912345|NCT04852432|Device|high flow nasal cannula|The heated air is administered at a rate of 2L/kg/min using an Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand). Inhalation oxygen concentration starts with 50%.
75912346|NCT04852432|Device|nasal prong|Oxygen is administered via nasal prong
75620579|NCT02773654|Other|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
75620580|NCT02773654|Other|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
75912347|NCT05163704|Drug|Dexmedetomidine|Dexmedetomidine is a beneficial sedative for children. It provides a sedation equivalent to a natural deep sleep with negligible respiratory effects. Administration via the nose provides better absorption and faster impact effect. The drug does not taste and does not sting when administered.
75465793|NCT01901887|Drug|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
75773753|NCT01078142|Drug|Temsirolimus, Rituximab, Bendamustin|"Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)"
75912348|NCT03037840|Device|Low intensity amplitude-modulated RF EMFs|Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
75912349|NCT04838002|Device|Extracorporeal shock wave|Focus and Radial types Extracorporeal shock wave therapy
75912350|NCT03130556|Drug|Glasdegib|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
75912351|NCT03130556|Other|High Fat, High Calorie Meal|A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
75912352|NCT03130556|Drug|Rabeprazole|A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
75912353|NCT04838080|Biological|Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 4 µg/0.5 ml Vaccine|Two applications on Days 0 and 21
75912354|NCT04838080|Biological|Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 6 µg/0.5 ml Vaccine|Two applications on Days 0 and 21
75912355|NCT04838080|Biological|Placebo|Two applications on Days 0 and 21
75912356|NCT04842838|Device|paclitaxel DCB|Drug-coated balloon is a new kind of coronary interventional device. The balloon coated with anti-cell proliferation drugs (paclitaxel, etc.) is sent to the stenosis site. The balloon is closely adhered to the vascular wall during the expansion, and the drug is rapidly and evenly coated on the disaffected vessels.In recent years, DCB has gradually become an alternative for the treatment of in-stent restenosis (ISR), small vessel disease (SVD) and bifurcation disease.
75912357|NCT04842838|Device|DES|Provisional T technique is the preferred method for the treatment of bifurcation lesions with the existing stent.According to the 2018 European Guidelines on revascularization and the consensus group of the European Bifurcation Club (EBC), Provisional T technique is still the first choice for the treatment of Bifurcation, despite the problems related to side branches.
75912358|NCT03877016|Procedure|TENS|TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
75319877|NCT05582486|Behavioral|obstetric violence prevention education intervention|While the training program for the prevention of obstetric violence consisting of 16 sessions was applied by the researcher to the midwives and nurses in the experimental group, no intervention was applied to the midwives and nurses in the control group.
75465794|NCT01901913|Device|MD-bolus calculator for pre-meal bolus|
75773754|NCT03689452|Device|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is defined as an autologous concentration of human platelets that is 3 to 5 times greater than physiologic concentration of platelets in whole blood. Using the Eclipse PRP system, the participants PRP will be attained. The PRP will then be used as described in the arm/group description section.
75773755|NCT03689452|Drug|Normal saline|Preservative-free normal saline will be used as described in arm/group description section.
75773756|NCT04067050|Device|comfilcon A asphere|Contact Lens
75773757|NCT04067050|Device|Spectacles|Habitual spectacles
75912359|NCT03037606|Drug|Rabelis DDR 50 mg Capsules|Rabelis DDR 50 mg Capsules once daily for seven days.
75912360|NCT03037606|Drug|Pariet 20 mg Enteric Coated Tablets|Pariet 20 mg Enteric Coated Tablets once daily for seven days.
75912361|NCT05391152|Device|robotic assisted total knee replacement|the study group used robotic-arm assisted total knee replacement.
75912362|NCT05391152|Device|traditional total knee replacement|the control group used traditional total knee replacement
75319878|NCT05582330|Other|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke
75319879|NCT00608491|Drug|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
75465795|NCT01901913|Device|No MD-bolus calculator for pre-meal bolus|
75465796|NCT01901926|Procedure|Non Surgical Periodontal Treatment|one time intervention in the form of scaling and root planing
75465797|NCT01901939|Other|exercise|daily tailored low level pedaling exercise at bedside
75465798|NCT01901952|Behavioral|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
75620581|NCT02887430|Other|foot reflexology therapy|standard care and foot reflexology
75620582|NCT00940485|Drug|entecavir|0.5mg po daily for 8 weeks
75620583|NCT00940485|Drug|entecavir|0.5mg po daily for 48 weeks
75620584|NCT00940485|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
75620585|NCT02696356|Biological|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
75773758|NCT04060654|Drug|Sublocade|SUBLOCADE to be administered approximately every 4 weeks per local standard of care
75620586|NCT02765932|Procedure|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
76072783|NCT01866709|Drug|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
75620587|NCT02765932|Procedure|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
75620588|NCT02773186|Other|monitoring cerebral oxygen saturation|Children undergoing urological surgery also required of locoregional blockade. Anesthetic induction was achieved with high concentration sevoflurane 6-8% (Sevorane®, Abbvie) and oxygen 50%. Anesthetic maintenance was done with sevoflurane 2-3%, 50% O2/air mixture, fentanyl 1 µg.kg.-1 iv, and rocuronium 0.3 µg.kg.-1 iv if required. Electrocardiogram (ECG), non-invasive arterial pressure, pulse oximetry, end-tidal carbon dioxide and cerebral NIRS oximetry was monitoring by using an INVOSTM5100 (Somanetics Corporation, Troy, MI, USA).
75773759|NCT00096200|Drug|Carboplatin|Given IV
75773760|NCT00096200|Drug|Paclitaxel|Given IV
75773761|NCT00096200|Drug|Sorafenib Tosylate|Given orally
75912363|NCT04851652|Other|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
75912364|NCT04851574|Drug|Sugammadex Injection|Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.
75620589|NCT05655416|Procedure|Endovenous chemical ablation with Trendelenburg's operation (eCAT)|Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
75773762|NCT04059094|Drug|BI 1265162|Inhalation solution
75773763|NCT04059094|Drug|Placebo|Inhalation solution
75773764|NCT03745378|Other|JAK2V617F mutation|JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
75773765|NCT00096044|Biological|rituximab|IV
75773766|NCT00096044|Drug|lenalidomide|Oral
75773767|NCT01082822|Biological|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
75773768|NCT03963128|Dietary Supplement|Supplementation Vitamin D3|Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)
75912365|NCT04842994|Device|IONM tube|The standardized technique of IONM-RLNs (bilaterally) will be used, including indirect vagal response evaluation at the beginning and also at the end of surgery according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group (INMSG) (Randolph GW, Dralle H. 2011).
75912366|NCT05165420|Other|Cosmetic product|RV4941A is a face cream product
75912367|NCT04842370|Drug|PHI-101|PHI-101, oral, once-daily administration, consisting of 28-days per 1 cycle
75912368|NCT03037450|Procedure|Miniinvasive corneal neurotization|Neurotization of a neurotrophic cornea
76072784|NCT04621630|Drug|PN-235|Active Drug
76072785|NCT04621630|Drug|Placebo|Matching Placebo
76072786|NCT01841593|Drug|Raltegravir|Isentress 400mg tablet taken twice daily
76072787|NCT01841593|Drug|Amlodipine|generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
75912369|NCT03037372|Drug|ART, Atorvastatin|ART, Atorvastatin
75912370|NCT03037372|Drug|ART, Rosuvastatin|ART, Rosuvastatin
75912371|NCT03037372|Drug|ART, No statin|ART, No statin
76072788|NCT05238298|Device|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
76072789|NCT05231824|Behavioral|Standard Behavioral Weight Loss Treatment|Behavioral weight loss treatment is the current gold standard treatment for obesity.
76072790|NCT05231824|Behavioral|AI-optimized Behavioral Weight Loss Treatment|AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
76072791|NCT02520544|Device|Accolade stem|Total hip replacement
75773769|NCT03963128|Dietary Supplement|Placebo|Placebo administred every two months
75773770|NCT01082900|Other|Prophylactic CPAP Administration|"EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room"
75773771|NCT01082978|Device|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
75912372|NCT03037372|Drug|Healthy-HIV-negative|Age-matched, Healthy HIV-negative
75912373|NCT03037138|Other|Blood flow Rate profiling|Blood flow rate profiling during dialysis session
75912374|NCT04851418|Device|Possible NSTE-ACS|As mentioned in the group description
76072792|NCT02520544|Device|Accolade II stem|Total hip replacement
76072793|NCT02520544|Device|Trident/Tritanium cup|Total hip replacement
76072794|NCT02454322|Drug|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
76072795|NCT04505566|Drug|Ketorolac 0.45% ophthalmic solution|Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
76072796|NCT04505566|Drug|Placebo - Preservative-free artificial tears|Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
75620590|NCT02854683|Drug|Normal Saline|1 liter of intravenous saline will be delivered over 1 hour
75773772|NCT01082978|Device|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
75773773|NCT03963050|Other|Exercise Training|The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
75773774|NCT03963050|Other|Exercise Training + Cognitive Training|"ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.~CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts."
75620591|NCT02854683|Dietary Supplement|Oral Rehydration Solution|1 liter of ORS solution given by mouth
76072797|NCT04505566|Other|Aqueous PGE2 and inflammatory cytokines measurements|After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
75773775|NCT03963050|Other|Control|NO changes in lifestyle
75912375|NCT04851730|Procedure|Orthopedic Physical Therapy Intervention|"First, a deep slow breathing protocol is intended to increase the expansion of the pelvic floor, utilizing the relationship between the diaphragm and the pelvic floor, resulting in a gentle stretching of the pelvic floor.~Next, abdominal soft tissue mobilization, or scar mobilization of the lumbopelvic abdominal area will take place.~Next, manual therapy to the thoracic or lumbar spine or the hips will be performed based on the impairments found in the orthopedic evaluation.~The participant will be given a home exercise program to support breath training, and manual therapy. During the initiation of the second visit each participant will watch a standardized pain education video on the tablet, Understanding pain in less than 5 minutes and what to do about it The above plan of care will be completed 2 times/week for 4 weeks for a total of 8 visits."
75912376|NCT04851730|Device|Dry Needling|"Third, the investigator will dry needle appropriate muscles. Dry needling treatment technique will include insertion of a sterile, disposable, solid filament needle into the muscle belly in the area palpated as listed below. A 0.30 × 0.50mm, or specified size below, stainless steel Seirin J-type or Myotech needle will be used (Dommerholt 2011). Clean technique will be employed throughout the treatment procedure which includes hand washing, clean latex-free glove use, and skin-surface preparation with an alcohol swab ( Baima & Isaac 2008). Each muscle will receive a maximal number of 2 insertions and each insertion consists of up to 5 seconds of a pistoning (in and out motion) technique in an attempt to elicit a local twitch response. Standard protocol for each muscle will be established prior to beginning data collection.~Details about the dry needling protocol can be found in Appendix L."
75912377|NCT03708068|Other|Early exclusive enteral nutrition|Infants will be fed at least 80% of reference daily fluid intake from day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards to meet reference daily fluid intake until infant reaches full enteral feed.
75912378|NCT04842136|Other|Scales and indexes|Patients with TMD regardless of diagnosis with sleep bruxism were assessed with the Jaw Function Limitations Scale (JFLS), Neck Disability Index (NDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and Headache Impact Test-6 (HIT-6) scales.
75912379|NCT04646330|Drug|AK104+anlotinib|Subjects receive AK104 10mg/kg intravenously (IV) every 2-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
76072798|NCT04387864|Device|Whole-body Vibration Device|Power Plate® (pro5TM; Power Plate North America, Inc., Northbrook, IL, USA)
76072799|NCT02132650|Behavioral|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
75319880|NCT00608491|Device|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
75319881|NCT02985086|Drug|Cefoxitin|
75319882|NCT02985086|Drug|oxytocin/misoprostol|
76072800|NCT02132650|Behavioral|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
75620592|NCT04317248|Drug|Cyclophosphamide|Intravenous drip，250mg/m^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
75620593|NCT04317248|Biological|Multiple Signals loaded Dendritic Cells Vaccine|one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, intravenous driptotal 6 times;
75773776|NCT03962660|Other|HaRTS-TRENDS|"HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS."
75773777|NCT03962660|Other|Standard Care (SC)|The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
75773778|NCT03962582|Device|Matrix back|The Matrix back will replace the individual's back and the measures will be taken.
76072801|NCT05122936|Combination Product|SRXPY-based Obesity Wellness Intervention(SOWI)|It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
76072802|NCT04959994|Device|Novel Motorized Spiral Enteroscopy|All the patients with suspected small bowel disease and an indication to undergo total enteroscopy and satisfying inclusion criteria will undergo novel motorized spiral enteroscopy
76072803|NCT04815070|Procedure|Ultrasonic measurement of antral area|"Ultrasound exam is done before the induction of spinal anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~The cross-sectional area (CSA) of antrum is shown by the following formula: CSA = AP x CC x ㅠ/4.~Antral area will correspond to the average of the three measures."
75319883|NCT04143542|Procedure|trunk blocks|Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
75319884|NCT03586310|Device|ear-EEG|soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
75319885|NCT03586232|Dietary Supplement|Arnica Montana|Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
75319886|NCT03586232|Dietary Supplement|Bromelain|Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
75319887|NCT03586232|Other|Placebo|A pharmacologically inert preparation
75620594|NCT02765776|Other|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
75620595|NCT05655338|Device|antimicrobial photodynamic therapy|
75319888|NCT04186767|Dietary Supplement|Very Low Carb Ketogenic Diet|Patients will be submitted to very low-calorie ketogenic dietary intervention (VLCK) according to the recommendations of the Pronokal® Method program including lifestyle and physical activity guidelines. The ketogenic stage (phase 1-3) consists of a VLCD diet (600-800 kcal / d), with low carbohydrate intake and lipids. The amount of high biological value proteins ranges from 0.8 to 1.2 g / kg of body weight / day. This first stage (ketogenic) is maintained until the patient reaches the goal of reducing the target weight by 80% to be reduced, being variable in time, according to the response of each patient. After this period, it evolved to a non-ketogenic stage, initiating the hypocaloric diet (800 to 1500 Kcal), with progressive introduction of other food groups, reducing weight more slowly. The maintenance stage consists of a balanced diet, ranging from 1500 to 2000 Kcal.
75319889|NCT03586076|Biological|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
75620596|NCT05655338|Drug|systemic antibiotics|
75620597|NCT00943605|Device|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
75620598|NCT00943605|Device|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
75620599|NCT02765620|Other|drug&radiation|"Early treatment response assessment: using baseline data and early follow-up data~Evaluate treatment response: using baseline data, early follow-up data and final data~Compare PERCIST to RECIST criteria: correlation analysis~Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)"
75773779|NCT01083212|Drug|AZD1656|Single dose,oral tablet
75773780|NCT01083212|Drug|Gemfibrozil|Oral tablet bid on day 1 - 5.
75773781|NCT01083212|Drug|Placebo|Oral tablet bid on day 1-5
75773782|NCT01083290|Drug|Spironolactone|single dose of one tablet; 25 mg tablet
75773783|NCT01083290|Drug|Spironolactone|single dose of one tablet; 50 mg tablet
75773784|NCT01083290|Drug|Spironolactone|single dose of one tablet; 100 mg tablet
75912380|NCT04646330|Drug|AK104+anlotinib|Subjects receive AK104 15mg/kg intravenously (IV) every 3-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
75912381|NCT04646330|Drug|AK104+anlotinib|Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until progression.
75912382|NCT05165342|Device|Rexon-eye|a technique in which low-intensity, high-frequency (a spectrum of frequencies ranging from 4 MHz to 64 MHz) electric currents are administered to a biological tissue through contact electrodes
75319890|NCT03586076|Biological|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
75773785|NCT01326650|Drug|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
76072804|NCT04789330|Drug|Norepinephrine|Norepinephrine administered during anesthesia
76072805|NCT04789330|Drug|Phenylephrine|Phenylephrine administered during anesthesia
75773786|NCT01326650|Drug|placebo|daily oral placebo supplement for three years
75912383|NCT04842526|Drug|Anlotinib and irinotecan combined with temozolomide|Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.
76072806|NCT02339038|Drug|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
75912384|NCT04851106|Diagnostic Test|Endoscopic ultrasound|Diagnosis of pancreatic adenocarcinoma with endoscopic ultrasound.
75620600|NCT05655260|Other|Comparison of adjuvant therapies|"Chemotherapy (paclitaxel-carboplatin) vs. chemoradiotherapy (paclitaxel-carboplatin followed by whole pelvic radiotherapy)~Patients assigned to chemotherapy receive paclitaxel (175 mg/m2) and carboplatin (area under curve, 5) every 3 weeks for 6 cycles. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
75620601|NCT05655260|Other|Comparison of adjuvant therapies|"Vaginal brachytherapy vs. whole pelvic radiotherapy~Patients randomized to vaginal brachytherapy receive cuff brachytherapy at 21 Gy in 3 fractions of 7 Gy at 0.5 cm depth. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
75773787|NCT03689374|Drug|Semaglutide|Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.
75773788|NCT03689374|Drug|Insulin aspart|Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days
75773789|NCT03689374|Drug|Insulin glargine U100|Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
75773790|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
75773791|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions during fast
75773792|NCT00123734|Drug|ThromboView|
75773793|NCT03745300|Drug|ATORVASTATIN|Scaling and Root Planing (SRP) followed by placement of atorvastatin gel
75773794|NCT03745300|Drug|SIMVASTATIN|Scaling and Root Planing (SRP) followed by placement of simvastatin gel
75773795|NCT03745300|Drug|PLACEBO|Scaling and Root Planing (SRP) followed by placement of placebo gel
75773796|NCT00112736|Drug|erlotinib|Given orally
75773797|NCT00112736|Drug|temsirolimus|Given IV
75773798|NCT00112736|Procedure|therapeutic conventional surgery|Undergo surgical resection
75773799|NCT00112736|Other|laboratory biomarker analysis|Correlative studies
75319891|NCT04167579|Device|Transcutaneous Valve Therapy|Any patient who undergoes an attempted transcutaneous aortic or mitral valve therapy procedure, with an FDA approved device.
75319892|NCT05582252|Other|Non-Invasive saliva sampling|"There are two types of intervention in this ambidirectional study.~Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records."
76072807|NCT04497298|Biological|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
75620602|NCT02773420|Procedure|HET Application|The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
75773800|NCT00112736|Other|pharmacological study|Correlative studies
75773801|NCT00123422|Behavioral|Breathing retraining|exercise training with computerized training program
75773802|NCT00123422|Behavioral|Heliox|exercise training with a helium oxygen combination
75773803|NCT00123422|Behavioral|Exercise|exercise training
75773804|NCT04052620|Drug|Diclofenac diethylamine 2.32% gel|Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm^2 two times daily for 7 days.
75773805|NCT04052620|Drug|Diclofenac diethylamine 1.16% gel|Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm^2 four times daily for 7 days.
75773806|NCT04052620|Other|Placebo|Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm^2 two times daily for 7 days.
75773807|NCT01083524|Drug|Dichloroacetate Sodium|3 mg po bid for 28 weeks
75773808|NCT01083524|Drug|Dichloroacetate Sodium|6.25 mg po bid
75773809|NCT01083524|Drug|Dichloroacetate Sodium|12.5 mg po bid
75773810|NCT05018260|Behavioral|Attention Bias Modification|Feedback according to participants' viewing patterns, in order to modify their attention bias to threat
75773811|NCT05018260|Behavioral|Attention Control|Feedback according to participants' viewing patterns, in order to strengthen their attention control
75773812|NCT03752086|Procedure|greater omentum binding|Bind pancreatic stump using greater omentum after distal pancreatectomy
75319893|NCT04157985|Drug|Continue PD-1/PD-L1 Inhibitors treatment|Continued treatment with PD-1/PD-L1-1 inhibitor
75319894|NCT04157985|Other|Discontinue PD-1/PD-L1-1 inhibitor|Discontinued treatment with PD-1/PD-L1-1 inhibitor
75773813|NCT03752086|Procedure|Pancreatic stump exposed without omentum binding|Pancreatic stump exposed without greater omentum binding after distal pancreatectomy
75773814|NCT00112580|Biological|ipilimumab|
75773815|NCT04238650|Drug|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
75773816|NCT04238650|Drug|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
75912385|NCT05326958|Device|HRT RCM|Imaging with HRT RCM done only at site 1 (on normal eyes of subjects without DM).
75912386|NCT05326958|Device|HRT RCM-E|imaging done on eyes of all enrolled subjects at site 1 and site 2.
75912387|NCT04837690|Procedure|UEMR|(1) the colorectal lumen was completed deflated with 500-1000 mL sterile water using a flushing pump; (2) the lesion and 2-3 mm of normal mucosa surrounding the base of the polyp were snared and subsequently resected with an electrosurgical generator
75912388|NCT03445754|Device|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
75912389|NCT03445754|Device|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
75912390|NCT04837612|Other|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
75319895|NCT03021122|Device|PedAMINES™ / Conventional Method|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• PedAMINES™ (Period 1) and then Conventional Method (Period 2)"
75319896|NCT03021122|Device|Conventional Method / PedAMINES™|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Conventional Method (Period 1) and then PedAMINES™ (Period 2)"
75465799|NCT01901952|Behavioral|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
75620603|NCT05655104|Other|Couplet Care|In the Couplet Care model, the parents are provided access to the infant stabilisation room and encouragement for early skin-to-skin contact, mothers receive their postpartum care in the same NICU room with the infant, and fathers/partners also have a bed in the same NICU room.
75773817|NCT03752008|Behavioral|Active Play (AP)|This intervention focused on promoting PA in preschoolers through structured, teacher-led activities that could be incorporated into daily curriculum. Teachers attended a 3-hour workshop that included presentation and discussion of 1) the importance of daily physical activity for children's health and development, 2) teachers' beliefs and barriers to promoting PA, and 3) the Active Play! Intervention materials. Teachers were introduced to and given the Active Play! Fun Physical Activities for Young Children Book and Digital Video Disk (DVD), which promotes PA and fundamental movement skills in young children. Clips of the DVD demonstrating various activities were shown and activities were modeled. Examples of activities include jumping on bubble wrap, hula hoop limbo and an indoor obstacle course. The end of the book has a suggested curriculum that teachers could follow. Centers in the Active Play! intervention also received a set of portable toys needed for the suggested activities.
75912391|NCT03352232|Combination Product|HBOT and OMT|Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.
75465800|NCT01901978|Behavioral|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
75912392|NCT04837456|Dietary Supplement|Calorie restricted diet and exercise intervention|the calorie restricted diet were prescribed a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement.Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%[36]. Participants were guided by a dietitian for adjustments of their caloric intake weekly for six months.Participants performed 1 or 2 sets at a resistance of approximately 65% of their one-repetition maximum, with 8 to 12 repetitions of each exercise; they gradually increased the intensity to 2 to 3 sets at a resistance of approximately 80% of their one-repetition maximum, with 6 to 8 repetitions of each exercise.
75912393|NCT04837456|Procedure|libitum diet and waiting list control group|libitum diet and waiting list control group, participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
75912394|NCT04837456|Procedure|Early arthroscopic partial menisectomy group|Early APM group participants received APM with syndrome within 3 to 6 months
75912395|NCT04837456|Procedure|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
75912396|NCT04850950|Drug|Tenofovir Alafenamide fumarate 25mg Oral Tablet|Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.
75912397|NCT03140852|Behavioral|Mind Over Matter; Healthy Bowels, Healthy Bladder|This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
75465801|NCT01901991|Procedure|Radioactive seed localization (RSL)|Localization of nonpalpable breast lesions with Radioactive seed localization
75465802|NCT01901991|Procedure|Wire-guided localization (WGL)|Localization of nonpalpable breast lesions with Wire-guided localization
75465803|NCT01902017|Drug|Ketotifen|5 mg PO bid
75620604|NCT00604227|Other|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
75620605|NCT02772874|Other|No intervention|No intervention
75620606|NCT02887352|Other|assessment of problem-solving ability|
75620607|NCT00603603|Other|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
75620608|NCT00603603|Other|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
75319897|NCT04141436|Behavioral|Interventions Based on Hypnofertility|Affirmation Visualization Imagination Relaxation
75319898|NCT04141436|Other|Routine clinical procedure|Routine clinical procedure
75465804|NCT01902017|Drug|Placebo|5 mg placebo PO bid
75465805|NCT01902056|Procedure|One layer allograft|The acellular dermal matrix was placed on the facial surface.
75465806|NCT01902056|Procedure|Two layer allograft|The acellular dermal matrix was placed on the facial surface.
75620609|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
75620610|NCT01132313|Drug|BI 201335|40 weeks, QD
75620611|NCT01132313|Drug|BI 207127|4 weeks, low dose TID
75912398|NCT02608450|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
75620612|NCT01132313|Drug|BI 201335|24 weeks, QD
75912399|NCT02608450|Drug|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
75319899|NCT03890900|Other|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
75319900|NCT00609271|Behavioral|low carbohydrate diet|<40 grams carbohydrate/day
75319901|NCT00609271|Behavioral|low fat diet|<30% fat, <7% saturated fat
75319902|NCT00609739|Drug|cyclosporine|Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients >40 kg with normal renal function (creatinine <1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
75319903|NCT00609739|Drug|cytarabine|3000 mg/m^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m^2/day) on days -9 through -4.
75319904|NCT00609739|Drug|filgrastim|Patients with absolute neutrophil count (ANC) <0.2 x 10^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
75465807|NCT01902069|Dietary Supplement|Phospholean|"Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).~PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994)."
75465808|NCT01902069|Dietary Supplement|Placebo|Placebo consists of rice flour
75465809|NCT01902082|Drug|Mesenchymal stem cells|
75620613|NCT01132313|Drug|Ribavirin|16 weeks, according to label
75620614|NCT01132313|Drug|Ribavirin|28 weeks, according to label
75620615|NCT01132313|Drug|Ribavirin|28 weeks, according to label
75620616|NCT01132313|Drug|BI 207127|40 weeks, high dose, TID
75620617|NCT01132313|Drug|BI 207127|24 weeks, very high dose, BID
75620618|NCT01132313|Drug|BI 207127|16 weeks, standard dose, BID
75620619|NCT01132313|Drug|BI 201335|24 weeks, QD
75620620|NCT01132313|Drug|Ribavirin|48 weeks, according to label
75620621|NCT01132313|Drug|Ribavirin|40 weeks, according to label
75620622|NCT01132313|Drug|BI 207127|16 weeks, high dose, TID
75620623|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
75620624|NCT01132313|Drug|BI 201335|28 weeks, QD
75620625|NCT01132313|Drug|BI 201335|16 weeks, QD
75620626|NCT01132313|Drug|Ribavirin|24 weeks, according to label
75620627|NCT01132313|Drug|BI 201335|24 weeks, QD
75465810|NCT01902082|Drug|Placebo|
75620628|NCT01132313|Drug|BI 201335|28 weeks, QD
75620629|NCT01132313|Drug|BI 207127|24 weeks, standard dose, BID
75620630|NCT01132313|Drug|BI 201335|24 weeks, QD
75620631|NCT01132313|Drug|BI 201335|16 weeks, QD
75620632|NCT01132313|Drug|BI 207127|16 weeks, high dose, BID
75620633|NCT01132313|Drug|BI 201335|24 weeks, QD
75912400|NCT05165030|Genetic|Blood Sample|clinical-radiological evaluation, genetic analysis by whole exome sequencing and constitution of a bio-collection
75936326|NCT03191708|Diagnostic Test|Fractional Flow Reserve (FFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
75936327|NCT02291367|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
75620634|NCT01132313|Drug|Ribavirin|16 weeks, according to label
75620635|NCT01132313|Drug|Ribavirin|16 weeks, according to label
75620636|NCT01132313|Drug|BI 207217|28 weeks, high dose BID
75620637|NCT01132313|Drug|BI 201335|16 weeks, QD
75620638|NCT01132313|Drug|BI 207127|24 weeks, high dose, TID
75620639|NCT01132313|Drug|Ribavirin|48 weeks, according to label
75620640|NCT01132313|Drug|BI 207127|4 weeks, high dose, TID
75620641|NCT01132313|Drug|BI 201335|28 weeks, QD
75620642|NCT01132313|Drug|Ribavirin|24 weeks, according to label
75620643|NCT01132313|Drug|Ribavirin|24 weeks, according to label
75620644|NCT00422565|Device|Endeavor, Medtronic|Zotarolimus-eluting stent
75620645|NCT00422565|Device|Cypher, Cordis|Sirolimus-eluting stent
75620646|NCT00422565|Device|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
75620647|NCT04316936|Drug|Omidria|phenylephrine 1% and ketorolac 0.3% intraocular solution
75620648|NCT04316936|Drug|Dextenza (dexamethasone ophthalmic insert) 0.4mg|intracanalicular dexamethasone insert
75620649|NCT04316936|Drug|Dexycu, 9% Intraocular Suspension|dexamethasone intraocular suspension
75620650|NCT04316936|Drug|Prednisolone Acetate 1%|standard postoperative ophthalmic drop regimen
75620651|NCT02772952|Other|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
75620652|NCT02772952|Other|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
75620653|NCT02850627|Drug|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
75620654|NCT02850627|Drug|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
75620655|NCT02765386|Device|Hybrid fittings for cochlear implant recipients|
75620656|NCT02850861|Device|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
75620657|NCT05658068|Behavioral|SAFE Spaces training and coaching|Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching.
75773818|NCT03752008|Behavioral|Outdoor Play (OP)|This intervention focused on promoting outdoor time in preschoolers as a means to increasing their PA, using both child initiated and teacher-led activities. The training and materials were designed to emphasize the teacher's own connection with nature, the benefits of outdoor time for children and adults, and problem solving around barriers encountered. Teachers at participating centers attended one 3-hour workshop (delivered at the childcare center) that focused on having participants recognize their own connection with the natural world and how to transmit that to the next generation. Teachers were given hats and gloves for themselves, a set of rain jackets and boots for the preschoolers, and ideas on what children could do outdoors to be active.
75773819|NCT03751930|Other|Samples|Urinary and faecal samples
75773820|NCT00095576|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 adenovirus genomes [ad-vg]/dose).~This dose is equivalent to 3x10^10 vp/dose used in study V520-016."
75773821|NCT00095576|Drug|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
75620658|NCT00861757|Drug|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
75773822|NCT04049578|Drug|Balovaptan|Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
75912401|NCT05309486|Other|Online and Face-to-face Pilates trainings|Key elements of Pilates, including breathing, focusing, rib cage position, shoulder position, and head and neck positions, will be taught in both groups on the first day. Individuals will be asked to maintain the smoothness of these critical elements throughout the exercises. Different imagery techniques will be used in the exercises, and the exercises will be combined with breathing exercises. The intensity of the exercises will be increased by using different positions and elastic bands (Theraband Elastic Band Hygienic Corporation, Akron, Ohio). Band Resistances will be increased in biweekly periods. Stretching and posture exercises will be used during the cool-down period. The subjects in pilates group will be informed about the side effects such as shortness of breath, dizziness, headache, and muscle pain. Participants will be asked to stop the exercise in case of any side effects.
75773823|NCT04044352|Biological|Influenza A/Bethesda/MM2/H1N1 Challenge|Reverse-genetics derived live A/California/04/2009/H1N1-like influenza virus passaged six times in Vero cells.
75912402|NCT02629016|Other|Mindfulness|
75912403|NCT02629016|Other|Wellness|
75912404|NCT04837300|Other|Resisted Sprint Traininig|The Participants in this group had received plyometrics exercises; double leg jumping, drop jumping, hopping, bounding and hurdling.
75319905|NCT00609739|Drug|methotrexate|MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m^2 IV on days +3, +6, and +11.
75620659|NCT00861757|Drug|Placebo|PO, QD (30 min after meal) for 12 weeks
75620660|NCT00861757|Drug|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
75620661|NCT02762734|Other|MEDIA|"The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent."
75620662|NCT02850783|Procedure|89Zr-nanocoll and Indocyanine Green|
75620663|NCT00604305|Device|Acrysof|Monofocal IOL
75773824|NCT04043962|Behavioral|Web-based CBT (Web-MAP)|see arm description
75773825|NCT04043728|Behavioral|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
75773826|NCT04043416|Other|Motivating reminiscence technology|The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
75773827|NCT00095498|Drug|placebo|placebo subcutaneous injection
75773828|NCT00095498|Drug|denosumab|For subcutaneous injection
75773829|NCT04237792|Drug|dexmedetomidine|dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
75773830|NCT04237792|Drug|propofol|propofol IV administration will be given if needed to maintain sedation
75773831|NCT00122954|Drug|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
75773832|NCT00122954|Drug|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
75773833|NCT04491994|Drug|HCQ|Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days
75773834|NCT04041700|Device|Osia 2 system|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound processor.
75773835|NCT03225430|Behavioral|Cognitive behavioural treatment for tics|Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.
75936328|NCT02291367|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
75319906|NCT00609739|Drug|methylprednisolone|Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
75319907|NCT00609739|Drug|mitoxantrone hydrochloride|10 mg/m^2 over 30 minutes intravenously (IV) on days -9 through -7.
75319908|NCT00609739|Procedure|allogeneic bone marrow transplantation|Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 >10^8/kg recipient weight. Infused on Day 0.
75620664|NCT00604305|Device|Acuity's AIOL|Accommodating IOL
75620665|NCT05657756|Device|Randomize clinical trial using hand dynamometer|Our research article involves 100 patients aged over 18 years old with ASAI&II divided into two groups, 50 patients will receive atracurium (0.5 mg/kg) and 30 patients receive Rocuronium (0.6 mg/kg). All of our patients will be undergoing elective laparoscopic surgery for cholecystectomy; the patients will randomly select to receive standard anesthesia induction with propofol (2 mg/kg), fentanyl (1-2 mcg/kg), and isoflurane 1.2 Mac, except muscle relaxant. Neuromuscular will monitoring by Train-of-Four (TOF) during surgery.
75620666|NCT01131455|Biological|Autologous Concentrated Plasma|Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
75620667|NCT02765542|Other|Automated disease assessment & self-care support phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
75620668|NCT05657600|Behavioral|Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments|Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.
75319909|NCT00609739|Procedure|umbilical cord blood transplantation|Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
75620669|NCT05657600|Other|Video-based yoga|Video-based yoga
75620670|NCT05657600|Other|Face-to-face yoga|Face-to-face yoga
75620671|NCT05657600|Other|physical exercise|physical exercise
75620672|NCT02762812|Biological|BCD-055|
75620673|NCT02762812|Biological|Remicade®|
75620674|NCT05657522|Device|Rapid molar intruder|The rapid molar intruder was applied.
75620675|NCT02762890|Drug|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
75620676|NCT02762890|Drug|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
75773836|NCT03225430|Behavioral|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
75912405|NCT04837144|Device|Physical Rehabilitation with MAK exoskeleton|The participants will assist to 9 physical rehabilitation sessions with the MAK exoskeleton. During these sessions, different movements and therapies will be conducted using the studied device.
75620677|NCT00698191|Biological|Allogeneic MSC (AlloMSC)|"Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
75620678|NCT01138007|Drug|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
75620679|NCT01138007|Drug|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
75620680|NCT04223128|Procedure|Ultrasound guided transversus abdominis plane block|Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
75773837|NCT03746938|Device|VB-C01|Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
75912406|NCT05164952|Drug|Zoledronic Acid 4 MG|(4 mg via 15-min infusion every 6 months) for 24 months
75912407|NCT04841824|Other|Observational study|Observational study. Groups are defined based on baseline patients' characteristics : presence or absence of sepsis.
75912408|NCT03037216|Other|Exercise Intervention|10 Week aerobic exercise training
75912409|NCT05164874|Device|Mobile Mammography Unit|The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS
76072808|NCT04497298|Biological|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
75319910|NCT00609739|Drug|Cis-Retinoic acid|Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
75319911|NCT04141124|Other|breathing exercise/HRV-biofeedback|5 min of relaxing breathing, coupled with biological feedback.
75319912|NCT04141124|Other|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
75319913|NCT04141124|Other|Control|5 minutes of reading fictitious biological medical results
75912410|NCT04850482|Other|MyJourney|MyJourney is an online self-help interactive program based on Contextual Cognitive Behavioural Therapy.
76072809|NCT04497298|Biological|One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo
75319914|NCT03020654|Other|Virtual environment with fast moving objects|A beach/park environment with graded moving objects, the individual will complete head and eye exercises.
76072810|NCT04497298|Other|Placebo|Physiological saline solution (0.9% NaCl)
75773838|NCT04036630|Device|Transcranial alternating current stimulation (tACS)|"The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition."
75620681|NCT05375864|Other|Absorption test|Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
75773839|NCT04036630|Device|Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)|"TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple."
75620682|NCT02613715|Dietary Supplement|Blackberry juice with 12% ethanol|
76072811|NCT04387786|Drug|Dornase Alfa|nebulized in-line endotracheal dornase alfa co-administered with albuterol
75773840|NCT03751852|Behavioral|Exercise Coaching|28 classes in 16 weeks
75773841|NCT03751852|Behavioral|Psychoeducation|28 classes in 16 weeks
75912411|NCT05294042|Other|Navigation|The intervention in this study is a model of navigation for families seeking services at the two mental health agencies collaborating on this study. Navigators (PP and CM) will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
75620683|NCT02613715|Dietary Supplement|Blackberry juice|
75912412|NCT04850560|Biological|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
75319915|NCT03020654|Other|Virtual environment with no movement|A beach/park environment with static objects, the individual will complete head and eye exercises.
75319916|NCT05246059|Other|Olfactory Training|Sniffin' Sticks (Duft-Quartett, Burghart Messtechnik, GmbH, Germany)
75620684|NCT02762968|Dietary Supplement|Placebo|Placebo capsules similar to the experimental treatments.
75773842|NCT04227340|Device|Photobiomodulation Therapy (PBM)|The PBM will be delivered through application of the LED Cluster Probe externally to the right external buccal, left external buccal, mid face with mouth open and submandibular and left/right cervical. Patients who develop an oral lesion, intra-oral directed therapy will be administered with the dental light probe. For patients that can tolerate, an intraoral probe will deliver light directly onto the oral mucosa, this will then replace the mid face application with mouth open. Each laser application will be timed at 60 seconds.
75912413|NCT02522702|Other|Photography of polyps, resection of polyps|Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
75912414|NCT04850404|Procedure|abdominal nerve block|All Patients of group A-M will be administered with rectus abdominis block combined with TAPB after anesthesia. Rocuronium was infused continuously (concentration: 1 mg/ml) when TOF recovered to 1. The starting rate was 0.3mg/kg/h, and the TOF count was maintained between 1~3 (moderate NMB) and recorded during the operation. Whether and how to add rocuronium was based on TOF count and request of surgeons. When TOF Watch- SX showed 4 or ratio, the investigators increased the speed of rocuronium pump infusion and record the score at the time of shallow NMB. When the chief surgeon thought the vision could not satisfy the needs of the operation, rocuronium 0.1mg/kg in bolus was added as a rescue. Then, the pump speed was lowered or even decreased to 0 to make the TOF count recover to 1~3 as soon as possible.
76072812|NCT02136004|Device|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
76072813|NCT00569530|Drug|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
76072814|NCT00569530|Drug|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
76072815|NCT04509622|Drug|Venetoclax|Tablet; Oral
76072816|NCT04509622|Drug|Cytarabine|Subcutaneous Injection
76072817|NCT04388098|Other|Diagnosis of caries experience and periodontal health|
76072818|NCT00570700|Drug|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
76072819|NCT00571324|Drug|Exendin-(9-39)|A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
75319917|NCT03421808|Device|Transcranial Magnetic Stimulation (TMS)|TMS
75620685|NCT02762968|Dietary Supplement|HMB|Capsules containing calcium HMB.
75620686|NCT02762968|Dietary Supplement|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
75620687|NCT02613559|Biological|TK001|Intravitreal Injection
75465811|NCT01902095|Device|Tooth powder|Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
75465812|NCT01902095|Device|Tooth paste (control)|Active Comparator
75465813|NCT01902108|Drug|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
75465814|NCT01902108|Drug|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
75465815|NCT01902121|Drug|Technosphere® Insulin 10U + 20U|Inhaled Insulin
75465816|NCT01902121|Drug|Technosphere® Insulin 30U|Inhaled Insulin
75620688|NCT02762656|Drug|Lidocaine|Lidocaine drip during surgery
75620689|NCT05657210|Genetic|Mutation|
75620690|NCT02613637|Other|Registry|
75620691|NCT02764996|Device|Acupuncture|
75620692|NCT05657132|Drug|herbal intracanal medication paste|study the effect of costus herbal paste on enterococcus faecalis bacteria
75620693|NCT05657132|Drug|Meta paste|compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
75319918|NCT05245903|Device|Emerald Device Monitoring|The study participants will have the Emerald device deployed in their home for up to 12 weeks as they participate in the parent study (ClinicalTrials.gov identifier NCT04430517). The device will be deployed in the bedroom of each subject to capture behavior continuously. The Emerald device is a radio-wave sensor that will use signal processing and machine learning algorithms to track the gait, movement, respiration, and sleep of these subjects via low-powered radio signals. Reflections of the radio signals are processed using algorithms to convert them into movement data, sleep stages, and key sleep parameters. These data will supplement bioenergetic, imaging, and biochemical data with digital biomarkers and phenotyping using this device.
75620694|NCT02765152|Other|Conventional Physical Therapy|Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
76072820|NCT00571324|Other|Vehicle|A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
75319919|NCT04140812|Diagnostic Test|mass spectrometry (LC-MS/MS)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.
75319920|NCT00571987|Device|AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)|Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
75319921|NCT04140656|Other|Plantar sensitive exercises|"Plantar sensitive exercises:~40 minutes / 3 days per week / 8 weeks Warm up exercise (5 minute) Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min) Cooling exercise (5 min)"
75319922|NCT04140656|Other|Textured insole|"Textured insole group.~Plantar sensitive exercises with insole 40 minutes / 3 days per week / 8 weeks (all exercises will be done with insoles) Warm up exercise (5 minute) Walking on flat ground (15 minute) Exercise with roller under the sole of the foot (5 minute) Seated work with barbed balance pad (5 min) Dorsi flexion and plantar flexion and hip flexion exercises (5min). Cooling exercise (5 min)"
75319923|NCT00610987|Drug|cefazolin|Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
75465817|NCT01902147|Other|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
75465818|NCT01902160|Drug|Brentuximab Vedotin|Given IV
75465819|NCT01902160|Other|Laboratory Biomarker Analysis|Correlative studies
75620695|NCT02765152|Other|Discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
75620696|NCT02765152|Other|Rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
75620697|NCT00865345|Device|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
75620698|NCT01131299|Other|Placebo|2 tablets PO 3 times a day for 12-14 weeks
75620699|NCT01131299|Drug|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
75620700|NCT02762422|Other|Phlebotomy|Removal of 500 cc of blood via forearm vein
75620701|NCT04316858|Drug|Sodium phosphate|90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.
75620702|NCT04316858|Dietary Supplement|Water|800 ml of water will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
75773843|NCT04227340|Other|Pain and Oral Function Assessment|After the 6-minute laser/ treatment session the child and parent will complete the mucositis evaluation scale on paper or ipad which includes self-report oral function specific to ability to swallow, eat and drink, as well as the patient's self-reported need for medication specific to mouth pain.
76072821|NCT04338646|Other|Clinical tests|Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
76072822|NCT00573508|Drug|Placebo|Oral Administration
76072823|NCT00573508|Drug|Solifenacin Succinate|Oral Administration
76072824|NCT00574834|Drug|Ramipril|Ramipril 20 mg once daily for 6 months
76072825|NCT00574834|Drug|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
75465820|NCT01902160|Drug|Temsirolimus|Given IV
75465821|NCT01902186|Drug|raltegravir and atazanavir and ritonavir|switch tenofovir/emtricitabine to raltegravir
75465822|NCT01902186|Drug|tenofovir/emtricitabine and atazanavir and ritonavir|no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
75465823|NCT01901861|Drug|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
75465824|NCT01901861|Drug|Placebo|Placebo is given before meal ingestion
75620703|NCT04316858|Dietary Supplement|Zero calorie carbonated drink|800 ml of zero calorie diet cola will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
75773844|NCT04227340|Other|Parent-Reported Satisfaction Survey|A parent-reported satisfaction survey will be administered via paper questionnaire after the initial LLLT treatment. Parent satisfaction will be reported by parents on a 5-point Likert scale to questions adapted from a parent satisfaction survey used in a study regarding child life services in pediatric imaging.
75773845|NCT03746860|Drug|Tablet, Dispersible|1 tablet/day with 12 SQ-HDM per lyo-tablet
75773846|NCT03744988|Diagnostic Test|serum androgen levels|measurement of serum free and total testosterone
75912415|NCT04842058|Other|Mobilisation procedure|A standardized mobilization procedure was performed preoperatively ~ 1h before surgery and was repeated 6h and 24h after surgery. The mobilization procedure included patient supine rest (5 minutes), followed by 45° passive leg raise (PLR) (3 minutes), supine rest (5 minutes), sitting on the edge of the bed with feet resting on the floor (3 minutes) followed by standing using a walker while the patient was encouraged verbally to stand on toes and shift body weight from one leg to the other (3 minutes) and finally rest in supine position (5 minutes). The procedure was terminated prematurely in any position if patients experienced unbearable symptoms of OI or upon a decrease of systolic arterial pressure (SAP) > 30 mmHg.
75773847|NCT04033432|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
75773848|NCT04223830|Device|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
75773849|NCT04032652|Procedure|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
75912416|NCT05400278|Other|No intervention|No intervention
75912417|NCT04850248|Other|no intervention, this is an observational study|no intervention, this is an observational study
75912418|NCT05400044|Procedure|Three dimensional maxillary bone augmentation|mixing of bone marrow aspirate concentrate with xenograft to show the bone quality and bone gain compared to the xenografts mixed with autografts
75912419|NCT04778722|Dietary Supplement|Oral probiotics|containing four Lactobacillus strains (Lactobacillus crispatus -Lbv88, Lactobacillus rhamnosus -Lbv96, Lactobacillus jensenii -Lbv116, and Lactobacillus gasseri -Lbv150)
75912420|NCT05399810|Other|Computer Application (ICOGNI) Training|Participants will be given App-based training under supervision for 40 sessions, which will include multiple games with multiple levels along with routine physiotherapy.
75319924|NCT00610987|Drug|Placebo|Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
75319925|NCT04140578|Drug|Ertapenem|inject from iv drip before endoscopic cyanoacrylateinjection obliteration
75912421|NCT04850326|Dietary Supplement|AP green tea extract|single intake of AP green tea extract
75319926|NCT00574171|Drug|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
75773850|NCT04032652|Drug|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
75773851|NCT04031404|Device|Single-pulse TMS|Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
75773852|NCT05256628|Other|Early Weightbearing|Patients randomized to undergo this study intervention will bear weight, as tolerated, on the affected side straight after surgery, with crutches for additional support and stability. They will be allowed to stop using crutches in the weeks after surgery as they feel more comfortable and stable on their surgical leg.
75773853|NCT05256628|Other|Protected Weightbearing|Patients randomized to undergo this study intervention will be instructed to be touch weightbearing for 6 weeks after surgery. They will use crutches and put no more weight on the surgical side than what it takes to crack an egg. After the 6-week mark, they will be able to bear weight.
75773854|NCT03746782|Diagnostic Test|Flow Cytrometry; Thrombin Generation Assay|Apixaban combined with blood specimens (in vitro) of study participants
75773855|NCT03746626|Behavioral|Chaplain visit|The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.
75773856|NCT03751696|Behavioral|Group Coaching|4 sessions of 1-1.5-hour group coaching intervention within 8 weeks
75773857|NCT03751696|Behavioral|SMS self-help tips|4 mental well-being tips through sms within 8 weeks
75773858|NCT04476784|Device|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
75773859|NCT04476784|Device|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
75773860|NCT04476784|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
75773861|NCT04026568|Drug|4-Aminopyridine|Single drug test for nerve continuity
75773862|NCT04026568|Drug|Placebo oral tablet|Placebo arm
75773863|NCT04025632|Drug|zilucoplan|Daily subcutaneous (SC) inection
75773864|NCT04025632|Other|Placebo|Daily subcutaneous (SC) inection
75912422|NCT02408276|Other|dGEMERIC MRI technique|"Patients will be treated surgically (hip arthroscopy) or nonoperatively (physical therapy) and pain medications as needed. For surgical patients, cartilage samples and surgeon operative reports will be a source of research. For both cohorts, MRIs, radiographs and patient reported outcome surveys will be additional research sources.~All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant."
75912423|NCT03039946|Device|Closed-Loop GDFT|Patients receive fluids in the form of 100ml boluses of crystalloid (Plasmalyte) over 6 minutes via an automated closed-loop goal-directed fluid therapy (GDFT) system guided by non-invasive flow monitoring (Clearsight system). Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
75773865|NCT04024228|Biological|Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
75773866|NCT04024228|Biological|High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
75773867|NCT04023994|Drug|RO7126209|Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.
75773868|NCT04023994|Drug|Placebo|Participants will be administered a single intravenous dose of matching placebo.
75773869|NCT04023682|Drug|Provodine Hand Sanitizer|Intervention with Provodine
75773870|NCT04018612|Drug|Acetaminophen|Acetaminophen is an analgesic and antipyretic
75773871|NCT04018612|Other|Placebo|Saline
75773872|NCT04209400|Biological|Sci-B-Vac®|Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml
75773873|NCT04209400|Biological|Engerix-B®|Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml
75773874|NCT03751540|Procedure|ostap|this block is performed under general anesthesia in this patients for postoperative analgesia.
75773875|NCT03751540|Procedure|SIPB plus rectus sheath block|this block is performed under general anesthesia in this patients for postoperative analgesia.
75912424|NCT03039946|Other|Restrictive Fluid Therapy|Patients receive fluids (Plasmalyte) via a restrictive approach with a baseline of of 4ml/kg/h. Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
75319927|NCT00574171|Drug|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
75773876|NCT05346094|Other|No intervention|No intervention
75773877|NCT04207840|Combination Product|Epinephrine (0.125 mg/inhalation)|Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.
75773878|NCT04207840|Combination Product|Epinephrine Injection Auto-Injector (0.3mg/0.3mL)|Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.
75773879|NCT04207840|Combination Product|Albuterol Sulfate (0.09 mg/inhalation)|Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.
75912425|NCT04850014|Other|Anthropomorphism|Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender
75773880|NCT03746548|Device|Adhear|Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
75773881|NCT03746548|Device|Contact Mini (CM)|Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
76072826|NCT00574834|Drug|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
76072827|NCT00575146|Dietary Supplement|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
76072828|NCT04095520|Procedure|Laser Etching|Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.
75319928|NCT05581862|Behavioral|3 meals+3 snacks|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals and 3 snacks for 3 months
75319929|NCT05581862|Behavioral|3 meals|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals for 3 months
75319930|NCT03585998|Drug|Durvalumab|Concurrent radiotherapy Maintenance therapy
75319931|NCT00612235|Drug|Lamotrigine|Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.
75319932|NCT00612235|Drug|Levetiracetam|Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.
75319933|NCT00612235|Drug|Carbamazepine|Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.
75319934|NCT00612235|Other|No Intervention|No intervention was given
75773882|NCT05226520|Dietary Supplement|Experimental probiotic product|Probiotic supplementation
75319935|NCT03585842|Other|No intervention|No intervention
75319936|NCT00613405|Other|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
75319937|NCT00613405|Other|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
75319938|NCT05245435|Diagnostic Test|FDHT-PET Scan|[18F]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)
75773883|NCT05226520|Other|Placebo comparator|Placebo
75773884|NCT04006366|Behavioral|Time restricted feeding|We propose a pilot and feasibility trial of a 10 hour time restricted eating intervention among post-bariatric surgery patients.
75773885|NCT03744520|Procedure|Erector spinae plane block|Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
75773886|NCT03744442|Procedure|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
75773887|NCT03744442|Procedure|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
75773888|NCT03744442|Procedure|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
75773889|NCT04191148|Drug|LBP-EC01|crPhage cocktail: at approximately 1.5 x 10^10 to 3.0 x 10^10 PFU/vial dosed BID by intraurethral administration
75620704|NCT02614807|Dietary Supplement|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
75620705|NCT04555720|Behavioral|Interdisciplinary Visit|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
75620706|NCT04119895|Other|Neuromuscular electrical stimulation and core stabilization exercise|"In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second"
75773890|NCT04191148|Drug|Placebo|Lactated Ringers Solution for Injection dosed BID by intraurethral administration
75773891|NCT04004260|Behavioral|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
75773892|NCT03744364|Drug|Misoprostol 25 mcg|To determine efficacy and safety of vaginal 'Misoprostol 25 mcg' every 4 hours with a maximum of 6 doses for induction of labor.
75773893|NCT03744364|Drug|Dinoprostone 10mg|To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.
75319939|NCT05245435|Diagnostic Test|liquid biopsies|circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients
75620707|NCT04119895|Other|Sham neuromuscular electrical stimulation and core stabilization exercise|In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
75620708|NCT02764840|Other|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
75620709|NCT02764840|Other|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
75620710|NCT00637325|Drug|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
75620711|NCT02762344|Drug|heparin|routinary heparin administration during coronary angiography/PCI
75773894|NCT03744208|Drug|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
75773895|NCT05069896|Drug|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
75773896|NCT05069896|Drug|Mirikizumab Autoinjector|Administered SC by autoinjector
75773897|NCT01562626|Drug|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
75773898|NCT01562626|Drug|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
75620712|NCT04316780|Other|Retrospective observational study- no intervention to occur.|Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
75465825|NCT01902199|Behavioral|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
75465826|NCT01902212|Other|Oral Nutritional Supplement|
75465827|NCT01902225|Drug|Istodax|
75465828|NCT01902225|Drug|Doxil|
75620713|NCT02764684|Drug|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
75620714|NCT01130831|Drug|Lanthanum carbonate|
75620715|NCT02764450|Device|Astralis 10 HPM|The cavity to be filled is in quadrant I or III
75620716|NCT02764450|Device|Astralis 10 RM|The cavity to be filled is in quadrant II or IV
75319940|NCT05582408|Device|Measures of Standard Noise Reduction NR1|Each participant will be fitted with the Standard Noise Reduction (NR1)
75319941|NCT05582408|Device|Measures of Noise Reduction Principle NR2|Each participant will be fitted with the novel Noise Reduction principle NR2 on the same hearing aid
75319942|NCT05582408|Device|Measure of Noise Reduction Principle NR3|Each participant will be fitted with the novel Noise Reduction principle NR3 on the same hearing aid
75319943|NCT00575029|Drug|megestrol acetate|600 mg by mouth daily
75319944|NCT03912584|Device|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
75620717|NCT04663282|Drug|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
75773899|NCT01562626|Drug|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
75912426|NCT04850014|Other|Relevant clinical datas|"Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.~Imaging."
75912427|NCT04841746|Behavioral|Physical therapy that include a standardized cycling training with functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the experimental group will received functional electrical stimulation administered to surface electrodes attached to lower limb muscles (quadriceps, hamstrings, gluteus maximus and triceps). Electrical stimulation will be delivered appropriately to the muscle during cycling regarding the angle of the pedal by a stimulator (Motimove-8 de 3Fit Fabricando Faber).
75912428|NCT04841746|Behavioral|Physical therapy that include a standardized cycling training with no additional functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the control group will received no additional functional electrical stimulation during cycling.
76072829|NCT04095520|Procedure|Phosphoric acid etching|Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
75620718|NCT04663282|Drug|Insulin Degludec|Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
75773900|NCT04470622|Drug|Aprepitant injectable emulsion|Aprepitant injectable emulsion, once daily (QD) for 14 days.
75773901|NCT04470622|Drug|Saline Placebo|Saline Placebo, once daily (QD) for 14 days.
76072830|NCT04251520|Diagnostic Test|Pharmacogenomics testing|Participants will undergo pharmacogenomics testing and will be asked to provide a one-time buccal scraping. These results will be utilized for clinical treatment decisions.
76072831|NCT04251520|Other|Pharmacist review|Participants will have their medical information, including patient demographics, problem list, medication list, allergies, and relevant lab work reviewed by a One Point pharmacist. The pharmacist will work with the Palliative Medicine team to make medication related recommendations to improve individual patient care. The pharmacist will call the patient roughly 48 hours following their outpatient consultation or hospital discharge to review the medication list and address any medication-related questions. The pharmacy will send refill reminders to the patients.
76072832|NCT01592110|Drug|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
76072833|NCT01592110|Other|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
75620719|NCT02764606|Biological|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
75620720|NCT01130597|Drug|patiromer|Active investigational drug
76072834|NCT01592110|Drug|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
76072835|NCT01592110|Drug|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
76072836|NCT03843580|Device|optiflow|we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
76072837|NCT00604552|Device|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
76072838|NCT00605644|Drug|MOA-728|Oral Capsules
75620721|NCT01130597|Drug|spironolactone|
75773902|NCT04465630|Device|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
75319945|NCT03912584|Device|P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
75465829|NCT01902238|Procedure|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
75620722|NCT02762188|Device|Genotype analysis|"After signing informed consent, a blood sample is taken and DNA extracted according to standard procedures. The samples are genotyped with the Mass Array iPlex Gold. Processing of the data is done using the previously described protocol by Lambrechts and co.~Statistical analysis will be done to evaluate the association between the different genetic variants and the clinical outcomes collected during the standard of care follow-up for ARMD."
75773903|NCT04182880|Drug|CPL-01|CPL-01 will be administered
75773904|NCT04182880|Drug|Placebo|Placebo will be administered
75773905|NCT04465396|Drug|Teduglutide|Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.
75773906|NCT04465396|Device|Syringe Injection|Teduglutide was administered using syringe.
75773907|NCT04465396|Device|Pen injector|Teduglutide was administered using pen injector.
75773908|NCT03751462|Device|Purkinjemeter|The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
75465830|NCT01902251|Drug|Enzalutamide tablet|Oral
75465831|NCT01902251|Drug|Enzalutamide capsule|Oral
75620723|NCT02761876|Behavioral|Mentor farmer training (Malawi)|Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.
75620724|NCT02761876|Behavioral|Mentor farmer training (Singida, Tanzania)|Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.
75620725|NCT02761876|Behavioral|Mentor farmer visits and facilitation|Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
75773909|NCT03744130|Diagnostic Test|Contrast-enhanced Ultrasound|"administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~the original DICOM loop is sent to a work station"
75773910|NCT03999892|Behavioral|ACHIEVE|The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (~20-30 minutes) and group exercise (~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
75773911|NCT03996694|Drug|Belbuca 300 µg|Belbuca 300 µg buccal film
75773912|NCT03996694|Drug|Belbuca 600 µg|Belbuca 600 µg buccal film
75912429|NCT04836676|Device|C-REX Device|"The investigational devices are C-REX LapAid Cath or C-REX RectoAid Cath. C-REX LapAid Cath consists of an invasive surgical part, i.e. anastomotic ring comprised of two LapAn coupled by DMC/DM, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX RectoAid Cath consists of an invasive surgical part, i.e. an anastomotic ring comprised of RectoAn and LapAn, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX LapAid Cath and C-REX RectoAid Cath are easy to use, with unique possibility to control and validate the integrity of the anastomosis during and after surgery."
75912430|NCT04836598|Other|laparoscopic cholecystectomy|A Prospective randomized controlled trial study was undertaken along 4 years Between November 2016 and October 2020, in two institutions. 400 patients were selected, 200 patients underwent BLLC and 200 patients underwent multiple port laparoscopic cholecystectomy (MPLC).
75620726|NCT02696278|Other|Lesson about vegetables|During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
75773913|NCT03996694|Drug|Belbuca 900 µg|Belbuca 900 µg buccal film
75773914|NCT03996694|Drug|Oxycodone 30 mg|Oxycodone 30 mg capsule
76072839|NCT00605644|Drug|Placebo|Placebo
75319946|NCT05219695|Procedure|Harmonic motion imaging guided focused ultrasound (HMIgFUS)|"Harmonic motion imaging guided focused ultrasound (HMIgFUS) is a combined treatment and imaging method, in which focused ultrasound (FUS) is used to thermally ablate tissue and harmonic motion imaging (HMI) is used for FUS guidance and monitoring. FUS applies high intensity focused ultrasound waves at its specified target to heat the tissue over a specified duration, causing cell death at the target area. HMI is an elasticity imaging technique which induces dynamic tissue vibrations at the target for tissue elasticity characterization.~One of the inclusion criteria for this study is that participants must be scheduled for surgical excision of their breast tumor. In this study, HMIgFUS will be applied to anesthetized participants immediately prior to their scheduled surgery. HMI imaging will also be performed immediately prior to and after HMIgFUS application."
75319947|NCT03585608|Procedure|Neck extension|The neck extension is routine posture during palatoplasty. We will evaluate the change in optic nerve sheath diameters before and after neck extension.
75620727|NCT02696278|Other|Vegetables|During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
75773915|NCT03996694|Drug|Oxycodone 60 mg|Oxycodone 60 mg capsule
75773916|NCT03996694|Drug|Placebo|placebo buccal film and oral placebo
75773917|NCT04179838|Behavioral|Sleep-Deprived|Sleep for 4 hours at home.
75912432|NCT06059573|Procedure|dental implant robot|Implant placement will be navigated by a dental implant robot based on a digital plan.
75912433|NCT06059573|Procedure|Freehand surgery|Implant will be placed under freehand surgery.
75912434|NCT06059560|Dietary Supplement|Nutritional therapy|Intensive nutritional therapy based on real world therapy
75912435|NCT06059547|Drug|Nivolumab|Biological, monoclonal antibody
75912436|NCT06059547|Drug|Visugromab (CTL-002)|Biological, monoclonal antibody
76072840|NCT00578734|Drug|Lucinactant|Slow intra-tracheal instillation
75912437|NCT06059547|Drug|Placebo|Placebo for Visugromab (CTL-002)
75912438|NCT06059521|Device|Software refraction with Eye Test Technology in a mobilerone|Refraction is done by software App by a mobilerone software installed.
75912439|NCT06059521|Device|Retinoscopy|Retinoscopy is an objective refraction method with retinoscope.
76072841|NCT00578734|Other|Sham Comparator|Slow intra-tracheal instillation
76072842|NCT00578968|Drug|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
75620728|NCT02696278|Other|Hummus|During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
75773918|NCT04179838|Behavioral|Non-Sleep Deprived|Sleep for 8 hours at home.
75620729|NCT05163119|Behavioral|Commercial Cellphone-Blocking App (Active)|The Fleetsafer app, which is a commercial cellphone app that uses a cellphone's standard sensors and function to block handheld cellphone use while driving, will be downloaded on the participant's smartphone.
75773919|NCT03744052|Other|Motivational Messages|Messages regarding physical activity will be texted to participants.
76072843|NCT00578968|Drug|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
76072844|NCT00579280|Drug|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
75773920|NCT03994120|Other|RTMS|Altering the connectivity of trans-synaptic pathways
76072845|NCT00579280|Drug|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
75319948|NCT00499109|Drug|Docetaxel|"GD Group: 40 mg/m^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m^2 on day 1~DV Group: 50 mg/m^2 on days 1 and 15, every 28 days"
75465832|NCT01902264|Drug|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
75620730|NCT05163119|Behavioral|Driving Mode|"Apple's Do Not Disturb driving mode provided by Apple for iPhones or Google Do Not Disturb, Verizon Messages +, Android Auto or have another app, called LifeSaver installed on their Android phone (collectively referred to as driving modes; the specific driving mode for participants in this arm will be determined based on smartphone type and service provider)."
75773921|NCT04178590|Drug|SRP + Injectable Platelet-Rich Fibrin|Injectable Platelet-Rich Fibrin application as adjunct to scaling and root planing
75620731|NCT00939003|Biological|Adalimumab|40 mg every other week up to Week 12
75620732|NCT00939003|Biological|Placebo|Placebo every other week up to Week 12
75773922|NCT04178590|Drug|SRP + placebo|Saline application during scaling and root planing
75773923|NCT03743974|Procedure|arthroscopic shoulder surgery of rotary cuff (ISB)|ISB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
75465833|NCT01902329|Drug|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
75465834|NCT01902329|Drug|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
75465835|NCT01902342|Drug|Oseltamivir 75 mg 1 cap|
75620733|NCT00939003|Biological|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
75620734|NCT01188668|Drug|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
75773924|NCT03743974|Procedure|arthroscopic shoulder surgery of rotary cuff (CSB)|SCB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
75773925|NCT03751384|Dietary Supplement|Möllers Omega-3 Ekstra Sterk|
75773926|NCT03751384|Dietary Supplement|Nutrifriend Cachexia|
75798345|NCT03870828|Diagnostic Test|Bronchoalveolar lavage and taking bronchial mucosa samples|"Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units.~Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved."
76072846|NCT00579280|Drug|placebo|placebo
76072847|NCT00579436|Drug|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
76072848|NCT00579436|Drug|placebo|4 inert capsules daily by mouth for 12 weeks.
76072849|NCT03573466|Procedure|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
76072850|NCT00580294|Drug|Oxymorphone|IV PO
75319949|NCT00499109|Drug|Vinorelbine|DV Group: 35 mg/m^2 on days 1 and 15
75319950|NCT00499109|Drug|Carboplatin|"GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
75319951|NCT00499109|Drug|Gemcitabine|"GCb Group: 1,250 mg/m^2 on days 1 and 8~GD Group: 1,250 mg/m^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
75319952|NCT03585530|Drug|raltitrexed|Raltitrexed 2.6mg/m2 was administered on d1、d22
75912440|NCT06059482|Other|Assessment|Evaluations will be made once.
75620735|NCT01188668|Drug|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
75465836|NCT01902355|Procedure|modified Seldinger technique|modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
75465837|NCT01902355|Procedure|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
75620736|NCT02882945|Other|Group A|150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
75620737|NCT02882945|Other|Group B|200 cases of type 2 DM without complications were enrolled in the study.
75620738|NCT02882945|Other|Group C|120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
75620739|NCT04524286|Other|Interviews only.|Interviews will be conducted with childbearing women and midwives.
75620740|NCT04192084|Procedure|microvascular partial toe transfer|we will perform microvascular partial toe transfer for patients with traumatic amputation of one or more digits
75620741|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
75620742|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
75620743|NCT05301998|Other|Skin and thickness measurement/breast MRI|"Patient will be installed in dorsal decubitus position. Measurements will be performed at 3 sites on one breast: at the areola, above the areola and below. Measurements will be performed by a single gynecologist using a cutometer provided by TIMC-IMAG laboratory of Grenoble. Three measurements will be performed at each site. Duration of measurements will be approximately 15 minutes.~Measurement of skin thickness will be performed using an ultrasound device available in obstetrics/gynecology consultation department. The measurement will be performed at 3 sites. The duration of the measurements will be of approximately 10 minutes.~Among the 200 patients, 10 patients who should benefit from a breast MRI as part of their follow-up, will have a breast MRI in 3 different positions: prone (standard protocol) and two additional acquisitions (as part of the research) in dorsal and right lateral decubitus. This examination will be scheduled in the senology department of the Lapeyronie Hospital"
75620744|NCT00865189|Drug|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
75620745|NCT00865189|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m^2) as a 2-hour IV infusion.
75620746|NCT00865189|Drug|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m^2 as a 2-hour infusion.
75620747|NCT00865189|Drug|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m^2 as an IV bolus, then at a dose of 600 mg/m^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
75620748|NCT00865189|Radiation|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
75620749|NCT00865189|Procedure|Surgery|Radical rectal excision based on the TME technique.
75620750|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 125|125 mg to take BID for 14 weeks in Arm 1
75620751|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 250|250 mg to take BID for 14 weeks in Arm 2
75620752|NCT02762032|Drug|Placebo|Placebo supplement to take BID for 14 weeks in Arm 3
75912441|NCT06059469|Diagnostic Test|Ga-PSMA PET/CT|Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment
75912442|NCT06059430|Other|no intervention|no intervention
75465838|NCT01902368|Other|gluten free diet|
75465839|NCT01902394|Other|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
75465840|NCT01902394|Other|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
75465841|NCT01902433|Procedure|Astym|
75620753|NCT02764372|Behavioral|Serious games|Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113
75620754|NCT02764372|Behavioral|Exergames|Participants played exergames existent in the Wii game console
75620755|NCT04311905|Device|Diode laser|Diode laser activated irrigation
75620756|NCT04311905|Other|Placebo|mock Laser activated irrigation
75620757|NCT00697489|Procedure|correction of POP plus preventive continence procedure|
75620758|NCT00697489|Procedure|POP surgery followed by eventual incontinence procedure|
75620759|NCT02764216|Radiation|Elective mucosal irradiaton|Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
75620760|NCT00698269|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75620761|NCT00698269|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75620762|NCT00698269|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75620763|NCT01182194|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
75620764|NCT01182194|Drug|YAZ®|3 mg/0.02 mg Tablets
76072851|NCT00580372|Drug|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
75620765|NCT02761798|Device|Automated Mobile Interactive Audiometer|iPad game
75773927|NCT03746392|Behavioral|Jumpstart Intervention|"The intervention has 4 steps: use electronic medical record (EHR) to identify seriously ill, hospitalized patients with no documentation of a goals-of-care (GOC) discussion during their current admission; the enrolled patient or his/her surrogate completes a survey assessing preferences for discussions about GOC, barriers to having such discussions, and current GOC which is used to create a Jumpstart form designed to prompt and guide a GOC discussion between the patient or surrogate and the clinicians caring for the patient; use natural language processing/machine learning (NLP/ML) approach to identify GOC discussions or advance directives in the EHR that occurred prior to admission and include this information on the Jumpstart form; and, deliver the Jumpstart form to the primary clinician team. The patient or surrogate is also provided with a version of the form."
75620766|NCT04133779|Procedure|neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
75773928|NCT03743896|Drug|Transdermal Glucosamine Cream|
75773929|NCT01562860|Procedure|Pronator Teres Release|Surgical release of median nerve compression
75773930|NCT01562860|Procedure|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
75773931|NCT01562860|Procedure|dual compression release|both procedures will be done on the same day
75773932|NCT01562860|Procedure|median nerve release only|only the carpal tunnel compression is released
75773933|NCT04175392|Drug|Align Probiotic Supplement Capsule|Align Probiotic 1 billion units, 1 capsule once daily
75773934|NCT04175392|Drug|Placebos|Placebos capsule 1 capsule Once daily
75912443|NCT06059417|Other|2x2 inch piece of 3M microfoam adhesive|"A 2x2 inch piece of 3M microfoam adhesive will be applied to the medial aspect of the subject's upper arm.~The adhesive will remain in place for 48 hours at which time an investigator will remove the adhesive and assess the study area. A numerical value will be assigned based on the Cutaneous Irritancy Scoring System (CISS). The study site will be compared to the contra-lateral upper extremity at the end of the 48 hour period."
75912444|NCT06059404|Behavioral|Meals + RD services only|Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education
75912445|NCT06059404|Behavioral|Meals + OT services only|Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies
75912446|NCT06059404|Behavioral|Meals + RD + OT services|A combination of tailored registered dietitian and occupational therapy services will be provided
75465842|NCT01902446|Drug|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
75465843|NCT01902485|Other|Timing of Contraceptive Initiation in Medical Abortion|
75465844|NCT01902498|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
75465845|NCT01902498|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
75620767|NCT04133779|Procedure|neurological evaluation, ecocolor-Doppler|For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
75773935|NCT01562938|Drug|Placebo|Placebo
75773936|NCT01562938|Drug|MEDI-557|MEDI-557 low-dose
75773937|NCT01562938|Drug|MEDI-557|MEDI-557 high-dose
75773938|NCT03737422|Dietary Supplement|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
75773939|NCT03737422|Other|control|no supplementation
75773940|NCT03743818|Device|dry needling|dry needling on the trigger point of the vastus medialis of the quadriceps
75773941|NCT03743818|Other|ultrasound|aply ultrasound on the knee
75773942|NCT03743818|Device|hyauluronic acid|aply hyaluronic acid on the knee
75773943|NCT03986866|Other|Video|A 5 minute video on the risks and benefits of opioids, alternative methods to reduce pain, and the proper handling and storage of opioids will be shown.
75912455|NCT06059365|Behavioral|Hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward
76072852|NCT00580372|Drug|High-Dose cyclophosphamide|"Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1"
76072853|NCT00580372|Procedure|Hemopoietic stem cell procurement|Collection target = 10 x 10^6 cells/kg
75465846|NCT01902498|Drug|Aspirin|Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
75773944|NCT03743740|Other|Spinal stabilization exercise|The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.
75620768|NCT04133779|Procedure|medical history, vital signs, ecocolor-Doppler|For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
75773945|NCT03751306|Procedure|Transcranial Photobiomodulation|"Photobiomodulation Rehabilitation:~Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) ."
76072854|NCT00580372|Drug|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
75319953|NCT03021590|Drug|Clarithromycin 500Mg Oral Tablet|"Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth"
75620769|NCT04268667|Other|Spinal manipulation|Application of upper cervical spine thrust joint manipulation or application of a full combination of cervical, cervico-thoracic and thoracic spine thrust joint manipulation.
75620770|NCT02764294|Other|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
75620771|NCT02764294|Other|Stress Ball Group|"Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
75620772|NCT02764294|Other|DVD Group|DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
75620773|NCT04131205|Diagnostic Test|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
75773946|NCT03751306|Procedure|Transcranial Photobiomodulation (Placebo)|"Photobiomodulation Placebo Therapy:~The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off."
75773947|NCT03751306|Procedure|Cardiorespiratory Rehabilitation|"Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives."
75620774|NCT05381571|Other|Motivating reminiscence physical therapy|The jDome BikeAround system involves participants using a stationary bike while their selected location is displayed in front of them on a domed projector screen using Google Street View. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
75773948|NCT01562002|Procedure|Stem Cell with Amniotic Membrane Transplant|Single stem cell expansion in amniotic membrane transplant
75912456|NCT06059365|Behavioral|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day- surgery unit where they were discharged according to ALDRETE criteria.
75912457|NCT06059326|Drug|HSK7653 10 mg|Tablet, HSK7653 10 mg Q2W, 12 weeks
75912458|NCT06059326|Drug|HSK7653 25 mg|Tablet, HSK7653 25 mg Q2W, 12 weeks
75319954|NCT03021590|Drug|Levofloxacin 500Mg Oral Tablet|Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
75912459|NCT06059326|Drug|HSK7653 50 mg|Tablet, HSK7653 50 mg Q2W, 12 weeks
75912460|NCT06059326|Drug|Placebo|Tablet, 0 mg Q2W, 12 weeks
76072855|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
76072856|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
75465847|NCT01902511|Drug|G-CSF+Erythropoetin|
75465848|NCT01902511|Drug|G-CSF|
76072857|NCT00580372|Drug|Maintenance|3 months after Transplant 2: Intron A 3 X 10^6 units /m2 M-W-F subcutaneously until relapse
75319955|NCT02125721|Drug|Tiopronin 1g per day|500mg PO BID x 7 days
75319956|NCT02125721|Drug|Tiopronin 2g per day|1g PO BID x 7 days
75319957|NCT02125721|Drug|Tiopronin 3g per day|1.5g PO BID x 7 days
75465849|NCT01902524|Drug|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
75465850|NCT01902537|Drug|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
75465851|NCT01902550|Drug|Metoprolol tartrate immediate-release (metoprolol IR)|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
75465852|NCT01902550|Drug|JNJ-54452840|JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
75465853|NCT01902550|Drug|Placebo|Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
75465854|NCT01902563|Other|Osteopathic Manipulative Treatment|
75773949|NCT03737344|Drug|IL-1Ra Kineret®|Kineret® 100 mg in 0.67 ml Prefilled Syringe
75773950|NCT03737344|Other|IL-1Ra Placebo|Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
75319958|NCT03021278|Other|Saline injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.
75773951|NCT03751228|Drug|BMS-986165|Swish and expectorate after tasting
75773952|NCT03751228|Drug|Active Pharmaceutical Ingredient|Swish and expectorate after tasting
75773953|NCT05668546|Device|isokinetic testing CSMI HUMAC NORM instrument|The strength (PT) of the bilateral knee flexors and extensors were tested with isokinetic test. Tests were performed under the guidance of a rehabilitation medicine specialist, and the system was calibrated prior to their commencement. The patients were seated in upright position and were fixed with pelvic and thigh belts. Concentric extension (PT_E) and concentric flexion (PT_F) were measured between the 0° and 90° knee ranges at angular velocities of 60°/s and 180°/s (60 PT_E, 60 PT_F, 180 PT_E, and 180 PT_F, respectively) The tests were repeated five times at each velocity, and the highest PTs were selected for statistical analysis. The participants performed repeated trials before sets, while a 20-second rest was provided between sets.
75773954|NCT03980938|Drug|neflamapimod|40 mg neflamapimod capsule
75773955|NCT03980938|Other|Placebo|matching placebo capsule
75773956|NCT03737188|Device|Blood glucose monitoring systems for self-testing|Capillary blood samples will be used for the evaluation of system accuracy.
75773957|NCT03743584|Procedure|Targeted temperature management|Target temperature management at 33°C
75773958|NCT03743584|Procedure|Standard care, early treatment of fever|Standard of care with early treatment of fever
75620775|NCT02764060|Device|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
75773959|NCT03108352|Drug|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)
75773960|NCT03108352|Other|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)
75773961|NCT03751150|Other|Exercise program|The runners will be asked to perform the training program twice a week. The intervention consist of muscle control and foam rolling exercises for the lower extremities.
75773962|NCT03656692|Drug|Acthar Gel|Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL)
75620776|NCT02764060|Device|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
76072858|NCT00581230|Device|Laryngoscopy with RAMP|inflatable positioning ramp
75620777|NCT01181726|Drug|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
75620778|NCT01181726|Drug|Activella®|1 mg/0.5 mg Tablets
75773963|NCT04439266|Drug|Crizotinib|Given PO
75773964|NCT03682120|Biological|A/H7N9|"Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1)."
75773965|NCT03682120|Drug|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
75773966|NCT03682120|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
75773967|NCT03736642|Biological|blood sampling|12 ml sample
75912461|NCT06059300|Diagnostic Test|Digital Breast Tomosynthesis|Screening with Digital Breast Tomosynthesis instead of Digital Mammography, for two screening rounds
75912462|NCT06059287|Drug|Henagliflozin|Henagliflozin 10mg qd po
75912463|NCT06059287|Drug|Metformin|Metformin 1000mg bid po
75620779|NCT01137071|Biological|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
75773968|NCT03736642|Other|stool sampling|20 g sample
75773969|NCT03736642|Other|urine sampling|18 ml sample
75773970|NCT03736642|Diagnostic Test|neuropsychological tests|"Go-nogo~flexibility~food stroop~implicit and explicit evaluation~Child Depression Inventory~Hamilton Depression Rating Scale"
75773971|NCT01329796|Drug|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
75773972|NCT01329796|Drug|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
75773973|NCT04428502|Drug|Enbrel|As provided in real world practice
75773974|NCT03736330|Biological|Combinations treatment|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5*10^10 cells)were incubated with low dose anti-PD-1 antibody（pembrolizumab, Merck & Co., Inc.） and were transferred to participants via intravenous infusion .
75773975|NCT04428424|Drug|Enbrel|As provided in real world practice
75773976|NCT01562080|Dietary Supplement|Armolipid Plus|one tablet per day during 12 weeks
75773977|NCT01562080|Dietary Supplement|placebo|one tablet per day during 12 weeks
75773978|NCT03655756|Biological|IFx-Hu2.0|Subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).
76072859|NCT00581230|Device|Laryngoscopy without RAMP|Laryngoscopy without RAMP
76072860|NCT00581386|Device|LTS-D|supra-glottic airway device
76072861|NCT00581386|Device|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
75620780|NCT04046419|Other|Turkish validity and reliability|"Explanation of the Turkish version of the scale.~Translating the Turkish version of the scale into English to ensure consistency with the original scale.~First application of scales to participants.~Second application of the scales to the participants.~Statistical analysis and scaling"
75620781|NCT00603681|Drug|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
75620782|NCT00603681|Drug|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
75620783|NCT00699127|Behavioral|Lecture|Lecture of information regarding prematurity, NICU hospitalization, etc.
75620784|NCT02763904|Dietary Supplement|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
75620785|NCT02763904|Other|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
75620786|NCT02853045|Drug|period with drug (trade name) then period with generic|"The list of drugs is detailed in the study description"
75620787|NCT02853045|Drug|period with generic then period with drug (trade name)|"The list of drugs is detailed in the study description"
75319959|NCT03021278|Other|Sham injection|In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
75319960|NCT00552695|Device|Lidocaine tetracaine|Lidocaine 70 mg/tetracaine 70 mg
75620788|NCT04131049|Other|High GI calculated by CC (CHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
75620789|NCT04131049|Other|Low GI calculated by CC (CLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
75620790|NCT04131049|Other|High GI calculated by FII (FHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
75620791|NCT04131049|Other|Low GI calculated by FII (FLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
75620792|NCT00603759|Drug|celecoxib|100 mg qid
75620793|NCT00603759|Drug|placebo|1 cap qid
75773979|NCT03735784|Behavioral|AWARE|AWARE consists of four group sessions. The AWARE curriculum involves sharing basic information on sexually transmitted diseases; providing condom use skills training; providing normative feedback on substance use and sexual risk behavior among young adults; discussing unrealistic beliefs about substance use and sexual risk; discussing potential benefits of both cutting down and stopping risky behaviors; and discussing risky situations and coping strategies.
75620794|NCT04130815|Drug|Inhaled furosemide|4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
75912464|NCT06059261|Drug|Envafolimab and recombinant human endostatin combined with chemoradiotherapy|Induction treatment phase:Envafolimab administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 3 cycles, cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles, gemcitabine was administered by intravenous infusion on days 1 and 8 of each cycle at 1 g/m2 every 3 weeks for 3 cycles, recombinant human endostatin was administered on day 1 every 3 weeks at 210 mg for 3 cycles. Concurrent treatment phase: Envafolimab was administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 2 cycles. For high risk group, cisplatin was administered by intravenous infusion on day 1 of each cycle at 100mg/m2 every 3 weeks for 2 cycles, for low risk group, there is no need for chemotherapy. Adjuvant treatment Phase: Envafolimab was administered on day 1 every 3 weeks at 300 mg for 5 cycles as a subcutaneous injection. Intensity-modulated radiotherapy: 69.96Gy/33fractions/7weeks,5 fractions/week, 1 fraction/day.
76072862|NCT00581386|Device|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
76072863|NCT02134210|Drug|Etanercept|Head-to-head comparison
76072864|NCT02134210|Drug|CHS-0214|
75319961|NCT00552695|Device|Placebo|Placebo patch identical in appearance to Synera
75319962|NCT03899948|Behavioral|Teacher Anxiety Program for Elementary Students|TAPES consists of three core components: 1) training in evidenced-based anxiety reduction strategies that teachers will implement to identify and assist specific anxious students and classroom-wide strategies helpful to all students, 2) evidenced-based material for teachers to review with parents regarding how to reduce student anxiety at home, thus improving school-home communication and shared goals and 3) training in how to conduct 5 brief (30 minute) teacher-parent-student meetings to teach and practice the TAPES anxiety-reduction strategies.
75620795|NCT02761564|Other|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
75620796|NCT02761564|Other|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
75620797|NCT04256265|Drug|Risdiplam|Risdiplam will be administered orally once daily
75620798|NCT02763982|Other|Physical evaluation|
75620799|NCT04312061|Drug|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
75620800|NCT04312061|Drug|Placebo oral tablet|oral placebo tablet given 1 hour before LNG-IUD insertion
75620801|NCT02852811|Other|Group education|Intervention involving two education session with topics common in menopause transition.
75620802|NCT00860743|Drug|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
75773980|NCT00095238|Drug|Irbesartan|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
75773981|NCT00095238|Drug|Placebo|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
75773982|NCT01083888|Drug|roxadustat|oral
75319963|NCT03899948|Behavioral|Teacher Anxiety Training|The TAT is a 3-hour professional development training for teachers. Training focuses on recognizing the signs and symptoms related to child anxiety and utilizing classroom-wide strategies to help reduce anxiety in the classroom.
75620803|NCT04317170|Other|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia during their routine standard of care dermatologic procedure
75620804|NCT02761720|Other|No Intervention|
75319964|NCT00615433|Drug|Lurasidone|120mg/day
75620805|NCT04311593|Diagnostic Test|CD4, CD19, CD38, CD56 and CD11b|measuring CD markers by flowcytometry
75620806|NCT01186796|Drug|Fulvestrant|"Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~**Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit)."
75620807|NCT05383131|Drug|HEC585|Mulltiple doses of HEC585 for up to 10 days
75620808|NCT05383131|Drug|Pirfenidone|Mulltiple doses of Pirfenidone for up to 3 days
75620809|NCT05383131|Drug|Nintedanib|Mulltiple doses of Nintedanib for up to 7 days
75620810|NCT02763670|Other|PRETICARD patient care management|"A standardized and specialized network to take care of the severe cardiac insufficiency:~An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~At 6 and 18 months, one cardiology consultation~At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)"
75620811|NCT02763670|Other|"As usual  patient care management"|"Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook)."
75620812|NCT04119817|Dietary Supplement|Mucosave® capsules|400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
75620813|NCT04119817|Dietary Supplement|Placebo|400 mg/day of placebo capsules for a period of 8 weeks, once a day.
75620814|NCT01136915|Drug|Iopamidol 370|one time administration for PCI
75620815|NCT01136915|Drug|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
75620816|NCT02761486|Drug|Aspirin|325mg aspirin per day
75620817|NCT02761486|Drug|Placebo|placebo in matching capsules
75620818|NCT02617225|Behavioral|DHaAL Intervention|"This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors."
75620819|NCT02617225|Behavioral|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
75620820|NCT04268589|Other|virtual reality game|routine
75620821|NCT02882789|Drug|LCB01-0371|Cohort1 & 3: Placebo-controlled, Single ascending dose administration
75620822|NCT02882789|Drug|LCB01-0371 400mg|Cohort 2: Crossover designed administration
76072865|NCT02134522|Device|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
76072866|NCT02134756|Drug|NutraStem Active|
76072867|NCT02134756|Drug|NutraStem Placebo|
75319965|NCT00615433|Drug|Olanzapine|15mg/day
75319966|NCT00615433|Drug|Placebo comparator|Placebor Comparator
75319967|NCT00615433|Drug|Lurasidone 40 mg tablets|Lurasidone 40 mg tablets
75319968|NCT00553163|Behavioral|Gut focussed hypnotherapy|Gut focussed hypnotherapy
75319969|NCT00553163|Behavioral|Control educational sessions|Control educational sessions
75319970|NCT03585374|Combination Product|Methoxyflurane and Penthrox inhaler|3ml of methoxyflurane vaporized through an inhaler (Penthrox). Inhalation, by regular breathing, last about 25 minutes.
75319971|NCT03585374|Drug|Morphine|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a dose of 0.10 mg/Kg body weight. The time of infusion should be not longer than 10 minutes.
75319972|NCT03585374|Drug|Paracetamol|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 1 g dose The time of infusion should be not longer than 10 minutes.
75319973|NCT03585374|Drug|Ketoprofen|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
76072868|NCT01798732|Procedure|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
75620823|NCT02617381|Other|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
75620824|NCT00940017|Drug|anidulafungin and voriconazole|Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
75912465|NCT06059248|Other|"the head in the mandibular adduction position"|"Intubation was performed with the head in the mandibular adduction position"
75912466|NCT06059235|Other|pharmaceutical care|"consultation with a pharmacist performing advanced pharmaceutical care : Package of clinical pharmacy activities including :~Medication history (during assessment consultation) Medication review and consultation with the geriatrician Therapeutic education (during results consultation) Shared decision (at results consultation) One-week follow-up call + usual care"
75319974|NCT00499343|Drug|Etoposide|150 mg/m^2 given intravenously over 2 hours every 12 hours x 6 doses.
75319975|NCT00499343|Drug|G-CSF|Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.
75319976|NCT00499343|Drug|GM-CSF|250 mcg/m^2 injection given every evening till the completion of apheresis.
75319977|NCT00499343|Drug|Isophosphamide|10 g/m^2 given intravenously continuous infusion over 72 hours.
75319978|NCT00499343|Drug|Rituximab|Days +1 (375 mg/m^2) and +8 (1000 mg/m^2) given intravenously.
75620825|NCT01129583|Drug|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
75620826|NCT01129583|Drug|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
75465855|NCT01902589|Other|Helicobacter Pylori Culture|"Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.~The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.~4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere."
75620827|NCT01186328|Drug|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg
75773983|NCT03962478|Device|biliary stent and high-intensity focused ultrasound ablation system|Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
75773984|NCT03962478|Device|biliary stent|Self-expandable biliary nitinol alloys stent
75773985|NCT01087008|Drug|zoledronic acid|Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
75912467|NCT06059209|Dietary Supplement|Enfamil NeuroPro|FDA Infant formula
76072869|NCT00607126|Device|Lokomat|locomotor training using body weight support on a treadmill
76072870|NCT00607126|Procedure|resistive training|resistive training using theraband and/or weights
76072871|NCT00607594|Drug|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
76072872|NCT01866319|Biological|Pembrolizumab|10 mg/kg IV, administered Q2W or Q3W based upon randomization.
76072873|NCT01866319|Biological|Ipilimumab|3 mg/kg IV Q3W.
76072874|NCT00607672|Drug|Placebo|Placebo
76072875|NCT00607672|Drug|Ramipril|Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
75465856|NCT01902641|Drug|Succinylcholine|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.
75465857|NCT01902641|Drug|Rocuronium/Sugammadex|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
75773986|NCT01087008|Other|No treatment control|Patients doesn't receive treatment
75912468|NCT06059209|Dietary Supplement|Enfamil Infant|FDA Infant formula
75912469|NCT06059170|Behavioral|LARS score/ EORTC QLQ C30|administering questionnaire
75912470|NCT06059157|Device|Advanced MRI|resting-state functional MRI, diffusion with advanced post-processing (microstructure analysis), myelin mapping
76072876|NCT00607672|Drug|Candesartan|Candesartan 16mg/d
76072877|NCT01802515|Drug|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
75319979|NCT00499343|Procedure|Apheresis|Peripheral blood stem cell collection.
75319980|NCT00615589|Drug|Fludarabine/Busulfan x 4 days|"Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day."
75319981|NCT00615589|Procedure|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
76072878|NCT01802515|Drug|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
76072879|NCT01802515|Drug|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
75773987|NCT01087086|Behavioral|Crononutrition|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
75773988|NCT01087086|Behavioral|American Heart Association|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
75773989|NCT01084044|Drug|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
75773990|NCT01090440|Drug|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
75912471|NCT06059144|Drug|Peripheral intravenous norepinephrine|Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
76072880|NCT01802437|Drug|Fluoxetine|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
75773991|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
75773992|NCT01090518|Drug|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
75773993|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
75773994|NCT00082368|Drug|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
75773995|NCT00082368|Drug|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
75773996|NCT03960216|Procedure|Scaling and root planning|Patients received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.
75773997|NCT03960216|Procedure|Supragingival Prophylaxis|Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.
75773998|NCT03958032|Other|No intervention|No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
75773999|NCT01090596|Drug|Naproxen|500mg naproxen, twice daily for 7 days
76072881|NCT01802437|Behavioral|Increased Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increased dose of interpersonal psychotherapy (4 extra therapy sessions) or fluoxetine.
76072882|NCT01802437|Behavioral|Continue to Receive Initial Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be assigned to continue initial dose of interpersonal psychotherapy.
76072883|NCT00608062|Drug|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
75620828|NCT01186328|Drug|Cytarabine|"Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:~1-1.99 years: 30 mg 2-2.99 years: 50 mg~Greater than or equal to 3 years: 70 mg.~Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:~- 1.99 years: 16 mg~- 2.99 years: 20 mg~- 8.99 years: 24 mg~Greater than or equal to 9 years: 30 mg"
75620829|NCT01186328|Drug|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
75620830|NCT01186328|Drug|Prednisone|40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.
75620831|NCT01186328|Drug|Vincristine|1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
75774000|NCT01090596|Drug|Placebo|1 tab,twice a day for a seven days
75774001|NCT01084122|Drug|Iron sucrose|Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
75774002|NCT01084200|Drug|Propofol for maintenance|Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
75774003|NCT01084200|Drug|Sevoflurane|Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
75774004|NCT01084200|Drug|Sevoflurane+Propofol|Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
75912472|NCT06059131|Other|KeenMind|320 mg/d (2 capsules/d) during 3 months
75912473|NCT06059131|Other|Placebo|320 mg/d (2 capsules/d) during 3 months
75912474|NCT06059105|Device|Immediate Implant Surgery|Inverted Co-Axis 12º Southern Implants
75912475|NCT06059105|Device|Immediate Implant Surgery|Internal Conical (Deep Tapered Conical) South Implants
76072884|NCT00608062|Drug|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
75620832|NCT01186328|Drug|PEG-asparaginase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.
75465858|NCT01902641|Drug|Rocuronium|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
75465859|NCT01902654|Other|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
75620833|NCT01186328|Drug|Methotrexate|"Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~- 1.99 years: 8 mg~- 2.99 years: 10 mg~- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
75620834|NCT01186328|Drug|Hydrocortisone|"Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~- 1.99 years: 8 mg~- 2.99 years: 10 mg~- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
75620835|NCT00848497|Drug|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
75620836|NCT00848497|Other|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
75620837|NCT00848497|Drug|Viagra®|Viagra 25mg was the dose given to the patient which he started.
75620838|NCT02763592|Drug|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
75774005|NCT03957798|Behavioral|RecoveryWarrior 2.0|"RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style."
75774006|NCT01087164|Behavioral|Compliance|Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
75774007|NCT01087164|Behavioral|Message sidedness|Parent will receive either a one-sided or two-sided message about the HPV vaccine
75912476|NCT06059092|Behavioral|Adapt Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to coping strategies, locus of control, coping metacognition, positive psychology strategies. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
76072885|NCT00608062|Drug|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
76072886|NCT02138578|Radiation|SBRT|
76072887|NCT02138578|Radiation|RFA|
75319982|NCT05703230|Other|Structured preoperative multidisciplinary team meeting|"The intervention to be investigated is the introduction of a preoperative structured multidisciplinary team (sMDT) meeting for high risk noncardiac surgical patients, which is attended by at least the treating surgical specialist, an anesthesiologist and another medical consultant with expertise relevant for the patients comorbidities and preferences. In the preoperative sMDT meeting, at least the following questions will be discussed as recommended by the Dutch Perioperative Guideline:~Is the proposed surgical intervention appropriate care for the patient?~Is the risk/benefit ratio of the proposed surgical intervention acceptable for the patient?~Should the patient's condition be optimized before undergoing the proposed surgical intervention?"
75465860|NCT01902654|Other|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
75620839|NCT02763592|Other|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
75620840|NCT04268043|Device|flexible laryngeal airway mask|Ventilation with flexible laryngeal mask airway
75620841|NCT04268043|Device|proseal laryngeal mask airway|Ventilation with proseal laryngeal mask airway
75620842|NCT02882867|Other|Injuries in Swedish Youth Athletics. The KLUB-study.|
75620843|NCT02763748|Procedure|Laparoscopic endoscopy combined surgery|
75620844|NCT02763748|Procedure|laparoscopic and endoscopic cooperative surgery|
75620845|NCT02763748|Procedure|Single-arch laparoscopic and endoscopic cooperative surgery|
75774008|NCT01084434|Dietary Supplement|probiotic|Bifidobacterium lactis HN019 10^9 CFU/day 1 sachet once a day for 7 weeks
75774009|NCT01084434|Dietary Supplement|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
75774010|NCT01084434|Dietary Supplement|Synbiotic|(Bifidobacterium lactis 10^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
75774011|NCT01084434|Dietary Supplement|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
75912477|NCT06059092|Behavioral|Engage Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to goal setting, planning, strengths identification, motivation; goal pursuit metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
75912478|NCT06059092|Behavioral|Interact Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to social cognition, assertive communication and conflict resolution, proactive prosocial behaviors, interactional metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
75912479|NCT06059092|Behavioral|Control Group|Sessions will be devoted to serious game training cognitive and executive functions through individual and group activities based on board games.
75620846|NCT04268355|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
76072888|NCT00608140|Procedure|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
76072889|NCT00608140|Drug|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
75465861|NCT01902654|Other|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
75620847|NCT00857623|Drug|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
75620848|NCT00857623|Drug|Placebo|Capsule, once daily
75620849|NCT04312607|Diagnostic Test|BCR-ABL gene PCR|peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
75620850|NCT02761096|Device|acupuncture|"Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session."
75620851|NCT02761096|Other|conventional treatment|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
75774012|NCT01087242|Drug|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
75774013|NCT00094770|Drug|sitagliptin (MK0431)|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
75774014|NCT00094770|Drug|Comparator: glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
75774015|NCT00069576|Behavioral|nutritional counseling|
75774016|NCT00069576|Behavioral|self blood glucose monitoring|
75774017|NCT01090674|Other|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
75798346|NCT03870828|Diagnostic Test|6minute walk test|a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation
75465862|NCT01902667|Procedure|Magnetic Resonance Imaging|
75465863|NCT01902680|Radiation|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
75465864|NCT01902719|Behavioral|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
75465865|NCT01902719|Behavioral|Communication Skills Training|"Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training."
76072890|NCT02135146|Drug|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
76072891|NCT02135146|Drug|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
75620852|NCT01185782|Drug|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
76072892|NCT02829268|Drug|dantrolene sodium|"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires."
76072893|NCT00581854|Drug|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
75620853|NCT01185782|Drug|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
76072894|NCT00610480|Drug|1st visit Optive, then 2nd visit Systane|"First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes."
76072895|NCT00610480|Drug|1st visit Systane, then 2nd visit Optive|"First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes."
76072896|NCT02202772|Drug|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
76072897|NCT02202772|Drug|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
75465866|NCT01902719|Behavioral|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
75465867|NCT01902732|Device|Implantation of valves (IBV)|Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
75620854|NCT04119349|Behavioral|Extra counseling|Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
75620855|NCT02761174|Drug|Brimonidine|Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control
75620856|NCT02761174|Other|IPL+air-cooling|IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
75620857|NCT01129115|Behavioral|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
75620858|NCT01129115|Behavioral|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
75620859|NCT01129115|Behavioral|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
75774018|NCT01087398|Drug|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|"For sibling full match:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~Fludarabine 160 mg/m^2"
75774019|NCT01087398|Procedure|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~Sibling full match~Other related full match~Sibling or other related with 1 mismatch antigen~Cord Blood~Haploidentical"
75774020|NCT01087398|Drug|Cyclosporin, Methotrexate (GVHD prophylaxis)|"Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)"
75774021|NCT01087476|Drug|Doxycycline hyclate|Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
75774022|NCT00069264|Drug|E7389|E7389 Dose-escalation starting at 0.25 mg/m^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
75774023|NCT00069108|Drug|5 FU|As prescribed, in 2 week cycles
75774024|NCT00069108|Drug|Leucovorin|As prescribed, in 2 week cycles
75774025|NCT00069108|Drug|Oxaliplatin|As prescribed, in 3 week cycles
75774026|NCT00069108|Drug|Oxaliplatin|As prescribed, in 2 week cycles
75774027|NCT00069108|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
75774028|NCT03961776|Device|MRI-guided radiotherapy by on-board DWI sequences|The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.
75774029|NCT00094536|Device|Extended treatment regimen using Her Option Cryotherapy|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
75774030|NCT00405587|Drug|PLX4032|Oral capsules administered BID
75912480|NCT06059079|Other|No Intervention|No Intervention
75912481|NCT06059040|Procedure|eliminating gastric residual volume monitoring|eliminating gastric residual volume monitoring from routine care
75319983|NCT03832244|Diagnostic Test|Sub-mental ultrasonography|Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries
75319984|NCT00575185|Drug|Valomaciclovir|4 grams orally of valomaciclovir (2 grams BID) for 21 days.
75912482|NCT06059001|Drug|OMO-103|Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion
75912483|NCT06059001|Drug|Nab-Paclitaxel|IV infusion - Standard of Care
75912484|NCT06059001|Drug|Gemcitabine|IV infusion - Standard of Care
75912485|NCT06058988|Drug|Trastuzumab deruxtecan|All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
75912486|NCT06058871|Behavioral|Regular messages|The EMI-I messages will be delivered in sequence over three months. The content, frequency, and timing of the messages will be determined by participant preferences, as determined during the baseline evaluation, as personalisation is central to such cognitive and behavioural changes. The messages will mainly be text-based, but other forms such as videos will also be used, depending on the needs of the participants.
75912487|NCT06058871|Behavioral|Nurse-led real-time support messages (chat type)|The nurse will initiate 10-15-minute chats via an online platform (e.g., WhatsApp) after all instant messages for each session have been delivered. The nurse will guide the participants to set goals for breastfeeding. Any anticipated barriers will be discussed. The participants can also initiate the chats. While there is no limit to the number of chat messages, nurse-led real-time support messages will be provided during working hours (i.e., 9 am-6 pm on weekdays).
75319985|NCT00575185|Drug|placebo|Placebo tablets orally twice daily for 21 days.
75620860|NCT01129115|Behavioral|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
75465868|NCT01902745|Behavioral|Social Cognitive Theory|Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
75465869|NCT01902771|Biological|Dendritic Cell Vaccine|Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
75620861|NCT04119583|Device|U-shape Automatic Electric Toothbrush|The U-shape Automatic Electric Toothbrush will be applied for 30-45 seconds on the teeth of both arches without the use of toothpaste.
75620862|NCT04119583|Other|Usual home toothbrushing procedure|Usual home toothbrushing procedure either with manual or electric toothbrush without the use of toothpaste.
75620863|NCT04119583|Other|Conventional Electric Toothbrush|The Conventional Electric Toothbrush will be applied for 2 minutes on the teeth of both arches without the use of toothpaste.
75774031|NCT01040429|Drug|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients < 35 kg; 50 microgram (2 capsula) x 2/day for patients > 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients < 35 kg; 25 microgram (2 capsula) x 2/day for patients > 35 kg."
75774032|NCT01040429|Drug|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients < 35 kg; 2 capsula x 2/day for patients > 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients < 35 kg; 1 capsula x 2/day for patients > 35 kg"
75774033|NCT00581243|Drug|SLV-313 SR|sustained relase tablets taken once daily for 14 days
75774034|NCT01039883|Drug|Albaconazole tablet 400mg|Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
75774035|NCT01039883|Drug|Albaconazole 100mg capsules, then albaconazole 400mg tablet|Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
75774036|NCT00405275|Drug|Etanercept|etanercept, subcutaneous injection
75774037|NCT00405275|Drug|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
75912488|NCT06058832|Device|Low-intensity Shockwave Therapy|patients will receive 6 sessions, once per week - of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level (Shendy et al, 2021) plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
75912489|NCT06058832|Other|Kegel Exercises|"The training program consists of active exercises. Each patient will be taught how to contract the pelvic-floor muscles. He will be asked to mimic holding in the flow of urine and to contract the target muscles as hard as possible. The exercises will be done in a supine position with the knees flexed because it is easier to feel the pelvic-floor muscles in this position.~The patient will be asked to perform short (1 second) and long-lasting (6-10 seconds) contractions of the target muscles. Later, the exercises will be done with the patient sitting or standing.~Patient will be asked to repeat the contractions daily. Each patient will be performed 40 short and 50 long-lasting contractions in a prone, sitting, or standing position. Patients will be asked to do 30 contractions in the morning, 30 contractions in the afternoon, and 30 contractions in the evening."
76072898|NCT02202772|Drug|Cisplatin|Intravesical installation of Cisplatin for 2hours
75319986|NCT00499655|Drug|erlotinib hydrochloride|Given orally
75319987|NCT00499655|Drug|celecoxib|Given orally
75319988|NCT00499655|Other|placebo|Given orally
75319989|NCT00499655|Other|laboratory biomarker analysis|Correlative studies
75319990|NCT00499655|Other|immunohistochemistry staining method|Correlative studies
75319991|NCT00499655|Genetic|fluorescence in situ hybridization|Correlative studies
75319992|NCT00499655|Genetic|mutation analysis|Correlative studies
75319993|NCT00499655|Genetic|protein expression analysis|Correlative studies
75319994|NCT00499655|Genetic|gene expression analysis|Correlative studies
75465870|NCT01902771|Biological|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
75774038|NCT00405275|Drug|Sulfasalazine|sulfasalazine, oral
75774039|NCT00405275|Drug|Hydroxychloroquine|hydroxychloroquine, oral
75620864|NCT04222738|Dietary Supplement|GINOFF1|The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
75319995|NCT03585140|Other|Normal diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins.
75620865|NCT04119661|Device|Max-i-Probe|Using Max-i-Probe as endodontic needle during syringe irrigation
75620866|NCT04119661|Device|NaviTip|Using NaviTip as endodontic needle during syringe irrigation
75319996|NCT03585140|Other|Low glycemic diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.
75620867|NCT04315922|Diagnostic Test|Microbiome and Plasma Characterisation|Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
75620868|NCT04312217|Behavioral|Medical clowning|Medical clowning
75620869|NCT04116307|Dietary Supplement|Polymethylsiloxane|
75620870|NCT04116307|Dietary Supplement|Lactobacillus reuteri|
75620871|NCT02763436|Procedure|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
75620872|NCT04311359|Drug|Drugs, Generic|All drugs having 19 or more Brain Oedema cases reported to the FAERS database
75620873|NCT02882555|Behavioral|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity <10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
75620874|NCT02882555|Drug|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
75620875|NCT02882555|Drug|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
75620876|NCT02761018|Behavioral|Behavioral: Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
75774040|NCT00405275|Drug|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
75774041|NCT00405275|Drug|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
75774042|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
75774043|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
75912490|NCT06058806|Other|Multimodal Physical Therapy|Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises
75319997|NCT03585140|Drug|Adapalene 0.1% Gel|Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
75319998|NCT03585140|Drug|Doxycycline|Doxycycline 100 mg per day orally, before breakfast
75620877|NCT02761018|Behavioral|Fitness Tracker|will use a fitness tracker and will be able to see other member's daily and weekly results
75620878|NCT04119427|Device|ultrasonic therapeutic apparatus 1|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
75620879|NCT04119427|Device|ultrasonic therapeutic apparatus 2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
75774044|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
75774045|NCT00404651|Biological|DTaP-HBV-IPV vaccine|0.5 mL, IM
75774046|NCT03908021|Diagnostic Test|Microbiome analysis and 16S rRNA gene-based analysis|microbial DNA is extracted from the saliva and 16s library is prepared for sequencing.
75774047|NCT00404495|Drug|Irinotecan|Irinotecan 10 mg/m^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
75912491|NCT06058780|Procedure|Implantable Collamer Lens (ICL)|Phakic intraocular lenses (pIOL) have proven to be a great alternative to corneal refractive surgery in certain situations. They offer several advantages over corneal techniques, such as being suitable for high myopes and causing relatively fewer higher-order aberrations
75319999|NCT03584984|Procedure|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio
75320000|NCT03584984|Procedure|Anorganic Bovine Bone (ABB)|Filling the socket with Anorganic bovine bone graft material only
75320001|NCT03584984|Procedure|Absorbable gelatin sponge|Filling the socket with an absorbable gelatin sponge foam pack
75620880|NCT02763358|Device|Bite Counter|This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
75620881|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg I.V.
75774048|NCT00404495|Drug|Temozolomide|Temozolomide 100-125 mg/m^2 daily on days 1-5 in repeated 3 week cycles
75774049|NCT01039961|Drug|losmapimod 1 mg|IV infusion
75774050|NCT01039961|Drug|losmapimod|IV infusion (dose to be determined based on PK from first dose)
75774051|NCT01039961|Drug|losmapimod 15 mg|oral, two 7.5 mg tablets
75774052|NCT00409409|Drug|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
75774053|NCT00409409|Drug|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
75774054|NCT00409331|Drug|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
75320002|NCT00575887|Drug|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
75320003|NCT03219125|Device|Dixon Magnetic Resonance Imaging|MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
75465871|NCT01902771|Other|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
75774055|NCT00409331|Procedure|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
75774056|NCT00409175|Drug|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
75774057|NCT00409175|Drug|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
75774058|NCT00362219|Other|Placebo|Gel with no active ingredient.
75774059|NCT00362219|Drug|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
75774060|NCT00362219|Drug|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
75774061|NCT00362219|Drug|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
75912492|NCT06058780|Procedure|Implantable Intraocular Lens (IPCL)|The IPCL offers a distinct economic advantage as the cost of the IPCL implant is only 2. times that of the ICL implant. Moreover, the IPCL can correct higher degrees of myopia, up to -30. D, compared to the maximum correction of -18. D provided by the ICL.
75912493|NCT06058754|Behavioral|The ADAPT Program|The ADAPT Program is a structured and individualized 10-week group-based program, in which two occupational therapists teach groups of people, the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT Program 3.0 includes 2 individual two-hour sessions (sessions 1 and 10) conducted in the clients homes and eight two-hour group-based sessions (sessions 2-9). Moreover, two booster sessions (sessions 11 and 12) are delivered to support sustainable gains after termination of the 10-week ADAPT Program 3.0
75912494|NCT06058754|Behavioral|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focused on improving ADL ability e.g. by practicing the performance of ADL task or adjusting home environments. UOT typically includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement in collaboration with the individual client
75774062|NCT01040585|Drug|Linezolid|Treatment for VAP as indication approved and as physician criterium.
75774063|NCT01040117|Procedure|Sensory-motor Integration Training|Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.
75774064|NCT01040117|Procedure|Conventional neurorehabilitation treatment|"The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.~Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position."
75774065|NCT01040663|Other|Dietary intervention|Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
75320004|NCT03219125|Device|dual-energy X-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
75320005|NCT04147052|Behavioral|iSLEEPms|Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.
75320006|NCT00575965|Drug|Simvastatin|Oral tablets taken daily
75620882|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
75620883|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
75620884|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
75620885|NCT01185704|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
75774066|NCT01040741|Other|Non-intervention observational study|Non-intervention observational study
75774067|NCT01040897|Behavioral|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
75774068|NCT01040897|Behavioral|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
75774069|NCT01040195|Drug|Methotrexate, Hydroxychloroquine|Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
75774070|NCT01040195|Drug|Placebo|Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
75774071|NCT01040975|Behavioral|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
75774072|NCT01040273|Drug|Bupivacaine|
75774073|NCT01040273|Drug|Placebo|
75774074|NCT00408629|Biological|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
75774075|NCT00408629|Biological|placebo|Matching Placebo for prefilled syringe, 40 mg,
75912495|NCT06058715|Procedure|Transverse Abdominal Plan block (TAP block)|Bilateral TAP block is administered intraoperatively at laparoscopy, directly after insufflation and insertion of the first trocar and camera. The ultrasound probe is placed longitudinally on the midaxillary line near umbilicus, and the transversus abdominis and internal oblique muscles are scanned and observed. The needle (22-gauge 90 mm disposable spinal needle) is inserted in plane and after placing the needle-tip into the fascia between transversus abdominis and internal oblique muscles, 20 ml of ropivacaine 0.25% is injected bilaterally. It is all done by one Anesthetist which is expert in that area and is not in charge of collecting the data.
75774076|NCT00408317|Drug|Ultrase® MT20|Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
75774077|NCT00408317|Drug|Placebo|Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
75774078|NCT00112502|Drug|Celecoxib|400 mg orally twice a day continuous dosing
75774079|NCT00112502|Drug|Isotretinoin|40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.
75774080|NCT00112502|Drug|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
75320007|NCT04142060|Drug|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
75620886|NCT01185704|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day
75774081|NCT00112502|Drug|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
75912496|NCT06058702|Drug|Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.
75774082|NCT03965546|Combination Product|Sorafenib combined with ET140202-T cell|"Sorafenib starting dose of 400mg b.i.d. a.c.~Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion"
75912497|NCT06058702|Drug|Placebo|Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
75912498|NCT06058689|Drug|Pomalidomide 4 MG Oral Capsule|A single dose of 4 mg Pomalidomide per os, capsule, 4 mg, per period
75774083|NCT03965546|Combination Product|TAE combined with ET140202-T cell|"Transarterial embolization(TAE) treatment~Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)"
75774084|NCT03965546|Biological|ET140202-T cell|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
75774085|NCT01080404|Procedure|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
75774086|NCT01080404|Device|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
75774087|NCT01083992|Drug|Galvus (vitagliptin)|Galvus (vitagliptin)
75774088|NCT01083992|Drug|Galvus + vitamin D|Galvus + vitamin D
75774089|NCT01084070|Other|Early oral feeding|"Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated."
75774090|NCT01084070|Other|Traditional Care|They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
76072899|NCT00582400|Drug|arsenic trioxide|"Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
75320008|NCT01797887|Behavioral|Diet and Lifestyle Counseling|Diet and Lifestyle Counseling
75320009|NCT03217097|Drug|Oxaliplatin-based chemotherapy|"The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
75620887|NCT01128959|Drug|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
75620888|NCT04222582|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
75912499|NCT06058676|Procedure|carotid artery stenting|The procedures will be performed for patients with general or local anesthesia. Implantation of stents at the site of carotid artery stenosis for the treatment of carotid severe stenosis. A suitable balloon will be selected based on the internal carotid arterial（ICA）diameter, as shown on the digital subtraction angiography（DSA）image. The use of a balloon for predilatation or postdilatation depends on the degree of stenosis. The type of stent will be selected according to several factors, such as the length and configuration of the lesion, vascular morphology, vessel diameter, plaque characteristics, stent characteristics, and surgeon experience.
75912500|NCT06058637|Device|Eye screening|Nurse-assisted eye-screening will take place with the Easee app, which is implemented on the tablet or laptop of the community nurse. The nurse's smartphone will function as a remote control by which he/she submits input to a computer screen that displays the test. If the participant can do the test by him or herself, the nurse will merely supervise to ensure correct application. Standard audio instructions guide the nurse and participant through the test. The test will start with triage questions, which are used to set up a correct referral. During the test, both eyes are tested consecutively, covering one eye at a time. The participant will wear his/her spectacles, if present. The participant is presented a sequence of optotypes (i.e. tumbling-E and triangle-circle optotypes) that the participant must correctly identify, in addition to various grate sizes, both near and at a distance. The Amsler grid test is performed to detect any macular problems.
75912501|NCT06058624|Behavioral|Veteran ACT for Chronic Pain (VACT-CP)|"Participants receive 7 online modules, provided as weekly sessions that feature Coach Anne as a virtual, animated treatment guide. All content is presented interactively, through text-based conversations with Coach Anne. Veterans will hear what Coach Anne says and respond to her using text-based dialogue options that will trigger different responses from Coach Anne as the conversation progresses, to allow the system to responsively interact in a personalized manner with the Veteran. Veterans will also be presented with videos (e.g., Veteran narratives, metaphors), in-module assessments (e.g., values assessments), and interactive opportunities for goal setting."
75912502|NCT06058624|Behavioral|Online Pain School|"Participants will receive 7 modules (15 to 20 minutes each) of content based on a common non-ACT based VA treatment option, Pain School. The adaptation used for this study, Online Pain School, will support Veterans' self-management of their chronic pain by providing informational videos on chronic pain and its health impacts, short behavioral exercises to help with pain management, and psychoeducation on different wellness techniques for their pain management toolbox."
75912503|NCT06058611|Other|Cognitive stimulation|Cognitive stimulation through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
75912504|NCT06058611|Other|Stimulating leisure activities|"Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (< 30 min, 30min-1 hour, 1-2 hours, > 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life."
75912505|NCT06058585|Drug|Mineralocorticoid receptor antagonist|Oral, once daily
75912506|NCT06058585|Drug|Placebo|Matched placebo tablets, oral, once daily
75912507|NCT06058507|Diagnostic Test|CT angiography|No intervention was made
75912508|NCT06058494|Procedure|Anterior Cruciate Ligament Reconstruction|Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.
75912509|NCT06058481|Device|Blockbuster|The investigator inserted the BlockBuster in Group A patients.
75912510|NCT06058481|Device|Proseal-LMA|The investigator inserted the Proseal-LMA in Group B patients.
75912511|NCT06058442|Drug|NORTASE®|10-15 capsules of NORTASE® per day - over 6 months
75320010|NCT03217097|Drug|Alkylating-based chemotherapy|"The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
75320011|NCT04147988|Other|screening and diagnostic assessment DONALD T unit list|Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
75465872|NCT01902771|Procedure|Leukapheresis|Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
75912512|NCT06058442|Drug|Placebo|10-15 capsules of placebo per day - over 6 months
75912513|NCT06058390|Drug|Bepirovirsen|Bepirovirsen will be administered.
76072900|NCT00582946|Device|Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
76072901|NCT00583414|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
76072902|NCT00583492|Biological|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
76072903|NCT00583492|Radiation|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
75320012|NCT03623828|Drug|Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe|Product administered using an external continuous subcutaneous infusion pump.
75320013|NCT03581006|Dietary Supplement|Low-Calorie Mediterranean Diet|Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity
75320014|NCT03581006|Combination Product|Technology based monitoring and behavioral participation|Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary
75465873|NCT01902784|Behavioral|Storytelling Interview|
75774091|NCT01084226|Dietary Supplement|Rye-2008|
75774092|NCT01078532|Other|SMART PHR|Patient receives an active PHR
75774093|NCT01078532|Other|usual care|Usual passive PHR
75774094|NCT03822182|Drug|liposomal bupivicaine|"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline"
75774095|NCT03822182|Drug|Dexamethasone|steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
75774096|NCT01078610|Biological|adalimumab (Humira)|40 mg adalimumab (Humira) every other week.
75774097|NCT03741296|Procedure|Single stage revision|One-stage exchange hip joint replacement surgery
75774098|NCT03741296|Procedure|Two-stage revision|Two-stage exchange hip joint replacement surgery
75774099|NCT03964766|Device|Rotary instrumentation|using pedo rotary files in cleaning and shaping the root canals of infected primary molars
75774100|NCT03964766|Device|Hand instrumentation|using conventional hand files in cleaning and shaping the root canals of infected primary molars
75774101|NCT01080482|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
75774102|NCT03965624|Drug|Ninlaro|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
75774103|NCT00111800|Drug|Placebo|Placebo capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
75774104|NCT00111800|Drug|DEN 2.5 mg|DEN 2.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
75774105|NCT00111800|Drug|DEN 7.5 mg|DEN 7.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
75774106|NCT00111800|Drug|DEN 15 mg|DEN 15 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
75774107|NCT00111800|Drug|DEN 30 mg|DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
75774108|NCT00111800|Drug|DEN 45 mg|DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
75774109|NCT01326806|Behavioral|Families Talking Together|The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
75774110|NCT01326806|Behavioral|Active Control on Hygiene & Nutrition|The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
75774111|NCT02530892|Procedure|EmbryoHug|"An oocyte or embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the oocyte or embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the oocyte or embryo."
75774112|NCT01080560|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
75912514|NCT06058364|Dietary Supplement|Intervention 1 - Triglyceride|Triglyceride (1 softgel each morning with a glass of water)
75774113|NCT00094328|Drug|Bicalutamide|oral
75774114|NCT00094328|Drug|Anastrozole|oral
75774115|NCT00094172|Drug|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
75774116|NCT00094172|Drug|Placebo|tablet form
75774117|NCT00094094|Drug|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
76072904|NCT04583527|Device|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
76072905|NCT01801735|Drug|Meloxicam Test Capsules|
75774118|NCT01078766|Other|CIMT+HABIT|The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
75912515|NCT06058364|Dietary Supplement|Intervention 2 - Placebo|Placebo (1 softgel each morning with a glass of water)
75912516|NCT06058351|Behavioral|ABI-motion program|The ABI-motion program strengthens the cooperation between outpatient rehabilitation professionals and community care providers.
75912517|NCT06058325|Other|Healthy school lunch|The healthy school lunch will be co-created together with school staff, parents, and children, and should be healthy according guidelines of the Dutch nutrition center.
75620889|NCT04119739|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
75620890|NCT04119739|Drug|Ibuprofen|Oral tablets
75912518|NCT06058312|Other|Self-questionnaire|The self-administered questionnaires to be completed at the time of inclusion will be presented to the patient on a tablet during the inclusion visit and will be completed on the same day in the Day Hospital using the Compusense software. Online self-questionnaires and sensory tests at the 9th week of treatment will also be conducted using the Compusense software in small groups at a designated location within the center.
75620891|NCT02760706|Device|Computed Tomography scan|
75465874|NCT01902797|Other|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
75774119|NCT03962816|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
75620892|NCT00625235|Dietary Supplement|VLED followed by a high protein or high carbohydrate diet|
75774120|NCT03962816|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
75774121|NCT03962816|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
75774122|NCT01080638|Drug|glycoprotein IIb/IIIa inhibitor (abciximab)|patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
75774123|NCT01084928|Behavioral|Lifestyle Intervention Classes|The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
75774124|NCT01079000|Behavioral|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
75774125|NCT01079000|Behavioral|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
75774126|NCT01079000|Behavioral|Usual care|Usual care provided to asthma patients when discharged from the ED
75774127|NCT03965312|Device|Continuous temperature monitor|Temperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated.
75774128|NCT03965312|Device|Neonatal Incubator|Infants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia.
75774129|NCT03965312|Device|Patient monitor|Temperature will be measured using a commercially available patient monitor.
75912519|NCT06058312|Other|Self-questionnaire|The MediLite questionnaire consists of nine items that assess daily consumption of fruits, vegetables, grains, meats and meat products, dairy products, alcohol, and olive oil, as well as weekly consumption of legumes and fish.
76072906|NCT00612430|Drug|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG & 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data & order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
76072907|NCT01571128|Other|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
76072908|NCT01571128|Other|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
76072909|NCT01571128|Drug|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
75465875|NCT01902810|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization
75774130|NCT00110396|Biological|Interferon-beta-1a FBS-free/HSA-free|Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
75465876|NCT01902810|Drug|Placebo|Placebo by mouth given daily throughout hospitalization
75465877|NCT01902823|Behavioral|Services from a Nurse Navigator|Services from a Nurse Navigator
75620893|NCT04206098|Other|Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)|Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
75620894|NCT02763514|Dietary Supplement|3 g PronovaPure 150:500 EE EU|
75620895|NCT02763514|Dietary Supplement|3 g PronovaPure 500:200 EE EU|
75620896|NCT02763514|Dietary Supplement|3 g Placebo|
75620897|NCT00859573|Drug|Modafinil|400 mg/day
75620898|NCT00859573|Drug|Placebo|inactive substance
75620899|NCT04312295|Behavioral|ACP-SCT program|The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
75620900|NCT02760940|Drug|oral liposomal iron|After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
75774131|NCT03819218|Drug|MC2-01 cream|MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
75774132|NCT00093470|Procedure|Clinical Observation|Undergo observation
75774133|NCT00093470|Drug|Tipifarnib|Given PO
75774134|NCT00407537|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
75774135|NCT00094458|Biological|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
75774136|NCT00094458|Other|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
75774137|NCT00094458|Drug|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
75774138|NCT00406367|Drug|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection"
75774139|NCT00406367|Drug|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
75774140|NCT01041443|Drug|5-fluoro-2-deoxycytidine|Given IV
75774141|NCT01041443|Drug|tetrahydrouridine|Given IV
75774142|NCT01041443|Other|laboratory biomarker analysis|Correlative studies
75774143|NCT01041443|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
75774144|NCT01041443|Genetic|DNA methylation analysis|Correlative studies
75774145|NCT03961464|Drug|d-cycloserine|Single dose
75774146|NCT03961464|Drug|Placebo|Single dose
75774147|NCT01087632|Dietary Supplement|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
75774148|NCT00394589|Drug|Infliximab Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks
75774149|NCT00394589|Drug|Infliximab Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks
75774150|NCT00394589|Drug|Infliximab Control|Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
75774151|NCT00068406|Radiation|3-Dimensional Conformal Radiation Therapy|
75774152|NCT00068406|Drug|Cisplatin|Given IV
75774153|NCT00068406|Procedure|Conventional Surgery|
75774154|NCT00403559|Drug|Elidel|
75774155|NCT00403559|Drug|Ketoconazole Cream|
75774156|NCT01087710|Other|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
75774157|NCT01087710|Other|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
75774158|NCT00403481|Drug|olmesartan medoxomil|Olmesartan medoxomil tablets, once daily
75774159|NCT00403481|Drug|Olmesartan medoxomil plus Hydrochlorothiazide|Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
75774160|NCT03759275|Other|pMDT(Baseline Investigation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
75774161|NCT01043783|Other|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
75774162|NCT00402779|Drug|Erlotinib|150 mg by mouth daily
75774163|NCT00402779|Drug|Placebo|Tablet by mouth daily
75774164|NCT00394433|Drug|Bevacizumab|
75774165|NCT00394433|Drug|Docetaxel|
75774166|NCT00394433|Drug|Cisplatin|
75774167|NCT00394433|Drug|Irinotecan|
75774168|NCT00092534|Biological|Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|A 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
75774169|NCT00092534|Biological|Matching Placebo|A placebo 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
75774170|NCT01324193|Dietary Supplement|Pomegranate extracts|a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
75774171|NCT00068250|Drug|rituximab|375 mg/m2, intravenously three days prior to the first cycle of methotrexate
75774172|NCT00068250|Drug|methotrexate|Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
75774173|NCT00068250|Drug|temozolomide 100 mg/m^2|Temozolomide 100 mg/m^2 by mouth per day for five days on weeks 4 and 8.
75774174|NCT00068250|Drug|temozolomide 150 mg/m^2|Temozolomide 150 mg/m^2 by mouth per day for five days on weeks 4 and 8.
75774175|NCT00068250|Drug|temozolomide 200 mg/m^2|Temozolomide 200 mg/m^2 per day by mouth for five days on weeks 4 and 8.
75774176|NCT00068250|Radiation|radiation therapy|Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
75774177|NCT00068250|Drug|post-radiation therapy temozolomide|Temozolomide (TMZ) 200 mg/m^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
75774178|NCT01080872|Device|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
75774179|NCT00393887|Device|Biodesign IHM|Biodesign IHM is placed to reinforce the hernia repair
75774180|NCT00393887|Device|Polypropylene mesh|Polypropylene mesh is used to reinforce the hernia repair.
75774181|NCT03957720|Drug|DMPS|Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
75774182|NCT03957720|Drug|Penicillamine|Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
75320015|NCT03581006|Other|Usual care group|Control group, who will receive no dietary or behavioral intervention during the trial
75320016|NCT00501995|Drug|IV Cyclophosphamide|Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
75320017|NCT03589898|Drug|Gabapentin|Single dose of gabapentin 900 mg
75620901|NCT01136291|Other|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
75620902|NCT02763280|Dietary Supplement|Ginseng extract 1g|Ginseng extract 1g, parallel design
75620903|NCT02763280|Dietary Supplement|Ginseng extract 3g|Ginseng extract 3g, parallel design
75620904|NCT02763280|Dietary Supplement|Placebo|placebo, parallel design
75620905|NCT02758444|Dietary Supplement|Micronutrient Powder (MNP) + 15 mg Zn|Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
75620906|NCT02758444|Dietary Supplement|MNP + 10 mg Zn|Same as above except MNP will contain 10 mg Zn
75620907|NCT02758444|Dietary Supplement|MNP + 5 mg Zn|Same as above except MNP will contain 5 mg Zn
75620908|NCT02758444|Dietary Supplement|MNP without Zn|Same as above except MNP will not contain Zn
75620909|NCT02760784|Behavioral|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
75620910|NCT02695966|Procedure|Whipples Surgery|Whipples Surgery
75620911|NCT01185548|Drug|Tolbutamide|Administered orally
75620912|NCT01185548|Drug|Tasisulam|Administered intravenously
75620913|NCT01128569|Drug|Fluticasone Furoate|FF
75620914|NCT01128569|Drug|FF/Vilanterol (VI; GW642444M)|FF/VI
75620915|NCT01128569|Drug|Placebo|Placebo Inhaler
75774183|NCT03957720|Drug|DMSA|Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
75320018|NCT03584828|Behavioral|Tele Cardiac Rehabilitation|"A multidisciplinary intervention that aims to optimize structured exercise performed in the community as prescribed by rehabilitation cardiologist, cardiac care nurse, and exercise physiologist.~Additionally, in the intervention arm, we will provide psychological support, dietary intervention and disease management services that complement the structured physical activity - all by innovative smartphone applications and smart wearable devices, thus complementing the comprehensive secondary prevention program."
75320019|NCT03666377|Other|Gum chewing|1 piece of sugarless gum to be chewed three times daily for 1 hour each.
75320020|NCT00577135|Drug|Furosemide-Q12 hour bolus|Q12 hours bolus
75620916|NCT02696044|Drug|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
75620917|NCT04582942|Drug|PEG|Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
75774184|NCT03957720|Drug|Zinc gluconate|Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
75320021|NCT00577135|Drug|Furosemide-Continuous Infusion|Continuous infusion
75320022|NCT00577135|Drug|Furosemide-Low Intensification|1x oral dose
75320023|NCT00577135|Drug|Furosemide-High Intensification|2.5x oral dose
75320024|NCT03583580|Radiation|Accelerated Partial Breast Irradiation|Patients are irradiated to the region of tumour bed using intensity modulated radiation therapy (IMRT)
75320025|NCT00502853|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
75320026|NCT00502853|Drug|Methotrexate|10-25mg/week
75320027|NCT00617539|Drug|irinotecan hydrochloride|
75320028|NCT00617539|Drug|temozolomide|
75320029|NCT03584750|Other|Floating|Floating in specialized tank with full floatation and sensory deprivation.
75620918|NCT04582942|Drug|PEG+lactulose|On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
75620919|NCT02883179|Drug|lidocaine injection|anhydrous solution
75620920|NCT02883179|Drug|lidocaine-prilocaine cream|topical cream
75620921|NCT02758366|Drug|Doxorubicin|
75620922|NCT05125601|Other|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH)|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH) will be completed once.
75620923|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr >80 mL/min)
75620924|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
75620925|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - <50 mL/min)
75620926|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr <30 mL/min and not on hemodialysis)
75774185|NCT00393029|Biological|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
76072910|NCT01571128|Behavioral|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
76072911|NCT00614458|Drug|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
75774186|NCT00393029|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
75774187|NCT00393029|Biological|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count > 1.0 x 10^9/L x 3 days or > 5.0 x 10^9/L.
75774188|NCT00393029|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
75774189|NCT00393029|Drug|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
75774190|NCT00402233|Drug|Pramipexole|
75774191|NCT00402233|Drug|Placebo|
75774192|NCT03993431|Drug|Bio-active cement|A cement used for crown cementation, specially recommended for pediatric esthetic crowns
75774193|NCT03993431|Drug|Packable glass ionomer|Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
75774194|NCT01044017|Drug|Placebo|single oral dose
75774195|NCT01044017|Drug|RO4998452|single oral doses
75774196|NCT00092456|Biological|rotavirus vaccine, live, oral, pentavalent|Three oral doses (~8.81 X 10^7 IU/Dose for Lot 1; ~8.01 X 10^7 IU/Dose for Lot 2; and ~6.91 X 10^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
75774197|NCT00092456|Biological|Placebo|"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"
75774198|NCT00067470|Drug|Placebo|
75774199|NCT00067470|Drug|N-acetylgalactosamine 4-sulfatase|
76072912|NCT01429168|Drug|Etoricoxib|One 60-mg tablet orally daily
76072913|NCT01429168|Drug|Placebo for etoricoxib|One 60-mg tablet orally daily
75320030|NCT03584750|Other|Placebo floating|Floating in specialized tank with reduced floatation and sensory deprivation.
75320031|NCT05214625|Other|Questionnaire|Questionnaire concerning artificial intelligence and its implementation in healthcare. GI patients and GI physicians will be provided with slightly different questionnaires.
75320032|NCT03584672|Other|Static Balance Test|Balance control is assessed by the Static Balance Test.
75320033|NCT03584672|Other|Berg Balance Scale|Functional balance is assessed by the Berg Balance Scale.
75774200|NCT00401843|Biological|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
75774201|NCT00401843|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
75774202|NCT00401843|Drug|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
75774203|NCT00401843|Drug|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
75774204|NCT00401531|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
75774205|NCT00401531|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
75774206|NCT00401375|Drug|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
76072914|NCT00771160|Drug|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
76072915|NCT00756418|Drug|montelukast|montelukast 5 mg QD 4-weeks.
76072916|NCT00756418|Drug|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
76072917|NCT00615472|Drug|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
76072918|NCT00615472|Drug|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
75320034|NCT03584672|Other|Timed Up an Go Test|Functional mobility is assessed by the Timed Up and Go test.
75774207|NCT00401375|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
75774208|NCT00400985|Device|Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.|SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.
75620927|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
75620928|NCT02758288|Other|New Protocol - BK viremia or BK virus nephropathy|Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
75912520|NCT06058312|Other|Self-questionnaire|"The CITAS is a self-administered questionnaire consisting of 18 items evaluated on a five-point Likert scale and divided into three dimensions: 1) quantitative changes in taste perception (hypogeusia and ageusia), 2) qualitative changes in taste perception (heterogeusia, cacogeusia), and 3) nutrition-related problems (difficulty eating hot or fatty foods).~Using a Likert scale ranging from 1 to 5 (where 1 = no difficulty or absence of disturbance and 5 = maximum difficulty or disturbance), CITAS assesses the four dimensions of taste disturbances: taste intensity, discomfort, phantogeusia, and parageusia, as well as overall taste alterations.~For the original version by Kano and Kanda (2013), five items assessing changes in smell from the modified CITAS version by Drareni et al. 2021 will be added in this study."
75912521|NCT06058312|Other|Self-questionnaire|"Food neophobia will be assessed using the Food Neophobia Scale (FNS) developed by Pliner & Hobden (1992). The FNS consists of ten statements evaluated on a 7-point agreement scale ranging from 1 = I strongly disagree to 7 = I strongly agree. Individual FNS scores are calculated as the sum of the ratings given to the ten statements after reversing the neophilic items; thus, scores theoretically range from 10 to 70, with higher scores reflecting higher levels of food neophobia."
75912522|NCT06058312|Other|Self-questionnaire|The quality of life related to food in cancer patients is composed of 46 items with a 4-point scale (never, almost never, almost always, always). The questionnaire is divided into different subdomains: Cooking, where one eats and conviviality, Eating and drinking, After eating.
75912523|NCT06058312|Other|Self-questionnaire|Individual baseline disgust sensitivity is assessed using the Disgust Sensitivity-Short Form (DS-SF) questionnaire; this questionnaire is a shortened version of the disgust scale aimed at measuring disgust of animal origin, based on contamination and revulsion (Haidt, 2004; Haidt et al., 1994; Inbar, Pizarro, and Bloom, 2009; Olatunji et al., 2007). This measure consists of 8 items divided into 2 parts. In the first part, statements were rated on a scale from 1 (not at all agree-very false about me) to 5 (completely agree-very true about me); for the second part, additional statements were rated from 1 (not at all disgusting) to 5 (extremely disgusting). The total disgust sensitivity score is obtained by summing the scores after two items have been reversed and ranges from 8 to 40.
75620929|NCT02758288|Other|Standard Protocol - BK viremia or BK virus nephropathy|Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
75774209|NCT00400517|Biological|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
75774210|NCT00400517|Drug|thalidomide|doses up to 400 mg/day
75320035|NCT03584672|Other|Four Square Step Test|Dynamic balance is assessed by the Four Square Step Test.
75320036|NCT03584672|Other|Functional Reach Test|Limits of stability is assessed by the Functional Reach Test.
75320037|NCT03584672|Other|One-leg Stance Test|Postural steadiness is assessed by the One-leg Stance Test.
75774211|NCT00400517|Procedure|conventional surgery|SOC care surgery
75774212|NCT00400517|Procedure|neoadjuvant therapy|post radical prostatectomy
75774213|NCT01044095|Biological|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
75320038|NCT03620123|Drug|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
75320039|NCT03620123|Drug|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
75774214|NCT01044095|Biological|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
75774215|NCT01044173|Device|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
75798347|NCT03870828|Diagnostic Test|Arterial blood gas|If SpO2 is measured to be < 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.
75320040|NCT03581162|Diagnostic Test|Carotid Ultrasound and venous blood sampling|Carotid ultrasound and blood sampling
75320041|NCT00578071|Drug|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
75320042|NCT00578071|Drug|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
75320043|NCT00578071|Drug|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
75798348|NCT03870828|Procedure|Blood drawing|A vein will be punctured in order to take a blood sample for further tests
75798349|NCT01283802|Procedure|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|"Techniques are as follows:~Direct ultrasound exploration without any contrast agents.~IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);~IOCUS injection of an air bolus into the bile duct."
75320044|NCT00578071|Radiation|Radiation Therapy (RT)|Daily for 6 weeks
75320045|NCT03584438|Device|Real iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)
75320046|NCT03584438|Device|Sham iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
75320047|NCT00555581|Drug|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
75774216|NCT01324427|Behavioral|virtual medical visit|"At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits."
75774217|NCT00392171|Drug|Temozolomide|Subjects will receive temozolomide 50 mg/m^2 for cycles of 28 days for 12 months or until progression
75912524|NCT06058312|Other|Self-questionnaire|The subscale of reward sensitivity from the short version of reward and punishment sensitivity has been selected (17 items). Each item will be assessed on a 4-point Likert scale, ranging from 1 (completely no) to 4 (completely yes).
75912525|NCT06058312|Other|Self-questionnaire|"The EmoPrefMed questionnaire was developed to measure declared appreciation and emotional responses to selected Mediterranean diet (RM) products and changes in appreciation before and after chemotherapy.~The assessment of the acceptability of a series of RM foods (listed in the questionnaire appendix) will be evaluated using a nine-point hedonic scale ranging from a minimum of 1 = I don't like it at all to a maximum of 9 = I like it a lot (Peryam & Pilgrim, 1957).~Emotions will be assessed using a check-all-that-apply (CATA) list of emotions, including 4 negative and 4 positive emotions with low, moderate, and high arousal levels (It brings me joy, It intrigues me, It relaxes me, It annoys me, It leaves me indifferent, It makes me sad, It's monotonous, It disgusts me). Patients will be asked to select all the emotions they deem appropriate to describe the food product."
75912526|NCT06058312|Other|Self-questionnaire|"Food-related attitudes will be measured using the HTAS (Health and Taste Attitude Scale) proposed by Roininen et al. (1999), consisting of six subscales focusing on perceived health and taste aspects of foods. The two scales selected in this study are general interest in health (eight items, measuring overall interest in a healthy diet) and the use of food as a reward (six items, measuring attitudes towards using food as a reward). Each subscale consists of an equal number of statements phrased positively and negatively (Roininen et al., 1999). All items were rated on a seven-point category scale, ranging from strongly disagree to strongly agree. As suggested by Roininen et al. (1999), negative statements were reversed and recoded for the calculation of final scores."
76072919|NCT00615472|Drug|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
76072920|NCT00615784|Drug|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
75620930|NCT01128413|Device|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
75774218|NCT00391625|Drug|GA-GCB|15-60 U/kg every other week via intravenous infusion
75774219|NCT03993275|Device|MindMotion GO|Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.
75774220|NCT00091832|Biological|Denosumab|Denosumab administered by subcutaneous injection
75774221|NCT00091832|Drug|IV Bisphosphonates|Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
75320048|NCT03589820|Other|artificial liver support system|Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
75774222|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
75774223|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
75774224|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
76072921|NCT00755794|Drug|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
76072922|NCT00652444|Drug|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
76072923|NCT00652444|Drug|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
76072924|NCT00652444|Drug|Placebo (Unspecified)|Matching ezetimibe placebo
75774225|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
75774226|NCT01085162|Drug|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
75774227|NCT01044251|Drug|Frovatriptan|2.5 mg po bid for 10 days
75774228|NCT01044251|Drug|Placebo|1 tab po bid for 10 days
75774229|NCT01044329|Drug|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
75774230|NCT01044329|Drug|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
75774231|NCT01044407|Device|Pacemaker manipulation|Alternation of cardiac output by modulation of heart rate, atrioventricular delay and modulation from biventricular pacing to right ventricular pacing (where applicable)via a cardiac pacemaker
75620931|NCT01128413|Device|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
75774232|NCT01018589|Other|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application."
75774233|NCT00091442|Drug|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
75620932|NCT01128413|Device|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
75774234|NCT00091442|Drug|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
75774235|NCT00390689|Drug|Pramipexole 0.125 mg tablet|
75774236|NCT00390689|Drug|Pramipexole 0.5 mg tablet|
75774237|NCT01085240|Other|Mission Possible|The intervention focuses on leisure education, exercise and community re-integration.
75320049|NCT00504023|Drug|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
75774238|NCT01079078|Drug|Acetaminophen|
75774239|NCT03965156|Procedure|1) Ultrasound guided Erector spinae block|In the lateral position, after skin sterilization, erector spinae plane block will be performed at the level of T9. Counting down from the spine of seventh cervical vertebrae, the spine of the nine thoracic vertebrae (T9). A linear low frequency ultrasound transducer (US) (3-5 MHz) will placed sagittal 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between transverse processes. A 22-gauge short bevel needle will be inserted in cranial-caudal direction towards transverse process (TP) in plane to the US transducer until needle touched the TP crossing all the muscles. The location of the needle tip will be confirmed by visible normal saline fluid separating erector spinae muscle off the bony shadow of the transverse process on ultrasound imaging. Then 20 ml of bupivacaine 0.375% plus plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side of the back.
75320050|NCT00504023|Procedure|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
75774240|NCT03965156|Procedure|Ultrasound guided transversus abdominis plane block|in supine position and after skin sterilization. The linear high frequency transducer (6-13 MHz) will be placed in the transverse plane to the the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. The three abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) are visualized. The needle inserted in plane and advanced anterior to posterior under continual visualization until the tip between the internal oblique and the transversus abdominis muscle. After negative aspiration, a 20 ml of bupivacaine 0.375% plus 5ug/ml adrenaline (1:200000) will be injected. The success of the injection will be confirmed by separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in between. The procedure will be repeated following the same steps on the other side.
75774241|NCT00121238|Drug|cilengitide|Given IV
75774242|NCT00390455|Drug|Fulvestrant|Given IM
75774243|NCT00390455|Other|Laboratory Biomarker Analysis|Correlative studies
75774244|NCT00390455|Drug|Lapatinib Ditosylate|Given PO
75774245|NCT00390455|Other|Placebo Administration|Given PO
75774246|NCT03812510|Drug|A-101|hydrogen peroxide topical solution 45%
75774247|NCT01583114|Drug|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
75320051|NCT00504023|Procedure|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
75320052|NCT03020108|Other|Blood sample|2 cc blood samples will be drawn from antecubital vein
75320053|NCT03580850|Other|No intervention in this restrospective study|This study is an obervational study
75320054|NCT03589586|Other|DermACELL AWM|DermACELL AWM is a sterile, ready to use acellular dermal matrix
75320055|NCT03589508|Behavioral|In-person sessions: ABCP_P|6 weekly sessions of alcohol prevention conducted in person.
75320056|NCT03589508|Behavioral|Video conference sessions: ABCP_T|6 weekly sessions of alcohol prevention conducted by video conference.
75320057|NCT03028688|Device|High flow nasal cannula oxygen|Participants will receive high flow nasal cannula oxygen delivery during anesthesia. Participants will also have transcutaneous PCO2 measurements performed using a cutaneous electrode.
75774248|NCT01583114|Drug|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
75320058|NCT03589430|Other|Laboratory investigations ( protein C, protein S , antithrombin III)|laboratory investigations ( protein C , protein S , antithrombin)
75320059|NCT05702762|Drug|Gentamicin|5 mg/kg intramuscular injection
75320060|NCT05702762|Drug|Standard of Care|Usual oral antibiotic multi-day dosing based on local antibiogram
75620933|NCT01128413|Behavioral|CURVES Questionnaire|The CURVES (CardiovascUlar Response & Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
75320061|NCT03584126|Diagnostic Test|Electrocardiography, ecocardiography and MRI.|AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
75620934|NCT01128413|Biological|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, & 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
75320062|NCT03589274|Behavioral|I-FS-CBT|12 manual-guided sessions of I-FS-CBT
75320063|NCT03589274|Behavioral|G-FS-CBT|12 manual-guided sessions of G-FS-CBT
75912527|NCT06058312|Other|Self-questionnaire|"The response to PROP (6-n-propyl-2-thiouracil) is measured using 1.5 cm diameter paper disks previously soaked in a solution of deionized water with a concentration of 3.2 mM PROP, dissolving 0.5477 g/L of PROP. Each paper disk will contain approximately 0.280 mg of PROP. Participants are asked to place the paper disk on the tip of their tongue for 20 seconds, then remove it and assess the perceived bitter intensity on a Labelled Magnitude Scale (LMS).~The LMS scale consists of a vertical line of 100 units with labels placed at no sensation, 0; barely detectable, 1.4; weak, 6; moderate, 17; strong, 34.7; very strong, 52.5; and the strongest imaginable sensation of any kind, 100. Numeric labels are not reported on the scale. Participants are instructed to think of the strongest imaginable sensation as the most intense sensation they can imagine in the realm of taste. Participants are encouraged to ask questions about the use of the scale if they need more clarification."
75320064|NCT03583970|Device|Left Ventricular Assist Device Implantation|Veno-arterial extracorporeal membrane oxygenation prior to left ventricular assist device implantation : initial patients characteristics and 6 Month Follow-up
75620935|NCT01128413|Biological|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
75620936|NCT01128413|Biological|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
75620937|NCT02760628|Behavioral|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
75774249|NCT01085474|Other|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
75774250|NCT01085474|Other|2|The best intervention used in the pilot study will be chosen and included in the main study.
75320065|NCT03020810|Drug|Dupilumab|The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
75912528|NCT06058312|Other|Self-questionnaire|The odors (Mint, Anise, Banana, Pine, Garlic, Cinnamon, Lemon) are trapped in tightly packed microcapsules (aminoplast type, diameter: 4-8 μm). Microcapsule-based ink is printed on cardboard paper (SILK-250 g; Size: 11 cm × 21 cm). Each odorant has been printed in a defined area (2 cm in diameter). The odor is released by simply rubbing the printed microcapsule reserve (scratch-and-sniff method).Patients receive a disposable single-use sample and are asked to identify the odors and evaluate on a visual analog scale the perceived intensity, perceived irritation, and appreciation of each odor.
75912529|NCT06058312|Other|Self-questionnaire|"Two model foods were developed to investigate responses to variations in sweetness, acidity, and freshness. The first range consists of Apple-Mint Juice, composed of four samples containing different concentrations of mint syrup (0, 15, 60, 240 g/kg). The second range is a chickpea mousse made up of four samples containing different quantities of citric acid and glucose-fructose syrup (glucose-fructose syrup: 0, 50, 100, 200 g/kg; citric acid: 8, 6, 4, 4 g/kg). Participants are asked to evaluate the samples using the Labelled Affective Magnitude Scale. Regarding the LAM scale, subjects are instructed to consider the extremes of appreciation, the best I can imagine and the worst I can imagine. After a break, they are asked to taste the samples again and rate the intensity of sweetness, acidity, apple flavor, mint flavor, and freshness on the Labeled Magnitude Scale: from 'not detectable' to 'the strongest imaginable'."
75774251|NCT01079312|Device|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
75912530|NCT06058299|Drug|TBAJ-876|tablet
75912531|NCT06058299|Drug|Pretomanid|200 mg
75320066|NCT05702606|Other|Radial extracorporeal shock wave therapy (rESWT)|Radial shock waves are ballistic waves generated by injection of compressed air inside an applicator that fires a projectile into the itself and impacts against the application head
75320067|NCT03580694|Drug|REGN4659|REGN4659 will be administered by intravenous (IV) infusion.
75320068|NCT03580694|Drug|Cemiplimab|Cemiplimab will be administered by intravenous (IV) infusion.
75620938|NCT02760628|Behavioral|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
75620939|NCT01185080|Drug|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
75620940|NCT01185080|Drug|Placebo|Nasal spray solution, intranasal, three times weekly for one month
75620941|NCT01185080|Drug|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
75620942|NCT00625313|Device|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
75620943|NCT02882399|Other|Shortystrap|
75774252|NCT01079312|Device|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
75912532|NCT06058299|Drug|Linezolid|600 mg
75620944|NCT04498156|Other|No intervention|No intervention, observational study
75774253|NCT01079312|Drug|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
75774254|NCT01079312|Drug|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
75774255|NCT01079312|Drug|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
75465878|NCT01902836|Biological|Conventional treatment plus DLE|"Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month"
75774256|NCT01079312|Drug|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
75774257|NCT00390299|Biological|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or IT
75774258|NCT00390299|Other|Laboratory Biomarker Analysis|Correlative studies
75774259|NCT00390299|Procedure|Therapeutic Conventional Surgery|Undergo en bloc resection
75620945|NCT02760550|Other|No intervention|Participants of all three groups completed a questionnaire.
75774260|NCT01044485|Drug|lapatinib|escalation dose from 1250 to 1500 mg in association with docetaxel
75774261|NCT01044485|Drug|docetaxel|escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
75774262|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
75774263|NCT00119678|Drug|Placebo|Injectable, intravenous, 0 mg, every 28 days, 12 months
75774264|NCT00119678|Drug|Prednisone|Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
75774265|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, every 28 days
75774266|NCT00110084|Drug|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
75320069|NCT03583892|Drug|Gabapentin|One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
75465879|NCT01902836|Biological|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
75774267|NCT00110084|Drug|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
75320070|NCT03583736|Behavioral|Virtual visit|Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
75320071|NCT03583736|Behavioral|Office visit|Scheduled office visit with oncologist following uterine cancer diagnosis.
75320072|NCT05702528|Device|Apollo Neuro|The group will complete daily use of the Apollo Neuro, a wrist-worn consumer wellness device
75465880|NCT01902849|Other|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~T0- before the induction of anesthesia (venous cannula insertion time)~T1- after induction but before starting surgery~In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~T2, T3- at 2 and 24 hours after surgery"
75620946|NCT01128179|Drug|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
75620947|NCT01128179|Drug|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
75620948|NCT02883257|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
75620949|NCT01181102|Drug|edoxaban|
75620950|NCT01181102|Drug|enoxaparin sodium|
75620951|NCT02757820|Device|LMA Classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
75620952|NCT02757820|Device|i- gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
75774268|NCT00390221|Biological|BIIB019 (Daclizumab High Yield Process)|SC injection
75774269|NCT00390221|Drug|Placebo|Placebo SC injection
75774270|NCT00389831|Drug|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
75774271|NCT00389831|Other|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
75774272|NCT00389597|Device|Cervical Artificial Disc|Cervical artificial disc mechanical device
75774273|NCT00389519|Drug|ramipril|once a day oral ramipril capsules given for 4 weeks
75774274|NCT00389519|Drug|placebo|once a day oral placebo capsule for 4 weeks
75774275|NCT00389441|Drug|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
75620953|NCT02757820|Device|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
75774276|NCT00118898|Drug|Abacavir/Lamivudine|600 mg abacavir/300 mg lamivudine tablet taken orally daily
75774277|NCT00118898|Drug|Atazanavir|300 mg tablet taken orally daily
75774278|NCT00118898|Drug|Efavirenz|600 mg tablet taken orally daily
75620954|NCT00858637|Drug|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
75620955|NCT00858637|Drug|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
75620956|NCT00858637|Drug|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
75620957|NCT00858637|Drug|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
75620958|NCT04221646|Device|BTL-899|Treatment with study device.
75620959|NCT02760394|Device|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
75620960|NCT04221334|Device|Electric Toothbrush|Electric Toothbrush used to remove dental plaque and resolve gingivitis
75774279|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
75912533|NCT06058299|Drug|Bedaquiline|200 mg for 8 weeks followed by 100 mg for 18 weeks
75465881|NCT01902862|Drug|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
75620961|NCT04221334|Other|oral health care application|phone application that shows the user brushing efficiency real time
75620962|NCT00699439|Other|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
75774280|NCT00118898|Drug|Ritonavir|100 mg tablet taken orally daily
75774281|NCT00118898|Drug|Abacavir/Lamivudine placebo|Placebo tablet taken orally daily
75774282|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate placebo|Placebo tablet taken orally daily
75774283|NCT00118430|Behavioral|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
75774284|NCT00118430|Drug|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
75774285|NCT00118430|Drug|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
75774286|NCT01085552|Drug|Epoetin Beta|Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
75774287|NCT03962426|Device|SocialVille Social Cognitive Training|"SocialVille exercises in this study include 4 exercises:~Recognition: a speeded face matching task~Face to Face: a speeded facial emotion matching task~Gaze Match: a speeded gaze matching task~Face Poke: a continuous performance task with facial expressions"
75774288|NCT01085708|Drug|rabeprazole|10 mg normal tablet
75912534|NCT06058299|Drug|HRZE|Isoniazid (H) + rifampicin (R) + pyrazinamide (Z) plus ethambutol (E) fixed dose combination tablets dosed by weight
75912535|NCT06058299|Drug|HR|Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight
75465882|NCT01902862|Drug|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
75465883|NCT01902875|Drug|Paclitaxel + Cisplatin|Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
75465884|NCT01902875|Biological|CIK cell therapy|Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
75465885|NCT01902914|Procedure|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
75620963|NCT04173520|Drug|DDA|Follow up after SVR
75620964|NCT02760316|Drug|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
75620965|NCT02760316|Drug|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
75620966|NCT02760316|Drug|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
75620967|NCT02760316|Drug|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
75620968|NCT02760316|Drug|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
75774289|NCT01085708|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
75774290|NCT01085708|Drug|rabeprazole|Type 2 granules containing rabeprazole 10 mg
75774291|NCT01085708|Drug|rabeprazole|Type 3 granules containing rabeprazole 10 mg
76072925|NCT00585910|Drug|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
76072926|NCT00489346|Drug|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
75620969|NCT02760316|Drug|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
75620970|NCT02760316|Drug|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
75774292|NCT01081106|Procedure|Low-Level Laser Therapy|"A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.~administration."
75774293|NCT00090584|Drug|Tolterodine|4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
75774294|NCT00090584|Behavioral|Behavioral training|Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
75774295|NCT01326884|Device|ZLP|ZLP Graft
75774296|NCT03965000|Other|Mixed-meal-tolerance-test|To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
75774297|NCT01081184|Biological|blood sample|blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
75774298|NCT03964922|Biological|blood sample|20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT
75774299|NCT03964922|Biological|bone marrow sample|3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
75774300|NCT01079624|Other|Glucose-insulinotropic peptide, Glucagon-like peptide-1|GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
75774301|NCT01086020|Drug|atorvastatin|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
75774302|NCT01086020|Drug|atorvastatin plus ezetimibe|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
75774303|NCT03670810|Drug|Lasmiditan|Administered orally.
75774304|NCT03670810|Drug|Placebo|Administered orally.
75774305|NCT03962192|Other|Attitudinal measures|A collection of 3 distinct attitudinal instruments comprise this survey.
75320073|NCT03589196|Procedure|Ejaculation Preserving Photoselective Vaporization|Ejaculation Preserving Photoselective Vaporization
75320074|NCT03589196|Procedure|Ejaculation Preserving Plasma Kinetic Vaporization|Ejaculation Preserving Plasma Kinetic Vaporization
75620971|NCT02760316|Drug|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
75620972|NCT02760316|Drug|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
75620973|NCT00858403|Drug|Dasatinib|Take tablets of Dasatinib by mouth once a day.
75774306|NCT01086176|Device|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
75774307|NCT01086254|Drug|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: 60-minute IV infusion"
75774308|NCT01086254|Drug|gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: 30-minute IV infusion"
75774309|NCT01086254|Drug|cisplatin|"Pharmaceutical form: solution for infusion~Route of administration: 1- to 4-hour IV infusion, according to the local standard"
75774310|NCT01081340|Behavioral|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
75774311|NCT01081340|Behavioral|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
75774312|NCT01086332|Drug|Nelfinavir|1250 mg twice daily
75774313|NCT01086332|Drug|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
75774314|NCT03962270|Device|shock wave device|The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
75774315|NCT01811368|Biological|rituximab|Given IV
75774316|NCT01811368|Biological|ibritumomab tiuxetan|Given IV
75774317|NCT01811368|Biological|anti-thymocyte globulin|Given IV
75774318|NCT01811368|Radiation|total nodal irradiation|Undergo TLI
75774319|NCT01811368|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
75774320|NCT01811368|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
75774321|NCT01811368|Drug|cyclosporine|Given PO or IV
75774322|NCT01811368|Drug|mycophenolate mofetil|Given PO or IV
75465886|NCT01902927|Other|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
75465887|NCT01902940|Other|Natural History|Assessment of natural history in IBM and CCFDN
75465888|NCT01902979|Behavioral|Lifestyle intervention|
75465889|NCT01902992|Drug|Depiquick Birch (DPG103)|
75465890|NCT01902992|Drug|Placebo|
75320075|NCT03589196|Procedure|Ejaculation Preserving Transurethral Resection Of The Prostate|Ejaculation Preserving Transurethral Resection Of The Prostate
75320076|NCT03503474|Other|No intervention|There is no intervention, this is observational only
75320077|NCT03589118|Other|Qi Gong sessions|13 sessions of Qi Gong in a 9 weeks period
75465891|NCT01903018|Drug|P276-00|
75465892|NCT01903018|Radiation|Radiation Therapy|
75465893|NCT01903018|Drug|Cisplatin|
75465894|NCT01903044|Procedure|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
75465895|NCT01903057|Drug|azithromycin|
75465896|NCT01903057|Drug|ivermectin|
75620974|NCT02760472|Drug|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
75620975|NCT02760472|Drug|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
75912536|NCT06058286|Other|Continuous quality improvement|Continuous quality improvement (CQI) is an approach to develop healthcare providers' capacity to improve quality of care processes and improve adherence to clinical guidelines. Key features of CQI include systematic, data-guided activities, designing interventions (or changes to facility processes) with local conditions in mind, and iterative development and testing of interventions. The approach is based on the premise that valuable improvement in organisational processes can be achieved through bottom-up initiatives of stakeholders and providers. It requires a 'team-based' culture of staff working together to collect and use available data to evaluate the effect of local solutions. Facility staff drive the development of solutions to quality of care shortcomings that they feel are best suited to the local context, and CQI works within existing resource constraints so it does not require large long-term investments to sustain improvements.
75912537|NCT06058273|Behavioral|Bruni® training|10 sessions (7 individual and 3 group) based on the Bruni method, which was born as a method for the artistic voice (rock, pop, gospel, R&B, grunge, metal), acting and dubbing. It is a method based on the didactic desire to lead any artist to the ability to produce various types of noise, specifically generically supraglottic, predominantly arytenoid and falsechordal emissions, providing the perceptive, proprioceptive and praxis tools to safely emit and manage the many sounds generated from a supraglottic source
75936329|NCT03191474|Behavioral|T-POWr Intervention|"All participants will be asked to complete a secure confidential online survey focusing on needs assessment.~Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management."
76072927|NCT00489346|Drug|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
75465897|NCT01903057|Drug|albendazole|
75465898|NCT01903057|Drug|placebo|
75774323|NCT00089648|Drug|Sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
75774324|NCT01086488|Drug|FOSCAN|Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
75465899|NCT01903070|Drug|Linagliptin|
75774325|NCT01079702|Drug|Everolimus|Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.
75774326|NCT01079702|Drug|Capecitabine|Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
75774327|NCT00118040|Drug|Genistein|Given orally
75774328|NCT00118040|Other|Laboratory Biomarker Analysis|Correlative studies
75774329|NCT00118040|Other|Pharmacological Study|Correlative studies
75774330|NCT00118040|Other|Placebo Administration|Given orally
75774331|NCT00118040|Procedure|Therapeutic Conventional Surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
75774332|NCT03961958|Drug|Propofol reduction|Reduction of propofol target concentration
75774333|NCT01081418|Behavioral|Assertive Community Treatment (ACT)|ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
75465900|NCT01903083|Drug|Tadalafil|One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
75465901|NCT01903083|Drug|Gemcitabine|Three doses of gemcitabine (1000 mg / m^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
75774334|NCT00389207|Drug|nevirapine bid|nevirapine twice daily
75774335|NCT00389207|Drug|nevirapine qd|nevirapine once daily
75774336|NCT00389207|Drug|atazanavir|atazanavir once daily
75774337|NCT00388973|Drug|Quetiapine|
75465902|NCT01903083|Radiation|Radiation|Patients will receive 3 doses of radiation (8-10 Gy per fraction).
75465903|NCT01903083|Procedure|Pancreaticoduodenectomy|Surgical resection.
75774338|NCT01018745|Drug|BMS-907351 (XL184)|Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
75320078|NCT03583502|Dietary Supplement|krill oil and fish oil supplement|Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
75320079|NCT03589040|Drug|Etonogestrel 68Mg Implant|Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
75320080|NCT03589040|Drug|rilpivirine|Oral rilpvirine 25mg
75320081|NCT03589040|Drug|darunavir|Oral darunavir+ritonavir 600/100mg
75320082|NCT03580538|Other|resistive exercise with elastic tube|performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
75774339|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
75774340|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
75774341|NCT00117572|Drug|docetaxel|75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)
75774342|NCT00117572|Drug|cisplatin|75 mg/m2 on day 1
75774343|NCT00117572|Drug|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
75774344|NCT00117572|Drug|fluorouracil|750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
75620976|NCT00858247|Dietary Supplement|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
75620977|NCT04222348|Drug|Metformin|850-2550 mg every 24h.
75774345|NCT00117572|Procedure|chemotherapy|See protocol for details
75774346|NCT00117572|Procedure|radiotherapy|See protocol for details
75774347|NCT00388505|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder (TIP) capsules for inhalation.
75774348|NCT00388505|Drug|Tobramycin Solution for Inhalation|Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
75774349|NCT00388349|Drug|Gemcitabine|
75774350|NCT00388349|Drug|Vinorelbine|
75912538|NCT06058247|Dietary Supplement|Active nutritional supplementation|"The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day.~NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active nutritional supplementation arm were protein supplementation at over 1.5 g/kg/day, calorie provision at over 20 kcal/kg/day, and energy adequacy of at least 80%. Energy target was estimated by multiplying the resting energy expenditure using the Harris and Benedict equation by an activity factor of 1.3 and a stress factor of 1.1. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%."
75912539|NCT06058247|Dietary Supplement|Conventional nutritional supplementation|The participants in conventional nutritional supplementation arm received conservative nutritional management without specific protein or caloric targets.
75912540|NCT06058234|Drug|Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease|FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
75912541|NCT06058208|Behavioral|Olfactory stimulation|Olfactory stimulation: Mothers will be made to smell their babies' odor.
75912542|NCT06058208|Behavioral|Visual stimulation|Mothers will be shown video images of their babies.
76072928|NCT00617188|Drug|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
75465904|NCT01903096|Behavioral|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
75774351|NCT00388349|Drug|Carmustine|
75774352|NCT00388349|Drug|Etoposide|
75774353|NCT00388349|Drug|Cyclophosphamide|
75774354|NCT00388349|Procedure|Autologous HCT|
75912543|NCT06058143|Procedure|CLIF-LP|CLIF-LP surgery method was applied
75320083|NCT03580460|Behavioral|Computer delivered smoking cessation counseling|15 to 20 minute computer-delivered interactive smoking cessation counseling
75320084|NCT03583424|Drug|Carmustine|Given IV
75620978|NCT04222348|Drug|Insulin Detemir|Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
75620979|NCT04222114|Drug|Catumaxomab|The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.
75620980|NCT04222114|Drug|The treatment of investigator choice|the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
75774355|NCT00117338|Drug|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
75912544|NCT06058143|Procedure|TLIF|TLIF surgery method was applied
75912545|NCT06058117|Other|No intervention|no intervention, this is an observational study
76072929|NCT00618436|Drug|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
76072930|NCT00618436|Drug|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
75320085|NCT03583424|Drug|Cytarabine|Given IV
75320086|NCT03583424|Drug|Etoposide|Given IV
75320087|NCT03583424|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
75320088|NCT03583424|Drug|Melphalan|Given IV
75320089|NCT03583424|Drug|Venetoclax|Given PO
75320090|NCT03583346|Drug|M6495|Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
75774356|NCT00117338|Drug|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
75774357|NCT00388037|Drug|sunitinib malate|Given PO
75774358|NCT00388037|Other|laboratory biomarker analysis|Correlative studies
75774359|NCT00387881|Drug|sumatriptan succinate / naproxen sodium|sumatriptan 85mg / naproxen sodium 500mg
75774360|NCT00387881|Drug|Placebo|Placebo to match Treximet tablets
75774361|NCT00084656|Biological|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
75774362|NCT00084656|Biological|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
75774363|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
75774364|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
75774365|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
75774366|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
75774367|NCT01086566|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
75774368|NCT01045811|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
75774369|NCT01045811|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
75774370|NCT00102596|Drug|1-Octanol|1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
75912546|NCT06058104|Device|Charades based mobile digital therapeutic|The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child 15 minutes 3-4 times per week for 8 weeks.
75774371|NCT00387647|Drug|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
75620981|NCT02757976|Device|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
75774372|NCT01086722|Drug|"karolinska cocktail"|"The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol"
75774373|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus PAP|Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
75620982|NCT02757976|Device|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
75620983|NCT00838435|Drug|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
75620984|NCT02760160|Other|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) [114, 217, 343, 500, 619, 848].
75774374|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus Supplemental Oxygen|Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
75774375|NCT01086800|Other|Healthy Lifestyles and Sleep Education|Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
75774376|NCT00386009|Drug|Tadalafil|20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
75912547|NCT06058000|Drug|1.5% QLM3003|QLM3003 topical cream
75912548|NCT06058000|Drug|2% QLM3003|QLM3003 topical cream
75912549|NCT06058000|Drug|Vehicle (Placebo)|Vehicle topical cream
75912550|NCT06057961|Other|Art Therapy|8 meetings in 1 year
75320091|NCT03583346|Drug|Placebo|Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
75320092|NCT00578305|Biological|Rituximab|Rituximab was supplied as a sterile liquid for iv administration.
75620985|NCT02757586|Genetic|shRNA|Using shRNA interfered the expression of the gene of CLL
75620986|NCT04111042|Device|stenting|stenting procedure in patients diagnosed malignant large bowel occlusion
75774377|NCT00386009|Drug|Placebo|Placebo tablet taken by mouth once a day for 12 weeks.
75774378|NCT01045889|Other|Rituximab and CHOP regimen + PBSCT|
75774379|NCT00373685|Drug|Celecoxib|open-label
75320093|NCT00578305|Drug|Placebo|Placebo was supplied as a sterile liquid in single-use vials for iv administration.
75774380|NCT00373685|Drug|Any commercially available NSAID with the indication for osteoarthritis|dosing as per USPI label related to the chosen commercially marketed NSAID
75774381|NCT00373529|Drug|clofarabine|"Induction cycle 1: cycle 1 of clofarabine 30 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days."
75912551|NCT06057948|Biological|OPT-821 (QS-21)|Comprised of the immunological adjuvant OPT-821 (QS-21)
75912552|NCT06057948|Dietary Supplement|oral β-glucan|Participants will be randomized to receive this agent in two different schedules
75912553|NCT06057935|Drug|Pemetrexed|Pemetrexed will be administered intravenously
75320094|NCT00578305|Drug|Methylprednisolone|
75320095|NCT00578305|Drug|Methotrexate|
75320096|NCT00578305|Drug|Folic acid or folate|
75774382|NCT00373295|Drug|Baclofen|Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
75774383|NCT00373295|Drug|Marijuana|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
75774384|NCT00373295|Drug|Placebo|
75774385|NCT03395795|Device|NAVA|"The study has 3 phases:~Phase 1:~The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~Phase 2:~Switch to NAVA mode (1h).~Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording."
75620987|NCT02757664|Device|Shock Wave Therapy|Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
75774386|NCT01044563|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
75774387|NCT01044563|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
75774388|NCT00385541|Drug|Morphine PCA|Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
75774389|NCT00385541|Drug|Hydromorphone PCA|hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
75774390|NCT01046045|Drug|everolimus|everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
75774391|NCT01044719|Drug|Ceftazidime|Ceftazidime 2g TDS IV
75774392|NCT01044719|Drug|Tobramycin|Tobramycin 7mg/kg/day OD IV
75774393|NCT01044719|Drug|Meropenem|Meropenem 2g TDS IV
75774394|NCT00392015|Biological|NMRC-M3V-Ad-PfCA|Malaria Vaccine
75774395|NCT00392015|Biological|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA|Malaria Vaccines
75774396|NCT01044875|Procedure|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
75774397|NCT01044953|Other|shortened winter break|winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
75774398|NCT01045109|Dietary Supplement|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
75774399|NCT01045109|Dietary Supplement|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
75774400|NCT01045343|Other|Integrated diagnositic system|Heart failure will be managed using the integrated diagnostic system which consists of patient tools and a new Heart Failure Clinician's website which displays a new Heart Failure Risk score. This Heart Failure Clinician's website will be reviewed every 2 weeks in addition to scheduled in-office visits every three months.
75774401|NCT01045343|Other|Routine in office visits|Heart failure will be managed with scheduled in-office visits every three months.
75465905|NCT01903096|Drug|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
75465906|NCT01903109|Drug|Cevimeline|
75774402|NCT00094302|Drug|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
75774403|NCT00094302|Drug|Placebo|Placebo of spironolactone
75774404|NCT00372905|Drug|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
75774405|NCT00372905|Drug|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
75774406|NCT00372905|Drug|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
75465907|NCT01903122|Drug|Cevimeline|
75465908|NCT01903135|Procedure|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
75620988|NCT02757664|Other|Eccentric Exercises|12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
75620989|NCT02757664|Device|Placebo|Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
75620990|NCT02757508|Dietary Supplement|protein powder supplement|
75620991|NCT02757508|Dietary Supplement|Vitamins/minerals|
75620992|NCT02760082|Other|Qualitative evaluation|
75912554|NCT06057935|Drug|Cisplatin|Cisplatin will be administered intravenously
75465909|NCT01903135|Procedure|Pneumologist consult to establish the diagnosis of OHS|"complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.~Medical history, previous treatments."
75465910|NCT01903161|Procedure|delayed remote ischemic preconditioning|In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
75774407|NCT00384839|Drug|azacitidine for injectable suspension|Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
75774408|NCT01046279|Drug|Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
75774409|NCT01084590|Behavioral|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
75774410|NCT01084590|Behavioral|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
75774411|NCT00384293|Drug|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
75774412|NCT00384293|Drug|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
75774413|NCT01087866|Drug|Metformin|
75912555|NCT06057935|Drug|Carboplatin|Possible substitution with carboplatin based on clinician discretion
75912556|NCT06057870|Other|Application on Apple watch|To determine the feasibility and engagement with remote management of acutely decompensated cirrhosis patients using CirrhoCare® App, CyberLiver ART App, and remote monitors by assessing patient adherence to the monitoring device and the Apps over a 3-month period.
75320097|NCT03583268|Other|Exercise|The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
75320098|NCT03156374|Device|Test use|Use of home ovulation test to predict ovulation
75320099|NCT03583112|Drug|Dapoxetine Hydrochloride Tablet|oral one dapoxetine hydrochloride tablet before MRI scan
75320100|NCT03583112|Drug|Placebo Tablet|oral one placebo tablet before MRI scan.
75320101|NCT03156530|Device|Auricular acupunture|Evaluation of balance before, during and after applying of auricular acupuncture.
75320102|NCT03156530|Other|Control|Not receive stimulation.
75620993|NCT04435678|Diagnostic Test|ALEX² test using the MAX 45k automated laboratory system|"The ALEX² test system is a quantitative in vitro diagnostic (IVD) test for the measurement of allergen specific IgE (sIgE) and a semi-quantitative in vitro diagnostic test for the measurement of total IgE (tIgE) in human serum or plasma (exception EDTA plasma).~The MAX 45k analyzer is intended for an automated in-vitro diagnostics use for quantitative determination of allergen specific Immunoglobulin E and semi-quantitative determination of total IgE. The MAX 45k is suitable for human serum or plasma (Heparin, Citrat, but no EDTA). MAX 45k is intended to be used only in conjunction with RAPTOR SERVER analysis software and ALEX based technology arrays."
75620994|NCT02757196|Drug|Rituximab plus methylprednisolone|rituximab （1000mg IV day1, week 3, week 17 , and week 19）
75620995|NCT02757196|Drug|methylprednisolone|1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
75465911|NCT01903161|Procedure|control|In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
75465912|NCT01903174|Device|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
75465913|NCT01903200|Drug|FK949E|Oral
75465914|NCT01903213|Drug|bixalomer|Oral
75620996|NCT04403698|Drug|Alendronate Effervescent Oral Tablet|At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
75774414|NCT01087866|Drug|Insulin|
75774415|NCT01046357|Drug|AZD7687|Single oral dose
75774416|NCT01046357|Drug|Placebo|Single oral dose
75774417|NCT01084746|Behavioral|PC-based tailored intervention|Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.
75912557|NCT06057857|Other|conventional oral examination|conventional oral examination
75936330|NCT05706077|Device|active tDCS|The electrode will measure 5x5 cm and a current of 2mA will be applied for 20 minutes. The current density will be 0.08mA/cm². tDCS will be applied three times a week for 20 minutes over four weeks.
75320103|NCT00578383|Device|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
75320104|NCT05702294|Device|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the control arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
75320105|NCT05702294|Device|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the Lower Urinary Tract Symptoms ( LUTS) arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
75320106|NCT03583034|Procedure|Holmium laser enucleation of the prostate (HoLEP)|Surgery for benign prostatic hyperplasia
75465915|NCT01903226|Other|High intensity training|
75465916|NCT01903226|Other|Moderate intensity training|
75465917|NCT01903239|Procedure|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
75465918|NCT01903278|Drug|PEG-IFN-SA /RBV|
75465919|NCT01903278|Drug|Pegasys /RBV|
75465920|NCT01903291|Drug|dimethyl fumarate|As described in the treatment arm
75465921|NCT01903304|Other|Olive Oil|3 months intervention
75774418|NCT01084746|Behavioral|Printed educational materials|Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
75620997|NCT02759770|Other|no intervention|This is a clinical observational study, no intervention was included.
75620998|NCT02759926|Drug|Denatonium benzoate|
75912559|NCT06057831|Radiation|Chemoradiation treatment|"Patients initially receive long-course chemo-radiotherapy treatment (CRT).~Radiotherapy regimen consists of 50Gy delivered in 25 fractions over 5 weeks.~Concurrent chemotherapy regimen includes either oral capecitabine or continuous infusion 5-Fluorouracil (5-FU)~On completion of concurrent CRT, patients will receive neoadjuvant consolidation chemotherapy which consists of 8-9 courses of FOLFOX or 5 - 6 courses of CAPEOX delivered over 4 - 6 months.~Patients will undergo total mesorectal excision (TME) after completion of consolidation chemotherapy."
75912560|NCT06057831|Other|18FDG-PET/MRI scan|18FDG-PET/MRI scan within 4 weeks of commencing chemo-radiation and within 1 - 2 weeks before radical rectal cancer surgery.
75912561|NCT06057792|Device|negative pulsed pressure AeroFlow system|"For the application of pulsatile negative pressure, the AeroFlow® equipment will be used, carried out by one of the researchers participating in the project.The application will be carried out addressing the structure of interest (scar), following the protocol established by INDIBA to release adhesions between the different depth planes. The work will consist of an application of pulsed negative pressure using suction cups, which will work automatically at a frequency and intensity tolerable by the patient.~Treatment protocol in 2 phases Total application time 15min~Static cup: preparation: Prepare the tissue surrounding the scar. 5min~Dynamic Cup: work: Lock the tissue around the scar and the scar itself.10min Suction mode: continuous with continuous sliding of the cup The number of treatment sessions will consist of a total of 6 sessions, so there will be two sessions over 3 weeks."
75912562|NCT06057740|Behavioral|Acceptance and commitment therapy (ACT)|ACT is a psychological intervention that aims to improve psychological flexibility, the ability to hold thoughts and emotions lightly in a given context and pursue valued ends (Hayes et al., 1999; Twohig & Levin, 2017).
75912563|NCT06057740|Behavioral|Cognitive behavioral therapy (CBT)|CBT is a psychological intervention which targets cognitions and behaviors in attempt to change emotions.
75912564|NCT06057051|Device|iStent Infinite|iStent Infinite Trabecular Micro-Bypass System
75912565|NCT06056687|Drug|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha Lipoic Acid 600 MG Oral Tablet once daily
75912566|NCT06056687|Other|Placebo Tablet|Placebo Tablet once daily
75912567|NCT06056349|Drug|Midazolam oral solution|Buccal administration
75912568|NCT06056349|Drug|ClonazePAM Oral Product|Orodispersable
75320107|NCT03582644|Other|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
75620999|NCT02759926|Drug|Quinine hydrochloride|
75320108|NCT03580226|Other|No intervention|No intervention
75465922|NCT01903317|Other|Topical Therapy|Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
75465923|NCT01903317|Other|Phototherapy and Systemic Therapy|Subjects will continue use of phototherapy (e.g. ultraviolet B [UVB] or ultraviolet A and psoralen [PUVA]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
75621000|NCT02759926|Drug|Tap water|
75621001|NCT02759536|Radiation|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
75621002|NCT04221256|Drug|Administration of SSRI escitalopram|Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation
75621003|NCT04221256|Behavioral|Paired Associative stimulation|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
75912569|NCT06056349|Other|Usual medication/ traditional|Medication that is usually used in the emergency department
75912570|NCT06056271|Device|AF Ablation|Percutaneous, catheter-based ablation of atrial fibrillation
75912571|NCT06056128|Device|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways for the purpose of biopsying lung lesions
75912572|NCT06055998|Device|MRI|MRI SPINE
75320109|NCT00578461|Drug|Ara C|3000 mg/m^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
75320110|NCT00578461|Drug|Mesna|45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide
75320111|NCT00578461|Drug|Cyclophosphamide|45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
75320112|NCT00578461|Radiation|TBI-Total Body Irradiation|Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4
75320113|NCT03580070|Biological|Immunotherapy|Patients with primitive head and neck squamous cells carcinoma diagnosed on surgical resection or biopsic sample, between 2008 and 2015. They were included when expressing p16 as assessed by immunochemistry and positive HPV DNA by in situ hybridation or positive HPV PCR
75465924|NCT01903317|Other|Biologic Therapy|Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
75465925|NCT01903343|Device|shear wave elastography|ultrasound
75465926|NCT01903369|Device|Shear Wave Elastography|Shear wave elastography
75774419|NCT01090830|Drug|Belinostat, carboplatin, paclitaxel and bevacizumab|"Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles."
75774420|NCT01084824|Drug|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
75774421|NCT01084824|Drug|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
75774422|NCT01088022|Drug|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
75774423|NCT01088022|Drug|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
75774424|NCT00067002|Procedure|Expanded allogeneic cord blood (CB)|Transplantation of Two Unmanipulated Cord Blood Units.
75774425|NCT00067002|Procedure|One Unmanipulated and One Expanded Cord Blood Unit|Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
75774426|NCT00067002|Drug|Rituxan|375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
75774427|NCT00067002|Drug|Melphalan|140 mg/m2 by vein on Day -8.
75774428|NCT00067002|Drug|Thiotepa|5 mg/Kg by vein on Day -7.
75774429|NCT00067002|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
75774430|NCT00067002|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6.
75774431|NCT00067002|Drug|Mesna|10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
75774432|NCT00067002|Radiation|Total body irradiation (TBI)|Total body irradiation (TBI) given on Day -1 at 2 Gy.
75774433|NCT03962556|Other|bimanual palpation|bimanual palpation....i..
75774434|NCT01084902|Drug|Latanoprost|once daily
75774435|NCT01084902|Drug|Brinzolamide|Two times daily
75774436|NCT01084980|Drug|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
75774437|NCT01088100|Genetic|Genotyping|Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
75774438|NCT01085058|Drug|lenograstim|
75774439|NCT03961542|Other|Chewing|Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
75774440|NCT01088178|Device|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
75774441|NCT01091064|Other|Randomization early depart|Patients will be randomized to either an early depart or for being seen by a physician.
75774442|NCT01091142|Drug|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
75774443|NCT01091142|Drug|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
75774444|NCT01088256|Drug|Etoricoxib|the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
75774445|NCT01088256|Drug|placebo|patients get one pill of placebo (sugar-pill) per day for 8 days.
75774446|NCT03957486|Other|arterila cannulation on same arm|arterila cannulation on same arm receiving continous hemoglobin monitoring
75774447|NCT03957486|Other|arterila cannulation on different arm|arterila cannulation different arm receiving continous hemoglobin monitoring
75465927|NCT01903395|Behavioral|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
75465928|NCT01903447|Drug|SSRI|
75774448|NCT03957408|Device|Visual Stimuli|Subjects will be presented various visual stimuli and may be asked to perform tasks. Their accommodative response will be measured.
75774449|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution, 0.7%|Treatment A
75774450|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution vehicle|Treatment B, inactive ingredients used as placebo
75774451|NCT01326858|Drug|Ketotifen fumarate ophthalmic solution, 0.025%|Treatment C
75774452|NCT01088334|Other|screening|CT-Chest/abdomen and mammography in women
75774453|NCT00091572|Drug|Temozolomide|"oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop."
75774454|NCT00091572|Drug|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
75774455|NCT01091220|Biological|Certolizumab pegol|400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
75774456|NCT01091220|Biological|Placebo|2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
75774457|NCT03961386|Behavioral|FallsTalk-C|The FT-C experimental intervention involves two face-to-face visits including Initial and Follow-up Interviews, CG training, daily interaction with the PwD using a computer with FT-C software, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
75912573|NCT06054763|Combination Product|Buyang Huanwu Decoction|Buyang Huanwu Decoction is a common prescription for treating stroke. The possible mechanism is to replenish qi, activate blood circulation, and remove blood stasis.
75621004|NCT04221256|Drug|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
75621005|NCT00838201|Drug|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
75621006|NCT02695888|Behavioral|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
75621007|NCT02695888|Behavioral|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
75621008|NCT02757118|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
75621009|NCT02757118|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
75621010|NCT04222036|Other|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
75621011|NCT04222036|Other|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
75621012|NCT04222036|Other|Reliability|The reliability of the materials will be tested with Cronbach alpha.
75621013|NCT00837967|Drug|Symbicort Turbuhaler|160/4.5μg for 3 days
75621014|NCT00837967|Drug|Terbutaline Turbuhaler|0.4 mg for 3 days
75621015|NCT02759614|Drug|Bevacizumab|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
75621016|NCT02759614|Drug|Erlotinib|Erlotinib 150mg, orally once a day
75621017|NCT02757040|Drug|Ibrutinib combined with As2O3|arsenic trioxide combined with ibrutinib in CLL
75621018|NCT02757040|Drug|ibrutinib|ibrutinib
75774458|NCT03961386|Behavioral|FallsTalk|The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
75774459|NCT00084266|Drug|linezolid (Zyvox)|Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
75912574|NCT06054763|Other|Placebo|90% starch and 10% Buyang Huanwu Decoction
75912575|NCT06054438|Other|Chinese medicine nutritional supplement Cs4|Cs4 will be provided by Chinese Pharm, produced by GMP standard manufacturing. The intervention will be given according to the product instruction. Each capsule is 0.4g. According to the product sheet, adults should take 3-4 capsules daily as a way to nourish and strengthen the lungs and kidneys. In our study, the participants are people with long-COVID symptoms. Therefore, in order to achieve maximum efficacy, we will follow the directions and let participants take the maximum amount allowed by the product which is 4 capsules daily. Participants will take one capsule (each 400mg) 4 times a day, for a total of 1.6g. Treatment will last 12 weeks.
75912576|NCT06053632|Behavioral|Low-load and high-velocity - lying prone - eccentric hamstring exercise|Low-load and high-velocity - lying prone - eccentric hamstring exercise 3 times per week for 4 weeks.
75774460|NCT00084266|Drug|vancomycin|Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
75912577|NCT06052501|Procedure|Removable of the full arch implant-supported prostheses|The intervention planned will be the removal of full arch implant-supported prostheses and the acquisition of a digital image through a facial scanner before and after this moment.
75912578|NCT06052358|Device|LAAC with Watchman FLX device|LAAC with Watchman FLX device
75465929|NCT01903447|Behavioral|CBT|
75465930|NCT01903499|Other|Other: Bean patty|
75465931|NCT01903499|Other|Other: Beef patty|
75465932|NCT01903512|Procedure|TMJ arthrocentesis|lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
75465933|NCT01903538|Device|Cathodal transcranial direct current stimulation (tDCS)|Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
75465934|NCT01903538|Device|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
75465935|NCT01903551|Device|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
75465936|NCT01903577|Other|Robotic Task Performance|Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
75465937|NCT01903577|Other|Laparoscopic Task Performance|Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
75774461|NCT01091298|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
75465938|NCT01903590|Procedure|TVT surgery TOT surgery|
75774462|NCT01091298|Other|Placebo|Single dose (0.5 mL) of the placebo administered orally
75912579|NCT06051903|Other|Mobilization wih movement|The purpose of this study is to determine the effect of talar mobilization with movement versus acupuncture on knee pain and function in the postmenopausal women
75912580|NCT06050811|Dietary Supplement|2'-Fucosyllactose|2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.
75912581|NCT06050811|Dietary Supplement|Placebo|Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
75320114|NCT03156296|Drug|Dexmedetomidine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
75320115|NCT03156296|Drug|Bupivacaine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
75465939|NCT01903629|Device|MCE|MCE first, followed by standard gastroscopy
75465940|NCT01903629|Device|Standard gastroscopy|
75465941|NCT01903642|Other|proteomic analysis|
75465942|NCT01903655|Other|telomere length|
75465943|NCT01903681|Drug|Circadin 2 mg|First arm lower dose
75621019|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
75621020|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
75621021|NCT02756884|Biological|LoFU and aADSC|Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
75621022|NCT02756884|Biological|adipose derived stem cells|control arm will only received the adipose derived stem cells.
75774463|NCT03957564|Drug|Neoadjuvant chemotherapy with PSOX regimen.|"Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle."
75774464|NCT03957564|Other|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in 3 time points：Before neoadjuvant chemotherapy, After 2-3 cycles of neoadjuvant chemotherapy, 10 days after operation.
75912582|NCT06050395|Behavioral|Quality fo Life Questionnaire (FHSI)|Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14). The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much. A lower total score indicates better quality of life.
75912583|NCT06050395|Behavioral|Vioscreen Food Frequency Questionnaire (FFQ)|Participants will receive a web-based link and information to complete VioScreen, a web-based food frequency questionnaire, which allows participants to choose the average frequency of consumption of food items over a given time frame (1 month, 3 month, 1 year, etc.) on a Likert scale with choices ranging by individual questions. Total energy and nutrient intake is estimated by summing intakes from each food based on the selected portion size, reported frequency of consumption, and nutrient content of each food item. Anti-inflammatory and pro-inflammatory dietary patterns are calculated using the energy-adjusted dietary inflammatory index (DII) score to represent the inflammatory potential of an individual's overall diet, using data from FFQ responses. Higher DII scores represent more pro-inflammatory diets while lower (i.e., more negative) DII scores represent more anti-inflammatory diet.
75912584|NCT06050395|Behavioral|Educational Handouts|Participants will receive educational handouts on diet.
75912585|NCT06050395|Behavioral|NutritionCoaching|Participants will receive bi-weekly nutrition coaching on anti-inflammatory dietary patterns and foods.
75465944|NCT01903681|Drug|Circadin 10 mg|Second arm higher dose
75320116|NCT00578539|Drug|ARA C|Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
75320117|NCT00578539|Drug|Cyclophosphamide|Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
75320118|NCT00578539|Drug|MESNA|MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
75320119|NCT00578539|Radiation|Total Body Irradiation (TBI)|TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
75320120|NCT00578539|Biological|Campath-1h|CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
75320121|NCT00578539|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
75320122|NCT03517085|Genetic|DTX401|DTX401 administered as a single peripheral intravenous (IV) infusion
75320123|NCT03517085|Drug|steroid regimen|prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
75465945|NCT01903694|Drug|Sorafenib + Pravastatin|
75465946|NCT01903694|Drug|Sorafenib|
75465947|NCT01903707|Other|Cognitive Remediation Therapy|Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks
75465948|NCT01903707|Other|Placebo comparator|Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
75465949|NCT01903759|Other|Blood samples|
75465950|NCT01903772|Other|Inspiratory Muscle Training|
75465951|NCT01903785|Drug|Salbutamol|60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
75621023|NCT02759224|Drug|BRI-1501|
75621024|NCT02759224|Drug|Lafutidine|
75621025|NCT02759224|Drug|Irsogladine maleate|
75621026|NCT02756806|Device|Picosecond Q-switched laser|Each subject will receive laser treatments with Enlighten laser
75320124|NCT00619255|Behavioral|Adolescent Trauma Support Program|The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
75320125|NCT03582410|Procedure|laparoscopic sacral colpopexy with absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture
75465952|NCT01903785|Drug|Placebo|
75621027|NCT02756728|Biological|BI-505|Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
75621028|NCT02756728|Other|High dose melphalan|High dose melphalan (HDM)
75621029|NCT02756728|Other|Autologous stem cell transplantation|Autologous stem cell transplantation (ASCT)
75621030|NCT02759068|Behavioral|sounds and odors|presentation of sounds and odors
75621031|NCT00638170|Biological|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
75621032|NCT00638170|Biological|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
75621033|NCT00635518|Behavioral|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
75621034|NCT04586920|Drug|LY3509754|Administered orally
75621035|NCT04586920|Drug|Placebo|Administered orally
75774465|NCT03957564|Other|Detect the tumor related DNA in pathological tissues after operation.|Detect the tumor related DNA in pathological tissues after operation.
75774466|NCT03957564|Other|Follow-up of DFS and OS in patients with gastric cancer after operation.|Follow-up of DFS and OS in patients with locally advanced or resectable gastric or gastro-oesophageal Junction cancer.
75774467|NCT01086878|Drug|cotrimoxazole|"Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim"
75912586|NCT06050395|Behavioral|Follow-Up Survey|Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators. This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree. A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
75465953|NCT01903824|Drug|CEP-26401|CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
75465954|NCT01903824|Drug|donepezil hydrochloride|Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated
75621036|NCT04586920|Drug|Itraconazole|Administered orally
75621037|NCT04586920|Drug|Midazolam|Administered orally
75621038|NCT02756494|Biological|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
75621039|NCT02758990|Dietary Supplement|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
75621040|NCT02758990|Dietary Supplement|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
75621041|NCT02758990|Dietary Supplement|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
75621042|NCT02758990|Dietary Supplement|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
75774468|NCT01086956|Drug|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
75912587|NCT06050395|Behavioral|Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire|The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much. A higher score indicates better appetite and quality of life.
75912588|NCT06050395|Behavioral|Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire|Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits. The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never. A higher score indicates higher cognitive function.
75465955|NCT01903824|Drug|modafinil|modafinil 200 mg tablet, over-encapsulated
75621043|NCT02758990|Dietary Supplement|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
75621044|NCT02758990|Dietary Supplement|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
75621045|NCT02758990|Other|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (~91 grams) per day.
75621046|NCT02758990|Other|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (~30 grams) per day.
75621047|NCT02758990|Dietary Supplement|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
75621048|NCT02758990|Other|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
75621049|NCT02758990|Device|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
75320126|NCT03582410|Procedure|laparoscopic sacral colpopexy with non absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
75320127|NCT03156140|Other|Motion|Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
75465956|NCT01903824|Drug|Placebo|Placebos formulated to match each active drug
75465957|NCT01903850|Device|spray cryotherapy|spray cryotherapy
75465958|NCT01903889|Other|clinic based intervention|counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
75621050|NCT02758990|Other|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
75774469|NCT00091026|Biological|cetuximab|Given IV
75774470|NCT00091026|Drug|gemcitabine hydrochloride|Given IV
75774471|NCT00091026|Biological|bevacizumab|Given IV
75774472|NCT00091026|Drug|erlotinib hydrochloride|Given orally
75774473|NCT01087034|Device|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
75774474|NCT01087034|Radiation|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
75774475|NCT01087034|Other|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
75774476|NCT03961074|Other|Iron deficiency anemia in Chinese pregnant women|Iron deficiency anemia exists in Chinese pregnant women during pregnancy
75774477|NCT01583634|Device|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
75320128|NCT00578617|Drug|Rate Control|Metoprolol 50-100mg
75621051|NCT02756416|Device|MRI brain|Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
75621052|NCT02756416|Device|ASL-MRI brain|ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
75774478|NCT01583634|Device|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
75774479|NCT01091376|Drug|Erlotinib|Erlotinib 150mg/day
75774480|NCT01091376|Radiation|Thoracic radiotherapy|60-70Gy/30-35f
75774481|NCT00116558|Device|Early NIPPV|Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).
75621053|NCT02756416|Device|MRA brain|MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
75774482|NCT00116558|Device|Standard NIPPV|Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
75621054|NCT02758912|Drug|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
75621055|NCT02758756|Other|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
75621056|NCT02758756|Other|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
75621057|NCT02756104|Other|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
75621058|NCT02756104|Other|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
75774483|NCT01085292|Drug|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
75774484|NCT01085292|Drug|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
75774485|NCT01085370|Other|Early psychological intervention|3 modules: psychoeducation, reconstruction of the trauma, coping skills
75774486|NCT00116168|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
75774487|NCT00116168|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
75320129|NCT00578617|Device|Ablation Therapy|
75320130|NCT00578617|Drug|Rate Control|Atenolol 50-100mg,
75774488|NCT00116168|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
75774489|NCT00116168|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
75774490|NCT00115934|Procedure|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
75774491|NCT00115934|Procedure|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
75774492|NCT00115778|Drug|IVIG|10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks
75774493|NCT00115778|Other|Placebo|0.1% Albumin in an equal volume to the investigational product
75774494|NCT01081574|Drug|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
75320131|NCT00578617|Drug|Rate control|Propranolol 40-80mg
75774495|NCT00100178|Drug|Mycophenolate mofeteil (MMF)|
75774496|NCT00100178|Drug|Daclizumab (DZB)|
75774497|NCT00100178|Drug|Placebo control for Mycophenolate mofeteil (MMF)|Placebo pills taken orally
75774498|NCT00100178|Drug|Placebo control for Daclizumab (DZB)|saline intravenous infusions
75774499|NCT01087112|Behavioral|Mother-Infant Psychoanalytic tmt|Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.
75774500|NCT01087112|Behavioral|Child Health Centre care|Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
75774501|NCT00099632|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate|200mg/300mg as one tablet taken orally once daily
75320132|NCT00578617|Drug|Rate control|Acebutolol 200mg
75320133|NCT00578617|Drug|Rate control|Carvedilol 6.25mg
75320134|NCT00578617|Drug|Rate Control|Diltiazem 180-240mg
75320135|NCT00578617|Drug|Rate Control|Verapamil 180-240mg
75320136|NCT00578617|Drug|Rate Control|Digoxin 0.125mg
75320137|NCT00578617|Drug|Rhythm Control|Propafenone 450mg
75320138|NCT00578617|Drug|Rhythm control|Flecainide 200mg
75320139|NCT00578617|Drug|Rhythm control|Sotalol 240mg
75320140|NCT00578617|Drug|Rhythm control|Dofetilide 500mcg
75320141|NCT00578617|Drug|Rhythm control|Amiodarone 200mg
75320142|NCT00578617|Drug|Rhythm control|Quinidine 600-900mg
75774502|NCT00099632|Drug|Lamivudine/Zidovudine|150mg/300mg as one tablet taken orally twice daily
75774503|NCT00099632|Drug|Lopinavir/Ritonavir|133.3mg/33.3mg as three capsules taken orally twice daily
75912589|NCT06048406|Combination Product|Health education|The intervention group will receive a health education intervention focused on influenza vaccination literacy, while the control group will continue with their standard school health education without any additional intervention. An influenza vaccination health education including topics such as the importance of influenza vaccination, benefits of vaccination, and vaccination methods, will be developed and reviewed by an expert group. The package for the intervention group will include educational activities, distribution of promotional materials, vaccination services, and distribution of vaccination souvenirs.
75912590|NCT06047392|Diagnostic Test|CT coronary angiography|Patients will undergo a CTCA according to local, standard protocol.
75774504|NCT00099632|Drug|single dose Nevirapine|one 200 mg tablet taken orally
75621059|NCT02755870|Other|CNM-Au8|Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a new nanocatalytic drug class
75320143|NCT00505895|Drug|Melphalan|Arm 1 = 140 mg/m^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m^2 intravenous over 20 Minutes on Day -1.
75774505|NCT01087190|Drug|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
75912591|NCT06047262|Drug|Dapansutrile|Patients receive investigational product.
75912592|NCT06047262|Drug|Placebo|Patients receive placebo.
75320144|NCT00505895|Drug|Fludarabine|30 mg/m^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
75320145|NCT00505895|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
75621060|NCT02755870|Other|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
75621061|NCT02756026|Dietary Supplement|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
75774506|NCT01090466|Drug|cisplatin|
75774507|NCT01090466|Drug|gemcitabine hydrochloride|
75912593|NCT06045988|Device|Non-Contact Sleep Quality Monitor System|Residents of long-term care facilities with Alzheimer's or other related dementias will utilize a sleep monitoring device for the four-week period they are involved in the study.
75912594|NCT06045663|Procedure|laminectomy without lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
75912595|NCT06045663|Procedure|laminectomy with lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
75912596|NCT06044909|Procedure|Minimal invasive hepatectomy, intraoperative stage|Trocar layout is recorded by photo or diagram. The video of conventional or robot-assisted laparoscopy and intraoperative laparoscopic ultrasound images (where applicable) are recorded by the surgeon and anonymized. Depth measurements of internal structures (tumors, cysts, vascular network, anatomical landmarks) are taken using identifiable points on the surface of the liver for tumour resection.
75912597|NCT06044909|Procedure|Minimal invasive hepatectomy, postoperative stage|The registration of imaging data in conventional or robot-assisted laparoscopy is performed by the scientific team using the developed registration algorithm. The data obtained from the clinical intervention will help improve the registration algorithm.
75912598|NCT06044909|Other|Preoperative data collection|Patient code (anonymised) + inclusion number, repeated on each page. Anonymised CT or MRI scan and date of scan. Type of cancer, planned surgery and approach (robotic or laparoscopic). Patient's age. Patient's surgical history. Toxic habits: tobacco, alcohol. Healthy liver, liver disease, cirrhosis. Anticoagulant and antiaggregant treatment.
75912599|NCT06044909|Other|Intraoperative data collection|Endoscope calibration. Intraoperative surgical and ultrasound images. Measurements for tumor's size and tumor's distances from liver surface and vascular vascular structures.
75320146|NCT00505895|Drug|Rituximab|375 mg/m^2 intravenous on Day -5, +2 +9 and +16.
75320147|NCT03582332|Drug|Indomethacin SR, 75 Mg Oral Capsule, Extended Release|Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily
75320148|NCT03582332|Drug|Indomethacin 25 Mg Oral Capsule|Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily
75320149|NCT03582332|Drug|Etoricoxib 90 mg|Etoricoxib 90 mg once daily orally
75320150|NCT03582332|Drug|Etoricoxib 60 mg|Etoricoxib 60 mg once daily orally
75320151|NCT03156218|Drug|Modulation of FiO2|Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
75320152|NCT00619723|Drug|Citicoline|Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
75320153|NCT00619723|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
75320154|NCT00619723|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
75320155|NCT03582254|Radiation|[18F]-FDG PET/MR|"[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~after two chemotherapy cycles (PET#2),~at the end of the first-line chemotherapy regimens (PET#3)."
75320156|NCT01798693|Dietary Supplement|Placebo (maltodextrin)|
75320157|NCT01798693|Dietary Supplement|Multi-nutrient Blend|
75621062|NCT02755714|Drug|Ipratropium bromide spray|The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
75774508|NCT01090466|Drug|temsirolimus|
75320158|NCT03582098|Drug|Idelalisib|Tablets were administered in accordance with the marketing authorization.
75320159|NCT03582098|Drug|Rituximab|Tablets were administered in accordance with the marketing authorization.
75621063|NCT02755792|Behavioral|Calligraphy Training|
75621064|NCT02755792|Behavioral|iPad Training|
75774509|NCT01090466|Other|pharmacological study|
75465959|NCT01903889|Other|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
75774510|NCT04116398|Drug|Dexamethasone with 2 loading doses followed by PRN regimen.|"Loading dose with 2 systematic intravitreal injections (IVI) of ozurdex at the baseline and 12 weeks.Followed by a PRN regimen with strict retreatment criteria (already used and published in the Prediamex study, Bellocq,Kodjikian et al Ophthalmology Retina 2017)~Retreatment criteria: Reduction in VA ≥ 5 ETDRS Letters; and/or CSMT ≥ 275 microns by OCT-Cirrus® or ≥ 285 microns by OCT Spectralis®; and/or increase of CSMT > 50 microns; and/or onset of recurrent retinal cysts; and/or residual edema considered by the practitioner to be clinically significant.~Minimal time limit between two IVI : 12 weeks~Visits: monthly during 1 year (to check efficacy and safety) and then for the 2nd-year only at Month18 (M18) and Month 24 (M24)"
75774511|NCT01090544|Device|Nasal Insufflation|Breathing therapy
75621065|NCT02758678|Biological|A single 2 ml heparinised peripheral blood sample|A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
75621066|NCT02758522|Drug|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
75621067|NCT02758522|Drug|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
75774512|NCT00098774|Biological|filgrastim|5 mcg/kg subQ injection daily Day 14 until ANC > or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
75621068|NCT02758522|Drug|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
75774513|NCT00098774|Biological|rituximab|375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, & 24 of Cycle 1 nad Days 3 & 10 of Cycle 2
75774514|NCT00098774|Drug|cytarabine|2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
75621069|NCT02758600|Other|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
75621070|NCT00942357|Drug|Carboplatin|Given IV
75621071|NCT00942357|Drug|Cisplatin|Given IV
75774515|NCT00098774|Drug|etoposide|5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
75774516|NCT00098774|Drug|leucovorin calcium|100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX < or = 0.05uM Cycles 1-5.
75774517|NCT00098774|Drug|methotrexate|8 g/sq m IV infusion over 4 hrs Days 1 & 15 Cycles 1, 2, & 3; Day 15 Cycle 4 and Day 1 Cycle 5.
75774518|NCT00098774|Drug|temozolomide|150 mg/sq m PO Days 7-11 Cycles 1-5.
75774519|NCT01087268|Other|questionnaire administration|
75774520|NCT01087268|Procedure|gastrointestinal complications management/prevention|
75774521|NCT01087268|Procedure|quality-of-life assessment|
75774522|NCT01081652|Drug|Micronised Progesterone|Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
75774523|NCT01081652|Drug|Progesterone|Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
75774524|NCT01087424|Drug|R mini CHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
75774525|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
75774526|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
75774527|NCT01087580|Drug|Radiation Therapy|"GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
75912600|NCT06044909|Other|Postoperative data collection|Definitive anatomical pathology with the measurement of resection margins.
75936331|NCT05706077|Device|sham tDCS|The electrode will measure 5x5 cm. The sham-type current will show a rising ramp where the initial 30 seconds will be real current with the same parameter as the active group. After this time, the current will be automatically stopped by the device. tDCS will be applied three times a week for 20 minutes over four weeks.
75465960|NCT01903902|Device|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length < 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
75465961|NCT01903928|Biological|ASP0113|injection
75465962|NCT01903941|Behavioral|Aerobic Exercise|
75465963|NCT01903941|Behavioral|Only Counseling|
75465964|NCT01903980|Other|No intervention. It is a retrospective study|No intervention. It is a retrospective study
75465965|NCT01904006|Procedure|New Culture Condition|Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
75465966|NCT01904006|Procedure|Standard Culture Condition|Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
75621072|NCT00942357|Radiation|Internal Radiation Therapy|Undergo brachytherapy
75621073|NCT00942357|Drug|Paclitaxel|Given IV
75621074|NCT00942357|Other|Quality-of-Life Assessment|Ancillary studies
75621075|NCT00942357|Radiation|Radiation Therapy|Undergo radiation therapy
75621076|NCT02755402|Device|Xpert HCV Viral load|HCV viral load testing
75621077|NCT02755402|Device|Transient elastography|Evaluation of liver fibrosis
75621078|NCT02755480|Device|Ultralow Dose Thoracic Computed Tomography|Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
75621079|NCT02755324|Biological|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
75621080|NCT02755558|Behavioral|Low energy density|Low energy density milk served
75621081|NCT02755558|Behavioral|High energy density|High energy density milk served
75621082|NCT02755558|Behavioral|Small portion|Small portion of milk served
75621083|NCT02755558|Behavioral|Large portion|Large portion of milk served
75621084|NCT02752828|Drug|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75621085|NCT02752828|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75936332|NCT05706077|Other|real Physical Therapy|Manual maneuvers and therapeutic exercises will be performed for 30 minutes, three times a week over four weeks.
75774528|NCT03961412|Behavioral|family-based intervention|The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
75936333|NCT05706077|Other|placebo Physical Therapy|The placebo Physical Therapy will be applied for 30 minutes, three times a week over four weeks. The initial 20 minutes will be used for the application of simulated ultrasound bilaterally in the middle portion of the upper trapezius muscle. In the final 10 minutes, the researcher will place the palms of the hand under the occipital region without applying any force or movement with the participant in the supine position.
75465967|NCT01904045|Other|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
75465968|NCT01904045|Other|tacrolimus Prograf|intake of Prograf twice daily for 3 months
75465969|NCT01904084|Device|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
75465970|NCT01904084|Device|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
75465971|NCT01904097|Drug|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
75465972|NCT01904097|Other|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
75465973|NCT01904097|Other|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
75465974|NCT01904110|Drug|Risedronate/Cholecalciferol combination(montly)|once a month
75465975|NCT01904110|Drug|Risedronate/Cholecalciferol combination(weekly)|once a week
75465976|NCT01904162|Drug|400 mg finafloxacin (2 x 200 mg tablets)|
75465977|NCT01904214|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
75621086|NCT02752828|Drug|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: oral"
75621087|NCT02755636|Behavioral|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
75621088|NCT02755636|Other|Usual care|Primary care as usual
75621089|NCT02753062|Drug|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
75621090|NCT00939783|Drug|Dimebon|Tablet for oral administration
75621091|NCT02752594|Biological|probiotic|Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
75621092|NCT02752594|Other|placebo|placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
75621093|NCT02755246|Dietary Supplement|Polyamine supplementation|3 months of polyamine supplementation (3 capsules/day)
75621094|NCT02755246|Dietary Supplement|Placebo supplementation|3 months of placebo intake (3 capsules/day)
75621095|NCT04220710|Diagnostic Test|DNA extraction and methylation detection|DNA extraction and methylation detection
75621096|NCT00602199|Drug|ABT-510|
75621097|NCT00602199|Other|immunoenzyme technique|
75621098|NCT00602199|Other|immunohistochemistry staining method|
75621099|NCT00602199|Other|laboratory biomarker analysis|
75621100|NCT00602199|Other|pharmacological study|
75320160|NCT00555893|Drug|Oseltamivir|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
75621101|NCT00602199|Procedure|biopsy|
75774529|NCT03961412|Behavioral|Participant only intervention|Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
75774530|NCT01087658|Drug|Glutamine|Per os
76072931|NCT04345900|Drug|Plinabulin|a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
75320161|NCT00555893|Drug|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
75912601|NCT06042465|Other|acupuncture and Tui-na manipulations|"i. Patients in supine position with knee elevated 20-30 degrees bending using a pillow below.~ii. Acupuncture needle using 0.25 mm diameter and 1.5-inch length. iii. Choose 'A shi point' to inject the acupuncture needles. iv. Inject 4 acupuncture needles respectively at the upper, lower, lateral and medial edge of the patella, along the medial and lateral edge at the posterior surface of patella.~v. Connect the needles with electro-therapy, selecting high frequency and strength that the patients have sensation and acceptable. Time duration is 30 minutes each time. Infra-radiation is provided and warm above the treatment region.~vi. Tui-na manipulations using the method of 'Tui-na'. Time duration is 2-5 minutes. Patella is pushed up and elevated during treatment.~vii. No external herbal medicine for TCM group , other medication such as painkiller is required to record"
75912602|NCT06042465|Other|Physiotherapy|"i. Total 12 sessions of physiotherapy for 8 weeks training; ii. Treatment: Closed kinetic chain exercises program will be used when appropriate, which include:~Mini walk squat exercise~Forward step up~Lateral step up~Terminal knee extension~Knee taping~Unstable base training~Pain control~Manual Therapy Each session will approximately cost each patient 1 hours' time. There is no Chinese medicine is allowed for PT group , other medication such as painkiller is required to record."
75320162|NCT00578929|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
75320163|NCT00578929|Drug|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
76072932|NCT04345900|Drug|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
75320164|NCT00556049|Drug|Gemcitabine|Intravenously on days 1 and 8 of each 21-day treatment cycle.
75320165|NCT00556049|Drug|Sunitinib|Orally on days 1-14 of each 21-day treatment cycle
75320166|NCT01797107|Drug|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
75320167|NCT03155984|Drug|Anti-CD20 antibody|All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
75320168|NCT00620191|Drug|Metformin|Metformin 1000 mg twice a day titrated from 500 mg once a day
75621102|NCT02755168|Procedure|External Pop-Out Cesarean Section|During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.
75320169|NCT00620191|Drug|Placebo|Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
75621103|NCT02755168|Procedure|Classic technique|During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
75774531|NCT01087658|Drug|Calcium and Magnesium|Intravenous
75320170|NCT05701904|Other|Local mechanical vibration|Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.
75320171|NCT05701904|Other|Shotblocker group|It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injection (Tugrul, Celik, and Khorshid 2017). The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.
75320172|NCT00506597|Drug|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
75320173|NCT01797419|Drug|GS-5806|Single dose, oral liquid, .5 mL/kg
75320174|NCT01797419|Drug|Placebo|Single dose, oral liquid, .5 mL/kg
75320175|NCT03589976|Drug|Sirolimus 2 MG|Dose will be adjusted throughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose will be 6mg/day.
75320176|NCT03589976|Other|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
75320177|NCT00620503|Drug|Proellex 25 mg formulation A|One Proellex 25 mg formulation A capsule
76072933|NCT00619060|Drug|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
75320178|NCT00620503|Drug|Proellex 25 mg formulation B|One 25 mg Proellex capsule formulation B administered both fed and fasted
75320179|NCT01797497|Behavioral|Care plan and coaching|In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
75320180|NCT03581630|Drug|naltrexone/bupropion|Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
75320181|NCT03581630|Behavioral|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
75774532|NCT03958058|Drug|Anti-borrelial antibiotic therapy|Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
75774533|NCT03958058|Other|No antibiotic.|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
75774534|NCT01090622|Drug|XPF-001|Oral capsule
75320182|NCT03349073|Drug|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
75465978|NCT01904227|Behavioral|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
75465979|NCT01904227|Behavioral|Inpatient Adaptation of DBT|"The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly."
75774535|NCT01090622|Drug|Placebo|Oral capsule
75774536|NCT01081730|Biological|anti-TNF biologics|as prescribed
75774537|NCT01081730|Other|general population|non-treated cohort
75774538|NCT01081730|Biological|non-anti-TNF biologics|as prescribed
75774539|NCT01081730|Biological|ustekinumab|as prescribed
75774540|NCT01081730|Drug|systemic non-biological treatments|as prescribed
75774541|NCT01090700|Drug|TMC435|TMC435 150 mg daily for 7 days
75774542|NCT01090700|Drug|Escitalopram|Escitalopram 10 mg daily for 7 days
75774543|NCT01090700|Drug|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
75774544|NCT03957980|Other|Occupational therapy|Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
75774545|NCT01087892|Dietary Supplement|Probiotic drink containing the live strain|Probiotic drink contains no strain
75774546|NCT01087892|Dietary Supplement|placebo probiotic|Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
75912603|NCT06039072|Drug|Patients with cardiac function recovered for more than one year and discontinued were in the discontinuation group.|Among the patients with perinatal cardiomyopathy who were included in the study, their heart function returned to normal in 1 year after receiving standardized treatment, and then after another 1 year of standardized treatment to respect the patients' individual wishes, fully inform the patients of the relevant information and potential risks, including the possibility of deterioration of heart function after discontinuation of the medication, and only after obtaining the patients' informed consent and signing the informed consent form could they be included in the discontinuation group, and the rest were in the non-discontinuation group.
76072934|NCT00619060|Drug|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
76072935|NCT00092716|Drug|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
75774547|NCT03957902|Drug|acetylsalicylic acid|Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
75774548|NCT00384059|Biological|13-valent Pneumococcal Conjugate Vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
75774549|NCT00384059|Biological|7vPnC|Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
75774550|NCT00384059|Biological|Pediacel|concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
75774551|NCT00384059|Biological|NeisVac-C|concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
75774552|NCT00384059|Biological|Menitorix|concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
76072936|NCT00092716|Drug|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
76072937|NCT00619684|Drug|lenalidomide|Given PO
76072938|NCT00619762|Device|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
76072939|NCT01799122|Device|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
75320183|NCT03155672|Behavioral|Art therapy|Art Therapy
75320184|NCT00506675|Device|Patching|42 hours per week of patching
75465980|NCT01904253|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
75621104|NCT04221100|Device|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
75621105|NCT02754934|Other|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
75621106|NCT04289740|Behavioral|7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals|Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period
75621107|NCT04289740|Behavioral|a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure plus same number of sessions as the experimental intervention.|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
75621108|NCT02754700|Other|Neuromuscular Training|Standardized, comprehensive neuromuscular training
75621109|NCT02754700|Other|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
75621110|NCT02754700|Other|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
75621111|NCT04220788|Other|Enhanced pharmacist service|Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
75621112|NCT04220788|Other|Usual care|Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
75621113|NCT02752360|Procedure|Biodegradable Stenting Anastomoses|Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
75774553|NCT00383123|Biological|Fluarix™|"Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.~*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1."
75774554|NCT00383123|Biological|Fluzone|"Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.~*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1."
75774555|NCT01046435|Procedure|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
75774556|NCT01046435|Procedure|Two placebos|Two placebos 3 times a day for 7 days
75774557|NCT00382967|Procedure|DaTSCAN SPECT imaging|A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
75774558|NCT01046591|Procedure|Polysomnography|Overnight sleep studies will be performed on all children.
75774559|NCT00858364|Drug|Darbepoetin alfa|Administered subcutaneously once every 3 weeks
75912604|NCT06035042|Procedure|Scheduled surgery|All subjects will be exposed to surgery
76072940|NCT05246956|Other|Intradialytic exercise|Intradialytic exercise group
75465981|NCT01904253|Drug|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
75465982|NCT01904253|Drug|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
75465983|NCT01904266|Procedure|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
75320185|NCT00506675|Drug|Atropine|daily atropine (1%)
75320186|NCT00506675|Device|Patching|two hours of daily patching for 4 weeks, then no treatment
75320187|NCT00506675|Drug|Atropine|once weekly atropine for 4 weeks, then no treatment
75320188|NCT03580304|Behavioral|Industrial work|Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
75320189|NCT03580304|Behavioral|Physical load|The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
75465984|NCT01904266|Procedure|GA + sham block|Injection of 1 cc saline subcutaneously
75465985|NCT01904279|Drug|Tocilizumab|Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
75465986|NCT01904292|Drug|Tocilizumab|Subcutaneous 162 mg dose QW or Q2W for 52 weeks
75465987|NCT01904318|Drug|IDP-73152 mesylate 40 mg|IDP-73152 mesylate 40 mg single dose administration
75465988|NCT01904318|Drug|IDP-73152 mesylate 80 mg|IDP-73152 mesylate 80 mg single dose administration
75621114|NCT02752360|Procedure|Double-layer Hand Sutures|Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
75621115|NCT00635596|Biological|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
75621116|NCT04527796|Other|Rehabilitation|"During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients.~The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided."
75621117|NCT02752204|Drug|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
75621118|NCT02752204|Drug|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
75621119|NCT04220398|Drug|Neoadjuvant chemotherapy combined with hormone therapy|Docetaxel 75mg/m2 IV (every 3 weeks) +Prednisone 5mg BID orally + HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 4-6 cycles
75621120|NCT04220398|Drug|Neoadjuvant hormone therapy|HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 3-6 cycles
75621121|NCT04220398|Procedure|Radical Prostatectomy (RP)+ extended lymph node dissection|"Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery."
75621122|NCT02752126|Radiation|Conventional radiotherapy|Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
75621123|NCT02752126|Radiation|Esophageal-Sparing Intensity-Modulated Radiotherapy|Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
75621124|NCT04220944|Drug|Sintilimab|Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
75621125|NCT04220944|Procedure|Microwave Ablation|The ablation area should covered at least two thirds the size of the nodules.
75621126|NCT04220944|Procedure|TACE|Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
75621127|NCT04221022|Other|Light physical activity|Each session started with leisure walk, duration of which was set to 35 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
75774560|NCT00858364|Drug|Placebo|Administered subcutaneously once every 3 weeks
75774561|NCT00382733|Drug|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
75774562|NCT01045577|Drug|Masitinib|6 mg/kg/day
75774563|NCT01045577|Drug|Masitinib|3 mg/kg/day
75774564|NCT01045577|Drug|Placebo|Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
75774565|NCT03992885|Drug|Icotinib|"Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally~Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle"
75912605|NCT06033534|Device|STIMULAN|"Procedures:~Surgical repair of the open fracture, as per standard-of-care guidelines. Insertion of the STIMULAN device at the site of the fracture. Standard post-operative care, including monitoring of inflammatory markers and clinical signs of infection."
75936334|NCT02440958|Drug|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
75936335|NCT05587283|Drug|Experimental: Low dose LABTHERA-001 capsule|Low dose LABTHERA-001 capsule, 0.2 x 10^9 CFU/capsule with excipients.
75320190|NCT03580304|Behavioral|Cognitive load|The cognitive load of an industrial task will be simulated in this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
75320191|NCT00507767|Drug|dasatinib|Given PO or via PEG tube
75320192|NCT00507767|Procedure|pharmacological study|Correlative studies
75320193|NCT00507767|Procedure|laboratory biomarker analysis|Correlative studies
75465989|NCT01904318|Drug|IDP-73152 mesylate 160 mg|IDP-73152 mesylate 160 mg single dose administration
75465990|NCT01904318|Drug|IDP-73152 mesylate 320 mg|IDP-73152 mesylate 320 mg single dose administration
75465991|NCT01904318|Drug|IDP-73152 mesylate 640 mg|IDP-73152 mesylate 640 mg single dose administration
75320194|NCT04405544|Diagnostic Test|CT-scan|chest CT-scan
75465992|NCT01904318|Drug|IDP-73152 mesylate 1280 mg|IDP-73152 mesylate 1280 mg single dose administration
75320195|NCT04405544|Diagnostic Test|EEG|Electroencephalography
75465993|NCT01904318|Drug|Placebo|Placebo single dose administration
75465994|NCT01904344|Device|Sensor testing and validation|
75465995|NCT01904357|Drug|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
75621128|NCT04221022|Other|Moderate physical activity|Each session started with brisk walk, duration of which was set to 30 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
75621129|NCT04221022|Other|Vigorous physical activity|Each session started with jogging, duration of which was set to 15 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
75621130|NCT02754622|Other|Observational Group|Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
75621131|NCT02752516|Drug|Anlotinib|Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
75621132|NCT04278352|Behavioral|Mindfulness Based Relapse Prevention|The intervention is a group skills training program that is delivered once weekly for eight weeks. Content focuses on mindfulness and cognitive-behavioral relapse prevention skills, including psychoeducation, experiential exercises, and between session homework assignments.
75621133|NCT02751892|Behavioral|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
75621134|NCT02754466|Other|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
75621135|NCT02754466|Other|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
75621136|NCT02754232|Other|Telemedical training|Intervention will involve resistance training and anaerobic training
75621137|NCT04220632|Drug|Itacitinib|at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
75774566|NCT05668702|Other|crossover design|The researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
75774567|NCT03739294|Drug|Fluticasone Furoate/ Vilanterol Trifenatate|Asthma inhalation medication
75774568|NCT03739216|Device|ClariFix|The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
75774569|NCT03739060|Device|Transcutaneous electric nerve stimulation|Conventional transcutaneous electric nerve stimulation
75774570|NCT03631732|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
75774571|NCT03631732|Drug|NRTIs|"The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)"
75774572|NCT03631732|Drug|Third Agent|"Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~delavirdine (DLV)~efavirenz (EFV)~nevirapine (NVP)~rilpivirine (RPV)~doravirine (DOR)~Integrase inhibitors~dolutegravir (DTG)~elvitegravir (EVG)~raltegravir (RAL)~Protease inhibitors (PIs)~atazanavir (ATV)~darunavir (DRV)~lopinavir (LPV)~nelfinavir NFV)~saquinavir (SQV)~tipranavir (TPV)~Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)"
75936336|NCT05587283|Drug|Experimental: Medium dose LABTHERA-001 capsule|Medium dose LABTHERA-001 capsule, 1 x 10^9 CFU/capsule with excipients.
75621138|NCT04220632|Drug|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
75621139|NCT04220632|Drug|Methylprednisolone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
75621140|NCT02751970|Procedure|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
75621141|NCT02751970|Procedure|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
75621142|NCT02751970|Procedure|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
75621143|NCT02751970|Procedure|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
75621144|NCT02751970|Procedure|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
75621145|NCT02752438|Device|HFOV|HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
75621146|NCT00939627|Biological|cetuximab|Given IV
75621147|NCT00939627|Other|placebo|Given orally
75621148|NCT00939627|Drug|sorafenib tosylate|Given orally
75621149|NCT00939627|Other|laboratory biomarker analysis|Correlative studies
75621150|NCT00939627|Procedure|quality-of-life assessment|Ancillary studies
75774573|NCT03732508|Drug|Irinotecan liposome|Irinotecan liposome intravenous infusion will be administered during the first day of treatment.
75774574|NCT03732508|Drug|SHR-1316|SHR-1316 intravenous infusion will be administered during the first day of treatment.
75774575|NCT03732508|Drug|Fluorouracil|Fluorouracil intravenous infusion will be administered during the first day of treatment.
75774576|NCT03732430|Drug|IBI308|A humanized anti-PD-1 monoclonal antibody
75774577|NCT03630016|Diagnostic Test|Pulse oximetry with Owlet BabySat v1.0 sensor|A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
75774578|NCT03628924|Drug|Guselkumab dose 1|Participants will receive guselkumab dose 1 IV.
75774579|NCT03628924|Drug|Guselkumab dose 2|Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
75621151|NCT02752282|Other|Anticipatory Counseling|Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
75621152|NCT02752282|Other|Cancer Screening Guidelines|Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
75936337|NCT05587283|Drug|Experimental: High dose LABTHERA-001 capsule|High dose LABTHERA-001 capsule, 5 x 10^9 CFU/capsule with excipients.
75320196|NCT04405544|Diagnostic Test|EP|Evoked potential
75621153|NCT05382741|Drug|Durvalumab Injection for intravenous use 500 mg vial solution for infusion|MEDI4736
75621154|NCT05382741|Drug|Regorafenib 30 mg capsules|BAY73-4506
75774580|NCT03628924|Drug|Guselkumab dose 3|Participants will receive guselkumab dose 3 SC in Group 3.
75774581|NCT03628924|Drug|Placebo|Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
75774582|NCT03738982|Device|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
75320197|NCT04405544|Diagnostic Test|Pulse oximetry|Pulse oximetry
75320198|NCT04405544|Diagnostic Test|Blood tests|Blood tests
75465996|NCT01904357|Drug|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
75320199|NCT00621049|Drug|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
75465997|NCT01904396|Drug|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
75465998|NCT01904422|Procedure|conventional periodontal treatment|
75465999|NCT01904461|Device|Vacuum device|
75466000|NCT01904461|Procedure|Conventional surgery|
75466001|NCT01904474|Other|Next.Step - e-therapeutic intervention program|
75466002|NCT01904474|Other|Standard treatment protocol|
75466003|NCT01904487|Radiation|[11C]flumazenil|[11C]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
75466004|NCT01904487|Drug|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
75466005|NCT01904500|Drug|Pre-operative cefazolin|
75466006|NCT01904513|Dietary Supplement|Pasteurized Whole Milk|
75466007|NCT01904513|Dietary Supplement|Lactobacillus rhamnosus GR-1|
75466008|NCT01904539|Drug|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
75466009|NCT01904552|Device|Electronic Root Canal Length Measurement Device|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
75621155|NCT05090007|Device|magnetic resonance image|Imaging data were collected in a strong magnetic field
75621156|NCT05090007|Other|gut microbiota|gut microbiota
75774583|NCT03735706|Radiation|Radiation dose reduction|The radiation dose is is different between groups
75936338|NCT05587283|Other|Placebo Comparator: Low dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
75936339|NCT05587283|Other|Placebo Comparator: Medium dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
75936340|NCT05587283|Other|Placebo Comparator: High dose Placebo capsule|High dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
75466010|NCT01904565|Radiation|Hyperthermia and Proton Beam|"Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose."
75621157|NCT02754076|Drug|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
75621158|NCT05381415|Other|Inhalation of bronchodilation therapy at FRC|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from FRC (functional residual capacity, in a random order, with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
75774584|NCT03735706|Other|Contrast media volume reduction|Contrast media volume is different between groups
75774585|NCT03735706|Radiation|Unenhanced slice|One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
75774586|NCT03735706|Diagnostic Test|Weight|A weighing scale is used to measure a patients body weight right before the scan.
75774587|NCT03735550|Device|Contact thermographic breast examination device|A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
75774588|NCT03627832|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, & Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
75774589|NCT03627832|Behavioral|Sleep Hygiene|All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
75774590|NCT00112437|Drug|Odanacatib|Odanacatib 3 mg, once weekly for 24 months
75774591|NCT00112437|Drug|Odanacatib|Odanacatib 10 mg, once weekly for 24 months
75912606|NCT06032780|Other|Eccentric Resistive Training + Aerobic training Group|"Eccentric Resistive training includes upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings) 2 sets of 12 repetitions (reps) for each group of muscles in lengthened position for eccentric training in approx. 20 minutes (min). Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair descending training and squatting position and eccentric hamstring curls with weights at ankle for lower limb eccentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain) . (approx. 20 min).~+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
75466011|NCT01904578|Other|true accupressure|Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
75466012|NCT01904578|Other|sham acupressure|Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
75621159|NCT05381415|Other|Inhalation of bronchodilation therapy at RV|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR , with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
75621161|NCT04220476|Radiation|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
75936341|NCT03186170|Other|SSA sperm selection|The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
76072941|NCT05246800|Other|Structured 8-week mHealth mindfulness program|The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
76072942|NCT00588406|Drug|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
76072943|NCT00588406|Drug|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
76072944|NCT00588406|Drug|Ipratropium bromide|2.5 mg, one dose
75320200|NCT00621049|Drug|Docetaxel/Carboplatin|"Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
76072945|NCT00588406|Drug|Prednisone|60mg PO
76072946|NCT00668434|Drug|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
75320201|NCT00508469|Drug|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
75320202|NCT00508469|Drug|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
75320203|NCT00508469|Drug|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
75466013|NCT01904591|Dietary Supplement|Selenium|"Selenium 50 micrograms daily per oral~1 year of treatment"
75466014|NCT01904591|Dietary Supplement|Vitamin E|"Vitamin E 400 international units daily per oral~1 year of treatment"
75466015|NCT01904617|Other|Dextrose|
75466016|NCT01904617|Other|Normal Saline|
75774592|NCT00112437|Drug|Odanacatib|Odanacatib 25 mg, once weekly for 24 months
75774593|NCT00112437|Drug|Odanacatib|Odanacatib 50 mg, once weekly for 24 months
75774594|NCT00112437|Dietary Supplement|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
75774595|NCT00112437|Dietary Supplement|Calcium Carbonate|Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
75774596|NCT00112437|Drug|Placebo|Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
75774597|NCT03735472|Device|Thoraflex™ Hybrid|"The Thoraflex™ Hybrid device is particularly suited to the treatment of extended lesions of the ascending aorta, the aortic arch and the descending aorta, which constitute a major challenge in cardiovascular surgery.~It enables, during a single surgical operation, combination of the Frozen Elephant Trunk technique and a 4-branch prosthesis of the aortic arch, thus enhancing the arsenal of the surgeon in the treatment of complex diseases of the aortic arch."
75774598|NCT03738592|Other|behavioral exploration of spatial hearing performances|"Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion."
75774599|NCT03738592|Other|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for cochlear implant children and their parents)|"For cochlear implant children and their parents, a SSQ questionnaire will be given and completed during the first visit (at the inclusion).~This questionnaire offers a version for parents of children with hearing loss (SSQ Parents CI) and a version for the children themselves (SSQ Children CI)."
75774600|NCT03738592|Other|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for parents of CI children)|"The SSQ questionnaire for Parents of CI children is composed of three distinct sections (A, B and C).~Each section will be filled separately by parents of CI children with one of the study collaborators during 3 telephone calls spaced 1 week apart. Thus, section A will be completed 7 days (+/- 2 days) after inclusion , section B 14 days (+/- 2 days) after inclusion, and section C 21 days (+/- 2 days) after inclusion."
76072947|NCT00668434|Drug|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
75621162|NCT04220476|Drug|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
75621163|NCT04220476|Drug|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
75621164|NCT00937833|Procedure|Prostatectomy|
75621165|NCT00937833|Device|Surgisis Male Sling|
75621166|NCT02695810|Drug|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
75774601|NCT03653416|Device|Ipack|IPACK block - local anesthesia injected safely under ultrasound guidance in the interspace between the popliteal artery and capsule of the knee.
75774602|NCT03653416|Drug|Bupivacaine|20 cc of bupivacaine(o.25%) injection
75774603|NCT03653416|Procedure|Peri Articular Infiltration|Adductor Canal Catheter and Peri Articular Infiltration
75320204|NCT00508469|Device|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
75320205|NCT03155750|Other|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
75320206|NCT03155750|Other|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
75774604|NCT03738514|Other|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks
75774605|NCT03738514|Other|5% potassium nitrate dentifrice|5% potassium nitrate dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
75774606|NCT03738514|Other|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks
75774607|NCT01076673|Biological|Peripheral blood stem cells and hyaluronic acid injections|Peripheral blood stem cells and hyaluronic acid injections
75912607|NCT06032780|Other|Resistance Training + Aerobic training Group|"Resistive training (concentric) includes Upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings), 2 sets of 12 reps for each group of muscles in approx. 30 min. Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair climbing training and quadriceps training + standing hamstring curls with weight at ankle for lower limb concentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain)~+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
75320207|NCT05702996|Drug|Eculizumab administration|Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab
75320208|NCT00580333|Drug|cisplatin|Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
75320209|NCT00580333|Drug|bevacizumab|Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
75320210|NCT00580333|Drug|doxorubicin|Postoperative: Given intravenously for four 2-week cycles
75320211|NCT00580333|Drug|cyclophosphamide|Postoperative: Given intravenously for four two-week cycles
75621167|NCT02695810|Drug|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
75621168|NCT02695810|Behavioral|Exercise|Interval training, 5 times per week, 30 min per session
75621169|NCT04204161|Biological|CAR-T19/CAR-T22|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10^5/kg-2.5x10^8/kg .
75621170|NCT02753764|Drug|AZD7624|
75621171|NCT02753764|Drug|prednisone|oral prednisone 20 mg bid for one week
75621172|NCT02753764|Drug|Placebo|
75621173|NCT05382429|Procedure|OWHTO|OWHTO Surgical procedure For the OWHTO Surgical procedure, only medial split biplanar osteotomy performed.
75621174|NCT05382429|Procedure|CWHTO|CWHTO Surgical procedure For the OWHTO Surgical procedure, only lateral closure osteotomy was performed.
75320212|NCT00580333|Drug|paclitaxel|Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
75320213|NCT05622617|Drug|no intervention|no intervention
75466017|NCT01904630|Genetic|gene sequencing|Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
75466018|NCT01904643|Drug|lenalidomide|Given PO
75466019|NCT01904643|Drug|mitoxantrone hydrochloride|Given IV
75621175|NCT02695654|Drug|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
75621176|NCT02695654|Drug|Clonidine|Clonidine 100 mcg
75621177|NCT02751736|Dietary Supplement|CJLP243|Perioperative administration till postoperative weeks 3
75320214|NCT05013541|Other|No intervention|Observational study, standard record of need to void during cystometry
75320215|NCT00509171|Device|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
75320216|NCT05622539|Combination Product|CONVENTIONAL ACUTE STROKE MANAGEMENT|Conventional treatment for acute stroke patients, with or without reperfusion treatments
75320217|NCT00580645|Drug|varenicline|2mg/day or 1mg/day with 1-week medication lead-in period.
75320218|NCT00580645|Drug|placebo|placebo
75320219|NCT00580957|Drug|Blocked|Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
75320220|NCT00580957|Drug|Intact|Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
75320221|NCT00581347|Other|outreach services|Tracking/reminder/recall/home visit strategy.
75466020|NCT01904643|Drug|etoposide|Given IV
75466021|NCT01904643|Drug|cytarabine|Given IV
75466022|NCT01904682|Drug|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
75466023|NCT01904695|Drug|Herbs|Herbs 180ml by mouth every 12 hours for 8 weeks
75466024|NCT01904695|Drug|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
75466025|NCT01904708|Other|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
75466026|NCT01904734|Drug|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
75621178|NCT02751736|Dietary Supplement|Placebo|Perioperative administration till postoperative weeks 3
75621179|NCT02751658|Other|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
75621180|NCT00635674|Device|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
75621181|NCT02696122|Procedure|Local Group|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
75621182|NCT02696122|Procedure|Spinal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
75621183|NCT02753608|Other|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
75621184|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
75621185|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
75621186|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
75320222|NCT04387903|Procedure|Surgical re-interventionafter pancreaticoduodenectomy|Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.
75320223|NCT00509249|Biological|ziv-aflibercept|Given IV
75466027|NCT01904747|Drug|Palbociclib administered Fasted|palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
75621187|NCT01135511|Drug|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
75466028|NCT01904747|Drug|Palbociclib administered Fed high calorie|palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
75466029|NCT01904747|Drug|Palbociclib administered Fed low calorie|palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
75466030|NCT01904747|Drug|Palbociclib administered Fed moderate calorie|palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
75466031|NCT01904786|Drug|Melatonin|
75466032|NCT01904786|Drug|placebo|
75466033|NCT01904799|Other|Cognitive Assessment test|
75466034|NCT01904812|Other|Questionnaire about quality of life and satisfaction|
75466035|NCT01904877|Behavioral|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
75466036|NCT01904890|Behavioral|CRC Prevention and Screening Education|Refer to Arm Description
75466037|NCT01904890|Behavioral|Nutrition Education|Refer to Arm Description
75466038|NCT01904916|Procedure|Histological biopsy procedure|
75621188|NCT01135511|Drug|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
75621189|NCT02753140|Drug|Cetuximab|
75621190|NCT02753140|Radiation|radiation|
75912608|NCT06032780|Other|Aerobic training Group|Aerobic training as a control will be given to this group as well for approximately 60 minutes per session. Aerobic training exercise will be completed via a ergometer/stationary cycle; type will be continuous aerobic exercise and intensity of 60% of max HR (or peak VO2) in HF individuals.
75912609|NCT06021860|Drug|Spironolactone Oral Suspension|"Spironolactone will be dosed on a mg/kg basis, with actual weight on Day 1 (pre-dose) determining the spironolactone suspension volume administered. Therefore, for a given patient, the dose administered on Day 1, based on the weight measured on Day 1, will be administered throughout their participation in the study.~Spironolactone will be administered as a single dose in the single-dose periods (Group 4, Parts 1 and 2), and as QD dosing in the multiple-dose periods (Groups 1 to 4, Parts 1 and 2).~The low and high doses to be administered during Part 2 of the study will be determined by the Safety Review Committee following their review of Part 1 data."
76072948|NCT00668902|Drug|[13C]Pantoprazole|[13C]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
75320224|NCT00509249|Other|laboratory biomarker analysis|Correlative studies
75320225|NCT00509249|Other|pharmacological study|Correlative studies
75320226|NCT00624013|Drug|sertraline|50 mg up to 100 mg daily for 6 months
75320227|NCT00624013|Drug|Placebo|50 mg up to 100 mg daily for 6 months
76072949|NCT00669214|Drug|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
75320228|NCT02121041|Drug|Amlodipine|Amlodipine 5 mg or 10 mg
75320229|NCT02121041|Drug|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
75621191|NCT02753140|Drug|Docetaxel|
75320230|NCT02121041|Drug|Losartan|Losartan 50 mg or 100 mg
75320231|NCT00509873|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
75320232|NCT00509873|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
75320233|NCT02133781|Biological|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
75320234|NCT02133781|Biological|FluMist® 2009-2010 Formula|This vaccine is given intranasally
75320235|NCT01855451|Drug|Cetuximab|
75320236|NCT01855451|Radiation|RT (70 Gy in 35 fractions)|
75320237|NCT01855451|Drug|Cisplatin|
75621192|NCT02753140|Drug|Cisplatin|
75621193|NCT02753218|Drug|Midazolam|
76072950|NCT00669214|Drug|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
75320238|NCT02134951|Drug|Ketamine|intravenous infusion of saline solution with ketamine
75320239|NCT02134951|Drug|Normal saline|Normal saline will be used for placebo in this group
75320240|NCT00510497|Biological|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
75320241|NCT03029780|Biological|Opdivo|Specified dose on specified days
75320242|NCT03029780|Biological|Yervoy|Specified dose on specified days
75621194|NCT02753218|Drug|LEO 32731|
75320243|NCT00624559|Drug|celecoxib (Celebrex)|Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
75320244|NCT00624559|Other|Placebo|Placebo pill taken twice per day on each day of the diet
75320245|NCT00510809|Drug|Policosanol|Policosanol 20 mg daily
75320246|NCT00510809|Other|Placebo|Placebo daily
75320247|NCT00510809|Drug|Policosanol Plus Already In Use Statin Therapy|Policosanol 20 mg daily Statin Therapy
75320248|NCT02776982|Procedure|Confocal endomicroscopy|Confocal endomicroscopy will be performed during clinically indicated endoscopy.
75621195|NCT05429554|Drug|Vildagliptin|observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
75621196|NCT04220164|Other|Education and inform the optimal threshold of LDL-C levels|Physicians educate patients and provide a clear information about optimal LDL-C value according to individual patient's condition according to current guidelines
75320249|NCT02776982|Procedure|Mucosal impedance|Mucosal impedance will be performed at the time of clinically indicated endoscopy.
75320250|NCT02776982|Procedure|Research biopsies|Research biopsies will be obtained during clinically indicated endoscopy.
75320251|NCT02776982|Procedure|Bravo ambulatory pH monitor|Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
75320252|NCT00625729|Biological|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
75320253|NCT00625729|Biological|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10^7 cells/kg).
75320254|NCT00625729|Biological|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m^2
75320255|NCT00625729|Drug|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
75320256|NCT00625729|Drug|fludarabine phosphate|Day -6 through day -2, 25 mg/m^2 intravenous (IV)
75320257|NCT02335502|Device|Implantation with the commercially available Axium neurostimulator|
75320258|NCT00581971|Drug|celecoxib|400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
75320259|NCT00581971|Drug|Carboplatin|IV, AUC 2.0, weekly for weeks 1 through 7
75320260|NCT00581971|Drug|Paclitaxel|IV 30 mg/m2, weekly for weeks 1 through 7
75320261|NCT00581971|Radiation|Radiation Therapy|70.2Gy, at 1.8Gy qd, Monday through Friday
75774608|NCT01076673|Drug|Hyaluronic Acid|Hyaluronic acid injections
75774609|NCT00112359|Drug|AZLI 75 mg three times a day (TID)|
75912610|NCT06020573|Device|Clip-on electrode with fiber optics|The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
75912611|NCT06019832|Procedure|Total Knee Arthroplasty (TKA)|Both study arms will undergo TKA
75912612|NCT06019832|Device|Stemmed Tibial Implant|A stemmed tibial implant
75912613|NCT06019832|Device|Non-stemmed tibial implant|non-stemmed tibial implants
75912614|NCT06019026|Device|Tri-Lock|Implant Stem
75912615|NCT06019026|Device|Summit|Implant Stem
75621197|NCT05429398|Drug|Linperlisib Tablet|"Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib."
75912616|NCT06007742|Other|parent-administered pediatric tuina|"Parents in intervention group will participate in a pediatric tuina course to improve eating and sleep symptoms of ADHD, followed by an 8-week treatment period for the children. The course will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The course content will be taught by a registered TCM practitioner.~. Parents assigned to this group will participate in a Parent-Child Exercise for ADHD program, which will complete with their children in the next 8 weeks. The program will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The content will be taught by a registered physiotherapist.~The two intervention groups are manipulated every other day for 25-30 minutes each. A total number of interventions equal to or greater than 24 is considered a completed intervention."
75466039|NCT01904929|Other|Walk-tests|"Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2."
75621198|NCT04220086|Procedure|Pediatric massage therapy|Children with ASD will receive pediatric massage therapy twice a week for 12 consecutive weeks by professional pediatric massage doctor. In addition, they will receive parent provided pediatric massage therapy at home after their parents received the professional pediatric massage therapy training. The frequency of pediatric massage will not be more than once every day and each session last about 30 minutes.
75466040|NCT01904981|Drug|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
75466041|NCT01904981|Drug|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
75621199|NCT04220086|Procedure|Usual care|Including Applied Behavior Analysis (ABA), Educational intervention, Interpersonal development intervention.
75621200|NCT04220086|Other|No intervention|No intervention for healthy controls
75621201|NCT04088968|Behavioral|Prehabilitation|Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
75621202|NCT05429086|Drug|Remimazolam combined propofol|Remimazolam combined propofol
75621203|NCT05429086|Drug|Remimazolam|remimazolam only
75621204|NCT05429086|Drug|Propofol|propofol only
75621205|NCT04219930|Diagnostic Test|Expression of nucleotide protein -3|Expression of nucleotide protein -3 will be measured in serum by ELISA
75621206|NCT00638248|Drug|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
75621207|NCT00638248|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
75774610|NCT00112359|Drug|Placebo three times a day (TID)|
75912617|NCT06002750|Other|disease|Do you have dermatomyositis
75621208|NCT00638248|Drug|Placebo|Placebo i.v. bolus
75621209|NCT04219306|Other|Alert on dispatchers screen 'Suspect cardiac arrest'|Alert on dispatchers screen 'Suspect cardiac arrest'
75621210|NCT04219150|Device|Electrical cardiometry|Four sensors of EC will be applied : first approximately 5 cm above the base of the neck, second on the base of neck, third on the lower thorax at the level of the xiphoid and the fourth one on the lower thorax approximately 5 cm below the 3rd electrode at the level of anterior axillary line. The EC monitor (Electrical Cardiometry monitor, ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, serial number 1725303) will be connected to the sensor cable and the patient data will be fed. Corrected flow time (FTC) and stroke volume (SV) will be measured continuously in less than 30 seconds after placing the sensors and inputting the height and weight.
75774611|NCT01080183|Other|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
75774612|NCT00119379|Drug|NucleomaxX|NucleomaxX 36 grams TID every other day
75774613|NCT00119379|Drug|Tenofovir Disoproxil Fumarate|Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate
75912618|NCT06001931|Other|handgrip force and bioimpedance values in healthy Turkish children.|Demographic characteristics, calf circumference , Hand grip strength , TANITA BIA analysis
75912619|NCT06001346|Behavioral|ActiveCBT|Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
75912620|NCT06001346|Behavioral|CalmCBT|Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
75912621|NCT05994820|Behavioral|Happy Baby Programme -Vaccine Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi.
75774614|NCT00118911|Behavioral|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
75774615|NCT00118911|Other|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
75774616|NCT01076829|Other|Spice polyphenols|spice
75774617|NCT01080417|Drug|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
75621211|NCT04219150|Drug|"Fluid and Catheter Treatment Trial FACTT Lite"|The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
75912622|NCT05994820|Behavioral|Happy Baby Programme- Vaccine ++ Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi as part of a holistic healthy baby approach that includes nutrition and sanitation.
75621212|NCT04220242|Other|Video recordings with analysis thereafter applied|Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis
75621213|NCT04220242|Other|Examination of microsections of tissue excised for the purposes of cancer resection|Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution
75912623|NCT05989165|Drug|Minoxidil 5% Topical Solution|Patient will be given minoxidil 5% topical solution, twice a day for 12 weeks
75320262|NCT03029234|Drug|Dexamethasone|20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
75621214|NCT04220242|Other|Cancer organoid development and testing|Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer
75621215|NCT04468204|Device|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
75621216|NCT04468204|Device|Sham SinuSonic Device|Sham positive expiratory pressure intervention using the SinuSonic Device.
75774618|NCT01079481|Drug|taxol plus everolimus|taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
75774619|NCT01076907|Other|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
75774620|NCT01076907|Other|Control|Air will be used instead of warm water for unsedated colonoscopy.
75912624|NCT05989165|Device|microneedling|Patient will be given microneedling treatment every 4 weeks
75912625|NCT05988489|Behavioral|Dynamic Deconstructive Psychotherapy (DDP)|DDP treatment with an assigned therapist for up to 12 months
75621217|NCT04219462|Device|active extracorporeal shock wave|Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months
75621218|NCT04219462|Device|sham extracorporeal shock wave|twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
75621219|NCT04219852|Other|data collection|data collection
75621220|NCT04467736|Device|Gengigel Forte©|Gengigel (hyaluronic acid) will be administered by the patient 3 times per day during 7 days following alveolar ridge preservation
75621221|NCT04218994|Other|Flossing technique|Subjects instructed on flossing technique
75621222|NCT05428228|Other|TP1|Participants will be administered TP1 during one of the experimental visits.
75621223|NCT05428228|Other|TP2|Participants will be administered TP2 during one of the experimental visits.
75621224|NCT05428228|Other|Placebo|Participants will be administered placebo during one of the experimental visits.
75774621|NCT03965169|Procedure|Prone spinal surgery|spinal surgery in prone position under general anesthesia
75774622|NCT03964779|Diagnostic Test|Hormonal assay|Measurement of Thyroid stimulating hormone
75774623|NCT03964779|Diagnostic Test|Antibody assay|antithyroglobulin and antithyroid peroxidase
75774624|NCT00131937|Drug|sorafenib tosylate|Given orally
75774625|NCT03964701|Other|no intervention|no interventional study
75912626|NCT05988489|Behavioral|Brief Intervention and Contact (BIC)|BIC treatment with an assigned therapist for up to 12 months
75912627|NCT05974176|Behavioral|Trauma Focused CBT (TF-CBT)|TF-CBT is an evidence-based treatment for children and adolescents impacted by trauma and their parents or caregivers. It is a components-based treatment model that incorporates trauma-sensitive interventions with cognitive behavioral, family, and humanistic principles and techniques.
75912628|NCT05974176|Behavioral|Trauma Systems therapy (TST)|Trauma Systems Therapy (TST) is focused on the factors that contribute to children and adolescents who experience traumatic stress through the lens of the social context, vulnerabilities, and strengths of the person undergoing treatment.
75912629|NCT05969301|Other|Specific spinal exercises for idiopathic scoliosis|The spinal esercises mainly include: active self-correction, strengthening spinal deep muscles while maintaining self-correction, segmentary stretching involving the limbs and back muscles, and postural task-oriented exercises (e.g. walking, standing, sitting).
75912630|NCT05969288|Other|Behavioral survey|"Behavioral survey by administering a short self-administered questionnaire (read more in the Detailed description section)."
75320263|NCT03029234|Drug|Carfilzomib|Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.
75320264|NCT01670318|Device|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
75320265|NCT03155828|Device|CPAP|Women with diagnosed obstructive sleep apnea will be treated using continuous positive airway pressure as per standard of care.
75320266|NCT03155204|Drug|tiotropium pMDI|inhalation
75320267|NCT03111992|Drug|PDR001|Anti-PD1 antibody
75320268|NCT03111992|Drug|CJM112|Anti-IL-17A antibody
75320269|NCT03111992|Drug|LCL161|Oral small molecule SMAC-mimetic
75912631|NCT05963815|Other|Spine surgery|Patients operated with laminectomy, microscopic discectomy, percutaneous transforaminal endoscopic discectomy, and spondylodesis.
75912632|NCT05958368|Other|Avocado|The Hass Avocado group will consume 7 avocados a week (1 / day; ~240 kcals/d).
75912633|NCT05958368|Other|Other Fruit(s)|The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).
75912634|NCT05948371|Other|High Intensity interval Training|"High Intensity interval Training~Frequency: 3-5 day per week~Intensity: 60 to 80% of HRR. If atrial fibrillation present use RPE of 11-14 on a 6-20 scale.~Time: total 30 mint time.6 mint exercise with high intensity and 2 mints of low intensity for active recovery until 30 mints complete.~Type: walking and static cycling. Walking~Frequency 3 -5 days per week Intensity : use RPE of 11-14.~Time:30 mint total. 6 mint walk with high intensity and 2 mint walk with low intensity until 30mints completed."
75912635|NCT05948371|Other|Continuous Aerobic training|"Continuous Aerobic training~Frequency : 3-5 days per week.~Intensity:40-70% of HHR.~Time : initial 5-10 then 10-15 until 30mints without rest interval~Type : walking and static cycling."
75912636|NCT05948306|Other|Critical Patient-Centered Skin Care Protocol|"A patient-centered skin care protocol prepared by the researchers in accordance with the Stetler Model will be applied to the experimental group.~Sub-titles of this protocol; evaluation of risk factors, examination of the skin from head to toe, skin hygiene, examining the effects of critical illness on the skin, mobilization and re-positioning, incontinence management, maintaining nutrition, and using a support surface. For each sub-heading, application items regarding patient demands and suggestions will be added."
75621225|NCT04219228|Diagnostic Test|Ophthalmic examinations|Ophthalmic examinations include visual acuity, cover test and ocular dominance, noncycloplegic autorefraction, cycloplegia, ocular biometric measurements, cycloplegic auto-refraction, subjective refraction, and anterior and posterior segment examination.
75621226|NCT04219228|Device|Wearable devices|Physical activity, light intensity, and visual information will be measured with wearable devices.
75912637|NCT05947032|Other|Supervised endurance exercise training + Patient Education|"ENDURANCE TRAINING:~Treadmill Walking:~Frequency: 15 to 20 sessions for 3 to 5 days per week. Intensity: 40% to 60% of HRR Time: 15 Min Type: aerobic training~Recumbent Bike:~Frequency: 15 to 20 sessions for 3 to 5 days/week. Intensity: 40% to 60% HRR Time: 15 Min Type: aerobic training~+ Patient Education"
75912638|NCT05947032|Other|Home exercises + Patient Education|"HOME EXERCISES:~CONVENTIONAL Treatment:~Walking:~Frequency: 2 times/ day Intensity: as tolerated Time: 30 Min Type: aerobic training~Stair climbing:~Frequency: 1 flight/ day Type: aerobic training~+ Patient Education"
76072951|NCT00589888|Drug|Intralipid 20% @ 20cc/hour|In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
75621227|NCT00624728|Radiation|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
75912639|NCT05946226|Biological|IMC002 injection|"three different IMC002 Doses will be escalated in 3+3 design"
75320270|NCT00626431|Drug|Leuprolide acetate - Formulation A|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
76072952|NCT00589888|Drug|Intralipid 20%@ 40cc/hour|In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
76072953|NCT00589888|Drug|Normal Saline|In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
75621228|NCT01184846|Biological|10% liquid formulation of human immunoglobulin|
75912640|NCT05942898|Other|The present study does not contain any intervention|The present study does not contain any intervention
75912641|NCT05913921|Drug|Amphotericin B liposome for injection|IV infusion, 2.0 mg/kg
75621229|NCT01180400|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
75621230|NCT01180400|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
75621231|NCT04316000|Other|Initial Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
75621232|NCT04316000|Procedure|Endoscopic band ligation without resection of the subpetihelial tumour.|Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
75912642|NCT05913921|Drug|AmBisome|IV infusion, 2.0 mg/kg
75912643|NCT05908409|Drug|IDP-121|IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
75912644|NCT05906641|Dietary Supplement|High-protein diet|Protein intake will be increased to be 30% calories from protein with calcium caseinate.
75912645|NCT05903092|Drug|Durvalumab|1500mg IV on Day 1 of every Cycle
75912646|NCT05903092|Drug|Monalizumab|1500mg IV on Day 1 of every Cycle
75912647|NCT05903092|Drug|Carboplatin or Cisplatin|"On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m^2"
75320271|NCT00626431|Drug|Leuprolide acetate - Formulation B|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
75621233|NCT04316000|Other|1-2 Months Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
75621234|NCT04316000|Other|1 Year Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
75912648|NCT05903092|Drug|Etoposide|80-100mg/m^2 IV on Days 1-3 of Cycles 1-4
75912649|NCT05891834|Drug|INV-202|tablet, once daily, oral
75621235|NCT01180244|Device|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
75621236|NCT01180244|Device|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
75621237|NCT01191086|Drug|USL255|
75621238|NCT04316312|Device|Threshold inspiratory muscle trainer|Threshold inspiratory muscle trainer will be set between 15% to 30% of maximal inspiratory pressure.
75621239|NCT01088412|Drug|Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)|Dose, frequency and duration at discretion of attending physician.
75621240|NCT04198714|Procedure|Pudendal block|Administration of a pudendal block at the conclusion of vaginal surgery.
75621241|NCT00635752|Other|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
75621242|NCT00635752|Other|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
75621243|NCT04218916|Drug|Rhodiola Rosea Capsules|0.28g per capsule, 0.56g once (2 capsules), three times a day
75621244|NCT04218916|Drug|Placebo|2 placebo capsules once, three times a day
75621245|NCT05383924|Procedure|postplacental IUD insertion|"patients will have immediate postplacental IUD insertion as follows: The IUD is inserted after removal of the placenta and after the uterus has become hemostatic. After initiating closure of the uterine incision, the IUD is placed at the top of uterine fundus manually. Before closing the uterine incision, the strings are placed gently in the lower uterine segment manually. After this is accomplished, the uterine incision closure can be completed. The strings will usually descend spontaneously through the cervix during the puerperal period. If the cervix is closed, it'll be dilated from above with ring forceps. Strings can be passed through the cervix with ring forceps. If this is done, the surgeon will recheck to make sure IUD remains at the fundus of the uterus prior to closing the uterine incision. Strings can be trimmed at a follow-up visit.~Ultrasound will be done after the CS to ensure proper placement of the IUD."
75621246|NCT05383924|Procedure|delayed IUD insertion|cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit as follows: Prepare IUD prior to starting procedure Place vaginal speculum then prepare vaginal wall with betadine Apply tenaculum at anterior cervical position then insert and remove uterine sound Place IUD according to package insert then cut threads 2-3 cm from cervical os. Ultrasound will be done to ensure proper placement of the IUD.
75912650|NCT05891834|Drug|Placebo|tablet, once daily, oral
75912651|NCT05868954|Behavioral|MedDiet Program|Subjects allocated to the MedDiet Program group will receive counseling based on the principles of the traditional MedDiet with a focus on a general change in diet instead of micronutrients or macronutrients. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional MedDiet meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive olive oil and nuts during their enrollment visit and during their routine 26-30 week prenatal visit.
75621247|NCT04948840|Biological|Blood sampling|Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
75621248|NCT05318560|Drug|Lidocaine 2% Injectable Solution|for MPS
75621249|NCT05318560|Drug|Ozone|for MPS
75621250|NCT05318560|Other|stretching exercise|for MPS
75621251|NCT04171258|Drug|Botulinum toxin type A injection|Experimental
75621252|NCT04171258|Drug|Botulinum Toxin Type A Injection [Botox]|Active Comparator
75621253|NCT04165564|Other|Institutional standard of care|Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
75621254|NCT04165564|Other|Biosamples of airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
75621255|NCT05247814|Genetic|Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism|All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism
75621256|NCT05247814|Other|Adverse Drug Reaction detection|During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment
75912652|NCT05868954|Behavioral|ACOG-based Dietary Program|Following ACOG recommendation, subjects allocated to the ACOG-based Dietary Program group, will receive routine counseling on healthy eating. This will include advice on the consumption of grains, fruits, vegetables, protein, and dairy foods recommended during pregnancy. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional healthy meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive canola oil and healthy snacks during their enrollment visit and during their routine 26-30 week prenatal visit.
75912653|NCT05864742|Drug|Ibrutinib|560 mg daily continuously
75912654|NCT05864742|Drug|Venetoclax|Oral daily. Dose escalation every 7 days (if no TLS) 20mg, 50mg, 100mg, 200mg and 400mg
75621257|NCT05247814|Other|Falls Efficacy Scale International (FES-I)|The FES-I wil be obtained to estimate fear of falling
76072954|NCT00589888|Dietary Supplement|32-gram oral fat load|In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
76072955|NCT00589888|Dietary Supplement|64-gram oral fat load|In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
75621258|NCT02695576|Procedure|Lumbar Fusion Surgery|Interbody fusion with fixation
75621259|NCT02695576|Other|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
75621260|NCT02695576|Other|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
75774626|NCT01079559|Device|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
75912655|NCT05864742|Drug|Navitoclax|Oral daily. Dose-escalation every 14 days (if plt >75x10^9/L) 50mg, 100mg, 150mg, and 200mg (target dose)
75912656|NCT05864742|Drug|Rituximab|375mg/m2, intravenous. To be given on day 1 of weeks 1, 2, 3, 4 of C1 and day 1 of C2-C8
75912657|NCT05861141|Other|Selected physical therapy program|"Patients will receive a selected physical therapy program for 1 hr, 3 times per week, for 3 successive months in the form of:~Balance and postural control exercises for 15 minutes, including the following:~Standing on balance board.~Stoop and recovery.~Gait training for 45 minutes, including the following:~Forward, backward, and sideways walking.~Walking with obstacles using wedges and rolls with different diameters and heights."
75912658|NCT05861141|Device|Aerobic training|"Patients will receive the same selected physical therapy program as the control group for 15 minutes in addition to treadmill training for 45 minutes, 3 times per week, for 3 successive months.~Treadmill training: Will be practiced according to the following stages:~A- Warm up: 5 minutes.~B- The exercise phase: 35 minutes (three-minute stages), the speed will be increased gradually every 3 minutes intervals until the child no longer be able to walk at the current stage.~C- Cool down: 5 minutes."
75912659|NCT05859490|Biological|17D|Vaccine administration in subjects previously vaccinated with 17D.
75912660|NCT05857696|Other|walking quantified analysis|Test to measure anthropometry, joint amplitudes, muscle strength and spasticity of the lower limbs on a treadmill.
75912661|NCT05845996|Drug|SAR441344|Solution for intravenous/subcutaneous injection
75912662|NCT05845996|Drug|placebo|Solution for intravenous/subcutaneous injection
75912663|NCT05845996|Biological|Keyhole limpet hemocyanin|Subcutaneous Lyophilized powder for reconstitution
75912664|NCT05844878|Behavioral|Cognitive behavioral therapy (CBT) by using Distraction technique.|"Distraction: The distraction in this arm will be done by hearing of soft music; the name of music that will be used is relaxing piano music and water sounds 24/7 - ideal for stress relief. This music will be used in both the reception room and in the dental room treatment from the time-point that patient enters the reception room, and continues into the dental treatment room until the end of dental treatment when the patient exits the dental treatment room"
75936342|NCT02291757|Dietary Supplement|NEM brand eggshell membrane|NEM 500 mg, once daily, p.o.
75936343|NCT02291757|Dietary Supplement|Placebo|Placebo, 500 mg, once daily, p.o.
76072956|NCT00669682|Other|Congestive heart failure|Spontaneous occurrence of fluid overload.
76072957|NCT00669916|Biological|AIN457|single infusion of 3 mg/kg
76072958|NCT00669916|Drug|Placebo|single infusion of placebo
76072959|NCT00621946|Drug|Placebo|Placebo Matching Escitalopram
76072960|NCT00621946|Drug|Escitalopram|Active Escitalopram
75621261|NCT01086384|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
75621262|NCT01086384|Drug|Fluticasone furoate|Inhaled corticosteroid
75621263|NCT00635986|Drug|Fentanyl|100 mcg Fentanyl intravenous or epidural route
76072961|NCT00591760|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
76072962|NCT00623506|Drug|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
76072963|NCT00623506|Drug|Placebo|"Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
75621264|NCT04866784|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive
75621265|NCT01127633|Drug|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
75621266|NCT01127633|Drug|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
75621267|NCT04799626|Drug|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
75621268|NCT02751112|Biological|Predictor' kit|Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
75621269|NCT00636064|Drug|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
75936344|NCT02440802|Genetic|Saliva sample collection for genetic analyses|Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
75320272|NCT01670474|Drug|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
75320273|NCT01670474|Drug|rt-PA|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
75621270|NCT00636064|Drug|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
75621271|NCT00636064|Other|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
75621272|NCT01122173|Device|Ablation|Atrial fibrillation ablation procedure
75621273|NCT02751034|Device|Neuramis® Deep Lidocaine|HA filler
75621274|NCT02751034|Device|Restylane® PERLANE-L|HA filler
75621275|NCT02750878|Other|Informational Handout|
75621276|NCT04217668|Drug|Isosorbide Mononitrate 60 MG|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
75621277|NCT01127165|Drug|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1~2 weeks to 3~4mg/kg/day.
75621278|NCT01127165|Drug|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2~4 weeks to 6~8mg/kg/day.
75621279|NCT02750722|Device|Flutter®|Acute exercise with Flutter® breathing therapy.
75621280|NCT02750722|Device|No Flutter®|Acute exercise without Flutter® breathing therapy.
75621281|NCT04110106|Other|no intervention|All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H&Y scale by a neurologist.
75936345|NCT05581277|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-individual format.
76072964|NCT02139358|Drug|Gemcitabine|The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
76072965|NCT02139358|Drug|Trastuzumab|Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
75621282|NCT00941733|Device|IN.PACT Amphirion|Balloon Angioplasty
75621283|NCT00941733|Device|Standard PTA|Balloon Angioplasty
75621284|NCT04278508|Drug|Progesterone|To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
75621285|NCT04454242|Other|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
76072966|NCT02139358|Drug|Pertuzumab|Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
76072967|NCT02140372|Drug|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
76072968|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
75320274|NCT03155360|Other|Non interventional study|Non interventional study
75320275|NCT00582205|Drug|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
75774627|NCT01079559|Device|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
75621286|NCT05382351|Drug|Entecavir|Entecavir group will receive entecavir orally once a day, 0.5mg each time, and fasting for 2h before and after taking the medicine
75774628|NCT01079637|Procedure|Surgery with Midfoot Fusion Bolt|Surgery with Midfoot Fusion Bolt
75774629|NCT01079637|Procedure|Cast treatment|Cast treatment
75774630|NCT01080495|Procedure|TEE (transesophageal echocardiography)|a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
75774631|NCT00131469|Drug|Teriparatide (FORTEO)|Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
75621287|NCT05382351|Drug|Entecavir combined with Tenofovir Amibufenamide|Entecavir combined with Tenofovir Amibufenamide group will be treated with entecavir and tenofovir amibufenamide. Entecavir is administered in the same way as before. enofovir amibufenamide orally 25mg once a day with meals
75466042|NCT01904994|Procedure|POC (point-of-care) CD4+ (cluster of differentiation 4) Count|Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
75621288|NCT04218760|Drug|Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
75621289|NCT04218760|Other|Blood sample|3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
75774632|NCT00131469|Drug|Placebos|
75774633|NCT00372593|Drug|asparaginase|Given intramuscularly
75774634|NCT00372593|Drug|cytarabine|Given IV
75774635|NCT00372593|Drug|daunorubicin hydrochloride|Given IV over 6 hours
75774636|NCT00372593|Drug|etoposide|Given IV over 1-4 hours
75774637|NCT00372593|Drug|gemtuzumab ozogamicin|Given IV over 2 hours
75774638|NCT00372593|Drug|mitoxantrone hydrochloride|Given IV over 1 hour
75912665|NCT05844878|Behavioral|Mindfulness technique by using of relaxation breathing with muscle relaxation|"The mindfulness technique consist of combination of 2 procedures:~Relaxation breathing: this will be done during the course of dental treatment by asking the patient to do the following Gently breathe in - hold - and let go. This procedure will be applied at the first moment when the patient sits on the dental chair before any dental treatment is done and the patient is asked to repeat this twice, each for a duration of 10 seconds. This procedure will be repeated twice; at zero time and after an interval of 16 minutes of dental treatment that extend for a 30-minute duration for each patient.~Muscle relaxation: this will be done by asking the patient during dental treatment to do the following Hands - gently clench - hold - and let go. This procedure will be applied after 8 minutes from starting dental treatment, and ask the patient to do it twice for about 10 seconds. This procedure will be repeated twice; at 8 minutes and at 24 minutes of dental treatment."
75466043|NCT01904994|Procedure|Accelerated ART (antiretroviral therapy) Initiation|"Accelerated ART initiation for patients with POC CD4+ < 350 cells/uL (micro-liter) within 1 week from testing.~2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting"
75774639|NCT01324583|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution~Route of administration: intravenous"
75774640|NCT01324583|Drug|prednisolone|"Pharmaceutical form:tablet~Route of administration: oral"
75774641|NCT03992807|Other|A patient decision aid|Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
75774642|NCT03992807|Other|A usual education booklet|Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
75774643|NCT03666988|Drug|GSK3368715|GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
75912666|NCT05843253|Drug|Ribociclib|Ribociclib PO qd on days 1-21
76072969|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
76072970|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
75774644|NCT03666988|Drug|GSK3368715|GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
75774645|NCT00382109|Drug|thiotepa|Given IV
75774646|NCT00382109|Drug|cyclophosphamide|Given IV
75774647|NCT00382109|Drug|tacrolimus|Given IV or orally
75774648|NCT00382109|Drug|methotrexate|Given IV
75774649|NCT00382109|Drug|sirolimus|Given orally
75774650|NCT00382109|Radiation|total body irradiation|Part of the transplant preparatory regimen
75774651|NCT03640000|Diagnostic Test|Impedance measurements in Cardiac Resynchronization therapy|Bioimpedance measurements
75774652|NCT03735394|Diagnostic Test|ultrasonic probe|apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
75621290|NCT02750488|Drug|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
75774653|NCT03738358|Dietary Supplement|Trehalose|80 mL pouch/day for 12 weeks, containing trehalose 5 g, water 74.92 g and scent additive 0.08 g
75774654|NCT03738358|Other|Placebo|80 mL pouch/day for 12 weeks, containing water 79.92 g and scent additive 0.08 g
75774655|NCT03651622|Behavioral|Hypocaloric, low carbohydrate diet|Participants will be advised on use of a hypocaloric, low carbohydrate diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
75774656|NCT03651622|Behavioral|Hypocaloric, moderate low fat diet|Participants will be advised on use of a hypocaloric, moderate low fat diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
75774657|NCT03651622|Behavioral|Mediterranean diet, no caloric restriction|Participants will be advised on use of a healthy Mediterranean-based eating plan using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
75774658|NCT00381797|Biological|Bevacizumab|Given IV
75774659|NCT00381797|Radiation|Fludeoxyglucose F-18|Undergo fludeoxyglucose F18 PET
75912667|NCT05843253|Drug|Everolimus|Everolimus PO qd on days 1-28
75912668|NCT05836974|Procedure|Ex-utero cord blood collection|SCU units are collected after placental delivery (ex-utero) by trained obstetric personnel. The cord is clamped at one minute postpartum. Once the placenta is expelled, it is rapidly transported to the collection area, which contains supplies and a surgical table designed for ex-utero SCU collection. This table has a top tray supported by an armrest. The placenta is placed on this specially designed tray with a central hole that allows the umbilical cord to hang. Proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol. Subsequently, the umbilical vein is cannulated at the most distal point of the placenta, and placental blood is collected by gravity into a sterile bag. Gentle massage can be applied to the placenta to continue draining blood by gravity. If visible blood remains, a second puncture can be made by bringing the needle insertion point closer to the placenta.
75774660|NCT00381797|Drug|Irinotecan Hydrochloride|Given IV
75774661|NCT03738124|Device|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
75774662|NCT03738046|Behavioral|Cognitive Behavioral Therapy|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, & Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, & Wykes, 2016).
75774663|NCT03665038|Drug|Brexanolone|Administered as IV infusion.
75774664|NCT03664024|Drug|Pembrolizumab|Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
75912669|NCT05836974|Procedure|In-utero cord blood collection|The cord blood is clamped in a delayed modality, defined as after at least 1 minute after delivery. The cord is sterilized, and cord blood is collected using aseptic technique (proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol). Blood is allowed to flow by gravity and the needle is removed when blood flow ceases.
75912670|NCT05836766|Drug|Y-6 sublingual tablets|Take Y-6 sublingual tablets for 28 days continuously.
76072971|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
76072972|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
76072973|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
75466044|NCT01904994|Behavioral|Basic Care and Prevention Package|Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
75621291|NCT02750488|Other|Untreated skin|One site is patched without treatment as control
75621292|NCT00604539|Drug|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
75621293|NCT00604539|Drug|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
75774665|NCT03664024|Drug|Pemetrexed|Pemetrexed, 500 mg/m^2 infusion, standard of care, Q3W, IV
75774666|NCT03664024|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
76072974|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
76072975|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
76072976|NCT00624442|Drug|Placebo|IV infusion for 2 hours
76072977|NCT00624442|Drug|Placebo|IV infusion for 24 hours
75466045|NCT01904994|Behavioral|Cellular Appointment Reminders and Follow-Up|"SMS (short messaging service) appointment reminders for follow-up appointments.~Telephone call within 7 days of missed appointment for all patients."
75774667|NCT03664024|Drug|Cisplatin|Cisplatin, 75 mg/m^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
75774668|NCT03737890|Other|Inspiratory Muscle Training|"Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
75774669|NCT03737890|Other|Hold Relax Pectoral Stretch|"In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
75774670|NCT00381563|Device|Patellofemoral realigning knee brace|Knee brace that changes the tracking of the patella over the femur bone
75774671|NCT00381563|Device|Non-aligning knee brace|Knee brace that does not change the tracking of the patella over the femur bone
75774672|NCT01045655|Behavioral|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
75774673|NCT04516733|Other|supportive care|visit with supportiv unit and neuropsychologue every 3 months
75774674|NCT03624946|Biological|Zika Virus Immune Globulin (ZIKV-IG)|Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.
75320276|NCT05630612|Drug|Sparsentan|6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
75774675|NCT03624946|Other|Placebo|Placebo is a normal saline solution (0.9% sodium chloride).
75774676|NCT03735160|Device|pressure sensor|Pressure sensor at the angle of intratracheal tube and nasal alar
75320277|NCT04717453|Other|No Intervention|No Intervention
75621294|NCT02750254|Drug|Fludarabine|
75621295|NCT02750254|Radiation|Fractionated total body irradiation|
75774677|NCT01310218|Other|extended postoperative dressing|2 weeks of bulky dressing
75320278|NCT00626743|Drug|SK3530 100mg, Placebo, Amlodipine|
75320279|NCT01670708|Behavioral|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
75621296|NCT02750254|Drug|Busulfan|
75621297|NCT02750254|Drug|Cyclophosphamide|
75621298|NCT02750254|Radiation|Single dose total body irradiation|
75621299|NCT02750254|Drug|Melphalan|
75774678|NCT01310218|Other|short postoperative dressing|2 days bulky dressing followed by bandaid
75774679|NCT03732274|Drug|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
75774680|NCT03735082|Drug|Apatinib|apatinib 250mg,qd,d1-14,14day/cycle
75320280|NCT01670708|Behavioral|Probation as Usual|Probation officer supervises following standard protocols.
75320281|NCT03154190|Other|Best Practice|Receive usual care
75320282|NCT03154190|Other|Laboratory Biomarker Analysis|Correlative studies
75320283|NCT03154190|Procedure|Supportive Care|Undergo health care coach support
75320284|NCT03154190|Other|Survey Administration|Ancillary studies
75320285|NCT00582361|Procedure|Standard Wound Dressing|Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
75466046|NCT01904994|Other|Financial Incentive|Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
75466047|NCT01905007|Device|Defibrillation testing|Defibrillation testing at initial ICD implantation
75621300|NCT02750254|Drug|Granulocyte-colony stimulating factor|
75621301|NCT02750254|Procedure|Stem cell transplant|
75621302|NCT02750254|Drug|Azacitidine|
75621303|NCT00941655|Drug|Oxaliplatin|"Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m^2 over 120 minutes,"
75621304|NCT00941655|Drug|Irinotecan|Irinotecan 165 mg/m^2 IV over 90 minutes
75621305|NCT00941655|Drug|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m^2 continuous intravenous over 48 hours."
75621306|NCT00941655|Drug|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m^2 intravenous over 120 minutes."
75621307|NCT00941655|Procedure|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
75774681|NCT03735082|Drug|Paclitaxel|paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
75774682|NCT03735082|Drug|Carboplatin|carboplatin AUC=4,d1,14day/cycle;
75774683|NCT00381095|Drug|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
75774684|NCT00381095|Drug|Placebo|Placebo
75774685|NCT03619174|Device|Viveve Treatment|The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
75912671|NCT05836766|Drug|Placebo tablets of Y-6 sublingual tablet|Take Placebo tablets of Y-6 sublingual tablet for 28 days continuously.
75912672|NCT05833113|Device|Placebo-Transcutaneous Electrical Nerve Stimulation (TENS)|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~The control group will also receive the TENS-pants electrodes, connected to TENS treatment. In the placebo-TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. However, the TENS treatment to the control group will be set so that no electricity will reach the patient.~A multimodal analgesia regimen will be applied postoperatively"
76072978|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
75774686|NCT05665894|Device|Hematoma Vaacum Assisted Biopsy|The patient was placed supine and meticulous aseptic measures were applied. Prior procedure local anesthesia (lidocaine 1%) was administered following disinfection. A 5 mm skin incision is performed to guarantee appropriate access for the needle insertion in the hematomas. The evacuation was achieved using a Mammotome® vacuum-assisted system (Devicor Medical Products, Inc., Cincinnati, OH, USA), with an 8-G needle, under the guidance of the same high-resolution US equipment (MyLabTM 9 XP; Esaote SpA, Genoa) for preoperative assessment. Empty-needle function and the tissue-biopsy option is preferred to fragment the fibrotic tissue until the hematoma empties and its walls collapsed. Once VAEv is performed, the postoperative US is carried out and VAEv is repeated until more than 90% evacuations of hematoma volume if no complication occurs.
75774687|NCT03737656|Drug|Progesterone vaginal ring|Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
76072979|NCT00624442|Drug|Placebo|IV infusion for 72 hours
76072980|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
76072981|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
75621308|NCT00605787|Drug|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
75774688|NCT00112047|Drug|Emtricitabine (FTC)|Capsule containing 200 mg FTC, taken once daily, for 96 weeks
75774689|NCT00112047|Drug|Tenofovir Disoproxil Fumarate (TDF)|Tablet containing 300 mg TDF, taken once daily, for 96 weeks
75774690|NCT00112047|Drug|Efavirenz (EFV)|Tablet containing 600 mg EFV, taken once daily, for 96 weeks
75774691|NCT00112047|Drug|FTC/TDF|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
76072982|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
75621309|NCT00939393|Device|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
76072983|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
75621310|NCT00939393|Device|Balloon Sinuplasty|Balloon dilatation of sinuses
75621311|NCT05382273|Behavioral|T-Break Guide|"The T-Break Guide was designed to help people complete a 21-day break from cannabis. For each day of the break, the Guide offers inspiration in the form of a quote, reflections based on likely experiences occurring at that point during the break, advice on ways to overcome challenges, alternative activities in which to engage, and encouragement.~The first week focuses on physical symptoms of cannabis withdrawal (e.g., sleep, appetite).~The second week focuses on the emotional experience (e.g., anxiety, boredom).~The third week focuses on behavioral aspects (e.g., examining patterns, connections).~The T-Break Guide follows the Motivational Interviewing principles of affirmation and autonomy."
75621312|NCT05382195|Other|hospital anxiety and depression scale|questionare on patients with multiple sclerosis
75621313|NCT04441996|Biological|Therapeutic plasma exchange (TPE)|Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
75621314|NCT04441996|Other|Standard of care|Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
75621315|NCT04267965|Procedure|parathyroidectomy plus bilateral thymectomy and autotransplantation|Patients should receive total parathyroidectomy plus bilateral thymectomy and autotransplantation
75621316|NCT05380869|Diagnostic Test|Point-of-care Test|to test Point-of-care procalcitonin in suspected pneumonia
75621317|NCT02750020|Other|Questionnaire|Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
75774692|NCT00112047|Drug|FTC/TDF/EFV|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
75774693|NCT00112047|Drug|Lamivudine/zidovudine|Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
75774694|NCT03737578|Other|Delivery of a connected pedometer / accelerometer|"Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months"
76072984|NCT00670462|Behavioral|Standard Behavioral Treatment (SBT)|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
75774695|NCT03658876|Drug|Iron Sucrose Solution for Injection|200mg iron sucrose given on 5 successive haemodialysis sessions
75774696|NCT03658876|Drug|Epoetin Beta|Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
75774697|NCT03618628|Device|Carbon Fiber Off Loading Orthosis (CFO)|A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
75774698|NCT03734926|Drug|ZSP1241|ZSP1241 tablets for oral administration.
75774699|NCT03617770|Behavioral|Sleep Opt-In|8-week intervention that includes a wearable sleep tracker, didactic content, smartphone application and counseling
75774700|NCT03617770|Behavioral|Healthy Living|8-week intervention that includes weekly telephone counseling on healthy living.
75774701|NCT03734848|Drug|Bilateral Ultrasound Guided Pectoralis Nerve Block.|Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
75774702|NCT03639922|Drug|Imatinib 400mg|2 tablets of Imatinib 400mg per day for 6 days
75774703|NCT03639922|Drug|Placebo Oral Tablet|2 tablets of placebo per day for 6 days
75774704|NCT03616600|Other|Breath-O-Correct Lens|Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
75774705|NCT03734614|Drug|Low dose of aspirin|Low dose of aspirin, 100 mg daily for longer than one year
75774706|NCT00380393|Biological|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
75774707|NCT00380393|Biological|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
75774708|NCT01046747|Procedure|Placement of external fixation pins|The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
75774709|NCT00380081|Drug|zolpidem tartrate sublingual tablet 3.5mg|Zolpidem tartrate sublingual tablet 3.5 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
75621318|NCT04190836|Behavioral|Self-Managed Exercise Strategy|The intervention is a personalised supported self-management intervention which emphasises dynamic, progressively loaded exercises for the shoulder. The intervention consisted of 1-5 individual sessions provided over 3 months, with a duration of 1 hour for the first session and 45 minutes for the following. The participants will have the opportunity to contact the physiotherapist by phone, text message or e-mail for advice during the treatment period (12 weeks). The personalised supported self-management intervention will be based on the components of the self-management framework, provided by Lorig and Holman (2003). The five self-management skills and the operationalization of these will be described when publishing the study. For specific content reporting of the self managed exercises we will follow the Consensus on Exercise Reporting Template.
75621319|NCT00936117|Drug|Posaconazole|200 mg (liquid) by mouth 3 times per day.
75774710|NCT00380081|Drug|zolpidem tartrate sublingual tablet 1.75mg|Zolpidem tartrate sublingual tablet 1.75 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
75774711|NCT00380081|Drug|Placebo|Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
75774712|NCT03579940|Drug|Lasmiditan|Administered orally.
75774713|NCT03579940|Drug|Placebo|Administered orally.
75912673|NCT05833113|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~In the TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. TENS device will be applied 4 times a day with treatment periods of 30 minutes.~A multimodal analgesia regimen will be applied postoperatively"
75912674|NCT05825235|Drug|Pramipexole|6 months of treatment with add-on Pramipexole
75936346|NCT02440724|Device|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
75621320|NCT04218682|Behavioral|Shadow's Edge Mobile Application Gameplay|6 weeks of individual, interactive game play of the Shadow's Edge mobile app.
75621321|NCT04267653|Drug|Lactoferrin Bovine|treatment for 30 days
75912675|NCT05822375|Behavioral|Better Together Physician Coaching|Better Together Physician Coaching Program thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
75621322|NCT04267653|Drug|Ferrous Sulfate|treatment for 30 days
75621323|NCT04088500|Biological|Nivolumab|Specific dose on specific days
75621324|NCT04088500|Biological|Ipilimumab|Specific dose on specific days
75621325|NCT05379153|Device|Laser Therapy|Undergo vaginal fractional CO2 laser therapy
75621326|NCT05379153|Device|Sham Intervention|Undergo placebo procedure
75621327|NCT05379153|Other|Questionnaire Administration|Ancillary studies
75621328|NCT05379153|Other|Quality of Life Assessment|Ancillary studies
75774714|NCT03729934|Dietary Supplement|Ketone Ester|This arm receives 25 g ketone ester.
75774715|NCT03729934|Dietary Supplement|Ketone Salt|This arm receives 25 g ketone salt.
75912676|NCT05818800|Device|digital solution|randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions
75912677|NCT05818800|Other|Standard Care|randomised controlled trial where patients with hypertension will be randomised r to standard care
75912678|NCT05812924|Biological|Platelet-rich plasma (PRP)|0.1-0.2 mL injections of platelet-rich plasma (PRP) will be injected to the vulvovaginal area. The injections will be placed every 5mm and at an angle of 60° into the mucosa and lamina propria of the posterior wall of the vagina.
75912679|NCT05806190|Device|Continuous Glucose Monitoring|Continuous Glucose Monitoring using a Dexcom G6 Continuous Glucose Monitoring Device
75912680|NCT05796648|Behavioral|RN-CHeFRx|The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
75912681|NCT05791877|Device|pneuRIP|Respiratory sensor to measure pulmonary function
75912682|NCT05787418|Drug|HH-120 Nasal Spray|HH-120 nasal spray 8 times per day for 7 consecutive days
75912683|NCT05787418|Drug|Placebo|Placebo 8 times per day for 7 consecutive days
75912684|NCT05785442|Drug|Anakinra Prefilled Syringe|Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 4 days)
75912685|NCT05785442|Drug|Placebo|0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 4 days)
75912686|NCT05774132|Procedure|ultrasound guided Subgluteal sciatic nerve block|Patients will be positioned in lateral decubitus and the ultrasound scanning for the sciatic nerve in the subgluteal region will be started between the two bony landmarks (greater trochanter and ischial tuberosity ) using high frequency linear probe then approached via 5 cm block needle under ultrasound guidance after which bupivacaine 0.25% (0.3 ml/kg) will be administered in increments .
75621329|NCT04218214|Other|LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)|Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
75774716|NCT03732040|Other|miswak stick|miswak stick use as preventive hygiene measures
75936347|NCT02440724|Device|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
75774717|NCT03732040|Other|Miswak plus tooth brushing and tooth paste|use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures
75774718|NCT03732040|Other|Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)|use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
75936348|NCT03117608|Biological|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
75936349|NCT03117608|Biological|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
76072985|NCT00670462|Behavioral|Maintenance-Tailored Treatment (MTT)|
75621330|NCT05379075|Other|26 styles of Chen Taichi training based on Relaxation guidelines|The arms and legs and the spine should rotate follow the arrow tips in order to cause a stretch reflex slightly. And then, the exerciser should use relaxation skills to eliminate the stretch reflex, such as exhaling, drop the control of body
75774719|NCT00098306|Drug|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
75774720|NCT00098306|Drug|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
75774721|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
75774722|NCT00098306|Drug|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
75912687|NCT05774132|Procedure|ultrasound guided Caudal block|Patients will be positioned in lateral decubitus and their sacral hiatus will be palpated under the scanning of the ultrasound using high frequency linear probe then approached via 5 cm block needle that pierce the sacrococcygeal ligament then will be advanced to caudal canal under ultrasound guidance after which bupivacaine 0.25% (1 ml/kg) will be administered in increments.
75621331|NCT05379075|Other|26 styles of Chen Taichi training based on Coordination guidelines|"When the posture needs to open the arms should accompany with inhale and when the posture needs to close the arms should accompany with exhale. Similarly, if the arm is lifting should accompany with inhale, and the put down should accompany with exhale."
75621332|NCT02750098|Other|Glucose measurement|"Elective cataract surgery~Blood glucose measurement - glucometer~Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~Perioperative Hemoglobin A1c level - blood laboratory test"
75621333|NCT01082874|Drug|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
75621334|NCT01082874|Drug|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
75621335|NCT01082874|Drug|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
75621336|NCT01082874|Drug|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
75621337|NCT04009408|Device|Expiratory muscle strength therapy (EMST150, Aspire LLC)|Active therapy calibrated to the participant's maximum expiratory pressure
75621338|NCT00933543|Drug|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
75621339|NCT00933543|Drug|Vehicle cream (placebo)|Cream application followed by illumination with red light.
75621340|NCT00933543|Procedure|PDT|Photodynamic Therapy - Light dose 37 J/cm2
75621341|NCT02749942|Device|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
75621342|NCT02749942|Device|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
75774723|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
75912688|NCT05769309|Procedure|Erector spinae block|After induction, the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
75912689|NCT05769309|Drug|Fentanyl|fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
75912690|NCT05766735|Behavioral|Routine Care + Glycemic Excursion Minimization (RC+GEM)|In addition to receiving routine care, participants will receive GEM, a structured, self-directed, and personalized program that will allow participants with pre-diabetes to improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their blood glucose levels and variability.
76088859|NCT04550676|Behavioral|CME (active control)|Following a 4-minute warm-up, the participant will walk/jog for up to 42 continuous minutes at 60% VO2peak. This is followed by a 4-minute cool-down. The total exercise time is 50 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
75466048|NCT01905020|Other|Carbohydrate-rich meal|At 19:30, patients will eat a standardized large meal (110g carbohydrate for males; 90g carbohydrate for females). Conventional insulin pump therapy or closed-loop system will be use to control glucose levels from 21:00 until 7:00 next morning.
75466049|NCT01905020|Other|Exercise|Study participants will go to a training facility around 18:00 to perform a 60min workout at 60% heart rate reserve. The workout will be on a treadmill and/or a stationary bicycle. Conventional insulin pump therapy or closed-loop system will be use to regulate glucose levels from 21:00 until 7:00 next morning.
75621343|NCT00607503|Drug|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
75621344|NCT04264533|Drug|VC|12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
75621345|NCT04264533|Drug|Sterile Water for Injection|50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
75774724|NCT03615040|Drug|MSTT1041A|"MSTT1041A (RO7187807; formerly made by Amgen [AMG] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2."
75466050|NCT01905059|Drug|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
75621346|NCT02750176|Other|Closed chain exercises|Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
75621347|NCT01082328|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
75621348|NCT04172584|Behavioral|correct use of the contraceptions|know the emergency contraception and how to use
75621349|NCT03796000|Procedure|tissue samples, blood and stool sample|Tissue samples from gastroscopy/colonoscopy.
75621350|NCT02749786|Other|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
75912691|NCT05766735|Other|Routine Care (RC)|RC participants will meet with their primary care provider to determine the best diabetes medication and proper dose. The participant will be allowed to change medications, or use a combination of medications, that is best suited for their care during the duration of the study. The study team will not influence these decisions.
75912692|NCT05763862|Genetic|Genetic testing|Same information as details in the experimental arm.
75912693|NCT05754515|Procedure|target controlled infusion (TCI) group|"Patients in the TCI group will be anesthetized with propofol and remifentanil throughout the operation.~Patients included in the inhalation anesthesia group will be anesthetized with desflurane and remifentanil with a bispectral index of 40-60 throughout the operation."
75912694|NCT05753059|Drug|Placebo|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
75912695|NCT05753059|Drug|Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
75912696|NCT05753059|Drug|Bendroflumethiazide|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
75912697|NCT05752903|Drug|Dexmedetomidine-propofol|1 microgram/kg dexmedetomidine+2.5 mg/kg propofol intravenous (IV) bolus, 0.5 microgram g/kg/h dexmedetomidine+2.5 mg/kg/h propofol infusion
75912698|NCT05752903|Drug|Ketamine-Propofol|1 mg/kg ketamine+2.5 mg/kg propofol iv bolus, 0.25 mg/kg/h ketamine+2.5mg/kg/h propofol infusion
75912699|NCT05751694|Procedure|Visceral manual treatment|The patient will be placed in a reclining sitting position and triple flexion of the lower limbs to keep the abdominal region relaxed. The therapist will be placed to the right of the patient at the height of the abdomen, with the hands placed in the epigastric area. He will make a skin fold that reduces tension in the area, so that the contact is focused on the visceral tissue of the area. The patient will be asked to take deep breaths, and during the exhalation, the therapist will perform a zigzag movement with vibration of the hands while pulling the tissue caudally. This procedure will be performed for 5 minutes.
75912700|NCT05751694|Procedure|Respiratory listening|The patient and the therapist will be placed in the same position as in the experimental group. The therapist will place his hands in contact with the lower rib cage, and the patient will be asked to take a deep breath. The therapist will not exert any pressure, nor place restrictions on the tissues or movements of the ribcage.
75912701|NCT05747014|Device|Novapak Nasal Sinus Packing and Stent|Potential subjects will have the need to undergo nasal/sinus surgery using a space-occupying stent and will perform daily self-saline nasal irrigations.
75912702|NCT05744778|Other|Dry needling|In addition to the physical therapy and exercise program, the dry needling group will consist of patients who have had 3 sessions of dry needling applied to the trigger points in the trapezius muscle, 5 days apart.
75912703|NCT05744778|Other|Physical therapy and rehabilitation|The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.
76088860|NCT03136848|Drug|Normothermic ex-vivo kidney perfusion Solution -Toronto|"The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney."
76088861|NCT02465658|Other|Medical records were reviewed.|retrospective study
75621351|NCT04218058|Procedure|reduction of zygomatic arch in zygomaticomaxillary complex fracture|ultrasound guided reduction of zygomatic arch
75621352|NCT04217434|Procedure|400 µm fibre length will be used in continuous contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
75774725|NCT03615040|Drug|Placebo|Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
75774726|NCT02531204|Drug|ASP1585|oral
75774727|NCT00068822|Device|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
75774728|NCT00068822|Procedure|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
75774729|NCT03964064|Radiation|Stereotactic Radiotherapy|"GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report"
76088862|NCT05040750|Other|laboratory investigation|observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients
76088863|NCT04705350|Drug|Zampilimab|Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
75621353|NCT04217434|Procedure|400 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
75621354|NCT04217434|Procedure|300 µm fibre length will be used in continuous mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used continous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
75651606|NCT05833919|Drug|Eribulin Mesylate|"The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes.~The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date"
75774730|NCT03964064|Radiation|3D-printing Template-assisted CT-guided I125 Seed Implantation|CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
75774731|NCT01090778|Drug|Norditropin SimpleXx (growth hormone)|3mg/subject/day over two consecutive days
75774732|NCT00068588|Biological|GTI-2040|Given IV
75774733|NCT00068588|Drug|capecitabine|Given orally
75774734|NCT01088126|Procedure|radiofrequency catheter ablation|radiofrequency catheter ablation, NavX system
75774735|NCT01088204|Procedure|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
75774736|NCT01088204|Procedure|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
75912704|NCT05743803|Other|Sensititization campaign on preoperative fasting rules|"Planned and repeated mandatory on site lecture about pre-operative guidelines for surgeons, anesthetists and paramedics.~Reminder display in surgical wards and consults.~Individualized fasting cards for patients.~Short message service reminder on pre-operative fasting rules for patients.~Medical fasting prescription with clear fasting times."
75320286|NCT00582361|Device|VAC|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
75774737|NCT01088282|Procedure|Cataract surgery|Implantation of multifocal or monofocal IOL
75774738|NCT03963752|Drug|Ziyinxiehuo Granules Herbs|1 pack of Ziyinxiehuo granules Herbs is administered after dissolved, 2 times per day after a meal.
75774739|NCT03963752|Drug|Megestrol Acetate Tablet|the dose is 6-8mg/d, three times per day after meals.
75774740|NCT03963752|Drug|Leuprorelin Acetate 3.75mg Injection|Usage： 80μg/kg by subcutaneous injection, every 4 weeks
75912705|NCT05735353|Behavioral|High-Speed Circuit Resistance Training|three times per week; 45 minutes per session; 12-weeks
75912706|NCT05735353|Behavioral|High-Speed Multidirectional Yoga|two times per week; 60 minutes per session; 12-weeks
75936350|NCT02432534|Drug|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
75936351|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
75936352|NCT04919447|Procedure|pacemaker implantation|cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients.
75320287|NCT01670786|Procedure|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
75320288|NCT05701592|Procedure|DB-PCLR|DB-PCLR with reconstruction of both PCL bundles: anterolateral and posteromedial bundle will be performed.
75936353|NCT02432612|Drug|Sativex|Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
75936354|NCT02432222|Behavioral|Visual Arts Training|Visual arts training
75936355|NCT02432222|Behavioral|Music Training|Music training
75936356|NCT05705843|Drug|Intraosseous Vancomycin Injection|• IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and draping has occurred prior to skin incision (500mg in 150mL NS).
75621355|NCT04217434|Procedure|300 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. .Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
75912707|NCT05734638|Behavioral|MIM-DASH|Randomized participants will receive the MIM DASH, MIM or DASH intervention in eight weekly, 1-hour group sessions via telehealth (video and telephone access). Participants will receive session materials such as PowerPoint presentations so they can follow along by phone or videoconferencing. After completion of the eight weekly sessions, the participants will receive one follow-up call every other week for 8 weeks. The 3- and 6-month data will be collected as listed in the study AIMs. A manual of operations will detail all procedures related to the protocol, including participant recruitment, data collection, database usage, and database management.
75912708|NCT05734638|Behavioral|MIM Only|"The MIM-only intervention group will receive the MIM education only in eight weekly sessions of 30 minutes each. To maintain equipoise among the intervention groups, this group will also have 30 minutes of social time to interact with the trainer and peers. To avoid cross contamination, the interventionist will not also deliver the intervention to the MIM DASH group. Each participant will have access to the digital meditations with mindfulness practice recordings as well as a weekly diary to document study activities. Participants will be instructed to perform mindfulness meditations at least five times a week and record the time in their diary. After completion of the eight weekly sessions, these participants will receive six coaching calls (two per month for 3 months) focused on mindfulness practice."
76072986|NCT00670774|Drug|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
76072987|NCT00672100|Drug|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
75912709|NCT05734638|Behavioral|DASH Only|"The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of social time to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles."
75912710|NCT05733780|Drug|Prolectin-M|"Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus"
75912711|NCT05730881|Procedure|ECMO|VA-ECMO is a life support measures, we need to estimate the survival by different techniques to allocate therapeutic interventions properly
75912712|NCT05728619|Drug|HTMC0435|Oral administration.
75912713|NCT05728619|Drug|Temozolomide|Oral administration.
75912714|NCT05726032|Drug|Empagliflozin 10 MG|Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
76072988|NCT00672100|Drug|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
75621356|NCT04217512|Drug|Pantoprazole low dose|Pantoprazole 0.6 mg/kg
75621357|NCT04217512|Drug|Pantoprazole high dose|Pantoprazole 1.6 mg\kg
75621358|NCT04217512|Other|Standard hydration|Standard hydration alone
75621359|NCT04217512|Drug|Cisplatin|Cisplatin
75774741|NCT01081808|Biological|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
75774742|NCT03650452|Drug|TAK-935|TAK-935 tablets or mini-tablets.
75774743|NCT03650452|Drug|Placebo|TAK-935 placebo-matching tablets or mini-tablets.
75774744|NCT03729856|Behavioral|intervention|The adapted physical activity (APA) intervention is a theory-based physical activity (PA) promotion intervention. The APA model is comprised of 4 steps: 1) pre-participation evaluation of physiological, personal and environmental factors that influence PA adoption and maintenance; 2) application of individualised, evidence based strategies associated with increased PA participation tailored to the participant's motivational readiness; 3) development of structured exercise and/or lifestyle PA program; and 4) tailored relapse prevention strategies to maintain physical activity beyond the duration of the program. The intervention will be conducted in the participant's home environment.
75912715|NCT05726032|Drug|Matching Placebo|Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
75936357|NCT05705843|Drug|Intravenous Vancomycin|IV Vancomycin will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL NS).
76072989|NCT00672100|Drug|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
76072990|NCT00593866|Radiation|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
76072991|NCT00593866|Drug|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
76088864|NCT04705350|Drug|Placebo|Participants will receive matching placebo at a pre-specified time point to maintain the blinding.
76088865|NCT04993638|Device|hip arthroplasty|Hip prosthesis surgery
75774745|NCT03729856|Other|B|Participants will undertake their usual activities during the baseline period. An extended pre-intervention time frame is needed to establish a stable control phase and enhance internal validity.
75774746|NCT03729856|Other|Follow-up|Participants will have no contact with intervention personnel during the 5 week follow-up, withdrawal period. The withdrawal phase enables initial assessment of physical activity behavior change.
75774747|NCT03734458|Other|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
75774748|NCT03734458|Other|Group B - PRF only with a CAF|Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
75774749|NCT03734458|Other|Group C - CTG with a CAF|Group C - CTG with a CAF will be used surgically to cover the exposed roots.
75621360|NCT02749708|Drug|IRX5183|IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 [DL1] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
75774750|NCT03731962|Procedure|Coronary Angiography|All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
75774751|NCT03734380|Behavioral|Laboratory-based gait retraining (LGR)|Subjects in the LGR group will be encouraged to modify the gait pattern (e.g. adjusting foot progression angle, performing medial knee thrust, and/or lateral trunk lean) to lower their KAM to 80% of respective average baseline KAM obtained during normal unmodified gait. Real-time auditory feedback will be delivered using stereo speakers from both sides of the staircase. A middle C (261.6 Hz) tone and a high-pitched C (4186.0 Hz) of equal intensity will be generated at a footfall below and above the targeted 80% value, respectively. They will be advised to maintain their new gait pattern during their daily living after training.
75774752|NCT03734380|Behavioral|Sensor-based gait retraining (SGR)|Subjects in the SGR group will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. In addition, the auditory feedback will be delivered through a pair of earphones connected to a smartphone, which has been pre-installed with an app for KAM measurement. They will be advised to maintain their new gait pattern during their daily living after training.
75774753|NCT03734380|Behavioral|Walking exercise control (Ctrl)|Subjects in the Ctrl group will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups. They will not be given any instructions for out-of-lab activities.
75774754|NCT03729700|Other|Almond|The almond dose will be provided as 20% of total energy (20% E) in the diet.
75774755|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
75774756|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
75774757|NCT03734146|Behavioral|Aerobic Exercise|180 minutes of moderate-vigorous intensity aerobic exercise per week
75774758|NCT03734146|Behavioral|Resistance Exercise|180 minutes of resistance exercise per week
75774759|NCT03734146|Behavioral|Combined aerobic and resistance exercise|180 minutes of exercise per week with 90 minutes per week coming from moderate-vigorous intensity aerobic exercise and 90 minutes per week coming from resistance exercise
76072992|NCT00624910|Drug|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
76072993|NCT00624910|Drug|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
76072994|NCT00594022|Device|"Electric stimulation of the Vestibular Nerve - VirtuSom"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
75621361|NCT03632434|Device|transcranial direct current stimulation|tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.
75774760|NCT05665816|Device|Stent PULSAR® -18 T3,|"Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions."
75774761|NCT03731884|Other|Time from the onset of symptoms to PCI|Patients will be divided in two groups according to the time from the onset of symptoms to PCI
75774762|NCT03729622|Other|Low FODMAP Diet|Both arms will receive the intervention but at different time points.
75936358|NCT02436044|Procedure|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
75936359|NCT02436044|Drug|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
75936360|NCT02436044|Drug|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
75936361|NCT02436044|Drug|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
75936362|NCT02435732|Drug|Placebo saline solution|saline solution
75936363|NCT02435732|Drug|Heparin|Added to the one of the arms receiving 200U/kg dose of CINRYZE
75936364|NCT02435732|Drug|CINRYZE|200U/kg IV dose with or without heparin, or 500U/kg IV dose
75320289|NCT00582517|Device|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
75621362|NCT04217980|Diagnostic Test|Lung ultrasonography (LUS) or Chest X ray (CXR)|pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.
75774763|NCT03729466|Other|clinical pilates|The intervention group will be performed in clinical pilates 45 to 60 minutes twice a week for 8 weeks.
75621363|NCT01079988|Drug|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
75774764|NCT03734068|Device|Chemoembolization Using LifePearl|Chemoembolization Using LifePearl
75621364|NCT01079988|Drug|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
75621365|NCT01079988|Drug|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
75621366|NCT01079988|Drug|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
75621367|NCT01079988|Drug|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
75621368|NCT02876718|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
75621369|NCT04217122|Other|strawberry powder|Participants consume 2 packages of standard strawberry powder (13 g x 2) daily for 4 weeks
75621370|NCT04217122|Other|placebo powder|Participants consume 2 packages of placebo powder (13 g x 2) daily for 4 weeks
75320290|NCT00582517|Procedure|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
75621371|NCT01074216|Drug|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
75621372|NCT04217044|Diagnostic Test|Histopathology images based prediction of molecular pathology|Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
75621373|NCT04218136|Biological|Blood samples|A minimum of 4 blood samples and a maximum of 6 blood samples will be collected. Venous return blood samples collected as part of routine monitoring of patients for bioclinical parameters. Samples will be collected before start of the infusion and end of the infusion
75621374|NCT01079832|Radiation|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
75621375|NCT01079832|Procedure|quality-of-life assessment|Ancillary studies
75621376|NCT02749630|Drug|Placebo|Matching placebo to UTTR1147A administered intravenously
75621377|NCT02749630|Drug|UTTR1147A|Escalating doses of intravenously administered UTTR1147A
75774765|NCT03734068|Drug|Doxorubicin|Doxorubicin is loaded to LIfePearl
75774766|NCT03575806|Combination Product|TACE plus autologous Tcm immunotherapy|"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."
75774767|NCT03575806|Procedure|TACE|TACE:transcatheter arterial chemoembolization.
75320291|NCT03155048|Drug|oral estrogen replacement therapy|oral estradiol group for endometrial preparation
75621378|NCT00626730|Procedure|adjuvant therapy|
75621379|NCT00626730|Radiation|radiation therapy|
75621380|NCT03209128|Radiation|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
75621381|NCT04788342|Device|pulse wave recording, echocardiography.|pulse wave recording using a single-channel electrocardiogram cardiomonitor with photoplethysmography, conducting echocardiography according to a standard protocol with the determination of systolic function of the left ventricle
75621382|NCT02749318|Genetic|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
75621383|NCT03199144|Drug|Chemotherapy|3 cycles of Gemzar-Abraxane
75621384|NCT03199144|Radiation|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
75621385|NCT03199144|Procedure|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
75621386|NCT04306536|Dietary Supplement|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
75774768|NCT03610048|Drug|ALKS 5461|samidorphan + buprenorphine administered sublingually
76088866|NCT04993170|Diagnostic Test|Bleeding assessment tool|The standardized application of the questionnaire serves to identify patients at risk of bleeding at an early stage and to adapt and optimize perioperative coagulation management accordingly by initiating targeted diagnostics and therapy
75774769|NCT03733912|Other|Phthalate metabolites measurement|To measure phthalate metabolites of urine and house dust in Pregnancy and Non-pregnancy groups
75774770|NCT03608254|Other|100% watermelon juice|Participants consumed a one-time dose of 100% watermelon juice. Blood was sampled before and 2 hours after ingestion. Blood pressure and brachial artery flow-mediated dilation were measured before and 2 hours after ingestion.
75774771|NCT03733756|Procedure|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
75912716|NCT05723159|Device|Clinical Validation of the Hyfe Cough Monitoring System|The subjects will be instructed to not turn off either watch for the duration of the 24 hours. In addition, participants will be instructed to avoid environments with active coughers and to inform others in their environment that sound is being recorded. Additionally, participants will be told to avoid getting the watches wet. Participants will be instructed to charge the watches on a nightstand next to the bed while they sleep using the provided watch chargers. At the end of the 24-hour period, participants will be instructed to turn off and remove the watches. Additionally, participants will be given a printed Hyfe diary to write down the exact time when the device was turned on/off and any times the watch was not being worn. The devices will be returned to the researchers once the recording period is complete.
75621387|NCT04304664|Other|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
75774772|NCT03733756|Procedure|POEM involving longitudinal muscle|participants are operated POEM involving both circular and longitudinal muscle
75774773|NCT03731728|Behavioral|Group CBT|"All therapists will use a manualized Cognitive-Behavior Therapy (CBT) protocol with the same handouts and schedule developed based on the book Mind Over Mood. Group CBT will be provided to a group of maximum 10 participants. Each session will be 2 hours long and will be provided by certified therapists with special training to deliver group CBT. The structure of the session will be agenda setting, check-in, review of homework, new concepts/skills, homework assignment, and feedback."
75912717|NCT05720143|Procedure|Osseodensification|Procedure: the horizontal and vertical osteotomy will make by Piezo and bone splitting will do by osseodensification bur. After that Immediate implantation will be done.
75912718|NCT05720143|Procedure|Magnetic mallet|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by chisels of magnetic mallet. Immediate implantation will be done after splitting.
75621388|NCT00636142|Biological|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
75621389|NCT04305522|Dietary Supplement|Probiotic 1|Probiotic mixture with maltodextrin as a carrier.
75621390|NCT04305522|Dietary Supplement|Placebo|Placebo comparator with maltodextrin as a carrier.
75320292|NCT03155048|Drug|Estradiol transdermal patch|transdermal estradiol group for endometrial preparation
75320293|NCT03155126|Other|Fluid resuscitation|Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
75621391|NCT04305522|Dietary Supplement|Probiotic 2|Probiotic mixture with maltodextrin as a carrier.
75774774|NCT03731728|Behavioral|Group exercise|Participants enrolled in the group exercise plus TAU arm of the study will be wait-listed for TAU and will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks.
75774775|NCT03606460|Drug|Ocrelizumab Dose 1|300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.
75774776|NCT03606460|Drug|Ocrelizumab Dose 2 and Dose 3|600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48
75774777|NCT03729310|Device|Propel 'implant'|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
75774778|NCT03729310|Drug|Triamcinolone|Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA.
75912719|NCT05720143|Procedure|Piezo-surgery|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by inserts of piezosurgery and bone expander. Finally, immediate implantation will be placed.
75912720|NCT05706285|Procedure|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
75912721|NCT05700994|Behavioral|Peer Contingency Management|Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
75912722|NCT05700994|Behavioral|Standard of Care Contingency Management|Participants allocated to standard of care contingency management will receive incentives for peer encounters.
75912723|NCT05694286|Procedure|Juvederm Volbella XC hyaluronic acid dermal filler injection|Infraorbital filler injection
75912724|NCT05692791|Diagnostic Test|Two-point Discrimination Test|Two-point discrimination (2PD) is the ability to discern that two nearby objects touching the skin are truly two distinct points, not one. It is often tested with two sharp points during a neurological examination and is assumed to reflect how finely innervated an area of skin is.
75912725|NCT05692791|Diagnostic Test|Semmes-Weinstein monofilament test|Semmes-Weinstein monofilament test is used to assess light touch sensations.
75912726|NCT05686902|Other|CLEANING SOLUTION|The difference in peristomal skin integrity between the groups will be examined.
75774779|NCT03729310|Device|Nasopore|"This packing' is a sponge-like material which dissolves while releasing triamcinolone."
75621392|NCT02499562|Drug|Hydronidone|The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
75774780|NCT05666440|Procedure|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.|A superior limbal-based conjunctival flap and a paracentesis. A superficial rectangular scleral flap 4×4 mm was fashioned and dissected forward toward the limbus. A deep sceral flap (2×2 mm) was then created toward the limbus underneath the superficial flap exposing the scleral spur and deroofing SC. Viscoelastic (Healon GV, Pfizer, NY) was injected (using a standard 30 G viscocanalostomy cannula) into the ostia of SC Then, the 5/0 polypropylene suture tip was cauterized into a blunt tip (to ensure atraumatic probing of SC). The tip was inserted into the left ostium of SC using a microsurgical forceps and advanced through the whole circumference of the canal. When the tip presented to the right ostium the AC was filled with a viscoelastic through the paracentesis and traction was applied to approximate both ends of the 5/0 polypropylene suture, thus creating a visco-360-degree trabeculotomy.
75774781|NCT05666440|Procedure|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.|A fornixbased conjunctival incision followed by creation of a partial thickness (about 50% thickness) triangular (4×4×4 mm) scleral fap, followed by localization of Schlemm's canal by radial incisions straddling the limbus. High viscosity sodium hyaluronate (Healon GV, Pfzer) was then slowly injected into both ends of Schlemm's canal. Trabeculotomy was completed using the standard Harm's trabeculotome (Geuder Instruments), the scleral fap was then secured tightly with interrupted 10/0 Nylon sutures and conjunctival closure ensued.
75774782|NCT03729076|Other|Crystalloid|Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
75621393|NCT02499562|Drug|Placebo|
75466051|NCT01905059|Drug|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
75621394|NCT02499562|Drug|Entecavir|
75912731|NCT05678790|Other|Passive Stretching|Sustained passive stretching of hamstring, tendo-achilles, and adductors 10 (30 s, with three repetitions, five times per week)
75912732|NCT05678790|Other|Mobilization|Grade four mobilizations is a stretching motion performed at the talocrural joint with anterior-posterior gliding. Mobilization was performed once a day, 6 times a day, and 5 times a week, only on both deformed feet of the older sibling
75320294|NCT00513461|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
75466052|NCT01905072|Other|Education Home Visits|"Intervention will include educational home visits on:~Growth monitoring and feedback~Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.~Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.~Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.~Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby."
75912733|NCT05678790|Other|Muscle strengthening|Abdominal muscle strengthening exercises were given to both siblings once a day, 10 times a day, 5 times a week. In the supine position, the patients were asked to lie on their knees with the knees flexed. The hip extensors were trained in the prone position on the bed by resisting hip extension
75912734|NCT05678790|Other|Balance and Coordination|"The following exercises were applied 5 times a week, with 1o repetition once a day.~Standing on one leg in front of the mirror,~Tandem walking,~Rhythmic Dynamic Stabilization,~Swiss ball sitting (eyes open and closed),~Counting the alphabet or numbers while marching"
75936365|NCT02435654|Drug|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
75936366|NCT02435498|Other|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
75621395|NCT02877654|Procedure|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
75621396|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program.
75320295|NCT00513461|Other|placebo|Given PO
75320296|NCT00513461|Other|laboratory biomarker analysis|Correlative studies
75621397|NCT04304430|Drug|Dapagliflozin|Initiation of dapagliflozin according to clinical indication
75621398|NCT04304430|Drug|DPP-4 inhibitor|Initiation of DPP-4i according to clinical indication
75621399|NCT04216966|Device|Control group|No intervention was given
75621400|NCT04216966|Device|Gracey Curette|Lingual surface of tooth was debrided by Gracey Rigid curette
75320297|NCT00513461|Other|immunoenzyme technique|Correlative studies
75320298|NCT00513461|Other|high performance liquid chromatography|Correlative studies
75320299|NCT00627367|Drug|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
75320300|NCT00627367|Drug|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
75466053|NCT01905085|Device|No intervention|
75621401|NCT04216966|Device|After Five|Lingual surface of tooth was debrided by After Five Rigid curette
75621402|NCT04216966|Device|Mini Five|Lingual surface of tooth was debrided by Mini Five Rigid curette
75774783|NCT03729076|Other|Colloid|Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
75774784|NCT03728998|Other|Passive leg raise (PLR)|"A PLR will simulate an autotransfusion of 250-300 cc.~1. Starting in semi-succumbed position (45 degree head-up)~2. PLR is performed by lowering head-end and putting a for this purpose designed device of 45 degrees under the patients legs. The PLR is non-invasive."
75912735|NCT05676606|Device|Remote 1-minute single-lead electrocardiogram (ECG) monitoring in cancer patients after the first polychemotherapy cycle.|Recording of the ECG using smart-phone at rest, 15 minutes before registering ECG patient should not smoke,having tea, coffee, alcohol. During the ECG recording hands should be fixed to avoid poor quality. Patient sitting on a char with tow hands fixed on a table holding electrocardiograph with index fingers placed at the ECG electrode (left) and at the photoplethysmograph sensor(right).ECG signals are recorded from the fingers using first standard ECG lead. After registration, all ECG and photoplethysmography data will be sent to the server. The data will be automatically compared with a standard for data quality, after that the data will be sent to cardiologist. If quality will be not sufficient, the data will be deleted and the doctor will contact the patient to solve the quality issue. Thereafter, the parameters will be carried out by cardiologist, on the basis of which value of ECG monitoring will be estimated.
75912736|NCT05673070|Dietary Supplement|Ritual Epre Multivitamin-mineral supplement|The Ritual Epre supplement uses methyl folate instead of folic acid and has higher vitamin D and biotin contents compared to the control supplement.
75936367|NCT02435498|Other|Video|The online video will contain the same information within the website.
75936368|NCT02435498|Other|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
75936369|NCT04830605|Behavioral|Internet-based treatment|The intervention is an internet-based psychotherapy treatment with eight modules based on acceptance and commitment therapy and with written therapist contact through eight weeks.
75466054|NCT01905098|Other|Sauna Detoxification Protocol|"All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment."
75621403|NCT02875002|Drug|volasertib|Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m^2, is schedule to increase to 100mg/m^2, and be administered on days 1 and 8 of each 28-day cycle.
75936370|NCT02440490|Behavioral|Computerised cognitive training|
75320301|NCT01670864|Behavioral|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
75320302|NCT01670864|Behavioral|SMS intervention group|The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
75466055|NCT01905098|Other|Observation Sessions|All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
75466056|NCT01905111|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
75320303|NCT04387981|Drug|[14C]-orvepitant|Oral solution of [14C]-orvepitant
75320304|NCT03154892|Procedure|Intracameral injection|Intracameral Conbercept injection for the treatment of NVG
75320305|NCT03154892|Procedure|Intravitreal injection|Intravitreal Conbercept injection for the treatment of NVG
75320306|NCT00559013|Device|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
75320307|NCT03154736|Other|Interview|Individual interview and group interview Socio-economic questionnaire
75621404|NCT02875002|Drug|belinostat|Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m^2 , is scheduled to increase to 1000 mg/m^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
75621405|NCT02749396|Drug|Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
75774785|NCT03728998|Other|Clearsight non-invasive hemodynamic monitoring system|3 baseline readings will be done for CO, CI, SV and SVR, separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CO, CI, SV and SVR will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CO, CI, SV and SVR is done. Then all patients will receive a fluid challenge of 500cc natriumchloride 0.9% IV, considered as normal treatment/ common practice in our ED. 120 seconds after finishing the fluid challenge the final reading of CO, CI, SV and SVR is done.
75774786|NCT03733522|Procedure|Rubber dam isolation|Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration
75774787|NCT03733522|Procedure|Relative isolation|No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
75936371|NCT02440490|Behavioral|Video watching|
75936372|NCT03186014|Device|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
75621406|NCT02749396|Drug|Extavia (interferon beta-1b), Novartis Pharma AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
75774788|NCT03731650|Procedure|maxillary sinus lift|non grafted maxillary sinus floor augmentation with simultaneous implant placement
75774789|NCT03605836|Drug|Centanafadine SR|100 mg, BID, oral tablets
75774790|NCT03605836|Other|Placebo|BID, oral tablet
75774791|NCT03605836|Drug|Centanafadine SR|200 mg, BID, oral tablets
75320308|NCT05622305|Behavioral|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
75466057|NCT01905124|Drug|CF101|CF101 1 mg tablets orally every 12 hours for 24 weeks
75466058|NCT01905124|Drug|Placebo|Matching placebo tablets orally every 12 hours for 24 weeks
75466059|NCT01905137|Drug|Intervention-Botulinum Toxin Type A|Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
75466060|NCT01905137|Drug|placebo|
75466061|NCT01905150|Drug|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, and Oxaliplatin
75466062|NCT01905150|Drug|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
75466063|NCT01905150|Dietary Supplement|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
75621407|NCT02749396|Drug|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
75621408|NCT02749396|Drug|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
75621409|NCT02749396|Drug|Avonex (interferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
75621410|NCT02749396|Drug|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
75621411|NCT02749396|Other|No MSDMDs therapy (control)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
75621412|NCT04305132|Device|Electroconvulsive therapy|Thymatron System IV electroconvulsive therapy device
75621413|NCT00627120|Drug|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
75621414|NCT02749162|Drug|Dexamethasone phosphate|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
75621415|NCT02749162|Drug|Paracetamol|After the block regression, at the first analgetic request the patients received the analgesia protocol
75774792|NCT03605680|Drug|Centanafadine SR|100 mg, BID, oral tablets
75774793|NCT03605680|Other|Placebo|BID, oral tablet.
75774794|NCT03605680|Drug|Centanafadine SR|200 mg, BID, oral tablets
75774795|NCT03728764|Other|Preterm infant formula|Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
75774796|NCT03733288|Behavioral|Education and training sessions|Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
75466064|NCT01905163|Procedure|Tumor Debulking Surgery by laparoscopy|
75466065|NCT01905176|Other|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
75621416|NCT02749162|Drug|Morphine|After the block regression, at the first analgetic request the patients received the analgesia protocol
75621417|NCT02749162|Drug|Lidocaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
75621418|NCT02749162|Drug|Ropivacaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
75621419|NCT02874612|Other|Psychosocial Survey Questionnaires|Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
75621420|NCT02041234|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
75774797|NCT03733288|Behavioral|Support emails|Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.
75936373|NCT02440412|Other|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
75936374|NCT02440412|Other|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
75774798|NCT03733288|Behavioral|Team leader training|Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.
76072995|NCT00594022|Device|"Electric stim of the Vestibular Nerve - VirtuSom - SHAM"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
75621421|NCT02041234|Drug|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily
75320309|NCT00627679|Drug|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
75320310|NCT00627679|Drug|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
75320311|NCT00627679|Drug|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
75320312|NCT00627679|Drug|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
75621422|NCT02041234|Drug|Xenical|Xenical: Up to 120 mg tds
75774799|NCT03733288|Device|Height-adjustable workstation|After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
75774800|NCT03728686|Other|Different given time|Fentanyl 2mcg/kg (F) was given at either 1,2,3 minutes before intubation
75466066|NCT01905176|Other|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
75466067|NCT01905176|Other|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 & 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 & 2
75466068|NCT01905189|Procedure|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
75621423|NCT02041234|Drug|SGLT2 inhibitors|SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
75621424|NCT02041234|Drug|DPP-4 Inhibitors|Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
75621425|NCT04305210|Drug|F-18 PMPBB3|In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
75621426|NCT04305210|Drug|18F-florbetapir|18F-florbetapir
75774801|NCT03728530|Other|Deep Breathing exercises|"In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable."
75320313|NCT03159884|Drug|Conbercept|
75320314|NCT00514709|Biological|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
75320315|NCT00514709|Biological|DTaP-HB-PRP~T vaccine|0.5 mL, IM
75320316|NCT00514709|Biological|Oral Polio Vaccine|Oral co-administered with study vaccine.
75320317|NCT01670942|Other|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
75320318|NCT03154814|Drug|ulinastatin|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
75320319|NCT03154814|Drug|control|conventional CPB was applied without ulinastatin treatment
75466069|NCT01905202|Drug|Secretrol|
75466070|NCT01905215|Biological|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
75320320|NCT00561431|Device|Standard dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr
75320321|NCT00561431|Device|High dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
75320322|NCT01671020|Drug|Fimasartan|Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
75320323|NCT01671020|Drug|Fimasartan|Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
75466071|NCT01905215|Biological|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
75621427|NCT04217824|Procedure|pilonidal sinus excision|Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.
75320324|NCT03154970|Device|Craniocervical flexion training|The cervical stabilization will be performed with craniocervical flexion training with two weekly sessions for 6 weeks
75774802|NCT03728452|Procedure|Trophic Nutrition|"According to previously published studies of Trophic Nutritions in critically ill patients, an energy goal of 20-30% estimated caloric needs of 20-30 kcal / kg and a protein intake of 1.2 to 2.0 g / kg / day of proteins will be established. at most 72 hours after the start of nutritional therapy.~The rhythm of initiation and increase of enteral contributions will be at the discretion of each participating ICU. Prokinetic or parenteral nutrition (PN) complementary will not be used routinely, leaving its indication at the discretion of the responsible physician.~A hyperproteic nutritional formula (10 g / 100 ml) will be used, with a caloric intake of 1.2 kcal / ml and a non-protein kcal / nitrogen ratio of 52: 1. TN will be administered over 23 hours each day by continuous infusion pump. The head of the patient's bed will rise above 30° as much as possible to reduce the risk of aspiration. The Gastric Residue Volume (GRV) will be measured every 24 hours."
75621428|NCT02749006|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
75621429|NCT02749006|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
75621430|NCT01072344|Drug|Chamomile (Matricaria recutita)|500 mg 3 times daily
75320325|NCT00515021|Drug|Eplerenone (Morning)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
75466072|NCT01905215|Biological|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
75466073|NCT01905215|Biological|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
75466074|NCT01905215|Biological|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
75466075|NCT01905215|Biological|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
75774803|NCT03728374|Drug|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle)
75774804|NCT03728296|Biological|islet body|Transplanting islet bodies under the diaphragm
75912737|NCT05673070|Dietary Supplement|control MVI|The control MVI supplement is a commercially available product from another brand. Since this MVI doesn't contain DHA, a pill of DHA will also be provided to participants in this group.
75912738|NCT05672654|Diagnostic Test|Blood draw|Blood draw
75912739|NCT05672602|Diagnostic Test|Measurement of ncRNAs and cytokines|Measurement of lncRNAs in PBMCs samples and miRNAs in plasma samples.
76072996|NCT00626626|Drug|Clofar, Cyclophos, Alemtuzumab|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
76072997|NCT00626626|Drug|Clofar, Cyclophos,Alemtuzumab(Ph II)|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
76072998|NCT00673114|Biological|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
75320326|NCT00515021|Drug|Eplerenone (Night-time)|Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
75320327|NCT03159650|Device|intravascular ultrasonography|intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
75320328|NCT03159728|Behavioral|Educative intervention:|"In the induction of the new group members are present, including caregivers who start the program and those who coordinated.~In Module I: to strengthen the knowledge of the situation and the people involved in care.~In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.~In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self."
75466076|NCT01905215|Drug|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
75466077|NCT01905228|Drug|CBL0137|"All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops"
75466078|NCT01905280|Procedure|Non-resorbable membrane|The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
75621431|NCT02695732|Drug|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
75912740|NCT05655962|Other|STARS|STARS is a structured framework for assessment of rehabilitation and sicklisting, applied by primarily the rehabilitation coordinators working at the primary health care centers.
75912741|NCT05654532|Drug|AC699|Participants will receive AC699 orally daily in 28-day cycles.
75936375|NCT05293535|Other|Prognostic study|No intervention... as it is a prognostic study and no intervention done on patients.
75936376|NCT02435420|Device|EMPERION Modular Primary Stem|Primary total hip arthroplasty using the EMPERION Modular Primary Stem
75621432|NCT02695732|Device|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
75320329|NCT03159494|Other|High-Intensity Training|"8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed"
75320330|NCT00515177|Behavioral|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
75774805|NCT03572218|Behavioral|BWL|The BWL sessions will be based on the Diabetes Prevention Program (DPP) manual. A diet of 1200-1499 calories per day will be prescribed for participants < 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 12 weeks will include self-monitoring, stimulus control, slowing eating, social support, cognitive restructuring, portion sizes, and goal-setting. Those during weeks 13-26 will focus on continued self-monitoring and skills required for weight loss maintenance and relapse prevention. Physical activity will be prescribed at a level consistent with data showing that >250 min/wk is associated with improved long-term weight loss. BWL sessions will last 60 minutes.
75774806|NCT03572218|Behavioral|BIAS|Following 60 minutes of BWL treatment, the BIAS intervention will devote 30 minutes to stigma-related content. Session topics will include: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to weight management. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies in the context of weight management.
75774807|NCT03728218|Device|Contact lenses (Orthokeratology)|Contact lenses
75621433|NCT02751268|Drug|Normal Saline|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
75774808|NCT03728218|Device|Contact lenses (Soft Multifocal)|Contact lenses
75912742|NCT05653739|Behavioral|Mindfulness Based Stress Reduction Intervention|MBSR is Mindfulness based intervention designed by Kabat-Zinn (1990) in order to deal with the stress and other psychological issues among individuals. This has been very effective intervention across different cultures . In this 8 week intervention participants will be given some home tasks to practice for at least 40 minutes a day.
75912743|NCT05647759|Behavioral|HEART Camp Connect|Once eligible and enrolled, participants will aim to complete 150 minutes of moderate-intensity exercise a week with the help of a virtual exercise coach
75320331|NCT00515177|Drug|eszopiclone|"One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use"
76072999|NCT00626782|Drug|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
75466079|NCT01905280|Procedure|Acellular dermal matrix|The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
75466080|NCT01905293|Other|Feeding Study|
75621434|NCT02751268|Drug|Ropivacaine|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
75466081|NCT01905306|Procedure|computer guided implant planning|
75621435|NCT02751190|Procedure|Totally ExtraPeritoneal (TEP) repair|
75621436|NCT02751190|Procedure|TransAbdominal PrePeritoneal (TAPP) repair|
75621437|NCT02751190|Procedure|Open anterior mesh repair|
75466082|NCT01905306|Procedure|free hand implants placement|
75621438|NCT02751190|Procedure|Open Anterior Non Mesh|
75621439|NCT02751190|Procedure|Combined anterior and posterior repair|
75621440|NCT02751190|Procedure|Open preperitoneal mesh repair|
75621441|NCT02748772|Drug|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
75320332|NCT03159806|Device|Microdialysis sampling|Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
75621442|NCT02748772|Drug|Pure chemotherapy（Xelox）|"CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops."
75621443|NCT02750956|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
75621444|NCT02748850|Biological|blood sample|a blood sample 20 milliliter
75621445|NCT02748850|Biological|Stem cell donation|The volume of stem cells remained in the tube is recovered
75621446|NCT02747056|Other|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
75320333|NCT00583375|Device|Augment® Bone Graft|Augment® Bone Graft
75466083|NCT01905319|Other|Blood collecting for storage of samples|
75466084|NCT01905332|Other|Literacy promoting home based program|The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
75466085|NCT01905332|Other|Literacy Toolkit|Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
75466086|NCT01905345|Procedure|Training|
75466087|NCT01905371|Drug|Dextroamphetamine|
76073000|NCT00626782|Drug|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
75621447|NCT02747056|Other|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
75774809|NCT03731494|Biological|Nickel oral hyposensitization treatment|Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
75774810|NCT00111813|Drug|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
75774811|NCT00111813|Drug|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
75774812|NCT00118287|Drug|azacitidine|Given SC or IV
75774813|NCT00118287|Biological|etanercept|Given SC
75621448|NCT02747056|Other|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
75774814|NCT03965247|Drug|Lithium|
75774815|NCT03965247|Other|Placebo - Rayotabs|
75774816|NCT01079715|Drug|Propranolol|"Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~Atropine.~Isoproterenol hydrochloride (isoprenaline.~Terlipressin.~Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular)."
75774817|NCT00130689|Drug|Cetuximab|
75774818|NCT01326585|Drug|Dexamethasone Sodium Phosphate Injection|8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
75774819|NCT01326585|Drug|Saline Injection|2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
75621449|NCT01071954|Biological|Romiplostim|Administered by subcutaneous injection once a week.
75621450|NCT02746978|Other|Peer directed education|No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators
75774820|NCT03964935|Drug|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
75774821|NCT03964935|Drug|Minocycline HCl 1mg Oral Powder|Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
75912744|NCT05645822|Other|Screen&treat|Study participants will be tested with an RDT to prove the presence of antibodies against Trypanosoma brucei gambiense. Should the RDT be positive, they will be offered the 10-day treatment with fexinidazole, and an additional blood sample will be taken for the post hoc confirmation of the disease.
76088867|NCT04467606|Behavioral|a discharge planning using the strategy of motivational interviewing|The experimental group will receive a discharge planning which use the strategy of motivational interviewing. The discharge planning will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, and then each month till one year.
75774822|NCT03964935|Other|Distilled water|Used to irrigate periodontal pockets after SRP
75774823|NCT03605212|Drug|Febuxostat|Intervention is orally administered to patients in this arm.
75774824|NCT03603652|Device|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound to confirm disease staging.
75774825|NCT00117507|Drug|Deferasirox|
75936377|NCT02435342|Drug|dalazatide|Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
75936378|NCT02435342|Drug|placebo|placebo, Subcutaneous injection twice per week for a total of 9 doses
75320334|NCT00583375|Procedure|Standard of Care|Autologous Bone Graft
75936379|NCT05571527|Biological|Platelet Rich Plasma treatment|Patients receive platelet-rich plasma via injection into the vaginal area.
75936380|NCT05571527|Drug|Vaginal Hyaluronic Acid supplement|Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
76088868|NCT02717130|Drug|Aripiprazole|
75320335|NCT04348760|Behavioral|Rotation Diet|Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
75320336|NCT03078218|Diagnostic Test|Pulse oximetry|The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
76073001|NCT00594256|Drug|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
75466088|NCT01905371|Other|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
75621451|NCT02746978|Other|Patient Engagement Portal|No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
75320337|NCT04664881|Device|SmartHeart Device|A body-worn device that allows an individual to immediately transmit a 12-lead ECG from anywhere and anytime, using a smartphone application to a physician's office, hospital or monitoring center where designated on-call staff interpret the ECG and make recommendations.
75774826|NCT03731416|Procedure|GBR by xenograft and autogenous bone|Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
75774827|NCT03621046|Drug|Zolpidem|Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.
75774828|NCT03621046|Other|Placebo|Placebo
75320338|NCT03154502|Diagnostic Test|Urinary sodium excretion|Urinary sodium and potassium were measured using the Ion-Selective Electrode (ISE) indirect Na-K-Cl for Gen.2 (Roche Diagnostic, Switzerland).
75774829|NCT03965013|Drug|NNC0268-0965|2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
75912745|NCT05628649|Behavioral|Teaching Kitchen Collaborative Curriculum|"Participants in the intervention arm will first attend 16 weeks of intensive 2-hour classes covering hands-on cooking skills, dietary recommendations (as described within the Harvard Healthy Eating Plate), mindfulness and stress reduction skills, activity and movement techniques, and tools for behavior change. Next, they will attend monthly booster classes for 8 months, with a final assessment for the sustainability of outcomes at 18 months. Sessions will be taught by a combination of a chef educator, dietitian, health coach, or medical doctor.~The study will consist of 2 cohorts of individuals from 4 teaching kitchen program institutions. Each institution will run one-two cycles of the program with each cycle including both a treatment and control group. Each individual cohort will consist of a maximum of 80 individuals; with 40 block-randomized to the intervention and 40 in the control group receiving normal standard of care (followed by their PCP)."
75912746|NCT05612581|Drug|VIR-3434|VIR-3434 given by subcutaneous injection
76073002|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
75621452|NCT04216888|Drug|Ketamine Hydrochloride|Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device
75621453|NCT02746744|Drug|Rituximab|Infusion of Mabthera/Rituximab every 6 months
75774830|NCT03965013|Drug|Placebo|A single dose of placebo given in Part 1
75774831|NCT03965013|Drug|insulin glargine|Insulin glargine given at a fixed dose level of 0.5 U/kg
75774832|NCT03603496|Behavioral|Transitional Tobacco Care Management (TTCM)|PTCM will provide sustained care after discharge by offering (1) 8 weeks of nicotine replacement therapy at no cost provided at hospital discharge and (2) up to 7 proactive contacts over 3 months delivered by automated IVR call, supplemented by text messaging and email (patient choice). At each contact the patient is offered a return call from the hospital-based tobacco coach who offer counseling, medication advice, and coordination of care with the patient's outpatient health care team.
75774833|NCT03603496|Behavioral|eReferral to State Tobacco Quitline (QL)|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the Quitline will be included in the patient's medical chart.
75774834|NCT03603496|Drug|Nicotine replacement therapy|Up to 8 weeks of nicotine replacement therapy provided at no cost to the patient.
75912747|NCT05612581|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
75912748|NCT05612581|Drug|TDF|TDF given orally
75912749|NCT05612581|Drug|PEG-IFNα|PEG-IFNα given by subcutaneous injection
76073003|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
76073004|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
76073005|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
75320339|NCT00628147|Device|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
75320340|NCT01671254|Dietary Supplement|FishOil|
75320341|NCT01671254|Dietary Supplement|CBE75|
75320342|NCT01671254|Dietary Supplement|CBE150|
75320343|NCT01671254|Dietary Supplement|placebo|
75466089|NCT01905371|Drug|Placebo|
75466090|NCT01905410|Drug|VVZ-149 Injection|VVZ-149 in water for injection
75466091|NCT01905410|Drug|placebo|water for injection
75466092|NCT01905449|Behavioral|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
75466093|NCT01905462|Other|Data Collection|Analyses of data collected within the CPRD GOLD database.
75320344|NCT04638283|Behavioral|Goal Attainment Scaling|Individual goals will be formulated and measured by Goal Attainment Scaling (GAS). GAS provides a method for quantifying the attainment of individualized goals, typically set in cognitive rehabilitation. Different levels of outcomes for each goal are operationalized in a five-point scale and given a numeric value. For each individual goal, minus two refers to the goal attainment much less than expected, minus one refers to a little less than expected, zero refers to expected outcome, plus one refers to a little bit better than expected and plus two refers to goal attainment much better than expected. The participants can establish as many goals as desired. Outcomes can be summed within different patient goals, as well as across patients to assess overall outcome of treatment outcomes.
75320345|NCT03154424|Procedure|External fixation in treatment the distal radius fracture|Compare two techniques
75774835|NCT03964389|Other|Therapeutic Neuroscience Education (TNE)|A talk on Neuroscience Education (EN). This intervention aims to provide information in a clear and simple way to the participants so that through it the patients may be able to modify their attitude towards pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without damage to the tissues or with damage that justifies the perceived disproportion of pain.
75774836|NCT03639844|Biological|rivogenlecleucel|BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.
75912750|NCT05600374|Device|Bossdevice|The bossdevice is a real-time digital signal processor consisting of hardware and software algorithms. It is designed to read-in a real-time raw data stream from a bio-signal amplifier (electroencephalography, EEG), to continuously analyze this data and to detect patterns based on oscillations in different frequencies. When such a specific bio-signal pattern is detected, the device indicates this through a standard output port. This enables a connected device to know with millisecond accuracy when a specific biosignal pattern occurs.
75912751|NCT05597774|Other|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
75912752|NCT05597774|Other|Inspiratory + expiratory muscle training sham group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
75912753|NCT05597774|Other|Exercise training program|Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.
75912754|NCT05593341|Other|Opioid education in person|"The presentation and handouts contain information regarding the following topics:~Reviewing opioids and strategies for analgesia~Defining and identifying opioids~Goals for postoperative pain management and utilizing opioids to treat pain~Alternative modes of treating pain~Regional anesthesia/analgesia defined~Side effects and risks of opioids~Common side effects of opioids~Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~Proper use and handling of opioids~Safe practices when taking opioids~Weaning off opioids~Safe storage and disposal of opioids"
76073006|NCT00673738|Drug|Cetuximab|"Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted."
75912755|NCT05593341|Other|Opioid education via video|"The video and handouts contain information regarding the following topics:~Reviewing opioids and strategies for analgesia~Defining and identifying opioids~Goals for postoperative pain management and utilizing opioids to treat pain~Alternative modes of treating pain~Regional anesthesia/analgesia defined~Side effects and risks of opioids~Common side effects of opioids~Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~Proper use and handling of opioids~Safe practices when taking opioids~Weaning off opioids~Safe storage and disposal of opioids"
75912756|NCT05590806|Other|Direct composite build-ups|Direct composite build-ups application
75912757|NCT05590364|Device|Profhilo® Body|Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.
76088869|NCT04947384|Diagnostic Test|To discern micro-RNA specific for right and left heart induced PH|While undergoing other procedures, the investigators will be collecting a total of three blood samples. The first sample will be obtained on arterial cannulation before the initiation of the intervention, the second sample will be collected upon the end of the procedure prior to leaving the procedure room, and the third sample will be collected on the day of discharge from the hospital.
76088870|NCT02256696|Drug|PA-824|200 mg QD
76088871|NCT02256696|Drug|Rifampin|600 mg QD
75320346|NCT04405310|Biological|Convalescent Plasma of patients with COVID-19|Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.
75320347|NCT04405310|Other|placebo (hartmann plus albumine)|use of albumin 20% in 250cc of Hartmann solution
75320348|NCT01671410|Drug|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
75774837|NCT03639844|Drug|rimiducid|Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD
75774838|NCT03603028|Device|Exergaming|Mixed Reality Gaming for Chronic Low Back Pain
75774839|NCT03602482|Behavioral|Standing|Participants will stand and complete cognitive tests.
75774840|NCT03602482|Behavioral|Supine|Participants will complete cognitive tests while supine.
75774841|NCT00096135|Biological|filgrastim|given subcutaneously (SC)
75774842|NCT00096135|Drug|cyclophosphamide|IV over 15-30 minutes
75774843|NCT00096135|Drug|cytarabine|IV over 3 hours twice daily
75774844|NCT00096135|Drug|daunorubicin hydrochloride|IV over 15 minutes
75774845|NCT00096135|Drug|dexamethasone|oral twice daily
75912758|NCT05590312|Other|general anesthesia|All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.
75320349|NCT01671410|Drug|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
75466094|NCT01905462|Biological|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
75621454|NCT02746744|Drug|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
75621455|NCT02746744|Drug|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
75621456|NCT02748304|Other|control|just follow up
75621457|NCT02748304|Drug|sorafenib|sorafenib 400mg bid po
75621458|NCT02748304|Drug|aspirin|aspirin 100mg qd po
75621459|NCT02748382|Other|higher chloride crystalloid|Normal saline
75621460|NCT02748382|Other|higher chloride albumin|5% Octalbin
75621461|NCT02748382|Other|lower chloride crystalloid|Ringers Lactate
75621462|NCT02748382|Other|lower chloride albumin|5% Plasbumin
75621463|NCT02746822|Other||
75774846|NCT00096135|Drug|etoposide|IV over 1 hour
75912759|NCT05576857|Other|Doppler ultrasonography|All volunteers will be monitored with cerebral oximeter, asked to answer the Montreal cognitive assessment test and cervical blood flow values and optic nerve sheath diameter will be determined with Doppler ultrasonography.
75912760|NCT05575492|Biological|mRNA-1647|Sterile liquid for injection
76088872|NCT02256696|Drug|Rifabutin|300 mg QD
76088873|NCT02256696|Drug|Pyrazinamide|25mg/kg QD
75320350|NCT01671566|Behavioral|Home based interval training|The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
75320351|NCT02676752|Procedure|Medical Examination|Evaluation of secondary lymphedema and fibrosis (LEF) status
75320352|NCT02676752|Other|Questionnaire Administration|Completion of questionnaires
75466095|NCT01905475|Drug|POL6326|
75466096|NCT01905475|Drug|Placebo|
75621464|NCT02746666|Behavioral|Pharmacist's behavioral intervention|Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
75774847|NCT00096135|Drug|leucovorin calcium|rescue IV over 24 hours
75774848|NCT00096135|Drug|mercaptopurine|oral
75774849|NCT00096135|Drug|methotrexate|intramuscularly (IM)
75774850|NCT00096135|Drug|pegaspargase|intramuscularly (IM)
75466097|NCT01905501|Drug|Balanced anesthesia|Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
75466098|NCT01905501|Drug|Total intravenous anesthesia|Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
75466099|NCT01905514|Device|internet mobile application|
75621465|NCT02746900|Procedure|Cervical cerclage|McDonald cervical cerclage
75621466|NCT04216654|Diagnostic Test|ELISA (enzyme-linked immunosorbent assay)|ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.
75774851|NCT00096135|Drug|therapeutic hydrocortisone|
75774852|NCT00096135|Drug|vincristine sulfate|given IV
75774853|NCT00096135|Radiation|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
75912761|NCT05575492|Other|Placebo|0.9% sodium chloride injection (normal saline)
75912762|NCT05569512|Drug|Uproleselan|Administered by intravenous infusion
75912763|NCT05569512|Drug|Fludarabine|Administered by intravenous infusion
75912764|NCT05569512|Drug|Clofarabine|Administered by intravenous infusion
75912765|NCT05569512|Drug|Busulfan|Administered by intravenous infusion
76088874|NCT02256696|Drug|Ethambutol|15mg/kg QD
76088875|NCT02256696|Drug|Isoniazid|300 mg QD
76088876|NCT02464488|Other|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
75466100|NCT01905527|Other|Standard Services of Group A (Group A1)|Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals
75466101|NCT01905527|Other|Customized Services of Group A (Group A2)|In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.
75466102|NCT01905527|Other|Group B|Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
75466103|NCT01905579|Procedure|Paracentesis of the anterior chamber|Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
75466104|NCT01905605|Drug|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
76088877|NCT02331498|Drug|Pazopanib|Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
76088878|NCT02192502|Drug|human albumin 5%|
75320353|NCT02676752|Procedure|Shear Wave Elastography|Undergo ultrasound shear wave elastrography
75621467|NCT02748148|Other|Medication therapy management|Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
75621468|NCT02746432|Drug|Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
75621469|NCT02746354|Other|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
75621470|NCT02746276|Drug|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
75774854|NCT00116805|Drug|TDF|300 mg tablet administered orally once daily
75774855|NCT00116805|Drug|ADV|10 mg tablet administered orally once daily
75774856|NCT00116805|Drug|TDF placebo|Tablet administered orally once daily
75774857|NCT00116805|Drug|ADV placebo|Tablet administered orally once daily
75774858|NCT00116805|Drug|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
75774859|NCT00116649|Drug|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
75912766|NCT05561959|Other|topical glyceryl trinitrate gel|topical nitroglycerin medication were treated with 1 gr nitroglycerin 2% gel
75912767|NCT05561959|Other|Eccentric exercises|stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee).
76088879|NCT02192502|Drug|HES 130/0.4 (Voluven)|
76088880|NCT01781429|Drug|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
75320354|NCT03159338|Biological|Platelet rich fibrin|Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
75320355|NCT03159338|Biological|Placebo|In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
75774860|NCT01080651|Drug|Voriconazole|Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
75774861|NCT01082913|Device|SSE|Use of SSE or not use of SSE
75912768|NCT05558228|Device|FloPatch FP120|FloPatch FP120 is an FDA 510(k) cleared device indicated for the non-invasive assessment of blood flow in the carotid artery by medical professionals, such as physicians and nurses. FloPatch uses ultrasound and the Doppler effect to assess blood flow.
75320356|NCT00630253|Biological|Anti-Thymocyte Globulin|30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
75320357|NCT00630253|Drug|Cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
75320358|NCT00630253|Drug|Fludarabine|35 mg/m^2 intravenously (IV) on days -6 through -2.
75320359|NCT00630253|Procedure|Hematopoietic Stem Cell Transplantation|Bone marrow or umbilical cord blood infusion on day 0.
75320360|NCT00630253|Drug|Methylprednisolone|Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
75912769|NCT05546437|Device|Ion Endoluminal System|Ion Endoluminal dye marking procedure for pulmonary nodule
76088881|NCT01773473|Drug|Insulin Lispro Mix25|Administered SC
76088882|NCT01773473|Drug|Insulin Lispro Mix50|Administered SC
75320361|NCT00630253|Drug|Filgrastim|5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count > or = 2.5 x 10^9/L
75320362|NCT00630253|Drug|Cyclosporine|Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
75320363|NCT00630253|Drug|Mycophenolate Mofetil|Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
75320364|NCT03158948|Drug|MOTREM|Formulated LR12 peptide
75320365|NCT03158948|Drug|Placebo|placebo
75320366|NCT01671722|Drug|Montelukast sodium|Montelukast sodium tablets 10mg
75320367|NCT00584701|Drug|Risperidone|Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
75320368|NCT03158870|Procedure|Surgery complications|Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
75320369|NCT01671878|Other|Reference Glucose|
75320370|NCT01671878|Other|Test Food 1 (Cereal)|
75320371|NCT01671878|Other|Test Food 2 (Biscuit)|
75320372|NCT00630409|Drug|Gemcitabine|800 mg IV day 1 and 8
75320373|NCT00630409|Drug|Doxil|24 mg/m2 every 21 days IV
75320374|NCT01671956|Biological|Bertilimumab|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
75320375|NCT01671956|Biological|Placebo|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
75320376|NCT00630955|Drug|memantine|Memantine 20 mg once per day for 7 days
75320377|NCT00630955|Drug|Memantine|Memantine 40 mg once per day for 7 days
75320378|NCT00630955|Drug|Placebo|Placebo once per day for 7 days
75466105|NCT01905605|Drug|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
75466106|NCT01905566|Drug|Clopidogrel|75mg once a day
75466107|NCT01905566|Drug|Ticagrelor|90mg twice a day
75320379|NCT00584857|Drug|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
75912770|NCT05545813|Dietary Supplement|Probiotic|Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.
76073007|NCT00673738|Radiation|Conformal Thoracic Radiotherapy (CTRT)|"Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC >1,000 and platelets >75,000) required. Patient may be delayed for a max. of 2 weeks. If > 2 week delay occurs, patient will come off study."
75621471|NCT02746276|Drug|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
75621472|NCT05629936|Other|digital interdisciplinary intervention|Digital medication interview, comprehensive medication review, interdisciplinary patient team discussion followed by a MTO-plan, follow-ups
75621473|NCT02747602|Drug|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
76073008|NCT00674206|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
75621474|NCT02747602|Drug|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
75774862|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
75774863|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
75774864|NCT01082991|Other|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
75774865|NCT02531061|Device|HR-pQCT|"The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes."
75774866|NCT01087047|Device|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
75912771|NCT05545813|Dietary Supplement|Placebo|Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
76073009|NCT00674206|Drug|Oxaliplatin|Oxaliplatin 100mg/m^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
76073010|NCT00595270|Biological|IC51|
76073011|NCT00628498|Drug|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
75320380|NCT03153800|Biological|bronchial basal cells|Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
75320381|NCT00585013|Drug|Nitric Oxide|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
75320382|NCT01672034|Procedure|Laparoscopic gastric bypass surgery|
75912772|NCT05544994|Other|Aerobic Exercise Training|Aerobic training will be performed 3 days a week for 12 weeks at 60%-%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.
75912773|NCT05544994|Other|Home exercise program|Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.
76073012|NCT00628498|Drug|Defibrotide|
75320383|NCT01672112|Drug|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
75621475|NCT02747602|Drug|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
75621476|NCT02745964|Device|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
75621477|NCT02745964|Device|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
75621478|NCT02746042|Drug|Sinupret extract coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
75912774|NCT05542303|Drug|ZB001 for injection|Dose Cohort1 (3mg/kg) ZB001 of single IV injection
75912775|NCT05542303|Drug|ZB001 for injection|Dose Cohort2 (10mg/kg) ZB001 of single IV injection
75912776|NCT05542303|Drug|ZB001 for injection|Dose Cohort3 (20mg/kg) ZB001 of single IV injection
75912777|NCT05538143|Other|Comprehensive ED syncope/presyncope management tool|This is a data-only, prospective observational cohort study to validate the performance metrics of the Canadian Syncope Risk Score in a diverse population of patients evaluated in community EDs of a U.S. integrated health care system.
75912778|NCT05537961|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness instruction incorporated in classroom-based curriculum
75912779|NCT05536206|Device|Wireless and continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge with data transmitted in real time to personnel at the hospital. Monitoring will last for a maximum of 72 hours.
75912780|NCT05531799|Procedure|OPTIMIZATION PHASE|"The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could~- identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and"
75912781|NCT05528874|Dietary Supplement|Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes|Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.
75912782|NCT05528874|Dietary Supplement|Crossover: Recipe 4 before recipe 5|"After the assessment of fasting parameters, subjects will consume recipe 4 (chocolate biscuits) and perform a 180 min curve with blood taken at 15, 30, 45, 60, 90, 120, and 180 minutes. In this case, both investigators and patients are blinded to the presence of an additional non-nutritive, non-toxic and without taste encapsulated bitter compound (artemisia absinthium), that could be present in recipe 4 or recipe 5. On the second day (with at least a week gap), patients will consume recipe 5. Questionnaires and a food diary will also be requested for subjects for lunch and dinner."
75912783|NCT05528874|Dietary Supplement|Crossover: Recipe 5 before recipe 4|Same as previous group, but starting with recipe 5
75912784|NCT05518162|Device|InBloom|The Rose Program (RPv2) application will be built for iOS and Android devices (including tablets) and will feature a video-based Learning Management System (LMS) which provides resources for people with postpartum depression to improve their wellbeing. Each InBloom session will contain 4-5 video modules with specific themes contained in each ROSE session which are 3-5 minutes each.
75912785|NCT05518162|Behavioral|ROSE|"ROSE will be offered as a psychoeducational course on adjusting to parenthood by a health professional embedded in the obstetric clinics. There are five 90-minute group sessions which provide interpersonal rationale for the program, a review of the course outline, ground rules for the group, and the signs and symptoms of baby blues and postpartum depression, stress management skills. managing role transitions with an emphasis on transition to motherhood and the development of a support system, identifying types of interpersonal conflicts common around childbirth and techniques for resolving them, skills for resolving interpersonal conflicts and an opportunity to review and reinforce the content of the previous sessions."
75912786|NCT05515744|Procedure|Childbirth|Induction or planned cesarean
75912787|NCT05514548|Drug|INV-202|INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
75912788|NCT05514548|Drug|Placebo|Placebo Matching size and number of tablets
75621479|NCT02746042|Drug|Placebo coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
75621480|NCT02748226|Procedure|endovascular treatment|endovascular treatment
75621481|NCT02747680|Other|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
75774867|NCT01080729|Drug|Recombinant-follicle stimulating hormone (r-FSH)|"The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml [22 micrograms/0.5 ml]; 450 IU/0.75 ml [33 micrograms/0.75 ml]; or 900 IU/1.5 ml [66 micrograms/1.5 ml].~The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG)."
75774868|NCT01080885|Behavioral|Busy Bodies/Better Bites|This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.
75774869|NCT01080885|Behavioral|Healthy Spots/Safe Tots|This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
75774870|NCT03962907|Drug|Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
75774871|NCT03962907|Drug|BACTROBAN® Nasal ong|Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
75320384|NCT01672112|Drug|Codeine|Oral Codeine 60mg 6hrly/prn
75621482|NCT02746198|Other|probiotic dairy drink|
75621483|NCT02746198|Other|acidified milk|
75621484|NCT02745886|Drug|metformin 0.85 twice daily for 6 months|
75621485|NCT02745886|Behavioral|Calorie restriction|
75621486|NCT02747446|Dietary Supplement|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
75621487|NCT02745652|Device|pulsed electromagnetic field|it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
75774872|NCT00083889|Drug|Interferon-alfa|3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
75774873|NCT00083889|Drug|SU011248|50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
75774874|NCT03572062|Biological|Formulation A|RSV vaccine
75774875|NCT03572062|Biological|Formulation B|Adjuvanted RSV vaccine
75774876|NCT03572062|Biological|Formulation C|RSV vaccine
75774877|NCT03572062|Biological|Placebo|Placebo
75774878|NCT03728062|Behavioral|Mindfulness meditation|Guided mindfulness meditation focused on breath sensations, thoughts and emotions.
75774879|NCT03728062|Behavioral|Physical exercise|Cardio exercise at gym like rowing, eliptical, cycling, or running outside.
75774880|NCT03639532|Procedure|COC THA|standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.
75774881|NCT03639532|Procedure|COP THA|standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
75774882|NCT03727828|Diagnostic Test|Patients with heart failure|Participants will have serial blood collection on medical therapy for heart failure
75912789|NCT05504850|Other|Multicultural Health Diet|The food-based components will be similar to the anti-inflammatory diet of the ongoing MHD study (NCT03240406), which emphasizes limiting animal and high saturated fat foods with focus on anti-inflammatory foods/food components specific to the cultural context of the participant. The diet will also be tailored to needs of the CKD population including a focus on lowering sodium intake. The intervention (dietary counseling) will be delivered by experienced kidney disease nutritionist.
76088883|NCT01772693|Device|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
75621488|NCT02745652|Device|Therapeutic ultrasound|Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
75621489|NCT02747524|Other|Vita Mamba peanut butter paste|
75621490|NCT02747212|Device|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
75621491|NCT02747290|Drug|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
75621492|NCT02747368|Device|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
75621493|NCT02745808|Biological|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
75621494|NCT02745808|Biological|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
75621495|NCT02747134|Behavioral|Emotion Regulation and Mindfulness skills|
75774883|NCT03571516|Drug|Teduglutide|SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
75774884|NCT03571516|Other|Standard Medical Therapy|Standard medical therapy will be administered for 24 weeks.
75774885|NCT03571516|Device|Syringe|Teduglutide will be administered using syringe (510k number: K980987).
75774886|NCT03571516|Device|Needle|Teduglutide will be administered using needle (510k number: K021475).
75912790|NCT05495932|Diagnostic Test|blood sample|blood sample taken to measure serum mepolizumab concentration at baseline, 1 month and 6 months during study follow-up
76088884|NCT01772693|Device|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
75774887|NCT03600376|Drug|Ryanodex and Standard of Care|Ryanodex to be administered as a rapid IV push
75774888|NCT03600376|Other|Standard of Care|Body cooling measures and supportive measures
75774889|NCT03961659|Drug|Liraglutid|Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
75774890|NCT03961659|Drug|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
75774891|NCT03961659|Drug|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
75774892|NCT03599362|Drug|Nivolumab + Cabiralizumab|Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.
75774893|NCT03599362|Radiation|Stereotactic Body Radiotherapy (SBRT)|Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
75774894|NCT03741309|Other|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.
75774895|NCT03741309|Other|Calcium sodium phosphosilicate|Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.
75774896|NCT03741309|Other|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
75774897|NCT01083147|Device|FORESEE HOME|Home Monitoring
75774898|NCT03598036|Drug|Voclosporin|"Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).~The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1."
75774899|NCT00082407|Drug|exenatide|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
75774900|NCT00082407|Drug|biphasic insulin aspart|subcutaneous injection, twice daily; titration to target blood glucose level
75774901|NCT03643432|Behavioral|Exercise adherence intervention|Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
75774902|NCT03643432|Behavioral|Usual Care|Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
75912791|NCT05488691|Behavioral|EMDR|The first session consists of recording the patient's history. In the second session the therapist evaluates the presence of coping mechanisms of the patient and, if necessary, suggests extra coping techniques. The following sessions are devoted to the reprocessing process. During these sessions, a target memory is identified and processed using EMDR. After a total of 8-10 sessions, it is expected that the patient will have achieved physiological reconciliation, relieved distress, and the ability to reformulate negative beliefs.
75621496|NCT02745574|Procedure|Combined maneuver|Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
75621497|NCT02745574|Procedure|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
75621498|NCT02745496|Procedure|TRUS Biopsy|Standard of Care Treatment
75621499|NCT02745496|Procedure|TRUS/FUSION Biopsy|Interventional Treatment
75621500|NCT02745730|Other|Glucose|
75774903|NCT03732976|Other|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
75774904|NCT03732976|Other|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
75774905|NCT01083225|Behavioral|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
75774906|NCT01083225|Behavioral|Treatment as usual|Treatment as usual, consultations
75774907|NCT01080963|Drug|Daptomycin|one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
75774908|NCT01080963|Drug|Cefuroxime|1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
75912792|NCT05488691|Behavioral|TAU|treatment as usual for substance use disorders
75912793|NCT05488093|Device|X-sens sensor|"the procedure will include:~7 to 8 sensors (Foot, leg, thigh, pelvis and chest possibly).~5 movements/exercises for the patients, each exercise performed 3 times except walking~Analysis of 20m walking cycle (normal speed, most natural arm movement, 4 return trips of 20m):~Climbing up and down stairs (using the public stairs of the rheumatology access department, 6 steps of 20 cm height, at normal speed, without using the handrail)~Getting up from a chair without the help of hands (start standing, then the patient sits, leans and stands up, feet together, without taking the feet off the floor, using one and the same chair for each patient with a height of 50 cm)"
75912794|NCT05487755|Drug|Tadalafil 20Mg Oral Tablet|Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
75912795|NCT05487755|Drug|Pentoxifylline 400 MG Oral Tablet|Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
75912796|NCT05482633|Other|Inspiratory muscle training (IMT)|Treatment group will perform IMT every day for eight weeks. Initial load is going to be set as the 60% of maximal inspiratory pressure (PImax) and is going to be increased by %10 of the initial load every two weeks.
75621501|NCT02745730|Other|Fructose|
75621502|NCT02745730|Other|Sucralose|
75621503|NCT02745730|Other|Allulose|
75621504|NCT02742142|Other|water as placebo|topical application of water as a placebo in the control arm
75621505|NCT02742142|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
75621506|NCT02742064|Other|Cogito Companion Mobile Phone Application|
75621507|NCT00636298|Drug|Bevacizumab, cetuximab|"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks"
75621508|NCT05629624|Dietary Supplement|Chickpea based RUSF|One group will receive locally produced RUSF, approximate at 50-100 kcal/kg/day, two of 50g packets daily (42) until anthropometric recovery ( WHZ > - 1SD) has been achieved or for maximum 3 months then immediately 1 packet / day SQLNS will be given throughout the study till the end of 2 years of follow-up.
75320385|NCT00632281|Radiation|Stereotactic Body Radiation Therapy|Prescription dose: 48 Gy or 60 Gy RT
75912797|NCT05480553|Drug|NPC-06|"Initial dose (Day 1) <Dose> An 18 mg/kg of NPC-06 will be injected by intravenous drip infusion once daily. The maximum dose of the test drug should not exceed 1,200 mg as fosphenytoin sodium.~<Administration method> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~<Dose> A 7.5 mg/kg of NPC-06 will be injected as needed by intravenous drip infusion once daily. The maximum dose of NPC-06 should not exceed 500 mg as fosphenytoin sodium.~<Administration method> Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
75320386|NCT05540366|Other|Physical therapy combined with aerobic exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.
75621509|NCT05629624|Dietary Supplement|E-RUSF|The other group will receive the E-RUSF at 50-100 kcal/kg/day which in this age group approximates one 92 g sachet daily until anthropometric recovery ( WHZ > - 1SD) has been achieved or for a of maximum 3 months, then immediately E-SQLNS 1 packet daily provided throughout the study till the end of 2 years of follow-up.
75621510|NCT05629624|Dietary Supplement|Outcome reference group/RUSF|We will also recruit 70 three-year-old previously untreated MAM children WHZ <-2 and ≥-3 z-score, and/or MUAC <12.5 and ≥11.5 cm as an outcome reference group for a singular assessment. All children (both case & control) will undergo a baseline nutritional, medical, biological and neuropsychological assessment (EF, ER, EEG and fNIRS). After all the assessments chick-pea based RUSF will be given for 2 months for nutritional rehabilitation.
75320387|NCT05540366|Other|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
75621511|NCT02741908|Behavioral|Calorie counting diet|
75621512|NCT02741908|Behavioral|Fixed diet plan|
75621513|NCT02745340|Other|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
75621514|NCT02745106|Procedure|Radiofrequency pulmonary artery denervation|Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
75621515|NCT02745106|Device|Ablation catheter|4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
75621516|NCT02745106|Device|Swan-Ganz catheter for right heart catheterization|"Standart procedure of right catheterization:~punction of right jugular vein with Seldinger technique, introducer placement~insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~positioning of swan-ganz catheter in pulmonary artery~direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~calculating of indirect parameters (pulmonary vascular resistance)"
75621517|NCT02741752|Procedure|Decortication|cortical bone perforation
75621518|NCT02695264|Device|HS-1000 recording|
75621519|NCT02745262|Other|Collect retrospectively the follow-up data|Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
75774909|NCT01083303|Behavioral|Weaning Preterm Infants from an incubator|Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
75621520|NCT02741674|Procedure|Roux-en-y gastric bypass (RYGB) - historical|Participant has had RYGB, as identified using existing data
75621521|NCT02741674|Procedure|Adjustable gastric banding (AGB) - historical|Participant has had AGB, as identified using existing data
75621522|NCT02741674|Procedure|Sleeve gastrectomy (SG) - historical|Participant has had SG, as identified using existing data
75774910|NCT01083381|Drug|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
75774911|NCT01083381|Drug|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
75621523|NCT02695186|Procedure|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
75320388|NCT00585637|Drug|Vitamin D|Taken orally every day for three months
75320389|NCT00585637|Dietary Supplement|Placebo|Placebo pill taken once daily for 3 month
75320390|NCT01670630|Procedure|Sheathed speculum examination|
75320391|NCT01670630|Procedure|Standard speculum examination|
75320392|NCT03158558|Behavioral|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson & Fredman, 2012)
75320393|NCT03158792|Drug|Enoxaparin 20Mg/0.2mL Prefilled Syringe|Enoxaparin 20mg subcutaneously once daily
75320394|NCT03158792|Drug|Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml|Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
75774912|NCT03810183|Drug|QAW039|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care
75621524|NCT02744950|Procedure|Pulley stitches|
75774913|NCT03810183|Drug|Placebo|Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
75320395|NCT01798771|Procedure|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
76088885|NCT01779869|Drug|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
75774914|NCT01087359|Drug|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
75774915|NCT03962517|Device|with Gait Enhancing and Motivating System-Hip (GEMS-H)|"The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living."
75774916|NCT03962517|Other|without Gait Enhancing and Motivating System-Hip (GEMS-H)|The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
75774917|NCT01087437|Dietary Supplement|gastrolith calcium|
76088886|NCT01772537|Drug|Propofol|Intravenous anesthetic
75621525|NCT02744950|Procedure|Intermediate Repair|
75912798|NCT05480553|Drug|Placebo|"Initial dose (Day 1) <Dose> A placebo will be injected by intravenous drip infusion once daily. <Administration method> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~<Dose> A placebo will be injected as needed by intravenous drip infusion once daily. Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
75621526|NCT02695108|Other|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
75774918|NCT01083537|Drug|Cisplatin|"1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
75774919|NCT01083537|Drug|Paclitaxel|"2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
75774920|NCT03597022|Drug|Befovacimab (BAY1093884)|Once weekly doses until premature termination of the study, subcutaneous injection
75774921|NCT01087515|Other|Blood donation|"In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).~In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.~In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects."
75774922|NCT03571204|Biological|3BNC117 and 10-1074|Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.
75774923|NCT03571204|Biological|Placebo|Placebo is two separate bags of 250 ml normal saline administered intravenously for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two separate bags of placebo are administered sequentially.
75774924|NCT03569098|Biological|Botulinum toxin type A|Investigators will inject the reconstituted solution into foot muscles.
75936381|NCT03185858|Behavioral|SINEMA intervention|"Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education."
76088887|NCT01772537|Drug|isoflurane|
75320396|NCT01798771|Procedure|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
75320397|NCT03158480|Biological|DC-CIK immunotherapy|Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
75320398|NCT05701202|Dietary Supplement|Super-Whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
75621527|NCT02695108|Other|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
75621528|NCT02695030|Device|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
75320399|NCT05701202|Dietary Supplement|Isonitrogenous whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
75320400|NCT00633919|Biological|SLITone(TM) Dermatophagoides mix|Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
75621529|NCT02744716|Drug|Aspirin|low dose of Aspirin after operation
75621530|NCT02744716|Device|intrauterine balloon|insert intrauterine balloon after operation
75621531|NCT02741362|Other|Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|
75774925|NCT03569098|Drug|Placebo|Investigators will inject the reconstituted solution into foot muscles.
75621532|NCT02741362|Other|Lipoaspiration|
75774926|NCT03727282|Procedure|adjust dobutamine according to the ejection volume index|adjust dobutamine dose
75774927|NCT03727282|Procedure|adjust dobutamine according to the attending physician|adjust dobutamine dose
75774928|NCT03568942|Drug|Gepotidacin|Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
75774929|NCT00110019|Drug|Carboplatin|Given IV
75774930|NCT00110019|Other|Laboratory Biomarker Analysis|Correlative studies
75774931|NCT00110019|Drug|Paclitaxel|Given IV
75774932|NCT00110019|Other|Pharmacological Study|Correlative studies
75774933|NCT00110019|Other|Placebo|Given PO
75774934|NCT00110019|Drug|Sorafenib Tosylate|Given PO
75936382|NCT02432066|Drug|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
76088888|NCT04572581|Other|Donor Breast Milk|Donor breast milk will be given to the newborn if supplementation is required
75621533|NCT00837811|Biological|LY2127399|60 milligrams [(mg) with potential for dose escalation to 120 mg] subcutaneously every 4 weeks for 48 weeks
75774935|NCT03595618|Drug|GLPG1972|Film-coated tablets of GLPG1972 for oral use.
75774936|NCT03595618|Drug|Placebo|Film-coated tablets of matching placebo for oral use.
75774937|NCT02954848|Drug|Placebo|TAK-438 placebo-matching tablets
75774938|NCT02954848|Drug|TAK-438 10 mg|TAK-438 tablets
75774939|NCT03642262|Drug|Mucinex®|Mucinex® 600 mg single dose ER bi-layer tablet
75774940|NCT03727204|Procedure|On-pump cardiac surgery|All participants will undergo on-pump cardiac surgery
75774941|NCT03727126|Procedure|Robotic esophagectomy|Removal of the esophagus and its draining lymph nodes using robotic surgical instruments
75774942|NCT03727126|Procedure|Thoracolaparoscopic esophagectomy|Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques
75774943|NCT03727048|Drug|Ketorolac|the investigators aimed to evaluate the effect of postoperative ketorolac after ankle fracture surgery on postoperative opioid consumption, pain control, an patient satisfaction.
75774944|NCT03727048|Other|No ketorolac|standard of care post operative pain management protocol
75774945|NCT03732742|Procedure|TOF repair with trans-annular patch VS preservation of PV|One group study
75774946|NCT00109707|Drug|Nilotinib|
75774947|NCT00095979|Drug|ixabepilone|Given IV
75936383|NCT02432066|Drug|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
75936384|NCT03050801|Device|rTMS|Altering the connectivity of trans-synaptic pathways
75936385|NCT03191318|Other|ERAS pathway|ERAS pathway after laparoscopic sleeve gastrectomy
75621534|NCT02744794|Device|Dermal Cooling System|Treatment with cryotherapy.
75621535|NCT02744872|Drug|Felodipine|Felodipine 10 mg once daily or identical placebo
75621536|NCT02744872|Drug|Placebo|Placebo
75621537|NCT02741206|Behavioral|Bellevue ROSE Intervention|
75774948|NCT01087593|Drug|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
75774949|NCT01087671|Drug|tafluprost|prostaglandin analogue
75774950|NCT00082173|Drug|Moxifloxacin|400mg daily for 8 weeks
75774951|NCT01087749|Drug|Propranolol|Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
75621538|NCT02741206|Behavioral|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
75621539|NCT02741206|Behavioral|One Psycho-education session and usual, standard of care Control|
75621540|NCT02744638|Other|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
75621541|NCT02744638|Other|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
75774952|NCT01087749|Drug|Losartan|Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
75774953|NCT01087749|Drug|Eprosartan|Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
75774954|NCT00108069|Drug|Tamoxifen citrate|oral dose 120 mg twice a day, every day
75774955|NCT00108069|Drug|Bortezomib|intravenous (IV) injection 1.3 mg/m^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
75774956|NCT01081119|Behavioral|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
75774957|NCT00079274|Drug|irinotecan hydrochloride|Given IV
75774958|NCT00079274|Drug|oxaliplatin|Given IV
75774959|NCT00079274|Drug|leucovorin calcium|Given IV
75774960|NCT00079274|Drug|fluorouracil|Given IV
75774961|NCT00079274|Biological|cetuximab|Given IV
75936386|NCT03191318|Other|Standard pathway|Standard pathway after laparoscopic sleeve gastrectomy
75936387|NCT03190850|Other|Intervention|The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
76088889|NCT01772147|Drug|Umeclidinium bromide 62.5mcg|Inhalation powder
76088890|NCT01772147|Drug|Umeclidinium bromide 125mcg|Inhalation powder
76088891|NCT01772147|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
75774962|NCT00079274|Drug|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
75912799|NCT05479760|Other|KP-Led HCV test and treat service|"After completing informed consent procedures, screening procedures will take place to assess eligibility. Clients who are anti-HCV and HCV-RNA positive, but meet one/more ineligible characteristics for simplified treatment will be referred to a hepatologist for treatment initiation.~Participants who are HCV-RNA positive and otherwise eligible will be offered to initiate DAAs at the CBO, followed by telehealth visits at week 4 and 8 and CBO visits at week 12, and week 24. If a visit is requested by the client, it can be conducted through telehealth or in-person at the clinic depending on client preferences. Substance use will be assessed using ASSIST, Retention in care, occurrence of adverse events during treatment, completion of treatment, and SVR achievement will be assessed. Clients who achieve SVR will be retested with HCV-RNA every 3 months to assess HCV re-infection. Clients who do not achieve SVR will be referred for further analysis and treatment."
75774963|NCT01081964|Drug|Zabofloxacin|Zabofloxacin 400mg capsule once daily for 3 days
75621542|NCT02744638|Drug|Arilin|2 tablets Arilin 500mg for 7 days
75621543|NCT02744560|Dietary Supplement|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
75621544|NCT00703417|Device|magnetic Resonance Imaging|MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
75912800|NCT05477225|Device|NovoSorb® BTM|a biodegradable polyurethane porous matrix adhered to a transparent sealing membrane. The sealing membrane is designed to physiologically close the wound limiting evaporative moisture loss during integration of the matrix.
75912801|NCT05477225|Device|Human Cadaveric Allograft|"The donated human tissue (Allograft) used in this study are from Maxxeus Medical, Kettering, OH . Tissue grafts are recovered from deceased human donors. All tissue is recovered, processed, stored and distributed for use in accordance with the standards of the American Association of Tissue Banks (AATB). Tissue is manufactured in a clean room environment, following rigorous quality assurance standards. The procedures executed to manufacture this graft including recovery, donor screening, testing, processing, packaging, labeling, storage, and distribution were performed in compliance with all applicable local, state, and federal regulations, including the U.S. Food and Drug Administration (FDA) regulations published at 21 CFR Part 1271, and the current edition of the American Association of Tissue Banks Standards for Tissue Banking.~The current sizes that are available for this study: 103 sq cm., 154 sq cm and 232 sq. cm"
75912802|NCT05477212|Dietary Supplement|Ketogenic Diet|all patients will receive a very low calorie ketogenic diet
75912803|NCT05476952|Procedure|"he patients who are administered rocuronium according to LBW were categorized as LBW, and The group number for those administer according to TBW was categorized as K."|Patients will be divided equally and validly by the one who will be placed in opaque sealed envelopes on a self-paid basis. One group will be given 0.6 mg/kg rocuronium on an LBW basis (Curon ® 50 mg/5 mL [Mustafa Nevzat, Istanbul, Turkey]), and the other group will be given 0.6 mg/kg rocuronium on a TBW basis.
75320401|NCT00633919|Biological|Placebo|Sublingual immunotherapy once daily for 2 years
75621545|NCT00703417|Device|Computed Tomography|CT scan of the lower back and hip
75621546|NCT00703417|Device|High resolution peripheral quantitative computed tomography|HR-pQCT of the distal radius and distal tibia
75621547|NCT05629078|Device|Toric intraocular lens Zeiss AT TORBI|Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.
75774964|NCT01081964|Drug|Levofloxacin 500mg|Levofloxacin 500mg orally for 7 days
75774965|NCT01081964|Drug|Zabofloxacin 400mg|Zabofloxacin 400mg orally for 5 days
75774966|NCT03960944|Other|Yoga|30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
75774967|NCT00079040|Drug|cisplatin|Given IV
75320402|NCT00633919|Drug|Salbutamol inhaler|200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
75621548|NCT02744404|Device|POC EID|
75621549|NCT02744326|Behavioral|Text message reminders|Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
75621550|NCT02740894|Drug|Gefitinib|
75621551|NCT00857389|Drug|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
75621552|NCT00857389|Drug|Clofarabine|40 mg/m^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
75621553|NCT00857389|Drug|Busulfan|"Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3."
75621554|NCT00857389|Procedure|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
75621555|NCT00857389|Drug|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
75621556|NCT00857389|Drug|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
75774968|NCT00079040|Drug|etoposide|Given IV
75774969|NCT00079040|Biological|bevacizumab|Given IV
75774970|NCT00079040|Other|laboratory biomarker analysis|Correlative studies
75774971|NCT01088516|Drug|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
75774972|NCT03961022|Dietary Supplement|Polyherbal supplement: ReWin(d) vs Placebo|Supplementation during 4 weeks + 72 hours post acute exercice
75774973|NCT00078806|Drug|Etanercept|Administered by subcutaneous injection twice a week
75774974|NCT00078806|Drug|Placebo|Administered by subcutaneous injection twice a week
75320403|NCT00633919|Drug|Budesonide/formoterol inhaler|80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
75621557|NCT00857389|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
75621558|NCT00857389|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
75621559|NCT00857389|Drug|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
75621560|NCT00857389|Drug|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
75621561|NCT02741050|Behavioral|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
75621562|NCT02741050|Behavioral|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
75621563|NCT03873376|Behavioral|Opt-in; Receive offer to order self-sampling kit|Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
75621564|NCT03873376|Behavioral|Opt-out; Receive self-sampling kit unsolicited|Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
75774975|NCT01090856|Procedure|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
75774976|NCT00078338|Drug|Rebif®|Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).
75774977|NCT00078338|Drug|Copaxone®|Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).
76073013|NCT00629122|Drug|Tacrolimus (Arm B)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
75621565|NCT03873376|Behavioral|Control; Receive open reminder to be screened by physician|Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
75912804|NCT05473624|Drug|HRS-1167|Participants will receive HRS-1167.
75621566|NCT03868930|Behavioral|STEP-Home|This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
75774978|NCT01088594|Drug|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
75774979|NCT01088594|Drug|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
75774980|NCT01088594|Drug|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
75774981|NCT01088594|Drug|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
75774982|NCT01088594|Drug|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
75912805|NCT05468307|Biological|Membrane Bound Cytokine Modified TIL|Adoptive transfer of 2x10^8-1x10^10 autologous TIL engineered with membrane-binding cytokine to patients i.v. in 30-120 minutes.
75912806|NCT05462483|Other|Rice Sock and Instructions to heat the quadriceps.|A rice sock will be provided to the experimental group to heat the quadriceps 3x per day for six weeks. The participants will be encouraged to heat before and after rehabilitation exercises as well.
75912807|NCT05433142|Biological|XmAb819|Monoclonal Bispecific Antibody
75912808|NCT05426174|Biological|mRNA NA vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75320404|NCT00633919|Drug|Prednisone tablet|5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
75320405|NCT00633919|Drug|Desloratadine tablet|5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
75320406|NCT00633919|Drug|Budesonide nasal spray|64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
75912809|NCT05426174|Biological|High Dose Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75774983|NCT01088594|Drug|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
75774984|NCT01583192|Procedure|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
75320407|NCT01672190|Other|Yoga Therapy Program|
75320408|NCT01672268|Other|cardiac computed tomography|cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
75621567|NCT03868930|Behavioral|PCGT|The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
75621568|NCT02744482|Drug|risedronate|risedrante tablet (75 mg)
75621569|NCT02744482|Drug|placebo|risedrante placebo tablet (75 mg)
75621570|NCT02744248|Drug|IOP Injection|IOP Injection 20 mg Fe/ml, intravenous injection
75621571|NCT02744248|Drug|0.9% normal saline|0.9% normal saline 10 ml, intravenous injection
75621572|NCT01071798|Drug|Rituximab|As prescribed by physician
75621573|NCT02744170|Device|1 continuous flow oxygen supplementation|This oxygen Supplementation is used in special order
75774985|NCT01090934|Device|High Resolution EEG|High Resolution EEG
75774986|NCT01090934|Device|Stereo-electroencephalography|SEEG
75774987|NCT01082120|Drug|AZD1656|Tablets orally, twice daily for 10 days
75912810|NCT05415202|Drug|Remimazolam 20 MG [Byfavo]|Remimazolam will be administered for sedation and efficacy and safety will be recorded
75320409|NCT03158246|Drug|Generic Zoledronic Acid|Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
75320410|NCT03158246|Drug|Original Zoledronic Acid|Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
75320411|NCT03158246|Dietary Supplement|calcium|600mg/d calcium for oral daily
75912811|NCT05414838|Dietary Supplement|Curcumin, Omega-3 and Vitamin-D (COD)|"Acumin™ Turmeric Complex (Dr. D's Ultra BioTurmeric) 500 mg daily (NPN 80087842)~Omega-3 supplements (combination of DHA and EPA) 900 mg daily (NPN 80019234)~Vitamin D3 supplements 2500 IU daily (NPN 80108995)"
75320412|NCT03158246|Dietary Supplement|vitamin D|925IU/d vitamin D for oral daily
75912812|NCT05406232|Procedure|Biopsy|Undergo tumor punch biopsy
75912813|NCT05406232|Procedure|Biospecimen Collection|Undergo blood sample collection
75912814|NCT05406232|Radiation|Radiation Therapy|Undergo RT
75912815|NCT05397470|Drug|Losmapimod|Losmapimod 15 mg will be administered BID by mouth along with food.
75320413|NCT03157856|Other|Fluorescence assessment|All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
75320414|NCT00515411|Drug|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
75320415|NCT00515411|Drug|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|"Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17~* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter."
75320416|NCT00515411|Drug|Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
75320417|NCT00586261|Drug|Pioglitazone|Pioglitazone 30 mg daily for 6 months
75320418|NCT00586261|Drug|Placebo|Placebo 30 mg daily for 6 months
75320419|NCT00586261|Drug|Nitroglycerin|0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
75320420|NCT03157778|Other|Obese men|Biological measures before, just before, and after lunch, in obese men
75320421|NCT03157778|Other|Normal-weight men|Biological measures before, just before, and after lunch, in normal-weight men.
75320422|NCT03157622|Behavioral|Exposure in vivo|10 sessions based on an individualized fear hierarchy
75621574|NCT02744170|Device|2 demand delivery liquid oxygen supplementation|This oxygen Supplementation is used in special order
75621575|NCT02744170|Device|3 demand delivery oxygen supplementation via concentrator|This oxygen Supplementation is used in special order
75621576|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
75621577|NCT00857311|Biological|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
75774988|NCT01082120|Drug|Pioglitazone|Tablet oral single dose for 10 days
75774989|NCT03808688|Drug|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye once daily in the evening
75774990|NCT03808298|Drug|Balovaptan therapeutic dose Treatment A|Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
75912816|NCT05397470|Drug|Placebo oral tablet|Placebo will be administered BID by mouth along with food.
75912817|NCT05393024|Drug|Belantamab mafodotin|MMRR patients included in Named Patient Program e Expanded Access Program
75936388|NCT03190850|Other|Control|The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
75936389|NCT03191006|Device|MEI BIN insoles|insoles
75621578|NCT00857311|Biological|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
75621579|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
75621580|NCT05629000|Procedure|Carotid revascularization|All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
75621581|NCT05629000|Diagnostic Test|MRI-PWI|Multi-modal MRI before and after surgery.
75621582|NCT05629000|Diagnostic Test|CTA|CTA before and after surgery.
75621583|NCT05629000|Diagnostic Test|PET/MRI|PET/MRI before surgery.
75621584|NCT05629000|Diagnostic Test|Ultrasound|Ultrasound before and after surgery.
75621585|NCT04118881|Other|Ear Acupuncture|Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
75621586|NCT02875626|Drug|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
75621587|NCT02744014|Behavioral|Add-on Therapy for Axial Spondyloarthritis|
75621588|NCT02874768|Drug|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
75621589|NCT02874768|Drug|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
75621590|NCT04118647|Drug|Wu-Chu-Yu tang|Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
75621591|NCT02740738|Device|Wagner Pain Algometer|applied at a 90 degree angle to the skin at a constant rate of 10kPa/s to minimize the impact of the examiner's reaction time on recorded pain thresholds
75621592|NCT02740738|Device|Dynamometer|Dominant Hand Grip strength measured by the average of 3 attempts
75621593|NCT04118725|Diagnostic Test|Pulmonary function test|Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
75621594|NCT05629312|Procedure|Maxillary expansion|The upper jaw is expanded with a removable expansion plate
75621595|NCT05629312|Procedure|Extraction of deciduous upper canines|Both deciduous upper canines are extracted in this group
75621596|NCT00857233|Drug|Memantine|20 mg oral tablets once daily
75621597|NCT05628922|Drug|Toripalimab|"Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w * 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w * 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months."
75621598|NCT05628922|Other|Induction chemotherapy and concurrent chemoradiation|"Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w * 2 cycles."
75621599|NCT02740426|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
75621600|NCT00856999|Drug|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
75621601|NCT02743624|Procedure|Variation of the level of pressure support during the mechanical ventilation|The pressure support of the patient was changed form the baseline to 20 cmH20 and then stepwise decreased to 2 cmH20,
75621602|NCT02743546|Drug|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
75621603|NCT02743546|Drug|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
75621604|NCT01071252|Drug|AIN457|
75621605|NCT01071252|Drug|Placebo|
75621606|NCT02743234|Other|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
75320423|NCT03157622|Behavioral|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
75320424|NCT00634621|Drug|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
75320425|NCT03157700|Behavioral|REAL media curriculum|REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
75621607|NCT02743234|Drug|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
75621608|NCT02743234|Drug|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
75621609|NCT02740270|Drug|GWN323|
75621610|NCT02740270|Drug|PDR001|
75621611|NCT00856843|Drug|BLI800|Solution for oral administration prior to colonoscopy
75621612|NCT00856843|Drug|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
75621613|NCT02875782|Behavioral|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
75621614|NCT02875782|Behavioral|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
75621615|NCT02740348|Behavioral|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
75621616|NCT02740348|Behavioral|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
75320426|NCT02744989|Device|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental tDCS group will receive the ACTIVE stimulation with the following parameters: oscillatory Direct Current with high frequency random noise stimulation (hf-tRNS - 100 to 500 Hz), Intensity = 2 mA, offset = + 1 mA, seance duration = 20 minutes ramp up/ramp down 30 seconds. Total number of sessions = 10 (sessions twice daily for 5 days separated by at least 2 hours for 5 consecutive weekdays).
75621617|NCT02743156|Procedure|IVUS-guided PCI|intravascular ultrasound-guided percutaneous coronary intervention
75621618|NCT02743156|Procedure|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
75621619|NCT02743390|Biological|Infliximab|Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
75621620|NCT02743390|Other|Saline|Saline for 2 hours (250mL)
75621621|NCT00856609|Drug|Byetta (exenatide)|Exenatide is an injectable medication
75621622|NCT00856609|Behavioral|Weight loss|Because response to weight loss
75621623|NCT00856609|Other|Metabolic Chamber|The subject stays in the small room
75621624|NCT00856609|Drug|Placebo|
75774991|NCT03808298|Drug|Balovaptan supra-therapeutic dose Treatment B|Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
75912818|NCT05384860|Device|Auricular Trauma Protocol (ATP) Acupuncture|Small filiform (needle) like needles use low frequency electrostimulation at eight ear points for 60 minutes while patient is sedated during surgery. All other aspects of the surgical procedure will go as planned according to the hospital's standard of care.
75912819|NCT05384860|Other|No Acupuncture Group|This involves not receiving the acupuncture treatment and surgery going entirely as normal according to the hospital's standard of care.
75621625|NCT02739958|Drug|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
75621626|NCT02739958|Drug|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
75621627|NCT02740036|Device|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
75621628|NCT02739802|Drug|Coppertone(BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.Formulation number - SR16-02.
75621629|NCT02739880|Device|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
75621630|NCT01071096|Drug|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
75621631|NCT01071096|Drug|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
75621632|NCT02742844|Biological|APZ2 application|Application of IMP on patients wound.
75621633|NCT02739646|Device|Functional MRI scan|7.0 Tesla functional MRI scan
75621634|NCT02739568|Drug|Pitolisant (BF2.649)|
75621635|NCT02739568|Drug|Placebo|
75621636|NCT02742688|Dietary Supplement|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)
75621637|NCT02742688|Dietary Supplement|Placebo|Placebo(4g/day)
75621638|NCT02742610|Behavioral|Mindfulness with Contingency Management|
75621639|NCT02742610|Behavioral|Active Control|
75774992|NCT03808298|Drug|Active control [moxifloxacin] on Day 2 Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
75774993|NCT03808298|Drug|Active control [Moxifloxacin] on Day 15 Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
75774994|NCT03808298|Drug|Placebo for Balovaptan Treatment C|Days 1-14: Matching placebo for balovaptan for 14 days.
75774995|NCT03808298|Drug|Placebo for Balovaptan Treatment D|Days 1-14: Matching placebo for balovaptan for 14 days.
75912820|NCT05383495|Drug|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg [100 mcg/mL (max 200 mcg or 2 mL)
75912821|NCT05383495|Drug|Midazolam Nasal Spray|Intranasal midazolam 0.4 mg/kg [5 mg/mL (max 10 mg or 2 mL)
75912822|NCT05383495|Drug|Nitrous oxide|50% nitrous oxide in 50% oxygen by face mask
75912823|NCT05381792|Diagnostic Test|Bacterial gene markers test|Bacterial gene markers test using qPCR
75912824|NCT05381129|Other|Detection of Pain, Quality of Life, Sleep and Functioning|All patients will be evaluated for allodynia, quality of life, headache-related disability, and sleep quality.
75621640|NCT02739724|Procedure|Adnexal surgery|
75621641|NCT00856375|Drug|NKTR-102|IV every 3 weeks
75621642|NCT00856375|Drug|irinotecan|IV every 3 weeks
75621643|NCT02739490|Procedure|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
75621644|NCT01070784|Drug|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
75621645|NCT01070784|Drug|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
75621646|NCT02694874|Drug|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
75621647|NCT02694874|Drug|Placebo|This is the placebo control
75621648|NCT00837577|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
75774996|NCT03808298|Drug|Placebo for Moxifloxacin Treatment A|Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
75320427|NCT02744989|Device|Sham tDCS|The control group will receive the SHAM stimulation (placebo) following the same regimen (i.e., twice daily sessions separated by at least 2 hours for 5 consecutive weekdays). Sham stimulation consists of a 20 minutes session including 40 seconds of active stimulation (same parameters as in the ACTIVE arm) at the beginning of the sessions, whatever the stimulator
75774997|NCT03808298|Drug|Placebo for Moxifloxacin Treatment B|Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
75774998|NCT03808298|Drug|Moxifloxacin Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
75320428|NCT05699798|Other|Conservative Treatment (CT)|Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
75774999|NCT03808298|Drug|Placebo for Moxifloxacin Treatment C|Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
75775000|NCT03808298|Drug|Placebo for Moxifloxacin Treatment D|Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
75775001|NCT03808298|Drug|Moxifloxacin Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
75320429|NCT05699798|Other|Instrument-assisted Soft Tissue Mobilization (IASTM)|"IASTM was performed only on the neck and upper back muscles on the aching side using the sweep technique on the origo and insertion lines. A total of 6 sessions were applied, two sessions per week for 3 weeks.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
75621649|NCT00837577|Drug|Sitagliptin|"Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20."
75621650|NCT00837577|Drug|Voglibose|"All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study."
75775002|NCT03961178|Diagnostic Test|High-risk HPV|High-risk HPV testing for the cytology of lower genital tract
75775003|NCT03961178|Diagnostic Test|TCT|Thin prep liquid-based cytology test for the cytology of lower genital tract
75775004|NCT00077636|Drug|Copegus|400mg po bid for 16 weeks
75775005|NCT00077636|Drug|Copegus|400mg po bid for 24 weeks
75775006|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 16 weeks
75775007|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks
75775008|NCT03963674|Other|Diacutaneous fibrolysis|Diacutaneous fibrolysis over the gastrocnemious muscles
75621651|NCT02742220|Other|Isometric Handgrip Training Group|Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
75621652|NCT02742220|Other|Control Group|Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
75621653|NCT02742298|Device|Muscle ultrasound|Ultrasound images of limb muscles will be collected.
75621654|NCT02742298|Other|Electrical Impedance Myography|A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
75621655|NCT01070550|Drug|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
75775009|NCT01082198|Biological|HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|
75775010|NCT01082198|Biological|HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|
75775011|NCT01082198|Biological|autologous melanoma lysate-pulsed autologous dendritic cell vaccine|
75775012|NCT01082198|Biological|autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|
75775013|NCT01082198|Biological|dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|
75775014|NCT01082198|Other|flow cytometry|
75775015|NCT01082198|Procedure|adjuvant therapy|
75912825|NCT05381129|Other|Temporomandibular joint dysfunction|Patients with jaw complaints will be evaluated for temporomandibular joint dysfunction.
75912826|NCT05381012|Other|Allodynia, quality of life, sleep, anxiety and depression, disability, and central sensitization|All patients will be evaluated for allodynia, quality of life, sleep, anxiety and depression, disability related to headache, and central sensitization.
75912827|NCT05381012|Other|Fibromyalgia syndrome|Patients who meet the diagnostic criteria for fibromyalgia syndrome will be evaluated with the Fibromyalgia Impact Questionnaire.
75320430|NCT05699798|Other|Extracorporeal Shock Wave Therapy (ESWT)|"ESWT therapy was applied on the muscle with active trigger point, at 1.5-2.0 bar pressure, at 10 Hz frequency, 2000 beats in each session, twice a week, in total 6 sessions.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
75320431|NCT00515723|Drug|risperidone|randomized to 12 week trial of risperidone.
75466108|NCT01905618|Behavioral|Web-based curriculum on tobacco dependence treatment|"The University of Massachusetts Medical School's web-based course, Basic Skills for Working with Smokers was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play."
75466109|NCT01905618|Behavioral|Tobacco Counseling Role Play|The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
75621656|NCT02742376|Other|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
75621657|NCT02742376|Other|Floor|A marked path on the floor where the subject is instructed to walk.
75621658|NCT02742376|Other|Kyboot shoes|Special shoes will be worn by the subject.
75621659|NCT02739178|Other|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
75621660|NCT04189900|Drug|Triptorelin|Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
75621661|NCT00848107|Drug|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
75775016|NCT01088828|Other|Magnetic Resonance Imaging (MRI) of calf and foot|Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
75775017|NCT03957746|Other|Resistance training|3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
75775018|NCT01091012|Drug|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
75912828|NCT05380765|Behavioral|Native PATHS|A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
75320432|NCT00515723|Drug|olanzapine|randomized to 12 week trial of olanzapine.
75320433|NCT00515723|Drug|quetiapine|randomized to 12 week trial of quetiapine.
75775019|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
75320434|NCT00515723|Drug|ziprasidone|randomized to 12 week trial of ziprasidone.
75320435|NCT04405154|Biological|Camrelizumab|Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.
75320436|NCT04405154|Drug|Cisplatin|75-100 mg/m^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.
75320437|NCT04405154|Radiation|IMRT or VMAT|66-70 Gy given in 33-35 fractions over 6-7 weeks.
75621662|NCT02739334|Behavioral|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
75621663|NCT02739334|Behavioral|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
75621664|NCT00703495|Device|transcranial oxygen saturation measurement (INVOS Somanetics 5100C)|rSO2 measurement
75621665|NCT02739256|Procedure|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
75621666|NCT04030741|Drug|Meronem and flagyl|meronem and flagy
75621667|NCT04030741|Procedure|Appendectomy|Appendectomy as treatment for acute appendicitis
75621668|NCT03689140|Behavioral|Smoke Free Together - App-only|Pregnant smokers and their life partners will use a smoking cessation app.
75621669|NCT03689140|Behavioral|Smoke Free Together - Telemedicine counseling only|Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation
75621670|NCT03689140|Behavioral|Smoke Free Together - app + telemedicine|Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
75621671|NCT04298632|Behavioral|Safety Education Program|this is a pesticide safety education program
75775020|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
75912829|NCT05374811|Other|Neuropathic Pain|Neuropathic pain degrees of the patients will be evaluated with the Douleur Neuropathic-4 (DN4) questionnaire.
75912830|NCT05369195|Procedure|LAAC procedure with the use of transcatheter cerebral protection system|After aortography the cerebral protection system will be delivered to cerebral arteries through radial access before accessing the left atrium.
75912831|NCT05369195|Procedure|LAAC procedure without the use of transcatheter cerebral protection system|Only the aortography through radial access will be done before accessing the left atrium.
75775021|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
75775022|NCT01082276|Drug|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
75775023|NCT01088906|Drug|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
75775024|NCT01082354|Drug|recombinant somatropin|as per standard practice
75775025|NCT01091090|Behavioral|Cognitive behavioral|Cognitive behavioral intervention for smoking cessation
75775026|NCT01091090|Behavioral|Control|Treatment as usual
75775027|NCT01082432|Other|electrically induced muscle activation|30 Hz frequency, 200 µs pulse duration, and 40% duty cycle (4 sec on, 6 sec off)
75775028|NCT00095199|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
75775029|NCT00095199|Biological|Cetuximab|Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
75775030|NCT00095199|Drug|Docetaxel|Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
75775031|NCT00075764|Drug|anastrozole|Given orally
75775032|NCT00075764|Drug|fulvestrant|Given intramuscularly
75320438|NCT00586573|Drug|memantine hydrochloride|tablet, 5-20 mg, twice daily, by mouth, 12 weeks
75466110|NCT01905618|Behavioral|Preceptor Training and Teaching Medical Students|The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
75775033|NCT03568162|Drug|ISB 830 - Part 1 Group 1|Subcutaneous injection (SC) every 2 weeks
75775034|NCT03568162|Drug|ISB 830 - Part 1 Group 2|Subcutaneous injection (SC) every 2 weeks
75775035|NCT03568162|Drug|ISB 830 - Part 1 Group 3|Subcutaneous injection (SC) every 2 weeks
75466111|NCT01905618|Behavioral|Booster Session|The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
75775036|NCT03568162|Drug|Placebo - Part 1 Group 4|Subcutaneous injection (SC) every 2 weeks
75775037|NCT03568162|Drug|ISB 830 - Part 2 Group 5|Subcutaneous injection (SC) every 2 weeks
75775038|NCT03568162|Drug|Placebo - Part 2 Group 6|Subcutaneous injection (SC) every 2 weeks
75466112|NCT01905644|Procedure|Perineal ultrasound|Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
75466113|NCT01905670|Device|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
75621672|NCT00636376|Procedure|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
75621673|NCT02736760|Drug|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
75775039|NCT03726970|Radiation|CBCT radiation|CBCT scanning
75775040|NCT03567616|Drug|Venetoclax|Tablet; oral
75775041|NCT03567616|Drug|Pomalidomide|Capsule; oral
75775042|NCT03567616|Drug|Dexamethasone|Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose [qw]
75775043|NCT03567382|Drug|Tenofovir Disoproxil Fumarate|300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.
75775044|NCT03567382|Biological|Monovalent HBV vaccine|Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
75775045|NCT03595384|Behavioral|Soccer-based adaptation to the DPP|"Participants will complete online education modules during an initial 12 week conditioning phase where they will participate in soccer drills and other fitness routines (two 1-hour sessions per week). At the 12 week mark participants will transition onto a soccer league team for the following 12 weeks where they will continue to complete online modules and meet with the soccer coach monthly.~During the soccer sessions and games participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. In addition, they will also be asked to wear a Garmin fitness tracker for the duration of the study to measure steps and moderate and vigorous activity.~The online education will be a version of the Diabetes Prevention Program and can be completed on a phone or computer with internet access."
75775046|NCT05666128|Drug|HD-6277|HD-6277 Oral tablet 100mg
75775047|NCT05666128|Drug|HD-6277|HD-6277 Oral tablet 50mg
75775048|NCT05666128|Drug|Placebo|Oral tablet
75912832|NCT05368012|Drug|MIDCAB|Ultrasound-guided administration of the nerve block MIDCAB into mid-calf as analgesic intervention for patients.
76088892|NCT01771913|Genetic|centrifuged fat graft|fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
75466114|NCT01905696|Drug|Oral N-acetylcysteine|
75466115|NCT01905709|Biological|Human fecal matter|
75775049|NCT03731026|Combination Product|LightPath® Imaging System and 68Ga-RM2|"Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical."
75621674|NCT02736760|Procedure|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
75621675|NCT02736838|Device|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
75621676|NCT02736838|Device|Laser Doppler|
75775050|NCT03731026|Drug|68Ga-RM2|Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
75775051|NCT03730870|Diagnostic Test|Pharmacogenomics report|Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
75912833|NCT05366530|Other|Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
75775052|NCT03591874|Drug|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.
75912834|NCT05366153|Diagnostic Test|Coronary CT|Screening/Management Plan
75912835|NCT05352646|Drug|Autologous memory lymphocyte Injection (NewishT), low-dose group|Recruited participants in low-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 4 weeks, a total of 2 times.
75912836|NCT05352646|Drug|Autologous memory lymphocyte Injection (NewishT), high-dose group|Recruited participants in high-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 2 weeks, a total of 4 times.
75912837|NCT05347147|Drug|Presendin|Presendin is supplied as 2 parts, one vial consisting of a drug part (white or greyish white powder in a clear vial) and one pre-filled syringe containing the diluent part (colourless liquid). The drug part is suspended in the diluent part solution and administered SC as a suspension.
76073014|NCT00629122|Drug|Clotrimazole Troche|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
75912838|NCT05347147|Drug|Placebo|Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
75912839|NCT05344755|Other|Plantar Sensorial Training|In addition to the routine treatment, plantar sensorial training will be added.
76088893|NCT01771913|Genetic|ADSCs enriched fat graft|fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
75466116|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
75775053|NCT03591874|Drug|Placebos|Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
75466117|NCT01905722|Other|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
75466118|NCT01905735|Drug|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
75466119|NCT01905735|Drug|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
75466120|NCT01905748|Other|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
75466121|NCT01905774|Drug|Deferasirox|
75466122|NCT01905800|Device|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
75466123|NCT01905878|Drug|DLBS1033|
75775054|NCT03730714|Drug|"Local Anesthetic, Epinephrine and Morphine"|local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
76073015|NCT00629122|Drug|Tacrolimus (Arm A)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
75912840|NCT05344755|Other|Control Group|Routine physiotherapy management of the Hallux valgus
75912841|NCT05343702|Drug|priming with rocuronium|Following induction (paralysis after onset of the induction effect) in routine rapid sequence intubation protocols While paralysis is applied, it is aimed to shorten the half-life of rocuronium by administering a subparalytic dose of rocuronium approximately 3-5 minutes before induction in the priming technique
76073016|NCT00629122|Drug|Nystatin Suspension|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
76073017|NCT00596440|Drug|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
76073018|NCT00631852|Drug|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
76073019|NCT00632632|Drug|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
76073020|NCT00632632|Other|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
75466124|NCT01905891|Procedure|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
75621677|NCT00856297|Biological|MenACWY-CRM conjugate vaccine|
76073021|NCT00633256|Drug|Cycloserine|50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
76073022|NCT00633256|Drug|Placebo|Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
76073023|NCT00634270|Drug|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
75320439|NCT05486234|Behavioral|modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Treatment Group will then complete four sessions of the modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias.
75621678|NCT00856297|Biological|Licensed comparator|
75936390|NCT02431910|Other|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
75936391|NCT02431910|Other|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
75466125|NCT01905904|Drug|sevorane|Sevorane 4% Sevorane 7%
75466126|NCT01905917|Other|Tele-rehabilitation|
75466127|NCT01905930|Device|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
75621679|NCT02875470|Device|Intensiv Perio Set|Diamond burs for root planing
75621680|NCT02875470|Device|Gracey curette|
75775055|NCT03730714|Drug|"Local Anesthetic, Epinephrine, Morphine and Surgicel"|Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
75775056|NCT03730714|Drug|"Normal Saline"|normal saline 0.9% to soak the surgicel according to the planned technique
75775057|NCT03726892|Device|PCI|Coronary Intervention
75775058|NCT03566680|Device|Orthokeratology|Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
75621681|NCT02738944|Behavioral|Telepsychiatry Collaborative Care|The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
76073024|NCT00635128|Biological|Boostrix-Polio|A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
75621682|NCT02738944|Behavioral|Telepsychiatry Enhanced Referral|"The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home."
75621683|NCT04304898|Other|Home spirometry|"Patients will perform daily home spirometry for three months with a Bluetooth-enabled validated, CE-marked home spirometer (Spiro bank Smart, MIR, Italy). Subsequently, patients will perform weekly home spirometry for two years in total. During this period, patients will be asked to perform three measurements each week on the same day.~Hospital-based spirometry will be performed according to international guidelines.~Patients will complete patient-reported outcomes (PROMs) online in the secured application every six months."
75621684|NCT02875938|Behavioral|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
75621685|NCT02875938|Behavioral|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
75621686|NCT02875938|Behavioral|Control|control condition using reading materials without music.
75621687|NCT02736604|Drug|nitrous oxide anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
75621688|NCT02736604|Drug|air anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
75775059|NCT00106353|Drug|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
75775060|NCT01087983|Drug|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
75912842|NCT05327062|Device|CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment|"The following information and data will be obtained from the routine clinical work up of the patients: Patient demographics, cardiovascular medical history, and clinical examination; 12-lead ECG; Standard echocardiography; Computed tomography angiography for visualization of atria, ventricle, and coronary sinus.~Imaging data will be transferred to the cloud-based web-platform using a dedicated software provided by study sponsor. Data processing includes evaluating the quality of the data and calculation of various anatomical and electrical parameters, and identification of the target zone as a point in the target vein closest to the latest activation zone.~LV-lead location is based on the information provided by the dedicated software followed by visual X-ray based verification of anatomically suitable/most desirable position.~The patient will undergo CRT device implantation according to local protocols."
76073025|NCT00676780|Drug|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
76073026|NCT00678418|Drug|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
76073027|NCT00678418|Drug|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
76073028|NCT00678496|Other|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
75466128|NCT01905930|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
75466129|NCT01905982|Procedure|reflectory breathing therapy|duration:2x60 minutes
75466130|NCT01905982|Procedure|conventional breathing therapy|duration:4x30 minutes
75466131|NCT01906021|Procedure|CT/CBCT thermometry method|The study consists of acquiring one or maximum two additional CT or CBCT of the liver during hepatic RFA or MWA and analyzing the images to obtain a temperature map
75621689|NCT02736604|Device|laryngeal mask airway (LMA Supreme Size 3/4|
75775061|NCT01087983|Drug|Sirolimus|Starting oral dose 1 mg daily.
75775062|NCT01087983|Drug|Metformin|Starting oral dose 1000 mg daily.
75775063|NCT00080301|Drug|Ixabepilone + Capecitabine|"Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity"
75912843|NCT05326126|Device|coronary physiology|To evaluate the association between microvascular disfunction and myocardial fibrosis identified per computed tomography among subjects undergoing TAVI for severe, symptomatic aortic stenosis.
75912844|NCT05321498|Drug|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week.
75912845|NCT05321498|Drug|Placebo|Placebo will be delivered by subcutaneous injection once a week
75912846|NCT05318482|Behavioral|Motivational group|In addition to the activities of the usual rehabilitation program, the PT will perform a daily motivational session of 15 minutes in a 1 patient: 1 physiotherapist modality. On that occasion, the patient will report the number of steps performed the previous day; the physiotherapist will check and promote the increase of 10% in the number of steps for the next day. If the patient fails to achieve the goal, the PT will analyze the reasons with the patient, in order to facilitate the achievement of the goal. The PT will advise on the time and place to perform physical activity and the patients will receive a diary to record his/her progress (number of steps and heart rate, Borg Fatigue and Borg Dyspnea before and after an exercise task). The PT will record all these evaluations on an excel database.
76073029|NCT00678496|Other|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
75466132|NCT01906021|Procedure|Ablation Probe|Temperature measured with thermocouples (current clinically approved method consisting of invasive needle placement for point measurement in area of concern)
76073030|NCT00599248|Biological|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
76073031|NCT00599248|Biological|Placebo|Placebo control (DMEM)
75320440|NCT05486234|Behavioral|modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Control Group will then complete four sessions of an Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
75320441|NCT05622227|Diagnostic Test|Drug: 68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of breast cancer by PET/CT.
75320442|NCT05459246|Other|Virtual reality glasses|"Beginning 1 minute before the start of the procedure, the patients will be watched (30-45 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30-45 minutes)."
75320443|NCT01799005|Dietary Supplement|Flavanol (410 mg)|
75320444|NCT01799005|Dietary Supplement|Control (no flavanols)|
75466133|NCT01906034|Behavioral|Exercise with supervision|
75466134|NCT01906034|Behavioral|Home-based without supervision|
75466135|NCT01906060|Device|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
75466136|NCT01906073|Drug|intranasal fentanyl spray|
75466137|NCT01906073|Drug|slow release morphine|
75621690|NCT02736604|Drug|sevoflurane|
75621691|NCT02613013|Device|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
75621692|NCT02613013|Device|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
75775064|NCT00080301|Drug|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
75775065|NCT01083927|Procedure|Rotational Narrow Strip Conjunctival Graft|Surgical technique
75775066|NCT01083927|Procedure|Full Conjunctival Graft|Surgical technique
75466138|NCT01906086|Other|nutritional intervention|
75466139|NCT01906086|Other|life style intervention|
75466140|NCT01906099|Other|nutritional intervention|
75466141|NCT01906099|Other|life style modification|
75466142|NCT01906112|Procedure|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
75621693|NCT02613013|Drug|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
75775067|NCT03961503|Drug|Daptomycin (DAP) treatment|Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
75775068|NCT03961503|Drug|Vancomycin (VAN) treatment|Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
75775069|NCT01084317|Other|medical documentation and telephone interview|medical documentation analysis supplemented by telephone interview conducted with parents of the child
75775070|NCT00079677|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
75320445|NCT00515879|Drug|D-cycloserine|50 mg
75912847|NCT05318482|Other|Control group|Besides the activities of the usual rehabilitation program, the patients of this group will be provided by the PT only with the generic recommendations of daily exercise during the in-hospital stay
75912848|NCT05311371|Other|Breathing exercise group|"The exercise was applied in accordance with the Guideline on Breathing Exercise for Reducing Nausea and Vomiting prepared by the researcher in accordance with the literature. In addition, the researcher has a breath coaching certificate. The guideline include the application steps of breathing exercise. First, the researcher will demonstrate to the patients the practice of breathing exercise in accordance with the guideline. In the next step, patients they will be asked to do this application on themselves. The training is planned to take about 15-20 minutes for each patient. This guide will be given to patients after the training. They will be asked to do this breathing exercise correctly and effectively in accordance with the guideline for at least 5 min in case of sensation of nausea and vomiting for 14 days. The researcher will follow up the patients for 14 days by visiting room them every day."
75621694|NCT02613013|Procedure|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
75912849|NCT05311371|Other|Control group|No intervention
75912850|NCT05303649|Device|Noninvasive transcranial brain stimulation: excitatory iTBS|600 pulses (3 pulses at 50 Hz given every 200 milliseconds in 2-second trains at 10-second intervals, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 Device: Magstim Co., Wales, UK.
75775071|NCT00079677|Drug|Placebo|Matching placebo tablets once daily
75621695|NCT02613013|Drug|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
75912851|NCT05303649|Device|Noninvasive transcranial brain stimulation: inhibitory cTBS|600 pulses (3 pulses at 50 Hz, repeated at 5 Hz, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 homologue Device: Magstim Co., Wales, UK.
75912852|NCT05303649|Behavioral|Individual speech-language therapy (SLT)|45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).
75912853|NCT05303649|Device|Sham TBS simulating left hemispheric iTBS|Sham TMS coil positioned exactly like an active TMS coil resulting in a very good approximation of the auditory effects Device: Magstim Co., Wales, UK.
75912854|NCT05289297|Procedure|Karydakis Flap Procedure|Pilonidal sinus surgery will be performed with the Karydakis Flap procedure.
75775072|NCT03961425|Behavioral|NO CO2|Traditional mechanical Deairing
75775073|NCT03961425|Device|CO2 Cannula|NON specific, low cost delivery system
75320446|NCT00515879|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
75775074|NCT03961425|Device|CO2 Cardia|Specific Commercial CO2 Diffuser
75775075|NCT01088139|Dietary Supplement|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
75320447|NCT00515879|Drug|Placebo|Same dosage as active pill
75320448|NCT03152942|Drug|Progesterone|Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
75775076|NCT03964155|Biological|Sample|After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
75320449|NCT03152942|Drug|Aminophylline|Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
75775077|NCT01081275|Behavioral|CI Therapy|CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
75775078|NCT01081275|Behavioral|CAM treatments|CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
76073032|NCT00599872|Biological|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
75320450|NCT03157544|Behavioral|multimodal non-pharmacological Pain Relief Kit|"Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain~The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit."
75320451|NCT00586729|Device|Vashe|Antimicrobial irrigant
75320452|NCT00586729|Drug|Mafenide acetate|Antimicrobial solution
75320453|NCT01672346|Procedure|PVAI followed by adenosine provocation|All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
75775079|NCT01081353|Drug|Acetylsalicylic Acid (Aspirin BAY1019036)|One tablet of new formula Aspirin under fasting conditions
75775080|NCT01081353|Drug|Alka Seltzer Extra Strength|One effervescent tablet under fasting conditions
75912855|NCT05289297|Procedure|Burow's Triangle Advancement Flap Procedure|Pilonidal sinus surgery will be performed with the Burow's Triangle Advancement Flap procedure.
75912856|NCT05281016|Behavioral|Usual Care|"Participants will be offered standard care which consists of the following:~Clinic consultation with physician and dietician,~pamphlets on weight management principles."
75775081|NCT01081353|Drug|Aspirin Migraine|One effervescent tablet under fasting conditions
75775082|NCT01081353|Drug|Aspirin Aspro|One effervescent tablet under fasting conditions
75775083|NCT01084395|Behavioral|Adolescent Safer Sex Intervention|Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
75912857|NCT05281016|Behavioral|Online community LITE programme|"Participants will be invited to participate in the online community LITE programme. Participants will also receive basic sports equipment for the online programme.~The online community LITE programme will consist of 2 sessions a week for 4-5 months. Each session is 1 hour long. The programme will deliver 3 domains: physical activity, nutrition and behaviour. It consists of relatively unstructured sessions comprising of cooking and nutrition classes, games and sports and peer support."
75912858|NCT05277519|Device|Vibrations|Sequenced muscle vibrations during 30 min., 3 times a week during 5 weeks
75912859|NCT05275608|Dietary Supplement|VLCKD diet with replacing meals|Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.
75621696|NCT02613013|Procedure|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
75912860|NCT05275608|Behavioral|Hypocaloric mediterranean Diet|Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry * physical activity score).
75621697|NCT04304976|Device|ROBERT®|Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.
75621698|NCT02738710|Procedure|transumbilical incision|incision within umbilicus
75621699|NCT02738710|Procedure|Infra umbilical incision|incision about 1 cm below umbilicus
75912861|NCT05270798|Drug|triiodothyronine|Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.
75912862|NCT05268653|Behavioral|Motivatıonal İnterviewing (Treatment Group)|Obese adolescents will be given a 6-session motivational interview.
75912863|NCT05255328|Dietary Supplement|Glutamine oral supplement|12-18 g /day of glutamine supplementation
76073033|NCT00599872|Biological|Placebo|Placebo, sublingual oral
75320454|NCT01672424|Other|Ice Chips|11 ounces of ice chips given to the laboring parturient
75621700|NCT02611921|Drug|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
75621701|NCT02611921|Drug|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
75621702|NCT02736448|Drug|Capecitabine|oral low dose of capecitabine
75621703|NCT02736448|Drug|Lu-PRRT|Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
75621704|NCT02736448|Drug|SS-LAR|long acting octreotide or lanreotide
75775084|NCT01084395|Behavioral|Parent Safer Sex Communication Intervention|Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
75775085|NCT01084395|Other|Adolescent Health Promotion Control Condition|Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
75775086|NCT01084395|Other|Parent Health Promotion Control Condition|Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
75775087|NCT00095121|Drug|Placebo (PLB)|Matching placebo
75775088|NCT00095121|Drug|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
76073034|NCT00600340|Biological|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
75320455|NCT01672424|Other|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
75775089|NCT00095121|Drug|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration >= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained >= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
75775090|NCT01081431|Drug|Lenalidomide|10 mg d1-d21 of a 28-day cycle
75775091|NCT03962829|Drug|mCPP|Healthy participants administrate one capsule of mCPP (30mg)
75912864|NCT05241366|Device|Transcranial Magnetic Stimulation|"The TMS group will be comprised of 10 patients, each subject will receive 12 sessions of low frequency (1 Hz) rTMS over the right dorsolateral prefrontal cortex with a total of 1500 pulses in each session. Each session will last approximately 30 minutes. There will be one session per day, five sessions per week. The total duration of the treatment will be four weeks.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
75775092|NCT03962829|Drug|Placebo oral tablet|Healthy participants administrate one capsule of placebo (containing lactose)
75775093|NCT00094809|Drug|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
75775094|NCT00094809|Drug|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
75775095|NCT03962751|Behavioral|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
75775096|NCT03962751|Behavioral|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
75621705|NCT00701077|Drug|3,4-Di-amino-Pyridine|a single 20 mg dosing
75775097|NCT03962751|Behavioral|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking event
75912865|NCT05241366|Device|Sham Transcranial Magnetic Stimulation coil|"Simulated TMS stimulation will be performed with a Sham TMS coil, which has a sound and scalp contact similar to those experienced during active stimulation. The duration of the treatment will be the same as in the experimental arm.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
75912866|NCT05238025|Biological|MVA-BN-RSV vaccine|One injection, suspension for injection, intramuscular use, 0.5mL MVA-BN-RSV virus with a titer of at least 3 x 10E8 infectious units (Inf.U)/0.5mL in a Tris buffer at pH 7.7.
75912867|NCT05238025|Biological|Tris Buffered Saline (TBS)|One injection, solution for injection, intramuscular use, 0.5mL TBS, pH 7.7.
76073035|NCT00600340|Biological|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
76073036|NCT01799356|Drug|Moxifloxacin|daily 400 mg moksifloksasin
75621706|NCT00701077|Drug|placebo|placebo
75621707|NCT02738476|Procedure|Patellofemoral arthroplasty|
75621708|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years
75621709|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years.
75320456|NCT00635479|Device|VAC device|Vacuum Assisted Closure (VAC) device for surgical incision
75320457|NCT00635479|Other|Gauze dressing|Gauze dressing for surgical incision
75320458|NCT00516503|Drug|baclofen/amitriptyline/ketamine gel|Applied topically
75320459|NCT00516503|Other|placebo|Applied topically
75320460|NCT03157310|Drug|Gefitinib|Daily oral administration of 250 mg Gefitinib
75320461|NCT03157076|Device|Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)|The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
75621710|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, IM. 1 injection/year for 3 years
75621711|NCT01046136|Drug|guaifenesin (Mucinex)|bid 7 days
75621712|NCT01046136|Drug|placebo|bid 7 days
75621713|NCT02736682|Drug|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
75621714|NCT02736682|Drug|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
75621715|NCT02736292|Behavioral|Mindfulness Practices for Healthcare Professionals|
75621716|NCT02874690|Drug|Methylphenidate|single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg
75621717|NCT02874690|Drug|Placebo|Placebo pill identical in appearance to methylphenidate
75775098|NCT01084473|Drug|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
75775099|NCT01084473|Drug|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
75775100|NCT01084473|Drug|Placebo|0.9 % NaCl will be infused.
75775101|NCT01088373|Drug|Azacitidine combined to Lenalidomide|Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
75621718|NCT02736214|Behavioral|Reproductive Life Plan (RLP)|A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
75621719|NCT05298007|Device|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
75621720|NCT05298007|Device|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
75621721|NCT02738242|Device|Novus system|The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
75912868|NCT05233137|Behavioral|PA coaching|PA coaching: Patients receive a step counter together with a coaching application (m-PAC, AppsOnly, KU Leuven) installed on a smartphone. The step counter and coaching application are connected via Bluetooth. The coaching application has the goal of PA promotion as well as detecting any new AECOPD.
75912869|NCT05233137|Other|Exercise training|"Each session will include at least the following components:~Resistance training of the lower limbs: Exercises for 6 muscle groups using minimal (e.g. ankle weights or elastic resistance bands) or no (body weight) equipment are foreseen. Each exercise will be performed in 3 series of 8 repetitions.~Functional training: Sit to stand exercise and stair climbing. During the first 2 weeks of the exercise training program, at least 3 strength exercises and 1 functional exercise will be performed each session.~Starting from the 3rd week of the exercise training program, whole body exercise training (interval training for walking, cycling, stair climbing and high knees) will be added. From this moment on, at least 1-2 whole body exercises and 2-3 strength and functional exercises will be performed during each physiotherapy session. By doing this, each session will consist of a minimum of 4 exercises in total."
75912870|NCT05219006|Dietary Supplement|ketogenic dieting|Atkins modified diet: 1.2-1.5 g/kg/day of protein with a ratio 1:1 (fat: carbohydrate + protein)
75621722|NCT02738632|Drug|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
76073037|NCT01799356|Drug|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
75621723|NCT02738632|Drug|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
75621724|NCT02738632|Drug|Placebo for Hydrochlorothiazide|
75621725|NCT01070394|Drug|LDX Treatment|30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
75621726|NCT00836953|Biological|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
75621727|NCT02736058|Device|Trans- abdominal sonography|
75621728|NCT02736058|Device|Trans-vaginal sonography|
75621729|NCT02736058|Procedure|post-operative pathological specimen examination|
75621730|NCT00703807|Drug|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
75621731|NCT00703807|Drug|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
75621732|NCT03649438|Drug|131 I-Metaiodobenzylguanidine|"Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~Dose of > 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available."
75621733|NCT03649438|Drug|Potassium Iodide|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
75775102|NCT01088451|Drug|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
75775103|NCT00075218|Drug|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
76073038|NCT01799356|Drug|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
76073039|NCT00602290|Drug|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were > 2 until treatment completion.
76073040|NCT00602290|Drug|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
75621734|NCT03649438|Drug|G-csf|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
75621735|NCT02738554|Other|Treatment cessation|Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
75621736|NCT00701233|Drug|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
75621737|NCT00701233|Drug|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
75775104|NCT00075218|Drug|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
75912871|NCT05219006|Dietary Supplement|healthy dieting|Normocaloric diet established by a nutritionist. 1.2-1.5 g/kg/day of protein with a maximum contribution of 50 % carbohydrates of the total calorie intake eliminating industrialized food.
75466143|NCT01906125|Drug|palbociclib capsule: phase 1 and 2 studies|125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
75912872|NCT05203419|Drug|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
75912873|NCT05203419|Drug|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
76073041|NCT00602290|Drug|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
76073042|NCT00637780|Drug|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
75320462|NCT00587041|Dietary Supplement|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
75320463|NCT00587041|Dietary Supplement|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
75466144|NCT01906125|Drug|Palbociclib capsule: phase 3 studies|125 mg dose of palbociclib. Formulation used in phase 3 studies
75466145|NCT01906125|Drug|Palbociclib capsule: ICH|125 mg dose of palbociclib. Intended final market formulation
75466146|NCT01906138|Device|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
75466147|NCT01906151|Device|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
75912874|NCT05182164|Drug|Association of pembrolizumab + cabozantinib|"A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis."
75912875|NCT05180955|Other|Digital drainage system|In the intervention group; chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data, the tube will not be clamped.
75912876|NCT05180955|Other|Digital drainage system + clamping trial|In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
75912877|NCT05179993|Other|Microplastics|Detection of microplastics as a yes/no value
75912878|NCT05169658|Biological|Mosunetuzumab|Given SC
75912879|NCT05169658|Biological|Obinutuzumab|Given IV
75912880|NCT05169658|Drug|Polatuzumab Vedotin|Given IV
75912881|NCT05164055|Drug|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
75912882|NCT05144152|Diagnostic Test|M3|A panel of four bacterial gene markers (Fn, m3, Ch and Bc)
75912883|NCT05144152|Diagnostic Test|FIT|faecal immunochemical test
75912884|NCT05143554|Device|Auricular percutaneous neurostimulation|Percutaneous neurostimulation
75466148|NCT01906164|Drug|ALS-008176|
75466149|NCT01906164|Drug|Placebo|
75466150|NCT01906190|Biological|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
75912885|NCT05143554|Device|Sham percutaneous neurostimulation|Sham percutaneous neurostimulation
75912886|NCT05134571|Drug|Laronidase|Solution for injection; Intravenous
75466151|NCT01906203|Device|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
75466152|NCT01906216|Drug|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
75466153|NCT01906216|Procedure|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
75775105|NCT03963440|Other|Exercise Adherence Rating Scale (EARS)|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
75775106|NCT01089140|Drug|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
75320464|NCT00587041|Other|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
75320465|NCT03157388|Drug|Combined Vancomycin and Gentamycin and Meropenem|"The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice."
75466154|NCT01906242|Other|water|
75466155|NCT01906242|Other|sodium hypochlorite|
75466156|NCT01906242|Other|sodium bicarbonate|
75466157|NCT01906242|Other|chlorhexidine|
75775107|NCT01089140|Drug|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
75775108|NCT01089140|Drug|Saline solution|Saline placebo
76073043|NCT00638014|Device|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
75320466|NCT04387825|Drug|ADSVF application in the right hand|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
75320467|NCT01672502|Behavioral|Sleep health education provided via a web-based program|All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
75775109|NCT00094653|Drug|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous [iv] infusion over 90 minutes), every 3 weeks for 4 doses
75775110|NCT00094653|Biological|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
75912887|NCT05128032|Device|Standard microcatheter|Small device used for mapping as part of radioembolization procedure
75912888|NCT05128032|Device|PEDD device|Pressure enabled small device used for mapping as part of radioembolization procedure
75912889|NCT05123755|Drug|AV-001 Injection|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
75912890|NCT05123755|Drug|AV-001 Placebo Injection|D-PBS
75320468|NCT01672502|Other|Sleep disorder detection and treatment|Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
75775111|NCT00104247|Drug|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
75775112|NCT03564184|Behavioral|MT during NICU|Music therapy (MT) by trained music therapist, 3 times/week for 30-40 minutes/session during NICU hospitalization. Involves primary caregiver and infant in musical communication matched to infant post-menstrual age, family/cultural preferences, and infant readiness for stimulation. Music therapist assesses infant´s needs and behavior state, supports caregiver in using basic touch (e.g., hand lightly and statically on infant´s chest or back to perceive breathing pattern) and caregiver´s hummed/sung voice matched to infant behavioral responses, to promote infant state regulation and bonding. Music includes input from music therapist as needed, and multimodal aspects such as gentle dynamic touch when infant demonstrates readiness. MT may occur while infant is held in a static manner by caregiver or is resting in his/her isolette or basinet. MT may occur during skin-to-skin care, if such care is part of standard care.
75775113|NCT03564184|Behavioral|MT after NICU|Music therapy offered by trained music therapist, 7 times for approximately 45 minutes/session across first 6 months following discharge from initial NICU hospitalization. Sessions include infant and caregiver, and siblings, if desired, and occur at home or in municipal settings. MT after NICU consists of a consult-to-parent model with each session including a brief verbal check-in regarding infant´s progress, musical interactions with music therapist modelling musical engagement, discussion of current challenges and strategies for using musical interactions to address needs in areas such as infant self-regulation, parent/infant interaction, and challenges with bonding. Caregivers will demonstrate techniques discussed during session, and form a brief plan for use of musical interaction in the interim before next session. Sessions will be adapted to infant developmental level and ongoing needs.
75775114|NCT03564184|Other|Standard care|Includes necessary medical care and standard supportive interventions offered as part of care during hospitalization, and standard follow-up procedures post-hospitalization.
75775115|NCT05665348|Drug|Ipilimumab Injection|Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm
75775116|NCT05665348|Drug|Atezolizumab Injection|One of the standard treatment's product for HCC management
75775117|NCT05665348|Drug|Bevacizumab|One of the standard treatment's product for HCC management
75775118|NCT03726814|Biological|EPC treatment group|Brain injection EPC
75912891|NCT05123729|Behavioral|Crowdsourced campaign package|COVID-19 prevention intervention developed using a crowdsourcing process.
75912892|NCT05123729|Behavioral|Standard information|Standard informational videos promoting the adoption of health-protective behaviors and COVID-19 testing
76073044|NCT00638014|Device|Conventional wire closure|Conventional wire closure of sternum
76073045|NCT00680524|Other|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
76073046|NCT01799902|Drug|Solifenacin|Oral
76073047|NCT00602446|Drug|deferasirox|20 mg/kg once daily orally for 6 months
76073048|NCT00635830|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
76073049|NCT00638716|Drug|CJC-1134-PC|1.5 or 2.0 mg CJC-1134-PC
76073050|NCT00638716|Drug|Placebo|Placebo
76073051|NCT00602836|Biological|Rituximab|Cycle 1: 100 mg by IV on day 1, 375 mg/m^2 by IV on day 2 Cycle 2-6: 375 mg/m^2 by IV on day 1 (every 21 days)
76073052|NCT00602836|Drug|Cyclophosphamide|600 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
76073053|NCT00602836|Drug|Lenalidomide|Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
76073054|NCT00602836|Drug|Pentostatin|2 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
75912893|NCT05106036|Other|Clinical Support Decision Tool|Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
75912894|NCT05095740|Device|repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation used to regulate the contribution of the laryngeal motor cortex to voice production and laryngeal motor muscle activation.
75621738|NCT03645694|Device|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
75621739|NCT03633058|Drug|Ketamine|oral ketamine dosed twice daily for 5 days
75621740|NCT01070316|Drug|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
75621741|NCT02737774|Drug|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
75621742|NCT02737774|Drug|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
75621743|NCT02735590|Drug|Isoniazid|Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
75775119|NCT03726736|Drug|Anlotinib combined Docetaxel|Anlotinib ( dose base on phase I study, QD PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
75912895|NCT05095740|Device|sham rTMS|Repetitive transcranial magnetic stimulation used to a cortical area not associated with change in outcomes at an intensity substantially lower than that of the established threshold.
75912896|NCT05093621|Drug|Furosemide|Standard of care diuretic
75320469|NCT01672502|Other|Optimization of Sleep in Fire Station|First, we will review and retrofit the sleeping quarters to provide a better environment for napping and sleep; light, noise, bed type, space, temperature, and location would all be considered and where possible, changes made to improve the sleeping environment. Secondly, we will work with management and union personnel to develop a 'sleep friendly' policy during the daytime, with specified protected times for naps during the day before the overnight work in order to reduce sleepiness during overnight work. Finally, we will upgrade the alerting systems, that is, we will work with management and union personnel to consider changing the policy that requires the sleeping areas of all stations to receive all alarm calls, even if that particular station is not required to attend the alarm.
75775120|NCT03726736|Drug|Docetaxel|Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
75775121|NCT03591406|Drug|Ferric carboxymaltose|Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.
75320470|NCT02135653|Radiation|Radiotherapy|
75320471|NCT02135653|Other|Eischens Yoga|
75320472|NCT05622149|Behavioral|Diet Only|Food tracking based on macronutrient goals.
75775122|NCT03591406|Drug|Iron sucrose|Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.
75775123|NCT03560986|Drug|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
75912897|NCT05093621|Drug|Torsemide|Standard of care diuretic
75912898|NCT05086744|Drug|Iptacopan|Iptacopan 200 mg BID
75912899|NCT05077774|Device|Harmony TPV System|Harmony Transcatheter Pulmonary Valve (sizes 22 mm and 25 mm) and Harmony Delivery Catheter System (DCS)
75912900|NCT05071963|Device|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™
75912901|NCT05054387|Drug|Agalsidase beta|Powder for concentration into a solution Intravenous (IV) infusion
75775124|NCT03560986|Drug|Placebo|Glass vials with matching placebo.
75775125|NCT03560518|Drug|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration)
75320473|NCT05622149|Behavioral|Training Only|Subjects completed 16 weeks of supervised resistance training
75320474|NCT05622149|Behavioral|Diet plus Training|Food tracking plus resistance training.
75621744|NCT02735590|Drug|Rifapentine|Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
75621745|NCT05626348|Drug|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
75621746|NCT05626348|Drug|Methotrexate|Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
75621747|NCT05626348|Drug|Adalimumab Injection|Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
75621748|NCT05626348|Drug|Leflunomide|Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
75775126|NCT03560518|Drug|Placebo|Placebo (prefilled syringe, weekly IV administration)
75775127|NCT03726580|Drug|Sevoflurane|Assess the effect of isoflurane, sevoflurane, propofol and regional anesthesia on the olfactory threshold, olfactory identification and endocrine regulation of associative memory in the postoperative period in old age group.
75775128|NCT03726502|Procedure|ureteroscopy with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
75775129|NCT03726502|Procedure|ureteroscopy alone|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
75775130|NCT03726502|Procedure|without safety guide-wire|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
75775131|NCT03726502|Procedure|with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
75775132|NCT03560206|Behavioral|Family SWaP intervention|The Family Sodium Watcher Program (Family SWaP) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food-the major source of sodium. The intervention is designed to improve adherence to a sodium restricted diet by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods. The Family SWaP intervention (6 weekly 45-minute sessions followed by 5 bi-weekly booster sessions) will be delivered remotely using a video-conferencing program on an iPad tablet.
75775133|NCT03560206|Behavioral|usual care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
75912902|NCT05045157|Procedure|Percutaneous A1 Pulley Release Under Ultrasound Guidance|the A1 pulley is cut off with Ultrasound guidance by a percutaneous insertion of the small needle under local anaesthesia.
75912903|NCT05045157|Drug|Corticosteroid injection|corticosteroid injection is performed
75912904|NCT05022667|Device|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements.
75912905|NCT05022641|Device|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console (see Figure 1), as per device functionality requirements.
75912906|NCT05004974|Drug|Sintilimab|Sintilimab is administered every 3 weeks (200mg, IV).
75912907|NCT05004974|Drug|Pemigatinib|Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
75912908|NCT05003401|Device|HabitAware Keen2|Participants will receive an awareness bracelet to be worn on the dominant wrist over a period of 4 weeks. The bracelet device will vibrate when the participant is engaging in hair pulling behaviors. As hair pulling behaviors may occur outside of awareness (i.e., automatic pulling behaviors), this vibration and detection is anticipated to increase the participants awareness of hair pulling behaviors.
75912909|NCT05001087|Other|Observation|Not applicable-Observational study
75912910|NCT05000996|Procedure|Bariatric Surgery|Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
75912911|NCT04998188|Procedure|Collagen|Patients will be treated with a single injection of collagen (2 ml) in the knee joint affected by osteoarthritis
75912912|NCT04998188|Procedure|Placebo (saline solution)|Patients will be treated with a single injections of saline solution (2 ml) in the knee joint affected by osteoarthritis
75912913|NCT04977453|Drug|GI-101|Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
75912914|NCT04977453|Drug|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
75912915|NCT04977453|Drug|Lenvatinib|Lenvatinib will be administered at an approved dose orally.
75912916|NCT04977453|Radiation|Local Radiotherapy|Patients will receive SBRT prior to the first dose of GI-101
75912917|NCT04977453|Drug|GI-101A|Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
75912918|NCT04977180|Drug|Cardioprotection|Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
75621749|NCT05626348|Drug|Hydroxychloroquine|Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
75651607|NCT05833919|Drug|Capecitabine|Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.
75651608|NCT05833893|Drug|XPO1 inhibitor|COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
75320475|NCT03156920|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
75912919|NCT04967833|Biological|Tumor Infiltrating Lymphocytes (TIL)|Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
76073055|NCT00683020|Behavioral|ATSM Intervention|"The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients."
75320476|NCT03156920|Drug|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
75912920|NCT04962711|Other|Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
76073056|NCT00683332|Drug|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
75912921|NCT04962711|Other|Usual care|provided by participants' usual healthcare professional(s)
75320477|NCT05247385|Drug|Prasugrel|Compared platelet inhibition and adenosine levels at baseline and after 15 days
75320478|NCT05247385|Drug|Ticagrelor|Compared platelet inhibition and adenosine levels at baseline and after 15 days
75621750|NCT02737696|Behavioral|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
75621751|NCT02737696|Behavioral|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
75775134|NCT02892760|Device|C-Brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
75775135|NCT03730558|Combination Product|aflibercept + FOLFIRI|aflibercept + FOLFIRI
75912922|NCT04960930|Drug|FMX101|topically once daily
76073057|NCT00683410|Biological|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
76073058|NCT00639418|Biological|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
76073059|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
75320479|NCT03156842|Drug|Fimasartan/Amlodipine, Rosuvastatin|"A fixed dose combination tablet of Fimasartan and Amlodipine and Rosuvastatin will be administrated once daily on treatment period."
75320480|NCT03156842|Drug|Fimasartan/Amlodipine|"A fixed dose combination tablet of Fimasartan and Amlodipine will be administrated once daily on treatment period."
75320481|NCT03156842|Drug|Fimasartan, Rosuvastatin|"Fimasartan and Rosuvastatin will be administrated once daily on treatment period."
75320482|NCT01672580|Behavioral|exposure to vitamin use|"Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village"
75775136|NCT03635086|Biological|MV-CHIK lyophilised formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, lyophilized low dose (powder for suspension in water for intramuscular [IM] injection): 5x10^4 ±0.5 log tissue culture infectious dose 50 (TCID50)/dose.
75775137|NCT03635086|Biological|MV-CHIK liquid frozen formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen low dose (suspension for IM injection): 1x10^5 ±0.5 log TCID50/dose.
75320483|NCT01672580|Behavioral|exposure to water chlorination|"Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village"
75320484|NCT01672580|Behavioral|high in-degree|"Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree"
75775138|NCT03635086|Biological|MV-CHIK SPS® formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid SPS® low dose (suspension for IM injection): 1x10^5 ±0.5 log TCID50/dose.
75775139|NCT03635086|Biological|MV-CHIK liquid frozen formulation, high dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen high dose (suspension for IM injection): 1x10^6 ±0.5 log TCID50/dose.
75912923|NCT04960072|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
76073060|NCT00640822|Drug|Tacalcitol Ointment|Once daily application for up to 8 weeks
76073061|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
76073062|NCT01799434|Other|treadmill run|
76073063|NCT02998216|Procedure|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
76073064|NCT00642694|Drug|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
76073065|NCT00642694|Drug|Ramelteon|Ramelteon 8 mg qd
76073066|NCT00642694|Other|Placebo|Matching placebo qd
76073067|NCT02998294|Device|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
75775140|NCT03635086|Other|Placebo|Sterile physiological saline solution (0.9% sodium chloride [NaCl]), administered by IM injection.
75775141|NCT03588910|Drug|Acetaminophen|50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
75775142|NCT03588910|Drug|Ibuprofen 600 mg|25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
75775143|NCT03588910|Drug|Oxycodone|The number of tablets of oxycodone prescribed is the only difference between the two arms.
75775144|NCT05666050|Behavioral|Mobile health intervention|Pregnant women with 26-28 weeks of gestation(based on world health organization eligibility criteria) will be recruited and baseline data will be collected at selected clusters. Women who will provide informed consent will be asked to complete a post-consent eligibility assessment including access to a mobile phone, and willingness to receive health messages on their mobile phone. Women who meet these eligibility criteria will be enrolled in the study and administered the baseline interview. Intervention will be started among randomly selected clustered pregnant women at 30 weeks of gestation and will be continued up to 6 weeks of post partum period for 4 months.
75912924|NCT04943913|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
76073068|NCT02998294|Device|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
76073069|NCT00705874|Drug|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
75320485|NCT01672580|Behavioral|nominated by random|"Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual"
75320486|NCT00636649|Drug|Escitalopram|10-20 mg
75320487|NCT00636649|Drug|Placebo|Placebo
75621752|NCT02738320|Other|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
75621753|NCT02737384|Biological|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
75621754|NCT03512392|Other|Conservative fluid and deresuscitation strategy|Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
75320488|NCT03156764|Other|Qp/Qs ratio monitoring|Op/Qs -monitor will be calculated using SpO2 and cerebral oximetry Op/Qs -blood will be calculated using ABGA and VBGA
75912925|NCT04943328|Device|Total Hip Arthroplasty|cemented hip arthroplasty
75912926|NCT04918784|Device|Restrata®|Restrata® is a sterile, single use device intended for use in local management of wounds. Restrata® is a soft, white, conformable, non-friable, absorbable matrix that provides a moist environment for the body's natural healing process to occur. Restrata® is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native extracellular matrix.
75912927|NCT04918784|Device|Wound Dressing|Alginate or Foam wound dressing is intended to manage wounds.
75912928|NCT04896632|Drug|INE 963|Part A: Single ascending dose with 7 planned cohorts> Part B: multiple dose with 2 planned cohort q24x3 days
75912929|NCT04896632|Other|Placebo|Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.
75912930|NCT04896047|Procedure|Meal test and muscle biopsies|"The FGF19 parameters will be assessed in fasting and in postprandial period after the consumption of a hyper-carbohydrate and hyper-lipidic test meal called Flexmeal.~A muscle biopsies by a needle will be performed before and after the Flexmeal."
75912931|NCT04883892|Procedure|BMAC|"patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.~During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability"
75912932|NCT04883892|Procedure|HA|patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.
75912933|NCT04874311|Drug|Bintrafusp alfa|Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.
75320489|NCT05061524|Drug|YH35324|Subcutaneous injection of YH35324
75621755|NCT03512392|Other|Usual care strategy|Usual care at the discretion of the clinical team
75621756|NCT02735434|Behavioral|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
75651609|NCT05833841|Diagnostic Test|Surface Electromyography and Video fluoroscopy|Surface EMG of three muscle groups (masseter, submental, and infrahyoid) and video fluoroscopy with Omnipaque
75912934|NCT04874311|Drug|Doxorubicin|Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
76073070|NCT00705874|Drug|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
75320490|NCT05061524|Drug|Placebo|Subcutaneous injection of None of active ingredient
75320491|NCT05061524|Drug|Omalizumab|Subcutaneous injection of Omalizumab
75775145|NCT03726190|Procedure|Oblique Lateral Lumbar Fusion|Oblique lateral lumbar interbody fusion (OLLIF) is a lumbar spinal fusion. OLLIF is performed with the patient in the prone position and employs an oblique lateral approach that enables the instrumentation to pass through Kambin's triangle which is defined as the space between the exiting nerve, the superior border of the caudal vertebra, and the superior articulating process of the inferior facet. This approach may be performed without direct visualization, guided by electrophysiological monitoring and biplanar fluoroscopy. During the approach, a blunt probe is used to make contact with the disc, followed by a series of gentle dilations. Discectomy is performed through a 10-mm access portal. The cage is inserted under continued electrophysiological monitoring and fluoroscopy.
75775146|NCT03726112|Device|SpotOn Specs|SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field
75912935|NCT04867434|Drug|RZL-012|small synthetic molecule for submental fat reduction
75912936|NCT04867434|Drug|Placebo|Placebo
75320492|NCT00636805|Drug|Palonosetron (Aloxi) and Dexamethasone|single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
75320493|NCT03153254|Device|Test upper limb robot assisted therapy device|During 1 session of 1/2 hour.
75320494|NCT03153254|Device|Training with new upper limb robot assisted therapy device|During 2 to 5 sessions of 1/2 hour.
75621757|NCT02735434|Other|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
75621758|NCT02737228|Drug|CG200745 PPA|CG200745 PPA IV every week three times per cycle (4 weeks)
75320495|NCT05247151|Other|Oxytocin|Oxytocin nasal spray in a positive social setting.
75320496|NCT05247151|Other|Placebo|Placebo nasal spray in a positive social setting.
75466158|NCT01906268|Other|Attentional Bias Modification Treatment (ABMT) - Active|"The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
75466159|NCT01906268|Other|Attentional Bias Modification Treatment - Placebo|"The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
75466160|NCT01906281|Other|Blood analyse, arthrocentesis, ultrasound examination|
75775147|NCT03726112|Device|Sham Specs|Sham device
75912937|NCT04859868|Device|Galvanic Vestibular Stimulation|Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.
75912938|NCT04851210|Other|No intervention|No intervention
75912939|NCT04843410|Other|Hand-foot exercise|The experimental group will be taught a regular exercise program for 15 minutes twice a day. The sensory exercise ball required for exercise will be given to the patients by the researcher. In addition, visual training material will be provided for the exercise program so that the patient can repeat the training at any time to ensure the permanence of the patient education. The standard care protocol of the clinic will be applied to the control group.
75912940|NCT04843410|Other|The routine care|Education about chemotherapy-associated peripheral neuropathy risk factors, why it develops and its management
75912941|NCT04837547|Biological|Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)|There will be two immunotherapy products manufactured and administered to subjects enrolled on this trial. The first product will be autologous dendritic cells (DCs) loaded with total tumor messenger ribonucleic acid (mRNA) (TTRNA) derived from malignant tumors. The second product will be autologous T lymphocytes stimulated ex vivo against TTRNA antigens for autologous transfer (TTRNA-xALT). DCs are professional antigen-presenting cells critical for the initiation of B and T-cell responses in vivo.
75912942|NCT04829643|Diagnostic Test|PET/MRI|A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited
75912943|NCT04826211|Diagnostic Test|PET/MRI|All included patients will undergo PET/MRI both prior to PST and prior to surgery. In order to analyze results the population will be divided into two groups: women with positive axillary lymph nodes after PST (Group 1) and women with negative axillary lymph nodes after PST (Group 2).
75320497|NCT03153098|Behavioral|Active Herts|Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
75320498|NCT02137447|Device|Negative Pressure treatment|
75466161|NCT01906294|Drug|antidiabetic treatment (ATC A10B)|
75621759|NCT02737228|Drug|Gemcitabine|1000 mg/m^2 intravenously every week three times per cycle (4 weeks)
75621760|NCT02737228|Drug|Erlotinib|100 mg per oral daily per cycle (4 weeks)
75621761|NCT01126541|Drug|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
75621762|NCT02735278|Other|different test paradigms|
75621763|NCT02737150|Device|CoreValve Evolut R|
75621764|NCT02737150|Device|Edwards Sapien 3|
75621765|NCT02737150|Procedure|Local anesthesia with conscious sedation|
75912944|NCT04821492|Diagnostic Test|Dual-Energy X-ray Absorptiometry (DXA)|BMD expressed in absolute values as g/cm2 and T-scores
76073071|NCT00705874|Drug|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
76073072|NCT00705874|Drug|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
76073073|NCT00705874|Drug|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
75466162|NCT01906307|Drug|LJPC-501|Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
75621766|NCT02737150|Procedure|General anesthesia|
75621767|NCT02736916|Radiation|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
75621768|NCT02736916|Radiation|Conventional PCI|LD-SCLC patients with conventional PCI
75621769|NCT02735356|Drug|Itraconazole|Applied topically
75775148|NCT03726034|Behavioral|Life Story Book|The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.
75775149|NCT03726034|Behavioral|Self-selected social activities|To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
75775150|NCT03587974|Behavioral|REACH-VIETNAM|Family caregiver education, stress-reduction, and skill-training related to providing care for a person with Alzheimer's disease
75775151|NCT03730402|Drug|Bupivacaine|utilizing local anesthetic to perform a regional block under laparoscopic guidance
75775152|NCT03730402|Drug|Exparel 266 milligram Per 20 ML Injection|utilizing local anesthetic to perform a regional block under laparoscopic guidance
75775153|NCT03730402|Drug|Saline|placebo injection of saline
75775154|NCT00103857|Drug|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
75912945|NCT04810858|Other|Multimodal, multi-parametric MRI|The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.
75912946|NCT04810858|Other|Immune and cytokine profiling|Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.
75320499|NCT02464904|Procedure|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
75912947|NCT04810858|Behavioral|Neuropsychological testing|Participants will have neuropsychological testing three times over 2 years.
75912948|NCT04807816|Drug|Association of berzosertib with gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
76073074|NCT00705874|Drug|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
76073075|NCT00705874|Drug|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
76073076|NCT00646048|Device|TriVascular Stent-Graft System|TriVascular Stent-Graft System
76073077|NCT00647998|Drug|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
75621770|NCT02735356|Other|Placebo|Applied topically
76073078|NCT00647998|Other|Standard care|
76073079|NCT00649792|Drug|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
76073080|NCT00685516|Dietary Supplement|green tea|6 cups of green tea daily for 2-8 weeks
75621771|NCT00625469|Drug|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
75621772|NCT05577910|Device|Vectored thermal pulsation (VTP) therapy|VTP purchased from TearScience®️ is an automated thermal pulsation system that is designed to heat and simultaneously evacuate the meibomian gland contents. It is performed by the unmasked treating investigators as described by the equipment manufacturer. In brief, one to two drops of topical anesthesia are applied prior to the bilateral application of the activators. The inner portion of the activator applies a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applies directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Participants will receive one session of VTP treatment only (month 0).
76073081|NCT00685516|Dietary Supplement|placebo|6 cups of water daily for 2-8 weeks
75775155|NCT00103857|Drug|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
75621773|NCT05577910|Device|Intense pulsed light with meibomian gland expression (IPL+MGX) therapy|"IPL is delivered using the proprietary dry eye mode setting of the Lumenis®️ M22TM system per the Toyos protocol. Pulse intensity (11-14 J/cm2) is inversely related to the Fitzpatrick skin phototype of each participant and will be used for the same patient throughout the study. IPL will be delivered to four overlapping zones inferior to each eye and a fifth pulse applied temporally adjacent to the lateral canthus four times. Both eyelids are closed and sealed with IPL-Aid disposable eye shields. MGX is immediately performed on both upper and lower eyelids of each eye and pain will be minimized by topical anesthetic. Participants will receive four-session IPL and MGX treatment (month 0, 1, 2 ,3)."
75621774|NCT05577910|Behavioral|Eyelid Warm Compress Therapy (EW)|EW using warm wet towel to each eye is performed twice daily for 10 mins. A treatment diary will be given for patients randomized to EW for daily recording which will be reviewed and recorded by the unmasked study coordinator at each study visit.
75775156|NCT00103857|Drug|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
75775157|NCT00103857|Drug|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
75775158|NCT00103857|Drug|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
75775159|NCT00103857|Drug|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
75775160|NCT03587584|Drug|liposomal bupivacaine|Experimental
75621775|NCT05577910|Drug|Topical eye drops (Hypromellose, 3mg/ml)|All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
75621776|NCT04311125|Procedure|Mini posterior approach Total Hip Replacement|Total hip replacement in patients suffering from hip osteoarthritis using the mini posterior approach
75621777|NCT04311125|Procedure|Anterior approach total hip replacement without a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis without the aid of a traction table
75775161|NCT03587584|Drug|Bupivacaine|Active Comparator
75775162|NCT03586726|Drug|Balovaptan|"In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16."
75775163|NCT03586726|Drug|Rifampicin|In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.
75775164|NCT03586648|Device|senofilcon A Multifocal|TEST Lens
75775165|NCT03586648|Device|senofilcon A Sphere|TEST Lens Sphere
75320500|NCT02464904|Other|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
75320501|NCT05246995|Drug|IBI325+Sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 monotherapy on Cycle 1 Day 1 ,and then receive IBI325 and sintilimab combination until progressive disease, intolerability, or other reasons leading to treatment discontinuation
75320502|NCT03153566|Biological|tuberculin|inject the mother wart with .3 ml tuberculin vaccine every 2 weeks
75466163|NCT01906320|Behavioral|High-Intensity Resistance training|"Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).~The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.~Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program."
75466164|NCT01906333|Other|Exercise|
75466165|NCT01906333|Other|Glucose|
75466166|NCT01906333|Other|Fasted|
75466167|NCT01906359|Other|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
75912949|NCT04807816|Drug|Gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
75912950|NCT04789655|Drug|CC-96191|CC-96191
75912951|NCT04786444|Biological|Biological Vaccine VLA1553|Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate
75320503|NCT03153566|Device|cryotherapy|10 sec 1 cycle into all genital warts
75912952|NCT04785092|Procedure|All Autologous Cartilage Regeneration|All patients will undergo firstly to a blood sampling and then to the arthroscopic debridement of the damage cartilage and subsequently will be harvested the surrounding healthy cartilage The harvested and healthy cartilage will shredded directly in situ with a shaver. This cartilage will then mixed with the patient's own Platelet Concentrate and may be injected directly into the cartilage defect. The Platelet Concentrate stimulates the healing of the cartilage most effectively. At the same time, the Platelet Concentrate will also used to produce autologous fibrin glue, which can be used to fix the applied cartilage chip / Platelet Concentrate product quickly and safely in the damaged cartilage.
75912953|NCT04783363|Other|Snoezelen session|before one of two repeated invasive care
75621778|NCT04311125|Procedure|Anterior approach total hip replacement with a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis with the aid of a traction table
75621779|NCT00637481|Drug|atorvastatin calcium|Given orally
75621780|NCT00637481|Other|laboratory biomarker analysis|Correlative studies
75621781|NCT00637559|Drug|Esomeprazole Magnesium|
75912954|NCT04771962|Drug|DESFLURANE AND SEVOFLURANE|COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS
75320504|NCT01676246|Drug|100 mg flupirtine intravenous|Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
75320505|NCT01676246|Drug|100 mg flupirtine per os|Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
75320506|NCT01676246|Drug|400 mg flupirtine per os|Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
75320507|NCT01676246|Procedure|induce delayed onset of muscle soreness (DOMS)|"The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from no pain to intolerable pain with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly."
75320508|NCT01676246|Procedure|electric pain measurement|"The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).~During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min."
75320509|NCT04275830|Behavioral|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
75466168|NCT01906359|Other|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
75621782|NCT02736994|Drug|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
75621783|NCT02736994|Drug|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
75621784|NCT02736994|Other|Water|Water
75775166|NCT03586648|Device|etafilcon A Multifocal|CONTROL Lens
75775167|NCT03586648|Device|etafilcon A Sphere|CONTROL Lens Sphere
75775168|NCT02892448|Other|Cardiac magnetic resonance imaging (CMR)|Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.
75912955|NCT04771026|Drug|Dexamethasone|Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
75912956|NCT04768309|Other|Ex vivo exploration of the effect of a probiotic over precursor indole production|Fresh feces in chronic kidney patients and healthy volunteers will be collected. The feces will be instilled in artificial intestine with and without selected probiotics and production of uremic toxins will be measured.
75466169|NCT01906359|Other|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
75466170|NCT01906398|Other|ketogenic diet|KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction
75466171|NCT01906411|Dietary Supplement|Dopamine depletion vs. Balanced aminoacid drink|
75621785|NCT04310969|Device|MiBoFlo Thermoflo|Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.
75912957|NCT04768010|Drug|Misoprostol|Participants will started by receiving 100 micrograms of oral misoprostol twice daily. If adverse effects are not noted dose can be titrated up to 200 micrograms of misoprostol twice daily. Participants will receive a total of five doses.
76073082|NCT00685516|Dietary Supplement|decaffeinated black tea|6 cups of decaffeinated black tea daily for 2-8 weeks
75912958|NCT04767997|Dietary Supplement|Probiotic formulation|Participants will be asked to take one capsule daily, containing 3 billion CFU of the probiotics.
75775169|NCT03725644|Behavioral|parent-training program|Parents in the treatment group received the training program from the registered pediatric occupational therapist in six hours over three weeks. The occupational therapist provided suggestions and gave feedback. The parents were encouraged to interact with their children for at least 15 hours per week. Between the fourth and 14th weeks, the parents implemented the intervention programs at home and recorded the daily intensity. The occupational therapist met with the parents and children at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered and to practice the child-initiated activities.
75775170|NCT03725644|Behavioral|traditional program|Parents in the control group also conducted a 14-week program. They received six hours of training over three weeks.Between the fourth and 14th weeks, the parents implemented parent-led activities at home and recorded the daily intensity. The parents were encouraged to do activities with their children for at least 15 hours per week. The occupational therapist met with the parents at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered while practicing the parent-led activities.
75912959|NCT04767997|Dietary Supplement|Placebo|Participants will be asked to take a placebo capsule daily.
75466172|NCT01906424|Device|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
75621786|NCT04310969|Procedure|forceful expression of the meibomian glands|Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
75775171|NCT03722134|Procedure|MOCA|Great saphenous vein occlusion with a mechanochemical chateter which cause mechanical injury to vessel intima and gives sclerosant to the intima.
75621787|NCT04310969|Device|LipiFlow|LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
75912960|NCT04765800|Behavioral|weekly, biweekly, or twice a week sessions of face-to-face outpatient psychotherapy|according to the German Psychotherapy Guidelines (Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie)
75466173|NCT01906437|Device|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
75621788|NCT05577208|Device|"Symplicity Spyral multi-electrode renal denervation catheter and Symplicity G3 generator (Renal Denervation System)"|Minimally invasive percutaneous interventional therapy aimed to modulate the sympathetic nervous system through endovascular ablation of both renal arteries
75621789|NCT04311047|Diagnostic Test|USPIO-enhanced MRI|Administration of USPIO contrast 24-36 hours before MRI scan of the abdomen to detect lymph node metastases.
75466174|NCT01906450|Drug|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
75466175|NCT01906450|Drug|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
75621790|NCT05553730|Behavioral|Digital Buddy program|Six months of ICT and psychoeducation delivered by youth mentors via an e-learning platform
75651610|NCT05833815|Drug|Everolimus 10 mg|Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx
75912961|NCT04749992|Procedure|Polysomnographic examination in sleep laboratory (PSG measurement)|Recording of sleep quality and quantity by sleep parameters, such as total sleep time - TST; duration of sleep stages - S1t, S2t, S3t, rapid eye movement - REMt; sleep onset latency - SL; wake after sleep onset - WASO, sleep efficiency - SE.
75912962|NCT04749108|Drug|Induction chemotherapy - modified FOLFIRINOX regimen|An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
75912963|NCT04749108|Other|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
75912964|NCT04749108|Radiation|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or Intensity-Modulated RadioTherapy (IMRT) (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of radiotherapy treatment (2 daily intake).
75466176|NCT01906502|Device|Sensimed Triggerfish|
75466177|NCT01906528|Drug|Mivacurium|Effect of Mivacurium in males vs females
75466178|NCT01906541|Genetic|ex-vivo gene-therapy|transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
75466179|NCT01906554|Other|Egg Dose|Different quantities of eggs
75651611|NCT05833815|Drug|Standard of care|GemOx or CapOx
75775172|NCT03722134|Procedure|EVLA|Great saphenous vein occlusion with a thermal laser chateter
75775173|NCT03722134|Procedure|RFA|Great saphenous vein occlusion with a thermal radiofrequency chateter
75775174|NCT03722056|Procedure|Laparoscopic resection|all patients with suspected Gastric GIST undergoes laparoscopic resection. Tumour location decides the approach used for resection. Therefore, a variety of options such as local resections, wedge resections, transgastric resections, intragastric resection and partial gastrectomies were performed.
75912965|NCT04749108|Procedure|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
76073083|NCT00686842|Drug|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
75466180|NCT01906580|Drug|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
75466181|NCT01906580|Drug|Entecavir|0.5mg,oral administration every day
75466182|NCT01906606|Behavioral|Parenting Program|A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
75466183|NCT01906632|Biological|DC-CIK Immunotherapy|
75651612|NCT05833802|Other|virtual anti-cancer drug|the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology
75775175|NCT03721900|Drug|SHX-001 Active low dose|ketamine transdermal patch
75775176|NCT03721900|Drug|Placebo|transdermal patch
75775177|NCT03721900|Drug|SHX-001 Active High dose|ketamine transdermal patch
75775178|NCT03585712|Drug|Norgestrel 0.075 mg|Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3
75775179|NCT03585244|Other|weekly weight|weekly weight data collection for six months
75775180|NCT03730246|Procedure|cesarean sectio|consecutive parturients due for cesarean sectio
75775181|NCT00074984|Biological|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
75775182|NCT00074984|Biological|Placebo|1 mg/kg placebo intravenously every 2 weeks
75775183|NCT01082510|Drug|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
75912966|NCT04746573|Device|Natrox Topical Oxygen Therapy|Device delivering humidified oxygen directly to the wound bed
75912967|NCT04744155|Behavioral|Multi-Level Intervention|Behavioral intervention that assesses uptake of contraception and seeks follow-up care.
75651613|NCT05833750|Other|Reflexology|In the intervention group, reflexology was applied to the feet twice a week for 8 weeks.
75912968|NCT04744155|Behavioral|Enhanced Standard of Care|Behavioral intervention that assesses uptake of contraception from follow-up care.
75912969|NCT04730544|Drug|Nivolumab 480mg + Ipilimumab|Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w
75912970|NCT04730544|Drug|Nivolumab 240 mg + Ipilimumab|induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w
75320510|NCT04275830|Behavioral|Heart rate variability biofeedback|"Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention."
75651614|NCT05833737|Drug|Belantamab mafodotin|Injection for refractory/relapsed multiple myeloma
75651615|NCT05833724|Drug|Chidamide|Subjects will receive a single dose of 30 mg chidamide. Twice a week.
75651616|NCT05833698|Diagnostic Test|Elevation of NLR|Blood test
75466184|NCT01906645|Other|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
75466185|NCT01906671|Drug|Xaluprine|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
75651617|NCT05833672|Drug|Terelizumab|q3w Terelizumab 200mg on day 1 of each cycle
75775184|NCT01082510|Drug|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
75775185|NCT03583606|Biological|ChAd3-EBO-Z|Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10^11 virus particles (vp)).
75775186|NCT03583606|Biological|MVA Multi-Filo Ebola Vaccine|A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10^8 Infectious Units (IU).
75775187|NCT03583606|Other|Placebo|0.5 mL normal saline administered via IM injection into the deltoid.
75775188|NCT03730168|Other|circuit weight training program|30 male diabetic patients performed circuit weight training for 12 weeks
75775189|NCT03583450|Device|Perioperative virtual reality headset with mobile app|Perioperative virtual reality headset with mobile app (Samsung Gear VR headset, ChariotVR software)
75775190|NCT03583372|Drug|Vibegron|single daily dose 75 mg
75775191|NCT03583372|Drug|placebos|placebo to match vibegron (experimental drug) and tolterodine (active comparator)
75912971|NCT04715178|Other|No intervention- registry only|No intervention- registry only
75936392|NCT05233514|Other|Aerobic exercise in addition to Metformin treatment|The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
75936393|NCT02431832|Drug|Augmentin tab|
75466186|NCT01906671|Drug|Puri-Nethol|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
75775192|NCT03583372|Drug|Tolterodine Tartrate ER|single daily dose of 4 mg
75466187|NCT01906684|Drug|Acthar Gel|Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
75466188|NCT01906697|Procedure|middle turbinate Radio Frequency (RF) turbinoplasty|middle turbinate Radio Frequency (RF) turbinoplasty
75466189|NCT01906697|Procedure|middle turbinate resection|middle turbinate resection
75466190|NCT01906697|Procedure|middle turbinate medialization|middle turbinate medialization
75775193|NCT03725566|Drug|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
75775194|NCT03582826|Behavioral|Nutritional counselling|Behavioral nutritional counselling delivered via the Internet.
75775195|NCT03582826|Behavioral|Stress-reduction counseling|The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
75775196|NCT01582958|Procedure|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
75775197|NCT01582958|Other|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
75775198|NCT03518008|Device|verofilcon A contact lenses|Investigational daily disposable soft contact lenses
75912972|NCT04697368|Device|Exoskeleton-Assisted Upper Limb Rehabilitation|"The patients will be undergone 25+/-3 Armeo-P training sessions, each lasting 40 minutes (i.e. five times a week for five consecutive weeks). During the first session, the device should be adjusted to the patient's arm size and the angle of suspension. The working space and the exercises will be selected once the UL has been fitted with the system. The selection of personalized exercises will be based on the motor skills of each patient and the difficulty can be gradually increased during training. In particular, a course of exercises has been defined in which the difficulty (suspension rate; the level of assistance; the complexity of movement (1D, 2D, 3D)).~The physiotherapist will choose the modality based on the patient's motor skills (standardized personalized training)."
75912973|NCT04697368|Other|Traditional Upper Limb Rehabilitation|The control group (CG), in addition to the conventional treatment based on the routine rehabilitation program, will follow 25+/-3 sessions of traditional upper limb rehabilitation (i.e. five times a week for five consecutive weeks). Each session will consist of passive, active-assisted, and active exercises addressed for shoulder, arm and hand motor rehabilitation.
75912974|NCT04692155|Drug|Ublituximab|Ublituximab (900mg) will be administered as an intravenous infusion through a dedicated line.
75912975|NCT04692155|Drug|Umbralisib|Umbralisib(800mg)will be administered orally once daily within 30 minutes of starting a meal.
75912976|NCT04676373|Drug|ALGLUCOSIDASE ALFA|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
76073084|NCT00686842|Genetic|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
75320511|NCT04275830|Behavioral|Heart rate variability waitlist and Digital storytelling Control intervention|Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
75621791|NCT00836875|Drug|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing <50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
76073085|NCT00686842|Genetic|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
76073086|NCT00686842|Genetic|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
76073087|NCT00686842|Other|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
75320512|NCT03152864|Behavioral|Full Package|Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
75775199|NCT03518008|Device|somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
75775200|NCT01091324|Drug|Dextromethorphan|60 mg, bid
75775201|NCT01091324|Drug|Silymarin|150 mg , tid
75775202|NCT01091324|Drug|sugar pill|placebo
76073088|NCT00686842|Other|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
75775203|NCT03725488|Other|Questionnaire|"students were involved in the pre-clinical prosthodontic lab. Participation in these labs were mandatory and it involved crown and bridge preparations on typodont models. There were 2 sessions of these labs per week, one for each gender. Each session lasted for 3 hours.~The study was conducted in 2 phases. At the beginning of the first phase of the study, the labs were conducted without any BM for 4 weeks. PSS(perceived stress scale), a standardized and validated, self-reporting international test was used for measuring the level of psychological stress were administered to all participants."
75775204|NCT03810014|Other|Conditional ACT subsidy, Arm 1 levels|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
75775205|NCT03810014|Other|Conditional ACT subsidy, Arm 2 levels|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
75775206|NCT03810014|Other|Conditional ACT subsidy, Arm 3 levels|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
75775207|NCT03810014|Other|Conditional ACT subsidy, Arm 4 levels|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
75621792|NCT02732314|Drug|Investigational OTC Cream|
75621793|NCT02732314|Other|Cosmetic Eczema Cream|
76073089|NCT00686842|Other|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
76073090|NCT00686842|Procedure|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
76073091|NCT00687076|Drug|Ezetimibe|Daily dose of 10 mg of Ezetimibe
75466191|NCT01906710|Other|integrated medicines management|"PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge"
75621794|NCT02732314|Drug|0.05% Desonide Cream|
75621795|NCT02732314|Other|Placebo Cream|
75621796|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
75621797|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
75621798|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
75621799|NCT02732236|Other|Rituximab|Cohort observation study
75621800|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 100mg OD|Magnesium Isoglycyrrhizinate Injection 100mg OD
75621801|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 200mg OD|Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
75621802|NCT02734966|Drug|Tiopronin Injection|Tiopronin Injection 200mg OD
75621803|NCT00847561|Behavioral|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
75621804|NCT00847561|Behavioral|Information Monitoring|Packet providing information on strategies for coping with anxiety
75621805|NCT05569837|Other|Regular meal pattern|6 meals every day
75621806|NCT05569837|Other|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
75621807|NCT01121549|Drug|Aromasin|25 mg daily continuously
75651618|NCT05833672|Drug|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
75651619|NCT05833659|Procedure|The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy|Group A:The prepectoral breast reconstruction. Group B:The subpectoral breast reconstruction
75651620|NCT05833646|Device|Group 1|In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.
75651621|NCT05833646|Device|Group 2|In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.
75651622|NCT05833646|Device|Group 3|In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.
75651623|NCT05833581|Other|New York Heart Association Classification Guide|The New York Heart Association Classification Guide is a questionnaire that assists in guiding the provider in selection of the patient's class
75651624|NCT05833568|Device|Active Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~tACS stimulation will be applied for 20 minutes for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: [right hemisphere: E83, E90, E96, E84, E91] and for the [left hemisphere: E58, E65, E70, E66, E59]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the tACS condition."
75651625|NCT05833568|Device|SHAM Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~SHAM stimulation will be applied for a 2-minute ramp-up, then the current will stop for 20 minutes, followed by a 2-minute ramp-down. This will be applied for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: [right hemisphere: E83, E90, E96, E84, E91] and for the [left hemisphere: E58, E65, E70, E66, E59]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the ramp-up and down in the SHAM conditions."
75651626|NCT05833555|Behavioral|MH task-sharing training|Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
75651627|NCT05833555|Behavioral|Supervision|Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
75651628|NCT05833555|Behavioral|Learning Collaborative|A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
75651629|NCT05833555|Other|Technology Intervention|To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
75320513|NCT00517595|Drug|Pemetrexed and Gemcitabine plus Bevacizumab|Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m^2 and gemcitabine 1500 mg/m^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
75775208|NCT05782725|Other|Comparison of laboratory test results in women in the 4 study arms|Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms
75775209|NCT05782621|Other|Acupoint focused ultrasound|An ultrasound beam is normally pulsed in the ratio of 1:5. For perfect transmission of power from the treatment head to the body, the head will be applied perpendicularly to the skin surface. A stationary technique pulsed ultrasound (1 w/cm2) will be used. The application will be two minutes for each acupuncture point and the head will be glided to the next point in the same side; then to the other side for no more than 10 points, then the device will be turned off
75775210|NCT05782621|Other|Laserpuncture|"The laser tip (0.03 cm2 of beam area) will be positioned with the probe head directly on the acupuncture point, in a perpendicular position and in direct contact with the skin, and every point will be treated for 2 min, totaling 16 min of treatment, plus 4 min of rest, to standardize with the traditional acupuncture time, which is 20 min"
75621808|NCT02732002|Procedure|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
75320514|NCT02014844|Drug|aldoxorubicin|
75775211|NCT05782621|Other|conventional treatment|the patients will receive selective neck strengthening ex for (extension, flexion, sidebending, lateral rotation) and selective neck stretching ex for (extension, flexion, sidebending, lateral rotation)
75775212|NCT05782595|Other|Aquatic therapy|"• Each session was divided into three phases:~Aquatic environment adaptation phase~stretching phase~a phase of static and dynamic exercises for balance"
75775213|NCT05782556|Device|Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
75320515|NCT01672814|Drug|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
75775214|NCT05782543|Procedure|Normothermic machine perfusion|To determine whether a 4-6 hour period of normothermic machine perfusion, following standard hypothermic machine perfusion, results in better graft function after transplantation, compared to hypothermic machine perfusion preservation alone of kidneys recovered from deceased donors aged 50 years or older
75775215|NCT05782504|Behavioral|Patient-centered teleprehabilitation|"Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes.~Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software.~Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced.~Motivational interviewing will be used during the whole intervention."
75912977|NCT04667234|Drug|AMG 510|Administered as an oral tablet.
75912978|NCT04663321|Drug|MK-1942|MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.
76073092|NCT00687076|Drug|Niaspan|Daily dose of 1500 mg of Niaspan
75320516|NCT01672814|Device|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
75466192|NCT01906723|Device|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
75466193|NCT01906749|Drug|Colchicine|0.5mg once daily orally
75466194|NCT01906749|Drug|Placebo|
75466195|NCT01906762|Drug|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
75466196|NCT01906762|Drug|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
75621809|NCT00847405|Drug|Sumatriptan Succinate|100 mg Tablets
75320517|NCT00638365|Biological|KB001|Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
75320518|NCT00638365|Other|Placebo|Placebo single-dose administered intravenously
75320519|NCT04764890|Other|Electroacupuncture|Electroacupuncture in several point
75320520|NCT04764890|Other|Manual therapy|Manual therapy in the lower spine.
75320521|NCT00524225|Drug|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
75320522|NCT00669019|Drug|saracatinib|
75320523|NCT01673048|Procedure|3-Nail-ESIN in femoral shaft fractures|
75320524|NCT05560373|Drug|Huperzine A injection, operational treatment, the best basic treatment|intramuscular
75320525|NCT05560373|Other|operational treatment, the best basic treatment|other
75621810|NCT00847405|Drug|Imitrex®|100 mg Tablet
76073093|NCT00687076|Drug|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
75320526|NCT05560373|Drug|Huperzine A injection, interventional treatment, the best basic treatment|intramuscular
75320527|NCT05560373|Other|Interventional treatment, the best basic treatment|other
75320528|NCT02140957|Behavioral|Educational Intervention|Parents of children in both intervention and control groups received standardized counseling on healthy nutrition based on Canadian Paediatric Society guidelines. In addition, during the same 9-month doctors visit, parents of infants allocated to the intervention group were given a sip cup (Avent Magic CupTM) and shown how to use it. A trained research assistant told intervention group parents the risks of continued bottle use. They were also instructed to limit daily milk consumption to 16 ounces. Parents were also counseled to discontinue bottle use in the next 1 week using a step-wise protocol described on a handout to be placed on their refrigerator. Parents of infants allocated to the control group did not receive this information.
75320529|NCT05560295|Procedure|Naser Al-Husban|uterine surgery
75466197|NCT01906775|Other|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
75466198|NCT01906788|Drug|Artemether Lumefantrine|
75621811|NCT04118413|Other|erector spinae plane block|Erector espine plane block will be administrated bilaterally to this group at low thoracic level (Th11).
75621812|NCT03268096|Device|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
75621813|NCT02734654|Procedure|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
75775216|NCT05782478|Diagnostic Test|Point of care Ultrasound according to study protocol|An emergency medicine specialist or resident will according to a structured protocol perform a structured ultrasound examination of the heart, the inferior vena cava and the lungs.
75775217|NCT05782465|Procedure|Blood Collection, processing and analyses|20ml of blood will be drawn from study participant at the baseline visit for molecular analyses.
75775218|NCT05782465|Procedure|Gastroscopy and biopsies collection|Study participant will undergo gastroscopy with collection of gastric mucosal biopsies at the baseline visit to ascertain OLGIM status and for molecular analyses. Study participant will undergo surveillance gastroscopy for gastric cancer at years 2 and 4 to assess whether they have reached endpoint.
75912979|NCT04663321|Drug|Placebo|Dose matched placebo capsules BID orally over 4 weeks.
75912980|NCT04663178|Other|Warm Salt Water Foot Bath|A training booklet about chemotherapy-induced fatigue + 20-minute warm salt water application to their feet for a week after the treatment by explaining and showing the video prepared about the preparation and practice of warm salt water foot bath.
75912981|NCT04654546|Other|Ultrasound abdominal scan|"A complete ultrasound scan of the abdominal organs using a clinical ultrasound device in the Imaging Institute at Haemek medical center. The ultrasound images will be visually coupled to previous CT images of the same patient at the time of the examination, using a Fusion system located in the ultrasound device mentioned above.~The coupled CT and ultrasound images will be encoded and be sent to the SAMPL laboratory in Weizmann institute, there it will serve as a learning platform for the artificial intelligence system."
75936394|NCT02435186|Drug|p53 gene|p53 gene will be given intraperitoneally.
75936395|NCT02435186|Drug|Cisplatin|150 mg/m^2 cisplatin will be given intraperitoneally.
75936396|NCT02435186|Drug|Paclitaxel|Paclitaxel (175 mg/m2, 3 h) will be given by iv
76073094|NCT00687076|Behavioral|Standard care|Standard of medical care for PAD
76073095|NCT00687076|Drug|Aspirin|Daily dose of 325 mg of aspirin
76073096|NCT00687076|Drug|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
76073097|NCT00687076|Drug|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
76073098|NCT00687076|Drug|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
76073099|NCT00687076|Procedure|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
75466199|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
75466200|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
75466201|NCT01906801|Drug|Glucosamine sulfate|
75466202|NCT01906801|Drug|Diacerein|
75466203|NCT01906801|Drug|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
75466204|NCT01906840|Drug|Turmeric|
75466205|NCT01906840|Drug|placebo|
75466206|NCT01906879|Drug|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
75466207|NCT01906892|Other|Group drumming (participatory)|Active participation in group drumming workshops
75466208|NCT01906892|Other|Group drumming (live)|Listening to live performances of group drumming
75466209|NCT01906892|Other|Group drumming (recorded)|Listening to recorded performances of group drumming
75621814|NCT04115995|Diagnostic Test|Dynamic infrared thermography (DIRT) and indocyanine green fluorescence angiography (ICG-FA)|DIRT and ICG FA are used intraoperatively to evaluate perfusion of the perforators and the anastomosis. Both technique are compared in their ability to visualize perfusion.
75621815|NCT02881931|Behavioral|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
75621816|NCT02731846|Drug|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
75621817|NCT02731846|Drug|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
75621818|NCT02731846|Drug|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
75621819|NCT02731846|Device|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
76073100|NCT00687544|Biological|Peginterferon alfa-2b (SCH 054031)|Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
75320530|NCT04747574|Drug|EXO-CD24|The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
75621820|NCT02731846|Drug|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
75775219|NCT05782465|Diagnostic Test|Urea Breath Test|Study participant will fast for 6 hours or overnight before undergoing the Urea Breath Test (UBT) to test for current H. pylori infection. Breath collection will be performed before ingestion of 13C urea, and at specified time intervals after ingestion.
75775220|NCT05782452|Procedure|Ophthalmic examination|Facial photographs of the participants were obtained at the time of enrolment. Pre- and post-operative anterior eye segment photographs were obtained under diffuse, direct focal and retro illumination. Clinical data, including basic information, family history, and comprehensive pre- and post-operative ophthalmic examination findings, were recorded.
75912982|NCT04652908|Biological|Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix|As in the current standard fetal surgery, under sonographic guidance, initial uterine entry will be accomplished by uterine stapling device or similar. The fetus will be given an intramuscular injection of pain medications and paralytic. The myelomeningocele will be closed in a standardized manner under magnification. As in the standard fetal operation, the spinal cord will be dissected from surrounding tissue and allowed to drop into the spinal canal. The PMSC-ECM product will then be tailored to the size of the spinal cord and applied topically, cell side down. The PMSC-ECM product will be sutured in place to the dura. Finally, the fetal skin will be closed in the standard fashion. The amniotic fluid volume will be replaced and antibiotics will be added. The uterus will be closed. The abdominal fascial layer and skin will be closed in routine fashion.
76073101|NCT00687544|Drug|Ribavirin (SCH 018908)|Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is <65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is >85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
75320531|NCT01676480|Behavioral|Endurance training|12 weeks of endurance training 3 times per week
75320532|NCT05560139|Device|a-tDCS|Transcranial direct current stimulation
75621821|NCT00836095|Device|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
75621822|NCT00836095|Device|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
75621823|NCT05564455|Other|Biometry with Kane formula|Kane formulae for intraocular lens (IOL) power calculation in cataract patients
75621824|NCT05564455|Other|Biometry with SRK-T formula|Sanders Retzlaff Kraff theoretical (SRK T) formulae for intraocular lens (IOL) power calculation in cataract patients
75621825|NCT02731924|Procedure|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
75621826|NCT02731768|Behavioral|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
75775221|NCT05782452|Genetic|Whole-exome sequencing|Performing whole-exome sequencing and bioinformatics analysis.
75775222|NCT05782439|Other|Manual evaluation of ITB tension|There will be a double evaluation for each sampling session: 1) if there is a uniformity of the tension between the two sides, or if there is a prevalence on one side; 2) quantification of the difference, if present, with a graduation in 3 levels.
75912983|NCT04652908|Other|Untreated contemporaneous cohort|The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.
75912984|NCT04649749|Diagnostic Test|MRI|MRI scan
75936397|NCT03842657|Combination Product|anticoagulation of the dialysis circuit|Each patient included in this study will receive two heparin-free dialysis sessions with heparin-grafted membrane (control group) or RCA with calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance (experimental group), alternatively
75320533|NCT00670267|Drug|nadolol|Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
75320534|NCT05621915|Drug|Nadroparin|Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.
75320535|NCT01673204|Drug|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
75936398|NCT02435108|Drug|crizotinib|crizotinib 250mg bid daily
75320536|NCT01673204|Drug|Placebo|
75775223|NCT05782426|Drug|paclitaxel polymeric micelles for injection|Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
75775224|NCT05782400|Radiation|CT scan|CT scan at baseline and then every three months as per clinical practice. The standardization of the procedure of images' collection through a CT- acquisition's protocol has been planned to control bias.
75775225|NCT05782400|Biological|Plasma collection|● Blood samples will be collected at baseline, at 1 month and at the first PD. Sixteen ml of blood will be collected in EDTA tubes and centrifuged at 1900×g for 10 min at 4 °C within 2 h after drawing to collect plasma, which will be stored at -80°C until analysis. Plasma samples will be sent to the Laboratory of Pharmacogenetics - Unit of Clinical Pharmacology and Pharmacogenetics - University Hospital of Pisa. Plasma samples will be used to isolate cell free DNA (cfDNA) and microvesicles-derived RNA for molecular analysis.
75912985|NCT04648787|Behavioral|family-integrated care|One week after admission, the parents of premature infants were informed by telephone one day in advance to enter the ward for family participation nursing, and the guidance of daily life nursing for premature infants was given on the same day, including hand hygiene, breast feeding, pacification, changing diapers, bathing and establishment of parent-child relationship. Before discharge, theparents of premature infants should be informed by telephone one day in advance to enter the ward again for family participation nursing, and half a day's guidance was given, including observation and treatment of common symptoms and signs, guidance of home safety prevention and learning to write diary of premature infants.
75775226|NCT05782374|Drug|Ibrutinib|ibrutinib alone or in combination with R-CHOP or R-CHOP like
75912986|NCT04648787|Behavioral|traditional nursing|In hospital education: the health education manual for premature infants will be issued at the time of discharge; the patient's condition will be answered by telephone from 14:00 to 16:00 every day.
75320537|NCT05621837|Other|MDSC quantification|Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
75912987|NCT04639869|Drug|Phenyramydol HCl 400 mg Film Tablet|Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
75912988|NCT04639869|Drug|Cabral 400 mg Film Tablet|Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
75320538|NCT00641563|Drug|Dexmedetomidine|Infusion of dexmedetomidine
75320539|NCT00641563|Drug|Midazolam|Midazolam infusion
75775227|NCT05782348|Behavioral|Cognitive behavioral intervention|A six-session CBI Intervention component will be used with the TEST GROUP I. This will examine a cognitive behavioral intervention designed to improve tooth brushing and oral hygiene. The components include oral health education, values-based activities, motivational interviewing, goal setting, problem solving skills, cognitive restructuring, verbal reinforcement and stress management.
75775228|NCT05782348|Other|Colgate smart toothbrush|A Colgate smart toothbrush that provides the user with details on toothbrushing habits and frequency
75320540|NCT00641563|Drug|Remifentanil|Infusion of remifentanil
75775229|NCT05782322|Behavioral|Upper-limb training involving RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
75912989|NCT04639128|Device|Adductor Canal Catheter|The adductor canal catheter is a medical device that consists of a tunneled catheter connected to an analgesic solution-containing reservoir that slowly infuses the anesthetic over the first 2-3 postoperative days
75320541|NCT02251262|Device|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
75936399|NCT02434952|Drug|Dihydroartemisinin piperaquine (DHA PP)|
75936400|NCT02434952|Drug|Primaquine|
75936401|NCT04741607|Device|Implant placement (BLX implant system, Straumann, Basel, Switzerland)|Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
75320542|NCT00641641|Drug|Tenofovir + emtricitabine + raltegravir.|TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
75320543|NCT03152474|Drug|Solumedrol 20mg|Dosed Intravenous every 8 hrs.
75320544|NCT03152474|Drug|Vitamin A 100,000 IU|Dosed Intramuscular once daily
75320545|NCT03152474|Other|Placebo|Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
75320546|NCT00641797|Drug|Meclizine|medication administration 25mg PO one time
75320547|NCT00641797|Other|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
75320548|NCT00641797|Drug|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
75320549|NCT00641797|Drug|Diphenhydramine|25 - 50mg PO/IV once prn
75320550|NCT00641797|Drug|Ondansetron|Ondansetron 4 - 8 mg PO/IV prn
75320551|NCT04333459|Biological|Hataan DNA Vaccine/Puumala DNA Vaccine|Vaccine compared in High and Lose Doses.
75320552|NCT00671515|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
75320553|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be administered 700mg BID in the fed state for three days.
75775230|NCT05782322|Behavioral|Upper-limb training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
75912990|NCT04631185|Drug|Single pre-operative dose of intravenous antibiotics with intraoperative redosing|Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
75912991|NCT04631185|Drug|One week of post-operative antibiotics|The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.
75912992|NCT04626284|Procedure|Heart Transplantation|Heart Transplantation
75912993|NCT04617587|Behavioral|Early Intervention|The early intervention (EI) is delivered during the NICU stay. It is a multisensory intervention which consists in three parts: parental training, massage therapy and visual interaction. The EI is first focused on parental training, according to PremieStart Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior through the identification of infant's behavioral states; adopt principles of graded stimulation; sustain infant's attention and respond to infant's cues; optimize interactions and avoid overwhelming infants through facilitation strategies. The program is held in eight main sessions and one additional post-discharge session. In addition, parents are trained and invited to daily promote preterm baby massage therapy and visual interaction (visual fixation/tracking and visual attention).
75912994|NCT04611282|Procedure|surgical techniques in the treatment of localized gingival recession defects.|Micro or macrosurgical echniques were performed using a coronally positioned flap with a subepithelial connective tissue graft.
75912995|NCT04604353|Diagnostic Test|Polygenic Risk Score|Risk description to patient based on PRS
75912996|NCT04604353|Diagnostic Test|Coronary Calcium Score|Risk description to patient based on CCS
75912997|NCT04588402|Biological|The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals.|"Women will be approached one time only, when they will attend the gynecology out-patients department for various reasons. After signing the informed consent, the participants will fill in a risk factor questionnaire to study the socio-demographic information, sexual history and HPV vaccination history and the determinent of HPV infection. The questionnaire will be administered by a trained social worker or nurse.~A gynecologist will collect cervical cells from the participant's cervix during a gynecological examination. The cervical specimen will be examined for presence of specific HPV genotypes and Chlamydia infection."
75912998|NCT04577807|Biological|Lerapolturev|Lerapolturev administered via direct lesion injection
75912999|NCT04577807|Biological|Anti-PD-1 Checkpoint Inhibitor|Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions
75913000|NCT04562987|Behavioral|Physical Activity|Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.
75913001|NCT04562987|Behavioral|Attentional Control|Mobile app intervention delivered during chemotherapy for breast cancer that includes telecoaching on general and cancer-related health topics and basic physical activity monitoring.
75913002|NCT04546295|Other|Brushlink application|Brushlink application + Interproximal brush
75913003|NCT04546295|Other|Water-flosser|Water-flosser
75913004|NCT04546295|Other|Interproximal brush|Interproximal brush alone
75913005|NCT04540861|Drug|Siponimod|1 or 2 mg film-coated tablets. The tablets have to be taken orally once daily and swallowed whole with water, with or without food.
75913006|NCT04525950|Procedure|Navio|New generation computer navigation with haptics and robotics
75913007|NCT04525950|Procedure|Conventional|Total knee arthroplasty using conventional instruments
75913008|NCT04508244|Drug|Placebo|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 & 4 and 1 ampoule/day for day-5 & 6.
76073102|NCT02998060|Procedure|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
75775232|NCT05782257|Dietary Supplement|Zinc Supplementation|Take one 25mg Zn gluconate tablet daily
75775233|NCT05782257|Other|Zn-Optimized Diet|Consume 11 mg/day of zinc-rich foods for females and 14 mg/day in males.
75775234|NCT05782192|Drug|SAL067|SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
75775235|NCT05782192|Drug|Alogliptin|Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)
75775236|NCT05782192|Drug|Placebo|placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
75913009|NCT04508244|Drug|Propranolol|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 & 4 and 1 ampoule/day for day-5 & 6.
75913010|NCT04507100|Behavioral|World Health Organization Health Promoting Schools|"Healthy eating: regulation and monitoring of food sold in school cafeterias, healthy eating behavior change campaign, provision of healthy breakfasts.~Physical activity: hourly active breaks during classes, quality physical education, active recess, and extra-curricular leisure activities and tournaments.~Healthy hydration: access to water fountains and regular monitoring of water safety, regulation and monitoring of beverages sold in the school, and social marketing campaign promoting drinking plain water.~Other cross-sectional activities: Referral of children identified as living with underweight, overweight, or obesity, training for school directors, teachers and parents, establishment of school objectives to become a health promoting school, monitoring progress, and publicly acknowledging school progress in becoming a health promoting school."
75913011|NCT04506190|Procedure|Revisional bariatric surgery|Subjects who undergo revisional bariatric surgery
75320554|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be given 450mg BID for a duration of 10 days.
75320555|NCT01893320|Drug|Vosaroxin|"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."
75621827|NCT02731768|Behavioral|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
75621828|NCT02731768|Device|Fitbit Zip|
75621829|NCT02731768|Device|Digital body weight scale|
75621830|NCT02694484|Other|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
75621831|NCT04248712|Drug|Famotidine|40 mg tab twice daily by mouth for 12 week duration
75621832|NCT04248712|Drug|Loratadine|10 mg tab once daily by mouth for 12 week duration
75621833|NCT04248712|Drug|Placebo|Contains no active ingredient
75621834|NCT02734732|Drug|Trimethoprim/Sulfamethoxazole|
75621835|NCT02734732|Drug|Ciprofloxacin|
75621836|NCT00835237|Biological|Boostrix®|Intramuscular, single dose.
75621837|NCT00835237|Biological|Decavac™|Intramuscular, single dose.
75621838|NCT02731378|Drug|Erythropoietins (EPO)|A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
75621839|NCT02731378|Drug|Aggressive iron dextran supplementation|Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
75621840|NCT02731378|Drug|Erythropoietins (EPO)|Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
75621841|NCT02731378|Drug|Sustained iron dextran supplementation|Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
75621842|NCT00704119|Drug|RhuDex®|"Treatment A.1: 31.65 mg RhuDex® once N=12~Treatment A.2: 63.33 mg RhuDex® once N=12~Treatment A.3: 126.63 mg RhuDex® once N=12~Treatment A.4: 253.26 mg RhuDex® once N=12~Treatment B.1: 31.65 mg RhuDex® once N=12~Treatment B.2: selected dose of RhuDex® once N=12~Treatment C: selected dose of RhuDex® once N=12~Treatment D: selected dose of RhuDex® twice daily for 6 days N=12"
75621843|NCT02731456|Other|altitude exposure|altitude exposure
75621844|NCT04118335|Other|Black Mulberry Syrup|The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
75621845|NCT02731534|Drug|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
75621846|NCT02731534|Drug|Saccharated Ferric Oxide|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
75913012|NCT04502719|Diagnostic Test|Nutritional screening.|Nutritional screening with the RFH-NPT and LDUST questionnaires.
75913013|NCT04499963|Drug|Theracurmin HP|The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment
75320556|NCT01893320|Drug|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
75320557|NCT01799707|Behavioral|vision restoration training|visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
75320558|NCT01799707|Behavioral|Discrimination Training|the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
75621847|NCT04115917|Device|Schocket scleral depressor|Scleral Depression on eye with Schocket scleral depressor
75621848|NCT04115917|Device|Cotton tipped applicator|Scleral Depression on eye with cotton tipped applicator
75621849|NCT02734420|Drug|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
75621850|NCT02734420|Drug|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
75621851|NCT02734420|Device|Laser|
75913014|NCT04479241|Biological|lerapolturev|Lerapolturev (5x10^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
75913015|NCT04479241|Biological|pembrolizumab|Pembrolizumab (200 mg IV) given every 3 weeks.
75913016|NCT04461210|Diagnostic Test|Thermographic Imaging and Mechanical Pain Assessment|Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera
75913017|NCT04460287|Dietary Supplement|DHA Wet Mixing method|Children will drink milk contain 100 mg DHA wet mixing daily for 30 days
75913018|NCT04460287|Dietary Supplement|DHA Dry Blending Method|Children will drink milk contain 100 mg DHA dry blending daily for 30 days
75913019|NCT04460287|Dietary Supplement|Fish Oil|Children will have this intervention every day for 30 days
75775237|NCT05782166|Behavioral|Betel Quid Educational Booklet|"Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
75320559|NCT00648115|Other|Basic Vocational Services|Vocational services
75775238|NCT05782166|Behavioral|Betel Quid Cessation Intervention Module|"All eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~An interactive, educational talk will be given regarding the content of the educational booklet.~Participants will undergo a 5-intervention sessions cessation program (M-BENIT) and will be given topical worksheets on every session to monitor their triggers, lifestyle changes, social support system and others.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
75775239|NCT05782140|Device|Mayo Clinic Watch Device|Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
75775240|NCT05782114|Other|Extracorporeal Shockwave therapy|The shockwave will be applied for the experimental group (Group A). The patients will be positioned on a chair, and the hand with the disorder will be placed on a surface with the radio ulnar joint will be in mid position and the thumb will be directed up. will be 1000 impulses with 2 bar pressure at a frequency of 15 Hz on the radial head and focused on the tissue surrounding the maximal pain point.
75621852|NCT04117867|Behavioral|Patiens with intraoperative hypotension|In this study, we will use four previously defined thresholds for intraoperative hypotension: two absolute thresholds (MAP less than 50 mmHg and MAP less than 60 mmHg) and two relative thresholds to the baseline MAP (a decrease of 30% or more and a decrease of 40% or more). A definition of baseline value most frequently reported was the arterial blood pressure before the induction of anesthesia. Therefore, the baseline MAP used in calculating the relative thresholds is defined as the mean MAP of all available blood pressure measurements before induction of anesthesia in the operating room.
75913020|NCT04451954|Biological|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75913021|NCT04451954|Biological|Quadrivalent RIV with H3 strain 1 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75913022|NCT04451954|Biological|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75913023|NCT04451954|Biological|Quadrivalent RIV with H3 strain 2 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75913024|NCT04451954|Biological|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75913025|NCT04451954|Biological|Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75320560|NCT00648115|Other|Self-Study|Veteran receives self-study resources
75621853|NCT02731066|Other|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
75913026|NCT04418804|Diagnostic Test|Chest ultrasound|"Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient."
75621854|NCT02731066|Other|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
75621855|NCT02731066|Other|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
75621856|NCT02731066|Other|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
75621857|NCT04118257|Dietary Supplement|Sugary beverage: Fruit juice|Participants consumed 100% fruit juice (~710mL) daily for three weeks, along with their habitual diets.
75621858|NCT04118257|Dietary Supplement|Sugary beverage: Soda|Participants consumed soda (~710mL) daily for three weeks, along with their habitual diets.
75621859|NCT04118257|Dietary Supplement|Control: Water|Participants consumed water (~710mL) daily for three weeks, along with their habitual diets.
75320561|NCT00648115|Other|Group Program|Veteran participates in group vocational program
75320562|NCT01799785|Behavioral|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
75320563|NCT01799785|Other|Usual Care|
75320564|NCT04244396|Device|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)|TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.
75621860|NCT01072500|Behavioral|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
75320565|NCT01673360|Device|Elevate PC|List of AMS prolapse products
75913027|NCT04366050|Drug|Ramipril 2.5 MG Oral Capsule|Include description or ramipril from protocol
75320566|NCT01673360|Device|Mini Arc Pro|List of AMS Urinary Incontinence devices
75621861|NCT01072500|Behavioral|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
75621862|NCT02731222|Other|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
75775241|NCT05782114|Other|Traditional physical therapy program|"Instruction to wear Thumb Spica splint:~The Thumb Spica splint will be used for 4 weeks for both groups of patients.~Ultrasound Therapy:~Therapeutic Ultrasound parameters will be mode: continuous, duration: 5 minutes, intensity: 1.2watt/cm2 and frequency: 1MHZ.~Stretching exercise:~1. Self-stretch of the thenar eminence: 2. Opposition stretches: 3. Wrist stretch:~4) Strengthening exercise:~Resisted exercise for thumb extension:~Resisted exercise for thumb abduction:~Resisted exercise for thumb opposition:~Wrist radial deviation strengthening:~Grip strengthening:~Finger spring:"
75621863|NCT00704275|Drug|0.05% cyclosporin eye drop|bid dosage for 4 months
75621864|NCT02734342|Other|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo & Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
75621865|NCT00847015|Drug|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
75621866|NCT00847015|Drug|Gemcitabine|Gemcitabine 1,000 mg/m^2
75621867|NCT00847015|Drug|cisplatin|cisplatin 35 mg/m^2 will be administered intravenously on days 1 and 8.
75621868|NCT04302792|Behavioral|Texture-modified foods for cancer patients (Stage 2)|Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.
75621869|NCT04302792|Behavioral|Taste-optimised foods for cancer patients (Stage 3)|Participants (cancer patients with taste & smell alterations) will be expected to evaluate three foods at home over a period of one month.
75621870|NCT00627354|Drug|etoposide|
75913028|NCT04366050|Drug|Placebo oral capsule|Placebo
75913029|NCT04330482|Behavioral|CARE-Well App|Participants randomized into this group will be instructed to use the CARE-Well App at least 4 times per week.
75320567|NCT01673360|Device|RetroArc|List of AMS Urinary Incontinence devices
75621871|NCT00627354|Drug|mitoxantrone hydrochloride|
75621872|NCT00627354|Drug|prednisone|
75621873|NCT00627354|Drug|vinorelbine tartrate|
75621874|NCT02612935|Device|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
75621875|NCT00704431|Drug|SB-480848 (darapladib)|160 mg darapladib
75621876|NCT02734186|Drug|Praziquantel|Anthelminthic
75621877|NCT00704509|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
75621878|NCT00704509|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
75621879|NCT00704509|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
75621880|NCT02730910|Other|Purple Wheat Crackers|Whole grain crackers manufactured with purple wheat
75913030|NCT04330482|Behavioral|Internet Links|Participants randomized into this group will be instructed to use a computer tablet pre-loaded with a list of internet links relevant to dementia caregiving at least 4 times per week.
75913031|NCT04325503|Drug|carbidopa|carbidopa and carbidopa-levodopa standard treatment
75913032|NCT04301843|Drug|Eflornithine|DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.
75913033|NCT04299191|Drug|LAM561|"Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561."
75913034|NCT04282031|Drug|BPI-1178|BPI-1178 once daily on Days 1 to 21 of a 28-day cycle
75320568|NCT00672451|Dietary Supplement|rhubarb extract|titrate rhubarb extract titrated up to 6grams daily by mouth
75320569|NCT00672451|Dietary Supplement|placebo|placebo titrated up to 6 pills daily as patient tolerates
75621881|NCT02730910|Other|Purple Wheat Granola Bars|Whole grain granola bars manufactured with purple wheat
75621882|NCT02730832|Other|Questionnaires completed at D0|
75621883|NCT02730832|Other|Questionnaires completed at D15 (test-retest for 30 patients)|
75621884|NCT02733952|Drug|Tranexamic Acid|
75621885|NCT02733952|Procedure|Pericervical Tourniquet|
75913035|NCT04282031|Drug|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and on Day 1 of Cycle 2 and beyond
75913036|NCT04282031|Drug|Letrozole|Letrozole 2.5 mg once daily of a 28-day cycle
75913037|NCT04282031|Drug|BPI-1178|BPI-1178 once daily of a 28-day cycle
75913038|NCT04263038|Drug|Rivaroxaban|Anticoagulation
75320570|NCT04095871|Other|Observational study|No intervention, patients record the time of CISC
75320571|NCT01673672|Biological|CYT003|7 subcutaneous injections, weekly/biweekly within 10 weeks
75320572|NCT01673672|Biological|Placebo|7 subcutaneous injections, weekly/biweekly within 10 weeks
75775242|NCT05782049|Other|Ultrasound of the salivary glands|"Salivary gland ultrasound is, a non-invasive, non-irradiating and easily accessible examination, offers promising results for the diagnosis of primary SS. It allows the identification of changes in the homogeneity of the echostructure of the main salivary glands in the parotid and submandibular region.The patient lies on the examination table with the head slightly turned to the side opposite the gland being examined. The examination will be done on the parotid and submandibular glands on both sides.The parotid glands will be measured in length and width.The surface of the gland will be calculated: (length x width)/2.The sub-maxillary glands will be measured in length and surface.~The exam will be performed in 10 minutes."
75775243|NCT05782049|Other|Measurement of salivary flow|Saliva flow measurement, which consists of measuring the quantity of saliva that the patient can emit in 15 minutes
75913039|NCT04263038|Drug|Placebo|Study drug without active agent
75775244|NCT05782049|Other|A Schirmer test|A strip of blotting paper graduated from five to five millimeters is placed in the eye for 5 minutes, avoiding any corneal contact.
75913040|NCT04241172|Device|Experimental: Immersive Virtual Reality (HIVR)|"the HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving a visual and auditory biofeedback."
75775245|NCT05782023|Behavioral|Digital empowerment|The intervention will consist of a minimal interaction face-to-face before hospital discharge for risk factors profiling followed by actions for health empowerment, delivered through an ad-hoc developed web platform, which include: a) periodic delivery of email messages with links to educational, motivational and supportive materials for secondary prevention, b) access to a message box for questions and answers and c) possibility of video-calls with the preventive team.
75775246|NCT05781997|Diagnostic Test|cycloplegic refraction|Cycloplegic autorefraction will be attempted on all children using a table-mounted autorefractor . Cycloplegia will be achieved with three drops of 1% cyclopentolate administered 5 min apart and autorefractive measurements will be performed 30 min after the instillation of the last drop. Auto refraction readings of three consecutive measurements will be obtained and the average will be computed automatically in each eye. Each child will be reexamined until three measurements fell within 0.50 diopters (D) if any two measurements varied by >0.50D.
75913041|NCT04241172|Procedure|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~exercises with a patients sitting on the swimming pool edge with lower limb immersed in the water;~flexion-extension of the knee;~leg and hip circling;~flexion-extension of the ankle;~triple flexion;~water walking exercises."
75913042|NCT04241172|Procedure|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~exercises with a patient sitting on a chair (3 minutes per exercise):~flexion-extension of the knee;~leg and hip circling;~flexion-extension of the ankle;~triple flexion;~walking (with and without aids)."
75913043|NCT04236557|Behavioral|Music listening|Other than usual care, subjects will listen to a 30-min individualized playlists with preferred music genres sequenced by a registered music therapist according to the ISO-Principle when agitated.
75913044|NCT04236557|Behavioral|Audio Book Listening|Other than usual care, subjects will listen to to a 30-min audio-script of book reading in Cantonese (a common dialect in Hong Kong being spoken by most people) when agitated.
75913045|NCT04235816|Drug|Azithromycin|Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
75913046|NCT04235816|Drug|Placebo|Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation
75775247|NCT05781984|Procedure|Microsugical Excsosion|Microsurgical excision of pineal region tumor or endoscopic biopsy
75913047|NCT04226963|Drug|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
75913048|NCT04220385|Other|Group A|Subjects will perform following exercises, Single Leg Extension, Arm and Leg Lift, Balance Bridge, Single-Leg Twist, Single Leg Reach, Sideways Leg Lift, Single Arm Stand, Torso Twists and Plank exercise with minimum one set and maximum two sets. 30 seconds will be rest time between each set. Subjects will be encouraged to increase the number of repetitions after every 2 weeks, except in Plank exercise in which holding position time will be initially 30 seconds in each set and will be encouraged to increase holding time after every 2 weeks.
76073103|NCT02998060|Device|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
76073104|NCT02998060|Device|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
75320573|NCT03154112|Device|Measurement of oxygen consumption and caloric expenditure|This study will involve an ~1 hour, single point in time measurement of oxygen consumption, carbon dioxide production, resting energy expenditure, and respiratory quotient using two methods while patients are breathing an FiO2 of 40%. These measurements will be measured using the novel, responsive device and compared with gas collected simultaneously collected from a Douglas bag.
75320574|NCT04120766|Drug|Nicorandil|20 mg po qd
75320575|NCT04120766|Drug|Placebo|Matching tablet
75320576|NCT01673750|Other|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
75320577|NCT03159416|Drug|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
75775248|NCT05781945|Dietary Supplement|probiotics|supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2
75775249|NCT05781945|Other|standard therapy|standard therapy for sars-cov-2
75775250|NCT05781932|Procedure|Dermal barb suture combined with medical glue|In the experimental group, after tension reduction and suture were completed, the wound and surrounding skin were wiped clean with normal saline and clean gauze, and the blood accumulated in the wound was squeezed out. Histoacryl medical tissue glue (specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4[(toluene)amino]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)) were evenly spread on the surgical incision and kept in the butt state for 4 to 6 seconds. After it got solidify and dry, a sterile gauze covered the surgical incision. There was no need to disinfect and change the dressings after the operation. Patients can shower normally on the day after the operation by just avoiding rubbing the incision covered with glue. Patients can move normally 1-2 days after the operation, and the glue film falls off on its own within 5-10 days.
75775251|NCT05781867|Other|Manual therapy and conventional physical therapy treatment|manual therapy (chest mobilization, diaphragmatic myofascial release, myofascial release for pectoralis minor, pectoralis major, scaleni ),pursed lip breathing, diaphragmatic breathing and active range of motion exercises of upper limbs
75775252|NCT05781854|Drug|Epidural analgesia with bupivacaine and dexmedetomidine|Epidural analgesia with bupivacaine and dexmedetomidine
75775253|NCT05781841|Diagnostic Test|Detection of expression of SOCS3 gene|Detection of expression of SOCS3, in each samples using Real-Time PCR
75775254|NCT05781841|Diagnostic Test|Detection of expression of IFN-α gene|Detection of expression of IFN-α gene in each samples using Real-Time PCR
75775255|NCT05781841|Diagnostic Test|Detection of expression of IFN-β gene|Detection of expression of IFN-β gene in each samples using Real-Time PCR
75775256|NCT05781815|Procedure|dynamic hip screw|using dynamic hip screw in treatment of trochanteric fracture and dynamic hip screw with trochanteric stabilizing plate
75775257|NCT05781789|Other|Telehealth for preoperative evaluation|Conduct of preoperative evaluation remotely using Zoom application
75775258|NCT05781763|Behavioral|High intensity interval training (HIIT)|"2 HIIT sessions/week in self-selected activity and type of interval-session with in total 15 minutes interval time (85-90% of MHR) with active rest (50-70% of MHR) between intervals for 12 weeks~1 self-selected session at moderate or high-intensity/week for 12 weeks Standardized physical and digital coaching by a physiotherapist"
75775259|NCT05781763|Other|Control group|Continuing with exercise as usual during 12 months
75621886|NCT02694796|Behavioral|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
75621887|NCT05435170|Drug|linerixibat|linerixibat will be administered per the treatment sequence
75621888|NCT02733640|Drug|Pantoprazole|pantoprazole 40 mg once-daily
75775260|NCT05781685|Drug|Testosterone|Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
75775261|NCT05781685|Other|Placebo Syrup|Oil-based sublingual product.
75775262|NCT05781659|Procedure|Ultrasound elastography guided pleural biopsy|The patients will undergo ultrasound elastography (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
75775263|NCT05781659|Procedure|Traditional ultrasound guided pleural biopsy|The patients will undergo traditional ultrasound (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
75775264|NCT05781646|Diagnostic Test|Xpert MTB/RIF|CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
75913049|NCT04220385|Other|Group B|Subjects will perform Side Bridge, Bird Dog and Beginner Curl-up exercise in the first three weeks and Side Bridge, Bird Dog and Intermediate Curl-up exercise in the last three weeks. Repetitions per set will be 5, 4, 3 in first two weeks, 7, 6, 5 in third and fourth weeks and 9, 8, 7 in last two weeks. 8-10 seconds will be holding time in each repetition. 30 seconds will be rest time between each set
76073105|NCT02143648|Drug|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
76073106|NCT02143648|Drug|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
76073107|NCT02143648|Drug|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
75320578|NCT00673075|Drug|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
75320579|NCT00673075|Drug|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
75320580|NCT02250014|Procedure|cryotherapy|Undergo cryotherapy
75320581|NCT02250014|Biological|sargramostim|Given subcutaneously
75320582|NCT00651625|Device|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
75320583|NCT00651625|Device|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
75621889|NCT02733640|Drug|Ranitidine|ranitidine 150 mg twice-daily
75621890|NCT02730520|Other|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
75621891|NCT02730676|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
75320584|NCT03156608|Device|Novii ECG/EKG System|External fetal heart rate monitoring
75320585|NCT03156608|Device|External fetal heart rate monitoring|External fetal heart rate monitoring
75320586|NCT04022096|Drug|Tegoprazan 25mg QD|Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.
75621892|NCT02730676|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
75466210|NCT01906892|Other|Comparative activity|Taking part in a literary-based activity
75621893|NCT00855595|Drug|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
75775265|NCT05781633|Drug|eutidrone etoposide bevacizumab|Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.MRI of the brain with contrast enhancement was performed at baseline and every 6 weeks after enrollment; thereafter, patients with stable disease or a response could be assessed at a reduced frequency to every 9 weeks; central nervous system and noncentral nervous system lesions were assessed according to RANO-BM criteria and RECIST v1.1 criteria until disease progression, respectively.
75775266|NCT05781581|Other|no intervention|no intervention
75775267|NCT05781529|Procedure|Alveolar ridge augmentation with injectable platelets rich fibrin|Injectable platelets rich fibrin is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
75775268|NCT05781529|Procedure|Alveolar ridge augmentation with hyaluronic acid|Hyaluronic is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
75775269|NCT05781529|Procedure|Alveolar ridge augmentation with xenograft|Xenograft is added alone as a active compatator
75775270|NCT05781490|Drug|Lumentin® 44 Powder for oral foam|Lumentin® 44 is a foam for oral use.
75775271|NCT05781477|Behavioral|Bmum supportive system|Bmum is a web-based online tracking system that aims to improve positive attitude about breastfeeding
75621894|NCT00855595|Drug|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
76073108|NCT02997982|Drug|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
76073109|NCT00689260|Device|easypod|Subjects is aware that the device records injection information that can be viewed by user
75466211|NCT01906918|Procedure|IRPC, Remote preconditioning|The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
75621895|NCT00855595|Drug|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
75621896|NCT05434858|Other|Dual-energy CT (DECT) and ultrasound|DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.
75621897|NCT02733718|Device|NIRS (near-infrared spectroscopy)|mesenteric oxygenisation measurement
75775272|NCT05781451|Drug|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
75775273|NCT05781373|Procedure|Peep individualization|Intraoperative Peep individualization in order to achieve the lowest driving pressure
75775274|NCT05781269|Other|VLCKD|VLCKD diet treatment with medical food
75621898|NCT05433532|Drug|Azacitidine|Azacitidine: 75mg/m2 qd, d1-d7, subcutaneous injection
75775275|NCT05781269|Other|r-MedDiet|Mediterranean diet treatment
75775276|NCT05781230|Behavioral|High Intensity Exercises Program|HIE program consisted of ankle pump exercise, Quadriceps isometric exercise, Terminal extension exercise, Passive-active assistive-active range of motion exercise, Heel sliding exercise, Straight leg raise exercise. All exercises were performed for 3 sets of 15 repetitions.
75320587|NCT04022096|Drug|Lansoprazole 15mg QD|Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
75466212|NCT01906931|Device|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
75466213|NCT01906931|Device|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
75466214|NCT01906944|Drug|Bupivacaine 0.25%|Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
75466215|NCT01906944|Drug|Triamcinolone|Triamcinolone is a long-acting synthetic corticosteroid.
75621899|NCT05433532|Drug|Venetoclax|Venetoclax: 100mg d1, 200mg d2, 300mg d3, 400mg d4-d14 or 21, oral (Adjusted according to the peripheral blood BCR/ABL1 results on day 14)
75621900|NCT05433532|Drug|Flumatinib|Flumatinib: 600mg qd, d4-d21, oral
75621901|NCT00855439|Drug|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
75775277|NCT05781230|Behavioral|Low Intensity Exercises Program|LIE program: LIE program was similar to the HIE program. Main differences from the HIE program was repetitions of exercises. All exercises were performed by the patients for 2 sets of 8 repetitions and CPM sessions lasted each exercises session. LIE program took thirty minutes while HIE program lasted sixty minutes. Exercise intensity was monitored using the rating of perceived exertion (RPE) scale, maintaining a range between 6 and 20 RPE (16). PRE< 8 indicates low intensity, PRE>14 indicates high intensity
75775278|NCT05781204|Other|Survey|Each participant completed an anonymous 62-item online survey.
75775279|NCT05781191|Biological|COMIRNATY|Booster (3rd) dose of COMIRNATY Seasonal dose of influenza vaccination based on patient's individual risk factors
75775280|NCT05781139|Diagnostic Test|levels of Neurofilaments (NfL) in serum|the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
75913050|NCT04218123|Drug|Venlafaxine|Daily oral intake 37.5 mg
76073110|NCT00689260|Device|easypod|Subjects is not aware that the device records injection information that can be viewed by user
76073111|NCT00689572|Drug|Ondansetron|4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
76073112|NCT00689572|Drug|Placebo|twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
76073113|NCT01840579|Biological|Pembrolizumab 2 mg/kg|Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
75621902|NCT00855439|Drug|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
75621903|NCT01064856|Biological|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
75775281|NCT05781126|Diagnostic Test|The Spatial Hearing Questionnaire, MINI-MENTAL STATE EXAMINATION, International Outcome Inventory - Hearing Aid, Glasgow Hearing Aid Benefit Profile, BECK-II and STAI questionnaires|a) medical history record, b) ENT examination, c) pure tone audiogram and speech audiometry (with and without the hearing amplification) d) listening effort evaluation (with and without the hearing amplification) Self-report and behavioral methods will be used: Evaluation of subjective performance (Spatial Hearing Questionnaire (SHQ) Evaluation of time response in auditory message Evaluation of speech comprehension with background noise or a competitive speaker e) cognitive function evaluation by using the Greek version of Mini-Mental State Examination, f) evaluation of hearing-aid satisfaction, by using the Glasgow Hearing Aid Benefit Profile (GHABP), and International Outcome Inventory - Hearing Aid (IOI-HA), questionnaires and g) evaluation of stress level and depression by using BECK-II and STAI questionnaires.
75775282|NCT05781061|Other|Screening for Eligibility|Asynchronous Screening for MA Eligibility
75775283|NCT05781048|Drug|HRS-6209|HRS-6209
75775284|NCT05781022|Procedure|endoscopic repair of iatrogenic esophageal perforation|"For patients in EG, we began with assessment of the site & size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
75775285|NCT05780996|Device|QMODE +|Atrial fibrillation radiofrequency ablation of the anterior and posterior wall with 90W (vHPSD)
75775286|NCT05780996|Device|QMODE|Atrial fibrillation radiofrequency ablation of the anterior wall with 50W (HPSD). Ablation of the posterior wall with 90 W (vHPSD)
75775287|NCT05780970|Other|No intervention|Non-treated children and caregivers complete assessments only. The primary (treated) parent / adolescent dyad participate in family based weight management treatment through the main trial. In the main trial, families are randomized to either TEENS+Parents as Coaches (parent skills training) or TEENS+Parent Weight Loss (parent behavioral weight loss).
75775288|NCT05780944|Behavioral|Paced Bottle-Feeding Education|Participants will be asked to review an educational handout that outlines how to implement PBF during bottle-feeding interactions. Participants will then be asked to watch a video that further describes PBF and illustrates how to implement it with a live infant. A trained research assistant will then answer questions, further explain PBF, and demonstrate PBF with a baby doll, using a standardized script
75775289|NCT05780905|Drug|Semaglutide Auto-Injector|"Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist.~At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively.~The target dose for subjects is 1mg per week up to the 52 week treatment duration."
75775290|NCT05780905|Other|Placebo|Placebo
75913051|NCT04218123|Drug|Placebo oral tablet|Daily oral intake
75913052|NCT04205240|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
75913053|NCT04205240|Drug|Cyclophosphamide|Given IV
75913054|NCT04205240|Biological|Daratumumab|Given IV
75913055|NCT04205240|Drug|Fludarabine|Given IV
75621904|NCT01064856|Biological|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
75466216|NCT01906983|Other|Doppler Ultrasound|Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
75913056|NCT04205240|Drug|Melphalan|Given IV
75913057|NCT04205240|Drug|Mycophenolate Mofetil|Given IV or PO
75913058|NCT04205240|Drug|Tacrolimus|Given PO or IV
75913059|NCT04201548|Other|Endurance Training|"These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980"
75466217|NCT01906996|Procedure|proximal row carpectomy|excision of the scaphoid, lunate and triquetrum
75466218|NCT01906996|Procedure|four corner fusion|excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
75936402|NCT04741607|Procedure|Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)|Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
76073114|NCT01840579|Biological|Pembrolizumab 10 mg/kg|Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
75621905|NCT02730442|Drug|F901318|Administration of F901318 intravenously
75621906|NCT02730442|Drug|Fluconazole|Oral administration
75621907|NCT02733874|Drug|Compound Clobetasol Propionate Ointment|
75621908|NCT02733874|Drug|Calcipotriol Betamethasone Ointment|
75621909|NCT02730364|Drug|Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
75621910|NCT02730052|Device|Omron 9200T plus Telemonitoring|Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
75320588|NCT01673906|Drug|Diagnostic work up|Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
75320589|NCT00673153|Drug|gemtuzumab ozogamicin|Given IV
75320590|NCT00673153|Drug|vorinostat|Given orally
75320591|NCT00673153|Other|laboratory biomarker analysis|Correlative studies
75320592|NCT00673855|Other|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
75621911|NCT02730052|Device|Omron 9200T without Telemonitoring|Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
75621912|NCT00846391|Drug|MK8245 5 mg (twice a day) b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening."
75621913|NCT00846391|Drug|MK8245 50 mg b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening."
75621914|NCT00846391|Drug|Placebo|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening."
75621915|NCT00636454|Behavioral|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
75621916|NCT00636454|Other|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
75621917|NCT01042392|Drug|Aliskiren|150 mg Aliskiren as film-coated tablet
75775291|NCT05780866|Other|Video and Activity Tracker|"At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study."
75775292|NCT05780840|Other|Dihydroxyacetone|Application of 10% dihydroxyacetone (2 mg per square cm skin)
75775293|NCT05780840|Other|Placebo|Application of lotion to the skin (2 mg per square cm skin)
76073115|NCT01840579|Biological|Pembrolizumab 200 mg|Administered as an IV infusion on Day 1 of each 21-day cycle
76073116|NCT01840579|Drug|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
76073117|NCT01840579|Drug|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
75320593|NCT00673855|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
75320594|NCT03956576|Other|[Pyr]apelin-13|Peptide [Pyr]apelin-13 infusion
75320595|NCT00654511|Drug|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
75320596|NCT00654511|Drug|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
75320597|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
75320598|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
75621918|NCT01042392|Drug|Ramipril|Ramipril 5 mg was given in capsule form.
75621919|NCT01042392|Drug|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
75621920|NCT01042392|Drug|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
75621921|NCT00704665|Drug|Relaxin|10 ug/kg/day or 25 ug/kg/day
76073118|NCT01840579|Drug|Carboplatin AUC 5 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
75621922|NCT00704665|Drug|Relaxin|Placebo
75320599|NCT01670084|Drug|nilotinib|Given PO
75320600|NCT01670084|Biological|rituximab|Given IV
75320601|NCT01670084|Drug|cyclophosphamide|Given IV
75320602|NCT01670084|Drug|doxorubicin hydrochloride|Given IV
75320603|NCT01670084|Drug|vincristine sulfate|Given IV
75320604|NCT01670084|Drug|methotrexate|Given IV or IT
75320605|NCT01670084|Drug|cytarabine|Given IV or IT
75320606|NCT01670084|Drug|prednisone|Given PO
75320607|NCT01670084|Drug|mesna|Given IV
75320608|NCT01670084|Drug|dexamethasone|Given IV or PO
75320609|NCT01670084|Drug|leucovorin calcium|Given IV
75320610|NCT01670162|Drug|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
75320611|NCT04345783|Drug|Camrelizumab for injection, apatinib mesylate and tegio|Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.
75320612|NCT04763954|Other|Rethink therapeutic game|The Rethink therapeutic game is a 7 levels online game developed and tested for children. Each level is based on a specific skill and its efficiency has been previously studies in children.
75320613|NCT02142361|Device|enfilcon A|Silicone hydrogel toric lenses.
75913060|NCT04201548|Other|Long High Intensity Interval Training|"The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000"
75913061|NCT04201548|Other|Short High Intensity Interval Training|"The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050"
75913062|NCT04176666|Device|NettOpp|NettOpp is a mobile application for adolescents aged 11-16 years who have been exposed to cyberbullying or cyberaggression.
75913063|NCT04174079|Drug|chemotherapy|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
75913064|NCT04153383|Drug|Milrinone Injection|giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV
75466219|NCT01907022|Device|Left DLPFC Butterfly Coil|"High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil"
75621923|NCT02694952|Biological|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
75621924|NCT02694952|Biological|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
75466220|NCT01907035|Behavioral|A cognitive-behavioral intervention|Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
75621925|NCT00913315|Drug|tolterodine|4 mg of tolterodine ER
75621926|NCT00913315|Drug|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
75621927|NCT00913315|Drug|placebo|placebo once a day for 8 weeks
75466221|NCT01907035|Other|Usual care|
75466222|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
75466223|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
75466224|NCT01907061|Drug|N-acetylcysteine|drug will be administered via IV,NG
75621928|NCT00701857|Drug|cisplatin|Standard weekly dose
75621929|NCT00701857|Drug|Pemetrexed|Biweekly pemetrexed dose escalation
75775294|NCT05780775|Other|HDL2|to perform additional blood samples during acute phase of complications (realized between Day 1 and Day 3) in SCD patients hospitalized for vasoocclusive crisis or priapism.
75775295|NCT05780554|Drug|Cyclophosphamide|Post transplant cyclophosphamide 25 mg/kg on day +3 and +4
75775296|NCT05780554|Drug|Cyclophosphamide|Post transplant cyclophosphamide 50 mg/kg on day +3 and +4
75466225|NCT01907061|Drug|Placebo|placebo or NAC will be given
75466227|NCT01907126|Behavioral|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
75466228|NCT01907126|Behavioral|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
75621930|NCT00701857|Radiation|radiation therapy|Weekly standard dose radiation therapy
75621931|NCT02730286|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
75775297|NCT05779709|Other|exercise|Reformer pilates is a specific type that provides resistance exercise at certain weights with the pulley system relying basically on the same principles. Pilates exercises provide breathing and activation of the deep stabilizing muscles of the trunk in coordination with the PFMs. It includes exercises that focus on pelvic stability, mobility and body alignment. PFMs activation is carried out simultaneously with the trunk muscles in various positions in coordination with breathing.
75775298|NCT05779709|Other|Urotherapy|Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation
75913065|NCT04127994|Other|Comparing 3 versus 6 meals in type 2 diabetes patients|We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability
75621932|NCT02733484|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
75621933|NCT02733484|Dietary Supplement|Placebo|the patients in this arm will receive placebo intervention
75621934|NCT02694640|Behavioral|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
75621935|NCT02694640|Behavioral|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
75621936|NCT02694640|Behavioral|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
75621937|NCT02733328|Procedure|CPB Surgery|
75621938|NCT05420272|Behavioral|Trunk performance and endurance lower extremity biomechanic|Trunk performance and endurance lower extremity biomechanic
75621939|NCT02729662|Drug|Tolvaptan|"Before administration of tolvaptan~TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)~24-hour urine collection・Hematology/urinalysis: Once/year~Physical findings: Blood pressure and medical interview at ambulatory visit~Hospitalization for education and examination at the start of tolvaptan administration~24-hour urine collection・Hematology/urinalysis・Inulin clearance~Physical findings: Body weight, blood pressure~Adverse Events~After administration of tolvaptan~TKV・Liver capacity・inulin clearance: Once/year~24-hour urine collection: Once/6 months~Hematology/urinalysis: Once/month in principle~Physical findings: Blood pressure and medical interview at ambulatory visit~Adverse Events"
75621940|NCT04203082|Behavioral|Exposure Intervention|Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
75621941|NCT04203082|Other|Usual Care|Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
75621942|NCT03195244|Other|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
75621943|NCT03194854|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
75621944|NCT02733250|Biological|Pembrolizumab|200mg IV Day 1 of each 21 cycles
75621945|NCT02733250|Drug|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
75621946|NCT02733094|Drug|Secukinumab|
75320614|NCT04764266|Diagnostic Test|Heparansulfate and Syndecan 1|Blood samples will be collected from the patient at 5 different time points. Three perfusate samples will be collected during normothermic machine perfusion (4,9ml each).
75621947|NCT03188068|Drug|Sirolimus|Oral administration
75466229|NCT01907139|Behavioral|Robot-assisted therapy|Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
75621948|NCT03188068|Drug|Prednisolone|Oral administered with sirolimus
75621949|NCT03304600|Device|Active stimulation|Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
75621950|NCT03304600|Device|Sham stimulation|Patients will receive a Sham stimulation during 30 mn
75621951|NCT02729506|Procedure|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
75913066|NCT04109222|Biological|Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75913067|NCT04109222|Biological|Fluzone High-Dose vaccine, 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
75320615|NCT01676636|Drug|Traditional Tablet|The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
75775299|NCT05777811|Procedure|Vertically coronally advanced flap combined with connective tissue graft.|The exposed root surfaces are planed with Gracey 1-2 curettes. An intrasulcular incision is made with a blade on the buccal aspects of the involved teeth. The incision is extended horizontally to the adjacent papilla. Then, slightly divergent vertical releasing incisions are carried 2 mm beyond the mucogingival junction. A full-thickness flap is raised with a periosteal elevator towards the mucogingival junction. After that, a partial-thickness dissection is carried out in the apical direction to release muscle tension and provide coronal advancement of the flap. The adjacent papillae are de-epithelialized. The connective tissue graft (CTG) is harvested from the lateral palate using the de-epithelialized gingival graft technique. After harvesting, the connective tissue graft is sutured to the recipient bed. Finally, the flap is positioned 2 mm over the cementoenamel junction and sutured with 6-0 polypropylene sutures. No periodontal dressing is applied.
75775300|NCT05777811|Procedure|Free gingival graft|A partial-thickness flap is elevated (using a blade #15c) with horizontal incisions at the cemento-enamel junction (CEJ) level of the adjacent teeth. Then, two vertical incisions extending to the apical are made from the two ends of the horizontal incision. The epithelium in the framed region is removed with a scalpel, and the underlying connective tissue is exposed. To achieve the best vascularization of the free gingival graft from the recipient site, bed preparation is completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region. The free gingival graft is stabilized using interrupted sutures and a sling suture.
75775301|NCT05776992|Device|Xbox virtual reality games|X-box balance evaluation was implemented in a completely dark and isolated room specially prepared for this treatment and evaluation
75775302|NCT05776992|Device|Biodex balance training|the Biodex Balance System SD has been designed to meet the needs of everyone looking to improve balance, increase agility, develop muscle tone and treat a wide variety of pathologies.
75913068|NCT04105920|Device|Hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
75913069|NCT04104126|Other|Standard of Care Physical Therapy|Will receive standard of care physical therapy
75913070|NCT04104126|Other|Blood flow restriction|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff. The cuff is placed around the desired limb before a specific exercise, the physical therapist determines the appropriate pressure and time, and the patient completes the exercise as they normally would. The monitor determines the limb occlusion pressure and has an automatic timer that will deflate after the specified time has elapsed.
75913071|NCT04080544|Drug|[18F]AV-1451|The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of [18F]AV-1451.
75913072|NCT04080544|Procedure|Positron Emission Tomography|Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
75913073|NCT04074798|Behavioral|assessment of hyperventilation, postural control and psychological behavior|assessment of hyperventilation, postural control and psychological behavior
75913074|NCT04066348|Biological|Etanercept|To treat blast or noise induced tinnitus
75913075|NCT04066348|Other|Saline|Placebo
75913076|NCT04055948|Behavioral|One-on-one teaching sessions|One-on-one teaching sessions with the caregiver during radiation treatments. (note - intervention sessions 2 & 3 delivered by phone during COVID-19)
75913077|NCT04055948|Behavioral|Telephone booster contact|Telephone booster contact 2 weeks post-treatment.
75936403|NCT04741607|Procedure|Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)|The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
75621952|NCT02729506|Procedure|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
75621953|NCT02732782|Other|Isometric exercise|
75621954|NCT02732782|Other|Eccentric exercise|
75621955|NCT02729428|Device|MRI|Participants will undergo an MRI scan
75621956|NCT02732548|Other|Negative Pressure Wound Therapy (NPWT)|
76073119|NCT01840579|Drug|Carboplatin AUC 6 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
76073120|NCT01840579|Drug|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
76073121|NCT01840579|Drug|Nab-paclitaxel 100 mg/m^2|Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
76073122|NCT01840579|Biological|Ipilimumab 1 mg/kg|Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
75621957|NCT02732548|Other|MIRODERM Application(s)|
75621958|NCT02732548|Other|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
75621959|NCT03303664|Other|IMPROVE Protocol|Comprehensive pain management protocol
75621960|NCT02729272|Procedure|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
75621961|NCT02729272|Procedure|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
75621962|NCT02729272|Device|Monopolar ESD|
75621963|NCT02729272|Device|Ultrasonic ESD|
76073123|NCT01840579|Drug|Etoposide 100 mg/m^2|Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
75621964|NCT02732470|Other|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
75621965|NCT03170362|Other|Pharmacogenetic Test|The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
75621966|NCT02732158|Other|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
75775303|NCT05774925|Diagnostic Test|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
75913078|NCT04044521|Other|Systems consultation|"Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 18 months.~AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit & feedback report on their prescribing.~PF: clinics will be randomized to receive practice facilitation. Facilitators will travel to each clinics. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly.~PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing."
75913079|NCT04037098|Dietary Supplement|Magnesium lactate.|2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months
75913080|NCT04037098|Dietary Supplement|Placebo|2 tablets orally every 12 hours of on inert placebo for three months
75913081|NCT04034316|Other|Cord-blood mesenchymal stromal cells|The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.
75913082|NCT04024917|Other|Cardiac coherence|"An initiation session to cardiac coherence will take place D-11 before the operation (during the surgical consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 11 days preceding the operation.~- The program cardiac coherence will be performed during 90 days after the surgery"
75913083|NCT04024917|Other|Standard care|Standard care
75913084|NCT03999957|Other|Telehealth web conferencing|Pediatric patient specific case discussions for enrolled pediatric patients at hospice staff interdisciplinary team meeting every 15 days for 60 min sessions via telehealth
75913085|NCT03992235|Other|Chest physiotherapy|"All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation."
76073124|NCT01840579|Drug|G-CSF (pegfilgrastim) 3.6 mg|Administered as a subcutaneous injection on Day 4 of Cycle 1
76073125|NCT00690040|Device|Foley catheter|Single balloon catheter
75621967|NCT02727166|Dietary Supplement|Inulin|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
75621968|NCT02727166|Dietary Supplement|Maltodextrine|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
75621969|NCT03112408|Behavioral|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
76073126|NCT00690040|Device|Atad catheter|Double balloon catheter
75775304|NCT05774652|Behavioral|Lifestyle intervention Dietary advise and/or advise on physical activity|Lifestyle intervention Dietary advise and/or advise on physical activity
75913086|NCT03992235|Other|Educational material|Exercise brochure with photos and explanations
76073127|NCT00690274|Drug|BF2.649|up to 20mg per day
76073128|NCT00690274|Drug|Placebo|up to 20mg per day
76073129|NCT00650260|Device|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
76073130|NCT00650260|Device|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
76073131|NCT00651040|Drug|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
76073132|NCT00651040|Drug|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
76073133|NCT01184950|Other|Trainer Curriculum|
75775305|NCT05769543|Procedure|WATSU application|20-minute application of WATSU
75621970|NCT03112408|Behavioral|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
75621971|NCT03112408|Behavioral|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
75621972|NCT03112408|Behavioral|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
75621973|NCT02727088|Procedure|Pulpotomy|Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
75621974|NCT02727088|Procedure|Pulpectomy|ablation of the whole dental pulp, preparation and filling of the whole root canal system
75775306|NCT05769543|Other|Lecture|20-minute lecture on WATSU technique
75775307|NCT05766722|Device|DORA AI|Dora will phone patients on the day of cataract surgery (2 to 4 hours after discharge home) and again at postoperative week three. Dora calls made on the day of surgery will evaluate if the patient has any acute post-operative concerns like pain, and will prompt a postoperative day 1 visit if necessary. Calls to Dora at postoperative week three will result in either a follow-up to check refractive difficulties and/or confirmation of second eye surgery.
75775308|NCT05763758|Other|No intervention|No intervention involved in this study
75775309|NCT05755763|Other|Anal incontinence patients with St. Mark's Incontinence Score|The scale was applied to the patients who applied to our clinic with the diagnosis of anal incontinence.
75775310|NCT05869942|Diagnostic Test|Light microscopic studies|Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected
75775311|NCT05869942|Diagnostic Test|Immunohistochemical studies|Monoclonal HMGB1 and active caspase 3 antibodies
75775312|NCT05869916|Behavioral|psychological first aid|The effect of psychological first aid on earthquake victims was measured using the resilience scale and the secondary traumatic stress scale.
75775313|NCT05869890|Device|MOSES laser system|A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
75775314|NCT05869877|Device|Bundled|An peripheral intravenous catheter will be inserted by an RN specially trained in PIVC placement, with or without ultrasound. Using best of class medical products, will evaluate dwell time and complications of the PIVC inserted using a bundled approach versus one inserted with the bundle
76073134|NCT02997748|Procedure|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
75320616|NCT01676636|Drug|Chewable tablets|Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
75621975|NCT02727244|Procedure|urgent or elective cesarean section|a kind of surgical procedure to deliver a baby
75621976|NCT02728960|Procedure|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
75775315|NCT05869695|Other|OSPRO-ROS Questionnaire|Completion of questionnaires
75775316|NCT05869695|Other|OSPRO-YF Questionnaire|Completion of questionnaires
75775317|NCT05869578|Procedure|Anesthesia Intervention|Patients exposed to any anesthesia intervention will be assessed to whether the exposure to anesthesia confers a risk for perioperative outcomes
75775318|NCT05869565|Drug|Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1|Patients will be enrolled in the study and randomized into one of four arms
76073135|NCT00654784|Drug|idebenone|idebenone 450 mg/day (150 mg three times a day)
76073136|NCT00654784|Drug|placebo|
76073137|NCT02997514|Behavioral|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
76073138|NCT02997514|Behavioral|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
75320617|NCT01676636|Drug|Unflavoured Powder|The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
75320618|NCT01676636|Drug|Flavoured Powder|The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
75320619|NCT04404296|Device|25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy|Pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
75320620|NCT00675259|Drug|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days [1 cycle] for 5 cycles
75320621|NCT00675259|Drug|carboplatin|AUC 2 IV on days 1, 8, and 15
75320622|NCT00675259|Drug|nab-paclitaxel|100 mg/M2 IV
75320623|NCT00675259|Procedure|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
75320624|NCT00675259|Drug|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
75621977|NCT02726932|Other|No intervention, merely observational|
75621978|NCT02728882|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
75621979|NCT01064310|Drug|pazopanib|oral anti-angiogenic treatment
75621980|NCT01064310|Drug|sunitinib|oral anti-angiogenic treatment
75621981|NCT00627276|Dietary Supplement|omega-3 fatty acid|Oral, 3 times daily
75621982|NCT00627276|Other|placebo|Oral, 3 times daily
75775319|NCT05869500|Device|Left Bundle Branch Area Pacemaker|Implantation of Medtronic 3830 lead for left bundle branch area pacing
75913087|NCT03940521|Other|Bioclinical evaluation|50-100ml blood extracted for flow cytometry and qPCR
75913088|NCT03915678|Drug|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
75775320|NCT05869500|Device|Right Ventricular Pacemaker|Implantation of a conventional right ventricular pacemaker lead
75775321|NCT05869435|Device|FastWire System Device - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
75775322|NCT05869409|Behavioral|Physical activity and sedentary behavior education|Enrolled patients will participate in an individual face-to-face education session, addressing: definitions and examples of sedentary and physical activity behaviors; physical health-related and mental health-related consequences of these behaviors; ways to break sedentary behaviors; age-adjusted physical activity recommendations (based on the guidelines of the World Health Organization).
75775323|NCT05869396|Diagnostic Test|echocardiography|Bedside echocardiography
75775324|NCT05869370|Other|High intensity resistance training|Twelve weeks of resistance training twice a week.
75775325|NCT05869370|Other|Low intensity resistance training combined with blood flow restriction|Twelve weeks of resistance training with blood flow restriction twice a week.
75775326|NCT05869344|Dietary Supplement|Black bean protein hydrolysates (BPH)|Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.
75775327|NCT05869344|Other|Commercial non-caloric beverage|Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.
75775328|NCT05869292|Device|Immediate implant loading|"Implants will be received immediately prosthetic restoration following surgical procedure.~For the provisional restoration, an open tray impression technique will be used. Plaster models with scan bodies will be digitized by the laboratory scanner (3Shape E1, 3Shape, Kopenhagen, Denmark), and the virtual design of provisional restoration will be performed with 3D designing software (Exocad-Matera 2.3, Exocad, Darmstadt, Germany). Provisional restorations will be then created using polymethyl methacrylate (PMMA) (Telio®CAD, Ivoclar Vivadent, Schaan, Lichtenstein) and were drilled from PMMA blocks using the 5-axis milling machine (Zenotec Select, Wieland, Pforzheim, Germany). Screw-retained abutments for the prosthetic bridge will be chosen according to implant angulation and surrounding soft tissue height.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
75775329|NCT05869292|Device|Early implant loading|"Implants won't receive immediately prosthetic restoration following surgical procedure and will be left only healing caps.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
75775330|NCT05869279|Biological|CARCIK-CD19|allogeneic cytokine induced killer cells transduced with a transposon CD19-chimeric antigen receptor (CARCIK-CD19) gene
75775331|NCT05869227|Drug|Capecitabine/Placebo combined with treprizumab|Combined
75913089|NCT03915678|Drug|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
75913090|NCT03915678|Drug|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
76073139|NCT01799824|Biological|ANT-1403|
76073140|NCT01799824|Biological|placebo|
76073141|NCT04387396|Other|Exercise|Exercise specific to knee osteoarthritis.
76073142|NCT01801111|Drug|Erlotinib|Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
76073143|NCT01801111|Drug|Alectinib|Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
75775332|NCT05869201|Biological|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
75775333|NCT05869201|Biological|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
75775334|NCT05869201|Biological|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
75775335|NCT05869110|Other|Effects of odours on calorie intake, food choice and metabolic parameters|"Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.~Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week."
75775336|NCT05869097|Drug|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
75775337|NCT05869097|Drug|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
75775338|NCT05869084|Diagnostic Test|pulmonary function tests|pulmonary function tests
75913091|NCT03915678|Drug|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
75913092|NCT03915678|Drug|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
75913093|NCT03915678|Drug|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
75913094|NCT03913442|Drug|Colchicine 0.8 mg or 0.6 mg orally once daily|Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)
75913095|NCT03913442|Drug|Placebo oral capsule|Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
76073144|NCT00691600|Drug|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
76073145|NCT00691600|Drug|Placebo|Placebo caps or suspension every 12 hours for 10 days
76073146|NCT00655642|Drug|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
75466230|NCT01907139|Behavioral|Distributed constraint-induced therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
76073147|NCT00655642|Drug|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
76073148|NCT00655642|Drug|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
76073149|NCT00655642|Drug|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
76073150|NCT02997436|Device|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
75320625|NCT01674218|Drug|Moxifloxacin|Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
75621983|NCT02726854|Drug|Apatinib|Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
75621984|NCT04724928|Radiation|Metastasis directed therapy (MDT)|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Concurrently, the oligometastasis will be treated with stereotactic body radiotherapy or metastasectomy.
75621985|NCT04724928|Drug|Immunotherapy|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
75621986|NCT04724928|Procedure|Standard of care|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards regular follow up is performed.
75621987|NCT02728570|Other|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
75320626|NCT01674218|Drug|PA-824|PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
75775339|NCT05869045|Other|Diaphragm shortening fraction measurement by point-of-care ultrasound.|A noninvasive and feasible method to assess diaphragmatic function and predict the prognosis of patients with respiratory failure presenting to the emergency department. The method consists of measuring the diaphragmatic thickness at the end of inspiration and expiration using a linear probe placed in the subcostal region and calculating the percentage of change using the formula: diaphragmatic thickness at the end of inspiration - diaphragmatic thickness at the end of expiration/diaphragmatic thickness at the end of expiration×100. A value lower than 10% indicates diaphragmatic dysfunction and a higher risk of adverse outcomes.
75775340|NCT05868993|Drug|Dose of 0.5% Ropivacaine|Dose varied by 5mL of 0.5% Ropivacaine
75775341|NCT05868980|Other|vital signs by postpartum position|Evaluation of vital signs and NIRS values in 4 different positions after birth
75913096|NCT03897478|Diagnostic Test|ISCDX blood test|"The ISCDX test is based on gene expression changes that occur as a result of the ischemic stroke. When the stroke occurs, the immune system in the body reacts and causes changes in gene expression in several types of cells, including white blood cells, related to activation of innate and adaptive immune systems.~The ISCDX test distinguishes between cardioembolic and large artery atherosclerotic origin of stroke using a gene signature. The pattern or signature of up or down regulation for all genes for a patient determines whether the patient's pattern of gene expression is more like the pattern seen in other cardioembolic patients or more like the pattern seen in patients with large artery atherosclerotic cause of stroke."
75913097|NCT03896646|Procedure|Computed Tomography|Undergo SPECT/CT HIDA scan
75913098|NCT03896646|Other|Hepatobiliary Iminodiacetic Acid Scan|Undergo SPECT/CT HIDA scan
75775342|NCT05868967|Drug|[14C]DWP14012|Each subject will receive a single oral dose of [14C]DWP14012 suspension (containing approximately 40 mg/80 μCi [14C]DWP14012) under fasting conditions.
75913099|NCT03896646|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT HIDA scan
76088894|NCT01606787|Drug|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
75466231|NCT01907139|Behavioral|Dose-matched control therapy|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
75913100|NCT03896646|Radiation|Yttrium Y 90 Glass Microspheres|Undergo radioembolization with yttrium Y 90 glass microspheres
75913101|NCT03896646|Procedure|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere radioembolization
75913102|NCT03884712|Device|CalmiGo|The CalmiGo handheld device is a device of similar size to an inhaler that uses guided breathing, aromatherapy and grounding techniques to regulate breathing to bring users a sense of calm and relaxation. The CalmiGo handheld device is being tested in this study to alleviate participants' anxiety and panic attack symptoms.
75913103|NCT03868020|Procedure|Computed Tomography|Undergo PET/CT
75913104|NCT03868020|Radiation|Fluciclovine F18|Given IV
75320627|NCT01674218|Other|Placebo|Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
75466232|NCT01907152|Other|Protein enriched yoghurt drink and bread|
75466233|NCT01907165|Drug|Temozolomide|
75320628|NCT00656305|Device|ExAblate MRfFUS|MR guided focused ultrasound.
75466234|NCT01907165|Drug|Disulfiram|
75466235|NCT01907165|Dietary Supplement|Copper gluconate|
75466236|NCT01907204|Drug|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
75913105|NCT03868020|Procedure|Positron Emission Tomography|Undergo PET/CT
75913106|NCT03854110|Drug|GP-2250|GP-2250 monotherapy for pharmacokinetics and safety; GP-2250 plus gemcitabine for safety, tolerability, pharmacokinetics, and biomarker assessments
75913107|NCT03846050|Behavioral|BAC feedback/warning|Participants will receive a warning when their BAC reaches a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
75913108|NCT03846050|Behavioral|No BAC feedback/warning|Participants will receive no information on their current intoxication and will be asked to report less information on their driving decisions.
75320629|NCT00656305|Device|Sham|sham comparator
75320630|NCT03868423|Drug|Brigatinib|90 mg orally QD for 7 days followed by 180 mg orally QD continuously thereafter. One cycle of therapy will consist of 28 days of treatment.
75320631|NCT03868423|Other|Laboratory Biomarker Analysis|Correlative studies
75320632|NCT03868423|Other|Quality-of-Life Assessment|Ancillary studies
75466237|NCT01907204|Drug|Budesonide|Budesonide by metered dose inhaler
75320633|NCT03868423|Other|Questionnaire Administration|Ancillary studies
75320634|NCT01670240|Drug|Adalimumab|
75320635|NCT01670240|Drug|Placebo|
75320636|NCT04404686|Drug|Indomethacin|Per vagina administration of 100 mg followed by a second 100 mg dosage the following day
75320637|NCT04404686|Drug|Nifedipine|Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
75913109|NCT03845205|Behavioral|Integrated AUD Treatment|IAT will include computer-delivered BI in the hospital, nurse-delivered alcohol monitoring counseling at each outpatient LT follow-up visit, and at-home participation in web-based, 7-session CBT4CBT, supplemented by tailored text messages.
75913110|NCT03829462|Drug|Regorafenib|regorafenib tab 40 mg i.e 160 mg/day
75320638|NCT00675415|Diagnostic Test|Capnography|Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
75466238|NCT01907204|Drug|Budesonide|Budesonide by nebulization
75466239|NCT01907230|Drug|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
75621988|NCT02728570|Other|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
75621989|NCT02728492|Drug|Quisinostat|
75621990|NCT02728492|Drug|Paclitaxel|
75913111|NCT03829462|Drug|Irinotecan|irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
75913112|NCT03828799|Combination Product|Folfirinox + regorrafenib|folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days
75913113|NCT03825796|Drug|Enasidenib Mesylate|Given PO
75913114|NCT03825796|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
75913115|NCT03818061|Drug|Atezolizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
75466240|NCT01907243|Procedure|spreader flap|producing of upper lateral cartilage flap as a spreader flap
75466241|NCT01907256|Procedure|inverted V incision|It is a type of incision
75466242|NCT01907256|Procedure|stair step incisions|It is a type of incision
75466243|NCT01907282|Behavioral|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
75621991|NCT02728492|Drug|Carboplatin|
75621992|NCT02728492|Drug|Gemcitabine|
75621993|NCT02728492|Drug|Cisplatin|
75621994|NCT02726776|Other|Suspension in a harness|
75621995|NCT02726776|Other|Climbing|
75621996|NCT02726152|Procedure|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
75621997|NCT02726152|Procedure|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
75621998|NCT02726308|Drug|Dexamethasone|5 mg I.V. Dexamethasone just before induction
75466244|NCT01907282|Behavioral|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
75466245|NCT01907308|Drug|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
75466246|NCT01907308|Drug|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
75621999|NCT02726308|Drug|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
75622000|NCT02726308|Drug|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
75622001|NCT02728414|Dietary Supplement|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
75622002|NCT02728414|Dietary Supplement|placebo|the patients in this arm will receive placebo intervention
75622003|NCT01037244|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
75622004|NCT01037244|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
75622005|NCT00833989|Drug|GSK249320|I.V. infusion
75913116|NCT03818061|Drug|Bevacizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
75913117|NCT03799354|Other|Maximal strenght training (MST) plus endurance training (ET)|"Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression."
76088895|NCT01606787|Other|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
76088896|NCT01778855|Other|IV t-PA and normothermia|
75320639|NCT01674374|Other|placebo|Given PO
75320640|NCT01674374|Procedure|quality-of-life assessment|Ancillary studies
75320641|NCT01674374|Other|questionnaire administration|Ancillary studies
75320642|NCT01674374|Drug|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules|Given PO
75622006|NCT00833989|Drug|PLACEBO|Placebo
75622007|NCT02728180|Drug|Xingnaojing injection|Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
75622008|NCT02728180|Other|Standard care|Guidelines-based standard care for acute ischemic stroke.
75622009|NCT02873832|Biological|Blood sample|
75622010|NCT02873832|Other|Flow cytometry|
75622011|NCT02873832|Other|western blot|
75622012|NCT02728024|Other|Missing items, Errors in Completion, Difficulties|
75622013|NCT00627432|Drug|gemcitabine hydrochloride|
75622014|NCT00627432|Drug|oxaliplatin|
75775343|NCT05868941|Device|Broncho Muco Cleaner|"The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract.~In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally."
75775344|NCT05868915|Biological|HV-101|"Biological: HV-101~HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification.~Drug: IL-2~Following cell infusion, the patient receives intravenous IL-2.~Drug: Fludarabine~Part of the non-myeloablative lymphocyte-depleting preparative regimen.~Drug: Cyclophosphamide~Part of the non-myeloablative lymphocyte-depleting preparative regimen."
75775345|NCT05868811|Behavioral|Music Together|The intervention consists of 45-minute weekly classes for 16 weeks. Each class is delivered by a trained Music Together facilitator and includes music activities such as singing, dancing, moving and playing musical instruments. At the start of the program, participants receive materials for home use that consist of a song book and online access code for song recordings used in the class.
75622015|NCT02726230|Behavioral|Ananya|The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
75775346|NCT05868811|Behavioral|Play Group|The play group consists of 45-minute weekly classes for 16 weeks. During each class parents are encouraged to play with their child and interact with other participants using the provided age appropriate toys. At the start of the program participants receive an age appropriate toy for use at home.
75913118|NCT03799354|Other|Endurance training (ET)|"Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician."
75913119|NCT03783351|Genetic|CYP2C19 genotype testing|CYP2C19 genotype testing will be conducted in a designated central laboratory.
75466247|NCT01907373|Drug|olmesartan medoxomil|
75913120|NCT03761186|Behavioral|traditional diabetes diet|Diet with carbohydrate content 50-60% of total energy intake
75913121|NCT03761186|Behavioral|moderately low carbohydrate diet|Diet with carbohydrate content 30-40% of total energy intake
75775347|NCT05868798|Drug|Ammonia Inhalant|For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
75913122|NCT03761186|Behavioral|strictly low carbohydrate diet|Diet with carbohydrate content 15-20% of total energy intake
75913123|NCT03729869|Drug|Progesterone|200 mg of exogenous progesterone twice a day
75913124|NCT03729869|Drug|Placebo|One dose of matched placebo twice a day.
75913125|NCT03722420|Drug|Radotinib|Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
75913126|NCT03722420|Drug|Imatinib|Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
75913127|NCT03713437|Diagnostic Test|Measurement of differentially methylated insulin DNA|A serum sample will be drawn to measure differentially methylated insulin DNA.
75913128|NCT03703960|Other|hypnotic analgesia|classic three-step hypnosis procedure (induction, trance and return to consciousness).
75913129|NCT03703960|Other|music|calm music conducive to relaxation
75466248|NCT01907373|Drug|olmesartan medoxomil+probenecid|
75466249|NCT01907386|Other|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
75466250|NCT01907399|Other|Blood samples|
75466251|NCT01907425|Other|Blood samples|
75466252|NCT01907464|Other|clinical parameters description|description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
75466253|NCT01907464|Other|para clinical parameters description|description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
75466254|NCT01907464|Other|hormonal parameters dosing|dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
75466255|NCT01907464|Other|bone modeling markers dosing|dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
75466256|NCT01907477|Other|Samples taken at the clinical hematology unit|
75466257|NCT01907503|Procedure|Evaluation of the balance of force platform|
75775348|NCT05868759|Radiation|Roentgen Stereophotogrammetric Analysis (RSA)|"Roentgenstereophotogrammetric analysis (RSA) is a radiographic technique, highly accurate both to evaluate the primary stability of the implant, then the micromovements between bone and implant prosthetic, both for the evaluation of the kinematics of the prosthetic components. The RSA technique in dynamics is able to obtain, with patient in motion, a series of radiographic frames in sequence in two projections, which are captured simultaneously. Each pair of orthogonal projections corresponds to a specific moment of the movement carried out by the patient and will be used to obtain, through dedicated software, a reconstruction three-dimensional instant defined RSA scenes."
75775349|NCT05868759|Device|Delos Postural Proprioceptive System (computerized oscillating platform)|The Delos Postural Proprioceptive System uses electronic tilting tables (on a single axis or three axes) with high frequency that allows very short stop and reversal times that allow both to study the proprioception and the patient's response to the modification of movement of the inclined plane
75775350|NCT05868759|Diagnostic Test|Modified Star Excursional Balance Tests|The Star Excursional Balance Test (SEBT) is a clinical test designed for the evaluation of dynamic physical performance of the tibiotarsica. The first literary references date back to 1998 and the test, remaining in balance with the ankle in the studio, the achievement of the maximum possible distance with the contralateral foot along well-defined axes.
75913130|NCT03690557|Behavioral|IncentaHealth|IncentaHealth is a comprehensive, behavioral weight management program designed to help individuals initiate and maintain weight loss. Individuals participate in the IncentaHealth program from their homes, receive program information electronically through daily emails and through a smartphone app for the duration of the study, and have the option to receive text messages and speak with health coaches over the telephone. Participants in this study will be enrolled in the IncentaHealth program for 12 months, and will engage with health coaching, tracking of body weight, and are provided a number of resources for healthy living throughout the 12 months.
75622016|NCT02727946|Other|optimal resuscitation|optimal resuscitation to achieve mean arterial blood pressure above 65 mmHG , Central venous pressure more than 8 mmHg , urine out put more than 0.5 ml /Kg/hour
75622017|NCT01037088|Drug|Mild dose cannabis|3.53% THC by weight
75775351|NCT05868759|Device|Inertial sensors Xsens MVN|"The inertial motion acquisition system Xsens MVN is easy to use and economic to detect the movement of different anatomical districts. MVN is based on inertial sensors in miniature through communication solutions combined with advanced fusion algorithms sensors, using hypotheses of biomechanical models.~This MVN system is a system of inertial kinematic measurement of the whole body, which incorporates synchronized data. Instant graphic output is provided, including angles of motion articular."
75775352|NCT05868759|Other|American Orthopaedic Foot and Ankle Score (AOFAs)|American Orthopaedic Foot and Ankle Score (AOFAs) is a clinical trial commonly used in scientific literature which serves to assess, in terms of value from 0 to 100, the autonomy, pain, stability, ankle alignment and back foot of the patient.
75775353|NCT05868759|Other|Visual Analogue Scale (VAS)|The Visual Analogue Scale (VAS) is a visual representation of the extent of pain that the patient subjectively warns. The VAS is represented by a 10 cm long line in the original version validated, with or without notches at each centimeter. One end indicates the absence of pain and corresponds to 0, the other end indicates the worst pain imaginable and corresponds to 10.
75775354|NCT05868759|Other|12-Item Short Form Survey (SF-12)|The 12-Item Short Form Survey (SF-12) is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
75775355|NCT05868733|Drug|Day 1 Lower Dose (2×106 pfu)|rVSV∆G-LASV-GPC
75775356|NCT05868733|Drug|Day 1 Higher Dose (1×107 pfu)|rVSV∆G-LASV-GPC
75913131|NCT03687671|Other|Animal-assisted therapy|Animal-assisted occupational therapy, animal-assisted physiotherapy and animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
75913132|NCT03687671|Other|Treatment as usual|Speech therapy, occupational therapy or physiotherapy
75466258|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
75913133|NCT03687658|Behavioral|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
76088897|NCT01778855|Device|IV-tPA and hypothermia|
76088898|NCT04570319|Dietary Supplement|Probiotic Bths-08|A capsule containing the probiotic blend (dietary supplement), administered once daily for 12 weeks
75622018|NCT01037088|Drug|Low dose cannabis|1.29% THC by weight
75622019|NCT01037088|Drug|Cannabis|0.00% THC by weight
75622020|NCT02727790|Device|Stimulator|
75622021|NCT04189120|Procedure|Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block|neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
75775357|NCT05868733|Drug|Placebo|Placebo
75466259|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
75466260|NCT01907542|Procedure|stapled skin closure|as above
75775358|NCT05868720|Drug|Risperidone, Aripiprazole|The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
75466261|NCT01907542|Procedure|monocryl skin suture|as above
75466262|NCT01907581|Other|Quality of life questionnaires|
75320643|NCT01674452|Behavioral|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
75913134|NCT03683069|Drug|Eplerenone vs Amlodipine|We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
75913135|NCT03682588|Other|Physical activity|The Functional exercise group performed functional exercise training for 45 minutes twice a week for 14 weeks. The Stretching exercise group performed stretching exercises with the same duration and frequency.
75913136|NCT03662737|Diagnostic Test|Visuomotor adaptation task|We will measure performance of the subjects of each group on the visuomotor adaptation task, especially in the rotation condition, in which a perturbation will be induced between the anticipated location of the hand and the provided visual feedback, and in the washout condition, in which the rotation will be removed. We expect that subjects with cannabis use disorder will not show the expected implicit motor adaptation to the perturbation and consequently no deterioration of performance on the task, due to cannabis-induced cerebellar damage. In other words, we want to show that this visuomotor task is a cheap and quick biomarker of cerebellar dysfunction in chronic cannabis users.
75913137|NCT03581240|Drug|eflornithine HCl|"In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID~Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS."
75913138|NCT03580668|Drug|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
75913139|NCT03573297|Drug|Cariprazine|Cariprazine capsules, oral administration, once daily
75622022|NCT02725996|Biological|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
75913140|NCT03573297|Drug|Placebo|Matching placebo capsules, oral administration, once daily
75913141|NCT03571789|Device|Vine™|"The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.~The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters"
75913142|NCT03536884|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
75913143|NCT03536884|Drug|Secukinumab|Subjects will receive secukinumab at pre-specified time-points.
75913144|NCT03536884|Other|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
75913145|NCT03535116|Drug|Ketorolac|Toradol is a type of brand name. We will be using the generic version.
75913146|NCT03535116|Drug|Saline|injectable normal saline
75913147|NCT03519295|Drug|MPDL3280A|MPDL3280A administered every 2 weeks at 800 mg for 12 months.
75913148|NCT03519295|Drug|mDCF|8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks
75913149|NCT03515213|Drug|Fenofibrate|145mg of fenofibrate
75913150|NCT03515213|Drug|Placebo|Placebo
75913151|NCT03507790|Drug|CT1812|Active Study Drug
75913152|NCT03507790|Drug|Placebo|Non-active study drug
76088899|NCT04570319|Dietary Supplement|Placebo|A capsule containing the placebo (dietary supplement), administered one daily for 12 weeks
75320644|NCT01674452|Behavioral|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
75622023|NCT02725996|Other|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
75622024|NCT02725762|Device|LT-300 Active (PBM)|
75622025|NCT02725762|Device|LT-300 Inactive (Sham)|
75622026|NCT02727712|Procedure|bilateral thoracic paravertebral block|group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4)program
75622027|NCT02727712|Device|Transesophageal Echocardiography（TEE）|"Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~Goal-directed fluid management"
75622028|NCT02727712|Device|Lung protection measure during the surgery（Dräger Primus）|Protective ventilation strategy(Low tidal volume about 6~7ml/kg, joint use of PEEP)
75775359|NCT05868681|Device|Delos instrument (computerized balance board)|"Proprioceptive training using Delos instrument (computerized balance board).~Static and dynamic evaluation through Delos with the Riva method; Physiatric visit; Clinical scores (AOFAs); Functional scores (SPPB); SF12 satisfaction."
75775360|NCT05868655|Other|Exercise with supervisor|A program of stability and balance exercises will be provided. Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
75775361|NCT05868655|Other|Standart exercise|Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
75775362|NCT05868642|Procedure|subarachnoid block|subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
75775363|NCT05868616|Device|Cardiac Resynchronization Therapy (CRT)|Cardiac resynchronization therapy (CRT) is a modality of cardiac pacing used in patients with left ventricular (LV) systolic dysfunction and dyssynchronous ventricular activation that provides simultaneous or nearly simultaneous electrical activation of the LV and right ventricle (RV) via stimulation of the LV and RV (biventricular pacing) or LV alone.
75622029|NCT02727712|Drug|Anesthesia drugs during the surgery|"Bilateral thoracic paravertebral block before induction of anesthesia;~Fast channel anesthesia • Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01~0.04ug/kg•min, Sevoflurane 0.5~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
75622030|NCT02727712|Procedure|thoracic paravertebral block|group B under(TPVB T3/4)by ropivacaine(0.3%,20ml*2)program
75775364|NCT05868603|Other|Remineralization gel|Remineralization gel
75775365|NCT05868590|Other|Toothpaste|Using two different toothpastes for removal of the dental plaque in children.
75622031|NCT04118101|Drug|ESPB block|A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
75775366|NCT05868564|Device|Atherectomy+Drug-coated balloon|Patients in experimental group will undergo endovascular treatment for femoropopliteal lesions. The lesion will be treated by atherectomy+drug-coated balloon in the experimental group
75320645|NCT00676585|Drug|Normal Saline|Normal Saline
75466263|NCT01907594|Drug|D-cycloserine|
75466264|NCT01907594|Drug|Nicotine Replacement Therapy (patch)|
75622032|NCT04118101|Other|control|no ESPB will be given.
75775367|NCT05868564|Device|Drug-coated balloon|drug-coated balloon only in the active comparator group.
75320646|NCT00676585|Drug|Hydrocortisone|Hydrocortisone 100mg
75320647|NCT03856580|Behavioral|Alternative long-acting PrEP injection strategies|"Participants in the two intervention groups will complete injection procedures (e.g., self-injection, injection by healthcare providers at drop-in clinics) to determine if this could facilitate improved adherence to an inert version of long-acting cabotegravir injections"
75466265|NCT01907594|Behavioral|Smoking Cue Exposure|
75466266|NCT01907594|Behavioral|Progressive Muscle Relaxation|
75466267|NCT01907594|Drug|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
75466268|NCT01907620|Other|blood sample|
75320648|NCT03856580|Behavioral|mHealth adherence app|"Participants in the two experimental arms will be given a smartphone application, designed to facilitate adherence (this app will be developed during earlier phases of the study using in-depth interviews and design session groups)"
75320649|NCT00658411|Drug|deferoxamine|Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
75320650|NCT01674530|Drug|Lubiprostone|24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA
75320651|NCT01674530|Drug|Lubiprostone|24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)
75466269|NCT01907633|Drug|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
75466270|NCT01907646|Device|bladder training|vescical catheter
75466271|NCT01907646|Procedure|No bladder training|
75466272|NCT01907659|Other|Release of test results|Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
75622033|NCT01042236|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
75622034|NCT02725918|Drug|Pemetrexed|500 mg/m2,iv,d1,q3w,until PD
75622035|NCT02725918|Drug|Cisplatin|75 mg/m2,iv,d1,q3w,×4 cycles
75775368|NCT05868551|Procedure|nodulectomy|incision in an onchocerciasis nodule to extract adult worms
75320652|NCT01674530|Drug|Placebo|24 mcg capsules of both experimental Lubiprostone and AMITIZA
75466273|NCT01907672|Procedure|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
75466274|NCT01907685|Drug|AVE8062|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
75775369|NCT05868538|Diagnostic Test|Serum calprotectin and IMA concentrations|Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.
75775370|NCT05868512|Diagnostic Test|Dry needling|Dry Needling Along With Routine Physical Therapy for Chronic Neck Pain
75775371|NCT05868512|Diagnostic Test|Therapeutic ultrasound|Therapeutic ultrasound Along With Routine Physical Therapy for Chronic Neck Pain
75466275|NCT01907685|Drug|Docetaxel|"Pharmaceutical form: solution for infusion~Route of administration: Intravenous"
75466276|NCT01907698|Behavioral|Vaginal intercourse|vaginal intercourse at least twice a week
75775372|NCT05868499|Biological|EXG34217|Single infusion
75775373|NCT05868486|Procedure|Biospecimen Collection|Undergo blood sample collection
75466277|NCT01907711|Device|Acupuncture.|"Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi."
75466278|NCT01907724|Drug|IDX719|IDX719 will be supplied as a 50 mg tablet for oral administration.
75466279|NCT01907724|Drug|Simeprevir|Simeprevir will be supplied as 75 mg capsules for oral administration.
75775374|NCT05868486|Genetic|Genetic Testing for Cancer Risk|Undergo germline testing
75775375|NCT05868486|Procedure|Liquid Biopsy|Undergo liquid biopsy testing
75775376|NCT05868486|Procedure|Magnetic Resonance Imaging of the Whole Body without Contrast|Undergo whole body MRI without contrast
75775377|NCT05868486|Other|Survey Administration|Complete surveys
75913153|NCT03486704|Behavioral|Face to Face VRRS and telerehabilitation|"Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
75913154|NCT03486704|Behavioral|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
75913155|NCT03486704|Behavioral|FTF VRRS plus unstructured CS|"Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week."
75913156|NCT03486704|Behavioral|Face to Face VRRS plus active tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
75913157|NCT03486704|Behavioral|Face to Face VRRS plus placebo tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
75913158|NCT03477942|Biological|Autologous Mesenchymal Stem Cells|Bone marrow will be harvested from each individual patient's iliac crest, followed by stem cell isolation, expansion and preparation. Stem cell will be injected approximately 3-4 weeks after bone marrow harvest, injecting 50x10^6 MSCs in the knee via a medial parapatellar approach under sterile technique in 8 patients with generalized knee OA or focal chondral defects.
75913159|NCT03470155|Procedure|mitral valve repair|operative reconstruction
75913160|NCT03446040|Biological|BMS-986258|Specified dose on specified days
75913161|NCT03446040|Biological|Nivolumab|Specified dose on specified days
75651630|NCT05833542|Behavioral|Health education materials|Participants will receive informational material (designed to be self-guided), including a video and an information sheet about current HIV treatment options (i.e., long-acting injectable and daily oral antiretroviral therapy). These materials will provide a comparison of the risks and benefits of long-acting injectable and oral regimens, set expectations about clinic visits, present information about side effects, and provide additional resources for patients to assist them in preparing to discuss HIV treatment and support options with their medical case manager and clinical provider. Participants receiving this intervention will be offered/pointed to these materials by a medical case manager or patient navigator and will be encouraged to review the materials on their own, but may also go over the materials with staff during a medical case management visit.
75913162|NCT03446040|Drug|rHuPH20|Specified dose on specified days
75913163|NCT03428646|Drug|Dupilumab|Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.
75466280|NCT01907724|Drug|TMC647055|TMC647055 will be supplied as 150 mg capsules for oral administration.
75913164|NCT03406286|Drug|Tolvaptan|
75913165|NCT03406273|Radiation|Cerebral Spinal (CS) radiation|Surgery plus Cerebral Spinal (CS) radiation
75466281|NCT01907724|Drug|RTV|RTV will be supplied as 80 mg/mL solution for oral administration.
75775378|NCT05868473|Diagnostic Test|Mobilization With Movement|Mobilization With Movement Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
75775379|NCT05868473|Diagnostic Test|Kinesotaping|Kinesotaping Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
75775380|NCT05868447|Procedure|Stabilization surgery|"hourly blood gas analysis and hemoglobin and hematocrit control and blood transfusion will be performed when necessary~If a low pO2 value is observed in the blood gas, the fi02 values or fresh gas flow will be increased."
75775381|NCT05868434|Procedure|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy.|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy. Management of any accompanying patellofemoral lesions will be performed as well.
75466282|NCT01907750|Device|biliary drainage tube|
75466283|NCT01907763|Drug|SOTB07 200mg|
75466284|NCT01907763|Drug|SOTB07 400mg|
75466285|NCT01907763|Drug|SOTB 200mg placebo|Placebo of SOTB07 200mg
75466286|NCT01907763|Drug|SOTB 400mg placebo|Placebo of SOTB07 400mg
75466287|NCT01907776|Drug|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
75466288|NCT01907776|Drug|ME1100 placebo inhalation solution|Vehicle placebo
75466289|NCT01907802|Drug|Dabrafenib|Given PO
75466290|NCT01907802|Other|Laboratory Biomarker Analysis|Correlative studies
75466291|NCT01907802|Other|Pharmacogenomic Study|Correlative studies
75466292|NCT01907802|Other|Pharmacological Study|Correlative studies
75466293|NCT01907841|Other|Ischemic Preconditioning|
75466294|NCT01907867|Drug|Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days|
75775382|NCT05868395|Drug|Polatuzumab, bendamustin und rituximab|"Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle~Bendamustine 90 mg/m2 i.v. day 2 & 3 of cycle 1, then on day 1 & 2 of each subsequent cycle~Rituximab 375 mg/m2 i.v. on day 1 of each cycle~Each cycle is 21 days long~Up to 6 cycles per patients planned"
75775383|NCT05868369|Device|iVR Group|"On the day of surgery, the iVR group will receive a 30-minute sessions or dose of iVR therapy in the ambulatory post-anesthesia care unit (PACU) during their stay. The three distraction-based or skills-based iVR modules will consist of either 1) Mindful Escape; 2) Empowered Breathing; or 3) Relaxation videos. The iVR group will be sub-randomized into receiving only one of the three types of modules. The modules will start approximately 30 minutes upon arriving in PACU and will last approximately 30 minutes."
75775384|NCT05868369|Drug|Standard pain management regimen|In the ambulatory post-anesthesia care unit (PACU) during their stay with have standard postoperative pain protocol (including a pre-operative local field block).
75775385|NCT05868356|Drug|Treatment A|Oral adagrasib 200 mg twice daily (BID) for 8 days (Days 1 to 8). Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 2 to 7. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Days 1 and 8.
75775386|NCT05868356|Drug|Treatment B|Oral adagrasib 200 mg BID and gemfibrozil 600 mg BID for 10 days (Days 9 to 18), with no evening dose of adagrasib or gemfibrozil on Day 18. Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 9 to 17 before the morning dose of adagrasib. Predose PK blood samples for the measurement of gemfibrozil trough concentration will be collected on Days 15 to 18 before the morning dose of gemfibrozil. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Day 18.
75775387|NCT05868343|Other|Center-based Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. Participants will travel to the center twice a week for the duration of the program. Participants receive an individualized exercise program to be completed at the center according to Canadian recommendations. Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
75775388|NCT05868343|Other|Hybrid Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. For the first six weeks, participants are required to attend the hospital twice a week. After that, there will be a gradual increase in home sessions for the remaining six weeks. When a patient has a home session, health professionals follow up with a phone call.Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
75775389|NCT05868317|Drug|Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan)|"Induction chemotherapy with six cycles of modified 5 fluorouracil,oxaliplatin and irinotecan followed by short course radiotherapy (RT) (5x5 Gy), then two cycles of 5 fluorouracil and oxaliplatin based chemotherapy and surgery will be performed 6 to 8 weeks after completion of RT.~After surgery , continuation of chemotherapy with 4 cycles of 5 fluorouracil and oxaliplatin regardless of pathological response"
75320653|NCT01799551|Behavioral|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
75775390|NCT05868317|Radiation|Radiotherapy|Short Course Radiotherapy
75775391|NCT05868304|Device|BFR|Exercises may involve warm up on a stationary bike for 5 minutes, application of a BFR cuff (a cuff that often uses air to inflate around a limb) on the selected extremity, and exercise sets (e.g. banded squats, step ups, Romanian dead lifts). We will record metrics on an iPad. Testing will be done with ForceDecks and ForceFrames (system for measuring muscle strength and imbalance).
75775392|NCT05868304|Other|Stanard strengthening program.|"The exercise program will be completed 3 times per week Participants will warm up on a stationary bike for 5 minutes~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
75913166|NCT03406273|Radiation|Focal radiotherapy (SRS)|Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed [SRS])
75913167|NCT03383289|Other|R-REM training|three training modules for front-line long-term care staff to aid in recognition, management and reporting of R-REM
75913168|NCT03337646|Drug|Lisdexamfetamine Dimesylate|Medication to treat ADHD
75913169|NCT03326921|Biological|CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|Given IV
75913170|NCT03326921|Drug|Fludarabine|Given IV
75320654|NCT00676897|Drug|Simvastatin|Simvastatin 40mg PO or NGT
75320655|NCT00676897|Drug|Placebo|Corn Starch
75913171|NCT03326921|Other|Laboratory Biomarker Analysis|Correlative studies
75320656|NCT02115074|Drug|Fluvastatine|"Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
75466295|NCT01907880|Drug|Pamidronate|90mg IV once every 4 weeks for 3 cycles
75466296|NCT01907880|Drug|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
75466297|NCT01907880|Drug|placebo|
75466298|NCT01907893|Behavioral|Trauma Collaborative Care Plus Treatment as Usual|
75466299|NCT01907932|Device|VScan Ultrasound (GE Healthcare, USA)|VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
75913172|NCT03308058|Behavioral|Breastfeeding computer education|Breastfeeding computer education
75913173|NCT03299348|Behavioral|AgingPLUS|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) how negative views on aging and negative age stereotypes undermine adults' health-promoting behaviors; (b) how adults can take control of their own aging; and (c) how personal goals can be achieved through more effective goal planning and action plans.
75913174|NCT03299348|Behavioral|Active Control Group|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) four major health conditions that affect the lives of many middle-aged and older adults (e.g., cardiovascular disease, cancer, type 2 diabetes; clinical depression); and (b) how these conditions can be managed successfully.
75775393|NCT05868213|Drug|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
75913175|NCT03268135|Diagnostic Test|measurement of RNAs|
76073151|NCT02997280|Drug|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight > 40 kg, 0.08 mg/kg bid for children with body weight < 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
75622036|NCT02727634|Other|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
76073152|NCT01773967|Drug|LGG|LGG 10^10 cfu PO BID X 5 days
76073153|NCT01773967|Drug|micro-crystalline cellulose|1 capsule PO bid x 5 days
75466300|NCT01907945|Behavioral|Microclinic Water Program|Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
75466301|NCT01907945|Behavioral|Household education|Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
75466302|NCT01907984|Drug|Diclofenac|
75466303|NCT01907984|Drug|Midazolam|
75466304|NCT01907997|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
75775394|NCT05868200|Drug|Capitano zenzero toothpaste|"Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months ."
75913176|NCT03225287|Drug|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
75622037|NCT02725606|Biological|Pegylated Recombinant Human G-CSF|subcutaneous
75622038|NCT02725606|Biological|GW003|subcutaneous
75913177|NCT03189641|Device|Cilostazol eluting stent system (CES-1)|Implantation of drug eluting stent
76073154|NCT00656656|Drug|Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine|"Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks~Rituximab: 1000 mg i.v. given twice at a 2-week interval~Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks~Azathioprine: 2.5 mg/kg body weight daily p.o."
76073155|NCT01773889|Drug|Denileukin Diftitox/SC Pegylated IFNα-2a|
76073156|NCT00656968|Drug|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
76073157|NCT00656968|Drug|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
75466305|NCT01907997|Drug|normal saline infusion|In group C, the patients receive same volume of normal saline
75466306|NCT01908010|Drug|ABT-354|ABT-354 Low Dose
75466307|NCT01908010|Drug|ABT-354|ABT-354 High Dose
75913178|NCT03158389|Drug|APG101|weekly i.v.
75913179|NCT03158389|Drug|Alectinib|twice daily (oral)
75913180|NCT03158389|Drug|Idasanutlin|orally on 5 days of a 28 days cycle
75913181|NCT03158389|Drug|Atezolizumab|i.v. every 3 weeks
75913182|NCT03158389|Drug|Vismodegib|daily orally
75913183|NCT03158389|Drug|Temsirolimus|weekly i.v.
75913184|NCT03158389|Drug|Palbociclib|orally on 21 days of a 28 days cycle
75913185|NCT03140670|Drug|RUCAPARIB|Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
75466308|NCT01908010|Drug|Placebo|Placebo
75775395|NCT05868200|Drug|Colgate total toothpaste|Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
75775396|NCT05868187|Behavioral|Exercise, Problem-Solving Session and Education|Complete assigned exercises three times a week Complete Action plan co-developed Complete part or all of one of the four interactive educational modules
75775397|NCT05868135|Behavioral|eMeistring|Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit
75775398|NCT05868083|Drug|SNC-109 CAR-T Cells|SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
75775399|NCT05868031|Other|alternative teaching methods|This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.
75775400|NCT05868018|Behavioral|Education|This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
75775401|NCT05867979|Diagnostic Test|Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes|The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
75775402|NCT05867966|Behavioral|psychoeduc/self-care/self-hypnosis group|See arm description.
75775403|NCT05867823|Behavioral|OcuApp|The participants will have instaled a mobile aplication (OcuApp) by a member of the researchs team who will teach them how to use it. The person must register the activities they carry out throughout a week and mark each one of them with a punctuation (from 1 to 5) related to the meaning of the following dimensions: identity, pleasure, competence, importance and value of the activity by other people.The application also allows to collect other information such as where the activity takes place, its duration, and the people with whom it is carried out. Also, at the end of the week, the application will ask users about their perceived occupational balance. All the information registered in the mobile application will be returned to the person in a dynamic and understandable way. Based on this, the person can establish two goals to accomplish. In this sense, OcupApp will offer personalized recommendations based on the objectives to be achieved related to the dimensions of meaning.
75775404|NCT05867823|Behavioral|Three-part work|The intervention on the control group will focus on offering to the participants an informative three-part work on the positive effects of performing activities to control anxiety and depression. After providing this information, any doubts in this regard will be answered.
75775405|NCT05867771|Drug|PM1022|PM1022 Injection
75913186|NCT03037346|Other|Questionnaire Administration|Complete questionnaires about MPOAD
75913187|NCT03037346|Other|Questionnaire Administration|Ancillary studies
75466309|NCT01908023|Behavioral|exercise|One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
75466310|NCT01908049|Dietary Supplement|Probiotic.|
75622039|NCT02725684|Other|Observational study, no intervention|Observational study, no intervention
75622040|NCT02725450|Behavioral|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
75913188|NCT03037346|Other|Video|Watch educational video
76073158|NCT00657280|Drug|Sitagliptin|No one is blinded to the treatments.
75913189|NCT02999646|Other|MVX-ONCO-1|Autologous cells: 1 vial containing 4x10^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10^5 MVX-1 cells
75913190|NCT02986178|Biological|PVSRIPO|A single dose of an oncolytic polio/rhinovirus recombinant (PVSRIPO)
75913191|NCT02945280|Drug|apixaban|12 weeks of apixaban treatment to monitor for efficacy in the prevention of VTE-related mortality
75466311|NCT01908049|Dietary Supplement|Placebo|
75466312|NCT01908075|Drug|FP/SAL|
75466313|NCT01908075|Drug|BDP/FOR|
75466314|NCT01908088|Biological|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
75466315|NCT01908114|Behavioral|Enhanced Community mobilization|
75466316|NCT01908114|Biological|Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA|
75466317|NCT01908166|Procedure|ultrasound elasticity imaging|Undergo ultrasound elastography
75466318|NCT01908192|Drug|NaBen®|The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
75466319|NCT01908192|Drug|Placebo|The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
75913192|NCT02900079|Device|rapid diagnostic test for malaria antigen|rapid diagnostic test for malaria antigen to be used by travelers when febrile
76073159|NCT00692692|Procedure|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
75466320|NCT01908244|Other|Music|Pentatonic music
75466321|NCT01908257|Drug|lesinurad 400 mg|
75466322|NCT01908257|Drug|ranitidine 150 mg|
75775406|NCT05867758|Other|Psychosocial group intervention|"The psychosocial group intervention is composed of 8 weekly sessions of 90 minutes each and the receiving of self-help digital materials. Both organized as following: 2 on isolation, loneliness and social connection, 2 on well-being, 2 on the use of digital tools, 2 on the fostering of socialization with peers.~To evaluate the effects of the blended intervention and of the two conditions we will ask participants to fulfill the following clinical questionnaires: ULS-6 (Russell et al. 1980), MSPSS (Zimet et al., 1988), GAD-7 (Spitzer et al., 2006), PHQ-9 (Kroenke, Spitzer & Williams, 2001), SWLS (Diener et al., 1985), MLQ (Steger et al., 2006) before starting the intervention in presence and online (T0), at the end of that period (T1) and 2 months after (T2)."
75320657|NCT02115074|Drug|Celebrex|"Dose levels : 100 mg twice a day (< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
75320658|NCT03850730|Drug|Pazopanib|Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study
75320659|NCT01674686|Drug|Sarpogrelate|Sarpogrelate 100mg twice a day
75320660|NCT01674686|Drug|Atorvastatin|Atorvastatin 80mg daily
75775407|NCT05867745|Other|Interview|As previously specified
75775408|NCT05867745|Other|Survey|As previously specified
75320661|NCT02082392|Drug|Escitalopram|
75775409|NCT05867745|Other|Letter to a friend (autoethnography)|As previously specified
75775410|NCT05867693|Dietary Supplement|palmithoylethanolamide/polydatin|"Palmitoyl-ethanolamide, a saturated fatty acid amide of palmitic acid commonly found in egg yolk and peanuts, is chemically related to anandamide but exhibit low affinity for cannabinoid receptors, and participate in the control of inflammation and nociception mainly via down-regulation of mast cell activity. In addition, palmitoylethanolamide is able to reduce human colonic permeability both in vitro and in vivo. Interestingly, palmithoylethanolamide may act as mast cell modulator as a possible agonist for cannabinoid 2-like receptors; and as agonist for PPAR-α, transient receptor potential vanilloid type 1 (TRPV1), and 'orphan' G protein-coupled receptor 55.~For these reasons, palmithoylethanolamide has emerged as potential regulators of nociception. Polydatin, a resveratrol glucoside, is a common dietary component derived from grapes which may act synergistically with palmithoylethanolamide in reducing mast cell activation and local oxidative stress."
75775411|NCT05867693|Dietary Supplement|placebo|After the screening phase, eligible patients will be randomly assigned to equivalent placebo
75775412|NCT05867680|Behavioral|Online Mothers and Babies Course (eMB)|The eMB is an online, asynchronous, self-administered intervention modeled after the efficacious and in-person Mothers and Babies Course. (4) The eight-week course includes psychoeducational modules containing YouTube videos, vignettes, interactive quizzes, homework, guided meditations, and downloadable resources that teach strategies to promote a healthy outcome for mothers and their newborns: 1) overview, 2) thoughts and my mood, 3) fighting harmful and increasing helpful thoughts, 4) activities and my mood, 5) pleasant activities help make a healthy reality, 6) contact with others and my mood, 7) planning for the future and graduation, 8) relaxation exercises.
75913193|NCT02889172|Behavioral|Problem Solving Therapy|It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
75913194|NCT02848001|Drug|CC-90009|CC-90009
75913195|NCT02779855|Biological|Talimogene laherparepvec|Talimogene laherparepvec injection. Phase I: Dose escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD) from Phase I. The MTD dose level is defined as the highest dose level with ≤1 out of 6 patients experiencing a dose limiting toxicity (DLT).
75913196|NCT02779855|Drug|Paclitaxel|Paclitaxel chemotherapy infusion. The paclitaxel weekly dose is fixed at 80 mg/m^2.
75913197|NCT02687906|Drug|Vabomere|Vabomere (meropenem-vaborbactam) for IV injection
75913198|NCT02684474|Biological|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
75913199|NCT02682927|Drug|ZX008 (Fenfluramine Hydrochloride)|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
75913200|NCT02682927|Drug|Matching Placebo|Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
75913201|NCT02677493|Biological|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
75913202|NCT02677493|Biological|IL-YANG Flu Vaccine Prefilled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
75913203|NCT02677493|Biological|IL-YANG Trivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
75320662|NCT02082392|Drug|Placebo|A substance or treatment of no intended therapeutic value in a pill form.
75320663|NCT02100800|Other|MR and CT measurements of emphysema quantification|
75320664|NCT01674764|Procedure|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
75320665|NCT01674764|Procedure|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
75466323|NCT01908257|Drug|lesinurad 400 mg + ranitidine 150 mg|
75466324|NCT01908270|Behavioral|Yoga|
75466325|NCT01908270|Other|Usual care|
75466326|NCT01908283|Biological|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
75466327|NCT01908296|Drug|FK949E|Oral
75466328|NCT01908296|Drug|fluvoxamine|Oral
75466329|NCT01908309|Drug|Iobitridol 350|
75466330|NCT01908309|Drug|Iodixanol 320|
75466331|NCT01908322|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
75466332|NCT01908335|Drug|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
75466333|NCT01908335|Drug|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
75622041|NCT02725450|Behavioral|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
75466334|NCT01908335|Drug|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
75775413|NCT05867641|Behavioral|Immersive VR Therapy in Head-Mounted Device (HMD)|"Caregivers will be trained to administer VR&R therapy to their loved ones with dementia, in their private home/residence. Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, approximately every other day (or as desired), for three weeks. The caregiver will use the custom VR&R web-based application on their personal device (laptop, tablet, or mobile phone) to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
75775414|NCT05867628|Other|Activities-based locomotor training (physical therapy)|AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
75775415|NCT05867602|Drug|Albumin|intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g
75320666|NCT03849794|Other|Experimental Group|"Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 40 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required."
75775416|NCT05867589|Drug|68Ga/18F-FAPI-04|Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
75775417|NCT05867576|Behavioral|Acceptance and Commitment Therapy (ACT)|"Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a third wave cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations."
75775418|NCT05867537|Dietary Supplement|Gluten-free diet|Implementation a 78-week dietary intervention to patients with ulcerative colitis, crohn´s disease and UC patients with associated PSC (PSC-IBD).
75775419|NCT05867524|Other|Oral Glucose Tolerance Test|75g oral glucose tolerance test, sampled over three hours
75775420|NCT05867524|Other|Cycling test|2 hours of moderate activity level cycling
75775421|NCT05867511|Behavioral|iPAL App|"The intervention will have a duration of eight weeks. It is theory-based, will be delivered to participants' smartphones via the study app (except components 5 and 6), and comprises the following components:~Theory-based individualized feedback.~Self-generated motivational messages.~Motivation for habit formation through push messages.~Motivational images and videos that participants handed in or selected will be sent to them through the app.~Study-specific social media groups. Participants will be offered the option to participate in study-specific social media groups.~Posting motivational stories. A story of a person, who successfully changed his or her lifestyle to be more physically active and/or less sedentary, will be posted once a week in the study-specific social media groups."
75466335|NCT01908335|Drug|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
75466336|NCT01908348|Dietary Supplement|Erythritol|
75913204|NCT02670161|Drug|Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)|brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
75913205|NCT02633059|Drug|Dexamethasone|Given PO
75913206|NCT02633059|Drug|Idasanutlin|Given PO
75913207|NCT02633059|Drug|Ixazomib Citrate|Given PO
75466337|NCT01908361|Behavioral|Unilateral Hybrid (InMotion3 plus CIT) Intervention|"During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.~During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions."
75622042|NCT02725294|Other|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
75622043|NCT00592501|Radiation|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
75622044|NCT00592501|Drug|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
75913208|NCT02633059|Other|Laboratory Biomarker Analysis|Correlative studies
75913209|NCT02633059|Other|Pharmacological Study|Correlative studies
75320667|NCT03849794|Other|Control group|The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 15 minutes in duration.
75913210|NCT02630043|Drug|Tolcapone|Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
75913211|NCT02630043|Drug|Oxaliplatin|Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
75913212|NCT02614534|Drug|MITOMYCIN-C 30 mg|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC with Mytomicin C for 60 minutes.
75913213|NCT02614534|Procedure|Proactive cytoreductive surgery|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women)
75913214|NCT02566850|Device|Ekso|powered lower extremity exoskeleton
75913215|NCT02477176|Other|Discectomy|Lumbar discectomy
75913216|NCT02460692|Drug|Placebos|Administration of vaporized cannabis plus either dronabinol or placebo pill
75913217|NCT02460692|Drug|dronabinol|Administration of vaporized cannabis plus either dronabinol or placebo pill
75913218|NCT02460692|Drug|Vaporized Cannabis 3.7% THC/5.6% CBD|Administration of vaporized cannabis plus either dronabinol or placebo pill
75913219|NCT02408120|Drug|Insulin glargine|"Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.~Daily insulin dose will be adjusted as follow:~If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
75913220|NCT02408120|Drug|Insulin aspart|"Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.~Daily insulin dose will be adjusted as follow:~If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
75913221|NCT02408120|Drug|Supplemental insulin aspart|"Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~BG >141-180 mg/dL; 2-4 units of insulin aspart~BG between 181-220 mg/dL; 3-6 units of insulin aspart~BG between 221-260 mg/dL; 4-8 units of insulin aspart~BG between 261-300 mg/dL; 5-10 units of insulin aspart~BG between 301-350 mg/dL; 6-12 units of insulin aspart~BG between 351-400 mg/dL; 7-14 units of insulin aspart~BG > 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~BG between 261-300 mg/dL; 5-10 units of insulin aspart~BG between 301-350 mg/dL; 6-12 units of insulin aspart~BG between 351-400 mg/dL; 7-14 units of insulin aspart~BG > 400 mg/dL; 8-16 units of insulin aspart"
75913222|NCT02393183|Drug|ASTED|A tablet of ASTED will be taken twice a day
75913223|NCT02393183|Dietary Supplement|Selenium|A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
75913224|NCT02393183|Other|Placebo|A tablet of Placebo (same shape and color) will be taken twice a day
75320668|NCT03293030|Drug|Dupilumab|Dupilumab treatment
75320669|NCT01674842|Radiation|Radiation Therapy|Once daily, Monday - Friday for six weeks
75913225|NCT02391545|Drug|Duvelisib|PI3K Inhibitor
75913226|NCT02391545|Drug|Rituximab|monoclonal antibody
75913227|NCT02391545|Drug|Obinutuzumab|monoclonal antibody
75913228|NCT02295475|Drug|Apixaban|
75913229|NCT02295475|Drug|Warfarin|
75913230|NCT02257723|Drug|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
75913231|NCT02257723|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
76073160|NCT00692692|Procedure|standard of care tissue expander breast reconstruction surgery after mastectomy|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
75320670|NCT01674842|Drug|Cisplatin|Intravenously, once weekly for six weeks
76073161|NCT00693160|Drug|ketorolac|single intrathecal injection of ketorolac 2 mg
75320671|NCT04404764|Drug|Nusinersen Injectable Product|The patient´s treatment is provided by SUS. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.
75320672|NCT03161132|Drug|Olaparib|Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.
75913232|NCT02257723|Procedure|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
76073162|NCT00693160|Drug|placebo|subject will receive a placebo (preservative free normal saline) spinal injection
75622045|NCT00592501|Drug|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
75913233|NCT02257723|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
75913234|NCT02257723|Procedure|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
75913235|NCT02254863|Biological|DUOC-01|Intrathecal administration of DUOC-01
75913236|NCT02193503|Other|Treatment|Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
76073163|NCT00693160|Drug|remifentanil|All subjects will receive a remifentanil infusion
76073164|NCT00693160|Drug|Capsaicin|Topical capsaicin pain model utilized for each subject
75622046|NCT02727556|Behavioral|visual images|
75622047|NCT03097666|Device|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
75622048|NCT02721628|Procedure|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
75622049|NCT02721628|Procedure|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
75622050|NCT02721628|Device|Femtosecond laser|Use in the epic-keratoplasty surgery
75622051|NCT02721472|Procedure|micro- and macro-circulatory vascular remodelling measures not practice in routine care|Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
75622052|NCT02721472|Procedure|Biological measures not practice in routine care|Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
75622053|NCT02721394|Behavioral|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
75622054|NCT01040832|Drug|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] over 120 minutes followed by 250 mg/m^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
75775422|NCT05867485|Other|COVID-19 Discharge Education|"A discharge education brochure has been developed based on information from the literature to complement the verbal information provided to patients. The content of the education brochure includes the following:~Information about the spread of the virus and precautions to be taken.~Guidelines for cleanliness and disinfection of the environment.~Precautions regarding personal and wearable items.~Information about food and beverages.~Guidelines for personal hygiene practices.~Information about quarantine and isolation.~Guidelines for maintaining health and care (e.g., respiratory hygiene, cough etiquette, movement, range of motion exercises) (CDC, 2019; Ministry of Health of Turkey, 2020; CDC 2019 A-B-C-D)."
75775423|NCT05867459|Diagnostic Test|Serum creatinine|The test wil be measured for all pt in study to detect of their grade of CKD
75775424|NCT05867459|Diagnostic Test|Alb /creat ratio or 24h urine protein|Test will be measured to detect type and sevirity of proteinuria
75775425|NCT05867459|Diagnostic Test|Serum electrolyte|The test will be measured in all pt to detect renal tubular state
75775426|NCT05867459|Diagnostic Test|Urine analysis|It is mirror of kidney
75775427|NCT05867459|Diagnostic Test|Abdominal ultrasound|To detect the anatomy and any structural abnormality in kidneys
76073165|NCT00694018|Other|Education and standard care|Educational program for individuals with chronic back pain.
76073166|NCT00694018|Behavioral|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
76073167|NCT00694564|Drug|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
76073168|NCT00695188|Drug|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
76073169|NCT00695188|Drug|methotrexate|25 mg oral administration
75320673|NCT03161132|Drug|Pegylated Liposomal Doxorubicin|PLD 40mg/m2 every 28 days intravenous
75320674|NCT01674920|Behavioral|Choices|The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
75320675|NCT03844256|Combination Product|nivolumab 480mg|Immuno-chemoradiotherapy
75320676|NCT03844256|Combination Product|nivolumab 3mg/kg, ipilimumab 1mg/kg|Immuno-chemoradiotherapy
75320677|NCT03844256|Combination Product|nivolumab 1mg/kg, ipilimumab 3mg/kg|Immuno-chemoradiotherapy
75320678|NCT01675076|Drug|Dabigatran|NOAC
75320679|NCT01675076|Drug|Rivaroxaban|NOAC
75320680|NCT01675076|Drug|Apixaban|NOAC
76073170|NCT00658138|Device|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
75913237|NCT02162732|Device|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
75913238|NCT02156739|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
75913239|NCT02156739|Drug|Gadobutrol|Given IV
75913240|NCT02156739|Drug|Gadoxetate Disodium|Given IV
75913241|NCT01994252|Device|Optimal Medical therapy plus ICD|
75913242|NCT01994252|Device|Optimal Medical therapy plus CRT/ICD|
76073171|NCT00658138|Device|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
75622055|NCT01040832|Drug|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram [mg/kg] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
76073172|NCT00706264|Device|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
75622056|NCT02721550|Drug|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
75622057|NCT02721238|Biological|20% Albumin|
75622058|NCT02721238|Other|Plasmalyte|
75622059|NCT02721004|Drug|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
75622060|NCT04302090|Other|Regulated expiratory method|This method was originally a postpartum abdomino-perineal rehabilitation technique. It allows a functional abdominal rehabilitation by combining a regulated breath in a specific mouthpiece and an abdominal stimulation triggered by this same breath. The use of this method was extended to labor and childbirth. In fact, the application of the method during labor is based on the use of a flow regulating device (Winner Flow + URO-MG®). By regulating the flow of breath during a uterine contraction, it allows better pain management.
75622061|NCT04304196|Other|TEMPO|TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).
75775428|NCT05867459|Diagnostic Test|Renal biobsy|Is done but not for all pt but for pt that can do it and agree for it .the test is used for detection of type of CKD or type of glomerionephritis
75775429|NCT05867459|Other|Clinical assesment|"Clinical assessment:~age, kidney disease history, history of DM or HTN ,history of pregnancy during study, therapy in early pregnancy , body weight, body height, and . Mean arterial pressure (MAP) . Body mass index (BMI). According to age and Scr level, the estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI Creatinine Equation (2021)~Evaluation of pregnancy outcomes :Adverse pregnancy outcomes included maternal death, severe preeclampsia ,eclampsia ,duration of hospital stay and type of care need, mode of delivery ,need of blood transfusion , gestational age during delivary for detet preterm birth early preterm or late preterm from or extremely preterm > 28W, birth weigh for low birthweight ,very low birth weight , extremely low birth weight,NICU admission,IUGR, still birth ,abortion, and neonatal death."
75775430|NCT05867394|Other|Stress ball|Stress ball squeeze
75320681|NCT02029430|Drug|aldoxorubicin|
75775431|NCT05867355|Procedure|surgical fixation|compare implant removal rates between surgical fixation techniques.
75913243|NCT01985568|Behavioral|Sequential BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.
76073173|NCT04344964|Other|None - NA|Observational study
76073174|NCT00695500|Drug|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
76073175|NCT00695500|Drug|Placebo|Placebo tablets, 0 mg per day for 3 weeks
76073176|NCT00695578|Drug|Biafine|Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
75320682|NCT01675232|Other|Soak and smear|Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
75320683|NCT01675232|Other|Dry Smear|Corticosteroid ointment applied to dry skin twice a day.
75320684|NCT01675388|Other|Hypothermia|Hypothermia to 33.5 deg C
75320685|NCT01673438|Drug|aldoxorubicin|
75320686|NCT03838796|Drug|lenvatinib|for patients <60kg, lenvatinib 8mg bid po for patients >60kg, lenvatinib 12mg bid po
75320687|NCT03838796|Procedure|TACE|The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
75775432|NCT05865275|Device|Low-level laser treatment|a single preliminary treatment for a few seconds for each tooth using low level diode laser before of tooth bleaching could reduce risk to arise of tooth sensitivity
75775433|NCT05865275|Other|tooth bleaching procedure|The gingival tissues of the teeth to be bleached were isolated from the bleaching gel using a light-cured resin dam (OpalDam Kit, Ultradent; Milan, Italy). A 38 % ready-to-use Hydrogen peroxide-containing gel (The Smile® Strong, Italy) was applied from the first premolar right to the first premolar left of both jaws for a total period of 20 minutes for a 1 single whitening session.
75775434|NCT05865080|Drug|Ketamine|0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution before spinal anesthesia
75775435|NCT05865080|Drug|Placebo|Normal saline
75913244|NCT01985568|Behavioral|Standard BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
75913245|NCT01920932|Drug|brentuximab vedotin|Given intravenously (IV).
75622062|NCT04304196|Other|Usual care|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
75622063|NCT02832856|Behavioral|Healthy Relationship Education|RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.
75622064|NCT02832856|Behavioral|Job Readiness Curriculum|"Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
75622065|NCT02720770|Drug|norditropine simplex|
75622066|NCT02733406|Other|Target Controlled Infusion|
75622067|NCT02733406|Other|Velocity Controlled Infusion|
75622068|NCT02720926|Drug|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
75622069|NCT02720926|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
75622070|NCT02720926|Drug|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
75622071|NCT00854581|Biological|PEG-interferon alfa-2b|Administered subcutaneously.
75775436|NCT05864105|Biological|PM8002|PM8002 20mg/kg Q2W
75775437|NCT05864105|Drug|FOLFOX regimen|day 1: oxaliplatin [85 mg/m2, 2-h infusion] plus leucovorin [200 mg/m2, 2-h infusion], followed by 5-fluorouracil [400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion]; day 2: leucovorin [200 mg/m2, 2-h infusion], followed by 5-fluorouracil [400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion]
75622072|NCT00854581|Biological|Interferon alfa-2b|Administered intravenously.
75622073|NCT00854581|Drug|Valproic Acid|Administered orally.
75913246|NCT01920932|Drug|etoposide|Given IV.
75913247|NCT01920932|Drug|prednisone|Given orally (PO).
75913248|NCT01920932|Drug|doxorubicin|Given IV.
75913249|NCT01920932|Drug|cyclophosphamide|Given IV.
75913250|NCT01920932|Drug|Dacarbazine(R)|Given IV.
75913251|NCT01920932|Drug|filgrastim|Given subcutaneously (SQ) as clinically indicated.
75913252|NCT01920932|Other|quality of life assessment|Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
75913253|NCT01920932|Radiation|radiation therapy|At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
75913254|NCT01774253|Drug|Vismodegib|
75913255|NCT01505608|Drug|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
75913256|NCT01505608|Drug|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
75913257|NCT01505608|Drug|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
75913258|NCT01491893|Biological|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
75913259|NCT01483820|Drug|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
75913260|NCT01143766|Drug|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
75913261|NCT01143766|Other|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
75913262|NCT01108120|Drug|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
75913263|NCT01108120|Drug|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
75913264|NCT01106898|Drug|cyclophosphamide|Given IV
75913265|NCT01106898|Drug|paclitaxel|Given IV
75913266|NCT01106898|Biological|trastuzumab|Given IV
75913267|NCT01106898|Other|laboratory biomarker analysis|Correlative studies
75913268|NCT01059071|Drug|DFMO|"Escalating doses of DFMO in a 3 +3 cohort design.~DFMO at current cohort Dose Level orally each day for 21 day cycles~Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID"
75622074|NCT00854581|Drug|Zidovudine|Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
75622075|NCT02720458|Other|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
75320688|NCT03719690|Drug|Tipifarnib|Tablet for oral administration
75775438|NCT05864040|Device|Bitrack System-assisted laparoscopic radical/simple nephrectomy|Robot-Assisted Laparoscopic Transperitoneal Radical/Simple Nephrectomy is performed under general anesthesia. Using blunt dissection, the inferior pole of the kidney is lifted, and ureter and gonadal veins released from fat and connective tissue. The ureter is dissected caudally and sectioned after being sealed with a distal endoscopic clip. Dissection proceeds along the psoas muscle with anterior elevation of the ureter and lower renal pole towards the hilium. Main hilar are circumferentially dissected and sectioned and the kidney is entirely mobilized and released. Gerota´s capsule and suprarenal gland may be preserved if oncologically safe. Once the specimen is completely released, a laparoscopic bag is introduced by the assistant and the specimen entrapped. The robot is undocked, gas evacuated from the abdomen and specimen retrieved. Abdominal wall incisions over 10mm are closed using a continuous suture. Skin incisions are closed using skin staplers.
75775439|NCT05863286|Drug|Botulinum toxin type A|"Botulinum toxin is produced by the gram-positive, anaerobic, spore-forming bacterium Clostridium botulinum, and is one of the most lethal biological toxins known to man.~Botulinum toxin has seven antigenically different serotypes and exerts a paralytic action by rapidly and strongly binding to presynaptic cholinergic nerve terminals. It is then internalized and ultimately inhibits the exocytosis of acetylcholine by decreasing the frequency of acetylcholine release. Without its nerve supply, the muscle fiber will deteriorate; however, the muscle will regain its strength as the nerves regenerate."
75775440|NCT05857228|Procedure|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery for removal of nasal polyps and sinus tissue.
75775441|NCT05855408|Biological|Intramuscularly administered Ad5-nCoV vaccine|This vaccine is produced by CanSino Biologics Inc.
75775442|NCT05855408|Biological|Aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc.
75775443|NCT05855408|Biological|DelNS1-2019-nCoV-RBD-OPT1|This vaccine is produced by Wantai Biopharmaceutical Company.
75775444|NCT05855408|Biological|SYS6006|This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
75775445|NCT05840237|Other|"Anhydrous Enol-Oxaloacetate, a Medical Food"|"Treatment with the medical food Oxaloacetate CFS, 2 - 500 mg capsules BID with food"
75622076|NCT02720458|Behavioral|Short-term simple self-help program|"The short-term simple self-help program consists in:~Restriction of time in bed~Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
75775446|NCT05840237|Other|White Rice Flour|"Treatment with the food White Rice Flour, 2- 500 mg capsules BID with food"
75775447|NCT05834725|Behavioral|Promoting Resilience in Stress Management|Resilience coaching program.
75775448|NCT05834725|Other|Usual Care|Combination of physical therapy, occupational therapy, and psychological counseling as recommended by the treating provider.
75775449|NCT05831748|Other|Classic Exercise|Classic exercise group consists of straight leg raising, back extensor strengthening, and abdominal strengthening exercises.
75775450|NCT05831748|Other|Clinical Pilates|In the Clinical pilates group, pilates exercises will be given. Clinical pilates exercises improve back extensors, trunk flexors, and pelvis stabilization. These exercises will be applied along with breathing exercises.
75775451|NCT05828368|Procedure|Non surgical periodontal therapy|"Scaling and root planing is a deep cleaning below the gumline used to treat gum disease.~Gum disease is caused by a sticky film of bacteria called plaque. Plaque is always forming on your teeth, but if they aren't cleaned well, the bacteria in plaque can cause your gums to become inflamed."
76073177|NCT00695578|Drug|Polysporin|over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
75775452|NCT05825885|Drug|E2|micronized E2 at a daily dose of 4-6mg,
75775453|NCT05807724|Other|Phone-based fall-prevention strategy|Written education material and Phone-Based Fall-Prevention Strategy
76073178|NCT01792102|Drug|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16."
76073179|NCT02996734|Procedure|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
76073180|NCT00699010|Drug|Acurox 5/30mg taken first|followed by oxycodone 5mg with 48 hour washout
75622077|NCT02720614|Radiation|Hypofractionated radiation/chemotherapy|Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
75622078|NCT02720380|Other|Buteyko|Intervention will be held twice a week during 3 weeks.
75320689|NCT03719690|Device|HRAS Detection Assay|In Vitro Assay to detect HRAS mutations
75622079|NCT02720380|Other|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
75622080|NCT00833911|Drug|Tramadol Once A Day|
75320690|NCT01675466|Procedure|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
75320691|NCT01675466|Procedure|General anaesthesia|
75320692|NCT01675466|Device|Laparoscopic instruments|
75775454|NCT05807724|Other|Home-visit fall prevention strategy|Written education material and Home visit-Based Fall-Prevention Strategy
75913269|NCT01059071|Drug|Etoposide|Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
75913270|NCT01001637|Dietary Supplement|Curcumin Formulation|2000mg or 3000mg daily BID
75320693|NCT04747106|Biological|plasma exchange|when ADP inhibition >30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
75320694|NCT01675700|Drug|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
75320695|NCT01676558|Drug|131I-rituximab|
75320696|NCT01675856|Other|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
75320697|NCT01675856|Other|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
75622081|NCT02719756|Drug|Metformin|Metformin tablets 1000 mg
75622082|NCT02719756|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets
75320698|NCT02510300|Drug|Sofosbuvir (SOF)|Exposure of interest for participants who received a SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
75622083|NCT02719756|Drug|Metformin up-titration|
75622084|NCT02719678|Other|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
75622085|NCT01125293|Drug|Everolimus|
75775455|NCT05768373|Device|3M™ Clinpro™ Fluoride Aqueous Solution|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
75775456|NCT05768373|Device|3M™ Vanish™|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
75775457|NCT05761886|Other|telehealth-based clinical pharmacy intervention|The pharmacist will perform an initial comprehensive review of the medication regimen, make any adjustments, document those in the patient's electronic health record (EHR) and communicate with the patient's T2D care team as needed. They will also call (using an EHR-based software) the patient using phone/video to educate them about T2D self-management and identify any medication-related unmet needs. Periodic reviews of the medication regimen and roughly biweekly follow-up patient calls will occur with frequency based on need (as judged by the pharmacist). Patient intervention calls will be personalized depending on HbA1c levels, comorbidities, and medication complexity
75775458|NCT05756088|Diagnostic Test|Blood draw to measure the levels of dd-cf DNA|Blood draw to measure the levels of dd-cf DNA.
75913271|NCT01001637|Dietary Supplement|Placebo|Placebo
75913272|NCT00923702|Biological|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.
75913273|NCT00867568|Drug|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
75913274|NCT00737698|Other|Exercise|Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks
75913275|NCT00737698|Other|Repetitive magnetic stimulation|Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks
75913276|NCT00626366|Radiation|Sinus CT Scan|Subjects will undergo a Xoran miniCAT scan of their sinuses
75913277|NCT00626366|Drug|Omnipaque 240 Contrast Solution|Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
75913278|NCT00626366|Drug|Omnipaque 240 mg I/mL|Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
75913279|NCT00601003|Drug|Nifurtimox|30mg/kg/day PO divided into TID dosing q day
75913280|NCT00601003|Drug|Cyclophosphamide|250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
75913281|NCT00601003|Drug|Topotecan|0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
75936404|NCT03117842|Other|Automated text and voice messages|Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
75320699|NCT02510300|Drug|Ledipasvir/Sofosbuvir (LDV/SOF)|Exposure of interest for participants who received a LDV/SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
75320700|NCT02510300|Drug|Sofosbuvir/Velpatasvir (SOF/VEL)|Exposure of interest for participants who received a SOF/VEL-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
75320701|NCT02510300|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)|Exposure of interest for participants who received a SOF/VEL/VOX-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
75320702|NCT00678535|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
75320703|NCT00678535|Drug|Capecitabine|Capecitabine 1000 mg/m^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
75622086|NCT01125293|Drug|Rituximab|
75622087|NCT01125293|Drug|Bortezomib|
75622088|NCT02702986|Procedure|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
75622089|NCT02702986|Device|Laser|
75622090|NCT02719912|Device|mitral valve replacement|transcatheter mitral valve replacement
75775459|NCT05753683|Behavioral|mHealth-Women's CoOp|The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a gender-specific human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and gender-based violence through education, skills-building, and role-play and rehearsal via a mobile app. The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period. Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.
75775460|NCT05753683|Behavioral|Virtual Group|The enhanced online group component will be available to be accessed using the mHealth-Women's CoOp platform for participants in the enhanced arm. The purpose of this component is to allow for young women who use alcohol to interact with young women like them and also discuss issues related to substance use and sexual risk-taking via a guided conversation to allow for motivational and informational support. The virtual group component will include online live discussions moderated and monitored by a trained online facilitator.
75622091|NCT05111483|Other|Tupler technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~Repositioning with diastasis rehab splint :~Protect the connective tissue~Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~Diastasis safe exercises program to maintain the gains"
75775461|NCT05743959|Procedure|No intervention|No intervention
75622092|NCT05111483|Other|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~Tie a scarf around abdomen while performing exercises~Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~Respiratory rehabilitation manoeuvre"
75775462|NCT05737108|Dietary Supplement|Bilberry capsule product|A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
75775463|NCT05737108|Dietary Supplement|Placebo(starch)|30 days of placebo or Bilberry capsule product with crossover to the other.
75775464|NCT05734690|Drug|SGLT2i, beta blocker, ARNI, MRA, MTD|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
75775465|NCT05734690|Behavioral|Education-First|For the first 3-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 3 months, be invited to participate in the remote heart failure clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for heart failure therapy. Provider education will also consist of the program's medical algorithm and a summary sheet on indications, outcomes, prescribing, and monitoring information
76073181|NCT00699010|Drug|Oxycodone 5mg taken first|followed by Acurox 5/30mg with 48 hour washout
75622093|NCT02719834|Drug|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
75775466|NCT05733624|Drug|SCAI-001 0.01% eyedrop|BID for 12weeks
75775467|NCT05733624|Drug|SCAI-001 0.02% eyedrop|BID for 12weeks
75775468|NCT05733624|Drug|Restasis 0.05% eyedrop|BID for 12weeks
75775469|NCT05702268|Drug|ICP-332|Tablet, 40 mg
75775470|NCT05702268|Drug|ICP-332 Placebo|Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332.
75775471|NCT05684575|Other|Phone satisfaction questionnaire|Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
75775472|NCT05674370|Device|GRIP Electronic Diagnostic Chip|Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab
75775473|NCT05674370|Diagnostic Test|Laboratory-based nucleic acid amplification tests (NAATs)|Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab
75775474|NCT05658731|Radiation|substructure informed planning|Radiation Therapy with substructure informed planning determined by the PI.
75320704|NCT00678535|Drug|Cisplatin|Cisplatin 80 mg/m^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
75320705|NCT04404374|Procedure|A-PRF/EMD|Comparing healing effect of an autologous and a xenogenic product
75320706|NCT03834116|Device|Inspiratory muscle training|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
75622094|NCT02719834|Other|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
75651631|NCT05833542|Behavioral|Patient-provider decision tool|Participants will receive a shared patient-provider assessment and decision-making tool, utilizing techniques from Motivational Interviewing and based on the Ottawa Patient Decision Aid framework, for weighing each patient's treatment options and their fit to patient interests, needs, assets, and constraints. The tool will facilitate and record patient-provider agreement on an antiretroviral treatment and support-services plan, to be integrated into the broader existing medical case management care plan signed by both patient and provider. The tool will be administered during a medical case management visit and completed by the participant and a patient navigator or medical case manager.
75775475|NCT05658731|Other|Neurocognitive Testing|California Verbal Learning Test (CVLT) and other cognition assessments.
76073182|NCT02996812|Drug|Exendin (9-39)|
76073183|NCT00661570|Device|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
75320707|NCT01675934|Procedure|Retroflexion with the adult colonoscope.|
75320708|NCT01675934|Procedure|Retroflexion with the pediatric colonoscope.|
75320709|NCT00659737|Drug|Aprepitant|40mg tablet
75622095|NCT04311203|Behavioral|Mental Health First Aid|The intervention has 3 parts:1.Two-day MHFA training provided by MHFA England. A manualised programme designed to provide individuals with: an in-depth understanding of mental health and the factors that can affect wellbeing, practical skills to spot triggers and signs of mental health issues, confidence to step in, reassure and support a person in distress, enhanced interpersonal skills such as non-judgemental listening, knowledge to help someone recover their health by guiding them to further support - whether that's self-help resources, through their employer, the NHS, or a mix. 2.Raising awareness of the presence of MHFA in the organisation. 3.The application of MHFA to participants in the workplace using the manualised five-stage approach, ALGEE: Approach the person, assess and assist with any crisis; Listen and communicate non-judgementally; Give support and information; Encourage the person to get appropriate professional help and Encourage them to seek other forms of support.
75775476|NCT05658731|Diagnostic Test|MRI|Magnetic resonance imaging (MRI) using whole brain diffusion tensor imaging (DTI) and resting state functional MRI (rsfMRI).
75775477|NCT05642572|Procedure|Biospecimen Collection|Undergo collection of blood samples
75775478|NCT05642572|Drug|Capmatinib|Given PO
75775479|NCT05642572|Procedure|Computed Tomography|Undergo CT scan
75775480|NCT05642572|Procedure|Magnetic Resonance Imaging|Undergo MRI
75775481|NCT05642572|Drug|Osimertinib|Given PO
75775482|NCT05642572|Biological|Ramucirumab|Given IV
75775483|NCT05640466|Device|Reduction and fixation of metatarsal neck fracture by metaizeau's technique|Reduction and fixation of metatarsal neck fracture by metaizeau's technique
75775484|NCT05639166|Biological|IBIO123|IBIO123 10 mg
75775485|NCT05639166|Other|Placebo|Matching Placebo
75775486|NCT05614869|Device|Prevena Plus Incision Management System with Prevena Dressings|Negative pressure pump and dressings
75320710|NCT00659737|Drug|Scopolamine|1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
75622096|NCT02719600|Behavioral|Virtual reality|Evaluation of observational motor learning using virtual reality
75622097|NCT02719288|Other|CLARIX® CORD 1K graft|
75775487|NCT05614128|Other|IVIg|Patients will be treated with IVIg as recommended by expert guidelines for treatment of CIDP under care of their primary neurologist. This will not be provided by the study.
75775488|NCT05609513|Other|HTN-BASIC|The HTN-BASIC intervention will consist of providing consistent access to diagnostic equipment and evidence-based antihypertensive drugs at no cost to the hypertensive patients. Access to a consistent supply of three anti-hypertensive drugs (amlodipine 5, 10mg; valsartan 80, 160mg; and hydrochlorothiazide 12.5, 25mg) will be supplied to each clinic in the trial.
75775489|NCT05609513|Other|HTN-PLUS|In addition to receiving all the components of HTN-BASIC, HTN-PLUS sites will receive an enhanced, more human-resource intensive package of interventions that have been developed in consultation with key stakeholders during our human-centered design phase. The intervention components will include four broad categories- (1) hypertension training, (2) differentiated service delivery and (3) remote patient monitoring for hypertension and (4) Performance Improvement Program. Uptake of all components will be assessed on a monthly basis during the intervention period. These interventions will by nature cost more, and so cost data will be rigorously collected as well.
75775490|NCT05583890|Device|Continuous glucose monitors|Participants will wear continuous glucose monitors for a 7 day period.
76073184|NCT00706810|Drug|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
75320711|NCT00660049|Device|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
75775491|NCT05583890|Device|Activity tracker|Participants will wear the activity tracker for a 7 day period.
75775492|NCT05583890|Behavioral|Food Diary|Participants will complete a food diary of everything they eat for 7 days.
75775493|NCT05583890|Behavioral|Questionnaires|Participants will complete FACT-Hep, DiPcare-Q and health inequality related questions.
75775494|NCT05582161|Drug|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
75775495|NCT05536778|Other|Realization of the 3 tests|The participants will have to perform the isokinetic evaluation during one session and the two functional tests during another session. Those sessions will be separated by 14 days.
75775496|NCT05520866|Behavioral|PrehabPal|Web based application
75775497|NCT05518799|Drug|Midazolam|Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.
75775498|NCT05500846|Device|The Visual Ice Cryoablation System|Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.
75775499|NCT05486806|Drug|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
75775500|NCT05486806|Radiation|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
75775501|NCT05447702|Drug|Camrelizumab|Intravenous (IV) infusion
75320712|NCT00660049|Other|SNaP|Daily use
75320713|NCT00660049|Other|SNaP|Daily application per protocol
75320714|NCT04763876|Drug|Ketorolac Injection 15 mg|A single dose of 15 mg ketorolac administered intramuscularly.
75320715|NCT04763876|Drug|Ketorolac Injection 60 mg|A single dose of 60 mg ketorolac administered intramuscularly.
75320716|NCT00680797|Drug|Testosterone|Testosterone gel
75320717|NCT00680797|Drug|Estrogen|Estrogen patch
75320718|NCT02081456|Other|Soft Tissue Mobilization|Patients in the STM group received treatment in supine, with their head resting on one pillow and the involved UE positioned in abduction and external rotation to preload the neural structures of the upper limb. Manual pressure was applied to the soft tissues of the upper quadrant in a deep, stroking manner with the intention to improve the mobility of the soft tissues surrounding the pathway of the neural structures of the upper limb as well as any tender or tight tissues. The therapist spent approximately 7 minutes on the neck and scapular region, 4 minutes on the upper arm, and 4 minutes on the forearm and hand. The therapist was allowed to vary the time spent on each region according to his/her assessment of the patient's condition. The procedure lasted a total of 15 minutes.
75775502|NCT05447702|Drug|Apatinib|po.
75775503|NCT05447702|Drug|Nab-paclitaxel|IV infusion.
75320719|NCT02081456|Device|Therapeutic Ultrasound|Patients received therapeutic US applied for a period of 5 minutes to the most painful region of the neck, then a second 5-minute dose at the most painful region of the upper extremity. The US dose was 0.5 w/cm2, with sonation time 50% and frequency 1 MHz.40,52 The patient lay supine with the hand of the involved upper extremity placed on the abdomen and the elbow supported on a pillow. The two US doses and interaction time with the patient lasted a total of 15 minutes in an attempt to have equal patient/therapist contact between the two groups.
75622098|NCT02719210|Biological|High Volume Plasma Exchange|
75775504|NCT05447702|Drug|Epirubicin|IV infusion.
75320720|NCT02984852|Drug|Darunavir (DRV)|Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
75622099|NCT02719210|Drug|Hypertonic 3% saline|
75775505|NCT05447702|Drug|Cyclophosphamide|IV infusion.
75775506|NCT05418010|Drug|Tysabri Injectable Product|Tysabri® is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis. Tysabri® 300mg concentrate for solution for infusion and matching placebo are collectively referred to as IMP when detailing to blinded trial procedures. Tysabri® 300mg will be colourless, clear to slightly opalescent solution.
75775507|NCT05418010|Drug|Placebo|Placebo is colourless, clear to slightly opalescent liquid. The formulation of the is the same as that of commercial Tysabri® minus the active ingredient. Placebo is in the same containers/vials as Tysabri®.
75775508|NCT05391971|Drug|Bupivacaine|At the C6 level, a total of 7cc of 0.5% bupivacaine will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of 0.5% bupivacaine.
75775509|NCT05391971|Drug|Saline|At the C6 level, a total of 7cc of saline control will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of saline control.
75775510|NCT05370014|Behavioral|Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM)|The intervention consists of two planning sessions with the dyad (over 2 weeks) followed by eight topic-guided sessions delivered the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly) (Table 3). Key components of these televisits include COVID-19 risk mitigation, chronic disease management, medication adherence, family functioning/support, and community and health systems resource identification and referral with ongoing goal planning. The RN-CHW will meet weekly for progress review, follow up planning, and setting up anticipatory guidance for the next session with the dyads. The RN and CHW will also review IC or survivor dissatisfaction and other issues that require more immediate attention. RN-CHW planning will be assessed to make sure each televisit remain topic focused yet incorporates flexibility to suit the needs of each dyad.
75320721|NCT02984852|Drug|Cobicistat (COBI)|Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
75320722|NCT02984852|Drug|Emtricitabine (FTC)|Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
75775511|NCT05332093|Diagnostic Test|skin biopsy|4mm skin biopsy
75775512|NCT05332093|Diagnostic Test|venous blood sample (plasma, PBMC, WB)|venous blood sample to acquire plasma, PBMCs and whole blood
75775513|NCT05332093|Genetic|venous blood sample (HLA)|venous blood sample used for HLA typing
75775514|NCT05332093|Genetic|skin slit|genome sequencing of parasite DNA that is extracted from the skin slit
75775515|NCT05323396|Drug|Antiparasitic medication|"Participants in the parasite-positive group (based on positive result of either stool microscopy, stool PCR, or Strongyloides IgG) will be administered antiparasitic treatment. Antiparasitic medication administered will be targeted to treat the parasite identified. See detailed description of protocol for medication, dose, and frequency that will be given for each parasitic infection identified.~Participants with stool microscopy, stool PCR, and Strongyloides IgG all negative will not be administered treatment, thus will serve as controls."
75775516|NCT05323383|Behavioral|Mindfulness Meditation|Participants in the mindfulness meditation condition will listen to a 20minute guided mindfulness meditation practice that holds the breath and body as the object of meditation.
75936405|NCT03626753|Drug|Nefopam 20 MG/ML|given by Oral route the dose of 20mg every 6 hours.
75320723|NCT02984852|Drug|Tenofovir Alafenamide (TAF)|Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
75622100|NCT02719210|Drug|Mannitol|
75622101|NCT02719210|Device|Elective positive pressure ventilation|
75622102|NCT02719132|Drug|Dapagliflozin|Dapagliflozin, 10 mg
75622103|NCT02719132|Drug|Metformin|Metformin, up to 2500 mg
75622104|NCT02719054|Behavioral|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
75622105|NCT02718976|Procedure|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
75622106|NCT02718976|Procedure|Ultrasound guided lumbar plexus block (Shamrock)|
75651632|NCT05833477|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin treatment three times per week for three weeks
75775517|NCT05323383|Behavioral|Self-hypnosis|Participants in self-hypnosis will listen to a 20-minute audio-guided hypnosis practice with an induction phase, followed by suggestions tailored towards shifts in affect and decentering, and then a re-alerting with post-hypnotic suggestions phase.
75913282|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement Therapy. questionaires|"brief face-to-face or telephone tobacco cessation counseling provided by a tobacco cessation specialist prior to admission and during hospitalization (15-20 minutes per encounter)provision of multi-media self-help materials (e.g., Smoking Cessation Guide for Cancer Patients and Their Families) tailored to address cancer-specific issues such as the benefits and barriers of quitting for cancer patients; 3) tobacco cessation pharmacotherapy, unless medically contraindicated (for this study we will standardize the pharmacotherapy as transdermal nicotine patch), and; 4) two brief telephone counseling (15 minutes) sessions completed as seen clinically appropriate by the tobacco cessation specialists. The content of these counseling sessions is based on the patient's smoking status."
75936406|NCT03626753|Drug|"Nefopam (Acupan) 20 MG/ML Injectable Solution"|given by intravenous route at the dose of 20mg every 6 hours.
75936407|NCT03626753|Drug|"Acetaminophen, (paracetamol) 500Mg Tab"|"2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours."
75936408|NCT03626753|Drug|"(Acetaminophen paracetamol) IV Soln 10 MG/ML"|Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
75320724|NCT04764500|Other|examination of stool sample|Each participant provides stool samples before and after travelling, after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks. Stool samples will be used for isolating both a) ESBL E. coli strains and b) pan-sensitive E. coli strains. Part of the stool sample is stored for isolation of further E. coli clones and microbiota analysis of the isolation of other microbiota strains. All found Enterobacteriaceae will be screened for additional resistance such as Carbapenem and Colistin. In case of a specific resistance, this will be confirmed with additional phenotypic and genotypic tests such as ROSCO disk and polymerase chain reaction (PCR) based panel and whole genome sequencing in order to detect specific resistance mechanisms and genes. Bacteria will be sequenced using Illumina and Nanopore based sequencing. Bioinformatic analysis will allow to determine the whole bacterial genome with containing resistance genes and also describe the microbiota diversity over time in single individuals.
75320725|NCT04764500|Other|patient questionnaire|Each participant will have to provide a questionnaire before and after travelling, as well after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks.
75320726|NCT04764500|Other|examination of blood sample|Each participant will have to provide a blood sample before and after travelling and after 6, 12 and 20 weeks. A serum sample (5mL) for antibody measurement and a 50 ml blood sample for recovery of peripheral blood mononuclear cells (PBMCs in 6 CPTs) for cell mediated immunity will be collected. Serum and PBMCs will allow the analysis of anti-E. coli humoral and cellular responses in order to characterize the individual immune response to specific bacteria over time. Single nucleotide polymorphisms associated with humoral and cellular immune responses will be characterized and linked to immunological and clinical phenotypes and endpoints of the study.
75466338|NCT01908361|Behavioral|Bilateral Hybrid (BMT plus BAT) Intervention|"During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.~During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands."
75622107|NCT02718976|Drug|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
75622108|NCT02718664|Other|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
75622109|NCT02718742|Other|Laboratory Biomarker Analysis|Correlative studies
75622110|NCT02718742|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
75622111|NCT02718742|Other|Quality-of-Life Assessment|Ancillary studies
75622112|NCT02718508|Behavioral|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
75622113|NCT02718430|Drug|VXM01|Oral immunotherapy targeting VEGFR2
75622114|NCT02718352|Other|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
75622115|NCT02718274|Device|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|Community based distribution of self-tests
75775518|NCT05323383|Other|Attention Control|Control participants will listen to a 20-minute natural history recording which was chosen as past research has found that individuals who listen to it report this to be a neutral, but relaxing passage, and it has been used as an effective control condition in previous research.
75622116|NCT02718274|Other|Home-based initiation of ARVs|Home-based initiation of ARVs by study nurse linked to follow-up at clinic
75775519|NCT05309863|Behavioral|Lifestyle management|Increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support.
75775520|NCT05308927|Drug|Norditropin|Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.
75775521|NCT05303142|Other|Heat Tolerance Assessment|60-90 minutes exercise in hot (34 °C; 45% R.H.) conditions at 60%VO2max
75775522|NCT05301101|Radiation|Re-irradiation|Patients will undergo re-irradiation following treatment planning based on current standard practice as determined by treating physicians and multidisciplinary teams.
75775523|NCT05297526|Behavioral|Culturally adapted children's book|Tribe-specific children's book celebrating tribal culture with an embedded oral health message
75775524|NCT05297526|Behavioral|Standard informational brochure on children's oral health|Informational brochure about children's oral health designed by the NIH for American Indian/Alaska Native parents.
75775525|NCT05296447|Other|No Intervention|All subjects that previously received RGX-314 in a parent study
75775526|NCT05287555|Other|Telemonitoring Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, SpO2 sensor and modems.
75622117|NCT02717884|Drug|tranylcypromine|"TCP p.o., daily either 20, 40**, 60**, 80** mg/day, (28d/cycle)~**TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)"
75622118|NCT02717884|Drug|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
75622119|NCT02717884|Drug|cytarabine|40mg s.c. (days 1-10)
75622120|NCT02718196|Behavioral|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
75775527|NCT05287555|Other|Standard Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, and modems
75775528|NCT05265377|Device|Stelo|Use of Stelo exoskeleton in nine rehabilitation sessions
75775529|NCT05256316|Other|Previously admitted COVID-19 patients in intensive care units|Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission
75775530|NCT05210803|Other|No intervention.|All subjects that previously received RGX-314 in a parent study
75775531|NCT05178550|Drug|Heparin|intravenous [iv] injection
75775532|NCT05174546|Diagnostic Test|T2 magnetic resonance|Samples for assessment by the T2MR will be collected once daily in occasion of any consecutive febrile episode during neutropenia when blood cultures are ordered as per standard of care. T2 magnetic resonance will be run according to manufacturer's instructions
75775533|NCT05168566|Drug|Sutetinib Maleate Capsule|Study drug to be taken orally with or without food (with food preferred) for up to13 cycles
75775534|NCT05157945|Drug|ALTO-300 PO Tablet|One tablet daily
75775535|NCT05157061|Dietary Supplement|Galacto-oligosaccharides (GOS)|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a prebiotic supplement is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
75775536|NCT05157061|Dietary Supplement|Maltodextrine|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a placebo is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
75775537|NCT05118750|Drug|ALTO-300 PO tablet|One tablet daily
75775538|NCT05104242|Other|Diet low in Advanced Glycation End-Products (AGE)|The low AGE diet will primarily consist in reducing the amount of AGEs in foods by changing cooking methods. Participants will also be advice to choose foods low in AGEs; however, the advice will be tailored to participants' food preferences
75775539|NCT05093036|Other|Variations in PrEP care delivery at public health services|Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring
75775540|NCT05087758|Other|Matrion|Decellularized placental membrane applied to Wagner 1 and 2 diabetic foot ulcers
75775541|NCT05087758|Other|Conventional Care Wound Management|Advanced wound care with debridement and dressings
75775542|NCT05085782|Drug|Propranolol Hydrochloride|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
75775543|NCT05085782|Drug|Placebo|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
75775544|NCT05085782|Behavioral|Reactivation procedure|Description/visualization of painful movements/activities
75775545|NCT05085782|Behavioral|Pain neuroscience education|In the form of 10 videos that participants will watch on their own time
75913283|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires|Same components of HC+NRT as well as the PS/SRS enhancement.The research team will provide education about scheduled reduced smoking either in person or over the phone. Purpose of the training session, will be audio taped, to prepare participants for daily PDA use over the dur of the scheduled-reduced smoking intervention. Training will demonstrate use of PDA and simulate common technical and procedural issues that might arise during the intervention (e.g., forgetting to record a cigarette or wake time; repeating a day's schedule if needed, prior to the quit date). The simulation will reflect anticipated problems and those identified by users of the PDA. A study helpline number and instructional manual will be provided. A member of the research staff will contact the study participants, once the reduced smoking schedule has begun, to check that the patient understands the schedule and that the PDA is working properly. Estimate patient training with the PDA will require 30 minutes.
75913284|NCT00571493|Drug|Bortezomib|Patients will receive bortezomib in four dose cohorts ( .8. 1.0, 1.3, 1.5 mg/m²). Patients will receive bortezomib on days -11, -8, -5, and -2 before infusion of autologous stem cells.
75913285|NCT00571493|Drug|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|"All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells."
75913286|NCT00552461|Drug|rituximab|IV, 1000 mg, two weeks, 2 times
75320727|NCT00660517|Drug|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
75320728|NCT00660517|Drug|azelastine Hcl|azelastine Hcl nasal spray one spray per nostril two times a day
75320729|NCT00660517|Drug|fluticasone propionate|fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
75622121|NCT04100512|Device|Oscillating Positive Expiratory Pressure Device|Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.
75775546|NCT05075356|Device|The intelligent total body scanner (iToBoS)|"The intelligent total body scanner (iToBoS) device will be an AI diagnostic platform for early detection for melanoma, which includes a novel total-body high-resolution scanner and a Computer Aided Diagnostics (CAD) tool. The prototype iToBoS imaging device used in this study, will not have the integrated CAD system.~The device consists of a horizontal bed on which the participant would lie on. The bed will slide under a series of 5 arc shaped rails that have a total of 15 vision units mounted on rails (3 vision units per arc). The vision units incorporate high-resolution cameras and LED lighting system. When imaging is initiated by an operator, the vision units systematically move along the arch rails taking numerous images capturing majority of the skin surface. The imaging process will take approx. 10 minutes.~Purpose built software will be used to stitch images together to create a body avatar on which skin lesions can be viewed and monitored with."
75775547|NCT05057897|Biological|AZD1222|10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
75775548|NCT05053620|Device|Calculation of the arcuate intrasomal incisions|All patients participating in the study will undergo femtosecond laser treatment for the correction of astigmatism through arcuate intrastromal incisions with the Catalys laser (Johnson & Johnson, USA, CE marked). The calculation of intrastromal arcuate incisions will be carried out using the following nomogram indicated on the laser: 9.0 mm optical zone and symmetrical incisions of 50 degrees for 0.50D, 55 degrees for 0.75D, 60 degrees for 1.00D and 65 degrees for 1.25D of corneal astigmatism. After the incisions, conventional cataract surgery will be performed using the Centurion phacoemulsifier equipment (Alcon, USA, with CE marking) in the ZCB00 monofocal intraocular lens (IOL) implant (Johnson & Johnson, USA, with CE marking). All patients will be treated according to standard clinical practice.
75775549|NCT05053074|Device|Nasal High Flow (NHF)|Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.
75913287|NCT00507572|Other|Medical Chart Review|Medical records are reviewed
75913288|NCT00479128|Drug|Bortezomib|Starting dose: 0.8 mg/m^2 IV Over 3-5 Seconds
76073185|NCT00706810|Drug|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
75775550|NCT05040659|Device|AROMHA Longitudinal Smell Test|The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.
75775551|NCT05033028|Other|Smartphone app|SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.
75775552|NCT05022615|Diagnostic Test|Topcon Camera|Standard 7 field imaging
75775553|NCT05022615|Diagnostic Test|Optos Camera|Ultrawide field imaging
76073186|NCT00661960|Drug|raltegravir|400mg tablet twice daily by mouth for nine months
76073187|NCT00661960|Drug|efavirenz|600mg capsule once daily by mouth without regard to food
75775554|NCT05022615|Diagnostic Test|Clarus Camera|Ultrawide field imaging
75775555|NCT04978363|Device|BOOT|A walking boot is a common type of brace/boot that restricts ankle and foot movement.
75775556|NCT04978363|Device|HFC|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands.
75775557|NCT04978363|Device|SAC|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries.
75775558|NCT04978363|Device|HFC+BOOT|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
75775559|NCT04978363|Device|SAC+BOOT|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
75913289|NCT00479128|Drug|Gemcitabine|Starting dose: 225 mg/m^2 IV Up to 90 Minutes
75622122|NCT04100512|Device|Incentive spirometry|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
75622123|NCT02717572|Radiation|Fludeoxyglucose F 18|
75913290|NCT00479128|Drug|Doxorubicin|Starting dose: 12.5 mg/m^2 IV Over 15-30 minutes
75913291|NCT00159367|Device|Repetitive magnetic stimulation to the quadriceps|
75913292|NCT04833478|Behavioral|Anxiety|Techniques used to reduce anxiety in paediatric patients.
75913293|NCT04833868|Other|hippotherapy and schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week hippotherapy intervention combined with Schroth exercise
75622124|NCT02717572|Device|Positron Emission Tomography|
75622125|NCT02717572|Device|Computerized Tomography|
75913294|NCT04833868|Other|schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week of Schroth exercise
75913295|NCT04833712|Radiation|Stereotactic Radioablation|Stereotactic Radioablation targets on the pulmonary vein ostium aiming to achieve PVI
76073188|NCT00662818|Drug|Telcagepant|Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
76073189|NCT00662818|Drug|Acetaminophen/Paracetamol|Acetaminophen/Paracetamol (500 mg X 2 dosage units)
76073190|NCT00662818|Drug|Placebo to Telcagepant|Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
76073191|NCT00662818|Drug|Placebo to Acetaminophen/Paracetamol|Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
75775560|NCT04974554|Behavioral|FIT|FIT Families is a home-based intervention that works with youth and caregivers to lose weight and improve their health. The intervention lasts 6 months. Sessions are held twice a week for the first 3 months and then once a week for the second 3 months. These sessions will take place in home with a community health worker. In addition, participants will have the opportunity to earn prizes for completing certain intervention related tasks.
75775561|NCT04974554|Behavioral|Home-Based Family Support|Home-Based Family Support Group will receive six months of weekly family counseling in the home. The weekly visits have 3 goals: 1) provide basic education in nutrition and physical recommendations for adolescent and adult obesity; 2) assess and monitor weight, physical activity, and diet via logs; and 3) offer opportunities to discuss barriers they identify to adherence to weight loss recommendations. The HBFS CHW will also address non-weight related problems such as peer or family relationship problems during the visits.
75775562|NCT04942054|Drug|Part 1|Dose escalation cohort
75775563|NCT04942054|Drug|Part 2|Pharmacodyanamic (PD) dose exploration cohorts
75775564|NCT04942054|Drug|Part 3|Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
75775565|NCT04923048|Biological|GB261|Drug:GB261 IV, participants with B-cell NHL or CLL will receive GB261 via IV infusion weekly for the first two cycles(1cycle=21days), followed by Q3W from C3 and afterwards in given doses until progression disease or other situations specified in the protocol, whichever comes earlier.
75775566|NCT04876625|Device|myTAP oral appliance plus mouth shield|myTAP anti-snoring oral appliance worn with mouth shield for all 8-weeks; the mouth shield is a comfort accessory that fits over the oral appliance itself and extends into the oral vestibule.
75775567|NCT04876625|Device|myTAP oral appliance alone for first 4 weeks|myTAP anti-snoring oral appliance worn alone for first 4 weeks followed by wearing it for 4 weeks with the mouth shield
75775568|NCT04845048|Biological|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute
75775569|NCT04838912|Behavioral|Cool Kids (Chilled) Anxiety program adapted to children and youths with autism and anxiety disorders.|CBT program for anxiety in teenagers with autism
75913296|NCT04841200|Drug|Chinese medicine compound combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.~Each type of granule will be given orally, twice a day, for 52 weeks."
75913297|NCT04841200|Drug|Chinese medicine compound placebo combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 placebo Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules placebo for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules placebo for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules placebo for syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. The appearance, shape, color and packaging of Chinese medicine compound placebo are the same as those of drugs.~Each type of granule will be given orally, twice a day, for 52 weeks."
75913298|NCT03036592|Behavioral|Early OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
75913299|NCT03036592|Behavioral|Late OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
75913300|NCT04836130|Procedure|patient specific guide|patient specific guide reduction
75913301|NCT04836130|Procedure|conventional technique|conventional anatomical reduction
75466339|NCT01908361|Behavioral|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
75913302|NCT04428814|Biological|CT-P43|45mg single dose
75913303|NCT04428814|Biological|EU-approved Stelara|45mg single dose
75622126|NCT02717572|Device|Magnetic Resonance Imaging|
75622127|NCT05041192|Dietary Supplement|Synaquell|7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
75622128|NCT05041192|Dietary Supplement|Placebo|7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
75775570|NCT04831697|Behavioral|Multi-Caregiving Intervention|The multi-caregiving intervention consists of individual-based, social support, and health educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15 minutes); and Structured Diabetes Education and Skills Training (15 minutes). The last 5 minutes will be used to debrief and review goals.
75775571|NCT04831697|Behavioral|Diabetes Enhanced Usual Care Intervention|This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
75913304|NCT04428814|Biological|US-licensed Stelara|45mg single dose
75913305|NCT03036514|Device|Sublingual sufentanil tablet system|Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
75936409|NCT03626753|Drug|"(Piroxicam piroxan) 20 MG Oral Tablet"|"2 tablets of piroxicam (piroxan) administrated orally once per 24 hours."
75622129|NCT02717806|Behavioral|PATHway|Patients will use the PATHway platform for 6 months
75622130|NCT02717026|Device|Optical coherence tomography|Sections including the retinal vasculature will be taken.
75913306|NCT03036514|Drug|Patient-controlled intravenous analgesia|Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
75913307|NCT04836052|Drug|Omega 3 fatty acid|omega-3-oil 2 gm twice daily PO/NGT/OGT for 28 days or ICU discharge or death.
75775572|NCT04830072|Behavioral|Brief AWARD advice and active referral to somking cessation services|The AWARD advice includes: (1) Ask about smoking history; (2) Warn about the high risk of smoking; (3) Advise to quit or reduce smoking as soon as possible; (4) Refer smokers to smoking cessation services (with a referral card); (5) Do it again: to repeat the intervention.
75913308|NCT03036436|Behavioral|Intervention|A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
75913309|NCT04841278|Device|EUS/ERCP|EUS with possible interventions, including liver biopsy and/or cholangiography, and possible ERCP. No new experimental procedures are proposed, only new protocol for diagnosis and treatment of liver graft dysfunction.
75913310|NCT03036358|Other|teledermatology consult|Information from the dermatologic assessment will be entered into the patients chart.
75913311|NCT03036358|Other|Routine Care|The dermatologic assessment will occur but not added to the patients medical record. Dermatology may still be consulted but will be at the prerogative of the treating hospitalist.
75913312|NCT04833244|Behavioral|Triangular Forearm Support|The intervention, the Triangular Forearm Support requires drawing the shoulders away from the subject's head and neck. This requires at least a mild force that this action can oppose. The most-favored maneuver is to have patients stand 2 feet away from a wall, interlock their fingers, and place their forearms to form two sides of an equilateral triangle against the wall. They then place their heads within the triangle, the backs of their heads close to or in on contact with the heels of their hands. Then, pressing against the wall with their elbows and forearms, they draw their shoulders as far away from the wall as possible, retaining contact between the wall and the tops of their heads. Subjects remain in this position for 45 seconds, at which time they stand erect and repeat the abduction and flexion maneuver.
75913313|NCT04833244|Behavioral|Placebo|Patients will be asked to raise arms overhead for 45 seconds.
75913314|NCT04835740|Other|High intensity Interval Training|All the participants underwent 5 weeks of High intensity interval training.
76073192|NCT00699556|Drug|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
76073193|NCT00699556|Drug|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
76073194|NCT00699556|Drug|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
76073195|NCT00700336|Drug|pemetrexed, cisplatin and CBP501|"CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
76073196|NCT00700336|Drug|pemetrexed and cisplatin|"Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
76088900|NCT01777997|Drug|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
76088901|NCT01770509|Device|NMBM|Daily application of NMBM in addition to compression therapy
76088902|NCT01770509|Other|Compression garments|Compression garments
75320730|NCT00660517|Drug|placebo|placebo nasal spray one spray per nostril two times a day
75320731|NCT04764032|Diagnostic Test|Echocardiography|Echocardiography will be undertaken by a range of appropriately competent practitioners including; intensive care clinicians, cardiologists and specialist echocardiographers. Imaging obtained will be in keeping with the protocol required for a Focused Intensive Care Echo (FICE) scan and should include ECG monitoring at all times. A focused dataset will be used to answer the primary outcome. If available and the echocardiographers competency and experience permit, further measures of RV function will be obtained at this time.
75622131|NCT02717026|Device|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
75320732|NCT02141581|Biological|Fluzone® (IM)|This vaccine is given intramuscularly (IM)
75320733|NCT02141581|Biological|Fluzone® Intradermal (ID)|This vaccine is given intradermally (ID)
75320734|NCT02141581|Biological|2011-2012 FluMist®|This vaccine is given intranasally
75320735|NCT03828344|Biological|hUC-MSC suspension|Patients will be treated at dose of 0.75×10^6 cells/kg of body weight (Cohort 1) or 1.5×10^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit.
75320736|NCT03828344|Biological|Placebo|Placebo contains the same cell suspension as BX-U001 but without cells.
75622132|NCT02717026|Device|Fundus photography|30 and 50 degree fundus images
75622133|NCT01121393|Drug|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
75775573|NCT04830072|Behavioral|Chat-based support through Instant Messaging apps|Participants in the intervention group will receive 3 months of chat-based support through Instant Messaging apps (e.g., WhatsApp, WeChat). The support mainly includes (1) regular messages on health warnings, benefits and methods of quitting, coping craving approach, and promotion to use the SC services; (2) real-time, personalized, and interactive behavioral and psychosocial support through Instant Messaging apps.
75775574|NCT04830072|Other|Leaflet|Leaflet on harms of smoking
75775575|NCT04830072|Behavioral|AR images|AR images of the harms of smoking and the benefit of abstinence.
75775576|NCT04779411|Other|Weekly Food Frequency Questionnaire|A purpose designed 91-item questionnaire to measure frequency of consumption of a selection of L/Z containing foods over the prior 7 days.
75775577|NCT04779411|Other|Monthly Food Frequency Questionnaire|A purpose designed 95-item questionnaire completed at visit 1 to measure frequency of consumption of a selection of L/Z containing foods over the prior month.
75775578|NCT04779411|Other|24-Hour Diet Recall|the diet recall via the online Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24®) takes approximately 25 minutes to complete, and investigates food and beverages consumed in the prior 24-hours.
75775579|NCT04779411|Other|Electronic Device Use Questionnaire|1. The EDUQ: A 22-item questionnaire that takes 20 minutes to complete, and measures participant demographic information (weight, height, age, highest level of education, occupational status, post-code and country of residence), usual daily ED use from present up to 20 years ago, occupational influence to use, and differences to ED use between a weekend and weekday.
75775580|NCT04779411|Other|24-Hour Electronic Device Use Diary|Participants asked to record their electronic device use in hours and minutes over 24 hours.
75775581|NCT04746781|Behavioral|Mobile 360° Video intervention|Using 360° Videos to educate participants about the effect of diabetes.
75775582|NCT04746781|Behavioral|Motivation and Problem Solving (MAPS)|Using Motivation and Problem Solving to help people enroll in the Diabetes Prevention Program.
75775583|NCT04746781|Behavioral|Risk notification/education|Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
75775584|NCT04732195|Device|Pilocarpine microneedle patch|Each microneedle (MN) patch contains an array of solid, water-soluble, micron-scale needles that encapsulate the medication (Pilocarpine). The patch form can be placed directly on the skin.
75775585|NCT04732195|Device|Pilocarpine Iontophoresis|Pilocarpine Iontophoresis is a process of transdermal pilocarpine delivery by use of a voltage gradient on the skin. An agar gel disc containing pilocarpine is placed under the electrodes which are connected to the Macroduct 3700 Sweat Inducer device.
75775586|NCT04706975|Drug|difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg administered twice daily
76088903|NCT01770353|Drug|Ferumoxytol|Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
75320737|NCT04594226|Procedure|EA combined with medication|"Primary acupoints include Ashi points, Jiaji acupoints and Xi-cleft points. Jiaji points on the ipsilateral side will be selected according to the corresponding ganglia involved by HZ. Xi-cleft points will be selected based on the distribution regions of PHN. For pain sites that mainly distributed in the gallbladder meridian, GB36 will be selected. For pain sites that mainly distributed in the stomach meridian, ST34 will be selected. For pain sites that mainly distributed in the gallbladder meridian, BL63 will be selected. For pain sites that mainly distributed in the large intestine meridian, LI7 will be selected. Supplementary acupoints will be chosen based on TCM syndrome differentiation.~Operation: Two paired of acupoints are connected to the EA apparatus. EA parameter is selected as 2/100Hz wave. EA intensity is selected according to the patients' endurance. Needles will be retained and EA will last for 30 mins for each session."
75466340|NCT01908374|Dietary Supplement|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
75466341|NCT01908387|Drug|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
75466342|NCT01908400|Biological|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
75466343|NCT01908413|Drug|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
75466344|NCT01908439|Other|whole-body vibration|High amplitude whole-body vibration
75466345|NCT01908452|Drug|Pyridoxine|1200 mg/d during 12 weeks
75466346|NCT01908478|Drug|Veliparib|
75466347|NCT01908478|Drug|Gemcitabine|
75466348|NCT01908478|Radiation|Intensity modulated radiation therapy|
75775587|NCT04706975|Drug|Placebo|Oral Placebo administered twice daily
75775588|NCT04704921|Genetic|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
75775589|NCT04704921|Genetic|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
75775590|NCT04704921|Biological|Ranibizumab (LUCENTIS®)|0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
75775591|NCT04703426|Drug|Sargramostim (GM-CSF)|Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.
75775592|NCT04703426|Drug|Pembrolizumab (anti-PD-1)|Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion
75775593|NCT04681482|Drug|Apixaban|Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.
75775594|NCT04635644|Procedure|Erector Spinae Plane Block|Patients will be turned into the prone position. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T8 spinous process. The erector spinae muscles will be identified superficial to the tip of the T8 transverse process. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine, a 21G 10 cm needle will be inserted using an in-plane approach in a cranial to caudal direction to contact the T8 transverse process. The location of the needle tip will be confirmed by hydrodissection with 2 mL of lidocaine 2% and visualizing linear fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of 0.25% Bupivacaine is injected will be injected at this point. The same procedure will be repeated for the opposite side.
75936410|NCT03626753|Drug|"(Piroxicam piroxan) 20Mg/1mL Injection"|"2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours."
75775595|NCT04635644|Procedure|Intrathecal morphine|Patients will be placed on their right side. An intrathecal injection of morphine 200 μg (0.2 mL of morphine sulfate 1 mg/mL) diluted in 1.8 mL normal saline will be administered at the L3-L4 or L4-L5 level with a 25 G Whitacre spinal needle.
75775596|NCT04580277|Drug|Tofacitinib 10 mg|Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
75775597|NCT04571229|Drug|L-MTP-PE|L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
75775598|NCT04569682|Device|LifePort transrenal artery perfusion|transrenal artery perfusion group
75775599|NCT04569682|Device|LifePort transrenal vein perfusion|transrenal vein perfusion group
75320738|NCT04594226|Drug|Medication|The dosage of gabapentin starts from 100mg Tid. 100mg-300mg can be increased every 3-7 days and taken in three doses, but the total amount is not more than 1800mg/day. The dosage of gabapentin will be adjusted according to the patient's condition until his pain is effectively controlled. After maintaining the medication for two weeks, the dosage can be gradually reduced and 100mg can be reduced every 3-7 days.
75466349|NCT01908491|Device|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
75466350|NCT01908491|Device|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
75320739|NCT01568060|Other|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
75622134|NCT01121393|Drug|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related Adverse Event (AE), dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
75775600|NCT04567550|Genetic|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
75775601|NCT04567550|Genetic|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
75775602|NCT04567550|Genetic|RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
75775603|NCT04567550|Drug|Topical Steroid|Topical Steroid
75775604|NCT04544020|Dietary Supplement|NG feeding|NG feeding
76073197|NCT00700336|Drug|pemetrexed, cisplatin and CBP501, dose finding|"Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
75622135|NCT02717338|Behavioral|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
75775605|NCT04535713|Drug|Gemcitabine|600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
75775606|NCT04535713|Drug|Doxorubicin|18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
75775607|NCT04535713|Drug|Docetaxel|25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
75775608|NCT04535713|Drug|Nivolumab|240 mg i.v. on Day 1 beginnning Cycle 2+
75775609|NCT04526132|Drug|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
75775610|NCT04526132|Drug|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
75775611|NCT04514653|Genetic|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
75775612|NCT04514653|Genetic|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
75775613|NCT04514653|Biological|Ranibizumab|Ranibizumab (anti-VEGF agent)
75775614|NCT04514653|Genetic|RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
76073198|NCT02996422|Behavioral|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
75622136|NCT02717338|Behavioral|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
75775615|NCT04514653|Drug|Local steroid|Local Steroid
75775616|NCT04514653|Drug|Topical steroid|Topical steroid
75775617|NCT04505670|Drug|Donepezil|donepezil orally 5mg
75775618|NCT04505670|Drug|Placebo oral tablet|Placebo
75775619|NCT04505670|Drug|Topical Zinc Oxide|Topical Zinc Oxide 20%
75320740|NCT04747262|Behavioral|SPACE|SPACE program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and OCD (Lebowitz, 2013; Lebowitz, Omer, Hermes & Scahill, 2014)
75775620|NCT04493320|Drug|Carbidopa/levodopa|150-450mg carbidopa/levodopa 3 times daily
75775621|NCT04493320|Drug|Placebo|Carbidopa/levodopa-matched placebo tablet 3 times daily
75775622|NCT04478890|Diagnostic Test|Hemodynamic assessment|Hemodynamic assessment of the right ventricle using pressure-volume loop catheter and pulmonary artery catheter
75775623|NCT04440059|Drug|ICP-022|ICP-022 at a dose of 150mg PO QD
75775624|NCT04417166|Drug|Pembrolizumab|50 mg powder for concentrate for solution for infusion
75775625|NCT04417166|Radiation|Involved Field Radiation Therapy|"50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age > 60 years, stage II, elevated serum LDH levels).~Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed."
75775626|NCT04408495|Procedure|Intervention group_MRA|"Tidal Volume (Vt) =6-8 mL/kg of predicted body weight (PBW), Peep=8 cmH2O, recruitment maneuvers=30cm H2O every 30 min after intubation (except during CPB), after any disconnection and at the admission in ICU.~Recruitment maneuvers are performed in accordance with the surgical team an if SAP≥90 mmHg or MAP≥65 mmHg.~Ventilation is maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O"
75775627|NCT04408495|Procedure|Control group|Vt=6-8 mL/kg of PBW, Peep=5 cmH2O , No recruitment maneuvers. Ventilation maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O.
75775628|NCT04384627|Radiation|Delineating the GTV according to the pretreatment or post-IC tumor extension|Delineating the GTV according to the pretreatment or post-IC tumor extension
75775629|NCT04317664|Combination Product|In-vehicle device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data; and 3) A customized biweekly driving summary report.
76073199|NCT02996422|Behavioral|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
76073200|NCT01795846|Other|Allergen specific immunotherapy and placebo injections|
76073201|NCT00701896|Drug|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
75320741|NCT04747028|Diagnostic Test|Dmf score|A chart to calculate the caries index
75320742|NCT03755570|Diagnostic Test|Repeatable Assessment of Neuropsychological Status|Cognitive Function Test (Questionnaire-based)
75320743|NCT03755570|Diagnostic Test|Hospital Anxiety and Depression Scale|Cognitive Function Test (Questionnaire-based)
75466351|NCT01908504|Other|PET-CT|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
75622137|NCT02717338|Behavioral|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
75622138|NCT02717260|Device|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
75622139|NCT02717182|Other|interviews|interviews
75622140|NCT02882477|Drug|Deferiprone|
75622141|NCT02882477|Drug|Acetylcysteine|
75775630|NCT04317664|Behavioral|Parent Communication|An individualized virtual training in communication strategies about driving safety along with a booster session will be delivered by a traffic safety communication specialist to subjects in the Feedback and Parent Communication Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
75775631|NCT04317547|Behavioral|Steering Teens Safe (STS)|The goal of STS is to provide intervention parents with guidance and communication skills, which will enable parents to effectively communicate with their teens about specific driving safety topics (e.g., speeding, seatbelt use, distracted driving). Our proposed parent training has two components: an individualized virtual communication training (provided to parents via Skype by a trained research team member) and a parent-teen safe driving communication guide (available online).
75775632|NCT04317547|Behavioral|Driving Feedback Technology.|The driving feedback technology will include the Azūga™ in-vehicle device and smartphone app.
75775633|NCT04316221|Dietary Supplement|Eggs plus standard of care|Eggs will be secured locally and delivered to families weekly.
76073202|NCT00701896|Drug|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
76073203|NCT00701896|Other|Biological Control|No treatment intervention only information and procedures.
76073204|NCT00701896|Behavioral|Motivational Interview|60 minute one-on-one Interview
75320744|NCT03755570|Diagnostic Test|Frontal Assessment Battery|Cognitive Function Test (Questionnaire-based)
75320745|NCT03755570|Diagnostic Test|Trail Making Test Part A and B|Cognitive Function Test (Questionnaire-based)
75320746|NCT03755570|Diagnostic Test|Test of Premorbid Functioning|Cognitive Function Test (Questionnaire-based)
75775634|NCT04316221|Other|Standar of care|frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
75775635|NCT04306341|Behavioral|real time fMRI neurofeedback|Participants will use real time feedback about their amygdala activity to learn to decrease amygdala activity.
75775636|NCT04296331|Diagnostic Test|POC|DC DOC's current testing practice offers opt-out POC testing with the INSTI® finger stick test at entry
75775637|NCT04296331|Diagnostic Test|Ag/Ab|The DC DOC will transition from offering their current POC testing upon entry to offering opt-out HIV testing with Ag/Ab: ARCHITECT® laboratory-based test.
75775638|NCT04296331|Diagnostic Test|POC + Ag/Ab|As the DC DOC transitions to utilizing the Ag/Ab: ARCHITECT® laboratory-based test from their current POC testing, jail nurses will offer new entrants op-out testing with the two methods
75775639|NCT04291144|Radiation|PET-CT using FEOBV|We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes). The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.
75775640|NCT04291144|Radiation|MRI-scan|All patients will have an MRI scan of the brain. T1-weighted images will be used to assess general anatomy and identify white matter. T2-weighted sequences will be performed to quantify competing brain pathology. Also, we will collect functional MRI data.
75775641|NCT04291144|Diagnostic Test|Cognitive assessment|Full neuropsychometric examination including tests in 5 cognitive domains.
75775642|NCT04291144|Diagnostic Test|Clinical assessment|Age, sex, duration of disease, patient history and full somatic and neurological examinations. Constipation assessed with Rome-III criteria. Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire. Test for orthostatic hypotension, heart rate variability, and deep breathing.
75775643|NCT04275037|Other|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
75775644|NCT04275037|Other|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
75775645|NCT04189744|Drug|IPTp-sulphadoxine-pyrimethamine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-DP plus MTZ to assess whether DP is superior to SP in preventing adverse birth outcomes. This intervention arm will also be compared to the IPTp-SP plus MTZ placebo arm to assess whether the combination of MTZ with IPTp-SP is superior to IPTp-SP alone in reducing adverse pregnancy outcomes.
75775646|NCT04189744|Drug|IPTp-dihydroartemisinin-piperaquine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-SP plus MTZ to assess whether DP is superior to SP in in reducing adverse pregnancy outcomes.
75775647|NCT04189744|Drug|IPTp-sulphadoxine-pyrimethamine|The World Health Organization (WHO) recommends providing intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) to pregnant women during the second and third trimesters of pregnancy to clear placental infection.
75913315|NCT03039400|Behavioral|Physiotherapist-guided home exercise with web-based support|Those in the web-based physio group will access their exercise program online and will be able to leave messages for their physiotherapist on the platform. Physiotherapists will monitor usage and respond to messages every two weeks.
75913316|NCT03039400|Behavioral|Physiotherapist-guided home exercise with standard support|Those in the standard care group will receive a written, home-based exercise program. Participants in the usual care group will be asked to keep an exercise diary, in paper format.
75913317|NCT04835896|Drug|M7824+paclitaxel|M7824 will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with paclitaxel 80 (or 70) mg/m2 once a week for 3 weeks (each cycle is 4 weeks)
76073205|NCT01797406|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
75622142|NCT02882477|Drug|Sitagliptin and Metformin|
75622143|NCT04081168|Device|Stereotactic Body Radiotherapy|Patients will undergo Stereotactic Body Radiotherapy (SBRT)
75913318|NCT04835662|Behavioral|Complementary feeding promotion|The intervention engaged fathers through community meetings, religious services, and mobile phone text and voice messages. Mothers received home visits from community health extension workers (CHEWs), which fathers also could attend. Social behavior change communication materials included TV and radio messages, sermon guides, counseling cards, pamphlets, posters, and feeding bowls.
75913319|NCT04833322|Dietary Supplement|D-Galactose|Galactose supplementation, once per day, up to 1.5g/kg per day
75913320|NCT01668004|Biological|Golimumab|GLM 50 mg subcutaneously once monthly.
75913321|NCT03039556|Behavioral|Normal Daily Steps|Complete normal daily ambulation for one week
75913322|NCT03039556|Behavioral|Step-Reduction|Reduce daily ambulation to fewer than 1000 steps per day for two weeks
75913323|NCT03039556|Behavioral|Return to Normal Daily Steps|Increase daily ambulation to 100% of normal daily step-count for two weeks
75913324|NCT04835350|Device|Pancreas4ALL - meal announcement or full closed loop|Patient using AID Pancreas4ALL in mode meal announcment or full closed loop.
75913325|NCT04840966|Diagnostic Test|Flavor test|A simplified self-administrable flavor test has been proposted to all the enrolled subjects
75913326|NCT04840966|Other|Self-assesment questionnaire|"Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to no smell/flavor perception and 10 corresponding to excellent smell/flavor perception."
75622144|NCT04081168|Device|Microwave Ablation|Patients will undergo Microwave Ablation (MWA)
75622145|NCT02716870|Other|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
75775648|NCT04175470|Drug|Bevacizumab|10 mg/kg intravenously every three weeks
75775649|NCT04175470|Dietary Supplement|Tocotrienol|Capsules, 300 mg orally three times daily
75913327|NCT01667926|Drug|Ketamine|ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.
75320747|NCT03885518|Other|Playground Stencils|The stencils (hopscotch, agility trail, foursquare, bullseye, etc.) will be painted on the playgrounds at each childcare center. A toolkit and training video will be distributed to staff at each center to aid in instructing the children on how to perform the tasks.
75913328|NCT01667926|Drug|Placebo|
75913329|NCT03039322|Diagnostic Test|Serum Golgi Protein 73|Serum test
75913330|NCT04366882|Procedure|CT-scan with minimal invasive autopsy|CT-guided biopsies will be performed directly following the diagnostic CT-scan. Biopsies will be taken from heart, liver, lungs, spleen, kidneys and abdominal fat according to a standard operation procedure. Biopsies will be taken for further histological examination and storage in the biobank. Of the lung, additional samples will be taken for microbiological examination. Additional samples will be taken in case of (focal) abnormalities on CT-imaging. In case of pleural, cardiac or abdominal fluid, this will be aspirated for further cytological, biochemical and microbiological examination. Finally, 15 cc blood will be drawn from the heart.
75913331|NCT04841044|Dietary Supplement|Cetoleic acid|Very long monounsaturated fatty acid ( C22:1n-11)
75913332|NCT04841044|Dietary Supplement|Control Oil|Control oil consisting of: mix of anchovy oil, olive oil, high-oleic sunflower oil and rapeseed oil
76073206|NCT01797406|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
76073207|NCT01839487|Drug|PEGPH20|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
75320748|NCT04055961|Device|Atrial Fibrillation Ablation|A procedure used to treat an irregular heart rhythm (arrhythmia)
75622146|NCT04163224|Device|RibFix Advantage|Class II device in the United States; consists of bridges (with locking posts) and locking caps for the thoracoscopic fixation and stabilization of ribs. These implants are manufactured from commercially pure titanium and titanium alloys. When fully assembled, the bridge plate is placed on the underside of the rib (pleural cortex); the threaded locking posts extend through pre-drilled holes in the rib, and the locking caps are fixed to the locking post on the anterior (cutaneous) side of the rib. The combined threaded locking post and cap provides for fixation of the bridge and stabilization of the fracture.
76073208|NCT01839487|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
76073209|NCT01839487|Drug|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
76073210|NCT01839487|Drug|Dexamethasone|Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
75622147|NCT02716792|Drug|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
75622148|NCT02716636|Procedure|Slow placement of the tenaculum|Slow placement of the tenaculum on the cervix
76073211|NCT01839487|Drug|Enoxaparin|Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
75775650|NCT04165330|Drug|AL3818|"AL3818: Part 1 - 12 mg, 10 mg, 8 mg, or 6 mg (by dosing cohort), Part 2 - RP2D (as determined from Part 1).~Administered orally once daily on Days 1-14 per 21 day Cycle."
75775651|NCT04165330|Drug|Nivolumab Injection|Nivolumab 240 mg Administered by injection every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
75775652|NCT04151628|Device|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent
75775653|NCT04129268|Other|Cycle ergometry exercise at 60% VO2max|Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
75775654|NCT04129242|Device|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training|A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.
76073212|NCT00665470|Drug|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
76073213|NCT00665704|Behavioral|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
76073214|NCT00666406|Drug|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
75320749|NCT03991299|Drug|Botox 200 UNT Injection|Botox will be injected into duodenums of subjects by endoscopy.
75320750|NCT03885362|Device|Dexcom G6 and Abbott Freestyle Libre|Dexcom G6 - continuous glucose monitoring device - blinded. CE mark 2018 Abbott Freestyle Libre - flash glucose monitoring device. CE mark 2014
75775655|NCT04128228|Behavioral|8-week outpatient treatment|All patients will receive outpatient treatment for alcohol use disorder for 8 weeks. There will be two appointments each week for individual therapy sessions using cognitive behavioral therapy combined with stress management.
75775656|NCT04115878|Drug|Atomoxetine and oxybutynin (ato-oxy)|Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
75775657|NCT04101422|Behavioral|Augmented Reality 1|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) and non-smoking related stimuli (pens, notebook, eraser).
75913333|NCT04835974|Diagnostic Test|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured:~LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio.~Glycemia will be assessed : RBS ( random blood sugar ) .~Serum Uric acid : S .UA"
75913334|NCT04832542|Other|outpatient follow-up|The patients were evaluated every six months in order to assess the incidence of traumatic syncope recurrence during follow-up after implantable loop recorder implantation.
75775658|NCT04101422|Behavioral|Augmented Reality 2|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of smoking related AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.). They will also be presented with real smoking (e.g., ashtray) and non-smoking (e.g., pencil) items. Their urge to smoke rating following each presentation will be compared for AR images vs. vivo items, and smoking-related vs. non-smoking related.
75775659|NCT04101422|Behavioral|Augmented Reality 3|Participants will use an Augmented Reality )AR) application on smart phones in locations and situations where they typically smoke. the application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays). Participants will have a goal of using application at least 5 times per day for 7 days. Usage and rating data will be collected in real-time.
75775660|NCT04101422|Behavioral|Augmented Reality 4|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.) Their urge to smoke rating following each presentation will be compared from baseline urge to smoke. The post-test urge to smoke will be compared between control group and extinction group.
75775661|NCT04007536|Other|No Intervention|No Intervention
75775662|NCT03966755|Behavioral|UFA dietary recommendations|The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
75320751|NCT03819530|Dietary Supplement|Vitamin and Mineral Powder|Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.
75320752|NCT02279667|Drug|BIA 2-093|oral suspension 50 mg/mL
75622149|NCT02694016|Procedure|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
75622150|NCT02359318|Procedure|Resin infiltration|Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.
75320753|NCT02279667|Drug|BIA 2-093|200 mg tablet
75320754|NCT02279667|Drug|BIA 2-093|800 mg tablet
75320755|NCT03833271|Biological|Influenza vaccine, Immune function|Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
75622151|NCT02359318|Procedure|Bonding and debonding of brackets.|Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
75775663|NCT03965130|Drug|Glucagon|PINTA study with or without glucagon
75775664|NCT03900884|Drug|Venetoclax|At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.
75775665|NCT03900884|Drug|Palbociclib|At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.
75775666|NCT03900884|Drug|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
75466352|NCT01908517|Behavioral|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
75466353|NCT01908556|Drug|Letrozole|
75622152|NCT02716558|Other|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
75622153|NCT02716558|Other|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
75622154|NCT02716402|Radiation|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
75775667|NCT03890107|Device|OtoSight Middle Ear Scope|OtoSight imaging using a near-infrared laser
75913335|NCT04832464|Other|RACE Protocol: Balance training along with resistance, aerobic and cognitive exercises.|therapy for the preservation, enhancement, or restoration of movement and physical function impaired or threatened by disease, injury, or disability that utilizes therapeutic exercise, physical modalities (such as massage and electrotherapy), assistive devices, and patient education and training.
75913336|NCT04840732|Behavioral|VR training program|Use VR software to make a training education program.
76073215|NCT00666406|Drug|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
76073216|NCT02996344|Other|Didactic training|Six online training modules pertaining to suicide prevention in primary care.
76073217|NCT02996344|Other|Standardized patient interaction|Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
76088904|NCT01770353|Drug|MM-398|MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
76088905|NCT01777763|Drug|Posaconazole 200 mg|
75320756|NCT03749564|Behavioral|SMT|"The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
75913337|NCT04840732|Behavioral|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
76073218|NCT02999152|Other|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
76073219|NCT02996188|Procedure|routine therapeutic paracentesis|
76073220|NCT02996032|Other|Vascular and Pulmonary Ultrasound|
75622155|NCT02716480|Behavioral|Mobility coaching|"The intensive follow-up for the patients of Mobility Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by a Mobility coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used."
75775668|NCT03887078|Behavioral|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks pre and or post-surgery.
75622156|NCT02716480|Behavioral|Diet coaching|"The intensive follow-up for the patients of Diet Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery."
75622157|NCT04964596|Diagnostic Test|colonoscopy|colonoscopy
75775669|NCT03884946|Other|Getting Off App|"A mobile phone application based on the Getting Off methamphetamine treatment manual. Participants download the app and progress through the sessions of the Getting Off intervention through the administration of games, activities, lessons, quizzes, and tutorials. There are 24 sessions total in the app, each addressing a different component of the methamphetamine treatment process. The fundamental basis of the app is gay-specific cognitive behavioral therapy, with elements of motivational interviewing, social support theory, and health belief model dynamics included."
75775670|NCT03875833|Device|Collagen Nerve Wrap Conduit|The collagen nerve wrap conduit will be placed on all exposed radial and ulnar nerves at the time of free flap harvest.
75775671|NCT03870906|Behavioral|Occupational-specific health talk|Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
75775672|NCT03870906|Behavioral|WhatsApp interaction|Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.
75775673|NCT03870906|Behavioral|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
75775674|NCT03870906|Biological|Text message|Participants will receive regular text messages with similar frequency to those in the intervention group.
76073221|NCT02995954|Drug|Perindopril/Amlodipine|Single table containing Perindopril/Amlodipine
75466354|NCT01908569|Other|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
75466355|NCT01908569|Other|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
75775675|NCT03859232|Other|Delta Dry® Waterproof Pantaloon|Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.
76088906|NCT01777763|Drug|Posaconazole 300 mg|
75466356|NCT01908621|Drug|G-CSF (filgrastim)|
75466357|NCT01908621|Drug|Cytosine arabinoside + G-CSF (filgrastim)|
75466358|NCT01908647|Behavioral|RT fMRI|Real-time fMRI with neurofeedback.
75466359|NCT01908647|Behavioral|Cognitive Training|Computer based attention training.
75622158|NCT04964596|Diagnostic Test|FIT test|faecal immunochemical test
75622159|NCT04964596|Diagnostic Test|CT colonography|noninvasive medical imaging technique that uses computed tomography to visualize the interior of the colon and rectum especially to screen for polyps or cancerous growths
75913338|NCT03039478|Dietary Supplement|Xylitol 7g|Xylitol 7g in 300mL tap water
75913339|NCT03039478|Dietary Supplement|Erythritol 10g|Erythritol 10g in 300mL tap water
75913340|NCT03039478|Dietary Supplement|Xylitol 17g|Xylitol 17g in 300mL tap water
75913341|NCT03039478|Dietary Supplement|Xylitol 35g|Xylitol 35g in 300mL tap water
75913342|NCT03039478|Dietary Supplement|Erythritol 25g|Erythritol 25g in 300mL tap water
75913343|NCT03039478|Dietary Supplement|Erythritol 50g|Erythritol 50g in 300mL tap water
75936411|NCT03117686|Diagnostic Test|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
75936412|NCT02431520|Procedure|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
75936413|NCT02431520|Procedure|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
75936414|NCT03626675|Procedure|phaco- trabeculectomy|combined phaco-trabeculectomy surgery
75913344|NCT03039244|Other|Photodynamic therapy|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
75913345|NCT03039244|Other|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
75913346|NCT03039244|Device|Diode Laser|
76073222|NCT01799941|Drug|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
76073223|NCT00702364|Drug|atomoxetine|
76073224|NCT00702364|Drug|placebo|
76073225|NCT00667186|Other|Targeted Screening|Selection method for screening is based on risk
75466360|NCT01908647|Behavioral|Control RT fMRI|Control condition for real-time fMRI.
75466361|NCT01908647|Behavioral|Control Cognitive Training|Computer-based games used as a control for the computer based cognitive training intervention.
75466362|NCT01908660|Drug|antiretroviral drugs|zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
75466363|NCT01908673|Behavioral|HRV biofeedback|
75466364|NCT01908673|Behavioral|ASTM|
75466365|NCT01908686|Behavioral|Pivotal Response Training|Behavioral intervention for autism
75466366|NCT01908764|Drug|AL-60371 otic suspension|
75622160|NCT04964284|Biological|rhTSH|rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH
75622161|NCT04964284|Radiation|Radioiodine (131I)|Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).
75622162|NCT02716168|Other|Shared video consultation between patient, general practitioner and oncologist|At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
75622163|NCT04896346|Other|Punch biopsy|punch biopsies will be used for histologic analysis and biochemical assays
75622164|NCT04896346|Other|non-invasive photography, assessments, and measurements|photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity
75622165|NCT02716090|Drug|Adapalene and Benzoyl peroxide Dalap Duo®|
75622166|NCT02716090|Drug|Adapalene and Benzoyl peroxide Epiduo®|
75775676|NCT03859232|Other|Cotton Padding|Cast with traditional cotton liner.
75775677|NCT03841604|Drug|Safinamide Methanesulfonate|50 mg, 100 mg
75775678|NCT03841604|Other|Safinamide methanesulfonate matching placebo|50 mg, 100 mg
75775679|NCT03827109|Behavioral|Group educational activities|Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.
75775680|NCT03827109|Behavioral|IBD educational website|Website with age-appropriate educational information, including information from the group educational activities.
75775681|NCT03827109|Behavioral|Monthly check-in calls from program coordinator|Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.
75913347|NCT04832776|Drug|Cetuximab|one group plus cetuximab
75913348|NCT04832776|Drug|Bevacizumab|one group plus bevacizumab
75913349|NCT04832776|Drug|FOLFOXIRI|FOLFOXIRI
75913350|NCT03039166|Device|MRI 7T|
75913351|NCT03039166|Device|MRI 3 T|
76073226|NCT00667186|Other|Routine Screening|Selection method for screening is not based on risk
76073227|NCT01799239|Device|Test product|The test product consists of an adhesive with a new top film
76073228|NCT01799239|Device|SenSura|SenSura is the CE-marked and commercially available comparator product
76073229|NCT02995798|Other|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
76073230|NCT00713284|Drug|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
76073231|NCT00702754|Biological|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
76073232|NCT02995720|Drug|Fimasartan/Amlodipine combination drug, Rosuvastatin|
76073233|NCT02990728|Drug|Metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
76073234|NCT02990728|Device|Mirena®|
76073235|NCT02995486|Other|Exercise|Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
76073236|NCT02995564|Behavioral|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
76073237|NCT04387006|Other|OMT|OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
75775682|NCT03827109|Behavioral|Mentor|Mentees will be matched with a mentor for a year-long, 1:1 mentee-mentor relationship. Matching mentors and mentees is based on gender (same), age, geographical proximity, ethnicity, and interests. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month, one of which can be attending a group activity together. Due to the COVID-19 pandemic, a modification was approved so that all study activities can be conducted virtually, e.g., the in-person mentor-mentee monthly activity can be conducted via Skype, and group activities are live streamed
75775683|NCT03827109|Behavioral|Fun group activities|"Program participants vote on fun group activities to participate in for support and to learn self-management skills through experiential opportunities and modeling. These are live streamed during the COVID-19 pandemic."
75775684|NCT03827109|Behavioral|Parent support group|Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing during group events (virtually during the COVID-19 pandemic).
75775685|NCT03772509|Other|CATI|The participants in this arm were read the introduction and asked for consent by a call center employee using computer-assisted telephone interviewing and then were sent a noncommunicable disease risk factor survey via interactive voice response. This mode was used to motivate participants to complete the survey.
75775686|NCT03761030|Drug|L-DOPA|We will be using generic sinemet 25/100 tablets in this study.
75775687|NCT03761030|Drug|Placebo Oral Tablet|25/100 placebo tablets
75622167|NCT02715934|Other|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
75775688|NCT03742505|Drug|Cholecalciferol|Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)
75913352|NCT03039166|Biological|blood sample|
75913353|NCT04835116|Drug|Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.|Group A patients were administered per-operative peri tract local anesthesia infiltration with 0.25% bupivacaine augmented by post-operative oral analgesia with a combination of Paracetamol 650 mg and Orphenadrine 50mg 6 hourly.
75913354|NCT04835116|Drug|paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.|Group B patients were only given post-operative intra-venous analgesia by Paracetamol 1gm intravenous 8 hourly augmented with a combination of Tramadol 50mg and Dimenhydrinate 50mg as and when required
75913355|NCT04824976|Dietary Supplement|Blueberry|freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal
75913356|NCT04824976|Dietary Supplement|Placebo|matched powder maltodextrin twice daily = 60kcal
75466367|NCT01908790|Device|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
75466368|NCT01908790|Device|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
75622168|NCT02715934|Other|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
75466369|NCT01908855|Behavioral|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
75622169|NCT01227616|Drug|Ferumoxytol|IV Ferumoxytol
75622170|NCT01227616|Drug|Iron Sucrose|IV Iron Sucrose
75622171|NCT02715544|Other|Healthy lifestyle|The families will receive a designed for these purposes intervention
75622172|NCT02715544|Other|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
75622173|NCT04189276|Biological|ETV/TDF+T101 No.1|Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
75775689|NCT03742505|Other|Placebo|Single enteral placebo dose equivalent in volume to the appropriate weight-based dose of cholecalciferol
75775690|NCT03663205|Drug|Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed|Treatment for advanced NSCLC
75775691|NCT03663205|Drug|Cisplatin or Carboplatin,Pemetrexed|Treatment for advanced NSCLC
75775692|NCT03617744|Procedure|Sleeve gastrectomy|Open sleeve gastrectomy
75775693|NCT03575650|Other|Cardiac imaging modalities|Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy
75775694|NCT03572088|Drug|Terlipressin|Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)
75775695|NCT03572088|Drug|normal saline|Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
75775696|NCT03560934|Drug|Dronabinol|Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
75913357|NCT03036826|Drug|Piperacillin/tazobactam|antiinfective therapy with Piperacillin/Tazobactam within routine care
75913358|NCT03036826|Drug|Meropenem|antiinfective therapy with Meropenem within routine care
75913359|NCT04832308|Behavioral|Exercise Therapy|This is a health coach driven exercise prescription for patients recommending 30 minutes or more of moderate effort walking 3-5 days a week with expected walk-rest-walk-rest intervals.
75775697|NCT03541187|Biological|German cockroach allergenic extract|Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
75775698|NCT03541187|Biological|Placebo for German cockroach allergenic extract|Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
75775699|NCT03535675|Drug|Muscadine Plus|Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
76073238|NCT04387006|Other|MP|MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
75775700|NCT03535675|Drug|Placebos|The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
75622174|NCT04189276|Biological|ETV/TDF+T101 No.2|Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.
75775701|NCT03527472|Drug|Memantine|Memantine is an FDA-approved drug for the treatment of Alzheimer's disease.
75775702|NCT03527472|Drug|Placebo|The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (memantine).
76073239|NCT04386772|Procedure|PVE with coils plus TAGM|PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
75622175|NCT04189276|Biological|ETV or TDF|Patients will be administrated ETV or TDF once each day successively until Day420.
75622176|NCT04189276|Biological|ETV/TDF+Peg-IFNα-2b|Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
75320757|NCT03749564|Behavioral|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
75622177|NCT00956488|Behavioral|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
75622178|NCT02714998|Drug|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
75775703|NCT03488966|Behavioral|Mindfulness Based Eating and Awareness Training|Eight sessions of Mindfulness Based Eating and Awareness Training (MB-EAT) will be delivered once per week over the course of 8 weeks, following an introductory session. The treatment uses general mindfulness meditation and eating meditation to help participants bring greater awareness and understanding to their relationship with food. Homework consists of weekly mindfulness exercises.
75775704|NCT03477396|Drug|Aromatase Inhibitor|Aromatase inhibitor per treating investigator's discretion
75775705|NCT03477396|Other|Laboratory Biomarker Analysis|Correlative studies
75775706|NCT03477396|Other|Pharmacokinetic Study|Correlative studies
75775707|NCT03477396|Other|Questionnaire Administration|Ancillary studies
75775708|NCT03477396|Drug|Ribociclib|Given PO
75775709|NCT03440736|Drug|Secukinumab|Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
75775710|NCT03440736|Behavioral|Life-style intervention|A structured program to guide weight loss and increased physical activity
75775711|NCT03388788|Radiation|PET Imaging|Positron Emission Tomography (PET) imaging for research.
75775712|NCT03388788|Behavioral|Circadian Study Protocol|5-day circadian study schedule
75775713|NCT03388788|Drug|11C-Meta-Hydroxyephedrine (mHED)|11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.
75913360|NCT02604160|Drug|LY3113593|Administered by slow intravenous (IV) infusion.
75913361|NCT02604160|Drug|Placebo|Administered by slow intravenous (IV) infusion.
75913362|NCT03036046|Drug|F901318 with fluconazole low dose|adverse events
75913363|NCT03036046|Drug|F901318 with fluconazole high dose|adverse events
75622179|NCT02714998|Procedure|salpingectomy|Laparoscopic unilateral salpingectomy
75775714|NCT03388788|Drug|11C-CGP12177|Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.
75775715|NCT03388788|Drug|O15-water|Blood flow will be measured via PET imaging with infusion of O15-water.
75913364|NCT03036046|Drug|F901318 with posaconazole|adverse events
75775716|NCT03386006|Behavioral|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks.
75775717|NCT03321539|Drug|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
75775718|NCT03321539|Drug|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.
75913365|NCT04831528|Drug|Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others|After PD, patients received ctDNA testing, and different research protocols were selected according to different gene states of ctDNA, as follows: 1.No secondary changes related to drug resistance were found. Cetuximab cross-line + second-line chemotherapy (FOLFOX/FOLFIRI/ Irinotecan monotherapy, etc.) was used.2. If there is a RAS secondary mutation, change of beacizumab bead sheet resistance + second-line chemotherapy (FOLFOX/XELOX/stand for kang single-agent FOLFIRI mXEIRI/Iraq, etc.);3. If BRAF secondary mutation occurs, replace it with vimofenib + cetuximab + irinotecan;4. If HER2 amplification occurs, replace it with trastuzumab + lapatinib or trastuzumab + pertuzumab;5. In case of other secondary mutations, bevacizumab plus second-line chemotherapy should be replaced.
75913366|NCT04834804|Other|Physical activity|12 weeks of exercise training
76073240|NCT04386772|Procedure|PVE with multiple coils|Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
76073241|NCT02995330|Procedure|Bone marrow transplantation|Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
76073242|NCT02995330|Drug|Cytoxan|Cytoxan 50mg/kg IV on Days +3 and +4
75622180|NCT04162054|Other|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).
75466370|NCT01908855|Behavioral|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
75466371|NCT01908868|Other|EBUS-TBNA|Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
75466372|NCT01908868|Other|Conventional TBNA|Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
75622181|NCT00765310|Dietary Supplement|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
75622182|NCT00765310|Dietary Supplement|Placebo|two capsules once daily in morning on empty stomach
75913367|NCT04824664|Other|survey|survey among surgeon
75913368|NCT04824586|Drug|Fast-acting human insulin|Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.
75913369|NCT04834570|Behavioral|Quality of life in Breast Cancer Survivors|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30~EORTC QLQ - BR-23~FACT-B"
75913370|NCT04825054|Device|Mechanical ventilation with NAVA mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
75913371|NCT04825054|Device|Mechanical ventilation with PCV mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
76073243|NCT02995330|Drug|testosterone cypionate|testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
76073244|NCT02990884|Drug|ketamine|
76073245|NCT02990650|Behavioral|Balance Task Training with therapist guarding support|"Nine balance tasks:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The therapist will provide guarding support"
76073246|NCT02990650|Behavioral|Balance task training with robotic guarding support|"Nine balance tasks:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The guarding support will be provided by a robot"
76073247|NCT02990650|Behavioral|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The guarding support will be provided by a robot"
75466373|NCT01908868|Other|Endobronchial and transbronchial biopsy|Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
75775719|NCT03306121|Drug|TPF+CCRT|"Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
75775720|NCT03306121|Drug|CCRT+ PF|"Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
75775721|NCT03240081|Drug|50mcg estradiol cream|Use of study drug nightly applied to vulvar vestibule
75775722|NCT03240081|Drug|100mcg estradiol cream|Use of study drug nightly
75775723|NCT03236857|Drug|chemotherapy|Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
75775724|NCT03236857|Drug|venetoclax|Oral tablet for participants; Tablet for oral suspension (participants who cannot swallow a tablet)
75775725|NCT03122808|Diagnostic Test|Uterine Activity Analysis|Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
75320758|NCT03749564|Behavioral|Mobilizing Exercises|Mobilizing exercises include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
75622183|NCT02715154|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
75775726|NCT03122808|Diagnostic Test|Partogram Analysis|Analysis of slope of partogram
75775727|NCT03097120|Drug|0.625 mg of conjugated equine estrogen|one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
75775728|NCT03097120|Drug|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate|one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
75775729|NCT03097120|Drug|placebo tablets|two placebo tablets daily
75775730|NCT03079024|Device|Targeted Cognitive Training|"Auditory Training Module (20 hours): exercises designed to improve speed and accuracy of auditory processing while engaging working memory and cognitive control. Exercises adjust difficulty level to maintain an ~80% correct performance. Exercises contain stimuli spanning the acoustic organization of speech. In the initial stages, stimuli exaggerate the rapid temporal transitions by increasing amplitude and stretching in time. The exaggeration is gradually removed so that by the end, all stimuli have characteristics representative of real-world speech.~Social Cognition Module (10 hours): exercises designed to improve core deficits of social cognition in psychosis. Exercises apply principles of implicit learning to restore capacity to process and utilize socially-relevant information, and includes training to improve perception of affect (visual/vocal) and social cues (faces, gazes, social situations), theory of mind, self-referential style, emotion labeling and working memory."
75775731|NCT03079024|Device|General Cognitive Exercises|The GCE will focus on executive dysfunction, as this domain is a significant, functionally important area of deficit in schizophrenia and has been the target of many previous studies. We will train this domain using a suite of engaging, adaptive web-based exercises that target executive function, intelligence, and spatial navigation developed by Posit Science. The exercises will be provide engaging, adaptive training as described in the Targeted Cognitive Training.
75320759|NCT03749564|Behavioral|Extended SMT|Additional 6 SMT sessions provided
75320760|NCT03155373|Diagnostic Test|Cardiac catheterisation|Pre-operative left heart catheterisation +/- right heart catheterisation
75320761|NCT03155373|Diagnostic Test|Cardiopulmonary exercise testing|Pre and post-operative cardiopulmonary exercise testing
75775732|NCT03079024|Other|Coordinated Specialty Care for First Episode Psychosis|Individuals in this study are receiving care from a coordinated specialty care clinic (CSC) for first episode psychosis. These clinics are following the NAVIGATE treatment model for early psychosis.
75913372|NCT04825054|Device|Mechanical ventilation with PSV mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
75913373|NCT04824742|Procedure|Neoadjuvant PDT + radical surgery|Patients with cholangiocarcinoma will undergo radical surgery after photodynamic therapy
75913374|NCT04824742|Procedure|Radical surgery|Patients with cholangiocarcinoma will only receive radical surgery
75913375|NCT04824898|Drug|Simvastatin|Statins are first known as drugs that decrease the cholesterol level by inhibiting hydroxy-methyl-glutaryl co-enzyme-A reductase as they improve the lipid profile and help in the treatment of many cardiac diseases and has a role in osteoblasts diffrentiation
75913376|NCT04824898|Other|injectable plasma rich fibrin|I- PRF is obtained by taking a blood sample from patients and then is centrifuged for three minutes at 3300 rpm, the I-PRF first will be in the form of liquid and then coagulate after few minutes from the injection
75913377|NCT04834492|Procedure|Total hip arthroplasty|Total hip arthroplasty in Crowe type 4 developmental dysplasia of the hip.
75913378|NCT04824352|Drug|apatinib|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA < 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
75913379|NCT04325620|Drug|HIP1601|HIP1601
75913380|NCT04325620|Drug|HGP1805|Placebo of HIP1601
75320762|NCT03155373|Diagnostic Test|Pulmonary function tests|Pre and post-operative pulmonary function tests
75622184|NCT02715154|Drug|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
75913381|NCT04824196|Other|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirrorAnterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear
75913382|NCT04824196|Other|propriocetion exercise|"Alternate knee flexion-extension with extended trunk posture using both hands for support.~Hip and knee flexion-extension with swiss ball between the back and wall.~Hip raises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises. then all exercise are perfomed on gym ball"
75913383|NCT04319614|Drug|Tranexamic Acid Injectable Product|A single dose of tranexamic acid, corresponding to 20 mg/kg in 100 ml saline, will be administered in the beginning of procedure.
75622185|NCT02715232|Drug|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
76073248|NCT02995018|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-174)
76073249|NCT02995018|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75466374|NCT01908881|Behavioral|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
75622186|NCT02715232|Drug|Lynestrenol|2-3 tablets/day, if menstruation still occurs
75622187|NCT02715232|Drug|Cyproterone Acetate|25mg daily
75622188|NCT02715232|Drug|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
75622189|NCT02715232|Drug|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
75622190|NCT02714608|Drug|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
75622191|NCT02714608|Drug|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
75622192|NCT02714608|Drug|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
75913384|NCT04319614|Drug|Placebos|100 ml of saline will be administered in the beginning of the procedure.
75913385|NCT04314856|Drug|18F-FTC-146|18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.
75913386|NCT03037060|Other|[11C]-(+)-PHNO PET scan|PET scan
75622193|NCT00643864|Behavioral|mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests."
75622194|NCT02693860|Drug|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute.
75913387|NCT03037060|Other|Alcohol Self-Administration|Session for assessing motivation for consuming alcohol.
75913388|NCT03037060|Other|Craving Task|Cue exposure paradigm
75913389|NCT03037060|Other|MRI scan|MRI scan scan to analyze the PET data will be administered.
75913390|NCT03037060|Other|Neuropsychological Assessment|Cognitive questionnaires administered over course of study.
75913391|NCT04823728|Genetic|Autoimmune encephalitis and paraneoplastic neurological syndromes|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
76073250|NCT02992990|Procedure|Bladder tumor biopsy|Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
76073251|NCT02997592|Device|SpinCare|The burn wound is treated using the SpinCare Systen
75913392|NCT04834180|Dietary Supplement|Hypocaloric diet plan|The hypocaloric diet is one in which there is a reduction of daily calories or foods with high caloric density usually in order to aid weight loss.
76073252|NCT02990494|Behavioral|STANDARD|Standard Internet-delivered behavioral weight loss
76073253|NCT02990494|Behavioral|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
76073254|NCT02990494|Behavioral|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
75320763|NCT03155373|Diagnostic Test|Cardiac MRI|Pre and post-operative cardiac MRI
75320764|NCT03155373|Other|Quality of life survey|Pre and post-operative quality of life survey (SF36)
75320765|NCT03155373|Procedure|Mitral valve operation|Clinically indicated mitral valve repair/replacement +/- coronary artery surgery +/- tricuspid valve surgery +/- atrial fibrillation surgery
75320766|NCT03155373|Procedure|Myocardial biopsies|Right and left epicardial ventricular biopsies taken at time of clinically indicated surgery
75775733|NCT03074643|Behavioral|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
75775734|NCT03074643|Behavioral|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
75775735|NCT03074643|Dietary Supplement|Carbohydrate supplement for months 0-6|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
75775736|NCT03074643|Dietary Supplement|Protein supplement for months 0-6|Participants in the higher protein / lower CHO diet groups (6-mon HiProt and 18-mon HiProt) will be provided a protein supplement (~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
75320767|NCT03985449|Other|Uterine Fibroid Option Grid encounter patient decision aid (text only)|The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.
75622195|NCT02693860|Drug|89Zr-J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
75651633|NCT05833451|Other|Reiki|Reiki, one of integrative practices, is an energy therapy involving the use of energy that flows naturally from the hands of the practitioner to strengthen the body's ability to heal itself in order to increase well-being. Reiki improves well-being in many areas, ensures that blood and lymph circulation is maintained properly, regulates blood pressure and pulse rate by stimulating the autonomic nervous system, increases comfort, reduces depression and anxiety levels. In this way, Reiki facilitates physical and mental relaxation and promotes health
75651634|NCT05833425|Device|Respiratory Pressure Meter (MicroRPM)|Peripheral muscle strength, respiratory muscle strength and postural controls of all adolescents will be evaluated. The values of the scoliotic and healthy groups will be compared.
75775737|NCT03074643|Dietary Supplement|Protein supplement for follow-up months 7-18|Participants in the higher protein / lower CHO diet (18-mon HiProt) will be provided a protein supplement (~50 g of protein and 220 calories) to consume daily during the 12-month follow-up.
76073255|NCT02990416|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
76073256|NCT02990416|Biological|Pembrolizumab|A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
75775740|NCT03003520|Drug|Durvalumab|"Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection.~Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion."
75775741|NCT03003520|Drug|Rituximab|Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.
75775742|NCT03003520|Drug|Doxorubicin|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
75913393|NCT04834180|Other|Auricular Acupuncture|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
75913394|NCT04834180|Other|Acupressure|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
75913395|NCT01359904|Other|High Dialysate bath|The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
76073257|NCT02990416|Radiation|Ionizing Radiation|Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
75320768|NCT03985449|Other|Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)|The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.
76073258|NCT02994862|Other|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
76073259|NCT02994862|Other|Conventional Bonding|Normal Bonding Protocol
75320769|NCT03985449|Other|Uterine Fibroid Option Grid encounter patient decision aid (online)|Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
75320770|NCT03984903|Other|Multimedia Learning of Exercises|Patients learn exercise from multimedia content.
75320771|NCT03984903|Other|Face-to-face Learning of Exercises|Physiotherapist teach exercises to patients
75320772|NCT03984903|Other|Manual Therapy|Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area
75320773|NCT03984903|Other|Home Exercise Program|Patients do at least 20 minutes motor control exercise in a day at home.
76073260|NCT02990260|Dietary Supplement|Saccharomyces cerevisiae|Live Saccharomyces cerevisiae
76073261|NCT02990260|Dietary Supplement|Lynside Wall Basic|yeast cell walls
75775743|NCT03003520|Drug|Vincristine|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
75320774|NCT03815396|Drug|INBRX-101/rhAAT-Fc|INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
75622196|NCT02721160|Other|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~nb of cases screened and referred to HC for acute malnutrition (AM)~nb of classes promoting good nutrition~HC level~nb of cases screened and cared for severe and moderate AM~nb of growth follow-ups~Hospital level~nb of treated severe AM cases with complications~length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
75622197|NCT02714686|Behavioral|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
75622198|NCT02714842|Drug|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
75622199|NCT02714842|Drug|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
75622200|NCT02714842|Drug|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
75775744|NCT03003520|Drug|Cyclophosphamide|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
75775745|NCT03003520|Drug|Prednisone|"Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle.~Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm."
75775746|NCT03003520|Drug|Lenalidomide|Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.
75775747|NCT02989597|Drug|Methadone Hydrochloride|IV administration of methadone intra-operatively for a single dose
75775748|NCT02989597|Other|Standard pain regimen|Standard medications for pain control administered after spinal surgery to be either fentanyl or morphine
75775749|NCT02989597|Procedure|Spinal Fusion Surgery|Clinically-indicated spinal fusion surgery
75775750|NCT02989597|Drug|Dexamethasone|Post operative swelling and pain control
75775751|NCT02989597|Drug|Ketamine|Perioperative anesthesia medication
75775752|NCT02989597|Drug|Remifentanil|Perioperative pain medication
75775753|NCT02989597|Drug|Sufentanil|Perioperative pain medication
75775754|NCT02986698|Biological|in utero hematopoietic stem cell transplantation|This is a phase 1 safety study to demonstrate it is safe for both the mother and fetus to perform In utero hematopoietic stem cell transplantation of maternal derived stem cells at the time of intrauterine transplantation of red blood cells to treat fetuses affected with alpha-thalassemia major.
75775755|NCT02958527|Drug|venlafaxine|The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.
75775756|NCT02860273|Device|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.
75775757|NCT02860273|Device|Treadmill|Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
75913396|NCT04834258|Other|Walking and respiratory training|"Walking and respiratory muscle training group ( W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged"
75320775|NCT01931163|Drug|Everolimus|
75320776|NCT04763642|Procedure|pancreaticoduodenectomy|Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation
75320777|NCT04763486|Drug|Cefazolin (Cefamezin)|Cefamezin 2 gr within 6 hour of delivery
75320778|NCT02988063|Drug|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
75622201|NCT02714842|Drug|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
75622202|NCT02714530|Drug|Erlotinib|Tarceva daily during radiotherapy course
75622203|NCT02714530|Radiation|Radiation|Radiotherapy
75622204|NCT02714452|Behavioral|Person-centred care|Person-centred and thriving promoting care
75775758|NCT02768701|Drug|Pembrolizumab|Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.
75775759|NCT02768701|Drug|Cyclophosphamide|A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
75775760|NCT02692105|Radiation|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
75775761|NCT02692105|Radiation|High Dose Rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
75775762|NCT02621944|Drug|Melatonin|Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
75775763|NCT02621944|Other|Magnetic Resonance Imaging|All participants will receive an MRI between 7-12 days of age.
76073262|NCT02990260|Dietary Supplement|Placebo|Maize starch and magnesium stearate
75775764|NCT02621944|Other|Pharmacokinetics|All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
75775765|NCT02621944|Behavioral|Neurological Outcome Assessment|All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
75775766|NCT02586025|Drug|FEC Chemotherapy|Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
75775767|NCT02586025|Procedure|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
75775768|NCT02586025|Drug|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
75775769|NCT02586025|Drug|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
75775770|NCT02586025|Drug|Placebo|Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
75775771|NCT02586025|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
75466375|NCT01908881|Behavioral|Usual Care|"According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team."
75466376|NCT01908894|Drug|BIOD-123|
75775772|NCT02505906|Radiation|Simultaneous Integrated Boost Technique|
75775773|NCT02465164|Device|Cook catheter|
75775774|NCT02465164|Drug|Oxytocin|
75775775|NCT02297672|Radiation|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
75775776|NCT02297672|Device|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
75775777|NCT02297672|Device|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
75775778|NCT02260271|Other|Database Entry/Biospecimen Collection|blood, urine, buccal samples and medical data collected
75775779|NCT01955512|Drug|Clopidogrel|Clopidogrel 75mg daily for 7 days
76073263|NCT02994706|Procedure|Home Monitoring|Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
76073264|NCT02994706|Other|Clinical Care|Participants selected for this arm will continue to receive routine clinical care.
76073265|NCT02999776|Device|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
76073266|NCT02999776|Drug|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
75466377|NCT01908894|Drug|BIOD-125|
75622205|NCT02714296|Drug|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
75622206|NCT02714296|Dietary Supplement|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
75466378|NCT01908894|Drug|Humalog|
75466379|NCT01908920|Other|Osteopathic manipulative treatment|
75466380|NCT01908920|Other|SHAM|
75622207|NCT02714374|Biological|GL-ONC1|"Dose and Regimen:~Single dose group: Cohort 1 dose is 1 × 109 pfu~Multiple dose groups:~Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."
75775780|NCT01955512|Drug|Placebo|Matched placebo
75775781|NCT01789008|Other|Determination of Advanced Fibrosis in Alcoholic Liver Disease|
75775782|NCT01721577|Drug|AXL1717|IGF-1 receptor inhibitor
75775783|NCT01705886|Procedure|Total Knee Arthroplasty|Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
75775784|NCT01705886|Procedure|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
75775785|NCT01705886|Device|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
75775786|NCT01705886|Device|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
76073267|NCT02999776|Drug|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
76073268|NCT02999698|Other|Observational|Observational
76073269|NCT02990026|Behavioral|Specialty Mental Health Probation|Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
75775787|NCT01705886|Device|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
76073270|NCT02996656|Drug|Cefazolin|Antibiotic that will be give before a Trauma or elective open shoulder surgery
76073271|NCT02996656|Drug|Ceftriaxone|Antibiotic that will be give before a Trauma or elective open shoulder surgery
75622208|NCT04010266|Device|RelieVRx headset|RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
76088907|NCT01769339|Drug|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
75622209|NCT04010266|Drug|multi-modality pain management|combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
75466381|NCT01908920|Other|CONTROL|
75466382|NCT01908933|Device|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
75622210|NCT02714140|Behavioral|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
75775788|NCT01411332|Radiation|SIMRT|A total dose of 80 Gy will be delivered in 40 fractions to the Clinical Target Volume (CTV).
75466383|NCT01908946|Behavioral|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
75622211|NCT02714140|Behavioral|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
75622212|NCT02714140|Behavioral|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
75775789|NCT01411332|Radiation|HTIMRT|Dose escalation to the Multiparametric MRI (MP-MRI) by dose painting at 2.35-2.40 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 76 Gy. The hypofractionated targeted (HT) boost region will receive an absolute dose of 89.3-91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 95.5 Gy in 2.0 Gy fractions.
75775790|NCT00227617|Biological|bevacizumab|5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
75775791|NCT00227617|Drug|5-fluorouracil|2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
75775792|NCT00227617|Drug|leucovorin|200mg/m2 IV q2 wk on day 1 over a 2-hour period.
75775793|NCT00227617|Drug|oxaliplatin|200mg/m2 IV q 2 wk on day 1 over a 2-hour period
75775794|NCT05747742|Device|RLRL device|Crossover device (RLRL of 50% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
75913397|NCT04834258|Other|Respiratory muscle training|In the Respiratory muscle training group, Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged.
75913398|NCT04823572|Procedure|A-PRF/OFD|Comparing healing effect of an autologous and open flap debridement
75913399|NCT04834102|Diagnostic Test|Blood Tests|Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity
75913400|NCT04823416|Procedure|Resection|Left hemicolectomy
75913401|NCT04823416|Procedure|Stoma|Colostomy
75913402|NCT04816318|Other|Social and public health measures against COVID-19|"Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings~Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds~Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds"
75913403|NCT04816318|Other|Control|The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)
75913404|NCT04823182|Diagnostic Test|Cardiovascular Magnetic Resonance Imaging|The Cardiac MRI protocol consists of static T2 weighted in all three planes and T2 weighted imaging with fat saturation in the short axis plane.
76088908|NCT01769105|Device|Lipiflow|Patients receive a single Lipiflow-treatment
76088909|NCT01769105|Behavioral|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
75622213|NCT02714140|Behavioral|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
75622214|NCT02714140|Behavioral|SMS Reminder|Participants will receive an SMS reminder to test.
75622215|NCT02713906|Device|X-Ray Knee Guide group|
75622216|NCT02713984|Biological|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
75622217|NCT02713672|Other|Dose adjustment according to genotype|Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
75622218|NCT02713750|Other|reversible contraceptive methods|"Consistent male condom use only~Consistent female condom use only~Hormonal contraception, combined oral contraceptive pills and male/female condom~Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~Hormonal contraception , progestin only hormonal implant and male/female condom~Intrauterine device and male/female condom"
75775795|NCT05747404|Diagnostic Test|Echocardiography|- Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume
75622219|NCT04000906|Drug|Nab paclitaxel|Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
75622220|NCT04000906|Drug|Cisplatin|10.5 mg/m2
75775796|NCT05729009|Diagnostic Test|skin microvascular reactivity|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
75775797|NCT05727670|Procedure|exposure of the tooth crown|surgical exposure of the crown of a retentive tooth
75775798|NCT05724043|Device|SmartJournal|SmartJournal is a tablet application with three modules: Module 1 offers a system for simple check-box registration of daily oral hygiene routines. This module also includes an open text field where the caregiver can give a brief description of strategies used if the patient shows resistant behaviors. Module 2 offers a system for monitoring the patient's oral health through monthly check-ups. This module is an image-based, interactive learning- and assessment tool. Upon completion of the monthly oral health assessment health personnel receive a summary report with suggestions for tailored preventive and/or curative measures to be initiated. Module 3 offers an easily accessible knowledge base which includes information on geriatric oral health, standard equipment and procedures for daily oral hygiene routines for patients with various care needs. It also includes scientifically documented strategies that may be used to approach patients with dementia refusing oral care assistance.
75775799|NCT05714878|Behavioral|aerobic exercise; resistance exercise; nutritional support; psychological support|Patient with gastric cancer received two weeks of prehabilitation intervention. An individualized exercise program was established according to the FITT (Frequency, Intensity, Time and Type) principle. Aerobic exercise: 3-5 times/week, 30-60 min jogging or brisk walking per time, intensity based on heart rate and modified Borg-scale. Resistance exercise: 2-3 times/week, 10-12 RM per sets, 2-3 sets with 2 min interval rest, seated knee up, knee extension, etc. Nutritional support: 30kcal/kg/d, 1.5mg/kg/d protein, oral nutritional supplement with suggested recipes. Psychological support: provided with guidance on gastric cancer, regular online chat through Wechat, alcohol quitting, smoking cessation and light music.
75775800|NCT05713916|Other|Intervention: Population Health Coordinator|After being notified of the finding of LVH in their patient, the population health coordinator will offer to schedule a dedicated visit for the provider and their patient to discuss this finding through a structured correspondence. Additionally, the population health coordinator will offer to coordinate 24-hour ambulatory blood pressure monitoring before or after the patient visit as part of the evaluation of LVH. Finally, for patients without established cardiovascular care and whose etiology of LVH remains undetermined, the population health coordinator will offer to coordinate a visit with a cardiologist to discuss the finding of LVH.
75775801|NCT05710081|Biological|Bacterial Lysate|Bacterial Lysate
75775802|NCT05710081|Drug|Placebo|Placebo
75775803|NCT05706740|Other|Physician survey on antithrombotic medication during end-of-life care in cancer patients|"Participating healthcare professionals will be asked to complete the survey electronically within seven days. The survey will consist of general questions (i.e., Have you ever considered deprescribing antithrombotic medicine?), a discrete choice experiment (DCE), and questions involving actual decision-making in patients.~For the DCE, participants will be presented a sequence of choice sets with (hypothetical) scenarios that vary along several characteristics (attributes; e.g., bleeding risk, thrombotic risk). Attributes will be further specified by varying choice levels (attribute levels; e.g., low or high bleeding risk). Participants will be asked to select the healthcare intervention with the highest benefit for the patient according to their opinion.~Finally, participants will be asked to describe actual decisions they made in max. three consecutive patients with active cancer, who were considered to receive end-of-life care."
75775804|NCT05703191|Device|Nitric Oxide Generator and Delivery System|Initial at 20ppm is recommended by guidelines. The concentration is adjusted based on actual condition of subjects.
75775805|NCT05694338|Other|Frailty survey|Frailty survey using the Clinical Risk Analysis Index (RAI-C).
75775806|NCT05692479|Other|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data
75775807|NCT05683366|Device|No Intervention|There is no intervention in this study
75775808|NCT05679882|Other|Masking Sounds|Masking sounds will be played from outdoor speakers.
75622221|NCT00636766|Drug|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
75622222|NCT00636766|Drug|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
75651635|NCT05833399|Drug|Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone|Medications are prescribed orally for outpatient or inpatient treatment of addicted patients.
75775809|NCT05679882|Other|No Masking Sounds|No masking sounds will be played from outdoor speakers.
75775810|NCT05677867|Drug|Formulation A (PF-07081532 20 mg plus 60 mg)|Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet
75775811|NCT05677867|Drug|Formulation B (PF-07081532 80 mg)|Formulation B: administered as a 80 mg immediate release tablet
75775812|NCT05676268|Procedure|Implant-supported fixed dental prostheses with cantilever extension|Healthy patients in need of replacement of missing teeth with dental implants supporting partial fixed dental prostheses with cantilever extensions
75320779|NCT03746600|Behavioral|Project TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
75320780|NCT03815006|Device|Free Style Libre 2|FreeStyle Libre 2 (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
75320781|NCT03746054|Combination Product|Optimal medical treatment|Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months
75775813|NCT05675670|Other|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
75320782|NCT03746054|Combination Product|usual clinical practice|usual clinical practice in each center
75622223|NCT00636766|Drug|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
75775814|NCT05672082|Drug|[18F]DPA-714|Participant received one injection of 200 MBq of [18F]DPA-714
75775815|NCT05671341|Diagnostic Test|Assessment|Tandem walking test, Tandem Stance test, Activity-specific Balance Confidence Parkinson's Disease Quality of Life-8 N/L ratio Tinetti Balance Test UPDRS
76088910|NCT01777139|Drug|Retigabine IR|Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
75775817|NCT05657470|Drug|Tenecteplase|intra-arterial tenecteplase
75775818|NCT05652257|Drug|[14C]-brensocatib|Oral solution.
75775819|NCT05652127|Other|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14
75622224|NCT00636766|Drug|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
75775820|NCT05639686|Drug|Tranexamic acid injection|Within 10 minutes of general anesthetic induction, 15mg/kg TXA suspended in 100mL of normal saline will be administered intravenously.
75775821|NCT05639686|Drug|Total Intravenous Anesthesia|Within 10 minutes of induction, patients in the control (TIVA) group will be administered a 100mL bolus of normal saline as placebo.
75775822|NCT05639686|Drug|Inhalational isoflurane|Inhalational isoflurane or sevoflurane will be administered as a general anesthetic at the induction of the surgical procedure.
75913405|NCT04823260|Drug|Nicotinamide Mononucleotide|Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells involved in fundamental biological processes. Depletion in the levels of NAD+ is associated with traits of aging, many age-related diseases like cancer, metabolic disorders and neurological disorders. Evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity and delaying the progression of age-related diseases
75622225|NCT02713360|Behavioral|Cognitive Therapy|
75775823|NCT05633576|Drug|steroid eye drops|Self-administration of steroid eye drops three times a day for four consecutive weeks.
75775824|NCT05633576|Drug|Placebo|Self-administration of placebo eye drops three times a day for four consecutive weeks.
75775825|NCT05627986|Other|No intervention|No intervention
75775826|NCT05622929|Behavioral|Digitally-enabled Multifaceted Quality Improvement Intervention|"Digitally-enabled multifaceted strategy in addition to access to a RWE platform to provide clinical data. The digitally-enabled multifaceted strategy will include various tools that will provide support to the health professionals responsible for treating ASCVD patients in each center as well as patients, including:~Knowledge of effective lipid lowering therapies~Clinical decision support~Audit and feedback on adherence to optimal clinical management~Audit and feedback on LDL-C control"
75775827|NCT05622929|Behavioral|Usual care|Health professionals responsible for treating ASCVD patients in each center will continue to provide usual care to ASCVD patients in addition to provide data through a RWE platform.
75913406|NCT04823260|Other|Placebo|Rice flour in white capsule resembling NMN
75913407|NCT04823338|Behavioral|Conectar Jugando Online Program|Online play sessions with modern board and card games guided by the study researchers
75913408|NCT04816240|Drug|Midodrine|5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (>75 mm and <90)
76088911|NCT01768637|Drug|Aspirin|Aspirin 81 mg by mouth daily
75622226|NCT02713282|Drug|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
75622227|NCT00611104|Dietary Supplement|standardized freeze-dried table grape powder|
75622228|NCT00611104|Other|laboratory biomarker analysis|
75622229|NCT00611104|Other|pharmacological study|
75320783|NCT03874754|Other|Tailored Technology-Enhance Home-based exercise program (iHBE)|The tailored technology enhanced home-based exercise (iHBE) program is a 12-week program with 1 assessment home visit session, 5 home visits and 7 phone follow ups during exercise. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate [HR], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.
75775828|NCT05621993|Drug|Azvudine|Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in the Diagnostic and therapeutic protocol for COVID-9 in China.
75775829|NCT05615935|Other|Experiential HIV Testing|The content of experiential HIV Testing includes HIV testing, counselling, and education and discussion.
75775830|NCT05615428|Diagnostic Test|LS-ratio|Included infants will have a gastric aspirate sampled via an NG tube at birth. This sample will be analyzed to determine the LS-ratio The LS-ratio will retrospectively be compared to RDS development and need for surfactant treatment to establish the cut-off ratio for LS-ratio with respect to surfactant treatment.
75775831|NCT05615402|Other|Bone-specific strength training|Muscular strength and rate of force development (RFD) will be assessed in the key exercises of the intervention protocol
75775832|NCT05615402|Dietary Supplement|Nutrition optimalisation|Dietary supplement of protein, vitamin D and Calcium 3x/w Dietary counselling based on individual dietary records
75775833|NCT05586685|Other|effect of diaphragmatic release on upper crossed syndrome|"The patients will be positioned in the supine position. The therapist stood at the head of the patient.therapist make manual contact of ribs and ask patient to inspire the move ribs laterally and then expire~conventional exercise Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position"
75775834|NCT05586074|Drug|Clifutinib|tablet, oral
75775835|NCT05586074|Drug|LoDAC|subcutaneous (SC) or intravenous (IV) injection
75775836|NCT05586074|Drug|Azacitidine|SC or IV
75320784|NCT03025269|Drug|Ocrelizumab|This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
75622230|NCT02713516|Other|Virtual Reality|Use of virtual reality to deliver exposure therapy
75622231|NCT02713048|Other|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
75622232|NCT00611260|Behavioral|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
75775837|NCT05586074|Drug|Decitabine|IV
75775838|NCT05586074|Drug|Ara-C±IDA|SC and IV
75775839|NCT05586074|Drug|FLAG-IDA|SC and IV
75775840|NCT05584254|Dietary Supplement|yeast-beta glucan|
75775841|NCT05583630|Device|A gap plate with the function of knee joint pressure detection|A gap plate can measure knee joint pressure by tension sensor. This is a part of routine medical care.
75913409|NCT04816240|Biological|Albumin|80grams/week for 2 weeks followed by 40gram/week
75913410|NCT04816240|Other|Standard Medical Treatment|Standard Medical Treatment
75320785|NCT03029871|Biological|Ad5-yCD/mutTKSR39rep-ADP Adenovirus|oncolytic adenovirus
75622233|NCT00611260|Other|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
75622234|NCT02712970|Procedure|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of <1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
75651636|NCT05833295|Procedure|Downhill walking|Change in the H/M ratio after a downhill walk.
75651637|NCT05833295|Procedure|Walking on flat ground|Change in the H/M ratio after a Walking on flat ground
75651638|NCT05833165|Behavioral|Feasibility of a supportive approach|Evaluating reasons for patients to use the approach
75775842|NCT05582967|Other|Completion of focused Electronic Case Report Form|All patients will have a focussed Electronic Case Report Form completed collecting information around Presenting complaint, Past Medical History, Family History, Physical Examination findings, and Investigations.
75913411|NCT04816240|Other|Placebo|Placebo
75913412|NCT03986944|Drug|75 mg linzagolix tablet|For oral administration once daily
75913413|NCT03986944|Drug|200 mg linzagolix tablet|For oral administration once daily
75913414|NCT03986944|Drug|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
75913415|NCT03986944|Drug|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
75775843|NCT05578599|Device|Swiftsure CCS device|The Swiftsure CSS device will be used twice per patient in addition to standard oral health care procedures among intubated adult patients undergoing mechanical ventilation in the ICU.
75775844|NCT05571566|Other|Educational Book|An educational book with information about appendicitis for patients, parents and caregivers
75651639|NCT05833152|Procedure|total knee arthroplasty|To observe the postoperative functional outcome of patients with knee extension lag at different angles
75775845|NCT05571254|Other|Data collection|All patients will have a focussed Case Report Form completed collecting routine data describing the prevalence, clinical presentation, assessment, management and ESC risk category of patients, at the time or shortly after the patients ED attendance.
75913416|NCT03986944|Drug|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
75913417|NCT03986944|Drug|Placebo capsule to match Add-back capsule|For oral administration once daily
75913418|NCT04822792|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
75775846|NCT05556837|Other|Control Cereal (no beta glucan)|A portion of cereal (25g available carbohydrate) will be fed to participants and postprandial glucose and insulin will be measured
75775847|NCT05556837|Other|Cereal with oat beta glucan (OBG)|A portion of cereal (25g available carbohydrate) containing OBG will be fed to participants and postprandial glucose and insulin will be measured
75775848|NCT05556837|Other|Cereal with barely beta glucan (BBG)|A portion of cereal (25g available carbohydrate) containing BBG will be fed to participants and postprandial glucose and insulin will be measured
75775849|NCT05552365|Behavioral|Adapted Cognitive Behavioural|8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder. Intervention includes psychoeducative, bodily relaxation, graded exposure, cognitive restructuring and brainstorming. Adaptations include increasing the number of visual supports, use of physical objects to illustrate concepts in addition to language.
75622235|NCT02712970|Procedure|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
75651640|NCT05833009|Device|Acupuncture|All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
75775850|NCT05552365|Other|Treatment as Usual|Participants given a mental health brochure with contact information, where they can access services provided by mental health support service providers.
75775851|NCT05549453|Device|Nexstim SNBT use|Active device use
75775852|NCT05545605|Drug|Sodium oligomannate|Patients with acute ischemic stroke were recruited, and after signing informed consent, those who met the inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive treatment in the trial group (receiving sodium oligomannate)
75775853|NCT05545605|Drug|Placebo capsule|the control group (receiving placebo capsule) for 24 weeks.
75775854|NCT05541146|Combination Product|Intraperitoneal chemotherapy|Patients will undergo intraperitoneal chemotherapy with Paclitaxel (4 cycles) associated with systemic chemotherapy. After treatment, patients will be reassessed and if there is a peritoneal response, they will undergo gastrectomy
75775855|NCT05532358|Drug|anle138b (TEV-56286)|Anle138b (TEV-56286) as perpetrator
75775856|NCT05532358|Drug|Fluvoxamine 100 mg QD for 5 days|Anle138b (TEV-56286) as victim
75775857|NCT05527067|Other|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
75775858|NCT05527067|Other|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
75775859|NCT05525416|Drug|Sodium Nitroprusside|A bolus injection of sodium nitroprusside will be given to lower blood pressure and evaluate baroreflex function.
75775860|NCT05525416|Drug|Phenylephrine Hydrochloride|A bolus injection of phenylephrine will be given to raise blood pressure and evaluate baroreflex function immediately following the sodium nitroprusside infusion.
75775861|NCT05525416|Drug|Phenylephrine Hydrochloride|Investigators will give three incremental doses via brachial artery catheter to observe α1-adrenoreceptor mediated vasoconstriction. This will occur three times throughout the protocol.
75775862|NCT05525416|Drug|Norepinephrine|Investigators will give three incremental doses via brachial artery catheter to observe adrenoreceptor activation. This will occur three times throughout the protocol.
75775863|NCT05525416|Other|Isometric Handgrip and Post-Exercise Circulatory Occlusion|Participants will perform 2 minutes of isometric handgrip at 30% maximal voluntary contraction followed by 2 minutes of post-exercise circulatory occlusion to assess the reactivity of the blood vessels to exercise and the metaboreflex.
75775864|NCT05525416|Other|Rhythmic Handgrip|Participants will perform 3 minutes of rhythmic handgrip at 25% maximal voluntary contraction to assess the reactivity of blood vessels to dynamic exercise.
75775865|NCT05525416|Other|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
75775866|NCT05525416|Drug|Propranolol Hydrochloride|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Propranolol is a beta-adrenergic antagonist and will allow investigation of the role of beta receptors in responses to various stressors. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
75775867|NCT05525416|Drug|Phentolamine Mesylate|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Phentolamine is an alpha-adrenergic antagonist and will allow investigation the role of alpha receptors in responses to various stressors. It will be continuously infused with propranolol. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
75913419|NCT04816084|Diagnostic Test|Anti-SARS-CoV2 Serology|"Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®)~Other: Questionnaire~Data concerning personal exposure factors are collected in a questionnaire:~Socio-demographic factors: sex, age,~known risk-factor for Covid-19~Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination~Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays"
75913420|NCT04822558|Other|Plantar pressure measurement|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
75913421|NCT04822558|Other|Gait analysis|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
75651641|NCT05832996|Drug|Refresh Plus Preservative-free Lubricant Eye Drops|Refresh Plus Preservative-free Lubricant Eye Drops at 4 degree Celsius
75775868|NCT05523284|Diagnostic Test|SonoPODography|SonoPODography (SPG) is a novel ultrasound-guided technique whereby saline is injected through the cervix and flushed into the POD, creating an acoustic window for diagnosing superficial endometriosis.
75775869|NCT05516680|Device|electro-acupuncture|Acupoints consist of Neiguan (PC6, bilateral), Shuigou (GV26), Sanyinjiao (SP6, affected side), Yintang (EX-HN3), Shangxing (GV23), Baihui (GV20), and Sishencong (EX-HN1). Disposable stainless-steel needles (0.25mm× 40 mm）will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensation of achiness, heaviness, and numbness (known as de qi) at all acupoints. Following needle manipulations, electroacupuncture instruments(SDZ-V) will be used to attached the needle handles at EX-HN3, GV23, GV20 and EX-HN1 with a dilatational wave of 5 ~ 10 Hz and a current intensity of 1 ~ 3 mA depending on the patient's tolerance. The needles will be removed after 30 minutes except for GV26 without needle retention. Participants will receive 12-20 electroacupuncture sessions over four weeks at a frequency of 3-5 times per week.
75775870|NCT05516680|Device|MRI-navigated rTMS|MRI:All MRI scans were taken to acquire high-resolution T1-weighted anatomical images on the 3T MRI Scanner. Electromyography(EMG):Surface EMG was used to record MEPs from the abductor pollicis brevis for determining RMT of the non-lesioned motor cortex.A single TMS pulse was delivered to the location to identify the RMT,defined as the minimum intensity capable of evoking at least 5 MEPs of >50 μV in 10 consecutive trials.MRI-navigated rTMS:Using BrainSight system,left DLPFC targeting was individualized by reconstructing MRI data into a 3-dimensional brain image for neuro-navigation. Left DLPFC localization was central middle frontal gyrus,between superior frontal sulcus and middle frontal sulcus based on T1-weighted anatomical images.Focal rTMS was administered using a Magstim Rapid 2 connected to Y125-round coil that was identical.rTMS was applied at 110% RMT to the left DLPFC.At each session,3000 pulses were applied at 10 Hz with a total of 12-20 rTMS sessions over a 4-week period.
75775871|NCT05491512|Diagnostic Test|18 F-FMISO PET/CT|The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. At between 150-180 mins post injection, 18F-FMISO images will be acquired.
75775872|NCT05491512|Radiation|Radiation|Total Radiation Dose (over 3 weeks) 30Gy** in 2 Gy per fraction
75775873|NCT05491512|Drug|Cisplatin|Concurrent chemotherapy (2 cycles) will be given. At the start of week 1 of radiation, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2 ), typically on days 1 and 2, or as a single dose, typically on day 1.
75775874|NCT05491512|Drug|Carboplatin|"If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).~(Cohort B to start carboplatin (AUC 1.5) and paclitaxel 45 mg/m2 at the start of RT)"
75775875|NCT05491512|Drug|5-fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
75775876|NCT05460325|Drug|Lanadelumab|Lanadelumab subcutaneous injection.
76088912|NCT01768637|Drug|Clopidogrel|Clopidogrel 75 mg by mouth once daily
76088913|NCT01768559|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
75320786|NCT03744026|Device|SonoCloud-9|Escalating numbers of ultrasound beams at constant acoustic pressure
75320787|NCT03744026|Drug|Carboplatin|Dose of carboplatin infusion is AUC4-6
75320788|NCT03872258|Behavioral|Control|Counseling on physical activity
75320789|NCT03872258|Behavioral|Intervention group|Program of combined exercise and a Smartband for 6 months.
75320790|NCT03806114|Procedure|Posterior Approach Precautions|These patients will be advised not to bend their leg or trunk more than 90 degrees, avoid crossing the leg or crossing midline, and rotating the leg inwards. Patients will also be instructed to put a pillow in between their legs while sleeping for 6 weeks and to avoid bathing for 6 weeks.
75320791|NCT03806114|Procedure|Anterior Approach Precautions|These patients will be advised to avoid extending the leg back, rotating the leg outwards, and lifting their bottom when lying down after their surgery for 6 weeks.
75320792|NCT03806114|Procedure|No Precautions|For the non-precautions group, there will be no mention of precautions by any providers before, during, and after surgery. No equipment will be given, but a list of self-care equipment will be available for 'comfort' purposes. Patients will be instructed to avoid bathing for 4 weeks. All groups will have instructions to use a walking aid and a toilet seat if needed, to weight-bear as tolerated, and to avoid driving for 3 weeks.
75622236|NCT02712970|Procedure|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
75622237|NCT02712970|Procedure|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
75622238|NCT03987568|Other|Blood draws|Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
75622239|NCT03987568|Diagnostic Test|Magnetic resonance imaging (MRI)|At the beginning of study magnetic resonance imaging MRI will be completed.
75622240|NCT02712892|Genetic|Non Interventional Study|
75622241|NCT02693782|Dietary Supplement|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
75622242|NCT02693782|Dietary Supplement|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
75622243|NCT00611338|Behavioral|HIV Skills-based Prevention|
75622244|NCT04188886|Other|Practice survey|Practice survey on
75622245|NCT02712580|Device|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
75775877|NCT05449405|Combination Product|Chlorpheniramine Maleate 1% Nasal Spray|Chlorpheniramine Maleate 1% Nasal Spray
75622246|NCT02712580|Device|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
75775878|NCT05449405|Combination Product|Placebo|Placebo nasal spray
75775879|NCT05447273|Diagnostic Test|Multi-parametric, functional magnetic resonance imaging (MRI)|Multi-parametric, functional magnetic resonance imaging (MRI) will be performed in all included patients prior to surgery.
75775880|NCT05441735|Combination Product|APP|APP as an instructional tool for visiting health education
75775881|NCT05434806|Dietary Supplement|Jarlsberg cheese|Daly oral intake
75775882|NCT05434169|Biological|Arterial Blood Gas|The procedure of arterial blood collection will be conducted in a seated position for all three groups. The patient is in a supine position, with the forearm comfortably placed on a small table. The needle used for blood collection is a 25 gauge needle without local anesthetic. This method of sampling is identical to the one used in daily practice in the Emergency department of Fribourg
75775883|NCT05430529|Behavioral|Standard Smoke Cessation Service|Both of the intervention group and control group will receive standard smoke cessation service, which is same as usual practice.
75775884|NCT05430529|Behavioral|Short Advice for Control Group|If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.
75775885|NCT05430529|Behavioral|Brief Alcohol Intervention for Intervention Group|"During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to the intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~In addition, HCPs can choose to discuss with participants the reasons for consuming alcohol.~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants."
75320793|NCT03741842|Behavioral|COMBO-KEY|The intervention will last for eight weeks with four home visits and five phone coaching sessions. It will also consist of a 4-item resource package for stroke survivors (including a stroke self-management and self-discovery workbook, a health and life planning toolkit, and videos on sharing of experience by survivors who managed their post-stroke challenges successfully, and a stroke self-management quick reference guide). A telephone hotline for survivors and caregivers to seek information and support related to stroke self-management will also be established. A programme protocol will be developed to ensure the consistent delivery of the programme.
75466384|NCT01908959|Behavioral|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
75466385|NCT01908985|Procedure|high intensity focused ultrasound for cyclodestruction in the eye|
75913422|NCT04822558|Procedure|Ankle and hindfoot reconstruction surgery|Ankle and hindfoot reconstruction surgery
75466386|NCT01908998|Other|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
75622247|NCT02712580|Device|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
75622248|NCT02712580|Device|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
75622249|NCT00611416|Dietary Supplement|green tea|different catechin combinations
75622250|NCT00611416|Dietary Supplement|Mix of catechins and caffeine|3 tablet a day
75775886|NCT05416931|Drug|ACD440 Gel 14mg/g|Topical application to painful area
75775887|NCT05416931|Drug|Placebo Gel|Topical application to painful area
75775888|NCT05411549|Behavioral|Diet Modification to Adopt Mediterranean Diet|Participants enrolled in group 1 will be counselled by a dietician and asked to adopt a Mediterranean diet for a 12-week period from counselling. Participants will complete a series of Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora.
75775889|NCT05398510|Drug|SHR-2010 injection|Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.
75913423|NCT04815460|Behavioral|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
75913424|NCT04815460|Behavioral|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
75775890|NCT05398510|Drug|SHR-2010 injection placebo|Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.
75775891|NCT05394740|Drug|Regorafenib|"90 mg administered orally, once daily for 21 consecutive days followed by 7 days off~*Repeat every 4 weeks as Regorafenib therapy"
75775892|NCT05394740|Drug|Nivolumab|CohotA:360 mg administered intravenously, every 3 weeks *Administered on the same day as CapeOX therapy Cohort B: 240 mg administered intravenously, every 2 weeks *Administered on the same day as FOLFOX therapy
75775893|NCT05394740|Drug|CapeOX|"For Cohort A only~Capecitabine 1,000 mg/m^2 administered orally, twice daily (Days 1 to 14 continuous dosing of CapeOX therapy)~Oxaliplatin 130 mg/m^2 administered intravenously (Day 1 of CapeOX therapy) *Repeat every 3 weeks as CapeOX therapy"
75775894|NCT05394740|Drug|FOLFOX regimen|"For Cohort B only~Leucovorin 400 mg/m^2 administered intravenously (Day 1 of FOLFOX therapy)~Fluorouracil 400 mg/m^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)~Oxaliplatin 85 mg/m^2 administered intravenously (Day 1 of FOLFOX therapy) *Repeat every 2 weeks as FOLFOX therapy"
75775895|NCT05390021|Combination Product|PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent|The research study procedures include a screening for eligibility and a single study visit. PET/MRI in one study visit of approximately four hours.
75775896|NCT05389761|Dietary Supplement|fibroDAO®|One DAO enzyme capsule is taken with water 20 minutes before each meal, 3 times a day. DAO enzyme capsules contains 0.3 mg DAO enzyme divided into 2 white/beige tablets (each gastro-resistant tablet contains 0.15 mg DAO enzyme) and 80 mg magnesium divided into 2 lilac tablets (each immediate-release tablet contains 40 mg of Mg).
75622251|NCT00611416|Dietary Supplement|EGCG|3 tablets a day
75622252|NCT00611416|Dietary Supplement|EGC|3 tablets a day
75775897|NCT05389761|Dietary Supplement|Placebo|One placebo capsule is taken with water 20 minutes before each meal, 3 times a day. Placebo capsules consist of microcrystalline cellulose and gelatin capsules with the same shape, size and colour as the DAO enzyme.
75775898|NCT05389033|Dietary Supplement|Probiotic bacteria|28 days daily supplementation with active probiotic
75622253|NCT00611416|Dietary Supplement|Caffeine|3 tablets a day
75622254|NCT00611416|Dietary Supplement|Placebo|3 tablets a day
75775899|NCT05389033|Other|Placebo Capsule|28 days daily supplementation with placebo
75775900|NCT05388279|Drug|JS012|JS012, i.v., q3w
75775901|NCT05388279|Combination Product|JS012 combine with chemotherapy|JS012 i.v., q3w combine with chemotherapy
75913425|NCT04815538|Behavioral|the subscale of Health-Promoting Lifestyle Profile II|"Nutritional health behavior included the following nine items: choose a low-fat diet; limit the use of sugars; eat servings of bread, cereal, and rice; eat servings of fruit; eat servings of vegetables; eat servings of meat, poultry, fish, dietary guidelines"
76088914|NCT01768559|Drug|Insulin glulisine QD|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
76088915|NCT01768559|Drug|Insulin glulisine TID|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
75466387|NCT01909024|Procedure|Coil embolisation|transjugular coil embolisation of pelvic veins
75466388|NCT01909024|Procedure|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
75466389|NCT01909037|Dietary Supplement|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
75466390|NCT01909063|Dietary Supplement|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
75466391|NCT01909063|Dietary Supplement|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
75622255|NCT02712658|Drug|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
75622256|NCT02712658|Drug|Placebo|
75622257|NCT02712736|Other|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
75466392|NCT01909063|Dietary Supplement|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
75622258|NCT00611494|Drug|MMF|Gradual optimization of drug dosage, as clinically tolerated.
75466393|NCT01909076|Behavioral|Electronic decision support tools|"Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate."
75622259|NCT00611494|Drug|EC-MPS|Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
75622260|NCT02712502|Drug|Levofloxacin|"Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
75775902|NCT05386654|Device|imPulse™ Tor System|Self-directed blood pressure data capture
75775903|NCT05371951|Device|Erchonia HLS|84 procedure administrations with the Erchonia® HLS™ administered by the subject at home: twice daily procedure administrations for 6 weeks.
75775904|NCT05353517|Device|Device: focal muscle vibration and theta burst stimulation|non invasive techniques of neuromodulation for inducing plasticity in M1 and spinal cord
75775905|NCT05347732|Diagnostic Test|Successfull thrombolysis|Biomarker levels will be compared between patients with successful and failed thrombolysis.
75775906|NCT05343039|Device|Non-invasive Transcutaneous Nerve Stimulation (tVNS)|Participants will engage in 25-minute tVNS sessions every day for 30 days.
75775907|NCT05343039|Device|No Intervention|Participants will not receive any intervention.
75775908|NCT05328726|Drug|GZR-18|As previously described in Arms
75775909|NCT05328726|Other|Placebo|Placebo will be dosed in an identical manner to active study drug.
75775910|NCT05306678|Behavioral|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
75775911|NCT05306678|Behavioral|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
75775912|NCT05306613|Behavioral|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
75913426|NCT04815694|Radiation|RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT|The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously. A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated. If ERI will be inferior than 13.1 the patient will continue the original treatment. If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
75466394|NCT01909076|Behavioral|Enhanced patient education materials|Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
75622261|NCT02712502|Drug|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
75622262|NCT02712346|Drug|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
75622263|NCT02712346|Drug|Placebo|One inactive pill daily for twelve weeks
75622264|NCT02712190|Device|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
75913427|NCT04822714|Behavioral|Mobile Career Competencies Intervention|Mobile career competencies intervention aim to enhance the career competencies (career behavioral action) among the participants
75913428|NCT04822870|Procedure|quadratus lumborum block|Quadratus lumborum block is an effective nerve block method in post-cesarean section analgesia. It is a relatively new technique that may provide analgesic effect in somatic pain and visceral pain, but has not been verified yet.
75913429|NCT04822870|Procedure|iliohypogastric/ilioinguinal nerve block|Iliohypogastric/ilioinguinal nerve block is a widely used nerve block technique. It can provide somatic analgesia effect in post-cesarean section.
75913430|NCT04822870|Procedure|epidural analgesia|Epidural analgesia is a traditional analgesia method. Epidural morphine can provide effective analgesia but may cause plenty adverse effect.
75622265|NCT02712268|Other|Checklist|Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
75622266|NCT02712034|Behavioral|MAT + A-CHESS|"Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~Advice on where to go for help and on how to make the best use of health and human services; and~A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects)."
75622267|NCT02712034|Other|MAT|"Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care."
75622268|NCT02711722|Device|Neurally adjusted ventilatory assist|"Ventilation supported by NAVA~Blood gas analysis~Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured."
75622269|NCT02711722|Device|PScli1|Pressure support set by clinicians prior to inclusion
75913431|NCT04822324|Other|Spencer Muscle energy technique with conventional Physiotherapy|"shoulder extension with elbow flexion. shoulder flexion with elbow extension. circumduction with compression circumduction with distraction shoulder abduction and internal rotation with elbow flexion. shoulder adduction and external rotation with elbow flexion stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises"
75913432|NCT04822324|Other|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
76088916|NCT01768559|Drug|Insulin Glargine (Mandatory background drug)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
75936415|NCT02440256|Other|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
75622270|NCT02711722|Device|PScli2|Pressure support at the same level as prior to the study
75622271|NCT04161742|Device|Nevisense|Nevisense measures electrical impedance of skin lesions and provides an output called the electrical impedance spectroscopy (EIS) score
76088917|NCT01768559|Drug|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
75466395|NCT01909076|Behavioral|Nurse care management|The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
75622272|NCT02711566|Device|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
75622273|NCT02711566|Device|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
75622274|NCT02711488|Behavioral|Intervention group|"The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager."
75622275|NCT02711410|Drug|Clopidogrel|
75622276|NCT02711176|Drug|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
75622277|NCT02711176|Drug|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
75622278|NCT02711176|Drug|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
75622279|NCT02711176|Drug|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
75622280|NCT02711176|Drug|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
75622281|NCT02711176|Drug|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
75622282|NCT02711098|Biological|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
75622283|NCT02711098|Biological|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
75622284|NCT00611650|Drug|defined green tea catechin extract|Given orally
75622285|NCT00611650|Other|placebo|Given orally
75622286|NCT02711332|Other|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
75622287|NCT02711332|Other|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
75622288|NCT02711020|Behavioral|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
75775913|NCT05306613|Behavioral|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
75775914|NCT05273996|Drug|Sertraline, bupropion, desvenlafaxine|Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.
75775915|NCT05263726|Behavioral|DSMP through a Mobile Applications|This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
75622289|NCT02711020|Behavioral|Personal Construct Therapy|"Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives."
75913433|NCT04822246|Procedure|Control: Hand instrumentation for caries excavation|"An enamel hatchet will be used to create access to the carious lesion and then removal of soft carious tissue will be undertaken with excavators. Excavation will be stopped when some resistance to excavation will be felt and the cavity will be then conditioned with polyacrylic acid for 20 s, washed and dried with cotton pellets. A high-viscosity glass-ionomer cement will be used to restore the cavity. Moisture control will be achieved with the use of cotton wool rolls. A chair-side assistant will hand-mix the glass-ionomer according to manufacturers' instructions and it will be placed in the cavity using the press-finger technique whenever the type of cavity allows it. In the case of root restorations, a glove coated with petroleum jelly will be used similarly to the press-finger technique to better condense the material into the cavity. Excess material will be removed; the restoration will be coated with petroleum jelly. No local anaesthetic will be used to provide ART treatment."
76073272|NCT04270162|Device|Respiratory muscle training 1|"For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups."
76088918|NCT00983619|Drug|MEDI-551|MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
75622290|NCT02710942|Behavioral|SPHERE|
75622291|NCT02710942|Behavioral|PRISM|
75622292|NCT02710708|Drug|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
75622293|NCT02710552|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
75622294|NCT02710552|Drug|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
75622295|NCT02710396|Drug|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks."
75622296|NCT02710396|Drug|Carboplatin|Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
75622297|NCT02710396|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
75622298|NCT02710396|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
75622299|NCT04564768|Behavioral|Online Mindfulness-Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
75622300|NCT02710318|Behavioral|Electronic immunization alert|Immunization alert in the electronic health record
75622301|NCT02710162|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
75622302|NCT02710162|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
75775916|NCT05262244|Drug|Bevacizumab-IRDye800CW|Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
75320794|NCT03803150|Procedure|PRA approach|A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.
75775917|NCT05262244|Drug|Vedolizumab-IRDye800CW|Vedolizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
75775918|NCT05256810|Drug|ALN-XDH|ALN-XDH administered by SC injection
75775919|NCT05256810|Drug|Placebo|Placebo administered by SC injection
75775920|NCT05244213|Biological|Sintilimab|200mg Q3W
75320795|NCT03803150|Procedure|RT approach|The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
75466396|NCT01909076|Behavioral|Electronic Patient Registry|The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
75622303|NCT02710162|Device|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
75622304|NCT02710162|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
75775921|NCT05244213|Drug|Carboplatin|AUC 5, d1 every 3 weeks
75775922|NCT05244213|Drug|Nab paclitaxel|260 mg/m2, d1 every 3 weeks
75775923|NCT05231148|Procedure|local debridement and local calcium sulfate loaded by antibiotics|debridement of infected non united fractures and placement of local calcium sulfate loaded by antibiotic then follow up at regular intervals
75775924|NCT05202704|Procedure|Procedure/Surgery: Experimental: Hidden conditioning + Positive Expectation|Patients will be submitted to quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectations about the treatment by means of a workshop. Immediately after the first session of manipulative therapy, participants will be submitted again to the QST but now the heat pain threshold of the hidden conditioning group will be surreptitiously downgraded (the intense noxious stimulus will be downgraded to the moderate stimulus - individually obtained during the QST) as a mean to conditioning patients to believe that spinal manipulative therapy promoted pain relief. Patients will be invited to report the pain intensity perceived just after the QST (second test - conditioning procedure). The objective of questioning the pain intensity after the conditioning test is a procedure check to ensure that the conditioning procedure worked.
75775925|NCT05202704|Procedure|Procedure/Surgery: Active Comparator: Positive Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate whether the positive instructions will show any effect.
75775926|NCT05202704|Procedure|Procedure/Surgery: Active Comparator: Neutral Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce neutral expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate/confirm the effect of neutral instructions.
75775927|NCT05202704|Procedure|Spinal Manipulative Therapy|All the groups recruited in the study will receive five sessions of Spinal Manipulative Therapy. The intervention will be performed with the patient in the supine position. The clinician-researcher will passively lean over the patient to the side to be manipulated and ask the patient to place their hands behind their head. The researcher will then passively rotate the patient on the side to be manipulated and perform a posterior and inferior thrust on the opposite anterosuperior spine. The patients will receive 4 maneuvers (twice towards right side and twice towards left side).
75775928|NCT05169112|Drug|Lupron Depot|Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months
75775929|NCT05165628|Combination Product|CYP-006TK|CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing
76073273|NCT04270162|Other|Respiratory muscle training 2|"Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups."
76073274|NCT04270162|Other|Respiratory muscle training 3|The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
75913434|NCT04822246|Procedure|Intervention 1: EMS Airflow device for caries excavation|An enamel hatchet will first be used to gain access into the cavity. Then the powder-water prophylaxis device will be used for the removal of soft carious tissue with the sodium bicarbonate powder-water jet. Excavation will be stopped when the colour of the lesion begins to darken and all the soft deposits are evacuated. The excavation will be done intermittently allowing sufficient time to check with hand instrument the surface hardness of the lesion. If the lesion is still soft excavation will be continued until the surface is hard suitable for restoring. The cavity will be then rinsed with copious water spray to evacuate all the powder-water material. The restoration procedure with a glass-ionomer cement will be done following the same procedures as in the control group.
75622305|NCT02710162|Procedure|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
75622306|NCT02710162|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
75622307|NCT02710162|Other|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
75622308|NCT02710162|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
75622309|NCT02710162|Other|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
75622310|NCT02710162|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
75622311|NCT02710162|Other|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
75622312|NCT02710162|Other|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
75622313|NCT02709928|Drug|TD-0714|
75622314|NCT02709928|Drug|Placebo|
75622315|NCT02710006|Procedure|Sonohysterography|Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
75622316|NCT00611728|Drug|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 & 1/2 hrs on 1st day of each cycle & then again on days 14 & 28.~Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 & continue daily for 4 wks by mouth.~Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height & weight. Irinotecan will be given intravenously over 90 min on days 1, 14 & 28 of 6wk cycle.~You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, & then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, & then within 1 week prior to completion of every other cycle."
75622317|NCT04497610|Diagnostic Test|Breath sample|Patient will blow into a tube 5 times.
75622318|NCT02709850|Drug|IONIS ANGPTL3-LRx|
75622319|NCT02709850|Drug|Placebo|0.9%NaCl, water, riboflavin
75622320|NCT02709772|Behavioral|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
75622321|NCT02709304|Drug|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
75622322|NCT02709304|Drug|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
75622323|NCT04189666|Drug|Rivastigmine Transdermal System [Exelon]|compare the ability of the drug in preventing postoperative delirium
75622324|NCT04189666|Drug|Melatonin|compare the ability of the drug in preventing postoperative delirium
75622325|NCT04160338|Device|specular microscopy|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo specular microscopic examination of corneal endothelium before CXL procedure.~Patients will be assigned to undergo accelerated (epithelium-off ,transepithelial ) CXL .~Follow up specular microscopy will be done 3 months and 6 months after corneal collagen cross linking procedure ."
75622326|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation I
75622327|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation II
75622328|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation III
76073275|NCT04387630|Drug|Metformin|Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.
76073276|NCT04387630|Drug|Placebo oral tablet|Simethicone 60 mg three times daily.
76073277|NCT04270318|Other|CH Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
76073278|NCT04270318|Other|CH pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
75622329|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation IV
75775930|NCT05158361|Other|Acupuncture|Participants will receive acupuncture, three times per week for eight weeks. The selected acupoints include bilateral BL33, BL35, SP6, and ST36. All acupoints areas have been sterilized before acupuncture. For BL33, a needle (Ф0.40×100mm) will be inserted with an angle of 60° in an inferomedial direction at a depth of 90-100mm. For BL35, the same needle will be inserted with a direction to the ischial rectal fossa at a depth of 60-70 mm deep. For SP6 and ST36, needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. After the needles are inserted, a portable electro-acupuncture machine will be connected to the handles of needles located in BL33 and BL35 to provide the electrical stimulation for 30 minutes with a disperse-dense wave (4/20Hz). All current intensities will be as high as can be tolerated.
75775931|NCT05158361|Other|Sham acupuncture|The sham acupoints will be located at 20 mm outward to BL33, BL35, SP6, and ST36, and the needless will be inserted with a depth of 2 mm. The BL33 and BL35 will not receive any electrical stimulation, though the handles of needles will be connected to the same machine as the acupuncture group, and the parameter setting and course are also the same.
75775932|NCT05157451|Other|Quality of Life|Ancillary studies
75320796|NCT03872024|Device|For the first 60 patients: 3 XXL probe prototypes of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~An ultrasound examination~One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~Three examinations with the FibroScan® 630 Expert - Research model fitted with the 3 XXL probe prototypes."
75466397|NCT01909076|Behavioral|Academic detailing|All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
75466398|NCT01909115|Drug|1000 IU of Vitamin D3|1000 IU of Vitamin D will be administered in capsule form, once daily.
75466399|NCT01909115|Drug|4000 IU of Vitamin D3|4000 IU of Vitamin D will be administered in capsule form, once daily.
75466400|NCT01909128|Dietary Supplement|fermented milk|fermented milk with Lactobacillus CBA-L74
75466401|NCT01909128|Dietary Supplement|fermented rice|fermented rice wit Lactobacillus CBA-L74
75466402|NCT01909193|Behavioral|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
75466403|NCT01909193|Behavioral|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
75466404|NCT01909219|Drug|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
75622330|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation V
75622331|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation VI
75622332|NCT00937521|Biological|Control|Control
75775933|NCT05157451|Other|Questionnaire Administration|Ancillary studies
75775934|NCT05157451|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75913435|NCT04822246|Procedure|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|The participants allocated to this group will have the caries excavated as described for the control group. Then prior to filling the excavated cavity, the procedure of sodium bicarbonate powder-water jet irrigation as described for the intervention group #1 will be performed to condition the prepared excavated cavity. Then the restorative procedure will be completed with the restorative material and procedures as described for the previous groups.
75913436|NCT04815148|Drug|MH004 Ia(0.1%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
75466405|NCT01909258|Other|Goniometric measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured via goniometry.~The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes)."
75466406|NCT01909258|Other|Photographic measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using photography.~Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements)."
75466407|NCT01909258|Other|EOS measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using the imaging system EOS.~Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed."
75622333|NCT00937521|Biological|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
75622334|NCT02709460|Procedure|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
75466408|NCT01909271|Behavioral|Stroke Education Film Viewing|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
75622335|NCT02709460|Procedure|Cervical occlusion|Cervical occlusion of the uterine artery
75622336|NCT02709382|Drug|Cefepime and Tazobactam combination|
75622337|NCT02708992|Drug|Azithromycin|
75622338|NCT02708992|Drug|Cefixime|
75622339|NCT02709070|Procedure|resection|hepatectomy for HCC
75775935|NCT05157451|Procedure|Yttrium-90 Microsphere Radioembolization|Given via injection
75622340|NCT02709070|Procedure|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
75775936|NCT05133011|Procedure|Tongue base reduction surgery|Tongue base reduction surgery which remove the extra soft tissue of the base of the tongue and soft palate in this study
75775937|NCT05131347|Behavioral|motor intervention|Children in the motor intervention group will receive motor skills training based on motor learning theory. Movement activities include playing on trampoline and tilt board, walking on knees, toes and heels, creeping and crawling under different obstacles, jumping forward and backward, driving scooter board, playing balance devices, hopping, and visual motor coordinated movement. These activities are designed from easy to complex.
75775938|NCT05131347|Behavioral|cognitive intervention|Children in the cognitive intervention group will receive cognitive training. The activities consist of 12 exercises with progressive cognitive demands at 10 levels to improve cognitive functions such as attention, cognitive flexibility, inhibitory control, and working memory.
75775939|NCT05123300|Diagnostic Test|18F-PSMA-1007|18F-PSMA-1007 is a tracer for a PET/CT. Prostate cancer often has marked uptake of PSMA, hence PSMA-PET/CT is in the guidelines in the European Union for detecting relapse. But we will use it for staging primary prostate cancer.
75775940|NCT05114135|Device|Osteo3 ZP Putty|Transforminal Interbody Fusion at one spinal level (L2-S1) with instrumented posteriorlateral fusion on at least the contralateral side to the TLIF approach.
75775941|NCT05108116|Diagnostic Test|EOS|EOS Micro Dose imaging will be done. SterEOS 3D recontruction of the lower limb and pelvis will be performed.
75775942|NCT05104060|Procedure|pectoralis minor intervention group|The subjects in pectoralis minor group will received manual therapy for pectoralis minor by physical therapist, the technique including stretch and soft tissue mobilization. The subjects asked to perform the scapular control exercise and shoulder strength exercise.Subjects will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
75775943|NCT05104060|Procedure|shoulder strengthening group|The subjects in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
75775944|NCT05097209|Drug|Camrelizumab|Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
75775945|NCT05097209|Drug|Gemcitabine|Gemcitabine 1g/m2, d1 & 8 of every cycle, every 3 weeks for 3 cycles before radiation
75775946|NCT05097209|Drug|Induction Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation
75775947|NCT05097209|Radiation|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
75775948|NCT05097209|Drug|Concurrent cisplatin|Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
75913437|NCT04815148|Drug|MH004 Ia(0.3%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
75913438|NCT04815148|Drug|MH004 Ia(1%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
75913439|NCT04815148|Drug|MH004 Ia(3%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
75913440|NCT04815148|Drug|MH004 Ib-1(0.1%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
75913441|NCT04815148|Drug|MH004 Ib-1(0.3%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
75466409|NCT01909271|Other|Stroke Education Pamphlet Exposure|"Usual Care: Stroke Education pamphlet and brochure distribution."
75466410|NCT01909284|Device|Acupuncture|"BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.~Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture."
75466411|NCT01909284|Procedure|Epidural nerve block|Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
75466412|NCT01909297|Device|PROSEAL LMA|Size 3,4 or 5 supraglottic device with orogastric drainage tube
75466413|NCT01909297|Device|SUPREMA LMA|Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube
75775949|NCT05093361|Procedure|Total Hip Arthroplasty|Total Hip Arthroplasty for the treatment of hip arthritis.
75775950|NCT05093361|Procedure|Physical Therapy|Self-driven training according to the training plan instructed by physical therapist.
75913442|NCT04815148|Drug|MH004 Ib-1(1%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
75913443|NCT04815148|Drug|MH004 Ib-2(0.3%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
75913444|NCT04815148|Drug|MH004 Ib-2(1%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
75913445|NCT04815148|Drug|MH004 Ib-2(3%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
75913446|NCT04822012|Diagnostic Test|Anti COVID19 IgG Antibodies|Detection of antibodies to SARS Cov 19 post infection or vaccination , measurements of female hormones in folicular fluid as compared to serum and Perlecan as a follicular quality marker
75913447|NCT04814914|Other|KB109 + Self Supportive Care|KB109 is a novel glycan
75913448|NCT04814914|Other|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
75622341|NCT02709148|Device|Activa PC+S|DBS
75622342|NCT00611962|Drug|Oxaliplatin, Paclitaxel|"Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient~Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL."
75622343|NCT05380791|Other|Follow-up visits|Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
75622344|NCT00606099|Drug|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
75466414|NCT01909297|Device|I-GEL LMA|Size 3,4,5 disposable supraglottic device with noninflatable cuff
75466415|NCT01909310|Procedure|head extension|the lungs are ventilated with the patient´s head extended
75466416|NCT01909310|Procedure|neutral position|the lungs are ventilated with the patient´s head in neutral position
75622345|NCT00606099|Drug|adefovir dipivoxil|Active Comparator
75913449|NCT05399732|Drug|Luspatercept|Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
75622346|NCT02708602|Genetic|β2AR polymorphism|
76073279|NCT04270318|Other|MTA Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
76073280|NCT04270318|Other|MTA pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
75466417|NCT01909310|Procedure|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
75622347|NCT00935883|Drug|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
75622348|NCT00935883|Drug|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
75622349|NCT02708446|Drug|Mifepristone|200mg oral mifepristone to both study arms
75622350|NCT02708446|Drug|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
75622351|NCT02708446|Drug|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
75775951|NCT05082298|Behavioral|Dental FearLess app|Dental FearLess, is a self-administered psychoeducational intervention that will be accessed by participants via their personal smart device (In other words, this is an online application in which investigators present information about dental procedures. The user selects the procedure on which they would like information and then views a brief video on the selected procedure. It uses evidence-based tools to help participants manage their thoughts, feelings, and behavior related to dental fear to reduce fear during encounters with dental professionals.
75913450|NCT05399576|Drug|Nicorandil|Prophylactically combined intracoronary of Nicorandil and verapamil
75913451|NCT05399576|Drug|Saline|intracoronary of 4ml saline
75913452|NCT04789382|Device|LID018869+RepleniSH|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
75913453|NCT04789382|Device|LID018869+Biotrue|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
75913454|NCT04789382|Device|Biofinity+RepleniSH|Comfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
75913455|NCT04789382|Device|PV+Biotrue|Balafilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
75913456|NCT05088902|Diagnostic Test|TERABio Ltd.|Covid- 19 investigational breath test compared to RT- PCR test. TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19 ).
75913457|NCT05068076|Drug|Perfluorobutane|Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
75622352|NCT02708056|Drug|Sugammadex|
75622353|NCT04426708|Drug|HMS5552|single dose of HMS5552 25mg
75913458|NCT05697458|Other|computerized tomography scanning|In all patients the investigators will perform CT for determination of iliac arteries calcifications
75913459|NCT05697302|Behavioral|Education|Interviews will be held twice a week in the first two weeks of the first month, once a week in the following weeks, and once every two weeks in the second month, 8 times in a total of 2 months. The number of 8 interviews planned in the research may increase specifically for the situation of the mother and the baby. Interviews will be held at the mothers' homes or at the Family Health Center. An individualized message will be sent to mothers, two days a week, in accordance with their mobile communication tool, relactation needs. In addition, if the mothers request, they can call the researcher via mobile communication via video or voice and receive live support regarding their questions and questions.
76073281|NCT02998372|Procedure|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
76073282|NCT02994472|Radiation|Gastric emptying scintigraphy using 99mTc-DTPA|
76073283|NCT02993692|Device|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
76073284|NCT04386382|Procedure|ridge splitting flapless technique using interchangeable guide followed by implant placement|"An informed consent is taken from all the patients~I. Presurgical phase:~Proper dental and medical history.~Scaling and oral hygiene measurements.~Clinical examination.~Radiographic examination. Clinical bucco-lingual measurements was done using calipers to ensure the patients would meet our initial inclusion criteria prior to further investigations.~III. Fabrication of interchangeable surgical guide stent from primary impression:~Optical scanning of the dental casts was done using Ceramill map 400~surgical stent was designed using Mimics Innovation Suite 19 ™ software.~Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique.~All patients will be operated under local anesthesia, stent was placed on ridge and adapted well after disinfection osteotomy was done using piezotome splitting tips Implant-insertion was started immediately"
75466418|NCT01909323|Other|maltitol 85% / FOS15%|
75466419|NCT01909323|Other|maltitol alone|
75466420|NCT01909323|Other|maltitol 68% / FOS 32%|
75466421|NCT01909323|Other|maltitol 50% / FOS 50%|
75466422|NCT01909323|Other|FOS alone|
75466423|NCT01909323|Other|Placebo|
75466424|NCT01909349|Behavioral|self-regulation|Web-based support for behavior change regarding physical activity and fruit & vegetable consumption
75466425|NCT01909388|Radiation|MRI-TRUS fusion guided real time HDR|
75913460|NCT05697302|Behavioral|Follow-up|Among the data collection forms, LATCH-Breastfeeding Diagnostic Scale and IMDAT-The Baby's Breastmilk Scoring System will be applied at each interview, and the Breastfeeding Self-Efficacy Scale and Breastfeeding Motivation Scale will be applied at the first interview, at the end of the 1st month and at the end of the 2nd month. Interviews will be held between the 3rd and 7th days of the week, between 10:00 and 16:00, at the mothers' homes or at the Family Health Center (whichever they prefer). At each meeting, an appointment schedule will be made for the next meeting and this information will be shared with the mothers in writing.
75913461|NCT05697302|Behavioral|Referral to Lactation and Relactation Polyclinic|Due to the nature of the research, mothers in the control group will not be given any training, and they will be referred to the Lactation and Relaxation Polyclinic in Erzincan Mengücek Gazi Training and Research Hospital.
75913462|NCT05399420|Diagnostic Test|Blood sampling|One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes
75913463|NCT05399264|Behavioral|Auditory-working memory training program|"The AT-WMT program is comprised of 1,200 daily used sentences either created or selected from newspapers, books, TV programs and magazines by the research assistants. The sentences are political-, cultural-, and religious-neutral sentences. Each of them contains 10 words. Noise was recorded from the upper and lower decks of a bus, in a café, a Chinese restaurant, an MTR (the Mass Transit Railway) carriage, and from a street.~During the training, the following two adaptive tasks will be administered simultaneously: repeating the sentences masked by noise (i.e., AT component) and recalling the first or the final two words of all sentences in a given sentence set (i.e., WMT component)."
75913464|NCT05399264|Behavioral|Auditory training program|During the training, an adaptive speech-in-noise perception task will be administered. Specifically, the sentences in a sentence set will be presented binaurally using a headphone at a level the listeners felt is comfortable. The trainees are expected to immediately repeat each noise-masked sentence after hearing it. If they cannot repeat the sentence, then the sound intensity of the noise will be automatically decreased (step size = 2 dB) until the sentence can be correctly repeated. If the sentence can be repeated at the first attempt, then the intensity of the noise will be automatically increased by 2 dB in the next sentence. To provide feedback, the targeted sentence will be replaced by an asterisk and only shown after clicking the sentence.
75913465|NCT05399264|Behavioral|Mindfulness training program|Participants in this group will participate in a mindfulness training program using newlife.330 (Psychiatric Rehabilitation Association, 2018) which is a Cantonese online platform for self-guided mindfulness training.
76073285|NCT02999854|Biological|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
76073286|NCT02999854|Drug|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
76073287|NCT02999854|Procedure|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
76073288|NCT02999854|Procedure|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
76073289|NCT02999542|Other|Music|Children will be randomised to receive either music via headphones or silence via headphones
76073290|NCT02999542|Other|No music|Children will be randomised to receive either music via headphones or silence via headphones
76073291|NCT02999620|Dietary Supplement|Alpha-cyclodextrin|Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
76073292|NCT02999620|Dietary Supplement|Placebo|Identical looking placebo tablet to active (Alpha-cyclodextrin)
76073293|NCT04270708|Drug|Dexmedetomidine|Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
76073294|NCT04270708|Drug|Triclofos 100 MG/ML|Patients with Autism will be treated with oral Triclofos as a sedative for EEG
76073295|NCT02999464|Other|Qigong|The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
76073296|NCT02999464|Other|Fitness exercise|Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
76073297|NCT02999308|Other|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
75622354|NCT05305209|Other|Intervention group|The patients will receive 12 minutes of intravaginal application with an average power of 1 watios and total applied energy of 720J and an extracavitary application for 4 minutes with an average power of 3 watios and a total dose of 720J with all effects at 200%, twice a week for 6 weeks.
76073298|NCT00704938|Biological|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
76073299|NCT00704938|Biological|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10^8 cells to 5 x 10^10 cells.
75466426|NCT01909401|Drug|boceprevir|
75466427|NCT01909440|Behavioral|exercise intervention|Receive whole body RT
75466428|NCT01909440|Dietary Supplement|nutritional supplementation|Given whey protein supplementation PO
75466429|NCT01909440|Procedure|quality-of-life assessment|Ancillary studies
75466430|NCT01909440|Other|questionnaire administration|Ancillary studies
75466431|NCT01909440|Other|pharmacological study|Correlative studies
75466432|NCT01909440|Other|laboratory biomarker analysis|Correlative studies
75466433|NCT01909544|Other|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
75466434|NCT01909557|Drug|Acetyl-L-carnitine|
76073300|NCT00704938|Biological|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
75622355|NCT05305209|Other|Control Group|The patients will receive 12 minutes of intravaginal application and 4 minutes of extracavitary application, twice a week for 6 weeks. The difference compared to the intervention of group 1 is that the device will be off and therefore will not emit energy.
75622356|NCT05378919|Radiation|Radiotherapy 50 Gy|Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks
75622357|NCT05378919|Drug|Fluorouracil/folic acid|Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
75622358|NCT05378919|Drug|Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)|oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
75622359|NCT05378919|Radiation|Radiotherapy 50 Gy|"Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil."
75622360|NCT00607581|Drug|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
75622361|NCT00607581|Drug|lenalidomide|lenalidomide: 15 mg orally on days 1-21
75622362|NCT00607581|Drug|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
75622363|NCT02707900|Drug|Vorinostat|"At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.~Step 5 - Approximately 7- 10 days after the 4th dose of AGS-004 in Step 4 (Visit 11), ten (10) doses of VOR 400 mg will be administered at 72 hour intervals.~Steps 6 - 7 & EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
75775952|NCT05082298|Behavioral|In-Chair Treatment Protocol|This session is a 1-hour-in-person Cognitive Behavioral Therapy (CBT) dental fear session by study staff at the dental office. Participants will practice managing their thoughts, behaviors, and/or feelings when exposed to stimuli that they report still fearing. After each practice situation, the mental health provider and participant discuss the disconfirmatory evidence generated by the situation.
75775953|NCT05050539|Behavioral|Low Intensity|5 implementation strategies: formal commitments, local champions, implementation blueprint , remind educators (cutting board with WISE EBPs), task-focused facilitation.
75775954|NCT05050539|Behavioral|High Intensity|Low intensity implementation strategies with the addition of holistic individualized facilitation and tailored educational materials.
75775955|NCT05033171|Diagnostic Test|3D Scanning|3D scanning of the rod using Artec Eva Spider type manual 3D scanner
75775956|NCT05033171|Diagnostic Test|EOS 2D/3D scanning|EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery.
75775957|NCT05029310|Drug|Patiromer Oral Product|interaction study
75775958|NCT05025293|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|100ml Zoledronic acid (5mg/100ml) administered intravenously
75775959|NCT05025293|Drug|sodium chloride|100ml NaCl 9mg/ml administered intravenously
75775960|NCT05024474|Other|Inspiratory muscle training (IMT)|Inspiratory muscle training (IMT) at 20-50 % of maximal inspiratory pressure (MIP), 2 x 30 repetitions, twice a day for 8 weeks.
75775961|NCT05024474|Other|Physical exercise|A physical exercise program at least two times a week for 8 weeks. Including strength, aerobic and mobility exercises.
75775962|NCT05023018|Drug|NEO100|NEO100 is a purified form of perillyl alcohol.
75913466|NCT04637984|Behavioral|PREP2 algorithm|A) PREP2. It combines clinical measures and neurological biomarkers in the initial days after stroke: 1) SAFE score (day 3), which is the sum of shoulder abduction and finger extension strength in the paretic upper limb using the Medical Research Council (MRC); 2) NIH Stroke Scale (day 3); 3) transcranial magnetic stimulation (day 3-7) to determine the presence of MEPs in the paretic arm. According with the aforementioned measures, 4 categories of upper limb recovery will be identified: EXCELLENT, GOOD, LIMITED and POOR.
75913467|NCT04956068|Combination Product|PIPAC|A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.
75913468|NCT04453904|Other|"sequential radiochemotherapy in a sanwich mode"|Patients will randomized into two different modalities of radiochemotherapy.
76073301|NCT00704938|Biological|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
76073302|NCT00704938|Drug|cyclophosphamide|60mg/kg/day (Days-7,-6)
76073303|NCT00704938|Drug|fludarabine phosphate|25mg/m^2 (Days -5, -4, -3, -2, and -1)
76073304|NCT02994316|Other|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
76073305|NCT02994628|Other|Water|Water only without carbohydrate
75466435|NCT01909557|Drug|placebo|
75466436|NCT01909583|Other|STAGES-Booklet|STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
75466437|NCT01909596|Other|Without orthoses|Condition control
75466438|NCT01909596|Device|6° lateral wedge insoles|Insoles with a lateral inclination set at 6°
75466439|NCT01909596|Device|10° lateral wedge insoles|Insoles with a lateral inclination set at 10°
75466440|NCT01909596|Device|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
75320797|NCT03872024|Device|From patient 61 to patient 120: 1 XXL probe prototype of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~An ultrasound examination~One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~One examination with the FibroScan® 630 Expert - Research model fitted with 1 adjusted XXL+ probe prototype (H+F prototype probe)."
75320798|NCT03869450|Device|Restylane Volyme|Hyaluronic based filler
75622364|NCT02707900|Biological|AGS-004|"Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.~Steps 6 - 7 & EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
75775963|NCT05021640|Drug|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
75775964|NCT05021640|Drug|Placebo for DCR-AUD|0.9% saline for injection
75913469|NCT05697224|Diagnostic Test|urinary micro RNA detection|Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR_71a gene expression analysis MAPK-3 gene expression analysis
75913470|NCT05283590|Diagnostic Test|Automated echocardiographic inferior vena cava measurement|Patients will be place in supine position. view: subcostal view, importantly supine is standard position for IVC measurement, the IVC is larger in the right lateral decubitus position and vice versa, alternatively directly through a transhepatic approach. Measures will be performed in the two dimensional mode close to the hepatic vein (1 - 3cm from the IVC connection to the right atrium). The IVC will be measured by MM-Mode manually and with the automated mode (both measures will be recorded. In the manual mode this measure requires concurrent utilization of M-Mode and two dimensional mode
75913471|NCT05650112|Biological|FB-001|FB-001 is formulated as a powder in capsule intended for oral administration
75913472|NCT05650112|Biological|Placebo|In order to maintain study blinding, matching placebo in identical packaging is manufactured using an inactive powder in capsule
75913473|NCT05640284|Diagnostic Test|Nuclear Factor-Kappa B Ligand (RANKL) analysis|samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
75913474|NCT05640284|Diagnostic Test|Osteoprotegerin (OPG) analysis|samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
76073306|NCT02994628|Other|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
75622365|NCT05380479|Drug|Mirtazapine|mirtazaine15 mg tablet daily for 8 weeks.
75913475|NCT05640284|Diagnostic Test|Tumor Necrosis Factor Alpha (TNF-α) analysis|samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
76073307|NCT02994628|Other|Cavendish banana|Ingest Cavendish banana (common banana)
76073308|NCT02994628|Other|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
76073309|NCT02994004|Other|no intervention|
75320799|NCT03869450|Device|Restylane Defyne|Hyaluronic based filler
75320800|NCT03869450|Device|Restylane Lyft Lidocaine|Hyaluronic based filler
75320801|NCT04403906|Diagnostic Test|PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)|The PCL COV05 - COVID 19 Ag Rapid FIA test has FSC and CE approvals for the qualitative detection of SARS-CoV-2 Antigens from human oropharyngeal swabs and deep sputum samples. The manufacturer is PCL Corporation Ltd 17F, 128 B-dong, Courthouse-ro, Songpa-gu, Seoul, South Korea.
75320802|NCT01212926|Device|Echographic analysis of myocardial deformation in 2D strain|
75775965|NCT05012293|Other|Baseline|5-min urban park video clip (Presented on a TV)
75775966|NCT05012293|Other|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
75775967|NCT05011318|Other|Baseline|5-min urban park video clip (Presented on a TV)
75775968|NCT05011318|Other|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
75775969|NCT05009784|Other|Baseline|5-min urban park video clip (Presented on a TV)
75775970|NCT05009784|Other|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
75775971|NCT05009784|Other|Traffic Sound|Active Comparator: Traffic Sound (Played through speakers)
75913476|NCT05640284|Diagnostic Test|MicroRNA-223 analysis|samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
75913477|NCT05640284|Diagnostic Test|Microrna-27a analysis|samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
75913478|NCT05398718|Drug|Sotrovimab|collect local clinical evidence for sotrovimab effect in the real-life setting
76073310|NCT02995408|Behavioral|Relaxation Response Resiliency Program for Parents of Children with ASD|
76073311|NCT02994082|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
75320803|NCT04747184|Other|DNA extraction and 16S rRNA sequencing|DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.
75622366|NCT05380479|Drug|Megestrol Acetate|megestrol acetate 160 mg tablet daily for 8 weeks.
75622367|NCT02707822|Other|Clinical and genetic factors|
75622368|NCT00936975|Radiation|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
75775972|NCT05009784|Other|Traffic and Masking Sound|Experimental: Traffic and Masking Sound (Played through speakers)
75775973|NCT05009784|Other|Silence|No Intervention: No sound (Played through speakers)
76073312|NCT02994082|Behavioral|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
75622369|NCT02707978|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
75622370|NCT00604929|Dietary Supplement|carbohydrate and protein|The intake of carbohydrate and protein during endurance type exercise
75622371|NCT04410718|Other|Glycaemic levels|Glycaemic levels during admission for COVID-19
75622372|NCT02707510|Other|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
76073313|NCT02994082|Behavioral|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
76073314|NCT02994082|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
76073315|NCT02994082|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
75320804|NCT03795506|Device|Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment|12 weeks of overnight treatment with active TLA device
75320805|NCT03795506|Device|Placebo TLA Device|12 weeks of overnight use of placebo TLA device
75622373|NCT02707354|Device|Probe based confocal laser endomicroscopy (Cellvizio)|"The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data."
75622374|NCT04335682|Drug|Darolutamide|Patients randomized to darolutamide.
75622375|NCT04335682|Drug|Enzalutamide|Patients randomized to enzalutamide.
75622376|NCT02707120|Drug|PRGF-Endoret|Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
75466441|NCT01909596|Device|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
75622377|NCT02707120|Drug|Artificial tears eye-drops|Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
75320806|NCT03795038|Device|Lipoprotein Apheresis MONET and DALI|Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
75466442|NCT01909596|Device|7° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 7°
75466443|NCT01909596|Device|8° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 8°
75622378|NCT02706808|Dietary Supplement|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
75622379|NCT02706808|Dietary Supplement|Placebo|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
75466444|NCT01909596|Device|9° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 9°
76073316|NCT02994082|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
75622380|NCT02693470|Drug|Ustekinumab|50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
75622381|NCT00936897|Drug|Ibandronate|Ibandronate 150mg PO QM (tablet)
75622382|NCT00936897|Drug|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
76073317|NCT02994082|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
76073318|NCT02994082|Drug|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
76073319|NCT02994082|Drug|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
75320807|NCT03795038|Device|Lipoprotein Apheresis DIAMED and DALI|Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
75320808|NCT03794882|Combination Product|Quadratus Lumborum Block|30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.
75320809|NCT03794882|Procedure|Standard Medical Management|Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
75466445|NCT01909596|Device|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
75622383|NCT02706418|Procedure|Clinical Massage Therapy|
75775974|NCT05004857|Behavioral|Book reading|Prior to the first session, a research assistant will place electrodes on the infant and mother so that they study team can gather autonomic nervous system (ANS) response (sympathetic and parasympathetic) non-invasively using MindWare Portable Lab System (MindWare Technologies, Gahanna, Ohio). These electrodes will remain on the infant and mother throughout each session and be removed via adhesive removing pads following each session's data collection. This will minimize discomfort to both parties secondary to electrode removal and minimize risk of skin irritation by leaving electrodes in place for a prolonged period of time. Additional observational data before and after the reading sessions will be collected by the research assistant, including but not limited to: where the session is conducted (mother's arms, bassinet), activity level, vital signs, and any other observed behaviors throughout the session.
75775975|NCT05002049|Behavioral|Intervention Group|Teenagers with leadership skills from intervention schools (called ambassadors) and stakeholders will participate in focus groups to gain insights on the barriers and facilitators for healthy lifestyles of teenagers, and how science could help address these. Building on the information of the focus groups, ambassadors, stakeholders and other peers will participate in a collaborative competition event where the SEEDS intervention(s) will be designed. The intervention(s) will be implemented at intervention high-schools during 6 months. Outcomes in health behaviours and science literacy will be assessed by validated questionnaires at the start and end of the project.
75775976|NCT05000905|Behavioral|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
75775977|NCT05000905|Behavioral|Questionnaires|Computer based assessments measuring attention, memory, daily habits, and mental health
75775978|NCT04996173|Device|Spray cryotherapy|A novel FDA cleared technique that allows for Liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
75775979|NCT04996173|Device|Ballon Dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3 to 9 atm) using a syringe and pressure manometer.
75622384|NCT00607659|Other|No intervention, only observational|No intervention, only observational
75622385|NCT02706340|Other|No intervention - observational study only|
75775980|NCT04996173|Device|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
75622386|NCT04266561|Other|hernia repair|Two 3-mm needle holders were used for stitching the wide IIR. Then the suture was continued along the upper margin of IIR, but in a deeper plane to include the peritoneum and the deeper fascia transversalis.
75775981|NCT04991974|Behavioral|Patient Navigation|A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
75622387|NCT02706184|Drug|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
75622388|NCT02706184|Drug|Placebo|Placebo
75622389|NCT04264689|Procedure|serratus anterior block|ultrasound guided block
75622390|NCT04264689|Procedure|thoracic epidural|thoracic epidural
75622391|NCT04264689|Procedure|erector spinae block|ultrasound guided block
75775982|NCT04991974|Drug|Buprenorphine|"Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community."
75622392|NCT05265676|Drug|Enoxaparin Sodium (Venus Remedies Limited)|The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
75775983|NCT04971473|Biological|rhTSH|Scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.
75775984|NCT04968236|Other|Deep Dry Needling|In-and-out into different directions technique to encounter sensitive spots in an MTrP region.
75622393|NCT05265676|Drug|Enoxaparin Sodium (Sanofi)|The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
75622394|NCT00606333|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
75622395|NCT00606333|Device|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
75622396|NCT04264611|Other|Experimental: Short Foot Exercise Group|Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
75775985|NCT04968236|Other|Superficial Dry Needling|This technique involves inserting a needle at a depth that is into the subcutaneous tissue and may be combined with manipulation of the needle while in situ.
75775986|NCT04968236|Other|passive stretching|Type of stretching in which you stay in one position for a set time. In this case, hip extension and knee flexion.
75913479|NCT05398562|Diagnostic Test|Mycobacterial recombinant allergens 0.1 μg|solution for intradermal injection, 0.1 µg / 0.1 mL
75913480|NCT05398562|Diagnostic Test|Mycobacterial recombinant allergens 0.2 μg|solution for intradermal injection, 0.2 µg / 0.1 mL
75913481|NCT05398562|Diagnostic Test|Placebo|solution for intradermal injection
76073320|NCT02994082|Drug|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
75622397|NCT04264611|Other|Experimental: Towel Curl Exercise Group|Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
75622398|NCT05265442|Drug|Methadone|titration of Zoryon (methadone): increase of posology untill pain relieved is reached
75622399|NCT05265130|Drug|YiQiFuMai|YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
75622400|NCT05265130|Drug|0.9% Normal Saline 250ml|0.9% Normal Saline 250ml IV, about 40 drops per min.
75622401|NCT02691117|Drug|garlic concentrate|Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
75622402|NCT02693626|Behavioral|intensive cessation message|Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
75622403|NCT02693626|Behavioral|Not intensive cessation message|Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
75622404|NCT04266405|Dietary Supplement|Placebo drink|consume 1 bottle (50 mL) per day for 28 days
75622405|NCT04266405|Dietary Supplement|Collagen Cubilose Drink|consume 1 bottle (50 mL) per day for 28 days
75622406|NCT05264662|Drug|Adacel (Tdap)|Administer Adacel to hiv infected and hiv uninfected pregnant mothers
75622407|NCT00606411|Drug|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
75622408|NCT00631293|Dietary Supplement|lactisole|administration of lactisole followed by placebo
75622409|NCT00631293|Other|placebo|administration of placebo followed by lactisole
75622410|NCT00612196|Drug|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
75622411|NCT00612196|Drug|Placebo|
75622412|NCT00607737|Drug|insulin detemir|3 cutaneous injections
75622413|NCT00607737|Drug|saline|3 cutaneous injections
75622414|NCT05264428|Dietary Supplement|Honey|Participants need to drink honey every day for four weeks.
75622415|NCT05264428|Dietary Supplement|Water|Participants need to drink water every day for four weeks.
75622416|NCT05264272|Other|Prospective serological assays|"Investigators will measure the levels of hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, and HDV RNA genotype at the enrollment of the study.~BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
75622417|NCT05264272|Other|Retrospective serological assays|"Investigators will measure hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, HDV RNA genotype BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study.~The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
75622418|NCT01120691|Drug|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
75622419|NCT01120691|Drug|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
75622420|NCT01120691|Drug|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
75622421|NCT01120691|Drug|Salbutamol/albuterol|As needed throughout the study
75775987|NCT04935489|Device|Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form|The intervention is used regularly for patients with treatment resistant depression, however, in this trial it will be given multiple times per day and over less days than the usual protocol
75775988|NCT04917692|Drug|Empagliflozin|2.5 mg daily
76025563|NCT03850171|Other|Exercise Training|Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
75622422|NCT00612274|Drug|tacrolimus|Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
75622423|NCT00612274|Drug|Sirolimus|Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
75622424|NCT00612274|Drug|Methotrexate|Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
75622425|NCT05263882|Drug|Gemcitabine combined with eribulin|"Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
75622426|NCT02725138|Dietary Supplement|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
75622427|NCT02725138|Other|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
75913482|NCT05398406|Other|TAP Block group|TAP Block: the US probe was placed on the imaginary line connecting the anterior superior iliac spine and the umbilicus. The ilioinguinal and iliohypogastric nerves in the fascia of the internal obliq and transverse abdominis muscles were visualized by US. A total of 40 ml of local anesthetic was infiltrated ESP Blok : a 100 mm 21G peripheral nerve block needle was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. 40 ml of the prepared solutions were injected PVB: In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made
75320810|NCT03736928|Biological|AbobotulinumtoxinA dose level 1 or 2|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
75622428|NCT05261230|Behavioral|Vedic Counselling|Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week sessions were provided on one to one bases on personalised approach.
75622429|NCT05261230|Behavioral|Standard Care|The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
75622430|NCT05261152|Drug|drug product: capsules are containing S. boulardii, administered twice daily (250 mg)|Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
75622431|NCT05261074|Other|No intervention|No intervention (retrospective study)
75622432|NCT05260996|Other|Pilot Group|12 Weeks, 1-1 Hour Session Per Week for 10 Total Curriculum Sessions,including 1 Week of Orientation and 1 Week of Debriefing/Program Graduation.
75622433|NCT02724904|Procedure|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
75622434|NCT02724904|Drug|Fludarabine|Standard Treatment
75622435|NCT02724904|Drug|Thiotepa|Standard Treatment
75622436|NCT02724904|Drug|Methotrexate|IV Bolus
75622437|NCT00935493|Drug|Guanfacine|Guanfacine 0.1 mg po qhs
75622438|NCT00935493|Drug|Guanfacine|Guanfacine 0.5 mg po qhs
75622439|NCT00935493|Drug|Placebo|Placebo po qhs
75622440|NCT05380245|Drug|Voriconazole 200 mg x 2 Tablets|Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).
75622441|NCT05380245|Drug|Clarithromycin 500 mg x 1Tablets|Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.
75622442|NCT03856996|Biological|Stable CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
75622443|NCT03856996|Biological|Transient CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
75622444|NCT03856996|Biological|Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)|Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
75622445|NCT05378685|Procedure|Endotracheal intubation|The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.
75913483|NCT05398406|Other|Paravertebral block group|In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®, USA) was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made bilaterally in the form of 20+20 ml.
76025564|NCT04937465|Other|No intervention done|No intervention was done. This was an observational study.
76025565|NCT04725877|Biological|VIR-1111|VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.
75622446|NCT03853252|Other|Skin biopsy|Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
75622447|NCT02724826|Behavioral|Qigong therapy|Medical qigong
75622448|NCT02724826|Behavioral|Exercise therapy|Regular exercise
75622449|NCT00605241|Drug|GSK598809|Drug
75622450|NCT04266171|Behavioral|Diet education based on CGMS data|Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.
75622451|NCT04266171|Behavioral|Conventional diet education|Control group will receive conventional diabetes diet education without CGMS data.
75622452|NCT00935259|Drug|Simvastatin|40 mg once daily for 2 weeks
75622453|NCT00935259|Drug|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
75622454|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
75622455|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
75622456|NCT02724748|Behavioral|Educational intervention|Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
75622457|NCT05260450|Device|1064 nm Nd:YAG-laser therapy|"All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy."
75775989|NCT04893785|Drug|Cabozantinib and Temozolomide|"Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.~Patients will be required to attend clinic on Day 1, Day 8, Day 14 and Day 22 of every 4 week cycle.~Patients will return to clinic at 30 days (+/- 5 days) of their last dose of cabozantinib or temozolomide (whichever is discontinued last), for an end of treatment visit.~Following their end of treatment visit patients will be followed-up 3-monthly during routine clinic appointments to collect data on further anti-cancer treatment and survival. Follow-up will continue until 6 months after the last patient stops study treatment or up to 18 months after the last patient is randomised, whichever is sooner."
75775990|NCT04888013|Other|Positive Birth Environment|The intent is to surround the woman and her caregivers with specific types of auditory, visual, and tactile stim uli. One key feature of the ambient room is what is missing-the standard hospital bed. As an alternative, a portable double-sized mattress with several large pillows is set up in a corner of the room. The intent is to allow the woman freedom in positioning and to permit close contact with support people, and to limit the routine use of continuous elec tronic fetal heart rate monitoring and other technologies during normal labor. Lighting is dimmed. A wide variety of music selections are also available.
75622458|NCT00606567|Other|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
75775991|NCT04881747|Drug|Lasmiditan|Administered orally.
75913484|NCT05398406|Other|Erector spinae block group|In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
75913485|NCT04454060|Procedure|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
75320811|NCT03736928|Other|placebo|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
75320812|NCT03736928|Biological|AbobotulinumtoxinA dose 3|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
75320813|NCT03736928|Biological|AbobotulinumtoxinA dose 4|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
75775992|NCT04879875|Device|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed after end of surgery.
75775993|NCT04879875|Device|IscAlert 72h|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed 72 hours after end of surgery
75775994|NCT04874155|Device|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode.
75775995|NCT04874155|Device|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode.
75775996|NCT04874155|Device|NTX100 Neuromodulation System - Open-Label|Noninvasive peripheral nerve stimulation device programmed to active mode.
75775997|NCT04862949|Drug|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
75775998|NCT04854213|Device|Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment
75775999|NCT04841772|Dietary Supplement|Recover Vegan Protein Supplement|Post exercise protein supplement (26g pea protein)
75913486|NCT03130400|Procedure|Observational gait analysis procedure|All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
76073321|NCT02994082|Drug|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
76073322|NCT02994082|Behavioral|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
75320814|NCT01101464|Drug|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
75320815|NCT01101464|Drug|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
75320816|NCT01676948|Drug|ACZ885|
75320817|NCT01676948|Drug|Canakinumab|
75320818|NCT01676948|Drug|Canakinumab|"Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients"
75320819|NCT01676948|Drug|Canakinumab|Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
75466446|NCT01909596|Device|Orthotist integrated lateral customized foot orthoses|Foot orthoses with arch support and integrated lateral inclination set according to orthotist experience
75466447|NCT01909596|Device|Orthotist lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set according to orthotist experience
75466448|NCT01909609|Other|AAP Documents|
75466449|NCT01909609|Other|Parent Survival Guide|
75622459|NCT04267419|Diagnostic Test|salivary biomarker|MDA and NO as salivary biomarkers
75651642|NCT04274699|Diagnostic Test|Hemosonics Quantra coagulation monitor|There is no categorisation or allocation of any subject to any intervention vs non-intervention group. Blood sampling and the addition of a Quantra coagulation test is the only 'intervention', and the sampling protocol is identical for all subjects. Post-testing treatment of all subjects is as per established routine and Quantra results will not be used by clinical team.
75466450|NCT01909622|Dietary Supplement|Vitamin D|
75466451|NCT01909622|Dietary Supplement|No vitamin D|
75466452|NCT01909635|Behavioral|Food Feelings|
75466453|NCT01909635|Behavioral|Other Feelings|
76073323|NCT02994082|Behavioral|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
75320820|NCT04403672|Device|performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection|"IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results.~A*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit."
75320821|NCT01676792|Drug|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon & before bed time. Medication should be reapply after bathing or cleaning.
75320822|NCT03728036|Behavioral|conventional rehabilitation|The investigated cohort will be exposed to 'standard care' including conventional rehabilitation therapy.
75622460|NCT05378451|Procedure|Totally Extraperitoneal Groin Hernia Repair|"Patients will undergo totally extraperitoneal groin hernia repair, by a single senior experimented surgeon and without modifications from the routine clinical practice due to study inclusion. TEP approach will be assessed by placement of 3 trocars in the lower midline. Preperitoneal space will be dissected under direct vision using Spacemaker Dissection Balloon (Applied Medical®). Systematic complete dissection of the myopectineal orifice, Retzius and Bogros spaces will be performed to identify all potential sites of hernia formation. It will be used a laparoscopic self-fixating mesh (ProGrip™). Preperitoneal instillation of local anesthesia (15 mL of 0.5% bupivacaine) will be placed placed by the surgeon under direct visualization into triangle of pain. Local anesthesia (levobupivacaine 10mL 1%) will be applied in all the incisions."
75622461|NCT00606645|Biological|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
75622462|NCT02724670|Radiation|IGRT|MR-based IGRT
75622463|NCT04267341|Other|Timed Up and Go Test|It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again
75622464|NCT04267341|Other|10 Meter Walk Test|10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance
75622465|NCT04267341|Other|Purdue Pegboard Test|Purdue Pegboard test evaluates the fine manuel dexterity
75776000|NCT04841772|Dietary Supplement|Placebo|Post exercise placebo supplement (32g maltodextrin)
75776001|NCT04839978|Behavioral|Connect Program|The Connect program includes school-based screening, brief intervention and referral, and will be treated as part of the participating schools' prevention programs. A computer-based screening and brief intervention will be supported by Cherokee Nation Behavioral Health (CNBH) supervised Connect coaches universally, to reduce potential stigma associated with speaking to a Connect coach and to reinforce drugfree norms among all students. Follow-up of moderate to high-risk youth will be conducted by a Connect Coach through Zoom, other electronic communication, or in-person visits, with referral to Cherokee Nation or community services if deemed necessary.
75776002|NCT04839978|Behavioral|Communities Mobilizing for Change and Action (CMCA)|The community-level intervention Communities Mobilizing for Change and Action (CMCA) will involve educating and organizing of adult volunteers and consent will be assumed by their participation. We will provide trainings and tools, including Family Action Kits, to support local families, community organizations and citizens, including information on national and local opioid and other drug use, evidence-based policies, programs and practices, and how to motivate and create family and local action for drug prevention.
75776003|NCT04800146|Procedure|Blood sample|Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination
75776004|NCT04795622|Device|Ultherapy treatment|Focused ultrasound energy delivered below the surface of the skin
75776005|NCT04795622|Device|Untreated-control / delayed-treatment|Untreated-control, followed by Ultherapy treatment (focused ultrasound energy delivered below the surface of the skin)
75776006|NCT04791033|Procedure|Hysterectomy|Elective procedure with hysterectomy due to benign gynecological condition
75776007|NCT04790266|Diagnostic Test|Cardiac MRI|cCardiac MRI, ecocardiography and cardiotoxicity blood tests will be repeated as previously scheduled
75913487|NCT05398016|Behavioral|low-intensity intervention for anxiety|Brief (4-6 weekly 30-min sessions) delivery of a structured behavioral treatment for mild-to-moderate anxiety. Treatment will be based on principles of cognitive behavioral therapy (CBT).
75913488|NCT04615286|Other|Short course (2-3 weeks) of antibiotics|Shorter course of antibiotic than standard care of 4-6 weeks
75913489|NCT04615286|Other|Standard (long course) of antibiotics|4-6 weeks of antibiotics
75913490|NCT05397938|Drug|JMT103|JMT103, subcutaneous injection, once every 6 months (Q6M)
75622466|NCT02724514|Other|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
75622467|NCT05260372|Diagnostic Test|Quantification of donor-derived cell-free DNA|Quantification of ddcfDNA on serial plasma samples during follow-up after lung transplantation
75913491|NCT05397938|Drug|Alendronate sodium|Alendronate sodium tablet, once every week (QW)
75913492|NCT05397938|Drug|JMT103 placebo|JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)
75913493|NCT05397938|Drug|Alendronate sodium placebo|Alendronate sodium tablet placebo, once every week (QW)
76073324|NCT01270048|Drug|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
76073325|NCT01270048|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
76073326|NCT02995096|Procedure|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
76073327|NCT02995096|Drug|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
76073328|NCT02993848|Other|No intervention|
76073329|NCT01275820|Dietary Supplement|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
75622468|NCT04264377|Procedure|Bronchoscopy|Bronchoscopy for retrieval of airway cells
75776008|NCT04787003|Drug|oncolytic virus (OVV-01) injection|intratumoral injection of OVV-01 with or without immune checkpoint inhibitors
75622469|NCT05260294|Procedure|Epidural space identification with cervical epidural steroid injection employing CST and LORT.|Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.
75776009|NCT04786691|Other|Addition of half and half to coffee|1 oz of half and half is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
75776010|NCT04786691|Other|Addition of non-dairy creamer to coffee|1 oz of non-dairy creamer is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
75776011|NCT04786691|Other|Black|No Creamer
75776012|NCT04784871|Behavioral|5waysA Intervention|Web-based 10 week intervention, encouraging participants engaging in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
75776013|NCT04784871|Behavioral|5waysA Active wait-list control|Writing activity log in the waiting time. Then, after five months and the writing of activity log, the participants get the web-based intervention and SMS massages, which encourage the participants to engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
75776014|NCT04784871|Behavioral|5waysA Inactive wait-list control|No activity while the participants wait. After five months of waiting, the participants get the web-based intervention and SMS messages, which encourage participants engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
75776015|NCT04781959|Drug|Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy
75913494|NCT05133674|Drug|Tamoxifen 20 mg|i) a self-testing capillary kit, the rhelise™ kit for measuring the concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen and ii) a patient interactive digital tool (app) mBraze to collect data about symptoms and guide breast cancer patients on adjuvant tamoxifen.
75913495|NCT04593134|Behavioral|exercise group|"exercise education: A 12-week regimen of homebased walking exercises, include moderate intensity for 40 min, three times a week.~We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the heart rate reserve, as determined by the Karvonen method, or 13-14 on the RPE.~Exercise education:~Weekly telephone or mobile application LINE consultations concerning exercise.we discussed whether participants' exercise fulfilled the prescribed intensity, duration, frequency and whether the participants experienced any adverse effects."
76073330|NCT02993536|Other|Biospecimen Collection|
75320823|NCT03725930|Drug|Clonidine|clonidine intranasal premedication in preschool infants
75320824|NCT03725930|Other|Placebo|Placebo intranasal premedication
75913496|NCT02522936|Drug|Biotene oral spray|Biotene oral spray will be provided to participants.
75913497|NCT04674566|Drug|COR-101|Administered intravenously (IV) single dose
75913498|NCT04674566|Drug|Placebo|Administered intravenously (IV) single dose
75913499|NCT04405466|Procedure|Blood sampling|Blood samples
75913500|NCT04405466|Procedure|Throat swab|Throat swab
75320825|NCT03781388|Drug|Bupivacaine|Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) <0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
75320826|NCT03652220|Behavioral|Meditation Based Lifestyle Modification|8 weekly modules, each 3.5 hours of Life ethics, Yoga exercises and Mantra Meditation
75466454|NCT01909648|Other|Blood withdrawal|
76073331|NCT02993770|Procedure|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
76073332|NCT02993770|Procedure|External DCR|External DCR
76073333|NCT00709306|Device|UV-Detect Photos|UV-Detect Photos
75466455|NCT01909648|Genetic|Blood withdrawal|
75466456|NCT01909661|Other|Damira/Celia peptide hydrolyzed casein|
75466457|NCT01909661|Other|Picot riz/Celia rice/Sanutri arroz|
75466458|NCT01909687|Device|Blood glucose monitoring systems|
75466459|NCT01909700|Device|Single Incision Mesh|Single Incision Mesh is implanted for pelvic floor reconstruction
75466460|NCT01909726|Other|ScreenPlay|Interactive technology
75466461|NCT01909739|Drug|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
75466462|NCT01909739|Drug|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
75466463|NCT01909752|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
75466464|NCT01909752|Biological|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
75776016|NCT04781959|Drug|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
75776017|NCT04745156|Device|RNS System Implantation|Following resection consistent with SoC, if there is evidence of residual tumor which cannot be resected due to invasion of hand-M1 but which is small enough to be covered by two four-electrode strips, these strips will be placed on the functional cortex of interest and secured to the dura. The location of the leads will be registered into the navigation software (either Medtronic Stealth or Brainlab). The dura will then be closed as watertight as possible, and the RNS System will be incorporated into the craniotomy on closure Prior to closure, four bone screws will be placed and registered to the intraoperative navigation system as internal fiducials to be retrieved for future procedures.
75776018|NCT04729608|Drug|Batiraxcept|Batiraxcept is an experimental drug
75776019|NCT04729608|Drug|Paclitaxel|Paclitaxel is the standard of care, background therapy
75776020|NCT04729608|Other|Placebo|Matching placebo
75776021|NCT04720625|Behavioral|Adapt2Quit|Motivational text messages and quitline facilitation text messages will be sent to participants; these participants will receive Adapt2Quit (experimental) messages as well as quitline facilitation messages.
75776022|NCT04720625|Behavioral|Control|Quitline facilitation text messages will be sent to participants; these participants will receive quitline facilitation-only messages.
75776023|NCT04710355|Device|Spinal cord stimulation|Adhesion of Intellis spinal cord stimulator to the skin of the abdomen for 4 weeks for baseline recording of activity level prior to trial with spinal cord stimulation.
75913501|NCT04373954|Other|Forgiveness Therapy|The Forgiveness Therapy model mainly includes four stages: uncovering, decision, work and deepening. The book 8 Keys to Forgiveness (2015, a forgiveness therapy manual authored by Dr. Enright) is the basis for the therapy as a way to ensure that the treatment is uniformly founded on the forgiveness process developed at the University of Wisconsin-Madison.
75913502|NCT04373954|Other|Carey Guides|The Carey Guides is a primary educational program deliberately chosen and approved by the Department of Corrections in Wisconsin, in which all inmates are encouraged (not required) to complete as they work toward custody reduction. Some aspects emphasized in it include anti-social thinking, emotional regulation, moral reasoning, and so on. It is the basis for the control group therapy as a way to ensure that the treatment has a uniform process as it is taught in the Department of Corrections (DOC) prison system.
75913503|NCT04525898|Drug|Methadone|The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
75913504|NCT03130166|Procedure|Intracorporeal anastomosis|Use of intracorporeal anastomosis technique
75320827|NCT03652220|Other|Minimal treatment|Drug continuation under medical supervision
75320828|NCT03652220|Other|Multimodal specific treatment:|Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR
75320829|NCT03779204|Behavioral|Mentorship|The mentors will be encouraged to incorporate the key relationship-based components of natural mentors (e.g., a 'coach' or 'cheerleader' role) to assist with mainstream integration. The mentors will have more flexibility than a typical formal mentorship program in the types of activities they pursue with their mentees. They will not be mandated to attend shelter-based social events, but rather engage in activities that direct their mentees away from the shelter system (and their old identities as homeless youth) and toward the mainstream (e.g., meeting for coffee at a local university campus). All of the mentors will meet monthly with their mentees for two years. In addition, the mentor will be encouraged to touch base with their mentee via phone or text message every week. If a mentor is unable to continue their role and there are at least six months left in the study, the study participant will be matched with a new mentor.
75320830|NCT03779204|Behavioral|Rent Subsidies|Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.
75622470|NCT00606723|Biological|Hematopoietic stem cells from bone marrow or peripheral blood|> = 2 x 10*8 nucleated cells (WBC)/kg body weight of the recipient or rather > = 4 x 10*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
75913505|NCT03130166|Procedure|Extracorporeal anastomosis|Use of the conventional extracorporeal anastomosis technique
75913506|NCT04452656|Procedure|bilateral erector spinae block|"An ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius , rhomboids major , and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process..~0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle andthe transverse process12."
75913507|NCT04362800|Other|MRI|MRI at baseline and J90
76073334|NCT00709306|Behavioral|Motivational Interviewing|Motivational Interviewing
75622471|NCT03826576|Behavioral|Multicomponent intervention|"The multicomponent intervention will be consist of:~Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~Nutritional and food allergen analysis of the menu of the restaurant~Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~Marketing campaign about healthy and food allergen adapted menus in the restaurants"
75651643|NCT05832970|Other|Brief skin cooling|Brief skin cooling will be applied to the hand using the cold-bath immersion
75776024|NCT04707001|Other|Catheterization based on ultrasound|Bladder volume ultrasound
75776025|NCT04707001|Other|Catheterization based on evaluation of symptoms|Ask for symptoms: Need to urinate, lower abdominal pain
75776026|NCT04689568|Behavioral|Moodkit|"MoodKit is divided into four main sections: Activities, Thoughts, Mood and Journal. In the Thoughts section, the user is asked to briefly describe stressful situations and their reactions to the event and is later educated on a number of thought distortions. In the Mood section, the user is asked to give an overall rating of mood, which can be done several times per day. In the Journal section, the user can write freestanding journal entries. Additional areas of advice and goal setting are contained in a section called Thrive Tips."
75776027|NCT04689568|Behavioral|Moodgym|The program consists of five modules each taking 20- to 40-minutes to complete, which are completed in a prescribed order.
75320831|NCT03779048|Behavioral|Behavioral Treatment|Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).
75776028|NCT04689568|Behavioral|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey.
75913508|NCT04362800|Other|Electro-Encephalography-High Density|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
75320832|NCT03779048|Drug|Placebo|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
75466465|NCT01909752|Drug|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
75913509|NCT04362800|Other|3D and EMG analysis|3D and EMG analysis at baseline and J90
75776029|NCT04686136|Drug|Atogepant 60 mg|Tablets containing 60 mg of Atogepant
75913510|NCT04362800|Other|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
75913511|NCT04282070|Drug|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
75913512|NCT04282070|Drug|Gemcitabine|Maximum 6 cycles for combined therapy.
75913513|NCT04282070|Drug|Cisplatin|Maximum 6 cycles for combined therapy.
75320833|NCT03779048|Drug|Phentermine 15 MG|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
75466466|NCT01909752|Drug|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
75913514|NCT04282070|Drug|Albumin Paclitaxel|Maximum 6 cycles for combined therapy.
75913515|NCT05397626|Behavioral|Heart Rhythm Biofeedback|Heart rhythm biofeedback is a non-invasive intervention intended to improve heart rate variability and physical resilience that is often limited in chronic fatigue syndrome
75776030|NCT04679636|Behavioral|heart rate variability biofeedback|receive biofeedback training for heart rate variability for eight weeks
75913516|NCT05397626|Dietary Supplement|Hydrogen Water|Hydrogen water, if ingested daily over several weeks, may have antioxidant and anti-inflammatory effects in chronic fatigue syndrome
75320834|NCT03778580|Dietary Supplement|Pyridoxamine Dihydrochloride|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid
75320835|NCT03778580|Drug|placebo|placebo
75320836|NCT03722342|Drug|TTAC-0001 and pembrolizumab combination|"Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~Treatment groups: 3 dose levels~Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Cycle: 3 weeks (21 days per cycle)"
75320837|NCT03722108|Combination Product|Regorafenib and Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
75776031|NCT04671862|Device|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~1 Treatment 4J continuous prior to RT. (Within 14 days of RT start)~3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)"
75776032|NCT04670770|Drug|Drug - SHR1459|Oral Tablets taken once daily for 52 weeks
75776033|NCT04657406|Drug|Zofin|Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10^11 particles/mL.
75776034|NCT04653896|Device|Keeogo|The Keeogo is the only commercially available (in Canada) robotic exoskeleton for a non-paralyzed population who can stand and initiate a stepping action, but have impaired mobility for functional tasks. Keeogo provides active assistance during stance and swing phases and assists users to perform functional mobility tasks including walking, stair climbing, sit-to-stand, bending, squatting, and kneeling.
75776035|NCT04652245|Drug|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3
75913517|NCT05397626|Combination Product|Combined treatment: Heart rhythm biofeedback plus hydrogen water|This treatment is intended to explore the possible additive or synergistic effects of combining heart rhythm biofeedback and hydrogen water.
75913518|NCT04347122|Drug|Tranexamic Acid (TXA)|Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.
76025566|NCT04725877|Drug|Placebo|A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.
76025567|NCT02388529|Drug|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
76025568|NCT02388529|Drug|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
76025569|NCT02388529|Drug|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
76025570|NCT02388529|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
76025571|NCT05343013|Drug|TAS-102|GIven by PO
76025572|NCT02388373|Drug|Fluticasone 250/formoterol 10|
76025573|NCT02388373|Drug|Fluticasone 250/salmeterol 25|
76025574|NCT02388373|Drug|Fluticasone 125/formoterol 5|
76025575|NCT05231239|Device|tDCS : Transcranial direct current stimulation|Transcranial direct current stimulation
75320838|NCT03722108|Drug|Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
76073335|NCT00709306|Behavioral|Education|Education
75320839|NCT03775070|Drug|Simvastatin|"Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~The basic anti-congestive medication will be kept as the same.~The dosage may be titrated to a lesser dose by investigators according to the patient's condition."
75913519|NCT04453826|Drug|Camrelizumab plus chemo-radiotherapy|"Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.~Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
75913520|NCT04453826|Drug|Chemo-radiotherapy alone|"Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
75913521|NCT05439746|Device|Microlyte® Matrix|Microlyte® Matrix is indicated for the management of wounds and can be used over-the-counter for minor wounds such as abrasions and lacerations, minor cuts, and minor scalds and burns. Under the direction of a healthcare professional, Microlyte® Matrix may be used for more serious wounds such as partial and full thickness pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds. Microlyte® Matrix may be used over debrided and grafted partial thickness wounds.
75913522|NCT03467438|Drug|Zinc-l-carnosine|Patients will be asked to take the investigational product as already mentioned (blindly).
75913523|NCT03467438|Other|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
75913524|NCT05397314|Dietary Supplement|Punalpin|
75320840|NCT03645824|Drug|Pacritinib|Patients receive up to 4 cycles of pacritinib before allo-SCT
75913525|NCT05397314|Other|Placebo|
76073336|NCT01275976|Drug|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
76073337|NCT01275976|Other|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
75320841|NCT02083406|Drug|800mg OZ439 prototype formulation 1|
75320842|NCT02083406|Drug|800mg OZ439 prototype formulation 2|
75320843|NCT02083406|Drug|800mg OZ439 prototype formulation 3|
75320844|NCT02083406|Drug|960mg PQP|
75320845|NCT03773666|Drug|Durvalumab|Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
75320846|NCT03773666|Drug|Oleclumab|Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
75320847|NCT03770468|Procedure|Blood drawl|
75320848|NCT04762784|Drug|Tocilizumab|Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.
75622472|NCT00607971|Drug|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
75622473|NCT02724436|Procedure|TACE|
75622474|NCT02724436|Procedure|radioembolization with Y-90|radioembolization with Y-90
75776036|NCT04652245|Drug|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5|Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
75776037|NCT04652245|Drug|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5
76073338|NCT00725530|Device|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
75622475|NCT01120379|Device|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
76073339|NCT00725530|Device|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
75622476|NCT02724358|Procedure|TACE|iodized oil (5ml) + Pirarubicin (20mg)
76073340|NCT01270360|Device|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
76073341|NCT01270438|Drug|FOLFOX regimen|Given IV
76073342|NCT01270438|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
76073343|NCT01270438|Biological|bevacizumab|Given IV
76073344|NCT01270438|Drug|oxaliplatin|Given IV
75622477|NCT02724358|Drug|Rg3|20mg, BID, maintained though Month 12.
75622478|NCT02724358|Other|TACE + Rg3|
75622479|NCT02724358|Procedure|protective therapy|standard liver protective therapy
75776038|NCT04652245|Drug|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3|Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
75776039|NCT04642287|Drug|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriene is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
75776040|NCT04642287|Drug|Vaseline|Placebo
75776041|NCT04642287|Drug|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
75622480|NCT05260138|Other|Gentle Body message|The intervention group received gentle body massage twice/day and position change from supine to lateral every two hours under the phototherapy for three consecutive days in addition to routine NICU care.
75776042|NCT04635735|Drug|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
75776043|NCT04611334|Behavioral|heart rate variability biofeedback|Heart rate variability biological feedback training is carried out in the outpatient meeting room of the hospital, including once a week, 30 minutes of hospital training each time, using Medea physiological feedback device portable Bluetooth physiological signal Feedback system (Medical Device Input No. 027390). Designed as two stages, stage one (the first week) first teaches the subject how to perform abdominal breathing, and connects the physiological feedback device to monitor the patient's breathing and heart rate changes, and sets the breath per minute according to the subject's resonance frequency . Stage two (second-four weeks) guide the case to understand the resonance relationship between breathing and heart rate, and then achieve the effect of matching heart and breath. It is also equipped with a pressure relief device (Helico Inc., New York, NY, USA) for self-practice at home.
75776044|NCT04606589|Device|neoGuard vital signs monitor|The neoGuardTM device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate, respiratory rate and blood oxygen saturation in newborns.
75776045|NCT04595513|Drug|TAVT-18 (sirolimus)|The investigational drug product to be used in this study is TAVT-18, a proprietary formulation of sirolimus in clinical development, by Tavanta Therapeutics, Inc. It is provided in a powder formulation in pre-measured vials.
75913526|NCT05397236|Drug|Bupivacaine- Magnesium|Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
75776046|NCT04595032|Device|3DCRT, IMRT, VMAT, SBRT|Radiation treatment
75913527|NCT05397236|Drug|Bupivacaine dexamethasone|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
75622481|NCT05260138|Other|Routine NICU Care|received the conventional NICU care of infants undergoing phototherapy. Phototherapy was given by single Blue LEDs emitting light in a narrow spectrum (450-470 nm). Initially, phototherapy lamps were checked and adjusted at the height of 30 cm from the neonates who were kept naked in the incubator/crib except for the reproductive organs with shielded eyes. The neonates were positioned supine under the phototherapy. The treatment was given continuously, except while feeding and nursing for 30 minutes every 3 hours. The neonates' skin was cleaned with warm water without applying any sorts of ointments oils or creams. They were also observed for signs of dehydration.
75622482|NCT00608049|Behavioral|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
75622483|NCT00608049|Behavioral|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
75622484|NCT00608049|Behavioral|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
75776047|NCT04584138|Behavioral|Study of eye movements|The assessment of eye movement during autobiographical retrieval (i.e., retrieval of personal memories) in patients with Alzheimer's Disease.
75776048|NCT04576403|Device|activated mittens|activated mittens (with electronic heat)
75776049|NCT04576403|Device|deactivated mittens|deactivated mittens (without electronic heat)
75913528|NCT05397236|Drug|Bupivacaine saline|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
75913529|NCT04306562|Dietary Supplement|enteral nutrition supplement|enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day for at least 14 days from a preanesthetic clinic visit to a day of surgery.
75913530|NCT03467282|Dietary Supplement|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
75913531|NCT03467282|Dietary Supplement|Placebo|1g polydextrose/maltodextrin - twice day
75913532|NCT05397002|Procedure|patient specific inverted L mandibular osteotomy modified with inferior alveolar nerve relocation|preoperative CBCT was requested for virtual planning and fabrication of cutting and drilling guides. Cutting lines were outlined to be consisted of four cuts; lateral ostectomy to uncover and lateralize the inferior alveolar nerve (IAN), posterior cut run horizontally from the anterior border of the ramus to a point just above the mandibular foramen, two anterior vertical cuts run from the anterior end of the lateral ostectomy to the inferior mandibular border. The guide was removed and the osteotomy lines were completed then the mandibular setback was oriented and fixed using pre-bent plates osteosynthesis. Plane transfer was checked using CBCT and Inferior alveolar nerve function was assessed.
75913533|NCT05439278|Radiation|Hypofractionated radiotherapy|40.05 Gy in 15 fractions (daily treatment, 5 per week)
75913534|NCT05439278|Radiation|Conventional radiotherapy|60 Gy in 30 fractions (daily treatment, 5 per week)
75913535|NCT05439278|Drug|Temozolomide|concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
75913536|NCT03130010|Drug|Nefopam or saline|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
75913537|NCT05396144|Drug|Nitrous oxide|Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
75913538|NCT04453670|Procedure|autopsy|autopsy
75913539|NCT06150898|Procedure|Prospective data and sample collection|Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity
75913540|NCT06150898|Drug|Ketorolac 10 Mg Oral Tablet|Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
75913541|NCT06150898|Drug|Pregabalin 75mg|Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
76073345|NCT01270438|Drug|leucovorin calcium|Given IV
76073346|NCT01270438|Drug|fluorouracil|Given IV
75913542|NCT06150885|Biological|HLA-G-CAR.BiTE allogeneic γδ T cells|"Phase I is a multiple escalating dose, single arm, open-label and 3+3 design that implemented with five cohorts: low dose for single administration, low dose for twice administrations for 2 weeks, low, middle and high dose for 4 repeated administrations for 4 weeks.~Phase IIa is a single-arm, open-label and dose-expansion study and the effective dose of CAR-positive cells will be administered to 27 evaluable subjects with TNBC, NSCLC, CRC or GBM via intravenous infusion weekly for 4 weeks."
75320849|NCT04762784|Drug|Glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
75622485|NCT00608049|Behavioral|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
75622486|NCT05259748|Behavioral|Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors|Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
75622487|NCT02724202|Drug|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
75622488|NCT02724202|Drug|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
75622489|NCT04265859|Behavioral|Cognitive Behavioral Training|The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
75622490|NCT04265859|Behavioral|Mindfulness|The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
75622491|NCT01120067|Behavioral|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
75622492|NCT01120067|Behavioral|Treatment as Usual|Treatment as Usual.
75622493|NCT02724280|Device|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
75622494|NCT02724280|Device|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
75622495|NCT05282043|Other|Evaluation of Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults|Participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, O2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. In addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods.
75622496|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
75913543|NCT06150833|Biological|Boya IVIG|"The initial dose and other dose changes will be determined by the investigator on a case-by-case basis aiming to prevent infection and minimum serum IgG levels of 5 g/L. The total number of doses administered will depend on the treatment regimen and run-in period:~Between 16 and 20 intravenous injections for participants receiving infusions every 28 days, or;~Between 21 and 25 intravenous injections for participants receiving infusions every 21 days"
75913544|NCT06150781|Drug|erenumab-aooe|Dose and treatment duration will be advised by the HCP
75320850|NCT00003644|Drug|carboplatin|
75320851|NCT00003644|Drug|paclitaxel|
75320852|NCT02142049|Drug|Ibrutinib|Ibrutinib
75320853|NCT02142049|Drug|DA-EPOCH-R|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
75320854|NCT02142049|Drug|Lenalidomide|Lenalidomide
75320855|NCT03640286|Device|VeSTAL|The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.
75320856|NCT03715244|Procedure|Spinal anesthesia with short-acting local anesthetics|Spinal anesthesia in patients with duration of surgery < 90 minutes
75622497|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
75622498|NCT00625547|Drug|cabergoline|Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
75622499|NCT00625547|Drug|levodopa|Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
75622500|NCT05241340|Drug|Sasanlimab|Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1). Manufactured by Pfizer, Inc.
75622501|NCT05241340|Radiation|Stereotactic Body Radiation Therapy|This current study is designed to deliver a biologically equivalent dose of 43.2Gy using a strategy of HD hypo-fractionated radiation therapy 8Gy x 3 in combination with Sasanlimab
75651644|NCT05832905|Behavioral|Mobile and Wearable-assisted Case Management|The MCM group received case management and Mobile-and wearable recording. The actual intervention for Panic disorder, including pharmacotherapy or psychological treatment is the same as in MCM and TAU group
75622502|NCT05241340|Procedure|Radical Cystectomy + pelvic lymph node dissection + urinary diversion|"This will include a cysto-prostatectomy in males or a radical cystectomy with anterior exenteration in females, bilateral pelvic lymph node dissection, and creation of a urinary diversion (ileal conduit, Indiana pouch or orthotopic neo-bladder). Robotic assisted or open surgery will be permitted.~Because there is currently equipoise regarding standard or extended template pelvic lymph node dissection, the limits of node dissection will not be protocol mandated. In the standard template, nodal packets will include the common iliac, external iliac, internal iliac (or hypogastric) and obturator nodes. Patients receiving an extended template will have the standard nodes with the addition of the para-aortic, para-caval, pre-sacral, and pre-sciatic node packets. The decision for urinary diversion is multifactorial involving patient factors (e.g., adequate renal function) and preference; thus, it will be made on a case-by-case basis."
75913545|NCT06150703|Drug|Ovulation induction with hCG + Luteal phase support with vaginal progesterone|hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg morning, noon and evening) vaginally from the evening of the puncture until the pregnancy test result
75776050|NCT04576195|Other|Real PENS|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~TENS Frequency 2 Hz TENS Pulse width - 250 microseconds Duration - 30 minutes. TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~Administration - One single session."
75776051|NCT04576195|Other|Sham PENS|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One single session"
75913546|NCT06150703|Drug|Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin|Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test
75622503|NCT04265469|Other|Diabetic foot education|Give Diabetic foot education via mobile phone
75776052|NCT04572880|Procedure|Trabeculectomy|Trabeculectomy is performed
75776053|NCT04572880|Device|XEN®|Microinvasive Surgery with XEN® is performed
75913547|NCT06150690|Other|No intervention|The participants did not receive any study-specific intervention
76073347|NCT01270594|Behavioral|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
75320857|NCT03715244|Procedure|General anesthesia (current standard)|General anesthesia in patients with duration of surgery < 90 minutes
75320858|NCT03634982|Drug|RMC-4630|RMC-4630 for oral administration
75320859|NCT03714620|Drug|Ketamine|Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
75776054|NCT04572880|Device|Preserflo®|Microinvasive Surgery with Preserflo® is performed
75320860|NCT03634436|Drug|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
75776055|NCT04566783|Diagnostic Test|Psychological/psychiatric examination|Thorough diagnostic and (neuro)psychological assessment using standardized clinical interviews (e.g. MINI, SOMS) as well as questionnaires assessing sexual function (e.g. SIS/SES), depression and anxiety (HADS), childhood trauma (CTQ) and life quality (WHOQOL-BREF). In a semi-structured interview sociodemographic data, drug history and sexual characteristics are captured.
75776056|NCT04566783|Diagnostic Test|Neurological examination|Standardized clinical neurological examination as well as neurophysiological measurements (Pudenus-SEP, ENoG, clinical EEG).
75913548|NCT06150651|Other|CAR T-cell therapy|1x10^6 cells/kg CD-19 CAR-T cells
75913549|NCT06150625|Other|Orthopedic Manaual Therapy|Can include either spinal mobilizations or spinal manipulation therapy targeting the stiff or symptomatic level of the lumbar spine. Various types of mobilization or manipulation may be used based on the therapists clinical reasoning. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data. Common mobilizations techniques involve gently and repeatedly applying pressure over different parts of the patient's spine that is associated with their symptoms. For a manipulation, the patient will be positioned in side-lying position. The therapist will then position the patient further to target the symptomatic level. The patient is asked to take a deep breathe in and out. The therapist will slowly add pressure through the trunk and apply a fast but small thrust motion toward the table.
76073348|NCT01270594|Behavioral|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
76073349|NCT01270672|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
76073350|NCT01270672|Drug|carvedilol|50 mg per os, single dose
76073351|NCT01270672|Drug|placebo|capsules identical to MDMA or carvedilol
76073352|NCT02992834|Biological|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
75320861|NCT03634436|Drug|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
75320862|NCT03631550|Device|Relivion active|1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation
75320863|NCT03631550|Device|Relivion Sham|1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation
75320864|NCT03629912|Behavioral|Socially-Based Exercise Intervention for Older Adults|A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
75320865|NCT03629288|Other|Lactose tab|Tablet containing lactose Procedure: Periodontal treatment Scaling and root planning
75776057|NCT04566783|Diagnostic Test|Gynecological/urological examination|Standard clinical investigation including ultrasound of the genital organs will be conducted to look for any somatic pathology (e.g. varices, tumors).
75776058|NCT04566783|Diagnostic Test|Laboratory assessment|Blood sample will be analyzed to evaluate (epi-)genetic markers of increased central excitability or decreased inhibition including specific parameters of the serotonin-, dopamine- and endocannabinoid system.
75776059|NCT04566783|Diagnostic Test|Structural and Functional Magnetic Resonance Imaging|"Structural MRI of the pelvis is conducted to rule out any anatomical pathologies underlying PGAD (e.g. varices).~Structural MRI of the lumbosacral spinal cord to look for any pathologies on the spinal level, especially spinal level S2-4 (e.g. Tarlov cysts).~High-resolution structural MRI (T1) including brain stem will be applied to all participants in order to explore alterations in gray matter volume or density.~Structural differences in white matter will be assessed using a high-resolution DTI sequence. In addition to standard voxel-wise comparison of DTI derived parameters for white matter microstructural integrity, a tractography-based analysis will test for alterations in structural connectivity.~Resting-state functional MRI including brain stem scans will evaluate abnormal brain circuitry at rest (resting-state functional connectivity, RSFC).~Functional MRI to assess brain response towards sexual cue reactivity."
75776060|NCT04554264|Other|questionnaire|Inventory of Complicate Grief (ICG) score in relative from patients who died in ICU after SARS-Cov2 infection. This is the most commonly used assessment tool for complicated grief which focuses on different symptoms than depression or anxiety. A score > 25 indicate complicated grief.
75776061|NCT04543110|Drug|Durvalumab|Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
75776062|NCT04543110|Radiation|Immune Modulating Radiation|Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
75776063|NCT04507659|Drug|Jaktinib Hydrochloride Tablets|Morning: 2*50mg simulated tablets and 1*75mg Jaktinib Hydrochloride Tablets; Evening: 2*50mg simulated tablets and 1*75mg Jaktinib Hydrochloride Tablets.
75776064|NCT04507659|Drug|Jaktinib Hydrochloride Tablets|Morning: 1*75mg simulated tablet, 2*50mg Jaktinib Hydrochloride Tablets; Evening: 1*75mg simulated tablet, 2*50mg Jaktinib Hydrochloride Tablets.
75776065|NCT04507659|Drug|Placebo|Morning: 1*75mg simulated tablet, 2*50mg simulated tablets; Evening: 1*75mg simulated tablet, 2*50mg simulated tablets.
75776066|NCT04506970|Diagnostic Test|Comprehensive Doppler Ultrasound of the Placenta|Ultrasound measures to be collected include uterine artery (UtA) and umbilical artery (UA), systolic/diastolic (S/D) ratio, resistance index (RI), pulsatility index (PI) and presence of early diastolic notch.
75776067|NCT04506970|Other|Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)|In addition, a Verasonics ultrasound scanner will be used for ultra-sensitive Doppler imaging. Data will be collected on vessel density, periphery-to-center vessel density ratio (VDR) and microvessel morphology.
75622504|NCT05240326|Other|exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks. The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes relaxation and stretching exercises.
75622505|NCT05240326|Other|control training group|The control group will be followed up as a home program by giving the relaxation exercises. Patients will be asked to do the exercises regularly for 3 days/week, 1 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
75776068|NCT04490148|Device|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
75776069|NCT04490148|Device|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
75776070|NCT04490148|Behavioral|Nurse Respiratory Health Coaching (NRHC)|"Nurse Respiratory Health Coaching - The NRHC intervention follows the teamlet model described by Bennett et al. [Bennett2010], made up of the research coordinator who performs respiratory testing, and the nurse practitioner who coaches using the GROW (goals, realities, options, wrap-up) model."
75776071|NCT04487652|Other|Gingival recession coverage|The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.
75913550|NCT06150625|Other|Dry Needling|dry needling both sides of the symptomatic level(s) of the lumbar spine as well as needling other areas in the lower extremity and pelvis based on the results of their clinical evaluation and/or the subjects presenting symptoms. Dry needling involves the insertion of a monofilament needle (nothing is injected) into symptomatic soft tissue. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data.
75913551|NCT06150625|Other|Home exercise program|5 exercises will be selected from 10 options intended to reinforce the improvements made from treatment.
75913552|NCT06150625|Other|Patient education|Patient education on the low back condition, advice to stay active, and home exercise performance.
75913553|NCT06150599|Device|Sacral neuromodulation|Interstim X, which includes an implantable pulse generator and lead, will be implanted surgically in a single-stage procedure.
75913554|NCT06150586|Other|Skin Conductance (SC) Measurement|SC will be measured using a specific monitor and three self-adhesive electrodes on one foot of the infant (one plantar and two on the ankles). Peaks per second (the rate of firing in the sympathetic nerves), average amplitude (mean peaks) and area under curve (forcefulness of sympathetic nerve firing) will be automatically analyzed. Corresponding data will be transferred to a separate tablet computer via bluetooth.
75913555|NCT06150586|Other|Video Recording|The video recording for later N-PASS assessment will be done by a camera fixed above the incubator / resuscitation unit, not interfering with the LISA procedure. The video will show the full body of the newborn as well as the hands / forearms of the treating clinical team with the awareness and oral consent of the treating team.
75913556|NCT06150560|Drug|Losartan|50mg administered orally once daily for 52 weeks.
75913557|NCT06150560|Drug|Amlodipine|5mg Amlodipine administered orally once daily for 52 weeks.
75622506|NCT02881853|Drug|XmAb7195|
75622507|NCT02881853|Drug|Placebo|
75622508|NCT02724046|Drug|Ciprofloxacin|Single-dose oral ciprofloxacin
75776072|NCT04487652|Drug|with CoQ10 spray application|After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.
75776073|NCT04487652|Drug|with placebo spray application|After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
75776074|NCT04485871|Dietary Supplement|Omega-3 fatty acids|Tripple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
75776075|NCT04451980|Procedure|Subcutaneous adipose tissue biopsy|Percutaneous adipose tissue biopsy
75776076|NCT04451980|Radiation|CT scan|CT scan of chest and abdomen without contrast
75913558|NCT06150560|Drug|Placebo|Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
75913559|NCT06150547|Diagnostic Test|F-DOPA Positron Emission Tomography|Imaging using a F-DOPA radioactive tracer to look at the head.
75622509|NCT05379621|Other|COVID-19 infection|All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
75622510|NCT02724124|Other|Static Stretching|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
75622511|NCT02724124|Other|warm up|Warm-up for 10 minutes at 70-80% of maximum heart rate.
75622512|NCT02724124|Other|static stretching + warm up|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
75622513|NCT02724124|Other|warm up+static stretching|Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
75622514|NCT02724124|Other|Control|No intervention
75622515|NCT00608127|Device|LupusorbTM|Single treatment
75651645|NCT05832853|Behavioral|Wu Qin Xi exercise|The training schedule for Wu Qin Xi consisted of two phases: the first phase lasted for eight weeks, while the second phase lasted for 16 weeks. In the first phase, Wu Qin Xi group was given twice repetitions of the intervention. The second phase consisted of three repetitions of the Wu Qin Xi group. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
75776077|NCT04451980|Diagnostic Test|Oral glucose tolerance test|Ingestion of 75g of oral glucose syrup and measurement of blood glucose and insulin at time 0, 15 min, 30 min, 60 min, 90 min, and 120 min.
75776078|NCT04451980|Diagnostic Test|Blood collection|Fasting blood collection for plasma cytokines and T cell phenotypes.
75776079|NCT04429334|Drug|nangibotide|nangibotide 1.0 mg/kg/h
75776080|NCT04429334|Drug|placebo|matching placebo
75776081|NCT04408443|Dietary Supplement|Lactobacillus reuteri DSM 17938 + Vitamine D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
75776082|NCT04408443|Dietary Supplement|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
75798350|NCT03868878|Other|Capoeira training|The Capoeira training protocol, based in the modern styles was applied by an instructor with 16 years of experience. The protocol followed the directions of the ABADÁ Capoeira system, being adapted to the sample of older adults of the present study. The experimental protocol for Capoeira progressive training program lasted 12 weeks and was performed twice a week with duration of 60 minutes each. Each session was divided in three parts, being: 1) initial part: consisting of 10 minutes warm-up with recreational activities at low intensity; 2) main part: consisting of 30 minutes of basic movements in the modality and; 3) final part: consisting of 20 minutes with theoretical instructions related to Capoeira and musicality (singing and touch of typical instruments). In order to perform the Capoeira progressive training program, the technical improvement naturally occurred every week, resulting in a higher speed in movements execution and thus to a gradual increase in training intensity.
75798351|NCT03869112|Behavioral|Physical activity intervention|Physical activity group will be given a charge 2 FitBit device to monitor their PA specially steps count, step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home-based intervention.
75798352|NCT03869112|Other|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
75798353|NCT01168050|Drug|Nilotinib|Nilotinib 400 mg twice per day
75798354|NCT01170312|Biological|Autologous conditioned plasma (ACP)|ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
75913560|NCT06150547|Diagnostic Test|Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.
75798355|NCT01170312|Other|Normal saline|Normal saline injection
75798356|NCT01165710|Other|Patients with Atrial Fibrillation (AF)|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
75798357|NCT03870594|Diagnostic Test|glycated hemoglobin|hemoglobin A1c level in blood
75798358|NCT01165788|Procedure|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
75798359|NCT01165866|Drug|Treatment 1. Metoclopramide|metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.
75798360|NCT01165866|Drug|Treatment 2 Ondansetron|Single dose of Ondansetron 0.15 mg/kg
75798361|NCT02504697|Other|Biosamples from airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
75798362|NCT01168128|Other|Tailored Change Strategy|e.g. Education, decision support tools
75798363|NCT01170468|Drug|Vitamin D3|Vitamin D3 5000 IU orally, daily for 2 years
75798364|NCT01170468|Drug|Placebo|Placebo orally, daily for 2 years
75913561|NCT06150508|Behavioral|O2O digital healthcare service|The O2O service includes a mobile app and web-based portal that allows patients to monitor their blood glucose levels, track their medication use and physical activity, receive personalized feedback and education, and communicate with healthcare providers. The treatment group will receive a blood sugar checker and blood pressure checker that send the records automatically to the application through Bluetooth.
75622516|NCT04265547|Behavioral|Breast Cancer Risk Reduction Household Intervention|This study will focus the intervention on ways at the individual level to reduce sources of Polycyclic Aromatic Hydrocarbons (through cooking methods, exposure to cigarette smoking, indoor air filters) and also individual ways to reduce sources of other Endocrine Disrupting Chemicals. Mother-daughter pairs will partake in an educational session at the baseline visit, covering topics on reading labels, cleaning habits, and cooking methods for reducing exposures. Participants will also be introduced to free resources for consumer product safety information. The intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy measurement, and questionnaire completion. The control arm will be offered the intervention products at this time.
75622517|NCT01124045|Drug|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
75913562|NCT06150482|Other|No intervention|No intervention
75622518|NCT01124045|Drug|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
75913563|NCT06150469|Combination Product|"Blend of ginger and lemon essential oils, Neutral oil"|Patients will be given aromasticks to inhale the blend of essential oils.
75622519|NCT04265391|Dietary Supplement|cookies|Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
76025576|NCT02388451|Device|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
76025577|NCT03239587|Behavioral|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
75320866|NCT03629288|Drug|Azithromycin|Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
75622520|NCT01123889|Biological|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
75622521|NCT01123889|Drug|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
75622522|NCT05226208|Diagnostic Test|Visual analogue scale (VAS)|In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.
75622523|NCT05226208|Diagnostic Test|General anxiety scale (GAD-2) and survey|In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
75622524|NCT05379543|Other|Echocardiography|Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.
75622525|NCT02723968|Other|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
75622526|NCT02723968|Procedure|HGPIV diagnosis test|
75622527|NCT02723968|Procedure|HOMAR-IR diagnosis test|
75622528|NCT00606879|Drug|SGX523 Capsules|This is a dose escalation study
75622529|NCT00605631|Device|Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System|No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
75622530|NCT02723890|Device|Tyto Device|
75776083|NCT04405739|Drug|EIDD-2801|Oral capsule of EIDD-2801
75776084|NCT04405739|Drug|Placebo|Oral placebo capsule
75776085|NCT04396457|Drug|Pembrolizumab|Human PD-1 Monoclonal antibody
75776086|NCT04396457|Drug|Pemetrexed|Antineoplastic antimetabolite
75776087|NCT04395521|Behavioral|Diabetic foot self-management support|Daily educational organic or inorganic posts (2 to 5) released in a timed sequence through a Hootsuite application plus peer interactions/support for three months.
75776088|NCT04377204|Drug|marcaine bupivacaine|This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
75320867|NCT01676870|Behavioral|1x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down."
75320868|NCT01676870|Behavioral|4x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down."
75776089|NCT04377204|Drug|Lidocaine|This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
75320869|NCT01676870|Behavioral|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
75320870|NCT04763096|Drug|Advagraf|"Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks."
75320871|NCT05347472|Other|Smartphone application|the smartphone application intervention will consist daily physical therapy exercises program. The application will include all the videos about the exercises and all information about the repetition, frequency, intensity, and position.
75622531|NCT00606957|Dietary Supplement|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
75622532|NCT02723656|Behavioral|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
75622533|NCT02723656|Behavioral|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
75622534|NCT05192512|Drug|TQB2928 injection|TQB2928 injection is a CD47 Blocker.
75622535|NCT00934947|Drug|Propranolol|40 mg
75622536|NCT00934947|Drug|Placebo|sugar pill
75622537|NCT00934947|Drug|Propanolol|120 mg twice per day
75320872|NCT05347472|Other|Sham Smartphone application|ham application that includes information and general advice about UI only
75622538|NCT05191810|Behavioral|Educational information|Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
75622539|NCT02723578|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
75622540|NCT02723578|Drug|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
75798365|NCT01273584|Drug|Metformin|Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
76025578|NCT03239587|Procedure|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
75466467|NCT01909752|Biological|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
75466468|NCT01909765|Other|Dorsal slit|Skin and mucosa incision made together
75466469|NCT01909765|Other|Double incision|Skin and mucosa incision made separately
75466470|NCT01909817|Procedure|Routine coronary angiogram|
75466471|NCT01909830|Drug|Arm A : Gemcitabine + Pemetrexed|"Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
75466472|NCT01909843|Biological|ALX-0171|Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
75466473|NCT01909856|Drug|Palonosetron|Palonosetron 0.25mg d1,d3
75466474|NCT01909856|Drug|Granisetron|Granisetron 3mg d1-3
75466475|NCT01909856|Drug|Dexamethasone|Dexamethasone 10mg d1-3
75466476|NCT01909856|Drug|Cisplatin|3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3
75466477|NCT01909869|Device|EXCEL-Ⅱ|A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
75622541|NCT04267263|Behavioral|Self-guided lifestyle intervention|The intervention will consist of one 60-minute group based online session, adapted specifically for young men based previous work with young adults, followed by a self-guided program for 12-weeks. Participants will receive a tool kit that includes evidence-based resources (scale for self-weighing, handouts that will include free self-monitoring apps and strategies for no-cost exercise, sample meal plans and meal planning tips, and tips for healthy living that emphasize risk areas) to assist them during the self-guided phase, as well as weekly health risk text messages.
75622542|NCT01123655|Drug|APLA12|Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
75622543|NCT01123655|Drug|Placebo|Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
75622544|NCT05379465|Other|No intervention|No intervention was done.
75622545|NCT04189198|Drug|Articaine|Supraclavicular block with 30 ml articaine 2%
75622546|NCT04189198|Drug|Bupivacaine|Supraclavicular block with 30 ml bupivacaine 0.5%
75622547|NCT04253535|Other|questionnaries|Study on questionnaries
75622548|NCT00608361|Drug|Dasatinib|Given PO
75622549|NCT00608361|Other|Pharmacological Study|Correlative studies
75622550|NCT04311281|Biological|[F-18]FDDNP-PET|[F-18]FDDNP, or 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.
75622551|NCT02694406|Device|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
75622552|NCT00934791|Drug|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
75622553|NCT00934791|Drug|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
75776090|NCT04362475|Behavioral|Community Health through Engagement and Environmental Renewal (CHEER)|FYI and ESPI intervention activities will be implemented in the overall study, CHEER. It will also allow us to examine possible synergistic effects of both interventions when implemented in the same neighborhoods. Separate sets of participants will be selected for the FYI comparisons and for the ESPI comparisons. Because the FYI intervention focuses on mothers and their children, participants for the FYI comparisons will be selected by Respondent Driven Sampling of eligible families from the neighborhoods in all four cells. The ESPI intervention targets the whole neighborhood, and thus a random sample of neighborhood residents will be enrolled in each of the four cells. Because the primary outcomes for FYI and ESPI are connected but differ from each other, the FYI samples will be assessed for the FYI outcomes in all four cells and the ESPI samples will be assessed for the ESPI outcomes in all four cells.
75776091|NCT04346589|Biological|Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.
75776092|NCT05934357|Other|Fiber|The intervention treatment will contain fiber.
75320873|NCT04762940|Device|Robotic|"The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user."
75776093|NCT05934357|Other|Control|The control treatment will contain corn meal.
75776094|NCT05934344|Other|Action observation training|The activities proposed will be based on items from the FMA scale (Voluntary movement within synergies, voluntary movement mixing synergies, voluntary movement with little or no synergy, grip, coordination/speed, passive joint movement), and the exercises for the lower limbs will be designed by the authors of the study, based on Vivifrail (32), a multicomponent physical training program for the prevention of deconditioning and falls in older adults. These exercises will be progressive each week, focusing on strengthening, balance, and functional exercises to improve gait. The sessions will last between 20 and 30 minutes, with a frequency of three days per week. The intervention will last for 5 weeks.
75913564|NCT06150443|Other|Osteopathic manipulative treatment (OMT)|Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.
75913565|NCT06150443|Other|Conservative treatment|Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical therapy will be excluded from the conservative therapy regimen.
75913566|NCT06150417|Drug|Androgen deprivation therapy (ADT)|Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.
75320874|NCT04762940|Device|Vibration|Vibration duration of approximately 20 minutes with a high vibration frequency will be conducted prior to robotic treatment. The intensity and timing of this treatment has been based on previous protocols, as previously justified in this project. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible (high frequency vibration of 300 Hz).
75320875|NCT03627728|Drug|Regorafenib|regorafenib/placebo
75320876|NCT03627728|Other|placebo|regorafenib/placebo
75320877|NCT03704792|Device|FibroScan 530 Compact|The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
75320878|NCT04403594|Other|dry needling|dry needling followed by functional electrical stimulation and treadmill training
75622554|NCT00934791|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
75622555|NCT00934791|Drug|Prednisone|Prednisone tapered to 5 mg/day by day 92
75622556|NCT02882165|Other|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
75622557|NCT02723812|Biological|GCFLU® Influenza vaccine (Split virion, Inactivated)|
75776095|NCT05934318|Dietary Supplement|L-citrulline|Twice daily 6.0 g sachet, each containing 5.00 g of quality-assured L-citrulline powder, 0.66 g maltodextrin and 0.30 g lactose anhydrous, 0.03 g citric acid, 0.01 g lemon flavour + antenatal standard of care with enhanced monitoring
75776096|NCT05934279|Device|Resistance Training|All training exercise involve balance and strength improvement. Consist of 8 weeks of trainings per 2 trainings in each week, ongoing 45 minutes.
75913567|NCT06150417|Drug|Androgen receptor signaling inhibitor (ARSI)|Standard androgen receptor signaling inhibitors (ARSI) will be administered at the discretion of the treating physician.
75913568|NCT06150417|Other|Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)|"Local therapy will either be radiotherapy (RT) or radical prostatectomy (RP).~Prostate +/- pelvic nodal radiation~Radical prostatectomy + pelvic lymph node dissection"
75776097|NCT05934266|Device|Use of n-hexyl cyanoacrylate for mesh fixation|Mesh fixation with tissue adhesive (n-hexyl cyanoacrylate) in open hernia repair
75776098|NCT05934188|Diagnostic Test|Magnetic Resonance Imaging|The Magnetic Resonance Imaging protocol will comprise both structural and functional sequences.
75776099|NCT05934188|Behavioral|Neuropsychological protocol|Neuropsychological tests will be administered to participants to assess general cognitive state and a range of high-level cognitive functions (memory, executive, language). In addition, disease-specific tests will be administered to patients to investigate disease staging and the level of disability and autonomy.
75776100|NCT05934188|Behavioral|Eating habits|Information on eating habits will be derived from food questionnaires.
75776101|NCT05934188|Diagnostic Test|Microbiome analyses|The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).
75776102|NCT05934188|Diagnostic Test|Inflammatory markers|Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.
75776103|NCT05934188|Diagnostic Test|Alzheimer's Disease biomarkers|The Alzheimer's Disease biomarkers will be measured in the plasma of prodromal Alzheimer's Disease patients.
75320879|NCT00680953|Drug|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
75320880|NCT00680953|Drug|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
75320881|NCT00680953|Drug|Alendronate sodium hydrate|Oral tablet once a week for 24 months
75622558|NCT05268159|Other|Cognitive assessment|Assessment of unilateral spatial neglect, attention, executive functions and memory
75622559|NCT02723422|Procedure|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
75622560|NCT02723422|Procedure|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
75622561|NCT00605709|Drug|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
75776104|NCT05934123|Behavioral|EMNODN NEC Care Bundle|A care bundle created by the East Midlands Neonatal Operational Delivery Network to guide neonatal services in the region to implement practices that support own mother's milk feeding and other interventions that may reduce the risk of NEC in babies born <32 weeks' gestational age.
75776105|NCT05934110|Drug|EMP16-120/40|"EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID)."
75776106|NCT05934110|Drug|MR orlistat 120 mg|"MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID)."
75776107|NCT05934110|Drug|Conventional orlistat 120 mg,|"Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID)."
75776108|NCT05934110|Drug|EMP16-60/20|"Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)"
75776109|NCT05934110|Drug|Placebo|"Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)"
75320882|NCT03154801|Other|Paramedical care|Paramedical early detection of sexual dysfunction and sexual health counseling
75622562|NCT02882009|Drug|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
75622563|NCT02882009|Drug|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
75622564|NCT00636688|Behavioral|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
75622565|NCT00636688|Behavioral|Control - general information|General information about healthy food choices and exercise
75776110|NCT05934097|Drug|FT596|Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously
75913569|NCT06150417|Radiation|Metastasis directed radiotherapy (MDRT)|In participants randomized to the MDRT arm, MDRT to all lesions will be performed by the end of Week 24. Selection of a particular regimen (the dose and fractionation) will based on the size and location of the participant's metastatic site and the surrounding normal tissue constraints.
75320883|NCT00681031|Biological|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
75320884|NCT00660985|Drug|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
75320885|NCT00660985|Drug|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
75320886|NCT03551522|Drug|Seladelpar|10 mg, 20 mg, or 50 mg
75320887|NCT03551522|Drug|Placebos|Matching placebo Capsule
75320888|NCT03704714|Drug|Cyclophosphamide|Given IV
75320889|NCT03704714|Drug|Doxorubicin Hydrochloride|Given IV
75320890|NCT03704714|Biological|Nivolumab|Given IV
75320891|NCT03704714|Drug|Prednisone|Given PO
75320892|NCT03704714|Other|Quality-of-Life Assessment|Ancillary studies
75320893|NCT03704714|Biological|Rituximab|Given IV
75320894|NCT03704714|Drug|Vincristine Sulfate|Given IV
75622566|NCT00607035|Drug|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
75622567|NCT00607035|Drug|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
75776111|NCT05934097|Drug|Cyclophosphamide|750 mg/m^2 intravenously
75776112|NCT05934097|Drug|Doxorubicin|50 mg/m^2 intravenously
75776113|NCT05934097|Drug|Vincristine|1.4 mg/m^2 (maximum dose 2 mg) intravenously
75776114|NCT05934097|Drug|Prednisone|100 mg orally
75776115|NCT05934097|Drug|Rituximab|375 mg/m^2 intravenously
75776116|NCT05934097|Drug|Bendamustine|90 mg/m^2 IV infusion
75776117|NCT05934071|Drug|SGLT2 inhibitor|optimization of the medical therapy for heart failure with reduced ejection fraction with SGLT2 inhibitor, according to clinical guidelines
75776118|NCT05934045|Biological|RNAseq|there is no intervention done.
75776119|NCT05934032|Other|observational, non-interventional|observational, non-interventional
75776120|NCT05934006|Biological|spot urine samples|No intervention, but measurement of urinary iodine concentration by 6 repeated spot urine samples
75913570|NCT06150404|Behavioral|White Noises and Maternal and/or Paternal voices|"The intervention group will receive white noise and maternal and/or paternal voice for a maximum of 4 hours per day, alternated as follows: 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice, 1-hour break, 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice. The intervention is expected to start at 08:00 in the morning and conclude at 13:00 and will be delivered from the day after the enrollment - when the parents provide their voice recording - until the day of discharge.~The device for administering white noise and maternal and/or paternal voice will be placed approximately 30 cm from the head of the infant in the incubator and at the foot of the infant in the open crib.~The volume will be 45 dB for infants in incubators and infants in open cribs."
76025579|NCT03239587|Behavioral|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
75320895|NCT02984774|Procedure|Cystectomy|Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
75320896|NCT02984774|Procedure|Endometrial sampling|Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
75320897|NCT02984774|Procedure|Peripheric blood sampling|4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
75320898|NCT02984774|Procedure|Ovarian tissue sampling|2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
75320899|NCT02336360|Drug|Flortaucipir F18|No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.
75320900|NCT00661141|Drug|Antizol|
75320901|NCT00661141|Drug|Placebo|
75320902|NCT00661141|Other|Ethanol|oral dose of ethanol (0.5 g/kg)
75622568|NCT05060081|Other|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
75622569|NCT05060081|Other|Traditional plank exercise program group|Traditional plank exercise program group will do a warm-up for 10 minutes and then perform five exercises includes prone bridge, side bridge, supine bridge on exercise ball, prone bridge on exercise ball, superman on exercise ball. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
75622570|NCT02723266|Behavioral|STOPPING-GDM|Educational counseling and skills building Intervention
75320903|NCT03616730|Diagnostic Test|NICOM (non-invasive cardiac output monitor)|Transthoracic bio-reactance, or the non-invasive cardiac output measurement [NICOMTM, Cheetah Medical Inc., Portland, OR] system, is a new technique that is able to measure multiple hemodynamic parameters with four transdermal electrodes placed on the patients' thorax. It is based on frequency- and phase-modulation of the voltage signal measured in response to an applied transthoracic current. It has shown acceptable accuracy, precision and responsiveness for cardiac output monitoring in patients experiencing a wide-range of hemodynamic situations and is a FDA-approved device.
75622571|NCT00608439|Drug|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
75776121|NCT05933993|Other|Elective cesarean section|The study does not contain an intervention in itself, but women are included if they undergo an elective cesarean section
75776122|NCT05933980|Drug|Sinti+Rego+Cele|combination of sintilimab,regorafenib and celecoxib
75776123|NCT05933928|Other|Simulation-based electronic fetal monitoring training|"Practices will be carried out with the students in the intervention group with the NOELLA Birth Simulator, which is a high-reality simulator located in the Simulation laboratory of the Department of Midwifery of the Faculty of Health Sciences of Hamidiye. A simulator will be practiced with a separate scenario including early, late, variable deceleration, reactive, sinusoidal and non-reactive trace interpretation and intervention."
75776124|NCT05933915|Other|group-based laughter yoga|"Midwives in the intervention group of the research will apply 8 sessions of laughter yoga, 2 sessions a week. Laughter yoga will be practiced by researchers with leadership certification. Each session will take an average of 45 minutes. Laughter Yoga sessions will be held on the web through the Zoom program. Each session will consist of groups of 8 people."
75776125|NCT05933876|Diagnostic Test|To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).|Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
75776126|NCT05933876|Diagnostic Test|To propose a diagnostic test to determine the effectiveness of SABR.|Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
75776127|NCT05933876|Diagnostic Test|To propose a diagnostic test for Oligometastatic Cancer (OC).|Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
75622572|NCT00608439|Other|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
75622573|NCT02693236|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
75622574|NCT04265313|Other|Measurement of Quality of Life|Quality of life will be measured using The Neck Dissection Impairment Index, Modified Constant-Murley Score, Short Form-36 Health Survey version-2.0.
75622575|NCT02722954|Drug|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
75622576|NCT02722954|Drug|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
75622577|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
75466478|NCT01909882|Other|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
75622578|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
75622579|NCT04262973|Other|education|six-hour dementia care course
75622580|NCT04262973|Other|education and workshop|six-hour dementia care course, half-day interprofessional education workshop, and interprofessional practice
75622581|NCT00625859|Drug|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
75622582|NCT00625859|Drug|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
75622583|NCT00625859|Drug|Placebo|Placebo tablets will be given to subjects.
75622584|NCT02723110|Other|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
75622585|NCT02723110|Other|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
75622586|NCT04262739|Drug|NYH817G|Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
75622587|NCT04262739|Drug|NYH100P|Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
75622588|NCT04262739|Drug|NYH817G and NYH100P|Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
75622589|NCT02691195|Drug|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
75622590|NCT02691195|Drug|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
75622591|NCT02723032|Device|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
75622592|NCT02722876|Other|Contralateral Rehabilitation|Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
75622593|NCT02722876|Other|Placebo flexibility exercise|Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
75622594|NCT04131946|Other|Community-Based (Intervention Arm)|Community dispensed FIT
75466479|NCT01909908|Device|ECM|ECM in saline applied to wound
75466480|NCT01909908|Biological|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
75622595|NCT03808090|Other|Normal Individuals|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
75622596|NCT03808090|Other|Calcium Oxalate Kidney Stone Formers|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
75622597|NCT03808090|Other|Type 2 Diabetes|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
75622598|NCT03808090|Other|Type 2 diabetic kidney stone formers|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
75622599|NCT02722642|Biological|Bronchial basal cells|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
75622600|NCT02722720|Procedure|Transradial carotid artery stenting|The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
75798366|NCT01273584|Drug|Placebo|Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
75776128|NCT05933863|Drug|PD-(L)1 antibody immunotherapy|The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
75320904|NCT03702764|Diagnostic Test|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.
75622601|NCT02722720|Procedure|Transfemoral carotid artery stenting|The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
75622602|NCT01111019|Drug|Recombinant human growth hormone (r-hGH)|Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
75622603|NCT02883400|Drug|Spironolactone|spironolactone 25 mg up to 50 mg
75622604|NCT01119287|Drug|Dexamethasone 0.1% ophthalmic suspension|Maxidex
75466481|NCT01909908|Device|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
75913571|NCT06150391|Device|Visionary: computer exercises using dichoptic Gabor Patches and band-filtered noise masks|Visionary exercises are computer gammified activities that run on a computer with internet connection to facilitate home therapy. Patient must wear anaglyph glasses. Visual stimuli consists in dichoptic Gabor Patches presented to the amblyopic eye. Frequency is adjusted to actual patient visual acuity, and contrast to actual patient performance (contrast sensitivity). A band-filtered noise mask at the same frequency than the Gabor patch is presented to the fellow eye in certain ocassions.
75776129|NCT05933837|Diagnostic Test|Troponin I|Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.
75776130|NCT05933811|Procedure|exploratory laparoscopy|Laparoscopic exploration for impalpable maldescended testis in pediatric age group
75913572|NCT06150391|Device|Patching|PEDIG (Pediatric Eye Disease Investigator Group) recommended amblyopia treatment. Consist on covering a child's better-seeing eye with a patch for 2 hours per day for mild and moderate amblyopia or 6 hours per day for severe amblyopia
75320905|NCT03616574|Drug|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).
75466482|NCT01909947|Other|Cardiorespiratory signal acquisition|"Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~A 60-minute period while the infant receives any mode of conventional mechanical ventilation~A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant"
75776131|NCT05933798|Other|ICOPE|The ICOPE approach with locally adapted care pathways was implemented by trained integrated care managers (ICMs) advised by multi-disciplinary teams, delivered in primary care settings
75622605|NCT01119287|Drug|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
75622606|NCT01119287|Other|Inactive ingredients, used as placebo|Tears Naturale II
75776132|NCT05933798|Other|Usual Care|Participants in the Control Group would have their care plan after assessment and seek health and care services as usual without additional advice or support on implementing the care plan
75776133|NCT05933785|Procedure|transanal endoscopic ISR|perform ISR using laparoscopy through transanal port
75913573|NCT06150378|Drug|Corticosteroid|Patients that receive an injection with corticosteroid
75320906|NCT03616574|Drug|LONSURF|LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.
75320907|NCT00681265|Drug|glycerin|Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
75320908|NCT00681265|Drug|polyethylene glycol 400/propylene glycol|Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
75320909|NCT03548324|Device|HHHFNC|Application to HHHFNC to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
75320910|NCT03548324|Device|NCPAP|Application to NCPAP to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
75320911|NCT01677104|Drug|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
75320912|NCT01677104|Drug|Placebo|
75320913|NCT00661453|Drug|Valproic Acid and Levocarnitine|Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
75622607|NCT02694172|Other|Fiber rich cereal bars|Two cereals per day and per subject for 4 weeks
75622608|NCT01110707|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day [mg/day]).
75622609|NCT01110707|Drug|Recombinant human luteinizing hormone (r-hLH)|Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
75622610|NCT03772600|Device|Dexcom G6 CGM|Use of Dexcom G6
75622611|NCT04931368|Drug|Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix|De-escalated induction treatment with R/HD-MTX and two courses of MATRix
75913574|NCT06150378|Biological|Plathet rich plasma|Patients that receive an injection with Plathet-rich plasma
75913575|NCT06150365|Biological|KSX01-TCRT cell therapy|Patient autologous T cell therapy
75913576|NCT06150352|Device|Continuous Positive Airway Pressure or other management for OSA per clinical indications.|PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria
75622612|NCT04931368|Drug|Control intervention: four courses of MATRix|Patients receive four courses of MATRix as induction treatment.
75622613|NCT02694250|Device|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
75913577|NCT06150339|Other|OASIS Walking Intervention|Communication Care Plan, Sit to Stand Activity, Walking Program
75913578|NCT06150326|Device|medical honey Activon® 25g Tube|no blinding procedures will be set up for the adminisration of the treatement
75913579|NCT06150326|Device|standard of care|no blinding procedures will be set up for the adminisration of the treatement
75913580|NCT06150313|Behavioral|Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T)|"This is a 36-hour group training involving 4 theoretical + 11 practice online sessions using video-feedback, the core component of MISC original trainings.~Session 1: MISC presentation; Session 2: Bases of the interaction and MISC culture-context components; Session 3: The emotions in the interaction and MISC emotional components; Session 4: MISC cognitive components and implications for learning; Session 5: Practice with you-tube examples of interaction; Session 6: Practice with trainer's examples of video-feedback. Sessions 7 to 14: Practice with participants' video-recordings. Session 15: End of the intervention, last video-feedback training and preparing for post-assessment."
76025580|NCT01674647|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
76025581|NCT01674647|Drug|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
76025582|NCT02669407|Procedure|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
75320914|NCT03547622|Drug|MAT taper with galantamine|Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
75320915|NCT03547622|Drug|MAT taper with placebo|Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
75466483|NCT01909960|Other|Flow imaging|"Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in Larson's score and MMSE"
75466484|NCT01909986|Drug|[14C]ONO-4053|Single dose [14C]ONO-4053
75622614|NCT01119131|Drug|Vitamin D3|Vitamin D3 at 10,000 IU a day
75622615|NCT01119131|Dietary Supplement|calcium|1000mg calcium daily
75622616|NCT01119131|Other|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
75622617|NCT00636922|Drug|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
75622618|NCT02722252|Device|Embryoscope|
75622619|NCT02722252|Device|Embryo culture system without incorporated camera|
75622620|NCT02722096|Drug|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
76025583|NCT02669407|Drug|regional nerve block with a local anesthetic (Lidocaine)|
75320916|NCT00681889|Drug|Ranibizumab|10 Patients will receive treatment (Ranibizumab)
75622621|NCT02722096|Drug|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
75622622|NCT04893538|Diagnostic Test|First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
75622623|NCT04893538|Diagnostic Test|First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
75622624|NCT04862962|Drug|Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose|Oral Tablets 10 mg/10 mg or 20 mg/10 mg
76025584|NCT02388139|Procedure|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
76025585|NCT02388139|Procedure|coronarography|
76025586|NCT02388139|Procedure|coronary angioplasty|
75776134|NCT05933759|Behavioral|Telemedical coaching|Individual telemedical coaching delivered by a nutritional consultant
75776135|NCT05933759|Behavioral|Low-Insulin-Method|Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps
75776136|NCT05933720|Drug|Polypeptides|The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
75622625|NCT01118975|Drug|Vorinostat|"300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
75776137|NCT05933720|Device|Femoral-popliteal bypass grafting with a synthetic graft above the knee|The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee
75776138|NCT05933720|Other|Routine conservative treatment|The patients will undergo routine conservative treatment as per clinical guidelines (acetylsalicylic acid 100mg daily, atorvastatin 20mg daily)
75622626|NCT01118975|Drug|Lapatinib|1,250 mg once daily
75320917|NCT03697538|Procedure|Nerve Block for pain control post-revision total knee arthroplasty|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
75776139|NCT05933694|Other|ArtiQ.Spiro diagnostic and quality assessment report|ArtiQ.Spiro diagnostic and quality assessment report
75776140|NCT05933668|Biological|YK0901 cells|On day 0, the TCR-T cells will be administered one time. Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 300mg/m²/day×3 days Oxaliplatin：100mg×1day Drug: IL-2 After 18-24 hours of infusion of YK0901 cells, the patients will be given a small dose of IL-2 subcutaneously, 500,000 IU/time, twice a day (interval 10-12 hours), for 14 days.
75776141|NCT05933655|Behavioral|Peer Coach|Peer coaching session to support shared decision making among patient with limited health literacy.
75776142|NCT05933629|Behavioral|Online EmReg|A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
76073353|NCT02992834|Biological|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
75776143|NCT05933629|Behavioral|Consultation Sessions|3 months of bi-weekly consultation sessions
75776144|NCT05933590|Diagnostic Test|Cervical Joint Repositioning Error Assessment|The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.
75776145|NCT05933564|Other|No intervention (cross-sectional study)|This is a cross-sectional study examining the association between cognitive reserve, pain catastrophizing, and cognitive function in geriatric patients with chronic pain; no intervention is being implemented or tested.
75776146|NCT05933551|Other|Z Technique Training|Training on Z technique will be given on the planned day, time and place. The education is planned to be given at Tarsus University. The training content will be presented to the participants as a powerpoint presentation (30 min), laboratory practice (15 min) and question-answer (15 min).
75320918|NCT02869945|Genetic|Identification of COMT HH, COMT HL or COMT LL genes|COMT HH, COMT HL or COMT LL genes identification
75320919|NCT02869945|Other|Brain MRI with resting state scan|MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
75622627|NCT02722018|Drug|GDC-0810 Phase II Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
75622628|NCT02722018|Drug|GDC-0810 Phase III Prototype Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
75622629|NCT04310111|Procedure|EUS-RFA|Use EUS-RFA to treat unresectable pancreatic cancer
75776147|NCT05933512|Biological|SCTV01E-2|intramuscular injection
75776148|NCT05933512|Biological|SCTV01E|intramuscular injection
76025587|NCT02388139|Procedure|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
76025588|NCT02388139|Procedure|body composition monitoring|using Fresenius device
76025589|NCT05135741|Device|pressure bio feedback|The pressure biofeedback unit was placed between the plinth and the posterior aspect of the neck just below the occiput and inflated to a baseline of 20 mmHg. A trained physiotherapist was observing and correcting any substitution movements to ensure that all subjects could perform the exercises correctly. All exercise protocols and programs were taken from previously published studies8-10. A conventional DCF exercise protocol was performed three times a week for four weeks in both groups. The duration of the conventional DCF exercise protocol was 20-30 minutes, once a day in the control group, and 15-20 minutes, once a day in the experimental group
75320920|NCT02869945|Other|Brain MPET|Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
75622630|NCT02721940|Procedure|Control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
75622631|NCT02721940|Biological|Mononuclear Cells|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
75622632|NCT02721940|Biological|Platelets|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
75622633|NCT02721940|Drug|Zoledronic Acid|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
75622634|NCT02721940|Drug|Normal saline|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
75622635|NCT04851340|Other|Cow's Milk|Participants will consume 200 mL, 300 mL, and 400 mL of 1% bovine milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
75622636|NCT04851340|Other|Soy Milk|Participants will consume 200 mL, 300 mL, and 400 mL of soy milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
75622637|NCT04829422|Drug|Lazertinib 240 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
75622638|NCT04094350|Other|ACF with a seed-and-recruit model|The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
75622639|NCT04094350|Other|ACF targeting household and neighborhood contacts|In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
75622640|NCT04094350|Other|ACF targeting the older population using mobile screening units|The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
75622641|NCT04094350|Other|Passive case finding|Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
75622642|NCT01110239|Procedure|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
75622643|NCT02721862|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
75622644|NCT02721862|Drug|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
75622645|NCT02721862|Radiation|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
75913581|NCT06150313|Behavioral|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 36-hour individual training involving 25-weekly online, individual, self-administered 50' sessions (21h) + 4 online 1.5-hour group meetings with a supervisor (6h) and 9h of between sessions work (readings, video-recordings for later video-feedback, reflection exercises). Session 1 (Supervisor): Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC: Session 9 (Supervisor): Summary, online group exercises and keys for forward recordings; Sessions 10-11 (Christmas Homework): Recording daily life interactions; Sessions 12-17 (SA): guided reflection with video-feedback; Session 18 (Supervisor): Control session for doubts and video-feedback group training. Sessions 19-28 (SA): guided reflection with video-feedback. Session 29 (Supervisor): Final online video-feedback group training.
75913582|NCT06150313|Other|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|This is an equivalent 36-hour online self-administered training involving 27 x 45' individual online sessions (20.25h), mostly based on reflection exercises around brief readings, animated shorts, or pills, but not video-feedback. This is complemented with 2 x 1.5h online group face-to-face sessions with a supervisor (3h) and 13h of between-sessions work based on looking for new information, adult-child activities (but not for video-feedback) or out-of-line guided reflective exercises. Session 1 (Supervisor): group meeting for program presentation; Sessions 2-28 (Self-Administered): Online self-administered sessions doing readings or watching pills; Session 29 (Supervisor): Final doubts session to close de course.
76025590|NCT02667457|Radiation|99mTc-rhAnnexin V-128|
75913583|NCT06150300|Behavioral|Pulmonary rehab program|Exercise videos, breathing exercises, and educational messages delivered virtually
75913584|NCT06150300|Behavioral|Placebo|Breathing exercises and educational messages
75913585|NCT06150287|Other|Florajen Digestion|Florajen Digestion is a probiotics. One probiotics capsule contains 15 billion Colony Forming Unit (CFU) of live microorganisms. No live microorganisms are present in the placebo capsules.
75913586|NCT06150274|Device|Percutaneous Balloon Mitral Valvulotomy|Stenotic mitral valve will be dilated to open the commissures
76073354|NCT01276210|Drug|sorafenib tosylate|Given PO
75320921|NCT03610022|Drug|Treatment with vismodegib|Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
75320922|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
75320923|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
75320924|NCT00682357|Drug|Placebo and Lidocaine|Placebo and lidocaine 20 mg
75320925|NCT00662155|Drug|Zolpidem|sedative-hypnotic
75622646|NCT00612898|Drug|apricitabine|800mg BID apricitabine orally for 48 weeks
75622647|NCT00612898|Drug|lamivudine|150mg BID lamivudine orally for 48 weeks
75776149|NCT05933486|Drug|Tongluo-Kaibi tablet plus placebo of pregabalin|Tongluo-Kaibi Tablet 0.93g qd； Placebo of pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
75913587|NCT06150261|Dietary Supplement|AvailOm|5 capsules taken once daily with main meal
75913588|NCT06150261|Dietary Supplement|Placebo|5 capsules taken once daily with main meal
75913589|NCT06150235|Other|Data collection|Data collection
75913590|NCT06150209|Device|Vendaje|Dehydrated Human Amniotic Membrane
75913591|NCT06150196|Behavioral|Mindfulness-based Stress Reduction class|9-week standard Mindfulness-based Stress Reduction class training on mindfulness techniques, medication, and yoga
75913592|NCT06150196|Behavioral|Brain Health Education class|9-week Brain Health education class that involves lectures/discussion about how the brain works and recovers after brain injury
75913593|NCT06150131|Other|Exercise|Aerobic and strength exercise.
75913594|NCT06150131|Other|Exercise|Aerobic and strength exercise.
75913595|NCT06150079|Procedure|Pes-Guided PEEP titration|Lung recruitment is performed at each time point, involving a switch from volume-controlled (VCV) mode to pressure-controlled (PCV) mode with a pressure setting of 20 cmH2O, RR of 15 bpm, I:E ratio of 1:1, FiO2 of 0.4, and PEEP of 5 cmH2O. During lung recruitment, PEEP is gradually increased in increments of 5 cmH2O, maintained for 5 respiratory cycles until PEEP reaches 20 cmH2O and airway pressure reaches 40 cmH2O, and then maintained for 10 respiratory cycles. After lung recruitment, ventilation is adjusted based on the target PEEP. Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability. PEEP is chosen to maintain a positive transpulmonary pressure at end-expiration (Ptp_ee = PEEP - Pes_ee). Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability.
75320926|NCT00662155|Drug|Placebos|Placebo
75622648|NCT01118663|Drug|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
75622649|NCT01118663|Drug|Acetadote|Acetadote [old formulation] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
75622650|NCT02721706|Other|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h <50%, serum albumin <3 g/dl, body mass index <18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
75622651|NCT02721784|Device|mpMRI/VERDICT|Combined MRI sequences of T2, DCE, Diffusion and VERDICT
75622652|NCT02721784|Radiation|External Beam Radiotherapy|78Gy (Gray) to Prostate +/- Pelvic
75622653|NCT01118351|Drug|sunitinib malate|Given orally
75622654|NCT01118351|Other|immunohistochemistry staining method|Correlative studies
75622655|NCT01118351|Other|TdT-mediated dUTP nick end labeling assay|Correlative studies
75622656|NCT01118351|Other|light microscopy|Correlative studies
75622657|NCT01118351|Other|laboratory biomarker analysis|Correlative studies
75622658|NCT04188496|Other|Pulmonary Function Test group|The interventional group received the same conventional Chest physiotherapy Techniques for 30 minutes followed by 10 minutes rest. The patients then received additional 15 minutes protocol of thoracic joint mobilization
75776150|NCT05933486|Drug|placebo of Tongluo-Kaibi tablet plus pregabalin|placebo of Tongluo-Kaibi Tablet 0.93g qd； Pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
75776151|NCT05933473|Procedure|Percutaneous coronary intervention|percutaneous intervention to oseal LAD with or without LM stenting
75776152|NCT05933460|Dietary Supplement|dietary supplement with probiotics, prebiotics, magnesium and saffron extract|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Saffron extract 28mg was administered 3 times per day
75913596|NCT06150066|Other|Recruiting samples|The GCF, plaque, and saliva samples will recruited from participants.
76073355|NCT01276210|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
76073356|NCT01276210|Other|laboratory biomarker analysis|Correlative studies
76073357|NCT00727636|Biological|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
76073358|NCT01270750|Drug|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
75913597|NCT06150027|Other|Systematic referral to a palliative care team|"Patients randomized in the experimental arm will be systematically referred to a palliative care team.~A follow-up in palliative care will be initiated for all within a maximum of 15 days after the date of randomization."
76073359|NCT00709696|Drug|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
76073360|NCT00709696|Drug|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
75622659|NCT04188496|Other|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
75622660|NCT04034134|Drug|Jaktinib Hydrochloride Tablets|50 mg twice-daily (BID)
75622661|NCT04034134|Drug|Jaktinib Hydrochloride Tablets|150 mg quaque die (QD)
75622662|NCT04034134|Drug|Jaktinib Hydrochloride Tablets|200 mg quaque die (QD)
75622663|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® (5 billion CFU/capsule)|One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
75776153|NCT05933460|Dietary Supplement|dietary supplement with probiotics, prebiotics, magnesium|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg was administered 3 times per day
75776154|NCT05933447|Drug|Rodatristat Ethyl|Oral, Tablet, 300 mg QD, 300 mg BID, 600 mg BID, 900 mg BID, 900 mg QD
75776155|NCT05933447|Drug|Moxifloxacin|Oral, Tablet, 400 mg QD
75776156|NCT05933447|Drug|Placebo for Rodatristat|Oral, Tablet, O mg QD, 0 mg BID
75776157|NCT05933447|Drug|Placebo for Moxifloxacin|Oral, Tablet, 0 mg QD
76073361|NCT01270906|Drug|CHIR-258 (TKI258)|
76073362|NCT01270984|Drug|Luckyvec 400mg film coated tablet|•400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
76073363|NCT01270984|Drug|Glivec 100mg film coated tablet|•100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
76073364|NCT01276366|Other|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
76073365|NCT01276366|Other|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
76073366|NCT01276366|Other|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
76073367|NCT02992678|Drug|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
76073368|NCT02992678|Drug|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
76073369|NCT01276444|Device|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
76073370|NCT01276444|Device|transpulmonary thermodilution + central venous saturation|Described in details above
76073371|NCT01271062|Procedure|gastric bypass surgery|
75622664|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)|One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
75622665|NCT02693314|Dietary Supplement|Placebo|One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
75622666|NCT02693392|Drug|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~Sulfonylurea based oral hypoglycemic agents~Metformin based oral hypoglycemic agents~Metformin plus Sulfonylurea based oral hypoglycemic agents"
75622667|NCT02693392|Dietary Supplement|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
75913598|NCT06150001|Drug|rocuronium-normal-saline mixture|rocuronium will be pre-diluted with 2mL of normal saline. Researchers will inject the mixture into intravenous catheter.
75913599|NCT06150001|Drug|rocuronium-lidocaine mixture|rocuronium will be pre-diluted with 2mL of 2%lidocaine. Researchers will inject the mixture into intravenous catheter.
75913600|NCT06150001|Drug|rocuronium-blood mixture|Researchers will connect a syringe which contains 0.8mg/kg of rocuronium intravenous catheter, and then withdraw blood into the syringe. Finally inject the mixture into intravenous catheter.
75913601|NCT06149988|Drug|THC/CBD S.E powder|A single dose of THC/CBD S.E powder- 500 mg, given orally.
75913602|NCT06149988|Drug|THC/CBD oil|Followed by a 30-day washout- A single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
76073372|NCT01271062|Procedure|abdominal surgery|
76073373|NCT01271062|Behavioral|very low caloric diet|
76073374|NCT02992912|Drug|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
76073375|NCT02992912|Procedure|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
76073376|NCT01276522|Drug|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
76073377|NCT02992444|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
76073378|NCT02992444|Other|Experimental adhesive strip|This is a strip of a newly developed adhesive.
75913603|NCT06149975|Other|motor-cognitive training|"The motor-cognitive training in this study will be conducted in form of a step-based dual-task training. A mat (approximately 90 x 90 cm) made from extra non-slip yoga mats is required. The mat is divided into 9 equal squares with a 3 x 3 pattern. Participants will be presented with stepping patterns which they must memorize and then execute on the mat in the pace given by a metronome. All participants will start at the same level. The progression will be adjusted individually according to the fixed criteria of the StepIt concept within the sessions. All sessions will be supervised by at least one physical therapist."
75913604|NCT06149962|Procedure|FLEXOR TENDON REPAIR|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture under WALANT technique and brachial plexus block.
76073379|NCT01271140|Drug|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
75622668|NCT04175626|Device|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
75622669|NCT00613054|Drug|Zactima, Gleevec, Hydroxyurea|"Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate & hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs & 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate & that such doses are safe & well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety & pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate & hydroxyurea for 28 days for purpose of scheduling evaluations."
75622670|NCT04687696|Other|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions.This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
76073380|NCT01271218|Other|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
75622671|NCT04687696|Other|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
75622672|NCT04687696|Other|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
75776160|NCT05933369|Behavioral|Clincal pharmacist intervention|Patients in the intervention group will receive a protocol-defined intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits for education on disease and treatment 40 minutes, administration and dosage 6 minutes, drug interaction and other drug therapy problems 20 minutes for a total of 66 minutes. The intervention will include education about asthma triggers and the need of minimizing them, asthma symptoms, warning signs, proper inhalation use technique, cigarette smoking cession when appropriate, the need of adherence and they will also counseled to wash their mouth after the use of controller medications. In addition, pharmaceutical care evaluation will be carried out and any drug therapy problems will be addressed accordingly and finally every intervention provided will be recorded.
75776161|NCT05933356|Behavioral|playing exergames|"will be provided with the individual brain training exergames three times a week and 30 minutes each time"
75776162|NCT05933356|Other|scheduled activities|scheduled activities
75913605|NCT06149949|Other|Observational study|the aim of the study is to define the prevalence of rhinosinusitis cronic in intestinal bowel disease patients, to assess how it affects the patient's quality of life, and any correlations between these two entities
75913606|NCT06149936|Device|excimer light|Excimer laser using high-dose monochromatic UV radiation
75913607|NCT06149923|Genetic|quantitative Real-time PCR|: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems
75913608|NCT06149910|Other|Multiple Myeloma Pathway|Use and adherence to a multiple myeloma pathway.
75913609|NCT06149910|Other|All4Cure Platform|Participant in the All4Cure platform.
75913610|NCT06149910|Other|Documentation Pathway|Use of multiple myeloma pathway through written documentation.
75913611|NCT06149897|Device|tDCS|Non invasive brain stimulation with sham and active comparators
76088919|NCT00983619|Drug|Rituximab|Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
75622673|NCT04167436|Other|Prehabilitation|A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
75622674|NCT00613132|Drug|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort & will be increased to 600 mg po/day & then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 & hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
75913612|NCT06149884|Procedure|Sentinel lymph node biopsy, axillary lymph node dissection|"SLNB was performed using single or dual tracers. For the single tracer technique, Technetium 99, a radioactive substance, was administered periareolarly prior to surgery, and SLNs were identified intraoperatively via a gamma detection system (Neoprobe®). The dual tracer method employed both an isosulfan blue dye and Technetium 99 concurrently. The choice of SLNB technique was contingent upon the surgeon's discretion. SLNs were categorized as one or multiple, and any LN identified by either or both methods was defined as SLN. LNs resected during SLNB without tracer signal were not classified as SLNs.~ALND was characterized by the removal of all LNs in axillary levels I and II. Patients documented to have undergone ALND in surgical records were primarily selected from our registry. Among them, those with fewer than 10 LNs were excluded, based on the assumption that a competent ALND necessitated the removal of 10 or more LNs as defined in previous studies"
75622675|NCT03712852|Procedure|PRF+CAF treated patients|Patients will be treated by coronally advanced flap with addition of PRF membrane
75913613|NCT06149871|Behavioral|Physical activity|resistance, aerobic, and flexibility exercises
76073381|NCT01271218|Other|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
75622676|NCT03712852|Procedure|SCTG+ CAF treated patients|Patients will be treated by coronally advanced flap with addition of SCTG graft
75622677|NCT03712852|Procedure|CAF treated patients|Patients will be treated by coronally advanced flap
75622678|NCT00613444|Device|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
75622679|NCT04143100|Other|Survey|For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
75622680|NCT04558216|Drug|Vonoprazan|20 mg tablets administered orally
75622681|NCT04558216|Drug|Rifampin|600 mg (Two 300 mg capsules)
76073382|NCT01271296|Dietary Supplement|Liquorice|24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
75320927|NCT03546608|Drug|Tepotinib|Participants will receive a single oral dose of tepotinib in Part 1.
75622682|NCT04132180|Other|Early Mobilization|Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
75622683|NCT04132180|Other|Late Mobilization|The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
75776163|NCT05933343|Procedure|Ethibond suture|An Ethibond™ 1 suture will be placed as a drainage seton for complex anal fistula
75776164|NCT05933343|Procedure|Vessel loop|A vessel loop will be placed as a drainage seton for complex anal fistula
75776165|NCT05933317|Diagnostic Test|Functional lung MRI|Functional lung MRI
75776166|NCT05933304|Biological|mRNA-1273|Sterile liquid for injection
75776167|NCT05933291|Drug|steroid|Moderate- or high-dose steroids
75622684|NCT04120870|Drug|Etomidate Injection 0.2 mg/kg|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
75622685|NCT04120870|Drug|Ketamine injection 2 mg/kg|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
75622686|NCT01118117|Device|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
75622687|NCT00613522|Other|polygraphic study|"Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale > 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview"
75622688|NCT04310657|Diagnostic Test|mNGS|Metagenomics second generation sequencing technology
75622689|NCT03747562|Drug|Gabapentin|Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
75776168|NCT05933252|Other|Augmented reality (AR)|an app on an iPad every 15 minutes
75776169|NCT05933239|Drug|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
75776170|NCT05933213|Drug|Mescaline sodium enteric-coated tablets|Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d
75776171|NCT05933213|Drug|Morte-mescaline|Induction period: orally, twice a day, 1-2 g/d; Maintenance period: orally, twice a day, 0.5-0.75 g/d
75776172|NCT05933213|Drug|Glucocorticoids|glucocorticoids
75776173|NCT05933135|Drug|Factor XIII Injection|Patients could have had an Factor XIII Injection in clinical routine
75776174|NCT05933122|Other|sexologist consult|"in the cohort called here, after the diagnosis of rectal cancer, patients will be seen by a sexologist before any kind of treatment for rectal cancer. Sexual dysfunctions will be assessed by a sexologist. After the surgery of rectal cancer, the sexologist will see them again to assess sexual dysfunctions after such a management of rectal cancer. If there is any discovery of a sexual dysfunction or aggravation of a previous one or alteration of sexual life, the sexologist will help the patients to improve their sexual quality of life."
75913614|NCT06149858|Procedure|hernioplasty|ventral hernia repair with mesh
75913615|NCT06149845|Procedure|Full Pulpotomy|Pulpotomy is a more conservative pulp treatment option where only the coronal pulp is removed and a medicament placement over the remnant radicular pulp after haemostasis is achieved.
75913616|NCT06149832|Biological|Mesenchymal Stem Cells (MSCs)|The patient's mouth (including buccal mucosa, tongue and lip) was applied with MSCs: MSCs (1×10^6/ml) dressing was applied 4 times/day for 2 weeks.
75913617|NCT06149806|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
76073383|NCT01271296|Dietary Supplement|Grapefruit Juice|200 ml pink grapefruit juice three times a day, taken orally, for three days.
76073384|NCT01271374|Drug|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
76073385|NCT01271374|Drug|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
76073386|NCT00710944|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
76073387|NCT01271530|Other|Upper Limb Ergometry|Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
76073388|NCT01271608|Device|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
76073389|NCT01276834|Drug|everolimus|comparison of everolimus-based and CNI-based immunosuppression
76073390|NCT01276912|Drug|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
76073391|NCT01276912|Behavioral|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
76073392|NCT00728260|Biological|None administered in this study|N/A in this study
75622690|NCT03747562|Other|Placebo|Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
75776175|NCT05933122|Other|standart of care|"in the cohort called elsewhere , patients will be treated according to standards of care, without specific care by a sexologist"
75776176|NCT05933070|Biological|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent. INKumne is a replication-incompetent tumor cell line that does not require donor matching.
75776177|NCT05933031|Drug|Tegoprazan 50 mg Triple Therapy|Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
75776178|NCT05933031|Drug|Tegoprazan 100 mg Triple Therapy|Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
75776179|NCT05933031|Drug|Lansoprazole Triple Therapy|Lansoprazole/Clarithromycin/ Amoxicillin BID peroral, 14 days
75776180|NCT05933018|Diagnostic Test|liver elastography|the imaging of the liver will perform in the fasting state, in the morning hours by one specialist, dedicated to this procedure,
75776181|NCT05932979|Drug|L-arginine|L-arginine 2-amino-5-guanidino-pentanoic acid is a proteinogenic amino acid that is a natural constituent of the protein diet.
75776182|NCT05932979|Other|Placebo|Starch
75913618|NCT06149780|Device|Patients treated with laser|Patients treated with laser with topical steroid Patients treated with laser with vehicle
75913619|NCT06149767|Drug|Adebrelimab|"The medication regimen for all enrolled patients is as follows, and the dose can be adjusted during treatment due to adverse reactions and other circumstances:~Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.~First of all, after 2 cycles of concurrent chemoradiotherapy, the sequential chemotherapy combined with adbalizumab for 2-4 cycles, and the subsequent investigators selected Adbalizumab or other drugs to maintain the treatment according to the patient's situation or the patient's own will until the disease progressed or intolerable toxicity occurred or the subjects voluntarily withdrew from the study.adebrelimab until disease progression or intolerable toxicity or the subject voluntarily withdrew from the study。"
75913620|NCT06149754|Device|BraiN20(R) monitoring of N20 somatosensory evoked potential|N20 monitoring will be carried out using the BraiN20 medical device and appropriate electrodes. The device measures one N20 wave per 33 seconds. Scalp electrodes will be located on band and wrist electrodes on a globe. The device provides an automatic reading of N20 and outcome prediction and do not require a specific training.
75913621|NCT06149715|Device|Bottle Filter|The household is given a Sawyer Squeeze Water Filtration System.
76073393|NCT01276990|Drug|BI 224436|Oral drinking solution
75776183|NCT05932953|Other|questionary|questionary about cutaneous tolerance
75913622|NCT06149715|Device|Bucket Filter|The household is given a Sawyer International Bucket System, which is a Squeeze Water Filtration System that is integrated with a hose and bucket.
76073394|NCT01276990|Drug|BI 224436|Oral drinking solution
75622691|NCT04510246|Behavioral|Enhanced case management|"The health care worker will offer support to the GP for all aspects of the cascade of hepatitis C care including:~Further testing advice~Awareness that treatment can be prescribed by the general practitioner~Conducting pre-treatment work-up assessment~DAA prescription guidelines, including linkage to specialist consultation~Providing treatment support~Advising on testing process for cure~Advising on post-cure management including methods of follow-up to manage risks (e.g. harm minimisation, reducing re-infection risk, opioid substitution therapy)~Linking GP to resources for patients with cirrhosis or other concerns to specialist support for ongoing management.~The GP will be offered the option of the DoH specialist to contact the patient directly with the GP's consent to notify them of their result and to educate them on testing and treatment options and referral back to their GP."
76073395|NCT01276990|Drug|BI 224436|Oral drinking solution
75622692|NCT01109849|Behavioral|behavior therapy|combination of individual and group parent training plus school consultation
76073396|NCT01276990|Drug|BI 224436|Oral drinking solution
75622693|NCT01109849|Drug|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
75622694|NCT01109849|Other|monitoring|monthly weight, height and BMI checks
75622695|NCT01109849|Other|drug holiday|switch from seven day a week dosing to medication only on school days
75622696|NCT01109849|Dietary Supplement|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
75622697|NCT04094662|Drug|Mirogabalin|Mirogabalin tablets for oral administration
75622698|NCT04094662|Drug|Placebo|Matching placebo tablets for oral administration
75622699|NCT01061736|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75913623|NCT06149715|Device|Tap Filter|The household is given a Sawyer Tap Water Filtration System.
75913624|NCT06149702|Other|Keep-on-Keep-Up|Keep-On-Keep-Up (KOKU) programme in the app will be used by the participants for 6 weeks and outcome assessments will be performed at baseline and 6 weeks of use
75913625|NCT06149676|Drug|Saccharomyces Boulardii 250 MG [Florastor]|All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
75913626|NCT06149663|Drug|LP352|LP352 will be administered as a liquid either orally or through a G-tube or PEG tube.
75622700|NCT01061736|Drug|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75622701|NCT01061736|Drug|Methotrexate|Same weekly dose as received prior to enrollment
75622702|NCT01061736|Drug|Folic Acid|According to local standard
75776184|NCT05932927|Biological|Proteomic sequencing|Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups
75913627|NCT06149637|Procedure|Traditional neck dissection approach|.1. A transverse cervical incision is made with horizontal extension towards the affected side. 2. It is dissected through the subplatysmal plane, the posterior edge of the sternocleidomastoid muscle is dissected along its entire length. 3. Identification and dissection of the spinal nerve at Erb's point. 4. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it 5. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level 6. Identification and dissection of level III nodes 7. Identification and dissection of level IIA and IIB ganglia with identification and preservation of the accessory nerve.
76073397|NCT01276990|Drug|BI 224436|Oral drinking solution
76073398|NCT01276990|Drug|BI 224436|Oral drinking solution
76073399|NCT01276990|Drug|BI 224436|Oral drinking solution
76073400|NCT01276990|Drug|BI 224436|Oral drinking solution
76073401|NCT01276990|Drug|BI 224436|Oral drinking solution
75622703|NCT04083820|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
75622704|NCT02881463|Other|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
75622705|NCT02881541|Procedure|Enhanced support|
75622706|NCT02881541|Procedure|Usual care|
75622707|NCT04058782|Other|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
75622708|NCT01117337|Procedure|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
75622709|NCT04465162|Other|Radiation Therapy|Undergo radiation therapy
75776185|NCT05932875|Other|Exercise Training|4 day per week concurrent exercise training program
75776186|NCT05932849|Drug|Benralizumab|Patients were initiated on benralizumab as part of routine clinical practice
75776187|NCT05932836|Other|No interventions.|No interventions to be administered.
75776188|NCT05932823|Other|Laminary airflow|A ventilation system that reduces the number of bacteria in the air compared to conventional ventilation.
76073402|NCT01276990|Drug|Placebo|Oral drinking solution
76073403|NCT01277068|Procedure|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
76073404|NCT01271764|Other|no drug|The role of G9a protein in patients with endometrial cancer
76073405|NCT01277146|Drug|OMP-59R5|IV infusion
76073406|NCT00711022|Device|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
75622710|NCT05033873|Other|Universal Exercise Unit Therapy (UEU)|Standing, walk standing, half standing, kneel standing, half kneel standing, quadruped position, three point quadruped , alternative quadruped , transitions, walking all these will be done in Universal Exercise Unit with a standardized protocol regimen.
75776189|NCT05932797|Other|Multimodal intervention in Long Covid19|The intervention will consist of physical, psychological, cognitive and nutritional training and treatment to be carried out at the Teaching and Research Assistance Center of the University of Magellanus (CADI UMAG), program includes 12 sessions of cognitive behavioral therapy sessions, 12 kinesic rehabilitation sessions, 12 treatment sessions per nutrition professional, 12 rehabilitation sessions with occupational therapy professional and 12 rehabilitation sessions with a speech therapist.
75622711|NCT05033873|Other|Sling Exercise Therapt (SET)|"The patient's bilateral knee joints/feet will be suspended by a rope belt, and then the patient's pelvis will be elevated and maintained in supine or lateral position, adding flexion and extension training to lower limb if permitted.~In supine or lateral position, with patient's head, trunk and pelvis fixed, the therapist will use appropriate elastic bands to assist patient's limbs to do passive-power assisted-power resistance training in all directions (bending, stretch, outreach, and adduction).~The patient's chest and abdomen will be suspended by a wide elastic band, positioned him-self in the prone position with the fulcrum of bilateral elbows and knees, and then the torso swayed in all directions, therapists could assist~Target elbow and wrist will be suspended, according to the patient's ability to do passive/active open and close chain movement"
75622712|NCT05033873|Other|Routine Physical Therapy / Control Group|"Control group will receive routine physiotherapy with duration one hour including~Active and passive joint movement~Muscle strength training~Bridging exercises~Balance training in sitting and standing positions, according to the patients' functional state.~Weight bearing exercises on affected Limbs"
75776190|NCT05932784|Device|transesophageal echocardiography|Utilizing transesophageal echocardiography (TEE) during resuscitation allows medical professionals to determine if a patient's aortic valve is being compressed while receiving chest compressions, providing valuable insight to optimize the resuscitation process.
75776191|NCT05932771|Dietary Supplement|Experimental: Consumption of three different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
75776192|NCT05932771|Dietary Supplement|Experimental: Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams maltodextrin was used in 0 grams HC. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
75320928|NCT00684541|Behavioral|Interpretation Modification Program|"The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence."
75776193|NCT05932706|Device|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
75776194|NCT05932706|Device|sham high definition transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 30-minute intervention.
75776195|NCT05932550|Drug|Maraviroc 300 mg|10 week treatment as add-on therapy to anti-depressants
75622713|NCT02874378|Drug|Dexmedetomidine|
75622714|NCT02874378|Drug|0.9%NaCl solution|
75622715|NCT01108523|Device|HP828-101|
75776196|NCT05932524|Drug|Baricitinib 2 MG|Baricitinib 2 mg q.d., p.o., for 6 consecutive months.
75622716|NCT01035606|Behavioral|training in goal-directed attention regulation|training in goal-directed attention regulation
75776197|NCT05932524|Drug|Dexamethasone|Dexamethasone 40 mg q.d. for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10)
75776198|NCT05932498|Procedure|Hip surgery|"Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively."
75776199|NCT05932485|Procedure|Stellate nerve block|Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
75622717|NCT01035606|Behavioral|brain health education|brain health education workshops
75622718|NCT01035606|Behavioral|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
75622719|NCT01117181|Drug|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
76073407|NCT00728728|Drug|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
75622720|NCT01117181|Drug|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
75622721|NCT01117181|Other|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~Review and adjustment of the patient and caregiver supportive care plans~Emotional support and opportunity to ventilate feelings~Counseling regarding specific caregiving skills~Assistance with problem solving of specific issues that the caregiver brings to the sessions~Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day"
75622722|NCT04302714|Procedure|Hysteroscopic injection|Hysteroscopic injection
75622723|NCT04302714|Procedure|Cervical injection|Cervical injection
75622724|NCT02881619|Drug|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
75622725|NCT02881619|Drug|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
75622726|NCT04303806|Drug|rosuvastatin|receive rosuvastatin orally once daily.
75622727|NCT02882087|Drug|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
75622728|NCT02882087|Drug|RC18 160 mg plus MTX|
75622729|NCT04303884|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
75776200|NCT05932472|Drug|Aspirin|Aspirin at currently prescribed dose
75776201|NCT05932433|Behavioral|Exercise|Each session (45 minutes aprox) is made by: mobility, endurance and final exercise to rest. The sesion is going to perform twice a week during 6 weeks.
75776202|NCT05932420|Dietary Supplement|Placebo|16.4g pure medium triglyceride oil mixed with 1 mM of bitter sucrose octaacetate. A dose of 25g of the placebo drink is provided immediately after each training session and 30 minutes before sleeptime throughout the training period.
75776203|NCT05932420|Dietary Supplement|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime throughout the training period.
75913628|NCT06149637|Procedure|Anterior neck dissection approach|"A transverse cervical incision is made with horizontal extension towards the affected side.~It is dissected through the subplatysmal plane, the anterior edge of the sternocleidomastoid muscle is dissected along its entire length.~Level V nodes are dissected up to the spinal nerve without identifying or dissecting it~The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level~Identification and dissection of level III nodes~Identification and dissection of level IIA and IIB nodes with identification and preservation of the accessory nerve."
76073408|NCT00728728|Dietary Supplement|Placebo|Placebo
76073409|NCT04270006|Biological|adipose derived stem cells exosomes|they are small extracellular vesicles
76073410|NCT01271998|Drug|TR-701 FA|200 mg, oral, once daily for 3 days.
76073411|NCT00717418|Drug|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
76073412|NCT00798226|Dietary Supplement|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
76073413|NCT00798226|Dietary Supplement|olive oil|Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
75622730|NCT00625625|Drug|isosulfan blue|
75622731|NCT00625625|Genetic|polymerase chain reaction|
75622732|NCT00625625|Other|diagnostic laboratory biomarker analysis|
75622733|NCT00625625|Other|immunohistochemistry staining method|
75622734|NCT00625625|Procedure|diagnostic lymphadenectomy|
75622735|NCT00625625|Procedure|therapeutic conventional surgery|
75622736|NCT00625625|Procedure|therapeutic lymphadenectomy|
75622737|NCT05032547|Behavioral|Therapist-supported digitally delivered transdiagnostic emotion regulation treatment|Please see description of experimental arm (arm one)
75622738|NCT05032547|Behavioral|Therapist-supported digitally delivered supportive treatment|Please see description of active comparator arm (arm two)
75622739|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
75622740|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
75622741|NCT01040130|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
75622742|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high dose
75622743|NCT01040130|Drug|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
75776204|NCT05932407|Drug|Vortioxetine Tablet|Vortioxetine Tablet
75776205|NCT05932407|Drug|SSRI|SSRI: Selective Serotonin Reuptake Inhibitor
76073414|NCT00717574|Drug|Sevoflurane group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
76073415|NCT00717574|Drug|Propofol group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
76073416|NCT00718120|Biological|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
76073417|NCT02992054|Other|stimulating activities|
75776206|NCT05932394|Behavioral|Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery|"Patients are randomized into two groups (control group and intervention group). Initially, all patients are administered the Mini-Mental State Examination scale (MMSE) to assess their initial cognitive state and their sociodemographic and anthropometric data.~In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered.~In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered."
75776207|NCT05932394|Behavioral|the usual unit treatment|CAM-ICU scale is administered to the Control group. No visual material is used.
75913631|NCT06149611|Drug|[14C] TQB3616|TQB3616 is a new type of cyclin-dependent kinase (CDK) 4/6 inhibitor.
75913632|NCT06149585|Other|Microbial Sampling|Pool microbial sampling will be performed and changes in the microbiome will be evaluated and compared for differences
76073418|NCT01277614|Behavioral|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
75913633|NCT06149572|Procedure|lateral position procedure|Lateral positioning will be used as an intervention for spinal hypotension.
76073419|NCT01277692|Drug|GSK2336805 10mg|single dose once daily
76073420|NCT01277692|Drug|GSK2336805 30mg|single dose once daily
76073421|NCT01277692|Drug|GSK2236805 100mg|single dose once daily
76073422|NCT01277692|Drug|GSK2236805 200mg|single dose once daily
76073423|NCT01277692|Drug|GSK2236805 10mg|repeat dose once daily for 7 days
76073424|NCT01277692|Drug|GSK2236805 dose to be determined up to 100mg|repeat dose once daily for 7 days
76073425|NCT01277692|Drug|GSK2236805 5mg|single dose in HCV infected patients
76073426|NCT01277692|Drug|GSK2236805 30mg|single dose in HCV infected patients
76073427|NCT01277692|Drug|GSK2236805 100mg|single dose in HCV infected patients
76073428|NCT00719134|Drug|Maxalt|anti-migraine drug
76073429|NCT00719134|Drug|placebo pill|placebo pills
76073430|NCT00719134|Drug|placebo pills|placebo pills
76073431|NCT04146363|Biological|Lebrikizumab|Subcutaneous injection
76073432|NCT04146363|Other|Placebo|Subcutaneous Injection
76073433|NCT01272154|Other|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
76073434|NCT01277770|Drug|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
76073435|NCT01277770|Other|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
76073436|NCT01277770|Drug|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
76073437|NCT02992210|Genetic|4SCAR-GD2|
76073438|NCT00721162|Biological|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
76073439|NCT01838941|Drug|Betaine|"Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~6 g/day in children < 30 kg, in 3 divided doses (2 g at meal time)~12 g/day in children > 30 kg, in 4 divided doses (3 g at meal time and bed time)."
75622744|NCT05012969|Device|Hipstop bandage|12 weeks use of a bandage to prevent hip dislocations in patients with previous dislocations
75622745|NCT00932451|Drug|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
75622746|NCT02874456|Other|virus detection|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
75622747|NCT05297682|Device|anesthesia with propofol|General anesthesia with propofol
75622748|NCT01108055|Drug|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
75622749|NCT01108055|Drug|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
75622750|NCT00609375|Drug|cefepime|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
76073440|NCT01773109|Drug|Etirinotecan pegol (NKTR-102)|Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
76073441|NCT02991976|Procedure|Oxygen concentration|Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
76073442|NCT01772719|Drug|Simvastatin and zoledronic acid|"Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
75776208|NCT05932381|Other|Complete decongestive therapy|the patients will receive Complete decongestive therapy in the form of intermittent pneumatic compression, Exercising, bandaging, and manual lymphatic drainage with Pressures of 50, 80, and 120 mmHg and timing 5, 20, and 50 secs
75913634|NCT06149572|Procedure|sitting position porocedure|parturients will get spinal punctures in the sitting position
75913635|NCT06149546|Dietary Supplement|Control|"High protein, high energy diet~Fish oil supplement (ProSure®)~Pancreatic Enzymes (Creon®)~A daily individualised step target (10% above your own baseline)~Four scheduled appointments with a dietitian"
75913636|NCT06149546|Dietary Supplement|Intervention|"High protein, high energy diet~Fish oil supplement (ProSure®)~Pancreatic Enzymes (Creon®)~A daily individualised step target (10% above your own baseline)~Seven scheduled appointments with a dietitian~Six scheduled appointments with a physiotherapist"
75622751|NCT00609375|Drug|cefepime|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
75776209|NCT05932381|Other|Medical treatment|the patients will receive routine medical treatment
75913637|NCT06149533|Drug|Edoxaban|Edoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.
75913638|NCT06149494|Drug|Vapendavir|Participants randomized to the experimental cohort will be administered Vapendavir.
75913639|NCT06149494|Drug|Placebo|Participants randomized to the placebo cohort will be administered placebo.
75913640|NCT06149468|Other|inclusion in the register|socio-demographic data collection and proposed therapy
75913641|NCT06149455|Other|Duration of antibiotics|Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.
75913642|NCT06149429|Behavioral|Personalized virtual reality experience|"The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset."
75913643|NCT06149416|Device|Experimental Masimo RD SET SpO2 Adhesive Sensors|Masimo RD SET SpO2 Adhesive Sensors, Adult (4000 Adt), Adult & Neonate (4003 Neo)
75913644|NCT06149390|Drug|consolidation with ASCT|high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion
75913645|NCT06149364|Behavioral|ISKE|"The intervention will consist of an e-health software Programme that we have named Istumisen Keskeyttäminen (ISKE) will be installed on the desktop of participants.~Functionality of the software: the primary purpose of the software is to remind users (basically office-based workers) to take a break on a regular basis (recommended time 30 minutes).~At the end of the workday, the software provides information on the number of breaks taken and how long each lasted. The user will also have access to such information.~What happens during the prompted break: once the software prompts the user to take a break, she/he can click the Continue button to proceed with the break. The software will include activities that are suggested for the user to do during break. After the break, the record of the time (duration of the break, and when the break was taken) can be taken."
75913646|NCT06149351|Diagnostic Test|Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion|Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.
75913647|NCT06149325|Procedure|Repetitive somatosensory stimulation (RSS)|Tactile stimuli on the index finger of the intact hand, for a duration of 45 minutes
76073443|NCT05582265|Drug|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
76073444|NCT05582265|Drug|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
76073445|NCT05582265|Drug|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
75622752|NCT01107899|Drug|clopidogrel|taken orally, day one, single dose
75622753|NCT01107899|Drug|prasugrel|taken orally, day one, single dose
75622754|NCT04264299|Procedure|T tube drainage|closure of common bile duct over T tube
75622755|NCT04264299|Procedure|Primary closure|Primary closure of common bile duct
75776210|NCT05932316|Diagnostic Test|spirometry|participants will undertake spirometry testing before and after bronchodilators and placebo
75776211|NCT05932316|Drug|Salbutamol|Salbutamol inhalation to determine bronchodilator response
75776212|NCT05932316|Drug|placebo|placebo inhalation prior to repeating spirometry
76073446|NCT05582265|Procedure|Surgical resection|Standard of care
76073447|NCT05582265|Drug|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
75622756|NCT04264299|Procedure|Antegrade stenting|Closure of common bile duct over antegrade plastic biliary stent
75622757|NCT04265157|Procedure|Surgical technique surgical occlusion|Occlusion of hepatoduodenal ligament by clamp or occlusive bands
75622758|NCT05259735|Combination Product|Clinical Guideline based Management|Clinical guidline based management will be done for Type 2 diabetes Mellitus
75622759|NCT05259735|Other|Comparator|In this arm usual management of T2DM without any clinical guideline
75776213|NCT05932277|Drug|BMS-986419|Specified dose on specified days
75776214|NCT05932277|Drug|Caffeine|Specified dose on specified days
75776215|NCT05932277|Drug|Bupropion|Specified dose on specified days
75776216|NCT05932277|Drug|Flurbiprofen|Specified dose on specified days
75776217|NCT05932277|Drug|Omeprazole|Specified dose on specified days
75776218|NCT05932277|Drug|Midazolam|Specified dose on specified days
75776219|NCT05932277|Drug|Fexofenadine|Specified dose on specified days
75776220|NCT05932264|Drug|Apatinib + Fluzoparib|Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid
75776221|NCT05932264|Drug|Apatinib + Fluzoparib + Adebrelimab|Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w]
75776222|NCT05932212|Drug|AK104|15mg/kg, Q3W, IV infusion,
75913648|NCT06149325|Procedure|Sham Repetitive somatosensory stimulation (RSS)|Tactile stimuli on the index finger of the intact hand, for a duration of 4 minutes spread over 45 minutes in 6 blocks of 40 seconds
75776223|NCT05932186|Procedure|Interscalene brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position. Interscalene block will be done as follows. US probe will be placed slightly lower to the level of the cricoid cartilage, followed by scanning of the neck to search for C5 and C6 nerve roots enclosed between the anterior and middle scalene muscles. The needle will be introduced in-plane from lateral to medial through the middle scalene muscle until the tip enters the brachial plexus sheath between the C5 and C6 roots, where LA will be injected.~Patients will be transported to the operation room where general anaesthesia will be induced with tracheal intubation Fentanyl (0.5 μg/kg) will be given to maintain the heart rate and mean blood pressure 20% lower than preinduction values. Intravenous 1 gram paracetamol and 8 mg dexamethasone will be given to all patients as part of multimodal analgesia"
75776224|NCT05932186|Procedure|Upper trunk brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position like the the ISB group~Upper trunk will be visualized distal to the convergence of the C5 and C6 nerve roots but proximal to the departure of the suprascapular nerve (This nerve is a small hypoechoic circle that depart the lateral aspect of the upper trunk and courses posterolateral under the omohyoid muscle). The needle will be introduced in-plane from lateral to medial under the deep cervical fascia and through a very small portion of the middle scalene muscle, until the needle tip lies adjacent to the upper trunk, LA will be distributed below and above the upper trunk. Scanning for the upper trunk can be started from the supraclavicular fossa and moving proximal or opposite to cricoid cartilage and moving distal.~The following steps will be done as in the ISB group"
75776225|NCT05932147|Other|Pilates exercise|"Shoulder Abduction with External Rotation exercise~Shoulder bridge exercise~Mermaid sitting exercise.~Standing Pilates mermaid exercise with towel~Rocking exercise~Saw Pilates exercise.~Bird-dog Pilates exercise.~Roll up exercise.~Cobra pose exercise.~Child pose exercise."
75776226|NCT05932147|Other|Manual lymphatic massage|"procedures of Manual lymphatic drainage program Things to know about MLD Massage~Use only gentle pressure, just enough to see your skin move.~Massage should not be painful.~Do not rub your skin red.~Do massage each day.~Repeat each step 5 to 10 times.~The massage should take about 15 to 30 minutes."
75776227|NCT05932134|Dietary Supplement|UC + high protein diet (HP)|The HP groups will maintain unchanged total daily caloric intake and increasing protein content to 1.5g/kg/day.
75776228|NCT05932134|Behavioral|UC + HP + core muscle rehabilitation|Core muscle rehabilitation is sitting on bedside with or without aids, for 30 minutes, twice per day, 5 days per week, for 3 weeks
75776229|NCT05932134|Device|UC + HP + core muscle rehabilitation + neuromuscular electric stimulation (NMES)|NMES was applied for 30 min, twice per day, 5 days per week, for 3 weeks via surface rectangular electrodes. Electrodes were placed on back designed to activate latissimus dorsi and abdominal wall designed to activate the transversus abdominis and internal and external oblique muscles. Electrical muscle stimulation was performed by using a commercial stimulator (GEMORE, GM300E, Taipei, Taiwan) with biphasic waves at a simulation frequency of 30 Hz and pulse width of 400s, cycling 2s on and 4s off. Electrical muscle stimulation intensity was gradually increased until a visible muscle contraction was observed (median 60 mA [range 50-65 mA].
75913649|NCT06148870|Device|Myopia Control Lens-1 (MCL1)|The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.
75913650|NCT06148870|Device|Myopia Control Lens-2 (MCL2)|The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.
75913651|NCT06148688|Other|Digital Story|"Digital storytelling; It is used in education and training, business marketing, non-profit organizations such as libraries, community centers and museums, and health sciences education. Digital storytelling in health sciences can be a tool for patients and health science professionals to share their experiences, cope with diseases, and add a human element to health problems.~In the study, digital stories were created to increase the self-management of pregnant women with gestational diabetes. In creating a digital story; Qualitative studies involving the self-management experiences of women with gestational diabetes have been examined in the literature. Using the results of the studies, scenarios were created that included factors that facilitate and complicate diabetes self-management. The created scenarios were used in the digital storytelling initiative. A total of four long and four short digital story videos were prepared."
75320929|NCT00684541|Behavioral|Interpretation Control Condition|Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
75622760|NCT01115933|Device|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
75651646|NCT05832853|Behavioral|Wu Qin Xi, resistance training and endurance training|During the first 8 weeks, the training consists of learning and consolidating the movements of the Wu Qin Xi. In the second 16 weeks, participants perform a full set of movement exercises. Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and two sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 15 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
75913652|NCT06147323|Other|Normal Healthy Diet|Participants aged 18-65 years in general good health will be following the Eatwell booklet advice*and NICE/NHS guidelines (https://www.nice.org.uk/).
75320930|NCT05347394|Drug|VX-708|Solution or suspension for oral administration.
75320931|NCT05347394|Drug|Placebo|Placebo matched to VX-708 for oral administration.
75776230|NCT05932121|Procedure|Thyroid lobectomy via trans-axillary approach|Patient with PTC underwent thyroid lobectomy via trans-axillary approach
75776231|NCT05932121|Procedure|Thyroid lobectomy via open approach|Patient with PTC underwent thyroid lobectomy via open approach
75776232|NCT05932095|Behavioral|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 12-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
75776233|NCT05932095|Behavioral|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
75776234|NCT05932056|Behavioral|Miles de Manos (Thousands of Hands)|Miles de Manos (Thousands of Hands) is a school-based group intervention that incorporates elements of evidence-based behavior management interventions in parent, teacher, and parent-teacher joint sessions.
75776235|NCT05932030|Other|Survey|Submission of a survey to solid organ transplant patients and health professionals working in transplantation to assess their knowledge and perception of the use of artificial intelligence in transplantation
75913653|NCT06147323|Dietary Supplement|Seaweed Group|Participants aged 18-65 prediabetics will take 2 seaweeds brown extract capsules/day (information detailed in the safety product sheet, total dose of 700 mg before each of the two main meals. All participants will be advised on product storage and use conditions prior to use to ensure product consistency throughout the period of the study.
75913654|NCT06147323|Other|Placebo Diet Group|Participants aged 18-65 prediabetics will take 2 capsules/day (750mg Maltodextrin placebo comparator) before each of the two main meals without any advice on the diet to follow.
76073448|NCT05582265|Drug|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
76073449|NCT05582265|Radiation|Radiation|Recommended, standard of care
76073450|NCT01798927|Device|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
75776236|NCT05932004|Other|Reformer pilates exercise|The reformer Pilates group will receivea 6-week exercise program (45 minutes/twice per week) , while the participants in the control group will be selected from those on the exercise list who will start exercise after the study finishes, but are on a waiting exercise program list
75776237|NCT05931978|Other|CKD dashboard|Online dashboard that visualizes patients' individual PROM- and clinical data related to their kidney disease.
75776238|NCT05931926|Device|Fluispotter®|The Fluispotter® has been developed for automated extraction, collection and storage of up to 20 dried venous dried blood spot samples of 3-10 μl over the course of up to 20 hours. The system is attached to the patient through a multilumen microcatheter inserted into a peripheral vein in the arm. The Fluispotter will be inserted in both healthy subjects and patients with adrenal insufficiency.
75913655|NCT06147310|Procedure|Study Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Alveolar ridge preservation with blood platelet concentrate: heat-treated albumin (Alb-PRF) and advanced platelet-rich fibrin. The experimental site will be filled with A-PRF plugs/membranes until level flushed with the level of bone. An additional Alb-PRF membrane will be tucked and inserted below the buccal and oral flap. Surgical flaps will not be raised. Soft tissue will be tunnelled and undermined for insertion of the Alb-PRF membrane. The extraction site and membranes will be stabilized by cross-mattress sutures and allowed for secondary intention healing.
76073451|NCT00729430|Drug|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
75913656|NCT06147310|Procedure|Control Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Cross mattress suture will be applied and site allowed to heal naturally.
75913657|NCT06147128|Procedure|Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model|Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system
75913658|NCT06147102|Procedure|Surgery|Surgical treatment for the unruptured intracranial aneurysm
76073452|NCT00729430|Drug|Placebo|Placebo tablets taken orally once per day for 6 months
76073453|NCT04144101|Drug|Etoricoxib|Etoricoxib 60 mg QD Oral
76073454|NCT04144101|Drug|Aceclofenac|Aceclofenac 100 mg BID Oral
75622761|NCT01107743|Drug|Amlodipine/Atorvastatin|"Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.~Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.~For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.~Amlodipine~Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.~Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin~Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.~Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily."
76073455|NCT01278004|Drug|Ethosuximide|Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
76073456|NCT01278004|Drug|Placebo|Capsule
76073457|NCT02700009|Behavioral|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
76073458|NCT02700009|Other|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
76073459|NCT01278238|Drug|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
76073460|NCT01278238|Device|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
76073461|NCT01278238|Other|Placebo|Neither phenylephrine nor lower limb bandaging
76073462|NCT02706795|Biological|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
76073463|NCT00722020|Device|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
76073464|NCT04143867|Device|Nolix Device|For temporary management of SUI
75776239|NCT05931848|Other|Warm-up and Cool-down Program|"Each exercise in the warm-up and cool-down protocols consisting of active movements and static stretching exercises will be performed as 1 set and 10 repetitions. Active movements will be performed for 10 seconds. The detailed protocol is shown below.~Neck flexion/extension/lateral flexion Circles made with the head chin-tuck Backward bilateral shoulder circumduction Shoulder external rotation with hands clasped at neck Circles with wrists clasped clockwise and counterclockwise Reciprocal upper extremity flexion-extension cat-camel Trunk lateral flexion with hands clasped overhead Trunk rotation in both directions Ankle dorsi/plantar flexion with knee extension Static Stretching Exercises Neck lateral flexor stretch Posterior capsule stretching Hands clasped trunk flexion lateral Trunk lateral flexion with hands clasped Trunk rotation in both directions Knee extensor and ankle plantar flexor stretching by reaching for toes"
75776240|NCT05931848|Other|Strengthening Exercises|"The progression of the strengthening program will be achieved by gradually changing the number of repetitions, sets, resistance and the number of exercises.~1-6 Weeks Upper extremity strengthening in unilateral PNF D2 pattern, Scapulothoracic strengthening with shoulder extension in elbow extension, Scapulothoracic strengthening with shoulder extension in elbow flexion, hip flexor strengthening, Hip abductor strengthening in knee flexion, when sit on the chair fingertip ups and downs 7-12 Weeks Added exercises Scapular adductor strengthening with shoulders in horizontal abduction position, Shoulder adductor strengthening in elbow extension with trunk lateral flexion in arms overhead position, hip abductor strengthening 13-16 Weeks Added exercises Shoulder abductor/flexor strengthening in the scapular plane, Elbow flexor strengthening, Upper extremity strengthening in unilateral PNF D2 pattern with trunk rotation, Taking a lateral step in a mini-squat position"
75622762|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
75320932|NCT00662545|Drug|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
75776241|NCT05931848|Other|Balance Exercises|"Balance exercises will be applied following the strengthening exercises. The exercises will be gradually made more difficult. Participants will be encouraged to complete the balance exercises by standing next to the grab bar and with as little support as possible.~1-6. Week Rising and falling on the heels Hands at waist trunk extension hip abduction 6-9. Week Hip abduction and extension without lowering the foot to the ground, respectively 5 sec stop on tiptoe 5 seconds standing on one leg 10-12. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~5 sec stop on tiptoe 10 sec stop on tiptoe 5 seconds standing on one leg 10 seconds standing on one leg 13-16. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~10 sec stop on tiptoe 15 sec stop on tiptoe 10 seconds standing on one leg 15 seconds standing on one leg"
75776242|NCT05931848|Other|Otago Home Exercise Program|"The exercises included in the Otago Home Exercise Program will be taught to the participants after the group exercise session held at the Social Life Center. At the same time, home exercise training will be supported by brochures and videos. In addition to the exercises in the program, participants will be asked to do 30 minutes of moderate-intensity walking 2 days a week. Participants will be asked to record the exercises they did during the week in the exercise diary given to them.~Balance Exercises~Knee bend (half squat)~Walking backwards~Walk and turn around~Sideways walking~Tandem stance~Tandem walking~Standing on one leg~Walking on the heel~Toe walking~Tandem walking backwards~Sit down~Going up and down stairs Strengthening Exercises~1. Knee extension 2. Knee flexion 3. Hip abduction 4. Ankle plantar flexion 5. Ankle dorsiflexion"
75913659|NCT06147102|Procedure|Endovascular|Endovascular treatment for the unruptured intracranial aneurysm
75622763|NCT01059864|Drug|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
75622764|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
75622765|NCT01059864|Drug|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
75622766|NCT04310033|Other|Questionnaires|Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone
75913660|NCT06146868|Other|Doing questionnaire|Participants will provide their opinions in a questionnaire
75913661|NCT06146777|Drug|Pembrolizumab|Intravenous infusion
75913662|NCT06146777|Drug|Placebo|Intravenous infusion
75913663|NCT06146699|Device|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross-sectional view of the retina.
75913664|NCT06146699|Device|Fundus fluorescein angiography (FFA)|Fundus fluorescein angiography (FFA) is an invasive diagnostic procedure. It helps to assess the anatomy, physiology, and pathology of retinal and choroidal circulation. It aids in the diagnosis of various ocular pathologies.
75913665|NCT06146452|Other|Not|Not
75913666|NCT06146413|Drug|Double trigger|GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before ovum pick-up
75913667|NCT06146413|Drug|HCG trigger|hCG ( 10000 IU) is administered 36 h before ovum pick-up
75913668|NCT06146153|Diagnostic Test|digital impression|intra oral scanning
75913669|NCT06145815|Procedure|Arthroscopic rotator cuff repair|Patients underwent an arthroscopic repair for rotator cuff lesions
75320933|NCT00662545|Drug|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
75320934|NCT03696446|Behavioral|Virtual Cardiac Rehabilitation Program|This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
75320935|NCT03696446|Behavioral|Case Managed Home Program|This group will receive their Rehab program over the phone with a trained facilitator
75320936|NCT03693716|Procedure|Dynamic Anterior Stabilization|All-arthroscopic trans subscapular Long Head of the Biceps tenodesis in the anterior-inferior glenoid with all-suture anchors
75622767|NCT04309955|Procedure|pigtail catheter|After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
75622768|NCT02880917|Device|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
75320937|NCT03539198|Radiation|Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)|Patients will be receiving proton SBRT
75776243|NCT05931822|Other|Silver Diamine Fluoride 38%|silver diamine fluoride 38% brushed on the cavity for 1 minute before adding high viscosity glass ionomer restoration in one molar
75776244|NCT05931822|Other|fluoride varnish|fluoride varnish brushed after adding the high viscosity glass ionomer restoration in the contralateral molar
75776245|NCT05931809|Behavioral|Serqual tool|The SERVQUAL scale will be applied with the questionnaire of expectations in the first 24 hours after admission and perception questionnaire within the first 24 hours after discharge.
75913670|NCT06145646|Device|Muscle warm-up|Passive heating of the vastus lateralis of the right quadriceps will be performed using a microwave device. The device will be set at a power of 150 W and a distance of 10-15 cm from the skin surface for 20 minutes with the purpose of increasing local muscle temperature to 40 ºC.
75913671|NCT06145503|Device|Dance Intervention Group|The dance sessions, tailored to participants' preferences, were accompanied by music from the 80s and 90s. A dance instructor demonstrated each dance step, and the sessions comprised a 10-minute warm-up, 40 minutes of dancing, and a 10-minute cool-down. The complexity and intensity of the dance routines were adjusted based on individual abilities, functional variations, and capacity.
75913672|NCT06145386|Behavioral|Aerobic Exercise and Strength Training|Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19
75913673|NCT06144567|Drug|Upadacitinib|As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.
75913674|NCT06144320|Other|Acupuncture|Acupuncture is performed using acupuncture points recorded in traditional Chinese medicine books as helpful for cognitive impairment.
75913675|NCT06143592|Other|Inspiratory Muscle Training|Inspiratory muscle training is performed using POWERbreathe® (Powerbreathe, POWERbreathe International Ltd.Warwickshire, England) with a working range of 10-90 cmH2O with the inspiratory threshold pressure loading method. The device is given to each participant to use at home, so Gazi University Scientific Research Projects Coordination Unit (BAP) was applied for the supply of the devices. At the end of the session in which the initial evaluations of all participants are made, the participants are told how to work with the device, the resistance levels of the device and the points to be considered during the application. A sample application session is performed with the participants under the supervision of a specialist physiotherapist. Participants are called by the same physiotherapist every two days by phone to ensure their compliance with the training.
75622769|NCT02880917|Device|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
75320938|NCT03539198|Radiation|Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients will receive proton SBRT.
75622770|NCT02880917|Other|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
75622771|NCT01035138|Drug|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
75622772|NCT03739840|Drug|Padsevonil|Padsevonil in different dosages.
75622773|NCT03739840|Drug|Placebo|Placebo will be provided matching padsevonil.
75622774|NCT04301700|Behavioral|mindfullness and relaxation|three arms: mindfullness and relaxation
75776246|NCT05931757|Drug|Olverembatinib|Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.
75776247|NCT05931744|Drug|Budesonide|after application of topical vasoconstrictor packs into both nasal cavities, using 1 cc 28 gauge needle sterile syringe, one pack of budesonide ampule 0.5 mg/2ml was injected into visible polyps on both cavities 1 ml in each cavity weekly for 5 consecutive weeks
75776248|NCT05931744|Drug|Prednisone|patients given oral prednisone 1 mg/ kg with max. dose 70 mg/d divided into two doses for 3 days then tapered gradually for two weeks
75913676|NCT06143449|Other|Observational study - registry|Observational study - registry
75913677|NCT06143410|Drug|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
75913678|NCT06143410|Drug|Saline administration as placebo|administration of a bolus of saline solution as a placebo
75913679|NCT06143410|Drug|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol using target controlled infusion (TCI)
75913680|NCT06143410|Procedure|gastroscopy|esogastroduodenoscopy
75913681|NCT06142656|Drug|Metformin Hydrochloride tablet|Metformin Hydrochloride 850 mg oral tablet
75320939|NCT03539198|Drug|Nivolumab 3 mg/kg IV q2 weeks|Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.
75622775|NCT02875236|Drug|OctaplasLG®|"OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
75622776|NCT02875236|Drug|Ringer-acetat|Crystalloid used as standard of care.
75622777|NCT01039428|Dietary Supplement|HS219|Chewing for 30 min three time a day far after meal
75622778|NCT01039428|Dietary Supplement|Placebo|Chewing for 30 min three times a day far after meal
75622779|NCT00613600|Dietary Supplement|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
75622780|NCT00613600|Dietary Supplement|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
75622781|NCT03962608|Device|Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
75622782|NCT03962608|Device|Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
75913682|NCT06142656|Drug|Vildagliptin 50 MG|Vildagliptin 50 MG oral tablets
75622783|NCT01034358|Biological|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
75622784|NCT03470818|Other|Preparatory instructional videos (flipped classroom model)|"The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
75622785|NCT03470818|Other|Sham video|"Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
75622786|NCT04302402|Drug|Rifaximin|Rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia
75622787|NCT04302402|Drug|Placebo|Similar looking placebo
75622788|NCT03935620|Behavioral|Enhanced Milieu teaching|"Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies."
75622789|NCT04408300|Procedure|Ophthalmological exam|Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
75622790|NCT03931408|Drug|Gentamicin Sulfate|Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
75622791|NCT03931408|Other|Placebo instillation (saline alone)|Saline will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
75622792|NCT03931408|Other|No instillation|Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
75622793|NCT03398824|Drug|metformin HCl|Receive metformin HCl
75622794|NCT01033734|Drug|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
75622795|NCT03792256|Drug|Palbociclib|Given PO (or via NG- tube)
75622796|NCT03792256|Drug|Cytarabine|Given intrathecally (IT)
75622797|NCT03792256|Drug|Methotrexate|Given intrathecally (IT)
75622798|NCT03792256|Drug|Hydrocortisone|Given IT
75622799|NCT03792256|Drug|Doxorubicin|Given intravenously (IV)
75320940|NCT03539198|Radiation|Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
75622800|NCT03792256|Drug|Prednisolone|Either prednisone or prednisolone is given PO
75776249|NCT05931744|Drug|Saline|saline intrapolyp injection
75913683|NCT06142305|Procedure|DDH surgery and casting|DDH surgery and casting
75913684|NCT06141876|Drug|APEX-002-A02|Active
75913685|NCT06141876|Other|Placebo|placebo
75320941|NCT00663169|Biological|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
75320942|NCT00663169|Drug|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
75913686|NCT06141733|Other|NIRS group|Standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.
75320943|NCT00663169|Other|placebo matching canakinumab|5% glucose in water intravenous infusion.
75320944|NCT00663169|Other|placebo matching dexamethasone|Placebo intravenous infusion.
75622801|NCT03792256|Drug|Vincristine|Given IV
75913687|NCT06140693|Other|Continuous exercise at an intensity below the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 80% of the intensity at the ventilatory threshold
75776250|NCT05931731|Other|Mechanical interference|The patients will receive mechanical interference treatment in the form of five techniques, including wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, the release of palmar hand fascia, gliding of the finger flexor tendons (using the oscillatory flexion-extension movement of the metacarpophalangeal joint) and release of the upper forearm muscle and fascia were applied. Manual techniques were performed total of 15 minutes in each session each technique included 3 sets for 3 minutes and conventional treatment
75776251|NCT05931731|Other|Neural mobilization|the patients will receive neurodynamic mobilizations, including sliding techniques and tensioning techniques which are thought to enhance ulnar nerve gliding and restore neural tissue mobility and conventional treatment
75622802|NCT03792256|Drug|Pegaspargase|Given IV
75622803|NCT03792256|Drug|Hydrocortisone|Given intrathecally (IT)
75622804|NCT03792256|Drug|Prednisone|Either prednisone or prednisolone is given PO
75622805|NCT04301856|Drug|CFTR Modulators|CFTR modulators as recommended in routine care by the french health authorities
75622806|NCT00613288|Drug|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~Placebo (hypogonadism after leuprorelide injection)~Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~No treatment."
75622807|NCT03711838|Dietary Supplement|N-Acetylcysteine|N-Acetylcysteine in a powder form diluted in a 250 ml drink containing 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
75622808|NCT03711838|Dietary Supplement|Placebo|Placebo consisted of 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
75622809|NCT00613678|Behavioral|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
75622810|NCT00613678|Behavioral|Education|The health education program is based on educational materials from the Arthritis Foundation.
75622811|NCT03656848|Diagnostic Test|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
75622812|NCT03656848|Diagnostic Test|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
75622813|NCT04275778|Drug|Plaquenil 200Mg Tablet|Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery
75622814|NCT04275778|Drug|Placebo oral tablet|placebo will be taken at a dosage of 400 mg / day until delivery
75622815|NCT04260880|Other|periodontal status in mild depression patients|Assessment of periodontal status in mild depression patients
75622816|NCT04260880|Other|periodontal status in moderate depression patients|Assessment of periodontal status in moderate depression patients
75622817|NCT04260880|Other|periodontal status in systemically healthy patients|Assessment of periodontal status in systemically healthy patients
75622818|NCT01115855|Drug|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
75622819|NCT01115855|Drug|Placebo|Placebo once daily or every once daily
75913688|NCT06140693|Other|Continuous exercise at an intensity at the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 100% of the intensity at the ventilatory threshold
75913689|NCT06140693|Other|Continuous exercise at an intensity above the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 110% of the intensity at the ventilatory threshold
75320945|NCT04762004|Behavioral|Maternal speech|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
75622820|NCT03669094|Dietary Supplement|Lactobacillus salivarius V4II-90|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the Lactobacillus salivarius V4II-90 (1*10E9 CFU) probiotic supplement over a 12 weeks period. A visit will then be completed one month after delivery.
75622821|NCT03669094|Dietary Supplement|Placebo|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the placebo supplement over a 12 weeks period. A visit will then be completed one month after delivery.
75776252|NCT05931731|Other|conventional treatment|the patients will receive therapeutic ultrasound (frequency of 1 MHz, intensity of 1 W/cm2, for 5 minutes), transcutaneous electrical nerve stimulation (TENS) (frequency of 80 Hz, pulse duration of 60 μs, at the level of comfortable tingling sensation, for 20 minutes) and therapeutic exercises.
75913690|NCT06140693|Other|Sprint interval training|22 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by four 30-s 'all-out' sprints, each with a 4-min recovery intervals at 25 W
75913691|NCT06140693|Other|Reduced-exertion high-intensity interval training|10 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by two 20-s 'all-out' sprints, with a 3-min and a 4-min recovery interval at 25 W after the first and second sprint respectively
75913692|NCT06139133|Drug|Placebo supplementation|Placebo
75913693|NCT06139133|Drug|Vitamin D supplementation|Vitamin D3 supplementation (2 00,000 IU/Week)
75622822|NCT03615508|Drug|10% phenylephrine|10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
75622823|NCT05331976|Diagnostic Test|Proof Lab Test System|Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette
75622824|NCT05288296|Device|dynamic taping|"The intervention of dynamic tape can improve the LESS, which also means that we may reduce the probability of ACL injury through the intervention of dynamic tape.~By establish a native model of single-leg and double-leg LESS can predict the occurrence of ACL injury early and further prevent it."
75622825|NCT00614068|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
75622826|NCT00614068|Behavioral|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
75622827|NCT05274802|Drug|ALS-4|Single dose of ALS-4 before Breakfast
75622828|NCT05274802|Drug|Placebo|Single dose of placebo before Breakfast
75622829|NCT05274802|Drug|ALS-4|Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
75622830|NCT05274802|Drug|ALS-4|Multiple dose of ALS-4 up to two times daily
75622831|NCT05274802|Drug|Placebo|Multiple dose of placebo up to two times daily
75622832|NCT02880995|Device|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
75622833|NCT02880995|Behavioral|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
75776253|NCT05931718|Biological|cytokine essays|evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples
75776254|NCT05931718|Biological|NGS|evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples
75776255|NCT05931718|Biological|Fecal microbiome|evaluation of fecal microbiome on fecal samples
75776256|NCT05931718|Drug|Erythropoietin|evaluation of recombinant erythropoietin use, safety and efficacy in patients with autoimmune hemolytic anemia according to clinical practice
75776257|NCT05931718|Drug|Luspatercept|evaluation of cytokine levels, molecular profile and bone marrow microenvironment by single cell analysis in patients treated with luspatercept according to clinical practice
75776258|NCT05931718|Drug|Thrombopoietin Receptor Agonist|evaluation of TPO-RA use, safety and efficacy in patients with ITP according to clinical practice
75776259|NCT05931718|Drug|G-CSF|evaluation of G-CSF use, safety and efficacy in patients with CIN/AIN according to clinical practice
75776260|NCT05931705|Other|questionnaire|questionnaire
75776261|NCT05931679|Device|VR Headset|A VR headset will be used for participants in the Interactive VR and 360 degree video groups.
75776262|NCT05931679|Other|Traditional Theatre-based simulation|Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
75913694|NCT06137391|Procedure|Vital Pulp Therapy|The pulp is accessed after caries removal then the inflamed part of the pulp is excavated. After haemostasis is achieved, a pulpootmy medicament is used to coronally seal the remaining pulp tissue. In partial pulpotomy only part of the pulp chamber is excavated while in full pulpotomy the whole pulp chamber is excavated.
75913695|NCT06137313|Other|questionnaire|completion of a questionnaire
76025591|NCT05135507|Behavioral|An integrated parenting intervention for families of children with developmental disabilities|Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
76025592|NCT05135429|Other|Bathing|The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
76088920|NCT01767857|Drug|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
75776263|NCT05931640|Device|Virtual Reality|Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.
75776264|NCT05931640|Device|Plyometric Training|Plyometric therapy that includes 10 minutes of ball throwing, push-ups, jumping and hopping/skipping. At start intensity and speed is low, but will be increased gradually. Every score will be noted with the help of additional tools.
75776265|NCT05931614|Other|Unlimited fluid restrictions|Patients are recommended unlimited fluid intake
75622834|NCT02880995|Drug|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
75622835|NCT03522064|Drug|Testosterone Enanthate 100 MG/ML Injectable Solution|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
75622836|NCT03522064|Drug|Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
75622837|NCT01115309|Device|XprESS Balloon Device|Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
75622838|NCT04310579|Drug|Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day."
75913696|NCT06136494|Behavioral|Internet-delivered cognitive behavioural therapy|Psychoeducation aims at teaching patients about chest pain and anxiety and their impact on daily life. Mindfulness is used to raise awareness of what is going on in the body and emotions and to learn how to relate to chest pain. Physical activity consists of psychoeducation and recommendations regarding physical activity with the goal to get patients to learn that their heart tolerates physical activity and to reduce cardiac anxiety and avoidance of physical activity. Avoidance/exposure is to teach patients how avoidance and safety behaviours can maintain/exacerbate chest pain and negatively impact daily life. Acceptance is about learning to accept having the chest pain without letting it take over one's life. The participants will have weekly assignments with weekly feedback and advice. Reminders and encouraging messages will be sent to motivate participants to complete the intervention. The treatment will be carried out through our own web platform.
75913697|NCT06136494|Behavioral|Attention control|General support via weekly email contact to check how participants are feeling and how they are dealing with their situation. iCBT will be offered after 3 months.
75913698|NCT06136403|Drug|deucravacitinib|treatment by deucravacitinib in two phases of challenge
75913699|NCT06136351|Drug|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
75913700|NCT06136351|Drug|Rituximab|375 mg/m^2 ivgtt, D0 of each 28-day cycle
75913701|NCT06136351|Drug|Bendamustin|90mg/m^2 ivgtt, D0 of each 28-day cycle
76073465|NCT01272310|Biological|Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin|"HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.~Ribavirin - will be taken daily based on the patient body weight. If body weight is < 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is >= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening)."
76073466|NCT01272466|Biological|peptides derived from antiapoptotic proteins|8 Vaccinations on day 2 and 9 in every bortezomib treatment series
75622839|NCT04310579|Drug|Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
76073467|NCT04143789|Drug|AP-002|Dose escalation
76073468|NCT01272700|Procedure|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
76073469|NCT01272700|Procedure|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
76073470|NCT02991742|Other|contrast media|Compare 2 contrast media
76073471|NCT01278316|Behavioral|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
76088921|NCT01767857|Drug|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
75622840|NCT04188340|Behavioral|Su-Man formula massage oil|bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
75622841|NCT05244538|Device|Virtual reality distraction|Patients will be exposed to a virtual reality representing a forest walk. A reduction of at least 50 percent in the remifentanil and propofol doses required for oocyte retrieval is expected.
75776266|NCT05931588|Other|Pilates excercises, streching and breathing|international group receive Pilates exercises, stretching and breathing two times a week (30 min per session) perform 3 to 5 reps of Pilates exercises under supervision
75776267|NCT05931588|Other|stretching and breathing|control group guided with stretching and breathing home based program both group till 8 week both groups
75776268|NCT05931562|Other|Fermented Foods|Participants will recieve dietary education to include 4 to 6 portions of fermented foods to their normal diet.
75776269|NCT05931562|Other|High Fibre|Participants will recieve dietary education to increase their fibre intake to 24-35g/day in their normal diet.
75776270|NCT05931562|Other|Combined Diet|Participants will recieve dietary education to increase their fibre intake to 25-30g/day and include 3 to 4 portions of fermented foods to their normal diet.
75776271|NCT05931562|Other|Control|Participants will recieve dietary education based on the Irish healthy food pyramid.
75776272|NCT05931536|Other|Dietary fibre|Habitual dietary consumption from a variety of foods will be assessed using 7-day food logs entered by the participant and assessed for accuracy by a dietitian.
75622842|NCT05244538|Drug|Propofol-remifentanil sedation|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml."
75622843|NCT05175742|Biological|PTX-COVID19-B|Sterile solution for injection
75622844|NCT05175742|Biological|Pfizer-BioNTech COVID-19 vaccine|Sterile solution for injection
75776273|NCT05931510|Other|Myofscual release|I will apply myofascial release on group A patients and observse its effects on shin splint
75776274|NCT05931510|Other|Post isometric relaxation.|I will apply post isonetric relaxation on group b patients and observe effects on shin splint
75776275|NCT05931484|Drug|Gemfibrozil|Oral Solution
75622845|NCT05175742|Biological|Placebo|0.9% sodium chloride (normal saline) injection
75622846|NCT03638128|Drug|Denosumab|Solution for injection
75622847|NCT03638128|Drug|Alternative osteoporosis medications|Alternative osteoporosis medication/s at the discretion of the investigator.
75622848|NCT00614146|Device|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
75622849|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
75622850|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
75622851|NCT03555838|Other|transcranial direct current stimulation|Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
75622852|NCT03555838|Other|sham transcranial direct current stimulation|an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
75622853|NCT05108194|Behavioral|SMS Personalized Sleep Intervention|"All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions."
75622854|NCT03529630|Other|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
75622855|NCT04940026|Drug|amcenestrant|Tablet Oral
75776276|NCT05931484|Drug|Placebo|Daily dose of Placebo
75776277|NCT05931458|Procedure|Appendectomy|Laparoscopic appendectomy is a relatively simple surgical procedure that can be performedby most surgeons, either on an outpatient basis or with a single-night hospital stay. The laparoscopic approach is now the recommended option due to faster recovery times and fewer wound complications.
75776278|NCT05931458|Drug|Infliximab|Administration of Infliximab (Anti-TNF-a biologic drug)
75776279|NCT05931445|Other|e-PRO monitoring|"The e-PRO monitoring will concern treatment of each predefined type of cancer or characteristic symptoms of the condition. PRO-CTCAE (Patient-Reported Outcome-Common Terminology Criteria for Adverse Events) will be used as the scale for monitoring symptoms. The patient and (sub)investigator will share the monitoring results during examinations and use them to determine treatment strategies, etc. Threshold values will be predefined for a diagnosis of severe for individual symptoms. When it is reported that a threshold value has been exceeded, an alert notification will be sent to the study staff member assigned to the patient. The (sub)investigator who receives the notification will assess the information in the notification and take the best course of action."
75776280|NCT05931406|Behavioral|Control|A normal working day from of 12h
75776281|NCT05931406|Behavioral|Sit-and-stand desk|a working day during which the participants have to get up at least 5 min/hour
75776282|NCT05931406|Behavioral|Cycloergometer|a working day during which they can use a cycloergometer installed under the desk
75776283|NCT05931354|Other|HPV test and Pap Smear|HPV test and Pap Smear
75776284|NCT05931328|Drug|thiotepa combined with pomalidomide|thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
75776285|NCT05931263|Drug|C-BEAM Regimen|Chidemide，carmustine, etoposide, cytarabine, and melphalan
75776286|NCT05931263|Drug|BEAM Regimen|carmustine, etoposide, cytarabine, and melphalan
75776287|NCT05931250|Device|DC-Stimulator Plus (NeuroConn GmbH, Germany)|Transcranial alternating current stimulation
75776288|NCT05931250|Device|Sooma direct current stimulator (Sooma, Finland)|Transcranial direct current stimulation
75776289|NCT05931237|Dietary Supplement|Cranberry extract capsules|Cranberry extract capsules (Prebiocran(TM))
75776290|NCT05931224|Drug|D064, D702, placebo of D660|Experimental Group Subjects assigned to this group are treated with D064, D702, placebo of D660
75776291|NCT05931224|Drug|D660, placebo of D064, placebo of D702|Experimental Group Subjects assigned to this group are treated with D660, placebo of D064, placebo of D702
75622856|NCT04940026|Drug|[14C]-SAR439859 microtracer|Solution for infusion Intravenous
75622857|NCT04940026|Drug|[14C]-SAR439859|Powder for oral solution Oral
75622858|NCT04825912|Behavioral|Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience|The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
75622859|NCT03448120|Procedure|Acupuncture|Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.
75622860|NCT03448120|Procedure|Dry needling|Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
75622861|NCT00614224|Behavioral|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
75622862|NCT04748926|Drug|rilzabrutinib SAR444671|Pharmaceutical form: caplet Route of administration: oral
75622863|NCT04748926|Drug|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
75622864|NCT04748926|Drug|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
75776292|NCT05931198|Other|Modified illusion of the rubber (syncrhone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis at the same time (synchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
75776293|NCT05931198|Other|Modified illusion of the rubber (asynchrone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis not at the same time (asynchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
75776294|NCT05931133|Other|NO INTERVENTION|NO INTERVENTION WILL BE GIVEN
75622865|NCT03261076|Behavioral|Strategies Enhancing Reading in Older Underperf. Students|Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
75622866|NCT03221218|Other|Enhanced screening-informed follow up letter|Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
75622867|NCT00614302|Drug|TPV|
75320946|NCT04762004|Behavioral|Maternal singing|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
75622868|NCT05345236|Drug|Aflibercept|Intravitreal (IVT) injection
75776298|NCT05931081|Device|Thermal imaging in diagnostics of chronic ulcers|atypical: vasculitic or pyoderma gangraenosum ulcers
75776299|NCT05931068|Other|Pre- and postoperative assessment|Pre- and postoperative assessment will consist of measurement of energy expenditure (direct and indirect calorimetry), aerobic capacity (cardiopulmonary exercise test), and physical activity (accelerometry).
75776300|NCT05931055|Diagnostic Test|Fragmentomics|The fragmentation patterns of cfDNA fragments in plasma and the uneven coverage of the genome can indirectly reflect the state of gene expression regulation in vivo. Its characteristics mainly include copy number variation (CNV), Nucleosome footprint, fragment length and motif. Fragomics relies on WGS (Whole Genome Sequencing), and the target covers the whole Genomics level. Thus, the cfDNA Fragmentomics testing can help differentiation and early diagnosis.
75776301|NCT05931042|Drug|Trastuzumab|Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)
75776302|NCT05931029|Drug|Idebenone|The control group took Idebenone orally for 12 weeks.
75776303|NCT05931029|Drug|Naohuan Dan and Idebenone|The treatment group took Naohuan Dan combined with Idebenone for treatment. Naohuan Dan is a granular preparation taken once a day, while Idebenone is a tablet taken three times a day for a total of 12 weeks.
75776304|NCT05931016|Diagnostic Test|6-MWT|Measurement of saturation and blood gas parameters under 6-MWT with different masks.
75776305|NCT05931016|Diagnostic Test|Spiroergometry|Measurement of saturation and blood gas parameters under spiroergometry with different masks.
75776306|NCT05931003|Procedure|Carotid stenting|In carotid stenting, a long, hollow tube (catheter) is threaded through the arteries to the narrowed carotid artery in the neck. A metal mesh tube (stent) is inserted into the vessel to serve as a scaffold that helps prevent the artery from narrowing again. The catheter and the filter - which catches any debris that may break off during the procedure - are removed.
75913702|NCT06133816|Behavioral|Framed Introductory Message A|Randomly assign patients to receive introductory message encouraging them to complete the survey (version A).
75913703|NCT06133816|Behavioral|Framed Introductory Message B|Randomly assign patients to receive introductory message encouraging them to complete the survey (version B).
75913704|NCT06133816|Behavioral|Framed Introductory Message C|Randomly assign patients to receive introductory message encouraging them to complete the survey (version C).
75913705|NCT06133816|Behavioral|Framed Tobacco Use Message A|Randomly assign patients to receive norming message related to tobacco use (version A).
75913706|NCT06133816|Behavioral|Framed Tobacco Use Message B|Randomly assign patients to receive norming message related to tobacco use (version B).
75622869|NCT02692690|Device|Stimulette r4x|
75622870|NCT02692534|Other|Urine cocaine negative|Preoperative urine cocaine negative
75622871|NCT02692534|Other|Urine cocaine positive|Preoperative urine cocaine positive
75913707|NCT06133816|Behavioral|Financial Incentive|Randomly assigned patients to be entered into a drawing to receive a $100 gift card.
75913708|NCT06130774|Other|Retro walking and conventional|Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue his retro-walk for 20 minutes
75622872|NCT04153318|Device|full-field optical coherence tomography|Pancreatic tissue sample obtained by EUS-FNB will be used for FFOCT imaging. The Images will be sent to trained pathologists for diagnosis. The same tissue sample will be sent to the pathology department for routine histological examination. Compare the diagnoses made by the 2 different methods.
75622873|NCT04413370|Diagnostic Test|Dry eye diagnostic test|The artificial intelligent dry eye screening platform
75622874|NCT05344768|Other|aerobic exercise|Moderate intensity aerobic exercise training will be applied.
75622875|NCT05344768|Other|high-intensity interval exercise training|High-intensity interval exercise training will be applied.
75622876|NCT05344768|Other|resistance exercise training|resistance exercise training will be applied
75622877|NCT00613912|Other|Magnetic Resonance Imaging|"Morphological sequences~Arterial Spin Labelling (Perfusion)~Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter"
75776307|NCT05931003|Procedure|Carotid endarterectomy|"Carotid endarterectomy is a procedure to treat carotid artery disease. In carotid endarterectomy receive general anesthesia. Surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging artery. Then, surgeon repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Sometimes surgeons may use another technique called eversion carotid endarterectomy. This involves cutting the carotid artery and turning it inside out, then removing the plaque. Surgeon then reattaches the artery."
75622878|NCT05344612|Radiation|CT Coronary Angiography|Upfront ct-coronary angiography
75622879|NCT00614536|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
75622880|NCT05344222|Device|Infrared LED|The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
75622881|NCT05344222|Device|Similar device - Infrared ED|For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
75622882|NCT04333654|Drug|Hydroxychloroquine SAR321068|Pharmaceutical form:Tablet Route of administration: Oral
75798367|NCT03868800|Other|SDM-DC|The SDM-DC intervention is designed for patients with kidney failure who must make a decision regarding type of dialysis: haemodialysis or peritoneal dialysis. SDM-DC consists of patient and his or her relative(s) being given a patient decision aid called 'Dialysis choice' and booked for meetings with a dialysis coordinator. There were optional videos describing other patients' experiences making this decision. The dialysis coordinators were trained in the why, what and how in relation to SDM-DC and to deliver the intervention by tailoring to patients' needs and using three different communication skills: mirroring, active listening and value clarification.
75913709|NCT06130774|Other|conventional therapy|Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
75913710|NCT06128954|Drug|900mg TETA 4HCl Once Daily Formulation|3x300mg trientine base tablets as a single AM dose
75913711|NCT06128954|Drug|900mg TETA 4HCl Cuprior®|6 x150mg trientine base tablets in two equally divided doses
75913712|NCT06128512|Other|Auricular acupuncture|Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch containing the needle will remain in place until the student completes the examination.
75622883|NCT04333654|Drug|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
75913713|NCT06128512|Other|Sham Auricular acupuncture|Sham Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, without a needle. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch will remain in place until the student completes the examination.
75320947|NCT04762004|Behavioral|Standard care|the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
75320948|NCT00663403|Drug|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
75320949|NCT00004418|Drug|glyceryl trierucate/glyceryl trioleate|Administration of glyceryl trierucate/glyceryl trioleate
75320950|NCT00663793|Drug|Acyline|300 mcg/kg
75622884|NCT01059630|Drug|Obinutuzumab|IV infusion.
75622885|NCT01059630|Drug|Bendamustine|IV infusion.
75622886|NCT05344144|Other|Emotional Freedom Technique|EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.
75622887|NCT05344144|Other|Music|Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
75320951|NCT00663793|Drug|Testosterone|"24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
75320952|NCT00663793|Drug|Finasteride|1 mg PO once daily [day -2 to day 12) 14 days total
75622888|NCT04314700|Device|OCT- based investigational imaging device|Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
75622889|NCT04226170|Drug|DAS-001|ondansetron + pyridostigmine
75622890|NCT05343910|Other|Aroma massage|The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
75622891|NCT05343676|Device|ultrasonography|"For assessment of LNS ( cervical , axillary and inguinal LNS ), The choice of transducer is an important consideration when evaluating lymph nodes as higher frequencies provide better resolution for superficial structures~For color Doppler assessment of the lymph nodes, scanning will be done using the slow frame rate, low pulse repetition frequency~Assessment features including lymph node location, size, shape, border, echogenicity, calcifications, necrosis or cystic change, and adjacent soft tissue edema"
75622892|NCT04200976|Behavioral|Tele-CABA|"Tele-CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of Tele-CABA focus on learning about TBI and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.~The Tele-CABA intervention will be delivered over 10 weekly, 60-minute telephone sessions."
75622893|NCT04200976|Behavioral|Usual Care|Participants in the UC group will continue to receive their regular medical, psychiatric, and psychotherapeutic care.
75622894|NCT04192240|Other|WB Training with external feedback|WB during sit-to-stand and stepping with external feedback, follow by overground walking.
75622895|NCT04192240|Other|WB Training without external feedback|WB during sit-to-stand and stepping without external feedback, follow by overground walking.
75320953|NCT00667381|Device|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
75622896|NCT05343520|Behavioral|Pelvic floor muscle exercises|Pelvic floor muscle exercises were applied to the pregnant women in the experimental group from the 30th gestational week to the 6th postpartum week.
75913714|NCT06123390|Other|The Responses to Illness Severity Quantification (RISQ) System|The RISQ System involves: [1] the RISQ score: calculated routinely using the [2] documentation record and linked to [3] score-matched recommendations. Introduction into clinical care is supported by [4] the RISQ System implementation package. During the 2 month prior to implementation, front-line staff in the intervention arm will be trained on and will practice the use of the RISQ System .
75913715|NCT06122272|Other|Test Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Test Formula will be provided during this 12 month.
75913716|NCT06122272|Other|Control Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Control Formula will be provided during this 12 month.
75622897|NCT04672980|Drug|RTX-321|RTX-321 monotherapy
75913717|NCT06119295|Behavioral|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants. Depending on the condition participants are in, they will be served either a portion size which consists of the amount of food they consumed in the first test session, or a reduced portion size. Within these two reduced portion size conditions, one group of participants will be made aware that their portion size has been reduced, the other will not and instead will be told that this portion size is the same as the amount of food they consumed in the previous session.
75320954|NCT02336438|Dietary Supplement|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
75622898|NCT04143958|Drug|agalsidase beta (GZ419828)|Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
75622899|NCT04143958|Drug|agalsidase alfa|Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
75622900|NCT04303338|Procedure|Masotherapy with neural tension and masotherapy with non-neural tension|To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
75622901|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
75622902|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
75622903|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
75622904|NCT04142086|Biological|Yellow fever vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
75622905|NCT04643184|Other|Management Program|Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
75651647|NCT05832853|Behavioral|Resistance training and endurance training|Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and three sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 30 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
75320955|NCT00667615|Drug|rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim|Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
75320956|NCT00667693|Device|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
75913718|NCT06115902|Drug|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
75622906|NCT05343442|Procedure|Percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
75622907|NCT02874222|Other|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
75622908|NCT05333302|Biological|CD19 CAR-T-cells|One dose of CD19 CAR-T cells (1*10e6 CAR+ T-cells/kg) by intravenous infusion.
75622909|NCT05333302|Drug|Tocilizumab|Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
75622910|NCT05343208|Diagnostic Test|EFP Psychometric assessment to determine level of afflication|Patients were asked to complete a psychometric assessment in relation to their psychological wellbeing. Results were presented to the patient and validdated by the patient.
75622911|NCT03456778|Procedure|Ultrasound-guided Percutaneous Tenotomy with Platelet-Rich Plasma (PRP)|Using an aseptic procedure, 7 cubic centimeters (cc) of blood will be collected and processed for the PRP injection. The site to be injected will be prepared with isopropyl alcohol and then sprayed with ethyl chloride to achieve cutaneous anesthesia. Next, with continuous sonographic visualization, the skin and subcutaneous tissues overlying the tendon will be infiltrated with 0.5% bupivacaine and 1% sodium bicarbonate (50 milliequivalents (mEq)/50 mL) via a 25-gauge hypodermic needle. Once adequate anesthesia is achieved, a 20-gauge needle will be used to repeatedly fenestrate the tendinotic portion of the tendon along the long plane. Any calcifications within the substance of the tendon will be mechanically fragmented. When the region of interest has been treated, a PRP injection (5 cc) will be delivered.
75622912|NCT03664882|Drug|Fexofenadine M016455|Pharmaceutical form: tablet Route of administration: oral
75622913|NCT03664882|Drug|Placebo|Pharmaceutical form: tablet Route of administration: oral
75622914|NCT03903016|Drug|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75622915|NCT03903016|Drug|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75622916|NCT03571750|Behavioral|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
75776308|NCT05930990|Behavioral|Mamas in Harmony|Mothers attend 8x 1 hour weekly classes with their infant. Classes take place in a community venue. Mothers sit with their infant on the floor in circle formation on cushioned mats. Group singing facilitated for 40 minutes by the intervention facilitator, a professional musician/choir leader. A mix of songs are introduced that are easy to learn without the need for lyric sheets. Mothers will be encouraged to sing along. Mothers will be encouraged to interact with their infant through various sensory stimuli involving touch, sound and visual. The end of each singing session involves a short period of quiet time, soothing sounds are provided by the intervention facilitator using voice and instruments. 20 minutes of facilitated social support will follow and mothers will be provided with refreshments. Mothers will be encouraged to interact with other mothers to promote social connection.
75798368|NCT03868644|Behavioral|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
75798369|NCT03868644|Behavioral|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
75913719|NCT06115278|Other|survey|survey
75913720|NCT06113302|Drug|Luspatercept|Given by SC or (Injection)
75913721|NCT06110624|Other|Survey|A survey study will be conducted to evaluate if GHCPs have the Intention to Use (IU) MuSt-PC in daily practice.
75913722|NCT06108180|Other|Dry Needling|3 treatment to eliminate active trigger points that patients have
75320957|NCT00667693|Device|Pentax AWS|Intubation with Pentax AWS
75320958|NCT03604640|Other|Physical Training|Physical exercise program and health education
75320959|NCT03687008|Behavioral|Cognitive Computer Based Intervention|25 sessions [each 30-45 minutes, 5 days a week / for 5 weeks], supervised by trained coaches
75320960|NCT00667849|Device|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
75320961|NCT00667849|Device|Sham|sham device identical to active device with the exception of administration of ultrasound
75320962|NCT03532958|Drug|BNZ-1|PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
75320963|NCT03532958|Drug|Normal saline|Dose volume consistent with weight-based dosing of BNZ-1
75320964|NCT02998489|Other|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
75320965|NCT02998489|Other|Traditional milk advancement|20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
75320966|NCT02827513|Drug|CTN SR1|
75622917|NCT03571750|Behavioral|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
75776309|NCT05930977|Procedure|total thyroidectomy followed by thyroid auto transplantation|"All studied cases received general endotracheal anaesthesia, and all underwent total thyroidectomy.~Frozen section will be done intraoperative to exclude malignancy and obtain piece of healthy tissue part .~Most healthy-looking part of gland was selected after complete excision. Thyroid tissue to be transplanted weighed between two and five grammes. This section was finely split into ten-fifteen fragments with scalpel. Small pocket was created in sternomastoid muscle, into which these minor fragments were implanted, and this pocket was closed with absorbable sutures to prevent displacement of implanted fragments and was marked with metallic stables, as well as good hemostasis of thyroid bed and skin was closed with subcuticular sutures using absorbable three-zero Vicryl sutures."
75320967|NCT02827513|Drug|CTN XR1|
75776310|NCT05930912|Diagnostic Test|Psychoanalysis|Case-specific psychoanalysis is performed, including the participant's background during birth.
75776311|NCT05930912|Drug|sertraline 50mg|After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.
75651648|NCT05832775|Biological|MRx0029|Megasphaera massiliensis MRx0029 (Treatment A) and Placebo
75776312|NCT05930912|Drug|Duloxetine 20 MG|Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.
75776313|NCT05930912|Behavioral|Cognitive Behavioral Therapy|CBT is tailored to the participant's current activities and life decisions.
75320968|NCT02827513|Drug|CTN XR2|
75320969|NCT02827513|Drug|CTN XR3|
75776314|NCT05930873|Behavioral|Immersive room|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented on one of the four walls of the immersive room and a set of stimuli, including the target stimulus, which the subject will have to touch within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
75651649|NCT05832775|Biological|MRx0005|Parabacteroides distasonis MRx0005 (Treatment B) and Placebo
75776315|NCT05930873|Behavioral|stimuli in a paper format|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented in a paper format and a set of stimuli, including the target stimulus, which the subject will have to indicate within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
75776316|NCT05930860|Procedure|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
75776317|NCT05930847|Device|Digital Game Application|The digital game contains brief information about the respiratory system adapted to children, and it is a game whose duration can be adjusted manually to follow the treatment process of the patient, taking into account the ½ ratio in the inhalation and exhalation process in the clinic.
75776318|NCT05930847|Drug|Use of medication for asthma|The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
75798370|NCT01170624|Device|ICD|Paradym CRT model 8750 - Paradym DR model 8550 - Paradym VR model 8250
75798371|NCT01168206|Dietary Supplement|TK3|Tritofano 160mg / Timina140mg and starch 150 mg
75798372|NCT01168206|Dietary Supplement|1 capsule, 3 times per day|Placebo
75798373|NCT01168284|Behavioral|Coping Effectiveness Training|
75798374|NCT01274052|Other|Meal test|Liquid meal test
75798375|NCT01281852|Drug|Cisplatin|Given IV
75320970|NCT03683810|Dietary Supplement|Lactoferrin|Lactoferrin in tablets 4g/daily
75320971|NCT03683810|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin (rHuEPO, epoetin alfa)
75320972|NCT01587235|Drug|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
75320973|NCT01587235|Drug|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
75320974|NCT03530306|Device|PS1-PS4|Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
75320975|NCT03530306|Device|PS6-PS10|Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
75320976|NCT03530306|Device|PS7-PS4|Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
75320977|NCT03530306|Device|PS9-PS6|Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
75466485|NCT01909999|Procedure|Osteogenic markers Evaluation|"The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.~The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA)."
75622918|NCT03521362|Device|MyT1DHero|MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
75622919|NCT03521362|Device|Other T1D Mobile App|A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
75622920|NCT03514732|Drug|MELATONIN (MELATL07959)|Pharmaceutical form:Capsule Route of administration: Oral
75622921|NCT03800836|Drug|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28 day cycle for all arms except for arms F1/F2 where it will be administered at a dose of 300 milligrams (mg) orally daily for the first two cycles and 400 mg for the remaining three cycles.
75622922|NCT03800836|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion on Days 1, 8, and 15 of each 28 day cycle for all arms, with the exceptions of Arms F1, F2, G1 and G2, where it will be also administered on Day 22 as well, of each 28 day cycle.
75622923|NCT03800836|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28 day cycle for all arms, although in Arms C1/C2, it will be administered on Day 15 of Cycle 1 followed by Days 1 and 15 in subsequent cycles.
75622924|NCT03800836|Drug|Nab-Paclitaxel|Nab-paclitaxel will be administered by IV infusion at a dose of 100 mg/m^2 on Days 1, 8, and 15 of each 28 day cycle.
75622925|NCT03800836|Drug|AC|AC (Doxorubicin and Cyclophosphamide) will be administered by IV infusion at 60 mg/m^2 and 600 mg/m^2 respectively on Days 1 and 15 of Cycles 1 and 2 for Arms F1, F2, G1 and G2.
75622926|NCT00932373|Drug|trastuzumab-MCC-DM1|Intravenous escalating dose
75622927|NCT03511690|Behavioral|BRCA-Gist|"BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing."
75622928|NCT04265235|Other|Home-based exercise program|see 'arm' section
75622929|NCT03509506|Behavioral|App Group|"The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~The vital signs show undesired readings~The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent."
75622930|NCT04265079|Other|Additional weight at hand|Added weight of an inactive hand orthosis (300 gram)
75622931|NCT04265001|Drug|Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash|Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
75622932|NCT03488290|Behavioral|LTP Plus TF-CBT|Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
75622933|NCT03488290|Other|Treatment as Usual|The Treatment as Usual group will receive routine care
75622934|NCT04263753|Procedure|Bladder conservative surgery in placenta accretta|"After control of both superior vesical vessels Finding a fresh noninvaded plan between isthmocervical junction and posterior bladder wall aided by filling the bladder 150 cc saline Then cervical stump control sutures and severing the specimen above the clamps~* Now the placenta is only attached to the bladder , apply intestinal clamp or foley cath on the bladder below the level of invasion if feasible to reduce bleeding~* cut through the placenta, heavy back flow bleeding of old blood stored in the placenta will be noticed , but there is no hemodynamic change since the cervical stump is already severed~, dissect the bladder with a large safety margin cutting through the placenta.. Then in cases with hematuria saline irrigation of the bladder is usually enough to clear the hematuria 15 out of 20"
75798376|NCT01281852|Other|Laboratory Biomarker Analysis|Correlative studies
75798377|NCT01281852|Drug|Paclitaxel|Given IV
75798378|NCT01281852|Drug|Veliparib|Given PO
75798379|NCT01168440|Drug|Sunitinib|Sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of treatment followed by 2 weeks of rest).
75466486|NCT01909999|Procedure|Clinical parameters evaluation|"The following parameters were assessed:~Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;~Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants."
75622935|NCT03463486|Behavioral|Physical activity|50min of endurance training combined with 50min of calisthenics; 1-3x/wekk; 6weeks up to 1year
75798380|NCT01170780|Drug|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
75798381|NCT01170780|Drug|Saline|2 ml IV
75776319|NCT05930821|Behavioral|Aerobic and Resistance Exercise Program (GEMS program)|"Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.~The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~Other components of the GEMS program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters."
75776320|NCT05930821|Behavioral|Flexibility and Stretching Program (FLEX-MS program)|"Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.~The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GEMS program, and account for activity, social-contact, and attention.~Other components of the FLEX-MS program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GEMS program."
75622936|NCT00607347|Other|Glucose|Oral Glucose Tolerance Test
75913723|NCT06107946|Other|USD questionnaire|After a baseline screening symptom assessment, all eligible patients with at least 2 simultaneously occurring symptoms with a numeric rating score ≥4 on the 11 point scale on the Utrecht Symptom Diary, will be asked to fill out the Utrecht Symptom Diary during two weeks. In the first week twice daily (morning and evening), in the second week once daily (evening).
75913724|NCT06107777|Procedure|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
75913725|NCT06107777|Procedure|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
75913726|NCT06105359|Behavioral|Dignity therapy|"Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session."
75320978|NCT01796509|Other|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
75320979|NCT02998099|Drug|Rivipansel|A single dose of IV rivipansel over 20 minutes.
75622937|NCT00608595|Drug|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
75622938|NCT00608595|Genetic|gene expression analysis|not noted
75622939|NCT00608595|Genetic|protein expression analysis|Not noted
75622940|NCT00608595|Other|immunohistochemistry staining method|not noted
75913727|NCT06105359|Other|standardize care|Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
75913728|NCT06104878|Other|No Intervention|No Intervention will be administered in this study.
75913729|NCT06103955|Behavioral|Digital Breathing Biofeedback system|The biofeedback system provides information to the patient and physio about the muscle coordination of breathing.
75913730|NCT06097325|Diagnostic Test|Clance impostor phenomenon scale|"The CIPS will be used as diagnostic test in the online survey."
75466487|NCT01909999|Procedure|Implant instalation|The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
75466488|NCT01909999|Procedure|Prosthesis installation|The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
75466489|NCT01909999|Procedure|Suture|Soft tissues sutures were done using absorbable polygalactin 910 suture.
75466490|NCT01909999|Drug|Post-operative care|"Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash"
75466491|NCT01910038|Drug|corticoids+ tocilizumab 8mg/Kg/4 weeks|
75466492|NCT01910077|Drug|Tacrobell capsule 1mg|1 capsule, oral, over the period I&II(crossover)
75466493|NCT01910077|Drug|Prograf capsule 1mg|1 capsule, oral, over the period I&II(crossover)
75466494|NCT01910090|Drug|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
75466495|NCT01910090|Drug|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
75466496|NCT01910142|Dietary Supplement|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
75622941|NCT00608595|Other|laboratory biomarker analysis|not noted
75622942|NCT00608595|Other|mass spectrometry|
75622943|NCT00608595|Procedure|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
75622944|NCT00608595|Procedure|neoadjuvant therapy|not noted
75622945|NCT00608595|Procedure|therapeutic conventional surgery|not noted
75622946|NCT00614770|Procedure|standard of care colonoscopy|"Standard White Light Colonoscopy~one exam per patient"
75776321|NCT05930795|Procedure|pectopexy|pectopexy: surgery performed by suspending prolapsed uterus or vault to the pectineal ligament
75913731|NCT06097325|Diagnostic Test|Maslach Burnout Inventory for Medical Professional|"The MBI-HSS-MP will be used as diagnostic test in the online survey."
75913732|NCT06093269|Biological|Blood samples|"For all subjects (short kinetics):~Pre-injection of cefazolin~Start of next dialysis~Two hours after start of subsequent dialysis~End of next dialysis, before cefazolin administration~Only in hospitalized subjects (rich kinetics):~30 minutes, 1h and 2h after cefazolin injection, to describe the cefazolin peak and possible post-dialysis rebound~12h, 24h and 36h after cefazolin injection, to better describe cefazolin elimination and distribution"
75913733|NCT06088160|Procedure|Total Hip Arthroplasty|Total hip arthroplasty is a common surgical procedure performed in people with advanced hip osteoarthritis
75913734|NCT06087978|Drug|14C RPT193|Radiolabelled RPT193
75913735|NCT06085911|Behavioral|One day course|a physical one-day course at the Covid rehabilitation clinic. During these six hours, general information about rehabilitation principals will be given. Theory about three 15 focus areas of importance will be presented; daily routine, importance of being active and cognitive training. They will meet others with similar problems and will be given an opportunity to exchange experience. 8-10 patients will participate in the group.
75622947|NCT00614770|Procedure|colonoscopy|"Narrow Band Imaging Colonoscopy~one exam per patient"
75622948|NCT00614770|Procedure|standard of care colonoscopy|"High Definition White Light Colonoscopy~one exam per patient"
75622949|NCT03761134|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
75622950|NCT03761134|Drug|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
75622951|NCT03761134|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
75776322|NCT05930795|Procedure|lateral suspension|lateral suspension: surgery performed by suspending prolapsed uterus or vault to the lateral walls of the abdomen corresponding to the 3 cm anterior superior to the iliac crest
75776323|NCT05930769|Procedure|Gynecological laparoscopic surgery without augmented reality|Minimally invasive gynecological surgery assisted by laparoscope.
75776324|NCT05930769|Procedure|Gynecological laparoscopic surgery with augmented reality|Minimally invasive gynecological surgery assisted by laparoscope with the display of additional information through augmented reality.
75776325|NCT05930691|Diagnostic Test|Optic nerve sheath diameter measurement|Prediction of intracranial pressure by using Ultrasonography on optic nerve sheath diameter.
75913736|NCT06085911|Behavioral|Individual follow-ups|the patient will meet a therapist in a physical consultation at the Covid rehabilitation clinic lasting for 1.5 hours. Together they will in detail map out symptoms and impairment of function in the patient's life. Together the patient and the therapist will create plan to address these problems consisting of tailored home-based exercises within the three focus areas. Tree follow-up consultations will be given.
75913737|NCT06083818|Other|Application of an anterior cruciate ligament injury prevention protocol for female football players with dynamic knee valgus for 12 weeks.|12-week ACL Injury Prevention Protocol
75913738|NCT06083818|Other|Placebo - Conventional fitness programme|Conventional training and physical preparation programme
75913739|NCT06082856|Drug|Dexmedetomidine|Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
75622952|NCT03761134|Drug|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
75776326|NCT05930665|Drug|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin|Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks
75913740|NCT06082856|Drug|Sufentanil|Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
75913741|NCT06082141|Procedure|Transversus thoracis plane block combined with serratus anterior plane block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 5 ml 0.5% bupivacaine + 5 ml NaCl under US-guidance
75913742|NCT06082141|Procedure|Serratus anterior plan block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 10 ml NaCl under US-guidance
75913743|NCT06081283|Drug|Phenobarbital Sodium Injection|Loading dose 20 mg/kg intravenous. Max dose 1000mg Maintenance dose 4mg/kg/day. Max dose 300mg/day. Adult population Loading dose 20 mg/kg intravenous. Maintenance dose 4mg/kg/day.
75320980|NCT00705133|Drug|Treprostinil|For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated
75466497|NCT01910142|Dietary Supplement|calcium|
75466498|NCT01910155|Drug|Ciprofloxacin/Dexamethasone|
75466499|NCT01910155|Drug|Ciprodex (R)|
75466500|NCT01910155|Drug|Placebo|
75466501|NCT01910194|Drug|Luyxumia versus Lantus|
75466502|NCT01910220|Drug|REGN1033 (SAR391786)|
75466503|NCT01910220|Other|placebo|
75466504|NCT01910246|Drug|Metformin|
75466505|NCT01910259|Drug|Amiloride|Comparison with placebo
75466506|NCT01910259|Drug|Riluzole|Comparison with placebo
75466507|NCT01910259|Drug|Fluoxetine|Comparison with placebo
75466508|NCT01910259|Drug|Placebo|Placebo comparator
75466509|NCT01910272|Device|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
75466510|NCT01910285|Drug|Remifentanyl - sufentanil placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
75466511|NCT01910285|Drug|Sufentanil - remifentanyl placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
75798382|NCT01165944|Drug|Pramlintide|Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
75320981|NCT02998255|Drug|Single dose of 2L PEG|Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
75622953|NCT05241717|Behavioral|Web-based Management of Adolescent Pain (WebMAP)|Participants will be asked to complete one module per week, which are approximately 20 minutes in length. Survivors and parents will be asked to spend approximately 4.5 hours each over the course of the intervention on WebMAP including 4 hours to complete the modules and 30 minutes total corresponding with a coach. Each week, patients log into WebMAP to learn a new skill and practice that skill for 1 week to allow time for skills acquisition. WebMAP consists of two separate, password-protected programs including one for adolescents and one for parents (http://webmap2.com).
75622954|NCT01055496|Drug|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
75622955|NCT01055496|Drug|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
75622956|NCT03436498|Drug|Insulin aspart SAR341402|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
75622957|NCT03436498|Drug|Insulin aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
75622958|NCT00609453|Behavioral|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
75776327|NCT05930652|Diagnostic Test|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning (including well-being, mental health conditions, coping skills), and socio-demographics, academic performance, home, relationships, general health, habits, and attitudes.
75622959|NCT01055262|Device|Heatwrap 1|8 hours continuous topically-applied heat
75622960|NCT00609531|Drug|Citalopram|Pill, 5-20mg once a day for twelve weeks
75622961|NCT00609531|Drug|Placebo|Placebo pill once a day for twelve weeks
75622962|NCT03414736|Drug|SAR425899|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
75622963|NCT04301466|Drug|Qi Zhi Tong Luo capsule|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. QZTL capsule, a traditional Chinese medicine. Each capsule was weighted 0.5g.
75622964|NCT04301466|Drug|Placebos|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
75622965|NCT04264923|Other|HyGIeaCare Prep|Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
75622966|NCT03406000|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection"
75622967|NCT02874300|Other|High intensity supervision arm|The higher-intensity supervision arm will comprise 6 occupational therapist (OT) home visits and 5 physiotherapist visits (1,1,2,2,6,12,18,24,30,36 and 52) plus supervised support from a rehabilitation support worker (RSW) twice a week for 3 months, once a week for 3 months, once a fortnight for 3 months and once a month for 3 months. Initially, and at review and progression points, the RSW will visit jointly with the therapists.
75622968|NCT02874300|Other|Moderate intensity supervision arm|The moderate-intensity supervision arm will be based on an ongoing Australian trial (83, 112). There will be 6 OT home visits and 5 physiotherapist visits (weeks 1,1,2,3,4,5,6,7,8,10,12) and three OT telephone calls (weeks 9,10,11). Participants will be expected to exercise independently in-between supervised sessions.
75776328|NCT05930639|Other|Surgical Site Infection (SSI) prevention package|"Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.~Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.~Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.~In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.~Before the operation and before discharge, the patient is educated about infection prevention measures."
75776329|NCT05930626|Other|Biomarkers of acrylamide, glycidol, POPs, PFAS|These are food contaminants (acrylamide, glycidol) and environmental pollutants (POPs, PFAS). Assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with POPs and PFAS using a prospective cohort study utilizing and integrating various 'OMICs' technologies.
75776330|NCT05930600|Device|Ultrasonography of Internal Jugular Vein|Non invasive monitoring of fluid responsiveness
75776331|NCT05930600|Device|Doppler Echocardiograhy|Non invasive monitoring of fluid responsiveness
75776332|NCT05930574|Procedure|Abdominal surgery|surgical interventions by gastrointestinal emergencies, hepatobiliary emergencies and trauma
75798383|NCT03870516|Procedure|Mitral valve replacement|Replacing the diseased mitral valve in cases with severe mitral regurgitation with a prosthetic valve.
75913744|NCT06081283|Drug|Levetiracetam|Pediatric population Loading dose 60 mg/kg intravenous. Max dose 4000mg. Maintenance dose 40mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 2000mg-4000mg intravenous. Maintenance dose 1500mg to 3000mg/day.
75320982|NCT02998255|Drug|Split dose of 4L PEG|All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
75320983|NCT00652717|Drug|Ezetimibe|Ezetimibe 10 mg daily for 42 days.
75622969|NCT04262037|Diagnostic Test|lung ultrasound|Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
75622970|NCT01052844|Drug|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
75622971|NCT01052844|Drug|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
75622972|NCT04261881|Dietary Supplement|ATP-Fuel|5 capsules daily with breakfast and 5 capsules daily with lunch
75622973|NCT04261881|Dietary Supplement|ATP-II|3 capsules daily with breakfast
75622974|NCT04261881|Dietary Supplement|ATP-II|3 capsules daily with breakfast and 3 capsules daily with lunch
75622975|NCT05319795|Behavioral|Effortful Swallow Maneuver|Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
75622976|NCT04261647|Other|kinesio-taping techniques.|
75622977|NCT04261647|Other|Pelvic floor exercise|
75622978|NCT04261647|Other|traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.|
75622979|NCT03679936|Diagnostic Test|PET/CT dynamic scan|This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.
75622980|NCT04261803|Biological|salivary sample|spit of saliva in a tube
75622981|NCT04261803|Biological|blood test|2millilitter blood test
75622982|NCT01049412|Drug|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
75622983|NCT01049412|Drug|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
75622984|NCT02692378|Drug|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
75622985|NCT02692456|Device|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
75622986|NCT02692456|Device|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
75776333|NCT05930548|Other|Low Shrinkage Giomer|Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).
75913745|NCT06081283|Drug|Lacosamide Injectable Product|Pediatric population Loading dose 10 mg/kg intravenous, Max dose 400mg. Maintenance dose 4mg to 8mg/Kg/day. Max dose 300mg. Adult population Loading dose 200mg to 400mg intravenous. Maintenance dose 200mg to 400mg/day.
75622987|NCT04302480|Other|Worksheets for ASP|The ASP intervention will cover the harms and misleading marketing strategies of ASPs and other related information.
75622988|NCT04302480|Other|Worksheets for SSB|The SSB intervention will cover the general information on SSBs, such as the sugar content of SSBs, nutrition labels and the harms of SSBs.
75622989|NCT04302480|Other|E-messages for ASP|In the subsequent month after the main intervention, students in the ASP group will receive 4-6 e-messages on ASPs, after which students will be invited to complete a 1-month follow-up assessment.
75622990|NCT04302480|Other|E-messages for SSB|In the subsequent month after the main intervention, students in the SSB group will receive 4-6 e-messages on SSBs, after which students will be invited to complete a 1-month follow-up assessment.
75622991|NCT02873988|Other|bronchial epithelial cell culture|
75622992|NCT05494918|Drug|JSKN003|JSKN003 is to be administered via intravenous (IV) dose
75622993|NCT04593498|Diagnostic Test|Holter recording|Holter recording with Zenicor Flex ECG during 14 days.
75622994|NCT04593498|Diagnostic Test|Echocardiography (Echo)|Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.
75622995|NCT04593498|Diagnostic Test|Blood sample|Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.
75622996|NCT04593498|Diagnostic Test|24 hour ambulatory blood pressure monitoring And Arteriograph|To assess artery stiffness.
75622997|NCT02584426|Device|Ultrasonic Distribution of Cefazolin|
75622998|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
75622999|NCT00934089|Drug|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
75623000|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
75623001|NCT00934089|Drug|latanoprost|Topical ocular solution, once-daily for 14 days
75623002|NCT05333068|Procedure|PCI revascularization strategy based on combined FFR and OCT assessment|PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with > 70 % AS or MLA < 2.5 mm2.
75623003|NCT05333068|Procedure|PCI revascularization strategy based FFR assessment|PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)
75623004|NCT01032174|Drug|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
75623005|NCT01032174|Drug|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
75623006|NCT03344146|Behavioral|Medication intake reminders|Acoustic and visual alarm at predefined DOAC-intake timepoints.
75776334|NCT05930470|Other|Magnetic Mitohormesis Therapy|The MMT device that will be used in the trial will be the QuantumTx BIXEPS Fitness and Wellness. The apparatus will provide pulsed electromagnetic fields at flux densities 1.5 mT. During the treatment period, participants will receive PEMF therapy during two ten-minute sessions each week for a total of 12 weeks. The treatment period will be preceded or followed by 12 weeks of twice-weekly sham treatments depending on randomization.
75776335|NCT05930392|Procedure|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
75623007|NCT03344146|Behavioral|Pillbox use and counselling|All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
75913746|NCT06081283|Drug|Valproate Sodium|Pediatric population Loading dose 30mg/kg intravenous. Max dose 3000mg Maintenance dose 20mg to 30mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 30 mg/kg intravenous. Maintenance dose 20mg to 30mg/Kg/day
75913747|NCT06081283|Drug|Phosphenytoin|Pediatric population Loading dose 20 mg PE/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day. Max dose 300mg PE/day. Adult population Loading dose 20 mg/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day.
75913748|NCT06079268|Other|the initial gastric ultrasound|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
75913749|NCT06079268|Other|the gastric ultrasound last 3 minutes|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
75623008|NCT02704780|Drug|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
75320984|NCT00652717|Drug|simvastatin|simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
75623009|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
75623010|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
75623011|NCT02704546|Drug|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
75776336|NCT05930392|Procedure|Conventional surgical depigmentation|GINGIVAL DEPIGMENTATION USING CONVENTIONAL SURGICAL TECHNIQUE
75776337|NCT05930899|Other|Genetics|TOmAS is a biobank and all patients will be genotyped
75776338|NCT05930379|Other|LSVT-Loud delivered by telerehabilitation|LSVT-Loud treatment delivered by telerehabilitation
75776339|NCT05930379|Other|LSVT-Loud in the clinic|LSVT-Loud delivered face-to-face in the clinic
75776340|NCT05930366|Procedure|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
75776341|NCT05930366|Procedure|Gingival Depigmentation using Diode Laser|GINGIVAL DEPIGMENTAION USING DIODE LASER
75776342|NCT05930353|Other|COHORT|this evaluation includes a brief interview with perma profiler scale
75776343|NCT05930314|Drug|CNCT19 cell injection|"Leukapheresis and manufacturing of CNCT19: enrolled subjects will undergo a leukapheresis to target a yield of > 1x 10^9 mononuclear cells~Lymphodepleting chemotherapy i. Fludarabine 25 to 30 mg/m2, once daily for 3 days ii. Cyclophosphamide 500 mg/m2, once daily for 3 days~CNCT19 administration i. 0.25 to 0.5 x 10^8 CAR-positive viable T cells"
75913750|NCT06079021|Device|CytoSorb|Application of CytoSorb treatment for 72 hours in patients with ACLF
75466512|NCT01910324|Behavioral|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
75466513|NCT01910324|Behavioral|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
75623012|NCT02704546|Drug|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
75623013|NCT01032018|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
75651650|NCT05832762|Procedure|Endovascular treatment (EVT) + Best medical treatment (BMT)|Endovascular treatment (EVT) in the experimental arm can be performed with any recanalization strategy based on the operator's choice, and anatomical and radiological situation: MT using aspiration or stent retriever, with or without stenting (CE-labelled) or angioplasty. In case of acute stenting, the use of antiplatelet drugs will be based on the operator's preference, anatomical situation, and risk of hemorrhage.
75913751|NCT06075810|Drug|MBQ-167|MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
75913752|NCT06074861|Procedure|Fasting-mimicking diet + non-surgical periodontal therapy|Test group will receive a full-mouth non-surgical periodontal therapy (also named professional mechanical plaque removal-PMPR) and, in the same day (starting at morning), a fasting-mimicking diet (FMD) will be started (for a cycle of 5 days). Other two cycles of FMD will be followed at 45- and 85- days after treatment, respectively.
75913753|NCT06068504|Other|Arm-cranking exercise|Arm-cranking exercise
75913754|NCT06068504|Other|Heating|Immersion of the foot in warm water
75913755|NCT06066424|Drug|Rimiducid|Given by (IV) vein
75913756|NCT06066424|Drug|TROP2-CAR-NK Cells|Given by (IV) vein
75913757|NCT06066424|Drug|Fludarabine phosphate|Given by (IV) vein
75913758|NCT06066424|Drug|Cyclophosphamide|Given by (IV) vein
75913759|NCT06065462|Drug|Dostarlimab|Given by vein (IV)
75913760|NCT06065462|Drug|LB-100|GIven by vein (IV)
75776344|NCT05930262|Device|TCM acupuncture therapy|TCM acupuncture therapy: Zusanli, Quchi, Hegu, Taichong, Feishu and Fenglong were selected as the main acupoints, and the auxiliary acupoints were selected according to the symptoms, including Fengchi, Dazhui, Lieque, Tiantu, Shenshu, Zhongfu, etc.
75776345|NCT05930262|Drug|Conventional drug therapy|Antibiotics were selected based on drug sensitivity test results. Patients with body temperature > 38.5℃ were treated with physical cooling and antipyretic drugs. In patients whose sputum was thick and difficult to cough up, nebulization and inhalation therapy was given, as well as effective coughing and patting the back to expel phlegm were guided.
75776346|NCT05930262|Behavioral|Rehabilitation therapy|Comprehensive training for hemiplegic limbs included a joint range of motion training, bridging exercise, turnover training, balance training, gait training, hand function training and self-care ability training, 40 min/d, 6 times/w.
75776347|NCT05930262|Behavioral|Breathing training|Training was conducted daily in the morning, or after symptom relief in the case of fever or other discomforts, once a day, 30-40 min/time.
75776348|NCT05930249|Behavioral|Personalized multidomain intervention|"Patients will complete personalized cognitive training based on baseline fNIRS on APP (20-30 mins/day, 3-4 days/week, 6 months).~Shared decision-making on risk factor of stroke between doctors and patients~Social support by grouping patients online to ensure close interaction with other patients in the same arm"
75776349|NCT05930236|Diagnostic Test|Lumbar medial branch block|The lumbar medial branch block on three lumbar levels (L3-L4, L4-L5 and L5-S1) will be performed by ultrasound-guidance in a longitudinal plane and the correct placement of the needle will be verified by radiography to show if the two modalities are equivalent.
75776350|NCT05930236|Drug|Lidocain|Linisol infiltration with depomedrol and omnipaque
75776351|NCT05930236|Drug|Methylprednisolone|infiltration with linisol and omnipaque
75776352|NCT05930236|Drug|Omnipaque|infiltration with linisol and methylprednisolone
75913761|NCT06063642|Device|Neurofeedback training|Neurofeedback training is a type of non-invasive brain modulation technique that enables individuals to self-regulate brain activity patterns by providing them feedback on specific activity measures. Effective self-regulation is often linked to changes in cognition, behavior, and clinical symptoms.
75913762|NCT06063642|Device|Sham feedback training|A controlled form of neurofeedback training that provides feedback irrelevant to the targeted mental process.
76073472|NCT01278316|Behavioral|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
76073473|NCT02991664|Other|Equia Forte|Glass ionomer restorative system
75623014|NCT01032018|Drug|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
75623015|NCT01032018|Other|Standard care|Participants will receive standard of care from the current physicians
75623016|NCT05332912|Behavioral|Spatial Ability Experience|Participants will engage in puzzle construction, block play, visual search, hide and seek
75623017|NCT04264221|Behavioral|New management mode|"New management mode intervention: Pharmaceutical care~SMS text messages and Phone Calls~Behavioural Educational leaflet~Self-Administered Therapy A financial incentive for mobile use"
75651651|NCT05832762|Procedure|Best medical treatment (BMT)|Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies.
75776353|NCT05930223|Drug|VAL-1221|VAL-1221 20mg/kg intravenous (IV) infusion every other week
75776354|NCT05930184|Procedure|peri-wound Transversus Abdominis Plane Block|0.25% bupivacaine 20ml was injected using no24 needle into a plane between internal oblique muscle and transversus abdominis muscle around every wound 2 cm. from wound opening. The procedure was confirmed by laparoscopic vision and the injection was done before removal of laparoscopic port.
75776355|NCT05930184|Procedure|Local wound infiltration|0.25% bupivacaine 20ml was injected using no24 needle into subcutaneous tissue after the abdominal sheet was sutured.
75776356|NCT05930132|Procedure|submucosal conchoplasty|Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved
75798384|NCT03870516|Device|Speckle tracking echocardiography|We will perform Speckle tracking echocardiography in order to identify patients with early subclinical left ventricular or left atrial dysfunction and refer them to surgery, Then after surgery, speckle tracking echocardiography will be performed for all patients to assess improvement of left atrial (conduit, reservoir and booster contractile functions) and left ventricular (global longitudinal strain) function
75913763|NCT06061848|Drug|SLIT Grazax ALK Nordic 75 000 SQ-T|Daily sublingual grass allergen tablets
75913764|NCT06061848|Drug|ILIT + Vitamin D|1 mL of Vicotrat D3, Heyl Pharma, 100 000 IU/mL, as intramuscular injection. Followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
76073474|NCT02991664|Other|G-aenial Posterior|Micro hybrid composite resin
76073475|NCT04386850|Drug|Oral 25-Hydroxyvitamin D3|Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.
76073476|NCT01278472|Device|Single Port Cholecystectomy|Using transumbilical single port device: SILS Port
76073477|NCT01278472|Device|4 Port Cholecystectomy|using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
76073478|NCT01272778|Drug|Lorazepam|Oral capsule, 0.2 mg, single acute dose
75776357|NCT05930132|Procedure|classic lateral lamellectomy|"Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period."
75913765|NCT06061848|Drug|ILIT + placebo|1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
75913766|NCT06060639|Diagnostic Test|transthoracic echocardiography|E wave, A wave, e' and vdi measurement
75913767|NCT06056297|Drug|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
75913768|NCT06056297|Drug|Placebo|Placebo will be administered per schedule specified in the arm description.
75913769|NCT06054009|Behavioral|Brief CBT|In Study 1: x4 CBT sessions addressing cognitive appraisals of dissociation. In Study 2: x4 CBT sessions addressing rumination/worry. In Study 3: x4 CBT sessions addressing affect intolerance.
75913770|NCT06053775|Device|Transcranial Direct Current Stimulation|tDCS+OCT
75623018|NCT00609687|Procedure|Diagnostic Vitrectomy|"Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.~Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance."
75623019|NCT00614848|Device|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
75320985|NCT04387591|Procedure|Fu's subcutaneous needling(FSN)|In this study, the doctor will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin of the middle of medial epicondyle and radial styloid process. Then the doctor will push forward the needle parallel to the skin surface (maintaining in the subcutaneous layer), towards the subject's medial epicondyle. The docotr will sway the needle 50 times in 30 seconds. After swaying the needle, the doctor will instruct the subject to do elbow flextion for 10 seconds resisting the doctor's opposite force, then the subject take a rest for 10 seconds. The above actions(elbow flexion and rest) are 3 repetitions. Then the subject do palmar flexion in the position of elbow flexion for 10 seconds resisting the doctor's opposite force, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the doctor will take out the needle to finish the treatment.
75913771|NCT06053775|Device|Transcranial Alternating Current Stimulation|tACS+OCT
75623020|NCT01031706|Drug|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
75623021|NCT01031706|Drug|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
75623022|NCT04260165|Procedure|Proximal Row Carpectomy|Excision of the proximal carpal row - the scaphoid, lunate and triquetrum
75913772|NCT06053775|Device|tES sham|tES sham + OCT
75466514|NCT01910337|Device|Use the Polar Cardiac rate meter|
75466515|NCT01910350|Behavioral|Kin KeeperSM Cancer Prevention Intervention|
75466516|NCT01910350|Other|Standard of care|
75466517|NCT01910363|Drug|A2NTX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
75623023|NCT04260165|Procedure|Four-corner fusion|Scaphoid excision and four-corner fusion with cannulated headless compression screws/dorsal plate
75623024|NCT00627510|Other|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
75913773|NCT06053775|Device|Online Cognitive Training|OCT
75466518|NCT01910363|Drug|BOTOX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
75623025|NCT05484934|Procedure|Regenerative post mastectomy surgery|Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
75623026|NCT05118243|Other|Control cracker|The gut symptoms caused by control crackers are studied in IBS persons
75466519|NCT01910415|Drug|Lumacaftor|
75466520|NCT01910415|Drug|Lumacaftor Placebo|
75466521|NCT01910415|Drug|Ivacaftor|
75466522|NCT01910415|Drug|Ivacaftor Placebo|
75466523|NCT01910415|Drug|moxifloxacin hydrochloride|
75466524|NCT01910428|Drug|L-asparaginase encapsulated in RBC|"50 IU/kg IV~100 IU/kg IV~150 IU/kg IV~200 IU/kg IV"
75623027|NCT05118243|Other|Enzyme-treated cracker|The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
75623028|NCT02873910|Dietary Supplement|IQP-AS-119|
75623029|NCT02873910|Dietary Supplement|Placebo|
75623030|NCT02704234|Other|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
75913779|NCT06047899|Dietary Supplement|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
75913780|NCT06047899|Other|Placebo|mannitol formulated for oral administration (capsules)
75913781|NCT06047613|Biological|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
76073479|NCT01272778|Drug|Lorazepam|oral capsule, 0.5 mg, single acute dose
75913782|NCT06047613|Other|Hetero-questionnaires and auto-questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself."
76073480|NCT01272778|Drug|Lorazepam|oral capsule, 1.0 mg, single acute dose
75320986|NCT04387591|Procedure|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced bya device to stimulate the nerves for therapeuticpurposes. TENS, by definition, covers the completerange of transcutaneously applied currents usedfor nerve excitation although the term is often usedwith a more restrictive intent, namely to describe thekind of pulses produced by portable stimulators usedto treat pain. The unit is usually connected to theskin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied athigh frequency (>50 Hz) with an intensity below motorcontraction (sensory intensity) or low frequency (<10Hz) with an intensity that produces motor contraction
75623031|NCT02704234|Other|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
75623032|NCT00927069|Drug|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
75623033|NCT00927069|Drug|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
75623034|NCT01031628|Drug|Imatinib mesylate|400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
75623035|NCT01031628|Drug|Imatinib mesylate|600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
75623036|NCT01031628|Drug|Imatinib mesylate|400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
75623037|NCT02704468|Other|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
75623038|NCT00609843|Other|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
75623039|NCT02691988|Other|ICS withdrawal|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
75776358|NCT05930080|Drug|SKCPT|the randomly assigned subjects took the study drug for 12 weeks
75776359|NCT05930080|Drug|Celebrex|the randomly assigned subjects took the study drug for 12 weeks
75913783|NCT06047613|Other|Magnetic Resonance Imaging (MRI)|MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
75913784|NCT06047132|Diagnostic Test|Salivaru biomarkers|C-reactive protein (CRP), triggering receptor expressed on myeloid cells-1 (TREM-1), interleukin (IL)-1beta, metalloproteinase (MMP)-8, IL-10, IL-6, monocyte chemoattractant protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Alpha (MIP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), Tumor Necrosis Factor-Alpha (TNF-alpha)
75320987|NCT00553891|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
76073481|NCT01272778|Drug|Lorazepam|oral capsule, 2.0 mg, single acute dose
76073482|NCT01272778|Drug|Placebo|oral capsule, single acute dose
76073483|NCT01272856|Drug|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
76073484|NCT01273090|Drug|imetelstat sodium|
75320988|NCT00553891|Drug|placebo nasal spray|One spray in each nostril once daily for 3 months.
75623040|NCT02691988|Other|Usual care|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
75623041|NCT01031004|Device|narafilcon B|contact lens
75623042|NCT01031004|Device|etafilcon A|contact lens
75623043|NCT01904656|Behavioral|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
75623044|NCT01904656|Behavioral|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
75623045|NCT00608673|Drug|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
75623046|NCT00608673|Drug|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
75623047|NCT01622062|Biological|PVRV|0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally
75623048|NCT01622062|Biological|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
75623049|NCT01622062|Biological|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
75776360|NCT05930054|Device|skeletal anchorage and rapid palatal expansion|Eighteen patients were randomly divided into 2 groups through a free randomization program (Random Allocation Software 2.0). Baseline demographic characteristics were matched in both groups. All appliances were fabricated by the same technician in the orthodontic lab. All individuals were treated by a single practitioner.
75776361|NCT05930015|Behavioral|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for eight weeks
76073485|NCT01273090|Other|laboratory biomarker analysis|
76073486|NCT01273090|Other|pharmacological study|
75623050|NCT02873676|Behavioral|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
75623051|NCT02873676|Behavioral|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
75623052|NCT02873676|Behavioral|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
75623053|NCT02873676|Behavioral|control|The intervention involve dietary pattern modification and protein intake standardization
75623054|NCT04263519|Drug|Tacrolimus|Oral Immunosuppressant
75623055|NCT04215718|Procedure|fistulotomy and marsupialization|the anal fistula was laid open and the the wound edges was marsupialized using vicryle 3\0 sutures
75623056|NCT04215718|Procedure|fistulectomy and wound closure|anal fistula was excised with both openings and the wound was closed
75623057|NCT00609921|Drug|ARQ197|treatment
75623058|NCT02704078|Device|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
75623059|NCT02704078|Device|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
75623060|NCT00637650|Procedure|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
75623061|NCT00637650|Procedure|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
75623062|NCT00637767|Drug|melphalan|
75623063|NCT00637767|Procedure|autologous hematopoietic stem cell transplantation|
75320989|NCT03599492|Diagnostic Test|SMART Pill Pre-TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
75320990|NCT03599492|Diagnostic Test|SMART Pill Post TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
75320991|NCT00684775|Combination Product|Work Plus Naltrexone Contingency|"Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition earned access to working and earning salary by taking depot naltrexone injections once per month."
75623064|NCT00637767|Radiation|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
75623065|NCT03570190|Other|Coordinator|"A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~Determination of the status quo~Dedicated reflection and training followed by implementation of tailored changes~Determination of the effect"
75623066|NCT01280500|Behavioral|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
75623067|NCT01280500|Other|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
75623068|NCT01280500|Other|usual care|No EMR
75623069|NCT01280500|Other|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
75623070|NCT01280500|Other|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
75623071|NCT05100849|Procedure|Kinect-based cognitive training|The Kinect-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. The cognitive training content will be projected onto a wall and patients will interact with the content, i.e., the selection of the appropriate response, through movement (kinect).
75623072|NCT05100849|Procedure|Tablet-based cognitive training|The Tablet-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. Patients will interact with the cognitive training content through a tablet.
75623073|NCT01221688|Procedure|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
75623074|NCT01221688|Procedure|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
75623075|NCT00609999|Drug|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
75623076|NCT00951652|Behavioral|CBT|
75776362|NCT05930015|Behavioral|Sports games intervention only|Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice; twice a week for eight weeks
75776363|NCT05930015|Behavioral|Music and sports games intervention|Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for eight weeks
75776364|NCT05930002|Drug|Ivermectin Tablets|oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days.
75776365|NCT05930002|Drug|Colchicine 0.5 MG|0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
75776366|NCT05930002|Drug|Standared managment|(Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks
75913785|NCT06045234|Other|Urine sampling|"Among the 300 people recruited:~300 will each provide 3 urine samples collected on 3 different days during a week (e.g. Monday, Wednesday and Friday)~50 will each provide 3 urine samples collected at sunrise, in the middle and then at the end of the day over a period of 24 hours, on 3 different days during a week (e.g. Monday, Wednesday and Friday)."
75913786|NCT06043739|Drug|Filgotinib|Commercially developed film-coated tablet administered orally
75913787|NCT06043739|Drug|Filgotinib|Film-coated mini-tablets administered orally
75776367|NCT05929989|Diagnostic Test|ELISA TEST|ELISA TEST for cystatin D and fibrinogen like protein
75623077|NCT00951652|Other|Interpersonal and emotional processing therapy|
75623078|NCT00951652|Behavioral|supportive listening|
75776368|NCT05929976|Other|No intervention|No intervention
75776369|NCT05929963|Other|HCV infection status|Divided into 3 groups based on HCVAb and HCVRNA status
75776370|NCT05929599|Drug|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
75776371|NCT05929599|Combination Product|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
75776372|NCT05929573|Diagnostic Test|Neutrophil Gelatinase-Associated Lipocalin|Neutrophil Gelatinase-Associated Lipocalin, which can be measured from serum or urine, can detect acute kidney failure that may occur after surgery in the early stages.
75776373|NCT05929573|Diagnostic Test|Renal Doppler Resistive Index|Renal Doppler Resistive Index (RDRI) is a non-invasive index believed to reflect renal vascular perfusion. RDRI measurement is a repeatable, inexpensive, and easy-to-apply technique. RDRI has been found to be associated with AKI in conditions such as renal dysfunction, hypertension, and post-traumatic hemorrhagic shock. Furthermore, due to the impact on renal perfusion in patients undergoing major surgery, RDRI, which reflects renal vascular resistance, can serve as an indicator of kidney perfusion.
75776374|NCT05929092|Procedure|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, the TFBC regimen (TBI/Flu/Bu/Cy) combined with UCBT is safe and feasible for the treatment of patients with high-risk malignant hematological diseases, which has enormous potential to improve patient outcomes.
75776375|NCT05928923|Device|CPAP|CPAP usage 3 months
75776376|NCT05928897|Drug|Disitamab Vedotin combined with Sintilimab|Disitamab Vedotin combined with Sintilimab
75913788|NCT06042751|Behavioral|Exercise Therapy|Six online consultations will take place on the basis of the sports medicine assessment every two weeks, resulting in 300 min in 3 months. For the home-based implementation, participants receive wearables with which the activity and training data are collected. In conjunction with feedback, the goal is to ensure that the interventions lead to improvements in self-control, reduced resilience, and fatigue without overwhelming participants with volume or intensity. Due to the expected large differences in personal performance, determined in the initial assessment, the exercise plan is individually designed and regularly adjusted. This includes control of everyday activity as well as moderate endurance and strengthening exercises totalling up to 30min daily. The individual training intensity is below the aerobic lactate threshold so that overload is avoided. The average training heart rate is planned to be in the range between 50 and 70% of the maximum heart rate.
76025593|NCT05403905|Procedure|non surgical treatment|Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
76025594|NCT05403905|Procedure|surgical treatment|The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
75623079|NCT00608751|Radiation|IMRT|
75623080|NCT00931515|Device|NuBac|NuBac device implanted at the L4/5 level.
75623081|NCT00931515|Device|Prodisc-L|Prodisc-L implanted at the L4/5 level.
75623082|NCT02703766|Behavioral|overfeeding induced weight gain|
75623083|NCT00823108|Drug|GIK|12 hour infusion of GIK solution
75623084|NCT04259619|Device|Low-Level Laser Therapy|The low-level laser emits monochromatic, coherent, bundled laser light. In each therapy a energy dose of 2-4 Joul (J) / centimeter (cm)^2 is applied over a duration of about 30 seconds using level 1 (20 percent of maximum output) of the 350 milliwatt (mW) device.
75623085|NCT04259619|Device|Placebo Therapy|The intervention is conducted identically to the low-level laser therapy but the placebo laser that is used emits only red light that is polychromatic, leading to a reduction in energy being emitted and therewith to no or a smaller effect.
75623086|NCT00627250|Drug|Amantadine|Amantadine 100 mg every morning and 12 noon
75623087|NCT05330949|Diagnostic Test|Optical coherence Tomography Angiography, Uterine artry doppler|vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters
75776377|NCT05928663|Other|double surgical gloves|In the intervention group, the surgical team members wore brown colored ENCORE® Latex Micro as the inner glove, while white MEDI-GRIP® Latex Standard was used as the outer glove
75776378|NCT05928663|Other|single surgical gloves|MEDI-GRIP® Latex Standard surgical gloves were included in the study as a single layer sterile surgical glove in the control group
76025595|NCT04893707|Biological|CM310|"adults and teenagers (12 ~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 ~ 18 years) with weight ≥30 kg and <60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
75623088|NCT04301232|Other|Modified Aldrete Scoring System (mASS)|Activity( Moves all extremities, Moves two extremities, Unable to move extremities), Respiration( Breathes deeply, coughs freely, Dyspneic, shallow or limited breathing, Apneic), Circulation (blood pressure) ( 20 mm Hg > preanesthetic level, 20 - 50 mm Hg > preanesthetic level, 50 mm Hg > preanesthetic level), Consciousness (Fully awake, Arousable on calling, Not responding), Oxygen saturation( SpO2 > 92% on room air, Supplemental O2 required to maintain SpO2 > 90%,SpO2 < 90% with O2 supplementation), scoring is done as 2,1,0, respectively. A score of 9 or more would be required for a patient after general anesthesia for discharge
75320992|NCT03681860|Biological|ChAdOx185A|ChAdOx1 85A is an adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A. Adenoviruses are attractive candidates for use as viral vectors and have been used as vaccine vectors for a number of conditions; however, the use has been limited by the high level of anti-vector immunity present in humans in whom adenovirus is a ubiquitous infection. This has led to the consideration of simian adenoviruses, which are not known to cause pathology or illness in humans and to which the prevalence of anti-vector antibodies is low. The ChAdOx1 vector has been developed by the University of Oxford and been used with different inserts for vaccination, for example the vaccine ChAdOx1 NP+M1 has demonstrated an excellent safety profile in the Influenza trial FLU004. A BCG - ChAdOx1 85A - MVA85A prime boost regime is more protective than BCG alone in mice.
75320993|NCT03681860|Biological|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly-attenuated strain of vaccinia virus which cannot replicate in human cells. It is known to be highly immunogenic in UK adults but has been less immunogenic in African children and infants. It is suitable for use as a viral vector in a prime-boost regime in new vaccine development. It has an excellent safety record as it was administered intradermally to approximately 120,000 people during the smallpox eradication campaign, and has since been used in numerous clinical trials of candidate vaccines against viral, mycobacterial and protozoal infections.
75320994|NCT03681860|Biological|BCG|BCG is the only vaccine currently approved for use against Tuberculosis.
75320995|NCT00685477|Drug|Experimental Sequence ABC|Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
75623089|NCT04301232|Other|White's Fast-Track Scoring System (WFTSS)|Physical activity (Able to move all extremities on command, ,Some weakness in movement of extremities, Unable to voluntarily move extremities),Respiratory stability(Able to breathe deeply,Tachypnea,Dyspneic),Hemodynamic stability; (Blood pressure(MAP)<15%, Blood pressure 15-30%, Blood pressure>30%, Level of consciousness,(Awake&orientated Arousable with minimal stimulation, Responsive only to tactile stimulation),Oxygen saturation status(Maintains value>90% on room air, Requires supplemental oxygen, Saturation<90% with supplemental oxygen), Postoperative pain assessment(None or mild discomfort, Moderate to severe pain controlled with analgesics, Persistent severe pain), Postoperative emetic symptoms(None or mild nausea w/no active vomiting, Transient vomiting or retching, Persistent moderate to severe nausea&vomiting), Scoring is done as 2,1,0, respectively. A minimal score of 12(with no score<1 in any individual category)would be required for a patient after general anesthesia
75651652|NCT05832749|Device|Ophtesis Bio 3% ophthalmic viscosurgical device|Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.
75776379|NCT05928494|Other|Scenario-based high-fidelity simulation method|Postpartum care applications were carried out with the high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the midwifery department to the students in the intervention group.
75776380|NCT05928195|Dietary Supplement|Acute Moderate-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with one capsule containing 600 mg AmaTea® and 1 containing 600 mg dextrose.
75776381|NCT05928195|Dietary Supplement|Acute High-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with each capsule containing 600 mg AmaTea® (1200 mg total).
75776382|NCT05928195|Dietary Supplement|Placebo|Participants will consume two vegan capsules with each capsule containing 600 mg dextrose (1200 mg total).
75776383|NCT05927909|Diagnostic Test|Low Back Activity Confidence Scale (Lobacs)|Confidence Scale (LOBACS) is a self-report questionnaire designed to assess an individual's level of confidence in performing various physical activities involving the lower back region, to evaluate their perceived functional ability, and to assess the impact of low back pain on their daily life and functional performance.
75776384|NCT05927896|Diagnostic Test|6-item Carpal Tunnel Syndrome Symptoms Scale|6-item Carpal Tunnel Syndrome Symptoms Scale is a self-reported 6 item questionnaire.
75776385|NCT05926921|Other|music|Brahms' Lullaby will be played from a speaker at 50 decibels
75776386|NCT05926557|Procedure|Spermidine gel|First step: Non-surgical mechanical debridement (NSMD) Second step: application of spermidine gel
75776387|NCT05926557|Procedure|NSMD|Only mechanical debridement with curettes and scaler peek tips
75320996|NCT00685477|Drug|Experimental Sequence ACB|Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
75320997|NCT00685477|Drug|Experimental Sequence BAC|Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
75320998|NCT00685477|Drug|Experimental Sequence BCA|Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
75320999|NCT00685477|Drug|Experimental Sequence CAB|Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
75321000|NCT00685477|Drug|Experimental Sequence CBA|Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
75913789|NCT06042751|Behavioral|Psychotherapy|Six online consultations will take place based on the psychosocial assessment and the initial psychosomatic interview every two weeks, resulting in 300 min in 3 months. A structured, telemedicine-supported, modularized, brief psychosomatic intervention is planned with a focus on psychoeducational elements, promotion of self-management, improvement of illness acceptance, modification of self-monitoring, and learning to cope with altered performance levels. The six modularized telemedical sessions taking into account the specific deficits identified in the psychosomatic evaluation. Within the sessions, starting points are identified with the patients, which the patients can work on independently between the sessions.
75623090|NCT04301232|Other|SPEEDS criteria|"Extremity movement (moves all four) Y/N, Stable vital signs( SBP > 90 and < 180, HR > 50 and < 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation >90% in roExtremity movement (moves all four) Y/N, Stable vital signs( SBP > 90 and < 180, HR > 50 and < 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation >90% in room air Y/N, Pain Control (VAS < 4) Y/N, Emesis Control Y/N. A patient must have a response of yes to all parameters to progress to phase II recovery"
75623091|NCT02692144|Other|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
75623092|NCT04300374|Other|The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively|routine remifentanil infusion during general anesthesia
75623093|NCT02703376|Drug|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
75623094|NCT04259697|Other|Clinical pilates|Clinical pilates exercises will be performed progressively. The duration of each exercise session will be an average of 40 minutes initially and then will be increased to 60 minutes as the program progress.
75623095|NCT04259697|Other|Whole body vibration|Whole body vibration exercises will be performed using the Power Plate pro5 AIRdaptive machine.The duration of each exercise session will be an average of 20 minutes initially and then will be increased to 30 minutes as the program progress.
75623096|NCT04301388|Procedure|Transvaginal ultrasound|Transvaginal ultrasound to measure cervical length if persist regular uterine contraction
75623097|NCT00615394|Procedure|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
75623098|NCT02873442|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
75623099|NCT02873442|Biological|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline~+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
75623100|NCT04261179|Drug|Lymphoseek|50 μg microgram(s), timepoint: 30-60 minutes
75623101|NCT04261179|Drug|Nanocoll|500 μg microgram(s), timepoint: 30-60 minutes
75623102|NCT00610077|Drug|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
75623103|NCT00610077|Drug|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
75623104|NCT00823576|Drug|Ropivacaine|Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
75776388|NCT05925894|Drug|Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma|60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
75776389|NCT05925582|Other|vestibular based exercise program|this group's participants will involve in vestibular based exercise program
75776390|NCT05925582|Other|calisthenic based exercise program|this group's participants will involve in calisthenic based exercise program
75776391|NCT05924867|Other|plasma activated saline|The plasma activated normal saline used in the intervention was prepared by a self-made machine, and the safety of the plasma activated water produced by the machine has passed the national quality inspection.
75776392|NCT05924867|Other|Routine nursing|For postoperative incision infection group and infected ulcer group, conventional dressing change treatment was given, namely chlorhexidine disinfectant washing, drainage and bandaging; For the fat liquefaction group, conventional treatment was given, namely negative pressure suction.
75776393|NCT05924620|Drug|finerenone|Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
75776394|NCT05924282|Procedure|Curative intent surgery|Curative intent surgery means that surgeons intend to perform R0 resection.
76025596|NCT02669095|Device|Investigational Contact Lenses (Test)|
76025597|NCT02669095|Device|Marketed Contact Lenses (Control)|
76025598|NCT04637555|Drug|sacubitril/valsartan|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
76025599|NCT02388061|Drug|Tenecteplase|
76025600|NCT02388061|Drug|Tissue Plasminogen Activator|
75776395|NCT05923385|Diagnostic Test|Four Square Step Test|These are standardized test which will be applied to subjects with pencil, paper and time recorder.
75321001|NCT03594890|Biological|OVX836 (Intramuscular)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
75321002|NCT03594890|Biological|Placebo (Intramuscular)|2 consecutive administrations of placebo at Day 1 and Day 29.
75623105|NCT01028352|Drug|Duloxetine|"Patients will be treated with open-label duloxetine:~30 mg daily x 7 days, then~60 mg daily x 3 weeks, then~If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
75623106|NCT03172780|Drug|Diclofenac sodium gel 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
75623107|NCT03172780|Drug|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
75623108|NCT03172780|Drug|Placebo gel|Vehicle Gel 4 gm, 4 times a day for 4 weeks
75623109|NCT00929643|Other|no intervention|success of the initial empiric treatment
75623110|NCT05011617|Device|Non-intubation and monitoring anesthesia care (MAC)|Non-intubation and monitoring anesthesia care (MAC) consisted of non-intubation technique, local anesthesia at the site of sternotomy, sedation with dexmedetomidine, analgesia with remifentanil/sufentanil, and electroacupuncture.
75623111|NCT02703298|Drug|TRX-818 capsules|
75623112|NCT04259385|Behavioral|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
75623113|NCT04259385|Behavioral|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
75623114|NCT04261101|Other|Test-enhanced learning|Test-enhanced learning with short answers of questions regarding diabetes and adrenal
75623115|NCT03101488|Drug|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
75623116|NCT00926367|Drug|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
76073487|NCT04386694|Device|Active PBMT/sMF|The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
75623117|NCT00926367|Drug|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
75623118|NCT02703142|Procedure|Patients after esophagectomy|postoperative endoscopic evaluation
75623119|NCT04261023|Drug|Orencia 125 MG Per 1 ML Prefilled Syringe|Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
75776396|NCT05923086|Drug|ORE001|Administration before major meal
75321003|NCT03594890|Biological|OVX836 (Intranasal)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
75321004|NCT03594890|Biological|Placebo (Intranasal)|2 consecutive administrations of placebo at Day 1 and Day 29.
75321005|NCT02997943|Behavioral|Step 1 Treatment: APP|Participants will receive a smartphone app to track weight, dietary intake and physical activity, and a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker. Participants will use their own smartphone to receive the study smartphone application.
75321006|NCT02997943|Behavioral|Step 1 Treatment: APP + Coaching|Participants will receive a smartphone app to track weight, dietary intake and physical activity; a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker; 12 weekly telephone coaching sessions. Participants will use their own smartphone to receive the study smartphone application.
75321007|NCT02997943|Behavioral|Step 2 Treatment Strategy: Modest Step-up|In addition to first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) for the remaining 12 weeks.
75623120|NCT05086341|Device|My COPD|In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
75623121|NCT01114529|Drug|Everolimus|Early CNI to everolimus conversion
75623122|NCT01114529|Drug|Prograf or Neoral|Active CNI-based control (Prograf or Neoral)
75776397|NCT05923086|Drug|Placebo|Administration before major meal
75776398|NCT05922423|Behavioral|MBSR|Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
75776399|NCT05922423|Behavioral|health education|For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
75776400|NCT05921006|Drug|RJ4287|Oral，tablets，Once daily for 14 days
75776401|NCT05921006|Drug|Placebo|Oral，tablets，Once daily daily for 14 days
75776402|NCT05915351|Drug|Enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg on D1, D8, D15 every 28 days
75321008|NCT02997943|Behavioral|Step 2 Treatment Strategy: Vigorous Step-up|In addition to the first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) plus a traditional weight loss intervention component (coaching, meal replacements).
75321009|NCT00686257|Device|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
75321010|NCT00686257|Device|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
75321011|NCT04403360|Procedure|ESPB|Ultrasound guided performance of ESPB at T12 level after the induction of anesthesia but before the start of the surgery
75321012|NCT04403360|Procedure|Local infiltration by the surgeon|Local infiltration of anesthetics at surgical site after skin incision
75623123|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
75623124|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
75623125|NCT00926289|Drug|Hydrochlorothiazide|Hydrochlorothiazide25mg
75776403|NCT05913024|Biological|Enterovirus Type 71 Vaccine|Participants received two doses of the vaccine, 28 days apart
75776404|NCT05912153|Diagnostic Test|SPECT/CT|SPECT/CT of the foot and ankle
75776405|NCT05912153|Diagnostic Test|MRI|MRI of the foot and ankle
75776406|NCT05910073|Device|Lamina curved plate|Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC
75776407|NCT05909839|Other|7T MRI network analysis for deep brain stimulation in essential tremor|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in ET patients.
75776408|NCT05909657|Other|questionnaires (surveys)|Mixed-methods study. Both the qualitative interview guides and the questionnaire surveys are adapted from the Sickle Cell Disease Implementation Consortium (SCDIC) project which is a multicentre study occurring in the United States.
75776409|NCT05909618|Drug|Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]|5 mg/kg solution for injection
76025601|NCT04598789|Other|no intervention|no intervention, observational study
76025602|NCT05134961|Procedure|Pancreaduodenectomy and possible adjuvant therapy|Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.
75321013|NCT06146647|Behavioral|Positive body image TV show|This is a 15 minute (approximately) show that has positive body image content embedded in the storyline. It also showcases a diverse range of body sizes in the casting.
75321014|NCT06146647|Behavioral|Positive body image music video|This is a positive body image song with strong visual representation of diverse body sizes in the music video.
75321015|NCT06146647|Behavioral|Active control TV show about a visit to the dentist|14 minute tv show following a tv character as he visits the dentist.
75623126|NCT02707276|Device|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
75623127|NCT02707276|Device|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
75623128|NCT02699398|Behavioral|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
75623129|NCT02699398|Behavioral|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
75623130|NCT04309643|Drug|CTP-543|Investigational Drug
75776410|NCT05909618|Drug|Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]|3 mg/mL solution for injection
75776411|NCT05905263|Other|Application group with virtual reality|Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously.
75776412|NCT05903183|Biological|IVX-A12|IVX-A12 without adjuvant
75776413|NCT05903183|Biological|IVX-A12|IVX-A12 with adjuvant
75776414|NCT05903183|Biological|Placebo|Diluent
75776415|NCT05902962|Drug|VP-001|Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy
75776416|NCT05902884|Device|MSOT Acuity Echo|Imaging of muscles applying Multi-spectral optoacoustic tomography (MSOT)
75776417|NCT05902117|Diagnostic Test|Troponin and Copeptin assay|Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
75776418|NCT05900180|Behavioral|Speech Therapy|Delivery of speech therapy services
75798385|NCT01166022|Other|Exercise|Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
76025603|NCT04587635|Dietary Supplement|PHGG|PHGG
76025604|NCT04587635|Dietary Supplement|Placebo|Maltodextrin
76025605|NCT02387827|Behavioral|Diet+ short term versus long -term physical activity|
75776419|NCT05899010|Drug|Vaginal progesterone 600mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH <7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone <10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
75776420|NCT05899010|Drug|Vaginal progesterone 800mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH <7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone <10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
75776421|NCT05896085|Other|REThink game|The Rethink therapeutic game is an online game developed based on Rational-Emotive Behavioral Therapy and has two versions: for children and adolescents and for adults. The Rethink therapeutic game for adults is available in 3D and VR version and consists of four levels, each of them training a specific emotion regulation ability such as: emotional awareness, mindfulness, cognitive change
75776422|NCT05895890|Genetic|Sequential sampling (stool, saliva, serum) .|Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.
75776423|NCT05894564|Drug|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
75776424|NCT05894564|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
75776425|NCT05894473|Other|Motor-Motor Dual Task Physical Exercises|Only physical exercise and motor dual tasks will be given
75776426|NCT05888064|Diagnostic Test|diffusion MRI sequences|Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
75776427|NCT05885958|Other|Time|Patients will be given up to 30 minutes to void.
75776428|NCT05885958|Other|Time|Patients will be given up to 60 minutes to void.
75913794|NCT06042491|Behavioral|Prehabilitation intervention|The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions >= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.
75913795|NCT06042231|Behavioral|Exercise Intervention|Exercise and education intervention. Participants will be prescribed a tailored exercise program to complete before ('pre-habilitation') and after their AF ablation procedure (rehabilitation).
75913796|NCT06042231|Behavioral|Education Intervention|Education intervention. Participants will be given a 1-1 education session (up to 3 sessions) before and after their AF ablation procedure. Participants will be given behavioural strategies to improve adherence and compliancec to risk-factor modification.
76025606|NCT04556357|Drug|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
75321016|NCT06146647|Behavioral|Active control music video about washing a car|Music video of a tv character singing while washing his transport.
75321017|NCT05310084|Biological|BNT162b2|Intramuscular injection
75321018|NCT05310084|Other|Placebo|Saline intramuscular injection
75321019|NCT05310084|Biological|Seasonal Inactivated Influenza Vaccine|SIIV intramuscular injection
75321020|NCT04859114|Behavioral|Format of outcome data presentation|Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.
75321021|NCT04859114|Behavioral|Displayed chance of survival|In the outcome data provided to participants, they view either a 30% or 60% chance of survival.
75623131|NCT04309643|Drug|Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)|Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
75623132|NCT02881073|Other|Maternal plasma PlGF quantification|A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
75623133|NCT03208036|Device|TDCS|1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes
75623134|NCT03208036|Device|Sham Stimulation|Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition
75776429|NCT05885217|Other|measure serum MicroRNA in acne vulgaris|Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)
75776430|NCT05878912|Other|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
75776431|NCT05877573|Drug|Toripalimab|Toripalimab 240mg,d1,q3w
75776432|NCT05877573|Radiation|short-term radiotherapy|25Gy/5Fx
75776433|NCT05877573|Drug|Oxaliplatin|135mg/m2 d1 q3w
75776434|NCT05877573|Drug|Capecitabine|1200mg/m2 d1-14 q3w
75776435|NCT05875649|Combination Product|CLAG|Acute myeloid leukemia patients are re-induced by CLAG Regimen after first-induction failure
75776436|NCT05872542|Drug|Silver Diamine Fluoride (SDF)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
75776437|NCT05872542|Other|Glass Ionomer Restoration (GI)|Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.
75776438|NCT05872542|Other|Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
75776439|NCT05872425|Drug|DingKunDan(GuangYuYuan)|"The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment."
75798386|NCT01281930|Procedure|Full packing into abscess cavity|After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
75913797|NCT06034496|Device|Active CES|Active CES group will receive a minimum of 250µA and up to 500µA depending on thresholding, once daily for 20 days (over the course of 4~6 weeks), 20 minutes per day.
75623135|NCT03208036|Behavioral|Cognitive Remediation|Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.
75623136|NCT03208036|Behavioral|Bridging Group|Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.
75623137|NCT04259307|Drug|Omapone Peri 724mL or Winuf Peri 654mL|Additional intravenous nutrition of 500 kcal per day for 3 weeks
75623138|NCT00926211|Device|ARTAS™ System|Hair harvest using a computer-assisted system
75798387|NCT01281930|Procedure|Wick placement into abscess cavity|After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
75913798|NCT06034496|Device|Sham CES|Sham CES group will be identical to Active CES group with the exception of the device not administering any electrical current
75913799|NCT06034366|Drug|0.01% atropine|0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
75913800|NCT06034366|Other|0.9% sodium chloride|placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks
75913801|NCT06030908|Procedure|Reconstruction of Achilles tendon insertion|knotless double-row anchor fixation of the achilles tendon insertion
75913802|NCT06029959|Device|Continuous positive airway pressure (CPAP)|Eligible participants with a diagnosis of OSA will be set up with autotitrating CPAP by the study's sleep technologist. The CPAP device includes an auto-titrator that adjusts the delivered pressure between 5 to 15 cm of water to eliminate obstructive events.
76025607|NCT04556357|Drug|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
75623139|NCT00926211|Procedure|Manual Hair Harvest|Hair harvesting via the manual technique
75623140|NCT04310813|Diagnostic Test|Multimodal spectroscopic analysis|During time of bladder or prostate resection, freshly excised cold cup biopsies of both bladder cancer or healthy bladder mucosa were taken and sent for inspection through label-free multimodal fiber optic spectroscopy (MFOS) within 30 minutes
75321022|NCT04581863|Device|pulse oximeter|Patients will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is >3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
75623141|NCT03188146|Drug|Ursodeoxycholic Acid|Standard care of PBC patients
75623142|NCT00610233|Procedure|deep brain stimulation ON|deep brain stimulation in the ON state
75321023|NCT04581863|Other|COVID Watch|Enrolled patients receive text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately.
75321024|NCT04349891|Device|Transcutaneous Electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
75623143|NCT00610233|Procedure|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
75623144|NCT02880839|Device|Partial cervical lamina excision group|Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
75776440|NCT05872425|Drug|Drospirenone and Ethinylestradiol Tablets (Ⅱ)|The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
75623145|NCT02880839|Device|Pipeline-dredge discharge group|Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
75776441|NCT05870709|Other|sacubitril/valsartan|There is no treatment allocation. Patients with a first ambulatory sacubitril/valsartan prescription who are interested in study participation will be enrolled.
75776442|NCT05870514|Drug|Fospropofol disodium for injection|Patients in the experimental group received fospropofol disodium for injection at an initial infusion rate of 10 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
75776443|NCT05870514|Drug|Propofol|Propofol
75776444|NCT05867862|Other|Test|"A dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist.~If dental treatments are needed, they will be done at the same time, or they will be programmed for another time at the center of dental care (CSD).~Due to the fact that most patient live far away from Nantes and the hospital, teleconsultation for patient in the test groups will happen every 2 months"
75776445|NCT05866913|Procedure|Sciatic nerve slippage.|Sciatic nerve slippage.
75776446|NCT05866913|Procedure|Passive stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
75776447|NCT05866913|Procedure|passive shoulder mobilization.|passive shoulder mobilization.
75776448|NCT05859880|Behavioral|Expressive writing intervention|4 videoconference-delivered group-based expressive writing sessions
75776449|NCT05858385|Other|Routine oral care|During the radiotherapy period, all patients received pain management, diet consultation and appropriate dental preventive management every week by radiologists, dietitian and dentists, and all patients completed treatment unrelated to the severity of mucositis.
75776450|NCT05854719|Behavioral|Speechreading training with an application|Optic Track application developed for this intervention will be used in speechreading training. The target is that, during the eight intervention weeks, it would be used for 15 minutes at least three times a week.
75776451|NCT05851911|Biological|sars-cov-2 vaccine or infection|Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2
75776452|NCT05851794|Procedure|endomanometric guided LNF|use of endomanometry during LNF
75776453|NCT05851794|Procedure|laparoscopic Nissen fundoplication alone|laparoscopic Nissen fundoplication alone
75776454|NCT05851560|Drug|Oxidized regenerated cellulose(ORC)|Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
75776455|NCT05851560|Drug|Hyaluronic acid(HA)|Hyaluronic acid(HA)
75776456|NCT05850923|Other|speech competition training|Speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction.
75776457|NCT05850923|Other|the soothing music|the soothing music
75913803|NCT06029959|Behavioral|CPAP technical support intervention|SCOUTS 3 sleep technologists (ST) will make mask type/size or device adjustments, as needed, and provide training to participants and CPAP partners to improve skills involved with mask placement and device maintenance. For participants with non-acceptance of CPAP over the first night, a standardized desensitization program will be implemented. Persistent problems with CPAP use or mask fit, or any high residual respiratory events will be discussed between the sleep technologist and the study's board-certified sleep medicine physician.
76025608|NCT02933281|Biological|MTBVAC|Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
76025609|NCT02933281|Biological|BCG|BCG 5 x 10^5 CFU
75321025|NCT04349891|Device|Sham TEA|Sham will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
75321026|NCT02258451|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of NIST update)
75623146|NCT02880839|Device|Digital navigation group|Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
75623147|NCT02699320|Other|Complications|Not involved
75623148|NCT04259073|Drug|Pregabalin 150mg|two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section
75623149|NCT04259073|Drug|Placebos|two capsules filled with sugar ingested orally one hour before cesarean section
75623150|NCT04259073|Drug|Pregabalin 300mg|two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
75776458|NCT05847894|Diagnostic Test|Ophthalmic examination|Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
75776459|NCT05847894|Diagnostic Test|Pulmonary Examination|Various pulmonary examination modalities, including radiography, chest CT, pulmonary function measurement, etc.
75776460|NCT05842902|Behavioral|mPRISM|PRISM is a brief, 1:1, skills-based resilience intervention delivered in-person by trained layperson coaches. PRISM's development was based on iterative research within the AYA oncology population, stress and coping theory, resilience theory, and successful cognitive-behavioral and mindfulness interventions. mPRISM is a digital version of the PRISM program with no in-person delivery. mPRISM includes coping skills modules: managing stress, goal-setting, cognitive reframing, and meaning-making.
75798388|NCT01170858|Drug|Icodextrin PD solution|2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
75798389|NCT01170858|Drug|glucose solutions|
75321027|NCT02258451|Drug|Placebo (saline)|Up to 6 cycles of saline injection
75321028|NCT02258451|Drug|Exemestane|One 25 mg tablet once daily after a meal.
75623151|NCT04303793|Device|Percutaneous PDA closure|transcatheter patent ductus arteriosus closure
75321029|NCT02258451|Drug|Everolimus|"The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice."
75776461|NCT05838963|Diagnostic Test|CTQ-SSS scores|"The CTQ-SSS is a self-reported questionnaire that measures the severity of symptoms related to carpal tunnel syndrome, including pain, numbness, tingling, and weakness in the hand and wrist.~Participants in this study will complete the CTQ-SSS and other functional measures that include:~demographic information~hand dominance~Boston Carpal Tunnel Questionnaire (BCTQ)~nerve conduction studies (NCS) to measure median nerve conduction velocity (NCV), distal motor latency (DML), and sensory nerve action potential (SNAP) amplitude, Compound muscle action potential (CMAP) amplitude.~Hand grip strength~Outcomes will be measured at baseline, 3 months, 6 months, and 12 months.~The primary outcome will be progression to carpal tunnel release surgery, and logistic regression models will be used to assess the predictive value of baseline CTQ-SSS scores for this outcome, adjusted for potential confounding factors such as age, sex, and baseline symptom severity."
75776462|NCT05835869|Diagnostic Test|Optical coherence tomography angiography and pattern electroretinogram|Optical coherence tomography angiography is an infrared eye scan that analyzes retinal vascularization and anatomy
75776463|NCT05835193|Other|Diagnostic Test: Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity and reading capacity of pre-school students in Alexandroupolis, Greece will be examined via a web-based digital visual acuity chart
75623152|NCT00609063|Drug|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
75776464|NCT05833516|Diagnostic Test|Cardiac Catheterization|"The cardiac catheterization is an invasive procedure in which right or left radial artery of patient will be accessed to obtain cardiac angiogram. The study participants are both operators and patients by obtaining the amount of radiation they both were exposed in these two different arm techniques.~The patient will have to do nothing more than following the existing standard protocols which are followed nationwide. As, the radiation exposure to patients are already measured in the software itself. The operators however would be wearing radiation badges in 4 different anatomic locations to record radiation data for study."
75623153|NCT00609063|Drug|Placebo|Placebo capsules taken daily for 6 months
75776465|NCT05830656|Behavioral|Exposure to nearby nature|Participants spend a minimum of 20 minutes in their favourite place in nearby nature.
75776466|NCT05830656|Behavioral|Exposure to virtual nature|Participants spend a minimum of 20 minutes watching virtual nature videos.
75776467|NCT05827289|Device|Cancer Patients Better Life Experience (CAPABLE)|The CAPABLE system serves three main goals for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing. These are available to the patient as a smartphone application that is connected to a smartwatch to monitor activity, blood pressure, sleep and heart rate. Patients are able to report symptoms experienced from the treatment and are eligible to do interventions such as mindfulness or yoga. Patients will receive the CAPABLE application and smartwatch for a minimum 3 to a maximum of 6 months after start treatment.
75913804|NCT06029959|Behavioral|Motivational Enhancement Therapy (MET)|In-person Motivational Enhancement Therapy (MET) sessions by a trained sleep coach will occur within a week of starting CPAP and, with permission, conducted with a CPAP partner, when available. The MET session recordings will be uploaded into the HIPAA compliant Lyssn platform for evaluation, including feedback to the sleep coach. The goal will be 5 total MET sessions, either in-person or by phone, spanning the inpatient and then outpatient settings.
75913805|NCT06029959|Behavioral|Mobile Health intervention|Study participants will be assisted in registering for and trained on the ResMed myAir app. Participants will also receive mobile health messages based on Self-Determination Theory.
75776468|NCT05825300|Behavioral|Email message|Email message encourages patients to donate blood
75913806|NCT06029114|Diagnostic Test|Magnetic Resonance Elastography (MRE)|Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.
75913807|NCT06027801|Other|Iron-fortified cookies|Study cookies fortified with ferrous fumarate, providing 15 mg of elemental iron in each portion.
75913808|NCT06027801|Biological|Japanese encephalitis (JE) vaccine|All participants will be administered the live attenuated JE vaccine
75913809|NCT06027801|Biological|Typhoid Vi polysaccharide (Vi-PS) vaccine|All participants will be administered the typhoid Vi-PS vaccine
75913810|NCT06027801|Other|non-fortified cookies|Study cookies containing no iron
75913811|NCT06027437|Drug|Danicamtiv|Specified dose on specified days.
75913812|NCT06024434|Other|Exercises|Experimental Group Exercises for Core: Crunches, Glute bridges Crunches Glute bridge Week 1-2 (set/rep/sec) Week 3-4 (set/rep/sec) Week 5-6 (set/rep/sec) Exercises for upper body: Push up (4), Bicep curls Exercises Weeks Reps/sets Push up walk out Bicep curls 1-3 16-20*3 Push up Bicep curl with Dumbbell 4-6 12-15*3 Exercises for Lower body: Lunges and Squats Exercises Weeks Reps/set Split Squat with body weight Body weight Squat 1-3 16-20*3 Split Squat with Dumbbell Squat with Dumbbell 4-6 12-15*
75623154|NCT02703064|Dietary Supplement|Furocyst|Furocyst caps BD
75623155|NCT01114373|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
75623156|NCT01114373|Drug|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
75913813|NCT06024434|Other|Walking|Walking for 30min, 5 days a week
75913814|NCT06024291|Other|8-week HIIT programme|See arm description
75913815|NCT06024291|Other|Physical activity recommendation|See arm description
75623157|NCT02699476|Behavioral|Psycho-Social Therapy|
75623158|NCT02699476|Device|Cognitive Behavioral Computer Training|
75623159|NCT02699476|Behavioral|Interactive Trainer-Subject Sessions|
75623160|NCT02699476|Device|Active Control Games|
75623161|NCT00925899|Drug|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
75623162|NCT00925899|Drug|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
75623163|NCT02601586|Drug|PR Oxycodone|PR Oxycodone
75623164|NCT02601586|Drug|Levodopa|Levodopa
75623165|NCT02601586|Drug|Oxycodone Placebo|Placebo of PR Oxycodone
75623166|NCT02601586|Drug|Levodopa placebo|
75776469|NCT05825300|Behavioral|Social responsibility|Message specifies that there is a shortage of the patient's blood type
75776470|NCT05815433|Other|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
75776471|NCT05814133|Device|Thulium Fiber Laser|Thulium Fiber Laser will be used to break renal stones < 2 cm into fragments small enough to remove or pass spontaneously through the ureter.
75623167|NCT00609141|Biological|cixutumumab|Given IV
76073488|NCT04386694|Device|Placebo PBMT/sMF|The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
75623168|NCT00609141|Other|pharmacological study|Correlative studies
75623169|NCT00609141|Other|laboratory biomarker analysis|Correlative studies
75623170|NCT00615862|Other|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
75623171|NCT05330715|Other|Management|Comparison if different strategies to manage acute emergencies in the pre-hospital setting.
75623172|NCT02702830|Other|Cardiopulmonary Exercise Testing|Undergo CPET
75776472|NCT05812755|Drug|Vericiguat|Vericiguat 10 mg administered orally starting 2 days prior to heart surgery through the day of surgery
75776473|NCT05812755|Drug|Placebo|Matched placebo administered orally starting 2 days prior to heart surgery through the day of surgery
75776474|NCT05810363|Drug|Etomidate - propofol mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min ~0.3 μg/kg/min for maintenance.
75776475|NCT05810363|Drug|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min ~0.3 μg/kg/min for maintenance.
75776476|NCT05803954|Other|Sustained natural apophyseal glides (SNAGS)|SNAGS will be applied with the patient sitting comfortably on a stool. The therapist stand behind the patient and the medial border of one thumb's distal phalanx is placed on the articular pillar on the chosen side of the suspected site of lesion. The thumb nail slope at approximately 45 degree (in the direction of the eyeball). SNAGS mulligan will be given by active movement followed by passive overpressure based on the movement restricted by frequency of treatment will be three sets of ten repetitions. SNAG the anteroposterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s depending on response. A maximum of 6 repetitions will be given if there is a reduction in headache intensity at the time of the first application. A total of 20 oscillations (1 oscillation/1 second) will be given to each joint with a total duration of 15 minutes
75798390|NCT01170936|Drug|canakinumab|Single dose of canakinumab 300mg s.c. injection
75798391|NCT03868488|Behavioral|Imagery tasks|All participants need to finish both visual imagery tasks and auditory imagery tasks. Visual imagery tasks and auditory imagery tasks will be carried out at intervals to avoid the influence of different tasks. The sequence of imagery tasks will be counterbalanced across participants.
75623173|NCT02702830|Device|Magnetic Resonance Imaging|Undergo MRI
76073489|NCT01273246|Biological|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
75623174|NCT05208957|Other|No intervention|No intervention
75623175|NCT02702908|Other||Historical Reference group.
75623176|NCT00610389|Biological|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
75623177|NCT01114217|Drug|Ferumoxytol|IV Ferumoxytol
75623178|NCT01030536|Drug|CAT-8015 20 mcg/kg|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
75623179|NCT01030536|Drug|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
75623180|NCT01030536|Drug|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
75623181|NCT01030536|Drug|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
75623182|NCT01030536|Drug|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
75623183|NCT01030458|Drug|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
75623184|NCT01030458|Drug|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
75623185|NCT02692222|Other|Calculation of PPV and CO with two methods|
75623186|NCT02702674|Drug|propranolol|propranolol 20 mg given before induction of labor
75623187|NCT02702674|Drug|placebo|starch tablet containing no active drug material given before induction of labor
75776477|NCT05803954|Other|Neural mobilization|Neural mobilization will be applied with grade three neural mobilization and traditional therapy: Subjects will be placed in supine position and remained relaxed with the feet uncrossed. The patient will be slightly angled obliquely for easier access to the scapula. The therapist will be depressed the scapula with concomitant upper extremity joint positioning as per median nerve bias i.e., ULTT2 (shoulder abduction, elbow extension with forearm supination, wrist and fingers extended and ulnar deviated and thumb abduction). The wrist will be used as a tension factor and at the point where tension was felt by the therapist and perceived by the subject. Grade 3 oscillations were given rhythmically and slowly to each joint from proximal to distal. A total of 20 oscillations (1 oscillation/1 second) were given to each joint with a total duration of 15 minutes.
75913816|NCT06023472|Device|microfluidic chip|Microfluidic chip method has been used for sperm sorting in order to select the most motile and morphologically normal sperm for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
75623188|NCT02702674|Drug|Oxytocin|intravenous infusion of oxytocin
75623189|NCT00930969|Device|ICD|Subjects implanted with an ICD.
75623190|NCT02702752|Other|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
75623191|NCT01114139|Drug|Ferumoxytol|IV Ferumoxytol
75623192|NCT01114139|Other|Placebo|IV Placebo
75623193|NCT02699242|Device|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
75623194|NCT01027884|Drug|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
75623195|NCT01027884|Drug|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
75623196|NCT02699164|Device|DRX 9000, Axiom Worldwide, Tampa, Florida|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
75623197|NCT02699164|Other|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
75623198|NCT02699164|Other|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
75623199|NCT02699008|Drug|Clopidogrel|Antiplatelet agent
75623200|NCT02699008|Drug|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
75623201|NCT00627666|Biological|anti-thymocyte globulin|
75913817|NCT06023472|Device|density gradient centrifugation|Density-gradient centrifugation is a commonly used method for sperm separation and purification. It is a technique that involves layering a semen sample on top of a gradient of different densities of a solution, typically a mixture of colloidal silica and sucrose, and then centrifuging the sample. The centrifugal force causes the sperm to migrate through the gradient, where they become separated based on their density.
75623202|NCT00627666|Drug|busulfan|
76073490|NCT01273246|Biological|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
75321030|NCT02168270|Dietary Supplement|ascorbic acid|Given IV
75321031|NCT02168270|Drug|temozolomide|Given PO
75321032|NCT02168270|Other|quality-of-life assessment|Ancillary studies
75321033|NCT02168270|Other|laboratory biomarker analysis|Correlative studies
75321034|NCT00395473|Drug|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
75321035|NCT00393211|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
75321036|NCT00393211|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
75321037|NCT03676556|Drug|Lidocaine|Two sterile gauzes will be dampen with the content of the syringe (20ml lidocaine 0.5%) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
75623203|NCT00627666|Drug|fludarabine phosphate|
75623204|NCT00627666|Drug|leucovorin calcium|
75623205|NCT00627666|Drug|methotrexate|
75623206|NCT00627666|Procedure|allogeneic bone marrow transplantation|
75623207|NCT00627666|Procedure|allogeneic hematopoietic stem cell transplantation|
75623208|NCT00627666|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75623209|NCT03387514|Drug|PSMA-based 18F-DCFPyL PET tracer for PET/CT exams|"18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~PET2A - Post-surgery and prior to start of standard of care systemic therapy~PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~PET3A - Prior to start of additional anti-angiogenesis therapy~PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy"
75623210|NCT01022580|Drug|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
75623211|NCT01022580|Drug|Sham (No Treatment)|Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
75623212|NCT02698930|Drug|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
75623213|NCT02698930|Drug|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
75623214|NCT02880683|Device|NeuroTronik CANS Therapy System|
75623215|NCT04215094|Diagnostic Test|postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun|All patients in Intracranial Infection group were cured with antibiotic treatment
75623216|NCT02698852|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
75623217|NCT01107353|Drug|Imipramine Pamoate|75 mg capsule
75776478|NCT05803954|Other|Traditional physical therapy|traditional therapy will be applied in the form of stretching for bilateral upper and middle trapezius muscles and bilateral neck rotators and isometric strengthening exercises for neck rotators, extensors, side bending muscles. Exercise was repeated for ten repetitions per session. In addition to hot pack was placed over the neck and upper part of shoulders musculature. This was being applied for ten min, over middle trapezius trigger Point itself.
75776479|NCT05803772|Drug|APHD-012|Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
75913818|NCT06023355|Procedure|HYBRID|It involves the combination of a sternal sparing left internal mammary artery (LIMA) bypass and percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for non-left anterior descending (LAD) lesions. Through minimally invasive surgical techniques, HCR carries the potential for faster recovery postoperatively, fewer in-hospital complications, and lower utilization of healthcare resources, while providing the key benefits of LIMA-LAD grafting.
75913819|NCT06022887|Behavioral|TRE|daily ad libitum food intake, 8-h 12pm - 8pm, 8 wks active weight loss phase;
75623218|NCT02702206|Drug|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
75913820|NCT06022887|Behavioral|MBSR|Completed 30 sessions of a Mindfulness-Based Stress Reduction (MBSR) interventions for 8 weeks
75913821|NCT06021977|Drug|Zanubrutinib|Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
75776480|NCT05803772|Drug|APH-012P|Distal jejunal-release placebo beads
75776481|NCT05803148|Procedure|Cardioneuroablation|The left atrium model was established under the guidance of three-dimensional mapping. Atrial septum puncture、left atrium mapping and right atrium mapping will be performed according to standard EP lab protocol. The location of GPs will be detected with HAFE potential (duration ≥ 50ms， deflections ≥ 8 times， amplitude ≥ 1.95mV) and high frequency stimulation (HFS; 30 Hz, 20 mV, pulse width 2ms) through positive vasovagal response (transient ventricular asystole, atrioventricular block, or R-R interval increased by 30%) . Saline Irrigated-tip catheter with pressure monitoring will be applied for the procedure, and radiofrequency energy is limited to 40W and 43℃ for at least 30s at each site. The ablation endpoint for each GP is defined as the complete elimination of all targeted HAFE potential and elimination of positive vasovagal response. The endpoint of the procedure was that the heart rate reach 75% of the maximum heart rate in atropine test.
75913822|NCT06020261|Behavioral|Parent Management Training|developing parenting skills and competencies dealing with oppositional and irritable behaviors in the child.
75913823|NCT06018350|Behavioral|Clinician-led adherence intervention|The clinician will review real time pharmacy refill data during clinic and use effective communication techniques to discuss adherence with the patient
75321038|NCT03676556|Drug|Saline Solution|Two sterile gauzes will be dampen with the content of the syringe (20ml saline serum) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
75321039|NCT00686803|Drug|PL3994|Study drug
75321040|NCT00686803|Drug|Placebo|Placebo
75913824|NCT06017960|Other|Dry needling + usual care|"Participants assigned to the dry needling group will receive a weekly session for four weeks of ultrasound-guided dry needling in the inner gastrocnemius muscle with disposable stainless-steel needles, according to the depth of the muscle to be treated. For the realization of the technique, the diagnostic criteria of the Dry Needling in Hypertonia and Spasticity technique (DNHS®) developed by Herrero et al. will be applied adapted to the characteristics of the study, as well as the procedure for its application.~The ultrasound guidance will be the same ultrasound device than in the assessments. This ultrasound-guided intervention allows to guarantee the safety of the approach, to have the certainty in the location of the target structure and to see the responses of local spasm. During the application of the technique, patient will not look at the ultrasound screen to ensure the blindness of the patient to the group allocated."
76073491|NCT01273246|Biological|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
76073492|NCT01273246|Biological|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
76073493|NCT00730522|Drug|CPP-109 vigabatrin|tablets, bid for 12 weeks
75321041|NCT02144233|Procedure|Occlusal adjustment|"The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)"
75321042|NCT02144233|Procedure|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
75321043|NCT00269191|Drug|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
75321044|NCT00269191|Drug|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
75623219|NCT02702206|Drug|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
75623220|NCT02702206|Drug|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
75623221|NCT01107197|Dietary Supplement|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
75623222|NCT01107197|Dietary Supplement|Control formula|Isonitrogenous isocaloric oral formula
75623223|NCT04216186|Drug|Atomoxetine|Atomoxetine once daily
75623224|NCT04216186|Drug|Coenzyme Q|Coenzyme Q once daily
75623225|NCT02702440|Other|Liquid calories from sugars|
75321045|NCT02997631|Device|MEDi Robot|Distraction therapy using an interactive humanoid robot
75321046|NCT00690235|Drug|Pramlintide|180mg subcutaneous injections, twice daily
75321047|NCT00690235|Drug|Placebo|180mg subcutaneous injections, twice daily
75321048|NCT04387279|Other|Interview|Surveys on medical use patterns and patient's perceptions about COVID-19
75321049|NCT00092833|Drug|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
75623226|NCT02881697|Other|Adipose tissue sampling|
75776482|NCT05803148|Drug|Midodrine Oral Tablet|Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
75321050|NCT01799083|Drug|Decitabine|A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
75321051|NCT01799083|Biological|cytokine-induced killer cell|Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
75321052|NCT01795573|Biological|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
75623227|NCT02698540|Other|Nutritional Supplement|High calorie, high protein peptide based
75623228|NCT02698696|Other|ECo program|
75623229|NCT02698696|Other|CRT program|
75623230|NCT02698696|Other|Supportive psychotherapy|
75623231|NCT01989598|Other|Laboratory Biomarker Analysis|Correlative studies
75321053|NCT01799161|Biological|gp96-Ig Vaccine|
75321054|NCT01799161|Drug|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
75776483|NCT05803148|Behavioral|patients educaiton|Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and told patients to avoid triggering factors as much as possible . At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.
75776484|NCT05802849|Drug|Acetazolamide|Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.
75776485|NCT05799261|Procedure|Control (standard protocol)|The control group will be treated according to standard protocols of the Department of Periodontology of the university of Bern and receive conventional scaling and root planing. Supra- and subgingival hard and soft tissue deposits are being removed by means of hand instruments and ultra-sonic scalers followed by rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists.
75776486|NCT05799261|Procedure|Test (Guided Biofilm management)|"The test group will be treated according to a novel treatment concept (Guided biofilm management, GBM):~Staining of all tooth surfaces to detect soft and hard deposits.~Removal of supra- and subgingival hard and soft bacterial deposits by means of an erythritol powder air-polishing.~If present, the supra- and subgingival hard deposits (e.g. calculus) will be removed by means of a slim ultrasonic tip (Piezon PS, EMS, Nyon Switzerland) without any additional use of hand instruments.~Another sub- and supragingival application of erythritol powder air-polishing without any rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists."
75776487|NCT05795959|Behavioral|Receive education on precision medicine|Patients who consent to participating in the study and are randomized to the intervention group, will meet 1 on 1 with a trained lay VA volunteer. The trained lay VA volunteer will conduct phone calls with patients until the end of the 1 month enrollment period to deliver education regarding precision medicine.
75776488|NCT05795764|Behavioral|Crisis Response Planning|Crisis Response Planning (CRP) is a brief psychotherapeutic intervention.
75776489|NCT05795764|Behavioral|Treatment as Usual|Standard care provided for patients at risk for suicide
75776490|NCT05791344|Device|ECG monitoring|Intra-procedural ECG changes during TAVR
75776491|NCT05789472|Behavioral|Assessment|Executive functions and reaction times of all participants will be measured.
75776492|NCT05787665|Other|phone call at 3 months|patients will be called at 3 months to know if they are alive and to know if they have been rehospitalized
75776493|NCT05771506|Other|Balance Assessment|"Balance assessment will be done with the Biodex Balance System® (Biodex Medical Systems, Shirley, New York, United States). Postural stability test overall score, stability limits test overall score, and sensory integration test of balance composite score will be recorded."
75776494|NCT05771506|Other|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) in accordance with ATS/ERS criteria. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
75798392|NCT01171014|Dietary Supplement|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
75321055|NCT01799161|Other|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
75623232|NCT01989598|Other|Pharmacological Study|Correlative studies
75623233|NCT01989598|Drug|Trametinib|Given PO
75623234|NCT01989598|Drug|Uprosertib|Given PO
75623235|NCT04214938|Other|Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization|Hypertonic sea water, Vemcaine, Otrivine, and a placebo were applied by intranasal before the nasoendoscopy procedure for improving the field of view of clinician and reducing the patient discomfort.
75623236|NCT02702050|Other|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
75623237|NCT02702050|Other|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
75623238|NCT00615160|Drug|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
75623239|NCT00615160|Drug|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
75776495|NCT05771506|Other|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
75776496|NCT05771506|Other|Peripheral muscle strength test|Peripheral muscle strength will be assessed by measuring M. Quadriceps muscle strength with a digital handheld dynamometer (MicroFET® Hoggan Scientific; USA). The test will be done in three measurements for the dominant side lower extremity. The average of the obtained values will be recorded in kilograms.
75776497|NCT05771506|Other|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
75776498|NCT05771506|Other|Cognitive assessment|Cognitive function will be assessed with the Montreal Cognitive Assessment (MoCA) test. The MoCA test is a questionnaire developed to evaluate different cognitive functions and mild cognitive impairment. The maximum score that an individual can obtain from the test is 30, and a score of 21 or above is considered as mild cognitive impairment. Test; will be administered by a certified physiotherapist who has received training on practice and scoring directives
75776499|NCT05769556|Other|Brain Gym Exercises|Brain gym exercises is a collection of simple movements that function to stimulate the development of all parts of the brain synergistically.
76073494|NCT00730522|Drug|Matching Placebo|tablets, bid, 12 weeks
76073495|NCT04345276|Drug|Danoprevir+Ritonavir|Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.
75776500|NCT05769556|Other|Traditional physiotherapy|A Group of exercises
75776501|NCT05767437|Behavioral|Abdominal drawing-in maneuver exercise|From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising
75776502|NCT05767437|Behavioral|sham|Release pain or upper limb mobilization
75776503|NCT05761743|Diagnostic Test|Urine and Blood Test|Urine N-telopeptide and serum osteocalcin
75776504|NCT05761509|Drug|Doravirine|The study treatments will used during 28 days according to the routine care of each investigator center.
75776505|NCT05757531|Drug|[¹⁴C]-LY3437943|Administered SC.
76073496|NCT02991352|Device|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
76073497|NCT01278628|Other|exercise training|exercise class once a year
75321056|NCT01799161|Procedure|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response [frequency of CD4+, FoxP3 (Treg), et al] in treated patients.
75623240|NCT02702362|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
75623241|NCT02702284|Behavioral|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
75776506|NCT05752747|Other|Cold Massage Group|Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.
75776507|NCT05752747|Other|ShotBlocker© Group|It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
75776508|NCT05748366|Procedure|Serratus Anterior Plane Block (SAPB)|The ultrasound-guided serratus anterior plane block (SAPB) will be performed in a manner previously described in published medical literature. Patients will be consented and monitored. Bupivacaine 0.5% (5 mg/ml) diluted to 30-40 ml will be used in a dose not to exceed 2 mg/kg. The serratus anterior fascial plane will be identified in the 4th/5th intercostal space. The needle will be advanced under real-time ultrasound guidance targeting the superficial serratus anterior fascial plane. The procedure assistant will inject small volumes to hydrodissect the muscle bellies evenly under direct visualization, indicating local anesthetic spread within the fascial plane. Anesthetic will then be injected in 5 ml increments and the needle will be removed. Patient will be continuously monitored on telemetry and pulse-oximetry. Reassessment of the patient will continue for 30 minutes to monitor for signs of local anesthetic systemic toxicity.
76073498|NCT00731614|Behavioral|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
76073499|NCT00731614|Behavioral|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
76073500|NCT00731614|Behavioral|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
76073501|NCT01273324|Device|ADM Cup|ADM Cup
75321057|NCT02997397|Procedure|tourniquet(+)|A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.
75623242|NCT02702284|Behavioral|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
75623243|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
75623244|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Medical management
75623245|NCT04215484|Diagnostic Test|serum BNP assessment|serum BNP assessment in pregnant women with placenta previa, associated or not to a suspected abnormal placental invasion, compared to a control group
75776509|NCT05748366|Drug|Standard Analgesic Medications|Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
75623246|NCT02698618|Procedure|Diagnostic|"Pre-PCI and treatment:~At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
75623247|NCT02698618|Drug|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence [Body Mass Index (BMI) ≥30 kg/m2] with the implementation of a dedicated randomization list.
75913825|NCT06017960|Other|Sham dry needling + usual care|"Participants assigned to this group will receive the same assessments, the same number of sessions, and the sham dry needling at the same site as the dry needling group, but with a sham intervention, where the needle is dropped through the guide tube and touch the skin. The patient will not feel anything, or at most that the needle touches the skin, since it does not get into the subcutaneous cell tissue, as placebo interventions were performed in similar studies. The context will be simulated in its entirety, using the same ultrasound and disposable needles for the intervention.~Both groups will continue their daily motor rehabilitation treatment during the 4 weeks, which consists of strength training, balance, motor control, gait training, and mass practice oriented to tasks of intensity and duration appropriate to each patient, allowing the fastest possible clinical improvement, as recommended by clinical practice guidelines."
75913826|NCT06013800|Other|Measurement of sodium levels|Patients will get measurements of sodium levels daily in the first 48 hours, then daily or every other day until normal sodium levels (>135mEq/L).
75776510|NCT05747859|Other|teletherapy|speech therapy remotely delivered
76073502|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
76073503|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
76073504|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
75776511|NCT05747599|Behavioral|Intervention with contingent incentives and text-based support|Contingent incentives on abstinence from alcohol, tobacco, and cannabis; Text-based support based on educational components
75776512|NCT05743062|Behavioral|Virtual Reality|Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds. Participants will be asked to fill out a survey before the intervention to collect the baseline data, after each session of VR intervention and a final survey at the end of the study.
75776513|NCT05743062|Other|Control|For case control, participants will service as their self control and no VR intervention will be given at first. Participants will be asked to fill out a survey before the intervention to collect the baseline data.
75776514|NCT05739305|Other|Risk factor|No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
75321058|NCT02997397|Procedure|tourniquet(-)|
75321059|NCT02997007|Device|active tDCS|Participants will receive active tDCS over the angular gyrus on five consecutive days
75776515|NCT05738161|Drug|Magrolimab|Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
75776516|NCT05738161|Drug|Cisplatin|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
75776517|NCT05738161|Drug|Gemcitabine|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
75321060|NCT02997007|Device|sham tDCS|Participants will receive sham tDCS over the angular gyrus on five consecutive days
75321061|NCT00006110|Biological|trastuzumab|infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
75321062|NCT00006110|Drug|cyclophosphamide|600 mg/m2, intravenous infusion every 3 weeks for four cycles
75321063|NCT00006110|Drug|doxorubicin hydrochloride|60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
75321064|NCT00006110|Drug|paclitaxel|90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
75321065|NCT00006110|Procedure|conventional surgery|Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
75321066|NCT00691327|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
75776518|NCT05737550|Device|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
75798393|NCT01171014|Dietary Supplement|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
75798394|NCT01171014|Dietary Supplement|Placebo|Placebo, once a day for 14 days
75776519|NCT05735704|Diagnostic Test|Blood sampling for HemaChip screening/diagnostic testing|"Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed."
76073505|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
75776520|NCT05735704|Diagnostic Test|Bone marrow sampling|as part of the discovery stage, bone marrow samples will be obtained at Tel-Aviv Sourasky Medical Center (TASMC) from up to 50 MM patients and up to 50 AML patients that undergo bone marrow aspiration as part of the standard care procedure. Additionally, up to 50 bone marrow samples will be taken from healthy volunteers that will undergo hip or knee replacement surgery.
75913827|NCT06007794|Other|JUMP group|patients will have a femoral ultrasound and blood tubes in addition to the blood sample taken as part of the treatment
75913828|NCT06007443|Other|pain related variables assessment|Pressure pain threshold, conditioned pain modulation, temporal summation, and two-point discrimination will be evaluated on the upper trapezius muscle. Average pain intensity will be asked.
75623248|NCT02698618|Procedure|PCI|"Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
75623249|NCT02698462|Other|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
75623250|NCT02698150|Device|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
75623251|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
75913829|NCT06005532|Drug|Adalimumab|Adalimumab injection 40 mg / 0.8 ml
75913830|NCT06005532|Drug|Humira|Adalimumab injection 40 mg / 0.4 ml
75913831|NCT06005415|Dietary Supplement|Wire-cut cookie|Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.
75913832|NCT06005311|Device|Microfluidic chip|The Sperm Separation Device - ZyMōt Multi 850µL (ZyMōt Fertility, Inc) will be used. The microfluidics chamber will be used according to the manufacturer's instructions. 850 μL of the semen sample will be inserted into the inlet port of the device and 750 μL of fertilization media will be inserted into the outlet port. The device with the semen sample inside will be incubated in 6% CO2 at 37°C. After 30 min, 500 μL of the sample at the outlet port will be removed from the outlet port and pipetted into a labelled test tube.
76073506|NCT02991274|Procedure|genomic testing of T790M mutation|patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
76073507|NCT02991508|Drug|Placebo|
76073508|NCT02991508|Drug|Adrecizumab|
75623252|NCT01112267|Drug|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
75776521|NCT05729347|Behavioral|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
75776522|NCT05728749|Other|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
75776523|NCT05726266|Other|Music|Patients will listen daily to a musical playlist for 30 - 60 minutes in a row; the psychologist will set up a music playlist according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
75913833|NCT06005311|Device|Density-gradient centrifugation|After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.
75913834|NCT06005194|Behavioral|InMotion|A manualized physical activity counseling program that is based on the Diabetes Prevention Program (DPP) that has been adapted for TBI
75913835|NCT06005064|Dietary Supplement|Krill oil|Superba krill oil
75913836|NCT06005064|Dietary Supplement|Vegetable oil|Mixed vegetable oil
76073509|NCT01273558|Drug|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
76073510|NCT00733096|Drug|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
76073511|NCT00733096|Drug|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
76073512|NCT00733096|Drug|normal saline|Two transforaminal epidural saline injections, two weeks apart
75776524|NCT05726266|Other|Audiobook|Patients will listen daily to an audiobook for 30 - 60 minutes in a row; the psychologist will set up a list of audiobooks according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
75776525|NCT05723055|Drug|Axatilimab|Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
75776526|NCT05723055|Drug|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
75776527|NCT05719454|Device|CNT testing|The effect of CNT on blood pressure will be obtained throughout the year long follow up period.
75913837|NCT06003647|Other|Educational Intervention|Educational module and video
75913838|NCT06003439|Behavioral|Virtual Reality Program|The VR Program will be pre-installed on Meta Quest 2 headsets, which will be donned by students as a class to experience the intervention for approximately the length of one school class period (approximately 45 minutes). Each participant will experience the program once a week for 3 weeks. Participants who missed a week will complete the program by the 4th or 5th week.
75913839|NCT06003439|Behavioral|Augmented Reality Program|VR program participants will be able to download an optional mobile app that complements and reinforces the school-based VR session.
75623253|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
76073513|NCT02991196|Drug|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered [90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
76073514|NCT01278706|Procedure|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
75623254|NCT01112267|Drug|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
75623255|NCT04216030|Other|High Fe IP meal labelled with Fe-58|500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
75623256|NCT04216030|Other|Control OFSP meal labelled with Fe-57|500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
75623257|NCT00616096|Procedure|immunoadsorption|"First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5"
75623258|NCT00925587|Drug|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
75623259|NCT02698306|Drug|Dexamethasone|Dexamethasone
75623260|NCT02698306|Drug|Diclofenac Sodium|Diclofenac Sodium
75623261|NCT02698228|Drug|Bupivacaine (femoral nerve block)|0.5% bupivacaine
75623262|NCT02698228|Drug|Morphine|Intravenous injection of 0.1mg/kg of morphine
75623263|NCT02698228|Device|Ultrasound|
76073515|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
75776528|NCT05718947|Diagnostic Test|Brain MRI (3T, 7T, 9.4T)|All patients will undergo anatomical brain imaging on a 3T, 7T and 9.4T MRI scanner within the same day at baseline and again 6 months later. An optimized protocol for every separate field strength will be run. Sequences will include at least T1-weighted, T2*-weighted and a T2 SPACE or FLAIR sequence. No intravenous contrast will be used.
75776529|NCT05715606|Drug|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
75776530|NCT05714046|Behavioral|Control|An informative presentation
75776531|NCT05714046|Behavioral|Yoga training|Yoga exercise training
76073516|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
75623264|NCT02698072|Other|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
75623265|NCT02698072|Device|Dry needling|Dry needling needle AGUPUNT®
75913840|NCT06000748|Drug|MAP-Target Algorithm|This is a clinical treatment algorithm that will determine the escalation and deescalation of vasoconstrictor utilization based on a target MAP, either high (≥80 mmHg) in the treatment group and low (< 80 mmHg) in the comparator group.
75623266|NCT02698072|Device|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
75623267|NCT00616174|Procedure|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
75623268|NCT02702128|Drug|Tranexamic Acid|1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
75913841|NCT05999409|Other|practice on birth simulator|making attempts at labor
75913842|NCT05998915|Other|observe only|observe only
75623269|NCT02702128|Drug|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
75776532|NCT05710926|Behavioral|Evolutionary Systems Therapy for Schizotypy|A novel therapy for schizotypal traits integrating evolutionary psychopathology, compassion focused therapy, and metacognitively oriented psychotherapy.
75776533|NCT05710926|Behavioral|Cognitive Behavioral Therapy|An adaptation of Cognitive Behavioral Therapy for those diagnosed with personaloty disorders.
75776534|NCT05709977|Other|Acupuncture|Fixed set of acupuncture points
75776535|NCT05709977|Drug|Antihistamine nasal spray|Carelastin® (1 mg/ml) azelastine nasal spray
75776536|NCT05709561|Procedure|Acupresur|acupressure application was applied 2 times a week for a total of 12 weeks and 24 times.
75623270|NCT05194683|Behavioral|Relational Letter Writing|The intervention consists of two interviews and a between-session writing task. In the first session, couples will be interviewed regarding their relationship story and preferences. Between the two sessions, each couple member will write a letter from their relationship point of view. In the second interview, the task is reviewed and paths for relationship improvement are outlined.
75913843|NCT05998863|Drug|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
75913844|NCT05998863|Other|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate.
75913845|NCT05997849|Behavioral|Mobile application|A mobile application for the management of anxiety and depressive symptoms through self-applied emotional regulation tools.
75913846|NCT05997758|Other|SEEG stimulation|Electrodes already implanted in patient's anterior insula will be stimulated below the patient-specific threshold at which a seizure was induced. This stimulations will coincide with certain trials in the adaptation task.
75623271|NCT00610545|Drug|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
75623272|NCT00610545|Drug|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
75623273|NCT00193414|Drug|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
75623274|NCT00193414|Drug|Gemcitabine|1500mg/m2, 30min IV
75623275|NCT05330559|Other|Fluid MAX group|to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and microscope image post-processing systems, for the treatment of High Grade Gliomas (HGGs)
75776537|NCT05709561|Procedure|Mindfulness|Mindfulness practice was applied with the students once a week for 8 weeks, accompanied by a researcher. Then, students were asked to apply for 3 cycles.
75776538|NCT05709561|Procedure|Plasebo|No intervention was applied to the control group.
75776539|NCT05705804|Drug|Pitavastatin|Pitavastatin 4 mg will be given.
75623276|NCT02701972|Device|BACE Device|Implanted BACE device
75776540|NCT05705804|Drug|Pitavastatin plus Ezetemibe|Pitvastatin 4 mg plus ezetemibe 10 mg will be given.
75776541|NCT05705804|Drug|Atorvastatin|Atorvastatin 40 mg will be given.
76073517|NCT01278784|Device|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
76073518|NCT01278784|Device|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
75623277|NCT02701816|Device|innova stent (Boston scientific)|
75623278|NCT04260711|Drug|DMT|Discontinuation of patients' own disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
75623279|NCT00610623|Drug|azithromycin|300 mg/day, IV from day 1 to 20
75623280|NCT00610623|Drug|placebo|once per day, IV from day 1 to 20
75623281|NCT02701660|Device|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
75623282|NCT04214782|Diagnostic Test|Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm|AI Enabled Transvaginal Ultrasound diagnosis for ovarian cancer
75776542|NCT05703659|Dietary Supplement|B. longum subsp. infantis|Infants will receive 1 dose of a B. infantis probiotic daily for 4 weeks
75776543|NCT05703659|Dietary Supplement|L. reuteri probiotic|Infants will receive 1 dose of an L. reuteri probiotic daily for 4 weeks
75776544|NCT05703347|Behavioral|Fixed sleep goal|Investigators will determine if a fixed guideline-based goal (≥9 hours per night) is more efficacious for increasing sleep duration.
75776545|NCT05703347|Behavioral|Personalized sleep goal|Investigators will determine if a personalized goal (≥9 hours per night, but can be lowered to a personalized level, capped at +30 minutes per night above baseline) is more efficacious for increasing sleep duration.
75798395|NCT01274832|Device|Deep Brain Stimulation|Deep Brain Stimulation of STN in Parkinsonian patients
75913847|NCT05997758|Behavioral|Adaptation task|Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.
75913848|NCT05996250|Other|Immersive virtual reality task|participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks
75913849|NCT05996120|Procedure|Hypothermic Cardiopulmonary Bypass|Mild hypothermia (between 32 - 35 °C) during cardiopulmonary bypass
75913850|NCT05996120|Procedure|Normothermic Cardiopulmonary Bypass|Normothermia (active maintenance of temperature between 36.5 °C to 37.5°C; no active cooling below 36.5 °C) during cardiopulmonary bypass
75913851|NCT05995249|Drug|TAK-279|TAK-279 capsules
75623283|NCT02697994|Other|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
75623284|NCT02697994|Other|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
75623285|NCT02697838|Drug|Apatinib|Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
75798396|NCT01171092|Drug|bortezomib and G-CSF|"Bortezomib injection:~1.3mg/m2 11 days before and 8 days before the stem cell collection~G-CSF injection:~10mcg/kg on days -4 to day -1 once daily"
75913852|NCT05995249|Drug|Erythromycin|Erythromycin tablets
75913853|NCT05995249|Drug|Phenytoin|Phenytoin capsules
75913854|NCT05995249|Drug|Efavirenz|Efavirenz tablets
75913855|NCT05988918|Drug|ESK981|160 mg, PO, Once daily 5 days on and 2 days off
76073519|NCT04386226|Dietary Supplement|Ambrotose LIFE|Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.
76073520|NCT04386226|Dietary Supplement|Advanced Ambrotose|Advanced Ambrotose contains aloe vera extract inner leaf gel, arabinogalactan, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, and rice starch
76073521|NCT04386226|Other|Placebo|Maltodextrin
75623286|NCT02697838|Drug|Paclitaxel-based chemotherapeutic regimens|"Paclitaxel-based chemotherapeutic regimens including:~The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~other paclitaxel-based regimens"
75321067|NCT04403438|Other|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
75913856|NCT05988203|Biological|BNT166a|Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.
76073522|NCT04386070|Drug|RESP301|RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
75321068|NCT02997241|Biological|OncoCare|Personalized monitoring
75623287|NCT02697682|Biological|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
75623288|NCT02697526|Other|Terumo|
75623289|NCT02697526|Other|Tensoplast|
75623290|NCT02690428|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
75623291|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
75623292|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
75623293|NCT02706106|Device|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
75623294|NCT02697760|Radiation|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
75623295|NCT04956705|Dietary Supplement|Vitamin D and calcium|Either as tablets, droplets or sprays. Preferably daily doses of 20 µg of vitamin D and 800-1000 mg of calcium as recommended.
75623296|NCT04260633|Device|Dental Monitoring assisted aligner change, 12-hour tray wear time and VPro+ are the interventions for the trial.|"The current standard of care for clear aligner use as suggested by Invisalign is unclear as to how frequently aligners should be changed. We suspect that the frequency for aligner change as determined by the orthodontist using Dental Monitoring will be variable for every participant.~Vpro+ is an adjunctive therapeutic tool for clear aligner treatment. It is proposed to deliver high frequency vibrations to reduce treatment time and pain associated with clear aligners.~Align Technology suggests 22-hour wear time for clear aligner therapy. Participants in two arms of the study will be asked to wear the trays for about half the recommended wear time to assess whether night-time aligner wear will be sufficient for successful treatment."
75321069|NCT02997241|Drug|chemotherapy for colorectal carcinoma|chemotherapy for colorectal carcinoma
75623297|NCT02705950|Drug|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
75623298|NCT02705950|Other|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
75776546|NCT05703347|Behavioral|Digital sleep health messaging without virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.
75776547|NCT05703347|Behavioral|Digital sleep health messaging with virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. The participants will be randomized to additionally receive virtual study visits where doctoral-level psychology trainees will be trained to implement evidence-based behavioral sleep health guidance.
75776548|NCT05703347|Behavioral|Inactive Parent-Directed Loss-Framed Incentive|No parental incentive
75798397|NCT01171170|Drug|carboplatin paclitaxel bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
75913857|NCT05987475|Procedure|Breast reconstruction|Breast reconstruction and breast augmentation based on the indications as listed out in the instructions for use of the medical device under investigation
76073523|NCT04386148|Procedure|Obsidian ASG®|As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.
76073524|NCT01276288|Drug|BI 10773|multiple oral doses
76073525|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
76073526|NCT01276288|Drug|torasemide|multiple oral doses
76073527|NCT01276288|Drug|BI 10773|multiple oral doses
76073528|NCT01276288|Drug|torasemide|multiple oral doses
76073529|NCT01276288|Drug|BI 10773|multiple oral doses
76073530|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
75623299|NCT04951323|Drug|anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
75623300|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
75776549|NCT05703347|Behavioral|Active Parent-Directed Loss-Framed Incentive|Parents will receive a financial incentive when their child achieves their sleep goal. The incentive will be loss-framed; parents will receive an endowment of $10 at the start of each intervention week, in a virtual bank account; Investigators will deduct $2 each weeknight the sleep duration goal is not met; the funds remaining in the virtual account will be dispensed each Sunday. The weekly endowment-payment approach allows for fresh starts each week. The incentive will be directed at parents as a method to enhance engagement. Investigators will ask parents at baseline and at the end of each month to rate their perceived support in helping their child to meet their sleep duration goal.
75776550|NCT05703347|Behavioral|Inactive Supportive Feedback|No supportive feedback
75776551|NCT05703347|Behavioral|Active Supportive Feedback|Participants will receive a weekly performance summary message each Sunday during the intervention period, with supportive feedback included to motivate children to maintain their good performance in the week ahead, or to try and improve upon a weak or moderate performance in the week ahead. Investigators will ask children will complete an online survey each Sunday to measure how motivated they are to achieve their sleep goal in the week ahead.
75776552|NCT05699434|Behavioral|Obstetrics and Gynecology residents and experts'|Obstetrics and Gynecology residents and experts' knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey (Istanbul)
75776553|NCT05696301|Device|Winback® on|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is activated."
75321070|NCT04403750|Procedure|Combined laser-surgical technology of RRD treatment|"Nd-YAG laser excision of the vitreoretinal traction zone~Pneumatic retinopexy (10% C3F8)~barrier laser photocoagulation around retinal break after retinal attachment (2-3 days after pneumatic retinopexy)"
75321071|NCT00692185|Drug|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
75321072|NCT00692185|Drug|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
75321073|NCT04348526|Procedure|Corticision|Surgical intervention is going to be used in the interdental areas between the lower anterior teeth to accelerate tooth movement. Three incisions are going to be made
75913858|NCT05986747|Behavioral|Video-based CBT guided self-help Interventions|"Seven modules were developed from the corresponding modules of self help. Each video was of 3-5 minutes duration. Each week 2-3 videos will be sent to participants through secure WhatsApp connection. Participants received daily reminders in the form of short pre-recorded audio messages through whatsapp.~Trained RAs will provide guidance as well as technical assistance during the intervention period. They will call participants once a week for 15 minutes. This call will include, feedback from previous session, explanation of current week and discussion on home work assignments."
75321074|NCT04348526|Procedure|Traditional orthodontic treatment|No surgical intervention will be used, just normal orthodontic sequence of procedures.
75321075|NCT04270279|Drug|Xueshuanxinmaining tablet|A kind of Chinese patent medicine
75321076|NCT04270279|Drug|Xueshuanxinmaining placebo|The simulant of Xueshuanxinmaining tablet
76025610|NCT05134883|Other|PNF|A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).
76025611|NCT05134883|Other|SMR|For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
76025612|NCT05134805|Procedure|Bipolar hemiarthroplasty , proximal femoral nail|"Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail)."
75321077|NCT04270279|Drug|Nitroglycerin tablets|Be used when angina attack
75321078|NCT03515096|Drug|Eltrombopag|Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
75321079|NCT03515096|Drug|rhTPO|rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
75623301|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
75623302|NCT04215016|Biological|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
75321080|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
75623303|NCT02701894|Dietary Supplement|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
75776554|NCT05696301|Device|Winback® off|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is not activated."
75623304|NCT02706028|Device|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
75776555|NCT05696301|Behavioral|self-massage of the scar|The women in both groups will have the standard recommended treatment: manual self-massage of the scar. Women's instruction in this self-massage will be structured and identical for both groups, including the provision of an informational document describing how to perform the massage. This training will be provided immediately after randomization and before the intervention or control measures.
76073531|NCT02702271|Device|WATCHMAN FLX|Left atrial appendage closure with WATCHMAN FLX
76073532|NCT00722566|Drug|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
75623305|NCT02706028|Device|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
75623306|NCT02701348|Other|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
75776556|NCT05694091|Other|Collecting clinical data, blood gas data, Magnetic Resonance Spectroscopy (MRS) data and blood,urine, and feces sample|Collecting clinical data(before induction of anesthesia and first day after surgery), blood gas data(before induction of anesthesia and first day after surgery) ，MRS data (not more than 24h after surgery）and blood,urine, and feces sample （before induction of anesthesia and first day, third day and 7th day after surgery）
75623307|NCT02701348|Drug|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
75623308|NCT02701348|Procedure|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
75776557|NCT05693441|Other|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
75776558|NCT05693441|Other|Reference berry-like product|Subjects should consume a reference product (isocaloric to active product, containing berry aromas and colouring but no actual berry compounds) daily during the 12 week intervention period.
75776559|NCT05690906|Device|ReSpace™|The experimental group subjects will be injected with ReSpace™ hydrogel.
75776560|NCT05690906|Device|gauze packing|The subjects of both groups will be given gauze packing
75913859|NCT05986643|Behavioral|Exergame+Neurofeedback|Electroencephalography (EEG) is a device that measures the electrical activity of the brain (brain waves). There are several frequencies of brain waves when we are awake; alpha (medium), beta (fast), and theta (slow). Alpha frequencies of brain activity are linked to maintaining balance, with more alpha activity being associated with poorer balance. EEG neurofeedback treatment involves placing electrodes on a person's head to monitor and change brain activity by giving cued audio or visual feedback. It has been used in PwP to show improvements in balance and walking. Other preliminary research in PwP has shown that exercise can also improve balance.
75913860|NCT05986643|Behavioral|Exergame [alone]|"The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. They are also be instructed to stand still and catch stars that appear and these will be used to score points and are associated with a monetary reward, ensuring motivation.~This group will receive SHAM feedback."
75623309|NCT02701348|Other|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
75623310|NCT02701426|Behavioral|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
75623311|NCT00615706|Other|No intervention|no intervention
75623312|NCT02700880|Device|LifeVest|LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
75623313|NCT00930813|Device|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
75623314|NCT00930813|Device|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
75623315|NCT05324800|Dietary Supplement|Curcuma Longa Extract Mixture|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
76073533|NCT00722566|Drug|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
75321081|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
75321082|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
75623316|NCT05324800|Dietary Supplement|placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
75623317|NCT04216108|Device|Vitrectomy (23G gauge needle)|Vitrectomy surgery with 23G gauge needle technique
75623318|NCT04216108|Device|Vitrectomy (27G gauge needle)|Vitrectomy surgery with 27G gauge needle technique
75623319|NCT04215796|Device|ReX-C system|CFTR modulators are dispensed to patients via ReX-C system
75623320|NCT02700958|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
75623321|NCT02700958|Procedure|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
75623322|NCT04215328|Dietary Supplement|Mixed-Meal|Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses
75623323|NCT04215328|Dietary Supplement|Electrolyte Solution|Electrolyte Solution 500mLs by tube daily in 4 doses
75776561|NCT05685979|Procedure|Robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down).
75776562|NCT05685797|Procedure|trigminal nerve block with RFT|trigminal nerve block with RFT
75776563|NCT05675696|Other|Esophageal Catheter|Newly designed external monitor that will capture esophageal pressure from a proprietary nasogastric tube combined with simultaneous pressure, flow, and volume measurements from the ventilator tubing.
75776564|NCT05665777|Drug|Qingyan Lihou Decoction|Chinese medicine granules
75776565|NCT05665777|Other|Placebo|Placebo granules
75913861|NCT05985486|Behavioral|Diet|A reduced calorie diet which uses frozen meals purchased at the store and focuses on increasing fruits and vegetables associated with brain health.
75913862|NCT05985486|Behavioral|Health Education|Monthly health education sessions delivered remotely.
76073534|NCT04143633|Other|Low FODMAP diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
76073535|NCT04143633|Other|Standard diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
75321083|NCT03674840|Procedure|angle kappa based SBL-3 implantation|SBL-3 implantation based on kappa angle guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
75321084|NCT03674840|Procedure|0 to 180 degree SBL-3 implantation|SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
75321085|NCT03514394|Behavioral|Usual Care|The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).
75321086|NCT03514394|Behavioral|Modified Behavioral Activation (Task Sharing)|This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
75321087|NCT00589849|Procedure|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
75623324|NCT04258527|Drug|Pemigatinib|Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.
75776566|NCT05665660|Behavioral|CARE|CARE is a culturally tailored mammography education module.
75776567|NCT05665660|Behavioral|CARE + COACH|CARE + COACH is a culturally tailored mammography education module + access to an Apache paraprofessional women's health coach who functions as a patient navigator
75776568|NCT05655936|Behavioral|Heart Health Doula Intervention Program|The intervention group will be given a smart blood pressure cuff and a smart scale to monitor weight. The intervention group will receive support provided a postpartum doula until 8-12 weeks postpartum. The doula will provide individualized support during this time, and after 8-12 weeks, women will transition to a doula-moderated support group for the remainder of the study. The intervention group will continue to receive blood pressure and weight monitoring for the remainder of the study.
75776569|NCT05655936|Behavioral|Usual Care|Usual care includes enrollment into a clinical 6-week home-based blood pressure monitoring program with text messaging support which includes receiving a home blood pressure cuff. Women in the intervention group will be offered the same support as the usual care group, and in addition will receive the intervention and supplies.
75776570|NCT05654675|Diagnostic Test|FDG PET/CT|Besides the standard care FDG PET/CT examination, subjects receive a dynamic whole body PET/CT examination.
75913863|NCT05980520|Dietary Supplement|Taurine+corn starch+white sugar|Taurine granules mixed with corn starch and white sugar, 0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day. The use of taurine is strictly in accordance with the specifications of Chinese Pharmacopoeia.
75913864|NCT05980520|Dietary Supplement|Corn starch+white sugar|0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day.
75913865|NCT05980520|Behavioral|Behavioral rehabilitation therapy|Structured training courses which included: visual arrangement, routine, environmental arrangement, program schedule, personal work system consists of five parts. The course is designed and implemented by qualified behavioral rehabilitators who have worked for more than 5 years, with the participation of parents. The daily training time is about 6-8 hours, and the total intervention time is not less than 40 hours per week.
75321088|NCT00525629|Dietary Supplement|Walnuts|48 Grams of Walnuts Daily
75913866|NCT05980481|Drug|RC48-ADC|2.5 mg/kg IV every 2 weeks
75623325|NCT00615238|Behavioral|Diet plus continuous bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
75623326|NCT00615238|Behavioral|Diet plus short bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
75623327|NCT00615238|Behavioral|Diet plus moderate lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
75623328|NCT04946799|Behavioral|Low-intensity training combined with blood flow restriction (LI-BFR)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve), with compression belts attached on both thighs, during exercise the belts are inflated with 50% of the participant's arterial occlusion pressure. Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. The compression belt is deflated during the rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
75776571|NCT05653752|Drug|YL202|"YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle.~The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes."
75776572|NCT05652907|Drug|FSD201|Tablets for oral administration.
75913867|NCT05980481|Drug|Herceptin|First load dose is 8.0mg , then 6.0 mg/kg IV every 3 weeks
75913868|NCT05980481|Drug|Toripalimab|3.0 mg/kg IV every 2 weeks
75321089|NCT00525629|Dietary Supplement|Control|Control Diet with No Walnuts
75913869|NCT05980481|Drug|Oxaliplatin injection|100mg/m2 Q3W
75321090|NCT00692419|Behavioral|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
75913870|NCT05980481|Drug|Capecitabine|1000mg/m2 Q3W
75913871|NCT05977699|Drug|salbutamol aqueous solution|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
75913872|NCT05977699|Drug|salbutamol pressurized metered dose inhaler|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
75913873|NCT05977699|Other|placebo|matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer
75913874|NCT05976451|Combination Product|melatonin with collagen matrix|(CMX) with melatonin in the esthetic zone using Modified Coronally Advanced Tunneling Technique (MCAT)
75913875|NCT05976451|Combination Product|connective tissue graft (CTG)|control group connective tissue graft using Modified Coronally Advanced Tunneling Technique (MCAT)
75913876|NCT05974579|Drug|89Zr-DFO-AP-101|"At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.~At 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated."
75321091|NCT00692419|Behavioral|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
75321092|NCT04763018|Device|iTEAR100|Neurostimulation external nasal nerve to stimulate tear production
75776573|NCT05652907|Drug|Placebo|Placebo tablets matched to FSD201 for oral administration.
75776574|NCT05644093|Drug|SPL026 IV|IV dosing
75776575|NCT05644093|Drug|SPL026 IM|IM dosing
75913877|NCT05974462|Drug|Methylprednisolone 125 MG [Solu-Medrol]|125 mg daily for 3 days diluted in saline solution 250 mL
75913878|NCT05974462|Other|IV saline solution 250 mL [Placebo]|Saline solution 250 mL
76073536|NCT05581563|Procedure|total knee arthroplasty(TKA)|Knee replacement, also called knee arthroplasty or total knee replacement, is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap. This surgery may be considered for someone who has severe arthritis or a severe knee injury.
75321093|NCT05559827|Drug|Isatuximab|Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes <10 G / L, and a third at day 29 if reticulocytes <10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
75321094|NCT02122445|Device|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
75321095|NCT00694603|Drug|Cetuximab|Given intravenously once per week.
75321096|NCT05559281|Other|Botulinum|injection of Botulinum Toxin injection in lip muscles following cleft lip repair surgically.
75321097|NCT05559281|Procedure|Fisher technique|The cleft lip will be treated surgically using the Fisher technique only.
75776576|NCT05643625|Other|Pilates exercise and myofascial release|Pilates exercise and myofascial relaxation technique will be applied to the experimental group and pilates exercise will be applied to the control group.
75776577|NCT05636787|Drug|Treosulfan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
75776578|NCT05636787|Drug|Melphalan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
75913879|NCT05968703|Device|Combined STN+NBM DBS|This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)
75913880|NCT05968157|Procedure|Breast MRI|Patients who are identified as high risk for breast cancer by Mirai guidelines are invited to receive supplemental MRI. In addition, the patients eligible for MRI screening according to other guidelines will also be screened to collect additional comparison data. Cancer outcomes will then be compared between patients only identified as high risk by Mirai and patients identified as high risk by existing guidelines.
75913881|NCT05966623|Other|Video Remote Interpretation|To assess the effectiveness of the VRI system in improving communication outcomes between Deaf patients and doctors Produce a VRI model addressing the challenges faced by Deaf people that will be tested, implemented, and sustained in Bogota Colombia.
76073537|NCT00722722|Drug|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
76088922|NCT04394091|Device|ultrasensitive PET CT|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.
75913882|NCT05966506|Behavioral|Dyad-based Zoom health coaching|This will be delivered by a certified nurse coach, certified in holistic nursing who will provide 6 sessions of Zoom health coaching over 12 weeks to dyads, biweekly (weeks 1, 3, 5,7, 9 &11) for 45 minutes
76073538|NCT04143555|Procedure|endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy|Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
76073539|NCT03021603|Behavioral|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
75321098|NCT03509792|Behavioral|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
75623329|NCT04946799|Behavioral|High-intensity aerobic exercise (HI)|Participants (n=20) receives high intensity aerobic exercise intervention on a cycle ergometer (at 70% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
75623330|NCT04946799|Behavioral|Low intensity exercise (LI)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
75776579|NCT05633316|Device|Investigational device named ICSIA|Oocytes will undergo intracytoplasmic sperm injection using the ICSIA (the investigational) device.
75776580|NCT05633316|Device|Manual ICSI|Oocytes will undergo intracytoplasmic sperm injection using the ICSI manual protocol
75776581|NCT05632679|Other|personalized music intervention|participants who are randomly selected to this group will choose three set of music they prefer among the available selection of instrumental music in the application
75623331|NCT00610779|Dietary Supplement|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
75776582|NCT05632679|Other|selected audio book|participants who are randomly selected to this group will choose one audio book they prefer among the available selection of audio books on the tablet
75776583|NCT05631912|Biological|Autologous CD19-STAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1×10^6 cells/kg) ,dose 2 (3×10^6 cells/kg) ,dose 3 (1×10^7 cells/kg); Phase 2 : Appropriate dose
75776584|NCT05631912|Drug|Fludarabine|Intravenous fludarabine 25-30 mg/m^2/day on days -5, -4, and -3.
75776585|NCT05631912|Drug|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m^2/day on days -5, -4, and -3.
75776586|NCT05630820|Drug|Bepirovirsen|Bepirovirsen will be administered.
75776587|NCT05630820|Other|Placebo|Matching placebo will be administered.
75776588|NCT05629286|Device|McConnell taping|non-stretch rigid McConnell tape will be applied
75776589|NCT05629286|Device|Patella Stabilizer Brace|An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro
75776590|NCT05623839|Drug|LY3305677|Administered SC
75776591|NCT05623839|Drug|Placebo|Administered SC
75776592|NCT05622799|Behavioral|Mind-Body Medicine Training Program|A mind-body medicine training program that teaches mind-body skills including meditation, autogenics and biofeedback, guided imagery, body awareness, genograms, and self-expression through writing and drawings. The first 4 day training consists of lectures and small groups where the mind-body techniques are practiced. The second 4 day training allows participants to lead a mind-body skills group and teach the techniques under supervision.
75776593|NCT05617898|Behavioral|Motivational Interviewing|Three motivational interviewing sessions will target sensitivity to social reward, including subjective evaluation of social interaction, socially rewarding stimuli, and events (e.g., interactions with others, feedback from others).
75776594|NCT05617898|Behavioral|Nutrition Didactic Training|The Nutrition didactic training will ask participants to discuss pros and cons of healthy eating habits and how to improve their current eating habits.
75913883|NCT05966506|Behavioral|Fitbit activity monitor|"Participants will be instructed to use the Fitbit to monitor their partners' PA in addition to their own. All participants will be instructed to friend their health coach to enable real-time monitoring of PA to inform coaching zoom calls. The Fitbit will provide feedback on steps, active minutes, and calories burned. Participants will be asked to wear the device on most days and while they sleep."
75321099|NCT03509792|Behavioral|Attention placebo|Smartphone activity for same amount of time.
75623332|NCT00610779|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
75623333|NCT02700724|Other|Immediate Surgery|
75623334|NCT02700724|Other|Observation|
75623335|NCT02700724|Procedure|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
75623336|NCT04258371|Drug|Dapagliflozin 10 MG|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
75776595|NCT05617495|Other|Mindfulness + fMRI Neurofeedback|Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
75776596|NCT05615948|Drug|VTS-K|Proprietary oral formulation of 486mg aspirin and 80mg ketamine
75776597|NCT05615532|Drug|LY3209590 (SC)|Administered SC.
75776598|NCT05615532|Drug|LY3209590 (IV)|Administered IV.
75776599|NCT05615064|Other|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players
75776600|NCT05614349|Drug|Paxlovid|This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
75776601|NCT05614349|Drug|Other|As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.
75776602|NCT05614349|Other|Other|As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.
75913884|NCT05966506|Other|Electronic newsletters|Newsletters will be sent twice monthly during months 1-3 via email or text with an online link. Newsletters will be designed to share educational PA-related information from publicly available resources. Newsletters will also contain tips for overcoming barriers to PA ,finding time to exercise, low-cost ways to be active and being active with kids.Newsletters will also contain links to brief exercise routines that participants can do in their homes and information on low cost/free exercise classes in the community, which may help to overcome perceived access barriers
75913885|NCT05965479|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
75623337|NCT04258371|Drug|Placebo oral tablet|Placebo once daily for 12 weeks
75776603|NCT05610358|Device|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory or cardiovascular diseases.
75776604|NCT05609812|Drug|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
75913886|NCT05965440|Drug|impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients|Analysis of microbiota
75623338|NCT00609219|Biological|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10^7 cells/m2 Day 14 - 2 x 10^7 cells/m2~Group Two:~Day 0 - 2 x 10^7 cells/m2 Day 14 - 1 x 10^8 cells/m2~Group Three:~Day 0 - 1 x 10^8 cells/m2 Day 14 - 2 x 10^8 cells/m2"
75913887|NCT05964686|Combination Product|Conventional group (NaOCl/EDTA)|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
75321100|NCT05559203|Behavioral|danceSing Care|The programme was a digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/) and consisted of three movement sessions and one music session each week, the recommended dose agreed between danceSing Care and the Advisory group, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
75321101|NCT00590161|Drug|pentoxifylline (PTX)|400 mg PO tid
75321102|NCT00590161|Drug|placebo|placebo tid
75623339|NCT00930579|Drug|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
75623340|NCT00609297|Other|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
75623341|NCT00609297|Other|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
75623342|NCT00609297|Other|survey administration|Given to patient and caregivers throughout the study
75913888|NCT05964686|Combination Product|Dual laser group (Er,Cr:YSGG/Diode):|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
75913889|NCT05964686|Combination Product|Combined group (EDTA/Diode):|17% EDTA was used to remove smear layer followed by diode laser for disinfection
75913890|NCT05963529|Other|Humidity-ramp protocol|Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which esophageal temperature (and rectal temperature and heart rate) inflect is subsequently determined.
75913891|NCT05963529|Other|Above-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is ~5% higher than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
75623343|NCT04257981|Device|Brain stimulator v3.0|Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research
75776605|NCT05609812|Drug|Placebo|placebo
75776606|NCT05608421|Behavioral|1MoreStep|Cognitive behavioral intervention to reduce HIV and IPV stigma.
75776607|NCT05608421|Behavioral|1MoreStepControl|This is an equal attention control group.
75776608|NCT05595837|Other|Standard organ transplant|Standard organ transplant procedures and follow up care
75776609|NCT05595460|Drug|RYZ101 Dose Level 1|6.5 MBq/175 μCi administered by IV for up to 6 infusions once every 4 or 6 weeks
75776610|NCT05595460|Drug|RYZ101 Dose Level 2|8.3 MBq/225 μCi administered by IV for up to 6 infusions once every 4 or 6 weeks
75776611|NCT05595460|Drug|RYZ101 Dose Level 3|10.2 MBq/275 μCi administered by IV for up to 6 infusions once every 4 or 6 weeks
75776612|NCT05595460|Drug|RYZ101 Dose Level -1|4.6 MBq/125 μCi administered by IV for up to 6 infusions once every 4 or 6 weeks
75776613|NCT05595460|Drug|Atezolizumab|1200 mg administered IV for 4 x 21-day cycles, followed by 1680 mg every 28-days (maintenance)
75776614|NCT05595460|Drug|Carboplatin|AUC 5-6 administered IV for 4 x 21-day cycles
75776615|NCT05595460|Drug|Etoposide|80-100 mg/m2 administered IV on 3 consecutive days for 4 x 21-day cycles
75776616|NCT05594667|Drug|Psilocybin|25mg of psilocybin provided by Filament Health
75776617|NCT05591911|Diagnostic Test|Urine PCR testing|The urine PCR panel will be performed to evaluate the bacterial growth in the patient's urine who is admitted with acute urinary tract symptoms.
75776618|NCT05589818|Drug|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV. Patients will be offered this schedule, also an FDA-approved option, at the discretion of the treating physician, based on tolerability of the q3week regimen and clinician assessment of need for closer follow up intervals. Pembrolizumab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or death.
75776619|NCT05589623|Other|Copenhagen adduction exercise|The CAE is a progressive eccentric training program that enhances hip adduction. The fact that exercises are done with a partner and do not require special equipment makes them more useful in a team setting. The MPCA program, adapted from the original CAE, included six progressive levels for eight weeks, beginning with an assisted isometric adduction hold (level 1) and progressing incrementally to a complete CAE as the original exercise (level 6). The progression in levels will depend on a pain score ≤ 4/10 numeric rating scale (NRS) in the adductor squeeze test and post-session DOMS score ≤ 4/10 NRS.
75776620|NCT05589623|Other|Usual rehabilitation program|The usual rehabilitation program will include leg swings extension/flexion, leg swings abduction/adduction, standing hip circles, isometric standing hip adduction using elastic bands, stretching exercises, balance training on a wobble board, and single leg coordination exercises. Difficulty and volume are progressing incrementally.
75776621|NCT05584345|Other|Conventional Treatment|Cold pack, ultrasound, TENS, finger ladder, Codman, shoulder wheel, and Wand exercises, as well as stretching and capsule exercises, will be used in addition to conventional physiotherapy. Exercises with a wand will be performed 10 times in each direction. There will be 30 repetitions in each direction of the Codman exercises. 5 days a week, for a total of 30 sessions, the afflicted shoulder will get 6 minutes of daily US treatment, with complete contact to the shoulder area and at a right angle. All patients will receive manual stretching in the shoulder flexion, abduction, extension, external rotation, and internal rotation directions. The physiotherapist will perform these stretches 5 times in each direction, pausing for 20 seconds at the conclusion of each repeat. TENS will be applied for 20 minutes. In addition, a 15-minute cold pack application will be made to the shoulder region. The application of theraband strengthening exercises will depend on the patients' state.
75776622|NCT05584345|Other|Respiratory Exercises|Diaphragmatic breathing and thoracic expansion breathing exercises will be applied 5 days a week.
75913892|NCT05963529|Other|Below-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is ~5% lower than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
75623344|NCT04257981|Other|Sham Comparator: Control group|The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
75623345|NCT04260555|Drug|DW1601|Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
75776623|NCT05578443|Drug|Astragalus|Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
75776624|NCT05578443|Behavioral|Routine treatment|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
75776625|NCT05573360|Other|NGF5-A test formulation|One drop of investigational product instilled on the eye
75913893|NCT05963529|Other|Control fixed-condition exposure|Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.
75913894|NCT05962463|Procedure|Canal adductor blockade|The same experienced anesthesiologist has performed all blocks. Always after surgical cleaning of the anteromedial thigh, all participants in this group received single shot ultrasound guided canal adductor blockade. After the blockade, all participants were monitored in our ambulance for the next hour.
75623346|NCT04260555|Drug|DW16011|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
75623347|NCT04260555|Drug|DW16012|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
75776626|NCT05573360|Other|NGF4-B test formulation|One drop of investigational product instilled on the eye
75776627|NCT05573360|Other|NGF6-B test formulation|One drop of investigational product instilled on the eye
75776628|NCT05573360|Other|NGF6-E test formulation|One drop of investigational product instilled on the eye
75776629|NCT05573360|Other|Systane eye drop|One drop of commercial product instilled on the eye
75776630|NCT05572606|Behavioral|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
75623348|NCT04260321|Device|AI|Artificial intelligence colonoscopy
75623349|NCT02700568|Drug|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
75623350|NCT00925353|Drug|4% lidocaine gel|1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
75623351|NCT02700646|Behavioral|Developmental recommendations|
75776631|NCT05572359|Device|cryo-and compression brace|patients in the intervention groups are instructed to use the cryo- and compression brace during the six postoperative weeks five times a day, for a maximum of 20 minutes. The amount of compression is dependent on a patients' own preference.
75776632|NCT05571319|Drug|Metformin Extended Release Oral Tablet|Glucophage XR 500 mg
75776633|NCT05570227|Other|[U-13C]Glucose Infusion|Peri-operative infusion of [U-13C]glucose
75776634|NCT05570162|Other|Diabetes educational program|30-minute long diabetes educational program
75776635|NCT05569278|Drug|GE200486 0.5M Injection|Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush
76073540|NCT00723580|Drug|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
75623352|NCT02700646|Behavioral|Standard care|standard care
75776636|NCT05561452|Other|Single PRP Injection|"In single-PRP injection group, 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
75798398|NCT01171170|Drug|Standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
75798399|NCT03868176|Other|short message service|short message service
75913895|NCT05962463|Procedure|Canal adductor pulsed radio-frequency therapy|The same experienced anesthesiologist has performed all PRF therapy After surgical cleaning of the anteromedial thigh, all participants in this group received ultrasound-guided pulsed radiofrequency therapy. We've previously scanned the adductor canal and chose the middle of the canal as the entry point of the RF 10 cm needle with a 1 cm free tip. After sensory and motor checking all patients have gotten 6 minutes of therapy divided into 3 sequences of 2 minutes of 50 V current and 42ºC. After the treatment, all participants were monitored in our ambulance for the next hour.
75913896|NCT05959252|Drug|Unfractionated heparin|Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
75913897|NCT05959252|Drug|Bivalirudin|Bivalirudin protocol with target aPTT 50-70 seconds
76073541|NCT05581251|Behavioral|Food and cooking skills|The researchers collected the study data using the face-to-face interview method through a questionnaire including the Descriptive Information Form, Cooking Skills and Food Skills Scale, and Three-Factor Eating Questionnaire-R21.
76073542|NCT01273948|Drug|Bavituximab|"Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or"
76073543|NCT01273948|Drug|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
76073544|NCT00734344|Drug|Raltegravir|Raltegravir 400 mg. BID
76073545|NCT00734344|Drug|Efavirenz|600 mg once daily
75321103|NCT03672110|Drug|Advagraf|intervention: different advagraf dosing in the study compared to the control arm, see above
75321104|NCT04825067|Device|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
75623353|NCT02705560|Other|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
75913898|NCT05957393|Other|Quantity of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
75623354|NCT02705560|Other|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
76073546|NCT00734344|Drug|Emtricitibine|200mg once daily
76073547|NCT00734344|Drug|Tenofovir disoproxil once daily|300mg once daily
76073548|NCT00734344|Drug|Tenofovir disoproxil twice daily|300mg twice daily
76073549|NCT04148937|Drug|LY3475070|Administered orally
76073550|NCT04148937|Drug|Pembrolizumab|Administered IV
76073551|NCT03021057|Drug|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
75623355|NCT02705560|Other|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
75623356|NCT04203615|Device|Transcranial magnetic stimulation- sham rTMS|Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
75623357|NCT04203615|Device|Transcranial magnetic stimulation- real rTMS|Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.
76073552|NCT00734500|Drug|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
76073553|NCT04148391|Drug|Placebo Oral Capsule|Matching placebo capsules.
75623358|NCT02705482|Biological|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
75623359|NCT02705482|Biological|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
75623360|NCT02705482|Biological|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
75623361|NCT00615316|Drug|Guaraná|Guaraná extract 75mg/day
75623362|NCT00615316|Drug|Placebo|Placebo 1tab/d
75623363|NCT00611013|Device|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
75623364|NCT04215172|Drug|Macrolides|administration of azithromycin three times weekly for six months
75623365|NCT02700490|Behavioral|Psychotherapy|"Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia."
75623366|NCT04260399|Other|Lavender Aromatherapy|Participants in the experimental group will be passively exposed to lavender essential oil
75623367|NCT04260399|Other|Placebo Aromatherapy|Participants in the control group will be passively exposed to saline water aromatherapy
75623368|NCT02705638|Drug|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
75623369|NCT02705638|Drug|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
75623370|NCT04877223|Other|No intervention|No intervention
75623371|NCT02705170|Procedure|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
75623372|NCT04260009|Drug|Brigatinib|Brigatinib tablets
75623373|NCT04260009|Drug|Brigatinib AAF|Brigatinib age-appropriate formulation (AAF)
75623374|NCT02705092|Other|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
75623375|NCT02705092|Other|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
75623376|NCT04257825|Device|Chili Sleep System|A mattress pad that cools or warms bed to maintain a constant temperature.
75623377|NCT02700256|Behavioral|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
76073554|NCT04148391|Drug|NYX-458|NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
75623378|NCT02692066|Biological|varicella vaccine|
75623379|NCT02691910|Drug|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
75623380|NCT02691910|Drug|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
75623381|NCT04215250|Other|andropulous method|Counts the CVC depth using specific equation
75623382|NCT04215250|Device|ECG|Using ECG to monitor the insertion of the CVC
75623383|NCT02705326|Device|Opti-Speech|Uses visual feedback of the tongue's motion to guide speech sound production
75623384|NCT02700802|Other|Feed1st|Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
75623385|NCT02705014|Drug|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
75623386|NCT02700178|Other|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
75623387|NCT02704624|Dietary Supplement|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
75623388|NCT02704624|Other|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
75623389|NCT02701114|Procedure|Proximal Adductor Canal Block|Continuous Nerve Block
75623390|NCT02701114|Procedure|Distal Adductor Canal Block|Continuous Nerve Block
75623391|NCT02700100|Device|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~Tetralogy of Fallot~Truncus Arteriosus~Pulmonary Atresia~Transposition of Great Arteries with Ventricular Septal Defect (VSD)~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
76073555|NCT00734734|Biological|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
76073556|NCT04143321|Drug|Empagliflozin 25 MG|after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
76073557|NCT00734968|Drug|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
76073558|NCT00734968|Other|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
75776637|NCT05561452|Other|Multiple PRP Injections|"In multiple-PRP injection group, two PRP injections will be performed with an interval of 3 weeks. 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained is planned to be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
75776638|NCT05561452|Other|Placebo Injection|"In placebo-injection group,10 ml of venous blood will be taken and after the same waiting time 4 ml of 0.9% saline will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
75798400|NCT01282320|Behavioral|Physical activity intervention program|Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
75913899|NCT05957393|Other|Quality of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
75623392|NCT04213846|Behavioral|Experimental: Mobile Alcohol Expectancy Challenge (mAEC)|Participants randomized to the mAEC condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
75623393|NCT02700022|Drug|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
75913900|NCT05957393|Other|Control|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
75913901|NCT05956119|Device|dry needling + physiotherapy (standard/usual care)|same that arm descrption
75913902|NCT05956119|Other|sham dry needling + physiotherapy (standard/usual care)|same that arm description
75321105|NCT00590395|Drug|18FDG (an FDA-approved radiopharmaceutical)|Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
75623394|NCT02699944|Device|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
75623395|NCT02699788|Device|Multifunction Cardiogram|
75623396|NCT02699710|Drug|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
75623397|NCT02699710|Drug|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
75321106|NCT00006170|Drug|Bupropion|smoking cessation medication aid
75321107|NCT00006170|Drug|Placebo|A matched placebo pill
75623398|NCT02699710|Drug|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
75623399|NCT02699710|Drug|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
75623400|NCT00618670|Behavioral|Walking Exercise|Three times per week for 3 months
75623401|NCT00618670|Behavioral|Control--Resistance Training|Three times per week for 3 months
75623402|NCT04212520|Other|No intervention|No intervention
75623403|NCT05119348|Other|STOPCOV|Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
75623404|NCT00618904|Dietary Supplement|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
75798401|NCT03873324|Drug|CPL500036 compound|IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
75913903|NCT05955755|Other|butterfly vacuum blood collection set|Blood collection from the children in the experimental group will be performed with a butterfly vacuum blood collection set.
75913904|NCT05949944|Drug|Linperlisib in combination with CHOP|Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
75913905|NCT05949606|Drug|SI-B001|Administration by intravenous infusion
75913906|NCT05949606|Drug|SI-B003|Administration by intravenous infusion
75913907|NCT05949424|Drug|Olaparib|Starting dose of 200mg 2dd.
75321108|NCT00006170|Behavioral|weight concerns intervention|cognitive behavioral treatment to address weight concners
75321109|NCT00006170|Behavioral|smoking cessation intervention|Cognitive behavioral intervention for smoking cessation
75623405|NCT00618904|Dietary Supplement|Placebo|Placebo administered bid for 6 weeks.
75623406|NCT05324722|Other|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
75623407|NCT05324722|Other|cross body stretch|crossbody stretch performed by an individual
75913908|NCT05949424|Drug|Lenvatinib|Starting dose of 10mg 1dd.
75623408|NCT05324644|Behavioral|Motivational interview|In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
75623409|NCT04214704|Device|Genteel lancing device|Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively
75466525|NCT01910454|Behavioral|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
75623410|NCT04214704|Device|Conventional lancing device|Conventional lancing device
75623411|NCT03140488|Drug|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
75776639|NCT05561244|Device|Weekly monitoring using the capillary International Normalised Ratio strategy|Patients in the interventional group will be monitored using the capillary International Normalised Ratio strategy every week, and more often if the International Normalised Ratio is not in the therapeutic target. Venous International Normalised Ratio punctures will also be performed as described for the control group in order to calculate the Time in Therapeutic Range equivalently in both groups. Specific training in handling the device and the dose adjustment protocol will be provided to nurses and prescribers.
75776640|NCT05555407|Diagnostic Test|Scintigraphic gastric emptying scan|Nuclear medicine scan that provides an assessment of gastric motility
75776641|NCT05555407|Device|Wireless patch system (WPS)|Wireless wearable patches applied to the abdomen after 3 small areas of the abdomen that connect to a recording device for a total of 6 days and subjects will track mealtimes, bowel movements, and sleep using an iPhone app.
75776642|NCT05551520|Device|Normative|ImPACT will be administered at baseline testing
75776643|NCT05551520|Device|Reliability|ImPACT will be administered again within 60 days of baseline test
75776644|NCT05551156|Behavioral|Animal-assisted interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the participant will be able to pet the dog if they wish. The handler will talk with the participants about the dog, the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
75776645|NCT05551156|Behavioral|Conversational interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants without a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the handler will talk with the participants about the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
75776646|NCT05542615|Drug|Prolonged-Release Pirfenidone|1200 mg / day of Pirfenidone (KitosCell® LP)
75776647|NCT05534438|Radiation|Stereotactic body radiotherapy|SBRT will be initiated as soon as possible, at not beyond 8 weeks of baseline measurements. Recommended dosing is per department standards for oligometastatic disease (ie, 10 Gy x 3 or 7-8 Gy x 5 fractions daily, excluding weekends and departmental holidays)
75776648|NCT05532163|Drug|Natalizumab|Administered as specified in the treatment arm
75776649|NCT05523414|Behavioral|SKY|The SKY intervention will be administered in-person over three sessions spread over three consecutive days by qualified instructors. Participants will then be followed up over eight weeks' time, where they will be given the option to attend daily 35 minute breathwork sessions, again, guided by experienced instructors. Participants will be required to log whether or not they practiced for each day in the eight-week period. They will also receive intermittent reminders about their daily practice during the 8-week follow-up period.
75776650|NCT05515081|Procedure|blood sample collection|blood sample colletion at regular intervals
75913909|NCT05949424|Drug|Sunitinib|Starting dose of 25mg 1dd 28/42 days.
75913910|NCT05949424|Drug|Palbociclib|Starting dose of 75mg 1dd 21/28 days.
75913911|NCT05949424|Drug|Pazopanib|Starting dose of 200mg 1dd.
75913912|NCT05949424|Drug|Olaparib|Starting dose of 300mg 2dd.
75913913|NCT05949424|Drug|Lenvatinib|Starting dose of 20mg 1dd for RCC or endometrial carcinoma, starting dose of 24mg 1dd for thyroid carcinoma.
75913914|NCT05949424|Drug|Sunitinib|Starting dose of 50mg 1dd 28/42 days.
75913915|NCT05949424|Drug|Palbociclib|Starting dose of 125mg 1dd 21/28 days.
75913916|NCT05949424|Drug|Pazopanib|Starting dose of 800mg 1dd.
75913917|NCT05949177|Behavioral|Graded Exposure and Mindfulness Meditation|Participants will complete graded exposure and will be encouraged to face fear-eliciting situations. Participants will also complete mindfulness meditation guided through the Headspace mobile application. Participants will complete the graded exposure one time per week and will complete the mindfulness meditation 4 times per week.
76073559|NCT03753945|Diagnostic Test|MRI of the spine|Perform a clinically indicated MRI of the spine in DBS patients
76073560|NCT03918837|Other|Sham rTMS|Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.
75776651|NCT05512403|Drug|PET/CT with 18F-DOPA|"A 18F-FDOPA PET exam is then performed (acquisition of 30 minutes in List Mode format) according to the French guidelines for PET neuro-oncological indications (Verger et al. Med Nuc, 2020, (5)).~Patient preparation and acquisition:~4 hours of fasting~No carbidopa premedication~2 MBq / kg of 18F-FDOPA~Dynamic acquisition in List Mode format for 30 min starting simultaneously with the patient's injection~Low dose scanner for attenuation correction"
75776652|NCT05510141|Other|Virtual reality gaming|Instead of nitrous oxide, which is the standard procedure, virtual reality gaming is applied to reach pain reduction in minor surgery procedures
75776653|NCT05510141|Drug|Nitrous oxide|Standard procedure
75776654|NCT05502367|Drug|ABI-2280|Vaginal Tablet
75776655|NCT05501600|Device|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using an electric nerve stimulator.
75776656|NCT05501600|Drug|Lidocaine IV|Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
75776657|NCT05492825|Other|Yoga|Each yoga class will follow a standardized structure, allowing participants to easily re-join if they miss classes. Yoga classes will be adapted to the abilities and limitations of each study participant, for example, using a chair for sitting exercises rather than the floor and to assist with balance. Postures (asanas) will target back pain and include mindfulness, relaxation, and breathing practices integral to hatha yoga, with focus on breath-based movement throughout. Each group will have 1-2 yoga instructors and no more than 5 participants per yoga instructor (up to 10 participants/group).
75776658|NCT05492825|Other|Physical Therapy|The assessment at the second screening visit by the Physical Medicine & Rehabilitation physician/Physical Therapy staff will be available to physical therapists in the Electronic Health Record and will guide the type of exercises, to focus on stabilization (strengthening core trunk muscles) and flexion or extension exercises. Sessions are divided into 30 minutes of working directly with a physical therapist and 30 minutes of supervised aerobic exercise (on treadmill or recumbent bike). Participants will receive a guidebook for guiding and recording home practice, based on Saper's guidebook and modified based on feedback from experts and stakeholders for clarity and cultural appropriateness.
75913918|NCT05949177|Behavioral|Waitlist Control|Participants will receive an email stating that they will receive access to 5-weeks of Headspace after 5-weeks. Participants will be also asked to not change their normal routines or download apps for relaxation, meditation, or sleep during 5-weeks. After completion of the outcome assessments at 5-weeks, participants in this group will receive access to 5-weeks of Headspace.
75913919|NCT05944718|Device|Continuous glucose monitor|"Continuous Glucose Monitoring (CGM) is a technology used to measure glucose levels in people with diabetes. Unlike traditional finger prick self-monitoring of blood glucose (SMBG), CGM devices provide continuous and real-time glucose readings throughout the day and night.~CGM systems consist of a small sensor that is inserted under the skin to measure glucose levels in the interstitial fluid, a transmitter that sends the glucose data to a receiver or smartphone, which shows the glucose readings. The sensor measures glucose levels automatically at regular intervals, eliminating the need for frequent finger pricks.~CGM devices can track glucose trends, identify high or low glucose levels, and provide alerts for hypo- or hyperglycemia. This can help individuals make more informed decisions regarding their diabetes management, such as adjusting insulin doses, dietary choices, or physical activity levels."
75913920|NCT05941780|Diagnostic Test|Pain classification method|A current clinical algorithm will be used to determine the predominant type of pain in individuals with FMS. The classification to diagnose nociceptive, neuropathic and nociplastic pain will based on a recent method developed by Nijs et al. This method consists of seven steps in total. These steps question the following, respectively: duration of pain, pain distribution, presence of nociceptive pain, presence of neuropathic pain, phenomenon of hypersensitivity, presence of hypersensitization and presence of specific comorbidity. Besides, inter-rater and intra-rater reliability of pain classification algorithm will be determined by two independent researchers.
75466526|NCT01910454|Behavioral|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
75623412|NCT00616408|Drug|Octreotide-LAR|Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
75623413|NCT03093610|Procedure|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
75623414|NCT03093610|Procedure|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
75623415|NCT05323942|Other|Education and Exercise Therapy Group|"82 children were evaluated. Among those, 37 volunteered children were trained and demonstrated in practice about bruxism, parafunctional oral habits, sleep hygiene education, and 5x5 therapeutic exercises. Therapeutic exercises program 5x5 included breathing exercises, head-neck, and scapular posture exercises which included jaw muscle and neck muscle stretching and strengthening exercises. They were asked to repeat each exercise with 5 set and 5 times a day for 8 weeks.~Sleep hygiene education was given to parents and children with explanation of the parafunctional oral habits to raise awareness about being conscious about the oral habits. Sleep hygiene education includes routines about bedtime, sleeping room environment, and timing for exercise."
75623416|NCT03088150|Procedure|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
75623417|NCT03088150|Procedure|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
75623418|NCT02691754|Other|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
75321110|NCT02996539|Other|Clinical examination and laboratory measurements|Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
75623419|NCT02691676|Drug|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
75623420|NCT02691676|Drug|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
75623421|NCT00616486|Device|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
75623422|NCT00616486|Device|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
75623423|NCT05321602|Drug|LY03010 156 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
75623424|NCT05321602|Drug|LY03010 156 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
75623425|NCT05321602|Drug|LY03010 351 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
75623426|NCT05321602|Drug|LY03010 351 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
75623427|NCT05318872|Device|ENDOSWIR|Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
75623428|NCT01106651|Drug|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
75623429|NCT01106651|Drug|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
75776659|NCT05492825|Other|Treatment As Usual|Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians. Those patients who receive on-site medical care have the opportunity to address nonpharmacological and pharmacological treatment with onsite physicians and physician assistants, and to receive referral to specialty care including physical therapy and orthopedics at multiple Montefiore locations throughout the Bronx.
75776660|NCT05487209|Diagnostic Test|MRI,SCC-Ag|Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen
75913921|NCT05941663|Other|Dental implant surface|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface
75913922|NCT05939310|Procedure|Fluorescence guided detection of tumor positive margins.|Intraoperative fluorescence imaging detection of tumor positive margins using the targeted tracer bevacizumab-IRDye800CW.
75913923|NCT05928624|Device|Withings Home Blood Pressure Device and Scale|The intervention will be whether the data generated from home monitoring devices are shared with the clinical providers. The investigators are not testing the efficacy of these approved devices.
75913924|NCT05928624|Other|Standard of Care|Standard of Care
75321111|NCT02123849|Drug|Aspirin|Given PO
75623430|NCT01106651|Drug|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, metformin, insulin [all types]) and their combinations (sulfonylurea agent and insulin [all types], metformin and insulin [all types], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4]) are used as per protocol specifications.
75623431|NCT01106651|Drug|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
75623432|NCT00637078|Other|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
75623433|NCT05323162|Other|encapsulated autologous fecal microbiota transplantation|Individuals will recieve encapsulated freezedried own fecal microbiota to potentially extingish auto-immunity directed against the residual beta cell fraction
75623434|NCT05323006|Other|scapular stabilization exercises|the effect of the scapular stabilization exercise on the clavicular motion on the adolescent girls
75623435|NCT04214470|Other|No intervention|There is no intervention for this study
75623436|NCT00616564|Drug|GM-CSF|Concomitant Priming with GM-CSF
75776661|NCT05481905|Drug|ENX-101|Adjunctive treatment to current antiseizure medication
75798402|NCT03873324|Drug|Placebo|matching placebo capsules
75798403|NCT01166100|Drug|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
75913925|NCT05928104|Other|Medication review|Pharmacist-led medication review in primary care using a co-designed document
75321112|NCT02123849|Other|Laboratory Biomarker Analysis|Correlative studies
75321113|NCT02123849|Other|Placebo|Given PO
75321114|NCT01798303|Drug|LY2940094|Administered orally
75321115|NCT01798303|Drug|Placebo|Administered orally
75913926|NCT05928013|Diagnostic Test|Neurothesiometer|The 'gold standard' device for Vibration Perception Threshold testing
75776662|NCT05475600|Behavioral|Classical APA group:|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
75913927|NCT05928013|Diagnostic Test|NERVE|The experimental device for Vibration Perception Threshold testing developed by the project team
75913928|NCT05926258|Drug|Chloroprocaine 3% eye gel|ocular surface anesthesia
75776663|NCT05475600|Behavioral|APA with Exergaming device|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
75913929|NCT05926258|Drug|Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops|ocular surface anesthesia
75913930|NCT05923008|Drug|IBI130|Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
75913931|NCT05920122|Drug|2% Chlorhexidine gluconate with 70% alcohol|Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
75623437|NCT04214314|Behavioral|NeuronUp APT attentional program|NeuronUp APT attentional program consists of 4 types of attention with 20 activities each and 5 different levels of difficulty per activity. These 20 activities will be divided into two blocks (block A or block B) of 10 activities each and then, randomly, participants will be administered one block or another. The administration of the entire program is approximately one month and a half or 2 months per patient, with sessions of one hour, 3 times per week.
75623438|NCT05003609|Other|Early Rehabilitation|The intervention involves a progression of rehabilitation exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 mins) at each session. The intervention will be administered 5 days per week (weekdays) while the patient remains in ICU, censored at 28 days after randomisation.
75913932|NCT05920122|Drug|4% Chlorhexidine Gluconate aqueous solution|Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
75913933|NCT05917613|Behavioral|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR/MPE)|Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD)
75913934|NCT05915884|Other|SGLT-2 inhibitors|This study is an observational study. It is not planned to do an interventional activity.
75913935|NCT05909969|Other|Pelvi-Fit app Training|This group will receive Pelvic Floor Muscle Strengthening exercises through software application.
75798404|NCT01166256|Device|Non-invasive ventilation|Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 >92% or PaO2 >65 mmHg.
75798405|NCT01166256|Device|High flow nasal cannula system|High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 >92% or PaO2 >65 mmHg.
75913936|NCT05909969|Other|Control|This group will receive Pelvic Floor Muscle Strengthening exercises through instructions and pamphlets describing exercises.
75913937|NCT05908760|Device|CO2 ReHaler|The ReHaler captures expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2.
75913938|NCT05902312|Device|transcranial magnetic stimulation|Participants will receive either rTMS or dTMS
75913939|NCT05901246|Dietary Supplement|PS-containing dietary supplement|Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
75321116|NCT05347160|Procedure|Biodentine|using of biodentine , calcium hydroxide and platelet rich fibrin as pulpotomy agents
75321117|NCT03505112|Other|Goal-directed therapy|"The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).~After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI <10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of <10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion."
75913940|NCT05901246|Other|Placebo|Sachet containing the excipients of the ingredient (2,25 g placebo/day)
75913941|NCT05898113|Other|EXTRA VIRGIN OLIVE OIL|Participants will consume a daily amount of extra virgin olive oil. Can consume the oil either raw or cooked
75913942|NCT05898113|Other|OLIVE OIL LOW POLYPHENOL|Participants will consume a daily amount of olive oil low polyphenol. Can consume the oil either raw or cooked
75913943|NCT05893771|Drug|Methylprednisolone Injection|Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.
75913944|NCT05893771|Drug|Bupivacaine Hcl 0.5% Inj_#2|Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline
75913945|NCT05893771|Drug|normal saline|Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
75776664|NCT05475600|Behavioral|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à Exergaming device 3 - Cool down: 20min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
75776665|NCT05471622|Behavioral|Nudge for PHPC Referral|The case manager and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for Penn Home Palliative Care (PHPC) upon hospital discharge will be asked to refer their patient for these home palliative care services.
75776666|NCT05467631|Other|Topical oil application|Topical Comparison
75776667|NCT05467007|Diagnostic Test|BioFire® Respiratory Panel 2.1-EZ|BioFire RP2.1-EZ Panel uses a syndromic approach to quickly identify SARS-CoV-2, along with 18 additional viral and bacterial pathogens in patients suspected of SARS-CoV-2. This PCR test provides results in about 45 minutes.
75776668|NCT05462106|Biological|Placebo|Administration of Placebo
75776669|NCT05462106|Biological|ACI-24.060 at Dose A|Administration of Dose A of ACI-24.060
75776670|NCT05462106|Biological|ACI-24.060 at Dose B|Administration of Dose B of ACI-24.060
75776671|NCT05462106|Biological|ACI-24.060 at Dose C|Administration of Dose C of ACI-24.060
75776672|NCT05462106|Biological|ACI-24.060 at Dose D|Administration of Dose D of ACI-24.060
75776673|NCT05462106|Biological|Placebo|Administration of Placebo
75776674|NCT05462106|Biological|ACI-24.060 at Dose X|Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
75776675|NCT05462106|Biological|ACI-24.060 at Dose Y|Administration of Dose Y of ACI-24.060
75776676|NCT05459675|Other|Very low-calorie diet|Meal replacement (800 kcal/day, protein 90 g/day)
75913946|NCT05893238|Procedure|Natural cycle In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) without hormonal stimulation
75321118|NCT05558969|Drug|pregnant women taking magnesium|The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
75321119|NCT05558969|Drug|Placebo|Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
75623439|NCT00625781|Drug|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose >5.0 mmol/l or post meal value >6.5 mmol/l according to study protocol.
75623440|NCT02867644|Other|standard care|Patients coming for preoperative breast assessment will have standard care.
75623441|NCT02867644|Other|standard care + conversational hypnosis|Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
75776677|NCT05459675|Procedure|Bariatric surgery|Bariatric surgery will be performed by single surgeon at Ramathibodi Hospital Mahidol University, Thailand. Postoperative diet progression according to the current guideline will be prescribed from early post-op period to 1 year after surgery
75776678|NCT05458440|Other|Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors|The investigators aim to demonstrate that it is possible to implement a biobank of leucocytes from convalescent donors that could be used as raw material to generate anti-SARS COV-2 viral specific T cells. The protocol will be explained during hospitalisation for each donor. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
75776679|NCT05456503|Drug|FPI-2620|Radiotracer
75776680|NCT05452616|Other|ART first- Therapeutic use trial|ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease. The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
75776681|NCT05452616|Other|TB results first- Therapeutic use trial|Deferral of ART initiation until active TB has been refuted or confirmed. PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations. Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
75776682|NCT05432544|Drug|SHR-1918|Ascending dose
75776683|NCT05432544|Drug|SHR-1918 placebo|Ascending dose
76073561|NCT03918837|Other|Active rTMS|Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
76073562|NCT04143399|Procedure|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
75913947|NCT05893238|Diagnostic Test|Blood samples for analysis|Test hormone levels in serum
75913948|NCT05893238|Diagnostic Test|Follicular fluid for analysis|Test hormone levels in follicular fluid Test Oxidation-reduction potential
75913949|NCT05893238|Diagnostic Test|Sperm samples for analysis|Oxidation-reduction potential
76073563|NCT04143399|Procedure|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
76073564|NCT00735436|Drug|Gliadel/Avastin/CPT-11|
75623442|NCT02880449|Behavioral|Intervention|A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
75623443|NCT01027650|Drug|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
75623444|NCT01027650|Drug|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
75776686|NCT05416944|Other|Personalized blood pressure management|Personalized blood pressure management: Intraoperative mean arterial pressure will be maintained at least at the mean nighttime mean arterial pressure (assessed using preoperative automated blood pressure monitoring) with a minimum mean arterial pressure of 65 mmHg, and maximum mean arterial pressure of 110 mmHg.
75776687|NCT05416658|Other|The Antipsychotic Medication Decision Aid (APM-DA)|The APM-DA intervention is the first and only International Patient Decision Aid Standards (IPDAS) approved shared decision making (SDM) decision aid intervention for Antipsychotic Medication decisions in psychiatric visits. The APM-DA intervention developed by the research team addresses a common issue among psychiatric care providers and patients that lies in the heart of pharmacotherapy - taking, tapering or stopping APM. The APM-DA has a print format and can be used online as a PDF. It includes a concise table describing what each option involves, its benefits, risks, and strategies to reduce risks. The intervention was developed in co-production with various stakeholders (patients, clinicians, service leadership, family members, researchers). Additional intervention materials are an evidence document to support the information and an APM side effects table.
75776688|NCT05416281|Other|Robotic Vacuum|Participants will be provided with a Roomba iRobot vacuum and will be asked to use the vacuum in their home for 8 weeks. Exposure to environmental exposures will be evaluated before and after the intervention using silicone wristbands.
75776689|NCT05416021|Drug|dapivirine|dapivirine vaginal ring
75466527|NCT01910467|Device|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
75466528|NCT01910467|Device|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
75776690|NCT05411341|Device|Argos (Alcon Laboratories, Inc.)|An ocular biometry examination will be performed on the affected eyes using the Argos device.
75913950|NCT05893238|Procedure|Conventional In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) with conventional hormonal stimulation
75623445|NCT02880527|Other|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~general practitioners~the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
75913951|NCT05892341|Device|AQUACEL® Ag+ Extra™|Wound treatment with AQUACEL® Ag+ Extra™ dressing
75913952|NCT05892341|Device|Cutimed® Sorbact®|Wound treatment with Cutimed® Sorbact® dressing
75321120|NCT00590707|Device|Deeper sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
75913953|NCT05891899|Other|observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
75321121|NCT00590707|Device|Moderate sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
75321122|NCT03504800|Device|Optical Coherence Tomography|This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B & C.
75321123|NCT05557019|Device|Booster Balloon Catheter|The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
75913954|NCT05889741|Drug|Ropivacaine injection|6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
75321124|NCT05549141|Other|treadmill gait training with gait facilitators|6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator
75776691|NCT05411341|Device|IOLMaster 500 (Carl Zeiss Meditec AG)|An ocular biometry examination will be performed on the affected eyes using the IOL Master 500 device.
75913955|NCT05889741|Drug|Normal saline|6.5cc of Normal Saline one time into the stellate ganglion.
75776692|NCT05408117|Device|5-0 Polypropylene epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
75913956|NCT05889559|Device|Tissue Ultrafiltration Catheters|patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle.
75913957|NCT05888610|Behavioral|Digital Outpost|A mobile application that allows caregivers of patients diagnosed with Alzheimer's Disease and Related Dementias to report patient symptom remotely to their clinical team.
75913958|NCT05887570|Behavioral|Educational intervention|intervention through extra education, modules, instruction on models
75913959|NCT05887570|Other|Control - Regular Instruction|participants receive usual training
75321125|NCT05549141|Other|treadmill gait training not-associated with gait facilitators|6 sessions of 30 minutes each of treadmill gait training
75321126|NCT00671528|Drug|Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)|Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
75466529|NCT01910480|Drug|NBI-98854 50 mg capsule once daily|
75466530|NCT01910480|Drug|Ketoconazole 400 mg (200 mg twice daily)|
75466531|NCT01910493|Behavioral|SMS reminders|Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
75913960|NCT05887557|Other|Active Referral|As an implementation science study, all clinical intervention components will be delivered as part of routine clinical care at participating clinical sites. Clinicians and staff at referral sites throughout San Francisco and Alameda counties (emergency departments, psychiatric emergency services, community clinics, care navigation and case management programs, and community-based services) will refer eligible patients who are out of care and are interested in linking to drop-in and/or mobile care services at one of the study sites. Clinical referrals will include basic patient information and contact/locator information to facilitate linkage to care. Referrals will be site-specific based on the site where the patient is interested in accessing care.
76073565|NCT04143165|Drug|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
76073566|NCT04143087|Drug|withdrawal TKIs or halve TKIs|Stop TKIs or treated by half TKIs
76073567|NCT00735670|Drug|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
76073568|NCT00735670|Other|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
76073569|NCT00735826|Drug|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
75623446|NCT05322772|Device|ECG|ii. 12 leads ECG: 12 leads ECG will be done to all infants & children using (FUKUDA DENSHI, CARDIMAX, model FCP 7101). The electrocardiograms will be reviewed through the creation of descriptive reports and determination of the following variables: heart rate, QRS duration, The QT interval was measured from the onset of the QRS complex to the end of the T wave, defined by the return of the terminal T wave to the isoelectric T-P baseline. When U waves were present, the end of the T wave will be taken as the nadir between the T and U waves. Then QT interval will be corrected for heart rate using Bazett's formula Interpretation of every ECG paper
76073570|NCT04765995|Drug|HZBio1 0.96mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
75321127|NCT00671528|Drug|Cream (betamethasone diproprionate and gentamicin)|Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
75623447|NCT05000567|Other|12 week nordic hamstring exercise program|12 weeks progressive eccentric strength training program targetting the hamstring muscles.
75623448|NCT04214548|Other|No Intervention|There is no intervention for this study
75321128|NCT00671528|Drug|Cream (betamethasone diproprionate)|Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
75623449|NCT04309331|Dietary Supplement|Motion|Amino acid based protein substitute
76073571|NCT04765995|Drug|HZBio1 3mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
75776693|NCT05408117|Device|5-0 Fast gut epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
75776694|NCT05406791|Device|VIRA App|Support from coach and using the VIRA app
75776695|NCT05406791|Device|Mood Education App|Support from mood education app
76073572|NCT04765995|Drug|HZBio1 6mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
75321129|NCT05347706|Dietary Supplement|formula|Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed
75466532|NCT01910506|Drug|RDEA3170 10 mg|
75466533|NCT01910532|Drug|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
75466534|NCT01910545|Drug|OTS167IV|
75466535|NCT01910558|Dietary Supplement|Alpha-cyclodextrin and digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch
75776696|NCT05405868|Drug|Nicotinomide|Nicotinamide tablets (750mg)
75466536|NCT01910558|Dietary Supplement|Alpha-cyclodextrin|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin
75466537|NCT01910558|Dietary Supplement|Digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
75466538|NCT01910571|Drug|P7435|
75776697|NCT05405868|Drug|Matching placebo|Matching placebo
75776698|NCT05400174|Diagnostic Test|Tilt table (upright position)|Different versions of cognitive assessments will be administered in the supine and upright positions.
75776699|NCT05397184|Biological|Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months
75776700|NCT05397041|Drug|BMB-101|Participants will receive one of several different oral doses of BMB-101 once or twice daily
75776701|NCT05397041|Drug|Placebo|Matched Placebo
75776702|NCT05393271|Drug|VH4011499|VH4011499 will be administered.
75776703|NCT05393271|Drug|Placebo|Placebo will be administered.
75776704|NCT05393271|Drug|Midazolam|Midazolam will be administered
75466539|NCT01910571|Other|Placebo|
75776705|NCT05391087|Other|Mean arterial pressure based management|Mean arterial pressure group: Low MAP will be intervened in accordance with the protocol as described in the arm
75321130|NCT01798121|Biological|To compare new PPD to reference standard material|Aplisol@ will be compared to reference standard material
75321131|NCT01798121|Biological|Reference standard|Response of reference standard material compared to Aplisol@.
75623450|NCT00616876|Drug|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
75623451|NCT00616876|Dietary Supplement|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
75623452|NCT01106027|Drug|Eculizumab|Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
75623453|NCT00616954|Drug|ATG-F|ATG-f
75623454|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
75623455|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
75623456|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
75623457|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
75623458|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
75623459|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
75623460|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
75623461|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
75623462|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
75321132|NCT00590863|Drug|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
75623463|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
75623464|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
75623465|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
75623466|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
75776706|NCT05391087|Other|Cardiac index based management|Cardiac index group: Low CI will be intervened in accordance with the protocol as described in the arm. Additionally, if MAP is lower than target MAP along with a normal CI, this will be intervened with noradrenalin infusion/titration
75913961|NCT05887557|Other|Drop-In Multidisciplinary HIV Care|Each site will independently implement a drop-in multidisciplinary site-based HIV care model. Core intervention features include drop-in care (no appointments), panel management to review clinical progress for all referred patients, and case management. Each site may include adaptations to the care model determined during Aim 1 formative work.
75913962|NCT05887557|Other|Mobile HIV Care|Each site will independently implement a mobile care model using site-specific resources. At a minimum, the mobile care team will include a clinical nurse with telemedicine (video visit) consultation with a clinician (MD/NP/PA). Mobile teams will also administer medications (including long-acting ART when available) and collect laboratory specimens (e.g. HIV viral loads)
76073573|NCT04765995|Drug|HZBio1 9mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
76073574|NCT04765995|Drug|HZBio1 12mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
75623467|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
75623468|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
75623469|NCT04257513|Diagnostic Test|Brain MRI|Neurological and Cognitive evaluation; Brain MRI
75776707|NCT05385991|Biological|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
76073575|NCT04765995|Drug|Placebo|Matching placebo will be administered intramuscularly.
76073576|NCT01276054|Radiation|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
76073577|NCT01276054|Drug|methylene blue|Given subcutaneously
76073578|NCT01276054|Drug|indocyanine green solution|Given subcutaneously
76073579|NCT01276054|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
76073580|NCT01276054|Procedure|axillary lymph node biopsy|Undergo axillary lymph node biopsy
75623470|NCT01027416|Drug|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
75776708|NCT05383157|Behavioral|Brief mindfulness|Training in mindfulness focused on breathing and pain sensations to enhance decentering, meta-awareness, and interoceptive awareness.
75623471|NCT04259931|Diagnostic Test|microbiome analysis|gut microbiome composition of C. difficile infected patients with relapsing (basal, at the end of first treatment, at the begin of the relapses and at four and twelve weeks after definitive treatment) and non-relapsing ( basal and four and twelve week after treatment) , will be analyzed.
75623472|NCT04300842|Device|smart bracelet|to measure the stress, fatigue, and activity.
75623473|NCT05331495|Device|Intraoperative Hemoperfusion|During the operation, the hemoperfusion device and the membrane oxygenator of the extracorporeal circulation device were operated in parallel.
75623474|NCT02873520|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
75623475|NCT02873520|Biological|Precision Cell Immunotherapy|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
75623476|NCT05026203|Drug|Ketamine Hydrochloride|Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days
75623477|NCT05026203|Drug|Midazolam|Midazolam
75623478|NCT00923559|Other|Treatment as Usual at Child Health Centre|Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.
75623479|NCT00923559|Other|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
75623480|NCT01015638|Drug|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
75623481|NCT01015638|Drug|Clindamycin phosphate and benzoyl peroxide 2.5% gel.|Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
75623482|NCT04257591|Other|hamstring strengthening|A progressive and individualized hamstring strengthening protocol
75623483|NCT01022502|Drug|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
75623484|NCT01022502|Drug|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
75623485|NCT04907877|Dietary Supplement|Probiotic|Probiotic will be taken 1 time a day before breakfast for 28 days.
75776709|NCT05383157|Other|Usual care|Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
75776710|NCT05372172|Other|none, observational study|none, observational study
75776711|NCT05368168|Device|Posterior tibial nerve stimulation (PTNS)|"Posterior tibial nerve neurostimulation in postoperative patients treated for rectal neoplasms for 6 weeks at a rate of 2 sessions per week (12 sessions).~The sessions will be carried out by the nursing staff of the anorectal functional testing cabinet. The sessions will begin 3 weeks after hospital discharge for patients without lateral ileostomy and after ileostomy closure for patients with lateral ileostomy."
75321133|NCT00590863|Drug|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
75776712|NCT05363553|Dietary Supplement|Infant formula based on whole goat milk|Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months
75776713|NCT05363553|Dietary Supplement|infant formula based on cow milk proteins|Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months
75776714|NCT05356806|Other|Supportive periodontal and periimplant care|"Periodontal and peri-implant maintenance therapy will be carried out at baseline, 3 and 6-month visit. This session will include the removal of biofilm and calculus on teeth and implants (except those that have just been restored) with an ultrasonic device using a plastic tip ( for implants. and a conventional metal tip ( for teeth. At the end, polishing will be done with a rubber cup~Subsequently, patients will be explained that they must continue with their usual oral hygiene technique on their teeth, using the same type of brush (which can be electric or manual), interproximal devices, toothpaste or mouthwash used to date. Finally, they will receive specific instructions for the supragingival biofilm control in the area of the new restoration and will be given interdental brushes that suit to the space"
75776715|NCT05355818|Drug|Delgocitinib|Cream for topical application
75623486|NCT04907877|Dietary Supplement|Placebo|Placebo will be taken 1 time a day before breakfast for 28 days.
75776716|NCT05355818|Drug|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
75776717|NCT05355571|Dietary Supplement|LAB4 + Saccharomyces boulardii|Probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day
75776718|NCT05355571|Dietary Supplement|Placebo|Placebo
75798406|NCT03870282|Behavioral|Sleep Extension|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
75798407|NCT03870126|Other|Flavored beverage|Consume one beverage at the beginning of each visit of the cross-over sequence
75321134|NCT00590863|Drug|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
75321135|NCT00591019|Drug|Modafinil|200 mg/day, morning dose
75321136|NCT00591019|Other|Placebo|Sugar pill once per day in the morning.
75623487|NCT02872506|Drug|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
75623488|NCT02872506|Procedure|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
75623489|NCT05331417|Diagnostic Test|Patients with herpes-simplex infection requiring bronchoscopy|Due to the observational design of the study, no study-specific interventions are performed. The indication for bronchoscopy is determined by the responsible ICU physicians. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.
75623490|NCT00627744|Drug|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
75623491|NCT01105091|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
75623492|NCT01105091|Drug|Flolan®|Per Prescribing Information
75623493|NCT04257435|Behavioral|Positive Psychological Group Treatment|Positive psychological group treatment will involve engagement in traditional behavioral health treatment, as well as a group treatment focusing on previously researched exercises that have been demonstrated to relate to reduced depression and increased positive emotionality (Seligman, Rashid, Parks, et al., 2005; Seligman, Rashid, & Parks, 2006; Rashid, 2015).
75623494|NCT04257435|Behavioral|Traditional Behavioral Health Treatment|Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).
75623495|NCT04253301|Device|InnoVein Valve Treatment|Subjects will have the InnoVein Valve implanted
75623496|NCT00628056|Drug|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
75623497|NCT00924729|Drug|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
75623498|NCT00924729|Drug|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
75623499|NCT01099709|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
75623500|NCT01099709|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
75623501|NCT04257357|Behavioral|8-weeks supervised exercise program|Please refer to group description
75623502|NCT04257357|Behavioral|Active control|Please refer to group description
75623503|NCT01099397|Other|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
75623504|NCT04907019|Drug|rifampicin，SY-004|"On the morning of D1, the subjects will take orally 80 mg of SY-004 Capsules on an empty stomach.Fasting will be performed within 4 hours after taking the medicine. From D8 to D14, the subjects will take orally 600 mg rifampicin before breakfast every day. On the day of D15, the subjects will take orally 600 mg rifampicin and 80 mg SY-004 Capsules on an empty stomach.~From D16 to D21, subjects will take orally 600 mg of rifampicin before breakfast every day.The patient can be discharged from the hospital after completing the safety examination on D22."
75623505|NCT01022424|Drug|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
75623506|NCT05329857|Drug|Metformin and Vildagliptin 1000/50 mg|50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
75623507|NCT01026948|Drug|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
76073581|NCT01276054|Procedure|bioimpedance spectroscopy|Correlative studies
75321137|NCT02128919|Device|tDCS|Transcranial Direct Current Stimulation
75321138|NCT02996695|Drug|Artesunate|Artesunate is a succinic ester of artemether.
75321139|NCT02996695|Drug|Chloroquine|4-aminoquinolone, antimalarial agent for oral administration
75776721|NCT05340959|Device|Devices: Osstell®, Periotest® and AnyCheck®.|"Osstell®: is a device that measure implant stability and based on resonance frequency analysis (RFA). Due to stiffness in the interface between the implant surface and the bone smart peg will vibrates accordingly. the more dense bone the higher stability, the higher frequency and higher Implant Stability Quotient (ISQ) value which is from 1-100.~Periotest®: is a device used to assess osseointegration of dental implants, so it measure implant stability . it is based on damping effect of implant. Showing the measurement digitally on a scale from -8 (low mobility) to 50 (high mobility) PTV units.~AnyCheck®: this is an implant stability meter that measures the stiffness of alveolar bone-implant interface through a tapping motion. Showing the measurement on a scale from 30 (low stability) to 85 (high stability)."
75776722|NCT05332561|Drug|Atezolizumab 1200 mg in 20 ML Injection|Arm 1
75623508|NCT01026948|Device|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
75776723|NCT05332561|Drug|Inavolisib|Arm 2
75776724|NCT05332561|Drug|Ipatasertib|Arm 3
75321140|NCT02996695|Biological|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
75321141|NCT02996695|Other|Placebo|Placebo
75776725|NCT05332561|Drug|Olaparib|Arm 4
75776726|NCT05332561|Drug|Sacituzumab govitecan|Arm 5
75776727|NCT05332561|Drug|Trastuzumab/pertuzumab|Arm 6
75776728|NCT05332366|Drug|Delgocitinib cream|Cream for topical application
75776729|NCT05332366|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
75776730|NCT05329948|Other|Haptonomy application|Feeling the fetus by touching the mother's womb with meditation
75321142|NCT00359138|Drug|desloratadine|5 mg tablet once daily
75321143|NCT00359138|Drug|levocetirizine|5 mg capsule once daily
75776731|NCT05328791|Behavioral|Dietary and mindfulness intervention|"Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program"
75776732|NCT05326815|Diagnostic Test|N-Telopeptide, Bone Marker|"This is a prospective specimen collection cohort study to evaluate the correlation between serum and urine values of the bone marker of interest (N-Telopeptide), and their association with baseline DEXA scan measures and fracture risk within 6 months.~Study samples will be obtained longitudinally. One collection of both serum and urine collection will be obtained. The urine will be collected as second void of day and at the same time the blood collection is drawn."
75776733|NCT05323591|Drug|Filgotinib|Tablets are administered in accordance with the product label
75776734|NCT05319470|Diagnostic Test|Intraocular pressure (IOP)|Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.
75321144|NCT00359138|Drug|Desloratadine placebo tablet|once daily
75321145|NCT00359138|Drug|Levocetirizine placebo capsule|once daily
75321146|NCT00003404|Radiation|Adjuvant Radiotherapy|Adjuvant radiation therapy
75321147|NCT00697801|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
75321148|NCT00697801|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
75321149|NCT00697801|Drug|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
75913963|NCT05887557|Other|Staged Care|Clinical decision rules to escalate/de-escalate care intensity will be finalized developed during Aim 1 formative work, though will be based on a combination of clinical assessment and patient preference.
76073582|NCT01276054|Procedure|quality-of-life assessment|Ancillary studies
75321150|NCT05503979|Drug|Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]|1 tab every 24 hrs for 12 weeks
75321151|NCT02996461|Biological|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
75321152|NCT03669302|Other|Robotic gait training|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
75321153|NCT03669302|Device|Robotic gait training and low-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a single pulse at 0.3 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
75321154|NCT03669302|Device|Robotic gait training and high-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
75321155|NCT02996383|Device|Internal fixation|Internal fixation of the fracture with a Targon FN implant (BBraun Ltd, Germany)
75623509|NCT04951089|Device|i-gel Supraglottic device insertion|i-gel insertion for oxygenation
75623510|NCT04951089|Device|Air-Q SP 3G Supraglottic device insertion|Air-Q SP 3G insertion for oxygenation
75776735|NCT05319470|Diagnostic Test|Tear Break-up Time (TBUT)|TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.
75776736|NCT05319470|Diagnostic Test|Conjuctival Hyperemia|Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.
75776737|NCT05319470|Diagnostic Test|Schirmer Test|Schirmer test will be performed on both eyes to asses tear production.
75798408|NCT03868098|Drug|Crisaborole 2%|Crisaborole ointment 2% (application rate A, B, C) for 15 days (double blind)
76073583|NCT01276054|Other|lymphedema management|Undergo axillary reverse mapping
75776738|NCT05319470|Diagnostic Test|Visual Fields and OCT RNFL|Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.
75776739|NCT05307952|Diagnostic Test|Tone Audiometry|Evaluation of the participants' audiometrical thresholds
75776740|NCT05307952|Diagnostic Test|Spectrotemporal Assessment|Evaluation of the participants' promptness in detecting a modulation of a harmonic complex
75321156|NCT02996383|Device|Cemented Hemiarthroplasty|Replacement of the femoral head with a cemented hemiarthroplasty
75913964|NCT05887557|Other|Identify and prepare champions at referral sites|Identify implementation champions at each referral site. Champions will receive marketing materials to promote uptake of clinical referrals to a drop-in/mobile care site by referral site providers/staff. This strategy is aimed at improving referring provider confidence in the value of referral to the care model, reduce perceived referral complexity/improve provider capability to refer, and provide positive peer pressure to promote referrals.
76073584|NCT05580627|Other|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment group.
75776741|NCT05307952|Diagnostic Test|Phoneme and Speech Perception|Evaluation of the participants' understanding of phonemes and short words, both in quiet and in noise
75776742|NCT05307952|Diagnostic Test|Digit Triplet Test|Evaluation of the participants' ability to discern speech in noise
76073585|NCT05580627|Other|Live Modality (control)|For this evaluation, the live modality is considered the control group.
76073586|NCT01798849|Drug|MK-8892|
75321157|NCT04541225|Drug|NUV-422|NUV-422 is an investigational drug for oral dosing.
75321158|NCT02996227|Procedure|TAP block|Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
75776743|NCT05307952|Other|Personalized fitting|Adjustment of the parameters of the participants' cochlear implants aimed at improving their speech perception
75321159|NCT02996227|Procedure|Epidural analgesia|Epidural catheters will be inserted preoperatively.
75776744|NCT05307952|Behavioral|Personalized training|Self-administered training exercises focused on the speech components the participants are experiencing difficulties into
75776745|NCT05307432|Behavioral|SPI+ Delivered by ED Staff|ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
75913965|NCT05887557|Other|Audit and feedback at referral sites|Investigators will provide monthly reports to implementation champions at each referral site on aggregate number of referrals and the success of referrals (proportion linking to care). This strategy is aimed at improving perceived value of the intervention and increasing provider motivation to refer.
75913966|NCT05887557|Other|Build a coalition among referral and clinical sites|Investigators will facilitate formation of a coalition of referral and clinic sites to improve cross-site collaboration and promote positive peer pressure to improve intra-site communication and increase referrals.
75321160|NCT02996227|Drug|EXPAREL|Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
75776746|NCT05307432|Behavioral|SPI+ Delivered by SPCC Clinicians|The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
75776747|NCT05303935|Drug|Quetiapine 50 MG|A single dose of 50mg of quetiapine taken at bedtime for one night.
75776748|NCT05303935|Drug|Placebo|A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
75798409|NCT03868098|Drug|Placebo ointment|Placebo ointment (vehicle)
75913967|NCT05887557|Other|Assess for readiness and identify barriers|Investigators will conduct patient in-depth interviews and clinical team focus group discussions to assess barriers to implementation of the clinical intervention. Findings from interviews and focus group discussions will inform site-specific implementation plans and adaptation of the intervention.
75913968|NCT05887557|Other|Promote adaptability|During a co-design workshop among drop-in/mobile care site teams and site-specific meetings, the study team will collectively finalize core clinical intervention components and outline site-specific adaptations (i.e. adaptable periphery of clinical intervention).
75321161|NCT02996227|Drug|Bupivacaine|Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
75321162|NCT03497936|Behavioral|Women's Stories|Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.
75321163|NCT00698035|Drug|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
76073587|NCT01798849|Drug|Placebo for MK-8892|
75321164|NCT00698035|Drug|Estring|2mg ring inserted vaginally once every 12 weeks
75321165|NCT04762394|Behavioral|The Child Behavior Checklist (CBCL),|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
75321166|NCT03496844|Diagnostic Test|F-18 fluciclovine-PET/CT scan|PET/CT imaging with F-18 fluciclovine
75321167|NCT01793311|Other|decaffeinated coffee|contains caffeine 0.5-2 mg
76073588|NCT05580471|Device|Use 4DryField|Patients randomly use 4DryField in Colorectal resection combined with temporary stomy before fascia closure. We observed the adhesion severity and adhesion extent when stomy closure.
75321168|NCT01793311|Other|regular dose coffee|contains 91.8 mg of caffeine
75321169|NCT01793311|Other|high dose coffee|contains 144 mg of caffeine
75798410|NCT01166334|Behavioral|WebQuit study group|Description withheld to protect integrity of study
76073589|NCT05580393|Diagnostic Test|RFLP analysis of SSU rRNA|"Genomic DNA will be extracted from Blastocystis-positive fecal samples using a specific DNA Stool Mini Kit according to the manufacturer's instructions and will be stored at -20°C until use.~PCR will be used to amplify a region of Blastocystis small subunit ribosomal RNA (SSU rRNA) gene.~The amplified products for the SSU rRNA gene will be digested to determine the strain subtype of Blastocystis spp. using specific restriction enzymes."
76073590|NCT04405947|Procedure|Reverse Shoulder Arthroplasty|implantation of a reversed shoulder prostheses through two different surgical approaches
75623511|NCT05033652|Other|WARNING KD|"Within 48h of detecting an abnormal creatinemia value (GFR<30 or AKIN2 and AKIN3), the biology laboratory will communicate the patient's information to the WARNING KD team. This team consists of one nephrologist and one clinical pharmacist who will trigger the initial management in the department and then, if the patient has a persistant warning signal during hospitalization, define the patient's course of treatment for discharge. Patients requiring special care will be oriented towards a nephrologist and the patient's GP will be alerted to the benefit of addressing the patient to a nephrologist for multidisciplinary management with a therapeutic project according to the recommendations for good therapeutic practices."
76073591|NCT00724594|Drug|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
75623512|NCT01104779|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
75623513|NCT01104779|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
75623514|NCT00918957|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
75623515|NCT00918957|Drug|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
75623516|NCT04308161|Drug|vitamin D oral gel|vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis
75623517|NCT04308161|Drug|Miconazole Topical Gel|topical anti fungal agent
76073592|NCT00724594|Drug|Control|Saline was given in the same volume, at the same timing as NAC infusions
76073593|NCT04142931|Combination Product|ImmunicomAIAC|filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
76073594|NCT00724750|Device|Gauze suction (G-SUC)|Negative pressure wound therapy
76073595|NCT00724750|Device|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
76073596|NCT04140825|Device|Resmon PRO FULL|Measurement of lung impedance by the Forced Oscillation Technique
76073597|NCT01797835|Behavioral|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
76073598|NCT01797835|Behavioral|usual care|Youth receive a brochure with information on AOD use.
76073599|NCT01275430|Device|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
76073600|NCT01275430|Other|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
75321170|NCT05572463|Combination Product|Sintilimab + IBI110|IBI110 infusion in combination with Sintilimab (IBI308) infusion will be given on a Q3W schedule
75321171|NCT02995993|Drug|Moss-aGal (recombinant human alpha-galactosidase A produced in moss)|Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
75321172|NCT02996071|Procedure|laparoscopic sleeve gastrectomy|a sleeve gastrectomy operation that is performed laparoscopically.
75321173|NCT02339389|Other|Labor analgesia|Measuring maternal ventilation after placement of epidural analgesia compared to baseline
75321174|NCT02129075|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
75321175|NCT02129075|Drug|Poly ICLC|Given SC
75321176|NCT02129075|Biological|Recombinant Flt3 Ligand|Given SC
75321177|NCT03662204|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
75321178|NCT02775903|Drug|Azacitidine|Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
75321179|NCT02775903|Biological|Durvalumab|Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
75321180|NCT01679912|Other|phone to the call center|recommendations to phone to the call center for all the patients who have an acute attack
75321181|NCT03573752|Other|outpatient management for promontofixation by laparoscopy|postoperative H8 exit after laparoscopic promontofixation
75623518|NCT04308161|Drug|BBC oral spray|Topical anesthetics and anti-inflammatory agent
75623519|NCT04308161|Drug|Oracure gel|Topical analgesic gel
75623520|NCT04308161|Other|Alkamisr sachets|Sodium bicarbonate mouthwash
75623521|NCT04939467|Drug|Pirfenidone 267 mg Oral Tablet|Fixed sequence use of active product, TID
76073601|NCT04142775|Other|complication versus no complication|development of ICH
76073602|NCT01838551|Drug|Levoketoconazole|Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
76073603|NCT03021369|Device|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
76073604|NCT04142853|Other|Training intervention + Dance intervention|Training intervention + Dance intervention
76073605|NCT05580081|Behavioral|i-CAN|online support and consultation to providers
76073606|NCT05587413|Procedure|periodontal care|periodontal treatment
76073607|NCT04143477|Drug|peficitinib|Oral
75776749|NCT05298449|Drug|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder"
75623522|NCT04939467|Drug|Nintedanib 150 mg Oral Capsule|Fixed sequence use of active product, BID
75623523|NCT04939467|Drug|BLD-0409 750 mg Oral Tablet|Fixed sequence use of active product, QD
75776750|NCT05298449|Drug|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
75623524|NCT01015560|Drug|anti-CCR2 monoclonal antibody MLN1202|
75776751|NCT05297890|Drug|Lorlatinib|Dosage Form: Lorlatinib tablet, Dosage: 25mg/tablet, Dosing Regimens: 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
75776752|NCT05296837|Drug|Doxycycline 40 MG ( 20mg twice daily)|Submicrobial dose doxycycline (40mg) to be administered as 20mg twice daily
75321182|NCT03573752|Other|questionnaire|Each patient will complete a questionnaire on the experience of management, both in terms of pain management, anxiety and overall satisfaction.
75321183|NCT04392791|Other|balneotherapy|Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
75321184|NCT01679990|Biological|PLX-PAD Low dose|
75321185|NCT01679990|Biological|PLX-PAD high doses|
75623525|NCT01015560|Genetic|polymorphism analysis|
75623526|NCT01015560|Other|laboratory biomarker analysis|
75623527|NCT02878889|Drug|S-1|
75623528|NCT04581174|Diagnostic Test|24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated|Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
75623529|NCT02879045|Other|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
75623530|NCT04253223|Biological|REMD-477|REMD-477 will be administered as a subcutaneous injection for three weekly doses
75623531|NCT00918879|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
75623532|NCT00918879|Drug|Placebo|Oral tablet, once daily for 24 weeks
75623533|NCT04874805|Other|Measurement of oxygen saturation|Measurement of oxygen saturation by pulse oximetry once a day, at 6 a.m., for a minimum of 3 days, thanks to three pulse oximeters (1 measurement point per device/day), in parallel with a synchronous sampling, programmed as part of the usual care, of arterial gasometry.
75776753|NCT05296837|Drug|Doxycycline 200 MG ( 100 mg twice daily)|200 mg dose doxycycline to be administered as 100mg twice daily
75776754|NCT05296837|Drug|Placebo|Placebo to be administered in tablet form twice daily
75913969|NCT05887557|Other|Develop a formal implementation blueprint|With each drop-in/mobile care team, develop site-specific implementation plan that includes defining care team and leadership structure, clinic workflow, implementation timeline, and progress measures. This process, and the resulting blueprint, will incorporate site-specific barriers and facilitators to implementation.
75913970|NCT05887557|Other|Develop educational materials; conduct ongoing training|Compile a manual that includes detailed description of core intervention features, planned local adaptations, and implementation guidance. We will conduct site-specific meetings to provide training on this manual. We will also conduct regular (at least monthly) meetings between the study team and the clinic site to provide technical assistance and coaching.
75321186|NCT01679990|Biological|Double Placebo|
75321187|NCT01679990|Biological|high dose +Placebo|
75321188|NCT05461703|Behavioral|Planet Nutrition Program|It is a 6-month school-based obesity prevention program that includes: nutrition education sessions, physical activity and family participation.
75623534|NCT01026792|Drug|Temsirolimus|Given IV
75623535|NCT01026792|Other|Laboratory Biomarker Analysis|Correlative studies
75623536|NCT01026324|Drug|dinaciclib|Given IV
75623537|NCT01026324|Other|pharmacological study|Correlative studies
75623538|NCT01026324|Other|laboratory biomarker analysis|Correlative studies
75623539|NCT04300686|Biological|Tocilizumab|"The tocilizumab group is prescribed with tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of tocilizumab is maintained for another 24 weeks, otherwise (resistant), patients would be given adalimumab (40mg.bim.IH.) for 24 weeks instead."
75776755|NCT05296525|Drug|GDA-201|NAM-expanded allogeneic NK cells
75776756|NCT05292547|Device|Repetitive Transcranial Magnetic Stimulation|rTMS using Magventure TMS system is delivered at the dorsolateral prefrontal cortex of consented subjects according to 3 different stimulation schedules.
75798411|NCT01166334|Behavioral|WebQuit control group|Identity and description withheld to protect integrity of study
75798412|NCT01277016|Drug|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
75321189|NCT00700063|Drug|PEP005 Topical Gel|0.005%, two days treatment
75321190|NCT00700063|Drug|PEP005 Topical Gel|0.01%, two days treatment
75321191|NCT00700063|Drug|PEP005 Topical Gel|0.015%, two days treatment
75321192|NCT00700063|Drug|Vehicle gel|two days treatment
75321193|NCT00700063|Drug|PEP005 Topical Gel|0.005%, three days treatment
75321194|NCT00700063|Drug|PEP005 Topical Gel|0.01%, three days treatment
75321195|NCT00700063|Drug|PEP005 Topical Gel|0.015%, three days treatment
75776757|NCT05292469|Behavioral|Comprehensive approach to hypertension management|Trained health workers will review blood pressure (BP) logs and provide treatment. The patients will receive a BP lowering informational package, BP monitoring device and log book and pill-box and medication table. The participants will receive monthly home visits (6 visits) to discuss hypertension and ways to manage it. They will be encouraged to identify problems and developing an action plan to solve them. The participants will be encouraged to set behavioral goals. The follow up visits will review the progress made in implementing action plan and goals set and updating them. Review BP logs and facilitate tailored discussion on topics based on problems faced by participants on barriers to medication adherence, physical activity, weight management or diet. The family members will be involved and be accountable in supporting the patients in achieving the action plans.
75776758|NCT05291247|Device|Peripheral lithotripsy system (Shockwave Medical)|The combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device for calcified femoropopliteal disease.
75776759|NCT05291130|Device|Plasmafit® Vitelene® Vitamin E|Plasmafit® Acetabular Cup System with an insert Aesculap ® Vitelene ® Vitamin E Stabilized Highly Crosslinked Polyethylene and BIOLOX delta Ceramic Femoral Head or ISODUR® Metal Femoral Heads
75776760|NCT05283200|Behavioral|Yoga|Yoga instructor will teach gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction
75776761|NCT05283200|Behavioral|Cognitive Behavioral Therapy|Psychologist will provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills
75776762|NCT05283200|Behavioral|Music|Music therapist will teach a variety of ways that participants might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.
75623540|NCT04300686|Biological|Adalimumab|"The adalimumab group is prescribed with adalimumab (40mg.bim.IH) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of adalimumab would be maintained for another 24 weeks, otherwise (resistant), patients would be given tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks instead."
75776763|NCT05280691|Other|Family Support Intervention (FSI)|In addition to usual care, families in the intervention group will receive (1) specialist nurse support along the patient pathway at defined time-points, from admission to discharge including follow-up care, and (2) nurse-coordinated liaison and structured, interprofessional communication by the ICU team. The intervention is grounded in a family systems approach and guideline-based strategies for family engagement in the ICU and has been pilot-tested in one ICU.
75776764|NCT05279508|Behavioral|Make My Day - stroke prevention program|A stroke prevention program within primary healthcare
75776765|NCT05276505|Other|Lavender Aromatherapy Tablet|Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff
75623541|NCT04299282|Device|CanGaroo|CIED ECM envelope
75776766|NCT05275842|Behavioral|Cognitive Processing Therapy- Lifesteps (CPT-L)|"CPT-L is designed to help people with HIV and PTSD take their medications as prescribed. Cognitive Processing Therapy (CPT) uses education and cognitive training to help individuals identify thoughts and feelings about their trauma and gives them tools to help them change unhelpful beliefs. Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will receive a 12-session Cognitive Processing Therapy-Lifesteps (CPT-L) treatment program at the Ryan White clinic. The CPT-L program will be delivered twice a week for 6 weeks. Each session last about 90-minutes."
75776767|NCT05275842|Behavioral|Lifesteps|"Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will complete one Lifesteps education session. This session lasts about 60 minutes. Participants may attend this session either in-person or over the internet if they have an internet ready device with audio."
75776768|NCT05274022|Other|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. As part of the study, all patients will receive the same exercise program. Exercises will include lower extremity strengthening, balance, and mobility exercises with the use of modalities as needed
75776769|NCT05274022|Other|Speed Walking Intervention|The 4-6 week program will consist of a warm up of active stretching. Following the warm up, subjects will perform a 2 minute warm up followed by 1 minute of walking at their fastest comfortable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing for 4cycles and then a 2 minute cool down. The program will be performed 12 visits over 4-6 weeks.
75776770|NCT05247710|Procedure|Punch biopsy|Punch biopsy of basal cell carcinoma tumor and a control biopsy of healthy skin are collected during primary tumor excision surgery from each recruited patient.
75321196|NCT00700063|Drug|Vehicle gel|three days treatment
75321197|NCT03568682|Behavioral|Nutritional counseling + urban gardening|Peer nutritional counseling and urban gardens
75321198|NCT05400005|Other|Dietary protein|"Intervention of the study include consuming a higher protein diet. Depending on the group allocation, this is done by asking the subjects to follow My Healthy Plate diet and consumption of 20g of protein isolates (casein or soy)."
75321199|NCT03904173|Diagnostic Test|Multi-parameter tests|Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
75623542|NCT01098539|Biological|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
75623543|NCT01098539|Drug|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
75623544|NCT02880215|Behavioral|Attention Bias Modification|Behavioral intervention designed to decrease negative attention bias.
75623545|NCT02880215|Behavioral|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
75623546|NCT01098461|Biological|albiglutide|subcutaneous injection of albiglutide
75623547|NCT01098461|Biological|placebo|subcutaneous injection of placebo to match albiglutide
75623548|NCT01098305|Drug|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
75623549|NCT01098305|Behavioral|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
75776771|NCT05247190|Behavioral|Treating self-criticism|A psychological treatment given i a group format targeting self-criticism. The treatment is based on treatment principles from Cognitive behavior therapy, Self-compassion, Acceptance and Commitment Therapy and also contains psychoeducation. The group treatment consists of 8 sessions delivered once a week for 2 hrs during 8 weeks in a child- and adolescent psychiatric outpatient setting.
75321200|NCT04343495|Device|Wearable Ultra Violet (UV) and blue-light sensors|Non-blinded
75321201|NCT01933425|Drug|rocuronium|
75776772|NCT05243797|Drug|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
75776773|NCT05243797|Drug|Lenalidomide|Lenalidomide will be administered orally
75776774|NCT05233878|Other|Characterization of a population with cervical paragangliomas|Characterization of a population with sporadic or genetically predisposed cervical paragangliomas in order to evaluate : the initial presentation of the PGL, patients management and patients outcome
75623550|NCT00833833|Drug|Pomalidomide|1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
75623551|NCT00833833|Drug|Dexamethasone|oral dexamethasone
75623552|NCT00833833|Drug|Aspirin|As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
75776775|NCT05222087|Radiation|Radiotherapy|35Gy/5# Central 40Gy/5# Large Tumours >5cm (non-central) 36Gy/12# or 40Gy/15# Ultracentral lesions 50Gy/5# Peripheral Tumours ≤5cm
75321202|NCT01933425|Drug|sugammadex|
75321203|NCT01933425|Drug|placebo|
75321204|NCT04239599|Radiation|Hypofractionated IMRT Radiation treatment|
75321205|NCT00594061|Device|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
75623553|NCT04308083|Procedure|dental implant placement|Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
75623554|NCT02878733|Drug|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
75623555|NCT01098071|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
75776776|NCT05222087|Drug|SoC systemic therapy|Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
75776777|NCT05221008|Drug|SHR6508；Placebo|Group A:SHR6508 low dose
75776778|NCT05221008|Drug|SHR6508；Placebo|Group B:SHR6508 medium dose
75776779|NCT05221008|Drug|SHR6508；Placebo|Group C:SHR6508 high dose
75776780|NCT05221008|Drug|SHR6508；Placebo|Group D:SHR6508 high dose(single dose)
75913971|NCT05887557|Other|Create a learning collaborative|Create a cross-site learning collaborative with periodic meetings and workshops throughout the study period to facilitate cross-site communication, sharing of best practices and encourage positive peer pressure to support implementation.
75321206|NCT02996149|Procedure|Endoscopic lung volume reduction coil treatment|
75321207|NCT03565172|Diagnostic Test|isokinetic dynamometer with ultrasound|children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.
75321208|NCT03565172|Other|Visual Analog Scale (VAS)|the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort
75321209|NCT03565172|Diagnostic Test|Stretching|the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
75321210|NCT01795417|Device|RF XP200|Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
75321211|NCT01795417|Device|XP200 RF device|4 RF treatments of periorbital region on one side of the face
75466540|NCT01910584|Procedure|Novasure endometrial ablation|Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
75466541|NCT01910597|Drug|SBG|
75466542|NCT01910610|Biological|FOLFIRI-cetuximab|
75466543|NCT01910610|Biological|mFOLFOX6-bevacizumab|
75466544|NCT01910610|Biological|OPTIMOX-bevacizumab|
75466545|NCT01910610|Biological|irinotecan-based chemo + bevacizumab|
75466546|NCT01910610|Biological|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
75466547|NCT01910610|Biological|XELOX + bevacizumab|
75466548|NCT01910623|Other|Health Related Quality of Life (HRQOL) measures|
75466549|NCT01910649|Drug|Drisapersen|Subcutaneous and Intravenous
75466550|NCT01910662|Other|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
75466551|NCT01910662|Other|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
75623556|NCT04307771|Behavioral|m-Health application|Dental Buddy is a mobile application that has been designed to improve oral hygiene maintenance behaviours in teenagers
75776781|NCT05209581|Diagnostic Test|Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity of refugees/immigrants will be examined via a web-based digital visual acuity chart
75776782|NCT05206266|Other|Turmeric|Three amounts of dietary turmeric will be tested: 1) turmeric 300 mg/day, 2) turmeric 1 g/day, 3) turmeric 3 g/day.
75776783|NCT05206266|Other|Turmeric+Black Pepper|Three amounts of dietary turmeric (300mg/day, 1g/day or 3g/day) with black pepper (300 mg) added to the turmeric.
75776784|NCT05197465|Other|Questionnaires|Participants will complete pain and quality of life questionnaires. Opioid consumption will also be assessed using validated questionnaires.
75913972|NCT05886868|Drug|BL0020|"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."
75321212|NCT05322317|Other|ADVANCE-PC training via ECHO|To assess the feasibility of using a technology-based platform to deliver the ADVANCE-PC program to multiple primary care clinics. This model will be based on the ECHO program, a tele-mentoring program which uses communications technology to provide facilitated education, case review, and peer-to-peer problem solving remotely. Our working hypothesis is that the use of ECHO will be efficient (allowing several clinicians and teams to be supported simultaneously while creating a community of practice), feasible (that clinicians will enroll and share experiences via mentoring, guidance, feedback, and didactic education), and have the potential to impact patients as clinicians perceptions shift to favor ACP, their skills increase, and they are able to integrate ACP for patients with dementia into their clinic.
75623557|NCT02612545|Drug|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
75623558|NCT02612545|Drug|Mefloquine (MQ)|ACT partner drug
75321213|NCT02723019|Behavioral|Volunteer Peer Mentor+Behavioral Health Nurse|Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
75321214|NCT03487016|Drug|Gemcitabine|Arm A
75623559|NCT02878577|Device|fMRI|fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).
75321215|NCT03487016|Drug|Nab-paclitaxel|Arm A
75321216|NCT03487016|Drug|5-FU|Arm B Arm C
75321217|NCT03487016|Drug|Irinotecan Liposomal Injection|Arm B Arm C
75623560|NCT00704743|Device|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
75623561|NCT00704743|Device|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
75623562|NCT00704743|Device|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
75623563|NCT01097057|Drug|Carboplatin|Given IV
75623564|NCT01097057|Drug|Etoposide|Given IV
75623565|NCT01097057|Biological|Filgrastim|Given SC
75623566|NCT01097057|Drug|Ifosfamide|Given IV
75623567|NCT01097057|Procedure|Leukapheresis|Given through catheter
75623568|NCT01097057|Drug|Plerixafor|Given SC
75623569|NCT01097057|Biological|Rituximab|Given IV
75623570|NCT02612701|Other|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
75623571|NCT02612701|Other|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
75623572|NCT02612701|Other|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
75623573|NCT02612701|Other|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
75623574|NCT05065463|Drug|AZD8233|Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
75623575|NCT02878811|Other|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
75776785|NCT05196100|Device|Amparo confidence socket|Confidence socket involves thermoplastic material being moulded onto the patient's residual limb and a socket is produced in a single session. The socket can be remoulded to adjust to changes in residual limb volume.
75776786|NCT05195333|Other|The exercise program|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient.
75623576|NCT01022112|Drug|TA-7284-Low|TA-7284-Low
75623577|NCT01022112|Drug|TA-7284-Low-middle|TA-7284-Low-middle
75623578|NCT01022112|Drug|TA-7284-High-middle|TA-7284-High-middle
75623579|NCT01022112|Drug|TA-7284-High|TA-7284-High
75623580|NCT01022112|Drug|Placebo|Placebo
75623581|NCT04299204|Procedure|Percutaneous nephrolitotomy|Pediatric PCNL
75623582|NCT01096667|Drug|Placebo to Ertuglilflozin 1 or 5 mg|Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
75623583|NCT01096667|Drug|Ertugliflozin 1 mg|Ertugliflozin tablet 1 mg once daily for 28 days
75623584|NCT01096667|Drug|Ertugliflozin 5 mg|Ertugliflozin tablet 5 mg once daily for 28 days
75623585|NCT01096667|Drug|Ertugliflozin 25 mg|Ertugliflozin tablet 25 mg once daily for 28 days
75776787|NCT05195333|Other|The exercise program|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy.
75776788|NCT05190757|Other|Airway and Ventilation|Insertion of Laryngeal Mask airway for ventilation or use of Face Mask
75776789|NCT05188898|Other|MINSD and Hyaluronic acid|After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, a hyaluronic acid-based gel will be applied to the intraosseous periodontal pockets.
75776790|NCT05188898|Other|MINSD|Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
75776791|NCT05183360|Drug|BI 706321|BI 706321
75776792|NCT05183360|Drug|Placebo|Placebo
75623586|NCT01096667|Drug|HCTZ 12.5mg|Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
75623587|NCT01096667|Drug|Placebo to HCTZ|Placebo to HCTZ 12.5 mg capsule once daily for 28 days
75913973|NCT05880810|Device|Continuous Glucose Monitor Dexcom G6 PRO|Connected to a smart phone that transmits continuous glucose monitoring data in real time to Advanced Care at Home Command Center for monitoring.
75623588|NCT01096667|Drug|Placebo to ertuglilflozin 25 mg|Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
75321218|NCT03487016|Drug|Oxaliplatin|Arm C
75321219|NCT02622295|Behavioral|Single-session electrically induced exercise|A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.
75321220|NCT02622295|Behavioral|Electrically-induced exercise training|Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
75321221|NCT01677806|Procedure|Percutaneous vertebroplasty|Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
75321222|NCT01677806|Other|Conservative therapy|Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
75623589|NCT01014624|Drug|Prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
75321223|NCT02335671|Procedure|Intra-operative Magnetic Resonance Imaging (MRI)|
75321224|NCT02335671|Other|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
75321225|NCT04148807|Behavioral|Progressive Walking with Gait Retraining|A progressive walking program with gait retraining will be performed on a treadmill at self-selected comfortable walking speed wearing an inertial measurement unit (IMU) on the medial aspect of the distal tibia. The (vertical) peak positive acceleration (PPA) of the tibia is a measure of tibial shock. Subjects will be provided real-time audio feedback to reduce PPA by 20% of their average peak PPA. During retraining sessions, a faded feedback approach will be used. Feedback will be provided continuously during the first four sessions and will be faded over the last 4 sessions. Walking time will increase over the 8 sessions.
75623590|NCT01014624|Drug|Clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
75623591|NCT01021878|Other|icodextrin|glucose sparing dialysis solution
75623592|NCT01021878|Other|Dianeal|glucose based dialysis solution
75623593|NCT02872428|Drug|Valproic Acid|By infusion over 1 hour
75623594|NCT02872428|Drug|Isotonic saline solution|By infusion over 1 hour
75623595|NCT02873364|Drug|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
75623596|NCT02873364|Drug|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
75623597|NCT02872740|Procedure|Embolization of Left Gastric Artery|Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
75623598|NCT02872740|Procedure|Embolization of Gastroepiploic Artery|Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
75321226|NCT04148807|Behavioral|Progressive Walking Program|A progressive walking program will also be performed on a treadmill where subjects will walk at a self-selected comfortable speed with the same walking times per session as the retraining group without any feedback or retraining cues.
75321227|NCT05346926|Device|3D-printed cast|The 3D-printed casts are produced using 3D print technology based on software by Belgian software company: The patient's forearm is scanned with a tablet (duration: approx. 5 min), whereupon the cast is printed overnight according to the scan (duration: approx. 4h) and adjusted to the patient during the next appointment.
75623599|NCT02871960|Procedure|Robotic and Laparoscopic Colectomy|
75623600|NCT00628290|Drug|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
75623601|NCT00628290|Drug|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
75623602|NCT04559412|Device|Sofusa DoseConnect|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
75623603|NCT04559412|Drug|Enbrel|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
75623604|NCT00854113|Drug|EGT0001474|Oral ascending doses given daily as capsules for up to 14 days
75623605|NCT00854113|Drug|Placebo|Placebo to match EGT0001474
75321228|NCT05346926|Device|Conventional cast|A conventional plaster cast is applied for treatment of the distal radius fracture.
75321229|NCT01936389|Drug|AR-12286|
75321230|NCT03023319|Drug|Bosutinib|100mg daily for 4 cycles (21 days per cycle)
75321231|NCT03023319|Drug|Pemetrexed|500 mg/m2 every 21 days for 4 cycles
75321232|NCT01679522|Procedure|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
75321233|NCT01679522|Procedure|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
75321234|NCT02980653|Drug|Megestrol acetate (MA) 400 mg/day|Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
75913974|NCT05879978|Drug|BI 764532|BI 764532
75913975|NCT05879978|Drug|Ezabenlimab|Ezabenlimab
75321235|NCT03560648|Device|High definition surface electromyography combined with accelerometer|HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.
75913976|NCT05876221|Drug|Cablivi|Patients with immune Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
76073608|NCT04142463|Other|Care pathway|A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
76073609|NCT04144803|Diagnostic Test|Cerebral near-infrared spectroscopy|Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
76073610|NCT05586009|Drug|cisplatin with hydration magnesium|Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
76073611|NCT03020979|Drug|Apatinib|Patients will take 500mg apatinib daily orally.
75623606|NCT02872584|Drug|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
75623607|NCT00704821|Drug|PTC299|Oral
76073612|NCT04142151|Drug|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
75623608|NCT00704821|Drug|Docetaxel|Intravenous infusion
75623609|NCT00704899|Procedure|Physiotherapy|Structured exercise regimen
75623610|NCT00704899|Drug|Amitryptiline|Amitryptiline 25mg once daily
75623611|NCT00845845|Drug|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
75623612|NCT00845845|Drug|Placebo|Daily placebo with dietary counseling for 24 weeks.
75623613|NCT01104701|Drug|exenatide once weekly|subcutaneous injection, 2 mg, once a week
75776793|NCT05179395|Other|Brasthesis|Brasthesis is a harness that is integrated with an off the shelf sports bra
75776794|NCT05169489|Biological|bbT369|bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.
75776795|NCT05169268|Drug|ARIPiprazole Injection [Abilify]|subject already receiving the combination of Abilify Maintena and Rexulti
75776796|NCT05169268|Drug|Brexpiprazole|subject already receiving the combination of Abilify Maintena and Rexulti
75776797|NCT05166746|Drug|Clindamycin|Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.
75913977|NCT05874154|Procedure|Tibial nerve selective neurotomy|Patients in the STN group will undergo a pre-anaesthetic visit before surgery to validate the possibility of general anesthesia. The surgery will be performed at maximum 3 months after inclusion. The muscles that have been defined pre-randomization will be targeted by the surgery. The duration of the surgery is about 1 hour and 30 minutes.
76073613|NCT04142151|Drug|Aspirin|Aspirin produced by Bayer Co., Ltd.
76073614|NCT04142151|Drug|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
76073615|NCT04142151|Drug|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
76073616|NCT02985099|Drug|SRP plus Rosuvastatin gel|SRP followed by 1.2% Rosuvastatin placement into intrabony defect
76073617|NCT02985099|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
76073618|NCT04142229|Device|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
76073619|NCT04142229|Other|Sensor-Augmented Pump|Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
76073620|NCT04149873|Procedure|MIE|MIE
76073621|NCT05583591|Device|Combined cataract surgery with Hydrus microstent|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
76073622|NCT05583591|Device|Combined cataract surgery with iStent Inject W|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
76073623|NCT03904329|Drug|Oral Anticoagulant|Oral tablets of anti coagulations either warfare or NOACs
76073624|NCT04149561|Other|communication skill measurement with self report questionnaire|Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
76073625|NCT04141683|Diagnostic Test|Stress Echocardiography|Dynamic stress echocardiography using a cycle ergometer on a semi supine exercise table.
76073626|NCT04141683|Diagnostic Test|Pressure volume loop analysis|Pressure volume loop analysis unsing conductance catheter measurements during right heart catheterization.
75623614|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
75623615|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
75623616|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
75623617|NCT00833755|Drug|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
75623618|NCT00833755|Drug|Placebos|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
75623619|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|oral
75623620|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|oral
75776798|NCT05166746|Other|Placebo|"The Clindamycin placebo appear identical to active clindamycin by filling capsules with Mannitolium.~The LACTIN-V placebo product has no intrinsic effect and is used to study the effect of the therapeutically active product. It is supplied as a pre-filled vaginal applicator packaged under nitrogen gas with one desiccant packet (0.25 g) in a sealed foil pouch. Each applicator contains 200 mg of LACTIN-V placebo powder containing the inactive ingredients of the LACTIN-V drug product, but not Lactobacillus crispatus CTV-05 (CTV-05), the active ingedient. The excipients used in the manufacture of LACTIN-V placebo are identical to those in the LACTIN-V drug product. Each placebo applicator contains the following constituents: maltodextrin, trehalose, xylitol, colloidal silicon dioxide, and sodium ascorbate"
75776799|NCT05165121|Device|MDHearing smart hearing aid|air conduction hearing aid with app support
75623621|NCT00704977|Procedure|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|"The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs."
75623622|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
75623623|NCT00923091|Drug|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
75623624|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
75623625|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
75623626|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
75623627|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
75623628|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
75623629|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
75623630|NCT04030819|Behavioral|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
75623631|NCT04115683|Other|Dual Task Training|45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
75623632|NCT04115683|Other|Single Task Training|45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
75623633|NCT04299126|Device|high absorption pad for blood and pus|High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
75623634|NCT04299126|Device|commercial wound dressing|Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
75623635|NCT00853957|Drug|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
75623636|NCT00853957|Drug|Amlodipine|Amlodipine 5 mg titrated to 10mg
75623637|NCT04571034|Procedure|Sham Therapeutic Ultrasound|A standard ultrasound machine (Vectratm by Chattanooga Group, Inc.) with inactive probe will be used to deliver sham massage.
75623638|NCT04571034|Procedure|Medium-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (25 newtons of force directed perpendicular to the surface of the thigh).
75623639|NCT04571034|Procedure|High-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (45 newtons of force directed perpendicular to the surface of the thigh).
75776800|NCT05160298|Drug|Ropivacaine 0,2% Injectable Solution|Echo-guided bilateral erector spinae block
75776801|NCT05160298|Other|Control group|Sham block
75776802|NCT05155579|Biological|R21/Matrix-M - single vial formulation|Adjuvanted malaria vaccine in a single vial formulation
75776803|NCT05155579|Biological|R21/Matrix-M - two vial formulation|Adjuvanted malaria vaccine in a double vial formulation
75913978|NCT05874154|Drug|Botulinum toxin injection|Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
75776804|NCT05155579|Biological|Licensed vaccine - Measles-rubella|Licensed vaccine part of the EPI vaccination schedule
75913979|NCT05871580|Radiation|Low frequency laser activated photobiomodulation|"Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients.~apex tongue: 3 points~lateral edge of the tongue: 4 points~tongue dorsum: 10 points~jugal mucosa: 8 points~labial mucosa: 5 points~hard palate: 8 stitches~soft palate: 3 stitches~gingiva or alveolar mucosa: 3 stitches per sextant.~Time of 30 seconds in each application point, with dosage: 3 J/point."
75913980|NCT05871580|Other|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
75623640|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
75623641|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
76073627|NCT04141683|Procedure|Tricuspid valve repair or replacement|Tricuspid valve repair or replacement using a surgical or interventionale approach according to local heart team recommendation and patients' preference.
75623642|NCT01021020|Drug|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
75623643|NCT04256187|Other|Qualitative interview|Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
75623644|NCT00833053|Drug|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
75623645|NCT00833053|Drug|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
75623646|NCT02873130|Behavioral|Telepractice Global Voice Prevention Model|
75321236|NCT03559634|Diagnostic Test|Intervention Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. Contraceptive choices being offered include the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. The participant can then decide if they would like to start a medication they qualify for in the ED.
75623647|NCT02873130|Behavioral|In-person Global Voice Prevention Model|
75623648|NCT02873130|Behavioral|Telepractice, Vocal Hygiene and Vocal Education|
75623649|NCT04299984|Procedure|Open Conversion after EVAR|"See Open Conversions group description."
75623650|NCT04299984|Procedure|SemiConversion after EVAR|"See SemiConversions group description."
75623651|NCT05329467|Other|Validation of Faces Thermomether Scale|Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
75623652|NCT04256031|Other|Assessment|The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.
75623653|NCT04245735|Diagnostic Test|perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.
75321237|NCT03559634|Other|Control Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. This includes the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. Participants will then be given follow up information on outpatient locations where they can receive these contraceptive methods.
75466552|NCT01910662|Other|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
75466553|NCT01910662|Other|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
75466554|NCT01910675|Drug|PCC|15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
75623654|NCT04253067|Device|Active fCO2 laser treatment|The laser probe is inserted into the vagina. Laser treatment is delivered at 6 points at each level of the vaginal wall (12, 2, 4, 6, and 10 o'clock positions). Delivery begins at the most proximal and the probe is retracted by 1 cm and another row of laser treatments are delivered. The number of levels is determined by the patient's vaginal length.
75623655|NCT04253067|Device|Sham fCO2 laser treatment|The laser probe is inserted into the vagina. The laser will remain in standby mode during the treatment preventing laser exposure. The treatment will appear to be the same as the active treatment with the probe starting at the most proximal and following the same 6 points of treatment delivery. The probe is retracted in the same manner and another row of treatment is simulated. The machine maintains a low humming noise while in standby mode. No active laser treatment is delivered.
75623656|NCT04252989|Other|data collection|"Demographic data: age, sex~Ophthalmological history: refraction of parents, previous refractions~Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics~Potential undesirable events (halos, photophobia...)"
75776805|NCT05155579|Biological|Licensed vaccine - Yellow fever|Licensed vaccine part of the EPI vaccination schedule
75913981|NCT05870345|Device|Butterfly IQ|Butterfly IQ is a pocket sized ultrasound device. Each participant will undergo a ultrasound exam of both elbows using a pocket sized ultrasound device.
75913982|NCT05865756|Other|Acoustic cough features analysis|Acoustic cough features analysis
76073628|NCT04149483|Drug|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
76073629|NCT04149483|Drug|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
76073630|NCT04149639|Dietary Supplement|NeuroQ|Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
76073631|NCT04141371|Drug|Molar Sodium Lactate|daily 3-hour infusion of sodium molar lactate during the vasospasm period
75623657|NCT01020786|Drug|Pemetrexed|"Induction Therapy: 500 milligrams per square meter (mg/m^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity."
75623658|NCT01020786|Drug|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
75623659|NCT00918645|Drug|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
75623660|NCT04255719|Procedure|DBS|Unilateral DBS for treatment of patients with PD
75623661|NCT00922935|Device|Cresco|Cresco components loading 10 days post surgery
75623662|NCT00922935|Device|Cresco|Cresco loading at 6-8 weeks post surgery
75623663|NCT00922935|Device|Straumann components|Straumann components loading 6-8 weeks post surgery
75623664|NCT01020474|Drug|placebo|matching placebo capsules twice daily.
75623665|NCT01020474|Drug|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
75623666|NCT02872818|Drug|17β estradiol hemihydrate|4mg/kg/day for 20 days
75623667|NCT02872818|Drug|Metformin|50 mg/kg/day last 10 days
75623668|NCT02872818|Drug|medroxyprogesterone acetate|1mg/kg/day last 10 days
75776806|NCT05155579|Biological|Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)|Licensed vaccine part of the EPI vaccination schedule
75776807|NCT05155579|Biological|Licensed vaccine - Oral Polio Vaccine (OPV)|Licensed vaccine part of the EPI vaccination schedule
75776808|NCT05155579|Biological|Licensed vaccine - Rotavirus|Licensed vaccine part of the EPI vaccination schedule
75776809|NCT05155579|Biological|Licensed vaccine - Pneumococcal vaccine|Licensed vaccine part of the EPI vaccination schedule
75776810|NCT05155579|Biological|Licensed vaccine - Inactivated Polio Vaccine (IPV)|Licensed vaccine part of the EPI vaccination schedule
75776811|NCT05154916|Other|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
75776812|NCT05152810|Other|Transcranial Magnetic Stimulation sessions|"10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase"
75776813|NCT05152810|Other|Evaluations|"Before the first stimulation session, just after the 10th session, at 6 weeks, at 12 weeks and at 24 weeks.~The assessment included the collection of AEs/EIGs, the TAC, the VAS on desire to smoke, the TCQ, the QSU, BDI-II (except at S1), the CO tester, GoNoGo, the PQI and the ISI."
75776814|NCT05150002|Device|Spinal cord stimulation|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
75776815|NCT05143281|Drug|Dexamethasone 0.4 MG [Dextenza]|Ophthalmic Intracanalicular Insert
75776816|NCT05139719|Drug|HEC585 dose A|taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
75776817|NCT05139719|Drug|HEC585 dose B|taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage
75321238|NCT01936467|Device|Standard technique EUS-FNA|Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
75321239|NCT01936467|Device|Capillary suction technique for EUS FNA|Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
75321240|NCT02995759|Other|Seizure Action Plan|The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
75623669|NCT00922779|Drug|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
75623670|NCT00922779|Drug|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
75623671|NCT04205448|Behavioral|Physical exercize|10 weeks group exercize followed by community-based voluntary exercize
75776818|NCT05139719|Drug|Placebo|taking Placebo orally once daily, up to 24 weeks in main stage
76073632|NCT04141371|Drug|physiological serum|daily saline infusion over 3 hours during the vasospasm period
75321241|NCT01677338|Drug|13C-uracil|PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
75623672|NCT04532892|Dietary Supplement|Meta 18.06 Day and Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 & V4) and calls for antistress advices and adverse events, concomitant medication reporting & compliance (V1 & V3)
75623673|NCT04532892|Dietary Supplement|Placebo Meta 18.06 Day and Placebo Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 & V4) and calls for antistress advices and adverse events, concomitant medication reporting & compliance (V1 & V3)
75623674|NCT00924651|Behavioral|exercise|home based walking and progressive resistance training exercise
75623675|NCT04570410|Procedure|primary focal resection plus lymph node dissection|Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma
75623676|NCT04570410|Drug|Tislelizumab|Tislelizumab IV infusion of 200 mg Q3W
75776819|NCT05137210|Other|Male Counseling and Facility Navigation|At enrollment, study staff distribute pamphlet with male-specific messaging and contact information for nearest facility. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling. Meeting at location of participants choice. Follow-up male-specific counseling is offered every 14 days thereafter until 90 days is reached OR 4-week follow-up ART refill visit is completed. Participants who choose to initiate ART are escorted to nearest health facility and provided facility navigation assistance.
75798413|NCT01168752|Drug|Debio 0932|"Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met."
75913983|NCT05864794|Diagnostic Test|MRI|MRI scan of the brain
75623677|NCT04570410|Drug|Gemcitabine plus cisplatin|GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks
75623678|NCT04203771|Dietary Supplement|Probiotic AB-DENTALAC|Orodispersible tablets containing Lactobacillus plantarum [now Lactoplantibacillus plantarum] KABP051 (CECT7481) and Lactobacillus brevis [now Levilactobacillus brevis] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.
75623679|NCT04203771|Other|Placebo|Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.
75623680|NCT04203771|Procedure|Surgical removal of mandibular third molars at baseline|Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
75623681|NCT04203771|Drug|Ibuprofen|Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
75466555|NCT01910675|Drug|FFP|4 units Octaplas. Additional fibrinogen if needed.
75623682|NCT04256733|Biological|Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
75623683|NCT04256733|Biological|Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer|Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
75623684|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
75623685|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
75623686|NCT00922623|Device|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
75623687|NCT01025232|Drug|Ranibizumab|Intravitreal Injection of 2.0mg formulation
75623688|NCT04300452|Drug|Carbetocin|Administration of Carbetocin after placental detachment
75623689|NCT04300452|Drug|Ergometrine Maleate|Administration of ergometrin after placental detachment
75623690|NCT04252755|Behavioral|EEG Neurofeedback|Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
75623691|NCT01025154|Drug|Clofarabine|Induction Cycle: 20 mg/m^2 IV over approximately 1 hour daily for 5 days (days 1-5)
75623692|NCT01025154|Drug|Idarubicin|Induction Cycle: 10 mg/m^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
75623693|NCT01025154|Drug|Cytarabine|Induction Cycle: 1 g/m^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
75798414|NCT01277250|Behavioral|Web-based smoking cessation program|"Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay."
75623694|NCT04252833|Drug|CT-044|CT-044 HCl is a reactive species decomposition accelerant
75623695|NCT04252911|Other|Bispectral index score|Bis value from two sites gives similar results
75623696|NCT04252365|Drug|Sintilimab|Given i.v.
75623697|NCT04252365|Drug|Pembrolizumab|Given i.v.
75623698|NCT04256499|Procedure|Acute water load test|The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.
75623699|NCT04256577|Diagnostic Test|serum ceramides level in blood|Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)
75623700|NCT04252443|Other|Evaluation of nurses' knowledge and attitudes about opioid analgesics working in a university hospital|Interventions involving nurses' pharmacological level
75623701|NCT00832819|Drug|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
75798415|NCT01171326|Drug|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
76073633|NCT04140981|Device|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
75623702|NCT00832819|Drug|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
75623703|NCT00832819|Drug|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
75623704|NCT00832819|Drug|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
75623705|NCT04820361|Drug|Cannabis sativa L., folium cum flore|Muscle Relaxation
75623706|NCT04820361|Drug|Placebo|Muscle Relaxation
75798416|NCT02526186|Device|Battlefield Auricular Acupuncture|
75798417|NCT01171482|Drug|5-FU|15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
75466556|NCT01910701|Behavioral|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
75623707|NCT04256655|Drug|cohort 1 0.225g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
75913984|NCT05860842|Other|exercise|Six months of supervised combined exercise training program, consisting of 2 sessions/wk of 75 min each, followed by a six-month period of follow-up. Each session will comprise a 5-min warm-up, 30-min endurance exercise, 30-min resistance exercise, 5-min flexibility and 5-min cool-down.
76073634|NCT04149093|Diagnostic Test|Calretinin staining|"A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.~Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining."
75321242|NCT01677338|Drug|99mTc sulfur colloid|PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
75623708|NCT04256655|Drug|Cohort 2 0.75g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
75623709|NCT04256655|Drug|Cohort 3 2.25 g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
75623710|NCT05320497|Device|Transparent cap|Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
75623711|NCT00853723|Drug|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
75623712|NCT00853723|Drug|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
75623713|NCT00853723|Drug|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
75623714|NCT01104545|Drug|MK-3614|
75623715|NCT01104545|Drug|Comparator: Placebo|
75623716|NCT04117789|Behavioral|Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
75623717|NCT04117789|Behavioral|Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
75623718|NCT04117789|Other|Treatment as usual|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
75623719|NCT00918255|Biological|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
75623720|NCT00918255|Drug|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
75623721|NCT04252131|Drug|cassia seed tablet|traditional Chinese herbs
75623722|NCT04252053|Other|Pilates Based Core Stabilization Training|Pilates-based core stabilization training (PBCST) is a controlled form of exercise provided improvement in stabilization of abdominal and back muscles.
75623723|NCT04252053|Other|Home based exercise|Home exercises which include pilates based core stabilization training will be structured for the people with MS according to their physical condition and will perform at home by them.
75623724|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
75623725|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
75623726|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
75623727|NCT01096589|Device|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
75623728|NCT04252521|Drug|metoclopramide|10 mg Metpamid in 100 ml normal saline solution
75623729|NCT04252521|Drug|dexketoprofen trometamol|50 mg dexketoprofen trometamol in 100 ml normal saline solution
75623730|NCT04252521|Drug|metoclopramide+dexketoprofen trometamol|10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution
75623731|NCT04819659|Device|Pharyngeal packing|Placing gauze-like material in the nasal cavity to absorb blood or other fluids right after tracheal intubation.
75623732|NCT04918745|Device|Cochlear Vestibular Implant (CVI)|"The Cochlear Vestibular Implant (CVI) is a modified cochlear implant (CI) which also incorporates a vestibular component (VI) in order to restore both hearing and vestibular function. Three vestibular stimulation algorithms will be compared in a randomized order (3 treatments x 3 periods, = 6 arms). These stimulation algorithms are:~A - Baseline stimulation, no modulation stimulation~B - Baseline stimulation, modulated stimulation~C - Reduced baseline stimulation, modulated stimulation"
75623733|NCT00845065|Drug|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
75623734|NCT00845065|Other|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
75623735|NCT00845065|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
75623736|NCT00845065|Drug|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
75798418|NCT01171482|Drug|Mitomycin|4mg/day IV push from day 1 to day 4 every 28 days
75798419|NCT01171482|Drug|sorafenib|400 mg BID every 28 days
75913985|NCT05859269|Drug|Methylprednisolone|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course.~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
75623737|NCT04772001|Drug|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 12 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 10mg or 8mg will be taken.
75623738|NCT04772001|Drug|cis Platinum/carboplatin|Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime. For patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug.
75623739|NCT04772001|Radiation|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks.
75623740|NCT02880059|Device|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
75623741|NCT00702091|Drug|Ramipril|10 mg capsule
75623742|NCT00626171|Procedure|Allergen Challenge|Allergen challenge
75623743|NCT00832585|Drug|Alefacept|Alefacept 15mg IM every week for 12 weeks
75623744|NCT00918567|Drug|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
75623745|NCT00918567|Behavioral|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
75623746|NCT04255797|Behavioral|baby massage|The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
75623747|NCT05252325|Device|hyaluronic acid plus lidocaine|local injection for correction of nasolabials fold
75623748|NCT05252325|Device|hyaluronic acid without lidocaine|local injection for correction of nasolabial folds
75623749|NCT04255641|Other|time lapse analysis|grading of the embryos before freezing using time lapse/
75623750|NCT04770051|Procedure|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
75623751|NCT05252091|Drug|herombopag olamine tablets|The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
75623752|NCT01024920|Drug|BIBF 1120|VEGF inhibitor
75623753|NCT01024920|Drug|sunitinib|VEGF inhibitor
75623754|NCT00832117|Drug|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
75623755|NCT00832117|Drug|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
75321243|NCT02995447|Other|differences between surface and intracerebral EEG|No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
75623756|NCT00832117|Drug|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
75623757|NCT00832117|Drug|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
75623758|NCT02873052|Device|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
75623759|NCT02611843|Behavioral|Peer-Supported Web CBT|
75623760|NCT02611843|Behavioral|Self-Managed Web CBT|
75623761|NCT02872272|Drug|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
75623762|NCT02872896|Procedure|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
75623763|NCT02612467|Other|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
75623764|NCT02612467|Other|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
75623765|NCT04205292|Procedure|hysteroscopic|Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
76073635|NCT04149327|Drug|amoxicillin 500 mg + metronidazole 500 mg|500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
75913986|NCT05859269|Other|Standard of Care|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
75321244|NCT03557216|Diagnostic Test|Colonoscopy|Anal introduction of a long, flexible, tubular instrument about 1/2-inch in diameter that transmits an image of the lining of the colon so the doctor can examine it for any abnormalities
75321245|NCT03557216|Diagnostic Test|Fecal immunochemical and occult blood test|A test for fecal occult blood looks for blood in your feces. It can be a sign of a problem in the digestive system, such as a polyp or cancer in the colon.
75321246|NCT03557216|Diagnostic Test|Fecal calprotectin test|Calprotectin is a protein released by neutrophils. When there is inflammation in the colon, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. This test measures the level of calprotectin in stool as a way to detect inflammation and lesions in the colon.
75321247|NCT03088280|Drug|Thymoglobulin|reduced dose (3mg/Kg)
75321248|NCT03087968|Drug|GS-4997|Experimental drug
75321249|NCT03087968|Drug|Prednisolone|Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
75321250|NCT03087968|Device|HepQuant SHUNT Test|"The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples."
75321251|NCT03087968|Drug|Placebo|Placebo
75321252|NCT05241743|Other|radiological examination, pain, nomophobia, phone addiction|120 patients who applied to the clinic with the complaint of neck pain and were diagnosed with cervical hypolordosis by radiological examination will be included in the study. After giving the necessary verbal and written information about the study, a link will be sent to the phones of the patients whose informed consent was obtained. Patients will access evaluation questions and survey questions via this link. Personal information with the Sociodemographic Data Form prepared by us; pain severity by Visual Analogue Scale (VAS); phone addiction level with the Smartphone Addiction Questionnaire (Young Population); nomophobia levels will be evaluated with the Nomophobia Scale.
75623766|NCT01104311|Procedure|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
75623767|NCT01104311|Procedure|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
75623768|NCT02612389|Other|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
75623769|NCT04205214|Behavioral|Integrative Cognitive Behavioural Therapy|This intervention involves the psychological intervention of Cognitive Behavioural Therapy. This intervention also includes third wave psychological interventions of Mindfulness and Narrative Therapy which has been found to be helpful for people with chronic health conditions and chronic skin conditions.
75623770|NCT00702247|Procedure|Hematopoietic Stem Cell Transplantation|
75623771|NCT00831493|Radiation|Chemoradiation (Radiation Therapy)|Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
75321253|NCT03845049|Other|Inclusion examinations|Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
75623772|NCT00831493|Drug|Vorinostat|Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
75623773|NCT00853567|Drug|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
75623774|NCT00853567|Other|placebo|Placebo
75623775|NCT00853489|Device|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
75623776|NCT00853489|Procedure|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
75623777|NCT00705445|Dietary Supplement|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
75776820|NCT05137210|Other|Home-Based ART Initiation and Facility Navigation|"At enrollment, study staff distribute two pamphlets on: 1) male-specific messaging and 2) details about home-based ART initiation. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling, and a detailed description of home-based ART initiation with a nurse. Meeting at the location of participants choice. Follow-up male-specific counseling and information about home-based initiation is offered every 14 days thereafter until 90 days OR 4-week ART follow-up refill visit is complete. Participants who choose to initiate ART at home or in the community will meet with a nurse at a place of the participants choosing. Those who choose to initiate at the facility will receive facility navigation and initiation. All clients will receive a warm handover for their 4-week ART follow-up visit."
75798420|NCT01171560|Procedure|endotracheal intubation|The patients will be randomized to one of two groups: EZ Blocker or conventional double lume tube. After induction of anesthesia, intubation using respective device will be performed in dorsal position.
75798421|NCT01171638|Device|Near infrared spectroscopy (NIRS)|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
76073636|NCT04149327|Procedure|non-surgical periodontal and peri-implant treatment|"Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned."
76073637|NCT05582733|Other|Cervical spine manipulation|hot pack for 10 minutes will be applied followed by cervical manipulation (chin hold kaltenborn) once and then stretching
75623778|NCT00705445|Dietary Supplement|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
75623779|NCT00705445|Other|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
75623780|NCT02879981|Drug|Guaifenesin|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
75913987|NCT05859022|Other|Roux-en-Y gastric By-pass (RYGB) surgery|RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J& company.
75776821|NCT05137210|Other|Stepped Intervention|"Day 0-14 Arm 1 (Male-specific counseling and facility navigation arm) implemented. Day 14-30, if not yet initiated, a psychosocial counsellor will trace the participant to provide advanced counselling and motivational interviewing. Psychosocial counsellors will act as 'Male Mentors' and meet with men as frequently as needed. Day 30-89 if not yet initiated, nurse-led home-based ART initiation will be offered, following the same steps as listed in the Home-Based ART Initiation Arm."
75776822|NCT05128422|Other|Normobaric oxygen therapy|it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group
75776823|NCT05126043|Diagnostic Test|Triglycerides/high density lipoprotein ratio|Lipid profile
75913988|NCT05859022|Other|Bariatric Arterial Embolization (BAE) procedure|use of Embosphere Microspheres (EM) that are designed to offer controlled, target embolization.
75913989|NCT05855382|Other|Persistent COVID-19|To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
75623781|NCT02879981|Drug|Sulfamethoxazole|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
75623782|NCT02879981|Drug|Trimethoprim|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
75623783|NCT04307693|Drug|Lopinavir/ritonavir|Lopinavir / Ritonavir tablet
75623784|NCT04307693|Drug|Hydroxychloroquine sulfate|Hydroxychloroquine sulfate tablet
75623785|NCT02878421|Device|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
75321254|NCT03845049|Drug|Aflibercept Injection [Eylea]|Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
75321255|NCT03845049|Drug|SHAM injection|Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
75321256|NCT03845049|Other|Examinations during study (every month)|visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
75321257|NCT05252819|Diagnostic Test|Magnetic Resonance Imaging and an optional blood test|One whole-Body MRI that takes approximately 35minutes One blood test, which it is an optional component at this stage
75776824|NCT05125419|Diagnostic Test|Homocysteine level|diagnostic test
75776825|NCT05119270|Device|Femtosecond laser assisted cataract surgery with Active Sentry handpiece|"The LenSx laser (Alcon Laboratories Inc., USA) automates key steps in the procedure including capsulorhexis, incision making and phaco. The Frequency Domain - Optical Coherence Tomography (FD-OCT) optical imaging system provides high-resolution, real-time visualization of ocular structures and their dimensions. The device sends the results to the interface which programs the laser and indicates the exact location, size and depth of the desired incisions.~Diagnostic tests:~Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
75913990|NCT05854524|Procedure|Aerobic exercise|The intervention is exercise and there are no drugs or devices used in this trial. The exercise consists of two intensity levels of a 30-minute aerobic exercise intervention with both arms crossing over to both conditions: low intensity exercise (60-70% of estimated maximum heart rate (EMRH)) and moderate-vigorous intensity exercise (75-85% of EMHR).
75913991|NCT05853861|Behavioral|JASPER|JASPER is an evidence based early intervention that focuses on the core social communication and engagement skills of young children that are important to improvements in communication and language.
75913992|NCT05853861|Behavioral|Babble Bootcamp|Babble Bootcamp is a new intervention focusing on the speech-motor system and aims to improve babbling and early word use in infants known to be at risk for language delay.
76073638|NCT05582733|Other|traction|Hot pack will be applied followed by sustained pressure or MPR for 90 sec and then stretching.
76073639|NCT05582655|Behavioral|ONLINE|The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
75321258|NCT00594997|Behavioral|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
75321259|NCT00594997|Behavioral|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
75321260|NCT03790839|Drug|Sitagliptin|Sitagliptin (Januvia® 100 mg tablets for oral administration)
75623786|NCT02878421|Other|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
75623787|NCT02878421|Other|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
75623788|NCT02878187|Device|Doppler|"Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum"
75913993|NCT05853835|Drug|LPX-TI641|LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
75623789|NCT04307303|Device|abdominal functional electrical stimulation|functional electrical stimulation of the abdominal muscles
75623790|NCT02879903|Procedure|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
75913994|NCT05853497|Behavioral|Multi-Component Weight Loss Intervention|The intervention group will receive weekly 1-on-1 health coaching with a very-low calorie nutrition plan prior to total knee replacement and a conventional weight maintenance nutrition plan after surgery.
75913995|NCT05853484|Other|Bimodal lifestyle program|Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
75623791|NCT02879903|Procedure|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
75623792|NCT02879903|Procedure|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
75913996|NCT05851781|Drug|Lacosamide tablet|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
75913997|NCT05851781|Drug|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
75913998|NCT05851157|Drug|VX-548|Tablets for oral administration.
75913999|NCT05849610|Drug|Daratumumab|Daratumumab will be administered by SC injection.
75914000|NCT05849610|Drug|Bortezomib|Bortezomib dose will be calculated using the patient's actual body surface area (BSA) at baseline and will be administered by subcutaneous (SC) injection.
75914001|NCT05849610|Drug|Lenalidomide|Lenalidomide will be administered by oral route.
75914002|NCT05849610|Drug|Teclistamab|Teclistamab will be administered by SC injection.
75914003|NCT05849610|Drug|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
75914004|NCT05848765|Drug|Epcoritamab|Bispecific antibody
75914005|NCT05848765|Drug|Lenalidomide|Immunomodulatory agent
75914006|NCT05848765|Drug|Rituximab|Monoclonal antibody
75914007|NCT05848765|Drug|Obinutuzumab|Monoclonal antibody
75914008|NCT05848765|Drug|Bendamustine|Alkylating agent (chemotherapy drug)
75914009|NCT05848765|Drug|Vincristine|Antineoplastic, Vinca Alkaloid
75914010|NCT05848765|Drug|Doxorubicin|Anthracycline
75914011|NCT05848765|Drug|Cyclophosphamide|Alkylating agent (chemotherapy drug)
75321261|NCT03790839|Drug|Dorzagliatin|Glucokinase activator currently under development
75623793|NCT04307459|Other|standard operating procedures|standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.
75623794|NCT01019694|Drug|Combivent CFC-MDI|36/206 mcg Four times a day (QID)
75623795|NCT01019694|Drug|Combivent Respimat 20/100 mcg|Open label randomized parallel
75623796|NCT01019694|Drug|Atrovent HFA 42 mcg + Albuterol HFA 200 mcg|Open label randomized parallel
75914012|NCT05848765|Drug|Prednisone|Corticosteroid
75914013|NCT05848765|Drug|Investigation agent 2|The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
75914014|NCT05848765|Drug|Investigation agent 3|The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
76073640|NCT05582655|Behavioral|COACH|COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, & Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, & Arbuckle, 2021).
76073641|NCT05582577|Combination Product|Intravitreal bevacizumab injection with subthreshold micropulse laser|Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser
76073642|NCT05582577|Drug|Intravitreal bevacizumab injection alone|Group B: Intravitreal injection of Bevacizumab alone
75914015|NCT05847933|Device|rTMS (cTBS experiment)|"rTMS using cTBS protocol with the following characteristics:~Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~Intensity: 80% of resting motor threshold (rMT)~Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~Duration: 40 seconds for each hemisphere, 80 seconds in total.~Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
75914016|NCT05847933|Device|rTMS (cTBS sham)|"rTMS using cTBS protocol with the following characteristics:~Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~Intensity: 0%~Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~Duration: 40 seconds for each hemisphere, 80 seconds in total.~Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
76073643|NCT04149015|Drug|paclitaxel ,oxaliplatin,fluorouracil|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
75623797|NCT00831415|Drug|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
75623798|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
76073644|NCT04140591|Drug|Proton-pump inhibitor|PPI: Pariet EC 20mg/QDAC
75623799|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
75914017|NCT05847933|Device|rTMS (cTBS active control)|"rTMS using cTBS protocol with the following characteristics:~Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~Intensity: 80% of resting motor threshold (rMT)~Location: Right superior frontal cortex~Duration: 40 seconds for each hemisphere, 80 seconds in total.~Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
75914018|NCT05847933|Device|rTMS (high frequency)|"rTMS using high frequency protocol with the following characteristics: Frequency: 5 Hz~Intensity: 100% of rMT~Location: bilateral temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~Duration: 2.5 seconds during the presentation of pictures (3 minutes in total)~Timing: Only during the picture viewing part of memory task (On-line)"
75914019|NCT05847933|Device|rTMS (low frequency)|"rTMS using Low frequency protocol with the following characteristics:~Frequency: 1 Hz~Intensity: 110% of rMT~Location: temporo-occipital cortex of dominant brain hemisphere (MNI left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~Duration: 30 minutes, continuously~Timing: Starting 10 minutes before and continuing during the picture viewing and valence rating of the pictures of the memory task (on-line)."
76073645|NCT04140591|Drug|Propranolol+Proton-pump inhibitor|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure >90mmHg) PPI: Pariet EC 20mg/QDAC
75623800|NCT01095653|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
75623801|NCT01095653|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
75623802|NCT00913159|Procedure|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
76073646|NCT03909321|Behavioral|Beach tennis training group|Beach Tennis Training Group (BTG) will perform two sessions of 40-60 min of beach tennis during 12 weeks. BT sessions will be composed by a warm up of 5-10 min of BT technical exercises (i.e., serve, volley, forehand and backhand exercises) followed by 3 BT small games of 10-15 min each.
75623803|NCT00920907|Biological|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
76073647|NCT05582109|Drug|Envafolimab, Lenvatinib Combined With TACE|PD-L1 inhibitor
76073648|NCT04140123|Drug|ZSP1601|ZSP1601 tablets be taken orally for 28 days.
76073649|NCT04140123|Drug|ZSP1601 Placebo|Subjects will receive matching placebo of ZSP1601
76073650|NCT03020901|Drug|Teicoplanin for Injection|Use Teicoplanin for Injection
76073651|NCT04140201|Drug|Simvastatin 40mg|Drugs that lower lipid level
76073652|NCT04140201|Drug|Fenofibrate 200mg|Drugs that lower lipid levels
76073653|NCT04140201|Drug|Omega 3 fatty acid|Drugs that lower lipid levels
76073654|NCT05581875|Drug|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
76073655|NCT05581875|Drug|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
76073656|NCT05581875|Drug|Pomalidomide|Pomalidomide will be administered per os.
76073657|NCT05581875|Drug|Dexamethasone|Dexamethasone will be administered intravenously or per os.
75623804|NCT00705601|Procedure|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
75623805|NCT01103141|Device|Micropuncture needle set|Groin access for vascular intervention
75623806|NCT01103141|Device|Standard gauge-18 needle set|Groin access for vascular intervention
75623807|NCT00700297|Drug|Colchicine|100 mg Colchicine per day for 4 months
75623808|NCT00700297|Drug|Placebo|One tablet placebo per day for 4 months
75623809|NCT05298501|Other|No intervention/exposure|No interventions/exposures will be administered or evaluated
75623810|NCT04307147|Drug|Capecitabine|Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
75623811|NCT04307147|Drug|Vinorelbine|Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
75623812|NCT00844831|Drug|Lubiprostone|24 mcg bid for 28 days
75623813|NCT02878343|Behavioral|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
75623814|NCT02878343|Behavioral|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
75623815|NCT04117633|Device|Laparoscopy|Laparoscopic Procedures for Rectopexy
76073658|NCT03945045|Procedure|Subclavian vein approach|Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
75776826|NCT05119270|Procedure|Standard phacoemulsification with the Active Sentry handpiece|"Phacoemulsification is done by using the Active Sentry handpiece to allow for a better control of the intraocular pressure throughout the surgery.~Diagnostic tests:~Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
75776827|NCT05119270|Procedure|Standard phacoemulsification with the OZil handpiece|"Phacoemulsification is done by using the traditional OZil handpiece that allows rotational movement of the phaco tip.~Diagnostic tests:~Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
75914020|NCT05845177|Procedure|Primary Total Hip Arthroplasty|All patients surveyed have undergone primary total hip arthroplasty approximately 1 year prior to survey distribution
75914021|NCT05845047|Behavioral|PICTURE-IT|"The speech-language pathologist (SLP) will provide one of the following stimuli hierarchically:~Single words depicted in the picture, then with written and spoken labels~2-word phrases depicted in the picture and then with written and spoken word~Subject-Verb-Object sentence depicted in the picture and then with written and spoken sentences~Two-sentence event, depicted with photos and subsequently with two written and spoken sentences~Short story depicted with a video clip and subsequently with printed and spoken narrative.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
75914022|NCT05845047|Behavioral|CoDeLT|"The speech-language pathologist (SLP) will facilitate the computer-delivered naming treatment, consisting of a picture/seen and heard spoken word verification task.~A picture will be presented for two seconds on a laptop computer screen and will be immediately followed by an audio-visual display of a speaker's mouth saying a noun. The spoken word either will or will not match the preceding picture, and the participant must indicate whether the picture and video match or do not match. The computer will provide immediate visual feedback following a response.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
75914023|NCT05844891|Behavioral|Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER)|TEACH-ER aims to provide primary care management and educational support for families managing childhood asthma throughout the transition from emergency department to home, and includes several core components: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine, featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices. We anticipate that all three telehealth visits (1 provider visit, 2 educator visits) will be completed within 2 months of enrollment.
76073659|NCT03945045|Procedure|internal jugular vein approach|internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
76073660|NCT04148469|Procedure|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
75623816|NCT00920829|Drug|Naltrexone 50 Mg|Naltrexone 25 or 50 mg per titration schedule
75623817|NCT00920829|Drug|Placebo|placebo
75623818|NCT04306835|Behavioral|Cognitive behavioural therapy for insomnia|a technique for treating insomnia without medications
75623819|NCT05010876|Drug|C1 Inhibitor Human|standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units
75623820|NCT05010876|Drug|Icatibant Injection|a single injection of 30 mg subcutaneously
75623821|NCT05010876|Other|Placebo|The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.
75623822|NCT04307069|Drug|Oxytocin|The drug wil be adminisrate for augmentation of labor at admission.
75623823|NCT02878265|Dietary Supplement|Vitamin A|Vitamin A supplements
75623824|NCT02878265|Dietary Supplement|Vitamin A and ZInc|Combination of vitamin A and zinc supplements
75623825|NCT02878265|Dietary Supplement|Vitamin A , Zinc and Multivitamin|Combination of vitamin A, zinc and multivitamins
75623826|NCT00831181|Drug|5-FU|5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
75623827|NCT00831181|Drug|Oxaliplatin|Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
75623828|NCT00831181|Drug|leucovorin|Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
75776828|NCT05117710|Drug|Ebselen|Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).
75776829|NCT05117710|Drug|Placebo|Matched placebo capsules
75623829|NCT00831181|Procedure|mesorectal excision|mesorectal excision
75623830|NCT01023672|Drug|Armodafinil|150-250 mg armodafinil by mouth daily
75623831|NCT04251429|Other|CPH-NEW Healthy Workplace Participatory Program|A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.
75623832|NCT05252013|Other|Experimental: Bean Hull Bread|The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
75776830|NCT05117515|Device|Vascular reconstruction|Vascular reconstructions in the carotid, profunda, femoral and iliac arteries
75776831|NCT05109637|Device|Konectom NMD Application|Administered as specified in the treatment arm.
75776832|NCT05105022|Drug|Propofol|Intravenous induction of general anesthesia in infants 3 months or less.
75776833|NCT05102760|Procedure|Nerve Block using FIC Proceedure|Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
75776834|NCT05102760|Procedure|Nerve Block using PENG Proceedure|Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
75776835|NCT05099718|Procedure|palatal soft tissue harvesting|A 6x2mm palatal soft tissue graft will be harvested.
75776836|NCT05099718|Device|Hyaluronic acid|application 3-times per day for 7 days
75914024|NCT05844891|Behavioral|Enhanced Care (EC)|Similar to children in the TEACH-ER group, participants in the EC group will receive a symptom assessment using NHLBI guidelines, a recommendation for appropriate preventive medications, and asthma education materials given at the time of the ED visit. After baseline and randomization, we will send the child's PCP a symptom report with guideline-based recommendations for preventive care and recommend a follow-up visit with the PCP. We will also give all providers a summary of the current national guidelines. We will provide systematic feedback to the family and child's PCP at intervals that parallel the TEACH-ER group's telemedicine assessments. This feedback will include prompting caregivers to schedule a recommended follow-up appointment with the PCP, and encouraging providers to adhere to the NHLBI guidelines. While participants will not be blinded to their group allocation, they will be told that they are randomly assigned to two different ways of approaching asthma management.
75914025|NCT05840185|Device|Test myopia control lenses (DAL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
75914026|NCT05838352|Other|telerehabilitation exercise|The telerehabilitation program is as follows; Respiratory exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities, using medium-hardness resistance exercise band. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. Exercises 1st-3rd weeks with 10 repetitions; 15 repetitions in weeks 4-6; In the 7th and 8th weeks, it will be done as 2 sets of 10 repetitions.Posture exercises: Basic posture exercises will be explained. Tabletop movements will be taught in clear, various positions that concern the spine, scapula and pelvis.Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking).
75623833|NCT05252013|Other|Experimental: Plain Bread|The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
75623834|NCT00705835|Biological|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
75623835|NCT01094171|Biological|Poliorix TM|Intramuscular administration, 3 doses
75623836|NCT01094171|Biological|Infanrix TM|Intramuscular administration, 3 doses
75623837|NCT00702637|Drug|Modafinil|
75623838|NCT05251935|Other|Foot Muscle Exercise Protocol|Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program
75623839|NCT05251935|Combination Product|Arch Support Insole and One Leg Balance Activities|Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
75623840|NCT01093625|Device|Narafilcon B Contact Lens|
75623841|NCT01093625|Device|Spectacles|spectacle wearers
75776837|NCT05099718|Other|Saline solution (placebo)|application 3-times per day for 7 days
75776838|NCT05096624|Other|DD-TENS system|Use of DD-TENS system
75776839|NCT05096624|Other|Gold Standard|Gold standard
75776840|NCT05096624|Other|Digital Denture system|Use of Digital Denture system
75776841|NCT05096468|Drug|S-ketamine and pregabalin|"Drug: Pregabalin~150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~Drug: S-ketamine infusion~0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
75623842|NCT01023516|Drug|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
75623843|NCT01023516|Drug|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
75623844|NCT00844753|Drug|atomoxetine|atomoxetine
75623845|NCT00844753|Drug|Placebo|Placebo + parent management treatment
75623846|NCT00844753|Behavioral|Parent Management Training|
75623847|NCT02878109|Device|Post-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
75623848|NCT02878109|Device|Pre-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
75623849|NCT05525611|Drug|Cabergoline 0.5 MG|Cabergoline 0.5 mg once a week in 12 weeks
75776842|NCT05096468|Drug|Normal saline and placebo capsule|"Drug: Placebo capsules~Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~Drug: Normal saline~0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
75776843|NCT05093842|Behavioral|Sedentary Behavior Reduction|Participants receive bimonthly behavioral health coaching, a sit-stand desk attachment or table, and an activity prompter if they do not already have one (e.g., fitbit, as needed).
75776844|NCT05093842|Behavioral|Information on Physical Activity Recommendations during Pregnancy|Participants in the study will receive educational materials provided one time by email about the currently recommended physical activity during pregnancy.
75798422|NCT01171716|Other|Meal Patterning|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
75798423|NCT01284036|Drug|PF-05230905|Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
75798424|NCT01168830|Device|AMS-3.0|
75798425|NCT01282398|Drug|Simvastatin|The experimental group will take 40 mg each 24 hours for at least two years.
75798426|NCT01282398|Drug|placebo|the control group wiil take placebo pills for at least two years.
75776845|NCT05088421|Drug|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days."
76073661|NCT04148469|Procedure|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
76073662|NCT04148469|Procedure|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
75321262|NCT03088046|Drug|Micronized Progesterone|"Anovulatory women with Polycystic ovary syndrome and clinical hyperandrogenism attended in our Hospital will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study.~Blood samples will be collected at baseline (Sample #1) and between the 3rd and the 5th day of withdrawal after 7 days of 100mg vaginal MP every 12 hours of administration(Sample#2)."
75321263|NCT03088124|Drug|Apalutamide|Patients will take orally everyday 240 mg of Apalutamide.
75466557|NCT01910714|Behavioral|Focus On Youth|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
75623850|NCT05525611|Other|Placebo|Placebo once a week in 12 weeks
75914027|NCT05838352|Other|Control Group|The surveys in the outcome measures section will be applied once as a pre-test. Children in both groups will receive conventional institutional rehabilitation in the rehabilitation center. Children in the conventional rehabilitation group, which is the control group, will only be included in the supervised program. This group will not receive a telerehabilitation program.
75623851|NCT04309175|Device|base rate programming of a permanent cardiac pacemaker|Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
75776846|NCT05088421|Drug|Placebo|SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
75776847|NCT05085392|Behavioral|Trauma-Informed Yoga|6 weeks of twice weekly trauma-informed yoga for 45 minutes per session
75776848|NCT05085028|Drug|Pembrolizumab 25 MG/ML [Keytruda]|Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
75776849|NCT05084365|Drug|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
75776850|NCT05084365|Drug|Placebo|Placebo
75914028|NCT05835973|Other|Sleep activity|"Actinography : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard).~Ancillary study :~DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months."
75914029|NCT05835973|Other|Questionnaires|"The PSQI, EPWORTH, FACIT-F, ISI, and ICSD-3 questionnaires will be completed by patients every 3 months during their follow-up consultation according to the usual management.~The questionnaire by Horne and Ostberg will be completed by the patients only during the inclusion visit."
76073663|NCT04406025|Procedure|participation in Regional Anesthesia Seminar|this group of anesthesiologists attended the Regional Anesthesia Seminar
76073664|NCT04406025|Procedure|no participation in Regional Anesthesia Seminar|this group of anesthesiologists did not attend the Regional Anesthesia Seminar
76073665|NCT04140045|Other|Water intake|Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
76073666|NCT05587881|Biological|COVID-19 vaccine(donor)|Donor received COVID-19 vaccine before stem cells collection.
76073667|NCT05587881|Biological|COVID-19 vaccine(patient)|Patient received COVID-19 vaccine before allo-HSCT.
76073668|NCT05586165|Behavioral|Reminder to boost protection against COVID-19|Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.
75321264|NCT00700375|Drug|Sodium bicarbonate|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
75623852|NCT00830947|Device|OrthoAccel Device|The OA device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
75623853|NCT00830947|Device|Sham Device|Inactive sham device that is held in the mouth for 20 minutes.
75623854|NCT05524129|Other|rehabilitation exercise|Conventional rehabilitation exercise.
75623855|NCT05524129|Other|electrotherapy|A middle frequency electro-therapy
75623856|NCT01018992|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
75623857|NCT01018992|Drug|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
75776851|NCT05080166|Other|Interview with Clinicians|One time, qualitative interview of clinicians for feedback on UPLYFT intervention
75776852|NCT05080166|Other|Field Test of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors for feedback
75776853|NCT05080166|Behavioral|Pilot of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors
75776854|NCT05079789|Drug|Amiloride|Treatment with amiloride, start dose 5 mg
75776855|NCT05079789|Drug|Furosemide|Treatment with furosemide, start dose 40 mg
75776856|NCT05063227|Diagnostic Test|Observational: analgesia monitoring indices and changes in heart rate|After the end of surgery (defined as the time of skin closure or wound dressing), but before awakening (BIS will still be < 60), SPI, PPI and NOL are recorded in a quiet setting without any other stimulation. Within the five minutes data acquisition period nociception indices are recorded every minute (T0, T1, T2, T3, T4, T5). The highest SPI, PPI and NOL are used for further analysis.
75776857|NCT05057884|Behavioral|Breathing training|Slow nasal breathing with intermittent end-expiratory apnoea for 15 min twice per day over 12 weeks.
75776858|NCT05051995|Drug|Open-label placebo|Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
75776859|NCT05051995|Other|No-treatment|During the no-treatment phase, participants receive no treatment for 2 weeks.
75623858|NCT00628368|Genetic|gene expression analysis|
75623859|NCT00628368|Genetic|mutation analysis|
75623860|NCT00628368|Genetic|polymorphism analysis|
75776860|NCT05039554|Behavioral|Acceptance and commitment therapy|Intervention will be provided over 12 weeks with weekly 1-hour sessions using a group format with the overall goal to foster psychological flexibility. ACT will assist participants to notice their internal triggers; abandon their attempts to manage these triggers via active avoidance (suppression or other control-based strategies including opioid or other substance use) and to make commitments to engage in behaviors consistent with their chosen values or goals (rather than allowing negative thoughts, feelings, or pain symptoms to dictate behavior).
75776861|NCT05039554|Other|Valera Smartphone Application|For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.
76073669|NCT05586165|Behavioral|Flu Tag Along|This message will also encourage patients to protect themselves against the flu by asking for their flu vaccine at the booster appointment (at UCLA Health) or adding the flu vaccine to the COVID-19 vaccine booster appointment (at CVS).
75776862|NCT05039554|Other|Treatment as Usual|TAU for BUP treatment typically consists of regularly scheduled visits every 1-2 months with primary care physicians and/or nurse care managers in Montefiore primary care settings. During these 15-min follow up visits, providers typically inquire about opioid and other substance use, opioid craving, symptoms of opioid withdrawal, and risk of relapse. In addition, at each visit, urine toxicology tests are conducted and providers review results of prior urine toxicology tests with patients. If opioid or other substance use is ongoing, typically providers will intensify treatment, including increasing the frequency of visits, referring to social workers or mental health providers, recommending self-help groups, and/or recommending outpatient drug treatment programs (e.g., individual and group counseling).
75776863|NCT05039151|Biological|interstitial fluid sampling|The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
75623861|NCT00628368|Other|laboratory biomarker analysis|
75623862|NCT00628368|Procedure|biopsy|
75623863|NCT00628368|Procedure|endoscopic biopsy|
75623864|NCT02872350|Device|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
75776864|NCT05039151|Biological|blood sampling|A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
75776865|NCT05036018|Device|ACURATE neo2|The ACURATE neo2 valve will be implanted using a two-step mechanism during transfemoral transcatheter aortic valve implantation (TAVI). Balloon predilatation will be recommended in the ACURATE neo 2 valve group.
75798427|NCT01169142|Dietary Supplement|Vitamin D3|50,000 units of Vitamin D3 weekly
75798428|NCT01169142|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 units weekly
75914030|NCT05829434|Drug|Magrolimab|Patients will receive magrolimab on day 1; 4: IV 1 mg/kg; day 8: IV 15 mg/kg; day 11, 15 and 22: IV 30 mg/kg (plus 30 mg/kg for 5 weeks weekly and then q2w until the end of consolidation)
75914031|NCT05829434|Drug|7+3|"Patients will receive during Induction cycle 1: cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on study days 3, 4, 5~optional during Induction cycle 2: cytarabine at 100 mg/m² on days 1-7 of the second induction cycle (i.e. study days 29-35) as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on days 3, 4, 5 of the second induction cycle (i.e. study days 31, 32, 33)~optional during Consolidation cycle: cytarabine at 1 g/m² administered on days 1, 3, 5 of each consolidation cycle as an infusion for 2 hours every 12 hours (for patients < 60 years up to 3 CONS cycles and for patients ≥ 60 years up to 2 CONS cycles)"
75623865|NCT00917553|Drug|doxycycline monohydrate|50 mg
75623866|NCT00917553|Drug|Placebo|Cellulose Placebo Capsule
75914032|NCT05829434|Drug|CPX-351|"Patients will receive during Induction cycle 1: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 1, 3, 5~optional during Induction cycle 2: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 29 + 30~optional during Consolidation cycle: CPX-351 with daunorubicin 29 mg/m² and cytarabine 65 mg/m² on days 1, 3"
75914033|NCT05828693|Behavioral|SysLife©|Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.
75623867|NCT04809909|Procedure|Peripheral stimulation of acupuncture points (PSAP)|Electrode leads will be implanted at Bladder 25-bilateral (BL25), the acupoint commonly used for relief of chronic Low Back Pain in standardized acupuncture.
75623868|NCT04809909|Procedure|Peripheral nerve field stimulation (PNFS)|Electrode leads will be implanted at the region of pain.
75623869|NCT05251857|Behavioral|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|Behavioral: Animation Education Program The investigators will apply Animation Education Program.
75914034|NCT05828693|Behavioral|SysLife©, as intervention after closing the RCT-design|Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
75623870|NCT04747509|Other|Blackburn exercises|"Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
75776866|NCT05036018|Procedure|minimalist approach|Isolated local anesthesia. Central venous lines, additional arterial lines for blood pressure monitoring, and urinary catheters will be avoided. Insertion of temporary pacemakers is optional and should be avoided whenever possible, and peri-procedural pacing can then be performed on the left ventricular wire. Presence of an anesthesiologist is optional. Patients will be directly transferred to the cardiology ward after the procedure, which can be postponed in case of complications.
75776867|NCT05036018|Device|CoreValve Evolut Pro and Pro+|The Evolut Pro or Pro+ valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.
75776868|NCT05036018|Procedure|Standard of care|Sedation should be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -2 according to local standard of care.The use of EEG monitoring (i.e. BIS, Sedline) can be applied. Continuous CO2-monitoring via face mask should be established during sedation. All patients will receive supplemental oxygen by face mask to maintain an oxygen saturation of approximately 95%. Presence of an anesthesiologist is obligatory. The use of central venous catheters, additional arterial lines for blood pressure monitoring, and urinary catheters can be implemented according to local institutional standards.
75776869|NCT05029934|Procedure|use of EndoClot|deployment of EndoClot adhesive spray
75321265|NCT00700375|Drug|Sodium Chloride|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
75776870|NCT05025423|Drug|Venetoclax Oral Tablet [Venclexta]|Sequential dose levels for Venetoclax dependent on patient response. Fixed doses of 375 mg/m2 rituximab. Fixed dose of Bendamustine 90 mg/m2 added for those with continued PR at Cycle 8
75914035|NCT05828641|Procedure|Supination-flexion maneuver|In the Supination-flexion group, the forearm will be supinated first, followed by full flexion of the elbow joint (Supination-flexion maneuver).
75914036|NCT05828641|Procedure|Hyperpronation maneuver|In the hyperpronation group, the forearm will be pronated with the child's palm facing down (hyperpronation maneuver).
75914037|NCT05825937|Device|ClearSight System|Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.
75776871|NCT05024994|Drug|E7820|100mg of E7820 QD
75776872|NCT05023993|Other|Exercise Intervention|Complete home exercise
75914038|NCT05824780|Other|Exercise training|4-week weightlifting strength training
75914039|NCT05824611|Other|collect movement data from epileptic seizures|non-invasive recording of movement data during care as usual
75914040|NCT05822596|Device|Tablet-based interactive games experimental group intervention|"The program consists of 24 facilitated sessions and, depending on the capability of the participants, the availability of mobile devices and the service setting, 0 - 84 non-facilitated sessions.~In 30-minute facilitated session, a program facilitator will lead 1-8 participants in playing the tablet-based interactive games and helpers (e.g., health workers, program workers, and volunteers) will assist the program facilitator in running the sessions. The games may be played individually or together with other participants. In non-facilitated sessions, the participants can play cognitive games depending on the capability of themselves and at their own pace for 10 - 30 minutes"
75914041|NCT05822414|Procedure|Erector spinae plane block|Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
75776873|NCT05023993|Dietary Supplement|Nicotinamide Riboside|Given PO
75776874|NCT05021926|Device|DKL crosslinked sodium hyaluronate 26|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 26 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
75776875|NCT05021926|Device|Juvéderm Voluma™ with lidocaine (Allergan, Inc)|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Voluma™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
76073670|NCT05586165|Behavioral|COVID-19 Booster & Flu Bundle|This message will simultaneously encourage patients to enhance their protection against COVID-19 and the flu and will inform them that, to save time, they can bundle two vaccines at once. Patients will learn that at UCLA Health, they can book an appointment for the booster and then ask for the flu vaccine at their appointment; at CVS Pharmacy, they can book one appointment to get both the bivalent COVID-19 booster and the flu vaccine.
76073671|NCT03944265|Other|Counseling|Participate in treatment decision counseling session
75321266|NCT01677884|Drug|Bevacizumab|Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
75776876|NCT05021913|Device|DKL crosslinked sodium hyaluronate 23|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 23 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
75798429|NCT01169220|Drug|Go-Lytely|Bowel cleansing agent
75321267|NCT01677884|Drug|Capecitabine|Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
75321268|NCT01677884|Drug|Irinotecan|Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)
75321269|NCT02124083|Drug|Vorinostat|Histone deactylase inhibitor
75321270|NCT02405078|Drug|Chemotherapy|Given standard salvage chemotherapy
75321271|NCT02405078|Procedure|Computed Tomography|Undergo FDG-PET/CT scan
76073672|NCT03944265|Other|Questionnaire Administration|Ancillary studies
76073673|NCT03944265|Other|Medical Chart Review|Ancillary studies
75776877|NCT05021913|Device|Juvéderm Volift™ with lidocaine (Allergan, Inc)|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Volift™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
76073674|NCT04148547|Device|Sooma transcranial direct current stimulation device|This group received brain training through transcranial direct current for 20 minutes.
75466558|NCT01910714|Behavioral|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
76073675|NCT04148547|Device|Placebo Sooma transcranial direct current stimulation device|This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
75321272|NCT02405078|Drug|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
75623871|NCT04747509|Other|Conventional Physical therapy|"Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
75321273|NCT02405078|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT scan
75623872|NCT04255251|Drug|Silver Diammine Fluoride|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
75623873|NCT04255251|Drug|Fluoride Varnishes|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
75776878|NCT05021328|Drug|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
75776879|NCT05021328|Drug|Anlotinib|Anlotinib 12 mg/d, d1-14, q3w.
75776880|NCT05021328|Drug|SBRT 7Gy✖️5 QD|SBRT 7Gy✖️5 QD
76073676|NCT03588897|Dietary Supplement|Nutridrink Multi Fibre|Dietary supplementation of 300 kcal for 14 days
76073677|NCT03941847|Other|music|listening music
76073678|NCT05582421|Drug|Diclofenac Sodium|intracanal medication
75321274|NCT00701389|Drug|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
75321275|NCT00701389|Drug|sumatriptan|single oral dose of 100 mg sumatriptan
75623874|NCT04859439|Drug|DBPR108 tablets|Drug: DBPR108, tablet, oral
75623875|NCT04855851|Procedure|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|The subjects of this group will receive an amount of six sessions that will be applied within 12 weeks. Every 15 days, the subjects will come for a consultation to receive a PNE session and review of the exercise program, which will be carried out 3 times a week for 12 weeks.
75776881|NCT05018910|Other|Skin to Skin|During routine Skin-to-skin sessions, the heart rate variability of the infant will be measured.
75776882|NCT05016037|Behavioral|Lexically based speech recast|a child's spontaneous or elicited production containing phonological errors is immediately followed with a clinician model that corrects the error(s) at the word level rather than the isolated phoneme level. As an example, a speech recast of child's production of the word bake as [be] would be the whole lexeme bake [bek] rather than production drill on [k] in isolation.
75776883|NCT05011292|Behavioral|Educational Video about SCB|3-4 minutes video about SCB.
75776884|NCT05011292|Behavioral|Survey on child feeding and related knowledge and practices|Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.
76073679|NCT03897933|Procedure|Erector Spinae Plane block ( Group I)|ESP Block was performed preoperative to all patients in ESP block group. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
76073680|NCT03897933|Procedure|non- blocked Group (GROUP II)|This group was received no intervetion. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
75321276|NCT00701389|Drug|sumatriptan placebo|single oral dose
75321277|NCT00701389|Drug|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
75321278|NCT01796587|Device|LoFric Origo|
75321279|NCT02336594|Drug|RDEA3170 10 mg|
75321280|NCT02336594|Drug|RDEA3170 2.5 mg|
75321281|NCT03964181|Other|Change in school start times|Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.
75321282|NCT01799317|Drug|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
75321283|NCT01677962|Biological|Poly-ICLC|
75321284|NCT01677962|Biological|dendritic cell|
75321285|NCT05161247|Other|Zona pellucida sperm selection|Sperm selection for ICSI based on the spermatozoa ability to adhere to immobilized zona pellucida proteins.
75321286|NCT05161247|Other|Conventional sperm selection|Sperm selection for ICSI based on the sperm morphology.
75776885|NCT05011292|Behavioral|Educational Video other than SCB|Educational video about a topic other than infant SCB consumption.
75321287|NCT05161247|Other|Intracytoplasmic Sperm Injection (ICSI)|Normal ICSI procedure.
75776886|NCT05001620|Other|Palliative Care Consultation|The PC provider conducts the structured PCC-PAC via videoconference or telephone with the PLWD and/or their care partner and the social work (SW) champion in the NH. The SW and PC provider will set up a mutually agreed upon consultation day/time with the PLWD and/or care partner, within 5 business days of NH admission and follow up visits will occur no more than 30 days later (if needed).
75776887|NCT04999241|Combination Product|exclusive enteral nutrition|Administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks, then patients can administration of regular food.
75776888|NCT04999241|Combination Product|regular food|Administration of regular food in the induction phase and the later time.
75776889|NCT04992065|Drug|NNC0385-0434 A 15 mg|15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
75776890|NCT04992065|Drug|NNC0385-0434 A 40 mg|40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
75776891|NCT04992065|Other|Placebo I A (for NNC0385-0434 A 15 mg)|Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level
75776892|NCT04992065|Drug|NNC0385-0434 A 100 mg|"100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces)."
75776893|NCT04992065|Other|Placebo I A (for NNC0385-0434 A 40 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
75776894|NCT04992065|Other|Placebo II A (for NNC0385-0434 A 100 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
75776895|NCT04992065|Drug|Evolocumab 140 mg/mL, Repatha®|"Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL"
75776896|NCT04985747|Other|Polished palatal surface|Polishing of the anterior palatal surface using a polisher
75321288|NCT00595153|Drug|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
75321289|NCT03419468|Other|Self Geriatric Assessment Measure (SGAM)|Self Geriatric Assessment Measure
75623876|NCT04855851|Procedure|USUAL CARE|"Aerobic exercises will consist of a standard table of low intensity stretching exercises, commonly prescribed to fibromyalgia patients. There will be three series of 30 seconds of each stretch, having a total duration of approximately 40 minutes. Each session will be held twice a week, following the recommendations of the American College of Sport Medicine. Monitoring will be performed every 15 days by a physiotherapist."
75623877|NCT01018680|Drug|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
75623878|NCT01018680|Drug|Placebo|Taken by mouth, once daily for 10 weeks
75623879|NCT04255017|Drug|Abidol hydrochloride|Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
75623880|NCT04255017|Drug|Oseltamivir|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
75623881|NCT04255017|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
75623882|NCT04255173|Diagnostic Test|Body mass index|Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
75776897|NCT04985747|Other|Roughened palatal surface|Roughening of the anterior palatal surface using a sandblaster
75776898|NCT04985747|Other|Opened palatal surface|Opening of the anterior palatal surface using acrylic bur
75776899|NCT04967690|Drug|SI-053|SI-053 will be used as an add-on to SoC for newly diagnosed GBM.In conjunction with surgical resection, SI-053 will be applied intracranially (i.c.) into the cavity that is formed after tumor resection. Post-operative chemoradiotherapy (including concomitant and adjuvant TMZ or following the CeTeG protocol) will be initiated at least 21 and no later than 35 days after SI-053 administration.
75776900|NCT04965857|Diagnostic Test|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
75776901|NCT04954326|Drug|Lyophilized S95014|"Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
75623883|NCT04255173|Diagnostic Test|waist circumference|waist circumference is measured as cm
75623884|NCT04255173|Diagnostic Test|hip circumference|hip circumference is measured as cm
75321290|NCT05151965|Procedure|Bankart Repair and Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
75321291|NCT05151965|Procedure|Latarjet Coracoid Transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
75623885|NCT04255173|Diagnostic Test|height|height is measured as cm
75321292|NCT02995291|Drug|OraVerse|1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
75623886|NCT04255173|Diagnostic Test|Fat percentage|Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
75623887|NCT04255173|Diagnostic Test|Skeletal muscle index|Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height [m2].
75321293|NCT02995291|Drug|Saline Water (Control)|1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
75623888|NCT04255173|Diagnostic Test|A body shape index (ABSI)|ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
75623889|NCT04255173|Diagnostic Test|Dual energy x ray absorptiometry (DXA)|Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
75623890|NCT04255173|Diagnostic Test|The Rapid Assessment of Physical Activity (RAPA) aerobic assessment|Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
75623891|NCT04255095|Procedure|experiment|Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。
75623892|NCT04255095|Procedure|control|Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
75623893|NCT04592991|Diagnostic Test|Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.
75623894|NCT04592991|Diagnostic Test|AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.
75623895|NCT01012440|Device|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
75623896|NCT01012440|Device|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
75623897|NCT00916929|Device|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
75623898|NCT04299750|Procedure|Tooth extraction and Alveolar ridge preservation|Tooth extraction and alveolar ridge preservation with deproteinized bovine bone mineral and a collagen matrix seal
75623899|NCT04299750|Procedure|Tooth extraction|Tooth extraction and socket natural healing
75623900|NCT04299516|Procedure|Two-team simultaneous bilateral total knee arthroplasty|Bilateral total knee arthroplasty can be performed in three different ways: single-stage, two-team simultaneous bilateral total knee arthroplasty; single-stage, one-surgeon, and two-stage bilateral total knee arthroplasty. Two surgeons will operate simultaneously on one side for two-team SBA.
75623901|NCT04299516|Procedure|Single-team simultaneous bilateral total knee arthroplasty|One surgeon will operate sequentially on both sides for one-surgeon SBA
75623902|NCT02872194|Drug|BAY987516, Y55-170|10 uL in one eye
75623903|NCT02872194|Drug|BAY987516, X72-151|10 uL in one eye
75776902|NCT04954326|Drug|Liquid S95014|"Liquid S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
75321294|NCT02408432|Other|Laboratory Biomarker Analysis|Correlative studies
75321295|NCT02408432|Other|Standard of Care|Undergo mesenchymal stem cell infusion
75321296|NCT02408432|Drug|Mesenchymal Stem Cell Transplantation|Undergo mesenchymal stem cell infusion
75321297|NCT01798043|Other|Cardiac MRI with pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
75321298|NCT01798043|Other|Cardiac MRI with and without pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
75321299|NCT03087734|Device|Implantation of new model of bar with oblique stabilizers|Implantation of new model of bar with oblique stabilizers
75623904|NCT02872194|Drug|BAY987516, Y49-034|10 uL in one eye
75623905|NCT02872194|Drug|Standard shampoo mixture (control)|10 uL in one eye
75776903|NCT04942717|Behavioral|CONVO intervention|The CONVO intervention consists of oncology nurse-led discussions exploring patients' health-related values as part of routine oncology care for all patients, from the beginning of oncologic care. Nurses will use the Nurse's Values Discussion Guide. At these sites, chemotherapy nurses will deliver the CONVO discussion, as patients at these sites do not have primary nurses assigned and because oncology doctors, BPs and PAs do not work one-on-one as a pair with a unique nurse.
75776904|NCT04942574|Other|Total sleep deprivation|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.
75623906|NCT04298736|Procedure|Bariatric Surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy
76073681|NCT03588663|Device|Baseline Bionic Leg Assessment|The 'Bionic Leg' (BL) [Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.
76073682|NCT03588663|Other|Baseline Control Condition Assessment|Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.
75623907|NCT04298736|Behavioral|Lifestyle modification|guided low-calorie diet and physical activity.
75623908|NCT02871336|Other|Data collection|
75623909|NCT00844597|Drug|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
75623910|NCT01017120|Drug|Tazarotene Foam|Tazarotene foam once a day application to the face
75623911|NCT01017120|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
75623912|NCT04297410|Radiation|177Lu-PSMA-I&T Radionuclide|Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
75623913|NCT04298580|Procedure|PVB block|PVB block before surgery versus after surgery
75623914|NCT02872038|Drug|Cefepime|Cefepime intraperitoneal continuous dosing
75623915|NCT02872038|Drug|Cefazolin plus Ceftazidime|
75623916|NCT02871804|Procedure|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
75623917|NCT02871804|Procedure|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
75623918|NCT04298424|Other|PLSM|The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
75623919|NCT01016964|Device|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
75623920|NCT01016964|Device|Sham Device|Sham Device
75623921|NCT00627900|Device|bare metal stent|implantation of a bare metal stent
75623922|NCT00627900|Device|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
75623923|NCT04299360|Device|Cardiac Resynchronization Therapy device programming|Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
75623924|NCT02996110|Biological|Nivolumab|Specified Dose on Specified Days
75623925|NCT02996110|Biological|Ipilimumab|Specified Dose on Specified Days
75623926|NCT02996110|Biological|Relatlimab|Specified Dose on Specified Days
75623927|NCT02996110|Drug|BMS-986205|Specified Dose on Specified Days
75623928|NCT02996110|Drug|BMS-813160|Specified Dose on Specified Days
75623929|NCT04213768|Procedure|Lateral rectus plication|The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.
75623930|NCT04213768|Procedure|Lateral rectus Resection|Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
75623931|NCT00916617|Drug|bapineuzumab|5 mg/week subcutaneous bapineuzumab
75623932|NCT04214236|Device|ciNPT group|Closed-incision negative pressure therapy (ciNPT) will be applied for 7 day using continuous suction at 125 mmHg. To deliver ciNPT we will use a commercially available, FDA-approved device, used according to the manufacturer' indications (PREVENA™ Incision Management System (KCI, San Antonio, Texas, USA). After the first 7 post-operative days, subjects will discontinue the ciNPT and follow a standard wound care protocol.
75623933|NCT04214236|Other|Control group|Standard non-adherent surgical dressing (Vaseline petrolatum gauze) will be used for management of incisional wounds in the control group. Dressing changes will be performed per standard wound care protocol.
75623934|NCT01103063|Drug|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
75623935|NCT01103063|Drug|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
75321300|NCT03087734|Device|Implantation of regular bar with perpendicular stabilizers|Implantation of regular bar with perpendicular stabilizers
75321301|NCT04403048|Procedure|Provisional DCB approach PCI procedure|Intervention is explained in detail in group description
75321302|NCT04403048|Procedure|Standard provisional approach PCI procedure|Intervention is explained in detail in group description
75321303|NCT00595231|Drug|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
75321304|NCT00595231|Drug|Placebo|0 mg tablets
75776905|NCT04942574|Other|Normal sleep|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.
75776906|NCT04933435|Other|Quality of life questionnaires|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
75776907|NCT04927364|Device|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil|The study will utilize the H7 coil to administer Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
75776908|NCT04914819|Behavioral|Online Behavioral Weight Loss Program|Participants will be enrolled in a 16-week online behavioral weight loss program based on the Diabetes Prevention Program (DPP). The program involves weekly brief videos, a self-monitoring platform, automated feedback, and access to a health coach.
75623936|NCT04214158|Other|Assessment|Assessment
75623937|NCT02987998|Drug|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
75776909|NCT04914819|Behavioral|Virtual weigh-in|Participants will be sent a digital scale and will be asked to complete a virtual weigh-in at home at the start of the study and again after 16 weeks.
75776910|NCT04913077|Other|removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
75776911|NCT04906096|Drug|PAXALISIB|Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol
75776912|NCT04905537|Other|No intervention|It's only observational study. No interventions.
75776913|NCT04902339|Behavioral|Mindfulness-Oriented Recovery Enhancement|8 weeks of therapy integrating mindfulness, reappraisal, and savoring skills.
75776914|NCT04902339|Other|Neurofeedback|Near-infrared spectroscopy neurofeedback during savoring practice.
75776915|NCT04902339|Behavioral|Supportive Psychotherapy|8 weeks of supportive, process-oriented psychotherapy.
75776916|NCT04898114|Drug|Magnesium sulfate|Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
75776917|NCT04898114|Drug|Sildenafil Citrate|Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
75776918|NCT04898114|Other|Isotonic saline|Nebulized isotonic saline (4 ml) every 15 minutes
75776919|NCT04897217|Drug|Megestrol Acetate|The control arm will consist of oral progesterone therapy (megestrol acetate 160mg po daily). The intervention will be administered on an outpatient basis.
75914042|NCT05818501|Device|The dysphagia cups|"After the training period of the one of dysphagia cups, participants will start using cup to consume water during a designated period of time every day.~Participants consuming water with Cup A will drink from a static position with their chins towards their chests, the so-called Chin-Tuck maneuver. This position leads epiglottal naturally covering the trachea and causes liquid only ﬂowing to the esophagus and thus stomach. The restoring force of the membrane ensures a constant level of liquid at the upper edge of the cup and thus enables this preferred and safe drinking position.~Cup B limits the maximum volume of water flowing out of the Cup B designated by the staff. Controlled liquid flow prevents overflowing the mouth and gulping, thus reduces the risk of choking and liquid aspiration. Participants can choose to drink the water from Cup B with a straw when necessary."
75914043|NCT05818488|Other|Experimental mind-body intervention|A meditation will be guided by an audio through headphones. The audio will last 15 minutes with an initial invitation to centering (full attention to the state of the body and the breath, bringing the attention to the present moment), followed by body scanning, followed by targeting the seven dimensions of interoceptive capacity (noticing, not being distracted, not worrying, attentional regulation, emotional awareness, self-regulation, and trust), and the passive control group (waiting room)
75776920|NCT04897217|Drug|Levonorgestrel Drug Implant|Participants in the comparison arm will have a levonorgestrel intrauterine device placed in the office or in the operating room if the office procedure not tolerated or if they have not had a prior dilation and curettage.
75776921|NCT04892251|Combination Product|MORE+KAP|Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly
75776922|NCT04892251|Behavioral|MORE|Mindfulness-Oriented Recovery Enhancement
75798430|NCT01169220|Drug|Go Lytely|Bowel cleansing agent
75321305|NCT02400554|Behavioral|Yappalli|"Month 1-3: Up to 8 group sessions on Choctaw history, traditions, cultural systems, & women's roles. Up to 3 individual Motivational Interviewing (MI) sessions to identify community leadership & personal change goals on the main outcome.~Month 2: Overnight Culture Camp to strengthen group cohesion & synthesize goals.~Month 3: Walk for a week on the Choctaw Trail of Tears, upon completion make a commitment to conduct a community-wide event based on personal & leadership goals & experience on the Trail.~Months 3-12: Up to 6 group meetings to plan community leadership events related to ATOD & obesity prevention. Includes: digital storytelling training to create a story related to ATOD & obesity prevention & an individual MI booster session to revise their personal & community leadership goals.~Month 12: Share digital stories & community event experiences & undergo a ceremony to transition to health leaders within their communities."
75321306|NCT02995603|Device|Nano-X patient rotation|Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
75321307|NCT03736733|Other|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
75623938|NCT02987998|Drug|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
75623939|NCT02987998|Drug|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
75623940|NCT02987998|Drug|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
75623941|NCT04141306|Other|Administrative data|Evaluation of month and year of birth, sex, referent doctor and surgeon
75623942|NCT04141306|Other|Clinical data|Evaluation of diagnostic circumstances, vital status at last follow up
75623943|NCT04141306|Other|Histological data|Evaluation of Pathology report of thyroid surgery
75623944|NCT04141306|Other|Imaging data|Evaluation of scintigraphy, MRI, scan
75776923|NCT04888221|Drug|Tocilizumab|"Tocilizumab will be administered subcutaneously at a dose of 162mg/0.9mL weekly (each week, on the same day) from week 0 to week 24.~At the first injection (Baseline D0), a therapeutic education is provided for patients/caregivers who can carry out the injections themselves as part of their usual care."
75776924|NCT04888221|Drug|Placebo|Placebo administered subcutaneously (SC) weekly during 24 weeks
75776925|NCT04875624|Diagnostic Test|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
75776926|NCT04875091|Behavioral|Ready SET Health|"This behavioral weight loss intervention will span 16 weeks. The first session (Week 1) will be a virtual Weight Loss 101 group kick-off followed by 15 weeks of a technology-mediated program consisting of the following: weekly emailed content (videos and readings explaining key skills and strategies to produce weight loss) and weekly emailed tailored feedback (based on self-monitoring data from participants). A trained interventionist (coach) will lead the group session, provide weekly tailored feedback, and monitor participant progress."
75914044|NCT05816733|Drug|Dapagliflozin|Patients randomized in this arm will receive dapagliflozin at a target dose of 10mg once daily and routine treatment.
75914045|NCT05816733|Drug|Placebo|Patients randomized in this arm will receive placebo at a target dose of 10mg once daily and routine treatment.
75776927|NCT04870203|Drug|baricitinib treatment|4 mg daily during 12 months
75914046|NCT05813223|Drug|Gefapixant|Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.
75914047|NCT05804552|Device|Dorsal genital nerve stimulation|Two types of stimulation electrodes will be used: UCon Patch Electrodes (InnoCon Medical ApS, Denmark) and ValuTrodes/EconoStim Electrodes (5x5 cm, Axelgaard Manufacturing Co. Ltd., United States). The UCon Patch Electrode acts as a cathode and will be placed on the clitoris. The ValuTrode/EconoStim acts as an anode and will be placed on the lower abdomen. The continuous stimulation consists of a train of single pulses provided continuously with a frequency of 20 Hz and a pulse duration of 200 μs. The burst stimulus pattern consists of a train of bursts. The length of the train is 10 s and will consist of 20-30 bursts/s. One burst consists of 5 identical square pulses (monophasic). The inter-pulse interval is 4 ms (time between the onset of 2 consecutive pulses) while a pulse duration of 200 μs will be used.
75914049|NCT05794425|Drug|Cyclosporine A|3-5 mg per kilogram per day.
75914050|NCT05794425|Biological|Umbilical cord blood & Umbilical cord derived mesenchymal stem cells|Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10^7) at 1 week interval.
75914051|NCT05793736|Device|Biofeedback training|The intervention lasts 5 weeks, twice a week, each session lasts 45 minutes in which HRV (Heart Rate Variability) is detected, through plethysmographic sensors placed on the finger or earlobe during assigned tasks. During tasks that involve progressively more complex phases, they allow the person to receive immediate feedback on the video screen.
75914052|NCT05793736|Drug|Treatment as usual|The sample will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
75914053|NCT05792007|Procedure|Biological sampling in patients|blood and bone marrow samples from patients with Acute Leulemia.
75914054|NCT05792007|Procedure|Biological sampling in control patients|blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
75914055|NCT05791708|Drug|Sutimlimab|CAD patients in Sutimlimab cohort must be treated according to routine clinical practice
75321308|NCT03736733|Other|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
75321309|NCT02995057|Device|Gold- or silver-coated, or uncoated nickel microneedles|The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
75623945|NCT04141306|Other|Biological data|Evaluation of thyroglobulin, antithyroglobulin antibodies
75623946|NCT04141306|Other|Further treatment|Evaluation of surgery, radiotherapy, targeted therapy
75623947|NCT04213378|Device|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon
75623948|NCT04213378|Device|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon
75623949|NCT02879591|Other|Social Skills training with Avatar therapist|
75623950|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^10 DNase resistant particles (DRP) / mL joint volume
75776928|NCT04870203|Drug|adalimumab|40 mg every 2 weeks during 6 monts
75914056|NCT05791565|Drug|Salbutamol HFA-152a|Salbutamol HFA-152a will be administered.
75914057|NCT05791565|Drug|Salbutamol HFA-134a|Salbutamol HFA-134a will be administered.
75914058|NCT05791474|Drug|ATI-2231|Provided by Aclaris Therapeutics, Inc.
75914059|NCT05789979|Device|The resident-handling device|Care staff will perform resident-handling tasks using the new resident-handling devices. For low dependency during trial, the device helps care staff to assist residents in making a transition from a sit to a standing posture, vice versa. This device is used for functional activities and transferring and lifting participants. For high dependency during trial, when care staff are performing resident-handling tasks, the device moves with little force in any direction.
75914060|NCT05789901|Other|MARVIN|Chatbot on Meta (Facebook) Messenger for HIV Patients
75914061|NCT05789901|Other|MARVIN-Pharma|Chatbot on Meta (Facebook) Messenger for community pharmacists
75914062|NCT05789901|Other|MARVINA|Chatbot on Meta (Facebook) Messenger for breast cancer patients
75914063|NCT05789901|Other|MARVIN-CHAMP|CHatbot to Assist the Management of Pediatric patients with Infectious conditiONS
75914064|NCT05787652|Behavioral|ARTEMIS mobile app|Access to a self-regulation based mobile application.
75914065|NCT05786118|Other|No intervention|There is no intervention in this study
76073683|NCT03588663|Other|Training|Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.
76073684|NCT03588663|Other|Follow-up Assessment|45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
75623951|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single dose 1x10^11 DNase resistant particles (DRP) / mL joint volume
76073685|NCT03580473|Drug|SATURNO II association|opthalmic solution, 4 times a day
75321310|NCT05102279|Dietary Supplement|Giving subjects different phosphorus diets at different stages of the trial|Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg
75321311|NCT02474173|Other|Laboratory Biomarker Analysis|Correlative studies
75321312|NCT02474173|Drug|Onalespib|Given IV
75776929|NCT04870203|Drug|Placebo|40 mg every 2 weeks during 6 months
75321313|NCT02474173|Drug|Paclitaxel|Given IV
75321314|NCT02474173|Other|Pharmacological Study|Correlative studies
75776930|NCT04867707|Drug|Zanamivir|5 days of treatment with 10mg zanamivir inhaler BID
75776931|NCT04867447|Diagnostic Test|Psychological trauma evaluation|"Psychological trauma exposure is assessed by validated scales:~Childhood Trauma Questionnaire (CTQ)~Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)~Cumulative Trauma Scale.~The Holmes and Rahe Stress Scale.~Other clinical scales used:~Positive and Negative Syndrome Scale (PANSS).~Dissociative Experiences Scale (DES)~Mini-Mental State Examination (MMSE)."
75776932|NCT04860661|Drug|Esketamine|After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump
75776933|NCT04860661|Drug|Normal saline|10 ml normal saline
75776934|NCT04853199|Drug|Quercetin|Each patient should receive one tablet twice a day 30 minutes before the meal
75776935|NCT04853199|Drug|Placebo|Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
75776936|NCT04841590|Other|Intervention of the experimental group (EG)|Treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
75776937|NCT04841590|Other|Control Group (CG)|Subjects in the control group (CG) will not receive any treatment
75776938|NCT04834297|Other|Prapela SVS mattress|The intervention will be using the Prapela SVS crib mattress to complement non-pharmacological management of NOWS for the purposes of prevention of pharmacological treatment of NOWS
75776939|NCT04826991|Device|Active UV Device|Active water treatment system
76073686|NCT03580473|Drug|Vigadexa®|opthalmic solution, 4 times a day
76073687|NCT03581721|Device|enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer|"The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group"
76073688|NCT04148859|Procedure|amnioreduction|The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate.
75321315|NCT03482102|Drug|Tremelimumab|Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
75623952|NCT00617032|Genetic|tgAAC94 placebo|Single dose
75623953|NCT02877953|Behavioral|the prevention of complications post-TIPS|Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.
75623954|NCT04213924|Drug|Bupivacaine HCl 0.5 % in 10 ml and 2 % lidocaine in 10 ml|Erector spinae plane block, 30 min before the ESWL procedure.
75623955|NCT04213924|Drug|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
75623956|NCT00616720|Biological|aldesleukin|
75776940|NCT04826991|Device|Inactive UV Device|Inactive water treatment system
75776941|NCT04818346|Drug|INCB054707|INCB054707 will be administered once daily
75776942|NCT04818346|Drug|Placebo|Placebo or INCB054707 will be administered once daily
75776943|NCT04813276|Behavioral|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.
75776944|NCT04813276|Behavioral|Enhanced Care as Usual|A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
75623957|NCT00616720|Biological|idiotype-pulsed autologous dendritic cell vaccine APC8020|
75321316|NCT03482102|Drug|Durvalumab|Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
75623958|NCT00616720|Biological|recombinant interferon gamma|
75623959|NCT00616720|Genetic|polymerase chain reaction|
75623960|NCT00616720|Genetic|reverse transcriptase-polymerase chain reaction|
75623961|NCT00616720|Other|flow cytometry|
75623962|NCT00616720|Other|laboratory biomarker analysis|
75623963|NCT01091675|Drug|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
75623964|NCT00620230|Drug|NVP-VAK694|
75623965|NCT00620230|Drug|NVP-VAK694|
75623966|NCT00617110|Other|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
75623967|NCT00617110|Other|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
75623968|NCT04140370|Other|There is no intervention|There is no intervention
75623969|NCT02739412|Biological|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
75623970|NCT04213612|Drug|pegylated liposomal doxorubicin, cyclophosphamide, vincristine,|PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity
75623971|NCT01091519|Other|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
75623972|NCT01091519|Other|Toviaz(fesoterodine) without educational materials|No educational materials
75321317|NCT03482102|Radiation|Radiation|Radiation therapy is used to shrink cancer cells.
75776945|NCT04812171|Procedure|non-surgical endodontic treatment|standard non-surgical endodontic treatment performed by endodontic specialist
76073689|NCT03588507|Combination Product|PPF+NCHA bone graft substitute|nanocrystalline hydroxyapatite bone graft is a a newly developed HA containing about 65% water and 35% nanostructured apatite particles. This gave the nanocrystalline hydroxyapatite bone graft many advantages such as providing a close contact with the surrounding tissues, bioresorbability and extremely high number of nano-sized particles and molecules on the surface .
76073690|NCT03897309|Biological|VXA-G1.1-NN|Monovalent GI.1 tableted vaccine
75321318|NCT02995135|Drug|BAY987517|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z43-094)"
75321319|NCT02995135|Drug|SFP Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75623973|NCT00620308|Drug|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
75623974|NCT00620308|Drug|Placebo|Dextrose 5% in water (the vehicle)
75623975|NCT02878031|Drug|Oral amoxicillin for CI pneumonia|"CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age <12 months (4 - <10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age <3 years (10 kg - <14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children <5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days."
75623976|NCT00572962|Procedure|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
75623977|NCT02879669|Biological|ONCOS-102|
75623978|NCT02879669|Drug|Pemetrexed/cisplatin (carboplatin)|
75623979|NCT02879669|Drug|Cyclophosphamide|
75623980|NCT04213690|Other|No Intervention|There is no intervention for this study
75776946|NCT04808271|Dietary Supplement|Bifidobacterium breve Bif195|1 capsule daily for 8 weeks
75321320|NCT01798199|Other|The training by Verve System|
75321321|NCT02402270|Drug|NuLYTELY® (PEG 3350)|
75321322|NCT02402270|Drug|ECP-019|
75623981|NCT05339321|Genetic|SCG101|SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.
75623982|NCT05339321|Biological|PD1/PD-L1 checkpoint inhibitor|Commercially approved for HCC treatment.
75623983|NCT00620386|Device|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
75623984|NCT00620386|Device|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
75623985|NCT00918333|Drug|panobinostat|Given PO
75623986|NCT00918333|Drug|everolimus|Given PO
75623987|NCT00918333|Other|laboratory biomarker analysis|Correlative studies
75776947|NCT04808271|Dietary Supplement|Placebo|1 capsule daily for 8 weeks
75776948|NCT04804722|Device|18F-FDG PET-CT (fluorodesoxyglucose positron emission tomography)|18F-FDG PET-CT exams during 30 minutes with injection of radiopharmaceutical product
75321323|NCT02402270|Drug|MoviPrep® (PEG 3350)|
75321324|NCT00701935|Drug|placebo|subcutaneous injection, twice a day
75623988|NCT00918333|Other|pharmacological study|Correlative studies
75623989|NCT04929730|Other|Nephrology care bundle|Nephrology care bundle
75623990|NCT01091363|Behavioral|Standard|10 minute brief cessation counseling
75623991|NCT01091363|Behavioral|Deep Cultural|Deep culturally tailored cognitive behavioral therapy
75623992|NCT04910542|Other|Epi-Net Intervention|The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
75623993|NCT04306757|Device|Evone|Airway ventilation device
75776949|NCT04801485|Dietary Supplement|D-chiro inositol|Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
76073691|NCT03897309|Biological|VXA-G2.4-NS|Monovalent GII.4 tableted vaccine
76073692|NCT03897309|Biological|Placebo Tablets|Tablets matching in number and appearance to active vaccine doses
75776950|NCT04801485|Dietary Supplement|Placebo|Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
75776951|NCT04799067|Other|observational study|no study drug involved, observational study.
75321325|NCT00701935|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
75914066|NCT05785897|Device|Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation|"'All-comer' subjects with acute STEMI undergoing primary PCI according to current ESC guidelines will be eligible.~Eligible subjects will be pre-treated with DAPT consisting of aspirin (loading dose: 150-300 mg orally or 80-500 mg intravenously, maintenance dose: 75-100 mg daily orally) and a potent P2Y12 receptor inhibitor, either ticagrelor (loading dose: 180 mg orally, maintenance dose: 90 mg bd orally) or prasugrel (loading dose: 60 mg orally, maintenance dose: 10 mg od orally or 5 mg od orally if age >75 years or weight <60 kg) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI.~Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation and final residual stenosis <30% by visual estimation or 20% by QCA."
75914067|NCT05785702|Device|The anti-wandering system|During the testing period, the system will promptly notify care staff if a participant enters unauthorized areas. A care staff will then go to that area and search for the participant. After the participant is found, care staff will reset the system, and then return the participant to a safe place.
75914068|NCT05784792|Other|Lugol -|Patients that undergo total thyroidectomy without Lugol solution pretreatment
75914069|NCT05784103|Device|Clarifi Modulum|During consenting period, the Modulim equipment will be calibrated and setup ready for scanning. Subject's volar aspect of the thumb along with the palm surface will be ready to target the optical camera head. Actual scanning takes less than 60 seconds. The images will be processed offline. During processing 3-5 different regions of interest will be taken to measure the oxygen parameters such as tissue oxygen saturation, oxy-hemoglobin, deoxy-hemoglobin, superficial hemoglobin, and sub-surface hemoglobin.
75914070|NCT05784103|Device|Perimed PeriFlux 5000|Transcutaneous oxygen monitoring (TCOM or TcpO2) is a noninvasive, clinically-approved method to obtain skin oxygen levels. The method is quantitative, and measures oxygen delivery to the skin from underlying tissue. Before positioning the electrode, an adhesive fixation ring will be placed on the dry skin on the volar aspect of the thumb and an electrolyte as a contact liquid will be filled half and the probe is aligned into it by rotating clock-wise to fasten it. Recording will be started and waited for the oxygen level to stabilize and a fixed value will be recorded. The probe will be heated to about 45oC. Although this device has other options, only the measurement of O2 will be performed using this device.
76073693|NCT03588429|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
76073694|NCT03588429|Drug|Isoflurane|Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
76073695|NCT03581019|Procedure|uterus transplantation|uterus transplantation from deceased donor
75776952|NCT04795141|Drug|ABY-035|ABY-035 Solution for injection
75776953|NCT04795141|Drug|Placebo|Normal Saline for injection
75776954|NCT04768907|Drug|MaaT013|
75776955|NCT04766632|Device|Brain PET-CT of 18F-DOPA|PET-CT is a nuclear medicine exam with radiopharmaceutical injection of 18F-DOPA for the patient
75776956|NCT04753970|Drug|Cilostazol|Cilostazol 100mg BID
75776957|NCT04741204|Drug|Metformin Extended Release Oral Tablet|initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.
75798431|NCT01169298|Drug|Lenalidomide|Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
75798432|NCT01169376|Genetic|DNA analysis|
75321326|NCT03087188|Other|Utilization of inhalator|"After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.~While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them."
75321327|NCT03432143|Other|Community Reviewers|Intervention manuscripts will be reviewed by both a trained community member and scientific reviewers. Community reviewers will follow each journal's instructions regarding electronic access to manuscripts, use of drop-down menus and free-text boxes to address specific aspects of the review, and completion within the time frame specified by the journal.The journal editorial team will use all reviews to make decisions about acceptance, revision, or rejection of manuscripts.
75321328|NCT03087266|Procedure|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
75321329|NCT03087266|Procedure|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
75321330|NCT02995213|Behavioral|Accelerometer based feedback about paretic arm use|
75321331|NCT02984696|Drug|1 mg of transdermal estradiol daily and 10mg of oral MPA|
75623994|NCT04306757|Device|Primus|Airway ventilation device
75623995|NCT00617266|Other|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
75623996|NCT00617266|Other|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
75623997|NCT00617266|Other|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
75623998|NCT00617266|Other|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
75776958|NCT04727723|Drug|Lutathera®|Treatment with Lutathera® will be independent from participation in this observational study and must not be initiated for the purpose of participating in this study. The decision to treat patients with Lutathera® will occur before patients are enrolled in the study.
75776959|NCT04725188|Biological|Pembrolizumab/Vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
75776960|NCT04725188|Drug|Docetaxel|Docetaxel 75 mg^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
75776961|NCT04725188|Drug|Placebo|Normal saline IV infusion Q3W up to approximately 2 years
75776962|NCT04723394|Drug|AZD7442|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
75776963|NCT04723394|Drug|Placebo|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
75321332|NCT00596167|Drug|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
75321333|NCT03087032|Drug|Liraglutide|Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
75321334|NCT03087032|Drug|insulin glargine|Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
75321335|NCT02994745|Drug|Fimasartan, Atorvastatin|
75321336|NCT03480074|Procedure|Staple Ligation|Using a stapler that staples the DVC and then cuts it.
75776964|NCT04722523|Drug|Cisplatin|Cisplatin 75mg/m2 AUC 5 on weeks 2, 5, and 8
75776965|NCT04722523|Drug|Carboplatin|Carboplatin AUC 5 on weeks 2, 5, and 8
75776966|NCT04722523|Drug|Docetaxel|Docetaxel 75mg/m2 on weeks 2, 5, and 8
75776967|NCT04722523|Drug|Cetuximab|Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10
75776968|NCT04722523|Drug|Cemiplimab|Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37
75776969|NCT04722523|Procedure|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
75776970|NCT04722523|Radiation|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic stage following induction systemic therapy and surgery is ypT1-2N0 without the presence of adverse features that include positive margins or a combination of perineural invasion, vascular invasion, and a depth of invasion of >0.5mm, adjuvant radiation will not be administered, consistent with the NCCN guidelines [2]. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
75321337|NCT03480074|Procedure|Selective Suture Ligation|Suture the DVC, suspend it to the pubic bone, and then cut.
75321338|NCT03480074|Procedure|Single Suture Ligation|Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.
75466559|NCT01910727|Behavioral|Together on Diabetes-Hopkins|The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
75776971|NCT04719897|Behavioral|FIRST: Repairing Thoughts|"This intervention uses the Repairing Thoughts cognitive restructuring module of the FIRST (Feeling Calm, Increasing Motivation, Repairing Thoughts, Solving Problems, Trying the Opposite) cognitive behavioral therapy protocol. This psychotherapy module teaches adolescents that thoughts are linked to feelings and behaviors, and that thoughts are often guesses to interpreting the world around us. Adolescents are taught to notice their thoughts in real-time and evaluate the evidence that supports or contradicts the thoughts and interpretation. Adolescents are then taught strategies to re-interpret thoughts in a more realistic manner and notice changes in emotional and behavioral responses. Clinicians are provided with examples to enhance learning, and between-session practice is assigned as homework."
75776972|NCT04718792|Drug|Psilocybin|A single administration psilocybin (25mg, opaque capsule for oral ingestion). The psilocybin is synthetically manufactured under current Good Manufacturing Practices (cGMP)
75776973|NCT04713033|Diagnostic Test|surface electromyogram (sEMG)|A device that measures electrical signals from your skin will be connected to those stickers and will make a graph that is characteristic to your vocal function.
75776974|NCT04713033|Diagnostic Test|flexible laryngoscopy|"A device that examines the throat and nasal passages. The flexible laryngoscope or scope consists of an eyepiece and a fiber-optic light enclosed in a thin, flexible tube. The scope looks like a strand of black spaghetti with a tiny light on the end of it. The scope is inserted through the nose, and can be moved around to help the doctor see all areas of the nasal passages and throat."
75776975|NCT04706195|Behavioral|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
75776976|NCT04701931|Device|Maestro2 OCTA|The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
75776977|NCT04701931|Device|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
75776978|NCT04701931|Device|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
75798433|NCT01169376|Genetic|DNA methylation analysis|
75798434|NCT01169376|Genetic|RNA analysis|
75321339|NCT01678118|Behavioral|Patient Navigator|The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder & to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs & barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
75321340|NCT00703261|Drug|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
75321341|NCT00703261|Drug|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
75321342|NCT02982785|Behavioral|Standard post-operative rehabilitation|
75321343|NCT03452774|Other|Clinical Trial Matching|Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
75321344|NCT04346147|Drug|Imatinib tablets|Imatinib 400 mg QD oral
75321345|NCT04346147|Drug|Baricitinib Oral Tablet|Baricitinib 4 mg QD oral
75623999|NCT01090973|Drug|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
75624000|NCT04755933|Behavioral|Raising Confident Children Course|An online learning tool consisting of 8 different modular components, designed to reduce the transmission of anxiety from parents to children. The modular components include: a core starter about anxiety, the role of avoidance, using play to develop childrens confidence, using Emotion Coaching with children, managing difficult behaviour, the role of sleep, exercise and diet, reducing overprotection, modelling confident behaviour and managing difficult behaviour.
75624001|NCT02607904|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
75624002|NCT04604925|Behavioral|Remote patient monitoring for hypertension|Intervention involves practices making available remote physiologic monitoring treatment management services allowable under Medicare for blood pressure (and weight if desired) to Medicare patients in the practice when ordered by the patient's clinician.
75624003|NCT05295394|Drug|Dolutegravir plus lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
75624004|NCT01090739|Device|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
75624005|NCT02871648|Drug|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
75624006|NCT02871648|Drug|Fludrocortisone|Fludrocortisone 0.1 mg
75624007|NCT02871648|Drug|Eplerenone|Epleronone 100 mg
75776979|NCT04693624|Other|Hormonal levels|"A total of ten (10) blood samples (2ml/each) will be collected during the study for subsequent analysis of progesterone, hCG, inhibin-A, and 17-OH-progesterone:~Day of triggering (before the injection of hCG, appx. 6 pm) Twelve (12 hours) after hCG injection (appx. at 6 am) Twenty-four (24) hours after hCG injection (appx. at 6 pm) Thirty-six (36) hours after hCG injection (appx. at 8 am, 2 hours after OPU) One (1) day after OPU (60h after hCG) (appx. at 6 am) Two (2) days after OPU (84h after hCG) (appx. at 6 am) Three (3) days after OPU 108h after hCG) (appx. at 6 am) Four (4) days after OPU (132h after hCG) (appx. at 6 am) Five (5) days after OPU (156h after hCG) (appx. at 6 am) Six (6) days after OPU (180h after hCG) (appx. at 6 am)"
75776980|NCT04681651|Drug|Normobaric Hyperoxia|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
75798435|NCT01169376|Genetic|comparative genomic hybridization|
75798436|NCT01169376|Genetic|mutation analysis|
75798437|NCT01169376|Genetic|polymorphism analysis|
76073696|NCT03580161|Other|18-F FDG PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
76073697|NCT03580161|Other|Ga-68 PSMA PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
75624008|NCT04873024|Device|cMAP Flow V 2.0|"Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment."
75624009|NCT00637845|Drug|Esomeprazole Magnesium|40mg once daily
75624010|NCT00637845|Drug|Lansoprazole|30mg twice daily
75624011|NCT04297878|Dietary Supplement|probiotic supplement Streptococcus salivarius K12 (Bactoblis®)|Probiotic food supplement
75624012|NCT04209712|Biological|haploid allogeneic NK cell therapy|NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
75914071|NCT05784103|Device|Apple Watch Oxygen Sensor|The apple watch is equipped with green, red, and infrared LEDs that shine light onto the blood vessels in the wrist, with photodiodes measuring the amount of light reflected back. Apple's algorithms use this information to calculate the color of the blood, which is an indication of how much oxygen is in the blood. Bright red blood is well oxygenated, while darker blood has less oxygen. This can measure blood oxygen levels between 70 and 100 percent. Most healthy people have blood oxygen levels that range from 95 to 100 percent. The apple watch sensor will be positioned on the user's preferred wrist.
75624013|NCT02497300|Drug|Spironolactone|
75321346|NCT04346147|Other|Supportive tratment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
75321347|NCT00703729|Device|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
75624014|NCT02497300|Drug|Amiloride|
75321348|NCT00703729|Other|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
75624015|NCT04254471|Drug|AL3810|5mgQD, 7.5mgQD, 10mgQD
75321349|NCT03478358|Drug|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
75624016|NCT04254471|Drug|carboplatin + etoposide|Carboplatin and etoposide are background treatment.
75624017|NCT04254471|Drug|Placebo|Placebo
75624018|NCT04299672|Procedure|Postural reconstruction|Interventions are described in group descriptions
75624019|NCT00631527|Drug|Leuprolide|Injections given through a needle in the muscle every 3 months.
75624020|NCT00631527|Drug|Goserelin|Subcutaneous injections given once every 3 months.
75624021|NCT00631527|Drug|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
75624022|NCT00631527|Drug|Casodex|Once a day by mouth for 2 weeks.
75624023|NCT00631527|Radiation|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
75624024|NCT00620620|Drug|Inhaled placebo|Inhaled Staccato Placebo
75624025|NCT00620620|Drug|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
75624026|NCT00620620|Drug|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
75624027|NCT00620620|Drug|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
75624028|NCT00620620|Drug|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
75624029|NCT04209556|Drug|PF-06826647 100 mg QD|Investigational Product
75624030|NCT04209556|Drug|PF-06826647 300 mg QD|Investigational Product
75624031|NCT04209556|Drug|PF-06826647 600 mg QD|Investigational Product
75624032|NCT04209556|Drug|Placebo|Matched Placebo
75624033|NCT04209556|Drug|PF-6826647 400 mg QD|Investigational Product
75624034|NCT00916383|Drug|350 mg Donepezil Transdermal Patch|Active and placebo patches will be applied to opposite sides for 7 days.
75624035|NCT00916383|Drug|Placebo Patch|Active and placebo patches will be applied to opposite sides for 7 days.
75624036|NCT00617500|Other|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
75624037|NCT00617500|Other|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
75624038|NCT00617500|Other|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
75624039|NCT00617500|Drug|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
75624040|NCT04845555|Other|Observation of the association between clotting factor level and risk of bleeding whilst physical activity|"The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit."
75624041|NCT04254003|Device|DT1 Toric contact lenses|Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
75624042|NCT04254003|Device|AO1DfA contact lenses|Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
75776981|NCT04681651|Drug|Sham Normobaric Hyperoxia|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；
75624043|NCT04703998|Procedure|Arthroscopic rotator cuff repair|A double-row rotator cuff repair will be performed.
75624044|NCT04703998|Biological|platelet rich plasma|A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.
75776982|NCT04681651|Procedure|Endovascular Thrombectomy|EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
75776983|NCT04678258|Procedure|HR electroanatomic mapping and MVG catheter ablation|High resolution CTI mapping using the mini-electrodes at the 8 mm catheter tip followed by voltage guided ablation
75776984|NCT04678258|Procedure|Conventional bipolar mapping and linear catheter ablation|Bipolar mapping and conventional anatomic linear catheter ablation
75624045|NCT04209478|Drug|Tramadol hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration
75624046|NCT05252715|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.
75624047|NCT05252715|Biological|Meningococcal A and C Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.
75624048|NCT00617578|Device|ATP One Shot ON|"The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery"
75624049|NCT00617578|Device|ATP One Shot OFF|Standard defibrillation shock delivery
75624050|NCT05252637|Procedure|Laparoscopic Fascial Posterior Vagina Duplication|Laparoscopic Fascial Posterior Vagina Duplication with absorbable sutures for posterior prolapse (plus standard Sacral Colpopexy)
75624051|NCT04209244|Dietary Supplement|Eskimo-3 Pure Fish Oil|Dosage: 10 ml/day (2.6 g EPA+DHA)
75624052|NCT04209244|Dietary Supplement|Rapeseed Oil|Dosage: 10 ml/day (0 g EPA+DHA)
75624053|NCT05251623|Other|walking program|Subjects in PG walked to target steps daily with pedometer for 6 weeks
75624054|NCT04209166|Drug|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
75624055|NCT04209166|Drug|SSRIs/SNRIs+Mood Stabilizer|Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
75624056|NCT04209166|Drug|SSRIs/SNRIs+Quetiapine|Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
75624057|NCT04209166|Drug|Usual Treatment|Patients' treatment will be decided by the clinical doctor.
75624058|NCT00916305|Other|Modified Audio video|An audio video modified to mimic noise induced hearing loss after one night at a loud club
75624059|NCT00916305|Other|Unmodified audio video|An audio video with unaltered music
75624060|NCT02446444|Drug|Enzalutamide|
75624061|NCT02446444|Drug|Conventional NSAA|
75624062|NCT02446444|Drug|LHRHA|
75776985|NCT04667585|Radiation|De-escalated radiation dose|Reduced dose of radiation applied to remaining radiation therapy when favorable interim PET-CT signature is produced
75321350|NCT03478358|Drug|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
75624063|NCT02446444|Radiation|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
75624064|NCT04253925|Other|Kegel exercises|global postural correction exercises
75624065|NCT04766008|Drug|Metformin|Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
75624066|NCT00916149|Drug|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
75624067|NCT00916149|Drug|Lamotrigine|"The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study."
75624068|NCT04742920|Device|Middle Meningeal Artery Embolization|MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 72 hours after randomization in addition to standard management
75624069|NCT04742920|Procedure|Standard Management|"Procedure : Surgical Management Surgical evacuation of the subdural hematoma~Other: Conservative Management Standard medical management: drug treatment and/or observation"
75624070|NCT00631761|Other|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
75624071|NCT00631761|Other|no intervention (usual resident activities)|usual activities
75914072|NCT05784103|Device|Innovo iP 900AP|The pulse oximeter enables transcutaneous monitoring of the oxygen saturation of hemoglobin in arterial blood. In this study, volar aspect of thumb and index finder of the subject will be used to measure blood oxygen saturation.
75776986|NCT04667585|Radiation|Standard radiation dose|Standard dose of radiation applied to remaining radiation therapy when favorable PET-CT signature is not produced
75798438|NCT03867942|Drug|Monolayer group|Monolayered combination of gemigliptin and rosuvastatin
75798439|NCT03867942|Drug|Bilayer group|Bilayered combination of gemigliptin and rosuvastatin
75798440|NCT01277484|Drug|Decitabine|"1. Dose finding study (cycle 1-cycle4)~Indicated dose for 5 consecutive days every 28 days~Cohort 1: 5mg/m2 of decitabine~Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model"
76073698|NCT03580161|Other|68-Ga Dotatate PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
75321351|NCT03478358|Drug|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
76073699|NCT03580161|Other|99mTc Pertechnetate Thyroid dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
75321352|NCT03478358|Drug|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
75321353|NCT03478358|Drug|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
75321354|NCT03478358|Drug|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
75321355|NCT04200833|Drug|Golimumab|subcutaneous injection
75624076|NCT00620932|Behavioral|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
75624077|NCT00175162|Device|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
75624078|NCT04690660|Other|Data collection for parameters of organ damage (cardiac and renal blood markers)|Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
75624079|NCT04690660|Other|Data collection for blood pressure (BP)|Clinic blood pressure and 24hour BP Measurements
75624080|NCT04690660|Other|Home-based blood pressure management (substudy)|Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
75624081|NCT04690660|Other|Biomarker Profiles (substudy)|Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
75624082|NCT04690660|Other|Data collection on patient reported outcomes|Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )
75624083|NCT00621010|Drug|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
75624084|NCT00621088|Procedure|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
75624085|NCT04213222|Drug|Bevacizumab|bevacizumab combined with chemotherapy
75624086|NCT00621166|Drug|generic lopinavir/ritonavir|"Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.~Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional."
76073700|NCT03580161|Other|99mTc DMSA(III) Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
75321356|NCT01678352|Biological|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
75321357|NCT01678352|Drug|Imiquimod|Cohort 1 Cohort 2 Cohort 3
75321358|NCT02994667|Device|Permanent Pacemaker Placement|
75321359|NCT01678430|Drug|Ofatumumab|
76073701|NCT03580161|Other|99mTc MAG3 Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
76073702|NCT03580161|Other|99mTc MDP/HDP Bone dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
76073703|NCT03583437|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
76073704|NCT03588351|Drug|chitosan nanoparticles gel|intracanal medicament
76073705|NCT03588351|Drug|chitosan gel|intracanal medicament
76073706|NCT03588351|Drug|chlorhexidine gluconate|intracanal medicament
75321360|NCT01678430|Drug|Chlorambucil|
75321361|NCT01678430|Drug|Bendamustine|
75321362|NCT04149743|Diagnostic Test|Standard of Care with Hemotag|Comparison of outcomes
75321363|NCT02853149|Behavioral|Spinal Cord Injury (SCI)|"The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
75624087|NCT04563832|Other|Standardized respiratory management program|Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years
75624088|NCT04563832|Other|CoughAssist|self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)
75776987|NCT04667585|Other|18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)|The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
75776988|NCT04665336|Behavioral|Circadian Timing Program|"Sleep hygiene training will be provided to the participants. They will be asked to make lifestyle changes according to the Circadian Timing Program created by the researcher."
75624089|NCT04555798|Drug|Meropenem Injection|patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
75776989|NCT04665336|Behavioral|Sleep Hygiene Training|Sleep hygiene training will be given by the researcher. There will also be sleep hygiene training sections on the website.
75914073|NCT05781464|Procedure|Traditional chest physiotherapy|"Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator)."
75914074|NCT05781464|Procedure|Prolonged slow expiration technique|The therapist places one hand on the thorax below the suprasternal notch and the other hand over the upper abdomen while the neonate is supine. Both hands will have hypothenar contact with the thorax and abdomen. At the end of the expiratory phase, the therapist places a compression force with both hands. Compression at the end of expiration with hypothenar eminence is kept for 2 or 3 breathing cycles. This technique is repeated several times, with a rest time between applications of about 5 or 10 spontaneous breaths.
75914075|NCT05776459|Drug|AC102 gel|Drug: AC102 Single intratympanic injection
75624090|NCT04555798|Device|A-V ECMO|Only patients of group B connected to A-V ECMO for two weeks
75624091|NCT04549090|Drug|QL (quadratus lumborum) block administration|Fo the QL block group, they will be receiving bilateral QL block. A total of 40ml of 0.25% bupivacaine (Marcaine) and 10ml of liposomal bupivacaine (Exparel) will be administered
75624092|NCT00617812|Biological|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
75624093|NCT04515550|Diagnostic Test|lumbar puncture|Some participants will have an optional lumbar puncture
75624094|NCT00617968|Drug|DOCETAXEL|
75624095|NCT00621400|Drug|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
75624096|NCT00621400|Drug|Melphalan|0,18mg/Kg/day from day 1- 4
75624097|NCT00621400|Drug|Dexamethasone|40mg/day from day 1- 4.
75624098|NCT04208932|Drug|SSRIs|Selective Serotonin Reuptake Inhibitors
75776990|NCT04663061|Behavioral|Medical weight loss|Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight
75776991|NCT04663061|Behavioral|Diabetes education|Participants will receive standard of care diabetes education
75776992|NCT04663061|Behavioral|Continuous glucose monitoring|Participants will use CGM devices to track blood glucose levels in near real time
75776993|NCT04661033|Drug|Isatuximab SAR650984|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
75914076|NCT05776459|Drug|Prednisolone|Active comparator: Prednisolone Tablets taken daily by mouth
75914077|NCT05776459|Other|Placebo Tablets|Placebo Tablets taken daily by mouth
75914078|NCT05776459|Other|Placebo gel|Placebo Single intratympanic injection
75914079|NCT05774002|Behavioral|Aims to Decrease Anxiety and Pain Treatment (ADAPT)|One pre-operative and 4 post-operative sessions of cognitive behavioral therapy (CBT) treatment in the first two months, beginning 2-3 weeks after surgery, will be completed.
75624099|NCT02691364|Procedure|Blood withdrawal|
75624100|NCT04208854|Drug|Vinorelbine|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
75624101|NCT01090427|Drug|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
75624102|NCT01090427|Drug|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
75624103|NCT01090427|Other|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
75624104|NCT04208776|Drug|Propranolol|maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.
75624105|NCT04208776|Drug|Midodrine|It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate
75624106|NCT02879435|Drug|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
75914080|NCT05773768|Device|EHRA-PATHS software tool|Newly developed care pathways integrated into a care-management software tool
75624107|NCT02879435|Other|Placebo|pre-operative wound infiltration with 10 ml of sterile water
75624108|NCT05662774|Diagnostic Test|Ultrasound contrast agent (Sonovue)|Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments
75624109|NCT02879513|Drug|Paclitaxel|
75624110|NCT02879513|Drug|Cisplatin|
75624111|NCT02879513|Drug|Epirubicin|
75624112|NCT02879513|Drug|Cyclophosphamide|
75624113|NCT02879513|Drug|5-fluoruracil|
75624114|NCT04874207|Drug|Regorafenib|Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15
75624115|NCT00621478|Drug|lorazepam or diazepam|"Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push."
75624116|NCT00621556|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
75624117|NCT00618046|Drug|Oxcarbazepine|
75624118|NCT04308551|Drug|Indobufen|Indobufen Tablets
75624119|NCT04308551|Drug|Aspirin|Aspirin Tablets
75624120|NCT04209010|Procedure|one-stage technique|breast reconstruction in one stage using silicone implant and acellular dermal matrix.
75624121|NCT04306991|Device|Auscultation using an electronic stethoscope (EKO CORE 4)|"Auscultation using an electronic stethoscope (EKO CORE 4). Record of at least 3 cardiac cycles.~Measurement of cardiac output using echocardiography."
75624122|NCT04212988|Procedure|Increase the SCO2 value|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
75624123|NCT04306913|Drug|Esmolol|esmolol 250 mg in cardioplegia solution every 25 minutes
75624124|NCT04306913|Drug|Potassium Cardioplegic Solution|15 meq potassium added to cardioplegia solution
75624125|NCT02299414|Drug|Anti-hypertensive therapy|1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
75624126|NCT02299414|Other|No anti-hypertensive therapy (unless BP is severe)|Treatment will not be started if blood pressure remains <160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
75624127|NCT02877875|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with Attention-deficit/hyperactivity disorder (ADHD). MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
75624128|NCT02877875|Other|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Feelings Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
75624129|NCT02877875|Behavioral|Treatment as usual|Treatment in the UC condition will use the procedures therapists (e.g., school counselors) and their supervisors consider appropriate and believe to be effective.
75776994|NCT04656145|Device|3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing|On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
75798441|NCT01282632|Drug|Risperidone|Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
75624130|NCT04309097|Behavioral|Digital intervention|"REAP is a live-streaming platform that allows users to shoot short videos or photos related to their physical exercise or eye relaxation (e.g., staring out of the window) using their smartphones. The app has been optimised to be used with the iPhone or Android.~When taking a online course recess, students will have access to the REAP platform that allows them to watch stay-at-home workout videos developed by exercise physiologists. Students will then be asked to create their own workout videos/photos and upload them to the live-streaming platform. When upload is completed, students will receive instant motivational messages to increase their engagement with the program."
75624131|NCT04309097|Behavioral|Information-only intervention|Participants will have access to online health information and stay-at-home workout videos.
75624132|NCT01016262|Drug|MAX-002|MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
75624133|NCT01016262|Drug|Placebo|Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
75914081|NCT05772949|Device|Experimental group intervention|"The caregivers will calibrate the smart hearing aids for the participants in the experimental group at the first day of week 1 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the experimental group can use the smart hearing aids whenever they want during the trial period (i.e. from week 1 to week 6). For participants living in residential setting, caregivers will facilitate them to use the smart hearing aids upon request from the participants or when the caregivers deem the aids beneficial. For participants living in community setting, they will use the smart hearing aids when needed. Their caregivers shall provide assistance in facilitating the participants to use the smart hearing aids. The smart hearing aids do not require any payment from the study participants. They have to return the hearing aids after the study."
76073707|NCT03940209|Behavioral|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
75914082|NCT05772949|Device|Wait-list control group intervention|"The caregivers will calibrate the smart hearing aids for the participants in the wait-list control group at week 8 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the wait-list control group will continue the current practice (i.e. using conventional hearing aids or no hearing aids) from week 1 to week 8, and will use the smart hearing aids from week 8 to week 14. Caregivers will facilitate the participants to use the smart hearing aids."
76073708|NCT03588273|Drug|Amoxil 500 MG Oral Capsule|
76073709|NCT04747821|Biological|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
75321364|NCT02853149|Behavioral|Caregiver Intervention(CCC)|"The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
75624134|NCT01016262|Drug|Canasa®|Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
75624135|NCT00625937|Drug|cisplatin|
75624136|NCT00625937|Drug|docetaxel|
75624137|NCT00625937|Drug|tegafur-gimeracil-oteracil potassium|
75624138|NCT00625937|Radiation|radiation therapy|
75624139|NCT00621634|Dietary Supplement|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
75624140|NCT00621634|Dietary Supplement|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
75624141|NCT05662696|Other|Raabta Telemonitoring Program (Mobile Application)|Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.
75624142|NCT01001910|Drug|Carboplatin|Given IV
75624143|NCT01001910|Other|Laboratory Biomarker Analysis|Correlative studies
75624144|NCT01001910|Drug|Pemetrexed Disodium|Given IV
75624145|NCT04308629|Other|Transcranial direct current stimulation|
75624146|NCT00621712|Device|GamCath® central venous catheter|choice of catheter type
75624147|NCT00621712|Device|GamCath Dolphin® Protect central venous catheter|choice of catheter type
75624148|NCT04308317|Drug|Tetrandrine|Tetrandrine 60mg QD for 1week
75624149|NCT04212208|Device|IV cannulation|IV cannulation in the preoperative period
75776995|NCT04646616|Other|Community popular opinion leader (POL) based intervention|A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
75776996|NCT04639583|Device|Near-infrared spectroscopy (NIRS) utilization|The NIRS devise will be applied so that cerebral regional oxygen saturation (cRSO2) can be measured.
75776997|NCT04635657|Other|Long-term Cognitive testing|These patients will undergo their standard of care cognitive testing at baseline, six weeks post-operatively and one year post-operatively.
75624150|NCT04212130|Other|BCA method for assessing environmental cleanliness|"Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
75624151|NCT01009554|Device|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
75624152|NCT01009554|Drug|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
75624153|NCT04211896|Drug|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
75624154|NCT04211896|Drug|Nivolumab|Nivolumab will be given at a dose of 240 mg every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
75624155|NCT02012374|Behavioral|Intensive Language Action Therapy|
75624156|NCT04188184|Drug|Tranexamic Acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
75624157|NCT04188184|Drug|Epinephrine|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
75624158|NCT04016662|Device|Tandom t:slim X2 with HCL or PLGS|"The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands."
75624159|NCT04495218|Biological|Blood samples|Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
75624160|NCT05093764|Device|VIV TAVR with BVF using TCEP|The insertion and retrieval of the SENTINEL device is performed at the time of the patients TAVR procedure in the same setting while they are sedated under moderate sedation or general anesthesia depending on the case. The device is inserted at the initiation of the procedure through 6F right radial artery access and the filters are positioned in the left common carotid artery and brachiocephalic artery. After deployment, the usual TAVR procedure is performed. At the conclusion of the procedure, the SENTINEL device is extracted and hemostasis is achieved at the radial access site in the usual fashion with patent hemostasis.
75624161|NCT01006590|Drug|Saxagliptin|5 mg, oral tablet, once daily
75624162|NCT01006590|Drug|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
75776998|NCT04618718|Device|cerebral embolic protection during TAVR|The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.
75776999|NCT04613206|Biological|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
75777000|NCT04613206|Biological|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
75777001|NCT04610892|Biological|MEDI6570|MEDI6570
75777002|NCT04610892|Biological|Placebo|Buffer
75777003|NCT04601285|Drug|JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)|"Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.~Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose."
75777004|NCT04596514|Procedure|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)
75777005|NCT04596514|Procedure|usual procedure according to guidelines|Treatment as described in the guidelines from the European Resuscitation Council, the Norwegian Resuscitation Council, and other local national guidelines
75321365|NCT02853149|Behavioral|Caregiver Control (CC)|The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
75321366|NCT01678664|Drug|Everolimus|10 mg per day of everolimus during 24 months or until progression disease
75466560|NCT01910740|Other|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
75466561|NCT01910740|Other|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
75777006|NCT04595279|Behavioral|Smoking sessions|Participants undergo topography and behavioral economic sessions where they can make choices to earn cigarette puffs by pulling plungers on experimental equipment
75777007|NCT04590508|Drug|Xanthohumol|The xanthohumol supplement will be administered in a capsule and taken orally.
75777008|NCT04590508|Other|Placebo|The placebo will be administered in a capsule and taken orally.
75321367|NCT01678664|Device|embolization|2 sessions embolization with spheric particles
75777009|NCT04585581|Behavioral|time-restricted eating|Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours.
75777010|NCT04585581|Behavioral|high intensity exercise|Participants will be encouraged to exercise with high intensity 2-3 times per week
75777011|NCT04585581|Other|Standard Care|Standard clinical care
75777012|NCT04582695|Behavioral|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder. Sessions will be 60 minutes in length. It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes. In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).
75777013|NCT04582695|Behavioral|Written Exposure Therapy|Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
75914083|NCT05768815|Behavioral|Breaking the Cycle Program|BTC is a prevention and early intervention program in Toronto, Canada, serving substance-using pregnant and/or parenting women with children under six years of age. Established by the Canadian Mothercraft Society in 1995, BTC is funded by the Community Action Program for Children and the Canadian Prenatal Nutrition Program through the Public Health Agency of Canada. BTC provides three program components that act synergistically: a) individualized services for mothers, b) individualized services for children, and c) relational interventions that enhance the mother-child relationship and promote infant mental health. Coordinated supports are offered through formal partnerships across service sectors. In 2004, BTC was recognized by the United Nations as an exemplary program serving pregnant and parenting women with substance use problems, and their young children.
75914084|NCT05768815|Behavioral|Maxxine Wright Program|Founded in 2005 and located in Surrey, British Columbia, the Maxxine Wright Community Health Centre (MWCHC) supports women who are pregnant and/or have young children and are impacted by substance use and/or violence. Women do not need to have children in their care to receive services. The program is funded and operated by the Fraser Health Authority, with additional in-kind support from the BC Ministry for Children and Family Development and the BC Ministry of Social Development and Poverty Reduction. MW addresses maternal substance use and exposure to violence through women-centered, trauma-informed, culturally grounded, and interdisciplinary approaches. Primary services offered include addiction counselling, primary health care, and group therapy to address interpersonal violence. Within MW, child-focused services are limited to primary health (e.g., well baby checks, childcare).
75777014|NCT04580043|Behavioral|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
75777015|NCT04580043|Device|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
75777016|NCT04580043|Behavioral|Sham Training|Computer-based task practice in a non-active/inert task.
75777017|NCT04580043|Device|Sham Transcranial Magnetic Stimulation|Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
75777018|NCT04569539|Device|Ultrasound|Ultrasound scan of the cricothyroid membrane
75777019|NCT04567043|Behavioral|MORE+JITAI|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse. JITAI involves stress-triggered reminders to practice mindfulness skills.
75777020|NCT04567043|Behavioral|Supporive Psychotherapy|A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
75777021|NCT04557527|Procedure|Pars plana vitrectomy, laser or cryo retinopexy and intraocular gas tamponade|Conventional pars plana vitrectomy procedure is used to treat rhegmatogenous retinal detachment- laser or cryo retinopexy intraocular gas tamponade (SF6, C2F6 or C3F8) are chosen according to the number and size of the causative retinal break(s) and surgeons clinical judgement
75777022|NCT04557527|Device|Suprachoroidal viscobuckle with 2.3% Sodium hyaluronate (Healon 5 Ophthalmic viscoelastic device)|After drainage of subretinal fluid, approximately 0.5 ml of Healon 5 is injected in to the suprachoroidal space underlying the retinal break. Laser retinopexy is applied around the break .
75777023|NCT04544852|Behavioral|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test."
75777024|NCT04544852|Behavioral|Targeted intervention programme|The targeted intervention programme includes participants undergoing a structured educational program regarding colorectal cancer and the importance of screening in its prevention. The details will be explained to them using the pamphlet from MOH on Colorectal Cancer Screening. They will also be offered two FIT kits free of charge. Research team will educate participants on how to perform the FIT test. A detailed information guide on how to collect stool samples for FIT kit and how to return the completed FIT kit to the NUH Colorectal Centre will be given to them. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test.
75321368|NCT01678664|Drug|Doxorubicin|2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
75321369|NCT00597493|Drug|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
75321370|NCT03087422|Behavioral|Text message intervention|The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
75466562|NCT01910740|Other|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
75466563|NCT01910753|Procedure|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
75624163|NCT02010112|Other|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
75624164|NCT00619138|Behavioral|individual cognitive-behavioural therapy|1 session per week for 12 weeks
75624165|NCT00619138|Behavioral|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
75624166|NCT04212832|Drug|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
75624167|NCT04212832|Other|Standard pain|Standard pain follow up and monitorization
75624168|NCT04211974|Diagnostic Test|whole-exome sequencing|"Fresh frozen or formalin-fixed, paraffin-embedded samples were obtained from patients following resection along with matching peripheral blood samples.~whole-exome sequencing will be performed to identify mutations in tumor tissue and matching blood"
75624169|NCT00621790|Drug|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
75624170|NCT00621790|Drug|placebo|placebo
75624171|NCT00618124|Drug|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
75624172|NCT02252380|Device|Transcranial ExAblate System|MR Guided Focused Ultrasound
75624173|NCT05067946|Biological|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
75624174|NCT05067946|Other|Placebo|GX-19N formulation buffer
75624175|NCT00621868|Drug|ipragliflozin|Oral
75624176|NCT00621868|Drug|Placebo|Oral
75624177|NCT02246374|Device|ExAblate Transcranial System|ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
75624178|NCT01882660|Drug|Decitabine|
75624179|NCT05662618|Procedure|Percutaneous selective arteriography of peripheral arteries|Treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery with rapamycin coated balloon catheter.
75624180|NCT05662618|Procedure|Percutaneous selective arteriography of peripheral arteries|Paclitaxel coated balloon catheter for the treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery.
75777025|NCT04543383|Drug|Milvexian|Milvexian will be administered orally.
75624181|NCT02216500|Dietary Supplement|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
75624182|NCT01001832|Drug|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
75624183|NCT01001832|Drug|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
75624184|NCT01873456|Other|multifactorial nutritional intervention|
75624185|NCT01851694|Drug|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
75624186|NCT01851694|Drug|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
75624187|NCT01001598|Drug|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
75466564|NCT01910766|Drug|Coenzyme Q10|no more details
75466565|NCT01910766|Drug|clomiphene citrate|
75466566|NCT01910779|Procedure|100 joule as first biphasic shock energy|
75624188|NCT04208620|Drug|Placebo|Placebo administered subcutaneously
75624189|NCT04208620|Drug|Cotadutide|Cotadutide administered subcutaneously
75624190|NCT01006356|Drug|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
75624191|NCT03836092|Procedure|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
75624192|NCT04213066|Device|Portable tablet|Each training session was limited to 15 minutes a day, 5 days a week. The entire training period was 6 months.
75624193|NCT01089725|Biological|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
75624194|NCT01089725|Biological|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
75624195|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
75466567|NCT01910779|Procedure|120 joule as first biphasic shock energy|
75624196|NCT01089725|Biological|Placebo IV|1 ml placebo administered IV every 8 weeks
75624197|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
75624198|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
75777026|NCT04543383|Biological|4-Factor Prothrombin Complex Concentrate (4F-PCC)|4F-PCC will be administered intravenously.
75777027|NCT04543383|Biological|Recombinant Human Factor VIIa (rFVIIa)|rFVIIa will be administered intravenously.
75777028|NCT04543383|Biological|Placebo matching to 4F-PCC|Placebo matching to 4F-PCC will be administered intravenously.
75777029|NCT04543383|Biological|Placebo matching to rFVIIa|Placebo matching to rFVIIa will be administered intravenously.
75798442|NCT01282632|Drug|Olanzapine|Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
75321371|NCT02708147|Other|Physiotheraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
75321372|NCT02708147|Other|Conventional treatment|Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
75321373|NCT03086954|Biological|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
75321374|NCT02999893|Drug|APR-246|APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
75777030|NCT04532606|Drug|Remimazolam|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
75777031|NCT04532606|Drug|Propofol|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.
75777032|NCT04513145|Drug|Ropivacaine injection|Ropivacaine is a local anesthetic that is FDA approved for local anesthetic nerve block.
75777033|NCT04513145|Drug|Saline Injection|Saline will be used as a placebo injection
75777034|NCT04513145|Procedure|Total Knee Arthroplasty|All subjects participating in this study will undergo primary total knee arthroplasty
75777035|NCT04460885|Drug|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.
75777036|NCT04460885|Drug|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks
75624199|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
75624200|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
75624201|NCT01089725|Biological|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
75624202|NCT01089725|Biological|Placebo SC|1ml placebo administered SC every 8 weeks
75624203|NCT00622102|Behavioral|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
75624204|NCT00622102|Behavioral|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
75624205|NCT00619216|Drug|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
75624206|NCT00619372|Drug|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
75624207|NCT00619372|Drug|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
75777037|NCT04459715|Drug|Xevinapant (Debio 1143)|Xevinapant (Debio 1143) administrated as oral solution from Day 1 to 14, every 21-day cycle.
75321375|NCT03086720|Procedure|Sodium hypochlorite|Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
75321376|NCT03086720|Procedure|Water|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
75321377|NCT03990779|Diagnostic Test|Echocardiography|Echocardiographic examination before and after cardiopulmonary bypass
75321378|NCT03450668|Device|mOm incubator|24 hour usage of test incubator
75321379|NCT03450668|Device|standard incubator|standard incubator
75624208|NCT00619372|Drug|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
75624209|NCT00619372|Drug|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
75624210|NCT00619372|Drug|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
75624211|NCT00619372|Drug|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
75624212|NCT02879279|Device|Amadeo, Pablo, Diego and Motore.|In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
75624213|NCT02879279|Other|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
75777038|NCT04459715|Drug|Cisplatin|Cisplatin administered as an IV infusion every 3 weeks (Q3W).
75777039|NCT04459715|Radiation|Intensity Modulation Radiation Therapy (IMRT)|70 Gy given in 35 fractions over 7 weeks.
75777040|NCT04459715|Drug|Placebo|Matched placebo administrated as oral solution from Day 1 to 14, every 21-day cycle.
75777041|NCT04452188|Other|Normoxia (with controlled re-oxygenation)|"Participants will receive lower levels of oxygen during surgery and after surgery on the ventilator.~As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation with an FiO2 of 50% or less (unless clinically necessary) to achieve oxygen saturation and PaO2 goals that fit within the expected range for the patient's physiology:~Single ventricle patients (PaO2:35-45 and oxygen saturation 75%-85%)~Two ventricle patients (PaO2: 60-100 and oxygen saturation >92%)"
75777042|NCT04452188|Other|Standard of care ventilation|As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation per standard protocols. Ventilation will be continued in the ICU and adjusted per standard goals per the intensivist.
75798443|NCT03873090|Other|SBRT|hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam. The schedule will be [ 4 x 9.5 Gy = 38 Gy ] delivered in 5 alternative days, corresponding to an NTD2 between 95 and 119 Gy for an α/β estimate between 3 and 1.5 Gy.
75798444|NCT03867786|Behavioral|Exercise|Participants will complete an acute exercise visit.
75798445|NCT03867786|Behavioral|Video Control|Participants will complete a video control visit.
75777043|NCT04440202|Behavioral|Conventional sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional sea bream fillets and will be asked to consume them twice weekly for 1 month. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
75777044|NCT04440202|Behavioral|Enriched sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 enriched sea bream fillets and will be asked to consume them twice weekly for 1 month. Enriched sea bream fillets will be produced by a fish farming company from fish bread with a diet enriched with a fraction of bioactive polar lipids extracted from olive oil by-products. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
75777045|NCT04435158|Drug|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous injection
75777046|NCT04435158|Drug|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous injection
75624214|NCT00618202|Drug|Balsalazide|
75624215|NCT02877719|Other|Questionnaires|Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
75624216|NCT00619450|Other|3D C-arm CT scan|The patient will be given an intravenous contrast dye and then hold their breath for 15 seconds while pictures are taken. The equipment used to take the pictures is like an arch that will rotate around the body. As the arch rotates, it will collect the pictures of the heart. These pictures will then be used to compute a three-dimensional image of the heart. The physicians will then continue with the planned procedure. The three-dimensional images will be reconstructed and available for the doctor to view during the case. The images will also be examined after the procedure by the physician.
75624217|NCT00626015|Biological|PEP-3-KLH conjugate vaccine|Given intradermally
75624218|NCT00626015|Biological|daclizumab|Given IV
75624219|NCT00626015|Drug|temozolomide|Given by mouth.
75624220|NCT00626015|Other|placebo|Given IV
75624221|NCT00626015|Biological|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
75777047|NCT04425395|Behavioral|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance. Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min. The procedure is safe because the hand is removed before adverse effects can occur. The participant will be given a break of 5 min in between trials, and will interchange hands between trials. During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand.~Each participant will complete no more than three trials (conditions) in a randomised order."
75777048|NCT04425395|Behavioral|Acoustic Recordings|During the experiment, the vocalizations produced will be systematically recorded for each participant and an analysis of the acoustic structure of these vocalizations will be carried out.
75777049|NCT04425395|Diagnostic Test|Index measurement NOL™|Four sensors placed non-invasively on one finger. of the participants will be able to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
75777050|NCT04425395|Diagnostic Test|Video pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
75777051|NCT04417192|Drug|Olaparib|Olaparib will be administered at a dose of 300mg as oral dose, twice a day.
75777052|NCT04417192|Drug|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
75777053|NCT04416958|Device|cardiac implantable electronic device (CIED) implantation|CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony
75914085|NCT05765903|Other|Standard of Care|"Diagnosis education.~Follow-appointment scheduling assistance.~Offer resources in the community.~Offer weekly follow-up calls for one month.~Social Determinants of Health (SDoH) assessment."
75914086|NCT05765903|Other|Enhanced Care|"Additional educational training using computer tablet devices, such as iPads.~Focus on readmission risk.~Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH)."
75914087|NCT05756387|Device|Non-invasive ventilation|NIV as in standard care
75624222|NCT03787498|Drug|PLX2853|Tablets
75624223|NCT00618280|Drug|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
75624224|NCT01101191|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
75624225|NCT01101191|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
75624226|NCT04212754|Other|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
75624227|NCT02879357|Behavioral|Training|"Clinician training~System for patient selection~System of triggering and tracking conversations~Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
75624228|NCT00622258|Drug|Everolmus|
75624229|NCT01812616|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
75777054|NCT04414930|Drug|AMPH|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
75914088|NCT05754385|Behavioral|Ambulatory monitoring of liver fat|Participants will be given a novel portable, home-based device called the Gense-EIT liver scan the participants and will practice ambulatory liver fat monitoring for 6 months.
75914089|NCT05754385|Behavioral|Standard of care|Subjects will have follow-up every 6 months by hepatologists for routine care
76073710|NCT03588195|Other|Educational Program|Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
76073711|NCT03588195|Device|Transcutaneous Nerve Electro-Stimulation|Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
76073712|NCT03585621|Radiation|SBRT|Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.
76073713|NCT03588819|Radiation|SABR|26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
75321380|NCT03963167|Drug|BDP/FF/G fixed combination|Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
75321381|NCT03086252|Procedure|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
75321382|NCT03963089|Procedure|Tidal volume_6mL/kg|Set tidal volume to 6mL/kg for 1 minute
75624230|NCT01812616|Drug|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs & Cosmetics (FD&C)certified color additives; FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
75624231|NCT00618358|Device|Vascular Sealant System|The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
75624232|NCT00618358|Other|Gelfoam/Thrombin|
75624233|NCT04212676|Other|Body Awareness Therapy|The BAT for the participants was based on the works of Roxendal and Dropsy. Activities include relaxation exercises, breathing exercises, floor exercises for trunk and pelvic movements, weight transfer using extremities and proprioceptive movements. Movements will be made in various positions to determine the centerline of the body. All exercises will be started in the supine position to maximize proprioceptive motion feedback and minimize energy requirements during tasks. Movements will be taught in a series of lessons over a period of 8 weeks with advance advancement of selected movements depending on participant comfort.
75624234|NCT04212676|Other|Pulmonary Rehabilitation|Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
75321383|NCT03963089|Procedure|Tidal volume_10mL/kg|Set tidal volume to 10mL/kg for 1 minute
75624235|NCT01178762|Drug|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
75624236|NCT03629236|Other|GrafixPL|Debridement, GrafixPL application, dressing application, standard compression therapy
75624237|NCT03629236|Other|Control|Debridement, dressing application, standard compression therapy
75798446|NCT01172028|Drug|Taxotere (Docetaxel)|Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
75914090|NCT05744817|Behavioral|Inspiratory muscle strength training|30 breaths/day against a set resistance
75914091|NCT05741593|Other|Analysis of the verbatim from the transcription of the recorded interviews.|recorded semi-structured interviews between the patients and the pharmacist
75914092|NCT05739981|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV
75914093|NCT05739981|Drug|Carboplatin|Carboplatin AUC 5-6 IV
75914094|NCT05739981|Drug|Bevacizumab|BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: [1] Cycle 1, [2] the last cycle of neoadjuvant therapy immediately preceding ICS, and [3] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
75914095|NCT05739981|Drug|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
75914096|NCT05738057|Drug|Camrelizumab|200mg on day1 of every 3 weeks, starting on day1 of cycle1
75321384|NCT03963089|Procedure|Tidal volume_14mL/kg|Set tidal volume to 10mL/kg for 1 minute
75321385|NCT03963089|Procedure|Fluid loading|Administer 10mL/kg of crystalloid for 5 minutes
75321386|NCT04402112|Drug|Pitavastatin|1mg, 2mg, or 4mg, Once a day, at least 8 weeks
75321387|NCT00597727|Drug|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
75321388|NCT00597727|Drug|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
75321389|NCT01678742|Dietary Supplement|High-protein diet|"The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea."
75466568|NCT01910805|Behavioral|Lifestyle and Risk Assessment class|"Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.~The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices."
75624238|NCT03563560|Drug|Alvocidib|ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
75624239|NCT03563560|Drug|Cytarabine|300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
75624240|NCT03563560|Drug|Mitoxantrone|14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
75624241|NCT03563560|Drug|Cytarabine|100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
75624242|NCT03563560|Drug|Daunorubicine|60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
75624243|NCT01178294|Biological|OBI-1|Intravenous infusion
75624244|NCT01799044|Device|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
75624245|NCT00619606|Device|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
75777055|NCT04414930|Drug|SHAM|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
75777056|NCT04414735|Other|Extracorporeal Photopheresis|Infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence of a photosensitizer. The cellular product is obtained through leucopheresis and its subsequent exposure to 8-methoxypsoralen (8-MOP) and irradiation with UV-A light.
75777057|NCT04409002|Drug|Niraparib|Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment
75777058|NCT04409002|Drug|Dostarlimab|Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study
75777059|NCT04409002|Radiation|Radiation|Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1
75777060|NCT04407962|Behavioral|SMS group|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
75777061|NCT04404361|Drug|Pacritinib|100 mg capsules
75777062|NCT04404361|Drug|Placebo|Placebo capsules matching pacritinib 100 mg capsules
75777063|NCT04401826|Procedure|Tunneling micro-surgical crown lengthening approach using piezo-surgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery via tunneling
75777064|NCT04401826|Procedure|Micro-surgical crown lengthening approach using Piezosurgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery with conventional flap elevation.
75777065|NCT04394910|Dietary Supplement|Pomegranate Juice|
75777066|NCT04394910|Dietary Supplement|Placebo Juice|
75777067|NCT04388384|Drug|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
75777068|NCT04384016|Biological|Skyvaricella Injection|"The main target is evaluating the safety of SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection.~The secondary target is to Assess the immunogenicity of SKYVaricella inj. in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
75777069|NCT04373525|Other|Genome analysis|Venous blood will be obtained for later genome analysis
75777070|NCT04364646|Behavioral|Personalized Integrated Chronotherapy|Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
75777071|NCT04353375|Drug|HMPL-453|Cohort_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days [Day 1 to 14], followed by 7 days off [Day 15 to 21], 21 days as a treatment cycle)
75777072|NCT04343885|Drug|177Lu-PSMA-617|Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
75777073|NCT04343885|Drug|Docetaxel|Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
75777074|NCT04338061|Drug|Evobrutinib|Evobrutinib twice daily (BID) in DBTP.
75777075|NCT04338061|Drug|Placebo (match to Teriflunomide)|Placebo match to Teriflunomide once daily in DBTP.
75777076|NCT04338061|Drug|Teriflunomide|Teriflunomide once daily in DBTP.
75777077|NCT04338061|Drug|Placebo (match to Evobrutinib)|Placebo match to Evobrutinib BID in DBTP.
75777078|NCT04331249|Procedure|surgery or catheter based cardiac procedure (catheter ablation)|patients with implanted CIED (pacemaker, ICD or CRT) that undergo any surgery or any catheter based cardiac procedure (e.g. radiofrequency ablation)
75624246|NCT00619606|Device|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
75624247|NCT00619606|Device|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
75624248|NCT00619606|Device|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
75624249|NCT01178138|Drug|Prazosin|Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
76073714|NCT03588117|Behavioral|Physician-supervised nonsurgical weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
76073715|NCT03545607|Biological|MultiStem|single intravenous infusion 18-36 hours after stroke
75624250|NCT04211428|Other|No intervention|There is no intervention for this study
75321390|NCT01678742|Dietary Supplement|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
75321391|NCT03474770|Drug|BIS-001ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
75321392|NCT03952169|Dietary Supplement|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
75321393|NCT03952169|Other|Placebo controls|placebo with a similar appearance to probiotics supplement
75321394|NCT04270201|Other|Saliva collection|Saliva collection
75466569|NCT01910844|Drug|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
75466570|NCT01910844|Drug|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
75624251|NCT00618592|Dietary Supplement|PreOp carbohydrate drink|800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
75624252|NCT04206254|Biological|gp96|heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
75624253|NCT04206410|Dietary Supplement|Probiotic|Multispecies probiotic mixture administered to patients according to the randomization list
75777079|NCT04310995|Drug|Nicorandil 5mg tid|oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
75777080|NCT04310995|Drug|Diltiazem 180mg qd|oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
75777081|NCT04310995|Drug|Isosorbide Mononitrate 50mg qd|oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
75777082|NCT04310644|Other|No intervention planned, but all patients get our standart treatment|Patients are selected from clinical Routine and get our standart Treatment based on their disease
75624254|NCT04206410|Dietary Supplement|Maltodextrin|Maltodextrin as placebo
75624255|NCT05662150|Diagnostic Test|Low frequency repetitive stimulation|Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
75777083|NCT04310462|Other|New e-prescribing interface|The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). Through randomization of clinicians to the new interface, the investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines.
75777084|NCT04302324|Drug|Daratumumab SC|Given as 1800mg via injection
75777085|NCT04302324|Drug|Clarithromycin|Given as 500mg oral capsule
75777086|NCT04302324|Drug|Pomalidomide|Given as 4mg oral capsule
75777087|NCT04302324|Drug|Dexamethasone|Given as 20mg IV and 20mg or 40mg oral tablets
75777088|NCT04299386|Device|NeoPhylaxis|NeoPhylaxis® gel is designed for the non-surgical decontamination of the implant surface and can be used for professional regular implant maintenance, with or without peri-implant mucositis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in non-sterile form.
75777089|NCT04299386|Device|ImplanTreat|ImplanTreat® gel can be used for the surgical decontamination of the implant surface and can be used to decontaminate implants with peri-implantitis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in sterile form.
75777090|NCT04290741|Procedure|Auricular (Battlefield) Acupuncture|Placement of needles based on battlefield acupuncture protocol which includes up to 5 sites on each ear to treat pain.
75777091|NCT04290741|Procedure|Peripheral Acupuncture|Placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
75798447|NCT01172028|Drug|Alimta (Pemetrexed)|ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
76073716|NCT03545607|Biological|Placebo|single intravenous infusion 18-36 hours after stroke
76073717|NCT04148235|Other|No Intervention|There is no intervention for this study
75466571|NCT01910857|Behavioral|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
75466572|NCT01910870|Drug|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
75466573|NCT01910870|Drug|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
75466574|NCT01910883|Drug|Finafloxacin i.v. solution 200 mg|
75466575|NCT01910883|Drug|Finafloxacin i.v. solution 400 mg|
75466576|NCT01910883|Drug|Finafloxacin i.v. solution 600 mg|
75466577|NCT01910883|Drug|Finafloxacin i.v. solution 800 mg|
75466578|NCT01910883|Drug|Finafloxacin i.v. solution 1000 mg|
75466579|NCT01910883|Drug|Placebo i.v. solution|
75624256|NCT02558530|Other|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
75624257|NCT04208542|Drug|ESP block|Ultrasound guided Erector spinae block (ESP) will perform.
75624258|NCT01190228|Biological|JE-CV Vaccine|0.5 mL (single dose), Subcutaneous
75624259|NCT01190228|Biological|Varicella Vaccine|0.5 mL (single dose), Subcutaneous
75777092|NCT04289363|Behavioral|Clinical program implementation|Using mixed methods and triangulating multiple sources of data collected over the course of parent and ancillary studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED-initiated BUP clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness. Converging provider and patient perspectives and field notes with process measures and intervention outcomes, including proportions screened, treated, and engaged in treatment, will provide explanation to contextualize and better understand feasibility, acceptability, and factors associated with the rate with which the ED-initiated BUP innovation is adopted and how well it is sustained.
75777093|NCT04284943|Procedure|Long limb Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
75798448|NCT02525952|Procedure|Hepatectomy|Surgical removal of all lesions
75914097|NCT05738057|Drug|Gemcitabine Injection|1000mg/m2 on day1 & day8 of every 3 weeks, starting on day1 of cycle 1
75914098|NCT05738057|Drug|Cisplatin injection|25mg/m2 on day1 & day8 of every 3 weeks, starting on day1 of cycle 1
75914099|NCT05738057|Drug|Cisplatin-Eluting Beads|used for D-TACE
75914100|NCT05738057|Procedure|D-TACE|TACE with Cisplatin-Eluting Beads (with Cis 30mg). More TACE can be done if clinically necessary.
75914101|NCT05732948|Drug|autologous T cells & cyclophosphamide|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T administered one day after pretreatment with cyclophosphamide.
75914102|NCT05732584|Other|structured family voice stimulation|The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.
75914103|NCT05732584|Other|unstructured family voice stimulation|The unstructured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death.
75624260|NCT01009086|Drug|Placebo|SC injections
75321395|NCT03949907|Other|Nutritional counseling alone|"Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss >10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition."
75624261|NCT01009086|Drug|Ustekinumab 45 mg|SC injections
75914104|NCT05722236|Behavioral|IBD Strong Peer2Peer|Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.
75914105|NCT05722236|Other|Waitlist control|Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
75624262|NCT01009086|Drug|Ustekinumab 90 mg|SC injections
75624263|NCT05662072|Behavioral|Motor imagery|Mental imagery of respiratory exercises
75624264|NCT05662072|Behavioral|Action observation|Action observation of respiratory exercises
75914106|NCT05721742|Other|virtually administered dietitian consults for IBS patients.|Participants will receive virtual one on one consults with a dietitian who has training in the dietary management of IBS.
75914107|NCT05721742|Other|IBS Group Online Session|IBS online group session run by Happy Bellies Nutrition
76073718|NCT03587649|Drug|[18F]MNI-1126|"Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures."
76073719|NCT04148313|Other|No Intervention|There is no intervention for this study.
75624265|NCT05662072|Other|Placebo Intervention|Placebo observation
75624266|NCT01190150|Drug|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
75624267|NCT04211662|Behavioral|Tailored Multidimensional Intervention. the tailored intervention will be implemented through 6 months using a multidimensional approach (skill building, psychoeducation and peer support).|Skill-building can be defined as training the family caregivers the following skills (1) hands-on training in such skills as positioning, transferring and mobility techniques and assistance with activities of daily living; (2) coping strategies and stress management (3) communicating with healthcare professionals. Psycho-education is teaching and provision the family caregivers the knowledge and information regarding stroke (stroke definition, types of stroke, risk factors, prevention of recurrent stroke, medication management, stroke complications and measures for prevention and management of these complications). Besides, family caregivers will be taught and given the knowledge and information regarding managing stroke survivors' emotions and behaviors. Peer support can be defined as engaging the family caregivers of stroke survivors in interactions with their peers for support and exchanging advices and experiences.
75624268|NCT04315688|Drug|insulin degludec|Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
75321396|NCT03949907|Other|Early supplemental parenteral nutrition plus nutritional counseling|"Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated."
75914108|NCT05719675|Behavioral|Intervention|"The general outline of the intervention is divided into three phases:~Dispositional alteration, where the aim will be to obtain precise information on the barriers that patients encounter in carrying out their treatment and thus focus the issues to achieve an awareness of the disease by altering some of the factors that give rise to the realization of behaviors that interfere with treatment adherence.~Alteration of one's own behavior, focused on the development of healthy habits that are consistent with the indications of the health team for the proper management of the disease.~Alteration of the behavior of others, focused on the development of skills in the participants so that they are able to modify the behavior of other people close to them through health promotion strategies."
75914109|NCT05719519|Procedure|Initial periodontal therapy and 3D intraoral scanning|Initial periodontal therapy using GBT ( guided biofilm therapy) principle and 3D intraoral scanning
75321397|NCT00707863|Drug|Escitalopram|10 mg of Escitalopram by mouth once a day for 8 weeks
75777094|NCT04284943|Procedure|Conventional Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
75777095|NCT04284943|Procedure|Billroth II reconstruction after subtotal gastrectomy|The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)
75321398|NCT00565643|Device|modified sodium hyaluronic acid and carboxymethylcellulose|Adhesion barrier applied at the time of initial cesarean delivery
75624269|NCT05210062|Other|Iterative exposure to suxamethonium during ECT sessions|"The study is divided into 2 phases: phase P and phase E. Phase P: 10 patients to be included in 1 month with a unique dose of suxamethonium during one session of ECT. One blood sample will be taken from patients before their index ECT session. The objective is to evaluate the feasibility of antibody detection relative to the main objective of the study, to ensure the number of patients to include in phase E (analysis in the following month). Depending on the frequency of antibodies detected, particularly IgG4, the number of patients required for phase E will be revised. If no antibodies are detected, the study will be discontinued.~Phase E: 60 patients to be included in 12 months with 5 blood samples: before the first session of ECT (S0), at 2 weeks (S2), at 4 weeks (S4), between 6 - 14 weeks (preferably at S10) and at 6 months (M6). Only first-time patients or those not having been exposed to ECT in the past 10 years will be included in this phase."
75624270|NCT01001520|Drug|Tolcapone|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
76073720|NCT03589755|Behavioral|Mindfulness meditation|The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
75624271|NCT01001520|Drug|Placebo|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
75466580|NCT01910896|Device|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
76073721|NCT03589599|Other|Flavored tobacco|Effects of flavored tobacco
75777096|NCT04280952|Device|CONVIVO|tumor tissue with the CONVIVO system
75777097|NCT04270175|Drug|Daratumumab SC|Given as 1800mg via injection
75777098|NCT04270175|Drug|Pomalidomide|Given as 4mg oral capsule
75777099|NCT04270175|Drug|Dexamethasone|Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.
76073722|NCT03589599|Other|Non-flavored tobacco|Effects of non-flavored tobacco
76073723|NCT02984865|Drug|Sulfentanyl|
75321399|NCT00565643|Device|Placebo|Routine abdominal closure without placement of adhesion barrier
75624272|NCT00619840|Drug|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
75466581|NCT01910935|Behavioral|Physical activity prescription to develop program in group.|Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks. Led by the trained staff in physical activity to patients with chronic diseases.
75624273|NCT00619840|Drug|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
75777100|NCT04267549|Drug|sintilimab|a checkpoint inhibitor via blocking PD-1 (programmed cell death-1) site of signaling.
75777101|NCT04267549|Drug|apatinib|a multi-target anti-angiogenic tyrosine kinase inhibitor (TKI)
75798449|NCT02525952|Procedure|TACE|Transarterial chemoembolization with lipiodol and pirarubicin
75798450|NCT01166490|Drug|ASG-5ME|0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
76073724|NCT02984865|Drug|Nalbuphine|
76073725|NCT02984865|Drug|flubiprofen axetil|
75321400|NCT00708019|Behavioral|PRO-SELF PLUS Pain Management Program|The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls [total time 12.3 hours]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls [8.0 hours]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
75624274|NCT02871258|Device|The MetaNeb® System|
75914110|NCT05715073|Dietary Supplement|TeaCrine and Caffeine|Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
75914111|NCT05715073|Dietary Supplement|Caffeine|Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
75914112|NCT05715073|Other|Placebo|Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.
75914113|NCT05711862|Drug|SUVO|Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
75914114|NCT05711862|Drug|Placebo|Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
75624275|NCT04463082|Procedure|Intravenous administration of fluids|Intravenous administration of fluids (20ml/kg, but the maximum volume will be limited up to 500ml) within 60 minutes.
75914115|NCT05710666|Drug|trastuzumab deruxtecan (T-DXd) (IV)|Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.
75914116|NCT05710536|Other|Formulation X|This formulation containing stem cell secretome and liquorice root extract
75914117|NCT05710185|Drug|Deucravacitinib|See arm/group description
75777102|NCT04267549|Drug|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).
75777103|NCT04267549|Drug|Nab paclitaxel|Nab paclitaxel is a albumin-bound well tolerated paclitaxel than traditional paclitaxel
75777104|NCT04262336|Drug|DB-020|Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water
75914118|NCT05707208|Drug|ST-01|A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.
75914119|NCT05707208|Drug|1% Lidocaine HCL|Currently approved lidocaine
75914120|NCT05694858|Combination Product|Lignocaine-loaded maltose microneedle array patch|A biodegradable maltose microneedle array patch containing 12.5 mg lignocaine that will be applied on the participant's dorsal aspect of the hand for 30 minutes prior to intravenous cannulation
75914121|NCT05694858|Drug|EMLA 5% patch|EMLA 5% cream applied on the dorsum of the participant's hand which will be subsequently covered with PVA-PET adhesive for 30 minutes prior to intravenous cannulation
75914122|NCT05693948|Other|Other: Serum X|Serum X contain arbutin and glutathione
76073726|NCT02984865|Procedure|rectus sheath block|Transversus abdominis plane (TAP) block combined with rectus sheath (RS) block will be applied in Group ESRD
76073727|NCT03696069|Other|Non-Interventional|Non-Interventional
76073728|NCT03589521|Behavioral|ABCT_Military|15 Weekly Couple Therapy Sessions
76073729|NCT03589443|Drug|Multiplexed heptapeptides|Heptapeptides QRH and KSP
75321401|NCT05246501|Other|Simulation|A case scenario with a diagnosis of dementia was used in the study. The scenario consisted of preliminary preparation, implementation and evaluation parts. Psychiatric nursing laboratory practice was applied to the students in the scenario study group. An elderly female standard patient who was diagnosed with dementia took part in the scenario. During this simulation, students were expected to perform mental state examination of the patient, use therapeutic communication techniques and ensure environmental safety.
75624276|NCT02344108|Device|Inspire® Upper Airway Simulation System (Model 3028 IPG )|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
75624277|NCT04415658|Drug|Thyroxine|Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.
75624278|NCT04415658|Drug|Saline|The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.
75777105|NCT04262336|Drug|Placebo|Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
75777106|NCT04249726|Procedure|Direct composite resin restoration|A direct composite resin restoration will be provided intracoronally without cuspal coverage.
75777107|NCT04249726|Procedure|Direct composite resin restoration followed by full coverage metal ceramic crown|A direct composite resin restoration will be provided intracoronally followed by a full cuspal coverage metal ceramic crown.
76073730|NCT03589365|Other|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
76073731|NCT03587415|Diagnostic Test|preptin and amylin level|we will take both of group blood samples to compare them serum preptin and amylin
76073732|NCT03020433|Device|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
75777108|NCT04244266|Other|NO INTERVENTION, it is an observational study|No intervention
75777109|NCT04242238|Drug|DCC-3014|DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.
75777110|NCT04242238|Drug|Avelumab|Start Day 1 on first cycle with further infusions of avelumab every 14 days
75624279|NCT02871024|Device|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
75777111|NCT04235959|Drug|Tirzepatide|Administered SC
75777112|NCT04235959|Drug|Placebo|Administered SC
75777113|NCT04235101|Drug|SYD985 + Niraparib|SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
76073733|NCT03020433|Device|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
76073734|NCT03020433|Device|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
75321402|NCT05246501|Other|No simulation|The students in the control group did not receive simulation training.
75321403|NCT04386733|Other|no intervention, it was an observational study which looked at the reasons for surgical cancellations|the investigators observed how many patients had their surgeries cancelled and analysed the reasons of these cancellations
75321404|NCT05246423|Diagnostic Test|Observation group|Patients with paroxysmal atrial fibrillation undergo cardiopulmonary exercise testing, echocardiography, 24-hour ambulatory electrocardiographic monitoring and plasma biomarkers' measurement
75777114|NCT04231747|Biological|CC-97540|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection."
75777115|NCT04228692|Procedure|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
75777116|NCT04228692|Device|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
76073735|NCT03020433|Device|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
75321405|NCT02321527|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
76073736|NCT01797445|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
76073737|NCT01797445|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
76073738|NCT01797445|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
76073739|NCT01797445|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
75321406|NCT02321527|Device|Contrast-Enhanced Ultrasound (CEUS)|Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
75321407|NCT02321527|Procedure|Biopsy + Radioactive Seed Placement|Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
75321408|NCT02321527|Behavioral|Phone Call|Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
75466582|NCT01910948|Drug|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
75624280|NCT01189604|Drug|Placebo|Infusion of placebo, same infusion rates as for arm 2
75624281|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
75624282|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
75624283|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
75624284|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
75777117|NCT04223557|Device|focused power ultrasound treatment|Patients will be placed in the lateral decubitus position and receive treatment with sequential bilateral PRF ablation. Before the treatment, a professional sonographer will be responsible for the length, thickness, and width of PRF sac measurement and localisation, and utilise the ultrasonic diagnostic transducer to delineate the targeted region. The treatment will launch layer-by-layer. After confirming accurate localization of the treatment, layer-by-layer PRF ablation will be performed on the patients. The device generates and delivers a pattern of conic-shaped ultrasound energy to the PRF sac noninvasively. The treatment of FPU-mediated PRF ablation will be implemented once.
75777118|NCT04223557|Device|Sham treatment|Participants will receive the same procedure as those in the FPU treatment including PRF ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the PRF.
75777119|NCT04218617|Device|Diagnostic MRI|Diagnostic MRI
75777120|NCT04218617|Device|Planning MRI|Planning MRI: high definition (HD) MRI of the region of interest (1 vertebral level above and below the level(s) being treated)
75777121|NCT04218617|Other|Simulation CT|Simulation CT is obtained (1.5 mm slice thickness)
75914126|NCT05692622|Other|Whole-body exercise and respiratory exercise|The study involves an 8-week intervention involving whole-body and respiratory exercises. The whole-body exercise component will involve doing exercises while watching a total of 32 Comic Kids yoga movies. These movies have been adapted to suit the needs and abilities of the target population. For the first 7 weeks of intervention, children will be provided with 4 yoga movies for each week, providing around 67 minutes of exercise in each week. In the last week of intervention, children will have the choice to practice any 4 exercises of their choice from the 28 movies. The respiratory exercise component will involve watching a 10-minute-long movie that involves practicing different styles of breathing and breath holding. Participants will be provided a respiratory trainer to use while practicing these breathing exercises. Children will be asked to practice these breathing exercises by watching the movie at least 2 days each week.
75777122|NCT04218617|Other|QOL assessment|QOL assessment
75777123|NCT04218617|Other|Brief pain inventory (BPI)|Brief pain inventory (BPI), including narcotic assessment
75777124|NCT04218617|Radiation|sSRS in 1 fraction|sSRS 18 Gy in 1 fraction
75777125|NCT04218617|Radiation|sSRS in 2 fraction|sSRS 24 Gy in 2 fractions to be delivered either on consecutive days or one day apart.
75914127|NCT05691413|Other|Other: Product X facial cleanser|Product X facial cleanser contain olive oil, virgin coconut oil, butylene glycol and hyaluronic acid
75914128|NCT05690516|Behavioral|Wearing face masks|Participants are asked to wear face masks in public spaces.
75914129|NCT05680857|Other|Placebo|Product doesn't have active ingredients i.e. marine collagen peptide and Coenzyme Q10.
75914130|NCT05680857|Other|Product containing marine collagen peptide and Coenzyme Q10.|Product containing marine collagen peptide and Coenzyme Q10.
75914131|NCT05680545|Other|Sevoflurane vaporized in ECMO machines|Sevoflurane will be directly vaporized into the ECMO machine through the sweep gas.
75914132|NCT05679349|Other|Survey Administration|Complete survey
75624285|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
75624286|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
75914133|NCT05679349|Other|Educational Activity|Undergo online shared decision making training and distance learning
75914134|NCT05679349|Other|Survey Administration|Complete survey
75914135|NCT05679349|Other|Electronic Health Record Review|Undergo electronic health record review
75466583|NCT01910961|Procedure|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
75466584|NCT01910974|Procedure|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
75466585|NCT01910987|Drug|bortezomib (optimized retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
75624287|NCT02697058|Biological|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
75624288|NCT02697058|Drug|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
75624289|NCT04294524|Other|Sleep apnea treatment|Sleep apnea treatment as decided according to routine practice. This may be Continuous positive airway pressure (CPAP) or wearing a mandibular advancement device (MAD).
75777126|NCT04204811|Other|Prehabilitation|A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.
75777127|NCT04187131|Behavioral|augmented reality|The participants will be wearing an EEG cap and Augmented Reality headset (AR-based EEG-guided system) for 10 sessions with a licensed occupational therapist, provided in addition to usual rehabilitation care (either in inpatient rehabilitation or at home). These sessions will focus on activities of daily living that the participants want to practice. All sessions will last approximately 1 hour. These sessions will be scheduled around the existing therapy schedule to cause the least amount of interference with planned clinical activities.
75777128|NCT04182360|Drug|Carbetocin|Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.
75777129|NCT04168645|Behavioral|Cognitive Behavioral Therapy|Up to 4 sessions of BCBT (depending on length of stay) will be provided. The first session lasts 1.5 hours and subsequent sessions are 1 hour.
75624290|NCT05661994|Dietary Supplement|Omega-3 fatty acid supplementation|"Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group."
75777130|NCT04155606|Device|microsurgery; endovascular interventions|microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
75777131|NCT04147533|Drug|Imatinib withdrawal|withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
75777132|NCT04147533|Drug|Dasatinib|withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
75777133|NCT04147533|Drug|Nilotinib|withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
75777134|NCT04136587|Other|Colonic fluid collection during endoscopy for analysis of the bacterial secretome|Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
75777135|NCT04121962|Behavioral|Peer Mentor|Participants will be trained to be Peer Mentors and promote home-based testing to their social network
75777136|NCT04121962|Behavioral|Website only|Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
75777137|NCT04112368|Drug|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
75777138|NCT04112368|Drug|Oral Micronized Progesterone 200mg|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)
75777139|NCT04112368|Drug|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
75624291|NCT04294602|Other|Exercise|Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
75777140|NCT04112368|Drug|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
75777141|NCT04111770|Device|IVUS guided Percutaneous Coronary Intervention|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
75777142|NCT04111770|Device|QCA guided Percutaneous Coronary Intervention|QCA will be used to determine lesion characteristics
75777143|NCT04096443|Biological|Fecal microbial transplant (FMT)|Oral fecal microbial transplant capsules
75777144|NCT04088188|Drug|Cisplatin|Given IV
75777145|NCT04088188|Drug|Gemcitabine|Given IV
75777146|NCT04088188|Drug|Ivosidenib|Given PO
75914136|NCT05679349|Other|Educational Activity|Undergo online shared decision making training and distance learning
75914137|NCT05679349|Other|Counseling|Undergo shared decision making counseling
75624292|NCT04294602|Other|Low Level Laser Therapy|LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.
75777147|NCT04088188|Drug|Pemigatinib|Given PO
75777148|NCT04087811|Device|Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) (Superion® implant)
75777149|NCT04085796|Other|ICCI|Intentional Compassionate Communication Intervention
75777150|NCT04066192|Drug|Brexpiprazole|Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
75777151|NCT04066192|Drug|Placebo|A medically inert placebo medication will be used as described in the study arms.
75777152|NCT04062123|Drug|Dexmedetomidine|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.
75777153|NCT04062123|Drug|Propofol|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.
75914138|NCT05679349|Other|Survey Administration|Complete survey
75914139|NCT05679349|Other|Electronic Health Record Review|Undergo electronic health record review
75914140|NCT05677997|Behavioral|Intervention|Sessions to go through goals, problem areas, areas they want to improve.
75914141|NCT05676619|Device|3D foot scanner|Reliability of 3D foot scanner during repeated scans
75914142|NCT05676554|Other|An Enhanced Psychological Mindset Session for Adolescents|"It is a ten-minute psychoeducation video (animation) delivered on the internet, followed by five minutes of stories from fictional students about how they used the concepts. Participants then complete three multiple choice questions aimed to assess their understanding and ability to apply concepts from the video, followed by 'letter of advice' task where participants have to give advice to a fictional younger student based on the information presented in the animation and videos.~The intervention itself was developed by Perkins et al (2021) based on promoting a growth mindset. It was deemed to be a feasible and acceptable tool to promote mental health (Perkins et al., 2021) in their feasibility trial."
75777154|NCT04062123|Drug|Fentanyl|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.
75777155|NCT04062123|Device|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.
75914143|NCT05675956|Device|Experimental group with 100% intensity setting on Apollo Neuro device|The group will have the device set to 100% intensity at one of their two experimental visits.
75624293|NCT04294602|Other|Manuel Pressure Release|MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles
75624294|NCT04294602|Other|Patient Education|Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
75914144|NCT05675956|Device|Active Comparator group with 10% intensity setting on the Apollo Neuro device|The group will have the device set to 10% intensity at one of their two experimental visits.
75466586|NCT01910987|Drug|dexamethasone (optimized retreatment)|Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6
75624295|NCT02696824|Behavioral|Cognitive Behavioral Therapy for Adherence and Depression|"This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach."
75624296|NCT04296786|Drug|Sintilimab|200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment
75624297|NCT04296786|Drug|Chidamide|20mg po per week continuously
75624298|NCT00622414|Biological|ziv-aflibercept|Given IV
75624299|NCT01008696|Drug|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
75777156|NCT04062123|Drug|Placebo|Crystalloid IV solution will be infused, with no active drug.
75777157|NCT04061941|Behavioral|Cognitive Assessment|Assessment on cognitive dysfunction using standardised cognitive tests
75777158|NCT04059562|Combination Product|Combination of Lonsurf® and Irinotecan|"Trifluridine/Tipiracil (Lonsurf®) and Irinotecan~Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose."
75777159|NCT04032717|Drug|Q-Griffithsin (Q-GRFT) enema|Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
75777160|NCT04032717|Other|Placebo enema|Approximately 125mL of 0.9% sodium chloride solution
75777161|NCT04024267|Other|Eurythmy therapy|Mind-body therapy
75777162|NCT04024267|Other|CoordiFit|Fitness training
75914145|NCT05674383|Procedure|Axillary plexus nerve block|Axillary plexus nerve block: an ultrasound-guided axillary plexus nerve block with a single injection of lidocaine 1%.
75914146|NCT05674383|Procedure|Fracture hematoma block|Fracture hematoma block: a blinded single injection into the fracture with lidocaine 1%.
75914147|NCT05672628|Device|Oculus VR|During the first visit, the Oculus headset will be placed on the stroke survivor's head and demonstrate how to use the headset. participant will be then allowed to play a game using the hand controllers for up to 30 minutes. Finally, a copy of exercises for their home rehabilitation program will be provided. During the next rehabilitation visits, a trained research assistant will guide the stroke survivor with using the gaming headset. The session will be stopped every 20 minutes to make sure that the stroke survivor is feeling well and to give them a break. The stroke survivor may stop the session at any time. This session will last for an hour.
75466587|NCT01910987|Drug|bortezomib (standard retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression
75466588|NCT01910987|Drug|dexamethasone (standard retreatment)|Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
75466589|NCT01911000|Radiation|RT and hyperthermia after TACE|
75466590|NCT01911026|Other|Reinforcement Nurse Education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions from reinforcement educated nurse
75466591|NCT01911039|Biological|Regulatory T Cells|
75624300|NCT01008696|Drug|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
75624301|NCT01955980|Drug|Budesonide|Inhalation
75624302|NCT01955980|Drug|Budesonide|Nasal Spray
75624303|NCT02870478|Drug|Atropine|Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
75624304|NCT00622492|Other|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
75624305|NCT05661838|Procedure|transfusion|transfusion
75624306|NCT04296162|Drug|Vinorelbine|Vinorelbine chemotherapy (oral)
75777163|NCT04022343|Drug|Cabozantinib|Given PO
75777164|NCT03992261|Drug|Halobetasol Topical Foam|Foam
75777165|NCT03991884|Drug|Etoposide|Given IV
75777166|NCT03991884|Drug|Doxorubicin|Given IV
75777167|NCT03991884|Drug|Vincristine|Given IV
75777168|NCT03991884|Drug|Prednisone|Given PO or IV
75777169|NCT03991884|Drug|Cyclophosphamide|Given IV
75777170|NCT03991884|Biological|Inotuzumab Ozogamicin|Given IV
75777171|NCT03990493|Biological|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV (1 injection)
75624307|NCT04296162|Drug|Capecitabine|Capecitabine chemotherapy (oral)
75777172|NCT03990493|Biological|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)|IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
75777173|NCT03989895|Biological|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
75321409|NCT03889535|Device|Resin strip crowns|"Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish"
75624308|NCT04296162|Drug|Trastuzumab|Trastuzumab target therapy
75321410|NCT03889535|Device|Zirconia crowns|I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
75321411|NCT01798511|Procedure|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
75624309|NCT00619996|Drug|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
75624310|NCT00619996|Drug|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
75624311|NCT02870790|Drug|TDF/FTC|one pill daily
75624312|NCT05028400|Device|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
75624313|NCT05661526|Other|Bloodpoly board game|Blood transfusion training given by Bloodpoly board game
75624314|NCT05661526|Other|Text-to-speech group|Blood transfusion training given by text-to-speech
75624315|NCT00622570|Drug|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
75624316|NCT00622570|Drug|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion"
75624317|NCT04208308|Dietary Supplement|Chia seeds supplementation (25 g)|Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg
75624318|NCT04208308|Dietary Supplement|Chia seeds supplementation (15 g)|Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
75624319|NCT04208308|Dietary Supplement|Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20|"Chia seeds - 1 daily dose Fish oil TID~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
75777174|NCT03989869|Other|Immediate treatment|Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
75777175|NCT03988985|Other|Patient-targeted feedback|The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
75914156|NCT05670340|Device|Switched Prosthetic Profile|The implant will be rehabilitated with a switched emergence profile
75914157|NCT05670340|Device|Matched Prosthetic Profile|The implant will be rehabilitated with a matched emergence profile
75914158|NCT05668026|Drug|Venetoclax|In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
75914159|NCT05663268|Biological|Infliximab-dyyb biosimilar|Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab-dyyb that inhibits the activity of tumour necrosis factor (TNF)-alpha.
75914160|NCT05657379|Other|Other: Product X moisturizer|Product X moisturizer containing Hyaluronic Acid and Rosa Damascena Flower Water
75914161|NCT05654454|Drug|Bevacizumab|Bevacizumab 15 mg/kg
75914162|NCT05654454|Drug|Paclitaxel|Paclitaxel 175 mg/m2
75914163|NCT05654454|Drug|Carboplatin|Carboplatin AUC 6
75914164|NCT05653713|Drug|CSL324|Single intravenous (IV) dose of CSL324
75914165|NCT05653713|Drug|Placebo|IV dose of 0.9% saline
75777176|NCT03988985|Other|GP-targeted feedback|The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
75777177|NCT03986593|Device|cryoablation|cryoablation of bone metastases by cone beam-CT image-guidance
75777178|NCT03984565|Drug|Cannabidiol|High-CBD, low-THC sublingual product formulated in palm oil
75777179|NCT03984565|Drug|Placebo|Placebo sublingual product formulated in palm oil
75624320|NCT04208308|Dietary Supplement|Fish oil supplementation|"TID~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
75777180|NCT03978039|Drug|Chemotherapy|treatment as per standard of care
75777181|NCT03978039|Drug|Immunotherapeutic Agent|treatment as per standard of care
75777182|NCT03978039|Drug|target treatment|treatment as per standard of care
75914166|NCT05653024|Drug|Salbutamol|8 puffs of 100 mcg inhaled salbutamol administered with spacer
75914167|NCT05653024|Drug|Placebo|8 puffs of placebo inhaler administered with spacer
75914168|NCT05650411|Device|LMCA PCI with Biofreedom Ultra drug-coated stent (Biosensors International, Switzerland)|Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland).
75321412|NCT01798511|Other|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
75321413|NCT02998411|Other|Titration|
75624321|NCT01473004|Device|Sir-Spheres®|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
75624322|NCT05368792|Dietary Supplement|Complex Carbohydrate (PREcovery)|Each serving of the complex carbohydrate drink is a clear, colorless, 12.5% maltodextrin drink with a citrus taste, prepared by mixing 54 g of powder (50g carbohydrate) with 400mL of cold water. Participants will consume 2 servings of the complex carbohydrate drink the evening before colonoscopy (100g carbohydrate, 800mL fluid), and 1 serving 2 hours before their colonoscopy (50g carbohydrate, 400mL fluid)
75624323|NCT04141072|Diagnostic Test|Shrunken Pore Syndrome|eGFR Cystatin C ≤ 60% of eGFR Creatinine
75624324|NCT00925678|Drug|DSP-3025|
75624325|NCT00925678|Drug|Placebo|
75624326|NCT00890266|Procedure|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
75624327|NCT04208152|Drug|anle138b|capsule containing excipient and anle138b
75777183|NCT03978039|Procedure|Surgery|treatment as per standard of care
75777184|NCT03978039|Radiation|Radiotherapy|treatment as per standard of care
75777185|NCT03974945|Device|Passive-elastic prosthetic foot|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using their own passive-elastic prosthesis with and without visual feedback of peak propulsive force targets.
75777186|NCT03974945|Device|Powered ankle-foot prosthesis|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using a battery-powered ankle-foot prosthesis with and without visual feedback of peak propulsive force targets.
75777187|NCT03968679|Radiation|Unilateral elective nodal irradiation|After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.
75777188|NCT03964376|Other|Nasal High Flow|Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher & Paykel Inc.) with airflow of 20 to 50 Litre/minute
75777189|NCT03964376|Other|Usual Care|Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask
75777190|NCT03963531|Other|chemotherapy, surgery, radiotherapy, interventional radiology.|
75624328|NCT04208152|Drug|Placebo|matching placebo capsule containing excipient
75914169|NCT05650411|Drug|P2Y12 inhibitor-based SAPT|Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.
75914170|NCT05650411|Drug|Conventional DAPT|6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
75914171|NCT05648006|Biological|OH2|Oncolytic Type 2 Herpes Simplex Virus
75914172|NCT05648006|Drug|Capecitabine|1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
75914173|NCT05648006|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
75914174|NCT05646641|Other|Strength exercise|The protocol consists of 8 weeks of training, consisting of 16 sessions of 50 minutes, twice a week on alternate days.
75914175|NCT05645835|Behavioral|intervention|the digital meditation app will be installed on participants iPad or android. Lonely older adults will use the app five days a week for six weeks total. Neuroimaging will be performed before and after the intervention.
75914176|NCT05645835|Behavioral|waitlist control|Participants in the waitlist group will have to wait six weeks after being screened before being able to use the meditation app after the assessment of primary and secondary endpoints
75914177|NCT05645354|Behavioral|SmokefreeSGM|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of LGBTQ+ smokers.
75914178|NCT05645354|Behavioral|SmokefreeTXT|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of the general population
75914179|NCT05644626|Drug|BGB-B167|Intravenous administration
75914180|NCT05644626|Drug|Tislelizumab|Intravenous administration
75914181|NCT05642533|Other|No treatment given|No treatment given
75914182|NCT05639244|Behavioral|Time restricted eating (TRE)|Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.
75321414|NCT01798277|Procedure|Catheter Ablation|Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
75466592|NCT01911052|Other|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
75624329|NCT00622804|Procedure|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
75624330|NCT00622804|Procedure|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
75624331|NCT00622804|Procedure|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
75624332|NCT05367934|Behavioral|Therapeutic Touch|Therapeutic Touch for stress
75466593|NCT01911052|Other|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
75466594|NCT01911078|Procedure|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
75624333|NCT05661760|Behavioral|interdisciplinary multimodal pain treatment|A combination of physical and psychosocial treatment methods is employed, including Emotional Awareness and Expression Therapy (EAET), Pain Neuroscience Education (PNE), Acceptance and Commitment Therapy (ACT), graded activity, exposure in vivo, and experiential learning through physical training.
75624334|NCT04210960|Radiation|Magentic resonanace imaging|The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) _ 9583 sec, echo time (TE) _ 25 sec, inversion time (TI) _ 3400 sec, IR delay _ 325 sec, echo train length (ETL) _ 17, 50 contiguous axial slices, thickness _ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.
75777191|NCT03936647|Procedure|surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
75777192|NCT03936647|Device|WEB embolization device|WEB embolization device
75777193|NCT03917264|Procedure|Peri-implantitis debridement|Mechanical cleaning of titanium implants, peri-implantitis debridement.
75777194|NCT03917264|Other|Dental hygiene procedures|Titanium scalers and nylon brushed used for implant cleaning
75777195|NCT03915821|Device|ECT|"Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,"
75777196|NCT03913325|Other|PREVSAM model|A person-centred rehabilitation plan, including coordinated measures within primary health care as well as in collaboration with participants' employers, and when relevant the Swedish Public Employment Agency
75914183|NCT05639244|Behavioral|Regular diet|Participants have to consume their regular diet within an unrestricted time period for 2 weeks
75321415|NCT01798277|Drug|Medical therapy (sotalol or amiodarone)|Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
75321416|NCT04344847|Procedure|Laparoscopic sleeve gastrectomy|Excision of Gastric GIST along fundus or body of stomach in the same specimen of LSG with safety margin 1-2cm
75321417|NCT00598507|Drug|ZK-EPO|Participants were treated with 16 mg/m^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
75466595|NCT01911078|Device|EnligHTN™ Renal Denervation System.|
75466596|NCT01911156|Drug|Continue NA treatment|Prescribed NA during the 72 week study period
75466597|NCT01911156|Drug|Discontinue NA Treatment|Discontinue NA Treatment
75466598|NCT01911182|Other|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
75466599|NCT01911195|Drug|ISOFLURANE- Experimental Arm|The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
75466600|NCT01911195|Other|Control Group: Cognitive Testing|The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
75624335|NCT04210960|Radiation|Magentic resonanace spectroscopy|Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.
75624336|NCT04211038|Device|inspiratory threshold load device|"Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV."
75321418|NCT00566579|Procedure|Cryotherapy|Double freezing technique
75321419|NCT00566813|Drug|Islet Cell Transplant|1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml
75777197|NCT03913325|Other|Treatment as usual (standard treatment)|Treatment as usual (ordinary/standard) treatment. Can include unimodal or multimodal treatment of physiotherapy solely and/or occupational therapy
75624337|NCT04187638|Dietary Supplement|Olive oil|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
75624338|NCT04187638|Dietary Supplement|Butter|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
75624339|NCT04211116|Device|Central venous line insertion|Pediatric patients indicated to central venous line insertion
75624340|NCT02691832|Device|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
75777198|NCT03907501|Dietary Supplement|Synbiotic|an herbal prebiotic plus probiotic
75777199|NCT03907501|Dietary Supplement|Probiotic|Triphala alone
75777200|NCT03907501|Dietary Supplement|Placebo|Inert capsule
75777201|NCT03900533|Behavioral|Adjunctive group emotion regulation skills training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual
75321420|NCT00566813|Drug|Islet Cell Transplant plus|1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.
75777202|NCT03900533|Behavioral|Treatment as usual|Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
75321421|NCT00088166|Drug|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
75321422|NCT00088166|Drug|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
75321423|NCT00566969|Drug|sugar pill|Subjects randomized to placebo, carvedilol 25mg or 50mg
75624341|NCT01176968|Drug|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
75624342|NCT01176968|Drug|Placebo|Matching placebo tablets
75624343|NCT04211584|Device|transradial interventions|percutaneous coronary interventions in stable patients - diagnostic and treatment
75624344|NCT02697370|Drug|Pharmacokinetic based dosage change|Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
75624345|NCT02691442|Drug|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
75777203|NCT03900000|Other|Physiotherapy|Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
75321424|NCT00566969|Drug|Carvedilol 25 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
75321425|NCT00566969|Drug|Carvedilol 50 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
75321426|NCT03086564|Biological|ADCC & TACE|Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2*10^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
75321427|NCT03086564|Procedure|TACE|TACE solely in the first day of a clinical course.
75321428|NCT05363423|Procedure|Draf III procedure with lateral pedicled nasoseptal flaps applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa. After Draf III procedure, type 1 flaps were used to cover the bare bone of the ipsilateral frontal process and part of the ipsilateral anterior frontal table, which also constituted the bare bone area of the Draf II procedure. Type 2 flaps were used to cover for the bare bone of the ipsilateral frontal process and bilateral anterior or posterior frontal table."
75624346|NCT02691442|Drug|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
75777204|NCT03890289|Drug|Idelalisib|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
75777205|NCT03890289|Drug|Obinutuzumab|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
75321429|NCT05363423|Procedure|Draf III procedure without any flap applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre."
75624347|NCT02691442|Drug|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
75624348|NCT00622648|Drug|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
75624349|NCT00622648|Drug|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
75624350|NCT04316234|Other|Passive vape|On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
75624351|NCT04208386|Drug|JNJ-73763989|JNJ-73763989 will be administered SC under fasted condition.
75624352|NCT02886806|Other|BIS XP, Covidien, Ireland|Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
75624353|NCT02886806|Other|EV-1000 TM, Edwards Lifesciences, Irvine, California, USA|Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
75624354|NCT02687854|Drug|Apixaban|As prescribed by treating physicians
75624355|NCT02687854|Drug|Vitamin K antagonist|As prescribed by treating physicians
75624356|NCT03991468|Diagnostic Test|Whole Slide Imaging|Scanning of a glass slide to create a digital image that can be viewed on a monitor
75624357|NCT03991468|Diagnostic Test|Light Microscopy|Use of traditional light microscopy per institutional standard practice
75624358|NCT01006122|Drug|Placebo|Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
75624359|NCT01006122|Drug|PF-03654746|Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
75624360|NCT02687698|Other|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
75624361|NCT02689570|Other|observational|no interventions; observational study
75321430|NCT00598663|Device|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
75624362|NCT00639028|Other|Ankle echography|Ankle echography
75624363|NCT00639028|Other|Ankle echography + stress radiography|Ankle echography + stress radiography
75777206|NCT03846791|Other|Observational Study Post MAKO Robotic Surgery|To assess clinical outcomes and surgery related resource use in the year post surgery for patients undergoing hip replacement surgery using the MAKO robot
75777207|NCT03825289|Drug|Hydroxychloroquine|Given PO
75321431|NCT00598663|Device|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
75321432|NCT04350489|Other|Non-surgical periodontal treatment|Conventional non-surgical periodontal treatment were performed
75321433|NCT02987673|Procedure|MGB/OAGB|
75321434|NCT02987673|Procedure|LSG|
75321435|NCT03731819|Diagnostic Test|Abbreviated PB MRI|Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).
75321436|NCT00704353|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
75624364|NCT00639028|Other|stress radiography|ankle stress radiography
75624365|NCT04186156|Drug|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
75624366|NCT01005966|Drug|Sodium Fluoride Toothpaste|Test product
75624367|NCT01005966|Drug|Amine Fluoride Toothpaste|Test product
75624368|NCT01005966|Drug|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
75624369|NCT01005966|Drug|Placebo|placebo and washout treatment
75624370|NCT01005966|Drug|675 ppmf toothpaste|dose response
75321437|NCT00704353|Drug|Standard Medical Care (SMC)|Per product label
75321438|NCT05246033|Drug|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
75321439|NCT05246033|Drug|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
75321440|NCT00598819|Device|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
75624371|NCT03937960|Other|Carbohydrate restricted group|Prescribed low carbohydrate diet with set recipes
75624372|NCT03937960|Other|Standard low fat diet|Diet with less than 20% total calorie intake from dietary fats
75321441|NCT00087698|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
75624373|NCT01005732|Device|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and <5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
75777208|NCT03825289|Drug|Trametinib|Given PO
75321442|NCT00087698|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
75624374|NCT00628680|Device|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
75624375|NCT00628680|Drug|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
75321443|NCT03755739|Drug|Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy|vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
75321444|NCT05363033|Device|sarcopenia nursing guidance mobile application was developed|The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
75624376|NCT00603382|Drug|GW685698X|GW685698X
75624377|NCT00603382|Drug|Placebo|placebo comparator
75777209|NCT03816956|Drug|AR-301|AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
75777210|NCT03816956|Other|Placebo|Placebo comparator
75777211|NCT03803397|Biological|PV-001-DC|Patient-specific cellular therapeutic for cancer immunotherapy
75777212|NCT03800602|Drug|Metformin|Given PO
75777213|NCT03800602|Biological|Nivolumab|Given IV
75777214|NCT03779191|Drug|Alectinib|Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol
75777215|NCT03779191|Drug|Bevacizumab|Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
75777216|NCT03775902|Drug|Placebo|placebo tablet
75777217|NCT03775902|Drug|Nicorandil|20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)
75777218|NCT03765463|Behavioral|Habit Reversal Training|4 sessions of habit reversal training
75777219|NCT03743662|Radiation|Re-irradiation (RT)|Re-RT will start on day 28 +/- 5 days for 5 fractions of 600cGy every other day over a 2-week period.
75777220|NCT03743662|Drug|Bevacizumab|Bevacizumab if deemed beneficial by the investigator, will be started at the initiation of re-RT and continued for three doses in the medical arm. Patients in the surgical arm will omit the first bevacizumab dose to assure adequate wound healing after surgery and receive two doses. Bevacizumab will be dosed at 10mg/kg and given intravenously on day 28 (medical arm only), day 42 and day 56. Following day 56, further bevacizumab doses can be given every two weeks at the discretion of the treating physician.
75777221|NCT03743662|Drug|Nivolumab|"Nivolumab will be started at enrollment and each patient will receive two doses of nivolumab prior to radiation.~Nivolumab will be dosed at 3mg/kg given intravenously before re-RT (day 1 +/- 5 and 14 +/- 5) and when given with bevacizumab if deemed beneficial by the investigator, (day 28 +/- 5 (medical arm only), day 42 +/- 5, and day 56 +/-5). Nivolumab will be dosed based on body weight while combined with re-radiation and bevacizumab for safety considerations to reduce adverse events. Single agent nivolumab will be given at 240mg flat dose every 2 weeks thereafter until disease progression, withdrawal, adverse event, or death."
75777222|NCT03743662|Procedure|Re-resection|Re-resection will be performed in the surgical arm at day 14 (+/- 5 days).
75777223|NCT03736564|Combination Product|68Ga-DOTATATE PET/CT|Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein. Subjects will rest for approximately 50 minutes, after which approximately a 30 minute image of subjects body will be completed via PET/CT scan.
75777224|NCT03726086|Diagnostic Test|laryngoscopy|A flexible camera (fiberoptic endoscope) is placed in the patient's nose to view the nose, throat, and airway.
75777225|NCT03712891|Dietary Supplement|Coffee|Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
75777226|NCT03712878|Radiation|Total-Body Irradiation|Undergo TBI
75321445|NCT05245721|Drug|Nalbuphine|Caudal nalbuphine injection in pediatrics undergoing infra-umbilical surgeries
75321446|NCT05245721|Drug|Bupivacain|Caudal bupivacaine in pediatrics undergoing infra-umbilical surgeries
75321447|NCT04402892|Other|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
75321448|NCT04402892|Other|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
75321449|NCT02987985|Drug|Acetaminophen, gabapentin|acetaminophen 15 mg/kg, gabapentin 10 mg/kg
75321450|NCT02987985|Drug|Acetaminophen|acetaminophen 15 mg/kg
75624378|NCT01176266|Drug|asfotase alfa|
75624379|NCT01182428|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
75624380|NCT01182428|Device|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
75777227|NCT03712878|Procedure|Donor Lymphocyte Infusion|Given IV
75777228|NCT03712878|Drug|Cyclophosphamide|Given IV
75777229|NCT03712878|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
75777230|NCT03712878|Drug|Tacrolimus|Given IV
75777231|NCT03712878|Drug|Mycophenolate Mofetil|Given IV
75777232|NCT03691870|Procedure|Standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
75321451|NCT02987985|Drug|Ketamine , Lidocaine , Dexmedetomidine|Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
75624381|NCT00603304|Drug|Saw Palmetto - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
75624382|NCT00603304|Drug|Placebo - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
75624383|NCT00603304|Drug|Saw Palmetto - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
75624384|NCT00603304|Drug|Placebo - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.
75624385|NCT00603304|Drug|Saw Palmetto - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
75624386|NCT00603304|Drug|Placebo - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
75624387|NCT01176032|Drug|Aliskiren|Aliskiren 300 mg film coated tablets
75624388|NCT01176032|Drug|Losartan|Losartan 100 mg tablets
75624389|NCT01176032|Drug|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.
75624390|NCT01176032|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (<140/90 mmHg) had not been reached.
75624391|NCT02691598|Drug|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
75624392|NCT01008618|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
75624393|NCT01008618|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
75624394|NCT01001208|Drug|Methotrexate|Methotrexate tablets over-encapsulated for blinding
75624395|NCT01001208|Drug|Etanercept|1 mL for subcutaneous injection
75624396|NCT01001208|Drug|Placebo|Matching placebo to methotrexate capsules
75624397|NCT04296708|Other|Exergame Training|An exergame combines exercise and gaming in a holistic approach.
75624398|NCT04296630|Other|Social media message #1|Social media message promoting colorectal cancer screening
75624399|NCT04296630|Other|Social media message #2|A different social media message promoting colorectal cancer screening
75624400|NCT04296630|Other|Social media message #3|A different social media message promoting colorectal cancer screening
75777233|NCT03691870|Procedure|Trans-Venous Embolization (TVE)|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion."
75777234|NCT03651206|Drug|Niraparib|PARP Inhibitor
75777235|NCT03651206|Combination Product|Niraparib + TSR-042 (Dostarlimab)|Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1
75777236|NCT03651206|Drug|Chemotherapy Drugs|Chemotherapies given in standard of care
75777237|NCT03650322|Behavioral|Yoga|12 weeks, total of 150 minutes of exercise per week.
75777238|NCT03650322|Behavioral|Stretching and Toning|12 weeks, total of 150 minutes of exercise per week.
75777239|NCT03650322|Behavioral|Aerobic Walking|12 weeks, total of 150 minutes of exercise per week.
75777240|NCT03525613|Drug|APL-2|Complement (C3) Inhibitor
75321452|NCT02987985|Drug|Fentanyl, Dexmedetomidine|Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
75321453|NCT02987985|Drug|Dexamethasone , Ondansetron|Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
75321454|NCT02987985|Drug|Sevoflurane|Sevoflurane (dose titrated to effect)
75321455|NCT02987985|Drug|Sevoflurane, Fentanyl|Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
75624401|NCT04296630|Other|Tailored social media messages|Tailored social media messages promoting colorectal cancer screening.
75624402|NCT04295460|Drug|Randomize|Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
75777241|NCT03525613|Drug|APL-2|Complement (C3) Inhibitor
75777242|NCT03525613|Other|Sham Procedure|Subjects will receive a Sham procedure every month
75777243|NCT03525613|Other|Sham Procedure|Subjects will receive a Sham procedure every other month
75777244|NCT03511807|Other|Electrical|"For the electrical stimulation:~An electrode will be inserted into the ear canal which will be stimulated."
75777245|NCT03511807|Other|Acoustic|"For the acoustic stimulation:~A typical sound will be presented for 6 minutes. Loudness is reported for 4 minutes after the stimulus offset to measure the presence and duration of the residual inhibition. If a successful acoustic stimulus is found, the subject will be given a series of sound files to listen to on a digital music player (CD or MP3 player) and will be asked to listen to each sound file (5 minute duration) and record their tinnitus loudness/annoyance during and after each sound stimulation. For some subjects, the investigators will use music on a digital music player (MP3 player) to see if music listening and music exercises will help reduce the intensity or annoyance level of the tinnitus (using the same surveys). These music-based exercises will involve training in recognition of musical intervals (e.g., octaves, fifths, and thirds)."
75777246|NCT03500692|Device|MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
75777247|NCT03495882|Drug|AGEN1884 + AGEN2034|AGEN1884 + AGEN2034 according to protocol design
75777248|NCT03485417|Drug|Aripiprazole|for oral or depot preparation
75777249|NCT03485417|Drug|Paliperidone|for oral or depot
75777250|NCT03485417|Other|Treatment as Usual|to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone
75777251|NCT03485274|Drug|Vortioxetine|oral medication taken once daily
75777252|NCT03485274|Other|Treatment as Usual|Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
75914184|NCT05637502|Other|Graded Motor Imagery|Graded Motor Imagery programme consisting on three stages that will be gradually implemented. (i) Implicit Motor Imagery, that will be implemented through a developed app that resembles the Recognize app but adapted for Pelvic Floor disorders, (ii) Explicit Motor Imagery, applied through several sessions of motor imagery assisted through audio recordings and (iii) Graded Exposure, also guided through audio recordings and several practical tasks to perform.
75914185|NCT05637502|Other|Education|Participants will receive a therapeutic educational programme specifically developed for Genito-Pelvic Pain Penetration Disorder. The programme will include content involving Pelvic Floor anatomy, pain-processing and sexuality discussions.
75914186|NCT05636995|Diagnostic Test|Aldosterone/Renin Ratio|Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
76073740|NCT03587181|Procedure|Cryoablation of the pulmonary veins and myocardial biopsy|"Before intervention blood samples will be collected for biobank storage. After left atrial appendage thrombus exclusion, a cardiac biopsy from intraventricular and interatrial septum will be performed. PV isolation will be performed with cryoablation. Successful PV isolation will be confirmed by the confirmation of bi-directional block. Phrenic nerve function will be assessed in a standard fashion during intervention of the right PVs using high output phrenic nerve pacing from the superior vena cava. Loop recorder implantation will be performed during the same procedure.~In patients with recurrent atrial tachyarrhythmias an EP study will be performed to assess the mechanism of recurrence. PV reconnections will be re-isolated and linear lesions performed as required."
76073741|NCT04765683|Other|questionnaire|Survey of views on outpatient consultation format
76073742|NCT03589131|Procedure|Total Operative time|Investigators compare the preparation time of the procedure in the operating room and the actual operative time
75624403|NCT02871102|Procedure|Recruitment Maneuver with PEEP and Tidal Volume Optimization|A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
75624404|NCT01000974|Biological|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
75624405|NCT01000974|Biological|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
75624406|NCT01000974|Biological|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
75624407|NCT01000974|Biological|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
75624408|NCT01000974|Biological|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
75777253|NCT03474575|Other|Prevention|The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
75777254|NCT03457077|Behavioral|Brief intervention|A brief motivational intervention with feedback about drinking levels compared to norms
75914187|NCT05636774|Drug|Heart failure medication|Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.
75914188|NCT05636774|Drug|Placebo|Placebo tables / infusion
76073743|NCT03589131|Procedure|Margin assessment|In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.
76073744|NCT03589131|Procedure|Conversion rate to open surgery|In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
76073745|NCT03589131|Procedure|Baseline demographics|These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
76073746|NCT03589131|Procedure|Preoperative data|"These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared"
75624409|NCT01000974|Biological|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
75914189|NCT05636111|Drug|Paclitaxel|Given by (IV) vein
76073747|NCT03589131|Procedure|Postoperative data|These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission & 30-days mortality. All were analyzed and compared
75624410|NCT01000974|Biological|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
75624411|NCT01000974|Biological|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
75624412|NCT04295616|Device|Intrapulmonary percussive ventilation (IPV)|"IPV is a well-tolerated method to pump air jets into the lungs via a mouth mask at frequencies of 100-400 pulses per minute.~Each IPV session lasts 15 minutes, whereby the person with MS is firstly administered with a mask for 3 minutes at a high frequency (250 to 400 cycles per minute) and then 12 minutes with a low frequency (75 to 150 cycles per minute). The pressure (1.1 - 1.4 bar) is adjusted so that it is comfortable for every participant, yet there is the maximum possible expansion of the thorax. The sessions are given by speech therapists who are familiar with IPV. The IPV treatment will be provided 5 days a week, during 3 or 4 weeks."
75777255|NCT03434028|Drug|Early Vasopressors|"Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met."
75914190|NCT05636111|Drug|Bevacizumab|Given by (IV) vein
75914191|NCT05636111|Drug|Lurbinectedin|Given by (IV) vein
75914192|NCT05635617|Procedure|Lower Extremity Surgery|Patients 18 years of age or older with high energy lower extremity fractures. Provision of informed consent.
75624413|NCT04295616|Behavioral|Active breathing training|The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.
75777256|NCT03434028|Other|Early Fluids|"Additional 2 liter intravenous fluid infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter). Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. Rescue vasopressors may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted."
75914193|NCT05627167|Other|day time cyclic nutrition|Continuous isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100 mL for 10 hours during the day (e.g. 08:00 to 18:00), via nasal or oro-gastric tube
75624414|NCT01004406|Device|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks
75624415|NCT01004406|Drug|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
75624416|NCT04210804|Dietary Supplement|Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)|200mls Smoothie
75777257|NCT03433404|Procedure|Soft Tissue Mobilization|The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.
75777258|NCT03433404|Procedure|Soft Tissue Massage|For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes
75624417|NCT04210570|Device|Memsorb|Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit
75624418|NCT04210570|Drug|Chemical granulate absorber|Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
75624419|NCT01187368|Device|EVAHEART Left Ventricular Assist System (LVAS)|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
75624420|NCT01187368|Device|HeartMate 3|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
75777259|NCT03404960|Drug|Niraparib + Nivolumab|Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
75777260|NCT03404960|Drug|Niraparib + Ipilimumab|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
75777261|NCT03393845|Drug|Pembrolizumab|Pembrolizumab 200mg IV, 21 day cycles
75777262|NCT03393845|Drug|Fulvestrant|Fulvestrant, 500mg IM, Loading dose: C1 D1 & 15. Thereafter, Q4 wks
75777263|NCT03391466|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously following a conditioning chemotherapy regimen of fludarabine and cyclophosphamide
75777264|NCT03391466|Drug|Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.|Platinum-containing salvage chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP as selected by treating investigator) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
75777265|NCT03391466|Drug|Cyclophosphamide|Administered intravenously
75777266|NCT03391466|Drug|Fludarabine|Administered intravenously
76073748|NCT03589053|Device|Limb remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
76073749|NCT03589053|Device|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
75624421|NCT01093612|Procedure|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
75777267|NCT03391427|Drug|Lidocaine|This group will receive lidocaine infusion
75777268|NCT03391427|Drug|Ketamine|This group will receive Ketamine infusion
75777269|NCT03391427|Drug|Lidocaine+ketamine|This group will receive mixture of ketamine and lidocaine infusion
75777270|NCT03391427|Drug|Saline|This group will receive saline infusion
75777271|NCT03384446|Other|Tooth-borne treatment|Titanium curettes
75777272|NCT03384446|Other|Implant-specific treatment|Implant brush
75777273|NCT03373084|Other|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
75777274|NCT03373084|Other|ultrasound|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
76073750|NCT03587103|Behavioral|Protocol initiate with A|The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
75624422|NCT01093612|Radiation|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
75777275|NCT03373084|Other|Self-questionnaire|Self-questionnaire will be completed by patient. In this questionnaire patients will describe the circumstances of the injury and their personal characteristics and level of sporting practice.
75777276|NCT03339765|Behavioral|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
75777277|NCT03307343|Behavioral|Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
75777278|NCT03290950|Drug|daratumumab|Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.
75777279|NCT03290950|Drug|carfilzomib|Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
75777280|NCT03290950|Drug|lenalidomide|Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
75914194|NCT05627167|Other|continuous nutrition|Isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100ml, continuously 24 hours a day by nasal or oro-gastric tube
76073751|NCT03587103|Behavioral|Protocol initiate with C|The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
76073752|NCT03587103|Behavioral|Protocol initiate with D|The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
75624423|NCT01093612|Procedure|Biopsy|Correlative Studies
75624424|NCT01093612|Other|Immunohistochemistry staining method|Correlative studies
75624425|NCT01093612|Other|laboratory biomarker analysis|Correlative studies
75624426|NCT01093612|Genetic|mutation analysis|Correlative studies
75624427|NCT00620152|Behavioral|1|Low glycemic load diet by telephone counseling
75624428|NCT00620152|Behavioral|2|Low fat diet by telephone counseling
75624429|NCT04210648|Device|Mobile app|Mobile app for self-managing emotional dysregulation
75624430|NCT02687308|Procedure|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
75624431|NCT02687308|Procedure|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
75624432|NCT03900832|Other|Without Heating|Subject will complete walking protocol without any heating procedure
75777281|NCT03290950|Drug|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, 16 and 22; Cycles 3-4: Dexamethasone 20mg/dose, days 1,2,8,9,15 and 16, Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16
75777282|NCT03290950|Drug|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 1, 2, 22; 40 mg/dose days 8 and 15, Cycles 2: Dexamethasone 40mg/dose, days 1, 8, 15; 20 mg/dose day 22, Cycles 3-4: Dexamethasone 40mg/dose, Days 1, 8 15, Cycles 5-8: Dexamethasone 20mg/dose, Days 1, 8, 15
75777283|NCT03269396|Procedure|Larynx Allograft Transplantation|This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
75777284|NCT03267849|Other|wearing swimming goggles or having laser suturelysis|Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the interventions
75777285|NCT03264404|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks until progression
75777286|NCT03264404|Drug|Azacitidine|50 mg/m2 subcutaneous daily for 5 days every 28 days
75777287|NCT03254758|Biological|Mesenchymal stem cell|"Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.~Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1."
75777288|NCT03241745|Drug|Nivolumab|Nivolumab 480 mg IV once every 4 weeks
75914195|NCT05627115|Drug|Tislelizumab, AVD, Radiotherapy|"GROUP A: Early stage disease without adverse features in CMR: 2 further cycles tislelizumab then radiotherapy then 200mg IV tislelizumab once every 3 weeks until a maximum of 2 years total treatment. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP B: Early stage disease with adverse features in CMR: 2 cycles of AVD plus tislelizumab then radiotherapy. PET-CT (PET2) 12 weeks after the completion of radiotherapy.~GROUP C: All early stage disease not in CMR: 4 cycles of AVD plus tislelizumab then PET-CT and radiotherapy. PET-CT 12 (PET2) weeks after radiotherapy.~GROUP D: Advanced stage disease in CMR: 4 cycles of AVD plus tislelizumab then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP E: Advanced stage disease not in CMR: 6 cycles of AVD plus tislelizumab then PET-CT then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy."
75624433|NCT03900832|Other|Warm Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 38-41°C. Subjects will remain in the tub for ≤ 30 minutes. If the HR increases more than 15 -20 bpm, or a significant BP drop occurs (e.g. BP >20 mmHg), the subject will be removed from the bath even if the time is <30 min."
75624434|NCT03900832|Other|Neutral Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 35 - 37°C. Subjects will remain in the tub for ≤ 30 minutes."
75624435|NCT03900832|Other|Heating Suit|The mean skin temperature Tsk will be controlled with a water-perfused suit worn by subjects. Whole-body heating will be accomplished by perfusing warm water (~ 45 - 50 °C) through the suit to elevate the Tsk to ≤ 38 °C (100 oF). Warm water is through plastic tubes, and subjects' skin will not directly touch warm water. The heating will be continued until the ∆Tcore reaches ~ 0. 6 - 1.0 °C. This may take approximately 60 - 90 min.
75624436|NCT03900832|Other|Lower limb warm water immersion|Subjects will sit on a chair and put their lower legs and feet in a bucket with warm water. The water level will be just below the knees (depth of approximately 40 cm). The water temperature will be monitored and controlled at ~38 - 42 °C throughout the 30 minutes. BP, HR, Tcore, the skin temperature and skin blood flow (e.g. on a thigh and/or forearm) will be measured before, during and after the lower limbs warm water immersion.
75624437|NCT03900832|Other|Gardner walking protocol|The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.
75624438|NCT00639106|Procedure|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
75624439|NCT00639106|Procedure|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
75624440|NCT01182350|Drug|Bevacizumab|
75624441|NCT01182350|Drug|Erlotinib|
75624442|NCT01182350|Drug|Temozolomide|•
75624443|NCT01182350|Radiation|Radiation|
75624444|NCT02886416|Other|Non interventional study|
75624445|NCT04315844|Device|Ewata balloon guiding|The balloon guide catheter is coaxial cavity and reinforced braided catheter with varying stiffness echelon.The distal end is marked by an impermeable ray, the proximal end has a bifurcated ruhr interface, and the end is embedded with a compliance balloon.The product label indicates the size of the balloon guide catheter and the maximum volume of the balloon.
75624446|NCT05367518|Dietary Supplement|Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
75624447|NCT05367518|Dietary Supplement|Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
75624448|NCT01163474|Other|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
75624449|NCT00603538|Drug|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
75624450|NCT03854734|Behavioral|Community Event|Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
75777289|NCT03218384|Drug|Ferric Carboxymaltose|Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.
75624451|NCT03854734|Behavioral|Educational Material|Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
75624452|NCT04545580|Drug|Placebo|Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
75624453|NCT04545580|Drug|BAY1817080|BAY1817080 will be taken twice daily orally as tablet(s)
75624454|NCT04185766|Dietary Supplement|Administration of a placebo solution (0.5 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
75624455|NCT04185766|Dietary Supplement|Administration of a placebo solution (1 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
75624456|NCT04185766|Dietary Supplement|Administration of 40% glucose in gel (0.5 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
75624457|NCT04185766|Dietary Supplement|Administration of 40% glucose in gel 1 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
75624458|NCT02537938|Drug|NGP 555|
75777290|NCT03218384|Drug|Placebo|100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.
75777291|NCT03218384|Device|31P MRS/MRI|Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.
75777292|NCT03208387|Diagnostic Test|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
75624459|NCT04033900|Device|Forced air warming devices|"In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room"
75777293|NCT03208387|Diagnostic Test|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
75777294|NCT03208387|Behavioral|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
75777295|NCT03208387|Behavioral|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
75777296|NCT03208387|Behavioral|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
75777297|NCT03208387|Behavioral|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
75777298|NCT03208387|Behavioral|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
75777299|NCT03208387|Diagnostic Test|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
75777300|NCT03157115|Device|Kinocardiography|"This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group."
75777301|NCT03129555|Drug|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
75777302|NCT03129555|Drug|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
75777303|NCT03129555|Drug|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
75777304|NCT03129555|Drug|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
75777305|NCT03129490|Drug|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
75777306|NCT03129490|Drug|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
75624460|NCT00639184|Other|Early intervention counseling|Bi-monthly home visits by counselor
75321456|NCT03739749|Procedure|Arthroscopic superior capsular reconstruction|The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft
75624461|NCT00639184|Other|Health education counseling|World Health Education health education counseling program at home visits,twice per month
75624462|NCT02537860|Other|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
75624463|NCT02537860|Other|Placebo at T11 and L3|Two injections that contain saline are performed
75624464|NCT02537860|Other|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
75624465|NCT02537860|Procedure|Herniorrhaphy|Unilateral inguinal hernia repair
75624466|NCT02537860|Drug|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
75624467|NCT02537860|Drug|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
75624468|NCT02687230|Drug|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
75624469|NCT02687230|Drug|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
75777307|NCT03129490|Drug|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
75777308|NCT03129490|Drug|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
75624470|NCT04210102|Diagnostic Test|Lung Ultrasound (LUS)|"Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs."
75624471|NCT04210102|Diagnostic Test|Chest radiography (CR)|The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
75777309|NCT03121014|Drug|Fludarabine|40 mg/m^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
75777310|NCT03121014|Drug|Busulfan|targeting a 4800μM/min/ day from day -5 through day -2
75777311|NCT03121014|Drug|ATG|0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
75777312|NCT03121014|Radiation|Total Marrow Irradiation|dose of 3Gy on days -3, -2 and -1
75624472|NCT02885792|Other|Illness history|Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
76073753|NCT01611259|Drug|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
75777313|NCT03121014|Procedure|Stem Cell Product Infusion|Day 0 according to BMT unit policy
75777314|NCT03121014|Drug|Tacrolimus|The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
75777315|NCT03121014|Drug|Methotrexate|5mg/m^2 on Day 1, 5 mg/m^2 on Days 3, 6 and 11
75777316|NCT03118570|Drug|setrusumab|Intravenous infusion
75777317|NCT03118570|Dietary Supplement|Calcium|tablets
75777318|NCT03118570|Dietary Supplement|Vitamin D|capsules
75777319|NCT03118570|Drug|zoledronic acid (optional)|Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
75914196|NCT05619822|Behavioral|TAU + A comprehensive third-generation intervention|This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience. Session 2. Life history and immediate reactions to trauma. Session 3. Preparing to deal with trauma. Session 4. Regulating emotions. Session 5-9. Focusing on retelling and processing the traumatic event (EMDR PHASES_PHASE 3: Evaluation of the traumatic memory. EMDR PHASE 4: Desensitization. EMDR PHASE 5: Positive Belief Installation. PHASE 6: Body Scan). Session 9. Re-evaluating traumatic memory and self-care through positive emotions. Session 10. Cultivating self-kindness. Session 11. Developing a healthy identity. Session 12. Building a better future
75914197|NCT05619822|Behavioral|TAU|Treatment as usual
75624473|NCT02885792|Other|Measure of social conditions|A self-report questionnaire measuring social isolation, including relations to family and friends.
75777320|NCT03076320|Combination Product|PDF+M-DDO|Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.
75777321|NCT03076320|Combination Product|A+PBO|Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
75914198|NCT05616650|Drug|18F-DCFPyL|Each participant will receive a single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi; dose variations will be in accordance with the Nuclear Regulatory Commission (NRC) standard dose variation (i.e., 20%) permitted for diagnostic clinical studies.
75777322|NCT03066739|Drug|Remifentanil|0.1 micrograms/kg/mL
75466601|NCT01911208|Behavioral|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
75466602|NCT01911208|Behavioral|Control|Non-intervention control.
75466603|NCT01911234|Biological|TNF-Kinoid|IM administration
75466604|NCT01911234|Other|Placebo|IM administration
75466605|NCT01911247|Drug|Metformin|Metformin 850 mg once daily
75466606|NCT01911286|Procedure|Apnea test - Standard|
75466607|NCT01911286|Procedure|Apnea test - CPAP|
75624474|NCT02885792|Other|Measure of psychiatric condition|This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
75777323|NCT03066739|Drug|Remifentanil+ Placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
75777324|NCT03066739|Drug|Remifentanil +ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
75777325|NCT03033303|Biological|Hu3F8|Day 1: hu3F8 infused iv over ~30 to 90 minutes. Day 3: hu3F8 infused iv over ~30 to 90 minutes. Day 5: hu3F8 infused iv over ~30 to 90 minutes.
75777326|NCT03033303|Drug|GM-CSF|Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
75777327|NCT03033303|Drug|Isotretinoin|Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
75777328|NCT03021135|Procedure|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection
75777329|NCT03021135|Procedure|Underwater Endoscopic Mucosal Resection|Underwater Endoscopic Mucosal Resection
75777330|NCT03013829|Behavioral|KPD Educational Video|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
75914199|NCT05616650|Radiation|Stereotactic Body Radiation Therapy|Intensity modulated radiotherapy will be delivered to a dose of 26Gy in two fractions with the second fraction performed within 8 days of the first session.
75914200|NCT05611476|Behavioral|Cognitive Muscular Therapy for low back pain|Psychologically informed physiotherapy which used biofeedback training to reduce muscle overactivity and improve postural control
75624475|NCT02885792|Procedure|Cardiovascular measurement|This procedure is used to detect early identification of cardiovascular disease progression.
75914201|NCT05610514|Other|E-Cigarette|Altering the availability of e-cigarettes
75914202|NCT05610514|Behavioral|Financial Incentives|Altering the availability of financial incentives for abstaining from combustible cigarettes
75914203|NCT05605197|Drug|U87 CAR-T|Subjects will be pretreated with cyclophosphamide 250~500 mg/m2( body surface area) for 3 days prior to Intratumoral injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2. This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3~6 patients.
75914204|NCT05604963|Procedure|Total Thyroidectomy|Total Thyroidectomy - surgical removal of entire thyroid gland
75914205|NCT05604963|Procedure|Hemithyroidectomy|Hemithyroidectomy - surgical removal of partial thyroid gland
75914206|NCT05603026|Device|Self-expanding valve (Medtronic Evolut FX)|Bioprothesis Medtronic Evolut FX supra-annular self-expanding valve
75624476|NCT01162304|Drug|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
75777331|NCT03009981|Drug|Apalutamide|Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
75914207|NCT05603026|Device|Balloon-expanding valve (Edwards Sapien 3 Ultra)|Bioprosthesis Edwards Sapien 3 Ultra valve
75914208|NCT05602220|Behavioral|Brain training|Participants will play a few brain training games using an online interface each day. These games train attention, memory and other cognitive functions.
75914209|NCT05602220|Behavioral|Paced breathing|After completing brain training, they will then immediately do one 15-minute session of paced breathing, followed by a second 15-min session of paced breathing later in the day. During the paced breathing sessions, participants will clip a pulse monitor to their ear lobe and try to inhale and exhale in synchrony with a ball that moves up and down on the screen. They will receive heart rate biofeedback regarding whether they are achieving their relaxation/alertness goal.
76073754|NCT04147767|Dietary Supplement|Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|"Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)***, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~*** Equivalent to 2% Free Plant Sterols"
75914210|NCT05600868|Behavioral|A comprehensive third-generation intervention EMDR + dual attention|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with double attention.
75914211|NCT05600868|Behavioral|A comprehensive third-generation intervention EMDR + fixed point|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with fixed point.
75914212|NCT05600868|Behavioral|A comprehensive third-generation intervention EMDR + exposition|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with exposition.
75914213|NCT05597969|Behavioral|FoodCoach|The FoodCoach app displays transparent analysis and recommendations regarding participant's food purchases recorded on their loyalty cards. It tries to help participants understand why and how they should/can shop more healthily, motivating them to change their unhealthy food purchase behavior.
75914214|NCT05597306|Drug|Bomedemstat|Bomedemstat will be administered orally once daily via capsule.
75914215|NCT05597306|Drug|Venetoclax|Venetoclax will be administered orally once daily via tablet.
76073755|NCT04147767|Dietary Supplement|Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)|Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
76073756|NCT03586869|Drug|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
76073757|NCT03586869|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
75466608|NCT01911299|Dietary Supplement|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
75624477|NCT01162304|Drug|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
75624478|NCT04515394|Drug|Tepotinib|Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 [RECIST v1.1]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
76073758|NCT03586869|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
76073759|NCT03586869|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2
76073760|NCT03586869|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
76073761|NCT03586869|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
76073762|NCT03586869|Biological|GI-4000|RAS yeast
76073763|NCT03586869|Biological|GI-6207|Carcinoembryonic Antigen (CEA) yeast
76073764|NCT03586869|Biological|GI-6301|Brachyury yeast
76073765|NCT03586869|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
75624479|NCT04515394|Biological|Cetuximab|Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 [RECIST v1.1]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
75624480|NCT04206176|Drug|Ticagrelor|Ticagrelor 45mg twice daily per oral administration
75624481|NCT01175018|Drug|Anakinra|Anakinra 100 mg s.c. daily for 14 days
75777332|NCT03009981|Drug|LHRH Analogue|"Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~OR:~Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1."
75777333|NCT03009981|Drug|Abiraterone Acetate|Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
76073766|NCT03586869|Biological|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
76073767|NCT03586869|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75624482|NCT01175018|Drug|Placebo|0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
75624483|NCT02685514|Device|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
75624484|NCT04314986|Drug|Cohort 1: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
75624485|NCT04314986|Drug|Cohort 2: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days.
75624486|NCT04314986|Drug|Cohort 3: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
75624487|NCT04314986|Drug|Cohort 4: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
75624488|NCT02685280|Device|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
75914216|NCT05593835|Device|METHIS Platform|The METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.
75914217|NCT05593835|Other|Goal-Oriented Care Training Program|The training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
76073768|NCT03586869|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
76073769|NCT03586869|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
76073770|NCT03586869|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
76073771|NCT03586869|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
76073772|NCT03586869|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
76073773|NCT03586869|Biological|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
75624489|NCT03754972|Diagnostic Test|Sagittal plane shear index (SPSI)|Report SPSI to surgeon after surgeon records an initial surgical plan, and determine whether the objective spinal stability metric influences a change in the surgical plan.
75624490|NCT01174784|Device|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
75624491|NCT02686918|Other|Advanced Practice Nurse consultation|
75624492|NCT04314440|Behavioral|Music therapy|"An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby twinkle twinkle little star will be sung for ~5 minutes, followed by the same songs played on acoustic guitar for ~5 minutes and another ~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session."
75624493|NCT02686996|Dietary Supplement|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
75624494|NCT02686996|Other|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
75624495|NCT02687074|Device|HFNC|patients treated with high flow nasal cannula
75624496|NCT02687074|Device|NIV|patients treated with noninvasive ventilation
75624497|NCT01174550|Procedure|Coronary Angiography|Use of standard equipment for usual-care testing
75624498|NCT01174550|Procedure|Stress Echocardiogram|Use of standard equipment for usual-care testing
75624499|NCT01174550|Procedure|Nuclear Stress Test|Use of standard equipment for usual-care testing
75777334|NCT03009981|Drug|Prednisone|Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
75777335|NCT03009240|Drug|Decitabine|Given IV
75777336|NCT03009240|Other|Laboratory Biomarker Analysis|Correlative studies
75777337|NCT03009240|Drug|Pevonedistat|Given IV
75777338|NCT03009240|Other|Pharmacological Study|Correlative studies
75777339|NCT02986087|Device|Fetal Tracheal Occlusion|Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of <25%, LHR <1, o/e LHR<30% (moderate), singleton pregnancy, no known other anomalies, gestational age < 29 weeks 6 days, no maternal disease, maternal age > 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center as a requirement to enter the TOTAL trial.
75777340|NCT02971683|Drug|Abatacept subcutaneous|Specified dose of Abatacept subcutaneous on specified days
75777341|NCT02971683|Drug|Placebo|Placebo of Abatacept subcutaneous
75777342|NCT02950051|Drug|Fludarabine|Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
75777343|NCT02950051|Drug|Cyclophosphamide|Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
75777344|NCT02950051|Biological|Rituximab|Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
75914218|NCT05592847|Other|Nurse Navigator Program|Identification of specific chronic conditions and suggestion of management care of primary care physicians and referrals to specialists via nurse navigator team members.
76073774|NCT03586869|Procedure|SBRT|Stereotactic Body Radiation Therapy
75466609|NCT01911299|Dietary Supplement|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
75777345|NCT02950051|Drug|Bendamustine|Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
75777346|NCT02950051|Drug|Venetoclax|"Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d"
75777347|NCT02950051|Biological|Obinutuzumab|"Obinutuzumab i.v.~cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d~cycles 2-6: 1000 mg, d1, q28d"
75777348|NCT02950051|Drug|Ibrutinib|"Ibrutinib p.o.~cycles 1-12: 420 mg, d1-28, q28d~cycles 13-36: 420 mg, d1-28, q28d"
75914219|NCT05592652|Other|Survey|Survey including demographic, clinical and psychopathological questions
75624500|NCT01174550|Procedure|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
75777349|NCT02944955|Drug|BLEX 404 Oral Liquid|"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."
75777350|NCT02921022|Drug|Gemcitabine|
75777351|NCT02921022|Drug|Nab-paclitaxel|
75777352|NCT02921022|Drug|PEGPH20|
75914220|NCT05591248|Device|VRR|Eligible patients meeting the inclusion criteria and signed a consent, will have 3x/week the guided rehabilitation session with the VR-tool (with a maximum of 9 VRR-sessions).
75624501|NCT00638326|Drug|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
75624502|NCT00638326|Drug|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
75624503|NCT04184830|Device|non-invasive brain stimulation|
75914221|NCT05589389|Other|High Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.
75466610|NCT01911312|Device|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
75466611|NCT01911312|Device|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
75624504|NCT04187560|Drug|LB-102|(N-Methyl amisulpride)
75466612|NCT01911325|Drug|Buparlisib|
75466613|NCT01911325|Drug|Buparlisib matching placebo|
75466614|NCT01911325|Drug|Docetaxel|
75466615|NCT01911338|Device|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
75624505|NCT04314674|Drug|%3 HS bolus|After head fixation %3 HS bolus 3 ml/kg will be administered
75624506|NCT04314674|Drug|%3 HS infusion 20 ml/h|After head fixation %3 HS 20 ml/h infusion will be administered
75624507|NCT04314674|Drug|20% mannitol|After head fixation %20 mannitol 0.6 ml/kg will be administered
75777353|NCT02918162|Drug|Pembrolizumab|Pembrolizumab dosed IV at 200mg every 21 days per cycle.
75777354|NCT02918162|Drug|Standard of care chemotherapy regimen|"Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily."
75777355|NCT02899299|Biological|Nivolumab|
75777356|NCT02899299|Biological|Ipilimumab|
75777357|NCT02899299|Drug|Pemetrexed|
75914222|NCT05589389|Other|High Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.
75914223|NCT05589389|Other|Typical Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.
75914224|NCT05589389|Other|Typical Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
75914225|NCT05585697|Other|None - crossectional|None - crossectional
75777358|NCT02899299|Drug|Cisplatin|
75624508|NCT00639262|Drug|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
75624509|NCT00639262|Drug|Temozolomide|For Cohort 2 - Gliomas only.
75624510|NCT00639262|Radiation|Radiotherapy|Radiation Therapy (XRT)
75624511|NCT02886104|Procedure|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
75777359|NCT02899299|Drug|Carboplatin|
75777360|NCT02899195|Drug|Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration. Maintenance: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
75777361|NCT02833233|Procedure|Cryoablation|
75777362|NCT02833233|Drug|Ipilimumab|
75777363|NCT02833233|Drug|Nivolumab|
75777364|NCT02814916|Drug|Dalbavancin single dose|Dalbavancin, weight-adjusted dose, up to 1500mg. Intravenous (IV) administration. Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used. Patients age birth to <3 months will only receive the single-dose regimen of dalbavancin; any concomitant antibacterial therapy may be administered in this age group based on local standard of care.
75777365|NCT02814916|Drug|Dalbavancin two dose|Dalbavancin, weight-adjusted dose, up to 1000mg. Intravenous (IV) administration, with second dalbavancin weight-adjusted dose, up to 500mg. Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.
75777366|NCT02814916|Drug|Comparator|Course of either vancomycin not to exceed a total daily dose of 4000 mg;or oxacillin; or flucloxacillin not to exceed a total daily dose of 2000 mg. Intravenous (IV) administration. Possible oral switch after at least 72 hours from oxacillin or flucloxacillin to oral cefadroxil, or from IV vancomycin to oral clindamycin (for MRSA). Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used. Additional comparator drugs may be used, if an alternate comparator regimen is indicated by local susceptibility patterns. No patient age birth to < 3 months will be randomized to the comparator arm.
75624512|NCT02886104|Device|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
75914226|NCT05579652|Diagnostic Test|Abdominal tension measurement|A tensiometer scale will be used to measure the tension needed to pull each side of the abdominal wall to midline
76073775|NCT04147377|Behavioral|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
75624513|NCT02689102|Device|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
75777367|NCT02804594|Drug|N-acetyl cysteine|1250 mg of N- acetyl cysteine taken three times daily
75777368|NCT02804594|Drug|Placebo|placebo taken three times daily
75777369|NCT02786940|Device|Cardiophone|Remote live monitoring for 15 days for detection or exclusion of arrhythmias
75777370|NCT02757794|Other|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
75777371|NCT02757794|Other|standard remediation|A speech therapy and / or academic support is realized.
75777372|NCT02728050|Drug|Cladribine|Given IV
75777373|NCT02728050|Drug|Cytarabine|Given IV
75914229|NCT05578898|Behavioral|CLEAR Care Companion (CC) application|The CLEAR CC application is an EPIC-based, electronic application, downloaded to the patient's Smartphone or Tablet. The CLEAR CC leverages patient-reported symptoms assessment vis-a-vis push notifications to complete clinically meaningful questions and validated questionnaires pertaining to symptoms that serve as early indicators of readmission. The CLEAR CC application will send notifications beginning two days prior to surgery and continue until the 6 week post operative appointment.
75914230|NCT05572333|Drug|EP395|Capsule for oral use
75914231|NCT05572333|Drug|Placebo|Capsule for oral use
76073776|NCT03581253|Other|"Facial disability Index (FDi)"|questionnaires regarding to quality of life
75624514|NCT02885558|Drug|Efonidipine|8 weeks treatment with either efonidipine
75624515|NCT02885558|Drug|Nifedipine|8 weeks treatment with either nifedipine
75624516|NCT04185688|Other|Functional Reach Test|The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.
75624517|NCT01008150|Drug|Paclitaxel|
75624518|NCT01008150|Drug|Trastuzumab|
75624519|NCT01008150|Drug|Neratinib|
75624520|NCT01008150|Drug|Doxorubicin|
75777374|NCT02728050|Biological|Filgrastim|Given SC
75777375|NCT02728050|Other|Laboratory Biomarker Analysis|Correlative studies
75777376|NCT02728050|Other|Quality-of-Life Assessment|Ancillary studies
75777377|NCT02728050|Drug|Mitoxantrone|Given IV
75777378|NCT02728050|Drug|Sorafenib|Given PO
75777379|NCT02711878|Behavioral|Let's Move Program|Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
75777380|NCT02711878|Behavioral|Let's Flex Program|Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
75777381|NCT02711878|Behavioral|Group Motivational Interviewing|Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
75777382|NCT02600208|Biological|CliniMACs|Depletion of Alpha Beta T cells in the PBSC graft
75777383|NCT02598349|Radiation|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
75777384|NCT02598349|Drug|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
75777385|NCT02598349|Procedure|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
75777386|NCT02581943|Drug|Carboplatin|Given IV
75777387|NCT02581943|Other|Laboratory Biomarker Analysis|Correlative studies
75624521|NCT01008150|Drug|Cyclophosphamide|
75624522|NCT02687152|Other|N-hydroxy-nor-L-arginine|
75624523|NCT04186936|Drug|Combination Caplet with Loperamide HCl and Simethicone|Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
75624524|NCT04186936|Drug|Loperamide HCl|Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
75777388|NCT02581943|Drug|Paclitaxel|Given IV
75777389|NCT02581943|Biological|Pembrolizumab|Given IV
75624525|NCT04186936|Drug|Simethicone|Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
75777390|NCT02581943|Other|Quality-of-Life Assessment|Ancillary studies
75777391|NCT02527200|Drug|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
75914232|NCT05571995|Behavioral|TRIMOSH|TRIMOSH will improve the knowledge, attitude and practice on occupational and health
75624526|NCT01007916|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
75624527|NCT01007916|Device|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
75777392|NCT02527200|Drug|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
75777393|NCT02510040|Device|Prism|Ground-in or Fresnel prism
75624528|NCT02689180|Drug|Placebo|Replacement of furosemide by placebo
75624529|NCT02689180|Drug|Furosemide|Maintenance of furosemide on usual doses
75624530|NCT01007838|Other|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
75624531|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
75777394|NCT02510040|Other|Orthoptic Exercises|Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
75777395|NCT02510040|Procedure|Eye Muscle Surgery|"Bilateral medial rectus muscle resection surgery~Single medial rectus muscle resection surgery~Recess lateral rectus muscle resection medial rectus muscle surgery~Bilateral lateral rectus muscle recession surgery~Single lateral rectus muscle recession surgery~Bilateral lateral rectus muscle resection surgery~Single lateral rectus muscle resection surgery~Recess medial rectus muscle resection lateral rectus muscle surgery~Bilateral medial rectus muscle recession surgery~Single medial rectus muscle recession surgery~Vertical rectus muscle recession surgery~Vertical rectus muscle mini-tenotomy (snip) surgery"
75777396|NCT02510040|Procedure|Botox Injection|Botulinum toxin injection
75777397|NCT02464436|Drug|hRPC|Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
75798451|NCT01282788|Dietary Supplement|Caterpillar Cereal|Infants will receive once-daily servings of caterpillar cereal (30 g from 6-12 months of ages and 45 g from 12-18 months of ages). Study food will be delivered to homes weekly by Community Coordinators, who will also observe feedings of the cereal during the home visit. Feedings will be observed 3x/week for the first 3 weeks after enrollment, then 1x/week until 18 months of age. Parents and other care providers will receive specific instructions about cereal preparation and general education about feeding practices, food preparation and hygiene. This information will be reinforced during weekly visits.
76073777|NCT03581253|Other|"Facial Clinimetric Evaluation (FaCE)"|questionnaires regarding to quality of life
76073778|NCT03581175|Procedure|Colonoscopy|
76073779|NCT03581175|Drug|Bowel cleansing regimen|
75914233|NCT05571358|Device|Virtual Reality (Nature Trek)|"At the end of each session, participants will experience an immersive virtual landscape displayed by Nature Trek VR software (httpp://naturetreksvr.com/). First, participants will be placed in a sit down position and guided for their breathing control during 5 minutes (meditation Lotus option). After that, they will be encouraged to freely move around a relaxing virtual environment during 15 minutes taking special attention to soothing sounds of nature. The themes environment will be selected based on the preferences of the participants.~At the beginning of the study, advice is given on general care, in physical activity and issues concerning drug intake. Patients are advised to refrain from any other specific training during the intervention period. Any deviations from the adherence and practice of the VRi are recorded daily, noting any adverse incidents."
75914234|NCT05569486|Device|Green Light|This is a low-energy device. It produces almost no heat because it uses an LED source for light. The device does not store energy or electrical power that can be discharged later.
75321457|NCT03626129|Procedure|Oximetry guided deflation|"At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A."
75624532|NCT01007838|Other|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
75624533|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
75624534|NCT02686762|Drug|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
75914235|NCT05563129|Other|First aid lessons|The school children will have first aid training
75624535|NCT02686762|Drug|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
75624536|NCT02686762|Drug|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
75624537|NCT02689336|Biological|Erlotinib|
75624538|NCT02689336|Drug|Temozolomide|
75624539|NCT02685592|Drug|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
75624540|NCT04417972|Drug|SHR7280|treatment
75624541|NCT04417972|Drug|Placebo oral tablet|blank control
75624542|NCT01007448|Drug|Bexarotene|Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
75777398|NCT02414269|Genetic|iCasp9M28z T cell infusions|Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI. Patients who do not have enough cells to match the current dose cohort will be treated in the cohort in which they have cells available
76073780|NCT03586791|Procedure|Pupillometry guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
75624543|NCT02686684|Drug|Dimethyl fumarate|
75624544|NCT04294056|Drug|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
75624545|NCT04294056|Drug|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
75624546|NCT02870556|Device|cervical epidural analgesia|
75624547|NCT00628602|Device|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
75624548|NCT03538756|Device|Walkasins|Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
75777399|NCT02414269|Drug|cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2)
75777400|NCT02414269|Drug|pembrolizumab|Pembrolizumab will be given as 200 mg flat dose infusion intravenously.
75798452|NCT01278186|Procedure|Balloon angioplasty|Coronary angioplasty using the paclitaxel-coated balloon catheter
75798453|NCT01278186|Procedure|Stent implantation|Coronary angioplasty using the paclitaxel-eluting stent
75321458|NCT03715959|Procedure|Aspiration of Breast|Undergo NAF
75624549|NCT04204824|Other|Ultrasound and exercise|"The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home"
75914236|NCT05560425|Behavioral|Koru Mindfulness (KM) Training|The Koru Basic curriculum consists of four weekly interactive 75-minute classes delivered online through Zoom. Each class consists of an overview of 2-3 skills, group practice of the skills, and group reflection. Topics discussed during each training visit include: belly breathing, dynamic breathing, body scan (week 1); walking meditation, gatha (week 2); guided imagery, labeling thoughts (week 3); eating meditation, and labeling feelings (week 4). Participants are instructed to practice a skill for 10 minutes/day and log any reflection on that practice using the Koru phone application.
76073781|NCT03586791|Procedure|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
76073782|NCT03586791|Procedure|Standard management|"During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60.~Remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients."
76073783|NCT01795495|Drug|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
75321459|NCT03715959|Procedure|Biospecimen Collection|Undergo NAF
75624550|NCT04186702|Procedure|INTRAVITREAL RANIBIZUMAB INJECTION|interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)
75624551|NCT04187014|Drug|Aminocaproic Acid 1000Mg Tab|Oral administration of a total 6 g of aminocaproic acid to reduce blood loss
75624552|NCT04187014|Drug|Tranexamic acid tablets|Oral administration of 3.9 g of tranexamic acid to reduce blood loss
75624553|NCT02686840|Drug|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
75624554|NCT02686840|Drug|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
75624555|NCT00638482|Drug|Hydrochlorothiazide|Hydrochlorothiazide
75777401|NCT02390518|Radiation|Stereotactic Radiosurgery|"Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a and 1a Expansion (starting at Dose Level 3) Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a *Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a~**Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions."
76073784|NCT01795495|Drug|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
76073785|NCT01795495|Drug|Remifentanil|
75321460|NCT00708721|Drug|Clofarabine|Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
75624556|NCT00639964|Other|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
75624557|NCT00639964|Other|diet questionnaire|questions about nutrition before and during pregnancy
75624558|NCT00639964|Other|umbilical cord blood collect|collected at the delivery
75624559|NCT00639964|Other|placenta collect|collected at the delivery
75624560|NCT02684968|Procedure|Colorectal surgery|
75624561|NCT04034290|Biological|GamFluVac|The drug is a vaccine that induces high-level immunity against influenza A viruses
75624562|NCT04034290|Other|Placebo|Placebo
75624563|NCT04105894|Device|MSCT of nose and PNs|MSCT of nose and PNs axial, coronal and sagittal cuts without contrast to evaluate the state of the sinuses at the beginning of evaluation and after 2 months duration of medical treatment for GERD
75624564|NCT04105894|Diagnostic Test|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin at the at the beginning of evaluation and after 2 months duration of medical treatment for GERD
75624565|NCT04105894|Drug|medical treatment of GERD t|medical treatment of GERD only for 2 months as described by gastroenterology department
75624566|NCT02688946|Other|Not provided|
76073786|NCT04765527|Dietary Supplement|Turmeric Strength for Joint|Turmeric-based tablets
75777402|NCT02369354|Behavioral|TALKS Social Worker Intervention|TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
75777403|NCT02369354|Other|Financial Assistance Intervention|"The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating."
75777404|NCT02341989|Drug|Bleomycin Etoposide and Cisplatin|
75624567|NCT04184596|Other|Discrete Choice Experiment|An online-based Discrete-Choice Experiment (DCE) using a survey for stated treatment preferences and socio-demographics. Furthermore, the neuropathic pain component will be assessed in all patients with the Numeric Pain Rating Scale instrument.
75777405|NCT02341989|Drug|Carboplatin|
75777406|NCT02312401|Device|multi-parametric MRI(MP-MRI)|
75777407|NCT02312401|Device|dynamic contrast-enhanced MRI (DCE)|
75777408|NCT02312401|Procedure|biopsy|
75624568|NCT00638560|Dietary Supplement|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
75777409|NCT02285192|Radiation|18F-Fluorodeoxyglucose (18F-FDG)|
75624569|NCT00638560|Dietary Supplement|Antioxidant treatment|no treatment
75624570|NCT04405648|Behavioral|CVS GROUP|the students will respond to CVS-F3 questionnaire to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors.
75777410|NCT02285192|Device|PET/CT imaging|
75777411|NCT02285192|Device|PET/MRI imaging|
75777412|NCT02267603|Other|Laboratory Biomarker Analysis|Ancillary studies
75777413|NCT02267603|Biological|Pembrolizumab|Given IV
75777414|NCT02244125|Drug|PCD|"STUDY TREATMENT PHASE: All patients~4x 28 days cycles of PCD~[Pomalidomide: 4mg/day oral route on 21 days per cycle]~[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]~[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~Melphalan 200mg/m2 followed by Autologous Transplantation~2x 28 days cycles of PCD, three months post transplantation~Arm B:~5x 28 days cycles of PCD~[Pomalidomide: 4mg/day oral route on 21 days per cycle]~[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]~[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle]~MAINTENANCE PHASE: All patients~- Until progression/relapse or discontinuation for any other reason~[Pomalidomide: 4mg/day oral route on 21 days per cycle]~[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle]"
75777415|NCT02244125|Procedure|Autologous transplantation (ASCT)|"Arm A:~•Melphalan 200mg/m2 followed by Autologous Transplantation"
76073787|NCT04765527|Dietary Supplement|Placebo|Placebo tablets
75624571|NCT04185064|Device|Game Ready ATX shoulder wrap; Game Ready GRPro 2.1|the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
75624572|NCT04185064|Other|Standard Care|Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
75624573|NCT02685124|Dietary Supplement|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
75624574|NCT00638638|Drug|Abciximab|"Abciximab: 0.25 mg/Kg bolus~Abciximab placebo bolus~Abciximab infusion 10 µg/Kg/min"
75777416|NCT02243878|Radiation|Stereotactic radiotherapy (16 Gray or Sham)|Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
75777417|NCT02243878|Drug|0.5 mg ranibizumab|Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
75777418|NCT02208362|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given via intratumoral or intraventricular catheter
75777419|NCT02208362|Biological|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given via intratumoral, intracavitary, or intraventricular catheter
75777420|NCT02208362|Other|Laboratory Biomarker Analysis|Correlative studies
75777421|NCT02208362|Procedure|Magnetic Resonance Imaging|Correlative studies
75624575|NCT00638638|Drug|Abciximab placebo|"Abciximab placebo Bolus~Abciximab: 0.25 mg/Kg bolus~Abciximab infusion 10 µg/Kg/min"
75624576|NCT02684812|Drug|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
76073788|NCT04570111|Other|MOD Diet|The macro-optimized diet alters the timing of macronutrient intake to provide fewer carbohydrates at breakfast, while maintaining recommended amounts of macronutrients delivered throughout the course of the day
75777422|NCT02208362|Procedure|Magnetic Resonance Spectroscopic Imaging|Correlative studies
75777423|NCT02208362|Other|Quality-of-Life Assessment|Ancillary studies
75777424|NCT02207985|Procedure|Allogeneic hematopoietic stem cell transplantation|
75798454|NCT01169688|Other|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
76073789|NCT04570111|Other|Standard Care Diet|The standard care diet provides macronutrients within standard amounts (40% carbohydrate, 20% protein, 40% fat) at all meals and snacks per day.
75624577|NCT04185376|Other|Questionnaire|a self-administered questionnaire for the assessment of pelvic floor disorders, their risk factors and their impact of quality of life during pregnancy and postpartum period which integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bothersomeness and conditions specific quality of life in women with urinary incontinence (UI) and/or POP. The questionnaire is divided into four main domains (bladder, bowel, pelvic organ prolapse, sexual function) and each question is scored from zero to three. The additive scores are divided by the maximum reachable score and multiplied by ten, giving a value between zero (0 = no symptoms) and ten (10 = maximum symptoms) for each of the domains.
75777425|NCT02199236|Radiation|endorectal brachytherapy|Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
75777426|NCT02199236|Drug|concurrent capecitabine or 5-FU|"Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days."
75777427|NCT02199236|Behavioral|Questionnaires|Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
75777428|NCT02157051|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
75777429|NCT02157051|Other|Laboratory Biomarker Analysis|Correlative studies
75777430|NCT02136797|Biological|CMVpp65 Specific T-cells|
75777431|NCT02099734|Behavioral|Questionnaires|
75777432|NCT02099734|Other|sample of blood or saliva|A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
75624578|NCT02686216|Drug|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
75624579|NCT02686294|Drug|HL151|Test drug : HL151. 1T, once a day oral administration, for 4 days
75321461|NCT00087152|Drug|Capecitabine|1,000 mg/m^2 by mouth twice daily Days 1-14 of each 21 day cycle
75624580|NCT02686294|Drug|TALION tab.|Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
75624581|NCT02688478|Other|Phthalate|Delivered by inhalation on day 1 of the triad
75777433|NCT02098252|Procedure|Neurosurgery|Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
75321462|NCT00087152|Drug|Imatinib mesylate|400 mg by mouth daily
75321463|NCT05362799|Drug|Letrozol (Femara, Novartis)|Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
75777434|NCT02098252|Radiation|Radiation therapy|when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
75777435|NCT02098252|Procedure|Embolization|Curative embolization, when the lesion is considered curable by embolization.
75777436|NCT02022774|Drug|Fimasartan|Fimasartan 60 ~ 120 mg/po take one tablet once a day
75777437|NCT01986634|Procedure|Laser Treatment|Patient will have split face laser resurfacing as per standard of care. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
75777438|NCT01972243|Other|no intervention|
75321464|NCT05362799|Drug|Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)|Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
75321465|NCT05362799|Drug|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
75321466|NCT05362799|Drug|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
75624582|NCT02688478|Other|Filtered Air|Delivered by inhalation on day 1 of the triad
75624583|NCT02688478|Other|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
75777439|NCT01935089|Drug|Pegylated Interferon alpha 2b|1µg/kg/week
75624584|NCT01004250|Drug|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
75624585|NCT01004250|Drug|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
75777440|NCT01916122|Drug|Fluorestradiol (FES)|
75777441|NCT01916122|Procedure|PET/CT Imaging|
75777442|NCT01824745|Other|educational intervention|Receive the SCP-BCS template booklet
75624586|NCT01004250|Drug|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
75777443|NCT01824745|Other|counseling intervention|Receive counseling sessions with a patient navigator
75777444|NCT01824745|Procedure|standard follow-up care|Receive standard follow-up care
75777445|NCT01824745|Procedure|quality-of-life assessment|Ancillary studies
75777446|NCT01824745|Other|questionnaire administration|Ancillary studies
75777447|NCT01803152|Biological|Dendritic Cells Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
75777448|NCT01803152|Biological|Lysate of Tumor|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
75777449|NCT01803152|Drug|Gemcitabine|Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.
75777450|NCT01803152|Drug|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
75777451|NCT01803152|Procedure|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
75777452|NCT01773707|Drug|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
75777453|NCT01773707|Drug|Placebo|Saline given as 30 minute IV infusion
75777454|NCT01737827|Drug|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
75914237|NCT05560425|Behavioral|Navigating College (NC) Training|With topics discussed from the Freshman Survival Guide book, this training provides a closely matched active control group for KM Training. The training consists of four weekly 75-minute classes delivered online through Zoom. Each class consists of lecture and group discussions on topics related to navigating college. Topics discussed during each training visit include: habits, roommate issues, homesickness, the internet (week 1); strategies when sinking, study skills, getting involved, habit formation (week 2); HALT, gateway habit (week 3); and academic success tips, taking notes, and procrastination (week 4). Participants are instructed to journal about learned information and skills for 10 minutes/day.
75914238|NCT05559879|Drug|Cabo + Dostarlimab|Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
75914239|NCT05556187|Other|Individualized automated oxygen titration|Automated oxygen titration based on the oxygen saturation during the entire day.
75914240|NCT05553847|Other|Automated oxygen titration based on the oxygen saturation during activity|A device will be used, which automatically adjusts the oxygen flow to the dosage necessary for keeping the saturation at the recommended level (90-94%). If the saturation falls below 90%, oxygen flow will increase, and if the saturation increases above 94%, oxygen flow decreases in order to stay on target.
75914241|NCT05552989|Other|this is a non-interventional study|this is a non-interventional study
75624587|NCT02688634|Drug|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
75624588|NCT00639496|Drug|n-acetylcysteine|600 mg x 3, for 12 months
75624589|NCT00639496|Drug|placebo|Placebo
75624590|NCT04186624|Drug|Subacromial-subdeltoid bursa corticosteroid injection|1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
75624591|NCT00639574|Drug|Néfopam|"There are two groups :~a group N : néfopam~a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes."
75624592|NCT04184752|Diagnostic Test|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position [14]. A 20-minute pad test for each woman was also performed [15, 16]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS [3]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
75624593|NCT02685046|Drug|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
75624594|NCT01004172|Drug|carboplatin|
75624595|NCT01004172|Drug|bevacizumab|
75777455|NCT01735955|Drug|Nilotinib|Nilotinib can be provided as 200 mg and 150 mg hard gelatin capsules for oral use. Additional strengths of nilotinib can be provided if specified in the parent protocol. The starting dose of nilotinib should be the same as the last dose that was given in the parent nilotinib study. After this, the dose of nilotinib is based on the investigator's judgment.
75777456|NCT01668563|Procedure|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
75798455|NCT01282944|Behavioral|Financial Incentive|Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
75798456|NCT01282944|Behavioral|Peer Network|Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
75624596|NCT01004172|Drug|herceptin|
75624597|NCT02688244|Procedure|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
75777457|NCT01668563|Procedure|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
75777458|NCT01628640|Other|Laboratory Biomarker Analysis|Correlative studies
75777459|NCT01628640|Other|Pharmacological Study|Correlative studies
75777460|NCT01628640|Biological|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Given intratumorally
75777461|NCT01521026|Behavioral|Cognitive Training|12-week compensatory cognitive training in group format
75777462|NCT01504815|Drug|cisplatinum|i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
75777463|NCT01504815|Radiation|Conventional radiotherapy|conventional radiotherapy, 70Gy in 7 weeks
75777464|NCT01504815|Radiation|Adaptive radiotherapy|adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
75777465|NCT01349582|Procedure|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
75777466|NCT01349582|Other|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
75321467|NCT01940523|Drug|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
75777467|NCT01349582|Procedure|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
75914242|NCT05545527|Drug|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
75914243|NCT05545527|Drug|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
75914244|NCT05545527|Drug|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
75624598|NCT02688244|Procedure|No irrigation|Suction only, using suction device
75914245|NCT05544474|Other|Delphi questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of radical right colectomy. The Delphi questionnaire will be administered via www.surveymonkey.com.~In the first survey, panel members will agree on surgical steps, definition of surgical steps and nomenclature for radical right colectomy In subsequent surveys, panel expert will agree on a common definition, nomenclature and reporting for right colectomy. Multiple rounds will be conducted until consensus is reached. After each round, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 70% in the first round or need further explanation, additional rounds of the survey may be performed."
75321468|NCT01940523|Drug|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
75321469|NCT04403282|Drug|Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
75321470|NCT04403282|Drug|Placebo Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
75624599|NCT02688322|Drug|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
75624600|NCT02870400|Drug|REGN2477|Participants will receive ascending doses of REGN2477
75624601|NCT02870400|Drug|Placebo|Participants will receive matching placebo
75624602|NCT02685904|Biological|ENIA11|
75624603|NCT02685904|Biological|Placebo|
75777468|NCT01349582|Procedure|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
75777469|NCT01349582|Procedure|surgical clipping|clipping of the aneurysm following invasive brain surgery
75777470|NCT01340612|Device|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
75777471|NCT01340612|Device|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
75777472|NCT01334944|Drug|Intravenous ibuprofen|400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
75798457|NCT02526108|Other|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
75798458|NCT01172106|Behavioral|drug compliance|Mothers and their caregivers will be encouraged to comply with the given medication
75798459|NCT01172106|Behavioral|Encouragement of drug compliance|Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement
75624604|NCT00638794|Device|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
75777473|NCT01140373|Biological|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10^7 CAR+ T cells/kg, 3 x 10^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
75777474|NCT01140373|Drug|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10^7 CAR+ T cells/kg, 3 x 10^7 CAR+ T cells/kg, and 1 x 10^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
75777475|NCT01139892|Procedure|Surgical management|
75777476|NCT01139892|Procedure|Endovascular management|
75624605|NCT03098290|Procedure|Catheter-based endovascular revascularization|(e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
75624606|NCT03098290|Procedure|Bypass-Surgery|Venous or alloplastic or comparable Bypass
75624607|NCT03098290|Procedure|Endarterectomy|Endarterectomy, Patchplasty
75624608|NCT04184986|Diagnostic Test|dry blood test|screening test for Fabry disease
75777477|NCT00902720|Other|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
75777478|NCT00840047|Drug|Methionine|Intravenous injection
75914246|NCT05539573|Device|Planned TAVI with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.|"The study will collect data from patients treated with the ACURATE neo2™ and its transfemoral delivery system following standard TAVI practice at each participating center. All patients will be followed to 12 months after the implant procedure. The study is divided into three periods:~Screening period: from screening to enrollment if study criteria are met.~Implantation procedure: immediately pre-implant to 24 hours post-procedure.~Follow-up period: at hospital discharge, at 30 days and at 12 months post-procedure."
75466616|NCT01911338|Device|Traditional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
75624609|NCT00639652|Procedure|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
75624610|NCT00639652|Procedure|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
75624611|NCT04186234|Radiation|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
75624612|NCT02685748|Drug|Aspirin|1000 mg pd in two doses
75624613|NCT02685748|Drug|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
75624614|NCT02685748|Drug|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
75624615|NCT04112992|Procedure|Any treatment that is used for a defect of any long bone|Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
75777479|NCT00810732|Drug|Open|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
75777480|NCT00810732|Drug|Nifedipine|Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
75777481|NCT00810732|Drug|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
75777482|NCT00764920|Device|non-invasive imaging modalities for assessment of skin|skin imaging
75777483|NCT00719888|Drug|Cyclophosphamide|Given IV
75466617|NCT01911364|Drug|BDP/FF/GB|Superiority over Tiotropium
75777484|NCT00719888|Drug|Cyclosporine|Given IV and PO
75466618|NCT01911364|Drug|Tiotropium|Superiority of CHF5993 over Tiotropium
75466619|NCT01911364|Drug|BDP/FF + Tiotropium|non inferiority vs CHF5993
75466620|NCT01911377|Drug|Botulinum Toxin Type A|
75466621|NCT01911377|Drug|Normal Saline for Injection|
75466622|NCT01911416|Drug|LDE225|
75466623|NCT01911455|Drug|acamprosate|
75466624|NCT01911455|Drug|Placebo|
75466625|NCT01911468|Drug|metformin|
75466626|NCT01911468|Drug|liraglutide|
75466627|NCT01911468|Drug|metformin and liraglutide|
75466628|NCT01911481|Other|hydration|
75777485|NCT00719888|Procedure|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
75777486|NCT00719888|Drug|Fludarabine|Given IV
75777487|NCT00719888|Other|Laboratory Biomarker Analysis|Correlative studies
75777488|NCT00719888|Drug|Mycophenolate Mofetil|Given IV and PO
75777489|NCT00719888|Radiation|Total-Body Irradiation|Undergo high-dose or moderate-intensity TBI
75777490|NCT00719888|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
75624616|NCT04104802|Device|MRI|"All patients included will benefit from both methods of assessing anatomical relationships between the facial nerve and the parotid tumor:~1) New medical imaging technique evaluated: 3 Tesla Parotidic MRI High Resolution with Specific Sequences and Gadolinium Injection 2) Standard Gold: Intraoperative Exam"
75624617|NCT04186312|Behavioral|ACCESS - Accessing Campus Connections & Empowering Student Success|Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions
75777491|NCT00719888|Drug|Thiotepa|Given IV
75777492|NCT00571727|Drug|mecasermin|injections BID of rhIGF-1, mecasermin
75777493|NCT00427349|Drug|AMG 706|AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
75777494|NCT00427349|Drug|octreotide|One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
75777495|NCT00309985|Drug|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
75321471|NCT02994199|Other|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
75321472|NCT03577379|Other|Whole Blood Fibrin Clot|For all patients assigned to the treatment group, 35mL of whole blood will be obtained during surgery by an anesthesiologist. 5 mL of the blood will be sent for pre-clot formation cell count evaluation for platelets, red blood cells and white blood cells. The remaining 30mL will be placed into a sterile container with a sintered glass cylinder supported by the lid for fibrin clot formation. The clot formation cups will be placed on a rotator at room temperature for 10 minutes at 125rpm. The fibrin clot will be removed and 5mL of the post-clot serum sent for post-clot formation cell count evaluation for platelets, red blood cells, and white blood cells.
75624618|NCT04184440|Dietary Supplement|Cyclocarya paliurus extract|The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .
75624619|NCT04184440|Dietary Supplement|Cyclocarya paliurus compounds|The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .
75624620|NCT04184440|Dietary Supplement|placebo|The participants are divided randomly into three groups，one of which are asked to take placebo for three months .
75777496|NCT00309985|Drug|docetaxel|Given IV
75777497|NCT00298064|Genetic|Tissue Repository|
75777498|NCT00285935|Other|Standard Clinical Care with an SSRI|"Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.~Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)"
75914247|NCT05538091|Drug|Vismodegib|A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
75624621|NCT02685982|Device|Rhythmic Sensory Stimulation|"The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation."
75777499|NCT00200174|Drug|Raloxifene followed by combination therapy|Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
75777500|NCT00200174|Drug|Exemestane followed by combination therapy|Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
75777501|NCT00195091|Drug|Tetrathiomolybdate|"Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.~When target Cp window is reached, then the maintenance phase begins.~Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg~Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime."
75777502|NCT00098787|Biological|bevacizumab|Given IV
75777503|NCT00098787|Drug|fluorouracil|Given IV
75914248|NCT05538091|Drug|Atezolizumab|Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
75321473|NCT02994433|Drug|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
75624622|NCT04184908|Drug|gel xerostomia|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
75777504|NCT00098787|Drug|irinotecan hydrochloride|Given IV
75777505|NCT00098787|Drug|leucovorin calcium|Given IV
75777506|NCT00098787|Drug|Oxaliplatin|Given IV
75914249|NCT05536830|Other|Nutrition Status|Participants will be examined by a registered dietitian to assess nutrition status.
75914250|NCT05536115|Device|Alveogyl|"The patients will be treated by Alveogyl. Global treatment protocol (curettage, cleaning, local anaesthesia etc.) of the dry socket is at the discretion of the Investigator.~Alveogyl is used as an alveolar dressing. Placement of Alveogyl (about 0.2 g of paste) into the dental socket is done according to its instruction for use by a dental professional only."
75914251|NCT05535140|Other|G8 Screening Tool|Determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.
75321474|NCT02994433|Drug|Placebo gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen.
75321475|NCT02994433|Device|MRI|MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
75321476|NCT01679288|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electrics)|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
75321477|NCT04388189|Drug|Duloxetine|FDA approved antidepressant
75321478|NCT04388189|Drug|Bupropion|FDA approved antidepressant
75321479|NCT02994277|Device|1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm|The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
75777507|NCT00091169|Dietary Supplement|levocarnitine|Given orally
75777508|NCT00091169|Other|placebo|Given orally
75777509|NCT00075946|Biological|rituximab|Given IV
75914252|NCT05533528|Procedure|periodontal surgery|A sulcular incision will be made in the affected teeth, followed by an incision from the buccal aspect in the mid-portion of the interproximal tissues The buccal and lingual flaps will be elevated. For periodontal granulation tissue preservation group, the soft tissues covering the alveolar crest will be prepared. A third incision will separate the pocket epithelium from the soft tissue (granulation tissue) attached to the bone. The pocket epithelium will be removed. The root surfaces will be carefully scaled and planed in both groups. Ethylenediaminetetraacetic acid (24%) will be applied to the root surfaces and removed after 2 minutes with abundant saline solution. In the experimental group, the preserved attached soft tissue and the space between it and the root surface will be irrigated with 10% polyvinylpyrrolidone-iodine. Finally, the flaps will be positioned and sutured.
75914253|NCT05533216|Other|Performance of different upper limb functional tests|The participants will have to perform 3 to 5 different upper libm functional tests, depends on the sport they practice.
75914254|NCT05526391|Drug|TAK-341|TAK-341 IV infusion
75321480|NCT05362643|Other|Acupuncture|Manual acupuncture on acupoint Tai Xi(KI3), bilateral;Sanyinjiao (SP6), bilateral; Zusanli (ST36), bilateral; Shenmen (HT7) unilateral, in the arm without arteriovenous fistula;Guan Yuan (CV4), unilateral, attempt to achieve De qi sensation. After generating needling sensation, needles were manipulated for one minute, every ten minutes during needle retention (20 minutes), using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
75321481|NCT05362643|Other|Sham Acupuncture|Manual acupuncture performed as superficial needling (5mm depth) on non-acupuncture points without an attempt to achieve De qi sensation and without stimulation, lasting 20 minutes, using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
75777510|NCT00074165|Drug|Rituxan|Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
75777511|NCT00074165|Drug|Cyclophosphamide|Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
75777512|NCT00074165|Drug|Etoposide|Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
75624623|NCT04184908|Other|gel placebo|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
75624624|NCT00639730|Dietary Supplement|modified Atkins diet|High fat, low carbohydrate diet
75624625|NCT04184674|Other|Pneumotachograph|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~The first measurement will be performed 5 minutes after the initial ventilator settings.~Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
75777513|NCT00074165|Drug|Etoposide phosphate|Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
75777514|NCT00074165|Drug|Carboplatin|Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
75777515|NCT00074165|Drug|Sodium thiosulfate|"Dose: 4 hrs post carboplatin = 20gm/m2;~Dose: 8 hrs post carboplatin = 16gm/m2~Infused IV x 2 days"
75777516|NCT00074165|Drug|Neupogen|48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
75777517|NCT00074165|Drug|Neulasta|Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
75777518|NCT00074165|Drug|Cytarabine|Dose: 40mg on Day 14 following chemotherapy
75777519|NCT00059930|Drug|FOLFOX regimen|
75777520|NCT00059930|Drug|dexamethasone|
75777521|NCT00059930|Drug|floxuridine|
75777522|NCT00059930|Drug|fluorouracil|
75777523|NCT00059930|Drug|leucovorin calcium|
75777524|NCT00059930|Drug|oxaliplatin|
75777525|NCT00059930|Procedure|adjuvant therapy|
75777526|NCT00059930|Procedure|conventional surgery|
75777527|NCT00057876|Drug|Gemcitabine|"Induction: Patients receive the first cycle of gemcitabine 1000 mg/m^2 intravenously once per week for 6 weeks followed by 1 week rest.~Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles."
75777528|NCT00057876|Radiation|radiation therapy|"Induction: Patients receive gemcitabine 600 mg/m^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.~Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy."
75777529|NCT00057837|Biological|G-CSF|G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery > 10,000 dL.
75777530|NCT00057837|Drug|Cisplatin|Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
75624626|NCT04184674|Other|Esophageal catheter|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~The first measurement will be performed 5 minutes after the initial ventilator settings.~Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
75624627|NCT04184674|Other|Transthoracic and / or transesophageal cardiac ultrasound|"The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~The first measurement will be performed 5 minutes after the initial ventilator settings.~Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
75624628|NCT04184674|Other|Electrical impedance tomography (EIT) for pediatric patients|For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
75624629|NCT02684500|Device|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
75777531|NCT00057837|Drug|Etoposide|Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
75914255|NCT05526391|Drug|Placebo|TAK-341 placebo-matching IV infusion
75777532|NCT00057837|Drug|Irinotecan|50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
75321482|NCT00599053|Drug|Azithromycin|10 mg/kg IV per dose given for 10 days
75321483|NCT05223023|Other|questionnaire|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
75321484|NCT05362565|Biological|Salivary Sampling|"The DNA study will be carried out from saliva sample~1 saliva sample per patient will be performed at the inclusion visit"
75321485|NCT02999971|Other|circuit class therapy in water|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
75777533|NCT00057837|Drug|Topotecan|Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
75777534|NCT00046930|Biological|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
75777535|NCT00046930|Biological|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
75777536|NCT00046930|Drug|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
75777537|NCT00046930|Drug|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
75798460|NCT01172106|Behavioral|Family psychoeducation|The experimental group will receive family psychoeducation for 12 sessions
75914256|NCT05525585|Dietary Supplement|Early HMF|Mom's milk or donor milk will be fortified between postnatal day 4 and 7
75914257|NCT05525585|Dietary Supplement|Delayed HMF|Mom's milk or donor milk will be fortified between postnatal day 10 and 14
75914258|NCT05521880|Drug|Oritavancin|Sequential therapy with weekly doses of oritavancin 1200 mg in stable, discharge appropriate patients with opioid use related invasive infections collocated in setting of treatment for opioid use disorder
75914259|NCT05518396|Diagnostic Test|CoDE-HF decision support tool|We will assess the diagnostic performance of the CoDE-HF decision support tool
75914260|NCT05518188|Biological|MELPIDA|MELPIDA, a recombinant serotype 9 adeno-associated virus (AAV) encoding a codon-optimized human AP4M1 transgene
75914261|NCT05517902|Biological|StrataGraft|StrataGraft® Construct
75624630|NCT02685670|Biological|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
75624631|NCT02685670|Drug|Fludarabine|
75624632|NCT02685670|Drug|Cyclophosphamide|
75624633|NCT02684656|Procedure|Hemodialysis|Hemodialysis >/=4h
75624634|NCT02684656|Procedure|Hemodiafiltration|Hemodiafiltration >/=4h, > 20l convection
75624635|NCT00640120|Device|WIM-PC™ device|wheeze detection during dynamic bronchial situations in infants
75777538|NCT00046930|Drug|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
75777539|NCT00046930|Drug|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
75777540|NCT00042939|Biological|cetuximab|Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
75777541|NCT00042939|Drug|docetaxel|Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
75321486|NCT02999971|Other|circuit class therapy on land|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
75624636|NCT02688010|Behavioral|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
75624637|NCT00638872|Drug|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
75777542|NCT00042939|Drug|irinotecan hydrochloride|After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
75777543|NCT00008385|Other|placebo|Given orally
75777544|NCT00008385|Drug|selenium|Given orally
75777545|NCT00003927|Biological|filgrastim|
75914262|NCT05514223|Other|Biomaterial collection for observational purpose|The semen will be collected to measure the free radical concentration in seminal plasma and sperm together with the diversity of microbiota. Both males with a normal semen analysis (SA) and abnormal SA according to the WHO guidelines (2010) will be included. Blood plasma will be collected to measure systemic radical concentration and all outcomes will be related to lifestyle factors and food intake acquired through hospital charts and routinely conducted questionnaires together with a food frequency Questionnaire (FFQ).
75321487|NCT01941927|Drug|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
75321488|NCT01941927|Drug|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
75321489|NCT05220917|Drug|SGLT2 inhibitor|Any SGLT2i dispensing claim
75321490|NCT05220917|Drug|DPP-4 inhibitor|Any DPP-4 inhibitor claim
75321491|NCT05220917|Drug|GLP-1RA|Any SGLT2i dispensing claim
75914263|NCT05513404|Dietary Supplement|Honeyberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of honeyberries grown in Scotland.
75914264|NCT05513404|Dietary Supplement|Cherry|To investigate changes in postprandial glucose and cognitive performance, after consumption of cherries grown in Scotland.
75914265|NCT05513404|Dietary Supplement|Raspberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of raspberries grown in Scotland.
75914266|NCT05512013|Drug|Ibuprofen 800 mg|Ibuprofen taken orally 2 hours prior to exercise
75914267|NCT05512013|Drug|Celecoxib 200mg|Celebrex taken orally 2 hours prior to exercise
75914268|NCT05512013|Drug|Flurbiprofen 100 mg|Flurbiprofen taken orally 2 hours prior to exercise
75624638|NCT00638872|Other|0.9% NaCl|same as PDRN
75624639|NCT00638950|Dietary Supplement|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
75914269|NCT05512013|Drug|Placebo|Inert placebo taken orally 2 hours prior to exercise
75624640|NCT00638950|Dietary Supplement|Placebo|The placebo products were commercial dairy products with comparable fat contents.
75624641|NCT00639808|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
75777546|NCT00003927|Drug|amifostine trihydrate|
75777547|NCT00003927|Drug|cyclophosphamide|
75777548|NCT00003927|Drug|doxorubicin hydrochloride|
75777549|NCT00003927|Drug|paclitaxel|
75777550|NCT00003927|Procedure|peripheral blood stem cell transplantation|
75777551|NCT00003910|Drug|Cyclophosphamide|Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
75777552|NCT00003910|Drug|Methotrexate|Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
75777553|NCT00003910|Drug|Prednisone|Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
75777554|NCT00003907|Drug|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
75777555|NCT00003907|Drug|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
75798461|NCT01284192|Drug|ASP3026|Tablet
75777556|NCT00003907|Drug|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
75777557|NCT00003907|Procedure|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
75777558|NCT04334499|Other|Sample collection from tissue discard|Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.
75777559|NCT04331067|Drug|Paclitaxel|-Given standard of care
75777560|NCT04331067|Drug|Carboplatin|-Given standard of care
75777561|NCT04331067|Biological|Nivolumab|-Given standard of care
75777562|NCT04331067|Biological|Cabiralizumab|-Will be provided by Bristol Myers Squibb
75914270|NCT05505604|Procedure|PENG|patients will receive an ultrasound-guided Pericapsular Nerve Group Block with 20mL of 0.25% bupivacaine (not to exceed 2mg/kg)
75914271|NCT05505604|Procedure|FICB|Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block with 20 mL of 0.25% bupivacaine (not to exceed 2 mg/kg) diluted to total volume of 40 mL of injectate
75914272|NCT05504863|Drug|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
75914273|NCT05504863|Drug|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
75914274|NCT05504863|Drug|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
75914275|NCT05499871|Behavioral|Gait retraining intervention|Participants will receive a training to modify their footstrike pattern toward a more forefoot strike and increase their cadence by 7.5%.
75914276|NCT05499871|Device|Transition to minimalist footwear.|Participants will receive a running minimalist footwear.
75624642|NCT00639808|Drug|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
75777563|NCT04331067|Procedure|Tumor biopsy|-Baseline, week 5, surgery, and at time of relapse (optional)
75777564|NCT04331067|Procedure|Bone marrow|-Time of port placement (baseline), time of surgery, and time of recurrence (optional)
75777565|NCT04331067|Procedure|Blood draw|-Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)
75777566|NCT04329221|Drug|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriol (Calcipotriene) is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
75777567|NCT04329221|Drug|Vaseline|Placebo
75777568|NCT04329221|Drug|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
75777569|NCT04316013|Drug|Sevoflurane|Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice
75914277|NCT05499663|Behavioral|POSTHOC app|The POSTHOC app is a smartphone application that will deliver the Survivorship Care Plan and promote healthy lifestyle behaviors consistent with the individual's Care Plan
75914278|NCT05492331|Other|Music Therapy|Patient preferred artist or music genre to be playing from an iPad
75914279|NCT05491005|Behavioral|Total diet replacement|Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
75914280|NCT05491005|Behavioral|eHealth|All follow-up through an eHealth application and video meetings.
75914281|NCT05491005|Behavioral|Face-to-face|All follow-up through face-to-face meetings.
75914282|NCT05481177|Drug|Ivabradine|Ivabradine is a drug approved to treat tachycardia in volunteers with heart failure. This study is to determine benefit of ivabradine treatment in postural orthostatic tachycardia syndrome (POTS) in participants with Long haul Covid.
75914283|NCT05481086|Other|No Interventions|There is no interventions in this study
75914284|NCT05480982|Behavioral|Cognitive functional therapy via tele rehabilitation|Participants in the CFT group will be treated by a physiotherapist with seventeen years of clinical experience and that has attended six CFT workshops with three of the international tutors of the method. She has completed 212 hours of training including workshops, patient examinations and a pilot study under the supervision of a physiotherapist with more than seven years of clinical experience in CFT. Another two physiotherapists, one with more than fifteen years and the other with more than ten years of clinical experience, and both with more than 106 hours of CFT training including CFT via tele physiotherapy, will complete the staff.
75624643|NCT02687932|Drug|LCZ696|
75624644|NCT02687932|Drug|Valsartan|
75624645|NCT00641602|Drug|Esomeprazole|40mg once daily
75624646|NCT00641602|Drug|Lansoprazole|30mg once daily
75624647|NCT04183972|Procedure|ultrasound examination|the participants will be placed in the supine position, with head turned slightly away from the operating side and arms beside the body. The operator will identify right and left interscalene brachial plexuses by ultrasound equipment (Sonosite EDGE or GE LOGIQ e). Clear images and videos of brachial plexus will be captured and saved.
75624648|NCT01161524|Drug|Perampanel|2 mg titrated up to 8-12 mg maximum; taken once daily.
75624649|NCT01161524|Drug|Placebo|Matching Placebo taken once daily.
75777570|NCT04316013|Drug|Propofol|Intravenous anaesthetic used for induction and maintenance of anaesthesia
75777571|NCT04316013|Drug|Lidocaine IV|1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.
75777572|NCT04313257|Other|Monocular Active Occlusion|Occlusion treatment of one hour daily with action video game.
75777573|NCT04313257|Other|Monocular Passive Occlusion|Occlusion treatment of two hour daily.
75777577|NCT04295798|Other|Traditional tDCS|The participant will receive a single-session of traditional tDCS for 20 minutes.
75777578|NCT04295798|Other|Traditional Sham|The participant will receive a single-session of traditional sham for 20 minutes.
75777579|NCT04295798|Other|Personalized tDCS|The participant will receive a single-session of personalized tDCS for 20 minutes.
75777580|NCT04295798|Other|Personalized Sham|The participant will receive a single-session of personalized sham for 20 minutes.
75777581|NCT04281849|Behavioral|BAMS-HF Program|"BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components.~Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully."
75777582|NCT04278794|Other|Transitional Care Stroke Intervention (TCSI)|"Core components:~Comprehensive Hospital Discharge Plan. The Care Coordinator will meet with staff in the in-patient unit along with patients and their caregivers to develop and implement a comprehensive discharge plan.~Structured home visits and telephone support. As part of the structured home visits and telephone support, a member of the IP team will provide up to 6 home visits over 6 months. The team will provide: screening and assessment; medication review and reconciliation; self-management support; education; and caregiver assessment.~Monthly IP case conferences. 6 monthly IP team case conferences will be held to discuss goals identified by the patient, collectively develop a plan of care, and identify needs.~Linkages to services. Facilitate timely follow-up with the primary care provider and build relationships with local health and social service providers. These referrals and links will provide the foundation for continued use post-intervention."
75777583|NCT04270474|Other|Deprescribing of target anticholinergics|The active intervention group (ACT) will receive a pharmacist-based deprescribing intervention focused only on targeted anticholinergic medications. The intervention pharmacist will serve as the central source of communication between participants, providers, and (as needed) dispensing pharmacy to coordinate the deprescribing process. The study pharmacists will navigate a shared-decision model between the physicians and participant in order to personalize the selection of appropriate alternatives and switch/titration schedules. Importantly, the pharmacist will supervise the titration and deprescribing plan and communicate with both participants and physicians throughout the study.
75777584|NCT04270474|Other|Usual Care|Those in the usual care group will not have access to the study intervention, but will receive a one-time information packet through the mail reviewing risks of polypharmacy, but no information specific to anticholinergic medications. They will receive clinical care as usually provided by their primary care or specialty care physicians.
75777585|NCT04266431|Behavioral|EMPOWER|Behavioral weight loss intervention
75777586|NCT04264897|Drug|Metformin|"Metformin (Hunter Pharmacy) following a ramp up dosing protocol with a targeted dose of 1500 mg/day for 12 weeks."
75914285|NCT05480982|Other|Pilates via tele rehabilitation|Physiotherapist will have the freedom to judge about the exercises´ progression and the need of adaptation considering both the level of difficulty to perform each exercise according to the original proposal and the individual´s demands. The treating physiotherapists will have at least 2 years of clinical practice in Pilates and clinical experience in Pilates via teleconference.
75914286|NCT05478941|Combination Product|Progressive Muscular Relaxation via Zoom, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"Four individual PMRT sessions via Zoom.~In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
75914287|NCT05478941|Combination Product|Progressive Muscular Relaxation via Audio-track, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"Four individual PMRT sessions via Audio-track.~In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
75914288|NCT05478941|Behavioral|Progressive Muscular Relaxation via Zoom, and Exposure to a Guided Imagery Exposure.|"Four individual PMRT sessions via Zoom.~In vivo PMRT relaxing session and Guided Imagery conducted by the Psychotherapist (T1; day 7).~Follow-up phase (T2; day 14), after two weeks. Recovering the in-imagination relaxing scenario and PMRT session."
75914289|NCT05477927|Biological|Dual-targeting VEGFR1 and PD-L1 CAR-T cells|"In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.~In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition."
75624650|NCT02681224|Other|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
75777587|NCT04264897|Drug|Placebo oral tablet|Silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate
75777588|NCT04262908|Other|Telephone call|Patients who did not return to work after the SL prescribed initially and had an extension of the SL will be called at 4 months postoperatively to collect infomation
75624651|NCT02681224|Other|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
75624652|NCT02681224|Other|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
75624653|NCT02681224|Other|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
75321492|NCT05220917|Drug|2nd generation SU|Any 2nd generation SU claim
75321493|NCT01942707|Procedure|abdominoplasty with Scarpa's Fascia|During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
75624654|NCT04182646|Device|Spartz Balloon|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required
75624655|NCT02683096|Other|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
75624656|NCT02680990|Behavioral|Band Together|Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
75624657|NCT02680990|Other|Exercise Education|Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
75624658|NCT04184128|Diagnostic Test|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position [14]. A 20-minute pad test for each woman was also performed [15, 16]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS [3]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
75624659|NCT02682940|Device|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
75624660|NCT05663944|Drug|Sirolimus 0.5Mg Tab|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
75624661|NCT05663944|Diagnostic Test|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be undertaken at Sir Peter Mansfield Imaging Centre, University of Nottingham at the start of the trial, and at the end, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
75624662|NCT05663944|Procedure|1st Percutaneous or Endoscopic Ultrasound guided liver biopsy|After informed consent, participants will undertake up to a 4-week screening period to provide baseline data to ensure eligibility. During this period, participants will undergo blood tests, percutaneous or endoscopic ultrasound-guided liver biopsy, unless the participant has undergone a liver biopsy within the past 3 months, in which case the previous liver biopsy sample will be utilised for this study. They will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate with sirolimus when compared to placebo
75624663|NCT05663944|Drug|Placebo 0.5mg capsule|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. The placebo is unmatched. Participants will start on a dose of 1mg daily (2 x 0.5mg capsules) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels, to maintain blinding of the research team members carrying out blood tests. Placebo doses will be adjusted randomly, in a pattern that mirrors the adjustments made to participants on sirolimus.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
75624664|NCT05663944|Diagnostic Test|Baseline Blood Tests|"During the initial clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~Full blood count~Urea and electrolytes~Liver function tests~Clotting screen~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
75624665|NCT05663944|Diagnostic Test|Baseline Clinical Examination|A thorough medical examination will be undertaken at the first clinical visit (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants are clinical stable. This will also serve as a comparator for future clinical examinations once participants have commenced the study drug.
75777589|NCT04262713|Other|Radiographs|Radiographs of the implanted hip with Meije duo size1 or 2 are performed in eligible patients ( Weigh>60, Long neck stem, Varus; DEVANE score ≥ 4)
75777590|NCT04241315|Drug|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
75777591|NCT04241315|Device|Near infrared camera imaging system|Near infrared camera imaging system
75777592|NCT04225026|Drug|GC4419 (avasopasem manganese)|90 mg, by 60-minute IV infusion, prior to each fraction of RT
76073790|NCT04170907|Other|standardized vaping protocol|The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.
75914290|NCT05472311|Other|Thermal Ablation|Thermal ablation is based on local heating (around 100 degrees centigrade), applied for 20 to 60 seconds to destroy abnormal tissue by burning and inducing necrosis of pre-cancer and surrounding tissue. It has been used in by gynecological surgery for over 50 years, proven safe and easy to use by middle level health care providers in primary care settings.
75914291|NCT05471986|Device|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Subjects will have underwent Fundus Photography using FDA approved non-mydriatic fundus cameras compatible with EyeCheckup which are either TOPCON NW400, CANNON CR2, CANNON CR2 Plus or OPTOMED AURORA IQ
75624666|NCT05663944|Diagnostic Test|Week 1 - 5 Titration Blood Tests|"Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly bloods:~full blood count,~urea and electrolytes and~liver function tests to check the study drug is not causing any significant organ damage.~Sirolimus trough levels will be measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Therefore, participants will have a minimum of 3 weeks of blood tests during this period, The need for week 4 and 5 blood tests will be decided by the trial pharmacist who will be monitoring results.~Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding."
75624667|NCT05663944|Other|Month 2 Clinical Examination|A thorough medical examination will be undertaken at Month 2 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
75914292|NCT05471037|Procedure|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
75914293|NCT05471037|Procedure|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
75624668|NCT05663944|Diagnostic Test|Month 2 Blood Tests|"During the Month 2 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~Full blood count~Urea and electrolytes~Liver function tests~Clotting screen~Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
75624669|NCT05663944|Other|Month 4 Clinical Examination|A thorough medical examination will be undertaken at Month 4 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
75624670|NCT05663944|Diagnostic Test|Month 4 Blood Tests|"During the Month 4 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~Full blood count~Urea and electrolytes~Liver function tests~Clotting screen~Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
75624671|NCT05663944|Other|Month 6 Clinical Examination|A thorough medical examination will be undertaken at Month 6 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants have remained clinically stable whilst on the study drug. At this visit, they will be asked to finish taking the study drug. They will also be asked about potential side effects in detail.
75624672|NCT05663944|Diagnostic Test|Month 6 Blood Tests|"During the Month 6 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~Full blood count~Urea and electrolytes~Liver function tests~Clotting screen~Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
75624673|NCT05663944|Procedure|2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy|All participants will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate when compared to their first biopsy.
75624674|NCT05663944|Diagnostic Test|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
75914294|NCT05464368|Drug|[18F]RO-948|"Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
76073791|NCT03156387|Procedure|Diode laser|2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
76073792|NCT03156387|Procedure|Scalpel|Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
75321494|NCT01942707|Procedure|Abdominoplasty without Scarpa´s Facia|During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
75321495|NCT00086996|Drug|fluorouracil|Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
75321496|NCT00086996|Drug|oxaliplatin|Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
75321497|NCT00086996|Procedure|conventional surgery|The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
75624675|NCT01000506|Biological|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
75466629|NCT01911494|Behavioral|Community Engagement|The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
75624676|NCT01000506|Biological|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
75624677|NCT01000506|Biological|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
75624678|NCT01000506|Drug|Placebo saline|Placebo saline every four weeks by i.v.
75624679|NCT02682862|Drug|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
75624680|NCT02682862|Drug|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
75624681|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
75624682|NCT00640198|Behavioral|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
75624683|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
75624684|NCT00640198|Drug|placebo|Placebo
75624685|NCT04296552|Other|Dietary lowFODMAP intervention|Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
75624686|NCT04293822|Drug|Cetirizine|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Cetrizine 1% gel, which will be prepared at the department of Pharmaceutics, Faculty of Pharmacy, Assiut University in the form of Nano-transferosomes (NTF)."
75624687|NCT04293822|Drug|Minoxidil|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Minoxidil 5% gel"
75624688|NCT02680600|Drug|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
75624689|NCT02680600|Other|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
75624690|NCT02680600|Other|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
75624691|NCT02680600|Other|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
75777593|NCT04199637|Other|TVG|Therapeutic video game
75777594|NCT04177108|Drug|Atezolizumab|Atezolizumab will be administered to participants by intravenous (IV) infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28-day cycle until unacceptable toxicity.
75777595|NCT04177108|Drug|Ipatasertib|Ipatasertib will be administered to participants at a starting dose of 400 mg QD PO (one tablet a day orally) for 21 days of each 28-day cycle on Days 1 - 21 unless held for management of adverse events.
75777596|NCT04177108|Drug|Paclitaxel|Paclitaxel will be administered to participants at a starting dose of 80 mg/m^2 by IV infusion for 3 of 4 weeks on Days 1, 8, and 15 of each 28-day cycle unless deferred to Day 22 because of an adverse event.
75624692|NCT02680600|Other|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
75624693|NCT02680600|Other|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
75624694|NCT02680600|Other|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
75624695|NCT02680678|Other|Colloid Preload|preload infusion
75624696|NCT02680678|Other|colloid co-load|co-load infusion
75624697|NCT02680678|Other|Crystalloid preload|preload infusion
75624698|NCT02680678|Other|Crystalloid Co-load|co-load infusion
75624699|NCT05663788|Other|E-learning module|"The intervention is a structured e-learning module on a web-based platform (www.trainingopticaldiagnosis.com) that consists of:~10 modules, including theoretical knowledge and multiple exercises.~2 seminars with a tutor (after Module 5 and Module 10)~feedback from the tutor on three cases recorded by the participant.~20-images test before and after the content described above (10 Modules, 2 seminars with tutors and feedback on three cases)~All the Gastroenterologists participating in the study will predict deep submucosal invasion in their routine colonoscopies and will register clinical outcomes during 12 months. The randomisation and intervention will be conducted 6 months after starting to predict deep submucosal invasion and registering clinical outcomes."
75624700|NCT04182724|Drug|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
75624701|NCT02680912|Device|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
75624702|NCT02680912|Device|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
75624703|NCT02682628|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75624704|NCT04183816|Other|Total cold-water immersion|TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C.
75624705|NCT04183816|Other|Ice massage|Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
75624706|NCT04184518|Drug|Cediranib Maleate|Cediranib 20mg, oral, 5 days on and 2 days off until disease progression
75624707|NCT04184518|Drug|Durvalumab|Durvalumab 1500mg, intravenous, every 4 weeks until disease progression
75624708|NCT02680522|Other|Exercise|exercise training with virtual reality in videogame
75624709|NCT01174238|Drug|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
75624710|NCT01174238|Drug|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
75624711|NCT01174238|Drug|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
75624712|NCT04315532|Other|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed for pregnant and non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken from all patients baseline and after 8 weeks.
75624713|NCT04315532|Other|Saliva samples|Saliva samples were taken from patients for the evaluation of sex steroid and stress markers baseline and after 8 weeks.
76073793|NCT03586713|Diagnostic Test|light induced fluorescence camera|The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
76073794|NCT01794949|Device|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
75624714|NCT04315532|Other|GCF samples|GCF samples were taken from patients for the evaluation of stress markers baseline and after 8 weeks.
75624715|NCT02682472|Other|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
75624716|NCT00640900|Behavioral|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
75624717|NCT00640900|Behavioral|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
75624718|NCT02680444|Behavioral|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
75624719|NCT02680444|Behavioral|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
75624720|NCT02680444|Behavioral|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
75624721|NCT02928406|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
75624722|NCT01174160|Drug|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
75777597|NCT04177108|Drug|Placebo for Atezolizumab|Placebo will be administered to participants at a fixed dose of 840 mg IV infusion for Atezolizumab on Days 1 and 15 of each 28-day cycle until unacceptable toxicity.
75914295|NCT05464368|Drug|18F-MK6240|"18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
75914296|NCT05464368|Drug|18F-GTP1|"18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location."
75914297|NCT05464264|Drug|Ketamine|Participants suffering from TRD will receive their ketamine treatment intravenously twice weekly for two weeks (4 treatments in total). A dose of 0.5 mg/kg is infused over 40 minutes, with dose adjustments made at the psychiatrist's discretion.
76073795|NCT04414501|Behavioral|Separation Anxiety|Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.
76073796|NCT03586557|Device|Corticosteroid & Plasma exchange|High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper, combined simultaneous plasma exchange 5 times in all
76073797|NCT03586557|Drug|Corticosteroid|High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper
75624723|NCT01174160|Drug|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
75624724|NCT04313894|Biological|Wharton Jelly Originated Mesencimal Stem Cell|In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
75624725|NCT02683798|Dietary Supplement|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
75321498|NCT00086996|Radiation|radiation therapy|Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
75466630|NCT01911494|Device|PIERS on the Move mHealth decision aid|This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (>160mmHg systolic) or proteinuria (>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
75777598|NCT04177108|Drug|Placebo for Ipatasertib|Placebo will be administered to participants at a starting dose of 400 mg QD PO (one tablet a day orally) for Ipatasertib for 21 days of each 28-day cycle on Days 1 - 21 unless held for management of adverse events.
75777599|NCT04175769|Dietary Supplement|Nutritional supplement|Subjects will orally consume two gelatin capsules of nutritional supplement (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
75777600|NCT04175769|Other|Placebo|Subjects will orally consume two gelatin capsules of placebo (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
75777601|NCT04145934|Behavioral|ADSTEP|ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.
75624726|NCT02683798|Dietary Supplement|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
75624727|NCT04315454|Drug|Levobupivacaine|A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
75624728|NCT02683720|Dietary Supplement|ONS|randomized clinical trial involving different ONS strategies
75624729|NCT02885480|Behavioral|questionnaires|
75777602|NCT04140513|Radiation|Fludeoxyglucose F-18|Given via injection
75777603|NCT04140513|Procedure|Positron Emission Tomography|Undergo dPET
75777604|NCT04139538|Procedure|orthodontic treatment|Malocclusion will be treated with orthodontic appliances (fixed or removable)
76073798|NCT05702775|Procedure|Endoscopic treatment group (EUS-GBD group|The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
75777605|NCT04111627|Behavioral|Aerobic exercise|Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
76073799|NCT05702697|Device|focus extracorporeal shock wave therapy|F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
76073800|NCT05702697|Behavioral|Home stretching program|The leaflet on hamstring stretching exercises (in a sitting posture)
76073801|NCT02947503|Drug|Metformin TEVA 850 mg|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
75624730|NCT02682550|Procedure|blood drawing|blood drawing
75624731|NCT01161446|Behavioral|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
75624732|NCT01161446|Device|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
75624733|NCT02680210|Other|Questionnaires and cognitive measures|
75624734|NCT00641680|Drug|Budesonide|
75624735|NCT00641680|Drug|Fluticasone propionate|
75777606|NCT04111627|Drug|Duloxetine|Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
75777607|NCT04105491|Device|IInvisalign® Aligners|Clear aligner orthodontic treatment
75777608|NCT04090710|Drug|Ipilimumab/ Nivolumab|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression
75777609|NCT04090710|Radiation|SBRT + Ipilimumab/Nivolumab|SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.
75777610|NCT04070703|Behavioral|The Go for Exercise & Healthy Aging Project|Exercise and Cognition
75777611|NCT04069312|Drug|Roflumilast|Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
75777612|NCT04069312|Drug|Azithromycin|Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
75777613|NCT04064463|Behavioral|Standard care|standard treatment for substance use disorders, along with sample monitoring
75777614|NCT04064463|Behavioral|Contingency management|Participants can earn reinforcement for attending group and abstinence from alcohol
75777615|NCT04042480|Drug|SGN-CD228A|SGN-CD228A administered into the vein (IV; intravenously)
75777616|NCT04025528|Procedure|Bariatric Surgery|Weight loss surgery with either gastric sleeve or gastric bypass surgery
75777617|NCT04023825|Drug|suprazygomatic maxillary nerve block|in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.
75777618|NCT04019665|Other|MMSE (mini mental state examination)|mini mental state examination takes place during the consultation. The consultation is a general or post-emergency geriatric consultation.
75777619|NCT04019665|Other|SAGE (Self-Administered Gerocognitive Exam)|SAGE test contains a series of questions that assess the cognitive functioning. Sage was developed by the Ohio State University Wexner Medical Center. it's an online, at-home, self-screening dementia tool that has been scientifically evaluated, and it's demonstrated good results in accurately identifying cognitive deficits.
76073802|NCT03586323|Drug|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
76073803|NCT03586245|Dietary Supplement|Ferric pyrophosphate|57 Iron isotopically labeled FePP powder.
75624736|NCT00641680|Drug|Placebo|
75624737|NCT04183582|Behavioral|Behavioural Activation|"Behavioural Activation is a treatment for depression, the current programme has been adapted to suit the needs of postnatal women Session 1: Getting Started Session 2: Identifying Triggers, Reactions and Avoidance Patterns (TRAPs) Session 3: Turning TRACs in to Triggers, Reactions and Alternative Coping (TRACs) Session 4: Support and Communication Session 5: Being a Good Enough Mum Session 6: Staying Well"
75624738|NCT04033588|Device|Freedom® Total Knee System|To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
75624739|NCT01174004|Drug|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
75624740|NCT01174004|Drug|placebo|placebo, tablet, once daily by mouth for 6 weeks
75624741|NCT02680288|Drug|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
75624742|NCT02680288|Drug|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
75624743|NCT02680288|Other|Oral Placebo|Oral inert treatment
75624744|NCT02885402|Other|MRI Sodium ( 23Na )|
75624745|NCT04184206|Behavioral|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness component
75624746|NCT04184206|Behavioral|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness component
75624747|NCT04184206|Behavioral|attention training intervention 3|14-day smartphone-based audio-guided attention training program without mindfulness component
75624748|NCT01173692|Drug|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
75624749|NCT01173692|Drug|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
75624750|NCT00641758|Drug|Pycnogenol|Pycnogenol 100mg twice daily
75624751|NCT00641758|Drug|Placebo|Placebo 100mg twice daily
75624752|NCT00640276|Drug|pitavastatin|Pitavastatin 2mg daily once
75624753|NCT00640276|Behavioral|Lifestyle Modification|conducting mainly exercises and diet
75624754|NCT00640354|Device|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
75624755|NCT00640354|Device|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
75624756|NCT02680132|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
75624757|NCT02680132|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
75624758|NCT02790346|Procedure|arthrodesis talonavicular|
75624759|NCT02790346|Procedure|tendon gestures|
75624760|NCT02683564|Drug|BOW015|monoclonal antibody against TNF-alpha
75624761|NCT02683564|Drug|Remicade|monoclonal antibody against TNF-alpha
75624762|NCT01101035|Drug|Febuxostat|Febuxostat tablets
75624763|NCT01101035|Drug|Allopurinol|Allopurinol tablets
75624764|NCT04306679|Other|Animation clips|The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies
75624765|NCT04306679|Other|Instructions|Routine preoperative preparations, which included a section on pain assessment instructions.
75777620|NCT03982277|Drug|Rifampin 300 Mg Oral Capsule|High dose rifampicin at 35mg/kg
75777621|NCT03979443|Procedure|Discharge on the day of surgery|Patient discharge on the day of the surgery, usually within 6-8 hours after procedure
76073804|NCT03586245|Dietary Supplement|Aspiron|58 Iron isotope intrinsically labeled Aspergillus oryzae.
75624766|NCT01100567|Device|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
75624767|NCT01160822|Biological|Canakinumab|Intra-articular injection
75624768|NCT01160822|Drug|Placebo to canakinumab|Intra-articular injection
75624769|NCT01160822|Drug|Naproxen|Tablets for oral administration
75624770|NCT01160822|Drug|Placebo to Naproxen|Tablets for oral administration
75624771|NCT01006980|Drug|Vemurafenib|960 mg (as 240 mg tables) orally twice daily
75624772|NCT01006980|Drug|Dacarbazine|1000 mg/m2 intravenously every 3 weeks
75624773|NCT00887926|Biological|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
75624774|NCT04182178|Other|10 years follow up|Questionnaires
75624775|NCT02679898|Other|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
75624776|NCT02679898|Other|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
75624777|NCT04296240|Drug|Oxaliplatin and capecitabine|Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months
75624778|NCT04296240|Procedure|Total Mesorectal Excision|Patient receive total mesorectal excision after neoadjuvant chemotherapy
75777622|NCT03955978|Drug|TSR-042|-TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
75777623|NCT03955978|Radiation|Brachytherapy|-This trial will include image-guided brachytherapy with three-dimensional (3-D) treatment planning and in cases where pelvic radiation is deemed appropriate by the treating radiation oncologist, external beam radiation therapy (EBRT) using intensity modulated radiation therapy (IMRT) technique.
76073805|NCT03586245|Dietary Supplement|Ferrous sulfate|57 Iron isotopically labeled FeSO4 powder.
75777624|NCT03955978|Procedure|Endometrial biopsy|-Prior to the start of treatment with TSR-042. If this biopsy yields insufficient tumor tissue, an archival sample may be requested, with Fraction 1 of brachytherapy, with Fraction 4 of brachytherapy
75777625|NCT03955978|Procedure|Blood draw for immune response|-Prior to the start of any treatment, at the time of brachytherapy fractions 1 and 4 (corresponding to endometrial biopsy), prior to fourth dose of TSR-042, 6 weeks after the completion of all protocol related therapy
75777626|NCT03927703|Drug|SB206 12%|Topically once daily
75624779|NCT04205058|Dietary Supplement|Standard coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
75624780|NCT04205058|Dietary Supplement|Caffeine-free coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
75624781|NCT04205058|Dietary Supplement|Drinking water|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
75624782|NCT04183738|Drug|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
75624783|NCT04183738|Drug|Darunavir|800mg tablet by mouth once daily for 96 weeks.
76073806|NCT03890991|Behavioral|SCOPE-DM|The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing
75624784|NCT04183738|Drug|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
75624785|NCT04183738|Drug|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
75777627|NCT03927703|Drug|Placebo|Topically once daily
75777628|NCT03918499|Drug|Cyclophosphamide|Given IV
76073807|NCT03890991|Behavioral|SCOPE-DM with 3 months' supply of glucometer|Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.
76073808|NCT03890991|Behavioral|SCOPE-DM with 6 months' supply of glucometer|Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
75466631|NCT01911494|Drug|Magnesium Sulfate|Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
75466632|NCT01911494|Drug|Methyldopa|Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
75466633|NCT01911507|Drug|INC280|Given PO
75466634|NCT01911507|Drug|erlotinib hydrochloride|Given PO
75466635|NCT01911520|Drug|Sugammadex 2 mg/kg|Patients receive 2 mg/kg Sugammadex.
75624786|NCT02870322|Behavioral|Fruit and Vegetable CSA Prescription|Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.
75624787|NCT02870322|Behavioral|Bikeshare Prescription|Study participants will use bikeshare for transportation and physical activity for 10 weeks
75624788|NCT02682160|Other|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
75624789|NCT04033666|Other|High Flow Nasal cannula|The HFNC will be instituted therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight, ranging from 2 l / min to 30 l / min. The therapy will begin with diaphragmatic exercises 3x10 breaths and after high-flow therapy with nasal cannula for 45 minutes, after which will be performed the vital signs evaluations and Peak Flow, HRV, FEV1.
75777629|NCT03918499|Biological|Cytokine-based Biologic Agent IRX-2|Given SC
75777630|NCT03918499|Biological|Pembrolizumab|Given IV
75777631|NCT03916276|Behavioral|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts; recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
75777632|NCT03916276|Behavioral|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
75798462|NCT02526732|Other|individual training program|Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
75466636|NCT01911520|Drug|Sugammadex. 4 mg/kg|Patients receive 4 mg/kg Sugammadex.
75466637|NCT01911520|Procedure|Neuromuscular monitoring.|Neuromuscular monitoring using a TOF watch SX (Organon).
75624790|NCT04033666|Other|NIV Noninvasive Ventilation|The Therapy consisted of 3x10 diaphragmatic re-education exercises after a Bipap device was coupled in bipedal mode with parameters Ipap 12 cm H2O and Epap 8 cm H2O, for 45 minutes, according to the patient's tolerance, with Full face facial mask. After therapy evaluated vital signs and measures of Peak Flow, HRV, FEV1.
75624791|NCT02871414|Behavioral|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
75466638|NCT01911520|Procedure|Clinical evaluation of residual curarization .|Every 30 min, during the first 2 hours after the end of the surgery.
75624792|NCT02871414|Behavioral|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
75624793|NCT00641134|Other|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
75624794|NCT02682082|Procedure|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
75624795|NCT02682082|Drug|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
75624796|NCT02870946|Procedure|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
75624797|NCT02870946|Procedure|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
75624798|NCT00640432|Drug|Diclofenac|75 mg oral capsule twice daily for 7 days
75624799|NCT00640432|Drug|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
75624800|NCT02870244|Biological|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10^7/kg TIL 1383I TCR transduced T cells."
75624801|NCT02679664|Drug|Rosuvastatin|20 mg tablet of rosuvastatin
75624802|NCT02871180|Dietary Supplement|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
75624803|NCT02871180|Other|No late night snack|Patient consumed no nutrients at late night.
75624804|NCT02679742|Dietary Supplement|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
75624805|NCT02679742|Dietary Supplement|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
75624806|NCT04295226|Other|Structured follow-up after stroke.|Stroke-nurse managed follow-up 3 and 12 months after stroke and multidisciplinary rounds resulting in individual treatment plans for stroke-related health problems.
75624807|NCT02679586|Device|Diffusion weighted MRI|
75624808|NCT04295070|Biological|CodaVax-RSV|Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper
75624809|NCT04295070|Biological|Normal saline|Saline (0.9%) administered via dropper
75624810|NCT00641836|Procedure|Transplantation of autologous endothelial progenitor cells|
75624811|NCT02870010|Biological|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
75624812|NCT02870010|Radiation|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
75624813|NCT02870712|Procedure|Suture of perineum|suture of the tear to obtain hemostasis
75624814|NCT02870712|Procedure|hemostatis by digital compression|Digital compression of the tear to obtain hemostasis
75624815|NCT02537782|Device|Cardiac resynchronisation therapy|
75624816|NCT02537782|Other|Echocardiography|
75624817|NCT02537782|Other|Magnetic Resonance Imaging|
75466639|NCT01911559|Device|standing-frame|
75466640|NCT01911585|Behavioral|Prolonged Exposure Therapy|Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
75466641|NCT01911598|Drug|5-FU|5-FU will be administered as per schedule specified in the respective arm.
75624818|NCT02537782|Other|Positron Emission Tomography|
75624819|NCT00998400|Behavioral|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
75624820|NCT00641212|Drug|Budesonide|
75624821|NCT00641212|Drug|Placebo|
75624822|NCT02869776|Behavioral|Questionnaire|Behavioral questionnaires
75624823|NCT02869776|Procedure|Rapid finger stick|HIV and HCV testing through rapid finger stick
75624824|NCT02869776|Procedure|Venipuncture|HIV and HCV testing through venipuncture
75624825|NCT04293900|Other|24-hour dietary recall|Dietary intake assessment conducted by a Registered Dietitian Nutritionist. This assessment will occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
75624826|NCT04293900|Other|Hand grip strength|Measurement of grip strength using a hand dynamometer. This will test occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
75624827|NCT04293900|Other|International Physical Activity Questionnaire|Survey about physical activity over the previous 7 days. This survey will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
75798463|NCT03872934|Behavioral|implant anxiety|to determine the type of music that reduces anxiety in patients undergoing implant surgery.
75777633|NCT03916276|Behavioral|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
75624828|NCT04293900|Other|Patient-reported outcomes survey|Survey about symptoms and side effects experienced during cancer treatment. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
75624829|NCT04293900|Other|Pittsburgh Sleep Quality Index|Survey about sleep habits and quality over the past month. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
75624830|NCT04293900|Other|Functional Assessment of Cancer Treatment - Lymphoma|Survey about quality of life for people with a diagnosis of lymphoma. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
75624831|NCT04293900|Other|urine sample (optional)|Collect three urine samples either in the clinic or at home. This specimen collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
75624832|NCT04293900|Other|fecal sample (optional)|Collect a fecal sample either in the clinic or at home. This sample collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
75624833|NCT04183192|Biological|Mepolizumab|Mepolizumab 3 mg administered SC
75624834|NCT04183192|Biological|Mepolizumab|Mepolizumab 6 mg administered SC
75624835|NCT04183192|Biological|Mepolizumab|Mepolizumab 12 mg administered SC
75624836|NCT04183192|Biological|Mepolizumab|Mepolizumab 24 mg administered SC
75624837|NCT04183192|Biological|Reslizumab|Reslizumab 0.1 mg/kg administered IV
75624838|NCT04183192|Biological|Reslizumab|Reslizumab 0.2 mg/kg administered IV
75624839|NCT04183192|Biological|Reslizumab|Reslizumab 0.4 mg/kg administered IV
75624840|NCT04183192|Biological|Reslizumab|Reslizumab 0.8 mg/kg administered IV
75624841|NCT04183192|Biological|Placebo|Placebo (administered either IV or SC)
75624842|NCT02681848|Drug|Varenicline|Smoking cessation medication
75624843|NCT02681848|Drug|Nicotine replacement therapy|
75624844|NCT00997386|Drug|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
75624845|NCT02394574|Other|Clean Cookstove|Ethanol
75624846|NCT02394574|Other|Traditional Cookstove|Firewood / Kerosene
75624847|NCT02870088|Behavioral|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
75624848|NCT02870088|Behavioral|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
75624849|NCT04182256|Device|MS|Magnetic Spiderman (MS) is a novel surgical instrumentIt. It consists of a circular neodymium iron boron magnet packed in a stainless-steel case with a spring and a jagged clamp, which gives it a spider-like appearance.
75624850|NCT02869620|Other|Data collection|
75624851|NCT02679820|Device|Copper T intrauterine device|
75466642|NCT01911598|Drug|Carboplatin|Carboplatin will be administered as per schedule specified in the respective arm.
75624852|NCT02683330|Behavioral|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
75777634|NCT03904602|Device|Edema Wear fuzzy wale compression garment|net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
75798464|NCT01284270|Other|Cardiac MRI|Cardiac MRI
75798465|NCT01278264|Drug|Ropivacaine 0.25%, 0.5 ml/kg|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
75466643|NCT01911598|Drug|Cisplatin|Cisplatin will be administered as per schedule specified in the respective arm.
75624853|NCT00641914|Drug|budesonide|
75624854|NCT00641914|Drug|Placebo|
75624855|NCT02683408|Other|placebo|inactive placebo
75624856|NCT02683408|Dietary Supplement|diosmiplex|diosmiplex is an FDA regulated medical food product
75624857|NCT00640588|Drug|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
75624858|NCT00640588|Drug|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
75624859|NCT05663398|Drug|Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
75466644|NCT01911598|Drug|MEHD7945A|MEHD7945A will be administered as per schedule specified in the respective arms.
75466645|NCT01911598|Drug|Paclitaxel|Paclitaxel will be administered as per schedule specified in the respective arm.
75466646|NCT01911611|Drug|RO6870868|Single ascending doses
75466647|NCT01911611|Drug|placebo|Single ascending doses
75466648|NCT01911624|Drug|direct thrombin inhibition|
75466649|NCT01911624|Drug|enoxaparin|
75624860|NCT05663398|Drug|Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
75624861|NCT02683252|Other|T1 mapping and MR perfusion acquisition|One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
75624862|NCT02681926|Procedure|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
75624863|NCT00640666|Behavioral|Exercise Behavior Change|Multidisciplinary
75624864|NCT02679352|Device|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
75624865|NCT00640744|Drug|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
75624866|NCT02678026|Device|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
75624867|NCT05663008|Procedure|128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)|128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
75624868|NCT02678104|Procedure|Tooth extraction|Tooth removal
75624869|NCT02678104|Drug|Chlorhexidine mouth wash|Chlorhexidine mouth wash
75624870|NCT02678104|Drug|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
75624871|NCT04183036|Procedure|Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The operator positioned the clip and assessed the clip position and made sure the incision was clipped. Four to five endoclips were positioned in the incision in a zipper way from distal to proximal papillary sphincterotomy
75624872|NCT02681536|Drug|Triptorelin|
75624873|NCT02681536|Drug|Combined oral contraceptive pills|
75624874|NCT02681536|Drug|HMG|
75624875|NCT04183114|Biological|Measles-Rubella vaccine Bio Farma|MR vaccine produced by Bio Frama with 3 consecutive batches
75624876|NCT04183114|Biological|MR Vaccine SII|MR Vaccine produced by SII (Already registered in Indonesia)
75624877|NCT02681692|Device|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
75624878|NCT00996996|Biological|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
75624879|NCT04182568|Drug|nab-paclitaxel followed by anthracycline and cyclophosphamide|nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
75624880|NCT04182568|Drug|Docetaxel followed by anthracycline and cyclophosphamide|Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
75624881|NCT02681380|Other|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
75624882|NCT02681380|Other|Control group|No session will be planned for the participants.
75624883|NCT02681068|Other|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
75624884|NCT02870868|Behavioral|Slow breathing|Slow breathing techniques from yoga
75624885|NCT04283682|Behavioral|Early skin-to-skin combined with breast-feeding|Premature infants in the intervention group have access to skin-to-skin once a day for 1 hour at least once no ventilation support needed. During the skin-to-skin period,the breastfeeding is encouraged for about 5-10 minutes. The whole intervention stop until the baby achieve the full oral feeding.
75466650|NCT01911637|Drug|VBY-036|Study drug VBY-036
75624886|NCT04033744|Procedure|extraction of mandibular third molar|After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
75777635|NCT03870945|Biological|MB-CART2019.1 Dose level 1|This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.
75466651|NCT01911637|Drug|Placebo|Placebo
75466652|NCT01911650|Other|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
75466653|NCT01911650|Other|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
75466654|NCT01911650|Other|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
75914298|NCT05463042|Behavioral|Intermittent Hypoxia|During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.
76073809|NCT05702619|Drug|Optional non-IMP pimonidazole|patients will be asked to ingest an oral formulation of pimonidazole hydrochloride (HCl) (Oral HypoxyprobeTM-1). Pimonidazole HCl is a marker for hypoxia in tumour tissue when ingested as an encapsulated solid. Following oral administration, pimonidazole distributes throughout the body where it covalently binds to normal and tumour tissues that have regions of low oxygen concentrations (pO2 of ≤ 10 mmHg at 37oC). The tissue binding can be visualised by immunohistochemistry / light microscopy. The capsules are to be taken within 8-16 hours (optimal timepoint 12 hours) before the planned first biopsy within Arm 1 and before radical prostatectomy for patients in Arm 2. If the patient refuses the pimonidazole, forgets to take it, or if it is not available, the patient can still participate in the study and their samples will be stained for hypoxia post-biopsy.
75624887|NCT00628836|Device|BION stimulation|"The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated."
75624888|NCT02679196|Drug|KA2237|PI3 Kinase p110β/δ inhibitor
75321499|NCT05362253|Procedure|Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation|"Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation.~The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture.~After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva.~Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm ~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture.~Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing."
75624889|NCT00641368|Behavioral|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
75624890|NCT00641368|Other|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
75624891|NCT00641446|Drug|budesonide|
75624892|NCT00641446|Drug|varicella zoster virus|
75624893|NCT02677948|Drug|Pacritinib|
75777636|NCT03870945|Biological|MB-CART2019.1 Dose level 2|This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL.
75914299|NCT05463042|Behavioral|Normoxia (sham)|During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.
75624894|NCT02677948|Drug|Ibrutinib|
75624895|NCT02869854|Behavioral|Mindfulness|Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
75624896|NCT02869854|Behavioral|PAP|Physical Activity on Prescription, after 3 months a new prescription
75624897|NCT02681146|Other|Multimodal intervention|Educational advice + physiotherapist treatment
75624898|NCT02679118|Device|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
75624899|NCT00641524|Procedure|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
75624900|NCT02677636|Drug|MSRD-100|MSRD-100 is a topical gel.
75624901|NCT02677636|Drug|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
75624902|NCT05663164|Drug|Vitamin B|vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days
75777637|NCT03868735|Device|CleanSweep Closed Suction System|Device with balloon sweeping technology
75777638|NCT03838549|Procedure|Prophylactic mastectomy with immediate breast reconstruction|It is an endoscopic approach for prophylactic mastectomy using an axillary single port
75777639|NCT03833193|Radiation|Hypofractionated radiotherapy|Radiation: Hypofractionated radiotherapy at 3Gy/f
75777640|NCT03819829|Other|Blood sample|Blood sample
75777641|NCT03815890|Drug|Nivolumab|2 courses 240 mg flat dose
75777642|NCT03815890|Drug|Ipilimumab|single dose ipilimumab (1mg/kg) at day 1
75777643|NCT03815890|Drug|Ipilimumab|two courses ipilimumab (1mg/kg) at day 1 and 21
75914300|NCT05458986|Other|Media Intervention|Watch an educational video
75914301|NCT05458986|Other|Best Practice|Receive usual care
75624903|NCT05663164|Drug|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
75321500|NCT05362253|Procedure|Conventional Autologous Conjunctival Transplantation|"Routine disinfection and anaesthesia.~To bluntly separate and excise pterygium.~Remove pterygium tissue on the corneal surface with a round blade.~Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later.~After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture.~The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture.~Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation."
75624904|NCT02677558|Other|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
75624905|NCT00643318|Radiation|CyberKnife Stereotactic Radiosurgery|"Central tumors defined as < 2 cm from carina and < 2 cm from right and left mainstem bronchus and/or < 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being > 2 cms from the carina and > 2 cms from the right and left mainstem bronchus and/or > 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)"
75624906|NCT02537470|Drug|Biphasic Remogliflozin Etabonate|Experimental Drug
75624907|NCT02537470|Other|Placebo|Placebo Comparator
75624908|NCT02678728|Drug|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
75624909|NCT02678728|Drug|normal saline|IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
75624910|NCT04180072|Drug|Atezolizumab|Atezolizumab 1200 mg IV on day 1 every 3 weeks
75624911|NCT04180072|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
75624912|NCT02678806|Radiation|Postoperative radiotherapy|The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy
75777644|NCT03803943|Behavioral|Parent-Implemented Communication Intervention (PICT)|Weekly hour long intervention sessions for 6 months
75321501|NCT03453203|Other|Osteopathic Manipulative Treatment Using Counterstrain|Described in arm/group descriptions
75321502|NCT01943565|Drug|Hydromorphone 25mcg|Intrathecal Hydromorphone 25mcg
75321503|NCT01943565|Drug|Hydromorphone 50mcg|Intrathecal Hydromorphone 50mcg
75321504|NCT01943565|Drug|Hydromorphone 100mcg|Intrathecal Hydromorphone 100mcg
75321505|NCT01943565|Drug|spinal anesthesia|bupivacaine 0.75% 1.6 mL (12mg)
75321506|NCT05362175|Device|Obstetric ultrasound|ultrasound measurement of the cross sectional area of umbilical cord within 1 cm from the cord insertion in to fetal abdomen and the standard Hadlock's formula
75321507|NCT03316859|Drug|Naloxegol 25 MG|Naloxegol 25 mg administered 1 hour pre-operatively
75321508|NCT03316859|Other|Placebo pill|Placebo pill administered 1 hour pre-operatively
75321509|NCT04401878|Drug|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.
75624913|NCT02678806|Drug|Postoperative TACE|In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 ~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
75624914|NCT02676076|Drug|CHF 5993 100/6/12.5 µg|
75624915|NCT02676076|Drug|CHF 1535 100/6 µg|
75624916|NCT02537626|Device|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
75624917|NCT02537626|Device|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
75624918|NCT04181554|Other|Measurement of postural stability|The postural stability will assess by using Biodex balance system.
75624919|NCT02678650|Drug|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
75777645|NCT03803943|Other|No Intervention - Business-as-usual control|Does not receive PICT internvention
75777646|NCT03802695|Biological|OrcaGraft (Orca-Q)|engineered donor allograft
75798466|NCT01278264|Drug|Ropivacaine 0.25%, 0.5 ml/kg|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
75798467|NCT03867864|Device|Necklace with essential oil for the first 4 weeks|The necklaces contain essential oil.
75798468|NCT03867864|Device|Necklace without essential oil for the first 4 weeks|The necklaces do not contain essential oil.
75321510|NCT01880073|Device|FemVue device|The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
75321511|NCT05216159|Behavioral|HAPA behavioural counselling + weekly HAPA worksheets|Behavioural counselling grounded in the Health Action Process Approach (HAPA; ie., action planning and coping planning) paired with weekly HAPA based worksheets delivered through a mobile application, SEMA3, to reduce consecutive workplace sedentary behaviour.
75321512|NCT01679366|Drug|Placebo|1 tablet 2 times daily
75321513|NCT01679366|Drug|Probiotics|1 tablet twice daily
75321514|NCT05362019|Drug|Compound Norethisterone Enanthate Injection|Combined injectable contraceptive use
75321515|NCT05362019|Other|One-to-one Service|"A mobile phone based service system will be used to pushing contraceptive knowledges, reminding injection, providing consultation on adverse reactions and ect."
75624920|NCT02678650|Drug|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
75624921|NCT04180150|Drug|TQ-A3334|TQ-A3334 is a kind of TLR7 receptor agonist.
75624922|NCT04180150|Drug|Placebo|Placebo is a treatment which is designed to have no therapeutic value.
75624923|NCT04180150|Drug|Entecavir Tablet|Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
75624924|NCT00643396|Radiation|thoracic radiotherapy|
75624925|NCT02678338|Drug|Hu5F9-G4|
75624926|NCT00642226|Procedure|Grid Laser|ETDRS Grid Laser
75624927|NCT00642226|Procedure|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
75624928|NCT02675608|Biological|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
75624929|NCT02678494|Other|Neurofeedback training|
75624930|NCT02677402|Other|immersion|
75624931|NCT02677480|Dietary Supplement|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
75624932|NCT02677480|Dietary Supplement|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
75624933|NCT00996918|Drug|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
75321516|NCT05362019|Other|Family Planning Service|routine family planning service and contraceptive service.
75321517|NCT03654105|Drug|Cytisine|"Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects."
75321518|NCT03654105|Drug|Acetylsalicylic acid|The treatment will consist of Acetylsalicylic acid at 100mg once a day
75321519|NCT03654105|Other|Diet Modification and Physical Activity Increase|"It will be proposed:~an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~a regular and sustainable physical activity program with periodic verification of the results."
75321520|NCT03654105|Diagnostic Test|early lung cancer detection|standard treatment for early lung cancer detection with ultra low dose CT
75321521|NCT03654105|Diagnostic Test|spirometry with CO test|spirometry with CO test
75321522|NCT03654105|Other|anthropometic data collection|anthropometic data collection
75321523|NCT03654105|Other|blood test|blood test to assess the metabolic and inflammatory profile
75321524|NCT05361863|Device|Orthodontic brackets|Interventions involving orthodontic brackets of different slot sizes
75321525|NCT05361707|Drug|Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension|Once Daily
75624934|NCT00996918|Drug|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
75624935|NCT02675530|Drug|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"
75624936|NCT04179994|Other|Miswak extract-containing toothpaste|Miswak extract-containing toothpaste will be applied to the tooth diagnosed with DH
75624937|NCT04179994|Other|Potassium nitrates-containing toothpaste|Potassium nitrates-containing toothpaste will be applied to the tooth diagnosed with DH
75624938|NCT04179994|Other|Placebo|A toothpaste containing the same ingredients of the test toothpaste except for the active ingredient
75624939|NCT04179916|Diagnostic Test|stimulation in virtual reality|"HTC VIVE pro was used to stimulate patients in virtual reality. The glasses enable high resolution and high fluidity (90Hz) images to be displayed. The display used inside the glasses, OLED class, allows for accurate color replication. Numerous sensors placed in the glasses (such as gyroscope, accelerometer, magnetometer) supported by dedicated processors processing data from the sensors, instantly transfer the movement of the head of the rehabilitated person to virtual reality. Such a set allows to achieve full immersion in the virtual world. Various scenarios will be presented during the stimulation, such as beach, snow landscape, darkened room, rollercoaster ride.~It was planned to submit 3 scenarios with a total stimulation time of up to 20 minutes."
75624940|NCT02675374|Drug|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
75624941|NCT02675374|Drug|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
75624942|NCT05662930|Behavioral|First arithmetic problem solving|"In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation."
75624943|NCT05662930|Behavioral|Second arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the first subtraction process, patients were asked to subtract 7 from 6828 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
75624944|NCT05662930|Behavioral|Third arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 13 from 9561 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
75321526|NCT04388111|Drug|Morphine|10mg of Morphine delivered Intraosseously
75321527|NCT01880697|Biological|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
75624945|NCT05662930|Behavioral|Fourth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 8 from 5113 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
75321528|NCT03309137|Device|Chlorhexidine flush|"For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.~After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.~Discard the syringe and device in biohazard waste.~Blue Cap the IV as per routine practice."
75466655|NCT01911702|Other|Standard fluidic resuscitation.|"Goals:~arterial pressure mean ≥ 65 mmHg or equal to the pre-operative~diuretic rhythm ≥ 1 ml / Kg / h~venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%~BE> - 3~Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg."
75777647|NCT03786952|Behavioral|Stress immediately before learning in males|Male participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
75777648|NCT03786952|Behavioral|Sham control immediately before learning in males|Male participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
75777649|NCT03786952|Behavioral|Stress 30 minutes before learning in males|Male participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
75914302|NCT05458986|Other|Questionnaire Administration|Ancillary studies
75624946|NCT05662930|Behavioral|Fifth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 14 from 8318 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
75624947|NCT05662930|Behavioral|Sixth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 17 from 9994 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
75777650|NCT03786952|Behavioral|Sham control 30 minutes before learning in males|Male participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
75798469|NCT03867864|Other|Washout|Washout (do not wear the necklace) for one week for two groups, then two groups cross-over.
75798470|NCT03867864|Device|Necklace with essential oil for last 4 weeks|The necklaces contain essential oil.
75798471|NCT03867864|Device|Necklace without essential oil for last 4 weeks|The necklaces do not contain essential oil.
75798472|NCT03867708|Radiation|ASD device closure|transcatheter secundum ASD device closure
75914303|NCT05457439|Behavioral|Sustainable diet promotion through behavioral change intervention|15 weeks digital intervention to promote sustainable diets through workshops, and behavioral change techniques in a mobile application, to decrease environmental impact of diets and improve health.
75914304|NCT05444348|Behavioral|Advance consultation concerning your life and treatment (ACT )|The ACT intervention consists of: an 8 h training day for clinicians including clinical materials such as a conversation aid and conversations guide. 6o minutes ACT-intervention sessions in daily clinic. the patients and caregivers will receive preparatory material prior for the ACT-intervention sessions, and a 30 min follow-up telephone call from the nurse within one week after the ACT-session. Clinicians will receive five sessions of followup supervision within the 24 months of intervention. The 60 min ACT-intervention session is an interdisciplinary conversation with nurse, physician, patient, and caregiver discussing issues of importance of patient and caregiver. The issues are based on the preparatory material focusing on information level and prognosis, patient's and caregiver's values, hopes, fears and worries regarding the future care with progressive disease.
76073810|NCT05702619|Diagnostic Test|CT-guided Bone Biopsy|A CT-guided biopsy of a bone metastasis that is deemed to be easy to biopsy and in an area without major risk for pathological fracture or bleeding will be taken during the biopsy visit. Patients will receive routine local anaesthetic of the region to be biopsied followed by thorough disinfection of the biopsy site with antiseptic wipes. Patients will be asked to fast on the day of the procedure and to have an intravenous cannula inserted to allow the use of medication causing minimal sedation (for example midazolam and/or fentanyl) during the procedure if required to alleviate discomfort or pain.
75624948|NCT02678260|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
75624949|NCT02677168|Device|cNEP|continuous negative external pressure
75624950|NCT04181398|Diagnostic Test|Anthropometry|"Actual Height and weight~Calculated BMI from measured weight and height.~Pubertal development (Tanner stage)~Waist circumference~Skin fold measurement (Triceps and Subscapular)~Waist-to-height ratio will be calculated from measured height and waist circumference."
75624951|NCT04181398|Diagnostic Test|Blood pressure|Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
75624952|NCT04181398|Diagnostic Test|Peripheral arterial tonometry|The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).
75624953|NCT04181398|Other|Questionnaire|General questionnaire on cardiovascular risk factors
75624954|NCT04181398|Diagnostic Test|Blood sample|Blood sample for hs-CRP
75624955|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the RESOLVE TM technique
75624956|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the Cytori PureGraft TM technique
75624957|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the Coleman technique
75624958|NCT02677012|Procedure|Reconstructive Surgery|Undergo reconstructive surgery
75624959|NCT02677090|Drug|Placebo (including Maltodextrin)|
75624960|NCT02677090|Drug|Dose 1 - Promitor®|
75624961|NCT02677090|Drug|Dose 2 - Promitor®|
75624962|NCT02677090|Drug|Dose 3 - Promitor®|
75624963|NCT04179682|Procedure|40-hour constraint-induced movement therapy|Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.
75624964|NCT04179604|Drug|Levosimendan|Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
75624965|NCT04179604|Drug|Placebos|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
75624966|NCT05277142|Other|oral motor training|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
75624967|NCT05277142|Device|Neuromuscular Electrical Stimulation|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks
75624968|NCT02673580|Other|Open Access telePRO|"In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk."
75624969|NCT02673580|Other|Standard telePRO|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
75624970|NCT02675218|Other|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
75624971|NCT02673502|Dietary Supplement|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
75624972|NCT02673502|Dietary Supplement|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
75624973|NCT04179370|Other|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
75321529|NCT05361629|Procedure|Intralesional steroid administration|Treatment by administering steroids into the lesion
75321530|NCT05361629|Procedure|Intraoperative cavity steroid administration|Treatment by administering steroids into the surgical cavity
75321531|NCT03197675|Other|Acupuncture|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
75624974|NCT00643474|Device|Accu-Chek Aviva Meter|4-point daily glucose monitoring profile 3 times per week
75624975|NCT00643474|Device|Accu-Chek Aviva Meter|Frequency and timing of SMBG not specified
75624976|NCT02537704|Behavioral|Group Lifestyle Balance Program|
75624977|NCT02673658|Behavioral|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
75624978|NCT02673658|Behavioral|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
75624979|NCT04178356|Other|Proprioceptive Neuromuscular Facilitation Training|The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
75624980|NCT04178356|Other|Control Group|Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
75914305|NCT05443009|Drug|Lidocaine|A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.
75914306|NCT05443009|Drug|Articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
75914307|NCT05441449|Device|Cooling Vest|"A self-regulating cooling vest for persons with SCI that can utilize both conductive and evaporative methods to dissipate body heat as a proof-of-concept to prevent an excessive rise in Tcore and thermal discomfort during a controlled exposure to a warm environment. The vest is an article of clothing, is made of commercially-available wicking material, which once saturated with water, uses evaporation to dissipate heat. Channels embedded in the vest supply cooled water to keep the wet vest cool. The cooling capacity of the vest is regulated by a microprocessor which continuously receives feedback from the user's skin and core temperature. The vest is non-invasive and supplies no energy to the user."
75321532|NCT01881087|Drug|Hyperbaric Levobupivacaine 0.75%|Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
75624981|NCT02675140|Drug|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
75624982|NCT02675140|Drug|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
75624983|NCT00642538|Drug|MKC253 Inhalation Powder|Inhalation Powder, prandial
75624984|NCT00642538|Drug|Technosphere Inhalation Powder|Inhalation Powder, prandial
75624985|NCT00642538|Drug|subcutaneous injection|10µg Exenatide, prandial
75624986|NCT00644254|Procedure|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
75624987|NCT02674906|Drug|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
75624988|NCT02674906|Drug|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
75624989|NCT02674672|Device|VenaTech® (VenaTech Retrievable Filter)|
75624990|NCT02673268|Procedure|Mastectomy|
75624991|NCT02673268|Device|Da Vinci Robot Xi|
75624992|NCT04179214|Other|Thoracic manipulation|Session will be performed twice a week for a three week period if a pop sound occurred then the therapist moved on next procedure ,if not subject will be repositioned and technique will performed again. This procedure will be performed for maximum of two attempts. Approximately 3 minutes of time is required to complete thrust manipulation subjects assigned to thrust manipulation also received general exercise program and manual pressure release technique as the control group. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
75624993|NCT04179214|Other|conventional pt protocol|This group will receive manual pressure release technique along with general exercises program. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
75624994|NCT00641290|Device|Vigileo FloTrac Sensor|Comparing the Vigileo FloTrac against the conventional Pulmonary Artery Catheter using the thermodilution method for measurements of cardiac output.
75624995|NCT00643630|Device|Tetrix|Twice daily topical application
75624996|NCT00643630|Device|Tetrix|Twice daily topical application
75321533|NCT01944423|Drug|d-cycloserine|d-cycloserine is a medication thought to be associated with fear extinction.
75321534|NCT01944423|Drug|Pill Placebo|
75321535|NCT01944423|Drug|Nicotine replacement therapy|All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
75624997|NCT01160744|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
75624998|NCT01160744|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
75624999|NCT01160744|Drug|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
75625000|NCT01160744|Drug|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
75625001|NCT01160744|Drug|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
75625002|NCT01160744|Drug|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
75625003|NCT02677246|Drug|Denosumab|"Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils > 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab"
75625004|NCT02673112|Behavioral|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
75625005|NCT02673112|Behavioral|Light stretching (LS)|Brief daily stretching routine.
75625006|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
75625007|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
75625008|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
75625009|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
75914308|NCT05441410|Drug|Pyronaridine Tetraphosphate, Artesunate Drug Combination|Combination drug for treatment of uncomplicated malaria
75625010|NCT04181164|Other|Microindentation|Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
75625011|NCT04181164|Other|High resolution peripheral quantitative computed tomography (HRpQCT)|HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
75777651|NCT03786952|Behavioral|Stress immediately before learning in females|Female participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
75777652|NCT03786952|Behavioral|Sham control immediately before learning in females|Female participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
75777653|NCT03786952|Behavioral|Stress 30 minutes before learning in females|Female participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
75777654|NCT03786952|Behavioral|Sham control 30 minutes before learning in females|Female participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
75777655|NCT03782688|Diagnostic Test|FFRCT planner|Non-invasive post-PCI fractional flow reserve prediction
75777656|NCT03732261|Other|Exercise and dietary|The 12-week study invention will take place between 6 to 8-weeks postpartum and 18 to 20-weeks postpartum, with a follow-up at one year postpartum. The six-week postpartum time point is to allow for exercise clearance from the participant's obstetrician. The exercise clearance is needed prior to the baseline laboratory measurement. Women will be randomized to an intervention group or minimal care group after all baseline measurements (anthropometrics, cardiovascular fitness test, human milk and blood samples and DXA) at six-weeks postpartum. A random numbers table will be used to stratify by parity and determine groups.
75914309|NCT05441410|Biological|PfSPZ Challenge (NF54)|cryopreserved Plasmodium falciparum sporozoites injected by intravenous inoculation
75914310|NCT05441410|Biological|MVA ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Modified Vaccinia Ankara (MVA)
75625012|NCT04181164|Biological|Biochemical analysis of different bone markers.|Measurement of different bone markers by biochemical analysis of blood samples.
75777657|NCT03730324|Diagnostic Test|mpMRI|Study subjects will undergo urine and plasma biomarker testing and mpMRI prior to biopsy
75914311|NCT05441410|Biological|ChAd63 ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Chimpanzee Adenovirus 63 (ChAd63)
75914312|NCT05441410|Biological|Sodium chloride (NaCl) 0.9%|0.9% NaCl solution for injection
75914313|NCT05440916|Radiation|Palliative Radiotherapy: 5 x 4Gy|Palliative irradiation of 2 to 5 sites (metastatic sites or/and primary lung tumour) in one week before systemic therapy. Systemic therapy should be given as soon as possible after irradiation.
75914314|NCT05440916|Drug|chemotherapy + immune checkpoint inhibitors|Systemic therapy according to national/European recommendations.
75914315|NCT05436353|Other|Turkish validity and reliability|Contact with developers and formation of steering committee Translation from English to Turkish Back translation from Turkish to English Comparison of translation Review of translated versions. Reaching consensus and development of pilot version Testing in clinical setting Revision of pilot version Testing of final version
75914316|NCT05435209|Drug|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|Gardasil
75914317|NCT05433623|Procedure|Surgery|It will be documented if the patient underwent surgery for their vascular issue
75914318|NCT05433285|Biological|COVID-19 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
75625013|NCT02672800|Behavioral|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
75625014|NCT04180774|Biological|Tag-7 gene modified inactivated tumor cells|Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
75777658|NCT03730324|Diagnostic Test|Urine and plasma biomarkes.|Study subjects will undergo urine and plasma biomarker testing prior to standard biopsy
75777659|NCT03727490|Other|Repair|The subscapularis will be repaired.
75777660|NCT03727490|Other|Standard Treatment|No repair will be performed
75914319|NCT05433285|Biological|Active Comparator|Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus
75914320|NCT05432336|Diagnostic Test|NGS for endohtalmitis / Multiplex PCR for keratitis|"For endophtalmitis : optimizing culture and NGS will be realized~For keratitis: Multiplex PCR will be added on ocular samples"
75914321|NCT05430919|Drug|REGN5713|Administered subcutaneously (SC)
75914322|NCT05430919|Drug|REGN5714|Administered SC
75777661|NCT03724448|Drug|aleozen|treatment with herbal medicine
75914323|NCT05430919|Drug|REGN5715|Administered SC
75914324|NCT05430919|Other|Placebo|Administered SC
75914325|NCT05430152|Drug|Low-Dose Naltrexone|"Study drug dosing schedule (LDN):~Week 1: 1 mg/day (1 mg cap)~Week 2: 2 mg/day (two 1 mg caps)~Week 3: 3 mg/day (three 1mg caps)~Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
75777662|NCT03724448|Drug|Placebo Oral Tablet|No aleozen treatment
75914326|NCT05430152|Other|Placebo|"Study drug dosing schedule (Placebo; capsules made to match LDN doses):~Week 1: 1 mg/day (1 mg cap)~Week 2: 2 mg/day (two 1 mg caps)~Week 3: 3 mg/day (three 1mg caps)~Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
75914327|NCT05429190|Radiation|Short MRI surveillance (SMS) protocol|Bi-annual, non-contrast agents, MRI screening consisting of Diffusion Weighted Imaging (b-values of 50 and 800 s/mm2), T2-weighted imaging and T1-weighted in- and out-of-phase imaging
75914328|NCT05429190|Radiation|Bi-annual ultrasonography screening|Bi-annual ultrasonography for screening of HCC in high-risk patients
75466656|NCT01911702|Other|Volemic small treatment|"Goals of the treatment:~arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values~diuretic rhythm ≥ 0.5 ml / kg / h~venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG~BE> - 5~PVC goal not necessary~To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be > 10-15 ml / kg / h an infusion of furosemide should be initiated"
75466657|NCT01911715|Drug|MDV3100|Oral
75625015|NCT02674828|Behavioral|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
75625016|NCT02674828|Other|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
75625017|NCT01160354|Drug|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
75625018|NCT01160354|Drug|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
75777663|NCT03711474|Drug|Dexamethasone|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
75777664|NCT03711474|Drug|Saline|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgey
75777665|NCT03693287|Drug|Standardized-parenteral nutrition (S-PN)|NUMETA G13%E 300 mL is a triple-chamber (lipid emulsion, amino acids solution with electrolytes, and glucose solution), ready-to-use parenteral nutrition product available to treat preterm infants (less than 37 weeks gestational age).
75777666|NCT03693287|Drug|Personalized-parenteral nutrition (P-PN)|"Intravenous glucose will be dextrose 50%, amino acids (AA) will be Primene® and lipids (FAT) will be Clinoleic®.~Parenteral nutrition bags will be prepared by the hospital pharmacy according to the prescription of the attending neonatologist."
75777667|NCT03681028|Drug|Individualized therapy|"For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose."
75777668|NCT03677713|Procedure|No nasal packing.|No nasal packing at the end of the surgery
75914329|NCT05428358|Diagnostic Test|Preoperative MRI|Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
75914330|NCT05425953|Other|No intervention other than obtaining biopsies|Biopsies will be obtained.
75914331|NCT05425303|Diagnostic Test|Exposure to risk for injury|Athletes will be examined in the preseason stage and will be monitored during the competitive season.
76073811|NCT05702619|Diagnostic Test|TRUS-guided Targeted Transperineal Prostate Biopsy|Transperineal Prostate Biopsy will be performed following standard clinical practice of local department. This will include pre-operative oral analgesia and prophylactic antibiotic treatment according to local hospital policy for transperineal prostate biopsies.
76073812|NCT05702619|Procedure|Radical Prostatectomy|Radical Prostatectomy will be performed according to standard of care robotic approach and as relayed to the patient by the attending urologic surgeon. The side effects of the surgery are the ones reported in the literature and the latest participant information leaflet provided prior patient consent (e.g. risk of erection disfunction, incontinence, etc.).
76073813|NCT05702619|Diagnostic Test|Whole-body MRI|Whole-body MR imaging (wbMRI) will be performed once, before or after the biopsy study visit, depending on available examination slots in the Department of Radiology. WbMRI images will allow comparison of the numbers of bone metastases detected by routine bone scan and wbMRI for sensitivity assessment of both techniques for oligometastatic disease.
75466658|NCT01911728|Drug|MDV3100|Oral
75466659|NCT01911728|Drug|Pioglitazone|Oral
75466660|NCT01911728|Drug|Warfarin|Oral
75466661|NCT01911728|Drug|Omeprazole|Oral
75466662|NCT01911728|Drug|Midazolam|Oral
75466663|NCT01911741|Drug|MDV3100|Oral
75466664|NCT01911754|Biological|H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)|
75777669|NCT03677713|Procedure|Nasal Packing|Patients will have nasal packing at the end of the surgery
75777670|NCT03647826|Behavioral|Mind Power Intervention|The intervention has a total sample of 110 schoool classes, which are devided in two arms: Mind Power Intervention Group 1 or Mind Power Intervention Group 2
75914332|NCT05422560|Procedure|Embolization of the inferior mesenteric artery|"The procedure is performed in a dedicated angiography room. After local anesthesia, a common femoral arterial approach is performed according to the Seldinger technique with the placement of a 4 French valve introducer.~Catheterization of the superior mesenteric artery with a Cobra 4F catheter and angiography to confirm patency of the border arcade.~Catheterization of the inferior mesenteric artery with a 4F cobra/shepherd hook catheter and angiography. Microcatheterization of the artery with a 2.7F or 2.8F microcatheter and embolization with microcoil leaving the first centimeters of the IMA in order not to interfere with the surgery.~Catheterization of the superior mesenteric artery and final angiography to confirm the reinjection of the inferior mesenteric by the border arcade.~Removal of the material and manual compression of femoral access. Clinical monitoring for 6 hours and discharge the same day of the procedure."
75321536|NCT01944423|Behavioral|Panic and Smoking Reduction Treatment|PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
75914333|NCT05420129|Device|MAD Therapy|Participants will be treated with a Mandibular Advancement Device therapy
75777671|NCT03515460|Other|sugar oral load|The individuals will receive a sugar oral load (high sugar meal)
75777672|NCT03515460|Other|fat oral load|The individuals will a receive fat oral load (high fat meal)
75914334|NCT05420129|Device|CPAP Therapy|Participants will be treated with a Continuous Positive Airway Pressure therapy
75466665|NCT01911806|Device|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
75625019|NCT00643786|Drug|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
75625020|NCT00643786|Drug|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
75914335|NCT05418777|Drug|Trimethoprim Sulfamethoxazole|Receipt of suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
75466666|NCT01911806|Procedure|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
75466667|NCT01911832|Procedure|esophagojejunostomy after total gastrectomy|
75914336|NCT05418777|Drug|Placebo|Receipt of suspension with placebo by mouth every 12 hours for 10 days
75914337|NCT05416879|Device|Actigraph GT3X+BT|7 day monitoring of physical activity, sedentary behaviour and sleep using the Actigraph GT3X+BT
75914338|NCT05416372|Behavioral|Religious Engagement in Health Intervention|Religious Engagement in Health Intervention for blood pressure (BP) includes three evidence-based components: (1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, (2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and (3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
75914339|NCT05415176|Dietary Supplement|Taurine supplementation|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
75914340|NCT05415176|Other|Pshysical exercise|Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks
76073814|NCT05702619|Diagnostic Test|Prostate MRI scans|Patients within Arm 2 will be offered the option to undergo additional MR imaging of the pelvis in addition to any standard of care imaging acquired. In patients who agree to undergo additional scans, MRI scans will be performed on 2 occasions prior to the radical prostatectomy. MRI scans will be acquired on either the MR sim diagnostic scanner, on the MR Linac scanner or on both.
75625021|NCT04178512|Drug|Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control|prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
75625022|NCT02674360|Behavioral|SDM Training|
75625023|NCT04179292|Other|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
75777673|NCT03515460|Other|sugar and fat oral load|The individuals will a receive sugar and fat oral load (high sugar and high fat meal)
75777674|NCT03493958|Behavioral|Sleep Healthy Using the Internet (SHUTi)|The SHUTi program is an automated, interactive, internet-based intervention based on well-established face-to-face cognitive behavioral therapy for insomnia (CBT-I) components including sleep restriction, stimulus control, sleep hygiene, cognition
75777675|NCT03486223|Drug|GSK2256294|Drug will be taken daily by mouth for 7 days.
75466668|NCT01911832|Procedure|Roux-en-Y gastrojejunostomy after subtotal gastrectomy|
75777676|NCT03486223|Drug|Placebo oral capsule|Placebo will be taken daily by mouth for 7 days.
75777677|NCT03482024|Drug|Tirzepatide|Administered SC.
75625024|NCT04179292|Other|Hand Therapy as home program|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
75321537|NCT03112499|Procedure|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
75625025|NCT01160198|Drug|ferrous ascorbate|100 mg elemental iron
75625026|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
75625027|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
75625028|NCT02676934|Device|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
75625029|NCT05277220|Device|Thermal Camera Thermo Malin TC|"Thermo Malin TC thermal camera (also called HIKVISION TP 31B portable thermal camera). Manufacturer of the researched product is HIKVISION.~This thermal camera is equipped with a thermal detector with a resolution of 160 x 120 elements or an infrared resolution of 19,200 pixels.~Thermal sensitivity of the Thermo Malin TC thermal imager is 40 milliKelvin (0.04 °C), with a spatial resolution of 5.48 mrad and a field of view of 37.2 x 50 °. Temperature accuracy at one point varies by +/- 0.5 °C. This thermal imager has four color palettes to highlight the desired elements.~This camera is specially designed for measuring body temperature in a temperature range from +30 to + 45 °C.~As part of the research, the thermal camera will enable the acquisition and recording of thermographic images at three times of study. These images are then transferred to the operating software for the Thermo Malin Series to process, analyze and make changes to elements of thermographic images."
75625030|NCT05351086|Drug|PUR3100|PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
75625031|NCT05351086|Drug|Dihydroergotamine (D.H.E 45)|D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
75625032|NCT05351086|Other|Matching Placebo for PUR3100|Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).
75625033|NCT05351086|Other|Matching Placebo for D.H.E 45|The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
75625034|NCT02885168|Drug|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
75914341|NCT05415176|Other|Placebo control|The participants will receive a supplementation capsule containing placebo in the morning in single-dose capsules. The intervention will last 16 weeks.
75914342|NCT05414292|Drug|Rapamune (sirolimus) 1Mg Tablet|Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.
75914343|NCT05414292|Behavioral|Unilateral resistance exercise training|Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
75914344|NCT05411848|Dietary Supplement|2kcal HP PlantBased|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
75466669|NCT01911832|Procedure|wide tube reconstruction after subtotal gastrectomy|
75466670|NCT01911832|Procedure|narrow tube reconstruction after subtotal gastrectomy|
75466671|NCT01911858|Device|Askina Calgitrol Paste|
75466672|NCT01911871|Biological|Blood sample|a blood sample was taken on the day of inclusion
75466673|NCT01911884|Behavioral|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
75466674|NCT01911923|Procedure|No CPAP/PEEP and 100 % oxygen|This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
75466675|NCT01911923|Procedure|CPAP/PEEP and 30 % oxygen|During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
75466676|NCT01911936|Drug|LM716|
75466677|NCT01911949|Drug|Single shot femoral nerve block|Nerve block in lingual crease using ultrasound guidance
75466678|NCT01911962|Procedure|transvaginal laparoscopic surgery|
75466679|NCT01911975|Drug|Lacosamide|comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
75466680|NCT01911975|Drug|Placebo|comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
75466681|NCT01912001|Other|Telephone follow-up|
75466682|NCT01912001|Other|Sympton Assessment|
75466683|NCT01912014|Behavioral|Psychosocial support and counselling|
75466684|NCT01912027|Procedure|Open Latarjet technique|
75466685|NCT01912027|Procedure|Arthroscopic Latarjet techniques|
75466686|NCT01912053|Radiation|Therasphere® in association with Gemcitabine and Cisplatin|Therasphere® is a radioelement
75777678|NCT03468309|Genetic|Genecept Assay and G-DIG decision tool|Participating providers will review results of the Genecept Assay using a secure web-based program and will utilize the G-DIG tool in order to determine the optimal medication regime for the patient, based on their individual genetic profile. Genomind will provide training to all investigators prior to the study start regarding the interpretation of the pharmacological assay and the use of the G-DIG tool. Genomind representatives will be available throughout the duration of the study for consultation regarding the interpretation and implementation of the testing results. All final decisions about changing dosage, adding medications, or removing medications will be determined by the provider.
75625035|NCT02885168|Device|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
75777679|NCT03466723|Genetic|biomarker identification in Parkinson disease|circulating miRNAs profiling by NGS analysis functional miRNA characterization association of miRNA levels with genetic variants
75625036|NCT02885168|Drug|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test."
75625037|NCT02885168|Biological|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
75777680|NCT03451253|Other|amino acid mixture beverage|commercially available amino acid mixture. Contains 5 amino acids, electrolytes and natural flavoring.
75777681|NCT03451253|Other|glucose-based sports drink|Commercially available glucose-based sports drink, contains electrolytes, sugar and artificial flavoring.
75777682|NCT03444337|Device|Catheter Ablation|
75914345|NCT05409781|Other|No Intervention|No Intervention
75625038|NCT05657002|Other|patient A with accurate problem list|A problem list that contains a diagnosis code that is contraindicated with a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis relevant for the question asked.
75777683|NCT03443076|Dietary Supplement|EPA + DHA in SMEDS Formulation|A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
75777684|NCT03443076|Other|Lovaza (active comparator; already FDA approved)|A single dose of 840 mg EPA + DHA administered as Lovaza. This intervention was used as an active comparator in this study. Lovaza was already FDA-approved when the study was conducted.
75777685|NCT03430167|Other|home therapy|Patients will be given a set of instructions for completing home therapy for range of motion and strengthening
75777686|NCT03430167|Other|formal therapy|Patients will be sent to physical therapist for formal treatment to regain range of motion and strengthening exercises
75777687|NCT03423199|Drug|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
75777688|NCT03423199|Drug|Placebo|Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
75777689|NCT03423199|Drug|Tamoxifen|Tamoxifen, 20mg, orally once daily (continuously)
75777690|NCT03423199|Drug|Goserelin|For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
75777691|NCT03423147|Drug|2% chlorhexidine gluconate cloth|applied to their abdomen
75777692|NCT03423147|Drug|4% Chlorhexidine gluconate vaginal scrub|applied as a vaginal cleanse in the operating room prior to cesarean section
75777693|NCT03419585|Device|Intervention systematic light exposure|30 minutes of intervention systematic light exposure daily
75777694|NCT03419585|Device|Comparison systematic light exposure|30 minutes of comparison systematic light exposure daily
75777695|NCT03418532|Combination Product|MP0250 DARPin® drug candidate, Osimertinib|Number of Cycles: until progression, unacceptable toxicity or other reasons for withdrawal
75777696|NCT03417401|Procedure|Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.|Standard 3-port pars plana vitrectomy with surgical stabilizer assisted ( surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..
75914346|NCT05408741|Other|The Intervention Group|Participants will complete a 20-minute guided imagery exercise (which includes deep breathing exercises) every day at home using the selected app and/or resource you downloaded at the beginning of this study.
75777697|NCT03417401|Drug|Intravenous Infusion|Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
75777698|NCT03417297|Device|High Intensity Focused Ultrasound|Participants will undergo high intensity focused ultrasound surgery utilizing magnetic resonance (MR) imaging guidance using a 3 Tesla scanner.
75777699|NCT03414385|Other|Exercise|Acute bout of aerobic exercise at moderate intensity for 2 hours
75466687|NCT01912066|Drug|Stillen|
75466688|NCT01912066|Drug|Cytotec (reference drug)|
75466689|NCT01912066|Drug|NSAID (Aceclofenac)|
75466690|NCT01912092|Device|Askina Calgitrol paste|
75466691|NCT01912105|Device|Airway medix closed suction system|
75466692|NCT01912105|Device|standard closed suctioning systems|
75466693|NCT01912118|Drug|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
75466694|NCT01912118|Drug|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
75466695|NCT01912131|Behavioral|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
75466696|NCT01912131|Behavioral|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
75466697|NCT01912131|Behavioral|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences,
75625039|NCT05657002|Other|patient B with inaccurate problem list|"A problem list that does not contain the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
75625040|NCT05657002|Other|patient A with inaccurate problem list|"A problem list that does not contain the diagnosis code that is contraindicated with the type of medication (Y). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
75625041|NCT05657002|Other|patient B with accurate problem list|A problem list that contains the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis and details relevant for the question asked.
75625042|NCT02674282|Procedure|ACL reconstruction|ACL reconstruction with hamstrings autograft.
75625043|NCT02672722|Drug|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
75625044|NCT02672722|Other|Exercise|
75625045|NCT02672722|Other|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
75625046|NCT00643942|Other|No intervention required|
75625047|NCT02672878|Device|Bioresorbable vascular scaffold|
75625048|NCT01159574|Drug|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
75625049|NCT01159574|Drug|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
75625050|NCT01159574|Drug|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
75625051|NCT00910156|Device|Airtraq laryngoscope|Airtraq intubation
75625052|NCT00910156|Device|Glidescope laryngoscope|glidescope intubation
75625053|NCT00910156|Device|Macintosh laryngoscope|Macintosh intubation
75625054|NCT04179058|Other|Follow-up|Clinical data, radiological data and laboratory tests follow-up
75625055|NCT01158950|Drug|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
75777700|NCT03322631|Drug|Tirzepatide|Administered SC.
75777701|NCT03322631|Drug|Placebo|Administered SC.
75777702|NCT03290612|Dietary Supplement|Vitamin C|1.5g Ascorbic Acid
75777703|NCT03290612|Other|Placebo|Inactive placebo to mimic 1.5g ascorbic acid.
75777704|NCT03288753|Other|Satisfaction questionnaire|Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.
75777705|NCT03288753|Behavioral|Speech intelligibility in quiet|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
75625056|NCT01158950|Other|Placebo|Placebo (200mg) administered at study visit
75777706|NCT03288753|Behavioral|Speech intelligibility in noise|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
75777707|NCT03288753|Behavioral|VRB (Vocale Rapide dans le Bruit)|Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
75777708|NCT03190473|Device|DES|PCI with implantation of a DES
75914347|NCT05408741|Other|The Control Group|Participants will continue to receive your current care, but will not receive guided imagery or deep breathing exercises from a social worker.
75914348|NCT05404048|Other|89Zr-atezolizumab PET-imaging|89Zr-atezolizumab tracer injection + PET/CT-scan
75466698|NCT01912131|Behavioral|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
75466699|NCT01912131|Behavioral|Part 2|Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
75466700|NCT01912144|Other|Coffee|
75466701|NCT01912157|Behavioral|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
75625057|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3*10^8/kg/once.
75625058|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3*10^8/kg/once.
75625059|NCT02676856|Drug|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
75625060|NCT02676856|Drug|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
75625061|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
75625062|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
75625063|NCT00910234|Drug|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
75625064|NCT04315220|Other|Corestability training|"Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats."
75777709|NCT03157999|Behavioral|Intervention group (CAST)|"Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:~care coordination and system navigation (including facilitating timely primary care follow-up);~medication management;~assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);~evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;~patient and caregiver education; and goal setting and problem-solving therapy."
75777710|NCT03148210|Drug|Treatment strategy using evidence-based guidelines for asthma or COPD|The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
75777711|NCT03148210|Behavioral|Smoking Cessation|Smoking cessation counselling by a qualified educator if currently smoking
75777712|NCT03148210|Behavioral|Participant Education|Standardized education for asthma or COPD disease
75321538|NCT03112499|Procedure|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
75466702|NCT01912170|Dietary Supplement|Fish oil|
75466703|NCT01912170|Dietary Supplement|Flaxseed oil|
75466704|NCT01912183|Behavioral|Communication through PHR outside clinic|
75466705|NCT01912183|Behavioral|Monitoring device in PHR|
75625065|NCT04315220|Other|No Intervention|No Intervention
75625066|NCT05652322|Drug|Furosemide Pill 150% equivalent iv dose|change from intravenous to oral furosemide
75625067|NCT05652322|Drug|Furosemide Pill 200% equivalent iv dose|change from intravenous to oral furosemide
75625068|NCT05652322|Drug|Furosemide Injection|change from intravenous to oral furosemide
75625069|NCT01172288|Drug|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
75625070|NCT01172288|Drug|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
75625071|NCT02676622|Drug|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
75625072|NCT02676622|Other|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
75625073|NCT02676622|Drug|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
75625074|NCT02676622|Other|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks"
75777713|NCT03107546|Device|Hyalomatrix|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
75777714|NCT03107546|Other|Skin graft|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
75466706|NCT01912183|Device|Physical activity and sleep monitor|
75466707|NCT01912183|Other|PHR|Access to their PHR
75466708|NCT01912196|Drug|MSI-195|
75466709|NCT01912196|Drug|Placebo|
75625075|NCT02676622|Drug|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is > 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
75625076|NCT04313816|Other|questionnaire|no intervention at all apart from filling a brief questionnaire
75625077|NCT00644020|Drug|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
75625078|NCT04178980|Drug|Simvastatin in relapsing remitting multiple sclerosis|Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
75625079|NCT02674048|Other|Metvix|
75625080|NCT02674126|Behavioral|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
75625081|NCT02674126|Behavioral|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
75625082|NCT04178902|Drug|ABBV-467|Intravenous (IV) Infusion
75625083|NCT02672566|Drug|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
75625084|NCT02672566|Other|Usual care|Patients will all benefit from the usual care
75777715|NCT03090750|Drug|Lavender Oil|Lavender essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
75777716|NCT03090750|Drug|Bergamot Oil|Bergamot essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
75914349|NCT05402982|Device|Electrical Cardiometry (EC) ICON|Electrical Cardiometry (EC) ICON (Osypka Medical, Berlin, Germany) is an FDA approved device used for non-invasive measurement of some hemodynamic parameters as cardiac output,cardiac index, stroke volume,stroke volume variation, systemic vascular resistance, thoracic fluid content, ICON (index of contractility), variation of ICON,corrected flow time and systolic time ratio.The set data of EC are the height, weight,hemoglobin, Oxygen saturation(SPO2),age, gender ,blood pressure and heart rate(HR) of the patient
75914350|NCT05402982|Other|Rohrich formula|Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2
75914351|NCT05400486|Other|Therapeutic exercise|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
75914352|NCT05400486|Other|Therapeutic exercise group + high frequency TENS|TENS (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda) will be applied to the cervical region through 4 silicon-carbon electrodes measuring 4 x 4 cm, with a water-based gel to reduce the impedance at the interface electrode skin. Thus, TENS will be applied with a rectangular, biphasic, and symmetrical pulse, with a pulse width of 100 µm, and a frequency of 100 Hz, at the maximum tolerated sensitive threshold, for 30 minutes (VANCE et al., 2012).
75914353|NCT05400486|Other|Therapeutic exercise group + Interferential|In sequence, the interferential current will be applied. Through the Endophasys® device - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square) will be positioned around the center of the neck. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (Sweep Mode), 60 Hz Amplitude of frequency modulation (AMF), 30 Hz (Delta AMF), automatic vector mode, with intensity at the motor threshold of sensation, lasting 30 minutes (Albornoz-Cabello et al., 2019).
75914354|NCT05400473|Other|Therapeutic exercise|This group will consist of 30 participants. A program consisting of specific therapeutic exercises for the cervical region will be applied.
75914355|NCT05400473|Other|Photobiomodulation|Photobiomodulation will be applied on the cervical region. To perform the photobiomodulation protocol, a low power infrared laser therapy unit will be used.
75914356|NCT05400226|Drug|VGT-309|VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
75914357|NCT05397951|Device|Multi-modality Noninvasive Biosensor|The wearable sensor devices will be placed on the finger, wrist, temple, subclavian, arm, neck, and thigh of the participant and will provide continuous tissue mechanics, heart rate, respiration rate, blood flow, and pulse oxygenation measurements continuously throughout the experimental period.
75914358|NCT05397951|Device|Oximeter|The oximeter device will be placed on the right middle finger of the participant and will provide continuous pulse oxygenation and heart rate measurements continuously throughout the experimental period.
75625085|NCT02672488|Drug|Sorafenib|Standard treatment for advanced HCC
75625086|NCT02672488|Drug|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
75777717|NCT03090750|Other|Water|Tap water applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
75777718|NCT03086642|Drug|Talimogene laherparepvec|"T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).~On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL. The second injection up to 4.0 mL of 10^6, 10^7, or 10^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion."
75777719|NCT03077776|Procedure|Biopsy|Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy
75625087|NCT02673892|Other|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
75914359|NCT05397951|Device|Portable Blood Pressure Monitor|The blood pressure monitor device will be placed on the left arm of the participant and will take a blood pressure measurement every 5 minutes throughout the 15 minute experimental period, and every 15 minutes throughout the 2 hour experimental period.
75321539|NCT03112499|Procedure|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
75466710|NCT01912209|Behavioral|My Everyday Health|MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.
75625088|NCT00644098|Dietary Supplement|soluble fibre complex and medium chain triglycerides|
75625089|NCT00644098|Dietary Supplement|cellulose and soybean oil|
75625090|NCT02537392|Dietary Supplement|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
75625091|NCT02537392|Dietary Supplement|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
75625092|NCT02537392|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid.
75625093|NCT05613712|Other|Patients|Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
75625094|NCT05613712|Other|Referring physician|Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
75625095|NCT02676700|Behavioral|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
75466711|NCT01912235|Other|2-15N glutamine|Glutamine with N15 isotope tracer
75466712|NCT01912235|Other|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
75466713|NCT01912235|Other|1-13C glutamine|Glutamine carbon isotope tracer
75466714|NCT01912248|Other|strength training|strength training, lower limb.
75466715|NCT01912261|Drug|Placebo|one capsule orally daily times 84 days
75466716|NCT01912261|Drug|Polysaccharide iron complex|150 mg daily orally times 84 days
75466717|NCT01912300|Behavioral|experimental condition: Passvice Video game; Avtive Video game; Exercise|
75466718|NCT01912326|Device|Pacemaker Implantation|Implantation of a dual chamber pacemaker
75466719|NCT01912365|Procedure|Above Elbow Cast|
75625096|NCT02676700|Behavioral|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
75625097|NCT02676544|Device|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
75625098|NCT04178278|Diagnostic Test|Shuttle walking test|Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
75777720|NCT03077776|Procedure|Biopsy (optional)|[Optional] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy
75777721|NCT03077776|Procedure|Biopsy (metastatic)|Biopsy of metastatic site to be performed at the time of relapse
75777722|NCT03057795|Drug|Brentuximab Vedotin|Given IV
75777723|NCT03057795|Other|Laboratory Biomarker Analysis|Correlative studies
75777724|NCT03057795|Biological|Nivolumab|Given IV
75777725|NCT03018704|Drug|Topiramate|anticonvulsant medication. The medication was dosed twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
75777726|NCT03018704|Drug|placebo|inactive medication. the doses of placebo were titrated the same as the active intervention.
75777727|NCT02978612|Drug|Capecitabine|Capecitabine is a prodrug to 5-fluorouracil. It is used for adjuvant chemotherapy after surgery for colon cancer. The tablets are either 150 mg or 500 mg
75777728|NCT02970500|Drug|Methylphenidate HCl 10Mg SR|Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)
75777729|NCT02970500|Drug|Placebo Group|Placebo
75466720|NCT01912365|Procedure|Long Arm Splint|
75466721|NCT01912378|Drug|Oxytocin|
75466722|NCT01912378|Drug|Placebo nasal spray|
75466723|NCT01912391|Drug|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
75321540|NCT05270603|Other|ICARUS intraoperative adverse events calculator|"The ICARUS calculator is a web-based tool that uses answers to Boolean, yes/no questions to determine the iAE grade (appendix I). The calculator providers iAE grade outputs for the 5 iAE classification systems.~https://garnmile.com/iaecalc/~Development of the ICARUS calculator was performed as follows: Referencing the 5 classification systems, we first assembled a list of Boolean questions based on the iAE grade descriptions. This list was distilled to the minimum number of questions necessary to represent all descriptions in the combined list of iAE grades. Next, these questions were used to independently establish the conditional logic required to determine iAE grade for each classification system. The questions and logic were translated into Hypertext Preprocessor (PHP), a server-side programming language, and JavaScript, a client-side scripting language."
75321541|NCT01798667|Drug|DA-8031|
75625099|NCT04178278|Diagnostic Test|Exercise stress test|Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
75625100|NCT04178278|Diagnostic Test|6 minutes walking test|When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
75625101|NCT00642928|Drug|Placebo|1 capsule per day during 4 weeks
75625102|NCT00642928|Drug|BF 2.649 5 mg|one BF 2.649 capsule of 5 mg per day during 4 weeks
75625103|NCT00642928|Drug|BF 2.649 10 mg|One BF 2.649 capsule of 10 mg per day during 4 weeks
75625104|NCT00642928|Drug|BF 2.649 20 mg|One BF 2.649 capsule of 20 mg per day during 4 weeks
75625105|NCT00642928|Drug|BF 2.649 40 mg|One BF 2.649 capsule of 40 mg per day during 4 weeks
75625106|NCT02676232|Behavioral|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
75625107|NCT02673814|Biological|durvalumab|
75321542|NCT01798667|Drug|Placebo|Placebo of DA-8031, undistinguishable
75625108|NCT02673814|Biological|bavituximab|
75625109|NCT00644176|Drug|azithromycin immediate release (Zithromax)|azithromycin IR 500 mg tablet by mouth for 1 dose
75777730|NCT02951130|Drug|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo
75777731|NCT02951130|Drug|Placebo (5% Dextrose)|The study intervention is an intravenous infusion of milrinone or placebo
75777732|NCT02924571|Device|Bone Marrow Aspirate Concentrate (BMAC) + Allograft|Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest. Harvest BMAC System delivers high stem cell concentration to the graft site.
75466724|NCT01912391|Drug|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
75466725|NCT01912417|Other|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
75777733|NCT02924571|Device|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|INFUSE rhBMP-2 Bone Graft used according to its approved FDA labels, both from an anterior approach using titanium cages as well as from a posterior interbody approach using polyetheretherketone (PEEK) cages.
75777734|NCT02924571|Procedure|Autograft|Autograft with bone marrow aspirate.
75777735|NCT02881515|Other|Low Sodium Diet|Ten days of low sodium diet
75777736|NCT02881515|Other|Medium Sodium Diet|Ten days of a medium sodium diet
75321543|NCT04388657|Diagnostic Test|Echo-Doppler|Utrasound Doppler of the lower limbs
75777737|NCT02881515|Other|High Sodium Diet|Ten days of a high sodium diet
75321544|NCT00600925|Drug|gentamicin-collagen sponge dipped in saline|2 gentamicin-collagen sponges inserted before closure of the laparotomy
75466726|NCT01912430|Behavioral|ICC (Integrated Care Coaching) Intervention Group|
75466727|NCT01912443|Drug|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
75466728|NCT01912469|Drug|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
75466729|NCT01912469|Drug|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
75625110|NCT00644176|Other|placebo|placebo
75625111|NCT00644176|Drug|azithromycin SR|2.0 g by mouth in the form of liquid for 1 dose
75625112|NCT00644176|Other|placebo|placebo
75777738|NCT02861846|Biological|profile of CSF biomarkers of AD|dosage of biomarker of AD
75777739|NCT02768597|Device|ReUnion System with a Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
75625113|NCT02673424|Procedure|FFR-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI"
75625114|NCT02673424|Procedure|IVUS-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden >70%)"
75625115|NCT02673736|Drug|PLX73086|
75625116|NCT04178200|Drug|Lidocaine 2% Injectable Solution 0.75 ml|0.75 ml of Lidocaine will be added to the anesthetic solution.
75625117|NCT04178200|Drug|Bupivacaine Hcl 0.5% Inj 0.75 ml|0.75 ml of Bupivacaine will be added to the anesthetic solution.
76073815|NCT05702619|Other|Baseline bloods - for germline testing|"Arm 1 -~1-2 x 3.5mL blood samples collected into EDTA tubes for germ line DNA extraction and processing to PBMC for banking and future profiling of immune cell populations~1 x 10mL serum tubes for future, biobank related research projects, ie lipidomics, metabolics and microRNA analysis~ARM 2 -~A blood sample (maximum 20ml) will be taken for standard of care blood tests prior to prostatectomy including Full Blood Count, Renal Function and PSA. At the same time these standard of care bloods are taken, additional bloods - a maximum of 30ml - will be taken for research purposes as required for the following downstream analysis:~Germ line DNA extraction and optional processing to PBMC for banking and future profiling of immune cell populations~Biobank related research projects, ie lipidomics, metabolics and microRNA analysis"
75466730|NCT01912482|Other|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
75625118|NCT04178200|Drug|Lidocaine 2% Injectable Solution 1.5 ml|1.5 ml of Lidocaine will be added to the anesthetic solution.
75625119|NCT04178200|Drug|Bupivacaine Hcl 0.5% Inj 1.5 ml|1.5 ml of Bupivacaine will be added to the anesthetic solution.
75625120|NCT00644410|Biological|Mesenchymal stromal cell|Mesenchymal stromal cells 20 - 40 mill.
75625121|NCT00644410|Biological|Saline|12 injection with 0.2 ml saline
75625122|NCT02537158|Drug|Sorafenib|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
75625123|NCT02537158|Procedure|TACE|TACE group patients will accept TACE therapy once at a month after resection.
75625124|NCT04177420|Device|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
75625125|NCT04177420|Device|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
75625126|NCT04177420|Device|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
75625127|NCT04177420|Device|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
75625128|NCT02676154|Drug|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
75625129|NCT02676310|Drug|Bimatoprost|
75321545|NCT02673203|Device|Continuous Glucose Monitoring System (CGMS)|The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
75466731|NCT01912482|Other|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
75625130|NCT04180618|Other|Personal health wallet service for emergency situation|Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
75625131|NCT04177888|Device|Hot Pack|It is a single-use pack filled with magnesium sulfate and water, which was squeezed between the hands to activate their warming effect. The temperature ranges between 40°C to 50°C, which is safe to use. Thus, it provided a consistent heat therapy for up to 30 minutes. They can be used directly on the skin or covered with gauze to avoid direct skin contact. Applied to the lower back area for 30 minutes, followed by 10 minutes rest between each hot pack application, then it was reapplied for another 30 minutes. This procedure was repeated till delivery.
75466732|NCT01912521|Behavioral|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
75625132|NCT00643084|Procedure|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
75625133|NCT00643084|Procedure|standard bowel preparation|standard bowel preparation
75625134|NCT02676388|Procedure|Freeze-dried, Capsulized FMT|
75625135|NCT02676388|Procedure|Fresh FMT|
75625136|NCT04094974|Device|ANSiscope|Heart rate variability will be assessed using ansiscope before surgery
75625137|NCT04177186|Other|Strength training|Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
75625138|NCT04177186|Combination Product|Strength training with botulinum toxin|Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
75625139|NCT04094194|Other|Nordic diet|Healthy dietary pattern that is consumed in Nordic countries
75625140|NCT02672020|Biological|omics identity card|
75625141|NCT04096846|Diagnostic Test|laboratory investigation|detection of serum level of methotrexate and serum level of vitamin D
75625142|NCT04092244|Diagnostic Test|CTHRC1 biomarker|its a biomarker detected in the serum of the patients
75625143|NCT04180384|Drug|Oraxol|"Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate"
75777740|NCT02768597|Device|ReUnion System with a Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
75777741|NCT02768597|Device|ReUnion System with a Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
75777742|NCT02768597|Device|ReUnion System with a Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
75777743|NCT02663349|Behavioral|Social Cognition and Intervention Training|A manualized group therapy that teaches social cognitive skills.
75625144|NCT04091776|Radiation|CT scan|"Quantitative CT scan to measure localized osteoporosis and detection of cortices comminution.~Blinded surgeon decision as regard to replace or to fix using DHS or PFN (depending on x-rays data only).~Pathological assessment of osteoporosis in retrieved bone in patients whom hip replacement was decided.~Assessment of fixation failure in fixed fractures if occurred.~Fixation failure is defined as:~5.1. Lag cut through 5.2. Lag cutout 5.3. Z-effect (lag penetration) 5.4. Non-union (within 6 months) 5.5. Loss of reduction with progressive varus deformity 5.6. Femoral fracture 5.7. Intra-operative fracture of lateral wall or anterior cortex"
75625145|NCT02672254|Radiation|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
75625146|NCT04177732|Diagnostic Test|Collection of sulcular (crevicular) fluid|Sterile paper strips will be used for collecting crevicular fluid
75625147|NCT04177732|Diagnostic Test|Probing depth|Williams SE manual probe will be used to measure the probing depth
75625148|NCT04177732|Diagnostic Test|Bleeding on probing|Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
76073816|NCT05702619|Other|Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1|2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
76073817|NCT05702619|Other|Post-pimonidazole bloods for CTCs and ctDNA|ARM 1 - 2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
75625149|NCT04177732|Diagnostic Test|Gingival index|Modified Löe and Silness criteria will be used for evaluating the gingival index score
75625150|NCT04177732|Diagnostic Test|Bone loss rate of alveolar bone|Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
75466733|NCT01912534|Drug|Valsartan|40, 80 and 160 mg tablets of Valsartan
75466734|NCT01912534|Drug|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
75777744|NCT02617407|Drug|Livionex® Dental Gel|Dental Plaque, Gingivitis and Oral Microbiome Control.
75777745|NCT02617407|Drug|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Dental Plaque, Gingivitis and Oral Microbiome Control.
75466735|NCT01912547|Procedure|Blood draw for TEG analysis|Blood drawn for TEG analysis
75466736|NCT01912573|Drug|Intranasal (IN) naloxone|
75777746|NCT02617407|Device|Kolibree Toothbrush|Electric Toothbrush
75777747|NCT02562040|Procedure|Early Adenotonsillectomy (eAT)|Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
75466737|NCT01912573|Drug|Intravenous (IV) naloxone|
75466738|NCT01912573|Drug|Intramuscular (IM) naloxone|
75466739|NCT01912573|Drug|Intraosseus (IO) naloxone|
75625151|NCT02671942|Drug|Roflumilast|
75625152|NCT02671942|Drug|Placebo|
75625153|NCT00643240|Radiation|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
75914360|NCT05397951|Device|Vicorder Pulse Wave Velocity Monitor|The pulse wave velocity monitor device will be placed on the right side of the neck and the right thigh and will provide measurements continuously throughout the experimental period.
75466740|NCT01912586|Other|vacuum erection device|sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months
75625154|NCT00643240|Radiation|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
75625155|NCT00644488|Drug|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
75625156|NCT02675920|Drug|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
75625157|NCT02671474|Other|4-dimensional volume-rendered computed tomography|
75625158|NCT02671630|Other|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
75777748|NCT02562040|Behavioral|Watchful Waiting with Supportive Care (WWSC)|Information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
76073818|NCT01770379|Biological|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
76073819|NCT01770379|Biological|Placebo|
76073820|NCT01986881|Drug|Ertugliflozin|Oral, once daily, for up to approximately 6 years
76073821|NCT01986881|Drug|Placebo|Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
75625159|NCT02671552|Drug|Perflutren Protein-Type A Microspheres|Given IV
75625160|NCT02671552|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
75625161|NCT05277064|Other|Oral FOB|After induction of anesthesia and muscle relaxation, An investigator who has experiences of numerous fiberoptic intubations will measure the optimal preliminary insertion depth of the fiberoptic bronchoscope for oral fiberoptic intubation.
75625162|NCT02671006|Other|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
75625163|NCT00644566|Other|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
75625164|NCT04176328|Drug|Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.|Teicoplanin Sandoz administered by inhalation (aerosol).
75625165|NCT04178044|Biological|GB223,7mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg 2 subjects receive placebo.
76073822|NCT01986881|Drug|Glycemic Rescue|Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea [SU], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
75321546|NCT02673203|Behavioral|Food log|The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
75625166|NCT04178044|Biological|GB223,21mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:21mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
75625167|NCT04178044|Biological|GB223,63mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:63mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
75625168|NCT04178044|Biological|GB223,119mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:119mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
75625169|NCT04178044|Biological|GB223,140mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:140mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
75625170|NCT04175860|Behavioral|The intervention with the patient (Chronic Patient Care Group and his family.)|"Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home."
75625171|NCT02671396|Behavioral|Virtual reality based intervention|Virtual reality based balance training
75625172|NCT02671396|Behavioral|Conventional intervention|Conventional balance training
75625173|NCT04177342|Drug|Fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
75777749|NCT02558491|Device|Decision Support System|"The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump or MDI. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:~An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data~An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment.~A smart bolus calculator based on CGM glucose measurements and insulin sensitivity estimation."
75321547|NCT02653001|Other|Stool sample collection|Collection of complete stool sample
75321548|NCT01881867|Biological|Glycosylated Recombinant Human Interleukin-7|Given SC
75321549|NCT01881867|Other|Laboratory Biomarker Analysis|Correlative studies
75321550|NCT01882413|Other|No intervention|No intervention
75321551|NCT02338973|Drug|Interferon gamma-1b|
75625174|NCT04177342|Drug|Oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
75625175|NCT02671786|Other|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories & 15-17 gms of proteins.
75625176|NCT00644644|Other|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
75625177|NCT04016506|Other|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
75321552|NCT03458403|Procedure|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
75321553|NCT00601627|Biological|panitumumab|
75321554|NCT00601627|Drug|capecitabine|
75321555|NCT00601627|Drug|fluorouracil|
75321556|NCT00601627|Drug|gemcitabine hydrochloride|
75777750|NCT02558491|Other|Usual Care|During the Control study admission, DiAs will be programmed with the home insulin dosing parameters. The study subject will use the home basal/bolus MDI or continuous subcutaneous insulin infusion (CSII) insulin regimen via the home insulin pens or pump and determine the amount of insulin to give for the entire admission per the subject's home carb counting parameters and as calculated by the DiAs meal screen.
75777751|NCT02537509|Drug|Cholecalciferol|
75777752|NCT02537509|Drug|Placebo of cholecalciferol|
75777753|NCT02490878|Drug|bevacizumab|IV
75777754|NCT02490878|Drug|corticosteroids|IV
75777755|NCT02490878|Other|placebo|IV
75321557|NCT00601627|Radiation|radiation therapy|
75321558|NCT01882725|Device|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
75321559|NCT01883427|Drug|Placebo|placebo containing saline+glucose
75321560|NCT01883427|Drug|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
75777756|NCT02458027|Dietary Supplement|Hemp Shake|Hemp Protein
75777757|NCT02458027|Dietary Supplement|Hemp|Hemp Protein Shake
75777758|NCT02458027|Dietary Supplement|Soybean Shake|Soybean Protein
75777759|NCT02458027|Dietary Supplement|Soybean|Soybean Protein Shake
75321561|NCT02527187|Biological|10 HEP/mL Betula verrucosa allergen extract|The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
75466741|NCT01912638|Device|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
75625178|NCT02668276|Other|Standard NCCN counseling|
75625179|NCT02668276|Other|Standard NCCN counseling and Oncotype DX results|
75625180|NCT04175158|Biological|GB222|Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
75625181|NCT04175158|Biological|Bevacizumab|Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
75777760|NCT02458027|Dietary Supplement|Control|Non-Protein Shake
75914361|NCT05393570|Behavioral|Healthy Lifestyle Behavioral Intervention (MBS -supported intervention)|After patient/parent consent is completed, participants will begin the pre-MBS intervention phase. A minimum of 6 1- hour sessions will occur pre-MBS, and 26 will occur post-MBS.Dr. Klement, MBS coordinator and a diabetes educator will manage session delivery to adolescents/parents. All content will follow the Diabetes Prevention Program (DPP)-adapted curriculum flow. After that the research assistant will perform outreach, reminder calls, and follow-up for missed appointments. Pre-and post-MBS intervention delivery (based on adapted curriculum/model) may consist of a combination of 1-on-1 and group sessions (in-person or virtually), and online support tools, dependent upon adolescent/parent qualitative feedback on delivery method preference.
75321562|NCT02527187|Biological|25 HEP/mL Betula verrucosa allergen extract|The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
75466742|NCT01912638|Drug|Provisc|Provisc is an cohesive viscoelastic.
75466743|NCT01912677|Drug|Nifedipine|
75466744|NCT01912677|Drug|Labetalol|
75777761|NCT02421601|Drug|Condoliase|1.25 U, intradiscal injection, one time
75777762|NCT02382614|Device|Spiration Valve System|
75777763|NCT02332850|Biological|Isatuximab|Given IV
75777764|NCT02332850|Drug|Carfilzomib|Given IV
75777765|NCT02332850|Drug|Dexamethasone|Given IV or PO
75777766|NCT02284802|Procedure|Confocal endomicroscopy|Confocal endomicroscopy examination during endoscopy
75777767|NCT02262325|Radiation|hypofractionated radiation therapy|Radiation boost in week 1 (days 1-5)
75777768|NCT02262325|Drug|cisplatin|Given IV
75777769|NCT02262325|Drug|etoposide|Given IV
75777770|NCT02262325|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
75777771|NCT02262325|Other|laboratory biomarker analysis|Correlative studies
75914362|NCT05393401|Device|VOP1k|Photoplethysmographic records
75466745|NCT01912677|Drug|Methyldopa|
75466746|NCT01912690|Other|aerobic training|
75466747|NCT01912690|Other|aerobic and strength training|
75466748|NCT01912703|Other|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
75466749|NCT01912742|Behavioral|Very-low calorie diet (VLCD)|
75777772|NCT02205762|Drug|Prednisone|Stratum I
75777773|NCT02205762|Drug|Vinblastine|Stratum I
75777774|NCT02205762|Drug|mercaptopurine|Stratum I
75777775|NCT02205762|Drug|INDOMETHACIN|Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
75777776|NCT02205762|Drug|Methotrexate|fixed dose weekly orally for total treatment duration of 24 months.
75777777|NCT02205762|Drug|Cytosine Arabinoside|
75777778|NCT02205762|Drug|2-chlorodeoxyadenosine|
75777779|NCT02205762|Procedure|hematopoietic stem cell transplantation (RIC-HSCT)|
75777780|NCT02205762|Biological|Intravenous immunoglobulin|
75777781|NCT02204228|Device|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
76073823|NCT03156075|Behavioral|Nutrition and exercise program|"Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn."
75625182|NCT02671318|Drug|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
75914363|NCT05391698|Behavioral|Behavioral Parent Training (BPT)|The parent training consists of 8 weekly group sessions where parents are trained on behavior modification techniques, optimal parental practices as well as techniques for the enhancement of their children's cognitive deficits.
75777782|NCT02197923|Procedure|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
75777783|NCT02197923|Procedure|endometrial biopsy|transcervical endometrial biopsy
75914364|NCT05391698|Combination Product|Child Training (iVR + CBT)|The child training program is comprised of 16 individualized weekly sessions. It utilizes the potentials of immersive virtual reality (iVR) technology for the training of focused and sustained attention and combines practices based on cognitive-behavioral approach for children's training on behavioral and emotional self-regulation skills.
75914365|NCT05389319|Biological|Prime-2-CoV_Beta|1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
75914366|NCT05388617|Device|Brera|The applicators will be placed in contact with the skin. The entire defined treatment area will then be treated by delivering energy to the skin. Temperature may be continuously monitored and recorded during treatment. Parameters may be adjusted throughout the treatment to increase subject comfort.
76073824|NCT03585855|Other|MSC transplantation|MSC transplantation: patients with ABMR treated with MSC transplantation
76073825|NCT03580395|Drug|Apatinib|500mg, day1-21,neoadjuvant therapy
75914367|NCT05387590|Behavioral|Preventiometer device with wellness coaching|Four wellness coaching sessions with a certified wellness coach to develop and implement your own personalized wellness plan will be included in this study.
76073826|NCT03580395|Drug|paclitaxel|paclitaxel 165mg/m2 day 1
76073827|NCT03580395|Drug|cisplatin|cisplatin 40mg, day 1-3
75625183|NCT02671318|Drug|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
75625184|NCT02668510|Biological|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
75625185|NCT02668510|Drug|Normal saline|placebo injection of normal saline immediately following shockwave therapy
75777784|NCT02146378|Drug|Vyndaqel|20mg/day
75777785|NCT01996267|Drug|PTC+Pertuzumab|Cycle repeated every 21 days
75777786|NCT01996267|Drug|FEC-T+Pertuzumab|Cycle is repeated every 21 days
76073828|NCT01609543|Drug|erlotinib [Tarceva]|150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
76073829|NCT03585699|Diagnostic Test|Fluoroscopy Guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
76073830|NCT03585699|Diagnostic Test|CT guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
76073831|NCT03580239|Drug|Everolimus|Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
76073832|NCT03580239|Drug|Placebo|Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
76073833|NCT03156153|Drug|Bumetanide|bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
76073834|NCT03156153|Drug|Placebo|placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
76073835|NCT03155919|Dietary Supplement|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
75321563|NCT02527187|Biological|50 HEP/mL Betula verrucosa allergen extract|The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
75466750|NCT01912742|Behavioral|Low calorie diet (LCD)|
75466751|NCT01912755|Drug|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
75466752|NCT01912755|Drug|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
75777787|NCT01941563|Drug|Condoliase|1.25U, intradiscal injection, one time
75777788|NCT01941563|Drug|placebo|
75777789|NCT01934218|Device|Gel-One|
75777790|NCT01934218|Device|PBS|
75777791|NCT01898364|Drug|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
75777792|NCT01898117|Drug|Carbo/cyclo|
75777793|NCT01898117|Drug|Carbo/cyclo + atezolizumab|
75777794|NCT01898117|Drug|Paclitaxel|
76073836|NCT03155919|Dietary Supplement|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
76073837|NCT02003183|Radiation|[F-18]FDDNP|Each participant was injected with [F-18]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
75777795|NCT01898117|Drug|Paclitaxel + Atezolizumab|
75777796|NCT01812447|Device|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
75625186|NCT00644722|Device|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
75625187|NCT00644722|Device|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
75777797|NCT01812447|Other|Medical Management|Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
75777798|NCT01789229|Other|Tumor tissue collection|"Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.~Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.~Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger."
75914368|NCT05385328|Device|EYEFUL: healthy people|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
75914369|NCT05385328|Device|EYEFUL: people with pathology|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
75625188|NCT02668588|Drug|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
75914370|NCT05385016|Behavioral|Cooking Skills|This session will consist of a hands-on cooking demonstration in a demo kitchen. Skills addressed in this portion of the session will include proper kitchen utensil and appliance use, measuring dry and wet ingredients, following/reading a recipe, preparing ingredients, cooking a meal, etc. The participant will follow a visual recipe that provides a breakdown of each skill needed to complete each step of the recipe. Additionally, during the cooking session investigators will address nutrition topics related to food/kitchen safety, basic nutrition education (i.e., portion sizes, food groups, reading food labels, meal planning etc.) in a discussion format.
75625189|NCT02668588|Drug|extended release of placebo|1 intramuscular injection of extended release of placebo
75914371|NCT05385016|Behavioral|Physical Activity|This session will consist of a group functional fitness class. Each session will include a warm-up (~5 min) moderate-to-vigorous intensity aerobic and resistance exercise (~20 min) and cool-down/stretching (~5 min). Exercises may be accompanied by music and will include walking/jogging, dancing, imitating animal movements, vertical/horizontal jumps, squats, hurdles, walking on balance beam etc. Thera-Band, kettle bells, free weights, and medicine balls will be used during strength exercises for major muscle groups. These sessions will be led by certified personal trainers with experience in adaptive physical activity.
75914372|NCT05384353|Other|[18F]-SynVesT-1|PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density
75914373|NCT05384249|Drug|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
75914374|NCT05384249|Drug|Placebo|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
75321564|NCT02527187|Biological|100 HEP/mL Betula verrucosa allergen extract|The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
75625190|NCT02668042|Biological|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
75625191|NCT04174690|Device|Force platform|In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
75777799|NCT01789229|Other|Sampling of ascites and pleural effusion|Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
75777800|NCT01789229|Other|Collecting urine samples|Patient is asked to give a urine sample. Urine is collected in urine beaker.
75321565|NCT01947153|Drug|Metformin|Free combination
75321566|NCT01947153|Drug|Linagliptin|Fixed dose combination
75321567|NCT01947153|Drug|Metformin|Combination
75625192|NCT02671084|Drug|sevoflurane|compare effect of sevoflurane when administered before PCI
75625193|NCT02671162|Drug|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
75625194|NCT02671162|Drug|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
75777801|NCT01789229|Other|Collecting saliva sample|Saliva sample is collected by spatula from the mouth cavity of the patient.
75777802|NCT01789229|Other|Collecting sputum|Patient is asked to produce sputum into a 50ml lab tube.
75777803|NCT01789229|Other|Collecting stool samples|Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
75321568|NCT01947153|Drug|Linagliptin|Free combination
75777804|NCT01789229|Other|Lavage/Irrigation|Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
75777805|NCT01763125|Other|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
75625195|NCT04175782|Procedure|Enhanced recovery after surgery (ERAS) protocol|"Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
75777806|NCT01725919|Behavioral|CI therapy|constraint induced movement therapy
75777807|NCT01702805|Procedure|Liberal Cell Transfusion|
75625196|NCT04176796|Other|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = [number of patients surviving after transplant with excellent organ]/[number of patients for whom excellent organ was accepted for transplant] marginal transplant survival = [number of patients surviving after transplant with marginal organ]/[number of patients for whom marginal organ was accepted for transplant]"
75777808|NCT01702805|Procedure|Restricted red cell transfusion|
75625197|NCT04176484|Other|Survey|Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
75625198|NCT02667964|Other|spiroergometry|Spiroergometry on a bicycle ergometer
75625199|NCT05276986|Other|DOMS protocol|For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
75625200|NCT00644800|Drug|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
75625201|NCT04083586|Other|All investigations; laboratory and radiological, needed for diagnosis|mri brain, ct brain, drug screening
75625202|NCT02670616|Drug|Ibrutinib|560 mg by mouth daily on day 1-21 per each cycle
75625203|NCT02670616|Drug|Rituximab|375 mg/m2 IV, day 1
75625204|NCT02670616|Drug|Cyclophosphamide|750 mg/m2 IV day 1
75625205|NCT02670616|Drug|Doxorubicin|50 mg/m2 IV day 1
75625206|NCT02670616|Drug|vincristine|1.4 mg/m2 IV on day 1
75466753|NCT01912794|Other|Sensory Intervention|"full sensory information, whose participants will practice balancing tasks without constraint sensory body;~sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;~control, whose participants will exercise activities involving cognitive and upper limbs."
75625207|NCT02670616|Drug|Prednisolone|100mg per day on day 1-5
75625208|NCT00996840|Drug|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
75625209|NCT00996840|Drug|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
75777809|NCT01656603|Biological|unlicensed CBU|infusion of unlicensed cord blood units
75777810|NCT01654133|Device|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft|Repair of thoracoabdominal aortic aneurysms
75777811|NCT01545674|Procedure|Blood Draw|Blood will be drawn from the mother and father
75777812|NCT01282606|Drug|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
75777813|NCT01236287|Drug|Voclosporin|Subjects will receive voclosporin capsules, twice daily
75777814|NCT01233648|Other|rate control via CRT-D and AVN ablation|rate control
75777815|NCT01233648|Other|rhythm control via pharmacologic, electrical or ablative therapies|rhythm control
75777816|NCT01233635|Other|no drug|none, no drug
75466754|NCT01912820|Dietary Supplement|green tea extract|Given PO
75466755|NCT01912820|Drug|quercetin|Given PO
75466756|NCT01912820|Other|placebo|Given PO
75466757|NCT01912820|Procedure|therapeutic conventional surgery|Undergo prostatectomy
75466758|NCT01912820|Other|laboratory biomarker analysis|Correlative studies
75466759|NCT01912846|Behavioral|Interactive advance care planning|"The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.~Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.~Facilitating EOL care discussions throughout the dying process.~A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP."
75777817|NCT01233635|Drug|start cozaar|start cozaar
75777818|NCT01233635|Drug|continue cozaar|continue cozaar
75777819|NCT01172561|Behavioral|Lay Health Advisor Education Intervention|The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
75914375|NCT05377580|Drug|Placebo|Participants will receive placebo IV or SC
75914376|NCT05377580|Drug|IBI112|Participants will receive IBI112 IV or SC
75914377|NCT05377580|Drug|IBI112|Participants will receive IBI112 IV or SC
75777820|NCT01172561|Behavioral|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
75777821|NCT01168921|Drug|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle
75777822|NCT00634946|Drug|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
75777823|NCT00634946|Drug|Placebo|Placebo is administrated into the nucleus pulposus of an intervertebral disc.
75777824|NCT00512577|Other|Red blood cell transfusion|Pre-operative red blood cell transfusion
75777825|NCT00481936|Drug|VB6-845|Intravenous infusion once weekly for 4 weeks
75625210|NCT00996840|Drug|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
75625211|NCT00996840|Drug|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
75625212|NCT00996840|Other|Placebo|Placebo to match intervention
75777826|NCT00385606|Drug|gemcitabine|
75777827|NCT00385606|Drug|prolonged continuous infusion gemcitabine|
75777828|NCT00385606|Drug|cisplatin|
75625213|NCT00645502|Drug|risperidone|
75777829|NCT00385606|Drug|rofecoxib|
75777830|NCT03721744|Drug|Napabucasin|Napabucasin will be administered twice daily, at 240 mg bid (480 mg total daily dose), one hour prior or two hours after meals
75466760|NCT01912846|Behavioral|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
75777831|NCT03721744|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle
75777832|NCT03721744|Drug|Gemcitabine|Gemcitabine 600 mg/m^2 will be administered intravenously following paclitaxel infusion on Days 1, 8 and 15 of every 28-day cycle
75777833|NCT03721744|Other|Standard of care treatment options|Patient will receive standard of care treatment options, including Fluorouracil /Leucovorin, Gemcitabine, Onivyde plus Fluorouracil /Leucovorin (if Onivyde has been approved to treat pancreatic cancer in the country/region) or best supportive care (BSC) alone, one of which will be assigned by the investigator, per Investigator decision
75777834|NCT01589354|Procedure|Interscalene brachial plexus block|An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.
75777835|NCT01589354|Procedure|Intra-articular Ropivacaine injection|The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound
75777836|NCT01589354|Device|Ultrasound guided technique|The block will be performed under U/S guidance
75777837|NCT01589354|Drug|Ropivacaine|20ml of 0.375% Ropivacaine
75777838|NCT01589354|Drug|Ropivacaine|20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
75777839|NCT01583660|Drug|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
75777840|NCT01583660|Drug|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
75777841|NCT03960788|Drug|Gadoxetate Sodium|Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
75777842|NCT01583738|Drug|V0251|single dose
75625214|NCT04174768|Procedure|Bariatric surgery|Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
75625215|NCT00644956|Drug|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
75466761|NCT01912859|Behavioral|Nutrition/physical activity intervention|Nutrition/physical activity intervention
75466762|NCT01912885|Device|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
75625216|NCT00644956|Drug|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
75625217|NCT04175002|Drug|utrogestan|oral uterogeston 200mg daily to achieve window of implantation from previous study
75625218|NCT04174846|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|SAM children will receive approximately 190 kcal/kg/day of standard RUTF
75625219|NCT04174846|Dietary Supplement|Ready-to-use-supplementary food (RUSF)|SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
75625220|NCT02670772|Drug|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
75777843|NCT01583738|Drug|placebo|single dose
75777844|NCT00097370|Drug|mepolizumab|Study Drug
75777845|NCT01583816|Drug|Resiquimod 0.03%|topical application
75777846|NCT01583816|Drug|Resiquimod 0.01%|topical application
75777847|NCT01583816|Drug|placebo|topical application
75777848|NCT01583270|Dietary Supplement|Arabinoxylan|Porridge rich in arabinoxylan
75777849|NCT01583270|Dietary Supplement|Rye kernel|Porridge made of rye kernels
75777850|NCT01583270|Dietary Supplement|Arabinoxylan and rye kernels|Porridgde made of rye kernels and arabinoxylan
75777851|NCT01583270|Dietary Supplement|Semolina|Semoline porridge. control meal.
75777852|NCT01583348|Procedure|Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy|During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
75777853|NCT01089218|Drug|oral amoxicillin/clavulanate 1g (875/125mg)|oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
75777854|NCT01089218|Drug|control|no intervention with the same procedure of FB
75777855|NCT03957668|Drug|PEG 3350|PEG 3350 17 g once daily for 14 days
75777856|NCT03957668|Drug|Lactulose|Lactulose 10 g once daily for 14 days
75777857|NCT03963362|Drug|GLA5PR tablet 75 mg|GLARS-NF3 tablet
75625221|NCT02670772|Drug|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
75625222|NCT02667730|Drug|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
75777858|NCT03963362|Drug|GLA5PR tablet 150 mg|GLARS-NF3 tablet
75777859|NCT01091402|Procedure|autologous serum skin test, serum IL-18|
75777860|NCT03515824|Biological|MK-1697|Administered by IV infusion on Day 1 of each 21-day cycle
75625223|NCT02667730|Drug|Naproxen|naproxen 500mg twice daily for 7 days
75625224|NCT02667730|Drug|Celecoxib|celecoxib 100mg twice daily
75625225|NCT02667730|Other|physiotherapy only|physiotherapy only (no drug)
76073838|NCT03156231|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
75625226|NCT02667808|Other|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
76073839|NCT03156231|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
75466763|NCT01912885|Device|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
75625227|NCT02667808|Other|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
75625228|NCT02667184|Dietary Supplement|Low FODMAP Oral Nutrition Supplement|
75625229|NCT04294992|Drug|Ondansetron 8mg|Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
75625230|NCT02670460|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
75625231|NCT00628914|Drug|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
75625232|NCT00628914|Drug|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
75777861|NCT01089374|Radiation|Partial breast radiation after lumpectomy|Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
75777862|NCT01089452|Drug|Perindopril|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
75777863|NCT01089452|Drug|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
75777864|NCT01089452|Drug|Olmesartan/amlodipine|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
75777865|NCT04880980|Drug|Terbinafine Pill|Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.
75777866|NCT04880980|Drug|Itraconazole capsule|Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.
75777867|NCT01089530|Behavioral|Lifestyle intensive group|hipocaloric diet smoking cessation physical exercise
75777868|NCT03960710|Other|Anonymized CT examinations|The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.
76073840|NCT03585387|Procedure|Navigation|Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
75466764|NCT01912885|Device|TENS 2-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
75466765|NCT01912885|Device|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
75466766|NCT01912885|Device|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
75625233|NCT00628914|Drug|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
75625234|NCT02670850|Other|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
75625235|NCT02870634|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
75625236|NCT02537236|Dietary Supplement|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
75625237|NCT02537236|Behavioral|TLC nutritional intervention|nutritional orientation.
75625238|NCT02537236|Dietary Supplement|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
75625239|NCT04174066|Other|blood sample|blood sample during planned in the follow-up of patients.
75777869|NCT03960710|Other|Training (1)|"An initial training phase of the artificial intelligence network will be carried out :~- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals"
75777870|NCT03960710|Other|Training (2)|"An initial training phase of the artificial intelligence network will be carried out :~- Use of computer data to drive the artificial intelligence network."
76073841|NCT05702151|Procedure|ESP Block|After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.
76073842|NCT05702151|Drug|Morphine injection|Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
75777871|NCT03960710|Other|Validation (1)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by an intern at the Lyon hospitals"
75777872|NCT03960710|Other|Validation (2)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by the neural network"
75777873|NCT01089686|Procedure|Venoplasty|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
75777874|NCT01089686|Procedure|Sham procedure (non-treatment)|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
75777875|NCT01082666|Device|Continuous control of cuff pressure|Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
75777876|NCT01082666|Device|Manual control of cuff pressure|Manual control of cuff pressure is a routine practice in ICU patients
75777877|NCT03511378|Drug|Lupin's Pegfilgrastim|Administration of Pegfilgrastim
75777878|NCT03511378|Drug|Neulasta®|Administration of Neulasta®
75625240|NCT04174066|Other|tissue sample|tissue sample during planned in the follow-up of patients.
75914378|NCT05376007|Behavioral|Serious game 'Broodles'|The serious game 'Broodles' is a newly developed web-based, educational game that can be played by siblings on a computer or tablet without support from an adult. The game discusses the nine domains of sibling quality of life (Moyson & Roeyers, 2012) in eight 20-minute levels. The main characters of the game are the Broodles, which are little monster creatures that experience things that siblings of children with ID and/or VI can also experience. The game includes animations, videos of siblings talking about their experiences, quizzes and mini-games. These elements are focussed on emotions, thoughts and difficult situations that siblings can experience. In addition to the game, siblings make offline worksheets and parents receive an information brochure. Siblings complete the game in four weeks.
75914379|NCT05375214|Device|Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)|Novel intermittent theta burst stimulation protocol with individualized targets in the brain for stimulation using structural and functional MRI inputs
75914380|NCT05372393|Procedure|Distal median nerve block and local infiltration anaesthesia|Local infiltration anaesthesia: The anaesthetic cocktail consists of 4,5 ml of lidocaine with adrenalin 1%, 4,5 ml of bupivacaine with adrenalin 0.5% and 1 ml of (7.5%) sodium bicarbonate. The investigators use a 24 gauge hypodermic needle to inject the solution.
75914381|NCT05372393|Procedure|Local infiltration anaesthesia|The anaesthetic cocktail consists of 4,5 ml of lidocaine with adrenalin 1%, 4,5 ml of bupivacaine with adrenalin 0.5% and 1 ml of (7.5%) sodium bicarbonate. The investigators use a 24 gauge hypodermic needle to inject the solution.
75914382|NCT05371717|Other|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
75914383|NCT05371717|Other|Biorepair Total Protection|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
76073843|NCT01986647|Behavioral|On the Move exercise - exercise leader|exercise physiologists
75466767|NCT01912898|Device|No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D|
75466768|NCT01912924|Device|Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery
75625241|NCT04174066|Other|excreta|urine sample during planned in the follow-up of patients.
75625242|NCT00645580|Drug|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
75466769|NCT01912937|Device|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
75625243|NCT02666872|Behavioral|Motivational interviewing|
75625244|NCT02670304|Drug|letrozole|letrozole from the day of oocyte retrieval for 5 days
75625245|NCT02670304|Drug|Aspirin|aspirin from the day of oocyte retrieval for 5 days
75625246|NCT02671708|Drug|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -12 and -10.
75625247|NCT02671708|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
75625248|NCT02671708|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
75625249|NCT05060458|Other|No intervention|No intervention
75625250|NCT00998946|Drug|Pralatrexate|Pralatrexate injection administered as intravenous (IV) push
75625251|NCT00998946|Dietary Supplement|Vitamin B12|1 mg intramuscular (IM) injection
75625252|NCT00998946|Dietary Supplement|Folic Acid|Oral 1 mg tablet
75625253|NCT05146180|Device|Parametric positron emission computed tomography|Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy
75625254|NCT01158404|Drug|LY900009 - Dose Escalation Phase (Part A)|"2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
75625255|NCT01158404|Drug|LY900009 - Dose Confirmation Phase (Part B)|"30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
75625256|NCT02670070|Drug|gemigliptin 50mg, rosuvastatin 20mg|gemigliptin/rosuvastatin 50/20mg
75625257|NCT00645034|Drug|placebo|placebo by mouth as a single dose
75777879|NCT01583504|Procedure|Ultrasound guided injection of steroid and local anaesthetic|2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.
75914384|NCT05371054|Device|Vysis LSI MYC Break Apart Rearrangement Probe Kit|MYC rearrangement FISH testing is performed using the Vysis LSI MYC Break Apart Rearrangement Probe (Abbott Molecular, Inc.) in the Chromosome Pathology Section, Laboratory of Pathology, CCR, NCI. This kit is not FDA approved. It is being used as a treatment determining in-vitro diagnostic device in this study.
75777880|NCT01583504|Procedure|High volume saline injection|After steroid and local anaesthetic has been delivered, a bolus of normal saline will also be infused into the space between Kager's fat pad and the achilles tendon through the same needle, using ultrasound guidance and sterile technique. At least 14mls will be given but up to 40mls could be used. Saline will be injected until the injector determines that the appearance of neovascularisation on ultrasound has disappeared.
75777881|NCT01583504|Behavioral|exercise programme|a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
75777882|NCT01091636|Procedure|Hyperthermic Intraperitoneal Chemotherapy|41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
75914385|NCT05371054|Drug|venetoclax|administered orally, days 1-10, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
75914386|NCT05371054|Drug|VIP152|administered intravenously, days 2 and 9, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
75914387|NCT05371054|Drug|prednisone|administered orally, days 1-10, at a dose of 100 mg; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
75625258|NCT00645034|Drug|sildenafil|sildenafil 100 mg by mouth as a single dose
75625259|NCT02885090|Procedure|Blood sampling|In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
75625260|NCT04173832|Drug|Tianqi Pingchan Granule Combined With Amantadine|Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
75625261|NCT04173832|Drug|Placebo Combined With Amantadine|Placebo and Amantadine are given to patients simultaneously
75777883|NCT01583036|Drug|Digoxin Alone|Single administration of digoxin 0.25mg
75777884|NCT01583036|Drug|Digoxin + Retigabine|Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
75777885|NCT03511066|Drug|CT-P27 90 mg/kg|Influenza A treatment drug.
75777886|NCT03511066|Drug|CT-P27 45 mg/kg|Influenza A treatment drug.
75777887|NCT03511066|Drug|Placebo|Placebo.
75777888|NCT01091714|Dietary Supplement|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
75777889|NCT01091714|Dietary Supplement|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
75777890|NCT01091714|Dietary Supplement|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
75777891|NCT01091792|Drug|Bevacizumab|Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
75777892|NCT03510910|Drug|Acetaminophen|acetaminophen 600 mg to be taken every 8 hours (TID)
75914388|NCT05363397|Drug|TBO-309|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.
75625262|NCT04173910|Procedure|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
75777893|NCT03510910|Drug|Percocet|"Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN"
75777894|NCT01091870|Drug|Placebo|Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.
75777895|NCT01091870|Drug|Sildenafil Citrate, 25 mg, 3 times a day.|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
75777896|NCT01091870|Drug|Sildenafil Citrate 50 mg, 3 times a day|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
75914389|NCT05358509|Drug|Ferric carboxymaltose|Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
75625263|NCT00998790|Device|American Medical Systems (AMS) AdVance™ Male Sling System|The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
75625264|NCT02537002|Drug|PF-05230907|A single intravenous dose of 3 μg/kg
75625265|NCT02537002|Drug|PF-05230907|A single intravenous dose of 5 μg/kg
75625266|NCT02537002|Drug|Placebo|A single intravenous dose of matched placebo
75625267|NCT00645658|Drug|Testim (1% testosterone gel)|Subjects apply contents of gel packet to skin daily.
75625268|NCT01001988|Other|Blood sample|Blood sample for immunogenicity assessment
75625269|NCT01001988|Biological|JE-CV administered in Study JEC02|Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
75625270|NCT02667340|Dietary Supplement|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game & at halftime)
75625271|NCT02667340|Other|Placebo|0.7 g glucose per kg body mass in two ingestions (before game & at halftime)
75625272|NCT04293354|Procedure|Serratus Plane Block|Serratus Plane Block was performed
75625273|NCT04293354|Procedure|Control|No block was performed
75625274|NCT02666170|Drug|Alpha-lipoic acid|
75625275|NCT02670148|Procedure|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
75625276|NCT02667262|Other|Algorithm to identify patients experiencing opioid abuse/addiction|
75625277|NCT04077268|Other|GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals
75625278|NCT00645736|Other|No intervention|No intervention
75625279|NCT02666404|Other|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
75625280|NCT00646126|Drug|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
75625281|NCT00646126|Drug|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
75625282|NCT02670226|Other|Samples|Blood samples, muscle biopsy
75625283|NCT02537080|Drug|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
75625284|NCT02537080|Drug|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
75625285|NCT02667496|Drug|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
75625286|NCT02667496|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
75625287|NCT02667496|Drug|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
75625288|NCT00645112|Drug|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
75625289|NCT00645112|Drug|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
75625290|NCT02666482|Behavioral|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
75625291|NCT02667106|Drug|RX0041-2|Pharmacokinetic study
75625292|NCT02666092|Other|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
75625293|NCT02666092|Biological|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
75625294|NCT02669524|Drug|LY2409021|
75625295|NCT02669524|Drug|LY2409021 placebo|
75914390|NCT05358509|Drug|Iron isomaltoside|Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
75625296|NCT02669524|Procedure|OGTT|
75625297|NCT02669524|Procedure|IIGI|
75625298|NCT02669524|Procedure|Standardised liquid meal|
75625299|NCT04071496|Other|Blood samples|1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml
75625300|NCT04076566|Device|alfapump system|active implantable device for treatment of malignant ascites
75625301|NCT04950712|Procedure|Blood sampling|Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).
75625302|NCT04950712|Procedure|Anogenital lesion swab collection|Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
75625303|NCT00996606|Drug|DMARDs|Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
75625304|NCT00996606|Drug|Tocilizumab|Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.
75625305|NCT00645814|Drug|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
75625306|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
75625307|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
75625308|NCT02669836|Procedure|Posterior fossa decompression|Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
75625309|NCT02669836|Procedure|Dural Augmentation|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
75625310|NCT04174378|Drug|Decapeptyl 0.2mg|IM Decapeptyl o.2 mg was given 2 days before embryo transfer
75625311|NCT02669446|Device|Medical devices|
75625312|NCT02669446|Device|traditional household remedy|
75625313|NCT00645892|Drug|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
75625314|NCT00645892|Drug|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
75625315|NCT00645190|Drug|Galantamine HBr|
75625316|NCT04293120|Other|Training with weighted ball|Participants will stop or catch a weighted ball
75777897|NCT03721666|Other|CCTV footage to the medical dispatcher in OHCA|The medical dispatchers' perception of bystanders' responses and dispatchers' reflections about the added value of visual information in out-of-hospital cardiac arrests (OHCA) situations.
75625317|NCT04174456|Diagnostic Test|FDG PET|baseline and 6-month follow-up FDG PET
75625318|NCT02870166|Other|blood sample|
75625319|NCT02869308|Drug|stannous pyrophosphate|Injection of 1ml Angiocis
75625320|NCT02869308|Drug|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
75625321|NCT02869308|Device|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
75625322|NCT02869308|Device|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
75625323|NCT00910390|Other|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
75625324|NCT00910390|Other|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
75625325|NCT00910390|Other|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
75625326|NCT02869698|Procedure|Spectral Dynamic Imaging|
75625327|NCT02869698|Device|Hybride electrode|
75625328|NCT02869698|Device|Macro electrode|
75625329|NCT02665936|Drug|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
75625330|NCT02665936|Drug|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
75625331|NCT02665936|Drug|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
75625332|NCT04292262|Other|Observational|Observational
75625333|NCT02665858|Other|OCT Imaging|
75625334|NCT02869386|Procedure|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
75625335|NCT02869386|Procedure|Regular care|A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
75625336|NCT02665780|Procedure|Periodontal debridement|teeth cleaning
75625337|NCT02665780|Other|Cetylpyridium chloride|mouthrinse
75625338|NCT02869464|Other|Imaging-Ultrasound|Abdominal Ultrasound
75625339|NCT02869464|Other|Imaging-MRA|Non-contrast Enhanced Magnetic Resonance Angiogram
75625340|NCT02869464|Genetic|DNA, RNA testing|To test for the co-prevalence of shared genetic markers in afflicted populations.
75777898|NCT01089764|Behavioral|Couplelinks.ca website|Participation in the Couplelinks.ca program, an online intervention.
75625341|NCT00646360|Dietary Supplement|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
75625342|NCT00646360|Dietary Supplement|Placebo|2 tablets daily during pregnancy
76073844|NCT01986647|Behavioral|Standard program - exercise leader|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
75625343|NCT04293510|Procedure|renal biopsy and blood sampling|renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
75625344|NCT04174300|Procedure|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
75625345|NCT00995436|Device|Extraoral anchorage|Extra oral anchorage
75625346|NCT00995436|Device|Miniscrews|Intraoral skeletal anchorage using mini screws
75625347|NCT00995436|Device|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
75625348|NCT04173598|Behavioral|Cognitive Adaptation Training for Caregivers (CAT Famille)|Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
75777899|NCT01089842|Behavioral|Health coaching|Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.
75777900|NCT01089842|Other|Usual care|Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
75625349|NCT04173598|Behavioral|Usual Care|Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
75625350|NCT02667028|Procedure|PCI|percutaneous coronary intervention
75625351|NCT04292886|Drug|Tamoxifen and femoston|oral
75625352|NCT04292886|Drug|Vitamin C and femoston|Vitamin C and femoston
75625353|NCT02669134|Other|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
75777901|NCT03509350|Drug|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
75777902|NCT03509350|Drug|Thiamine|Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
75777903|NCT03509350|Drug|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
75777904|NCT03509350|Drug|Vitamin C Placebo|A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
76073845|NCT01986647|Behavioral|On the Move exercise - staff activity personnel|this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
75777905|NCT03509350|Drug|Thiamine Placebo|A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
75777906|NCT03509350|Drug|Hydrocortisone Placebo|A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
75777907|NCT01089920|Other|Green tea|Infusion (tea bags) from commercially available green tea
75777908|NCT01089920|Other|Coffee|Soluble coffee commercially available
75777909|NCT03956420|Behavioral|Premedication visit|detailed information about surgery, anaesthesia and postoperative period
75777910|NCT03956420|Dietary Supplement|Preoperative period|avoidance of prolonged fasting, intake of fluids with carbohydrates before surgery
75777911|NCT03956420|Drug|Preoperative period|administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
75777912|NCT03956420|Other|Postoperative period|Fluids 1 ml/kg/h; Discontinuation of propofol at the moment of drainage and cardiovascular system stabilization; Fluids administered orally 2 hours after extubation; Early mobilisation
75777913|NCT03956420|Other|Intraoperative period|deep temperature (necessity to maintain normothermia during the stay in the operating theatre 36 °C. Normothermia should be maintained rather than restored.
75914391|NCT05358509|Drug|Ferric Sulfate|Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
75625354|NCT04292418|Drug|Tacrolimus capsule , mycophenolic acid|measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
75777914|NCT03956420|Drug|Intraoperative period|Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
75777915|NCT03956420|Drug|Intraoperative period|Ketamine 30 mg i.v. after induction of anaesthesia
75777916|NCT03956420|Drug|Intraoperative period|Sevoflurane 1.5 MAC higher in patients < 60 years old
75777917|NCT03956420|Drug|Intraoperative period|Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
75777918|NCT03956420|Drug|Intraoperative period|Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
75777919|NCT03478696|Drug|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
75777920|NCT03478696|Drug|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
75777921|NCT03478696|Drug|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
75777922|NCT03478696|Drug|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
75777923|NCT03478696|Drug|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
75777924|NCT03478696|Drug|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
75777925|NCT03478696|Drug|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
75914392|NCT05354986|Other|Toothpaste with hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation (Dentaid, Barcelona, Spain) includes hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
76073846|NCT01986647|Behavioral|Standard program - staff activity personnel|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.
76073847|NCT03582657|Device|dental implant (KONTACT N)|Implant-supported prosthetic restoration
75625355|NCT02666716|Drug|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
75625356|NCT04292028|Other|Pilates|The Pilates group participated in an 8-week clinical Pilates training program
75625357|NCT04292028|Other|Home exercises|Control group were given a home-based exercise program.
75777926|NCT03478696|Device|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
75777927|NCT03478696|Device|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
75777928|NCT03478696|Device|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
75777929|NCT03719638|Device|D-blade of videolaryngoscope|intubation will be done using d-blade of videolaryngoscope
75777930|NCT03719638|Other|simulated difficult airway|extension of head will be limited by using collar.
75777931|NCT03719638|Device|Macintosh videolaryngoscope|intubation will be done using macintosh videolaryngoscope
75777932|NCT03477838|Device|FreeStyle LibrePro CGM|a professional CGM device will be worn by the participant for up to 14 days
75777933|NCT00072176|Drug|temsirolimus|Given IV
75777934|NCT00072176|Other|laboratory biomarker analysis|Correlative studies
75777935|NCT00071396|Drug|Campath-1H|15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
75777936|NCT00071396|Drug|Rituximab|375 mg/m^2 IV infusion on day 1, then 500 mg/m^2 on days 8, 15, and 22.
75777937|NCT03473236|Drug|GB002|Inhaled GB002
75777938|NCT03473236|Device|Generic Dry Powder Inhaler|dry powder inhaler used for inhalation of active drug or placebo
75777939|NCT03473236|Drug|Placebo|Inhaled placebo
75914393|NCT05354986|Other|Toothpaste without hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation without tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
75777940|NCT03550378|Drug|MEDI0382|Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
75777941|NCT03550378|Drug|Placebo|Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.
75777942|NCT05660590|Other|complex decongestive physiotherapy with low pressure compression bandage|both group received complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with low bandage interface pressure (20-30 mmHg)
75914394|NCT05348330|Procedure|Thoracic intervertebral foramen block|Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
75914395|NCT05348330|Procedure|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
75914396|NCT05343741|Other|Psychological Intervention|The CPA provides outpatient psychological services to individuals: children, adolescents and adults, couples and families. At the CPA, care is carried out through the co-therapy model, which involves the participation of a professional clinical psychologist and a trainee. Psychotherapists with diverse theoretical and clinical backgrounds (mainly psychodynamic, cognitive, systemic and integrative), but a common constructivist approach, work in the center. The following elements are transversal in their practice: therapeutic alliance, healing environment, and a collaborative procedure between the client, the psychotherapist and the trainee co-therapist.
75914397|NCT05336786|Drug|Perflutren Lipid Microspheres|Given IV
75625358|NCT04064476|Drug|Paliperidone Palmitate|This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.
75777943|NCT05660590|Other|complex decongestive physiotherapy with high pressure compression bandage|complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with high bandage interface pressure (45-55 mmHg)
76073848|NCT03585309|Procedure|The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:|"Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside."
76073849|NCT03585231|Behavioral|Immediate access to novel messaging program intervention|The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
76073850|NCT03585231|Behavioral|Immediate access to standard of care messaging program intervention|The immediate control intervention uses a standard of care messaging program for smoking cessation.
76073851|NCT03585231|Behavioral|Delayed access to novel novel messaging program intervention|The delayed control intervention uses the novel messaging program for smoking cessation.
76073852|NCT02002091|Other|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
75625359|NCT02869230|Procedure|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
75777944|NCT03639454|Procedure|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
76073853|NCT02926521|Device|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
76073854|NCT02926521|Device|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
75625360|NCT02869230|Procedure|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
75625361|NCT02669290|Other|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
75625362|NCT02669290|Other|Non-guided|LV lead placement will be conventional posterolateral placement
75625363|NCT02868840|Behavioral|Tai Chi exercise|exercise twice a week each for one hour
75625364|NCT02868840|Behavioral|symptom management|sending text message weekly to manage symptoms related to stroke
75777945|NCT03639454|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
75321569|NCT05094557|Behavioral|Experimental Group 1: Body swapping VR intervention + psychoeducational video + Treatment As usual|The patient will be embodied in his/her own avatar and will maintain a conversation with a counsellor's avatar of his/her choice. Once the experiment starts, the patient, embodied in his/her own body, will start describing his/her problem in terms of subjective experiences of being obese in daily life. Then, he/she will be body swapped to the counsellor's body and try to respond to the problem just manifested by the patient. The crucial aspect here is that the patient, from the counsellor's viewpoint, will see a representation of his/her real body when looking at the patient's avatar speaking and moving. Therefore, the patient will have the opportunity to see himself/herself in first person (1PP) and second person (2PP) perspectives.
75321570|NCT05094557|Behavioral|Experimental Group 2: VR intervention without body swapping + psychoeducational video + Treatment As usual|"Participants from the Experimental Group 2 will be embodied in their own body and will participate in pre-established discourse provided by the chosen counsellor, who will ask about the perceived barriers for engagement with a healthier lifestyle and will give practical recommendations about how to achieve a healthier and happier life, in terms of healthy eating and physical activity. No body swapping will take place for this group. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle."
75321571|NCT05094557|Behavioral|Control Group: Psychoeducational video + Treatment As usual|Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
75321572|NCT02987595|Other|Whole-grain rye, high lignan|Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day
75321573|NCT02987595|Other|Whole-grain wheat, low lignan|Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
75321574|NCT02993965|Other|Vaccine Reminder/Recall|The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.
75321575|NCT02476409|Drug|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
75321576|NCT02476409|Other|Placebo|Placebo for tolvaptan
75321577|NCT02993887|Behavioral|Resourcefulness Training|This intervention will include a one time face to face instruction on Resourcefulness Training that entails 8 self-help and help-seeking skills plus viewing short video vignettes of caregivers describing application of the resourcefulness skills. In addition, participants will use daily journaling to describe application of the resourcefulness skills in their daily caregiving with their technology-dependent child.
75321578|NCT02993887|Behavioral|Mindfulness|The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
75625365|NCT02669368|Drug|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
75625366|NCT02669368|Drug|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
75625367|NCT02669368|Drug|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
75625368|NCT02669368|Drug|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
75625369|NCT00645268|Drug|sildenafil|In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
75625370|NCT00645268|Drug|placebo|In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
75914398|NCT05336786|Procedure|Ultrasound|Undergo ultrasound
76073855|NCT03584997|Procedure|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
76073856|NCT03584997|Procedure|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
76073857|NCT01985321|Drug|ethanol/glycolic acid solution|ethanol/glycolic acid solution
76073858|NCT01985321|Drug|Placebo/Ethanol|ethanol solution
76073859|NCT03584919|Drug|doxycycline|patients received oral doxycycline 100 milgrams bid for 15 days
76073860|NCT03584919|Drug|Cefuroxime Axetil 500Mg Tab|patients received cefuroxime axetil 500 milgrams bid for 15 days
76073861|NCT03584919|Other|control subjects|no intervention
76073862|NCT03584841|Diagnostic Test|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
76073863|NCT02000921|Other|VLNC cigarettes|Modified risk tobacco product
75321579|NCT02999737|Biological|Platelet Rich Plasma for 4 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every month x 3 sessions then every 3 months x 1 session (total 4 sessions)
75914399|NCT05331521|Drug|CETEG|At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.
75914400|NCT05331521|Drug|PCV|In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).
75625371|NCT00645268|Drug|sildenafil|Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
75914401|NCT05331521|Radiation|RT|Radiotherapy at 50.4/54 Gy in 1.8 Gy fractions for grade II and 59.4 Gy in 1.8 Gy fractions for grade III gliomas
76073864|NCT02000921|Other|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
76073865|NCT02000921|Other|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
75321580|NCT02999737|Biological|Platelet rich plasma for 2 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every 3 months x 2 sessions (total 2 sessions)
76073866|NCT02000921|Other|CN cigarettes|Experimental cigarettes with conventional nicotine content.
75321581|NCT01884519|Biological|Fluarix/Influsplit SSW® (2013-2014 season)|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
75625372|NCT00646438|Drug|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
75625373|NCT02666014|Drug|Sugammadex|Reversal of neuromuscular blockade
75321582|NCT02468687|Drug|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
75777946|NCT03721588|Other|Clinical interviews, psychometric scales were applied.|
75321583|NCT02993653|Radiation|High-dose Intensity-modulated radiotherapy|Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
75321584|NCT01808937|Other|Morphea|
75625374|NCT02666014|Drug|Neostigmine|Reversal of neuromuscular blockade
75625375|NCT02665702|Drug|NVB|25mg/m2 ，D1，8
75625376|NCT02665702|Drug|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
75625377|NCT02665702|Drug|Endostar|15mg/d，d1-d7 civ
75625378|NCT04173676|Drug|Indocyanine Green for Injection|The sentinel lymph nodes were observed by submucosal injection of ICG
75777947|NCT03725254|Procedure|lymphadenectomy|The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.
75777948|NCT03725254|Radiation|chemoradiotherapy|Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).
75466770|NCT01912976|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
75777949|NCT03472534|Drug|diacerein 1% ointment|diacerein 1% ointment applied to the skin of the infrascapular area of the back under occlusive patch for 21 days.
75466771|NCT01912976|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
75466772|NCT01911663|Dietary Supplement|KRG|500 mg Korea red ginseng (KRG)
75777950|NCT03725020|Other|Fluoride varnish|The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
75777951|NCT03721432|Drug|Pregabalin 150mg|pregabalin 150 mg capsules (Lyrica®,Pfizer) given 60 minutes prior to epidural anesthesia
75914402|NCT05328700|Other|Kinesiotaping|Perform a neuromuscular bandage with kinesiotape in patients with plantar fasciitis
75914403|NCT05328700|Other|Tape|Perform a neuromuscular bandage with tape (Hipofix(R)) in patients with plantar fasciitis
76073867|NCT03584685|Device|Mask|All participants will initially be treated without the mask. In the next appointment, half will be treated with the mask.
76073868|NCT03584685|Procedure|Routine wound treatment|All participants will initially be treated for their wounds without the mask. In the next appointment, half will again be treated for their wounds without the mask.
76073869|NCT03587337|Other|POEM|Pt. are going to submit a POEM procedure.
76073870|NCT03586947|Drug|Vitamin D3 400 UNT Oral Capsule|50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
76073871|NCT04765215|Biological|CoronoVAC|SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
75914404|NCT05327933|Procedure|Surgery plus endovascular MMA embolization|A micro catheter is inserted transfemorally into the branches of the middle meningeal artery (MMA) in a minimally invasive manner and the periphery is occluded using polyvinyl alcohol (PVA) particles to prevent future bleeding. If the desired catheter position cannot be achieved due to the anatomical conditions, a more proximal closure of the MMA using Onyx® or micro-electric coils is performed. Embolization of the MMA by PVA particles with sizes between 40-300 µm is preferred over embolization by coils and Onyx®, since the capillary network of the dura is entirely blocked when using particles. In order to identify the vessels to be closed, a digital subtraction angiography (DSA) is performed.
75914405|NCT05327933|Procedure|Surgery alone|Evacuation of cSDH
75625379|NCT02665156|Procedure|Intracorporeal stapled neobladder using robotic staplers|"Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana."
75625380|NCT04173130|Device|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
75777952|NCT03721432|Drug|Placebo oral capsule|Placebo oral capsule given 60 minutes prior to epidural anesthesia
75777953|NCT03721354|Other|NAVA vs PSV - TCCD|"Patients will be submitted to 3 different 30 minutes ventilation trials: the first one in PSV mode, the second one in NAVA mode and the third one in PSV mode again. PSV will have PEEP setted by clinician and pressure support set in order to obtain Vt 6-8 ml/kg. NAVA will have the same PEEP as PSV and NAVA level will be set to obtain the same Peak of Inspiratory Pressure) of PSV.~Trans cranial doppler technique will be performed to evaluate the blood cerebral flow speed (average/systolic speed) at the end of every ventilation trial. At the end of each trial, ABGs will be performed. Traces of flow, airways pressure (Paw) and electric diaphragmatic activity (EAdi) will be recorded and acquired through a dedicated ventilator software called NAVA tracker."
75777954|NCT03639298|Device|Intendu|intensive training with Motion Based Cognitive Video Games Software
75625381|NCT04173286|Procedure|antibiotherapy|< 7 days
75625382|NCT00646750|Drug|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
75625383|NCT00646516|Drug|budesonide/formoterol (Symbicort)|
75625384|NCT04033198|Procedure|Appendectomy|patients diagnosed as acute appendicitis , appendectomy done
75625385|NCT02665624|Drug|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
75625386|NCT02665624|Drug|Senna alone|comparison of bowel cleansing and patient comfort.
75914406|NCT05327426|Biological|Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL) admixed with 0.47µg of recombinant double mutant [LT(R192G/L211A)] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant.
75914407|NCT05327426|Biological|Intradermal fractional dose inactivated polio vaccine (fIPV)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL).
75466773|NCT01911663|Dietary Supplement|Placebo|500 mg placebo
75466774|NCT01912989|Behavioral|Lifestyle counseling|Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
75466775|NCT01913002|Drug|LX4211 800 mg|
75466776|NCT01913002|Drug|LX4211 2000 mg|
75466777|NCT01913002|Drug|moxifloxacin 400 mg|
75466778|NCT01913002|Drug|LX4211 Placebo|
75625387|NCT05258266|Drug|ZX-101A|Q.D., oral dosing
75625388|NCT02668744|Behavioral|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
75625389|NCT02668900|Behavioral|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
75625390|NCT00910546|Device|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
75625391|NCT00646594|Drug|budesonide/formoterol (Symbicort)|
75625392|NCT00646594|Drug|fluticasone/salmeterol (Advair)|
75625393|NCT00646984|Drug|Standard continuous antiretroviral therapy|
75777955|NCT03724864|Dietary Supplement|delivery of snacks|Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
75466779|NCT01913015|Drug|abiraterone acetate|Given PO
75466780|NCT01913015|Dietary Supplement|dietary intervention|Receive low fat breakfast
75466781|NCT01913015|Dietary Supplement|dietary intervention|Receive high fat breakfast
75321585|NCT02429063|Other|Bright White Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
75321586|NCT02429063|Other|Dim Red Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
75625394|NCT00646984|Drug|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
75625395|NCT00646984|Drug|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
75625396|NCT00910468|Procedure|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
75625397|NCT04173052|Device|Testis' shocker|The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
75625398|NCT04172896|Procedure|Intraperitoneal Uterosacral Ligament Suspension|Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
75625399|NCT04172896|Procedure|Extraperitoneal Uterosacral Ligament Suspension|Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
75625400|NCT02665390|Procedure|Percutaneous cryoablation|Percutaneous cryoablation
75625401|NCT04172818|Behavioral|quality of life questionnaire|Since 10 years ago, diaries are used in intensive care unit to limit these symptoms after a coma.In analogy, the diary for patients with allogenic hematopoietic stem cell transplantation could be a mean to reduce the psychological adverse impact and long term consequences. The psychological impact of a diary on patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives will be evaluated.
75625402|NCT02668978|Device|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
75625403|NCT02668978|Procedure|Standard surgical technique|Lung resuturing or restapling
75625404|NCT00647140|Other|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
75625405|NCT04172428|Diagnostic Test|Functional MRI (fMRI)|fMRI will be done on 3 separate MRI scanners to compare.
75914408|NCT05327426|Biological|Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain|Monovalent oral polio vaccine (OPV) challenge administered as a test of mucosal immunity.
75914409|NCT05326776|Drug|Pitocin|At each session, 4mcg/2ml oxytocin or 2ml isotonic saline (0.9% sodium chloride; placebo control) will be injected into the middle of the dorsal forearm. Sessions will be separated by at least 48 hours to ensure drug clearance.
75914410|NCT05326646|Dietary Supplement|Low FODMAP diet|After the realisation of a wireless motility capsule, patients will underwent 6 weeks of low FODMAP diet after dietician education. Symptomatic scores (IBS-SSS, GIQLI, HAD) and stools samples (metabolomic and lipidomic) will be performed before and after the low FODMAP diet.
76073872|NCT03155763|Procedure|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
75321587|NCT02993809|Biological|BM-ECs and PRPE|
75625406|NCT00647218|Drug|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
75625407|NCT00647218|Drug|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
75625408|NCT00647218|Procedure|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
75625409|NCT00647218|Radiation|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
75625410|NCT00647218|Drug|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
75625411|NCT00994890|Drug|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
75625412|NCT00994890|Drug|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
75625413|NCT00994890|Drug|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
75914411|NCT05326399|Behavioral|renal biospy|Standard percutaneous biopsy has been performed in all participants. Modification of treatment will be jointly decided by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks.
75914412|NCT05323656|Drug|Setanaxib|Oral tablets, 400 mg per tablet
75914413|NCT05323656|Biological|Pembrolizumab|200 mg IV infusion
75914414|NCT05323656|Drug|Placebo|Oral tablets
75914415|NCT05322512|Drug|18F-FDG|All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
75914416|NCT05322356|Other|Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D|Target dose supplement with the TRINITY® PERINE 3D system
75914417|NCT05321043|Other|Vitamin B2 labeling|Using medical non-toxic fluorescent agents, VB2 solution, to mark the patient's hands before endoscopy examination.
75321588|NCT02993809|Biological|BM-ECs|
75625414|NCT02663830|Drug|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
75625415|NCT02663830|Drug|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
75625416|NCT00910702|Device|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
75625417|NCT02665078|Other|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
75625418|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablet
75625419|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablets
75625420|NCT00645346|Biological|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
75625421|NCT00645346|Biological|Placebo|Subjects will receive one dose of placebo
75625422|NCT00647374|Other|this is an observational study|
75625423|NCT04175314|Other|Clinical examination of gingival tissues|Measure of the periodontal recession
75625424|NCT00648622|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
75625425|NCT00648622|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
75625426|NCT00994422|Drug|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
75625427|NCT00994422|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
75625428|NCT00647452|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
75625429|NCT00648700|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
75625430|NCT00648700|Drug|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
75625431|NCT04172662|Behavioral|Facilitated Music Listening|The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
75625432|NCT00648778|Drug|Loxapine Succinate Capsules 25 mg|25mg, single dose fasting
75625433|NCT00648778|Drug|Loxitane® Capsules 25 mg|25mg, single dose fasting
75625434|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
75914418|NCT05320822|Other|Active Rehab (Group 2)|"The Active Rehab protocol builds off of initial chief complaints and duty profile and addresses symptom control followed by a progressive and prescribed integration of activities to full return to duty that should be integrated with the current PRA TBICoE protocols. The specific activity areas in the intervention include low-intensity aerobic exercise that does not exacerbate symptoms, cognition, balance, visual/vestibular, and comfort/ general well-being.~Participants can be progressed daily according to symptom limitations. At least 3-4 sessions each week are recommended based on a trial of sport-related mTBI and other interventions of this type concerning mTBI/concussion. During each phase, low level aerobic exercise that does not significantly exacerbate symptoms, such as nature walks, will be recommended. The additional activity types that may be chosen include cognitive, balance, visual/vestibular, and comfort/general well-being."
75321589|NCT01886235|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
75321590|NCT01886235|Drug|Fluorescein Sodium Injection|Given IV
75625435|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
75914419|NCT05320822|Other|Progressive Return to Activity (Group 1)|Participant will be asked to use symptoms to guide activity from the time of the injury until participant is asymptomatic. Once asymptomatic, participant will begin the PRA TBICoE clinical recommendation. During this time clinicians will document activities in each stage in addition to initial symptom checklist, stage of PRA CoE progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
75625436|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
75625437|NCT04172740|Device|Radiesse (calcium hydroxylpatite)|"RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy)."
75321591|NCT01886235|Other|Laboratory Biomarker Analysis|Correlative studies
75321592|NCT01886235|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75466782|NCT01913015|Other|pharmacological study|Correlative studies
75466783|NCT01913015|Other|questionnaire administration|Ancillary studies
75466784|NCT01913015|Other|laboratory biomarker analysis|Correlative studies
75466785|NCT01913028|Drug|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
75466786|NCT01913028|Drug|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
75466787|NCT01913054|Drug|Fentanyl Injection|
75466788|NCT01913054|Drug|Etomidate Fat Emulsion Injection|
75466789|NCT01913054|Drug|Propofol Injection|
75777956|NCT03549130|Device|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
75777957|NCT03549130|Other|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
75777958|NCT03470194|Other|Interpretation Modality: In Person|Use of In-Person interpretation support for LEP participant during clinical appointment
75625438|NCT04172350|Other|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
75777959|NCT03470194|Other|Interpretation Modality: Telephonic|Use of telephonic interpretation support for LEP participant during clinical appointment
75777960|NCT03724786|Diagnostic Test|Six-hour urine protein collection|This intervention includes the analysis of a 6-hour urine collection for protein, to serve for a calculated 24-hour result, according to which pregnancy will be managed.
75777961|NCT03469336|Drug|PF-06763809|Three different concentrations will be administered to three different treatment fields: 2.3%, 0.8% and 0.23%
75777962|NCT03469336|Other|Vehicle|Vehicle matching PF-06763809.
76073873|NCT03155529|Procedure|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
76073874|NCT04764981|Other|Essence oils|Consists in olfactory training using essence oils
75625439|NCT04172350|Other|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
75625440|NCT02664844|Behavioral|Physical activity|
75625441|NCT02665000|Procedure|Structured training programme|Participants will undergo 5-days training sessions
75625442|NCT02663596|Drug|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
75625443|NCT04171336|Behavioral|Animal-assisted therapy|Six sessions of animal-assisted intervention for children and adolescents, group format. The sessions will focus on psycho-education on pain, mindfulness, defocusing, getting active, and resources. Additionally, the intervention includes two family visits.
75625444|NCT00647530|Biological|panitumumab|
75321593|NCT02993575|Drug|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
75321594|NCT02999581|Dietary Supplement|C4 Extreme, C4 Extreme (without Advantra Z)|
75321595|NCT02993497|Device|Infrared camera|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an Infrared camera.
75625445|NCT00647530|Drug|capecitabine|
75625446|NCT00647530|Drug|fluorouracil|
75625447|NCT00647530|Drug|oxaliplatin|
75777963|NCT03469336|Drug|Calcipotriene/calcipotriol|Calcipotriene/calcipotriol 50 ug/mL solution
75321596|NCT02993497|Device|RVM(Respiratory Volume Monitor)|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an RVM(Respiratory Volume Monitor).
75625448|NCT00647608|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
75625449|NCT00647608|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fed
75625450|NCT02663440|Radiation|Hypofractionated IMRT|Hypofractionated IMRT
75625451|NCT02663440|Biological|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
75625452|NCT02663440|Drug|Temozolomide|Temozolomide
75625453|NCT04171180|Drug|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
75625454|NCT02660008|Drug|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
75321597|NCT05010941|Device|Hypotension Prediction Index|Hypotension Prediction Index monitored via radial arterial line
75466790|NCT01913067|Drug|Cabazitaxel|Intravenous, 25 mg/m2 every 3 weeks
75466791|NCT01913067|Procedure|Contrast-enhanced whole brain MRI|Evaluation of the volumetric reduction in the size of the brain lesion(s).
75777964|NCT03469336|Drug|Betamethasone|Betamethasone 1 mg/g solution
75777965|NCT03719560|Drug|Methotrexate|Systemic methotrexate
75777966|NCT03719560|Drug|Cytarabine|Systemic cytarabine
75777967|NCT03469258|Drug|Pancrelipase|Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.
75777968|NCT03503188|Device|Littmann ®|electronic stethoscope
75777969|NCT03502798|Device|scanning a/LCI|Imaging of the cervical epithelium using the scanning a/LCI device.
75777970|NCT03719482|Drug|[18F]MNI-1054|Healthy Volunteers recruited for the study will undergo a single [18F]MNI-1054 injection and PET scan.
75777971|NCT03724708|Device|IUD|IUD insertion
76073875|NCT03584451|Behavioral|rehabilitation sport|rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
76073876|NCT03584529|Drug|Vitamin D 3|Non-Vitamin D3 Drops group Patients in this group would take nothing.
75777972|NCT03639220|Device|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
75777973|NCT00066170|Drug|Xyrem|Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.
75625455|NCT02660008|Drug|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
75777974|NCT00066170|Drug|Xyrem Placebo|Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
75777975|NCT00066170|Drug|Modafinil at established dose|Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.
75777976|NCT00066170|Drug|Modafinil (Placebo)|Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
75777977|NCT03957122|Device|repetitive transcranial magnetic stimulation|"Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~2000 pulses~intensity of 110% resting motor threshold~10 sessions (daily from Monday to Friday)~positioning of coil according to EEG position CP5/CP6"
75777978|NCT01094054|Procedure|Adjustable gastric banding|Placement of adjustable gastric band - laparoscopically
75777979|NCT01094054|Behavioral|Dietary and lifestyle modification|"Dietary and lifestyle modification~Subjects will meet with a dietitian and a psychologist on a weekly basis and consume a diet matched to that of the banding arm"
75777980|NCT03741218|Other|Freeze-dried grape (GRAP)/Placebo (PLA)|The subjects will receive, after overnight fasting, either a monodose of freeze-dried grapes (equivalent to 300 g of fresh grapes) or isocaloric placebo solved in water, together with a high-fat breakfast. Blood samples will be collected before the intake, up to 5 h after breakfast, then a medium-fat lunch will be provided and blood samples will be collected for three additional hours. A total of 10 samples will be collected: 0-30-60-120-180-240-300-330-360-420 min. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
75777981|NCT00065468|Drug|Interferon Alfa|Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
76073877|NCT00724984|Drug|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
75625456|NCT02664766|Behavioral|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
75466792|NCT01913080|Other|Health Log|"The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:~Personal information and emergency contact(s)~Physician names and contact information~Insurance information~Medications, vitamins and supplements~Surgeries~Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.~The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed."
75625457|NCT02664688|Other|Lumbar stabilization exercises|"The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)"
75625458|NCT02664688|Other|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
75625459|NCT00649168|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
75625460|NCT00649168|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
75625461|NCT02659774|Behavioral|workshop (Motivational intervention)|Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
75777982|NCT00065468|Drug|CCI-779|25 mg of CCI-779 given Intra Venously once per week
75777983|NCT00065468|Drug|Interferon Alfa and CCI-779|15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
75625462|NCT02659774|Behavioral|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
75625463|NCT02659774|Behavioral|Face to Face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
75625464|NCT02659774|Behavioral|Phone counseling|Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
75777984|NCT00071006|Drug|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
75777985|NCT00094575|Procedure|Endovascular Repair|Endovascular Repair
75777986|NCT00094575|Procedure|Standard Open Repair|Standard Open Repair
75466793|NCT01913106|Drug|HSV-tk +Valacyclovir in Combination with Brachytherapy|"The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein."
75466794|NCT01913119|Drug|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
75625465|NCT02659774|Behavioral|SMS|Use motivational interview strategies through telephone messages to provide smoking cessation intervention
75625466|NCT02659774|Behavioral|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
75625467|NCT02663206|Procedure|peroral endoscopic myotomy|peroral endoscopic myotomy
75625468|NCT02663206|Procedure|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
75625469|NCT02663284|Drug|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
75625470|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
75625471|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h|single application
75625472|NCT04172272|Drug|Systemic multimodal analgesia administered intravenously|"Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
75625473|NCT04172272|Procedure|Transversus abdominis plane block (TAP block)|"The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacin in 40 ml bilaterally. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
75625474|NCT04172272|Other|Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously|TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
75625475|NCT02663050|Other|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
75625476|NCT02663050|Drug|NSAID's|twice a daily
75625477|NCT00648856|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
75625478|NCT00648856|Drug|Zoloft® Tablets 100 mg|100mg, single dose fed
75625479|NCT01171976|Drug|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
75625480|NCT00996216|Drug|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
75625481|NCT00996216|Drug|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
75466795|NCT01913145|Device|A1c, Self-collection, Blood sample|This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
75466796|NCT01913171|Other|Exercise|
75466797|NCT01913184|Device|AKITA|
75466798|NCT01913197|Other|An MRI-based technique to identify prostate cancer|
75625482|NCT00647764|Drug|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
75625483|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
75625484|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h|single application
75625485|NCT02662972|Drug|Botulinum Toxin Type A|
75625486|NCT04291716|Device|Motor Seizure Detection Algorithm (mSDA)|A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
75625487|NCT02662894|Drug|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
75625488|NCT02662894|Drug|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
75625489|NCT02662894|Drug|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
75625490|NCT02662894|Drug|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
75625491|NCT04291794|Drug|Propofol|2mg/kg single bolus
75625492|NCT04291794|Drug|Propofol Injection [Diprivan]|Tritiated Target-Controlled Infusion
75777987|NCT01089998|Drug|BAY86-9596|Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine
75777988|NCT01089998|Drug|BAY86-9596|Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
75625493|NCT02662660|Drug|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
75625494|NCT02662660|Drug|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
75625495|NCT02662660|Drug|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
75625496|NCT00628992|Other|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
75625497|NCT00628992|Other|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
75625498|NCT00628992|Other|Cycloergometer training|Muscular rehabilitation of the leg
75625499|NCT00628992|Other|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
75625500|NCT02868606|Other|Physiologic Insulin Therapy|
75625501|NCT02868606|Other|Sliding-Scale Insulin Therapy|
75625502|NCT02659852|Procedure|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
75625503|NCT02659852|Procedure|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
75625504|NCT02662738|Dietary Supplement|Natural fruit extract|
75625505|NCT02662738|Other|Placebo|
75625506|NCT02662738|Other|Glucose solution|
75625507|NCT00647920|Biological|adalimumab|40 mg adalimumab sc, every other week
75625508|NCT00647920|Biological|placebo|placebo sc, every other week
75625509|NCT02664454|Other|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care"
75625510|NCT04172116|Device|Continuous glucose monitoring|see arm/group descriptions
75625511|NCT02662816|Device|Proton magnetic resonance spectroscopy (1H MRS)|
75625512|NCT02662816|Other|a protein rich breakfast at home|
75625513|NCT02662816|Other|a protein rich lunch at the Clinical Investigation Center|
75777989|NCT01089998|Drug|BAY86-9596|Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
75777990|NCT01089998|Drug|Fludeoxyglucose (18F)-IBA|Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
75777991|NCT00057746|Radiation|Prophylactic cranial irradiation, 2.5 Gy fx|Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
75777992|NCT00057746|Radiation|Prophylactic cranial irradiation, 2.0 Gy fx|Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
75625514|NCT00830869|Drug|IXAZOMIB|"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
75625515|NCT02662504|Device|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
75625516|NCT02662504|Procedure|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
75625517|NCT02662504|Drug|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
75777993|NCT00057746|Radiation|Prophylactic cranial irradiation, 1.5 Gy fx|Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
75798473|NCT01172574|Other|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
75798474|NCT01172652|Drug|Ziprasidone|The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
75798475|NCT01172652|Drug|Placebo|Inactive control
75625518|NCT04061902|Other|Participation with enhanced patient perioperative information|Improved information and dialogue about the care goals in the fast track protocol.
75625519|NCT00648934|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
75625520|NCT00648934|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
75625521|NCT04170868|Other|ADHD Psycheducation|The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
75625522|NCT02659228|Device|EEG recording|EEG recording with anesthetic (DIPRIVAN)
75798476|NCT01278732|Other|no intervention performed|no intervention is performed
75466799|NCT01913210|Dietary Supplement|Ginseng|
75466800|NCT01913223|Device|Nestis® jet injector system with a bi-functional catheter|
75466801|NCT01913236|Other|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
75914420|NCT05317663|Behavioral|Test Health Warning Label (HWL)|Effect of Health Warning Label (HWL)
75625523|NCT02659228|Drug|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
75914421|NCT05317663|Behavioral|Test without Health Warning Label (no-HWL)|Effect of no Health Warning Label (no-HWL)
75777994|NCT01094132|Device|Multispectral Digital Colposcope (MDC)|"The MDC has 2 components: an optical probe & a multispectral colposcope. The optical wand makes use of fluorescence & reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer & healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence & polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.~This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.~All study subjects will receive this same intervention."
75914422|NCT05310721|Behavioral|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
75914423|NCT05310721|Behavioral|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
75914424|NCT05310721|Behavioral|Self-selected time-restricted eating|Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
75914425|NCT05306353|Drug|Placebo for VIB4920|26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)
75914426|NCT05306353|Drug|VIB4920 with TNFi|52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)
75914427|NCT05306353|Drug|VIB4920 without TNFi|Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
76073878|NCT03583983|Behavioral|Personalized Health Recommendations|Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).
76073879|NCT03583983|Behavioral|Generic Health Recommendations|Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
76073880|NCT05703165|Behavioral|animal-assisted intervention|horse-assisted intervention
76073881|NCT05703165|Behavioral|watching the countryside|just watching the countryside
76073882|NCT03589287|Biological|Chondrochymal®|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
76073883|NCT03113253|Drug|Tranexamic Acid|
76073884|NCT03113253|Drug|Placebo|0.9% sodium chloride to mimic tranexamic acid
76073885|NCT03020277|Other|Ecological Momentary Assessment with Smartphone© Application|Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
75625524|NCT00844519|Drug|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
75625525|NCT00844519|Drug|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
75625526|NCT02664376|Other|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~Walking speed measurement~Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected."
75625527|NCT02659462|Other|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
75625528|NCT00702793|Drug|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
75625529|NCT04170166|Procedure|Anterolateral subacromial steroid injection|Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
75625530|NCT04170166|Procedure|Posterior subacromial steroid injection|Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach
76073886|NCT02800317|Procedure|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
75777995|NCT03960398|Drug|Iatrogenic disease impact on emergency consultations|Determination of the proportion of emergency consultations linked to iatrogenic diseases
75777996|NCT01090232|Other|blood samples|
75625531|NCT01171820|Device|TAXUS® Liberté™|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
75625532|NCT01171820|Device|XIENCE V® EECSS|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
75777997|NCT01090232|Other|blood samples|
75625533|NCT02658916|Drug|BIIB092|Same dose as corresponding CN002003 study panel.
75625534|NCT05518747|Dietary Supplement|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for a period of 12 weeks.
75625535|NCT05518747|Dietary Supplement|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 12 weeks.
75625536|NCT02662426|Drug|Lingdancao granules|4 packs per time (3g/pack), three times per day
75466802|NCT01913249|Procedure|LIFT|Ligation of intersphincteric fistula tract
75466803|NCT01913262|Behavioral|Standard Behavioral treatment|Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
75625537|NCT02662426|Drug|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
75625538|NCT02662426|Drug|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
75625539|NCT02662426|Drug|analogous Lingdancao granules|4 packs per time, three times per day
75777998|NCT00094107|Drug|Axitinib [AG-013736]|VEGFR [vascular endothelial growth factor Receptor] and PDGFR [Platelet-Derived Growth Factor Receptor] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
75777999|NCT00102063|Drug|Aripiprazole tablet, 10 mg|Aripiprazole tablet 10 mg po qd x 42 days
75778000|NCT00102063|Drug|Aripiprazole tablet, 30 mg|Aripiprazole tablet 30 mg po qd x 42 days
75778001|NCT00102063|Drug|Placebo tablet|Placebo tablet po qd x 42 days
75778002|NCT00065156|Drug|lenalidomide|10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
75778003|NCT01092026|Other|cord blood transplantation|One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
75778004|NCT01094210|Drug|Fluorides, Topical|500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
75466804|NCT01913275|Procedure|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
75625540|NCT00994110|Drug|Pasireotide (SOM230)|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
75625541|NCT00994110|Other|placebo|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
75778005|NCT01094366|Procedure|Paracervical Block|Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.
75778006|NCT01094366|Procedure|Sham Paracervical Block|In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
75778007|NCT01327040|Other|light exposure|12-hour light exposure of approximately 200 lux
75778008|NCT01094444|Other|Vitamin K3|Lotion containing 1.5 mM Vitamin K3
75778009|NCT00064298|Dietary Supplement|fruit and vegetable extracts|Given orally
75778010|NCT00064298|Dietary Supplement|placebo|Given orally
75778011|NCT00078819|Drug|Etanercept|Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week
75778012|NCT00078819|Drug|Placebo|Placebo matching to etanercept administered by subcutaneous injection once a week
75778013|NCT01088607|Drug|ursodeoxycholic acid (UDCA)|Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
75778014|NCT01583205|Behavioral|Coping Effectiveness Training - ALS|Eight coping effectiveness training counseling sessions.
75778015|NCT03961191|Diagnostic Test|DNA methylation|DNA methylation for the cervical cytology
75466805|NCT01913275|Procedure|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
75466806|NCT01913288|Other|Biological Maternal Sounds|
75466807|NCT01913301|Drug|Alagebrium|
75466808|NCT01913366|Behavioral|CM-PST|
75466809|NCT01913366|Behavioral|SG-PST|
75466810|NCT01913379|Drug|MDV3100|Oral
75466811|NCT01913379|Drug|Gemfibrozil|Oral
75625542|NCT04315376|Behavioral|Exercise-Diet Intervention|The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
75625543|NCT04315376|Behavioral|Diet Intervention|This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
75625544|NCT02662348|Drug|Recombinant Human Interleukin-2|Given SC
75625545|NCT02662348|Drug|HER2Bi-Armed T Cells|Given IV
75625546|NCT02868372|Drug|Povidone iodine|After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
75625547|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
75625548|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
75625549|NCT02662192|Other|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
75625550|NCT02662192|Other|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
75625551|NCT00993954|Procedure|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
75625552|NCT02662114|Other|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
75625553|NCT01157234|Drug|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of < 140/ 90.
75625554|NCT01157234|Drug|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure < 140/90.
75625555|NCT04170712|Other|Tampons|Collection of tampons, blood, cervical swabs, tissue and ascites
75625556|NCT02661802|Other|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
75625557|NCT00991302|Behavioral|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
75625558|NCT04170790|Drug|Saxagliptin 5mg|Saxagliptin 5mg oral tablet
75625559|NCT04170790|Drug|Sildenafil 50 mg|Sildenafil 50 mg Oral Tablet
75625560|NCT02661958|Drug|S6G5T-3|once a day topical cream
75625561|NCT02661958|Drug|S6G5T-1|once a day topical cream
75625562|NCT02661958|Drug|S6G5T-5|once a day topical cream
75625563|NCT02661958|Drug|S6G5T-6|once a day topical cream
75625564|NCT02661958|Drug|S6G5T-7|once a day topical cream
75625565|NCT02661958|Drug|S6G5T-8|once a day topical cream
75625566|NCT04291872|Other|Glass -Ionomer Cement with /without Led Light Cure|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
75778016|NCT03961191|Diagnostic Test|high-risk HPV|High-risk HPV testing for the cervical cytology
75778017|NCT03961191|Diagnostic Test|TCT|Thin prep liquid-based cytology test for the cervical cytology
75778018|NCT00098865|Drug|temozolomide|The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.
75778019|NCT00098865|Drug|thalidomide|Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
75625567|NCT04171648|Other|Roasted Peanut Treatment|The subjects will consume 2 ounces or ~48 grams of roasted in shell peanuts a day for two weeks.
75625568|NCT04171648|Other|Boiled Peanut Treatment|The subjects will consume 2 ounces or ~48 grams of boiled peanuts a day for two weeks.
75625569|NCT00995670|Drug|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
75625570|NCT00995670|Drug|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
75625571|NCT00995670|Drug|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
75625572|NCT00995670|Drug|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
75625573|NCT02661724|Behavioral|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
75625574|NCT02658838|Drug|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
75625575|NCT02658838|Drug|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
75778020|NCT01084863|Drug|CT-P6|CT-P6: administered every 3 weeks
75625576|NCT02658838|Drug|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
75625577|NCT02658838|Drug|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
75625578|NCT04293588|Diagnostic Test|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
75625579|NCT02536534|Other|Correlation assessment|
75625580|NCT00648076|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
75625581|NCT00648076|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fed
75625582|NCT02868294|Device|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
75625583|NCT02869152|Other|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
75625584|NCT02869152|Other|Endoscopic injection of ICG|Dye injection around the rectal tumor for SLN mapping with NIR imaging.
75625585|NCT02869152|Other|Endoscopic injection of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
75625586|NCT02869152|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
75625587|NCT02869152|Procedure|Endoscopic NIR imaging and gamma probe|Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
75625588|NCT02869152|Procedure|Dissection of sentinel lymph node(s)|Surgical removal of identified lymph nodes in the rectum.
75625589|NCT00629070|Other|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
75625590|NCT00629070|Other|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
75625591|NCT00649012|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
75625592|NCT00649012|Drug|Actos® Tablets 45 mg|45mg, single dose fed
75625593|NCT02869542|Other|Data collection|
75625594|NCT04293432|Drug|Drugs, Generic|All drugs having ≥10 TdP cases reported in the FAERS database
75625595|NCT02661334|Dietary Supplement|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
75625596|NCT02661334|Dietary Supplement|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
75625597|NCT04274712|Diagnostic Test|INNOGRAFT Heart Suite|Liquid biopsy to identify acute rejection
75625598|NCT04291248|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
75625599|NCT04291248|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
75625600|NCT04170088|Drug|Tranexamic Acid|Tranexamic acid intradermal injections were used for treatment of melasma
75778021|NCT01084863|Drug|Herceptin|Herceptin: administered every 3 weeks
75625601|NCT04170088|Drug|0.9% Normal Saline|Normal saline used for comparision of efficacy of tranexamic acid
75625602|NCT02867670|Device|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
75321598|NCT02993419|Drug|Bacillus licheniformis Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
75625603|NCT00648154|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
75625604|NCT00648154|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fed
75625605|NCT02869074|Genetic|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
75625606|NCT02664142|Procedure|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
75778022|NCT01084863|Drug|Paclitaxel|Paclitaxel: administered every 3 weeks
75778023|NCT01081587|Procedure|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
75625607|NCT02664142|Procedure|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
75466812|NCT01913379|Drug|Itraconazole|Oral
75466813|NCT01913392|Procedure|laparoscopic sleeve gastrectomy|
75466814|NCT01913418|Drug|Suan-Zao-Ren Tang|SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
75466815|NCT01913418|Drug|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
75466816|NCT01913431|Drug|Baracle Tab.®|
75625608|NCT02664142|Drug|Anaesthetics|Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
75798477|NCT03867630|Procedure|Transforaminal Block|Epidural block via neural foramen of lumbar spine
75798478|NCT02526030|Drug|Aripiprazole|
75914428|NCT05304507|Behavioral|I-PROTECT model|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application specifically developed for the I-PROTECT project (the I-PROTECT GO), including coach, player, club administrator, and caregiver modules. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Players will have support for conducting exercises on their own, and club administrators for developing an implementation strategy. Caregivers will have tailored information about injury prevention training.
76073887|NCT02753751|Other|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
76073888|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
76073889|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
75321599|NCT02993419|Other|placebo Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
75321600|NCT01798433|Device|One stent technique alone|One stent technique alone with drug-eluting stent
75321601|NCT01798433|Device|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
75321602|NCT01798433|Procedure|Provisional approach|Provisional approach with drung-eluting stents
75466817|NCT01913431|Drug|Baraclude Tab.®|
75466818|NCT01913444|Drug|Recombinant Antithrombin|
75625609|NCT04291638|Behavioral|Remote Caregiver Training|The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.
75625610|NCT04291638|Behavioral|Remote Intensive Group Behavioral Treatment (IGBT)|The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
75778024|NCT01081587|Behavioral|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
75778025|NCT01081587|Other|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
75778026|NCT02954458|Drug|TED|0.05 mg/kg SC injection once daily.
75778027|NCT02954458|Other|SOC|Standard safety assessments and adjustments in nutritional support.
75778028|NCT02954458|Device|Syringe|Teduglutide will be administered using syringe.
75778029|NCT02954458|Device|Needle|Teduglutide will be administered using needle.
75778030|NCT03719404|Procedure|sodium hypochlorite|sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
76073890|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
76073891|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
75466819|NCT01913496|Other|ebalance|using the ebalance application for 14 weeks
75778031|NCT03719404|Procedure|chlorhexidine|Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
75321603|NCT01798433|Device|Elective 2-stent|Elective 2-stent with drug-eluting stents
75321604|NCT00602953|Other|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
75321605|NCT01998191|Other|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
75466820|NCT01913509|Device|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
75625611|NCT02664064|Behavioral|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
75625612|NCT04291482|Behavioral|Choosing Health Intervention|The intervention consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention, basic information on healthy eating and behaviour change and tables allowing self-monitoring of weight, physical activity and eating (i.e., brief food diary). The book is non-tailored and it has weekly tasks for the participants to complete during 26 weeks (initial 6 months) to support their weight loss. The intervention group will also receive a series of daily text messages and weekly email messages supporting their weight loss and promoting weight loss maintenance. In phase I (month 0-3), the messages and emails will be generic and factual; in the phase II of the intervention, participants will receive text messages and emails tailored to the strongest predictors of outcomes identified in phase I.
75778032|NCT03500224|Drug|[14C]-TAK-954|[14C]-TAK-954 intravenous infusion.
75798479|NCT02526030|Drug|Quetiapine|
75778033|NCT03721198|Combination Product|Acidulated phosphorous flouride|Acidulated phosphorous flouride is used to prevent white spot lesions
75778034|NCT03721198|Other|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish is used to prevent white spot lesions
75778035|NCT04868734|Behavioral|Supportive Psychotherapy|Supportive Psychotherapy give to patient with Acute Coronary Syndrome
75778036|NCT03720886|Biological|rhPTH（1-34） 28.2μg|Administered by subcutaneous injection
75625613|NCT04291482|Behavioral|Choosing Health Control|The control consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention and basic information on healthy eating and physical activity. The control group will also receive monthly email messages with generic and factual information.
75625614|NCT04169854|Drug|Lidocaine 5% patch|The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
75778037|NCT03720886|Biological|rhPTH（1-34） 56.5μg|Administered by subcutaneous injection
75321606|NCT01998191|Other|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
75321607|NCT01998191|Other|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
75625615|NCT04169854|Drug|Placebo patch|The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
75778038|NCT03720886|Biological|teriparatide acetate(Teribone™)|Administered by subcutaneous injection
75778039|NCT03720808|Other|Balloon Blowing|The parents of the children in this group were asked whether their children had the latex allergy or not and the children without the allergy were included in the group. The children's skills of blowing balloon were observed before the procedure. Before starting the venous blood sampling procedure, the children were asked to choose a balloon in the color they preferred and to start blowing the balloon at least 20 seconds before the procedure. Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
75778040|NCT03720808|Other|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
75778041|NCT03720808|Other|Coughing|The children included in this group were asked to cough after taking a deep breath during the venous blood sampling procedure. Before the procedure, the researcher showed the children how they should cough and asked them to imitate. The venous blood sampling was not performed until the child successfully completed coughing. The child was directed by the researcher during the procedure. Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
75778042|NCT03720808|Other|Control|No intervention was performed to reduce pain and fear in the control group.
76073892|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
76073893|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
75778043|NCT03720496|Biological|CD19-TriCAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10^6 CAR+ T cells/kg body weight.
75778044|NCT00077649|Drug|ribavirin [Copegus]|600mg po bid for 48 weeks
75778045|NCT00077649|Drug|ribavirin [Copegus]|800mg po bid for 48 weeks
75778046|NCT00077649|Drug|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|180 micrograms sc weekly for 48 weeks
76073894|NCT03020121|Procedure|Colposcopy/biopsy|Colposcopy/biopsy will be performed on all subjects
76073895|NCT01275196|Drug|Nilotinib|
75321608|NCT02329587|Other|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
75466821|NCT01913509|Device|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
75466822|NCT01913522|Procedure|Pulmonary Vein Isolation|
75466823|NCT01913561|Device|Master Caution Garment|"Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.~The electrodes are dry, textile ECG electrodes."
75466824|NCT01913561|Device|ECG gel electrodes|Standard gel electrodes that are been in use in hospital for ECG monitoring.
75466825|NCT01913613|Device|IASD|IASD device implantation
75466826|NCT01913626|Behavioral|cognitive group therapy|the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
75778047|NCT00077649|Drug|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|270 micrograms sc weekly for 48 weeks
75778048|NCT03494374|Device|UCBL orthosis|toe walking exercise
75778049|NCT00038948|Drug|Sirolimus|Sirolimus, Cyclosporine A & Tacrolimus are concentration controlled
76073896|NCT01275196|Drug|Imatinib|
76073897|NCT03584139|Device|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
75466827|NCT01913652|Drug|Cabazitaxel|
75466828|NCT01913665|Other|B.lactis|
75466829|NCT01913665|Other|Inulin|
75466830|NCT01913665|Other|B.Lactis +Inulin|
75466831|NCT01913665|Other|Placebo|
75778050|NCT00038948|Drug|tacrolimus|
75778051|NCT00038948|Drug|Cyclosporine A|
75778052|NCT03953378|Other|Multi-parametric Flow Cytometry analysis on patients and healthy donors samples|"Collection of venous blood (16 mL) and synovial fluid (when available) samples, for each patient, at inclusion and in the frame of the usual medical follow-up at 3 months and between 6 and 12 months, before the onset of MTX (untreated patients) or during the course of MTX treatment (MTX-treated patients).~Collection of anonymous healthy donors blood samples, age- and sex-matched, obtained from the Etablissement Français du Sang.~Multi-parametric Flow Cytometry analysis was performed on these samples to assess CD73 expression on total memory T cells and within T helper lymphocyte subsets, their cytokine production and AMPase functions. For FoxP3 intracellular staining, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life Technologies), according to manufacturer instructions. Stainings were analyzed on a LSR-Fortessa™ (BD Biosciences) with conserved settings throughout the entire study and data were analyzed using FlowJo™ Software (Tree Star v10.4)."
75914429|NCT05304507|Behavioral|Control group|"Youth coaches in the control group club will be asked to use injury prevention training available in the coach education material (Ready for handball), i.e., current practice in Sweden."
75914430|NCT05300711|Procedure|Bilateral salpingectomy|Removal of both fallopian tubes.
75914431|NCT05300711|Procedure|Colorectal surgery|Colorectal surgery as indicated by attending surgeon.
75914432|NCT05298319|Device|high flow nasal cannula|The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.
75914433|NCT05295875|Drug|ALT-801|Injected subcutaneously (SC)
75914434|NCT05295875|Other|Placebo|Injected subcutaneously (SC)
75914435|NCT05295810|Drug|Sequential Gas Delivery|Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
75914436|NCT05295225|Device|Green Light Emitting Diode|GLED exposure for two hours
75914437|NCT05295225|Device|White Light Emitting Diode|WLED exposure for two hours
75914438|NCT05289869|Drug|High-dose oxytocin|Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
75914439|NCT05289869|Drug|Low-dose oxytocin|Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
76073898|NCT03584139|Device|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
75798480|NCT02526030|Drug|Ziprasidone|
76073899|NCT03152643|Procedure|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
75321609|NCT02329587|Other|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
75914440|NCT05289804|Device|NITESGON|"NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain."
75914441|NCT05289804|Drug|Lidocaine / Prilocaine Topical Cream|A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.
75914442|NCT05289804|Device|C5/C6 stimulation|The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.
75321610|NCT02999503|Behavioral|Nutritional education|Nutritional education trough a personal online nutritional consultant
75321611|NCT00603187|Drug|Acyline|20 mg GIPET enhanced oral dose, daily for 7-days
75914443|NCT05289804|Device|Sham NITESGON|Sham NITESGON
75914444|NCT05282381|Behavioral|DRS : Decision Regret Scale|"The DRS is a self-administered questionnaire including 5 items assessing decisional regret in a score graduated between 0 and 100 (0 = no regret).This scale is associated with the ReTransQoL, a specific quality of life questionnaire.~Questionnaires are administrated at 1, 3, 6 and 12 months post-transplantation."
75914445|NCT05281172|Behavioral|Guided Self-Change therapy (GSC)|The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
75914446|NCT05281172|Behavioral|Psychoeducation program about healthy habits|The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
75914447|NCT05278819|Other|upper extremity elevation|5 repetitions of active upper extremity elevation in a sitting position
75914448|NCT05278819|Other|upper extremity elevation with deep breathing|5 repetitions of active upper extremity elevation with deep breathing in a sitting position
75914449|NCT05278585|Procedure|RAP TAVI|All patients undergoing TAVI with no pre-existing pacemaker and in sinus rhythm at the time of the procedure will receive RAP by placing the temporary wire in the right atrium
75914450|NCT05271864|Device|Apple Watch|Apple Watch
75625616|NCT02536768|Behavioral|Minimum package of interventions to improve ART adherence|Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
75625617|NCT02661100|Drug|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
75625618|NCT02661100|Biological|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
75466832|NCT01913678|Other|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
75466833|NCT01913678|Other|Complete diet|The participants will be given all dietary items in their diet with no additional products.
75466834|NCT01913678|Other|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
75625619|NCT02661100|Biological|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
75625620|NCT00648232|Behavioral|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
75625621|NCT00648232|Behavioral|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
75625622|NCT00648232|Behavioral|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
75625623|NCT00648232|Behavioral|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
75625624|NCT00601354|Behavioral|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
75625625|NCT00601354|Drug|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
75625626|NCT02660866|Drug|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
75625627|NCT02660866|Drug|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
75625628|NCT04169932|Biological|CD20 CAR-T|The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 ^ 6 cells/kg,2 × 10 ^ 6 cells/kg,4 × 10 ^ 6 cells/kg,8 × 10 ^ 6 cells/kg).
75625629|NCT04169620|Other|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
75778053|NCT01084941|Behavioral|Lifestyle Intervention group|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
75778054|NCT01084941|Behavioral|Standard of Care|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
76073900|NCT03152643|Procedure|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
76073901|NCT03153579|Drug|LSD|"Lysergic Acid Diethylamide~200ug per os, single dose"
76073902|NCT03153579|Drug|Placebo|Capsules containing mannitol looking identical to LSD
76073903|NCT03583905|Drug|CKD-330|CKD-330 Tab.
75466835|NCT01913691|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
75466836|NCT01913704|Device|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
75466837|NCT01913756|Dietary Supplement|Gamalost (Norwegian traditional cheese)|
75466838|NCT01913756|Dietary Supplement|Gouda-type cheese|
75321612|NCT00603889|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
75625630|NCT04169620|Other|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
75321613|NCT01886937|Drug|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
75321614|NCT01886937|Drug|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
75321615|NCT00708877|Procedure|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
75321616|NCT02993341|Drug|Tranexamic Acid|
75321617|NCT02993341|Other|Saline Wash|
75466839|NCT01913769|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
75466840|NCT01913808|Drug|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
75321618|NCT01948947|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
75321619|NCT01948947|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
75625631|NCT02663986|Behavioral|Organizational Skills Training (OST) Intervention|
75625632|NCT00853099|Biological|adalimumab|
75625633|NCT00853099|Drug|placebo|
75625634|NCT00648310|Drug|Tolterodine 4 mg|
75625635|NCT00648310|Drug|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
75625636|NCT00702871|Drug|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
75321620|NCT01334801|Procedure|Blood Draw|"Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:~BNP (Brain Natriuretic Peptide)~(PFA) Platelet Function Analyzer 100~von Willebrand Factor (vWF) antigen~(vWF) multimers~(vWF) *activity by latex aggregation~Plasma stored for development of new testing approaches"
75321621|NCT04270903|Device|EPR measurement|Subject put in a magnet, magnetic field sweeping around 40 mTesla. Irradiation with a wave with a frequency of 1.1 GHz. A resonator (surface coil) is put at the surface of the skin (arm). The EPR signal is recorded.
75466841|NCT01913808|Drug|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
75321622|NCT04387799|Diagnostic Test|Serology for Covid-19|Antibody tests designed to provide results to individuals or healthcare providers can show whether someone was previously infected with SARS-CoV-2 being the RT-PCR negative for the population of patients
75321623|NCT04693637|Biological|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion
75321624|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
75321625|NCT00086684|Drug|Placebo|One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
75321626|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
75321627|NCT02999425|Other|Education|Educational intervention
75466842|NCT01913834|Drug|Forsteo|Subcutaneous administration 20 micrograms
75466843|NCT01913834|Drug|CP046 PTH CriticalSorb|Comparison of different doses of drug and nasal delivery devices
75466844|NCT01913847|Drug|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
75466845|NCT01913847|Drug|Placebo|Oral placebo TID for 12 weeks
75466846|NCT01913860|Behavioral|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
75625637|NCT00702871|Drug|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
75625638|NCT00700453|Behavioral|Control group with no video game play|Subjects will abstain from all video game play during study participation.
75625639|NCT00700453|Behavioral|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
75625640|NCT00700453|Behavioral|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
75914451|NCT05271162|Drug|Empagliflozin 10 MG|Empagliflozin 10 mg q.d; p.o
75321628|NCT02992873|Device|Layperson allocated to start CPR and fetch nearest AED|Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest
75321629|NCT02992873|Device|Layperson allocated to start CPR|Dispatching laypersons to start CPR out-of-hospital cardiac arrest
76073904|NCT03583905|Drug|Placebo of CKD-330|Placebo of CKD-330 Tab.
76073905|NCT03583905|Drug|D086|D086 Tab.
76073906|NCT03583905|Drug|Placebo of D086|Placebo of D086 Tab.
75321630|NCT02987907|Drug|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
75625641|NCT00700453|Behavioral|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
75321631|NCT02987907|Drug|Normal Saline|use normal saline 2ml I.A. during TACE
75466847|NCT01913873|Other|serum concentration changes cardiac biomarkers|Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
75466848|NCT01913886|Procedure|MSCs injection|MSCs cells will be injected in two aliquots of 10 ml by catheterism
75625642|NCT00992784|Biological|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
75625643|NCT00992784|Biological|FluarixTM|Single dose, intramuscular injection
75625644|NCT00830167|Drug|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
75625645|NCT00830167|Drug|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
75625646|NCT02611531|Behavioral|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
75625647|NCT02611531|Behavioral|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
75625648|NCT00992394|Drug|etanercept|etanercept 50 mg once weekly as requested.
75625649|NCT00992394|Drug|etanercept|etanercept 25 mg or 50 mg as requested.
75625650|NCT04291170|Other|QDASH|completing the tasks on the QDASH: open jar, wash wall, carry shopping bag, wash back, cut food, hammer wood
75625651|NCT04291170|Other|KOOSJR|completing tasks on the KOOSJR: pivot, straighten, go up/down stairs, stand upright, rise from sitting, bend over
75625652|NCT00829933|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
75625653|NCT00829933|Drug|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
75321632|NCT02992795|Device|BrainPulse|JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
75466849|NCT01913899|Other|Occupational/ physical therapy|
75466850|NCT01913899|Other|Mirror therapy|- Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
75625654|NCT01170962|Drug|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
75625655|NCT01170962|Drug|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
75625656|NCT01170962|Drug|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
75778055|NCT01088685|Device|Experimental Blister Patch|Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals
75778056|NCT01088685|Device|Marketed Pflaster|Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
75321633|NCT04402814|Diagnostic Test|Clungene rapid test cassette|Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.
75321634|NCT01887171|Drug|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
75625657|NCT01170962|Drug|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
75625658|NCT01170962|Drug|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
75778057|NCT01096940|Drug|AZD1656|Oral tablet, BID dose
75778058|NCT01096940|Drug|simvastatin|Oral tablet, single dose
75778059|NCT01085019|Dietary Supplement|Cinnamon|2.8g/day of cinnamon in capsules during 4 weeks.
75778060|NCT01085019|Dietary Supplement|Oregano|2.8g/day of oregano in capsules during 4 weeks.
75778061|NCT01085019|Dietary Supplement|Ginger|2.8g/day of ginger in capsules during 4 weeks.
75778062|NCT01085019|Dietary Supplement|Rosemary|2.8g/day of rosemary in capsules during 4 weeks.
75778063|NCT01085019|Dietary Supplement|Black pepper|2.8g/day of black pepper in capsules for 4 weeks.
76073907|NCT03583905|Drug|D723|D723 Tab.
75321635|NCT01679444|Procedure|Magnetic Resonance Spectroscopy|
75321636|NCT00713479|Drug|Varenicline, then placebo|Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
75466851|NCT01913925|Other|Tyrosine-Containing Food Bar|
75625659|NCT00843193|Drug|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
75625660|NCT00843193|Drug|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
75625661|NCT00843193|Drug|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
75625662|NCT00829621|Other|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
76073908|NCT03583905|Drug|Placebo of D723|Placebo of D723 Tab.
76073909|NCT01984697|Biological|V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
75466852|NCT01913925|Other|Placebo Bar|
75466853|NCT01913964|Drug|Acetylcarnitine|
75466854|NCT01913964|Drug|Placebo|(sugar pill)
75466855|NCT01913990|Drug|Dexamethasone, Ondansetron, Aprepitant|Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
75466856|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|Treating physician's discretion for type of anti-emetic to be prescribed.
75625663|NCT00829621|Other|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
75625664|NCT01157078|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
75625665|NCT01157078|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
75625666|NCT00591721|Behavioral|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
75625667|NCT04117399|Other|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
75625668|NCT01156844|Drug|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
75625669|NCT01156844|Drug|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
75625670|NCT00853021|Biological|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
75625671|NCT00853021|Biological|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
75625672|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
75625673|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
75625674|NCT05367284|Drug|Testosterone|Testogel 16.2 miligrams/ gram (mg/g) gel
75625675|NCT00843115|Other|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
75625676|NCT01156376|Device|Potassium Oxalate without Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
75321637|NCT00713479|Drug|Placebo, then varenicline|Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
75321638|NCT01679678|Device|PolyHeal 2|PolyHeal is a sterile medical device
75321639|NCT01679678|Device|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
75466857|NCT01914016|Other|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
75466858|NCT01914042|Drug|Morphine|
75466859|NCT01914042|Drug|Milnacipran|
75466860|NCT01914055|Device|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
75466861|NCT01914055|Device|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
75466862|NCT01914068|Other|Supervised exercise in hospital|
75625677|NCT01156376|Device|Potassium Oxalate with Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
75625678|NCT01156376|Device|Active Comparator PO-116-A|Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
75625679|NCT00700531|Device|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
75625680|NCT00700531|Procedure|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
75625681|NCT00829387|Behavioral|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
75625682|NCT00829387|Behavioral|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
75625683|NCT00705913|Device|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
75625684|NCT00705913|Device|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
75625685|NCT01156142|Drug|doxepin hydrochloride|Oral rinse
75625686|NCT01156142|Other|placebo|Oral rinse
75778064|NCT01085019|Dietary Supplement|Placebo|2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
75778065|NCT02530424|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
75778066|NCT02530424|Drug|Pertuzumab|Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
75778067|NCT02530424|Drug|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
75778068|NCT02530424|Drug|Fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
75778069|NCT01088763|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
75778070|NCT01088763|Other|diagnostic laboratory biomarker analysis|Correlative studies
75778071|NCT01088763|Other|pharmacological study|Correlative studies
75321640|NCT01679756|Procedure|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
75625687|NCT00842257|Drug|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
75778072|NCT01088763|Drug|dexamethasone|Given IV
75778073|NCT03953456|Drug|elafibranor 120mg|elafibranor 120mg is a coated tablet for oral administration, once daily
75625688|NCT00705991|Procedure|ROTEM|
75914452|NCT05271162|Other|Placebo|Placebo 1 tabl q.d; p.o
75625689|NCT05603377|Diagnostic Test|functional endoscopic evaluation of swallow|functional endoscopic evaluation of swallow
75625690|NCT00706069|Drug|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
75914453|NCT05269966|Biological|Injection Brolucizumab|"Single-chain antibody fragment (scFv)~Brolucizumab 6 mg will be administered by IVT injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients will receive loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) will be performed based on BCVA and OCT to assess whether the patient will require q8w or q12w dosing."
75914454|NCT05268081|Other|Virtual specialist conferences|"The intervention consists of four virtual conferences (45 min each in month 2, 5, 8 and 11) and an introductory webinar (90 min in month 1) to learn GPs about how to use the electronic Diabetes Overview to identify and manage patients with T2D. Each general practice is assigned to one specific endocrinologist they meet with throughout. The four virtual conferences are thematic: T2D and cardiovascular disease and heart failure, T2D and lipids, T2D and kidney disease and blood pressure, and T2D and a free topic selected by the GP. At each conference, the GP must bring 2-3 patient cases related to the theme and 1-2 patients of their own choice. The GP chairs the meeting. Each conference follows the same format: Check in (5 min); Short presentation by the endocrinologist (10 min); Presentation by GP and joint dialogue about theme-related patients (20 min); Presentation by GP and joint dialogue about theme-unrelated patients (optional, 5 min); (5) Wrapping-up (5 min)."
75914455|NCT05259943|Drug|Psilocybin first|Participants will receive 8 doses of 2mg psilocybin.
75625691|NCT00706069|Drug|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
75625692|NCT00700609|Behavioral|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
75625693|NCT02884622|Other|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
75778074|NCT03953456|Drug|Placebo|Placebo is a coated tablet for oral administration, once daily
75914456|NCT05259943|Drug|Placebo first|Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin
76073910|NCT03583827|Other|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
75321641|NCT03470558|Other|Dietary habits|Sleeve gastrectomy patients will be asked to monitor dietary habits before surgery and at 2, 6, and 12 months after surgery.
75778075|NCT01088841|Dietary Supplement|lactisole|lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
75778076|NCT02530580|Drug|20 mg AZD7325|A single 20 mg oral dose of AZD7325
75778077|NCT02530580|Drug|Placebo|A single oral dose
75778078|NCT03963921|Drug|HepaStem|Heterologous human adult liver-derived progenitor cells
75778079|NCT01094600|Drug|Synthetic Human Secretin|Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
75778080|NCT01097174|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
75778081|NCT01097252|Radiation|radiation|radiation with cisplatin 40mg/m2, 6 cycles, every week
75778082|NCT01097252|Drug|weekly cisplatin|weekly cisplatin 40mg/m2, 6 cycles
75778083|NCT01097252|Drug|tri-weekly cisplatin|cisplatin 75mg/m2, 3cycles, every 3 weeks
75778084|NCT03957356|Device|HLBLS-200|The amount of HLBLS-200 applied will be determined by the investigator based on the resection area.
75321642|NCT02990689|Device|Trifocal Intraocular Lens|bifocal intraocular lens (IOL)
75625694|NCT02884622|Other|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
75914457|NCT05255952|Procedure|Electrical stimulation|Electrical stimulation of the cardiac plexus
75778085|NCT03956264|Device|Virtual Reality|Deepsen offers a VR platform that provides patients with immersive contents aimed to distract, inform, soften and improve the healthcare experience
75778086|NCT03956264|Drug|Kalinox|Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen
75778087|NCT00054704|Drug|Riluzole|Riluzole
75914458|NCT05255731|Radiation|Low frequency laser activated photobiomodulation|"Protocol description Infrared: analgesia, biostimulation of tissues, edema and hyperemia (hard and soft tissues). There will be 11 laser application points, 3 intra-oral and 8 extra-oral, with a total dose of 33J.~Intraoral: one point in the region of the mandibular lingula (point of submersion of the mandibular nerve), one vestibular point and one lingual point in relation to the alveolus of the extracted wisdom tooth.~Extraoral: for muscle relaxation, five points on the masseter muscle; for oedema drainage, one point in each lymph node region: parotid, submandibular and buccal."
75914459|NCT05255731|Other|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
75914460|NCT05255692|Diagnostic Test|invasive urodynamic evaluation|Invasive urodynamic evaluation to define maximum cystometric capacity. By means of catheterisation the bladder gets filled and volumes en pressures are measured.
75914461|NCT05255692|Diagnostic Test|functional magnetic resonance imaging during bladder filling|Functional MRI is used to capture brain activity during tasks. The task in the current study is bladder infusion and withdrawal by means of the INFSYS-2 infusion/withdrawal pump (Leitner et al. 2017)
75914462|NCT05249361|Other|no intervention|no intervention
75321643|NCT02990689|Device|Bifocal Intraocular Lens|trifocal intraocular lens (IOL)
75321644|NCT02990689|Device|Low Addition Bifocal Intraocular Lens|low near addition intraocular lens (IOL)
75321645|NCT02998957|Device|AcuTENS|Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles
75321646|NCT02998957|Device|Sham AcuTENS|Portable TENS electrostimulation device with no electrical output
75625695|NCT04188002|Behavioral|Intervention Physical Activity|4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
75625696|NCT04188002|Other|Usual Care|4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
75321647|NCT03414086|Other|Healthy Control|Ten healthy adult patients evaluating serum, PBMC's, and RNA.
75778088|NCT00054704|Drug|Placebo|Placebo
75321648|NCT03414086|Other|Myositis in Remission|Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
75321649|NCT02992483|Drug|MIK665|MIK665
75321650|NCT02992639|Behavioral|Control group|The participants who included in control group did not receive any treatment.
75321651|NCT02992639|Behavioral|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
75778089|NCT01097408|Drug|AZD7295|Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
75778090|NCT01097408|Drug|Placebo comparator|Placebo capsules
75778091|NCT01097486|Biological|NeoFuse|Single Dose NeoFuse Surgical Implantation
75321652|NCT03085706|Biological|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
75321653|NCT03085550|Procedure|Fat grafting|Single treatment fat grafting infiltrated into diabetic ulcer wound
75625697|NCT00852475|Dietary Supplement|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
75625698|NCT00852475|Dietary Supplement|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
75625699|NCT01155284|Drug|Sitagliptin and Lansoprazole|"Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~Subjects age 18-45 years at Visit 2 will take 2 capsules once daily"
75625700|NCT01155284|Drug|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
75778092|NCT01097486|Procedure|Allograft|Single Dose Allograft Surgical Implantation
75778093|NCT02530814|Other|Blood Collection|Onetime blood collection.
75914463|NCT05248789|Biological|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
75914464|NCT05246592|Procedure|Branches Sparing|The patients will undergo axillary lymph node dissection with preserved axillary vein branches
75914465|NCT05246592|Procedure|None Branches Sparing|The patients will undergo axillary lymph node dissection without preserved axillary vein branches
75914466|NCT05246410|Device|Spot stent system|Spot stent system designed and produced by Acotec
75914467|NCT05246410|Device|Self-expanding peripheral stent system|Self-expanding peripheral stent system designed and produced by Ev3, Inc
75914468|NCT05244967|Other|vaginal swab|self-sampling, vaginal swab
75625701|NCT00852397|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
75778094|NCT01092572|Drug|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
75778095|NCT01092572|Drug|placebo|placebo 1 tablet once daily for 12 weeks
75778096|NCT01092650|Drug|Deuterated phenanthrene|Deuterated phenanthrene 10 micrograms
75778097|NCT03952988|Dietary Supplement|Probiotic ice cream|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (>10(exp7)/g) every day for 4 weeks
75778098|NCT03952988|Dietary Supplement|Placebo ice cream|One portion (50g) of an ice-cream without probiotic every day for 4 weeks
75625702|NCT00852397|Drug|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
75778099|NCT03953222|Device|Wearable real-time feedback device|The proposed wearable device can provide real-time feedback of primary gait and posture measures through auditory feedback. The feasibility of people with Parkinson's disease (PD) to utilize to feedback to modulate and improve their gait and posture will be investigated. Two types of feedback will be studied: (a) continuous feedback involving sonification of movements to facilitate learning proper movements (such as to take big steps, swing arms, rhythmic walking, maintain upright posture, etc.) and (b) on-demand feedback where the feedback is provided only if necessary to reduce overload of information and prevent developing dependency on the system.
75778100|NCT01097564|Genetic|COL4A1 genetic testing|genetic testing
75778101|NCT03952910|Other|Online pain education program|Online pain education program
75778102|NCT01094678|Device|Zilver® PTX™ Stent|Stenting of the superfemoropopliteal artery.
75778103|NCT03952676|Device|Moving cupping|"We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)~(1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds."
75778104|NCT03952676|Device|Moving cupping placebo|Using of special perforated cups, the manipulation method is the same as the intervention group.
75625703|NCT00852397|Other|Placebo|Placebo tablet for 24 weeks
75625704|NCT00841321|Drug|Ginkgo biloba|120 mg orally twice a day for 12 weeks
75321654|NCT03085550|Procedure|Fat grafting + platelet rich plasma|Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
75466863|NCT01914081|Other|Resveratrol|Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
75321655|NCT02998801|Other|IPAD|Patients undergoing surgery will watch the video using an PAD
75321656|NCT02998801|Other|VR Goggles|Patients undergoing surgery will watch the video using goggles
75321657|NCT02992405|Behavioral|FOCUS Resilience Enhancement Program|Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).
75466864|NCT01914081|Other|Placebo|Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period
75466865|NCT01914107|Procedure|real-time monitoring and instruction of cancer pain|as description in arm
75466866|NCT01914107|Procedure|standard cancer pain care|as description in arm
75466867|NCT01914133|Drug|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
75466868|NCT01914133|Drug|Placebo|Placebo given prior to meal the standardized meal
75466869|NCT01914146|Other|Insulin|Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
75466870|NCT01914146|Other|No Insulin|Study session will occur prior to initiation of insulin therapy.
75625705|NCT00841321|Drug|Placebo|One capsule orally twice a day for 12 weeks
75625706|NCT00986232|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
75625707|NCT00986232|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
75625708|NCT00986232|Biological|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
75625709|NCT00852241|Drug|Restalyne|one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
75625710|NCT00852241|Drug|Perlane|One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
75625711|NCT02612233|Drug|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
75625712|NCT01169636|Drug|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
75321658|NCT02992405|Behavioral|Waitlist (No Study Treatment)|Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
75321659|NCT02998723|Other|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
75321660|NCT02998723|Other|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
75466871|NCT01914172|Other|online questionairres|see group descriptions
75625713|NCT01169636|Drug|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
75625714|NCT01169636|Drug|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
75625715|NCT01169636|Drug|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
75625716|NCT01169636|Drug|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
75625717|NCT01169636|Drug|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
75625718|NCT00706225|Drug|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
75778105|NCT00031694|Drug|paclitaxel|Given IV
76073911|NCT03583827|Other|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
75914469|NCT05244499|Other|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
75321661|NCT04402580|Drug|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
75625719|NCT00703105|Biological|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
75625720|NCT00706303|Behavioral|Supported self management training and support|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
75625721|NCT04117009|Drug|Remifentanil 2 MG|Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
75625722|NCT04117009|Diagnostic Test|Echocardiographic evaluation|Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
75625723|NCT04117243|Drug|Misoprostol|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)
75778106|NCT00031694|Drug|bryostatin 1|Given IV
75778107|NCT03953066|Other|The calculation of blood IL-6 and coloctral milk melatonin|Collected maternal colostral milk will be sampled for melatonin levels.Blood samples driven before and after delivery will be evaluated for IL-6 levels in each group
75914470|NCT05244499|Other|Conventional training|7-modules online training over six months. Independent reading only.
75914471|NCT05244382|Other|Overcome|Multimodal program individualized and supervised 12 weeks duration (three months), with two sessions weekly face-to-face. This program will combine aerobic exercise in unloading through the use of the TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy. Physical activity will be measured in parallel with the test. Likewise, the patients will be monitored by means of a heart rate sensor.
75914472|NCT05238246|Behavioral|Behavioral guidance with tell-show-do|The effect of tell-show-do technique during dental treatment on behavior in pediatric patients was evaluated and compared.
75914473|NCT05238246|Behavioral|Behavioral guidance with robot|The effect of the tell-show-do and distraction technique during dental treatment on behavior in pediatric patients was evaluated and compared.
75914474|NCT05237570|Procedure|Interradicular septum window|In this group, the maxillary sinus will be accessed through a window in the interradicular septum and the membrane will be elevated, carrying out the regeneration of the area to facilitate subsequent implant placement.
75914475|NCT05236842|Drug|Sulthiame|oral
75914476|NCT05231486|Behavioral|Cognitive Orientation to daily Occupational Performance|CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.
75914477|NCT05230940|Biological|TURKOVAC|Inactive COVID-19 Vaccine - TURKOVAC
75914478|NCT05230940|Biological|CoronaVac|It has 600 subunit of SARS-CoV-2 virus antigen
75914479|NCT05221853|Diagnostic Test|cardiovascular magnetic resonance|CMR scan at 3 Tesla
75914480|NCT05218382|Device|Virtual reality|immersive virtual reality technology
75914481|NCT05218382|Device|No virtual reality|Virtual reality with blank screen
75914482|NCT05217498|Drug|Istradefylline|Consume 20mg tablet of istradefylline for 28 consecutive days.
75914483|NCT05217498|Device|low oxygen therapy|Breath intermittent low oxygen 4 days/week over 2 consecutive weeks. Intermittent low oxygen consists of 15, 90-second episodes of breathing low oxygen at 10% oxygen with 60-second intervals at 21% oxygen.
76073912|NCT03155607|Behavioral|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
76073913|NCT03583749|Drug|Subcutaneous (SC) route for antibiotic treatment|Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
76073914|NCT03583749|Drug|Intravenous (IV) route for antibiotic treatment|Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
76073915|NCT02000531|Drug|Erlotinib|150 mg oral dose of erlotinib given once daily
75321662|NCT04402580|Drug|Mycophenolate Mofetil|1,200 mg/1,73 sqm orally divided in 2 daily doses
75778108|NCT03957044|Other|The education of sensory integration with vestibular education|"Tactical, proprioceptive, visual and auditory senses were used in sensory integrity training sessions. In this group, the training program on tactile, proprioceptive, visual and auditory sensory activities was carried out for 2 weeks and 40 minutes. Sensory integrity training was performed by the physiotherapist and in the sensory room.~At the end of the training sessions, mothers were informed about the application of sensory integrity training to daily activities.Sensory integrity therapy room added tactile, proprioceptive, visual and auditory sensory materials as well as materials for vestibular sensation. Vestibular sensory materials, skateboard, swing, hammock, bowl, ball, ball pool, slide, climbing bar, trampoline, and balance board were used."
75625724|NCT04117243|Drug|Tranexamic acid|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)
75778109|NCT01094756|Dietary Supplement|meal replacements, psychotherapy, dietary education|After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
75321663|NCT01275781|Drug|[14C]-AZD9742|1000 mg intravenous over 2 hours
75625725|NCT04117243|Drug|Oxytocin|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
75625726|NCT01169558|Drug|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
75625727|NCT01169558|Drug|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
75625728|NCT00700687|Drug|PA32540|aspirin/omeprazole
75625729|NCT00700687|Drug|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
75625730|NCT00700687|Drug|aspirin and [NSAID]|aspirin and [NSAID]
75625731|NCT00706459|Device|Magnetic Resonance Imaging|All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
75625732|NCT04314908|Procedure|Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will be opened. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
75321664|NCT04402736|Behavioral|The modified Barthel Index-based rehabilitation nursing program|The intervention with the program based on the MBI classified function of patients into five levels, with every 20 points as a level, Each level corresponds to different training items. Training items included self-care training and training in transfer activities, sitting balance, walking, and sit-to-stand, etc. Each training session lasting at least 30 minutes, two sessions per day, for seven continuous days. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
75321665|NCT04402736|Behavioral|Usual care|Patients in the control group received clinical usual care including the activities of daily living assessment, early mobilization guide and health education. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
75321666|NCT00709891|Device|cobas® 4800 HPV Test|
75321667|NCT03085160|Behavioral|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
75625733|NCT04314908|Procedure|Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
75625734|NCT04314908|Procedure|Non Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
75625735|NCT04314908|Procedure|Non Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
75778110|NCT01097798|Drug|Aliviador|The study medication should be applied regimen of 8/8 hours over 2 days.
75778111|NCT01097798|Drug|Gelol|The study medication should be applied regimen of 8/8 hours over 2 days.
75778112|NCT00093795|Drug|Cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles"
75778113|NCT00093795|Drug|Docetaxel|75 mg/m2 IV every 21 days for 6 cycles
75321668|NCT03085160|Behavioral|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
75778114|NCT00093795|Drug|Gemcitabine|2000 mg/m2 IV every 14 days for 4 cycles
75466872|NCT01914185|Other|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
75466873|NCT01914198|Other|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
75466874|NCT01914211|Drug|Tranexamic Acid|100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.
75625736|NCT02884778|Diagnostic Test|Detection of pain after nociceptive stimulus|We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
75778115|NCT00093795|Drug|Paclitaxel|175 mg/m2 IV every 14 days for 4 cycles
75778116|NCT00093795|Drug|Doxorubicin|"Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles"
75778117|NCT03952442|Other|standardized nutrition education|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
75778118|NCT03952442|Other|routine nutrition education|Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
75778119|NCT03467152|Drug|Irsenontrine|Oral hypromellose capsules.
75778120|NCT03467152|Drug|Placebo|Oral hypromellose capsules.
75914484|NCT05217199|Other|Measurements|Demographic information of infants and parents, prenatal, postnatal and natal risk factors, Magnetic Resonance Images (MRI), General Movements (GMs) evaluations of babies with Prechtl method from NICU will be recorded. Video recordings for General Movements (GMs) analyzes with the Prechtl method will be taken at postterm 12th to 20th weeks. The infants' sensory processing (general, auditory, visual, tactile, movement, oral) will be evaluated with the adjusted Infant Sensory Profile-2 (ISP-2) family scale, which will be filled in by their mothers at the 3rd month. For motor assessments, the postterm corrected 3 month Hammersmith Infant Neurological Examination (HINE) will be used. A pediatric neurologist who was blinded to all testing made the diagnosis of CP in a 2-year-old child based on neuroimaging and clinical tests.
76073916|NCT02000531|Drug|Chemotherapy|Cisplatin (75 mg/m^2 intravenously [IV]) on Day 1 and gemcitabine (1250 mg/m^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
75321669|NCT00710203|Device|Pulsed dye laser|One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
75321670|NCT00710203|Procedure|Curettage|A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
75321671|NCT00710203|Procedure|Electrodesiccation|A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
75321672|NCT00710203|Other|No treatment|A fourth lesion will not be treated and will serve as a control.
75321673|NCT02990923|Device|High-Flow Needleless Valve|
75466875|NCT01914211|Procedure|Acute Normovolemic Hemodilution|Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If > 5Kg draw 20% of circulating blood volume without PRBC replacement)
75466876|NCT01914224|Behavioral|dietary education of low sodium and high potassium consumption|
75466877|NCT01914224|Behavioral|dietary education of low sodium consumption only|
75466878|NCT01914237|Device|Castor Stent Graft|Endovascular Repair of Aortic Dissection
75466879|NCT01914250|Drug|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
75625737|NCT00840463|Drug|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
75625738|NCT00840463|Other|Placebo|Sugar pill
75625739|NCT00706615|Biological|Ad-sig-hMUC-1/ecdCD40L vaccine|
75625740|NCT00703183|Drug|ACU-4429|administered as a single dose, orally
75625741|NCT00703183|Drug|matching placebo|administered as a single dose, orally
75625742|NCT00706693|Dietary Supplement|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
75625743|NCT00706693|Dietary Supplement|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
75778121|NCT01094834|Drug|DWP05195|tablets, oral administration, multiple administration
75778122|NCT01097876|Drug|PF-04447943 25 mg|25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
75778123|NCT01097876|Drug|Placebo PF|Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
75778124|NCT01092806|Drug|Tacrolimus|Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
75778125|NCT01094912|Drug|opioids|
75625744|NCT00706693|Dietary Supplement|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
75321674|NCT02990923|Device|DualCap Disinfection Devices|
75466880|NCT01914263|Biological|cytokine induced killer cell|The eligible patients are infused with a single dose of 8x10^9 cord blood-derived cytokine indued killer cells.
75466881|NCT01914289|Procedure|Resection|
75778126|NCT03719248|Device|thoracic epidural|high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG
75778127|NCT01092962|Drug|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
75625745|NCT02613325|Device|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
75625746|NCT02613325|Procedure|Standard of care surgical excision|
75625747|NCT02613325|Device|Single cell photoacoustic microscopy|
75466882|NCT01914289|Radiation|Radiotherapy|
75778128|NCT01092962|Drug|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
75466883|NCT01914302|Device|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
75778129|NCT03639142|Other|Prunus domestica|Patients will receive prunes at dose 3,5 g/kg/d (max.100mg/day) in three portions a day, for 4 weeks (amount of prescribed prunes will be calibrated with the weight that child ought to have on WHO growth charts at 50th percentile). Prunes should be introduced every day in three meals. Prunes can be chopped or grinded before eating them. They can be eaten alone or child may eat them as a part of bigger meal (which is preferred version). Prunes can be introduced with yogurt, cereals, nuts and seeds as a morning meal.
75778130|NCT03639142|Drug|Polyethylene Glycol 4000|Patients will receive PEG at dose 0,5 g/kg/d once daily orally, for 4 weeks.
75778131|NCT01098188|Drug|LFB-R603|intravenous administration, dose-escalation study
75778132|NCT03466060|Device|Opti-Free : RevitaLens / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
75778133|NCT03466060|Device|Opti-Free : RevitaLens / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
75778134|NCT03466060|Device|Clear Care : RevitaLens/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
75778135|NCT03466060|Device|Clear Care : RevitaLens / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
75321675|NCT04386109|Other|No intervention - exposure is to COVID-19|No intervention - exposure is to COVID-19
75321676|NCT00710905|Device|AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
75321677|NCT04386421|Other|Video on oral hygeine instructions|A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.
75321678|NCT04386421|Drug|Plaque disclosing tablets|"Plaque disclosing tablets:~Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %"
75321679|NCT01887327|Procedure|Phototherapy|Phototherapy starts within 30 minutes before or after injection
75466884|NCT01914302|Device|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
75466885|NCT01914302|Device|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
75466886|NCT01914302|Device|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
75466887|NCT01914302|Device|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
75466888|NCT01914302|Device|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
75466889|NCT01914302|Device|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
75466890|NCT01914302|Device|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
75625748|NCT00700765|Drug|insulin detemir|For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
75625749|NCT02611999|Behavioral|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
75625750|NCT02611999|Behavioral|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
75625751|NCT04030897|Behavioral|Parent-Directed Online Single-Session Program|Online, 15-minute self-administered program for parents
75625752|NCT04030897|Behavioral|Youth-Directed Online Single-Session Program|Online, 30 minute self-administered program for youths
75625753|NCT04030897|Behavioral|Information/Psychoeducation/Referral|Usual care at pediatric primary care clinics participating in this study
75625754|NCT04117165|Diagnostic Test|Biotherapy Prescription with SinnoTest® software|The rheumatologist will use the SinnoTest® software to give the best biotherapy to the patient according to the results of the software.
75466891|NCT01914315|Behavioral|Cardiac Rehabilitation|Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
75466892|NCT01914315|Other|Internal Medicine|Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
75466893|NCT01914341|Other|Music|Live music played on the pentatonically tuned children's harp
75466894|NCT01914380|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients will be followed-up for 24 months
75466895|NCT01914419|Drug|Oxytocin|
75466896|NCT01914432|Drug|YH16410|
75625755|NCT04117165|Drug|Patient Current Care|The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
75625756|NCT00828451|Biological|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
75625757|NCT00839917|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
75625758|NCT00839917|Biological|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
75625759|NCT00839527|Drug|placebo to match albiglutide|albiglutide matching placebo weekly subcutaneous injection
75625760|NCT00839527|Biological|albiglutide|albiglutide weekly subcutaneous injection
75778136|NCT03466060|Device|RevitaLens : Clear Care/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
75778137|NCT03466060|Device|RevitaLens : Clear Care / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
75778138|NCT03466060|Device|RevitaLens : Opti-Free / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
75778139|NCT03466060|Device|RevitaLens : Opit-Free / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
75778140|NCT00092547|Biological|V501|0.5 mL intramuscular injection of V501
75778141|NCT00092547|Biological|Comparator: Placebo|0.5 mL intramuscular injection of placebo
75466897|NCT01914432|Drug|Rosuvastatin|
75625761|NCT00839527|Drug|metformin|metformin
75625762|NCT00839527|Drug|glimepiride|glimepiride
75625763|NCT00839527|Drug|pioglitazone|pioglitazone
75625764|NCT00839527|Drug|placebo to match pioglitazone|pioglitazone matching placebo
76073917|NCT05647161|Device|BAX602|Consists of the spray agent, spray set, and spraying device (regulator). Dissolves a polyethylene glycol (PEG) derivative with an N-hydroxysuccinimide group at the end (COH102) and a PEG derivative with a thiol group (COH206) as an anti-adhesion agent, which is sprayed on the surgical surface to reduce the degree, frequency, and extent of organ adhesions after surgery.
75625765|NCT00706771|Drug|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
75466898|NCT01914432|Drug|Telmisartan|
75466899|NCT01914432|Drug|YH16410 placebo|
75466900|NCT01914432|Drug|Rosuvastatin placebo|
75466901|NCT01914432|Drug|Telmisartan placebo|
75466902|NCT01914445|Drug|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
75466903|NCT01914458|Procedure|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
75466904|NCT01914471|Behavioral|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
75466905|NCT01914484|Drug|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
75625766|NCT00706771|Drug|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
75625767|NCT04031053|Other|Pharmacokinetic study|The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
75778142|NCT03802994|Drug|23 valent pneumococcal polysaccharide vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.
76073918|NCT05647161|Device|No Intervention|Control Group
75466906|NCT01914484|Drug|Ruxolitinib|"In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor"
75466907|NCT01914497|Device|Acutus Medical System Mapping|
75625768|NCT00706927|Drug|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
75625769|NCT00706927|Drug|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
75625770|NCT00707083|Drug|dexamethasone|Given oral
75625771|NCT00707083|Drug|mercaptopurine|Given orally
75625772|NCT00707083|Drug|methotrexate|Given orally
75625773|NCT00707083|Drug|vincristine sulfate|Given IV
75321680|NCT01887327|Drug|Stannsoporfin|Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)
75321681|NCT01887327|Drug|Placebo|Matching placebo administered by IM injection
75321682|NCT04386889|Other|Vasculitis In SLE|20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
75321683|NCT04386031|Diagnostic Test|Throat culture for fungal pathogens|Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation
75321684|NCT02987751|Drug|Glargine + Glulisine|Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
75321685|NCT02987751|Drug|Premixed analogue insulin (70/30)|Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
75321686|NCT04387123|Procedure|Vaginoscopy|Vaginoscopic examination and possible operative endoscopic management
75321687|NCT01889355|Device|AgaMatrix Blood Glucose Monitor|
75778143|NCT03802994|Biological|13 valent conjugated pneumococcal vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.
76073919|NCT01609231|Drug|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
76073920|NCT01609231|Drug|Irinotecan|Irinotecan 180 mg/m^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
76073921|NCT01609231|Drug|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m^2 followed by weekly infusions of 250 mg/m^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
75321688|NCT04385719|Drug|Remdesivir|Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses
75321689|NCT00082628|Drug|Placebo|Placebo matched to serostim® as subcutaneous injection.
75321690|NCT00082628|Drug|Serostim® 4 mg|Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
75321691|NCT00082628|Drug|Serostim® 2 mg|Serostim® 2 mg as subcutaneous injection on alternate days.
75321692|NCT01275859|Drug|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
75321693|NCT01950039|Drug|Betaine|Betaine or placebo administered orally in divided doses over 12 weeks
75321694|NCT01950039|Drug|Placebo|Placebo administered orally in divided doses over 3 months
75321695|NCT01275937|Drug|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
75321696|NCT01275937|Drug|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
75321697|NCT03029793|Other|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
75321698|NCT03029793|Other|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
75321699|NCT04761926|Device|Audiometry|"Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit.~Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)).~Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off."
75321700|NCT02990455|Drug|Reduced nicotine cigarettes|Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
75321701|NCT01889667|Drug|ORMD-0801 Dose # 1|Oral Insulin Formulation
75321702|NCT01889667|Drug|ORMD-0801 Dose # 2|Oral Insulin Formulation
75321703|NCT01889667|Drug|Placebo|Oil Capsules
75321704|NCT00711997|Biological|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
75466908|NCT01914523|Device|Macintosh|Laryngeal exposure and tracheal intubation using that device
75466909|NCT01914523|Device|King Vision|Laryngeal exposure and tracheal intubation using that device
75466910|NCT01914523|Device|Glidescope|Laryngeal exposure and tracheal intubation using that device
75466911|NCT01914523|Device|AirTraq|Laryngeal exposure and tracheal intubation using that device
75466912|NCT01914562|Drug|OCA 10 mg|OCA 10 mg tablet oral
75466913|NCT01914562|Drug|OCA 25 mg|OCA 25 mg tablet oral
75466914|NCT01914575|Device|Mapping with the Acutus Medical System followed by Ablation|
75625774|NCT05500261|Drug|Dexmedetomidine|intranasal administration of dexmedetomidine
75625775|NCT04116931|Drug|Switch ticagrelor to clopidogrel|Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
75625776|NCT00600886|Drug|Pasireotide|Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
75625777|NCT00600886|Drug|Octreotide|Octreotide LAR - i.m. depot injection given once every 28 days.
75625778|NCT00649324|Drug|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
75625779|NCT00649324|Drug|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
75625780|NCT00648388|Drug|Cilostazol Tablets 100 mg|100mg, single dose fasting
75625781|NCT00648388|Drug|Pletal® Tablets 100 mg|100 single dose fasting
75625782|NCT02658760|Drug|Dexmedetomidine|dexmedetomidine plus placebo
75625783|NCT02658760|Drug|Bupivacaine|dexmedetomidine and Bupivacaine
75321705|NCT00712075|Behavioral|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
75321706|NCT00712075|Behavioral|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
75321707|NCT00712075|Behavioral|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
75625784|NCT02536690|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
75625785|NCT02536690|Drug|Remifentanil|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
75625786|NCT02536690|Drug|Midazolam|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
75625787|NCT02660632|Other|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
75625788|NCT02660632|Other|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
75625789|NCT00649090|Drug|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
75625790|NCT00838903|Biological|albiglutide|albiglutide
75625791|NCT00838903|Drug|sitagliptin|sitagliptin
75625792|NCT00838903|Drug|glimepiride|Glimepiride
75625793|NCT00838903|Drug|metformin|Metformin
75625794|NCT00838903|Biological|placebo albiglutide|placebo to match albiglutide
75321708|NCT01891305|Drug|VT-1161|
75625795|NCT00838903|Drug|placebo sitagliptin|placebo to match sitagliptin
75625796|NCT00838903|Drug|placebo glimepiride|placebo to match glimepiride
75625797|NCT02660398|Procedure|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
75625798|NCT00648466|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
75321709|NCT01891305|Drug|placebo|
75625799|NCT00648466|Drug|Imitrex® Tablets 100 mg|100mg, single dose fasting
75625800|NCT04170322|Device|thin pvc gastric tube|a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon
75625801|NCT04170322|Device|thick silicone gastric tube|a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
75625802|NCT00649402|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
75625803|NCT00649402|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
75625804|NCT00649480|Drug|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
75625805|NCT00649480|Drug|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
75625806|NCT02656108|Procedure|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
75625807|NCT02656108|Procedure|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
75625808|NCT02656342|Drug|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
75625809|NCT02656342|Drug|Placebo|Predicted to have no enhancing effect
75625810|NCT04116385|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
75625811|NCT02656186|Dietary Supplement|Pre-intervention|First 2-weeks : keeping routine dietary habit
75625812|NCT02656186|Dietary Supplement|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
75625813|NCT04169464|Drug|Sofosbuvir Oral Product|to investigate the drug effect on renal function and insulin resistance
75625814|NCT02656030|Other|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
75625815|NCT02656030|Other|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
75625816|NCT02656030|Other|usual care|usual care, 2 time per week, 6 weeks duration
75625817|NCT00650416|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
75625818|NCT00650416|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
75625819|NCT00649948|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
75625820|NCT00649948|Drug|Glucophage XR 500 mg|500mg, single dose fed
76073922|NCT03583593|Dietary Supplement|DIAMEL|Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.
76073923|NCT03583593|Dietary Supplement|Placebo|Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.
76073924|NCT03583515|Behavioral|Alcohol-Specific Personalized Normative Feedback|Participants will receive personalized normative feedback about drinking.
75625821|NCT04254328|Device|Nintendo Wii Fit|Nintendo Wii Fit group will perform including a series of yoga, balance, aerobics and muscle workout exercises by providing visual feedback on the TV screen with the Nintendo wii fit plus game console. Patients will perform these exercises in a room allocated to the thesis supervisor and together with the thesis supervisor physiotherapist. This process takes 40-50 minutes. Before starting test and after test, weight, blood pressure, pulse, respiratory rate, oxygen saturation value will be recorded. Patients will be rested if necessary during exercise.
75625822|NCT04254328|Device|Threshold IMT|Patients in the breathing exercise group will perform deep breathing exercises at home by a small breathing apparatus called as Threshold IMT. It has no unexpected side effects.Patients will do this exercise twice in a day ; morning and evening during 15 minutes. After 4-5 deep breath, patients will take normal breath till feeling relaxed.
75625823|NCT04167982|Procedure|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
75778144|NCT03802994|Other|Peripheral blood sample|Peripheral blood samples (30-60 mL) will be collected at day 0 (pre-immune), day 7, and day 30 (4 weeks post-PPV23) for groups 1-4 and at days 366, 373 and 396 for group 5. In addition, day 5, and 10 blood samples will be obtained from a limited (n=10) number of elderly RT participants to determine the optimal time point for circulation of PPS-specific B cells. Yearly blood samples will be obtained thereafter for serum antibody and OPA analyses to test longevity of antibody and OPA responses. Samples obtained from days 0, 30 and yearly samples will be used for antibody titers and opsonophagocytic assays. Samples from day 0 (day of vaccination with PCV13) and day 7 will be used for flow cytometric analysis.
75778145|NCT01088919|Drug|ASP1941|oral tablet
75778146|NCT01088919|Drug|pioglitazone hydrochloride|oral tablet
75778147|NCT01085175|Drug|LMI 1195|Single bolus intravenous injection of LMI 1195
75778148|NCT03960879|Diagnostic Test|DNA methylation|DNA methylation for the cervical cytology
75778149|NCT03960879|Diagnostic Test|High-risk HPV|High-risk HPV testing for the cervical cytology
75625824|NCT04167982|Drug|Oral conventional-dose isotretinoin|Conventional-dose isotretinoin
75778150|NCT03960879|Diagnostic Test|TCT|Thin prep liquid-based cytology test for the cervical cytology
75914485|NCT05215327|Biological|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
75914486|NCT05215327|Biological|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
75914487|NCT05210179|Biological|TURKOVAC-Dollvet|TURKOVAC-Dollvet vaccines produced by Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.
75778151|NCT03465904|Device|Verum Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.
75778152|NCT03465904|Device|Sham Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.
75778153|NCT03802916|Drug|Deferiprone DR tablets 1000 mg (Low dosage)|Deferiprone DR tablets 1000 mg
75778154|NCT03802916|Drug|Deferiprone DR tablets 1000 mg (High dosage)|Deferiprone DR tablets 1000 mg
75778155|NCT03724474|Behavioral|Be SMART|The behavioral intervention will examine 12-week changes in sleep metrics and physical activity, compared to baseline measures, between subjects randomly assigned to a treatment (Be SMART) and an active control (Fitbit Only) condition (n=30, respectively).
75321710|NCT01276015|Drug|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
75321711|NCT03830593|Procedure|Laparoscopic Adrenalectomy|minimally invasive lateral transperitoneal adrenalectomy
75625825|NCT04167982|Drug|Oral low-dose isotretinoin|low-dose isotretinoin
75778156|NCT03720340|Drug|Recombinant Human Interleukin-11|Recombinant Human Interleukin-11 was administed through respiratory tract.
75778157|NCT03720340|Drug|Saline|saline was administed through respiratory tract
75778158|NCT01093040|Drug|CAT-354|150 mg CAT-354 or placebo given SC on Day 1
75778159|NCT01093040|Drug|CAT-354|300 mg CAT-354 or placebo given SC on Day 1
75914488|NCT05210179|Biological|TURKOVAC-Koçak|TURKOVAC-Koçak vaccines produced by Koçak Farma Pharmaceutical and Chemical Industry Co., Ltd.
75778160|NCT01093040|Drug|CAT 354|600 mg CAT-354 or placebo given SC on Day 1
75321712|NCT01950663|Device|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
75321713|NCT02130635|Drug|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
75321714|NCT02130635|Drug|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
75321715|NCT02130635|Drug|PLACEBO|Lactose administered using a matching dry powder inhaler device
75321716|NCT01276093|Procedure|PVI ablation|Pulmonary Vein Ablation using RF.
75321717|NCT01276093|Drug|Amiodarone|Amiodarone tablets
75321718|NCT03370185|Drug|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
75321719|NCT01892007|Behavioral|Cogmed RM - Online adaptive working memory training|
75625826|NCT02651974|Behavioral|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
75625827|NCT02651974|Behavioral|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
75778161|NCT03719014|Device|NovaCross|The NovaCross micro-catheter will be used during a standard of care Percutanous Coronary Intervention (PCI) on subjects diagnosed with at least one coronary chronic total occlusion (CTO), in order to assist the operator in guidewire stability and centralization.
75778162|NCT01094990|Drug|Dexamethasone|dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
75625828|NCT02651974|Behavioral|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
75778163|NCT01584050|Dietary Supplement|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
75625829|NCT00649558|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
75778164|NCT01584050|Dietary Supplement|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
75778165|NCT01584050|Dietary Supplement|Placebo|frequency: once daily, duration: 12 weeks
75914489|NCT05207098|Other|Neurocognitive Tests|Baseline only: WRAT Reading Test, WMS-IV Logical Memory Subtest, Hopkins Verbal Learning Test (HVLT), Oral Trailmaking - Part A and B, NAB Digit Span, Category Fluency Test, Oral Symbol Digit Modalities Test, Brief Test of Attention, FAS - Controlled Oral Word Association Test (COWAT), Verbal Naming, Enformia Cogsuite Battery
75914490|NCT05207098|Other|Questionnaires|Sociodemographics, Computerized Cognitive Training Programs Questionnaire, CDC Behavioral Risk Factor (Smoking Assessment), Alcohol Consumption CDC, Current Health Rating (KPS), OARS Physical Health section, COVID Medical History, Hospital Anxiety and Depression Scale (HADS), Fatigue Symptom Inventory (FSI), Functional Assessment of Cancer Therapy-General (FACT-G V4), Functional Assessment of Cancer Therapy-Cognition (FACT-Cog V3), Sensory Gating Inventory (SGI)
75914491|NCT05200130|Other|Home Exercise Group|The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.
75321720|NCT01892007|Behavioral|Cogmed RM - Online non-adaptive (placebo) working memory training|
75321721|NCT00725959|Behavioral|Online social networking HIV prevention|messages about HIV posted in online social networking sites
75625830|NCT00649558|Drug|Actos® Tablets 45 mg|45mg, single dose fasting
75625831|NCT02658604|Other|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
75625832|NCT02658682|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
75625833|NCT02658682|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
75778166|NCT01310608|Other|A-View|Pre-operative imaging of the thoracic aorta with A-View technique
75778167|NCT03724240|Biological|Placebo solution|4 x 2 injection over 21 days the dosage is100 µg/ml
75778168|NCT03724240|Biological|gpASIT+TM|4 x 2 injection over 21 days the dosage is100 µg/ml
75778169|NCT03952832|Drug|Leflunomide|Given PO
75778170|NCT03952832|Other|Quality-of-Life Assessment|Ancillary studies
75778171|NCT03952832|Other|Questionnaire Administration|Ancillary studies
75778172|NCT01311076|Drug|TAK-329|TAK-329 50 mg, tablets, orally, single dose, one day.
75778173|NCT01311076|Drug|TAK-329|TAK-329 200 mg, tablets, orally, single dose, one day.
75778174|NCT01311076|Drug|Insulin|Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
75321722|NCT02990143|Procedure|Ologen|Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
75321723|NCT00557973|Drug|XP19986 SR1, 10 mg BID|XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
75321724|NCT00557973|Drug|XP19986 SR1, 20 mg BID|XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
75321725|NCT00557973|Drug|XP19986 SR1, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
75778175|NCT01311076|Drug|Placebo|TAK-329 placebo-matching tablets, orally, single dose, one day.
75778176|NCT01098344|Drug|Notch signaling pathway inhibitor MK0752|
75778177|NCT01098344|Drug|gemcitabine hydrochloride|
75778178|NCT01098344|Other|imaging biomarker analysis|
75778179|NCT01098344|Other|laboratory biomarker analysis|
75778180|NCT01098344|Other|pharmacological study|
75778181|NCT01095068|Behavioral|Physical exercise|
75778182|NCT01098656|Drug|lenalidomide|"The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.~Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)"
75914492|NCT05200130|Other|Manual Therapy Group|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to shoulder and neck complex, active and resistant shoulder complex movements, shoulder complex mobilization, mobilization cervical joints.~The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex."
76073925|NCT03583515|Behavioral|Social Media Personalized Normative Feedback|Participants will receive personalized normative feedback about social media use.
75778183|NCT01098734|Drug|WBI-1001|A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
75466915|NCT01914588|Procedure|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
75625834|NCT04169308|Drug|Restylane-L® Filler injection|Restylane-L® Filler injection into the soft tissue of the nose
75625835|NCT02658526|Behavioral|anesthesia - surgery|
75625836|NCT02655718|Other|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
75625837|NCT02655718|Device|MRI|
75778184|NCT01093118|Drug|TMI-358|Micro implant monthly x 3
75778185|NCT01093118|Drug|MMI-467|Micro implant monthly x 3
75778186|NCT00076011|Drug|Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor|
75778187|NCT03956108|Diagnostic Test|MRI+targeted biopsies+Stockholm3-test|MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.
75625838|NCT02651818|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
75625839|NCT02651896|Radiation|HypoIGRT|"Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.~For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).~Image guidance with cone beam CT will be mandatory before every treatment fraction."
75778188|NCT03956108|Diagnostic Test|PSA + systematic biopsies|Systematic biopsies and PSA test
75778189|NCT03465436|Drug|Lasmiditan|100 mg administered orally (PO)
75778190|NCT03465436|Drug|Lasmiditan|400 mg administered PO
75778191|NCT03465436|Drug|Placebo|Placebo administered for lasmiditan or moxifloxacin
75778192|NCT03465436|Drug|Moxifloxacin|400 mg moxifloxacin administered PO
75778193|NCT01098890|Drug|Tissue Plasminogen Activator|2mg tPA will be given every twelve hours for a maximum of 5 doses
75778194|NCT01098890|Drug|Placebo|Placebo will be administered every 12 hours for a maximum of 5 doses.
75778195|NCT03963999|Diagnostic Test|Ultrasound Elastography|Ultrasound shear wave elastography
75778196|NCT03963999|Drug|Contrast Enhanced Ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
75778197|NCT03955796|Device|Hydrophobic IOL|RayOne Hydrophobic Aspheric, hydrophobic IOL
75778198|NCT03955796|Device|Non-hydrophobic IOL|RayOne Aspheric, non-hydrophobic IOL
75778199|NCT03963765|Procedure|Group I (Standard DL-PDT)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)
75778200|NCT03963765|Procedure|Group II (DL-PDT with microneedles)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)
75778201|NCT03963765|Procedure|Group III (DL-PDT with CO2 laser)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass
75778202|NCT03963765|Procedure|Group IV (DL-PDT with microdermabrasion)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
75778203|NCT01081743|Other|Intervention of the social worker|Systematic home visits and regular follow-ups by phone from a social worker
75778204|NCT03962673|Radiation|NB-UVB light exposure|Participants are exposed to three low dose Narrow Band UVB light.
75778205|NCT00053846|Drug|buspirone hydrochloride|The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
75778206|NCT00053846|Drug|Placebo|Placebo
75778207|NCT01089075|Drug|Hydrocortisone|20 mg po for 7 days (2 tablets)
75778208|NCT01089075|Drug|Placebo|2 tablets po
75778209|NCT01098968|Behavioral|Physical activity program|School intervention program specifically designed to increase health-related physical fitness
75778210|NCT01099046|Behavioral|Lifestyle|water intake, tympanic tubing, regular sleep
75778211|NCT00090987|Drug|imatinib mesylate|400 mg orally once a day for up to 6 months.
75778212|NCT01085253|Other|3T and 7T MR imaging|all patients and controls will be explored using a 3T and 7T MR imaging
75466916|NCT01914588|Other|Standard care|"Detailed instruction about medical therapy and lifestyle counseling~Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~Follow-up visits"
75466917|NCT01914601|Device|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
75778213|NCT03464422|Behavioral|ESTEEM conneCT|"The intervention adapts the ESTEEM (Pachankis et al, 2015) intervention to address the multiple-stigma stressors faced by MSM of color, including sexual orientation and racial stigma in a manualized, CBT-based intervention. Approximately thirty participants (divided between two cohorts) will complete ten group sessions will take place at regular times once per week over the course of three months. The groups will be closed, in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members."
75466918|NCT01914601|Device|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
75466919|NCT01914627|Drug|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
76073926|NCT04438187|Other|antimicrobial initiation|antimicrobial initiation based on protocol assignment.
75778214|NCT03720184|Procedure|HAR|"HAR, the 6 steps procedure that results in 300ml of haemodilution. Step 0: Circuit is primed with 1000ml of crystalloid solution. Step 1: Venous line content is drained to the reservoir. Step 2: arterial srystalloid priming is displaced to the reservoir retrogradely by autologous blood. Step 3: Crystalloid priming is discarded to the collector bag. Step 4: An amount of 300ml of arterial blood is sequestered to the reservoir avoiding the mixture. Step 5: The centrifugal pump and the oxygenator are reprimed with autologous blood displacing the priming and GME to the collector bag. Step 6: CPB is initiated with a low haemodilution of 300ml.~Available at: https://zenodo.org/record/4276132#.X7K8AchKgRk"
75778215|NCT03489304|Drug|Zaleplon|non-benzodiazepine hypnotic agent
75778216|NCT03724006|Behavioral|Psychoeducational intervention|"The intervention, prepared by a multidisciplinary team, will consist of two 90 minutes collective sessions (max. 8 families). Sessions will consist of lectures, group discussion and relaxation. The program includes content on the effects of a diagnosis of a congenital anomaly on a child in the parents and in the family, stages of mourning, adaptation process, coping strategies, legislative framework and social protection. This is a non-specific intervention for CHD, where the main focus is the diagnosis of a congenital anomaly.~In second session, written support material will be distributed. Participants will be asked to practice relaxation in the next 4 weeks."
75778217|NCT03720106|Other|GOAL therapy plan|The GOAL algorithm designs a therapy plan based on the LIMOS assessment, patient goals and subject-specific treatment pathways. The adherence of this therapy plan is examined.
75778218|NCT03720028|Behavioral|Observation|Describe communication and sensory profile using standardized tests and observations.
75321726|NCT00557973|Drug|Placebo|Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
75321727|NCT00790049|Drug|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
75321728|NCT00790049|Drug|Placebo; oral|matching placebo
75321729|NCT01892865|Other|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
75321730|NCT01892865|Other|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
75625840|NCT02658370|Device|animated home-based exercises (Wii-fit)|
75625841|NCT02658370|Procedure|conventional home-based exercise program|
75625842|NCT00650494|Drug|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
75625843|NCT00650494|Drug|Valtrex® 1000 mg|1000mg, single dose fed
75625844|NCT02655874|Biological|Influenza vaccine|Administered at day 1
75625845|NCT02655874|Biological|Influenza vaccine|Administered at day 180
75625846|NCT02655874|Biological|Tetanus-diphtheria-pertussis vaccine|Administered at day 180
75625847|NCT00828139|Biological|ziv-aflibercept|Given IV
75625848|NCT00828139|Drug|topotecan hydrochloride|Given IV
75625849|NCT02655796|Device|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
75625850|NCT04222192|Other|Epidural block|Epidural catheter insertions
75625851|NCT04169386|Drug|AK102|AK102 single dose administered subcutaneously
75778219|NCT03720028|Behavioral|Parental experiences|Survey parents' experiences with parent-child interaction and augmentative and alternative communication.
75778220|NCT03718702|Other|ePain|Electronic pain management programme (ePain)
75778221|NCT03718624|Drug|apatinib|apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.
75778222|NCT03718624|Drug|paclitaxel|Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.
75778223|NCT03718624|Drug|S-1|S-1： According to the body surface area, BSA <1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA >1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
75625852|NCT04169386|Drug|Placebo|Placebo single dose administered subcutaneously
75321733|NCT00726739|Biological|aldesleukin|IL-2 Alone - administer 10 x 10^6 International Units subcutaneously (SQ) will be given on day 1 and day 2 every 4 weeks until disease progression or for a maximum of 12 treatment cycles.
75321734|NCT00726739|Biological|allogeneic large multivalent immunogen vaccine|Allogeneic tumor cell membrane-coated large multivalent immunogen (LMI [1 x 10^7, 5-μm silica spheres]) will be given as an intradermal injection every 4 weeks for up to 12 injections. Each vaccine dose will be 0.2 ml.
75466920|NCT01914627|Drug|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
75625853|NCT02658214|Drug|paclitaxel + carboplatin|IV infusion
75321735|NCT00569309|Biological|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
75625854|NCT02658214|Drug|carboplatin + etoposide|IV infusion
75321736|NCT00569309|Other|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
75466921|NCT01914653|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
75466922|NCT01914692|Drug|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
75466923|NCT01914705|Procedure|Landmark Procedure|Using Landmarks to guide SCVC placement
75466924|NCT01914705|Procedure|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
75466925|NCT01914718|Drug|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
75625855|NCT02658214|Drug|gemcitabine + carboplatin|IV infusion
75625856|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
75625857|NCT02658214|Drug|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
75778224|NCT03543358|Drug|rovalpituzumab tesirine|Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles
75778225|NCT03543358|Drug|rovalpituzumab tesirine|Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
75778226|NCT03485950|Drug|Cefepime|Given IV
75778227|NCT03485950|Drug|Ceftolozane|Given IV
75466926|NCT01914731|Drug|Fecal Microbiota Transplant|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule"
75914493|NCT05200130|Other|Telerehabilitation Group|The telerehabilitation program applied to the same home exercise group. In addition, to the home exercises, these patients will apply active mobilization called self-mobilization. Self-myofascial release, active glenohumeral joint mobilization, thoracic mobilization, and active cervical mobilization.
75625858|NCT02658214|Biological|durvalumab|IV infusion
75778228|NCT03485950|Other|Laboratory Biomarker Analysis|Correlative studies
75778229|NCT03485950|Drug|Meropenem|Given IV
75778230|NCT03485950|Drug|Piperacillin-Tazobactam|Given IV
75914494|NCT05199844|Device|Apple Watch|Apple Watch device measures heart rate and oxygen saturation
75914495|NCT05199454|Other|Exercise training|Aerobic exercise training using a treadmill or a bike for 12 weeks, 3 times per week, 60 minutes per session.
75466927|NCT01914744|Drug|Entecavir|entecavir 0.5 mg/day PO
75914496|NCT05191979|Other|Exercise regiment (aerobic exercise on bike)|Subjects participating in the current study will be trained progressively and intensively for 12 months primarily on bike indoors and outdoors
75466928|NCT01914744|Drug|Lamivudine|lamivudine 100 mg/day PO
75625859|NCT02658214|Biological|tremelimumab|IV infusion
75778231|NCT03485950|Drug|Tazobactam|Given IV
75778232|NCT00060944|Drug|Yondelis|1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
75778233|NCT00060944|Drug|Yondelis|0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
75914497|NCT05178563|Procedure|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
75914498|NCT05178563|Procedure|IPT+Placebo|IPT+Placebo
75625860|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
75625861|NCT02658214|Drug|cisplatin + 5-fluorouracil (5FU)|IV infusion
75625862|NCT04169230|Drug|Citalopram|Single dose administration of citalopram (20mg)
75625863|NCT04169230|Drug|Placebo oral tablet|Single dose administration lactose placebo tablet
75625864|NCT02655952|Drug|Foxy-5|
75625865|NCT02655640|Other|Questionnaires|Questionnaires will be provided to patients
75625866|NCT02658058|Other|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
75778234|NCT00060944|Drug|Dexamethasone|Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
75778235|NCT00060944|Drug|Dexamethasone|Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
75778236|NCT03719872|Diagnostic Test|Pre-Operative Transabdominal Ultrasound|Pre-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
75914499|NCT05177419|Drug|Lysergic Acid Diethylamide|100 micrograms LSD base
75914500|NCT05177419|Drug|Lysergic Acid Diethylamide|Low dose of LSD base
75914501|NCT05175820|Other|No intervention|Survey questions were sent through the mailing list of the Turkish Dental Association, where all dentists in Turkey are registered
75321737|NCT00569309|Other|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
75321738|NCT01952301|Device|Xenogeneic Collagen Matrix|A type I and III porcine collagen matrix, as cleared by FDA (K012423)
75321739|NCT01952301|Device|Free Gingival Graft|Autogenous, full-thickness soft tissue graft harvested from patient's palate.
75321740|NCT04470089|Drug|Myramistin|Oromucosal application
75321741|NCT00714571|Behavioral|Mnemonic strategy training (MST)|
75321742|NCT00714571|Behavioral|Repeated exposure (XP)|
75321743|NCT00714571|Behavioral|Subtracting Cues training|
75914502|NCT05170633|Device|Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)|70 random infant will receive the packed red blood cell transfusion with the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
75914503|NCT05162417|Other|Methylene Blue|1mg/ml of Methylene as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
75914504|NCT05162417|Other|Toluidine Blue O|1mg/ml of Toluidine blue o as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
75914505|NCT05156749|Device|short-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass short-arm cast
75914506|NCT05156749|Device|long-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass long-arm cast
76073927|NCT03583125|Drug|EOC317|tablet(s) PO
76073928|NCT01793935|Drug|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
75778237|NCT03719872|Diagnostic Test|Post-Operative Transabdominal Ultrasound|Post-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
75778238|NCT03485794|Procedure|Biospecimen Collection|Undergo collection of blood
75778239|NCT03485794|Other|Laboratory Biomarker Analysis|Correlative studies
75778240|NCT01095224|Biological|rAd35 Env A|1 x 10^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
75778241|NCT01095224|Biological|rAd5 Env A|1 x 10^10 PU administered as 1 mL IM in deltoid
75778242|NCT01095224|Biological|rAd5 Env B|1 x 10^10 PU administered as 1 mL IM in deltoid
75778243|NCT03462082|Other|Asymmetric STN-DBS|Asymmetric deep brain stimulation
75778244|NCT03956732|Dietary Supplement|Milk Protein (high)|High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
75778245|NCT03956732|Dietary Supplement|Vitamin D|One daily tablet containing 20 μg of vitamin D3, cholecalciferol.
75625867|NCT02658058|Other|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
76073929|NCT01793935|Drug|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
75466929|NCT01914770|Drug|Belimumab 1 mg/kg|Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
75778246|NCT03956732|Dietary Supplement|Milk Protein (medium)|Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
75778247|NCT01093274|Drug|Sodium Picosulphate|2 Sachets
75778248|NCT01093274|Drug|Polyethylene Glycol|3 Liters solution
75778249|NCT01093352|Procedure|Alveolar-decortication.|Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
75778250|NCT01099124|Drug|M2ES|polyethylene glycol rh recombinant endostatin
75778251|NCT01584206|Drug|Ezetimibe|10mg ezetimibe/day, at least 4 months
75778252|NCT03955952|Procedure|Bariatric Surgery|"Patients chosen using the following codes:~Current Procedural Terminology (CPT): 43633, 43634, 43770, 43775, 43644, 43645, 43659, 43842, 43843, 43844, 43845, 43846, 43847 International Classification of Diseases (ICD): 44.31, 43.82,44.95, 43.89, 44.38, 44.39, 44.68 Healthcare Common Procedure Coding System (HCPCS): S2082, S2085"
75778253|NCT03541252|Drug|AFL-assisted cisplatin+5-FU|Patients will receive AFL-assisted cisplatin+5-FU as a treatment for their BCC. In brief, treatment areas consisting of tumors and a 5 mm margin will undergo CO2 laser exposure followed by 60 min topical application of a marketed and commercially available IV cisplatin solution (0.1%) After removal of cisplatin, a commercially distributed 5-FU cream (5%) will be applied to the treatment area at a dose of 0.125 ml per cm2 and left under occlusion. After skin evaluations on Day 1 and 5 after treatment, the same 5-FU dose will be applied, again left under occlusion. In total, 5-FU will remain on the skin for 7 days after AFL treatment whereafter it will be washed off. An additional repeat AFL-cisplatin+5-FU treatment on Day 30 will be offered if tumors persist, based on clinical evaluation and imaging on Day 30.
75914507|NCT05152316|Other|Observational study|This is an observational study and no additional interventions will be done except for those that are standard care. Blood and tracheal aspirates will be taken to assess the surfactant protein levels and inflammatory markers including cell counts and cytokine levels.
75914508|NCT05151003|Other|Data collection|Collection and analysis of data related to AKI epidemiology, treatment and outcomes
75914509|NCT05149092|Dietary Supplement|Chicken protein hydrolysate supplement|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
76073930|NCT03292029|Diagnostic Test|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
76073931|NCT02092025|Drug|Azilsartan|Azilsartan tablets
76073932|NCT04405011|Drug|24-week Entecavir|Entecavir 0.5mg for 24 weeks will be delivered
76073933|NCT04405011|Drug|12-week Entecavir|Entecavir for 12 weeks will be delivered and serve as the active comparator arm
75321744|NCT00569855|Drug|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
75321745|NCT02991781|Other|Biofeedback and Neurofeedback Training|The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
75625868|NCT02658058|Other|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
75625869|NCT02655484|Device|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
75625870|NCT02651506|Procedure|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
75625871|NCT02651506|Procedure|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
75625872|NCT02655250|Other|Microbiome|
75625873|NCT04201756|Drug|Afatinib|"①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)"
75625874|NCT02651350|Drug|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
75625875|NCT02651350|Drug|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
75625876|NCT02658292|Drug|Naftifine hydrochloride foam, 3%|Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
75625877|NCT02658292|Drug|Vehicle|Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
75625878|NCT02657824|Other|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
75625879|NCT02655328|Other|blood sample|blood sample
75625880|NCT02655328|Other|urine sample|urine sample
75625881|NCT04169152|Procedure|Cap-assisted endoscopic sclerotherapy|Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
75625882|NCT04168840|Diagnostic Test|Compare clinical test with ultrasound parameters|Compare various clinical test with four ultrasound parameters to predict difficult intubation.
75625883|NCT02655172|Other|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
75625884|NCT02655172|Other|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
75778254|NCT00031460|Drug|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
75778255|NCT00031460|Drug|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
75778256|NCT03951974|Behavioral|Social Emotion Regulation Strategy Development|Participants will work one-on-one with an interventionist to develop goals (in the form of implementation intentions) to develop social emotion regulation strategies to combat frequent emotional challenges.
75778257|NCT03951974|Behavioral|Control|Participants will work one-on-one with an interventionist to report on their frequent emotional challenges, and report the emotion regulation strategies that they frequently use to combat them.
75321746|NCT02991781|Drug|Varenicline use for smoking cessation|The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
75778258|NCT03540160|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
75778259|NCT03952052|Other|Determination of mutation|Recurrent mutation determination by digital PCR and next generation sequencing
75778260|NCT01584284|Biological|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
75914510|NCT05149092|Dietary Supplement|Placebo|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
75778261|NCT03955562|Other|Footbridge|Access to a pedestrian footbridge.
75778262|NCT03955562|Other|Comparison villages|Villages that do not receive a footbridge.
75778263|NCT01099280|Drug|SYNPITAN FORT 5 IU|A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
75914511|NCT05146310|Device|I.SPACE®|"I.SPACE® is a viscoelastic sodium hyaluronate gel use as a surgical aid in ophthalmic anterior segment surgery by maintaining the intraocular space and protecting the corneal endothelium.~The baseline injection is performed at V1. The volume of product to use will be at the Investigator discretion, and will be completely removed after surgery."
75914512|NCT05146193|Other|Nude back photo|Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
75778264|NCT01099280|Drug|Propess,SYNPITAN FORT|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
75625885|NCT02657980|Device|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
75625886|NCT02657980|Device|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
75625887|NCT04168996|Behavioral|Individualized discharge planning|Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
75625888|NCT00650572|Drug|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
75625889|NCT02651038|Drug|Micafungin|Measurement of PK
75778265|NCT03459196|Device|THERMOCOOL SMARTTOUCH SF-5D Catheter|radiofrequence ablation with THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode
75778266|NCT01093430|Procedure|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
76073934|NCT01769443|Drug|bortezomib|Bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
75321747|NCT02991781|Other|Sham Neurofeedback|Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
75321748|NCT02991781|Other|Passive Control|Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
75321749|NCT01893801|Drug|nab-paclitaxel|25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
75321750|NCT01893801|Drug|Cisplatin|25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
75625890|NCT00650026|Biological|adalimumab|40 mg adalimumab every other week
75625891|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail|
75625892|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
75625893|NCT02536924|Behavioral|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
75625894|NCT02536924|Behavioral|Treatment as usual.|The patient will receive treatment as usual.
75778267|NCT01093430|Procedure|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
75778268|NCT01095302|Drug|OMBRABULIN (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
75778269|NCT01095302|Drug|cisplatin|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
75778270|NCT01095302|Drug|docetaxel|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
75914514|NCT05122546|Drug|Cabozantinib S-malate|Given PO
75914515|NCT05122546|Drug|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
75914516|NCT05122546|Biological|Nivolumab|Given IV
75914517|NCT05121272|Behavioral|cognitive task|cognitive task
75914518|NCT05120115|Other|Weight belt|Wearing belt around waist with various weights attached.
75914519|NCT05105360|Procedure|Closure method of Petersen's space|Surgeons closed Petersen's space between the mesentery of the jejunal Roux limb and the mesentery of the transverse colon at the posterior side of esophago-jejunostomy or gastro-jejunostomy from the mesentery root to the bowel side using a nonabsorbable barbed suture V-LocTM 3-0 (Medtronic VR, Minneapolis, MN, USA).
75914520|NCT05105360|Procedure|Mesentery fixation method|Surgeons fixed the jejunal mesentery (jejunojejunostomy[J-J] distal 30 cm) to the transverse mesocolon using non-absorbable barbed suture VLocTM 3-0 sutures. The suture area was exposed by grasping the jejunum side mesentery (jejunal side, at site 30cm distal J-J) and the transverse mesocolon (colonic side). The jejunal side mesentery was fixed to the colonic side mesocolon between the jejunum and the transverse colon using nonabsorbable barbed V-LocTM 3-0 sutures.The suture started between jejunal mesentery just below of SMA vascular arcade and transverse mesocolon, and it finished when it reaches the root of the mesentery. To anchor the mesentery, continuous suturing with V-Loc two-point backward sutures were performed at the final step.
75778271|NCT03955718|Behavioral|Motherly App|The Motherly app is a behavioral intervention aimed at preventing maternal depression and promoting child development.
75778272|NCT03955718|Behavioral|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
75778273|NCT03459040|Drug|Alpha 1-Antitrypsin|AAT will be given either in the hospital or the outpatient clinic two times per week.
75321751|NCT01893801|Drug|gemcitabine|1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
75625895|NCT02657746|Other|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
75778274|NCT01093508|Drug|APD916|
75778275|NCT02530736|Other|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
75778276|NCT03457636|Drug|Doxycycline Anhydrous 40 MG|One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
75778277|NCT03457636|Drug|Adapalene/Benzoyl Peroxide Gel 0.3-2.5%|Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
75625896|NCT02657668|Behavioral|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
75625897|NCT04033042|Device|Prototype 0.5|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
75914521|NCT05103033|Behavioral|Systems Analysis and Improvement Approach for Mental Health (SAIA-MH)|The 5 steps of SAIA-MH include: (1) cascade analysis to visualize treatment cascade drop-offs and prioritize areas for system improvements; (2) process mapping to identify modifiable facility-level bottlenecks; (3) identification and implementation of modifications to improve system performance; (4) assessment of modification effects on the cascade; and (5) repeated analysis and improvement cycles.
75625898|NCT02650882|Procedure|Device POWERbreathe|
75625899|NCT00838513|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
75778278|NCT01099436|Drug|cyclophosphamide|
75778279|NCT01099436|Drug|docetaxel|
75625900|NCT04032886|Other|kinesio tape|This is a taping method used for correction of rounded shoulders.
75778280|NCT01099436|Drug|doxorubicin hydrochloride|
75778281|NCT01099436|Drug|zoledronic acid|
75778282|NCT01099436|Procedure|neoadjuvant therapy|
75625901|NCT04032886|Other|exercise|Exercises include basic postural exercises.
75778283|NCT01099514|Drug|Nilotinib|D1~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
75914522|NCT05103033|Behavioral|Attentional Placebo Control|Facilities randomized to attentional placebo control will attend a 1-week in-person training which will include the same minimum staff above for SAIA-MH. This training will focus on reviewing data collection tools, ethics, mental health stigma and burnout for mental health professionals. Following the 1-week in person training, attentional placebo control facilities will receive regular supervision following the same schedule as SAIA-MH focused on reviewing data collection tools.
75778284|NCT03951896|Biological|PRP|A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects.All of the injections were done every two weeks, for a total of 3 times using 21 G injection needles with injection technique of posterior approach.
75321752|NCT00570089|Drug|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
75778285|NCT03951896|Other|Saline injection|2 ml's of NaCl solution with 0,9% concentration was applied to the shoulders of the participants.
75321753|NCT00570089|Drug|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
75778286|NCT01099592|Drug|Citalopram|All patients will take citalopram once daily. Medication will be commercial tablets of 20 mg or 40 mg. All patients will start on a half dose of 10 mg and, if there are no severe side effects, will be increased to 20 mg after 1 week, and if the HAMD-24 at 6 weeks is not < 8, the dose will increase to 40 mg.
75778287|NCT01099670|Drug|NRL001|Rectal suppository Placebo
75778288|NCT01099670|Drug|Placebo|Placebo
75778289|NCT03955484|Diagnostic Test|Urinary Glycosaminoglycan|Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
75778290|NCT01099748|Drug|Methadone|Methadone 50 - 150 mg QD (Day 1)
75778291|NCT01099748|Drug|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
75778292|NCT03951662|Other|Alcoholic Hepatitis Group|Alcoholic hepatitis is defined as having a total bilirubin level >3mg/dL and AST level>50U/L
75778293|NCT03951662|Other|Heavy Drinking Controls without Hepatitis|Normal levels of AST, ALT and total bilirubin and without evidence of cirrhosis or hepatosplenomegaly
75778294|NCT03481816|Biological|ETBX-071; adenoviral PSA vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
75778295|NCT03481816|Biological|ETBX-061; adenoviral MUC1 vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
75778296|NCT03481816|Biological|ETBX-051; adenoviral brachyury vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
75914523|NCT05102474|Other|Polysomnography (PSG)|PSG is the gold standard for objectively measuring sleep in the laboratory setting. The procedure consists of electrodes measuring brain activity (electroencephalography, EEG), eye movements (electrooculography, EOG), muscle activity (electromyography, EMG), respiratory events, snoring activity, blood oxygen saturation, and body position. Video surveillance during the sleep study can also monitor for itching events that occur during the night.
75914524|NCT05100433|Procedure|Ultrasonic irrigation|Ultrasonic irrigation will be used as a complementary step to chemomechanical procedures to test whether it can improve root canal disinfection.
75914525|NCT05097612|Device|Placebo LiftSuit Exoskeleton|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). In this condition the EES are removed from the device to create a placebo device.
76073935|NCT01769443|Procedure|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
75321754|NCT00727597|Drug|Efavirenz 600mg|"QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~To resolve a Grade 3 or 4 Adverse Event~The subject experienced a virologic failure (as defined in section 3.6.2)~The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
75625902|NCT02536222|Other|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
75625903|NCT00649636|Drug|Fluoxetine Capsules 40 mg|40mg, single dose fasting
75625904|NCT00649636|Drug|Prozac Pulvules 40 mg|40mg, single dose fasting
75914526|NCT05097612|Device|LiftSuit Exoskeleton (low support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
75625905|NCT04030663|Drug|papaverine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
75625906|NCT04030663|Drug|nitroglycerine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
75625907|NCT04030663|Drug|xlyocaine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
75625908|NCT02654938|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
75778297|NCT02530346|Drug|No Mechanical Bowel Preparation|no enemas or oral laxatives will be given in this group
75914527|NCT05097612|Device|LiftSuit Exoskeleton (medium support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
76073936|NCT03154827|Drug|BL-8040|Subjects will receive once daily SC injections of 1.25 mg/kg of BL-8040 on the first 3 days of each cycle.
76073937|NCT03154827|Drug|Atezolizumab|Subjects will receive Atezolizumab 1200 mg by IV infusion on Day 2 of every cycle.
76073938|NCT03159507|Dietary Supplement|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
76073939|NCT01768117|Biological|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
75778298|NCT02530346|Drug|Mechanical Bowel Preparation|oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed
75778299|NCT01099826|Behavioral|Tailored counseling|education tailored to baseline beliefs by trained counselor over phone
75778300|NCT01099826|Behavioral|Motivational Interview|motivational interview by trained MI counselors by phone
76073940|NCT03582969|Other|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
76073941|NCT03582969|Other|Placebo|Placebo capsules
75778301|NCT03723616|Behavioral|Control|Participants will view 24 ads with and without health warnings. Additionally, 16 control non-tobacco ads matched for graphical content, presence of text, people, and other factors will be randomly distributed among these ads.
75778302|NCT03723616|Behavioral|Text Only|Participants will view at random 24 ads twice, each ad will have a different health warning chosen at random with the caveat that each health warning will be seen 3 times. The 16 control ads will have text disclaimers to control for physical features of the ads.
75778303|NCT03723616|Behavioral|Text + Graphic|This arm is identical to the text only intervention except a graphic will be added to the health warning. Thus, each ad will be seen twice; the text + graphic warnings will be seen three times. The 16 control ads will have text disclaimers and logos or other images to control for physical features of ads.
75778304|NCT03956888|Drug|N-acetylcysteine|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
75778305|NCT03719794|Dietary Supplement|Probiotic supplement|Probiotic supplement once daily (xyz) for 12 weeks
75778306|NCT03719794|Dietary Supplement|Placebo supplement|Placebo supplement once daily for 12 weeks
75778307|NCT01099904|Drug|RO5024048|multiple oral doses for 5 days
75778308|NCT03955406|Procedure|Conventional Low flow Anesthesia|During the initial wash-in period 4 L/min Fresh gas flow will be used.
75778309|NCT03955406|Procedure|Low Flow Anesthesia with fixed fresh gas flow rate|Fresh gas flow rate will be 1 L/min throughout the procedure.
75778310|NCT01093664|Biological|AFFITOPE AD02|s.c. injection
75778311|NCT03538054|Drug|Dextromethorphan|(1)10 mg, by mouth, twice daily every 12 hours.
75778312|NCT03538054|Drug|Placebo|1 capsule, by mouth, twice daily every 12 hours.
75778313|NCT03480802|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
75778314|NCT03480802|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
75914528|NCT05097612|Device|LiftSuit Exoskeleton (high support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
75914529|NCT05092399|Procedure|Bariatric Surgery|No study interventions
75914530|NCT05084742|Device|Biodentine™|"Biodentine™ is a bioactive dentin substitute from the  Active Biosilicate Technology®  innovation.~Study participants were treated from 1 year to 5,5 years ago through an endodontic microsurgery using Biodentine™ used in its endodontic indications, i.e., root end-filling, external or internal root resorption repair, root and furcation perforation repair, apexification, and revitalization procedure by means of revascularization."
76073942|NCT01767493|Drug|[18F]Florbetapir PET imaging|[18F]Florbetapir and PET imaging
75625909|NCT02654938|Drug|Placebo|5% infusion solution of dextrose
76073943|NCT03159429|Behavioral|Standard rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
75625910|NCT00700921|Drug|Lovastatin|40mg po once daily
75625911|NCT00700921|Drug|Placebo|One capsule, once daily
75625912|NCT00600106|Drug|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
75625913|NCT00600106|Drug|Placebo|1 mg placebo
75625914|NCT04168918|Behavioral|Group psychological Intervention|There will be 6 sessions covering 6 topics (Understanding mental disorders, Self-stigma, Social support, Substance use and mental illness, Self-help strategies, Available mental health services). Each session will begin with welcoming, reviewing what was done in the last session and home assignments (where applicable), question-guided discussion, lecture, group sharing and home assignment
75625915|NCT02650726|Dietary Supplement|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
75625916|NCT02650726|Other|Placebo|placebo 320mg daily for 24 weeks
75625917|NCT00850993|Drug|Stannsoporfin|Stannsoporfin administered as a single IM injection
75625918|NCT00850993|Other|Placebo|Placebo (sterile saline solution) administered as a single IM injection
75625919|NCT00850993|Other|PhotoTherapy (as needed)|PT standard care administered as needed, based on bilirubin levels throughout the treatment period
75778315|NCT03480802|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
75778316|NCT00050960|Drug|bexarotene with carboplatin and paclitaxel|bexarotene capsules (400 mg/m^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
75778317|NCT00050960|Drug|carboplatin and paclitaxel|carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m^2) every 3 weeks.
75778318|NCT03719716|Other|Anticipatory care planning letter|Patient letter to take to GP and GP literature
76073944|NCT03159429|Behavioral|Nasal breathing rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
76073945|NCT03159819|Genetic|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
76073946|NCT01274182|Biological|GP2013|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
76073947|NCT01274182|Biological|MabThera|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
76073948|NCT01274182|Biological|Rituxan|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
75778319|NCT03456856|Drug|Ivabradine|Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.
75625920|NCT04168762|Other|Transcranial Ultrasound Magnetic Stimulation|Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
75778320|NCT00058214|Drug|perifosine|Given orally
75778321|NCT00058214|Other|laboratory biomarker analysis|Correlative studies
75625921|NCT02657512|Drug|rivaroxaban|rivaroxaban 40 mg/day (1 day)
75778322|NCT00097773|Drug|Tobramycin solution for inhalation (TOBI)|Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
75778323|NCT00097773|Drug|Oral placebo|Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
75778324|NCT00097773|Drug|Oral ciprofloxacin|Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
75778325|NCT01095380|Other|Locomotor training|Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping
75778326|NCT03480022|Drug|Liraglutide Pen Injector [Saxenda]|daily sc injection of liraglutide with final dose of 3mg daily
75778327|NCT03480022|Drug|Placebo Liraglutide Pen Injector|daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo
76073949|NCT01984229|Drug|Alectinib|Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).
75778328|NCT01093742|Drug|HM10560A|Subcutaneously administrate at 0 hour on Day 1
75625922|NCT02657512|Drug|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
75625923|NCT00818779|Drug|Aliskiren|150 - 300 mg once daily for 6 weeks
75625924|NCT00818779|Drug|Amlodipine|5-10 mg once daily for 6 weeks
75625925|NCT02654548|Other|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
75625926|NCT02657278|Procedure|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
75625927|NCT00850759|Device|virtual pedestrian environment|a computer-driven virtual pedestrian environment
75625928|NCT00850759|Device|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
75625929|NCT00850759|Behavioral|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
75625930|NCT02657200|Other|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
75625931|NCT02650492|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
75778329|NCT01093742|Drug|Placebo|Placebo
75778330|NCT01081821|Drug|single dose NJ-39758979/ matching placebo|Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
75778331|NCT01081821|Drug|multi-dose JNJ-39758979 /matching placebo|JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
75778332|NCT01095458|Behavioral|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
75778333|NCT01584596|Behavioral|Adapted Dietary Guidelines|"This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist."
75778334|NCT01584596|Behavioral|Adapted Physical Activity Guidelines|The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
75914531|NCT05082714|Drug|Tocilizumab|tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)
76073950|NCT01984229|Drug|Posaconazole|Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
76073951|NCT03582735|Other|Nerve gliding exercise|A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
76073952|NCT03582501|Other|Lower body negative pressure|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
76073953|NCT01835899|Drug|Placebo|Placebo to BI 1015550
76073954|NCT01835899|Drug|BI 1015550|medium dose 1 powder for oral solution
76073955|NCT01835899|Drug|BI 1015550|medium dose 2 powder for oral solution
76073956|NCT01835899|Drug|BI1015550|low dose 2 powder for oral solution
76073957|NCT01835899|Drug|BI 1015550|low dose 1 powder for oral solution
75625932|NCT00827827|Other|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
75625933|NCT00827827|Other|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
75625934|NCT00650728|Procedure|placing gastric tube|
75625935|NCT02654704|Biological|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
75625936|NCT02650336|Drug|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
75625937|NCT02654626|Drug|KBP-7072|Drug Intervention
76073958|NCT03582423|Other|electro-acupuncture|Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
76073959|NCT01274104|Dietary Supplement|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
76073960|NCT01274104|Other|Placebo|Placebo
75625938|NCT02654626|Other|Placebo|
75625939|NCT00649714|Drug|Zonisamide Capsules 100 mg|100mg, single dose fed
75625940|NCT00649714|Drug|Zonegran® Capsules 100 mg|100mg, single dose fed
75625941|NCT02654392|Dietary Supplement|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
75625942|NCT02654392|Dietary Supplement|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils) every day for 5 weeks
75625943|NCT02654158|Drug|Low-dose of Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
75625944|NCT02654158|Drug|High-dose of Fuganlin Oral Liquid|"less than 1 years old: 10mL each time and three times a day~1~3 years old: 20mL each time and three times a day~4~6 years old: 20mL each time and four times a day~7~12 years old: 20mL each time and five times a day"
75625945|NCT02657122|Drug|TD-1473 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
75625946|NCT02657122|Drug|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
75625947|NCT02657122|Drug|TD-1473 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
75625948|NCT02657122|Drug|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
75625949|NCT00600028|Drug|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
75625950|NCT00600028|Drug|Placebo|Placebo 50-100 mg by mouth per day
75625951|NCT02650102|Drug|Risperidone|a kind of antipsychotics
75625952|NCT02650102|Drug|Olanzapine|a kind of antipsychotics
75625953|NCT02650102|Drug|Quetiapine|a kind of antipsychotics
75625954|NCT02650102|Drug|Aripiprazole|a kind of antipsychotics
75625955|NCT02650102|Drug|Ziprasidone|a kind of antipsychotics
75625956|NCT02657044|Procedure|EMR|
75625957|NCT02657044|Procedure|ESD|
75625958|NCT00650182|Drug|fentanyl; naltrexone|
75625959|NCT02650180|Device|Soberlink Cellular Device|Alcohol Breath Analyzer
75625960|NCT02653924|Other|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
75625961|NCT02653924|Other|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
75625962|NCT02653924|Other|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
75625963|NCT02653924|Other|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
75625964|NCT00650884|Device|Ankle Dorsiflexion Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
75625965|NCT00910780|Drug|Aripiprazole|via oral tablets, everyday
75625966|NCT00910780|Drug|Zyprexa|via oral tablets, taken once daily
75625967|NCT00910780|Drug|Risperdal|via oral tablets, taken once daily
75625968|NCT02649712|Device|biliary stent|Self-expandable biliary nitinol alloys stent
75914532|NCT05082714|Drug|Baricitinib|The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2
75321755|NCT00727597|Drug|Boosted Lexiva|"Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~To resolve a Grade 3 or 4 Adverse Event~The subject experienced a virologic failure (as defined in section 3.6.2)~The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
75625969|NCT02656888|Drug|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
75625970|NCT02656888|Drug|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
75625971|NCT02656966|Device|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
75625972|NCT02656810|Drug|Teriparatide|Single subcutaneous injection
75625973|NCT02536612|Other|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
75625974|NCT02536612|Other|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
75625975|NCT02653846|Procedure|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
75321756|NCT04748913|Device|Radiographic examination|Standardized bitewing radiographs will be performed by the principal investigator
75321757|NCT04748913|Device|Scanning with DIAGNOcam|The surface of the selected teeth will be examined under near infrared light using the DIAGNOcam device
75625976|NCT02653846|Procedure|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
75625977|NCT02649478|Drug|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
75625978|NCT02649478|Drug|Placebo|
75625979|NCT02649478|Drug|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
75625980|NCT00650962|Other|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
75625981|NCT00650962|Other|Rhythm analysis|Rhythm analysis as soon as AED is ready
75625982|NCT02653612|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
75625983|NCT04167592|Drug|Benzydamine Hydrochloride 0.15% Oral Rinse|Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
75321758|NCT04748913|Device|Scan with DIAGNOcam and Indocyanine|One the dye has been applied, a new series of images will be taken with Diagnocam
75321759|NCT04748913|Diagnostic Test|Visual-tactile exploration with separation|The point of contact will be open in the corresponding proximal area of the lesion using an elastic orthodontic separator
75321760|NCT04386473|Device|pacemaker|electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP
75625984|NCT04167592|Drug|Water|Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
75625985|NCT02656732|Biological|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
75625986|NCT02656732|Procedure|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
75625987|NCT04168294|Drug|Propofol|patients in sedation group will be intravenous injected propofol in bolus
75625988|NCT04168294|Device|endoscopy|endoscopy system
75625989|NCT02653534|Behavioral|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
75625990|NCT02656576|Procedure|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
75625991|NCT02656576|Procedure|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
75625992|NCT04167202|Procedure|Hydrogen-rich water|Hydrogen-rich water (one hydrotherapy every 4 hours)
75625993|NCT04167202|Procedure|RICE|RICE protocol
75625994|NCT02649244|Behavioral|The Family Caregiver Training Program|The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
75625995|NCT02653378|Behavioral|DIET|25% Energy Depletion by Diet only for 3 Days
75625996|NCT02653378|Behavioral|EX|25% Energy Depletion by Exercise only for 3 Days
75625997|NCT04168138|Drug|rhTPO|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)>20*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet>50*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
75625998|NCT02653222|Procedure|Renal sympathicolysis|
75914533|NCT05078866|Biological|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Given IM
75914534|NCT05078866|Procedure|Biospecimen Collection|Undergo blood sample collection
75914535|NCT05078866|Procedure|Endoscopic Biopsy|Undergo endoscopy with biopsy
75625999|NCT02653222|Procedure|Ambulatory Blood Pressure Monitoring|1 month before and after surgery the patient will have an ABPM over 24h
75778335|NCT03723382|Other|SECRET structured 5 bundles of standard healthcare services|THE 5 BUNDLES OF Stroke SERVICE They the mix of the services for stroke patient which are available at the SS EVT bundle: is the availability of the Endovascular services Telemedicine core bundle : is the ability to guide or guided via tele-medicine for decision making for stoke patients tPA core bundle : the availability of all infrastructure to administer tPA in the first 3 hours of onset (NNT=8) DISMAST bundle : which refer to the availability of Dysphagia detection and management ,Aspirin in hyper acute phase , The Mobilization plans and programs for the patients, anticoagulant and statin prescription for selected patients for secondary prophylaxis programs Process of care bundle : like registering patients and morphology of the disease, screening programs for risk factors , following primary prevention plans all bundles should be judged by the 8M approach
75778336|NCT01584674|Device|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
75778337|NCT03716986|Diagnostic Test|MRI Oxygen Saturation Map|Calculation of the oxygen saturation map of gliomas cases
75778338|NCT01093820|Drug|methoxy-polyethyleneglycol epoetin beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
75778339|NCT03718468|Biological|GC FLU Quadrivalent|A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.
75778340|NCT03718468|Biological|Fluarix Tetra|A single dose administration of Fluarix Tetra will be through intramuscular injection.
75778341|NCT03533608|Behavioral|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
75778342|NCT00049322|Biological|bevacizumab|"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
75778343|NCT03437512|Device|Anodal tDCS|20 minutes of 2mA anodal stimulation.
75914536|NCT05078866|Biological|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|Given IM
76073961|NCT03582345|Procedure|EEG/fMRI|"All the patients recruited will undergo to the following interventions:~1. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2."
75626000|NCT02653222|Radiation|Magnetic Resonance Angiography|1 month before and after surgery the patient will have a MRA
75626001|NCT02653222|Biological|Blood test|complete blood count, blood platelets, coagulation profile, irregular agglutinins search
76073962|NCT01766401|Drug|Placebo|
75778344|NCT03437512|Behavioral|Fluency training|Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
75778345|NCT03437512|Device|Sham tDCS|For sham stimulation, current is ramped up and back down over 30 seconds.
75321761|NCT04387045|Behavioral|Guilty feelings|Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.
75321762|NCT00571259|Drug|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
75321763|NCT00571259|Drug|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
75778346|NCT00058058|Procedure|MRI|Breast contralateral to the breast diagnosed with cancer was scanned prior to initiation of chemotherapy and within 90 days of a negative mammogram of the study breast. A recent (within 90 days) negative or benign mammogram (defined by final BI RADS category 1 or 2) and negative or benign clinical breast exam of the study breast were required for entry into the study.
75778347|NCT03532048|Behavioral|The Papás Saludables, Niños Saludables Program|Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.
75914537|NCT05078866|Other|Questionnaire Administration|Ancillary studies
75914538|NCT05077176|Biological|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
75914539|NCT05077176|Biological|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
75321764|NCT01893879|Drug|placebo for study drug|Given PO
75914540|NCT05075187|Diagnostic Test|Genetic Screening|Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.
76073963|NCT01766401|Drug|Vilazadone|Viibryd
75321765|NCT01893879|Drug|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
75321766|NCT01893879|Other|laboratory biomarker analysis|Correlative studies
75626002|NCT02656498|Drug|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
75626003|NCT02656654|Other|Whole-body compression|
75626004|NCT02653066|Other|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
75626005|NCT02653066|Other|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
75626006|NCT00649870|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
75914541|NCT05071937|Drug|ZEN003694|ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
75914542|NCT05071937|Drug|Talazoparib|Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.
75914543|NCT05070351|Drug|PPI deprescribing|Patients currently on a proton pump inhibitor (PPI) undergoing transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized to receive instructions to stop taking their PPI.
75914544|NCT05069051|Drug|Belimumab 200 MG/ML [Benlysta]|Patients obtain belimumab treatment in combination with rituximab and venetoclax
75914545|NCT05069051|Drug|standard of care|Patients obtain the standard of care: combination rituximab and venetoclax
75914546|NCT05067387|Drug|Placebo|Oral placebo
75914547|NCT05067387|Drug|THC|Oral THC (20 mg)
75914548|NCT05067387|Drug|CBD|Oral CBD (20 mg)
75914549|NCT05067387|Drug|THC + CBD|Oral THC (20 mg) + CBD (20 mg)
75626007|NCT00649870|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fed
75626008|NCT02536144|Procedure|magnetic-controlled capsule endoscopy system|"A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
75914550|NCT05064280|Drug|Pembrolizumab|Given by IV (200 mg IV D1 Q3W)
75914551|NCT05064280|Drug|Lenvatinib|Given by PO (20 mg PO QD)
75626009|NCT02536144|Procedure|Colonoscopy|"Bowel preparation should be well done before the examination.~A tube with illumination and camera system would insert into colon from anus.~From the pictures captured by the camera ,the doctor would see the mucous of the colon."
75626010|NCT04167280|Drug|Ipratropium Metered Dose Inhaler|MDI to deliver 20mcg per puff ipratropium bromide
75626011|NCT04167280|Drug|placebo metered dose inhaler|matched MDI to deliver inactive drug
75626012|NCT02652910|Drug|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
75914552|NCT05064007|Behavioral|A: 40 Hz music|The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks
75914553|NCT05064007|Behavioral|B: 40 Hz sound|The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks
75321767|NCT01894503|Drug|S8 Sinus Implant (mometasone furoate, 1350 mcg)|Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
75321768|NCT02991547|Other|Observational|
75626013|NCT04167046|Procedure|Erector spinae block|Preoperative erector spinae block.
75626014|NCT02652832|Device|non invasive brain stimulation|non invasive brain stimulation
75626015|NCT02652988|Other|Active-tDCS|Active home-based tDCS applied at home.
75626016|NCT02652988|Other|Sham-tDCS|Sham home-based tDCS applied at home.
75626017|NCT04166968|Device|Anodal transcranial direct current stimulation (A-tDCS)|Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA
75626018|NCT04166968|Device|Cathodal transcranial direct current stimulation (C-tDCS)|Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA
75626019|NCT04166968|Device|Sham stimulation (sham-tDCS)|placebo stimulation
75626020|NCT04166968|Behavioral|Neuromotor training|conventional neuromotor treatment
75626021|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
75626022|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
75626023|NCT02649010|Device|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
75626024|NCT02649088|Device|Microscan|It allows to look at sublingual microcirculation
75914554|NCT05064007|Behavioral|C: Preferred music|The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks
75914555|NCT05061030|Biological|the ATMP Protrans|Protrans consists of Wharton's jelly derived mesenchymal stromal cells
75914556|NCT05058456|Device|Shockwave Medical Mini S Peripheral IVL Catheter|The Shockwave Medical Mini S Peripheral IVL Catheter is intended for lithotripsy-enhanced catheter dilatation of lesions, including calcified lesions found in the peripheral vasculature, such as the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. The Mini S IVL Catheter is not for use in the coronary or cerebral vasculature.
75914557|NCT05056948|Other|artificial intelligence (AI) computer assisted design (CAD)|Maxillary right first molar will be removed in the computer and will be designed by artificial intelligence system
75914558|NCT05051722|Diagnostic Test|Tampon Collection|A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
75914559|NCT05051722|Diagnostic Test|Blood Collection|A blood sample will be collected from each participant prior to undergoing any exams or procedures.
75914560|NCT05051449|Drug|Ketamine Hydrochloride|Ketamine will be administered by a nurse in a 2-week treatment phase, during which participants will receive six IV infusions of 0.5 mg/kg (over 40-50 minutes) ketamine three times per week. Infusion days for patients will be on Mondays, Wednesdays, and Fridays, +/- 1 day. Ketamine infusions will take place at the UMB General Clinical Research Center (GCRC). The GCRC nurse will deliver ketamine within a private exam room. The infusions will last 40-50 min, and the participant will be observed by the GCRC clinical staff for 2 hours post-infusion. Vital signs will be monitored throughout the treatment; specifically, blood pressure, pulse ox and heart rate will be checked prior to treatment, q20 minutes during infusion, and q30-60 minutes after infusion for up to three hours.
76073964|NCT03159273|Dietary Supplement|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
76073965|NCT01279096|Drug|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
76073966|NCT03582267|Dietary Supplement|Docosahexaenoic Acid (DHA)|Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
76073967|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
76073968|NCT03582111|Other|Study of medical records|Study of medical records
75321769|NCT02991391|Other|None, use of a questionnaire|Telephone health survey using 2015 Behavioral Risk Factor Surveillance Survey in Texas, Florida, South Carolina, and Kentucky that includes questions regarding tobacco exposure and respiratory symptoms
75626025|NCT02649088|Device|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
75626026|NCT04281160|Device|BeCare Mobile App|The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
75778348|NCT03532048|Behavioral|The Papás Saludables, Niños Saludables Wait-list Control|The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
75778349|NCT01100918|Device|BiV ICD|Biventricular ICD
75321770|NCT02990065|Dietary Supplement|PROTEIN SUPPLEMENTATION|
75321771|NCT00571961|Drug|Kaletra (lopinavir/ritonavir)|4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
75321772|NCT00571961|Drug|buprenorphine|Buprenorphine will be obtained through prescription at the subject's drug treatment program.
75321773|NCT00571961|Other|Clinical evaluations/Blood draws|Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
75321774|NCT02990377|Behavioral|RL-supported IVR intervention|Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
75626027|NCT02652598|Drug|Tolcapone|
75778350|NCT01100918|Device|ICD|Implantable Defibrillator
75778351|NCT00008138|Drug|carboplatin|pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
75778352|NCT00008138|Drug|paclitaxel|pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
75778353|NCT00008138|Procedure|debulking surgery|exploratory laparotomy, interval cytoreduction (to < 1 cm residual)
75914561|NCT05044611|Drug|Anhydrous Amiloride Hydrochloride|"Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI.~Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase"
75914562|NCT05044611|Drug|Placebo|Route of administration : oral the control arm will receive a placebo twice daily during 2 months
75321775|NCT04386655|Behavioral|Brain Injur Coping Skills - Telemedicine|"BICS sessions (both in-person and telemedicine) will occur once a week for 12 weeks. Each session will last two hours.~Modules of BICS include: Introduction to Brain Injury, Expectations for Recovery, Tips on Managing Challenging Problems, Learning about Depression after the Brain Injury, The 4 R's of Stress Management, Communicating Effectively with Professionals"
75626028|NCT02648776|Drug|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
75626029|NCT02648464|Drug|Hydroxychloroquine|
75626030|NCT02648464|Drug|Placebo|
75626031|NCT02648542|Other|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
75626032|NCT02648542|Device|transcranial direct current stimulation|Low-current electrical brain stimulation
75626033|NCT02648542|Other|Combined CAS and tDCS|Combined auditory and electrical stimulation
75626034|NCT02648542|Other|Sham stimulation|Sham stimulation
75626035|NCT02652754|Drug|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
75778354|NCT01100996|Other|control enteral nutrition|This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
75778355|NCT01100996|Other|enriched enteral feeding|This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
75778356|NCT01101074|Other|This is non-intervention observational study|This is non-intervention observational study
75778357|NCT03436732|Drug|LMB-100|administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles
75778358|NCT03436732|Drug|SEL-110|administered on day 1 of each cycle for up to 4 cycles
75778359|NCT01100060|Drug|azithromycin (AZ) microsphere|AZ microsphere (2000 mg) single dose on Day 1.
75778360|NCT01100060|Drug|test chloroquine (CQ) formulation|Test CQ formulation, 620 mg CQ base, single dose on Day 1.
75778361|NCT01100060|Drug|azithromycin (AZ)|AZ IR 4 x 500 mg tablets, single dose on Day 1.
75778362|NCT01100060|Drug|chloroquine (CQ)|CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
75778363|NCT01100216|Other|Nicotine Lozenge|4 mg for 12 days
75778364|NCT01100216|Other|Stonewall Dissolvable Tobacco Pieces|5.6 mg nicotine pieces for 12 days
75778365|NCT01100216|Other|Camel Snus Frost|pouches, 6.2 mg nicotine, for 12 days
75626036|NCT02652520|Procedure|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
75914563|NCT05044234|Drug|Cedirogant|Capsule, Oral
75914564|NCT05044234|Drug|Placebo|Capsule, Oral
75914565|NCT05038280|Behavioral|Let's Talk about Children intervention|The LTC -intervention includes two steps: Let´s Talk about Children discussion and Let´s Talk about Children network meeting. Students, students´ parents, and a teacher take part in the LTC -discussion. The LTC logbook is used as the framework for the discussions. The LTC discussion depicts the child's ordinary day in all developmental contexts and an action plan is made with parents to enhance the identified strengths and to give support in vulnerabilities. When the action plan is difficult to carry out without further participants, the LTC-Network meeting is planned with parents (and sometimes also the child). LTC-Network meeting provides a forum for case-based cross-sectoral collaboration, including also the families and their social network.
75626037|NCT02645110|Device|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
75626038|NCT02645110|Device|Tap water|Washing hand with water alone in comparison to hand washing with soap
75626039|NCT02645188|Other|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
75626040|NCT02645032|Biological|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
75626041|NCT02645032|Biological|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
75626042|NCT02645032|Biological|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
75626043|NCT02536066|Behavioral|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
75626044|NCT02644954|Drug|Metformin|Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
75626045|NCT02644954|Drug|Placebo|Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
75626046|NCT02644954|Drug|Topical Coal tar|Topical coal tar to be applied once daily
75626047|NCT02644954|Drug|Topical calcipotriol|Topical calcipotriol to be applied once daily
75778366|NCT01100216|Other|Skoal Wintergreen|Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
75778367|NCT01100294|Biological|Vaccination with FLUVAL P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml (total 3 μg HA), single dose."
75778368|NCT03436420|Drug|Gemcabene|Participants will take 300 milligrams (mg) of gemcabene, once per day for 12 weeks.
75778369|NCT01100372|Drug|gemcitabine hydrochloride|
75321776|NCT00572117|Drug|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
75321777|NCT01895127|Drug|Eculizumab|
75321778|NCT01895127|Biological|Immunoglobulin|
75321779|NCT01895127|Procedure|Plasmapheresis|
75914566|NCT05037799|Drug|Rb-82 Radioisotope|Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight
75914567|NCT05036213|Drug|BEET IT - Concentrate Beet root juice|Each bottle contains 75ml of concentrated beetroot juice with approximately 6.2mmol of inorganic nitrate. The product is provided by BEET IT, James White Drinks, Ipswich, UK.
75321780|NCT02991235|Dietary Supplement|PRJ212|6 capsules of study product will be taken daily and orally.
75321781|NCT02991235|Dietary Supplement|Placebo|6 capsules of study product will be taken daily and orally.
75321782|NCT02992171|Behavioral|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
75626048|NCT02652286|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
75626049|NCT00650338|Drug|DE-104 ophthalmic solution, low concentration|Topical ocular application
75626050|NCT00650338|Drug|DE-104 ophthalmic solution, medium concentration|Topical ocular application
75626051|NCT00650338|Drug|DE-104 ophthalmic solution, high concentration|Topical ocular application
75626052|NCT00650338|Drug|Placebo|placebo
75626053|NCT00650338|Drug|0.005% latanoprost|Topical ocular application
75626054|NCT02644720|Procedure|multifocal intraocular lens implantation|In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
75914568|NCT05036213|Drug|BEET IT - Concentrate Beet root juice (nitrate depleted)|Each bottle contains 75ml of concentrated beetroot juice with depleted nitrate, thus, no inorganic nitrate is found in thisbeverage. The product is also provided by BEET IT, James White Drinks, Ipswich, UK.
75914569|NCT05035394|Procedure|Cataract surgery|Cataract Surgery in a standardized fashion
75914570|NCT05035394|Procedure|KDB|Goniotomy with KDB glide will be performed at the end of Cataract Surgery
75914571|NCT05035394|Procedure|Istent|Two iStent inject W will be injected into Schlemms Canal at the end of Cataract Surgery
76073969|NCT01272934|Drug|Diclofenac Sodium|Topical gel 1%-4 times daily
76073970|NCT01272934|Other|Placebo|Topical gel-4 times daily
75778370|NCT01100372|Drug|liposome-encapsulated doxorubicin citrate|
75778371|NCT01100372|Procedure|quality-of-life assessment|
75778372|NCT00027560|Biological|alemtuzumab|"Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.~Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours."
75778373|NCT00027560|Drug|cyclosporine|Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
75778374|NCT00027560|Drug|fludarabine phosphate|Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.
75778375|NCT00027560|Drug|melphalan|Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.
75778376|NCT00027560|Procedure|allogeneic bone marrow transplantation|
75778377|NCT00027560|Procedure|peripheral blood stem cell transplantation|
75626055|NCT02644720|Procedure|monofocal intraocular lens implantation|In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
75321783|NCT01276561|Procedure|Single Incision Splenectomy|Patients will undergo laparoscopic splenectomy through a single incision
75321784|NCT01276561|Procedure|Laparoscopic Splenectomy|Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
75626056|NCT02644720|Drug|Dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery
75626057|NCT02644720|Device|multifocal intraocular lens (IOL) (Tecnis ZMB00)|
75626058|NCT02644720|Device|monofocal intraocular lens (IOL) (Tecnis ZCB)|
75321785|NCT01953081|Drug|TD-8954|
75321786|NCT01953081|Drug|Metoclopramide|
75321787|NCT02991313|Device|Endocardial Ablation Procedure|
75321788|NCT00572897|Drug|Fludarabine, Melphalan +/- ATG|"Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 [given over 6 hours], and 2 mg/kg on days -2 and -1 [given over 4 hours])"
75321789|NCT01276717|Drug|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
75321790|NCT01276717|Drug|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
75321791|NCT02991157|Drug|Nimodipine|
75321792|NCT01953237|Behavioral|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
75321793|NCT01953237|Device|Smartphone|
75321794|NCT04386499|Dietary Supplement|Resveratrol|mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6
75321795|NCT04386499|Dietary Supplement|Folic acid|400 mcg of folic acid
75321796|NCT01276795|Dietary Supplement|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
75321797|NCT01896687|Device|Scrambler|Electrotherapy
75321798|NCT00573287|Drug|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
75321799|NCT00573287|Drug|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
75626059|NCT03542266|Drug|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
75778378|NCT03951740|Device|Fitbit Charge 2|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
75321800|NCT04385797|Other|Telephone interview|Sociodemographic data. Clinical data. PMCI/MD quality of life, cognition, depression, technophilia and perceived stress and caregiver quality of life and burden assessments.
75321801|NCT05735925|Diagnostic Test|Skin Swab & Skin Biopsies & Blood Sample|These intervention will be necessary to phenotype the immune cells that are present in the skin and blood of HS patients
75778379|NCT03951740|Device|Mio Slice|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
75778380|NCT03951740|Device|Oxycon Mobile|"The Oxycon Mobile will be used as the reference method/golden standard to calculate energy expenditure (kcal). This device (consisting of a face mask and gas analyzer unit) will be worn during the entire laboratory activity protocol.~Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF)."
75778381|NCT01327352|Drug|Oshadi D|oral administration
75778382|NCT03951428|Diagnostic Test|Menstrual Blood Screening Test|The sponsor will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing three early stage cancers via self-collected menstrual blood using FDA approved devices.
75778383|NCT01100450|Behavioral|Progressive Resistance Training|12-week progressive resistance training (PRT) exercise program
75778384|NCT03951506|Other|Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
75778385|NCT03951506|Other|Conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
75778386|NCT03951350|Behavioral|Lifestyle Modification Program (LMP)|"Patients will follow TAU and LMP. This program will consist of 6 weekly group sessions (lasting 90 minutes each) led by an experienced psychologist and complemented by PowerPoint presentations. The content is the following:~Presentation of the project and psychoeducation on depression.~Behavior activation.~Sleep hygiene habits and careful exposure to sunlight.~Physical activity.~Adherence to the Mediterranean diet.~Summary of previous sessions with practical final suggestions."
75778387|NCT03951350|Behavioral|Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)|Patients will follow TAU and LMP and will be monitored using a wearable smart wristwatch that will track their daily sleep patterns and physical activity (LMP+ICTs).
75626060|NCT03542266|Drug|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
75914572|NCT05031273|Behavioral|Residents moving into a congregate-living development with more features that support healthy living|Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
75321802|NCT04385641|Other|Cell infusion for Dose-finding (Group A)|Group A：HLA-I and HLA-II molecular typing were performed at the serological and molecular levels, and the HLA-I and HLA-II molecular antigens of donor and subjects match on 3, 4, 5 or 6 / 6. After the successful matching, the non myeloablative immunosuppressive pretreatment with cyclophosphamide (900 mg / m＾2 / day) and fludarabine (30 mg / m＾2 / day) will be performed 6, 5, 4 and 3 days before the infusion of UCB-NK cells. After the pretreatment, the cell infusion was started on day 0, and the cell infusion could be divided into 50% and 50% for two consecutive days or every other day. To ensure clinical safety, if treatment-related adverse events reach DLT after the first infusion, the cell infusion will stop.
75321803|NCT04385641|Other|Cell infusion for Extended research (Group B)|Group B：Non myeloablative immunosuppressive pretreatment and cell transfusion were the same as group A.
75626061|NCT02648386|Procedure|Laparoscopic surgery|Completely resected rectal tumor.
75626062|NCT02648386|Device|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
75626063|NCT02648386|Biological|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
75626064|NCT02648386|Biological|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
75626065|NCT02641600|Device|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
75778388|NCT02530190|Device|intermittent pneumatic compression|20 minutes of intermittent pneumatic compression to lower extremities
75778389|NCT02530190|Procedure|massage|20 minutes of massage to lower extremities
75778390|NCT01100684|Drug|Asimadoline|0.5 mg Asimadoline BID
75914573|NCT05030298|Radiation|Radiation Therapy|Undergo radiation therapy
75914574|NCT05030298|Radiation|Radiosurgery|Undergo radiosurgery
75321804|NCT01896921|Drug|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
75626066|NCT02641600|Device|Placebo stockings|Placebo stocking with pressure applied to the legs
75626067|NCT02648308|Behavioral|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
75778391|NCT01100684|Drug|Placebo|Placebo
75914575|NCT05030298|Procedure|Stereotactic Biopsy|Undergo MRI-guided stereotactic biopsy
75914576|NCT05030298|Drug|Temozolomide|Drug
75321805|NCT01276873|Device|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
75321806|NCT01897077|Drug|Peanut Dissolving Film|
75778392|NCT03451084|Drug|ASLAN003|Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
75914577|NCT05030298|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75914578|NCT05030298|Procedure|Tumor Treating Fields Therapy|Undergo TTF
75914579|NCT05029362|Behavioral|SmokefreeSGM|Participants will have access to a text-based smoking cessation program tailored to sexual minority individuals (SmokefreeSGM). The text-based program will be beta-tested by these participants for a period of 2 weeks before and 10 weeks after their quit date. Messages originated from the text-based smoking cessation program will be sent by a fictitious quit coach who will offer evidence-based advice on quitting smoking based on real-life experiences of sexual minority individuals.
75626068|NCT02644876|Drug|Penehyclidine inhalation|Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
75914580|NCT05029336|Biological|Depletion of CD3/CD19 in an autologous stem cell transplant|The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.
75914581|NCT05020080|Other|Operant conditioning of motor evoked potentials|MEPs elicited by TMS will be applied at the hot spot for the wrist extensor carpi radialis. During training trials, participants will be asked to increase the size of their MEP response. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
75914582|NCT05012722|Diagnostic Test|Sphygmocor CVMS (Atocr Medical, Sydney Australia) PWV measurement|All patients included in this study will have a pulse wave velocity measurement measured using SphygmoCor cardiovascular management system (CVMS) (Atocr Medical, Sydney Australia) which is a tonometry-based device used to noninvasively obtain vital cardiovascular data.
75914583|NCT05003778|Other|Traditional equipment resistance training|Participants will undergo 6 weeks of traditional equipment resistance training
75626069|NCT02644876|Drug|Placebo inhalation|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
75626070|NCT00652600|Drug|Propranolol|ER Capsules, 160 mg, single-dose
75626071|NCT00652600|Drug|Inderal-LA|ER Capsules, 160 mg, single-dose
75626072|NCT02644642|Other|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
75626073|NCT03520504|Radiation|Proton craniospinal irradiation (CSI)|Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
75914584|NCT05003778|Other|Minimal equipment resistance training|Participants will undergo 6 weeks of minimal equipment resistance training
75914585|NCT05003778|Other|Blood flow restriction training|Participants will undergo 6 weeks of blood flow restriction training
75626074|NCT04166578|Drug|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
75778393|NCT02529878|Drug|S1/Paclitaxel chemotherapy plus Apatinib|S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
75914586|NCT05000372|Drug|68Ga-grazytracer|68Ga-grazytracer PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
75914587|NCT04984733|Drug|Temozolomide|"Metronomic TMZ 50mg/m2/day orally for 3 months then nivolumab 240mg IV +/- TMZ until progression.~Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths. Patients who progress on TMZ will start monotherapy with nivolumab. Patients will remain on monotherapy with nivolumab or combination therapy until progression or up to a maximum of 24mths."
75626075|NCT04166578|Procedure|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
75626076|NCT04166578|Procedure|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
75626077|NCT04166578|Behavioral|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
75778394|NCT03451006|Drug|Metformin|Oral metformin (up to 2gm) will be given in divided doses
75778395|NCT03451006|Drug|Placebo|Oral Placebo will be given in divided doses
75778396|NCT05625854|Behavioral|Blow a fan to the face combine aromatherapy|Blow a fan with aromatherapy to the face
75778397|NCT05625854|Behavioral|Blow a fan to the face|Blow a fan to the face
75778398|NCT05625854|Behavioral|Blow a fan to the feet|Blow a fan to the feet
75778399|NCT01327118|Drug|Prostaglandin F2alpha|intravenous injection
75778400|NCT01327118|Drug|Isoton sodium chloride|intravenous injection
75914588|NCT04984733|Drug|Temozolomide 50mg/m2/day|Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression
75914589|NCT04984733|Drug|Temozolomide 3 month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until progression.
75914590|NCT04984733|Drug|Temozolomide 24month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until a maximum of 24 months
75778401|NCT03450070|Device|Light Therapy Mask Cream|test panel
75778402|NCT03723304|Procedure|Bridging followed by transplant|Trans-arterial chemoembolization or percutaneous alcohol injection or radio-frequency ablation during the waiting time followed by liver transplant
75914591|NCT04984421|Behavioral|Healthy School Start|The Healthy School Start program is a universal 4-component family support program for children starting school (5-7 years of age) promoting healthy dietary habits and physical activity in the home environment to prevent childhood obesity and parents' risk of developing type 2 diabetes. It is targeting both children and parents.
75914592|NCT04982250|Behavioral|Formal peer PrEP referral + HIVST delivery|After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
75914593|NCT04982224|Drug|REGN5093-M114|Administered by intravenous (IV) infusion
75626078|NCT04166578|Behavioral|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
75321807|NCT00749749|Drug|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
75321808|NCT00749749|Drug|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
75321809|NCT02993263|Device|VectraplexECG System with CEB®|The device will be used after noncardiac surgery
75321810|NCT01898013|Drug|Pregnenolone|
75321811|NCT01898013|Drug|Placebo|
75321812|NCT02991937|Drug|Piperacillin/Tazobactam|24 hours of IV antibiotic administration
75321813|NCT02991937|Procedure|Surgical Treatment|Appendectomy
75321814|NCT00420667|Drug|Enoxaparin|
75321815|NCT02328807|Procedure|Radio-Frequency Ablation (RFA)|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
75626079|NCT04166578|Diagnostic Test|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
75626080|NCT04166578|Diagnostic Test|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
75626081|NCT02647996|Procedure|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
75626082|NCT04166734|Drug|Pembrolizumab|"Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks."
75626083|NCT04166734|Radiation|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
75626084|NCT00653536|Device|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
75778403|NCT03723304|Procedure|Direct liver transplant|Direct liver transplant (no neoadjuvant approaches during the waiting time period)
75778404|NCT03449758|Drug|SARILUMAB|Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous
75626085|NCT00651352|Drug|4 mg nicotine lozenge|marketed formulation
75626086|NCT00651352|Drug|2 mg nicotine lozenge|marketed formulation
75778405|NCT03449758|Drug|Azathioprine|Pharmaceutical form:Tablet Route of administration: Oral
75778406|NCT03449758|Drug|Chloroquine|Pharmaceutical form:Tablet Route of administration: Oral
75778407|NCT03449758|Drug|Hydroxychloroquine|Pharmaceutical form:Tablet Route of administration: Oral
75626087|NCT00651352|Drug|2 mg nicotine prototype|2 mg
75626088|NCT00651352|Drug|4 mg nicotine prototype|4 mg
75778408|NCT03449758|Drug|Leflunomide|Pharmaceutical form:Tablet Route of administration: Oral
75778409|NCT03449758|Drug|Methotrexate|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular
75778410|NCT03449758|Drug|Sulfasalazine|Pharmaceutical form:Tablet Route of administration: Oral
75914594|NCT04979949|Biological|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
75914595|NCT04979949|Biological|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
75914596|NCT04979598|Other|Home exercise program|A home exercise program is provided but this is an observational study. The effect of the exercise program is not under investigation.
75914597|NCT04975958|Drug|AN2025|oral administration
75914598|NCT04975958|Drug|AN0025|oral administration
75466930|NCT01914770|Drug|Belimumab 10 mg/kg|Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
75321816|NCT01277107|Drug|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
75321817|NCT01277107|Drug|Placebo capsule|Identical placebo capsule
75626089|NCT02641678|Device|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
75626090|NCT02641444|Procedure|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
75626091|NCT02641444|Procedure|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
76073971|NCT03159117|Drug|PF-06688992|(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
75778411|NCT03716752|Procedure|Modified connective tissue graft wall with wing technique|the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
75778412|NCT03449446|Drug|SEL|18 mg tablet administered orally once daily without regard to food
75778413|NCT03449446|Drug|FIR|20 mg tablet administered orally once daily without regard to food
75778414|NCT03449446|Drug|CILO|30 mg tablet administered orally once daily without regard to food
75321818|NCT04768959|Behavioral|FelizMente|The intervention aims to improve well-being, without denying the existence of symptoms or problems, focusing on generating positive emotions and actions congruent with the person's values through 11 weekly 90-minute group sessions. The multi-component intervention manual was composed of evidence-based exercises of Positive Psychoterapy Interventions, Acceptance and Commitment Therapy and Mindfulness and was theory driven according the broaden-and-build-theory (Fredrickson, 2001) and the self-serving model of paranoia (Murphy et al., 2018). It was also informed by previous pilot studies carried out on people with paranoid tendencies (see Valiente et al., 2020) and with Severe Psyquiatric Condition samples.
75321819|NCT05735691|Procedure|High-Intensity Treadmill Training|Participants will walk on a treadmill at a speed that produces 70-80% of age-adjusted heart rate reserve or a rating of perceived exertion of 17/20. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
75321820|NCT05735691|Procedure|Treadmill Training with Perturbations|Participants will walk on a treadmill and a perturbation of the treadmill will be produced every 20s. Perturbations will randomly occur in the forward, backward, right or left directions, with a perturbation size set to 80% of stability threshold. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts with 2-3 minutes rest between bouts.
75321821|NCT05735691|Procedure|Standard Treadmill Training|Participants will walk on a treadmill at a speed that produces 30-40% of age-adjusted heart rate reserve. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
75778415|NCT03449446|Drug|Placebo to match FIR|Tablet administered orally once daily without regard to food
75778416|NCT03449446|Drug|Placebo to match CILO|Tablet administered orally once daily without regard to food
75914599|NCT04975958|Drug|Atezolizumab 1200 mg in 20 ML Injection|infusion
75778417|NCT03449446|Drug|Placebo to match SEL|Tablet administered orally once daily without regard to food
75778418|NCT03723148|Drug|Oral Fedratinib|Oral fedratinib administered as directed by treating physician.
75778419|NCT03435016|Diagnostic Test|Diagnostic work-up|Patients are examined with all modalities. MR enterocolonography, ultrasound, and small bowel capsule endoscopy are compared against ileocolonoscopy (gold standard).
75914600|NCT04975581|Biological|Allograft Patch|Rotator Cuff repair with Allograft Patch (Graftjacket Now)
75914601|NCT04971018|Device|Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
75914602|NCT04971018|Device|Sham Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
75914603|NCT04970511|Behavioral|BBAT (Basic Body Awareness Therapy)|The group I: BBAT Face-to-Face Training (60 min) will be provided.
75914604|NCT04970511|Behavioral|Online BBAT training|The group II: Online BBAT training (60 min) will be provided.
75914605|NCT04969341|Other|Survey Administration|Complete survey
75914606|NCT04969341|Other|Electronic Health Record Review|Review of medical records
75914607|NCT04965961|Drug|EPO|Please refer to the arm description
75914608|NCT04965961|Other|Control group - saline injection|Please refer to the arm description
75914609|NCT04961762|Other|Navigator Program|The main role of the Homeless Outreach Counsellor is to support continuity and comprehensiveness of care by helping participants follow their post-discharge plans and facilitating strong links with community-based health and social services. The Homeless Outreach Counsellor also helps address specific needs of participants, develop comprehensive care plans with members of patient's multidisciplinary circle of care, and facilitate the transition of clients to long-term community-based health and social services.
75914610|NCT04948918|Procedure|Anatomically optimized distal renal denervation|Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter
75914611|NCT04945993|Device|Endomethasone N|Endomethasone N is a powder intended to be mixed extemporaneously with a eugenol-based liquid (i.e, Endomethasone Liquid) to obtain a permanent root canal sealer. After selection of dentists, they will screen consecutively and systematically eligible patients, will send them the Patient Information Letter and will enroll them in the clinical investigation if non opposition from the patient. Patient clinical data will be recorded in an electronic Case Report Form. Pseudonymized retro-alveolar radiographies at baseline consultation and at 5 and 10 years post-obturation consultations will be recorded in the e-CRF. These radiographies will be examined by 2 independent endodontists and the results of these examinations will be recorded in the e-CRF. Site data will be collected on a Site Questionnaire with Visual Analog Scales.
75914612|NCT04945603|Other|Standard management according to international/national guidelines|Standard management according to international/national guidelines. Observational study
76073972|NCT01279252|Drug|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
76073973|NCT03159351|Device|active rTMS treatment|active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
75778420|NCT03716674|Device|Metronome|Patients completed 4 walking sessions of at least 10 minutes each. During each session, no auditory rhythm was given, or the rhythm of a Rhythmic Auditory Stimulation (RAS) adapted to the pace of comfort of each patient using a metronome was broadcasted via headphones. In all, 4 conditions were tested: walk with no RAS or an isochronous RAS or a random RAS or a RAS with an autocorrelated metronome rhythm.
75778421|NCT03716596|Radiation|SBRT|SBRT radiation dose is 40-50 Gy in total.
75778422|NCT03716596|Drug|anti-PD-1 antibody|Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
75321822|NCT01277185|Dietary Supplement|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
75778423|NCT03718390|Drug|Formulation A|Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
75778424|NCT03718390|Drug|Formulation B|Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
75778425|NCT03718390|Drug|Formulation C|Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
75778426|NCT03718390|Drug|Formulation D|Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
75778427|NCT03718390|Drug|Formulation E|Placebo Capsule containing microcrystalline cellulose
75778428|NCT03718390|Procedure|Endoscopy|Endoscopy at 2 hours post dosing
75778429|NCT03718390|Procedure|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
75778430|NCT03449134|Drug|Placebo|Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.
75778431|NCT03449134|Drug|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID during the 12-week main study period and during the 40-week extension period, according to randomization.
75778432|NCT03722992|Other|MBSR|Guided yoga and meditation practices
75778433|NCT05650840|Procedure|Charcoal based whitening toothpaste (signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded.~Intervention drug : whitening toothpaste charcoal based whitening toothpaste compared to calcium carbonate and perlite whitening toothpaste~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush (Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination"
75778434|NCT05650840|Procedure|Calcium carbonate /perlite containing whitening toothpaste (signal whitening moonlight toothpaste Unilever Mashreq - Egypt).|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using calcium carbonate /perlite containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded. The main operator will perform the tooth brushing procedures for all the patients himself twice daily.~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush(Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination Device used is atomic force microscopy to determine enamel abrasion after brushing"
75778435|NCT03722914|Drug|Benzonatate 200 mg|200 mg/pellet, 1pellet/time, 3times/day
75914613|NCT04944173|Drug|Durvalumab|Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
75914614|NCT04944173|Radiation|Stereotactic Body Radiotherapy|Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.
75321823|NCT01277185|Dietary Supplement|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
75321824|NCT01277263|Device|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
75914615|NCT04944173|Diagnostic Test|Circulating Tumor DNA assay|After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
75914616|NCT04937361|Other|rectal swab|collection of rectal swabs
76073974|NCT03159351|Device|sham rTMS treatment|sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
76073975|NCT01279330|Other|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
76073976|NCT01279330|Other|Control|No intervention (Patients receive by mail the materials needed for stool samples).
75321825|NCT05735613|Procedure|osteotome crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. The drills can be sequentially used to widen the osteotomy site to the same level (1 mm short of the sinus floor), an osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level, the osteotome will be tapped gently to fracture up the sinus floor.Clinical check for membrane still intact, blocking the patient's nostrils and asking the patient to blow through his or her nose. Xenograft will be added as the grafting material and pushed to the sinus through the osteotomy site until the desired height of sinus elevation will be gained, the implant fixture will be inserted. Smart peg will be placed on implant and Ostell will be used to record ISQ.
75466931|NCT01914770|Drug|Placebo|Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
75626092|NCT02641444|Procedure|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
75626093|NCT02644564|Other|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
75321826|NCT05735613|Procedure|osseodensification crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. Change the drill motor to reverse-densifying Mode (counterclockwise drill speed 800-1500 rpm with copious irrigation), Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor, use the next wider Densah Bur (3.0mm) in the same mode and advance it into the previously created osteotomy with modulating pressure and a pumping motion. When feeling the haptic feedback of the drill reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments, the next wider densah drills advance in the osteotomy.Clinical check for membrane still intact. Xenograft added and pushed to the sinus through the osteotomy site then the implant fixture will be inserted.
75466932|NCT01914783|Other|ultrafine particles|exposure to ultrafine particles
75626094|NCT02648074|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
75778436|NCT03722914|Drug|blank control 0mg|0 mg/pellet, 1pellet/time, 3times/day
75778437|NCT03716518|Drug|Tonifying Spleen and Kidney Sequential Regimen|TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
75778438|NCT03716518|Drug|Placebo of 'Tonifying Spleen and Kidney Sequential Regimen|Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
75778439|NCT03529162|Procedure|Long head of Biceps Tenodesis|Patients will be randomized into two different groups to compare biceps tenodesis techniques
75778440|NCT03722758|Device|Spectrum TPH3|tooth restoration with two different restorative materials
75914617|NCT04931420|Drug|Standard of Care Chemotherapy|"If you have cancer of the stomach or food pipe (esophagus): the preferred chemotherapy regimen includes two or three medications. These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.~If you have cancer of the pancreas or ampulla: the preferred chemotherapy medicines include Gemcitabine or a three-drug combination chemotherapy called FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.~If you have bile duct cancers: a combination of Gemcitabine, platinum agents, or fluoropyrimidine will be considered."
75914618|NCT04931420|Procedure|Video-Assisted Thoracic Surgery (VATS)|If you have lung cancer, you may receive video-assisted thoracic surgery (VATS): a type of minimally invasive thoracic surgery of the chest, performed with a thoracoscope (small videoscope) using small incisions and special instruments to minimize trauma.
75466933|NCT01914783|Other|ultrafine particles and ozone|exposure to ultrafine particles and ozone
75466934|NCT01914783|Other|clean air|Exposure to clean air.
75466935|NCT01914796|Drug|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
75466936|NCT01914796|Drug|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
75466937|NCT01914809|Other|samples blood|
75466938|NCT01914809|Other|biopsy placentaire|
75466939|NCT01914822|Drug|methylphenidate hydrochloride|
75466940|NCT01914822|Drug|Sugar pill (placebo)|
75466941|NCT01914835|Behavioral|Motivational Chess|"The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).~The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions)."
75466942|NCT01914848|Other|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
75466943|NCT01914848|Other|Control Group|A routine care discharge planning with the social service
75466944|NCT01914874|Behavioral|Mindfulness Meditation|
75466945|NCT01914887|Drug|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
75466946|NCT01914913|Biological|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
75466947|NCT01914939|Drug|Oxytocin|
75466948|NCT01914939|Behavioral|Social Skills focused CBT|
75466949|NCT01914939|Behavioral|Stress management/relaxation training|
75466950|NCT01914939|Drug|placebo drug|
75466951|NCT01914952|Dietary Supplement|CaHMB capsule|1.0 gram of CaHMB powder in a gelatin capsule
75778441|NCT03722758|Device|Riva LC|tooth restoration with two different restorative materials
76073977|NCT00739336|Behavioral|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
75626095|NCT02648074|Other|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
75626096|NCT02641210|Procedure|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
75626097|NCT02641210|Drug|Albendazole|All participants took Albendazole 400 mg before the intervention.
75626098|NCT02641366|Device|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
75626099|NCT02641366|Procedure|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
75778442|NCT03447730|Drug|SYNB1020|SYNB1020 was supplied at a concentration of approximately 1 × 10^11 CFU/mL in a buffered solution in 5 mL cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
75778443|NCT03447730|Other|Placebo|Subjects received placebo orally in a chilled buffered solution (100 mL).
75778444|NCT03716440|Other|Nature exposure|Participants will view images of nature.
75778445|NCT03716440|Other|Non-nature exposure|Participants will view non-nature images.
75778446|NCT03722602|Other|Standard rehabilitation after stroke|The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.
75778447|NCT03716362|Device|Otoacoustic emissions device|as a screening tool for Auditory brainstem response
75914619|NCT04931420|Procedure|Lobectomy|"If you have lung cancer, you may receive a lobectomy:~A major/invasive surgical procedure where an entire lobe of your lung is removed."
75466952|NCT01914952|Dietary Supplement|HMB free acid gelcap|0.8 g HMB free acid is a soft gel capsule
75466953|NCT01914952|Dietary Supplement|HMB free acid mixed in water|0.8 g HMB free acid in water
75466954|NCT01914952|Dietary Supplement|CaHMB in water|1.0 g CaHMB powder mixed in water
75466955|NCT01914952|Dietary Supplement|HMB free acid|0.8 g HMB free acid
75466956|NCT01914965|Drug|Bupropion|Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
75466957|NCT01914965|Drug|Placebo|Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
75466958|NCT01914978|Other|Food allergy handbook for parents|The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.
75466959|NCT01914978|Other|Food allergy treatment as usual|
75466960|NCT01914991|Procedure|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
75466961|NCT01914991|Procedure|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
75466962|NCT01915004|Other|Educational Intervention|Bladder Training Video
75466963|NCT01915017|Behavioral|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
75914620|NCT04931420|Radiation|Consolidative Radiation|A type of radiation treatment used to kill any cancer cells that may be left in the body. It may also include a stem cell transplant or treatment with drugs that kill cancer cells.
75914621|NCT04931420|Radiation|Ablation Treatment|"Depending on the location of you cancer and the state of your cancer after chemotherapy, you may receive on the the following ablation treatments:~-Microwave or Radiofrequency Ablation: Radiofrequency ablation (RFA) and microwave ablation (MWA) are treatments that remove liver tumors by placing a needle through the skin into the tumor. In RFA, high-frequency electrical currents are passed through an electrode in the needle, creating a small region of heat. In MWA, microwaves are created from the needle to create a small region of heat. The heat destroys the liver cancer cells.~-General Tumor Ablation Treatment: a minimally invasive surgical method to treat solid cancers. Special probes are used to burn or freeze cancers without the usual surgery. Doctors use images of your tumor to guide where they place the needle. This requires only a tiny hole, usually less than 3 mm via which the probe is introduced."
75466964|NCT01915017|Behavioral|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
75466965|NCT01915017|Behavioral|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
75466966|NCT01915017|Other|Treatment as Usual|Standard medication follow up and limited case management
75466967|NCT01915030|Other|High protein diet|controlled feeding trail. Both arms are caloric restricted
75466968|NCT01915030|Other|standard protein diet|
75626100|NCT02641366|Procedure|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
75626101|NCT02644330|Procedure|transthoracic device closure|minimally invasive transthoracic device closure
75626102|NCT02644330|Procedure|surgical repair|surgical repair with cardiopulmonary bypass
75466969|NCT01915043|Other|health education for lymphedema prevention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach
75466970|NCT01915056|Other|GA-driven Intervention|For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
75466971|NCT01915069|Drug|Cilostazol|
75626103|NCT02644408|Drug|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
75778448|NCT03718078|Device|Confocal Laser Endomicroscopy|"The study is divided in two parts. For the two parts, patients will receive an intravenous injection of indocyanine green:~Ex vivo study~- Images/sequences of normal and abnormal hepatic tissues and surgical margins will be acquired on surgical specimens~In vivo study - Intra-operative pCLE imaging will be performed on hepatic masses and surgical margins"
75778449|NCT01310764|Procedure|Trabeculectomy|Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
75914622|NCT04931420|Procedure|Resection or Excision|Depending on the type of GI cancer you have and the state of your cancer after chemotherapy, you may receive a resection or excision: a surgical procedure that focuses on removing all or part of a tumor/organ/body using a sharp knife (scalpel) or other cutting instrument.
75626104|NCT02644408|Radiation|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
75914623|NCT04931420|Procedure|Peritonectomy|Peritonectomy is a surgery used to remove peritoneal tumors (tumors in the lining of the abdomen/stomach) from a patient. Following surgery, a heated chemotherapy bath (HIPEC) is commonly administered.
75778450|NCT03429556|Biological|Botulinum Neurotoxin Serotype E|Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
75778451|NCT03429556|Drug|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
75466972|NCT01915082|Drug|Azithromycin|"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
75626105|NCT02644408|Other|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
75626106|NCT02644486|Drug|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
75626107|NCT02644486|Drug|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
75626108|NCT02644486|Drug|Irbesartan|Irbesartan 300mg/d
75626109|NCT00652756|Device|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
75626110|NCT00652756|Other|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
75626111|NCT00827359|Drug|Everolimus|Tablet form taken orally once a day
75626112|NCT02641288|Drug|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
75626113|NCT02641288|Drug|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
75626114|NCT04165174|Drug|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
75778452|NCT03428152|Procedure|superior hypogastric block|superior hypogastric blockade during surgery
75778453|NCT05664802|Behavioral|e-HERO: Ending the HIV Epidemic in Rural Oklahoma|A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.
75778454|NCT03444766|Drug|Nivolumab|specified dose on specified days
75778455|NCT03526432|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
75914624|NCT04931420|Other|Transarterial Radioembolization|"If you have cancer in your biliary tract (gallbladder, pancreas or liver), you may receive transarterial radioembolization known as TARE.~TARE allows doctors to deliver radiation treatment directly to the liver using a minimally invasive technique that is designed to cause few side effects. TARE allows doctors to thread a catheter through a small incision in the participant's upper thigh through the artery that goes directly to the liver."
75914625|NCT04931251|Behavioral|Financial Navigation|providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
76073978|NCT03158415|Behavioral|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
76073979|NCT04385836|Drug|alpha one antitrypsin inhalation|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
75626115|NCT04165174|Radiation|SBRT|6-10Gy/F,5-8F
75626116|NCT02613247|Device|Hylan G-F 20|Intra-articular injection of 6 mL Hylan G-F 20
75626117|NCT02641132|Drug|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
75626118|NCT02641132|Procedure|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
75626119|NCT02647840|Behavioral|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
75626120|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
75778456|NCT03526432|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
75626121|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
76073980|NCT04385524|Biological|Adjuvanted Hepatitis B Vaccine|Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
76073981|NCT01274260|Drug|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
75626122|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
75778457|NCT01310842|Behavioral|Questionnaires|Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.
75778458|NCT01310842|Drug|Nicotine Patch Therapy|4 weeks of nicotine patch therapy
75778459|NCT01310842|Behavioral|Counseling Sessions|5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.
75778460|NCT03716206|Device|Exergame|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
75778461|NCT03716206|Other|Physical therapy|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
75778462|NCT03722368|Behavioral|RCHC|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills.
75778463|NCT03722368|Behavioral|RCHC+|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills. This intervention group will also receive on-going support groups and one on one counseling as needed.
75778464|NCT03722368|Other|Waitlist control|This group will served as the control group and will receive treatment as usual until the end of the study. At the end of the study they will have the opportunity to take part in the RCHC or RCHC+
75778465|NCT03426436|Diagnostic Test|Two consecutive 15-lead ECGs|The 15-lead ECG consists of a traditional 12-lead ECG and an additional three leads on the right side of the body. The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
75914626|NCT04930874|Other|NIRS (Near-Infrared Spectroscopy)|NIRS assessment of cerebral autoregulation and cerebral blood flow
76073982|NCT01274260|Drug|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
75626123|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
76073983|NCT03154983|Drug|docetaxel|Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
75321827|NCT05735613|Procedure|piezoelectric crestal sinus lifting|initial osteotomy will be performed with a 2-mm twist drill to remove the cortical bone, then the intralift tips (Intralift; TKW1, TKW2, TKW3,TKW4, TKW5; Satelec). TKW1 to TKW4 tips have diameters of 1.35 mm, 2.1 mm, 2.35 mm, and 2.8 mm and will be used to gradually widen the access canal to the Schneider membrane, gentle pressure will be applied on the tips to deepen the pathway, and a sterile spray (80 mL/min) cooling the tips to avoid heat injury. The TKW5 tip will be then inserted into the access canal, and the ultrasonic activation for 5 seconds with internal irrigation of 40 mL/min and repeated at 50 mL/min and then 60 mL/min. The sinus membrane will be pushed upward by the hydraulic pressure, the floating of the sinus membrane will be evaluated, and then the TKW4 (Ø 2.8 mm) will be used again to widen the access canal to the sinus membrane before plugging the bone graft.xenograft added. Implant fixture inserted and flap statured
75321828|NCT02987361|Device|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
75321829|NCT01274533|Drug|Lenalidomide|25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
75466973|NCT01915082|Drug|Ora-Plus|"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
75321830|NCT01277497|Drug|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
75626124|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
75626125|NCT00653614|Drug|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
75321831|NCT01277497|Drug|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
75778466|NCT03717766|Device|intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology|"5-aminolevulinic acid (5-ALA) is a pro-drug that causes fluorescent protoporphyrins that accumulate in malignant gliomas. Fluorescence can be visualized during surgery by the use of a modified microscope, which helps the surgeon define the margins of the tumor.~Neuro-navigated intraoperative ultrasound is an imaging technique that allows us to visualize intracranial lesions during surgery and correlate them with the image provided by the neuronavigator, obtaining a real-time view of the lesion and possible tumor remains.~To achieve greater tumor resections without increasing the incidence of neurological deficits, the use of intraoperative neuromonitoring has been progressively implemented. This technology and specifically the brain mapping allows us to locate the functional areas of the brain and perform more aggressive resections with lower morbidity"
75778467|NCT05664724|Behavioral|Receives interdisciplinary sessions|"Along with usual care, participants receive six interdisciplinary sessions at 2 months and 1 month pre-operatively and 2 weeks, 6 weeks, 3 months, and 6 months post-operatively attended by an orthopedic surgeon, a physiotherapist, a patient navigator, and the patient. The pre-operative interdisciplinary sessions will outline expectations, explore patients' questions and concerns, set expectations for the next interdisciplinary session, and ensure goal congruence between all members of the team.~Along with usual care during the post-operative period, participants will receive interdisciplinary sessions that address safety and medical issues, revisit patient expectations, reinforce care team expectations, focus on a personalized rehabilitation plan, and ensure goal congruence between the various team members."
75778468|NCT03722290|Drug|Metformin|Oral administration of metformin 250mg (twice a day) for the 1st week followed by metformin 500mg (twice a day) for the next 8 weeks.
75778469|NCT03423238|Other|Exercise|Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
75321832|NCT01956279|Drug|Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
75321833|NCT01956279|Drug|Placebo|Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
75321834|NCT00351793|Device|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
75321835|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
75321836|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
75321837|NCT01956435|Device|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
75466974|NCT01915121|Behavioral|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
75626126|NCT00653614|Drug|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
75626127|NCT00653614|Drug|Placebo|Placebo administration in each arm
75626128|NCT02647762|Drug|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
75626129|NCT02647762|Drug|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
75626130|NCT02647762|Drug|Placebo|Placebo tablets, 1mg BID for 12 weeks
75626131|NCT02647762|Drug|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
75626132|NCT02644252|Drug|Day 1: Cisplatin 75 mg/m2|
76073984|NCT01274416|Behavioral|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
75778470|NCT03423238|Behavioral|Health Education|Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.
75778471|NCT03423238|Other|Exercise Compliance|Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
75778472|NCT03423238|Dietary Supplement|Calorie-Restricted Diet|Diet plans will provide a caloric deficit of 500 kcals per day. The lowest calorie level permitted will be 1,100 kcals for women and 1,200 kcals for men. The calorie distribution goal will be 15-20% from protein, <30% from fat, and 45-60% from carbohydrates. Participants will consume 2 meal replacements per day (Premier Protein shakes and bars); provided by the study)), along with one meal composed of traditional foods (500-750 kcals, low in fat, high in vegetables), and 1-3 snacks as needed (e.g., cereal bar, fruit, or vegetable, providing 100-150 kcals each). For the meal, patients will follow a weekly menu plan and recipes provided by the study. The food plan will be tailored to individual preferences and energy needs.
75778473|NCT03423238|Behavioral|Behavioral Modification|During months 1-3, participants will attend weekly individual behavioral counseling sessions with the study registered dietitian (RD); individual sessions will be held twice per month during months 4-6. The sessions will focus on self-monitoring, portion control, mindful eating, coping with negative thoughts, eating at regular times, and stress management. The RD will review individual progress, solve problems, answer questions, and set weight loss goals.
75914627|NCT04930081|Behavioral|Positive Parenting Program, Mindful Parenting|"The Positive Parenting Program (Triple P) consists of 5 weekly group sessions (each lasting for 2 hours) plus three weekly individual telephone interview sessions (each lasting for around 20 minutes). Program materials is available in Chinese.~The Mindful Parenting program consists of 8 weekly group sessions, each lasting for 2 hours. Programme materials have already been translated into Chinese by local partners of the programme developer."
75914628|NCT04927052|Device|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
76073985|NCT01274416|Behavioral|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
76073986|NCT03154593|Other|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
76073987|NCT00252850|Genetic|CERE-120: AAV2-NTN|
76073988|NCT01983683|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
76073989|NCT01983683|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
76073990|NCT01983683|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
76073991|NCT01983683|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
75626133|NCT02644252|Drug|Day 1: Vinorelbine 25 mg/m2|
76073992|NCT05610111|Device|CLC + BAM|Closed Loop Control with the Behavioral Adaption Module for 4 weeks
76073993|NCT05610111|Device|CLC + ABC|Closed Loop Control with Adaptive Biobehavioral Control for 16 weeks
76073994|NCT04405713|Procedure|from the onset of symptoms within the first 3 days|ELC within 3 days of onset of ACC
75626134|NCT02644252|Drug|Day 8: Capsule vinorelbine 50 mg/m2|
76073995|NCT04405713|Procedure|: from the onset of symptoms within the 4-7 days|ELC 4-7days of onset of ACC
76073996|NCT04405713|Procedure|from the onset of symptoms beyond 7 days|ELC after 7days of onset of ACC
76073997|NCT03154515|Drug|Ingavirin|
76073998|NCT03154515|Drug|Placebo|
76073999|NCT03158103|Drug|MEK162|MEK162 at 30mg twice daily
76074000|NCT03158103|Drug|Pexidartinib|pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)
76074001|NCT03581799|Other|Oral dispersible tablet|Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
75626135|NCT02644252|Drug|Day 1: Carboplatin AUC=5|
75626136|NCT02644252|Drug|Day 1: Vinorelbine 30 mg/m2|
76074002|NCT03158025|Drug|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
76074003|NCT03158025|Drug|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
75626137|NCT02644252|Drug|Day 8: Capsule vinorelbine 60 mg/m2|
75626138|NCT02644252|Dietary Supplement|Tocotrienol 300 mg x 3 daily until progression|
75626139|NCT02644252|Drug|Placebo 1 capsule x 3 daily until progression|
75626140|NCT00818389|Drug|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
75626141|NCT00818389|Drug|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
75626142|NCT00818389|Drug|placebo|an inactive substance
76074004|NCT03158025|Drug|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
76074005|NCT03158025|Drug|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
76074006|NCT03158025|Drug|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
76074007|NCT03158025|Drug|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
76074008|NCT01998893|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
75778474|NCT03423238|Other|Weight-Loss Compliance|Participants will be asked to record their food and beverage intake in daily logs which will be reviewed weekly by the RD to verify compliance to the diet. Body weight will be measured weekly to ensure that participants are losing weight at an appropriate rate. If a participant is not meeting weight loss goals, energy intake will be modified accordingly to produce the desired rate of weight loss.
75778475|NCT03423238|Other|Dietary Counseling|Participants have one meeting with the Rehab dietitian upon starting.
75778476|NCT03717688|Drug|Entresto|Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan
75778477|NCT03717688|Drug|Sitagliptin 100mg|2 x 100mg sitagliptin as single dose.
75778478|NCT03717688|Drug|Placebos|No treatment
75778479|NCT03714100|Behavioral|Tai Ji Quan: Moving for Better Balance|Participants will attend one-hour Tai Ji Quan: Moving for Better Balance classes twice a week for 16-weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
75778480|NCT03717610|Procedure|radical surgery with HIPEC|Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).
75778481|NCT03717532|Procedure|Placebo|Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.
75778482|NCT03717532|Procedure|Personalized Tourniquet System for Blood Flow Restriction|Patients will be receiving blood flow restriction therapy with a pressure cuff
75778483|NCT02953678|Drug|Ruxolitinib|
75778484|NCT02953678|Drug|Prednisone or methylprednisolone|Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
75778485|NCT03412084|Behavioral|Stand up and move more|4 week behavioral intervention involving the development and implementation of action plans
75778486|NCT00090753|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
75778487|NCT00090753|Drug|Epoetin alfa|Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
75778488|NCT00090753|Drug|Epoetin beta|Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
75778489|NCT00090753|Drug|Darbepoetin alfa|Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
75778490|NCT00048932|Drug|Double-blind Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight < 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Day 1, 15, and 29.
75914629|NCT04927052|Device|Juvederm Voluma with Lidocaine.|Juvederm Voluma with Lidocaine. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine
75914630|NCT04926857|Other|Non-Interventional|Non-Interventional
75466975|NCT01915121|Behavioral|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
75466976|NCT01915134|Drug|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
75466977|NCT01915134|Drug|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
75778491|NCT00048932|Drug|Double-blind Placebo|Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
75778492|NCT00048932|Drug|Open-label Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight < 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Every 28 days.
75778493|NCT00073983|Biological|filgrastim|filgrastim
75778494|NCT00073983|Biological|pegfilgrastim|pegfilgrastim
75778495|NCT00073983|Drug|docetaxel|docetaxel
75778496|NCT00073983|Drug|gemcitabine hydrochloride|gemcitabine hydrochloride
75778497|NCT00073983|Genetic|microarray analysis|microarray analysis
75778498|NCT00073983|Other|laboratory biomarker analysis|laboratory biomarker analysis
75778499|NCT00073983|Other|pharmacokinetic study|pharmacokinetic study
75914631|NCT04919265|Other|No intervention - mother-infant cohort study|There are no interventions because it is a mother-infant cohort study
75914632|NCT04913012|Combination Product|Systematic aerobic training|Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
75914633|NCT04913012|Combination Product|Systematic resistance training|Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
75914634|NCT04913012|Combination Product|Aerobic training booster sessions|Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).
76074009|NCT01791985|Drug|AZD4547 / anastrozole or letrozole|"Patients will continue or restart the NSAI which they have progressed* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
75914635|NCT04913012|Combination Product|Resistance training booster sessions|Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).
75914636|NCT04911127|Drug|200mg Cannabidiol by capsules twice daily|200mg twice daily via 50mg capsules
75626143|NCT02640976|Drug|Human menopausal gonadotrophin (HMG)|[Merional® 75 IU ampoules, IBSA institut]
76074010|NCT03157869|Device|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
76074011|NCT03157869|Other|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
75321838|NCT01277575|Device|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
75321839|NCT01277575|Device|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
75321840|NCT01270087|Drug|Adalimumab|40 mg IV every 14 days
75321841|NCT01277653|Device|tumor maker interval shortly|tumor maker interval every 3 month
75321842|NCT01958073|Drug|Conjugated Estrogen Vaginal Cream|
75626144|NCT02640976|Drug|GnRH antagonist Cetrorelix|[Cetrotide® 0.25 mg syringes, Merck Serono]
75466978|NCT01915147|Drug|OXN PR followed by OxyPR tablets|
75914637|NCT04911127|Drug|400mg Cannabidiol by capsules twice daily|400mg twice daily via 50mg capsules
75914638|NCT04911127|Drug|Placebo capsules|MCT oil capsules as placebo for CBD
75914639|NCT04907565|Biological|Blood sampling|4 tubes of 7 mL of blood will be collected
75914640|NCT04907565|Biological|white adipose tissue sampling|At the beginning of the surgery, samples of white adipose tissue from the surgical wound will be collected.
75914641|NCT04903925|Procedure|Impacted tooth extraction|All patients will undergo a surgical tooth extraction
75914642|NCT04903262|Procedure|Ultraprotective ventilation with Extracorporeal CO2 removal|HLS5.0 Cardiohelp® (Getinge Cardiopulmonary Care, Rastatt, Germany): 1.3 m² polymethylpentene hollow fiber membrane oxygenator. The extracorporeal blood flow is in the range of 1000 to 1500 mL/min. Sweep gas (air or oxygen) is drawn through the hollow fibers by a vacuum pump, creating a diffusion gradient for gas exchange across the membrane.
76074012|NCT04664621|Diagnostic Test|HepQuant|Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.
76074013|NCT04176497|Drug|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
75321843|NCT01958073|Drug|Estradiol Ring|
75321844|NCT01958073|Drug|Placebo|
75321845|NCT01270165|Drug|telbivudine|600mg, oral daily over 12 months
75321846|NCT05740215|Drug|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
75321847|NCT05740215|Drug|Lenvatinib|Lenvatinib capsules
75321848|NCT01272661|Behavioral|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
75321849|NCT01272661|Behavioral|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
75466979|NCT01915147|Drug|OxyPR followed by OXN PR tablets|
75466980|NCT01915160|Behavioral|eTF-CBT|Standard treatment with the edition of in-treatment/session iPad activities.
75466981|NCT01915160|Behavioral|TF-CBT|Treatment as usual.
75466982|NCT01915186|Dietary Supplement|Dihydroepiandrosterone (DHEA)|DHEA capsules are given at 25mg 3 times a day for 12 weeks
75466983|NCT01915199|Other|Intensive Care|Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
75466984|NCT01915264|Drug|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
75466985|NCT01915277|Drug|Dexmedetomidine|
75466986|NCT01915316|Other|prostate biopsy|Measurements of Zinc concentration along fresh Specimens taken during Trans-Perineal saturated repeat Prostate Biopsy before Specimens are sent to Pathology.
75466987|NCT01915329|Device|RSS (repetitive sensory stimulation)|"RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted."
75466988|NCT01915329|Device|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
75466989|NCT01915342|Device|Focal muscular vibration|
75466990|NCT01915355|Device|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
75626145|NCT02640976|Drug|Human chorionic gonadotrophin (hCG)|[Choriomon® 5000 IU ampoules, IBSA institut]
75626146|NCT04166344|Behavioral|Happyair Ecosystem|"Happyair Ecosystem is a Smart Community for the integral care of patients with chronic or rare respiratory diseases such as Asthma, COPD or Alfa-1.~Our community provides online & offline training and resources in digital health and social care to patients, family, caregivers, healthcare professionals and researchers.~Using our platform, all of our members will be able to connect in order to improve the health and well-being of patients, learn to manage self-care, ensure an active lifestyle, and contribute to the development of current and future research projects."
75626147|NCT04116463|Behavioral|Chronic Disease Self-Management Program (CDSMP)|
75466991|NCT01915368|Behavioral|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
75626148|NCT04116463|Behavioral|Financial Self-Management Program (FSMP)|
75626149|NCT02644018|Drug|Imidazolyl ethanamide pentandioic acid|
75626150|NCT02644018|Drug|placebo|
75778500|NCT01081899|Other|The LCP-I Program|The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
75778501|NCT03812679|Device|AMIA APD Solution Generation System|The AMIA APD Solution Generation System consists of the AMIA APD Cycler, Sharesource Platform, AMIA APD Concentrates, a disposable set, a bag tray, a Water Softener, and a Water Device (WD).
75778502|NCT01081977|Procedure|Early Cord Clamping|Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
75778503|NCT01081977|Procedure|Delayed Cord Clamping|Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
76074014|NCT03157947|Behavioral|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
76074015|NCT03157947|Behavioral|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
75466992|NCT01915368|Behavioral|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
75466993|NCT01915368|Behavioral|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
75466994|NCT01915381|Other|multimodal intervention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
75466995|NCT01915433|Other|Wahls Paleo Plus|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
75466996|NCT01915433|Other|Wahls Diet|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
75466997|NCT01915459|Biological|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
75466998|NCT01915459|Biological|Botulinum toxin type A(Botox®)|
75466999|NCT01915472|Drug|IMMU 130|This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
75467000|NCT01915485|Radiation|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
75467001|NCT01915524|Biological|CV9202|Intradermal injection of CV9202
75467002|NCT01915524|Radiation|local radiation|Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
75467003|NCT01915537|Drug|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
75467004|NCT01915537|Drug|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
75467005|NCT01915550|Drug|Metformin|
75467006|NCT01915550|Drug|Humulin Insulin Mixtard|
75467007|NCT01915576|Drug|BAY1125976|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
75467008|NCT01915576|Drug|BAY1125976|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
75467009|NCT01915576|Drug|BAY1125976|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
75467010|NCT01915589|Drug|Refametinib (BAY86-9766)|All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
75467011|NCT01915602|Drug|Refametinib (BAY86-9766)|Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
75467012|NCT01915602|Drug|Sorafenib (BAY43-9006)|Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
75467013|NCT01915628|Device|BioMatrix Flex|Percutaneous coronary intervention
75321850|NCT01272661|Behavioral|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
75321851|NCT05740137|Device|AI-assisted colonoscopy|The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
75321852|NCT01277731|Drug|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
75467014|NCT01915641|Device|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
75467015|NCT01915654|Procedure|study population|Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
75467016|NCT01915667|Drug|200 mg GLPG0634 as capsules, fasted|single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
75467017|NCT01915667|Drug|200 mg GLPG0634 as tablets, fasted|single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
75467018|NCT01915667|Drug|200 mg GLPG0634 as tablets, fed|single oral dose of 200 mg GLPG0634 given as tablets in fed condition
75626151|NCT02647684|Behavioral|Self-Directed Triple P|10 Week Triple P Self directed workbook
75626152|NCT00850135|Device|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
75778504|NCT01583127|Behavioral|Positive Behavioral Interventions & Supports|Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
75778505|NCT02952820|Drug|lemborexant|
75626153|NCT02647918|Drug|Sotagliflozin|Single dose
75626154|NCT02647918|Drug|Sotagliflozin|2 single doses
75626155|NCT02644174|Procedure|Bariatric Surgery|
75626156|NCT02647450|Other|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
75778506|NCT02952820|Drug|Placebo|
75778507|NCT03962439|Behavioral|High-Demand Photography|The high-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured high-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
75778508|NCT03962439|Behavioral|Moderate-Demand Photography|The moderate-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured moderate-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
75778509|NCT03962439|Behavioral|At-Home Engagement|The placebo control group will engage, alone at home, in tasks that are relatively low in intellectual engagement such as listening to music and radio or completing work-books that rely primarily on activation of knowledge.
75778510|NCT01583361|Drug|Oxaliplatin+S-1|S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
75778511|NCT01583361|Drug|Adjuvant Oxaliplatin/S-1（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
75778512|NCT01085487|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
75321853|NCT02283333|Behavioral|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
75321854|NCT02283333|Behavioral|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
75321855|NCT00728923|Drug|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
75321856|NCT01277809|Behavioral|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
75321857|NCT01277809|Behavioral|Walking Program|Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
75778513|NCT01085487|Drug|Hormonal treatment|Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
75778514|NCT01085487|Drug|Antifibrinolytic treatment|Antifibrinolytic treatment (such as tranexamic acid)
75778515|NCT01085565|Device|ExAblate 2100|Conformal Bone System
75778516|NCT03962361|Other|Concentration of circulating microparticles.|The microparticles contained in the blood sample will be isolated by ultracentrifugation and quantified by flow cytometry. The microparticles concentration will be determined by the number of microparticles per uL of plasma, based on the volume of the sample, the flow rate of the cytometer and the number of fluorescent events.
75778517|NCT01089309|Drug|Spironolactone|Spironolactone orally, at a dose of 50 mg/day for 12 months
75914643|NCT04903262|Procedure|Conventional protective ventilation|"Conventional lung protective mechanical ventilation, as described in the arm description (standardized ventilation)"
76074016|NCT03157947|Behavioral|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
76074017|NCT02665377|Drug|ANP|
75778518|NCT03962205|Behavioral|cognitive-behavioral life style intervention|Cognitive Behavioral life-style modification: The intervention will be composed of 12 weekly sessions. Each session will last about two hours and will be administered in a group setting (maximum 20 participants). During the first two sessions, a clinician will introduce the program to the participants and motivate them to make life-style changes.In the next eight sessions a dietician will provide participants with basics of nutrition and will coach them to use a structured diary to monitor their eating behavior and physical activity. Next, a physician will introduce to the patients various weight loss surgeries in terms of the adverse events, indications and effects of each option.The last session will be held by a psychologist and will focus on providing participants with useful strategies to promote healthy eating habits and physical activity, including problem solving and goal setting.
75778519|NCT03962205|Behavioral|wellbeing intervention|This program will consist of 4 weekly group-based sessions and each meeting will last about two hours. During the sessions, participants will be coached how to self-monitor their well-being episodes in everyday life, especially those associated with life-style change, by means of a structured diary. Patients will be then ecounraged to discuss their well-being experiences during group sessions, focusing on dysfunctional thoughts/beliefs interrupting them, fostering the identification of more functional thoughts. The psychologist will also teach them how to promote well-being situations through behavioral exercises and will introduce to the participants relevant psychological well-being dimensions (based on Carol Ryff's multidimensional model) associated with patients' experiences emerged during the treatment.
75321858|NCT01277965|Other|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
75778520|NCT03962205|Other|treatment as usual|The treatment as usual will involve any recommendation given to the participants by their physicians, including diet, physical activity and medication.
75778521|NCT03717454|Other|Surgery|The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .
75321859|NCT01277965|Other|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
75321860|NCT01277965|Other|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
75626157|NCT02640898|Radiation|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
75626158|NCT02640898|Radiation|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
75626159|NCT02647606|Procedure|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
75626160|NCT02647606|Device|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
75778522|NCT03717454|Drug|Drug treatment|The medication will continue if DA causes tumors to shrink.
75778523|NCT01311310|Other|RIPC (remote ischemic preconditioning)|RIPC will be performed by four 5-min cycles of lower limb ischemia and 5 in reperfusion using blood-pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure measured via arterial line.
76074018|NCT02665377|Drug|Placebo|
75626161|NCT02647606|Device|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
75626162|NCT02647606|Device|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
75626163|NCT02535910|Dietary Supplement|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
75626164|NCT02535910|Dietary Supplement|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
75626165|NCT02535910|Dietary Supplement|Control|Subjects are asked to consume a breakfast without vitamin D
75626166|NCT01154816|Drug|Alisertib|Given orally
75626167|NCT01154816|Other|Laboratory Biomarker Analysis|Correlative studies
75626168|NCT01154816|Other|Pharmacological Study|Correlative studies
75321861|NCT01277965|Other|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
75321862|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change
75321863|NCT01898403|Drug|Indocyanine green solution|Administered peri-tumoral and intradermally
75321864|NCT01898403|Drug|Isosulfan blue (ISB)|Administered peri-tumoral and intradermally
75321865|NCT01898403|Diagnostic Test|Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)|
75321866|NCT01901211|Other|Exergaming Intervention|The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
75321867|NCT00715741|Other|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
75321868|NCT00715741|Other|FiO2 0.3 without PEEP|FiO2 0.3 without PEEP
76074019|NCT03154437|Biological|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
75321869|NCT00715741|Other|FiO2 >0.9 with 3-5 cm water PEEP|FiO2 >0.9 with 3-5 cm water PEEP
75626169|NCT03057808|Behavioral|Gestational weight gain intervention|This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
75626170|NCT03057808|Behavioral|Postpartum weight loss intervention|The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
75626171|NCT00849901|Drug|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
75626172|NCT00849901|Drug|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
75626173|NCT00849901|Drug|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
76074020|NCT05703087|Behavioral|Positive cueing in the information video before a primary TKA|Two weeks before the surgery, in the outpatient clinic (during their preoperative appointment), the pre-surgery information video was shown to the patients. Patients were randomly allocated to either the positive cueing group (intervention) or the standard care group (control) with Castor EDC (14) using a variable block randomization model. Patients did not know whether they watched the adapted video or the standard video.
75626174|NCT04313660|Drug|Anlotinib In Combination With PD-1/L1 Inhibitor|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
75626175|NCT02641054|Drug|CVXL-0107|
75626176|NCT02641054|Drug|Placebo|
75626177|NCT02641054|Drug|Levodopa|
75626178|NCT02643784|Drug|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
75778524|NCT01089387|Biological|injection of bone marrow mononucleated cells|Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
75778525|NCT01085721|Drug|Dexchlorpheniramine, pseudoephedrine, guaifenesin|5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days
75778526|NCT01085721|Drug|Dexchlorpheniramine|5 mL (2 mg dexchlorpheniramine) qid for 5 days
75626179|NCT02643784|Other|Control|"Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
75778527|NCT01085799|Behavioral|Health Education Intervention|This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
75778528|NCT01089465|Other|Collection of the bedbugs and dermatological follow-up of the stings|Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
75914644|NCT04899583|Device|Sirolimus Coated Balloon Catheter|a Sirolimus Coated Balloon Catheter designed and produced by Acotec
75914645|NCT04899583|Device|a Paclitaxel Coated Balloon Catheter|a Paclitaxel Coated Balloon Catheter(trade name:Bingo)
75321870|NCT00715741|Other|FiO2 >0.9 without PEEP|FiO2 >0.9 without PEEP
75321871|NCT00750373|Procedure|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
75778529|NCT00006392|Drug|Vitamin E|400 IU daily by mouth for 7-12 years
75778530|NCT00006392|Drug|Selenium|200 mcg daily for 7-12 years
75778531|NCT00006392|Other|Vitamin E placebo|daily for 7-12 years
75778532|NCT00006392|Other|selenium placebo|daily for 7-12 years
75778533|NCT01089621|Drug|Duloxetine|30 mg to 120 mg administered orally, daily for 12 weeks
75778534|NCT03951272|Device|Lyoplant® Onlay/DURAFORM™ Dural Graft Implant|Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
75914646|NCT04896827|Other|Conditioned pain modulation test|Conditioned pain modulation (CPM) protocol consist of evaluating pain during a heat test, before and after one conditioning stimulus (cold water bath); 3 cameras will be capturing participants' facial expressions during the tests.
75914647|NCT04896476|Device|EchoMark|The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.
75914648|NCT04895631|Drug|18F-Fluorocholine|One-time injection of 4-7 millicurie (mCi)
75321872|NCT05739903|Drug|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
75321873|NCT05739903|Drug|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
75321874|NCT02987517|Other|Increased running cadence gait retraining|Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence
75321875|NCT02987517|Other|Forefoot Strike gait retraining|Runners use a forefoot strike running gait instead of a rear foot strike running gait.
75321876|NCT02987517|Other|Strengthening exercises|foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
75467019|NCT01915693|Radiation|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
75467020|NCT01915706|Procedure|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
75467021|NCT01915719|Procedure|Early non invasive ventilation|
75626180|NCT04166890|Drug|Articaine / EPINEPHrine Cartridge|The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
75626181|NCT02610907|Other|Buffer|The sleeve contains phosphate buffered saline buffer
75626182|NCT02610907|Other|Own output|The sleeve contains the subject own ileal effluent
75626183|NCT02610907|Other|simulated output|The sleeve contains simulated output
75626184|NCT02640820|Drug|Sensitizing DPCP Ointment|Sensitization
75626185|NCT02640820|Drug|Treatment DPCP Ointment|Treatment
75626186|NCT02610985|Device|3-D laparoscopy|3-D laparoscopy
75626187|NCT02610985|Device|2-D laparoscopy|2-D laparoscopy
75626188|NCT00652912|Drug|Clonazepam|ODT, 1 mg
75626189|NCT00652912|Drug|Klonopin Wafers|ODT, 1 mg
75626190|NCT01168232|Drug|Ixabepilone|Given IV
75626191|NCT01168232|Other|Laboratory Biomarker Analysis|Correlative studies
75626192|NCT02647528|Device|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
75626193|NCT02647528|Device|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
75626194|NCT02640430|Device|standard treatment|20 minutes, twice a day for 10 sessions
75914649|NCT04895631|Procedure|Positron emission tomography (PET)|Imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
75914650|NCT04893863|Drug|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
76074021|NCT01791517|Other|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
76074022|NCT01791517|Other|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
76074023|NCT01791517|Other|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
76074024|NCT01791517|Other|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
75467022|NCT01915719|Procedure|Oxygen therapy only|
75467023|NCT01915745|Other|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
75467024|NCT01915758|Drug|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
75467025|NCT01915758|Drug|vehicle gel|vehicle gel
75467026|NCT01915784|Device|Genuair®|Inhaler with placebo only. Once daily, for 14 days.
75626195|NCT02640430|Device|Free Aspire|20 minutes, twice a day for 10 sessions
75914651|NCT04893863|Drug|PluroGel|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
75467027|NCT01915784|Device|Breezhaler®|Inhaler with placebo only. Once daily, for 14 days.
75467028|NCT01915836|Other|web-based video game (Quit IT)|
75626196|NCT00817531|Drug|Dasatinib|pill form, 100 mg daily
75626197|NCT00651586|Drug|Gatifloxacin 0.3% ophthalmic solution|Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
75626198|NCT00651586|Drug|Ciprofloxacin 0.3% ophthalmic solution|Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
75626199|NCT02640508|Drug|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
76074025|NCT01998581|Device|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
76074026|NCT01998581|Device|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
76074027|NCT03154203|Other|No intervention in this study|No intervention in this study
75778535|NCT01101152|Drug|Desvenlafaxine succinate|"Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day"
75778536|NCT00379769|Drug|Rosiglitazone|Rosiglitazone maximum 8 mg per day
75778537|NCT00379769|Drug|Sulfonylurea|Sulfonylurea (SU) maximum permitted daily dose
75778538|NCT00379769|Drug|Metformin|Metformin maximum permitted daily dose .
75778539|NCT00006164|Drug|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight <75 kg, >75 kg) daily in two divided doses for 24 weeks
75778540|NCT00006164|Drug|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
75626200|NCT02640508|Drug|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
75778541|NCT00378599|Drug|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|"Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"
75321877|NCT00751777|Biological|heat-labile enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
75321878|NCT00751777|Biological|Placebo|Travelers' Diarrhea Vaccine System
75321879|NCT01902459|Biological|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
75321880|NCT01902459|Other|Standard of Care|Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
75321881|NCT01274611|Drug|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
75321882|NCT01274611|Device|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
75321883|NCT05735145|Drug|paclitaxel combined with platinum|Adjuvant chemotherapy with paclitaxel combined with platinum
75321884|NCT00729781|Device|Polyester Implants|Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
75626201|NCT05312606|Other|Aftoral Oral gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
75626202|NCT05312606|Other|Unidea Chlorhexidine digluconate mouthwash 0.20%|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
75626203|NCT02647372|Procedure|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
75321885|NCT01903005|Drug|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
75626204|NCT02647372|Procedure|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
75778542|NCT01046981|Procedure|Tumescent Antibiotic Delivery of cefazolin with or without metronidazole|TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations
75778543|NCT01046981|Procedure|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
75778544|NCT00378209|Drug|Bortezomib|Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
75778545|NCT00378209|Drug|Lenalidomide|Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles
75321886|NCT01278121|Dietary Supplement|Diet A|3 days, 6 meals a day
75321887|NCT01278121|Dietary Supplement|Diet B|10 days, 6 meals a day
75321888|NCT00614029|Device|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
75321889|NCT01905423|Drug|Albendazole (annual)|Albendazole 400 mg pnce annually
75321890|NCT01905423|Drug|Diethylcarbamazine (annual)|Diethylcarbamazine 6 mg/kg once annually
75321891|NCT01905423|Drug|Albendazole (semiannual)|Albendazole 400 mg twice annually
75626205|NCT02643550|Biological|Monalizumab|
75626206|NCT02643550|Biological|Cetuximab|
75626207|NCT02643550|Biological|Anti-PD(L)1|
75626208|NCT00817063|Drug|alitretinoin|Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
75626209|NCT00817063|Drug|Placebo|Patients receive matching placebo for up to 24 weeks
75626210|NCT02640352|Dietary Supplement|Probi Defendum|
75626211|NCT02640352|Dietary Supplement|Placebo|
75626212|NCT04166188|Procedure|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
75778546|NCT00378209|Drug|Dexamethasone|Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
75778547|NCT01047059|Drug|Erlotinib, Bevacizumab|Erlotinib 150mg/d d1-d43 p.o. Bevacizumab 15mg/kg b. w. d1, d22, d43 i.v.
75778548|NCT01047059|Drug|Fluoro-D-glucose|Tracer for PET imaging
75778549|NCT01047059|Drug|Fluoro-L-thymidine|FLT-PET tracer for imaging
75778550|NCT01047059|Drug|Gadolinium-DPTA|Contrast agent for DCE-MRI imaging
75778551|NCT01045733|Device|AcrySof IQ Toric IOL|AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
75778552|NCT01045733|Device|AcrySof IQ Aspheric IOL|AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
75778553|NCT01045733|Procedure|Limbal Relaxing Incision (LRI)|An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
75778554|NCT00377819|Drug|alendronate|70 mg oral QW
75778555|NCT00377819|Drug|Denosumab (AMG 162)|60 mg SC q 6 mos
75778556|NCT03419962|Drug|MaxSpiolto® Respimat® 160 Characters...|as per the approved SmPC
75778557|NCT00377429|Drug|catumaxomab|Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
75626213|NCT04165876|Device|Primary Motor Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration
75626214|NCT04165876|Device|Dorsolateral Prefrontal Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration
75778558|NCT03715816|Behavioral|Work break schedule|Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
75778559|NCT03992963|Device|Hearing Aid without frequency lowering enabled|Each participant will be fitted with frequency lowering disabled. Disabled means standard hearing loss compensation without lowering higher frequencies in lower frequency areas. The input frequency is mapped to the same frequency in output.
75778560|NCT03992963|Device|Hearing Aid with frequency lowering enabled|Each participant will be fitted with frequency lowering enabled. The principle of the frequency lowering algorithm is to lower high frequencies to a lower frequency region with the aim of ensuring high frequency audibility to improve auditory emotion recognition.
75778561|NCT03713788|Other|Cold pressor test|Participants placed their non-dominant hand into cold water for 2 minutes
75778562|NCT01047137|Behavioral|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
75626215|NCT04165876|Device|Multimodal Stimulation (DLPFC+M1)|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
75626216|NCT04165876|Device|Sham stimulation|Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.
75626217|NCT01166750|Behavioral|CD-ROM|"Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material."
76074028|NCT03581565|Other|zinc polycarboxylate (with the requirements of ISO 9917)|intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
75626218|NCT01166750|Behavioral|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
75626219|NCT02640196|Device|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
75626220|NCT02640196|Device|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope followed with intubating the difficult airway simulator
75626221|NCT02640196|Device|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq followed with intubating the difficult airway simulator
75626222|NCT02640196|Device|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
75626223|NCT04311242|Other|Diet|Ketogenic diet
75778563|NCT01047137|Behavioral|General Supportive Therapy|There is no focus on stress intervention.
75778564|NCT03715738|Other|arm 1 : Creaform3D + MyotonPRO|"After inclusion,are carried out:~estimation of the volume of the breast to be reduced with the 3D digital camera~measurement of breast density by Likert scale and MyotonPRO~The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair to be as still as possible over a period of 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~In peroperative, the weight of tissues removed is weighed (in grams). The removed weight is recorded in the observation notebook.~In postoperative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete."
75626224|NCT02640274|Behavioral|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
75626225|NCT02640274|Other|Usual care|
75778565|NCT01047215|Drug|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
75914652|NCT04888247|Device|CLARITY|Trans-septal mitral valve replacement
75914653|NCT04885959|Behavioral|Personalized Prevotella sp. and butyrate enriching diet guidelines|specially design dietary guidelines with biomarkers monitoring
75914654|NCT04883476|Other|Observation study only|
75914655|NCT04882982|Behavioral|Caria app|App to improve symptoms of menopause
75778566|NCT05625646|Other|quality assurance program|The program consists of an online quiz using a multiple choice questionnaire (MCQ) design. The participants are expected to complete the online MCQ at 3, 6, 9, and 12 months following baseline. The MCQ includes still-pictures and video sequences of the 10 application specific POCUS examinations from the course curriculum. Through 15-20 questions, the quiz tests the OSAUS dimentions Each question has four possible answers of which up to three answers are correct. Each MCQ will have ten questions pertaining to pathologies within the ten applications of the curriculum. Further, there will be five to ten questions relating to image recognition, image optimisation, ultrasound artifacts. Once each MCQ is finalized, the participating GP's will receive feed-back on the answers with suggestions for improvement and guidance toward continuing self-directed learning.
75778567|NCT03715660|Diagnostic Test|Xpert bladder cancer monitor|Xpert Bladder Cancer Monitor, is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.The test utilizes a voided urine specimen and measures the levels of five targetmRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR). The Xpert Bladder Cancer Monitor is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer and should be used in conjunction with other clinical measures to assess disease recurrence.
75778568|NCT03713242|Drug|ACT-541468 25 mg|Administered as a tablet.
75778569|NCT03713242|Drug|ACT-541468 25 mg (or 10 mg depending on interim results)|Administered as a tablet.
75778570|NCT03715582|Drug|trimetazidine|Pills of masking drug - trimetazidine
75778571|NCT03715582|Drug|Placebo Oral Tablet|Pills of masking drug - placebo
75778572|NCT00376961|Biological|rituximab|375 mg/m^2 on day 1 for cycles 1-6.
75914656|NCT04882982|Behavioral|Menopause Education|Educational materials about symptoms of menopause
75914657|NCT04881123|Drug|SER150|Dosage Level(s): 30 mg (1 capsule of 15 mg twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
75914658|NCT04881123|Drug|Placebo|Dosage Level(s): Matched placebo (1 capsule twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
75914659|NCT04877834|Drug|Dexlansoprazole|Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.
75626226|NCT04313270|Drug|Evolocumab|12 weeks of treatment with Evolocumab
75626227|NCT02640118|Drug|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
75778573|NCT00376961|Drug|bortezomib|1.3 mg/m^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
75778574|NCT00376961|Drug|cyclophosphamide|750 mg/m^2 on day 1 of cycles 1-6.
75778575|NCT00376961|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 1 of cycles 1-6.
75778576|NCT00376961|Drug|prednisone|100 mg on days 1-5 of cycles 1-6.
75914660|NCT04877834|Drug|Dexlansoprazole|Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.
76074029|NCT03154281|Drug|niraparib|Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
75778577|NCT00376961|Drug|vincristine sulfate|1.4 mg/m^2 on day 1 of cycles 1-6.
75778578|NCT03418324|Drug|TRC105|Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks
75778579|NCT03418324|Drug|Abiraterone|Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.
75914661|NCT04873128|Genetic|Multi-OMICS|Measurement of gene expression in immune cells (Human Peripheral Blood Mononuclear Cell (PBMCs) or total blood) using functional genomics, proteomics, metabolomics and lipidomics tools and compare the dynamics of immune response before and after vaccination against COVID-19.
75914662|NCT04870957|Behavioral|PainGuide|A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.
75626228|NCT02640118|Drug|Lixisenatide-Placebo|
75626229|NCT02640118|Other|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
75626230|NCT02643316|Drug|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
75626231|NCT02643316|Drug|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
75626232|NCT02647138|Other|white noise|exposure to white noise
75914663|NCT04870957|Behavioral|MBSR|"In this group (mindfulness-based stress reduction) participants will take part in 9 group sessions.~The groups sessions will be divided into 8 weekly 2-hour groups sessions and one 6-hour retreat. During the sessions participants will practice mindfulness exercises directed by the a MBSR therapist. Additionally, participants will also be asked to practice daily formal mindfulness at home using audio recordings of 30-45 minute guided meditation exercises. These audio recordings can be accessed online. The sessions may take place in-person or virtually."
76074030|NCT03154281|Drug|everolimus|Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
76074031|NCT03157791|Drug|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
76074032|NCT01983293|Device|QLV based implant strategy|
76074033|NCT01983293|Device|Standard of care implant strategy|
75467029|NCT01915836|Behavioral|Questionnaires|
76074034|NCT04765293|Other|Physical Therapy|Physical Therapy Gravity strengthening exercises vs standard physical therapy
76074035|NCT03157479|Drug|Intravenous anesthetic|Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
75626233|NCT02647216|Behavioral|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
75626234|NCT02647216|Behavioral|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
75626235|NCT00653770|Biological|FP85A|Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10^7 pfu)
75778580|NCT03418324|Drug|Enzalutamide|Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
75778581|NCT03713164|Dietary Supplement|Pomegranate Juice|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
75778582|NCT03713164|Dietary Supplement|Ellagic Acid|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
75778583|NCT00376259|Drug|telbivudine|600mg/day oral tablet for 96 weeks
75778584|NCT00376259|Drug|adefovir dipivoxil|10 mg of adefovir by mouth once daily
75778585|NCT03715348|Drug|Prothrombin Complex Concentrate (PCC)|PCC is a blood product produced through pooling of thousands of human plasmas, which is then treated to inactivate enveloped viruses. From the pooled plasma, vitamin K dependent clotting factors (factors II, VII, IX and X, and protein C and protein S), are selected to produce the concentrated form called PCC.
75778586|NCT03715348|Biological|Fresh Frozen Plasma|Fresh Frozen Plasma a blood component manufactured from whole blood collection.
75778587|NCT01324505|Drug|semaglutide|Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
75778588|NCT01324505|Drug|placebo|Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
75778589|NCT01324505|Drug|Microgyn®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
75778590|NCT01049321|Dietary Supplement|DASH diet|
75778591|NCT01049321|Dietary Supplement|a usual diabetic diet|
75778592|NCT01049399|Drug|tideglusib|800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
75778593|NCT01049399|Drug|tideglusib|600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
75778594|NCT01049399|Drug|placebo|powder for oral suspension administered once daily in fasting conditions for 52 weeks
75778595|NCT01049477|Other|Music group|The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.
75778596|NCT01049477|Other|Non music group|Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
75778597|NCT01041755|Drug|L-ornithine-L-aspartate|a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
75778598|NCT01041755|Drug|Lactose|a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
75778599|NCT02535143|Other|Test Cavity Preparation|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
75778600|NCT02535143|Drug|Taurine|250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
75778601|NCT02535143|Other|Post intervention test cavity|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
76074036|NCT03157479|Drug|Crystalloid Solutions|Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician
75467030|NCT01915836|Behavioral|Evaluation Interview|
75626236|NCT00653770|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10^7 pfu)
75626237|NCT00910936|Behavioral|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
75626238|NCT02640040|Device|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
75626239|NCT02640040|Device|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
75626240|NCT02640040|Procedure|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
75626241|NCT02643160|Other|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
75321892|NCT01905423|Drug|Diethylcarbamazine (semiannual)|Diethylcarbamazine 6 mg/kg twice annually
76074037|NCT03157479|Diagnostic Test|Esophageal pressure measurement|A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure
75778602|NCT02535143|Dietary Supplement|Carbonated Apple Juice|250ml of commercially available carbonated apple juice to be administered three hours after the last meal and half an hour prior to performing the second test cavity
75321893|NCT04345549|Other|Individualised Ayurveda|Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing
76074038|NCT03157479|Diagnostic Test|Lung volume measurement with the nitrogen washin-washout technique|Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
76074039|NCT03031587|Other|Additional MRI acquisition sequences|It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
76074040|NCT03031587|Device|MRI|cardiac MRI
76074041|NCT01670331|Behavioral|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
76074042|NCT03013491|Drug|CX-072|
75321894|NCT05734911|Drug|Niraparib|We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
75321895|NCT01278355|Device|Ear acupuncture|Ear acupuncture
75626242|NCT04165642|Other|Laser ballon ablation for Pulmonary vein isolation|The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring
75626243|NCT00826267|Drug|lapatinib|lapatinib tablets 1500 mg daily
75778603|NCT04468451|Behavioral|A 48-hour ROC training program with a standing posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
75778604|NCT04468451|Behavioral|A 24-hour ROC training program with a standing posture|The 1-hour training session is composed of a 30-to-35-minute car play and a 25-minute natural play. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
75778605|NCT04468451|Behavioral|A regular therapy program without receiving any ROC training|The regular therapy group will be an active control group without receiving any additional training. The training dosage will be their own therapy, including occupational, physical and speech therapy. They will continue their regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks.
75778606|NCT01049555|Other|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
76074043|NCT03013491|Drug|ipilimumab|
76074044|NCT03013491|Drug|vemurafenib|
75778607|NCT01041833|Drug|atRA|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
76074045|NCT01272232|Drug|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
76074046|NCT01272232|Drug|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
76074047|NCT01272232|Drug|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
75321896|NCT05739825|Other|FMT from healthy donors|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through FMT
75321897|NCT01270477|Other|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
75626244|NCT00826267|Drug|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
75626245|NCT00826267|Drug|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
75626246|NCT02639962|Radiation|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
75626247|NCT00653848|Drug|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
75321898|NCT01278433|Biological|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
75467031|NCT01915875|Other|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
75626248|NCT00707551|Drug|Ketoconazole|Tablet, administered as repeated doses.
75914664|NCT04870957|Behavioral|PT and exercise|"Participants will take part in 10 physical therapy visits over the course of 8 weeks. Participants will meet with the physical therapist twice a week for a 1-hour session for weeks 1 and 2 and then weekly for the remaining 6 weeks. The physical therapist will tailor a program to the participant's needs according to recommended PT practice guidelines that will include in-person treatment, home exercise prescription, and encouragement of progressive, low-intensity, submaximal fitness and endurance activities, such as walking.~Participants will be given a home program of exercises to be done daily and asked to engage in daily walking with a set goal based on the individual's capacity and current fitness level. Walking was selected as the aerobic exercise of focus for this treatment because it is recommended for patients with all levels of pain severity, is highly feasible to complete, and has shown effects on outcomes such as pain and disability."
76074048|NCT03157401|Drug|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
76074049|NCT03157401|Drug|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
76074050|NCT03157401|Drug|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
76074051|NCT03153735|Device|CMDHA0101|Maximum injection dose : 22 ml
75626249|NCT00707551|Drug|Verapamil|Extended Release tablet, administered as repeated doses.
76074052|NCT03153735|Device|PowerFill®|Maximum injection dose : 22 ml
76074053|NCT03153891|Other|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
76074054|NCT03153891|Other|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
76074055|NCT01670643|Behavioral|Video camera magnifier|reading with video camera magnifier
75626250|NCT00707551|Drug|AZD1305|Extended Release tablet, administered as a single dose.
75626251|NCT02535754|Behavioral|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
76074056|NCT03153813|Drug|capsaicin 8% patches (Qutenza)|
76074057|NCT03153813|Other|Placebo patches|
75626252|NCT02535754|Behavioral|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
75626253|NCT02535754|Behavioral|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
75626254|NCT02642926|Procedure|Monopolar current|Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
75626255|NCT02642926|Procedure|Bipolar current|Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
75626256|NCT00986154|Drug|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
76074058|NCT03157167|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
75778608|NCT01041833|Drug|Placebo|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
75778609|NCT03410056|Drug|Efavaleukin alfa|Efavaleukin alfa administered as a subcutaneous injection.
75778610|NCT03410056|Drug|Placebo|Placebo administered as a subcutaneous injection.
76074059|NCT03157245|Diagnostic Test|DOPPLER ULTRASOUND|MESURE OF THE PRESENCE OR NOT OF A CATHETER RELATED VEIN THROMBOSIS
76074060|NCT03156855|Drug|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
76074061|NCT03156855|Drug|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
75778611|NCT03409666|Device|Taperloc Complete Microplasty stem|Total hip replacement with Taperloc Complete Microplasty stem and G7 acetabular shell with E1 liner
75778612|NCT03409666|Device|Taperloc Complete Reduced Distal stem|Total hip replacement with Taperloc Complete Reduced Distal stem and G7 acetabular shell with E1 liner
75778613|NCT03715270|Device|Image surgical area|Image surgical area
75778614|NCT03440944|Device|Ultrasound Guided Peripheral IV Catheter|Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.
75778615|NCT03440944|Device|Midline Catheter|Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.
76074062|NCT01791127|Device|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
75914665|NCT04870957|Device|Self -administered acupressure|"A device called the AcuWand will be used to administer the self-acupressure intervention for approximately 30 minutes daily for 8 weeks. Participants will use a mobile application (app) called MeTime that will have daily instructions on how to use the AcuWand. Research staff will show participants how to use the AcuWand and MeTime app. In addition, participants will keep a daily log to track at-home acupressure sessions."
76074063|NCT03157011|Other|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.
75914666|NCT04870957|Drug|Duloxetine|For days 1-7, patients will take 30mg of duloxetine once a day, in the morning. Starting day 8, participants tolerating the medication will be escalated to 60mg once a day. They will also have the option of staying at 30mg, once a day or stopping the medication. At the end of the 8-week intervention period, participants will have the option to continue the medication commercially (non-study medication) under the care of their physician or taper off the medication. During the entire 8-week intervention, patients will be asked to keep a daily log of medication dosage, any missed doses, and any side-effects they may have experienced.
75914667|NCT04870957|Device|Pro-Diary monitor|"Participants will wear during 5 separate 7-day home monitoring periods to assess physical activity (objectively measured via accelerometry), and ecological momentary assessment (EMA) of mental and physical symptoms. EMA will be collected during Weeks 1, 6, 15, 24 and 36."
75914668|NCT04868370|Other|Assessment of the upper limb (VPIT + PPIT)|Assessment of the upper limb sensorimotor function (VPIT and PPIT)
75914669|NCT04867395|Behavioral|HELPix Care Plan|"A web application tool for CMC - Health literacy-informed, disease and medication-specific, standardized discharge instructions that will: 1) facilitate plain language provider/parent communication at hospital discharge and 2) act as stand-alone handouts that parents can use at home."
75914670|NCT04862273|Diagnostic Test|Native T1 CMR|Observed method
75914671|NCT04862273|Diagnostic Test|Web-based ATTR probability estimator (Pfizer, New York)|Observed method
75914672|NCT04862273|Diagnostic Test|99mTc-DPD scintigraphy|Reference method
75914673|NCT04862273|Diagnostic Test|Laboratory screening for multiple myeloma / AL amyloidosis|Reference method
75626257|NCT00986154|Drug|low molecular weight heparin/unfractionated heparin|"LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment"
75626258|NCT00986154|Drug|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
75778616|NCT00365105|Dietary Supplement|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
75914674|NCT04862273|Procedure|Cardiac biopsy|If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive
76074064|NCT01274650|Procedure|Indirect Calorimetry|Indirect Calorimetry
76074065|NCT03157323|Behavioral|Low Glycemic Index Diet|The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
76074066|NCT00739960|Drug|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
75778617|NCT00365105|Dietary Supplement|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
75778618|NCT00365105|Drug|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
75778619|NCT00365105|Drug|Sm-153|Single dose intravenously 1 mCi/kg body weight.
75778620|NCT00365105|Radiation|Sr-89|Single dose intravenously 4 mCi.
75778621|NCT01041911|Drug|Euphorbia tablets|50 mg, tablet, once daily, 14 days
75778622|NCT01041911|Drug|Euphorbia tablets|100 mg, tablet, once daily, 14 days
75778623|NCT01041911|Drug|Euphorbia tablets|200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
75778624|NCT01041911|Drug|Placebo tablets|placebo, tablet, once daily, 14 days
75914675|NCT04862156|Device|Normothermic Machine Perfusion (NMP)|Storage and transportation of the donated liver using the OrganOx metra device.
75914676|NCT04854005|Procedure|Breast surgery|Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice.
75467032|NCT01915888|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
75467033|NCT01915901|Drug|bismuth subsalicylate (Pepto-Bismol®)|524 mg bismuth subsalicylate twice a day (BID)
75626259|NCT02611375|Other|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
75778625|NCT01049633|Biological|Allogeneic Pancreatic Islet Cells|200mL sterile suspension of allogeneic human pancreatic islets
75778626|NCT01049633|Drug|Sirolimus|Dosed to maintain whole blood 24-hr trough levels 10-15ng/mL for first 3 months and 8-12ng/mL thereafter daily. Sirolimus is used to prevent transplant rejection.
75778627|NCT01049633|Biological|Basiliximab|20mg intravenously (IV) 2hrs prior to islet infusion and on Day 4 post-transplant. Basiliximab is used to prevent transplant rejection
75778628|NCT01049633|Drug|Tacrolimus|Initial dose of 0.015mg/kg p.o. daily on Day 1 post transplant, and adjusted to maintain 12-hr trough levels 3-6ng/mL. Tacrolimus lowers the risk of organ rejection
75914677|NCT04853251|Device|SUSVIMO Port Delivery System with ranibizumab (PDS)|The ranibizumab 100 mg/mL will be delivered via the Port Delivery System
75778629|NCT01049633|Drug|Antibacterial, Antifungal, and Antiviral Prophylaxis|Broad spectrum antimicrobial prophylaxis administered preoperatively
76074067|NCT05537181|Device|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
76074068|NCT00751972|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
76074069|NCT03153657|Drug|Piroxicam-Beta-Cyclodextrin|The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
75626260|NCT02611375|Other|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
75626261|NCT02611375|Other|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
75778630|NCT01049633|Drug|Trimethoprim/sulfamethoxazole|80mg/400mg by mouth once a day starting on Day 1 for duration of the study follow-up. This medication is used to prevent bacterial infections.
75778631|NCT01049633|Drug|Clotrimazole|1 troche by mouth 4 times daily starting two days prior to transplant until 3 months after the transplant. This medication is used to prevent fungal infections.
75778632|NCT01049633|Drug|Valganciclovir|450mg dose by mouth once a day starting two days pre-transplant and increasing to 900 mg once a day by Day 12 and continuing for 14 weeks post-transplant. This medication is used to prevent cytomegalovirus infections.
75778633|NCT01049633|Drug|Heparin|70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
75778634|NCT01049633|Drug|Enoxaparin|30mg subcutaneously twice a day from 48 hrs post-transplant through Day 7 post-transplant. This medication is used to prevent the formation of blood clots.
75778635|NCT01049633|Drug|Pentoxifylline|400mg slow release tablet by mouth three times a day beginning 2 days prior to transplant and continue for 7 days post transplant. This medication improves blood flow.
75778636|NCT01049633|Drug|Aspirin|81mg enteric coated aspirin by mouth every night, starting 24hrs post-transplant. This medication prevents blood clots.
75778637|NCT00399893|Drug|Octreotide|Octreotide to be administered by subcutaneous injection three times daily
75778638|NCT00399893|Drug|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
75778639|NCT03992027|Behavioral|CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis|CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
75778640|NCT03992027|Behavioral|Waitlist Control|Participants receive usual care for 3 months followed by CF-CBT. CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
75778641|NCT04587479|Drug|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
75778642|NCT01049711|Drug|erythropoietin|
75778643|NCT01042067|Other|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
75778644|NCT00048542|Biological|Double-Blind Adalimumab/Placebo + MTX|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
75778645|NCT00048542|Biological|Double-Blind Adalimumab/Placebo|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
75778646|NCT00048542|Drug|OLE BSA Adalimumab +/- MTX|Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
75778647|NCT00048542|Drug|OLE FD Adalimumab +/- MTX|Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
76074070|NCT03153657|Drug|Placebo|The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
76074071|NCT01670955|Dietary Supplement|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
76074072|NCT01670955|Drug|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
76074073|NCT01274806|Other|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
76074074|NCT01274884|Procedure|Tightrope fixation|Arthroscopic repair
76074075|NCT03156933|Other|Assessment of splicing variants|This is a biological study with primary samples without any intervention on patients.
75321899|NCT01906515|Device|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
75321900|NCT00730483|Drug|PVA microporous hydrospheres/doxorubicin hydrochloride|
75626262|NCT00653926|Drug|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
75778648|NCT03955328|Diagnostic Test|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
75914678|NCT04853251|Drug|LUCENTIS (ranibizumab injection)|Ranibizumab (intravitreal 0.5-mg intravitreal injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a study patient discontinues study treatment, he/she may start receiving intravitreal ranibizumab injections in the study eye, per investigator's discretion.
76074076|NCT01275040|Other|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
76074077|NCT01275040|Other|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
75778649|NCT03814590|Biological|RSV Vaccine (GSK3844766A) unadjuvanted low dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
75778650|NCT03814590|Biological|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
75778651|NCT03814590|Biological|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
75321901|NCT01907607|Drug|PD 0332991|"PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day."
75321902|NCT01270633|Device|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
75321903|NCT01270633|Other|Standard of Care|Following sharp debridement, moist wound therapy
75626263|NCT00653926|Drug|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
75626264|NCT02613091|Drug|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
75778652|NCT03814590|Biological|RSV Vaccine (GSK3844766A) unadjuvanted medium dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
75778653|NCT03814590|Biological|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
75778654|NCT03814590|Biological|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
75467034|NCT01915901|Drug|matching placebo (bismuth subsalicylate)|placebo twice a day (BID)
75467035|NCT01915901|Drug|dimethyl fumarate (DMF)|dimethyl fumarate (DMF) twice a day (BID)
75626265|NCT00653146|Behavioral|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
75626266|NCT00653146|Behavioral|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
75778655|NCT03814590|Biological|RSV Vaccine (GSK3844766A) unadjuvanted high dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
75778656|NCT03814590|Biological|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
75778657|NCT03814590|Biological|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
75778658|NCT03814590|Drug|Placebo (Saline solution)|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
75778659|NCT01088568|Procedure|the implantation of toric implantable collamer lens|perform the implantation of toric implantable collamer lens for both eyes
75778660|NCT01088568|Procedure|customized laser-assisted in situ keratomileusis|perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
75914679|NCT04852393|Procedure|Block|cervical medial branch block
75914680|NCT04844333|Other|Extubation under deep anesthesia|When the patient in sedation or anesthesia state, no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, stable circulation, the patient is in deep anesthesia state, and the endotracheal tube is removed.
75914681|NCT04844281|Device|Precision1® Daily Disposable Toric Contact Lens|Soft, toric contact lens used to correct distance vision and astigmatism.
75914682|NCT04840381|Behavioral|Questionnaire administrations|Administration of an ad hoc questionnaire to register food frequency consumption and meal time, main recipes; phisical activity questionnaire and list of questions concerning the previous and actual health status of participants
75914683|NCT04838613|Drug|[18F]CTT1057|Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
75914684|NCT04838613|Drug|[68Ga]Ga-PSMA-11|Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
75914685|NCT04834999|Other|Validation of questionnaires in Kinyarwanda|Four questionnaires, three self-report instruments (Medication Adherence Rating Scale, Internalized Stigma of Mental Illness Inventory - 9-item Version and the Mood Disorder Questionnaire) and one clinical interview (the Young Mania Rating Scale)
75914686|NCT04834817|Device|Celluma POD|A blue and near infrared handheld LED device
75914687|NCT04832750|Device|intermittent theta burst stimulation (iTBS) or sham stimulation|30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
75914688|NCT04828174|Drug|anti-TRBC1 CAR-T cell therapy|TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
75321904|NCT01278511|Other|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
75778661|NCT01085448|Other|Core Stabilization|"The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis[TrA], lumbar multifidus[LM]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.~Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
75321905|NCT05734833|Dietary Supplement|Culturelle Probiotic + Fiber|The experimental group will receive the study product which is Culturelle Probiotic + Fiber
75321906|NCT05734833|Other|Placebo|The Placebo comparator arm will receive placebo sachets
76074078|NCT01275274|Drug|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of < 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to < 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
75626267|NCT02642848|Procedure|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
75626268|NCT02642848|Procedure|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
75626269|NCT02642848|Procedure|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
75626270|NCT02646904|Drug|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
75626271|NCT02646904|Drug|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
75778662|NCT01583244|Drug|No Intervention (subjects were previously treated with Orencia®)|No Intervention
75778663|NCT01085526|Biological|Alutard phleum pratense subcutaneous immunotherapy|standard regimen of SCIT
75778664|NCT01085526|Drug|Alutard phl prat|
75914689|NCT04827563|Device|EndoPAT|An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
76074079|NCT01275274|Drug|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
75626272|NCT00848965|Drug|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
75626273|NCT00848965|Drug|Placebo|Placebo comparator
75914690|NCT04827563|Device|Blood Pressure Cuff|A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
75914691|NCT04827563|Diagnostic Test|Echocardiogram|A test used to conduct an ultrasound of participant's heart.
75914692|NCT04827563|Other|Quality of Life Assessment|A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
75914693|NCT04827563|Other|Blood Tests|Routinely collected for all participants who begin carfilzomib treatment.
75914694|NCT04824092|Drug|Tafasitamab|Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
75914695|NCT04824092|Drug|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
75914696|NCT04824092|Drug|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
75321907|NCT01909011|Device|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
75321908|NCT01909011|Device|Sham CES|The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
75321909|NCT00753337|Device|Assurant® Cobalt Iliac Stent System|Iliac Stenting
75321910|NCT03029637|Device|RBBs with no or minimal preparation of their abutment teeth|Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth
75321911|NCT03029637|Device|RBBs with routine tooth preparation of their abutment teeth|Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
75626274|NCT02642770|Device|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
75626275|NCT00654082|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
75321912|NCT03029481|Drug|Ganitumab|The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
75778665|NCT01085604|Other|Core Stabilization|"The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis[TrA], lumbar multifidus[LM]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.~Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
75626276|NCT00654082|Drug|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
75778666|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|2mg iv every 2 months
75778667|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|2.5mg po daily
75778668|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
75626277|NCT02639416|Dietary Supplement|Polymeric formula|Polymeric formulae are recommended in the management of inflammatory bowel disease in children
75778669|NCT01102868|Device|Needle in acupuncture point Li11|Acupuncture needle in acupuncture point Li11
75778670|NCT01102868|Device|IMS of the musculus pronator teres|Acupuncture needle in musculus pronator teres
75778671|NCT02529956|Drug|UCB4940|"Active Substance: UCB4940~Pharmaceutical Form: Solution for infusion~Concentration: 80 mg/ml~Route of Administration: Intravenous use"
75778672|NCT02529956|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for infusion~Concentration: 0.9 % sodium chloride aqueous solution~Route of Administration: Intravenous use"
75778673|NCT03831191|Drug|LY3375880|Administered SC
75778674|NCT03831191|Drug|Placebo|Administered SC
75778675|NCT01102946|Drug|Ranibizumab|Ranibizumab (Lucentis), intravitreal injections of 0.05ml
75778676|NCT01102946|Procedure|Panretinal Photocoagulation|Panretinal photocoagulation with green laser according to ETDRS
75778677|NCT03955094|Device|Intubation via AMBU® AURAGAIN™|Success rate of paediatric intubation through AMBU® AURAGAIN™
75778678|NCT01103024|Biological|AIN457|
75778679|NCT01103024|Biological|AIN457|
75778680|NCT01103024|Biological|AIN457|
75778681|NCT01103024|Biological|Placebo|
75778682|NCT01103102|Drug|Iocide Oral Rinse|Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
75778683|NCT01103102|Drug|Placebo|Placebo
75778684|NCT02534831|Procedure|Soft tissue manual therapy protocol|The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
75778685|NCT01049789|Behavioral|COMB - Combination Cognitive Behavioral Therapy and Medication Management|"Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48."
75778686|NCT01049789|Behavioral|TAU - Treatment as Usual|"Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48."
75778687|NCT01103258|Procedure|high ligation and stripping (surgery)|surgery consisting of high ligation in combination with long saphenous stripping
75778688|NCT01103258|Procedure|FOAM|duplex guided foam sclerotherapy
75778689|NCT01101386|Drug|Voriconazole|Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
75778690|NCT00005906|Drug|Octreotide|Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
75626278|NCT02639416|Dietary Supplement|Elemental formula|Elemental formulae are recommended in cow's milk and other food intolerances in children.
75626279|NCT02639416|Other|Standard management|Standard management with F-100 and/or RUTF
75626280|NCT00654160|Drug|fluorouracil|
75778691|NCT03951038|Procedure|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
75626281|NCT00654160|Drug|irinotecan hydrochloride|
75914697|NCT04824092|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
75467036|NCT01915927|Drug|MSC-AFP|
75626282|NCT00654160|Drug|leucovorin calcium|
75626283|NCT00654160|Other|pharmacogenomic studies|
75626284|NCT00654160|Other|pharmacological study|
76074080|NCT01671033|Behavioral|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
75778692|NCT03951038|Procedure|Lateral TLIPB group|"both sides of the spine, a single injection of ropivacaine by nerve stimulating needle under ultrasound-guided between the longissimus and iliocostalis muscles .~The regimen of Lateral TLIPB group is0.2% 20ml ropivacaine and the regimen of PCIA is same with PCIA group."
75778693|NCT03949010|Other|Kinesiotaping with space correction technique|Kinesiotaping with space correction technique twice per week for two weeks along with home exercise program
75778694|NCT03949010|Other|Kinesiotaping with muscle inhibition technique|Kinesiotaping with muscle inhibition technique twice per week for two weeks along with home exercise program
76074081|NCT01671033|Behavioral|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
76074082|NCT01997333|Drug|CDX-011|
76074083|NCT01997333|Drug|Capecitabine|
76074084|NCT01271920|Drug|AUY922|
76074085|NCT01271920|Drug|Trastuzumab|
75321913|NCT00731341|Procedure|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
75321914|NCT04279171|Diagnostic Test|Greyson NDE scale|Questionnaire to detect occurence of NDE. A NDE is identified if score > or = 7/32
75321915|NCT04279171|Diagnostic Test|DES dissociation scale|Screening for dissociative symptoms
75651653|NCT05832749|Device|Healon Endocoat 3% ophthalmic viscosurgical device|"Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including:~Cataract surgery with an intraocular lens~Cataract surgery without an intraocular lens~Secondary intraocular lens implantation~Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation."
75778695|NCT03949010|Other|Home exercise program|Home exercise program which consists of stretching exercises towards neck area
75778696|NCT01103336|Drug|pretreatment with intravenous nicorandil vs. placebo before coronary angiography|"Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography"
75778697|NCT03950960|Drug|BMS-986256|Specified dose on specified days
75778698|NCT03950960|Drug|Itraconazole|Specified dose on specified days
75778699|NCT03955016|Other|Pulmonary rehabilitation|"Rehabilitation program consisting of 2 weeks inpatient (supervised training 5 times per week), 2 weeks outpatient (supervised sessions 3 times per week) and 11 weeks home-based exercise training (weekly phone call).~During the inpatient phase, patients will receive on top of the supervised training sessions a consultation of the dietitian, PH psychologist, social worker and specialized nurse. During the ambulatory rehabilitation phase patients will have 2 session with the occupational therapist.~Every supervised training session contains:~Interval training on a cyclo-ergometer~Strength training of the upper and lower extremities~Guided walks"
75778700|NCT03954860|Other|Drainage Tube|The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients.
75321916|NCT04279171|Diagnostic Test|WHOQOL-SRPB|WHOQOL-SRPB is an instrument developed to evaluate how spirituality, religiosity and personal beliefs (SRPB) are related to quality of life in health and health care.
75778701|NCT03954860|Drug|Tranexamic Acid|Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
75778702|NCT03954860|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
75914698|NCT04824092|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
75914699|NCT04824092|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
75914700|NCT04824092|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
75914701|NCT04824092|Drug|Tafasitamab placebo|0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
75914702|NCT04824092|Drug|Lenalidomide placebo|Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
76074086|NCT05479149|Other|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
76074087|NCT05479149|Other|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
76074088|NCT01275352|Drug|Eplerenone|Eplerenone 50 mg/day
76074089|NCT01275352|Drug|placebo|placebo
76074090|NCT01279720|Biological|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
76074091|NCT01676259|Drug|siG12D-LODER|The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
76074092|NCT01676259|Drug|Gemcitabine+nab-Paclitaxel|Gemcitabine+nab-Paclitaxel
76074093|NCT01676259|Drug|Folfirinox|Folfirinox or modified Folfirinox
76074094|NCT01270282|Drug|AM-101 0.81 mg/mL|
76074095|NCT01270282|Drug|Placebo|
75321917|NCT04279171|Diagnostic Test|cerebral magnetic resonance imaging|Types of images to be acquired: T1, T2, Diffusion Weighted Imaging-DWI, Fluid Attenuated Inversion Recovery and spectroscopy
75321918|NCT01911351|Drug|Nitrous Oxide|Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
75778703|NCT03949166|Other|food during labor and delivery|The food that will be allowed during labor and delivery was approved by the anesthesia team. It includes - fruits, energy bars, yogurt,
75778704|NCT01095692|Procedure|Pelvic Organ Prolapse and Suburethral TOT implantation|Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation
75778705|NCT01095692|Procedure|Pelvic Organ Prolapse intervention|Procedure/Surgery: Pelvic Organ Prolapse intervention
75626285|NCT02639572|Biological|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
75626286|NCT02639572|Biological|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
75778706|NCT01103570|Procedure|cholecystocholangiography|a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
75626287|NCT02639104|Radiation|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;~The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
75321919|NCT04276051|Device|Cryoablation of the Vagus Nerve|The Visual ICE Cryoablation System is a mobile console system intended for cryoablative tissue destruction using a minimally invasive procedure. The Visual-ICE System uses high-pressure argon gas that circulates through closed-tip cryoablation needles to induce tissue freezing. Active tissue thawing is achieved by circulating helium gas through the needles or, alternatively, by the use of Galil Medical i-Thaw technology. The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40 degrees Celsius) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.
75321920|NCT04276051|Behavioral|Lifestyle Intervention|The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.
75778707|NCT01103570|Procedure|cystic duct cholangiography|Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
75778708|NCT03949088|Other|UF and Na profiling|Modulation of UF and dialysate sodium
75778709|NCT03409276|Biological|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid.
75778710|NCT03409276|Biological|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid.
75778711|NCT03409276|Biological|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
75778712|NCT03409276|Biological|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
75778713|NCT00004562|Drug|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
75321921|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
75321922|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
75321923|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
75914703|NCT04819503|Drug|Spinal anaesthesia (sub-study 1)|We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.
75914704|NCT04819503|Device|Repetitive transcranial magnetic stimulation (sub-study 2)|After sub-study 1, the same patients will enter sub-study 2 where they are randomly assigned to receive either first active rTMS (10 days over 2 weeks), and then after a 9 week washout period, sham rTMS (10 days over 2 weeks), or they first receive sham rTMS, and then after 9 weeks of washout, active rTMS. Thus, patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial with a 2 x 2 cross-over design, receiving both active and placebo stimulation
75321924|NCT01278589|Dietary Supplement|Placebo|Liquid (80g) without Plantago asiatica L. extract
75626288|NCT02639104|Other|Electromyography|"Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
75626289|NCT04274556|Other|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
75626290|NCT02642380|Drug|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
75778714|NCT00004562|Drug|Platelet inhibitors|Participants will receive platelet inhibitors.
75914705|NCT04808570|Drug|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
75778715|NCT00004562|Procedure|PTCA and stents|Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.
75778716|NCT00004562|Drug|ACE Inhibitors|Participants will receive ACE inhibitors.
75914706|NCT04806178|Biological|Bacillus Calmette Guerin|0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
75914707|NCT04806178|Other|PLACEBO|0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.
76074096|NCT01671189|Other|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
75626291|NCT02642380|Drug|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
75626292|NCT02642692|Procedure|Patellar Tendon graft|Acl reconstruction with patellar tendon graft
75778717|NCT00004412|Drug|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
75778718|NCT00004412|Other|Standard local care dressing|To heal leg ulcers.
75778719|NCT03715192|Biological|LY3462817 IV|Administered IV
75778720|NCT03715192|Biological|LY3462817 SC|Administered SC
75778721|NCT03715192|Drug|Placebo|Administered IV
75778722|NCT03713008|Diagnostic Test|Fluid bolus|All patients included in the study will receive 5 ml/kg fluid bolus of a balanced crystalloid solution.
75914708|NCT04800198|Procedure|non-invasive ventilation|none, measurements only
75914709|NCT04799821|Other|Control|Participants will be asked to refrain from walnut intake and to follow an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
76074097|NCT01273012|Drug|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
75321925|NCT05734677|Behavioral|Emotion regulation group|90 minute sessions once a week for 8 weeks, in groups of eight participants. DBT, MBT and MBI inspired, psychoeducative intervention.
75626293|NCT02642692|Procedure|Hamstring Graft|Acl reconstruction with hamstring graft
75626294|NCT02642302|Behavioral|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
75626295|NCT02642302|Behavioral|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
75626296|NCT02642302|Behavioral|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
75626297|NCT01154036|Drug|ezetimibe 10 mg|
75626298|NCT01154036|Drug|atorvastatin|
75626299|NCT01154036|Drug|Comparator: rosuvastatin|
75626300|NCT00816595|Biological|bevacizumab|Given IV
75626301|NCT00816595|Biological|pegfilgrastim|Given subcutaneously
75626302|NCT00816595|Biological|rituximab|Given IV
75626303|NCT00816595|Drug|cyclophosphamide|Given IV
75626304|NCT00816595|Drug|pentostatin|Given IV
75626305|NCT02886026|Device|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
75626306|NCT02886026|Device|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
75778723|NCT03715114|Drug|GV-971|Oral GV-971
75778724|NCT03715114|Drug|Placebo|Oral Placebo
75778725|NCT03440320|Behavioral|MY-SKILLS - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of yoga and an hour of self-management designed to meet the needs of a caregiving dyad with chronic pain
75778726|NCT03440320|Behavioral|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain..
75778727|NCT01091532|Drug|UK-396,082|"100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
75626307|NCT00922909|Behavioral|Simon task|Reaction time task
75626308|NCT01166438|Drug|Botulinum toxin A (Botox A®)|A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
75626309|NCT01166438|Drug|Solifenacin 5mg|Oral Solifenacin 5mg once a day for up to 6 months
75626310|NCT01166438|Drug|Solifenacin 10mg|Oral Solifenacin 10mg once a day for up to 4 months
75626311|NCT01166438|Drug|Trospium chloride|Oral Trospium chloride XR 60mg once a day for up to 2 months
75778728|NCT01091532|Drug|placebo|given orally twice daily for 14 days
75778729|NCT01091532|Drug|UK-396,082|"300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
75778730|NCT01091532|Drug|placebo|given orally twice daily for 14 days
75914710|NCT04799821|Other|Walnut intake|Participants will be asked to consume walnuts along with an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
75914711|NCT04798898|Device|RFA (radiofrequency ablation)|Preoperative RFA-induced partial necrosis of the liver metastasis
76074098|NCT01676337|Other|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
76074099|NCT00746122|Procedure|Open repair|Standard treatment of emergency open surgery
76074100|NCT00746122|Procedure|EVAR|Emergency endovascular aneurysm repair
75321926|NCT05734599|Device|NMR-based metabolic profiling|Clinical parameters and VCTE results of each patient will be collected. Patients will be grouped into two groups according to VCTE, FIB-4 and NFS, and undergo NMR-based metabolic profiling
75321927|NCT04385407|Drug|Sofosbuvir + Simeprevir + Ribavirin|
75914712|NCT04797715|Drug|AXS-05|AXS-05 tablets, taken twice daily
75914713|NCT04797715|Drug|Placebo|Placebo tablets, taken twice daily
75914714|NCT04794582|Device|ProGrip™ Self-Gripping Polyester Mesh|Supra-aponeurotic placement of ProGrip® macroporous polyester mesh in the supra-aponeurotic position
76074101|NCT04538079|Device|Multimodal objective non-invasive Monitoring|Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
76074102|NCT02662257|Drug|Sevoflurane|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
75321928|NCT00731653|Drug|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
75321929|NCT00573989|Drug|erlotinib hydrochloride|
75321930|NCT00573989|Drug|pemetrexed disodium|
75321931|NCT00573989|Procedure|quality-of-life assessment|
75321932|NCT00573989|Radiation|intensity-modulated radiation therapy|
75321933|NCT02286921|Drug|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
75626312|NCT00707707|Drug|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
75626313|NCT00707707|Drug|Paclitaxel|Intravenous infusion over 1 hour
75626314|NCT02611297|Procedure|Cryoprobe|
75626315|NCT01153958|Drug|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
75626316|NCT01153958|Drug|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
75626317|NCT00707785|Dietary Supplement|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
75626318|NCT00599638|Drug|pregabalin|75mg bid titrating to 150mg bid on day 4
75626319|NCT00599638|Drug|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
75626320|NCT00599638|Drug|Placebo|Placebo
75626321|NCT00654316|Biological|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
75778731|NCT01091532|Drug|UK-396,082|"1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
75778732|NCT01091532|Drug|placebo|given orally twice daily for 14 days
75914715|NCT04789018|Other|Educational Intervention|Attend virtual genetics board
75914716|NCT04789018|Other|Survey Administration|Complete survey
75321934|NCT02286921|Drug|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
75626322|NCT04165252|Diagnostic Test|Collection of vaginal, neonatal buccal and placental samples|Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
75626323|NCT02642146|Drug|Calcium Channel Blockers|
75626324|NCT02642146|Drug|Phosphodiesterase Inhibitors|
75626325|NCT02642146|Drug|Endothelin receptor blocker|
75778733|NCT01091532|Drug|UK-396,082|"UK-396,082 given orally, once on Days 1 & 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
75914717|NCT04789018|Other|Interview|Complete interview
75914718|NCT04770948|Device|19 gauge needle|EBUS-TBNA performed using 19G needle
75914719|NCT04770948|Device|22 gauge needle|EBUS-TBNA performed using 22G needle
75914720|NCT04767022|Device|Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)|Drug Coated Balloon
75914721|NCT04767022|Device|Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)|Drug Coated Balloon
75914722|NCT04764721|Device|18F-FDG PET-CT|Enrolled patients in Neurocog-Covid will receive a 18F-FDG PET-CT
75321935|NCT02286921|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
75321936|NCT02987439|Other|Pulmonary rehabilitation|The intervention is pulmonary rehabilitation
75626326|NCT02642146|Drug|Prostanoids|
75321937|NCT05734521|Biological|avalglucosidase alfa-NGPT (GZ402666) IV|intravenous infusion
75626327|NCT02642146|Drug|Other vasodilator|
75626328|NCT02646514|Device|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
75626329|NCT02646514|Device|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
75626330|NCT00654394|Drug|Rosuvastatin|
75778734|NCT01091532|Drug|placebo|given orally, once on Days 1 & 14, and twice daily on Days 3-13.
75778735|NCT05621200|Device|Transcranial stimulation over the cerebellar hemispheres|Single session of Transcranial stimulation over the cerebellar hemispheres
75778736|NCT01091610|Other|no intervention|purely observational retrospective study. no interventions are planned.
75778737|NCT03712774|Other|EORTC QLQ C30|standardized questionaire
75778738|NCT03712774|Other|EORTC QLQ OES-18|standardized questionaire
75778739|NCT03712774|Other|EORTC OG-25|standardized questionaire
75778740|NCT00004088|Biological|filgrastim|
75778741|NCT00004088|Biological|recombinant interferon alfa|
75778742|NCT00004088|Drug|busulfan|
75778743|NCT00004088|Drug|cyclophosphamide|
75778744|NCT00004088|Drug|melphalan|
75778745|NCT00004088|Drug|pamidronate disodium|
75778746|NCT00004088|Drug|thalidomide|
75778747|NCT00004088|Procedure|peripheral blood stem cell transplantation|
75778748|NCT01091688|Behavioral|Just-in-Time information|Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
75914723|NCT04761991|Diagnostic Test|CMR and CTCA with CT-FFR|multi-parametric CMR assessment and CT coronary angiography with FFR assessment
75914724|NCT04760522|Genetic|WGS Diagnostic: Blood take for genetic diagnostic|Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).
75914725|NCT04757987|Other|Pain|As above
75914726|NCT04757753|Device|ready-to-use root canal sealer: PA1704|The participant will be treated with the ready-to-use root canal sealer (PA1704) in combination with gutta percha.
75914727|NCT04757753|Device|root canal sealer: BioRoot™ RCS|The participant will be treated with BioRoot™ RCS sealer in combination with gutta percha.
75914728|NCT04754282|Other|Position of labouring women for epidural analgesia catheter placement : Traditional Sitting Position (TSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
75778749|NCT03962322|Other|Weaning TDI|"Patients will be subjected to a spontaneous breathing test (Cpap 5), that consists in applying a positive end-expiratory pressure of 5 cm H2O for 20 minutes.~A tissue doppler evaluation will then be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration and calculating the speed of muscles displacement and other derived index of muscle function in the modality of ventilation which precedes the trial, during the SBT and after extubation."
75778750|NCT03439072|Drug|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
75778751|NCT03439072|Drug|Lilly Glucagon|1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])
75778752|NCT01095770|Procedure|AF Ablation with Ablation Frontiers Technology|AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.
75778753|NCT01095770|Procedure|AF Ablation with LASSO catheter|AF Ablation with traditional LASSO catheter
75778754|NCT01095770|Device|Reveal XT|Reveal XT implantable loop recorder monitored group
75778755|NCT01095770|Device|Permanent Dual Chamber Pacemaker|This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
75778756|NCT00078312|Drug|CEP-10953 (Armodafinil)|Armodafinil (po) 100 to 250 mg/day up to 12 months
75626331|NCT00911014|Other|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
75626332|NCT00653302|Drug|Lantus (insulin glargine) + Glucophage (Metformin)|
75626333|NCT02638870|Drug|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
75626334|NCT02641990|Drug|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
75321938|NCT05734521|Biological|avalglucosidase alfa-NGPT (GZ402666)|exposed via pregnancy and lactation
75626335|NCT02641990|Drug|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
75626336|NCT00653380|Drug|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
75778757|NCT03712696|Device|DIGNICAP™|Scalp cooling to prevent chemotherapy-induced alopecia
75778758|NCT03717220|Procedure|flap transferring|we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
75778759|NCT01085838|Drug|Erlotinib|Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
75778760|NCT03715036|Diagnostic Test|Point-of-care US|The intervention includes reassuring the AC and DVP
75778761|NCT00003896|Drug|cisplatin|
75778762|NCT00003896|Drug|liposomal doxorubicin|
75626337|NCT00653380|Drug|Monodox|Capsules, 100 mg, single-dose
75626338|NCT02646592|Drug|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
75778763|NCT00003896|Drug|paclitaxel|
75778764|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
75778765|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
75626339|NCT02646592|Drug|sevoflurane or propofol|
75626340|NCT02646670|Drug|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
75626341|NCT02646670|Drug|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
75778766|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
75778767|NCT03712540|Drug|BMS-986278|Oral administration 30 mg
75778768|NCT03712540|Drug|Rifampin|Oral administration 600 mg
75778769|NCT01091844|Procedure|Voiding Trial|After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
75778770|NCT03714802|Procedure|Szabo T-Stenting Technique|2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
75778771|NCT03714802|Procedure|T-Stenting Technique|2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
75778772|NCT00003830|Procedure|conventional surgery|Sentinel node resection immediately followed by axillary dissection.
75778773|NCT00003830|Procedure|Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.
75778774|NCT03714724|Diagnostic Test|Intraabdominal Pressure Measurement|In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.
75626342|NCT02646670|Drug|Ranibizumab and Aflibercept|- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
75778775|NCT03638986|Other|No intervention planned|No Intervention planned.
75778776|NCT03714646|Dietary Supplement|beta glucan and resistant starch|12g per day the day before the CID Resistant starch 7.5 g
75778777|NCT03714646|Dietary Supplement|Placebo|isocaloric maltodextrin before the CID
75778778|NCT03714646|Dietary Supplement|beta gluten|12 g beta gluten there day before the CID
75778779|NCT03712384|Other|Semi structured face to face interview|Face-to-face semi-structured interview conducted in the hospital, where young adults were hospitalized 10 years before, in a quiet and isolated office. The topic guide was built according to literature review, without further change after pilot test. Interviews where audio-recorded and transcribed
75321939|NCT00574067|Drug|Buprenorphine +OTP|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
75914729|NCT04754282|Other|Position of labouring women for epidural analgesia catheter placement : Cross-legged Sitting Position (CSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
75626343|NCT02646670|Drug|Aflibercept and ranibizumab|- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
75626344|NCT00651976|Drug|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
75626345|NCT00651976|Other|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
75626346|NCT00651976|Procedure|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
75626347|NCT02638792|Behavioral|Internet-based exposure therapy (I-ET)|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
75626348|NCT02638792|Behavioral|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
75914730|NCT04752696|Drug|Onvansertib|Oral capsule
75778780|NCT03714568|Drug|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
75778781|NCT03714568|Drug|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
75778782|NCT05472220|Drug|Alpelisib|Given orally
75914731|NCT04752696|Drug|Nanoliposomal irinotecan|Intravenous infusion
75467037|NCT01915966|Dietary Supplement|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
75467038|NCT01915966|Dietary Supplement|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
75467039|NCT01915979|Biological|Plasma rich in growth factors (PRGF)|
75321940|NCT00574067|Drug|Buprenorphine +CHC|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
75651654|NCT05832697|Drug|Ursodeoxycholic Acid 250 Mg Oral Tablet|Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
75778783|NCT05472220|Drug|Carboplatin|Given IV during imaging
75778784|NCT05472220|Drug|Hyperpolarized Carbon-13 (13C) Pyruvate|Given IV
75778785|NCT05472220|Device|Continuous Glucose Monitor (CGM)|Self-applied devices that sit partially beneath the skin
75778786|NCT03407482|Drug|GDC-0853|Participants received GDC-0853 at a dose of 200mg, as per the dosing schedule described above.
75778787|NCT00003782|Drug|cyclophosphamide|Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
75778788|NCT00003782|Drug|docetaxel|Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
75778789|NCT00003782|Drug|doxorubicin|Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
75914732|NCT04752696|Drug|Leucovorin|Intravenous infusion
75914733|NCT04752696|Drug|Fluorouracil|Intravenous infusion
75914734|NCT04749862|Other|Online symptom reporting|Online symptom reporting questionnaire with linked self-management advice
75778790|NCT03389308|Drug|diacerein 1% ointment|"Topically apply study medication to lesions identified by the Investigator that require.~treatment"
75321941|NCT00574067|Drug|Counseling +OTP|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
75626349|NCT02638636|Behavioral|Internet-based exposure therapy|The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
75626350|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
75321942|NCT00574067|Drug|Counseling +CHC|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
75626351|NCT02646436|Other|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
75626352|NCT02638714|Biological|Stem Cells|Intervention: Transplantation of autologous purified stem cells
75778791|NCT03714490|Radiation|SCPRT plus neoadjuvant chemotherapy|Short-course preoperative radiotherapy(SCPRT) with neoadjuvant chemotherapy, which consists of SCPRT, 5 Gy x 5, 4Gy for boost on the GTV with MRI-simulation alone, then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are scheduled before surgery.
75778792|NCT03714490|Radiation|long course chemoradiation|Long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively.
75778793|NCT03407170|Biological|pembrolizumab|200 mg by IV infusion Q3W for up to 24 months
75778794|NCT01103648|Drug|Simvastatin|Tablets of simvastatin 20 mg administered once a day for 12 weeks
75778795|NCT01103648|Drug|Ezetimibe|Tablets of ezetimibe 10 mg administered once a day for 12 weeks
75778796|NCT01103648|Drug|Combination Simvastatin plus Ezetimibe|"Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study."
75778797|NCT05625620|Device|Active Transcranial Pulse Current Stimulation|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes.
75778798|NCT05625620|Device|Sham Transcranial Pulse Current Stimulation|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes. Electric Current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
75467040|NCT01915979|Drug|Celestone cronodose (Bethametasone)|
75321943|NCT01913535|Drug|CERC-501|"Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
75467041|NCT01915992|Other|blood samples|
75467042|NCT01916018|Other|Clinical and radiologic exams and blood samples|
75467043|NCT01916031|Behavioral|Education|
75626353|NCT00654550|Drug|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
75626354|NCT00652054|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
75626355|NCT04164862|Device|AccuVein AV400 Device Versus Ultrasound-guided Cannulation|Accuvein AV400 device versus Ultrasound guided cannulation
75626356|NCT02646358|Drug|Vepoloxamer|
75626357|NCT02642224|Behavioral|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
75626358|NCT01166282|Biological|adalimumab|Adalimumab solution for subcutaneous injection.
75467044|NCT01916044|Other|Ultrasound|Measure of Uterine Segment by Ultrasound
75626359|NCT01166282|Biological|placebo for adalimumab|Placebo for adalimumab solution for subcutaneous injection.
75651655|NCT05832684|Drug|ZVS101e|ZVS101e contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human wild type CYP4V2 gene.
75778799|NCT05625464|Other|SCTP|Real-time automated monitoring of the electronic medical record to identify suspected sepsis patients without completion of sepsis bundle measures within 1-hour of the completion deadline and generated reminder pages. Clinicians responsible for patients randomized to the intervention receive reminder pages whereas no pages are sent for control arm patients.
75778800|NCT03406858|Biological|HER2Bi-Armed Activated T Cells|Given IV
75467045|NCT01916057|Device|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
76074103|NCT02662257|Drug|Propofol|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
75321944|NCT01913535|Drug|Placebo|"For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
75321945|NCT01914159|Drug|Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)|Monthly intravitreal injections
75778801|NCT03406858|Other|Laboratory Biomarker Analysis|Correlative studies
75778802|NCT03406858|Biological|Pembrolizumab|Given IV
75778803|NCT01095848|Biological|DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG|Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
75778804|NCT05621330|Drug|QL0911|The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
75778805|NCT05621330|Drug|Placebo comparator|The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
75778806|NCT01095926|Drug|doxorubicin|blood sampling before, during and after doxorubicin administration
75321946|NCT00575159|Drug|GSK189075|investigational drug
75626360|NCT02884700|Biological|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
75778807|NCT01103726|Drug|PF-02545920|1 and 5 mg tablets, 6 mg single dose
75778808|NCT01103726|Drug|placebo|matching placebo tablets, single dose
75778809|NCT01103726|Drug|PF-02545920|1 mg tablets, 3 mg single dose
75321947|NCT00575159|Drug|placebo|placebo comparator
75321948|NCT01915173|Drug|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
75321949|NCT01915173|Drug|Placebo|Lactose tablets
75321950|NCT01915173|Behavioral|Expanded Interview|
75321951|NCT01915173|Behavioral|Standard Interview|
75321952|NCT01915563|Procedure|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
75321953|NCT00576251|Drug|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
75321954|NCT00576251|Drug|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
75321955|NCT00578279|Drug|dehydrated alcohol|subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
75321956|NCT01916655|Behavioral|Self-Management Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
75321957|NCT01916655|Behavioral|Self-Management Mobile Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
75321958|NCT01916655|Behavioral|Usual Care|standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
75626361|NCT01153724|Drug|BI 1744|10 mcg solution for oral inhalation
75626362|NCT01153724|Drug|Fluconazole|400 mg capsule
75626363|NCT02884388|Procedure|combined nerve block|Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
75626364|NCT02884388|Procedure|general anesthesia|Patients in this group were assigned to receive general anesthesia.
75626365|NCT02885870|Procedure|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
75321959|NCT00578669|Drug|Fluoxetine|20mg once daily for 16 weeks
75321960|NCT00578669|Drug|Dextrose|Once daily for 16 weeks
75321961|NCT01917513|Device|G-EYE™ colonoscopy|G-EYE™ colonoscopy
75321962|NCT01917513|Device|Standard Colonoscopy|Standard Colonoscopy
75321963|NCT00578903|Drug|Cytoxan|Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
75467046|NCT01916096|Device|Delica Device|
75467047|NCT01916135|Radiation|[18F]-SKI-249380|
75778810|NCT01103726|Drug|PF-02545920|5 mg tablets, 15 mg single dose
75778811|NCT01103726|Drug|Placebo|matching placebo tablets, single dose
75778812|NCT01584986|Biological|ACP injections|Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)
75778813|NCT01585064|Other|DAS28-IOMS|Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of < 2.4.
75778814|NCT01585064|Other|0SJ-IOMS|Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
75778815|NCT01585064|Other|Routine Care (RC)|Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
75626366|NCT04314596|Other|Cross Training Course|One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
75626367|NCT04314596|Dietary Supplement|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
75778816|NCT01585142|Other|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
75778817|NCT03406702|Drug|CX-8998|T-type calcium channel blocker
75778818|NCT00003656|Biological|recombinant interferon alfa|
75778819|NCT00003656|Drug|tretinoin liposome|
75778820|NCT00003590|Drug|hydroxyurea|20 mg/kg/day PO
75778821|NCT01327430|Dietary Supplement|Milk phospholipid|During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
75778822|NCT03948620|Drug|Macrolides|Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
75778823|NCT03948620|Drug|Penicillins|The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
75778824|NCT01096004|Drug|AZD4017|oral suspension, 1200mg, once daily, for 10 days
75778825|NCT01096004|Drug|Placebo|
75778826|NCT03948542|Other|Outcome|"Nerve Recovery~NCV~Funcional assessment"
75626368|NCT02885948|Drug|Naloxone|used to block the effects of opioids, especially in overdose
75778827|NCT03416374|Drug|Ixazomib|Ixazomib capsules
75778828|NCT03416374|Drug|Bortezomib|Bortezomib injections
75778829|NCT03416374|Drug|Carfilzomib|Carfilzomib intravenous infusions
75778830|NCT03416374|Drug|Lenalidomide|Lenalidomide capsules
75778831|NCT03416374|Drug|Dexamethasone|Dexamethasone tablets
76074104|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
75321964|NCT00578903|Drug|Campath|Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
75321965|NCT00578903|Radiation|Total Body Irradiation (TBI)|TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
75321966|NCT00578903|Drug|FK-506|FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
75321967|NCT00578903|Drug|Methotrexate|Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
75626369|NCT02885948|Drug|Placebo|Placebo, ineffective control arm
75626370|NCT01152788|Drug|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
75626371|NCT01152788|Drug|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
75626372|NCT01165424|Drug|mometasone furoate|"MFNS 50 μg spray device~3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
75626373|NCT01152554|Drug|TC-5214|Tablet, oral, twice daily for 52 weeks
75626374|NCT01152554|Drug|Placebo|Tablet, oral, twice daily for 52 weeks
75626375|NCT00598702|Drug|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
75626376|NCT01148810|Drug|BAF312|
75626377|NCT01148810|Drug|Placebo|
75778832|NCT03799952|Behavioral|Zoomers on the Go Exercise Program|60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
75778833|NCT00077766|Drug|Darbepoetin alfa|Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
75778834|NCT00077766|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram [µg]) was based on the dose of darbepoetin alfa at the time of randomization (< 40, 40 to 80, or > 80 µg per week, respectively).
75778835|NCT03714412|Device|Implantation|Implantation of the Cardiovalve transfemoral mitral valve replacement system
75778836|NCT04149912|Diagnostic Test|Online questionnaire|Online questionnaire via SoSciSurvey
75778837|NCT01096082|Drug|Lithium Carbonate|300 mg tablets, starting dose 300 mg/day
75778838|NCT01096082|Drug|Placebo|Similar shape, color and taste and the same number of tablets from the experimental group
75778839|NCT03388138|Combination Product|etafilcon A with ketotifen|Etafilcon A with ketotifen
75778840|NCT03388138|Device|1-Day ACUVUE|1-Day ACUVUE
75778841|NCT05613530|Behavioral|MAX NEONAT|"Participants use a digital, hand-held, cognitive aid (a mobile application named MAX NEONAT) and the ILCOR 2020 algorithm poster.~This group consists of a resident in pediatrics + 2 midwifes."
76074105|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
75626378|NCT00624962|Dietary Supplement|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
75778842|NCT05613530|Behavioral|standard of care|no cognitive aid but poster/paper only
75321968|NCT00578903|Procedure|Stem cell infusion|Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10^6 CD 34+ cells/kg should be collected, with a target of 10 X 10^6/kg.
75321969|NCT01918761|Drug|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
76074106|NCT03153267|Drug|Controls without a history of lyme disease.|No intervention.
76074107|NCT03153501|Diagnostic Test|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
75321970|NCT00579137|Biological|Campath -1H|"Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients >15 kg to 30 kg the dose 5 mg; for patients > 30 kg the dose is 10 mg"
75321971|NCT00579137|Drug|Fludarabine|"Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2"
75321972|NCT00579137|Biological|Anti-CD45|"Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg"
75321973|NCT00579137|Procedure|Stem cell infusion|stem cells are infused on day 0
75321974|NCT04290377|Device|BMI-assisted motor imagery OT|As the goal of the intervention is to promote finger extension in participants who are unable to extend his/her finger due to stroke, the pneumatic glove provides extension assist when appropriate brain activity is present. The brain activity is obtained by Functional Near-Infrared Spectroscopy (fNIRS). Hypothetically, this will repeatedly induce brain activation that is related to finger extension.
75321975|NCT04290377|Other|Motor imagery OT|In Motor imagery OT, Subjects try to extend their fingers (imagine) without BMI assistance. All other setting is equal to BMI-assisted motor imagery OT.
75321976|NCT00580073|Drug|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
75321977|NCT00580073|Drug|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
75626379|NCT00624962|Dietary Supplement|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
75626380|NCT04313426|Other|Integrative Yoga Therapy|Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
75626381|NCT02884310|Drug|Remifentanil adapted to SPI|
75626382|NCT02884310|Drug|Remifentanil fixed|
75626383|NCT01151618|Device|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
75626384|NCT01164956|Drug|methylphenidate|
75778843|NCT01327586|Behavioral|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
75778844|NCT01327586|Behavioral|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
75626385|NCT01164956|Other|Placebo|
75626386|NCT02884232|Procedure|Nasofibroscopy|
75626387|NCT01164722|Other|clinical observation|Patients undergo observation
75778845|NCT01101620|Drug|Levosimendan|
75778846|NCT03954548|Device|CB-17-08 CADe|CB-17-08 Augmented Endoscopy System with Computer Aided Detection (CADe) function
75778847|NCT02952898|Drug|GDC 695|GDC 695 is a topical gel.
75321978|NCT00580151|Drug|clonidine|3-5 microgram per kilogram every 6 hours for 10 days
75321979|NCT00580151|Drug|placebo|1 dose every 6 hours
75321980|NCT01919697|Drug|Plecanatide|
75321981|NCT00580229|Drug|prednisone|prednisone 40mg by mouth 30-60 minutes prior to rituximab
75321982|NCT00580853|Drug|varenicline|2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
75321983|NCT00580853|Drug|bupropion|300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
75321984|NCT00580853|Drug|Placebo|Placebo
75626388|NCT01164722|Device|infrared photocoagulation therapy|Anal infrared coagulator ablation
75626389|NCT04314830|Device|Gait training with perturbations|Changes in speed of one of the belt of the split belt treadmill during swing phase
75626390|NCT04314830|Device|Gait training without perturbation|Walking on a treadmill with steady belt speed
75626391|NCT01151540|Drug|Rufinamide|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
75778848|NCT02952898|Drug|Diclofenac Sodium Gel, 3%|Diclofenac sodium gel, 3% is an FDA-approved drug.
75778849|NCT02952898|Drug|Vehicle gel|Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
75778850|NCT01101698|Drug|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
75778851|NCT01101698|Drug|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
75778852|NCT05563142|Procedure|deploying vascular closure device versus manual compression|patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
75778853|NCT05592886|Other|SMT04 formula|The SMT04 formula is a synbiotic containing probiotics and prebiotics
75778854|NCT05592886|Other|Active placebo|The active placebo is 2 mg Vitamin C with an inert substance made of starch filler. The flavor, coloring and appearance are unidentifiable to the study product.
75778855|NCT05592340|Behavioral|Exposure to calorie information|Calories for all foods and beverages
75778856|NCT05592340|Behavioral|Exposure to carbon footprint information|Carbon footprint labels for all foods and beverages
76074108|NCT01671579|Procedure|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
75914735|NCT04744298|Other|TheraPPP|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
76074109|NCT01671579|Procedure|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
76074110|NCT00746512|Drug|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
76074111|NCT00746512|Drug|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
75321985|NCT05739045|Drug|nivolumab combined with SOX|nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles);
75321986|NCT00604019|Drug|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
75626392|NCT02884466|Behavioral|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
75626393|NCT02883998|Other|Outpatient Physical Therapy|traditional outpatient physical therapy which occurs at a physical therapy office
75626394|NCT02883998|Other|Home Base Physical Therapy|Patients will be provided a packet of exercises via a website which allows access to instructional physical therapy videos specifically designated for UKA patients and equipment to perform the home based physical therapy
75626395|NCT01163786|Drug|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
75626396|NCT00984282|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
75626397|NCT00984282|Drug|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
75626398|NCT01147874|Procedure|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
75626399|NCT04292184|Drug|Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%|The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
75778857|NCT00045734|Drug|imatinib mesylate|Given orally
75778858|NCT00045734|Other|laboratory biomarker analysis|Correlative studies
75778859|NCT00045734|Other|pharmacological study|Correlative studies
75778860|NCT05513768|Diagnostic Test|level of myosin binding protein c in serum|Serum samples will be taken from the participants in the first trimester, transferred to eppendorf tubes after appropriate procedures, and stored at -80 degrees until the time of deliveryParticipants will be divided into two groups according to the timing of birthThe first group is those who gave birth earlier than 37 weeks those who gave birth on time in the other group The mbpc levels will be looked at and compared.
76074112|NCT00746512|Drug|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
76074113|NCT00746512|Drug|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
76074114|NCT05409027|Drug|SPI-62|SPI-62 is supplied as 1 mg tablets for oral dosing.
76074115|NCT05409027|Drug|Cortisone-d8|Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion
75321987|NCT00604019|Drug|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
75778861|NCT03387046|Dietary Supplement|D-aspartate|D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.
75778862|NCT03387046|Drug|Placebo|Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
75321988|NCT05732571|Other|Breathing techniques over 12 sessions / 6 weeks inc yoga|as above
75778863|NCT03387046|Biological|IFN beta-1a|IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
75321989|NCT00581399|Device|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
75321990|NCT00581399|Device|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
75321991|NCT01922115|Drug|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
75321992|NCT01922115|Drug|Placebo|
75321993|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.5 ug/kg/week subcutaneously (SC) for 48 weeks
75321994|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.0 ug/kg/week SC for 48 weeks
75321995|NCT00081770|Drug|REBETOL (ribavirin; SCH 18908)|weight based dose 800-1400 mg/day orally (PO) for 48 weeks
75914736|NCT04742257|Device|MyoRegulator® device|Trans-spinal DCS paired with peripheral DCS
75914737|NCT04739371|Drug|Insulin, Regular, Human|The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
75778864|NCT03387046|Drug|Methylprednisolone|Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
75321996|NCT00081770|Biological|PEGASYS (peginterferon alfa-2a)|180 ug/week SC administered for 48 weeks
75778865|NCT01101776|Drug|Interferon beta-1a (Rebif)|Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.
75778866|NCT03712306|Other|Dietary advice|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d
75626400|NCT01147640|Drug|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
75321997|NCT00081770|Drug|COPEGUS (ribavirin)|1000-1200 mg/day PO for 48 weeks
75321998|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.2 ug/day implant
75626401|NCT01147640|Drug|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
75626402|NCT02867982|Procedure|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
75778867|NCT03712306|Other|Dietary advice and advice on timing|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d plus advice on consuming protein in close proximity of usual physical activity
75778868|NCT00045110|Drug|erlotinib hydrochloride|given orally
75778869|NCT00045110|Other|laboratory biomarker analysis|correlative studies
75778870|NCT00045110|Other|pharmacological study|correlative studies
75778871|NCT03353740|Drug|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
75778872|NCT04814602|Drug|Proglumide|CCK receptor antagonist
75778873|NCT01311466|Procedure|Liver transplantation|
75778874|NCT00003476|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
75778875|NCT00003470|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75321999|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.5 ug/day implant
75778876|NCT03948308|Biological|blood sample|blood sample before, during and after infection treatment
75778877|NCT01104038|Behavioral|EXCEL|Children in the EXCEL intervention will receive 12 weeks of supervised physical activity, guided by principles of behavior change, in the form of exergaming (technology-mediated interactive physical activity)3 times per week for 12 weeks and will also receive weekly group nutrition education sessions
75778878|NCT01104038|Behavioral|EXCEL|Participants in the EXCEL intervention will receive 12 weeks of supervised physical activity in the form of exergaming (technology-mediated physical activity). Sessions will be held 3 times per week with 60 minutes of supervised physical activity.
75778879|NCT01104038|Behavioral|Nutrition Education ONLY|Children in the nutrition education group will receive 30 minutes per week of group nutrition education in the school environment and delivered by a registered dietitian The nutrition education sessions will be identical to those provided for the EXCEL group.
75322000|NCT05730699|Biological|divozilimab|anti-CD20 monoclonal antibody
75322001|NCT05730699|Drug|Placebo|Placebo
75322002|NCT00606047|Radiation|Magnetic resonance imaging (MRI)|Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
75626403|NCT02867982|Procedure|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
75626404|NCT02867982|Drug|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
75626405|NCT02867982|Device|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
75626406|NCT02867982|Radiation|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
75626407|NCT02884154|Device|Echotip ProCoreⓇ HD Ultrasound Biopsy Needle|
75626408|NCT01121900|Drug|Trazodone HCl|"Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours."
75626409|NCT01121900|Drug|Trazodone HCl|"Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period."
75626410|NCT00625040|Other|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test."
75626411|NCT01121666|Drug|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
75626412|NCT00984126|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
75778880|NCT01104194|Dietary Supplement|omega-3 fatty acids supplements (fish oil)|1.74g eicosapentaenoic acid (EPA) and 0.25g docosahexaenoic acid (DHA)
75626413|NCT00984126|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
76074116|NCT01275742|Behavioral|Brief Cognitive Therapy Intervention|The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
75778881|NCT01104194|Dietary Supplement|Placebo|softgel capsules (identical in appearance to fish oil capsules) containing olive oil. 3 capsules/day, 4 weeks
76074117|NCT04385134|Other|No intervention|No intervention
76074118|NCT03153423|Procedure|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
75626414|NCT02867748|Procedure|TVT-Abbrevo|
75626415|NCT02867748|Procedure|Serasis|
75778882|NCT01327664|Biological|AIN457|
75778883|NCT01104272|Device|LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)|Study of Adipose Tissue Treatment Using Focused Ultrasound
75778884|NCT03386344|Drug|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
75778885|NCT03386344|Drug|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
75778886|NCT00399035|Drug|Cediranib|oral tablet
75778887|NCT00399035|Drug|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
75778888|NCT00399035|Drug|XELOX (Capecitabine and Oxaliplatin)|intravenous oxaliplatin 130 mg/ m^2(day 1) followed by oral capecitabine 1,000 mg/ m^2twice daily (day 1 to day 15)
75778889|NCT00399035|Drug|Cediranib Placebo|oral tablet
75322003|NCT01923129|Drug|Prazosin given 6 hours prior to catheter removal in the 24 hour group|Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
75322004|NCT00581867|Drug|Insulin Aspart|40IU insulin aspart applied intranasally
75322005|NCT00581867|Drug|Placebo|Placebo
75778890|NCT00073749|Drug|Inotuzumab ozogamicin [CMC-544]|CMC-544, IV, dose escalation trial
75626416|NCT02867514|Device|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
75626417|NCT02868060|Drug|Romiplostim|
75626418|NCT02868996|Drug|Recombinant human tissue kallikrein|Intravenous DM199
75778891|NCT03960801|Drug|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
75778892|NCT03960801|Drug|neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
75778893|NCT01089699|Behavioral|online support group|online support group
75778894|NCT01089699|Behavioral|online support group|online support group
75778895|NCT01089699|Behavioral|home study support materials|self-study materials
75778896|NCT01583439|Drug|highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine|Atripla: one tablet administered orally once daily at bedtime, each tablet comprised of co-formulated: Efavirenz (EFV) 600mg, Emtricitabine (FTC) 200mg, Tenofovir disoproxil fumarate (TDF) 300mg(EFV/FTC/TDF). Note: the study will generally provide the fixed-dose combination Atripla, but it will also be permissible for the same drugs to be used at the same doses as individual components (or as Truvada, coformulated TDF/FTC). Other drug substitutions may be made per the protocol.
75778897|NCT02530827|Drug|use of lipid-lowering drugs.|The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
75778898|NCT00398567|Drug|HKI-272|HKI-272 by mouth
75778899|NCT00398567|Drug|trastuzumab|trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter
75778900|NCT01082289|Drug|Lurasidone|
75914738|NCT04739371|Drug|Placebo|The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
75322006|NCT01925469|Drug|Benzocaine|
75322007|NCT01925469|Drug|Saline spray|A saline spray will be used in the placebo group
75322008|NCT02139137|Other|Computerized Cognitive Training - active|Cognitive training using working memory span task
75322009|NCT02139137|Other|Computerized cognitive training - sham|Sham training condition
75322010|NCT00583661|Device|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
75322011|NCT01925781|Drug|Nicotine polacrilex|2 mg and 4 mg gum will be used according to the FDA approved product labelling
75322012|NCT01925781|Other|STAM 1100mAh CE4 eGo Clearomizer|
75322013|NCT01927575|Device|Standard X-Ray + CT|Standard of Care X-Ray Imaging + CT
75914739|NCT04734392|Procedure|TAVR|TAVR implantation in cusp overlay technique
75914740|NCT04732507|Combination Product|1% plain lidocaine and 0.25% plain bupivacaine|A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.
75778901|NCT05842226|Other|Micro-teaching enriched with standard patient|The practice group will be shared the 4 most common symptoms in palliative care nursing: pain, fatigue, respiratory distress and loss of appetite. The practice group will be 5 groups and there will be 4 students in each group. During the practice, each student will provide patient education about only one symptom. The standard patient will participate in the intervention in the application laboratory and the students will participate in the intervention in the computer environment. Video recordings will be taken while the students are giving education. After watching the experts, peers and their own video with the micro-teaching group evaluation form, the student himself/herself will make an evaluation. At the same time, a lecturer from outside the research will fill in the Standard Patient Check-List Evaluation Form. The application will be repeated one week later.
75778902|NCT05842174|Drug|Hydroxychloroquine|Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure
75778903|NCT05842174|Drug|Lipiodol|Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.
75778904|NCT05842174|Drug|Placebo|Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
75914741|NCT04731857|Genetic|Retrospective data analysis|The outlined evaluation contributes to the improvement of molecular genetic diagnostics in patient care - for example when which diagnostics can be sensibly recommended for patients with which indications or not. Diagnostic gaps can be systematically evaluated and specifically addressed in the future. This potentially affects every examination assignment for current and future patients. In addition, the evaluation of the PRSs for example, can contribute significantly to the timely introduction to routine diagnostics. For familial breast cancer, according to the guidelines, there may be very specific preventive measures. Estimates currently assume up to 5% of patients, which would mean up to 25 cases per year with a potentially adapted management for patients with the question of a tumor disease alone.
75914742|NCT04726319|Other|FHAMe Intervention|Patients will receive an invitation email prior to their scheduled clinical visit which includes information about the study, a link to the YouTube patient presentation, and a link to the consent form and questionnaire. Patients will be invited to fill out the questionnaire prior to their appointment. After patients complete the initial questionnaire, physicians will receive an EMR message on the day of patient's clinic visit alerting them that patient family history information is available and to complete the Family History Action Form. They will be prompted to respond to the message which will open the action form and ask what action the provider intends to take with this family history information. The form will then link to management support tools for use during the patient visit. All participants will attend their clinical visit after which they will receive a post-visit electronic survey regarding their clinical visit and whether family history was reviewed with their provider.
75914743|NCT04725812|Drug|Eculizumab|Eculizumab Intravenous Solution
75322014|NCT01927575|Device|Standard X-Ray + MRI|Standard of Care X-Ray Imaging + MRI
75322015|NCT01927575|Device|TOMO|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
75626419|NCT04290702|Procedure|regional analgesia for labor|three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia
75778905|NCT05842135|Procedure|Laparoscopic approach to small bowel obstrcuction|Bowel viability assessment by indocyanine green fluorescent angiography during laparoscopic approach to small bowel obstruction
75778906|NCT05842031|Behavioral|Quality of Life Questionnaires|Identify what interventions may be helpful in improving quality of life.
75626420|NCT00629226|Biological|cetuximab|Given IV
75626421|NCT00629226|Drug|bortezomib|Given IV
75626422|NCT00629226|Drug|cisplatin|Given IV
75626423|NCT00629226|Radiation|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
75626424|NCT04291326|Diagnostic Test|Transfontanelle ultrasound|cerebral blood flow measurement using transfontanelle ultrasound
75626425|NCT00979602|Biological|GSK2340274A|One intramuscular injection
75626426|NCT00979602|Biological|GSK2340273A|One intramuscular injection
75626427|NCT02866734|Other|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
75778907|NCT05842031|Behavioral|Patient Educational Needs|Identify what interventions may be helpful in improving patient educational needs
75778908|NCT05842031|Behavioral|Symptom Management|Identify what interventions may be helpful in improving symptom management Improve symptom management
75914744|NCT04717765|Device|Preventive, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
75914745|NCT04717765|Device|Curative, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
75914746|NCT04717765|Device|Preventive, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
75626428|NCT02866734|Other|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
75626429|NCT02866734|Other|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
75626430|NCT00629304|Device|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
75626431|NCT00629304|Device|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
75626432|NCT00629304|Device|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
75322016|NCT01927887|Drug|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
75626433|NCT00816361|Drug|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
75778909|NCT05842018|Drug|Toripalimab, Anlotinib and Chemotherapy|"Combination therapy:~Toripalimab 240mg will be intravenously administered on Day 1, Q3W; anlotinib: 12 mg qd d1-d14, d15-d21 discontinued, Q3W; investigator selected chemotherapy regimen (paclitaxel, pemetrexed or gemcitabine and other chemotherapeutic drugs which were not administered in the first-line therapy) for a total of 4 cycles.~Maintenance therapy:~After combination therapy, Patients who achieved complete response（CR）, partial response (PR), or stable disease (SD) were administered with toripalimab plus anlotinib as maintenance therapy. until disease progression or intolerable toxicity, treatment for 2 years, investigator decision, withdrawal of consent, or death."
75778910|NCT05842005|Device|Mesh-reduced Sling|In this proposed study, the investigators aim to evaluate the role of using a ¾ x ⅜ inch cm polypropylene mesh suspended by sutures as a mesh-reduced solution for SUI.
75778911|NCT05841992|Drug|Al18F-PSMA-617|Intravenous injection of one dosage of 0.1mCi/kg Al18F-PSMA-617. Tracer doses of Al18F-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
75778912|NCT05841992|Drug|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
76074119|NCT00746668|Behavioral|Module 1: Visual Awareness and Eccentric Viewing|"In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.~This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice."
75914747|NCT04717765|Device|Curative, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
75322017|NCT01927887|Device|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
75626434|NCT05297929|Drug|Irbesartan Tablet|Drug: Irbesartan Oral administration on an empty stomach／fed condition
75626435|NCT00826111|Drug|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
75778913|NCT05841966|Diagnostic Test|Transoral Ultrasound|The tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia.
75778914|NCT05841927|Dietary Supplement|Docosahexaenoic acid supplement|Docosahexaenoic acid supplement
75778915|NCT05841927|Dietary Supplement|ASD placebo|ASD placebo
75322018|NCT01929057|Procedure|Skin biopsy|4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)
75778916|NCT05841901|Drug|Huang-long Zhi-xiao Granule|The experimental group was given Huang-long Zhi-xiao Granule.1 dose per day, oral in 2 divided doses, 1 course every 4 weeks, for a total of 8 weeks of treatment.
75778917|NCT05841901|Drug|Huang-long Zhi-xiao Granule placebo|The toncral group was given placebo Huang-long Zhi-xiao Granule.The course of treatment was the same as that of the experimental group.
75778918|NCT05841875|Other|C reactive protein|The attending physicians will be instructed to follow a flowchart created by the research team that uses clinical variables and the serum CRP value to guide the prescription and the duration of antibiotic therapy. This flowchart will be available in the application for mobile devices developed specifically for this study. CRP levels will be collected on a daily basis. Antibiotic suspension will be encouraged when CRP value is < 35mg/L and after a minimal duration of 3 days (if peak CRP is below 100mg/L), or when CRP value reduces by 50% and after a minimal duration of 5 days (if peak CRP is above 100mg/L or if the patient fills the criteria for sepsis or septic shock). Before suspension, the physician will be instructed to make sure the patient is in clinical improvement, without any signs of persistent infectious focus and if the SOFA score is stable or in decrease.
75778919|NCT05841849|Drug|Aprepitant|oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3
75626436|NCT00826111|Drug|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
75626437|NCT00982644|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
75626438|NCT00982644|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
75914748|NCT04716231|Biological|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
75914749|NCT04716231|Other|Placebo to match Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
75914750|NCT04713969|Drug|Pantoprazole 40mg|Pantoprazole 40mg twice daily
75322019|NCT01929057|Procedure|Blood draw|Approximately half a tube of blood will be drawn from all participants in the study
75322020|NCT00081458|Drug|Placebo|placebo injectable subcutaneously daily into thigh or abdomen
75322021|NCT00081458|Drug|Teduglutide 0.05 mg/kg/d|Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
75914751|NCT04713774|Device|High-resolution peripheral quantitative CT scanner (HRpQCT)|HR-pQCT images of the distal radius and distal tibia (non-dominant, non-fractured limb) will be obtained using the XtremeCT device with standard protocols. HR-pQCT images wil be analysed with standard software and extended cortical measures software. This software identifies the periosteal and endosteal boundaries, enabling assessment of cortical micro- structural bone properties, including apparent cortical thickness (Ct.Th, mm), cortical tissue mineral density (TMD, mgHA/cm3) and cortical porosity (Ct.Po, %).
75914752|NCT04710602|Procedure|Minimally invasive surgical fixation of unstable rib cage|Minimally invasive and muscle sparing surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes).
75626439|NCT00815659|Drug|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
75626440|NCT02867904|Drug|Methylprednisolone (40 mg depomedrol, 1ml, injection)|Experimental Drug
75626441|NCT02867904|Drug|Marcaine (4ml 0.5%, injection)|Control
75626442|NCT00825175|Behavioral|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
75626443|NCT00825175|Device|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
75626444|NCT04290936|Drug|Vemlidy® (Tenofovir Alafenamide; TAF)|Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
75914753|NCT04710602|Procedure|Large incision surgical fixation of unstable rib cage.|Surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes). Large non muscle sparing incision with simultaneous thoracotomy.
75626445|NCT04290936|Drug|Placebo|Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
75626446|NCT00707941|Drug|Oseltamivir|"Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
75626447|NCT00707941|Drug|Placebo|"Children < 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
75626448|NCT02866890|Device|Laryngeal Tube Suction|Laryngeal Tube Suction Measurement of leak pressure
75626449|NCT04038931|Other|Liver biopsy collection|Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.
75626450|NCT04290312|Other|Mastiha oil|After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing ~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
75626451|NCT02867826|Device|Cap|Cap-assisted endoscopy
75626452|NCT02867358|Drug|KT07 Capsule|
75626453|NCT02867358|Other|Placebo|
75778920|NCT05841849|Drug|Palonosetron|oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
75778921|NCT05841849|Drug|Fosaprepitant|intravenous fosaprepitant 150mg for D1 before chemotherapy
75778922|NCT05841836|Device|the Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
75778923|NCT05841836|Device|Perclose ProGlide Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
75914754|NCT04706429|Drug|Trientine|Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.
75914755|NCT04706429|Drug|Placebo|Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
75914756|NCT04701021|Biological|TENDU|The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.
75914757|NCT04699227|Procedure|Cuff application with inflation|The blood pressure cuff will be placed on the arm and inflated.
75626454|NCT00824473|Drug|Placebo|Placebo
75914758|NCT04699227|Other|Sham inflation|The blood pressure cuff will be placed on the arm and not inflated.
75914759|NCT04697719|Drug|Aspirin 81mg|81mg oral capsule
75914760|NCT04697719|Drug|Aspirin 325mg|325mg oral capsule
75914761|NCT04697459|Other|chronic phase|1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.
75914762|NCT04697459|Other|acute phase|30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning
75626455|NCT00824473|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
75626456|NCT04291092|Drug|Immunotherapy|Immunotherapy for brain metastasis
75626457|NCT04291092|Radiation|WBRT|local therapy for brain metastasis
75626458|NCT04291092|Drug|Chemotherapy|Chemotherapy for brain metastasis
75626459|NCT04041037|Device|Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix|Porcine-derived extracellular matrix will be used in powder and 2-Layer wound sheet form in masses up to 1000 mg. Each product is intended for a one-time use only.
75626460|NCT02867436|Other|Gluten-free diet|
75626461|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
75626462|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
75914763|NCT04694807|Behavioral|Group-based Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 2.25 hours for the group format.~Group-based CBTgrief will follow the same content and exercises for each session as individually delivered CBTgrief."
75914764|NCT04694807|Behavioral|Individually delivered Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 1 hour for the individually delivered format.~Individually delivered CBTgrief will follow the same content and exercises for each session as group-based CBTgrief."
75626463|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
75914765|NCT04692259|Diagnostic Test|MRI|Liver MRI before liver resection
75914766|NCT04690907|Behavioral|Dietary intervention|Written material on healthy diet during pregnancy and 2 virtual dietary counseling sessions.
75322022|NCT00081458|Drug|Teduglutide 0.1 mg/kg/d|Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
75322023|NCT00610727|Drug|Prochlorperazine 0.5 mg IV over 5 sec|IV Prochlorperazine for bioavailability
75626464|NCT02867280|Drug|Sorafenib|red round tablet
75626465|NCT00815191|Device|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
75626466|NCT00815191|Device|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
75626467|NCT04290390|Drug|Segesterone Acetate and Ethinyl Estradiol|Contraceptive Vaginal System
75626468|NCT04290390|Drug|Rifampin|CYP3A inducer
75626469|NCT04290390|Drug|Itraconazole|CYP3A inhibitor
75626470|NCT00708253|Device|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
75778924|NCT05841823|Behavioral|Virtual reality exposure therapy (VRET)|The relaxation scene includes four beautiful landscapes, and patients can choose any of these four, as perceived to be the most comfortable landscape. The visual stimulation of high-risk scene is designed as any combination of four different scenes (street barbecue stands, restaurant, bar and home) and four kinds of alcoholic beverages (Chinese liquor, beer, grape wine and cocktail), which are customized according to the patient's personal preference. At the same time, the odor of the alcoholic beverage of the patient's choice will be provided as an olfactory stimulation. The aversive situation will be the visual and auditory stimulation provided by a video of an alcoholic vomiting, while olfactory stimulation will be provided by cotton balls soaked in fermented dairy products.
75778925|NCT05841823|Behavioral|Acceptance and commitment therapy (ACT)|The initial session began with case formulation. Subsequent sessions involved learning on acceptance and acknowledgement of unpleasant thoughts and feelings associated with alcohol craving and clinical features of alcohol use disorder, cognitive defusion on how to dissociate self avoidance of unpleasant thoughts and feelings, learning and practicing mindfulness exercise (such as mindfulness breathing) to make self aware of the many things that occurred presently which can be enjoyed and focus on rather than focusing on unpleasant thoughts and feelings, and learning to be aware of the safe self which is separated from the unpleasant thoughts and feelings and identifying values in life and strategies to achieve these values (therapeutic processes in hexaflex).
75626471|NCT00708253|Device|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
75626472|NCT04119960|Device|Aided read with InferRead Lung CT.AI|Radiologists read chest CT scans with the aid of InferRead Lung CT.AI
75322024|NCT00610727|Drug|Inhaled prochlorperazine 0.625 mg|Inhaled Staccato Prochlorperazine 0.625 mg
75322025|NCT00610727|Drug|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato Prochlorperazine 1.25 mg
75322026|NCT00610727|Drug|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato Prochlorperazine 2.5 mg
75322027|NCT00610727|Drug|Inhaled prochlorperazine 5 mg|InhaledStaccato Prochlorperazine 5 mg
75322028|NCT00610727|Drug|Inhaled prochlorperazine 10 mg|InhaledStaccato Prochlorperazine 10 mg
75322029|NCT00610727|Drug|Inhaled placebo|Inhaled Staccato Placebo (0 mg)
75322030|NCT00610727|Drug|Prochlorperazine 10 mg IV over 5 sec|Prochlorperazine 10 mg IV over 5 sec for patient qualification
75626473|NCT00708331|Device|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
76074120|NCT00746668|Behavioral|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
75778926|NCT05841771|Drug|Venetoclax|"Participants will receive maintenance therapy with venetoclax and azacitidine or decitabine after allogeneic stem cell transplantation.~Azacitidine will be administered once daily subcutaneously (32mg/m2/d) on days 1-5, and venetoclax will be administered once daily orally (400mg/day) on days 1-7. If the patient is refractory or allergic to azacitidine, they will receive decitabine. Decitabine will be administered intravenously (5mg/m2/d) on days 1-5. If the patient is treated with CYP450 inhibitors(such as posaconazole or voriconazole), the dose of venetoclax will reduce to 100 mg once daily on days 1-7. Maintenance therapy will start from the 60th to 120th days after allogeneic hematopoietic stem cell transplantation and repeat every 28 days for up to 10 cycles within the first year after transplantation."
75322031|NCT03081104|Device|hystroscopy|The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
75626474|NCT04007952|Procedure|Anterior Gastropexy|Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
75626475|NCT02866968|Procedure|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
75626476|NCT04145388|Other|online cancer risk assessment|Electronic surveys to collect family cancer history information.
75626477|NCT04145388|Other|Usual care|Family cancer history captured by provider during a clinical encounter
75626478|NCT04145310|Drug|BOL-DP-o-04 + SCO|sublingual drops
75626479|NCT04145310|Drug|Placebo + SCO|sublingual drops
75626480|NCT04290858|Drug|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
75626481|NCT02866656|Other|Conventional conservative treatment|Treatment last for 4 weeks, three times a week,
75626482|NCT02866656|Device|therapeutic ultrasound|Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
75626483|NCT00812929|Drug|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
75914767|NCT04688515|Behavioral|Nutrition program developed using positive deviance approach|It is a 3-month nutrition program including nutrition education session and rehabilitation session. The education session consists of half hour education lesson and one and half hours peer-led cooking session. The cooking demonstration will be led by volunteers from PD family. Participating mothers will need to bring along their children during this session, prepare meal according to pre-planned menu and feed their children with the prepared meal after cooking as snack or additional meal. The rehabilitation session will be the rest of the days following each education session until the next education session. Growth monitoring session will also be conducted in each session, whereby mothers will be taught and trained to weigh their children.
75626484|NCT00812929|Drug|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
75626485|NCT04034017|Other|no intervention|descriptive study, no intervention
75914768|NCT04688385|Biological|Multipeptide Vaccine+ XS15|Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as > 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
75914769|NCT04684459|Biological|Dual-targeting HER2 and PD-L1 CAR-T cells|serosal cavity infusion
75914770|NCT04681768|Drug|Abemaciclib|Abemaciclib tablets 150 mg, 100 mg, 50 mg as clinical routine: 150 mg twice daily per os, in-label administration in combination with endocrine therapy (aromatase inhibitor or Fulvestrant)
75914771|NCT04673760|Behavioral|Specialized palliative home care|"Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team."
75914772|NCT04666090|Drug|Carillizumab|administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.
75914773|NCT04666090|Procedure|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
75626486|NCT05326555|Diagnostic Test|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
75778927|NCT05841771|Drug|Azacitidine or decitabine|azacytidine 32mg/m2 or decitabine 5mg/m2
75626487|NCT00824161|Drug|TAS-109|"14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation."
75626488|NCT02610829|Dietary Supplement|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
75626489|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
75626490|NCT00979134|Drug|AZD4547|Patients start at a dose of 80 mg twice daily, with no washout
75626491|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose
75778928|NCT05841758|Drug|Hydroxychloroquine|Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)
75626492|NCT00824005|Biological|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
75626493|NCT00824005|Biological|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
75626494|NCT04289844|Other|Elastic-explosive and resistance strength|"The resistance exercises are: running (3 minutes), 2 farmers carrying marching, 3 side to side ankle hops, 4 plyo lunge jump, 5 lateral jump over barrier, 2 monopodalic jump with ball pass, 3 board throw with half court sprint, 4 lateral shuffle mirror, and 5 combo finisher 4x4.~Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride"
75778929|NCT05841758|Drug|Placebo|Placebo during a 12 months double blind placebo-controlled period
75778930|NCT05841745|Device|Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console. A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI.
75778931|NCT05841732|Other|Usual Care|Education; Pain Medication, imaging, referrals to other health services, other health care appointments
75778932|NCT05841732|Other|MyBack Program|A tailored exercise and behavioural change program
75778933|NCT05841680|Behavioral|SSI Module|Single Session Intervention (SSI) module for youth with anxiety disorders and their parents. The SSI module will include psychoeducation on the cognitive behavioral conceptualization of anxiety, introduction to self-regulation strategies to manage physiological manifestations of anxiety, and cognitive restructuring of anxiogenic thoughts. The SSI module will also involve parents and present strategies on how parents can support their children in managing anxious feelings and thoughts.
75914774|NCT04666090|Other|Samples|Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use
75914775|NCT04662996|Biological|Blood sample|one blood sample is done before beginning a first treatment line for a metastatic castration resistant prostate cancer
75914776|NCT04661683|Other|Combustible Hookah Smoke|Exposure to combustible hookah smoke for a duration of 60 minutes.
75626495|NCT04289844|Other|Elastic-explosive strength|Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride
75914777|NCT04661683|Other|Electronic Hookah Aerosol|Exposure to electronic hookah aerosol for a duration of 60 minutes.
75914778|NCT04661683|Other|Clean Room Air|Exposure to room air for a duration of 60 minutes.
75626496|NCT05756647|Device|Interventional Arm|The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.
75626497|NCT05756647|Combination Product|Conservative treatment Arm|Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
75626501|NCT05758051|Procedure|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
75626502|NCT04290468|Device|Dynamic ultrasound|"The ultrasound examination will be carried out blinded to the results of MRI using the Affiniti 70 ultrasound machine by Philips (USA) via a 5-12MHz linear transducer.~MRI was performed on a high field system (1.5 Tesla) magnet units (Philips Acheiva)."
75626503|NCT04289610|Device|Transcutaneous pulse radiofrequency therapy|Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality
75626504|NCT00814879|Drug|Raltegravir|400 mg BID
75626505|NCT00814879|Drug|Atazanavir|300 mg BID
75626506|NCT00814879|Other|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
75626507|NCT04289532|Drug|99mTc-RWY|99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
75626508|NCT02866422|Other|No Intervention|Observational Study: No intervention
75626509|NCT00708409|Procedure|Cardiac valve surgery|Different autograft implantation techniques.
75626510|NCT03347422|Drug|sutimlimab (BIVV009)|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
75626511|NCT03347422|Drug|placebo|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
75778934|NCT05841654|Drug|Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI|The patient's ECG information will be monitored through the ECG monitoring patch, and the time of the first atrial fibrillation event will be recorded. Monitoring whether the patient's blood pressure is controlled dynamically, using echocardiography to evaluate cardiac function, and using scales to assess the quality of life.
75778935|NCT05841641|Device|Laser Bandage|The Diode Laser will create a biological bandage at a wavelength of 810 nm, set at 5W in continuous-wave mode, applied via a 400-µm optical fibre.
75322032|NCT03081104|Device|ultrasound|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
75322033|NCT03081104|Procedure|Aspiration|The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
75914779|NCT04659174|Drug|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
75914780|NCT04658342|Diagnostic Test|Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)|"The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment."
75914781|NCT04651296|Behavioral|compassion meditation|manualized compassion meditation training
75322034|NCT00584831|Device|senofilcon A|toric contact lens
75626512|NCT00814801|Drug|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
75778936|NCT05841641|Procedure|Hemostatic agent with surgical stent|Following graft harvesting, the donor site was secured with a hemostatic agent and protected with a palatal stent
75778937|NCT05841602|Other|descriptive|This research was conducted to evaluate nursing care from the perspective of hospitalized children during the Covid-19 pandemic process and to determine their feelings during this process.
75914782|NCT04651296|Behavioral|health education|manualized health education group
75914783|NCT04641416|Diagnostic Test|Routinely performed echo, ECG and hemodynamic monitoring|The pump data of patients on the ICU or normal ward are stored in a continuous data acquisition system (CDAS) on a notebook which is operated in battery operation, and analyzed afterwards with a mat-lab based software. For outpatients a mobile data-recorder will allow a continuous data acquisition for a period up to 2 months on a SD card. During this non-invasive pump data monitoring, routinely available hemodynamic monitoring, ECG and echo data will be collected.
75322035|NCT00584831|Device|balafilcon A|toric contact lens
75322036|NCT00584831|Device|omafilcon A|toric contact lens
75322037|NCT00584831|Device|lotrafilcon B|toric contact lens
75322038|NCT03081260|Other|Patellar resurfacing|The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.
75322039|NCT03081260|Other|Patellar non-resurfacing|Non-resurfacing of the patella does not involve any additional surgical action
75322040|NCT01929291|Biological|Boostrix|Single intramuscular injection
75322041|NCT01929291|Other|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
75322042|NCT03084848|Other|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
75322043|NCT03084848|Other|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
75626513|NCT00814801|Drug|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
75626514|NCT00814801|Drug|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
75778938|NCT05841589|Procedure|Green tea extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
75778939|NCT05841589|Procedure|Garlic with lime extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
75778940|NCT05841589|Procedure|Pomegranate extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
75778941|NCT05841589|Procedure|Chlorhexidine mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
75778942|NCT05841576|Other|COMET monitoring device|Cellular Oxygen METabolism (COMET) mitochondrial oxygen tension monitoring device
75914784|NCT04638933|Other|No intervention|No intervention
75914785|NCT04628338|Drug|IFN-γ (interferon gamma-1b) injection|Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)
75914786|NCT04626570|Other|Cognitive and Behavioral Therapy|12 sessions of CBT using a standardized approach
75914787|NCT04622020|Procedure|Cervical Plexus Block with Local Anaesthesia|Ultrasound guided intermediate cervical plexus block
75914788|NCT04622020|Procedure|Cervical Plexus Block with Depot Steroids|Ultrasound guided intermediate cervical plexus block
75778943|NCT05841511|Behavioral|"Chinese handwriting intervention program for children with ASD, named Go Go Handwriting - ASD version"|"The intervention program was developed and finalized by a group of occupational therapist specialists in the pediatric field. Thirty-six 20-minute activities with twelve activities for each handwriting fundamental skill were designed in this program.~All intervention activities were designed based on the characteristic of Chinese characters and included different types of characters.~The activities designed will also be graded according to the following principle: (1) the similarities between the character given, (2) the complexity of the figure or character in the activities, and (3) the frequency and level of therapist assistance.~Furthermore, a playful and interesting intervention context will also be integratedinto the program with the design of the adventure journey of an astronaut to further facilitate the motivation and participation of the participants in our program."
75778944|NCT05841498|Device|Immunoadsorption|Immunoadsorption (IA) is a well-established extracorporeal therapy for several autoimmune diseases such as systemic lupus. Its therapeutic effect is based on the removal of antibodies (ABs) from the plasma including auto-ABs and it is used if an immediate response to therapy is necessary. Side effects (SE) of the IA with the TR-350 adsorber are rare, but angiotensin-converting enzyme (ACE)-inhibitors are prohibited concomitant medication. Notable SE may include increased susceptibility to infection, transient disorders of blood coagulation, or allergic reactions to materials of the adsorber or tubing system. To ensure an effective therapy, a blood flow of at least 45 ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins but in most patients is the placement of a central venous catheter necessary. Central venous catheter placement carries potential risks such as injury to the lung or mispuncture of the carotid artery.
75914789|NCT04612036|Device|Journey II Bi-Cruciate Stabilized TKA|Total Knee Arthroplasty System
75914790|NCT04612036|Device|Journey II Cruciate Retaining TKA|Total Knee Arthroplasty System
75626515|NCT00708487|Other|Embryo incubator oxygen concentration|Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
75322044|NCT01929759|Drug|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
75322045|NCT03085082|Diagnostic Test|blood type test|a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups
75322046|NCT03084692|Behavioral|Therapeutic Yoga and Resistance Exercise|Combined Program of Yoga and Resistance Exercise
75626516|NCT02638558|Other|written + oral explanation|
75626517|NCT02638558|Other|written explanation|
75626518|NCT04164628|Other|Quality of life assessment|Quality of life will be assessed with Nottingham Health Profile
75626519|NCT00823615|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
75626520|NCT00823615|Device|Senofilcon A multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
75626521|NCT00653458|Drug|Ondansetron|ODT, 8 mg, single-dose, fed conditions
75626522|NCT00653458|Drug|Zofran|ODT, 8 mg, single-dose, under fed conditions
75626523|NCT00708565|Drug|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
75626524|NCT02638246|Behavioral|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
75626525|NCT02638246|Behavioral|Internet-delivered, non-contingent incentives + Motivational Interviewing|
75626526|NCT00812461|Drug|Placebo|as-needed use, tablets, orally, 6 months
75626527|NCT00812461|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
75914791|NCT04612036|Device|Journey II Bi-Cruciate Retaining TKA|Total Knee Arthroplasty System
75914792|NCT04610697|Behavioral|Cognitive Remediation|Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.
75914793|NCT04610697|Behavioral|Active Control|Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.
75914794|NCT04609683|Device|AleriTM sensors|"AleriTM sensors are worn on the bicep or forearm and communicates through BLETM to a mobile App. The data is sent through the mobile App to web-based system processing where PHI is calculated and sent back to the mobile App.~The AleriTM sensor has a form factor similar to a conventional arm band, with a hockey puck shape of approximately 48mm in diameter and 15mm in thickness the AleriTM sensor is a non-significant risk (NSR) device as it does not meet the definition of significant risk device (21 CFR 812.3(m)) because it is: not an implant; is not purported or represented to support or sustain human life; its use is not of substantial importance in the diagnosis, cure, treatment, mitigation, or prevention of impairment of health; and it does not present a serious risk to the health, safety, or welfare of a subject."
75626528|NCT00599326|Drug|Deferasirox|250 mg of deferasirox once daily for 6 months
75626529|NCT02646280|Other|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
75626530|NCT02646280|Other|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
75626531|NCT00978432|Drug|RAD001|10 mg/day for Part 1 of the trial
75626532|NCT00978432|Drug|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
75778945|NCT05841498|Device|Sham-apheresis|Sham-apheresis is a procedure without any known therapeutic effects. As there are no known therapeutic effects there are also no known side effects excepted the risk of an allergic reaction to materials of the tubing system or to citrate, which is necessary to prevent clotting inside the extracorporeal system. To ensure a smooth operation a blood-flow of at least 45ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins. However, in most patients, placement of a Shaldon catheter into the internal jugular vein is necessary. Shaldon catheter placement carries other potential risks such as injury to the lung resulting in pneumothorax or mispuncture of the carotid artery. However, since the catheter placement is sonography-guided, the risks for such adverse events are minimized.
75778946|NCT05841446|Drug|test apixaban tablets|specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China
75778947|NCT05841446|Drug|reference apixaban tablets|specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA
75322047|NCT03437330|Drug|Empagliflozin (Jardiance®)|Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG > 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs)
75322048|NCT03437330|Drug|Insulin Glargine (Lantus®)|"insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L~If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG > 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia < 3.9 mmol/L occurs)"
75778948|NCT05841407|Dietary Supplement|High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
75778949|NCT05841407|Dietary Supplement|No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
75778950|NCT05841394|Drug|Esomeprazole 40mg|40 mg i.v. twice daily (q12h)
75778951|NCT05841394|Drug|Ilaprazole Sodium|10 mg i.v. once daily, 20 mg i.v. in the first day.
75626533|NCT00978432|Drug|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
75626534|NCT02646202|Procedure|Sclerotherapy|Injection of varices
75626535|NCT02646202|Procedure|Band ligation|endoscopic banding of varices
75626536|NCT02646202|Procedure|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
75778952|NCT05841394|Drug|Placebo 1|Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
75914795|NCT04607746|Device|Capsule Endoscope|Capsule endoscope used to view colonic mucosa
75914796|NCT04596670|Drug|68Ga-ICAM-1pep|68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
75626537|NCT02638480|Device|KneeMD|KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
75626538|NCT00629538|Procedure|Therapeutic thoracentesis|Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.
75626539|NCT04166812|Diagnostic Test|oscillometry|assessment of peripheral airway resistance using oscillometry
75626540|NCT04166812|Diagnostic Test|multiple breath washout testing|assessment of ventilation heterogeneity using multiple breath washout testing
75626541|NCT04166812|Diagnostic Test|spirometry|assessment of lung function using spirometry
75626542|NCT04166812|Diagnostic Test|body plethysmography|assessment of lung function using body plethysmography
75778953|NCT05841394|Drug|Placebo 2|Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
75778954|NCT05841381|Drug|Pyrotinib|pyrotinib: 400mg orally daily for 1 year
75778955|NCT05841381|Drug|Trastuzumab|8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
75778956|NCT05841381|Drug|Paclitaxel|80mg/m2 per week for a total of 12 weeks
75778957|NCT05841368|Diagnostic Test|CAM-ICU|Delirium in adult patients will be screened according to CAM-ICU
75778958|NCT05841368|Diagnostic Test|pCAM-ICU|Delirium in adult patients will be screened according to pCAM-ICU
75778959|NCT05841342|Other|No intervention|No intervention
75778960|NCT05841329|Device|tDCS|High-definition tDCS (HD-tDCS, 4×1 montage, with 1 anode and 4 cathodes, (Soterix Medical, New York, NY, USA) was applied with battery-driven electrical stimulator (2001&4×1-C3A). The center electrode was anode and placed over FPz (according to the EEG 10-20 system in order to target the medial prefrontal cortex). The reference electrodes were cathodes and placed over AF7, AF8, F3, F4(see fig. 3). Participants were randomized to receive 20 minutes of active(1.5mA) or sham (0 mA) tDCS in a single-blind design. In order to ensure that participants can gradually adapted to the current change, there was a 15-second current rising process before the stimulation and, a 15-second current falling process after the stimulation. For sham tDCS, the device was automatically turned off after current reached 1.5 mA, thus providing 30s of ramping current stimulation, which made it difficult for participants to distinguish which kinds of stimulation they received.
75914797|NCT04591574|Biological|Red Blood Cells (Transfusion)|Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines
75914798|NCT04590313|Procedure|Arthrodesis|MTPJ I arthrodesis
75626543|NCT04166812|Diagnostic Test|fractional exhaled nitric oxide|assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide
75626544|NCT04166812|Diagnostic Test|transfer factor|assessment of gas transfer using single breath transfer factor for carbon monoxide
75626545|NCT04166812|Diagnostic Test|health status|assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire [SGRQ], COPD Assessment Test [CAT])
75322049|NCT01271803|Drug|Cobimetinib|Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
75778961|NCT05841329|Behavioral|virtual reality exposure therapy|The VRET was adapted on the basis of Öst's single exposure treatment paradigm and conducted by experienced psychotherapists following a standard exposure treatment manual.. An exposure therapy was divided into three parts: psychological education, exposure intervention and summary. Each scene started with a 10-min psychological education followed up with the tDCS stimulation. In exposure trail, participants ought to take an elevator to 100th, observe the environment and look down on the platform. The psychotherapist guided participants to be exposed to the VR environment and helped them experience the process of anxiety decline in the exposure trail.
75322050|NCT01271803|Drug|vemurafenib|Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
75322051|NCT00585377|Drug|Bevacizumab and Erlotinib|Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
75778962|NCT05841303|Drug|Vit C|Vit c is proven to be an anti-inflammatory and antioxidant agent. also play a great role in collagen biosynthesis (collagen type I), as it helps in fibroblasts proliferation. It reduces the potentiality of scaring via inhibiting cross-linking of collagen fibers and fibrosis. It acts as a cofactor in hydroxyproline synthesis to produce collagen type IV and improves endothelial cell vitality and function..
75778963|NCT05841303|Other|injectable PRF|5 ml of peripheral blood from each patient , blood will be transferred to a glass coated plastic vacutainer tube without anticoagulant. Then this tube will immediately centrifuged at 700 rpm for 3 mins [Centrifuge Machine 5000rpm.After centrifugation, two fluid layers will formed, upper being yellow fluid layer (i-PRF) while lower layer containing red blood cells. Yellow fluid layer containing i-PRF will be immediately aspirated using micro needle to be injected for management of gingival phenotype
75322052|NCT00080288|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
75322053|NCT00080288|Drug|Placebo|Matching placebo tablets once daily
75322054|NCT05722119|Diagnostic Test|FilmArray GI|Rapid multiplex Polymerase Chain Reaction (PCR) assay for digestive infectious agents in stool sample in the baseline diagnostic tests panel
75322055|NCT05499507|Behavioral|COH|Incorporates two, evidence-based individual-level interventions (home blood pressure telemonitoring coupled with the interactive obesity treatment approach, that includes nutrition and physical activity text messages with tailored feedback) and an institutional-level intervention (anti-racism training of providers and staff along with patient feedback to inform respectful care).
75322056|NCT05499507|Behavioral|COH+|Includes all components of COH plus interpersonal support for Black women by Black women (community doula care, mental health services, and lactation support).
75322057|NCT02984618|Procedure|Sphenopalatine ganglion block|Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
75322058|NCT02984618|Procedure|Epidural blood patch|Autologous sterile blood (20ml) will be infused in the lombar epidural space.
75322059|NCT03084458|Behavioral|Fitbit|The Fitbit device will allow experimental group participant access to their daily step count.
75322060|NCT05721183|Behavioral|NOST|"The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period."
75626546|NCT04166812|Diagnostic Test|computed tomography|assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)
75626547|NCT04166812|Diagnostic Test|induced sputum|various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)
75626548|NCT04016155|Device|Abbott FreeStyle Libre|Flash CGMS
75626549|NCT04016155|Device|Patient Own SMBG|Market SMBG
75626550|NCT02641756|Other|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
75626551|NCT00975780|Other|Enhanced Oral Care|oral brushing plus oral chlorhexidine plus upright feeding positioning
75626552|NCT00975780|Other|Usual oral care|Usual oral care and feeding positioning
75626553|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
75626554|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
75626555|NCT02865252|Other|MWM Treatment|
75322061|NCT01798745|Drug|JNJ-54452840|Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
75322062|NCT01798745|Other|Placebo|Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
75626556|NCT02865252|Other|MWM Sham|
75626557|NCT02646046|Behavioral|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
75626558|NCT02646046|Behavioral|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
75914799|NCT04586569|Other|Pediatric Interactive Relational Agent (PIRA)|The PIRA is an interactive, online tool used to educate children and families about their child's upcoming surgical and anesthesia experience.
75914800|NCT04586530|Behavioral|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
75626559|NCT00814489|Biological|GSK2231395A|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.
75626560|NCT00814489|Biological|Engerix-B|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.
75778964|NCT05841264|Behavioral|good feeding, cleaning|taking healthy food which contain minerals, vitamins essential for normal growth
75778965|NCT05841251|Drug|Topical Phenylephrine Solution|phenylephrine-soaked pack using the whole 5 ml of the solution provided with.5% phenylephrine will be applied after induction of surgery and intubation, 15 minutes before surgery. 100 ml of normal saline will be given.
75626561|NCT02610595|Drug|Jianpixiaozhong particles and Wuse Dietotherapy|Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
75626562|NCT00708799|Other|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
75626563|NCT02610127|Biological|OBIZUR|Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
75626564|NCT00814333|Drug|Thrombin-JMI|5,000 IU, to nasal mucosa via syringe spray applicator
75626565|NCT00814333|Drug|Merocel pack|8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
75626566|NCT01147250|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
75626567|NCT01147250|Drug|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
75626568|NCT04205864|Drug|Thrombi-Gel|Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy
75626569|NCT04205864|Procedure|Conventional Pelvic lymphadenectomy|Conventional Pelvic lymphadenectomy
75626570|NCT00813943|Drug|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
75626571|NCT00813943|Drug|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
75778966|NCT05841251|Drug|intravenous tranexamic acid|patients will receive intravenous Single dose of tranexamic acid 15 mg/kg in 100 mL normal saline over 10 minutes. Saline-soaked pack will be applied.
75778967|NCT05841225|Behavioral|Food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are high-calorie and low-calorie food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
75626572|NCT00813943|Drug|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
75626573|NCT00813943|Radiation|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
75914801|NCT04586530|Behavioral|Supportive Therapy (ST)|Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
75914802|NCT04581889|Other|Diagnostic test|Presence of antibodies in saliva
75626574|NCT05403931|Device|Low level laser therapy|Omega XP is the particular device producing low level laser therapy and has been in use for therapeutic purposes to treat different musculoskeletal conditions.
75626575|NCT04037371|Other|Cold exposure|Participants were tested for white fat thermogenic activity against their environmental temperature exposure
75626576|NCT00821509|Behavioral|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
75778968|NCT05841225|Behavioral|Non-food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are non-food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
75778969|NCT05841186|Other|Timing of pegfilgrastim administration|Timing of pegfilgrastim administration
75778970|NCT05841147|Drug|Tirofiban|Intravenous administration of tirofiban
75778971|NCT05841147|Drug|normal saline|Intravenous administration of normal saline
75778972|NCT05841121|Drug|Dexamethasone|Antenatal dexamethasone will be given a course of four intramuscular injections of dexamethasone 6 mg (1.2 milliliter), 12 hours apart.
75778973|NCT05841121|Other|Placebo|Placebo will be given by intramuscular injection of normal saline 1.2 milliliter at points of 0h,12h, 24h and 36h.
75778974|NCT05841069|Procedure|Adhesiolysis|Median laparotomy with subsequent detection of intestinal obstruction cause and adhesiolysis.
75914803|NCT04581460|Other|Questionnaire|Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
75914804|NCT04580940|Device|SpyGlass™ Discover Digital System|Observational, prospective, registry study for the clinical utility of the SpyGlass Discover digital catheter during a PTCS procedure.
76074121|NCT00746668|Behavioral|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation [RSVP]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
75322063|NCT05496777|Procedure|Home-based prehabilitation program|The home-based prehabilitation program will consist of a four-week program, where patients are expected to perform a high-intensity interval training on a home-trainer combined with functional mobility training three times a week. The program is partly supervised by a trained physiotherapist.
75322064|NCT00088010|Drug|Arzoxifene|20mg, oral, tablet, once a day for 36 months
75322065|NCT00088010|Drug|Placebo|oral, tablet, once a day for 36 months
75322066|NCT03084380|Biological|Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|transcatheter arterial chemoembolization + CAR-T infusion
75322067|NCT03084380|Drug|Fludarabine|Fludarabine will be administered at dose of 25mg/m2/d
75322068|NCT03084380|Drug|Cyclophosphamide|Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
75322069|NCT00586001|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Cognitive-behavioral treatment in development for emotional disorders
75626577|NCT00821509|Behavioral|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
75626578|NCT00821431|Device|Compression Device|"Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:~Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.~Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day."
75914805|NCT04575883|Device|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
75914806|NCT04565470|Other|online questionnaire|Web-based questionnaire about use of self-management strategies
75626579|NCT00821431|Device|Profore|Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
75626580|NCT05389345|Behavioral|Transcranial direct current stimulation|Participants will receive bilateral prefrontal anodal stimulation with cathode placed on the back of the upper neck. Transcranial direct current stimulation (tDCS) will be delivered by a research assistant under the supervision of a psychiatrist.
75651656|NCT05832671|Procedure|Erector Spinae muscle block|In the ESB group, the patient will be placed in the lateral position. The site of surgery is upward. After skin preparation using 10% povidone-iodine, a high-frequency linear ultrasound transducer will be placed over the ipsilateral site of surgery 1-2 cm lateral to the spine at the T10 level, counting upward from the sacrum. After identifying the erector spinae muscles and transverse process, a needle will be inserted with an in-plane technique in the craniocaudal direction
75778975|NCT05841069|Radiation|X-ray examination|Plain X-ray of abdomen (1-4 times) with water insoluble contrast.
75778976|NCT05841069|Procedure|Conservative treatment|A set of measures aimed at non-operative resolution of acute intestinal obstruction - nasogastric tube, infusion therapy.
75914807|NCT04562051|Other|prophylaxis regimen|All recipients were divided into two groups: stratified prophylaxis group based on donors' and recipients' characteristics and routine prophylaxis group based on clinical experience
75914808|NCT04560582|Procedure|Blood Draw|Participants will have blood drawn for analysis at baseline and every 4 weeks for a total of 7 blood draws over 24 weeks.
75914809|NCT04557176|Device|CRP, point-of-care assay|CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
75914810|NCT04549155|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
76074122|NCT01275118|Device|Tecnis Multifocal IOL|Presbyopia correcting IOL
76074123|NCT01275118|Device|crystalens Accommodating IOL|Presbyopia correcting IOL
75778977|NCT05841043|Drug|SHR8028 eye drops|SHR8028 eye drops
75322070|NCT02986737|Device|ACURATE neo™ and ACURATE TA™ LP|ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
75322071|NCT03080792|Behavioral|Experimental: moderate to high-intensity exercise|2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)
75322072|NCT05738421|Diagnostic Test|fiberoptic endoscopic evaluation of swallowing|Questionnaire, FEES, OPES
75778978|NCT05841043|Drug|Vehicle eye drops.|Vehicle eye drops.
75778979|NCT05841017|Behavioral|Psychotherapy with Immersive Virtual Reality support.|Psychoeducational group intervention and cognitive behavioural therapy individual intervention.
75322073|NCT00084344|Drug|4-hydroxytamoxifen|
75322074|NCT00084344|Procedure|breast imaging study|
75322075|NCT00084344|Procedure|radiomammography|
75322076|NCT02986815|Other|[11C]Acetate Brain Imaging|Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the [11C]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
75626581|NCT05389345|Behavioral|Executive function training|The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
75626582|NCT04037293|Diagnostic Test|CIMT and baPWV measurement|All patients will receive carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) measurement at baseline and 5-year follow-up.
75626583|NCT00813865|Drug|afegostat tartrate|
75626584|NCT05756335|Behavioral|(Un)predictable and (un)attended stimuli|Subjects will complete four task conditions in each scan session: (1) Visual Unpredictable, (2) Visual Predictable, (3) Auditory Unpredictable, and (4) Auditory Predictable. In visual and auditory conditions subjects attend to visual or auditory stimuli and ignore the other domain, pressing a button when they detect an infrequently occurring stimulus inversion in the target domain. In unpredictable and predictable conditions, the attended domain either presents random (unpredictable) stimuli, or the same face or word stimuli repeated (predictable).
75322077|NCT03084068|Other|Human dehydrated umbilical cord allograft|human dehydrated umbilical cord allograft
75322078|NCT03084068|Other|Placebo|Open rotator cuff surgery with standard suture repair
75626585|NCT04311164|Other|Questionnaire-based survey|The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.
75626586|NCT04311164|Other|No intervention given.|No intervention was given.
76074124|NCT01982435|Drug|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
75322079|NCT05738343|Other|dieta mediterranea|nutritional education or Mediterranean food scheme
75626587|NCT02883296|Other|Pelvis Magnetic resonance imaging|
75626588|NCT01147172|Device|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
75626589|NCT02610517|Behavioral|Provider Training|All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
75626590|NCT02610517|Behavioral|Patient Intervention|Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
75778980|NCT05840965|Other|Foot muscle strengthening|"A specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The exercises are: short foot exercise, toe spread out, first toe extension, second to fifth toe extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles."
75778981|NCT05840965|Other|Foot orthotics|Custom-made foot orthotics
75778982|NCT05840926|Dietary Supplement|Probiotic Streptococcus salivarius K12|Oral 1 billion CFU of Probiotic Streptococcus salivarius K12
76074125|NCT01982435|Drug|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
76074126|NCT00747214|Drug|CRx-102|
75322080|NCT00611897|Drug|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
76074127|NCT00747214|Drug|Placebo|
76074128|NCT00747214|Drug|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
76074129|NCT01279798|Biological|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
75322081|NCT00611897|Drug|placebo and ketamine|placebo N-acetylcysteine
75322082|NCT04401644|Diagnostic Test|Novel laser inferometry test for CORONA virus|detection of virus particles by light absorbtion patterns.
75322083|NCT03080714|Device|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
75322084|NCT03080714|Device|3D OCT-1 Maestro|The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
75322085|NCT03080324|Drug|Fentanyl sublingual|Fentanyl sublingual
75322086|NCT03080324|Drug|Fentanyl ev|Fentanyl ev
75778983|NCT05840926|Other|No probiotic supplementation|Children who did not receive any probiotic supplementation
75778984|NCT05840913|Drug|Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge|Local anesthetic injection for intra- operative pain control
75914811|NCT04546178|Behavioral|Prolonged exposure (PE)+ therapy|The intervention will be adapted prolonged exposure therapy, called PE+ therapy. Participants will receive 15 weekly 90-minute sessions of PE+; these appointments will be divided into five sets of three sessions each: 1) psychoeducation about AEs, SM, and the interplay of both with psychosis; 2) emotion regulation strategies; 3) imaginal exposures, 4) in vivo exposures, and 5) review of treatment and planning for termination and maintenance.
75914812|NCT04546178|Other|Treatment as usual (TAU)|The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.
75914813|NCT04545424|Device|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
75914814|NCT04545424|Drug|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
76074130|NCT03808012|Other|Braking performance in a brake simulator|Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
76074131|NCT00753142|Drug|Intralipid 20%|Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
76074132|NCT00753142|Drug|Glucose infusion|Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m^2/min for 20 hours.
76074133|NCT00762424|Drug|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
75626591|NCT05154032|Other|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions three times a week for 3 weeks.
75778985|NCT05840822|Drug|Cannabidiol|Nightly capsules prior to bed containing 0mg (placebo), 75mg cannabidiol or 150mg cannabidiol
75778986|NCT05840809|Drug|First line tuberculosis treatment|This is an observational study - the decision to use first-line tuberculosis treatment will have already been made by the responsible clinician. The study itself does not require any additional intervention.
75778987|NCT05840796|Dietary Supplement|soy protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
75778988|NCT05840796|Dietary Supplement|casein protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4 months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
76074134|NCT00762424|Drug|placebo|cornstarch
75322087|NCT03080324|Drug|Placebo sublingual|Placebo sublingual
75778989|NCT05840068|Drug|MetFORMIN 500 Mg Oral Tablet|MetFORMIN 500 Mg Oral Tablet
75778990|NCT05840068|Drug|Chemotherapy|The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
75778991|NCT05839665|Device|Humidified high-flow nasal oxygen|Humidified high-flow oxygen delivered via the Optiflow device
75778992|NCT05839665|Device|Standard nasal cannula|Oxygen delivered with high flows via a standard nasal cannula
75778993|NCT05839665|Device|Facemask|Oxygen delivered with facemask
75778994|NCT05837312|Behavioral|Reconnecting to Internal Sensations and Experiences|Reconnecting to Internal Sensations and Experiences (RISE) is a novel, self-guided interoceptive intervention designed to be accessible and convenient. RISE is hosted on Qualtrics and accessed on any internet-enabled device. RISE consists of four interactive 30-minute modules: (1) Progressive Muscle Relaxation and Body Functionality, (2) Understanding, Noticing and Managing Emotions, (3) Self-care and Communication, and (4) Body Sensations. The training consists of a mix of audio clips, psychoeducation, self-guided reading, and interactive writing prompts. Intervention materials are separated by multiple free-response prompts so that participants can relate the materials to their own lives, practice the introduced skills, and problem-solve difficulties implementing the skills.
75322088|NCT03080324|Drug|Placebo ev|Saline
75322089|NCT03080558|Drug|Indocyanine green|Use of Indocyanine Green during Rectal shaving by laparoscopy.
75778995|NCT05836311|Device|One Perclose Proglide Suture|One Perclose Proglide Suture
76074135|NCT01620983|Behavioral|Pain Coping Skills Training|
76074136|NCT01620983|Behavioral|Arthritis Education|
76074137|NCT01620983|Other|Usual Care|
76074138|NCT01279876|Drug|Melatonin|3mg oral, daily, one hour before sleep
76074139|NCT01996709|Device|Hydrogen peroxide-based contact lens solution|
76074140|NCT01996709|Device|Habitual contact lens solution|Biguanide-preserved
76074141|NCT01996709|Device|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
76074142|NCT00753220|Biological|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8 cells"
75626592|NCT00913861|Behavioral|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
75626593|NCT00913861|Drug|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
75626594|NCT00913861|Behavioral|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
75778996|NCT05836311|Device|Two Perclose Proglide Suture|One Perclose Proglide Suture
75626595|NCT04030273|Diagnostic Test|Diagnostic hysteroscopy|"Diagnostic hysteroscopy performed in outpatient setting, using no touch vaginoscopy technique with a 2.9 mm 30-degree rigid hysteroscope with a single inflow sheet using normal saline as distention media."
75626596|NCT00709189|Drug|Norgestimate/Ehinyl Estradiol; Folic acid.|
75626597|NCT02866188|Device|Check pulse with Smart watch on 3 parts of patient's body surface|Check pulse with smart watch on wrist, carotid artery, and eye of patients in shock or cardiac arrest state.
75778997|NCT05834803|Procedure|Renal artery stenting|Optimal medical therapy and percutaneous transluminal renal angioplasty with stent placement.
75626598|NCT00709267|Drug|Folic acid|
75626599|NCT01120964|Drug|Intravenous L-Citrulline|
75626600|NCT01120964|Drug|Placebo of Intravenous L-Citrulline|Placebo of intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
75626601|NCT02865408|Dietary Supplement|Peptamen 1.5% via enteral|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.
75778998|NCT05834803|Procedure|Sham treatment|Optimal medical therapy and sham treatment.
75778999|NCT05833412|Diagnostic Test|Septicyte Rapid ®|SeptiCyte RAPID is based on the measurement of two gene expression biomarkers in peripheral blood (PLAC8 and PLA2G7) using quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Based on the results obtained in 1 hour from whole blood (100 mcl), the device issues a report with a sepsis probability scale according to 4 bands (1 low probability, 2-3 intermediate probability and 4 high probability).
75779000|NCT05833412|Diagnostic Test|FilmArray® blood culture identification (BCID2®)|After 6 to 8 hours of blood culture incubation, BCID2 will be performed on each of the 4 bottles. The BCID2 assay is an approved molecular test for the direct identification of pathogens causing bloodstream infections from blood cultures. The BCID2 Panel analyzes 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeasts and 10 antimicrobial resistance genes, all with a single test and with results available in approximately one hour from the blood culture. In addition, the BCID2® Panel menu includes seven additional resistance genes, including carbapenemases, colistin resistance genes and a MREJ assay that enables more speciﬁc MRSA identiﬁcation.
75779001|NCT05828173|Device|LithiX Coronary Hertzian Contact Lithotripsy Catheter (LithiX Coronary HCLC; LithiX)|Vessel preparation of moderately to severely calcified coronary artery lesions prior to stenting allows for full stent expansion and apposition to the vessel wall
76074143|NCT00753220|Drug|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
75779003|NCT05819073|Other|Plain water|Subjects will use plain water as an oral rinse twice a day for 3 days.
75779004|NCT05819073|Other|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
75779005|NCT05814393|Drug|Treatment Period(JW0201)|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
75779006|NCT05814393|Drug|Treatment Period(Placebo)|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
75779007|NCT05814393|Drug|Extension Period(JW0201)|JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)
75779008|NCT05807555|Other|Ambulatory ECG|24h ECG monitoring
75779009|NCT05807555|Biological|Blood sample|The usual biological tests necessary for the management of the child and the addition of 1 tube of 2 ml
75779010|NCT05782816|Drug|Oxytocin|Low dose oxytocin
75779011|NCT05782816|Drug|Oxytocin|High dose oxytocin
75779012|NCT05781919|Other|Immersive virtual reality imaging|Segmentation and post-processing of DICOM 2D imaging will generate a 3D file able to be used in immersive virtual reality googles, for further analysis of the tumor and anatomic structures that could facilitate surgical planning.
75779013|NCT05781919|Other|Gold standard imaging|Use of traditional gold standard 2D imaging (TC and/or MRI) for surgical planning
75779014|NCT05778565|Procedure|Extraocular muscle stretching|Extraocular muscle stretching to test its efficacy as a weakening procedure
75779015|NCT05778123|Other|Type of disease|Different types of pathogen: brain injury by trauma or hydrocephalus due to various diseases.
75779016|NCT05778110|Other|Type of disease|Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
75779017|NCT05770817|Other|N/A: SKyRoCKeT is an observational study|None; this is an observational study
75914815|NCT04545424|Device|Standard of care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature >38°C will receive 650 mg acetaminophen and, if temperature remains >38°C, surface cooling will be initiated to return core temperature to 37-38°C.
75626602|NCT02865408|Dietary Supplement|Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.
75626603|NCT02865408|Dietary Supplement|Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.
75626604|NCT05757739|Procedure|Tenex|In the Tenex procedure, the surgeon inserts a special needle into the damaged portion of the tendon under ultrasound guidance. Ultrasonic energy vibrates the damaged tissue and it can be suctioned out. This procedure is done with local anesthesia in surgeon's office.
75779018|NCT05768932|Drug|BAL0891|BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
75779019|NCT05768932|Combination Product|Carboplatin|Carboplatin is an Antineoplastic agent
75779020|NCT05768932|Combination Product|Paclitaxel|Paclitaxel is a natural product with antitumor activity
75779021|NCT05757778|Procedure|Sensory Nerve Coaptation|Nerve reconstruction will employ an off-the-shelf nerve graft coapted to the donor anterior intercostal nerve branch laterally and medially at the underside of the nipple. The anterior intercostal nerve branch and nerve graft coaptation will be performed in a standard fashion with a 1 mm gap between the ends of the graft and the donor nerve. Medially, the nerve graft will be inset into the underside of the preserved nipple-areola complex using 8-0 or 9-0 epineural stitches from the nerve allograft. All nerve coaptations will be performed under loupe magnification as is standardly performed.
75914816|NCT04521426|Other|No other than standard care|No other than standard care.
75322090|NCT03083834|Diagnostic Test|Cosyntropin stimulation test|At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
75779022|NCT05751863|Other|Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects|"The Intervention is using a sedation strategy for MV trauma that initially targets pain by intermittent boluses followed by an IV drip only if required. Sedatives are limited to agitation management and for a limited duration as needed. This analgo-sedation approach differs from the approach of using IV drips of analgesics and sedatives simultaneously and discontinuing both once daily to assess subjects."
75779023|NCT05751863|Other|Protocol Directed Sedation and Daily Sedation Interruption|The active comparator in this study is using a sedation strategy for MV trauma that uses IV drips of analgesics and sedatives simultaneously and discontinues both once daily to assess subjects.
75779024|NCT05744193|Other|Exempt Infant Formula|Liquid human milk fortifier to be added to human milk daily
75779025|NCT05726318|Drug|Antibiotics|Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoaxole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
75779026|NCT05722483|Other|Virtual Intensive Outpatient Program|Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
75779027|NCT05704491|Diagnostic Test|artificial intelligence (AI) algorithm of the MONA DR model|A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.
75779028|NCT05701371|Other|Biological samples collection|blood drawing + feces collection in a dedicated device
75779029|NCT05697770|Drug|Sodium bicarbonate|Sodium bicarbonate 8.4% will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
75322091|NCT04761380|Diagnostic Test|balloon-based tongue pressure measurement device|The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
75779030|NCT05697770|Drug|5% Dextrose|5% dextrose will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
75779031|NCT05669287|Diagnostic Test|CT Perfusion|CT Perfusion
75322092|NCT03402230|Drug|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
75467048|NCT01916135|Procedure|PET/CT scan|PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. This includes an initial 30-minute PET scanning period, performed. At each subsequent time-point, a 30 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A 30-45 minute scanning time-period is typical for clinical PET studies. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point.
75779032|NCT05654740|Device|Virtual Reality Experiences|Virtual Reality experiences including stress reduction, distraction and entertainment
75914817|NCT04516993|Drug|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
75914818|NCT04516993|Drug|The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|Best treatment arm
75914819|NCT04514978|Procedure|Blood donation and blood transfusion|24 subjects (12 female, 12 male) is phlebotomized and four weeks later ~130 mL packed red blood cells are re-infused in the same subjects.
75914820|NCT04514445|Other|Observational|
75914821|NCT04513015|Dietary Supplement|Antioxidant diet|"The antioxidant diet will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed."
75914822|NCT04513015|Dietary Supplement|Normal dietetic scheme|Isocaloric, normolipidic diet for age and sex
76074144|NCT01279642|Device|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
76074145|NCT01279642|Other|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
75914823|NCT04506372|Drug|Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers|Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
75467049|NCT01916135|Other|Blood draws|Blood will be drawn at the multiple time points for pharmacokinetic & metabolite analyses of 18F-SKI-249380. We anticipate these time points to be approximately 1, 5, 15, 30, and 90 minutes and 3 hours (optional), post-injection.
75626605|NCT05757661|Other|Focal Vibration|"A single 30-minute focal vibration procedure will be performed on both quadriceps with the V-Plus Wintecare® machine.~Three channels will be used on the muscle bellies of the rectus anterior, vastus internus and vastus externus. The positioning of the vibration heads will be done with straps designed by the manufacturer to keep the vibration focus stable on the muscle belly.~The configuration of the vibration program will be in an automatic mode of 10 seconds of vibration and 3 seconds of rest to avoid the coupling of the mechanoreceptors. The frequency used will be between 60 Hz to 150 Hz with a power of 80%."
75626606|NCT05757661|Other|Sham Group|The same procedure of the intervention group will be performed but without the focal vibration head contacting the skin (sham). A sufficient space will be left between the head and the headgear so that the vibration does not touch the skin.
75626607|NCT02865330|Other|Registry|National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years.
75914824|NCT04506372|Diagnostic Test|Blood draw|Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
75626608|NCT02611219|Other|General Health Module-Baseline Adolescent-Self Report (13-18 years)|"38 question questionnaire~Answers range from 1=all of the time to 5=none of the time"
75626609|NCT02611219|Other|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|"38 question questionnaire about child~Answers range from 1=all of the time to 5=none of the time"
75626610|NCT02611219|Other|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|"38 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
75626611|NCT02611219|Other|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|"38 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
75626612|NCT02611219|Other|General Health Module-Baseline Parent Report-School Age (5-12 years)|"34 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
75626613|NCT02611219|Other|General Health Module-Follow Up Parent Report-School Age (5-12 years)|"34 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
75626614|NCT02611219|Other|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
75626615|NCT02611219|Other|SCT Daily Activity Log|"Uses Fitbit Flex~Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed"
75626616|NCT02611219|Other|The Functional Independence Measure for Children|"18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category."
75626617|NCT02611219|Other|Manual Muscle Testing|"-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade."
75626618|NCT02611219|Other|3-Minute Step Test|"Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance"
75626619|NCT02611219|Other|HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|"7 question questionnaire about child~Answers range from 1=all of the time to 5=none of the time"
75914825|NCT04506372|Behavioral|Diary to register drug adherence|To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
75626620|NCT02611219|Other|HSCT Module-Follow Child-Self Report (5-12 years)|"10 question questionnaire about child~Answers range from 1=all of the time to 5=none of the time"
75626621|NCT02611219|Other|HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|"7 question questionnaire about child~49 question questionnaire about parent~Answers range from 1=all of the time to 5=none of the time"
75626622|NCT02611219|Other|HSCT Module-Follow Up Parent Report-School Age (5-12 years)|"7 question questionnaire about child~49 question questionnaire about parent~Answers range from 1=all of the time to 5=none of the time"
75914826|NCT04506372|Behavioral|Quality of life questionnaire|Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
75914827|NCT04506372|Behavioral|WHODAS questionnaire|Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
76025613|NCT02667301|Device|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
75626623|NCT02611141|Procedure|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack & Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
75914828|NCT04495686|Behavioral|Telehealth-delivered Care Coordination Program|"Participants in the interventional arms of this program will be assigned a Dementia Care Manager (DCM) who will work with caregivers to develop goals and plans that are aimed at providing the best support possible, specific to your needs. These services include supportive counseling, education on dementia, information and referrals to community-based organizations, behavioral symptom management training and assistance with finding available community and government-sponsored programs.~DCM's will meet with you at least once monthly and will be available if you need assistance between meetings. At the first meeting, your DCM will explain the questionnaires you will take and how to use the technology in the program. They will then provide a link, via email, where you will download the free teleconferencing software that will be used throughout the program. Questionnaires will then be sent via email invitations through a secure survey platform."
75914829|NCT04483089|Device|Transcatheter heart valve procedure|Transcatheter treatment of TR with Abbott TriClip™.
75779033|NCT05640947|Device|The Hot AXIOS™ Stent and Electrocautery-Enhanced Delivery System|EUS-guided gastro-gastrostomy using the Hot Axios device: Using a therapeutic endoscopic ultrasound endoscope with a working channel of 3.7mm and under fluoroscopic control, the excluded stomach will be identified and punctured with a 19G needle. Contrast injection will confirm the good position of the needle in the excluded stomach. If needed, the excluded stomach will be filled with blue-stained aqua (5% indigocarmine) until a sufficient distension is obtained for placement of the lumen-apposing metal stent. A lumen-apposing metal stent with a diameter of 20mm will be used according to the manufacterers' instructions to create a gastrogastrostomy. Position will be checked with fluoroscopy.
75779034|NCT05637398|Drug|Colchicine|The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
75322093|NCT03402230|Other|Laboratory Biomarker Analysis|Correlative studies
75322094|NCT03402230|Other|Questionnaire Administration|Ancillary studies
75322095|NCT02780609|Drug|Selinexor|Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
75322096|NCT02780609|Drug|Melphalan|Melphalan 100 mg/m^2 IV over 30-45 minutes.
75322097|NCT02780609|Drug|Dexamethasone|Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).
75626624|NCT01146860|Drug|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
75626625|NCT01146860|Drug|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
75626626|NCT00591565|Drug|Acamprosate|acamprosate 333mg tab, 3 by mouth 3 times a day
75626627|NCT01146782|Device|Attune Sleep Apnea System|Console and mouthpiece sleep apnea system
75626628|NCT00978120|Biological|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
75626629|NCT00978120|Biological|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
75779035|NCT05621408|Behavioral|Attention Training Technique|Attention Training Technique is a six weeks psychological intervention provided by trained professionals
75779036|NCT05604729|Drug|Botulinum toxin type A|Botulinum Neurotoxin type A
75779037|NCT05604729|Drug|Placebo|Saline solution
75779038|NCT05598788|Other|Measurement of drug concentrations|Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample
75322098|NCT02780609|Procedure|Autologous Hematopoietic Cell Transplantation (HCT)|Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
75322099|NCT02780609|Drug|Fosaprepitant|Fosaprepitant at 150 mg IV on days -3 and -2.
75322100|NCT05345912|Drug|CG-745 IV Solution|CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
75322101|NCT05345912|Drug|CG-750 125mg capsule|CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
75322102|NCT05345912|Other|PO Placebo|PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
75322103|NCT05345912|Other|IV Placebo: 0.9 % normal saline|IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
75322104|NCT03089918|Drug|11C-JNJ-63779586|Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
75322105|NCT03080090|Behavioral|Aerobic exercise|Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.
75322106|NCT03080090|Behavioral|Smoking Cessation Intervention|Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.
75322107|NCT03086096|Device|LifePearl Microspheres loaded with Irinotecan|LifePearl Microspheres are embolisation microspheres for transcatheter chemoembolisation (TACE), that can be loaded with chemotherapeutic agents. In this registry, LifePearl Microspheres will be loaded with Irinotecan.
75322108|NCT03083600|Dietary Supplement|Plant-based Protein Hydrolysate 1|Plant-based Protein Hydrolysate 2 for 12-weeks
75467050|NCT01916161|Other|Questionnaire|
75914830|NCT04480541|Behavioral|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their own mobile phones/tablet
75626630|NCT04288986|Behavioral|Keep Achieving|The 8-week group based activity programme will consist of 8 sessions each lasting 50 minutes.
75626631|NCT04289064|Device|Taking a fundus image|The participant only needs to take a fundus image as usual.
75322109|NCT03083600|Dietary Supplement|Plant-based Protein Hydrolysate 2|Plant-based Protein Hydrolysate 2 for 12-weeks
75626632|NCT03971760|Other|Suction drain removal|Removal of negative pressure suction drain left in place to drain the surgical space after a neck surgery
75322110|NCT03083600|Dietary Supplement|Placebo|Cellulose Placebo for 12-weeks
75322111|NCT03402152|Drug|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
75322112|NCT03402152|Drug|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
75626633|NCT00978042|Device|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
75626634|NCT01133678|Drug|Everolimus|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel (175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus 5 mg PO daily. Following induction patients received [paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
75626635|NCT01133678|Drug|Placebo|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received [paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
75626636|NCT03693040|Device|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
75626637|NCT02638324|Procedure|Renal nervous denervation|The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
75626638|NCT00652132|Drug|cisplatin|
75626639|NCT00652132|Drug|sodium thiosulfate|
75626640|NCT02645890|Drug|CKD-397|Arm A:Tamsulosin/ Tadalafil Fixed dose combination
75626641|NCT02645890|Drug|TD+TM|Arm B: Tamsulosin/ Tadalafil Coadministration
75626642|NCT04164784|Behavioral|therapeutic monitoring|According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,the investigators give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
75626643|NCT00655174|Drug|fluvoxamine|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
75779039|NCT05595707|Other|Expert-Guided Early Tracheostomy|Patients judged to be at moderate to high risk of prolonged ventilation(26, 27) were those who had chronic respiratory failure, advanced Effectiveness of an Expert-Guided Early Tracheostomy Pathway Page 6/27 age, thrombocytopenia or coagulopathy, persistent vasopressor shock, requirement for renal replacement therapy, an admission trauma diagnosis amongst other criteria, were included. In the absence of these criteria, a consensus for low risk of prolonged MV was reached. Early PDT, within the first 7 days from intubation, was recommended for patients with a moderate/high risk of prolonged MV (Early Group). Continued MV by ETT was recommend for low-risk patients with the potential for delayed PDT in the event of delayed weaning and liberation (Late Group).
75914831|NCT04480541|Other|Wearable activity sensor|Caregivers and patients will receive a Fitbit wearable activity sensor
75914832|NCT04480541|Other|Survey administration|Caregivers and patients will be asked to complete health-related quality of life surveys
75914833|NCT04478942|Drug|Misoprostol Oral Product|Misoprostol will be dosed using the preexisting UnityPoint Health-Meriter Protocol for oral misoprostol administration.
75914834|NCT04478942|Drug|Intravenous Oxytocin|Intravenous oxytocin administration will also follow standard, UnityPoint Health-Meriter Protocol.
75914835|NCT04472416|Device|VRD in addition to standardized analgesic protocol|Use of VRD in addition to standardized analgesic protoco for abdominal VAC dressing change
75914836|NCT04467489|Other|observational|There is no intervention for any group in this observational study.
75914837|NCT04459052|Dietary Supplement|N acetyl cysteine|Intervention: IV NAC infusion: Dose: 50mg in 200ml of Dextrose 5% in Water (D5W), frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 500 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
76074146|NCT00753298|Device|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
76074147|NCT00753298|Device|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
75626644|NCT00655174|Drug|sertraline|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
75626645|NCT00655174|Drug|Placebo|Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
76074148|NCT01996319|Drug|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
75322113|NCT03402152|Drug|Placebo|Placebo oral capsule
75322114|NCT05346146|Drug|Sintilimab; Gemcitabine; Albumin-paclitaxel|Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
75322115|NCT03083522|Drug|Ojeok-San|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
76074149|NCT01996319|Drug|Placebo|Placebo once a day via Breezhaler® device
75322116|NCT03083522|Drug|Placebo|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
75626646|NCT04166422|Other|Cardiac rehabilitation program|Aerobic treatment plus strength exercises
75626647|NCT04166422|Other|Experimental intervention|Aerobic treatment plus strengh exercises plus virtual reality
75626648|NCT00655018|Dietary Supplement|Vitamin treatment (alpha tocopherol plus ascorbic acid)|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
75779040|NCT05595148|Procedure|Immediate WBAT|Men or women over 18 years who present with a fracture of the acetabulum, pelvis, distal femur, proximal tibia, distal tibia, who will undergo fracture fixation within 7 days of their injury and consent to the research study.
75914838|NCT04459052|Drug|[F-18] Fluorodopa Positron Emission Tomography|FDOPA PET diagnostic imaging to to measure dopamine function, serum measures of NAC concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, and neurological measures to assess clinical symptoms, in patients with PD who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD for 6 months.
75322117|NCT05346380|Device|Olympus VE2 NIR Imaging System|A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.
75779041|NCT05595148|Other|No Intervention: Delayed WBAT|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
75779042|NCT05586243|Other|No intervention|This is an observational study looking at brain chemicals related to oxidative stress and inflammation using magnetic resonance spectroscopy (MRS).
75779043|NCT05583071|Drug|Tafasitamab|IV
75779044|NCT05583071|Drug|Lenalidomide|Oral
75914839|NCT04451161|Behavioral|Beliefs and Attitudes for Successful Implementation in Schools (BASIS)|BASIS blended (i.e., multifaceted and protocolized) implementation strategy, which occurs at the beginning of active implementation. BASIS is designed to facilitate observable implementation outcomes, including EBP adoption and intervention fidelity, via strategic education, motivational Interviewing, and social influence strategies.
76074150|NCT04276948|Dietary Supplement|NAD3|NAD3 is an over-the-counter dietary supplement available online to consumers.
76074151|NCT01279954|Drug|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
76074152|NCT01278862|Device|DVS veneer|CAD/CAM milled porcelain veneer for Lava crown
75322118|NCT05346380|Drug|Indocyanine green|intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
75467051|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
75626649|NCT00655018|Dietary Supplement|Placebo|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
75626650|NCT02635750|Drug|BI 409306|
75626651|NCT02635750|Drug|Donepezil low dose|
75626652|NCT02635750|Drug|Donepezil high dose|
75626653|NCT04164706|Device|HumiGard device|HumiGard is a CE marked device that delivers warmed humidified CO2 during laparoscopic surgery
75626654|NCT04164706|Other|Standard care (with sham HumiGard device)|Standard methods of keeping the patient warm whilst in theatre, including warmed IV fluids, warming blankets/forced air warming devices.
75626655|NCT04164238|Drug|Toripalimab|Toripalimab Injection
75626656|NCT04164238|Drug|Paclitaxel|Paclitaxel Injection
75626657|NCT04164238|Drug|Carboplatin|Carboplatin Injection
75626658|NCT04164238|Drug|Cisplatin|Cisplatin injection
76074153|NCT01278862|Device|Conventional Veneer|CAD/CAM milled Lava crown with lab fabricated veneer
76074154|NCT03807388|Device|ReMindCare Intervention Group|Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
76074155|NCT03807388|Other|Treatment as Usual|Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
76074156|NCT00763048|Drug|Fluoride|Brush twice daily for 6 weeks
75626659|NCT04164238|Drug|5-fu|5-fu injection
75626660|NCT04164160|Other|integrated-care-model benefiting group|Patients will be called for the ﬁrst interview of the study by the healthcare professional. Their data will be automatically entered in the Salut + Social app, they will be asked to respond to the study questionnaires (ad hoc questionnaire for sociodemographic data, EuroQol-5D, Zarit questionnaire and Morisky-Green test) and will take part in the future actions to be planned for them. Patients will receive an appointment to attend their PCC at 6, 9, and 12 months after their incorporation into the program. In those follow-up, the same questionnaires will be provided together with the IEXPAC questionnaire, which evaluates the experience of the chronic patient with the new care model.
75626661|NCT02645734|Drug|bevacizumab|1.25 mg of bevacizumab is injected
75626662|NCT02645734|Drug|ziv-aflibercept 1.25 mg|1.25 mg of ziv-aflibercept is injected
75626663|NCT02645734|Drug|ziv-aflibercept 2.5mg|2.5 mg of ziv-aflibercept is injected
75626664|NCT02635594|Dietary Supplement|L-Carnitine|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
75626665|NCT02635594|Other|Placebo|1000mg cellulose + 475mg L-tartaric acid
75626666|NCT02635906|Other|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
75779045|NCT05583071|Drug|Rituximab|IV
75779046|NCT05583071|Drug|Methotrexate|IV
75779047|NCT05534087|Drug|mFOLFIRINOX-FOLFIRI intensified chemotherapy|"(1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks~Oxaliplatin 85mg/m2 IV infusion over 120 min D1~Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)~Irinotecan 150mg/m2 IV infusion over 60-90 min D1~5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2"
75914840|NCT04451161|Behavioral|Trauma-Focused Cognitive-Behavioral Therapy|TF-CBT is an evidence-based treatment that helps children from elementary to high school to address the negative effects of trauma and promote greater emotion and behavior regulation, including processing their traumatic memories, overcoming problematic thoughts and behaviors, and developing effective coping and interpersonal skills. It also includes a treatment component for parents or other caregivers. Parents can learn skills related to stress management, positive parenting, behavior management, and effective communication.
75914841|NCT04451161|Behavioral|Treatment as Usual|Scaffolded intervention as usual. Includes: initial assessment of trauma symptoms, psychoeducation, follow-up planning and support.
75914842|NCT04451161|Behavioral|Attention Control|Didactic presentation of implementation-related content (e.g., information about the importance of implementing, definitions of key terms, etc.) to control for facilitator, dose, information provided, and delivery platform
75626667|NCT02635906|Other|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
75914843|NCT04447716|Drug|Venetoclax|Given PO
75914844|NCT04447716|Drug|Lenalidomide|Given PO
75626668|NCT00652210|Other|Multiphoton microscopy|Use of multiphoton microscopy to diagnose cancer
75322119|NCT03084926|Drug|MP0274|Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
75626669|NCT01133522|Biological|Evolocumab|Administered by subcutaneous injection
75626670|NCT01133522|Biological|Placebo|Administered by subcutaneous injection
75626671|NCT04164394|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
75626672|NCT04164394|Dietary Supplement|I31 Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
75626673|NCT01133288|Device|Yulex gloves|Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (~30 minutes per day) over a 3 month period.
75626674|NCT02881892|Other|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
75914845|NCT04447716|Biological|Rituximab|Given IV
75626675|NCT02635516|Device|Near-Infrared Phototherapy|"The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized."
75914846|NCT04447716|Biological|Rituximab and Hyaluronidase Human|Given SC
75914847|NCT04447027|Drug|Romidepsin|Romidepsin (12mg/ m2 ) will be administered on days 1 and 10 of each cycle through a peripheral or central intravenous catheter for 6 cycles.
75914848|NCT04447027|Drug|Lenalidomide|Lenalidomide will be administered by oral intake in a dose-escalation with a starting dose of 5mg daily, a second dose level of 10mg daily, a third dose level at 15mg daily, and a fourth dose level at 20mg daily on days -7 to day 10 of first cycle. After the second cycle, lenalidomide will be given from day 1 to day 10 in each cycle for up to 6 cycles.
75914849|NCT04447027|Drug|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.
75626676|NCT00655252|Drug|Everolimus|
75626677|NCT02645578|Device|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
75914850|NCT04447027|Drug|Dexamethasone|Dexamethasone, 40mg, PO, will be given on days 1 and 10 of each cycle.
75914851|NCT04446000|Biological|CSL730|solution for injection and infusion
75914852|NCT04446000|Drug|Placebo|A solution matching the excipient profile of CSL730 without the active substance
75914853|NCT04429087|Drug|BI 764532 - parenteral 1|BI 764532 - parenteral 1
75914854|NCT04429087|Drug|BI 764532 - parenteral 2|BI 764532 - parenteral 2
75914855|NCT04427826|Drug|Morphine hydrochloride|A single open-label injection of morphine (T0) at the dose closest to that defined by the model (estimation by Bayesian method) from among the following 4 doses: 0.02; 0.04; 0.07 and 0.1mg/kg will be adminestred to the patients.
75322120|NCT03083444|Diagnostic Test|Ultrasound|Measurement of thickness of radial artery wall thickness by ultrasound
75322121|NCT03087110|Biological|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (>1x10^7 cells/kg)
75322122|NCT03080246|Behavioral|Strength Training Exercise|
75322123|NCT00613379|Drug|PRO 140|10 mg/kg PRO 140, one IV dose (N=10)
75779048|NCT05534087|Drug|FOLFOX or CAPOX adjuvant chemotherapy|"FOLFOX regimen: 6 cycles every 2 weeks~Oxaliplatin 85mg/m2 IV infusion over 120 min D1~Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)~5-fluorouracil 400mg/m2 IV bolus D1~5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or~CAPOX regimen: 4 cycles every 3 weeks~Oxaliplatin 130mg/m2 IV infusion over 120 min D1~Capecitabine 1,000mg/m2 PO bid D1-14"
75779049|NCT05497882|Behavioral|E-Learning Prototype for Dementia Care|Usability testing System Usability Scale
75779050|NCT05490641|Behavioral|Glucose-based biofeedback|Participants will wear a Fitbit activity tracker and receive personalized text messages over a 12-week period.
75779051|NCT05490641|Behavioral|Standard feedback|Participants will wear a Fitbit activity tracker and receive non-personalized text messages over a 12-week period.
75914856|NCT04424511|Drug|Placebo|Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
75914857|NCT04424511|Drug|Azithromycin|Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
76074157|NCT00763048|Drug|Fluoride, triclosan|Brush twice daily
75914858|NCT04412486|Biological|COVID Convalescent Plasma|One unit of COVID Convalescent Plasma transfused on Day 0
75914859|NCT04409093|Procedure|Nail bed repair with eponychial sent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will be secured under the eponychial fold with suture. The stent can be the native nail plate, suture container foil, or nonadherent gauze (i.e. Xeroform). If the injury avulsed the nail plate and the patient presents without it, either the foil from the suture wrapper/container or a piece of nonadherent gauze (i.e. Xeroform) will be used as a stent. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
75914860|NCT04409093|Procedure|Nail bed repair without eponychial stent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will not be secured under the eponychial fold. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
75914861|NCT04408521|Other|NEUROFEEDBACK|EEG recording during alpha-related TV viewing
75914862|NCT04408521|Other|CONTROL|EEG recording during passive TV viewing
75626678|NCT04058626|Diagnostic Test|Transcutaneous pressure of oxygen (TcPO2)|Measurements will be taken from the dorsum of the foot using an automated machine equipped with Clark electrodes.
76074158|NCT03807466|Behavioral|Dynamic/Interactive vs. Static/Paginated Report|Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
75467052|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
75626679|NCT04058626|Diagnostic Test|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
75626680|NCT04058626|Diagnostic Test|Podiatry Ankle Duplex scan (PAD-scan)|Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.
75626681|NCT04058626|Diagnostic Test|Duplex Assist|Continuous Doppler device which gives visual display of arterial spectral waveform at the ankle.
75779052|NCT05490641|Device|Glucose monitoring|During the first 4 weeks of the study period, participants will also wear a continuous glucose monitor to check their glucose levels in real-time and receive text messages based on their activity and glucose data.
75779053|NCT05483101|Other|Alternative birth units|"Midwife-led alternative birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative birth units named Filière physiologique (FP) co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room."
75914863|NCT04403295|Behavioral|Collaborative Specialty Care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
75914864|NCT04403295|Behavioral|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
75914865|NCT04393259|Other|Rainbow Clinic Model of Antenatal Care|Rainbow Clinic Model is an antenatal model of care with initial ultrasound scan at 23 weeks' gestation including uterine artery Doppler, frequency of subsequent scans determined using data from this initial scan. Continuity of care is provided by obstetricians and midwives.
75914866|NCT04392050|Other|Interview|Complete interview
75914867|NCT04392050|Other|Focus Group|Attend focus groups
76074159|NCT03807466|Behavioral|LTC Physicians Enrolled vs. Not Enrolled in Reports|Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
76074160|NCT00160732|Drug|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
76074161|NCT00160732|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
76074162|NCT01278394|Drug|AN2690 Solution, 5.0%|Once daily application for 360 days
76074163|NCT01981187|Drug|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
75467053|NCT01916187|Drug|Imetelstat|
75626682|NCT04058626|Diagnostic Test|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the DPA and PTA.
75914868|NCT04392050|Other|Questionnaire Administration|Ancillary studies
76074164|NCT00240916|Biological|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
76074165|NCT00240916|Biological|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
76074166|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
75779054|NCT05480917|Other|Patients receiving PsoPlus care|As stated before, both outcomes (via VOS) and costs will be collected. Data on clinical outcomes, such as skin clearance, in the VOS will be collected during follow-up visits at our clinic. Outcomes which are assessed via a questionnaire will be collected using a specialized patient platform (PsoQuest). In addition, for this study the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire will need to be filled in. When consultations do not coincide with the time points, data will be collected by a study nurse on a study visit (at our department or the patient's home) and via PsoQuest. A 1 month period will be in place around the time point, meaning that the data can be collected 2 weeks beforehand or afterwards. Cost data will be collected using the TD-ABC approach over the full cycle of care.
75779055|NCT05478603|Drug|PF-07081532|PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1
75779056|NCT05441826|Drug|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
75779057|NCT05440019|Device|IMAGE CAPTURE SESSION|"The M3T FERTIGO® is an instrument to be used by a certified gynecologist and in particular by an IVF expert physician in order to observe and monitor the state of the endometrium lining of patients. The M3T device serves as a mini hysteroscope capable of magnification, capturing images and optional image processing thereof. The M3T enables to acquire in-vivo, magnified images of the endometrium surface, to identify key morphological parameters, calculate their attributes and statistics thereof and compare those for different acquisition images and to some standard tissue state tracks. One may then attempt to predict the Embryo transfer optimal timing, based on this analysis."
75779058|NCT05430165|Other|Standard mHealth screening (triage) tool|"Standard mHealth triage tool administered to eligible trauma patients by phone at 2 weeks, 1 month, 3 months, and 6 months post-hospital discharge. The mHealth triage tool is a survey that includes a 7-item questionnaire to identify their need for follow-up care.~The need for follow-up care at any of the 4 follow-ups is defined as a flagged response to ≥1 question on the 7-item screening survey."
75779059|NCT05417113|Drug|Liposomal bupivacaine|liposomal bupivacaine
75779060|NCT05417113|Drug|Bupivacaine|bupivacaine 0.25% in ESP blocks
75779061|NCT05403034|Procedure|Muscle biopsy|Peroperative muscle biopsy will be performed during a planned shoulder surgery (arthrolysis and/or muscle transfer)
75779062|NCT05396456|Procedure|Muscle Fiber Fragment (MFF) Injections|The participant will be treated with an injection of muscle fiber fragments into the external anal sphincter at 3, 6, 9 and 12 o'clock using a 21-gauge needle to a depth of 1-2 cm from the external skin using equal amounts in each quadrant.
75779063|NCT05394298|Drug|Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity from a pre-stablished list of antibiotics included
75779064|NCT05394298|Drug|Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity a pre-stablished list of antibiotics included
76074167|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
76074168|NCT01278160|Drug|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
76074169|NCT01996241|Behavioral|Multi-level, structural and norms-based intervention|Receive multi-level, structural and norms-based intervention
75322124|NCT00613379|Drug|PRO 140|5 mg/kg PRO 140, one IV dose (N=10)
75779065|NCT05393908|Procedure|TAP Block Group|Participants will receive a surgeon administered TAP block.
75779066|NCT05390359|Other|High-intensity and short-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a high intensity current (3 mA), that will be applied for 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
76074170|NCT00248404|Drug|NB1011|
75779067|NCT05390359|Other|Low-intensity and long-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a low intensity direct current (0.1 mA) during 90 seconds, with 3 seconds rests between pulses and 1 second of pulses ramp.~The total treatment time will be 366 seconds."
75779068|NCT05390359|Other|High-intensity, short-duration and 20 Hz|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 pulses of a high intensity compensated biphasic current (3 mA), during 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp. The alternating frequency will be of 20 Hz and the pulse width of 50 microseconds.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
76074171|NCT02091869|Other|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
76074172|NCT02091869|Device|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
76074173|NCT00748072|Drug|DDAVP|0.3 mcg/kg subcutaneous
76074174|NCT00748072|Drug|saline solution|saline solution 1 ml subcutaneous
76074175|NCT03806920|Dietary Supplement|Intervention A|
76074176|NCT03806920|Dietary Supplement|Intervention B|
76074177|NCT03806920|Dietary Supplement|Intervention C|
75322125|NCT00613379|Drug|Placebo|PBO, one IV dose (N=10)
75322126|NCT03088592|Device|Deep Brain Stimulation|Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
75914869|NCT04388943|Other|Observation|Physiological Measurements Patient reported questionnaire Blood sampling
75779069|NCT05390359|Other|Sham electrolysis|The control ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon, without electrical stimulation during 366 seconds.
75914870|NCT04384575|Diagnostic Test|blind spots|missed part during map the entire stomach through endoscopy
75322127|NCT03080168|Device|Actigraph|This is NOT an intervention but a monitoring device. All participants will wear an Actigraph for the duration of their inpatient stay, as well as complete paper and computer assessments.
75626683|NCT00883090|Biological|FXIII Concentrate (Human)|Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
75914871|NCT04364828|Genetic|Whole Genome Analysis|Whole Genome Analysis with whole transcriptome analysis and deoxyribonucleic acid (DNA) methylation analysis using Methylation beadchip (EPIC) arrays
75914872|NCT04364828|Genetic|T-cell receptor (TCR) repertoire|Longitudinal analysis of TCR repertoire of Cluster of Differentiation 4+ (CD4+) and CD8+ T cells from blood samples (Peripheral Blood Mononuclear Cells, PBMCs) from clinically characterized patients
75626684|NCT04162288|Other|Online Training - Shared Decision Making in Prenatal Screening|TThe intervention consisted of an online self-study training program lasting 3 hours which aims to engage SDM in a prenatal screening context. The training was divided into four main modules: 1)SDM, 2)DS prenatal screening, 3)Decision aid and 4)Communication between healthcare professionals and patients. In each module, the targeted learning objectives and the work to be carried out (e.g. readings to be made, video to be viewed, evaluation to be carried out, etc.) are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. A simulation in the end is done to put participants in context of an actual consultation with a pregnant woman and her partner. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
75626685|NCT04162288|Other|Online Training - Online Training on Prenatal Screening|The control intervention consisted of an online self-study training program lasting 3 hours which aims to provides knowledge for prenatal screening. The training has four main modules: 1)Context and history of prenatal screening(new), 2)DS prenatal screening(existing), 3)Consent in prenatal screening(new) and 4)Communication between healthcare professionals and patients(existing). In each module, the targeted learning objectives and the work to be carried out are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. For the 2 new modules, narrated capsules and reports have replaced videos of experts. There is no simulation at the end. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
75626686|NCT02645656|Drug|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
75626687|NCT04163848|Other|Pollution|CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
75626688|NCT01132820|Drug|Cediranib Maleate|Given PO
75626689|NCT01132820|Other|Laboratory Biomarker Analysis|Correlative studies
75626690|NCT04163770|Device|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
75626691|NCT04163770|Device|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
75626692|NCT04162444|Diagnostic Test|Physical examination|A physical examination is a routine screening procedure used to investigate a patient's symptoms or complaints. It consists of a series of questions regarding patient medical history followed by an examination of the symptoms to determine the correct diagnosis and treatment plan.
75914873|NCT04364828|Genetic|SARS-CoV-2 viral composition|Determined by Next Generation sequencing
76074178|NCT03806920|Dietary Supplement|Intervention D|
75779070|NCT05372276|Other|Assessment 1|Mental Toughness Questionnaire in Sport
75779071|NCT05372276|Other|Assessment 2|Sport Imagery Questionnaire
76074179|NCT04731701|Diagnostic Test|Hemophilia Joint Health Score (HJHS)|Joint examination with Hemophilia Joint Health Score (HJHS)
75322128|NCT01271725|Drug|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
75322129|NCT01271725|Drug|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
75779072|NCT05372276|Other|Assessment 3|The Pittsburgh Sleep Quality Index
75779073|NCT05372276|Other|Assessment 4|The Perceived Stress Scale (PSS)
75779074|NCT05364827|Diagnostic Test|CTCA|CTCA performed in intervention arm patients prior to CTO PCI
75914874|NCT04364308|Other|Fetal Echography|Fetal ultrasound and its parameters
75914875|NCT04363008|Diagnostic Test|serum inflammatory biomarkers|Serum biomarkers measured (IL-1 beta, IL-2, IL-6, IL-10, TNF alpha)
75914876|NCT04354623|Other|A 6-minute walk test|Each subject will perform a 6-minute walk test during which gait assessment will be obtained from the APDM system (Portland, OR). In addition there will be four video cameras (on the front, back and sides) that will measure raw video data for our gait analysis. The camera does not record any facial data (in fact, 'deepfake' software in the system deletes all facial details) and the patient's movements are converted to a 'stick figure' prior to being saved in the system.
75914877|NCT04353869|Biological|Bio collection|venous blood sampling and collection of urine
76074180|NCT00248794|Behavioral|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
75322130|NCT01271725|Drug|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
75322131|NCT00587483|Drug|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
76074181|NCT00248794|Behavioral|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
75322132|NCT00587483|Drug|Amiodarone|300 mg
76074182|NCT00248794|Behavioral|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
76074183|NCT03806686|Biological|Placebo|Sterile normal saline
76074184|NCT03806686|Biological|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
75322133|NCT00587483|Drug|Placebo|Saline
75322134|NCT04279886|Other|Three-dimensional scans|All included healthy volunteers received 6 three-dimensional scans, utilizing 3 different scanning systems (2 scans per system)
75322135|NCT03401060|Drug|Denosumab|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
75322136|NCT03401060|Drug|Placebo|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
75467054|NCT01916200|Drug|Paroxetine CR|Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
75467055|NCT01916213|Procedure|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
75467056|NCT01916239|Dietary Supplement|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
75467057|NCT01916239|Dietary Supplement|Pomegranate extract formulation-1|New pomegranate extract formulation-1
75914878|NCT04332029|Behavioral|CBT + WGP + CM|The intervention will be implemented in 8-week group-based sessions and includes: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating, and 3) a Contingency Management procedure reinforcing smoking abstinence. This component will consist on providing vouchers to reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
75626693|NCT04162444|Diagnostic Test|The Ross Classification for Heart Failure in Children|The assessment is performed by pediatric cardiologist according to the classic Ross scale. One of the 4 classes of chronic heart failure is registered.
75626694|NCT04162444|Diagnostic Test|The Aristotle score|Surgical risks will be assessed by the ARISTOTLE score developed specially for the task. The calculation will be performed online, available from http://www.aristotleinstitute.org.
75914879|NCT04332029|Behavioral|CBT + WGP|The intervention will be implemented in 8-week group-based sessions and will include only the first two components of the experimental intervention: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating.
75914880|NCT04325334|Behavioral|Running volume increase|"Participants will receive a 12-week running program to increase their running volume by approximately 10% per week on average, and in accordance with the 10% rule advocated to minimize injury rates. For the purpose of this study, participants will run using their habitual technique - i.e. no specific instructions on 'how' to run will be provided; rather, they will simply be instructed on 'how much' to run."
76074185|NCT01995539|Behavioral|therapy regimen|Subjects will be recommend changes in therapy regimens.
76074186|NCT01835587|Drug|CC-486|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
75322137|NCT05247437|Behavioral|Digital Intensive Lifestyle Intervention|The FitD consists of 8 digital lessons on how to improve dietary and exercise habits using self-monitoring, goal-setting, cognitive restructuring, and other behavioral and cognitive strategies. The FitD app offers a virtual coach that guides the participant to complete the treatment.
75322138|NCT05247437|Behavioral|Digital Self-Help Control Condition|The digital self-help control condition consists of educational materials related to diet and exercise. The materials are open for access all at once. There is no guidance by a virtual coach or digital lessons.
76074187|NCT01736917|Drug|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
76074188|NCT01736917|Drug|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
76074189|NCT01736917|Drug|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
76074190|NCT01277302|Drug|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
75322139|NCT01270321|Drug|Everolimus|Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
75322140|NCT01270321|Drug|Pasireotide|Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
75322141|NCT01270321|Drug|Everolimus and Pasireotide|Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
75914881|NCT04322929|Drug|Roflumilast Oral Tablet|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
75914882|NCT04322864|Other|Therapeutic exercises|Patients will perform strengthening exercises focusing on scapulothoracic muscles and shoulder lateral rotators.
75914883|NCT04318977|Device|high-frequency rTMS|repetitive transcranial magnetic stimulation
75914884|NCT04318977|Device|TBS|theta burst stimulation
75914885|NCT04318977|Device|placebo|placebo transcranial magnetic stimulation
75914886|NCT04315948|Drug|Remdesivir|The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.
75322142|NCT01271023|Device|Control-to-Range Automated Insulin Management System|The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
75467058|NCT01916239|Dietary Supplement|Pomegranate extract formulation-2|New pomegranate extract formulation-2
75467059|NCT01916252|Drug|bortezomib (Velcade ®)|
75626695|NCT04162444|Other|Assessment of administered specific therapy|"The data will be registered as groups of administered medicines:~Antiplatelet agents~Loop diuretics~Potassium-sparing diuretics~Angiotensin-converting enzyme inhibitors"
75626696|NCT04162444|Diagnostic Test|Multispiral computed tomography/3D echocardiography|"All patients enrolled in the study should be routinely examined with multispiral computed tomography (MS-CT) or 3D-echo before surgery and 3 years later. As a result, a 3D aortic root reconstruction will be made to assess its size and anatomy and subsequently build a 3D soft model for surgery imitation.~At the study onset, we plan to perform MS-CT, then 3D-echo. If the correlation resulting from 3D-echo and the actual sizes will be high, the isolated 3D-echo will be preferred in the future.~If none of the methods is available, the patients will not be enrolled in the study.~The following data will be registered for further analysis:~Perimeter of the aortic valve~Diameter of the aortic valve at sinuses level~Height of the aortic sinuses~Morphology of the aortic valve"
75626697|NCT04162444|Diagnostic Test|Transthoracic and transesophageal echocardiography|"Transthoracic echocardiography is carried out at baseline, at discharge and then annually. It is performed in order to assess the contractile function of the heart and hemodynamic characteristics of the aortic valve and its autopericardium graft.~Transesophageal echocardiography is carried out directly after the withdrawal of the artificial circulation when performing augmentation of the aortic valve with autopericardium in order to asses hemodynamic characteristics of the aortic neo-valve."
75626698|NCT04162444|Diagnostic Test|12-lead electrocardiogram|"Registering 12-lead electrocardiogram (ECG) is used as a tool for assessment of the regularity of the heart rhythm as well as screening and predictive tool for assessment of fibrosis and hypertrophy processes in the myocardium. The following data will be registered:~Heart rate~Sinus rhythm (yes/no)~Positive R wave in leads V5-6~Angle α less than 0~Presence/absence of abnormal Q wave~Presence/absence of ST-segment depression in precordial leads"
75914887|NCT04315948|Drug|Lopinavir/ritonavir|"The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the a logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL)."
76074191|NCT04414579|Drug|Faster Insulin Aspart (Fiasp®)|Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.
76074192|NCT01980875|Drug|Idelalisib|150 mg tablet administered orally twice daily
75322143|NCT03086486|Drug|Pretomanid|200mg tablets
75322144|NCT03086486|Drug|Linezolid|Scored 600mg tablets
75322145|NCT03086486|Drug|Bedaquiline|100mg tablets
75322146|NCT03086486|Drug|Placebo Linezolid|Scored 600 mg tablets
75467060|NCT01916252|Drug|lenalidomide (Revlimid®)|
75467061|NCT01916252|Drug|busulfan (Busilvex ®)|
75467062|NCT01916252|Drug|Dexamethasone acetate|
75914888|NCT04315948|Drug|Interferon Beta-1A|IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.
75322147|NCT00614315|Device|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
75322148|NCT02287779|Drug|SHP626|
75322149|NCT02287779|Drug|Placebo|
75467063|NCT01916252|Drug|Melphalan|
75467064|NCT01916265|Drug|Glucagon|
75467065|NCT01916291|Drug|Propess insertion group|
75467066|NCT01916343|Procedure|Study Laparoscopic Curriculum|
75467067|NCT01916356|Other|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
75626699|NCT00655330|Drug|Valsartan|Valsartan (160mg/day)
75779075|NCT05341219|Procedure|Light needle therapy|The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
75779076|NCT05341219|Procedure|Sham light needle therapy|The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
75779077|NCT05330078|Drug|Botulinum toxin type A|Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
75779078|NCT05330078|Drug|Vehicle|Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
75914889|NCT04315948|Drug|Hydroxychloroquine|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).
75914890|NCT04315948|Other|Standard of care|Standard of care
75779079|NCT05317585|Device|Continuous Glucose Monitor|Continuous Glucose Monitor
75914891|NCT04315948|Drug|AZD7442|AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.
75914892|NCT04315948|Other|Placebo|Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.
75914893|NCT04315727|Genetic|WGS Diagnostic Blood take for genetic diagnostic.|Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).
75322150|NCT00732901|Drug|Escitalopram|Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
75322151|NCT00732901|Drug|Placebo|Once daily days 1-28
75779080|NCT05317585|Device|Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)|Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
75322152|NCT03083210|Drug|Lanreotide|Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
75779081|NCT05309564|Drug|Botulinum toxin type A|Single intervention
75322153|NCT05689034|Drug|Azvudine|Azvudine po. 5mg daily for 7 days
75322154|NCT05689034|Drug|Placebo|Placebo po. 5 tablets daily for 7 days
75322155|NCT00616109|Drug|sunitinib|Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
75467068|NCT01916369|Biological|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
75467069|NCT01916382|Drug|Nitisinone|drug
75626700|NCT00655330|Drug|Placebo|Placebo
75626701|NCT00655330|Drug|Probucol|Probucol (750mg/day)
75626702|NCT00353470|Behavioral|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
75626703|NCT00353470|Behavioral|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
75626704|NCT00353470|Behavioral|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
75626705|NCT00655408|Drug|elemental iron|Iron supplementation.
75779082|NCT05301413|Behavioral|Culturally Tailored Diabetes Prevention Program|This intervention includes a culturally tailored DPP curriculum, class procedures, and handouts
75779083|NCT05301413|Behavioral|Culturally Tailored DPP Enhanced with Socioeconomic Supports|This intervention includes the culturally tailored DPP curriculum, class procedures, and handouts along with promotional items for class participation, opportunities to attend class in-person or virtually through a digital platform, and assistance from a community health worker to provide linkage to health care services and community resources
75779084|NCT05301413|Behavioral|Diabetes Prevention Program|This is the CDC TD2 evidence-based Diabetes Prevention Program
75779085|NCT05276115|Other|Interview|Interview discussion with individuals with ptsd.
75779086|NCT05263635|Other|Music therapy|Music therapy will include music intervention based on recommendations from literature such as slow, flowing rhythm, approximately 60-80 beats/minute and played by string instruments, played with a volume of approximately 45 decibel and will be reviewed by qualified music therapists.
75626706|NCT04163536|Drug|Methylprednisolone|In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
75914894|NCT04315727|Genetic|Hair collection|Hair including root will be collected from the scalp (~15-20) and transferred to cultivation medium for the organoid cultivation
75914895|NCT04310059|Dietary Supplement|Folic acid|women will be randomised into one of the three groups. Group A - Folic acid 5mg/day Group B - Folic acid 0.5mg/day Group C - Materna one tablet/day (a pregnancy supplement containing 0.6mg folic acid)
75914896|NCT04310059|Dietary Supplement|Materna|Materna
75914897|NCT04304235|Device|Pediatric Rapid Sepsis Trigger (PRST) tool|The digital platform consists of a mobile application integrating a pulse oximetry sensor attached to this device, with embedded smart algorithms that predict a critically ill state, or level of risk (below) in a child presenting at the hospital. The platform also includes an interactive dashboard located in strategic locations (e.g., laboratory, consultation rooms), which connects to the mobile application through a secure local network and displays the triage data to provide real-time monitoring for the physicians who manage the patients.
75779087|NCT05263635|Other|Standard of Care Enhanced Recovery After Surgery (ERAS)|Patients will receive the standard of care treatment for surgery and post-operative pain management, following the Enhanced Recovery After Surgery (ERAS) protocol
75779088|NCT05262426|Behavioral|Behavioral: Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
75914898|NCT04304235|Other|Emergency Triage and Treatment (ETAT) guidelines|These are the triage guidelines currently applied in the study hospital sites. This will be the comparator group.
75626707|NCT04163536|Drug|Placebos|in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
75626708|NCT02637544|Other|acupuncture|classical acupuncture therapy
75914899|NCT04302870|Drug|Memantine Hydrochloride Oral Solution|Memantine hydrocholoride taken once daily
75322156|NCT02330523|Device|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
75626709|NCT02645500|Behavioral|Holistic health training and physical exercise messages|The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
75626710|NCT02645500|Behavioral|Holistic Health Training with healthy diet messages|The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
75626711|NCT00652288|Drug|Insulin analogs (Lispro and Aspart)|Insulin bolus given through insulin pump
75626712|NCT00652288|Drug|Insulin analogs (Aspart and Detemir)|Drugs given separately
75626713|NCT00652288|Drug|Insulin analogs (Aspart and Detemir)|Drugs given in the same injection
75914900|NCT04302870|Drug|Trazodone Hydrochloride oral solution|Trazodone Hydrochloride taken once daily
75914901|NCT04302870|Drug|Placebo oral solution|Placebo taken once daily
75322157|NCT02330523|Device|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
75626714|NCT00652288|Drug|Insulin analogs (Lispro and Glargine)|Drugs given separately
75626715|NCT00652288|Drug|Insulin analogs (Lispro and Glargine)|Drugs given in single injection
75626716|NCT04162132|Device|Smartphone app|Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
75626717|NCT00911092|Procedure|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
75626718|NCT00911092|Radiation|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
75914902|NCT04302870|Drug|Amantadine Hydrochloride Oral Solution|Amantadine Hydrochloride taken once daily
75626719|NCT00911092|Drug|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11~Day 1 to day 4: Fluorouracil 1 gr/m²/day~Day 1 or 2: Cisplatin 75 mg/m²"
75914903|NCT04298203|Drug|Phentermine-Topiramate|The study medication to be tested for this study is a combination of phentermine and topiramate.
75914904|NCT04298203|Dietary Supplement|Meal Replacement Therapy|The first six weeks of the study, subjects will receive meal replacement therapy in an effort to reduce their BMI by at least 5%.
75914905|NCT04298203|Other|Placebo|A pill that looks like Phentermine-Topiramate but has no active medication.
75914906|NCT04294849|Other|Magnetic Resonance Imaging|A. Phosphorous 31 MR Spectroscopy to evaluate skeletal muscle metabolism via measurement of depletion and recovery of phosphocreatine (PCr) B. Non-invasive arterial spin labeling MRI to evaluate lymphatic flow velocities and venous flow
75914907|NCT04294849|Other|Bicycle Ergometry|To measure peak VO2 as a representation of global aerobic fitness
75914908|NCT04294849|Other|Lab Panel|A. Inflammatory lab panel (IL-6, IL-8, TNF alpha, P-selectin, high sensitivity CRP, IL-6 receptor, TNF R1/R2) drawn at diagnosis B. Thrombin Generation Assay to measure hypercoagulability and Thromboelastography prior to initiating anticoagulation
75914909|NCT04294849|Behavioral|Questionnaires|A. Dalhousie Dyspnea Scale B. Godin Leisure Time Exercise Questionnaire C. Pediatric Venous Quality of Life Questionnaire
76074193|NCT01980875|Drug|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
76074194|NCT01980875|Drug|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
75779089|NCT05262426|Behavioral|Enhanced YaCool|Enhanced YaCool is mobile application developed to support transgender women self-management of their gender and sexual health, including PrEP use. YaCool is a passcode-protected app that allows users to personalized text messaged reminders to take PrEP and/or clinic appointments, record PrEP adherence and sexual activity, and track lab tests. The application is set up to provide personalized recommendations for PrEP regimen, confirmed by clinic healthcare staff. Participants will be asked to download Enhanced YaCool to support PrEP use and gender/sexual health self-management between MES-PrEP sessions for 30 days, and thereafter until the end of Month 12 (if desired).
75322158|NCT05688878|Device|Threshold electrical stimulation|Threshold stimulation (EDS) is based on low-intensity (<100 Hz) and long-duration current and is applied with superficial electrodes. Threshold stimulation provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction.This treatment will be applied for 4 weeks, 3 days a week, for 1 hour.
75626720|NCT02637622|Other|Best-Worst Scaling (Case 2)|Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.
75914910|NCT04293874|Behavioral|Personalized Meal Plan|Personalized dietary plans will be developed incorporating the NPAGCS, while personalizing the plan based upon anthropometric characteristics, gender, age and self-reported activity level upon entry into the investigation, goals, typical dietary consumption patterns, and food preferences. A trained research assistant will use the USDA MyPlate88 site (www.choosemyplate.gov) to enter participant characteristics and determine the appropriate calorie level. A daily checklist will be then generated outlining the number of daily servings that should be consumed for each food group. Information will also be provided regarding serving sizes for different foods in the respective food groups and education will be provided regarding tailoring personal dietary preferences to meet the guidelines. Participants will be provided with a printed copy of their meal plan and instructed to initiate it for a 8-week period.
75626721|NCT02637622|Other|Discrete Choice Experiment|Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
75779090|NCT05262426|Behavioral|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3, 6, 9 and 12. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
75779091|NCT05249569|Drug|Axitinib|Axitinib to be administered orally BID
75779092|NCT05249569|Drug|Avelumab|Avelumab to be administered as a 1-hour IV infusion on Day 1 and Day 15 of each 28-day cycle.
75626722|NCT00655720|Other|infant formula|"hydrolyzed infant formula without probiotics~hydrolyzed infant formula with probiotics~hydrolyzed infant formula with probiotics"
75779093|NCT05249569|Drug|Bavituximab|Bavituximab to be administered weekly on Days 1, 8, 15 and 22 of the 28-day cycle.
75626723|NCT02635360|Drug|Pembrolizumab|200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
75779094|NCT05243030|Behavioral|Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
75322159|NCT03390764|Procedure|4:1 closure group|In this arm the incisions are closed by the 4:1-technique
75322160|NCT03390764|Procedure|RTL plus 4:1 closure group|In this arm the incisions are closed by a reinforced tension-line suture in addition to the 4:1-technique
75322161|NCT04401488|Biological|Prevenar 7 and Prevenar 13|pneumococcal conjugate vaccines
75322162|NCT04761536|Other|Rectal cancer case centralization|In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.
75467070|NCT01916395|Drug|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
75626724|NCT02635360|Radiation|Brachytherapy|Radiation is done for standard clinical care purposes.
75626725|NCT02635360|Drug|Cisplatin|40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
75626726|NCT02635282|Drug|intranasal ketamine|
75626727|NCT02635282|Drug|intranasal fentanyl|
75626728|NCT02635282|Drug|intranasal midazolam|
75626729|NCT02635438|Drug|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
75626730|NCT02635438|Drug|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
75626731|NCT00655798|Dietary Supplement|Placebo|plain yogurt and capsules containing cellulose
75626732|NCT00655798|Dietary Supplement|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
75626733|NCT00655798|Dietary Supplement|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
75626734|NCT00655798|Dietary Supplement|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
75626735|NCT02635048|Procedure|Mini Percutaneous Nephrolithotomy|patients undergo PNCL with 18Fr nephrostomy tract
75779095|NCT05243030|Behavioral|Motivational Interactive Text Messaging (MTM)|"Participants will receive automated motivational text messages to promote PrEP initiation and adherence. These contents will be customized based on their readiness to change in regards to PrEP. The message content is individualized based on participant response to baseline survey. Those participants who indicate that they are ready to set the goal to take PrEP will receive text messages reminding them to take PrEP. Those who indicate that they are less than ready to take their PrEP can choose from a range of alternatives, such as taking on-demand PrEP or just think about taking PrEP. For those who are not ready to take PrEP, the content will be individualized based on the participant's choice, i.e., a daily message encouraging them to work toward their chosen goal. Participants who are currently not on PrEP will receive daily text messages regarding PrEP effectiveness, HIV risk and where to access PrEP."
75779096|NCT05243030|Behavioral|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3 and 6. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
75779097|NCT05235022|Other|Questionnaires|"The participants included in the study will have to answer:~a questionnaire created specifically for the study concerning the possible difficulties encountered during their return to work,~the Multidimensional Fatigue Inventory (MFI), a questionnaire assessing fatigue through 5 dimensions (general fatigue, physical fatigue, mental fatigue, reduced activity and reduced motivation).~These 2 questionnaires will be filled during a 30-minute face-to-face or phone interview."
75779098|NCT05230498|Device|anatomy-based fitting then default fitting|Cochlear implant with anatomy-based fitting then default fitting
75914911|NCT04293874|Behavioral|Dietary Omega-3LC intervention|Following randomization, participants will be provided with fish to be consumed for 6 weeks. As a component of the dietary intervention, participants in high and low omega-3LC group will be provided with frozen, wild caught salmon (or if they dislike salmon, prepackaged, individual use foil packs of chunk light tuna). Salmon and chunk light tuna were chosen due to high omega-3LC content, low methylmercury content, low cost and ease of use. Vacuum packed, frozen salmon will be delivered to participants in large freezer bags and instructed to arrange visit times to ensure they can go directly home following the visit. Instructions for safe storage, fish handling and recipes to avoid fatigue of fish will be also be provided to participants when they receive the fish.
75626736|NCT02635048|Procedure|Percutaneous Nephrolithotomy|patients undergo PNCL with 24Fr nephrostomy tract
75914912|NCT04290429|Drug|Teduglutide|Treatment of patients with SR-GI-GVHD with teduglutide
75322163|NCT00249769|Biological|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
75914913|NCT04289662|Drug|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
75322164|NCT00249769|Biological|Measles Vaccine (MV)|"The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO).~SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979."
75322165|NCT05688800|Device|conventional therapy|Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect
75914914|NCT04289662|Drug|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
75467071|NCT01916408|Drug|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
75626737|NCT00652522|Device|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
75914915|NCT04289649|Drug|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
75626738|NCT00652522|Procedure|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
75626739|NCT00652522|Other|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
75626740|NCT02645344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
75626741|NCT02645344|Behavioral|Sensory Cueing (SC)|
75626742|NCT02645344|Behavioral|Conventional Rehabilitation|
75914916|NCT04289649|Drug|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
75914917|NCT04289649|Drug|K-924 LD Placebo|Pitavastain 2 mg
75626743|NCT02637700|Drug|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
75626744|NCT02637700|Drug|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
75626745|NCT02637466|Drug|Vortioxetine|
75626746|NCT02637388|Dietary Supplement|Oatwell28 Oatwell Original Powder|
75914918|NCT04289649|Drug|K-924 HD Placebo|Pitavastain 4 mg
75914919|NCT04281784|Behavioral|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page Jumpstart Guide provides information to the clinician about prior advance care planning documentation and code status derived from the EHR. The Jumpstart Guides includes tips to improve goals-of-care communication.
75322166|NCT05688800|Other|Experimental group 1 : pressure release technique|Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle
75779099|NCT05230498|Device|default fitting then anatomy-based fitting|Cochlear implant with anatomy-based fitting then default fitting
75779100|NCT05212662|Drug|TTI-0102|"The study treatment is a precursor to cysteamine, TTI-0102 (cysteamine-pantetheine disulfide). Each molecule of TTI-0102, after reduction and metabolism in the digestive tract, allows the absorption of 2 molecules of cysteamine and one molecule of pantothenic acid (Vit B5). Each dose of TTI-0102 comes in a vial as a powder to dissolve in water and absorb orally. Each vial contains 5.5g of TTI-0102, corresponding to the equivalent of 2.4g of cysteamine base. This single dose is less than the maximum daily dose authorized with other formulations of cysteamine (Cystagon or Procysbi, 1.95 g/m2/day) for patients over 1.25 m2 or 40 kg (88 lbs).~This dose of 5.5 g is justified by the need to maintain a thiol/disulfide ratio in favor of cysteamine over 24 h. It has been tested in healthy volunteers and has no side effects due to the specific pharmacokinetics of cysteamine after administration of TTI-0102."
75779101|NCT05212662|Drug|Placebo|Placebo comparator supplied in vials identical to the active intervention, TTI-0102
75779102|NCT05204316|Other|Digital Analysis of Speech|Recordings will be transcribed manually to written digital text formats, on which NLP tools such as tokenisation and lexical analysis will be performed.
75779103|NCT05199506|Device|RAP|Treatment of cellulite with RAP device
75626747|NCT02637388|Dietary Supplement|Control Breakfast|Isocaloric breakfast without added beta-glucans
75626748|NCT02634892|Device|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
75626749|NCT02634970|Drug|Ranibizumab|0.5 mg, intravitreal injection
75626750|NCT00885352|Drug|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
75626751|NCT00885352|Drug|Comparator: Placebo|Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
75322167|NCT05688800|Other|Experimental group 2: thoracic spine manipulation|Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
75322168|NCT03083054|Biological|Autologous dendritic cells electroporated with WT1 mRNA|Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
75322169|NCT00249613|Behavioral|Women-Only|Gender-responsive treatment for women only
75626752|NCT00885352|Drug|Pioglitazone|Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
75626753|NCT00885352|Drug|Metformin|Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
75914920|NCT04280692|Biological|PfSPZ Challenge|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites
75914921|NCT04280692|Drug|Sulfadoxine-Pyrimethamine|Sub-curative 500mg/25mg single dose regimen
75322170|NCT03434678|Drug|Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml|Patient will have their epidural started at the beginning of the surgery and receive fewer opioid drugs. The epidural is continued into the recovery room.
75322171|NCT03434678|Drug|Propofol+ Rocuronium+ Fentanyl + Inhalational|Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
75914922|NCT04280692|Drug|Piperaquine|Sub-curative 480mg single dose regimen
75914923|NCT04280692|Drug|Artemether lumefantrine|Three day curative regimen 20mg/120mg
75914924|NCT04280692|Drug|Primaquine|Single low dose regimen 0.25 mg base/kg
75779104|NCT05193084|Device|Heartfelt Device|"The Heartfelt Device is a CE marked device that measures the volume of the foot/lower leg. By positioning the Heartfelt device in the bedroom, automatic measurements can be made whenever the subject gets in and out of bed. Feet identification software, complemented by manual checks, ensures that photographs are only taken of the specified subject. Data is censored so that the part of the body which is 50cm above the floor is not stored. Encrypted, anonymised data is transmitted over the internet to the company's secure servers. For this study, no personal identifiable data will be stored on the device or on the servers used by the device.~The volume readings collected can be presented to the clinical team on a web interface. This is not presented against identifiable data, but only participant ID. However, in the current pilot, volume readings will not be reviewed by the clinical team until the point of data analysis, after the study period."
75914925|NCT04279262|Other|attendance by community first responders for medical emergencies|The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
75914926|NCT04276857|Device|Irreversible electroporation (NanoKnife® )|IRE is a unique treatment modality as it ablates tumor cells without using heat or radiation and hence does not cause injury to nearby blood vessels, ducts, and bowel. This makes it particularly appealing for the treatment of locally advanced unresectable pancreatic cancers. This local treatment for cancer involves delivering brief pulses of high voltage electrical current across the tumor (either percutaneously or open surgery), which results in the formation of tiny holes (nanopores) in the cell membranes.
75626754|NCT00885352|Drug|Glipizide|Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
75322172|NCT03434678|Procedure|Open Pancreaticoduodenectomy|Whipple' Procedure
75626755|NCT02637310|Drug|N02RS1 1200mg|1200mg/day, Three times a day orally, 2 tablets once, 7 days
75322173|NCT03082820|Diagnostic Test|Pain-related evoked potentials (PREP)|PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.
75322174|NCT03082820|Diagnostic Test|Quantitative Sensory Testing (QST)|QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.
75322175|NCT03082820|Diagnostic Test|Nerve conduction studies (NCS)|NCS were performed with patients only.
75467072|NCT01916408|Drug|PL 1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
75467073|NCT01916421|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|
75322176|NCT00733135|Device|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
75626756|NCT02637310|Drug|Placebo|1200mg/day, Three times a day orally, 2 tablets once, 7 days
75626757|NCT00655954|Procedure|Induced sputum|Used Ultrasonic nebuliser
75626758|NCT00656032|Other|paricalcitol|1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
75626759|NCT00656032|Other|cinacalcet|0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
75626760|NCT02637154|Behavioral|Motivational Interviewing|Motivational Interviewing method
75322177|NCT05688722|Procedure|Supine position|Patients preoxygenated in supine position before endotracheal intubation
75322178|NCT05688722|Procedure|20 degree head elevation position|Patients preoxygenated in 20 degree head elevation position before endotracheal intubation
75322179|NCT05688722|Procedure|30 degree head elevation position|Patients preoxygenated in 30 degree head elevation position before endotracheal intubation
75322180|NCT05688722|Procedure|45 degree head elevation position|Patients preoxygenated in 45 degree head elevation position before endotracheal intubation
75322181|NCT05688644|Device|InterStim II|Sacral neuromodulation
75467074|NCT01916434|Other|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
75467075|NCT01916434|Other|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
75467076|NCT01916434|Other|No salmon|The placebo group will continue to consume their habitual diet.
75467077|NCT01916447|Drug|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
75467078|NCT01916447|Drug|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
75626761|NCT02637154|Behavioral|Standard Education|Standard Education material will be used
75626762|NCT00656734|Biological|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
75626763|NCT00885118|Drug|Placebo (middle dose)|Placebo tablets once a day
75626764|NCT00885118|Drug|Placebo|Placebo tablets once a day
75626765|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
75626766|NCT00885118|Drug|BI 10773|BI 10773 high dose tablets once a day
75626767|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
75914927|NCT04274283|Other|Matched Tumour and Blood Sample - Research Pathway|"For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.~Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites"
75914928|NCT04274283|Other|Matched Tumour and Blood Sample - NHS GMS pathway|Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
75914929|NCT04270617|Behavioral|Yoga program|The intervention will be a 6-week ashtanga yoga program designed by world-renowned yogi Eddie Stern. Eddie Stern is an internationally known Ashtanga yoga teacher, in independent practice not affiliated with NYULH, who has done significant work exploring the physiology and science of yoga. He is not currently engaged in his own research. The yoga protocol for chronic back pain was designed with poses specific to addressing core strength but are gentle enough for patients in pain. The protocol is designed to be directed by a teacher initially but can be done at home and is only 18 minutes in duration.
75626768|NCT00885118|Drug|Placebo (high dose)|Placebo tablets once a day
75626769|NCT00885118|Drug|BI 10773|BI 10773 low dose tablets once a day
75914930|NCT04268277|Drug|Rituximab|100 mg concentrate for solution for infusion
75914931|NCT04268277|Drug|Pembrolizumab|100 mg/ 4mL concentrate for solution for infusion
75626770|NCT00885118|Drug|Placebo (low dose)|Placebo tablets once a day
75914932|NCT04263558|Behavioral|Emotion child|The MFS will include an idiographic measure of personal aims, symptom burden, displayed on a visual data dashboard to guide further intervention. The EMOTION intervention for children 9 to 12 years with symptoms of anxiety and/or depression will be used in a standard/long version (16 sessions) and a short (8 sessions) but optimized version, using a partial web-based solution with virtual reality (VR)-technology for behavioral experiments and exposure (in short and long version). Parental involvement: Parental participation in a 5-session parent group (high involvement) versus sharing information with parents via a brochure (low Parental involvement).
75914933|NCT04261569|Device|Ev-NIRT|Endoventricular near infra red treatment : Intraventricular pulsed, chronic, cyclic, near-infrared illumination of the Central Nervous System (CNS) at 150 Hz, 15 mW, 1 minute ON and 5 minutes OFF
75914934|NCT04254484|Behavioral|SIESTA Rehab Education|Staff nurses will be trained on how to improve sleep in stroke patients in the acute rehabilitation setting.
75322182|NCT05736627|Other|Online|Online research course delivered live digitally at a distance.
75322183|NCT00617981|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
75626771|NCT00656812|Drug|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
75626772|NCT00656812|Drug|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
75626773|NCT00656110|Drug|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
75626774|NCT00656110|Drug|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
75626775|NCT04163692|Other|Progressive relaxation exercises|"Following intructions have been performed by patients:~Punch your hands and contract your forearm~Punch your hands, push your elbow towards the seat~Bend your elbows~Push your shoulders back~Press your knee down and pull your toes towards you~Pull your knees towards you and push your feet down~Tighten your hips~Push your head back~Lift your eyebrows~Make wrinkles on your nose~Tighten your teeth~Push your chin down~Close your eyes and think of good things."
75626776|NCT00656188|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
75626777|NCT00656188|Drug|Placebo|Matching placebo
75322184|NCT00617981|Drug|5% Dextrose Solution|Single 30 minute intravenous infusion
75322185|NCT05688566|Device|pinnacle trainer|The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.
75322186|NCT03837873|Drug|Rituximab|rituximab 750mg/m2 i.v. on day 0
75626778|NCT00880906|Procedure|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
75626779|NCT00880906|Drug|Steroid and Proton Pump Inhibitor Therapy|
75779105|NCT05193084|Device|Connected weighing scales|"The connected weighing scales are Xiaomi Smart Scales (CE marked, manufactured by Anhui Huami Informeyshn Technologies).~The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional(s) (the fact that a participant has not used scales regularly in the past is not an exclusion criteria). The weighing scales display weight so that the participants can record the weight in their own heart failure records (paper weight diary).~The study team will check the patient's paper weight diary in case they choose to use another set of scales.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will record patient weight as well as the date and time of the measurements."
75322187|NCT03837873|Drug|Etoposide|50mg/m2, continuous i.v. on day 1-4
75322188|NCT03837873|Drug|Vincristine|0.4mg/m2, continuous i.v. on day 1-4
75322189|NCT03837873|Drug|Doxorubicin|10mg/m2, continuous i.v. on day 1-4
75322190|NCT03837873|Drug|Dexamethasone|30mg/day, i.v. on day 1-5 for R-DA-EDOCH regimen; 40mg/day, i.v. on day 1-4 for R(2)-DHAP regimen
75322191|NCT03837873|Drug|Cyclophosphamide|750mg/m2, i.v. on day5
75322192|NCT03837873|Drug|Lenalidomide|25mg/day, p.o. on day 0-9
75322193|NCT03837873|Drug|Cisplatin|100mg/m2 continuous i.v. on day 1
75626780|NCT04160182|Behavioral|Energy Conservation Work Simplification Education|"The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion."
75914935|NCT04254484|Diagnostic Test|ApneaLink|Stroke patients on the SIESTA Rehab unit will be screened for sleep disordered breathing using ApneaLink monitors. Results will be interpreted by a sleep specialist who will then advise the clinical team at SRALab.
75322194|NCT03837873|Drug|Cytarabine|2g/m2 q12h, i.v. on day 2
75322195|NCT03082742|Drug|Hydrochlorothiazide|
75626781|NCT04160026|Drug|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
75914936|NCT04246684|Drug|Oxaliplatin, 85 mg/m2|85 mg/m2,2h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapy
75914937|NCT04246684|Drug|5FU; 2400 mg/m2|2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm
75914938|NCT04246684|Drug|5FU, 250 mg/m2|250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;
75322196|NCT03082742|Drug|Furosemide|
75322197|NCT05434533|Drug|Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)|IV 1gm
75322198|NCT03432650|Drug|Bupivacaine + dexamethasone|Anesthetic that will help treat pain and sensation after hip arthroscopy
75322199|NCT03432650|Device|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the nerve block
75322200|NCT00248833|Biological|25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
75626782|NCT04160026|Drug|Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
75467079|NCT01916447|Drug|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
75322201|NCT00248833|Biological|50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
75322202|NCT00668525|Drug|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
75779106|NCT05182073|Drug|FT576 (Allogenic CAR NK cells with BCMA expression)|Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).
75779107|NCT05182073|Drug|Cyclophosphamide|Conditioning Agent
75779108|NCT05182073|Drug|Fludarabine|Conditioning Agent
75779109|NCT05182073|Drug|Daratumumab|Anti-CD38 Monoclonal Antibody
75779110|NCT05182073|Drug|Bendamustine|Conditioning Agent
75779111|NCT05177822|Drug|Anakinra|Anakinra 100 mg/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment;
75779112|NCT05177822|Other|Placebo|0.9% NaCl/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment.
75914939|NCT04246684|Drug|5FU, 2400 mg/m2|2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
75914940|NCT04246684|Drug|Oxaliplatin 50 mg/m2|50 mg/m2, 2h-civ, d1, d8, d21, d29 of radiotherapy and
75322203|NCT00668525|Drug|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
75322204|NCT00668525|Drug|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
75322205|NCT05736549|Drug|Bupivacaine-Liposomal Bupivacaine|A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
75779113|NCT05116137|Behavioral|Circuit-based resistance exercise (CRT)|CRT is a common training method used to foster aerobic fitness, muscular endurance and strength, as well as neuromuscular adaptations in one workout. CRT is comprised of several sets of different exercises with little rest in between each set.
75914941|NCT04246684|Drug|Folinic Acid, 400 mg/m2|2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
75914942|NCT04246684|Radiation|Radiotherapy control, 5x5 Gy: 25 Gy|Control arm: 5x5 Gy (total: 25 Gy) 5 fractions
75914943|NCT04246684|Drug|Capecitabine, 1000 mg/m2|1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
75914944|NCT04246684|Drug|Oxaliplatin 85 mg/m2|85 mg/m2, 2h-civ, d64, d78, d92, d106, d120, d134 of therapy
75914945|NCT04246684|Radiation|radiotherapy experimental, 30 x 1,8 Gy: 54 Gy|30 x 1.8 Gy (total: 54 Gy), 5 fractions per week
75322206|NCT05736549|Drug|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
75322207|NCT03082508|Device|Algisyl|Algisyl device (implants) administered during a surgical procedure
75322208|NCT03082508|Drug|Standard Medical Therapy|as per protocol
75322209|NCT05688488|Drug|Curcumin|Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
75322210|NCT05688488|Drug|Mitomycin-C|Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
75626783|NCT04160026|Drug|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer|Feasibility study to assess adherence to guidelines among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
75914946|NCT04246684|Drug|Capecitabine, 825 mg/m2|825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional
75626784|NCT02636920|Other|Therapeutic Education to the Patient (TEP)|"Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~Assessing of the knowledges acquired by patients."
75626785|NCT02634736|Device|Exergame plus usual treatment|An individualised [i.e. frequency and duration will be set according to each participant's baseline levels] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
75626786|NCT04159870|Drug|Rifaximin|Rifaximin pills 400 mg x 3/day
75626787|NCT04159870|Drug|Norfloxacin|Norlfloxacin 400 mg 1 pill/day
75626788|NCT02634658|Other|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
75626789|NCT02634658|Other|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
75626790|NCT02634658|Other|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
75626791|NCT00657514|Drug|Ranolazine|500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
75626792|NCT00657514|Drug|Placebo|1 tablet po bid up to 2 tablets po bid if tolerated
75626793|NCT04159792|Other|no intervention|No intervention
75626794|NCT04159948|Dietary Supplement|Carbohydrate drink|"This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes."
75626795|NCT04160104|Other|Questionnaire|Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.
75626796|NCT04160104|Other|Questionnair|Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
75626797|NCT04163146|Diagnostic Test|Measurements of PEF and FEV1|Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
75626798|NCT00656266|Drug|mycophenolate mofetil|immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept
75626799|NCT00656266|Other|placebo medication|medication that looks like mycophenolate mofetil
75914947|NCT04246684|Drug|Oxaliplatin, 130 mg/m2|day1every three weeks (optional)
75322211|NCT05423457|Behavioral|Vegan diet|The participants were advised to eat foods in their original type.
75322212|NCT00669383|Drug|betamethasone|12 mg IM q 24 hours x 2 doses
75322213|NCT00669383|Drug|placebo|Placebo IM q 24 hours x 2 doses
75626800|NCT00882310|Drug|Gemcitabine|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
75626801|NCT00882310|Drug|Docetaxel|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
76074195|NCT01995461|Drug|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
76074196|NCT04731623|Drug|ION904|ION904 will be administered by SC injection.
75626802|NCT00882310|Drug|Capecitabine|Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
75779114|NCT05099237|Device|OURA Ring|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
75467080|NCT01916460|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
75779115|NCT05099237|Device|WithingsScan Watch|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
75779116|NCT05099237|Drug|Isansys Patient Status Engine|Participants in cohort 3 will also be asked to wear Isansys monitoring devices whilst they are in hospital. They will begin to wear the monitors prior to CAR T-cell therapy and continue for 28 days post infusion. Participants will be asked to wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.
75779117|NCT05099237|Other|Quality of Life Surveys|On a weekly basis participants will be asked to complete satisfaction surveys for the devices they are wearing (ring and watch) and report on their quality of life through standardised questionnaires. These surveys will be delivered electronically to participants via their smartphone or tablet device. There will be an option for participants to report adhoc symptoms via an app on their smartphone or tablet device.
75779118|NCT05099237|Diagnostic Test|Blood Samples|"COHORT 3 ONLY~Participants in Cohort 3 only will be asked to provide a series of blood samples to measure inflammatory molecules during the study. These will be requested at various intervals during face-to-face visits and whilst the patient is in hospital:~Baseline blood sample during study enrolment~Post-lymphodepletion and prior to CAR T-cell infusion (this may be on day -1 or day 0 as needed)~Post CAR T-cell infusion:~Day 1~Day 3~Day 6~Day 9~Day 14 (if the participant remains in hospital)~A sample of blood will be taken at baseline and a further sample post lymphodepletion and prior to CAR T-cell infusion. Post CAR T-cell infusion, samples will be taken at two timepoints (morning and afternoon) on each of the sampling days."
75779119|NCT05099237|Other|Daily Weights|"COHORT 3 ONLY~During their inpatient stay, up to a maximum of 28 days, participants in Cohort 3 will be supported to weigh themselves daily using a Withings Body Scale."
75779120|NCT05098522|Drug|IRL201104|lyophilised powder for reconstitution for IV dosing
75779121|NCT05098522|Drug|Placebo|Matching placebo for IRL201104
75626803|NCT00656344|Other|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
75322214|NCT00733993|Drug|Caffeine 150 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
75322215|NCT00733993|Drug|Placebo|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
75626804|NCT00884650|Drug|oral analgesic|per clinical standard of care
75626805|NCT00884650|Drug|intravenous analgesic per pump|per clinical standard of care
75779122|NCT05096663|Dietary Supplement|Cobalamin|Given intramuscularly
75779123|NCT05096663|Drug|Dexamethasone|Given orally (PO)
75779124|NCT05096663|Drug|Docetaxel|Given IV
75779125|NCT05096663|Dietary Supplement|Folic Acid|Given PO
75779126|NCT05096663|Drug|Gemcitabine|Given IV
75779127|NCT05096663|Drug|Nogapendekin Alfa|Given SC
75322216|NCT00733993|Drug|Amphetamine|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
75322217|NCT00733993|Drug|Caffeine 300 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
75322218|NCT03089762|Biological|Intra-articular injection of SVF plus PRP|administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
75467081|NCT01916473|Other|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
75626806|NCT02636842|Drug|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
75626807|NCT04163380|Behavioral|Resistance Training|Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
75779128|NCT05096663|Biological|Pembrolizumab|Given IV
75779129|NCT05096663|Drug|Pemetrexed|Given IV
75779130|NCT05096663|Biological|Ramucirumab|Given IV
75779131|NCT05080699|Dietary Supplement|Peptamen Intense VHP, Nestlé Health Science, Switzerland|An enteral formula containing hydrolyzed whey protein, maltodextrin, long-chain triglycerides, medium chain triglycerides (MCT), vitamins and minerals. Compared to standard enteral formula, Peptamen Intense is higher in protein (37 kcal%) and lower in carbohydrates (29 kcal%). The energy content is 1.0 kcal/mL.
75779132|NCT05074303|Biological|Influenza Vaccine|All subjects will receive the influenza vaccine.
75779133|NCT05074303|Dietary Supplement|Beta-glucan|2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast
75779134|NCT05074303|Dietary Supplement|Placebo|2 - 250 mg capsules/day of cellulose
75779135|NCT05032573|Dietary Supplement|Olive oil and Dietary Guideline recommendations|60 mL of olive oil and healthy diet recommendations
75779136|NCT05032573|Other|Dietary Guideline recommendations|healthy diet recommendations
76074197|NCT04731623|Drug|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection.
75322219|NCT03029559|Other|Intermittent Hypoxia|"A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia)."
75322220|NCT03029559|Other|Inspiratory Threshold Loading|Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.
75322221|NCT03029559|Other|Sham Intermittent Hypoxia|Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
75322222|NCT04279808|Procedure|dilator depth|For soft tissue dilation just after guidewire insertion in central venous catheterization through the right internal jugular vein, investigators will measure the distance between the skin puncture site and outside of anterior wall of the vein with real-time ultrasonography in the measured depth group. Next, practitioner will insert the dilator by the measured length and continue to insert the central venous catheter. For the conventional group as a control group, practitioner will perform the central venous catheterization with a manner used routinely by the practitioner.
75322223|NCT01271257|Drug|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
75626808|NCT04163302|Biological|CD19-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
75626809|NCT02535598|Behavioral|Normal presentation|All the material will be presented as plain text.
75626810|NCT02535598|Behavioral|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
75626811|NCT02535598|Behavioral|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
75626812|NCT02535598|Behavioral|Enhanced support|Participants are offered daily support through the internet from trained therapists.
75626813|NCT04159636|Other|Carbohydrate beverage|The participants in this group are allowed to drink carbohydrate until 2 hours before surgery
75626814|NCT02634502|Procedure|radiofrequency ablation|
75626815|NCT02634502|Drug|S-1|
75779137|NCT05000840|Behavioral|Enrollment in existing SDRI diabetes education programs|Education will be based on a modification of the existing Ocho Pasos education program provided by SDRI.
75779138|NCT04994873|Behavioral|STEP|Behavioral intervention to increase positive affect
75779139|NCT04994873|Behavioral|Enhanced TAU|Standard care plus a phone app with a personalized safety plan
75779140|NCT04990973|Behavioral|Average American Diet (AAD)|"Participants will follow specified diet requirements.~Macronutrient targets for the AAD will be approximately 35-37% of energy from fat (13.5% from saturated fat), 15% from protein, and 48-50% from carbohydrates (10 g fiber/d for an average 2000 kcal/d diet)."
75779141|NCT04990973|Behavioral|Mediterranean Diet|"Participants will follow specified diet requirements.~Macronutrient targets for the Mediterranean diet will be approximately 40% of energy from fat (8.5% from saturated fat), 20% of energy from protein, and 40% from carbohydrates (40 g fiber/d for an average 2000 kcal/d diet)."
75779142|NCT04989075|Other|Oral prophylactic intervention|The oral prophylactic intervention will consist of the provision of specific package including a soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
75322224|NCT03089294|Device|Aries ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
75322225|NCT04385329|Other|Shock wave therapy on plantar fascia extended to the gastrocnemius-soleus trigger points|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia and the gastrocnemius-soleus trigger points were clinically targeted and treated with a perpendicular technique.
75322226|NCT04385329|Other|Shock wave therapy on plantar fascia only|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia was clinically targeted and treated with a perpendicular technique.
75322227|NCT03082430|Biological|autologous PRP.|one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
75322228|NCT03082352|Drug|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
75779143|NCT04982796|Drug|Psilocybin|See description of psilocybin-enhanced psychotherapy arm.
75779144|NCT04982796|Behavioral|Treatment-as-usual|See description of treatment-as-usual arm.
75779145|NCT04975867|Other|Targeted therapeutic hypothermia|Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
75779146|NCT04975867|Other|Targeted therapeutic normothermia|Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
75779147|NCT04969536|Dietary Supplement|Branched Chain Amino Acids|Supplementation with 8 g Nutrex Research Amino Acid Drive BCAA in 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
75626816|NCT04161820|Behavioral|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later.
75914948|NCT04242069|Behavioral|Healthy for my Baby|"Participants will start the preconception intervention by meeting with a health professional for a motivational interview session on healthy lifestyle habits. Following this interview, participants will have access to a mobile phone application that will allow them to track daily lifestyle modification goals. After a month, they will meet the health professional for a second motivational interview and review their progression. Participants will continue to make lifestyle changes through the preconception period by accomplishing smart goals followed daily in the mobile phone application.~If the woman becomes pregnant, the couple will participate in two more in-person motivational interviews, a month apart. The mobile application will be put in pregnancy mode, and participants will adapt their daily lifestyle goals for the pregnancy. Participants will continue to make lifestyle changes throughout pregnancy by accomplishing smart goals followed daily in the mobile phone application."
75322229|NCT03082352|Drug|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
75322230|NCT02290509|Biological|Flublok Quadrivalent|Intramuscular injection of study vaccine
75322231|NCT02290509|Biological|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
75322232|NCT03089450|Device|CGBio stent|Percutaneous Coronary Intervention
75322233|NCT03089450|Device|Biomatrix flex|Percutaneous Coronary Intervention
75322234|NCT03082274|Diagnostic Test|ConfirmMDx|ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.
75322235|NCT03082274|Diagnostic Test|SelectMDx|SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
75779148|NCT04969536|Other|Placebo|Supplementation with 2.0 milliliters of a sucralose-based drink mix with 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
75779149|NCT04941911|Drug|Octreotide Acetate|Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.
75779150|NCT04941911|Other|Placebo|Sodium chloride 0.9% w/v
75779151|NCT04906668|Procedure|Cryoballoon pulmonary-vein isolation|Electrical isolation of the pulmonary-veins using cryoenergy
75779152|NCT04906668|Procedure|Pacemaker implantation and ablation of atrioventricular-node|Pacemaker implantation and ablation of atrioventricular-node
75779153|NCT04875936|Behavioral|Motor Imagery and Real-Time fMRI Neurofeedback|Survivors of left-hemisphere stroke (<10 weeks post-stroke) or healthy volunteers will use right-hand motor imagery coupled with fMRI neurofeedback to help them re-engage the left hemisphere by shifting brain activation leftward relative to the initial left-right asymmetry. Following group assignment, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. During the MRI sessions they will receive real time neurofeedback about how well they are engaging the left side of their brain compared to the right side. They will also practice the same task for 30 min a day as homework using the most effective motor imagery strategy that worked for them in the MRI scanner.
75914949|NCT04242069|Other|Usual Care|"Participants in the control group will receive standard advice on healthy lifestyle habits as provided by their usual care provider. They will receive standard medical care in preconception and pregnancy.~To improve compliance with the study follow-up, participants in this group will have access to a simplified version of the mobile application that contains a fertility calendar and a research visit calendar. This version of the application does not include lifestyle goals or any information on healthy lifestyle habits."
75467082|NCT01916473|Other|Continuous wound infusion|Continuous wound infusion via catheter
75626817|NCT04161976|Drug|LY900027|LY900027 administered to participants with T1DM using CSII.
75322236|NCT05736393|Device|Back Exosuit|The device is worn like a backpack. It weighs 6 pounds. Participants will be able to perform movements naturally in the device. A ribbon serves as an external muscle to reduce the load and effort during lifting. As participants bend forward, the device assists the participant by supporting some of their body weight by gently pulling back. As participants stand up, the device assists them by gently pulling their trunk upright. Participants will feel the level of assistance change slightly as they move faster or slower. Participants will use this device during 20-40 minutes of physical therapy exercises during 12 visits over 4-6 weeks. Once it is fit and adjusted to each participant's comfort, the physical therapist will control the level of assistance the device provides similarly to how they would adapt any given exercise. Participants may start with more assistance and wean down over the course of the study.
75322237|NCT04402034|Behavioral|Application of tele-rehabilitation|Individuals that will perform the virtual reality intervention.
75626818|NCT04161976|Drug|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII.
75322238|NCT03089528|Device|Videolaryngoscopy|the trachea will be intubated with a videolaryngoscope
75626819|NCT04159558|Device|Mobile application|Experimental group will use a mobile application to help them in their self-care
75626820|NCT04163068|Other|Interview|The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed
75626821|NCT02634424|Device|MyPKFiT|Adjustment of the treatment dose using a decision support software according to the PK values
75626822|NCT00656422|Drug|insulin Levemir|The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
75626823|NCT00656422|Drug|insulin Lantus|The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
75626824|NCT00881608|Drug|Placebo|Placebo, 1 capsule daily for five days
75626825|NCT00881608|Drug|Proellex|Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
75626826|NCT04162912|Behavioral|Motivational Interviewing tailored Advance Care Planning|The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
75626827|NCT02636764|Other|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
75626828|NCT02636764|Device|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
75322239|NCT03089528|Device|laringoscope|the trachea will be intubated with a laringoscope
75322240|NCT00618839|Biological|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
75626829|NCT02636764|Device|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
75626830|NCT02636764|Device|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
75626831|NCT02636764|Device|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
75626832|NCT00657670|Device|Ready-made spectacles|Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
75626833|NCT00657670|Device|Spectacles|Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
75626834|NCT02632630|Drug|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
75914950|NCT04234997|Drug|Suvorexant 20 mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
75914951|NCT04234997|Drug|Suvorexant 0mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
75914952|NCT04234373|Other|Low Carb diet|Low Carb diet (max. 130g carbohydrates/d) for 6 months
75914953|NCT04233957|Dietary Supplement|High Sodium|10 days of 3900 mg of sodium/day in excess of normal dietary intake delivered via enteric capsules filled with table salt.
76074198|NCT01980095|Drug|RHB-105|"The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~Rifabutin 150 mg~Amoxicillin 3000 mg~Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days."
76074199|NCT01980095|Drug|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
75322241|NCT00618839|Procedure|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
75626835|NCT02632630|Dietary Supplement|Ensure product|Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
75626836|NCT02632630|Drug|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
75626837|NCT02632630|Dietary Supplement|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
75626838|NCT02634034|Drug|A: NK-104-CR 8 mg|NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
75626839|NCT02634034|Drug|B: Pitavastatin IR 4 mg|Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
75914954|NCT04233957|Other|Placebo|10 days of enteric capsules filled with dextrose.
75914955|NCT04227665|Other|Sea level|Sea level exposure / sea level exposure combined with microdoses of rHuEPO
75914956|NCT04227665|Other|Altitude|Altitude exposure / altitude exposure Iron metabolism
75914957|NCT04218201|Behavioral|PCP brief advice|Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. The summary advises the PCP that their patient participant screened positive for risky opioid use, lists the patient participant's screening results (TAPS Tool +/- COMM) and gives a suggested counseling script. The counseling script will include specific advice on opioid-related risks, will inform patient participants of resources to help them reduce their risk, and will include a recommendation to reduce their risk behavior.
75626840|NCT02634034|Drug|C: Pitavastatin IR 8 mg|Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
75626841|NCT00657748|Drug|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
75626842|NCT02636686|Drug|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
75626843|NCT02634190|Other|Thinprep® LBC|liquid based cytology
75626844|NCT02634190|Other|APTIMA® HPV Assay|in vitro diagnostic test
75626845|NCT02634190|Other|HR HC2® HPV DNA|in vitro diagnostic test
75626846|NCT02634190|Other|Colposcopy|Colposcopy
75626847|NCT04161586|Drug|Prilocaine Hydrochloride|Spinal Prilocaine for Ambulatory Surgery
75914958|NCT04218201|Behavioral|Video doctor|During the baseline visit with the research staff, patient participants will view a video on tablet or desktop computer that reinforces the PCP's counseling. The video is a recording of a provider delivering brief advice about opioid use that includes the same elements covered in the summary report outlined above.
76074200|NCT04667741|Other|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
76074201|NCT01980017|Behavioral|Ottawa Model for Smoking Cessation|
76074202|NCT04416347|Other|SARS-CoV2 Infection|Laboratory confirmed SARS-CoV2
76074203|NCT04659707|Drug|Hyperpolarized Xe129|Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
76074204|NCT01978145|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
76074205|NCT01978145|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
76074206|NCT01967537|Drug|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
75626848|NCT02636452|Other|cardiopulmonary exercise test|
76074207|NCT01967537|Procedure|Radio-guided surgery|Using 68Gallium DOTATATE
76074208|NCT01967225|Drug|Tedizolid Phosphate (Sivextro, BAY1192631)|BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
76074209|NCT01967225|Drug|Linezolid|Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
76074210|NCT01967147|Drug|Propylene Glycol, 0.6% eye drops|Commercially available eye drops used during Treatment Phase
76074211|NCT01967147|Drug|Preservative-free 0.9% Saline solution|Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
75322242|NCT03089372|Device|ARIES-ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
75626849|NCT02636218|Drug|Ketamine|500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
75626850|NCT02636218|Drug|0.9% NaCl|500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
76074212|NCT01967069|Drug|DFD01 Spray|
76074213|NCT01967069|Drug|Vehicle Spray|
75322243|NCT03082040|Behavioral|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
75322244|NCT03089138|Drug|Regan Tangjiang|The treatment duration is 3 consecutive days.
75626851|NCT01088399|Drug|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
76074214|NCT01790503|Drug|PLX3397|
76074215|NCT01790503|Radiation|Radiation Therapy|
75322245|NCT03082118|Device|Vesair Bladder Control System|Intravesical balloon
75626852|NCT04161508|Drug|Sugammadex Injection|injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery
75626853|NCT04161508|Drug|Neostigmine Injection|injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
75626854|NCT00598078|Drug|Sodium Oxybate|Dose 1
75626855|NCT00598078|Drug|Sodium Oxybate|Dose 2
75626856|NCT00598078|Other|Placebo|Dose 3
75626857|NCT02636296|Other|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
75626858|NCT02636296|Other|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
76074216|NCT01790503|Drug|Temozolomide|
76074217|NCT01790113|Device|Univers™|Control
76074218|NCT01790113|Device|Eclipse™ Total Shoulder Replacement|Investigational
76074219|NCT01789567|Device|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
75626859|NCT00656500|Behavioral|Standard brief advice|Brief general assistance with smoking cessation
75626860|NCT00656500|Behavioral|Quitline intervention|Brief intervention designed specifically to encourage quitline utilization
75626861|NCT00883558|Drug|Insulin Lispro|
75626862|NCT00883558|Drug|regular human insulin|
75626863|NCT00883558|Drug|recombinant human hyaluronidase PH20|
75626864|NCT00883558|Drug|Insulin glargine|
75626865|NCT04162834|Drug|Papaverine|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
75626866|NCT04162834|Drug|Normal saline|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
75626867|NCT00656578|Drug|4975|Single dose, solution
75626868|NCT00656578|Drug|Placebo|Single dose, solution
75626869|NCT00657904|Drug|Bicalutamide|150mg daily
75626870|NCT00657904|Drug|Placebo|once daily
75626871|NCT04161196|Procedure|tonsil pillars suturing|The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
75626872|NCT04161196|Procedure|tonsillectomy without tonsil pillars suturing|tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
75626873|NCT00880750|Drug|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
75914959|NCT04218201|Behavioral|Telephone health coaching|All patient participants in the STOP arm will receive telephonic health coaching sessions at approximately 2- and 4-weeks post-baseline. Patient participants who may benefit from additional coaching (for example, those who do not improve or who experience clinical worsening of unhealthy opioid use) may receive additional coaching sessions (approximately 4 sessions) from the telephone health coach. Coaching is delivered from a centralized call center, by staff that receive standardized training and supervision. To the extent possible, calls will be scheduled at the patient participant's convenience (e.g., evenings, weekends).
75626874|NCT00880750|Drug|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
75626875|NCT02636374|Behavioral|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
75626876|NCT02535676|Device|Transcranial Direct Current Stimulation|The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
75626877|NCT02633878|Drug|Chinese Herbal Medicine plus Progesterone Capsules|"New Shoutai Pill Granules plus Micronized Progesterone Capsules"
75626878|NCT02633878|Drug|Chinese Herbal Medicine Placebo plus Progesterone Capsules Placebo|"New Shoutai Pill Granules Placebo plus Micronized Progesterone Capsules Placebo"
75626879|NCT02633878|Drug|Chinese Herbal Medicine plus Progesterone Capsules Placebo|"New Shoutai Pill Granules plus Micronized Progesterone Capsules Placebo"
75626880|NCT02633878|Drug|Chinese Herbal Medicine Placebo plus Micronized Progesterone|"New Shoutai Pill Granules Placebo plus Micronized Progesterone Capsules"
75626881|NCT02877797|Device|Cap|cap assisted esophagogastroduodenoscopy
75626882|NCT00597766|Drug|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
76074220|NCT01765543|Drug|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
76074221|NCT01765543|Drug|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
76074222|NCT01765153|Behavioral|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
75322246|NCT03081962|Drug|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
75467083|NCT01916486|Behavioral|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
75467084|NCT01916486|Behavioral|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
75626883|NCT00597766|Drug|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
75626884|NCT00597766|Drug|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
75626885|NCT00597766|Drug|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
75626886|NCT02877563|Other|Contrast ultrasound perfusion imaging of the limb|Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
75626887|NCT04159090|Diagnostic Test|F18-PSMA|Patients with moderate or high risk of prostate cancer
75626888|NCT04161274|Procedure|Traditional method: Electrosurgery|"The patient will be prepared before this technique by removing all metal objects in his possession. The area should be disinfected with a local antiseptic, leaving the area aseptic. Afterwards, perilesional infiltrated local anaesthesia (subcutaneous or intradermal) will be applied. Once the area has been anaesthetised, excision is made with scissors cutting through the most proximal part of the skin tag pendulum and the lesion is coagulated with the handle or knife of the electrocoagulator (previously regulated with the intensity in coagulation mode). The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight."
75322247|NCT03081962|Procedure|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
75322248|NCT05345756|Device|Intraoral protraction device|Use of modified lingual arch with indirect anchorage from screws between lower lateral incisor and lower canine to protract maxilla after ALT-RAMEC protocol
75322249|NCT05345756|Device|Extraoral protraction device|Facemask which is an extraoral appliance used for maxillary protraction
75322250|NCT05736315|Other|Placebo dairy beverage|Placebo dairy beverage (placebo) is a sweetened dairy beverage.
75626889|NCT04161274|Procedure|Traditional method: Cryotherapy|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. for a few minutes the tip of an Adson forceps will be introduced in a container with liquid nitrogen until freezing. It will then be applied to the most proximal part of the skin tag pendulum until it is observed that the frostbite has reached the base of the lesion and the surface becomes whitish, with a halo of 1-3 mm. When this happens, it will be excise above the frost part in the pendulum. After application, it is disinfected with povidone- iodine and covered with a protective dressing of sterile occlusive gauze plaster. It will then form an eschar. Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight.
75626890|NCT04161274|Procedure|Traditional method: Silver nitrate|"The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag cutting through the most proximal part of the skin tag pendulum, then cauterized with the tip of the silver nitrate rod, trying not to apply in the perilesional zone.~The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or solar rays."
75626891|NCT04161274|Procedure|Moist healing environment method|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag by cutting through the most proximal part of the pendulum of the skin tag, later it will be disinfected with chlorhexidine and thin hydrocolloid dressing will be placed. Indications to the patient: the project participant will be told not to touch the dressing until the next control after 3 days with the research team. In case of incidents with the dressing (fall of the dressing), the patient will be given a replacement dressing for this purpose and be able to restore it immediately. It is recommended not to expose the area to the solar rays
75626892|NCT00657982|Drug|RAD001|10mg BID
75626893|NCT04159246|Device|Optical coherence tomography angiography|"Recent Optical coherence tomography angiography OCT-A will be performed to all patients before Treatment Administration.~Examination will be performed using Optovue AngioVue® Optovue, Inc., Fremont, CA, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.~The patient will be examined before and after finishing the treatment course"
75626894|NCT04159246|Drug|Sofosbuvir (Sovaldi)|Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months
75626895|NCT02636140|Other|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
75626896|NCT02633722|Behavioral|Lifestyle intervention B|Time limiting feeding from 8-5pm (TRFb)
75626897|NCT02633722|Behavioral|Lifestyle Intervention D|Time limiting feeding (12-9pm)
75626898|NCT02633566|Device|Plantar orthoses|
75779154|NCT04875936|Behavioral|Motor Imagery and Sham fMRI Neurofeedback|Survivors of left-hemisphere stroke (<10 weeks post-stroke) or healthy volunteers will practice right-hand motor imagery coupled with sham fMRI neurofeedback. As the experimental group, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. However, during the MRI sessions they will receive sham neurofeedback on the basis of another participant's brain activity. Like the experimental group, they will also practice the same task for 30 min a day as homework.
75779155|NCT04862676|Drug|Hyperbaric oxygen|The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes are spent during the compression and decompression phases and subjects have 5-10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
75779156|NCT04858490|Drug|Diazepam|Symptom-triggered diazepam treatment: 10 or 20mg, at the clinician's discretion
76074223|NCT01765153|Behavioral|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
76074224|NCT00248170|Drug|Letrozole|2.5 mg tablets
75467085|NCT01916486|Behavioral|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
76074225|NCT00248170|Drug|Anastrozole|1 mg tablets
75322251|NCT03088982|Other|Questionnaire|"FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.~The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity."
75467086|NCT01916499|Other|3 tesla magnetic resonance imaging findings; coronary artery status|
76074226|NCT01764997|Drug|Sarilumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
76074227|NCT01764997|Drug|Etanercept|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
76074228|NCT01764997|Drug|Methotrexate|Dispensed according to local practice.
76074229|NCT01764997|Drug|Placebo (for sarilumab)|
75914960|NCT04218201|Behavioral|Nurse Care Manager (NCM) intervention|NCMs will provide health education and counseling on risk reduction, overdose prevention and self-management skills. Patient participants will be asked to participate in a baseline visit with the NCM, which will occur on the same day as the baseline research visit if possible. The NCM continues working with patients in the STOP condition throughout their 12 months of study participation. Following the initial visit with the NCM, the frequency of visits depends on patient participant needs.
75322252|NCT03088904|Biological|FluMist® Quadrivalent|LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
75626899|NCT02633410|Procedure|Femoral tunnel creation|Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
75626900|NCT02633254|Device|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
75626901|NCT04160962|Procedure|lappg|Laparoscopic gastrectomy for pylorus preservation
75626902|NCT03960996|Procedure|dacryocystorinostomy|Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.
75626903|NCT04290156|Other|joint visits|The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist. One-year intervention period was chosen. In total, there are four joint visits every third months for the adolescents aged 17-18. Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit. Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
75626904|NCT00657124|Dietary Supplement|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
75626905|NCT00657124|Dietary Supplement|Placebo|placebo
75626906|NCT00658294|Other|Stop treatment|
75914961|NCT04212247|Behavioral|Well-Being Therapy|Well-Being Therapy (WBT) is a short-term psychotherapeutic strategy, that emphasizes self-observation with the use of a structured diary, interaction between patients and therapists and homework. WBT was based on the model of psychological well-being that was originally developed by Jahoda in 1958 and further refined by Ryff in 2014. The standard number of sessions is 8. The initial phase is concerned with self-observation of psychological well-being. Then, the patient is encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of wellbeing. The final part involves cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
76074230|NCT01764997|Drug|Placebo (for etanercept)|
76074231|NCT01764997|Drug|Adalimumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
76074232|NCT01276756|Drug|Pegylated interferon alfa-2a|Pegylated interferon 160ug once weekly 48 weeks
75322253|NCT03088904|Biological|Fluzone® Quadrivalent vaccine|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
75322254|NCT04768491|Drug|Dacomitinib|effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
75467087|NCT01916499|Other|3 tesla magnetic resonance imaging findings; ventricular function and morphology|
75467088|NCT01916525|Behavioral|Exercise based cardiac rehabilitation|The cost-effectiveness between the exercise training vs. control groups
75626907|NCT02866500|Behavioral|Quality of life survey/ dental statement|Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
75626908|NCT04080024|Drug|SN132D|Novel manganese-based macromolecular MRI contrast agent
75626909|NCT00979992|Other|Laboratory Biomarker Analysis|Correlative studies
75626910|NCT00979992|Drug|Sunitinib Malate|Given PO
75626911|NCT01079741|Biological|NY-ESO-1 protein; Poly-ICLC; Montanide|"Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.~Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B)."
75626912|NCT04289220|Biological|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-2.5x10^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
75626913|NCT02877641|Dietary Supplement|Cholecalciferol|Given PO
75626914|NCT02877641|Other|Laboratory Biomarker Analysis|Correlative studies
75626915|NCT02877641|Dietary Supplement|Multivitamin|Given PO
75626916|NCT02877641|Other|Placebo|Given PO
75626917|NCT02877641|Other|Questionnaire Administration|Ancillary studies
75626918|NCT01079663|Drug|Chlorhexidine 2.5 mg|
75626919|NCT01079663|Drug|Placebo chip|
75779157|NCT04856865|Biological|ADP101 vs Placebo Dose Regimen A|Active powder formulation at various volumes. Placebo powder formulation at various volumes.
75779158|NCT04856865|Biological|ADP101 vs Placebo Dose Regimen B|Active powder formulation at various volumes. Placebo powder formulation at various volumes.
75779159|NCT04855240|Drug|ACP-044 Dose A|Oral dose of ACP-044 Dose A
75779160|NCT04855240|Drug|ACP-044 Dose B|Oral dose of ACP-044 Dose B
75779161|NCT04855240|Drug|Placebo|Oral dose of placebo
75779162|NCT04850612|Other|Survey|Delphi Survey on core outcomes, CSDH definition and data elements
75467089|NCT01916564|Other|Split-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy"
75626920|NCT02867046|Drug|S1 transforaminal epidural steroid(dexamethasone) injection|"medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen"
75914962|NCT04212247|Behavioral|Control condition|The control condition will include 8 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drug misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
75914963|NCT04211207|Other|non invasive monitoring value|heart's respiratory quotient as non invasive monitoring value
75914964|NCT04204707|Other|PROMS|Patient Reported Outcomes after different types of surgery for rectal endometriosis
75914965|NCT04197362|Other|Evaluation|Subjects will be asked to walk across the gait laboratory floor at their self-selected walking speed. They will complete a 3-5 minute warm up period, as it was found to produce stable estimates of kinetic parameter mean values during treadmill activity. The positions of each marker will be recorded through the motion capture system. Ground reaction force will be obtained in real time from the gait laboratory force plates as marker dimensions are recorded. For walking data, two trials of 15 seconds each will be recorded. The second trial will be a redundancy in the setting of potential significant marker dropout.
75322255|NCT05374863|Device|Neuromuscular electrical stimulation (NMES) - Active|The NMES will be held for 20 minutes. Biceps musculature and bilateral wrist and finger flexors stimulated. For patients undergoing hemodialysis for fistula in the upper limb, NMES will be performed only in the limb without a fistula. points of points 4 electrodes in each, being 2 points of longitudinal position in the muscular belly of the biceps, and other 2 in the ventral region of the forearm. the parameters: frequency of 80 Hz, pulse frequency of 350 ms, time of 5 seconds and 10 seconds. The possibility will be greater for each patient who will have the contraction. Patients will be instructed to perform an isometric contraction of wrist and finger flexors during electrical stimulation.
75467090|NCT01916564|Other|Same-morning whole-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy"
75467091|NCT01916577|Drug|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
75914966|NCT04192695|Device|Cytosponge cell collection device|The Cytosponge™ is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus. Cytosponge™ has excellent safety profile and is approved by the Food and Drug Administration (FDA) and the Healthcare Products Regulatory Agency (HPRA) in the UK.
75914967|NCT04189406|Other|Venapunction|A blood sample of 3.5 mL (0.2 mL serum for FSH and LH, 0.15 mL serum for E2, 0.15 mL serum for T, 0.15 mL serum for AMH and 0.25 mL serum for Inhibin B) will be collected of all girls with TS at 3 months and 9 months of age. For the girls with TS, this will be collected with an extra venapuncture during a regular outpatient visit within the usual care.
75914968|NCT04187404|Biological|EO2401|Multiple dose of EO2401
75914969|NCT04187404|Biological|Nivolumab|Multiple dose of nivolumab
75914970|NCT04185545|Biological|Rotavirus RV3 Vaccine (Bio Farma)|Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains > 5x10^6 fcfu/mL rotavirus vaccine strain RV3
75914971|NCT04185545|Other|Placebo|Each 1 mL dose of placebo contains 30% of sucrose in DMEM
75914972|NCT04181710|Procedure|Kidney transplant|Organ preserved in preservation solution
76074233|NCT01276756|Drug|Nitazoxanide|Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
76074234|NCT01276756|Drug|Ribavirin|Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
76074235|NCT00246376|Behavioral|Diet|ATP-III diet
76074236|NCT00246376|Behavioral|Exercise|Supervised exercise in study gym
76074237|NCT00246376|Drug|Niacin|Niaspan, titrated up to 2 grams per day
75322256|NCT05374863|Device|Neuromuscular Electrical Stimulation (NMES) - Sham|It will be performed in the same way as in the experimental group, however, the intensity of the actuality will only reach the sensitive threshold.
75467092|NCT01916603|Behavioral|Normative Intervention|Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
75626921|NCT02865174|Drug|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
76074238|NCT00246376|Drug|Fenofibrate|Tricor, 120 mg per day
75914973|NCT04177498|Drug|Rigosertib Sodium|given PO or 72 hour continuous infusion
75914974|NCT04177498|Other|Quality-of-Life Assessment|Ancillary studies
75914975|NCT04171297|Procedure|Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.
75914976|NCT04160858|Other|Exercise|Spinal Cord Injury Exercise Guidelines: Participants will begin at the Starting Level which is 20 mins of moderate to vigorous aerobic activity 2x/week & 3 sets of 10 repeats of strength training 2x/week. They will progress to Advanced Level which is 30 mins of moderate to vigorous aerobic activity 3x/week and 3 sets of 10 repetitions of strength training 2x/week. The intervention duration is 6 months.
75914977|NCT04160858|Other|Control|Wait-list control
76074239|NCT00246376|Other|Placebos|Placebos for Niaspan and Tricor
76074240|NCT03806218|Device|Bipolar RFA|Bipolar RFA in which RF currents flow between two electrodes
75626922|NCT02865174|Drug|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
75626923|NCT02865174|Drug|Enoxaparin|Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
75626924|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
75779163|NCT04824443|Other|Aerobic Exercise Therapy|Aerobic Exercise Therapy/AT will consist of 30 weeks of treadmill walking sessions. AT will consist of supervised, individualized walking delivered up to 6 times weekly (over a 7-day period) to achieve a cumulative total duration ranging from 90 mins/wk up to 375 mins/wk following a non-linear dosing schedule. The planned dose and scheduling of AT will be continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period (i.e., non-linear periodized schedule).
75914978|NCT04160741|Other|Radiation and warm environment|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
75914979|NCT04160741|Other|Warm environment|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
75914980|NCT04160741|Radiation|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
75914981|NCT04160741|Other|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
75914982|NCT04160728|Other|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
75914983|NCT04160728|Other|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
75467093|NCT01916616|Behavioral|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
75467094|NCT01916642|Drug|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
75467095|NCT01916642|Drug|Lidocaine 1.5mg/kg|same as other
75467096|NCT01916642|Drug|Lidocaine 2mg/kg|same as other
75467097|NCT01916642|Drug|Lidocaine 2.5mg/kg|same as other
75626925|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
75626926|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
75626927|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
75626928|NCT02633176|Drug|Cetuximab|400 mg/m^2 intravenously on day 1,then 250 mg/m^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m^2 intravenously every week concurrent with radiotherapy.
75914984|NCT04160728|Other|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts
75467098|NCT01916694|Device|Blue tooth enabled glucose meter with smart phone application|
75467099|NCT01916694|Behavioral|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
75467100|NCT01916707|Drug|Dosing of enoxaparin for VTE prophylaxis|
75467101|NCT01916720|Drug|SB-480848 40 mg|Study Drug
75914985|NCT04160728|Other|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
75914986|NCT04160728|Other|Business as usual scenario|No interference with the usual work day of the participants
75914987|NCT04160728|Other|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
75914988|NCT04159389|Other|Mental visualization|Instruction in mental visualization by theoretical lessons and support of practice by audio guide and session of experience sharing.
76074241|NCT03806218|Device|SM-RFA|Monopolar RFA using multiple electrodes with switching mode
75467102|NCT01916720|Drug|SB-480848 80 mg|Study Drug
75467103|NCT01916720|Drug|Placebo|Study Drug
75626929|NCT02633176|Drug|Cisplatin|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m^2 intravenously every week concurrent with radiotherapy.
75626930|NCT02633176|Drug|Docetaxel|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
75626931|NCT02633176|Drug|Capecitabine|1000mg/m^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
75626932|NCT02633176|Radiation|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
75626933|NCT04156984|Drug|Golimumab Prefilled Syringe|See arm description
75626934|NCT04157140|Drug|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
75626935|NCT04157140|Device|TACE+RFA|TACE first, followed by RFA within day7（+/-3days）
75779164|NCT04809623|Drug|Edecesertib|Tablets administered orally
75779165|NCT04809623|Drug|Placebo|Placebo to match edecesertib tablets administered orally
75779166|NCT04797195|Other|CKD-PD app with home monitoring equipment|use home monitoring equipment to measure blood pressure, body weight, and dialysate fluid volume and record in CKD-PD app
75779167|NCT04790032|Drug|Cangrelor|All patients receiving Cangrelor during PCI will be enrolled and analyzed for platelet function tests.
75914989|NCT04159220|Procedure|Clamping of the ventilator endotracheal tube|The transport will be released in accordance with SFAR SRLF guideline. Before each disconnection from ventilator endotracheal tube will be clamped.
75914990|NCT04155281|Other|urine analysis|New Psychoactive Substances research in urine at admission in unit care
76074242|NCT03806218|Device|Twin internally cooled-wet electrodes|Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
75322257|NCT05374863|Device|Aerobic exercise with cycle ergometer|The exercise will be performed from the adaptation and positioning of a cycle ergometer (Mini Bike E5 Acte Sports®) in front of the hemodialysis chair. Each session will consist of three phases: duration (5 minutes), conditioning (20 minutes) and cool-down (5 minutes). During the development and cool-down phases, patients will be instructed to maintain a lower exercise intensity, with a level between 1 and 3 on the modified BORG scale. In the conditioning phase, patients will be instructed to slightly increase the intensity of the exercise, levels between 4 and 7 on the modified BORG scale. During exercise, patients will be asked every 5 minutes about the level of effort, and the load on the cycle ergometer will be possible to reach an intensity between 4 and 7 on the modified Borg Scale.
75322258|NCT03081572|Diagnostic Test|Platelet aggregation|Platelet aggregation
75322259|NCT03398252|Drug|Doxazosin XL|Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
75322260|NCT03398252|Drug|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
75626936|NCT04158778|Drug|MDMA|Two sessions of MDMA-assisted psychotherapy will take place (session 3 & 7) within the 10 week course of psychotherapy. An initial dose of 125mg MDMA will be followed by an optional dose of 62.5mg 2 hours later.
75626937|NCT04158778|Other|Psychotherapy|Two sessions of MDMA-assisted psychotherapy will take place (session 3 & 7) within the 10 week course of psychotherapy.
75626938|NCT01132664|Drug|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
75626939|NCT01132664|Drug|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
75626940|NCT01132664|Drug|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
75626941|NCT00591409|Drug|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."
75626942|NCT00591409|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered"
76074243|NCT03806218|Device|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
75626943|NCT02610361|Drug|BGB-283|"In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types"
75626944|NCT05756101|Device|Research on the application of novel restraint devices in postoperative patient safety management in cardiac surgery|According to the individual characteristics of ICU patients and the needs of patients, a new type of restraint device was innovatively made and the effectiveness and safety of the new restraint device were studied, which provided clinical reference and theoretical basis for standardizing postoperative patient restraint.
75779168|NCT04788303|Other|School meal, garden, education, and community workshops|"School meal: midday meal provided at intervention schools~School garden: garden used to grow crops (which will be used to supplement the school meal in the full intervention schools)~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
75779169|NCT04788303|Other|Garden, education, and community workshops|"School garden: garden used to grow crops~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
75779170|NCT04779879|Biological|Sotrovimab (Gen1)|Participants will be randomized to receive an IV infusion of Sotrovimab Gen 1 material
75914991|NCT04154865|Other|Hypercapnia|Eligible subjects will undergo transcranial Doppler assessment before and after hypercapnia exposure.
75322261|NCT04402268|Device|Cardioverter-defibrillator|We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.
75322262|NCT02285283|Drug|Itraconazole|
75914992|NCT04154865|Device|Transcranial Doppler|A transcranial Doppler ultrasound probe will be used to assess middle cerebral artery velocity to quantify cerebral blood flow at various time points throughout the study visit.
75322263|NCT02285283|Drug|Placebo|
75322264|NCT02285907|Other|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
75779171|NCT04779879|Biological|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion or by IM injection
75779172|NCT04779879|Biological|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion
75626945|NCT00709345|Behavioral|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
75626946|NCT00709345|Behavioral|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
75626947|NCT01078805|Drug|FORTEO|prescribed in accordance with usual clinical practice for up to 24 months
75914993|NCT04154865|Device|Cycle ergometer|A cycle ergometer will be used to acutely increase cerebral blood flow.
75914994|NCT04154865|Other|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
75626948|NCT00626249|Drug|Technosphere Inhalation Powder|Technosphere Inhalation Powder
75626949|NCT02876939|Other|kinesiology tape around the hip, knee and ankle joints|We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
75626950|NCT02876939|Other|No kinesiology tape around the hip, knee and ankle joints|Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
75626951|NCT00820027|Drug|Etoricoxib 90 mg|One 90 mg tablet once daily
75626952|NCT00820027|Drug|Etoricoxib 120 mg|Two 60 mg tablets once daily
75779173|NCT04768101|Drug|[11C]-PIB|[11C]-PIB is a PET radiotracer used to evaluate levels of Αβ burden.
75779174|NCT04753073|Procedure|Non-invasive physical plasma|Treatment with non invasive physical low-temperature plasma
75626953|NCT00820027|Drug|Ibuprofen 600 mg|One tablet three times daily
75779175|NCT04751968|Other|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
76074244|NCT03806062|Drug|domperidone|10 mg domperidone 3 times a day after meals
75779176|NCT04751968|Behavioral|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
75626954|NCT00820027|Drug|Matching Placebo for Etoricoxib 120 mg|Two tablets once daily
75626955|NCT00820027|Drug|Matching Placebo for Etoricoxib 90 mg|One tablet once daily
75779177|NCT04701073|Device|LombaStab belt|"Instruction given to the patient will be to wear the LombaStab belt from 4 to 8 hours per days, over the whole duration of the study (12 weeks). The investigator will explain to the patient how to adjust it.~The LombaStab belt will be equiped with thermosensor to evaluate the belt wearing time at the end of the study."
75779178|NCT04695860|Drug|Burosumab|Q4w, 1mg/kg Body weight, s.c.
75914995|NCT04153838|Other|Cognitive test administration|Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
75626956|NCT00820027|Drug|Matching Placebo for Ibuprofen|One tablet three times daily
75626957|NCT00820027|Drug|Morphine|As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
75626958|NCT00820027|Drug|Oxycodone|5 mg as needed
75626959|NCT02877407|Procedure|patient who undergo laparoscopic/robotic-assisted hysteropexy|
75626960|NCT02877407|Procedure|patient who undergo vaginal hysterectomy|
75914996|NCT04151472|Drug|Placebo|Placebo oral tablet, three times a day
75914997|NCT04151472|Drug|90mg Idebenone|Idebenone 30 MG Oral Tablet, three times a day
76074245|NCT03806062|Device|He-Ne laser (Bravo TrezaSerie) device|The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session
76074246|NCT03806062|Device|faradic current|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
75626961|NCT02876549|Drug|Chloroquine|10 mg/kg on day 0 & 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
75626962|NCT02876549|Drug|Primaquine 0.25 mg/kg/day|0.25 mg/kg/day for 14 days
75626963|NCT02876549|Drug|Primaquine 0.75 mg/kg weekly|0.75 mg/kg weekly for eight weeks
75626964|NCT02876627|Behavioral|Exercise training|twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
75626965|NCT00913549|Drug|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|
75626966|NCT00913549|Drug|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)|
75779179|NCT04693806|Other|Continuous CO2 Level|Embryos will be cultured in a single, continuous CO2 setting
75914998|NCT04151472|Drug|270mg Idebenone|Idebenone 90 MG Oral Tablet, three times a day
75914999|NCT04151433|Procedure|Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).|cf. different arms
75626967|NCT01076153|Drug|Clarithromycin (Klacid® MR)|Klacid MR 500mg (clarithromycin)
75626968|NCT01076075|Drug|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
75626969|NCT01076075|Drug|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
75915000|NCT04147247|Drug|BI 905681|Infusion
75915001|NCT04144907|Dietary Supplement|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
75626970|NCT01076075|Drug|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
75626971|NCT01076075|Drug|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
75626972|NCT01076075|Drug|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
75915002|NCT04136769|Procedure|Visceral Debranching|Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
75915003|NCT04132284|Behavioral|DBT-Based Parenting Intervention|The intervention will consist of 8-10 individual parent sessions, to be completed within one week after the teen completes the IOP program. Sessions will be 1 hour in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 10. Sessions will follow the standard agenda used for DBT skills training: 1) mindfulness practice, 2) homework review, 3) teaching of a new skill; 4) practice of the new skill; and 5) assignment of new homework (Linehan, 1993). The intervention will utilize the Middle Path module of the DBT Skills Manual for Adolescents (Rathus & Miller, 2015), which was created by the developers of DBT for adolescents and includes both instructions for therapists and handouts for clients.
75915004|NCT04132284|Behavioral|Treatment as Usual|No parenting intervention provided beyond standard practices in DBT IOP program.
75626973|NCT01076075|Drug|Metformin|"Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin"
75626974|NCT01076075|Drug|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
75467104|NCT01916733|Drug|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
75626975|NCT01075763|Drug|Interferon beta-1a|Interferon (IFN) beta-1a [Rebif® 22 microgram (mcg), three times per week (tiw)] administered subcutaneously (sc)
75626976|NCT01075763|Drug|Placebo|The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
75626977|NCT00881530|Drug|BI 10773|BI 10773 high dose once daily
75626978|NCT00881530|Drug|Metformin|open label comparator
75915005|NCT04130438|Drug|Nebivolol|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
75915006|NCT04130438|Drug|Diltiazem|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
75626979|NCT00881530|Drug|BI 10773|BI 10773 low dose once daily
75626980|NCT00881530|Drug|Sitagliptin|open label comparator
75626981|NCT01075685|Behavioral|interactive online programme to reduce alcohol consumption|"The programme includes several steps:~personalized feedback on alcohol consumption and related risks~reviewing motivations and fears regarding drinking reduction~analyse of drinking habits~reduction goal setting~follow-up tools (alcohol diary, craving scales, well-being scales)~a final screen allowing participants to monitor their progress through graphs and automatically adapted comments."
75626982|NCT01075685|Behavioral|Minimum information|"This intervention includes:~information about hazardous drinking~an alcohol diary"
75626983|NCT01075217|Drug|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
75626984|NCT01075217|Drug|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
75779180|NCT04681729|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
75779181|NCT04681729|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
75779182|NCT04681729|Drug|Non sedating H1-antihistamine|Pharmaceutical form:Tablet Route of administration: Oral
75915007|NCT04130438|Other|Placebo|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
75915008|NCT04128722|Drug|Sirolimus Oral Liquid Product 1mg/mL|0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation
76074247|NCT04385914|Other|COVID positive via testing|Following pregnancy outcomes whether they are COVID positive or negative
75779183|NCT04675099|Behavioral|pCARE|"Mothering from the Inside Out is an evidence-based intervention delivered in substance use treatment settings that helps mothers with substance use disorders foster parent-child attachment, cope with stressful parenting situations, and promote their child's healthy development. This 3 month counseling intervention both improves parent-child attachment and decreases rates of drug relapse among mothers. The proposed mechanism of action targeted by the intervention is a change in parental reflective functioning, defined as the capacity to recognize and make sense of mental states (especially emotional states) and understand how they influence behavior and relationships."
75779184|NCT04675099|Other|Standard Early Intervention services|The state of Massachusetts provides voluntary early childhood development services to substance-exposed infants through a system of Early Intervention programs. These programs offer coordinated services to all infants and toddlers with disabilities and those at risk for developmental delays in homes and child centers beginning at birth.
75626985|NCT02632474|Drug|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
75626986|NCT04156750|Drug|LY3556050|Administered orally.
75626987|NCT04156750|Drug|Placebo|Administered orally.
75779185|NCT04653402|Device|Hydrocelectomy surgery|The standardized hydrocelectomy operation i.e. Eversion of the TVT sac
75779186|NCT04644640|Other|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises for the knee, proprioception and balance training
75779187|NCT04644640|Other|In-person Rehabilitation Therapy|Range of motion exercises for the knee, proprioception and balance training
75779188|NCT04633824|Other|Retrospective Electronic Medical Record Review|Patients will be assessed retrospectively for evidence of successful or failed epidural extension in the setting of need for cesarean section
75779189|NCT04631692|Behavioral|Health literacy intervention|"We will translate and adapt an intervention developed by Ferreira et al. to address health literacy and improve CRC screening. This intervention combined a 2-hour health literacy training targeting primary care physicians (which also included information about CRC screening) and a patient level intervention that consisted of a brochure and video.~In order to promote generalizability, large-scale diffusion, dissemination and sustained use beyond the funded-research period, we will use blended learning to develop a 2-hour e-learning health literacy training in French and a one-hour booster session.~The patient-facing intervention (video + brochure) will follow key plain language and health literacy principles to translate evidence-based information in content that all patients can understand. Existing materials developed in France will be used and adapted as relevant."
75779190|NCT04599075|Drug|Insulin|IV Insulin Infusion
75626988|NCT04156750|Drug|Iohexol|Administered IV.
75779191|NCT04599075|Drug|Insulin|Continuous Subcutaneous Insulin Infusion (Pump)
76074248|NCT00754156|Device|ABRA Abdominal Closure System|ABRA Abdominal Closure System
75779192|NCT04594590|Genetic|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
75779193|NCT04580979|Genetic|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
75779194|NCT04574583|Drug|SX-682|SX-682 will be given orally at designated dose twice a day every day
76074249|NCT00754156|Device|V.A.C. Therapy|V.A.C. Therapy Alone
75626989|NCT04156750|Drug|Metformin|Administered orally.
75626990|NCT02877173|Drug|Alprostadil Liposomes for Injection|3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
75626991|NCT02877173|Drug|Alprostadil Injection|Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
75779195|NCT04574583|Drug|M7824|Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.
75779196|NCT04574583|Biological|MVA-BN-CV301|MVA-BN-CV301 will be given as four subcutaneous injections (4x10^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)
75779197|NCT04574583|Biological|recombinant fowlpox viral (FPV)-CV301|FPV-CV301 will be given as one subcutaneous injection (1x10^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).
75779198|NCT04555122|Behavioral|Social Distancing Advertisements|Participants will receive 3 types of advertisements to increase social distancing/staying at home.
75779199|NCT04536974|Diagnostic Test|SEFI tool|Detect the risk of malnutrition with the SEFI tool
75779200|NCT04535167|Drug|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
75779201|NCT04535167|Drug|Placebo|Placebo will be formulated for intravenous delivery
75779202|NCT04528771|Drug|SNO|Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
75779203|NCT04528771|Drug|Nitrogen gas|Six-hour nitrogen gas treatment by inhalation.Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
76074250|NCT00754156|Device|KCI ABThera|KCI ABThera
76074251|NCT03805984|Drug|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
76074252|NCT03805984|Drug|Placebo|Placebo will be administered ID on Day 0 and Week 4.
76074253|NCT03805984|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
76074254|NCT03805906|Procedure|L5 Dorsal ramus block|Ultrasound-guided L5 dorsal ramus block
75626992|NCT00658450|Behavioral|Cognitive rehabilitation training|"A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.~Children will complete these tasks in 16 session for 8 weeks."
75626993|NCT04305743|Drug|OnabotulinumtoxinA 100 UNT|Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
75915009|NCT04120805|Device|Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon
75626994|NCT00661180|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
75626995|NCT02632942|Procedure|HAQ criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~60% or greater diameter of the main AVF~50% diameter of AVF with at least one more av>40% in diameter.~50% in diameter and divides into branches of same size.~av likely to interfere with cannulation on physical examination.~>30% in diameter and associated with stenosis at site of origin."
75626996|NCT02632942|Procedure|Current Recommendation|Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
75626997|NCT04032574|Combination Product|Herbal Medicinal Product|
75626998|NCT04032574|Other|Placebo|
75626999|NCT04032496|Behavioral|Contemplative-Based Intervention for People Living with SLE|Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.
75627000|NCT04032496|Behavioral|Health Enhancement Program (HEP)|The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
75627001|NCT02876471|Other|CPAP|OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
75627002|NCT04032340|Other|dog presence|This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
75627003|NCT04032262|Diagnostic Test|Gastrointestinal and Parkinson's Disease|Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
75627004|NCT01078571|Biological|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
75627005|NCT04017364|Device|PCB PTCA|Predilatation of coronary de-novo stenosis followed by a PCB
75627006|NCT04017364|Device|SCB PTCA|Predilatation of coronary de-novo stenosis followed by a SCB
75627007|NCT02877329|Behavioral|Internet-delivered ACT|Therapist-guided Internet-delivered ACT (acceptance and commitment therapy) for 8 weeks
75627008|NCT04160416|Drug|Capecitabine-Oxaliplatin-Irinotecan Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
75627009|NCT02876237|Other|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
75779204|NCT04524416|Device|Minimally invasive glaucoma surgery (MIGS)|MINIject implant placed into supraciliary space. The implantation was done in a previous study in which patient participated and is not part of this study.
75915010|NCT04120805|Other|No Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
75627010|NCT02876237|Radiation|Radiotherapy|standard radiotherapy
75627011|NCT00661336|Drug|buthionine sulfoximine|
75627012|NCT00661336|Drug|melphalan|
75627013|NCT00661336|Genetic|microarray analysis|
75627014|NCT00661336|Other|high performance liquid chromatography|
75627015|NCT00661336|Other|laboratory biomarker analysis|
75627016|NCT00661336|Other|pharmacological study|
75627017|NCT00661336|Procedure|biopsy|
75627018|NCT04158700|Drug|LY3200882|LY3200882 administered orally
75779205|NCT04523363|Drug|Metformin|Maximum dosage of 500 mg tablets 2 times a day (with each meal)
75779206|NCT04517786|Device|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
75779207|NCT04506411|Dietary Supplement|Turmipure GOLD®|TPG: Turmipure GOLD® capsules - 4 capsules once daily- as prescribed
75915011|NCT04119180|Drug|Ketamine 50 MG/ML|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
75627019|NCT04158700|Drug|Pembrolizumab|Pembrolizumab administered IV
75915012|NCT04119180|Drug|Midazolam Hcl 2Mg/Ml Syrup|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine;
75915013|NCT04119180|Procedure|Protective stabilization|The legal guardian or accompanying person appointed by the legal guardian should sit in the dental chair with the child and contain leg and arm movements. A dental assistant keeps the child's head contained during care.
75322265|NCT02285907|Other|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
75322266|NCT02285907|Other|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
75467105|NCT01916746|Procedure|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
75467106|NCT01916759|Drug|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
75627020|NCT02876003|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
75627021|NCT04306289|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.
75627022|NCT00657202|Drug|Ranibizumab|Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
75627023|NCT00626483|Biological|RNA-loaded dendritic cell vaccine|Only one dose of DCs (2 x 10^7) is being assessed.
75915014|NCT04110730|Device|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion.
76074255|NCT03805828|Other|Educational program on parenting stress and coping mechanism|The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
76074256|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
75322267|NCT02285907|Other|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
75322268|NCT04402424|Diagnostic Test|Faecal Immunochemical Testing|Stool samples for both point of care and laboratory based faecal immunochemical testing via device specific sampling sticks
76074257|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
75467107|NCT01916772|Other|no interventions|no interventions
75467108|NCT01916785|Drug|Dasatinib|Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
76074258|NCT00754546|Drug|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
75467109|NCT01916798|Drug|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up & another dose at the day of embryo Transfer.
75627024|NCT00626483|Drug|basiliximab|Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
75627025|NCT02632864|Radiation|Proton arm|Proton beam therapy
75627026|NCT00626717|Procedure|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
75627027|NCT00626717|Procedure|Sham treatment|Fluorescein eye drops. Exposure with blue light
75627028|NCT00661414|Biological|ASONEP (sonepcizumab/LT1009)|"ASONEP [sonepcizumab/LT1009] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.~The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
75627029|NCT04160572|Behavioral|Morning sleep schedule|sleep right after night shifts
75627030|NCT04160572|Behavioral|Evening sleep schedule|sleep before night shifts
75627031|NCT04156204|Other|Medication Event Monitoring System (MEMS)|AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system
75627032|NCT04156204|Drug|Once-Daily Tacrolimus extended release|AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
76074259|NCT00754546|Drug|Placebo: Normal Saline|Normal saline was nebulized.
76074260|NCT00754546|Other|Treadmill Exercise|
75322269|NCT03429140|Drug|Gel-One|an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
75322270|NCT03429140|Other|Saline Placebo|a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery
75779208|NCT04506411|Dietary Supplement|Turmeric rhizome PE 95% curcuminoids|STE: Turmeric rhizome PE 95% curcuminoids - 4 capsules once daily- as prescribed
75779209|NCT04506411|Dietary Supplement|Placebo|Placebo: Maltodextrin - 4 capsules once daily- as prescribed
76074261|NCT00754546|Other|Cycle Exercise|
75627033|NCT04305821|Other|Dosage of S100β protein|Dosage of S100β protein
75322271|NCT04768179|Drug|3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)|Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
75322272|NCT03081494|Drug|spartalizumab (PDR001)|100 mg lyophilisate in vial received 400 mg every 4 weeks
75322273|NCT03081494|Drug|regorafenib|120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
75322274|NCT05658471|Other|Standardized Research E-Cigarette (SREC)|Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.
75322275|NCT05658471|Other|Over the Counter E-Cigarette (EC)|Usual brand e-cigarettes will be provided at the hospital stay.
75627034|NCT02631694|Drug|Propranolol|Intake of propranolol pill (40 milligram)
75627035|NCT02631694|Drug|Placebo|Intake of placebo pill (40 milligram)
75627036|NCT02631694|Other|Carbon dioxide|Inhalation of 35% carbon dioxide
75627037|NCT02631694|Other|Compressed air|Inhalation of air
75627038|NCT04306133|Procedure|PENG block|After performing spinal anesthesia, PENG block with 20 mL of 0.375 % Ropivacaine will be executed as described by Giron-Arongo et al with a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, Braun ) will be used.
75627039|NCT04306133|Procedure|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.
75627040|NCT04305587|Drug|PF-07081532|Investigational Drug once daily for up to 42 days; multiple ascending dose design.
75627041|NCT04305587|Other|Placebo|Placebo once daily for up to 42 days.
76074262|NCT03806140|Behavioral|text messages|receive about one health-related text message a day for 16 weeks
75322276|NCT05658471|Behavioral|Biological Samples|Blood, urine, and expired carbon dioxide will be obtained during the course of the study.
75322277|NCT05658471|Other|Smoking-related Questionnaires|Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
75322278|NCT03081728|Device|Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml|bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
75322279|NCT03081728|Drug|IV diclofenac and IV paracetamol|iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
75322280|NCT05651217|Device|disposable urinary catheter|The trial group was intervened with disposable sterile urinary catheter. The model of the trial group includes two chamber type (Fr8, Fr10, Fr12, Fr14, Fr16, Fr18, Fr20, Fr22, Fr24) and three chamber type (Fr16, Fr18, Fr20, Fr22, Fr24).
75627042|NCT04305587|Drug|Clopidogrel|Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
75627043|NCT00658840|Drug|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
75627044|NCT00658840|Radiation|Localization, simulation and immobilization|"Radiation dose and planning~Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated."
75627045|NCT00665782|Other|laboratory biomarker analysis|
75627046|NCT00665782|Other|questionnaire administration|
75627047|NCT00665782|Other|study of socioeconomic and demographic variables|
75627048|NCT00665782|Procedure|assessment of therapy complications|
75627049|NCT00665782|Procedure|psychosocial assessment and care|
75627050|NCT00665782|Procedure|therapeutic conventional surgery|
75779210|NCT04498845|Other|In-home assessment plan|The in-home family educational session provides participants with resources to identify and reduce exposures to metals in the home environment.
75779211|NCT04498845|Behavioral|Family educational session|The 1-hr in-home family educational session, administered during the first home visit to all participants, adapts a motivational interview model to reduce exposure to metals. this done by empowering families to make informed decisions regarding lead and metal exposures in their home environments that originate from different sources with an emphasis on sources from the workplace. The session will consist of both developing a plan tailored for the home and reviewing educational materials on strategies to reduce exposures in the home, focusing on barriers families experience when attempting to change their behaviors.
75779212|NCT04498845|Behavioral|Worker take home prevention training|The take home prevention 1-hour educational session guides the worker through 6 simple steps to identify and then prioritize change/s that can be made before leaving work to prevent take-home lead. It has been adapted from the AGILE model for prioritizing tasks. Participants will also be provided with a pamphlet about how to prevent lead from being taken home.
75779213|NCT04498845|Other|D-LEAD cleaner products|D-LEAD cleaner products include hand wipes, all surfaces cleaner and laundry detergent.
75779214|NCT04496284|Other|Vitrification via slush nitrogen|blastocyst stage embryos will be vitrified via slush nitrogen
76074263|NCT01764841|Drug|Ciprofloxacin DPI (BAYQ3939)|Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
76074264|NCT01764841|Drug|Placebo|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
76074265|NCT00245050|Dietary Supplement|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
76074266|NCT00245050|Drug|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
75467110|NCT01916837|Other|Sampling of tumor tissue|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
75467111|NCT01916837|Other|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
75779215|NCT04495894|Drug|Preoperative Ketorolac|30 mg ketorolac will be administered intravenously 30 minutes prior to incision.
75779216|NCT04490317|Diagnostic Test|Cardiac MRI|"Cardiac MRI be taken to CO poisoned patients~Cardiac CT be taken to CO poisoned patients~TTE be taken to CO poisoned patients~Brain MRI be taken to CO poisoned patients~Neurocognitive function tests be taken to CO poisoned patients~Laboratory tests be taken to CO poisoned patients"
75779217|NCT04490317|Procedure|Hyperbaric oxygen therapy|"Hyperbaric oxygen therapy be used for CO poisoned patients~Therapeutic hypothermia be used for CO poisoned patients"
75322281|NCT05651217|Device|super smooth antibacterial urinary catheter|the control group was intervened with ultra smooth antibacterial catheter. The control group models include single chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr), double chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr, 28Fr, 30Fr), and three chamber (16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr)
75322282|NCT02986971|Device|New IMD|The contraceptive implants of the subjects in this arm are removed by the new IMD.
75627051|NCT04305353|Other|Diary (blank journal) plus PTSD psycho-education|A blank journal where a prospective account of a patient's ICU course (everyday events) can be documented by family members and healthcare providers
75627052|NCT04305353|Other|PTSD psycho-education alone|"We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015."
75322283|NCT05687864|Diagnostic Test|Polysaccharide superparamagnetic ferric oxide injection|The polysaccharide superparamagnetic ferric oxide injection is a clinical diagnostic reagent
75322284|NCT00618917|Genetic|Manganese Superoxide Dismutase Plasmid Liposome|15 ml of liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
75322285|NCT00618917|Drug|carboplatin|Chemotherapy to stop the growth of tumor cells.
75322286|NCT00618917|Drug|paclitaxel|Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.
75322287|NCT00618917|Radiation|Radiation Therapy|1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
75322288|NCT05736081|Procedure|Intravitreal dexamethasone implant|Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
75322289|NCT00619073|Drug|clopidogrel + aspirin|Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
75627053|NCT00658918|Drug|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
75627054|NCT00658918|Drug|Placebo|placebo
75322290|NCT00619073|Drug|placebo|Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
75322291|NCT00619073|Drug|Aspirin|Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
75322292|NCT05687630|Other|elastic band resisted exercise|muscle strengthening exercise, 10-15 times of each set, for 3 sets
75322293|NCT00620711|Device|Olympic Cool Cap|Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
75322294|NCT05687552|Device|pet -ct|assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding
75322295|NCT05341869|Procedure|Para-cervical block|Block of inferior hypogastric plexus with local anesthetic
75627055|NCT02876081|Drug|Afatinib|to evaluate the efficacy of afatinib, an EGFR TKI, on lung adenocarcinomas, EGFR wild-type, bearing the NTS/NTSR1 complex with a high level of expression
75627056|NCT02631616|Drug|Somatostatin|Monthly injections of Somatostatin
75627057|NCT02876783|Other|Observational - No intervention|
75627058|NCT00661648|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
75627059|NCT04306055|Other|Questionnaire with precaution information|Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.
75627060|NCT04306055|Other|Experimental: Questionnaire without precaution information|Ever blood donors in this group would receive a questionnaire which dose not include the information above.
75627061|NCT04156282|Procedure|knot burial technique|surgical suturing intervention
75627062|NCT04156282|Procedure|classical closure|surgical suturing intervention
75627063|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|single iv infusion 8 mg/kg
75627064|NCT00977106|Drug|placebo|single iv infusion
75779218|NCT04478721|Drug|Temocillin|The intervention of experimental arm will be Intravenous administration of temocillin.
75779219|NCT04478721|Drug|Meropenem|The intervention of comparator arm will be intravenous administration of meropenem.
75779220|NCT04456764|Behavioral|SaFTiE|A multi-modal fatigue risk management program.
75779221|NCT04456764|Behavioral|Attention Placebo Control|A multi-modal teamwork assessment program.
75779222|NCT04441567|Other|Right-size clinic visits|The curve created in Phase 1 will be used to guide the number of clinic visits based on PROMs reported by the participants in Phase 2.
76074267|NCT00245050|Drug|doxorubicin HCL liposome|IV, 40mg/m2
76074268|NCT04345588|Drug|Dexamethasone injection|we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.
75779223|NCT04432883|Device|Active Comparator: Experimental: Active cathodal tDCS + language training|"Cathodal tDCS raises neuronal membrane potentials, leading to decreased probability of depolarization from incoming stimuli.~Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment."
75779224|NCT04432883|Behavioral|Sham Comparator: Placebo cathodal tDCS + Speech and language|Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment. .
75779225|NCT04391491|Diagnostic Test|Neuregulin-1β level in plasma|Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP
75779226|NCT04386252|Biological|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
75779227|NCT04370574|Diagnostic Test|Soluble Biomarkers dosage|"CytoLyt® fluid will be first processed for routine PDAC diagnosis. In essence, the samples are filtered, tissue fragments and cells are kept for analysis while flow-through is kept until the diagnosis is confirmed. Once this is completed, the samples will be transferred to the lab where the proteins found in the CytoLytR fluid will be precipitated and then solubilized. The protein extracts are stored at -80°C pending proteomic analysis. The remaining CytoLytR fluid supernatant is also stored at - 80°C to be used for metabolomics.~Blood sample will be collected from each patient that underwent diagnostic biopsy. Dry tube for serum analysis will be collected at the time of inclusion during the routine blood test. The serum samples are intended for the validation phase (WP4) and will be exclusively dedicated to this study."
75779228|NCT04359394|Other|biological sampling|In order to investigate the level of molecular pathophysiology, blood and punch biopsies will be collected of each patient. In up to two relatives per patient, 30mL blood will be collected only once.
75779229|NCT04359394|Other|Phenotypic description|Phenotypic characterization of the patient's clinical features
75779230|NCT04359394|Other|Photography|All affected areas will be photographed at each visit with 2-dimensional standardized photography
75779231|NCT04351113|Dietary Supplement|MITO-AO|Participants will receive 160 mg with breakfast on day 1 of bed rest and 40 mg with breakfast on days 2-5.
75779232|NCT04351113|Dietary Supplement|PB-125|Participants will receive 100 mg on days 1-5 of bed rest.
75779233|NCT04351113|Other|Placebo|Participants will receive Placebo on days 1-5 of bed rest.
75322296|NCT04401722|Procedure|PANCREATICODUDENECTOMY|dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ
75627065|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|iv infusion 8mg/kg every 4 weeks for 11 months
75627066|NCT00665860|Dietary Supplement|Placebo|Three pills per day for two years
75627067|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 80 mg of aglycone isoflavones per day for two years
75779234|NCT04351113|Other|Passive Leg Movement (PLM)|Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.
75322297|NCT00670241|Drug|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
75322298|NCT00670241|Drug|LEO 80185 vehicle|Once daily application
75322299|NCT00670241|Drug|Tacalcitol ointment|Once daily application
75322300|NCT03088670|Drug|Gosogliptin|20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
75322301|NCT03088670|Drug|Vildagliptin|50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
75322302|NCT03088670|Drug|Metformin|"1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally"
75779235|NCT04351113|Other|Plantar flexion|Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.
75779236|NCT04351113|Other|Isometric knee extensor test|Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.
75779237|NCT04351113|Other|Bed rest|Participants will undergo 5 days bed rest after 5 day baseline assessments
75915015|NCT04110730|Behavioral|Home Intervention|An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
75915016|NCT04107857|Behavioral|ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer|"Brief advise to quit smoking~Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov"
75915017|NCT04107857|Behavioral|ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer|-Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)
75915018|NCT04107857|Behavioral|Data Driven Feedback reports|-Feedback reports will be based on data
75322303|NCT03088358|Drug|TeaRx|
75322304|NCT03088358|Drug|Enoxaparin|
75322305|NCT03081026|Diagnostic Test|Bilateral hip to ankle x-ray, exam and strength testing.|Only an X-Ray is performed and reviewed to identify any growth disturbances.
75627068|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 120 mg aglycone isoflavones per day for two years
75627069|NCT00659074|Drug|Ondansetron|ODT, single-dose, fasting
75627070|NCT00659074|Drug|Zofran|ODT, single-dose, fasting
75627071|NCT02632318|Device|Light|30 minutes of dawn simulation
75627072|NCT00665938|Other|Infant formula|"Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics"
75322306|NCT00671177|Procedure|water immersion colonoscopy|instillation of 300cc of water in the rectum
75322307|NCT00671177|Procedure|standard air colonoscopy|air instillation in colon for visualization
75322308|NCT03396068|Drug|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
75322309|NCT03396068|Drug|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
75322310|NCT03383978|Biological|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
75627073|NCT01077713|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
75627074|NCT01077713|Drug|cisplatin|60mg/m2 on day 1 of each 3 week cycle
75915019|NCT04104607|Drug|CC-1, PSMAxCD3|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
75779238|NCT04304001|Behavioral|Community Health Advisor|"Intervention arm participants will receive one 45-minute face-to-face meeting followed by two CHA phone calls in one-week intervals over a period of three weeks beginning within one month following baseline survey completion. These CRC educational activities delivered by the CHAs will include the use of NCI CRC resources and materials, including an S2S PowerPoint presentation, and CRC educational brochures. The intervention will follow a conversation guide/standard script for intervention fidelity. CHAs will take notes following each interaction to document the call length, deviations from the script, and tone of the call. Participants will receive an additional text message reminder once a week for an additional three weeks - with instructions for participants to text yes to confirm they received the message - for a total of six weeks of intervention delivery. The personalized text messages will have positive tones and include short messages about the benefits of CRC screening."
75779239|NCT04304001|Behavioral|Usual care|Control arm participants will receive a FIT kit, a mailed targeted colorectal cancer brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
75779240|NCT04301596|Other|Collection of data|different set of data will be collected over a 6 months period
75779241|NCT04283500|Drug|Buprenorphine Naloxone|Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
75779242|NCT04223791|Drug|DOR/ISL|100 mg DOR/ 0.75 ISL FDC tablet taken orally once daily
75779243|NCT04223791|Drug|BIC/FTC/TAF|50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily
75779244|NCT04223791|Drug|Placebo to BIC/FTC/TAF|Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily
75779245|NCT04223791|Drug|Placebo to FDC DOR/ISL|Placebo to FDC DOR/ISL in a tablet taken orally, once daily
75915020|NCT04104555|Other|Birthday card|Birthday card sent to participants in the post
75915021|NCT04104555|Device|Prefabricated orthoses|Prefabricated insole
75915022|NCT04104555|Other|Signposting to multimedia|Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
75915023|NCT04104555|Other|Usual supportive care - exercises and footwear advice (the comparator)|Active comparator
75915024|NCT04090177|Behavioral|TEAM Wheels|A 1-month, peer-led, eHealth training program (TEAM Wheels) for individuals transitioning to manual wheelchair use to improve satisfaction with activity participation and related rehabilitation outcomes.
75915025|NCT04089696|Device|ExSprion|The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
75915026|NCT04086875|Behavioral|Focus Group|Participate in focus group
75915027|NCT04086875|Other|Text Message|Receive text messages
75915028|NCT04086875|Other|Best Practice|Receive usual care
75915029|NCT04086875|Other|Questionnaire Administration|Ancillary studies
75915030|NCT04083118|Diagnostic Test|clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI|Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta
75915031|NCT04083118|Diagnostic Test|Repeat 18F sodium fluoride PET/MRI|as per first study visit but without the PET/CT
75322311|NCT03383978|Drug|Ezabenlimab|Intravenous infusion of Ezabenlimab 240mg q 3 weeks
75467112|NCT01916837|Procedure|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
75627075|NCT01077713|Drug|gemcitabine|1200mg/m2 on days 1-8 of each 3 week cycle
75467113|NCT01916850|Drug|LX4211 400 mg|
75627076|NCT01077713|Drug|gemcitabine|1000mg/m2 on days 1-8 of each 3 week cycle
75627077|NCT04290234|Other|fMRI assessment of cognitive and reactive fear|An fMRI paradigm will be used to probe how childhood maltreatment may modulate the defensive survival circuitry that facilitates escape decisions when subjects encounter fast- or slow-attacking threats.
75627078|NCT00666016|Drug|TRO19622|TRO19622 500 mg once a day before noon meal during 6 weeks
75627079|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
75627080|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
75779246|NCT04171921|Procedure|Robotic ventral hernia repair|Laparoscopic robotically assisted trans-abdominal pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
75779247|NCT04171921|Procedure|Open ventral hernia repair|Standard open pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
75779248|NCT04155034|Procedure|Magnetic Resonance Imaging|Undergo MRI
75779249|NCT04155034|Radiation|Prophylactic Cranial Irradiation|Undergo PCI
75779250|NCT04151485|Behavioral|Mind/Body Program for Fertility (Domar et al., 2011)|see Arm Description
75779251|NCT04151485|Behavioral|Fertility Support Program|see Arm Description
75779252|NCT04149041|Diagnostic Test|ultrasound|POCUS is applied to adult patients in an emergency department.
75779253|NCT04148560|Other|Tests of the validity of the RFPM and SmartIntake app.|Participants who enroll will be trained in using the RFPM/SmartIntake app and a food record and will complete the Food Intake Assessment Preference Survey. They will also use both methods to estimate intake during a simulated lab-based meal (they will not eat during this simulated meal). They will be dosed with DLW at this visit and will use the RFPM for the subsequent 1-2 days to get accustomed to using the method, with the following three days comprising the data collection period.
75779254|NCT04147273|Device|Determination of postprandial glucose response by continuous glucose measurement after consuming different carbohydrate containing foods|"One day prior to the study beginning, participants were equipped with a CGM system (FreeStyle Libre®, Abbott Diabetes Care, Alameda, CA, USA). This CGM system provides glucose recordings every 15 min over a period of 14 days. The glucose data were downloaded manually by a scan with a handheld device.~On the second day of the study, participants consumed portions of these three test products containing 50 g of available carbohydrate on 3 separate days without a washout period. The products were tested in random order at the same time of the morning after a 10 h overnight fast. Venous blood samples were collected at 0, 15, 30, 45, 60, 75, 90, 105 and 120 min postprandial by inserting an intravenous cannula into a forearm vein. Capillary blood samples were obtained through finger pricking. Blood glucose levels in these samples were measured with a high quality SMBG system (ContourXT/Contour next, Ascensia Diabetes Care, Leverkusen, Deutschland, Germany)."
75915032|NCT04080167|Behavioral|InCharge Health mobile application|"The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a health partner; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a health partner, who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been <4 hours since not documenting the use of hydroxyurea. The app healthy partner will be encouraged to message the participant to remind him/her to take the medication."
75322312|NCT00620945|Drug|Phenoxybenzamine|"Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~For patients with obstructing lesions on systemic side:~0.25 mg/kg dose in the bypass circuit~None intravenous~For patients without obstructing left sided lesions:~0.5 mg/kg in the bypass circuit~0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~0.3 mg/kg P.O. every 8 hours for next 24 hours~0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group"
75627081|NCT00813709|Drug|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
75467114|NCT01916850|Drug|LX4211 800 mg|
75627082|NCT00813709|Drug|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
75627083|NCT04160884|Procedure|Indocyanine Green Injection through Peripheral Vein|After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
75627084|NCT02866266|Other|Retrospective database review|
75627085|NCT02865876|Procedure|Accelerated Corneal Cross-linking|All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
75627086|NCT04158622|Procedure|PnR + laser/cryotherapy|Pneumatic retinopexy plus laser/cryotherapy
75627087|NCT04158622|Procedure|PPV + laser/cryotherapy|Pars plana vitrectomy plus laser/cryotherapy
75627088|NCT02866110|Behavioral|Neurofeedback|The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.
75627089|NCT02866110|Device|MRI|Echo-planar Imaging of brain BOLD signal
75627090|NCT01077323|Drug|exenatide|subcutaneous injection, dosing according to normal clinical practice
75627091|NCT01077323|Drug|Other antidiabetic therapies|Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
75627092|NCT01077323|Other|No diabetes therapy|Subjects not diagnosed with diabetes
75627093|NCT00662116|Drug|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
75627094|NCT00662116|Drug|placebo|placebo tablets - two tablets taken twice daily
76025614|NCT02667301|Device|Tympanic Cavity Air Exchange Test|Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
76025615|NCT02667301|Device|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
75627095|NCT03870438|Drug|Lamivudine Oral Solution|In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight <8 kg; and 50 mg twice a day if weight >8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
75627096|NCT04287894|Drug|Durvalumab|The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg
75627097|NCT04287894|Drug|Tremelimumab|Per day 75mg
75627098|NCT04287894|Drug|Pemetrexed|500 mg/m2 on day 1 every 3 weeks for 2 cycles
75627099|NCT04287894|Drug|Cisplatin|6 mg / m2 on day 1 every 3 weeks for 2 cycles
75627100|NCT04287894|Radiation|chemo radiotherapy|Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
75627101|NCT04287894|Procedure|Resection|After CIT-CRT
75915033|NCT04080167|Behavioral|HU Toolbox mobile application|The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.
75915034|NCT04075461|Procedure|Arthroplasty|Arthroplasty is commonly used for a displaced femoral neck fracture.
75915035|NCT04075461|Procedure|Internal fixation|Internal fixation is commonly used for undisplaced femoral neck fracture
75627102|NCT04287582|Other|Electromyographic device|An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.
75627103|NCT02863848|Dietary Supplement|OraftiR inulin-type fructans|
75322313|NCT03088436|Device|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
75322314|NCT00621179|Drug|Leuprolide acetate in depot suspension|Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
75322315|NCT00621179|Other|No intervention|
75322316|NCT00247273|Drug|risedronate|tablet, 5 mg risedronate, once a day for 2 years
75627104|NCT02863848|Dietary Supplement|Placebo|maltodextrin
75627105|NCT04287426|Drug|Rocuronium 0.6 mg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
75627106|NCT04287426|Drug|Remifentanil 2 µg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
75627107|NCT05757505|Device|Intracranial Stent (Tonbridge)|Endovascular treatment with Intracranial Stent (Tonbridge).
75915036|NCT04075331|Drug|Mepolizumab|Mepolizumab 100mg subcutaneous injection
75915037|NCT04075331|Drug|Placebo|Saline solution for subcutaneous injection
75915038|NCT04070378|Drug|Daratumumab Injection|Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion
76025616|NCT02803333|Other|No Intervention|No intervention
75322317|NCT00247273|Drug|risedronate|oral, 150 mg risedronate, once a month for 2 years
75322318|NCT05685524|Diagnostic Test|DNA methylation test|Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.
75322319|NCT05480462|Biological|Clodivac|A dose of 0.5 ml should be administered intramuscularly into deltoid muscle.
75322320|NCT05480462|Biological|Td-Impfstoff Merieux|One dose (0.5 ml) intramuscular, preferably in the deltoid muscle of the upper arm.
75627108|NCT05757505|Device|Wingspan Stent System (Stryker Neurovascular)|Endovascular treatment with Wingspan Stent System (Stryker Neurovascular).
75627109|NCT04287504|Diagnostic Test|SavvyCheck Vaginal Yeast Test|Point-of-care test for the detection of vaginal candidosis
75627110|NCT04287504|Diagnostic Test|OSOM BVBLUE Test|Point-of-care test for the detection of bacterial vaginosis
75627111|NCT04047576|Drug|Sirolimus|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
75627112|NCT04047576|Drug|Corticosteroid|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
75467115|NCT01916850|Drug|LX4211 Placebo|
75467116|NCT01916863|Drug|LX4211 400 mg|
75627113|NCT00976950|Drug|Tipranavir|
75627114|NCT00976950|Drug|ritonavir|low-dose
75627115|NCT04290078|Device|Kaia Back Pain Study App|Kaia Back Pain is an integrated solution for self-management of low-back pain that digitizes multidisciplinary rehabilitation into a smartphone application.
75627116|NCT04290078|Other|Usual Care|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth
76025617|NCT04553939|Drug|Toripalimab|Toripalimab 3mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
76025618|NCT04553939|Drug|Gemcitabine|Gemcitabine 800mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
76025619|NCT03113773|Drug|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10^6 - 3.0 X 10^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10^6 IU will be allowed per day.
76025620|NCT03113773|Drug|Placebo Injection|Dextrose 5%
76025621|NCT05306041|Drug|Inavolisib|daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
76025622|NCT05306041|Drug|PHESGO|fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
76025623|NCT05306041|Drug|Endocrine therapy|Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
76025624|NCT04874831|Drug|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
75322321|NCT05056233|Other|Systane Hydration lubricant eye drops|Sterile solution indicated for the temporary relief of burning and irritation due to dryness of the eye
75779255|NCT04141085|Other|Endometrial biopsy|All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer
75915039|NCT04069754|Behavioral|Adapted Passport to Freedom|5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections.
76074269|NCT00778648|Dietary Supplement|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily."
75467117|NCT01916863|Drug|canagliflozin 300 mg|
75467118|NCT01916863|Drug|LX4211 Placebo|
75467119|NCT01916876|Other|Integrated medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~On day 3 they will be contacted telephonically to:~i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance~Reminders via SMS to attend there OPD appointment(s)~Medical out-patient review at 2-weeks and 6 weeks if required~Medical telephonic hot-line for advice"
75322322|NCT00671723|Drug|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
75322323|NCT00671723|Drug|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
75467120|NCT01916889|Other|RACY test|
75627117|NCT00629382|Device|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
75627118|NCT00629382|Other|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
75779256|NCT04115293|Drug|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
75322324|NCT00671723|Drug|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
75322325|NCT05685446|Other|Ice water|Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
75467121|NCT01916902|Drug|Ticagrelor- Delayed Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
75467122|NCT01916902|Drug|Ticagrelor- Immediate Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
75467123|NCT01916902|Procedure|Optical Coherence Tomography|
75467124|NCT01916915|Drug|Tramadol infusion via wound catheter|
75467125|NCT01916915|Drug|Levobupivacaine|
75779257|NCT04115293|Drug|Placebo|Daily subcutaneous (SC) injection
75467126|NCT01916954|Drug|3-day artemether-lumefantrine|
75467127|NCT01916954|Drug|5-day artemether-lumefantrine|
75467128|NCT01916993|Drug|NBI-98854 50 mg capsule|
75467129|NCT01917019|Drug|Placebo|matching placebo tablets
75467130|NCT01917019|Drug|BIIB041 (fampridine)|fampridine prolonged-release tablets
75779258|NCT04035499|Behavioral|GO-EXCAP Mobile App|A mobile app delivery platform and the EXCAP©® exercise program
75779259|NCT04002505|Other|Concussion and Brain Bleed App (CBB)|Tablet based decision aid that encourages shared decision making with the goal of educating patients to reduce unnecessary CT scans
75915040|NCT04068454|Device|Virtual reality device|Functional exercises will be done by virtual reality group
76074270|NCT00778648|Dietary Supplement|Placebo|Four capsules of placebo daily.
76074271|NCT03806374|Drug|Ketamine|ketamine
75915041|NCT04068454|Other|EBM rehabilitation exercises|scapular exercises will be done
76074272|NCT03806374|Drug|Propofol|propofol
75467131|NCT01917032|Dietary Supplement|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
75467132|NCT01917032|Dietary Supplement|placebo|
75467133|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
75467134|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
75467135|NCT01917045|Drug|Morphine|morphine 0. 5mg/ml
75467136|NCT01917058|Drug|Abatacept|"This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.~Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse."
75467137|NCT01917058|Drug|placebo|
76074273|NCT03806374|Drug|Fentanyl|fentanyl
76074274|NCT03806374|Drug|Cisatracurium|cisatracurium
76074275|NCT03806374|Drug|Lidocaine|lidocaine
76074276|NCT00763360|Device|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
75779260|NCT03997240|Procedure|Chiropractic Applied Clinical Neuroscience|Chiropractic Applied Clinical Neuroscience makes use of chiropractic care in addition to application of therapies designed to stimulate multisensory reintegration and cerebellar coordination. The multisensory reintegration and cerebellar therapies make use of the body's own sensory receptors as a target, with the purpose of realigning the brain's interpretation of different afferent signals. Observation of motor and autonomic output patterns during and after sensory stimulation afford the clinician real-time feedback, providing for adaptation of the sensory based protocol.
75915042|NCT04064567|Behavioral|PrEP-LINK|CHW will assist with healthcare and social service navigation and will utilize adherence counseling techniques. As per the model our intervention is based upon (the national Transitions Clinic Network [TCN]), our CHW has a history of incarceration. Participants randomized to the intervention group, the CHW will assist individuals with employment, housing (if needed), referrals to mental health or substance use treatment, keeping track of medical appointments and medication adherence.
76074277|NCT00763360|Drug|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
76074278|NCT00763360|Drug|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
75627119|NCT02865954|Device|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
76074279|NCT00763750|Drug|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
76074280|NCT00756106|Drug|temozolomide|Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
76074281|NCT00756106|Other|Imaging biomarker analysis|MRI
76074282|NCT00756106|Radiation|Photon Radiation Therapy|Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions.
75322326|NCT01799681|Behavioral|an 8-week blended indoor-outdoor exercise program|stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
75467138|NCT01917071|Other|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
75467139|NCT01917097|Drug|Dexmedetomidine|
75467140|NCT01917110|Device|omafilcon A|
75627120|NCT06200272|Combination Product|Germ and Carob Molasses Pulp added standard whole wheat breads|Test bread (bread with soluble pulp added, bread with added germ, and bread with soluble pulp + germ added) containing 50 g carbohydrate, samples taken from all four types of bread were collected for moisture, ash, fiber, protein, fat, digestible carbohydrate, and antioxidant capacity analysis will be performed. This experimental group consists of the group that will eat the test bread.
75627121|NCT06200259|Radiation|Spot Delete planning for proton therapy|The method of adjusting the placement of proton spots or targets that are placed by the treatment planning system during pencil beam scanning for proton therapy
75627122|NCT06200259|Radiation|Traditional proton treatment planning system|In the control arm, the proton spots placed by the treatment planning system are not modified.
75779261|NCT03996200|Device|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
76074283|NCT00243412|Drug|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
76074284|NCT00243412|Drug|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
76074285|NCT00243412|Drug|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
76074286|NCT00243412|Drug|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
76074287|NCT00243412|Drug|Rituximab|500 mg or 1000 mg IV*2.
76074288|NCT00765232|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
76074289|NCT00765232|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
76074290|NCT03805282|Drug|Lidocaine|Continuous infusion, variable dose of lidocaine.
76074291|NCT03805750|Drug|CBD/THC|Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
76074292|NCT03805750|Drug|Placebo oral capsule|Matched Placebo
75322327|NCT01799681|Behavioral|an 8-week upper limb and hand exercise program|upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
75322328|NCT02289105|Behavioral|Mandatory active choice|the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
75467141|NCT01917110|Device|Spectacle|
75467142|NCT01917123|Drug|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
75467143|NCT01917149|Drug|Benazepril|
75467144|NCT01917149|Drug|Valsartan|
75467145|NCT01917149|Drug|Metoprolol|
75627123|NCT06200220|Drug|Venetoclax|Observational study
75627124|NCT06200207|Drug|Ziltivekimab|Zilitivekimab will be administered subcutaneously once-monthly.
75627125|NCT06200207|Drug|Placebo|Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
75627126|NCT06200181|Drug|Olanzapine|Given by PO
75779262|NCT03988699|Device|Tinnitus Implant System|Device will deliver stimulation below hearing thresholds continuously or intermittently.
75915043|NCT04064567|Other|Enhanced Standard of Care|Participants will receive education about PrEP and referral to a community PrEP provider which exceeds the standards of care these individuals would otherwise receive.
76074293|NCT04385446|Procedure|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material during pterygium surgery.
75627127|NCT06200181|Drug|Olanzapine|Given by PO
75627128|NCT06200181|Drug|Placebo|Given by PO
76074294|NCT03804268|Other|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
75915044|NCT04061876|Drug|Ruxolitinib|Participants began oral administration of ruxolitinib at 5 mg QD;Methylprednisolone: 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
75915045|NCT04061876|Drug|Corticosteroid|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
75915046|NCT04058457|Device|DBS|Patients are tested pre-operatively and the post-operatively with their implanted neurostimulators ON and OFF. DBS implantation itself is part of routine care, and not part of the study.
75915047|NCT04048759|Behavioral|Remote Low|Participants will attend 40 min remotely delivered group MVPA sessions once a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
75915048|NCT04048759|Behavioral|Remote High|Participants will attend 40 min remotely delivered group MVPA sessions 3x a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
75915049|NCT04048759|Behavioral|Personal Coach|Participants will receive a step counter, access to resources for increasing MVPA, and monthly remote individual support/education.
75322329|NCT01799759|Behavioral|Online intervention|Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
75322330|NCT01799759|Other|Completion of instruments only|Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
75627129|NCT06200168|Device|Electroacupuncture|"The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz."
75627130|NCT06200168|Drug|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
75915050|NCT04046796|Genetic|NGS Diagnostic|Blood take for genetic diagnostic.
75915051|NCT04037527|Drug|Gemcitabine|Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
75779263|NCT03982030|Drug|Dalbavancin|Dalbavancin 1.5g IV at day 0, day 8-10
75779264|NCT03958695|Device|Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)|A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
75779265|NCT03958695|Device|Transobturator mid-urethral tape, Urosling (Lintex, LLC)|A transobturator tension-free mid-urethral sling
75915052|NCT04037527|Drug|Docetaxel|Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
75915053|NCT04037527|Radiation|Radiation|Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
75915054|NCT04037527|Procedure|Surgical Resection|Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
75322331|NCT05687240|Behavioral|Qigong/Tai Chi|Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.
75322332|NCT05687240|Behavioral|Heart rate variability biofeedback|"Randomized participants will be coached to practice a breathing technique that focuses attention on the sensations in the heart area, slowing and deepening the breath, and activating through memory or imagery a positive emotion. This practice is used along with a feedback device that provides information on achievement of the heart rate variability target, coherence that represents a neurocardiac state associated with vagal tone, or balance."
75467146|NCT01917162|Device|Nelfilcon A contact lens|Soft contact lens CE-marked for daily disposable wear.
75779266|NCT03915067|Drug|BOTOX® purified neurotoxin complex|BOTOX® superficial intramuscular injections.
75779267|NCT03915067|Drug|Placebo|Placebo injections.
75915055|NCT04037527|Other|Blood draws|Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
75915056|NCT04027374|Procedure|Fetal surgery for MMC repair|Fetal surgery for MMC repair
75915057|NCT04027101|Drug|Baricitinib|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
75915058|NCT04027101|Drug|Placebos|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
75779268|NCT03913611|Other|Accelerated rehabilitation protocol|Patients in this group will undergo an accelerated rehabilitation protocol, without movement restrictions. Movement restriction will instead be governed by patient comfort.
75779269|NCT03913611|Other|Traditional rehabilitation protocol|Patients in this group will undergo a traditional rehabilitation protocol, with movement restrictions and sling use for 6 weeks following surgery.
75915059|NCT04009421|Diagnostic Test|Coronary artery plaque assessment by CT coronary angiography QAngio CT RE|Assessment of segmental plaque volume and composition
75915060|NCT04007367|Drug|SAGE-217|SAGE-217 capsule
75915061|NCT04007367|Drug|Placebo|SAGE-217 matching placebo capsule
75915062|NCT03997552|Procedure|Non-incised papillae surgical approach (NIPSA)|Periodontal reconstructive surgery
75915063|NCT03997552|Procedure|marginal approach by palatal incision|Periodontal reconstructive surgery
75915064|NCT03997552|Procedure|Minimally invasive surgical technique (MIST)|Periodontal reconstructive surgery
75915065|NCT03992430|Drug|Eteplirsen|Solution for intravenous (IV) infusion.
75915066|NCT03979885|Behavioral|Smoking cessation counseling (Quitline)|Quitline offers community-based counseling session with a cessation counselor.
75915067|NCT03979885|Behavioral|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
75627131|NCT06200168|Device|Sham electroacupuncture|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation."
76074295|NCT03804268|Drug|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
76074296|NCT00765856|Drug|Oxymorphone ER|"Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications"
75915068|NCT03979885|Behavioral|Financial incentives for smoking cessation|Participants will receive financial incentives for bioconfirmed smoking cessation.
75322333|NCT03382106|Drug|Sildenafil 20 MG|Sildenafil, 20mg three times daily for 3 month period.
75322334|NCT03382106|Drug|Placebo Oral Tablet|Placebo manufactured to look like Sildenafil 20 MG
75322335|NCT03382106|Diagnostic Test|Pulse wave velocity|Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.
75322336|NCT03382106|Diagnostic Test|Carotid artery compliance and stiffness|An echocardiogram is done by using a probe placed on the skin.
75627132|NCT06200168|Drug|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
75915069|NCT03979885|Behavioral|Financial incentives for use of evidence-based smoking cessation therapies|Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
75915070|NCT03972072|Other|Pre-defined MR-linac based IGRT and plan adaptation protocol|daily MR-imaging/MR guided radiotherapy once weekly offline plan adaptation to a total of 6
75915071|NCT03972072|Diagnostic Test|salivary flow measurements|baseline, 6 month-, 12 month- and 24 month-follow up salivary flow measurements and LENT-SOMA subjective/objective evaluation of xerostomia
75915072|NCT03967717|Other|Characterization of parameters of medical history, examination and diagnostics.|Patients receive standard of care diuretics. The study only collects data to characterize parameters of medical history, examination and diagnostics.
76074297|NCT03805126|Behavioral|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
76074298|NCT03805126|Behavioral|Usual Care|Usual care includes consultation with a social worker and a community health worker.
76074299|NCT00756496|Device|Mammography screening and diagnosis|Mammography screening and diagnosis
76074300|NCT00780208|Drug|Daytrana (methylphenidate patch)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
76074301|NCT00243022|Drug|Boswellia serrata extract|given orally
76074302|NCT00243022|Dietary Supplement|cyanocobalamin|given orally
76074303|NCT03805360|Drug|Ropivacaine|Ropivacaine is a local anesthetic that is expected to provide numbness to the chest wall when injected into the erector spinae plane.
76074304|NCT03805360|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
75322337|NCT03382106|Diagnostic Test|Pressure wave reflection|Carotid pulse measurement taken using a tonometer probe
75322338|NCT00622427|Drug|Ramelteon|8 mg tablets every night for 2 weeks
75322339|NCT00622427|Drug|Placebo|placebo tablets for every night for 2 weeks
75322340|NCT00622895|Drug|fludarabine phosphate|Given IV
75322341|NCT00622895|Drug|Mycophenolic Acid|Given PO
75322342|NCT00622895|Drug|tacrolimus|Given PO
75322343|NCT00622895|Radiation|total-body irradiation|Undergo TBI
75322344|NCT00622895|Procedure|bone marrow transplantation|Undergo transplantation
75322345|NCT00622895|Procedure|reduced intensity allogeneic hematopoietic stem cell transplantation|Undergo transplantation
75627133|NCT06200142|Diagnostic Test|Untargeted metabolomics|Untargeted metabolomics in bloodspots and in plasma
75627134|NCT06200142|Genetic|WES and WGS|WES reanalysis and WGS analysis
75915073|NCT03966014|Drug|EM-amoxicillin 3 x 10 days|Patients will receive amoxicillin 500 milligram tid for 10 days
75915074|NCT03966014|Drug|EM-amoxicillin 3 x 14 days|Patients will receive amoxicillin 500 milligram tid for 14 days
75915075|NCT03966014|Drug|EM-amoxicillin 2 x 14 days|Patients will receive amoxicillin 500 milligram bid for 14 days
75915076|NCT03966014|Other|Controls|No intervention.
75915077|NCT03962452|Genetic|Next Generation Sequencing (NGS)|Determining the nucleic acid sequence
75627135|NCT06200129|Diagnostic Test|sws grade 1|Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 1.
75322346|NCT00622895|Procedure|quality-of-life assessment|Ancillary studies
75627136|NCT06200129|Diagnostic Test|sws grade 2|Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 2
75627137|NCT06200129|Diagnostic Test|control|Group of patients without scattered white lesions in the dueodenum on endoscopy.
75627138|NCT06200116|Other|Non-Interventional Study|Non-interventional study
75627139|NCT06200103|Procedure|Biospecimen Collection|Undergo blood sample collection
75627140|NCT06200103|Procedure|Bone Scan|Undergo bone scan
75627141|NCT06200103|Other|Clinical Observation|Undergo active monitoring
75627142|NCT06200103|Procedure|Computed Tomography|Undergo SPECT/CT or PET/CT
75627143|NCT06200103|Other|Gallium Ga 68 Gozetotide|Given IV
75322347|NCT00622895|Other|laboratory biomarker analysis|Correlative studies
75322348|NCT00622895|Other|flow cytometry|Correlative studies
75322349|NCT00622895|Procedure|biopsy|Punch biopsy of skin involved with scleroderma
75322350|NCT00734305|Drug|MM-121|Dose escalation Frequency - once weekly
75322351|NCT01278823|Procedure|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
75322352|NCT01278823|Other|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
75627144|NCT06200103|Drug|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
75627145|NCT06200103|Procedure|Positron Emission Tomography|Undergo PET/CT
75627146|NCT06200103|Other|Questionnaire Administration|Ancillary studies
75627147|NCT06200103|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
75627148|NCT06200090|Other|No intervention|No intervention
75627149|NCT06200077|Procedure|Modified Ridge-Splitting|Unlike the conventional ridge-splitting where bone grafting is done in the same visit after ridge splitting, modified ridge splitting involves splitting the ridge only at the first visit, then bone grafting is done either alone afterwards in the second visit (Modified 3-Staged Ridge-Splitting Group) and dental implants will be placed in the third visit, or, as in the Modified 2-Staged Ridge-Splitting Group, bone grafting and dental implants placement will be done in the second visit.
75627150|NCT06200051|Diagnostic Test|Prediction of high risk of cancer|This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.
75627151|NCT06200038|Other|Mulligan Reverse Natural Apophysial Glide Technique (RNAGS)|"Mulligan mobilization techniques was applied to the upper thoracic segments with the RNAGS technique. The application was performed with one hand (thumb in extension, other fingers flexed) that was used to perform the pushing maneuver on the transverse processes, while the other arm was used to gently grasp the head of the patient and recline the neck against the body for stabilization.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist."
75627152|NCT06200038|Other|Conventional physical therapy and sham manual therapy|"A sham Mulligan RNAGS technique with low pressure compression was applied to thoracic region.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist."
75627153|NCT06200038|Other|Conventional physical therapy|Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist
75627154|NCT06200025|Other|Cue-based speech therapy in virtual reality|Treatment applied with virtual reality headsets to provide 3d visual and auditory cues to individuals in a virtual environment. A treatment environment where the provision of cues can be controlled by the therapist, interacting with 3d clues and receiving feedback on the accuracy of the named objects.
75627155|NCT06200025|Other|Cue-based speech therapy|Treatment involving the assessment of language skills and the presentation of communication strategies to the individual, including the use of personalized phonological cues.
75627156|NCT06200012|Behavioral|Multi-level stigma reduction intervention: educational training plus controlled substance agreement policy change|Pairing a professional training targeting known attitudinal and knowledge drivers of substance use stigma with a policy altering potentially stigmatizing features of controlled substance agreements.
75627157|NCT06200012|Behavioral|Single-level stigma reduction intervention: educational training|A professional training targeting known attitudinal and knowledge drivers of substance use stigma
75627158|NCT06199999|Procedure|Erector Spinae Block|General anesthesia with Erector Spinae Plane Block: 20 - 25 mL of 0.5% ropivacaine/side (left and right)
75627159|NCT06199999|Procedure|Local infiltration with local anesthetic|General anesthesia with local infiltration of local anesthetic: 80-100 mL of 0.2% ropivacaine
75627160|NCT06199986|Behavioral|ADT Order Check Attestation (Or)|Clinical reminder order check in electronic health record
75322353|NCT01799291|Behavioral|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
75915078|NCT03954210|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is an in-person, one-on-one program with a graduate psychology research assistant who is trained in providing a standardized CBT-I. Participants will maintain a sleep diary during the course of the program to aid in tailoring the program. Each session will begin with a summary and graphing of sleep diary data and will include an assessment of treatment gains and adherence.
75915079|NCT03954210|Behavioral|Sleep and Lifestyle Education|Participants in the sleep and lifestyle education group will attend six weekly, in-person, one-on-one, stretching, and thinking activity sessions with a graduate research assistant to control for socialization and contact with research personnel.
75915080|NCT03941886|Other|Low-dose aspirin in women with high risk of preeclampsia|Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight <40 Kg, from <15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
75915081|NCT03934866|Radiation|Low Dose CT scan|Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.
75915082|NCT03934710|Drug|Placebo|Drug will be administered in solution form
75627161|NCT06199986|Behavioral|Provider Script (Sc)|Provider script added to progress note in electronic health record
75915083|NCT03934710|Drug|Serotonin agonist - 13ug|13ug lysergic acid diethylamide
75915084|NCT03934710|Drug|Serotonin agonist - 26ug|26ug lysergic acid diethylamide
75915085|NCT03929926|Other|Best Practice|receive usual care
75915086|NCT03929926|Behavioral|Cancer Educational Materials|Receive educational materials via mail
75915087|NCT03929926|Other|Behavioral, Psychological or Informational Intervention|Receive shared decision making and lung cancer screening information
75915088|NCT03929926|Other|Counseling|Undergo decision counseling session
75915089|NCT03914547|Behavioral|REDCHiP|REDCHiP includes 10 telehealth sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.
75915090|NCT03914547|Behavioral|ATTN|Provides a similar attention control. ATTN includes 10 telehealth sessions.
75915091|NCT03900650|Behavioral|High provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
75915092|NCT03900650|Behavioral|Low provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
75915093|NCT03900650|Behavioral|Alcoholic beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
75915094|NCT03900650|Behavioral|Non-alcoholic beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
75915095|NCT03896854|Biological|CART-19|CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10^6 CART-19 cells/kg).
75915096|NCT03890120|Drug|Cilofexor|100 mg tablet administered orally once daily
75915097|NCT03890120|Drug|Placebo|Tablet administered orally once daily
75915098|NCT03878524|Drug|Abemaciclib|Given PO
75915099|NCT03878524|Drug|Abiraterone|Given PO
75627162|NCT06199960|Other|Doustim protocol|In Duostim group, the follicular stimulation will be started with a ﬁxed dose of 150 IU of rFSH and HMG 75 IU for 4 days. Daily administration of a GnRH antagonist will be started when the leading follicle are 13-14mm in diameter and continue until the day of the trigger of the ovulation. Five days after the ﬁrst oocyte retrieval second gonadotropin stimulation will be started identical to the ﬁrst one..
75915100|NCT03878524|Drug|Afatinib|Given PO
75915101|NCT03878524|Biological|Bevacizumab|Given IV
75915102|NCT03878524|Drug|Bicalutamide|Given PO
75915103|NCT03878524|Procedure|Biospecimen Collection|Undergo collection of biospecimens (including tissue, blood, or previously collected archival specimens)
75322354|NCT00623441|Device|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
75322355|NCT00672737|Drug|Remifentanil|Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
75627163|NCT06199947|Other|Biopsies and Blood collection|Each participant will have 2 additionnal biopsies during his/her diagnostic endoscopy plus two blood test during his/her inclusion
75627164|NCT06199921|Drug|Atorvastatin 20mg|Participants will receive oral atorvastatin 20mg daily for 18 weeks
75627165|NCT06199921|Drug|Atorvastatin 40mg|Participants will receive oral atorvastatin 40mg daily for 18 weeks
75915104|NCT03878524|Drug|Bortezomib|Given IV
75915105|NCT03878524|Drug|Cabazitaxel|Given IV
75915106|NCT03878524|Drug|Cabozantinib|Given PO
75915107|NCT03878524|Drug|Capecitabine|Given PO
75915108|NCT03878524|Drug|Carboplatin|Given IV
75915109|NCT03878524|Drug|Celecoxib|Given PO
75915110|NCT03878524|Drug|Cobimetinib|Given PO
75915111|NCT03878524|Drug|Copanlisib|Given IV
75915112|NCT03878524|Drug|Dabrafenib|Given PO
75915113|NCT03878524|Drug|Dacomitinib|Given PO
75915114|NCT03878524|Drug|Darolutamide|Given PO
75915115|NCT03878524|Drug|Dasatinib|Given PO
75915116|NCT03878524|Drug|Doxorubicin|Given IV
75915117|NCT03878524|Biological|Durvalumab|Given IV
75915118|NCT03878524|Drug|Enasidenib|Given PO
75915119|NCT03878524|Drug|Entrectinib|Given PO
75915120|NCT03878524|Drug|Enzalutamide|Given PO
75915121|NCT03878524|Drug|Erlotinib|Given PO
75915122|NCT03878524|Drug|Everolimus|Given PO
75915123|NCT03878524|Drug|Fluorouracil|Given IV
75915124|NCT03878524|Drug|Idelalisib|Given PO
75915125|NCT03878524|Drug|Imatinib|Given PO
75915126|NCT03878524|Biological|Ipilimumab|Given IV
75915127|NCT03878524|Drug|Lenvatinib|Given PO
75915128|NCT03878524|Drug|Leucovorin|Given IV
75915129|NCT03878524|Drug|Lorlatinib|Given PO
75915130|NCT03878524|Drug|Losartan|Given PO
75915131|NCT03878524|Drug|Nab-paclitaxel|Given IV
75915132|NCT03878524|Drug|Neratinib|Given PO
75915133|NCT03878524|Biological|Nivolumab|Given IV
75627166|NCT06199921|Drug|Atorvastatin 60mg|Participants will receive oral atorvastatin 60 mg daily for 18 weeks
75915134|NCT03878524|Drug|Olaparib|Given PO
75915135|NCT03878524|Drug|Oxaliplatin|Given IV
75915136|NCT03878524|Drug|Palbociclib|Given PO
75915137|NCT03878524|Drug|Panobinostat|Given PO
75627167|NCT06199908|Drug|AMT-562|Administered intravenously
75915138|NCT03878524|Biological|Pembrolizumab|Given IV
75915139|NCT03878524|Biological|Pertuzumab|Given IV
75322356|NCT00672737|Procedure|Cold pain threshold and tolerance|Ice water was used to assess cold-related pain threshold and tolerance, defined as the time that the volunteers could keep their hands in the water before they started feeling pain or this feeling becomes unbearable, for threshold and tolerance, respectively.
75627168|NCT06199895|Drug|Paclitaxel Polymeric Micelles for Injection|300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
75627169|NCT06199882|Drug|SBRT Sequential Surufatinib Combined With Immunotherapy|"SBRT :~Bioequivalent total dose > 75Gy, completed within 2 weeks (once daily, 5 times a week).~Drug treatment (every 3 weeks is a treatment cycle) :~1) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle."
75779270|NCT03910491|Behavioral|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE emphasizes the 3 Ps (Praise, Paraphrase, and Point-out-Behavior). The training initially focuses on parenting skills including giving attention to the child's positive behaviors and ignoring minor misbehaviors. The second phase of training includes teaching techniques for giving children effective commands to set age-appropriate limits. The PriCARE curriculum also includes trauma and stress education components in order to contextualize the use of these skills with the types of behaviors and problems demonstrated by many children who have experienced psychosocial adversity and chronic familial stress. Throughout the curriculum, caregivers are encouraged to practice the skills. PriCARE has been evaluated in the primary care setting and has shown promise. There have been limited studies on PriCARE for foster caregivers.
75915140|NCT03878524|Drug|Ponatinib|Given PO
75915141|NCT03878524|Other|Quality-of-Life Assessment|Ancillary studies
75322357|NCT00672737|Device|Heat pain threshold and tolerance|TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), was used to assess the heat-related pain and tolerance of the volunteers defined as the respective temperatures where they started feeling as painful or unbearable.
75322358|NCT00672737|Procedure|Polysomnography|All volunteers underwent a polysomnography study at home or at Stanford Sleep Center, approximately one week before their experimental pain assessment in the laboratory
75467147|NCT01917162|Device|UltraFilcon B contact lens|Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
75467148|NCT01917201|Procedure|IVUS-guided group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used."
75627171|NCT06199843|Drug|Rifaximin|Rifaximin 550 mg BD
75915142|NCT03878524|Drug|Regorafenib|Given PO
75915143|NCT03878524|Drug|Ruxolitinib|Given PO
75915144|NCT03878524|Drug|Sirolimus|Given PO
75915145|NCT03878524|Drug|Sorafenib|Given PO
75915146|NCT03878524|Drug|Sunitinib|Given PO
75915147|NCT03878524|Drug|Trametinib|Given PO
75915148|NCT03878524|Biological|Trastuzumab Emtansine|Given IV
75915149|NCT03878524|Drug|Tretinoin|Given PO
75915150|NCT03878524|Drug|Vemurafenib|Given PO
75915151|NCT03878524|Drug|Venetoclax|Given PO
75915152|NCT03878524|Drug|Vismodegib|Given PO
75915153|NCT03878524|Drug|Vorinostat|Given PO
75915154|NCT03875235|Drug|Durvalumab|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
75915155|NCT03875235|Drug|Placebo|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
75915156|NCT03867370|Drug|Toripalimab (JS001 )|Given IV
75915157|NCT03867370|Drug|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
75915158|NCT03867370|Drug|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
75915159|NCT03866525|Biological|OH2 injection, with or without irinotecan or HX008|OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody
75915160|NCT03859921|Drug|Dydrogesterone|Progesterone
75915161|NCT03859921|Drug|Placebo|Placebo with appearance similar to Dydrogesterone
75779271|NCT03903133|Drug|Vitamin E|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
75627172|NCT06199843|Drug|Norfloxacin|Norfloxacin 400 mg OD
75915162|NCT03857672|Behavioral|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT intervention will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention (more than the sum of CT and hypnosis) that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience).
75915163|NCT03851419|Diagnostic Test|Diagnosis of (Neuro)cysticercosis|"Serological tests for cysticercosis~Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~Stool testing for T. solium"
75915164|NCT03848325|Behavioral|Sleep deprivation|Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
75915165|NCT03844412|Drug|5% lidocaine/5 mg/ml 0.02% estradiol compound cream|Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
75322359|NCT03380078|Behavioral|Teams Leadership Institute (TLI)|TLI is training for leaders in how to improve implementation of evidence-based interventions in community settings. TLI includes 5 key components : 1. Assessment: The Implementation Leadership Scale (ILS) and Implementation Climate Scale (ICS) will be completed by first-level leaders participating in the intervention, his/her subordinates (i.e. providers) and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training in implementation leadership Leaders will develop a plan for using specific implementation support strategies. 3. Coaching: Weekly, brief (15-30 min) coaching calls keep leaders on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up : At month 4, leaders attend a 2-hour booster session . 5. Graduation: TLI programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
75322360|NCT03380078|Behavioral|Motivational Enhancement (TIPS for Training)|The TIPS module applies MI principles and strategies to address attitudinal barriers and improve engagement in training. I AIM HI and CPRT trainers (in the TIPS Conditions ) will incorporate MI during training and ongoing consultation/coaching with providers to increase provider engagement and problem solving throughout training: 1. Providers will receive a call designed to provide information about training and the intervention. 2. During the workshop, trainers will assess concerns about participating and will use reflective problem solving to address barriers . Trainers will work with the provider to develop a plan through the use of Planning Worksheets . 3. During each consultation , planning worksheets will be updated collaboratively with the provider. 4. Providers will receive a weekly motivational text to encourage on-going participation.
75627173|NCT06199830|Diagnostic Test|positive bronchial provocation test|Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation. This test was stopped until a reducing in baseline FEV1 of 20%.
75627174|NCT06199804|Behavioral|Toy Hygiene Training|The training was given to the mothers in 2 sessions (morning and afternoon), each lasting approximately 30 minutes, accompanied by the Toy Hygiene Guide. The sessions were presented face to face in the mother's room in the form of explaining, showing, question and answer and power point, at a time convenient for the mother and the child, outside the morning and afternoon treatment and care hours. After the first session was completed, an appointment was made with the mother for the afternoon session. In the second session, the information in the book that was not given in the first session was presented to the mothers face to face in the mother's room, outside the treatment and care hours, at a time convenient for the mother and the child. After the training was completed, a final five-minute discussion was held with the mothers in the form of a general question and answer session. The training book was given to the mothers in the experimental group on the first day.
75627175|NCT06199791|Drug|Lamotrigine 100 MG|tablets
75779272|NCT03841305|Procedure|Liver preparation before major hepatectomy|Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
75779273|NCT03828370|Behavioral|B-SMART Intervention Group|The B-SMART mobile web app will contain four modules: 1) Supporting Abstinence, 2) Shared Positive Activities, 3) Common Challenges for Family Members with IID, and 4) Effective Communication. Within each module there will be a series of learning activities, including presentation text, interactive engagement, and videos. All app content will be available in both English and Spanish, based on user language preference.
75915166|NCT03844412|Drug|Nortriptyline|Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
75627181|NCT06199752|Dietary Supplement|probiotic agent 25 Billion CFU (Nowfoods, USA) , ). Inulin capsules 1000mg Herbamama USA|probiotic agent 25 Billion CFU (Nowfoods, USA), composed of ten strains of bacteria (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantaLactobacillus paracasei, Bifidobacterium breve, Streotococcus thermophiles, Lactobacillus salivarius, and Bifidobacterium longum),
75627182|NCT06199739|Behavioral|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
75627183|NCT06199726|Behavioral|REFLECT web-based tool|Partnering with Nest Genomics, Investigators have developed a customizable web-based tool to support AYA patients through their cancer diagnosis journey for topics related to future family building and genetics. This interactive tool will include educational content to organize knowledge, make connections between concepts, and will include web links to more in-depth content and embedded videos. The interface will allow users to document questions that would be helpful in provider discussions and include decision support to assist with determining values and needs for proceeding with consultations related to genetic counseling and testing, and fertility.
75627184|NCT06199700|Drug|Esketamine hydrochloride|Intravenous infusion of Ketamine
75627185|NCT06199687|Other|Use of Virtual Reality|Use of Virtual Reality after After Thyroid-Parathyroid Surgery
75627186|NCT06199674|Device|photobiomodulation therapy|Patients in the PBM group will be delivered a portable PBM device (PBM Healing Ortho) at the beginning of orthodontic treatment and will be instructed to use it daily at home for 8 minutes (4 min per arch) after tooth brushing.
75627187|NCT06199674|Other|orthodontic fixed-appliance|All eligible patients will receive orthodontic treatment with a pre-adjusted fixed appliance (0.022'' × 0.028'' slot system, MBT, 3M Unitek) provided by the same practitioner. At the start of treatment, a cantilever auxiliary arch bent with a 0.017'' × 0.025'' Stainless Steel wire (3M Unitek) will be used to apply a 100 g intrusion force to the premolars that will be extracted in 3 months. All other teeth will undergo regular orthodontic treatment with a standard archwire protocol (0.014'' NiTi, 0.016'' NiTi, 0.018'' NiTi, 0.017'' × 0.025'' NiTi, 0.019'' × 0.025'' NiTi, and 0.019'' × 0.025'' SS, 0.019'' × 0.025'' TMA) for alignment, leveling, space closure, detailing, and finishing. For en masse retraction, a 150 g force will be applied by coil springs, allowing bracket slots to slide along the 0.019'' × 0.025'' SS.
75779274|NCT03828370|Behavioral|Usual and Customary Information Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on the IID installed in their vehicle and the manufacturer information provided about the IID in PDF format, in both English and Spanish. This constitutes a UC group, as such pamphlets are widely available to DWI offenders who have IIDs installed in their vehicles. Thus, providing this pamphlet represents a standard information provision for first-time DWI offenders and their CFMs.
75779275|NCT03778307|Behavioral|Psychophysiological fear conditioning and extinction task|Behavioral task to assess psychophysiological measures of fear
75779276|NCT03778307|Behavioral|Eyetracking task|Behavioral task to assess dysphoria-relevant attention allocation
75779277|NCT03739502|Drug|Hyperbaric oxygen|"The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).~However, UCB as a graft source for a bone marrow transplant has drawbacks related to the limited cell dose available for transplant and defects in homing. Homing is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient it could delay the re-population of the stem cells (or engraftment), possibly lead to engraftment failure, and delay the rebuilding of the immune system after transplant. This could, in turn, provide a higher risk to infection after the UCB transplant."
75779278|NCT03727633|Drug|Idarubicin and Lipiodol|Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol
75779279|NCT03726931|Diagnostic Test|18F-Fluorestradiol PET/CT scan|[18F]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.
75915167|NCT03844412|Drug|Placebo cream|The comparison treatment will be an identical-appearing placebo Moisturel™ cream
75915168|NCT03844412|Drug|Placebo pill|The comparison treatment will be an identical-appearing placebo pill
75779280|NCT03694002|Drug|Carboplatin|Given IV
75779281|NCT03694002|Drug|Paclitaxel|Given IV
75779282|NCT03694002|Biological|Ramucirumab|Given IV
75915169|NCT03829410|Drug|Onvansertib|Onvansertib orally.
75915170|NCT03829410|Biological|Bevacizumab|Bevacizumab intravenously.
75779283|NCT03654404|Behavioral|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
75915171|NCT03829410|Drug|FOLFIRI|FOLFIRI intravenously.
75915172|NCT03826875|Drug|Fluoxetine|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life
75627188|NCT06199661|Behavioral|APEX|Three phases: warm-up, high-intensity interval training (HIIT) phase, cool-down. A 10-minute warm-up included deep breathing meditation and dynamic joint mobility exercises. Then, a 40-minute strength and balance workout in HIIT format with five different high-intensity (HI) exercises interspersed with five different postural stability recovery exercises. The HI intervals focused on enhancing cardiovascular fitness, muscle strength, and motor performance. The recovery intervals incorporated balance and mobility exercises. The HI exercises lasted 30 seconds for the first three weeks and then increased to 45 seconds in the fourth week while the recovery exercises lasted 60 seconds throughout the entire intervention. The HIIT phase was repeated three times in the 40 minute block. Lastly, a 10-minute cooldown consisting of standing and seated exercises similar to the warm-up.
75467149|NCT01917201|Procedure|Non-IVUS group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used."
75627189|NCT06199648|Other|web-based documentation and advice|Caregivers will be supported with a web-based documentation and advice system for home care for elderly people
75627190|NCT06199635|Device|Self-Forming Magnetic Anastomosis Device and Delivery System|Self-Forming Magnetic Anastomosis Device to create a gastrointestinal anastomosis
75627191|NCT06199622|Other|music|20 minutes of classical Turkish musicor classical western music
75322361|NCT03380078|Behavioral|Classroom Pivotal Response Teaching (CPRT)|CPRT is a naturalistic behavioral intervention adapted from pivotal response training (PRT) for use during classroom activities to target social, communication, behavior, and learning skills. CPRT is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. CPRT has an established training plan and the training curriculum that follows the manual. Training and coaching including standard EBI training is conducted by MA or postdoctoral level researchers with extensive training and experience with CPRT.
75627192|NCT06199609|Procedure|Hemodialysis pathway|AVF and TCC are two different vascular pathways for hemodialysis
75322362|NCT03380078|Behavioral|An Individualized Mental Health Intervention for ASD (AIM HI)|A package of well-established, evidence-based behavioral strategies designed to reduce challenging behaviors in children served in MH service settings. AIM HI is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. AIM HI is a package of evidence-based parent-mediated and child focused strategies, designed to reduce behavior problems in children with ASD ages 5 to 13 served in MH programs. AIM HI has an established training plan and the training curriculum follows the manual. Training and coaching is conducted by MA or postdoctoral level researchers with extensive training and experience with AIM HI.
75322363|NCT05296395|Other|Lactobacillus Plantarum 299v in fermented oat drink|The intervention is a probiotic lactobacillus that is contained in food products in the US
75627193|NCT06199609|Procedure|AVF|Left atrial changes caused by AVF establishment
75627194|NCT06199609|Procedure|AVF|New onset atrial fibrillation caused by AVF establishment
75627195|NCT06199596|Dietary Supplement|alpha-s1 casein hydrolysate|150mg of Prelactium per capsule
75627196|NCT06199596|Dietary Supplement|Maltodextrin|150mg of Maltodextrin per capsule
75627197|NCT06199583|Diagnostic Test|Shear-wave elastography|Ultrasound shear-wave elastography
75779284|NCT03637777|Diagnostic Test|16S rRNA gene sequencing|Specimens collected from patients will be used for next generation sequencing of the bacteria-specific 16S rRNA gene
75779285|NCT03625115|Behavioral|Family Navigator (FN)|The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.
75779286|NCT03623321|Drug|Pimavanserin|• Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
75915173|NCT03826875|Drug|Placebo|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life
75322364|NCT05296395|Other|Heat-Killed Placebo control fermented drink|The intervention is the GoodBelly StraightShort that has been treated to heat kill all Lp299v
75322365|NCT05687006|Procedure|Colour Doppler Ultrasound|The main perforators were examined using a LOGIQ S8/V1 CDU device (GE Healthcare, Chalfont St Giles, Great Britain) with a linear transducer of frequency 4-11 MHz. Measured parameters were: 1) calibre of artery and vein; 2) Peak systolic velocity (PSV) of blood in the artery [cm/s]; 3) blood velocity in the perforator vein [cm/s]; 2) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
75322366|NCT03367442|Other|no intervention|no intervention
75467150|NCT01917227|Behavioral|Video|
75467151|NCT01917240|Other|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
75779287|NCT03550118|Device|Adjustable socket|The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.
75915174|NCT03819361|Diagnostic Test|pulse-oximetry|Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
75915175|NCT03807076|Other|GIP-A|GIP-A
75779288|NCT03503396|Behavioral|BAC Driving Feedback/Warning|Participants will receive a warning at a set BAC limit, indicating they are too impaired to drive.
75779289|NCT03503396|Behavioral|No Feedback|Participants will receive no information about BAC, but will still complete study assessments and provide breath samples during drinking sessions.
75322367|NCT00673127|Drug|Ketoconazole, Hydrocortisone and Dutasteride|"Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal"
75467152|NCT01917253|Device|Standard Device for peripheral vein cannulation|
75627198|NCT06199570|Behavioral|Adapted Stress Management Program|Participants will receive a 15-minute orientation session in-person or remotely to introduce the program and to receive the study materials, including the instructional sheet, small booklet, and study tablet that will be used to promote practice of stress management exercises and for completing study assessments. They will complete self-guided web modules with stress management activities/skills on tablet devices, and will rate the modules' acceptability and perceived helpfulness. After visiting each module, they will be asked to practice at least one skill daily. In a 1-week pre-scan call, they will be reminded about the skills, make a plan for using them, and troubleshoot questions about using the materials. Participants will attend scans and scan result appointments with their oncologist as usual. In a 1-week post-scan phone call, the stress management plan will be revisited for new concerns.
75627199|NCT06199570|Behavioral|Enhanced Usual Care|Enhanced usual care includes a resource list, tablet for study assessments, and reminder calls.
75627200|NCT06199557|Drug|Hydroxyurea, Hydroxycarbamide|Hydroxyurea (HU/hydroxycarbamide) is a hydroxylated analogue of urea which prevents DNA synthesis by inhibiting the activity of ribonucleotide reductase (RNR). HU has been used to treat a variety of diseases. As an antineoplastic drug, HU has some advantages. It may be used by ambulatory patients and has relatively few side effects, which are relieved almost immediately after withdrawal of the drug. The drug is readily absorbed from the gastrointestinal tract following oral administration. At present, HU has an important role as standard of care for treating hyperleukocytosis in chronic and acute myeloid leukemia.
75915176|NCT03807076|Other|Placebo|Placebo
75915177|NCT03802591|Drug|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
75915178|NCT03802591|Drug|CS1001 placebo|Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
75915179|NCT03802591|Drug|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
75915180|NCT03802591|Drug|Capecitabine|Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
75915181|NCT03793114|Diagnostic Test|Cosyntropin stimulation test|Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.
75915182|NCT03793114|Diagnostic Test|Baseline blood tests|Medication-fasting morning levels of adrenocortical hormones.
75322368|NCT01799837|Drug|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
75322369|NCT00246259|Drug|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
75467153|NCT01917253|Device|Long Catheters for peripheral vein cannulation|
75915183|NCT03793114|Device|30-hour ambulatory sampling of intestinal fluid|30-hour ambulatory sampling of intestinal fluid for analysis of adrenocortical hormones.
75915184|NCT03793114|Other|Blood test|Cardiovascular and inflammatory biomarker profiles
75467154|NCT01917279|Drug|Docetaxel plus Capecitabine|"Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase."
75467155|NCT01917279|Drug|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
75627201|NCT06199557|Drug|Valproic acid|Valproic acid (VPA) has been used clinically as an anticonvulsant and mood-stabilizing drug. During the last two decades, VPA has been described as a histone deacetylase (HDAC) inhibitor and gained increased interest for use in cancer therapy. VPA is administered orally with available routine measurements of serum levels and has a low toxicity profile.
75627202|NCT06199557|Drug|6-Mercaptopurine (6-MP)|In 1953, 6-MP was an approved antileukemic agent resulting in remissions in children with acute lymphocytic leukemia (ALL). After adding 6-MP to methotrexate and prednisolone in the treatment regimen, the one-year mean survival of children with ALL was increased from 29% to 50%. 6-MP, even about 70 years after its discovery, remains the standard maintenance therapy once the children are in complete remission.
75627203|NCT06199544|Drug|Metformin|Comparing the effect of drugs on symptoms of PCOS
75779290|NCT03447314|Drug|GSK1795091|GSK1795091 will be available as solution for injection
75779291|NCT03447314|Drug|GSK3174998|GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
75779292|NCT03447314|Drug|GSK3359609|GSK3359609 will be available as solution for infusion.
75779293|NCT03447314|Drug|Pembrolizumab|Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
75779294|NCT03424174|Device|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
75779295|NCT03424174|Device|Standard Total Knee Arthroplasty|Implantation StandardTotal Knee Arthroplasty
75779296|NCT03423121|Drug|Tauroursodeoxycholic Acid|Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
75627204|NCT06199531|Genetic|GS-100|A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
75627205|NCT06199518|Procedure|transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)|extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures
75627206|NCT06199505|Drug|GZR101|Once daily
75627207|NCT06199505|Drug|insulin degledec/insulin aspart|Once daily or twice daily
75627208|NCT06199479|Procedure|MRI Scan|Performed by MRI Scan
75627209|NCT06199479|Procedure|CT Scan|Performed by CT Scan
75627210|NCT06199479|Procedure|Biopsy|Standard of Care Biopsy
75627211|NCT06199453|Drug|Lutetium (177Lu) vipivotide tetraxetan|6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
75627212|NCT06199440|Drug|Group I|First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
75627213|NCT06199440|Drug|Group II|Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.
75627214|NCT06199440|Drug|Group III|"Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol."
75627215|NCT06199427|Drug|Cyclophosphamide|Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD
75627216|NCT06199427|Drug|Ruxolitinib|Ruxolitinib 7 mg/m2 from day +5 after HSCT
75627217|NCT06199414|Device|Venous Closure|Vascular closure to achieve vascular hemostasis following femoral access with large bore sheaths in catheter ablation procedures
75779297|NCT03423121|Drug|Placebo oral capsule|Participants will be given four capsules of the placebo twice daily.
75779298|NCT03413423|Behavioral|BAT-CS|All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
75322370|NCT00246259|Drug|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
75467156|NCT01917279|Drug|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
75627218|NCT06199401|Procedure|Vascular Grafts Eversion and Built-in Technique(XJ-Procedure)|A 1.5-2cm wide bovine pericardial patch and graft ring will be placed inside and outside the aortic root and against the aortic wall, respectively, and continuously sutured near the commissure using 5-0 polypropylene. Then an eversion about 15mm of vascular graft will be intermittently sutured to full layers of aortic vascular with 2-0 pad polyester suture. Finally, the eversion and aortic wall will be continuously sutured together in one more turn.
75627219|NCT06199388|Other|Survival state|We recorded clinically relevant information and survival status of pediatric glioma patients
75627223|NCT06199349|Drug|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
75627224|NCT06199349|Other|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial
75627225|NCT06199336|Biological|JHM03|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.5 ml,0.1 ml per site.
75627226|NCT06199336|Biological|BOTOX®|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
75627227|NCT06199336|Biological|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
75779299|NCT03413423|Behavioral|Smoking Cessation and Health & Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
75779300|NCT03365882|Biological|Cetuximab|Given IV
75322371|NCT04400786|Procedure|intermittent treatment|According to the feeling of pain, the on-demand treatment group is prescribed with or without Imrecoxib (100mg/tablet, 100mg.prn.po), but the maximal dose does not exceed 100 mg per time, twice (morning and evening) per day. The duration lasted for 24 weeks.
75322372|NCT04400786|Procedure|continuous treatment|The continuous treatment group is prescribed Imrecoxib (100mg.bid.po) regardless of the pain in the treatment course for 24 weeks.
75779301|NCT03365882|Drug|Irinotecan Hydrochloride|Given IV
75779302|NCT03365882|Other|Laboratory Biomarker Analysis|Correlative studies
75915185|NCT03783689|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
75915186|NCT03771664|Drug|SAGE-217|Administered as capsules.
75915187|NCT03771664|Drug|Placebo|Administered as capsules.
75322373|NCT00624221|Procedure|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
75322374|NCT03317834|Device|Navio ™ Robotic-assisted Surgical System|Total Knee Replacement
75322375|NCT05686928|Drug|Cetaphil Healing Ointment|Topical ointment application twice daily
75322376|NCT00673439|Drug|fondaparinux|Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
75322377|NCT00673439|Drug|warfarin|Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
75915188|NCT03762447|Drug|INCB086550|INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
75467157|NCT01917292|Procedure|One-Stage Full-Mouth Disinfection|"Basic oral hygiene instructions~Dental extractions will be performed (only in cases of teeth that could not be saved)~Standard cycle of supragingival ultrasonic scaling and polishing~Scaling and root planning after the administration of local anesthesia, four quadrants in one session~Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets"
75779303|NCT03365882|Biological|Pertuzumab|Given IV
75779304|NCT03365882|Biological|Trastuzumab|Given IV
75779305|NCT03365882|Device|HER-2 testing|Central testing of HER-2 for eligibility
75915189|NCT03753074|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
75779306|NCT03364530|Drug|Gemcitabine-Oxaliplatin Regimen|"Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity."
75779307|NCT03364530|Procedure|Hepatic intra arterial chemotherapy|"The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor."
75915190|NCT03752411|Other|Research Bottle|The purpose of the study is to test a research prescription bottle that will monitor the physical environment inside the bottle.
75915191|NCT03752411|Other|Regular prescription Bottle|This will test if the research bottle changes behavior relative to the research bottle
75322378|NCT03316118|Drug|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
75322379|NCT03316118|Drug|saline|Group 2 will receive genicular nerve block using normal saline
75322380|NCT03029013|Drug|Apatinib|Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
75322381|NCT00674219|Drug|Memantine|Namenda 10mg BID for 12 weeks
75915192|NCT03743415|Behavioral|Handbook|see arm/group descriptions
75915193|NCT03743415|Behavioral|TIP-C plus Handbook|see arm/group descriptions
75915194|NCT03739853|Drug|Methotrexate|Used in all three arms of study
75915195|NCT03739853|Drug|Sulfasalazine|Used in arm 2 of study
75915196|NCT03739853|Drug|Leflunomide|Used in arm 2 of study
75915197|NCT03739853|Drug|Adalimumab|Used in arm 3 of the study only
75915198|NCT03733184|Procedure|Cytoreduction and Heated Intraperitoneal Surgery|Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).
75915199|NCT03731572|Other|Power Training|Hip abductor-adductor resistance exercises at maximum execution speed
75915200|NCT03731572|Other|Strength Training|Hip abductor-adductor resistance exercises at reduced execution speed
75915201|NCT03722693|Device|Functional electrical stimulation based treatment|Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
75915202|NCT03711214|Procedure|Periodontal scaling|Periodontal scaling and root planing
76074305|NCT03805048|Procedure|Percutaneous coronary intervention|PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
75322382|NCT03378908|Behavioral|Intervention Treatment|Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
75779308|NCT03335475|Behavioral|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
75779309|NCT03335475|Behavioral|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
75779310|NCT03316391|Other|Dosage of urinary podocyturia|Dosage of urinary podocyturia at admission, delivery and post-partum visit
75779311|NCT03303066|Drug|FG-4592|Oral
75779312|NCT03303066|Drug|Placebo|Oral
75779313|NCT03289910|Drug|Carboplatin|Given IV
75779314|NCT03289910|Drug|Topotecan|Given IV
75779315|NCT03289910|Drug|Topotecan Hydrochloride|Given IV
75779316|NCT03289910|Drug|Veliparib|Given PO
75779317|NCT03260478|Procedure|Red Blood Cells Transfusion|Transfusion of packed red blood cells unit(s).
75779318|NCT03253133|Drug|Oxaliplatin|"Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 * 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~* Start level"
75779319|NCT03253133|Drug|LV5FU or Folfiri|Association of chemotherapy by LV5FU or Folfiri according pratician choice
75779320|NCT03253133|Drug|Oxycodone|Oxycodone
75915203|NCT03707834|Behavioral|Antenatal Obesity Treatment (AO)|Participants in the treatment (AO) arm will receive a 4-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; and 4)WIC provider counseling Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
75915204|NCT03706677|Device|Cryoballoon (Arctic Front Advance Cryoballoon)|Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)
75915205|NCT03706677|Device|Radiofrequency Catheter (ThermoCool Smarttouch)|Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)
75322383|NCT00674297|Drug|Fluvastatin|Fluvastatin 40 mg daily for 3 months
75322384|NCT05608317|Device|ALLEVYN Non-Adhesive|"ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction.~ALLEVYN Non-Adhesive consists of the following layers:~Breathable top film~Highly absorbent foam core~Non-adhesive wound contact layer"
75322385|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
75779321|NCT03252756|Other|Placebo|Saline taken by mouth (PO)
75779322|NCT03252756|Drug|Phytocannabinoid cannabidiol (CBD)|CBD taken by mouth (PO)
75779323|NCT03225417|Drug|Ixazomib|Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.
75779324|NCT03225417|Drug|Tacrolimus|Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
75779325|NCT03225417|Drug|Sirolimus|Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
75322386|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
75322387|NCT00246025|Drug|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
75467158|NCT01917292|Procedure|Periodontal care|"Basic oral hygiene instructions~Standard cycle of supragingival ultrasonic scaling and polishing"
75627231|NCT06199284|Device|Atalante exoskeleton|The gait training program using Atalante exoskeleton consisted of 3 sessions per week for 6 weeks. For each participant, the assistance of the exoskeleton can be specifically adjusted and can be set symmetrically or asymmetrically bases on his capabilities.
75627232|NCT06199258|Diagnostic Test|pulmonary function test|pulmonary function testing
75627233|NCT06199219|Other|Sexual counseling, based on the extended (EX-PLISSIT)|"The EX-PLISSIT model is done in a cyclical manner. In other words, it is an interactive and repetitive model. All interventions must begin with Permission. Each stage of Limited Information, Special Recommendation and Intensive Therapy is supported by Allowing. Thus, the interaction between counselors and clients is improved (Taylor and Davis 2006; Punjani and Papathanasoglu, 2019)."
75627234|NCT06199193|Dietary Supplement|Personalized diet|Personalized supplement designed by artificial intelligence based on the intestinal microbiota and incorporated into diets
75627235|NCT06199193|Dietary Supplement|Dietary counseling|Dietary advice will be provided to adapt the diet to the nutritional objectives and recommended intakes.
75627236|NCT06199180|Device|pulmonary vein isolation with RFA|Patients randomised to RFA will undergo PVI with point-by-point RFA.
75627237|NCT06199180|Device|pulmonary vein isolation with PFA|Patients randomised to PFA will undergo PVI with PFA.
75627238|NCT06199167|Behavioral|Action Observation Therapy|The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes. In the 15-session treatment, a total of 18 ADL activities.
75627239|NCT06199167|Behavioral|Photo Observation|The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes. In the 15-session treatment, a total of 18 ADL activities.
75627240|NCT06199154|Drug|Misoprostol|Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.
75627241|NCT06199128|Dietary Supplement|carboxymethyl β-glucan|It is a vaginal spray gel designed for the prevention and treatment of cervical lesions caused by HPV. This is achieved by controlling the physiological conditions of the transformation zone of the cervico-vaginal mucosa. The composition of the gel, which includes polycarbophil and carboxymethyl-beta-glucan, effectively shields the cervico-vaginal mucosa from the damaging effects of external agents due to its bioadhesive capacity. Additionally, it contributes to the re-epithelialization and regression of cervical lesions
75627242|NCT06199115|Procedure|Photobiomodulation|"In oncology, photobiomodulation is used to help heal damaged tissues, improve immune response, reduce inflammation, and prevent or treat certain side effects of treatments such as chemotherapy. Photobiomodulation is also the subject of recent clinical studies to expand its indications (peripheral neuropathies induced by certain chemotherapies.~Patients in the experimental group will receive 3 photobiomodulation sessions per week during their oxaliplatin treatments (6 months), for a total of 72 sessions. Exposition to laser light is 30 minutes for each session."
75627243|NCT06199102|Dietary Supplement|cholecalciferol/ Devikap|Infants in the monitored group will receive an initial dose of 1000 IU of vit D. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). At 28±2 days of age, blood samples will be obtained for 25(OH)D concentration measurement, followed by measurements every 4 weeks and/or 35±1 weeks of PCA. In the monitored group, vit D doses will be appropriately modified, based on 25(OH)D levels, using the scheme described in the Polish recommendation. The intake from the diet will be calculated from the second month of life.
75627244|NCT06199102|Dietary Supplement|cholecalciferol/ Devikap|Infants in the controlled group will receive 250 IU for very low birth weight infants and 500 IU for infants weighing above 1000 g. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). Infants assigned to the standard therapy group will undergo the same blood sample collection procedure as the monitored group, but without any alterations in their dosing regimen.
75779326|NCT03225417|Drug|Any prophylaxis for GVHD|Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
75779327|NCT03209609|Device|VEST|External support for vein grafts, cobalt chrome braid
75322388|NCT00246025|Drug|placebo|matching placebo capsule, once a day, oral administration
75322389|NCT03311594|Drug|Low Alcohol|Low Alcohol Consumption
75322390|NCT03311594|Drug|Moderate Alcohol|Moderate Alcohol Consumption
75322391|NCT03311594|Drug|Placebo Alcohol|Placebo Alcohol Consumption
75322392|NCT03311594|Other|Pain Induction|10% capsaicin solution placed on forearm and heat induction
75322393|NCT03311594|Other|No Pain Induction|Water placed on forearm
75467159|NCT01917305|Device|platform-shifted implant|
75467160|NCT01917318|Drug|Iloperidone|"Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)"
75467161|NCT01917318|Drug|Placebo|During 8 weeks subjects will receive oral placebo
75467162|NCT01917331|Drug|Beclometasone/Formoterol/Glycopyrrolate|Active drug tested
75915206|NCT03680963|Procedure|Non-invasive strategy|"No indwelling arterial catheter insertion will be allowed during the first 28 days, excepted if predefined safety criteria (indicating absolute need of indwelling arterial catheter insertion) are reached.~In the non-invasive group, automated oscillometric monitor will be used to monitor BP (blood pressure)."
75322394|NCT05019053|Behavioral|Coping Crew|Coping Crew consists of five 60-minute virtual intervention sessions coinciding with five weeks of EMI. Participants will receive psychoeducation, challenge cognitive biases or mythbust, and participate in behavioral exposure and behavioral experiments. An EMI component of this treatment will be included for the purpose of treatment monitoring and homework tracking. Participation in this EMI component involves the daily report of levels of anxiety, depression, stress, and loneliness. When participants endorse elevated levels on any of these constructs, they will receive a targeted message reminding them of the topics covered in COPING CREW. One month after the intervention session, COPING CREW participants will complete follow-up questionnaires and interview. Participants will also participate in a feedback session 3 months after the intervention.
75322395|NCT01271335|Biological|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
75322396|NCT05596929|Diagnostic Test|Artificial intelligence|After the patients under triage classification to which randomly allocates in two groups. The group with AI intervention and the other without AI intervention.
75627245|NCT06199076|Drug|Oxytocin nasal spray|The clinical trial is a phase II-study double-blind placebo-controlled study. The trial will have a parallel group cross-over design where subjects with alcohol use disorder versus healthy controls will administer a single dose of intranasal oxytocin versus placebo on two study visits 1-3 weeks apart.
75627246|NCT06199063|Other|Self-Streching Exercises|The participants in the SSE group; received 1 session SSE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
75779328|NCT03209609|Procedure|Coronary artery bypass vein grafts|Bypass coronary arteries with autologous saphenous vein grafts
75627247|NCT06199063|Other|Post-Isometric Relaxation Exercises|The participants in the PIRE group; received 1 session PIRE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
75627248|NCT06199063|Other|Reciprocal-Inhibiton Exercises|The participants in the RIE group; received 1 session RIE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
75627249|NCT06199050|Other|Questionnaire: SPIRIT|"T0: Before the first intake at Maastro, the Trialpoli (TP) contacts a patient via phone to inform whether or not he is interested in participating in this study. If the patient shows interest in participating in the study, he will be invited for a consultation with the Trialpoli. This consultation takes place on the day of intake at Maastro. After consent, the patient is randomized to fill out T0 before or after the intake.~T1: After filling out T0, the patient receives the ENGAGE information card with the url en QR code to the VR-movie. After watching the VR movie and before start RT the patient is asked to fill in T1. This questionnaire is distributed with instructions by the TP.~T2: Between the 5th and the 15th radiation treatment, patients will be asked to fill in the questionnaires for the third and last time. The Patient Information Form (PIF) and Informed Consent (IC) are added in a separate document."
75779329|NCT03164356|Device|Bioimpedance monitor|Participant in aim 1 will be monitored using the bioimpedance monitor. Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
75779330|NCT03091660|Biological|BCG Solution|Given intravesically
75779331|NCT03091660|Biological|BCG Tokyo-172 Strain Solution|Given intravesically
75779332|NCT03091660|Biological|BCG Tokyo-172 Strain Vaccine|Given ID
75779333|NCT03091660|Other|Laboratory Biomarker Analysis|Correlative studies
75915207|NCT03680963|Procedure|Control strategy|An indwelling arterial catheter will be inserted as soon as possible (within the first four hours after randomization) and will be maintained except in case of indwelling arterial catheter futility, suspected or proven indwelling arterial catheter related infection or thrombosis (at discretion of attending physician) until day 28 or ICU (Intensive Care Unit) discharge (whichever comes first). After day 28, clinicians may choose to maintain or to remove indwelling arterial catheter.
75915208|NCT03672175|Drug|SAGE-217|SAGE-217 hard gelatin capsules.
75915209|NCT03672175|Drug|Placebo|SAGE-217 matched placebo hard gelatin capsules.
75915210|NCT03670524|Other|Greenness as a therapeutic intervention|Greenness to be used as a therapeutic intervention
75915211|NCT03653832|Drug|Dexmedetomidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
76025625|NCT04454879|Drug|Roxadustat|Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
76025626|NCT05122169|Drug|Povidone-Iodine|Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
76025627|NCT05122169|Drug|Chlorhexidine|Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
75467163|NCT01917331|Drug|Beclometasone/Formoterol|Active comparator
75467164|NCT01917357|Biological|Quinvaxem in Uniject|
75467165|NCT01917357|Biological|Quinvaxem in single dose vials|
75779334|NCT03091595|Drug|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
75779335|NCT03091595|Drug|20 mcg EE/3 mg DRSP|20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
75779336|NCT03089541|Behavioral|Survey Arm|Contingency Management for completion of surveys and evidence of tobacco use status
75779337|NCT03028402|Procedure|C5-C6 arthrodesis|A standard Smith Robinson anterior medial approach to the cervical spine. Vertebral endplates will be prepared by removing the cartilage endplate. Tricortical anterior iliac crest autografts will be harvested with a low-speed oscillating saw. Allografts will be fresh-frozen, vacuum-sealed, nonradiated tricortical grafts. All grafts will be fashioned in a typical Smith-Robinson formation. The motion segment will be distracted approximately 2-mm beyond the graft height before the insertion of each graft. Fusion plate will be contoured to cervical lordosis. Cervical plates will be positioned using surgical midline markers. All rigid anterior plate fixations will be performed using titanium anterior fixed-angle screw systems.
75915212|NCT03653832|Drug|Clonidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
75915213|NCT03653832|Drug|Propofol|Patients will continue to receive intravenous propofol according to current usual care.
76025628|NCT04387955|Diagnostic Test|Biological Sample Collection|"Diagnostic test : biological sample collection at Day 0~Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)~Anal swabbing at Day 0~Blood test at Day 0~Blood test at Month 1~Blood test at Month 2"
75322397|NCT00624923|Drug|Salsalate|Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
75322398|NCT00624923|Drug|Placebo|Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
75322399|NCT05593653|Drug|Suvorexant|20mg taken at bedtime for 4 weeks
75322400|NCT05593653|Drug|Placebo|placebo taken at bedtime for 4 weeks
75322401|NCT00625391|Drug|Placebo|500 mg medicinal starch pills daily
75322402|NCT00625391|Drug|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
75627250|NCT06199050|Other|Questionnaire: HADS|Hospital Anxiety and Depression Scale, 14 questions likert scale
75627251|NCT06199050|Other|Questionnaire: QSC-R23|Dutch version of the Questionnaire on stress symptoms, 23 questions likert scale
75627252|NCT06199050|Other|General questions|"Education level~Marietal status~Medication use (in order to assess influence on fear)~Previous cancer diagnosis~Acquired information on treatment~Expected fear and anxiety mitigation strategies~Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~PROM at baseline"
75322403|NCT00625391|Drug|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
75322404|NCT00625391|Drug|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
75322405|NCT03375866|Other|Pretzels|Subjects consume 240 kcal of pretzels daily for 16 weeks.
75322406|NCT03375866|Other|Mixed nuts|Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
75322407|NCT00735787|Biological|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
75322408|NCT00735787|Biological|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
75627253|NCT06199050|Other|Clinical data collected|"Clinical data in HIX:~Age~Gender~Cancer type~WHO status~TNM"
75779338|NCT03025971|Device|J-Valve Transcatheter Aortic valve replacement|Transapical Transcatheter Aortic Valve Replacement
75322409|NCT02986893|Behavioral|Dietary Intervention|Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
75322410|NCT02986893|Behavioral|Non-dietary Intervention Arm|Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
75627254|NCT06199037|Drug|SHR-1707|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection
75627255|NCT06199037|Drug|SHR-1707 placebo|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
75779339|NCT02926391|Device|UNiD 3D VBR|Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
76025629|NCT04359329|Drug|Estradiol patch|Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
76025630|NCT04326101|Other|Transmission of adherence records|Electronic transmission of patient adherence records by pharmacists into medical EHR (Electronic Health Records)
76025631|NCT04494035|Device|CAPERE Thrombectomy System|Arteriovenous graft thrombectomy
76025632|NCT03041285|Drug|idronoxil (NOX66) suppository|"Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~."
76025633|NCT03041285|Radiation|Stereotactic Body Radiation Therapy|All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
76025634|NCT04794023|Device|Corneal Ablation|Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
76025635|NCT04256681|Other|SNAP questionnaire|The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
75915214|NCT03650712|Diagnostic Test|Oral glucose tolerance test|oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
75915215|NCT03650712|Diagnostic Test|Continuous glucose monitoring|a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days
75915216|NCT03650712|Diagnostic Test|Dexa scan|low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
75915217|NCT03643276|Drug|Blinatumomab|Experimental therapy in randomizations R-HR and R-MR
75627256|NCT06199024|Dietary Supplement|Oral cinnamon supplementation|In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
75467166|NCT01917370|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
75627257|NCT06199011|Drug|Esketamine hydrochloride|A standardized non-opioid anesthesia will be achieved by using continuous intraoperative infusion of esketamine.
75627258|NCT06199011|Drug|Opioid|A standardized opioid anesthesia will be achieved by using continuous intraoperative infusion of opioids.
75322411|NCT04349943|Other|nutrition therapy|With enteral nutrition as the preferred solution, the gradual transition from slow to fast, from lean to dense, from essential to whole protein type is conducted.
75322412|NCT05418062|Behavioral|Acceptance and commitment therapy (ACT)|8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
75322413|NCT00628589|Drug|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
75467167|NCT01917396|Drug|Fleet enema|
75467168|NCT01917409|Device|conventional laryngoscopy|the device is to assist nasotracheal intubation
75627259|NCT06198998|Device|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides hemodynamics support for intraoperative protection during high-risk percutaneous coronary intervention.
75627260|NCT06198985|Procedure|Dynamic balance exercise with tecnobody prokin 252 balance device|Dynamic balance exercise with tecnobody prokin 252 balance device
75779340|NCT02923232|Device|Accommodative contact lens|Different downgaze angles will be experimented to determine whether the accommodative contact lens can alter its optical refraction at downgaze angles.
75779341|NCT02914808|Other|Patients will undergo a lower limb MRI and blood tests|
75467169|NCT01917409|Device|video-stylet|the device is to guide the nasotracheal tube into trachea
75467170|NCT01917435|Device|video-stylet|
75467171|NCT01917435|Device|fiberoptic bronchoscope|
75467172|NCT01917448|Drug|Morphine|spinal morphine 0.15 mg
75467173|NCT01917448|Other|control|Patient receive only local infiltration without spinal analgesia
75779342|NCT02887820|Device|Thromboelastograph|A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
75779343|NCT02861781|Other|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
75779344|NCT02626312|Other|Laboratory Biomarker Analysis|Correlative studies
75779345|NCT02626312|Procedure|Magnetic Resonance Imaging|Correlative studies
75915218|NCT03643276|Drug|Bortezomib|Experimental therapy in randomization R-eHR
75915219|NCT03643276|Drug|Cyclophosphamide|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
75322414|NCT00628589|Drug|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
75322415|NCT00628589|Drug|Inhaled placebo|Inhaled placebo
75915220|NCT03643276|Drug|Cytarabine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
75915221|NCT03643276|Drug|Daunorubicin|Part of standard chemotherapy
75915222|NCT03643276|Drug|Myocet|Part of intensification block Myocet-FLA for patients with very high relapse risk
75915223|NCT03643276|Drug|Dexamethasone|Part of standard chemotherapy
75915224|NCT03643276|Drug|Doxorubicin|Part of standard chemotherapy
75915225|NCT03643276|Drug|Etoposide|Part of standard chemotherapy
75915226|NCT03643276|Drug|Fludarabine Phosphate|Part of intensification block Myocet-FLA for patients with very high relapse risk
75322416|NCT04813445|Drug|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
75322417|NCT01271569|Drug|Fospropofol disodium|Fospropofol disodium： 0.5g
75322418|NCT05686772|Drug|Dopamine partial agonists|Use of antipsychotics (i.e., dopamine partial agonists vs dopamine antagonists)
75322419|NCT05686772|Other|Psychiatric comorbidities|Mainly substance use disorders and personality disorders
75322420|NCT05686772|Other|Sex|Biological sex at birth
75322421|NCT05686772|Other|Gender|Current gender identity
75322422|NCT05686772|Other|Socioeconomic status|Including main source of income, employment status, homelessness
75322423|NCT05686772|Other|Gambling history|History of gambling (i.e., recreational or problematic) prior to admission in the clinics
75322424|NCT04771871|Drug|Epirubicin|Epirubicin is an antitumor antibiotics with good activity on breast cancer. It has less cardiotoxic effect than doxorubicin
75322425|NCT04771871|Drug|Cyclophosphamide|Cyclophosphamide is a cytoxic drug indicated for the treatment of many malignancies including breast cancer
75322426|NCT04771871|Drug|Paclitaxel|Paclitaxel is a taxane chemotherapy agent indicated for the treatment of many cancers including breast cancer. It can be used alone or in combination with other drugs
75322427|NCT04771871|Drug|Carboplatin|Carboplatin is a platinum compound indicated for the treatment of many types of malignancies including breast cancer
75915227|NCT03643276|Drug|Ifosfamide|Part of standard chemotherapy
75915228|NCT03643276|Drug|6-Mercaptopurine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
75915229|NCT03643276|Drug|Methotrexate|Part of standard chemotherapy
75915230|NCT03643276|Drug|Pegaspargase|Part of standard chemotherapy
75322428|NCT05589207|Diagnostic Test|Vascular wall invaded|Inferior vena cava vascular wall is invaded according to pathologic examination on the postoperative tumor thrombus/ vascular wall specimen.
76074306|NCT03801772|Device|Metronome|Pacing aquatic exercises to the beats per minute of a metronome. The metronome will be adjusted to each patient's pain free exertion level. Patients will start with 10-20 repetitions of the exercises depending on their physical ability. The repetitions will be progressed as the patient's strength and endurance improve and noted in the chart and the flow sheet. The metronome will be synchronized during their second aquatic therapy treatment. The beats per minute (BPM) will be increased on the metronome during the series of treatments until the patient can no longer maintain proper technique with the exercises. The exercises will continue at this BPM during future visits. The patient will be instructed to keep pace with the beat of the metronome for the duration of the exercise.
76074307|NCT00756964|Drug|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
75627261|NCT06198972|Other|Pelvic Pnf exercises|"Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Pelvic patterns~Anterior elevation-Posterior depression~Anterior depression-Posterior elevation PNF techniques~Repetitive stretching~Rhythmic stabilization"
75627262|NCT06198972|Other|Strength exercises|"3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down Lower extremity movements~Hip flexion~Hip extension~Hip abduction~Hip adduction~Knee flexion~Knee extension Resistance exercise training"
75627263|NCT06198946|Device|External diaphragm pacing（EDP）|After the skin is disinfected, place the small electrode pads on the lower 1/3 of the outer edges of the sternocleidomastoid muscles on the left and right sides, and place the large electrodes on the surface of the pectoralis major muscles on both sides, and fix them with medical tape. Adjust the pacing according to the patient's tolerance. Frequency and stimulation intensity, each treatment time is 20 minutes, treatment is once a day, 5 days a week, and the treatment course is 4 weeks.
75627264|NCT06198946|Other|Routine rehabilitation treatment|Participants received comprehensive rehabilitation treatments such as muscle strength training, hemiplegic limb comprehensive training, balance function training, limb neuromuscular electrical stimulation, acupuncture and other comprehensive rehabilitation treatments. Each project was 30 minutes/time, once a day, 5 days a week, and the treatment course was 4 weeks.comprehensive rehabilitation treatments, each item is 30 minutes/time, once a day, 5 days a week, and the treatment course is 4 weeks.
75627265|NCT06198933|Device|Pulsed-field ablation|Patients will atrial fibrillation will undergo catheter ablation using pulsed-field energy
75627266|NCT06198907|Drug|Golidocitinib|Daily dosing of golidocitinib
75627267|NCT06198907|Drug|Sintilimab|Sintilimab, 200mg, intravenous, every 3 weeks.
75627268|NCT06198907|Drug|platinum doublet chemotherapy|Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
75627269|NCT06198855|Device|QMon-20 device|Automatic Blood pressure measurement with QMon-20 device in the waiting room for 20 minutes every 5 minutes.
75627270|NCT06198842|Drug|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
75627271|NCT06198829|Other|Physical examination tests and surveys|Patients'hip joint range of motion range of motion, pain levels, pressure-pain threshold levels, kinesiophobia levels, and hip dysfunction levels will be measured, and the alpha angle will be evaluated on hip radiographs.
75627272|NCT06198816|Other|ultrasound accelerated thrombolysis and venoplasty|IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).
75915231|NCT03643276|Drug|Prednisolone|Part of standard chemotherapy
75915232|NCT03643276|Drug|Tioguanin|Part of standard chemotherapy
76074308|NCT00756964|Drug|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
75322429|NCT01278979|Device|"Objective measurements of perineal tears with Peri-Rule"|"Four measurements will be used in this study.~Depth of tear, from the fourchette into the greatest depth of the perineal body.~Length of tear, from the fourchette to the apex of the vaginal tear.~Length of tear, from the fourchette along perineal skin towards the anus.~Length of the perineal body, from the fourchette to outer margin of anus."
75322430|NCT01278979|Other|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
75322431|NCT03374930|Procedure|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
75467174|NCT01917474|Dietary Supplement|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
75627273|NCT06198803|Drug|L Carnitine|The study population will be randomly divided into 2 groups, 1 group will receive Carnitine supplementation in a dose of 100mg/kg/day
75915233|NCT03643276|Drug|Vincristine|Part of standard chemotherapy
75627274|NCT06198777|Device|Magnetometer|Inspection equipment for magnetocardiography
75627275|NCT06198764|Drug|Colistimethate sodium for injection|Colistimethate Sodium for Injection is the Prodrug of Polymyxin E, which is hydrolyzed into Polymyxin E after entering the human body to play a bactericidal role.Polymyxin selectively acts on gram-negative aerobic bacteria with hydrophobic outer membrane, leading to cell death by destroying the cell membrane.
75627276|NCT06198764|Drug|Meropenem for Injection|Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.
75915234|NCT03643276|Drug|Vindesine|Part of standard chemotherapy
75915235|NCT03643276|Drug|Erwinase|Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
75915236|NCT03643224|Device|Radiofrequency Ablation|A procedure will be performed using a radiofrequency ablation catheter.
75915237|NCT03641287|Other|Exercise Counseling|Meet with exercise physiology
75915238|NCT03641287|Other|Aerobic Exercise|Receive prescription for moderate aerobic exercise
75915239|NCT03641287|Other|Physiological Support|Receive motivational support via telephone care
75915240|NCT03641287|Other|Quality-of-Life Assessment|Ancillary studies
75322432|NCT04386577|Dietary Supplement|Vitamin D3 (cholecalciferol)|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
75779346|NCT02626312|Radiation|Radiation Therapy|Undergo radiation therapy
75915241|NCT03641287|Other|Questionnaire Administration|Ancillary studies
75915242|NCT03641287|Other|Best Practice|Undergo habitual level of physical activity
75915243|NCT03624400|Behavioral|Internet-based CBT-I|The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 8 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.
75915244|NCT03624400|Behavioral|Internet-based psychoeducation|Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 8 weeks modules.
75467175|NCT01917474|Dietary Supplement|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
75467176|NCT01917539|Device|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.
75467177|NCT01917539|Device|Pulsed Light Therapy|Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
75627277|NCT06198764|Drug|Coly Mycin M Injectable Product|Coly Mycin M is the originally marketed colistimethate sodium for injection.
75627278|NCT06198751|Drug|6.0 mg/kg of TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 6.0 mg/kg.
75627279|NCT06198751|Drug|7.5 mg/kg of TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 7.5 mg/kg.
75627280|NCT06198725|Dietary Supplement|Trimtab|High fiber group will take Trimtab (a kind of multi bran and high fiber grain compound powder) 60g per day to intake 28g dietary fiber for 12 weeks.
75779347|NCT02626312|Other|Survey Administration|Ancillary studies
75627281|NCT06198712|Drug|Etavopivat|Participants will receive oral tablets of etavopivat once daily.
75627282|NCT06198699|Dietary Supplement|Jing Si Herbal Tea|Consuming Jing Si Herbal Tea for three months; twice per day with each time 14 g of Jing Si Herbal in 600 ml water
75627283|NCT06198673|Drug|Antiplatelet Agents|Antiplatelet agents more commonly used at time of percutaneous coronary intervention in patients with chronic coronary syndrome
75627284|NCT06198647|Procedure|Tui-na massage|Using Tui-na massage for the back muscles
75627285|NCT06198647|Procedure|positional release technique|using positional release manual technique to relax the back muscles
75627286|NCT06198621|Device|cardiometry|cardiometry is noninvasive method, while swan ganz is invasive method in hemodynamic parameters assessment
75779348|NCT02393924|Other|No intervention|
75779349|NCT02386553|Drug|Nusinersen|Solution for intrathecal injection
75779350|NCT02307058|Radiation|LEAD RT|The multiparametric-MRI (MP-MRI) defined Gross Tumor Volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SV), the Clinical Target Volume (CTV)1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs may be treated to 56 Gy in 38 Fxs or full dose (CTV2), and the pelvic lymph nodes may be treated to 56 Gy in 38 Fxs (CTV3).
75915245|NCT03617471|Procedure|Venopuncture for PK profiling|Blood samples at T0, T0.5, T1, T2, T4, T6
75915246|NCT03614858|Biological|CART-19/22|Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10^6 CART-19/22 cells/kg).
75915247|NCT03611595|Drug|Cabozantinib|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
75915248|NCT03611595|Drug|13-cis-retinoic acid|13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
75915249|NCT03611309|Other|Surgeon-palliative care team co management|Surgeon-palliative care team co management includes surgeon alone care and palliative care specialist team
75915250|NCT03611309|Other|Surgeon team alone management|The surgeon and surgical team will manage
75915251|NCT03599765|Other|Best Practice|Receive routine therapy
75915252|NCT03599765|Procedure|Local Consolidation Therapy|Receive LCT
75915253|NCT03595267|Other|Point-of-care screening|"After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a closed loop system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations. If a participant has no primary care provider, one will be found."
75915254|NCT03586284|Drug|Valganciclovir Hydrochloride|21 to 28 days of oral valganciclovir treatment
75915255|NCT03586284|Drug|Ganciclovir Sodium|21 to 28 days of topical ganciclovir solution treatment
75915256|NCT03586284|Drug|Placebo Oral Tablet|21 to 28 days of placebo pill treatment
75779351|NCT02307058|Radiation|HEIGHT RT|The MRI defined GTV(s) will receive a higher dose per day than the CTV by dose painting. The GTV(s) will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles (CTV1) will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full dose, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
75779352|NCT02245048|Other|Carotid Intima-Media Thickness (CIMT)|
75779353|NCT01981993|Biological|Urinary proteomic analysis|
75627287|NCT06198582|Other|Virtual Reality Exercises|In addition to conventional treatment, patients in the study group underwent a virtual reality-based task-specific exercise program in a computer-based virtual reality station. Two different virtual reality games that fit the definition of task-specific exercise were selected for our study. In order for the patient to complete the task in the game, the patient was asked to extend the upper extremity and hand to touch the virtual object through the reflection on the screen and to first grasp the object in the virtual environment by making active flexion with all fingers and to move it from one place to another on a certain plane without disturbing the grasping posture of the hand. These virtual reality exercises selected in our study were practiced under the supervision of the researcher 3 days a week for 15 minutes each for a total of 4 weeks. These sessions consisted of three sets of 2.5 minutes each for each game, with 15-second breaks between sets.
75627288|NCT06198569|Other|PNF EXERCISES|"Scapular PNF exercise training (6 Weeks) Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Scapular patterns~Anterior elevation-Posterior depression~Anterior depression-Posterior elevation PNF techniques~Repetitive stretching~Rhythmic stabilization"
76074309|NCT00780442|Drug|D-cycloserine|50 mg DCS
76074310|NCT00780442|Drug|Placebo|Placebo
75322433|NCT04386577|Drug|fish oil|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
75322434|NCT04766411|Other|Unresisted sprint training|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
75627289|NCT06198569|Other|strength exercises|"Upper limb exercise training (6 Weeks) 3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down~Upper extremity movements - Scapular retraction - Shoulder flexion - Shoulder extension - Shoulder abduction - Shoulder adduction Resistant exercise training with Theraband and weights"
75627290|NCT06198530|Behavioral|cognitive training in NLCs|In the nurse-led clinics(NLCs) training group, CCT was given twice a week during 1-6 months and once a week during 7-12 month in nursing clinic. There is 60 minutes at a time.
75779354|NCT01925131|Drug|cyclophosphamide|Given IV
75779355|NCT01925131|Drug|vincristine sulfate|Given IV
75779356|NCT01925131|Drug|prednisone|Given PO
75779357|NCT01925131|Biological|inotuzumab ozogamicin|Given IV
75915257|NCT03586284|Drug|Topical placebo|21 to 28 days of topical placebo treatment
75915258|NCT03575429|Behavioral|Engagement Intervention|"Family navigators will use MI to engage families to decrease resistance and build motivation and commitment to challenging behavior changes by eliciting and reflecting broader goals and values, linking those values to specific behavior change, and negotiating a menu of options for change based on individual preferences. PSE will be used by the Family Navigators to guide families in selecting an objective, measurable problem, then proceed through a series of steps that involve goal setting, brainstorming and evaluating solutions, choosing a solution, and action planning."
76025636|NCT04766645|Device|Robotic assisted intervention|Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
76025637|NCT04766645|Genetic|epigenetic analyses|Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
75322435|NCT04766411|Other|Resisted sprint training with load equal to 10% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
76025638|NCT04766645|Diagnostic Test|biochemical analyses|Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
76025639|NCT05301725|Other|PPI regimen|All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
75322436|NCT04766411|Other|Resisted sprint training with load equal to 20% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
75322437|NCT04766411|Other|Control trial|Participants will not perform any sprint training protocol
75467178|NCT01917578|Device|Ultrasound|"Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.~Measurement of tumor size refers to WHO standards."
75779358|NCT01925131|Other|laboratory biomarker analysis|Correlative studies
76025640|NCT05301725|Other|P-CAB regimen|All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
75779359|NCT01901094|Procedure|Axillary Lymph Node Dissection (ALND)|
75779360|NCT01901094|Radiation|Nodal Radiation Therapy|
75779361|NCT01901094|Radiation|Axillary Radiation Therapy|
75779362|NCT01767311|Drug|Lecanemab 2.5 mg/kg|2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
75779363|NCT01767311|Drug|Lecanemab 5.0 mg/kg|5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
75627291|NCT06198530|Behavioral|cognitive training in home|In the home-based training group, CCT was given four times a week during 1-6 months and twice a week during 7-12 month in nursing clinic. There is 30 minutes at a time. Nurses teach patients to acquire and carry out CCT at home during hospitalization. Nurses set the daily reminder function at 9:00am through training system.
75779364|NCT01767311|Drug|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
75779365|NCT01767311|Drug|Lecanemab 5.0 mg/kg|5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
75779366|NCT01767311|Drug|Lecanemab 10 mg/kg|10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
75779367|NCT01767311|Drug|Placebo|biweekly (once every 2 weeks) administered as i.v. infusion
75779368|NCT01767311|Drug|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
75915259|NCT03575429|Behavioral|Engagement + Coaching Intervention|ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that visit's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are invited to Autism Navigator How-To Guide for Families, a self-guided web-based course, with an online weekly group meeting.
75915260|NCT03571321|Drug|Ruxolitinib|"Participants will receive one of 3 doses [taken by mouth] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study.~Remission consolidation regimen:~Days 1-14 and 29-43~Interim maintenance regimen:~Days 1-14 and 29-43~Delayed Intensification regimen:~Days 1-14 and 29-43"
75915261|NCT03571321|Drug|Cyclophosphamide|"Remission consolidation regimen:~1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29~Delayed Intensification regimen:~1000 mg/m2 IV on Day 29"
75915262|NCT03571321|Drug|Cytarabine|"Remission consolidation regimen:~75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39~Delayed Intensification regimen:~75 mg/m2/day IV or SC on Days 29-32 and 36-39"
75915263|NCT03571321|Drug|Mercaptopurine|"Taken by mouth.~Remission consolidation regimen:~60 mg/m2 on Days 1-14 and 29-42~Maintenance Therapy:~75 mg/m2 on Days 1-84"
75627292|NCT06198530|Behavioral|cognitive training in tradition|In the traditional training group, the Home Cognitive Training Manual for Alzheimer's Disease compiled by our research team was distributed.
75627293|NCT06198504|Procedure|Protocol using end-tidal oxygen monitoring during preoxygenation before intubation|"According to previous studies a target of EtO2 ≥ 90% is proposed to trigger RSI and intubation. If this target is judged impossible to achieve and/or there is an imperative need to interrupt the pre-oxygenation phase, the operator is free to continue the procedure according to current recommendations.~Before the start of the inclusions, a training session on the use of the module will be organized with a reminder of the recommendations.~During the procedure, preoxygenation modalities and duration, achieved EtO2 level, conduction of the induction and intubation, minimum SpO2 and occurrence of complications will be recorded.~The procedure will stop ten minutes after completion of the orotracheal intubation procedure (defined as inflation of the balloon,clinical and capnography control)."
75627294|NCT06198491|Behavioral|Misbeliefs about HPV training|Intervention trainings mentioned false beliefs before or after the current knowledge
75627295|NCT06198465|Drug|adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil|adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；
75779369|NCT01698918|Drug|Everolimus|Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
75779370|NCT01698918|Drug|Letrozole|1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
76074311|NCT00767338|Behavioral|Timed intercourse|Timed intercourse
75627296|NCT06198452|Procedure|Vision Improvement|Laser Vision Improvement for Patients with Age-Related Macular Degeneration
75627297|NCT06198439|Device|Transcranial Magnetic Stimulation|Magstim Rapid2 Therapy System
75627298|NCT06198413|Genetic|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
75779371|NCT01698918|Drug|Exemestane|2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
75779372|NCT01698918|Drug|Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)|Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
75779373|NCT01698918|Drug|Standard of care to treat stomatitis (Stomatitis sub-study)|Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
75779374|NCT01495403|Drug|Hydroxychloroquine|daily dosing
75779375|NCT01347697|Procedure|Reconstruction with an acellular porcine dermal collagen implant (biological mesh)|Reconstruction of floor of lesser pelvis with an acellular porcine dermal collagen implant (biological mesh) after extended excision of rectum including levator muscles in advanced low rectal cancer.
75779376|NCT01347697|Procedure|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
75779377|NCT01208974|Procedure|Nipple-Sparing Mastectomy|Subcutaneous Mastectomy (SCM) to be performed, preserving the nipple and areola complex, after a frozen section of the tissue underneath the nipple-areola complex is sampled and found to be negative for tumor. Performed during Week 1.
76074312|NCT00767338|Procedure|Microsurgical varicocelectomy|Microsurgical varicocelectomy
76074313|NCT00767338|Procedure|Intrauterine insemination|Intrauterine insemination
75467179|NCT01917578|Procedure|CNB|Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
75779378|NCT01208974|Procedure|Breast Reconstruction|Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire. Performed during Week 1.
75779379|NCT01208974|Procedure|Axillary Surgery|Axillary Dissection or Sentinel Node Biopsy (SNB) will be performed at surgeon's discretion.
75627299|NCT06198400|Diagnostic Test|Perioperative assessment of the perfusion of post-resection pancreatic remnant using indocyanine green-VerDye|The adequacy of the vascular supply of the post resection pancreatic remnant after pancreatic neck division will be evaluated using ICG detector. Indocyanine green fluorescence product -Verdye™ will be intravenously applied. The application of the substance will be performed according to the current consensus statement and recommendation
75627300|NCT06198387|Radiation|hormone and RT|The patients will receive a two-year course of androgen deprivation therapy (ADT) in combination with abiraterone, along with synchronous metastasis-directed radiation and prostate radiotherapy(RT).
75627301|NCT06198387|Drug|ADT combined with abiraterone|The patients will receive a two-year course of ADT combined with abiraterone.
75627302|NCT06198374|Dietary Supplement|Sodium propionate|The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
75627303|NCT06198374|Other|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
75915264|NCT03571321|Drug|Vincristine|"Remission consolidation regimen:~1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50~Interim maintenance regimen:~1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41~Delayed Intensification regimen:~1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50~Maintenance Therapy:~1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57"
75915265|NCT03571321|Drug|Pegaspargase|"Remission consolidation regimen:~2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43~Interim maintenance regimen:~2500 IU/m2 IM or IV on Days 2 and 22~Delayed Intensification regimen:~2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43."
75915266|NCT03571321|Drug|Rituximab|"For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.~Remission consolidation regimen:~375 mg/m2 IV on Days 1, 8, 29 and 36~Interim maintenance regimen:~375 mg/m2 IV on Days 1 and 11~Delayed Intensification regimen:~375 mg/m2 IV on Days 1 and 8"
75915267|NCT03571321|Drug|Methotrexate (Intrathecal Administration)|"Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal [IT] administration).~Remission consolidation regimen:~15 mg on Days 1, 8, 15, and 22~Interim maintenance regimen:~15 mg on Days 1 and 31~Delayed Intensification regimen:~15 mg on Days 1, 29, and 36~Maintenance Therapy:~15 mg on Day 1~15 mg on Day 29 (First 4 courses only)"
75915268|NCT03571321|Drug|Methotrexate (Intravenous Administration)|"Interim maintenance regimen:~100 mg/m2 IV on Days 1, 11, 21, 31, and 41"
75915269|NCT03571321|Drug|Dexamethasone|"Taken by mouth or given by IV infusion.~Delayed Intensification regimen:~10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21~Maintenance Therapy:~6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61"
75915270|NCT03571321|Drug|Doxorubicin|"Delayed Intensification regimen:~25 mg/m2 IV on Days 1, 8, 15"
75915271|NCT03571321|Drug|Thioguanine|"Taken by mouth at least 1 hour after evening meal.~Delayed Intensification regimen:~60 mg/m2 on Days 29-42"
75915272|NCT03571321|Drug|Methotrexate Oral Product|"Taken by mouth.~Maintenance Therapy:~20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)~Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given]"
75915273|NCT03569878|Behavioral|Peer-Integrated Multidisciplinary Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
75467180|NCT01917578|Procedure|BCS, Modified Radical Mastectomy|All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
75627304|NCT06198348|Other|Aerobic Exercise|"Treatment Protocol to Group A It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 30 minutes.~It will include warm up phase, active phase and cool down phase Warm-up phase:~In which each participant will walk at 80 m/min at for 5 min.~Active phase:~Brisk walking or treadmill:~In which each participant will perform brisk walking for 15 mints initially. After that gradually duration of brisk walking will increase."
75779380|NCT01208974|Radiation|Prophylactic Nipple-Areolar Complex RT|Prophylactic Nipple-Areolar Complex Radiation Therapy per protocol. Administered between weeks 5 to 8.
75779381|NCT00897117|Genetic|gene expression analysis|Blood and lung tissue collection
75779382|NCT00897117|Genetic|microarray analysis|Blood and lung tissue collection
75779383|NCT00897117|Genetic|protein expression analysis|Blood and lung tissue collection
75779384|NCT00897117|Other|biologic sample preservation procedure|Blood and lung tissue collection
75779385|NCT00897117|Other|laboratory biomarker analysis|Blood and lung tissue collection
75779386|NCT00897117|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Blood and lung tissue collection
75779387|NCT00840177|Drug|cytarabine|1.5 g/m2/day given by continuous IV on days 4-7
75779388|NCT00840177|Drug|idarubicin|12 mg/m2/day given intravenously over 10-15 minutes on days 4-6
75779389|NCT00840177|Drug|pravastatin sodium|1,280 mg/day given orally on days 1-8
75779390|NCT00114985|Device|Prostate Immobilization Device|Device placed during radiation treatment
75779391|NCT01049867|Procedure|Intracoronary Infusion of CD133+ Cells|Single intracoronary infusion of a suspension consisting of 30 ml saline solution containing at least 1 million CD133+ endothelial precursor cells.
75779392|NCT01347580|Drug|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
75627305|NCT06198348|Other|Aerobic Exercises with Resistance training|"These groups will perform these exercises:~Aerobic exercise +resistance exercises Exercise~Session: 3 days per week Time of exercise session: 30-45 min~After following protocol of aerobic exercise as mentioned above the subjects will perform resistance exercises. These Exercises will perform:~Leg press (dual leg press):~Leg press targets the Glutes Quadriceps or quads .but they also work your Hamstrings.~Crunches:~Crunches Target the abdominal muscles specifically rectus abdominis and obliques.~Squats:~Squats targets the adductor muscles of the hip, glutes and rectus abdominis muscle Leg Extension~Total Exercise plan for 12 weeks:~1-2 weeks: Repitations: 10-15 times~No of sets: 1 set Resistance: minimum 3-4 weeks:~Repitations: 10-15 times~No of sets: 2 set Resistance: moderate 5-6 weeks:~Repitations: 15-16 times~No of sets: 2 set Resistance: moderate 7-8 weeks:~Repitations: 15-16 times No of sets: 2 set"
75467181|NCT01917578|Device|Pathologic Large Tissue Selected Table|"Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.~Each piece of breast tissues by cutting with the table has 3mm thickness."
75627306|NCT06198296|Genetic|21.15.GPC3-CAR T cells|"Three different dosing schedules will be evaluated.~The following dose levels will be evaluated:~The following dose levels will be evaluated:~DL0: 3x10^7/m2 DL1: 1x10^8/m2 DL2: 3x10^8/m2 DL3: 1x10^9/m2"
75779393|NCT01347580|Drug|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
75779394|NCT00398411|Drug|moxifloxacin|400 mg p.o. per day
75779395|NCT00398411|Drug|placebo|one tablet per day p.o.
75779396|NCT03352414|Drug|Alvimopan|alvimopan pill
75779397|NCT03352414|Drug|Placebo|placebo pill
75779398|NCT00364793|Drug|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|"Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)"
75779399|NCT03351478|Drug|Sotagliflozin|Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
75779400|NCT03351478|Drug|Empagliflozin|Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.
75779401|NCT03351478|Drug|Placebo|Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
75779402|NCT03351478|Drug|Placebo|Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
75779403|NCT04572737|Behavioral|Activity plan to break up sitting time|This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
75779404|NCT00363545|Biological|Lyophilized formulation of HRV vaccine|Lyophilized formulation of HRV vaccine
75779405|NCT00363545|Biological|Liquid formulation of HRV vaccine|Liquid formulation of HRV vaccine
75779406|NCT01042301|Other|Blood samplings|
75915274|NCT03569878|Behavioral|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
75915275|NCT03564275|Radiation|Proton Boost|13-15 treatments with proton therapy given as a boost to standard of care photon therapy
75915276|NCT03564236|Device|Nasal High Flow Therapy|Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates[2] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).[3]
75915277|NCT03564236|Other|Standard care|Standard regular care of a COPD exacerbation
75915278|NCT03549403|Behavioral|Patient-centered telephone education|The intervention will be carried out in accordance with the guidelines and the contents of the patient-centered telephone education intervention in the same way with every patient. The education call duration is approximately 15 to 30 minutes.
75779407|NCT03351244|Drug|BI 409306|28 week treatment period
76074314|NCT04384666|Drug|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
75779408|NCT03351244|Drug|Placebo|28 week treatment period
75627325|NCT06198153|Other|Stationary Cycling|In addition to the conventional physical therapy, children in this group will receive 10-15 minutes of stationary cycle training, 3 times a week for 6 weeks.
75627326|NCT06198153|Other|Progressive Functional Training|In addition to the conventional physical therapy, the training will follow a 6-week progressive functional training program for lower extremities. These exercises will include sit-to-stand exercise, lateral/forward step-up exercise (i.e. climbing a stair or stepping up onto a kerb), and half-knee rise exercise (i.e. rising from the ground). All exercises will be performed in 1-3 sets of 10-15 repetitions, with a 90 second rest in between the sets. Each exercise will be performed within 10-15 minutes. Training session will be given 3 times a week. During the training, intensity will be progressively increased by increasing the repetitions
75915279|NCT03531073|Drug|Methotrexate|This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
75915280|NCT03524118|Drug|Clesrovimab|Single ascending doses of clesrovimab will be administered via IM injection.
75467182|NCT01917578|Device|Leica TP1020|"Procedure:~Alcohol 70 % 1h~Alcohol 80 % 1h~Alcohol 85 % 1h~Alcohol 90 % 1h~Alcohol 95 % 1h~Alcohol Ⅰ 100 % 1h~Alcohol Ⅱ 100 % 1h~Xylene Ⅰ 2h~Xylene Ⅱ 2h~Xylene Ⅲ 2h~Paraffin 6h~Paraffin 6h"
75651657|NCT05832671|Procedure|caudal block|In the CB group, patients will be placed in a lateral position. An ultrasound transducer is first placed transversely at the midline to obtain a transverse view of the 2 cornua, the sacrococcygeal ligament, sacral bone, and sacral hiatus. At this position, the ultrasound transducer will be twisted to 90° to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the 2 cornua and on visualization of the frog sign (the 2 sacral cornua identified as 2 hyperechoic reverse U-shaped structure) the needle will be inserted into the sacral canal under direct real-time longitudinal visualization. After negative aspiration for blood or cerebrospinal fluid, bupivacaine (0.25%) 2.5 mg/kg will be injected over a one minute period while observing an ultrasound longitudinal image.
75915281|NCT03524118|Drug|Placebo|Placebo (0.9% sodium chloride [NaCl]) will be administered via IM injection.
76074315|NCT04384666|Other|Neupro 4 mg / 24 Hr. Transdermal Patch|Neupro 4 mg /24 Hr. Transdermal Patch
75627333|NCT06198101|Other|Myofascial Release Technique|The treatment will be applied by the therapist standing at the side of the patient with different levels according to subject's tolerance for duration of 3 minutes in each sitting. Level one will be performed by longitudinal movements without causing any tension to the tissues. The level two will be performed by longitudinal movements with light pressure to the tensed muscle. The level three will be performed by compressing the treatment area then passively fullest possible range of motion will be performed and then longitudinal movement will be done with same compression. In level four, the patient will actively move the tissue through the fullest possible range of motion. The taut band will palpate and then firm pressure will be maintained and then longitudinal movements will be performed. Treatment will be applied for two intervention sessions per week and a total of 12 sessions over 6 weeks.
75627334|NCT06198101|Other|Myofascial Release Technique along with segmental vibrator|this group will receive vibratory stimulations through segmental vibrator along the muscle fibers of upper limb flexors, extensors, and wrist flexors for 10-minutes each session with low amplitude (0.3-0.5 mm peak to peak) at fixed frequency of 150 Hz(23). Along with segmental vibrator group B will also receive myofascial release technique through the same method to the upper limb flexors, extensors, and wrist flexors. Group B will receive both treatments for two intervention sessions per week and a total of 12 sessions over 6 weeks.
75651658|NCT05832645|Other|Meditation with guided tea consumption|Mindful consumption of tea along with an approximately 10-min guide
75651659|NCT05832645|Other|Breathing meditation|10-min breathing meditation
75915282|NCT03522545|Biological|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
75915283|NCT03522545|Biological|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
75915284|NCT03516617|Drug|Acalabrutinib|Given PO
75915285|NCT03516617|Other|Laboratory Biomarker Analysis|Correlative studies
75915286|NCT03516617|Biological|Obinutuzumab|Given IV
75915287|NCT03516617|Other|Patient Observation|Undergo observation
75915288|NCT03516617|Other|Quality-of-Life Assessment|Ancillary studies
75322438|NCT05686694|Other|Video Education|"Sharing of Planned Education Videos on Instagram In this research, the platform where planned video education will be shared was determined as Instagram, which is the most used social media platform by pregnant women. In the Instagram user name @ogttegitim account, 6 education videos that will be created and shared."
75322439|NCT04270669|Biological|intravitreal injection of RC28-E 0.5mg|The patient received one treatment of RC28-E 0.5mg in the test group
75322440|NCT04270669|Biological|intravitreal injection of RC28-E 1.0mg|The patient received one treatment of RC28-E 1.0mg in the test group
75322441|NCT04270669|Biological|intravitreal injection of RC28-E2.0mg|The patient received one treatment of RC28-E 2.0mg in the test group
75322442|NCT05233293|Procedure|Spyglass + RFA|SpyGlass direct Vision guided RFA
75322443|NCT05233293|Procedure|Cytobrush + RFA|After Cytobrush ,taking RFA through ERCP
75322444|NCT03373604|Drug|18F-MK-6240|18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
75627343|NCT06198023|Behavioral|Educational|The educational intervention is an 8-session series of informational presentations about brain function and altered social processing related to eating disorders. Participants will receive a reflective prompt to complete as homework and will have an opportunity to discuss their responses during the following session.
75627344|NCT06198023|Behavioral|Interactive|The interactive intervention is an 8-session series of experiential art therapy tasks followed by education about social processing. Participants will complete the tasks as a group or in small teams. Afterward, they will be encouraged to discuss their thoughts and feelings related to their experience. The educational component will include a homework assignment that participants will have the opportunity to discuss at the following session.
75627345|NCT06197997|Behavioral|Chicago Parent Program (CPP)|The Chicago Parent Program (CPP) is a 12-session group-based parenting intervention designed to strengthen parenting skills and parent engagement in children's learning and improve children's social-emotional and behavioral competence.
75627346|NCT06197217|Drug|WPV01|Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
75627347|NCT06197217|Drug|Placebo|Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
75627348|NCT06196814|Drug|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
75627349|NCT06196710|Device|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto the vessels.
75627350|NCT06196710|Device|Hemo-clipping|Contact thermocoagulation using a 3.3mm probe, hemo-clips, or both. The use of the bipolar device involves firm mechanical compression and coagulation for about 8 seconds.
75627351|NCT06196125|Other|Four body positions|Physiological characteristics such as ventilation distribution and lung aeration patterns recorded by the electrical impedance tomography signals and ultrasound imaging will be measured when patients are in a initial supine position, then turned into a lateral positioning on each side then back in supine positioning.
75627352|NCT06196099|Device|Blood Flow Restriction|The study participants were instructed to rest quietly in a seated position for 10 minutes. During the last 3 minutes of the resting period, upper arm blood pressure was measured twice using an automatic blood pressure monitor (BP170, InBody, Korea). The blood flow restriction cuffs (BFR Therapy Cuff, BFR Therapy Co., USA) - measuring 5cm in width and 60cm in length - were applied to the upper third of the thigh on both legs. To maintain consistency in measurements, the distance from the proximal part of the kneecap to the distal edge of the cuff was measured. A Capillary Reaction Time (CRT) test was used to assess the appropriateness of the cuff pressure; this involved applying thumb pressure to the quadriceps muscle after cuff application and timing how long it took for the skin color to return to normal.
75322445|NCT03373604|Procedure|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
75915289|NCT03506945|Behavioral|mPEP|Behavioral Activation Therapy
76074316|NCT00767572|Drug|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
76074317|NCT00767572|Drug|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
76074318|NCT00240370|Drug|Muraglitazar|
75322446|NCT00755131|Other|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
75467183|NCT01917578|Device|Pathologic Large Tissue Embedded Table|"The table is made of brass .It is applying for a chinese patent.~The table can simultaneously embed 8 piece of breast tissues."
75779409|NCT03386032|Drug|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
75779410|NCT03386032|Drug|0.05% Desonide|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
75779411|NCT03386032|Other|Placebo Cream|Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
75779412|NCT03712150|Device|tdcs|application of optimised parameters of tDCS (anodal stimulation, 1.5 mA, 10 min) over the unconditioned hemisphere reverses the brain and behavioural consequences of inhibitory pre-conditioning
75779413|NCT05452486|Diagnostic Test|English APD assessment|Materials presented in English
75779414|NCT05452486|Diagnostic Test|Spanish APD assessment|Materials presented in Spanish
75779415|NCT00077610|Drug|Epoetin alfa or beta|intravenously 3 times weekly for 52 weeks, as prescribed
75779416|NCT00077610|Drug|RO0503821 (1x/2 Weeks)|60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
75779417|NCT00077610|Drug|RO0503821 (1x/4 Weeks)|120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
75779418|NCT03385564|Drug|BI 655064|subcutaneous injection
75779419|NCT03385564|Drug|Placebo|subcutaneous injection
75779420|NCT05344924|Drug|TACE+penpulimab+anlotinib vs. penpulimab+anlotinib|Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
75779421|NCT01085994|Other|Literature search|Literature search followed by systematic review and meta-analysis
76074319|NCT03804736|Biological|FMT-c|Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)
75627353|NCT06196099|Device|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation (NMES) was applied five times a week for one week using a four-channel stimulator (Compex Physio, Chattanooga, Switzerland). The stimulation protocol was set to a frequency of 35Hz, with electrodes attached to the vastus lateralis and vastus medialis muscles. The therapist adjusted the intensity and alternating output of the electrodes selectively to facilitate the squat exercises required during the intervention. During the stimulation period, participants were engaged in a squat exercise program, with the total duration of stimulation being 10 minutes.
75627354|NCT06196099|Behavioral|Squat exercise|In this study, the squat exercise was performed in four sets. Participants were instructed to position their feet shoulder-width apart and educated to squat in such a way that their knees did not extend beyond their toes. To ensure consistency in performing the squat at the same angle, a mark was made on the wall at the pelvic height during a 90° squat. This allowed participants to perform squats at the same height. The exercise was conducted under the guidance of a physical therapist with five years of clinical experience.
75627355|NCT06195891|Procedure|Biospecimen Collection|Undergo blood sample collection
75627356|NCT06195891|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
75627357|NCT06195891|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75779422|NCT03741270|Biological|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).
75779423|NCT00066222|Drug|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
75779424|NCT00066222|Drug|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
75779425|NCT00066222|Radiation|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
75779426|NCT00397943|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
75779427|NCT00397943|Biological|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Intramuscular injection, 2 doses at 0, 1 month
75779428|NCT00397943|Biological|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Intramuscular injection, 2 doses at 0, 1 month
75779429|NCT00397943|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
75779430|NCT00066066|Procedure|Scaling and root planing|Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
75779431|NCT00066066|Drug|Metronidazole|Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
76074320|NCT03804736|Biological|FMT-c Lactobacillus|Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
75627358|NCT06195891|Procedure|Dual-Energy Computed Tomography|Undergo DECT/MRI scan
75779432|NCT00066066|Drug|Amoxicillin|Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
75915290|NCT03506945|Behavioral|Bibliotherapy|Provide educational material on coping strategies pertinent to caregivers
75915291|NCT03472586|Biological|Ipilimumab|Given IV
75915292|NCT03472586|Biological|Nivolumab|Given IV
75915293|NCT03472586|Drug|Embolization Therapy|Undergo immunoembolization
75915294|NCT03462329|Drug|Antibiotics (preferentially oral doxycycline 100 mg bid)|Patients will be treated with antibiotics for Lyme disease.
75779433|NCT00066066|Drug|Doxycycline|The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
75779434|NCT01091922|Dietary Supplement|Low flavanol cocoa beverage|23 mg of total flavanols from cocoa
75915295|NCT03451370|Drug|Capecitabine|"750 mg/sqm/bid, day 2 to 15; if toxicities grade ≥2 do not occur, pts may subsequently receive capecitabine 1000 mg/sqm/bid, day 2 to 15 starting the second cycle based on investigator's choice.~To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal."
75915296|NCT03451370|Drug|Oxaliplatin|100 mg/sqm iv over 2 hours, day 1 To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.
76074321|NCT04384588|Biological|Convalescent Plasma from COVID-19 donors|Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
75627359|NCT06195891|Procedure|Echocardiography|Undergo echocardiography
75627360|NCT06195891|Drug|Fludarabine|Given IV
75627361|NCT06195891|Procedure|Magnetic Resonance Imaging|Undergo DECT/MRI scan
75627362|NCT06195891|Drug|Melphalan|Given IV
75627363|NCT06195891|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
75627364|NCT06195891|Biological|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Given IV
75627365|NCT06195891|Drug|Tacrolimus|Given tacrolimus
75627366|NCT06195891|Drug|Thiotepa|Given IV
75627367|NCT06195891|Radiation|Total Marrow and Lymphoid Irradiation|Undergo TMLI
75627368|NCT06195709|Combination Product|Endocrine therapy|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.
75627369|NCT06195709|Combination Product|Endocrine therapy combined with the local treatment of FES-negative lesions|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label. Cases with only 1 or 2 FES-negative lesions that are accessible to local treatment will be reviewed by the Centralized Reading Committee (including a radiation oncologist) to confirm the feasibility of local treatment.
75627370|NCT06195709|Combination Product|Chemotherapy|Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.
75627371|NCT06195410|Other|kangaroo care application|In the study, the mother applied kangaroo care to her premature baby for 65 minutes, and after a 24-72 hour washout period, the father applied kangaroo care for 65 minutes.
75627372|NCT06195189|Drug|Sunvozertinib|Sunvozertinib 200mg QD
75627373|NCT06195189|Drug|Chemotherapy|Pemetrexed +platinum
75627374|NCT06194669|Other|Blood and urine sample collection|One whole blood sample per individual (3 ml) will be collected. Up to 5 urine samples per individual will be collected
75779435|NCT01091922|Dietary Supplement|High flavanol cocoa beverage|495 mg of total flavanols from cocoa
75779436|NCT00363467|Drug|G-CSF|"Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.~Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously."
75779437|NCT00363467|Drug|Leukapheresis|leukapheresis
75779438|NCT00363467|Drug|Busulfan|Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2
75779439|NCT00363467|Procedure|Stem cell reinfusion|autologous stem cell transplant
75779440|NCT00397631|Drug|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
75915297|NCT03451370|Drug|Bevacizumab|"7.5 mg/kg iv over 90 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered in 30 minutes.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal. To be repeated every 3 weeks (21 days), for a maximum of 8 cycles."
75915298|NCT03678350|Device|Light Dosimetry for Intranoperative Therapy|Undergo IO-PDT
75915299|NCT03678350|Procedure|Photodynamic Therapy|Undergo IO-PDT
75915300|NCT03678350|Drug|Porfimer Sodium|Given IV
76074322|NCT00780676|Drug|Dasatinib|100 mg tablet by mouth daily
76074323|NCT00780676|Drug|AZD6244|75 mg by mouth twice daily.
76074324|NCT03800212|Drug|treatment for ampullary adenocarcinoma|all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
76074325|NCT03806998|Dietary Supplement|Ketoacids|Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
75627375|NCT06194487|Dietary Supplement|Placebo drink|consume 1 bottle (50mL) per day
75627376|NCT06194487|Dietary Supplement|MAXI Collagen drink|consume 1 bottle (50mL) per day
75627377|NCT06194487|Dietary Supplement|Normal fish collagen drink|consume 1 bottle (50mL) per day
75651660|NCT05832632|Behavioral|Headspace Basics Program|30-day smartphone-based mindfulness intervention consisting of 10 minutes per day. The program consist of generic mindfulness techniques such as breath awareness, body scans, mindful noting of thoughts and emotions.
76074326|NCT03806998|Dietary Supplement|Placebo|Provision of placebo capsules similar to active supplement
75322447|NCT05680454|Biological|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|For Low-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.
75322448|NCT05680454|Biological|Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine|A 3-dose regimen administered at months 0, 2 and 6.
75779441|NCT00397631|Drug|Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
75779442|NCT00077376|Biological|trastuzumab|Given IV
75322449|NCT04944927|Other|Recording of clinical parameters and electrocardiogram parameters|Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.
75322450|NCT04928703|Drug|Ketamine|Ketamine IV administration
75322451|NCT04278950|Drug|Povidone-Iodine|For the PVP-I group, the final concentration of available iodine in the solution will be 0.01%, (from diluting 10% PVP-I solution), as previously demonstrated to be below ciliotoxic levels of 1.25% and greater than 0.01% which is the lower limit of active potency.
75322452|NCT04278950|Drug|Placebos|The placebo will be 2.5mL of saline with brown food coloring.
75322453|NCT00755755|Drug|PGL4001 (ulipristal) and iron|tablets
75779443|NCT00077376|Drug|ixabepilone|Given IV
75779444|NCT00077376|Drug|carboplatin|Given IV
75779445|NCT00077376|Other|laboratory biomarker analysis|Correlative studies
75779446|NCT01088724|Drug|fludarabine, cyclophosphamide, doxorubicin, rituximab|Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
75779447|NCT03957174|Drug|Reboxetine|Single dose used to increase central norepinepherine
75651661|NCT05832632|Behavioral|Headspace Breathing Exercises|30-day smartphone-based breathing exercises. Each exercise consists of box breathing for 1 minute and participants are instructed to complete 10 sessions corresponding to 10 minutes per day.
75322454|NCT00755755|Drug|PGL4001 matching placebo and iron|tablets
75322455|NCT00755755|Drug|PGL4001 (ulipristal) and iron|Tablets
75322456|NCT05410808|Other|Questionnaires and physical examination|Patients will be examined and demographic data, disease characteristics will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
75322457|NCT05410808|Other|Questionnaire|Demographic data will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
75779448|NCT03957174|Drug|Rivastigmine|Single dose to increase central acetylcholine
75779449|NCT03957174|Drug|Placebo oral tablet|Single dose as control condition
75779450|NCT00363311|Drug|Dutasteride|Dutasteride 0.5mg
75779451|NCT00363311|Drug|Matching placebo|Matching placebo
75779452|NCT02534987|Other|iCPR2|clinical decision support guiding clinician through clinical prediction rule and associated evidence based orders for strep and pneumonia
75779453|NCT00362609|Drug|pantoprazole|
75779454|NCT03991871|Device|External Counter Pulsation (ECP) therapy|35 hours ECP treatment in 35 sessions
75779455|NCT00362375|Behavioral|Healthy Love Workshop|The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.
75322458|NCT05676398|Diagnostic Test|Ambulatory rhythm recording|Ambulatory rhythm recording by use of a wearable patch-type device.
75322459|NCT05672888|Drug|Jaktinib|100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.
75322460|NCT05672888|Drug|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
75322461|NCT05686616|Drug|Dapagliflozin Propanediol Hydrate 12.3 mg|Forxiga 10mg will be added on the conventional treatment for SGL2 inhibitor group.
75651662|NCT05832632|Behavioral|Headspace Stress Program|20-day smartphone-based mindfulness intervention consisting of 15 minutes per day. The Stress program content is based on well-established concepts and practices within stress management, and mindfulness, and is targeted to people with elevated stress.
75651663|NCT05832632|Behavioral|Active Control (Audiobook)|30-day smartphone-based Audiobook book consisting of 10 minutes per day.
75322462|NCT02292537|Drug|Nusinersen|Administered by intrathecal (IT) lumbar puncture (LP) injection
75779456|NCT00362375|Behavioral|HIV/AIDS 101 Workshop|The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
75779457|NCT02534753|Drug|Ascor L 500® (Ascorbic Acid Injection, USP)|A sterile, solution containing 500 mg ascorbic acid per mL
75779458|NCT01042457|Drug|Mycophenolate mofetil|Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
75779459|NCT00362297|Drug|acyclovir|800 mg orally three times daily for 7 weeks
75779460|NCT00362297|Drug|valacyclovir|500 mg orally once daily for 7 weeks
75779461|NCT00065442|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
75779462|NCT00065442|Biological|APC-Placebo|Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
75779463|NCT01042691|Drug|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
75779464|NCT01050023|Device|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
75779465|NCT01050023|Device|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
75779466|NCT01092000|Behavioral|Monitoring|Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.
75779467|NCT01092000|Other|Education|Monthly exercise tips handout.
75779468|NCT01050101|Dietary Supplement|No fiber|"The High GI low fiber meal consists of 0 grams fiber with total kcal of 573 with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein.~Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
76074327|NCT03804502|Device|TearCare|The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
76074328|NCT03804658|Device|Continue glucose monitor system|The cardiovascular risks and data from continue glucose monitor system
75322463|NCT02292537|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
76074329|NCT00768118|Dietary Supplement|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
75627378|NCT06194344|Behavioral|Individualized imagery|Study personnel will assist participants to create scripts that foster relaxation and safety. Objects, places, and/or scenarios that foster participant relaxation, sense of safety, and/or positive emotions will be identified. Participants will write or type the generated scenario using highly detailed elements (e.g., including visual, olfactory, auditory, tactile, and gustatory sensations, as applicable) associated with the imagery. Study personnel will assist with recording the imagery scripts; audio files will be recorded using an audio recording application. The imagery scripts will be played at night via Bluetooth earbuds connected to the Muse app and script recording while laying down to sleep. The imagery rehearsal prompts will play for approximately 15 minutes, based on 10-20-minute recommendations across imagery rehearsal therapy (IRT) studies
75627379|NCT06194344|Behavioral|Control|Participants will wear the earbuds, with use of Muse S headband to collect outcome data without the individualized imagery scripts.
75779469|NCT01050101|Dietary Supplement|Low GI high fiber viscous meal|"Test meal consists of 12 grams of fiber (9 grams soluble and 3 grams insoluble). The ratio is 80:20 ratio of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
75779470|NCT01050101|Dietary Supplement|Low GI high fiber non-viscous|"Test meal consists of 11 grams of fiber (3 grams soluble and 8 grams insoluble). The ratio is 20:80 of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
75915301|NCT03442101|Drug|Patients with psychosis will be treated with known antipsychotic medication|Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
75915302|NCT03437421|Dietary Supplement|Vitamin D3 (cholecalciferol)|"Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~Patients with : 25-OH-D3 <10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™)."
75915303|NCT03437265|Drug|PLENVU powder for oral solution|PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
76074330|NCT00768118|Genetic|electrophoretic mobility shift assay|
76074331|NCT00768118|Other|laboratory biomarker analysis|
75322464|NCT05686538|Other|iDLI|TCRab/CD19 depleted DLI 14 days after allogeneic stem cell transplantation. Targeted cell doses: >10e7 NK cells/kg and >10e6 TCRgd cells/kg
75322465|NCT00674765|Drug|Seroquel|400 mg/day
75627380|NCT06193278|Device|Neuromodulation|Noninvasive brain stimulation (NIBS) includes a variety of noninvasive neuromodulation techniques such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (TDCS), and so on. Theta burst stimulation(TBS) is a new form of excitatory or inhibitory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
75779471|NCT01050179|Other|carbon dioxide|sinusoidal carbon dioxide delivery
75779472|NCT00090402|Dietary Supplement|Fish Oil|Fish oil capsule
75467184|NCT01917578|Device|Leica SM2000 R|Each of paraffin section has 4 um thickness.
75779473|NCT00090402|Dietary Supplement|Lipoic Acid|Lipoic acid capsule
75779474|NCT00090402|Other|Fish Oil Placebo|Soybean oil placebo capsule
75779475|NCT00090402|Other|Lipoic Acid Placebo|Lipoic acid (LA) placebo capsule containing no LA
75322466|NCT00674765|Drug|Placebo|400 mg/day
75322467|NCT04761068|Device|VEST|Venous External Support for vein grafts in CABG
75627381|NCT06193135|Drug|Corifolitropin Alfa|Patients will receive a single dose of Colifolitropin alfa, then will receive daily dose of Folitropin Beta since triggering criteria are met.
76074332|NCT04278586|Behavioral|Live-Online M-ROCC|"LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50-60 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 16 weeks with 60 minutes/wk.~MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for graduates of LDM for 50-60 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
75627382|NCT06193135|Drug|Folitropin Beta|Patient will receive daily dose of Folitropin Beta since triggering criteria are met.
75627383|NCT06191159|Device|Scalpel and standard electrocautery or PEAK PlasmaBlade|Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.
75627384|NCT06191159|Device|PEAK PlasmaBlade|PEAK PlasmaBlade for entire surgery.
75627385|NCT06191159|Device|Standard Electrocautery|Standard Electrocautery for entire surgery.
75627386|NCT06190964|Other|Integrative medicine|Acupuncture; touch/movement techniques (for example, qigong, reflexology, shiatsu) and/or mind-body medicine (for example, relaxation and breathing exercises)
75627387|NCT06189937|Behavioral|Culturally Adapted Cognitive Behavioral Therapy (CA-CBT)|"In this study, an 8- session (90 to 120 minutes) group version of the transdiagnostic intervention CA-CBT tailored for earthquake survivors will be applied.~Contents of the sessions are:~Education on psychological trauma and its treatment, and basics of emotion regulation techniques~Education on anxiety and depressive disorders and their treatment~Muscle relaxation and stretching exercises~Education about depressive and grief-related disorders and disturbing memories protocol~Interoceptive exposure: head rotation and hyperventilation~Anxiety, worry, and stress~Anger and anger protocol; breathing exercises~Somatic complaints, sleep disturbance, and closing~There will be one facilitator and one co-facilitator. Groups will consist of 12-13 participants."
75627388|NCT06180616|Drug|Tirzepatide|Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW. If gastrointestinal adverse effects occur during dose escalation, the dose can be held at the lowest tolerable dose for a longer period (up to 3 weeks) until an increment can be tolerated (analysis will be by intention to treat).
75627389|NCT06176768|Drug|LY3972406|Administered orally
75627390|NCT06176768|Drug|Placebo|Administered orally
75627391|NCT06174961|Drug|Unfractionated heparin|15,000 units of unfractionated heparin administered in the thigh
75627392|NCT06174961|Behavioral|Double-legged cycle ergometer exercise|One hour of double-leg cycle ergometer exercise
75627393|NCT06174961|Behavioral|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
75627394|NCT06174961|Behavioral|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the non-exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
75627395|NCT06174961|Behavioral|No exercise|No exercise
75627396|NCT06172582|Behavioral|12-week lifestyle intervention|A 12-week lifestyle intervention delivered via weekly group meetings in the House Chat Leaders (HCL's) homes
75627397|NCT06166576|Procedure|Ablative radioembolization|The interventional radiologist utilizes a pre-test with 99mTc-MAA SPECT-CT and cone-beam CT for procedural planning. For tumors confined to a single segment, the treatment area is planned to receive a radiation dose of over 400 Gy using the single-compartment MIRD technique. For tumors extending beyond a single segment, the multi-compartment MIRD technique is used to plan a radiation dose of 700 Gy (± 20%) to the tumor. The upper limit for the estimated lung dose is set at 25 Gy, and the upper limit for the perfused non-tumoral liver dose is 250 Gy. In cases where tumors extending beyond a single segment cannot receive the planned dose of 700 Gy (± 20%) due to limits on lung or normal liver dose, the plan is adjusted to deliver the maximum dose to the tumor within the permissible range for lung and normal liver doses. Radioembolization is typically performed in a single session, and any methods not mentioned here should follow the instructions for use of TheraSphere.
75627398|NCT06165614|Drug|Artesunate pessary|Subjects will self-administer 200 mg of Artesunate pessary (vaginal insert) daily for 5 days, on weeks 1, 3, 5, 7.
75627399|NCT06165614|Procedure|Colposcopy|Colposcopy is a procedure that allows close examination of the cervix, vagina, and vulva, performed on weeks 8 and 14.
75627400|NCT06163222|Behavioral|Additional text message with behavioural science-informed content and associated web pages|Behavioural science-informed text messages sent 14-days prior to outpatient appointment which include links to re-designed web pages
75627401|NCT06163222|Other|Usual communication strategy|Usual communications sent from outpatient services to remind participants about their appointments
75627402|NCT06162143|Device|Gelsectan®|Gelsectan® is a CE-marked class II device containing xyloglucans, xylo-oligosaccharides, pea proteins, and tannins from grape seeds extract, already used in Irritable Bowel Syndrome (IBS).
75779476|NCT02534597|Behavioral|Promotores Training|
75779477|NCT02534597|Behavioral|Delayed Promotores training|
75779478|NCT02534597|Behavioral|Caregiver training|
75779479|NCT02534597|Behavioral|Delayed caregiver training|
75779480|NCT02534597|Behavioral|Materials support|
75322468|NCT05394896|Device|ACUMEN (Edwards Lifesciences, Irvine, USA)|ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.
75322469|NCT05394896|Device|Invasive Blood Pressure|Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)
75322470|NCT00676013|Procedure|Integra|Grafting using the Commercial product Integra as a skin substitute over full thickness burn following excision.
75779481|NCT02534597|Behavioral|Delayed materials support|
75627403|NCT06158880|Behavioral|Alcoholic Beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
75627404|NCT06158880|Behavioral|Non-alcoholic Beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
75627405|NCT06158880|Behavioral|Partner Negative Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
75627406|NCT06158880|Behavioral|Partner Positive Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
75627407|NCT06156202|Other|Comprehensive Rehabilitation|Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.
75627408|NCT06156202|Other|Augmented Usual Care|"Following randomization, subjects in the augmented usual care group will be given the results of their in-person baseline assessment as well as the WHO Guide Support for Rehabilitation Self-Management after COVID-19 Related Illness. This guide consists of ways to manage: breathlessness, difficulty with voice, eating, drinking and swallowing; problems with attention, memory and thinking clearly; limitations in activities of daily living, manage stress and mood dysfunction and advice for when to contact healthcare professionals. Follow-up interviews will assess process measures, including use of outpatient rehabilitation clinics, to examine possible contamination effects"
75627409|NCT06155838|Other|"Early Adolescent Skills for Emotions (EASE)"|"Weekly Schedule for Teen's and their parents Sessions:~Over the course of 7 sessions, with one session per week lasting 90 minutes, the following core components will be covered:~Week 1: Exploring My Feelings~Week 2: Learning to Calm~Week 3 & 4: Learning CBT- Restructuring My Thinking, Changing Feelings and My Actions & Managing My Emotions and Issues~Week 5 & 6: Fostering Independent Problem-Solving Skills and Seeking Help~Week 7: Relapse Prevention~2.0 For parents/ guardians~Week 3 Psychoeducation (to develop skills to be able to identify, listen, better respond and provide comfort to teens when they are overwhelmed by anxiety and depression).~Week 4 Positive parenting strategies~Week 5 Parents/ guardians Self-care"
75627410|NCT06153251|Drug|BMS-986453|Specified dose on specified days
75627411|NCT06153251|Drug|Fludarabine|Specified dose on specified days
75627412|NCT06153251|Drug|Cyclophosphamide|Specified dose on specified days
75627413|NCT06150664|Drug|CTX-8371|Intravenous (IV) infusion (0.1-10.0 mg/kg) every two weeks.
75627414|NCT06144645|Device|tVNS, intermittent stimulation|transcutaneous vagus nerve stimulation, intermittent stimulation
75627415|NCT06144645|Device|tVNS, continuous stimulation|transcutaneous vagus nerve stimulation, continuous stimulation
75627416|NCT06141642|Device|Self-adaptive serious game|A self-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
75627417|NCT06141642|Device|Non-adaptive serious game|A non-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
75627418|NCT06136481|Other|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT). CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. Prior to engaging in therapy, one session will be devoted to gathering information regarding psychosocial history, trauma, and current functioning. The following sessions will follow the standard outpatient CPT protocol. The standard outpatient CPT consists of 12 one-hour sessions conducted over a 6- to 12-week period. An additional 3 weeks will be provided in case of participant and therapist vacation and/or sick days. CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
75627419|NCT06123897|Other|Regular follow-up assessments without intervention.|Participants will undergo follow-up for a minimum of one year, with regular clinical data collection at baseline, 1st month, 3rd months, 6th months, 9th months and 12th months.
75627420|NCT06123897|Other|Cross-sectional assessment|Volunteers will undergo assessments, including SCID scale, SCL-90, the Measurement and Treatment Research to Improve Cognition in Schizophrenia(MATRICS) Consensus Cognitive Battery, blood test(blood routine, liver function, renal function, blood lipids, fasting blood glucose, fasting serum insulin, fasting blood glycosylated hemoglobin), as well as functional MRI, eye movement, functional near-infrared spectroscope and electroencephalogram. Blood samples for exploring difference between patients and healthy people will be collected and stored.
75627421|NCT06122844|Behavioral|Social, Emotional, and Ethical Development (SEED) curriculum|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), is a two-part program involving teacher training and delivery of SEED. The teacher training is consist of a 12-hour mindfulness course and a 1-day (6 hours) workshop to get familiarized with the understanding and practice of mindfulness, and the details of the SEED Curriculum. The SEED Curriculum involves 8 short sessions of basic techniques in mindfulness with 10 minutes each. In addition, it has 12 mindfulness-based lessons with specific themes for children in K2 and K3. Each lesson lasts for approximately 30-40 minutes.
75627422|NCT06119529|Drug|LY3872386|Administered either IV or SC.
75627423|NCT06119529|Drug|Prednisone|Administered orally.
75322471|NCT00676013|Procedure|AlloDerm|Grafting using the commercial product AlloDerm as a skin substitute
75322472|NCT00676013|Procedure|Homograft|Grafting using homograft as a skin substitute
75322473|NCT00676013|Procedure|Autograft|grafting using patients own skin from a separate donor site
75627424|NCT06119529|Drug|Placebo|Administered either IV or SC.
75915304|NCT03423628|Radiation|Radiation Therapy|"Arm A: 35 Gy of Intensity-modulated radiation therapy (IMRT) administered at daily fractions of 3.5 Gy over 10 fractions (2 weeks) Arm B: 30 Gy of whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT) administered at daily fractions of 3 Gy over 10 fractions (2 weeks).~**Arm B has now closed to recruitment** Arm C: 60 Gy of intensity-modulated radiation therapy (IMRT) administered at daily fractions of 2 Gy over 30 fractions (6 weeks)"
75322474|NCT00755911|Biological|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
75322475|NCT00755911|Device|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
75627425|NCT06118853|Behavioral|yoga or gentle massage plus standard treatment for HSCT|The yoga sessions will be conducted at the patient's bedside, using one or more of the following techniques: gentle stretches (asanas), guided relaxation (savasana), slow and deep diaphragmatic breathing (pranayama), and meditative exercises focusing on natural breathing or visualization of a soothing place (dhyana). From these techniques, the integrative therapist will choose what best suits the patient for each session, based on their psychophysical state and symptoms presented, as there can be many variations during HSCT. Gentle massage is characterized by soft touches using light pressure, primarily using the palm of the hand, with a slow and steady rhythm across the entire body. It can be performed over clothing or even over the bedsheet and blanket.
75627426|NCT06115642|Drug|HLX43|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
75627427|NCT06115369|Dietary Supplement|Medically Tailored Meals Delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
75627428|NCT06115369|Dietary Supplement|Medically Tailored Meals Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement unconditionally for the entire study duration.
75627429|NCT06115369|Dietary Supplement|Produce Boxes delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
75627430|NCT06115369|Dietary Supplement|Produce Boxes Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement unconditionally throughout the entire study period.
75627431|NCT06110975|Other|deprescribing-intervention|"The clinical guideline on Deprescribing drugs for OAB in The North Denmark Region serves as the basis for the intervention. The guideline provides recommended procedures for the deprescribing process. The guideline offers procedures for the deprescribing process and includes a deprescribing algorithm and a symptom questionnaire designed to evaluate the impact of medications utilized in the treatment of OAB."
75627432|NCT06109558|Drug|LMV-12(HE003) and Osimertinib|1 cycle was 28 days. LMV-12(HE003), 60mg, continuously for 21 days, and the drug was discontinued for 7 days. Osimertinib, 80mg, continuously for 28 days.
75627433|NCT06104683|Drug|Placebo|Administered orally
75627434|NCT06104683|Drug|Pirtobrutinib|Administered orally
75779482|NCT02534597|Behavioral|Technical assistance|
75915305|NCT03423628|Drug|AZD1390|"AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0 (arms A and C): 1 dose prior to Radiation Therapy. For optional food effect assessment in Arm A, 2 doses prior to RT under both fed and fasted conditions. *Note: the optional food effect assessment is currently not open to recruitment*.~Cycle 1 (all arms): Intermittent or continuous dosing during Radiation Therapy (except for first 2 cohorts of Arm A).~Cycle 2 (arms A and C): 2 weeks adjuvant treatment after Radiation Therapy."
75915306|NCT03414424|Device|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
75627435|NCT06100874|Drug|Sacituzumab Govitecan|Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.
75627436|NCT06100874|Drug|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.
75322476|NCT00676793|Drug|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
75322477|NCT00737737|Drug|MS Contin|
75322478|NCT00737737|Drug|Placebo|
75322479|NCT04279418|Dietary Supplement|Mixed functional foods supplementation|In this project, taking the method of random, double blindness and control, participants in the mixed functional foods group will take functional foods with main compositions of ginsenoside, green tea polyphenols and marine collagen peptide for three months. After that, neuropsychological tests and neuroimaging biomarkers will be compared between functional food group and placebo group.
75779483|NCT02534597|Behavioral|Delayed technical assistance|
75779484|NCT01043003|Other|educational intervention|Undergo Bilingual Breast Cancer Educational Intervention
75779485|NCT01043003|Procedure|quality-of-life assessment|Ancillary studies
75779486|NCT01043003|Other|Questionnaire Administration|Ancillary studies
75779487|NCT01043003|Other|psychosocial support for caregiver|Support for caregiver
75779488|NCT01043003|Procedure|assessment of therapy complications|Ancillary study
75779489|NCT01043003|Other|informational intervention|Undergo evaluation sessions
75915307|NCT03414424|Device|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
75627437|NCT06100874|Drug|Trastuzumab and Hyaluronidase-oysk|Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.
75627438|NCT06098079|Drug|Naltrexone-Bupropion (NB) Combination|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
75627439|NCT06098079|Drug|Placebo|A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
75627440|NCT06093880|Device|monofocal intraocular lens|monofocal aspheric hydrophilic-hydrophobic intraocular lens
75322480|NCT04279418|Dietary Supplement|Placebo|In this project, taking the method of random, double blindness and control, participants in the placebo group will take placebo for three months. After that, cognitive changes and neuroimaging biomarkers will be compared between functional food group and placebo group.
75322481|NCT04400552|Dietary Supplement|ONS Pre-op + ONS Post-op|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.
75627441|NCT06092879|Other|Asciminib|There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
75627442|NCT06091540|Behavioral|Beyond Quake: A Human-Centered SH+ Randomized Controlled Trial for Earthquake Survivors|The key parameter of interest will be the extent of psychological distress encountered by the participants. In addition, various secondary outcomes will also be evaluated, encompassing depression, anxiety, post-traumatic stress disorder (PTSD) symptoms, psychosocial well-being, and grief levels. The evaluation of the intervention's effectiveness on the sample of interest will hinge on the comparison of scores obtained during the pretest and posttest measurement phases.
75322482|NCT04400552|Dietary Supplement|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.
75627443|NCT06087393|Device|CONVIVO|Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant. The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation.
75627444|NCT06083675|Drug|Semaglutide|Administered as oral tablets.
75627445|NCT06083675|Drug|Empagliflozin|Administered as oral tablets.
75627446|NCT06083675|Drug|Metformin|Administered as oral tablets.
75627447|NCT06079164|Drug|KITE-197|A single infusion of CAR-transduced autologous T cells administered intravenously
75627448|NCT06079164|Drug|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
75627449|NCT06079164|Drug|Fludarabine|Lymphodepleting chemotherapy administered intravenously
75779490|NCT02534519|Other|Whole Genome Sequencing (WGS)|There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
75779491|NCT01050335|Behavioral|Simuvision Simulator|Participants will perform common surgical procedures on the simulator
75779492|NCT00361283|Drug|Atorvastatin|atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
75322483|NCT04400552|Dietary Supplement|Usual intake Pre-op + ONS Post-op|Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital
75627450|NCT06078566|Combination Product|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
75627451|NCT06075771|Drug|Carbidopa Levodopa|Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.
75627452|NCT06075771|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.
75627453|NCT06072040|Combination Product|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
75627454|NCT06067763|Behavioral|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
75627455|NCT06067763|Behavioral|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
75627456|NCT06067763|Other|The Weight of the Nation|This 2012 documentary discusses the facts and myths about obesity and the impacts of obesity on individuals and the health care system in the United States.
75627457|NCT06066983|Behavioral|DINOSAUR|This intervention aims to treat intolerance of uncertainty and anxiety in young autistic children.
75627458|NCT06066983|Other|Psychoeducation|This intervention provides psychoeducation regarding anxiety and autism.
75627459|NCT06065202|Dietary Supplement|Nutrition Supplement|Total parenteral nutrition (TPN) will be administered within 72 hours of abdominal surgery. Nutritional shakes will be started with a liquid diet and given 3 times a day. This will continue for 4 weeks after discharge.
75779493|NCT00077064|Drug|captopril|Captopril 12.5 mg t.i.d. for first two weeks, increased to 25 mg t.i.d. for the second two weeks of therapy. Thereafter, the dose will be increased to 50 mg t.i.d. for the remainder of the one-year of therapy (52 total weeks of drug administration).
75779494|NCT01043471|Other|Chewing gum|Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
75779495|NCT01043471|Other|Water|Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
75779496|NCT02534441|Other|Skin patch test|
75779497|NCT03962010|Drug|GX-G6|long acting anti-diabetic drug
75779498|NCT03962010|Drug|Control|Control
75627460|NCT06064266|Other|plant-based mild ketogenic controlled diet|Plant-based mild ketogenic diet (10-20EN% carbohydrates, 10-20EN% protein, and 60-70EN% fat), consisting of a daily breakfast, lunch, dinner, and snacks.
75322484|NCT00245011|Biological|filgrastim|Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.
75627461|NCT06064266|Other|high-fat shake|The high-fat shake consists of unsweetened almond milk, sunflower oil, and plant sterols, resulting in a shake containing 885 kcal (1.5g protein, 97.3g fat, and 0.8g sugar).
75779499|NCT00396383|Drug|plerixafor|Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4*10^6 CD34+ cells/kg body weight had been collected.
75779500|NCT01092078|Behavioral|MINT|Motivational interviewing for lifestyle changes associated with treating hypertension
75915308|NCT03407768|Behavioral|Individualized interventions|"A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques."
75915309|NCT03401294|Drug|FOLFOXIRI and Bevacizumab|Every 2 week for a total of 12 cycles
75915310|NCT03393884|Biological|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
75915311|NCT03393884|Drug|Carboplatin|AUC 6 IV over 1 hour on Day 1 of each cycle
75627462|NCT06059638|Device|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated|Antihypertensive therapy utilizing atrioventricular interval modulation.
75627463|NCT06059638|Device|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated|AVIM therapy is deactivated
75627464|NCT06056791|Biological|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent that does not require donor matching.
75627465|NCT06054776|Drug|Acalabrutinib|Given PO
75627466|NCT06054776|Procedure|Biospecimen Collection|Undergo blood sample collection
75627467|NCT06054776|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsies
75779501|NCT01092078|Behavioral|Patient Navigation|Patient navigation for colonoscopy.
75779502|NCT01088880|Drug|Canakinumab|
75779503|NCT02534363|Drug|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
75779504|NCT02534363|Drug|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
75779505|NCT02534363|Drug|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
75779506|NCT02534363|Behavioral|Cognitive battery|Completed in the following standardized sequence: 1-the Rey Auditory Verbal Learning Test (RAVLT); 2-WAIS-III digit symbol subtest; 3-Grooved Pegboard Test; 4-The Zoo Map Test; 5-Tower of London Test (ToL); 6-Rey Complex Figure (RCF); 7-Trail Making Test (TMT); 8-WAIS-III digits forward and backward subtests; 9-WAIS-III letter-number sequencing subtest; 10-WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11-Stroop Test; 12-letter (FAS) and semantic (animal) fluency tests; 14-Eyes Task; 15-Continuous Performance Test (CPT).
75779507|NCT01092234|Other|Traditional ward|provision of care in a traditional unit/ward.
75779508|NCT01092234|Other|Organizational change|Observational unit (new organizational unit) for organizing in-hospital care
75779509|NCT01043549|Device|rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
75779510|NCT01043549|Device|Sham rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
75779511|NCT03961230|Drug|Jueyin granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
75322485|NCT00245011|Drug|ifosfamide|Ifosfamide administered IV.
75322486|NCT00245011|Procedure|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
75322487|NCT00245011|Radiation|Sm-EDTMP (low dose)|Sm-EDTMP (low dose) administered after autologous stem cell collection
75322488|NCT00245011|Radiation|sm-EDTMP (higher dose)|Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
75627468|NCT06054776|Procedure|Computed Tomography|Undergo PET/CT or CT
75627469|NCT06054776|Procedure|Echocardiography|Undergo ECHO
75627470|NCT06054776|Biological|Glofitamab|Given IV
75627471|NCT06054776|Procedure|Multigated Acquisition Scan|Undergo MUGA
75627472|NCT06054776|Biological|Obinutuzumab|Given IV
75627473|NCT06054776|Procedure|Positron Emission Tomography|Undergo PET/CT
75627474|NCT06052891|Device|CHAMP Application|Children's Mercy Kansas City's CHAMP application was developed for data transfer of pediatric cardiac population vitals from home to the healthcare team in March 2014. CHAMP provides families and the clinical team with a new model of care leveraged by a remote patient monitoring (RPM) platform. CHAMP has been used in over 1000 patients, 28 states, and across 12 pediatric hospitals in pediatric cardiology. The CHAMP application is available in 11 languages for families to use on mobile devices (Apple and Android).
75627475|NCT06043323|Drug|Axicabtagene Ciloleucel|Given by IV (vein)
75627476|NCT06043323|Drug|Cyclophosphamide|Given by IV (vein)
75627477|NCT06043323|Drug|Fludarabine phosphate|Given by IV (vein)
75627478|NCT06043323|Drug|Prednisone|Given by IV (vein)
75627479|NCT06043323|Drug|Diphenhydramine|Given by IV (vein)
75627480|NCT06043323|Drug|Acetaminophen|Given by IV (vein)
75627481|NCT06042322|Other|Educational intervention|Multidisciplinary educational intervention was performed by orthopedic, anesthesia, and nursing team. This included a discussion of the patient's pain plan and a patient visit.
75627482|NCT06042153|Drug|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
75467185|NCT01917578|Procedure|HE Stain|"Procedure:~Xylene Ⅰ 60℃ 15-20 minutes~Xylene Ⅱ 60℃ 15-20 minutes~Alcohol 100% Ⅰ 3-5 minutes~Alcohol 100% Ⅱ 3-5 minutes~Alcohol 95% Ⅱ 3-5 minutes~Alcohol 90% Ⅱ 3-5 minutes~Wash in running tap water for 3 minutes~Hematoxylin 5-10 minutes~Wash in running tap water for 3 minutes~Differentiate in 1% acid alcohol for 30 seconds~Wash in running tap water for 1 minute~Bluing in 0.2% ammonia water for 30-60 seconds~Wash in running tap water for 3 minutes~Counterstain in eosin Y solution for 30-60 seconds~Wash in running tap water for 1 minute~Alcohol 90% Ⅱ 2-3 minutes~Alcohol 95% Ⅱ 2-3 minutes~Alcohol 100% Ⅱ 3-5 minutes~Alcohol 100% Ⅱ 3-5 minutes~Xylene Ⅲ 5-10 minutes~Xylene Ⅳ 5-10 minutes~Mounting with neutral resin"
75467186|NCT01917578|Device|CX22|The residual tumor areas are microscopically outlined on each slice by pathologist.
75467187|NCT01917578|Device|Epson V600|"Each slice that has been microscopically outlined is scanned by Epson V600.~Every image by scanning should be saved as JPG."
75627483|NCT06042153|Drug|Placebo|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
75627484|NCT06040840|Procedure|BAX|Injection of 30 mL of lidocaine (10 mg/ml) around the median, radial, ulnar and musculocutaneous nerves.
75627485|NCT06040840|Procedure|Tourniquet|Inflation pressure 75 to 100 mmHg above the patient's systolic blood pressure.
75627486|NCT06040840|Drug|Lidocaine|Axillary block with Lidocaine (10 mg/ml).
75627487|NCT06040840|Procedure|WALANT|"Preparation of a mixture of 20 ml of lidocaine (10 mg/ml) with epinephrine (0.005 mg/ml) + 3 ml Na bicarbonate (84 mg/ml) + 17 ml sterile normal saline.~The ultrasound probe will be placed to obtain a transverse image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 5 ml of the solution posterior and then anterior to the median nerve under the annular carpal ligament.~Then the ultrasound probe will be placed to obtain a longitudinal image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 15 ml of the solution anterior to the median nerve towards the carpal tunnel.~At last, a local infiltration with 5 ml of the solution will be performed around the surgical incision."
75627488|NCT06040840|Drug|Lidocaine + Epinephrine|WALANT technique with lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine.
75322489|NCT00628901|Procedure|Uterine Fibroid Embolization (UFE)|Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
75322490|NCT00628901|Device|Contour SE™ Microspheres|Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
75627489|NCT06034028|Device|J-Valve TF System|The J-Valve TF System is a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis, J-Valve TF Delivery Device, and Loading Accessories.
75627490|NCT06033703|Drug|Netarsudil Ophthalmic|Topical administration of Netarsudil
75627491|NCT06029985|Diagnostic Test|Hysteroscopic Follow Up|Office hysteroscopy was carried out to detect the scar site, performed with a 4-mm, continuous-flow operative hysteroscope by vaginoscopic approach, without analgesia or anesthesia. Distension of the uterus was obtained using a normal solution as distension medium, dispensed by an electronic suction/irrigation pump. This can maintain a constant intrauterine pressure of around 30-40 mmHg, balancing an irrigation flow of 200 mL/min with a vacuum of 0.2 bars, necessary to avoid overdistension of the muscle fibers and patient discomfort. The use of this distension medium allows blood or mucus to be washed out from the pouch if necessary.
75627492|NCT06016816|Procedure|Bilateral endoscopic sphenopalatine ganglion block|After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
75627493|NCT06016816|Procedure|placebo|Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
75627494|NCT06015022|Drug|Epigallocatechin gallate (EGCG)|EGCG is a green tea-derived catechin
75322491|NCT00628901|Device|Embosphere® Microspheres|Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
75467188|NCT01917578|Device|MRI|"Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.~Measurement of tumor size refers to WHO standards.~The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction."
75467189|NCT01917578|Procedure|Three-Dimensional Reconstruction|"A.Pathological images three-dimensional reconstruction:~Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.~Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.~Observe the shrinkage modes in three-dimensional space.~According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.~According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.~B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction"
75627495|NCT06015022|Other|Placebo|Placebo in the same capsule with the experimental agent (EGCG).
75627496|NCT06013423|Procedure|Biospecimen Collection|Undergo blood sample collection
75627497|NCT06013423|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspirate
75627498|NCT06013423|Drug|Cyclophosphamide|Receive IV
75627499|NCT06013423|Drug|Cyclosporine|Receive IV or PO
75627500|NCT06013423|Procedure|Diagnostic Imaging|Undergo diagnostic imaging
75627501|NCT06013423|Procedure|Echocardiography|Undergo ECHO
75627502|NCT06013423|Drug|Fludarabine Phosphate|Receive IV
75627503|NCT06013423|Procedure|Multigated Acquisition Scan|Undergo MUGA
75627504|NCT06013423|Drug|Mycophenolate Mofetil|Receive IV
75627505|NCT06013423|Other|Survey Administration|Ancillary studies
75627506|NCT06013423|Drug|Thiotepa|Receive IV
75627507|NCT06013423|Radiation|Total-Body Irradiation|Undergo high-dose or middle-intensity TBI
75915312|NCT03393884|Drug|Paclitaxel|175 mg/m2 IV over 3 hours on Day 1 of each cycle
76074333|NCT04278586|Behavioral|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
76074334|NCT04275076|Procedure|Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia|comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate
76074335|NCT04273438|Device|Visual field testing using Oculus Rift and Humphrey Visual Field Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
76074336|NCT04273438|Device|Visual Field Testing using HUmphrey 24-3 Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
76074337|NCT03809572|Behavioral|Mindfulness Based Cognitive Therapy|See Arm description
75467190|NCT01917578|Device|Mammography|"Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.~Measurement of tumor size and calcification extent refers to WHO standards.~Calcification extent is not only measured in mammography image but also under microscope."
75627508|NCT06013423|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
76074338|NCT04274218|Other|Perturbation|Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
76074339|NCT05744284|Device|electrocautery|advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
75779512|NCT03961230|Drug|Jueyin Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
75779513|NCT01050491|Drug|sitaxentan|100 mg once a day during one year. Bronchial fibroscopy
76074340|NCT05744206|Other|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
75627509|NCT06011772|Biological|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
75627510|NCT06011772|Drug|Leucovorin|Given IV
75627511|NCT06011772|Drug|Oxaliplatin|Given IV
75627512|NCT06011772|Drug|Fluorouracil|Given IV
75779514|NCT01050491|Drug|placebo|placebo, one per day, during one year. Bronchial fibroscopy
75779515|NCT01088958|Dietary Supplement|Micronutrient powders (Sprinkles)|"Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:~Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg"
75915313|NCT03384589|Biological|PCV13|Vaccine against pneumococcal disease
75915314|NCT03370614|Other|IBS Group|Participants will receive approximately 2 months of dietary and nutritional counseling.
75915315|NCT03370614|Other|Healthy Control Group|Participants will not receive any dietary or nutritional counseling.
75627513|NCT06011772|Biological|Bevacizumab|Given IV
75627514|NCT06011772|Drug|Irinotecan|Given IV
75627515|NCT06011772|Biological|Cetuximab|Given IV
75627516|NCT06011772|Procedure|Metastasectomy|Undergo metastasectomy
75627517|NCT06011772|Procedure|Biospecimen collection|Undergo collection of blood samples
75627518|NCT06010706|Other|Supervised physical therapy manual exercise program.|"Mobilization Techniques :~The joint mobilization technique will be the anterior-posterior glide of the talus. The participant will be positioned in supine or long sitting.~Stretching Exercise:~Passive stretching with therapist assistance was used for ankle dorsiflexion with the knee both flexed and extended. Force during passive stretching was modified to patient tolerance. Each participant flexed the knee slightly while standing on a 10° incline board. The participant was asked to slightly flex both knees until a stretch was felt in the calf muscle.~Strengthening Exercise:~The resistance training protocol will be based on the progressive resistance training principle and was a modification of the protocol used by Frontera et al [10] in older men. Plantar-flexion resistance training will be performed on a customized hydraulic apparatus, which provide a constant resistance over the entire ROM and allow for concentric as well as eccentric."
75915316|NCT03349476|Device|MFAM|"Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure.~mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy"
75915317|NCT03347838|Drug|Nivolumab|Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
75915318|NCT03339843|Drug|Abemaciclib|Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.
75322492|NCT03307070|Behavioral|Cognitive Behavioral Therapy for individuals with TBI|Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
75322493|NCT03307070|Other|Waitlist Control|Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
75322494|NCT02980419|Behavioral|presentation of visual and vestibular stimuli|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
75467191|NCT01917578|Drug|TAC,TC,TA,CAF,CEF|"TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)"
75627519|NCT06010706|Other|Stretching exercise, ROM, Strengthening exercises.|Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance.
75627520|NCT06001697|Behavioral|Park prescription|The park prescription given by the patients care-provider includes information about the health benefits of spending time in nature and detailed information about the parks in the neighbouring area (Monroeville, PA). As well as access to a web-based platform called ParkRx which includes information and details about events in the parks in or close by Monroeville, PA. Together with information about the frequency and duration of visits to the parks.
75627521|NCT06001697|Behavioral|Regular health advice|Regular health advice relating to lifestyle factors that can decrease the risk of chronic disease and/or reducing the burden of an existing chronic disease. Areas included are diet, physical activity, sleep, stress and medications.
75627522|NCT05998252|Device|Alveo HP Balloon Dilatation Catheter|Alveo HP Balloon is intended for dilatation of stenosis in the coronary artery.
75627523|NCT05984017|Other|No treatment is included in this study|No drug intervention or tissue sampling will be included in this study.
75627524|NCT05975970|Device|MyoTrain AR|MyoTrain AR is a virtual prosthesis functional training system. From a hardware perspective it consists of an augmented reality head-mounted display (HMD), four SteamVR kinematic trackers, eight surface EMG electrodes based on the Element electrode platform, and a desktop computer to facilitate wireless communication between the various hardware components. From a software perspective, MyoTrain AR was developed in the cross-platform Unity 4.0 game development engine.
75627525|NCT05975970|Behavioral|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
75627526|NCT05975658|Device|Gabi SmartCare Pediarity System [Gabi Band, Gabi Monitor App, Gabi Analytics]|Gabi SmartCare has created a monitoring system named Pediarity System that obtains pediatric vitals data through non-invasive means through a Gabi band. When paired with a proprietary algorithm and software - Gabi Analytics - the cloud-based platform measures blood oxygen levels, pulse rate (and variability), respiratory rate, actigraphy, inter-beat interval, and tracking for the time the device is worn (or not worn by the child). Three LEDs on the monitor are used for capturing this information. Peak wavelengths for the red, infrared, and green LEDs operate at 660nm, 950nm, and 526nm respectively. The Gabi band features an optical front end coupled with an analog front end using 24 bits. Bluetooth data transmission is utilized on a mobile phone application with a tablet-based system in a CSV format for the purpose of offline data processing.
75627527|NCT05973487|Biological|TSC-204-A0201|Escalating doses of TSC-204-A0201 as a monotherapy
75627528|NCT05973487|Biological|TSC-204-C0702|Escalating doses of TSC-204-C0702 as a monotherapy
75627529|NCT05973487|Biological|TSC-200-A0201|Escalating doses of TSC-200-A0201 as a monotherapy
75627530|NCT05973487|Biological|TSC-204-A0201 + TSC-204-C0702|Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702
75627531|NCT05973487|Biological|TSC-204-A0201 + TSC-200-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
75915319|NCT03337932|Drug|Doxycycline 100 milligram Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
75627532|NCT05973487|Biological|TSC-204-C0702 + TSC-200-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-200-A0201
75627533|NCT05973487|Biological|TSC-204-A0201 + TSC-203-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-203-A0201
75627534|NCT05973487|Biological|TSC-204-C0702 + TSC-203-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-203-A0201
75915320|NCT03337932|Drug|Doxycycline 100 milligram Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
75915321|NCT03337932|Drug|Controls without a history of lyme disease.|No intervention.
75627535|NCT05973487|Biological|TSC-200-A0201 + TSC-203-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-203-A0201
75627536|NCT05972954|Drug|OMT-28|once daily
75651664|NCT05832619|Drug|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
75915322|NCT03312634|Drug|Palovarotene|Palovarotene was taken orally once daily at approximately the same time each day following a meal.
75915323|NCT03305458|Behavioral|TFCBT|treatment as usual
75915324|NCT03305458|Behavioral|eTFCBT|tablet-facilitated Trauma Focused Cognitive Behavioral Therapy (eTFCBT)
75915325|NCT03289936|Device|NIPPV|Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
75467192|NCT01917578|Drug|AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF|"AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)"
75779516|NCT01050803|Behavioral|FDSME group|"In the intervention group, diabetes education sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
75779517|NCT01050803|Behavioral|FDSME|"In the intervention group, sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
75779518|NCT03962244|Device|EsoSponge|Endoscopically placed an EsoSponge for Negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
75779519|NCT03962244|Device|Self-Expanding Metal Stent|Endoscopically placed self-expanding-metal-stent (SEMS) for negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
75779520|NCT00395447|Procedure|Straight-forward Device Replacement|
75627537|NCT05966532|Behavioral|Hot Cognitive Task|"Emotion processing:~Participants will be shown a series of faces that appear quickly and be asked to identify what emotion is shown.~Participants will be shown a face of an emotion and indicate if participant can see the emotion changing.~Participant will be shown a series of emotions and asked to respond to only a specific emotion.~Motivation reward and processing:~Participant will play with a simulated roulette and make a bet to evaluate their decision-making behavior.~Participant will be shown colored circles and choose the one more likely to win money.~Impulsivity:~• Participant will be shown a series of stimuli where they will be asked to respond to the correct stimulus.~Social cognition:~Participant will be shown a series of moral situations in which a character is accidentally or intentionally harmed and be asked to rate the degree of guilt from the perspective of the victim or perpetrator."
75779521|NCT00395447|Procedure|Device Replacement with Upgrade|
75779522|NCT03404674|Biological|CssBA|Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B
75779523|NCT03404674|Biological|dmLT|Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211
75779524|NCT01050959|Device|bion|
75779525|NCT00064662|Procedure|Burch Modified Tanagho|The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
75779526|NCT00064662|Procedure|Autologous Fascia Sling|The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
75779527|NCT03404518|Drug|Norco|Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control
75779528|NCT03404518|Drug|Ibuprofen|Ibuprofen as first line therapy every 6 hours as needed for pain control
75467193|NCT01917591|Device|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
75467194|NCT01917591|Device|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
75467195|NCT01917617|Drug|Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|"Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
75467196|NCT01917617|Drug|Gemcitabine , Cisplatin|"Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
75467197|NCT01917630|Drug|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
75467198|NCT01917630|Drug|placebo|
75467199|NCT01917695|Drug|Chemotherapy|cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
75467200|NCT01917695|Radiation|External Beam Radiotherapy|50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
75467201|NCT01917695|Radiation|Brachytherapy|Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
75467202|NCT01917695|Procedure|Radical Hysterectomy|Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
75651665|NCT05832619|Device|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
75779529|NCT03404206|Drug|Naproxen Sodium (Aleve, BAY117031)|220 mg x 2 tablets, oral, single dose
75779530|NCT03404206|Drug|Ibuprofen (Advil)|200 mg x 2 tablets, oral, single dose
75779531|NCT03404206|Drug|Placebo|Matching placebo, 2 tablets, oral, single dose
75779532|NCT03403426|Device|Wingman Crossing Catheter|Endovascular CTO crossing
75779533|NCT00394901|Drug|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
75322495|NCT05686460|Behavioral|ice massage|"After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. The Hegu point of the participating students was detected with the acupuncture point finder. Ice cubes whose dimensions were 2x2x2 cm were wrapped with gauze and placed in a plastic bag. Vaseline® jelly was spread on the application area. The application applied 2 minutes of ice massage 7 times at 15-second intervals. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test).~On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS)."
75779534|NCT00394901|Drug|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
75627538|NCT05966532|Behavioral|Cold cognitive tasks|"Montreal Cognitive Assessment (MoCA) - This will ask participants questions related to their cognition such as visuospatial skills, naming, memory, attention, language, and recall.~Measurement of Everyday Cognition (ECog) - This scale will ask participants about their everyday memory, language, visuospatial ability, organization, and divided attention.~Test of Premorbid Function (TOPF) - This test will evaluate memory performance and abilities of stud participants before onset pre-morbid status.~California Verbal Learning Test -3rd Edition (CVLT-3) -This test will measure verbal learning and memory of study participants.~Three tests from the Delis-Kaplan Executive Function System (D-KEFS; Verbal Fluency, Color-Word Interference, and Tower Tests). -These measures assess word finding and problem-solving ability."
75322496|NCT05686460|Behavioral|music medicine|After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The volume of the music was adjusted based on the verbal feedback or facial expressions of the students. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test). On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).
75322497|NCT05186181|Behavioral|In situ fenestration|Interventional therapy of aortic dissection. In situ needle fenestration of left subclavian artery.
75627539|NCT05966532|Other|Structural magnetic resonance imaging (sMRI)|This is a non-invasive procedure to assess the structure and function of participant's brain. Structural neuroanatomical data will be acquired using structural magnetic resonance. Imaging (sMRI) with the University of Texas Southwestern (UTSW) 3T (three Tesla field) MRI scanner. Prior to participation, the investigator's team will screen participant's to ensure eligibility to participate in the sMRI scan.
75627540|NCT05966532|Other|Magnetoencephalography imaging (MEG)|This is a non-invasive procedure to measure participant's brain activity. Participants will be sitting inside the machine in a chamber, with more space than a traditional MRI machine. A hat will be placed on top of participant's head which records their brain activity. Resting-state and task-based MEG recordings will occur in a three-layer magnetically shielded room (MSR) following our UTSW Advanced Neuroscience Imaging Research (ANSIR) established procedures. Before the scan, five coils will be secured to participant's head and a three-dimensional (3D) digitizer will be used to map the location of the coils, fiducials, and scalp surface. During recording, an electric current with a unique frequency label (i.e., 320 Hz) will be fed to each coil, which will permit real time head location tracking and subsequent offline head motion correction.
75322500|NCT05663294|Radiation|external beams radiotherapy|"External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:~40 Gy in 15 fractions;~30 Gy in 5 fractions;~40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours)."
75467203|NCT01917708|Drug|Abatacept|All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
75627541|NCT05960851|Drug|LY3871801|Administered orally.
75627542|NCT05960851|Drug|Placebo|Administered orally.
75779535|NCT00394901|Drug|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
75779536|NCT00394901|Drug|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
75779537|NCT03349060|Drug|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
75779538|NCT03349060|Drug|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
75779539|NCT03349060|Drug|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
75322501|NCT05663294|Radiation|brachytherapy|"Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment.~The schedule for brachytherapy are:~32 Gy in 8 twice-daily fractions for HDR;~30.3 Gy in 7 twice-daily fractions for HDR;~50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR."
75322502|NCT00629525|Drug|RAD001|RAD001 at a dose of 10 mg PO daily
75322503|NCT00244855|Other|pharmacological study|Correlative studies
75322504|NCT00244855|Biological|rituximab|Given IV
75467204|NCT01917721|Drug|Doxycycline|The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.
75322505|NCT00244855|Drug|dexamethasone|Given IV
75467205|NCT01917721|Drug|Placebo|Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
75322506|NCT00244855|Other|laboratory biomarker analysis|Correlative studies
75467206|NCT01917734|Other|Therapeutic feeding for children with SAM|Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
75467207|NCT01917786|Device|ECG|
75467208|NCT01917799|Drug|Aspirin|75mg tab of LDA once daily for 7 months
75467209|NCT01917799|Drug|Heparin|0.4 mL/day of the Enoxaparin
75915326|NCT03289936|Device|SNIPPV|Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
75322507|NCT05182203|Drug|biologic/targeted therapy|TNF inhibitors or the JAK inhibitors
75467210|NCT01917838|Behavioral|MFG plus MyMFG|"Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.~The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
75627543|NCT05958316|Behavioral|Computerized Symptom Capture Tool (C-SCAT) Intervention|"The C-SCAT includes the 32 symptoms from the Memorial Symptom Assessment Scale (MSAS). Users select symptoms they have experienced over the past week, rate each symptom's severity and distress, and name a perceived cause. They then identify temporal and causal relationships between symptoms using lines and arrows, designate groups, i.e., clusters of symptoms, and give a name to each cluster. They are asked the reason for a symptom's designation as a priority symptom and what they do to alleviate that symptom. Next, they are asked to designate a priority cluster and finally, to confirm whether the image accurately reflects their symptom experience. Then, at the clinic visit, the AYA shares the visual image with the HCP, and more importantly, their priority symptoms, which can facilitate the symptom discussion. The C-SCAT intervention group will complete the C-SCAT prior to each of three encounters with their health care providers (HCPs)."
75627544|NCT05958316|Behavioral|Usual Care Control|Usual care is defined as the usual approach to assessing symptoms during the HCP encounter. To provide attentional control to the usual care control group and prevent disproportionate attrition from that group, study staff will contact participants three times during the intervention period (approximately 3 months) when they are in for a scheduled clinic visit and communicate the following: 1) express appreciation for ongoing study participation; 2) ask how everything is going with their treatment; 3) ask if anything has changed with their treatment plan since the last study visit; and 4) confirm continued participation in the study.
75779540|NCT01051037|Radiation|Stereotactic Body Radiation|3 fraction of stereotactic body radiation therapy within 10 days.
75779541|NCT01051037|Radiation|Radiofrequency Ablation|Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
75322508|NCT03359408|Behavioral|Dementia Care Management (DCM)|"A specialised discharge management, based on Dementia Care Management (DCM; Thyrian et al. 2017, Eichler, Thyrian, Fredrich et al. 2014, Eichler, Thyrian, Dreier et al. 2014, Dreier et al. 2016, ) will be applied to subjects with cognitive impairment. Specifically qualified will conduct comprehensive data assessments during the hospital stay, assess recommendations at discharge and assess unmet needs at home. Supported by a a computerized Intervention Management (IMS) and in close cooperation with the discharging hospital, treating physicians and other care providers, they will develop, implement and monitor a treatment and care plan. Interventional home visits will take place at the participants homes."
75322509|NCT00737893|Drug|Placebo|Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
75322510|NCT00737893|Drug|Erythropoietin (EPO)|Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
75322511|NCT00631319|Drug|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
75322512|NCT00631319|Drug|Placebo|Placebo
75322513|NCT05686382|Procedure|Continuous Wound Infusion|continuous local anesthetic infiltration of the wound
75322514|NCT05686382|Procedure|TAP block|ultrasound guided injection of local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles
75322515|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
75779542|NCT03990935|Other|ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
75779543|NCT03348904|Drug|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
75915327|NCT03284931|Drug|SAGE-217 high dose|high dose
75915328|NCT03284931|Drug|Placebo|placebo
75915329|NCT03284931|Drug|SAGE-217 low dose|low dose
75915330|NCT03284775|Device|Intraoperative ultrasound|Patients will undergo transsphenoidal surgery in the usual manner except that an intraoperative ultrasound device will be available for use to better visualise the tumour and surrounding neurovascular structures.
75915331|NCT03279471|Drug|Sertraline|Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks based on their tolerability to the medication. Dosing is capped at 125mg/day.
75915332|NCT03279471|Behavioral|CBT/BIACA|Participants receive 16 weeks of BIACA therapy.
75322516|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
75322517|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
75322518|NCT05686304|Behavioral|Internet-based self-help money management program|The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
75322519|NCT00680225|Drug|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
75322520|NCT04603391|Drug|di-Methylphenidate plus Cannabidiol|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) plus CBD 750 mg (administered as 7.5 ml of Epidiolex® solution [100 mg/ml] of CBD)
75322521|NCT04603391|Drug|di-Methylphenidate plus Cannabidiol Placebo solution|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) 7.5 ml of Epidiolex® placebo solution containing no CBD.
75322522|NCT05686148|Other|Vibration|The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.
75627545|NCT05957406|Device|Acumen HPI Smart Alerts and Smart Trends Software|Device: Acumen HPI Smart Alerts and Smart Trends Software The Acumen HPI Smart Alerts and Smart Trends Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The Acumen HPI Smart Alerts and Smart Trends Software suite is enabled by the minimally invasive Acumen IQ sensor.
75467211|NCT01917864|Behavioral|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
75467212|NCT01917890|Dietary Supplement|Curcumin|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)"
75322523|NCT01271647|Drug|Yin and Yang tonic granules|Yin and Yang tonic granules,18g per time,two times per day,six months
75322524|NCT01271647|Drug|placebo|granules,18g per time,two times per day,six months
75467213|NCT01917890|Dietary Supplement|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)"
75322525|NCT03368456|Behavioral|S4E|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol & drug use, HIV & STIs and a forthcoming module on tobacco prevention and cessation.
75467214|NCT01917942|Device|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
75627546|NCT05955157|Biological|Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy|DC+CIK immunotherapy will be administrated with S-1 chemo drug as maintenance treatment for patients with advanced PDAC
75627547|NCT05955157|Drug|Tegafur Only Product|Tegafur (TS-1) will be administrated alone as maintenance treatment to control group as standard of care
75322526|NCT03368456|Behavioral|Usual Care|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
75322527|NCT00738049|Drug|darusentan 100 mg|All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
75322528|NCT04536935|Behavioral|Mobile Mental Health App - 1|Free mobile mental health application that focuses on meditation
75322529|NCT04536935|Behavioral|Mobile Mental Health App - 2|Free mobile mental health application that assists with coping with COVID-19
75627548|NCT05954871|Drug|GDC-1971|GDC-1971 capsules or tablets will be administered as specified in each treatment arm.
75627549|NCT05954871|Drug|Osimertinib|Osimertinib tablets will be administered as specified in each treatment arm.
75627550|NCT05954871|Drug|Cetuximab|Cetuximab, solution for infusion will be administered as specified in each treatment arm.
75627551|NCT05951777|Biological|Autologous HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
75627552|NCT05951777|Drug|Normal Saline|Sterile Saline Solution 0.9%
75627553|NCT05945875|Drug|Panitumumab-IRDye800|Given by IV
75322530|NCT04536935|Behavioral|Mobile Mental Health App - 3|Free mobile mental health application that focuses on positive psychology.
75322531|NCT04536935|Behavioral|Mobile Mental Health App - 4|Free mobile application that addresses mental health issues through mood tracking
75627554|NCT05945875|Other|Indium In 111 Panitumumab|Given by IV
75627555|NCT05945875|Procedure|Single Photon Emission Computed Tomography|Undergo Single Photon Emission Computed Tomography
75627556|NCT05945875|Procedure|Computed Tomography|Undergo Computed Tomography
75627557|NCT05945875|Procedure|Resection|Undergo standard of care surgical resection
75627558|NCT05945875|Procedure|Fluorescence Imaging|Undergo standard of care fluorescence imaging
75627559|NCT05945849|Biological|CD33KO-HSPC; CART33|"CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells."
75627560|NCT05944237|Drug|HTL0039732 Capsules|HTL0039732 Capsules will be administered orally to fasted participants, although an exploration of food effects may be performed as a single dose at Cycle 0. A single dose will be administered between 3 and 9 days prior to commencement of Cycle 1. From Cycle 1 Day 1, HTL0039732 will be administered on a once daily (QD) schedule. Each administration cycle will consist of 21 days with no break between cycles. Participants may initially receive up to 18 cycles but may continue for a further 18 cycles if they are deemed to be benefitting.
75322532|NCT05640752|Diagnostic Test|2019 ESC guideline-determined diagnostic strategy|ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL <15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
75322533|NCT05640752|Diagnostic Test|2016 NICE guideline-determined diagnostic strategy|For subjects assigned to NICE strategy, ones with nonanginal chest pain and normal ECG were classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG were classified into high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
75467215|NCT01917942|Other|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
75467216|NCT01917981|Device|Personal Heart Rhythm Monitor|
75322534|NCT02291133|Procedure|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
75467217|NCT01917994|Behavioral|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
75467218|NCT01917994|Behavioral|Appointment Reminders|
75467219|NCT01918020|Behavioral|Go Wild with Fruits and Veggies!|Fruits and Vegetables
75467220|NCT01918020|Behavioral|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
75467221|NCT01918059|Procedure|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
75467222|NCT01918059|Procedure|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
75627561|NCT05944237|Drug|HTL0039732 Capsules and atezolizumab infusion|HTL0039732 Capsules will be administered orally on a QD schedule to fasted participants starting on Cycle 1 Day 1. Each administration cycle will consist of 21 days with no break between cycles. Cycle 1 will consist of HTL0039732 monotherapy. From Cycle 2 onwards, participants will also receive 1200 mg atezolizumab as an IV infusion on Day1 of each cycle (i.e. every 3 weeks). Participants may initially receive up to 18 cycles of HTL0039732 but may continue for a further 18 cycles if they are deemed to be benefitting, and they may receive up to 36 cycles of atezolizumab.
75627562|NCT05940324|Drug|Ketamine|Ketamine is an FDA-approved dissociative anesthetic.
75779544|NCT03348904|Drug|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
75779545|NCT03348904|Drug|Placebo|Matching placebo for epacadostat administered orally twice daily.
75779546|NCT03348904|Drug|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
75779547|NCT03348904|Drug|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
75627563|NCT05940324|Drug|Naltrexone Pill|Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
75627564|NCT05940324|Other|Placebo pill|An oral inactive placebo pill will be administered to preserve the blinded nature of the study.
75627565|NCT05932043|Diagnostic Test|This is a non-interventional study|None (this is a non-interventional study)
75627566|NCT05931276|Drug|Metoprolol Succinate|a dialyzable, beta-1 selective beta blocker
75627567|NCT05931276|Drug|Carvedilol|a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
75627568|NCT05926830|Device|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue. The process is then repeated in a stepwise fashion.
75627569|NCT05923736|Other|Intima media thickness ultrasound|EIM is a non-invasive ultrasound technique in which an ultrasound-generating probe is conventionally placed opposite the right primary carotid artery. By distinguishing between an inner layer, consisting of the intima and media, and the outer layer, the adventitia, the intima-media thickness can be assessed.
75779548|NCT03348904|Drug|Gemcitabine|Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
75779549|NCT03348904|Drug|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
75779550|NCT03348904|Drug|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
75779551|NCT00359021|Drug|TMC125|200 mg twice daily until commercially available
75915333|NCT03279471|Drug|Placebo|Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
75915334|NCT03275493|Biological|Humanized CD19 CAR-T cells|Express a Second Generation 4-1BB:humanized CD19 CAR-T cells
75322535|NCT02291133|Device|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization."
75322536|NCT02291133|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
75467223|NCT01918059|Procedure|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
75467224|NCT01918098|Drug|Oxycodone/naloxone prolonged release tablets|
75322537|NCT00680459|Drug|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
75322538|NCT00680459|Drug|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
75467225|NCT01918111|Procedure|Renal denervation|Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
75467226|NCT01918111|Drug|adenosine infusion treatment|Continue hypertensive medication
75322539|NCT04760366|Other|fascial- muscular lengthening therapy|"Patients in this group will receive interventional therapy~To perform this technique:~Have the patient in side lying position~Hip is maximally flexed to shorten the iliopsoas muscle.~Therapist fingers should be on to the targeted area.~Apply gentle pressure in upward direction.~While maintain the pressure, stretch the muscle by moving the hip in extension through full ROM.~Therapist will maintain the pressure in opposing direction. This is considered as one pass. This technique is performed bilaterally. Patients in this group will also receive the conventional therapy which will include:~Hot pack for 15 minutes.~Myofascial release of iliopsoas.~TENS for 15 minutes."
75322540|NCT04760366|Other|Stretching's of iliopsoas muscle|"Patients in this group will receive the interventional therapy which will include:~Stretching's of iliopsoas muscle which can be done in two positions:~modified lunge position.~The prone stretch.~Patients in this group will also receive the conventional therapy which will include:~Hot pack for 15 minutes.~Myofascial release of iliopsoas~TENS for 15 minutes."
75627570|NCT05923736|Other|hand ultrasound|Performed by the rheumatologist, to quantify the number of synovial thickenings in B mode and the number of synovitis in Doppler mode. The presence or absence of joint erosions on the metacarpophalangeal (MCP), proximal interphalangeal (PPI) or distal interphalangeal (DIP) joints.
75627571|NCT05923736|Other|EndoPAT™ 2000 system|It's a measurement that detects endothelial dysfunction in coronary arteries using reactive hyperemia.This examination will be carried out in accordance with the manufacturer's instructions by the Rheumatology Department nurse. The patient lies down for the duration of the examination (20 minutes). A probe is placed on the index finger of each hand and a cuff on the left arm. Recording begins with a 5-minute baseline period (at rest), followed by a 5-minute period of arm occlusion, and ends with a 5-minute period of return to normal.
75322541|NCT04760366|Other|the conventional therapy|the conventional therapy
75467227|NCT01918124|Radiation|radiotherapy|Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
75467228|NCT01918124|Drug|Cisplatin|Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
75322542|NCT04400864|Other|Dietary intervention|dietary counseling based on the principals pf the dietary intervention group.
75467229|NCT01918124|Drug|Cisplatin and Doxorubicin and Cyclophosphamide|Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
75322543|NCT00632411|Drug|Nicotine Patch|"Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment."
75467230|NCT01918124|Drug|Paclitaxel and Carboplatin|Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
75467231|NCT01918137|Dietary Supplement|chocolate bar|
75467232|NCT01918137|Dietary Supplement|Porridge|
75467233|NCT01918150|Device|Titan 2 stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
75467234|NCT01918150|Device|Cobalt-Chromium Bare Metal Stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
75467235|NCT01918163|Dietary Supplement|Pomegranate pills|
75467236|NCT01918176|Drug|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
75322544|NCT00632411|Behavioral|Tobacco Quit Line Program|"Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention."
75627572|NCT05923736|Other|X-ray absorptiometry (DXA)|This X-ray examination will be carried out on the Hologic device and the analyses by APEX 4.0 software. Two-photon X-ray absorptiometry (DXA) is a method commonly used to measure bone mineral density. It is based on a scan of the body by an X-ray beam at 2 different energy levels, which enables 3 compartments to be individualized: mineral mass, lean mass and fat mass. This low-radiation method (less than a conventional chest X-ray) is regarded as a benchmark for accurate measurement of both bone mineral density and the various body compartments. The examination lasts 10 minutes and is carried out by the department's electroradiology manipulators
75627573|NCT05918887|Device|NJOY ACE commercial e-cigarette|"The NJOY ACE is the commercial version of the Standardized Research E-Cigarette (SREC), which was developed by NIDA with NJOY for research purposes.~Nicotine pods:~Sealed, pre-filled, non-refillable~1.9 mL e-liquid with 5% w/w nicotine~Approx 300 (280-330) puffs/pod~Nicotine liquid characteristics:~Volume of liquid per pod 1.9 mL~Active (nicotine USP 5% wt/wt)~Propylene Glycol USP & Vegetable Glycerin USP - PG/VG Ratio 0.77~Lactic Acid USP~Battery characteristics:~USB Rechargeable~Storage Capacity ~ 400 mAh~Approx 200 (3s) puffs / charge~300 charge cycles to > 80% initial capacity~Time to full charge 75 - 85 min~Voltage / Temperature settings not user adjustable"
75627574|NCT05911997|Drug|MTC 01|Slurry to be administered via colonoscopy
75322545|NCT04840329|Behavioral|Education|One-time educational session about menstrual health and endometriosis
75627575|NCT05911997|Drug|Fecal Microbiota Transplantation (FMT)|Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
75627576|NCT05903118|Biological|RBMRNA-176|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection
75627577|NCT05903118|Other|Placebo|0.9% sodium chloride (normal saline) injection
75627578|NCT05900609|Dietary Supplement|WholeFiber|"WholeFiberTM is a product with high levels of prebiotic dietary fibers (~85%) mainly consisting of inulin, and some pectin, hemi-cellulose and cellulose that is derived from the root vegetable, chicory roots.~Fiber guidelines:~Subjects receive a booklet with recipes high in fiber. Subjects are recommended to use 2 recipes per day + a snack. Estimated average intake via the recipes in the recipe booklet is 24 grams/day.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
75627579|NCT05900609|Dietary Supplement|Kombucha|"The kombucha is produced by a minimum three-month long fermentation process. It is a live fermented herbal drink essence, without refined sugar, and an unpasteurized, organic product.~Fermented food guidelines:~Study participants in the fermented foods arm are asked to use 3 additional servings of fermented food per day, using the fermented food list / recipe booklet.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
75627580|NCT05900609|Dietary Supplement|Maltodextrin DE19/21|"Maltodextrin DE19/21 is a digestible carbohydrate, that is completely digested and does not reach the colon, which makes it a suitable placebo dietary compound and the reason why it is frequently used in comparable studies.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
75627581|NCT05897788|Behavioral|Text Message Check-ins|Patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything AND patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.
75627582|NCT05897788|Behavioral|Contingency Management|Patients will receive incentives for engagement with treatment. Participant will receive compensation for filling their buprenorphine scripts at discharge and attending their follow-up care appointments.
75627583|NCT05897320|Drug|Eptinezumab|Solution for infusion
75627584|NCT05897320|Drug|Placebo|Solution for infusion
75627585|NCT05892159|Behavioral|HRV biofeedback|An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.
75322546|NCT05685836|Drug|Bevacizumab Zirconium Zr-89|See Arm description.
75322547|NCT00632489|Drug|LBH589|LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
75322548|NCT00632489|Drug|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
75322549|NCT00632489|Drug|Lapatinib|Lapatinib, 1000 mg PO daily will be added to this combination.
75322550|NCT04387721|Other|Kind of trifocal IOL|Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D
75322551|NCT03355274|Diagnostic Test|Transcutaneous Oximetry|"The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up)."
75322552|NCT03355274|Diagnostic Test|Photopletysmography|Maneuvers are repeted with the photoplestysmography sensors and in front of a Kinect camera.
75467237|NCT01918176|Drug|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
75467238|NCT01918202|Drug|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
75627586|NCT05889572|Drug|MaaT033|MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.
75627587|NCT05888428|Device|MyoTrain|MyoTrain is a virtual prosthesis control training system. From a hardware perspective it consists of an Apple iPad tablet computer and an eight-channel EMG armband, based on the Element electrode platform, which interfaces with the tablet via Bluetooth™. From a software perspective, MyoTrain was developed in the cross-platform Unity 4.0 game development environment.
75627588|NCT05888428|Behavioral|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
75627589|NCT05886634|Drug|Etrumadenant|Will be administered PO daily for 24 weeks
75322553|NCT03355274|Other|Questionnaires of Quality of Life (QoL)|Each subject complete 2 QoL questionnaires : Sf-12 (Short Form 12) and DASH (Disabilities of the Arm, Shoulder and Hand).
75322554|NCT00243841|Radiation|Stereotactic Body Radiation|Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.
75627590|NCT05886634|Drug|Zimberelimab|Will be administered IV every 2 weeks for 24 weeks
75627591|NCT05874414|Drug|GNS561 + Trametinib|GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
75627592|NCT05869773|Drug|JZP258|0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution
75627593|NCT05869487|Radiation|Dual-energy X-ray absorptiometry|Whole body x-ray absorptiometry
75627594|NCT05868265|Drug|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.
75627595|NCT05868265|Procedure|Radical surgery|Radical surgery, such as radical nephroureterectomy, nephrectomy or ureterectomy is to take place within 60 days from the last dose of treatment end of cycle 3 (i.e., cycle 3 day 22).
75627596|NCT05867849|Drug|Cannabidiol|Cannabinoid
75915335|NCT03275493|Biological|Humanized CD19 CAR-T cells with CRS suppression technology|Express a Second Generation 4-1BB:humanized CD19 CAR-T cells with CRS suppression technology
75322555|NCT03832400|Biological|MET-2|MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.
75627597|NCT05867849|Other|Placebo|Inactive substance
75627598|NCT05864677|Drug|Cerebrolysin|Patients, who will be randomized to group CER, will receive Cerebrolysin at the dose of 50 mL before surgery, followed by 50 mL on the morning of days 1,2,3, and 4.
75627599|NCT05856227|Drug|Ceftobiprole medocaril|Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
75627600|NCT05850689|Drug|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
75627601|NCT05850689|Drug|Placebo|Matching capsules administered orally, once daily
75627602|NCT05843461|Other|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery. PIMR of the right and left pulmonary arteries will be obtained.
75627603|NCT05843461|Other|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
75627604|NCT05843461|Other|Pulmonary artery OCT|OCT of the pulmonary artery involves advancing an OCT catheter over the pressure wire to image the pulmonary artery. OCT of the right and left pulmonary arteries will be performed.
75627605|NCT05842161|Behavioral|QUIT-AD|An adapted, six-session cognitive behavioral therapy intervention for smoking cessation and treatment adherence
75627606|NCT05842161|Other|Enhanced Treatment as Usual|Standard treatment for HIV/TB with one session of psychoeducation.
75627607|NCT05836324|Drug|INCA33890|INCA33890 will be administered at protocol defined dose.
75651666|NCT05832619|Device|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20*1.5mm or φ0.20*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
75915336|NCT03231878|Drug|MIN-102|MIN-102 treatment
75915337|NCT03231878|Drug|Placebos|Placebo
75915338|NCT03229083|Other|Carevive software|In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
75322556|NCT03832400|Drug|Placebo oral capsule|Placebo oral capsule which is identical to the MET-2 capsules.
75322557|NCT00681083|Device|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
75322558|NCT00681083|Device|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
75322559|NCT05074875|Other|Questionnaires and Patient Reported Outcomes (PROs)|"EuroQol 5 Dimensional Quality of Life Questionnaire (EQ-5D).~St. George's Respiratory Questionnaire (SGRQ)~Impact of Events Scale Revised (IES-R)~Generalized Anxiety Disorder 7-Item (GAD-7)~Patient Health Questionnaire (PHQ-9)"
75322560|NCT05074875|Diagnostic Test|Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)|If required by the local site's COVID-19 guidelines, subjects should have the COVID-19 RT-PCR Nasal Swab collected at the beginning of the visit or within 5 days prior to the scheduled visit.
75322561|NCT05074875|Genetic|Blood Samples for Biomarkers|Venous blood will be collected using pre-labeled tubes.
75627608|NCT05834478|Device|Transcutaneous Cervical Vagal Nerve Stimulation|Participants will receive stimulation of the vagus nerve with the non-invasive transcutaneous cervical Vagal Nerve Stimulation (tcVNS), which does not require surgery or implantation, and electrically stimulates the vagus nerve as it passes through the neck, dampening the sympathetic nervous system and modulating brain regions to a single side of the neck with the GammaCore device. Participants will be trained on self-stimulation and from days 1-7 patients undergo four times daily self-stimulation with tcVNS first for two minutes on one side, followed by a one-minute pause, then two minutes on the same side. The intensity of the stimulus (i.e. the current amplitude) will be adjusted by the user, to the maximum tolerable level without causing excessive pain [typically 10-30 V and 60milliamperes (mA) (peak)], with an alternating current (AC) signal consisting of five 5 kilohertz (kHz) pulses 200 microseconds in duration, repeating at a rate of 25 Hz (about once every 40 milliseconds).
75627609|NCT05834478|Device|Sham Stimulation|Participants will have the same procedures as with the tcVNS but will instead receive a device that appears identical to the active tcVNS device in look, weight, visual and audible feedback, and also in user controls. The Sham device looks and sounds like an active device but does not deliver an electric current.
75322562|NCT05074875|Diagnostic Test|High Resolution Computed Tomography|Subjects will have HRCTs at Visits 1, 2, 3, and 4. Inpatient HRCT scans will be collected during the baseline visit (V0 or V1)
75627610|NCT05834478|Drug|[F-18]Fallypride|[F-18]Fallypride is a radioactive material. Each patient will have two [F-18]Fallypride PET scans. For each scan [F-18]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
75322563|NCT05074875|Diagnostic Test|Physical Exam and Vital Signs|"A complete physical exam, including height, weight, general appearance, neck, lungs, cardiovascular system, abdomen, extremities, and skin will be performed at Visit 1.A brief physical exam will be completed at subsequent visits, including weight, general appearance, lungs, cardiovascular symptoms, extremities, and other body systems pertinent to the participants health status, at the discretion of the investigator.~Blood pressure, heart rate, and oxygen saturation will be collected at all visits, prior to blood draws and after subjects have rested."
75322564|NCT05074875|Diagnostic Test|Medical Research Council Sum Score|The Medical Research Council Sum Score (MRC-SS) is used globally to detect peripheral muscle strength and to help diagnose ICU-acquired muscle weakness. The MRC-SS ranging from 0 (complete paralysis) to 60 (normal).
75651667|NCT05832606|Other|Food box containing 30 different plants|Food boxes during first 12 weeks of therapy. Clinical follow-up until end of immunotherapy.
75322565|NCT05074875|Diagnostic Test|Hand Grip Strength|Each subject will have hand grip strength measured at each visit. This is being done in order to assess the maximum isometric strength of hand and forearm muscles.
75322566|NCT05074875|Diagnostic Test|Spirometry|Spirometry will be assessed at Visits 1, 2, 3 and 4. Each site will use its own spirometry machine. Each subject should use the same machine at each visit and conduct measurements at approximately the same time. Before any testing, the maneuver should be demonstrated to the subject. The spirometry should be reviewed by the investigator.
75651668|NCT05832593|Other|Immunohistochemistry|Immunohistochemical expression of ERCC1
75779552|NCT02534207|Drug|Basmisanil|Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
75779553|NCT00360269|Drug|Atomoxetine|25 to 100 mg daily
75915339|NCT03218748|Behavioral|Honest, Open, Proud (HOP)|"Three lessons, one for each two-hour session plus one booster session~Considering the pros and cons of disclosure:~Discussion of one's idea of identity and mental illness, weighing the costs and benefits of (non-) disclosure~Different ways to disclose:~Discussion of different levels of (non-) disclosure, considering costs and benefits of each level, selecting persons to disclose to and how to test them out, anticipating responses of others to one's disclosure~Telling one's story:~Practice how to tell one's story, identifying peers who might be helpful with the coming out process~Booster session Reviewing previous intentions to disclose one's mental illness, discussion whether one disclosed and evaluating this experience"
75915340|NCT03212378|Other|percutaneous coronary interventions|Percutaneous coronary intervention.
75467239|NCT01918202|Drug|PF-02545920|"The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional."
75467240|NCT01918202|Drug|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
75467241|NCT01918228|Behavioral|Talks about what science says about LBP|Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
75467242|NCT01918241|Drug|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
75467243|NCT01918241|Drug|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
75467244|NCT01918241|Drug|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
75467245|NCT01918241|Drug|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
75651669|NCT05832580|Drug|Etidronate|Etidronate in capsules of 200 mg or 400 mg.
75651670|NCT05832580|Drug|Placebo|Placebo in similar capsules
75779554|NCT00360269|Procedure|Motivational enhancement therapy|Three sessions
75779555|NCT00360269|Drug|Placebo|25 to 100 mg daily
75915341|NCT03207672|Drug|E7389-LF|intravenous infusion
75915342|NCT03193281|Drug|Dasatinib|"In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment."
75915343|NCT03193281|Drug|Imatinib|Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
75915344|NCT03181867|Drug|18F-DCFPyL|Subjects will receive IV dose of 18F-DCFPyL by bolus injection. The maximum amount of injected active drug will be less than 4.02 mcg. The target administered activity will be 8 mCi.
75322567|NCT05074875|Diagnostic Test|Diffusing Capacity of Carbon Monoxide|The site will use its own DLCO equipment for measurements at Visits, 1, 2, 3, and 4. The Single-breath DLCO maneuver will be carried out in accordance with the 2017 American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Subjects should use the same device at approximately that same time at each visit. The maneuver should be demonstrated to the subject prior to the test.
75322568|NCT05074875|Diagnostic Test|6 Minute Walk Test|"The 6 Minute Walk Test (6MWT) will assess exercise capacity and tolerance. 6MWTs will be conducted at Visits 1, 2, 3, and 4.~The procedure of the 6MWT should be explained and demonstrated to the subject prior to the start of the test."
75322569|NCT05074875|Diagnostic Test|Sit to Stand (STS) Measurement|The STS will be conducted at Visits 1, 2, 3, and 4 to assess the physical functioning of the adult participants.
75627611|NCT05832229|Drug|Rosuvastatin|Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry) or matching placebo.
75322570|NCT01798979|Drug|GLPG0634|Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
75322571|NCT01798979|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
75322572|NCT00738361|Drug|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
75627612|NCT05832190|Other|Standard of care|Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
75627613|NCT05832190|Dietary Supplement|Biotin supplement|1 capsule per day of Biotin 450µg during 3 months before the surgery.
75627614|NCT05832190|Dietary Supplement|Fiber supplement|3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
75322573|NCT02337062|Drug|APD421|
75322574|NCT02337062|Drug|Placebo|
75322575|NCT01279213|Drug|paliperidone clozapine|dose 3 to 12 mg paliperidone ER daily during 12 weeks
75627615|NCT05831995|Drug|ABM-168|Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
75627616|NCT05818553|Drug|Part A: 0.5mg/kg/day PRAX-562 for 16 Weeks|Once daily oral or G-tube treatment.
75627617|NCT05818553|Drug|Part A: 0.5mg/kg/day PRAX-562 for 12 Weeks and Matching Placebo for 4 Weeks|Once daily oral or G-tube treatment with PRAX-562 for 12 weeks and matching placebo for 4 weeks.
75627618|NCT05818553|Drug|Part B: 0.5mg/kg/day PRAX-562|Once daily oral or G-tube treatment.
75627619|NCT05816317|Behavioral|Single-Session Mechanism-Focused Intervention (SSMFI)|A brief intervention for patients hospitalized for suicide risk that directly targets hopelessness and perceptions of social relatedness.
75627620|NCT05816317|Behavioral|Distress Tolerance Skills Review|Treatment as usual at the inpatient setting for this study.
75915345|NCT03181867|Drug|18F-FDG|Cohort 2 may receive a one-time 18F-FDG PET/CT after a positive 18F-DCPyL PET/CT. 18F FDG PET/CT imaging may be performed per clinical standard of care. FDG is administered at a dose of 10mCi intravenously. A whole-body PET/CT will be performed beginning post 18F FDG injection.
75915346|NCT03181867|Drug|PSMA-11|For up to 10 eligible patients from either cohort 1 or 2, an optional salivary gland blocking study may be performed in which a salivary gland is cannulated and injected with unlabeled DCFPyL or PSMA-11.
75915347|NCT03157934|Other|not applicable (observational study)|Observational study without study related intervention
75915348|NCT03150173|Behavioral|Onsite treatment|Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.
75322576|NCT00681473|Radiation|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
75915349|NCT03150173|Behavioral|Enhanced referral|Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment
75322577|NCT03301922|Behavioral|Metacognitive therapy and work-focused interventions|Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
75322578|NCT03301922|Other|Waiting list|Waiting list
75467246|NCT01918254|Drug|Paclitaxel|Paclitaxel IV infusion will be administered as per schedule described in individual arm.
75627621|NCT05807178|Device|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
75627622|NCT05807178|Device|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
75627623|NCT05804032|Drug|Isatuximab|IV isatuximab will be administered weekly in the first cycle (Cycle 1) on days 1, 8, 15, 22, 29, and biweekly on the 2 subsequent cycles at days 1, 15 and 29, at the dose of 10 mg/kg.
75627624|NCT05804032|Drug|Isatuximab|SC isatuximab will be administered on days 1, 8, 15, 22, 29 of cycle 1, and on days 1, 15 and 29 of cycles 2-3, at the dose of 1400 mg
75322579|NCT00634283|Drug|venlafaxine|venlafaxine IR 150mg
75322580|NCT01279291|Biological|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
75322581|NCT01279291|Drug|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
75322582|NCT01279291|Drug|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
75322583|NCT01279291|Drug|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
75467247|NCT01918254|Drug|Pertuzumab|Pertuzumab IV infusion will be administered as per schedule described in individual arm.
75467248|NCT01918254|Drug|Lumretuzumab|Lumretuzumab will be administered as per schedule described in individual arm.
75627625|NCT05804032|Drug|Lenalidomide|Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3
75915350|NCT03150173|Drug|Buprenorphine|all participants will receive buprenorphine
75915351|NCT03134196|Drug|Masked Placebo|Oral Placebo
75915352|NCT03134196|Drug|Masked Oral Valacyclovir|Oral Valacyclovir 1000 mg/day
75915353|NCT03104153|Procedure|Early-drain removal|Drain removal at hospital discharge
75915354|NCT03053973|Device|nocturnal noninvasive ventilation|Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.
75322584|NCT05628818|Device|Transcranial Direct Current Stimulation (tDCS)|Real anodal tDCS over the left dorsolateral prefrontal cortex in acute stroke patients to improve dysexecutive syndrome. Intensity: 2 mA. Stimulation period: 20 minutes.
75322585|NCT05628818|Device|Sham Transcranial Direct current Stimulation|Sham anodal tDCS over the left dorsolateral prefrontal cortex: anodal tDCS. Intensity: 2 mA. Stimulation period: 1 minute. Afterwards, the device will automatically shut down but the sham stimulation period will last a total of 20 minutes.
75322586|NCT02986425|Other|STRIP intervention|"The STRIP intervention consists of 9 steps:~structured history taking of medication~recording medication and diagnoses in STRIPA~structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~shared decision-making with the patient with possible adaptation of the recommendation~optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~generation of general practioner (GP) report~delivery of the report to the patient and to the GP (optional additional direct communication)~follow-up"
75467249|NCT01918280|Procedure|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
75467250|NCT01918293|Device|SMART ARM|The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
75467251|NCT01918319|Behavioral|Lifestyle intervention|Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
75467252|NCT01918358|Drug|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
75627626|NCT05804032|Drug|Bortezomib|Both arms: 1.3 mg/m^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
75627627|NCT05804032|Drug|Dexamethasone|20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3.
75627628|NCT05802940|Behavioral|Electronic health record best practice alert|The electronic health record will identify patients at high-risk for preeclampsia and candidate for low dose aspirin (LDA) prophylaxis. For those in the intervention group, a best practice alert will notify the healthcare provider within the patient's chart during a prenatal visit that LDA should be recommended.
75627629|NCT05800873|Drug|EVER001|A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
75651671|NCT05832528|Other|Low-FODMAP diet|6-week Low-FODMAP diet in patients with functional dyspepsia
75779556|NCT03990857|Other|Comprehensive care protocol in new diagnosis of Type 2 Diabetes Mellitus and associated comorbidities in Primary Care|This comprehensive intervention is developed in a structured way in the Primary care nurse office. 5 individual intensive visits will be carried out with a weekly or bi-weekly frequency (according to the learning process) to work for an integral care and to transmit the knowledge and skills required. The maximum time expected to receive this 5 visits is 3 months. At least one of the visits, preferably the one that deals with dietary aspects, the patient is asked to be visited with the partner, child or cohabiting person. The research team elaborated the support material with the minimum contents that every patient that begins with T2DM and other chronic pathologies should know. It allows incorporating cultural and emotional aspects. It was agreed with hospital diabetes educators and family doctors. A graphic designer gave an enticing design. A group of patients verified their utility and intelligibility. It is delivered to the person and discussed during the intensification.
75779557|NCT01052597|Drug|curcumin|Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
75467253|NCT01918358|Drug|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
75467254|NCT01918358|Drug|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
75651672|NCT05832515|Drug|Fludarabine Phosphate for Injection|Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.
75651673|NCT05832489|Drug|Placebo|"Patients will have 2 imaging sessions (MRI and EEG) after either:~methylphenidate immediate release 25 mg~placebo~in a cross-over design. The two imaging sessions will be separated by 1 to 7 weeks."
75915355|NCT03053973|Other|Standard Care|Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)
75915356|NCT03052036|Procedure|Coronary Angiography|Coronary angiography to determine location of blocked or narrowed arteries.
75915357|NCT03052036|Procedure|Coronary revascularisation|PCI or CABG will be performed following coronary angiography at the discretion of the treating cardiologist.
75915358|NCT03052036|Other|Optimal Medical Therapy|Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.
76025641|NCT05301647|Diagnostic Test|Nasal cytology|The cytological technique involves the following moments: sampling, processing, which includes fixation, staining and microscopic observation. Cytological sampling consists in the collection of superficial cells of the nasal mucosa with the help of a sterile swab or a small curette (scraping) in disposable plastic material (Rhino-probe).
75467255|NCT01918358|Drug|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
75322587|NCT02986425|Other|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
75322588|NCT04400942|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasonographic scan aims to evaluate number, size (diameter and volume), location and appearance of submucous uterine myomas, concomitant presence of adenomyosis
75322589|NCT04400942|Behavioral|Anamnesis|Anamnesis aims to collect data about age, BMI, previous hormonal therapies (such as ulipristal acetate or gonadotropin-releasing hormone agonists) with submucous uterine myomas
75627630|NCT05792436|Device|1-min interval oscillometric method|"Before induction of anesthesia, 20-gauge catheter is inserted to radial artery after local anesthesia with lidocaine, and continuous blood pressure monitoring is started. Anesthesia is induced using propofol, opioids (fentanyl or remifentanil), and neuromuscular relaxants (rocuronium, cisatracurium, or vecuronium). For maintenance of anesthesia, propofol infusion or inhalation anesthetics (sevoflurane or desflurane) are used.~From the start of anesthesia induction to 15 minutes after, arterial blood pressure is monitored at 1-min interval using oscillometric method. The display of continuous arterial pressure on the anesthesia monitor is turned off during the 15-min study period."
75322590|NCT04400942|Procedure|Operative hysteroscopy|Operative hysteroscopy allows a direct evaluation of number, size (diameter and volume), location and appearance of submucous uterine myomas. This exam allows the resection of the myomas.
75627631|NCT05792436|Device|arterial catheterization method|During the same time window for 1-min interval oscillometric method, arterial blood pressure is monitored using continuous blood pressure monitoring.
75627632|NCT05787860|Drug|Ruxolitinib 1.5% Cream|topical ruxolitinib 1.5% cream twice daily for 4 weeks
75322591|NCT00682565|Drug|CK-1827452 24mg and 6 mg iv infusion|I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
75322592|NCT00682565|Drug|CK-1827452 12.5mg capsule|12.5mg oral immediate release capsule
75779558|NCT01051115|Drug|Dasatinib|Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
75779559|NCT00076752|Drug|fludarabine phosphate|Conditioning and transplant regimen: 30 mg/m^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)
75779560|NCT00076752|Drug|cyclophosphamide|Priming regimen: 2000 mg/m^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
75779561|NCT00076752|Biological|Rituxan (rituximab)|Priming regimen: 375 mg/m^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m^2 intravenous infusion, day -7.
75915359|NCT03051984|Device|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
75915360|NCT03049007|Diagnostic Test|Survey|Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).
75322593|NCT00682565|Drug|CK-1827452 48 mg and 11 mg iv infusion|I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
75322594|NCT00682565|Drug|CK-1827452 25mg capsule|25mg oral immediate release capsule
75322595|NCT00682565|Drug|Placebo iv infusion|Matching placebo iv infusion
75322596|NCT00682565|Drug|Placebo capsule|Matching placebo oral immediate release capsule
75322597|NCT04788537|Behavioral|Training to Understand and Navigate Emotions and Interactions (TUNE In)|A three-part cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.
75467256|NCT01918358|Drug|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
75467257|NCT01918358|Drug|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
75627633|NCT05787561|Drug|Avutometinib (VS-6766)|3.2 mg PO, twice weekly
75627634|NCT05787561|Drug|Defactinib|200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
75627635|NCT05783622|Drug|JANX008|JANX008 is dosed via IV weekly in a 21-day cycle
75627636|NCT05775523|Drug|No intervention|No intervention
75627637|NCT05774951|Drug|Camizestrant|Camizestrant. Experimental. Administered orally
75627638|NCT05774951|Drug|Tamoxifen|Tamoxifen. Comparator. Administered per local approved label
75627639|NCT05774951|Drug|Anastrozole|Anastrozole. Comparator. Administered per local approved label
75627640|NCT05774951|Drug|Letrozole|Letrozole. Comparator. Administered per local approved label
75627641|NCT05774951|Drug|Exemestane|Exemestane. Comparator. Administered per local approved label
75627642|NCT05766579|Device|Elastic-compressive stockings|Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.
75779562|NCT00076752|Biological|filgrastim|Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC >500 microliters.
75779563|NCT00076752|Drug|methylprednisolone|Priming regimen:1000 mg intravenous over 30 minutes, day 1.
75779564|NCT00076752|Other|immunologic technique|Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.
75779565|NCT00076752|Other|laboratory biomarker analysis|Standard human immunology research laboratory ex vivo studies.
75779566|NCT00076752|Procedure|autologous hematopoietic stem cell transplantation|Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.
75467258|NCT01918384|Drug|NPC-14|"NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14"
76074341|NCT04345432|Drug|Gabapentin|"Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study."
76074342|NCT03803410|Procedure|blood test, noninvasive test for liver fibrosis|blood test of HCV serology and virology.noninvasive test including M2BPGi and fibroscan for liver fibrosis
76074343|NCT05744128|Biological|Zirconium 89Zr crefmirlimab berdoxam|Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.
76074344|NCT05744050|Behavioral|Low energy density lunch|Particpants will be provided with a lunch low in energy density (~1.1kcal/g)
76074345|NCT05744050|Behavioral|Medium energy density lunch|Participants will be provided with a lunch medium in energy density(~1.7kcal/g)
76074346|NCT05744050|Behavioral|High energy density lunch|Participants will be provided with a lunch high in energy density (~3kcal/g)
76074347|NCT03804190|Other|questionaire|dutch musculoskeletal questionaire
75322598|NCT05685680|Procedure|total mesorectal excision in rectal carcinoma|total mesorectal excision laparoscopic versus open technique in management of rectal carcinoma
75322599|NCT04367883|Drug|Antihistamine|No intervention is performed. We propose an observational study.
75322600|NCT04367883|Drug|Amantadine|No intervention is performed. We propose an observational study
75627643|NCT05764590|Drug|AP-306|A blood phosphorus lowering drug with a novel mechanism
75627644|NCT05764590|Drug|Sevelamer Carbonate|A phosphate binder
75627645|NCT05764330|Procedure|Biospecimen Collection|Undergo collection of blood samples
75627646|NCT05764330|Other|Dietary Intervention|Undergo CER intervention
75627647|NCT05764330|Other|Dietary Intervention|Undergo IF intervention
75627648|NCT05764330|Behavioral|Fasting|Undergo fasting
76074348|NCT00757666|Device|Rate adaptive pacemaker|Accelerometer sensor
75322601|NCT04367883|Drug|ACEI|No intervention is performed. We propose an observational study.
75322602|NCT04367883|Drug|ARB|No intervention is performed. We propose an observational study.
75322603|NCT04367883|Other|Influenza vaccine and COVID|No intervention is performed. We propose an observational study.
75322604|NCT00635453|Behavioral|Dietary Advice|The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
75467259|NCT01918384|Drug|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
75467260|NCT01918410|Device|Contact Lens with alginic acid|Worn for 7 days, at least 8 hours a day
75467261|NCT01918410|Device|Contact Lens without alginic acid|Worn for 7 days, at least 8 hours a day
75627649|NCT05754944|Diagnostic Test|ABI/TBI|ABI/TBI to be performed after surgery while patient is still admitted at the hospital.
75627650|NCT05754944|Other|Questionnaires|PAD symptoms questionnaire to be administered at baseline before surgery. mLEFS (included in PAD symptoms questionnaire) and WIQ to be administered at baseline before surgery. mLEFS and WIQ will be administered 1 month, 3 months, 6 months after surgery and every 6 months after that for a goal of at least 1 year.
75627651|NCT05751434|Behavioral|Exercise Therapy|The intervention will consist of exercise therapy, individualized, walking delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule, up to 5 individual treatment sessions/week to achieve a cumulative total duration of 225 to 300 mins/wk until the participant's next standard of care prostate biopsy (about 6-12 months).
75627652|NCT05741450|Device|Lens 1 (monthly replacement)|Monthly replacement spherical silicone hydrogel contact lens for 15 minutes
75627653|NCT05741450|Device|Lens 2 (daily disposable)|Daily disposable spherical silicone hydrogel contact lens for 15 minutes
75627654|NCT05741294|Drug|Tirbanibulin 2.5 mg ointment|Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm^2) of the face or scalp.
76074349|NCT00757666|Device|Rate adaptive pacemaker|Minute ventilation sensor
75779567|NCT00076752|Drug|Diphenhydramine|Conditioning and transplant regimen 25-50 mg orally or intravenously.
76074350|NCT03803956|Device|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
76074351|NCT03803956|Device|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
76074352|NCT01736683|Drug|Sotatercept|Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
76074353|NCT05743972|Diagnostic Test|Contrast-enhanced ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.
75322605|NCT03148743|Biological|Fecal microbiota|fecal microbiota transplantation
76074354|NCT05743972|Diagnostic Test|Conventional ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
76074355|NCT00757822|Drug|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
76074356|NCT00757822|Drug|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
75467262|NCT01918423|Behavioral|Lifestyle intervention during pregnancy|Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
76074357|NCT04561765|Device|iCanCope|The iCanCope mobile and web-based self-management program has been empirically evaluated for multiple painful diseases
76074358|NCT04561765|Device|iCanCope+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
76074359|NCT01788163|Genetic|EGFR mutation test|EGFR mutation being tested in tissue and blood
75467263|NCT01918436|Behavioral|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
75322606|NCT04329039|Drug|Somatostatin analog|Somatostatin analog plus perioperative antibiotics Placebo plus perioperative antibiotics
76074360|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
75467264|NCT01918436|Other|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
75467265|NCT01918449|Other|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
75467266|NCT01918475|Drug|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
76074361|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
75627657|NCT05737784|Drug|PRAX-222 - Initial Dose|PRAX-222
75627658|NCT05737784|Drug|PRAX-222 - Initial Ascending Doses|Ascending doses of PRAX-222
76074362|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
75627659|NCT05737784|Drug|PRAX-222 - Optional Ascending Doses|Escalation of PRAX-222 dose(s)
75627660|NCT05737784|Drug|PRAX-222 - Fixed Doses|Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
75779568|NCT00076752|Drug|Mesna|Priming regimen: 600 mg/m^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
75779569|NCT03960918|Behavioral|aerobic exercise therapy|aerobic exercise therapy: All enrolled subjects will perform a CPET before the training initiation. After CPET, the patients in the experimental group need to perform an additional bicycle training program with the intensity of 60 % maximal workload in the previous CPET (five days per week, for four weeks with a total of 20 times).
76074363|NCT00783952|Device|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
76074364|NCT00783952|Device|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
76074365|NCT00784030|Other|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
75322607|NCT02135861|Procedure|DCE-MRI scans|Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
75322608|NCT02135861|Other|Gadobutrol|Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
75467267|NCT01918475|Drug|Placebo|1ml of NaCl 0.9% is administered intravenously
75467268|NCT01918488|Dietary Supplement|Standardized salt diet|200 mmol NaCl per day given as three meals daily for 4 consecutive days.
75467269|NCT01918488|Drug|Amiloride|Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
75627661|NCT05737784|Procedure|Placebo|Placebo procedure
75627662|NCT05736367|Drug|U-13C-glucose|Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue
76074366|NCT03803644|Drug|CC-92480|Part 1 dose escalation
75627663|NCT05735652|Device|SpaceOAR Hydrogel|The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum
75627664|NCT05734846|Device|Control Lenses (control fitting approach)|Daily wear multifocal lenses for 1 week
75627665|NCT05734846|Device|Test Lenses (test fitting approach)|Daily wear multifocal lenses for 1 week
75651674|NCT05832489|Drug|Methylphenidate immediate release 25mg|"Patients will have 2 imaging sessions (MRI and EEG) after either:~methylphenidate immediate release 25 mg~placebo~in a cross-over design. The two imaging sessions will be separated by 1 to 7 weeks."
75651675|NCT05832476|Other|No intervention|No intervention
75627666|NCT05718505|Device|Atmo Motility Gas Capsule System|"The Atmo System measures whole gut and regional gut transit times. Measurements of GI tract transit times are used for evaluating motility disorders.~Gastric emptying time (GET) is indicated for the evaluation of patients with suspected gastroparesis. Delayed GET is implicated in such disorders as idiopathic and diabetic gastroparesis and functional non-ulcer dyspepsia.~Colonic transit time (CTT) is indicated for the evaluation of colonic transit in patients with chronic constipation, to aid in differentiating slow and normal transit constipation. In the case where ileocecal junction transit cannot be determined the system will report combined Small and Large Bowel Transit Time (SLBTT).~Transit times are derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of fermentation activity, capsule tumble, and antenna reflectance. Not for use in pediatric patients."
75627667|NCT05718505|Device|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
75627668|NCT05715528|Drug|Obeldesivir|Tablet administered orally without regard to food.
76074367|NCT03803644|Drug|CC-92480|CC-92480
75915361|NCT03011710|Device|ProVari v2.5 (E-cigarette)|An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
75322609|NCT05627024|Drug|30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
75627669|NCT05715528|Drug|Obeldesivir Placebo|Tablet administered orally without regard to food.
75627670|NCT05714488|Device|blue halo coil catheter|device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
75779570|NCT03384940|Drug|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
75779571|NCT00075582|Procedure|conventional surgery|Some patients may undergo second-look surgery
75915362|NCT03011710|Device|Marlboro Gold (Conventional cigarette)|Conventional cigarette
76074368|NCT01787461|Dietary Supplement|Imedeen|Two tablets per day for 6 months
76074369|NCT01787461|Dietary Supplement|Placebo|Two tablets per day for 6 months
75467270|NCT01918501|Procedure|Blood testing|Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
75467271|NCT01918514|Drug|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
75467272|NCT01918540|Procedure|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
75627671|NCT05712876|Drug|CK-0045|Interleukin-22 agonist
75627672|NCT05712876|Drug|Placebo|Matching placebo
75627673|NCT05712564|Other|Questionnaire|Questionnaire for fatigue assessment
75627674|NCT05709821|Drug|IMM60|IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
75627675|NCT05709821|Drug|Pembrolizumab|Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
75627676|NCT05706805|Device|Naviscore|Patients in whom treatment with (Naviscore) has been attempted
75779572|NCT00075582|Drug|dactinomycin|Given IV
75779573|NCT00075582|Drug|cyclophosphamide|Given IV
75779574|NCT00075582|Drug|vincristine sulfate|Given IV
75779575|NCT00075582|Radiation|radiation therapy|Undergo radiotherapy
75915363|NCT03011710|Device|Cigarette tip|Placebo device
75915364|NCT03000569|Drug|SAGE-217|
75915365|NCT03000569|Drug|Levodopa|Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
75915366|NCT03000569|Drug|Antiparkinsonian Agent(s)|Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.
75915367|NCT02997761|Biological|Blinatumomab|Given IV
75915368|NCT02997761|Drug|Ibrutinib|Given PO
75915369|NCT02961348|Other|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
75915370|NCT02961348|Other|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
76074370|NCT03803488|Device|DropSafe safety pen needle|
76074371|NCT03803722|Device|Eyestil Protection® unidose|to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
76074372|NCT00758836|Drug|placebo|
76074373|NCT00758836|Drug|ibuprofen|
76074374|NCT00758836|Drug|acetominophen|
76074375|NCT00758836|Drug|telcagepant|
76074376|NCT03809806|Procedure|4-arm polypropylene mesh surgery|Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
75322610|NCT05627024|Drug|60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
75915371|NCT02949921|Device|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
75915372|NCT02935205|Drug|Enzalutamide|Given PO
75915373|NCT02935205|Drug|Indomethacin|Given PO
75915374|NCT02872532|Procedure|Testicular tissue cryopreservation|Testicular tissue will be removed
76074377|NCT03809806|Diagnostic Test|The Female Sexual Function Index (FSFI) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
75322611|NCT00635609|Drug|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
75322612|NCT00635609|Drug|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
75322613|NCT04347902|Drug|Intravenous Lipid Emulsion|Various types of intravenous lipids
75322614|NCT02137499|Device|geko device|Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
75627677|NCT05704595|Other|Initial outpatient management strategy, including outpatient IV diuretics in clinic|Management strategy including IV diuretic in the outpatient clinic
75627678|NCT05704595|Other|Initial hospitalization-based management strategy|Direct admission to the hospital
75627679|NCT05701189|Drug|Efgartigimod Alfa-Fcab|Efgartigimod is an anti-neonatal Fc receptor (FcRn) immunoglobulin G1 Fc fragment. The FcRn plans a critical role in extending the half-life of IgGs by rescuing them from lysosomal degradation. Antibodies that bind and subsequently block the FcRn with high affinity result in IgGs being degraded more rapidly instead of salvaged. This approach has been shown to be beneficial in the antibody-mediated disorder myasthenia gravis.
75627680|NCT05701189|Drug|Intravenous Immunoglobulin (IVIg)|IVIg is the standard-of-care treatment for GBS.
75627681|NCT05700474|Behavioral|Comprehensive outpatient behavioral health care|Participation will include clinical assessment and outpatient behavioral health services, case management, individual and group counseling, peer support, case management, and education regarding behavioral health and medical care
75627682|NCT05691478|Procedure|Bone Scan|Undergo bone scintography
75779576|NCT01092312|Procedure|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
75779577|NCT01092312|Procedure|Vanguard Knee System with conventional Instruments|Vanguard Knee System with conventional Instruments
75779578|NCT00063258|Drug|Tarceva (OSI-774)|150 mg/day, starting day 1 and stopping night prior to surgery.
75915375|NCT02860091|Drug|Ropivacaine infusion|Delivered via paravertebral nerve block catheter.
75915376|NCT02844049|Device|Deep Brain Stimulation|surgical procedure
76074378|NCT03809806|Diagnostic Test|King Health Questionnaire (KHQ)|patients fulfilled questionnaire before and 1 year after procedure
76074379|NCT03809806|Diagnostic Test|Pelvic Organ Prolapse Quantification (POPQ) staging|Pelvic Organ Prolapse staging before and 1 year after the procedure
75322615|NCT01799369|Behavioral|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
75627683|NCT05691478|Drug|Cabozantinib S-malate|Given PO
75627684|NCT05691478|Drug|Cisplatin|Given IV
75627685|NCT05691478|Procedure|Computed Tomography|Undergo CT
75627686|NCT05691478|Drug|Doxorubicin Hydrochloride|Given IV
75779579|NCT00063258|Drug|Paclitaxel|Planned dose of 200 mg/m^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
75627687|NCT05691478|Procedure|Magnetic Resonance Imaging|Undergo MRI
75779580|NCT00063258|Drug|Carboplatin|Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
75779581|NCT03962088|Diagnostic Test|miRNA|"15 ml of whole blood samples are collected in Vacutainer tubes with spray-coated K2EDTA and stored at room temperature. To minimize the hemolysis and nucleic acids degradation, plasma separation undergoes within 2 h.~Within 1 h, tubes are subjected to a first centrifugation step at 2200 x g and room temperature for 15 min. Plasma supernatants are transferred to 15 mL tubes, carefully avoiding contact with the lymphocytic ring, and tubes are centrifuged a second time at 3000 x g and RT for 10 min to remove cellular debris.~Plasma samples are then collected into 1.5 mL cryovials and all the aliquots are stored at -80 °C."
75779582|NCT01086462|Drug|GSK2239633|100 ug GSK2239633 containing approximately 10kBq [14C]-GSK2239633
75915377|NCT02835222|Drug|Cytarabine|Given IV
75915378|NCT02835222|Drug|Daunorubicin Hydrochloride|Given IV
75915379|NCT02835222|Drug|Selinexor|Given PO
75915380|NCT02817230|Drug|Statin|
75915381|NCT02807805|Drug|Abiraterone Acetate|Given PO
75915382|NCT02807805|Drug|Niclosamide|Given PO
75915383|NCT02807805|Drug|Prednisone|Given PO
75915384|NCT02783092|Drug|Cannabidiol|Oral solution of cannabidiol 200 mg / mL dissolved in corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
75915385|NCT02783092|Drug|Placebo|The placebo will be an oral solution of corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
75915386|NCT02780128|Procedure|Biopsy|Needle or incisional tumor biopsy
75915387|NCT02780128|Genetic|Next Generation Sequencing|Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
76074380|NCT03809806|Diagnostic Test|Postoperative questionnaire|Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
76074381|NCT03809806|Diagnostic Test|The Short Form Health Survey (SF 36) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
75322616|NCT05618756|Dietary Supplement|Acute oral CBD supplementation|1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
75322617|NCT05618756|Dietary Supplement|Acute oral placebo supplementation|1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.
75467273|NCT01918540|Procedure|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
75467274|NCT01918540|Device|MS-30 femoral stem|This is the stem used in the study.
75627688|NCT05691478|Drug|Methotrexate|Given IV
75322618|NCT03294668|Behavioral|KONTAKT Australia|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
75322619|NCT03294668|Other|Super Chef|The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
75322620|NCT05339984|Procedure|Partial hepatectomy (open approach)|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
75627689|NCT05691478|Procedure|Surgical Procedure|Undergo surgery
75627690|NCT05691478|Procedure|X-Ray Imaging|Undergo X-ray
75322621|NCT05339984|Procedure|liver transplantation|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
75322622|NCT05339984|Procedure|Portal vein embolization|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
75322623|NCT05606978|Behavioral|FASTb|FAST blended
75627691|NCT05684068|Procedure|Gum Graft Placed on Denuded Bone|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will remove all of the subject's tissue, so that the bone is fully exposed before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
75627692|NCT05684068|Procedure|Gum Graft Placed on Split Thickness Periosteal Bed Preparation|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will dissect some of the tissue at the subject's recipient site but still keep a small layer of tissue at the subject's recipient site before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
75627693|NCT05678348|Drug|Pyrimethamine|Patients will be instructed to take their dose at approximately the same time each day.
75322624|NCT05606978|Behavioral|FASTr|FAST regular
75322625|NCT03066843|Drug|ALA (5-aminolevulinic acid)|ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
75322626|NCT03066843|Device|Blue light therapy|Subjects will be exposed to blue light
75627694|NCT05678322|Drug|18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent|Under development for the diagnosis of prostate cancer by Blue Earth Diagnostics. rhPSMA-7.3 (18F) will be administered intravenously as a single-dose injection. The molecular structure of the drug substance comprises a prostate-specific membrane antigen (PSMA) binding motif, a peptide spacer, an 18F-radiolabeled silicon fluoride acceptor moiety and a gallium chelator complex.
75915388|NCT02780128|Procedure|Tumor Scans|Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
75322627|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
75322628|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
75915389|NCT02780128|Procedure|Bone marrow Tests|Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
75322629|NCT00684047|Procedure|Manual Compression|Manual Compression. Primary Part (II)
75322630|NCT05062928|Other|Virtual coach|This group will be trained and assessed by the virtual coach.
75467275|NCT01918553|Other|clinical parameters|
75467276|NCT01918553|Other|visual acuity exams|
75322631|NCT04301505|Other|Intervention 1|Checklist will be delivered at the beginning of the study. The educational intervention program will consist of a checklist that provides family physicians with COPD management for the elderly.
75322632|NCT04301505|Other|Intervention 2|The same checklist will be delivered at the beginning of the study and repeated after 6 months.
75322633|NCT00636077|Device|Polyflux HD-C4 Big|Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
75322634|NCT00636077|Device|HD-C4 Small|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
75467277|NCT01918553|Other|retinophotography|
75467278|NCT01918553|Other|SD-OCT|
75467279|NCT01918553|Other|Intra ocular Pressure (IOP)|
75467280|NCT01918553|Other|retinal imaging (OPTOMAP)|
75467281|NCT01918553|Other|axial length (IOL master)|
75467282|NCT01918566|Dietary Supplement|tap water|
75467283|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
75322635|NCT00636077|Device|Optiflux 160NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
76074382|NCT03803800|Other|Classic, progressive endurance training|Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
75322636|NCT00636077|Device|Optiflux 200NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
76074383|NCT03803800|Other|Periodized exercise training|Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
75627695|NCT05678322|Device|PET MRI Imaging|rhPSMA-7.3 (18F) PET MRI imaging will be conducted once at baseline and a second time within one year of the initial scan.
75779583|NCT00088530|Drug|pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
75915390|NCT02780128|Other|Physical Exam|The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
75915391|NCT02780128|Other|Eye Exam|Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
75915392|NCT02780128|Other|Labs|Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
75322637|NCT05315336|Drug|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
75915393|NCT02780128|Other|Pregnancy Test|If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
76074384|NCT03803800|Dietary Supplement|beta-alanine|Some subjects will receive the ergogenic supplement beta-alanine.
76074385|NCT04384432|Other|Routine Physical Therapy with Thoracic mobility exercise|Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise
75322638|NCT00636389|Device|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
75322639|NCT00636389|Device|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
75322640|NCT04747977|Drug|OTX-DED|0.2mg dexamethasone ophthalmic insert
75322641|NCT04747977|Drug|OTX-DED|0.3mg dexamethasone ophthalmic insert
75322642|NCT04747977|Drug|OTX-DED|Hydrogel vehicle ophthalmic insert
75322643|NCT04746716|Other|Phone call|Phone call to the patient to complete quality of life scales
75322644|NCT04387409|Biological|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
76074386|NCT04384432|Other|Routıne Physıcal therapy|Exercise for Chronic Neck Pain
76074387|NCT01786993|Device|MultiPoint Pacing|Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
75322645|NCT04387409|Biological|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
75322646|NCT04746495|Drug|Placebo|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
75467284|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
75467285|NCT01918566|Dietary Supplement|25g Fructose in 300ml tap water|
75627696|NCT05677139|Other|None (Observational Study)|Not applicable since it's an observational study.
75627697|NCT05670301|Diagnostic Test|cytokine and lipidomic profiling|"FEBRIS Cytokine Profile Assay (quantification of inflammatory cytokines)~Serum amyloid A~Biobanking of leftover sample for future analyses and specific immunofunctional assay in selected cases~Lipidomics"
75627698|NCT05667662|Drug|Itraconazole Powder|Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)
75779584|NCT00088530|Drug|Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab|Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
76074388|NCT01786993|Device|Traditional Biventricular Pacing|Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
76074389|NCT00769600|Drug|Itraconazole|Itraconazole 200 mg once daily
76074390|NCT00769600|Drug|Pemetrexed|Pemetrexed every 21 days.
76074391|NCT05743894|Device|Symplicity Spyral RENAL DENERVATION (RDN) SYSTEMTM Livewire™ Reflexion™ Catheter|Renal sympathetic denervation (RDN) was considered an effective alternative for patients whose blood pressure (BP) is not optimally controlled. The RDN works mainly by selectively ablating the sympathetic fibres around the renal arteries and damping the sympathetic overdrive. Blood pressure response by renal nerve stimulation (RNS) during the RDN procedure using the previous generation of the Symplicity Flex catheter have been reported to be potential parameter to assess the intra-procedure efficacy and predict the BP response 6 months after RDN
76074392|NCT03809650|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
76074393|NCT01966445|Biological|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
75627699|NCT05667662|Drug|Placebo|Capsules with 11.8 mg total powder (excipients only)
75627700|NCT05664386|Drug|propofol|propofol 2～2.5mg/kg was used for anesthesia induction. propofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthesia of induction and maintenance.
75627701|NCT05664386|Drug|ciprofol|Ciprofol 0.4～0.5mg/kg was used for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid recovery of consciousness, minimal residual effects on the central nervous system and less injection pain.
76074394|NCT03809494|Device|HemaTrate™ Blood Filtration system|Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.
76074395|NCT03809494|Other|Saline|Normal (0.9%) saline
76074396|NCT04384042|Other|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
76074397|NCT03809260|Drug|Metformin (part 1)|1~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
76074398|NCT03809260|Drug|Vancomycin|11d: Vancomycin 250 mg bid, 12~17d: Vancomycin 500 mg bid
75627702|NCT05662397|Drug|HST-1011|Increasing doses of HST-1011 given orally as monotherapy.
75627703|NCT05662397|Biological|Cemiplimab|Cemiplimab administered via intravenous infusion in combination with increasing doses of HST-1011 given orally as monotherapy.
75627704|NCT05662319|Drug|Fitusiran|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
75627705|NCT05662319|Drug|Clotting factor concentrates (CFC) or bypassing agents (BPA)|"Coagulation factor VIII (ATC code: B02BD02)~Coagulation factor IX (ATC code: B02BD04)~Coagulation factor VIIa (ATC code: B02BD08)~Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)"
75627706|NCT05662319|Drug|Antithrombin concentrate (ATIIIC)|Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
75779585|NCT00359801|Drug|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
75779586|NCT00359801|Drug|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
75467286|NCT01918566|Dietary Supplement|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
75915394|NCT02780128|Behavioral|Interviews|A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
75915395|NCT02780128|Other|ECG|This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
75915396|NCT02780128|Other|Echocardiogram|The participant will have an ultrasound of the heart taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
75915397|NCT02780128|Drug|Ribociclib|Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
76074399|NCT03809260|Drug|Metformin (part 2)|1~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
76074400|NCT01763905|Biological|Evolocumab|Subcutaneous injection
75915398|NCT02780128|Drug|Ceritinib|Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
75915399|NCT02776735|Drug|Sarilumab|Pharmaceutical form:Solution Route of administration: Subcutaneous
76074401|NCT01763905|Drug|Placebo to Evolocumab|Subcutaneous injection
76074402|NCT01763905|Drug|Ezetimibe|Tablet for oral administration
75467287|NCT01918566|Dietary Supplement|300ml tap water with 450ppm lactisole|
75467288|NCT01918579|Procedure|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
75915400|NCT02775851|Procedure|Biopsy|Undergo tumor biopsy
76074403|NCT01763905|Drug|Placebo to Ezetimibe|Tablet for oral administration
75467289|NCT01918592|Device|MRI/acetate-PET imaging|
75627707|NCT05662098|Drug|Hydroxyurea|All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
75627708|NCT05639465|Behavioral|JoH-C19|Journey of Hope- COVID 19 (JoH-C19) includes eight, 1-hour consecutive sessions delivered in groups of 8 children during the school day and in after school settings. The 1.5 hour JoH-C19 caregiver workshop is delivered with groups of 8 parents prior to the child JoH-C19 curriculum
75627709|NCT05639465|Behavioral|Switch off Get Active|Switch off Get Active covers 4 topics, and its eight, 1- hour sessions are delivered in groups of 8 children. The 1.5 hour Switch Off Get Active caregiver workshop is delivered with groups of 8 parents prior to the Switch off Get Active child curriculum
76074404|NCT05743504|Drug|Tiragolumab|Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery
75779587|NCT02533817|Dietary Supplement|Dietary sugar|This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.
76074405|NCT02091167|Device|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
76074406|NCT03803254|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
75779588|NCT03990701|Combination Product|11C-Metomidate PET/CT Scan|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
75915401|NCT02775851|Procedure|Biospecimen Collection|Undergo blood sample collection
76074407|NCT03803254|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
76074408|NCT03803254|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
76074409|NCT03803254|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
76074410|NCT02091089|Device|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
76074411|NCT03803176|Procedure|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
76074412|NCT04730999|Drug|Etoposide|Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
76074413|NCT04730999|Drug|Carboplatin|Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
75322647|NCT04746495|Drug|Eplerenone 50mg|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
75322648|NCT04387487|Behavioral|Multimedia video information|"During pre anesthesia visit after regular pre anesthesia check up patient will be asked to fill the Hamilton scoring questionnaire about anxiety.~After this a multimedia video information about spinal anesthesia of around 6 minutes will be shown to the intervention group during pre anesthesia visit. This video will contain explanation about how spinal anesthesia procedure is conducted. Patient will be allowed to ask questions.~On the day of surgery in the pre surgical area again Hamilton scoring questionnaire will be asked with the patients to check the level of anxiety."
75467290|NCT01918605|Device|Diluted spacer|
75467291|NCT01918605|Device|Non-diluted spacer|
75467292|NCT01918631|Drug|tenofovir disoproxil fumarate|
75467293|NCT01918631|Drug|Entecavir|
75779589|NCT01051193|Drug|Oxcarbazepine|
75779590|NCT01051271|Drug|midazolam|midazolam 1.5 mg
75779591|NCT03991637|Device|Non-Invasive Comprehensive Metabolic Panel|The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
75779592|NCT01051427|Device|Surgiflo|Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.
75779593|NCT01051427|Device|Nasal catheter|In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
75779594|NCT01052909|Drug|Glimepiride|Glimepiride tablets 1 mg
75915402|NCT02775851|Procedure|Computed Tomography|Undergo CT scan
75915403|NCT02775851|Procedure|Magnetic Resonance Elastography|Undergo MRI
75915404|NCT02775851|Biological|Pembrolizumab|Given IV
75915405|NCT02775851|Procedure|Positron Emission Tomography|Undergo PET scan
75915406|NCT02775851|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
75915407|NCT02734719|Device|Bonestim|Bonestim is the multipad electrical stimulation device.
75915408|NCT02733159|Drug|pembrolizumab|anti PD-1
75915409|NCT02731612|Drug|lurasidone|Atypical Antipsychotic
75322649|NCT04257071|Behavioral|Usual Care|The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.
75627710|NCT05634551|Behavioral|Questionnaires|Participants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires
75627711|NCT05634551|Behavioral|Interview|The interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)
75322650|NCT04257071|Behavioral|OOP Cost Communication and Optimization|OOP Cost Communication and Optimization includes personalized discussion of OOP cost estimates for treatment plan obtained through an online price transparency tool, personalized analysis of patients' expenses by financial counselor, and patient enrollment in any cost optimization opportunities for which patient is eligible using a comprehensive financial navigation program.
75322651|NCT03347786|Drug|Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure
75322652|NCT00636701|Device|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
75627712|NCT05634070|Device|PCL Pectus scaffold implantation and autologous fat grafting|A suitable incision will be made using a scalpel and diathermy following standard surgical procedures.The implant pocket shall be rinsed with saline. The PCL Pectus Scaffold shall be inserted into the pocket following the Instruction for Use and fixed to the thoracic wall using 2 to 4 sutures. The device shall not be modified for any patient in any manner. The incision shall be closed using 2-0 Vicryl or Monocryl and 3-0 Monocryl sutures, if applicable. Number of layers to be sutured will be decided by the PI for each patient. Sterile bandaging as well as Steri-Strips shall be applied on the sutures. A prophylactic antibiotic such as Cefazolin 1g (3 shots per day x 2 days) shall be administered to the patient. In case the patient has Cefazolin allergy, Clindamycin 600 mg shall be prescribed. Autologous Fat Grafting procedure shall be performed immediately after implantation. The patients shall be hospitalized for the necessary number of days under clinical observation.
75627713|NCT05632627|Drug|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to improvements in cognition, TBI-related symptoms, pain, sleep, depression, anxiety, and peripheral markers of inflammation and oxidative stress.
75627714|NCT05632627|Drug|Placebo|Placebo arm
75627715|NCT05629364|Drug|KIO-101|Randomized, Controlled
75627716|NCT05629065|Other|Clinician Nudge Email|"-Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit"
75779595|NCT00045032|Drug|Herceptin|Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
75779596|NCT00045032|Drug|Herceptin|Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
75322653|NCT03286634|Drug|Daunorubicin|Given IV
75322654|NCT03286634|Drug|Prednisolone|Given PO or IV
75322655|NCT03286634|Drug|Vincristine|Given IV
75779597|NCT01052987|Drug|Tranilast|Tranilast tablets, 300 mg, QD
75779598|NCT01052987|Drug|Allopurinol|Allopurinol tablets 300 mg, QD
75779599|NCT01052987|Drug|Combination - Tranilast and Allopurinol|Tranilast, 300 mg QD; Allopurinol 300 mg QD
75779600|NCT01052987|Drug|400 mg Allopurinol|400 mg Allopurinol administered once daily for 7 days
75779601|NCT01052987|Drug|High dose combination|Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
75779602|NCT02533973|Drug|Xamiol® gel|
75779603|NCT02533973|Drug|Daivonex® scalp solution|
75779604|NCT02533895|Biological|AV0113 DC-CIT|Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
75915410|NCT02731612|Other|Placebo|Inactive substance
75322656|NCT03286634|Drug|Epirubicin|Given IV
75322657|NCT03286634|Drug|E-coli L-asparaginase|Given IM or IV
75915411|NCT02696876|Device|Arthroscopic synovial brushing|The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.
75915412|NCT02696876|Procedure|Microfracture|Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
75322658|NCT03286634|Drug|6-Mercaptopurine|Given PO
75915413|NCT02683486|Device|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
75322659|NCT03286634|Drug|Methotrexate|Given IV, PO or IT
75322660|NCT03286634|Drug|Hydrocortisone|Given IT
75322661|NCT03286634|Drug|Cytarabine|Given IV, IT or SC
75322662|NCT03286634|Drug|Cyclophosphamide|Given IV
75322663|NCT03345290|Device|PET with a cerebral step|Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography
75779605|NCT02533895|Other|Data evaluation|"For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc"
75779606|NCT01051505|Drug|AZD5069|oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
75915414|NCT02683486|Device|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
75915415|NCT02642172|Dietary Supplement|ITF (Inulin/OFS 75/25)|Participants will consume 16 g/day ITF
75915416|NCT02642172|Dietary Supplement|Placebo|Participants will consume 16 g/day maltodextrin
75915417|NCT02612662|Drug|AZD4076|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
75322664|NCT03345290|Device|Central blood pressure measurement|Central blood pressure measurement
75322665|NCT03345290|Other|Neurocognitive tests|Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB
75915418|NCT02612662|Drug|Placebo|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
75915419|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
75915420|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
76074414|NCT04730999|Drug|Bevacizumab|"Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal."
76074415|NCT04730999|Drug|Atezolizumab|"Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit."
76074416|NCT00759772|Drug|Placebo|sc daily for 6 months
75322666|NCT05011682|Behavioral|Regular diet|participant's usual diet during 2 weeks
75322667|NCT05011682|Behavioral|10-point nutrition plan|controlled portions of low glycemic index carbohydrates, avoidance of rapidly absorbed carbohydrates, adjustment of timing of meals and snacks, and attention to personal and cultural barriers to implementation
75322668|NCT04400630|Other|Physical exercise|The experimental group will receive supervised physical exercise treatment by high-intensity interval training (HIT), alternating high and moderate intensities (20 min). The participants will exercise two non-consecutive days per week for 16 weeks under supervision by exercise specialists.
75322669|NCT00637247|Drug|imexon in combination with gemcitabine|875 mg/m^2 imexon IV + 1000 mg/m^2 gemcitabine IV
75779607|NCT01051505|Drug|Placebo|oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
75779608|NCT02534051|Other|Clinical Care Pathway|The clinical care pathway guides aspects of care specific to obese pregnant women:1st trimester: offer of testing for pre-existing diabetes with either 75g OGTT or 50g GCT, nuchal translucency ultrasound (u/s), calculation of body mass index, counselling about weight gain, advising about medical complications, screening for obstructive sleep apnea, and referral to Maternal-Fetal Medicine if history of bariatric surgery, 2nd trimester: offer of maternal-serum alpha fetal protein (spina bifida), anatomy u/s, and 50g GCT and 75g OGTT, 3rd trimester: offer of consultation with anesthesiology, u/s for growth & well-being, counselling about birth risks, and discussion of breastfeeding.
75322670|NCT00637247|Drug|imexon placebo + gemcitabine|imexon placebo IV + 1000 mg/m^2 gemcitabine IV
75779609|NCT01581125|Behavioral|Sleep:wake 1|Sleep and Wake durations for arm 1
75322671|NCT04998032|Biological|supaglutide injection+metformin|supaglutide subcutaneous injection under RP3D dose combined with metformin treatment
75467294|NCT01918657|Drug|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
75779610|NCT01581125|Behavioral|Sleep:wake 2|Sleep and Wake durations for arm2
75779611|NCT01053065|Drug|Atorvastatin - Cholestyramine - Sitosterol|
75915421|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
75915422|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
75467295|NCT01918657|Drug|walnut powder|escalating doses of walnut powder
75779612|NCT02533661|Other|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
75915423|NCT02594072|Radiation|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
76074417|NCT00759772|Drug|Teriparatide|20 mcg sc daily for 6 months
75779613|NCT01051583|Procedure|Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin|The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
75915424|NCT02594072|Radiation|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
75915425|NCT02594072|Drug|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
75627717|NCT05629065|Other|Patient Nudge Letter and Share questionaire|"Involves patient nudge consists of a letter and SHARE questionnaire~- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit."
75915426|NCT02541955|Drug|Acthar|Injections will be self administered
75915427|NCT02530177|Other|Clinical Assessments|
75915428|NCT02530177|Behavioral|Questionnaires|
75915429|NCT02530177|Other|Saliva sample|(only once, preferably at baseline)
75915430|NCT02498132|Other|Behavioral Activation|BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, & Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
75915431|NCT02498132|Other|Cognitvie Based Therapy|CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
75915432|NCT02498132|Other|Treatment as Usual|Individuals will be provided with one on one therapy sessions
75627718|NCT05627466|Drug|Magrolimab|Administered intravenously
75627719|NCT05623397|Other|Acquisition of a digitized ECG by four modalities within 20 minutes|"Patients will have three visits during the cycle for a given dose (600mg/day, 400mg/day or 200mg/day): Baseline , Day 14, Day 28~At each visit, the patient will have the acquisition of a digitized ECG by four modalities within 20 minutes (A 10 second triplicate ECG with WELCH-ALYN ELI-280® with the three 10 sec ECGs collected at approximatively 2-minute intervals, 3 min holter acquisition with a CGM HI-patch ®, a 3 minutes acquisition with AliveCore 6L® device and 10 seconds triplicate acquisition with QT-medical ® device collected at approximatively 2-minute intervals ).~Concomitantly with the ECG acquisition, patients will have blood sampling for measurements of variables clinically important for assessment of QTc including potassium, fasting blood glucose, calcemia, magnesium, estradiol, progesterone, FSH, LH, D4-androstenedione, total and free testosterone, SHBG and TSH. Blood concentration of ribociclib will be also assessed."
75779614|NCT01053143|Biological|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
75915433|NCT02486133|Drug|Prezista|once daily
75915434|NCT02486133|Drug|Norvir|once daily
75915435|NCT02486133|Drug|Tivicay|once daily
75627720|NCT05611671|Drug|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
75627721|NCT05611671|Drug|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
75627722|NCT05611008|Device|CDSS|A Clinical Decision Support System (CDSS) that calculates older patients' personalized fall risk and provides the GP with advice on how to adjust the patient's medication in order to lower the fall risk.
75627723|NCT05611008|Device|Patient Portal|A patient portal that provides general information on falls and fall risk to the older patients and helps the patient to prepare for the consultation by filling out a Question Prompt List (QPL). The QPL is a list of possibly relevant questions and topics from which the patient can select those that are important to him/her. These will already be sent to the GP before the consultation takes place.
75779615|NCT02533583|Device|pulse oximetry (PHILIPS intelliven MP5)|all newborn monitor pulse oximetry in left hand
75779616|NCT01053299|Other|open, prospective cohort-study|Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
75915436|NCT02486133|Drug|Truvada|once daily
75915437|NCT02486133|Drug|Kivexa|once daily
75915438|NCT02486133|Drug|Descovy|once daily
75915439|NCT02457442|Drug|Propofol and Remifentanil|High propofol and low remifentanil, changing remifentanil (up-and-down method)
75467296|NCT01918670|Procedure|catheter ablation of atrial fibrillation|electric pulmonary vein disconnection
75915440|NCT02457442|Drug|Propofol and Remifentanil|Low propofol and high remifentanil, changing propofol (up-and-down method)
75915441|NCT02457442|Drug|Sevoflurane and Remifentanil|High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
75915442|NCT02457442|Drug|Sevoflurane and Remifentanil|Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
75915443|NCT02457442|Drug|SPR 1|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision."
75915444|NCT02457442|Drug|SPR2|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision."
75915445|NCT02427854|Behavioral|Education by animated training video|Training performed by watching an animated educational video.
75322672|NCT04998032|Other|placebo+metformin|placebo subcutaneous injection combined with metformin treatment
75467297|NCT01918696|Behavioral|Anger Reduction Treatment|Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.
75627724|NCT05603520|Other|Collection of Clinical Data|prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms
75627725|NCT05602194|Procedure|Biospecimen Collection|Undergo blood sample collection
75627726|NCT05602194|Drug|Calaspargase Pegol|Given standard of care calaspargase pegol
75627727|NCT05602194|Dietary Supplement|Levocarnitine|Given PO or IV
75627728|NCT05602194|Drug|Pegaspargase|Given standard of care pegaspargase
75627729|NCT05602194|Other|Quality-of-Life Assessment|Ancillary studies
75779617|NCT03950804|Drug|Eculizumab Injection|Patients receive eculizumab as deemed necessary by the primary physician
75915446|NCT02427854|Procedure|Interactive hands-on bedside training|Training performed as a traditional bedside training supported by a trainer in person.
75915447|NCT02407691|Other|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
75915448|NCT02407691|Other|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
75915449|NCT02391519|Procedure|Collection of myometrial, cord blood, and placental tissue samples|We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
75915450|NCT02347111|Drug|Flecainide|flecainide up to 150mg twice daily for the control of atrial fibrillation
75915451|NCT02347111|Drug|Sotalol|sotalol up to 120mg twice daily for the control of atrial fibrillation
75915452|NCT02323945|Other|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
75915453|NCT02323945|Other|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
75915454|NCT02323945|Other|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
75915455|NCT02320929|Procedure|Intraoperative flexor tendon sheath irrigation|
75915456|NCT02320929|Procedure|Postoperative flexor tendon sheath irrigation|
75915457|NCT02315768|Drug|GA101|
75915458|NCT02315768|Drug|ibrutinib|
75915459|NCT02315716|Procedure|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
75915460|NCT02315716|Drug|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
75915461|NCT02306382|Procedure|Perianal abscess drainage|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
75915462|NCT02306382|Device|3D ultrasonography|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
75915463|NCT02302833|Drug|Cabozantinib S-malate|Given PO
75779618|NCT03950882|Drug|PXL770|Oral capsule
75779619|NCT03950882|Drug|Placebo|Oral capsule
75779620|NCT00356915|Drug|Itraconazole 100mg capsules|Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
75915464|NCT02302833|Other|Laboratory Biomarker Analysis|Correlative studies
75915465|NCT02302833|Other|Questionnaire Administration|Ancillary studies
75322673|NCT04388033|Biological|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells.
75322674|NCT04388033|Drug|Interleukin-12|Given subcutaneously at dose of 6ug twice for interval of one hour.
75322675|NCT04388033|Drug|Temozolomide|Following concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days) , maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
75322676|NCT04179929|Drug|Pediatric-type of chemotherapy|Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
75467298|NCT01918696|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.
75627730|NCT05593016|Behavioral|Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)|"Participating in the SMILE arm of the study will consist of four, 60-minute sessions delivered over 6-8 weeks to patients in their homes using videoconferencing.~Intervention will provide training in behavioral symptom management skills (e.g.,relaxation training, activity-rest cycling) and include skills from ACT and MCP targeting avoidance of uncomfortable experiences (e.g., thoughts, emotions) and promoting engagement in value-directed activity."
75779621|NCT00356915|Drug|Itraconazole 200mg tablets|Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
75779622|NCT00356915|Drug|Placebo tablets|Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
75779623|NCT01051973|Behavioral|Cognitive behavior therapy|A 10-week treatment based on exposure to symptoms and related feelings.
75779624|NCT01051973|Behavioral|Stress management|A 10-week stress management treatment including applied relaxation and dietary advice.
76074418|NCT01763203|Behavioral|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
75322677|NCT04179929|Procedure|allogeneic HSCT|allogeneic HSCT
75322678|NCT04760756|Other|Fragility Fracture Integrated Rehabilitation Management|"At least 2 hours of rehabilitation management per day~Including occupational therapy (training to improve daily life performance)~Inpatient (the first 2 weeks): daily management (body control ability, mobility ability, hygiene management, etc.)~Outpatient (2-6 weeks): management once a week~The management period is for 2 weeks (1 week after surgery)"
75322679|NCT02980731|Drug|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
75322680|NCT04994288|Biological|Supaglutide injection|Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml
75322681|NCT04994288|Other|placebo injection|placebo injection 0.5ml
75779625|NCT00356759|Drug|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times|Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
75915466|NCT02290782|Radiation|Intraoperative radiotherapy (IORT)|"The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.~To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm."
76074419|NCT01763203|Behavioral|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
75627731|NCT05593016|Behavioral|Education Control Arm|"The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer, which provides basic strategies for symptom (e.g., pain, fatigue, stress) management, coping with negative emotions, and communication and will continue their usual medical care of advanced cancer."
76074420|NCT00771238|Device|P500 Mattress|Study mattress
76074421|NCT03809416|Device|Lasers|Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
75467299|NCT01918696|Behavioral|Control Condition|Eight 15-minute sessions of informative videos on healthy living.
75322682|NCT04345835|Procedure|Percutanous nephrolithotomy (PCNL)|different procedure positioning
75322683|NCT04400396|Dietary Supplement|standard HM fortification|Based on the assumed energy and macronutrient composition of HM, the commercial multi-component HM fortifier was added, in order to compensate identified nutritional deficits.
75322684|NCT04400396|Dietary Supplement|target HM fortification|Based on the measured energy and macronutrient composition of HM, modular protein and fat supplements are added, in addition to the commercial multi-component HM fortifier, in order to correct identified specific nutritional deficits. For this purpose, an Excel program to calculate modular protein and fat supplements to be added to fortified HM was developed and registered (Nona R, Cardoso M, Portuguese Directorate of Intellectual Property Services, IGAC-DSPI, nº 480/2020, 26 February 2020)
75467300|NCT01918709|Drug|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
75467301|NCT01918709|Drug|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
75467302|NCT01918709|Drug|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
75627732|NCT05589649|Procedure|Erector spinae plane block|Ultrasound-guided erector spinae plane block
75779626|NCT03804710|Drug|Developmental moisturizing cream 1|Participants will topically apply developmental moisturizing cream 1
75779627|NCT03804710|Drug|Developmental moisturizing cream 2|Participants will topically apply developmental moisturizing cream 2
75467303|NCT01918709|Drug|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
75915467|NCT02274116|Other|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.
75467304|NCT01918709|Drug|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
75467305|NCT01918709|Drug|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
75627733|NCT05589649|Procedure|Paravertebral block|Ultrasound-guided paravertebral block
75627734|NCT05587296|Drug|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
75627735|NCT05587296|Drug|Placebo|Matching placebo orally once daily.
75779628|NCT03804710|Other|Standard cleanser soap|Participants will cleanse the entire face and both lower legs (between the knees and the ankles)with simple pure soap
75627736|NCT05586334|Biological|Collection of vaginal secretions|In all women included: Vaginal secretion sampling at the time of the obstetrical emergency consultation.
75627737|NCT05586334|Biological|Collection of the placenta and the membranes|In cohort 1, for 30 patients at the Port Royal Maternity Hospital, the placenta and membranes will be collected after delivery
75627738|NCT05586334|Other|Administration of EPDS questionnaire|In cohort 3, the EPDS questionnaire will be administered to all participants after the consultation in the emergency department.
75779629|NCT00356603|Drug|Sumatriptan Succinate|Sumatriptan Succinate
75322685|NCT04164173|Device|EzPAP|Patient will receive 10 min EzPAP 4 times daily
75467306|NCT01918722|Drug|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
75467307|NCT01918722|Drug|placebo|placebo herbal medicine, one dose,bid, for 10 days
75467308|NCT01918722|Drug|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
75467309|NCT01918748|Device|Haptic Master|The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
75779630|NCT01052051|Dietary Supplement|Vitamin D3|Vitamin D3 2000 IU/daily
75915468|NCT02274116|Other|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
75627739|NCT05585307|Drug|GS-5894|Administered orally
75627740|NCT05585307|Drug|B/F/TAF|Administered orally
75627741|NCT05585307|Drug|Standard of Care (Substudy 01)|"Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)"
75627742|NCT05585307|Drug|GS-1720|Administered orally
75915469|NCT02205359|Device|aCRT ON|CRT device with AdaptivCRT enabled (AdaptivBiV and LV)
75915470|NCT02205359|Device|aCRT OFF|CRT device with AdaptivCRT disabled
75915471|NCT02183883|Drug|Afatinib|"40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.~EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade > 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg."
75915472|NCT02131584|Other|Questionnaire Administration|Ancillary studies
75915473|NCT02131584|Drug|Ruxolitinib Phosphate|Given PO
75915474|NCT02116140|Other|[C11]Acetate and HED PET|
75915475|NCT02101775|Drug|Adavosertib|Given PO
75915476|NCT02101775|Drug|Gemcitabine Hydrochloride|Given IV
75915477|NCT02101775|Other|Laboratory Biomarker Analysis|Correlative studies
75322686|NCT04164173|Device|Metaneb|Patient will receive 10 min Metaneb 4 times daily
75467310|NCT01918787|Device|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
75627743|NCT05585307|Drug|Standard of Care (Substudy 02)|"Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC"
75627744|NCT05584787|Procedure|Soractelite Echolaser Transperineal focal laser ablation|US/MRI fusion laser ablation of low- and intermediate risk prostate cancer
75627745|NCT05584267|Radiation|radiotherapy|Different cohorts received different doses of radiotherapy
75627746|NCT05584267|Drug|Chemotherapy + immunotherapy|Chemotherapy + immunotherapy
75627747|NCT05577468|Drug|Tegoprazan|tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
75779631|NCT01052051|Dietary Supplement|Calcium carbonate|Calcium carbonate 1500mg / daily
75779632|NCT03948230|Biological|Salt with / without water|Drinks with and without a salt containing capsule
75779633|NCT03990155|Procedure|HFNCOT+ECCO2R|NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
75915478|NCT02101775|Other|Pharmacological Study|Correlative studies
75915479|NCT02101775|Other|Placebo Administration|Given PO
75915480|NCT02101775|Other|Questionnaire Administration|Ancillary studies
75915481|NCT02088645|Drug|177Lu-PP-F11N|
75915482|NCT02064309|Device|Beta-Air device for encapsulation of transplanted human islets|
75915483|NCT02062346|Drug|BQ123|Intravenous infusion of BQ123 ( selective ETA antagonist )
75915484|NCT02062346|Drug|BQ123/788|or BQ123/788 (mixed ETA/B antagonists)
75322687|NCT04164173|Device|Intermittent Positive Pressure Breathing (IPPB)|Patient will receive 10 min IPPB 4 times daily
75322688|NCT04400162|Behavioral|Usability of the CCT|Evaluation of the usability of the provided training.
75322689|NCT04400162|Behavioral|Changes in regards to the depressive disorder|Evaluation of depressive symptoms and whether they change in regards to the provided training.
75322690|NCT03281096|Drug|Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
75627749|NCT05576467|Behavioral|Telephone|Classes follow MBCT protocol delivered via telephone by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
75915485|NCT02062346|Drug|Placebo|Intravenous infusion of saline
75915486|NCT02013648|Drug|Dasatinib|
75915487|NCT02013648|Drug|Cytarabine|
75915488|NCT02013648|Drug|Daunorubicin|
75915489|NCT02013648|Drug|Idarubicin|
75915490|NCT02004834|Drug|levobupivacaine|Comparing: 0,5% levobupivacaine with 2% lidocaine
75915491|NCT01979536|Drug|Brentuximab Vedotin|Given IV
75915492|NCT01979536|Drug|Crizotinib|Given PO
75915493|NCT01979536|Drug|Cyclophosphamide|Given IV
75915494|NCT01979536|Drug|Cytarabine|Given IT and IV
75915495|NCT01979536|Drug|Dexamethasone|Given PO or IV
75915496|NCT01979536|Drug|Doxorubicin Hydrochloride|Given IV
75915497|NCT01979536|Drug|Etoposide|Given IV
75779634|NCT03948152|Other|Standard of Care|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the sites standard of care.
75915498|NCT01979536|Drug|Ifosfamide|Given IV
75915499|NCT01979536|Drug|Methotrexate|Given IT and IV
76074422|NCT03809416|Other|Platelets Rich Plasma|Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
75467311|NCT01918813|Drug|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
75322691|NCT03281096|Drug|Placebo|pill manufactured to mmic Berberine hydrochloride 100mg tablet
75322692|NCT04731987|Behavioral|Beverage consumption|"Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal."
75627750|NCT05576467|Behavioral|Video|Classes follow MBCT protocol delivered via video by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
75467312|NCT01918826|Device|TENS|
75627751|NCT05576467|Behavioral|Online|Weekly online modules follow migraine and behavior principles delivered via web portal developed by a team of licensed clinical psychologists, neurologists, and mental health providers.
75627752|NCT05574153|Diagnostic Test|Cardiac MRI|Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
75627753|NCT05574140|Diagnostic Test|Cardiac MRI|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
75627754|NCT05570500|Behavioral|Oral health education|oral health education sessions that aims to improve both knowledge of primary school children regarding bacteria, caries, number of teeth, plaque formation and attitude of primary school children regarding tooth brushing techniques, number of times per day, dietary instructions to avoid dental caries.
75627755|NCT05569317|Other|primary nursing|The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
75627756|NCT05567692|Diagnostic Test|OGTT|Oral Glucose Tolerance Test
75779635|NCT03948152|Other|Mask Advice Tool|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the mask advice tool.
75779636|NCT01104428|Drug|Placebo|granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
75915500|NCT01880723|Drug|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
75915501|NCT01880723|Drug|Placebo saline|nebulized 3mL normal saline) using a Power Neb2 nebulizer
75915502|NCT01824836|Drug|anastrozole|Given PO
76074423|NCT03809416|Combination Product|Lasers plus Normal Saline Solution|Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
76074424|NCT03802942|Dietary Supplement|Glucerna|1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
76074425|NCT03803098|Device|reference measure|measure of a physiological parameter performed with the gold standard medical device
75322693|NCT04725591|Device|Dexcom G6 Continuous Glucose Monitoring|Collection of glucose data
75322694|NCT04725591|Device|MEDISAFE WITH External Insulin Pump|Insulin delivery
75627757|NCT05567692|Other|HbA1c|HbA1c measurement
75627758|NCT05567692|Other|Questionnaire|Follow-up questionnaire
75779637|NCT01104428|Drug|"ziying granules"|granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
75779638|NCT05370872|Diagnostic Test|Remote functional testing protocol|Clients in the remote functional testing protocol group will be asked to describe their functional capacity limits using a clinician guided motivational interviewing approach and will also be asked to complete a mobility screening protocol to provide the clinician with the opportunity to observe the clients natural movements.
75779639|NCT03947996|Other|Stretching exercise|Stretching (30 minutes, 5 days per week, 8 weeks)
75779640|NCT03947996|Other|Walking exercise|Walking (30 minutes, 5 days per week, 8 weeks)
75779641|NCT01104506|Procedure|fMRI|
75779642|NCT01104506|Procedure|mTMS|
75779643|NCT00002558|Biological|filgrastim|
75915503|NCT01824836|Other|questionnaire administration|Ancillary studies
75915504|NCT01824836|Other|laboratory biomarker analysis|Correlative studies
75915505|NCT01824836|Other|pharmacogenomic studies|Correlative studies
75915506|NCT01798992|Drug|Carvedilol|
75915507|NCT01798992|Drug|Metoprolol succinate|
75915508|NCT01798992|Drug|Metoprolol succinate + doxazosin|
75915509|NCT01746836|Other|Laboratory Biomarker Analysis|Blood draws.
75467313|NCT01918852|Drug|Capecitabine|
75467314|NCT01918852|Drug|Teysuno|
75467315|NCT01918852|Drug|Bevacizumab|
75467316|NCT01918865|Drug|ISIS-PTP1BRx|
75467317|NCT01918865|Drug|Placebo|
75467318|NCT01918865|Drug|daily OAD (metformin and/or sulfonylurea)|
75467319|NCT01918878|Drug|Aflibercept (EYLEA)|INTARAVITREAL INJECTION OF AFLIBERCEPT
75467320|NCT01918891|Behavioral|Nurse Practitioner Only|
75467321|NCT01918891|Behavioral|Nurse Practitioner + Health Coach|
75915510|NCT01746836|Drug|Ponatinib Hydrochloride|Starting dose: 30 mg by mouth once a day.
75915511|NCT01746836|Other|Quality-of-Life Assessment|Surveys completed.
75915512|NCT01697930|Drug|[18F] 4-L-Fluoroglutamine (2S,4R)|Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of [18F] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the [18F] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
75915513|NCT01619917|Device|Fractional Vascular Laser|laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
75915514|NCT01570868|Drug|Ponatinib|Starting dose: 45 mg by mouth once daily.
76074426|NCT03803098|Device|alternative measure|measure of a physiological parameter performed with the connected device under evaluation
76074427|NCT01763047|Device|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
76074428|NCT01763047|Device|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
76074429|NCT04384120|Device|Blood Flow Restriction Therapy|Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.
76074430|NCT04384120|Procedure|Traditional Therapy|Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
76074431|NCT05743348|Behavioral|Telepsychotherapy|Remotely delivered psychotherapy sessions
76074432|NCT03809338|Diagnostic Test|amh test|Antral follicle count with ultrasound on the 3rd day of menstruation
76074433|NCT01977677|Radiation|radiation therapy|Undergo radiation therapy
75627759|NCT05565118|Procedure|Standard Surgical Treatment|During this surgery, participants will also undergo a tissue biopsy at recording sites for correlation to neural recording data.
75627760|NCT05565118|Procedure|Intraoperative Electrocorticography|Each participant will undergo intraoperative electrocorticography (ECOG) through subdural grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording technology.
75627761|NCT05564468|Other|Best Practice|Receive standard of care
75627762|NCT05564468|Other|Internet-Based Intervention|Receive Peacefully's end-of-life planning program
75627763|NCT05564468|Other|Questionnaire Administration|Ancillary studies
75627764|NCT05558644|Other|single arm for all patients|"tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery."
75779644|NCT00002558|Drug|carboplatin|
75779645|NCT00002558|Drug|etoposide|
75627765|NCT05557864|Device|Deep Brain Stimulation|Pallidal Deep Brain Stimulation
75779646|NCT00002558|Drug|ifosfamide|
75779647|NCT00002558|Drug|paclitaxel|
75779648|NCT00002558|Procedure|peripheral blood stem cell transplantation|
75779649|NCT03950648|Behavioral|Spatial Cognitive Training|map reading and route-learning skills
76074434|NCT01977677|Drug|temozolomide|Given PO
76074435|NCT01977677|Drug|plerixafor|Given IV
76074436|NCT01977677|Other|laboratory biomarker analysis|Correlative studies
76074437|NCT01977677|Other|pharmacological study|Correlative studies
75322695|NCT04725591|Device|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
75322696|NCT04725591|Other|Declaration of meals|Patient inputs related to meals
75322697|NCT04725591|Other|No declaration of meals|No patient inputs related to meals
75322698|NCT04725591|Other|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
75322699|NCT03343574|Other|Abdominal Strengthening Exercise|Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
75467322|NCT01918904|Drug|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
75627766|NCT05557448|Drug|TYNADOTE|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
75627767|NCT05557448|Drug|Placebo Oral Tablet|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
75627768|NCT05556811|Device|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
75627769|NCT05556811|Device|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
75779650|NCT01101932|Drug|PF-04308515|PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
75779651|NCT01101932|Drug|Placebo|Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
75779652|NCT01101932|Drug|PF-04308515 Tablet|Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
76074438|NCT01762345|Device|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter & Gamble
75467323|NCT01918904|Drug|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
75467324|NCT01918917|Drug|Levobupivacaine|intraarticular
75779653|NCT00001880|Drug|methotrexate|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
75779654|NCT00001880|Drug|Cyclosporin|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
75322700|NCT02890095|Procedure|Breast cancer surgery|"First, 2 specific adipose tissue samples will be performed during the surgery :~1 sample near the tumor, to measure the contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~1 remote sample of the tumor bed, superficial, at least 5 cm from the tumor, to be used to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC.~These withdrawals are made during surgery, during surgery, as part of the intervention and the remodeling of the mammary gland (standard care for patients). This is unused balance for diagnostic.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
75322701|NCT02890095|Procedure|plastic surgery|"The excision piece will follow the classical pathological circuit.~A specific charge of subcutaneous adipose tissue will be performed as part of research on the surgical specimen. This sample will be used:~measuring contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC. These samples are all made during surgery, for usual care surgery these patients.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
75322702|NCT02980497|Other|Listerine Zero Mouthwash (without alcohol)|20 ml of rinse for 30 seconds, twice a day
75322703|NCT02980497|Other|Listerine Antiseptic Mouthwash (with alcohol)|20 ml of rinse for 30 seconds, twice a day
75322704|NCT05325086|Other|Adapted information arm|A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits
75627770|NCT05556811|Device|Dynamic Light Therapy Device, LSA, 3|Dynamic Light Therapy
75627771|NCT05555290|Combination Product|PT027|When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
75627772|NCT05555290|Combination Product|PT007|When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.
75627773|NCT05549544|Device|Left bundle branch area pacing|Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.
75627774|NCT05549544|Device|Biventricular pacing|Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
75627775|NCT05516615|Other|4 minute breathing maneuver|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
75322705|NCT05325086|Other|Neutral information arm|A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
75322706|NCT04260867|Other|Essential Oil|Those randomized to the treatment group will have containers filled with the essential oil of their choice.
75322707|NCT04260867|Other|No Essential Oil|Those randomized to the control group will then be given empty single-use handheld aromatherapy containers containing no essential oil.
75627776|NCT05515341|Device|Commercially Approved Interventional Medical Device/Therapy for Chronic Pain|Commercially Approved Interventional Medical Device/Therapy
76025642|NCT05301647|Other|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) consists of 23 questions in 5 domains (nasal symptoms, ocular symptoms, practical issues, limitation of activities, other symptoms) that are answered on a 7-point scale (0-6), where 0 represents the absence of problems and 6 the greatest symptom distress. Children will complete the questionnaire together with a parent at baseline and during the study. A Total Score was calculated as the mean of the 5 domains.
75467325|NCT01918917|Drug|Dexmedetomidine|intraarticular 1 ml (100 mcg)
75467326|NCT01918917|Drug|Morphine|intravenously, patient-controlled analgesia
75627777|NCT05514938|Drug|Polypill|Polypill formulation consisting of rosuvastatin, aspirin, and prasugrel or consisting of rosuvastatin, aspirin, and clopidogrel.
75627778|NCT05514938|Drug|Usual Care (individual medications prescribed by primary cardiologist)|Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.
75627779|NCT05513391|Biological|Recombinant influenza vaccine (RIV4)|Pharmaceutical form: solution for injection Route of administration: intramuscular
75627780|NCT05513391|Biological|Quadrivalent influenza vaccine (IIV4)|Pharmaceutical form: suspension for injection Route of administration: intramuscular
75627781|NCT05508334|Drug|RC88|Every 2 weeks for a maximum of 2 years
75627782|NCT05502237|Drug|Zimberelimab|Administered intravenously
75627783|NCT05502237|Drug|Domvanalimab|Administered intravenously
75627784|NCT05502237|Drug|Pembrolizumab|Administered intravenously
75627785|NCT05502237|Drug|Carboplatin|Administered intravenously
75627786|NCT05502237|Drug|Cisplatin|Administered intravenously
75627787|NCT05502237|Drug|Paclitaxel|Administered intravenously
75627788|NCT05502237|Drug|Nab-paclitaxel|Administered intravenously
75627789|NCT05502237|Drug|Pemetrexed|Administered intravenously
76025643|NCT05301647|Other|Total symptom score (TSS)|Total symptom score was the sum of 3 domains: i) nasal symptoms (TNSS) included itching, sneezing, rhinorrhea, nasal congestion; ii) ocular symptoms (TOSS): itching, hyperemia of the conjunctiva, tearing; and iii) throat symptoms (TTSS): itching, coughing. With the help of their parents, patients scored symptoms severity on a 4-point scale: 0 = absent or irrelevant, 1 = mild, 2 = moderate, 3 = severe. Total symptom score was assessed at 12 hours (TTS 12h) and two weeks (TTS 2W) before the visits. TSS represents the doctor's point of view of symptom severity
75779655|NCT01096472|Drug|LAS41003|Once daily
75779656|NCT01096472|Drug|LAS189961|Once daily
75779657|NCT01096472|Drug|LAS189962|Once daily
75779658|NCT01102010|Biological|Blood transfusion|An expanded indication for blood transfusion in the frail elderly
75779659|NCT05627648|Drug|KP-100LI|Intracordal injection, 20 mcg once per week, 3 weeks
75779660|NCT05627648|Drug|Placebo|Intracordal injection, once per week, 3 weeks
75779661|NCT01104740|Other|Biological sample collection|Blood (serum) sample collection
75627790|NCT05493423|Device|V Needle AV Fistula Set|Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.
75627791|NCT05487274|Procedure|Total Shoulder Arthroplasty + augmented glenoid component|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components. A prosthetic component is also implanted to correct for the amount of bone loss in the shoulder and restore stability.
75627792|NCT05487274|Procedure|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
75627793|NCT05485805|Drug|Naproxen sodium and caffeine (BAY2880376)|Tablet, oral use, single dose
75915515|NCT01550536|Behavioral|Resistance and aerobic exercise|Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
75322708|NCT04245501|Other|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related. Youth receive feedback aimed to reduce interpretation bias.
75627794|NCT05485805|Drug|Naproxen sodium (Aleve)|Tablet, oral use, single dose
75322709|NCT04245501|Other|Interpretation Control Condition (ICC)|"Computerized control condition in which youth see word-sentence pairs personalized to their anxiety symptoms. Youth indicate whether these are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
75627795|NCT05485805|Drug|Caffeine|Tablet, oral use, single dose
75779662|NCT01104818|Behavioral|Siblings in foster care curriculum, Parent Management Training|Each year, approximately 800,000 youth are cared for in foster homes across the nation. About 70% of these youth are known to suffer from mental health and educational disabilities and frequently transition to adulthood with lifelong deficits. The majority of youth in foster care have siblings in care. It is anticipated that the proposed intervention will significantly improve key outcomes for youth in the study and will provide much needed information on best practices to help youth in foster care.
75915516|NCT01424982|Drug|Cyclophosphamide|Given IV
75915517|NCT01424982|Drug|Cytarabine|Given IV
75322710|NCT05301686|Procedure|Patients with Cyclop lesion|Arthroscopy with resection of Cyclop formation
75322711|NCT02652429|Drug|Inhaled Nitric Oxide|
75322714|NCT02294253|Drug|Buprenorphine/naloxone|30 day oral Buprenorphine/naloxone
75467327|NCT01918943|Device|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
75467328|NCT01918956|Biological|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
75627796|NCT05485805|Drug|Placebo|Tablet, oral use, single dose
75627799|NCT05473598|Behavioral|Stand Down app|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
75627800|NCT05473598|Behavioral|Peer-Supported Stand Down|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
75779663|NCT03950726|Procedure|ileocolic resection|Ileocolic resection through McBurney incision
75915518|NCT01424982|Drug|Dexamethasone|Given IV or PO
75915519|NCT01424982|Drug|Doxorubicin|Given IV
75915520|NCT01424982|Drug|Doxorubicin Hydrochloride|Given IV
75915521|NCT01424982|Other|Laboratory Biomarker Analysis|Correlative studies
75915522|NCT01424982|Drug|Methotrexate|Given IV
75915523|NCT01424982|Drug|Ponatinib|Given PO
75322715|NCT02295735|Device|Mepilex® Border Sacrum and Mepilex® Border Heel|
75322716|NCT00684983|Drug|Capecitabine|Given PO
75467329|NCT01918995|Drug|Regadenoson|Intravenous (IV)
75467330|NCT01918995|Drug|Placebo|Intravenous (IV)
75467331|NCT01919008|Drug|FK949E|Oral
75467332|NCT01919021|Other|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
75322717|NCT00684983|Biological|Cixutumumab|Given IV
75322718|NCT00684983|Drug|Lapatinib Ditosylate|Given PO
75915524|NCT01424982|Drug|Ponatinib Hydrochloride|Given PO
75322719|NCT00684983|Other|Quality-of-Life Assessment|Ancillary studies
75322720|NCT04189341|Drug|Erector spinae plane block (Group E)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
75322721|NCT04189341|Drug|Modified-thoracolumbar interfascial plane block|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
75322722|NCT02337218|Device|SENSUS Pain Management System|An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
75467333|NCT01919021|Other|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
75467334|NCT01919021|Procedure|Assessment of Gastric motor and sensory function|
75467335|NCT01919047|Drug|Betanis|Oral
75467336|NCT01919073|Behavioral|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
75627801|NCT05473598|Other|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
75651676|NCT05832463|Dietary Supplement|Carbohydrate blocking supplement (CBS)|"The CBS is composed of a Hypromellose outer shell, and filled with mulberry leaf extract, berberine HCl, cinnamon bark powder, and cinnamon bark essential oil.~Mulberry leaf extract (Reducose) - 250 mg Berberine HCl (97%)(Berberis aristata root extract)- 25 mg Organic cinnamon powder (Cinnamon (Cinnamomum loureirii) bark powder) - 20 mg Essential oil blend (Grapefruit (Citrus paradisii) peel oil, Lemon (Citrus limon) peel oil Peppermint (Mentha piperita) aerial (leaf/stem) oil), Ginger (Zingiber officinale) root oil, Cinnamon (Cinnamomum zeylanicum) bark oil) - 5 mg"
75651677|NCT05832463|Dietary Supplement|Placebo capsule|The placebo is composed of a Hypromellose outer shell filled with extra virgin olive oil.
75779664|NCT03953924|Other|Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI)|The MI was implemented 2 times, 20 minutes each time, the trained nurse interviewed each patient face-to-face by bedside. Based on the evaluation results and motivational interviewing, the change stages of the patients' behavior changes were identified. According to the changing stage,TTM - based intervention was given 3 times in the form of a small course, 20 minutes each time, the key point was divided into three stages.
75779665|NCT01102088|Radiation|Radiation Therapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions."
75779666|NCT03947528|Drug|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fed condition
75779667|NCT01104896|Drug|Nicotine patch|One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days
75779668|NCT01104896|Drug|Placebo|One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
75779669|NCT01105052|Behavioral|Self-help CBT-I|Comparison between Bibliotherapy with and without support to a wait-list control group
75915525|NCT01424982|Drug|Prednisone|Given PO
75915526|NCT01424982|Biological|Rituximab|Given IV
75467337|NCT01919073|Behavioral|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
75915527|NCT01424982|Drug|Vincristine|Given IV
75915528|NCT01424982|Drug|Vincristine Sulfate|Given IV
75915529|NCT01415752|Biological|rituximab|Given IV
75322723|NCT02641587|Other|CHTP 1.2|Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.
75322724|NCT02641587|Other|CC|Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
75322725|NCT00638651|Device|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
75322726|NCT00638651|Drug|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
75467338|NCT01919125|Drug|IDX719|IDX719 supplied as 50 mg tablets.
75467339|NCT01919177|Dietary Supplement|Nitrate rich beetroot juice|Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
75467340|NCT01919177|Dietary Supplement|Nitrate depleted beetroot juice|Subjects will receive 140 mL of nitrate-depleted beetroot juice.
75915530|NCT01415752|Drug|bendamustine hydrochloride|Given IV
75915531|NCT01415752|Drug|bortezomib|Given IV or SC
75915532|NCT01415752|Drug|lenalidomide|Given PO
75467341|NCT01919203|Drug|Remifentanil|The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
75915533|NCT01415648|Other|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
76074439|NCT04384744|Drug|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
75322727|NCT02584647|Drug|PLX3397|PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.
75322728|NCT02584647|Drug|Sirolimus|"Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day."
75467342|NCT01919242|Procedure|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
75467343|NCT01919255|Drug|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
75467344|NCT01919255|Drug|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
75322729|NCT00685139|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered after an overnight fast.
75322730|NCT00685139|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered after an overnight fast.
75627802|NCT05468437|Behavioral|Telenutrition|Nutrition education and individualized nutrition counseling will be done with a Registered Dietitian via video-conferencing with iPad FaceTime, which is aimed to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. The telenutrition counseling consists of 6 sessions that are scheduled approximately 2 weeks apart. The first session will last approximately 1 hour, while sessions 2-6 will last approximately 30mins. During these sessions, the Registered Dietitian will share nutrition education tailored towards people with SCI. You will be involved in developing personal nutrition goals and the dietitian will help you address barriers to meeting your goals and provide individualized feedback to improve and maintain your nutrition. Telenutrition appointments will maintain privacy and will not be recorded.
75779670|NCT00043550|Behavioral|Supportive Expressive Therapy|The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
75627803|NCT05466890|Drug|PL8177 Placebo|Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
75467345|NCT01919268|Device|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
75627804|NCT05466890|Drug|PL8177|Approximately 3/4 of randomized patients will receive active PL8177.
75779671|NCT00043550|Drug|Sertraline|Participants will receive sertraline.
75779672|NCT00043550|Drug|Pill Placebo|Participants will receive a pill placebo.
75467346|NCT01919268|Device|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
75467347|NCT01919281|Behavioral|strength training|
75467348|NCT01919281|Behavioral|interval training|
75467349|NCT01919294|Drug|testosterone undecanoate|Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
75467350|NCT01919320|Device|C2 Driver System TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t
75467351|NCT01919320|Device|CSS Console TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
75467352|NCT01919346|Drug|Eculizumab|
75627805|NCT05466682|Behavioral|Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)|Relaxation technique delivered via RELAXaHEAD app.
75779673|NCT00043550|Drug|Venlafaxine|Participants will receive venlafaxine.
75779674|NCT03950258|Procedure|endovascular embolization|Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
75779675|NCT00041756|Drug|PG-530742|One 25 mg PG-530742 tablet, twice daily for for one year
75779676|NCT00041756|Drug|Placebo|One placebo tablet, twice daily for for one year
75915534|NCT01415648|Other|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
75915535|NCT01391962|Drug|Cediranib|Cediranib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
76074440|NCT03803020|Other|fractional flow reserve and SPECT detection|fractional flow reserve and SPECT detection
75467353|NCT01919346|Drug|Normal Saline|
75467354|NCT01919359|Dietary Supplement|Multizyme Cellular Vitality Cyruta Plus SHEP|
75467355|NCT01919372|Device|Telemedic assistance with a technological system|
75467356|NCT01919372|Other|Standard care|
75779677|NCT00041756|Drug|50 mg PG-530742|One 50 mg PG-530742 tablet, twice daily for for one year
75779678|NCT00041756|Drug|100 mg PG-530742|100 mg PG-530742 tablet, twice a day for one year
75779679|NCT00041756|Drug|200 mg PG-530742|200 mg PG-530742 tablet, twice a day for one year
76074441|NCT01761565|Drug|Single dose of SUF NT 15 mcg|
76074442|NCT01761565|Drug|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
75915536|NCT01391962|Drug|Sunitinib|Sunitinib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
75467357|NCT01919385|Device|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
75915537|NCT01288560|Other|Advanced cardiac imaging|
75322731|NCT03338036|Device|Heart Rate Variability Biofeedback|HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.
75467358|NCT01919424|Drug|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma"
75627806|NCT05466682|Behavioral|Monitored Usual Care (MUC)|Standard of care plus daily symptom reporting using the RELAXaHEAD app electronic diary.
75322732|NCT03338036|Device|Neurofeedback|LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
75467359|NCT01919424|Device|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
75467360|NCT01919424|Device|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada"
75467361|NCT01919437|Device|Web-Enabled Cognitive Neuropsychological Evaluation System|
75467362|NCT01919463|Behavioral|Abdominal Compression|Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
75627807|NCT05460832|Drug|MBS2320 5 mg|Oral capsule
75627808|NCT05460832|Drug|MBS2320 20 mg|Oral capsule
75467363|NCT01919463|Device|Guidance of Magnetic Endoscopic Imaging (MEI) System|Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
75467364|NCT01919476|Other|Bagel|
75915538|NCT01288560|Other|Standard Cardiac Imaging|
75915539|NCT01251965|Drug|Ruxolitinib|"Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I."
75915540|NCT01239693|Dietary Supplement|IFA|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
75467365|NCT01919476|Other|Cream Cheese|
75779680|NCT03950180|Other|Prostate Cancer Comorbidity Index (PCCI) score|Life expectancy information
75915541|NCT01239693|Dietary Supplement|MMN|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
75322733|NCT00685295|Drug|Fentanyl|Fentanyl rapid dissolving tablet 100mcg
75915542|NCT01239693|Dietary Supplement|LNS|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
75915543|NCT01224886|Behavioral|Physical activity|Supervised exercise intervention
76025644|NCT05301647|Other|Visual analogic scale (VAS)|A visual analogic scale (VAS) measured the parental perception of symptom severity (0=no symptom; 10=very severe symptoms).
76025645|NCT05403671|Other|Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer|Intervention includes exercising and relaxation in a group
75322734|NCT00685295|Drug|Lansoprazole|lansoprazole 15mg rapidly dissolving tablet
75322735|NCT00685295|Drug|Oxycodone|Oxycodone 5/325 mg tablet
75322736|NCT02319291|Device|P.F.C. Sigma PS150 RP Total Knee System|Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
75322737|NCT00686231|Drug|Nitroglycerin 15mg|15mg Nitroglycerin applied topically to one wrist
75322738|NCT00686231|Drug|Nitroglycerin 30mg|30mg Nitroglycerin applied topically to one wrist
75322739|NCT00686231|Drug|Lidocaine 20mg|20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
75627809|NCT05460832|Drug|MBS2320 40 mg|Oral capsule
75627810|NCT05460832|Drug|Placebo|Oral capsule
75627811|NCT05460533|Biological|Tisagenlecleucel|Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
75627812|NCT05460052|Other|Physical activity training program|"The physical activity training program will consist of 3 sessions per week for 6 weeks :~1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital~2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference."
75627813|NCT05460052|Other|Weekly phone call.|Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.
75627814|NCT05460052|Other|Personalized training plan.|After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.
75651678|NCT05832385|Radiation|IMRT|anal cancer: chemoradiotherapy, radiation dose>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
76025646|NCT04412759|Other|microbial cellulose|polymer dressing synthesized in abundance with Acetobacter Xylinum
76025647|NCT04203875|Drug|Orencia® (Abatacept)|Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
76025648|NCT05283785|Procedure|End To End or End to side sutures|End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
76025649|NCT04491461|Dietary Supplement|Herbal tea blend|1 cup of freshly brewed tea from an herbal tea blend.
76025650|NCT04491461|Dietary Supplement|Warm water|1 cup of warm water
75779681|NCT01102166|Other|Acapella with nebulization|"st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.~The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.~nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe T between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.~Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases."
75779682|NCT01102244|Drug|Tobradex ST|tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days
75779683|NCT01102244|Drug|Azasite|azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
75322740|NCT00686231|Drug|Lidocaine 40mg|40mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
75627815|NCT05452954|Behavioral|Brief behavioral parent training|In the newly developed intervention, both stimulus control and contingency management techniques will be offered in a brief behavioral parent training consisting of two intervention sessions and one booster session.
75627816|NCT05451108|Device|PCL Pectus Scaffold implantation and autologous fat grafting|A small incision is made in the chest and pre-sternal pocked is defined. Following this, an empty scaffold is implanted at the site of the defect with skin closed directly over it. At the same stage, autologous fat transfer will be performed, harvesting fat from available donor sites such as the thighs and abdomen - depending on scaffold volume and patient morphology. The area will be infiltrated with local anaesthetic tumescent fluid, liposuction performed, and fat transferred to syringes for filtration prior to injection into the scaffold. Fat will not be processed beyond simple filtration to separate liquid from fat to be injected. The scaffold provides structural stability to the chest during the infiltration of the tissue inside the scaffold.
75779684|NCT01105208|Drug|Cephalexin suspension (Optocef, BAYO5448 )|Single dose of 500 mg / 10 mL
75779685|NCT01105208|Drug|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
75779686|NCT05231252|Procedure|Cyclophotocoagulation|Transcleral cyclophotocoagulation is used to treat glaucoma secondary to silicone oil.
75322741|NCT00686231|Drug|Placebo|Topical skin moisturizing cream with same appearance as active agent
75915544|NCT01223248|Radiation|IGIMRT using a single dose of 24 Gy|Pts in both the hypofractionated & single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI & DCE-MRI pretreatment for both arms & 1 hour after their initial treatment for single fraction pts, & within one hour of their initial & final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule & MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, & approximately 24 hours [MCPG2.3]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
76025651|NCT04151927|Device|Normobaric Hypoxia|Low oxygen exposure to mimic ~8500 feet elevation.
75322742|NCT04122053|Behavioral|Intervention group with genotype information|Results of genotyping will be translated into personalised dietary recommendations. Subjects will be informed about their genotypes from the beginning of the study. The importance of personalised recommendations will be explained.
75322743|NCT04122053|Behavioral|Control group without genotype information|Subjects will receive personalised dietary recommendations, but at the beginning they will not be informed about their genotypes and the meaning of personalisation. Information about their genotype will be given to the participants at the and of study.
75322744|NCT04278716|Other|Safe return to play checklist|this objective checklist will be utilized by the physical therapy staff and surgeon to determine whether an athlete is safe to return to their sport
75322745|NCT05278208|Drug|LUTATHERA® (Lutetium Lu 177 dotatate)|Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
75322746|NCT03335774|Drug|Hydrocortisone Acetate Suppository, 25 mg (Nivagen)|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
75322747|NCT03335774|Drug|Placebo (Vehicle) Suppository (Nivagen)|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
75322748|NCT05520320|Device|Hypothermic oxygenated machine perfusion (any device)|After static cold storage, all grafts included in this study are subjected to >1 hour of hypothermic oxygenated machine perfusion at 4-12°C with an acellular perfusion solution.
75779687|NCT01327742|Device|Relay Thoracic Stent-Graft|Device implant
75779688|NCT01105286|Drug|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues|Once daily application
75779689|NCT00041132|Biological|filgrastim|5 ug/kg
75779690|NCT00041132|Biological|rituximab|375 mg/m^2 on day 1 of cycles 1-6
75779691|NCT00041132|Drug|cyclophosphamide|300 mg/m^2 on days 2-4 of cycles 1,3,5,7
75779692|NCT00041132|Drug|cytarabine|12 g/m^2 over days 3-4 of cycles 2,4,6,8
75779693|NCT00041132|Drug|dexamethasone|40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
75779694|NCT00041132|Drug|doxorubicin|16.6 mg/m^2/day for days 5-7 of cycles 1,3,5,7
75779695|NCT00041132|Drug|leucovorin|170 mg over days 3-5 of cycles 2,4,6,8
75779696|NCT00041132|Drug|methotrexate|1000 mg/m^2 over days 2-3 of cycles 2,4,6,8
75322749|NCT03335540|Biological|Nivolumab|Specified dose on specified day
75322750|NCT03335540|Biological|Relatlimab|Specified dose on specified day
75322751|NCT03335540|Biological|Cabiralizumab|Specified dose on specified day
75322752|NCT03335540|Biological|Ipilimumab|Specified dose on specified day
76025652|NCT04151927|Device|Normobaric Normoxia|Normal oxygen exposure to mimic ~1000 feet elevation (sham comparator).
75627817|NCT05450354|Other|Questionnaires|"Questionnaires will be completed only once :~Neurodevelopment in children: Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime version (K-SADS-PL-5), the Social Responsiveness Scale (SRS), The Children's Communication Checklist-2 (CCC-2), The Autism-Tics, ADHD and Other Comorbidities Inventory (A-TAC), CONNERS-3, Sensory Profile 2 (DUNN)~Psychopathological profile of the child by evaluating the presence of psychotic symptoms: K-SADS-PL-5, Prodromal Questionnaire (F PQ16)~Presence of mood and anxiety disorders: Child Depression Inventory (CDI), Revised Children's Manifest Anxiety Scale (RCMAS)~Presence of sleep disorders: Children's Sleep Habits Questionnaire (CSHQ). The K-SADS-PL-5 will only be completed by subjects who have attempted suicide after the start of the study; it requires a semi-structured interview of the child by a child psychiatrist and cannot be done remotely. The other scales will be completed by all included subjects."
75322753|NCT03335540|Drug|IDO1 Inhibitor|Specified dose on specified day
75322754|NCT03335540|Radiation|Radiation Therapy|Specified dose on specified day
75322755|NCT05265494|Device|Non invasive neuromodulation NESA (XSIGNAL device)|"The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions).~• The skin must be clean, free of creams and grease, lectrodes are connected to the control console and the targeting electrode located in over the intervertebral area between C7 and T1 (cervical area) and will follow the central treatment pattern with the following combination:~2 sessions: Program 1 (30 min), Program 7 (15min) and Program 8 (15min).~4 sessions: Program 2 (15min), Program 7 (30 min) and Program 8 (15min)~4 sessions: Program 7 (60min)"
75627818|NCT05450354|Other|Questionnaire|Determination of attachment style : Adolescent Relationship Scale Questionnaire (ARSQ). The questionnaire will be completed only once.
75627819|NCT05446571|Drug|Letermovir|Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
75322756|NCT04278638|Radiation|IORT|IORT in surgery of laryngocarcinoma
75322757|NCT04278638|Procedure|surgery|total laryngectomy or hemilaryngectomy
75627820|NCT05446571|Drug|Valacyclovir|Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
75627821|NCT05446298|Drug|ONC-392|ONC-392 will be given by IV infusion, q3w.
75627822|NCT05446298|Drug|Pembrolizumab|Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
75627823|NCT05445037|Device|hemodynamic continuous monitoring|Continuous monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to assess cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
75627824|NCT05445037|Device|Standard Monitoring|Standard monitoring will be done with non-invasive blood pressure, heart rate, NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, axillary temperature, BIS value. In addition, patients will use Clearsight, but the device will be blind to the anesthesiologist. Pressure monitoring will be every 5 min.
75627825|NCT05443126|Drug|EP0031|EP0031 is a potent next-generation selective RET-inhibitor (SRI)
75627826|NCT05435495|Procedure|Single-photon emission computed tomography|Imaging procedure
75627827|NCT05435495|Procedure|Blood Draw|Blood draw for future research tests (45-60 mL).
75627828|NCT05435495|Procedure|Tumor Biopsy|Guided biopsy of lesion
75779697|NCT00041132|Drug|vincristine|1.4 mg/m^2 on days 5 and 12 of cycles 1,3,5,7
75779698|NCT01102322|Behavioral|Quality|Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
75779699|NCT01105364|Drug|antiangiogenesis therapy|
75779700|NCT01105364|Drug|stabilized sulphur hexafluoride microbubble-based contrast agent|
75779701|NCT01105364|Other|imaging biomarker analysis|
76074443|NCT04385056|Biological|MSCTC-0010|MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
76074444|NCT04576741|Behavioral|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
75322758|NCT04278638|Radiation|External radiotherapy|External radiotherapy
75322759|NCT05255822|Drug|INNA-051|Liquid for intra-nasal administration
75322760|NCT05255822|Other|Placebo|Liquid for intra-nasal administration
75467366|NCT01919476|Other|Almond Butter|
75779702|NCT01105364|Other|pharmacological study|
75779703|NCT01105364|Procedure|computed tomography|
75779704|NCT01105364|Procedure|magnetic resonance imaging|
75779705|NCT00040742|Dietary Supplement|ginger|Given orally
75322761|NCT05514470|Other|Skin biopsy|"A skin biopsy performed on the forearm or thigh depending on the patient's age and wishes, with a biopsy punch with a diameter of 3 to 4 mm depending on the child's age (3 for children under 3 years, 4 beyond).~Culture of fibroblasts and immortalization."
75322762|NCT00643097|Biological|PEP-3 vaccine|Given intradermally
75322763|NCT00643097|Biological|sargramostim|Given intradermally
75322764|NCT00643097|Drug|Temozolomide|Standard of care chemotherapy
75322765|NCT03333668|Drug|Lisdexamfetamine dimesylate|Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet
75322766|NCT03333668|Drug|Guanfacine Extended Release Oral Tablet|Guanfacine Extended Release (0.05mg/kg) tablet
75322767|NCT03333668|Drug|Placebo|Vitamin C (10mg) tablet
75467367|NCT01919502|Device|Semi-quantitative urine pregnancy test|
75467368|NCT01919515|Device|ZR Crown|This is an esthetic primary molar crown.
75467369|NCT01919515|Device|Stainless Steel Crown|This is a conventional stainless steel crown.
75467370|NCT01919528|Procedure|ultrasound|catheterization of the axillary vein under ultrasound guidance
75779706|NCT00040742|Other|placebo|Given orally
75779707|NCT05189210|Drug|GV1001 Placebo|0.9% normal saline
75779708|NCT05189210|Drug|GV1001 0.56mg|Lyophilized peptide from hTERT
75779709|NCT05189210|Drug|GV1001 1.12mg|Lyophilized peptide from hTERT
76074445|NCT04576741|Behavioral|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
76074446|NCT01619579|Device|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
76074447|NCT01736215|Drug|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
75322768|NCT03280160|Drug|Ibrutinib 140 MG Oral Capsule [Imbruvica]|"Ibrutinib will be administered orally 420 mg (3 x 140 mg capsules) once daily on a continuous schedule on an outpatient basis until disease progression or unacceptable toxicity.~After 12 cycles of ibrutinib, patients that do not achieve a complete response (CR) will be treated with the combination of ibrutinib and ofatumumab. Patients in CR after 12 cycles of ibrutinib will continue with ibrutinib alone.~Ofatumumab will be administered by IV infusion, 300mg on Day 1 and 1,000 mg on Day 8 of cycle 13, followed by 5 monthly infusions of 1,000 mg (Day 1 of subsequent 28-day cycles for cycles C14, C15, C16, C17, and C18).~A treatment cycle will be defined as lasting 28 days"
75322769|NCT05502146|Drug|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
75627829|NCT05431777|Drug|Avelumab|As provided in real world setting
75779710|NCT00040664|Drug|ritonavir|ritonavir oral capsules or oral solution
75779711|NCT00040664|Drug|fosamprenavir|fosamprenavir oral suspension or tablet
75779712|NCT03947372|Procedure|Appendectomy|removal of acutely inflamed appendix
75779713|NCT02952586|Drug|Avelumab|Avelumab + SOC Chemoradiation
75915545|NCT01223248|Radiation|IGIMRT 27 Gy in 3 fractions|Pts in both the hypofractionated & single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI & DCE-MRI pretreatment for both arms & within 1 hour after their initial treatment for single fraction pts, & within one hour of their initial & final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule & MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, & approximately 24 hours [MCPG2.3]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
75322770|NCT05502146|Drug|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
75779714|NCT02952586|Other|Chemoradiation|Cisplatin + Radiation Therapy
75779715|NCT03949946|Procedure|Magnetic resonance imaging (MRI)|MRI scan uses radio waves in a magnetic field to obtain images of the breast. It is non-invasive and participants will not be exposed to harmful radiation. An image contrast agent will be used to enhance image clarity. Participants will be scanned lying face-down on a specially-designed bed and ear protectors will be provided to screen out background noise.
75322771|NCT05502146|Drug|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.
75322772|NCT05502146|Drug|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
75322773|NCT02302365|Device|Spectra Optia® Apheresis System|White Blood Cell Depletion
75467371|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
75779716|NCT03950102|Radiation|SBRT|Radiation dose of 27.5-50Gy in 5 fractions over 5-14 days with a radical dose as high as achievable based on mean liver dose (MLD), while fulfilling the dose constraints of OARs
75779717|NCT01096628|Other|Chiropractic + Exercise|"Treatment will include eight to 16 treatments provided over the 12-week period. Each treatment visit will last from 10-20 minutes and consist of manual spinal manipulation and mobilization. Light soft tissue techniques (i.e., active and passive muscle stretching, hot and cold packs, and ischemic compression of tender points) will be used as indicated to facilitate the manual therapy.~Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise."
75779718|NCT01096628|Other|Exercise|Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
75779719|NCT03949790|Procedure|ESPB and Intercostal nerve block|Erector spinae plane block + Intercostal nerve block
75779720|NCT03949790|Procedure|Intercostal nerve block|Intercostal nerve block
75779721|NCT01096706|Drug|NO clamp|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
75915546|NCT01190644|Drug|Sotatercept|single 35 mg SC dose of sotatercept on study Day 1, Day 43, and Day 85
76074448|NCT04384900|Procedure|Prone position ventilation|Patients are placed in a prone position using specialized equipment.
76074449|NCT03808714|Behavioral|TOUCHDOWN|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
75322774|NCT04027361|Drug|Amphetamine Extended Release (ER) Tablet 20 mg|A single 20 mg dose of amphetamine ER Tablet, orally administered
75322775|NCT04682847|Drug|Ferumoxytol injection|This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
75322776|NCT04024085|Other|completion of the test created Time to be Ready to Void|completion of the test created (Time to be Ready to Void) The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate
75779722|NCT01096706|Drug|Saline|"After a 20 minute saline washout, incremental doses of Urocortin 2, Urocortin 3 and Substance P (in doses as per Protocol 2) will be infused in the presence of saline placebo.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
75779723|NCT01096706|Drug|Fluconazole|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of Fluconazole (which serves to inhibit the EDHF pathway) that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
75779724|NCT01096706|Drug|Aspirin|"Oral Aspirin (600mg stat) will be administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of saline.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
75915547|NCT01187485|Drug|Androderm® 2.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
75915548|NCT01187485|Drug|Androderm® 5.0mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
75627830|NCT05409495|Procedure|periodontal surgical procedure (open flap debridement)|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed The IBD area in the control group was closed without applying any material. Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
75915549|NCT01187485|Drug|Androderm® 7.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
75322777|NCT04011839|Drug|Levobupivacaïne|Use of Levobupivacaïne instead ropivacaïne
75322778|NCT04878380|Device|Fitbit|A consumer sleep tracker will be used to monitor sleep patterns throughout the study
75915550|NCT01185158|Drug|ZD1839 (IRESSA)|ZD1839: 250mg/day po or via g-tube Q 24 hours
75322779|NCT04878380|Behavioral|Sleep education tips|Sleep tips will be provided before the intervention phase
75322780|NCT04878380|Behavioral|Goal-setting|During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.
75915551|NCT01177761|Procedure|physical exercise|Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
75322781|NCT03793439|Drug|Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial|Tofacitinib 5mg oral table twice daily for 16 weeks
75322782|NCT03793439|Diagnostic Test|Spirometry|Spirometry testing at baseline, week 4, week 8, week 12, and week 16
75322783|NCT03793439|Genetic|RNA Sequencing|RNA sequencing test at baseline and week 16
75322784|NCT03793439|Diagnostic Test|Laboratory testing|Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
75322785|NCT03793439|Drug|Corticosteroid|Taper corticosteroids starting at week 4
75322786|NCT03793439|Drug|Tofacitinib 5mg [Xeljanz] 1 year open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
75322787|NCT04672083|Drug|CPT31|CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
75322788|NCT04672083|Drug|Placebo|matching placebo
75322789|NCT00687167|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
75322790|NCT00687167|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
75322791|NCT04277780|Device|Continuous Glucose Monitoring Sensor|Placement of continuous glucose monitor sensor for 14 days. Instructions on how to peel off the sensor and mail it back to the clinician.
75322792|NCT04277780|Other|Diabetes Management Instructions|Instructions on checking fingerstick blood glucose and information on the required equipment including glucose test strips, lancets, and glucometer. Instructions on how to log blood glucose values onto the blood glucose log sheet for 14 days, and how to mail it back to the clinician.
75779725|NCT01096706|Drug|Combined|"Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.~This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.~Blood samples are taken as per previous arms."
75915552|NCT01172470|Drug|Gemcitabine|4 doses of induction chemotherapy every 2weeks, IV (in the vein)
75322793|NCT05208554|Behavioral|Integrated health counseling and step prescription|8 weekly dyad-based sessions with a health counselor to train couples in the use of communal coping strategies to support one another in achieving physical activity goals plus individualized step prescription based on remotely-monitored Fitbit-derived step counts the week prior
75322794|NCT00687713|Drug|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
75322795|NCT00687713|Other|Placebo|Placebo
75322796|NCT02304159|Drug|daclatasvir|
75627831|NCT05409495|Procedure|periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed (Figure 2a). The blood supply of the defect areas was taken into account. At the test site, IBDs were filled with T-PRF and T-PRF membranes were adapted over the defects both buccally and lingually, in addition to OFD (Figure 2b). Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
75627832|NCT05407285|Drug|cannabis 0 mg, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
75627833|NCT05407285|Drug|Cannabis 20 mg,|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
75779726|NCT03949712|Device|Transcranial Static Magnetic Field Stimulation (tSMS)|tSMS consists of a small compact cylindrical neodynium magnet (S-45-30-N, Supermagnete) with an estimated strength of up to 0.5 Tesla and a size of 30 mm x 45 mm.
75915553|NCT01172470|Drug|Pemetrexed|"Induction Chemotherapy:~4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.~Chemoradiotherapy:~Day 1,22, and 43through IV infusion over a period of 10 minutes"
75915554|NCT01172470|Drug|Carboplatin|"Chemoradiotherapy:~Day 1, 22 and 4 through IV infusion over a period of 1 hour."
75915555|NCT01167270|Behavioral|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
75915556|NCT01167270|Behavioral|Parenting Insights|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
75915557|NCT01085617|Biological|palifermin|
75915558|NCT01085617|Biological|rituximab|
75915559|NCT01085617|Drug|cyclophosphamide|
75915560|NCT01085617|Drug|cytarabine|
75915561|NCT01085617|Drug|daunorubicin hydrochloride|
75915562|NCT01085617|Drug|etoposide|
75915563|NCT01085617|Drug|fludarabine phosphate|
75915564|NCT01085617|Drug|imatinib mesylate|
75915565|NCT01085617|Drug|melphalan|
75915566|NCT01085617|Drug|mercaptopurine|
75915567|NCT01085617|Drug|methotrexate|
75322797|NCT02304159|Drug|Sofosbuvir, Sovaldi|
75467372|NCT01919541|Device|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
75915568|NCT01085617|Drug|nelarabine|
75915569|NCT01085617|Drug|pegaspargase|
75915570|NCT01085617|Drug|vincristine sulfate|
75915571|NCT01085617|Procedure|allogeneic hematopoietic stem cell transplantation|
75915572|NCT01085617|Radiation|total-body irradiation|
75915573|NCT00849290|Biological|APC8015F|APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
75915574|NCT00674479|Drug|INCB018424|Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
75915575|NCT00606866|Drug|placebo|Placebo for four weeks
75915576|NCT00606866|Drug|Sorafenib|Sorafenib 200 mg twice daily
75915577|NCT00606866|Drug|Sorafenib|Sorafenib, 400 mg twice daily
75915578|NCT00594542|Drug|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
75915579|NCT00580580|Drug|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
75915580|NCT00580580|Drug|Definity|intravenous injection at 0.05-0.20 mL
75915581|NCT00580580|Drug|PESDA|intravenous injections dosage 0.05-0.20 mL
75915582|NCT00564291|Other|Examination with an OCT device|
75322798|NCT02304159|Drug|Ribavirin|
75467373|NCT01919541|Device|hyperinsulinemic euglycemic hyperaminoacid clamp|
76074450|NCT03808714|Behavioral|Control Group|Alabama Quitline
76074451|NCT05743114|Device|Elemind Neuromodulation (ENMod)|The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
76074452|NCT01786603|Drug|Rasagiline|Rasagiline 2mg once a day for 12 months.
76074453|NCT01786603|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
75322799|NCT02143973|Drug|nalbuphine HCl ER|nalbuphine HCl ER
75627834|NCT05407285|Drug|Cannabis 50 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
75627835|NCT05407285|Drug|Cannabis 100 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
75779727|NCT03949712|Device|Sham Transcranial Static Magnetic Field Stimulation (tSMS)|Sham tSMS consists of a small compact metal cylinder, identical in appearance to the real tSMS device.
76074454|NCT00786916|Drug|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
75779728|NCT01102400|Drug|MEDI-575|MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
75322800|NCT04400240|Behavioral|CALLS|The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
75322801|NCT03028701|Drug|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
75779729|NCT01102478|Drug|losartan potassium / hydrochlorothiazide|100 mg / 25 mg tablet
75322802|NCT02267655|Drug|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
75779730|NCT05555368|Other|Quality of Recovery Score|Descriptive
75915583|NCT00542451|Drug|Paclitaxel|Every week for 12 weeks
75915584|NCT00542451|Drug|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
75915585|NCT00506493|Device|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
75915586|NCT00506493|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
76074455|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
76074456|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
76074457|NCT03802708|Diagnostic Test|Metabolomic analysis urine sample|a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
75322803|NCT02267655|Drug|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
75322804|NCT02267655|Drug|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
75779731|NCT01105520|Procedure|Diagnostic|SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
75779732|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (ascending dose), daily for 14 days
75779733|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (optimized dose), daily for 28 days
75779734|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (20 mg), daily for 14 days
75779735|NCT03384316|Biological|ETBX-051; adenoviral brachyury vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
75779736|NCT03384316|Biological|ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
75779737|NCT03384316|Biological|ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
75467374|NCT01919541|Dietary Supplement|whey protein supplementation|
75322805|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
75627836|NCT05407285|Drug|Cannabis 200 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
75467375|NCT01919541|Other|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
75779738|NCT01584752|Procedure|Gore-BioA Fistula Plug|Gore-BioA Fistula Plug
75779739|NCT01584830|Drug|Regorafenib (BAY73-4506)|Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
75915587|NCT00478712|Other|Identification of genetic causes of Hirschsprung Disease|Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
75915588|NCT00397163|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation
75915589|NCT00397163|Procedure|Placebo|Deflated cuff on upper arm and thigh for 20 min
75915590|NCT00368082|Biological|TGFbeta resistant LMP-specific CTLs|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10^7 cells/m2 Day 14 2 x 10^7 cells/m2~Group Two:~Day 0 6 x 10^7 cells/m2 Day 14 6 x 10^7 cells/m2~Group Three:~Day 0 1.5 x 10^8 cells/m2 Day 14 1.5 x 10^8 cells/m2"
75915591|NCT00336232|Drug|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
75915592|NCT00153075|Device|Berodual Respimat|
75915593|NCT00153075|Device|Berodual HFA-MDI|
75915594|NCT00131235|Drug|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points."
75915595|NCT00131235|Drug|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
75915596|NCT00131235|Drug|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
75915597|NCT04161638|Behavioral|Stigma Video Exposure|The participants watched a 10 minute video on a computer screen that consisted of brief clips from popular television shows that depicted women with overweight and obesity and evoked negative weight-based stereotypes (e.g., clumsy, loud, and lazy). Both the high blood pressure and normal blood pressure arms participated in this intervention.
75915598|NCT04161638|Behavioral|Neutral video exposure|The participants watched a 10 minute video on a computer screen that consisted of a series of clips depicting neutral scenes (e.g., insurance commercials). Both the high blood pressure and normal blood pressure arms participated in this intervention.
75915599|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
75915600|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
75915601|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
75467376|NCT01919554|Biological|SLIT tablets of HDM allergen extracts|
75467377|NCT01919593|Drug|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
75467378|NCT01919593|Drug|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
75627837|NCT05395221|Other|Guided Mediation Virtual Reality App|Guided Meditation Virtual Reality App uses over 40 lush environments with 30 hours of guided meditations on Anxiety, Depression, Maternity, Resilience, Sleep, or Zen and 200 relaxing audio tracks using Virtual reality.
75627838|NCT05394519|Drug|Cagrilintide|Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
75627839|NCT05394519|Drug|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) once-weekly
75779740|NCT01584830|Drug|Placebo|Placebo will be given 3 weeks on/1 week off (160 mg od po.)
75779741|NCT01105676|Procedure|skin biopsy|Two skin biopsies will be taken one time
75779742|NCT03403192|Device|EZ-Blocker|"The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation."
75779743|NCT03403192|Device|DLT|A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.
75779744|NCT03944642|Behavioral|Breastfeeding support|Breastfeeding self-efficacy enhancing through professional support
75627840|NCT05394519|Drug|Placebo cagrilintide|Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
75322806|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
75322807|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
75627841|NCT05394519|Drug|Placebo semaglutide|Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
75627842|NCT05391737|Diagnostic Test|Echocardiography|Echocardiography after swimming (acute) and at rest (baseline)
76074458|NCT04414267|Biological|BCG vaccine|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
75627843|NCT05391737|Diagnostic Test|Electrocardiogram (ECG)|Electrocardiogram (ECG) after swimming (acute) and at rest (baseline)
75779745|NCT01328210|Procedure|blood letting|blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
75627844|NCT05391737|Diagnostic Test|Cardiac biomarkers|high sensitive (hs)-Troponin I and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after swimming (acute) and at rest (baseline)
75627845|NCT05380544|Device|Extracorporeal Shockwave Therapy|ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
75627846|NCT05379166|Drug|Azacitidine|Given IV
75627847|NCT05379166|Other|Quality-of-Life Assessment|Ancillary studies
75627848|NCT05379166|Other|Questionnaire Administration|Ancillary studies
75779746|NCT03709420|Drug|Placebo|Placebo capsule to match active drug
75779747|NCT03709420|Drug|FOR-6219|FOR-6219 capsule
75915602|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
75915603|NCT02504580|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam) by injection.
75915604|NCT02504580|Drug|Placebo|Saline placebo by injection.
76074459|NCT04414267|Biological|Placebo|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
76074460|NCT01619423|Drug|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
76074461|NCT01619423|Drug|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
75627849|NCT05379166|Drug|Venetoclax|Given PO
75779748|NCT04958096|Device|Standard Therapeutic Deep Brain Stimulation|DBS to the standard subcortical targets (anterior limb of the internal capsule- ALIC) will be used to treat OCD
75779749|NCT04958096|Device|Cortical Stimulation for PFC|Patients enrolled in this study will have a second pair of leads placed in the prefrontal cortex (PFC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
75779750|NCT04958096|Device|Cortical Stimulation for ACC|Patients enrolled in this study will have a second pair of leads placed in the anterior cingulate cortex (ACC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
75779751|NCT04940156|Device|Confirm Rx (Implantable Cardiac Monitor)|Confirm Rx implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
75915605|NCT02504580|Drug|HTX-002|HTX-002, by injection or instillation (pooled).
75915606|NCT02504580|Drug|Bupivacaine HCI (Marcaine)|Bupivacaine HCI (Marcaine) by injection.
75915607|NCT02504580|Drug|HTX-011A|HTX-011A (bupivacaine/meloxicam) by injection.
75915608|NCT02504580|Drug|HTX-011B|HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
75915609|NCT02504580|Drug|HTX-009|HTX-009 by injection and instillation (combination).
75915610|NCT02235402|Drug|Lacidipine|
75915611|NCT02235402|Drug|Bendrofluazide|
75915612|NCT02235402|Drug|Placebo|
76074462|NCT01619423|Drug|PledOx (10 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
75915613|NCT02501304|Device|ReVENT Sleep Apnea System|The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
75779752|NCT04940156|Device|Reveal LINQ (Implantable Cardiac Monitor)|Reveal LINQ implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
75779753|NCT02529800|Drug|HIP1402|Tamsulosin HCl 0.4mg
75779754|NCT02529800|Drug|HGP0412|Tamsulosin HCl 0.2mg
75779755|NCT01105832|Drug|Teriparatide|Teriparatide (Forsteo) 20 micrograms daily during four weeks
75915614|NCT02484378|Drug|CER-001|Engineered pre-beta HDL particle
75915615|NCT02484378|Drug|Placebo|Normal saline
75915616|NCT02235480|Drug|Experimental Tazarotene Gel|
75915617|NCT02235480|Drug|Placebo|
75779756|NCT01105910|Other|Systane Ultra Lubricant Eye Drops|1 to 2 drops in each eye 4 times per day for 30 days
75322808|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
75915618|NCT02235558|Drug|Verapamil|Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
75915619|NCT04237350|Behavioral|Video recording for behaviors|"A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded."
75915620|NCT04220112|Procedure|Real-Time Functional Magnetic Resonance Imaging (RT-fMRI)|RT-fMRI neurofeedback targeting down-regulation of the amygdala
76074463|NCT01619423|Drug|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
75467379|NCT01919632|Behavioral|health-behavior seminar and endurance exercise|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
75627850|NCT05378373|Behavioral|Garmin, Pattern Health App|Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
76074464|NCT03802552|Drug|Cefadroxil|oral one-time dose of cefadroxil
75779757|NCT01105910|Other|Sensitive Eyes Eye Drops (Bausch & Lomb)|1 to 2 drops in each eye 4 times per day for 30 days
76074465|NCT03802552|Drug|Cephalexin|oral one-time dose of cephalexin
75467380|NCT01919645|Other|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
75467381|NCT01919658|Procedure|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
75627851|NCT05365958|Behavioral|HIV Podcast for Heterosexual African American Adults|"The video podcast will deliver HIV prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, & live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
76074466|NCT01735279|Drug|Omega 3|Each fish oil capsule contained 210.99 mg of EPA and 129.84 mg of DHA.
76074467|NCT01735279|Drug|Placebo|mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
76074468|NCT03802786|Drug|Imeglimin|Single administration dose of imeglimin
76074469|NCT03808792|Diagnostic Test|Ultrasound, CT and WB-DWI/MRI|Preoperative assessment with Ultrasound, CT and WB-DWI/MRI
76074470|NCT01759381|Device|Negative pressure wound therapy (NPWT)|
76074471|NCT03802318|Drug|Rabeprazole|Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
76074472|NCT04662671|Device|RD-X19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
76074473|NCT01758523|Drug|Dutasteride|
75779758|NCT03949322|Behavioral|Adapted Physical Activity Program|The sessions in this program are similar to the adapted physical activity sessions already offered by sports therapy practitioners. This is an aerobic exercise session, with Nordic walking, and a combined session of muscle building and breathing exercises.
75779759|NCT03949400|Other|Exercise therapy and education.|Exercise therapy and education, physiotherapy rehab at Aalborg Municipality
75779760|NCT01102634|Device|Transcutaneous electrical nerve stimulation (TENS)|Application of TENS over acupuncture points
75779761|NCT01102634|Device|Transcutaneous electrical nerve stimulation (TENS)|Placebo
75779762|NCT01105988|Other|Radiologic exams|FLT PET scan x 2 MRI scan x 2
75779763|NCT03946982|Procedure|low thoracic epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces
76074474|NCT01758523|Drug|sugar pill|
76074475|NCT00773422|Drug|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
75779764|NCT03946982|Procedure|lumbar epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces (conventional)
75779765|NCT03944564|Behavioral|Sitting|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
75915621|NCT04220112|Procedure|Sham Procedure|RT-fMRI with feedback non-contingently tied to their activation patterns (activation patterns from a prior participant)
75915622|NCT04214418|Drug|Cobimetinib|(40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2
75915623|NCT04214418|Drug|Hydroxychloroquine|(600mg) orally twice daily on days 1-28 of each 28-day cycle
75915624|NCT04214418|Drug|Atezolizumab|840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)
76074476|NCT00773422|Drug|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
75779766|NCT03944564|Behavioral|Static standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
75467382|NCT01919671|Drug|Tongxinluo capsule|for 90 days
75627852|NCT05353556|Device|Inspiratory Muscle Training (IMT)|The IMT protocol will consist of home-based high-intensity daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 50% of each patient's maximal inspiratory pressure measured every week and was adjusted weekly based on the modified Borg scale from 4 to 6 regarding respiratory effort performed during the session.
75779767|NCT03944564|Behavioral|Dynamic standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
75779768|NCT01102712|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
75915625|NCT02233608|Behavioral|Advanced Pelvic Floor Muscle Exercise (APFX)|
75915626|NCT02233686|Drug|XEN-D0501|
76074477|NCT00773422|Drug|placebo|placebo
75915627|NCT02233686|Drug|Placebo|
75915628|NCT02233764|Other|FeZnPM|Iron and zinc biofortified pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
76074478|NCT00786994|Drug|Oleogel-S10 100 mg/g|topical use once or twice daily
76074479|NCT00786994|Drug|Placebo (petroleum jelly)|topical use once or twice daily
76074480|NCT01757821|Device|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
75467383|NCT01919671|Drug|placebo capsule|for 90 days
75467384|NCT01919684|Drug|LGD-6972|
75467385|NCT01919684|Drug|Placebo (Captisol®)|
75627853|NCT05353556|Device|Sham IMT|The IMT protocol will consist of home-based daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to the lowest intensity of the IMT Threshold device.
75627854|NCT05317728|Device|BAL-FAIOL IOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
75915629|NCT02233764|Other|CtrlPM|Conventional pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
76074481|NCT01757821|Device|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
76074482|NCT01757821|Device|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
76074483|NCT00774202|Drug|Rituxan, Cyclophosphamide, Vincristine, Prednisone|'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
75467386|NCT01919710|Drug|rHSA/GCSF|for treatment of neutropenia
75915630|NCT02233920|Drug|Ventilat® - metered dose inhaler|
75915631|NCT02234076|Behavioral|VRET|
75915632|NCT02234076|Behavioral|TAU|Treatment as usual offered by the participating mental health care organisations
75915633|NCT02471898|Drug|HTX-011|
75915634|NCT02471898|Drug|Placebo|Saline
75915635|NCT01626378|Drug|TRx0237|TRx0237 100 mg tablet will be administered twice daily.
75915636|NCT01626378|Drug|Placebo|Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
75915637|NCT02263404|Device|Deep Brain Stimulation|DBS Implant Stimulation
76074484|NCT00774202|Drug|Higher Dose of Rituximab|rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
76074485|NCT01735201|Drug|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
75467387|NCT01919736|Behavioral|Gait Retraining|
75467388|NCT01919788|Drug|Insulin (Insuman Rapid)|
75467389|NCT01919788|Drug|Glucose|
75467390|NCT01919788|Other|Saline|
75467391|NCT01919827|Biological|Endobronchial infusion of adult mesenchymal stem cells|
75467392|NCT01919827|Biological|Autologous mesenchymal stem cells derived from bone marrow|
76074486|NCT01735201|Drug|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
76074487|NCT01735201|Drug|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
76074488|NCT01735201|Drug|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
75322809|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
75322810|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
75627855|NCT05317728|Device|Monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
75779769|NCT00356525|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
75779770|NCT00356525|Drug|gemcitabine|1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
75467393|NCT01919840|Procedure|Group ROTEM|"10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.~If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected."
75627856|NCT05317728|Procedure|Cataract surgery|Phacoemulsification with a clear cornea incision
75627857|NCT05308953|Drug|NVG-291|NVG-291 is a drug injected under the skin (subcutaneous).
75627858|NCT05308953|Other|Placebo|Salt water is being used as a placebo and will be injected under the skin (subcutaneous).
75627859|NCT05304377|Drug|ELVN-001|orally once daily
75915638|NCT02234154|Device|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
75627860|NCT05296603|Drug|IBI-322 Plus Lenvatinib|"IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg"
75627861|NCT05296278|Drug|IBI-323 combined with bevacizumab plus Platinum|IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression
75627862|NCT05293717|Drug|Ruxolitinib|1.5% Ruxolitinib cream
75627863|NCT05292248|Behavioral|Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving|Multicomponent psychoeducational intervention focused on financial wellbeing
75779771|NCT00356525|Drug|carboplatin|area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
75779772|NCT00356525|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
75915639|NCT03723954|Device|ECG Holter SpiderFlash-t|"Record at visit V0 (day without match) and the competition days (Visit V1, V2 et V3) during the matches the heart rate of the golf fans.~SpiderFlash-t™ from MicroPort is a long-lasting event recorder set in walking position by the investigator the day of the record and it is activated by detecting rhythm anomalies. This recorder is a Class IIA medical device (according to European Economic Community Directive 93/42). It benefits from European Economic marking."
75915640|NCT03723954|Device|Actigraph GT3Xp|"Record the study participant's physical activity while we record his heart rate.~The GT3Xp based activity monitors provide objective measurements of human activity and are used in many research and clinical applications. It includes a micro-electro-mechanical system (MEMS) based accelerometer and an ambient light sensor. It benefits from CE marking and FDA agreement (Class II medical device)."
75915641|NCT02235948|Drug|folic acid supplementation|0.8mg folic acid/day
75915642|NCT02236026|Drug|Supratherapuetic dose of Nestorone|
76074489|NCT05742880|Other|Wearing a mask|6 Minute walking test while wearing a Mask
75779773|NCT01106066|Drug|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
75779774|NCT01327898|Behavioral|empowerment theory-based small group discussion|four small group discussion sessions followed by one individual counseling session
75779775|NCT01327898|Behavioral|individual resilience counseling|one individual resilience counseling session
75779776|NCT02533739|Behavioral|Cognitive and neuropsychological assesment|
75779777|NCT03946592|Drug|Normal saline|Inject the Drug into submental fat via subcutaneous
76074490|NCT03808324|Diagnostic Test|Diagnostic investigations|Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.
76074491|NCT01734811|Biological|Biological vaccine|daily spray (2 puff of 100 µL) for six months
76074492|NCT03802006|Diagnostic Test|Ultrasound assessment of gastric content|Ultrasound assessment of gastric body is performed
76074493|NCT03808168|Drug|Nivolumab|Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
76074494|NCT03802162|Drug|CKD-355A (D797/Memantine HCl 20mg)|once a day
75467394|NCT01919840|Other|Group C|"10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.~If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result."
75467395|NCT01919853|Behavioral|Mindfulness-Based Stress Reduction|
75467396|NCT01919853|Behavioral|Attention Control|
76074495|NCT03802162|Drug|CKD-355B (D797/Memantine HCl 20mg)|once a day
76074496|NCT03802162|Drug|D797|once a day
75627864|NCT05287906|Other|Water|Each subject will receive one control and three treatments in the crossover design. The control contains water only.
75627865|NCT05287906|Other|Glucose|Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.
76074497|NCT03802162|Drug|D324 (Memantine HCl 10mg)|twice a day
76074498|NCT01757275|Drug|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
76074499|NCT01757275|Drug|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
75322811|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
75322812|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
75467397|NCT01919866|Other|Transplantation of CD3/CD19 depleted stem cells|
75467398|NCT01919879|Drug|Cetuximab + Afatinib|Afatinib taken orally, cetuximab administered intravenously
75467399|NCT01919879|Drug|Cetuximab|Cetuximab administered intravenously
75467400|NCT01919892|Drug|Lithium|
75467401|NCT01919905|Dietary Supplement|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
75627866|NCT05287906|Other|Steviol Glycosides|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.
75627867|NCT05287906|Other|Steviol Glycosides plus glucose|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.
75627868|NCT05287906|Other|Rebaudioside A|A leaf-based, extracted stevia product to compare to the Eversweet in the normal weight group only. The Rebaudioside A contains water and rebaudioside A.
75627869|NCT05287646|Device|Suction Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system inactive (traditional suction). Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system active.
75467402|NCT01919918|Drug|Muscle Contraction with Metabolite Solution Administration|Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
75467403|NCT01919944|Drug|VLY-686|capsules containing either 10 mg or 50 mg VLY-686
75915643|NCT02236026|Drug|Placebo|
76074500|NCT01757275|Drug|Esomeprazole Mg|40 mg tablet once daily for 27 days
76074501|NCT00787852|Drug|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily~Maintenance x 2 years*"
75467404|NCT01919944|Drug|Placebo|Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
75467405|NCT01919957|Other|No intervention|
75779778|NCT03946592|Drug|DWJ211|Inject the Drug into submental fat via subcutaneous
75779779|NCT03944408|Procedure|stent implantation|stent implantation
75779780|NCT01052129|Drug|Naproxen sodium|Naproxen Sodium Tablets 550 mg
75779781|NCT03991325|Diagnostic Test|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
75915644|NCT02236026|Drug|Moxifloxacin|
75915645|NCT02236104|Device|Plethysmography opto electronic|
75779782|NCT01053377|Drug|Tamiflu (verum)|
75779783|NCT01053377|Drug|Tamiflu placebo|
75915646|NCT02236104|Procedure|respiratory parameters|
75915647|NCT03973866|Device|Alfapump|Implantation of alfapump
76074502|NCT00787852|Drug|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily Maintenance x 2 years*"
75627870|NCT05287646|Device|Elevated Vacuum Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system active. Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system inactive.
75627871|NCT05287568|Drug|Venetoclax|Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with > 1,000-fold higher affinity to BCL-2 (Ki < 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki > 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
75322813|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
76074503|NCT01757197|Drug|Toclizumab|8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
76074504|NCT00788008|Drug|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
75322814|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
75322815|NCT04858958|Drug|Furmonertinib 160mg|randomized to 160mg QD
75322816|NCT04858958|Drug|Furmonertinib 240mg|randomized to 240mg QD
75467406|NCT01920009|Behavioral|Pharmacist counselling session with a motivational interview|"The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication"
75467407|NCT01920022|Drug|Mifepristone|Day one of medical abortion
75627872|NCT05287568|Drug|CC-486|An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.
75627873|NCT05285228|Behavioral|effect of choice on cooperation (pseudoalternative)|For the test group, before the standard check-up starts, the participant is given the choice of selecting the taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint), which will be applied at the end of the visit. Post-placement instructions provided by the manufacturer will be given to the caregiver and the child and questionnaires will be handed out.
75467408|NCT01920022|Drug|etonorgestrel|
75467409|NCT01920074|Drug|Nitroglycerin Ointment 0.4%|
75627874|NCT05285228|Behavioral|given fluoride varnish (control)|For the control group the participant is provided with a given taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint) according to the randomization list.
75779784|NCT03946904|Device|Er,Cr:YSGG Laser|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
75779785|NCT03991559|Drug|Manganese Chloride|Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
75779786|NCT03991559|Drug|Anti-PD-1 antibody|Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
75779787|NCT03991559|Combination Product|Systemic therapy|Whether and which should be given depends on the treatment regimen before enrollment.
75779788|NCT03949634|Drug|PLD|pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
76074505|NCT00760006|Drug|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
76074506|NCT00760006|Other|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
75779789|NCT03949634|Drug|CTX|cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
75779790|NCT03949634|Drug|Docetaxel|docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
75779791|NCT03949634|Drug|Paclitaxel|paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
75779792|NCT03949634|Drug|Doxorubicin|doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
75915648|NCT03970902|Other|Integrated Osteoporosis Care|Complex intervention in family physicians, primary caregivers, patients, informal caregivers. The intervention has a patient-tailored implementation. Family physicians: postgraduate education on osteoporosis management and integrated care, educational material. Primary care stakeholders (nurses, pharmacists, dietitians, physiotherapists): specialist training on patient-support in osteoporosis management with attention towards self-management support (nurses), treatment adherence and administration (pharmacists), fall risk, weight-bearing exercises, balance training and fear of falling (physiotherapists) and anti-inflammatory nutrition with sufficient calcium, vitamin D and protein intake (dietitians). Patients: patient-tailored complex intervention consisting of: education, support consultation(s)/telephones from an osteoporosis nurse, a pharmacist, a physiotherapist and nutritional a dietitian. Informal caregivers: education on supporting osteoporosis self-management.
75627875|NCT05279664|Other|Remote ischemic conditioning (RIC) + Standard of Care for NEC|RIC will consist of 4 cycles of limb ischemia (5 min) followed by reperfusion (5 min), repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure. Neonates in this arm will continue to receive standard of care for NEC.
75627876|NCT05279664|Other|Standard of Care for NEC|Neonates in this arm (i.e. the control arm) will receive standard of care for NEC.
75627877|NCT05273320|Drug|Nabilone|Nabilone capsules at a maximum dose of 1 mg twice a day
75627878|NCT05264779|Other|Periviable GOALS DST|An iPad application that contains outcomes information, values clarification and embedded short documentary style videos. The tool was designed with low-literacy and low-numeracy populations in mind, and utilizes graphics and video content to enhance meaning-making of complex medical information and jargon. The GOALS DST refers patients back to their physicians to discuss specific treatment options, local outcomes, and management strategies available to them. The DST's content focuses largely on helping patients better understand the choice they have between comfort care and life-sustaining efforts in the context of periviable delivery.
75627879|NCT05256225|Drug|Carboplatin|Given IV
76074507|NCT01784965|Drug|liraglutide|Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
76074508|NCT01784965|Drug|Placebo|Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
76074509|NCT05742724|Drug|Tetrahydrocannabinol-Cannabidiol Combination|Oral THC 0.1mg/kg and CBD 2.5mg/kg
76074510|NCT01784419|Drug|ivacaftor|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
76074511|NCT01784419|Drug|Placebo|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
76074512|NCT03801850|Device|3D surface scan|measurement of inter fractional deformations by surface scanning
76074513|NCT03808246|Other|using the demo version of a self-injector pen|Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.
76074514|NCT01784029|Drug|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
76074515|NCT00789256|Drug|Melphalan|Melphalan: 2mg orally, once daily
76074516|NCT00789256|Drug|Bortezomib|Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11
76074517|NCT00789256|Drug|Melphalan and bortezomib|
76074518|NCT01733329|Drug|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
76074519|NCT01733329|Drug|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
76074520|NCT01783483|Device|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
76074521|NCT01783483|Device|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
76074522|NCT02145676|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
75322817|NCT04102293|Procedure|NSK Endo motor Endomate|Rotary instrumenation used in pulp therapy
75322818|NCT04102293|Procedure|manual K-files|manual instrumentation used in pulp therapy
75322819|NCT00690833|Drug|topical desonide hydrogel 0.05%|apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
75627880|NCT05256225|Procedure|Echocardiography|Undergo ECHO
75627881|NCT05256225|Drug|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
75627882|NCT05256225|Procedure|Multigated Acquisition Scan|Undergo MUGA
75627883|NCT05256225|Drug|Paclitaxel|Given IV
75627884|NCT05256225|Other|Quality-of-Life Assessment|Ancillary studies
75627885|NCT05256225|Drug|Trastuzumab/Hyaluronidase-oysk|Given SC
76074523|NCT02145676|Drug|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
75627886|NCT05248880|Drug|AGN-151586|Intramuscular Injection
75322820|NCT02110641|Behavioral|Weight Loss Counseling|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
75322821|NCT04349553|Biological|ZH9PA and ZH9|150mL vaccine for oral administration
75322822|NCT04349553|Biological|Placebo|150mL vaccine for oral administration
75627887|NCT05248880|Drug|Placebo|Intramuscular Injection
75627888|NCT05245474|Combination Product|Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)|Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
75627889|NCT05233605|Drug|Dexmedetomidine|"Dexmedetomidine will have been administered at the end of sedation in the ICU to prevent or treat delirium after post-COVID-19 ARDS.~This drug was administered in accordance with its MA, as part of care, prior to inclusion in the protocol 24 months (+24 months) and independently of it."
75627890|NCT05232032|Drug|Nociceptin Receptor Antagonist|Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.
75627891|NCT05232032|Device|Aversive stimuli|As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
75627892|NCT05227222|Device|PEP-device|PEP-device
75627893|NCT05216146|Other|Strength and Conditioning|A specially designed strength and conditioning program will be delivered for a period of 6 months from the experienced strength and conditioning coaches. The program will consist of the basic aerobic and anaerobic exercises that could be practiced without additional equipment and with own body weight.
75627894|NCT05209295|Drug|Onureg|Specified dose on specified days
75322823|NCT04349553|Biological|ZH9PA|150mL vaccine for oral administration
75627895|NCT05204888|Device|myAirvo3|For patients assigned to the HFNT intervention group, a myAirvo 3 device will be provided. The myAirvo 3 is for the treatment of spontaneously breathing patients, infant to adult, who would benefit from receiving high flow warmed and humidified respiratory gases. This includes patients who have had upper airways bypassed. The flow may be from 2 - 60 L/min depending on the patient interface. The myAirvo 3 is for patients in homes and long-term care facilities.
75627896|NCT05204888|Device|Pulse oximeter|A pulse oximeter will be provided to measure heart rate and pulse oximetry; subjects will enter and transmit the data on the smartphone once daily before 11AM. Heart rate and pulse oximetry measures will be taken after wearing the device for approximately 2 minutes.
75627897|NCT05204381|Device|Theta-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.
75627898|NCT05204381|Device|Theta-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.
75627899|NCT05204381|Device|Arrhythmic near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.
75627900|NCT05204381|Device|Arrhythmic independent stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
75915649|NCT03970902|Other|Care As Usual|No intervention Patients receive care as usual from their family physician
75915650|NCT02236182|Drug|Ipratropium Bromide low dose|
75915651|NCT02236182|Drug|Placebo|
75915652|NCT02236182|Drug|Ipratropium Bromide high dose|
75915653|NCT03010904|Other|Dietary intervention|
76074524|NCT01607593|Drug|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
76074525|NCT00789724|Drug|Anakinra|100 mg daily subcutaneous injection for 14 days
76074526|NCT00789724|Drug|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
76074527|NCT01755637|Drug|Albendazole|Albendazole tablets 400 mg
75467410|NCT01920165|Other|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
75467411|NCT01920360|Other|SULPHUROUS WATERS IMMERSION BATHS|SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
75915654|NCT03466892|Other|Questionnaires and computer paradigm|Patients will complete different scales and also the visual probe task. First, we hypothesize the attention bias for pain-related information in the FM group is correlated with the level of negative repetitive thinking in the maintained attention phase. Second, we hypothesize the attention bias is more important in the attention maintenance phase (1250 ms) than in the attention orientation phase (500 ms).
76074528|NCT03801538|Drug|Peginterferon Alfa|Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
76074529|NCT03801538|Drug|Nucleoside Analog (Substance)|Patients do not need to change their NAs treatment.
75915655|NCT04453280|Diagnostic Test|Quantitative analysis of anti-SARS-CoV-2-antibodies|Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
76074530|NCT03801226|Drug|Two-hour dwell with 10% dextrose in sterile water|Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
75779793|NCT01052285|Procedure|Transversus abdominis plane block|UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
76074531|NCT03801226|Drug|Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose|Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
76074532|NCT02145754|Other|MKP media|one half of skin specimen was put in MKP media
76074533|NCT02145754|Other|BSK-H media|one half of skin specimen was put in BSK-H media
76074534|NCT03837808|Drug|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
76074535|NCT03837808|Drug|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
76074536|NCT05741398|Device|VR system by Demaod|non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
75627901|NCT05204381|Device|Alpha-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.
75467412|NCT01920360|Other|NOT SULPHUROUS WATERS IMMERSION BATHS|NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
75627902|NCT05204381|Device|Alpha-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
75779794|NCT01052285|Procedure|Saline|UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
75779795|NCT01052285|Procedure|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
75779796|NCT03944330|Dietary Supplement|standard hospital diet|patients were provided standard hospital diet that provided 25-30 kcal/kg/day
75779797|NCT04713800|Device|Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR-TiB)|In group ZR-TiB the implant impressions will be taken using an intra-oral scanner and the respective scanbody. The restorations will be manufactured by means of CAD/CAM procedures using monolithic zirconia. For sufficient aesthetics, the zirconia restorations can be manually veneered with veneering ceramic only at the buccal surface, while the occlusal surface will remain monolithic and will be high-gloss polished. The zirconia restorations will be extra-orally cemented onto titanium base abutments (Straumann® Variobase® for crown, Straumann AG), correctly polished and delivered to the patient, by screw-retention onto the implant.
75915656|NCT04453280|Diagnostic Test|SARS-CoV-2 diagnostic rapid test|The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
75915657|NCT04453358|Device|InCourage-Connect|This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.
75915658|NCT04453358|Device|InCourage|This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
76074537|NCT05739838|Device|Biolase ;Low Level Laser|Low Level laser ,940 nm
76074538|NCT03801070|Procedure|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
76074539|NCT05596708|Drug|Telitacicept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.
76074540|NCT01732549|Drug|Tasquinimod|A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
75915659|NCT01328756|Drug|Lisdexamfetamine dimesylate|Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
76074541|NCT01732549|Drug|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
76074542|NCT04383964|Device|Distraction Osteogenesis for Reconstruction of Ramus-Condyle|transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
76074543|NCT02148874|Biological|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
76074544|NCT01755091|Drug|Dronabinol|
76074545|NCT01755091|Drug|Placebo (for Dronabinol)|
76074546|NCT00789802|Drug|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
76074547|NCT00789802|Drug|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
76074548|NCT00789802|Drug|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
76074549|NCT04567225|Drug|Early Glargine|A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion
76074550|NCT04567225|Drug|Late Glargine|A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.
76074551|NCT04567225|Other|IV insulin infusion|Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
75322824|NCT04831190|Behavioral|Tailored Exercise Intervention|The exercise program to be implemented for neuro-oncology patients will combine aerobic, resistance, balance, and flexibility exercises delivered in one-to-one setting (i.e., personal training) twice per week, for 12 weeks. Based on needs and preferences, participants will have the option to join a circuit-type group class once per week in place of one of their personal training sessions. During COVID-19, all sessions will be delivered remotely. If facilities are open and deemed safe for cancer patients, participants will have the option to attend an in-person session, integrated in the community. Whether delivered in-class or remotely, the intervention will follow exercise progression principles (i.e., frequency, intensity, time, type, overload, and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs, with aims of promoting wellness and physical function. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
75322825|NCT04078269|Biological|Dendritic cell immunotherapy|Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
75467413|NCT01920360|Other|CONTROL GROUP|CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
75779798|NCT04713800|Device|porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM-GA)|In group PFM-GA implant impression will be taken using a polyvinyl siloxane or polyether impression material in a conventional manner with the use of stock trays and corresponding impression copings. The framework will be manufactured by the lost wax-technique using a gold-abutment (Straumann® Gold abutment for crown, Straumann AG) and a gold-alloy. All metal frameworks will be manually veneered with veneering ceramic, polished and glazed, and delivered to the patient, by screw-retention onto the implant.
75467414|NCT01920412|Device|LAmbre Left Atrial Appendage(LAA) Occluder|Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
75467415|NCT01920516|Drug|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
75467416|NCT01920698|Device|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
75627903|NCT05200208|Dietary Supplement|Citicoline supplement|Participants with AD will receive a dietary citicoline supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A & B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
75779799|NCT01108874|Drug|Metaraminol|Patients will be given metaraminol every time SBP falls below baseline value.
75779800|NCT00356369|Biological|meningococcal ACWY (vaccine)|One intramuscular dose.
75779801|NCT00356369|Biological|Mencevax™ ACWY|One subcutaneous dose.
75322826|NCT04078269|Biological|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIXNEO-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
75467417|NCT01920698|Other|control|
75467418|NCT01920750|Biological|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
75467419|NCT01920750|Biological|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
75467420|NCT01920750|Other|Mock Antigen|Physiological saline
75467421|NCT01920763|Other|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
75627904|NCT05200208|Other|Placebo|Participants with AD will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A & B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
75779802|NCT03383614|Drug|LSF emodepside (BAY 44-4400) or matching placebo|Emodepside administered as an LSF oral solution (1mg/mL)
75779803|NCT03403036|Drug|Brodalumab|Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.
75779804|NCT00356135|Drug|prasugrel 10 mg|10 mg tablet taken orally
75779805|NCT00356135|Drug|clopidogrel|75 mg tablet taken orally
75779806|NCT00356135|Drug|prasugrel placebo|oral, as blinding mechanism.
75779807|NCT00356135|Drug|prasugrel 60 mg|60 mg (six 10-mg tablets) taken orally
75915660|NCT03466580|Behavioral|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
75915661|NCT03130322|Other|Imagery and Sleep questionnaires|Participants complete a motor imagery questionnaire to assess their ability to form vivid mental images, as well as sleep questionnaires to control the quality of their sleep
75467422|NCT01920984|Drug|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
75779808|NCT00356135|Drug|clopidogrel placebo|oral, as blinding mechanism
75779809|NCT01053455|Device|SiPAP|biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
75779810|NCT01052363|Drug|Bevacizumab, CA4P|
75467423|NCT01921283|Device|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
75467424|NCT01921283|Drug|no- BIS sensor attachment|
75322827|NCT04078269|Biological|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
75322828|NCT00644657|Drug|Clopidogrel|All subjects will receive a 300 mg loading dose
75322829|NCT05154890|Drug|Pegtarviliase IV|Administered IV
75322830|NCT05154890|Drug|Pegtarviliase SC|Administered SC
75467425|NCT01921374|Biological|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
75467426|NCT01921374|Biological|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
75627905|NCT05194917|Other|Older Smoker Motivational Intervention|OSMI identified in Aim 2 of the study, motivational interventions will be delivered via mailer with QR video code.
75627906|NCT05194917|Other|Control Motivational Message|"One control motivational message with a standard health- and EBST access-related content (i.e., Quitting smoking is the best thing you can do for your health. Call 1-800-QUIT-NOW for help.), motivational interventions will be delivered via mailer with QR video code."
75627907|NCT05194514|Device|SherpaPak™ Device|The SherpaPak™ Cardiac Transport System has been developed to provide a safe, consistent method for cold ischemic storage of donor hearts for transplantation. This device is FDA approved.
75627908|NCT05194514|Other|Cold Storage|FDA-approved method for organ procurement
75627909|NCT05188248|Device|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
75779811|NCT03383146|Drug|Placebo|Placebo injected subcutaneously twice daily.
75779812|NCT03383146|Drug|Relamorelin|Relamorelin 10 μg injected subcutaneously twice daily.
75779813|NCT01053533|Drug|Chinese herbal medicines plus western therapy|injections of Chinese herbal medicines and Chinese herbal medicines decoction& supportive therapy and antivirus therapy when necessary
75779814|NCT01053533|Drug|western therapy|supportive therapy and antivirus therapy when necessary
75915662|NCT03130322|Other|MEG recordings (pre-test)|"Participants of the Day group perform two motor tasks (a finger sequential motor task and an adaptation motor task using a trackball) in the MEG, during a pre-test (Day 1 - 9h).~Task 1: Participants perform an 8-digit motor sequential task where each finger (except the thumb) is used twice. Performance is assessed by using a 4-keys keyboard. Participants are required to keep their fingers on the keys to minimize amplitude are instructed to tap the sequence as few errors as possible Task 2: Participants perform a motor adaptation task requiring scrolling a trackball to superimpose a geometric shape on another one, strictly similar but presented from another angle, as fast as possible."
75915663|NCT03130322|Other|Practice session|Participants of the Day group perform a block of motor imagery practice of the two motor tasks.
75915664|NCT03130322|Other|MEG recordings (Post-test)|Participants perform the two motor tasks in the MEG (post-test, strictly similar to the pre-test)
76074552|NCT04567225|Other|IV fluid and electrolytes replacement|The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
75779815|NCT03989921|Other|no intervention. observational study|no intervention. observational study
76074553|NCT04384510|Procedure|Planned Cesarean hysterectomy|This procedure refers to planned delivery of the fetus through Cesarean incision, leaving the placenta in situ and proceeding with hysterectomy
75322831|NCT00645047|Behavioral|Telemedicine CBT|Use of Videoconfrence Technology To Provide Cognitive Therapy
75322832|NCT00645047|Behavioral|In-Person CBT|In-Person Provision Of Cognitive Therapy
75322833|NCT04613024|Drug|Topamax|Experiment randomized group will be prescribed Topamax before and after surgery with follow up at regular interval
75322834|NCT04613024|Drug|Gabapentin|Control group will be prescribed gabapentin after surgery with follow up at regular interval
75322835|NCT04819334|Other|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
75467427|NCT01921374|Biological|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
75467428|NCT01921374|Biological|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
75779816|NCT01052519|Other|Goal directed fluid therapy|Fluid will be administered to reach maximal stroke volume during the intraoperative period.
75779817|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|remifentanil 0 ng/ml
75467429|NCT01921374|Biological|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
75915665|NCT03130322|Other|MRI|The registration of the brain anatomy of each participant will be done by MRI 3D / T the week before the first experimental session.
76074554|NCT04384510|Procedure|Conservative management|This term describes a single or combined intervention of uterine artery ligation, internal iliac artery ligation, prophylactic balloon placement in the aorta or internal iliac artery, uterine artery embolization, compression sutures, or excision and reconstruction of uterine wall
75467430|NCT01921972|Drug|Galantamine CR|24 mg/day with dose-titration over twelve weeks
75322836|NCT00645827|Other|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
75467431|NCT01921972|Drug|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
75467432|NCT01921972|Drug|Placebo|Placebo will be similar in appearance to Memantine
75467433|NCT01922362|Device|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
75467434|NCT01922362|Device|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
75467435|NCT01922414|Device|Laser|Patients will undergo laser lithotripsy durin PNL
76074555|NCT01754467|Behavioral|NEAT!|Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
75627910|NCT05176977|Behavioral|Peer Support-Whole Health Coaching|Participants will meet with a Peer Specialist for 18 sessions over a period of 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist and 2) a structured Whole Health Coaching curriculum.
76074556|NCT01753999|Device|Standard CPAP|Use of the REMstar Auto A-Flex in standard CPAP therapy mode
75627911|NCT05171166|Procedure|HAIC|Hepatic arterial infusion chemotherapy is consist of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 would be intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
75779818|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
75779819|NCT01053611|Drug|propofol + remifentanil 4 ng/ml|
75915666|NCT03466268|Drug|Glumetinib for tablet|Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
76074557|NCT01753999|Device|CPAP - Flex|Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
76074558|NCT02149342|Drug|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
75467436|NCT01922414|Device|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
76074559|NCT02149342|Drug|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
76074560|NCT03800446|Diagnostic Test|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
75467437|NCT01922830|Dietary Supplement|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
75467438|NCT01922830|Dietary Supplement|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
75467439|NCT01922882|Behavioral|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
75627912|NCT05171166|Procedure|TACE|A standard hepatic artery catheter would be introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery would be performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply, the proportion of the liver supplied by each artery would be estimated by the arteriography. After optimal positioning of the catheter, cTACE or DEB-TACE protocol would be performed to embolize the tumor supplying artery blood flow until the stasis of the supplying artery.
75627913|NCT05171166|Drug|FOLFOX|oxaliplatin,leucovorin, and 5-FU
75627914|NCT05171166|Drug|cTACE or DEB-TACE|lipiodol or microspheres that mixed with EPI
75779820|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
75779821|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|
75779822|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
75779823|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
75779824|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
75779825|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|
75779826|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
75779827|NCT01053611|Drug|propofol + remifentanil 4 ng/ml|
75915667|NCT02206334|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
75915668|NCT05326178|Other|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
76074561|NCT03800368|Other|Exercise|Indoor cycling exercise intervention
75322837|NCT00645827|Other|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
75322838|NCT04816604|Drug|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
75322839|NCT04816604|Device|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) delivery
75322840|NCT01799447|Behavioral|Early intervention|Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
75322841|NCT04746482|Procedure|single visit root canal retreatment|cases that were subject to root canal retreatment performed in single visit
75467440|NCT01923168|Drug|alpelisib|BYL719 + Letrozole
75467441|NCT01923168|Drug|buparlisib|BKM120 + Letrozole
75627915|NCT05171166|Drug|Donafenib|200 mg of donafenib (consisting of two 100-mg tablets) twice daily.
75627916|NCT05169346|Behavioral|Active Closed Loop Real Time fMRI Neurofeedback|Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
75627917|NCT05169346|Behavioral|Sham Closed Loop Real Time fMRI Neurofeedback|Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
75627918|NCT05166187|Other|Best Practice Advisory|Patients in this arm will have a Best Practice Advisory displayed in the Electronic Medical Record (EMR) as part of the discharge order workflow.
76074562|NCT03800368|Other|Non-exercise|Psycho-education
76074563|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
75467442|NCT01923168|Drug|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
75627919|NCT05149755|Device|Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)|Patients will have a Transcatheter Aortic Valve Replacement (TAVR) with either an Evolut PRO+ TAVR, or Evolut FX TAVR, heart valve, and given clinical site-determined guideline-directed management and therapy (GDMT).
76074564|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
75322842|NCT04399850|Other|Hypnosis group|Patients who receive hypnosis
75322843|NCT01933815|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
75467443|NCT01923454|Procedure|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
75627920|NCT05144542|Procedure|Participants smoke their usual brand of cigarettes for 26 weeks.|Participants smoke their usual brand of cigarettes for 26 weeks.
75627921|NCT05144542|Procedure|Participants will vape electronic cigarettes for 26 weeks.|Participants will vape electronic cigarettes for 26 weeks.
75467444|NCT01923454|Drug|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
75467445|NCT01923454|Procedure|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
75467446|NCT01923519|Procedure|bronchofiberscopy|
75467447|NCT01923688|Other|Informatics Alert/Nurse/physician responders|
75627922|NCT05144542|Drug|Nicotine Replacement|Smoke usual brand of cigarettes
75627923|NCT05144542|Drug|Nicotine Replacement|Vape e-cigarettes
75627924|NCT05144542|Other|Questionnaire Administration|Use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day.
75779828|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
75779829|NCT03712072|Device|Magnetoencephalography (MEG)|The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.
76074565|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
76074566|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
76074567|NCT01782859|Drug|Prednisone|
76074568|NCT01782859|Drug|Hydrocortisone|
76074569|NCT01782859|Drug|Placebo (for Prednisone)|
76074570|NCT05723536|Procedure|Partial Left Atrial Isolation|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
76074571|NCT05723536|Procedure|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
76074572|NCT05718622|Device|real EECP|Real EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 150 millimeters of mercury.
76074573|NCT05718622|Device|sham EECP|Sham EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 75 millimeters of mercury.
76074574|NCT01782313|Drug|tivozanib|Given PO
76074575|NCT01782313|Other|laboratory biomarker analysis|Correlative studies
76074576|NCT04575259|Drug|ANAVEX2-73|Oral capsules
75322844|NCT01933815|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
76074577|NCT00790192|Drug|Lurasidone|Lurasidone 80 mg tablets
75322845|NCT02144519|Behavioral|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
75627926|NCT05132400|Behavioral|Psychological-informed Physical Therapy (PiPT) Training|An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
75627927|NCT05131022|Drug|NX-5948|Oral NX-5948
75627928|NCT05130138|Other|Pharmaceutical intervention|Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.
75627929|NCT05114798|Behavioral|Time restricted eating|daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
75627930|NCT05114798|Behavioral|Calorie Restriction|daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
75627931|NCT05113251|Drug|Trastuzumab Deruxtecan|administered by intravenous infusion
75627932|NCT05113251|Drug|Paclitaxel|administered by intravenous infusion
75627933|NCT05113251|Drug|Trastuzumab|administered by intravenous infusion
75627934|NCT05113251|Drug|Pertuzumab|administered by intravenous infusion
75779830|NCT03712072|Device|Electroencephalography (EEG)|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp.
75779831|NCT03712072|Device|Transcranial Magnetic Stimulation (TMS)|The device will be used for motor mapping. Motor threshold is operationally defined as minimum machine output necessary to elicit a response from the abductor pollicis brevis right (APB), contralateral to the stimulated hemisphere, of 50 microvolts, on >50% of trials. Upper limb motor mapping is conducted at 110% abductor pollicis brevis motor threshold in each hemisphere, or at 100% machine output (MO). Lower limb motor mapping is conducted at a fixed machine output corresponding to the magnitude sufficient to elicit reliable tibialis anterior (TA) motor evoked potentials (MEPs). Single pulse TMS is performed while motor evoked potentials are recorded bilaterally from the APB, deltoid, and TA using surface electromyography (EMG).
75779832|NCT03616964|Drug|Baricitinib|Administered orally.
75779833|NCT03616964|Drug|Placebo|Administered orally
76074578|NCT00790192|Drug|Lurasidone|Lurasidone 4 40 mg tablets
76074579|NCT00790192|Drug|Quetiapine XR|Quetiapine XR 600mg
76074580|NCT00790192|Drug|Placebo|Matching Placebo to Lurasidone or Quetiapine
76074581|NCT01781611|Drug|extended release dipyridamole 200mg/aspirin 25mg|one tablet twice daily for 24 weeks
76074582|NCT01781611|Drug|81mg aspirin|half a tablet twice daily for 24 weeks
75322846|NCT03480971|Drug|Tempol|Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
75322847|NCT03480971|Drug|Placebo Solution|The placebo contains the same excipients as the active product plus FD&C Yellow #6 for color matching.
76074583|NCT00777634|Other|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
75627935|NCT05113251|Drug|Doxorubicin|administered by intravenous infusion
75627936|NCT05113251|Drug|cyclophosphamide|administered by intravenous infusion
75627937|NCT05104073|Behavioral|Intervention|Provided with educational materials, guidelines and instructions.
75627938|NCT05103605|Drug|Osimertinib|Single arm treated by osimertinib
76074584|NCT01781299|Device|AlloDerm RTU|
75627939|NCT05099679|Behavioral|Cognitive behavioral therapy (supportive counseling)|Patients will complete a psychosocial intake that generally takes up to 2 hours, but the time required for the intake varies per patient. Subsequently they will be offered up to 7 optional counseling sessions with a clinical social worker
75627940|NCT05099679|Behavioral|Virtual Cardiac Rehabilitation|If eligible, patients will be referred to Movn Health Virtual Cardiac Rehabilitation to provide approximately 3 exercise sessions per week, with approximately eight coaching sessions over a 12 week period
76074585|NCT01781299|Device|SurgiMend PRS|
76074586|NCT01732471|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
76074587|NCT00790270|Drug|Cyclobenzaprine|5 mg orally every 8 hours as needed
76074588|NCT00790270|Drug|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
76074589|NCT00790270|Drug|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
76074590|NCT01780987|Drug|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
76074591|NCT01780987|Drug|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
76074592|NCT01780987|Drug|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
76074593|NCT00790738|Drug|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
76074594|NCT00790738|Drug|placebo|placebo
76074595|NCT03800290|Drug|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
75627941|NCT05099640|Drug|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
75627942|NCT05099640|Drug|Placebo|Placebo matching to PTC923
75627943|NCT05096949|Other|Home visit delivery strategy|A nurse will deliver and administer Cabenuva injection at patient's home
75627944|NCT05093556|Behavioral|iCHART - Interactive CBT for Headache And Relaxation Training|IVR based cognitive behavioral therapy for headache
75627945|NCT05090566|Drug|Elranatamab + Nirogacestat|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
75627946|NCT05090566|Drug|Elranatamab + lenalidomide + dexamethasone|BCMA-CD3 bispecific antibody + immunomodulatory
76074596|NCT03800290|Drug|Placebos|Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
75627947|NCT05088395|Other|Blood sample|Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples taken per patient for up to 24 months.
75627948|NCT05088395|Other|Biopsy|If a specific tumor sample is required, it will be collected only once during the study
75627949|NCT05081843|Behavioral|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
75627950|NCT05081843|Behavioral|Usual health education curriculum|The schools' regular health education curriculum includes classroom lectures, hands on activities and group work.
75627951|NCT05076175|Drug|Ozanimod|Specified dose on specified days
75627952|NCT05064709|Device|Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.
75627953|NCT05064709|Device|OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
75627954|NCT05063032|Other|Radiofrecuency ablation|Radiofrequency ablation to treat left atrial flutter, guided by high-density mapping versus linear ablation.
75627955|NCT05059392|Behavioral|Training for Awareness, Resilience and Action (TARA)|See arm description
75627956|NCT05047731|Drug|Antihypertensive medication|Antihypertensive medication will be deprescribed to a blood pressure of 140 ±5 mmHg following the study algorithm.
75627957|NCT05047198|Procedure|Control - Catheter Ablation for VT|"Currently standard of care involves surgical resection of myocardial scarring in structural heart disease. Imaging is performed to identify culprit areas for ablation, pre procedural imaging involves echocardiography, CT scanning and PET imaging to assess cardiac function, ischemia, inflammation and scarring. Radiofrequency energy is delivered via catheter to the targets and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. A conventional approach will be used advancing multiple catheters via femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, scar, identified during endocardial mapping. CA procedures for VT are often long, averaging approximately 5 hours ."
75779834|NCT01208714|Drug|Optimal medical therapy|"Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c < 6.5%)."
75779835|NCT01208714|Procedure|revascularization|The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
75779836|NCT00350519|Drug|Epoetin alfa|Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
76074597|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
76074598|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75322848|NCT05148806|Diagnostic Test|self-administered lateral flow assays|The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.
75322849|NCT04399616|Other|Risk Map|The tool we test in this project (the visual hazard map) aims to enable the practitioner to quickly identify critical areas for systematically implementing relevant safe practices (appropriate for each situation).
75322850|NCT00646763|Drug|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
76074599|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75322851|NCT00646763|Drug|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
75627958|NCT05047198|Procedure|Treatment - Non-Invasive Radio Ablation for VT|Patients undergoing a non-invasive RA procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. A non-invasive electrophysiology study is performed under light sedation using ECGi mapping. This procedure requires only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the ECGi mapping system. The multimodal imaging data is digitally fused and combined with the ECGi data to identify the VT circuit(s) and to attain the targets for radio-ablation. This analogue process is performed off-line by a physician team. The treatment plan is sent for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators remotely. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.
75627959|NCT05034497|Drug|186RNL|"All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.~Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir."
75627960|NCT05029271|Device|InPen with Guardian 4 System|Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.
75627961|NCT05024773|Drug|ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)|Schedule: once a week for 12 consecutive weeks (induction phase). Patients who achieve a complete response at the end of the induction phase will enter the maintenance phase, during which ONCOFID-P-B is administered once a month for 12 months until recurrence or progression of the disease.
75627962|NCT05024513|Drug|oxaliplatin and 5-fluorouracil|Intra-arterial chemotherapy consisted of Oxaliplatin (40mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for22 hours) on days 1-3 every 4 weeks.
75627963|NCT05024513|Procedure|Biliary Drainage|External biliary drainage, or biliary stent placement; Biliary stent placement plus Iodine-125 seed strands is allowed
75627964|NCT05024513|Other|Best Supportive Care|Nutrition support, symptomatic treatment, and other supportive treatments
76074600|NCT05535478|Behavioral|STRIDE|a. Targeted providers for STRIDE program: i. Clinical staff at the LTCF who participate in deprescribing at the facilities (physicians (MDs), physician's assistants (PAs), nurse practitioners (NPs), clinical pharmacists): clinical staff members caring for LTCF residents with ADRD and diabetes at 6 LTCFs in the Ohio and Michigan areas will be invited via email from the LTCF leadership to participate in the STRIDE education program. The STRIDE program consist of practical algorithms and educational material, which they are free to view at any time, and participation in 2 webinars and monthly telementoring calls
76074601|NCT00808834|Device|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
76074602|NCT00808834|Device|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
75322852|NCT03237572|Drug|Pembrolizumab|Pembrolizumab (200 mg)
75627965|NCT05024513|Procedure|External biliary drainage|External biliary drainage
75627966|NCT05021250|Procedure|Lipiodol marking|HCC patients treated with TACE and the tumor marked with lipiodol.
75627967|NCT05020665|Drug|Entospletinib|400 mg, Orally as tablets
75627968|NCT05020665|Drug|Placebo|Orally as tablets
75627969|NCT05020665|Drug|Cytarabine|Continuous infusion
75627970|NCT05020665|Drug|Anthracycline|Either daunorubicin or idarubicin was administered via slow intravenous (IV) push
75779837|NCT00350519|Drug|Standard of Care|Participants will receive standard of care based on the Institution's treatment policy.
75779838|NCT01208792|Procedure|skin biopsy|The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
75322853|NCT03237572|Device|High-intensity focused ultrasound (HIFU)|Ablation will target 50% of the tumor, up to 3 cubic centimeters
75322854|NCT02986347|Procedure|Intravenous regional anesthesia (Bier)|Intravenous regional anesthesia (Bier Technique)
75322855|NCT02986347|Procedure|Local anesthesia with adrenaline|local anesthesia with adrenaline without limber garroting (Lalonde Technique)
75322856|NCT00649961|Drug|Melatonin injection|"A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr."
75322857|NCT05137028|Other|Otago Exercise|"Otago exercise protocol~Strengthening exercise:~Resistance exercise for knee flexors, knee extensors, hip abductor, ankle dorsiflexors, ankle planterflexors~Balance exercise:~knee bending, backward walking, walking and turning around, sideway walking, tendem stance, tendem walking, one leg stand, heel walking, toe walking, heel to toe walking, sit to stand, stair walking"
75627971|NCT05014893|Combination Product|multi-modal targeted intervention (e.g., cognitive training, exercise, games)|The Intervention group will be given recommended interventions tailored to individuals based on their risks (e.g., physical exercise programs, cognitive training, dietary advice, control of blood pressure and cholesterol, healthy diet, control obesity, stop smoking,reduce alcohol excess)
75627972|NCT04998318|Device|Pocket Colposcope|Both arms will receive treatment in order to prevent cervical cancer. However, the intervention using the pocket colposcope device will be used on half the enrolled subjects.
75627973|NCT04998318|Procedure|Standard of Care Colposcopy|VIA and VILI as previously described,
75779839|NCT01208792|Other|Blood Sample|a blood sample will be collected
75779840|NCT01053689|Drug|Glimepiride tablets 1 mg|
75779841|NCT03989765|Other|Programme to reduce involuntary treatment episodes|See description of trial arms
75779842|NCT01106612|Procedure|Coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
75915669|NCT05392634|Drug|Meropenem 1000 mg|Group B: prolonged antibiotic prophylaxis >72 hours (5 days) from the moment of the skin incision in accordance with the selected clinic drug + correction of the appointment based on clinical events after 5 days.
75915670|NCT05392634|Drug|Amoxicillin+clavulanic acid 1200 mg or Cefuroksim 1500mg|Group A: antibiotic prophylaxis within 24 hours from the moment of skin incision according to local clinical practice;
75915671|NCT05391386|Procedure|modified bonding technique|adding a layer of compomer adhesive at the molar/tube interface.
75915672|NCT03466190|Procedure|Titanium plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using conventional titanium plates will be performed.
75322858|NCT03235232|Drug|BREMEN eye drops|1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
75322859|NCT03235232|Drug|Combigan®|1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
75322860|NCT03344471|Other|Passation of questionnaires|Specific questionnaires (Perinatal PTSD Questionnaire evaluating the Post-Traumatic Stress Disorder) and (NEO-FFI evaluating personality)
75322861|NCT01781637|Drug|Omalizumab|subcutaneous injection
75322862|NCT01781637|Drug|placebo|subcutaneous injection
75322863|NCT04783142|Other|High-fiber, low-protein diet|Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.
75627974|NCT04994197|Other|Observational study only - no intervention|Observational study only - no intervention
75915673|NCT03466190|Procedure|Custom made PEEK plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using custom made PEEK plates will be performed.
75627975|NCT04982835|Device|M6-C Artificial Cervical Disc|An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed so that the M6-C artificial cervical disc can be placed into the space where the damaged disc was removed. This procedure will be performed using x-ray technology (fluoroscopy) guide the surgeon in placement of the M6-C in between the cervical vertebrae. This process will be repeated to replace the second damaged disc.
75627976|NCT04982835|Device|ACDF|One of four FDA-approved cervical plate systems will be used for the ACDF. An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed. Then, a piece of donor bone will be placed in the space where the damaged disc was removed and a metal plate will be screwed into the bones above and below the disc. This procedure will be performed using x-ray technology (fluoroscopy) to guide the surgeon in the placement of the cervical plate system. This process will be repeated to treat the other damaged disc.
75915674|NCT03922308|Other|Placebo|Participants will receive injection of placebo matched to SHP655.
75322864|NCT04783142|Other|Low-fiber, high-protein diet|Diet will consist of less than 15g fiber and greater than 18% of calories from protein
75915675|NCT03922308|Drug|SHP655|Participants will receive injection of SHP655.
75915676|NCT03922308|Other|Standard of Care|Participants will receive PEX as Standard of Care (SOC).
75915677|NCT02263482|Other|control|No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
75322865|NCT03330665|Behavioral|Meditation|Meditate 3 times a week using headspace app
75322866|NCT04349397|Behavioral|Medication Tracking Form|Parents will complete medication tracking form for 5 days after child's surgery. They will track medications administered, pain scores, nausea and vomiting
75322867|NCT04350099|Other|quetionnary|Participants will complete self-questionnaires at different times during the epidemic
75322868|NCT00652145|Drug|mesalamine|Increase dose by 2.4gm per day over baseline dose
75322869|NCT01618851|Radiation|Radiotherapy with IMRT and CyberKnife Boost|"Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.~The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.~For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions."
75322870|NCT03233126|Drug|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
75322871|NCT03241589|Other|Direct to patient facing mobile apps introduction|VA employees and Veterans begin use of OCC's direct to patient facing mobile app.
75627977|NCT04975997|Drug|Dexamethasone|Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
75627978|NCT04975997|Drug|Daratumumab|Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7 of a 28-day cycle
75627979|NCT04975997|Drug|Bortezomib|Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
75627980|NCT04975997|Drug|Iberdomide|Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
75627981|NCT04975997|Drug|Iberdomide|Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
75627982|NCT04975997|Drug|Iberdomide|Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
75915678|NCT02263482|Other|moderate-intensity group|Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
75915679|NCT02263482|Other|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
75915680|NCT02263560|Behavioral|Kinematic measurements|
75915681|NCT02264808|Other|Developmental Outcomes|A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
75322872|NCT03231722|Drug|Panitumumab|6 mg/kg iv over 60 minutes, day 1
75915682|NCT01593228|Drug|Iniparib (SAR240550/BSI-201)|"Pharmaceutical form:Solution~Route of administration: Intravenous"
76074603|NCT00809146|Drug|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
75779843|NCT01106612|Procedure|Myocardial perfusion imaging|Stress radionuclide myocardial perfusion imaging
75322873|NCT03231722|Drug|Irinotecan|150 mg/sqm iv over 60 minutes day 1
75779844|NCT01055561|Other|Acupuncture|Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
75779845|NCT01111448|Drug|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
75779846|NCT03382912|Biological|Pegilodecakin|Pegilodecakin plus Nivolumab
75779847|NCT03382912|Drug|Nivolumab|Nivolumab Alone
75779848|NCT03367286|Other|inspection mode|different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)
75915683|NCT01593228|Drug|Carboplatin|"Pharmaceutical form:Solution~Route of administration: Intravenous"
75915684|NCT01593228|Drug|Doxorubicin HCL liposome injection|"Pharmaceutical form:Solution~Route of administration: Intravenous"
75915685|NCT01593228|Drug|Gemcitabine|"Pharmaceutical form:Solution~Route of administration: Intravenous"
75915686|NCT01593228|Drug|Irinotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
76074604|NCT00809146|Drug|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
76074605|NCT00791908|Procedure|Electrodessication|Treatment applied to a third of the torso at each study visit.
76074606|NCT00791908|Procedure|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
75627983|NCT04965675|Drug|Eptinezumab|Eptinezumab will be administered per dose and schedule specified in the arm.
75627984|NCT04965675|Drug|Placebo|Placebo matching to eptinezumab will be administered per schedule specified in the arm.
75627985|NCT04941287|Biological|Atezolizumab|Given IV
76074607|NCT00791908|Procedure|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
75322874|NCT03231722|Drug|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
75322875|NCT03231722|Drug|l-leucovorin|200 mg/sqm iv over 2 hours
75322876|NCT03231722|Drug|5-fluorouracil|400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
75322877|NCT02298933|Drug|Eculizumab|300 mg single-use vials
75322878|NCT03163199|Device|Translesional Hemodynamic Measurement|Measurement of hemodynamics using the NAVVUS catheter during endovascular therapy
75627986|NCT04941287|Procedure|Biopsy|Undergo tumor biopsy
75627987|NCT04941287|Procedure|Biospecimen Collection|Undergo blood sample collection
75627988|NCT04941287|Drug|Cobimetinib|Given PO
75779849|NCT03942926|Drug|Sirolimus|Patients will receive sirolimus for 6 months.
75779850|NCT03942848|Drug|zicotinide followed by placebo|The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
75779851|NCT03942848|Drug|Placebo followed by zicotinide|The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
75779852|NCT00350207|Drug|Tiotropium bromide|
75779853|NCT00350207|Drug|Placebo|
75779854|NCT00350207|Drug|Salmeterol xinafoate|
75627989|NCT04941287|Procedure|Computed Tomography|Undergo a CT scan
75627990|NCT04941287|Procedure|Magnetic Resonance Imaging|Undergo MRI
75627991|NCT04941287|Drug|Varlilumab|Given IV
75779855|NCT03946826|Drug|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
75779856|NCT03946826|Drug|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
75779857|NCT03946826|Radiation|Pulsed dye laser (PDL)|Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis
75915687|NCT01593228|Drug|Paclitaxel|"Pharmaceutical form:Solution~Route of administration: Intravenous"
75915688|NCT01593228|Drug|Topotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
75915689|NCT02264886|Radiation|MRI-guided stereotactive body radiation therapy|
75915690|NCT02264964|Device|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
76074608|NCT05709184|Combination Product|Lyophilized fecal microbiome transfer|Five days of vancomycin followed by five days of lyophilized fecal microbiome transfer, administered in a loading dose of 15 capsules, and a daily maintenance dose of 10 capsules.
76074609|NCT05709184|Drug|Vancomycin|Ten days of oral vancomycin 125 mg four times daily
76074610|NCT00794170|Behavioral|Telephone and Print based intervention|Thiss intervention consisted of tailored phone calls and follow-up mailings.
75627992|NCT04934046|Other|Additional acquisition|Additional SPECT acquisition (30min added time approximately), with no added radiation
75915691|NCT02264964|Procedure|Arteriovenous fistula creation|500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
76074611|NCT03831334|Drug|oral minoxidil|Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
76074612|NCT04843774|Drug|SARS-COV-2 mRNA Vaccine|Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
76074613|NCT04383652|Other|Biological sample and clinical data collection|Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
76074614|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
76074615|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
76074616|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
76074617|NCT00809848|Drug|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
76074618|NCT00809848|Drug|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
75627993|NCT04924933|Diagnostic Test|Computerised associative memory task using abstract words and landscape photographs|Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
75627994|NCT04918355|Other|Clinical Decision Support (CDS) alerts|CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
75627995|NCT04906707|Device|EaseVRx|EaseVRx is a commercially available pain management program. It is a multi-modal, skills-based, 8-week, VR, mind-body approach to daily management of chronic pain that is designed for home use to be worn over the eyes. The program contains five types of modules that are as follows: Interoception, Education, 360-degree relaxation videos, Games, and Dynamic breathing. All program content is mapped to a therapeutically designed curriculum with weekly themes. The following core themes are infused into the curriculum: Acceptance, Attention shifting, Awareness, Rehabilitation, Self-compassion, Healthy Movement, Deep relaxation, Visualization, Knowledge of pain, Distraction, and Immersive enjoyment.
75627996|NCT04906707|Behavioral|Audio-only version of EaseVRx|Participants in the control group will be asked to use the audio-only version of EaseVRx, which excludes references to visual content, to complete 7 sessions weekly. They will receive an electronic link to the recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer.
75627997|NCT04903470|Drug|Bisacodyl|Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics
75627998|NCT04903470|Drug|Atropin|Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
75627999|NCT04903288|Genetic|Eladocagene Exuparvovec|Four 0.08 milliliters (mL) infusions at a dose of 0.45×10^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10^11 vg and a total volume of 320 μl per participant.
75628000|NCT04895696|Drug|Afimetoran|Specified dose on specified days
75628001|NCT04895696|Other|Placebo|Specified dose on specified days
75779858|NCT03711136|Procedure|aortic prosthesis|ascending aortic and/or aortic arch prosthesis with linear vascular prosthesis or hybrid prosthesis
75779859|NCT03946280|Procedure|conventional X-ray based Fluoroscopy|catheter tracking via conventional X-ray based Fluoroscopy
75915692|NCT02264964|Device|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
75915693|NCT02264964|Procedure|Arteriovenous fistula creation|900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
75915694|NCT02263638|Drug|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
75915695|NCT02236260|Procedure|Electroacupuncture|Acupuncture will be performed using an electrical stimulator (generating electrical stimulation) for electroacupuncture.
75779860|NCT03946280|Procedure|low X-ray 3D navigation technique|catheter tracking via low X-ray 3D navigation technique
75779861|NCT01311622|Drug|warfarin|2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
75779862|NCT01311622|Drug|fostamatinib|2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
75915696|NCT02236260|Drug|Local Anesthesia (lidocaine hydrochloride)|All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.
75915697|NCT01555554|Drug|Propranolol Hydrochloride|"Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol."
75628002|NCT04884945|Procedure|Open Pyeloplasty (OP)|Open approach for the surgical correction of UPJ obstruction
75779863|NCT04553120|Behavioral|Alternating single stimulus and multiple stimuli|"P-ARET for cockroach phobia alternating between two interventions: exposure to a single stimulus (always using the same projected cockroach) and exposure to multiple stimuli (different cockroaches in terms of number, shape, colour and movement). It will be counterbalanced to start the same number of participants in each of the two modalities. The two conditions will be randomly applied for each participant, with the restriction of that each condition will be applied 3 times.~There will be 6 weekly sessions of approximately 1 hour. The purpose of this exposure treatment is to confront patients to the phobic stimuli in a controlled manner, which favors the habituation process and allows them to accept that the negative consequences they fear do not actually occur. All exposure sessions should be recorded (patients will sign informed consent for recording prior to treatment initiation)."
75322879|NCT04349085|Device|Effective PBMT/sMF|A cluster with 20 diodes, manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used: 4 diodes of 905 nm (1.25 average power, 50 W of peak power for each diode), 8 diodes of 850 nm (40 mW of average power for each diode) and 4 diodes of 633 nm (25 mW average power for each diode). Effective PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The effective PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 270 J for knee extensors/hip flexors, 180 J for knee flexors/hip extensors, and 60 J for plantar flexors.
75467448|NCT01923701|Behavioral|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
75467449|NCT01923935|Drug|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)
75628003|NCT04884945|Device|Robotic-Assisted Laparoscopic Pyeloplasty (RALP)|Robotic approach with the da Vinci Surgical System for the surgical correction of UPJ obstruction
75322880|NCT04349085|Device|Placebo PBMT/sMF|A cluster manufactured by Multi Radiance Medical® (Solon, OH, USA) with 20 diodes will be used: Placebo PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The placebo PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
75628004|NCT04884152|Procedure|Home Exercise Group|Educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
75779864|NCT01053767|Biological|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P2 study."
75628005|NCT04884152|Procedure|Telerehabilitation Group|Telerehabilitation program combined with educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
75779865|NCT01053845|Other|Neuropathic pain|to study the working of down inhibitor bundle at patients suffering of neuropathic pain
75779866|NCT00349973|Drug|Dipyridamole|Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm
75779867|NCT00349973|Other|Olanzapine|Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm
75779868|NCT01106924|Other|Probiotic|daily probiotic consumption
75779869|NCT01106924|Other|Placebo|daily placebo consumption
75779870|NCT03989687|Device|Fuji Triage|glass ionomer sealant
75779871|NCT03989687|Other|isolation|rubber dam or cotton roll isolation
75467450|NCT01923935|Drug|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)
75779872|NCT03946436|Device|Active video games|Participants played the active video game Virtua tennis 4 on a playstation kinect device
75467451|NCT01923974|Drug|Melatonin 10 mg|
75467452|NCT01923974|Drug|Melatonin 100 mg|
75467453|NCT01923974|Drug|Placebo|
75628006|NCT04878952|Other|Garmin Vivofit Activity Tracker|Activity tracker that is worn on the wrist.
75628007|NCT04878328|Behavioral|Onsite Point-of-care|Guided by Social Cognitive Theory, O-PoC will employ CHWs with lived experience of incarceration to provide: 1) COVID-19 education; 2) SARS-CoV-2 testing with Cepheid XpertXpress PCR tests at Fortune facilities; 3) Needs assessments and facilitated access to masks and hygiene supplies; 4) Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters, or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5) Supportive counseling.
75628008|NCT04876248|Biological|Belantamab Mafodotin|Given IV
75628009|NCT04876248|Drug|Lenalidomide|Given PO
75779873|NCT03946436|Other|tennis training process|Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.
75915698|NCT01555554|Other|Placebo|"The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo."
75628010|NCT04871919|Drug|Filgotinib|Tablets are administered in accordance with the product label
75628011|NCT04869787|Device|Selective Cytopheretic Device|SCD in line with CRRT extracorporeal device
75915699|NCT03135600|Procedure|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk/run on the treadmill in barefoot at 4/6km/h.
75628012|NCT04854057|Other|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 4 times per week.
75628013|NCT04854057|Other|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 4 times per week.
75322881|NCT04746326|Procedure|Failure conservative treatment|Surgery was performed in patients who failed conservative treatment.
75628014|NCT04854057|Device|TESS - Transcutaneous Electrical Spinal Cord Stimulation + Functional Task Practice|Participants will receive transcutaneous electrical stimulation to the cervical spinal cord using the TESCoN device developed by SpineX, Inc. Training will consist of progressive functional task practice for upper extremity motor training. A total of 24 treatment sessions, which will last 45 minutes per session, will be completed in 3 weeks (4 days/week) per crossover arm.
75779874|NCT01053923|Other|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
75779875|NCT01107002|Procedure|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
75779876|NCT01111682|Drug|Mannitol|0.9% normal saline infusion and boluses of mannitol
75779877|NCT01111682|Drug|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
75779878|NCT03942692|Other|Phone call questionnaire|"Questionnaire for parents of subject about :~the frequency of consultations with an allergist~the information of the general practitioner or pediatrician~the prescription of epinephrin auto-injector~the frequency of renewal of epinephrin auto-injector~the specialty of doctor who prescribed the renewal~the implementation of specific measures in schools~the frequency of renewal of specific measures in schools~the number of recurrence of anaphylactic reaction~the use of medical advice in case of recurrence of anaphylactic reaction"
75915700|NCT01435044|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
75915701|NCT01435044|Drug|GS-0938|GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily
75915702|NCT01435044|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
75915703|NCT01435044|Drug|Placebo to match sofosbuvir|Placebo to match sofosbuvir administered orally once daily
75915704|NCT01435044|Drug|Placebo to match GS-0938|Placebo to match GS-0938 administered orally once daily
75915705|NCT01434498|Drug|GS-5885 tablet|GS-5885 tablet, 90 mg, QD
75628015|NCT04847232|Drug|Sodium Zirconium Cyclosilicate (SZC)|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the long interdialytic interval (LIDI).
75628016|NCT04847232|Drug|SZC Placebo|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the LIDI.
75628017|NCT04841785|Diagnostic Test|mailer-based finger-prick|All participants in the antibody measurement study will be sent a mailer-based finger-prick set. The sets will be sent to the home address of the patient, including a return envelope. After collecting and returning the samples SARS-CoV-2 antibodies will be analysed quantitatively at the laboratory.
75915706|NCT01434498|Drug|GS-9451 tablet|GS-9451 tablet, 200 mg QD
75628018|NCT04836936|Device|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. Application of this placebo device will be performed in the same manner as the treatment, but without the expulsion of nitrogen gas.
75322882|NCT04746326|Procedure|Surgery|Surgery was performed in patients who had generalized peritonitis and perforation.
75322883|NCT04746326|Other|Conservative treatment|Conservative treatment was performed in patients who had no generalized peritonitis and perforation.
75322884|NCT02959775|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
75322885|NCT02959775|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
75322886|NCT04399304|Procedure|simultaneous bilateral high tibial osteotomy|One-stage simultaneous bilateral high tibial osteotomy
75915707|NCT01434498|Drug|tegobuvir capsule|tegobuvir capsule, 30 mg BID
75915708|NCT01434498|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
75322887|NCT04399304|Procedure|Staged bilateral high tibial osteotomy|Two-stage bilateral high tibial osteotomy
75467454|NCT01924013|Dietary Supplement|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
75467455|NCT01924013|Dietary Supplement|Placebo|This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
75779879|NCT01109186|Other|biological parameters|blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
75628019|NCT04836936|Device|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. The tip of the cryopuncture will be sanitized and placed on each treatment point of the ear, releasing a spurt of nitrogen gas for 2 seconds on each point (6 points total).
75628020|NCT04809363|Other|CDPATH™|Crohn's disease risk prediction tool.
75628021|NCT04809363|Other|Blood Draw|Three blood samples will be drawn.
75779880|NCT03741140|Diagnostic Test|Motivation tests|Motivation tests will characterize elementary deficits of motivation
75779881|NCT03946046|Procedure|Clinical targeting|The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)
75322888|NCT04761848|Drug|Cilostazol 50 MG|Cilostazol 50 MG tablet twice daily
75779882|NCT03946046|Procedure|Ultrasonography targeting|The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method
75915709|NCT01434498|Drug|placebo matching ribavirin tablet|placebo matching ribavirin tablet, BID
75915710|NCT01434498|Device|placebo matching tegobuvir capsule|placebo matching tegobuvir capsule, BID
75915711|NCT03735966|Drug|Pyrotinib plus trastuzumab and docetaxel and carboplatin|pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles
75915712|NCT01554696|Drug|peficitinib|oral
75915713|NCT01554696|Drug|Placebo|oral
75915714|NCT01554696|Drug|methotrexate|oral
75915715|NCT01550484|Drug|18F-AV-133|222 MBq (6 mCi)
75467456|NCT01924208|Biological|Timothy, Phleum pretense|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
75779883|NCT04464122|Drug|Somatostatin analog; chemotherapy|According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
75779884|NCT01111994|Drug|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
75779885|NCT03187262|Drug|Daratumumab|Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
75779886|NCT03944252|Drug|Avelumab|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
75779887|NCT03944252|Drug|Cetuximab|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
75779888|NCT01107158|Biological|Whole blood sampling|Whole blood sampling for SNP polymorphism analysis
75779889|NCT01112150|Device|NormaTec Pump|Normatec Pump
75779890|NCT03944174|Procedure|Fixation of unstable pelvic fractures|Percutaneous fixation of both iliac bones through the sacrum using one screw
75779891|NCT03381196|Drug|Pimodivir 600 mg|Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6).
75915716|NCT02236416|Behavioral|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
75915717|NCT02236416|Behavioral|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
75322889|NCT04761848|Drug|Placebo|Placebo tablet twice daily
75322890|NCT04278248|Biological|23-Valent Pneumococcal Polysaccharide Vaccine|1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
75322891|NCT02334267|Device|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
75915718|NCT02236494|Behavioral|Brief Negotiated Interview|As per arm
75915719|NCT02236494|Behavioral|General Health Information|As per arm (this is the active comparator)
75915720|NCT02265120|Behavioral|Questionnaire|The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
75915721|NCT02265276|Drug|Saroglitazar|Tab Saroglitazar 4 mg oral daily for 24 weeks
75915722|NCT02265276|Drug|Pioglitazone|Tab Pioglitazone 30 mg oral daily for 24 weeks
75915723|NCT02263872|Drug|Minocycline|Minocycline 200mg perday
75915724|NCT02265354|Behavioral|Collective-Intelligence computer tailored health communication|
75915725|NCT02265354|Behavioral|Rule-based computer tailored health communication|
75915726|NCT02265432|Behavioral|General physical activity educational materials|
75628022|NCT04798924|Device|Subacute Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the intact field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
75628023|NCT04798924|Device|Subacute Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
75779892|NCT03381196|Drug|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6).
76074619|NCT03839836|Other|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
75779893|NCT03381196|Other|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
75915727|NCT02265432|Device|Wearable activity tracking devices (fitbit)|
75628024|NCT04798924|Device|Chronic Training in the blind field|After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.
75628025|NCT04791826|Behavioral|On-screen electronic alert|On-screen computer-based alert notifying the provider that the patient is at an increased risk of developing HF based on the WATCH-DM risk score and associated guideline recommendation for preventive management of these patients.
75779894|NCT01208948|Drug|1,2 dithiolane 3 valeric acid|600 mg alpha lipoic acid per day
75628026|NCT04791176|Radiation|concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance|Radiotherapy with IMRT or VMAT with 40-60Gy/20-30f; Concurrent Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients<60kg ) qd po. (Note: Levatinib can be given to patients in four weeks before Radiotherapy is applied, so that it can control disease during waiting for Radiotherapy). Maintenance Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients<60kg ) qd po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
75651679|NCT05832346|Behavioral|Laughter yoga programme|"Intervention for intervention group:~This is a 4-week laughter yoga programme (8 sessions) to help adolescents with intellectual and physical disabilities bring more happiness, laughter and joy to promote their mental health status. As laughter yoga therapy can reduce people's levels of stress, anxiety, depression, loneliness, strengthen the immune system and keep the mind positive. Each laughter yoga session will last for 15 minutes and in total there will be 8 sessions for four weeks (two sessions per week). Each laughter yoga session consists of hand clapping warming-up exercise, followed by deep breathing exercise, childlike playfulness exercise, and then laughter exercise. The intervention group also receives routine care provided by special school."
75779895|NCT01209026|Drug|Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination|Novel dry powder inhaler
75779896|NCT01209026|Drug|Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination|Novel dry powder inhaler
75779897|NCT01209026|Drug|Placebo Inhaler|Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
75779898|NCT01209026|Drug|Moxifloxacin 400mg|Film coated oral tablet
75915728|NCT02265432|Other|online map|
75915729|NCT02265432|Other|Personalized text messages|
75779899|NCT01209026|Drug|Moxifloxacin placebo|Film coated oral tablet
75779900|NCT01107314|Other|Phlebotomy|Blood draws (total 48 cc blood)
75779901|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
75915730|NCT02261376|Drug|DS-1971a|DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
75915731|NCT02261454|Other|Gum chewing|1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
75915732|NCT02261532|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
75915733|NCT01535508|Drug|Liquid Vitamin D|300 IU/Kg/day not to exceed 10,000 IU/day.
75915734|NCT01423110|Biological|BYM338|
75915735|NCT01423110|Biological|Placebo|
75915736|NCT01420770|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
75915737|NCT01529424|Drug|ISIS apoC-III Rx|Dose 1
75915738|NCT01529424|Drug|ISIS apoC-III Rx|Dose 2
75322892|NCT02334267|Device|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
75322893|NCT00693485|Drug|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
75322894|NCT00693485|Drug|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
75779902|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
75628027|NCT04790682|Biological|assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.|"At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood)."
75628028|NCT04789408|Drug|Cyclophosphamide|Administered intravenously
75779903|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
75779904|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
75779905|NCT01107548|Other|Systematic detection of vascular risk factors and subsequent evidence-based treatment|
75779906|NCT01109264|Drug|Bendamustine hydrochloride injection|d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles
75779907|NCT01109264|Drug|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
75779908|NCT01209104|Drug|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
75779909|NCT01209104|Drug|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
75779910|NCT03943940|Biological|BM-MNC and UC-MSC|"Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.~UC-MSC: 1-2 x 10^6 cells/kg"
75779911|NCT03943940|Other|Control|Standard medicine
75779912|NCT01311700|Drug|Injectable (i.v.) metoprolol tartrate (up to 15 mg).|"Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).~Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.~Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.~Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion."
75322895|NCT00693485|Drug|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
75467457|NCT01924208|Biological|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
75915739|NCT01529424|Drug|ISIS apoC-III Rx|Dose 3
75915740|NCT01529424|Drug|Placebo|Dose 1
75322896|NCT03942081|Device|Ulcer Measurement Software|Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
75467458|NCT01924208|Procedure|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
75628029|NCT04789408|Drug|Fludarabine|Administered intravenously
75322897|NCT00693719|Drug|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
75322898|NCT00693719|Drug|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
75467459|NCT01924507|Device|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
75467460|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
75467461|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
75628030|NCT04789408|Biological|KITE-222|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
75651680|NCT05832333|Biological|VaxigripTetra®|Suspension for injection Injection intramuscular
75779913|NCT01107704|Behavioral|Family Support Intervention|Multifaceted family support intervention
75779914|NCT01107782|Drug|sildenafil|50 mg TDS orally until birth
75779915|NCT01107782|Drug|placebo|50mg tid
75779916|NCT05520736|Behavioral|Appointment reminders, motivational interviewing and targeted vaccine drives|Automated and real time phone call reminders, motivational interviewing and targeted vaccine drives applied in sequence
75779917|NCT01107860|Device|Computed Tomography|In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
75915741|NCT01529424|Drug|Placebo|Dose 2
75322899|NCT00653861|Device|JUVÉDERM™ Injectable Gel with Lidocaine|Single treatment, volume determined by investigator
75322900|NCT00653861|Device|JUVÉDERM™ Injectable Gel|Single treatment, volume determined by investigator
75915742|NCT01529424|Drug|Placebo|Dose 3
75915743|NCT02637960|Drug|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
75322901|NCT00654329|Drug|Saline|Normal saline, given intranasally
75915744|NCT02637960|Drug|Placebo|One daily dose of placebo (matched to fedovapagon) for 12 weeks
75915745|NCT01523184|Drug|Placebo Capsule|This is the placebo capsule
76074620|NCT04382716|Other|No intervention|No intervention; observation only
76074621|NCT01730053|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
76074622|NCT01730053|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
75779918|NCT01107860|Device|Computed Tomography|In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
76074623|NCT01730053|Drug|Ezetimibe|Ezetimibe over-encapsulated tablets orally.
76074624|NCT01730053|Drug|Placebo|Placebo for alirocumab and ezetimibe.
76074625|NCT00794560|Behavioral|patient education|"Possible, individualized interventions:~Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~First self-injection under control of a specially trained pharmacist"
76074626|NCT01752985|Drug|BMS-813160|
76074627|NCT01752985|Drug|Placebo matching with BMS-813160|
76074628|NCT01751113|Drug|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
75628031|NCT04787926|Device|Locking Solution|The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.
76074629|NCT01751113|Drug|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
76074630|NCT01751113|Drug|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
76074631|NCT04761406|Dietary Supplement|Phaeosol group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
75322902|NCT00654329|Drug|Fentanyl|Fentanyl, nasal transmucosal, 2 micrograms/kilogram
75322903|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, transmucosal, 1 microgram/kilogram
75322904|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, 2 microgram/kilogram, transmucosal route
75467462|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
75322905|NCT00695435|Drug|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
75322906|NCT00695435|Drug|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
75322907|NCT00695435|Drug|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
75322908|NCT00654953|Drug|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
75322909|NCT00654953|Drug|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
75467463|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
75467464|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
75467465|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
75467466|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
75467467|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
75467468|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
75467469|NCT01924741|Procedure|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
75467470|NCT01925066|Drug|Vancomycin|
75779919|NCT03944096|Procedure|FMT+MTX|FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
75779920|NCT03709108|Other|SI-Informed Bolus Calculator|The SI-Informed Bolus Calculator will be used to dose the dinner meal insulin bolus during the Experimental Admission
75779921|NCT01107938|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
76074632|NCT04761406|Dietary Supplement|Placebo group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
76074633|NCT01750879|Drug|Peanut Flour|Peanut Flour
76074634|NCT01750879|Drug|Oat Flour|Oat Flour
76074635|NCT01719380|Drug|LGX818|
76074636|NCT01719380|Drug|Cetuximab|
76074637|NCT01719380|Drug|BYL719|
76074638|NCT00792142|Drug|bortezomib|Given IV
76074639|NCT00792142|Drug|dexamethasone|Given orally
76074640|NCT00792142|Drug|melphalan|Given IV
76074641|NCT00792142|Drug|thalidomide|Given orally
76074642|NCT00792142|Genetic|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
76074643|NCT00792142|Genetic|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
76074644|NCT00792142|Other|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
75915746|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 10 mg under investigation
75915747|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 20 mg under investigation
75322910|NCT00654953|Drug|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
75322911|NCT01790165|Drug|TDT067 and Lamisil|Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
75322912|NCT02299089|Drug|octreotide FluidCrystal® injection depot|
75322913|NCT01129791|Behavioral|Raw Milk|Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
75467471|NCT01925235|Procedure|remote ischemic preconditioning|
75628032|NCT04783077|Behavioral|WhatsApp|Participants assigned to the WhatsApp group will receive weekly messages developed by communication specialists aimed to motivate blood donation, be encouraged to discuss their blood donation experiences, and share their own motivations for donating blood in a moderated, closed group over a six-month duration. The moderator will provide guidelines on acceptable use of WhatsApp in the group, including images they can or cannot share. Participants will also receive standard NBSG communications for first-time donors.
75628033|NCT04783077|Behavioral|Control|Participants in this group will receive the standard NBSG communications for first-time donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to the second blood donation eligibility. The second blood donation eligibility is four months after the first donation.
75628034|NCT04783077|Behavioral|Docudrama|Participants will be exposed to a document-drama related to blood donation.
75628035|NCT04782297|Device|Long term hemodialysis catheter|There will be no interventions in this study. Strictly observational.
75628036|NCT04773054|Diagnostic Test|Microbiological analysis of periprosthetic tissue|Microbiological culture of tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
75628037|NCT04773054|Diagnostic Test|Histological analysis of periprosthetic tissue|Histological assessment of cellular reactivity associated with the infection on tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
75628038|NCT04773054|Other|Characterization of tissue microbiota|"Assessment of tissue microbiome composition using the next-generation sequencing of DNA extracted from samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone."
75628039|NCT04773054|Other|Characterization of gut microbiota|"Assessment of gut microbiome composition using the next-generation sequencing of DNA extracted from stool samples."
75628040|NCT04773054|Other|Characterization of oral microbiota|"Assessment of oral microbiome composition using the next-generation sequencing of DNA extracted from a buccal swab obtained by rubbing the mucosa of cheeks, gingivae, and palate."
75651681|NCT05832320|Drug|Etoposide|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
75651682|NCT05832320|Drug|Daunorubicin|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
75779922|NCT01107938|Drug|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
75779923|NCT01107938|Drug|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
75915748|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 30 mg under investigation
75915749|NCT02261610|Procedure|Procalcitonin algorithm|Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
75915750|NCT01416402|Drug|Arhalofenate|400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
75915751|NCT01416402|Drug|Febuxostat|80 mg once daily orally for 5 weeks
75915752|NCT01416402|Drug|Colchicine|Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
75915753|NCT01414920|Drug|Placebo|TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
75915754|NCT01414920|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
75915755|NCT01414920|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
75467472|NCT01925365|Dietary Supplement|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
75467473|NCT01925365|Dietary Supplement|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
75779924|NCT01209338|Behavioral|Health education|Health education about HPV infection, HPV vaccine and cervix cancer.
75779925|NCT02950558|Drug|Ropivacaine|Single injection of ropivacaine immediately prior to surgery.
75779926|NCT02950558|Procedure|Nerve block|insertion of catheter to deliver continuous 5 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
75779927|NCT02812706|Drug|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
75915756|NCT01414920|Drug|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
75915757|NCT01414920|Drug|TAK-875 and Sitagliptin|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
75915758|NCT01414920|Drug|TAK-875 and Sitagliptin|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
75915759|NCT01517880|Drug|Sialic Acid Extended Release (SA-ER)|SA-ER will be administered in doses of 3000mg per day or 6000mg per day
76074645|NCT00792142|Other|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
76074646|NCT00792142|Procedure|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
76074647|NCT00792142|Procedure|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
76074648|NCT00792610|Biological|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
76074649|NCT00792688|Drug|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
76074650|NCT00792688|Drug|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
75322914|NCT01129791|Behavioral|Pasteurized Milk|Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
75628041|NCT04760275|Drug|Fluoxetine|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT)."
75779928|NCT05514028|Other|Salivary samples|"For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):~During the inclusion visit,~At the postoperative visit,~At the 6-month follow-up visit~For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~At the inclusion visit,~During the postoperative visit,~At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)~For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~At the inclusion visit,~During the postoperative visit,~During pre- and post-chemotherapy visits (before and after each cycle)~During follow-up visits (every 4 months until 24 months)"
75779929|NCT05504590|Device|Tuohy needle group|Ultrasound-guided caudal epidural block with Touhy needle
75779930|NCT05504590|Device|Quincke needle group|Ultrasound-guided caudal epidural block with Quincke needle
76074651|NCT00792688|Drug|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
76074652|NCT05640778|Drug|Dalpiciclib combined with aromatase inhibitors|Dalpiciclib combined with letrozole or anastrozole
76074653|NCT05640778|Drug|anthracycline-cyclophosphamide followed by taxane|4 cycles of anthracycline-cyclophosphamide (EC) followed by 4 cycles of taxane
76074654|NCT01743560|Drug|RAD001|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
76074655|NCT01743560|Drug|Exemestane|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
76074656|NCT00796744|Drug|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
76074657|NCT01743092|Behavioral|Webinar|Some clients will receive a webinar as part of their treatment.
76074658|NCT01743092|Behavioral|Tutuorial workbook|A work book about their addiciton
76074659|NCT00797212|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
76074660|NCT00792922|Drug|Azithromycin|Comparison of community coverage rate
75322915|NCT01129791|Behavioral|Non-dairy milk|Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
75322916|NCT00655811|Drug|Capsaicin|Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
75322917|NCT00655811|Drug|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
75467474|NCT01925625|Biological|Early CDT Lung blood test|The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
75779931|NCT01108016|Behavioral|Videoconferencing support group|
75779932|NCT03345472|Device|Spinal Cord Stimulation System|Implanted neurostimulation system (neurostimulator and leads) with high dose stimulation parameters.
75779933|NCT02791334|Drug|LY3300054|Administered IV
75779934|NCT02791334|Drug|Ramucirumab|Administered IV
75779935|NCT02791334|Drug|Abemaciclib|Administered orally
75779936|NCT02791334|Drug|Merestinib|Administered orally
75779937|NCT02791334|Drug|LY3321367|Administered IV
75779938|NCT03710980|Device|Oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding arterial blood draw samples to assess oximeter accuracy.
76074661|NCT00792922|Drug|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is >5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
75628042|NCT04760275|Behavioral|Cognitive Behavioral Therapy (CBT)|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of weekly CBT implemented with Coping Cat (CC). In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with CBT. All participants who do not remit will be randomized (1:1) to either (1) optimization of CBT (intensifying exposure practice and skills review), or (2) optimization of CBT and addition of the medication fluoxetine."
75628043|NCT04758507|Biological|donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
75628044|NCT04758507|Other|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
75322918|NCT03931551|Drug|Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]|Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
75322919|NCT02011685|Behavioral|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
75322920|NCT02011685|Behavioral|Nurse Case Management (NCM)|Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
75322921|NCT00974415|Procedure|CO2|CO2 treatment delivered to randomized flank at each study visit
75322922|NCT00974415|Procedure|Sham|Sham treatment to other flank at each study visit
75628045|NCT04757714|Procedure|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius
75628046|NCT04757714|Procedure|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)
75628047|NCT04757714|Other|Questionnaires|"a physical activity questionnaire (PHAS instrument)~a COPD quality of life questionnaire (St George Hospital)"
75779939|NCT04252040|Device|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
75779940|NCT02624414|Device|PillCam® COLON 2 Capsule Endoscopy|
75628048|NCT04757714|Other|A search for sarcopenia by studying the strength of the grip (dynamometer)|A search for sarcopenia by studying the strength of the grip (dynamometer)
75779941|NCT03709030|Diagnostic Test|magnetic resonance cholangiopancreatography (MRCP)|magnetic resonance imaging of liver, gall bladder, pancreas
75779942|NCT01585220|Device|HA filler|The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
76074662|NCT01780831|Drug|Raltegravir|RAL was given as oral granules for suspension.
75628049|NCT04728113|Other|Supportive care visit with questionnaires|5 Questionnaires (SCNS, QLQ-C30, HADS, PTPQ, GSE) will be filled by the patient with introduction of supportive care visit
75628050|NCT04728113|Other|Oncological standard visit|Oncological standard visit
76074663|NCT04383730|Drug|Intravenous sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
75628051|NCT04722315|Dietary Supplement|Modified Atkins diet|12 weeks of modified Atkins diet
75779943|NCT03945344|Drug|Tiotropium|Oral capsule 20 μg
75779944|NCT03945344|Drug|Tiotropium|Oral capsule 20 μg
75779945|NCT01108172|Other|Virtual Ward|A multidisciplinary team to optimize medical and social care for patients residing in their own homes
75779946|NCT01108172|Other|Usual care|The usual care provided to patients after discharge from hospital
75779947|NCT01108250|Genetic|LOC387715/HTRA1 genotyping|Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
75779948|NCT01108328|Dietary Supplement|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
75779949|NCT01209416|Drug|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
75779950|NCT01209416|Drug|Ghrelin|Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
75779951|NCT01209416|Other|Placebo|placebo tablets or saline infusion
75779952|NCT00349349|Drug|ofatumumab|Intravenous infusion
75779953|NCT01112462|Drug|Paracetamol 500 mg/Phenylephrine 5 mg tablets|2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
75322923|NCT00696293|Drug|Duloxetine|Duloxetine up to 120 mg/day + Clinical Management
75322924|NCT00696449|Drug|Adapalene|All Subjects will treat the face once daily in the evening.
75628052|NCT04718441|Drug|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
75628053|NCT04716946|Drug|Durvalumab|Patients will receive durvalumab 1500mg durvalumab via IV infusion over 1 hour, once every 4 weeks (Q4W) for up to a maximum of 6 months (up to 6 doses/cycles) unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
75628054|NCT04716946|Radiation|Stereotactic Body Radiation Therapy|Radiation therapy will be performed with external beam ionizing radiation in accordance with institutional standard practice. 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist.
75628055|NCT04714372|Drug|Daratumumab/rHuPH20|Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches [7.5 cm] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
75628056|NCT04714372|Drug|FT538|FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
75628057|NCT04714372|Drug|Fludarabine|Fludarabine 25 mg/m^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
75628058|NCT04714372|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
75628059|NCT04710030|Drug|Valacyclovir hydrochloride 500mg caplet|Active Comparator
75628060|NCT04710030|Drug|Placebo sugar pill caplet|Placebo Comparator
75628061|NCT04700176|Drug|Daratumumab|During 28-day treatment cycles, patients will receive Dara 16 mg/kg intravenously (IV) at their current dose upon enrollment onto the study depending on their cycle. They will receive Dara depending on the cycle they are in. If they are on cycles 1-2 then they will receive Dara 16 mg/kg IV on days 1,8,15,22; if they are on cycles 3-6 they will receive Dara 16 mg/kg on days 1 and 15; and if they are on cycle 7 or beyond they will receive Dara 16 mg/kg on day 1.
75628062|NCT04700176|Drug|Pomalidomide|Pomalidomide will be administered at the patient's currently tolerated dose (4,3, or 2 mg po daily) on days 1-21
75628063|NCT04700176|Drug|All-trans retinoic acid|ATRA will be administered in a divided dose of twice daily as an oral formulation at 45mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled Dara infusion. The last administration of ATRA will be given in the evening of the day that Dara was administered
75628064|NCT04700176|Drug|Dexamethasone|Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.
75628065|NCT04686305|Drug|T-DXd|T-DXd: administered as an IV infusion
75628066|NCT04686305|Biological|Durvalumab|Durvalumab: administered as an IV infusion
75628067|NCT04686305|Drug|Cisplatin|Cisplatin: administered as an IV infusion
75628068|NCT04686305|Drug|Carboplatin|Carboplatin: administered as an IV infusion
75628069|NCT04686305|Drug|Pemetrexed|Pemetrexed: administered as an IV infusion (drug not used)
75628070|NCT04686305|Drug|MEDI5752|MEDI5752: administered as an IV infusion
75628071|NCT04677413|Radiation|Ultrafractionated radiotherapy for rectal cancer|To determine the toxicity of dose-escalated hypofractionated RT, in patients with locally advanced rectal cancer treated with RT, FOLFOX or CAPOX chemotherapy and selective omission of surgery.
75628072|NCT04661358|Drug|Fenofibrate|Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
75628073|NCT04661358|Other|Placebo|Participants begin with a dose of either 160mg or 54mg placebo, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
75628074|NCT04640584|Device|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
75628075|NCT04639258|Device|Medtronic Evolut™ PRO+ System|TAVR treatment with Medtronic Evolut™ PRO+ System
75628076|NCT04628585|Other|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
75628077|NCT04622670|Other|Media Intervention|Receive DVD
75779954|NCT01112462|Drug|Paracetamol 1000 mg/Phenylephrine 10 mg sachet|1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
75779955|NCT02950480|Drug|zafirlukast|Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.
75322925|NCT00696449|Behavioral|frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
75628078|NCT04622670|Other|Quality-of-Life Assessment|Ancillary studies
75628079|NCT04622670|Other|Questionnaire Administration|Ancillary studies
75628080|NCT04622670|Other|Survey Administration|Ancillary studies
75628081|NCT04622670|Procedure|Yoga|Attend yoga class
75628082|NCT04609046|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
75779956|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
75779957|NCT01328522|Drug|SAR153191 (REGN88)|"Pharmaceutical form:solution~Route of administration: subcutaneous"
75779958|NCT01109030|Drug|Pioglitazone+Citalopram+Chlordiazepoxide|"Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
75915760|NCT01517880|Drug|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
75322926|NCT00696449|Behavioral|electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
75322927|NCT00696449|Behavioral|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
75322928|NCT00696449|Behavioral|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
75322929|NCT00696761|Drug|Alfuzosin|10mg, once daily, 12months
75322930|NCT00696761|Drug|Alfuzosin|10mg, once daily, 12months
75628083|NCT04609046|Procedure|Computed Tomography|Undergo CT and PET/CT
75628084|NCT04609046|Procedure|Echocardiography|Undergo ECHO
75628085|NCT04609046|Drug|Lenalidomide|Given PO
75628086|NCT04609046|Procedure|Lumbar Puncture|Undergo lumbar puncture
75628087|NCT04609046|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628088|NCT04609046|Drug|Methotrexate|Given IV or PO
75628089|NCT04609046|Biological|Nivolumab|Given IV
75779959|NCT01109030|Drug|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
75779960|NCT05494528|Drug|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
75779961|NCT05494528|Drug|Entecavir|Entecavir 0.5 mg once per day
75779962|NCT03942380|Diagnostic Test|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA
75779963|NCT03987815|Drug|Nivolumab|Nivolumab
75628090|NCT04609046|Procedure|Positron Emission Tomography|Undergo PET/CT
75915761|NCT01412034|Drug|CER-001|Biweekly infusion
75915762|NCT02261688|Dietary Supplement|Low salt diet|Low salt diet, 10mmoL of sodium per day, for 6 days
75628091|NCT04609046|Biological|Rituximab|Given IV
75322931|NCT00696761|Drug|Alfuzosin|10mg, once daily, 12months
75628092|NCT04609046|Procedure|Ultrasound Imaging|Undergo testicular ultrasound
75628093|NCT04594486|Other|Medical treatment of acute appendicitis|All cases will be treated medically and will be followed for recurrences
75628094|NCT04592913|Drug|Durvalumab|Human monoclonal antibody
75628095|NCT04592913|Drug|FLOT chemotherapy|A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
75628096|NCT04587934|Device|iRes Warmer with ResusView|Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
75628097|NCT04587934|Other|iRes Warmer without ResusView|Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
75628098|NCT04585490|Drug|Durvalumab|Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)
75322932|NCT00696761|Drug|Alfuzosin|10mg, once daily, 12months
75628099|NCT04585490|Drug|Carboplatin|Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle
75915763|NCT02261688|Dietary Supplement|Low salt diet + IV normal saline|Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
75915764|NCT02261688|Dietary Supplement|Liberal salt diet|Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
75915765|NCT02261766|Device|Holter monitoring and Thumb ECG|5 days holtermonitoring and 30 days 30 seconds twice daily thumb ECG recording
75322933|NCT00656201|Drug|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
75628100|NCT04585490|Drug|Pemetrexed|500mg/m2 on Day 1 of every 21-day cycle
75628101|NCT04585490|Drug|Paclitaxel|175mg/m2 on Day 1 of every 21-day cycle
75628102|NCT04585490|Drug|Cisplatin|Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin
75628103|NCT04585490|Device|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
75628104|NCT04575896|Drug|Glecaprevir/pibrentasvir|Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.
75628105|NCT04575181|Drug|NNC0268-0965|For subcutaneous (s.c., under the skin) injection once daily for 26 weeks
75628106|NCT04575181|Drug|Insulin glargine|For s.c. injection once daily for 26 weeks
75628107|NCT04575181|Drug|Placebo (NNC0268-0965)|For s.c. injection once daily for 26 weeks
75628108|NCT04575181|Drug|Placebo (insulin glargine)|For s.c. injection once daily for 26 weeks
75628109|NCT04568122|Device|Saliva test kit|Kit including tube with closed reagents using loop-mediated isothermal amplification (LAMP) assay to detect SARS-CoV-2 virus.
75628110|NCT04551430|Drug|Cabozantinib|Cabozantinib will be supplied by Exelixis.
75628111|NCT04551430|Drug|Nivolumab|Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
76074664|NCT04383730|Drug|Inhaled sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
76074665|NCT04382170|Drug|Dexmedetomidine sublingual film|Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.
76074666|NCT01778023|Drug|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
75628112|NCT04551430|Drug|Ipilimumab|Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
75628113|NCT04537637|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
75628114|NCT04533880|Device|DBM|Demineralized bone matrix (Allosync, CDMB Putty, Arthrex, Naples, FL)
75915766|NCT02263950|Drug|Artemether|Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
76074667|NCT04933006|Diagnostic Test|Pulsevelocity|arterial stiffness evaluation with pulsewave velocity
76074668|NCT01753297|Drug|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
76074669|NCT04382794|Drug|Retrospective case-control analysis|Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
76074670|NCT04929496|Procedure|post-PCI FFR|final invasive physiology measurements after successful stent implantation, followed by functional optimization if physiology indexes remain positive.
76074671|NCT04920370|Drug|ALXN1720 SC|ALXN1720 will be administered via SC route.
76074672|NCT04920370|Drug|ALXN1720 IV|ALXN1720 will be administered via IV route.
76074673|NCT04920370|Drug|rHuPH20|rHuPH20 will be administered via SC route.
76074674|NCT04920370|Drug|Placebo SC|Placebo will be administered via SC route.
75779964|NCT04804930|Procedure|picture|We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns
75779965|NCT02539004|Other|Ultrasound study|Ultrasound study using real-time image fusion with a previous NCCT
75779966|NCT03711916|Device|PlasmaBlade 3.0S|PlasmaBlade (Medtronic) is approved by United States Food and Drug Administration (FDA) as a low thermal dissection device that has shown to be associated with effective cutting, and significantly lower temperature than traditional electrosurgical dissection devices.
75779967|NCT00348881|Biological|DTaP-HB-PRP~T combined vaccine|0.5 mL, Intramuscular
76074675|NCT04920370|Drug|Placebo IV|Placebo will be administered via IV route.
76074676|NCT01777321|Biological|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
76074677|NCT04718350|Drug|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
76074678|NCT04718350|Drug|milrinone at a dose of 50 mcg/kg|milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
75322934|NCT00656201|Drug|Intramuscular Progesterone|Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
75322935|NCT00759291|Drug|acipimox|250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
75628115|NCT04533880|Device|Calcium phosphate cement|Quickset, Arthrex, Naples, FL
75628116|NCT04533880|Other|Autologous bone graft|Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft
75628117|NCT04533815|Behavioral|LOCK sleep intervention|Nursing home staff are trained to use a collaborative problem-solving approach to sleep quality improvement using front-line huddling
75779968|NCT00348881|Biological|Tritanrix-HepB/Hib™ vaccine|0.5 mL, Intramuscular
75915767|NCT02261844|Dietary Supplement|Resveratrol|Resveratrol 1 gm po x 10 days prior to liver resection
75915768|NCT02261844|Drug|Placebo|Placebo 1 pill daily X 10 days
76074679|NCT01729819|Drug|Tolterodine tartrate extended release capsules|
75322936|NCT00759291|Drug|Placebo|1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
75779969|NCT00348881|Biological|Oral poliomyelitis vaccine (OPV)|Oral co-administered with study vaccine.
75779970|NCT04164290|Drug|Jiashen Tablets|1 tablet
75779971|NCT04164290|Drug|Jiashen Tablets|2 tablets
75779972|NCT04164290|Drug|Jiashen Tablets|4 tablets
75779973|NCT04164290|Drug|Jiashen Tablets|6 tablets
75779974|NCT04164290|Drug|Jiashen Tablets|8 tablets
75779975|NCT04164290|Drug|Jiashen Tablets|9 tablets
75915769|NCT02261922|Drug|ticagrelor|
75915770|NCT02261922|Drug|prasugrel|
75915771|NCT02264028|Drug|[14C]-DK-AH 269 CL, solution for infusion|
75915772|NCT02264028|Drug|[14C]-DK-AH 269 CL, drinking solution|
76074680|NCT01729819|Drug|Desmopressin orally disintegrating tablets|
76074681|NCT01729819|Drug|Placebo orally disintegrating tablets|
76074682|NCT01776541|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
75779976|NCT04164290|Drug|Jiashen Tablets Placebo|1 tablet
75779977|NCT04164290|Drug|Jiashen Tablets Placebo|2 tablets
75322937|NCT00657605|Drug|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
75322938|NCT00756405|Behavioral|Antioxidant diet|Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.
75322939|NCT00756405|Dietary Supplement|Antioxidant supplement|Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.
75322940|NCT00756405|Dietary Supplement|Placebo|Participants were asked to consume their usual diet and take a placebo pill.
75322941|NCT00697541|Drug|0.18% COL-118 facial gel (1.8 mg brimonidine)|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
75322942|NCT00697541|Drug|0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
75779978|NCT04164290|Drug|Jiashen Tablets Placebo|4 tablets
75322943|NCT00697541|Drug|Advanced Eye Relief|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
75779979|NCT04164290|Drug|Jiashen Tablets Placebo|6 tablets
75779980|NCT04164290|Drug|Jiashen Tablets Placebo|8 tablets
75779981|NCT04164290|Drug|Jiashen Tablets Placebo|9 tablets
75779982|NCT03376516|Drug|Wilate|von Willebrand factor / Factor VIII (plasma derived)
75779983|NCT03987737|Procedure|small urinary catheter placement in the rectum|The MRI technician will place a small urinary catheter in the rectum prior to MRI of the prostate to evacuate excessive gasses. This catheter will stay in the rectum during the whole MRI examination.
75779984|NCT01209572|Device|calorimetric chamber|Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.
75779985|NCT01209572|Device|Free living conditions|Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
75779986|NCT01055717|Other|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
75779987|NCT02257580|Drug|E-Aminocaproic acid|E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}
75779988|NCT01055795|Drug|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds"
75779989|NCT03987269|Behavioral|Embodied Virtual Reality|"The video will be formatted for viewing within a standard virtual reality headset. Once the video begins, subjects will follow the movements of the new body they are inhabiting in synchronicity to the video. Movement and haptic input include~Mimicking the hand gestures at the beginning in order to establish the body transfer illusion.~Shaking someone's hand~Someone holding the hand and elbow to assist them in standing, taking a few steps and returning to a seated position.~Shaking hands~Having their blood pressure taken~Having their pulse taken~Fill a pill organizer~Color a picture~All of the above interactions will be facilitated by the two Co-PI's (Blatter, Ware). Blatter and Ware have been creating and performing similar Virtual Reality Embodiments with haptics for the past year, and to date, have performed hundreds of them for demos, colleagues, students and the public."
75779990|NCT03987269|Behavioral|Narrative Video|The video will be formatted for a standard flat screen television. Participants will watch the video alone in a standard School of the Arts classroom.
75779991|NCT01108484|Behavioral|Exercise|Supervised exercise: Three 90-minutes sessions per week.
75779992|NCT01108484|Behavioral|Exercise + Diet counseling|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
75322944|NCT00697541|Drug|COL-118 facial gel vehicle|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
75779993|NCT01108484|Behavioral|Exercise + Diet counseling + psycho-emotional support|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
75779994|NCT01055873|Biological|A single blood sample (30 mL)|A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
75779995|NCT01055951|Device|Solo MicroPump|30 days treatment days with an optional extension period of up to 6 month of treatment.
76074683|NCT00811564|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
76074684|NCT00811564|Drug|latanoprost 0.005%|1 drop of study medication taken once daily
75322945|NCT04514913|Radiation|Multidetector Computed Tomography (MDCT) Scan|This is a low-dose CT scan of the chest using no contract material.
75779996|NCT01056029|Drug|G-202|Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
75322946|NCT04514913|Procedure|Virtual Navigation Bronchoscopy (VNB)|This is a procedure where a camera will be inserted into the lung in order to guide sample collection of bronchoalveolar lavages, bronchail brushes and endobronchial biopsies.
75779997|NCT03797144|Device|CD HORIZON® Fenestrated Screw System with Fenestrated Screw Cement|The CD HORIZON® Legacy™ and Solera™ Fenestrated Screw Spinal System consists of a variety of cannulated screws with a series of fenestrations to allow polymethylmethacrylate (PMMA) bone cement (Fenestrated Screw Cement) to be injected into the treated site. The Fenestrated Screw Cement is used to augment screw fixation in subjects with compromised bone quality.
75915773|NCT02264106|Drug|Lefradafiban tablet|
75628121|NCT04512716|Drug|131-I Apamistamab|Patients will receive 131-I apamistamab 75 mCi 5-7 days prior to a single infusion of 1x10^6 19-28z CAR T-cells/kg for those in the B-ALL cohort, or 2x10^6 19-28z CAR T-cells/kg, for those in the DLBCL. 131-I apamistamab may be administered inpatient or outpatient at the discretion and judgment of the treating investigators.
75628122|NCT04512716|Biological|CAR T-cell|19-28z CAR T-cells will be administered inpatient as a single infusion of 1x10^6 19-28z CAR T-cells/kg, for those in the B-ALL cohort, or 2x10^6 19-28z CAR T-cells/kg, for those in the DLBCL cohort. Patients will be observed inpatient for a minimum of 7 days (longer as clinically indicated and at the discretion of the treating physician).
75628123|NCT04512378|Behavioral|Behavioural Experiments for Intolerance of Uncertainty|Cognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique
75628124|NCT04508725|Diagnostic Test|Doppler Ultrasound|Power doppler measurements will be made
75628125|NCT04508725|Device|Vantage 256 with C5-2v transducer|Vantage 256 with C5-2v transducer, used for power doppler ultrasound, manufactured by Verasonics
75628126|NCT04508725|Drug|Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor|Participants will receive less than 4 weeks of TKI treatment during the first 12 weeks
75628127|NCT04508725|Other|non-ICI therapy|TKI monotherapy, combination of TKI with other kinase inhibitor, localized tumor therapy such as radiation, chemo- or radioembolization
75628128|NCT04508309|Biological|Cecolin®|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine
75628129|NCT04508309|Biological|Gardasil®|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine
75628130|NCT04500756|Drug|Metformin|Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
75628131|NCT04500756|Other|Placebo|One group will be randomized to receive the study drug Metformin and the other group will receive a placebo
75628132|NCT04474158|Behavioral|Creating Peace|Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
75628133|NCT04474158|Behavioral|Job Readiness|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
75322947|NCT00697697|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
75467475|NCT01925807|Behavioral|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
75467476|NCT01926262|Behavioral|Specific Strength Training|Specific Strength Training for the Neck and Shoulder Muscles
75628134|NCT04469842|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|Immunosuppression regimen with Tacrolimus Extended Release as the backbone.
75915774|NCT02264106|Drug|Lefradafiban double chamber sachet|
75915775|NCT02264106|Drug|Pantoprazole|
76074685|NCT00811798|Biological|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
75322948|NCT00697697|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
75322949|NCT03889275|Biological|MEDI5395|Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.
75322950|NCT03889275|Biological|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
75322951|NCT04349163|Other|Questionnaire|CD-RISC 25 questionnaire
75628135|NCT04469842|Drug|Tacrolimus|Standard Immunosuppression regimen with Intermediate-Release Tacrolimus.
75628136|NCT04469842|Drug|Mycophenolate Mofetil Hydrochloride|Standard immunosuppression of the anti-proliferative class.
75628137|NCT04469842|Drug|Prednisone|Standard immunosuppression (corticosteroid class).
75628138|NCT04469842|Drug|Azathioprine|Standard immunosuppression of the anti-proliferative class.
75628139|NCT04447755|Drug|Lenvatinib|Lenvatinib capsules administered orally at 14 mg/m^2 QD
75322952|NCT00657917|Drug|Paromomycin +Gentamicin topical cream|WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
75322953|NCT01959945|Biological|Flublok® Quadrivalent Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
75322954|NCT01959945|Biological|Fluarix Quadrivalent® Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
75322955|NCT00700661|Drug|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
75322956|NCT00700661|Drug|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
75322957|NCT03856749|Other|Remote wheelchair skills training|"Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days."
75628141|NCT04396535|Drug|Bintrafusp Alfa|Given IV
75628142|NCT04396535|Drug|Docetaxel|Given IV
75628143|NCT04341571|Dietary Supplement|Probiotics|Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
75628144|NCT04341571|Drug|Metformin|"Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks.~Homologated to the other intervention."
75628145|NCT04340843|Drug|Belinostat|Given IV
75628146|NCT04340843|Procedure|Biopsy|Undergo biopsy
75628147|NCT04340843|Procedure|Biospecimen Collection|Undergo collection of blood
75628148|NCT04340843|Procedure|Computed Tomography|Undergo CT
75628149|NCT04340843|Drug|Decitabine and Cedazuridine|Given PO
75628150|NCT04340843|Drug|Guadecitabine|Given SC
75628151|NCT04340843|Procedure|Magnetic Resonance Imaging|Undergo MRI
75779998|NCT03943784|Procedure|Endoscopic Variceal Ligation|Endoscopic varices ligation was performed with a six-shooter multiband ligator (Cook Medical, Limerick, Ireland) if medium to large varices or reddish spots, regardless of the grade of the varix, were observed. Each varix was ligated 1-2 cm above the gastro-esophageal junction, with 1 or 2 rubber bands and using no more than 5 rubber bands per session.
75779999|NCT03943784|Drug|Non-Selective Beta-Blocking Agent|Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
75780000|NCT00347009|Drug|adefovir dipivoxil|10mg once daily
75780001|NCT01209650|Drug|BIBW 2992|tablets
75780002|NCT01947140|Drug|Pralatrexate|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
75780003|NCT01947140|Drug|Romidepsin|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
75780004|NCT03945110|Device|iAluRil® intravesical instillations|50ml of a sterile solution of sodium hyaluronate (1.6% 800mg/50ml) and sodium chondroitin sulphate (2% - 1 g/50ml) is administered intravesically (directly into the bladder) via a pre-filled syringe connected to a catheter and held in the bladder for at least 30 minutes.
75780005|NCT01845116|Drug|Omegaven®|10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
75780006|NCT00346775|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate
75780007|NCT00346775|Drug|Flunisolide|Flunisolide
75780008|NCT01108562|Drug|Lidocaine|Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
75780009|NCT01108562|Other|Normal Saline|Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
75780010|NCT01328132|Drug|Saline|100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
75780011|NCT01328132|Drug|25% albumin|100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
75780012|NCT00346697|Drug|Omega-3 fatty acid administration|LOVAZA 1 gram capsules, 4 capsules daily
75780013|NCT00346697|Drug|Placebo|Corn-oil placebo
75780014|NCT03942614|Behavioral|Nordic pole walking|
75780015|NCT01666340|Other|Exercise intervention|Group asked to perform exercise at a given moderate intensity for a set time
75780016|NCT01666340|Other|Exercise intervention|High intensity exercise
75780017|NCT01112540|Drug|Morphine|0.1 mg/kg Intravenous bolus
75780018|NCT03986801|Other|pharmaceutical interview|pharmaceutical interview at the end of hospitalization
75780019|NCT03400852|Drug|MNK-1411|MNK-1411 (1 mg/mL suspension) for subcutaneous injection
75780020|NCT03400852|Other|Placebo|Placebo suspension for subcutaneous injection
75780021|NCT03986645|Device|MR data acquisition|MR data acquisition using CE and non-CE marked pulse sequences.
75780022|NCT01056419|Procedure|Total Thyroidectomy|Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
75780023|NCT01056419|Drug|Propylthiouracil|150-600 mg in two-three divided doses
76074686|NCT01742078|Drug|LY2541546 - IV|Administered IV
76074687|NCT01742078|Drug|LY2541546 - SC|Administered SC
76074688|NCT01742078|Drug|Placebo|Administered IV or SC
76074689|NCT01741688|Biological|Tocilizumab|Tocilizumab was administered according to the local label.
75628152|NCT04320888|Procedure|Computed Tomography|Undergo CT, PET/CT, and/or CT/MRI
75628153|NCT04320888|Procedure|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
75628154|NCT04320888|Procedure|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
75780024|NCT04097366|Diagnostic Test|ABUS|Automated whole breast ultrasound (ABUS) is undertaken with a large transducer panel placed on the breast in three positions. Resultant images are combined to make a 3D image of the breast.
75780025|NCT04097366|Diagnostic Test|CESM|A high kV and a low kV image is taken in two standard views of each breast following the intravenous injection of an iodinated contrast agent.
75780026|NCT04097366|Diagnostic Test|ABB-MRI|ABB-MRI is a shorter version of breast MRI. Standard T1W pre and post contrast images are acquired. A MIP and post-contrast T1 weighted image are read.
75780027|NCT05304832|Other|Aqua-Plyometric Exercise|The aqua-plyometric training was conducted for 45 minutes, twice weekly, for 12 successive weeks. The training was geared toward the lower body and was conducted under close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
75780028|NCT05304832|Other|Standard physical therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 40 minutes, two times a week for 12 successive weeks.
75780029|NCT01056497|Drug|alpha lipoic acid|A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will ingest 3 tablets 2 times per day with breakfast and supper, 1800mg per day
75780030|NCT01056575|Drug|OC000459|OC000459 100mg tablet, twice daily
76074690|NCT01709084|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
75780031|NCT03986567|Behavioral|gamification for partner notification among youngsters|"Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification"
76074691|NCT01709084|Drug|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
75322958|NCT00658385|Genetic|GCSF, Central venous line placement, Stem cell Collection (leukapheresis)|"Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.~These will be done again 24 hours after your stem cells are collected."
75322959|NCT00652847|Drug|ezetimibe|ezetimibe 10 mg/day for a six week course of treatment.
75322960|NCT00652847|Drug|statins|patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
75322961|NCT00652301|Drug|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
75628155|NCT04320888|Procedure|Radionuclide Imaging|Undergo scintigraphy
76074692|NCT01709084|Drug|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
76074693|NCT01709084|Drug|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
75628156|NCT04320888|Drug|Selpercatinib|Given PO
75628157|NCT04320888|Procedure|X-Ray Imaging|Undergo x-ray imaging
75628158|NCT04317053|Behavioral|RELAY|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
75628159|NCT04307615|Combination Product|Oxygen + continuous positive airway pressure (CPAP)|Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment
75628160|NCT04307615|Drug|Oxygen|Oxygen: 20 min treatment followed by 10 min rest and assessment
75628161|NCT04305925|Device|Focal Laser Ablation|Orion system to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy. MRI guidance will be achieved by MRI/ultrasound fusion, overlaying stored MRI images upon real-time ultrasound images. Interstitial laser treatments would be achieved by inserting the fiber into the cancerous regions guided by the Artemis image-fusion device. Applications of laser energy up to 15 watts of power will be used to treat the target region.
75628169|NCT04283552|Device|Dynamic PET/CT Imaging|-Will take approximately 60 minutes
76074694|NCT01729039|Behavioral|standard balance rehabilitation|All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
76074695|NCT01729039|Behavioral|gaze stability|Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
76074696|NCT01729039|Behavioral|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
76074697|NCT01775995|Behavioral|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
76074698|NCT01775995|Other|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
76074699|NCT01741532|Drug|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
76074700|NCT01741532|Drug|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
75628170|NCT04283045|Behavioral|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the TA.
76074701|NCT01719224|Procedure|elevated body position|45 degrees elevated upper body position
76074702|NCT01719224|Procedure|supine body position|non-elevated upper body position
75322962|NCT00652301|Drug|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
75628171|NCT04283045|Behavioral|JASPER Plus+|"JASPER Plus+ refers to direct instruction of social communication targets of pointing to share, showing gesures, and give to share gestures, and play targets at the child's target play level.~JASPER Plus+ will occur at a table top with repeated trials of instruction until the child can produce the desired behavior on their own."
75322963|NCT00652301|Drug|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
75628172|NCT04276116|Behavioral|Pulmonary age|Communication of pulmonary age
75628173|NCT04272606|Drug|Tranexamic Acid|Antifibrinolytic Agent
75628174|NCT04272606|Drug|Saline Solution|Placebo
75628175|NCT04272606|Diagnostic Test|Visual Acuity Exam|Supplemented into standard of care daily neurological exam on day of surgery and day after
75628176|NCT04272606|Diagnostic Test|3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)|3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
75628177|NCT04269993|Drug|Cannabis: placebo and medium THC/medium CBD|Vaporized cannabis: placebo and medium THC/medium CBD
75780032|NCT03398356|Drug|Metformin|"for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg~for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg."
75780033|NCT03945578|Other|Pelvic Floor muscle training - PFMT|Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).
75780034|NCT03945578|Other|Visceral Manual Therapy - VMT|Visceral manual therapy:is a manual treatment intended to the release of visceral fascias. The VMT protocol was based on the work proposed by Vanderheyden-Busquet (2014). To act on the abdominal and pelvic visceral fasciae, the VMT was performed through slow and deep mobilizations, respecting the participant's tissue resistance and painful response, in different regions of the abdômen.
76074703|NCT01717976|Behavioral|DISPO ED|primary care based nurse telephone support
76074704|NCT01740440|Device|BMR Face|BMR Face used in accordance with manufacturer IFU
75322964|NCT01961271|Drug|Buprenorphine transdermal patch|Please see Arm Description.
75322965|NCT01963143|Biological|Gammaplex (5%)|
75322966|NCT01963143|Biological|Gammaplex 10|
75322967|NCT04486599|Device|Electromagnetic Navigation|The echo-guided sclerotherapy procedure, assisted by electromagnetic navigation, will be carried out in a clean room during the day hospitalisation and followed by a control Echo-Doppler carried out 2 hours after the procedure.
75322968|NCT01963845|Drug|Sitagliptin|
75322969|NCT01963845|Drug|Placebo|
75628178|NCT04250545|Drug|Sapanisertib|Given PO
75628179|NCT04250545|Drug|Telaglenastat Hydrochloride|Given PO
75322970|NCT02332863|Device|Back-loaded Needle (Device)|"Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:~total length of procedure~how many markers are successfully deployed~technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
75322971|NCT02332863|Device|Preloaded Needle (Device)|"Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:~total length of procedure~how many markers are successfully deployed~technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
75322972|NCT01963923|Behavioral|Pulmonary Rehabilitation Program|The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
75322973|NCT01965561|Device|CRoC|Use of Combat Ready Clamp (CRoC)
75628180|NCT04242992|Behavioral|CETA|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based CBT elements so providers can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include SMS reminders of their HIV care appointments, similar to the active control group.
75628181|NCT04242992|Other|Short Message Service (SMS) text reminders|Short Message Service (SMS) text reminders for upcoming appointments will be sent monthly.
75628182|NCT04228419|Procedure|Total Shoulder Arthroplasty|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.
75628183|NCT04228419|Procedure|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
75628184|NCT04216316|Drug|Berzosertib|Given IV
75628185|NCT04216316|Procedure|Biospecimen Collection|Correlative studies
75628186|NCT04216316|Drug|Carboplatin|Given IV
75628187|NCT04216316|Procedure|Computed Tomography|Undergo CT
75628188|NCT04216316|Drug|Gemcitabine Hydrochloride|Given IV
75628189|NCT04216316|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628190|NCT04216316|Biological|Pembrolizumab|Given IV
75628191|NCT04214067|Procedure|Biospecimen Collection|Undergo collection of blood
75628192|NCT04214067|Radiation|Brachytherapy|Undergo vaginal brachytherapy
75780035|NCT03945578|Other|Manual Sham Therapy - MST|The manual sham therapy protocol was perfomed by gentle techniques applied to the thoracic spine, scapular waist and cervical spine
75780036|NCT04051190|Dietary Supplement|VLED group|10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.
75780037|NCT04051190|Procedure|Sleeve Gastrectomy group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy)
75628193|NCT04214067|Procedure|Computed Tomography|Undergo CT
75628194|NCT04214067|Radiation|External Beam Radiation Therapy|Undergo EBRT
75628195|NCT04214067|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628196|NCT04214067|Biological|Pembrolizumab|Given IV
75780038|NCT04051190|Procedure|Gastric Bypass group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (gastric bypass)
75780039|NCT01114256|Procedure|FNA Biopsy|
76074705|NCT01740128|Device|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
76074706|NCT01740128|Other|Harness-supported multimodal balance training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
75322974|NCT01965561|Device|AAJT|Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
75322975|NCT01965561|Device|JETT|Use of Junctional Emergency Treatment Tool (JETT)
75322976|NCT01965561|Device|SJT|Use of SAM Junctional Tourniquet (SJT)
75322977|NCT02984462|Procedure|percutaneous Akin osteotomy|The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
75322978|NCT00658619|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
75322979|NCT00658619|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
75322980|NCT00658619|Other|Sham (no implant)|Sham in one or both eyes on Day 1 and Month 6.
75628197|NCT04214067|Other|Quality-of-Life Assessment|Ancillary studies
75628198|NCT04214067|Other|Questionnaire Administration|Ancillary studies
75628199|NCT04214067|Procedure|X-Ray Imaging|Undergo x-rays
75628200|NCT04209660|Drug|Lenvatinib|Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.
75628201|NCT04209660|Drug|Pembrolizumab|Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
75628203|NCT04190550|Drug|Cytarabine|Given IV
76074707|NCT01976741|Drug|Rogaratinib (BAY1163877) oral solution|Participants received Rogaratinib oral solution as a single dose on Cycle 1 Day 1 (C1D1) and twice daily (BID) from Cycle 1 Day 3 (C1D3) onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
76074708|NCT01976741|Drug|Rogaratinib (BAY1163877) oral tablet|Participants received Rogaratinib oral tablet as a single dose on C1D1 and BID from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
76074709|NCT01976741|Drug|Rogaratinib (BAY1163877) 800 mg BID|Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
76074710|NCT01727713|Drug|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
76074711|NCT04658927|Drug|Dexamethasone, 0.4mg|iLUX + dextenza
75628204|NCT04190550|Drug|Idarubicin Hydrochloride|Given IV
75628205|NCT04190550|Drug|Navtemadlin|Given PO
75628206|NCT04180306|Other|pediatric early warning scoring system and resuscitation curriculum|teaching resuscitation to medical providers and implementing a scoring tool to help identify patients at risk for clinical deterioration in an inpatient setting
75628207|NCT04171856|Device|REAplan(R)|motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm
75628208|NCT04170062|Device|Nasal Delivery of High-Flow Air and Oxygen Therapy|They will receive high-flow air and oxygen via a dual lumen nasal cannula at rest. Participants will be administered the high-flow air and then titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
75628209|NCT04170062|Device|Nasal Delivery of Oxygen Therapy|They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
75628210|NCT04162613|Other|Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation|"The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test.~At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level."
76074712|NCT04658927|Drug|Prednisone acetate|Prednisolone acetate 1% and iLux
76074713|NCT04658927|Other|Control|iLUX alone.
76074714|NCT01965431|Drug|BI 207127|Medium dose oral administration
76074715|NCT01965431|Drug|BI 207127 placebo|
76074716|NCT01965431|Drug|Faldaprevir placebo|
76074717|NCT01965431|Drug|Faldaprevir|Medium dose oral administration
76074718|NCT01965431|Drug|Moxifloxacin (Avalox®)|
76074719|NCT01976663|Device|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
76074720|NCT01976663|Device|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
76074721|NCT01775137|Drug|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
76074722|NCT01976507|Drug|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
76074723|NCT04661579|Biological|RTS,S/AS01E|Vaccine
76074724|NCT04661579|Biological|Abhayrab rabies vaccine|Vaccine
76074725|NCT01964963|Drug|Alogliptin|Alogliptin tablets
75322981|NCT01966419|Drug|ornithine phenylacetate|Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
75322982|NCT01966419|Drug|placebo intravenous infusion|Placebo for continuous IV infusion that is visually identical to the experimental product
75628211|NCT04153747|Other|High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)|Pulmonary veins electrical isolation: high-power and short-duration ablation
76074726|NCT04739657|Device|Insight Lifetech IVUS System|The Insight Lifetech IVUS System is intended for examination of coronary intravascular pathology only, including TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
76074727|NCT04739657|Device|Boston Scientific IVUS System|The Boston Scientific IVUS System is intended for the examination of coronary intravascular pathology only, including Opticross IVUS diagnostic catheter and iLAB IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
76074728|NCT01964105|Device|3D Imaging|
76074729|NCT01974323|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
76074730|NCT01974323|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
76074731|NCT01963403|Drug|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
76074732|NCT01963403|Drug|Placebo|1 pill per day; daily during study participation (up to 84 days)
76074733|NCT04416503|Other|Foot reflexology|Foot reflexology was performed for 12 week in the study group,whereas the control group continued their routine treatment and follow-up.
75467477|NCT01926457|Other|Treatment of Prediabetes|"Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
75322983|NCT01966809|Drug|Photofrin photodynamic therapy.|"The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery."
75322984|NCT01967121|Device|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
75467478|NCT01926522|Device|Technological Rehabilitation|"The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.~Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.~The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions."
75322985|NCT01967121|Other|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
75322986|NCT04575584|Drug|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
75467479|NCT01926522|Other|Control Rehabilitation|When needed, more than on e therapist are employed in the intervention for safety reasons.
75467480|NCT01926535|Procedure|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
75467481|NCT01926535|Device|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
75628212|NCT04153747|Other|Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values|Pulmonary veins electrical isolation: low-power ablation.
75628213|NCT04153747|Other|Esophageal endoscopy|Esophageal endoscopy to detect postablation esophageal thermal lesions.
75780040|NCT00346151|Drug|Belatacept|10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
75322987|NCT04575584|Drug|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
75322988|NCT04277702|Drug|Montelukast 10mg|Oral administration of 10mg of montelukast daily for 12 months
75467482|NCT01926561|Other|Interscalene brachial plexus block|After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
75467483|NCT01927003|Procedure|Dorsal digito-metacarpal flap|The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
75467484|NCT01927016|Procedure|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
75628214|NCT04153747|Diagnostic Test|Daily 30-seconds ECG|Transtelephonic daily 30-seconds single lead electrocardiogram
75628215|NCT04144959|Device|Indigo Aspiration System|Indigo Aspiration System
75322989|NCT04277702|Procedure|Endovascular treatment|Percutaneous transluminal angioplasty combined with bare-metal stenting of lower limbs arteries
75322990|NCT04277702|Drug|Standard anti-platelet treatment|Standard antithrombotic treatment for patients undergoing endovascular procedures
75322991|NCT03999788|Procedure|lumbar puncture and blood withdrawal|lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening
75628216|NCT04122456|Radiation|Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.
75628217|NCT04122456|Other|No Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.
75628218|NCT04119063|Device|powered orthosis|Novel powered leg brace to provide assistance during walking.
75628219|NCT04115241|Device|Actigraph|Actigraphs are non-invasive, wearable devices that measure activity levels using an accelerometer
75780041|NCT00346151|Drug|Sirolimus|4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
75780042|NCT00346151|Drug|Anti-thymocyte globulin|1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
75780043|NCT00346151|Drug|methylprednisolone|500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
75780044|NCT03941210|Other|Detection of molecular Biomarkers|MicroRNA expression profile analysis by flow cytometry
75628220|NCT04115241|Other|Grip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles
75780045|NCT03940976|Drug|Afatinib|Afatinib is orally administered at 40mg Qd of each 28 day cycle.
75780046|NCT01109498|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
75780047|NCT01109498|Drug|Mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
75322992|NCT03999788|Procedure|Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity|iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
75322993|NCT03258632|Behavioral|Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
75628221|NCT04114084|Procedure|Bone Marrow Aspirate and Biopsy|The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
75628222|NCT04112160|Drug|Ketorolac|IM injection of either normal saline or Ketorolac
75780048|NCT01109498|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
75780049|NCT01109498|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
75780050|NCT00130286|Drug|Rosiglitazone|4 mg tablet twice a day x 12 weeks (double-blind phase)
75780051|NCT00130286|Drug|Recombinant human growth hormone + rosiglitazone|Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)
75780052|NCT03940898|Device|repetitive transcranial magnetic stimulation|"There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times."
75780053|NCT00346073|Biological|Boostrix™|Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine
75780054|NCT00346073|Biological|ADACEL®|Sanofi Pasteur
75780055|NCT03940664|Other|immunohistochemistry on Formalin fixed and paraffin embedded blocks|
75628223|NCT04112160|Drug|normal saline|normal saline
75628224|NCT04109456|Drug|IN10018|100 mg or 50mg, orally once daily continuously;
75628225|NCT04109456|Drug|Cobimetinib|60mg , orally once daily from day 1 to day 21 in a 28-day cycle
75628226|NCT04109456|Biological|Atezolizumab|biweekly 840 mg dose will be used in this study starting from Cycle 2.
75628227|NCT04108468|Drug|Golimumab|Simponi
75628228|NCT04108468|Drug|Methotrexate|Methotrexate
75628229|NCT04107181|Device|"Introducer calla device"|The research introducer will be used after the patient consents prior to the annual pap smear.
75628230|NCT04107181|Behavioral|Interviews only|Healthy volunteer interviews
75628231|NCT04100161|Dietary Supplement|Protein supplementation|Daily dose of 40 g whey protein for 3 months
75628232|NCT04100161|Dietary Supplement|Carbohydrate supplementation|Daily dose of 40 g maltodextrin for 3 months
75628233|NCT04100161|Procedure|Active rehabilitation|Progressive rehabilitation following a muscle strain injury for 3 months
75628234|NCT04087798|Behavioral|Control-EDI|Patients in the control group will receive Control-EDI from their primary care provider during clinic visit. Subsequent patient CKD education and follow-up will be provider dependent. Patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
75628235|NCT04087798|Behavioral|Intervention-EDI and health coaching|"Patients in the intervention group will receive a personalized Intervention-EDI from their primary care provider during visit, which will include their most recent BP, their urine protein level and most recent eGFR. There is also a space for their provider to type in a sentence about specific goals for the patient.~Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over an 11-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only)."
75628236|NCT04082754|Biological|Human beta common receptor antagonist monoclonal antibody|Human beta common receptor antagonist monoclonal antibody
75780056|NCT01211834|Drug|tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
75780057|NCT01211834|Drug|DMARDs|Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
75780058|NCT01211834|Drug|Placebo|intravenously over 1 hour infusion every 4weeks
75780059|NCT01211834|Drug|DMARDs|Methotrexate(MTX) and/or 1 DMARDs
75780060|NCT03941990|Drug|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
75780061|NCT03941990|Other|Placebo|inhale medical air (22% O2 - 78% N2)
75915776|NCT02262156|Other|Cognitive behavioral therapy|"The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.~The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention"
75915777|NCT02262156|Drug|SSRI|"Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned."
75628237|NCT04082754|Drug|Placebo|0.9% sodium chloride, same volume and same duration as CSL311
75628238|NCT04079712|Drug|Cabozantinib S-malate|Given PO
75628239|NCT04079712|Biological|Ipilimumab|Given IV
75915778|NCT02612922|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
75915779|NCT02612922|Drug|Placebo|Placebo administered orally twice daily for five days
75915780|NCT01516476|Drug|Placebo|Placebo for 12 weeks
75322994|NCT03257150|Procedure|Irreversible Electroporation|Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die. Eligible patients will undergo in situ IRE performed via laparotomy surgery.
75915781|NCT01516476|Drug|RO6807952|multiple doses for 12 weeks
75628240|NCT04079712|Biological|Nivolumab|Given IV
75628241|NCT04063397|Diagnostic Test|Echocardiogram|Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months
75628242|NCT04063397|Diagnostic Test|Blood draw|Serial blood draws at same time points as echocardiograms for biomarker levels
75628243|NCT04060680|Device|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
75915782|NCT01516476|Drug|RO6807952|multiple doses for 12 weeks
75915783|NCT01516476|Drug|liraglutide|liraglutide for 12 weeks
75628244|NCT04054050|Other|Light therapy|Bright light (10,000 lux) therapy will be administered via a light box.
75628245|NCT04048616|Dietary Supplement|whey protein isolate|one 15-25 gm (based on body weight) protein packet three times a day with each meal
75628246|NCT04048616|Dietary Supplement|potassium bicarbonate (KHCO3)|two 13.5 mmol capsules three times a day with each meal
75322995|NCT03257150|Device|NanoKnife System|A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the tumor.
75628247|NCT04048616|Other|microcrystalline cellulose|identical placebo capsule
75628248|NCT04048616|Other|maltodextrin powder|isocaloric placebo powder
75628249|NCT04036396|Behavioral|Mobile Enhanced Prevention Support|Access to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.
75780062|NCT03374488|Drug|Pembrolizumab|Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
75780063|NCT03374488|Drug|Epacadostat|Epacadostat administered orally twice daily.
75915784|NCT01516086|Drug|Fluticasone Propionate (FP)|FP Inhalation BID
75915785|NCT02265666|Drug|BIIL 284 BS Tablet FF|
75915786|NCT02265666|Drug|BIIL 284 BS tablet C|
75915787|NCT02265666|Other|standard breakfast|
75628250|NCT04036396|Behavioral|Usual Care plus Customized Referrals|Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.
75628251|NCT04036032|Other|Exercise program|Encourage to work out 4 to 5 times a week for 3 months. Patient chooses what exercise they would like to do. At YMCA visit for fitness assessments they provide exercise support
75628252|NCT04026620|Behavioral|Informational Pamphlet|The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.
75628253|NCT04026620|Behavioral|Brief Motivational Enhancement Therapy (MET) Session|The case control trial/efficacy study will provide a one-session MET session in Afrikaans (the predominant language of the region). The face-to-face session will provide information to help people and pregnant women who want to change their drinking behavior, become 'dry' and stay motivated to change their drinking behaviors. Sessions will be approximately one (1) hour and 30 minutes.
75780064|NCT03374488|Drug|Placebo|Matching placebo administered orally twice daily.
75915788|NCT01497834|Drug|BMS-790052 (Daclatasvir)|Tablets, Oral, 60mg, Once daily, 24 weeks
75915789|NCT01497834|Drug|BMS-650032 (Asunaprevir)|Capsules, Oral, 100mg, Twice daily, 24 weeks
75915790|NCT02262234|Other|Education Program Type 1|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
75915791|NCT02262234|Other|Education Program Type 2|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
75780065|NCT01209728|Other|Placebo/ethanol (blinded)|Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
75780066|NCT00345683|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)|Booster dose by intramuscular injection
75780067|NCT00345683|Biological|PedvaxHIB|Booster dose by intramuscular injection
75780068|NCT00345683|Biological|Prevnar|Booster dose by intramuscular injection
75915792|NCT02262312|Other|Transient elastography|All patients will have a transient elastography performed as a measure of liver stiffness.
75915793|NCT02265822|Drug|melatonin in children premedication|
75915794|NCT02265822|Drug|midazolam in children premedication|
76074734|NCT01973387|Drug|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
75322996|NCT03256994|Device|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
75628254|NCT04024059|Behavioral|Contingency Management for adherence|Incentives contingent on buprenorphine adherence
75628255|NCT04024059|Behavioral|Contingency Management for abstinence|Incentives contingent on opiate abstinence
75628256|NCT04001829|Drug|Docetaxel|Given IV
75780069|NCT00345683|Biological|M-M-R II|Single dose by subcutaneous injection
75780070|NCT00345683|Biological|Varivax|Single dose by subcutaneous injection
75780071|NCT03943862|Behavioral|2Share|"The peer-led group program contains of three lessons plus one booster session:~Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weigh their pros and cons of (non-)disclosing a suicide attempt.~Lesson 2: Different ways to disclose: Participants learn about the different ways to disclose and their respective pros and cons. Afterwards participants develop strategies to choose a person to disclose to, and discuss possible responses they might experience.~Lesson 3: Telling your story: Participants learn how to tell their own story.~In a booster session, participants will discuss their experiences with disclosure or non-disclosure."
75780072|NCT01211912|Drug|Arm 1 (20 patients)|Acetaminophen 1000 mg by mouth once
75780073|NCT01211912|Drug|Arm 2 (34 patients)|Acetaminophen 1000 mg by mouth once
75780074|NCT03943472|Biological|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
76074735|NCT01973387|Drug|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
76074736|NCT04657445|Diagnostic Test|visual analogue scale|A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
75628257|NCT04001829|Drug|Paclitaxel|Given IV
75628258|NCT04001829|Other|Quality-of-Life Assessment|Ancillary studies
75628259|NCT04001829|Other|Questionnaire Administration|Ancillary studies
75628260|NCT03989414|Drug|CC-92480|Specified dose on specified days
75628261|NCT03989414|Drug|Bortezomib|Specified dose on specified days
75628262|NCT03989414|Drug|Dexamethasone|Specified dose on specified days
75628263|NCT03989414|Drug|Daratumumab|Specified dose on specified days
75628264|NCT03989414|Drug|Carfilzomib|Specified dose on specified days
75628265|NCT03989414|Drug|Elotuzumab|Specified dose on specified days
75628266|NCT03989414|Drug|Isatuximab|Specified dose on specified days
75780075|NCT03943472|Drug|Fludarabine|30mg/m2/d
75915795|NCT01491516|Device|TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System|The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
75915796|NCT02265900|Other|Exercise|One type of exercise
75915797|NCT02265900|Other|Exercise|A different type of exercise
75915798|NCT02265978|Device|CopeSmart|Participants will use the CopeSmart app at least once per day for four weeks
75915799|NCT01385592|Drug|AFQ056|
75915800|NCT01385592|Drug|Placebo|
76074737|NCT01973231|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
75628267|NCT03989414|Drug|Carfilzomib|Specified dose on specified days
75628268|NCT03981614|Drug|Binimetinib|Given PO
75628269|NCT03981614|Drug|Palbociclib|Given PO
75628270|NCT03981614|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
75628271|NCT03981471|Behavioral|Exercise|Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.
75628272|NCT03979235|Diagnostic Test|Motor function assessment|perform motor function assessment by using scales, sEMG, and inertia sensors
75628273|NCT03974854|Drug|XELOXIRI-3|chemotherapy with XELOXIRI-3 regimen
75628274|NCT03974854|Drug|Gemcitabine|chemotherapy with Gemcitabine regimen
75628275|NCT03965689|Drug|Carboplatin|Given IV
75628276|NCT03965689|Drug|Paclitaxel|Given IV
75628277|NCT03965689|Drug|Pevonedistat|Given IV
75780076|NCT03943472|Drug|Cyclophosphamide|300mg/m2/d
75780077|NCT03943472|Drug|Immune inhibitors|Immune inhibitors
75780078|NCT01056731|Drug|Aliskiren and HCTZ|Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
75780079|NCT01207544|Behavioral|Fitball exercise|Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
75780080|NCT01207544|Behavioral|task-oriented motor training program|Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
75780081|NCT01056809|Procedure|Chemotherapy and surgery|Treatment not specified but in accordance with national guidelines
76074738|NCT01973231|Drug|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
76074739|NCT01961687|Device|Resorbable Mesh|Phasix Mesh
76074740|NCT04656275|Drug|BI 1323495|BI 1323495
76074741|NCT04656275|Drug|Placebo|Placebo
75915801|NCT02262390|Procedure|Partner Notification Reminders|"For all 3 arms, the following will be done:~All participants will have an antenatal clinic visit every 4 weeks until delivery.~All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.~Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test."
75322997|NCT03256994|Behavioral|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT-FR will incorporate a quality-of-life questionnaire. CIRT-FR will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
75322998|NCT03225794|Diagnostic Test|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
75628278|NCT03958877|Drug|BIIB017 (peginterferon beta-1a)|Administered as specified in the treatment arm
75628279|NCT03958877|Drug|Interferon beta type 1a|Administered as specified in the treatment arm
75628280|NCT03952377|Drug|SX600|Transforaminal Epidural Injection
75628281|NCT03952377|Drug|Placebo|Transforaminal Epidural Injection
75628282|NCT03950414|Biological|CMV specific T-cells|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMV-specific CD4+ and CD8+ T cells Suspension of CMV-specific T cells in 10 mL of 0.9% NaCl with 2% Human Serum Albumin(HSA) via IV bolus injection~Low Dose Tier - Viral-Specific T cell infusion 5 x10^3 cells/kg body weight(BW)~Mid Dose Tier - Viral-Specific T cell infusion 1.25 x10^4 cells/kg BW~High Dose Tier - Viral-Specific T cell infusion 2.5 x10^4 cells/kg BW Product will be administered fresh intravenously to recipient within four hours of collection."
75628283|NCT03945292|Drug|Fazisiran Injection|solution for subcutaneous (sc) injection
75628284|NCT03945292|Other|Placebo|sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
75628285|NCT03937375|Behavioral|High PEEP|Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
75628286|NCT03937375|Behavioral|Low PEEP|Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
75628287|NCT03932162|Drug|Insulin-Like Growth Factor 1|Growth factor protein
75628288|NCT03932162|Other|No Insulin-Lie Growth Factor 1|No Insulin-Like Growth Factor 1 will be given.
75628289|NCT03929614|Other|MOBI validation|Final version will be distributed to 176 French speaking subjects, 30 of whom are randomly selected and will fill it a second time, at after 72 hrs. To consider of its kind, Moreover, the Bem Inventory for Children will be completed by everyone as well as the SF-12 and SRS-22.
75628290|NCT03918629|Biological|Clostridium difficile|Toxoid-based Clostridium difficile vaccine
75628291|NCT03918629|Biological|Placebo|Normal saline solution (0.9% sodium chloride)
75628292|NCT03914300|Procedure|Biospecimen Collection|Undergo blood sample collection
75628293|NCT03914300|Drug|Cabozantinib S-malate|Given PO
75628294|NCT03914300|Procedure|Computed Tomography|Undergo CT
75628295|NCT03914300|Biological|Ipilimumab|Given IV
75628296|NCT03914300|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628297|NCT03914300|Biological|Nivolumab|Given IV
75628298|NCT03896217|Drug|Simvastatin|Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
75628299|NCT03887715|Device|Vagus Nerve Stimulation (VNS)|VNS is an implantable device that delivers stimulation to the vagal nerve.
75628300|NCT03870750|Other|Supportive Palliative Care|focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects
75628301|NCT03870750|Other|Clinical Management|physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education
75628302|NCT03870750|Other|Best Practice|Given standard of care
75628303|NCT03870750|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
75628304|NCT03870750|Other|Questionnaire Administration|Ancillary studies
75628305|NCT03870750|Other|Quality-of-Life Assessment|Ancillary studies
75628306|NCT03870750|Other|Survey Administration|Complete surveys
75628307|NCT03862157|Drug|Azacitidine|Given IV or SC
75628308|NCT03862157|Drug|Pevonedistat|Given IV
75628309|NCT03862157|Drug|Venetoclax|Given PO
75628310|NCT03858322|Drug|Paclitaxel|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
75628311|NCT03858322|Drug|Cyclophosphamide|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
75628312|NCT03858322|Drug|Carboplatin|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
75628313|NCT03842228|Procedure|Biopsy|Undergo tumor biopsy
75628314|NCT03842228|Procedure|Biospecimen Collection|Undergo collection of blood samples
75628315|NCT03842228|Procedure|Computed Tomography|Undergo CT
75628316|NCT03842228|Drug|Copanlisib Hydrochloride|Given IV
75628317|NCT03842228|Biological|Durvalumab|Given IV
75628318|NCT03842228|Procedure|Echocardiography|Undergo ECHO
75628319|NCT03842228|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628320|NCT03842228|Drug|Olaparib|Given PO
75628321|NCT03842228|Procedure|X-Ray Imaging|Undergo x-ray
75628322|NCT03816358|Biological|Anetumab Ravtansine|Given IV
75915802|NCT02262468|Radiation|x ray|
75628323|NCT03816358|Procedure|Biopsy|Undergo biopsy
75628324|NCT03816358|Procedure|Biospecimen Collection|Undergo collection of blood
75628325|NCT03816358|Drug|Gemcitabine Hydrochloride|Given IV
75628326|NCT03816358|Biological|Ipilimumab|Given IV
75628327|NCT03816358|Biological|Nivolumab|Given IV
75780082|NCT01056965|Drug|davunetide (AL-108, NAP)|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.
75628328|NCT03811002|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
75628329|NCT03811002|Drug|Atezolizumab|Given IV
75628330|NCT03811002|Procedure|Biospecimen Collection|Correlative studies
75628331|NCT03811002|Drug|Carboplatin|Given IV
75628332|NCT03811002|Drug|Cisplatin|Given IV
75628333|NCT03811002|Drug|Etoposide|Given IV
75628334|NCT03811002|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75628335|NCT03811002|Other|Quality-of-Life Assessment|Ancillary studies
75628336|NCT03811002|Other|Questionnaire Administration|Ancillary studies
75628337|NCT03765229|Drug|Entinostat|Oral drug 5 mg taken once weekly for up to nine 3-week (21 day) cycles. Take on an empty stomach i.e., at least 2 hours after a meal and at least 1 hour before the next meal. On days when entinostat is administered on the same day as pembrolizumab, entinostat should be taken before the pembrolizumab infusion.
75628338|NCT03765229|Drug|Pembrolizumab|200 mg IV starting on Day 22 (cycle 2, Day 1) given every 3 weeks for up to 8 cycles.
75780083|NCT01056965|Drug|Placebo nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
75780084|NCT01114490|Drug|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
75628339|NCT03754790|Drug|Fitusiran|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75628340|NCT03727971|Drug|Omalizumab Injection|The treatment is initiated with one injection with weight and serum-immunoglobulin E balanced omalizumab. After omalizumab treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
75780085|NCT01057043|Device|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
75780086|NCT01112774|Device|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
75780087|NCT01057199|Genetic|RNA analysis|
75628341|NCT03727971|Drug|NaCl|The treatment is initiated with one injection with placebo. After placebo injection treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
75780088|NCT01057199|Genetic|gene expression analysis|
75628342|NCT03713593|Drug|lenvatinib|Administered orally once a day
75628343|NCT03713593|Biological|pembrolizumab|Administered as an IV infusion on Day 1 Q3W
75628344|NCT03713593|Drug|saline placebo|Administered as an IV infusion on Day 1 Q3W
75628345|NCT03711760|Behavioral|telepsychology|CBT delivered by telepsychology
75915803|NCT02607930|Drug|ABC/DTG/3TC|600/50/300 milligrams (mg) tablets administered orally, once daily
75915804|NCT02607930|Drug|B/F/TAF|50/200/25 mg tablets administered orally, once daily, without regard to food
75628346|NCT03707431|Behavioral|Web-based CBT|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
75628347|NCT03707431|Behavioral|Pain Education|The pain education website provides publicly available educational information about pancreatitis and abdominal pain. There is general information about pancreatitis from available web sources (e.g., National Pancreas Foundation) as well as information about chronic pain in childhood. The content does not include any instruction in the behavioral and cognitive skills taught within the WebMAP program.
75780089|NCT01057199|Genetic|mutation analysis|
75780090|NCT01057199|Genetic|protein expression analysis|
75780091|NCT01057199|Other|fluorescence activated cell sorting|
75780092|NCT01057199|Other|laboratory biomarker analysis|
75915805|NCT02607930|Drug|ABC/DTG/3TC Placebo|Tablets administered orally, once daily
75915806|NCT02607930|Drug|B/F/TAF Placebo|Tablets administered orally, once daily
75915807|NCT02264184|Drug|Tamsulosin|
75780093|NCT01209806|Drug|simethicone|400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
75780094|NCT01114568|Drug|Ertugliflozin 10 mg tablet|A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
75780095|NCT01114568|Drug|Ertugliflozin OC Fast|Formulation B) Ertugliflozin 10 mg OC Fast
75780096|NCT01114568|Drug|Ertugliflozin OC Slow|Formulation C) Ertugliflozin 10 mg OC Slow
75780097|NCT03828383|Device|In-home technology|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using a trusted circle of friends and family who are encouraged to stay in contact and share photos and videos with the caregiver and person with dementia via the digital display.
75915808|NCT02264184|Drug|Paroxetine|
75915809|NCT02268162|Procedure|guiding equipments|The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.
75628348|NCT03694483|Diagnostic Test|Genetic analysis for the detection of prostasomes|"Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing."
75915810|NCT02264262|Other|Physiologic maneuvers|Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
75322999|NCT04276766|Other|Crossover intervention|"Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study."
75628349|NCT03685188|Drug|Oxycodone Hydrochloride|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
75780098|NCT03828383|Device|Limited in-home technology|Intelligent bot monitors the in-home water leak sensor and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome conditions occur.
75323000|NCT04276844|Diagnostic Test|Ultrasonography using the two-dimensional (2D) mode|Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.
75628350|NCT03685188|Drug|Sufentanil Citrate|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
75628351|NCT03668041|Drug|Trazodone|Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.
75628352|NCT03668041|Drug|Eszopiclone|Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.
75628353|NCT03668041|Other|Placebo|The active study medications listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it.
75628355|NCT03643744|Drug|Celecoxib 200mg|14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
75628356|NCT03643744|Drug|Placebo|14 placebo capsules taken 1 in the morning and 1 in the evening.
75628357|NCT03641313|Drug|Berzosertib|Given IV
75628358|NCT03641313|Procedure|Computed Tomography Assisted Biopsy|Undergo CT assisted biopsy
75780099|NCT01109654|Drug|Cetrorelix acetate and Follitropin alfa|Cetrorelix acetate given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection.Ovarian stimulation therapy with Follitropin alfa generally starts on cycle Day 2 or 3. The starting dose of Follitropin alfa is based on the Investigators' discretion
75628359|NCT03641313|Procedure|Endoscopic Biopsy|Undergo endoscopic biopsy
75780100|NCT01054001|Drug|sildenafil 100mg|sildenafil 100mg per oral twice a week
75780101|NCT03940820|Biological|ROBO1 CAR-NK cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
75628360|NCT03641313|Drug|Irinotecan|Given IV
75915811|NCT02264340|Behavioral|Relaxation technique Autogenic Training|Autogenic Training
75915812|NCT02264340|Behavioral|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
75915813|NCT02266056|Drug|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
75915814|NCT02266056|Drug|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
75915815|NCT01482390|Drug|Ribavirin|Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than [<] 75 kg) or 1200 mg (for participants weighing greater than or equal to [>=] 75 kg) orally for 24 or 48 weeks.
75915816|NCT01482390|Drug|Mericitabine|Participants will receive mericitabine 1000 mg orally twice daily.
75915817|NCT01482390|Drug|Peginterferon Alfa-2a|Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
75628361|NCT03641313|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628362|NCT03640325|Behavioral|PRISM (Promoting Resilience in Stress Management)|Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
75628363|NCT03631017|Drug|[18F]- PARPi|injection of a microdose (< 100 ug) of [18F]- PARPi
75628364|NCT03631017|Diagnostic Test|PET/CT Scans|"Patients will be injected with approximately 10 mCi of [18F]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings."
75780102|NCT01057355|Procedure|EUS and/or ERCP with ethanol injections of pancreatic cyst|Lavage of cyst with 80% ethanol
75915818|NCT01482390|Drug|Placebo|Participants will receive placebo matching to mericitabine orally twice daily.
75915819|NCT01482390|Drug|Telaprevir|Participants will receive telaprevir 750 mg orally three times daily.
75780103|NCT01054235|Behavioral|training|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
75915820|NCT04476342|Device|minimal invasive cardiopulmonary bypass (MICPB) system|The experimental group was MICPB group, with built-in micro-thrombotic oxygenator and MP formula (15mL 15%KCl+10ml compound potassium, calcium and magnesium +25ml normal saline)
75780104|NCT03940274|Behavioral|walking training|Participants will receive three sessions a week of BWSTT with assistive training device for 8 weeks; a total of 24 sessions. The duration of each training session will an hour. During walk-training, the participant will wear a harness which is attached to an overhead motorized lift to provide body-weight support and to prevent the risk of falling.
75915821|NCT02268240|Behavioral|Stepped Care|Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
76074742|NCT04174391|Behavioral|Mediterranean diet supplemented with extra-virgin olive oil|Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.
76074743|NCT04174391|Behavioral|Low-fat diet|Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods - equivalent to the extra-virgin olive oil allotment - will be received by participants of this group for free. In addition, advice on physical activity will be provided.
76074744|NCT02151994|Drug|BIA 5-1058|oral administration
76074745|NCT02151994|Drug|Placebo|oral administration
76074746|NCT04640974|Device|Cingal|CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe.
75628365|NCT03620786|Device|Sonablate HIFU device|In this study, we will be using the Sonablate 450 HIFU System. The Sonablate HIFU device was approved by the U.S. FDA for prostate tissue ablation in October, 2015. HIFU is an example of focal therapy, where the intervention involves targeting diseased areas of prostate tissue, while preserving healthy prostate tissue and minimizing damage to surrounding structures.
75628366|NCT03610490|Biological|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Given IV
75780105|NCT01057511|Drug|Crinone 8%|Crinone 8%, 90mg / p.v. / Qd, 7 days totally.
75780106|NCT01057511|Drug|Progesterone|Progesterone 20mg/ i.m./ Qd, 7 days totally.
75915822|NCT02268318|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 1 bottle of test product/day
75628367|NCT03610490|Drug|Cyclophosphamide|Given IV
75915823|NCT02268318|Other|2-Fermented dairy Product with No Phytosterols (control)|2-1 bottle of control product/day
76074747|NCT00812110|Drug|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
76074748|NCT05356468|Other|Structured pain neuroscience education|"Structured pain neuroscience~Neurophysiology of pain~The PNE occurred with the use of pictures, examples, metaphors and drawings as needed~Metaphor Alarm system: Your nerves working like an alarm system to protect you.~BOOKLET Consist of education about pain neurophysiology.(31)~Steps of booklet :~Extract content~English to Urdu translation~Content Validity~Expert Panel review by Physiotherapists~Content validity Analysis review(Focus Group)~Pilot study 4 to 5 patients~Content improved (PNE) and Finalized~After Analysis RCT"
75628368|NCT03610490|Drug|Fludarabine|Given IV
75628369|NCT03610490|Biological|Interleukin-2|Given IV
75628370|NCT03610490|Other|Quality-of-Life Assessment|Ancillary studies
75628371|NCT03601455|Biological|Durvalumab|Given IV
75628372|NCT03601455|Radiation|External Beam Radiation Therapy|Undergo EBRT
75628373|NCT03601455|Biological|Tremelimumab|Given IV
75628374|NCT03590652|Drug|Ixazomib|4mg PO days 1,8,15 on 28-day cycle
75628375|NCT03590652|Drug|Pomalidomide|4mg days PO 1-21/28 days
75780107|NCT01114802|Behavioral|Project Onward website + social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
75780108|NCT01114802|Behavioral|Project Onward website|Access to an interactive website that provides 8 weeks of Internet-based cognitive behavioral therapy.
75780109|NCT03986177|Behavioral|Self-management Intervention Package|"Children will receive basic asthma education, based on the National Heart, Lung, and Blood Institute A Breath of Life asthma education program. Children/caregivers in the intervention arm will also be assigned a designated nurse case manager who will provide home visits and be available via text message and phone-based support throughout follow-up. Intervention components:~Interactive education and support on use of an asthma action plan~Locally adapted patient-provider communication tool~Child-oriented educational materials in comic book format~Modeling and hands-on practice of inhaler technique (written instructions, in person, video)~Education regarding environmental trigger abatement~Patient navigation, home visits, and goal setting support from nurse manager"
75323001|NCT04276844|Diagnostic Test|Respiratory Functional Explorations|Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV) and total lung capacity (TLC) measured at day 7
75628376|NCT03590652|Drug|Dexamethasone|"40mg** PO weekly~** starting dose for age >75 may be 20mg"
75323002|NCT03725397|Behavioral|Outpatient|The offered (studied) intervention will be allowing the women with a transcervical Foley catheter in place to spend the night at home.
75628377|NCT03590652|Drug|Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)|1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly
75323003|NCT03725397|Behavioral|Inpatient|"Women with a transcervical Foley catheter to be admitted to the hospital overnight which has been a standard of care."
75323004|NCT00699491|Biological|Cixutumumab|Given IV
75628378|NCT03587805|Drug|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
75628379|NCT03587662|Drug|Doxorubicin|Given IV
75628380|NCT03587662|Drug|Doxorubicin Hydrochloride|Given IV
75628381|NCT03587662|Drug|Gemcitabine|Given IV
75628382|NCT03587662|Drug|Gemcitabine Hydrochloride|Given IV
75628383|NCT03587662|Drug|Ixazomib|Given PO
75628384|NCT03587662|Drug|Ixazomib Citrate|Given PO
75628385|NCT03585270|Drug|Clazosentan|Clazosentan will be administered as a continuous intravenous infusion at the dose of 15 mg/hour for up to 14 days.
75915824|NCT01478178|Drug|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
75915825|NCT01366014|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
75628386|NCT03585270|Drug|Placebo|Placebo will be administered at the same infusion rate as clazosentan for up to 14 days.
75915826|NCT01366014|Drug|Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral|multiple dose, single schedule
75628387|NCT03535259|Radiation|concurrent sorafenib and IMRT, followed sorafenib maintenance|IMRT 40-60Gy/20-30f; concurrent sorafenib 400mg bid po (it can be given to patients in four weeks before IMRT is applied, so that it can control disease during waiting for IMRT); maintenance sorafenib 400mg bid po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
75628388|NCT03535077|Other|Diagnostic Test|Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy
75628389|NCT03499249|Drug|N-Acetyl cysteine|Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
75915827|NCT01366014|Drug|Placebo; oral|matching placebo
75915828|NCT01475058|Biological|allogeneic cytomegalovirus-specific cytotoxic T lymphocytes|Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV
76074749|NCT05356468|Other|Conventional Treatment|"ELECTROTHERAPY MODALTIES-15 min~IFC (interferential current)IFC will be administered using following parameters: 80-150 watts, 4000 Hz, sweep on, 16.0-17.0 CV(26)~Hot pack(27)~Therapeutic exercises~Strengthening (Back extensors, quadriceps, hamstring and VMO, gluteus maximums, gluteus medius, transverse abdominis.~Stretching hamstring and, calf stretching. Soft tissue mobilization(5) McKenzie based exercises(28) BALANCE EXERCISES~Single Leg Stance (static balance) Patient is instructed to stand on one leg,close his/her eyes and maintain this position as long as they could.~Tandem gait (dynamic balance) patient is instructed to walk a total of 5 laps on a 2-meter-long line with the heel of the front foot touching the fingertip of the back foot.(29)~POSTURAL TRAINING~good posture when sitting standing and while driving~Avoid weight lifting~Avoid too much bed rest~Sit in firm places. (30)"
75323005|NCT00699491|Other|Laboratory Biomarker Analysis|Correlative studies
75323006|NCT00699491|Other|Pharmacological Study|Correlative studies
75323007|NCT00699491|Drug|Temsirolimus|Given IV
75780110|NCT03986255|Procedure|Lumbar Puncture|"The participant is placed lateral or sitting position. Fluoroscopy may be used to guide sampling. Full aseptic technique is used throughout.~The skin is prepared with either 2% chlorhexidine/70% alcohol or iodine. 1% lidocaine is used for skin local anesthesia an entry point is identified, this may be done using fluoroscopy. This will be at the lowest intervertebral foramina interspace to minimize the risk of spinal cord injury. A small amount to head up tilt will be allowed to optimize CSF flow.~Sampling is done using a needle through needle technique. An epidural needle is used to identify the epidural space using loss of resistance to saline technique. A spinal needle (26G) is then passed through the epidural needle into the subarachnoid space. Correct entry is noted once CSF is noted in the needle hub and 5 ml taken. This sample is then sent off for analysis.~Once the CSF is sampled, the needle is removed and pressure applied to the skin entry point."
75780111|NCT03942146|Behavioral|Information on smoking cessation|Smoking cessation is recommended 6 weeks before and after surgery
75323008|NCT03721965|Drug|Itacitinib|Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.
75323009|NCT03721965|Drug|Corticosteroids|Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
75323010|NCT04399148|Drug|Desloratadine 5 mg|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
75323011|NCT04399148|Drug|Aprepitant 125 mg|Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
75323012|NCT04399148|Drug|Ketotifen 1 MG|Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
75628390|NCT03475342|Drug|Tranexamic Acid|Ampoules and packaging for both arms will be identical in appearance.
75628391|NCT03475342|Other|Placebo|Ampoules and packaging for both arms will be identical in appearance.
75628392|NCT03447938|Procedure|MICS CABG|Coronary artery bypass grafting performed through small incisions between the ribs.
75628393|NCT03447938|Procedure|Conventional CABG|Coronary artery bypass grafting performed through an incision through the sternum or breastbone.
76074750|NCT04382950|Combination Product|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
75780112|NCT00345605|Drug|Sodium Phenylbutyrate|None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
75323013|NCT04672382|Drug|Morphine|During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), and two areas with an intradermal injection of isotonic saline.
75323014|NCT00699803|Drug|T-PRED|T-PRED sterile ophthalmic solution
75323015|NCT00699803|Drug|Pred Forte|Pred Forte sterile ophthalmic solution
75628394|NCT03423017|Other|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~Respiratory rate, respiratory signs, stridor : first and second visit~24h holter-ECG : first and second visit~24h impedance pH-metry : first visit~Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~succimetry procedure : at first visit only between birth and 2 months"
75628395|NCT03423017|Other|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life~General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~Respiratory rate, respiratory signs, stridor~24h holter-ECG~24h impedance pH-metry~Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index~Succimetry procedure : at first visit only between birth and 2 months"
75780113|NCT00345605|Drug|Arginine|Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
75628396|NCT03412773|Drug|Tislelizumab|200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
75780114|NCT01109732|Other|Systematic physical training with instructor|Training 3 times per week for 6 months, the first 3 months with an instructor
75780115|NCT01210040|Dietary Supplement|Folic Acid|2.8mg
75780116|NCT01210040|Dietary Supplement|Folic Acid and Iron|60mg Iron and 2.8mg Folic Acid
75780117|NCT01054313|Drug|Docetaxel (Taxotere)|Starting dose 30 mg/m^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
75780118|NCT01054313|Drug|Sirolimus (Rapamycin)|Starting dose 1 mg daily by mouth 1 time a day.
75323016|NCT01967433|Drug|Diphenhydramine|
75323017|NCT01967433|Drug|Placebo|
75323018|NCT01799525|Procedure|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
75628397|NCT03412773|Drug|Sorafenib|400 mg twice daily (BID), oral dosing
75323019|NCT03888014|Device|GLOW800|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
75323020|NCT03888014|Drug|indocyanine green (ICG)|This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
75323021|NCT00551447|Drug|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
75628398|NCT03410043|Drug|Osimertinib|Given PO
75628399|NCT03410043|Radiation|Radiation Therapy|Undergo radiation therapy
75628400|NCT03410043|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75780119|NCT01054313|Drug|Prednisone|5 mg by mouth twice a day with prostate cancer.
75780120|NCT01114958|Drug|Cisplatin, Thiosulfate|Cisplatin (150 mg/m^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m^2).
75915829|NCT01361802|Drug|Ambroxol Spray|low dose Ambroxol Spray
75915830|NCT01361802|Drug|Ambroxol Spray|medium dose Ambroxol Spray
75915831|NCT01361802|Drug|Ambroxol Spray|high dose Ambroxol Spray
75915832|NCT01361802|Drug|Placebo Spray|Placebo Spray
75915833|NCT01235754|Drug|transdermal testosterone gel 1%|300 mcg once daily transdermal testosterone gel 1%
75915834|NCT01235754|Drug|placebo gel|once daily transdermal placebo gel
75915835|NCT04477122|Other|Manual therapy and extracorporeal radial shock waves therapy|25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)
75323022|NCT00551447|Drug|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
75628401|NCT03392246|Drug|Osimertinib|"may stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
75780121|NCT03394924|Drug|EDP-305 1 mg|Two tablets daily for 12 weeks
75780122|NCT03394924|Drug|EDP-305 2.5 mg|Two tablets daily for 12 weeks
75780123|NCT03394924|Drug|Placebo|Two tablets daily for 12 weeks
75915836|NCT02266290|Procedure|taping of ankle sprain|All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
76074751|NCT04382560|Other|Deep Breathing training|The intervention will comprise a psychoeducational part on the theorethical background underlying this technique and a pratical session in which partecipant will be instructed to inhale air with his/her nose and exhale with his/her mouth for a period of 3 seconds of inhalation and 7 seconds of exhalation (i.e., 6 cycles of breaths per minute;). During the session, the participant will be encouraged to put one hand over his/her chest and the other over the abdomen in order to see the difference between normal breathing and deep breathing. To help the subjects in the training, an online pacer will give the rhythm of respiration and will be used as visual feedback.
76074752|NCT04382560|Other|Compassion focused intervention|"The short compassion focused intervention will begin with a short psychoeducation on the evolved nature and difficulties of the human mind, such as tendencies for negativity bias, negative rumination, and self-criticism. Participants will then be offered insights into how humans can work with their 'tricky brains' using body-based and psychological-based practices aimed at increasing a grounding and soothing compassionate attitude towards ourselves and others. In particular, participants will be instructed to pratice a mindfulness technique designed to help them to become more aware of their present moment-to-moment and more compassionate towards their own emotions. They will then be guided to create an image conveying warmth and compassion to them. Lastly, participants will be guided to bring the image to mind and then write write a brief self-compassionate letter to themselves from that point of view."
76074753|NCT01961609|Biological|Secukinumab (AIN457)|Secukinumab was supplied in 150mg pre-filled syringes.
75323023|NCT00551447|Drug|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
75323024|NCT02299479|Device|Dexcom G4 Platinum CGM|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
75323025|NCT02299479|Device|Activity monitor|Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
75323026|NCT01968057|Drug|Baricitinib|Administered orally
75628402|NCT03392246|Drug|Selumetinib|"may enhance the effect of osimertinib to stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
75628403|NCT03383861|Diagnostic Test|Dual-Energy X-ray Absorptiometry (DXA)|BMD t-score derived from DXA scan
75628404|NCT03375307|Procedure|Biospecimen Collection|Undergo blood collection
75628405|NCT03375307|Drug|Olaparib|Given PO
75628406|NCT03367741|Drug|Cabozantinib S-malate|Given PO
75628407|NCT03367741|Biological|Nivolumab|Given IV
75780124|NCT01324973|Behavioral|eWellness|A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
75780125|NCT03943394|Other|fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene|"Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris [pH 8.0], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with ~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope."
75915837|NCT02266290|Device|Sport tex® kinesiotape|
75915838|NCT02266290|Device|Pretape Cramer®|
75323027|NCT01968057|Drug|Ciclosporin|Administered orally
75323028|NCT01968135|Drug|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
75323029|NCT01968135|Drug|Placebo Sugar Pill|Placebo Sugar Pill
75323030|NCT00658697|Drug|Docetaxel|Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
75323031|NCT00658697|Drug|Bevacizumab|Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
75323032|NCT00658697|Drug|ADT|Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
75323033|NCT00658697|Drug|Bicalutamide|Starting on day 84 orally once daily until hormone therapy is completed
75915839|NCT04476264|Procedure|Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection|The present study serves to describe a novel approach to utilizing a single adjustable 8-0 polypropylene suture for scleral fixation without conjunctival dissection and to evaluate safety and efficacy outcomes associated with this technique.
75915840|NCT02264496|Behavioral|Exercise|
75915841|NCT03135444|Behavioral|PSA TOOL|Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
75915842|NCT03135444|Behavioral|Revised PSA TOOL|Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
75323034|NCT03873116|Drug|BCX7353 capsules|BCX7353 capsules administered orally once daily
75323035|NCT03873116|Drug|BCX7353 capsules|BCX7353 capsules administered orally once daily
75323036|NCT03873116|Drug|Placebo oral capsule|Matching placebo capsules administered orally once daily
75323037|NCT01968447|Other|hypocapnia|Hyperventilation to the level of hypocapnia
75323038|NCT01968447|Other|normocapnia|Normal ventilation to the level of nromocapnia
75628408|NCT03363711|Other|AYA STEPS|a mobile health application
75628409|NCT03301909|Device|PillCam™ Endoscopy System|Subject may be assigned to any procedure involving modification of any of the PillCam™ Endoscopy System component as listed in the arm description.
75628410|NCT03301909|Drug|Bowel prep combination|Subject may be assigned to any bowel preparation combination.
75628411|NCT03293147|Other|HPLC-MS/MS-guided intervention|The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
75323039|NCT01795469|Device|Zoex compression garment|5-strap compression of abdomen, thighs and legs
75323040|NCT04399226|Drug|Dexmedetomidine|Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine).
75323041|NCT00659165|Drug|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
75323042|NCT00659165|Drug|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
75323043|NCT02299791|Other|ALL|"This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.~EHR tools to expedite identification~a. EHR automated point-of-care alerts (Best Practice Alerts)~EHR tools to expedite prescribing~EHR order sets~EHR text shortcuts for notation~patient education materials (handout, poster)~EHR-based outreach support tools a. EHR registries"
75628412|NCT03293147|Other|Standard care|Standard care for hypertensive patients
75628413|NCT03292497|Procedure|Treatment Algorithm|Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle >=25 degrees, or repaired if the posterior leaflet tethering angle <25 degrees.
75628414|NCT03292497|Procedure|No Treatment Algorithm|Patients will have their valve repaired or replaced at the discretion of their surgeon.
75628415|NCT03273023|Device|Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System|Promus PREMIERTM Stent System
75628416|NCT03265964|Drug|Uridine|Uridine is the active treatment in this clinical trial.
75628417|NCT03265964|Drug|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
75628418|NCT03244384|Procedure|Biospecimen Collection|Undergo blood sample collection
75628419|NCT03244384|Other|Clinical Observation|Undergo observation
75780126|NCT03742115|Drug|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
75323044|NCT02299791|Other|ALL|These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
75628420|NCT03244384|Procedure|Computed Tomography|Undergo a CT scan
75628421|NCT03244384|Procedure|CT Urography|Undergo a CT urography
75628422|NCT03244384|Procedure|Cystoscopy|Undergo a cystoscopy
75628423|NCT03244384|Procedure|Magnetic Resonance Imaging|Undergo a MRI
75628424|NCT03244384|Biological|Pembrolizumab|Given IV
75628425|NCT03244384|Other|Pharmacological Study|Correlative studies
75323045|NCT00700973|Behavioral|Interpersonal Violence Prevention Intervention|This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
75323046|NCT00700973|Other|Usual care|Substance use disorder usual care
75628426|NCT03244384|Other|Quality-of-Life Assessment|Ancillary studies
75628427|NCT03244384|Other|Questionnaire Administration|Ancillary studies
75780127|NCT03742115|Drug|Dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
75780128|NCT03742115|Drug|Etoposide|150 mg/m2 weekly
75915843|NCT03135444|Behavioral|Informal Interview|Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
75915844|NCT01355406|Device|FlexStent® Femoropopliteal Self Expanding Stent System|Transcatheter over guidewire placement of an intravascular stent(s)
75628428|NCT03237780|Drug|Atezolizumab|Given IV
75628429|NCT03237780|Procedure|Biopsy|Undergo biopsy
75628430|NCT03237780|Procedure|Biospecimen Collection|Undergo blood sample collection
75628431|NCT03237780|Procedure|Computed Tomography with Contrast|Undergo CT scan
75628432|NCT03237780|Drug|Eribulin Mesylate|Given IV
75628433|NCT03233711|Procedure|Biopsy|Undergo biopsy
75628434|NCT03233711|Procedure|Biospecimen Collection|Undergo blood sample collection
75628435|NCT03233711|Procedure|Colonoscopy|Undergo colonoscopy
75628436|NCT03233711|Procedure|Computed Tomography|Undergo CT scan
75628437|NCT03233711|Procedure|Digital Rectal Examination|Undergo digital rectal examination
75628438|NCT03233711|Procedure|High Resolution Anoscopy|Undergo anoscopy
75628439|NCT03233711|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628440|NCT03233711|Biological|Nivolumab|Given IV
75628441|NCT03233711|Other|Patient Observation|Undergo observation
75628442|NCT03233711|Procedure|Proctoscopy|Undergo proctoscopy
75628443|NCT03233711|Procedure|Sigmoidoscopy|Undergo sigmoidoscopy
75628444|NCT03233711|Procedure|X-Ray Imaging|Undergo chest x-ray
75628445|NCT03220347|Drug|CC-90010|CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
75628446|NCT03212274|Procedure|Biopsy|Undergo tissue biopsy
75628447|NCT03212274|Procedure|Biospecimen Collection|Undergo blood sample collection
75915845|NCT02266368|Device|Antimicrobeal coated stents|Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
75915846|NCT02266446|Behavioral|Attention & Interpretation Modification|
75915847|NCT01234038|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
75628448|NCT03212274|Procedure|Computed Tomography|Undergo a CT scan
75628449|NCT03212274|Procedure|Magnetic Resonance Imaging|Undergo a MRI
75628450|NCT03212274|Drug|Olaparib|Given PO
75628451|NCT03209674|Procedure|Cardiothoracic surgery|Cardiac or thoracic procedure
75628452|NCT03175432|Drug|Atezolizumab|Given IV
75628453|NCT03175432|Biological|Bevacizumab|Given IV
75780129|NCT03742115|Drug|IVIG|0.5 g/kg, once every 4 weeks
75780130|NCT01115036|Drug|panobinostat|Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
75780131|NCT01207622|Drug|Atomoxetine|
75780132|NCT01207622|Drug|Placebo|
75628454|NCT03175432|Drug|Cobimetinib|Given PO
75780133|NCT01212146|Dietary Supplement|Lactobacillus paracasei IMPC 2.1 LMGP22043|participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10^10 CFU.
75628455|NCT03175432|Procedure|Quality-of-Life Assessment|Ancillary studies
75628456|NCT03158129|Drug|Carboplatin|Given IV
75780134|NCT01212146|Dietary Supplement|Ordinary artichokes|Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
75915848|NCT01234038|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
75915849|NCT01234038|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
75915850|NCT01234038|Drug|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
75628457|NCT03158129|Drug|Cisplatin|Given IV
75780135|NCT00345293|Biological|autologous dendritic cell vaccine (DC/PC3)|ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity
75780136|NCT03942068|Drug|albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor
75915851|NCT01234038|Drug|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
75915852|NCT01233960|Drug|adult human mesenchymal stem cells|PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
75915853|NCT02268708|Procedure|Oncological pulmonary resection|Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
75915854|NCT01229982|Drug|Latanoprost-PPDS|Punctal Plug
76074754|NCT04468672|Behavioral|Portion size|The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
75323047|NCT03864848|Device|Mitral Touch Implant|The study population for this study will be comprised of patients who are to undergo cardiac surgery with a sternotomy (e.g. CABG) and who present moderate to severe ischemic or functional MR. In order to be considered eligible for the study, each patient must meet the conditions listed in the inclusion and none of the exclusion criteria.
75323048|NCT02299869|Device|Verde (Competitor-control)|contact lens
75780137|NCT03942068|Drug|Apatinib|a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)
75780138|NCT03989531|Biological|Adrecizumab|Drip infusion over 60 minutes
75915855|NCT02264652|Device|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
75915856|NCT01226628|Biological|CNTO 2476|
75323049|NCT02299869|Device|Green (CVI-test)|contact lens
75323050|NCT02299869|Device|Cinza (Competitor-control)|contact lens
75323051|NCT02299869|Device|Grey (CVI-test)|contact lens
75323052|NCT02299869|Device|Esmeralda (Competitor-control)|contact lens
75628458|NCT03158129|Drug|Docetaxel|Given IV
75628459|NCT03158129|Biological|Ipilimumab|Given IV
75915857|NCT01226628|Procedure|iTrack Model 275 micro catheter|CNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula.
75628460|NCT03158129|Biological|Nivolumab|Given IV
75915858|NCT01225380|Drug|GS-9190|GS-9190 capsule, 20 mg BID, 16 or 24 weeks
75628461|NCT03158129|Drug|Pemetrexed|Given IV
75628462|NCT03141684|Drug|Atezolizumab|Given IV
75628463|NCT03141684|Biological|Bevacizumab|Given IV
75628464|NCT03141684|Procedure|Biospecimen Collection|Undergo collection of blood and urine
75628465|NCT03141684|Procedure|Computed Tomography|Undergo CT
75628466|NCT03140150|Device|Follow-up by Carelink express|Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express
75628467|NCT03140150|Other|Follow-up according to the usual recommendations|According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
75628468|NCT03138499|Biological|Nivolumab|Specified dose on specified days
75915859|NCT01225380|Drug|GS-9256|GS-9256 capsule, 150 mg BID, 16 or 24 weeks
75915860|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a, (solution for injection) 180 µg/week, up to 48 weeks
75915861|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), up to 48 weeks
75915862|NCT01225380|Drug|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
75915863|NCT01225380|Drug|GS-9256|GS-9256 capsule, 150 mg BID, 24 weeks
76074755|NCT04267198|Behavioral|Intention Treatment for Anomia|Word retrieval treatment for aphasia that engages right hemisphere intention mechanisms using a left-hand circular gesture.
76074756|NCT00800254|Device|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
76074757|NCT00800254|Other|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
76074758|NCT03753646|Other|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
76074759|NCT04383418|Drug|dexmedetomidine nasal spray|dexmedetomidine nasal spray
75780139|NCT03989531|Drug|Placebo|Drip infusion over 60 minutes
75915864|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, up to 48 weeks
75915865|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), up to 48 weeks
75780140|NCT01328288|Drug|standard ART according to the Thai Ministry of Public Health national guidelines|Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
75780141|NCT01054391|Device|NEC - Neurovascular Embolization Cover|Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
75915866|NCT01225380|Drug|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
76074760|NCT04383418|Drug|dexmedetomidine hydrochloride nasal spray blank preparation|dexmedetomidine hydrochloride nasal spray blank preparation
75628469|NCT03138499|Biological|Brentuximab vedotin|Specified dose on specified days
75628470|NCT03136185|Drug|Bomedemstat|Oral (capsule) administration according to dose allocation.
75628471|NCT03125902|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
75628472|NCT03125902|Drug|Atezolizumab Placebo|Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
75628473|NCT03125902|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 90 mg/m^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
75628474|NCT03085719|Drug|Pembrolizumab|Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells
75628475|NCT03085719|Radiation|Radiation|Radiation is used to shrink the cancer
75628476|NCT03083353|Drug|Isradipine|Isradipine will be administered 90 minutes prior to the initiation of cue exposure.
75628477|NCT03083353|Behavioral|Cue Exposure|Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.
75780142|NCT01112852|Drug|pantoloc 40 mg|pantoloc iv. infusion per day
75780143|NCT01112852|Drug|somatostatin or terlipressin|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
75780144|NCT01054469|Procedure|TAP block placement with placebo|20 ml of normal saline (placebo)
75915867|NCT01225380|Drug|GS-9256 placebo|placebo matching GS-9256 capsule BID, 24 weeks
76074761|NCT03414112|Biological|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
76074762|NCT02152540|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
75323053|NCT02299869|Device|Jade (CVI-test)|contact lens
75780145|NCT01054469|Procedure|Placement of block with ropivacaine|20 ml of 0.5% ropivacaine hydrochloride
75915868|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, 48 weeks
75915869|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), 48 weeks
75323054|NCT02299869|Device|Azul (Competitor-control)|contact lens
75628478|NCT03069131|Drug|Rifaximin|twice daily administration of 1 tablet containing 550 mg of active rifaximin
75323055|NCT02299869|Device|Blue (CVI-test)|contact lens
75628479|NCT03069131|Other|Placebo|twice daily administration of 1 rifaximin placebo tablet
75915870|NCT01349868|Drug|PT005 MDI|PT005 MDI taken as two inhalations
75323056|NCT00542087|Drug|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
75323057|NCT00542087|Drug|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
75323058|NCT04277624|Drug|fezolinetant - test formulation|Administered orally
75323059|NCT04277624|Drug|fezolinetant - reference formulation|Administered orally
75323060|NCT00541697|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
75323061|NCT00541697|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
75628480|NCT03049306|Drug|Propranolol Oral Tablet|Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
75628481|NCT03049306|Drug|Placebo Oral Tablet|Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
75628482|NCT03049306|Device|CPAP|Patients will sleep in the lab wearing CPAP
75628483|NCT02985957|Biological|Nivolumab|Specified dose on specified days
75628484|NCT02985957|Biological|Ipilimumab|Specified dose on specified days
75628485|NCT02985957|Drug|Cabazitaxel|Specified dose on specified days
75628486|NCT02985957|Drug|Prednisone|Specified dose on specified days
75628487|NCT02978625|Procedure|Biopsy|Undergo tissue biopsy
75915871|NCT01349868|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
75915872|NCT01349868|Drug|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
75915873|NCT01349868|Other|Placebo MDI|Matching placebo to PT005 MDI taken as two inhalations
76074763|NCT02152540|Device|Sham rTMS|Placebo Device that simulates active rTMS treatment
76074764|NCT04383184|Procedure|tracheoplasty|tracheoplasty and only left pulmonary artery transplantation
76074765|NCT05287204|Diagnostic Test|Musculoskeletal ultrasound|Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
76074766|NCT05287204|Diagnostic Test|Assessments of muscle strength and physical function|A battery of tests of physical function and muscle strength (see outcomes section for details).
76074767|NCT05287204|Diagnostic Test|Metabolomics|Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
76074768|NCT03839134|Device|DentalVibe® Comfort Injection System|Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.
75323062|NCT03223376|Combination Product|fruquintinib +paclitaxel|treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
75628488|NCT02978625|Procedure|Biospecimen Collection|Undergo blood sample collection
75628489|NCT02978625|Procedure|Computed Tomography|Undergo CT
75323063|NCT03223376|Combination Product|fruquintinib placebo + paclitaxel|control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
75323064|NCT00395603|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
75323065|NCT00395603|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
75323066|NCT00659633|Drug|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
75323067|NCT02300025|Drug|cobimetinib|single oral 10-mg dose of cobimetinib
75628490|NCT02978625|Other|Laboratory Biomarker Analysis|Correlative studies
75323068|NCT00328523|Drug|MK-0653, ezetimibe|
75323069|NCT00328523|Drug|Duration of Treatment: 3 months|
75323070|NCT03204266|Drug|Arginine recovery supplement|Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
75780146|NCT01115114|Behavioral|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
75780147|NCT01115114|Behavioral|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
75780148|NCT01115114|Behavioral|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
75323071|NCT03204266|Dietary Supplement|Omega-3 Fatty Acids|Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
75323072|NCT00295139|Behavioral|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
75780149|NCT01207700|Behavioral|CHW based intervention post ACS|CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
75780150|NCT01115192|Procedure|Group A|Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
75780151|NCT01115192|Procedure|Group B|Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
75780152|NCT03940430|Drug|Lactoferrin|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
76074769|NCT03839134|Drug|Lidocaine Epinephrine|Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
75628491|NCT02978625|Biological|Nivolumab|Given IV
75628492|NCT02978625|Procedure|Positron Emission Mammography|Undergo PET/CT
75628493|NCT02978625|Biological|Talimogene Laherparepvec|Given IT
75628494|NCT02971501|Biological|Bevacizumab|Given IV
75628495|NCT02971501|Procedure|Biopsy|Undergo tumor biopsy
75628496|NCT02971501|Procedure|Biospecimen Collection|Undergo blood sample collection
75628497|NCT02971501|Procedure|Computed Tomography|Undergo CT scan
75628498|NCT02971501|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628499|NCT02971501|Drug|Osimertinib|Given PO
75915874|NCT01348152|Drug|DAIKENCHUTO (TU-100)|Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.
75780153|NCT03940430|Drug|Ferrous sulfate|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
75780154|NCT01115270|Other|Non-invasive measures|assessment of cerebrovascular fluid movement
75780155|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
75780156|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
75780157|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
75780158|NCT03940118|Device|Catheter secretion suctioning|Catheter secretion suctioning with prior nebulization of hypertonic saline
75780159|NCT03940118|Combination Product|Secretion suctioning + hypertonic saline|Catheter secretion suctioning with prior nebulization of hypertonic saline
75915875|NCT01348152|Drug|Placebo|Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
76074770|NCT03180580|Behavioral|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
76074771|NCT03906526|Drug|VTX-2337|Motolimod
76074772|NCT03906526|Drug|Nivolumab|IV Nivolumab
75628500|NCT02966886|Procedure|Eccentric Reaming|"Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within < 10 degrees of neutral glenoid version."
75780160|NCT03940118|Device|Ins-exsufflation|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
76074773|NCT03088930|Drug|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
76074774|NCT03035188|Drug|Vismodegib|1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
76074775|NCT05265754|Behavioral|sujok therapy|sujok therapy
76074776|NCT02923882|Other|'$100Kitchen and improved cookstove'|
75780161|NCT03940118|Combination Product|Ins-exsufflation + Hypertonic saline|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
75780162|NCT02533349|Drug|Motilitone|30mg, 1 tablet, 3 times a day
75780163|NCT02533349|Drug|Pantoprazole|40mg, 1 tablet, 1time a day
75780164|NCT02533349|Drug|Placebo|30mg, 1 tablet, 3 times a day
75780165|NCT01115426|Drug|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
75780166|NCT03942458|Drug|Vicagrel 6mg|Vicagrel 24mg loading followed by 6mg/day for 6 days
76074777|NCT02152696|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
75628501|NCT02966886|Procedure|Augmented Glenoid Component Implantation|Patients will undergo standard glenoid preparation and implantation of a posteriorly augmented glenoid component. The degree of posterior augment will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
75780167|NCT03942458|Drug|Clopidogrel 75mg|Clopidogrel 300mg loading followed by 75mg/day for 6 days
75780168|NCT03989297|Radiation|Radiation|Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
75780169|NCT01210196|Procedure|MRI|Cardiac MRI after 12 and 24 months.
75780170|NCT03989375|Device|transcutaneous vagus nerve electric stimulator|The stimulator that can be attached to ears of the patient.We suppose that this device can reduce the incidence of perioperative neurocognitive disorders(PND)
75780171|NCT03989453|Other|Chi Kung|The duration of the intervention is 12 weeks, with 2 sessions per week of Chi Kung. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up (Based on breathing and concentration exercises), of 10 minutes duration, a 40-45 minute Chi Kung session and finally 10 minutes of guided relaxation.
75915876|NCT01461954|Drug|FST-100|FST-100
75915877|NCT01461954|Drug|FST-100 Vehicle|FST-100 Vehicle
75323073|NCT00295139|Behavioral|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
75628502|NCT02966886|Procedure|Posterior Glenoid Bone Grafting|Patient will undergo a total shoulder arthroplasty as per standard technique. Glenoid version will be restored to within 10 degrees of neutral with a posterior glenoid bone graft. The bone graft will be harvested from the humeral head and fixed to the posterior glenoid with mini-fragment screws.
75628503|NCT02955758|Biological|Pembrolizumab|Given IV, 200mg fixed dose, every 3 weeks
75780172|NCT01115504|Drug|Thiamine|300 mg daily for 30 days
75780173|NCT03940040|Other|Usual care|Usual Care
75780174|NCT03940040|Other|High flow nasal oxygen|High flow nasal oxygen
75915878|NCT02266524|Drug|Tamsulosin hydrochloride, very low dose|
75915879|NCT02266524|Drug|Tamsulosin hydrochloride, low dose|
75915880|NCT02266524|Drug|Tamsulosin hydrochloride, medium dose|
75915881|NCT02266524|Drug|Tamsulosin hydrochloride, high dose|
75915882|NCT01336686|Drug|Arhalofenate|Arhalofenate 400 mg once daily for 4 weeks
75915883|NCT01336686|Drug|Arhalofenate|Arhalofenate 600 mg once daily for 4 weeks
75915884|NCT01336686|Drug|Placebo comparator|Matching placebo once daily for 4 weeks
75915885|NCT01336686|Drug|Colchicine|0.6 mg colchicine daily for flare prophylaxis
75915886|NCT02266602|Radiation|Intraoperative Radiation Therapy|Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
75915887|NCT01221246|Drug|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
75915888|NCT01221246|Drug|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
76074778|NCT02152696|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
76074779|NCT02152696|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
76074780|NCT02153476|Drug|2.0mg of ALG-1001|
76074781|NCT02153476|Drug|Balanced Salt Solution|
76074782|NCT05206942|Diagnostic Test|Doppler ultrasound|Power doppler measurements will be made using a portable Siemens S2000 ultrasound scanner
75780175|NCT01212380|Drug|carfilzomib|Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
75915889|NCT01205334|Biological|Autologous CMV-specific CTL|"CMV-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The expected volume will be 1-50 cc.~At the discretion of the attending physician, subjects can receive repeat infusions of modified T cells at the same dose level as long as they do not have progressive disease (up to a maximum of 6 doses and the minimum interval between repeat infusions is 6 weeks). Infusion procedures and follow-up will be identical to those for the first infusion. Patients, who receive additional doses of CTLs will be monitored exactly like after the 1st CTL infusion."
75915890|NCT01455090|Drug|BMS-650032|
75915891|NCT01455090|Drug|BMS-790052|
75915892|NCT01455090|Drug|BMS-791325|
75915893|NCT01455090|Drug|Ribavirin|
76074783|NCT05206942|Diagnostic Test|Long Ensemble Angular-coherence Doppler [LEAD] ultrasound|Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner with a C5-2v
76074784|NCT05206942|Diagnostic Test|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
76074785|NCT03839290|Procedure|Early neonatal cheiloplasty|
76074786|NCT03834922|Other|Prospective data collection|No intervention. It's a prospective data collection.
75323074|NCT00295139|Behavioral|Critical Time Intervention (CTI)|Case management component
75323075|NCT04277156|Dietary Supplement|Lactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063|7 drops contain Lactobacillus rhamnosus GG 5x10^9 CFU; and Lactobacillus reuteri 1x10^8 CFU.
75323076|NCT04277156|Dietary Supplement|L rhamnosus ATCC 53103|5 drops contain Lactobacillus rhamnosus 5x10^9 CFU.
75323077|NCT04458584|Procedure|Trapeziectomy with ligament reconstruction (I; LRTI)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)
75628504|NCT02954874|Procedure|Biospecimen Collection|Undergo collection of blood samples
75628505|NCT02954874|Other|Laboratory Biomarker Analysis|Correlative studies
75628506|NCT02954874|Other|Patient Observation|Undergo standard monitoring
75628507|NCT02954874|Biological|Pembrolizumab|Given IV
75628508|NCT02954874|Other|Quality-of-Life Assessment|Ancillary studies
75628509|NCT02954874|Other|Questionnaire Administration|Ancillary studies
75628510|NCT02954874|Radiation|Radiation Therapy|Undergo radiation therapy
75628511|NCT02915523|Drug|entinostat|An orally available histone deacetylases inhibitor (HDACi).
75628512|NCT02915523|Drug|avelumab|A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
75628513|NCT02915523|Drug|Placebo|A pill containing no active drug ingredient.
75628514|NCT02912559|Drug|Atezolizumab|Given IV
75628515|NCT02912559|Procedure|Biospecimen Collection|Undergo blood sample collection
75628516|NCT02912559|Procedure|Computed Tomography|Undergo CT
75628517|NCT02912559|Drug|Fluorouracil|Given IV
75915894|NCT03135366|Behavioral|Keheala|
75915895|NCT03135366|Other|Standard of Care|Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
75915896|NCT01449162|Drug|Masitinib|6 mg/kg/day
75915897|NCT01449162|Drug|Placebo|
76074787|NCT03839992|Diagnostic Test|spirometry|measure spirometry and lung CT
76074788|NCT05172232|Diagnostic Test|Dermalyzer|To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
76074789|NCT02009176|Procedure|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
76074790|NCT02009176|Procedure|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
75323078|NCT04458584|Procedure|Trapeziectomy with suture suspensionplasty (II; SS)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)
75628518|NCT02912559|Drug|Leucovorin Calcium|Given IV
75628519|NCT02912559|Procedure|Magnetic Resonance Imaging|Undergo MRI
75323079|NCT04458584|Procedure|Arthroscopic Trapeziectomy (III; AT)|Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
75780176|NCT01212380|Other|Cytokine Assessment|TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
75780177|NCT01212380|Other|Pharmacodynamic Studies|Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
75780178|NCT01212380|Other|Proteosome Inhibition Assessment|Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
75915898|NCT02056782|Drug|Dociparstat sodium|"The following induction regimen was administered:~Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days."
75323080|NCT00701675|Drug|sertraline 50 mg daily|50 mg daily
75780179|NCT01212380|Other|Pharmacogenomic Studies|Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
75780180|NCT00343889|Biological|DTaP-HB-PRP~T vaccine + OPV|0.5 mL, Intramuscular
75915899|NCT01469832|Biological|MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
76074791|NCT01905436|Drug|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
75323081|NCT00701675|Drug|sertraline 100 mg daily|100 mg daily
75323082|NCT00701675|Drug|Placebo 50 or 100 mg|50mg or 100mg matching placebo
75323083|NCT01987089|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.
75323084|NCT04444154|Behavioral|Control group|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.
75323085|NCT04444154|Behavioral|Group with active participation|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
75323086|NCT04444154|Behavioral|Group with video and quizz|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
75628520|NCT02912559|Drug|Oxaliplatin|Given IV
75628521|NCT02912559|Other|Quality-of-Life Assessment|Ancillary studies
75628522|NCT02903940|Device|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
75628523|NCT02890355|Drug|Fluorouracil|Given IV
75628524|NCT02890355|Drug|Fluorouracil|Given IV bolus
75628525|NCT02890355|Drug|Irinotecan Hydrochloride|Given IV
75628526|NCT02890355|Other|Laboratory Biomarker Analysis|Correlative studies
75628527|NCT02890355|Drug|Leucovorin Calcium|Given IV
75628528|NCT02890355|Drug|Veliparib|Given PO
75628529|NCT02888743|Biological|Durvalumab|Given IV
75628530|NCT02888743|Radiation|Radiation Therapy|Undergo radiation therapy
75628531|NCT02888743|Biological|Tremelimumab|Given IV
75628532|NCT02844816|Drug|Atezolizumab|Given IV
75628533|NCT02834013|Procedure|Biospecimen Collection|Undergo blood sample collection
75628534|NCT02834013|Procedure|Computed Tomography|Undergo CT
75628535|NCT02834013|Procedure|Echocardiography|Undergo ECHO
75628536|NCT02834013|Biological|Ipilimumab|Given IV
75628537|NCT02834013|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628538|NCT02834013|Biological|Nivolumab|Given IV
75628539|NCT02782598|Device|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
75628540|NCT02745002|Device|navigated bronchoscopy|
75915900|NCT04475484|Other|Online questionnaire|"Parents will receive a link to an online questionnaire through computing services of Lyon's Academy. They have to give their consent to allow their child to participate in the study. Then, children can complete the online questionnaire.~The questionnaire starts with few explanations on the context of the study, and ends with psycho-education advices and what to do in the event of psychological distress."
75323087|NCT01969539|Drug|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
75323088|NCT01969539|Drug|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
75323089|NCT04277312|Behavioral|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
75628541|NCT02700230|Procedure|Computed Tomography|Undergo CT scan
75628542|NCT02700230|Other|Laboratory Biomarker Analysis|Correlative studies
75628543|NCT02700230|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
75323090|NCT04277312|Behavioral|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
75628544|NCT02700230|Other|Quality-of-Life Assessment|Ancillary studies
75323091|NCT00659789|Drug|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
75780181|NCT00343889|Biological|Tritanrix-HepB/Hib™ + OPV vaccine|0.5 mL, Intramuscular
75780182|NCT00343889|Biological|Oral Polio Vaccine|Oral co-administered with study vaccine
75780183|NCT01212458|Drug|Rufinamid|Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.
75780184|NCT03939884|Drug|MuscleCare Topical Product|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
75780185|NCT03939884|Drug|Voltaren Topical|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
75780186|NCT03939884|Drug|Nivea, Topical Cream|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
75780187|NCT01054547|Drug|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
75628545|NCT02700230|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT imaging
75628546|NCT02664545|Device|BEAR Scaffold|A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.
75628547|NCT02664545|Procedure|Tendon Graft|A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
75780188|NCT01054547|Drug|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
75780189|NCT01212536|Device|Airtraq laryngoscopy|laryngoscopy and intubation
75780190|NCT01115894|Drug|Naltrexone|100 mg oral dosage daily for 12 weeks
75780191|NCT01115894|Behavioral|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
75915901|NCT01198626|Drug|JNJ-32729463|150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
75915902|NCT01198626|Drug|moxifloxacin|400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
75915903|NCT01198626|Drug|JNJ-32729463 (Open-Label)|Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
75915904|NCT01194960|Drug|Docetaxel|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
75323092|NCT00659789|Drug|Sterile water|Sterile water is used in place of Vacc-4x and in place of Leukine
75323093|NCT04639310|Drug|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
75628548|NCT02645851|Drug|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
75628549|NCT02645851|Device|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
75780192|NCT01115894|Behavioral|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
75780193|NCT01115894|Drug|Placebo|Placebo
75915905|NCT01194960|Drug|TroVax|Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37
75780194|NCT03986489|Behavioral|Mindfulness-based dance/movement therapy (M-DMT)|M-DMT includes benefits of physical activity, group psychotherapy, mindfulness training, and an art-based intervention in a unified practice. Each online session focuses on different psycho-educational topics about chronic low back pain management and links these topics with specific M-DMT activities that incorporate mindfulness-based principles and techniques.
75780195|NCT03986489|Behavioral|Chronic pain social support group|"The therapist will facilitate online open group discussions about participants' experiences with or reactions to the topic of discussion and will promote empathy among group members. The therapist will use client-centered, reflective listening techniques but will not prescribe any specific recommendations for change.~Each week, SSG participants will receive emails with brief information about the topic discussed during the group session."
75780196|NCT01115972|Drug|ASP1585|oral
75780197|NCT01115972|Drug|valsartan|oral
75780198|NCT02533271|Radiation|Short-course radiotherapy with neoadjuvant chemotherapy|Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy
75780199|NCT02533271|Radiation|Long-term chemoradiotherapy|Standard chemoradiotherapy
75780200|NCT01116050|Drug|Misoprostol|5 tablets of 200 microgram geach intra rectal by opaque introducer
75780201|NCT01116050|Drug|Placebo|5 tablets in opque introducer
75915906|NCT02266680|Behavioral|Yoga Treatment Group|The breathing focused yoga intervention is a manualized yoga protocol developed at CAMH by the Mood and Anxiety Disorders group, with yoga teacher, Ms. Tiffany Garfinkel, as the lead. BFY incorporates postures and meditation, but there is a special focus on controlled breathing at different rates, including Ujjaji or slow inhalation, exhalation and holding of breath; Bhastrika or Kapalabhati, two types of vigorous breathing with forced exhalation; and cyclical breathing or a repeated pattern of slow, moderate and fast breathing.
75915907|NCT01331850|Drug|Copegus|1000 mg or 1200 mg daily oral doses for 24 weeks
75628550|NCT02645851|Device|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
75915908|NCT01331850|Drug|Copegus|1000 mg or 1200 mg daily oral doses for 48 weeks
75323094|NCT04639310|Drug|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
75628551|NCT02645851|Other|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
75915909|NCT01331850|Drug|Pegasys|180 microgram subcutaneously once weekly for 24 weeks
75915910|NCT01331850|Drug|Pegasys|180 microgram subcutaneously once weekly for 48 weeks
75323095|NCT02300727|Drug|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
75323096|NCT02300727|Drug|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
75628552|NCT02595944|Procedure|Biospecimen Collection|Undergo blood sample collection
75628553|NCT02595944|Procedure|Computed Tomography|Undergo CT
75915911|NCT01331850|Drug|RO5024048|1000 mg oral doses twice a day for 24 weeks
76074792|NCT00802204|Radiation|PET scan|"Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride [18F] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD"
75323097|NCT02300727|Drug|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
75323098|NCT00250445|Drug|MK0663, etoricoxib|
75323099|NCT00250445|Drug|Comparator: Diclofenac sodium|
75323100|NCT00242489|Drug|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
75323101|NCT00242489|Drug|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
75323102|NCT03836612|Other|No intervention|Observation of routine clinical practice
75323103|NCT00659945|Drug|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
75323104|NCT00659945|Drug|Ondansetron plus placebo|Ondansetron plus placebo
75628554|NCT02595944|Procedure|Echocardiography|Undergo ECHO
75628555|NCT02595944|Biological|Nivolumab|Given IV
75628556|NCT02595944|Other|Observation|Undergo observation
75628557|NCT02595944|Procedure|Positron Emission Tomography|Undergo PET-CT
75628558|NCT02595931|Drug|Berzosertib|Given IV
75628559|NCT02595931|Procedure|Biopsy Specimen|Undergo biopsy
75780202|NCT03939650|Device|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
75780203|NCT03941522|Other|Early discharge from hospital|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
75780204|NCT01054781|Drug|Rituximab|1st cycle R+R-CHOP 2-8th cycle R-CHOP
75915912|NCT01331850|Drug|danoprevir|100 mg oral doses twice a day for 24 weeks
75915913|NCT01331850|Drug|ritonavir|100 mg oral doses twice a day for 24 weeks
75915914|NCT02264730|Drug|ClotFoam|Patient has not received blood products between screenings
75915915|NCT01328808|Drug|Acetaminophen/APAP|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute"
75915916|NCT01968590|Drug|Cholecalciferol|DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
75915917|NCT02266836|Device|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
75915918|NCT01325688|Drug|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
75323105|NCT01534871|Behavioral|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
75915919|NCT01325688|Device|Aluminium disk|
76074793|NCT00802204|Procedure|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
75628560|NCT02595931|Procedure|Biospecimen Collection|Correlative studies
75628561|NCT02595931|Procedure|Computed Tomography|Undergo CT
75628562|NCT02595931|Drug|Irinotecan Hydrochloride|Given IV
75915920|NCT01325688|Device|OpSite(TM) disk|
75915921|NCT04666922|Drug|BI 765080|BI 765080
76074794|NCT00802204|Procedure|MRI|An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
76074795|NCT00802204|Behavioral|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study. Completed at baseline
76074796|NCT00802204|Other|Caloric Restriction|Obese participants only complete a short-term (~10days) very low calorie diet
76074797|NCT01853020|Drug|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
76074798|NCT01853020|Drug|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
76074799|NCT01256086|Drug|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
76074800|NCT01256086|Drug|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
76074801|NCT01256086|Drug|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
75323106|NCT04387565|Other|magnesium and vanadium measurements and compare|Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).
75628563|NCT02595424|Drug|Capecitabine|Given PO
75628564|NCT02595424|Drug|Carboplatin|Given IV
75628565|NCT02595424|Drug|Cisplatin|Given IV
75628566|NCT02595424|Drug|Etoposide|Given IV
75628567|NCT02595424|Other|Laboratory Biomarker Analysis|Correlative studies
75628568|NCT02595424|Drug|Temozolomide|Given PO
75628569|NCT02581930|Drug|Ibrutinib|Given PO
75628570|NCT02581930|Other|Laboratory Biomarker Analysis|Correlative studies
75628571|NCT02581930|Other|Pharmacogenomic Study|Correlative studies
75628572|NCT02581930|Other|Pharmacological Study|Correlative studies
75628573|NCT02568553|Biological|Blinatumomab|Given IV
75628574|NCT02568553|Drug|Lenalidomide|Given PO
75628575|NCT02567409|Drug|Berzosertib|Given IV
75628576|NCT02567409|Drug|Cisplatin|Given IV
75628577|NCT02567409|Drug|Gemcitabine Hydrochloride|Given IV
75628578|NCT02567123|Behavioral|Experimental|
75628579|NCT02527044|Procedure|Fractional Flow Reserve (FFR)|An FFR will be performed pre-operative to the CABG procedure
75915922|NCT04666922|Drug|Placebo|Placebo; 0.9% saline for injection
75915923|NCT01318434|Drug|EB-1010 25mg BID|capsule once daily
75915924|NCT01318434|Drug|SSRI Active|Active Comparator
75915925|NCT01318434|Drug|EB-1010 50mg BID|Experimental Active
75915926|NCT01318434|Drug|Placebo|Placebo comparator
75915927|NCT03465956|Procedure|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy using the gastro-intestinal anastomosis stapler.
75915928|NCT03465800|Behavioral|self-monitoring|self-monitoring of physical activity
75915929|NCT03465800|Behavioral|daily incentives|daily incentive payments for physical activity
75915930|NCT03465800|Behavioral|delayed lump sum incentives|delayed lump sum payments for physical activity
75915931|NCT04475094|Drug|Rubidium-82|Consented subjects will undergo a rest/regadenoson stress myocardial perfusion PET study.
75915932|NCT04475094|Behavioral|Seattle Angina Questionnaire-7|Consented subjects will complete a SAQ-7.
76074802|NCT01256086|Drug|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
76074803|NCT01149850|Biological|bevacizumab|Given IV
75915933|NCT04475094|Behavioral|Rose Dyspnea Scale|Consented subjects will complete a RDS.
75915934|NCT05229692|Device|NEUBIE|"Participants will be asked to undergo electrical stimulation with the NEUBIE at their treatment threshold. Treatment threshold will be described as uncomfortable, but not painful (a 7 out of 10 on a perceived intensity scale).~Session length: ≤ 30 minutes Treatment frequency: 2x per week for 5 weeks~Week 1 post-op (treatments 1-2) Activity: Passive Neubie on Abdominals & Obliques~Weeks 2-3 (treatments 3-6)~Passive Neubie~Isometric movements with Neubie on abdominals and obliques~Active mobilizations with Neubie on abdominals and obliques~Weeks 4-5 (treatments 7-10)~Active mobilizations with Neubie on abdominals and obliques~Core Strength Exercise circuit with Neubie on abdominals and obliques"
75323107|NCT02141555|Drug|Vaginal Misoprostol|Misoprostol inserted into vagina
75780205|NCT01057979|Behavioral|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
75323108|NCT02141555|Drug|Buccal Misoprostol|Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
75323109|NCT01799057|Drug|Metformin|Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
75323110|NCT01799057|Drug|Placebo|Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
75323111|NCT02320175|Behavioral|Patient and Family Centered I-PASS|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
75323112|NCT02421536|Other|Vibrogent Smartphone Application|
75323113|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
75628580|NCT02521103|Device|Triathlon Tritanium Cone Augments|The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
75628581|NCT02513563|Drug|Carboplatin|Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
75628582|NCT02513563|Drug|Paclitaxel|Participants will be treated with paclitaxel 175 mg/m^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
75628583|NCT02513563|Drug|AZD1775|Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
75628584|NCT02506153|Biological|Ipilimumab|Given IV
75628585|NCT02506153|Biological|Pembrolizumab|Given IV
75628586|NCT02506153|Other|Quality-of-Life Assessment|Ancillary studies
75628587|NCT02506153|Biological|Recombinant Interferon Alfa-2b|Given IV and SC
75628588|NCT02498600|Biological|Ipilimumab|Given IV
75628589|NCT02498600|Biological|Nivolumab|Given IV
75628590|NCT02496585|Drug|Nintedanib|
75780206|NCT01057979|Behavioral|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
75780207|NCT03941678|Dietary Supplement|Creatine monohydrate|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
75323114|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
75323115|NCT00588809|Drug|selumetinib|Given PO
75780208|NCT03941678|Dietary Supplement|Placebo|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
75915935|NCT01314222|Drug|BMS-954561|
75915936|NCT01314222|Drug|Pregabalin|
75323116|NCT00588965|Drug|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
75323117|NCT00588965|Drug|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
75323118|NCT00589277|Behavioral|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
75628591|NCT02496585|Drug|Prednisone|
75628592|NCT02496585|Other|Placebo|
75628593|NCT02496208|Procedure|Biopsy|Undergo biopsies
75628594|NCT02496208|Procedure|Biospecimen Collection|Undergo collection of blood
75628595|NCT02496208|Drug|Cabozantinib S-malate|Given PO
75628596|NCT02496208|Procedure|Computed Tomography|Undergo CT scan
75915937|NCT01314222|Drug|Placebo matching BMS-954561|
75915938|NCT01314222|Drug|Placebo matching Pregabalin|
75915939|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
75323119|NCT00589277|Behavioral|Standard care counseling + standard materials|Standard messages for quitting smoking
75323120|NCT00702299|Drug|cisplatin|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
75628597|NCT02496208|Procedure|Echocardiography|Undergo echocardiography
75628598|NCT02496208|Biological|Ipilimumab|Given IV
75628599|NCT02496208|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628600|NCT02496208|Biological|Nivolumab|Given IV
75628601|NCT02479841|Other|Self management program|
75628602|NCT02473536|Radiation|Stereotactic ablative radiation therapy|SABR
75628603|NCT02466971|Radiation|Brachytherapy|Undergo brachytherapy
75628604|NCT02466971|Drug|Cisplatin|Given IV
75628605|NCT02466971|Radiation|External Beam Radiation Therapy|Undergo EBRT
75628606|NCT02466971|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75915940|NCT01309932|Drug|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 24 weeks
75323121|NCT00702299|Drug|paclitaxel|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
75323122|NCT00702299|Drug|pemetrexed disodium|Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
75628607|NCT02466971|Other|Laboratory Biomarker Analysis|Correlative studies
75323123|NCT00702299|Other|biologic sample preservation procedure|Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
75628608|NCT02466971|Radiation|Radiation Therapy|Undergo conventional RT
75628609|NCT02466971|Drug|Triapine|Given IV
75628610|NCT02443545|Drug|Deferiprone|
75628611|NCT02443077|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
75628612|NCT02443077|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
75628613|NCT02443077|Drug|Carmustine|Given IV
75628614|NCT02443077|Drug|Cyclophosphamide|Given IV
75780209|NCT05282290|Drug|Antihypertensive drugs (no restriction on the type of drugs)|"The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out.~The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening."
75780210|NCT01311778|Drug|Cannabidiol|"Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl."
75780211|NCT01311778|Drug|Fentanyl|All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
75780212|NCT00354341|Drug|Epoetin beta|
75780213|NCT03708796|Diagnostic Test|SIRS, qSOFA, NEWS, RETTS scores evaluation|Simple data collection from regular vital signs recordings during the initial phase of care management in the emergency department. Missing data is then possibly completed by the physician when made available during the regular medical management of the patient.
75780214|NCT03708718|Drug|Prednisolone 5 mg|5mg prednisolone, once a day for 6 months
75780215|NCT03708718|Drug|Placebo oral capsule; From August 2020 'no additional treatment'|Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication
75780216|NCT01054859|Drug|avanafil|200 mg avanafil tablet QD plus 0.5 g/kg alcohol
75780217|NCT01054859|Other|alcohol|0.5 g/kg alcohol
75780218|NCT01054859|Drug|avanafil|200 mg avanafil tablet QD
75780219|NCT00354107|Biological|monoclonal antibody SGN-30|Given IV
75780220|NCT00354107|Drug|therapeutic hydrocortisone|Given IT
75780221|NCT00354107|Drug|ifosfamide|Given IV
75780222|NCT00354107|Drug|carboplatin|Given IV
75915941|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
75915942|NCT01309932|Drug|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 24 weeks
75915943|NCT01309932|Biological|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks
75323124|NCT00702377|Other|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
75323125|NCT00702377|Other|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
75323126|NCT00703391|Drug|AZD9668|30mg oral tablets twice daily (bid) for 14 days
75323127|NCT00703391|Drug|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
75323128|NCT00661583|Drug|Ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
75323129|NCT00661583|Drug|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
75323130|NCT00661583|Drug|MMC|MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
75323131|NCT00661895|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
75323132|NCT00661895|Drug|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
75323133|NCT00661895|Drug|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
75628615|NCT02443077|Drug|Cytarabine|Given IV
75628616|NCT02443077|Drug|Etoposide|Given IV
75628617|NCT02443077|Drug|Ibrutinib|Given PO
75628618|NCT02443077|Other|Laboratory Biomarker Analysis|Correlative studies
75628619|NCT02443077|Drug|Melphalan|Given IV
75628620|NCT02443077|Other|Pharmacogenomic Study|Correlative studies
75628621|NCT02443077|Other|Placebo Administration|Given PO
75628622|NCT02388906|Drug|Ipilimumab|Specified dose on specified days
75628623|NCT02388906|Drug|Nivolumab|Specified dose on specified days
75628624|NCT02388906|Other|Placebo matching Ipilimumab|Specified dose on specified days
75628625|NCT02388906|Other|Placebo matching Nivolumab|Specified dose on specified days
75628626|NCT02375555|Drug|Lenalidomide|
75628627|NCT02375555|Drug|Elotuzumab|
75628628|NCT02375555|Drug|Bortezomib|
75628629|NCT02375555|Drug|Dexamethasone|
75628630|NCT02375555|Procedure|Stem Cell Mobilization|
75628631|NCT02367040|Drug|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
75780223|NCT00354107|Drug|etoposide|Given IV
75780224|NCT00354107|Drug|methotrexate|Given IT
75780225|NCT00354107|Drug|cytarabine|Given IT
75780226|NCT00354107|Other|pharmacological study|Correlative studies
75780227|NCT00354107|Other|laboratory biomarker analysis|Correlative studies
76074804|NCT01149850|Drug|temozolomide|Given orally
75323134|NCT00661895|Drug|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
75628632|NCT02367040|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
75628633|NCT02367040|Drug|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
75628634|NCT02339311|Other|Educational intervention of Lifestyle and patient activation in diabetics|Participants underwent a one hour group didactic session led by Community Health Representatives (CHRs) who subsequently carried out monthly home-based educational interventions to encourage healthy lifestyles, including diet, exercise, and alcohol and cigarette avoidance until follow up at 6 months, when clinical phenotyping and the PAM survey were repeated.
75628635|NCT02330952|Drug|Prednisone|40mg/day per os for 5 days
75628636|NCT02330952|Drug|Placebo|40mg/day per os for 5 days
75628637|NCT02314169|Procedure|Biospecimen Collection|Undergo blood sample collection
75628638|NCT02314169|Procedure|Computed Tomography|Undergo CT scan
75628639|NCT02314169|Biological|Ipilimumab|Given IV
75628640|NCT02314169|Procedure|Magnetic Resonance Imaging|Undergo MRI
75628641|NCT02314169|Biological|Nivolumab|Given IV
75628642|NCT02311933|Drug|Endoxifen Hydrochloride|Given PO
75628643|NCT02311933|Other|Laboratory Biomarker Analysis|Correlative studies
75628644|NCT02311933|Other|Pharmacological Study|Correlative studies
75628645|NCT02311933|Drug|Tamoxifen Citrate|Given PO
75628646|NCT02308852|Device|tDCS|
75628647|NCT02306161|Drug|Cyclophosphamide|Given IV
75628648|NCT02306161|Drug|Doxorubicin|Given IV
75628649|NCT02306161|Drug|Doxorubicin Hydrochloride|Given IV
75780228|NCT00354029|Drug|S (+) Ketamine|0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
75323135|NCT00661895|Drug|Metoprolol tartrate|50 mg tablets & 100 mg tablets
75323136|NCT00661895|Drug|Atenolol|50 mg tablet
75323137|NCT00661895|Drug|Valsartan|80 mg tablets & 160 mg tablet
75323138|NCT00661895|Drug|Doxazosin|4 mg tablets
75323139|NCT00661895|Drug|Clonidine|0.2 mg tablets
75323140|NCT00661895|Drug|Hydralazine|50 mg tablets
75323141|NCT00661895|Drug|Metoprolol succinate|50 mg tablet & 100 mg tablet
75323142|NCT00661895|Drug|Amlodipine|5 mg tablets & 10 mg tablets
75323143|NCT00590369|Device|KCI -VAC|Negative pressure wound therapy device
75323144|NCT00590369|Device|Versatile One (EZCare)|Negative pressure wound therapy device
75323145|NCT00703937|Drug|Ferric Carboxymaltose (FCM)|
75323146|NCT00703937|Drug|Standard Medical Care (SMC) for the treatment of IDA|
75628650|NCT02306161|Drug|Etoposide|Given IV
75628651|NCT02306161|Drug|Etoposide Phosphate|Given IV
75628652|NCT02306161|Radiation|External Beam Radiation Therapy|Undergo EBRT
75628653|NCT02306161|Biological|Ganitumab|Given IV
75780229|NCT00354029|Drug|Placebo|isotonic saline
75780230|NCT00353873|Drug|Fluticasone propionate|200μg twice daily
75323147|NCT00662207|Device|Vibrator|A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
75323148|NCT00662207|Procedure|Anal dilator|A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
75323149|NCT01504373|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be placed in the NAVA mode of ventilation.
75323150|NCT04398212|Diagnostic Test|mfERG (multifocal-retinogram)|mfERG will be performed for the students to document the effect of CVS on retina
75628654|NCT02306161|Drug|Ifosfamide|Given IV
75628655|NCT02306161|Radiation|Stereotactic Radiosurgery|Undergo SBRT
75628656|NCT02306161|Procedure|Therapeutic Surgical Procedure|Undergo surgery
75628657|NCT02306161|Drug|Vincristine|Given IV
75628658|NCT02306161|Drug|Vincristine Sulfate|Given IV
75628659|NCT02299999|Drug|AZD2014|Target: m-TOR
75628660|NCT02299999|Drug|AZD4547|Target: EGFR
75628661|NCT02299999|Drug|AZD5363|Target: AKT
75628662|NCT02299999|Drug|AZD8931|Target: HER2, EGFR
75628663|NCT02299999|Drug|Selumetinib|Target: MEK
75628664|NCT02299999|Drug|Vandetanib|Target: VEGF, EGFR
75628665|NCT02299999|Drug|Bicalutamide|target: Androgen receptor
75628666|NCT02299999|Drug|Olaparib|Target: PARP
75628667|NCT02299999|Drug|Anthracyclines|DNA intercalation
75628668|NCT02299999|Drug|Taxanes|Target: mitotic tubulin and microtubules
75628669|NCT02299999|Drug|cyclophosphamide|Alkylating agents
75628670|NCT02299999|Drug|DNA intercalators|DNA intercalators
75628671|NCT02299999|Drug|Methotrexate|DNA intercalators
75628672|NCT02299999|Drug|vinca alkaloids|Target: mitotic tubulin and microtubules
75628673|NCT02299999|Drug|Platinum based chemotherapies|Platinum based chemotherapies
75628674|NCT02299999|Drug|Bevacizumab|Target: VEGF
75628675|NCT02299999|Drug|Mitomycin C|Alkylating agents
75628676|NCT02299999|Drug|Eribulin|Microtubule modulator
75628677|NCT02299999|Drug|MEDI4736|Target: PD-L1
75628678|NCT02275533|Procedure|Biospecimen Collection|Undergo collection of blood samples
75628679|NCT02275533|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75628680|NCT02275533|Other|Clinical Observation|Undergo standard of care clinical observation
75628681|NCT02275533|Procedure|Echocardiography|Undergo ECHO
75628682|NCT02275533|Biological|Nivolumab|Given IV
75628683|NCT02251548|Drug|Ibrutinib|Oral BTK inhibitor
75628684|NCT02251548|Drug|Fludarabine|IV purine analogue chemotherapy agent
75780231|NCT00353873|Drug|Fluticasone propionate/salmeterol|50/100μg twice daily
75915944|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks
76074805|NCT01149850|Other|laboratory biomarker analysis|Correlative studies
76074806|NCT01149850|Other|immunohistochemistry staining method|Correlative studies
76074807|NCT01149850|Genetic|microarray analysis|Correlative studies
76074808|NCT01149850|Genetic|DNA methylation analysis|Correlative studies
75323151|NCT02301039|Drug|Pembrolizumab|
75323152|NCT02984540|Other|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
75628685|NCT02251548|Drug|Cyclophosphamide|IV alkylator chemotherapy agent
75323153|NCT02984540|Other|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
75780232|NCT01058057|Drug|atorvastatin|atorvastatin 80mg p.o. daily seven days before PCI
75628686|NCT02251548|Drug|Rituximab|IV anti-CD20 monoclonal antibody
75628687|NCT02193282|Other|Clinical Observation|Undergo observation
75628688|NCT02193282|Drug|Erlotinib Hydrochloride|Given PO
75628689|NCT02193282|Other|Laboratory Biomarker Analysis|Correlative studies
75780233|NCT01058135|Other|Hi-maize starch (Low dose)|resistant starch
75780234|NCT01058135|Other|Hi-maize starch (High-dose)|resistant starch
75780235|NCT01058135|Other|Control (starch)|rapidly digestible starch
75323154|NCT00662675|Drug|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
75323155|NCT00662675|Drug|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
75915945|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks
75915946|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks
75915947|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks
75915948|NCT01309932|Drug|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 16 weeks
75915949|NCT01309932|Drug|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 16 weeks
75323156|NCT04760210|Other|Control Group|Treatment for this group is conventional physical therapy along with the bed rest.
75323157|NCT04760210|Other|Decompression Group|Treatment for this is conventional physical therapy along with the spinal decompression.
75323158|NCT04760210|Other|ELDOA|Treatment for this is conventional physical therapy along with the ELDOA.
75323159|NCT01970787|Device|Radiofrequency Ablation (RFA) using the HALO Ablation System|
75628690|NCT02193282|Other|Placebo Administration|Given PO
75780236|NCT03988751|Behavioral|Ambulation|Variation in ambulatory intensity.
75780237|NCT01054937|Drug|4SC-203|i.v. administration
75780238|NCT01054937|Drug|Placebo|i.v. administration
75915950|NCT01309932|Drug|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
75915951|NCT01309932|Drug|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Tablets, Oral, 0 mg, Once daily, 24 weeks
75915952|NCT01309932|Drug|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
75915953|NCT01309932|Drug|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 16 weeks
76074809|NCT01774981|Drug|Placebo|Administered IV
75628691|NCT02152982|Other|Laboratory Biomarker Analysis|Correlative studies
75628692|NCT02152982|Other|Placebo Administration|Given PO
75628693|NCT02152982|Other|Quality-of-Life Assessment|Ancillary studies
75628694|NCT02152982|Drug|Temozolomide|Given PO
75628695|NCT02152982|Drug|Veliparib|Given PO
75628696|NCT02143245|Diagnostic Test|Synovial Biopsy|Synovial biopsy is a procedure using a guided needle, where 6 to 8 small tissue samples with be extracted from the shoulder using an x-ray guided needle.
75628697|NCT02143245|Diagnostic Test|Open Tissue Biopsy|During the standard of care revision surgery, 6 to 8 small tissue samples will be taken in order to test for infection. This is standard of care treatment. As part of this study, an additional 1 to 2 samples of tissue would be taken in order to develop a test to determine more precisely what type of infection there may be.
75628698|NCT02129348|Drug|Lithium|
75628699|NCT02129348|Drug|Placebo|
75628700|NCT02117167|Drug|AZD2014|Target: m-TOR
75628701|NCT02117167|Drug|AZD4547|Target: FGFR
75628702|NCT02117167|Drug|AZD5363|Target: AKT
75628703|NCT02117167|Drug|AZD8931|Target: HER2, EGFR
75780239|NCT03986099|Diagnostic Test|Monitoring virus load|Near point of care
75780240|NCT03796676|Drug|Placebo|Placebo
75780241|NCT03796676|Drug|PF-04965842|100 mg QD
75780242|NCT03796676|Drug|PF04965842|200 mg QD
76074810|NCT01774981|Drug|LY3016859|Administered IV
76074811|NCT01972841|Drug|Solifenacin succinate|Oral tablet
76074812|NCT01972841|Drug|Mirabegron|Oral tablet
76074813|NCT01972841|Drug|Placebo to match solifenacin succinate|Oral tablet
76074814|NCT01972841|Drug|Placebo to match mirabegron|Oral tablet
76074815|NCT01774903|Drug|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
76074816|NCT01774591|Drug|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
76074817|NCT01774591|Drug|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
76074818|NCT01708915|Drug|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
76074819|NCT01708915|Drug|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
76074820|NCT01708915|Drug|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
76074821|NCT01708915|Drug|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
75628704|NCT02117167|Drug|Selumetinib|Target: MEK
76074822|NCT01708291|Behavioral|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
75780243|NCT02533115|Drug|CPX-351|"CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.~CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC."
76074823|NCT01708291|Behavioral|only pre and post evaluation measures|
75323160|NCT00591305|Dietary Supplement|diindolylmethane (DIM)|3-month DIM
75780244|NCT03342898|Biological|YF-17D|YF-17D SC injection.
75780245|NCT03342898|Biological|TDV|TDV SC injection.
75780246|NCT03342898|Drug|Placebo|Normal Saline (0.9% NaCl) SC injection.
75780247|NCT03988673|Other|Decision aid with implicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a grid where statements about the subject will be presented (decision aid with implicit VCM).
75780248|NCT03988673|Other|Decision aid with explicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a a grid where statements about the subject will be presented and men should indicate what statements they identify with (decision aid with explicit VCM).
75915954|NCT01846286|Behavioral|Questionnaires|Five questionnaires about pain and symptoms, each taking approximately 25 - 50 minutes to complete
75915955|NCT01846286|Other|Quantitative Sensory Testing|Tests measure sensitivity to touch, coolness, warmth, hot/cold feeling, and pin pricks. The sensory tests will take about 30 minutes to 1 hour to complete.
76074824|NCT01708057|Drug|AZD8683|AZD8683 administered via inhalation
76074825|NCT01708057|Drug|Placebo|Placebo administered via inhalation
76074826|NCT01708057|Drug|Tiotropium|Tiotropium administered via inhalation
76074827|NCT01972529|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
76074828|NCT01972529|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
76074829|NCT01972529|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
75323161|NCT00591305|Device|585 nm pulsed dye laser|once-time PDL
75323162|NCT01988415|Device|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).
75323163|NCT01799603|Drug|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
75323164|NCT04381130|Drug|EF-009|"Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy"
75323165|NCT01970943|Other|Placebo|Placebo will be compared to No Intervention.
75323166|NCT00666029|Drug|atorvastatin|40 m.g. o.d. tablets for 6 months
75323167|NCT00666029|Drug|placebo|Placebo
75323168|NCT03196778|Radiation|Low Dose Radiotherapy|Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks
75323169|NCT04372940|Drug|Tranexamic Acid Irrigation|Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, temporarily inhibiting the degradation of fibrin clots.
76074830|NCT01972529|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
76074831|NCT01747915|Drug|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
76074832|NCT01747915|Drug|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
76074833|NCT01747915|Drug|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
76074834|NCT03189004|Behavioral|Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh|"Identification and registration of pregnant women and services for them~Birth notification~Childhood vaccination services under EPI~Newly married couple identification~e-Referral.~e-monitoring"
76074835|NCT01961297|Drug|Sodium oxybate|Sodium oxybate
75323170|NCT04372940|Other|Saline Irrigation|Saline will serve as the control.
75323171|NCT01971255|Biological|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
75628705|NCT02117167|Drug|Vandetanib|Target : VEGF, EGFR
75628706|NCT02117167|Drug|Standard maintenance for squamous NSCLC|
75628707|NCT02117167|Drug|Pemetrexed|Standard maintenance for non squamous NSCLC
75628708|NCT02117167|Drug|Durvalumab|Target: PD-L1
75628709|NCT02117167|Drug|savolitinib|target : MET
75628710|NCT02117167|Drug|Olaparib|target : PARP
75628711|NCT02112526|Drug|Acalabrutinib|
75628712|NCT02106988|Radiation|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
76074836|NCT04656041|Drug|FOLFOX/ nal-IRI|"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~2) Oxaliplatin via IV, predetermined dosage per protocol~3) Leucovorin via IV, predetermined dosage per protocol~4) 5-Fluorouracil via IV, predetermined dosage per protocol"
75323172|NCT04355312|Diagnostic Test|Use of Indocyanine Green in laparoscopic ovarian cystectomy|"During intraperitoneal cystectomy or Plasmajet destruction of the cyst, as a benign organic cyst requiring surgical treatment, peroperatively, at the end of the cystectomy procedure, injection by the anesthetist on a peripheral venous route of a bolus of Indocyanine green diluted 0.2mg / kg. Installation of the SPIES camera system (KARL STORZ GmbH & Co.KG, Tuttlingen, Germany).~Evaluation of the degree of fluorescence at the location of cystectomy or destruction of the cyst.~A fluorescence score between 0 and 4 (on the model of a Likert scale) will be used for the evaluation of fluorescence.~A second reading of the Likert scale results will be carried out by a second inspector so that the score is as objective as possible. Then, second evaluation technique realized by the METAMORPH software, which will assign a raw and objective score according to the fluorescence visualized."
75323173|NCT00592475|Drug|conivaptan|IV
75628713|NCT02106988|Drug|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
75323174|NCT00592475|Drug|Placebo|IV
75628714|NCT02106988|Drug|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
75323175|NCT01989195|Drug|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
75323176|NCT00592943|Drug|armodafinil|tablet, taken by mouth, once each study day
75323177|NCT01973205|Drug|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
75628715|NCT02106988|Drug|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
75628716|NCT02106988|Drug|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
75628717|NCT02106988|Drug|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
75628718|NCT02101788|Drug|Letrozole|Given PO
75628719|NCT02101788|Drug|Paclitaxel|Given IV
75628720|NCT02101788|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75915956|NCT01733888|Device|Office Bleaching|Teeth will be cleaned with pumice first, followed by placing cheek retractors and covering of the lip surface with petroleum gel. Thereafter, teeth will be dried and gingival barrier will be applied to both arches - slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds. This is followed by homogeneous mixing of the powder and liquid in a powder pot the application of a thick layer of the resulting gel to all teeth undergoing treatment (35 % Hydrogen Peroxide, Pola Office, SDI, Australia). The gel will be left in place for 8 minutes and subsequently removed using a surgical aspirator tip.
75628721|NCT02101788|Other|Quality-of-Life Assessment|Ancillary studies
75628722|NCT02101788|Other|Questionnaire Administration|Ancillary studies
75628723|NCT02101788|Drug|Tamoxifen Citrate|Given PO
75628724|NCT02101788|Drug|Topotecan|Given IV
75628725|NCT02101788|Drug|Trametinib Dimethyl Sulfoxide|Given PO
75628726|NCT02100280|Drug|deep block|sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
75628727|NCT02060227|Procedure|Open Latarjet procedure|
75628728|NCT02060227|Procedure|Arthroscopic Bankart repair|
75628729|NCT02016872|Drug|18F-FMISO|
75628730|NCT02016872|Other|PET/CT|
75628731|NCT01950390|Biological|Bevacizumab|Given IV
75628732|NCT01950390|Biological|Ipilimumab|Given IV
75628733|NCT01935934|Drug|Cabozantinib S-malate|Given PO
75628734|NCT01935934|Other|Laboratory Biomarker Analysis|Correlative studies
75780249|NCT03988517|Other|timing of receiving the drug|each group took levothyroxine in different timing
75628735|NCT01935934|Other|Pharmacological Study|Correlative studies
75628736|NCT01928394|Biological|Nivolumab|
75628737|NCT01928394|Biological|Ipilimumab|
75628738|NCT01928394|Drug|Cobimetinib|
75628739|NCT01886872|Drug|Bendamustine Hydrochloride|Given IV
75628740|NCT01886872|Drug|Ibrutinib|Given PO
75628741|NCT01886872|Other|Laboratory Biomarker Analysis|Correlative studies
75628742|NCT01886872|Other|Quality-of-Life Assessment|Ancillary studies
75628743|NCT01886872|Biological|Rituximab|Given IV
75628744|NCT01864018|Drug|Cyclophosphamide|Given PO
75628745|NCT01864018|Drug|Dexamethasone|Given PO
75628746|NCT01864018|Drug|Ixazomib Citrate|Given PO
75628747|NCT01864018|Other|Laboratory Biomarker Analysis|Correlative studies
75628748|NCT01864018|Other|Pharmacological Study|Correlative studies
75628749|NCT01864018|Other|Quality-of-Life Assessment|Ancillary studies
75628750|NCT01864018|Other|Questionnaire Administration|Ancillary studies
75628751|NCT01856192|Drug|Cyclophosphamide|Given IV
75628752|NCT01856192|Drug|Doxorubicin Hydrochloride|Given IV
75628753|NCT01856192|Other|Laboratory Biomarker Analysis|Correlative studies
75628754|NCT01856192|Drug|Lenalidomide|Given PO
75628755|NCT01856192|Drug|Prednisone|Given PO
75628756|NCT01856192|Biological|Rituximab|Given IV
75628757|NCT01856192|Drug|Vincristine Sulfate|Given IV
75628758|NCT01850108|Drug|Thymoglobulin|"Day 9 before BMT: 0.5mg/kg IV; Days 8 & 7 before BMT: 2mg/kg IV~Days 8 & 7 - 2mg/kg IV before BMT"
75628759|NCT01850108|Drug|Fludarabine|Days 6 and 2 before BMT: 30mg/m2/day IV
75628760|NCT01850108|Drug|Cyclophosphamide (CTX)|Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day
75628761|NCT01850108|Drug|Mesna|Days 3 & 4 after BMT: 40 mg/kg IV
75628762|NCT01850108|Drug|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
75780250|NCT00339833|Drug|Salsalate|The intervention was salsalate (3g/day) for 7 days.
75780251|NCT00339833|Drug|Placebo|Identical placebo for 7 days.
76074837|NCT04656041|Drug|Paclitaxel|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
75628763|NCT01850108|Drug|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
76074838|NCT04656041|Drug|Carboplatin|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
76074839|NCT04656041|Radiation|Proton Radiation Therapy|Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
76074840|NCT01960907|Device|CHROMED monitoring system|Optimization of patient's treatment according to the data collected by the home monitoring devices
76074841|NCT01747837|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
75323178|NCT01973205|Drug|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
75323179|NCT03220802|Dietary Supplement|OMNI-BiOTiC PPI|The study product consists of a sachet containing 4g of yellowish powder made of corn starch, maltodextrin, fructo-oligosaccharide P6, inulin P2, vegetable protein and 12 bacterial strains (Bacillus coagulans W183, Bacillus subtilus W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200, Lactobacillus rhamnosus W71, in a concentration of 2 x 109 cfu/g).
75628764|NCT01850108|Procedure|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
75628765|NCT01850108|Radiation|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
75780252|NCT01058213|Behavioral|Resistance training|Supervised training will be performed on a cable exercise system (Body Solid, Forest Park, IL) using six exercises that involve concentric and eccentric muscle actions: leg press, knee flexion, knee extension, calf raise, hip adduction, hip abduction. Subjects will perform the lower extremity exercises under the direct supervision of an exercise specialist three times per week. Subjects will perform 2 sets of 8-10 repetitions at 70% of their maximum strength for 2 weeks, then will perform 2 sets of 8-10 repetitions at 80% of their maximal strength for 2 weeks, and for the next 4 weeks they will perform 3 sets of 8-10 repetitions at 80% of their maximal strength. Sets will be separated by at least a 2-3 minute rest period for multiple-joint exercises and at least 1-2 minutes for single-joint exercises. A moderate velocity of muscle contraction (~1-2 seconds for concentric and eccentric contraction) will be used.
76074842|NCT01971203|Drug|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
75628766|NCT01844505|Biological|Nivolumab|
75628767|NCT01844505|Biological|Ipilimumab|
75628768|NCT01844505|Biological|Placebo for Nivolumab|
75628769|NCT01844505|Biological|Placebo for Ipilimumab|
75915957|NCT01733888|Device|Resin Infiltration|Fluorosed teeth will be isolated using a rubber dam and the resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. In short, tooth surface will be dried using cotton rolls and air syringe. This is followed by an etching (Icon Etch) and drying step (Icon-Dry) to open the lesion surface. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds and subsequent cleaning of the surface with pumice and rubber polishing cup as well as rinsing with water for 30 sec.
75915958|NCT01733888|Device|Resin Infiltration twice|"The intervention will be done similar to the Resin infiltration arm, which the exception that the icon infiltration step will be done twice."
76074843|NCT01971203|Behavioral|CBT|16 weeks of treatment
76074844|NCT04654325|Diagnostic Test|conjunctival swab|Patients will have conjunctival swab for SARS-CV-2 genome detection
76074845|NCT01605877|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
76074846|NCT01970501|Drug|bucindolol hydrochloride|
76074847|NCT01970501|Drug|metoprolol succinate|
76074848|NCT01970501|Other|Placebo oral capsule|
76074849|NCT01969799|Drug|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
76074850|NCT01969799|Drug|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
75323180|NCT01990677|Drug|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
75628770|NCT01796171|Drug|10 MBq/kg Betalutin|
75628771|NCT01796171|Drug|15 MBq/kg Betalutin|
75628772|NCT01796171|Drug|20 MBq/kg Betalutin|
75628773|NCT01796171|Drug|40 mg lilotomab|
75628774|NCT01796171|Drug|100 mg/m2 lilotomab|
75628775|NCT01796171|Drug|60 mg/m2 lilotomab|
75628776|NCT01796171|Drug|Rituximab|
75628777|NCT01796171|Drug|12.5 mBq/kg Betalutin|
75628778|NCT01736592|Drug|Long term follow up in all patients who received SAR422459 in previous study TDU13583|Blood draw for the laboratory assessment
75628779|NCT01620944|Drug|Atazanavir|Capsule, oral, 300 mg, Once daily (QD), 96 weeks
75628780|NCT01620944|Drug|Ritonavir|Tablets, oral, 100 mg, QD, 96 Weeks
75628781|NCT01620944|Drug|Lamivudine|Tablet, oral, 300 mg, QD, 96 Weeks
75628782|NCT01620944|Drug|Tenofovir/Emtricitabine|Tablets, oral, 300/200 mg, QD, 48 Weeks
75628783|NCT01544699|Device|tDCS (ELDITH)|tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
75628784|NCT01522976|Drug|Azacitidine|Given SC or IV
75628785|NCT01522976|Other|Laboratory Biomarker Analysis|Correlative studies
75628786|NCT01522976|Drug|Lenalidomide|Given PO
75628787|NCT01522976|Drug|Vorinostat|Given PO
75628788|NCT01444469|Drug|Zithromax|250mg * 2 capsules once daily for three days
75628789|NCT01444469|Drug|Placebo|Lactose powder
75915959|NCT01733888|Device|Bleaching + Resin Infiltration|"In this arm, the fluorosed teeth of the patients will first be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) as explained in the intervention arm Office bleaching; followed by wash over period of 20 days. After these 20 days, patients will be recalled and the fluorosed teeth will treated according to the description in the Resin infiltrant intervention arm using the resin infiltrant (Icon, DMG, Hamburg, Germany) as per manufactures' instructions."
76074851|NCT01969721|Drug|fluticasone propionate|low dose
75628790|NCT01386385|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-conformal RT
75628791|NCT01386385|Drug|Carboplatin|Given IV
75628792|NCT01386385|Other|Laboratory Biomarker Analysis|Correlative studies
75628793|NCT01386385|Drug|Paclitaxel|Given IV
75780253|NCT01058213|Behavioral|Aerobic training|Cycle ergometry training will be performed in the lab on a stationary cycle ergometer, calibrated with a 4 kg weight (Monark 828E, Varberg, Sweden). Initial work rate will be 50% of peak work rate (PWR) as tolerated and will be evaluated weekly with progressive increases targeted to achieve the highest work rate tolerated for 3-5 minutes{: wks 1-2 50% PWR, wks 3-4 60% PWR, wks 5-6 70% PWR, wks 7-8 80% PWR}. An interval training protocol will be used with subjects performing four work sets of five minutes duration separated by rest intervals of unloaded cycling lasting 2-4 minutes.
75915960|NCT01181622|Drug|denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
75915961|NCT01181622|Drug|0.9% w/v sodium chloride solution|0.9% w/v sodium chloride solution by oral inhalation three times daily
75915962|NCT05210270|Radiation|Hypofractionation|"Phase 1 (Dose Escalation Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with nSIB 45 Gy (first dose level) and 48 Gy (second dose level); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)~Phase 2 (Efficacy Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with (or without) nSIB 45-48 Gy (depending on phase 1 results); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)"
75628794|NCT01386385|Other|Placebo Administration|Given PO
75628795|NCT01386385|Drug|Veliparib|Given PO
75628796|NCT01371981|Drug|Asparaginase|Given IM
75628797|NCT01371981|Drug|Bortezomib|Given IV
75628798|NCT01371981|Drug|Cytarabine|Given IT or IV
75628799|NCT01371981|Drug|Daunorubicin Hydrochloride|Given IV
75628800|NCT01371981|Drug|Etoposide|Given IV
75628801|NCT01371981|Other|Laboratory Biomarker Analysis|Correlative studies
75780254|NCT01311856|Behavioral|Standard Arm (mail/telephone)|Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.
75780255|NCT01311856|Behavioral|Internet Arm|Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
75628802|NCT01371981|Drug|Mitoxantrone Hydrochloride|Given IV
75628803|NCT01371981|Other|Pharmacological Study|Correlative studies
75780256|NCT01311856|Behavioral|Surveys and Questionnaires|9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
75915963|NCT01101594|Drug|hLL1-DOX (the doxorubicin conjugate of milatuzumab)|hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 & 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
75915964|NCT01304862|Behavioral|eSMART-MH intervention|Involves simulated interactions between participants and the virtual health care providers (avatars).
76074852|NCT01969721|Drug|salmeterol|
76074853|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
76074854|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
76074855|NCT01969721|Drug|tiotropium|tiotropium high dose
76074856|NCT01969721|Drug|olodaterol|
76074857|NCT01969721|Drug|olodaterol|
76074858|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
76074859|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
75628804|NCT01371981|Other|Quality-of-Life Assessment|Ancillary studies
75628805|NCT01371981|Other|Questionnaire Administration|Ancillary studies
75628806|NCT01371981|Drug|Sorafenib Tosylate|Given PO
75628807|NCT01345851|Radiation|hypofractionated radiation therapy|Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks
75628808|NCT01345851|Other|laboratory biomarker analysis|Correlative studies
75628809|NCT01345851|Radiation|image-guided radiation therapy|Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.
75628810|NCT01345851|Drug|carboplatin|The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.
75628811|NCT01345851|Drug|paclitaxel|The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.
75628812|NCT01345851|Radiation|stereotactic body radiation therapy|Undergo hypofractionated RT
75628813|NCT01274338|Biological|Ipilimumab|Given IV
75628814|NCT01274338|Other|Quality-of-Life Assessment|Ancillary studies
76074860|NCT01969721|Drug|tiotropium|tiotropium low dose
76074861|NCT01969721|Drug|fluticasone propionate|low dose
76074862|NCT01969721|Drug|salmeterol|
76074863|NCT01969565|Drug|Carfilzomib|
76074864|NCT01969565|Drug|Dexamethasone|
75628815|NCT01274338|Biological|Recombinant Interferon Alfa-2b|Given IV and SC
75628816|NCT01272037|Drug|Anastrozole|Given PO
75628817|NCT01272037|Drug|Exemestane|Given PO
75628818|NCT01272037|Other|Laboratory Biomarker Analysis|Correlative studies
75628819|NCT01272037|Drug|Letrozole|Given PO
75628820|NCT01272037|Other|Quality-of-Life Assessment|Ancillary studies (closed as of 12/1/12)
75628821|NCT01272037|Drug|Systemic Chemotherapy|Given IV
75628822|NCT01272037|Drug|Tamoxifen Citrate|Given PO
75628823|NCT01199575|Drug|Revlimid|
75628824|NCT01199575|Drug|Rituximab|
76074865|NCT04173923|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
75915965|NCT01304862|Behavioral|Educational videos about healthy living|20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
75915966|NCT05386628|Other|conventional physiotherapy|"A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~Shoulder passive/active abduction, flexion, internal and external rotation exercises~Posture exercises~Neck stretching exercises~Pectoralis major stretching exercises~Shoulder capsule stretching exercises~Scapular Mobilization exercises"
76074866|NCT04173923|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
75628825|NCT01194570|Drug|Ocrelizumab|Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.
75628826|NCT01194570|Other|Placebo|Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.
75628827|NCT01169922|Behavioral|SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION|2 hour 50 minute long intervention; includes presentation of STD/HIV facts, activities/games regarding safe sex, condom demonstration, video about sexual decision making, video about alcohol/sexual decision making, alcohol-related risk-reduction motivational interview, group discussion
75628828|NCT01169922|Behavioral|INFORMATION-ONLY SEXUAL RISK REDUCTION|1 hour 30 minute long intervention; includes presentation of STD/HIV facts, video about sexually transmitted diseases, review of STD/HIV facts
75780257|NCT01311856|Behavioral|Exercise and Diet|15 minutes of strength exercise every other day, >30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
75780258|NCT01058291|Drug|KW-6500|Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
75915967|NCT05386628|Other|Manual lymphatic drainage|manual lymph drainage is a manual technique that is applied to the lymphatic system with a pressure of 40-50 mmHg and increases the working speed of lymphatic nodules/collectors. Manual lymph drainage will be made to the anterior axillar-axillar, posterior axillar-axillar and axilla-inguinal anastomosis collectors and the arm region (up to the elbow) lymph collectors.
75628829|NCT01169337|Other|Clinical Observation|Undergo observation
75628830|NCT01169337|Drug|Lenalidomide|Given PO
75628831|NCT01169337|Other|Quality-of-Life Assessment|Ancillary studies
75915968|NCT05386628|Other|Myofascial relasing|it will be done with the thumb or 3rd finger from the acu points of the superficial arm-anterior myofascial chain. 6-8 seconds with thumb to these points. pressure will be applied and vibration will be given clockwise.
76074867|NCT04173923|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
76074868|NCT04173923|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
76074869|NCT04173923|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
75467485|NCT01927185|Device|Long Axis strategy|With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.
75628832|NCT01167712|Biological|Bevacizumab|Given IV
75628833|NCT01167712|Drug|Carboplatin|Given IV
75628834|NCT01167712|Procedure|Computed Tomography|Correlative studies
75628835|NCT01167712|Drug|Paclitaxel|Given IV
75628836|NCT01167712|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75780259|NCT01058291|Drug|KW-6500 Placebo|Twelve weeks subcutaneous injection for the OFF state
75780260|NCT03711682|Dietary Supplement|Cinnamon|Participants in this group will receive cinnamon capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of cinnamon powder (Cinnamomum verum), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
75780261|NCT03711682|Dietary Supplement|Wheat Flour|Participants in this group will receive placebo capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of wheat flour(fortified with iron, niacin, thiamin, riboflavin and folic acid), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
76074870|NCT04173923|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
75628837|NCT01081262|Biological|Bevacizumab|Given IV
75780262|NCT01055249|Drug|Ibuprofen, Hydrocortisone|Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
75780263|NCT01055249|Drug|Hydrocortisone|Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
75628838|NCT01081262|Drug|Capecitabine|Given PO
75628839|NCT01081262|Drug|Carboplatin|Given IV
75628840|NCT01081262|Other|Laboratory Biomarker Analysis|Correlative studies
75628841|NCT01081262|Drug|Oxaliplatin|Given IV
75628842|NCT01081262|Drug|Paclitaxel|Given IV
75628843|NCT01081262|Other|Quality-of-Life Assessment|Ancillary studies
75628844|NCT01064648|Drug|Cediranib Maleate|Given orally
75628845|NCT01064648|Drug|Cisplatin|Given IV
75628846|NCT01064648|Other|Laboratory Biomarker Analysis|Correlative studies
75628847|NCT01064648|Drug|Pemetrexed Disodium|Given IV
75628848|NCT01064648|Other|Placebo Administration|Given orally
75780264|NCT01055327|Drug|Lamotrigine monotherapy|Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
75323181|NCT01990677|Drug|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
75467486|NCT01927185|Device|Short Axis Strategy|With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
75780265|NCT01055327|Drug|No anti-epileptic drug exposure|No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
75780266|NCT01055327|Drug|Non lamotrigine anti-epileptic drug monotherapy|Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
75780267|NCT03988361|Diagnostic Test|Magnetic Activated Cell Sorting|At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group. Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.
75467487|NCT01927237|Other|HLR|
75323182|NCT00593645|Drug|Clofarabine|
75467488|NCT01927237|Other|EHR|
75467489|NCT01927276|Other|Gluten Free Flour|
75915969|NCT04475172|Combination Product|Self-Adhesive Flowable Composite|"Fusio Self-Adhesive Flowable Composite combines the benefits of adhesive and restorative technology into one product . Immediately upon application Fusio conditions, bonds, and seals without the need for an etchant or an adhesive.~It is based on the bonding technology that uses glycerophosphate dimethacrylate(GPDM)to etch enamel and dentin, and hydroxyethyl methacrylate (HEMA) to enhance wetting and penetration by resin into dentin."
76074871|NCT04173923|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
76074872|NCT01968707|Drug|ChloraPrep Hi-Lite Orange|Apply topically.
75323183|NCT00593645|Drug|Cytarabine|
75467490|NCT01927276|Other|Wheat Flour|
75467491|NCT01927302|Behavioral|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
75467492|NCT01927302|Behavioral|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
75323184|NCT00593645|Drug|Thymoglobulin|
75323185|NCT00593645|Procedure|Stem cell infusion|
75323186|NCT03219086|Procedure|combined spinal epidural anaesthesia|To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group
75323187|NCT03219086|Drug|Prilocaine|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
75467493|NCT01927302|Behavioral|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
75467494|NCT01927302|Behavioral|No Treatment|No treatment will be administered.
75467495|NCT01927380|Other|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
75467496|NCT01927445|Other|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
75467497|NCT01927549|Procedure|Immediate multivessel PCI|
75467498|NCT01927549|Procedure|Culprit Lesion only PCI|
75628861|NCT00980460|Drug|Cisplatin|Given IV
75628862|NCT00980460|Drug|Dexrazoxane|Given IV
75628863|NCT00980460|Drug|Doxorubicin Hydrochloride|Given IV
75467499|NCT01927640|Drug|Dexmedetomidine|Dexmedetomidine (0.3-0.6 mcg/kg) infusion.
75628864|NCT00980460|Drug|Fluorouracil|Given IV
75628865|NCT00980460|Drug|Irinotecan Hydrochloride|Given IV
75628866|NCT00980460|Other|Laboratory Biomarker Analysis|Correlative studies
75628867|NCT00980460|Procedure|Liver Transplantation|Undergo liver transplant
75628868|NCT00980460|Drug|Temsirolimus|Given IV
75628869|NCT00980460|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75628870|NCT00980460|Drug|Vincristine Sulfate|Given IV
75628871|NCT00977574|Biological|Bevacizumab|Given IV
75628872|NCT00977574|Drug|Carboplatin|Given IV
75628873|NCT00977574|Drug|Ixabepilone|Given IV
75628874|NCT00977574|Other|Laboratory Biomarker Analysis|Correlative studies
75628875|NCT00977574|Drug|Paclitaxel|Given IV
75628876|NCT00977574|Drug|Temsirolimus|Given IV
75915970|NCT05385770|Drug|AZM X mg + AML Y mg|tablet, single dose, QD, oral administration
75323188|NCT03219086|Drug|Bupivacaine|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
75323189|NCT04398290|Drug|Inhaled nitric oxide (iNO)|iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour
75323190|NCT04398290|Drug|Nitrogen gas|250 mcg/kg ideal body weight (IBW)/hour
75628877|NCT00972478|Drug|Cyclophosphamide|Given IV
75780268|NCT03708484|Other|Aerobic Interval Training|"Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
75780269|NCT03708484|Other|Aerobic + Resistive Interval Training|"Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
75323191|NCT04398290|Drug|Oxygen gas|Supplemental oxygen administered via nasal cannula
75323192|NCT04397510|Drug|Heparin|Nebulized Heparin
75323193|NCT04397510|Drug|0.9% Sodium-chloride|Nebulized 0.9% Sodium Chloride
75628878|NCT00972478|Drug|Doxorubicin Hydrochloride|Given IV
75628879|NCT00972478|Other|Laboratory Biomarker Analysis|Correlative studies
75780270|NCT03793556|Device|GERDOFF® + Omeprazole|GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
75780271|NCT03793556|Drug|Omeprazole|Omeprazole, 2 capsules 20 mg, once a day before breakfast
75915971|NCT05385770|Drug|AZM X mg + AML Y' mg|tablet, single dose, QD, oral administration
75915972|NCT05385770|Drug|AZM X' mg + AML Y mg|tablet, single dose, QD, oral administration
75915973|NCT05385770|Drug|AZM X' mg + AML Y' mg|tablet, single dose, QD, oral administration
75323194|NCT00704717|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) pen|PegIntron pen administered in accordance with approved labeling
75628880|NCT00972478|Drug|Prednisone|Given IV
75915974|NCT05385770|Drug|AZM X mg|tablet, single dose, QD, oral administration
75915975|NCT05385770|Drug|AZM X' mg|tablet, single dose, QD, oral administration
75915976|NCT05385770|Drug|AML Y mg|tablet, single dose, QD, oral administration
75915977|NCT05385770|Drug|AML Y' mg|tablet, single dose, QD, oral administration
76074873|NCT01968707|Drug|Normal saline|Apply topically.
75323195|NCT00704717|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling.
75323196|NCT03708224|Biological|Atezolizumab|Given intravenously (IV)
75323197|NCT03708224|Biological|Tocilizumab|Given IV
75323198|NCT03708224|Biological|Tiragolumab|Given IV
75323199|NCT03632642|Drug|Benzylpenicillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
75323200|NCT03632642|Drug|Flucloxacillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
75628881|NCT00972478|Biological|Rituximab|Given IV
75628882|NCT00972478|Drug|Vincristine Sulfate|Given IV
75628883|NCT00972478|Drug|Vorinostat|Given PO
75628884|NCT00900575|Device|Optical Spectroscopy Bench-Top System|This device is a bench-top optical spectrometer
75628885|NCT00900575|Device|Portable Optical Spectrometer|This device is a portable optical spectrometer
75628886|NCT00900575|Device|Transvaginal colposcope|
75628887|NCT00861705|Biological|Bevacizumab|Given IV
75628888|NCT00861705|Drug|Carboplatin|Given IV
75915978|NCT02269020|Procedure|Neck Dissection|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
75628889|NCT00861705|Drug|Cyclophosphamide|Given IV
75628890|NCT00861705|Drug|Doxorubicin Hydrochloride|Given IV
75628891|NCT00861705|Other|Laboratory Biomarker Analysis|Correlative studies
75628892|NCT00861705|Drug|Paclitaxel|Given IV
75628893|NCT00858884|Other|Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain|All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
76074874|NCT01968707|Drug|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
76074875|NCT01968707|Drug|3M CHG/IPA Prep Tint 26-mL|Apply topically
76074876|NCT04650191|Other|Identification of genetic variants|DNA will be extracted from whole blood from study subjects
76074877|NCT01959581|Device|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
76074878|NCT01746901|Drug|Placebo|Placebo solution + Placebo ALO-02 (intact)
75323201|NCT05038514|Other|musıc therapy|After the prone position was given to the patients, according to the randomization table, the intervention group was given 30 minutes by the nurse. nature-based music therapy will be applied.
75323202|NCT00594425|Drug|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
75323203|NCT03686384|Drug|SVT-15652|1 vial twice daily
75323204|NCT03686384|Drug|Placebo|1 vial twice daily
75323205|NCT04317404|Drug|40 mg Triamcinolone acetonide|Unilateral knee steroid injection
75323206|NCT04399070|Drug|S-ketamine|The depression patients received propofol and S-ketamine before ECT
75467500|NCT01927640|Drug|Normal Saline|Normal saline infusion (10 cc)
75780272|NCT03392194|Behavioral|Sleep hygiene intervention|The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.
75467501|NCT01927640|Drug|Intranasal cocaine|Intranasal cocaine (2 mg/kg)
75467502|NCT01927679|Drug|Vitamin E|
75467503|NCT01927679|Drug|Eucerin|Control
75467504|NCT01927965|Drug|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
75467505|NCT01928004|Device|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
75467506|NCT01928004|Procedure|Conventional reline|conventional reline of the existing mandibular complete denture
75628894|NCT00843882|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
76074879|NCT01746901|Drug|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
76074880|NCT01746901|Drug|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
76074881|NCT01746901|Drug|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
76074882|NCT01746901|Drug|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
76074883|NCT01746901|Drug|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
76074884|NCT01968551|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
76074885|NCT01968551|Drug|DRV|800 mg tablet administered orally once daily
76074886|NCT01968551|Drug|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
76074887|NCT01707992|Drug|Laquinimod|Laquinimod will be administered as per the dose and schedule specified in the respective arms.
76074888|NCT01707992|Drug|Placebo|Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
76074889|NCT01946165|Drug|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
75467507|NCT01928108|Behavioral|iPhone Application|"The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week."
75467508|NCT01928108|Behavioral|Android Application|"The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week."
75467509|NCT01928407|Drug|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
75467510|NCT01928407|Drug|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
75467511|NCT01928875|Device|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
75628895|NCT00843882|Biological|Epoetin Alfa|Given SC
75628896|NCT00843882|Other|Laboratory Biomarker Analysis|Correlative studies
75628897|NCT00843882|Drug|Lenalidomide|Given PO
76074890|NCT01946165|Drug|Prednisone|5 mg by mouth once daily for each 28 day cycle.
75323207|NCT04399070|Drug|ketamine|The depression patients received propofol and ketamine before ECT
75323208|NCT04399070|Drug|saline|The depression patients received propofol and saline before ECT
75323209|NCT00667511|Device|NxStage System One|Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
75467512|NCT01928875|Device|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
75467513|NCT01929486|Biological|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
75467514|NCT01929551|Other|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
75467515|NCT01929551|Other|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
75628898|NCT00792948|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
75628899|NCT00792948|Drug|Cyclophosphamide|Given IV
75628900|NCT00792948|Drug|Cytarabine|Given IT
76074891|NCT01946165|Drug|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
75323210|NCT00667589|Drug|urea 40% cream|urea 40% cream applied twice per day to affected areas
75323211|NCT00667589|Drug|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
75323212|NCT00667589|Drug|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
75323213|NCT00667589|Drug|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
75323214|NCT00667745|Drug|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
75467516|NCT01929551|Other|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
75628901|NCT00792948|Drug|Dasatinib|Given PO
75628902|NCT00792948|Drug|Dexamethasone|Given IV or PO
75628903|NCT00792948|Drug|Doxorubicin Hydrochloride|Given IV
75628904|NCT00792948|Drug|Etoposide|Given IV
76074892|NCT01946165|Drug|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
76074893|NCT01707667|Drug|prucalopride|One 2 mg tablet orally administered on Day 1
75628905|NCT00792948|Biological|Filgrastim|Given SC
75628906|NCT00792948|Other|Laboratory Biomarker Analysis|Correlative studies
75628907|NCT00792948|Drug|Leucovorin Calcium|Given IV
75780273|NCT03392194|Behavioral|Yoga intervention|Following the SH intervention, participants randomized to the SH+Y arm will participate in 8 weekly beginner level yoga classes. Classes will increase participants' skill and comfort with yoga postures and relaxing breathing exercises so that participants can adopt an evening yoga practice (10 weeks).
75915979|NCT05385380|Behavioral|Safe motherhood Promotion|Interventions included the training of community members, who subsequently led participatory educational sessions on safe motherhood topics with pregnant females. The project staff identified 2 community health workers and 15 female volunteers from each kebele cluster and trained them as research implementers. The implementers received 2 days of training led by the project team. The project staff and research implementers conducted safe-motherhood training comprising 2 h of information presentations and discussions with pregnant females in the intervention clusters. In addition to the pregnant-female intervention strategy, we also conducted a four-day training programme on clinical skills for local maternal and child healthcare providers in the study area. MWH intervention was also implemented in the intervention group, including upgrades to existing MWH services per national guidelines to standardize services and create a homelike environment for pregnant females.
76074894|NCT01707667|Drug|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
76074895|NCT01959503|Device|Progel Vascular Sealant|
75467517|NCT01929551|Other|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
75915980|NCT02264418|Drug|ODM 203|ODM 203
75915981|NCT02264418|Drug|ODM 203|ODM 203
75628908|NCT00792948|Drug|Methotrexate|Given IV or IT
75915982|NCT04474548|Other|Ultrasound use|Ultrasound will be used to determine location of IUD after insertion.
76074896|NCT01959503|Device|Gelfoam Plus|
76074897|NCT01605799|Behavioral|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
76074898|NCT01605799|Behavioral|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
75323215|NCT00667745|Drug|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
75467518|NCT01929551|Other|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
75628909|NCT00792948|Drug|Methylprednisolone|Given IV
75628910|NCT00792948|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic stem cell transplant
75628911|NCT00792948|Drug|Prednisone|Given PO
75628912|NCT00792948|Drug|Sirolimus|Given PO
75628913|NCT00792948|Drug|Tacrolimus|Given IV
75628914|NCT00792948|Radiation|Total-Body Irradiation|Undergo TBI
75628915|NCT00792948|Drug|Vincristine Sulfate|Given IV
75628916|NCT00769379|Other|Laboratory Biomarker Analysis|Correlative studies
75628917|NCT00769379|Biological|Trastuzumab|Given IV
75628918|NCT00769379|Radiation|Whole Breast Irradiation|Undergo standard whole breast irradiation
75628919|NCT00750841|Drug|cediranib|45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
75628920|NCT00658814|Drug|Azacitidine|Given IV or SC during induction; given SC during consolidation and maintenance
75628921|NCT00658814|Drug|Gemtuzumab Ozogamicin|Given IV
75628922|NCT00644228|Drug|Bortezomib|Given IV
75628923|NCT00644228|Drug|Dexamethasone|Given PO
75628924|NCT00644228|Other|Laboratory Biomarker Analysis|Optional correlative studies
75915983|NCT04474626|Drug|Isoquercetin|Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.
75915984|NCT01094496|Biological|CDX-1307 Vaccine Regimen|CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
75915985|NCT01094496|Drug|Chemotherapy|
75915986|NCT02736188|Drug|Aceneuramic Acid Extended-Release Tablets|
75915987|NCT02269176|Drug|Low dose of telmisartan|
75915988|NCT02269176|Drug|High dose of telmisartan|
75915989|NCT02269176|Drug|Low dose of losartan|
75915990|NCT02269176|Drug|High dose of losartan|
75628925|NCT00644228|Drug|Lenalidomide|Given PO
75628926|NCT00618553|Other|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
75915991|NCT02269254|Device|Persona PS Knee Prosthesis by Zimmer|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
75915992|NCT02269254|Device|NexGen PS Knee Prosthesis by Zimmer|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
75915993|NCT03135288|Device|Cell-phone|a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
76074899|NCT01706575|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
76074900|NCT01706575|Drug|Nucleos(t)ide Analogues (NA)|Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
76074901|NCT01959425|Other|Off OAT Group (Test)|Discontinuation of OAT Therapy
76074902|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
75628927|NCT00618553|Behavioral|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
75628928|NCT00588770|Biological|Bevacizumab|Given IV
76074903|NCT01725529|Drug|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
75323216|NCT03173612|Drug|Dasatinib|Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
75628929|NCT00588770|Drug|Carboplatin|Given IV
75323217|NCT02998775|Drug|Plasma Sampling|No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
75323218|NCT02999711|Drug|REGN3500|REGN3500 dose
75915994|NCT02266992|Biological|Live attenuated Vaccine- Fluenz Tretra|Intra-nasal administration of 0.2ml (0.1ml in each nostril).
75915995|NCT02522546|Other|nasopharyngeal swab|nasopharyngeal swab
75915996|NCT01094262|Drug|Oxycodone CR (standard pain medication)|Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
75915997|NCT01094262|Drug|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
75915998|NCT01094262|Drug|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
75915999|NCT01094262|Drug|Placebo|Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
75916000|NCT03441542|Behavioral|Data-assisted Case Navigation|"The researchers will develop a monthly task list for the patient navigator with patient by patient care cascade and treatment milestones that need to be accomplished per patient in the case group. The researchers will deliver the spreadsheet and the task list to the Grady Liver Clinic Director who will use it to direct and supervise the activities of the patient navigator.~Patient navigators will be responsible for reaching out to patients in only the intervention arm about their next step in the HCV care cascade."
76074904|NCT01725529|Drug|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms [μg] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
76074905|NCT01725529|Drug|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is < 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is > or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
75323219|NCT02999711|Drug|Placebo|Matching placebo
75628930|NCT00588770|Drug|Cisplatin|Given IV
75628931|NCT00588770|Drug|Docetaxel|Given IV
75628932|NCT00588770|Drug|Fluorouracil|Given IV
75628933|NCT00588770|Other|Laboratory Biomarker Analysis|Correlative studies
76074906|NCT01725529|Drug|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
75628934|NCT00470223|Drug|cisplatin|
76074907|NCT01605097|Radiation|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
75628935|NCT00470223|Drug|doxorubicin hydrochloride|
75628936|NCT00470223|Drug|etoposide|
76074908|NCT01605019|Device|CoSeal|3 - 8mls of Coseal
76074909|NCT01605019|Device|BioGlue® Surgical Adhesive|Total amount applied - 8 mls
76074910|NCT04413721|Procedure|RBC transfustion|When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
76074911|NCT04413565|Procedure|Simultaneous bilateral total knee arthroplasty|Two surgeon bilateral TKA group
75323220|NCT02999945|Dietary Supplement|SGA-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
75628937|NCT00470223|Drug|ifosfamide|
75628938|NCT00470223|Drug|methotrexate|
75628939|NCT00470223|Drug|zoledronic acid|
75628940|NCT00470223|Procedure|conventional surgery|
75628941|NCT00433511|Biological|Bevacizumab|Given IV
75628942|NCT00433511|Drug|Cyclophosphamide|Given IV
75628943|NCT00433511|Drug|Doxorubicin Hydrochloride|Given IV
75628944|NCT00433511|Other|Laboratory Biomarker Analysis|Correlative studies
75628945|NCT00433511|Drug|Paclitaxel|Given IV
75628946|NCT00433511|Other|Placebo Administration|Given IV
75628947|NCT00433511|Other|Quality-of-Life Assessment|Ancillary studies (closed as of 5/28/10)
75628948|NCT00408005|Drug|Asparaginase|Given IM or IV
75628949|NCT00408005|Drug|Cyclophosphamide|Given IV
75628950|NCT00408005|Drug|Cytarabine|Given IT, IV, or SC
75628951|NCT00408005|Drug|Daunorubicin Hydrochloride|Given IV
75628952|NCT00408005|Drug|Dexamethasone|Given IV or PO
75628953|NCT00408005|Drug|Doxorubicin Hydrochloride|Given IV
75628954|NCT00408005|Other|Laboratory Biomarker Analysis|Correlative studies
75628955|NCT00408005|Drug|Leucovorin Calcium|Given PO
75628956|NCT00408005|Drug|Mercaptopurine|Given PO
75628957|NCT00408005|Drug|Methotrexate|Given IT or PO
75628958|NCT00408005|Drug|Nelarabine|Given IV
75628959|NCT00408005|Drug|Pegaspargase|Given IM or IV
75780274|NCT04782466|Behavioral|Physical Activity (PA) Intervention|The ATOMIC intervention consists of four primary components: one-on-one chats with a PA coach, informational posts, PA self-monitoring through an activity tracker and educational modules regarding different aspects of becoming PA delivered through the MS-specific PA app. An overarching goal of moving youth with MS towards meeting current Moderate to Vigorous Physical Activity (MVPA) recommendations will be used in addition to initial results from accelerometer monitoring and evaluation of current PA intentions to establish step goals, with planned weekly incremental increases (10% weekly to goal).
75780275|NCT04782466|Behavioral|Waitlist attention-control|For a period of 6-months, participants will receive the control conditions that involve contact from study personnel and a nutritional educational module to ensure equivalent social contact in both arms of the study. After the 6-months, participants will receive the same intervention as the intervention arm.
75780276|NCT01113086|Device|Transcranial direct current stimulation|Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).
75780277|NCT01113164|Drug|Ondansetron and Sertraline|capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
75780278|NCT03828617|Biological|20vPnC|20vPnC
75780279|NCT03828617|Biological|20vPnC|20vPnC
75780280|NCT03828617|Biological|20vPnC|20vPnC
76074912|NCT04413565|Procedure|Sequenced bilateral TKA|Single surgeon bilateral TKA group
75323221|NCT02999945|Dietary Supplement|IUGR-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
75323222|NCT02999945|Other|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
75323223|NCT02999945|Other|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
75323224|NCT00595361|Drug|salmeterol|salmeterol 50 micrograms twice daily for 2 weeks
76074913|NCT01744483|Device|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
75323225|NCT02998463|Device|skin-to-skin facilitating garment|Fabric garment designed to accommodate term neonates having skin-to-skin contact.
75628960|NCT00408005|Drug|Prednisone|Given IV or PO
75628961|NCT00408005|Radiation|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
75780281|NCT03828617|Biological|13vPnC|Pneumococcal conjugate vaccine
75780282|NCT01113242|Other|Neuropsychological Assessment|Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,…) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) <16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.
75780283|NCT03391960|Device|Passive disinfection device|Add use of passive disinfection cap to existing central line needleless connector infection control procedure
75780284|NCT01210430|Drug|Losartan|Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
75780285|NCT01210430|Drug|Ascorbic Acid (Vitamin C)|Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
75780286|NCT01210430|Drug|Normal Saline|Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
75323226|NCT02999867|Dietary Supplement|triticale and mung bean|subjects are assigned to intake of triticale and mung bean for 30 days
75323227|NCT02999867|Dietary Supplement|adzuki bean|subjects are assigned to intake of adzuki bean for 30 days
75323228|NCT00596453|Drug|Ciprofloxacin hydrochloride|250 mg Ciprofloxacin hydrochloride twice a day for 14 days
75323229|NCT00596453|Drug|Placebo|Placebo twice a day for 14 days
75323230|NCT02998697|Drug|Ferrous Sulfate|Ferrous sulfate 200 mg t.i.d for 90 days
75323231|NCT02998697|Drug|Placebo Oral Capsule|Lactose 200 mg t.i.d for 90 days
75628962|NCT00408005|Drug|Thioguanine|Given PO
75628963|NCT00408005|Drug|Vincristine Sulfate|Given IV
75628964|NCT00324805|Biological|Bevacizumab|Given IV
75628965|NCT00324805|Drug|Cisplatin|Given IV
75628966|NCT00324805|Drug|Docetaxel|Given IV
75628967|NCT00324805|Drug|Gemcitabine Hydrochloride|Given IV
75628968|NCT00324805|Other|Laboratory Biomarker Analysis|Correlative studies
75628969|NCT00324805|Drug|Pemetrexed Disodium|Given IV
75628970|NCT00324805|Other|Questionnaire Administration|Ancillary studies
75628971|NCT00324805|Drug|Vinorelbine Tartrate|Given IV
75628972|NCT00310180|Drug|Anastrozole|Given PO
75628973|NCT00310180|Drug|Exemestane|Given PO
75628974|NCT00310180|Other|Laboratory Biomarker Analysis|Correlative studies
75628975|NCT00310180|Drug|Letrozole|Given PO
76074914|NCT01744483|Device|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
76074915|NCT01744483|Device|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
76074916|NCT01744093|Drug|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
76074917|NCT01744093|Drug|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
75323232|NCT02998307|Procedure|CPR Training|Brief CPR assessment and training done during working hours with real-time performance feedback
75323233|NCT00597545|Procedure|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
75323234|NCT00597545|Device|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
75467519|NCT01929551|Other|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
75628976|NCT00310180|Other|Quality-of-Life Assessment|Ancillary studies
75628977|NCT00310180|Radiation|Radiation Therapy|Undergo radiation therapy or partial breast irradiation
75628978|NCT00310180|Drug|Tamoxifen Citrate|Given PO
75628979|NCT00248040|Drug|Reparixin continuous infusion|The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.
75628980|NCT00248040|Drug|reparixin intermittent infusion|A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.
75628981|NCT00248040|Other|placebo infusion|placebo was volume/schedule matched saline
75628982|NCT04288440|Procedure|Surgery|Removal of epiretinal membrane and ILM
75628983|NCT04288440|Device|Vitrectomy machine|Pars plana vitrectomy
75628984|NCT02866032|Drug|MOB015B|
75628985|NCT02866032|Drug|Ciclopirox 80 mg/g|
75628986|NCT00976716|Drug|Celecoxib|"Day 1~The first dose: Celecoxib 400mg~The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~- Celecoxib 200mg twice daily"
75628987|NCT03842982|Drug|HIPEC|"HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours."
75628988|NCT05757349|Behavioral|Face-down position time 1-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
75323235|NCT00705107|Biological|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
75323236|NCT00705107|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
75323237|NCT00240331|Drug|10mg Rosuvastatin|
75467520|NCT01929551|Other|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
75467521|NCT01929590|Drug|PEG-3350 group 2|split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
75916001|NCT03441542|Behavioral|Standard of Care|Patients will be recruited into the study by the patient navigator, be provided information about HCV infection, and will be informed that treatment is freely available should they seek it. Patients will also be provided contact and address information for the treatment clinic.
75323238|NCT00240331|Drug|Placebo|
75323239|NCT00240097|Drug|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
75323240|NCT00240097|Drug|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
75323241|NCT00597935|Procedure|SSLF|sacrospinous ligament fixation (SSLF)
75323242|NCT00597935|Procedure|ULS|uterosacral vaginal vault ligament suspension (ULS)
75628989|NCT05757349|Behavioral|Face-down position time 3-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
75628990|NCT00973674|Drug|Premarin IV|One time dose of Premarin IV
75628991|NCT00973674|Drug|Placebo|One time dose of Placebo
75628992|NCT00819091|Drug|BI 1356|5mg orally (po) tablet qd
75628993|NCT00819091|Drug|Placebo|Placebo matching BI 1356 5mg one tablet daily
75628994|NCT04288596|Other|Participants undergoing ACHD intervention|Participants will receive standard of care for their ACHD intervention.
75916002|NCT02267070|Behavioral|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
76074918|NCT01725451|Drug|Testosterone|Administered topically to axillae
75323243|NCT00597935|Behavioral|PMT|Pelvic muscle training and exercises (PMT)
75323244|NCT00739765|Behavioral|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
75467522|NCT01929590|Drug|PEG-3350 group 1|PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
75467523|NCT01929590|Drug|PEG-3350 group 3|low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
75467524|NCT01930006|Drug|MGCD265|
75467525|NCT01930019|Drug|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
75467526|NCT01930071|Device|PQ Bypass Guide Wire Delivery System|The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
76074919|NCT01725451|Other|Deodorant Spray|Administered topically to axillae
75628995|NCT02864784|Drug|Amorphous calcium carbonate|Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
75628996|NCT02864784|Other|Placebo|
76074920|NCT01725451|Other|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
75780287|NCT05489146|Device|transcranial random noise stimulation and functional electrical stimulation facilitated task practice|Participants were randomized to one of the two intervention groups [transcranial current stimulation (tRNS) and functional electrical stimulation (FES) or FES with sham tRNS] before pre-intervention testing. After randomization, participants underwent pre-intervention testing, followed by intervention 3 times per week for 6 weeks. Each intervention session lasted for 1 hour, where tRNS or sham-tRNS were delivered concurrently with the FES-facilitated task practice. tRNS or sham-tRNS was delivered for the first 30 minutes. Both tRNS and sham tRNS were delivered by the Starstim system. FES was delivered using the Neuromove system. All participants were treated by a licensed occupational therapist, who was trained on a manualized protocol.
75628997|NCT04287270|Other|Assesment|Evaluations which explained in the arms section will be made as described.
75628998|NCT04287114|Behavioral|Acute exercise|Acute exercise with different exercise intensities
75628999|NCT04286724|Behavioral|"Brief behavioural procedure including a computerized visuospatial task (computer game Tetris)"|"Brief behavioural procedure including a computerized visuospatial task (the computer game Tetris) preceded by a reactivation of the traumatic memory of childbirth"
75629000|NCT00973362|Device|APTIMA HPV Assay|"The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44)."
75629001|NCT00973362|Device|FDA-Approved HPV DNA Test|A FDA-Approved HPV DNA Test is used as the comparator assay.
75629002|NCT00629694|Procedure|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
75629003|NCT00629694|Procedure|A-M|adenoidectomy and myringotomy alone
75629004|NCT05225454|Other||
75780288|NCT01210586|Behavioral|Part 2|Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
75780289|NCT01210742|Device|Synvisc One|Single intra-articular injection of a 6 mL of Hylan G-F 20 at baseline
75780290|NCT01210742|Other|Routine management|Routine non-operative management for knee OA (NICE guidelines)
75916003|NCT02267070|Behavioral|Family psychoeducation|All immediate family members will be invited to family psychoeducation sessions.
75916004|NCT02267070|Behavioral|Cognitive training|The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.
75916005|NCT02267070|Behavioral|Aerobic exercise|Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
75916006|NCT05626842|Other|Total Diet Replacement (800kcal/day)|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly for a further 36 weeks. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks.
75916007|NCT02522312|Other|No Intervention|No drug is administered in this study
76074921|NCT01725451|Other|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
76074922|NCT04558567|Drug|Vogelxo|50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)
76074923|NCT01707290|Drug|Ivacaftor|150 mg tablet, oral use, every 12 hours (q12h)
76074924|NCT01717040|Drug|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
76074925|NCT01717040|Drug|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
76074926|NCT04552262|Drug|BAY2327949|Single dose of 90 mg BAY2327949
76074927|NCT04552262|Drug|Placebo|Single dose of placebo to BAY 2327949
76074928|NCT00803062|Biological|Bevacizumab|Given IV
76074929|NCT00803062|Drug|Cisplatin|Given IV
75323245|NCT00739765|Behavioral|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
75629005|NCT04289766|Other|Conventional Treatment|These individuals will receive the conventional intervention including the routine rehabilitation therapy like active and passive ROMs, stretching, strengthening of upper limb, balance improvement exercises. Time duration is of 40 minute 3 times per week.
75629006|NCT04289766|Other|Focal Muscle Vibration (120Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
75629007|NCT04289766|Other|Focal Muscle Vibration (60Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
76074930|NCT00803062|Other|Laboratory Biomarker Analysis|Correlative studies
75916008|NCT04632134|Device|Transcutaneous vagal nerve stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) will be performed using a noninvasive battery powered Transcutaneous Electrical Nerve Stimulation device (Nemos ©; Cerbomed, Germany). Electrical stimulation will be delivered by external electrodes through the skin surface at the conca of right external ear. Electrical current will be applied continuously with a pulse width of 200 μs and pulse frequency of 25 Hz. Stimulation amplitude will be adjusted between 0.1-6 mA, to a maximal amplitude level without causing patient discomfort.
75323246|NCT00739765|Behavioral|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
75323247|NCT04270721|Behavioral|The EAGLE Safe Anastomosis Quality Improvement Intervention|"The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts:~Introduction of a routine patient risk stratification for anastomotic leak~Implementation of the ESCP Safe Anastomosis Checklist~Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence."
75323248|NCT04270487|Other|IBS Diet|Patients will be randomized to a diet or a mediation treatment
75323249|NCT04270487|Drug|Otilonium Bromide|Patients will be randomized to a diet or a mediation treatment
75323250|NCT00705653|Drug|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
75629008|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
75629009|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
75629010|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
75629011|NCT00819013|Biological|Saline placebo|0.5 mL, Intramuscular
75629012|NCT00976560|Drug|GW856553|Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
75629013|NCT00976560|Other|Placebo|Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
75629014|NCT02610049|Behavioral|Cognitive Processing therapy|8 sessions of standard CPT from CPT manual developed by Dr. S Resick, Monson & Chard (11/2010)
75629015|NCT02610049|Behavioral|Art + CPT|8 sessions of individual therapy of mixes techniques Art + CPT 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson & Chard (11/2010)
75629016|NCT02610049|Behavioral|CPT + Art Therapy|Subjects to complete 8 sessions of standard Cognitive Processing Therapy from manual developed by Dr. S. Resick, Monson & Chard (1/2010) CPT + Art Therapy of mixed individual techniques
75780291|NCT01113320|Drug|Placebo|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
75780292|NCT01113320|Drug|Safinamide|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
75780293|NCT01210898|Biological|Adjuvanted seasonal influenza vaccine|Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
75780294|NCT01116128|Drug|dasatinib|100 mg QD continuously (from day 1 to day 28)
75780295|NCT01116128|Drug|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
75780296|NCT01116128|Drug|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
75780297|NCT03390166|Biological|GPO Tri Fluvac vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
75780298|NCT03390166|Biological|Licensed influenza vaccine|The comparator licensed influenza vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
75916009|NCT04632134|Other|Placebo|tVNS electrodes will be positioned in the right ear of the POTS patients without delivering stimulus (Sham)
76074931|NCT00803062|Drug|Paclitaxel|Given IV
76074932|NCT00803062|Other|Quality-of-Life Assessment|Ancillary studies
76074933|NCT00803062|Other|Questionnaire Administration|Ancillary studies
76074934|NCT00803062|Drug|Topotecan Hydrochloride|Given IV
76074935|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
75629017|NCT04868461|Dietary Supplement|Unheated Whey Protein (UWP) beverage|The preload is made from whey protein powder. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
75629018|NCT04868461|Dietary Supplement|Heated Whey Protein (HWP) beverage|The preload is made from whey protein powder of 95% and it is heated for a certain amount of time. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
75629019|NCT04868461|Dietary Supplement|Casein (Cas) beverage|The preload is made from casein powder. The energy load of the preload is 105 kcal and has banana flavor and sweetener.
75629020|NCT04868461|Dietary Supplement|Water|The preload is water acting as a control and contain the same banana flavor and sweetener to match the other three intervention - protein beverages.
75629021|NCT02865642|Drug|Serotonin Uptake Inhibitors|
75629022|NCT02865642|Drug|Placebo|
75629023|NCT03774888|Procedure|Connective tissue graft at time of bone graft|following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
75629024|NCT03774888|Procedure|Acellular Demal Matrix at time of bone graft|following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
75629025|NCT03774888|Procedure|No soft tissue grafting at time of bone graft|Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
75323251|NCT02998073|Behavioral|Stop, Now and Plan|SNAP program was developed to target justice-involved youth (6 years and older) who have problems with aggression, CD, and/or gang affiliation. SNAP focuses on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP treatment is delivered over a 13-week period.
75323252|NCT00739999|Drug|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
75323253|NCT00739999|Drug|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
75323254|NCT02999555|Procedure|Ovum pickup|Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
75629026|NCT04204590|Other|Deprescribing algorithm|For this study an implicit, evidence-supported and patient-centred algorithm has been developed. The outcome of the algorithm is an advice to the doctor to deprescribe or not deprescribe the statin and/or PPI.
75323255|NCT02999321|Other|aspartame|will be given 5mg aspartame or 15 mg aspartame
75780299|NCT01207856|Behavioral|specific cognitive rehabilitation|"Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises)."
75323256|NCT02999321|Other|water|control group
75629027|NCT03762564|Drug|Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15
75780300|NCT01207856|Behavioral|non specific cognitive rehabilitation|A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
75323257|NCT01279525|Device|multifactorial|individual advice, information leaflet, physical exercise workshop and home visits
75780301|NCT01207856|Other|no intervention|no intervention
75780302|NCT01116206|Drug|Prucalopride|2 mg tablet, orally once daily, for 12 weeks
75780303|NCT01116206|Drug|Placebo|1 tablet, orally once dailyfor 12 weeks
75780304|NCT01210976|Drug|levosimendan|12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min
75780305|NCT01210976|Drug|placebo|nacl 0.9% coloured with thiamin in same volume and time than levosimendan
75780306|NCT03828539|Biological|Erenumab|70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks
75916010|NCT04632134|Device|Home daily transcutaneous vagal nerve stimulation|The home stimulation will consist of 4 hours of stimulation by the tVNS device organized as a 4 sessions of 1 hour. The home stimulation will last for 14 consecutive days.
75323258|NCT00600743|Drug|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
75467527|NCT01930084|Other|Point of care CD4+ after HIV diagnosis|Point of care (POC) CD4+ testing immediately following HIV diagnosis
75629028|NCT03762564|Drug|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, 8, 15
75916011|NCT04476186|Drug|Acyclovir|oral syrp
75916012|NCT04476186|Drug|KOH 10 %|solution for local application
75916013|NCT03440216|Drug|blood sampling|"temocillin: blood sampling every day for 7 days~ceftriaxone: blood sampling 12h after administration for 7 days~meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7"
75916014|NCT03440216|Drug|Tissue sampling (lung)|Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
76074936|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
75323259|NCT00600743|Behavioral|Instructions to binge eat|Subjects will be instructed to binge eat and will also be given either drug or placebo
75629029|NCT00975156|Other|Physical Therapy|Conventional physical therapy
75629030|NCT00975156|Device|Lokomat|Robotic-assisted walking device
75323260|NCT00600743|Behavioral|Instructions to eat normally|Subjects will be instructed to eat normally and will also be given either drug or placebo
75323261|NCT00600743|Drug|Placebo|Drug one trial vs placebo
75467528|NCT01930084|Other|Accelerated ART initiation|Accelerated ART initiation for eligible participants delivered by facility personnel
75467529|NCT01930084|Behavioral|SMS appointment reminders|Cellular appointment reminders delivered by study personnel
75467530|NCT01930084|Other|Non-cash Financial Incentives|Non-cash Financial Incentives
75651683|NCT05832294|Device|Treatment rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
75780307|NCT03828539|Drug|Topiramate|"Film-coated tablet taken orally:~25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase."
75780308|NCT03828539|Biological|Erenumab matching placebo|Erenumab matching placebo pre-filled syringue administered every 4 weeks
75780309|NCT03828539|Drug|Topiramate matching placebo|Topiramate matching placebo administered daily
75780310|NCT01109888|Drug|Cetrotide|
75323262|NCT02997995|Drug|Immune-attractant|The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
75323263|NCT02997995|Drug|Durvalumab|Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
75323264|NCT02997995|Procedure|Biopsy|After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
75916015|NCT03440216|Drug|Collection of fluid samples|Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment
75916016|NCT01166412|Drug|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|6.5mg patch daily for 11 weeks
75916017|NCT01166412|Drug|levonorgestrel patch with BMI <32 kg/m2|6.5mg patch daily for 11 weeks
75780311|NCT01212614|Procedure|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
75629031|NCT02610205|Other|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
75629032|NCT04204746|Other|We will observe and evaluate the temperature and moisture in the respiratory circuit by a thermo-hygrometer.|
75916018|NCT01166412|Drug|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|12.5mg patch daily for 11 weeks
75629033|NCT00629616|Drug|anastrozole|1 mg/day for either 4 months or 6 months depending on the clinical evaluation
75629034|NCT00629616|Drug|fulvestrant|500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
75629035|NCT02609971|Other|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
75629036|NCT04269096|Other|Protocol Compliance|Compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol
75916019|NCT01166412|Drug|levonorgestrel patch with BMI <32 kg/m2|12.5mg patch daily for 11 weeks
76074937|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
76074938|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
75629037|NCT04268940|Diagnostic Test|Thromboelastography|Thromboelastography (TEG 6s, global hemostasis cartridge) will be performed before ECMO insertion and at different time-points during the course of ECMO. In parallel a full coagulation work-up (aPTT, prothrombin time [PT], anti-Xa, activated clotting time[ACT], platelets count, d-dimers, von Willebrand panel and fibrinogen) will be measured simultaneously with each TEG.
75629038|NCT04832737|Behavioral|ADDapt Ability Framework|12 week individual therapeutic coaching intervention
76074939|NCT01743001|Drug|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
76074940|NCT01743001|Drug|Placebo|Macitentan-matching placebo oral tablet once daily
76074941|NCT00362284|Behavioral|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
76074942|NCT03839368|Procedure|fixation of angle fracture|open reduction and internal fixation of angle fracture
75323265|NCT00601367|Drug|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
75629039|NCT02864628|Biological|MVA-BN-RSV|MVA-mBN294B
75780312|NCT03336502|Drug|Posaconazole|Posaconazole 18 mg/mL IV solution; posaconazole 40 mg/mL oral suspension
75323266|NCT03620162|Biological|Prevnar 13™|Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.
75780313|NCT01116284|Procedure|Revision of gastric bypass|A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
75780314|NCT01325051|Drug|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
75916020|NCT04475796|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed after ERCP
75916021|NCT05370716|Drug|Polmacoxib|Polmacoxib
75916022|NCT05370716|Drug|Pregabalin|Pregabalin
75916023|NCT05626764|Other|QoL & irAEs determinants|Assesment of the QoL & irAEs determinants in patients diagnosed with solid tumor and treated in France, Netherlands, Portugal, Spain, with immunotherapy by immune checkpoint inhibitors.
75916024|NCT05626764|Other|QoL & irAEs determinants|Assesment of the QoL & irAEs determinants in patients diagnosed with hematologic cancer and treated in France, Netherlands, Portugal, Spain, by CAR-T cells.
75629040|NCT02864628|Other|Placebo|Tris Buffered Saline
75629041|NCT00810043|Device|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
75780315|NCT01212692|Behavioral|mentally stimulating activities|The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
75780316|NCT01058447|Drug|AZD1981|Oral tablet, 250 mg, single dose
75780317|NCT01109966|Other|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study > 500mls/day up to 12 months of age > 400mls/day between 12 and 18 months of age > 300mls/day over 18 months of age."
75780318|NCT01109966|Other|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study > 500mls/day up to 12 months of age > 400mls/day between 12 and 18 months of age > 300mls/day over 18 months of age."
75780319|NCT01055405|Drug|Sildenafil|Sildenafil 20mg TID orally
75780320|NCT01055405|Other|Placebo|Placebo TID orally
75916025|NCT03382496|Other|Non-Interventional|Non-Interventional
75916026|NCT05158244|Drug|PF-07081532|Study Drug, once daily for 42 days
75916027|NCT05158244|Drug|Placebo|Placebo, once daily for 42 days
75916028|NCT02269410|Dietary Supplement|GBP-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
75916029|NCT02269410|Dietary Supplement|GBP-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
75916030|NCT02269410|Dietary Supplement|VSG-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
75916031|NCT02269410|Dietary Supplement|VSG-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
75916032|NCT05156918|Other|Exercise|Participants will rotate between three exercise machines (randomly assigned rotation order at outset): A Concept C2 rowing machine, a stationary bicycle, and a treadmill. Study participants will use a different machine each day so that they are using each of the three exercise machines once per week. Two treadmills, two bikes, and two rowers are available during each exercise session. Participants will be randomly assigned to one of three machine orders: treadmill-rower-bike, rower-bike-treadmill, or bike-treadmill-rower. We will employ a percent of heart rate protocol as an exercise intensity measure (77-93% of age-adjusted maximum heart rate) rather than a less well-defined maximal effort protocol or rating of perceived exertion scale. For the purposes of this exercise protocol high intensity exercise will be defined as 77-93% of age adjusted maximum heart rate.
75916033|NCT05156918|Other|Non Exercise|There are no modifications to regular diet or exercise habits for 30 days.
75916034|NCT01038804|Drug|YM155|intravenous infusion
75916035|NCT01038804|Drug|Docetaxel|intravenous infusion
75916036|NCT03465566|Diagnostic Test|IDS;MMSPE;CDI 2;CBCL;tests of facial expression evaluation|Five pictures (including nonfacial features; i.e., hairs) were used for each emotion, giving a total of 25 trials.Stimuli consist of pictures of facial affect taken from the Ekman and Friesen series.
75916037|NCT05118776|Drug|ASC40 tablets|ASC40 tablets administered orally once daily
75629042|NCT04807933|Behavioral|Heart rate variability Biofeedback [HRV-BFB]|BFB consists of a physiological recording used as a visual physiological feedback that can teach us how to control our physiology, which is naturally unconscious and uncontrollable. The BFB focused on the heart rate variability (HRV-BFB) could regulate the autonomic nervous system (vagal tone and sympathetic-parasympathetic balance) and the emotional state. The HRV BFB has received several clinical and experimental confirmations as a physiological remediation method. It is an innovative and non-pharmacological therapy frequently used to relieve stress.
75916038|NCT05118776|Drug|Placebo tablets|Placebo administered orally once daily.
75916039|NCT05118776|Drug|Bevacizumab|Bevacizumab once every 2 weeks, intravenous drip.
75916040|NCT02269566|Drug|HollisterStier|0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
75916041|NCT02269566|Drug|Normal saline|0.1 ml of normal saline 3 injections into an inguinal lymph node
75916042|NCT02269644|Drug|Dalbavancin|dalbavancin 1500 mg IV over 30 minutes on Day 1
75916043|NCT02269644|Drug|Linezolid|linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
75916044|NCT02269644|Drug|Linezolid Placebo|Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
75916045|NCT02269644|Drug|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
75916046|NCT02269722|Device|Vascular compression device- RADAR TM-Short clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
75916047|NCT02269722|Device|Vascular compression device RADAR TM-Long clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
76074943|NCT00821626|Device|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
76074944|NCT00821626|Other|Control|No rapid flu test
76074945|NCT01704079|Drug|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime
75916048|NCT03367988|Drug|Opioid Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
75916049|NCT03367988|Drug|Opioid-free Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
75629043|NCT01120184|Drug|docetaxel|75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
75916050|NCT03465488|Drug|Albendazole Pill 400mg (GSK)|One single dose of 400mg Albendazole is provided at baseline.
75916051|NCT02267304|Drug|50 mL of sodium chloride (0,9%)|
75916052|NCT02267304|Drug|Morphine 0,05mg/kg|
75323267|NCT03620162|Biological|V114|V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.
75323268|NCT03620162|Biological|RotaTeq™|RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.
75629044|NCT01120184|Drug|paclitaxel|80 mg/m2 intravenously weekly for a minimum of 18 weeks
75629045|NCT01120184|Drug|pertuzumab|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
75629046|NCT01120184|Drug|pertuzumab-placebo|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
75780321|NCT01116362|Procedure|primary repair|during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
75629047|NCT01120184|Drug|trastuzumab [Herceptin]|trastuzumab [Herceptin] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
75780322|NCT01116362|Procedure|secondary repair|after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
75780323|NCT01058525|Procedure|median nerve block|median nerve block performed using ultrasound guidance
75780324|NCT01058525|Procedure|median nerve block after hydro-dissection|median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
75916053|NCT02267304|Drug|Naloxone 10mg|
75916054|NCT03465410|Drug|Standard dosage of Tacrolimus|Immediate release Tacrolimus (Prograf/Adoport)
75323269|NCT03620162|Biological|Pentacel™|Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
75629048|NCT01120184|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks
75629049|NCT01120028|Drug|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
75916055|NCT03465410|Drug|Bayesian Prediction Tacrolimus dosage|Immediate release Tacrolimus (Prograf/Adoport)
75629050|NCT01120028|Drug|Basiliximab|20 mg intravenously, two doses 96 hours apart
75629051|NCT01120028|Drug|Sirolimus|Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
75629052|NCT01120028|Drug|Tacrolimus|Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
75629053|NCT00878800|Drug|PXD101|Administered in combination with doxorubicin (BelDox)
75916056|NCT04475874|Other|supervised stretching exercises|30 to 45-minute supervised active stretching program by a trained physical therapist, three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
75916057|NCT04475874|Other|non-supervised active stretching home program|non supervised 30 to 45-minute supervised active stretching program three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
75629054|NCT00878800|Drug|Doxorubicin|Administered in combination with PXD101 (BelDox)
75629055|NCT00662272|Biological|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
75629056|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
75916058|NCT03130088|Other|no intervention planed|no intervention planed
75916059|NCT05332418|Other|selected exercise program|therapeutic ultrasound, Static neck exercise, Educational postural correction, and Home neck exercise program for patient
75629057|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
75780325|NCT01211132|Device|Cap - Transparent retractable extension device.|Attaching a Cap - Transparent retractable extension device.
75629058|NCT00662350|Device|The Wallterm™ System|The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
75629059|NCT00662428|Other|Symptom based discharge management|Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
75629060|NCT00662428|Other|Treatment as usual|Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
75629061|NCT04158856|Drug|Pyrotinib|400mg po every day
75629062|NCT04158856|Drug|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days
75629063|NCT00659308|Procedure|amniotic membrane transplantation|patients are submitted to amniotic membrane transplantation
75629064|NCT00659308|Procedure|anterior stromal puncture|the other group is submitted to anterior stromal puncture
75629065|NCT01119950|Drug|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
75916060|NCT05332418|Device|Electromagenetic Field therapy|Magnetotherapy application the device will be adjusted around the neck and shoulder area at low frequency (50 Hz), with intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60) , and the application time (10 minutes)
75916061|NCT02522234|Biological|F-627 240 μg/kg|F-627 at 240 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 240 μg/kg arm. And the arm should contain 6 evaluable subjects.
75629066|NCT01119950|Drug|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
75629067|NCT01119950|Drug|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
75780326|NCT01211132|Device|Standard|Without attaching a transparent cap to the tip of colonoscope.
75780327|NCT01055483|Drug|panobinostat/LBH589B|
75780328|NCT01110044|Biological|251154 vaccine|Intramuscular, single dose
75780329|NCT01110044|Biological|Infanrix hexa™|Intramuscular, four doses
75780330|NCT01110044|Biological|Synflorix™|Intramuscular, four doses
75780331|NCT01110044|Biological|Rotarix™|Oral, two doses
75780332|NCT03987971|Other|acupuncture|Acupuncture on GB26, every other day, 3 times a week, 2 weeks in total.
75780333|NCT03710668|Radiation|MRI if indicated|MRI brain if indicated
75780334|NCT01116518|Procedure|physiotherapy|
75780335|NCT01116518|Procedure|acromioplasty|
75780336|NCT01116518|Procedure|acromioplasty and rotator cuff reconstruction|
75780337|NCT03370510|Drug|Oxytocin|Oxytocin nasal spray.
75780338|NCT03370510|Behavioral|Pivotal Response Treatment|An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.
75780339|NCT03370510|Drug|Placebo|Placebo nasal spray.
75780340|NCT03985865|Drug|Intragastric quinine hydrochloride|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
75780341|NCT03985865|Drug|Intragastric denatonium benzoate|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
75780342|NCT03985865|Drug|Intragastric placebo|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
75780343|NCT03985865|Drug|Intraduodenal quinine hydrochloride|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
75780344|NCT03985865|Drug|Intraduodenal denatonium benzoate|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
75629068|NCT01119950|Drug|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
75780345|NCT03985865|Drug|Intraduodenal placebo|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
75780346|NCT01116596|Drug|Paracetamol|determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
75780347|NCT00351611|Drug|Lyrica (pregabalin)|150 mg twice a day, oral administration
75780348|NCT00351611|Drug|placebo|Twice a day, oral administration
75780349|NCT01211210|Drug|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
75780350|NCT01211210|Drug|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
75780351|NCT01211210|Drug|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
75780352|NCT01116752|Other|Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)|In addition to glycemic control in 2 groups, all children <1 year old and 25% of those >1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
75780353|NCT01110122|Dietary Supplement|Whey protein|20g, oral, dissolved in yoghurt-drink, after every training and match for 2 weeks
75780354|NCT01058603|Other|- Conventional culture medium for IVF|Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
75916062|NCT02522234|Biological|F-627 320 μg/kg|F-627 at 320 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 320 μg/kg arm. The arm should contain 6 evaluable subjects.
75916063|NCT03465332|Other|Doctor's questionnaire|The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
75916064|NCT03465332|Other|Subject file|All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
75467531|NCT01930097|Other|14 hours intervention|Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).
75629069|NCT01119950|Drug|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
75916065|NCT00154284|Drug|Everolimus (Certican)|
75323270|NCT03620162|Biological|RECOMBIVAX HB™|RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
75629070|NCT01119950|Drug|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
75629071|NCT01119950|Drug|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
75780355|NCT01058603|Other|- Endocell®|Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
75629072|NCT01119950|Drug|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
75916066|NCT00154284|Drug|Cyclosporine (Neoral)|
75323271|NCT03620162|Biological|HIBERIX™|HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
75323272|NCT03620162|Biological|M-M-R™ II|M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.
75323273|NCT03620162|Biological|VARIVAX™|VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.
75323274|NCT02999165|Other|Breast feeding|Infants on respiratory support will be allowed to attempt to breast feed (with a top up nasogastric tube feed if required).
75629073|NCT02882828|Drug|switched from Prograf® to Envarsus®|
75323275|NCT02999165|Other|Nasogastric feeding|The control intervention is feeding via nasogastric tube
75323276|NCT00742573|Drug|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
75323277|NCT00742573|Behavioral|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
75323278|NCT02321111|Drug|Eritoran|Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
75323279|NCT02321111|Drug|D5W (5% Dextrose in water)|D5W = 5% Dextrose Water Vehicle
75323280|NCT03809923|Drug|lidocaine and dexmedetomidine infusion|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
75780356|NCT01116830|Drug|Placebo|Orally daily for 6 weeks
75780357|NCT01116830|Drug|RO4917838|10 mg daily orally for 6 weeks
75780358|NCT01116830|Drug|Standard Antipsychotic Therapy|Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
75780359|NCT00351533|Drug|Fish oil (eicosapentaenoic acid and docosahexanoic acid)|Liquid fish oil 7.5cc enterally every 6 hours
75780360|NCT01208012|Drug|Victoza®|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
75780361|NCT03939806|Drug|Oxytocin|To be given to Oxytocin group following the clamping of the umbilical cord
75780362|NCT03939806|Drug|Carbetocin|To be given to Carbetocin group following the clamping of the umbilical cord
75780363|NCT03939494|Behavioral|Telehealth Encounter|Contact will be made with participants via Face Time or Skype.
75916067|NCT00154284|Drug|Steroid|Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
75916068|NCT00154284|Drug|Basiliximab (Simulect)|
75916069|NCT01293552|Biological|ANT-1207|single dose application
75916070|NCT01293552|Biological|Vehicle|
76074946|NCT01704079|Other|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
75467532|NCT01930110|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
76074947|NCT04556695|Other|Questionnaire survey|Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)
75629074|NCT02882126|Drug|Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
75629075|NCT01145222|Drug|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
75629076|NCT01145222|Drug|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
75916071|NCT04973306|Procedure|Neoadjuvant Chemoradiotherapy|"Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.~Radiotherapy: A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 days per week (Radiotherapy was performed on the 2nd, 3rd, 4th, 5th, and 6th day in each cycle, and only 3 times in the 5th cycle)"
75323281|NCT03809923|Drug|Saline infusion|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
75323282|NCT03809923|Drug|Lidocaine infusion|patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.
75323283|NCT03809923|Drug|Dexmedetomidine infusion|Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.
75323284|NCT02997917|Behavioral|Education|
75780364|NCT01585376|Genetic|mutation analysis|
75780365|NCT01585376|Genetic|nucleic acid sequencing|
75323285|NCT02997917|Behavioral|Sham|
75629077|NCT01145222|Drug|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
75629078|NCT01145222|Drug|D. Midazolam|Initial standardized dose plus supplemental doses as necessary.
75629079|NCT01145066|Drug|borage/echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
75629080|NCT01145066|Dietary Supplement|fish oil|1.6g/day EPA and 1.08g/day DHA
75629081|NCT01145066|Dietary Supplement|corn oil|contains 4.5 g/day linoleic acid
75629082|NCT02883920|Other|Allergy and respiratory functional tests|
75629083|NCT01132118|Drug|Hydroxychloroquine|Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
75780366|NCT01585376|Other|laboratory biomarker analysis|
75780367|NCT03939572|Behavioral|Accurate step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.
75780368|NCT03939572|Behavioral|Deflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count deflated by 40% (i.e., their step count multiplied by 0.6).
75323286|NCT02998853|Other|QFR measurement by dedicated workstation on xrays angio selected runs|The patient undergoes coronary angiography; if at least one stenosis from 40 to 90% in non culprit is present and FFR is indicated by guidelines the patient is enrolled to 3d Angio QFR evaluation; no adjunctive invasive procedures are needed for QFR measurements
75629084|NCT00637442|Drug|Reminyl retard|retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
75629085|NCT00972816|Biological|MF59-eH1N1|MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
75629086|NCT02882048|Procedure|NADA Protocol|NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
75629087|NCT02882048|Other|Medication management|Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
75629088|NCT05207306|Procedure|Type of interfascial plane block|"In the M-TAPA group, after finding the right 10th costal cartilage using ultrasound guidance, a anesthesiologist inject 0.375% ropivacaine 15ml into the lower aspect of the chondrium. Perform left M-TAPA in the same way.~In the subcostal TAPB group, a anesthesiologist inject 0.375% ropivacaine 15ml into end of right rectus abdominis muscle using ultrasound guidance. Perform left subcostal TAPB in the same way."
75629089|NCT00969618|Drug|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
75629090|NCT02864472|Procedure|PDT|PDT and ranibizumab
75629091|NCT02864472|Drug|Ranibizumab|Ranibizumab
75629092|NCT02864472|Drug|ranibizumab PRN|ranibizumab PRN
75629093|NCT00969540|Device|Active Mattress Cover|Active Mattress Cover
75629094|NCT00969540|Device|Placebo Mattress Cover|Placebo Mattress Cover
75780369|NCT03939572|Behavioral|Inflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count inflated by 40% (i.e., their step count multiplied by 1.4).
75916072|NCT04973306|Drug|Tislelizumab|"Tislelizumab (200mg/time) was administered intravenously on the 1st and 22nd day.~The intravenous injection lasts about 30 minutes (micropump is recommended, intravenous bolus is prohibited, duration should be not less than 20 minutes and not more than 60 minutes);"
75629095|NCT00975000|Drug|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
75629096|NCT00975000|Drug|Placebo|Administered orally following the same dosing regimen as the experimental arm.
75629097|NCT04286802|Device|Salt-meter|Salt-meter, developed by Faculty of Engineering at Mahidol University, is a device to measure sodium chloride content in the food and reflects to user with number and symbols for easy-understanding.
75780370|NCT03939572|Behavioral|Accurate feedback + mindset intervention|"After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.~Additionally, participants in this arm will receive a meta-mindset intervention in the first weekly survey on day 7, which consists of a series of videos and reflection exercises to teach participants about the power of mindsets and encourage them to choose adaptive mindsets that will benefit their health. There are also short booster reflection exercises in all subsequent daily and weekly surveys, reinforcing the message about adaptive mindsets."
75780371|NCT01113554|Other|questionnaire administration|
75916073|NCT04973306|Procedure|Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)|After neoadjuvant therapy, patients in groups receive Ivor-Lewis or Mckeown Esophagectomy (Mckeown Esophagectomy recommended)
75916074|NCT04438746|Behavioral|Emotion discussion|General discussion of emotions; no therapy or training is offered
76074948|NCT04556695|Device|Accelerometer study|Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.
76074949|NCT04556695|Other|Semi-structured interview study|Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
76074950|NCT01703845|Drug|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
75323287|NCT03802279|Other|Effort test|"Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~Muscle oxygenation is measured using a near-infrared spectroscopy device.~VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated."
75323288|NCT03802279|Other|Functional tests on fibroblasts|Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
75323289|NCT02998931|Drug|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
75323290|NCT02998931|Other|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
75629098|NCT04286802|Behavioral|Education|Program dietary education by certified dietician who did not know the patients arm allocation.
75629099|NCT02863614|Drug|Ibuprofen 600 mg|
75629100|NCT02863614|Drug|Lorazepam 1 mg|
75629101|NCT02863614|Drug|Placebo|
75629102|NCT04288908|Other|Cyberball experimental task|Cyberball is an experimental task in which participants have to pass a ball to two virtual players during 60 passes in total
75629103|NCT00974922|Drug|Aliskiren|150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
75629104|NCT00974922|Dietary Supplement|Cholecalciferol|3000 I.U. once daily for 6 weeks
75629105|NCT00974922|Dietary Supplement|Placebo|Placebo for two weeks
75780372|NCT01113554|Behavioral|exercise intervention|
75780373|NCT01113554|Procedure|quality-of-life assessment|
75780374|NCT01113554|Other|survey administration|
75916075|NCT04438746|Behavioral|Cognitive Behavioral Affective Therapy|Active training in regulating anger
76074951|NCT01703845|Drug|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
76074952|NCT01724359|Drug|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
76074953|NCT01703221|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
76074954|NCT01703221|Drug|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
76074955|NCT01703221|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
75916076|NCT01037166|Drug|Entecavir|Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
76074956|NCT01703221|Drug|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
76074957|NCT01722877|Device|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
75629106|NCT04288518|Drug|SPECT or SPECT-CT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
75629107|NCT04287972|Procedure|DPC|The anterior fat pad is dissected until the left crura is visible, pars flaccida is open and the right crura exposed. Phreno-oesophageal ligament is sectioned starting from the right crura. Posterior and anterior vagal nerve are recognized before the oesophageal dissection. An intra-abdominal oesophagus lengths of 2 or 3 cm is obtained in order to reduce tension. Left and right crura are sutured with 2 or 3 non absorbable 2-0 stitches; an additional anterior stitch is posed if necessary to calibrate hiatus size without oesophageal deviation.
76074958|NCT00822094|Drug|CPX-351|
76074959|NCT00822094|Drug|Intensive Salvage Therapy|
76074960|NCT00822328|Dietary Supplement|Yakult®300|"Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week."
76074961|NCT00822328|Dietary Supplement|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
75629108|NCT04287972|Procedure|LSG|After omental section close to gastric insertion, gastric stapling is realised with triple line endo stapler (normally 5 or 6 re-loads). The gastrectomy begins 5-6 cm from the pylorus; gastric fundus is totally resected keeping a distance of 5-10 mm from oesophagus. Any bleeding on staple line is controlled with surgical clips or coagulator.
76074962|NCT05098600|Other|Exposure of interest|Common autoimmune and atopic conditions consist of atopic dermatitis, allergic rhinitis, asthma, Crohn's disease, ulcerative colitis, Celiac disease, Pernicious anaemia, Type 1 diabetes, Autoimmune thyroiditis (Hashimoto's thyroiditis, Grave's disease, atrophic, unspecified), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Systemic lupus erythematosus, Sjogren syndrome, psoriasis, vitiligo, Multiple sclerosis
76074963|NCT00803686|Drug|Oral rsCT tablet|On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
76074964|NCT00803686|Drug|Oral Placebo Tablet|Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
75323291|NCT01272115|Behavioral|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
75323292|NCT02998619|Radiation|Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
75323293|NCT00719329|Drug|Chlorhexidine 4.0%|Solution (4.0%, 7.1% CHX-D)
75323294|NCT00719329|Behavioral|Dry Cord Care|Educational messages regarding clean cord care
75323295|NCT00602225|Drug|clofarabine|Given IV
75629109|NCT00972504|Drug|GSK835726 10mg|GSK835726 10mg tablet
75780375|NCT01113554|Procedure|management of therapy complications|
75780376|NCT01113554|Procedure|psychosocial assessment and care|
75780377|NCT00351377|Drug|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
75780378|NCT01110356|Drug|Ferinject|Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
75780379|NCT01110356|Other|Saline|Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
75780380|NCT01113788|Device|tricuspid isthmus imaging with Cartosound|tricuspid isthmus imaging with Cartosound
75916077|NCT03134976|Drug|Levothyroxine|Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
75916078|NCT04491032|Procedure|Caudal anesthesia|Caudal epidural injection will be performed after induction of general anesthesia.
75916079|NCT02269800|Drug|Benzalkonium chloride solution|Tid, 7 days
75780381|NCT03941366|Procedure|Standard of care chemotherapy with the change for avoidance of extensive surgery|All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.
75780382|NCT01211366|Other|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
75916080|NCT02269800|Drug|Normal saline|Tid, 7 days
75916081|NCT04487756|Drug|Atezolizumab 1200 mg in 20 ML Injection|"- Induction (4 cycles, every 3 weeks): Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)~- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks)"
76074965|NCT00803686|Drug|Oral rsCT tablet|Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
76074966|NCT00803686|Drug|Fortical (rsCT) nasal spray|Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
76074967|NCT01703065|Drug|Cabozantinib|Given orally once a day
75323296|NCT00602225|Drug|cytarabine|Given IV
75323297|NCT00602225|Biological|filgrastim|Given subcutaneously
75323298|NCT04297748|Combination Product|89Zirconium-M7824|PET imaging agent
75323299|NCT04297748|Drug|M7824|Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.
75323300|NCT00602771|Drug|tipifarnib|Given orally
75323301|NCT00602771|Drug|etoposide|Given orally
75629110|NCT00972504|Drug|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
75629111|NCT00972504|Drug|Cetirizine 10mg|Cetirizine 10mg active comparator
75629112|NCT00972504|Drug|placebo|placebo to match actives
75629113|NCT00969228|Biological|Rotarix ™|Two oral doses
75629114|NCT00969228|Biological|Placebo|Two oral doses
75323302|NCT04278482|Dietary Supplement|Dietary supplement, DHA or Placebo|Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo
75629115|NCT00969150|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
75780383|NCT01211366|Other|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
75780384|NCT01212848|Device|Transcranial Magnetic Stimulation|Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.
75916082|NCT04487756|Biological|ADC Vaccine|- Maintenance (only patients without PD after 4 induction cycles, up to PD): DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33.
75780385|NCT01212848|Device|Transcranial Magnetic Stimulation - Sham Comparator|"The control group will receive an identical dosing schedule of sham repetitive TMS over three days."
75916083|NCT04487756|Drug|Carboplatin|- Induction (4 cycles, every 3 weeks): Carboplatin AUC 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle)
75916084|NCT02269956|Behavioral|12 week feasibility study|: At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
76074968|NCT00823966|Drug|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
75323303|NCT02997683|Device|Body Vibration platform GALILEO|3 month home based training on whole Body Vibration platform GALILEO
75323304|NCT02997683|Other|exercises at home on the floor|exercises at home on the floor
75323305|NCT00742963|Drug|TH-302|"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"
75916085|NCT02270112|Device|ECG|Patients receive a 5 Minute ECG recording and have their pulse recorded by an iPhone.
75916086|NCT01281462|Drug|Ceftaroline fosamil and NXL104 (q8h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
75916087|NCT01281462|Drug|Ceftaroline fosamil and NXL104 (q12h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);
75916088|NCT01281462|Drug|Doripenem|500 mg doripenem IV q8h;
75323306|NCT02997839|Behavioral|sleep disruption|"Group two will have interrupted sleep at time periods of 2 hours post operatively.~Group two will be woken every 2 hours, which is the standard NCCU protocol."
75323307|NCT01279603|Drug|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
75323308|NCT02997527|Device|Intraluminal Impedance|Esophageal impedance testing measures epithelial integrity as reflected through the ability of the mucosa to conduct electric current. Recently, a site specific endoscopically placed impedance probe has been developed that can measure esophageal mucosal impedance at any point of the esophagus.
75780386|NCT00337727|Drug|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
75629116|NCT00969150|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
75780387|NCT00337727|Drug|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
75916089|NCT01281462|Drug|Placebo|On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
75916090|NCT01268280|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
75916091|NCT01268280|Drug|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
75916092|NCT01268280|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
75916093|NCT04453124|Biological|Topical antiseptic treatment|Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.
75916094|NCT02267460|Biological|AA4500|
75916095|NCT02267460|Device|ErecAid® Esteem® Manual Vacuum Therapy System|
76074969|NCT01702987|Dietary Supplement|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
76074970|NCT01702987|Dietary Supplement|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
75629117|NCT00974220|Drug|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
75629118|NCT00974220|Drug|normal saline (placebo)|single dose, 0.9% saline solution
75780388|NCT00337727|Drug|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
75629119|NCT03904758|Diagnostic Test|Pepsin in saliva test|The presence of pepsin in the saliva will be tested in both groups of patients.
75629120|NCT02863536|Device|Polybactum®|3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
75780389|NCT00337727|Drug|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
75780390|NCT00337727|Drug|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
75780391|NCT00337727|Drug|Comparator; Placebo (unspecified)|Aprepitant 80 mg & 125 mg Pbo capsules.
75780392|NCT03939338|Other|Treg levels and CMR results|This is an observational study. Exposure: Different Treg levels and CMR results.
75629121|NCT00971178|Drug|local dexmedetomidine|Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.
75629122|NCT00971178|Drug|Peripheral normal saline|Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
75780393|NCT03987893|Drug|PEG-3350 with Electolytes|experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.
75629123|NCT00971178|Drug|IV dexmedetomidine|IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
75780394|NCT03987893|Drug|Lactulose|Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
75780395|NCT01116908|Device|LifeStraw Family|LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
75780396|NCT01058681|Dietary Supplement|effect of metabolic variations on LH pulsatility|"Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia."
75780397|NCT01211444|Device|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
75780398|NCT01061099|Biological|Mesenchymal Stromal Cells|Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow
75780399|NCT01208480|Drug|Avastin, docetaxel, carboplatin|Avastin, docetaxel, carboplatin
75780400|NCT00324233|Device|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
75780401|NCT00324233|Device|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
75780402|NCT01113944|Behavioral|Program 1|
75780403|NCT01113944|Behavioral|Program 2|
75780404|NCT01114022|Device|Experimental 1|oeso pharyngeal device
75780405|NCT01114022|Device|Experimental|oeso pharyngeal device
75629124|NCT04288284|Procedure|Curative resection of colorectal cancer|
75780406|NCT01114022|Device|experimental 3|oeso pharyngeal device
75780407|NCT01114022|Device|Active comparator|oeso pharyngeal device
75780408|NCT01213004|Procedure|respiration correlated CT scan|Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.
75780409|NCT01213004|Procedure|respiration correlated CT scan|Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
75780410|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
75780411|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
75780412|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
76074971|NCT01702987|Drug|statin|statin was given for 1 month to 21 patients
75323311|NCT03579602|Drug|tozuleristide|Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
75323312|NCT03579602|Device|Canvas System|All subjects enrolled in the study will have their tissue imaged with the Canvas System.
75323313|NCT03190070|Dietary Supplement|Ingestion of protein|Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
75629125|NCT03670602|Behavioral|Episodic Future Thinking|Participants will practice using these cues when making decisions about health choices. Participants will implement EFT while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.
75780413|NCT03938714|Procedure|Hemorrhoidectomy|Excision of third and fourth degree hemorrhoids
76074972|NCT00824044|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
75916096|NCT02267460|Procedure|Investigator Modeling|
76074973|NCT00824044|Drug|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
75780414|NCT01208558|Behavioral|Diet A|"Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Guideline: 200-400 g of potatoes, 300-500 g of root crops, 400-600 g of vegetables, 200-300 g of beans, peas and corn, and 600 g of fruit and berries per day."
75780415|NCT01208558|Behavioral|Diet B|Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A: to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
76074974|NCT01702519|Drug|nicotine|nicotine transdermal patch
76074975|NCT01739803|Behavioral|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
75323314|NCT00744211|Drug|1mg/kg sitaxsentan sodium|1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
75780416|NCT01208558|Behavioral|Physiotherapy|Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
75780417|NCT03335566|Drug|Sonazoid™|Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
75780418|NCT03335566|Drug|SonoVue®|Single Dose of SonoVue® 2.4 mL as I.V. injection.
75780419|NCT01213160|Drug|AZD4547|film coated tablet, PO, twice daily
75780420|NCT04774120|Drug|Propofol|Propofol will be started at a rate of 15-20 mg/kg/hr in patients >65 years and 20-25 mg/kg/hr in younger patients (<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
76074976|NCT00824434|Device|PROMUS Element™|Drug eluting coronary stent system
75323315|NCT00744211|Drug|2mg/kg sitaxsentan sodium|2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
75323316|NCT00744211|Other|Vehicle|Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
75629126|NCT03670602|Behavioral|Daily Check in|Participants will be asked to access the electronic app at the same rate as the experimental group (e.g. daily). Participants will receive behavioral weight loss treatment including The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, and finding behavioral substitutes for highly reinforcing food.
75780421|NCT01110512|Drug|Flavonid|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day."
75780422|NCT01110512|Drug|Daflon|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day"
76074977|NCT01739335|Drug|Mifepristone Oral Tablet [Korlym]|2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
75780423|NCT01117220|Drug|Placebo|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- < 45kg max dose 40 mg BID).
75916097|NCT04453514|Behavioral|Trauma-informed yoga video recording|Pre-recorded video of a 45-minute trauma-informed yoga practice. The yoga practice can be done standing or sitting in a chair. The yoga practice is comprised of slow, gentle movements combined with paying attention to the body and the breath. The practice uses invitational language and encourages participants to make choices and customize the movements according to their individual needs.
75916098|NCT01024062|Drug|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
75916099|NCT04453436|Drug|Tenofovir Disoproxil|Genotipic resistance test
76074978|NCT01739335|Drug|Placebo Oral Tablet|2 Placebo Oral Tablets once daily for 7 days
75323317|NCT04274972|Diagnostic Test|Microbiome evaluation|The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
75323318|NCT02997371|Drug|Anakinra Prefilled Syringe|Administration as initially intravenous injection followed by a intravenous infusion
75629127|NCT00968526|Biological|GSK investigational vaccine GSK2340272A|One or two intramuscular injections in the deltoid region of the non-dominant or the dominant arm.
75629128|NCT03664674|Drug|OTO-104|Single intratympanic injection of 12 mg dexamethasone
75780424|NCT01117220|Drug|Ziprasidone Oral Capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- < 45kg max dose 40 mg BID).
75780425|NCT03707626|Other|Wellens Sign|presence or absence in presence of coronary collaterals to LAD
75467533|NCT01930110|Other|40-minute interval exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
75467534|NCT01930149|Behavioral|Mailed patient outreach intervention|This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
75467535|NCT01930201|Procedure|Caudal epidural block|
75467536|NCT01930201|Other|General anesthesia|
75629129|NCT03664674|Drug|Placebo|Single intratympanic injection of placebo
75629130|NCT00967668|Behavioral|Small change approach to improve physical activity and diet|"The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle."
75467537|NCT01930227|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
75467538|NCT01930227|Other|Non-acupoint stimulation|Electric stimulation was given through electrode attached to the shoulder
75629131|NCT00967668|Behavioral|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
75629132|NCT00970944|Drug|Amantadine Hydrochloride|184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
75467539|NCT01930240|Drug|TRIA-662|1-MNA Chloride
75467540|NCT01930240|Drug|Placebo|Double-blind placebo
75629133|NCT00970944|Drug|Placebo|Placebo administered twice daily.
75629134|NCT05780723|Drug|Treatment group: Rectal instillation of QHQYP|QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.
75629135|NCT05780723|Drug|Control group: Mesalazine enema treatment|Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
75467541|NCT01930266|Dietary Supplement|Experimental|
75780426|NCT03939260|Other|Extracorporeal CO2 Removal|Extracorporeal carbon dioxide removal (ECCO2R), a low flow extracorporeal CO2 removal, may be used in association with ultraprotective mechanical ventilation (tidal volume < 6 ml/kg and Pplat <20-25 cmH2O).
75780427|NCT05236972|Drug|Sintilimab|Sintilimab 200mg iv drip Q3W
75780428|NCT05236972|Drug|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
75780429|NCT05236972|Drug|capecitabine|1000 mg/m² po twice daily on days 1- 14 repeated every 21 days
75780430|NCT03941054|Other|Pressure Release|Subjets receive digitopressure during 90 seconds for the treatment of the Myosfascial Trigger Points
75780431|NCT01114100|Drug|sertraline|starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
76074979|NCT00824512|Drug|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
76074980|NCT00824512|Drug|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
75467542|NCT01930266|Behavioral|Active comparator|
75467543|NCT01930279|Other|Blood withdrawal|Blood withdrawal
75467544|NCT01930292|Drug|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
75467545|NCT01930292|Drug|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
75467546|NCT01930292|Drug|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
75467547|NCT01930292|Drug|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
75467548|NCT01930318|Drug|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
75629136|NCT05780697|Procedure|Surgery of Drainage of septic hip arthritis|Surgery for septic hip arthritis by anterior or lateral approach and inspection of femoral head
75629137|NCT05780528|Other|mulligan mobilization|The patients will receive mobilization with movement technique of lateral glide. the patients will be in supine subject and pronate forearm, during the application of the lateral glide by the physiotherapist, each patient was asked to perform the closure of the fist (provocative but painless gesture in the execution of the technique) for 3 sets of 10 repetitions.
76074981|NCT00824746|Drug|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
76074982|NCT01702363|Drug|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
75916100|NCT02267616|Device|Etonogestrel Implant|Subdermal arm implant
75323319|NCT02997371|Drug|Isotonic saline|Placebo, administration as initially intravenous injection followed by a intravenous infusion
75629138|NCT05780528|Other|instrumented assisted soft tissue mobilization|the participant will receive instrumented assisted soft tissue mobilization. The participant's elbow will rest on a table. A lubricant (Vaseline) will be applied to the skin around the elbow prior to treatment and the blade will be cleaned with an alcohol pad. First, the blade will be used to find the exact areas of restriction in the common extensor origin. Then the M2T blade will be used in the treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique)
75323320|NCT04248998|Dietary Supplement|Fasting-mimicking diet|Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks
75916101|NCT03465176|Other|Aromatherapy Blend|The essential oil intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
75323321|NCT04248998|Drug|Metformin|Metformin 850 mg twice a day
75916102|NCT03465176|Other|Placebo|The placebo substance is an odorless vegetable oil derived from avocados.
75916103|NCT02267694|Drug|Freeze-dried black raspberry powder|
75323322|NCT04248998|Drug|Preoperative chemotherapy|"Chemotherapy will consist of:~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~twelve consecutive cycles of weekly paclitaxel 80 mg/mq"
75323323|NCT00714233|Drug|Metformin|Metformin 425mg. capsules, 2 capsules BID x 24 weeks
75323324|NCT00714233|Drug|Oral Contraceptive Pills (Yasmin)|Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
75323325|NCT00714233|Behavioral|Lifestyle Modification|weekly classes x 24 weeks for training in diet, exercise and behavior modification skills
75323326|NCT00714233|Drug|placebo|placebo to the active metformin arm. 2 capsules BID x 24 weeks.
75323327|NCT00721357|Behavioral|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
75323328|NCT00721357|Other|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
75323329|NCT02984306|Dietary Supplement|Cherry powder|
75629139|NCT05780528|Other|conventional treatment|the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints
75629140|NCT05780515|Biological|ANX009|ANX009 will be administered per schedule specified in the arm description.
75629141|NCT05780502|Behavioral|Passive Dynamic Brace|Patient receiving the Passive Dynamic Brace
75916104|NCT05232734|Drug|Caffeine Citrate 20 MG/ML Oral Solution|Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
75916105|NCT05232734|Other|Syrup BP|Syrup BP will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
75916106|NCT02270346|Device|Inspiratory muscle training|"Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
76074983|NCT05049928|Other|Telerehabilitation solution (m-Rehab)|"The telerehabilitation program consists of the following elements:~Mobile applications and website usable on smartphone and tablet for the patient.~Teleconsultation solution for the patient and the doctors.~Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.~Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.~Withings® connected objects"
76074984|NCT01722097|Drug|Rocuronium|
76074985|NCT01722097|Drug|placebo|
76074986|NCT04383106|Other|no intervention|no intervention
75323330|NCT02984306|Dietary Supplement|Placebo|
75323331|NCT03809845|Device|High-density surface electromyography|High-density surface electromyography
75323332|NCT00714311|Behavioral|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
75323333|NCT00714311|Behavioral|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
75323334|NCT04213118|Drug|Anlotinib Hydrochloride|Anlotinib 12mg QD PO d1-14, 21 days per cycle.
75323335|NCT04213118|Procedure|TACE|TACE first, followed by anlotinib within day4（+/-1days）
75323336|NCT00746395|Drug|Lubiprostone|24 mcg oral administration
75323337|NCT00746395|Drug|Placebo|Oral administration
75323338|NCT04385615|Other|Fasting Mimicking Diet|Participants will be requested to follow three cycles (of 5 day each), for three consecutive months, of a Fasting Mimicking Diet, a plant-based, low-calorie, low-protein, low-carbohydrate, high-unsaturated fat diet. For the remaining 25 days of each month, participants should continue with their habitual eating habits.
75629142|NCT05780489|Diagnostic Test|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
75629143|NCT05780476|Behavioral|Psychoeducation|6 sessions of 2 hours over 6 weeks
75629144|NCT05780476|Behavioral|Psychoeducation + virtual reality|6 sessions of 2 hours over 6 weeks. Virtual reality experience will be carry out in the last 30 minutes of each meeting. Virtual reality consists of 360-degree videos depicting everyday situations and allowing the caregivers to feel the specific symptoms of dementia (e.g., disorientation, agnosia, apraxia and memory loss).
75629145|NCT05780411|Other|questionnaire|The symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire, Distress thermometer
75629146|NCT05780385|Device|nasotracheal intubation|patients requiring tracheal intubation receive nasotracheal intubation
75629147|NCT05780385|Device|orotracheal intubation|patients requiring tracheal intubation receive orotracheal intubation
75323345|NCT03426644|Behavioral|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
75629148|NCT05780359|Device|Drug eluting stent|Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.
75323346|NCT01275989|Other|Ear acupuncture|
75629149|NCT05780359|Device|drug coating balloon|A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.
75467549|NCT01930331|Drug|artemisinin/naphthoquine|"Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet))."
75780432|NCT01114100|Drug|placebo|patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
75916107|NCT02270346|Device|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
75916108|NCT02270502|Device|Ultrasound Philips CX50|The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
75916109|NCT02270502|Other|Frailty Index Questionnaire|Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
75916110|NCT02270502|Other|Muscle strength tests|MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
75323347|NCT02997137|Dietary Supplement|BOT-01|"Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
75323348|NCT02997137|Other|Placebo|"Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
75323349|NCT01276067|Drug|Donepezil|10 mg Tablet
75780433|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil
75780434|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
75323350|NCT04183868|Drug|Empagliflozin 10 MG|10 mg tablet daily
75323351|NCT04183868|Drug|Glimepiride 2 mg|starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
75323352|NCT02997215|Drug|Lidocaine|lidocaine infusion during surgery
75629150|NCT05780320|Other|Prophylactic amiodarone and posterior pericardiotomy|"Patients after the implementation of the protocol receive postoperative prophylactic amiodarone and a posterior pericardiotomy.~The amiodarone regimen consists of amiodarone 1mg/min x 10 hours (600 mg total) via central line upon arrival to the intensive care unit followed by 400 mg PO BID on postoperative days 1 and 2 followed by 200 mg PO BID on postoperative days 3 and 4 or until discharge, whichever occurs first.~The posterior pericardiotomy occurs during the cardiac procedure."
75629151|NCT05780294|Drug|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
75629152|NCT05780294|Drug|Lobaplatin|30mg/m2, used on the 1st and 28th day of each cycle.
75780435|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
75780436|NCT01110590|Drug|Placebo|Placebo
75780437|NCT03369418|Device|Alpha-Stim Active|The study device is a safe, commercially available take-home cranial electrotherapy stimulation device that applies an electrical current to a subject's head to treat anxiety, depression or insomnia
75323353|NCT02997215|Drug|Saline Placebo|saline infusion at same rate as intervention group during surgery
75323354|NCT02990507|Other|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
75323355|NCT02990507|Other|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
75323356|NCT02990507|Other|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
75323357|NCT02990507|Other|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
75323358|NCT03422744|Procedure|trans bronchial biopsy guided by echo-endoscopic miniprobes|We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.
75323359|NCT03422744|Procedure|if first one negative: samples under fluoroscopic control|If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
75323360|NCT02990351|Procedure|loco regional therapies for HCC|29 HCC patients received locoregonal therapy as a bridging therapy for those who were within milan and as downstaging for those were initially beyond milan. The main LRT types used for our patients were TACE and or RFA and microwave ablation
75780438|NCT03369418|Device|Alpha-Stim Inactive|The study device given to the inactive group will be identical to the active except the electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive.
75323361|NCT03381872|Procedure|Percutaneous coronary intervention for complex lesion|"In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms~Intravascular imaging arm~Angiography arm~Definition of Complex Lesions~True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size~Chronic total occlusion (≥3 months) as target lesion~PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)~Implanted stent length ≥38mm~Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)~Multiple stent needed (≥3 more stent per patient)~In-stent restenosis lesion as target lesion~Severely calcified lesion (encircling calcium in angiography)~Ostial coronary lesion (LAD, LCX, RCA)"
75629153|NCT05780294|Drug|Placebo|2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.
75629154|NCT05780294|Drug|leucogen|40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy.
75629155|NCT05780255|Device|VV-ECMO|veno-venous extracorporeal membrane oxygenation
75629156|NCT05780229|Procedure|Conservative treatment|The rehabilitation is based on restoring the balance of the shoulder joint. Aiming to diminish pain and restore function, pain control and inflammation are addressed during the firsts 3-6 weeks. Before week 3, pendulum movements are allowed to initiate mobilization of the shoulder joint. Aiming to gain (almost) complete shoulder joint mobility, a passive and active mobility exercise program is carried out. Lastly, the focus is on muscle reinforcement, performing a series of active exercises with weights or bands to exercise different muscles of the shoulder or the shoulder girdle.
75629157|NCT05780229|Procedure|Arthroscopic Decompression Surgery|Arthroscopic decompression surgery of the rotator cuff tear consists of cleaning the subacromial space. The procedures that are sometimes performed to diminish pain may include, removing the inflamed bursa, releasing the long head of the biceps (if injured), or lightly burring the acromion bone under which the tendons slide.
75629158|NCT05780229|Procedure|Reverse Prosthesis|The reverse prosthesis consists of shoulder articular joint replacement. The humeral head is sectioned, and, on the scapular side, a metal tray is placed, which is fixed with screws, and a metal half-sphere fixed to the metal tray. On the humeral side, a metal stem with a concave plastic component is placed to articulate with the metal half-sphere, allowing shoulder mobility without the need of rotator cuff muscles.
75629159|NCT05780229|Drug|Pain-Relief Medication|In the reverse prosthesis procedure and arthroscopic decompression surgery, the pain-relief medication plan is a standard regimen for all patients, which can be modified as needed. This plan is based on 50mg of dexketoprofeno, 1g of paracetamol, and 100mg of tramadol.
75629160|NCT05780229|Device|Reverse Prosthesis Device|In the reverse prosthesis procedure, a Delta III reverse shoulder prosthesis is applied. The original design was developed by Grammont in 1980's, and has 2 components: 1) a metal tray fixed with screws, and a metal half-sphere fixed to the metal tray, and 2) a concave polyethylene component.
75629161|NCT05780190|Device|New artificial liver CABA system (BS330+CA280) +PE|The new artificial liver CABA system (BS330+CA280) combioned plasma exchange in the treatment of end-stage liver disease with inflammatory status
75629162|NCT05780164|Other|Research readiness tool|Online/paper based tool containing information about lung cancer clinical trials
75629163|NCT05780151|Other|Methodological intervention|All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.
75629164|NCT05780151|Drug|Toujeo|All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.
75629165|NCT05780112|Other|breathing exercise|"Place one hand on your chest and the other on your stomach.~Slowly take a deep breath through the nose.~During inhalation, your hand on your stomach should rise upwards as the air fills the lungs. If it is under your hand on the chest, there should not be much movement.~Hold your breath and stretch your muscles in a second or two.~Take air through your nose with your mouth closed and exhale slowly through your mouth by pursing your lips like a whistle.~Set the time you use when exhaling air to be twice the time you use when exhaling.~As you exhale, focus on the inward movement of your abdominal hand."
75629166|NCT05780099|Other|Inpatient or Outpatient visit|Patients will be seen and treated at the clinics like in the usual care
75629167|NCT05780086|Drug|30% icodextrin and 10% dextrose|Dwell time of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose
75780439|NCT02529644|Behavioral|Taking It to the Pews (Comparison)|Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
75916111|NCT01023204|Drug|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
75916112|NCT04453748|Other|Complex diagnostic panel|Complex, multidisciplinary diagnostic panel, including blood, imaging and functional tests.
76074987|NCT00824824|Drug|Dorzolamide 2%-timolol 0.5%|BID OU for 6 weeks
76074988|NCT00824824|Drug|Brimonidine 0.2%-0.5% timolol 0.5|BID OU for 6 weeks
76074989|NCT01701973|Drug|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
76074990|NCT01701973|Drug|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
75916113|NCT04475562|Device|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
76074991|NCT01701973|Drug|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
76074992|NCT01701973|Drug|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
76074993|NCT01701973|Drug|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
76074994|NCT00825370|Drug|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
75916114|NCT04460456|Drug|SBT6050|Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2
76074995|NCT00825370|Drug|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
75916115|NCT04460456|Drug|pembrolizumab|400 mg IV
76074996|NCT01721317|Drug|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
76074997|NCT01721317|Drug|Placebo|Matching placebo will be available
75629168|NCT05779982|Procedure|Sentinel lymph node biopsy followed by axillary lymph node dissection|This is a retrospective study to determine the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) according to response to NAST and breast cancer subtypes. All patients received SLNB followed by axillary lymph node dissection after NAST.
75780440|NCT02529644|Behavioral|Taking It to the Pews (Experimental)|Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
75780441|NCT03938948|Device|low-level laser/light therapy|Participants will wear light therapy devices for 14 weeks
75916116|NCT04460456|Drug|Cemiplimab|350 mg IV
75916117|NCT03468452|Other|extubation|Time of extubation
75916118|NCT01022970|Drug|QAX576 placebo|
75916119|NCT01022970|Drug|QAX576|
76074998|NCT01701193|Drug|L-Alanyl/L-Glutamine|Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
76074999|NCT01701193|Drug|Physiologic saline|Placebo
76075000|NCT00826150|Biological|BC-819|"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."
76075001|NCT04382092|Diagnostic Test|FilmArray Pneumonia|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
76075002|NCT00827944|Device|Parietex Progrip|"Surgical technique:~Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation."
75629169|NCT05779891|Other|Mulligan Traction Straight Leg Raise Technique|The individuals in the Group A will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Mulligan straight leg raise technique . Three repetitions of Mulligan's Traction Straight Leg Raise will be done with 7 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes.
76075003|NCT00827944|Device|Low weight polypropylene mesh|"Surgical technique:~Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures"
76075004|NCT02153710|Behavioral|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
76075005|NCT02153710|Behavioral|Phonomotor Therapy|Experimental therapy.
76075006|NCT04989556|Other|Interview|Participate in interview
76075007|NCT04989556|Other|Palliative Therapy|Receive standard symptom management by palliative care team
76075008|NCT04989556|Other|Palliative Therapy|Receive provider initiated remote contact
76075009|NCT04989556|Other|Quality-of-Life Assessment|Ancillary studies
76075010|NCT04989556|Other|Questionnaire Administration|Complete questionnaire
76075011|NCT01959347|Procedure|Miduretheral Sling|MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health & Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).
76075012|NCT01959347|Other|Miduretheral Sling with behavioral/pelvic floor therapy|MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
76075013|NCT00828178|Drug|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
76075014|NCT00828178|Device|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
76075015|NCT00828178|Other|corn starch|3 capsules qd for 12weeks
75780442|NCT01117298|Drug|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
75916120|NCT02735096|Device|EquiCue (Intraoral Electronic Balance Aid)|When the device is worn, a subject will receive small electrical pulses on roof of the mouth as alternative feedback of head tilting or movement.
75916121|NCT02267928|Other|Check Symptoms|"Symptoms are Checked"
75323362|NCT03381872|Device|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
75323363|NCT03381872|Device|Intravascular imaging (IVUS or OCT)|"IVUS Reference site: Largest lumen, Plaque burden <50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter~OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: [1] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm.~[2] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm."
75323364|NCT03381872|Device|Drug-coated balloon|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
75629170|NCT05779891|Other|Slump Stretching|The individuals in the Group B will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Slump Stretching technique. Five repetitions of Slump stretching technique will be done with 30 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes
75467550|NCT01930331|Drug|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
75467551|NCT01925976|Behavioral|Individualized dietetic intervention-eating habits|The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
75323365|NCT02990585|Other|Back school|
75780443|NCT01117298|Drug|Placebo|Tab Placebo every alternate day for 8 weeks
75629171|NCT05779878|Other|Post Isometric Relaxation|Post-isometric relaxation (PIR) is a soft tissue stretching technique used by many health care professionals to lengthen both acute and chronic short muscles.
75629172|NCT05779878|Other|Myofascial arm pull technique|Myofascial therapy is described as the promotion of psychophysiological, neurological and structural adaptive capability as multiplexed via the myofascial system. Fascia covers all body structures, particularly muscles and their constituent myofibrils
75629173|NCT05779800|Device|Flowble resin composite stent|Flowble resin composite is a filling material used in operative dentistry and characterized by being flow and easily adapting the surfaces.
75916122|NCT02267928|Other|Uncheck Symptoms|"Symptoms are Un-checked"
75916123|NCT02267928|Other|Experienced|Focus of instructions is on symptoms the participant has experienced
76075016|NCT00828412|Device|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
75323366|NCT04158128|Other|non-intervention|non-interventional, prospective cohort study
75323367|NCT03331484|Drug|Ticagrelor|Ticagrelor 90 mg twice daily
75323368|NCT03331484|Drug|Rivaroxaban|Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
75323369|NCT00721513|Biological|cetuximab|
75323370|NCT00721513|Drug|cisplatin|
75629174|NCT05779800|Device|periodontal pack|Non eugenol containing dressing supplied in two tubes
75780444|NCT01117376|Drug|Erythromycin|Erythromycin 250 mg intravenous Q6h for 4 doses
75780445|NCT01117376|Drug|Methylnaltrexone|Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
75780446|NCT01213238|Drug|Oxaliplatin|140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.
75780447|NCT01213238|Drug|Capecitabine|Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
75780448|NCT01213238|Drug|Bevacizumab|10 mg/kg by vein on day 1 of a 21 day cycle.
75780449|NCT01110668|Drug|Nilotinib|
75780450|NCT03938558|Other|MS-Dance|The experimental group will perform 10 weeks of dance training
75916124|NCT02267928|Other|Not Experienced|Focus of instructions is on symptoms the participant has NOT experienced
75916125|NCT01022346|Drug|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
75916126|NCT01022346|Drug|RO5217790|RO5217790 will be administered at a dose of 5*10^7 pfu subcutaneously on Days 1, 8, and 15.
75323371|NCT00721513|Drug|docetaxel|
75467552|NCT01930344|Device|3D Laparoscopic visual system|Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
75467553|NCT01930344|Device|2D Laparoscopic visual system|Standard 2D HD Laparoscopic Visual System
75780451|NCT03938558|Other|MS-Art|The other group will contribute to the production in various ways (e.g. word art, photography, painting, …)
75780452|NCT01114178|Other|questionnaire|self completed questionnaire supervised by a technician
75780453|NCT01110824|Drug|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
75916127|NCT04890314|Other|Patient-reported questionnaire|Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.
75916128|NCT04880096|Other|eDOL|e-health tool (mobile app for patients and web platform for caregivers in pain clinics)
76075017|NCT00828412|Drug|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
76075018|NCT04638335|Biological|Blood test|blood test for Anti-HAV antibodies
76075019|NCT01959035|Drug|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
75780454|NCT03936140|Drug|Inhaled iloprost|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
76075020|NCT01700959|Drug|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
75323372|NCT00721513|Drug|fluorouracil|
75629175|NCT05779787|Procedure|TAVR Aligned|Investigate the feasibility of coronary re-engagement after commissural alignment technique in terms of success rate (%) and procedure complexity taking into account radiations, time and contrast used.
75323373|NCT00721513|Procedure|computed tomography|
75323374|NCT00721513|Procedure|positron emission tomography|
75323375|NCT00721513|Procedure|quality-of-life assessment|
76075021|NCT01700959|Drug|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
76075022|NCT00829036|Device|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
75780455|NCT03936140|Drug|Distilled water|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
75916129|NCT04475406|Other|PICF (Periopaper)|After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
75916130|NCT04475406|Other|Subgingival plaque, Gracey curette (Hu-Friedy)|After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.
76075023|NCT01738477|Biological|Boostrix|Single dose intramuscular administration.
75629176|NCT05779787|Procedure|TAVR Random|TAVR Random Feasibility comparison of coronary re-engagement between the randomly implanted Navitor valve (unaligned) and the others implanted with the commissural alignment technique in terms of success rate (%) and complexity of the procedure, taking into account radiation, time and contrast used
75629177|NCT05779748|Other|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
75629178|NCT05779722|Device|Vapor barrier|Vapor barrier
75780456|NCT03938090|Device|Optimised MultiSite Pacing|The intervention includes using optimal programming settings with MultiSite pacing configurations via the patient's CRT device. The device in use is the same for each arm, the only changes are the programming settings.
76075024|NCT00829738|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
76075025|NCT01737931|Drug|Topical steroid (Dexamethasone)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
76075026|NCT01737931|Drug|Topical antihistamine (Diphenhydramine)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
75323376|NCT00721513|Radiation|3-dimensional conformal radiation therapy|
75323377|NCT00721513|Radiation|intensity-modulated radiation therapy|
75323378|NCT03314558|Other|pulmonary rehabilitation|a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
75323379|NCT00706121|Drug|Vitamin E|400 IU daily by mouth for 7 - 12 years
75780457|NCT03938090|Device|Standard biventricular pacing|Conventional programming settings using biventricular pacing will be used
75780458|NCT01117532|Behavioral|EFT (Emotional Freedom Techniques)|Four 90 minute group therapy classes of this behavioral intervention
75323380|NCT00706121|Drug|Selenium|200 mcg daily for 7 - 12 years
75323381|NCT00706121|Drug|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
75323382|NCT00706121|Drug|selenium placebo|1 pill by mouth daily for 7 - 12 years
75323383|NCT03251612|Drug|Based on sensitivity analysis|"5FU, infusional~Capecitabine~Oxaliplatin (FOLFOX)~Irinotecan (FOLFIRI)~FOLFOXIRI (triplet)~Bevacizumab~Panitumumab~Cetuximab~Regorafenib~Tas-102~Ramucirumab~Aflibercept~Pembrolizumab~Nivolumab~Vinorelbine and capecitabine~Sorafenib~Gemcitabine and capecitabine~Olaparib~Epirubicin"
75323384|NCT00746863|Drug|0.125% Marcaine|Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
75323385|NCT04121156|Device|HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
75323386|NCT04121156|Device|sham (placebo) HD-tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 5 consecutive twice daily sessions
75916131|NCT04475406|Other|Clinical data, williams probe PCPNU (Hu-Friedy)|"A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).~The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton."
75467554|NCT01930370|Drug|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
75323387|NCT04385563|Drug|TQ-B211|Participants will receive TQ-B211 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
75323388|NCT04385563|Drug|Herceptin®|Participants will receive Herceptin® 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
75629179|NCT05779683|Device|Caretaker Device placement|placement of the device on the postoperative cardiac surgery patient that has a pulmonary artery catheter for comparison readings
75629180|NCT05779566|Diagnostic Test|bone densitometry|bone densitometry every 6 month
75323389|NCT04385563|Drug|docetaxel|Participants will receive docetaxel 75 milligrams/square meter (mg/m^2) iv.on day 2 in Cycle 1 followed by 75mg/m^2 iv.on day 1 in Cycles 2 to 8.
75629181|NCT05779553|Diagnostic Test|Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits|measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient
75629182|NCT05779540|Device|Safeback SBX|The intervention consists in the test of the active device.
75323390|NCT01279837|Behavioral|Pharyngocise|swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises
75629183|NCT05779540|Device|Sham device|The intervention consists in a similar device to that emits same noise but does not deliver airflow.
75467555|NCT01930370|Drug|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
75629184|NCT05779527|Behavioral|Mindful Parenting Programme|Online Mindful Parenting Programme with group support sessions
75467556|NCT01930396|Drug|Tinzaparin|
75467557|NCT01930396|Drug|Unfractionated Heparin|
75467558|NCT01930396|Drug|Placebo (for Tinzaparin)|0.9% Normal Saline
75780459|NCT01110980|Other|Swallow therapy in combination with individual dietary counselling|Weekly swallowing therapy (by speech language therapist) from start of (chemo)radiation until 6 months after last (chemo)radiation. Weekly Individual dietary counselling (by dietician) form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation. With close interaction between the both interventions.
75780460|NCT01110980|Other|Individual dietary counselling|Weekly Individual dietary counselling form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation.
75467559|NCT01930396|Drug|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
75780461|NCT01117610|Drug|Placebo (one of medication)|patients in Group C will receive none of medication preoperatively and intraoperatively
75780462|NCT01117610|Drug|Ropivacaine (epidural injection)|patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
75323391|NCT03082898|Device|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
75467560|NCT01930409|Behavioral|Telephone Support and Coaching|"The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~Health Status~Medication Management~Activity/Exercise Prescription and Goal-Setting~Falls Prevention~Clarification of Appointments~Coordination of Post-Discharge Home Services~What To Do If a Problem Arises"
75467561|NCT01930409|Behavioral|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
75467562|NCT01930422|Device|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
75629185|NCT05779514|Drug|Mirabegron|Health Volunteers ：Mirabegron p.o. 28 days 100mg qd./ Tumor patients ：Mirabegron p.o. 28 days 100 mg qd or 200 mg qd.
75629186|NCT05779488|Dietary Supplement|maca|2.25 g of Maca extract, twice per day for 12 weeks
75629187|NCT05779488|Dietary Supplement|placebo|2.25 g of starch, twice per day for 12 weeks
75780463|NCT01117688|Procedure|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
75780464|NCT03334630|Device|DiamondTemp Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
75780465|NCT03334630|Device|TactiCath Quartz Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
75629188|NCT05779462|Other|Dynamic MRI Sequence|Addition of a Dynamic MRI Sequence during the MRI examination performed in routine care
75629189|NCT05779423|Drug|Ipilimumab|Monoclonal antibody administered through intravenous infusion
75916132|NCT02522390|Other|Research activities|"Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.~The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts."
76075027|NCT04564261|Behavioral|Personalized Healthy Relationship and Safety Planning Tool|"The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources."
76075028|NCT04564261|Behavioral|Usual Care Teen Relationship and Health Website|The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
76075029|NCT01958489|Drug|Evacetrapib|Administered orally
75629190|NCT05779423|Drug|Nivolumab|Monoclonal antibody administered through intravenous infusion
75629191|NCT05779423|Procedure|Cryoablation|Procedure of freezing a tumor performed via CT-guidance by interventional radiologist.
76075030|NCT01958489|Drug|Pravastatin|Administered orally
75629192|NCT05779410|Dietary Supplement|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks
75629193|NCT05779410|Dietary Supplement|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
75629194|NCT05779384|Other|It was an observational study|data collected concerning the incidence of exacerbations
75629195|NCT05779371|Behavioral|Integrated-based Laughing Qigong Program|The protocol of the Integrated-based Laughing Qigong Program (IB-LQP) combined laughter intervention and mental health promotion courses. It was a two-hour community activity held twice a week for six weeks. The content was 50-60 minutes of a laughter practice program and 50 minutes of mental health lectures, separated by a 10-minute break.
75780466|NCT01111136|Behavioral|Stress intervention|To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
75629196|NCT05779358|Other|Expectancy and gluten|Effect of expectancy to receive gluten and/or actual gluten intake
75780467|NCT01215890|Drug|risedronate|
75780468|NCT01215890|Drug|placebo|
75780469|NCT03740828|Device|KIDScore D3|Embryos are scored using the KIDScore D3 algorithm based on annotated morphokinetic parameters.
75780470|NCT01117922|Other|Psychological intervention|Subjects will be randomized into either usual care or interconceptional intervention groups. If the subject is randomized into the intervention group, she will receive targeted interventions to reduce one of several risk factors: smoking, depression, infectious disease burden and maternal stress, and achieving an appropriate BMI. A woman who is randomized to the intervention group may receive interventions on one, two, three, four, or five of the targeted intervention methods, depending on her needs.
75780471|NCT01117922|Other|Usual Care Group|
75629197|NCT05779332|Other|survey application|Children's OHRQoL was measured by the Child Perceptions Questionnaire (CPQ8-10). Oral examination of children were conducted for presence and severity of MIH, dental caries experience and oral hygiene status.
75780472|NCT01118000|Procedure|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
75916133|NCT02268006|Radiation|IMRT-SIB|
75916134|NCT02268006|Drug|Capecitabine|
75916135|NCT02268006|Procedure|Surgery|
75916136|NCT03462212|Drug|Carboplatin|chemotherapy medication
75916137|NCT03462212|Drug|Paclitaxel|chemotherapy medication
75916138|NCT03462212|Drug|Bevacizumab|Angiogenesis inhibitor
75916139|NCT03462212|Drug|Rucaparib|PARP inhibitor
75916140|NCT01152216|Drug|Dimebon|20 mg orally three times daily
76075031|NCT01721161|Biological|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
75629198|NCT05779254|Drug|Neomycin Sulfate|Postoperative day-1 Oral Antibiotic Prophylaxis + patients get po. 3x1000mg Neomycin sulfate and 3x500 mg Metronidazole
75629199|NCT05779215|Other|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
75629200|NCT05779189|Behavioral|Game-based virtual reality (Game)|Besides reading the health education flier, they also need to trained with the game-based virtual reality in Biodex Medical Systems, which is a machine, includes 4 games: Catch Game, boating, Ball Maze, and Word Search. And all of the games are balance control games. The games were implemented in person for 30 minutes one time, total is 16 times (once to twice day a week).
75629201|NCT05779189|Behavioral|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the video of balance exercise was collected from the internet. Participants were assigned to read the health education flier, and follow suit the video of balance exercise at home of their free will.
75323392|NCT03568838|Drug|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
75629202|NCT05779176|Procedure|Therapeutic hypothermia|The study intervention is therapeutic hypothermia. After intubation, patients assigned to therapeutic hypothermia will receive central venous catheterization through right jugular vein or femoral vein depending on the cooling application and the unique needs, a flexible catheter will be inserted and iced saline was circulated through the multiple balloons of the catheter in a closed-loop design to induce therapeutic hypothermia. This system also has a hydrophilic coating with heparin and a triple-lumen central venous catheter to satisfy the need of fluid or drug infusion, blood draw and central venous pressure monitoring. After central venous catheterization, patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C.
75629203|NCT05779150|Other|CeraVe® Moisturising Cream|CeraVe® Moisturising Cream contains 3 kinds of skin-native ceramides, which can protect the skin against external stimuli, strengthen the damaged skin barrier, fill the intercellular lipids to deeply trap water, relieve dry skin, and increase skin hydration.
75916141|NCT04089098|Diagnostic Test|passive leg raising versus mini volume challenge|Blood samples will be collected and ultrasound evaluation of renal perfusion conducted in study participants immediately before conducting passive leg raising (PLR). PLR will then be carried out on study participants, followed by MVC. PLR- and/or MVC-responsive patients will receive a further 700 ml fluid immediately after the MVC. Renal perfusion will be further assessed 1 and 24 hours after the MVC.
75629204|NCT05779150|Other|Standard Cream|placebo cream
75629205|NCT05779098|Procedure|Extensive hepatectomy|Extensive hepatectomy
75629206|NCT05779085|Other|Dermocosmetic|Use of daily cleanser to treat facial acne
75629207|NCT05779059|Drug|De-escalation to ticagrelor 60 mg at day 30|Change of P2Y12 receptor antagonist regimen to ticagrelor 60 mg bid at day 30.
75629208|NCT05779059|Drug|De-escalation to prasugrel 5 mg at day 30|Change of P2Y12 receptor antagonist regimen to prasugrel 5 mg qd at day 30.
75629209|NCT05779059|Drug|Switch to ticagrelor 60 mg at day 45|Switch to ticagrelor 60 mg bid at day 45.
75629210|NCT05779059|Drug|Switch to prasugrel 5 mg at day 45|Switch to prasugrel 5 mg qd at day 45.
75629211|NCT05779046|Other|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).
75629212|NCT05779046|Other|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
75629213|NCT05778981|Diagnostic Test|FMD - Troponin measurement|Echographic FMD evaluation. Pre and post-operative troponin measurements.
75629214|NCT05778955|Genetic|detection and monitoring of cirulating tumor DNA|detection and monitoring of cirulating tumor DNA in pediatric soft tissue sarcoma
75651684|NCT05832294|Device|Sham rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
75651685|NCT05832242|Other|Ultrasound|Point-of-care ultrasound in the emergency department
75916142|NCT01016808|Drug|Q8003|Q8003 is a combination of morphine sulfate and oxycodone HCl
75916143|NCT01016808|Drug|Morphine sulfate|One morphine sulfate 12 mg IR capsule q6h
75916144|NCT01016808|Drug|Oxycodone HCl|One oxycodone HCl 8 mg IR Capsule q6h
75916145|NCT04452968|Behavioral|intermittent fasting|Women were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours.
75916146|NCT04452968|Behavioral|Caloric restriction|Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
75916147|NCT03462134|Other|Survey|Survey amongst orthopaedic surgeons
75916148|NCT03462056|Dietary Supplement|Cystic Fibrosis Ready to Use Supplemental Food|Specially formulated for use by children with Cystic Fibrosis
75916149|NCT01014078|Drug|Azithromycin Ophthalmic Solution, 1%|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
75916150|NCT01014078|Drug|Placebo|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
75323393|NCT00726713|Other|Metanx (a medical food)|Metanx one tablet twice a day
75323394|NCT00726713|Other|Metanx placebo|Metanx placebo one tablet twice a day
75323395|NCT01272349|Other|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
75323396|NCT01272349|Other|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
75323397|NCT03089684|Other|No intervention|No intervention
75323398|NCT03087344|Device|Fibroscan and Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
75323399|NCT03087344|Device|Fibroscan|Liver stiffness will be measured before and after a standard meal is administered
75323400|NCT03087344|Device|Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
75323401|NCT00759187|Drug|Fluoride|Brush twice daily
75323402|NCT00759187|Drug|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
75323403|NCT00759187|Drug|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
75916151|NCT02522078|Drug|dry misoprostol|400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
75651686|NCT05832216|Drug|Daratumumab|Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
76075032|NCT01721161|Drug|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
76075033|NCT01699867|Device|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
75651687|NCT05832203|Other|Counseling on planetary health diet with calorie restriction|Counselling on planetary healthy diet, calorie restriction diet, and healthy lifestyle through mobile application
75780473|NCT01213394|Drug|mycophenolate mofetil|"Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.~Target CNI trough levels in the Symphony study:~Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.~Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses* with a target trough level of 3-7 ng/mL (*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)"
75780474|NCT01213394|Other|standard immunosuppression|Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
75780475|NCT03708172|Device|Repetitive Transcranial Magnetic Stimulation|Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.
75780476|NCT03708172|Other|Cognitive Training|Computer-based cognitive training designed to enhance executive function
75780477|NCT03708172|Other|sham Cognitive Training|Computer-based inactive sham training
75780478|NCT03707548|Behavioral|BPT|BPT will consist of 6 weekly group sessions, based on a scientific approach, integrating body-oriented techniques to improve patients' awareness, perception, acceptance, and expression regarding their body.
75916152|NCT02522078|Drug|wet misoprostol|400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
75916153|NCT01146522|Drug|LCQ908|
76075034|NCT00830284|Procedure|Recruitment maneuver|"Three types of maneuvers will be performed.~6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
76075035|NCT00830362|Drug|Propranolol|40 mg administered once
76075036|NCT00830362|Drug|Placebo|administered once
76075037|NCT01699789|Other|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
76075038|NCT01699789|Behavioral|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
75780479|NCT03707548|Behavioral|Smartphone-triggered bodily interventions|Smartphone-triggered bodily interventions will consist of brief BPT exercises insuring the transfer from the group BPT sessions into patients' daily lives. Smartphone bodily interventions will be triggered by short audio-clips.
75780480|NCT03707548|Behavioral|Smartphone triggered control intervention|The smartphone triggered control intervention will be selected fairy tales presented by audio-clips.
75780481|NCT03938168|Diagnostic Test|Biopsy, fecal sample|Preoperatively and at 12 months after surgery, patients will obtain a fecal stool sample for microbioma analysis. Adhesions that are cut and released to acquire access to the operative field are stored for molecular and histological analyses.
75780482|NCT01118078|Genetic|DNA methylation analysis|Undergo DNA methylation analysis
75916154|NCT01146522|Drug|Placebo|
75916155|NCT03468374|Device|lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
75916156|NCT03468374|Device|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
76075039|NCT01699789|Behavioral|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
76075040|NCT00830596|Other|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
76075041|NCT00830596|Other|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
75780483|NCT01118078|Genetic|gene expression analysis|Undergo gene expression analysis
75780484|NCT01118078|Genetic|microarray analysis|Undergo microarray analysis
75780485|NCT01118078|Genetic|reverse transcriptase-polymerase chain reaction|Undergo RT-PCR
75780486|NCT01118078|Other|diagnostic laboratory biomarker analysis|Correlative studies
75916157|NCT00911274|Drug|Mycophenolate Mofetil|250 mg Capsule
75916158|NCT00911274|Drug|CellCept®|250 mg Capsule
75780487|NCT03937934|Behavioral|Nutrition Education|Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.
75629215|NCT05778929|Diagnostic Test|Radiomics Model|"A total of 694 consecutive eligible patients with first episode of acute pancreatitis that recommended for iopromide 370 mgI/ml enhanced pancreatic CT scan within 14 days after onset of symptoms (the sample size ratio of training set: test set: validation set is 5:2:3) will be sequentially enrolled at 10 sites (This study is observational in nature. The routine enhanced pancreatic CT protocol at all selected sites is similar or equivalent to that used in the PI site in the study).~Relevant clinical information of the enrolled subjects is collected. Radiomics features are extracted from the selected regions of interest on pancreatic CT images and classified. The subjects are followed up for 12 months and divided into recurrent group and non-recurrent group according to the first recurrence status."
75780488|NCT03368170|Drug|Mesdopetam (IRL790)|Mesdopetam (IRL790) capsule
75629216|NCT05778916|Procedure|5 year follow up on patients operated for hallux valgus deformity|Clinical and radiological control of patients operated for hallux valgus deformity between 2016-2018.
75629217|NCT05778643|Behavioral|TaKeTiNa music therapy|TaKeTiNa music therapy uses a group to perform music together. Each member of the group is needed for the synchronization of the whole group. The group actively makes Music with hands, feet, and the voice. At the same time, the therapist frequently introduces new elements into the process and challenges the group in this playful manner. Through this, patients consistently report an increase in mindful awareness and an alleviation of many depressive symptoms, although these effects have not been shown in controlled studies yet.
75780489|NCT01121744|Device|Supralimus-Core™ Sirolimus eluting Coronary Stent|Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.
75780490|NCT01111214|Other|no intervention|There is no intervention. This is a non interventional study.
75916159|NCT03468296|Drug|Intravitreal Aflibercept Injection 2mg|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
75780491|NCT01121822|Biological|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
75629218|NCT05778422|Drug|Suprascapular nerve block with bipuvacaine|Suprascapular nerve block with Bipuvacaine: a 50mm 22G needle (Stimuplex, BBraun) was introduced up to the suprascapular fossa, guided by ultrasound, and the location was confirmed by motor stimulation with contraction of the supraspinatus and infraspinatus muscles. Next, 5 ml of 0.25% bupivacaine with adrenaline was injected.
75629219|NCT05778422|Procedure|Pulsed radiofrequency|After confirming the location, the needle mandrel was removed and the radiofrequency cannula was introduced through the needle, 2ml of 1% lidocaine without epinephrine was injected, followed by application of pulsed radiofrequency for 180sec at 42°C by radiofrequency (radiofrequency generator system BMS-50N, Bramsys).
75629220|NCT05777161|Behavioral|Parent Coached Exposure Therapy - Individualized|Subject and parent begin by working with a therapist to create an individualized fear hierarchy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
75780492|NCT01121822|Biological|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
75780493|NCT03937856|Behavioral|Calm- Mindfulness Meditation smartphone application|Participants will be asked to register and download the Calm application on participants' phones or home computer. Daily use for a minimum of 5 minutes will be suggested and will be recorded at study end.
75780494|NCT01118156|Other|Education|75-minute training teaching utilization of new standardized suicide nomenclature
75780495|NCT01213550|Drug|Chlorhexidine gluconate|
75780496|NCT01213550|Drug|Placebo mouthrinse|
75780497|NCT03937622|Other|17 items questionaire|This is a prospective multicenter observational trial. Included patients and attending physician complete a standardised questionnaire.
75780498|NCT01213628|Device|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
75780499|NCT01213784|Other|all antidiabetic drugs will be appliable|We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%
75780500|NCT01213862|Behavioral|Home Based Education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
75780501|NCT01121978|Procedure|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
75916160|NCT05238636|Procedure|Anti-reflux surgery - Stretta procedure or LINX device or laparoscopic fundoplication|This is an observational study. Patients will choose which anti-reflux procedure (Stretta, LINX or fundoplication) they undergo with their clinician, as is standard practice, after which they will be offered recruitment to this study, which will perform investigations to assess for changes in physiology and symptoms.
75916161|NCT01130142|Drug|IPI-926 plus gemcitabine|Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
75916162|NCT01130142|Drug|Placebo plus gemcitabine|Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
75916163|NCT03464864|Drug|Treprostinil Inhalation Powder|Single ascending dose
76075042|NCT00830596|Other|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
76075043|NCT01944839|Drug|E10030|
76075044|NCT01944839|Drug|ranibizumab|
75467563|NCT01930422|Device|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
75467564|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (A)|Two sublingual tablets daily for 13 months
75467565|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (B)|Two sublingual tablets daily for 13 months
75467566|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (C)|Two sublingual tablets daily for 13 months
75467567|NCT01930461|Biological|Placebo matching the SLIT tablets of HDM allergen extracts|Two sublingual tablets daily for 13 months
75629221|NCT05777161|Behavioral|Cognitive Behavior Therapy|Subjects will work with a therapist using anxiety management strategies to address thoughts, feelings, and behaviors.
75629222|NCT05777161|Behavioral|Parent Coached Exposure Therapy - Group (removed from study)|Subjects and parents will work in a group setting to receive exposure therapy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
75323404|NCT04387175|Device|Carriere Motion 3D Class III Appliance|The device made of stainless steel consists of a flexible bar with two pads at the end which are bonded bilaterally with composite resin to the lower second deciduous molar or the lower first permanent molar at the rear and the lower deciduous canine at the front. The base on the lower deciduous canine has a hook to which bilaterally elastic latex bands are connected with the vestibular tubes of the cemented bands on the upper deciduous second molars (Force 2 elastics ) or on the first permanent upper molars (Force 1 elastics), on whose palatine surface the a rapid maxillary expander is welded.
75323405|NCT04387175|Device|Facial mask|The facial mask consists of a chin pad and frontal pad connected by a central steel bar. On the central bar there is a horizontal steel bar to which latex elastic bands are attached which develop 14 ounces of force. The elastics are connected to the rapid maxillary expander by means of two hooks welded on the bands of the second upper deciduous molars or the first upper permanent molars.
75467568|NCT01930500|Behavioral|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
75467569|NCT01930500|Behavioral|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
75467570|NCT01930526|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
75467571|NCT01930552|Drug|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
75467572|NCT01930552|Drug|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
75629223|NCT05777070|Behavioral|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive days
75780502|NCT01216046|Drug|VX-809|capsule, taken once daily
75780503|NCT01216046|Drug|VX-770|tablet, taken once every 12 hours
75780504|NCT01216046|Drug|VX-809 placebo|capsule, taken once daily
75323406|NCT03085940|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
75323407|NCT03085940|Drug|Placebo|Placebo
75323408|NCT00727337|Behavioral|LACE-computer|Computerized Auditory Training
75323409|NCT00727337|Behavioral|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
75629224|NCT05776355|Biological|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
75629225|NCT05774860|Other|No intervention|No intervention
75629226|NCT05774847|Other|No intervention|No intervention
75629227|NCT05774834|Other|No intervention|No intervention
75780505|NCT01216046|Drug|VX-770 placebo|tablet, taken once every 12 hours
76075045|NCT01944839|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
75323410|NCT00727337|Behavioral|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
75629228|NCT05774743|Other|Consent with Visual Aid|Participants who receive the study intervention will receive the standard anesthesia consent procedure with the addition of the visual aid. The visual aid is a poster with pictorial representations of the information that is verbally communicated to participants during the standard consent process.
75629229|NCT05774080|Other|Observational|Observational
75629230|NCT05772403|Diagnostic Test|CEUS|CEUS for atypical liver nodules
75629231|NCT05772338|Drug|BNP105 (25 + 25 + 15)|BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.
75629232|NCT05772338|Other|Placebo|Placebo. Up to six applications per day.
75629233|NCT05772000|Diagnostic Test|cerebrospinal fluids exams|cerebrospinal fluids will be examined by conventional cytology and flow cytometry
75629234|NCT05769842|Drug|propofol|Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1~2mg/kg before extubation when the patient recovered spontaneously.
75629235|NCT05769842|Drug|normal saline|Same dose as propofol.
75780506|NCT01216124|Drug|docetaxel oxaliplatin|"docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2~1 cycle=21 days DO*6"
75780507|NCT01219010|Biological|Siltuximab|15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
75780508|NCT01216280|Drug|placebo capsule|2 x 10 mg placebo capsules administered orally with water, b.i.d.
75780509|NCT01216280|Drug|10 mg Natura-alpha capsule and 10 mg placebo capsule|10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
75780510|NCT01216280|Drug|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
76075046|NCT00805870|Drug|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
75629236|NCT05768217|Behavioral|Community Resiliency Collective Efficacy Intervention (CRCEI)|The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention & Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.
75629237|NCT05768217|Behavioral|Health Education Sessions|Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
75629238|NCT05767190|Behavioral|Motivational interviewing|During the intervention, the trained-nurse will provide a motivational interviewing-based intervention consisting of one session divided into two parts: educational (the concepts of sleep apnea and the symptoms, and the CPAP treatment will be focused on) and training activity (using MI not directly advocate for behavioral change (i.e., use CPAP as prescribed), but asks key questions to help the patient explore conflicting feelings about the change, weighs the positive consequences and negatives of this change, and allows the patient to realize the discrepancy between current risk behavior (i.e. not using CPAP as directed) and the patient's self-identified goals. The intervention will be tailored on the patient's stage of change based on Prochaska and DiClemente transtheoretical model (1982), in fact, the nurse will use MI not only at the beginning of therapy but also in every contact with the patient throughout the treatment (subsequent follow-up visits, phone calls, etc.).
75780511|NCT01118234|Drug|Rituximab|Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
75780512|NCT00324155|Drug|Ipilimumab|"Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent~In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression"
75780513|NCT00324155|Drug|Placebo|Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
75780514|NCT00324155|Drug|Dacarbazine|Intravenous solution; intravenous; 850 mg/m^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
75780515|NCT03937544|Biological|CD19 CAR-T CELLS|CD19 CAR-T cells will be administered after completion of the chemotherapy.
75780516|NCT03937544|Drug|Cyclophosphamide|Patients will receive lymphodepleting chemotherapies consisting Cyclophosphamide 250mg/m2/day IV(Day -5, Day -4, Day -3 ).
75629239|NCT05760664|Other|Group Experimental/Fascial Fitness|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
75780517|NCT03937544|Drug|Fludarabine|Patients will receive lymphodepleting chemotherapies consisting of Fludarabine 25mg/m2/day IV (Day -5, Day -4, Day -3 ).
75780518|NCT01118390|Device|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
75780519|NCT01118390|Other|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
75780520|NCT01124474|Other|goal directed therapy|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
75780521|NCT01122056|Other|Physical exercise training|Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
75651688|NCT05832203|Other|Counseling on balanced nutrition diet with calorie restriction|Counselling on balanced nutrition diet, calorie restriction diet, and healthy lifestyle materials through mobile app
75780522|NCT01216436|Biological|Vaccination with RNA-transfected mature autologous DC|Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
75780523|NCT01219088|Drug|Bupivacaine, morphine|1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
75780524|NCT01122134|Drug|intravenous artesunate|Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
75780525|NCT01118702|Drug|Ritalin-SR|3-20mg tablets, once
75780526|NCT01118702|Drug|Concerta|one 54mg tablet, once
75780527|NCT01118702|Drug|Novo-Methylphenidate ER-C|one 54mg tablet, once
75780528|NCT02529410|Procedure|Cardiac Resynchronisation Therapy|
75780529|NCT03935828|Drug|Oral versus topical antibioitics|Previously described in two arms
75780530|NCT01219166|Procedure|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
75780531|NCT03334396|Drug|Baricitinib|Administered orally.
75780532|NCT03334396|Drug|Placebo|Administered orally.
75780533|NCT01118936|Dietary Supplement|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
75916164|NCT03468140|Drug|Eculizumab|Eculizumab will be given at a dose of 1200mg diluted in 0.9% sodium chloride (NaCl) to 5mg/mL for a total volume of 240 mL administered by IV infusion over 25-45 minutes in the anhepatic-phase during the transplant procedure, and a second dose of 900mg diluted in 0.9% NaCl to 5mg/mL for a total volume of 180 mL administered by IV infusion over 25-45 minutes will be given 24 hours following the first dose.
75916165|NCT03468140|Other|No intervention|Historical control arm
75323411|NCT00727337|Behavioral|Lace-DVD|DVD based Auditory Training
75323412|NCT01279915|Drug|ASP0456|oral
75323413|NCT01279915|Drug|Placebo|oral
75467573|NCT01930552|Drug|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
76075047|NCT00805870|Drug|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
76075048|NCT01944059|Drug|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
76075049|NCT01944059|Other|Placebo (l-alanine)|Theramine like placebo comparator
75629240|NCT05760664|Other|Group Sham/Static stretching exercise|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
75780534|NCT01118936|Dietary Supplement|Placebo|3 tablets of placebo daily for 12 weeks
75780535|NCT01119014|Drug|Aripiprazole|pill, 2,5-20 mg/day, maximum 16 weeks
75780536|NCT01119014|Drug|Quetiapine|pill, 50-600mg/day, maximum 16 weeks
75780537|NCT03937310|Diagnostic Test|Next-generation sequencing of swabs collected during surgery|Traditional swabs for culturing as well as swabs for NGS testing will be collected
76075050|NCT04646057|Device|DuraSorb®|Monofilament Surgical Mesh
75629241|NCT05760664|Other|Control Group/Placebo|The placebo intervention will be performed using ultrasound turned off in the thoracolumbar region for 15 minutes followed by rest for 15 minutes for 6 weeks, twice a week. Participants will be evaluated on the first day, fourth week and sixth week of intervention.
75780538|NCT01119092|Other|"Sham (laying of hands) intervention"|The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
75780539|NCT01119092|Other|Grade IV AP joint mobilizations|3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
75780540|NCT01219244|Behavioral|caloric restriction|6 months of caloric restriction (15 %)
75916166|NCT03129932|Dietary Supplement|gluten phase|2 cakes containing 9g of vital gluten/each will be consume during the 4 weeks of intervention
75916167|NCT03129932|Dietary Supplement|placebo phase|2 cakes without gluten will be consume during the 4 weeks of intervention
76075051|NCT01720225|Drug|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
76075052|NCT01720225|Drug|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
76075053|NCT01943591|Device|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
76075054|NCT01699087|Procedure|Photorefractive keratectomy (PRK)|In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
76075055|NCT01699087|Device|ALLEGRETTO WAVE EYE-Q excimer laser system|The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
75467574|NCT01930552|Drug|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
75629242|NCT05759689|Dietary Supplement|Dietary Supplement: Resource Energy|Carbohydrate Supplement
75629243|NCT05759689|Dietary Supplement|Dietary Supplement: Calogen|Polyunsaturated liquid fat supplement
75651689|NCT05832099|Radiation|Radiation|The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
75780541|NCT01219244|Behavioral|omega-3 supplementation|6 months of omega-3 supplementation
75780542|NCT01219244|Behavioral|resveratrol supplementation|6 months of resveratrol supplementation
75780543|NCT01219244|Behavioral|Placebo|6 months of placebo intake
75780544|NCT01219244|Behavioral|2nd step: intervention + physical / cognitive training|most effective dietary intervention plus physical and cognitive training
75780545|NCT01219244|Behavioral|2nd step: intervention + control|most effective dietary intervention plus control
75780546|NCT01119170|Other|Starter formula|standard starter formula given from birth to 6 months of age
75916168|NCT01009242|Biological|CDP6038|"Single dose:~1 mg/kg CDP6038 IV"
75780547|NCT01119170|Other|starter formula with D-lactate producing probiotics|starter formula containing probiotics given from birth to 6 months of age
75780548|NCT01119326|Procedure|Autologous Fat Transfer|one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
75780549|NCT03937232|Behavioral|Cross-Education|Home exercise program + usual care
75780550|NCT03937232|Behavioral|Mirror Visual Feedback|Home exercise program + usual care
75780551|NCT03937232|Other|Usual care|Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
75916169|NCT01009242|Biological|CDP6038|"Single dose:~0.1mg/kg CDP6038 IV"
75916170|NCT01009242|Biological|CDP6038|"Single dose:~1.0mg/kg CDP6038 SC"
75916171|NCT01009242|Other|Placebo IV|"Single dose:~Placebo IV"
75916172|NCT01009242|Other|Placebo SC|"Single dose:~Placebo SC"
75916173|NCT01009242|Drug|CDP 6038 SC|Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
75916174|NCT01009242|Drug|Methotrexate|Individual stable doses of methotrexate.
75916175|NCT03464786|Device|Lando® absorbable collagen membrane|Subjects who are fit for the study will be randomized to either intervention arms.
76075056|NCT01943435|Drug|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
76075057|NCT01943435|Procedure|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
76075058|NCT01943435|Other|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
76075059|NCT01943435|Other|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
75916176|NCT03464786|Device|Geistlich Bio-Gide resorbable bilayer membrane|Subjects who are fit for the study will be randomized to either intervention arms.
75629244|NCT05755841|Other|Outpatient management of preterm prelabor rupture of membranes|"Patients who will be managed as outpatients will be discharged after 48 hours of hospitalization with the following management:~Twice weekly fetal cardiotocography.~Complete blood count once a week.~A weekly clinical and ultrasound examination."
75780552|NCT01119482|Biological|MenAfriVac™|Children, adolescents and adults aged 1 to 29 years old will receive a single intramuscular injection of the meningococcal serogroup A conjugate vaccine .
75916177|NCT02272296|Device|jet injector|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
75323414|NCT03809455|Drug|Fentanyl citrate|"Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge…), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day"
75323415|NCT03809455|Drug|Placebo|one intake of placebo (intranasal or buccal)
75916178|NCT02272296|Device|Conventional pen (NovoPen IV)|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
75916179|NCT03468062|Drug|Dexmedetomidine|Patients assigned in Dexmedetomidine or Placebo group are given Dexmedetomidine or normal saline after induction of anesthesia.
75323416|NCT02990273|Biological|Blood transfusion|
75629245|NCT05755841|Other|Inpatient management of preterm prelabor rupture of membranes|In the Inpatient Care Policy group, the same protocol as outpatient group will be applied, but the patient will not be discharged until delivery.
75780553|NCT01119560|Other|Cytology Specimen Collection Procedure|Correlative studies
75323417|NCT01272427|Dietary Supplement|water with glucose|0.75 g/kg body weight of glucose added to water
75629246|NCT05739929|Drug|Colchicine 0.5 MG Oral Tablet|0.5 mg colchicine tablets twice daily.
75323418|NCT01272427|Dietary Supplement|water and whey protein|0.75 g/kg body weight of whey protein added to water
75323419|NCT01272427|Dietary Supplement|water with noncaloric sweetener|0.15 g of sucralose added to water
75629247|NCT05739929|Drug|Placebo|Placebo tablets twice daily
75629248|NCT05734547|Behavioral|Stepping Together for Children after Trauma (ST-CT)|ST-CT is Step One of Stepped Care CBT for Children after Trauma (previously called Stepped Care Trauma-focused Cognitive Behavioral Therapy; Salloum et al., 2014). It consists of five components: psychoeducation, stabilization, trauma narrative, in-vivo exposures and consolidation. The parent and child have 11 at-home-meetings and complete tasks in a workbook, Stepping Together (from the Preschool PTSD Treatment by Michael Scheeringa et al), over 6-9 weeks. In addition, there are weekly calls and five sessions with the therapist. Children who meet responder-criteria (i.e., no more than four symptoms of PTSS) continue to a 6-week maintenance phase, after which treatment is complete if the child still meets responder criteria. For those who do not meet responder-criteria, or are not able to complete the workbook, the responsibility for the treatment is transferred from the municipal service level to the corresponding child and adolescent mental health service (BUP).
75629249|NCT05734547|Behavioral|Usual care|Therapists in the control group will provide the treatment they usually provide, and develop a treatment plan in collaboration with the parents. This may consist of individual sessions with the child, parent sessions, group treatment, meetings with the school and other collaborating services, or referral to the second line mental health centres (BUP).
75629250|NCT05732675|Behavioral|"Vina-STEAM (Skills to Empower Affirmative Men)"|The investigators propose and pilot test a community-based, peer-driven minority stress as well as HIV-stigma reduction program in small group of GBM in Ho Chi Minh City, Viet Nam.
75629251|NCT05732610|Diagnostic Test|MGC Health COVID-19 & Flu A+B Home Multi Test|self-collected direct anterior nares swab samples
75629252|NCT05732610|Diagnostic Test|MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)|adult lay user collected anterior nares swab sample
75629253|NCT05726994|Biological|exhaled breath collection|Fasting children will be asked to breathe normally through a mouthpiece for the collection and analysis of exhaled breath.
75916180|NCT01008852|Drug|SBI-087|200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
75916181|NCT01008852|Drug|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
75916182|NCT01008852|Drug|SBI-087|200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
75916183|NCT01008852|Drug|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
75323420|NCT02997059|Drug|Fluconazole|200 mg/ day
75780554|NCT01119560|Other|Laboratory Biomarker Analysis|Correlative studies
75323421|NCT02997059|Other|Placebo|
75467575|NCT01930565|Other|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
75780555|NCT01119560|Other|Questionnaire Administration|Ancillary studies
75780556|NCT01119638|Drug|Escitalopram|Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
75916184|NCT01008852|Drug|Placebo|Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
75916185|NCT03464708|Dietary Supplement|HMB|Powder form
75916186|NCT03464708|Other|Lactose (placebo)|Powder form
75916187|NCT03464552|Drug|Celecoxib 200mg|oral capsule 3 hours before procedure
75916188|NCT03464552|Procedure|Colposcopic guided biopsy|Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
75916189|NCT03464552|Drug|Placebo oral capsule|oral capsule 3 hours before procedure
75780557|NCT01119638|Drug|Risperidone|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
75323422|NCT01279993|Procedure|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
75629254|NCT05726994|Other|Data collection|Clinical data will be collected in order to seek correlations with the exhaled breath profile.
75629255|NCT05721196|Behavioral|Culturally adapted Psychoeducation (CaPE)|This intervention consisted of 12 psychoeducation sessions, one session per week, that would be administered on an individual patient basis and to be added to treatment as usual. Each session lasted for approximately 1 h, beginning with a 20-30 min presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for relapse). The content is a reduced and modified version of the Barcelona Psychoeducation Program for bipolar disorders.
75323423|NCT02990117|Other|No Intervention|No Intervention
75323424|NCT00759811|Drug|Methotrexate|"Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
75323425|NCT00759811|Drug|Placebo|"Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
75323426|NCT03085628|Drug|Oxytocin|40IU
75323427|NCT03085628|Drug|Placebo|40IU
75323428|NCT00694577|Radiation|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
75629256|NCT05721196|Drug|Treatment as Usual (TaU)|This group of patients will receive routine treatment, which in Nigeria means attending the outpatient clinic and taking prescribed medication.
75629257|NCT05715684|Other|Exercise Training|Virtually supervised exercise training for four weeks prior to cystectomy
75629258|NCT05715684|Dietary Supplement|Nutritional Intervention|Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively
75629259|NCT05712265|Drug|Miricorilant|Miricorilant 6 x 100 mg coated tablets
75629260|NCT05712265|Drug|Fluvoxamine|Fluvoxamine 50 mg tablet
75780558|NCT03937388|Other|Cochlear stimulation strategy including time-fixed gaps|Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
75780559|NCT03935672|Procedure|PET-CT scans|"Patients will have three scans during the trial.~The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV_P. bGTV_P will then be used as an adjunct to help us delineate the GTV_P.~The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV_iP).~The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment."
76075060|NCT01943435|Other|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
75323429|NCT00694577|Radiation|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
75629261|NCT05709808|Other|Kinesio-taping|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance
75629262|NCT05709808|Other|exercises|A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
75629263|NCT05709808|Other|mixed kinesiotape plus exercises|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance. A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
75629264|NCT05690295|Other|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
76075061|NCT04644809|Drug|LY3561774|Administered SC.
75323430|NCT00694577|Radiation|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
75467576|NCT01930565|Other|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
75629265|NCT05683860|Drug|WVE-004|WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
75629266|NCT05677386|Diagnostic Test|Primary preventive treatment guided by CTCA|Computed tomography coronary angiography (CTCA)
75629267|NCT05677386|Other|Cardiovascular risk Score|Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction
75629268|NCT05661825|Other|phase II cardiac rehabilitation|Phase II cardiac rehabilitation was provided in the the department of physical medicine and rehabilitation in Wan Fang Hospital. The programs are two times a week, one session for 30 minutes (30 sessions in total). The training programs are focused on aerobic training with bicycles. The training intensity is calculated with 40% to 80% oxygen consumption reserve from the result of cardiopulmonary exercise test. In case of safety, heart rate, blood pressure, EKG and rate of perceived exertion will be monitored during training.
75629269|NCT05659654|Drug|Ursodeoxycholic acid|250 mg/capsule, 2 capsules per day, for 4 weeks
76075062|NCT04644809|Drug|Placebo|Administered SC.
75916190|NCT05628558|Drug|Desmopressin|"The interventions with desmopressin recorded in this study were all realized following the internationally recommended standard care of patients with mild/moderate hemophilia A. They were all retrospectively collected. These interventions comprised:~An intravenous administration of desmopressin infused during 30 minutes at a dosage of 0,3-0,4 µg/Kg~Measurements of Factor and von Willebrand factors levels just before the desmopressin infusion and after at 30 minutes, 1 hour, 2 hours, 4 hours and for some patients 6 hours and 24 hours.~The F8 gene variants were also diagnosed in the standard care."
75916191|NCT03461588|Radiation|free-breathing|patients are irradiated to whole breast +- regional nodal areas with free-breathing technique after breast conserving surgery
75916192|NCT03461588|Radiation|deep inspiratory breath-holding|patients are irradiated to whole breast +- regional nodal areas with deep inspiratory breast-holding technique after breast conserving surgery
75916193|NCT03461510|Procedure|Hyperglycemic clamp|Subjects with T2D will receive IV Dextrose infusion to maintain plasma glucose at ~250 mg/dL during fMRI.
75916194|NCT03461510|Procedure|Hyperinsulinemic Euglycemic clamp|Subjects with T2D will receive IV Dextrose and Insulin infusion to maintain plasma glucose at approximately 90 mg/dL during fMRI.
75323431|NCT02990039|Behavioral|Counseling letter|The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
75629270|NCT05654376|Behavioral|Art therapy|"Participant's creativity is stimulated by visual arts materials and various art therapy techniques, in relation to 6 topics: self-care, stress management, flourishing caregiving, challenging caregiving, loss and grief, and sense of professional meaning.~The strategy consists of stimulating an observant and symbolic gaze, facilitating visual expression, promoting communication about what it has been expressed, and gather learning from the multidimensional impact of the creative art process (sensations, emotions, cognitions and spiritual experiences)."
75629271|NCT05649683|Biological|Evaluation of cytokine production|The patient will have samples at initiation of treatment (J0), after treatments 1 and 2 (S6), after the first radiological assessment at S11 and/or the progression of the disease and/or occurrence of a grade 3-4 adverse event
75629272|NCT05641454|Dietary Supplement|ElevATP supplement|ElevATP supplement containing apple and ancient peat extract
75629273|NCT05641454|Dietary Supplement|Placebo|Maltodextrin placebo
75629274|NCT05638113|Procedure|Pleural injection of autologous blood|120 ml autologous blood will be drawn from simple venous puncture and immediately injected through the drain into the pleural cavity followed by flushing with 50ml of saline.
75629275|NCT05637060|Drug|Test Drug|One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
75629276|NCT05637060|Drug|Reference Drug|One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
75629277|NCT05636293|Drug|Ritlecitinib|200mg Ritlecitinib
75629278|NCT05636293|Drug|Placebo|Placebo
75780560|NCT03935672|Procedure|Outlining the biological GTVs (bGTV_P and bGTV_iP)|The biological GTVs (bGTV_P and bGTV_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.
75780561|NCT03935672|Procedure|Blood samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
76075063|NCT00805948|Device|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
76075064|NCT01942733|Drug|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
75323432|NCT02996747|Procedure|curettage (intralesional surgery)|comparison of two different tumors treated by curettage
75323433|NCT04397666|Diagnostic Test|conjunctival RT PCR|conjunctival sample in covid-19 patients
75323434|NCT01276613|Drug|Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.
75629279|NCT05636293|Other|Gluten|10g of gluten
75629280|NCT05622851|Device|Restylane Contour|Hyaluronic Acid dermal filler
75629281|NCT05622851|Device|Juvederm Voluma|Hyaluronic Acid dermal filler
75629282|NCT05619419|Behavioral|Mindfulness-enhanced positive affect induction|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the MPAI via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the MPAI to manage pain during the cold pressor test.
75629283|NCT05619419|Behavioral|Breathing Meditation|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the BM via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the BM to manage pain during the cold pressor test.
75629284|NCT05616494|Drug|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
75629285|NCT05614609|Drug|Lidocaine topical|Comparing lidocaine spray and muscle relaxing medication
75629286|NCT05601050|Other|There is no intervention|There is no intervention
75629287|NCT05599217|Other|Dietary and nutritional questionnaire|Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.
75323435|NCT01276613|Drug|Losartan|50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
75780562|NCT03935672|Procedure|Salivary samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
76075065|NCT00807586|Drug|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
75629288|NCT05599217|Other|Neurological function, cognitive function, and life quality assessment|Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.
75629289|NCT05599217|Other|Peripheral blood test|Collect peripheral blood samples from patients.
75780563|NCT01216592|Other|COPD treatment|Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
75629290|NCT05599217|Other|Metabonomic test|Collect urine and stool samples from patients.
75629291|NCT05599217|Other|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
76075066|NCT00807586|Drug|Placebo|Normal saline (1.6 cc)
76075067|NCT01957865|Device|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
75629292|NCT05598957|Diagnostic Test|Vitamin D Binding protein|Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels
76075068|NCT01957865|Device|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
76075069|NCT01957787|Device|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
75323436|NCT03077594|Device|Mucosal Impedance|Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
75323437|NCT03077594|Other|Research Biopsies|Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
75323438|NCT03077594|Device|Volumetric Laser Endomicroscopy|Aim 2: Volumetric laser endomicroscopy will be done and marked at 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
75629293|NCT05583162|Behavioral|Healthy Sport Project|2 interactive information lectures (given per class of 30 pupils), and 4 interactive workshops (given to sex-homogenous groups of 10 pupils). One per week, a total of 6 weeks with intervention.
75629294|NCT05580575|Device|Daily disposable toric soft contact lens|Daily disposable toric soft contact lens
75629295|NCT05580575|Device|Monthly replacement toric daily wear soft contact lens|Monthly replacement toric daily wear soft contact lens
75629296|NCT05576753|Procedure|Hernia repair|Robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia
75629297|NCT05576649|Other|Task difficulty adaptation according to Arvaneh et al. (2019)|The task difficulty in the P300 speller training will be adapted according to Arvaneh et al. (2019).
75629298|NCT05576649|Other|Random task difficulty|The task difficulty in the P300 speller training is chosen randomly.
75629299|NCT05576649|Other|Task difficulty adaptation according to iterative learning controller|The task difficulty in the P300 speller is determined by an iterative learning controller.
75780564|NCT03338998|Drug|BAF312 solution|Solution for intravenous (IV) infusion - 4.5mg/4.5mL
75780565|NCT03338998|Drug|Matching Placebo for BAF312 solution|Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo
76075070|NCT01698775|Drug|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
75323439|NCT02428205|Drug|Propranolol|Participant will receive Propranolol prior to each EIBI session
75780566|NCT03338998|Drug|BAF312 tablet|2 mg film-coated tablet
75780567|NCT03338998|Drug|Matching Placebo for BAF312 tablet|0 mg film-coated tablet matching placebo
75780568|NCT03935984|Drug|Calcitonin|Treatment with calcitonin to lower high calcium levels prior to reimaging exam
75780569|NCT01219322|Drug|Sodium bicarbonate|single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc
75780570|NCT01219322|Drug|normal saline|intravenous normal saline volume equivalent to sodium bicarbonate
75780571|NCT01119872|Other|Positive End-expiratory Pressure (PEEP)|"All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.~Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment."
76075071|NCT01698775|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
75323440|NCT02428205|Drug|Placebo|Participant will receive placebo prior to each EIBI session
75629300|NCT05573997|Diagnostic Test|Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers|Complete and comprehensive medical interview will be conducted in each eligible patient. In addition, patient's laboratory data will be recorded on admission and pre-discharge. Each patient will undergo a full echocardiographic examination with a specific protocol upon admission and pre-discharge. This will include among others 2-dimensional speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work indices of the left and right ventricle.
75629301|NCT05571813|Drug|CKD-341|A single dose of 1tablets under fasting condition
75629302|NCT05568667|Behavioral|Low risk|"remote support in physical activity and nutrition via digital media~monthly collective physical activity sessions~logbook"
76075072|NCT01698775|Drug|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
76075073|NCT01698775|Drug|Placebo to glipizide|Matching placebo to glipizide daily
75323441|NCT01276691|Drug|81 mg enteric coated aspirin|81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
75323442|NCT04398836|Dietary Supplement|Exclusive Enteral Nutrition|Mulnourished patients will drink an enteral polymeric formula suited to their energy expenditure calculated by 25-30 kcal/kg and at least 1 gr/kg of protein, a minimum of 1500 ml (1500 kcal, 54 gr of protein). The amount of formula to achieve nutritional requirements are based on body weight, but the average intake is of 6-8 cups of formula (36-48 scoops of formula mixed with 1260-1680 ml of water to achieve a concentration of 1 kcal per ml). During this period patients will be guided to avoid eating and drinking anything but the enteral formula. The formula will be supplied to the patients by the investigators. The formula used for this study will be VITAL - suitable for people with disease-related malnutrition and malabsorption. Vital 1.5kcal is peptide-based, nutritionally complete formulation for the dietary management of active phase of Crohn's disease. VITAL includes all the nutritional macro and micronutrients and can serve as a sole source of nutrition.
75323443|NCT04398836|Other|High energy / protein diet.|Mulnourished patients will receive a high energy / protein diet.
75323444|NCT04398836|Other|Standard nutrition|Well nurished patients will receive a standard nutrition
75323445|NCT04398602|Behavioral|behavior of the leader|A study investigator, expert in both PPH and simulation debriefing, not involved in the simulation, observed each scenario to record and check the team's technical skills according to the established 23 PPH key tasks. The behavioral scores were assigned by two independent observers, experts in communication and evaluation in simulation, who reviewed the videos of each simulation each simulation all participants were asked to complete a survey related to the leader and the team behaviors. Questions required a yes/no answer or an answer based on an ordinal scale (1=poor, 5=excellent).
75323446|NCT03081416|Drug|Ketamine|Intranasal ketamine administration
75323447|NCT03081416|Drug|Normal saline|
75467577|NCT01930578|Other|Treatment with 0.9% normal saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
75629303|NCT05568667|Behavioral|Moderate risk|"remote support in physical activity and nutrition via digital media~monthly collective physical activity sessions~one collective health education session~logbook"
75629304|NCT05568667|Behavioral|High risk|"remote support in physical activity and nutrition via digital media~monthly collective physical activity sessions~one collective health education session~3 individual sessions of motivational coaching~connected watch~logbook"
75629305|NCT05567068|Drug|Atorvastatin 80mg|Atrovastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement and immunomodulation independent of its basic lipid-lowering properties
75780572|NCT01219400|Drug|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
75780573|NCT03707470|Device|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and >20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
75780574|NCT03707470|Device|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 10 mmHg at both the ankle and thigh)
75780575|NCT03707470|Procedure|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
75916195|NCT05232474|Device|KomPas+|KomPas+ is a guideline-based clinical decision support system. With KomPas+, the aim is to integrate KomPas with the guideline recommendations for the conservative treatment process of patients with intermittent claudication. KomPas+ is a web-based tool, aimed to facilitate person-centered and participatory healthcare. Therapists have access to a tool that will help, for example, to improve consistency between patient-specific goals and the treatment plan. Using KomPas+, therapists are encouraged to discuss choices in the treatment plan with the patient. It is expected that the included topics in KomPas+ will not be burdensome for both patients and therapists. Topics to discuss are, for example, Frequency, Intensity, Time and Type (FITT) for drawing up a training schedule. KomPas+ is meant to facilitate therapists and patients in the SDM process. It does not force patients to take part in the SDM process against their will.
75323448|NCT03081416|Drug|Metoclopramide|Standard therapy
75323449|NCT03081416|Drug|Ketorolac|standard therapy
75323450|NCT03081416|Drug|Dexamethasone|Standard therapy
75323451|NCT03081416|Drug|Benadryl|Standard therapy
75323452|NCT00706589|Drug|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
75323453|NCT00706589|Drug|placebo|Initial dose: 2mg, Maximum dose:20mg
75629306|NCT05567068|Drug|Mesalamine|Mesalamine
75629307|NCT05565001|Drug|Levcromakalim|Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.
75780576|NCT01124630|Drug|CS-1008|CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
75780577|NCT01124630|Drug|FOLFIRI|The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
75780578|NCT01214018|Other|Questionnaires and interview|Questionnaires and interview
75780579|NCT05683054|Biological|Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels|In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).
75780580|NCT05683054|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
75780581|NCT05683054|Other|Dermatology Life Quality Index (DLQI)|The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
75780582|NCT05683054|Other|EQ-5D-5L questionnaire|The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
75780583|NCT05683054|Procedure|Dried blood spot sampling|A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
75780584|NCT03937076|Procedure|PECS II block|"Pectoral muscles Nerve block for postsurgical pain, PECS II, based on BUPIVACAINE:~Pectoral muscles nerve block is a procedure in which local anesthetic is injected into two sites.~between the major and minor pectoral muscles, in order to anesthetize the lateral and medial nerve. This injection is referred to as PECS I block.~between the minor pectoral muscle and the anterior serratus muscle, in order to anesthetize the intercostal nerves."
75780585|NCT01120106|Drug|levosimendan|patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
75323454|NCT03080402|Device|Mechanical Perturbation Training|The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
75323455|NCT01276769|Drug|Paclitaxel plus carboplatin|"Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.~1 cycle = 21days 2-6cycles"
75323456|NCT01276769|Drug|Paclitaxel and epirubicin|"Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.~1 cycle = 21days~2-6cycles"
75780586|NCT01120106|Drug|placebo|saline continuous infusion
75323457|NCT01279681|Biological|bevacizumab|Given IV
75323458|NCT01279681|Drug|capecitabine|Given PO
75780587|NCT01216670|Behavioral|remote patient's management|scheduled remote CareLink data transmission
75780588|NCT03338296|Drug|lorcaserin hydrochloride XR|oral tablet
75780589|NCT03338296|Drug|Placebo|oral tablet
75780590|NCT03935516|Other|Cast|The use of plaster and/or fiberglass for casting of subject arm.
75780591|NCT03933644|Device|Gastric Tube|SGA is inserted with a gastric tube as guide for insertion
75780592|NCT03933644|Device|No gastric Tube|SGA is inserted without a gastric tube as guide for insertion
75780593|NCT01214096|Drug|rhNRG-1|Subcutaneous Administration:0.6ug/kg/day for 10days
75780594|NCT01214096|Drug|rhNRG-1|Subcutaneous Administration 1.2ug/kg/day for 10 days
76075074|NCT01698775|Biological|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
76075075|NCT01941095|Drug|Azathioprine|Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
75323459|NCT01279681|Drug|fluorouracil|Given IV
75323460|NCT01279681|Drug|leucovorin calcium|Given IV
75323461|NCT01279681|Drug|oxaliplatin|Given IV
75323462|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
76075076|NCT01941095|Drug|Chloroquine|Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
76075077|NCT01941095|Drug|Hydroxychloroquine|Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
75323463|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
75323464|NCT01276925|Device|Ultrasound|All nerve blockades will be performed with ultrasound guidance.
75629308|NCT05561062|Drug|Atorvastatin 80mg|Atorvastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of its basic lipid-lowering properties
75629309|NCT05551819|Dietary Supplement|MDF then RUTF/RUSF|Children randomized to feeding order 1: children will be provided MDF for the first two weeks then crossover to consume RUTF/RUSF for a second two weeks.
75629310|NCT05551819|Dietary Supplement|RUTF/RUSF then MDF|Children randomized to feeding order 2: children will be provided RUTF/RUSF for the first two weeks then crossover to consume MDF for a second two weeks.
75780595|NCT01214096|Drug|rhNRG-1|Vein infusion:0.6ug/kg/day for 10 days
75780596|NCT01214096|Drug|placebo|Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
75780597|NCT03935438|Other|Cardiac rehabilitation|The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.
75780598|NCT03933566|Procedure|Ultrasound-Guided Superficial Cervical Plexus Block|Ultrasound-Guided Superficial Cervical Plexus Block
75780599|NCT03933566|Procedure|Landmark-Based Superficial Cervical Plexus Block|Landmark-Based Superficial Cervical Plexus Block
75780600|NCT01122368|Drug|micafungin|IV
75780601|NCT01122368|Drug|placebo|IV
75780602|NCT03338062|Diagnostic Test|Hepatobiliary Iminodiacetic Acid (HIDA) scan|HIDA scan was used as the planning scan for SBRT.
75780603|NCT01216826|Drug|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
75780604|NCT03364192|Behavioral|Whole Health Coaching|Veterans Health Administration variation of integrative health coaching.
75780605|NCT01328912|Other|Remote ischemic preconditioning stimulus|The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
75780606|NCT01328912|Other|control|These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
75780607|NCT01120262|Genetic|gene expression analysis|
75780608|NCT01120262|Genetic|polymorphism analysis|
75780609|NCT01120262|Other|laboratory biomarker analysis|
75780610|NCT01120340|Drug|mesalamine|mesalamine: 1.6 g/die for ten days/month until 24 months
75780611|NCT01120340|Other|placebo|2 pills/day for ten days/month until 24 months
75780612|NCT03707392|Other|Ostomy Education Video|Ostomy education video in addition to standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
75780613|NCT03707392|Other|Control - Standard ostomy education|Standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
75780614|NCT01214408|Drug|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
75780615|NCT01214408|Drug|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
75780616|NCT01214486|Drug|Raltegravir|Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA < 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
75780617|NCT05412550|Behavioral|Exercise self-management|Six walking exercise self-management telehealth sessions will focus on behavior change techniques and personalized action plans. Peer support groups will be held every three months, and will be focused on supporting participants in attaining sustained exercise. Text message prompts will focus on encouraging exercise and health self-management.
75780618|NCT05412550|Behavioral|Attention control|The six individual telehealth sessions, six peer-group sessions, and text message prompts will focus on general health education. No prompts for exercise or health self-management will be given.
75780619|NCT03710512|Procedure|Bilateral sagittal split osteotomy|Bilateral sagittal split osteotomy of the mandible is a surgical procedure used to correct dentofacial discrepancies
75780620|NCT03936842|Behavioral|Breast Pain video|An educational video of approximately 10 minutes about breast pain, self-examination and breast awareness will be shown to the participant.
76075078|NCT01941095|Drug|Leflunomide|Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
75780621|NCT03936842|Behavioral|Semi-structure interviews|A semi-structured, face-to-face interview will be then undertaken. The principles of Grounded Theory will be used to guide the interview. All of the interviews will be recorded and transcribed securely, only referencing the patient according to their study number. Their name and hospital number will not be used.
75780622|NCT03708016|Device|Robot gait training|Lokomat robot training was applied to stroke patients.
75780623|NCT03708016|Device|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
75780624|NCT01214564|Drug|PEP005 (ingenol mebutate) Gel|0.05%
75780625|NCT01216904|Drug|nicotine patch|7 mg patches to be worn for 16 hours per day
75629311|NCT05544214|Drug|CKD-371|PO
75629312|NCT05543512|Device|Algorithm to diagnose food allergens|An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm. Subjects randomized to this group will receive a diet assignment based on results of the algorithm.
75629313|NCT05543512|Other|Sham diet|Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
75629314|NCT05538689|Drug|Myfembree Oral Product|The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
75629315|NCT05535374|Device|Feetme Connected Soles|Walk for 10 meters (and 30meters): - By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphonecollection of data by smartphone - By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers). If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.
75651690|NCT05832073|Drug|Natural full human monoclonal antibody CBB 1 injection|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
76075079|NCT01941095|Drug|Methotrexate|Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
75780626|NCT01216904|Drug|placebo|placebo patch to be worn 16 hours per day
75780627|NCT05682898|Procedure|Timing of colorectal cancer surgery|The timing of colorectal cancer surgery is different according patients' different conditions which is difined as more than 7 weeks or less than 7 weeks.
75780628|NCT01125020|Drug|gemcitabine and oxaliplatin|Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
75780629|NCT01125020|Drug|doxorubicin, 5-Fu and cisplatin|Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
75780630|NCT01312012|Drug|antiviral therapy|100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level > 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
76075080|NCT01941095|Drug|Sulfasalazine|Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
76075081|NCT01941095|Drug|Tocilizumab|Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
76075082|NCT00831766|Drug|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
75323465|NCT01276925|Procedure|Peripheral nerve blockade|All patients will receive injections around the three nerves before surgery.
75323466|NCT01276925|Drug|Saline|Isotonic. 10 ml for the femoral nerve.
75323467|NCT01276925|Procedure|Total hip arthroplasty|All patients undergoes total hip arthroplasty.
75780631|NCT03935204|Biological|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
75780632|NCT03935204|Biological|Placebo|Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
75780633|NCT01216982|Drug|Lovaza, omega-3 fatty acid ethyl ester|Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
75780634|NCT01216982|Drug|Placebo, visually identical to Lovaza|Three 1g corn oil capsules/day for three months
76075083|NCT00831766|Drug|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
76075084|NCT00831766|Drug|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
75323468|NCT01276925|Drug|Bupivacaine|5 mg/ml. 3 ml for spinal anaesthesia.
75323469|NCT01272505|Procedure|converntional SILC|
75323470|NCT01272505|Procedure|Harmonic scalpel Single incision laparoscopic cholecystectomy|
75323471|NCT00728507|Drug|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects <= 45kg and 450mg for those >45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
75323472|NCT00728507|Drug|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
75323473|NCT03056534|Device|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
75323474|NCT01279057|Drug|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
75323475|NCT01279057|Drug|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
75323476|NCT01279057|Drug|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
75651691|NCT05832073|Drug|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
75651692|NCT05832073|Drug|Natural full human monoclonal antibody CBB 1 injection placebo|Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
76075085|NCT01957709|Other|Laboratory Biomarker Analysis|Correlative studies
76075086|NCT01957709|Biological|Recombinant Interferon Gamma|Given subcutaneously weekly for four weeks prior to surgery.
76075087|NCT00832390|Drug|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
76075088|NCT01957553|Device|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
76075089|NCT01957553|Device|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
76075090|NCT00807664|Device|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
76075091|NCT00807664|Device|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
76075092|NCT04636619|Procedure|Colonic polypectomy|Cold snare resection of colorectal polyps
76075093|NCT04636619|Behavioral|Online training course|Polypectomy technique online course
75780635|NCT03936764|Other|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~Education to bronchial drainage techniques as well as directed coughing."
75780636|NCT01120496|Drug|3% hypertonic saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
75323477|NCT01277003|Device|Aculife Magnetic Wave Therapist|two therapeutic points, each for 15 minutes
75323478|NCT01277003|Device|TENS|tow therapeutic points, each for 15 minutes
75780637|NCT01120496|Drug|normal saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
75780638|NCT03707002|Dietary Supplement|scFOS|daily intake for 6 weeks
75467578|NCT01930578|Other|Treatment with D5+ 0.45 saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
75629316|NCT05532631|Procedure|Percutaneous coronary intervention|The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.
75780639|NCT03707002|Dietary Supplement|Maltodextrin|daily intake for 6 weeks
75780640|NCT01125254|Drug|Amlodipine|5mg po for 12 months
75780641|NCT03710434|Drug|AZD4635 50 mg nano-suspension (reference)|Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.
75629317|NCT05532631|Procedure|Coronary artery bypass grafting|Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines
75629318|NCT05524064|Radiation|FLASH Radiotherapy|A dose of 8 Gy delivered in a single fraction will be prescribed to the PTV, delivered with FLASH Radiotherapy (>40 Gy/s).
75780642|NCT03710434|Drug|AZD4635 solid oral formulation - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
75323479|NCT05249738|Diagnostic Test|Measuring tongue cross-sectional area by submental ultrasonography|The tongue cross-sectional areas of both groups were measured with submental ultrasonography to detect tongue edema.
75323480|NCT04384783|Drug|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
75323481|NCT03186326|Drug|FOLFOX regimen|"A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
75323482|NCT03186326|Drug|FOLFIRI Protocol|"A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
75323483|NCT03186326|Drug|Avelumab|"A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.~Then:~Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed"
75323484|NCT03186326|Drug|Panitumumab|Administered at 6 mg/Kg
75467579|NCT01930578|Other|Treatment with D5|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
75629319|NCT05519293|Drug|H002|Small molecule, Capsule
75780643|NCT03710434|Drug|AZD4635 solid oral formulation - fed|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
75780644|NCT03710434|Drug|Lansoprazole and AZD4635 50 mg solid oral formulation|Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.
75780645|NCT03710434|Drug|AZD4635 solid oral formulation variant 1 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
75780646|NCT03710434|Drug|AZD4635 solid oral formulation variant 2 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
76075094|NCT00843622|Drug|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
75629320|NCT05475990|Drug|Hydroxyethyl starch|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75780647|NCT03710434|Drug|[14C] AZD4635 IV microtracer - fasted|Subjects will receive a single dose of [14C] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
75780648|NCT01120574|Other|Home mechanical ventilation|Home mechanical ventilation will be performed with a bilevel pressure ventilator.
75780649|NCT03706924|Drug|VM-1500FDC|A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets
75780650|NCT03706924|Drug|Elpida®|Elpida®, capsules, elsulfavirine 20 mg
75780651|NCT03706924|Drug|Truvada®|Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
75780652|NCT01120652|Behavioral|Mind-Body Skills Training (MBST)|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
75780653|NCT01120652|Behavioral|Supportive Counseling (SC)|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
75780654|NCT05682820|Diagnostic Test|Measurements on knee MRI performed during routine clinical practice|Patients after knee injury are often advised to undergo knee MRI for diagnosis. Measurements on knee MRI performed during routine clinical practice will be made.
75780655|NCT01120730|Drug|fluid resuscitation|fluid resuscitation with HES
75780656|NCT01120730|Drug|Fluid resuscitation|Fluid resuscitation in standardized fashion
75780657|NCT03706846|Procedure|fasting|fasting before gastrointestinal endoscopy
75780658|NCT05682586|Biological|umbilical cord mesenchymal stem cells|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1*10^6 cells/kg suspended in 100 ml albumin solution.
75780659|NCT05682586|Drug|paxlovid|Participants will receive standard dose of paxlovid therapy, which contains 300mg namatevir and 100mg litonavir twice a day for a total course of 5 days.
75780660|NCT01217138|Device|Epinephrine autoinjector|We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
75780661|NCT03710356|Drug|Danazol 200 MG|DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
75780662|NCT01125332|Drug|Indirect laryngoscopy in the flexible nasofibroscope|
76075095|NCT00843622|Other|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
75323485|NCT03186326|Drug|Cetuximab|Administered at 500 mg/m²
75323486|NCT03186326|Drug|Bevacizumab|Administered at 5 mg/Kg
75323487|NCT03186326|Drug|Aflibercept|Administered at 4 mg/Kg
76075096|NCT01957475|Device|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
76075097|NCT01957475|Device|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
75323488|NCT02999633|Drug|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
75323489|NCT02999633|Drug|dexamethasone|Pharmaceutical form:pills Route of administration: oral
75323490|NCT02999633|Drug|dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
75323491|NCT02999633|Drug|acetaminophen|Pharmaceutical form:pills Route of administration: oral
75323492|NCT02999633|Drug|ranitidine|Pharmaceutical form:solution Route of administration: intravenous
75323493|NCT02999633|Drug|diphenhydramine|Pharmaceutical form:solution Route of administration: intravenous
75323494|NCT02991599|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
75323495|NCT02991599|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
75323496|NCT00706823|Device|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
75323497|NCT00706823|Device|Laryngeal Mask Airway-Unique|supra-glottic airway device
75323498|NCT04348058|Behavioral|Telephone recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation
75323499|NCT04348058|Behavioral|Combined methods recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation
75629321|NCT05475990|Drug|Crystalloid|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75780663|NCT01125332|Drug|Indirect laryngoscopy in the flexible nasofibroscope|
75467580|NCT01930591|Drug|Ticagrelor|180 mg bolus followed by 90 mg BID
75780664|NCT01217294|Procedure|ultrasound guided fascia iliaca block|Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
75629322|NCT05473871|Behavioral|Faith in Action|"Interpersonal level: Group exercise classes offered 6 days/week (walking, cardio dance, strength training), Kickoff event~Individual level: Motivational Interviewing calls every 6 months, Health handouts on 14 topics distributed at PA classes"
75323500|NCT02996513|Other|Retinol Isotope Dilution (RID)|13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
75629323|NCT05473871|Behavioral|Faith in Action+|Standard Faith in Action Intervention plus: 1) Health Behavior Change Workshop for FBO leaders; 2) Targeted Messaging; and 3) Empowerment Training for Promotoras
75629324|NCT05473871|Behavioral|Faith in Action++|Enhanced Condition plus: 1) Foster community collaborations and 2) Provide maintenance support
75629325|NCT05456373|Device|ClearEdge device|ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
76075098|NCT01940939|Device|Repetitive Transcranial Magnetic Stimulation|The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
75780665|NCT01217294|Procedure|spinal morphine|Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
75629326|NCT05444946|Drug|Prednisone tablet and Itraconazole|Oral prednisolone 0.5 mg/Kg body weight tapered over 4 months and oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. traconazole will be given for 12 months
75629327|NCT05444946|Drug|Oral itraconazole|Oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. Itraconazole will be given for 12 months
75629328|NCT05409157|Drug|BMS-986166|Specified dose on specified days
75629329|NCT05409157|Drug|Bisacodyl|Specified dose on specified days
75629330|NCT05407519|Drug|Tislelizumab + Sitravatinib|Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI
75629331|NCT05404841|Dietary Supplement|CoffeeBerry Supplement|A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,
76075099|NCT01957397|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
76075100|NCT01957397|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
75323501|NCT05248412|Other|COVID-19 outbreaks|The intervention of the study is the COVID-19 outbreaks in Hong Kong. The pre-and post-COVID-19 outbreak periods will be defined as 1 January 2010 - 31 December 2019 and 1 January 2020 - 31 December 2024, respectively.
75323502|NCT01270061|Behavioral|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
75323503|NCT01270061|Behavioral|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
75323504|NCT01277237|Drug|Omacor|Active comparator: omacor 4g/day
75323505|NCT01277237|Drug|lactose tablet|placebo: lactose tablet 4g/day
75323506|NCT04276688|Drug|Lopinavir/ritonavir|400mg/100mg twice daily for 14 days
75323507|NCT04276688|Drug|Ribavirin|400mg twice daily for 14 days
75323508|NCT04276688|Drug|Interferon Beta-1B|0.25mg subcutaneous injection alternate day for 3 days
75467581|NCT01930591|Drug|Clopidogrel|300 mg bolus followed by 75 mg OD
75467582|NCT01930604|Drug|Botox (onabotulinumtoxinA)|
75467583|NCT01930604|Drug|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
75467584|NCT01930604|Drug|NaCl (placebo)|
76075101|NCT01957397|Device|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
75467585|NCT01930617|Procedure|Burr hole surgery with various drainage techniques|"Surgical technique~Continuous irrigation and drainage~Passive subdural drain~Active subgaleal drain"
75467586|NCT01930630|Device|Extraesophageal saline injection (ESI)|The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
75629332|NCT05404841|Dietary Supplement|Placebo|Placebo
75629333|NCT05399056|Behavioral|Telephonic Peer Coaching|Telephonic Peer Coaching from an individual with lived experience with COPD and Pulmonary Rehabilitation trained in motivational interviewing
75629334|NCT05399056|Behavioral|Storytelling|Video narratives of an individual with lived experience with COPD and Pulmonary Rehabilitation describing their journey through Pulmonary Rehabilitation
75629335|NCT05398107|Behavioral|Experimental: Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design aimed at promoting maternal mental health and supportive parenting. The BEAM Program app is hosted on the University of Manitoba secure servers and is designed/managed by Tactica Interactive. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or Doctoral-Level Clinical Psychology Student) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in a prior iteration of the BEAM program. Parent coaches will engage with participants on the community peer support forum and will also attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve symptoms of anxiety and depression as well as parenting skills, and will emphasize self-compassion, effective communication practices, and social support networks.
75651693|NCT05832073|Biological|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
75780666|NCT03783962|Behavioral|Active Intervention - Cooking|"Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings."
75629336|NCT05398107|Behavioral|Control: MoodMission|"MoodMission will be used as our Standard of Care control group. MoodMission is an app based on CBT principles which creates tailored missions for mothers. These missions are based on self-reported mood and are aimed to improve mental health symptoms."
75780667|NCT03783962|Behavioral|Demonstrations - Cooking|The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
75780668|NCT03361228|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
75780669|NCT03361228|Drug|Epacadostat|Epacadostat at the protocol-defined dose administered orally twice daily.
75780670|NCT03361228|Drug|Pembrolizumab|Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.
75323509|NCT02996435|Behavioral|Mobile Application Intervention|Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol.
75323510|NCT02996435|Other|No Intervention|Participants will receive physician- or nurse-guided standard of care.
75629337|NCT05386355|Behavioral|COVID-19 Vaccine Uptake App|A mHealth mobile application (app) that will provide educational and logistical information about the COVID-19 vaccination for children. The target audience will be parents of unvaccinated children.
75629338|NCT05386355|Other|General Health App|A mobile application (app) that will provide general pediatric health and infection prevention and mitigation strategies.
75629339|NCT05369065|Combination Product|Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
75629340|NCT05369065|Diagnostic Test|Arterial Angiography Only|Arterial Angiography Only without Intervention
75629341|NCT05369065|Combination Product|Single Arm non-Randomized Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
75629342|NCT05355311|Drug|Acetyl-l-carnitine|Acetyl-L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
75629343|NCT05355311|Drug|Placebo|Matching placebo (sugar pill)
75629344|NCT05354232|Device|2 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 2mA condition, the investigators will assist the administration of a 2mA current stimulation from the device.
75780671|NCT03936686|Other|Survey tool to assess CVD risk factor knowledge|The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.
75780672|NCT05175898|Device|VA-ECMO|Treatment with veno-arterial extracorporeal membrane oxygenation
75780673|NCT05175898|Device|ECMELLA|Treatment with veno-arterial extracorporeal membrane oxygenation plus Impella® micro-axial pump.
75780674|NCT01121042|Drug|Ondansetron|8mg per day oral capsule
75780675|NCT01121042|Drug|Placebo|daily oral capsule matched to active study medication. Made form 100% lactose powder
75780676|NCT05677438|Drug|CKD-498 dose#1|oral, once daily, 24 weeks
75780677|NCT05677438|Drug|CKD-498 dose#2|oral, once daily, 24 weeks
75780678|NCT05677438|Drug|CKD-498 dose#3|oral, once daily, 24 weeks
75780679|NCT05677438|Drug|Placebo of CKD-498 dose#1|oral, once daily, 24 weeks
75780680|NCT05677438|Drug|Placebo of CKD-498 dose#2|oral, once daily, 24 weeks
75780681|NCT05677438|Drug|Placebo of CKD-498 dose#3|oral, once daily, 24 weeks
75780682|NCT01217372|Dietary Supplement|Lemon supplementation|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
75780683|NCT01121120|Drug|TXA127|300mcg/kg/day, administered subcutaneously for up to 28 days
75780684|NCT01121120|Drug|Placebo|300mcg/kg/day administered subcutaneously for up to 28 days
75323511|NCT04275986|Procedure|Intensity modulated radiotherapy (IMRT)|Intensity-modulated radiation therapy (IMRT) with a total dose of 45Gy in 25 fractions
75323512|NCT04275986|Drug|Chemotherapy|Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
75323513|NCT05246150|Behavioral|nursing care practices|To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
75323514|NCT01277627|Drug|Nevirapine|nevirapine: 400 mg a day.
75780685|NCT03933488|Drug|TAK-994|TAK-994 tablets.
75780686|NCT03933488|Drug|TAK-994 Placebo|TAK-994 placebo-matching tablets.
75780687|NCT03706768|Other|Glycocalyx|Measure Degradation of the Glycocalyx
75780688|NCT01217450|Drug|selumetinib|Given orally
75780689|NCT01217450|Biological|cetuximab|Given IV
75780690|NCT01217450|Other|laboratory biomarker analysis|Correlative studies
75780691|NCT01217450|Other|pharmacological study|Correlative studies
76075102|NCT01940705|Other|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
76075103|NCT01940705|Other|Hearing-Aid DVD|Take-home DVD about hearing aids
76075104|NCT01940705|Behavioral|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
76075105|NCT01940705|Other|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
76075106|NCT00834106|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
75780692|NCT05682508|Other|Education group|"Based on the Health Belief Model, a educational booklet on diet and fluid control in individuals receiving hemodialysis treatment has been prepared. The training content consists of information on the structure and function of the kidneys, information about chronic renal failure, possible complications in case of non-adherence with the desired fluid control and diet, perceived benefits, the information on diet and fluid control consisted of perceived benefits, barriers, coping with barriers, perceived susceptibility in this regard, and information on the development of self-efficacy to improve dietary compliance and fluid control.~Individuals in the education group were given individual training by the researcher. The training was conducted in a single meeting of 20-30 minutes in the first hour when haemodialysis started and the patient's condition was stable."
76075107|NCT00834106|Biological|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
76075108|NCT01957163|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
76075109|NCT01957163|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
75323515|NCT01277627|Drug|efavirenz, protease inhibitors|efavirenz: 600 mg a day
75629345|NCT05354232|Device|1 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 1mA condition, the investigators will assist the administration of a 1mA current stimulation from the device.
75780693|NCT01219556|Drug|Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)|Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
75780694|NCT03710278|Device|LPat Device|Performing Lumbar Puncture utilizing LPat device
75916196|NCT05232474|Device|KomPas|KomPas is an online tool showing personalized outcome forecasts. These forecasts have been developed using real-world data of patients with intermittent claudication for physiotherapists in daily practice. The forecasts visualize the estimated outcome of supervised exercise therapy (walking distance and quality of life), for an individual patient with intermittent claudication. The information provided is based on patients similar to the individual patient from a large database. The actual outcome data of these similar patients are used to create an individual forecast. KomPas plots the estimated therapy outcome in time, thereby making personalized outcome forecasts. The forecasts are not used to direct the choices of treatment, but to motivate the patient, monitor the treatment process and to set realistic goals.
76075110|NCT01957163|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
75323516|NCT04397744|Behavioral|Unidas por Vida y Salud prevention program|The Unidas por Vida y Salud (United for Life and Health) prevention program is led by the El Paso Cancer and Chronic Disease Consortium (CCDC), the only Breast and Cervical Cancer Services (BCCS) provider in El Paso. This prevention program will use a well-integrated network of community organizations and health service providers to connect medically underserved women to services. To reach the most underserved women and increase preventive cancer screening and timely follow-up, diagnosis, and treatment, the multi-method approach uses evidence-based strategies, including face-to-face educational sessions led by promotoras (community health workers), client reminders, and provision of community-based navigation services to affordable and free screening services. The program also includes clinic-based navigation for those requiring diagnostics or treatment delivered by trained nurses and case workers.
75323517|NCT02996201|Other|Completion of PRO-CTCAE items before consultation|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
75629346|NCT05354232|Device|Sham transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the sham condition, the investigators will assist the administration of a sham stimulation from the device.
75780695|NCT01217528|Device|device settings for group A|VT zone: 350ms VF zone: 280ms
75780696|NCT01217528|Device|Device settings for group B|VT zone: 320ms VF zone: 250ms
75780697|NCT01121198|Drug|ASP1941|oral
75780698|NCT01121198|Drug|placebo|oral
75780699|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
75780700|NCT01121276|Drug|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
75780701|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
75780702|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
75780703|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
75916197|NCT03461432|Behavioral|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.
75916198|NCT01007292|Drug|YM155|intravenous infusion
75916199|NCT01007292|Biological|Rituximab|intravenous infusion
75916200|NCT03464474|Device|digital holographic microscopy|Colonic biopsies from all patients will be assessed using digital holographic microscopy in comparison to the existing Goldstandard (histopathological analysis).
76075111|NCT01957163|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
76075112|NCT00844090|Drug|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
76075113|NCT00844714|Drug|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
76075114|NCT00834652|Drug|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
76075115|NCT00834652|Drug|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
76075116|NCT00834808|Drug|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
75629347|NCT05354219|Other|Imaging|Imaging with 3 iris cameras
75629348|NCT05323266|Device|Nasal Continuous Positive Airway Pressure (nCPAP)|The two main interventions in this study were Nasal continuous positive airway pressure (nCPAP) and high-flow nasal cannula (HFNC) in patients with acute stroke. Nasal continuous positive airway pressure (nCPAP) is a way of ventilation completed in a non-invasive ventilator. In this study, the nasal mask is mainly used to replace the traditional oral and nasal mask.
75323518|NCT03009890|Procedure|Surgery (Open Reduction Internal Fixation)|Either volar of dorsal plating or both
76075117|NCT00850096|Other|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
75780704|NCT05682430|Behavioral|Heart rate based HIIT|Week1,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week2,90% HRmax long duration HIIT + 90% long duration HRmax HIIT. Week3,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week4,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week5,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week6,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week7,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week8,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week9,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week10,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week11,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week12,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT.
75916201|NCT03467984|Biological|LBVE|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
75916202|NCT03467984|Biological|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
76075118|NCT00850096|Drug|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
75629349|NCT05323266|Device|High-Flow Nasal Cannula (HFNC)|The high-flow nasal cannula (HFNC), as another oxygen therapy, is also used as an intervention in this study to study the effect of early prognosis in patients with acute ischemic stroke.
75629350|NCT05318703|Behavioral|tai ji quan|cognitively enhanced tai ji quan exercise
75629351|NCT05318703|Behavioral|Stretching|Stretching exercise
75629352|NCT05311033|Other|Exacyl|Healthy males with at risk of post-inflammatory hyperpigmentation have a skin samples for evaluate the activity of tranexamic acid.
75629353|NCT05310708|Diagnostic Test|Polysomnography|Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
75629354|NCT05303025|Other|Survey|Survey to acquire baseline demographic information as well as information regarding professional experience, working environment and attitudes towards artificial intelligence.
75916203|NCT03887208|Procedure|Laser therapy|non-ablative fractional laser therapy of skin
75916204|NCT03887208|Biological|Autologous ADSC injection|Subcutaneous injection of autologous ADSC
76075119|NCT01939223|Drug|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
75323519|NCT03009890|Procedure|Cast treatment|Hospitals may use their preferred protocol
75323520|NCT00728819|Device|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
75323521|NCT00728819|Device|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
75916205|NCT03887208|Procedure|Normal saline injection|Subcutaneous Normal saline injection
75916206|NCT03467828|Genetic|polymorphism analyzing|Blood samples will be taken to EDTA containing tubes and then will be analyzed for genetic polymorphisms.
75916207|NCT01005108|Drug|Gabapentin|Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
75323522|NCT05245214|Diagnostic Test|Magnetic Resonance Imaging|Muscle analysis by Magnetic Resonance Imaging
75916208|NCT00905346|Drug|Topiramate 25 mg Capsules|Topiramate Capsules 2 x 25 mg
75916209|NCT00905346|Drug|Topamax® 25 mg Capsules|Topamax® Capsule 2 x 25 mg
75916210|NCT00905346|Other|Applesauce|Applesauce
75916211|NCT03464240|Dietary Supplement|Glucose|glucose drink
75916212|NCT03464240|Dietary Supplement|Water|control
75916213|NCT00903552|Biological|Influenza VLP Vaccine|
75916214|NCT00903552|Biological|Placebo|phosphate-buffered saline (PBS)
75916215|NCT03461198|Device|Restylane® Silk|Restylane® Silk to a defined area of mid to low cheeks
75916216|NCT00902928|Drug|YM150|oral
75916217|NCT00902928|Drug|enoxaparin|SC injection
75916218|NCT03464162|Behavioral|Social Network Meetings|Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
75323523|NCT01270217|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
75323524|NCT05241470|Drug|ST-100 Ophthalmic Solution|One drop in each eye twice a day
75916219|NCT03467672|Other|Diagnosis of bacterial infection|use of eosinopenia in the diagnosis of bacterial infection
75629355|NCT05303025|Other|Semi-structured group discussion|Semi-structured group discussion.
75651694|NCT05832034|Drug|Immune Globulin Intravenous (Human)|IVIg is 2 g/kg over 2 to 5 days at baseline, followed by 2 g/kg IV in 2 to 5 days after 4 and 8 weeks. The rate of infusion is controlled by means of an infusion pump. The first dosage (30 grams IVIg) will be administered on the neurology ward.
75651695|NCT05832034|Drug|Placebo|Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
75651696|NCT05831852|Other|no intervention|no intervention
76075120|NCT01939223|Drug|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
76075121|NCT00834886|Dietary Supplement|Melatonin|Capsules, 3 mg, once every night
75629356|NCT05292703|Other|Participatory activity based on art and olfactory stimulation|practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities.
75651697|NCT05831202|Device|The SEAL™ Saccular Endovascular Aneurysm Lattice System|The SEAL™ Embolization System is a self-expanding, nitinol and platinum wire mesh braided implant as described above; that is available in a broad range of sizes (diameter widths 3mm to 20 mm, and heights; 2mm to 16 mm) and in two configurations with common Base Bridging Component (Base SEAL™, and ARC SEAL™ configurations).
75651698|NCT05830539|Drug|IN10018+PLD|IN10018 orally once daily; PLD 40mg/m2, Q4W
75916220|NCT03464006|Other|Online Support Module|The online support module is a computer software program which helps patients monitor factors related to their peripheral artery disease
75916221|NCT03464006|Other|Standard of Care|The normal care that patients receive at the institution.
75916222|NCT03467594|Behavioral|High-intensity interval training|• Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
75916223|NCT02522156|Behavioral|Looming Vulnerability Induction|guided imagery aimed at inducing smoking cessation attempts. See description of the looming vulnerability arm.
75323525|NCT05241470|Drug|Placebo Ophthalmic Solution|One drop in each eye twice a day
75780705|NCT05682430|Behavioral|VIFT speed-based HIIT with mechanical work|Week1,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week2,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week3,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week4,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week5,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week6,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week7,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week8,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week9,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week10,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week11,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT. Week12,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT.
75323526|NCT05245838|Biological|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg
75323527|NCT05245838|Biological|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)
75323528|NCT05245838|Biological|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg
75323529|NCT05245838|Biological|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
75323530|NCT05245838|Biological|Shingrix|a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
75916224|NCT02522156|Behavioral|Control|Neutral guided imagery scenarios making no reference to smoking.
75916225|NCT03463928|Biological|donor-derived CD19/22 bispecific CAR-T cells or CD19-directed CAR-T cells; donor-derived-HSCT|The allo-CAR-T cells will be infused in a fractionated manner, 1/3 on day 0, 2/3 on day 1.The allo-HSCT will be infused on day 2.
75916226|NCT05628168|Other|Neurodynamic Mobilization Techniques|The slider neurodynamic technique for the median nerve is conducted.Tensioner neurodynamic technique for the tibial nerve is conducted.
75916227|NCT05628168|Other|Selected Physical Therapy Program|The participants only received a selected therapy program similar to the NMG with no change in duration.
75916228|NCT01002924|Drug|EC145|EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
75916229|NCT03461042|Drug|Ramelteon 8mg|Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent
76075122|NCT00834886|Other|Bright light|Bright light therapy 10.000 lux by Miljølys AS
76075123|NCT00834886|Other|Placebo red light|Red light 400 lux as placebo light
76075124|NCT00834886|Other|Placebo capsule|Capsules containing 3 mng rice flour, once every night
75323531|NCT02996123|Other|cad/cam maxillary dentures|patients wearing cad/cam designed and milled dentures
75323532|NCT01270451|Other|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
75323533|NCT01270607|Procedure|Acupuncture|Treatment given twice per week for 4 weeks
75323534|NCT01277939|Behavioral|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
75323535|NCT01277939|Behavioral|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
75323536|NCT00729053|Drug|IMO-2055|immunostimulatory oligonucleotide
75323537|NCT00706979|Other|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
75323538|NCT00706979|Behavioral|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
75323539|NCT01278017|Drug|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
75323540|NCT01278095|Drug|GLPG0555 solid dispersion|solid dispersion capsules, 50 mg, single dose
75323541|NCT01278095|Drug|GLPG0555 nanosuspension|Nanosuspension, 50 mg, single dose
75916230|NCT03461042|Drug|Placebo|Placebo capsule once daily before bedtime for 12 weeks since informed consent
76075125|NCT05125289|Other|Graston technique group|Moist hot pack (10 minutes) Isometric quadriceps exercises (10 repetitions) Straight leg raise (10 repetitions) Graston technique steps 6 long strokes by the GT1 instrument on the hamstring muscle longitudinally. The Graston technique duration will be 5 minutes
75629357|NCT05292703|Other|practicing art virtually in conjunction with olfactory identification|"For the remote group, , they will receive the connection link to the internet application and an individual connection code.~The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop.~The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks."
75916231|NCT01130064|Biological|QAX576|every 3 weeks via intravenous infusion
75323542|NCT02995811|Other|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
75323543|NCT00729521|Other|facilitative system|The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
75323544|NCT00729521|Other|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
75323545|NCT01278251|Procedure|Distal Biceps Re-Insertion|
75629358|NCT05286736|Diagnostic Test|Neuroimaging|This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.
75629359|NCT05286736|Diagnostic Test|Quantitative assessments|Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function
75629360|NCT05283265|Behavioral|Sentence Type|Subjects read different types of sentences (object-relative, subject -relative and control sentences) to observe how that sentence affects their intracranially recorded neural activity.
75629361|NCT05283265|Other|Direct brain stimulation|On some trials the investigators will apply intracranial electrical current through the electrodes implanted in the participants and observe the effect this has on their behavior (which picture they choose at the end of the trial) and the effect this has on their neural activity that the investigators record simultaneously through-out the experiment.
75629362|NCT05281562|Drug|Lovaza|Daily dose of 1.68grams omega-3 fatty acids, 2 Lovaza pills per day.
75629363|NCT05281562|Drug|L-Arginine Powder|Daily dose of 4.5 grams L-Arginine, powder form.
75780706|NCT01214954|Other|Supervised progressive resistance training|Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.
75780707|NCT01214954|Other|Control group|Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
75780708|NCT05175508|Drug|Azacitidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days
75916232|NCT01130064|Drug|Placebo|every 3 weeks via intravenous infusion
75629364|NCT05281562|Drug|Vitamin C|Daily dose of 500 mg Vitamin C, powder form.
75651699|NCT05830539|Drug|IN10018+PLD+Toripalimab|IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W
75780709|NCT05175508|Drug|all trans retinoic acid|ATRA 20mg tid by po on days 1-21 of every cycle 28 days
75780710|NCT01125410|Drug|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
75780711|NCT01125410|Drug|Clindamycin|vaginal cream, 2%, once daily for 7 days
75780712|NCT03933332|Other|Diaphragm thickness|measured at apposition zone using ultrasonography in mm
75780713|NCT03933332|Other|Cross-sectional area of rectus femoris muscle|measured at lower one-third line between Spina iliaca anterior inferior (SIAI) and upper border femur patella using ultrasonography in cm^2
75780714|NCT03933332|Other|Cross-sectional area of biceps brachii|measured at biceps brachii muscle using ultrasonography in cm^2
75780715|NCT03933332|Diagnostic Test|C-Reactive Protein (CRP) Level|quantitative CRP using ELISA method in mcg/mL
75780716|NCT03706534|Device|Ultrasound Image review with CADe|This software is a computer-aided detection (CADe) software application, designed to assist radiologist to analyze breast ultrasound images. S-Detect automatically segments and classifies shape, orientation, margin, lesion boundary, echo pattern, and posterior feature characteristics of user-selected region of interest. The device uses deep learning methods to perform tissue segmentation and classification of images.
75780717|NCT03706534|Device|Ultrasound Image review with CADx|This software is also a computer-assisted diagnostic(CADx) software application, designed to assist a medical doctor in determining diagnosis by presenting whether a lesion is malignant in a breast ultrasound image obtained from an ultrasound imaging device.
75916233|NCT01129674|Drug|LY2140023|Administered orally, twice daily for 104 weeks
75916234|NCT01129674|Drug|Olanzapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
75916235|NCT01129674|Drug|Aripiprazole|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
75916236|NCT01129674|Drug|Risperidone|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
75916237|NCT01129674|Drug|Quetiapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
75916238|NCT03129854|Device|prostate cryotherapy|prostate cryotherapy added to experimental group within 6 months of ADT
75323546|NCT01270763|Behavioral|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
75629365|NCT05276596|Drug|Ephedrine|The control group will be taken care of according to the protocols in force. The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
75323547|NCT01270763|Behavioral|Diabetes support and education|Behavioral intervention focused on diabetes support and education
75323548|NCT00716963|Drug|Fluticasone propionate (Flovent Diskus) 250 mcg|Flovent Diskus 250 mcg
75323549|NCT00716963|Drug|budesonide 400 mcg|budesonide 400 mcg
75323550|NCT00716963|Other|Placebo|Placebo
75323551|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
75323552|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
75629366|NCT05276596|Drug|Norepinephrine|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
75629367|NCT05274971|Other|Active dietary management and aerobic exercise training.|Active dietary management and aerobic exercise training.
75629368|NCT05272644|Behavioral|surface electromyographic biofeedback assisted pelvic floor muscle training|participants will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
75629369|NCT05272644|Behavioral|surface electromyographic biofeedback and electrical stimulation|participants will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
75629370|NCT05245396|Drug|Ref (TF2)|Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
75629371|NCT05245396|Drug|Evobrutinib MR-T1|Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.
75629372|NCT05245396|Drug|Evobrutinib MR-T2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.
75629373|NCT05245396|Drug|Evobrutinib MR-T3|Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.
75629374|NCT05245396|Drug|Evobrutinib MR-T4|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.
75629375|NCT05245396|Drug|Evobrutinib MUPS-C1|Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.
75916239|NCT03928392|Behavioral|SCUBA with Occupational Therapy (OT)|Study participants will complete two OT sessions in conjunction to their regular SCUBA diving activity. OT intervention includes breathing techniques, mindfulness strategies and a journal activity.
75916240|NCT03928392|Behavioral|Self-Contained Underwater Breathing Apparatus (SCUBA) without OT|Study participants will continue their regular SCUBA diving activity through the Wounded American Veterans Experience SCUBA (WAVES) program. They will complete two dives.
75916241|NCT05045378|Drug|Midazolam (active placebo)|Arm1: Two 0.045mg/kg midazolam infusions at Day1 and Day3。
75629376|NCT05245396|Drug|Evobrutinib MUPS-C2|Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.
75629377|NCT05245396|Drug|Evobrutinib MUPS-C3|Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.
75629378|NCT05245396|Drug|Evobrutinib MUPS-C4|Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.
75629379|NCT05245396|Drug|Evobrutinib MR-T adapated|Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.
75629380|NCT05241262|Drug|N-Acetylcysteine|1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan
75629381|NCT05224011|Device|Boppli Infant Blood Pressure Monitor|The intervention is a medical device for the non-invasive measurement of blood pressure in infants
75780718|NCT03706534|Device|Ultrasound Image manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored.
75916242|NCT05045378|Drug|Ketamine and Midazolam (active placebo)|Arm2: First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion。
75916243|NCT05045378|Drug|Ketamine|Arm3: Two 0.5mg/kg ketamine infusions。
75916244|NCT04959032|Drug|Lumateperone 42 mg|Lumateperone 42 mg capsules administered orally, once daily.
75916245|NCT04959032|Drug|Placebo|Matching capsules administered orally, once daily.
75916246|NCT03460964|Device|Adhesive glucose sensor|"Will assess sensor's performance by comparing readings from an adhesive glucose sensor with those from a glucometer.~pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat"
75323553|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
75323554|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
75323555|NCT01278745|Biological|Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
75323556|NCT01278745|Drug|Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
75323557|NCT02995655|Drug|CX-01|CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
75323558|NCT02995655|Drug|Azacitidine|Azacitidine at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle.
75323559|NCT02995655|Procedure|Bone marrow biopsy|-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
75629382|NCT05218785|Drug|Botox|75 U in medial gastrocbemius head. x 3
75629383|NCT05189860|Device|C-MIC system|This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.
75780719|NCT03706534|Procedure|Biopsy|Suspicious lesions found on breast ultrasound are then followed either by ultrasound guided biopsy or ultrasound imaging every 6 months for two years. For those who undergo biopsy, ultrasound provides images which are used to localize the lesion and guide the placement of the biopsy needle. The sample is sent to pathology for diagnosis, while the ultrasound guidance images are stored. For those who have imaging follow-up, ultrasound images of the breast mass are obtained, digitally stored and interpreted by the radiologist typically using BIRADS scheme.
75629384|NCT05189821|Procedure|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation
75780720|NCT01328834|Drug|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
75916247|NCT03460964|Drug|Pilocarpine|Pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat; will apply a minimum of 2 doses to each participant.
75323560|NCT02995655|Procedure|Peripheral blood draw|-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
75323561|NCT01271153|Drug|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
75323562|NCT01271153|Drug|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
75780721|NCT01121354|Drug|Cefazolin 2g for Injection USP and Dextrose Injection USP|Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
75323563|NCT03809065|Drug|Nitroglycerin|Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) <3}.
75629385|NCT05189808|Procedure|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation
75629386|NCT05189314|Procedure|Thyroidectomy|Surgical Resection of thyroid nodules
75629387|NCT05189314|Procedure|Radiofrequency Ablation|Radiofrequency Ablation of thyroid nodules
75780722|NCT01121354|Drug|Cefazolin 1.5g|Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
75629388|NCT05161936|Drug|Lumasiran|Lumasiran will be administered by SC injection.
75629389|NCT05161936|Drug|Placebo|Placebo will be administered by SC injection.
75629390|NCT05158023|Drug|Placebo|Sterile solution for subcutaneous injection
75629391|NCT05158023|Biological|ASLAN004|Sterile solution for subcutaneous injection
75780723|NCT01122602|Drug|Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
75780724|NCT01122602|Drug|Acetylsalicyclic acid (Aspirin, BAYE4465)|Single dose of regular aspirin 2 x 325 mg = 650 mg total
75916248|NCT03460886|Device|Ipsilesional stimulation|anodal stimulation on Ipsilesional leg area of primary motor cortex and supplementary motor area for 30 minutes
75629392|NCT05158023|Biological|ASLAN004|Sterile solution for subcutaneous injection
75916249|NCT03460886|Device|Contralesional stimulation|anodal stimulation on contralesional leg area of primary motor cortex and supplementary motor area for 30 minutes
75629393|NCT05158023|Biological|ASLAN004|Sterile solution for subcutaneous injection
75629394|NCT05158023|Biological|ASLAN004|Sterile solution for subcutaneous injection
75780725|NCT01122602|Drug|Placebo|Two placebo tablets
75916250|NCT03460886|Other|Walking on treadmill|walking on treadmill for 10 minutes
75916251|NCT03460808|Drug|atorvastatin|Atorvastatin was used in combination with acetylcysteine and danazol.
75916252|NCT03460808|Drug|Acetylcysteine|Acetylcysteine was used in combination with atorvastatin and danazol.
75916253|NCT03460808|Drug|Danazol|Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
75916254|NCT04956926|Drug|JS201|JS201 is administered intravenously Q3W at the corresponding dose.
75916255|NCT05627934|Diagnostic Test|qICG|Evaluation of bowel fluorescence by pixel software, qICG
75629395|NCT05143424|Drug|Morphine Sulfate|Morphine sulfate 30 mg tablets as a single dose twice
75629396|NCT05134779|Procedure|Live Biobank|Tumor tissue will be collected from consented patients at sequential inflection points in the disease course: at the time of initial diagnosis, at the time of surgery and during recurrence or metastasis. In addition to this, 40ml of research bloods will also be collected at these key inflection points.
75629397|NCT05127837|Behavioral|CBTpro|CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis.
75651700|NCT05829174|Behavioral|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
75651701|NCT05829174|Behavioral|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
75651702|NCT05829174|Behavioral|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
75651703|NCT05829174|Behavioral|Behavioral module: Pomodoro Time Management Technique|Working in 25 minutes time intervals
75323564|NCT03809065|Drug|Labetalol|Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) <3}.
75629398|NCT05123313|Behavioral|Deprescribing intervention|"The intervention is comprised of a minimum of three consultations with a general practitioner (GP), where adjustment of the patient's medication is made according to the patient's preference, goals and needs~Consultation 1: Patient and GP discuss how the patient feels about their medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation.~Consultation 2: A clinical pharmacist have beforehand examined the patient's medication list and provided suggestions to the GP on which drugs can be deprescribed. The patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities.~Consultation 3: Patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal."
75780726|NCT03935048|Dietary Supplement|Higher protein, low glycemic load diet|"All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided."
75780727|NCT03359590|Drug|Sitagliptin 100 mg|The treatment consists of sitagliptin tablets (100 mg/day) for up to 24 weeks.
75780728|NCT03359590|Drug|Placebo|The treatment consists of placebo tablets for up to 24 weeks.
75916256|NCT03463772|Procedure|standard IVF|Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.
75916257|NCT03463772|Drug|In vitro maturation|Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
75323565|NCT01271387|Drug|tasimelteon|20 mg tasimelteon capsules, PO single dose
75916258|NCT05169762|Other|standard treatment|starndard treatment for transgender women
75916259|NCT04946630|Device|PreciseInhale|Three different settings of the medical device PreciseInhale will be used in the study; PreciseInhale Whole Lung Exposure, PreciseInhale Bronchial Bolus/Breath hold Exposure and PreciseInhale Alveolar Bolus/Breath hold Exposure.
75916260|NCT04946630|Other|Seretide Evohaler forte|Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.
75916261|NCT05164302|Procedure|Auricular acupuncture|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, we use press tack needles to perform auricular acupuncture.
75916262|NCT00900900|Dietary Supplement|dehydroepiandrosterone (DHEA)|one-time 400mg oral dose of DHEA
75916263|NCT00900900|Dietary Supplement|pregnenolone|one-time 400mg oral dose of pregnenolone
75916264|NCT00900900|Drug|Placebo|one-time dose oral dose
75323566|NCT01272739|Dietary Supplement|IHBG-10|500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
75323567|NCT01272739|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
75323568|NCT02995577|Other|Feeding tolerant|
75323569|NCT02995577|Other|Feeding intolerant|
75323570|NCT02995577|Other|Necrotizing enterocolitis|
75323571|NCT05137418|Biological|COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
75916265|NCT03460730|Biological|Pneumovax|23-valent pneumococcal polysaccharide vaccine
75916266|NCT05627778|Drug|68Ga-PSMA-11|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-11. Tracer doses of 68Ga- PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
75916267|NCT05627778|Drug|68Ga-P15-041|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P15-041. Tracer doses of 68Ga- 15-041 will be used to image lesions of prostate cancer by PET/CT.
75323572|NCT04278209|Other|Breakfast 1|Participant will receive Breakfast 1
75323573|NCT04278209|Other|Breakfast 2|Participant will receive Breakfast 2
75323574|NCT04278209|Other|Water|Participant will receive water
75323575|NCT05244434|Other|Best Practice|Given standard of care ribociclib + AI or palbociclib + AI
75323576|NCT05244434|Procedure|Biopsy|Undergo biopsy of tumor tissue
75323577|NCT05244434|Procedure|Biospecimen Collection|Undergo blood sample collection
75323578|NCT05244434|Other|Laboratory Biomarker Analysis|Undergo analysis of previously collected tumor tissue
75323579|NCT02995265|Device|Exoskeleton Program|Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.
75323580|NCT02995265|Other|Usual Care Program|Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
75323581|NCT02995187|Drug|Apatinib Mesylate tablet|Apatinib 500 mg in tablet once daily
75323582|NCT01278329|Other|"Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)"|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
75780729|NCT01219712|Procedure|Colloids, dobutamin, levosimendan|": The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.~Hb would be optimized to > 90 g/l~SaO2 > 96%~Stroke volume index (SVI) > 30~Heart rate should ideally be < 80~Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal"
75467587|NCT01930669|Other|Gravitational sympathetic stimulus|"Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique."
76075126|NCT05125289|Other|Active release technique group|"Moist hot pack (10 minutes)~Isometric quadriceps exercises (10 repetitions)~Straight leg raise (10 repetitions)~ART steps:~Subject lies on the plinth in prone or in side lying position with the dominant side facing upwards.~Gentle tension is applied to the hamstring muscle along the entire length while stretching the leg in prone lying or side lying positions, depending on the level of pain and tightness of muscle (5 repetitions at 5 seconds interval).~Gentle tension is also applied at the origin and insertion of the hamstring muscle until the patient feels full release."
75629399|NCT05118828|Behavioral|Guided internet-based cognitive behavioural therapy|AS-iCBT offers guided CBT intervention for anxiety and depression, each consisting of 6 modules. It is recommended for clients to complete 1 module weekly. The structure and content of the programme modules follow evidence-based CBT principles, and comprises cognitive and behavioural components such as self-monitoring, gradual stimulus control, exposure, behavioural activation, and cognitive restructuring. It is recommended that therapist support is provided weekly during short sessions that focus on progress monitoring and feedback on completed work. Support sessions should last 15-20 minutes and are preferably delivered by phone or video conference.
75629400|NCT05118828|Behavioral|Treatment as usual in Prompt Mental Health Care (TAU-PMHC)|TAU-PMHC includes both low-intensity (guided self-help, group-based psychoeducation) and high-intensity CBT (F2F-CBT). The TAU-PMHC condition basically represents how PMHC services currently operates (i.e. a pragmatic stepped care model) and provides therapists with more flexibility to accommodate client needs and preferences.
75629401|NCT05116852|Other|Survey|All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.
75323583|NCT01271621|Device|Intubation|Endotracheal intubation
75323584|NCT02394704|Other|Sensory attention training|"Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks."
75629402|NCT05112705|Diagnostic Test|Proximal lower limb ultrasound|Twice weekly proximal lower limb ultrasound
75629403|NCT05108649|Other|Nicotine Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will view nicotine corrective messaging at each in-person session or delayed control messaging at the final study session.
75629404|NCT05108649|Other|Cigarette Condition|After completing a 7-day period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive reduced nicotine content (RNC) cigarettes or normal nicotine content (NNC) cigarettes.
75651704|NCT05828940|Drug|Losartan Potassium|oral tablet, over-encapsulated
75651705|NCT05828940|Drug|Placebo|oral tablet, over-encapuslated
75651706|NCT05828329|Behavioral|Guided visualization of exams through immersive virtual reality|During 4 weeks (twice per week), students will visualize a 30-minutes 360º video that simulates the experience of an exam, from first person perspective.
75780730|NCT03710200|Other|Bologna 00+S. cerevisiae yeast|Bologna 00 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL of water
75780731|NCT03710200|Other|Bologna 1+S. cerevisiae yeast|Bologna 1 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
75916268|NCT01120470|Drug|OGX-427|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
75916269|NCT01120470|Drug|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427"
75916270|NCT00997152|Drug|JTT-654|Tablets
75916271|NCT00997152|Drug|JTT-654 Placebo|Tablets
75323585|NCT02995109|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z11-004)"
75323586|NCT02995109|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75467588|NCT01930682|Drug|Alteplase|Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
75780732|NCT03710200|Other|Bio2+S. cerevisiae yeast|Bio2 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
75780733|NCT03710200|Other|ICARDA+S. cerevisiae yeast|Icarda bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
75780734|NCT03710200|Other|Bologna 1+sourdough|Bologna 1 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
75780735|NCT03710200|Other|Bio 2+sourdough|109g of Bio2 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
75780736|NCT03710200|Other|ICARDA+sourdough|Icarda bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
75323587|NCT03554330|Other|Radiofrequency catheter ablation|(1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).
75323588|NCT03554330|Other|Balloon atrial septostomy|Graded balloon atrial septostomy is performed in all patients.
75629405|NCT05104515|Biological|OVM-200|"The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer."
75629406|NCT05100888|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Theta-burst stimulation
75323589|NCT02995031|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-177)
75323590|NCT02995031|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75323591|NCT01272089|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
75467589|NCT01930682|Procedure|Early post-fibrinolytic catheterisation|Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
75467590|NCT01930682|Procedure|Primary PCI|For STEMI Patients,primary PCI is performed within 12 hours after the onset.
75629407|NCT05097391|Behavioral|Warm-up (5 minutes)|Participants will benefit from passive stretches of hamstrings, calf muscles including a range of motion (ROM) exercise to the lower limbs as mat exercises.
75629408|NCT05097391|Behavioral|Conventional physiotherapy exercise (15 minutes)|The conventional treatments will be active-assisted and free active exercises to the lower limbs on the mat for five (5) minutes. This will be followed by strength training such as sit-to-stand exercises for five (5) minutes and squatting exercises for five (5) minutes prior to the over-ground training.
75780737|NCT03710200|Other|Grossi+sourdough|Grossi bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
75916272|NCT00993018|Drug|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
75916273|NCT00993018|Drug|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
75916274|NCT00993018|Drug|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
76075127|NCT05125289|Other|Proprioceptive Neuromuscular Facilitation stretching group|"Moist hot pack (10 minutes)~Isometric quadriceps exercises (10 repetitions)~Straight leg raise (10 repetitions)~PNF technique steps:~The subject is in supine position with his non-dominant leg strapped down the table while the dominant leg rests on the therapist right shoulder.~The therapist stretches the hamstring muscle until the subject first reports a mild stretch sensation; held for 7 sec by passively flexing the hip with knee fully extended, allowing no hip rotation.~Next, the subject isometrically contracts the hamstring muscle for 3 sec and then relax for 5 sec.~This sequence is repeated 5 times at a 20 second interval."
75467591|NCT01930708|Drug|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
75467592|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 60 degrees.
75467593|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
75467594|NCT01930734|Drug|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
75780738|NCT01217762|Device|IRay|Low voltage stereotactic radiotherapy system
75780739|NCT01121432|Procedure|endobronchial ultrasound-guided transbronchial needle aspiration|One time for aspiration/biopsy. The duration about 1-2 hour.
75780740|NCT05682274|Procedure|Partial restoration approach combined with CAF+CTG|The location of the CEJ prior to the restorative treatment was identified using the method developed by Zuchelli et al. 2006. The placement of the apical margin of the restoration was performed either at the level of estimated cementoenamel junction (CEJ) or within 1 mm apical to the CEJ. Two weeks after the restorative treatment, all recession defects were treated with CAF combined with CTG.
75780741|NCT01215266|Drug|Sorafenib|Day 3-21 2x2 800 mg(milligram) daily
75780742|NCT01215266|Drug|Placebo|Day 3-21 2x2 800 mg(milligram) daily
75467595|NCT01930734|Drug|Normal Saline|Normal Saline solution 0.9% Placebo Arm
75651707|NCT05828329|Behavioral|Guided visualization of exams through traditional method|During 4 weeks (twice per week), students will listen a 30-minutes audio that explains the experience of an exam from first person.
75651708|NCT05828134|Other|protein-enriched soup|The participants in experimental group have a protein-enriched soup a day and do exercise a week
75780743|NCT05682196|Drug|Rituximab added to standard of care treatment|Rituximab with standard of care treatment
75780744|NCT05682196|Drug|standard of care treatment|Standard of care treatment alone
75916275|NCT00993018|Drug|Placebo|Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
75916276|NCT01117584|Drug|ipragliflozin|oral tablet
75916277|NCT01117584|Drug|Placebo|oral tablet
75916278|NCT01117584|Drug|Metformin|oral tablet
75916279|NCT03135054|Drug|Quizartinib|Quizartinib is an oral FLT3 receptor tyrosine kinase inhibitor
76075128|NCT00835198|Drug|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
75629409|NCT05097391|Behavioral|Over-ground training with lower limb loading (15-25 minutes)|"Participants will perform the over-ground training exercise with an external 1.5kg load on the paretic lower limb placed 2cm above the ankle joint. Before commencing the over-ground training, all the participants will observe a pre-exercise rest period of about two (2) minutes during which their heart rate and blood pressure measurements will be recorded.~The over-ground training will involve the patients walking within a demarcated path. Each participant will be instructed to stand and walk 15meters to and fro for five (5) minutes after which they will be asked to stop and rest for two (2) minutes. The over ground training exercise will be repeated 3 times in the first 2 weeks of the training (15 minutes); 4 times in weeks 3-4 of the training (20 minutes); and 5 times in weeks 5-8 of the training (25 minutes)."
75629410|NCT05081401|Other|This is a non-intervention observational study.|No applicable intervention. This is a secondary data analysis observational study.
75916280|NCT03135054|Drug|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
76075129|NCT00835198|Drug|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
75323592|NCT01278563|Behavioral|Low glycemic index diet|dietitian interview and counselling for the low glycemic index diet group
75629411|NCT05075252|Procedure|laparoscopic lavage|This study aims to investigate the impact of laparoscopic lavage on the incidence of postoperative abscesses stratifying patients on the grade of appendicitis and peritoneal contamination.
75323593|NCT00748657|Biological|Bevacizumab|Given IV
75629412|NCT05070780|Device|Robot-assisted examination|evaluation of muscle tone with Robot-assisted perturbation
75629413|NCT05063461|Device|Tetanic stimulation|For each participant, record the first concentration that ANI≥50 after the tetanic stimuli, as the sufficient concentration.
75629414|NCT05063461|Procedure|Skin incision|Infuse the sufficient concentration for at least 5min of the steady-state period, then surgical stimulus is applied. The surgical stimulus is defined as the first skin incision to establish pneumoperitoneum.
75629415|NCT05057507|Diagnostic Test|Atrial cardiac magnetic resonance imaging|To include assessment of atrial size, shape, function, fibrosis and fat
75916281|NCT00991068|Drug|Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch|Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
76075130|NCT04636073|Device|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
75323594|NCT00748657|Other|Laboratory Biomarker Analysis|Correlative studies
75323595|NCT02994953|Drug|Avelumab|Subjects will receive avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
75323596|NCT02994953|Drug|M9241|Subjects will receive Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
75629416|NCT05057507|Diagnostic Test|Atrial electro-anatomic mapping|To include assessment of atrial voltage and local activation time
75629417|NCT05057507|Other|Atrial fibrillation symptom questionnaire|To include assessment of atrial fibrillation symptoms and quality of life
75629418|NCT05057507|Diagnostic Test|Patch-based 2 week ambulatory monitor|To assess atrial fibrillation burden post-ablation
75629419|NCT05046444|Diagnostic Test|Next Generation Sequencing|NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
75629420|NCT05032131|Biological|ADSVF|Group 1 and 2 : Escalating dose of ADSVF injection (5 millions of cells, 10 millions of cells and 20 millions of cells).
75629421|NCT05028621|Diagnostic Test|Genetic testing|Genetic testing of blood or tissue sample and limited medical information sent to an outside company. Database will link genome sequence data with human trait information, including cancer and other diseases, to be sent to participant's physician.
75629422|NCT05028309|Other|Mechanical unloading of the Thorax using an external cuirass|External cuirass (i.e., a plastic shell over the thorax) will be used to mechanically unload the chest wall. The cuirass has different operating modes. It can generate a constant negative pressure over the chest wall (e.g., -20cmH2O) or it can be triggered off mouth flow so it can generate a negative pressure on the chest wall during inspiration (e.g., -21cmH2O) and a positive pressure during expiration (e.g., +7cmH2O).
75629423|NCT05026619|Other|Information about age-related fertility|"The following information is provided:~Age and fertility IVF success rates and side effects"
75629424|NCT05026619|Other|Information about policy initiatives|"The following information is provided:~Assisted reproductive technology treatment subsidies Other fertility-related policies"
75629425|NCT05026619|Other|Information about diabetes|"The following information is provided:~Diabetes risk factors and treatment Diabetes-related policies"
75629426|NCT05023070|Drug|Cannabidiol|Cannabidiol 200 mg
75629427|NCT05023070|Drug|Cannabidiol|Cannabidiol 400 mg
75629428|NCT05023070|Drug|Cannabidiol|Epidiolex 400 mg
75629429|NCT05023070|Drug|Cannabidiol|Cannabidiol 400 mg
75629430|NCT05003713|Drug|CORT125236|CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
75629431|NCT05003713|Drug|Placebo matching CORT125236|Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
75916282|NCT01328444|Drug|GSK 573719 +GW642444 125/25|125mcg/ 25mcg
75323597|NCT02994953|Drug|Avelumab (Once weekly)|Subjects will receive avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
75323598|NCT02994953|Drug|M9241 (MTD)|Subjects will receive M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
75323599|NCT02994953|Drug|Avelumab (Expansion cohort)|Subjects in the expansion cohorts will receive Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
75916283|NCT01328444|Drug|GSK573719 + GW642444 62.5/25|62.5mcg/25mcg
75916284|NCT01328444|Drug|GSK 573719 125|125mcg
75916285|NCT01328444|Drug|GSK 573719 62.5|62.5mcg
75916286|NCT01328444|Drug|GW642444 25|25mcg
75629432|NCT05003713|Drug|Prednisone|Prednisone tablet 25 mg (20 mg + 5 mg tablets) for oral administration
75629433|NCT04980794|Behavioral|Parent-child intervention|Families (two adult caregivers, child between 4 and 17) receive four interactive, asynchronous psychoeducation modules to review on their own paired with weekly contact with a communication coach and two live sessions with a communication coach to discuss psychoeducation, receive feedback on their interactions, and practice a communication technique.
75629434|NCT04980794|Behavioral|Self-study Intervention|Families (two adult caregivers) receive information in a newsletter format to review on their own, paired with weekly contact from a communication coach to answer questions and direct their attention toward specific topics in the newsletter.
75629435|NCT04980781|Behavioral|Physical exercise and dietary therapy (PED-t)|Behavioral therapy: Physical exercise and dietary therapy (PED-t) is a treatment of bulimia nervosa and binge eating disorder, relying on guided, progressive resistance exercise therapy and dietary therapy (dietary education and group discussions) following a designed therapy manual.
75323600|NCT05249660|Other|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
75323601|NCT05249660|Other|Comparator: Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
75323602|NCT01272895|Device|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
75323603|NCT05244902|Drug|5% Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
75629436|NCT04980781|Procedure|Implementation program for PED-t in ERC|Participating in a training program for therapists in PED-t; to increase knowledge of eating disorders and to be able to implement and run the PED-t. Training program consists of a therapy manual, digital lectures, and 3 work shops.
75323604|NCT00717977|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor for 3-7 days
75323605|NCT01272973|Drug|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
75629437|NCT04961645|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"TMS is a safe and noninvasive method for affecting brain function relying on the properties of electromagnetic induction. Action potentials are triggered in neurons, along with a subsequent period of deactivation. Normal ongoing brain activity is disrupted providing a way for investigators to produce a transient and reversible period of brain disruption.~Participants will be seated comfortably in a chair and asked to complete either a simple computer-based task or a simple behavioral task that will require them to walk around in a small room. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur. The entire visit will last about one and a half hours."
75629438|NCT04955002|Other|No intervention|No intervention
75651709|NCT05825521|Other|MRI|During management, patients with hydrocephalus will be subjected to flow MRI and diffusion MRI. Flow parameters and diffusion parameters will be measured and compared to those found in control subjects receiving the same type of imaging
75780745|NCT03936374|Drug|BMS-986205|Participants will receive BMS-986205 on Days 1 and 15
75780746|NCT03936374|Drug|omeprazole|Participants will receive omeprazole on Days 10 to 15
75780747|NCT05366920|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
75780748|NCT05366920|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with 5mm suction irrigation blunt dissection starting from fundus
75780749|NCT01219790|Radiation|external radiotherapy|All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
75916287|NCT01328444|Drug|Plb|Comparator
75916288|NCT01114698|Drug|Venlafaxine XR|Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.
75323606|NCT01272973|Drug|placebo|Placebo (oral) administered once daily for 10 weeks.
75780750|NCT01219790|Drug|Acide zoledronic|The administration of zoledronic acid as defined under the Authorisation on the Market.
75916289|NCT01114698|Drug|Placebo|Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
75916290|NCT01114698|Drug|JNJ26489112|JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
75916291|NCT01114308|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
75916292|NCT01114308|Drug|placebo implant|Implant contains ethylene vinyl acetate
75916293|NCT01114308|Drug|Buprenorphine|sublingual buprenorphine/naloxone tablets
75323607|NCT01272973|Drug|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
75323608|NCT02924636|Behavioral|ePPOP-ID program|This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
75323609|NCT01273051|Drug|Capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
75323610|NCT01273051|Radiation|radiotherapy|radiation 25x2 Gy
76075131|NCT00835510|Drug|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
76075132|NCT00835510|Drug|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
76075133|NCT00835510|Drug|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
76075134|NCT01954745|Drug|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
75629439|NCT04943484|Procedure|imaging fluorescence NIR/ICG|"Preoperative upper GI endoscopy (UGE) UGE with submucosal injection of 2ml of ICG 0.125mg/ml solution to four peritumoral sites 15-20 hours before surgery Surgery D2 Distal gastrectomy with dissection of 1, 3, 4sb, 4sd, 5, 6, 7, 8a, 9, 11p, 12a lymph node stations (LNS) D2 Total gastrectomy with dissection of 1, 2, 3, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d, 12a LNS Intraoperative NIR/ICG technology, change of surgical conduct (CSC) A visualization of the operative field (OF) with NIR/ICG technology is performed at the beginning of surgery and before to dissect each LNS. Subsequently, surgery is performed with the naked eye.~At the end, a visualization of the OF is performed using NIR/ICG technology to verify whether residual lymph nodes in each D2 nodal station exist. CSC is defined as the occurring of the following situation: in case of persistence of nodal fluorescence in D2 nodal stations, the completion of the dissection of the residual nodal fluorescent structures."
76075135|NCT00835900|Drug|varenicline|variable dosing schedule
76075136|NCT00835900|Drug|placebo|placebo
75323611|NCT01273051|Procedure|TME resection|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation. Patients who do not respond or clinically have a T3 tumour either on visual measurements or post therapy MRI or endoanal ultrasound will be operated on with a TME resection 8 - 10 weeks after the last chemo radiation treatment.
75323612|NCT01273051|Procedure|TEM surgery|"All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation.Patients with a significant downsizing of the tumour (T0-T2) will be operated on by TEM surgery 8 -10 weeks after the last chemo radiation treatment.~After TEM surgery, pathological assessment will dictate further treatment. Conservative treatment with careful follow-up will be performed in patients with a complete resection of a ypT0-1 rectal tumour. Patients with lymphangio invasion, an incomplete resected ypT1 (<2 mm margin), an ypT2 or ypT3 tumour after TEM will subsequently undergo TME surgery to remove the rectum within 4 weeks."
75629440|NCT04907370|Drug|PD-1 blocking antibody|"IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1"
75629441|NCT04907370|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
75780751|NCT05682040|Diagnostic Test|Bedside Compression Ultrasonography|Point of Care Ultrasound (Bedside Compression Ultrasonography) vs formal lower extremity Doppler
75780752|NCT03936296|Procedure|mpMR guided MR-US fusion transrectal prostate biopsy|mpMR images will be loaded to US fusion platform and registration of the will be performed. Suspicious lesions on MR which have PIRADS score 3 and above are targeted. Additional 2-4 cores biopsies will be taken them
75916294|NCT05469126|Drug|LY3502970|Administered orally.
75916295|NCT05469126|Drug|Clarithromycin|Administered orally.
75916296|NCT04905836|Biological|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
75323613|NCT02994875|Dietary Supplement|N-acetylcysteine|NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
75323614|NCT02994875|Other|Placebo|Sugar pill
75780753|NCT03936296|Procedure|12 core standard transrectal prostate biopsy|Under the guidance of transrectal ultrasonography, 12 core biopsies taken from apex, apex lateral, mid, mid lateral, base and base lateral of right and left prostate lobe
75916297|NCT04905836|Drug|Placebo|Excipient solution
75916298|NCT00887250|Drug|losartan potassium|50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
75916299|NCT00887250|Drug|Comparator: losartan|50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
75916300|NCT00887250|Drug|Comparator: Placebo|Placebo to Losartan
75916301|NCT04859192|Other|gamified flipped classroom|moodle will be gamified
75916302|NCT03463616|Radiation|CT abdomen|CT scan of abdomen for metastasis staging of rectal cancer
75916303|NCT03463616|Radiation|MRI abdomen|MRI of abdomen for metastasis staging of rectal cancer
75916304|NCT00990912|Drug|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
75916305|NCT00990912|Drug|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
75916306|NCT00990912|Drug|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
76075137|NCT03838900|Device|Loop|The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
76075138|NCT01954121|Drug|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~Down-titration Period (Week 30 up to Week 33)"
76075139|NCT01954121|Drug|Carbamazepine|"Immediate release tablets at a strength of 200 mg.~Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~Down-titration Period (Week 30 up to Week 33)"
76075140|NCT04635761|Behavioral|Educational Intervention|Complete AIR Program and receive the High-Risk Lung Cancer Tip Sheet
75323615|NCT03809143|Drug|RBP-6000|All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
75323616|NCT02390960|Drug|Sildenafil Cream|Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
75629442|NCT04907370|Drug|Cisplatin (80mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
75467596|NCT01930760|Behavioral|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
75629443|NCT04907370|Drug|Cisplatin (100mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
75629444|NCT04907370|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
75629445|NCT04903054|Biological|Lulizumab|Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.
75629446|NCT04903054|Drug|Tacrolimus|Standard of Care: Renal transplant rejection prophylaxis.
75916307|NCT00886470|Biological|ST266|ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
75916308|NCT03460574|Behavioral|INFORMATION|After receiving expectation-disconfirming positive performance feedback, participants receive standardized information that stresses the relevance of this experience. In particular, participants are told that the performance test they worked on is highly relevant for both professional success and personal life satisfaction.
75916309|NCT03460574|Behavioral|SALIENCE|After receiving expectation-disconfirming positive performance feedback, partcipants in this condition are instructed to remember how well they performed on the performance test. Using a visual analogue scale, they were asked to specify how they performed relative to the other participants.
75629447|NCT04903054|Biological|Thymoglobulin®|Standard of Care: Renal transplant rejection prophylaxis.
75916310|NCT03460574|Behavioral|ATTENTION|Before working on the performance test, participants are instructed to pay attention to the feedback they receive. In particular, they are asked to enter what would be a personally good result for them. It is supposed that this shift of attention increases the salience of the expectation-disconfirming feedback.
75916311|NCT03460574|Behavioral|CONTROL|This group does not receive any further intervention. Instead, participants of this group pass through the standard procedure of the EXPEC paradigm.
75916312|NCT00973284|Biological|Norwalk VLP vaccine|Norwalk VLP vaccine dry powder
75916313|NCT00973284|Biological|mannitol and sucrose|Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder
76075141|NCT04635761|Behavioral|Questionnaire Administration|Ancillary studies
75323617|NCT02390960|Drug|Placebo Cream|Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
75629448|NCT04903054|Drug|Methylprednisolone|Standard of Care: Renal transplant rejection prophylaxis.
75629449|NCT04903054|Drug|Mycophenolate Mofetil|Standard of Care: Renal transplant rejection prophylaxis.
75629450|NCT04903054|Drug|Prednisone|Standard of Care: Renal transplant rejection prophylaxis.
75629451|NCT04894747|Dietary Supplement|Bolus ingestion of protein|Ingestion of 25g of protein
75629452|NCT04892147|Behavioral|Mobility-Oriented Behavioral Activation|12-weeks of mobility-oriented behavioral activation group
75916314|NCT00973284|Biological|Norwalk virus|Norwalk virus solution
75916315|NCT03893162|Dietary Supplement|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains:~Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.~Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram."
75323618|NCT02390960|Device|Penile Plethysmography (RigiScan)|During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
75323619|NCT03808831|Device|Fall detection and prevention system|The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
75323620|NCT03808831|Device|Sham fall detection and prevention system|The sham system with record but no alert function
75323621|NCT04270331|Other|PADS protocol|Assessment and management per PADS protocol
75629453|NCT04890249|Device|Investigational IOL Model C1V000|IOL replaces the natural lens removed during cataract surgery.
75629454|NCT04890249|Device|Investigational IOL Model C2V000|IOL replaces the natural lens removed during cataract surgery.
75629455|NCT04890249|Device|Control IOL Model ICB00|IOL replaces the natural lens removed during cataract surgery.
75629456|NCT04881838|Drug|P regimen|Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
75629457|NCT04881838|Drug|Course A1 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
75629458|NCT04881838|Drug|Course B1 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
75629459|NCT04881838|Drug|Course A2 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
75629460|NCT04881838|Drug|Course B2 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
75629461|NCT04881838|Drug|Course A3 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
75629462|NCT04881838|Drug|Course B3 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
75629463|NCT04881838|Drug|Maintenance therapy|Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
75629464|NCT04875234|Device|Clear-K Low Vision Aid Treatment|A Clear-K Low Vision Aid Device is used to produce small corneal shape and refraction changes in order to redirect light onto functional areas of the retina.
75629465|NCT04874051|Device|Experimental Group|The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.
75629466|NCT04874051|Other|Control Group|The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.
75629467|NCT04873245|Behavioral|Intensive Behavioral Program|Participants randomized to this group will receive intensive behavioral therapy.
75629468|NCT04873245|Drug|Semaglutide and Behavioral Program|Participants randomized to this group will receive semaglutide and behavioral therapy.
75629469|NCT04863014|Drug|evinacumab|Intravenous infusion every 4 weeks (Q4W)
75629470|NCT04863014|Other|Placebo|Intravenous infusion Q4W
75629471|NCT04846413|Other|Speech task|Speech task which consists of a sustained emission of the vowel /e/.
75629472|NCT04839289|Device|Receiver-in-canal hearing instrument; Manufacturer A|Commercially available receiver-in-canal hearing instrument from manufacturer A
75629473|NCT04839289|Device|Receiver-in-canal hearing instrument; Manufacturer B|Commercially available receiver-in-canal hearing instrument from manufacturer B
75629474|NCT04834557|Drug|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
75629475|NCT04834557|Drug|Digoxin 0.25 mg|All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
75916316|NCT03893162|Other|Placebo|Visually identical capsules in identical packaging containing no active bacteria.
75629476|NCT04834557|Drug|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
75629477|NCT04825093|Dietary Supplement|Vitamin D supplementation in pregnant women|Intervention group will be administered 1,000 UI of vitamin D and a control group will be administered 400 UI of vitamin D. Participants will take the supplementation from the enrollment to delivery.
75629478|NCT04820478|Dietary Supplement|Beta Hydroxybutyrate Ester (KetoneAid KE4)|see arm/group description
75629479|NCT04820478|Dietary Supplement|Placebo|see arm/group description
75629480|NCT04797039|Procedure|MR guided cryoablation|MR guided cryoablation of focal biopsy proven prostate cancer
75629481|NCT04793152|Drug|Vancomycin|Administration as outlined
75780754|NCT05085964|Drug|RNA antisense oligonucleotide for intravitreal injection|"QR-421a will be first administered to the fellow eye (as defined in the preceding study), and will be repeated every 6 months.~Treatment of the study eye (as defined in the preceding study) can commence 3 months (9 months for subjects from study PQ-421a-001) after the treatment of the fellow eye has been initiated and will be repeated every 6 months as well.~Continued subject treatment in this study will be pursued provided that the benefit-risk balance is positive for the individual subject."
75780755|NCT01215500|Radiation|Hypofractionated RT|"RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:~For all sites the dose levels are as follows:~8 Gy/ fraction x 3 fractions = 24 Gy~10 Gy/fraction x 3 fractions = 30 Gy~12 Gy/fraction x 3 fractions = 36 Gy~14 Gy/fraction x 3 fractions = 42 Gy~16 Gy/fraction x 3 fractions = 48 Gy~18 Gy/fraction x 3 fractions = 52 Gy~20 Gy/fraction x 3 fractions = 60 Gy"
75780756|NCT01125488|Device|LNG-IUS|levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years
75916317|NCT02599402|Drug|Nivolumab|
75916318|NCT02599402|Drug|Ipilimumab|
75916319|NCT00879762|Biological|IMVAMUNE® High Dose|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10^8 TCID50 (5×10^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
75780757|NCT01125488|Drug|GnRH agonist (triptorelin)|GnRH agonist (triptorelin 3.75 mg, sc q28day)
75780758|NCT01215578|Drug|Sutent|sunitinib 37.5 mg/day (per os) for 6 months
75780759|NCT01215656|Dietary Supplement|Lactobacillus fermentum|
75780760|NCT01215656|Dietary Supplement|Follow on formula without probiotics|
75780761|NCT01120418|Drug|Besifloxacin Ophthalmic Suspension 0.6%|administered 3 times a day for 5 days to one eye.
75780762|NCT03706378|Other|Glucose Reference 1|Glucose contains 50g of available carbohydrates
75916320|NCT00879762|Drug|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
75916321|NCT00879762|Biological|IMVAMUNE® Standard Dose|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route on Day 0 and 28 at standard dose (diluted with saline by study pharmacist to (1×10^8 tissue culture infectious dose 50 [TCID50] per 0.5 mL dose)
75916322|NCT03463538|Procedure|arthroscopic capsular release|surgical release of shoulder joint capsule
75916323|NCT03463538|Procedure|Hydro-dilatation|dilatation of shoulder joint capsule using water pressure under local anesthetic
75629482|NCT04787978|Other|Physical Activity and Education Intervention|"The intervention involves peer teams, health coaches and community health workers [CHW]. Each participant will be assigned to a CHW and grouped into a team of 10-20 participants based on participant proximity to a Columbus Recreation and Parks Center. Each team will be assigned 4 health coaches, 2 medical students, 1 undergraduate student and 1 nursing student from OSU Health Sciences Colleges.~The lifestyle intervention is 24 weeks consisting of 1 hour and 15 minutes of in person training time per week. The training time consists of 45 minutes of physical activity and 30 minutes of educational content was informed by evidence-based strategies and stakeholder feedback.~Health coaches will implement the curriculum based on the Diabetes Prevention Program and the American Heart Association Check, Change, Control Program and develop team-based SMART (specific, measurable, achievable, relevant, and time-bound) wellness goals."
75629483|NCT04773483|Dietary Supplement|Quorn Foods products|180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)
75629484|NCT04773483|Dietary Supplement|Meat/fish products|Standard meat/fish products matched to Quorn group for protein intake
75323622|NCT00759967|Procedure|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
75629485|NCT04770493|Drug|Lamotrigine|Participants will be randomized to lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks. A comparator group will receive placebo (sugar pills).
75780763|NCT03706378|Other|Glucose Reference 2|Glucose contains 50g of available carbohydrates
75780764|NCT03706378|Other|Glucose Reference 3|Glucose contains 50g of available carbohydrates
75780765|NCT03706378|Other|Wheat Yellow Noodle|Wheat Yellow Noodle will contain 50g of available carbohydrate
75916324|NCT05212194|Other|examination|Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.
75916325|NCT03460496|Behavioral|neonatologists|will continue to be contact persons for the APN, even after hospital discharge, and will be available for 3 fixed outpatient consultations with the APN and families that have difficulty getting to a paediatrician, because they live in a rural area with no paediatrician.
75916326|NCT03460496|Behavioral|psychological support|Psychological support will be standard for all families. In a first consultation, psychologist and family will decide about long-term psychological support. They will have at least 3 follow-up consultations during hospital stay and one before discharge; specific psychological interventions will be provided. The aim of the interventions is to re-establish emotional stability and improve the ability of parents to cope with the situation, to prevent parental and family adaptive disorders and child developmental disorders. Support focus on screening for psychological disorders. Techniques include family-centred, holistic interventions (e.g. activating parental resources and coping, crisis intervention, stabilization techniques etc.). Parents will receive outpatient psychological support.
75323623|NCT00759967|Procedure|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
75323624|NCT02394548|Radiation|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
75323625|NCT04385953|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
75323626|NCT02769806|Procedure|MRI|
75323627|NCT03808519|Dietary Supplement|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
75629486|NCT04770493|Drug|Placebo|Matching placebo (sugar pill)
75651710|NCT05818423|Behavioral|Brain Health Academy|The Brain Health Academy group will review online content about brain health (1 hour, 2 days/week for 12 weeks) and will complete a brief survey after each module to assess compliance (30 hours total).
75780766|NCT03706378|Other|Beta-glucan yellow Noodle|Beta-glucan yellow noodle will contain 50g of available carbohydrate
75780767|NCT03706378|Other|Rice Roll|Rice Roll will contain 50g of available carbohydrate
75780768|NCT03706378|Other|Rice Roll with resistant starch|Rice Roll fortified with resistant starch will contain 50g of available carbohydrate
75780769|NCT03706378|Other|Sucrose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of sucrose
75780770|NCT03706378|Other|Isomaltulose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of Isomaltulose
75323628|NCT03808519|Dietary Supplement|Placebo|Organic Sunflower Oil 5000mg per day
75323629|NCT03139838|Behavioral|EHR-Based Intervention A|Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
76075142|NCT04634045|Behavioral|Web Based Treatment|The literature regarding the efficacy of web-based platforms for behavioral weight management interventions in pediatric populations continues to grow. Considering the continued increase in technology and internet use among youth, web-based interventions have the potential to serve as a more cost-effective and personalized approach to pediatric behavioral weight management. Extant research supports this consideration. More research that compares web-based vs. traditional delivery of acceptance-based pediatric behavioral weight management interventions is necessary to understand the utility of this platform as well as which aspects are most effective.
75629487|NCT04763993|Procedure|Roux-en-Y-Gastric bypass, Sleeve gastrectomy|RYGBP consists in creating a small gastric pouch along the little curvature of the stomach, followed by the section of the small bowel. The restoration of the gastro-intestinal tract is achieved by performing a gastro-jejunal and a jejuno-jejunal anastomosis, giving this procedure the characteristic aspect of a Y. Also, for RYGBP the laparoscopic approach requires the placement of 5 trocars in the upper part of the abdomen.
75629488|NCT04763993|Procedure|SG|SG consists in removing the fundus and the body of the stomach, along the greater curvature. To perform it with a laparoscopic approach, we create the pneumoperitoneum with Veress needle and place 5 trocars in the upper part of the abdomen. The first step is the dissection of the greater curvature of the stomach, that starts at 6 centimetres from pylorus and it's conducted up to the angle of His, freeing the fundus and exposing the left pillar. A 38 Fr bougie is placed inside the stomach to calibrate its section. After it is carried out, the specimen is removed from the greater trocar site.
76075143|NCT00850642|Drug|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
76075144|NCT00850642|Drug|Placebo|"Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"
75629489|NCT04761432|Device|neoGuard|NeoGuard is a wireless wearable vital signs monitor that continuously measures temperature, pulse rate, respiratory rate and oxygen saturation.
75629490|NCT04745117|Behavioral|READHY - questionnaire|The READHY tool consists of 70 questions divided into three sections, one with a focus on eHealth literacy, one on self-management and one on the social context. The READHY consists of the eHealth Literacy Questionnaire (eHLQ) that includes seven scales, supplemented with four scales from the Health Education Impact Questionnaire (heiQ) and two scales from the Health Literacy Questionnaire (HLQ). The READHY tool has been validated. Each question presented to the participant as a statement and scored on a 4-point rating, from 1=strongly disagree to 4=strongly agree. The overall score of each scale was calculated as the mean score of the 4-6 items (i.e., statements) that constitute the scale (2).
75629491|NCT04741464|Drug|Tinzaparin|"Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.~Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT."
76075145|NCT00836758|Device|Analysis with AED and manual PSG scoring|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
75629492|NCT04740892|Other|Wash IP|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
76075146|NCT00852592|Device|7000lux broad-spectrum light|dosage - 15-60minutes NOON-2PM daily
75916327|NCT03460496|Behavioral|lactation consultant|during hospitalization, the lactation consultant will be involved more frequently than during standard care. Breastfeeding support will take a structured approach and will be performed in close collaboration with both parents. The main aims of structured breastfeeding support are strengthen parent-child bonding. Infants will be breastfed according to their needs. Parents will become competent in meeting their child's nutritional needs. After discharge, parents may schedule outpatient breastfeeding consultations.
76075147|NCT00852592|Device|50lux dim red light|dosage: 15-60minutes NOON-2PM daily
75323630|NCT03139838|Behavioral|EHR-Based Intervention B|Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
75323631|NCT00720473|Drug|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
75629493|NCT04740892|Other|Cream IP|Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
76075148|NCT01952015|Biological|Secukinumab|Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
76075149|NCT00838006|Device|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
75323632|NCT00637832|Biological|rituximab|
75323633|NCT00637832|Drug|cyclophosphamide|
75323634|NCT00637832|Drug|doxorubicin hydrochloride|
75323635|NCT00637832|Drug|prednisolone|
75323636|NCT00637832|Drug|vincristine sulfate|
75323637|NCT00637832|Radiation|yttrium Y 90 ibritumomab tiuxetan|
75323638|NCT01277887|Behavioral|Cognitive-Behavioral Counseling|The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.
76075150|NCT00838006|Device|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
76075151|NCT00838006|Device|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
76075152|NCT01951703|Device|senofilcon A|Control, senfilcon A
76075153|NCT01951703|Device|senofilcon A|Test, senofilcon A
75323639|NCT01277887|Behavioral|Smoking Cessation Counseling|The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
75323640|NCT04276454|Device|Flexitouch Plus system|A single treatment for external lymphedema using the FDA-approved Flexitouch Plus device.
75467597|NCT01930760|Behavioral|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
75467598|NCT01930773|Device|Genotyping|Patients harboring CYP2C19 *2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
75629494|NCT04727047|Device|neuromuscular electrical stimulation|All subjects will receive standard rehabilitation for Achilles tendon repair. In addition, neuromuscular electrical stimulation will be applied to the calf muscles of the injured leg. The stimulation volume, the electrode placement and the intensity of the stimulation will be selected based on the mechanical strength of healing Achilles tendon. The intervention will be applied for 6 weeks after repair.
75629495|NCT04715893|Device|Ostomy belt|Stealth ostomy belt continuous for eight weeks
75629496|NCT04698564|Drug|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) [ 13C]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize [13C]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and [13C]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as [1- 13C]pyruvate, [2- 13C]pyruvate and [1,2- 13C]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body [Koletzko et al., 1997]."
75629497|NCT04685265|Drug|anle138b|capsule containing excipient and anle138b
75629498|NCT04685265|Drug|Placebo|matching placebo capsule containing excipient
75629499|NCT04663555|Drug|Dexamethasone|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.
75629500|NCT04662632|Combination Product|VT-X7 Treatment System|Seven-day local antibiotic irrigation (alternating tobramycin sulfate and vancomycin HCl) via the VT-X7 Knee or Hip Spacer.
76075154|NCT00838162|Drug|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
75323641|NCT00720629|Drug|Visilizumab|3 mg/m^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
75323642|NCT00720629|Drug|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
75629501|NCT04662632|Drug|SOC|Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per SOC. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
75629502|NCT04662632|Procedure|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
75629503|NCT04662320|Device|Checkpoint BEST System|"Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair.~Other Name: Checkpoint BEST System"
75629504|NCT04630262|Device|ATTUNE Cementless CR Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.
75629505|NCT04630262|Device|ATTUNE Cementless PS Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.
75629506|NCT04616417|Procedure|Investigational Oocyte Cryopreservation|Transvaginal oocyte retrieval under ultrasound guidance
75629507|NCT04581369|Other|Care Coordinator Intervention for Direct Intervention Group|"The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers.~The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes.~The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians."
76075155|NCT00838162|Drug|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
76075156|NCT00838162|Drug|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
76075157|NCT00838162|Drug|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
76075158|NCT00838162|Drug|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
76075159|NCT00838162|Drug|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
75323643|NCT00720629|Drug|Methotrexate|15 mg/m^2 intravenously (IV) on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
75323644|NCT00720629|Drug|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
75323645|NCT00720629|Drug|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
75323646|NCT00720629|Drug|Methotrexate|15 mg/m^2 IV on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
75467599|NCT01930773|Device|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
75467600|NCT01930786|Drug|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
75916328|NCT03460496|Behavioral|physiotherapeutic interventions|physiotherapeutic interventions will also be structured. The physiotherapist will make an assessment during hospitalization, and decide which physiotherapeutic interventions are necessary. Each family will learn how to handle their premature child in everyday life, based on the child's developmental stage, in a single consultation.
75916329|NCT03460496|Behavioral|social workers|social workers will closely collaborate with the APN within the transitional model. They will be involved with every family and will assist the APN in establishing a network with social and medical services within and outside the clinic. They will also support families in coping with daily life and with their integration into society, family and work. Furthermore, they will give advice on social security issues and on asserting claims as well as clarify financial possibilities.
75629508|NCT04581369|Other|Care Coordinator Intervention for Standard of Care Group|For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge. Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months. This is the extent of interventions received for participants in this arm.
76075160|NCT01937351|Device|Pantheris System|Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
75916330|NCT03460496|Behavioral|music therapy|music therapy with premature infants and their parents creates a new dimension of contact, and helps stabilize the child and supports their development through music. It also reduces the anxiety of parents, and enhances self-efficacy and makes them more sensitive to their child 74,75, thus enhancing the parent-child relationship. In standard care, music therapy is offered only during hospitalization. In the new model of care, after NICU discharge, the program will offer 10 follow-up sessions at the family's home or in the music therapists' private practice.
75629509|NCT04581369|Other|Caregiver Intervention|Caregivers of the participants will be assessed for caregiver burden at 3 time points.
75629510|NCT04569136|Other|Education|The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
75629511|NCT04569136|Other|Therapeutic ultrasound|Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.
76075161|NCT00853606|Drug|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
76075162|NCT00841204|Drug|sulindac|Given orally
76075163|NCT00841204|Other|placebo|Inactive agent
75323647|NCT04759820|Drug|injecting Carbon Nanoparticles Suspension|injecting Carbon Nanoparticles Suspension for lymph node detection
75323648|NCT04759820|Drug|Injecting indocyanine green|Injecting indocyanine green for lymph node detection
75323649|NCT01272167|Behavioral|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
75467601|NCT01930812|Procedure|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
75467602|NCT01930812|Procedure|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
75467603|NCT01930812|Drug|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
75467604|NCT01930838|Procedure|Gastric bypass operation|
75629512|NCT04569136|Other|Sham ultrasound|Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.
75629513|NCT04569136|Other|Breast massage|Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
76075164|NCT00841204|Other|laboratory biomarker analysis|Correlative studies
76075165|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
75323650|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
75323651|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
75323652|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
75323653|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
75467605|NCT01930851|Procedure|Gastric bypass operation|
75467606|NCT01930864|Drug|metformin|metformin up to 2500mg/d
75467607|NCT01930864|Drug|irinotecan|Irinotecan 350 mg/m² IV q21d
75467608|NCT01930877|Drug|Lidocaine|Lidocaine iv bolus followed by infusion
75467609|NCT01930877|Other|Placebo (normal saline)|Normal saline bolus followed by infusion
75467610|NCT01930903|Device|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
75916331|NCT03460496|Behavioral|other health care professionals|the APN will contact and involve other health care professionals, like the family's paediatrician, the outpatient midwife, the community health care nurse or the mother and father counselling as soon as need becomes evident. The APN will help set up meetings between health care professionals and the family, and will keep them up-to-date on the family's situation.
75323654|NCT03183830|Dietary Supplement|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
75629514|NCT04569136|Other|Usual obstetric care|Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
75629515|NCT04565288|Drug|Atomoxetine|Participants randomized to receive the study medication, atomoxetine (brand name: Straterra) for 6-weeks (40 mg/day for 3 days then 80 mg/day thereafter). A comparator group will receive placebo (sugar pills).
75629516|NCT04565288|Drug|Placebo|Matching placebo (sugar pill)
75916332|NCT03460496|Behavioral|interprofessional roundtable meetings|interprofessional roundtable meetings with health care professionals involved in the care of a specific family will be held every two weeks. The meeting is aimed at developing consensus on the best possible support in the care of preterm infants and their families. Parents will be invited to participate in these meetings, led by the APN. The meeting will focus on two family situations, and then determine and initiate supportive interventions in collaboration with the parents.
75323655|NCT03183830|Dietary Supplement|Nitrate-deplete Beetroot Juice|"See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day."
75323656|NCT00721175|Device|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
75629517|NCT04560361|Other|Electroacupuncture treatment|Continue the electroacupuncture treatment as described above for 30 minutes.
75629518|NCT04560361|Other|Sham electroacupuncture treatment|Continue the sham electroacupuncture treatment as described above for 30 minutes.
75629519|NCT04544865|Device|Staple Line Reinforcement|ENDOPATH ECHELON Staple Line Reinforcement is used for reinforcement of staple lines during lung resection and bariatric surgical procedures, according to instructions for use.
75629520|NCT04511130|Drug|MT-401|MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
75629521|NCT04501393|Other|Clear liquid intake|Clear oral fluid including water, pulp-free juice and tea or coffee without milk
75629522|NCT04496024|Drug|ofloxacin|ofloxacin treatment in patients with bone and joint infections
76075166|NCT00853840|Drug|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
75780771|NCT01121510|Device|closure device|the invasive specialist must carefully manage the difficult balance of patient anticoagulation and coagulation for stopping the bleeding at the femoral artery puncture site. the QuickClose design 9 system is designed to benefit the patients and the medical staff by improving the process. the risks to patients associated with this study are considered reasonable in comparison to the anticipated benefits to the subjects, and the scientific knowledge that can be gained from the study.
75780772|NCT01125644|Drug|SPK-843|SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
75916333|NCT03460496|Behavioral|Advanced practice nurses' interventions|The APN will participate in comprehensively planning individual discharge, coordinating services, consulting with other healthcare professionals, assessing needs on a case by case basis, and coaching the family from birth to 6 months after discharge from the NICU. The APN will provide the Newborn Behavioral Observation (NBO), an infant-centred and family-focused method for building relationships, to parents and children, during and after hospitalization. The NBO helps sensitize parents to their infant's competencies and capabilities, teaching them to read their infant's signals and understand their behaviours. It promotes positive interactions between parent and preterm infant. The APN will also offer telephone support and follow-up Visits at home after discharge.
75916334|NCT01101906|Drug|OSI-906|OSI-906 administered orally
75916335|NCT01101906|Drug|Placebo|Matching placebo administered orally
76075167|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
76075168|NCT00853840|Drug|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
76075169|NCT01737697|Drug|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
75629523|NCT04496024|Other|questionnaire|questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
75629524|NCT04496024|Biological|Ofloxacin Serum concentration|Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
75629525|NCT04487171|Other|Questionnaire|The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.
75629526|NCT04482114|Radiation|ULD CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
75629527|NCT04442399|Behavioral|Family Connections|Ten intervention sessions were covered, ranging form understanding HIV and to handling stigma and discrimination.
75629528|NCT04440813|Behavioral|Education and Training by Clinicians|Training in the use of PPE and education about the risks of blood exposure.
75323657|NCT00721175|Device|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
75323658|NCT05245760|Drug|Intravenous Tislelizumab|Participants will receive 200mg, every three weeks for up to 51 weeks
75629529|NCT04440813|Behavioral|Training and Education from Traditional Healers and Clinicians|Training in the use of PPE and education about the risks of blood exposure.
75629530|NCT04425473|Drug|Esketamine|Esketamine will be administrated intravenously when suturing incision, with total dose of 0.2mg/kg and continuous infusion for 40 minutes.
75629531|NCT04425473|Drug|Normal saline|Equivalent amount of normal saline will be administrated intravenously suturing incision.
75629532|NCT04394468|Device|PlasmaJet|Data will be collected during two contact moments, in particular during her admission for surgical laparoscopy, and during her postoperative check-up. Both of these are standard of care. No additional questionnaires will be taken. During the admission the postoperative pain scoreswill be monitored and collected. The duration of her stay in the hospital will also be recorded. During the postoperative check-up, which takes usually place six weeks after the surgery, complications will registered.
75629533|NCT04387071|Biological|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Given IT
75629534|NCT04387071|Drug|VLP-encapsulated TLR9 Agonist CMP-001|Given SC and IT
75629535|NCT04385017|Other|COVID-19 patients|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
75629536|NCT04377490|Other|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge
75629537|NCT04377490|Biological|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge
75629538|NCT04374708|Diagnostic Test|fMRI|fMRI: body morph test and neurocognitive testing
75780773|NCT05577988|Other|single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.|"Individuals without genetic loss of function to metabolize clopidogrel: stop DAPT and switch to a single antiplatelet therapy by clopidogrel.~Individuals with genetic loss of function to metabolize clopidogrel (*2/*3, 1/*3, *2/*2, *1/*2): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.~Individuals with fast metabolization of clopidogrel (*1/*17 or *17/*17): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin."
75323659|NCT05245760|Drug|Chemotherapy|Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
75323660|NCT05245760|Radiation|Fractionated radiation|Concurrent with chemo, x5 weeks
75323661|NCT05245760|Procedure|Esophagectomy|Surgical resection of cancer after chemoradiation therapy when no disease progression found.
75780774|NCT01222052|Drug|5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel|"Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks"
75323662|NCT03808285|Other|mandibular osteomylitis|
76075170|NCT01737697|Drug|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
76075171|NCT01737697|Drug|Placebo (acute phase)|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
75323663|NCT03808363|Other|High Intensity Interval Training|Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
75323664|NCT01278641|Behavioral|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
75629539|NCT04367805|Diagnostic Test|nasopharyngeal Covid 19 RT-PCR|nasopharyngeal Covid 19 RT-PCR
75629540|NCT04366752|Other|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge
75629541|NCT04366752|Other|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge
75629542|NCT04336995|Diagnostic Test|contrast echocardiography|giving echocardiographic contrast and taking echocardiographic images before and after exercise
75629543|NCT04307381|Drug|Donidalorsen|Donidalorsen administered SC
75629544|NCT04300920|Drug|N-acetyl cysteine|600 mg N-acetylcysteine (NAC) oral tablets three times daily for 24 months.
75629545|NCT04300920|Drug|Placebo|Matching oral placebo tablet three times daily for 24 months.
75629546|NCT04287075|Procedure|Surgical Management of Neuroma|Surgical procedures targeted to treat the source of a participant's chronic, neuropathic pain
75629547|NCT04286568|Behavioral|WOW Intervention|Health education and coaching, health care navigation,
75629548|NCT04285515|Drug|Lumateperone|Lumateperone 42mg oral capsule
75629549|NCT04285515|Drug|Placebos|Placebo oral capsule
75629550|NCT04270734|Procedure|EEG|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed
75629551|NCT04270734|Procedure|NIRS|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
75651711|NCT05818423|Behavioral|Brain Health Together|The Brain Health Together group will participate in online, live-streaming, group-based Moving Together classes (1 hour/week); Brain Health education group classes (1 hour/week) and individual brain health coaching sessions (0.5 hours/week) for 12 weeks (30 hours total).
75651712|NCT05818423|Behavioral|Maintain Brain Health Together|The Maintaining Brain Health Together group will participate in the full Brain Health Together program (30 hours) for 12 weeks followed by weekly group classes and six individual coaching for an additional 12 weeks (additional 15 hours).
75629552|NCT04262232|Behavioral|Adapted Ca-HELP for Geriatric Cancer Patients|Intervention group: This intervention will be informed by social-cognitive theory10-13 and modeled after the tailored education and coaching intervention (TEC) used for Ca-HELP previously and consists of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
75629553|NCT04252768|Drug|Eftilagimod Alpha|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
75629554|NCT04252768|Drug|Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15.
75629555|NCT04246944|Procedure|harvesting induced membrane|The induced membrane will be harvested during the second step of the bone reconstruction.
75629556|NCT04233073|Drug|andexanet alfa|Andexanet is a recombinant version of human FXa
75629557|NCT04221763|Device|His-bundle pacing.|Cardiac resynchronisation therapy can be achieved using biventricular pacing involving placement of three leads into the right atrium, right ventricle and coronary sinus (epicardial left ventricle). Alternatively the third lead may be placed at the bundle of His or left ventricular septum to pace the left bundle directly.
75629558|NCT04186585|Drug|BP-C2|Oral daily intake
75629559|NCT04183803|Procedure|anatomic anterior cruciate ligament (ACL) reconstruction|The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
75651713|NCT05817929|Other|blood sample|5 ml blood sample will be withdrawn at the surgery start and at the surgery end
75780775|NCT03710044|Drug|Cyclosporine A|"Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks."
75780776|NCT01222208|Dietary Supplement|Oral Nutrition with dextrose and pressurized whey protein|Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.
75780777|NCT01222208|Dietary Supplement|Peripheral Parenteral Nutrition|Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
75916336|NCT04778384|Behavioral|Micro-training to promote self-management in pain therapy|Micro-training according to the checklist & targeted discussion / dismantling of patient-related barriers based on the answers in the second part of the questionnaire (BQII Barriers Questionnaire) In this discussion, the nurses give their opinion on any patient-related barriers that become apparent after completing the second part of the questionnaire. This is not done according to a fixed template, but with the specialist knowledge and everyday experience of the nurse.
75916337|NCT04778384|Other|Sham intervention|An unstructured conversation is carried out. Patient questions are answered correctly, but there is no training, rather patient information.
75323665|NCT01278641|Behavioral|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
75323666|NCT02674958|Drug|Aspirin|Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
75780778|NCT03706300|Drug|Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg|
75780779|NCT03934892|Diagnostic Test|serum lactate|check lactate levels during cardiopulmonary bypass in adult cardiac operations
75780780|NCT05082220|Procedure|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
75323667|NCT04385771|Device|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
75323668|NCT04385771|Device|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
75780781|NCT01219868|Behavioral|Physician-nurse team supervision|Physician-nurse team will supervise patient's flow in the ED
75780782|NCT05160142|Behavioral|DICE|10-week culinary and nutrition education program for children with type I diabetes
75780783|NCT03932006|Drug|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
75323669|NCT00760435|Drug|Infliximab|5 mg/kg IV over 2 hours once
75323670|NCT00760435|Drug|Placebo|Placebo (same volume as active drug)
75323671|NCT02144597|Dietary Supplement|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
75651714|NCT05816785|Drug|Cetuximab|Week 1: loading dose of 400mg/m2; Week 2: 250mg/m2
75651715|NCT05816785|Drug|Imatinib|400 mg orally daily
75651716|NCT05813418|Biological|blood retriewal|blood retriewal for cytokine concentration measurement
75651717|NCT05807386|Behavioral|Home-based exercise programme|A 12 week, online delivered, home-based exercise programme.
75629560|NCT04169646|Other|Multi-component intervention|Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
75629561|NCT04169646|Other|Control|No intervention takes place during the control phase.
75780784|NCT03932006|Drug|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
75916338|NCT00879606|Drug|ALT-836|In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
75323672|NCT02144597|Procedure|Roux-en-Y gastric bypass (RYGB)|Participant went through Roux-en-Y gastric bypass (RYGB) surgery
75780785|NCT03932006|Drug|Imrecoxib|Imrecoxib 0.1g twice a day,orally
75780786|NCT04737226|Diagnostic Test|myotonometric assessment|The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.
75323673|NCT02144597|Other|Control diet|
75323674|NCT03808129|Drug|Bupivacaine and Lidocaine|ESP block was administered under general anesthesia before the surgery. Patients with ESP block, 1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine
75916339|NCT00879606|Drug|Placebo|In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
75916340|NCT04768166|Drug|Miglustat 100 MG|100mg/TID in 4w then 200mg/TID in 8 w
75916341|NCT04822090|Other|Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)|red cell transfusion; plasma exchange; renal replacement therapy; intravenous immunoglobulin. plasma exchange
75916342|NCT00962832|Drug|Placebo|Placebo was supplied as a sterile liquid solution.
75916343|NCT00962832|Drug|Rontalizumab|Rontalizumab was supplied as a sterile liquid solution.
76075172|NCT01737697|Drug|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
76075173|NCT00853996|Drug|acolbifene hydrochloride|Given orally
75323675|NCT01273285|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
75323676|NCT00749125|Drug|Lexapro|10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
75323677|NCT02144675|Drug|choline magnesium trisalicylate|Given PO
75323678|NCT02144675|Drug|idarubicin|Given IV
75323679|NCT02144675|Drug|cytarabine|Given IV
75323680|NCT02144675|Other|laboratory biomarker analysis|Correlative studies
75323681|NCT00721253|Device|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
75323682|NCT00721253|Device|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
75629562|NCT04165694|Procedure|Single Anastomosis Duodenal Ileal Bypass (SADI)|The purpose of the research is to study additional weight loss and resolution of comorbidities in patients who undergo revision of their sleeve gastrectomy to a Single Anastomosis Duodenal Ileal bypass (SADI). The sleeve gastrectomy which you have already undergone is now the most common bariatric procedure performed. This operation was part of a 2-stage operation known a Duodenal Switch (DS) which was a sleeve gastrectomy followed by a long bypass of the intestine that involved 2 connections. This operation has many complications such as vitamin deficiencies and potential malnutrition. The SADI procedure is a version of the DS that bypasses less of the intestine and one less connection of the small bowel.
75629563|NCT04159571|Device|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; active sham coil (double blinded)
75780787|NCT04737226|Diagnostic Test|Ankle mobility assessment|The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.
75916344|NCT03463382|Procedure|Erector Spinae Plane Block|Erector Spinae Plane block will be administered under general anesthesia before the surgery
75916345|NCT03463382|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block will be administered under general anesthesia before the surgery
75916346|NCT03463382|Drug|Bupivacaine (Block Drug)|0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
76075174|NCT00841828|Drug|Epirubicin|
76075175|NCT00841828|Drug|Cyclophosphamide|
76075176|NCT00841828|Drug|Docetaxel|
76075177|NCT00841828|Drug|Lapatinib|
76075178|NCT00841828|Drug|Trastuzumab|
76075179|NCT00855010|Drug|pioglitazone|pioglitazone 45 mg daily
76075180|NCT00855010|Drug|placebo|one daily
76075181|NCT00855868|Drug|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
75323683|NCT00721253|Device|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
75323684|NCT00749515|Drug|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
75323685|NCT00749515|Drug|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
75629564|NCT04159571|Device|Sham cTBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
76075182|NCT00855868|Drug|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose [11C]-PIB
76075183|NCT00842296|Device|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
76075184|NCT00842608|Behavioral|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can & cannot receive Haldol"
75629565|NCT04159571|Device|Real TBS to the dlPFC|This will be delivered with the Magventure Magpro system; active sham coil (double blinded).
76075185|NCT00842608|Procedure|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
76075186|NCT00842608|Drug|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
76075187|NCT00842608|Procedure|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
76075188|NCT00856024|Biological|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
76075189|NCT00856024|Drug|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
75629566|NCT04159571|Device|Sham TBS to the dlPFC|The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
75629567|NCT04156386|Dietary Supplement|Recovery animal (20g whey) protein supplement|Animal protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
75629568|NCT04156386|Dietary Supplement|Recover vegan (26g pea) protein supplement|Vegan protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
75780788|NCT01222364|Procedure|Standard Cord Clamping|Immediate clamping (<5 seconds) of the umbilical cord after delivery.
76075190|NCT00856414|Biological|botulinum toxin Type A|20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
76075191|NCT00843466|Other|Mild, moisturizing hand cleanser|"Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water"
76075192|NCT00856726|Drug|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
76075193|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
76075194|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
75323686|NCT00749515|Radiation|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
75629569|NCT04156386|Dietary Supplement|Placebo (32g maltodextrin)|Placebo consumed post exercise to aid recovery of muscle function following strenuous exercise.
75629570|NCT04133701|Behavioral|Time-Restricted Feeding|After baseline measurements have been completed, participants will enroll in a time-restricted feeding intervention. Participants will be asked to restrict the time in which they eat each day to 10 hours, fasting for the remaining 14 hours. Participants will also be asked to finish their last meal of the day at least 2 hours prior to bedtime.
75629571|NCT04120116|Drug|FX-322 (One Dose)|Patients will receive one dose of FX-322.
75916347|NCT04427566|Radiation|Radiation therapy|Patients will be treated with a single dose of 80 cGy to the bilateral lungs in a manner that is simplified such that it can be designed and delivered quickly in one session. No specific normal tissue constraints are employed in this protocol.
75629572|NCT04120116|Drug|FX-322 (Two Doses)|Patients will receive two doses of FX-322.
75629573|NCT04120116|Drug|FX-322 (Four Doses)|Patients will receive four doses of FX-322.
75629574|NCT04120116|Drug|Placebo|Patients will receive Placebo.
75629575|NCT04116736|Device|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
75629576|NCT04116736|Device|Silicone Hydrogel Contact Lens|Any reusable spherical silicone hydrogel brand that is approved and marketed in the country conducting the study.
75780789|NCT01222364|Procedure|Delayed Cord Clamping|Clamping of the umbilical cord at 30-45 seconds after birth.
75780790|NCT05155540|Device|Trevo and or Merci devices for stent retreival|FDA approved devices for stent retrieval during mechanical thrombectomy
75780791|NCT05155540|Device|Penumbra system for stent aspiration|FDA approved devices for stent aspiration during mechanical thrombectomy
75780792|NCT05155540|Drug|recombinant tissue plasminogen activator|FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
75780793|NCT01329224|Other|Measurement of platelet anti-aggregation|Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
75916348|NCT04452812|Biological|Convalescent plasma|"Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
76075195|NCT03696784|Biological|iC9-CAR19 T cells|iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
75323687|NCT00707447|Behavioral|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
75629577|NCT04115553|Diagnostic Test|MRI examination|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. Standard MRI examination using a 32-channel head coil consists of angiographic, morphological and phase-contrast 2D flow sequences. The flow planes are set perpendicularly to the structure axis (blood or CSF regions). The velocity measured in the pixels inside the region of interest allow the calculation of a mean flow rate as well as the volume displaced during a cardiac cycle.
75629578|NCT04115553|Diagnostic Test|ECG|A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
75780794|NCT01122836|Other|Massage|Therapeutic Massage
75780795|NCT05155384|Other|Pain Neuroscience Education|main topics of pain neuroscience education; neurophysiology of the nervous system, protective mechanism of pain, acute pain formation and chronic pain, factors that increase/reduce pain, central sensitization mechanism, neuroplasticity and treatment strategies in chronic pain.
75323688|NCT00707447|Behavioral|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
75323689|NCT03807895|Behavioral|REBT Career Intervention|Eight sessions of regular career intervention with rational emotive behavioral therapy (REBT) methods.
75323690|NCT03807895|Behavioral|Regular Career Intervention|Eight sessions of regular career intervention.
75629579|NCT04103762|Procedure|laparoscopic cholecystectomy|laparoscopic cholecystectomy
75629580|NCT04103762|Diagnostic Test|systematic intraoperative cholangiography|systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)
75629581|NCT04099706|Procedure|Autologous Fat Grafting / Fat Transplant|See arm descriptions.
75780796|NCT05155384|Other|Relaxation exercises|Relaxation exercises are a training based on deep relaxation techniques and visual imagery. Relaxation exercises will be applied at the end of the training sessions.
75780797|NCT05155384|Other|Cognition target exercise|Cognition target exercises are a time-based approach that is not symptom-conditioned (not based on fatigue or pain). It includes functional and dynamic exercises.
75780798|NCT05155384|Other|Pelvic floor stretching exercises|Pelvic floor stretching exercises; consists of stretching exercises involving the pelvic floor muscles and surrounding group muscles (such as piriformis, hamstring, adductor group muscles and lumbar extensors).
75780799|NCT05155384|Device|Transcutaneous electrical nerve stimulation|It will be used with superficial electrodes attached to the suprapubic region of the patients for 20 minutes in each session.
75916349|NCT04814758|Diagnostic Test|MRI DWI sequence (ADC values)|Initially and after pre-operative chemotherapy To evaluate the differences in ADC values according to the malignancy degree of nephroblastoma in children
75916350|NCT00879138|Drug|VA106483|
75916351|NCT00879138|Drug|Sugar pill|
75916352|NCT04821700|Biological|Carotid Stenosis|To investigate if the concurrent presence of carotid stenosis has any effect on future outcomes of patients with ischemic stroke and atrial fibrillation
75916353|NCT04452734|Procedure|Platelet Rich Plasma (PRP)|PRP was prepared by withdrawing 8-10 ml of patients own blood (IV from antecubiodal area and collected in a vacuum tube coated with anticoagulant (Na citrate). For activation 1 ml of calcium chloride was added to Platelet Rich Plasma. This layer of approximately 2 ml of PRP was then taken into the residual bone cavity along with gel sponge to stimulate regeneration in wound healing after surgical extraction of mandibular third molar tooth followed by sutures
75916354|NCT04452734|Procedure|Surgical Extraction|Surgical extraction procedure under Local anesthesia on dental chair, followed by spongstone (gel sponge) and suture placement.
75916355|NCT00876798|Drug|Lixivaptan|Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
75916356|NCT00876798|Drug|Placebo|Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
75916357|NCT04814836|Procedure|Total-etch mode with 35% phosphoric acid (K-ETCHANT) (TE-A group)|35% phosphoric acid was applied to enamel and dentin for 10 s, washed and dried for 5 s. The universal adhesive, Clearfil Universal Bond Quick (CBQ) was applied to enamel and dentin surfaces with a single-use applicator, then gently air-dried for 5 s without waiting, and light-cured for 10 s.
76075196|NCT03696784|Drug|Bendamustine|70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
75323691|NCT00749671|Device|Bispectral index monitoring|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
75323692|NCT00749671|Other|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
75323693|NCT01272323|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
75323694|NCT01272323|Biological|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
75629582|NCT04084171|Device|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor [CGM].
75629583|NCT04080414|Behavioral|Home-based high-intensity interval training|Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
75629584|NCT04080414|Behavioral|Home-based moderate-intensity continuous exercise|Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
75629585|NCT04075318|Biological|UB-312|A synthetic peptide-based vaccine
75467611|NCT01930916|Device|INR capillary measurement with INRatio 2 device|INR capillary measurement with INRatio 2 device
75467612|NCT01930916|Other|antiphospholipid antibodies and lupus anticoagulant|Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
75323695|NCT01272323|Biological|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
75467613|NCT01930929|Procedure|Bariatric surgery|
76075197|NCT03696784|Drug|Fludarabine|30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion
75467614|NCT01930942|Radiation|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
75467615|NCT01931007|Drug|Autologous Bone Marrow Aspirate Concentrate|Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
75629586|NCT04075318|Biological|Placebo|Matching placebo
75629587|NCT04060589|Other|Tissue donation|Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
75629588|NCT04060589|Other|Blood Donation|Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
75629589|NCT04060589|Other|Urine Donation|Urine will be collected prior to prostate biopsy
76075198|NCT03696784|Drug|AP1903|"0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS."
75323696|NCT01272557|Drug|Doxorubicin|Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
75323697|NCT01272557|Drug|Sorafenib|Sorafenib 400 mg bid (oral) continuously
75323698|NCT01272713|Other|Oxygen therapy|"Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~In-hospital oxygen as per hospital protocol"
76075199|NCT03696784|Drug|Cyclophosphamide|500 mg/m2/day administered by IV over 3 consecutive days
76075200|NCT00857506|Drug|florbetapir F 18|370 Mega Becquerel (10 mCi)
75323699|NCT01272713|Other|No oxygen therapy|No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
75323700|NCT00762307|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
75467616|NCT01931007|Drug|Sterile saline|Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
75467617|NCT01931020|Drug|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
75467618|NCT01931020|Drug|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
75629590|NCT04060589|Other|Healthcare data linkage|Men will consent to healthcare data linkage via national databases.
75629591|NCT04050644|Drug|Preservative Free drop treatment|Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
75629592|NCT04050644|Drug|Preserved drop treatment|Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
75323701|NCT01273025|Dietary Supplement|Lime powder regime|1 sachet of lime powder regimen with 200 ml of water
75323702|NCT00639002|Drug|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
75323703|NCT00639002|Drug|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
75323704|NCT00761137|Drug|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
75323705|NCT00761137|Drug|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
75629593|NCT04047706|Biological|IDO1 Inhibitor BMS-986205|Given PO
75629594|NCT04047706|Biological|Nivolumab|Given IV
75629595|NCT04047706|Radiation|Radiation Therapy|Undergo radiation therapy
75629596|NCT04047706|Drug|Temozolomide|Given PO
75780800|NCT01122914|Drug|Anakinra|
75323706|NCT00761137|Drug|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
75629597|NCT04042493|Behavioral|Connect for Health|The program includes (1) electronic health record (EHR)-based clinical decision support tools to guide pediatric providers in child weight management; (2) clinician and medical staff training in obesity management best practices, (3) family educational materials focused on evidence-based behavioral targets; and (4) social- and community-informed text messages for parents to support behavior change.
75629598|NCT04041089|Behavioral|Recognition of objects|"Name of shapes / colors / images / objects~Classification of shapes / colors / images / objects"
75629599|NCT04041089|Behavioral|Location of objects|"Search for frequent/rarse targets among distractors sharing one or more characteristics with the target~Hit/catch a stationary/mobile target as quickly as possible"
75629600|NCT04041089|Behavioral|Manipulation of objects|"Storage of shapes/objects~Use of everyday objects (pen, cutlery, etc.)"
75629601|NCT04029623|Other|Partnered Rhythmic Rehabilitation (PRR)|Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
75916358|NCT04814836|Procedure|Selective-etch mode with 35% phosphoric acid (K-ETCHANT) (SE-A group)|35% phosphoric acid was used only on enamel for 10 s, then washed and dried for 5 seconds. Subsequently, the adhesive was applied in a similar manner to the TE-A group.
75916359|NCT04814836|Procedure|Total-etch mode with Er, Cr: YSGG laser (Waterlase MD) (TE-L group)|the enamel margin and dentin surfaces of lesions were irradiated with an Er,Cr:YSGG laser (2780 nm, Waterlase MD, BioLase Technology, Inc., San Clemente, CA). Then the adhesive was applied in a similar manner to the TE-A group.
75916360|NCT04814836|Procedure|Selective-etch mode with Er, Cr: YSGG laser (Waterlase MD) (SE-L group).|The laser system was applied in the same way as described in the TE-L group only on enamel surface. Subsequently, the adhesive was applied in the same way as described in the TE-A group.
75323707|NCT00761137|Drug|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
75323708|NCT01273103|Drug|200mg [14C]- GSK2248761|single oral suspension dose of [14C]- GSK2248761 200 mg
75916361|NCT04814836|Procedure|Self-etch mode Clearfil Universal Bond Quick (Kuraray, Japan) (SE group)|Universal adhesive system (CBQ) was applied to enamel and dentin surfaces without any previous etching. Then gently air-dried for 5 s without waiting, and light-cured for 10 s.
75916362|NCT03460418|Other|Phone contact|Assessment of the different outcomes by means of a phone contact
75916363|NCT03460340|Device|prefrontal deep rTMS of H1 Coil|prefrontal deep rTMS of H1 Coil
75916364|NCT03463226|Diagnostic Test|Cardiopulmonary exercise test|Oxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.
75323709|NCT04386161|Other|Scheduled exercise program|45 minutes of stretching, strengthening, and balance-coordination exercises and 20 minutes of balance training on the Balance Master® device twice a week for six weeks
75323710|NCT02575118|Device|Restoration of dental caries with dental composite|
75323711|NCT02145247|Drug|hCG|"3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4. Blood samples will be obtained at T = -0.5, 0, and +24 hours."
75323712|NCT00722111|Device|lingual press|lingual press (high-intensity, oral, non-swallowing)
75323713|NCT00722111|Behavioral|effortful swallowing|effortful swallowing (high-intensity swallowing)
75323714|NCT00722111|Behavioral|natural swallowing|natural swallowing (high frequency, low intensity swallowing)
75780801|NCT05360758|Other|Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia|Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia using laboratory tests, abdominal ultrasound, general condition of the patient and bone marrow
75780802|NCT01222442|Drug|AZD3199|Single dose, oral inhalation
75780803|NCT01222442|Drug|Moxifloxacin|Single dose, oral encapsulated tablet
75780804|NCT01222442|Other|Placebo comparator|Single dose, oral inhalation
75780805|NCT03709966|Device|Portable monitoring device|similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status
75780806|NCT03709966|Behavioral|Routine|Physical activity promotion supported by a kinesiologist
75780807|NCT03706222|Drug|elbasvir/grazoprevir|Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
75916365|NCT03463226|Diagnostic Test|Muscle Sympathetic Nerve Activity|Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.
75916366|NCT03463226|Diagnostic Test|Dual-energy X-ray absorptiometry|Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.
75323715|NCT00722111|Behavioral|non-oral sham (control) exercise|non-oral sham (control) exercise
75323716|NCT00638846|Device|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
75323717|NCT00638846|Device|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
75323718|NCT01273493|Drug|Trabectedin|Trabectedin 0.58 or 1.3 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1.
75323719|NCT01273493|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/m^2, 30 minutes prior to trabectedin.
75629602|NCT04029623|Other|Group walking (WALK)|WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
75629603|NCT04024150|Biological|Blood test|Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup
75629604|NCT04020432|Behavioral|questionary|"A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
75629605|NCT04020159|Other|Patient Registry|No intervention/treatment
75780808|NCT01222676|Drug|cisplatin|
75780809|NCT01222676|Drug|gemcitabine hydrochloride|
75780810|NCT01222676|Drug|sorafenib tosylate|
75780811|NCT01222676|Other|imaging biomarker analysis|
75780812|NCT01222676|Other|laboratory biomarker analysis|
75916367|NCT03463226|Diagnostic Test|Venous occlusion plethysmography|Venous occlusion plethysmography was used to assess non-invasively blood flow.
75916368|NCT03463226|Diagnostic Test|Blood sample collection|Blood samples were drawn in the morning after 12h overnight fasting.
75916369|NCT03463226|Diagnostic Test|Dynamometers for Handgrip Strength|Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.
75916370|NCT00875160|Drug|AT2101|225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
75323720|NCT00638456|Drug|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
75323721|NCT00638456|Drug|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
75323722|NCT01273571|Drug|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
75780813|NCT01222676|Procedure|computed tomography|
75916371|NCT04814290|Other|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 [SF-36]).|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 [SF-36]).
75916372|NCT00872430|Other|Placebo|In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.
75916373|NCT00872430|Other|Klein Laxative Tea|The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
75323723|NCT02147899|Drug|SYM-1219|Oral
75780814|NCT01222676|Procedure|neoadjuvant therapy|
75780815|NCT01222676|Radiation|fludeoxyglucose F 18|
75780816|NCT05681728|Drug|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
75780817|NCT05681728|Drug|Paclitaxel|On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
75780818|NCT05681728|Drug|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
75780819|NCT05681728|Drug|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
75780820|NCT03706144|Other|Prodigy Math Training|https://www.prodigygame.com/
75780821|NCT03931850|Procedure|Pudendal nerve block|Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
75780822|NCT03931928|Drug|(Z)-Endoxifen supplementation according to genotype|Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
75780823|NCT03931928|Drug|(Z)-Endoxifen supplementation according to plasma levels|Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, > 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and > 25 nM receive 0 mg (Placebo)
75780824|NCT05523310|Other|Daily questionnaire|All patients will be asked to complete a daily questionnaire regarding their migraine, medications, and prodromal symptoms during that day
75780825|NCT03934970|Diagnostic Test|Diffusion tensor imaging of peripheral nerves|All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.
75780826|NCT01220102|Drug|0.1% adapalene/ 2.5% benzoyl peroxide|topical application, once per day
75916374|NCT05617222|Other|Bed rest|5 days of strict bed rest
75916375|NCT05617222|Other|Neuromuscular electrical stimulation|Unilateral neuromuscular electrical stimulation (m. Quadriceps)
75916376|NCT04821388|Device|Rontis DCB|"The Rontis DCB is intended for use as a percutaneous transluminal angioplasty (PTA) catheter to dilate stenotic or obstructive vascular lesions in the lower extremities for the purpose of improving limb perfusion and decreasing the incidence of restenosis.~In this study, it is intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries"
75916377|NCT00872196|Drug|ABT-072|Blood samples are being taken from subjects previously treated with ABT-072.
75916378|NCT04813978|Other|Music|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
75916379|NCT00871182|Drug|Inhaled PT001|single dose, inhaled
75629606|NCT03999359|Other|Home-based Metacognitive Therapy|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
75916380|NCT00871182|Drug|Inhaled Placebo|single dose, inhaled
75323724|NCT02147899|Drug|Placebo|Oral
75629607|NCT03998397|Biological|blood alcohol concentration withdrawal|The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
75916381|NCT00871182|Drug|Tiotropium Handihaler|single dose, tiotropium 18 mcg administered via the Handihaler
75916382|NCT04821232|Other|yoga|"Content of education;~Breath Awareness Training (10 minutes)~Students will be checked on a routine basis~Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
75916383|NCT04821232|Other|Routin control|Students will be checked on a routine basis
75916384|NCT04814056|Drug|Afatinib Dimaleate|Afatinib is the second-generation TKI drug, which can irreversibly bind to receptors of erbB family. Afatinib will be administered orally at a dose of 40 mg per time, Q.D. If a patient cannot tolerate a dose of 40mg due to adverse reactions, when the adverse reactions restore to level 1 (CTCAE 5.0) or below, the dosage could be adjusted to 30mg per day, Q.D.
75916385|NCT04813744|Procedure|Atraumatic restorative treatment|
75916386|NCT05627310|Other|Diagnostic|Training dataset was used to train the deep learning model, which was validated and tested by external dataset.
75916387|NCT05617144|Other|Aromatherapy treatment|60 minutes after pain medication administration primary investigator will turn on the diffuser (manufacture ScentSationals)and administer aromatherapy with a mixture of four drops of lavender and four drops of peppermint for 60 minutes.
75916388|NCT04813432|Diagnostic Test|Computed Tomography of the Abdomen|"Multi-phasic CT scan of the abdomen: 1 low dose unenhanced scan + 10 low dose arterial perfusion scans + 1 portal-venous phase scan + 1 delayed phase scan.~Bolus-tracking threshold in abdominal aorta = 160 HU. Delay of first arterial scan 5 sec after bolus-tracking threshold has been reached; and then 1 scan every 3 sec until 35 sec after threshold.~Contrast media (CM) protocol: fixed injection duration: 25 sec, body weight-adjusted CM volume: 750 mgI/kg bodyweight (max 80 kg women, 100kg men), Iomeron 400mgI/ml.~Image-reconstruction: Motion-correction, noise-reduction and fusion of the best arterial time points to reconstruct one optimally timed early and one optimally timed late arterial phase."
75323725|NCT01273649|Device|cryotherapy|cryotherapy is given with other physical training
75323726|NCT02565992|Biological|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
75629608|NCT03987373|Other|non-interventional|This study is a non-interventional, observational study. After completing 12-month treatment from DACAB trial, investigators would not make any interventions or impact on subjects' therapeutic strategy.
75629609|NCT03976505|Other|reading a table format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
75629610|NCT03976505|Other|reading a textual format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
75323727|NCT02565992|Drug|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
75629611|NCT03976505|Other|filling a virtual pillbox displayed on the screen as prescribed in the prescription|filling a virtual pillbox displayed on the screen as prescribed in the prescription
75629612|NCT03976505|Other|eye-tracker|In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
75629613|NCT03976505|Other|cognitive tests and questionary|Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
75629614|NCT03969459|Biological|breast milk collection|3 samples of 20 ml of breast milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
75629615|NCT03969459|Biological|meconium collection|3 samples of 20 ml of meconium milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
75916389|NCT05627154|Drug|Citalopram|Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.
76075201|NCT00858130|Device|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
75323728|NCT03807583|Drug|Aminoven 10%|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~group A: RENORAL® product~group B: AMINOVEN® 10% product~group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care."
75323729|NCT03807583|Dietary Supplement|RENORAL|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~group A: RENORAL® product~group B: AMINOVEN® 10% product~group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care."
75629616|NCT03969459|Biological|newborn feces collection|3 samples of 20 ml of newborn feces will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
75629617|NCT03969459|Other|questionary of pesticide exposure of the mother|maternal questionary of pesticide exposure of the mother
75629618|NCT03967249|Drug|IONIS GHR-LRx|Participants will receive IONIS GHR-LRx by subcutaneous injection.
75629619|NCT03967249|Drug|Somatostatin Receptor Ligand (SRL)|Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
76075202|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
75780827|NCT05133310|Drug|Simvastatin|Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.
75629620|NCT03937102|Procedure|cardiac output measure with TTE|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
75629621|NCT03937102|Procedure|cardiac output measure with Physioflow® thoracic electrical bioimpedance|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
75629622|NCT03937050|Behavioral|Intervention|"Three film-based components:~Professional development of doctors and nurses to improve screening and management of GDM. Modules will cover knowledge and relevant clinical guidelines, skills for glucose monitoring and managing medication, specialist obstetric care, and lifestyle counselling. The films will be screened at professional development meetings.~Awareness-raising among pregnant women and family members regarding GDM and the importance of healthy lifestyles during pregnancy. The film will be culturally tailored and will be screened in waiting areas of antenatal clinics/electronic versions of the films will be made available for viewing on mobile devices.~Structured diabetes self-management programme for women with GDM to empower them with the necessary knowledge, skills, and confidence to manage GDM successfully. The programme will incorporate behavioural counselling and educational reinforcement. Films will be screened at group sessions/viewed on mobile devices."
75323730|NCT03802123|Drug|⁸⁹Zr-Df-IAB22M2C|⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)
75629623|NCT03935139|Biological|glucose measurement|Glucose values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
75629624|NCT03935139|Biological|lactacte measurement|Lactate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
75780828|NCT01217918|Drug|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
75916390|NCT05627154|Behavioral|Behavioural Activation|A NICE recommended psychological intervention for mild to moderate depression. In behavioural activation, the person with depression and the therapist work together to identify the relationships between the activities the person undertakes and their mood. It encourages people to become less mood-dependent when planning activities and doing constructive things that they would usually avoid doing.
75916391|NCT05627154|Drug|Placebo|A lactose-based tablet.
76075203|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
75323731|NCT00733343|Device|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
75323732|NCT00638378|Drug|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
75629625|NCT03935139|Biological|pyruvate measurement|pyruvate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
75629626|NCT03935139|Biological|glycerol measurement|glycerol values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
75629627|NCT03935139|Procedure|Bone free flap monitoring|Bone free flaps will be monitored with a microdialysis catheter directly positioned in bone tissue.
75629628|NCT03934632|Other|Postabsorptive|Saline will be infused to mimic postabsorptive circulating amino acid concentrations
75629629|NCT03934632|Other|Postprandial|An amino acid infusate will be administered to mimic postprandial circulating amino acid concentrations
75629630|NCT03934632|Procedure|Immobilisation|One leg will undergo 2 days immobilisation prior to the test day
75629631|NCT03926403|Other|"State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)"|"Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least lightly anxious about their management (score ≥ 36)."
75780829|NCT01217918|Drug|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
75780830|NCT01217918|Drug|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
75780831|NCT04576000|Drug|Janus Kinase Inhibitor|Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)
75780832|NCT01217996|Behavioral|Computerized working memory training program (intervention)|A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention
75916392|NCT04427176|Device|ARFC mask|Nurse will wear the ARFC mask during working days. The total duration of the study will be 48 hours for each participant, 2 consecutive working days of 8 or 12 hours.
75916393|NCT05627076|Device|Blood Sampling|Blood samples will be collected for the PSP measurement using the abioSCOPE.
76075204|NCT01682863|Drug|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
75780833|NCT01217996|Behavioral|Computerized working memory training program (control)|Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
75629632|NCT03926403|Procedure|hypnosis techniques|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
75629633|NCT03926403|Procedure|local anaesthesia|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
75629634|NCT03919188|Procedure|air temperature control (ATC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): second parameter : air temperature control (ATC)
75629635|NCT03919188|Procedure|skin servocontrol (SSC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): Third parameter : skin servocontrol (SSC).
75651718|NCT05805020|Procedure|cellvizio|During surgery an intravenous injection of fluorescein will be performed. The surgeon will, then, evaluate the ileal section margins on the mucosa, the serosa and the mesentery to evaluate if the section margin in microscopically inflammatory or not. She/he will then evaluate (in cm) the length between this section margin and the theorical section margin to be on a non-inflammatory tissue on the mucosa, serosa and mesentery. The data will be filled during surgery, blind from the pathological analysis. The pathological analysis will also be blind from the Cellvizio data. A video collection will be performed anonymously.
75780834|NCT03706066|Device|Acrysof IQ PanOptix IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
75916394|NCT04813666|Diagnostic Test|Urinary LAM ELISA:|
75916395|NCT04766346|Other|Fortified Cow's Milk-Based Oral Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form that provides the appropriate amount of energy and protein to promote growth in children.
75916396|NCT04813588|Other|Pantomiming|Pantomiming with fluency shaping techniques
75916397|NCT04813588|Other|Easy onset|Easy onset method with breathing exercises
75916398|NCT05379816|Procedure|5% DW perineural injection|5% DW perineural injection to intercostal nerve
75780835|NCT03706066|Procedure|Cataract surgery|Per investigator's standard of care
75780836|NCT03740750|Device|Thermacare heat wraps|low level continuous heat wrap
75916399|NCT05378022|Combination Product|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
75916400|NCT05378022|Drug|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
75916401|NCT04820608|Device|Cross-linking|Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.
75916402|NCT00957918|Drug|nicotine|Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
75916403|NCT00957918|Other|placebo comparator|oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
75916404|NCT04360720|Drug|Antiplatelet Monotherapy|"All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor or prasugrel alone until the end of the study, at Month 12."
75916405|NCT04474236|Other|thoracic lung ultrasound|Patients will be recruited the day of their hospital admission. All patients will be assessed by thoracic Computed Tomography scan then immediately before/after CT scan, patients will be clinically assessed (Q-SOFA, SpiO2/FiO2) and a lung ultrasound evaluation (mean time of evaluation 7 min +/- 3 min; fully respect of COVID-19 barrier measures) will be performed by an investigator. Patients clinical status and outcomes will be extracted from patient's medical file at day 1 and day 28 from patient's admission by investigators blinded from previously recorded lung ultrasound data.
76075205|NCT01682863|Drug|Placebo|To mimic QAB149
75780837|NCT03740750|Device|TENS|electrical stimulation
75780838|NCT03740750|Device|sham heat|expended heat wrap
75780839|NCT03740750|Device|sham Tens|tens applied but unit not turned on
75780840|NCT01222910|Drug|Valacyclovir hydrochloride|
75780841|NCT04533568|Drug|Ibuprofen 400 mg|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
75780842|NCT04533568|Drug|Dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
75916406|NCT02734862|Drug|CD101|Intravenous antifungal therapy
75916407|NCT02734862|Drug|Caspofungin|Intravenous antifungal therapy
75916408|NCT02734862|Drug|Fluconazole|oral antifungal therapy
75629636|NCT03907657|Drug|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
75780843|NCT01222988|Dietary Supplement|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
75916409|NCT02734862|Drug|intravenous placebo|normal saline
75916410|NCT02734862|Drug|oral placebo|microcrystalline cellulose
76075206|NCT02457832|Behavioral|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
76075207|NCT02457832|Behavioral|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
75629637|NCT03907657|Drug|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
75629638|NCT03897777|Behavioral|Exercise Training effect on Hypertension and Gut Dysbiosis|the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
75629639|NCT03877458|Other|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
75629640|NCT03877458|Other|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
75629641|NCT03877458|Other|Placebo|Taking 1 placebo capsule at bed time everyday for three months.
75780844|NCT03931694|Device|e-DOL|e-health program (smartphone and web platform)
75323733|NCT03807661|Procedure|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
75780845|NCT03705988|Device|Cranial Electrotherapy Stimulation(CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The current intensity could be adjusted continuously from 500 μA~2mA.
75780846|NCT03705988|Device|sham Cranial Electrotherapy Stimulation( sham CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The sham CES devices were identical to the active device, except the ear clip electrodes emit electricity intensity of lower than 100 μA.
75916411|NCT00818844|Drug|Nepafenac 0.1%|NSAID
75916412|NCT00818844|Other|BSS|BSS
75916413|NCT00862524|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
75916414|NCT00862524|Drug|Gemcitabine, nucleoside analogue; intravenous|multiple dose, single schedule
75916415|NCT03460262|Device|Standard cutiplast®|Our standard dressing consists in a usual ready-to-use Smith and Nephew Cutiplast®. This dressing is open 48 hours after the operation (CDC recommendation) for the first time and then changed every day after wound disinfection.
75916416|NCT03460262|Device|PICO®|PICO® is a negative pressure wound therapy consisting in a 4 layers ready-to-use dressing connected to a small console, responsible for the aspiration. The system is canister free. The fluid drained from the wound is lost by evaporation for 80% of it and only 20% remains in the dressing. This permits to the dressing to be kept in place for maximum 7 days. The wound is not checked during the hospital stay, allowing the patient to leave the hospital earlier after the operation.
75916417|NCT04427644|Procedure|Laparascopic Sleeve Gastrectomy|Operations performed for complciation of laparascopic sleeve gastrectomy
75916418|NCT04427644|Procedure|İnterventional radiologic drainage|İnterventional radiologic drainage of gastric leakage
75916419|NCT04427644|Diagnostic Test|Complte Blood Count and Biochemical evaluation|blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
76075208|NCT02417818|Device|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
75629642|NCT03871621|Drug|Diabetes Medicines|Anti-diabetic medications except SGLT2 inhibitors
75629643|NCT03871621|Drug|Dapagliflozin|Dapagliflozin tablet (10 mg)
75629644|NCT03867188|Drug|Liposomal Bupivacaine|A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
75780847|NCT01223144|Behavioral|Iowa Gambling Task and Ekman facial recognition test|"Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger)."
75629645|NCT03811743|Behavioral|Brenner FIT|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
76075209|NCT02417818|Device|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
75629646|NCT03811743|Behavioral|By Design|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
75629647|NCT03811743|Behavioral|Coordination|"This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment"
75780848|NCT05500924|Other|Intervention group|5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
75780849|NCT03934580|Other|hallucinated meal|a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis
75780850|NCT03934580|Other|Real meal|A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
75780851|NCT05494216|Other|PICSI|Sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
76075210|NCT01951625|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
76075211|NCT01951625|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
76075212|NCT01951625|Drug|Placebo|
75323734|NCT03807661|Device|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
75323735|NCT00762619|Drug|Fluoride|Brush twice daily
75323736|NCT00762619|Drug|Triclosan, fluoride|Brush twice daily
75323737|NCT05248568|Device|Core training|Core training lasts for 12 weeks, three times a week, one hour each time
75780852|NCT05494216|Other|MACS|Sperm selection using MACS for selecting sperm with lower DNA fragmentation index
75780853|NCT01312168|Device|Therapeutic CPAP|CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months
75780854|NCT01312168|Device|Subtherapeutic CPAP|Subtherapeutic CPAP ventilator, pressure <3 cmH2O, daily use at sleep, six months
75780855|NCT03934502|Drug|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
75780856|NCT01312246|Device|EnSeal Device|measurement of bursting pressure of colonic vessels after using the EnSeal Device
75780857|NCT05287282|Other|TECAR application|Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
75780858|NCT01123226|Procedure|spinal manipulation|A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
75916420|NCT04427644|Diagnostic Test|Computed tomography|Admitted to observe leakage
75916421|NCT00858702|Drug|olmesartan medoxomil and a CCB|olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks
75916422|NCT00858702|Drug|olmesartan medoxomil and a diuretic|olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
76075213|NCT04400890|Drug|Resveratrol|Resveratrol vs placebo given for 15 days.
76075214|NCT04400890|Dietary Supplement|Vitamin D3|Vitamin D3 100,000 IU given on day one.
76075215|NCT01936649|Drug|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
76075216|NCT04351438|Device|Active Comparator: centrifuge TPE with citrate|Patients who received citrate-based anticoagulation with centrifuge TPE
76075217|NCT04351438|Device|Active Comparator: Filter TPE with heparin|Patients who received heparin-based anticoagulation with filter TPE
76075218|NCT04351438|Drug|Active comparator: Filter TPE with citrate|Patients who received citrate-based anticoagulation with filter TPE
76075219|NCT04330846|Procedure|Surgical resection|The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
76075220|NCT01720069|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
76075221|NCT02337244|Device|Zimmer Persona Total Knee System|No Intervention
75323738|NCT02521142|Other|Non-invasive OCT based optical angiography|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
75629648|NCT03805451|Behavioral|Life Steps for PrEP for Youth|Life-Steps is a modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to pre-exposure prophylaxis.
75629649|NCT03773146|Other|1X Airtime Incentive|An incentive given in the form of airtime
75629650|NCT03773146|Other|Lottery Airtime Incentive|An incentive given in the form of airtime
75629651|NCT03758508|Device|High Flow Oxygen nasal cannula|High Flow Oxygen nasal cannula
75629652|NCT03758508|Device|Noninvasive ventilation|In this arm, participants receive noninvasive ventilation through an interface (such as full face mask or oro-nasal mask) alternated with continuous high flow oxygen though humidified nasal cannula
75629653|NCT03745040|Drug|Liposomal bupivacaine|20ml bupivacaine liposome injectable suspension 1.3% (266mg) + 50ml 0.25% Bupivacaine (150mg) + 70ml preservative-free 0.9% neutral saline
75629654|NCT03704532|Procedure|Operative treatment|Open surgical repair of tendon rupture
75780859|NCT01123226|Procedure|trigger point therapy|The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
75916423|NCT03460184|Diagnostic Test|G.A Group A:|"G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage."
75916424|NCT04427332|Other|Investigation of smell and taste disorders|The study consists of an epidemiological investigation by means of a prospective observational study with the aim of investigating the demographic and clinical factors related to the sense of smell and taste in patients with Sars Cov 2 infection.
75916425|NCT04735172|Other|specific MRI Acquisition (NMR spectroscopy) at 7T|"The MRI protocol will be performed at 7T on a Siemens NMR imaging system (Magnetom Terra, Siemens Healthcare, Erlangen, Germany), the radio frequency emission and signal reception will be done through a head quadrature resonator (64-channel phase-array coil). To avoid motion-related artifacts, the patient will be seated in a supine position, with the arms along the body and the head immobilized using a suitable head restraint. The MR protocol will take place in two phases:~Acquisition of 3D multi-slice T1 and T2-weighted morphological images to identify areas of interest;~Acquisition of 1D RMN spectra in the right and left putamen and STN. Spectra will be acquired in volumes of interest of 15mmx15mmx15mm using a localized spectroscopy sequence with and without suppression of the water signal. Main parameters are: TR (repetition time)=3000ms; TE (echo time)=20 ms; number of repetitions=128; scan time 6min)."
76075222|NCT00860314|Procedure|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
75629655|NCT03704532|Procedure|Nonoperative treatment|Nonoperative treatment with lower leg orthosis and functional rehabilitation
75629656|NCT03696082|Behavioral|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
75780860|NCT01223222|Drug|LTX-109|Topical administration. 3 times daily. 5 days.
75629657|NCT03696082|Behavioral|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
75629658|NCT03696082|Behavioral|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
75780861|NCT02529332|Dietary Supplement|Omega-3|Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
75780862|NCT03932942|Diagnostic Test|QIAstat at pediatric emergency room|Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
75780863|NCT03931382|Behavioral|Virtual Reality|The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.
75323739|NCT02521142|Other|Oxymap T1|The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
75629659|NCT03696082|Behavioral|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
75629660|NCT03675711|Device|Midline|Patient will receive a Midline catheter within 48h after disappearance of indication for CVC
75629661|NCT03675711|Device|PVC|Patient will receive a standard PVC within 48h after disappearance of indication for CVC
75323740|NCT02521142|Other|OCT|non-invasive imaging of retinal and choroidal structures.
75323741|NCT02521142|Other|FLA/ICG angiography|Fluorescein Angiography and Indocianine Angiography
75629662|NCT03674619|Procedure|Anterior discectomy|Anterior discectomy will be performed and a microscope is used. After separation of the platysma muscle the pre-vertebral space is reached by an approach medial to the sternocleido-mastoid muscle and the carotid artery and lateral to the trachea and oesophagus. Then the disc is incided and the corpora are distracted to perform discectomy. Usually the posterior ligament is cut and the spinal root is decompressed and if necessary the arthritic rims are removed. An inter-vertebral fusion device is inserted, two levels are allowed in the spondylosis study.
75629663|NCT03674619|Behavioral|Conservative treatment|Patients will first attend an experienced specialist in physical medicine and rehabilitation who will answer concerns and questions and if necessary repeat the information given before inclusion. The aim of the brief intervention is to promote better understanding and coping of the condition. The intervention will include supervision by a physiotherapist (6 sessions altogether) and provide advice on how to handle secondary neck muscle pain and dysfunction, reduce eventual fear avoidance, and advice to stay active.
75629664|NCT03673371|Other|Questionnaire|This is a questionnaire developed by DoD and VA researchers specifically for this study.
75629665|NCT03671967|Drug|Piperacillin/tazobactam|4.5 grams QID
75629666|NCT03671967|Drug|Meropenem|1 gram TID
75629667|NCT03657810|Drug|CL-108 5 mg|hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
75629668|NCT03657810|Drug|Norco|hydrocodone 5 mg/APAP 325 mg
75629669|NCT03657810|Drug|Placebo|Placebo matching CL-108
75629670|NCT03640026|Drug|Tacrolimus|Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.
75629671|NCT03618849|Device|tDCS|Real and sham tDCS/Mozart piano sonata (K.448)
75629672|NCT03616834|Drug|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
75629673|NCT03601949|Device|SInergy Cooled Radiofrequency|ablation of low back pain
75629674|NCT03601949|Other|Medical Management|physical therapy, medications, lifestyle changes
75780864|NCT03931382|Behavioral|Simulator Preparation|The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.
75780865|NCT03931382|Behavioral|Preparation Booklet for Non-Sedated MRI|The standard MRI preparation booklet provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
75780866|NCT01312324|Drug|neoadjuvant docetaxel/cisplatin|3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
75323742|NCT00734903|Behavioral|A Woman's Path to Recovery|WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.
75629675|NCT03601702|Device|Mechanical thrombectomy with EmboTrap ® II Device|Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)
75629676|NCT03594344|Procedure|Hyperbaric oxygen therapy|Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions
75629677|NCT03565029|Drug|XELOX|Capecitabine and Oxaliplatin (4x cycles)
75629678|NCT03565029|Radiation|Radiotherapy|Pelvic radiotherapy
75629679|NCT03555396|Behavioral|SMART Couples 2|The intervention will consist of 4 sessions with activities designed to strengthen communication and support within the couple to improve adherence to antiretroviral therapy and increase linkage to drug treatment services. The activities are based on cognitive-behavioral therapy. Participants' adherence will be monitored continuously through electronic monitoring devices and surveys completed at baseline and follow-up periods.
75629680|NCT03555396|Behavioral|Standard of Care|Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
75629681|NCT03544736|Drug|Nivolumab|Experimental: Nivolumab
75629682|NCT03544736|Radiation|Radiotherapy|Radiotherapy
75629683|NCT03544736|Drug|Chemotherapy|Chemotherapy
75629684|NCT03544736|Procedure|Surgery|Surgery
75629685|NCT03533010|Dietary Supplement|Ca500mg|subjects receive a daily dose of 500mg elemental calcium
75629686|NCT03533010|Dietary Supplement|VitD800IU|subjects receive a daily dose of 800IU VitD3
75629687|NCT03533010|Other|Placebo|subjects receive placebo tablet
75323743|NCT00734903|Behavioral|12-Step Facilitation|12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
75629688|NCT03529383|Device|Connected device|Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.
75629689|NCT03529383|Behavioral|Therapeutic education|"Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~a 1-hour individual session of educational assessment to evaluate whether their objectives were reached."
75629690|NCT03528031|Other|Intervention Daily Avocado|Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.
75629691|NCT03495440|Behavioral|Center Sessions|Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.
75780867|NCT03931226|Drug|Drug consumption|number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
75780868|NCT01127594|Drug|Temozolomide|Dose level selection will proceed according to the modified Accelerated Titration Design. The starting dose will be TMZ 200mg/m2 x 0.09 BSA for the upper extremity and 200mg/m2 x 0.18 BSA for the lower extremity. We will enroll one-patient cohorts with dose doubling between cohorts until 1st occurrence of a ≥ CTC (Common Terminology Criteria) grade 2 adverse event. At that time, the present cohort and all future cohorts will be extended to enroll 3 to 6 patients.
75780869|NCT05681416|Diagnostic Test|Panel sequencing, whole exome sequencing, whole genome sequencing|Besides the mutation positive men (group 2), all will receive multigene panel analysis in a patient care setting and if negative, whole exome sequencing (WES), whole genome sequencing and transcriptome analyses. In PCA-affected men (group 3), additional mutational analysis will be performed on formalin-fixed paraffin embedded (FFPE) - and fresh frozen (FF) tumor tissue from biobanked radical prostatectomy specimens using FFPE panel analysis (like TruSightOncology 500) or WES if FF samples are available.
75780870|NCT01127672|Biological|platelet rich plasma|"30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
75780871|NCT01127672|Drug|corticosteroid injection|"Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
75780872|NCT05452408|Drug|Antitumor B KAC|ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.
75780873|NCT01125878|Dietary Supplement|Placebo|placebo
75780874|NCT01125878|Dietary Supplement|Starch composite B|fiber mixture
75780875|NCT01125878|Dietary Supplement|Starch composite C|fiber mixture
75780876|NCT01125878|Dietary Supplement|Starch composite D|fiber mixture
75780877|NCT04955314|Other|PA vertebral mobilization|A PA mobilization is a technique in which one vertebra slides over another due to a force applied with the hands of the physiotherapist
75780878|NCT01218074|Device|Aggregometry+Thromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
75780879|NCT01218074|Device|Thromboelastography Alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
75780880|NCT04473742|Biological|Blood collection|4 EDTA tubes for 24 mL blood collection
75780881|NCT04473742|Biological|Blood sample|2 drying tubes for 12 mL blood collection
75780882|NCT04473742|Biological|Blood sample|1 drying tube for 6 mL blood collection
75780883|NCT04459156|Dietary Supplement|Fiber Inulin|Commercially available inulin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
75780884|NCT04459156|Dietary Supplement|Placebo Maltodextrin|Commercially available maltodextrin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
75780885|NCT04427488|Other|Morning Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
75323744|NCT01273753|Other|Intradialytic exercise|Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
75323745|NCT00735449|Drug|Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
75323746|NCT00735449|Drug|timolol maleate 0.5%|1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
75323747|NCT00735449|Drug|latanoprost 0.005%|1 drop of latanoprost 0.005% once nightly.
75629692|NCT03495440|Behavioral|At-home|Self-study resources paired with regular contact with study personnel.
75323748|NCT04386343|Drug|CH1701 for prevention and treatment of radiation burns.|Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.
75323749|NCT04386343|Drug|Safety assessment of CH1701|Safety assessment of CH1701 after 14 days of use on volunteers
75780886|NCT04427488|Other|Evening Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
75780887|NCT01220258|Drug|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
75780888|NCT01220336|Behavioral|Health coaching by medical assistants in primary care|Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model [Bodenheimer 2007] for 12 months.
75629693|NCT03490838|Drug|177Lu-PSMA-R2|radio-ligand therapy
75629694|NCT03462004|Biological|HPIV3/ΔHNF/EbovZ GP vaccine|Administered intranasally
75629695|NCT03462004|Biological|Placebo|Administered intranasally
75780889|NCT01218230|Drug|Intravitreal Pegaptanib|Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
75780890|NCT04395586|Other|Culture|Culture
75780891|NCT01125956|Behavioral|Assigned a peer counselor|Dyads will be given $20 per month if they have contact 4 or more times during a month.
75780892|NCT01125956|Behavioral|Financial incentives|Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
75780893|NCT01223534|Drug|Preventive treatment with Isoniazid.|If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.
75780894|NCT01223534|Drug|Preventive treatment with Isoniazid|If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
75780895|NCT02891200|Other|Peer support program|The Peer Support Program offers education and support to participants by especially trained 'peer mentors' with oversight from a social worker.
75780896|NCT02891200|Other|HCP support|Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
75780897|NCT01223612|Drug|Ranibizumab|Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
75780898|NCT01223612|Procedure|Modified ETDRS laser|Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
75780899|NCT01126034|Other|intervention letter|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~The name and medical record # of the patients involved~Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~A reminder of the adverse effect of long-term metoclopramide therapy~A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~A request that the physician document the discontinuation trial in the electronic medical record"
75780900|NCT01122992|Procedure|Limbal relaxing incision|
76075223|NCT00860314|Procedure|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
75323750|NCT04386343|Drug|Placebos|The placebo was used on patients as a control for the doses of CH1701
75323751|NCT01273831|Drug|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
75323752|NCT01273831|Drug|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
75323753|NCT00735839|Biological|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
75323754|NCT00735839|Biological|Placebo|Saline placebo (0.5 ml) single injection on Day 1
75629696|NCT03409198|Drug|Ipilimumab|Ipilimumab blocks CTLA-4 and may deplete regulatory T cells
75629697|NCT03409198|Drug|Nivolumab|Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.
75629698|NCT03409198|Drug|Pegylated liposomal doxorubicin|Chemotherapy
75780901|NCT01127750|Drug|FTY720|
75780902|NCT05177224|Other|Ultrasound acquisitions to define liner position during movements|"Ultrasound acquisition of the dual mobility cup will be performed before and after movement. Acquisitions will be performed on the groin area.~Movement will be performed 3 times and are:~Walking~Knee-bending~Standing up~Stair climbing Movement acquisition of the lower limb will be performed using reflective markers placed on the skin. The movements will be recorded using motion capture system (infrared cameras). The load applied by the patients on the ground when doing these movements will be recorded with a force plate."
75780903|NCT02946580|Drug|MOVANTIK™ (naloxegol)|
75780904|NCT02946580|Drug|Sugar Pill|
75780905|NCT01223690|Drug|Clarithromycin|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
75780906|NCT01223690|Drug|Dextrose 5%|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
75780907|NCT05681338|Other|the medium intensity coughing technique|The medium intensity coughing technique: Immediately before the subcutaneous LMWH injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
75780908|NCT05168488|Behavioral|Fasted morning resistance exercise|On three separate occasions, participants will perform a standardized resistance exercise protocol in the morning while fasting.
75780909|NCT05168488|Behavioral|Afternoon resistance exercise|On three separate occasions participants will perform a standardized resistance exercise protocol in the afternoon after eating their regular lunch
75467619|NCT01931046|Drug|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
75467620|NCT01931072|Behavioral|High-intensity interval training|Interval training 3 times a week for 8 weeks
75467621|NCT01931072|Behavioral|Moderate training|Moderate training 3 times a week for 8 weeks
75467622|NCT01931085|Drug|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
75467623|NCT01931098|Drug|topotecan|Taken .25 mg orally, daily continuous until progression up to one year.
75467624|NCT01931098|Drug|pazopanib|600 mg orally, daily until progression, up to one year.
75629699|NCT03409198|Drug|Cyclophosphamide|Chemotherapy
75629700|NCT03385980|Other|Proteomic analysis|Proteomic analysis of tissues collected from all sites of disease, guided by either imaging performed prior to the patient's death or post-mortem findings. Peripheral blood mononuclear cells (PBMC) will be collected with the purpose of identifying somatic changes occurring specifically in the tumor cells and not in normal DNA of the same patient.
75629701|NCT03374631|Device|active anodal tDCS|active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation
75629702|NCT03374631|Device|sham tDCS|sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation
75629703|NCT03371485|Biological|AST-VAC2|Allogeneic dendritic cell vaccine.
75629704|NCT03370341|Device|active anodal tDCS|active anodal tDCS with behavioral tasks to assess IA
75323755|NCT03805711|Device|HLT® Transcatheter System|Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
75467625|NCT01931124|Behavioral|High Intensity Training|
75467626|NCT01931124|Behavioral|Moderate Intensity Training|
75467627|NCT01931137|Drug|insulin 338 (GIPET I)|Dose level of 8100 nmol will be orally administered as one tablet per dose.
75780910|NCT03931304|Procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
75780911|NCT01123304|Drug|MORAb028|1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
75629705|NCT03370341|Device|sham tDCS|sham tDCS with behavioral tasks to assess IA
75780912|NCT05381350|Biological|COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)|The COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)was manufactured by Sinovac Research& Development Co., Ltd.1200SOU inactivated SARS-CoV-2 Omicron strain in 0.5ml of aluminium hydroxide solution per injection.
75780913|NCT05381350|Biological|COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
75780914|NCT03934736|Drug|HEPLISAV-B®|HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).
75629706|NCT03329170|Behavioral|educational intervention using motivational interviewing|A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is <12 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
75629707|NCT03321656|Drug|Tacrolimus|0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
75780915|NCT05176834|Device|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
75780916|NCT01223768|Drug|Acetyl-l-Carnitine|2g per day
75780917|NCT01223768|Drug|placebo|twice per day
75780918|NCT04759066|Device|HEALiX|HEALiX is a non-restraint patient safety device
75323756|NCT00735917|Drug|saracatinib|Given PO
75323757|NCT00735917|Other|pharmacogenomic studies|Optional correlative studies
75323758|NCT00735917|Other|pharmacological study|Optional correlative studies
75323759|NCT00735917|Procedure|positron emission tomography|Optional correlative studies
75323760|NCT00735917|Radiation|fludeoxyglucose F 18|Optional correlative studies
75323761|NCT00735917|Other|laboratory biomarker analysis|Optional correlative studies
75323762|NCT00779155|Device|The Resonator|active magnetic field therapy
75467628|NCT01931176|Biological|rDEN2Δ30-7169 vaccine|Administered at a dose of 10^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
75467629|NCT01931176|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
75467630|NCT01931189|Biological|NI-071|100mg/vial
75467631|NCT01931189|Biological|Infliximab|100mg/vial
75467632|NCT01931215|Other|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
75467633|NCT01931215|Other|TAP-block with ropivacaine and clonidine|
75467634|NCT01931228|Procedure|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
75916426|NCT04474080|Behavioral|Virtual Peer Support Platform|The intervention program will consist of 8 virtual 30-minute sessions delivered across three months. Sessions will follow a structured format including: check-in, issue identification & context, facilitated discussion, environmental strategies, occupational strategies, experiential component, as well as summary and sign-out. Meetings will finish with a stress relieving activity, to be performed together on the web-based platform. The facilitated discussions will follow important themes including focus on self, patients, and external stressors.
76075224|NCT04135027|Other|no interventions|no interventions
76075225|NCT00890656|Drug|Cyclophosphamide (CTX)|300 mg/m^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
76075226|NCT00890656|Drug|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
76075227|NCT00890656|Drug|Doxorubicin|50 mg/m^2 by vein (IV) over 24 hours
76075228|NCT00890656|Drug|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
75629708|NCT03321656|Drug|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
75629709|NCT03299335|Other|Blood collection|assay of CPK and anti-cN-1A antibodies
75780919|NCT01126112|Biological|Panitumumab|Panitumumab: 6 mg/Kg Q2W
75780920|NCT01127828|Other|Arla Yoghurt with no probiotic|two servings of 200 ml of investigational products per day
75916427|NCT04474080|Behavioral|Control Period|The control period will be the time prior to randomization and commencement of the intervention, whereby residents will receive a 30 minute break each week during their academic half-day.
75916428|NCT04820062|Other|Content Validity|For the validity of built, it is generally advisable to include a ratio of 100 participants for 30 questionnaire items. In order to have a suitable questionnaire, we will limit ourselves to 30 items which will be the size of our questionnaire. It was therefore planned to include 100 participants The selection of experts will be based on experience in this area, knowledge and availability. It will be a rescimant physician and an infectious disease doctor. Each expert will be invited in isolation to comment on the items in the questionnaire
75916429|NCT00817986|Drug|Arbaclofen placarbil, 20 mg|tablets
76075229|NCT00890656|Drug|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
76075230|NCT00890656|Drug|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
75916430|NCT00817986|Drug|Placebo|tablets
76075231|NCT00890656|Drug|Ara-C|3 gm/m^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
75916431|NCT00817986|Drug|Arbaclofen placarbil, 30 mg|tablets
75916432|NCT00817986|Drug|Arbaclofen placarbil, 40 mg|tablets
75916433|NCT04188080|Dietary Supplement|Jarlsberg Cheese|Oral daily intake of Jarlsberg cheese
76075232|NCT00890656|Drug|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
76075233|NCT04311112|Drug|Placebos|Placebo
76075234|NCT04311112|Drug|ZA Low dose|ZA low dose
75323763|NCT00779155|Device|The Resonator control|inactive magnetic field therapy with placebo fields
75323764|NCT00736073|Drug|aprepitant|one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
75323765|NCT00736073|Drug|Placebo|one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
75323766|NCT00736229|Drug|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
75323767|NCT00737243|Drug|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
75323768|NCT00737243|Drug|Carboplatin|AUC 6.0 IV Day 1
75629710|NCT03294148|Other|Open-Label Placebo Treatment for Chronic Back Pain|Subcutaneous injection of 1ml medical grade saline into the lower back.
75629711|NCT03294148|Behavioral|Psychotherapy Treatment for Chronic Back Pain|Twice weekly 50 minute psychotherapy sessions for 4 weeks, plus an initial medical history session
75629712|NCT03269032|Other|American Diet|"According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, >11% Saturated Fatty Acids, <12% Monounsaturated Fatty Acids, and >8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
75629713|NCT03269032|Other|Mediterranean-style Diet|"The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, <7% Saturated Fatty Acids, >18% Monounsaturated Fatty Acids and <5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
75780921|NCT01127828|Other|Probiotic yoghurt (Cultura)|200 ml per day
75780922|NCT02529176|Behavioral|Best-practice alert|The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
75780923|NCT03934424|Behavioral|Weight stigma|Subject will read an article depicting discrimination against individuals with higher body weights for 5-10 minutes on one day
75916434|NCT02598934|Drug|Ibandronate|Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
75916435|NCT00817362|Drug|IPI-504|IPI-504 IV infusion 300 mg/m2
76075235|NCT04311112|Drug|ZA high dose|ZA high dose
76075236|NCT00814138|Drug|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
76075237|NCT00814138|Other|Placebo|Weekly
76075238|NCT00860938|Drug|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
76075239|NCT00862186|Behavioral|'Fatigue Facts & Fixes'|"'Fatigue Facts & Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
75323769|NCT00737243|Drug|Bevacizumab|15 mg/kg IV infusion Day 1
75629714|NCT03236987|Drug|Clarithromycin 1000 MG|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
75629715|NCT03236987|Drug|Azithromycin 250 mg|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
75629716|NCT03236987|Drug|Rifampicin|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
75629717|NCT03236987|Drug|Ethambutol|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
75629718|NCT03187366|Other|Bottom-up intervention|Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
75629719|NCT03181282|Behavioral|Physical Therapy|Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
75629720|NCT03149380|Behavioral|Web-based education|The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
75780924|NCT03934424|Behavioral|Ethnic stigma|Subject will read a control article for weight stigma depicting discrimination against individuals from a minority ethnic group for 5-10 minutes on one day
75780925|NCT01123460|Other|enzyme-linked immunosorbent assay|
75780926|NCT01123460|Other|laboratory biomarker analysis|
75780927|NCT05358808|Drug|TCB008|administration of TCB008
75916436|NCT00817362|Drug|Trastuzumab|Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was <4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
75916437|NCT04176848|Drug|CFI-400945|Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: CFI-400945 orally once daily
76075240|NCT01719757|Drug|Oxycodone/Naloxone|Twice daily
76075241|NCT01718509|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
76075242|NCT01718509|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
76075243|NCT00862810|Biological|Received HPV vaccine first|
76075244|NCT00862810|Biological|Received concomitant vaccines first|
75780928|NCT01220492|Drug|conventional plus MSC treatment|received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 8 weeks.
75780929|NCT01220492|Drug|conventional plus placebo treatment|received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
75780930|NCT01123538|Drug|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
76075245|NCT00815698|Procedure|suture|suture for mesh fixation
75780931|NCT01123538|Drug|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
75780932|NCT03931148|Diagnostic Test|Geriatric Assesment with neuropsychological test more specific on decision making|The following tests will be made : MoCA, FAB, TMT, Stroop-Victoria, JAT
75780933|NCT03931148|Diagnostic Test|Functional RMI|With specific test of decision making (IGT) specially adapted to the population
76075246|NCT00815698|Procedure|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
76075247|NCT00863122|Drug|lapatinib|1500 mg lapatinib by mouth per day for 10 days
75323770|NCT00737243|Drug|Erlotinib|150 mg PO
75323771|NCT00737243|Other|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
75467635|NCT01931228|Procedure|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
75467636|NCT01931241|Drug|AHRO-001|Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
75916438|NCT04176848|Drug|Durvalumab|Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)
75916439|NCT00945672|Biological|PF-04360365 10 mg/kg|10 mg/kg every 90 days (5 total doses)
75916440|NCT00945672|Biological|PF-04360365 7.5 mg/kg|10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)
75916441|NCT00945672|Drug|placebo|placebo administered every 90 days or monthly to match experimental treatment arms.
75916442|NCT04163978|Drug|Nitric Oxide|in situ 240mL nitric oxide releasing sinus irrigation solution
75916443|NCT04163978|Drug|Budesonide|Saline based sinus irrigation 1mg Budesinide solution
75629721|NCT03129282|Other|Home-based Metacognitive Therapy (Home-MCT)|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
75629722|NCT03127059|Other|Breathing Exercises|"Key points in the intervention are~Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.~Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.~Inclusion of the breathing modification into walking and other physical activities.~Daily home exercise of BrEX."
75916444|NCT00811902|Drug|Nerispirdine|tablet, oral administration
75629723|NCT03127059|Other|Usual care|Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
75629724|NCT03122366|Diagnostic Test|Detection of single nucleotide polymorphisms (SNP)|Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood
75780934|NCT03931148|Diagnostic Test|High Resolution EEG|With specific test of decision making (BART) specially adapted to the population
75780935|NCT03931148|Other|Qualitative interview|Qualitative semi-directed interviews with participants, their caregivers and their geriatrician to analyse everyday life decision making ability.
75780936|NCT01223924|Other|placebo|placebo
75780937|NCT01223924|Drug|M2ES|M2ES IV 7.5mg-90mg
76075248|NCT01604941|Drug|SPD602|50 mg/kg/day orally twice daily for 24 weeks
75323772|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone|"Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
75629725|NCT03114644|Other|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
75780938|NCT01220570|Drug|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
75323773|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone|"Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
75629726|NCT03094637|Drug|Azacitidine|Given IV
75780939|NCT01220570|Drug|Ridaforolimus|Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
75780940|NCT01220570|Drug|Dalotuzumab|Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
75780941|NCT03930758|Combination Product|Behavior intervention of uphill exercise|40 minutes of uphill exercise
75780942|NCT03930758|Combination Product|Dietary intervention of exercise before the meal|40 minutes of uphill exercise completed 1 h before the meal
75780943|NCT03930758|Combination Product|Dietary intervention of uphill exercise|40 minutes of uphill exercise
75780944|NCT03930758|Combination Product|Dietary intervention of exercise after the meal|40 minutes of uphill exercise started 1 hour after gthe meal
75780945|NCT03930758|Combination Product|Behavior intervention of downhill exercise|40 minutes of downhill exercise
75780946|NCT03930758|Combination Product|Dietary intervention of exercise before the meal|40 minutes of downhill exercise completed 1 hour before the meal
75780947|NCT03930758|Combination Product|Behavioral intervention of downhill exercise|40 minutes of downhill exercise
75780948|NCT03930758|Combination Product|Dietary intervention of exercise after the meal|40 minutes of downhill exercise started 1 hour after the meal
75780949|NCT03930758|Combination Product|Behavioral intervention of sedentary no-exercise trial|Sedentary no-exercise trial
75780950|NCT03930758|Combination Product|Dietary intervention of eating two meals|Meals eaten at 10 and 17 h during a sedentary trial
75780951|NCT04682860|Drug|Hyoscine N Butylbromide|Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis
75916445|NCT00811902|Drug|placebo|tablet, oral administration
75916446|NCT02598622|Drug|Acetylcarnitine|Acetylcarnitine is taken 2 times a day for days 1 through 21.
75916447|NCT02598622|Drug|Placebo|Placebo is taken 2 times a day for days 1 through 21.
75916448|NCT03460028|Behavioral|Yoga Condition|Participants randomized to the Yoga Condition will participate in an integrated yoga program consisting of yoga postures, breathing exercises, and concentration/meditation practices.
75629727|NCT03094637|Biological|Pembrolizumab|Given IV
75629728|NCT03057834|Behavioral|Pelvic floor muscle exercise|Standardized pelvic floor muscle exercise regimen
75629729|NCT03055507|Drug|Ibuprofen 400 mg|Addition of ibuprofen to standard pain regimen.
75629730|NCT03055507|Drug|Acetaminophen 650 mg|Standard analgesic provided post-operatively to patients undergoing sinus surgery
75629731|NCT03055507|Drug|OxyCODONE 5 Mg Oral Tablet|Standard PRN medication offered post-operatively for breakthrough pain
75780952|NCT04682860|Other|Placebo|2 ml of normal saline injection as placebo
75780953|NCT01127906|Drug|PF-04531083 100mg|Oral PF-04531083 100mg suspension single dose
75780954|NCT01127906|Drug|PF-04531083 2000mg|Oral PF-04531083 2000mg suspension single dose
75916449|NCT03463070|Drug|rectal misoprostol 600mg|70 women who received 600 mg misoprostol postoperatively at operating theatre
75916450|NCT00809562|Drug|Placebo|po daily for 10 days
76075249|NCT01604785|Drug|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
76075250|NCT01604785|Drug|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
75629732|NCT03038256|Drug|concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
75629733|NCT03038256|Drug|concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
75780955|NCT01127906|Drug|Placebo suspension|Oral Placebo suspension (matched to PF-04531083 suspension)
75780956|NCT01127906|Drug|Placebo tablet|Oral Placebo tablet (matched to Oxycodone)
75780957|NCT01127906|Drug|Oxycodone 20mg|Oral Oxycodone 20mg (Oxycontin) controlled release formulation
75780958|NCT01127984|Drug|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
75780959|NCT01127984|Procedure|drainage system|application of vacuum drainage system
75780960|NCT01123616|Procedure|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
75780961|NCT01123694|Other|Survey Study|Survey regarding quality of life
75916451|NCT00809562|Drug|RO4917523|orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
75916452|NCT00807612|Biological|AMG 479|AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1
75916453|NCT00807612|Biological|AMG 479|AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1
75916454|NCT00807612|Drug|Carboplatin|Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6
75916455|NCT00807612|Biological|AMG 479|AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1
75323774|NCT01273727|Drug|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
75323775|NCT01273727|Drug|dexamethasone|intravitreal implant 0.7 mg duration 6 months
75780962|NCT03638830|Drug|Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)+placebo"
75780963|NCT03638830|Drug|Ftortiazinon (tablets 300 mg) full dose + Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)"
75780964|NCT03638830|Other|placebo+Maxipim|placebo
75916456|NCT00807612|Drug|Paclitaxel|Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
75916457|NCT03462992|Diagnostic Test|MonoMark|MonoMark (also known under the registered trademark ColonoKit), is a monocyte-based test using a transcriptomic signature and a mathematical predictive model aimed at discriminating between healthy individuals and CRC patients.
75780965|NCT01220648|Drug|Nilotinib, interferon-alfa|
75780966|NCT03638752|Other|Comprehensive education group|"The details of Comprehensive education are as follows:~introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
75780967|NCT01218386|Drug|Estradiol valerate|"Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation."
75323776|NCT00707915|Drug|Drug: Benzodiazepine (listed out below)|"The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks."
75323777|NCT02994407|Drug|turoctocog alfa pegol|"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."
75323778|NCT00708071|Biological|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
75323779|NCT02994641|Procedure|COMA Score Assessment|
75916458|NCT00805818|Drug|NNZ-2566|"Solution for intravenous infusion.~20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours."
76075251|NCT01681849|Drug|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
76075252|NCT01681849|Drug|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
76075253|NCT01681849|Other|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
75467637|NCT01931267|Behavioral|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
76075254|NCT01681771|Behavioral|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
75467638|NCT01931267|Behavioral|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
75629734|NCT02996253|Procedure|FHL transfer|endoscopic transfer og flexor hallucis longus
75629735|NCT02870738|Procedure|Pelvic Floor Physical Therapy|Internal and/or external myofascial release of the pelvic floor muscles
75629736|NCT02870738|Drug|Bladder Instillations|A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
75629737|NCT02811653|Device|Brain MRI|
76075255|NCT01681771|Behavioral|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
75323780|NCT02994485|Drug|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
75323781|NCT02994173|Drug|Oxycodone|Current clinical practice, used as a control in this study
75323782|NCT02994173|Drug|S-Ketamine 0.25|dosage
75323783|NCT02994173|Drug|S-Ketamine 0.5|dosage
75323784|NCT02994173|Drug|S-Ketamine 0.75|dosage
75323785|NCT01273961|Device|AuraLevée treatment|A single treatment, on day 0, on each of no more than two treatment sites, using the AuraLevée device. Treatment sites are the face, abdomen, upper arm, thigh or neck.
75467639|NCT01931280|Behavioral|Lifestyle Counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
75629738|NCT02811653|Other|neuropsychological evaluation|
75467640|NCT01931293|Dietary Supplement|Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic|Vitamin Supplement therapy
75780968|NCT03933098|Biological|Test Vaccine Vi-DT Typhoid conjugate|"Manufacturer: SK Bioscience Co., Ltd.~Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial"
75916459|NCT00805818|Drug|Placebo|Sodium Chloride 0.9% Injection
75323786|NCT00723749|Drug|Buprenorphine/Naloxone|"Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine & 0.5 mg naloxone and 8 mg buprenorphine & 2 mg naloxone.~The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity."
75323787|NCT00723827|Drug|Temozolomide|Administration of temozolomide based on the product labeling.
75323788|NCT00723827|Radiation|Radiotherapy|Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
75323789|NCT02995343|Procedure|Hypogastric and/or uterine artery ligation|
75323790|NCT02993861|Other|Anti-epileptics|
75467641|NCT01931306|Drug|Afatinib|BIBW2992 low to medium dose once daily
75629739|NCT02811653|Biological|Blood|
75467642|NCT01931319|Drug|Intravenous baclofen|
75467643|NCT01931332|Procedure|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
75629740|NCT02789982|Drug|β-adrenergic blocker propranolol|
75629741|NCT02789982|Behavioral|Treatment as usual|
75629742|NCT02746718|Other|Blood sample|A blood sample for CPK dosage and pompe disease test
75467644|NCT01931332|Procedure|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
75467645|NCT01931345|Behavioral|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
75629743|NCT02738645|Other|pneumonia|
75629744|NCT02714465|Other|hyperbaric oxygen therapy|hyperbaric oxygen therapy
75629745|NCT02701829|Other|CONTROL- Usual & Customary Health Fair Follow-up|participating drivers may fall into 1 of 2 categories- Regular follow-up, or Urgent Follow-up.
75629746|NCT02701829|Other|Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors and have the mobile health text messaging intervention.
75916460|NCT04566068|Behavioral|Intervention- Adapted Virtual Insomnia Program|4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors.
75916461|NCT04566068|Behavioral|Control- Enhanced usual care|Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
76075256|NCT04250350|Biological|Lebrikizumab|Subcutaneous injection
76075257|NCT03839680|Procedure|Endoscopy|The endoscopy procedure uses an endoscope to examine the interior of a hollow organ or cavity of the body.
75629747|NCT02701829|Other|Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors for daily BP self-monitoring and text messaging, and they will receive the social network support intervention including an SNS guide for each SNS.
75916462|NCT00805350|Drug|Eplivanserin|one 5 mg tablet once a day
75916463|NCT00805350|Drug|Placebo|Placebo of Eplivanserin one tablet once a day
75629748|NCT02673281|Other|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
75780969|NCT03933098|Biological|Control Vaccine Typbar TCV®|"Manufacturer: Bharat Biotech~Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein~Dose: 0.5 ml"
75780970|NCT01123772|Drug|INO-8875|eye drops for 14 days in one eye
75780971|NCT01123772|Other|Placebo control|Matched placebo
75780972|NCT05309746|Procedure|Laparoscopic surgery|Surgery used to remove the child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into the child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of the child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
75780973|NCT03930836|Behavioral|Hand Arm Bimanual Intensive Therapy Including Lower Extremities|Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface
75780974|NCT03930836|Behavioral|Conventional physical and occupational therapy|Conventional therapy (physical and occupational therapy) is mainly based on neurodevelopmental therapeutic principles. 50% of therapeutic time will be performed using the new interactive interface
75780975|NCT00323609|Procedure|Vertebroplasty|Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
75780976|NCT00323609|Procedure|Kyphoplasty|Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
75916464|NCT04549298|Other|No interventions|No interventions - observational study
75916465|NCT00801060|Drug|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
75916466|NCT00801060|Drug|FCR|Dosage, schedule, and duration in the protocol
75780977|NCT01224080|Device|Adiana placement|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
75916467|NCT03462836|Drug|IV ketamine/lidocaine/IV PCA apply|In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
75916468|NCT03462836|Drug|IV PCA only apply|IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
75916469|NCT00849576|Drug|Regular Human Insulin|0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
75323791|NCT00779311|Drug|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
75629749|NCT02673281|Other|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
75780978|NCT01224314|Other|Changing potassium concentration in dialysis fluids|The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
75916470|NCT00849576|Drug|Insulin Lispro|90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
75916471|NCT00849576|Drug|Insulin VIAject™ (75%)|75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
75629750|NCT02667886|Drug|X4P-001|Continuous, oral, once-daily dosing
75629751|NCT02667886|Drug|axitinib|Continuous, oral, twice-daily dosing
75916472|NCT00849576|Drug|Insulin VIAject™ (90%)|90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
75916473|NCT02521922|Device|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
76075258|NCT03839602|Radiation|Reducing CTV|CTVs were delineated in line with tumor stage, i.e. tumor invasion.
76075259|NCT00863356|Device|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
76075260|NCT00005398|Other|There is no intervention|No applicable
76075261|NCT00863434|Drug|clofarabine|Given IV
76075262|NCT00863434|Drug|cytarabine|Given IV
75323792|NCT00779311|Drug|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
75629752|NCT02637245|Other|No intervention|No intervention
75916474|NCT02521922|Device|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
75916475|NCT00842088|Drug|Placebo|Matching placebo capsule. Administered orally once a day on dosing days.
75916476|NCT00842088|Drug|HQK-1001|HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
75916477|NCT03457688|Dietary Supplement|prebiotic inulin-type fructans|
75916478|NCT03457688|Dietary Supplement|placebo maltodextrin|
76075263|NCT00863434|Biological|filgrastim|Given SC
75916479|NCT03462602|Procedure|NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was retained until the return of bowel function (passage of flatus or passage of stool) in the patients assigned to the NGT group.
75323793|NCT00779311|Drug|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
75780979|NCT01128140|Behavioral|Motivational Enhancement Therapy|MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.
75629753|NCT02587195|Drug|Teriflunomide|
75629754|NCT02582008|Drug|Bupropion Hydrochloride|Given PO
75629755|NCT02582008|Other|Laboratory Biomarker Analysis|Correlative studies
75629756|NCT02582008|Drug|Nicotine Replacement|Given NRT
75780980|NCT01128140|Behavioral|Education|Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
75780981|NCT04598152|Device|TDCS - transcranial direct current stimulation|TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
75780982|NCT01224392|Other|Chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
75916480|NCT03462602|Procedure|non-NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was removed in the operation room immediately after the surgery in those assigned to the non-NGT group.
75916481|NCT00841698|Drug|Paroxetine HCl|40 mg Film-Coated Tablet
75916482|NCT00841698|Drug|Paxil®|40 mg Film-Coated Tablet
75916483|NCT03457610|Behavioral|Speech and language intervention|Speech therapy includes education about cough and vocal hygiene, teaching strategies to reduce cough, breathing and vocal exercises. The whole therapy consists of eight sessions once a week.
75916484|NCT04383002|Drug|Nitric Oxide|iNO will be given at 160ppm for 6 hours, once a day, for 2 days
75916485|NCT00841542|Drug|Amlodipine Besylate|10 mg Tablet
75916486|NCT00841542|Drug|Norvasc®|10 mg Tablet
75323794|NCT01274039|Drug|Acetazolamide for glaucoma patients to lower eye pressure|Acetazolamide tablets 3 times daily for 3 to 4 weeks
75323795|NCT03802201|Drug|PTG-300|Subcutaneous (SC)
75629757|NCT02582008|Other|Quality-of-Life Assessment|Ancillary studies
75629758|NCT02582008|Other|Questionnaire Administration|Ancillary studies
75629759|NCT02582008|Drug|Varenicline|Given PO
75629760|NCT02544074|Behavioral|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
75629761|NCT02544074|Behavioral|eSAGE testing|Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
75323796|NCT01274117|Procedure|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
75323797|NCT00725153|Device|Balafilcon A contact lenses (PureVision)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
75323798|NCT00725153|Device|Etafilcon A contact lenses (Acuvue2)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
75323799|NCT03807349|Device|N-Force Screws Augmented with N-Force Blue|N-Force Fixation System 7.3 mm (Non-fenestrated/fenestrated) applied with washers; N-Force Blue (Bone Substitute Material)
75323800|NCT04387019|Diagnostic Test|blood sampling|blood sampling from peripheral vein
75323801|NCT01274195|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
75323802|NCT00779701|Drug|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
75629762|NCT02502799|Behavioral|Brief Early Intervention|Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
75629763|NCT02502799|Behavioral|Parent Training with Adolescent Cognitive Behavioral Therapy|Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
75629764|NCT02502799|Drug|Methylphenidate|Adolescents will receive methylphenidate.
75629765|NCT02456246|Procedure|FLT-PET|Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
75467646|NCT01931345|Behavioral|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
75916487|NCT03462524|Procedure|Esophagectomy|FEV1, FVC and DLCO will be assessed at baseline and one month post induction therapy. Radiation induced lung injury (RILI EORTC grade≥2), CCI, Clavien-Dindo, and pulmonary complications will be monitored. Changes in pulmonary function will be compared with cardiorespiratory symptoms and HR-QL among disease-free survivors.
75467647|NCT01931358|Biological|ALVAC-HIV|1 mL intramuscular injection containing 10^6 CCID50/dose
75916488|NCT03623750|Drug|EGFR-TK Inhibitor|Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
76075264|NCT00815776|Device|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
76075265|NCT00815776|Device|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
75780983|NCT01224392|Radiation|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
75780984|NCT01224470|Drug|Dexmedetomidine|Dexamedetomidine intravenous injection (1 ㎍/kg )
75916489|NCT03623750|Biological|EGF-PTI|"The first day of dosing with EGF-PTI will be designated Day 1. Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92. After the 5~th vaccination, patients will enter a maintenance phase during which reduced dose vaccinations will be performed every 2 or 3 months in conjunction with the interval between detailed check-up of the patient. As this interval can vary between patients, the interval for maintenance vaccination can also vary between 2 and 3 months."
75916490|NCT03623750|Drug|Cyclophosphamide|Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
75916491|NCT00840840|Drug|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
75916492|NCT00840840|Drug|Augmentin ES-600™|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
75323803|NCT04345055|Other|Treatment of the lumbar fasciae|Treat the lumbar facial with a manual technique
75780985|NCT04406428|Procedure|NKI followed by EBD|Needle-knife incision therapy followed by endoscopic bougie dilation
75780986|NCT01126346|Behavioral|HIPEC Orientation|Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session
75780987|NCT01126346|Behavioral|Consultation with Survivorship Navigator|Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month
75780988|NCT01126346|Other|Questionnaires|Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
75323804|NCT04345055|Other|Placebo intervention|Introduce in a machine off
75323805|NCT01279031|Device|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
75323806|NCT01279031|Device|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
75323807|NCT03802825|Behavioral|Diabetes Self-Management Training|The Decision-making Education for Choices in Diabetes Everyday (DECIDE) program is a nine-module, literacy adapted diabetes and cardiovascular disease education and problem-solving training program. Participants are taught the five steps of problem solving with each module going in depth on a single step: 1) identify the problem; 2) brainstorm possible strategies for problem resolution; 3) select the most appropriate strategy; 4) apply the strategy; 5) evaluate the effectiveness of the strategy. During the six months, CHWs will have weekly or bi-weekly contact with participants in-person or by phone to deliver the DECIDE modules and address social and economic needs.
75467648|NCT01931358|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
75467649|NCT01931358|Biological|ALVAC-HIV Placebo|1 mL per injection
75467650|NCT01931358|Biological|AIDSVAX B/E Placebo|1 mL per injection
75467651|NCT01931371|Procedure|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
75467652|NCT01931371|Procedure|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
75467653|NCT01931384|Drug|Human chorionic gonadotrophin|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
75467654|NCT01931384|Drug|Placebo|Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
75629766|NCT02427269|Other|Specimen Collection|"1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection~Up to 10 research-specific biopsies obtained from the esophagus during the routine care EGD.~Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),~Two biopsies from normal squamous epithelium, and~One biopsy from each area of esophageal nodularity seen during the procedure~Pathology slides from routine care biopsies taken during the enrollment procedure, as well as retrospective pathology slides from routine care biopsies taken prior to enrollment on the study.~Up to 4 cytology brushes during the procedure."
76075266|NCT00815776|Other|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
76075267|NCT03535636|Other|Polysomnography|Sleep architecture will be assessed by polysomnography
76075268|NCT04209790|Radiation|Neoadjuvant chemoradiation|Intensity modulation radiation therapy (IMRT) with a simultaneous integrated boost with Fixed-gantry IMRT, helical tomotherapy, or Vesicular Modulated Arc Therapy (VMAT) can be used. All photon treatments shall be delivered with megavoltage machines of a minimum energy of 6 Megavolt (MV) photons. Selection of the appropriate photon energy(ies) should be based on optimizing the radiation dose distribution within the target volume and minimizing dose to non-target normal tissue.
76075269|NCT04209790|Drug|Drug Therapy with Temozolomide (benzolamide) (Standard of Care)|During Concomitant Radiation Therapy on the same day as the first fraction of radiotherapy. Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days. The drug will be administered orally daily during radiotherapy, as best tolerated by the patient. During weekends without radiotherapy (Saturday and Sunday), the drug will be taken in the morning. The dose will be determined using actual body surface area (BSA) as calculated in square meters at the beginning of the concomitant treatment. The BSA will be calculated from the height obtained at the pretreatment visit. Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg. The daily dose will be rounded to the nearest 5 mg.
75780989|NCT05052502|Other|Case Management and Follow-up|"Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.~Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ.~At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions."
75916493|NCT03595982|Drug|Procardia XL 30Mg|Procardia XL 30 mg XL Q 12h
76075270|NCT04209790|Procedure|Surgery post Radiation and Temozolomide (benzolamide)|Surgical resection of GBM will be done after radiation and Temozolomide treatment.
76075271|NCT03838822|Dietary Supplement|Cofactors|Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
75916494|NCT03595982|Drug|Procardia XL 60Mg|Procardia XL 60 mg Q 24h
75323808|NCT03802825|Other|Standard Patient Navigation|Once the participant has completed the YCLS assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 months by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention.
75323809|NCT00738023|Drug|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
75323810|NCT00738023|Drug|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
76075272|NCT01718353|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
75467655|NCT01931410|Drug|Misoprostol|
75467656|NCT01931423|Behavioral|Placental cord drainage|
76075273|NCT01718353|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
76075274|NCT01718353|Drug|Prednisone|Pharmaceutical form: Tablet Route of administration: Oral
76075275|NCT01716715|Drug|Cabozantinib S-malate|Given PO
75467657|NCT01931449|Procedure|Modified method of digestive tract reconstruction|
75467658|NCT01931449|Procedure|Routine digestive tract reconstruction|
75323811|NCT00738023|Drug|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
75629767|NCT02420431|Behavioral|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
75629768|NCT02420431|Behavioral|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
75629769|NCT02400359|Drug|Lorcaserin HCl|Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
75629770|NCT02400359|Drug|Placebo|This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
75916495|NCT00944970|Drug|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
75916496|NCT00944970|Drug|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
75916497|NCT03456206|Other|Intake of red and processed meat and fibres|The intention is to analyse exposure groups in tertiles: 1) Upper tertile (33.3% of the total sample) based on the ratio: meat/fibre intake is associated with higher risk of CID. 2) Low intake of fibre (defined as below the lower tertile [33.3% of the total sample]) and high intake of red and processed meat (defined as those above the upper tertile [33.3% of the total sample]) are independently associated with higher risk of CID, and their synergy (interaction between the factors meat and fibres) gives the highest risk outcome.
76075276|NCT01716715|Other|Laboratory Biomarker Analysis|Correlative studies
75629771|NCT02290769|Device|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
75629772|NCT02290769|Device|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
75629773|NCT02269761|Device|Nuvis Diagnostic Ultrasound System|Ultrasound of the chest
75916498|NCT03456206|Other|Lifestyle factors independently or combined|Lifestyles factors are defined as: red and processed meat, vegetables, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/fat, protein/fat from red and processed meat, glycemic index.
75323812|NCT03808909|Other|Continuous Labor Support|Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
75629774|NCT02196818|Device|Mpact Acetabular Shell|Total Hip Replacement
75629775|NCT02175186|Drug|ALBIS|
75629776|NCT02175186|Drug|Placebo|
75780990|NCT05052502|Other|Reactive focal mass drug administration (rfMDA)|"Reactive focal mass administration (rfMDA) will be implemented around the index case household and to forest co-workers/co-travelers in Thailand. The VMV will conduct the investigation visit within 7 days after the notification of the index case. All members of the index case's household as well as all members of the nearest five households around the index case's household, including temporary visitors will be invited to participate in the study and to be treated for malaria without a malaria test. After obtaining participants' or parents/guardians' consent, the VMV will proceed with the participant questionnaire, and all consenting household members will be tested for G6PD using the G6PD quantitative test prior to administration of antimalarials.~For rfMDA, all eligible participants will be offered artesunate-mefloquine (AS-MQ). Per national policy, a 14-day course of primaquine will be administered to G6PD non-deficient study participants."
75780991|NCT03740516|Drug|CC-10004|CC-10004 will be administered orally
75780992|NCT01126502|Drug|alvespimycin hydrochloride|Given IV
75916499|NCT00840216|Drug|Clarithromycin ER 500 mg tablets|1 x 500 mg
75916500|NCT00840216|Drug|BIAXIN® XL 500 mg tablets|1 x 500 mg
75916501|NCT03462446|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
75916502|NCT03462446|Drug|Vitamin K antagonists (VKAs)|As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
75916503|NCT03455816|Device|Social Diabetes App|"Social diabetes is an app for diabetes, free with CE mark, that by means of the incorporation of a glucometer (glucomen Areo) allows through NFC technology the automatic introduction of data in the application"
75916504|NCT03455816|Device|Usual clinical monitoring group (Control group)|Active Comparator: Usual clinical monitoring group (control group) This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
75916505|NCT00944892|Drug|REGN475|2 Administrations of REGN475 within 24 weeks.
75916506|NCT00944892|Other|Placebo|Placebo to match REGN475 doses
75916507|NCT00939276|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
75916508|NCT00939276|Drug|Nepafenac ophthalmic suspension vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
75916509|NCT03455660|Other|no intervention|no intervention
75916510|NCT03449186|Other|Saliva collection|
75916511|NCT03449186|Other|GCF collection|
75916512|NCT00838890|Drug|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
75916513|NCT00838890|Drug|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
75916514|NCT03455426|Drug|letrozole|Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.
75916515|NCT00794586|Drug|FTI, AZLI|Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
75916516|NCT00794586|Drug|Placebo, AZLI|Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
75916517|NCT00794430|Drug|V3381|100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
75916518|NCT00794430|Drug|Placebo|Capsule, bid, for 13 weeks
76075277|NCT01716715|Drug|Paclitaxel|Given IV
75323813|NCT04385849|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
75323814|NCT04385849|Other|Saline|Sterile saline solution
75916519|NCT00791154|Drug|AMG 479|AMG 479 is administered to subjects
76075278|NCT01696279|Drug|Lanthanum Carbonate|Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
76075279|NCT01696279|Drug|Calcium Carbonate|Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
76075280|NCT01681069|Dietary Supplement|IQP-VV-102|
75323815|NCT00708851|Other|LCD Solution with NB-UVB Phototherapy|"LCD Solution: 2 applications / day~NB-UVB Phototherapy: 3 light sessions / week"
75323816|NCT00708851|Device|NB-UVB Light Device (311-315 nm)|NB-UVB Phototherapy: 3 light exposures / week
75323817|NCT03809221|Drug|Triptorelin acetate|Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
75323818|NCT02993627|Dietary Supplement|Spirulina|2 g(4* 500 mg tablets) daily intake of Spirulina Platensis
75629777|NCT02086448|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
75629778|NCT02086448|Device|sham-CPAP|
75629779|NCT02086448|Other|Sleep hygiene|Information about sleep apnea and healthy sleep. Information about local sleep resources
75629780|NCT02052583|Procedure|therapeutic hypothermia at 32 ° C|
75629781|NCT02052583|Procedure|therapeutic hypothermia at 34 ° C|
75629782|NCT01993836|Drug|Total intravenous anesthesia with propofol|
75629783|NCT01993836|Drug|General anesthesia with isoflurane|
75780993|NCT01126502|Other|diagnostic laboratory biomarker analysis|
75780994|NCT01126502|Other|pharmacogenomic studies|
75780995|NCT01126502|Other|pharmacological study|
75916520|NCT00791154|Drug|Etoposide|Etoposide is administered to subjects
76075281|NCT01681069|Other|Placebo|
75629784|NCT01988285|Other|Specimen Collection|Blood collection, possible saliva collection, possible urine collection, and biopsy collection
75629785|NCT01988285|Other|Questionnaires|Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
75629786|NCT01962818|Other|HFOV combined with sigh breaths|"It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
75629787|NCT01828190|Other|Hyperbaric oxygen|HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
75629788|NCT01818739|Procedure|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
75629789|NCT01818739|Drug|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
75629790|NCT01818739|Drug|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
75780996|NCT01224548|Other|vegan instruction and food accessibility|weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
75629791|NCT01818739|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
75629792|NCT01793623|Other|atrial tissue|retrieval of discarded atrial tissue
75629793|NCT01717586|Drug|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into three cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg or 40mg.
75629794|NCT01717586|Drug|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
75916521|NCT00791154|Drug|Placebo|Placebo is administered with Carboplatin and Etoposide
75916522|NCT00791154|Drug|AMG 102|AMG 102 is administered to subjects
76075282|NCT04555759|Other|2-minute walk test|The patients will do a 2-minute walk test, using their walking aids or braces
76075283|NCT01936181|Drug|Remicade (infliximab)|
76075284|NCT01936181|Drug|SB2 (proposed biosimilar to infliximab)|
75629795|NCT01714349|Procedure|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
75629796|NCT01639586|Behavioral|respite platform|Impact of the respite platform patient care on health profit
75629797|NCT01639586|Behavioral|Day care|Impact of the day care on health profit of patient
75629798|NCT01639586|Behavioral|No access to a respite structure|Control group without access to a respite structure
75629799|NCT01620541|Procedure|Ankle Arthrodesis|All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.
75323819|NCT02993627|Other|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
75780997|NCT01224548|Other|control|no intervention in until June 2011. The control group start vegan diet in July 2011.
75780998|NCT01218464|Drug|Conventional plus MSC treatment|Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 12 weeks.
75780999|NCT01218464|Drug|Conventional plus pacebo treatment|Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
75781000|NCT03933956|Drug|Empagliflozin 10 MG|Oral empagliflozin 10mg daily for 30 days
75781001|NCT01218620|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
75781002|NCT01218620|Drug|Ketoconazole|Given PO
75781003|NCT01218620|Drug|Rifampin|Given PO
75916523|NCT00791154|Drug|Carboplatin|Carboplatin is administered to some subjects in combination
75916524|NCT00791154|Drug|Cisplatin|Cisplatin is administered to some subjects in combination
75916525|NCT00938652|Drug|gemcitabine/carboplatin|"Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)"
76075285|NCT04642235|Other|Nature Nook|The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.
75323820|NCT02993315|Biological|nDC vaccination|
75323821|NCT02993315|Biological|placebo injection|
75323822|NCT00739583|Drug|CHG 2% w/v and IPA 70% v/v|Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds
75916526|NCT00938652|Drug|Iniparib|"Body weight adjusted dose~intravenous infusion (60 ± 10 minutes)"
75467659|NCT01931488|Other|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
75467660|NCT01931488|Device|SPECT imaging|
75467661|NCT01931501|Drug|Torrent's Montelukast Sodium Chewable Tablets 5mg|
75467662|NCT01931501|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
75629800|NCT01620541|Procedure|Ankle Arthroplasty|Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
75629801|NCT01316146|Drug|CAR.CD30 T cells|"Three dose levels will be evaluated:~Group One, 2x10^7 cells/m^2~Group Two, 1x10^8 cells/m^2~Group Three, 2x10^8 cells/m^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc."
75781004|NCT01218620|Drug|Midazolam Hydrochloride|Given IV
75781005|NCT01218620|Drug|Omeprazole|Given PO
75781006|NCT01218620|Drug|Tolbutamide|Given PO
75781007|NCT01218620|Drug|Dextromethorphan Hydrobromide|Given PO
75916527|NCT03550352|Drug|TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg)|Participants will start by taking 1 capsule twice daily for 1 week (5 mg THC/5 mg CBD) and increase the number of capsules as tolerated to a maximum of 6 capsules taken throughout the day by weeks 5-12 (15 mg THC/15 mg CBD total per day).
75323823|NCT00739583|Drug|Iodophor 0.7% and IPA 74% w/w|Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
75323824|NCT04385459|Other|Coronary artery disease|Exposure
75323825|NCT01274741|Behavioral|Creating Change (CC)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
75323826|NCT01274741|Behavioral|Seeking Safety (SS)|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
75467663|NCT01931514|Drug|Torrent's Montelukast Sodium chewable Tablets 5mg|
75467664|NCT01931514|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
75629802|NCT01233661|Other|short AVD pacing ; prior (stable) programming|short AVD pacing prior (stable) programming
75781008|NCT01218620|Other|Pharmacological Study|Correlative studies
75781009|NCT01218620|Other|Laboratory Biomarker Analysis|Correlative studies
75781010|NCT00323297|Drug|Bosentan|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
75781011|NCT00323297|Other|Placebo|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
75781012|NCT00323297|Drug|Bosentan|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
75629803|NCT01136343|Other|lifestyle modified project|education, counseling
75629804|NCT00753545|Drug|AZD2281|Tablets Oral BID
75916528|NCT03550352|Drug|TN-C200M2 oral capsules (CBD 200 mg)|Participants will start by taking 1 capsule once daily for 1 week (200 mg CBD) and increase the number of capsules as tolerated to a maximum of 4 capsules taken throughout the day by weeks 5-12 (800 mg CBD total).
75916529|NCT04266158|Device|Myoelectric UE Device-UE Orthosis-No Device|all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.
75916530|NCT00928590|Drug|Travoprost/Timolol Maleate Fixed Combination solution|
75629805|NCT00753545|Drug|matching placebo|matching placebo bid
75323827|NCT02993237|Drug|DRV/COBI FDC placebo tablet|Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
75323828|NCT02993237|Drug|D/C/F/TAF FDC placebo tablets|Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
75629806|NCT00674882|Other|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
75629807|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
75781013|NCT00323297|Drug|Sildenafil Citrate|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
75781014|NCT01126658|Other|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
75781015|NCT01218698|Drug|Losartan Potassium Tablets|
75781016|NCT02529098|Other|fMRI|functional magnetic resonance imaging
75781017|NCT02529020|Device|Mouthguard|Condition of wearing mouthguard
75781018|NCT02529020|Device|No mouthguard|Condition without mouthguard
75781019|NCT01224860|Drug|Telmisartan|One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
75323829|NCT03808597|Other|Digital health promotion intervention|Digital health promition related to HIV, Tuberculosis and TSCT in a digital format.
76075286|NCT04642235|Behavioral|Nature Coach|"The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
75629808|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
75781020|NCT01224860|Drug|Losartan|One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
76075287|NCT04642235|Other|Nature Nook + Nature Coach|The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
76075288|NCT04641611|Other|Bicaval cannulation|Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied
76075289|NCT04641611|Other|Cavoatrial cannulation|Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
76075290|NCT01696045|Biological|Ipilimumab|
75323830|NCT03808207|Other|Dietary counseling and DHA dietary increase in breastfeeding mothers|Specific dietary advices in order to increase the daily/weekly intake of docosahexaenoic acid of breastfeeding mothers for the first 3 months after delivery
75781021|NCT00323063|Drug|gemcitabine hydrochloride|Given IV
75781022|NCT00323063|Drug|imatinib mesylate|Given orally
75781023|NCT03930290|Diagnostic Test|Vaginal tactile imager|Vaginal elasticity evaluation by vaginal tactile imaging analysis.
75323831|NCT02993159|Drug|Afimoxifene|Applied to the breast
75323832|NCT02993159|Other|Laboratory Biomarker Analysis|Correlative studies
75781024|NCT03930368|Other|low GI diet with regular supplementation of raw corn starch|Patients will be guided with a low GI diet with 60%~70% of energy from carbohydrates. RCS constituted 30%~50% of daily carbohydrate, and was supplemented as snacks every 4~6 hours (25g per time) especially at night.
75916531|NCT03512756|Drug|SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)|Daily oral therapy for cancer
75916532|NCT03512756|Drug|Capecitabine, Gemcitabine, and 5-FU|"Investigator choice of the following therapies:~Capecitabine, Gemcitabine, and 5-FU"
75916533|NCT04697940|Biological|Decitabine-primed Tandem CAR19/20 engineered T cells|"Phase I dose escalation (3+3) : dose 1 (0.5 × 10^6 cells per kg) dose 2 (2 × 10^6 cells per kg) dose 3 (5 × 10^6 cells per kg)~Phase II: Appropriate dose"
75323833|NCT02993159|Other|Placebo|Given PO
75323834|NCT02993159|Other|Placebo|Applied to the breast
75916534|NCT04697940|Drug|Fludarabine|Intravenous fludarabine 25-30 mg/m^2/day on days -5, -4, and -3.
75916535|NCT04697940|Drug|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m^2/day on days -5, -4, and -3.
75916536|NCT03453398|Other|Shifts working hours with different schedules|"Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study."
75916537|NCT00836706|Drug|clarithromycin|500 mg Tablet
75323835|NCT02993159|Drug|Tamoxifen Citrate|Given PO
75323836|NCT03807505|Procedure|Interscalene brachial plexus nerve block|An interscalene brachial plexus nerve block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
75323837|NCT03807505|Procedure|Erector spinae plane block|An erector spinae plane block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
75629809|NCT00418821|Biological|Aldurazyme (laronidase)|dose of 0.58mg/kg body weight intravenously (IV) every week
75629810|NCT00408447|Drug|Busulfan|Busulfan 4 mg/kg/d x 4d
75629811|NCT00408447|Drug|Fludarabine|Fludarabine 30 mg/m2/d x 6d
75629812|NCT00408447|Drug|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
75629813|NCT00408447|Procedure|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
75781025|NCT01225016|Drug|Definity contrast agent|Thyroid ultrasound using contrast agent
75781026|NCT02532881|Other|Videos|Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.
75781027|NCT02532881|Other|Treatment as usual|Treatment as usual
75781028|NCT01329302|Procedure|Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration|In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid
75916538|NCT00836706|Drug|BIAXIN®|500 mg Tablet
75916539|NCT03453242|Other|Bone measurement by HR-pQCT and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites one measurement will be performed by HR-pQCT to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
76075291|NCT01716169|Device|Helicoll|Helicoll Collagen I Wound Dressing
75629814|NCT00278915|Drug|Fulvestrant|intramuscular injection
75629815|NCT02864238|Other|electronic milestone pathway|an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
75629816|NCT04285320|Drug|Intravesical antibiotic instillation|"Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~Amikacin-30 mg in 60 ml of sterile water~Gentamycin-80mg in 60ml sterile water~Tobramycin-80 mg in 100 ml of sterile water"
75629817|NCT04285320|Drug|Antibiotic oral suppressive therapy|"In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~Trimethoprim daily (100 mg)~Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~Cephalexin daily (125 mg)~Cephalexin daily (250 mg)~Fosfomycin every 10 days (3 grams)"
75467665|NCT01931540|Behavioral|Exercise Training|Three times a week, for four months.
75467666|NCT01931553|Other|Standardized attending morning rounds|
75467667|NCT01931579|Device|confocal endo-microscopy|The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
75467668|NCT01931592|Drug|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
75323838|NCT03802513|Other|Physical Therapy|Individualized physiotherapy including exercises to be performed by the Veteran at home.
75629818|NCT00970632|Drug|Tadalafil 5 mg|Tadalafil 5 mg po QD for 12 weeks
75781029|NCT01061255|Other|Evaluation of the stress|"Medical Students having to solve a medical problem in ambulatory setting (studied group) vs. in hospitalisation setting (control group).~Measures: The French version of the Anxiety Spielberger test is administered just before and after each problem solving session.~Cortisol salivary samples are taken before and after each problem solving session. Salivary cortisol levels have been shown to be correlated to stressful situations and some personality traits but with some difference according to gender."
75781030|NCT01220882|Radiation|Radiographic skeletal age assessment|bone age assessment from the elbow lateral radiograph
75781031|NCT03982745|Device|bonfils|bonfils intubation
75781032|NCT01328990|Drug|sulfadoxine-pyrimethamine plus amodiaquine|one dose of sulfadoxine-pyrimethamine 25/1.25 mg/kg plus three daily doses of amodiaquine, 10 mg/kg/day
75781033|NCT01047449|Procedure|No-touch SVG harvest vs conventional SVG harvest technique|Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)
75323839|NCT02993003|Device|Nasopharyngeal probe|nasopharyngeal probe insertion
75323840|NCT01279421|Behavioral|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
75323841|NCT01279421|Behavioral|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
75629819|NCT00970632|Drug|Placebo tablet|Placebo tablet po QD for 12 weeks
75781034|NCT01047449|Dietary Supplement|Fish oil supplementation vs placebo|Fish oil supplementation [1g tablets (55% fish oils - EPA:DHA 33%:22%)] taken twice daily for 1 year post-op
75781035|NCT01220960|Other|art therapy|Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
75781036|NCT01047605|Drug|Neurapas balance|6 tablets single dose
75781037|NCT01047605|Drug|Pascoflair 425 mg|3 tablets , single dose
75781038|NCT01047605|Drug|P-Tabletten weiß|3 tablets, single dose
75781039|NCT03934346|Other|Zinc amino acid complex|Zinc in the form of a Zinc Amino Acid Complex (ZnAA) is provided with a test diet, and the amount of zinc that dissociates from the ZnAA and is thus absorbed via an ionic zinc transport pathway is determined based on the Hill transport kinetics for the respective subject.
75781040|NCT03983213|Procedure|mpfl reconstruction|Harvested gracilis tendon is pulled through patella and femur in anatomic position and locked with interference screw.
75781041|NCT01329068|Behavioral|individual consult|regular individual consultations
75916540|NCT00836472|Drug|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
75916541|NCT00836472|Drug|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
75916542|NCT03452462|Device|Pacing|Programming of either Direct His Bundle pacing or biventricular pacing
75323842|NCT02992847|Other|Unenhanced MRI|
75629820|NCT00970632|Drug|Tamsulosin|Tamsulosin 0.4 mg po QD for 12 weeks
75323843|NCT00723931|Biological|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
75323844|NCT00740129|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
75629821|NCT00970632|Drug|Placebo capsule|Placebo capsule po QD for 12 weeks
75629822|NCT02863302|Other|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
75629823|NCT04285710|Device|Phototherapy|The key intervention aspect of this study is the application of 15 J/cm2 of 410 nm pulsed light directly onto the infected diabetic wounds of subjects every week over the course of 3 months, allowing for the cumulative exposure of around 180 J/cm2 for the entire study. This 15 J/cm2 weekly dosage of blue light will split up into two sessions every week, with each session applying 7.5 J/cm2 of light treatment. Phototherapy will be applied twice per week, with one phototherapy session occurring directly following the debridement surgery during the first visit of the week and the other session occurring after the study clinician removes the subjects wound dressings at the second visit.
75916543|NCT03451760|Drug|Feru-guard 100M|Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.
75781042|NCT01329068|Behavioral|group medical consult|group medical consult
76075292|NCT01716169|Device|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
76075293|NCT01935947|Drug|Azacitidine|Given SC
75323845|NCT00762853|Drug|Fluoride|Brush half mouth once with assigned study treatment
75781043|NCT01061489|Other|auditory discrimination training|10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
75916544|NCT03451760|Other|Feru-guard 100M Placebo|In order to conduct a double-blind, controlled trial, the placebo will be contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding. The placebo study drug will be matched to the Feru-guard 100M in terms of appearance, smell, and taste.
76075294|NCT01935947|Drug|Azacitidine|Given PO
75323846|NCT00762853|Drug|Fluoride and triclosan|Brush half mouth once with assigned study treatment
76075295|NCT01935947|Drug|Docetaxel|Given IV
76075296|NCT01935947|Drug|Entinostat|Given PO
75916545|NCT03134664|Procedure|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
75916546|NCT03134664|Procedure|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
75916547|NCT04184336|Other|surveillance|
75916548|NCT04473846|Drug|PK general anesthesia|Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).
75916549|NCT04473846|Drug|PFK combination|Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
76075297|NCT01935947|Drug|Gemcitabine Hydrochloride|Given IV
75323847|NCT00740207|Drug|VISIPAQUE 270|VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
75323848|NCT00740207|Drug|Isovue 250|ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
75323849|NCT00724009|Drug|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
75323850|NCT04384081|Drug|BI 456906|Solution for injection
75323851|NCT04384081|Drug|Placebo|Solution for injection
75323852|NCT01279499|Drug|Sevoflurane|Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
75467669|NCT01931592|Drug|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
75781044|NCT01061489|Other|physical movement training|10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
75916550|NCT03448874|Device|Seal-G MIST System|Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.
75916551|NCT05381532|Behavioral|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.
75916552|NCT03129698|Drug|Apatinib|Apatinib 250mg daily
76075298|NCT01935947|Drug|Irinotecan Hydrochloride|Given IV
76075299|NCT01935947|Other|Laboratory Biomarker Analysis|Correlative studies
76075300|NCT01935947|Drug|Pemetrexed Disodium|Given IV
76075301|NCT04547803|Other|Standard of Care|Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice
76075302|NCT04547803|Other|Video Visit|15-20 minute Video visit with an advanced practice provider (nurse practitioner or physician assistant) approximately 2-5 days after discharge.
76075303|NCT02986321|Drug|CHF6001|Dose response: Test one of 4 different doses of CHF6001
76075304|NCT02986321|Drug|Budesonide|active control
76075305|NCT02986321|Drug|Placebo|placebo control
76075306|NCT04554667|Behavioral|Exercise Intervention|Heavy Lifting Strength Training
76075307|NCT01618019|Dietary Supplement|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
76075308|NCT01618019|Dietary Supplement|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
76075309|NCT01593787|Drug|LCZ696|100 mg, 200 mg, 400 mg tablets.
76075310|NCT04410601|Procedure|Total thyroidectomy|DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.
75467670|NCT01931605|Device|Prostatic arterial embolization using BeadBlock (Terumo)|Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
75467671|NCT01931618|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
75916553|NCT04473456|Procedure|Simultaneous EGD and colonoscopy|Patients are examined simultaneously by EGD and colonoscopy
75467672|NCT01931618|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
75916554|NCT03355118|Other|General anaesthesia and major surgery|The effect of general anaesthesia and surgery on oxygen transport and how it relates to outcome
75467673|NCT01931618|Behavioral|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
75629824|NCT04285710|Procedure|Debridement Surgery and Wound Dressing|All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
75629825|NCT02862756|Other|diffusion-weighted MRI and clinical examination|
75781045|NCT01225094|Drug|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.
76075311|NCT01951157|Drug|Docetaxel|Powder for solution for infusion
76075312|NCT01951157|Drug|Gemcitabine|Powder for solution for infusion
75916555|NCT03332264|Device|SeQuent Please OTW|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter
75467674|NCT01931657|Drug|Mifepristone prior to Mirena|
75916556|NCT03332264|Device|Eluvia Vascular Stent System|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
75467675|NCT01931657|Drug|Placebo prior to Mirena insertion|
75467676|NCT01931683|Drug|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
75629826|NCT04285008|Device|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device (K191220), intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
75629827|NCT04286880|Procedure|PRP injection|"Clinically proven cases of Trigger points in masseter muscle will be randomly and equally divided into test group and control group. The selected subjects will be divided into two groups.~Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle according to symptoms of patient at baseline (0 week). PRP will be prepared as per methodology mentioned by Okuda et al 2003."
75629828|NCT04286880|Procedure|Dry needling|In control group all the armamentarium and procedure will remain same except that no PRP solution will be delivered. Only dry needling will be performed on the baseline.
75916557|NCT03332264|Device|Nitinol stent|Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent
75916558|NCT03263078|Drug|Propofol|For the maintenance of anesthesia, we used 2% propofol (Fresofol®, Fresenius Kabi, Germany) administered by the target controlled infusion (TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) in Schnider mode with an effect concentration (Ce) of 2.5-3.5 µg ml-1
75629829|NCT01144364|Drug|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
75629830|NCT04286490|Other|Prone position|Abdomen suspension in prone position
75629831|NCT01119248|Other|axillary temperature before MRI and after the MRI|observation of body temperature changes with axillary temperature measurement with MRI compatible device
75781046|NCT01225094|Other|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
75916559|NCT03263078|Drug|Sevoflurane|Anesthesia was maintained using 1-3% sevoflurane (ULTANE®, AbbVie Inc., USA) in the Sevoflurane group.
75916560|NCT05349006|Drug|Azathioprine|Dose related to weigh (100 mg for <50 kg, 150 mg 50-100 kg, 200 mg for >100 kg) = 2 to 4 50mg oral caps, daily, during all the study period
75916561|NCT05349006|Other|Placebo|Dose related to weigh (100 mg for <50 kg, 150 mg 50-100 kg, 200 mg for >100 kg) = 2 to 4 50mg oral caps, daily, during all the study period
75916562|NCT03450980|Other|EyeTurn App|App software which analyzes the position of ocular surface reflections in a photograph to quantify eye misalignment (strabismus)
76075313|NCT01951157|Drug|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
76075314|NCT01363349|Drug|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
76075315|NCT01363349|Drug|Risperidone|
76075316|NCT00867100|Drug|700 mg IV|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
75467677|NCT01931683|Device|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
75629832|NCT01131494|Other|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
75781047|NCT01128374|Procedure|Periodontal Scaling and root planing|Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
75781048|NCT03932474|Combination Product|SAMEUp|One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
75781049|NCT03932474|Other|Placebo|One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
75916563|NCT01984502|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
75916564|NCT00785226|Drug|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
75916565|NCT00785226|Drug|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
75916566|NCT05322278|Other|Data collection|No interventions
75916567|NCT00920946|Drug|Dimebon|20 mg Dimebon orally TID
75916568|NCT00920946|Other|Placebo|Orally TID
75323853|NCT01279499|Drug|Sevoflurane|Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
75323854|NCT01279499|Drug|Propofol- Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR > 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min"
75781050|NCT00322049|Biological|Tetravalent live attenuated dengue vaccine|"DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit)."
75781051|NCT00322049|Biological|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
75916569|NCT04686422|Device|Tetric PowerFill|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the PowerCure system.
75916570|NCT02598388|Biological|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles).
75916571|NCT02598388|Biological|MVA-BN-Filo|One 0.5 mL IM injection of (1x10*8 infectious units).
75916572|NCT02598388|Biological|Placebo|One 0.5 mL IM injection of 0.9 percent (%) saline.
75467678|NCT01931696|Device|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
75916573|NCT03448640|Drug|Drug used in the examination of premature infants.|to investigate side effects of eye drops used
75916574|NCT00836004|Drug|Clindamycin 300 mg capsule|1 x 300 mg
75916575|NCT00836004|Drug|Cleocin HCl 300 mg capsules|1 x 300 mg
75916576|NCT00917826|Drug|Arginine Butyrate|1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
75916577|NCT00917826|Drug|Ganciclovir|5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)
75916578|NCT00917826|Drug|Valganciclovir|900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
75916579|NCT03102320|Drug|Cisplatin|Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles
75916580|NCT03102320|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle
75916581|NCT03102320|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
76075317|NCT00867100|Drug|350 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
75916582|NCT00835692|Drug|Clarithromycin|500 mg Tablet
75916583|NCT00835692|Drug|Biaxin®|500 mg Tablet
75916584|NCT00835614|Drug|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
76075318|NCT00867100|Drug|Placebo|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
75629833|NCT04310852|Device|BioCue Concentration Kit|The treatment will be carried out in the operating room under ordinary hospitalization and involves the application of 9 ml of autologous bone marrow concentrate in the knee affected by arthrosis. Specifically, 3 ml will be applied at the level of the bone-cartilage interface of the femur, 3 ml at the level of the bone-cartilage interface of the tibia, and 3 ml will be injected into the joint for a simultaneous action also at the level of the cartilage. To obtain the necessary amount of bone marrow concentrate, an aspirate of bone marrow will be taken from the iliac crest (60 ml) and homolateral tibia (30 ml) of the patient and concentrated by BioCue Concentration Kit, company Zimmer biomet, and centrifuge. This autologous bone marrow concentrate will be injected by means of the Perfuse at the level of the tibial and femoral bone-cartilage interface of the percutaneous arthrosis affected compartment under radiographic control.
75781052|NCT01124240|Drug|Cilengitide|"Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption.~Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) is given over a period of 6 weeks (RTX Monday to Friday, both TMZ and PCB seven days a week).~After a break of 4 weeks, adjuvant TMZ (50mg/m2 p.o in first cycle, 60 mg/m2 p.o. in subsequent cycles) and PCB (50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) are then given daily D1 to 20. This TMZ/PCB cycle is repeated every 28 days over a total period of 6 cycles."
75629834|NCT01131260|Device|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
75916585|NCT00835614|Drug|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
75781053|NCT01124318|Drug|Lactofiltrum|Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
75781054|NCT01124318|Drug|Placebo|Placebo 2 tablets 3 times a day before meals during 21 days
75781055|NCT03930134|Procedure|sparse uterine suture|The slowly absorbed Vicryl 1 suture with a large round needle is introduced intramyometrially right above the endometrium. The suture starts in one corner and proceeds along the lower then the upper edge returning back to the incision point. Subserous layer is closed upon using the same thread in order to cover the purse suture and to complete the haemostasis while increasing the wound thickness.
75781056|NCT03930134|Procedure|one layer uterine closure|one layer classical continious uterine closure using slowly absorbed Vicryl 1
75781057|NCT01225328|Behavioral|Behavioral activation/problem-solving (BA/PS)|Six weekly telephone sessions to train participant in BA/PS procedures
75781058|NCT01221116|Drug|levosimendan|levosimendan 0.1 microgram/kg/min) for 24 hours
75467679|NCT01931696|Device|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
75781059|NCT03929744|Drug|LY3502970|Administered orally.
75629835|NCT00965094|Drug|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
75629836|NCT00965094|Drug|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
75781060|NCT03929744|Drug|Placebo|Administered orally.
75781061|NCT03929744|Drug|Atorvastatin|Administered orally.
75781062|NCT03929744|Drug|Simvastatin|Administered orally.
75916586|NCT04812886|Other|Epidemiological study|Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis
75916587|NCT03448562|Procedure|CPVI|ablate around the pulmonary vein orifice
75916588|NCT03448562|Procedure|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
75916589|NCT04819750|Device|MusicCare® device|The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
75781063|NCT03929744|Drug|Midazolam|Administered orally.
75781064|NCT01225406|Drug|Tenofovir|
75781065|NCT01128608|Procedure|24-Hr Esohpageal pH Monitoring|There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
75781066|NCT01128608|Procedure|PCO2 Acid Perfusion and 0.1N HCI Perfusion|A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
75781067|NCT01126814|Drug|Imatinib (Gleevec)|
75781068|NCT03929510|Drug|14C-PF-06651600|Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
75781069|NCT03929510|Drug|14C-PF-06651600 IV|IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
75916590|NCT04819750|Device|Headphones with noise reduction|Headphones with noise reduction without music
75916591|NCT00835536|Drug|Ribavirin 200 mg tablets|1 x 200 mg, single-dose non-fasting
75781070|NCT03929510|Drug|PF-06651600|Oral solution 200mg
75916592|NCT00835536|Drug|COPEGUS™ 200 mg Tablets|1 x 200 mg, single-dose non-fasting
75916593|NCT05321966|Other|Visual video education|The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment
75916594|NCT04812574|Procedure|Periurethral injection|Patients were in the lithotomy position for the procedure. After preparation, topical Lidocaine gel was instilled around the meatus and a 16 F probe was attached. The catheter balloon was inflated to localize the bladder neck and to ensure that injections were performed in the correct anatomical plane. Hypertonic saline (10% NaCl) was injected to the alignment of the urethral meatus in the order of 3-6-9-12 hours of the clock (5 cc to each site, totaling 20 cc). Syringes with 27 Gauge (0.40 mm) outer diameter were used to ensure controlled injection. Since the female urethra is about 4 cm in length, the needle was advanced about 3 cm. Due to the possibility of significant pain with hypertonic saline, 2 cc of Lidocaine hydrochloride was added into the solution.
75916595|NCT04812574|Drug|Hypertonic (10%) saline|Periurethral hypertonic saline (10%)
75629837|NCT00965094|Drug|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg [day 0 (2 hrs prior to Tx) and day 4 post Tx] to be applied as 10 sec. bolus injection, i.v.
75323855|NCT01279499|Drug|Propofol, Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR > 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min"
75467680|NCT01931722|Dietary Supplement|Branched chain amino acid|seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
75467681|NCT01931722|Behavioral|Strength training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
75629838|NCT00965094|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
75629839|NCT00965094|Drug|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg [prednisone, or equivalent, was used throughout the study period.
75629840|NCT04286256|Behavioral|Motivational Interviewing|Participants/caregivers will receive several telephone-based and in-person motivational interviewing sessions along with specific oral health recommendations.
75629841|NCT03634098|Device|new quantitative imaging techniques with contast products|magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue
75629842|NCT03634098|Diagnostic Test|blood sample|extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
75629843|NCT03634098|Diagnostic Test|second generation tests|second generation tests NIT-NASHr et NIT-A2F2
75629844|NCT04285944|Other|Mavig X-ray Protective Drapes|Mavig X-ray Protective Drapes®
75629845|NCT01131182|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
75629846|NCT01131182|Drug|Comparator: Sulfonylurea|Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
75781071|NCT03929276|Device|high-intensity laser therapy & exercises|A total of 15 sessions of high-dose laser treatment- i Lux Laser (Mectronic Medicale, Italy)- (in the first phase, 8 Watt for the analgesic effect; in the second phase, 12 Watt in burst mode for the biostimulation effect; and finally in the third phase with 8 Watt) will be applied.
75781072|NCT03929276|Device|Shame laser & exercises|Sham laser treatment (the same device to be used, 0 watts) will be given.
75781073|NCT03929276|Other|exercise|Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
75781074|NCT01221428|Biological|Umbilical Cord Mesenchymal Stem Cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1*10/7).
75781075|NCT01225484|Procedure|Continuous femoral nerve block + periarticular infiltration|Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.
75916596|NCT05321732|Drug|DWP16001|DWP16001 A mg
76075319|NCT00867100|Drug|140 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
75323856|NCT04384237|Procedure|Er,Cr:YSGG laser-aided CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a 9 x 0.5 mm laser tip into the gingival sulcus with an angle of 10-15º to the radicular surface
75467682|NCT01931748|Drug|MELSMON|
75467683|NCT01931748|Drug|UNCNT|
75467684|NCT01931761|Drug|[C14] selumetinib (oral)|Single oral administration [C14] 75mg
75629847|NCT01131182|Drug|Metformin|Participants could continue pre-study metformin as concomitant therapy during the study.
75629848|NCT02862444|Other|Culturally Appropriate Intervention|Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
75629849|NCT04312100|Other|oxygen treatment|different kinds of oxygen treatments will be given to patients according to their state of illness
75629850|NCT00964860|Device|Glide dental floss|Glide waxed dental floss
75629851|NCT01131104|Drug|PDE5 Inhibitors|Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
75629852|NCT02861430|Procedure|Immunochemistry and molecular biology on sentinel lymph node specimen|
75629853|NCT04264884|Drug|Daratumumab|Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.
75916597|NCT05321732|Drug|DWP202010|DWP202010 B mg
76075320|NCT05310370|Genetic|Testing of homologous recombination deficiency|A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
75629854|NCT04284696|Dietary Supplement|Pregnan-C-Gum(R) chewing gum|"Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days ad libitum"
75467685|NCT01931787|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
75467686|NCT01931800|Biological|Sampling of blood|
75467687|NCT01931826|Procedure|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
75467688|NCT01931826|Procedure|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
75629855|NCT04284696|Dietary Supplement|Placebo chewing gum|"Using a chewing gum without vitamin C (per piece/gum) for 14 days ad libitum"
75629856|NCT02861742|Other|Delivery of questionnaires|After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
75629857|NCT02861742|Behavioral|Questionnaire T1 to fill|T1 is to fill before chemotherapy.
75781076|NCT01225484|Procedure|Intraarticular and periarticular ropivacaine|Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
75781077|NCT03929354|Behavioral|Risk Factors Modification Programme|12-week supervised risk factor modification programme derived from the EuroAction Study standards.
75781078|NCT03929354|Behavioral|Standard Care|Patients advised to adjust lifestyle without the support of the structured supervised programme.
75916598|NCT04586556|Diagnostic Test|Polyps detection by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedback (polyp detection, tracking, and pathology prediction) will be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp or the information to predict pathology
75323857|NCT04384237|Procedure|Conventional CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a surgical blade (#11)into the gingival sulcus at an angle of 10-15º to the radicular surface
75323858|NCT01274975|Other|Autologous Adipose Derived Mesenchymal Stem Cells|Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells
75323859|NCT02992925|Biological|DPT-IPV-Hib-High（Combined Vaccine）|
75323860|NCT02992925|Biological|DPT-IPV-Hib-Low（Combined Vaccine）|
75323861|NCT02992925|Biological|Hib vaccine|
75467689|NCT01931917|Behavioral|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
75467690|NCT01931917|Behavioral|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
75629858|NCT02861742|Behavioral|Questionnaire T2 to fill|T2 is to fill after the 6th cycle of chemotherapy.
75629859|NCT02861742|Behavioral|Questionnaire T3 to fill|T3 is to fill at the end of radiotherapy.
75629860|NCT02861742|Behavioral|Questionnaire T4 to fill|T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
75629861|NCT02861742|Behavioral|Questionnaire T5 to fill|T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
75781079|NCT01128686|Other|No intervention|This study is retrospective chart review
75781080|NCT01218932|Drug|A|Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
75323862|NCT02992925|Biological|DPT-IPV|
75323863|NCT00762931|Device|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
75323864|NCT01275209|Drug|HCD122|
75323865|NCT00780715|Drug|Gliclazide MR|30mg daily increased to 60mg if HbA1c > 7% at 3 months
75323866|NCT00780715|Drug|Sitagliptin|Sitagliptin 100mg daily for 6 months
75323867|NCT00780715|Drug|Pioglitazone|Pioglitazone 30mg daily , increased to 45mg daily if HbA1c >7% at 3 months. 6 months duration
75323868|NCT00780715|Drug|Metformin|Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
75323869|NCT03807193|Behavioral|Self-selected treatment|The participants will select their own treatment material with the help of a written manual. The interventions possible to choose are all interventions used in standard cognitive behavior therapy for anxiety and depression.
75323870|NCT03807193|Behavioral|Predetermined treatment|The participants will be given a treatment program designed to address worry and generalized anxiety disorder. The program are based on newer forms of cognitive behavior therapy and include mindfulness and acceptance.
75323871|NCT03807193|Behavioral|Weekly support|The participants will have scheduled weekly support, once a week, during the treatment. The support till be delivered by students in clinical psychology.
75467691|NCT01931930|Dietary Supplement|Perilla extract|
75467692|NCT01931930|Dietary Supplement|Maltodextrin|
75467693|NCT01931943|Drug|selatinib ditosilate tablets|
75467694|NCT01931982|Drug|Victoza|
75467695|NCT01932021|Procedure|adipose tissue grafting|
75629862|NCT00630162|Genetic|amoeba|
75629863|NCT01118780|Drug|Duloxetine|Administered by mouth, daily for 10 weeks
75629864|NCT01118780|Drug|Placebo|Administered by mouth, daily for 10 weeks
75323872|NCT03807193|Behavioral|Support on demand|The participants will have support if and when they ask for it by themselves. If asked for the support will be delivered by students in clinical psychology.
75323873|NCT03806881|Device|reversed glenoid prothesis|All patients will undergo a primary or revision arthroplasty with Glenius according to the routine practice at the investigation site and will be followed at specified visiting moments, during which radiological and clinical data will be gathered.
75323874|NCT03800485|Device|IMT|A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
75323875|NCT01273987|Procedure|rONB|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
75467696|NCT01932034|Device|BestDose Computer Software|BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
75467697|NCT01932073|Device|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
75467698|NCT01932086|Dietary Supplement|White rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
75323876|NCT03806725|Diagnostic Test|Intravenous administration of iodinated contrast medium for coronary CT angiography|Administration of iodinated contrast medium for coronary CT angiography
75781081|NCT01218932|Drug|B|Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
75916599|NCT04819672|Other|Low Intensity Training associated with Partial Blood Flow|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
75916600|NCT04819672|Other|Low Intensity Training associated with Partial Blood Flow-Sham|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
75323877|NCT01274143|Behavioral|TeleCARE|Personalized telephone-delivered cancer risk assessment.
75323878|NCT01274143|Behavioral|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
75323879|NCT00740831|Drug|PGL4001|tablets
75629865|NCT04285632|Other|Plyometrics exercises|"Counter Movement Jump exercise. The subject will be placed in an upright standing position, with his hands on his hip. It will perform a rapid downward movement in which it will flex the hips and knees and, immediately, a rapid extension of the legs that will result in the maximum vertical jump. During the flight phase the subject will keep the legs straight. The landing will be done with both feet at the same time. The intervention will be carried out for 300 seconds, in 2 series of 30 jumps each and with 3 minutes of rest between series.~Drop Jump exercise. The players will be placed on a step, standing and with their feet shoulder-width apart. They will drop forward, landing with both feet at the same time. Upon touching the ground they will perform a maximum vertical jump. The intervention will be carried out for 600 seconds, in 2 series of 25 jumps each, and with 3 minutes of rest between series."
75781082|NCT03928496|Drug|AbobotulinumtoxinA|Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck
75916601|NCT04568460|Other|Intervention Group Sessions|Participants will undergo a multi-session group intervention over the course of six months.
75916602|NCT04819516|Procedure|high-intensity focused ultrasound therapy|Patients will receive high-intensity focused ultrasound therapy in local site.
75916603|NCT04819516|Drug|Toripalimab|Toripalimab plus regorafenib
75323880|NCT00740831|Drug|leuprorelin|solution for injection
75629866|NCT00629928|Drug|Esomeprazole|20mg oral capsule daily
75629867|NCT00629928|Drug|Esomeprazole|40mg oral capsule daily
75629868|NCT00629928|Drug|Placebo|
75781083|NCT03928496|Drug|Normal saline|Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
75781084|NCT01225796|Drug|Sodium bicarbonate|Sodium bicarbonate 650mg by mouth three times daily for 6 months.
75781085|NCT01128998|Drug|Sorafenib|"Name: Sorafenib~Dosage form: 200 mg / Tablet~Dosing schedule: 200 mg bid, po, everyday, since Day 8 of Cycle 1"
75781086|NCT01128998|Drug|S-1|"Name:S-1~Dosage form: 20 mg or 25 mg / Capsule~Dosing schedule: 20-40 mg/m2 bid,po, 14 days on & 7 days off"
75781087|NCT01221506|Drug|Pazopanib|800 mg PO QD x 28 days
75323881|NCT03806569|Behavioral|MAC-cbt group treatment for adult ADHD|Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.
75323882|NCT03806569|Behavioral|Jacobson|Relaxation treatment in technique of Jacobson in 8 sessions
75467699|NCT01932086|Dietary Supplement|Brown rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
75467700|NCT01932086|Dietary Supplement|Black rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
75467701|NCT01932086|Dietary Supplement|Bread|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
75467702|NCT01932086|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
75916604|NCT05321654|Behavioral|Education for Behavior Modification|Please see arm description for a detailed description of the intervention
75916605|NCT05321654|Behavioral|Corrective Exercise Program|Please see arm description for a detailed description of the intervention
75916606|NCT04819984|Device|TCM5 device (Radiometer) for PtC02 continuous measurement|Evaluation of PtC02 variation as a reflect of PaC02 during 30 minutes of weaning proof for mechanical ventilation (spontaneous ventilation on T-piece)
75916607|NCT04356664|Drug|GnRH agonist|One or two intramuscular injections of Decapeptyl 3 mg
75916608|NCT04037072|Drug|Mitomycin C|Topical application of Mytomycin C (MMC)
75916609|NCT04037072|Other|Control|Topical application of Normal Saline
75629869|NCT00964782|Drug|Sildenafil|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will be randomized to receive Sildenafil first and then crossed over to receive the opposite intervention, placebo.
75629870|NCT00964782|Drug|Placebo|Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
75629871|NCT00964782|Drug|Sildenafil 2|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will receive Sildenafil, the crossed over intervention from their initial intervention (Placebo).
75781088|NCT01221506|Device|DCE-MRI and Quantitative Doppler Ultrasound|Contrast-enhanced MRI
75916610|NCT05616988|Other|psychological-clinical intervention with three days of expressive writing by Pennebaker|"The psychological-clinical intervention involves five interviews with three days of expressive writing by Pennebaker. During the psychological-clinical interviews the following aspects will be explored:~Emotions and expectations related to the breast reconstruction process.~Feelings related to the perception of one's own body image to promote an integration between the image of one's body and the aspects related to one's own identity and femininity.~Thoughts and feelings related to one's relational and social life.~Expressive writing is a technique devised by Pennebaker (1986), who states that expressing deeper thoughts and feelings through writing can improve the physical and psychological health of the individual. The writing task consists of writing about a traumatic experience or a significant event for the person, for a controlled period (usually 15-30 minutes) and on consecutive days (from 2 to 3 days)."
75916611|NCT04549194|Biological|Blood collection|A blood sample will be collected before during and after the treatment.
76075321|NCT05310214|Other|Acupuncture|"Treatment with ACP will be performed by inserting sterile acupuncture needles 0.25 x 13 mm into the acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji , for the treatment of chronic non-specific low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~In order to increase the effectiveness of blinding for both groups, in this study the model was adopted: combined simulated control. In this case, Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. Thus, in the ACP group, the placebo LACP (without dosemetry) will be applied to these 4 points together with the real treatment."
75629872|NCT00964782|Drug|Placebo 2|Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
75629873|NCT02882984|Drug|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|radiation given along with one of kind TKI
75629874|NCT02882984|Radiation|WBRT|3750 cGy in 15 fractions given within 3 weeks time.
75629875|NCT02882984|Radiation|HFSRS|All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
75629876|NCT00966654|Drug|Placebo|1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
75629877|NCT00966654|Drug|GLP-1 (7-36) amide|1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
75629878|NCT00625196|Drug|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
75629879|NCT00625196|Drug|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
75629880|NCT00625196|Drug|Vilanterol|Vilanterol will be available as dry powder inhaler.
75629881|NCT00625196|Drug|Placebo|Placebo will be supplied as dry powder inhaler.
75781089|NCT00321893|Drug|Budesonide|Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
75781090|NCT00321893|Other|Placebo|Inhaled placebo twice daily for one year.
75916612|NCT04549194|Drug|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route daily over 1 month.
75916613|NCT04549194|Behavioral|Psychological questionnaires|"The participants will fill in several psychological questionnaires before, during and after treatment administration:~Life Event Checklist~Moral injury~Posttraumatic Checklist~Burnout Assessment Tool~State-Trait Anger Expression Inventory-2~Ruminative Response Scale - Reconsidered~Deployment Risk and Resilience Inventory-2~Questionnaire about tobacco use"
75916614|NCT04549194|Device|Photoplethysmography|Photoplethysmography recording will be performed before during and after the treatment.
75916615|NCT04549194|Drug|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route daily over 1 month.
75916616|NCT04819438|Drug|Riluzole 50 mg Oral Film|Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
75916617|NCT04819438|Drug|Rilutek 50Mg Tablet|One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
75781091|NCT01225874|Drug|SC-PEG E. coli L-asparaginase|Given IM
75781092|NCT01225874|Drug|cytarabine|Given IT
75781093|NCT01225874|Drug|daunorubicin hydrochloride|Given IV
75781094|NCT01225874|Drug|dexamethasone|Given orally
75781095|NCT01225874|Drug|methotrexate|Given IT
75781096|NCT01225874|Drug|pegaspargase|Given IM
75781097|NCT01225874|Drug|prednisone|Given orally
75781098|NCT01225874|Drug|vincristine sulfate|Given IV
75323883|NCT01275287|Drug|Standard of care treatment|"induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m^2 for patients > than 70 or with estimated Glomerular Filtration Rate (eGFR) < 20 ml/min) to be titrated up to 1 gm/m^2 depending on the 2 week white blood count (WBC) nadir > 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study."
75629882|NCT03262116|Drug|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
75467703|NCT01932138|Other|Enhanced CHW intervention|"The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention."
76075322|NCT05310214|Other|Laser acupuncture|"The use of LACP (808 nm wavelength, 100 mW, energy 6 J per acp point), on acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji will be used as a treatment for nonspecific chronic low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. These sham points will be inserted superficially so that the depth is sufficient to keep them fixed during the experiment, without individuals reporting the dequi."
75629883|NCT03262116|Drug|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
75629884|NCT03262116|Drug|BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
75629885|NCT03262116|Device|Bionic Pancreas|The insulin-only bionic pancreas will be used in all three arms of the study
75629886|NCT01130168|Drug|Placebo|Placebo, capsule taken orally once daily during 4 weeks of treatment
75629887|NCT01130168|Drug|Comparator: Amlodipine|Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
75629888|NCT01130168|Drug|Comparator: ISMN ER|ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
75629889|NCT02862834|Genetic|High-throughput exome sequencing|
75629890|NCT04283292|Drug|Capsaicin|Topical Capsaicin for the treatment of Cannabinoid Hyperemesis Syndrome
75629891|NCT04283292|Drug|Placebo|Placebo cream that is applied once topically
75629892|NCT01144052|Drug|interferon beta-1b|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units [MIU])
75629893|NCT01144052|Drug|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
75629894|NCT02862288|Device|Microwave ablation with Acculis Accu2i pMTA Applicator|
75629895|NCT04283526|Drug|MBG453|Intravenous. 600mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
75629896|NCT04283526|Drug|NIS793|Intravenous. 2100mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
75629897|NCT04283526|Drug|Spartalizumab|Intravenous. 300mg. Every first day of a 21-day cycle
75629898|NCT04283526|Drug|Decitabine|Intravenous. Starting dose: 5mg/m2 (dose cap at 20mg/m2). On days 1, 2 and 3 of a 42-day cycle
75629899|NCT01143896|Other|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
75781099|NCT01226030|Drug|M2ES 7.5mg|M2ES 7.5mg
75781100|NCT01226030|Drug|M2ES 15mg|M2ES 15mg
75781101|NCT01226030|Drug|M2ES 30mg|M2ES 30mg
75781102|NCT01226030|Drug|M2ES 60mg|M2ES 60mg
75781103|NCT01226108|Device|Patch|"One patch per day, Duration: three weeks, Administration: behind the ear~--------------------------------------------------------------------------------"
75781104|NCT03928340|Drug|Metformin|"40 patients will be treated with metformin~(1 gm twice daily (with the 2 main meals)), combined with insulin therapy"
75781105|NCT03928340|Drug|Insulin|40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)
75781106|NCT00371345|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average <6 months)
75629900|NCT04283214|Other|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
75629901|NCT01118312|Drug|Mometasone Furoate monohydrate|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day for 6 months
75323884|NCT01275287|Drug|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
75629902|NCT01118312|Other|Placebo|Intranasal placebo spray
75629903|NCT04312022|Dietary Supplement|Berry extract|Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)
75629904|NCT04312022|Other|Placebo|Placebo (flour capsule)
75629905|NCT04311788|Device|Prophylactic self gripping mesh|Prophylactic self gripping mesh, Propgrip by Medtronic.
75629906|NCT04311788|Device|Slowly absorbable continuous monofilament suture|Fascial closure by continuous slowly absorbable 4:1 suture
75629907|NCT05085236|Procedure|Fu's subcutaneous needling (FSN)|physician will use a disposable Fu's subcutaneous needling (FSN) to penetrate the subject's skin in the middle from elbow lateral epicondyle to radial styloid process. Then physician will push forward the needle parallel to the skin surface. the physician will sway the needle 100 times in a minute. After procedure of swaying needle, the physician will instruct subject to do several movements, and each movement will perform 10 seconds and rest 10 seconds for 3 repetitions. The movements are active isometric elbow flexion, active isometric shoulder internal rotation, passive shoulder external and internal rotation. After above re-perfusion approach of muscles, the physician will take out the needle to finish the treatment.
75629908|NCT05085236|Procedure|Rehabilitation|Rehabilitation mentioned here is the regular rehabilitation programs for treating post-stroke hemiplegic shoulder pain prescribed by the rehabilitation physician.
75629909|NCT02882750|Other|EORTC QLQ-C30 (version 3.0).|Quality of Life Questionnaire
75629910|NCT02882750|Other|PS Q18|Patients Satisfaction Questionnaire
75629911|NCT02882750|Other|Decision Self-Efficacy Scale|Questionnaire
75629912|NCT01117766|Drug|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
75629913|NCT01117766|Drug|Placebo|BID dosing for 28 days
75629914|NCT02883686|Behavioral|Alma|Alma peer-mentoring
75629915|NCT04312880|Drug|Tranexamic Acid|IV and topical form of TXA will be administered to patients in the respective groups.
75629916|NCT01117454|Drug|Flecainide Acetate|oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
75629917|NCT01117454|Drug|Placebo|placebo, similar in appearance to flecainide
75629918|NCT01117454|Drug|Beta blocker|Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
75629919|NCT01116440|Drug|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
75629920|NCT01116440|Drug|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
75629921|NCT04311944|Other|Early fast-track care|Participants will be eligible for fast-track care at 8 weeks if their HIV-1 RNA is <200 copies/mL and they meet other eligibility criteria. If HIV-1 RNA is 200 copies/mL or higher at 8 weeks, then it will be repeated at 12 weeks, and those with HIV-1 RNA <200 copies will then be eligible for fast-track care, if they meet other eligibility criteria.
75629922|NCT04311944|Other|Standard (deferred fast-track) care|Participants will be eligible for fast-track care at 24 weeks, if their HIV-1 RNA is <200 copies.mL, and they meet other eligibility criteria.
75323885|NCT05744245|Other|Swallow Strength and Skill Training|Practice swallowing exercises with biofeedback and strength and skill targets
75323886|NCT02992535|Device|Intense Pulse Light Energy delivery (IPL)|
75323887|NCT01275443|Drug|300mg TMC278LA|300mg TMC278LA intramuscular injection
75323888|NCT01275443|Drug|150mg TMC278LA|150mg TMC278LA intramuscular injection
75629923|NCT01129622|Drug|letrozole|Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
75629924|NCT04311398|Diagnostic Test|New QIAstat-Dx fully automatic multiple PCR detection platform|We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients
75629925|NCT02882672|Other|Experimental|Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
75629926|NCT02882672|Other|Control|They did not do ant exercise training during 8 weeks.
75629927|NCT01128842|Drug|Neratinib|240 mg once daily by mouth.
75629928|NCT01128842|Drug|Capecitabine|1500 mg/m^2 twice daily by mouth.
75629929|NCT00625274|Drug|Esomeprazole|40mg Oral
75629930|NCT00625274|Drug|Lansoprazole|30mg Oral
75629931|NCT00625274|Drug|Pantoprazole|40mg Oral
75629932|NCT01143038|Biological|Romiplostim|Romiplostim will be administered weekly by subcutaneous injection
75629933|NCT00966264|Drug|LNG-IUS|LNG-IUS releasing 25 microg of levonorgestrel
75629934|NCT00966264|Procedure|Hysterectomy|operation
75629935|NCT00915525|Biological|botulinum toxin Type A|Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
75629936|NCT04673565|Behavioral|Motivational interviewing|Each participant in the treatment group will attend a 1-hour MI group session with 9 other participants hosted by a practicing MI therapies via Zoom at one month after the initial visit. This session will utilize MI to elicit motivation in each participant. Participants will also receive standard care delivered at in-person audiology clinic visits.
75916618|NCT03448484|Dietary Supplement|Intervention (integrated package)|"Provided to all intervention households:~Soap (for daily hand washing)~Chlorine solution (for daily drinking water treatment)~8 birds of chicken (child consumes 1 egg/day)~Vegetable seeds (red onion, indigenous managu and sukuma)~Monthly trainings to all farmers on nutrition and WASH~Micronutrient powder (MixMe, 1g sachet every third day)~Oral rehydration solution (ORS) + zinc (to be used to treat acute diarrhoea: 20 mg zinc tablets; ORS sachets (10.3 g/sachet))~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group."
75916619|NCT03448484|Other|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. The control intervention is the same for study 1 and study 2. This agriculture-focused package consists of:~Agricultural training (every 2 weeks on average) for all~Free to enrol for the following products on credit:~Compost boosters~Cook stoves~Seeds (onions, maize, indigenous greens, beans)~Maize storage bags~Drying tarps~Trees~Solar lights~Fertilizer~Actellic dust (insecticide)~Re-usable sanitary pads"
75916620|NCT04542096|Device|Lung electrical impedance tomography monitoring|A belt for recording changes in electrical impedance in the skin will be fastened for the purpose of this study with no other additional procedures
75781107|NCT00371345|Drug|Dasatinib 100 mg|Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average <6 months)
75781108|NCT01226186|Behavioral|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
75916621|NCT03448328|Dietary Supplement|NUTRALYS pea protein supplement|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
75916622|NCT03448328|Dietary Supplement|Whey Protein|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
75323889|NCT01275443|Drug|1200mg TMC278LA|1200mg TMC278LA intramuscular injection
75629937|NCT04669041|Drug|Rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
75629938|NCT04669041|Drug|SPC ezetimibe/rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
75629939|NCT04669041|Drug|Rosuvastatin active capsule|Pharmaceutical form:Capsule Route of administration: Oral
75916623|NCT03448328|Dietary Supplement|Apple juice|1.2 calories per kilogram body weight before and after eccentric exercise, and each of 4 mornings of recovery
75916624|NCT03865316|Device|SedLine Vs Comparator Test Group|Subjects will receive electrodes that compare EEG signals between Masimo's SedLine system and the comparator's system.
75629940|NCT04669041|Drug|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
75629941|NCT04669041|Drug|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
75629942|NCT04253847|Procedure|Radical antegrade modular pancreatosplenectomy|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
75781109|NCT01226186|Behavioral|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
75781110|NCT01128764|Behavioral|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
75781111|NCT01128764|Behavioral|CBT for depression|Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
75916625|NCT02598076|Behavioral|motivational interviewing|Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
75781112|NCT03929198|Other|Healthy Lifestyle|6 week Diet, Exercise training, Behavioral modification
76075323|NCT00817804|Device|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
76075324|NCT03839524|Drug|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
76075325|NCT00818116|Device|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
75323890|NCT01275443|Drug|600mg TMC278LA|600mg TMC278LA intramuscular injection
75781113|NCT03982823|Procedure|Hand-Sewn Sleeve Gastrectomy|After laparoscopic sleeve gastrectomy, gastrectomy site is hand-sewn with 3/0 polypropylene suture and the specimen is removed transorally.
75781114|NCT03982823|Procedure|Stapled Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy is performed via 60 mm linear stapler (Endo GIATM Ultra, Covidien) .
75781115|NCT01128920|Behavioral|Skin and Needle Hygiene Intervention|Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
75323891|NCT01274221|Drug|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
75323892|NCT01274221|Other|Placebo|1 capsule per day for one week of the double-blind crossover phase
75467704|NCT01932138|Other|Standard of care|The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
75467705|NCT01932151|Drug|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
75467706|NCT01932177|Drug|Everolimus and sorafenib|Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
75916626|NCT02598076|Behavioral|standard psychotherapy|Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
75629943|NCT04253847|Procedure|Standard retrograde pancreatosplenectomy|"Standard retrograde pancreatosplenectomy(SRPS) includes several aspects. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
75916627|NCT03776630|Other|Blood sample|"Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample."
75467707|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
75916628|NCT04811950|Device|Emerald|Complete blood countdevice
75916629|NCT03448172|Drug|[14C]PF-05221304|a single oral dose of [14C]PF-05221304 (50 mg/100 µCi liquid formulation)
76075326|NCT00818272|Biological|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
76075327|NCT00868348|Drug|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
76075328|NCT00868348|Drug|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
75467708|NCT01932177|Drug|Everolimus and sorafenib|Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
75629944|NCT05227443|Procedure|Exercise aerobic training|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide only lower limbs training exercises.
75629945|NCT05227443|Procedure|Upper, lower and breathing (ULB) exercise|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide lower and upper limbs training exercises as well as breathing exercises.
75781116|NCT01128920|Other|No intervention - assessment-only condition|No intervention is assigned in this condition
75781117|NCT03928886|Device|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode|Patient-assisted mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
75323893|NCT03806023|Device|hand movements (signals from thumb muscle) triggered PNS and TMS|"PNS, TMS or PNS+TMS will be delivered while the participant performs specific finger tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
75781118|NCT03928886|Device|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode|"Standard compression mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure.~Study-related compressions will consist of the first and second CC and MLO compressions performed on each breast during each subject's exam."
75781119|NCT01228214|Drug|Placebo|Placebo 5mg/daily for 12 months
75781120|NCT01228214|Drug|amiloride|5mg/daily for 12 months
75781121|NCT00321737|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
75781122|NCT00321737|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
76075329|NCT01933919|Drug|Fluvoxamine maleate|Film-coated tablet containing 25 mg of fluvoxamine maleate
76075330|NCT01933919|Drug|Placebo|Placebo tablet matching to fluvoxamine maleate
75629946|NCT05132595|Drug|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
75916630|NCT04819828|Procedure|Extracorporeal shock wave lithotripsy|A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.
75916631|NCT04819828|Drug|Diclofenac|Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
75916632|NCT04819828|Drug|Tamsulosin|Oral tamsulosin (0.4 mg/day) for eight weeks.
75629947|NCT05132595|Drug|Esketamine at high dose|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
75916633|NCT02602288|Behavioral|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
75323894|NCT00741455|Procedure|Stem Cell Transplant|"Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be > 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml."
75323895|NCT00741455|Drug|G-CSF|10 mcg/kg/day on days 5, 6, and 7
75629948|NCT05132595|Drug|Esketamine at low dose|After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.
75629949|NCT05132595|Drug|Ketorolac at high dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.
75467709|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
75467710|NCT01932190|Procedure|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
75916634|NCT02602288|Behavioral|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
76075331|NCT00819286|Device|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates
75629950|NCT05132595|Drug|Ketorolac at low dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
75629951|NCT01074047|Drug|Azacitidine|75 mg/m^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
75629952|NCT01074047|Drug|Conventional Care Regimen|"Physician pre-selects prior to randomization from one of the following:~Intensive chemotherapy (cytarabine 100-200 mg/m^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~Best Supportive Care only; until study end"
75629953|NCT05210907|Biological|SNUH-CD19-CAR-T|SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.
75781123|NCT00321737|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
75781124|NCT03925064|Other|myocardial performance index|fetal right ventricular myocardial performance index measured with tissue doppler
75781125|NCT03924674|Other|Education, clinical decision support tools|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
75781126|NCT01325363|Device|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
75781127|NCT01126892|Drug|Nilotinib|
75781128|NCT01061645|Drug|MOC31-PE|Immunotoxines
75916635|NCT02602288|Behavioral|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
75916636|NCT02602288|Device|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
75916637|NCT02602288|Device|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
75916638|NCT02602288|Drug|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
75916639|NCT05321186|Procedure|minimally invasive spinopelvic fixation|"Bilateral percutaneous L4 and L5 pedicle screws will be placed under fluoroscopic guidance with Jamshidi needles, and these were will also be used the iliac fixation via percutaneous S2 alar iliac screws.~Cases presenting with significant instability, minimally invasive Transforaminal lumbar interbody fusion (MIS-TLIF) will be performed. Additionally, in cases with neurological deficit, posterior decompression will be performed."
75916640|NCT03745352|Drug|Azacitidine|Given IV or SC
75323896|NCT00741455|Drug|Fludarabine|25 mg/m2/d IV over 30 minutes on days -6 to -2
75323897|NCT00741455|Drug|cyclophosphamide|1 g/m2/d IV on days -3 and -2
75323898|NCT00741455|Drug|Cyclosporine|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
75629954|NCT05185401|Other|Observational study|Retrospective data-analysis
75916641|NCT03745352|Drug|Pevonedistat|Given IV
75916642|NCT04427410|Diagnostic Test|Salivary test|Salivary test for measured of oxytocin levels
75916643|NCT03129308|Diagnostic Test|Blood Sampling|4.5ml of blood will be collected and analyzed for the presence of cutaneous autoantibodies (indirect immunofluorescence, desmoglein1/3, BPAG1/2, collagenVII, and envoplakin ELISA)
75467711|NCT01932190|Procedure|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary"
75467712|NCT01932203|Drug|aspirin|100mg once a day
75781129|NCT01226264|Procedure|Diffusion weighted MRI (DW- MRI)|"An MRI examination (including diffusion-weighted sequences) belongs to the standard protocol for patients with cervical uterine cancer. The additional burden is therefore restricted to an extra MRI scan during and/or early after therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous and vaginal contrast medium will be administered. In most cases, patients do not experience any discomfort and the use of these contrast agents is part of the clinical routine."
75781130|NCT01047761|Other|Exercise|"3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity~Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises"
75916644|NCT03740126|Diagnostic Test|Whole body 18F-FDG PET/CT|In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
75467713|NCT01932203|Drug|cilostazol|200mg once a day
75467714|NCT01932216|Procedure|Cholecystectomy|Gallbladder removal
75916645|NCT05617690|Drug|Cyclopol|Cyclopol 0.4mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. Anesthesia maintenance strategy is cyclopol 0.8-2.4 mg/kg/h and remifentanil 0.15 - 0.2 μg/kg/h
75916646|NCT05617690|Drug|Propofol|Propofol 1-3mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. The anesthesia maintenance strategy is propofol 4-8mg/kg/h and remifentanil 0.15 - 0.2 μ g/kg/h
75916647|NCT05617456|Procedure|AF ablation|Patients with standard indications to AF ablation
75916648|NCT03448094|Dietary Supplement|Resveratrol|Participants will consume one of the treatment types daily for a period of three months.
75323899|NCT00741455|Drug|Methotrexate|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
75323900|NCT01274299|Procedure|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
75467715|NCT01932229|Drug|Afatinib treatment|
75467716|NCT01932255|Procedure|prophylactic spinal tap|
75467717|NCT01932255|Procedure|no prophylactic spinal tap|
75629955|NCT05226117|Drug|Sacituzumab govitecan|Sacituzumab govitecan is a humanized monoclonal antibody (mAb) with a hydrolyzable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors while reducing systemic toxicity. SN-38 is the active metabolite of irinotecan. Sacituzumab govitecan is administered at 10 mg/kg as an IV infusion on days 1 and 8 of a 21- day cycle till progression, toxicity or withdrawal of consent
75629956|NCT01142726|Drug|Abatacept|Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
75916649|NCT03448094|Dietary Supplement|Placebo|Participants will consume one of the treatment types daily for a period of three months.
75467718|NCT01932268|Drug|Rifampicin|single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
75467719|NCT01932281|Dietary Supplement|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
75467720|NCT01932281|Dietary Supplement|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
75467721|NCT01932307|Procedure|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
75629957|NCT01142726|Drug|Methotrexate|Tablets, oral, 2.5 mg, once weekly, 12 months
75629958|NCT01142726|Drug|Abatacept placebo|Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
75629959|NCT01142726|Drug|Methotrexate placebo|Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
75916650|NCT04819204|Drug|Cetrorelix Acetate|GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.
75916651|NCT04819204|Drug|Testosterone gel|Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
76075332|NCT00819286|Device|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
76075333|NCT04381702|Procedure|Pancreatoduodenectomy|Open or laparoscopic pancreato-duodenectomy with pancreatojejunal anastomosis
76075334|NCT05317468|Other|Contraceptive Counseling|Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.
76075335|NCT05318170|Procedure|Laparoscopic ultra-radical lymph node debulking|Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
76075336|NCT01933217|Drug|Methylphenidate|
76075337|NCT01933217|Drug|Placebo|
75323901|NCT01274377|Biological|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
75323902|NCT00742313|Biological|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
75323903|NCT05744011|Other|Tango intervention|"The interventions will be implemented by ABB Reportages and will be carried out by nursing staff who had previously received training in therapeutic tango at the University of Burgundy.~A dance movement therapist and a musician will accompany the interventions twice a month.~Participants will attend a 1-hour tango session, twice a week for twelve weeks."
75629960|NCT04526223|Other|comprehensive treatment regimen|"Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF)~With at least two month Ruxolitinib treatment prior to transplantation~DAC+BF as myeloablative conditioning regimen~received Rux at +5d in ASCT and continued to +60d"
75916652|NCT04819048|Device|Low-Level Laser Therapy+acupuncture|"The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.~The needles using are disposable, sterile, individually packed, and made of stainless steel (Hua Tuo; Suzhou Medical Supplies Factory Co, Ltd,Suzhou, China), in sizes 0.25 mm ×40 mm.Asepsis of the skin will be performed with cotton wool and 75% alcohol."
75629961|NCT05093127|Device|Carotid Artery Stenting|R-OneTM system is a tool available to physicians for performing CAS without changing the treatment of the pathology. R-OneTM system is designed to remotely deliver and manipulate guidewires and stent/balloon devices during Carotid Artery Stenting. The system is composed of the R-OneTM robotic platform used in combination with two accessories, the Mobile radioprotection screen and a sterile and single-use R-OneTM consumable kit. The physician, seated at the remote radio-protected control station, manipulates guidewires and/or balloon/stent catheters using joysticks on the Command unit.
75629962|NCT04472637|Drug|Atorvastatin|atorvastatin 10 mg, as one tablet /day for 24 weeks.
76075338|NCT01932437|Biological|ETI-204|monoclonal antibody
76075339|NCT01932437|Other|Placebo|Placebo for ETI-204
75629963|NCT04472637|Drug|Placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks)
75629964|NCT04305509|Other|no intervention|no intervention
75916653|NCT04819048|Device|Low-Level Laser Therapy|The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.
75916654|NCT02807454|Drug|Daratumumab|
75916655|NCT02807454|Drug|Durvalumab|
76075340|NCT01949051|Drug|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
76075341|NCT01949051|Drug|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
76075342|NCT01948193|Biological|Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
75323904|NCT05744011|Other|Adapted Physical Activity|"The intervention will be carried out by an Adapted Physical Activity professor and by nursing staff.~Music is prohibited during the sessions. Participants will attend a 1-hour APA, twice a week for twelve weeks."
75629965|NCT05123937|Other|BOBATH technique|In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
75781131|NCT01226342|Device|Transcutaneous electrical muscle stimulation|On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
75781132|NCT01061801|Behavioral|Emotional expression|Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
75781133|NCT03928262|Biological|Benralizumab|Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.
75323905|NCT00742469|Drug|Rifaximin|
75323906|NCT00742469|Drug|Placebo|
75781134|NCT03983135|Other|Laparoscopic mini gastric by-pass|Adhesions will separated along the left edge of the stomach and the left lobe of the liver. The remnant stomach will transected at the incisura angularis level with 60 mm Endo-GIA stapler(ATW 35, EthiconEndo-SurgeryInc., Cincinnati, OH, USA). Later ante-cholic distal of the Treitz ligament hadgastro-jejunal anastomosisof nearly 150 cm jejunal loop performed with 44 mm Endo-GIA stapler. Routinely, the omentum will be divided in two and omentopexy will be performed around the anastomosis. The stapler line will supported by absorbable stitches.
75781135|NCT03983135|Other|LaparoscopicRe-sleeve gastrectomy|Adhesions will be separated with blunt and sharp dissections, then the remnant stomach will completely freed. Due to dilated antral pouch or fundus, the remnant stomach will resect as a tube stomach between the pillory and left crus with 60 mm Endo-GIA stapler accompanied by 36F bougie.
75916656|NCT02807454|Drug|Pomalidomide|
75916657|NCT02807454|Drug|Dexamethasone|
75916658|NCT03718286|Drug|Alirocumab|150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
75916659|NCT03718286|Other|Sham Control|Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
76075343|NCT01694485|Biological|Abrilumab|Administered by subcutaneous injection.
76075344|NCT01694485|Drug|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
76075345|NCT01931735|Procedure|Randomized Meniscectomy|Arthroscopic meniscectomy
75323907|NCT00763243|Behavioral|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
75323908|NCT02992613|Procedure|total knee arthroplasty with ultra-congruent (UC) insert|
75323909|NCT02992613|Procedure|total knee arthroplasty with posterior-stabilized (PS) insert|
75629966|NCT05123937|Other|Task training|In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
75781136|NCT03983135|Other|Laparoscopic Roux-en-Ygastric bypass|all adhesions will separated then after the stomach pouch will formed by the linear stapler, 100 cm of jejunum will transected from the Treitz ligament. Side-to-side gastrojejunostomy will performed for the distal jejunum with the linear stapler. The anterior face of the anastomosis will manually sutured. Proximal jejunum end hadside-to-side jejuno-jejunostomy performed 150 cm distal of the gastrojejunostomy anastomosis with linear stapler on the posterior wall and manual suturing of the anterior wall.
75781137|NCT03740438|Diagnostic Test|Hemoglobin concentration|Perioperative hemogloin concentration
75781138|NCT01047917|Behavioral|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
75781139|NCT01129154|Drug|infusions of Panitumumab|Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
75781140|NCT03982667|Diagnostic Test|PCT-guided group|In the PCT-guided group, the study protocol encourages to stop the prescribed antibiotics if PCT concentration decrease by 80% or more of its peak value (or if PCT concentration is ≥0·25 and <0·5 μg/L), and strongly encourage to stop the prescribed antibiotics when it reaches a value of < 0·25 μg/L. The attending physician is free to decide whether to continue antibiotic treatment in patients who reach these thresholds. Reasons for non-adherence will be recorded. Antibiotics in the standard-of-care group will be stopped according to local or national guidelines and according to the discretion of attending physicians. Patients will be followed-up until hospital discharge.
75781141|NCT01226498|Procedure|Red blood Cells auto-transfusion|Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.
75781142|NCT03740594|Behavioral|KMC|Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.
75781143|NCT01129232|Drug|GAD-alum|20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
75781144|NCT01129232|Other|Placebo|Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
75781145|NCT01047995|Drug|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
75916660|NCT04819126|Other|Nintendo Wii Virtual Reality Application|The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes.
76075346|NCT01931735|Procedure|Randomized Lavage|Arthroscopic Lavage
76075347|NCT01931735|Procedure|Standard of Care Meniscectomy Pre-Amend|Arthroscopic meniscectomy
76075348|NCT01931735|Procedure|Standard of Care Meniscectomy Post-Amend|Arthroscopic meniscectomy
75323910|NCT01279577|Drug|Low dose TSO|Low dose TSO suspension
75323911|NCT01279577|Drug|Medium dose TSO|Medium dose TSO suspension
75323912|NCT01279577|Drug|High dose TSO|High dose TSO suspension
76075349|NCT01930799|Behavioral|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
76075350|NCT01947491|Drug|DFD01 Spray|
75323913|NCT01279577|Drug|Placebo|Placebo solution
75323914|NCT01275599|Drug|telaprevir|Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
75323915|NCT01275599|Drug|buprenorphine/naloxone|Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
75323916|NCT01279655|Device|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
75323917|NCT01279655|Behavioral|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
76075351|NCT01947491|Drug|Comp01 Lotion|
76075352|NCT01947491|Drug|Vehicle Lotion|
76075353|NCT01947491|Drug|Vehicle Spray|
76075354|NCT04638725|Other|Blood sample for genetic analysis|Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
76075355|NCT04553575|Biological|serology|biological blood samples withdrawn at 6, 12 and 24 months
76075356|NCT01692301|Drug|LCZ696|200 mg tablet
76075357|NCT01692301|Drug|Olmesartan|20 mg and 40 mg capsules
75323918|NCT00782821|Drug|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
75323919|NCT00782821|Drug|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
75323920|NCT00782821|Drug|Rituxan|Given via IV per group assignment.
75323921|NCT00743093|Drug|acetaminophen|500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
75323922|NCT00743093|Drug|placebo|placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
75629967|NCT04310618|Other|No intervention|No intervention
75629968|NCT05110053|Device|Spinal Cord Stimulator|"Spinal Cord stimulation is a recognized treatment of chronic neuropathic pain. The procedure of implantation is the same in this study. Surgery is done in local anaesthesia. A small electrode is placed in the epidural space corresponding approximately at the Th8-Th10 level.~An impulsegenerator, connected to the electrode, is placed in the subcutaneus fat in the gluteal region."
75323923|NCT03805945|Drug|dexmedetomidine group|After the fetus was delivered, low-dose dexmedetomidine intraoperative infusion, postoperative low-dose dexmedetomidine patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min).
75323924|NCT03805945|Drug|control group|After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
75781146|NCT01047995|Drug|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
75629969|NCT01073267|Radiation|TSEBT|Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
75781147|NCT01129310|Drug|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
76075358|NCT01692301|Drug|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
75629970|NCT04457349|Procedure|Therapeutic Plasma Exchange (TPE)|Treatment with Therapeutic Plasma Exchange (TPE)
75629971|NCT02876705|Other|Exercise|Completion of this study will took a total of three sessions, separated by one-week intervals. At week one, participants will complete a baseline incremental cycling and running tests to determine the workload and velocity values corresponding to their RPE (6-20 Borg's scale) = 15 (i.e., heavy). Participants also will be familiarized with the use of body maps and reporting procedures. At week two and three, participants will complete the constant-power cycling and constant velocity running tasks. The constant-power cycling and running will last up to volitional exhaustion. The end will be set when participants won't be able to cycle longer at the fixed cadence.
75629972|NCT01142336|Drug|Simvastatin|Simvastatin 40mg qHS for 1 year
75781148|NCT01221662|Drug|Siwu Tang|Siwu Tang 3 g bid(oral) continuously two weeks
75781149|NCT01129388|Drug|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
76075359|NCT01692301|Drug|Olmesartan matching placebo|Olmesartan matching placebo capsule
75781150|NCT01129388|Drug|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
75781151|NCT01129388|Drug|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
75781152|NCT01127048|Drug|Suppositories containing Ivy leaves dry extract|Suppositories containing Ivy leaves dry extract
75781153|NCT01127048|Drug|Placebo|Suppositories containing no Ivy leaves dry extract
76075360|NCT01692301|Drug|amlodipine|amlodipine 2.5 mg or 5 mg tablets
76075361|NCT01692301|Drug|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
76075362|NCT01592773|Drug|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
76075363|NCT01930175|Drug|VAY736|
76075364|NCT01930175|Drug|Placebo|
76075365|NCT01592695|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
75323925|NCT02992301|Drug|Alirocumab|Injectable prescription medicine called a PCSK9 inhibitor.
75323926|NCT00743717|Device|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
75323927|NCT00743717|Device|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
75323928|NCT00744965|Drug|Glyburide|Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
75323929|NCT00744965|Drug|Placebo|Sham dose adjustments of the placebo will be made.
75323930|NCT04385225|Other|Longitudinal follow-up|Longitudinal hearing, vestibular and cognitive follow-up
75323931|NCT00763867|Drug|Placebo|
75323932|NCT00763867|Drug|Sildenafil|
75629973|NCT01142336|Drug|Placebo|Placebo 1 tablet qHS for 1 year
75629974|NCT02875691|Dietary Supplement|green tea extract|Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
75629975|NCT02875691|Dietary Supplement|placebo|Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
75781154|NCT03928574|Procedure|Ultrasound-Guided Plane Block|Ultrasound-Guided Plane Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
75781155|NCT03928574|Procedure|Conventional Block|Conventional Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
76075366|NCT01592695|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
76075367|NCT01592695|Behavioral|Tobacco quit line referral|Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
76075368|NCT01592695|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
76075369|NCT01592695|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
76075370|NCT01592695|Drug|Bupropion Sustained Release|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
75629976|NCT05080023|Device|Enhanced External Counterpulsation (EECP)|Enhanced External Counterpulsation (EECP)
75629977|NCT00915681|Drug|Silibinin|20 mg/kg continuous IV is over 24 hours
75629978|NCT01128296|Drug|Hydroxychloroquine|Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
75323933|NCT00749879|Drug|Proellex|25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
75323934|NCT04385147|Other|Endoscopic management according to standard of care|Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case
75629979|NCT01128296|Drug|Gemcitabine|Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
75629980|NCT05072379|Device|colostomy self-care app|The study will use mixed methods as the study design in which content analysis will be used to identify the content suited for the App based on interviews with participants. A systematic research and development process will be utilized to design the text, videos, and images in the App's simulations to provide accurate, consistent, and complete knowledge of the skills needed for colostomy self-care and contending with any potential emergency.
75629981|NCT05082909|Drug|Probenecid|Addition of 500mg QDS to oral penicillin.
75629982|NCT04240509|Drug|Emtricitabine / Tenofovir|Incarcerated men identified at high risk for HIV transmission will be given a 30-day supply of the study drug and will be provided with patient navigation to follow up care upon release.
75629983|NCT04586283|Other|Maternal prone position|Women will be asked to lie in a prone position supported by a specially designed cushion for 30 minutes.
75629984|NCT04450329|Drug|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
75629985|NCT04450329|Drug|Eylea (Aflibercept)|Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
75629986|NCT04826055|Other|biliary limb as fixed length|n all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
75629987|NCT04826055|Other|biliary limb as a percentage from small intestine length|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
75629988|NCT01115738|Drug|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
75629989|NCT01115738|Drug|Clopidogrel|Loading dose administered once orally.
75629990|NCT01115738|Drug|Placebo|Loading dose administered once orally
75781156|NCT01228292|Drug|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
75781157|NCT01228292|Drug|Citrasate|Citrasate is infused as a dialysate
75781158|NCT03924596|Drug|AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)|AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
75781159|NCT03924596|Drug|Potassium Sodium Hydrogen Citrate|Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)
75781160|NCT01127126|Drug|Bryophyllum pinnatum, Placebo in form of Lactose|"Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d."
75781161|NCT00320801|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
75781162|NCT00320801|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
75781163|NCT01127204|Drug|AZT-3TC-LPV/r twice a day|AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
76075371|NCT01592695|Drug|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
76075372|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
76075373|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
76075374|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
76075375|NCT01592695|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
76075376|NCT01592695|Behavioral|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
75323935|NCT00711347|Device|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
75323936|NCT00711347|Device|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
75323937|NCT01276223|Drug|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
75323938|NCT01276223|Other|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
76075377|NCT01592695|Behavioral|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
76075378|NCT01929863|Drug|GSK2330672|GSK2330672 will be supplied as oral solution, and will be administered BID [45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period]
76075379|NCT01929863|Drug|Placebo|GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
75323939|NCT01275833|Device|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
75781164|NCT01127204|Drug|ABC-3TC-EFV once a day|ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
75781165|NCT01228370|Drug|silodosin|silodosin 8mg once a day for 12 weeks
75781166|NCT01221740|Drug|Savella|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
75781167|NCT01228448|Procedure|PET scan|In-Room PET scan
75781168|NCT01228526|Device|PriMatrix|
75781169|NCT01226576|Device|MRgFUS Treatment|Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
75781170|NCT03928106|Other|pharmacists' recommendation|For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
75916661|NCT05320874|Biological|KM257 Bispecific antibody|"Part 1a dose escalation:~There will be 3 increasing dose levels (3mg/kg,6mg/kg,12mg/kg). Patients will be intravenously administrated with one dose of KM257, QW for continuous cycles of 21 consecutive days for each cycle. The dosing interval may be adjusted during the study based on emerging data from this trial.~Part 1b dose expansion:~Part1b:For cohort 1 and cohort2, KM257 will be given at the RP2D identified in Part1a;~For cohort 3 to 7:KM257 will be given combined with one of the following selected drug combination:~Drug: Capecitabine Combination therapy with KM257 - Cohort 3~Drug: Paclitaxel or Docetaxel or Irinotecan Combination therapy with KM257 - Cohort 4~Drug: Gemcitabine+Cisplatin Combination therapy with KM257 - Cohort 5~Drug: Gemcitabine+Cisplatin or Carboplatin Combination therapy with KM257 - Cohort 6~Drug:Carboplatin+Paclitaxel Combination therapy with KM257 - Cohort 7"
76075380|NCT01929863|Drug|Metformin|Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
76075381|NCT01918085|Other|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
75781171|NCT01226654|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging EDSS
75781172|NCT03932396|Other|Observational study|No intervention is planned outside of usual clinical practice. Only active screening for hepatotropic virus infection, mainly hepatitis C virus, HIV, and mental illness will be carried out. If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
75781173|NCT03924284|Diagnostic Test|PB2 gene RT-PCR; NS gene RT-PCR|PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus
75781174|NCT00320489|Drug|olanzapine|10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
75916662|NCT05320640|Drug|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
75916663|NCT05320640|Drug|Decitabine|Low-dose decitabine inhibits the activity of DNA methyltransferase, which can increase tumor antigens and HLA expression, enhance antigen processing, promote T cell infiltration, and boost effector T cell function.
76075382|NCT01918085|Other|Strata strip|An adhesive strip made of the Strata adhesive
76075383|NCT01714687|Device|balloon sinus dilation|
76075384|NCT01714687|Other|medical therapy|
75323940|NCT01279733|Genetic|Microarray analysis|"Microarray performed on prenatal specimen:~Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.~Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed."
75323941|NCT01275755|Drug|Placebo|
75323942|NCT01275755|Drug|ADL5945 0.25 mg|
75323943|NCT00784225|Drug|selenium|200 mcg daily for 7-12 years
75323944|NCT00784225|Drug|vitamin E|400 IU daily by mouth for 7-12 years
75781175|NCT00320489|Drug|olanzapine pamoate depot|405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
76075385|NCT01714609|Drug|Placebo|Placebo Comparator: Placebo
76075386|NCT01714609|Drug|Sorafenib|Sorafenib, 400 mg twice daily
76075387|NCT01929707|Drug|LY3050258|
76075388|NCT01929707|Drug|Placebo|
76075389|NCT01714063|Device|Pressurized Metered-Dose Inhaler|Pressurized Metered-Dose Inhaler
76075390|NCT01929395|Device|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
75467722|NCT01932320|Drug|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
75916664|NCT05320640|Drug|Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）|Immune checkpoint inhibitors (ICIs) have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
75323945|NCT00784225|Drug|vitamin E placebo|daily for 7-12 years
75467723|NCT01932320|Drug|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
75467724|NCT01932320|Drug|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
75323946|NCT00784225|Drug|selenium placebo|daily for 7-12 years
75629991|NCT00632073|Drug|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
75629992|NCT04651413|Diagnostic Test|PCR Value|Data collection and interpretation
75629993|NCT01141478|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
75781176|NCT01127282|Drug|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
75781177|NCT01127282|Drug|Placebo (digestive tablet)|Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
75781178|NCT03924206|Device|Smoke evacuation system|The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated
75781179|NCT03923816|Drug|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).|comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery
75467725|NCT01932320|Drug|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
75467726|NCT01932333|Drug|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
75467727|NCT01932333|Drug|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
75467728|NCT01932333|Drug|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
75467729|NCT01932359|Other|rapidly absorbable suture (Vicryl Rapide)|
75467730|NCT01932359|Other|non-absorbable suture (Ethilon)|
75467731|NCT01932372|Drug|Tofacitinib (Xeljanz)|5 mg Tablet BID
75467732|NCT01932372|Drug|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
75467733|NCT01932385|Drug|Sorafenib|
75467734|NCT01932385|Other|Best Supportive Care|
75467735|NCT01932424|Device|Pelorus 1500|a bedside blood propofol measurement device
75467736|NCT01932424|Drug|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
75629994|NCT01141478|Drug|Sorafenib|400 mg po bid
75629995|NCT01114880|Biological|adalimumab|Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
75629996|NCT01114880|Other|placebo|Prefilled syringe, matching placebo administered subcutaneously every other week
75629997|NCT05188586|Other|MRI/Imaging|Blood collection and pancreatic cancer early detection testing with return of results.
75629998|NCT00625352|Drug|Gemcitabine, UFT|Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
75629999|NCT01114724|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
75630000|NCT00964392|Procedure|Atrial fibrillation ablation|Radiofrequency ablation
75630001|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
75630002|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
75630003|NCT00914589|Drug|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
75630004|NCT03561714|Behavioral|Cardometabolic Team Intervention|The CMC-TI team included a registered nurse/certified diabetes educator (RN/CDE) Care Manager, medical assistant (MA) Health Coach, and RN Depression Care Manager. Decision support tools guided therapy for glucose, BP, low-density lipoprotein cholesterol (LDL-c), and depression. At the intervention clinic, the 12-month CMC-TI was delivered to all qualifying patients; surveys were administered to evaluate relevant patient-reported outcomes over 12 months.
75630005|NCT04539873|Drug|Colchicine 0.5 MG|Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
75781180|NCT03927872|Other|blood biomarkers|assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome
75781181|NCT01129466|Dietary Supplement|Supplement A followed by Supplement B|Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)
75916665|NCT00835146|Drug|Ribavirin 200 mg tablets|1 x 200 mg, single-dose fasting
75916666|NCT00835146|Drug|COPEGUS™|1 x 200 mg, single-dose fasting
75630006|NCT04539873|Combination Product|CONTROL GROUP|In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
75630007|NCT02861040|Other|Laboratory Biomarker Analysis|Correlative studies
75467737|NCT01932450|Procedure|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
75467738|NCT01932450|Drug|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
75467739|NCT01932463|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
75467740|NCT01932476|Dietary Supplement|Gluten Challenge|Three-day gluten containing dietary challenge.
75467741|NCT01932476|Dietary Supplement|Sham Challenge|Three-day sham (gluten free) dietary challenge
75467742|NCT01932489|Procedure|Biopsy of a metastatic lesion.|
75467743|NCT01932502|Drug|clobazam (Onfi)|"Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated"
75323947|NCT02991989|Behavioral|Exercise Snacking|"Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours."
75467744|NCT01932502|Drug|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
75467745|NCT01932502|Drug|Conversion schedule - Week 1|"The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg."
75630008|NCT02861040|Other|Pharmacological Study|Correlative studies
75630009|NCT02861040|Drug|Vincristine Sulfate Liposome|Given IV
75630010|NCT02861040|Drug|Volasertib|Given IV
75630011|NCT02862366|Other|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
75630012|NCT04264338|Diagnostic Test|Thyromental height test|Assessment of difficult airway
75630013|NCT04639713|Device|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
75781182|NCT01129466|Dietary Supplement|Supplement B followed by Supplement A|Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
75916667|NCT01555892|Biological|EBV-specific T cells: A|Dose Level 3: 1 x 10^8 cells/m2 + 2 x 10^8 cells/m2
75916668|NCT01555892|Biological|EBV-specific T cells: B|Dose Level 3: 1 x 10^8 cells/m2 + 2 x 10^8 cells/m2
75323948|NCT02991989|Dietary Supplement|Yogurt|Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
75630014|NCT04282902|Drug|pirfenidone|Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
75781183|NCT01127360|Drug|Bevacizumab|Intravitreal injections
75323949|NCT02991911|Biological|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
75630015|NCT00912405|Device|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
75630016|NCT04284618|Diagnostic Test|assessment of standardized and off axis view radiographs|Radiographic assessment of hallux valgus interphalangeus angles is performed on preoperative standing anteroposterior and on off axis view radiographs. These radiographs are taken by equalizing the hyperpronation of the greater toe.
75781184|NCT01127360|Drug|Ranibizumab|Intravitreal injections
75781185|NCT03992573|Procedure|CGF application|CGF application into post-operative soft tissue and bone defects
75781186|NCT03928028|Behavioral|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition.
75781187|NCT03928028|Behavioral|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
75781188|NCT03923894|Dietary Supplement|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
75916669|NCT04819282|Diagnostic Test|Senior Fitness Test|Senior Fitness Test, simple and easy to use, was used to evaluate physical performance.
75916670|NCT04818736|Biological|COVID-19 Vaccination|Dose 1: 0.5 mL at Day 0 Dose 2: 0.5 mL at Day 28
75916671|NCT04818736|Other|Usual care|Participants can receive the COVID-19 whenever they are eligible according to local provincial guidelines.
75630017|NCT04950777|Behavioral|patient education document|The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
75630018|NCT02862054|Procedure|splenectomy|
75630019|NCT02860962|Drug|Dextromethorphan Hydrobromide|Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
75630020|NCT02862522|Other|Questionnaire of overall health|The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
75630021|NCT03548532|Device|G210 incubator|very stable culture temperature, up to 0.1°C, in both arms
75323950|NCT02991911|Biological|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
75630022|NCT04214613|Procedure|non-cardiac non-neurologic surgery|non-cardiac non-neurologic surgery
75781189|NCT03923894|Dietary Supplement|Placebo|Placebo 2.07 g/day for 8 weeks.
75630023|NCT04842513|Drug|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
75781190|NCT03923660|Other|Incremental Concentric-eccentric exercise test|Patients will perform incremental exercise test on semi recumbent eccentric ergometer
75781191|NCT03923660|Other|Incremental Eccentric-concentric exercise test|Patients will perform incremental exercise test on semi recumbent concentric ergometer
75916672|NCT04472520|Device|AliveCor Heart Monitor|Records single-channel ECG rhythms
75916673|NCT01235234|Drug|CF101|orally q12h
75916674|NCT03719430|Drug|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
75916675|NCT03719430|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
75916676|NCT04811326|Radiation|NB-UVB|radiation
76075391|NCT04124809|Device|laser assisted collapse|Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
76075392|NCT01713283|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
76075393|NCT01713283|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
76075394|NCT04768075|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
76075395|NCT04768075|Drug|Placebo|IV infusion Simulator of Camrelizumab
76075396|NCT04768075|Drug|Cisplatin|IV infusion
75323951|NCT02991911|Biological|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
75630024|NCT04240119|Other|According to current clinical care standards|Enrolled subjects may be treated with medical management or surgically using indirect revascularization surgery.
75630025|NCT00878722|Drug|PXD101|
75630026|NCT00878722|Drug|idarubicin|
75323952|NCT01275131|Drug|Insulin aspart|
75916677|NCT04811326|Drug|Latanoprost|eye drops
75916678|NCT00834990|Drug|divalproex sodium|delayed-release 500 mg tablet
75323953|NCT01275131|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
75323954|NCT00749957|Biological|rAAV2-CB-hRPE65|Recombinant adeno-associated virus vector expressing RPE65
75323955|NCT01274429|Drug|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
75467746|NCT01932502|Drug|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
75467747|NCT01932502|Drug|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
75630027|NCT04381455|Device|OSSIX Bone|subjects will be implanted with OSSIX Bone during sinus elevation surgery
75781192|NCT01221818|Drug|E6007|E6007 25mg single dose or matching placebo
75781193|NCT01221818|Drug|E6007|E6007 50mg single dose or matching placebo
75781194|NCT01221818|Drug|E6007|E6007 100mg single dose or matching placebo
75781195|NCT01221818|Drug|E6007|E6007 200mg single dose or matching placebo
75781196|NCT01221818|Drug|E6007|E6007 400mg single dose or matching placebo
75781197|NCT01221818|Drug|E6007|E6007 600 mg single dose or matching placebo
75916679|NCT00834990|Drug|Depakote®|delayed-release 500 mg tablet
75916680|NCT05320562|Procedure|Kinesio taping|"Additionally, they received kinesio taping application for 7 days. Blue color kinesio tape (manufactured by Theraband®, USA) was used. Kinesio taping was done by experienced physiotherapist with 5 years of experience. Two Y shape bands were applied for lymphatic taping and to improve anterior upper leg muscle function (lymphatic correction and muscle correction techniques were integrated together).~Then two I shape bands (75-100% tension) were applied above the patella tendon and medial/lateral collateral ligaments in order to improve mechanoreceptor stimulation, proprioception and knee stability."
76075397|NCT04768075|Drug|Carboplatin|IV infusion
76075398|NCT04768075|Drug|Pemetrexed|IV infusion
76075399|NCT04768075|Drug|Paclitaxel|IV infusion
76075400|NCT04768075|Drug|Albumin paclitaxel|IV infusion
76075401|NCT01592383|Drug|erlotinib hydrochloride|Given PO
76075402|NCT01691521|Drug|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
76075403|NCT01691521|Drug|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
76075404|NCT01691521|Drug|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
76075405|NCT01691521|Drug|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
75916681|NCT05320562|Procedure|Sham taping|Additionally, they received sham (placebo) taping: usual white patch was applied to the painful knee for 7 days. The technique of taping used was the same as in kinesiotaping group, but without stretching.
75630028|NCT04239183|Device|Stomatherapy|Demonstrate improvement of quality of life (difference of at least 5 points in the StomaQoL questionnaire (21)) among descending colostomy patients, establishing the following comparisons.
75630029|NCT03432897|Drug|Olaparib Pill|300 mg BID
75630030|NCT03432897|Procedure|Prostatectomy|22-42 days post Olaparib patients will undergo surgery
75630031|NCT02630836|Drug|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
75781198|NCT01228604|Drug|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
75630032|NCT02630836|Procedure|Surgical treatment|Isolated endomedullary nailing
75630033|NCT04238559|Other|Self-report questionnaire|Fill in the SWAMECO questionnaire
75630034|NCT04266015|Dietary Supplement|Enteral nutrition formula|Intervention group will receive nasogastric feeding with commercially available liquid enteral diet (250 ml/can, Kcal/ml, 10.4 g protein/can) during free flap reconstruction at feeding rates 10-30 ml/h.
75916682|NCT02597452|Device|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
75916683|NCT03447860|Behavioral|PAACC|Mindfulness based caregiver intervention that includes education , problem solving, skill building, stress management and mindfulness to help enhance compassion and acceptance of self and others
75916684|NCT03447860|Behavioral|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress
75916685|NCT04483050|Device|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
75916686|NCT04831372|Procedure|Off Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a standard operating room table
75916687|NCT04831372|Procedure|On Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a traction table
75630035|NCT02630758|Behavioral|Mindfulness-based Yoga|See study arm description.
75916688|NCT05320484|Other|Clinical Pilates Exercises|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
75916689|NCT05320484|Other|Classic Posture exercise|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
75916690|NCT04479072|Drug|Aspirin 81 mg|Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
75916691|NCT04479072|Drug|Placebo|Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
75916692|NCT04817878|Combination Product|Developmental assessment|Physical development assessment (head circumference, length, weight), Neurodevelopment assessment at 36 to 40 weeks of correction (GMS assessment, NBNA assessment), neurodevelopment assessment at 18 months, 24 months, and 36 months (ASQ scale, Language assessment, Wei-style scale), audiovisual screening, etc.
75916693|NCT05320328|Device|Radio frequency ablation|Radiofrequency ablation (RFA) uses heat to kill cancer cells. High-frequency electrical currents are passed through a special needle or probe called a needle electrode. The electrical current from the probe heats a small area containing cancer cells to high temperatures, killing the cancer cells. The area around the tumour is also usually treated because it may contain cancer cells.
75916694|NCT03036202|Drug|Epinephrine|This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
75916695|NCT05320016|Drug|Remimazolam|Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery
75916696|NCT03035968|Other|Vojta therapy|
75916697|NCT03035968|Other|conventional physiotherapy|
75916698|NCT03245918|Drug|Aprepitant Capsule 125 MG|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
75916699|NCT03245918|Drug|Aprepitant oral suspension 20 mg/mL|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
75916700|NCT00834756|Drug|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fasting
75916701|NCT00834756|Drug|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fasting
75916702|NCT00828854|Drug|Entinostat|Entinostat 5 mg PO every week
75916703|NCT00828854|Drug|Aromatase Inhibitor (AI) Therapy|AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
75916704|NCT04810936|Dietary Supplement|oral nutritional supplements|Oral nutritional supplements is usually administrated to improve nutritional status in cancer patients.
75916705|NCT04810468|Other|Anthropometric measurment|Anthropometric measurment used to asses the wheight in kelogram and asses height in cetemeter and also asses BMI
76075406|NCT01929317|Drug|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
76075407|NCT01929317|Drug|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
76075408|NCT01929317|Drug|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
76075409|NCT01711879|Drug|Aflibercept|Details covered in arm description
75916706|NCT05308082|Behavioral|Dance Movement Therapy (DMT)|The main Dance Movement Therapy (DMT) methods were dance-movement improvisations, body awareness exercises, and reflection through drawing/painting, writing, and verbalization. There was an orientation to personal space and body awareness, interaction in pairs, and interaction in the whole group. The themes included exploration of boundaries, somatic resources, symbols, pleasant and unpleasant emotions, mindfulness, and body awareness, enriched movement experiences, and safety and touch. In the present study, it consists of six sessions, including (1) Movement for Self-expression, (2) Movement for Emotional Health I, (3) Movement for Emotional Health II, (4) Movement for Connection & Creativity, (5) Embracing your Dancing Child, and (6) Movement for Self-compassion.
75781199|NCT03932084|Behavioral|Control group|"During hospitalization:~Monitor subjects' blood glucose;~One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
75781200|NCT03932084|Behavioral|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c<7% and LAGE<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
76075410|NCT00869206|Drug|zoledronic acid|Given IV
76075411|NCT04625231|Behavioral|Educational Shared-Decision Making Tool|Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
75630036|NCT02630758|Behavioral|Walking Control Condition|See study arm description.
76075412|NCT01689649|Drug|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
76075413|NCT01929083|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
76075414|NCT01929083|Drug|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
75630037|NCT00964158|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
75630038|NCT00659386|Drug|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
75781201|NCT01228682|Drug|Tolvaptan|Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
75630039|NCT00662584|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|transcranial magnetic stimulation (TMS) at .5 HZ for 20s
75630040|NCT03986541|Diagnostic Test|Immunohistochemistry|Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
75630041|NCT04155814|Drug|Iron Sucrose Injection|USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength
75781202|NCT01131416|Behavioral|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
75781203|NCT01221896|Procedure|C11-Choline PET/CT|
75916707|NCT00834522|Drug|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose non-fasting
75916708|NCT00834522|Drug|Kytril® 1 mg tablets|2 x 1 mg, single dose non-fasting
76075415|NCT01929083|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
76075416|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
76075417|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
76075418|NCT01689337|Drug|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
76075419|NCT04624529|Other|Self evaluation tool|This self-evaluation tool to evaluate cognitive function, developed by the occupational therapy department, is a paperwork task with guidelines for semi-structured interpretation.
76075420|NCT01688635|Drug|LY2963016|Administered subcutaneously
76075421|NCT01688635|Drug|US Approved Lantus|Administered subcutaneously
76075422|NCT04881409|Device|Respiratory support with nasal high-flow (NHF)|Patient with AECOPD is treated with NHF.
76075423|NCT04881409|Device|Respiratory support with non-invasive ventilation (NIV)|Patient with AECOPD is treated with NIV.
75467748|NCT01932515|Behavioral|A revised screening instrument for use in Deaf children|
75630042|NCT04155814|Drug|Venofer Injection|(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
75630043|NCT02860884|Procedure|liver biopsy|
75630044|NCT02860884|Other|infrared spectroscopy|
75630045|NCT00662662|Behavioral|Questionnaire|The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
75630046|NCT02630524|Behavioral|eHealth Behavioral Lifestyle Intervention Device: Telecoach|Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
75916709|NCT04818190|Procedure|Sensory neurotization|The donor nerve is a cutaneous nerve that is identified with the most inferior lateral perforator vessels. The nerve is then dissected for neurotization and divided at the level of the fascia where it is a pure sensory nerve. The recipient intercostal nerve is usually easily identified in the third intercostal space during the dissection of the internal mammary artery and vein. The anterior branch of the third intercostal nerve can usually be found at the junction of the inferior portion of the third rib and the sternum, approximately 80% of the time. The nerve is dissected and transected medially. It is then mobilized to give it the longest length possible in preparation for neurotization. Neurotization is performed by coapting the donor nerve to the third anterior intercostal nerve directly with a 9-0 nylon suture in standard fashion.
75630047|NCT00666094|Behavioral|Endurance training|supervised endurance training. Three sessions per week in three months.
75467749|NCT01932528|Drug|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as [14C]-LX1606.
75630048|NCT00666094|Behavioral|strength training|Supervised strength training. Three sessions per week in three months.
75630049|NCT04529031|Behavioral|Reminder Focused Positive Psychiatry|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
75630050|NCT04529031|Behavioral|attentional control condition (group process)|This group process will undergo telehealth relaxation therapy twice a week for 6-week. Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy
75630051|NCT00666172|Behavioral|Exercise|
75781204|NCT03923114|Radiation|Ga-68-NODAGA-exendin-4 PET/CT|PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
75630052|NCT00666172|Behavioral|Weight Loss|
76075424|NCT01591681|Device|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
75467750|NCT01932541|Drug|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
75630053|NCT04598139|Other|Study group|The study group uses a web-based medication error notification system
75630054|NCT04158076|Drug|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
75630055|NCT04158076|Drug|Telmisartan|PO, Once daily(QD), 8weeks
75781205|NCT03923192|Device|Vistacam|device for early proximal caries detection
75781206|NCT03923192|Radiation|Bitewing radiograph|radiograph for proximal caries detection
75916710|NCT04810312|Other|Combined exercise and nutrition intervention|Back extensor strengthening exercise and nutritional supplementation for 12 weeks
75916711|NCT00834444|Drug|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
75916712|NCT00834444|Drug|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
76075425|NCT04871503|Device|BTL-899 Buttocks|The treatment administration phase in both study groups will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 will be applied over the gluteal area.
76075426|NCT02986009|Behavioral|Parenting|"The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session."
76075427|NCT02986009|Behavioral|Information|The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
76075428|NCT02985931|Other|Diagnostic imaging scans of SPECT and MRI|
76075429|NCT00891436|Drug|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
76075430|NCT00891436|Drug|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
76075431|NCT01711645|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
75630056|NCT04158076|Drug|Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET|PO, Once daily(QD), 8weeks
75630057|NCT00911404|Behavioral|Low CHO|"Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat."
75630058|NCT00911404|Dietary Supplement|High CHO diet|Diet with 55% total calories from carbohydrates.
75630059|NCT00961350|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
75630060|NCT00961350|Drug|EC Aspirin 325|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
75630061|NCT00666250|Dietary Supplement|Xocai Activ drink|proprietary blend of cocoa powder and extracts of acai, grape and blueberry
75630062|NCT04155970|Other|Manual therapy|Manual therapy, which includes spinal manipulation; spinal mobilisation; light massage; and trigger point therapy.
75781207|NCT03923348|Device|Leva device|The leva® Pelvic Digital Health System by Renovia Inc is a novel tool for subjects with urinary incontinence to train and strengthen pelvic floor muscles via directional mechano-transductive feedback on performance in the privacy of their own homes.
75781208|NCT01228760|Drug|ASG-5ME|IV
75781209|NCT03927404|Device|Active vacuum test prosthesis|The adaptive vacuum prosthesis is sold as a commercial device by the company Willow Wood with suggested U.S. L-Code L5781. The device is designated as a Class 1 Medical Device and 510(K) Exempt. This category is part of a low or moderate risk to patient safety and health. The Prosthetic socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
75781210|NCT00320411|Drug|lapatinib|Lapatinib 1500mg QD
75781211|NCT01221974|Device|Essure Micro Insert|
75467751|NCT01932554|Drug|Abciximab|Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
75630063|NCT04155970|Other|Evidence-informed home management booklet|The home management booklet includes advice on posture, over the counter pain medication, cold and heat packs. The booklet also includes a section on patient reassurance and where to seek help from a medical professional in an emergency.
75781212|NCT01132040|Drug|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
75630064|NCT04408287|Other|WebEx Physical Activity Program|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
76075432|NCT04381546|Other|Functional Electrical Stimulation FES|Functional electrical stimulation (FES) is delivered to the quadriceps and hamstrings of the paretic limb in patients with hemiplegia. It is based on the real-time estimation of the knee angle and support phase during gait.
75630065|NCT03537690|Other|Laboratory Biomarker Analysis|Correlative studies
75630066|NCT03537690|Drug|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
75630067|NCT03537690|Other|Pharmacokinetic Study|Correlative studies
76075433|NCT00820534|Drug|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
76075434|NCT00820534|Drug|Placebo|Placebo every 2 hous during waking hours for 96 hours
75323956|NCT04272671|Other|Educational Intervention|The intervention has the following components: 1) alerts given to providers to identify patients taking opioids or benzodiazepines (BZD) and therefore at risk for falls; 2) educational materials to inform providers on best practices for de-prescribing opioids and BZDs in patients at risk; and 3) recommendations on de-prescribing provided by a consultant pharmacist. Impact of the intervention will be evaluated using pre-post surveys evaluating changes in providers' knowledge, confidence, and skills as well as information from the EHR to evaluate impact of the intervention on de-prescribing opioids and BZDs.
75323957|NCT01273883|Dietary Supplement|Magnesium|Magnesium 532 mg a day
75323958|NCT01273883|Other|Placebo|matching form/dosage
75323959|NCT01273805|Drug|Hydroxychloroquine|
75630068|NCT02630680|Drug|Eziclen®/Izinova®|
75630069|NCT03947541|Other|Thoracolumbosacral (TLSO) brace|Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.
75630070|NCT03947541|Other|No Bracing|Participants will not wear a brace in the study.
75630071|NCT04032184|Other|Fluoride toothpaste|regimen using fluoride toothpaste
75630072|NCT04032184|Other|fluoride toothpaste and chlorhexidine mouthwash|regimen using fluoride toothpaste and chlorhexidine mouthwash
75630073|NCT04032184|Other|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|regimen using fluoride toothpaste, chlorhexidine mouthwash, MI varnish
75630074|NCT00662896|Drug|naproxcinod 375 mg bid|naproxcinod 375 mg bid
75630075|NCT00662896|Drug|naproxcinod 750 mg bid|naproxcinod 750 mg bid
75781213|NCT03992495|Other|Exercise|All participants will be exposed to aerobic/strengthening exercises
76075435|NCT01590433|Drug|Exenatide|Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
76075436|NCT01590433|Drug|Placebo|Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
75630076|NCT00662896|Drug|naproxen 250 mg bid|naproxen 250 mg bid
76075437|NCT01590433|Behavioral|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.
76075438|NCT00820612|Drug|Indomethacin|100 mg PR once at the time of ERCP
75323960|NCT01273181|Biological|PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|
75323961|NCT01273181|Drug|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
76075439|NCT00820612|Other|Placebo suppositories|2 placebo suppositories at the time of ERCP
75323962|NCT01273181|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
75630077|NCT00662896|Drug|naproxen 500 mg bid|naproxen 500 mg bid
75630078|NCT00662896|Drug|ibuprofen 600 mg tid|ibuprofen 600 mg tid
75630079|NCT00963924|Drug|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
75630080|NCT00963924|Drug|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
75630081|NCT00963924|Behavioral|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
75781214|NCT03927560|Procedure|Robotic Assisted Percutaneous Coronary Intervention|Robotic Assisted Percutaneous Coronary Intervention
75781215|NCT01226966|Drug|liraglutide|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.
75781216|NCT01228838|Drug|NGX-1998|Capsaicin topical liquid to be applied for 5 minutes one time only.
75781217|NCT01228838|Drug|Placebo Liquid|Placebo topical liquid to be applied for 5 minutes one time only.
75781218|NCT03919838|Dietary Supplement|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive two probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
76075440|NCT01928927|Drug|Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
75630082|NCT04513899|Behavioral|Community health worker (CHW)/ registered nurse (RN) [CHW/RN]|A team of 2-3 CHWs and a research RN will deliver all components of the program including daily DOT delivery of Direct Acting Antiviral (DAA) and assess HCV side effects all under the guidance of their RN. Recruitment will be continuous: each CHW may be assigned up to 7-8 participants every 2-3 months until the target sample size (n=54 for the intervention group) is achieved. After the first dose of the DAA, the CHW will run a brief weekly 1:1 education and case management session over the 8 or 12 weeks (total 20 minutes). The CHW/RN team will assist the participant in picking up the monthly medication and storing the medication in a secure, locked cabinet at the research office. The CHW will rigorously track participants who have missed a dose, and will also be involved in facilitating medical, mental health, substance use, social service, legal appointments for participants, housing referrals, and accompany the participants to the appointments.
75467752|NCT01932554|Drug|Placebo|Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
75781219|NCT03919838|Dietary Supplement|Placebo - No probiotics|A half of the participants will be randomly allocated to the placebo group. They will receive two no probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
75781220|NCT01129700|Radiation|Radiation: short-course preoperative chemoradiotherapy|"Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).~Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day)."
75467753|NCT01932554|Other|Intravenous hydration|intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
75630083|NCT04513899|Behavioral|Clinic-based Standard of Care (cbSOC) Program (control group)|This program will be delivered by a clinic-based MD or clinic-based NP at the clinic site. Evaluation Staff (ES) will be hired and trained to do the interviewing/survey administration and follow-ups at the clinic-based site. The clinic NP will conduct, per usual care at the study clinics, the education and monitoring of these participants who will interact with the clinic-based-MD and/or NP monthly over the 8 or 12-week program. Usual care will include: 1) HCV pre-treatment education; 2) two month supply of DAA; 3) monitoring adverse events; and 4) responding to questions on HCV. Referral to drug/alcohol and housing programs will be provided over the standard of care. The cbSOC participants will not receive the community delivery of the DAA, or case management, or accompaniment to needed services. The cbSOC Program will receive the medication on a monthly basis from the clinic MD or NP.
75630084|NCT00659542|Procedure|cyanoacrylate glue|1 ml glue
75630085|NCT02862678|Other|diffusion-weighted MRI|Two diffusion-weighted MRI will be performed (one 8 days before chemoradiotherapy treatment and one 3 months after the end of chemoradiotherapy treatment).
75630086|NCT00659620|Biological|mesenchymal stem cell|transplantation of mesenchymal stem cell
75781221|NCT01229852|Device|DSF-rTMS|Effective Transcranial Magnetic Stimulation
75781222|NCT03923036|Drug|Antineoplastic Agents|Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.
75467754|NCT01932554|Drug|Ibuprofen|Scheduled ibuprofen,~10 mg/kg every 6-8 hours
75781223|NCT03919916|Procedure|Serratus plane block|Placement of initial local anaesthetic bolus and catheter for continuous infusion in the plane between latissimus dorsi and serratus anterior in the midaxillary line at the level of the 5th rib
75323963|NCT01273181|Drug|Fludarabine|25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
75323964|NCT01272947|Drug|Diclofenac sodium|Topical gel 1%- 4 times daily
75323965|NCT01272947|Other|Placebo|Topical gel - 4 times daily
75323966|NCT01279343|Device|Foley bulb|This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
75467755|NCT01932554|Drug|Parenteral narcotic|Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
75467756|NCT01932554|Other|Incentive spirometry|Patients will perform incentive spirometry every 2 hours while awake
75781224|NCT03919916|Other|Patient controlled analgesia|Computerised pump device facilitating the patient self administration and titration as needed of morphine
75781225|NCT01129856|Drug|Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
76075441|NCT00871624|Drug|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
76075442|NCT00871624|Drug|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
75323967|NCT03830645|Biological|Platelet Rich Plasma|Application of platelet rich plasma through the intercostal tube into the pleural space
75323968|NCT02991833|Other|A New Incontinence Care Product|The novel incontinent care product is dressed and removed removed by opening both sides. In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien. When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering. The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the novel incontinent care product was changed.
75467757|NCT01932554|Other|Supplemental oxygen|Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
75467758|NCT01932567|Other|Physiotherapy|
75323969|NCT02991833|Other|Diaper|In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the diaper was changed.
75323970|NCT01278797|Drug|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
75323971|NCT01278797|Drug|Amlodipine Monocomponent|Active Comparator
75323972|NCT04277273|Other|Questionnaire|Questionnaires WHOQOL-BREF and GOHAI
75323973|NCT01272869|Device|SenSura|The ostomy bag filter will be tested for a period of 14 days
75630087|NCT03265665|Behavioral|ACTION Intervention|The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive lifestyle physical activity intervention for African American (AA) women. There are 2 phases to the intervention: Adoptive (24 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. 1 Group session (maintenance): watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking, reinforce barriers and facilitators to walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.
75781226|NCT01129856|Drug|Sodium citrate buffer solution|Sodium citrate buffer solution 100 mM
75781227|NCT03919604|Procedure|Extracorporeal Life Support|Any extracorporeal blood treatment technique for respiratory and/or cardiac support
75781228|NCT01129934|Drug|Morphine-Promethazine|administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
75781229|NCT01129934|Drug|morphine|Administration of intravenous morphine 0.1 mg/kg
75781230|NCT01130012|Behavioral|Lifestyle: diet and exercise|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
75781231|NCT01130012|Behavioral|Close follow-up: reporting diaries of food and exercise|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
75781232|NCT03922568|Other|Density Gradient Centrifugation|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
75781233|NCT03922568|Device|Physiological ICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
75781234|NCT03922568|Device|Magnetic Activated Cell Sorting|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
75781235|NCT01131572|Drug|N-acetylcysteine NAC|N-acetylcysteine in the treatment of Bulimia Nervosa
75781236|NCT03922178|Device|Pressure/Volume Combination Catheter|Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.
75781237|NCT03922178|Device|Transthoracic echocardiography|A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
75781238|NCT03922178|Device|Transesophageal echocardiogram|A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
75781239|NCT01228916|Behavioral|Tobacco Cessation and Secondhand Smoke Reduction|Awareness raising and resources for cessation and secondhand smoke reduction
75781240|NCT01132196|Drug|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
75781241|NCT01228994|Drug|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
76075443|NCT05315518|Diagnostic Test|single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
76075444|NCT01710709|Drug|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
76075445|NCT05318404|Dietary Supplement|Jejunostomy feeding|Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
75323974|NCT01272869|Device|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
75781242|NCT01228994|Drug|placebo pill|placebo pill
75781243|NCT01228994|Drug|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
75781244|NCT03927170|Combination Product|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
75781245|NCT03927170|Combination Product|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
75781246|NCT01227200|Drug|dypiron, tramadol|dypiron 4 ML, tramadol 50 mg flashtab
75781247|NCT01132274|Procedure|Radiofrequency catheter ablation|Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
75630088|NCT03265665|Other|Enhanced usual care|"Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks."
75323975|NCT01272635|Drug|Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
75467759|NCT01932567|Procedure|Electrical impedance tomography|
75630089|NCT02861196|Procedure|Intensity modulated radiation therapy, Radical cystectomy|Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
75916713|NCT05174858|Device|Hemostatic dressing ETIK COLLAGENE|The hemostatic dressing ETIK COLLAGENE is placed in the alveolus immediately after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the surgical site is sutured.
76075446|NCT01617629|Biological|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
75630090|NCT04155658|Other|Experimental Toothpaste containing 1450ppm SMFP|Experimental Toothpaste containing 1450ppm SMFP
75781248|NCT01132274|Procedure|Radiofrequency catheter ablation|Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
75630091|NCT04155658|Other|Toothpaste containing 1450ppm SMFP|Toothpaste containing 1450ppm SMFP
75630092|NCT04155658|Other|Toothpaste with no fluoride|Toothpaste with no fluoride
75630093|NCT02861976|Other|Opioid risk screen development & implementation|Development of a screening tool for the risk of opioid misuse in patients with traumatic injury.
75630094|NCT00631839|Radiation|Thoracic 3-D Conformal Radiotherapy|Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies >=6MV.
75630095|NCT00666484|Drug|cyclophosphamide|
75781249|NCT03922022|Behavioral|EIM exercise classes and intervention|This is a complex intervention. On recruitment, they will be seen by a nurse and counselled using motivational technique. They will then undergo a 12-week class. The exercise levels will be regularly feedback to the patients by use of mobile devices and trackers. Peer support is formed during the 12-week class. Resources to continue exercise will be provided to patients. Regular monitoring of physical improvement will be feedback to patients to encourage continued exercise.
75781250|NCT03921632|Behavioral|Smiles Matter Oral Health Education Series|Three sessions scheduled 2 weeks apart consisting of 15-20 minutes of didactic learning, 10 minutes of a group/personal exercise, and 10 minutes of questions that the patients have on the topic discussed that day
75916714|NCT05174858|Other|Comparator|The alveolus is left empty after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the dressing ETIK COLLAGENE is placed in the alveolus and the surgical site is sutured.
75916715|NCT04810234|Device|transcutaneous vagal nerve stimulation (tVNS)|Cervical and auricular transcutaneous stimulation of the vagus nerve
76075447|NCT00874510|Behavioral|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
76075448|NCT01686373|Device|Activa Dose II Real tDCS|20 minutes of 1 milliamp active tDCS per treatment day (15 total sessions)
76075449|NCT01686373|Device|Activa Dose II Sham tDCS|20 minutes of sham stimulation per treatment day (15 total sessions)
76075450|NCT03838666|Drug|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
75323976|NCT01272635|Drug|Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
75323977|NCT01272635|Other|Placebo Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
75467760|NCT01932580|Drug|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
75467761|NCT01932593|Procedure|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
75467762|NCT01932632|Other|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
75467763|NCT01932658|Biological|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
75630096|NCT00666484|Drug|doxorubicin hydrochloride|
75630097|NCT00666484|Drug|etoposide|
75323978|NCT01272635|Drug|Placebo Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
75323979|NCT01272011|Other|Intermittent Hypoxia|Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
75323980|NCT01272011|Other|Locomotor Training|Individuals received 10 days of locomotor training, intense walking training on a treadmill with body weight support. Manual assistance was provided at the legs to optimize stepping patterns.
75323981|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
75630098|NCT00666484|Drug|prednisolone|
75630099|NCT00666484|Drug|procarbazine hydrochloride|
75630100|NCT00666484|Drug|vincristine sulfate|
75630101|NCT00666484|Radiation|radiation therapy|
75630102|NCT00662974|Other|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
75781251|NCT01227356|Drug|imatinib and pegylated interferon|imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
75781252|NCT01132352|Drug|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
76075451|NCT03838432|Device|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
75781253|NCT03922100|Drug|NMS-03592088|NMS-03592088 will be administered orally once daily for 21 or 28 consecutive days of each treatment cycle. A treatment cycle will comprise 21 days of NMS-03592088 administration (Day 1 to 21) followed by 7 days of rest for a total of 28 days (4 weeks) period for Schedule A and 28 days of NMS-03592088 administration (Day 1 to 28) for a total of 28 days (4 weeks) period for Schedule B.
75781254|NCT03919760|Behavioral|NAVIGATE|"NAVIGATE was developed in consultation with clinical and research experts, biostatisticians, health economists, consumers, family members, advocacy groups, and government officials. It is a form of coordinated specialty care for first episode psychosis consisting of 4 key intervention components:~individualized medication management using a decision support tool;~a package of psychoeducation and a blend of evidence-based psychotherapies called individual resiliency training (IRT);~supported employment and education (SEE);~a family education program"
75630103|NCT00662974|Other|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
75630104|NCT04507893|Other|Clinical, laboratory and imaging characteristics of pneumonia|"Evaluation of the clinical, laboratory and imaging characteristics in patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as COVID-19 patients and negative COVID-19 patients."
75630105|NCT00666640|Device|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
75630106|NCT00666640|Device|CT scan of hip|Computed Tomography scan
75630107|NCT00663130|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
75630108|NCT00663130|Drug|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
75630109|NCT01114646|Device|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
75630110|NCT01114646|Device|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
75630111|NCT00965562|Drug|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
75630112|NCT00965562|Drug|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
75630113|NCT00965562|Drug|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
75781255|NCT01131728|Drug|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
75781256|NCT03927326|Drug|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine
75630114|NCT02631382|Procedure|wet cupping|"In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected."
75630115|NCT00659698|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
75781257|NCT01130090|Device|Adjustment of back-up respiratory rate on bi-level ventilator|"3 consecutive nights in randomized order, in either S (Spontaneous) mode, ST (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in ST (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort"
75781258|NCT03919682|Other|Experimental: Training, Phase 1|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
76075452|NCT03838354|Drug|Chidamide|Chidamide 2.5 mg po biw, every four weeks for one cycle. It will be given three cycles.
76075453|NCT03838354|Drug|Chidamide|Chidamide 5 mg po biw, every four weeks for one cycle. It will be given three cycles.
76075454|NCT01709695|Drug|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
76075455|NCT01709695|Drug|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
76075456|NCT05312320|Other|Information film|"Sexual activity after MI does not increase risk of recurrence or death~Sexual activity is associated with improved outcome after MI~Resuming sexual activity as normal is recommended and completely safe"
76075457|NCT05310760|Drug|Vit C|Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
75323982|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
75323983|NCT04387097|Drug|remifentanil|postoperative drip-infusion of remifentanil
75323984|NCT01270841|Drug|Placebo|Placebo capsule 1x daily for 3 months
75323985|NCT01270841|Drug|topical testosterone|testosterone gel applied 1x daily for 3 months
75323986|NCT01270841|Drug|Androxal|Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
75323987|NCT04345523|Other|Blood and derivatives.|Administration of fresh plasma from donor immunized against COVID-19
75323988|NCT04345523|Drug|Standard of Care|Standard of care for the treatment of COVID-19 in hospitalized patients
75630116|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
75630117|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
75630118|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
75630119|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
75781259|NCT03919682|Other|Experimental: Training, Phase 2|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
75781260|NCT01132430|Behavioral|Motivational interviewing|Brief MI 3x30 minute sessions within 4-6 week period
76075458|NCT05236504|Dietary Supplement|Melatonin and magnesium-containing pod|A 50-100mL hot water drink, obtained from a coffee pod machine, containing 1.9mg of melatonin and 200mg of magnesium in a powdered form, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
76075459|NCT05236504|Other|Placebo comparator|A 50-100mL hot water drink of identical taste, obtained from an identical pod with the same ingredients except melatonin and magnesium, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
76075460|NCT02150044|Device|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
76075461|NCT01685983|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
76075462|NCT01685983|Drug|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
75323989|NCT01270139|Procedure|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
75323990|NCT01270139|Procedure|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
75630120|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
75630121|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
75630122|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
75630123|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
75630124|NCT00912093|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
75630125|NCT00912093|Drug|Placebo|Single subcutaneous injection of matching placebo
75781261|NCT01132430|Behavioral|Usual care|Standard medical care within 4-6 week period
75781262|NCT01132586|Drug|Lenalidomide|Given PO
75781263|NCT01132586|Drug|Cytarabine|Given IV
75781264|NCT01132586|Drug|Idarubicin|Given IV
75781265|NCT01132586|Other|Pharmacological Study|Correlative studies
76075463|NCT02151448|Biological|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
76075464|NCT02151448|Drug|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
76075465|NCT02151448|Drug|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
75323991|NCT01270139|Device|Stenting|60 - in sirolimus-eluting stenting control
75323992|NCT01278407|Drug|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
75323993|NCT01278407|Drug|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
75323994|NCT01278407|Drug|Donepezil matched placebo|
75323995|NCT01278173|Drug|Sabril|Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
75781266|NCT01132586|Other|Laboratory Biomarker Analysis|Correlative studies
75781267|NCT01130246|Drug|A-002, varespladib methyl|A-002 administered once daily in addition to atorvastatin and standard of care
75781268|NCT01130246|Drug|Placebo|Placebo administered once daily in addition to atorvastatin and standard of care
75781269|NCT03921710|Drug|CAPA-IVM|Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin [SAGE, Denmark] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
75781270|NCT03921710|Drug|Standard-IVM|Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
75781271|NCT03921476|Other|Online survey|Online survey completion through Northwestern's REDCap
76075466|NCT02151448|Biological|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
75323996|NCT00784303|Drug|Lenvatinib (DTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily, or 10 mg lenvatinib orally twice daily (20 mg total). Out of 58 participants in the DTC cohort, 56 participants received 24 mg lenvatinib once daily and 2 participants received 10 mg lenvatinib twice daily (total 20 mg daily), given continuously in 28-day treatment cycles.
75323997|NCT00784303|Drug|Lenvatinib (MTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily given continuously in 28-day treatment cycles.
75781272|NCT03921086|Drug|Antihypertensive medication according to the study's algorithm|"Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm."
75781273|NCT03739970|Dietary Supplement|Investigational Product (Silk Peptide)|"Ingredient: Silk Peptide~Type: Yellow granule stick~Storage: Room temperature~Weight: Silk Peptide 9g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
75630127|NCT03500484|Drug|Liraglutide|Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
75781274|NCT03739970|Dietary Supplement|Control Group - Placebo Product|"Ingredient: Microcrystalline Cellulose~Type: Yellow granule stick~Storage: Room temperature~Weight: Silk Peptide 0g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
75781275|NCT01227590|Drug|Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
75781276|NCT03927248|Drug|Nivolumab|See description in Arms/Groups section
75916716|NCT05265572|Behavioral|Domestic Hygiene and household hygiene Intervention|A demonstration on the domestic hygiene intervention will be conducted where participants will be guided on optimal cleaning of windowsills, floors and other surfaces with water and detergent, and advised on appropriate method of cleaning. Participants will be provided with a package of cleaning materials (mop, bucket, detergent, hand wash liquid soap and cloth for wet dusting) which will be used during the demonstration, and retained by participants to facilitate sustainability of the intervention during and after the study. Participants will be further engaged in an educational discussion, with the aid of a specially designed educational pamphlet containing information about health effects potentially associated with dust lead exposure from mine dumps and the personal hygiene and domestic hygiene steps that may be followed to reduce dust lead exposure.
75916717|NCT00834132|Drug|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fed
75916718|NCT00834132|Drug|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fed
75916719|NCT05265104|Drug|SDF with stainless steel crown|Silver Diamine Fluoride (38%) applied to the carious lesion in the primary molars with a brush and the tooth is sealed with a stainless steel crown
75323998|NCT00750815|Drug|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
75323999|NCT00750815|Drug|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
75324000|NCT00784849|Drug|Methylene blue|1 mC1
75781277|NCT03926780|Drug|Rivaroxaban 20 MG|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day
75781278|NCT03926780|Drug|Warfarin Sodium|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
75916720|NCT05265104|Device|Diode laser application with stainless steel crown|Diode laser will be applied to the carious lesions primary molars to eradicate the bacteria and then the tooth will be sealed with stainless steel crown
75916721|NCT05265104|Other|stainless steel crown only|the primary molars with carious lesions will be sealed with stainless steel crowns following the concept of hall technique
75324001|NCT04386707|Biological|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age
75324002|NCT04386707|Biological|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age
75916722|NCT02988830|Device|Subcutaneous Electric Lumbar Stimulation|
75916723|NCT03447548|Behavioral|Neurofeedback processing speed training|Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm
75916724|NCT03447548|Behavioral|Active control|Commercially available games on tablet
75916725|NCT00833586|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
75916726|NCT00833586|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
75324003|NCT04386707|Biological|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age
75324004|NCT04386707|Biological|Three doses control wIPV at the schedule of 2,3,4 months of age|Three doses control wIPV at the schedule of 2,3,4 months of age
75324005|NCT01277861|Drug|Fentanyl|FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
75781279|NCT01229306|Procedure|Ablation|Ablation of atrial fibrillation
75916727|NCT03712358|Biological|PVSRIPO|Intralesional injection of PVSRIPO.
75916728|NCT02605954|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
75916729|NCT02605954|Drug|ABC/3TC|600/300 mg tablets administered orally once daily
75630128|NCT00659854|Dietary Supplement|Non milk or soy based formula|Babies will be given a non milk or soy base formula for 12 weeks
75630129|NCT00659854|Dietary Supplement|milk based formula|Babies will be given a milk based formula for 12 weeks
75630130|NCT03372954|Drug|BMAC|retrograde administration on non-selected BMAC via coronary sinus
75630131|NCT02630446|Other|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
75781280|NCT03921164|Procedure|Trans-oesophageal Doppler|"As required by the standard of care of the interventional neuroradiology procedure, the neuroradiologist also cannulates the femoral artery. At the end of the procedure, during catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.~Descending aortic velocity is measured with a transesophageal Doppler CardioQ-ODM+ (Deltex Medical, Chichester, UK) in order to construct the VP Loop in descending thoracic aorta."
75781281|NCT03921164|Procedure|Trans-thoracic echocardiography|Estimation of ventricular diastolic pressure by measuring mitral and aortic flow gradients by echocardiography (EPIQ G7 Philips© or similar) Determination of left ventricular volumes during the cardiac cycle by echocardiography (3D EPIQ G7 Philips© or similar).
75781282|NCT03921164|Procedure|Applanation tonometry|"Measurements using the SphygmoCor radial tonometer (AtCor Medical, Pty Ltd, Sydney, Australia), the most widely used tonometer in clinical research for non-invasive central pressure measurement and pulse wave analysis. The central blood pressure is then estimated using a validated radial-aortic transfer function.~The tonometer requires prior calibration by mean (MAP) and diastolic (PAD) blood pressure measured with the conventional brachial cuff as validated in the literature."
75781283|NCT01229384|Device|Positive Airway Pressure nebulization|Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
75781284|NCT01229384|Device|Standard passive nebulization of respiratory medications|Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
75781285|NCT03920930|Procedure|Late local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
75781286|NCT03920930|Procedure|Early local infiltration analgesia|The local infiltration analgesia is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached.
76075467|NCT01685437|Biological|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
76075468|NCT00875212|Drug|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
75781287|NCT01585610|Behavioral|DVD Intervention|Four theory-based intervention DVDs will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. DVDs focus on motivating smoking cessation among people with mobility impairments using Behavioral Activation as the primary theoretical construct. Short (< 5 min.) phone calls will also be placed to each participant in between DVD deliveries and after receipt of DVD 4.
75781288|NCT01585610|Behavioral|Standard Care Printed Materials|Four sets of standard smoking cessation printed materials will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. Short (< 5 min.) phone calls will also be placed to each participant in between materials deliveries and after the 4th and final set is sent by mail.
75781289|NCT03926936|Drug|Fulvestrant|intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
75781290|NCT03927014|Other|thiol/disulfide levels|Venous blood will sample from the antecubital veins for measuring the serum concentration of thiol/disulfide levels. The serum thiol/disulfide levels will measure using commercially available reagent kits, which is produced to detect human thiol/disulfide levels (Rel Assay Diagnostics Gaziantep, Turkey). The thiol/disulfide levels measurements were performed in accordance with the company's protocol.
75781291|NCT03920618|Drug|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
75781292|NCT03920618|Drug|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
75781293|NCT03920618|Drug|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
75781294|NCT03920852|Drug|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
75630132|NCT00659932|Behavioral|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
75630133|NCT00659932|Behavioral|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
75630134|NCT02631460|Drug|S1 80-120 mg/d|d1, every 3 weeks
75630135|NCT02631460|Drug|pemetrexed 500 mg/m2|d1, every 3 weeks
75781295|NCT01131806|Drug|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
75781296|NCT01131806|Drug|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
75781297|NCT03919058|Other|Baseline activity (control regime)|This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
76075469|NCT00875212|Drug|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
76075470|NCT00875212|Drug|fluoride|use of a dentifrice containing fluoride (1500ppm) only
75630136|NCT02631460|Drug|carboplatin AUC=5|d1, every 3 weeks
75630137|NCT00965484|Device|New Genotropin Pen|Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
75916730|NCT02605954|Drug|Third Antiretroviral Agent|"Third antiretroviral agents could include one of the following:~ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~DRV+COBI or DRV/COBI FDC~darunavir (DRV; Prezista®) + RTV~lopinavir/ritonavir (LPV/r; Kaletra®)~atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~efavirenz (EFV; Sustiva®)~etravirine (ETR; Intelence®)~nevirapine (NVP; Viramune®)~rilpivirine (RPV; Edurant®)~dolutegravir (DTG; Tivicay®)~raltegravir (RAL; Isentress®)~fosamprenavir (FPV; Lexiva®) + RTV~saquinavir (SQV; Invirase®) + RTV~ATV (no booster)~Drug classes:~Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~Pharmacokinetic enhancer: COBI~Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~Integrase inhibitors: RAL and DTG"
75781298|NCT03919058|Other|Increased sitting time (sit regime)|Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
75630138|NCT02630602|Dietary Supplement|Functional goat cheese|60 g per day during 12 weeks
75630139|NCT02630602|Dietary Supplement|Control cheese|60 g per day during 12 weeks
75781299|NCT03919058|Other|Non-exercise physical activity (sit less regime)|Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
75781300|NCT03919058|Other|Structured exercise (exercise regime)|One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.
75916731|NCT00780000|Drug|Alvespimycin|Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
75916732|NCT03447470|Drug|RXC004|RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
75916733|NCT03447470|Drug|Nivolumab|"RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1"
75630140|NCT00666874|Behavioral|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
75324006|NCT00786487|Drug|20% lipid infusion|1.5 ml/min for 6 hours
75630141|NCT00666874|Behavioral|Control - general information|General information about healthy food choices and exercise
75630142|NCT00666952|Other|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
75630143|NCT00666952|Other|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
75630144|NCT04233723|Other|peripheral blood samples|venous puncture
75916734|NCT04817722|Drug|Intravenous Solution|Intraoperative hydration
75781301|NCT01229930|Drug|carboplatin|
75781302|NCT01229930|Drug|cediranib maleate|
75781303|NCT01229930|Drug|paclitaxel|
75781304|NCT01229930|Other|laboratory biomarker analysis|
75916735|NCT03447392|Behavioral|Discharge Education of Chinese Medicine|Discharge Education of Integrated Traditional and Western Medicine
76075471|NCT00875212|Drug|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
76075472|NCT00875836|Drug|Buspirone|Flexible dose, up to 60 mg daily
75630145|NCT04282824|Procedure|Biospecimen Collection|Undergo collection of saliva
75630146|NCT04282824|Procedure|Computed Tomography|Undergo PET/CT
75781305|NCT01229930|Other|pharmacological study|
75781306|NCT01229930|Procedure|quality-of-life assessment|
75781307|NCT03920540|Combination Product|GC1111|GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
75781308|NCT03920540|Combination Product|Comparator|Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
75781309|NCT01229540|Genetic|genetic analyzer|
75781310|NCT03927092|Other|Multiple Sclerosis Knowledge Questionnaire|A 25-item self-administered questionnaire
76075473|NCT00875836|Drug|Placebo|Flexible dose, up to 60 mg daily
76075474|NCT05235802|Diagnostic Test|Magnetic Resonance Imaging (MRI) (including functional MRI)|"Patients will undergo magnetic resonance imaging including the following protocols:~3D T1w MPRAGE~3D T2w FLAIR SPACE~3D T2w SPACE~3D T1w PSIR (cortical visualization)~2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~3D SWI~DWI b1000 32 directions and b3000 64 directions."
76075475|NCT05235802|Diagnostic Test|Blood sampling (serum/plasma preparation)|Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.
76075476|NCT05235802|Diagnostic Test|Cerebrospinal fluid (CSF)|CSF will be analyzed for inflammatory and neurodegenerative biomarkers.
75324007|NCT00786487|Drug|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
75324008|NCT02991443|Behavioral|Mindfulness based stress reduction|Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
75324009|NCT01277549|Device|Mononuclear cell collection.|Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
75781311|NCT01227746|Procedure|Tumor biopsies|
75916736|NCT00765804|Drug|EGP-437 with EyeGate® II System|Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
75324010|NCT01274455|Genetic|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
75324011|NCT03805633|Diagnostic Test|Venous blood sample|Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
75324012|NCT03805633|Diagnostic Test|Ultrasound of pancreas|Ultrasound of pancreas will be obtained on all study participants.
75324013|NCT01274845|Other|Heliox mechanical ventilation|Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
75467764|NCT01932684|Other|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
75467765|NCT01932684|Other|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
75781312|NCT01229618|Drug|Hyperpolarized Pyruvate (13C) injection|single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
75781313|NCT03919136|Device|Wrist-worn measurement device (LiveMetric)|Evaluation of the wrist-worn measurement devices accuracy referenced to interventional (A-line) measurements.
75781314|NCT02528708|Drug|fibrinogen concentrate|The dose of fibrinogen concentrate needed to achieve this target will be calculated using a formula that accounts for the baseline FIBTEM® - A10 value and the patient's body weight assessed at hospital admission . In general, a 70-kg patient requires a fibrinogen dose of approximately 0.5 g to increase the MCF by approximately 1 mm.
75781315|NCT02528708|Drug|Placebo|0.9% saline solution
75324014|NCT01276847|Drug|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing > 100 kg on Day 1, and Weeks 4 and 16
75324015|NCT01276847|Drug|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
75324016|NCT03830879|Other|No intervention|This cohort study have any no intervention.
75324017|NCT03805555|Procedure|Radiofrequency ablation|Pulmonary vein isolation by radiofrequency ablation
75324018|NCT03805555|Procedure|Cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation
75324019|NCT00945269|Biological|therapeutic autologous lymphocytes|Given IV
75630147|NCT04282824|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
75630148|NCT04282824|Dietary Supplement|Monosodium Glutamate|Given PO
75324020|NCT00945269|Biological|aldesleukin|Given SC
75630149|NCT04282824|Procedure|Positron Emission Tomography|Undergo PET/CT
75630150|NCT02631304|Procedure|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
75630151|NCT04236297|Device|bite block|Physicians performing transesophageal echocardiogram in patients under sedation or general anesthesia will use either standard or modified bite block.
75781316|NCT03920228|Drug|PTX-022|PTX-022 QTORIN
75324021|NCT00945269|Biological|denileukin diftitox|Given IV
75324022|NCT00945269|Procedure|biopsy|Optional correlative studies
75324023|NCT00945269|Other|immunohistochemistry staining method|Correlative studies
75324024|NCT00945269|Other|laboratory biomarker analysis|Correlative studies
75324025|NCT00945269|Genetic|polymerase chain reaction|Correlative studies
75467766|NCT01932684|Device|5000 Voldyne ® Sherwood Medical, USA|
75467767|NCT01932684|Device|Silicone face mask|
75630152|NCT00663286|Drug|IDP-110|Topical application for 12 weeks
75781317|NCT03920228|Drug|Placebo|Placebo topical
75781318|NCT03920150|Drug|Vitamin D3|Patient will be treated with 3 doses of alcoholic solution for 3 months.
75630153|NCT00663286|Drug|Clindamycin|Topical application for 12 weeks
75630154|NCT00663286|Drug|Benzoyl peroxide|Topical application for 12 weeks
75630155|NCT00663286|Drug|Vehicle|Topical application for 12 weeks
75630156|NCT04284462|Other|Flavored carbonated soft drink (CSD)|1-2 cans/day (330 ml per can)
75630157|NCT00660088|Other|Ketasyn|10g for 7 days, 20g for 7 or 14 days
75630158|NCT03237702|Dietary Supplement|Multi-Carotenoids|All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.
75781319|NCT03920150|Drug|Vitamin D oily capsules|Patient will be treated with 3 capsules for 3 months.
75781320|NCT03920150|Drug|Vitamin D oily capsules|Patient will be treated with weekly capsules for an individually calculated number of weeks.
75916737|NCT00765804|Drug|Sodium citrate buffer solution with EyeGate® II System|Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
75916738|NCT03447236|Behavioral|Feuerstein Program|Mediated learning cognitive enhancement program
75916739|NCT04830826|Procedure|Surgeries|Surgeries
75916740|NCT00764634|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182
75916741|NCT00764634|Biological|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182
75916742|NCT00764634|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182
75630159|NCT00667108|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
75916743|NCT00764634|Biological|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
75916744|NCT03447158|Procedure|15% Dextrose|inject 15% dextrose and xylocaine into subacrominal bursa under sonographically guidance
75781321|NCT01229696|Procedure|Catheter Placed At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
75324026|NCT00765193|Other|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
75324027|NCT02991287|Procedure|Inguinal hernia repair|
75467768|NCT01932710|Procedure|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
75467769|NCT01932723|Behavioral|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
75467770|NCT01932736|Other|changing ear canal pressure|ear canal pressure changes: pressure varied from +/-40 decapascals
75467771|NCT01932749|Device|Transcranial Magnetic stimulation|
75467772|NCT01932775|Device|GlucoTab System|
75467773|NCT01932827|Behavioral|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
75467774|NCT01932840|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
75781322|NCT01229696|Procedure|Catheter Placed 5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
75781323|NCT01131962|Procedure|Endoscopic control of hematemesis|Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
75916745|NCT03447158|Procedure|Normal saline|inject normal saline and xylocaine into subacrominal bursa under sonographically guidance
75324028|NCT02991287|Procedure|Abdominal hysterectomy|
75324029|NCT02991287|Procedure|Vaginal hysterectomy|
75324030|NCT02991287|Procedure|Thoracotomy|
75467775|NCT01932866|Other|diabetic risk score|
75467776|NCT01932905|Device|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
75467777|NCT01932918|Drug|Patient controlled analgesia|"PCA with morphine in liver transplant:~Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~PCA with morphine and ketorolac:~Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients."
75630160|NCT00667108|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
75630161|NCT00667108|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
75630162|NCT00961116|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
75630163|NCT00961116|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
75630164|NCT04158232|Other|Method|treatment of mature teeth with apical periodontitis
75630165|NCT04492449|Other|congenital malformation|congenital malformation
75630166|NCT04158388|Other|Mediterranean-diet enriched with a higher dose of tryptophan and magnesium|That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium
75630167|NCT04158388|Other|Isocaloric diet|That group eaten isocaloric diet plan based on Mediterranean diet.
75630168|NCT04158388|Other|Manual therapy|That group received moderate pressure digital manual therapy.
75630169|NCT04158388|Other|Placebo therapy|That group was treated with a US (in off mode) without conductive gel.
75781324|NCT01130324|Drug|VIBATIV|Observational
75781325|NCT01230008|Radiation|no drugs|Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
75916746|NCT03443804|Drug|Test(DW1401)|DW1401+Placebo of Stillen tab.
75916747|NCT03443804|Drug|Reference(Stillen tab.)|Stillen tab.+Placebo of DW1401
75916748|NCT00761826|Device|MEL 80 Mixed Astigmatism Treatment|Treatment of Naturally Occuring Mixed Astigmatic corrections up to 6.0 D.
75916749|NCT04830904|Device|personalized Lycra garments|the subjects wear lycra garments during the assessment time and for some days after the assessment
75916750|NCT03443726|Procedure|Nerve block technique|Inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve for third molar extraction.
75916751|NCT03443726|Procedure|Infiltrative technique|Infiltrative anesthesia buccally between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc lingually to the third molar using the same anesthetic solution.
75916752|NCT03443726|Drug|4% articaine 1:100.000 epinephrine|Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
75467778|NCT01932931|Dietary Supplement|cholecalciferol (50ug)|The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
75781326|NCT01229774|Drug|Etoricoxib|Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
75630170|NCT04283136|Drug|Padsevonil type 1 Tablet 200 mg|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period."
75781327|NCT01229774|Drug|Diclofenac|Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
75781328|NCT03918590|Drug|nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)|NSAID
75781329|NCT03918590|Drug|Theratears tear drop, (Akron, Ann 111 Arbor, MI)|preservative-free Artificial Tears
75324031|NCT01272791|Biological|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
75324032|NCT01272791|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
75324033|NCT00765661|Drug|Tacrolimus (Tacro™)|"The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release"
75467779|NCT01932944|Device|No treatment|
75467780|NCT01932957|Procedure|Laparotomy arm|Laparotomy as standard treatment for ruptured ectopic pregnancy
75467781|NCT01932957|Procedure|Laparoscopy arm|Laparoscopy as treatment for ruptured ectopic pregnancy
75630171|NCT04283136|Drug|Padsevonil type 2 Tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 2 tablet in a pre-specified sequence during the Treatment Period"
75781330|NCT03918590|Other|patching|no drug/ patching
75781331|NCT01231724|Device|Allstate Nasal Spray|Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.
75781332|NCT01231724|Device|Placebo Nasal Spray|2 sprays in each nostril
75630172|NCT04283136|Drug|Padsevonil type 3 Tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 3 tablet in a pre-specified sequence during the Treatment Period."
75781333|NCT03918746|Behavioral|internet Attachment-Based Compassion Therapy (iABCT)|"The internet version of Attachment-Based Compassion Therapy (iABCT) will be developed to be totally self-applied over the Internet through the website www.psicologiaytecnologia.com designed by Labpsitec (Laboratory of Psychology and Technology, Universitat Jaume I, and University of Valencia). The iABCT will consist of eight sequential modules: Module 0) Welcome module: approaching to the compassion; Module 1) Preparing ourselves for compassion. Kind attention; Module 2) Discovering our compassionate world; Module 3) Developing our compassionate world; Module 4) Understanding our relationship with compassion; Module 5) Working on ourselves; Module 6) Understanding the importance of forgiveness; Module 7) Consolidating the practice of compassion~The content will present through texts, audios, videos, pictures, vignettes, and interactive exercises. Downloadable PDF files will be available so that users can review them offline."
75630173|NCT04283136|Drug|Padsevonil type 4 Tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 4 tablet in a pre-specified sequence during the Treatment Period."
75630174|NCT04283136|Drug|Padsevonil type 5 Tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 5 tablet in a pre-specified sequence during the Treatment Period."
75630175|NCT03727893|Behavioral|Roller-based Intervention Group (IG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
75781334|NCT01230086|Device|ICD Implantation without DFT testing|Implantation
75781335|NCT01230086|Device|Upper limit of vulnerability testing|Upper limit of vulnerability testing
75781336|NCT01230086|Device|T-wave shock with induction of ventricular fibrillation|Traditional safety margin testing for defibrillation threshold
75781337|NCT03926390|Dietary Supplement|Bovine colostrum|bovine colostrum for first 2 weeks
75781338|NCT00320255|Drug|Apixaban|Oral tablets administered once daily in 5-, 10-, or 20-mg dose
75781339|NCT00320255|Drug|Placebo|Oral tablets administered once daily
75916753|NCT03443726|Procedure|Third molar extraction|Third molar extraction under local anesthesia.
75916754|NCT04336956|Other|hospitalized children with Covid19|All patients under 18 years hospitalized with a covid19 diagnosis
75916755|NCT04830670|Procedure|sinus floor elevation with lateral approach|sinus floor elevation with lateral approach. 6 months healing phase. implant site preparation with trephine bur and bone specimen retrieval.
76075477|NCT05235802|Diagnostic Test|Clinical assessments / questionnaires|"Glasgow Outcome Scale Extended (functional outcome)~Short-Form 36 (quality of life),~EQ-5D (quality of life),~Mini-Mental State Extended (MMSE) (mental state assessment).~Barthel Index (daily living disabilities),~Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed."
75467782|NCT01932983|Device|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
75324034|NCT00765661|Drug|Prograf|"Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
75916756|NCT04426864|Other|Supervised Aerobic Plus Stretching Exercises|An exercise prescription was developed for each woman based on the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70 % ergospirometric VO2max (moderate-intensity) was determined by the submaximal treadmill test. The participants were instructed to perform their exercises at 50 % of VO2max for six weeks. At seventh their exercise intensity was increased to target HR corresponding to 70 % of VO2max. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY). Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. The exercise program was applied 3 days a week for 12 weeks.
76075478|NCT00891982|Drug|CTGel/ BPO Wash|"Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days."
75467783|NCT01933022|Drug|Eligard|Subcutaneous Injection
75630176|NCT03727893|Behavioral|Control Group (CG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
75630177|NCT00663364|Drug|Physiogel AI Lotion, Physiogel Lotion|Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
75630178|NCT04283058|Drug|Ketamine|d. Ketamine 0.5mg/kg* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.
75630179|NCT04154254|Diagnostic Test|PET/MR|The PET will be performed with one of the following tracers: 18F-FDG, 18F-DOPA or 18F-flutemetamol (Vizamyl). Proper tracer will be determined by the physician according to the condition. Patients that will agree, will be asked to perform two scans each with different tracer. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, perfusion and diffusion images. Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Hidden image parameters will also be extracted for texture analysis purposes. Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity.
75781340|NCT03926234|Other|Four-level Chinese Emergency triage scale|a four-level category system, i.e. life-threatening (Level I), emergent (Level II), urgent (Level III) and semi-urgent (Level IV) . This system contains critical indicators (cardiac arrest, shock, and apnea), high risk indicators (ACS and DKA), single objective indicators (SBP, RR, HR, and SpO2) and MEWS (synthesis indicator). According to patients' health care problems, patients are rated by nurses into one of the four mentioned levels.
75781341|NCT03926546|Behavioral|ERP for Individuals|Comparing Group vs. Individual ERP for OCD
75781342|NCT01134302|Procedure|Norwood management strategy|Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
76075479|NCT00891982|Drug|Soap Free Cleanser and CTGel|"Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days."
76075480|NCT05312476|Drug|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|"Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~Dose extension study:3 cases (1 dose group)."
76075481|NCT01685203|Drug|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
76075482|NCT01685203|Drug|ABT-267|Tablet
75324035|NCT01274923|Device|"MEDISPEC treatment probe"|shock wave treatment
75324036|NCT00765895|Drug|Nortriptyline Hydrochloride|Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
75324037|NCT00765895|Drug|Placebo (for nortriptyline)|Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
76075483|NCT01685203|Drug|Ribavirin (RBV)|Tablet
76075484|NCT01928771|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
75467784|NCT01933035|Other|Immune Thrombocytopenics|Full blood count with extended platelet parameters
75467785|NCT01933035|Other|Hypo-proliferative thrombocytopenics|Full blood count with extended platelet parameters
75467786|NCT01933035|Other|Control Population|Full blood count with extended platelet parameters
75324038|NCT03805087|Procedure|Transarterial coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
75324039|NCT05743309|Behavioral|Video call sessions|Investigators made video call sessions with the participants.
75324040|NCT01275157|Drug|LY2452473|Administered orally as a liquid suspension
75324041|NCT05743231|Procedure|interpectoral area block + serratus anterior area block group|The interpectoral and serratus anterior area blocks will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used for two blocks.
75630180|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
75630181|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
75324042|NCT01276457|Drug|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
75630182|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
75630183|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
75630184|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
75630185|NCT00631995|Dietary Supplement|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
75630186|NCT00663442|Drug|OROS methylphenidate|18, 36, 54 mg
75630187|NCT03004755|Other|Tissue Harvest|
75630188|NCT00912015|Drug|Tramadol OAD|
75630189|NCT00912015|Drug|Tramadol OAD|
75630190|NCT00912015|Drug|Tramadol OAD|
75630191|NCT00912015|Drug|Tramadol OAD 100mg|
75630192|NCT00960804|Biological|Tanezumab|IV, 5 mg dose, q 8 weeks, for up to 80 weeks
75781343|NCT01134302|Procedure|Hybrid Strategy|"Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.~The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies."
75781344|NCT05402618|Other|No intervention|This is an observational study without any intervention.
75781345|NCT01231802|Drug|Eniluracil|Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, & 15
75781346|NCT01231802|Drug|5-Fluorouracil|5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, & 16
75781347|NCT01231802|Drug|Leucovorin|Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, & 17
75781348|NCT01231802|Drug|Capecitabine|Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
75324043|NCT01276457|Drug|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
75324044|NCT01276457|Drug|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
75630193|NCT00960804|Biological|Tanezumab|IV, 10 mg dose, q 8 weeks, for up to 80 weeks
75630194|NCT00960804|Other|Placebo|IV, q 8 weeks, for up to 80 weeks
75630195|NCT00630006|Genetic|TNF-alpha and IL-10|
75630196|NCT02859948|Drug|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
75630197|NCT01126580|Drug|Metformin|
75630198|NCT01126580|Drug|LY2189265|
75630199|NCT01126580|Drug|Placebo (oral)|
75630200|NCT01126580|Drug|Placebo (subcutaneous)|
75630201|NCT04204356|Behavioral|Language treatment for improving discourse production|All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.
75630202|NCT04204356|Device|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.
75630203|NCT00911157|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
75781349|NCT01329614|Behavioral|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
75781350|NCT01329614|Drug|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
75781351|NCT01329614|Behavioral|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
75781352|NCT01329614|Behavioral|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
75781353|NCT05402462|Diagnostic Test|upper endoscopy|detect esphageal motility disorder by upper endoscopy and esophageal manometry
75781354|NCT01231880|Drug|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
75781355|NCT01231880|Drug|Monthly IPT using DP|Given every month
75781356|NCT01231880|Drug|Placebo given every month|No active ingredient
75781357|NCT05402306|Other|Treatment group|Group metacognitive therapy, mainly with attention training technique over two weeks.
75916757|NCT04426864|Other|Supervised Resistance Plus Stretching Exercises Group|According to the data obtained from 1-RM tests, an exercise prescription was developed for each woman. The participants were instructed to perform their exercises with 50% of 1-RM for six weeks. In the 7. week, weights were increased to 70-80% of 1-RM. The number of sets increased progressively (10 repetitions per set; 1 set in the first two weeks; 2 sets in the 3rd and 4th week; 3 sets in the 5th and 6th week). The muscle groups which were involved in resistance exercises were bilateral biceps, deltoid, trapezius, pectorals, serratus anterior, latissimus dorsi, levator scapulae, rhomboid, gluteal, quadriceps, hip adductor and abductor, hamstring, gastrocnemius and abdominal muscles. Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. Stretching exercises were given for the muscle groups they worked on. The exercise program was applied 3 days a week for 12 weeks.
75324045|NCT03804931|Procedure|Fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from healthy donors' fresh feces was injected into the intestine
75916758|NCT04426864|Other|Home-based Stretching Exercises Group|Each exercise was described to the patient by visually. For each muscle group exercise was performed for 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. Exercise program was applied 3 days in a week during 12 weeks. Each participant was called every 2 weeks to maintain compliance.
75916759|NCT03443648|Procedure|External fixator assisted plaing|The plate length is marked on the skin. Limb reconstruction system (LRS) with one swivel clamp or Taylor Spatial frame (TSF) is used in all cases. The fixator is put in a plane parallel to that of the deformity. Two tapered pins are placed on either side of the planned osteotomy site and passed at a distance from the osteotomy so that they will not impede the subsequent internal fixation. Swivel clamps or the struts of the TSF are aligned in such a way that full correction is achieved. After osteotomy, swivel clamp is loosened and angular correction is achieved. Translation is carried out according to preoperative planning. If readjustment is required the swivel clamps or TSF struts are loosened and further correction is carried out. Once desired correction is achieved, the clamps or struts are tightened. Definitive internal fixation is carried out while external fixation holds the fragments. For internal fixation, locked T plate will be used.
75916760|NCT04810000|Device|tourniquet|Tourniquet release before/after wound closure
75916761|NCT03447080|Other|Control|White Bread containing 50g carbohydrate
75916762|NCT03447080|Other|Control|White Bread containing 50g carbohydrate
75916763|NCT03447080|Other|Ricebran soybean milk|White Bread with rice bran soybean milk
75916764|NCT03447080|Other|Soybean milk|White Bread with soybean milk
75916765|NCT00760344|Drug|SYR-472|SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
75324046|NCT03804931|Procedure|Infusion of Saline|Infusion of Saline
75916766|NCT00760344|Drug|SYR-472|SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
75916767|NCT00760344|Drug|SYR-472|SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
75916768|NCT00760344|Drug|SYR-472|SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
75916769|NCT00760344|Drug|Placebo|SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
75916770|NCT00760344|Drug|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
75916771|NCT03443570|Drug|Rituximab|given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally
76075485|NCT01928771|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
76075486|NCT04545229|Other|VR-based Pain Alleviation Tool (VR-PAT)|Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
75324047|NCT03804931|Drug|5-Aminosalicylic acid(5-ASA) and/or Prednisone|Mesalazine and/or Prednisone
75324048|NCT02991131|Drug|Tedizolid (Sivextro, BAY1192631)|Antibiotic
75324049|NCT02991131|Drug|Linezolid|Antibiotic
75630204|NCT00911157|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
75630205|NCT00960570|Drug|Efavirenz 600 mg|Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.
75630206|NCT00960570|Drug|Efavirenz 600 mg|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
75630207|NCT00960570|Drug|Fenofibric Acid|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
76075487|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
76075488|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
75324050|NCT00748865|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
75324051|NCT00748865|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
75467787|NCT01933061|Drug|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
75467788|NCT01933061|Drug|Abraxane|Abraxane 150 mg/m^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
75630208|NCT04463511|Other|Polyethylene bag before the umbilical cord is clamped|"11 x 16 (279mm x 406mm) sterile resealable PB (Resealable Polybag, Helapet Ltd, Bedfordshire, UK)"
75630209|NCT04204278|Device|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose in a 5-mL glass syringe.
75630210|NCT04235829|Procedure|Laparoscopic sleeve gastrectomy|Form of obesity surgery
75630211|NCT04181229|Procedure|Deep brain stimulation|Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
75916772|NCT03443570|Drug|Bortezomib|given subcutaneous injection at a fixed dose of 2.0 mg weekly, for 4 times totally
75916773|NCT03447002|Diagnostic Test|24 hours urine levels metanephrine and normetanephrine|24 hours rhythm recording and 24 hours urine measurement
76075489|NCT01928615|Drug|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
76075490|NCT01928615|Drug|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
75916774|NCT01695980|Procedure|ETT with non modified retractor|adenotonsillectomy
75916775|NCT01695980|Other|LMA with modified retractor|LMA with modified retractor
75630212|NCT00625430|Biological|Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine|"Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.~Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.~If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.~Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6."
75630213|NCT04282746|Drug|JNJ-54135419|Single dose of JNJ-54135419 oral solution will be administered sublingually.
75324052|NCT00766753|Biological|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
75467789|NCT01933087|Behavioral|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
75467790|NCT01933100|Other|Experimental Diet|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
75467791|NCT01933126|Drug|HCG injection|
75781358|NCT01231958|Behavioral|The Heart Healthy Initiative for Hispanic Adults (HIP)|This randomized controlled pilot intervention study will include 150 Hispanic adults (45-75y) in the Greater Boston area. Participants will be randomized to either the intervention or control group after completing their baseline interview. The intervention group will receive 6 months of weekly group educational sessions, Zumba fitness classes and interactions with an embodied computer agent (ECA). The fitness classes and interactions with the ECA will continue for the second 6 months of the 1 year intervention. Intervention activities will occur at community centers in the greater Boston area. Control participants will receive standard of care for the first 6 months and will be offered the full intervention (weekly group educational sessions, Zumba fitness classes and interactions with the ECA) for the second 6 months of the study. Participants will complete an interview and blood draw at baseline, 6 months, and 12 months.
76075491|NCT01928615|Drug|Chemotherapy|Standard chemotherapy for early breast cancer.
75781359|NCT00370331|Drug|eltrombopag|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
75781360|NCT00370331|Drug|Placebo|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
75916776|NCT02718404|Procedure|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI."
75916777|NCT02718404|Drug|MR contrast media and medications|During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
75916778|NCT02718404|Procedure|MR images|Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI.
76075492|NCT01589497|Drug|Rifampicin|Participants with body weight </= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight >50kg were administered one 600 mg tablet orally once daily.
75324053|NCT00766753|Biological|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
75467792|NCT01933126|Drug|Placebo|
75467793|NCT01933139|Other|Audio-visual presentation|
75916779|NCT03443492|Drug|S-1|Intervention is administered to patients in this Arm.
75916780|NCT03443492|Drug|Leucovorin(oral )|Intervention is administered to patients in this Arm.
75916781|NCT03443492|Drug|Gemcitabine|Intervention is administered to patients in this Arm.
75916782|NCT03443492|Drug|Oxaliplatin|Intervention is administered to patients in this Arm.
75916783|NCT03443492|Drug|Irinotecan|Intervention is administered to patients in this Arm.
76075493|NCT01589497|Drug|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
75467794|NCT01933152|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
75781361|NCT03739892|Behavioral|standard stroke rehabilitation|standard rehabilitation according to the french standard care and to the severity of the patient
75324054|NCT00766753|Biological|The second booster vaccine phase:|"At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays"
75467795|NCT01933165|Device|LipiView|
75630214|NCT03786549|Other|pediatric-adult care transition program|"Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~Educative, family (patient and parent), at home~Psychological, with the patient individually~Medico-social orientation, group of patients"
76075494|NCT01589497|Drug|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
76075495|NCT01589497|Drug|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
75324055|NCT03804775|Diagnostic Test|Serum lipid profile|Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa
75324056|NCT03804697|Drug|selective anticoagulation|Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
75324057|NCT00767767|Drug|Placebos|IV Saline infusion for 2 hours.
75630215|NCT02882360|Device|Kerlix-AMD|Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
75781362|NCT01232036|Drug|Glucophage 500mg|Single Oral Dose of
75916784|NCT03443492|Drug|5-FU|Intervention is administered to patients in this Arm.
75916785|NCT03443492|Drug|Leucovorin(IV)|Intervention is administered to patients in this Arm.
75916786|NCT03497520|Behavioral|asymmetric spinal stabilization exercise|"The patients were educated to strengthening weakness side of spinal muscle, as asymmetric spinal stabilization exercise(ASSE)~before teach ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity~after perform ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity"
76075496|NCT01589497|Drug|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
75324058|NCT00767767|Drug|Propofol 0.45mcg/mL|IV Propofol infusion for 2 hours.
75916787|NCT03446924|Dietary Supplement|Phosphatidic Acid|To be administered a single dose of 1.5 g phosphatidic acid in capsule form (250 mg / capsule).
75781363|NCT01232036|Drug|HL-018 500mg|Single Oral Dose of
75324059|NCT00767767|Drug|Propofol 0.90mcg/mL|IV Propofol infusion for 2 hours.
75781364|NCT01232036|Other|No administration of Drug|
75781365|NCT01130480|Device|Accu-Chek Integra Glucometer|
75781366|NCT01130558|Other|Diabetes Management|Using electronic insulin order template for basal-bolus insulin and education
75916788|NCT03446924|Dietary Supplement|Rice flour|Rice flour placebo to be administered a single dose of 1.5 g in capsule form (250 mg / capsule).
75916789|NCT03134508|Other|treated by antiTNFα|pregnant IBD women treated by antiTNFα
76075497|NCT01928381|Drug|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
76075498|NCT01928381|Drug|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
76075499|NCT01928381|Drug|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
76075500|NCT01928225|Biological|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
76075501|NCT04624061|Behavioral|Integrated HIV/HTN care model|The intervention is a multi-component intervention of combined HIV and HTN care, based on the PRECEDE framework, to continuously identify barriers and facilitators leads to better health outcomes including dual control of HIV/HTN among adults in HIV care in the intervention compared to control facilities
76075502|NCT01927757|Biological|Etanercept|Administered by subcutaneous injection
75781367|NCT01130636|Drug|Oseltamivir|Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
76075503|NCT01927757|Drug|Methotrexate|Background methotrexate at least 15 mg weekly
75324060|NCT00767767|Drug|Thiopental 1.5mcg/mL|IV Thiopental 1.5mcg/mL infusion for 2 hours
75324061|NCT00767767|Drug|Thiopental 3mcg/mL|IV Thiopental 3mcg/mL infusion for 2 hours
75324062|NCT00761345|Drug|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
75467796|NCT01933178|Device|Cirrus AS-OCT|
75467797|NCT01933191|Behavioral|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
75324063|NCT00761345|Drug|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
75324064|NCT00761345|Radiation|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
75630216|NCT02882360|Other|placebo--normal gauze|Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
75781368|NCT01132976|Behavioral|Personal Concerns Inventory|This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.
75630217|NCT03773445|Diagnostic Test|Golimumab trough levels|Golimumab trough levels taken immediately before the administration of the next subcutaneous dose of golimumab
75781369|NCT01132976|Behavioral|Treatment as usual|No specific motivational interview
75781370|NCT03926156|Drug|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food
75781371|NCT03926156|Drug|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
75781372|NCT03926078|Other|3D optical surface image|3D optical surface images will be acquired and used to calculate the EHI
75324065|NCT01273337|Biological|ALD-401|3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
75324066|NCT01273337|Procedure|Sham Procedure|Sham bone marrow harvest and sham product infusion procedures.
75630218|NCT03773445|Diagnostic Test|Antibodies to golimumab|Antibodies to golimumab taken immediately before the administration of the next subcutaneous dose of golimumab
75630219|NCT03773445|Diagnostic Test|Histology|Histology of colonic biopsies using the Geboes Index
75630220|NCT03773445|Diagnostic Test|Colonoscopy|Colonoscopy to evaluate the endoscopic activity by a Mayo endoscopic subscore
75630221|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
75781373|NCT03926078|Radiation|Chest radiography|Chest radiographies will be acquired and used to calculated the HI and EHI
75781374|NCT03926078|Radiation|CT scan|CT scans will be acquired and used to calculate the HI and EHI
75781375|NCT01228058|Procedure|RapidTEG test|The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
75781376|NCT01134458|Behavioral|Web-Based Intervention|"Health Dialog Cardiac Risk Calculator~Health Dialog's Living with Coronary Heart Disease~Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight"
75781377|NCT01134536|Drug|Tapentadol (OS) Oral Solution|Tapentadol OS Bodyweight <20 kg: Type=4 unit=mg/mL form=oral solution route=oral use or Tapentadol OS Bodyweight >=20 kg: Type=20 unit=mg/mL form=oral solution route=oral use. Single oral dose administered once.
75781378|NCT01134692|Drug|Propranolol, Norfloxacin, VSL#3|Propranolol: as per heart rate titration Norfloxacin: 400mg BD
75781379|NCT01134848|Drug|Morphine|10mg IM
75781380|NCT01134848|Drug|Neostigmine|1mg IM
75781381|NCT01134848|Drug|0.9% saline|0.1 ml/kg
75781382|NCT01134848|Drug|Secretin|1 unit/kg IV
75781383|NCT01134848|Drug|0.9% saline|1ml IM
75324067|NCT00761813|Device|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
75324068|NCT00761813|Device|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
75324069|NCT03803423|Other|The Donor App|The Donor app is a web-based application that helps transplant candidates tell the candidate's story via social media in the hopes of identifying an appropriate living donor. Sample stories created using the Donor App can be found at www.thedonorapp.com.
75467798|NCT01933191|Behavioral|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
75630222|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
75781384|NCT03926000|Drug|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
75781385|NCT03926000|Drug|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
75916790|NCT03134508|Other|not treated by antiTNFα|pregnant IBD women not treated by antiTNFα
75916791|NCT00724698|Drug|Desloratadine|Desloratadine 5 mg once daily
75916792|NCT00830154|Drug|pagoclone|0.30 mg BID, 0.60 mg BID
75916793|NCT00830154|Other|placebo|placebo
75916794|NCT00722592|Drug|Vintafolide|2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
75916795|NCT00722592|Drug|pegylated liposomal doxorubicin (PLD)|50 mg/m^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
75781386|NCT01230320|Procedure|Denture fabrication technique|"Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~the reproduction of denture-bearing tissues by means of impression techniques and casts;~the registration of maxillo-mandibular relations;~try-in of artificial teeth and carved denture bases."
76075504|NCT01927367|Other|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
76075505|NCT01913639|Drug|Regorafenib|
75630223|NCT03699501|Other|Questionnaires|"A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~A validated depression scale: the Beck scale~A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~A validated self-assessment questionnaire for coping: The Brief cope)"
76075506|NCT01913639|Drug|5-Fluorouracil|
76075507|NCT01913639|Drug|Leucovorin|
76075508|NCT01913639|Drug|Oxaliplatin|
76075509|NCT01913483|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
76075510|NCT01913483|Drug|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
75324070|NCT03807791|Procedure|Blood sample|"A blood sample will be taken by the nurse of our unit within a week after their consent. It consists as a simple blood sample and it will be taken during the normal analysis planed by the chief of the service in order to avoid to collect two different samples.~The measurement method will use equipment from the Lyon Sud hospital laboratory. The samples need a pre-treatment in the 3 hours after taking the blood to avoid the oxidation of vitamin C and a result lower than expected."
75630224|NCT03699501|Procedure|Oral examination|"An evaluation of dental health using the CAO index~An evaluation of oral hygiene with the IHO-S index"
75630225|NCT03699501|Other|questionnaires (test-retest)|SCOOHP and SOHP questionnaires
75630226|NCT01126424|Drug|Solifenacin|tablet
75630227|NCT01126424|Drug|Oxybutynin|capsule
75781387|NCT02529254|Behavioral|Video coaching session|A 30 minute video coaching session with a surgeon in witch the residaent and coach visualise the filmed anastomosis and where the surgeon gives constructive feedback.
75781388|NCT01134926|Drug|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
76075511|NCT04415723|Other|supportive care management programme|nurse-led management programme
75630228|NCT01126424|Drug|Placebo|tablet
75781389|NCT05401604|Dietary Supplement|Moderate probiotic beer consumption|Consumption of one can of probiotic beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
76075512|NCT01913405|Biological|PEGylated Recombinant factor VIII (rFVIII)|Lyophilized powder and solvent for solution for injection
75781390|NCT05401604|Dietary Supplement|Moderate normal beer consumption|Consumption of one can of normal beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
75781391|NCT01135004|Procedure|Thoracoscopic bullectomy|Thoracoscopic wedge resection of the diseased lung
75916796|NCT00722592|Other|EC20|During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
75916797|NCT00829998|Drug|Zaleplon 10 mg Capsules|1 x 10 mg, single-dose fasting
75916798|NCT00829998|Drug|Sonata® 10 mg Capsules|1 x 10 mg, single-dose fasting
75916799|NCT02551718|Other|Chemosensitivity Assay|Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations
76075513|NCT01927055|Drug|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
75630229|NCT02860806|Drug|JNJ-63623872|3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
75916800|NCT02551718|Other|Cytology Specimen Collection Procedure|Undergo blood or bone marrow collection
75916801|NCT02551718|Genetic|Gene Expression Analysis|Analysis of leukemia cell genes to identify possible drug targets
76075514|NCT01927055|Drug|Placebo|Placebo to match droxidopa capsules and strength designations
75630230|NCT02860806|Drug|Placebo|Intravenous infusion of matching placebo.
75630231|NCT01126268|Drug|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
75630232|NCT04372251|Procedure|Sinus tarsi approach (STA)|Osteosynthesis
75916802|NCT02551718|Genetic|Genetic Variation Analysis|Analysis of leukemia cell genes to identify possible drug targets
76075515|NCT01913327|Drug|Aripiprazole|
75630233|NCT04372251|Procedure|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Osteosynthesis
76075516|NCT01913327|Drug|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
76075517|NCT01913327|Drug|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
76075518|NCT01926509|Drug|MK-8892|
76075519|NCT01926509|Drug|Placebo for MK-8892|
76075520|NCT01926119|Device|Transcranial Magnetic Stimulation|
76075521|NCT01912781|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
76075522|NCT01912781|Device|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
76075523|NCT01912781|Device|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
76075524|NCT04415879|Device|N-95 Respirator|N-95 mask will be worn as personal protective equipment during a graded exercise test
76075525|NCT04415879|Device|Cloth Face Mask|A cloth mask will be worn as personal protective equipment during a graded exercise test
75916803|NCT02551718|Drug|In Vitro Sensitivity-Directed Chemotherapy|"Receive personalized chemotherapy with one or more of the following drugs:~Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin"
75916804|NCT00722358|Drug|BMS-650032|"Capsule, Oral, Q12h, 3/5 days~Panel 1: 200 mg~Panel 2: 400 mg~Panel 3: 600 mg"
75916805|NCT00722358|Drug|Placebo|"Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo"
75324071|NCT03807557|Other|Robotic Constraint-induced movement therapy|"i.Robotic repetitive task-specific training followed by task-oriented practice: during each session, participants first receive 60 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of functional practice using shaping technique.~ii.Restraint of the unaffected limb: Patients will wear a mitt to restrict the unaffected hand during training at clinic for 0.5 hours of functional practice each session, 3 sessions per week for 8 weeks.~iii. Transfer package: The transfer package aims at transferring the therapy gains to the participant's real world by use of a set of behavioral techniques. This is intended to have the participant responsible for adhering to the treatment requirements and encourage active engagement in the functional practice outside of the clinic setting. The participants will be given appropriated home assignment practicing daily activities outside of the clinic."
75630234|NCT00630318|Device|MRI|15-20 minutes MR imaging
75630235|NCT04284150|Drug|Dexmedetomidine; Midazolam;|Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
75630236|NCT02883842|Behavioral|Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
75630237|NCT04282512|Other|Sodium bicarbonate-rich mineral water|St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.
75630238|NCT02883608|Procedure|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
75630239|NCT02860026|Other|Marketed cow's milk-based infant formula|
75781392|NCT03918200|Other|Serum amyloid A level|For determination of SAA level, a 5-ml sample of venous blood will be taken from each participant under aseptic conditions, and centrifuged at 2500 g for 15 minutes at 4°C c. separated into serum aliquots,and stored frozen at -80°C until analysis of SAA ,which will be done by a double-antibody sandwich Enzyme Linked Immunosorbent Assay (ELISA) kits supplied by cusabio,USA according to manufacturers instruction .Each sample was tested in duplicate and the average will be taken. A cut off level of 30 mg/L SAA level will be chosen to reflect a real increase in its level
75781393|NCT04307056|Procedure|Radical Prostatectomy|The surgical approach can be open or laparoscopic. The procedure begins with lymph node dissection for the intermediate risk groups (PSA > 10 ng/mL and/or presence of grade 4 Gleason score). Total prostatectomy includes removal of the seminal vesicles. It can preserve 1 or 2 neurovascular bundles, depending on the cancer stage and/or the choice expressed by the patient. The vesicourethral suture is either a running or interrupted suture, and there is drainage by a bladder catheter for at least 5 days.
75781394|NCT04307056|Procedure|High Intensity Focused Ultrasound (HIFU) Treatment|The treatment with High Intensity Focused Ultrasound (HIFU) evaluated in this study will be delivered by 2 types of medical devices currently available on the market, Ablatherm® and Focal One®. They are both computer-controlled and provided with an endo-rectal probe with integrated ultrasound, enabling planning and the monitoring of treatment of localized prostate cancer in realtime.
75916806|NCT00719550|Drug|Capecitabine|Administered at 625mg/m2 BID orally every day while on study.
75916807|NCT00719550|Drug|Epirubicin|Administered day 1 of each cycle at 50mg/m2 IV.
75916808|NCT00719550|Drug|AMG 102|Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
75916809|NCT00719550|Drug|Cisplatin|Administered day 1 of each cycle at 60mg/m2 IV.
75916810|NCT00719550|Drug|Placebo|AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
75916811|NCT03443258|Other|Needs assesment tool integrated in nursing consultation.|Needs assessment tool consisting of 57 items related to functional, emotional, social and existential areas guide follow-up care and referral to multidisciplinary team rehabilitation e.g. dietician; speech-pathologist; psychologist, etc
76075526|NCT04415879|Diagnostic Test|Graded exercise test|No personal protective equipment during a graded exercise test
76075527|NCT01925417|Biological|RBX2660 (microbiota suspension)|
76075528|NCT01911845|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
76075529|NCT01911845|Drug|ABT-333|Tablet
76075530|NCT01911845|Drug|Ribavirin (RBV)|Tablet
76075531|NCT01925183|Drug|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
76075532|NCT01925183|Drug|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients <75kg; orally
76075533|NCT01925183|Drug|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
75630240|NCT02860026|Other|Cow's milk-based infant formula with added nutrients|
75630241|NCT05115812|Procedure|Pre-Operative Information|Demographics (e.g., age, gender), patient characteristics (e.g., BMI, American Society of Anesthesiologists class), and pre-operative medical history (e.g., tobacco use; comorbidities: hypertension, cardiopulmonary disease, diabetes; indication for RAT; lesions; previous renal revascularization; serum creatinine level).
75916812|NCT04256304|Behavioral|PHEinAction-Personalized Patient Engagement Plan|The intervention includes two face-to-face sessions, a telephone consultation, and written home-based exercises. The first session aims to promote an awareness of patients with diabetes management, define an action plan to encourage engagement, introduce the patient to follow their strategy for the next four weeks, and encourage them to adopt the instruments with home-based exercises to reach their specified health goals. Two weeks after the first interview session, the researcher will provide telephone consultation to check the patient for their progress and support them to maintain motivation. The second session will include collecting patient's experiences and discussing the home-based exercises, re-determining the patient health engagement phase through the PHE-s®, discussing the personalized care goals by providing feedback aiming to support improvements, and setting a new engagement goal with the current status and encouraging the patient to maintain the health engagement plan.
76075534|NCT01910519|Biological|H5N1 vaccine plus AS03 adjuvant|"Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."
76075535|NCT01910519|Biological|H5N1 vaccine without adjuvant|"Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."
75324072|NCT03807557|Other|conventional UE rehabilitation training|focusing on UE training and including neuro-developmental techniques(Bobath, 1990), trunk-arm control (ie, practice UE tasks during standing), weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
75324073|NCT03801083|Biological|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
75630242|NCT05115812|Procedure|Intra-Operative Data|Operative time, total OR time, concomitant procedures, transfusions, conversions, intraoperative adverse events, autotransplantation technique
75630243|NCT05115812|Other|Post-Operative Data (up to discharge)|Postoperative adverse events, discharge status, hospital length of stay, information on enhanced recovery program
75781395|NCT01135082|Biological|valent pneumococcal conjugated vaccine|Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
75781396|NCT05043532|Procedure|2 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of two passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
75781397|NCT05043532|Procedure|3 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of three passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
75781398|NCT01228136|Drug|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
75781399|NCT01228136|Other|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
75781400|NCT03140176|Drug|Sunitinib|Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.
75324074|NCT01279967|Drug|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
75324075|NCT03807635|Device|ergoLance safety lancet|The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
75324076|NCT03807635|Device|Acti-Lance safety lancet|The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.
75324077|NCT00762515|Drug|Fluoride|Brush teeth two times daily for 6 weeks
75324078|NCT00762515|Drug|Triclosan|Brush two times daily for 6 weeks
75324079|NCT00762515|Drug|Fluoride|Brush two times daily for 6 weeks
75324080|NCT00753935|Drug|enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
75630244|NCT05115812|Other|Short-Term Follow-Up Data|Adverse events, re- admissions, re-operations related to the index procedure
75630245|NCT03311334|Drug|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.
75630246|NCT03311334|Drug|Nivolumab|Nivolumab will be administered in the approved dose and schedule starting on Day 29 of the study.
75630247|NCT03311334|Drug|Pembrolizumab|Pembrolizumab will be administered in the approved dose and schedule starting on Day 22 of the study.
75630248|NCT04313036|Drug|Defibrotide|25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for >/= 21 days or per discretion of enrolling physician.
75630249|NCT02882438|Drug|infected group|Ginkgo Biloba in different dosage forms
75630250|NCT02882438|Drug|control group|placebo without Ginkgo Biloba
75630251|NCT02859870|Device|FUSE-TM colonoscope|Colonoscopy in conditions of normal security including patient clinical examination before leaving the hospital. Data collection by each operator.
76075536|NCT01910441|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
76075537|NCT01910441|Drug|Glimepiride|Glimepiride 1-6 mg once daily
76075538|NCT01910441|Drug|Metformin|Metformin (1000-1500 mg daily)
76075539|NCT01923467|Behavioral|Project Quit stop smoking program|This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
75916813|NCT03443180|Other|Gluten and Amylase Trypsin Inhibitors (ATI)-free diet|Participants will be asked to avoid foods containing gluten and ATI (a similar protein found in grains) for 4 weeks.
75916814|NCT05018702|Drug|ARX788|1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
75781401|NCT03918512|Other|nine online self-administered questionnaires|"patients will be invited to complete the following nine online self-administered questionnaires at baseline, 7 days and 3 months:~Demographical and clinical characteristics at baseline~Consolidated version of the CSS-48 questionnaire~Lumbar pain numeric rating scale (NRS)~Radicular pain NRS~Zurich Claudication Questionnaire (ZCQ) (physical function subscale)~Oswestry Disability Index (ODI)~Fukushima LSS Scale 25 (FLS-25)~12-Item Short Form Health Survey (SF-12)~Anchoring questions : 1 anchoring question about patient acceptable symptom state (at baseline, 7 days and 3 month) and 1 anchoring question about patient minimal clinically important difference (at 3 months)."
75916815|NCT05016518|Drug|Arm I (Propofol group)|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil .
75916816|NCT05016518|Drug|Arm II (Remimazolam group)|Remimazolam group will be started and maintained total intravenous anesthesia with remimazolam and remifentanil.
75916817|NCT04288622|Other|Weekly standardised, personalised feedback|The ESM-F group will receive standardised ESM-derived feedback immediately followed the weekly ESM data collection procedure, totalling 6 times in the entire intervention period. The feedback will be provided by the researcher in the format of written report and verbal explanation. The feedback on participants' momentary affective state in specific daily life contexts and the association with depressive symptoms will be given. The changes in positive affect level and the number of depressive complaints over the course of the ESM intervention will be shown.
75916818|NCT05389020|Other|Newly developed real-size infant's arm and leg manikin|The control group used conventional manikins made by Nasco; meanwhile, two newly designed real-size manikins were prepared for the intervention group: the right arm and right leg. Real-size manikins were developed based on the mean of anthropometric measurement of 50 Indonesian infants' arms and legs of healthy term neonates born in Dr Cipto Mangunkusumo Hospital. The manikins were made of Thermoplastic Polyurethane (TPU) filament using three-dimensional (3D) printing technology. The manufacturing process was carried out by the Medical Physics Department, Universitas Indonesia.
75916819|NCT00718692|Drug|Sym001|Each cohort will receive one single dose of Sym001 according the assigned dose level.
75916820|NCT05127356|Device|DIAGNOdent|Laser fluorescence device
75916821|NCT05127356|Diagnostic Test|ICDAS II|International Caries Detection and Assessment System (ICDAS II)
75916822|NCT04234490|Procedure|Parenteral nutrition|Impact of parenteral nutrition on patient quality of life over time and impact on carer burden
75324081|NCT00753935|Drug|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
75324082|NCT00779285|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
75324083|NCT00786643|Drug|5-Fluorouracil|5-FU bolus was administered at 400mg/m^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
75324084|NCT00786643|Drug|Leucovorin (LV)|Leucovorin 200mg/m^2 was administered over 2 hours on day 1 and day 2 of each cycle.
75781402|NCT04259164|Drug|QVM149|Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol
75781403|NCT04259164|Drug|QMF149|Mometasone / Indacaterol
75781404|NCT03918356|Device|electrical impedance myography|Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.
75781405|NCT03918356|Other|healthy control group|healthy control
75916823|NCT03446534|Drug|Amoxicillin|Imacillin mixture
75916824|NCT03446534|Drug|Placebos|Placebo manufactured to mimic amoxicillin mixture (Imacillin)
75916825|NCT00829764|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
75916826|NCT00829764|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
75916827|NCT00718224|Drug|Semuloparin sodium|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
75916828|NCT00718224|Drug|Enoxaparin|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
75916829|NCT00718224|Drug|Placebo|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
75781406|NCT01133054|Procedure|revascularization|surgery or stenting
75916830|NCT03129542|Drug|Midodrine Hydrochloride 10 milligrams|Three doses taken every 8 hours.
75916831|NCT03129542|Drug|Placebo capsule|Three doses taken every 8 hours.
75916832|NCT03129230|Procedure|free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
75916833|NCT04799028|Other|Traditional cow's milk|Fortified cow's milk
75324085|NCT00786643|Drug|Gamma-Interferon-1b (IFN-γ)|Gamma-Interferon 150 mcg/m^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
75324086|NCT00786643|Drug|Bevacizumab|Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
75324087|NCT01275469|Drug|GFT505 80mg|Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
75916834|NCT04799028|Other|Experimental milk|Milk with synbiotics and fat blend
75916835|NCT04799028|Other|Habitual diet|Habitual diet
75916836|NCT03129074|Drug|Varlitinib|everyday
75916837|NCT03129074|Drug|Capecitabine|from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.
75781407|NCT05401448|Biological|Influenza|Influenza: 0.5 ml of reconstituted Influenza vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
75324088|NCT01275469|Drug|Placebo|Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
75324089|NCT05742997|Device|PartoSure|Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1
75324090|NCT05742997|Device|Fetal Fibronectine|Diagnostic Kit for the Detection of Fetal Fibronectine
75467799|NCT01933204|Other|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
75467800|NCT01933204|Drug|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
75781408|NCT05401448|Biological|MMR vaccines|MMR: 0.5 ml of reconstituted MMR vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
75467801|NCT01933256|Drug|HIP2B|
75467802|NCT01933256|Drug|Placebo|
75467803|NCT01933269|Drug|FACBC|
75467804|NCT01933282|Drug|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
75467805|NCT01933282|Drug|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
75781409|NCT05401448|Other|Placebo|Placebo: 0.5 ml of 0.9% NaCl will be administered intradermally in the left upper arm.
75467806|NCT01933308|Other|Continuous high intensity training-CT80|Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
75324091|NCT03804463|Procedure|endometrial cancer radical surgery|Take hysterectomy and bilateral adnexectomy.
75467807|NCT01933308|Other|Training at ventilatory threshold-CTVT|Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
75467808|NCT01933308|Other|Interval training-IT|High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
75467809|NCT01933321|Biological|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
75467810|NCT01933347|Drug|Gefitinib|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
75467811|NCT01933360|Drug|Misoprostol sublingual, 1h|Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
75467812|NCT01933360|Drug|Placebo sublingual,1h|Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
76075540|NCT01923467|Drug|Nicotine patches 21 mg|Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
76075541|NCT01910129|Device|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
75324092|NCT03804463|Procedure|fertility-sparing surgery|Take endometrectomy , preserve uterus and bilateral ovaries.
75324093|NCT03804463|Procedure|ovarian preservation surgery|Take hysterectomy,preserve bilateral ovaries.
75324094|NCT01276379|Drug|FOLFIRI (m)|"FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.~One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
75467813|NCT01933360|Drug|Misoprostol sublingual, 3h|Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
75467814|NCT01933360|Drug|Misoprostol vaginal, 1h|Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
75467815|NCT01933360|Drug|Misoprostol vaginal, 3h|Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
75630252|NCT04310696|Other|Buteyko Breathing exercises|Buteyko breathing technique was performed by asking the patient to take a small breath in and then out and hold his/her breath and count the time in seconds, as long as he or she can, until first signs of air hunger start to appear, followed by normal breathing once again. This procedure was repeated 15 times, three sets of 15 repetitions were given to the patient per day, 3 days per week and the treatment was continued for 4 weeks.
75630253|NCT04310696|Other|Pursed lip breathing|Pursed lip breathing was performed as nasal inspiration followed by expiratory blowing against partially closed lips. Participants received a total of 3 sets of 15 repetitions per day, 3 times a week and the treatment was continued for 4 weeks.
75630254|NCT00879658|Drug|BAF312|
75630255|NCT00879658|Drug|Placebo|
75916838|NCT03446378|Device|Anodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
75916839|NCT03446378|Behavioral|Physical therapy|all patients will be submitted to a protocol of exercise with differents levels according with motor learing and neuroplasticity principles. All physical therapists were trained before the study.
75324095|NCT01276379|Drug|FOLFOX-6 (m)|"FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.~One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
75324096|NCT01276379|Drug|Cetuximab|- 500 mg/m2 i.v. Every 2 weeks.
75467816|NCT01933360|Drug|Placebo sublingual, 3h|Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
75467817|NCT01933360|Drug|Placebo vaginal, 1h|Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
75781410|NCT01133132|Behavioral|Survivorship CHESS|Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
75467818|NCT01933360|Drug|Placebo vaginal, 3h|Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
75781411|NCT01133132|Other|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
75781412|NCT01135316|Drug|Ablavar|One dose of Ablavar will be administered for use during a contrast MRI examination
75916840|NCT03446378|Device|Cathodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
75781413|NCT01130714|Behavioral|Exercise|Resistance training with resistance bands.
75916841|NCT03446378|Device|Sham tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
75916842|NCT03450044|Biological|Dendritic cells|Adoptive transfer of autologous DCs
75916843|NCT03449966|Device|Confocal group|Under pCLE, target biopsy at cancer lesion will be done. 5 pieces of forcep biopsy will be obtained.
75916844|NCT03449966|Device|Control group|Random biopsy around cancer lesion will be done under WLE. 5 pieces with forcep biopsy will be obtained.
75916845|NCT04451486|Drug|SB cells|1x10*5 CD61-Lin- cells /0.25mL DPBS
75916846|NCT04451486|Drug|SB cells|1x10*6 CD61-Lin- cells /0.25mL DPBS
75916847|NCT04451486|Drug|SB cells|1x10*7 CD61-Lin- cells /0.25mL DPBS
75324097|NCT01275547|Drug|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
75324098|NCT01275547|Drug|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
75324099|NCT03804385|Procedure|intercostal tube|surgical operation
75324100|NCT03804307|Radiation|standard treatment|3000 cGy in 10 daily fractions
75324101|NCT03804307|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
75324102|NCT03804151|Behavioral|FitSpirit intervention|The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
75781414|NCT01230476|Drug|Cetuximab|Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
75324103|NCT00789685|Drug|Interferon Beta|Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
75324104|NCT03804073|Radiation|standard treatment|3000 cGy in 10 daily fractions
75467819|NCT01933373|Procedure|Toupet|Laparoscopic posterior partial fundoplication plus myotomy.
75467820|NCT01933373|Procedure|Dor|Anterior partial fundoplication plus myotomy.
75467821|NCT01933386|Device|SoundBite|Non-surgical removable bone conduction device via the teeth.
75467822|NCT01933412|Biological|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
75467823|NCT01933412|Biological|Engerix B Hepatitis B Vaccine|
75467824|NCT01933438|Other|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
75630256|NCT00660166|Biological|NK-Cell Infusion|The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
75630257|NCT00959946|Drug|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
75630258|NCT00959946|Drug|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
75781415|NCT01135472|Drug|Esomeprazole Magnesium|NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
75781416|NCT01133210|Drug|Maraviroc|dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
75916848|NCT03446222|Procedure|Catheter ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
75916849|NCT03446222|Procedure|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
75916850|NCT03449810|Procedure|DSE plus MET group A|"The Dynamic stabilization exercises will consist of seven exercises, which are aimed to strengthen the lumbar stabilizing muscles. All seven dynamic stabilization exercises will be performed once and always in random order.~The procedure for MET involves voluntary contraction of the participant's muscle in a precisely controlled direction, at varying levels of intensity, against a distinctly executed counterforce applied by the therapist. In this type of therapy, a participant contracts muscles by pushing against resistance provided by the therapist. The therapist then assists the participant in stretching, strengthening and relaxing those muscles."
75916851|NCT03449810|Procedure|DSE alone group B|The DSE in this arm is the same a described in group A, i.e. it involves seven exercises activities administered randomly at every session of the study intervention.
75916852|NCT03449810|Procedure|Standard Physiotherapy treatment group C|In the control group, the participants will receive standard physiotherapy treatment offered for the management of chronic NSLBP patients in Nigeria. Therefore, individuals randomized to this therapeutic group will be treated with classical massage, therapeutic exercises and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region.
75916853|NCT05121506|Combination Product|CBD and THC with GT4 technology|A single topical dose of CBD and THC will be administered with GT4 technology. The material will be provided in a single use pre-filled syringe.
75916854|NCT03449654|Drug|Liraglutide|Liraglutid
76075542|NCT01909973|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
75324105|NCT03804073|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
75324106|NCT05742529|Procedure|TIP|TIP An 8F straight sound is passed into the hypospadiac meatus to assess skin coverage over the urethra., a circumscribing incision is made 2 mm proximal to the meatus, a U-shaped incision is extended proximally to healthy skin The key step in the operation is a midline relaxing incision made from within the meatus to the distal extent of the plate. This incision extends through the epithelial surface of the plate deeply into underlying connective tissues down to the corpora cavernosaNext, a 6F stent is passed into the bladder for postoperative urinary diversion. Then the urethral plate is tubularized. , stitches are ever taken further distally to ensure the neomeatus has a generous oval openingticular closures. .
75467825|NCT01933438|Other|Control|Standard treatment
75467826|NCT01933451|Other|Intraoperative fluid therapy|Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
75467827|NCT01933490|Other|high carbohydrate test meal|
75467828|NCT01933490|Other|high carbohydrate test meal after pre-treatment with rapid acting aspart insulin|
75630259|NCT00667264|Procedure|perineural ropivacaine|Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
75630260|NCT00660244|Drug|anastrozole|Oral
75630261|NCT04282200|Drug|Ketorolac|intravenous ketorolac 30 mg every 6 hours
75781417|NCT01133210|Other|placebo|subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
75467829|NCT01933490|Other|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal|
75467830|NCT01933503|Drug|OCA 5 mg|
75467831|NCT01933503|Drug|OCA 10 mg|
75467832|NCT01933503|Drug|OCA 25 mg|
75781418|NCT01135550|Drug|High dose dexamethasone|"Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
75916855|NCT03449654|Drug|Placebo (for liraglutide)|Placebo (for liraglutide)
76075543|NCT01617005|Drug|Tocilizumab|Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
75630262|NCT04157764|Device|HomeChoice Claria APD machine with SHARESOURCE|HomeChoice Claria APD machine with SHARESOURCE software. SHARESOURCE is a software can telemonitor patients' compliance
75630263|NCT04281966|Behavioral|Ability School Engagement Program Conference|"The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work."
75630264|NCT00667498|Drug|Metformin|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
75630265|NCT00667498|Drug|Placebo|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
75781419|NCT01135550|Drug|Low dose dexamethasone|"Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
75781420|NCT05401370|Procedure|Methylene blue dye|For MB group, the staining of the glandular tissue will be obtained with 3-4 mL of 1% MB that will be introduced into the gland via the salivary duct several minutes before the surgery.The trans-oral catheterization of the Stensen's duct will be performed and the solution will be injected via intravenous cannula.The glandular tissue will turn dark blue.
75916856|NCT03388008|Drug|Belatacept|Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)
75916857|NCT03388008|Drug|Tacrolimus|Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml
75630266|NCT02860650|Biological|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9*10^10 viral particles (vp).
75630267|NCT02860650|Biological|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5*10^8 infectious units (Inf U).
75630268|NCT02860650|Biological|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5*10^10 vp.
75781421|NCT03925376|Procedure|Redo cardiac surgery|Redo cardiac surgery is technically challenging due to scarring of tissues resulting in loss of tissue planes, adhesions, multiple comorbid factors and risk of injury during re-entry.Suggested techniques in coronary artery surgery with a left internal mammary artery include routing the graft through a slit in the pericardium to minimize the possibility of adherence to the sternal table.
75916858|NCT03388008|Drug|ATG|Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
75916859|NCT03388008|Drug|Mycophenolate Mofetil|Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
75324107|NCT05742529|Procedure|STITCH BY STITCH|SBS in brief Operative technique :starts with penile degloving, preparation of the flap (Site of hypospadic meatus is determined after degloving). Creation of a narrow strip of the urethral plate with wide glanular wings is done using bilateral incisions which are extended to the tip of the glans. The width of the urethral plate is about 3 mm then we suture the flap to the narrow urethral plate in two layers in continuous manner using vicryl 6/0 over a suitable plastic catheter. Triangular (Vshape) area of the distal part of the flap is excised a the midline. After this we anastomose the flap to thetip of the glans. The glans appears opened in the midline as inverted V shape. Closure of the glans is finished in the midline using three mattress interrupted sutures with another three simple stitches are used in between
75781422|NCT03917888|Diagnostic Test|lung ultrasound|lung ultrasound will be performed daily in mechanically ventilated patients after 48 hours of ventilation to screen for ventilator associated pneumonia
75916860|NCT03388008|Drug|Methylprednisolone|Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
75916861|NCT03388008|Drug|Prednisone|Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365
75324108|NCT03803917|Procedure|Injection with freshly collected autologous adipose tissue|
75324109|NCT04276987|Biological|MSCs-derived exosomes|5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
75324110|NCT00769015|Behavioral|BA-LVR|Low vision clinic-based optometry plus 6 in-home occupational therapy visits
75324111|NCT00769015|Behavioral|ST-LVR|Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
75324112|NCT02991677|Behavioral|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
75324113|NCT02991677|Other|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
75324114|NCT02991677|Behavioral|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
75324115|NCT04384549|Biological|BCG GROUP|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
75324116|NCT04384549|Other|PLACEBO GROUP|One intradermal injection of 0.1ml NaCl
75630269|NCT02860650|Biological|Placebo|IM injection of 0.9 percent saline.
75781423|NCT01130792|Dietary Supplement|Lactobacillus GG|10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
75781424|NCT01130792|Dietary Supplement|Inulin|Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
75781425|NCT01130870|Device|Sensory Threshold|Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
75781426|NCT01130870|Device|75% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
75781427|NCT01130870|Device|50% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
75916862|NCT00710580|Biological|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
75916863|NCT00710580|Biological|etanercept|SQ injection 50 mg BIW
75916864|NCT00710580|Drug|placebo|SQ placebo injections for ABT-874 and etanercept
75781428|NCT01130948|Other|altitude exposure|exposure to 490m, 1700m and 2590m
75630270|NCT02860650|Biological|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1*10^8 Inf U.
75630271|NCT00660322|Behavioral|Telephone Asthma Program|"The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:~Using asthma controller medications as prescribed~Having and Asthma Action Plan available to all who may need it.~Using asthma rescue medications with the child's first symptoms.~Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year."
75630272|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 10 mg|10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
75781429|NCT01131026|Drug|Levofloxacin|tablet, 500 mg, once a day for ten days
75781430|NCT01131026|Drug|Amoxicillin|tablet, 1000 mg, once a day for ten days
75781431|NCT01131026|Drug|Lansoprazole|capsule, 30 mg, twice a day for ten days
75781432|NCT01135628|Other|Auxiliary Treatment|Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
75916865|NCT05112380|Other|Performing Xco endurance test|The subjects will perform the test two times, with 7-10 days between the two sessions
75916866|NCT03446144|Drug|IONIS-FB-Lrx|Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70
75916867|NCT03446144|Drug|Placebo (sterline saline 0.9%)|Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
75916868|NCT00829686|Drug|Septra|(800/125) PO BID X 7 days
75916869|NCT00829530|Drug|Ramipril 10 mg capsule|1 x 10 mg
75916870|NCT00829530|Drug|Altace® 10 mg capsule|1 x 10 mg
76075544|NCT01925339|Device|Test (immediate restoration)|Test (immediate restoration)
75324117|NCT02149303|Drug|Dabigatran 75 mg|PO BID
75467833|NCT01933516|Drug|GP2013|GP2013
75630273|NCT00667966|Drug|Placebo|10/20 mg placebo in sequence in respective arm
75630274|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 20 mg|20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
75916871|NCT01377194|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
75916872|NCT01377194|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
75916873|NCT01377194|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
75916874|NCT00829452|Drug|Ramipril 10 mg capsule|1 x 10 mg
75916875|NCT00829452|Drug|Altace® 10 mg capsule|1 x 10 mg
75630275|NCT04283916|Drug|Botulinum Toxins|Botulinum toxin injection to abdominal wall
75630276|NCT00911937|Drug|Fesoterodine|Fesoterodine 4mg and 8 mg tablets taken daily.
75630277|NCT00911937|Drug|Placebo|Placebo sham 4mg and 8 mg tables taken daily.
75781433|NCT01135628|Dietary Supplement|Hyperproteic and fiber-rich diet|Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
75781434|NCT01135628|Drug|Nitazoxanide|Nitazoxanide tablets 400 mg, bid, orally for 6 months
75781435|NCT01135706|Other|No Intervention|This study does not include an intervention but is observational in nature.
75781436|NCT01232192|Behavioral|antenatal model|"Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:~Midwife training~Pregnant women campaigning~Early detection with self pH detection~Treatment of bacterial vaginosis"
75781437|NCT01135784|Dietary Supplement|MIGRA-ZEN RELIEF PLUS|one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
75781438|NCT01135784|Dietary Supplement|Placebo for Migrazen relief plus|2 capsule dose per 24 hours for 90 days
75781439|NCT01135862|Drug|platelets|6 packs of platelets will be administered
75781440|NCT01135940|Device|2-octylcyanoacrylate (Dermabond) closure|Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
75916876|NCT00829374|Drug|Dimebon|5 mg orally three times daily
75916877|NCT00829374|Drug|Dimebon|20 mg orally three times daily
75781441|NCT01135940|Device|Standard staple closure|Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
75781442|NCT02962960|Drug|Anifrolumab|subcutaneous administration every 2 weeks from week 0 to week 50
75781443|NCT02962960|Drug|Placebo|subcutaneous administration every two weeks from week 0 to week 50
76075545|NCT01925339|Device|Control: delayed restoration|Control: delayed restoration
76075546|NCT04621877|Behavioral|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
76075547|NCT04621877|Behavioral|Master's level clinician-delivered Behavioral Activation|Behavioral Activation as delivered by trained master's level clinicians
76075548|NCT01908803|Drug|AL-60371/AL-817 otic suspension|
76075549|NCT01908803|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension|CIPRODEX®
76075550|NCT01908101|Drug|Eribulin Mesylate|Given IV
75630278|NCT00663598|Drug|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
75781444|NCT01136018|Procedure|insertion needle via intentionally lateral direction.|evaluation of iodinated contrast flow patterns in caudal epidurography with intentional lateral caudal approach
75781445|NCT01133366|Drug|warfarin sodium|25 mg of warfarin oral (single dose)
75630279|NCT04155736|Behavioral|Renew|Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).
75781446|NCT01133366|Drug|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
75781447|NCT01136096|Behavioral|Physical activity promoting intervention|"An interview with a physiotherapist~An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home~An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model~The daily record to check their body weight, exercise mode and duration~Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details~Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule"
75781448|NCT01136096|Behavioral|General instruction and education|"Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic~Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule~Without individualized exercise program and interview with a physiotherapist"
75781449|NCT01232270|Drug|propofol|1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
75781450|NCT05400902|Drug|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Sintilimab and Bevacizumab treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Sintilimab 200 mg ivdrip, Q3W; Bevacizumab 15 mg/kg ivdrip, Q3W"
75781451|NCT01233206|Drug|Metformin|Metformin pre-treatment and co-administration
75781452|NCT01233206|Drug|Placebo administration|Placebo pre-treatment and co-administration
75781453|NCT00369941|Drug|MK-0518|400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
75781454|NCT00369941|Drug|Comparator: efavirenz|600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
75781455|NCT00369941|Drug|Comparator: Truvada|One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
75781456|NCT00369941|Drug|Comparator: Placebo to MK-0518|Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks
75781457|NCT00369941|Drug|Comparator: Placebo to efavirenz|Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
75916878|NCT00829374|Drug|Placebo comparator|Placebo orally three times daily
75916879|NCT03449420|Diagnostic Test|thromboelastography|TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample
75916880|NCT00747318|Drug|SKP FlutiForm HFA pMDI|Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
76075551|NCT01908101|Other|Laboratory Biomarker Analysis|Correlative studies
75916881|NCT00746616|Device|Durom Hip Resurfacing System|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
75324118|NCT02149303|Drug|Dabigatran 150 mg|PO BID
75467834|NCT01933529|Drug|ARA 290|ARA 290 is injected s.c. once daily during the study period
75467835|NCT01933542|Drug|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
75916882|NCT00744276|Drug|danazol|danazol applied topically once per day for 4 treatment cycles
75916883|NCT00744276|Drug|Placebo|placebo topically applied once daily for 4 treatment cycles
75916884|NCT00697710|Drug|50 mg S-777469|S-777469, 50 mg BID
75916885|NCT00697710|Drug|200 mg S-777469|S-777469, 200 mg BID
75916886|NCT00697710|Drug|800 mg S-777469|S-777469, 800 mg BID
75916887|NCT00697710|Drug|Placebo|Matching Placebo
75916888|NCT03438344|Biological|Multi-antigen CMV-Modified Vaccinia Ankara Vaccine|Given IM
75916889|NCT03438344|Other|Laboratory Biomarker Analysis|Correlative studies
75916890|NCT03438344|Other|Placebo|Given IM
75916891|NCT00743184|Drug|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
76075552|NCT01923389|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
76075553|NCT01923389|Drug|100 mg PF-05231023|100 mg IV infusion twice a week for 4 weeks
76075554|NCT01907087|Biological|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
76075555|NCT04620161|Drug|Pradigastat Tablets 20mg|20mg, once daily, oral administration
76075556|NCT04620161|Drug|Pradigastat Tablets 40mg|40mg, once daily, oral administration
75467836|NCT01933542|Drug|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
76075557|NCT04620161|Drug|Pradigastat Tablets 20mg matching Placebo|once daily, oral administration
76075558|NCT04620161|Drug|Pradigastat Tablets 40mg matching Placebo|once daily, oral administration
76075559|NCT01616771|Device|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
76075560|NCT01616771|Device|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
76075561|NCT01616771|Device|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
76075562|NCT01589185|Drug|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
76075563|NCT01589185|Drug|Placebo|Placebo administered as a single intravenous infusion
76075564|NCT01588951|Drug|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
76075565|NCT01588951|Drug|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
76075566|NCT01709383|Device|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
76075567|NCT01709383|Device|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
75630280|NCT04281264|Behavioral|Passive Hypoxia|During 30 minutes of session, the participants will perform an intellectual activity while they will be exposed to normobaric hypoxic conditions in a hypoxic chamber (CAT 310, Lousiville, Colorado). They will inspire oxygen fraction (FiO2) set to 16.1% (0.16)
75324119|NCT03803527|Procedure|Esophageal String Test|An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
75630281|NCT04281264|Behavioral|Normoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
75630282|NCT04281264|Behavioral|Hypoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
75781458|NCT01133444|Drug|Finasteride|Finasteride tablets 1 mg
75781459|NCT01230632|Dietary Supplement|high fat overfeeding|Dietary Supplement:3 days overfeeding
75781460|NCT01232426|Procedure|Biodegradable Meniscus Arrow®|Closed reduction of the Mallet fracture and fixation with 1 biodegradable meniscus Arrow®
75781461|NCT01232426|Device|Mallet splint|Conservative treatment of the Mallet fracture with the traditional Mallet splint.
75781462|NCT05608772|Procedure|revision surgery|revision procedure after failed sleeve gastrectomy
75781463|NCT00319553|Biological|ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
75781464|NCT00319553|Biological|BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
75781465|NCT03739736|Other|Combination of TB/HIV prevention activities (arm A)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In arm A ART was initiated regardless of CD4 count. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
75781466|NCT03739736|Other|Combination of TB/HIV prevention activities (arm B)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In this arm B ART was initiated according to national guidelines. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
75916892|NCT00743184|Drug|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
75916893|NCT00742716|Drug|CTA018 Injection|Comparison of different dosages of drug
75916894|NCT04640402|Biological|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
75916895|NCT04640402|Biological|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
75916896|NCT04640402|Biological|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
75916897|NCT04640402|Biological|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
76075568|NCT01588405|Drug|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
76075569|NCT01923311|Drug|EVG|Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
76075570|NCT01923311|Drug|Background regimen|Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
76075571|NCT01603615|Biological|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
75324120|NCT03803449|Drug|50-200mg propofol|participants in both groups are given standard regimen including 50-200mg propofol.
75324121|NCT03803449|Drug|50ug fentanyl|participants in fentanyl group are given intervention regimen: 50ug fentanyl.
75630283|NCT04281264|Behavioral|Normoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performed on platform.~Subjects will inspire FiO2 of 21.0% (0.21)"
75781467|NCT03739736|Other|Standard of care (arm C)|"The standard of care arm C communities have access to HIV testing services (usually at the health facility), HIV care and ART provision according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility. TB diagnostics are as per national guidelines including Xpert®TB/RIF for those who are HIV positive. All diagnosed cases of TB are treated as in the intervention arm. TB screening and prevention at HIV care clinics are as is in the intervention arm."
75781468|NCT01137656|Drug|Acetylcholine and Blood|The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
75781469|NCT03917732|Behavioral|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
75781470|NCT03917732|Behavioral|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
75916898|NCT04640402|Biological|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
75916899|NCT04640402|Biological|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
75916900|NCT04640402|Biological|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
75916901|NCT04640402|Biological|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
75916902|NCT04640402|Biological|Low-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
75916903|NCT04640402|Biological|Low-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
75916904|NCT04640402|Biological|High-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
75916905|NCT04640402|Biological|High-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
75916906|NCT04640402|Biological|Low-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
75916907|NCT04640402|Biological|Low-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
75916908|NCT04640402|Biological|High-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
75916909|NCT04640402|Biological|High-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
75916910|NCT00740610|Drug|GS-9450|GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
75916911|NCT00740610|Drug|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
75916912|NCT03442790|Procedure|Agitated Saline Method|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.
75324122|NCT03803449|Drug|1 mg midazolam|participants in both groups are given standard regimen including 1 mg midazolam.
75324123|NCT03803839|Drug|Clodronate|
75324124|NCT03803839|Drug|Saline|
75324125|NCT03803293|Diagnostic Test|Pharmacogenomic testing|A comprehensive PGx interpretive report created by OneOme (www.oneome.com) provides information on how an individual patient's genes may affect medication response. OneOme utilizes algorithms and curated clinical PGx knowledge to generate a highly intuitive personalized report based on a patient's genomic results.
75324126|NCT03803137|Other|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry
76075572|NCT01905683|Drug|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
75781471|NCT00369785|Drug|donepezil hydrochloride|Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
75781472|NCT00369785|Drug|Placebo|Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
75630284|NCT04281264|Behavioral|Hypoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performance on the platform.~Participants will inspire a fraction of inspired oxygen (FiO2) of 16.1% (0.16)"
75630285|NCT00663754|Behavioral|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
75630286|NCT00663754|Behavioral|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
75630287|NCT00660478|Device|Endeavor|Comparison of two different drug eluting coronary stents
75781473|NCT05476562|Other|Tyrosine Kinase Inhibitors (TKIs)|The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.
75781474|NCT01136252|Drug|Adalimumab|Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
75781475|NCT01232582|Device|Exablate treatment|MR guided Focused Ultrasound treatment
75781476|NCT00369707|Drug|Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
75781477|NCT00369707|Drug|bortezomib|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
75781478|NCT01136564|Drug|Zemplar|2 capsules of 1 microgram daily
75781479|NCT01136564|Drug|Placebo|2 capsules daily
75916913|NCT03442790|Procedure|chest x-ray|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator
75916914|NCT03445910|Drug|Human chorionic gonadotropin|intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
75916915|NCT00823992|Drug|placebo|sc once weekly
75916916|NCT00823992|Drug|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
75916917|NCT03442712|Other|Auricular acupressure plus smartphone App|Semen Vaccaria laccaria will be kept in place by a piece of adhesive patch. Seeds will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear, that is, we will meet the subjects twice per week. Subjects will be requested to apply pressure on the acupoints thrice per day, preferably within 30 min before eating, pressing for 20 times using a constant rhythm to each point. Coaching on how to self-administer AA on the acupoints will be given to the subjects, and a return demonstration from the subjects will be required to ensure the skills are performed properly. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. In addition, the subjects will be asked to input the number of bowel open and compliance with AA performance per day into the App. The total treatment period will be 8 weeks.
76075573|NCT01921829|Drug|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
76075574|NCT04416113|Procedure|photobiomodulation and photodynamic therapy|antiviral treatment
75324127|NCT00771277|Behavioral|Support Teams|Use of volunteers organized into teams with a coordinator to provide services to TBI family
75324128|NCT00789997|Drug|Prednisone|prednisone 40 mg daily for 10 days or placebo prednisone
75324129|NCT00789997|Drug|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
75324130|NCT00789997|Drug|levofloxacin|Levofloxacin 750 mg daily for 10 days.
75324131|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
75324132|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
75467837|NCT01933542|Drug|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
75781480|NCT05568758|Other|Thoracic lymphatic pump technique|The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
75630288|NCT00660478|Device|Cypher Select|Comparison of two different drug eluting coronary stents
75630289|NCT02859714|Other|screening data|
75630290|NCT04168437|Other|Health-Related Quality of Life Report|Two page report and interpretation guide based on SPADE cluster scores
75781481|NCT05568758|Other|Exercises (stretching and strenghtening )|"stretching exercises include: Hamstring stretching exercises~Lower back stretching exercises :~strenghtening exercises include:~Abdominal curl up exercises :~Supine bridging exercises. Trunk extension exercises"
75630291|NCT02860572|Other|follow-up without intervention|
75916918|NCT03442712|Other|Auricular acupressure|The participants will receive AA treatment and are required to perform daily self-administered seeds pressing, but no smartphone App will be provided, but a booklet containing relevant information will be provided to the subjects.
75916919|NCT03442634|Other|Early Hydration|this group will start oral hydration within 1 hour after cesarean section
75916920|NCT03442634|Other|Traditional Oral Hydration|this group will start oral hydration 6 hours after cesarean section
75630292|NCT02860572|Other|fluid bolus|
75630293|NCT04161417|Other|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
75630294|NCT04283838|Behavioral|Humanistic Care|Psychological and physical rehabilitation based humanistic care regimen
75630295|NCT00880048|Drug|orvepitant|neurokinin-1 antagonist
75781482|NCT02943460|Drug|Cilofexor|Tablet(s) administered orally once daily with food
75781483|NCT02943460|Drug|Placebo to match cilofexor|Tablet(s) administered orally once daily with food
75916921|NCT00823680|Drug|Placebo|po bid for 4 weeks
75916922|NCT00823680|Drug|RO5027838|200mg po qd for 4 weeks
75916923|NCT00823680|Drug|RO5027838|50mg po bid for 4 weeks
75916924|NCT00823680|Drug|RO5093151|400mg po bid for 4 weeks
75916925|NCT00823680|Drug|RO5093151|10mg po bid for 4 weeks
75916926|NCT03109496|Other|Collection of body fluids/swabs|Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.
75916927|NCT04619732|Diagnostic Test|Monitoring biochemical concentrations during cold machine perfusion|Three microdialysis probes will be introduced into the kidney tissues, the vein and ureter in order to measure creatinine, glucose and lactate while the organ is undergoing cold perfusion prior to transplantation.
75916928|NCT04600076|Behavioral|BabyCenter site and the community group|Participants will be asked to sign on to the BabyCenter community group for people with pregnancy or infant loss at least 3 times weekly for 6 weeks. Participants may choose to post or comment on the site but are not required to do so.
75916929|NCT00646542|Drug|Vildagliptin|
75916930|NCT00646542|Drug|Placebo|
75916931|NCT04203576|Device|FIRE1 System|FIRE1 System
75916932|NCT03445676|Behavioral|ABHR directly on gloves|HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
75916933|NCT03442478|Other|2D/3D Tomosynthesis|
75916934|NCT04198740|Diagnostic Test|Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry|During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.
75916935|NCT03445598|Behavioral|Interactive and personalized CCBT|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements along with personalized content and interactive features in the program
75630296|NCT00880048|Other|Placebo|Placebo to match orvepitant 30 mg and 60 mg
75630297|NCT02859480|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
75630298|NCT02859480|Drug|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
75630299|NCT00962208|Device|orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error for a period of two years
75630300|NCT00962208|Device|single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
75630301|NCT02861508|Other|Point-of-care ultrasound|
75630302|NCT02861508|Other|Usual care|
75630303|NCT00660556|Device|Archimedes Constant Flow Pump & System|Pump implanted in abdomen with intrathecal delivery (catheter) for pain.
75630304|NCT01076543|Other|Laboratory Biomarker Analysis|Correlative studies
75630305|NCT01076543|Drug|Lenalidomide|Given PO
75630306|NCT01076543|Drug|Temsirolimus|Given IV
75630307|NCT00922558|Other|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
75630308|NCT02861274|Device|pacemaker|
75781484|NCT05567978|Procedure|pupillometry index|Admission to the intensive care unit, measurement of pupillometry index every 4 hours for 7 days or at extubation of brain damaged patients
75781485|NCT03768206|Behavioral|Standard Physical Therapy|Participants will receive standard outpatient physical therapy that is typical following knee replacement
75916936|NCT03445598|Behavioral|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features.
75916937|NCT03445598|Other|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
75781486|NCT03768206|Behavioral|Physical therapist discuss aerobic physical activity|Physical therapists will provide recommendations to increase aerobic physical activity and set goals during standard physical therapy sessions after knee replacement.
75781487|NCT03768206|Behavioral|Physical activity session|Participants will receive a one hour coaching session on aerobic physical activity and goal setting after knee replacement.
75781488|NCT03767894|Device|EMG Band|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear an EMG band to control and activate the MyHand orthosis.
75781489|NCT03767894|Device|Shoulder harness|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear a shoulder strap to control and activate the MyHand orthosis, either with shoulder elevation or shoulder depression.
75781490|NCT04752904|Device|ClearSight System|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem
75781491|NCT01232660|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg once daily orally
75781492|NCT01137734|Device|Adjustable Annuloplasty Ring with option to adjust off pump.|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty repair, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
75781493|NCT01137734|Device|Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)|Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
75781494|NCT03766646|Device|Optiflow|45l.min oxygen
75781495|NCT03765164|Diagnostic Test|GlycoMark 1-5-AG|Online educational materials on GlycoMark 1,5-AG and sample test results for simulated patients
75781496|NCT03765164|Other|Clinical Performance and Value Vignettes|Simulated diabetic patients cared for online
75781497|NCT01233362|Biological|Modified killed oral cholera vaccine at 14 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.
75781498|NCT01233362|Biological|Modified killed oral cholera vaccine at 28 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.
75916938|NCT03445442|Procedure|SCP|Sacrocolpopexy (SCP) aims to secure the anterior vaginal wall, the uterus more or less the posterior vaginal wall using polypropylene prostheses and to secure them to the presacral ligament to restore the patient's anatomical features and improve pelvic symptoms
75916939|NCT03445442|Procedure|NTR|Native tissue repair surgery (NTR) consist of site-specific surgical repair of the existing defect (anterior and/or posterior) using non-absorbable sutures. Specifically, anterior and/or posterior colporrhaphy for cystocele and rectocele respectively after adequate hydrodissection of the vesicovaginal or rectovaginal space.
76075575|NCT04619615|Other|Asynchronous self-directed digital training|Resident participants will be able to complete the digital training at their own pace.
76075576|NCT04619615|Other|Synchronous large group online workshop|Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).
75324133|NCT02148835|Other|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
75781499|NCT03917576|Other|Behavioral|The resting heart rate (HRrest), maximum HR (HRmax), HR recovery (HRRTEST), delta HR recovery (ΔHRRTEST) were measured by continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland) during an incremental exercise test designed to obtain maximum oxygen consumption (VO2max) on a cycle ergometer (Lode Corival, Groningen, The Netherlands) similar with previous studies using similar cohort. An indirect calorimetry/ergospirometry system (Ultima CPXTM metabolic system, Medgraphics, Minnesota, USA) was used to measure VO2max until volitional exhaustion. Thus, the modified Astrand volitional protocol was applied in the participants of all NG, Pre-T2D and T2D groups increasing the load (i.e., Watts) 25 W each 2 min to women, and 50 W each 2 min to men.
75781500|NCT03917576|Other|Exercise training intervention|Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at ~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).
75781501|NCT01136642|Drug|Nicotrol|
76075577|NCT01904903|Drug|Trastuzumab|HER2 therapy
76075578|NCT01904903|Drug|Pertuzumab|HER2 therapy
75324134|NCT02148835|Other|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
75324135|NCT00790699|Device|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
75781502|NCT04891432|Procedure|Lateral lumbar interbody fusion|oblique lumbar interbody fusion or direct lateral interbody fusion
75781503|NCT02826382|Drug|[68Ga]P15-041|Imaging by Positron Emission Tomography after injection of [68Ga]P15-041
75781504|NCT00369629|Drug|Gemcitabine|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m^2.
75781505|NCT00369629|Drug|Pemetrexed|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m^2.
76075579|NCT01904903|Drug|Ado Trastuzumab Emtansine|HER2 therapy
76075580|NCT01921517|Device|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
75916940|NCT03445442|Procedure|VMR|Vaginal mesh repair surgery (VMR) is performed using a single-incision mesh system. A single vertical incision is made in the anterior and/or posterior vaginal wall. A full-thickness dissection is performed laterally and apically to the ischial spine.
75630309|NCT04154176|Other|CAM, Nu-DESC|Two trained raters, who are blinded and have no access to each other's evaluation, administer the CAM and Nu-DESC questionnaires in each shift, during the first postoperative day after the discharge from the post-anaesthesia care unit, independently. The two assessments are completed within 60 minutes of each other. If the research team set the diagnosis of POD, the appropriate treatment will be initiated, according to the Hospital's protocol
75916941|NCT03442244|Drug|LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
75916942|NCT03442244|Drug|Vehicle of LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
75916943|NCT02064387|Drug|GSK2857916|A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
75916944|NCT04896944|Other|No intervention|No intervention
75781506|NCT04744090|Drug|Roflumilast|"Roflumilast 500 mcg daily for up to 28 days~Total follow up time will be 28 days.~Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~Roflumilast will be combined with standard of care for ARDS.~During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended."
75781507|NCT04744090|Drug|Placebo|Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
75781508|NCT01233440|Biological|Recombinant Coagulation Factor IX Albumin Fusion Protein|Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
75781509|NCT01233440|Biological|Plasma derived FIX [pdFIX]|Single dose of 50 IU/kg of reference product, given as intravenous infusion
75916945|NCT03442166|Radiation|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
75916946|NCT03442166|Radiation|Sham group|Patients will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
75916947|NCT03437954|Other|Diet modification|Patients will be randomized to follow the standard post-tonsillectomy diet at our institution, which consists of soft foods for ten days, or will be in the non-restricted diet group following surgery.
75916948|NCT03437876|Other|intestinal microbiota transplant|All participants take 4 times IMT by gastroduodenoscopy with 2-week intervals
75916949|NCT03256344|Biological|Talimogene Laherparepvec|Virally based anti-cancer immunotherapy given by direct injection into tumors.
75916950|NCT03256344|Biological|Atezolizumab|A monoclonal antibody given by intravenous injection.
75916951|NCT04452266|Other|questionnaire assesment|Each patient will to answer questions about their medical history.
75916952|NCT03442010|Other|Detection of adverse drug events|Detection of adverse drug events
75916953|NCT02063139|Drug|Flutiform 50/5 ug (2 puffs bid) pMDI|
75916954|NCT02063139|Drug|Fluticasone 50 ug (2puffs bid) pMDI|
75916955|NCT02063139|Drug|Beclometasone Autohaler 50 ug (2 puffs bid)|
75916956|NCT03441932|Procedure|Fiberoptic endoscopic evaluation of swallowing (FEES)|"Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree."
76075581|NCT01921517|Device|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
76075582|NCT01921205|Drug|Lacosamide|"Subjects <30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to <50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
76075583|NCT01921205|Other|Placebo|"Subjects <30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to <50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
75324136|NCT00790699|Other|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
75324137|NCT03803215|Drug|Theophylline|Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
75630310|NCT04281732|Device|Virtual Reality Headset based tests|Visual task tests based on Oculus Rift
75630311|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv BID
75630312|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv TID
75916957|NCT04452110|Diagnostic Test|Ultrasonography|Temporomandibular joint diseases of ultrasonography its effectiveness and reliability in diagnosis disadvantages in MR and other imaging methods be ruled out.
75916958|NCT00690456|Drug|Rimonabant|Tablet, oral administration
75916959|NCT00690456|Drug|Placebo (for Rimonabant)|Tablet, oral administration
75916960|NCT00690456|Drug|Metformin|Metformin continued at stable dose as background therapy
75916961|NCT03445364|Other|Use of different injection pressure during primary PCI|Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi
75916962|NCT03441854|Device|HFNC group|Application of HFNC oxygen delivery after extubation.
75916963|NCT03437642|Behavioral|Short Term Psychotherapy|Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
75630313|NCT02860494|Drug|Everolimus|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
75630314|NCT02860494|Drug|Placebo|Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
75781510|NCT02469064|Other|Respiratory muscle training|Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
75781511|NCT02469064|Other|Cardiopulmonary Physical Therapy|Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
75781512|NCT01230944|Procedure|Laparoscopic Nissen fundoplication|
75781513|NCT01230944|Procedure|Open Nissen fundoplication|
75781514|NCT03917342|Device|EEG measure|Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women
75781515|NCT03739658|Other|Education|Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.
75781516|NCT01137188|Dietary Supplement|Low calorie diet|Low calorie diet containing 800-1000 kcal/day
75781517|NCT05528666|Other|High Efficacy Therapy (HET)|HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
75781518|NCT05528666|Other|Non High Efficacy Therapy (Non-HET)|Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
75781519|NCT05524220|Device|Standard care with a facemask.|The anesthesia provider will supply oxygen via the closed facemask at 10 liters per minute (LPM)
75630315|NCT04801823|Other|Home introduction|Cautious, graded introduction of individual tree nuts
75781520|NCT05524220|Device|SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)|The anesthesia provider will attach the SuperNO2VA™ EtCO2 circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min. The oxygenation, continuous positive airway pressure, and ventilation of the subject will be done via SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
76075584|NCT01920893|Drug|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
75630316|NCT04801823|Other|Multi Nut oral food challenge|In hospital multi nut oral food challenge (almond, cashew, hazelnut, walnut)
75630317|NCT04281810|Device|transcutaneous electric diaphragm stimulation|The electrodes were placed on the parasternal region beside the xiphoid process; and the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was set as biphasic waves, frequency of 30 Hz, pulse width of 400 μs, and rise time of 0.7s.
75781521|NCT01133600|Drug|Cubicin|dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is <30ml/min.
75781522|NCT01133600|Drug|Vancomycin|dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
75781523|NCT01138202|Drug|LPV/r|LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
75781524|NCT01138280|Device|CWP 103H (Gambro, Sweden): a heat disinfection device|Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
75781525|NCT01138358|Other|medical chart review|
75781526|NCT01138358|Other|study of socioeconomic and demographic variables|
75781527|NCT01138358|Other|survey administration|
75781528|NCT01138358|Procedure|quality-of-life assessment|
75781529|NCT01232972|Procedure|vitrification of oocytes|eggs will be preserved via vitrification the day they are retrieved from the participant
75781530|NCT05502224|Other|Ergospirometry|Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ
75781531|NCT01137266|Device|TENS|TENS
75781532|NCT01133912|Drug|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
75781533|NCT01140542|Drug|Roflumilast|500µg, once daily
75916964|NCT01370499|Drug|LY2216684|
75916965|NCT01370499|Drug|SSRI|Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
75916966|NCT04070196|Diagnostic Test|Periplex|Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
75916967|NCT03445286|Device|Silver Diamine Fluoride|Silver Diamine Fluoride (Advantage Arrest) for the experimental group
75916968|NCT03445286|Other|Normal Saline|Normal Saline for the control group
76075585|NCT01920893|Drug|Dupilumab|Solution for injection; Subcutaneous injection.
76075586|NCT01920893|Drug|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
76075587|NCT01709305|Drug|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
76075588|NCT01709305|Drug|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
76075589|NCT01709305|Drug|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
75467838|NCT01933542|Drug|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
75630318|NCT00663832|Drug|LBH589 (i.v. panobinostat)|"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"
75630319|NCT04281576|Device|NovoTTF-100L(P)|Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
75630320|NCT04281576|Drug|Oxaliplatin|Oxaliplatin 130 mg/m^2 intravenous infusion will be administered once every 3 weeks
75781534|NCT01234610|Behavioral|Supervised exercise training|Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
75781535|NCT01233596|Device|Canalicular intubation|Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
75781536|NCT05320094|Drug|Mavacamten|Specified dose on specified days
75781537|NCT05320094|Drug|Activated Charcoal with Sorbitol|Specified dose on specified days
75781538|NCT03917030|Procedure|Open flap debridement with osteoplasty|Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to >90 degrees relative to the apico-coronal axis of the toot.
75781539|NCT03917030|Procedure|Open flap debridement without osteoplasty|Treatment of furcation grade II defect with open flap debridement only.
75781540|NCT01233752|Drug|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.~Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h)."
75781541|NCT01140620|Drug|ketamine|ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
75781542|NCT01140620|Drug|risperidone|risperidone (2 mg) capsule. One dosing of 2 mg.
75781543|NCT01140620|Drug|saline|saline infusion. Duration approximately 3 hours
75781544|NCT01140620|Drug|placebo risperidone|placebo capsule to match risperidone 2 mg capsule
75781545|NCT01234688|Other|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
75781546|NCT03917108|Device|retraction cord|retraction cord ( Ultra dent sizes #0, #00, #000 ) is placed in the gingival sulcus using blunt instrument and using cotton roll isolation.
75781547|NCT03917108|Device|subgingival clamp|subgingival clamp (KSK clamps W8A, #44, #42, #43) or (Brinker clamps B5, B6) is placed to retract the gingiva with rubber dam isolation
75781548|NCT05298644|Biological|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
75781549|NCT05298644|Drug|Active Comparator|Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.
75781550|NCT01140698|Other|Blood sample on Guthrie paper from cord blood, and day 3 of life and before discharge|Mass spectroscopy on the blood sample that are taken as routine for the national inborn errors survey
75781551|NCT04725266|Behavioral|Family-based intervention|The intervention aims to motivate drug abusers to stay drug abstinence and improve family functioning with the support of their own families. In the component of engagement, we will use effective and appropriate skills to engage clients, understand their concerns, and provide necessary resources to them. In the component of role identification, we will help drug abusers identify their family roles through providing education on family roles and responsibilities. The component of affection is designed to learn affective responsiveness and enhance their emotional bonds with each other, while in the component of competence, we will enhance their competency to take care of the family. The intervention will be conducted in group sessions with 4-6 families per group. A total of 10 sessions will be delivered with 1.5-2 hour for each session (3 sessions for role identification, 4 sessions for affection, and 3 sessions for competence).
75781552|NCT04725266|Other|routine care|Routine care includes individual-session components of engagement, case assessment, drug education, service referral, family support, and etc.
75781553|NCT03739580|Device|DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
75781554|NCT03739580|Device|Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
75467839|NCT01933555|Behavioral|Empowerment Program|
75467840|NCT01933568|Radiation|SABR|combined CFRT and SABR with concurrent cisplatin
75630321|NCT04281576|Drug|Capecitabine|Capecitabine 1000mg/m^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
75630322|NCT04281576|Drug|Trastuzumab|Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
75467841|NCT01933568|Drug|Cisplatin|combined CFRT and SABR with concurrent cisplatin
75467842|NCT01933607|Device|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
75916969|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 2 - placebo with exemestane or fulvestrant
75467843|NCT01933633|Behavioral|Exercise|
75916970|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 3 - roll over to open-label AMG 479 with exemestane or fulvestrant
75324138|NCT00790855|Drug|Bendamustine|Starting dose of 50 mg/m^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
75324139|NCT03802747|Drug|Durvalumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
75324140|NCT03802747|Drug|Durvalumab and Tremelimumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
75324141|NCT03802747|Drug|Y-90 Selective Internal Radiation Therapy (SIRT)|Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
75324142|NCT03802747|Drug|Stereotactic Body Radiation Therapy (SBRT)|High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
75630323|NCT04795271|Other|Orthopedic intervention|"In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~Insole type and lining material~Materials of the added corrections~Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite."
75630324|NCT00668122|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin XR 1000 mg orally once a day
75630325|NCT00668122|Drug|Cipro IR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin IR 500 mg orally twice a day
75630326|NCT04304807|Drug|Melatonin 20 mg|Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
75781555|NCT03916952|Diagnostic Test|Six Minute Walk Test|The patients walked as far as possible for 6 minutes--over two separate trials. In one trial, an examiner walked with the participant. In the second trial, the participant walked independently. A paired T test was performed to see if there was a significant difference in the distance walked or gait speed between the trials.
75781556|NCT03916718|Behavioral|Care EcoSystem|This is a care management program and health care outcomes feasibility study utilizing the dementia Care Ecosystem (CE) program developed at UCSF and tailored to high need Ochsner PWD (patient with dementia) and their CGs (caregivers). Dyads (CGs and PWD) will receive a tailored clinical assessment addressing dementia severity, PWD and CG needs, education/strategies to management common dementia issues, medical issues and medication reconciliation, caregiver wellness strategies, linkages to community-based resources, advance care planning, education about the risk of ED and hospitalization, and care coordination with other specialties. Dyads will be followed on a monthly basis to monitor needs, provide support, and problem solve issues.
75916971|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 1 - AMG 479 administered with exemestane or fulvestrant
75916972|NCT03437408|Device|Mapping and ablation|High density substrate map. Data collection during ablation
75916973|NCT02064465|Drug|Lamotrigine Dispersible/Chewable tablet|Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1
75916974|NCT02064465|Drug|Lamotrigine Compressed tablet|Single dose of lamotrigine compressed 100mg tablet at Day1
75916975|NCT04530656|Biological|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of middle-dose (20µg/ 0.5ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
75916976|NCT04530656|Biological|Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
75324143|NCT00791089|Drug|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
75324144|NCT00791089|Drug|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
75324145|NCT00791089|Other|placebo|Control group will receive placebo before & after ablation.
75324146|NCT03802903|Device|Remo-Wax|topical treatment
75324147|NCT03802669|Other|oral mutans streptococcus|quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
75324148|NCT04384315|Other|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
75324149|NCT00791323|Drug|Ketorolac 0.4%|One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
75324150|NCT00791323|Drug|Lubricating Eye Drop|One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
75324151|NCT03802357|Procedure|Exercise training|Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.
75916977|NCT04530656|Biological|Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Three doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
75467844|NCT01933659|Drug|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
75467845|NCT01933685|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
75467846|NCT01933685|Biological|AIDSVAX B/E Placebo|1 mL per injection
75630327|NCT04304807|Drug|Traditional antibiotic treatment|Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
75630328|NCT04280874|Drug|Dinoprostone 0.5 MG|0.5mg dinoprostone applied intracervically
75630329|NCT04280874|Drug|Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly|2mg dinoprostone applied intravaginally
75630330|NCT00663910|Drug|Aminolevulinic Acid|On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
75630331|NCT00663910|Procedure|biopsy|Then local anesthesia, lidocaine 1% with epinephrine 1:100,000, will be administered and before the tumor is excised by one of the Cleveland Clinic MOHS surgeons, a 2mm punch biopsy will be taken from the area where the ALA was previously applied. The punch biopsy will be full thickness, extending to the subcutaneous fat.
75630332|NCT00663910|Procedure|diagnostic imaging technique|Two hours after the amniolevlulenic acid was applied, the measurements of surface fluorescence will be repeated with the hand held dosimeter.
75630333|NCT00663910|Procedure|therapeutic conventional surgery|The non-melanoma skin cancer will be excised using the MOHS procedure.
75781557|NCT04657250|Behavioral|Smoking cessation + quitline linkage text messages|Smoking cessation text messages will provide behavioral skills and support for quitting smoking. Quitline linkage text messages will include contact information for the quitline, option to be contacted by the quitline and active referral to the quitline upon setting a Quit Date.
75781558|NCT04657250|Behavioral|Passive quitline referral|Single text message with contact information for the Quitline
75781559|NCT01231178|Dietary Supplement|Alginate beverage|The dosage is 3x500ml daily
75781560|NCT01231178|Dietary Supplement|Control beverage|The dosage is 3x500ml daily
75630334|NCT02875769|Procedure|Dental prophylaxis|Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
75781561|NCT01140854|Procedure|Lumbar spine surgery|(non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
75781562|NCT01140854|Other|Neurologic/neuropsychometric examinations|To measure postoperative cognitive dysfunction.
75781563|NCT01234844|Behavioral|care of guinea pigs|twice weekly sessions of care with guinea pigs
75781564|NCT01234844|Behavioral|guinea pigs|"twice weekly pet therapy and twice weekly usual  occupational therapy"
75781565|NCT04619654|Procedure|Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold|Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
75781566|NCT01140932|Drug|Prednisolone|12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
75781567|NCT01140932|Behavioral|Lifestyle change|High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
75781568|NCT01138748|Radiation|hypofractionated radiation therapy|hypofractionated radiation therapy
75781569|NCT01138904|Drug|irinotecan, oxaliplatin|"OXIR: FOLFOX -> FOLFIRI~IROX: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
75467847|NCT01933698|Drug|amoxicillin|Comparison of pharmacokinetics of both formulations
75467848|NCT01933711|Drug|rituximab|
75781570|NCT01138904|Drug|oxaliplatin, irinotecan|"FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
75781571|NCT01231256|Behavioral|Preventive health consultation|A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
75781572|NCT01138982|Behavioral|Youth Mentoring program|
75781573|NCT01139060|Behavioral|organized care program for chronic or recurrent depression|
75781574|NCT01235000|Biological|2010-11 trivalent inactivated influenza vaccine|A single age-appropriate dose of 2010-11 trivalent inactivated influenza vaccine
75781575|NCT01134068|Other|Evaluation of a modified DD cut-off to rule out PE|Evaluation of a modified DD cut-off to rule out PE
75781576|NCT01134146|Radiation|IMRT|Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
75781577|NCT04582448|Drug|Insulin icodec|A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.
75781578|NCT01141010|Other|Language|Plain language without psychological intervention
75781579|NCT01141010|Other|Language|Psychological linguistic intervention will be given
75781580|NCT01141088|Procedure|Bilateral stent-in-stent insertion|Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
75916978|NCT04530656|Biological|Two doses of placebo at the schedule of day 0, 28（middle-dose group）|Two doses of placebo (0.5ml) at the schedule of day 0, 28
75916979|NCT04530656|Biological|Two doses of placebo at the schedule of day 0, 28（high-dose group）|Two doses of placebo (1.0ml) at the schedule of day 0, 28
75781581|NCT01141088|Procedure|Bilateral side-by-side insertion|Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
75781582|NCT05290142|Other|Digital Training with Coaching (DT-C)|An identical digital training course and helpline will be available for the participants in this group. In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. The focus will be on clarifying learning objectives and redirecting participants to relevant materials rather than providing new learning opportunities. Participants will also be able to send text messages to coaches with queries related to course content, progress and technical difficulties. Coaches will reply to participants' messages within one working day and send reminders about upcoming telephone sessions, as well as prompts if the participant has not logged into the course for 3 consecutive days.
75916980|NCT04530656|Biological|Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）|Three doses of placebo (1.0ml) at the schedule of day 0, 14, 28
75916981|NCT00690066|Drug|PROCHYMAL®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
75916982|NCT00690066|Drug|Placebo|Intravenous infusion of excipients of PROCHYMAL®
75916983|NCT01370265|Drug|Regadenoson|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
75916984|NCT01370265|Drug|Adenosine|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
75916985|NCT01370265|Drug|N-13 ammonia|Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
75916986|NCT00734292|Drug|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 2 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 3 Treatment Regimen C: placebo~SKP placebo; (two actuations)"
75916987|NCT00734292|Other|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 2 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 3 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)"
75916988|NCT00734292|Other|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 2 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 3 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)"
75916989|NCT03437096|Other|venipuncture pain|postoperative sleeve gastrectomy patients pain
75916990|NCT00687882|Other|Shortened duration (6 weeks) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
75916991|NCT00687882|Other|Conventional duration (3 months) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
75916992|NCT00687882|Other|No Intervention|Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
75916993|NCT00687882|Other|No Intervention|Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
75916994|NCT02064543|Other|GAITRite|mobility test assessing gait parameters
75916995|NCT02064543|Other|ADPM|mobility test assessing gait parameters
75916996|NCT04891094|Diagnostic Test|Ultrasound|daily ultrasound of the lung and the diaphragm
75916997|NCT02064621|Drug|Candesartan 32mg|Candesartan 32mg 1T, PO, QD for 9days
75916998|NCT02064621|Drug|Candesartan 32mg/Amlodipine 10mg|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
75916999|NCT03441698|Device|Genuine acupuncture (A)|A) Acupuncture is administered bilaterally to the acupuncture point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpii radialis. Sharp acupuncture needles were inserted into a depth of a half body-inch. The needles are manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
75917000|NCT03441698|Device|Sham acupuncture (B)|B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6. The telescopic Park Sham Device was used. The needle looks identical to a real needle, but is blunt and glides upward into its handle instead of penetrating. The marking tubes holds the needle in place. The therapist give an illusion of manipulating the needle by turning it three times until it touched the skin, but no deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
75467849|NCT01933737|Device|Kinesio Taping|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
75467850|NCT01933737|Device|3M Micropore|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
75467851|NCT01932879|Other|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
75467852|NCT01932879|Other|Jello|
75467853|NCT01933750|Device|PresVIEW Device Implantation|
75467854|NCT01933763|Drug|REGN1193|
75467855|NCT01933763|Other|Placebo|
75917001|NCT03441698|Other|Rest|C) Rest means resting for 30 minutes, either sitting or lying down. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
75917002|NCT03560115|Diagnostic Test|Single-heel rise test|Single heel-rise test is used to assess the strength of plantar-flexors clinically
75467856|NCT01933802|Biological|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
75467857|NCT01933828|Procedure|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
75467858|NCT01933828|Procedure|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
75467859|NCT01933828|Device|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
75467860|NCT01933841|Device|TOF-Watch SX|As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.
75467861|NCT01933841|Procedure|Notify the provider|"Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio."
75630335|NCT02875769|Drug|Mouthwash CPC+Zn+F|The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.
75917003|NCT03441620|Dietary Supplement|strawberries|Freeze-dried strawberry powder
75917004|NCT03441620|Other|Control powder|Control powder matched for fiber and strawberries
75467862|NCT01933867|Procedure|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
75917005|NCT00684918|Drug|Obatoclax|A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
75917006|NCT03445208|Drug|BMS-986036|Crossover administration to abdomen then upper arm
75467863|NCT01933867|Procedure|Air insufflation insertion|
75467864|NCT01933906|Drug|P1101|
75467865|NCT01933945|Procedure|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
75630336|NCT02875769|Drug|Mouthwash CHX|The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.
75630337|NCT02875769|Other|No rinsing|The volunteer did not rinse with any pre-procedural mothwash.
75467866|NCT01933945|Drug|Sorafenib (Nexavar, BAY43-9006)|
75467867|NCT01933971|Drug|Filgrastim test|0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
75630338|NCT02875769|Other|Water|The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
75917007|NCT00726648|Drug|CDP323|50mg capsules, 100mg bid for 4 weeks
75917008|NCT00726648|Drug|CDP323|250mg capsules, 500mg bid for 4 weeks
75917009|NCT00726648|Drug|CDP323|250mg capsules, 1000mg bid for 4 weeks
75467868|NCT01933971|Drug|Filgrastim reference|"0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous"
75467869|NCT01933997|Drug|Metadoxine (MG01CI )|
75467870|NCT01934023|Drug|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
75467871|NCT01934023|Drug|Placebo|
75467872|NCT01934036|Dietary Supplement|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
75467873|NCT01934036|Drug|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
75467874|NCT01934049|Procedure|hip arthroplasty|Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
75467875|NCT01934049|Drug|Total Intravenous Anesthesia and Peripheral nerve blocks|Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
75467876|NCT01934062|Procedure|Surgery|"All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.~--------------------------------------------------------------------------------"
75467877|NCT01934075|Behavioral|Mental health treatment|6 sessions of individual mental health counseling.
75467878|NCT01934088|Drug|Propofol|
75467879|NCT01934088|Drug|Midazolam|
75630339|NCT00663988|Procedure|human transplantation|Allograft composite tissue transplantation. procedure. medication
75917010|NCT00726648|Drug|CDP323|250mg capsules, 1000mg daily for 4 weeks
75917011|NCT00726648|Drug|Placebo|placebo capsules for 4 weeks
76075590|NCT01709305|Drug|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
75467880|NCT01934088|Drug|Fentanyl|
75781583|NCT05290142|Other|Self-Guided Digital Training|Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available offline and online on a smartphone app (called 'Sangath Training') as well as a website (https://training.sangath.in/login/index.php) that can be accessed through an internet-enabled device. The training will be delivered through didactic lectures, role-play demonstrations, and recommended readings spread across 16 modules. Participants will be provided with automated feedback on their learning through self-assessment quizzes after each module. Modules will be available sequentially and unlocked after accessing all content in the preceding module, over a period of 4 weeks. Technical helpline: Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface.
75781584|NCT01139138|Drug|Panitumumab|Panitumumab 6mg/kg IV every 14 days
75781585|NCT01139138|Drug|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
75781586|NCT01139138|Drug|Everolimus|Everolimus daily po (dosage varies with cohort)
75781587|NCT05403008|Other|Zirconomer improved|Zirconomer improved, is a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
75781588|NCT02446912|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
75781589|NCT02446912|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
75781590|NCT01235078|Device|EZ-IO|powered intraosseous vascular access system
75781591|NCT02528630|Other|Progressive resistance strength training program|Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.
75781592|NCT02528630|Other|Joint protection and energy conservation advice|A session regarding joint protection and energy conservation for hands was done before randomization.
75781593|NCT02528552|Device|LH80 PRO|
75781594|NCT02528552|Device|Sham Device|
75781595|NCT05402852|Drug|EuBone ® capsule|Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
75781596|NCT05402852|Drug|placebo|Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
75781597|NCT01134224|Drug|insulin degludec/insulin aspart|0.4 U/kg body weight injected subcutaneously (under the skin) once
75781598|NCT01134224|Drug|insulin degludec/insulin aspart|0.6 U/kg body weight injected subcutaneously (under the skin) once
75781599|NCT01134224|Drug|insulin degludec/insulin aspart|0.8 U/kg body weight injected subcutaneously (under the skin) once
75781600|NCT01134224|Drug|biphasic insulin aspart 30|0.4 U/kg body weight injected subcutaneously (under the skin) once
75781601|NCT01134224|Drug|biphasic insulin aspart 30|0.6 U/kg body weight injected subcutaneously (under the skin) once
75781602|NCT01134224|Drug|biphasic insulin aspart 30|0.8 U/kg body weight injected subcutaneously (under the skin) once
76075591|NCT01709305|Drug|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
75781603|NCT05308888|Diagnostic Test|18F-FDG PET-CT|The 18F-FDG PET-CT will be performed in the nuclear medicine department of the CHU of Brest. For this exam, the administration of 2-3 MBq/kg of 18F-FDG ([18F]F-fluorodeoxyglucose) will be performed to the patient in a single intravenous injection.
75781604|NCT01312636|Drug|activated recombinant human factor VII|Data will be collected at the baseline visit and approximately once a year until end of study.
75467881|NCT01934101|Drug|CHR-5154|CHR-5154
76075592|NCT01709305|Drug|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
75467882|NCT01934101|Drug|Placebo|Placebo
75467883|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789869A|One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
75467884|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789868A|One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
75630340|NCT04304885|Diagnostic Test|Sonication method|Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
75630341|NCT04157998|Drug|normal saline|intrvenous administration of 10ml normal saline preoperative
75630342|NCT04157998|Drug|Metoclopramide 10mg|intrvenous administration of 10mg metoclopramide diluted in 10ml normal saline preoperative
75781605|NCT01141166|Behavioral|nutritional and a rehabilitation plan.|The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
75630343|NCT02861352|Other|Diet zinc|4 mg zinc, as zinc sulfate, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period when an ad lib diet was consumed
75630344|NCT00668278|Device|Insertion of laryngeal mask airway (AuraOnce mask)|Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
75630345|NCT00668278|Device|Insertion of I-gel airway|Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg
75781606|NCT01233830|Drug|AZD2423|oral solution
75781607|NCT01233830|Drug|Placebo|oral solution
75781608|NCT04849234|Behavioral|newborn cries|"Their cries will be longitudinally registered from the age of birth until the first 15 minutes of birth using an automatic record device: Recorder ZOOM H4N.~The wav-sized files obtained from each recording will then be analyzed indiscriminately via an acoustic processing script created for the PRAAT software® by the post-doctoral fellows of the ENES laboratory (Sensory NeuroEthology Team) on the site of the Faculty of Sciences of Saint-Etienne."
75781609|NCT01231490|Drug|Placebo|Placebo
75781610|NCT01231490|Drug|Naproxen|Capsule
76075593|NCT01684423|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
75917012|NCT03445052|Behavioral|XPAND|The intervention is personalised to the psychosocial factors influencing poor photoprotection for each person. These factors could include beliefs that reduce motivation to protect as well as factors that prevent intentions being translated into action. The facilitator will use behaviour change techniques to target the factor most important for each person. Standardised content related to habit formation will be received. The intervention will be delivered via 7 1:1 sessions with a facilitator (psychologists or clinical nurse specialist). Sessions 1 (1.5 hours maximum) and 6 (45 minutes) will be delivered face to face in the home of the participant and the remaining sessions will be conducted via telephone calls or skype sessions.
75917013|NCT00726336|Drug|GSK1349572 and tenofovir|
75781611|NCT05308810|Procedure|Major Gynecologic- oncologic Surgery|Major Gynecologic-Oncologic surgery between january 2020 - january 2022
75781612|NCT01231568|Drug|Regimen A|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
75630346|NCT00668278|Other|Measurement of airway pressures|Measurement of peak airway pressure under steady state; measurement of device seal pressure
75781613|NCT01231568|Drug|Regimen B|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
75781614|NCT01231568|Drug|Regimen C|Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
75781615|NCT01231568|Drug|Regimen D|Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
75781616|NCT04065334|Behavioral|High dose training|4 x 4 minutes of high intensity workload on treadmill and 4 repetitions x 4 sets of high intensity workload in hack squat
75781617|NCT04065334|Behavioral|low dose training|1 x 4 minutes of high intensity workload on treadmill and 2 repetitions x 4 sets of high intensity workload in hack squat
75781618|NCT01141244|Drug|temsirolimus|Given IV
75781619|NCT01141244|Drug|temozolomide|Given orally
75781620|NCT01141244|Drug|irinotecan hydrochloride|Given IV
75781621|NCT01141244|Other|laboratory biomarker analysis|Correlative studies
75781622|NCT04011748|Combination Product|Stem Cell Educator therapy|AA subjects will be recruited and followed by the treatment with SCE therapy.
75917014|NCT03559959|Behavioral|Vouchers for HIV self-testing kits|Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.
75917015|NCT04414826|Behavioral|Mindfulness Alone (MO) Intervention|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness and non-reactivity skills.
75917016|NCT04414826|Behavioral|Mindfulness + Compassion Intervention (MC)|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness, non-reactivity, and compassion skills.
75917017|NCT02280720|Procedure|Stenting using Optimax™|
75917018|NCT02280720|Procedure|Stenting using PROMUS Element™ Plus|
75917019|NCT02068053|Drug|[14C] BMS-986020|
75917020|NCT02280798|Procedure|Endometrial Biopsy|4 endometrial biopsy
75630347|NCT04157842|Procedure|total hip replacement with subtrochanteral osteotomy|applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve
75781623|NCT03638284|Device|Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation that does not require general anaesthesia or surgical implantation of a device. It uses two AA size batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
75781624|NCT01141322|Drug|Ursodeoxycholic Acid|ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
75781625|NCT01141322|Drug|Placebo|The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
75781626|NCT05226572|Diagnostic Test|endoscopic ultrasound-guided fine needle biopsy|repeated endoscopic ultrasound-guided fine needle-biopsy after a previous non diagnostic or incoclusive endoscopic ultrasound-guided tissue aquisition for pancreatic solid lesions.
75781627|NCT05402774|Diagnostic Test|point-of-care ultrasound|point-of-care ultrasound
75781628|NCT01142804|Behavioral|Group|Walking programs with various levels of support will be administered to determine which one is most effective.
75917021|NCT03444974|Other|adapted treatment according to the MATRIX-A therapy|cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters
75630348|NCT04157842|Procedure|total hip replacement with no osteotomy|just total hip replacement
75630349|NCT02860260|Biological|Blood samples|
75917022|NCT02068131|Drug|Novaferon|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
75467885|NCT01934127|Biological|Placebo|One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
75630350|NCT02860260|Other|Cerebral MRI|
75630351|NCT04155268|Behavioral|Flotation-REST|Floating in a specialized device (float pod or float cabin) used to attenuate sensory input.
75630352|NCT04155268|Behavioral|Dark Room|Participants will lay on an air mattress in a dark room with no cell phone and reduced sensory input.
75630353|NCT01072877|Drug|Polidocanol injectable foam (PEM)|Injection of Polidocanol injectable foam
75630354|NCT01072877|Drug|Placebo Vehicle|Placebo vehicle
75781629|NCT01141556|Drug|Selenase|After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
75781630|NCT01141634|Other|Homeopathic Remedies|Homeopathic remedies prepared according to the standards as set out by Health Canada
75781631|NCT01139372|Other|FID 115958D (Lubricant Eye Drop)|1 drop in each eye at least twice daily
75781632|NCT01236248|Behavioral|Prevention|9-session computerized cognitive behavioral program that young girls and their mothers interact with on a weekly basis in the privacy of their home. Girls and their mothers will watch and interact with 10 compact disc (CD) intervention sessions to learn skills to help girls avoid substance use.
75781633|NCT01139528|Procedure|Bouquet pinning of the 5th metacarpal bone|The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
75324152|NCT00772915|Drug|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
75324153|NCT00772915|Drug|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
75324154|NCT00774163|Biological|Lactobacillus reuteri|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
75781634|NCT03638440|Drug|Naloxegol|Naloxegol is a PEGylated derivative of the μ-opioid receptor antagonist naloxone
75781635|NCT01719640|Drug|infusion of MSCs|infusion of MSCs
75781636|NCT01719640|Drug|infusion MCs|infusion of MCs
75781637|NCT01719640|Drug|insulin|intensive insulin care
75781638|NCT01141790|Other|Music and voice message|
75781639|NCT03638362|Dietary Supplement|Placebo|Participants consumed placebo beverage for 4 weeks.
75781640|NCT03638362|Dietary Supplement|Tart cherry juice|Participants consumed tart cherry juice (8 ounces; 240 mL) per day for four weeks.
75781641|NCT01141868|Behavioral|Internet Intervention|online treatment for insomnia
75781642|NCT02439658|Drug|Dofetilide and/or sotalol|This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.
75781643|NCT05191394|Diagnostic Test|Evolution of antibodies titre|For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session.
75781644|NCT03749720|Other|Blood sample|Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.
75781645|NCT00736840|Device|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
75781646|NCT01141946|Procedure|thoracic ultrasound|All patients will receive pre-operative pleural-based ultrasound during their initial consultation.
75917023|NCT02068131|Drug|Capecitabine|The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
75324155|NCT00774163|Other|Placebo|5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
75324156|NCT03801967|Drug|AZD9977|Randomized participants will receive oral dose of AZD9977.
75781647|NCT01141946|Procedure|pleural aspiration|Before proceeding to pleural aspiration, a radiography of the chest will be performed in order to ascertain the presence of a pleural effusion.
75781648|NCT04908514|Drug|ADX-629|ADX-629 administered orally twice daily (BID) for approximately 12 weeks.
75781649|NCT01142024|Drug|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
75781650|NCT01142024|Drug|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
75781651|NCT04895098|Drug|statin and ezetimibe combination therapy|Receiving statins (atorvastatin/rosuvastatin or others) in combination with ezetimibe 10mg/day in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
75781652|NCT04895098|Drug|statin monotherapy|Receiving statins (atorvastatin/rosuvastatin or others) as monotherapy in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
75781653|NCT04646044|Drug|Bempegaldesleukin|Administered as an intravenous infusion
75781654|NCT04646044|Drug|Standard of Care|Standard of Care Treatment for COVID-19 Infection
75781655|NCT04646044|Other|Placebo|Administered as an intravenous infusion
75781656|NCT01235390|Dietary Supplement|Walnuts|The consumption of assigned walnuts once a day during 4 weeks
75781657|NCT01142102|Radiation|Radiation Therapy|"A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.~Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.~Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV."
75917024|NCT02068209|Drug|Tramadol|patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
75917025|NCT02068209|Drug|Placebo|patients will receive a placebo 1 hour before outpatient hysteroscopy
75917026|NCT00680784|Drug|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
75917027|NCT00680784|Other|Placebo Patch|Placebo Patch
76075594|NCT01684423|Drug|Active comparator|Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
76075595|NCT01684423|Drug|Rivaroxaban (BAY59-7939) suspension|Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
76075596|NCT01709227|Drug|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
75781658|NCT04628962|Procedure|Collection and Raman analysis of saliva for the database|Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
75324157|NCT03801967|Drug|Placebo|Randomized participants will receive oral dose of matching placebo.
75324158|NCT03801889|Drug|SP-420|Self-administered by mouth
75781659|NCT00318461|Drug|liraglutide|0.6 mg for s.c. (under the skin) injection.
75781660|NCT00318461|Drug|metformin|1.5-2.0 g tablets
75917028|NCT04404218|Dietary Supplement|Açaí palm berry extract - natural product|Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.
75781661|NCT00318461|Drug|glimepiride|4 mg tablets
75917029|NCT04404218|Other|Placebo|Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.
75917030|NCT02068287|Drug|Esmolol|After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
75917031|NCT03444896|Device|Acupuncture group|Acupuncture needles were placed at acupoints Baihui (DU20), Shenting (DU24), Fengfu (DU16), Fengchi (GB20), Danzhong (RN17), Zhongwan (RN12), Qihai (RN6), Neiguan (PC6), Zusanli (ST36), Xuehai (SP10), Xinshu (BL15), Yixi (BL45), Tongli (HT5), and Zhaohai(KI6). Electrodes were attached the needle holders of the Baihui (DU20) and Shenting (DU24). The acupuncture needles are inserted through the adhesive pads and are retained for 20 minutes in every course. Treatment will be conducted over a period of 3 months, at a frequency of two times per week.
75917032|NCT03444896|Device|Sham acupuncture group|Sham acupoint (SA) 1 located in the midpoint of Shuaigu and Touwei. SA2 located in the midpoint of Touwei and Yangbai. SA3 located in the midpoint of Tianyou and Tianrong. SA4 located in 4 cun above umbilicus and 1 cun right of umbilical midline (UM). SA5 located in 2 cun below umbilicus and 1 cun right of UM. SA6 1 cun outside the point 1/4 of the line between Shenmen and Shaohai. SA7 located in 1 cun outside the midpoint of Shaohai and Tongli. SA8 located in 6 cun above mediosuperior border of the patella. SA9 located in 3 cun below the Yanglingquan and middle of the gallbladder and bladder channels. SA10 located in midpoint between Jiexi and Qiuxu. SA11 and SA12 located in 2 cun from the lower border of spinous process of fifth or sixth thoracic vertebra. Electrodes were attached the needle holders of the bilateral SA 2. Procedures, and other treatment settings were the same in the acupuncture group but with no skin penetration, electricity output, or needle manipulation for de qi.
75917033|NCT02068365|Drug|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
75917034|NCT02280876|Drug|1 - Andrographis paniculata p/st extract|"Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile."
75324159|NCT03801577|Dietary Supplement|Hepaxa|High concentrate EPA and DHA
75324160|NCT03801811|Procedure|Study of the efficacy of using skin glue in the application of Port a cath|The use of glue as a device in the implantation of central venous catheters has recently been introduced into European clinical practice. It is possible that the surgical incision created for the insertion of the PORT may be subject to complications such as: local bleeding, which if not properly treated may last even a few days, infections or surgical wound outbreaks. This possibility of bleeding occurs more easily in patients suffering from coagulation problems or when appropriate preventive measures have not been taken at the time of implantation of the device. A solution to this problem could be the application of the cyanoacrylate dermal glue on the edges of the surgical wound, after intradermal suture. The glue would have the purpose of sealing the surgical wound so as to immediately seal the skin incision with hemostatic effect and create a potential barrier against bacterial infections.
75324161|NCT03801733|Drug|Vadadustat|Oral dose of 600 mg QD
75324162|NCT03801733|Drug|Simvastatin|Oral Simvastatin
75781662|NCT00318461|Drug|placebo|Glimepiride placebo 1 mg and 2 mg tablets
75781663|NCT00318461|Drug|placebo|Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
75781664|NCT00318461|Drug|liraglutide|1.2 mg for s.c. (under the skin) injection
75781665|NCT00318461|Drug|liraglutide|1.8 mg for s.c. (under the skin) injection
75781666|NCT01235468|Biological|ex vivo expansion|ex-vivo expansion of cord blood for transplantation
75781667|NCT01235624|Genetic|genetic analysis|
75917035|NCT02280876|Drug|2 - Excipients|"Placebo 650mg tabs, 2/day, 365 days continuously.~Other Names:~• Excipients tablets EUROMED Specific. Santiago Chile"
75917036|NCT03444818|Drug|[14C]-E6007|Oral administration
75917037|NCT02068521|Drug|somavaratan|Subcutaneous injection
75917038|NCT02068677|Other|Sympathetic response|Sympathetic response will be defined as change in heart rate by >10 bpm and change in BP <10mmHg.
76075597|NCT01709227|Procedure|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
76075598|NCT01684033|Device|Opti-Free® PureMoist® MPDS|
76075599|NCT01684033|Device|Biotrue™ MPS|
75917039|NCT02068677|Other|no sympathetic response|no Sympathetic response will be defined as change in heart rate by <10 bpm and change in BP <10mmHg.
75917040|NCT01973166|Device|Picosecond Q-switched Laser Treatment|
75917041|NCT01973166|Device|Nanosecond Q-switched Laser Treatment|
75917042|NCT03444740|Other|ICIQ-FLUTS, ADMN-20|Questionnaire
75917043|NCT00680472|Drug|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
75917044|NCT00680472|Other|Placebo Patch|Treatment with Placebo Patch
75917045|NCT05575401|Procedure|Lateral pharyngoplasty|Two figure-of-8 sutures using 3-0 vicryl are used to approximate the anterior and posterior tonsillar pillars and reconstruct the continuous mucosal covering of the lateral pharyngeal walls.
75917046|NCT05575401|Procedure|Tonsillectomy|Extracapsular tonsillectomy
75324163|NCT03801733|Drug|Rosuvastatin|Oral Rosuvastatin
75324164|NCT03801733|Drug|Atorvastatin|Oral Atorvastatin
75324165|NCT03801733|Drug|Pravastatin|Oral Pravastatin
75467886|NCT01934153|Drug|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
75630355|NCT02875847|Dietary Supplement|HMO1|
75630356|NCT02875847|Dietary Supplement|HMO2|
75630357|NCT02875847|Dietary Supplement|Dextropur|
75630358|NCT00961896|Drug|Vehicle|Placebo cream
75781668|NCT01142180|Procedure|TAE|The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
75781669|NCT01142180|Procedure|No TAE|No TAE procedure will be performed after endoscopic treatment
75781670|NCT01142258|Drug|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
75781671|NCT01142258|Drug|Placebo|Inactive or inert pill which will be used as a comparator
75781672|NCT04043312|Device|Magstim SuperRapid|Transcutaneous magnetic stimulation targeting the left stellate ganglion.
75781673|NCT04043312|Device|Magstim SuperRapid|Sham transcutaneous magnetic stimulation.
75324166|NCT03801733|Drug|Sulfasalazine|Oral Sulfasalazine
75467887|NCT01934166|Drug|Nalmefene 18 mg|One single oral dose of 18 mg
75630359|NCT00961896|Drug|LDE225 0.25%|
75630360|NCT00961896|Drug|LDE225 0.75%|
75630361|NCT02858388|Device|Sinuclean Nebules 45|Nebulization of solution
75630362|NCT02858388|Other|Saline solution|Nebulization of solution
75781674|NCT01235702|Behavioral|12-week lifestyle modification|
75917047|NCT03444662|Dietary Supplement|Placebo supplement|Cellulose and Sunflower oil
75781675|NCT01139606|Other|Vibration resistance training|adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
75781676|NCT03764072|Drug|VX-150|Capsules for oral administration.
75781677|NCT03764072|Drug|Placebo|Capsules for oral administration.
75781678|NCT05133830|Drug|Obeticholic acid|OCA will be administered
75324167|NCT03801421|Procedure|Mass continous suture with PDS|The surgical incision will be treated by mass continous suture with PDS.
75324168|NCT03801421|Procedure|Interrupted suture with thread|The surgical incision will be treated by interrupted suture with thread.
75467888|NCT01934179|Other|cytology specimen collection procedure|Undergo blood sample collection
75467889|NCT01934179|Other|laboratory biomarker analysis|Correlative studies
75467890|NCT01934179|Other|questionnaire administration|Ancillary studies
75630363|NCT02859090|Procedure|tonsillectomy|
75630364|NCT02859090|Biological|blood sample|
75781679|NCT05133830|Drug|Linerixibat|Linerixibat will be administered
75781680|NCT01139684|Behavioral|Repeated sprint test|
75781681|NCT01234064|Device|Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)|Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.
75781682|NCT01234064|Device|No Graduated Compression Stockings|No stockings will be applied.
75781683|NCT03333928|Drug|HTD1801|HTD1801 tablets, 250 mg
75781684|NCT03333928|Drug|Placebo|tablets manufactured to mimic HTD1801 tablets
75781685|NCT03739424|Other|Whole egg powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole egg powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
75781686|NCT03739424|Other|Whole milk powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole milk powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
75781687|NCT03739424|Other|Gelatin food product|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with gelatin. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
75781688|NCT01139840|Dietary Supplement|vitamin D2|Study Supplement
75781689|NCT01139840|Dietary Supplement|vitamin D3|Study Supplement
75917048|NCT03444662|Dietary Supplement|Citicoline and Omega-3 supplement|Citicoline and Omega-3
75917049|NCT03444662|Dietary Supplement|Omega-3 supplement|Cellulose and Omega-3
75917050|NCT03444506|Drug|Molo 1 (also referred as GSP 301-2 NS)|
75917051|NCT03444506|Drug|Molo 2 (also referred as GSP 301-1 NS)|
75917052|NCT03444506|Drug|Placebo nasal spray|
75917053|NCT03444506|Drug|DYMISTA nasal spray|
75917054|NCT03444506|Drug|PATANASE nasal spray|
75917055|NCT02065947|Procedure|paravertebral block|catheter with 3-level-injection
75917056|NCT02065947|Drug|fentanyl, propofol, atracurium|endotracheal intubation
75917057|NCT02065947|Drug|lidocaine , adrenaline, ketamine bolus, midazolam|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
75917058|NCT02065947|Device|catheter with 3-level-injection|
75630365|NCT02706288|Other|Weight loss with very low fat plant-based diet and regular exercise|Participants will lose ~7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
75630366|NCT00630474|Drug|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
75781690|NCT01142882|Behavioral|Traditional Prevention|Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.
75781691|NCT01142882|Behavioral|Web-based Prevention|Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
75630367|NCT02860182|Other|measure the elastic properties of aortic wall|
75630368|NCT02860104|Device|microwave ablation|ultrasound guided percutaneous microwave ablation for breast lesions
75630369|NCT00957528|Drug|Testosterone|Weekly im injections of 100 mg testosterone enanthate.
75781692|NCT02945410|Other|Caloric Restriction|Participants will consume 30 kcal/kg FFM/day.
75781693|NCT02945410|Other|Protein|Participants will consume 1.7 g protein/kg BW/day.
75781694|NCT02945410|Other|Exercise|Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
75781695|NCT02945410|Dietary Supplement|Calcium and Vitamin D|Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
75781696|NCT02945410|Other|Maltodextrin|Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
75781697|NCT01142960|Dietary Supplement|Starch|1350mg/day
75781698|NCT01142960|Dietary Supplement|Lycium Barbarum|1350mg/day
75781699|NCT02945254|Device|NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)|
75781700|NCT05032508|Drug|Lidocaïne Aguettant 20 mg/ml|Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
75781701|NCT05032508|Drug|NaCl 0,9%|Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
75781702|NCT01140074|Drug|Zinc Sulfate|Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
75781703|NCT05010512|Device|Delefilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
75781704|NCT05010512|Device|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
75781705|NCT01142414|Biological|panitumumab|
75781706|NCT01142414|Drug|cisplatin|
75467891|NCT01934205|Drug|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
75630370|NCT00957528|Drug|Placebo|Weekly IM injections of sesame oil.
75630371|NCT02857062|Device|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
75781707|NCT01142414|Drug|fluorouracil|
75781708|NCT01142414|Other|laboratory biomarker analysis|
75781709|NCT01142414|Procedure|adjuvant therapy|
75781710|NCT01142414|Procedure|quality-of-life assessment|
75781711|NCT01142414|Radiation|3-dimensional conformal radiation therapy|
75781712|NCT01142414|Radiation|intensity-modulated radiation therapy|
75781713|NCT01235858|Procedure|wearing of sterile gowns|Anesthesiologists wearing sterile gown for epidural insertion
75781714|NCT01235858|Procedure|No gown|Anesthesiologists not wearing sterile gown for epidural insertion
75781715|NCT01329692|Behavioral|Lifestyle counseling|Weeks 1 and 2 consist primarily of a review of current dietary habits with initiation of a food journal; a basic review of macronutrients and metabolism; and the beginning of a weekly exercise regimen. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed. During this period, patients will also be given access to an interactive web-based tool providing additional emphasis on the aforementioned components and clinician follow-up.
75781716|NCT01236482|Drug|Oxytocin versus oxytocin-ergometrine|Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
75781717|NCT03992651|Device|Measurements of capnia and tissue oxygenation by optical transcutaneous sensors|Capnia and tissue oxygenation will be measured by optical transcutaneous sensors
75917059|NCT02065947|Drug|sevoflurane and 50% oxygen in air|
75917060|NCT03436706|Other|exposure|exposure to chronic stress
75917061|NCT02068833|Procedure|Gastrectomy|
75917062|NCT02068833|Procedure|BPD-DS|
75917063|NCT02068911|Device|Monitoring of ETCO2 and PTCO2|Concomitant monitoring of ETCO2 and PTCO2
75917064|NCT03436628|Device|MyT1DHero|A mobile phone application
75467892|NCT01934205|Drug|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
75467893|NCT01934244|Device|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
75781718|NCT02943070|Device|Rezum System|"The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
75630372|NCT00958776|Drug|Peramivir+SOC|"Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
75630373|NCT00958776|Drug|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
75630374|NCT02858856|Drug|Sipjeondaebo-tang|Herbal medicine which is a compound of 10 herbs.
75781719|NCT03629678|Other|mobile health application|The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
75781720|NCT01048151|Biological|TNFerade™ Biologic|AdGVEGR.TNF.11D
75781721|NCT01142492|Drug|Interferon beta-1a|Subjects first received Interferon beta-1a at a dose of 22 µg x3 over a period of 4 weeks. An attempt was then made to increase the dose of interferon beta-1a to 44 µg x3 as a self-administered subcutaneous (s.c.) injection. If intolerable interferon-specific side effects or problems of acceptance occured, the treatment with Rebif 22 µg three times weekly was continued.
75781722|NCT01236014|Drug|Eltrombopag|Eltrombopag & standard of care
75781723|NCT01236014|Drug|Romiplostim|Romiplostim & standard of care
75781724|NCT01236014|Drug|Placebo|Placebo & standard of care
75917065|NCT03129464|Device|Cold therapy via reusable cold gel pack|Patients in the experimental group will be asked to apply cold therapy to their abdominal incisions every 6 hours for the first 72 hours following their surgery (total laparoscopic hysterectomy). Cold therapy will be applied via a reusable cold gel pack.
75917066|NCT03436472|Drug|dexmedetomidine|low-dose dexmedetomidine infusion
75917067|NCT03436472|Drug|placebo|normal saline infusion
75917068|NCT02064699|Biological|CMV Infection|"Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.~Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV."
75917069|NCT02066103|Drug|Paclitaxel|
75917070|NCT03785847|Diagnostic Test|Ventica|Impedance pneumography measurement
75917071|NCT02521688|Procedure|incisional biopsy from placenta and GCF sample|A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
75917072|NCT04809532|Procedure|Transverse abdominis plane (TAP) block|Ultrasound guide bilateral TAP block at end of cesarean section
75917073|NCT04809532|Drug|Bupivacain|20ml 0.25% bupvicaine
75917074|NCT04809532|Drug|Tramadol|intravenous tramadol
75917075|NCT03444428|Other|Non Invasive Ventilation|Assessments for those participants who are being set up onto NIV
75917076|NCT03444428|Other|Without Non Invasive Ventilation|Assessments for those participants who are not being set up onto NIV
75630375|NCT02858622|Drug|bupivacaine|bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
75630376|NCT02858622|Drug|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
75630377|NCT02858622|Drug|perfalgan|intravenous paracetamol
75630378|NCT02858622|Drug|fentanyl|
75917077|NCT03436316|Drug|AZD8154|SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).
75917078|NCT04809142|Drug|TQB2450 Injection|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
75917079|NCT04809142|Drug|Anlotinib hydrochloride|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
75917080|NCT04809142|Drug|Oxaliplatin injection|Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
75630379|NCT04278456|Behavioral|postpartum depression|melatonin levels in c-sections with different anesthesia modalities.
75781725|NCT01142570|Other|Caloric Support (Group 1)|Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
75917081|NCT04809142|Drug|Capecitabine tablets|Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
75917082|NCT04809142|Drug|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
75781726|NCT01142570|Other|Caloric Support (Group 2)|For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
75781727|NCT01142570|Dietary Supplement|Protein dose of 1.1 to 1.5 grams per kilogram weight.|Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
75781728|NCT01142570|Dietary Supplement|Protein at 1.1 grams per kilogram weight.|Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
75781729|NCT01142570|Dietary Supplement|protein at a dose of 1.5 grams per kilogram weight.|Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
75781730|NCT03963154|Biological|Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)|Implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE))
75781731|NCT01236092|Other|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
75917083|NCT02064777|Drug|Tacrolimus|
75917084|NCT03444350|Device|Gaseous ozone|SRP plus gaseous ozone
75917085|NCT03444350|Device|SRP plus placebo|only SRP
75917086|NCT02066337|Procedure|scaling and root planing|
75917087|NCT02066337|Drug|placebo gel|
75917088|NCT02066337|Drug|Ozonated olive oil gel|
75917089|NCT03436394|Drug|Evobrutinib|Subjects will be administered a single oral dose of evobrutinib under fasting conditions.
75917090|NCT03441386|Behavioral|Physical Exercise Session|
75324169|NCT03801343|Dietary Supplement|Nutrakos®|"Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes."
75324170|NCT04383535|Other|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
75630380|NCT02191566|Drug|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
75630381|NCT02191566|Drug|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
75781732|NCT03776474|Biological|Blood collection|Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
75781733|NCT02145208|Device|TIND System|An implant
75781734|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
75917091|NCT02069145|Drug|OMP-54F28 with Sorafenib|
75917092|NCT04830358|Biological|EuPCV15|15-valent Pneumococcal conjugate vaccine
75917093|NCT04830358|Biological|Prevenar13|13-valent Pneumococcal conjugate vaccine
75467894|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
75467895|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
75467896|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
75630382|NCT00596830|Drug|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
75781735|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
75781736|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
75917094|NCT03436160|Drug|WR826647|100 mcg Carbon-14 radio labeled WR826647 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
75917095|NCT03436160|Drug|WR909388|100 mcg Carbon-14 radio labeled WR909388 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
75917096|NCT03436160|Drug|WR909390|100 mcg Carbon-14 radio labeled WR909309 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
75917097|NCT04830280|Procedure|posterior quadratus lumborum block|administration local anesthetic solution between the middle layer of the thoracolumbar fascia and QL muscle at the posterior edge of the quadratus lumborum muscle
76075600|NCT01684033|Device|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
76075601|NCT00878644|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
76075602|NCT00878644|Other|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
75324171|NCT04383535|Other|Placebo|Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
75630383|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
75630384|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
75324172|NCT04383613|Other|Prone positioning|The intervention is prone positioning (i.e., instructing a patient to lie on their stomach while they are in bed) for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for >24 hours or study outcome. Patients will be asked to aim for prone positioning four times per day for at least two hours each time, and will be encouraged to sleep on their stomach at night.
75781737|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
75917098|NCT04829968|Other|gingival conditions control|"Peri-implant mucositis: It was diagnosed on the basis of the following criteria:~Visual inspection demonstrating the following signs of inflammation in the peri-implant region: red as opposed to pink colour, swollen tissues as opposed to no swelling, and soft as opposed to firm tissue consistency.~Presence of profuse (line or drop) bleeding and/or suppuration on probing.~An increase in probing pocket depths (PPDs) compared to baseline. • Peri-implantitis: It was diagnosed on the basis of the following criteria:~1. Visual inflammatory changes in the peri-implant soft tissues combined with bleeding on probing and/or suppuration.~2. Increasing PPDs as compared to measurements recorded at the time of placement of supra-structures."
75324173|NCT00775411|Drug|dexamethasone|700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
75324174|NCT00775411|Biological|ranibizumab|Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
75917099|NCT03444272|Drug|Sofosbuvir and Daklatasuvir|HCV Treatment (Sofosbuvir and Daklatasuvir)
75324175|NCT03801655|Dietary Supplement|Bio-Kult|4 capsules/day
75324176|NCT03801655|Other|Placebo|4 capsules/day
75324177|NCT03801499|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75324178|NCT00808405|Drug|acyclovir|400mg taken orally three times daily for 5 days
75324179|NCT00808405|Drug|matching placebo|matching placebo taken orally three times daily for 5 days.
75324180|NCT00775645|Dietary Supplement|acetyl-L-carnitine hydrochloride|Given orally
75324181|NCT00775645|Other|placebo|Given orally
75917100|NCT03347331|Drug|[18F]F13640|"Radiotracer injection and PET scan acquisition of 90 min:~*150 Mbq + 1 MBq/Kg of [18F]F13640 at t=0 min~Arterial Blood Sampling during the 90min acquisition"
75917101|NCT03347331|Drug|[18F]F13640|2 Radiotracer injections and PET scan acquisition of 90 min distant from 1 to 3 weeks: For each exam: 150 MBq + 1 MBq/kg of [18F]F13640 at t=0 min
75324182|NCT04902781|Drug|AT-007|Treatment with AT-007 given orally
75630385|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
76075603|NCT05312086|Other|MRI|"Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes.~Performing MRI does not require the injection of contrast products or radiopharmaceuticals."
75324183|NCT04902781|Other|Placebo|Placebo given orally
75324184|NCT01974687|Drug|Uprifosbuvir|Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
75324185|NCT01974687|Drug|Placebo|Matching placebo to uprifosbuvir capsule administered by mouth.
75324186|NCT01974687|Drug|Itraconazole|Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
75630386|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
75630387|NCT00957372|Drug|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
75630388|NCT00957372|Drug|placebo (Part I)|once daily placebo comparator
75630389|NCT00957372|Drug|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
75630390|NCT02858778|Other|Early order of palliative care consultation|
75630391|NCT02610582|Drug|rAAV.hCNGA3|Single subretinal injection of rAAV.hCNGA3
75781738|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
75781739|NCT01234142|Drug|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
75781740|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
75781741|NCT01143194|Dietary Supplement|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
75917102|NCT04829734|Device|Active PBMT-sMF|The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
75917103|NCT04829734|Device|Placebo PBMT-sMF|The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
76075604|NCT05235490|Other|Non intervention|"Data study with inclusion of patients and retrospective clinical data collection, combining :~Proofreading by radiologist of the CT scan performed (within 2 months prior to surgical intervention)~Proofreading by iBiopsy® of the CT scan performed (within 2 months prior to surgical intervention)~Proofreading of tumor sample slides by pathologists~Patients follow-up (imaging, clinical)~Recurrence-free survival"
76075605|NCT00878878|Drug|Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
75630392|NCT04270968|Device|extra-corporeal shock wave therapy|Extracorporeal Shock Wave Therapy (ESWT) has been introduced efficiently for more than twenty years as a treatment modality in orthopedic and musculoskeletal disorders. ESWT has mechanical and cellular impacts on tissues regeneration and pain management through cavitation bubbles, acoustic micro streaming, and hyper-vascularity that can directly affect tissue calcifications, and modulate cell activity.
75917104|NCT05573373|Drug|Parimparib|The dosage and protocol of the drug were carried out according to the description.
75917105|NCT05573373|Drug|Chemotherapy drug|The dosage and protocol of the drug were carried out according to the description.
75781742|NCT01143194|Dietary Supplement|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
75781743|NCT01143194|Dietary Supplement|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
75781744|NCT01143194|Dietary Supplement|Placebo|1 capsule of placebo twice a day
75781745|NCT01140308|Drug|CoEnzyme Q10|Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment
75781746|NCT01140308|Drug|Placebo|Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
75781747|NCT01142648|Drug|Sugammadex|Sugammadex 200 mg iv, single dose, bolus.
75781748|NCT01142648|Drug|Neostigmine and glycopyrrolate|Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
75781749|NCT02143726|Drug|sorafenib|Given PO
75781750|NCT02143726|Drug|everolimus|Given PO
75917106|NCT05573373|Drug|Targeted Therapy Agent|The dosage and protocol of the drug were carried out according to the description.
75917107|NCT04816786|Other|no intervention will be administered, this is a retrospective observational study.|no intervention will be administered, this is a retrospective observational study.
75917108|NCT05056532|Diagnostic Test|patient assessment|subjective and objective measurement will be performed in patients with PAH
76075606|NCT00878878|Drug|Dextrose|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
76075607|NCT05311696|Other|psychoeducation|The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
76075608|NCT00879034|Drug|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
76075609|NCT00879034|Drug|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
76075610|NCT00879034|Drug|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
75630393|NCT04270968|Drug|topical none steroidal anti-inflammatory drug|participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
75630394|NCT02857998|Drug|HMPL-523|Oral administration, once daily
75630395|NCT05143164|Device|hydrocolloid dressing|Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.
75630396|NCT05143164|Drug|Gentamicin Sulfate, Topical|Application of gentamicin to exit site daily
75781751|NCT05397392|Other|guideline recommended routine treatment|
75781752|NCT03503864|Drug|Arsenic Trioxide|Arsenic trioxide（ATO） is administered 0.16mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10. Nine cycles at most of ATO-combined chemotherapy were applied in the whole scheme.
75781753|NCT02088112|Drug|Gefitinib|Gefitinib QD
75781754|NCT02088112|Drug|MEDI4736|MEDI4736 IV Q2W
75781755|NCT01237964|Drug|Xiaflex (FDA approved collagenase)|0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
75781756|NCT05397080|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.)~Cognitive restructuring (15 min.)~Mindfulness techniques (15 min.)~Physical exercise(15 min.)~Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
75917109|NCT03035812|Drug|Alkali|Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
75781757|NCT05397080|Behavioral|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
75917110|NCT03109652|Drug|Tranexamic Acid|"On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)"
75781758|NCT05397080|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.)~Cognitive restructuring (15 min.)~Mindfulness techniques (15 min.)~Physical exercise(15 min.)~Treatment as Usual (TAU)~4 face-to-face sessions (1 per mounth) Standard pharmacological treatment usually provided to patients with fibromyalgia."
75630397|NCT04278222|Drug|Anlotinib Plus Toripalimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w
75630398|NCT00664144|Drug|Rasburicase (SR29142)|
75630399|NCT04280484|Other|Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
75630400|NCT04280484|Other|Sham Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
75917111|NCT05566353|Other|Remote Check|Remote Check is a remote monitoring tool which permits patients with Cochlear Nucleus CP1000 or CP1150 processors to complete hearing tests (pure-tone and speech-in-voice audiometry, electrode impedance measures, implant functioning assessment) at home,
75324187|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
75324188|NCT00795145|Drug|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
75324189|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
75781759|NCT01312870|Dietary Supplement|Ensure, Abbott Nutrition|Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days
75781760|NCT01312870|Other|standard hospital diet|standard hospital diet
75630401|NCT00660634|Procedure|Endovascular Revascularization|Angioplasty/Stenting of femoro-popliteal lesions
75917112|NCT03444194|Procedure|liver biopsy|Liver biopsy of neoplastic tissue and normal liver tissue.
75917113|NCT02069223|Procedure|Gastrectomy|
76075611|NCT04089202|Other|eConsult|Completion of electronic consult utilizing data collected from flash glucose monitoring
75324190|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
75324191|NCT00795145|Drug|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
75324192|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
75324193|NCT00795145|Drug|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
75324194|NCT03801187|Procedure|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
75324195|NCT03801187|Procedure|Er:YAG laser|Er.YAg laser treatment will be provided on the implant surface.
75324196|NCT03801187|Procedure|Air-Powder|An air powder device will be treatment will be provided on the implant surface.
75630402|NCT02858700|Biological|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP|
75630403|NCT04157452|Procedure|flexible ureteroscopy|flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
75630404|NCT02819856|Drug|Placebo|0 mg SPI-1005 bid po x 21d
75781761|NCT01238042|Drug|HPPH|3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
75630405|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x1|200 mg SPI-1005 bid po x21d
75781762|NCT03484910|Other|Exercise therapy|Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
75781763|NCT01313026|Procedure|Percutaneous nerve evaluation|Implantation of a nerve stimulator to stimulate the sacral nerve plexus
75917114|NCT02069223|Procedure|BPD-DS|
75917115|NCT02069301|Behavioral|Integrated Depression/Microfinance Group|LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
75917116|NCT02069301|Other|Treatment as Usual|National Guideline for antidepressant care
75917117|NCT02069301|Other|Livelihood Support|Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
75917118|NCT03035656|Drug|Ropivacaine|Administration of Ropivaciane via epidural injection intra-operatively
75917119|NCT03035656|Other|Saline|Administration of saline via epidural injection intra-operatively
75917120|NCT03441230|Device|Balloon characteristics|Different size balloon
75917121|NCT03441074|Behavioral|enhanced olfactory stimuli|Patients in intervention group will get enhanced olfactory stimuli during perioperative period (7 days before and after the surgery), by using portable scented sachets.
75917122|NCT02069535|Biological|AVANZ Cupressus|AVANZ Cupressus
75917123|NCT04829032|Procedure|Hartmann's procedure|Hartmann's procedure
76075612|NCT04089202|Other|Standard of care|Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
75781764|NCT01144910|Other|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
75917124|NCT03444116|Diagnostic Test|Motion Analysis|Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
75324197|NCT00809185|Drug|everolimus|Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
75917125|NCT03444116|Diagnostic Test|sterEOS Imaging of Lower Extremities|Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
75917126|NCT03444116|Behavioral|Surveys|9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
75917127|NCT04829266|Behavioral|mental simulation|Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.
76075613|NCT00879190|Drug|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
76075614|NCT00879190|Drug|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
76075615|NCT01903811|Drug|Carfilzomib|Given IV
75324198|NCT00809185|Other|laboratory biomarker analysis|Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
75630406|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x2|400 mg SPI-1005 bid po x 21d
75630407|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x3|600 mg SPI-1005 bid po x 21d
75630408|NCT02630290|Drug|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
75781765|NCT01144910|Other|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
75781766|NCT01234298|Drug|SPD489 Low-Dose|SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
75917128|NCT03443960|Drug|TNX-102 SL 5.6 mg|Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
75917129|NCT03443960|Drug|Amrix 30 mg|Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.
76075616|NCT01903811|Drug|Dexamethasone|Given IV
76075617|NCT01903811|Other|Laboratory Biomarker Analysis|Correlative studies
75324199|NCT00809185|Procedure|Bone marrow aspirate/biopsy|Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
75324200|NCT03800953|Drug|Avelumab|The study treatment comprises two phases, the concurrent immune-chemoradiotherapy (Ave-PF-CRT) phase and the immune-chemotherapy (Ave-PF) phase. All the subjects will receive Avelumab at both phases.
75324201|NCT03809663|Drug|Tezepelumab|Solution for injection
75324202|NCT03809663|Other|Placebo|Placebo solution for injection
75467897|NCT01934270|Other|Anaerobic Test|To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
75467898|NCT01934283|Device|urine folly catheter|
75630409|NCT02630290|Drug|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
75630410|NCT04157530|Device|wang-bu-liu-xing|wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
75630411|NCT04157530|Device|acupuncture|acupuncture applied to Qingming and Qiuhou with Der-qi
75630412|NCT04157530|Device|Electroacupuncture|acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
75630413|NCT02856906|Other|occlusal adjustment|
75630414|NCT00668356|Drug|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
76075618|NCT00880360|Drug|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
76075619|NCT01709149|Drug|CK-2017357|CK-2017357 125 mg tablets twice daily
76075620|NCT01709149|Other|Placebo tablets|Tablets
75630415|NCT00668356|Drug|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
75630416|NCT00952848|Other|questionnaire administration|Pain Rating Score
75630417|NCT00952848|Other|Sensory Neuropathy Scale instrument|ECOG Common Toxicity Criteria for Sensory Neuropathy scale
75630418|NCT00952848|Other|Quality of Life instrument|Uniscale 0-100 scale global quality of life
75630419|NCT00952848|Device|MC5-A Scrambler device|Electrical stimulation for 60 minutes
75630420|NCT00664222|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
75781767|NCT01234298|Drug|SPD489 High-Dose|SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
75917130|NCT02069691|Device|virtual reality-cycling training system|
75917131|NCT03035734|Drug|BMS-986141 Form A Tablet|tablet
75917132|NCT03035734|Drug|BMS-986141 Form B tablet (low dose)|tablet
75917133|NCT03035734|Drug|BMS-986141 Form B tablet (high dose)|tablet
75917134|NCT03788187|Other|Blood test sample|
76075621|NCT01709149|Drug|Riluzole|Tablets
75917135|NCT03788187|Other|Peritumoral adipose tissue sample|
75917136|NCT05616754|Biological|Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|The antigen protein of this product is designed to be expressed in tandem with Delta variant R319-N356 and Omicron variant R319-N356. The antigen is called DO-RBD for short.
76075622|NCT05214196|Drug|Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)|SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.
76075623|NCT05213026|Procedure|Regenerative endodontics|Regenerative endodontic procedure with 3 Mix-MP
76075624|NCT01568593|Device|T2750|1 drop in each eye 3 to 6 times daily during 84 days
76075625|NCT01568593|Device|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
75630421|NCT04157374|Other|Action Observation training|They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.
75630422|NCT04157374|Other|Active Exercises|Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
75630423|NCT00668512|Biological|Antimelanoma injection of GSL alpha-Gal|Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
75630424|NCT00664300|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
75630425|NCT00668590|Behavioral|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
75630426|NCT00668590|Behavioral|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
75781768|NCT01234298|Drug|Placebo|Placebo capsule taken once-daily for up to 26 weeks
75781769|NCT05308342|Procedure|transplantation of human UC-MSCs into ovaries of POI patients|UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance.
75781770|NCT05308342|Drug|hormone replacement treatment|Routine estrogen progesterone replacement periodic therapy
75630427|NCT02856516|Other|Boost Glucose Control (A)|Oral nutrition supplement
75630428|NCT02856516|Other|Boost Glucose Control (B)|Oral nutrition supplement
75630429|NCT02856516|Other|Boost Original|Oral nutrition supplement
75630430|NCT04280250|Other|Volitional Help-Sheet|Self-help sheet in order to form implementation intentions
75917137|NCT05616754|Biological|Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|This strain was made from the NCP-RBD receptor binding region of the spike glycoprotein of novel coronavirus expressed in recombinant CHO cells, which was purified and added with aluminum hydroxide adjuvant
76075626|NCT05311228|Drug|Azithromycin Powder|Azithromicyn intravena for 14 days
76075627|NCT04382014|Dietary Supplement|MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
76075628|NCT01683565|Drug|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
76075629|NCT01683565|Other|Canola Oil Placebo|2.5mL per day for 90 days
75630431|NCT04280250|Other|Control condition|Psychoeducational self-help sheet
75630432|NCT02858544|Other|The Concussion Identification Index|Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
75630433|NCT02858544|Other|ImPACT|Patient- completed computerized neurocognitive test battery
76075630|NCT00882778|Drug|eptacog alfa (activated)|Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
76075631|NCT00892606|Drug|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
76075632|NCT00892606|Drug|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
76075633|NCT04416035|Biological|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
75630434|NCT02630134|Other|These patients receive the Baeta device and take it home|
75630435|NCT00952614|Device|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
75630436|NCT00668668|Drug|Lactic acid (Dermacid)|
75781771|NCT01585922|Procedure|noninvasive positive pressure ventilation (NPPV)|Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.
75917138|NCT03440996|Other|Clinpro™ 5000|Clinpro™ 5000 with 1.1% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
75917139|NCT03440996|Other|Clinpro™ Tooth Crème|Clinpro™ Tooth Crème with 0.21% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
75917140|NCT03440996|Other|MI-Paste Plus|MI-Paste Plus is a widely used anti-cavity toothpaste on the market and it is used as a control group in this study.
75917141|NCT03440840|Procedure|Transcranial Direct Current Stimulation (tDCS)|Application of a small electrical current (1-2 mA) across the head.
75917142|NCT03440840|Behavioral|Computer-based Cognitive Training|Use of computer-delivered games or exercises with the goal of improving cognitive performance.
75917143|NCT03440840|Behavioral|Watching Educational Videos|Watching educational videos and answering questions about them
75917144|NCT03440762|Behavioral|AF awareness education|Participants will receive education about a description of AF, complications, recognition of signs and symptoms of AF, pulse taking, and how to recognize an irregular pulse
75917145|NCT04808830|Other|Evaluation of musculoskeletal pain prevalence|Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.
75917146|NCT04808830|Other|Evaluation of quality of life|Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.
75917147|NCT04808830|Other|Evaluation of functional exercise capacity|Functional exercise capacity will be evaluated using 6-min walk test.
76075634|NCT04416035|Biological|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
75630437|NCT00911859|Drug|Siltuximab11 mg/kg|Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
76075635|NCT04416035|Drug|Carboplatin|Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
75630438|NCT00911859|Drug|Siltuximab 8.3 mg/kg or 11 mg/kg|Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
75630439|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
75630440|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
75630441|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
75781772|NCT01585922|Procedure|invasive mechanical ventilation|Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
75781773|NCT03332212|Drug|Empagliflozin|12 weeks
75917148|NCT04808830|Other|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form
75917149|NCT03436004|Device|Colonoscopy|Patients undergoing screening colonoscopy
75917150|NCT03436004|Device|Colonoscopy with specific device (Endocuff Vision)|Patients undergoing screening colonoscopy using the Endocuff Vision device
75630442|NCT00911859|Drug|Melphalan|Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
75630443|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
75781774|NCT03332212|Drug|Placebo|12 Weeks
75781775|NCT01144988|Drug|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
75781776|NCT01779388|Procedure|Bronchoscopy|During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
75781777|NCT01140464|Other|Collaborative care|Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
75781778|NCT01140464|Other|Enhanced Usual Care|Provision of screening results to provider, teen and parent with recommendation to seek further care
75781779|NCT04872842|Other|Obervation|This study is an observational study without any intervention
75781780|NCT03331666|Drug|Evolocumab|140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
75917151|NCT04808128|Other|Drink A + SC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with simple carbohydrates.
75917152|NCT04808128|Other|Drink B + SC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with simple carbohydrates.
75917153|NCT04808128|Other|Drink C + SC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with simple carbohydrates.
76075636|NCT04416035|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
75917154|NCT04808128|Other|Drink A + CC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with complex carbohydrates.
75917155|NCT04808128|Other|Drink B + CC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with complex carbohydrates.
75917156|NCT04808128|Other|Drink C + CC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with complex carbohydrates.
75917157|NCT04427878|Procedure|biopsies of subcutaneous adipose tissue|Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue
75630444|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
75917158|NCT03440684|Other|Exercise|"At the beginning of the training, participants were informed about the anatomy and biomechanics of core muscles and the effectiveness core stabilization exercises.~In all sessions, 5 minutes warm-up exercises and 5 minutes cool-down exercises were done before training. The exercises were first shown by the physiotherapist 2 to 3 repetitions and then the participants performed the exercise 10 to 12 repetitions.~Participants were included clinical pilates exercises for 6 weeks, which would be 3 days per week. Exercise programme were managed by one and the same physiotherapist. Each week the level of difficulty of the exercises was increased according to the tolerance of the participants and new exercises were added to the program."
75917159|NCT04816942|Biological|Convalescent Plasma|Two units of ABO compatible COVID-19 convalescent plasma will be administered.
75917160|NCT03443882|Dietary Supplement|Astaxanthin|an oral dose form
75324203|NCT04349787|Other|Computer-aided diagnosis (CADx)|Optical diagnosis of colorectal polyps made with computer-aided diagnosis (CADx) using state-of-the-art machine learning methods and deep learning architectures.
75324204|NCT04349787|Other|BLI Adenoma Serrated International Classification (BASIC)|Optical diagnosis of colorectal polyps made with BLI Adenoma Serrated International Classification (BASIC), both by exert endoscopists and novices.
75630445|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
75630446|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
75630447|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally according to the package insert.
75781781|NCT01234376|Device|Confocal laser endomicroscopy|Confocal laser endomicroscopy
75781782|NCT03391622|Device|Calibrated Automated Thrombogram|blood samples will be collected . Thrombin generation in platelet-poor plasma will be measured by means of the Calibrated Automated Thrombogram (CAT).
75781783|NCT03867916|Behavioral|Patient Navigation Program|Use patient navigation program
75781784|NCT03867916|Other|Quality-of-Life Assessment|Ancillary studies
75781785|NCT03867916|Other|Survey Administration|Ancillary studies
75781786|NCT03847714|Dietary Supplement|Omni-Biotic Stress Repair|The probiotic supplement is a commercially available food for special medical purposes and includes 9 bacterial strains with at least 7.5 billion organisms (7.5 × 109 Colony Forming Units/g) per 1 portion (= 3 g).
75630448|NCT00664612|Device|AirTraq|Laryngoscopy with AirTraq
75781787|NCT03847714|Dietary Supplement|placebo|similar looking and tasting powder
75630449|NCT00956592|Device|CMAC video laryngoscope|Intubation utilizing the assistance of video enhancement
75781788|NCT04828538|Dietary Supplement|Vitamin D|Daily 4000 IU Vitamin D for 60 days
75781789|NCT04828538|Dietary Supplement|Omega DHA / EPA|Daily 1000mg Omega DHA/EPA for 60 days
75781790|NCT04828538|Dietary Supplement|Vitamin C, Vitamin B complex and Zinc Acetate|"Combination 1000 mg Vitamin C, Vitamin B complex** and Zinc Acetate, 100 mg/day for 60 days~**(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)"
75781791|NCT04828538|Other|Placebo|Placebo
75781792|NCT01145144|Drug|dehydroepiandrosterone crystalline fine powder|
75917161|NCT04797988|Device|eon® FR 1064 nm device|The subject will be treatment area - flanks, will be treated with the eon device.
75917162|NCT04451174|Drug|Prednisone|Prednisone 40 mg days 1 to 4. Then, prednisone 20 mg days 5 to 8.
75324205|NCT00795769|Drug|ondansetron|Given IV
75324206|NCT00795769|Other|survey administration|Correlative studies
75324207|NCT00795769|Procedure|management of therapy complications|Ondansetron IV
75324208|NCT00796627|Genetic|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
75630450|NCT00956592|Device|Macintosh laryngoscope|Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
75630451|NCT00668824|Drug|Vasovist|
75630452|NCT02632162|Other|screening|Screening for sleep disordered breathing with the ApnoeLink Air device
75630453|NCT04231383|Other|dental caries, growth parametres|"The comparison of growth parameters before and after 6 months of treatment of dental caries will be compared.~Children's Sleep Habits Questionnaire and Early Childhood Oral Health Impact Scale will be compared before and at the 6th month of dental treatment."
75630454|NCT02739555|Device|Thermal destruction with radiofrequency or laser|
75630455|NCT02739555|Drug|Acide Zoledronique|
75630456|NCT03659955|Other|Autologous blood applied to dry eye|See previous description for the study arm.
75630457|NCT02725593|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
75630458|NCT02725593|Drug|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
75781793|NCT03331042|Drug|SM-1|3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
75781794|NCT03331042|Drug|D+Z|2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
75781795|NCT03331042|Drug|D+L|2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
75630459|NCT00911625|Drug|0.5 units/kg daily insulin|Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
75630460|NCT00911625|Drug|0.25 units/kg daily insulin|Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
75630461|NCT00596752|Drug|Alprostadil|"Active Substance: Prostaglandin E1~Pharmaceutical Form: solution for infusion~Concentration: 40 μg b.d.~Route of Administration: intravenous infusion"
75324209|NCT00796627|Other|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
75324210|NCT01975935|Drug|Amlexanox|25 mg amlexanox tablets blinded by encapsulation
75324211|NCT01975935|Drug|Placebo|placebo sham blinded by encapsulation in the same capsules as the study drug arm
76075637|NCT04381858|Drug|Plasma from COVID-19 convalescent patient|"Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~Further confirmation of a negative PCR test for COVID-19~In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~When quantification of IgG antibodies for COVID-19 is available a title > 1: 640 will be required for inclusion.~Apheresis will be used as the only method for plasma extraction."
75781796|NCT03331042|Drug|Placebo|Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.
76075638|NCT04381858|Drug|Human immunoglobulin|Human immunoglobulin 0.3 gr/kg/day (5 doses)
75630462|NCT00596752|Other|Placebo|"Active Substance: Lactose~Pharmaceutical Form: solution for infusion~Concentration: 40 μg b.d.~Route of Administration: intravenous infusion"
75781797|NCT03762668|Device|Modified delefilcon A contact lenses|Spherical soft daily disposable contact lens
75781798|NCT03762668|Device|Delefilcon A contact lenses|Spherical soft daily disposable contact lens
75781799|NCT03638206|Biological|CAR-T cell immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
75781800|NCT03728842|Other|Blood collection for laboratory studies|Peripheral whole blood will be collected
75781801|NCT03728842|Other|Data collection from medical record|Clinical data such as demographics and cancer characteristics, history and treatment will be collected
75781802|NCT00566488|Biological|Thymus/Parathyroid Transplantation|Thymus tissue, thymus donor, mother of thymus donor, & parental parathyroid donor screened for transplant safety. Depending on T cell phenotype & function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre & post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis & graft rejection.
75781803|NCT03762200|Device|SURGICEL Powder|SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material
76075639|NCT04381390|Dietary Supplement|Whole egg and resistance training|This intervention consisted of whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
76075640|NCT04381390|Dietary Supplement|Egg whites and resistance training|This intervention consisted of egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
76075641|NCT04088422|Procedure|peripheral blood collection|peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
75324212|NCT04345679|Biological|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~200 mL over 4 hours
75324213|NCT02305017|Drug|BIA 9-1067|BIA 9-1067 50 mg
75324214|NCT02305017|Drug|Paracetamol|Paracetamol 1g
75324215|NCT00249821|Drug|Saizen®|Saizen® [somatropin (recombinant deoxyribonucleic acid [rDNA] origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
75324216|NCT00249821|Drug|Saizen®|Saizen® [somatropin (rDNA origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
75630463|NCT04202523|Radiation|Radiofrequency ablation|Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.
75630464|NCT04202523|Device|IMRT & SBRT|Tumor radiation therapy is a local treatment method using radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioactive isotopes and x-rays, electron beams, proton beams, and other particle beams produced by various types of x-ray therapy machines or accelerators. Current mainstream radiotherapy technologies include stereotactic radiation therapy (SRT). Stereotactic radiation therapy (SRT) includes three-dimensional conformal radiation therapy (3DCRT) and three-dimensional conformal intensity modulated radiation therapy (IMRT).
75630465|NCT04151277|Drug|FOLFOX-A|Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
75630466|NCT04151277|Drug|Gemcitabe and Abraxane|Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4
75324217|NCT01976871|Drug|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
75324218|NCT03602781|Drug|Placebo|Placebo at a dose setting of 75 mcg/kg IBW/hr
75324219|NCT03602781|Drug|iNO|iNO at a dose setting of 75 mcg/kg IBW/hr
75781804|NCT04943302|Drug|Bendamustine Hydrochloride|To be given by IV at 70mg/m2 on cycle days 1 and 8 for up to 6 cycles
76075642|NCT05117086|Behavioral|DASH diet|Nutrition education and counseling on DASH diet, behavioral and lifestyle modifications
75630467|NCT04151277|Drug|G-CSF|Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
75630468|NCT00958074|Drug|vorinostat|Given PO
75630469|NCT00958074|Other|flow cytometry|correlative study
75781805|NCT04943302|Drug|Isatuximab|To be given by IV at10mg/kg IV on cycle 1 days 1,8,15, and 22; cycle 2-6 days 1,8; and cycle 7-12 days 1
75781806|NCT01234454|Drug|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
75781807|NCT01234454|Drug|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
75781808|NCT03638518|Other|Acupuncture|Acupuncture 5 weeks treatment. 2 sessions a week (30 minutes each session)
75781809|NCT03638518|Other|Physiotherapy|Core stability exercises programme. 2 sessions a week (30 minutes each session) during 5 weeks
75781810|NCT01143350|Other|Bras A (EHPAD Training and stimulation)|"EHPAD of the group of Training / Stimulation will benefit:~after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
75781811|NCT01143350|Other|EHPAD Control|EHPAD of the reference group, will have their habitual functioning
75781812|NCT03711370|Other|Clear Bottle|These mothers received usual care from their pediatric providers and each mother was given 12 conventional, clear bottles of various sizes (4-12 ounces) that were compatible with a variety of different nipples manufactured by leading bottle companies. Mothers were also given handouts about proper formula preparation and paced bottle-feeding, which included messages about feeding in response to infant cues.
75781813|NCT03711370|Other|Opaque Bottle|These mothers received everything provided to the clear group, but instead received 12 opaque bottles of various sizes (4-12 ounces). These bottles were stainless steel and compatible with a variety of different nipples manufactured by a leading bottle company. Mothers in the intervention group also received an additional handout that contained safety tips for their opaque bottles (e.g., never microwave your bottle).
75781814|NCT03379844|Device|Holmium-166 radioembolization|An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.
75630470|NCT00958074|Other|laboratory biomarker analysis|correlative study
75630471|NCT00660868|Drug|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
75630472|NCT02632240|Other|Surgery:The tunnel technique for covering gingival recession|The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
75781815|NCT04781452|Other|standard treatment|there ist no Intervention but our standart Treatment in the center
75781816|NCT01145456|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
75781817|NCT01145456|Drug|gemcitabine hydrochloride|Given IV
75781818|NCT01145456|Other|pharmacological study|Correlative studies
75781819|NCT01145456|Other|laboratory biomarker analysis|Correlative studies
75781820|NCT04939636|Dietary Supplement|Vitamin D3 capsules 4000IU/100µg.|Vitamin D3 supplementation
75781821|NCT04939636|Dietary Supplement|Vitamin D3 capsules 600IU/15µg.|Vitamin D3 supplementation
76075643|NCT01903031|Device|Nuvaring|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
75324220|NCT02280239|Drug|Acetaminophen|one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
76075644|NCT01903031|Drug|EFV|Participants received EFV 600 mg daily with two or more NRTIs
76075645|NCT01903031|Drug|ATV/r|Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
76075646|NCT01903031|Drug|TDF|Participants received 300 mg of tenofovir in Arm C
76075647|NCT01903031|Drug|NRTIs|Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
75630473|NCT04343157|Radiation|Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)|In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.
75630474|NCT00664690|Drug|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
75630475|NCT00664690|Drug|placebo|placebo given preop and BID postop
75630476|NCT00664768|Dietary Supplement|Neocate Infant|minimum of 8 fl. oz daily
75630477|NCT00664768|Dietary Supplement|new Neocate|minimum of 8 fl oz daily
76075648|NCT00883168|Drug|Placebo|Placebo
76075649|NCT00883168|Drug|azelastineHcl|azelastine hydrochloride 548 mg
76075650|NCT00883168|Drug|fluticasone propionate|fluticasone propionate 200 mcg
75324221|NCT02280239|Drug|Placebo|one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
75917163|NCT04807426|Other|Multi Sensory stimulation exercises|Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity is added by increasing speed of task performance. Conservative Management:Passive stretching exercises for paretic upper extremity muscles .Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
75917164|NCT04807426|Other|Task Oriented Exercises|"Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
75917165|NCT04807426|Other|Task-oriented exercises and Multisensory stimulation Exercises|"Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
75917166|NCT03433430|Device|truSculpt|Subjects will receive utreatments and will be followed at 12 weeks post final treatment.
75917167|NCT04828720|Drug|ozonated oil|All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
75917168|NCT03435770|Device|EUSRA RFA needle|A 19-gauge RFA electrode and a RF generator with a electrode that is needle-shaped and echogenic that allows EUS guided puncture of the target lesion. The active electrode tip is 1 cm in length. During ablation, the RF electrode is cooled and perfused internally with circulating chilled saline solution (0°C) delivered via a pump to maintain a constant temperature. A setting of 50W energy would be used for RFA and the duration of application is 10 seconds. Sequential applications of up to 7 times per session are allowed for complete ablation of the lesions.
75917169|NCT04828876|Behavioral|Yoga practice|"Yoga basically consists of breathing techniques, asanas (postures) and relaxation phases.~Practiced Yoga Stages; 10 min. standing breathing exercise, 10 min. breathing exercise with seated asana, 10 min. lying down breathing exercise with asana, 20 min. sitting breathing exercise, 10 min. The session will be completed in 60 minutes, including deep relaxation stages by lying down. At the end of each session, patients' feedback about yoga practice will be received."
76075651|NCT00883168|Drug|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
76075652|NCT01616693|Dietary Supplement|Probiotic|A capsule that contains at least 1 x 10^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.
76075653|NCT01616693|Dietary Supplement|Zinc|Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.
76075654|NCT01616693|Dietary Supplement|Probiotic placebo|The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.
76075655|NCT01616693|Dietary Supplement|Zinc placebo|The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.
76075656|NCT01616693|Biological|Rotavirus vaccine|1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
76075657|NCT01616693|Biological|Oral polio vaccine|A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
76075658|NCT00883246|Device|SilverHawk & TurboHawk Peripheral Plaque Excision System|Removal of atherosclerotic plaque from artery walls.
76075659|NCT04415645|Drug|[14C]-VVZ-149|A single IV infusion of radio-labeled VVZ-149
75324222|NCT01993875|Drug|Lubiprostone|Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
75630478|NCT04202913|Behavioral|Coaching|Child will receive 1:1 coaching with health coach.
75630479|NCT00809965|Drug|Rivaroxaban 2.5 mg|One tablet twice daily
75630480|NCT00809965|Drug|Rivaroxaban 5 mg|One tablet twice daily
75324223|NCT01993875|Drug|Placebo|Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
75630481|NCT00809965|Drug|Placebo|One placebo tablet twice daily
75630482|NCT00809965|Drug|Standard of care|
75630483|NCT02630914|Device|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
75630484|NCT04338165|Drug|Evolocumab 140 MG/ML [Repatha]|3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
75630485|NCT04054804|Diagnostic Test|D-Foot|A digital foot check i assessed by using the software D-Foot.
75781822|NCT01238276|Drug|Cefazolin|Cefazolin is approved for clinical use for some bacterial infections. The standard routes of administration are Intramuscular (IM) and intravenous (IV). For this study, the route of administration will be delivered using the Silberg TPS, which delivers the cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The concentration delivered is one gram/100 ml saline. Cefazolin can safely be given IM at the much higher concentration of 1 gram/2.5 ml of saline. The maximum dose that may be administered is 3 grams in 300 ml, which is within the approved guidelines of a daily dose. The concentration of antibiotic will be the same; only the dose may vary depending on the size of the wound or area of induration. Each subject will receive only one treatment in this study.
75917170|NCT03440606|Behavioral|Mindful-Compassion Art Therapy Supervision|"Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief)."
75324224|NCT03809741|Other|Bundled L&D Infection Prevention Interventions|"The following bundle of infection prevention interventions will be implemented at each study site for 12 weeks:~Education: 2 day module of Infection Prevention and Control (IPC) training and education at the beginning of the period, with specific information pertaining to labor and delivery. A refresher course will be administered at week 6.~Feedback: Monthly feedback sessions detailing IPC practices~Reminders: Visual poster reminders on hand hygiene and daily SMS reminders on best practices for peripartum and postnatal care.~Alcohol Hand Rub (AHR) supply: Provision of AHR, produced by WHO standards and guides in collaboration with district pharmacy"
75324225|NCT00796705|Drug|Adalimumab|40 mg injection of adalimumab administered subcutaneously
75324226|NCT00796705|Drug|Adalimumab placebo|1.0 ml .9% saline placebo administered subcutaneously
75324227|NCT00796705|Drug|Etanercept|50 mg dimeric fusion protein administered subcutaneously
75630486|NCT04117269|Device|External shoe lift|Height compensation will be made with cork or EVA (polyurethane + Ethylene Vinyl Acetate) depending the characteristics of the shoe. It will be made by the same orthophaedic technician. The prescription of the heigh of the lift will be made with the patient in a barefoot standing position, a calibre will be used to mark the femoro-tibial joint in both lower limbs in order to rule out the asymmetry. After this, the patient will shod the offloading device in the ulcerated feet and their conventional footwear in the other foot (with the use of their own foot orthosis). 5 millimeters splints will be added under the non affected footwear until the previous mark in both limbs been balanced. The difference in the heigh between limbs will be assessed measuring all the splints used previously
75630487|NCT00664846|Drug|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
75630488|NCT00664846|Drug|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
75630489|NCT00669058|Drug|Lactic acid (Dermacid)|
75781823|NCT01238276|Device|Silberg Tissue Preparation System|The TPS is FDA cleared for the subcutaneous infusion and ultrasonic dispersion of tumescent fluid excluding the parenteral delivery of drugs. Under this study, the TPS is a device to deliver cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The TPS consists of a medical grade peristaltic pump that is used to infuse antibiotic solution using a sterile blunt-tipped infusion cannula into a superficial subcutaneous plane. After the cannula has been removed, high frequency external ultrasound is delivered transcutaneously over the area of infusion in order to disperse the antibiotic solution. The power density is within the range allowed for physical therapy.
75781824|NCT03621124|Procedure|Resting Energy Expenditure|During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.
75781825|NCT03621124|Other|Thermal Comfort Questionnaire|Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.
75781826|NCT01145534|Drug|glibenclamide|5 mg as pills, taken daily during the morning for 60 days
75781827|NCT01145534|Other|medicinal plant infusion|INfusion fo Cissus verticillata L., 1 g in 150 mL water, ingested daily for 60 days.
75781828|NCT04652674|Behavioral|Telemedicine visit|A postoperative visit with the patient's surgeon conducted remotely via audio/video smartphone app
75781829|NCT04652674|Behavioral|In-person postoperative visit|A standard-of-care in-person postoperatively visit with the patient's surgeon
75781830|NCT01145612|Drug|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
75781831|NCT01145612|Drug|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
75781832|NCT01238354|Behavioral|With friend|
75781833|NCT01238354|Behavioral|Without friend|
75917171|NCT04828798|Device|Deep brain stimulation of the VIM Thalamic nuclei|Deep brain stimulation of the thalamus, in a directional and nondirectional manner
75917172|NCT04828642|Dietary Supplement|Vitamin C and vitamin E|1000 mg 235 mg
75917173|NCT04828642|Dietary Supplement|Placebo|Placebo
75917174|NCT03433352|Drug|Methimazole Pill|Patients who developed GD received methimazole treatment
75917175|NCT03433352|Drug|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
76075660|NCT00893074|Drug|Dronabinol 30mg/day|10mg dronabinol administered 3x/day for 5 days
76075661|NCT00893074|Drug|Dronabinol 60mg/day|20mg dronabinol administered 3x/day for 5 days
76075662|NCT00893074|Drug|Dronabinol 120mg/day|40mg dronabinol administered 3x/day for 5 days
76075663|NCT00893074|Drug|Placebo|placebo dronabinol administered 3x/day for 5 days
76075664|NCT00884806|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
75324228|NCT03800875|Drug|27-hour inpatient intervention|Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin and pramlintide will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
76075665|NCT00884806|Device|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
75324229|NCT02148523|Behavioral|Comparison to peers|
75324230|NCT02148523|Behavioral|Adherence feedback|
75324231|NCT02148523|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
75324232|NCT00809809|Drug|Zicam (Ionic zinc)|33mmol/l of ionic zinc
75324233|NCT00809809|Drug|placebo|placebo swab
75324234|NCT04384471|Other|Online survey|Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
75467899|NCT01934322|Other|Case Management|"Furnish specific assistance and to provide referrals for the patients:~If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
75467900|NCT01934348|Behavioral|Psychological First Aid|
75630490|NCT04229745|Device|THRIVE pre-oxygenation|Clinical Trial of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Oxygen in Women having Planned Caesarean Delivery
75781834|NCT05293366|Diagnostic Test|Assessments of endocrinological phenotypes of LO-COCO patients|Assessment of:thyroid-stimulating hormone(TSH),free triiodothyronine (FT3), free thyroxine (FT4),calcitonin,antibodies against thyroglobulin (AbTG) and against thyroperoxidase (AbTPO),adrenocorticotropic hormone (ACTH),cortisol, luteinizing hormone (LH),follicle-stimulating hormone(FSH),Testosterone,17-beta estradiol,sex hormone binding globulin (SHBG),progesterone, prolactin (PRL), growth hormone (GH), insulin growth factor-1 (IGF-1), dehydroepiandrosterone sulphate (DHEAS),delta 4-androstenedione,aldosterone,renin,glycemia, insulinemia, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, HbA1c, vitamin D, adiponectin, irisin, IL-6.Thyroid and ovarian ultrasounds, pituitary and adrenal MRI will be performed as well. Body composition will be assessed with bioimpedance analysis and DXA scans.Female sexual dysfunctions will be evaluated with Female Sexual Function Index (FSFI), Sexual Inhibition and Sexual Excitation Scale (SIS/SES),Body Uneasiness Test (BUT).
75324235|NCT03839797|Behavioral|Cadet Healthy Personal Skills|7.5 hour skills training group intervention
75324236|NCT03839797|Behavioral|Standard Health Education|Standard Health Education
75324237|NCT00248651|Drug|Amitriptyline|25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
75324238|NCT00248651|Drug|Escitalopram|10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
75467901|NCT01934348|Behavioral|Usual victim advocacy Services|
75467902|NCT01934361|Drug|buparlisib|Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
75467903|NCT01934361|Drug|carboplatin|Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
75467904|NCT01934361|Drug|lomustine|Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
75630491|NCT00597376|Other|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
75630492|NCT00597376|Other|Cerefolin NAC placebo|Placebo tablet once a day
75630493|NCT00669136|Drug|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
75630494|NCT00661024|Procedure|intraoperative RLN visualization|intraoperative RLN visualization
75630495|NCT00661024|Procedure|intraoperative neuromonitoring of the RLN|IONM
75630496|NCT00669292|Biological|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
75917176|NCT04828564|Drug|Ribavirin Capsules|Ribavirin 200 mg capsules
75917177|NCT04828564|Drug|Favipiravir|Favipiravir 200 mg tablets
75917178|NCT04449692|Drug|Dasiglucagon|Abdominal s.c. administration
75917179|NCT04449692|Other|Carbohydrate (dextrose tablets)|Oral administration
75917180|NCT04798300|Procedure|Newly Introduced Gradient Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Newly Introduced Gradient Monolithic Zirconia to measure wear
75917181|NCT04798300|Procedure|Full Strength Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Full Strength Monolithic Zirconia to measure wear
76075666|NCT00884806|Device|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
75630497|NCT00913783|Drug|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
75630498|NCT00913783|Drug|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
75630499|NCT00661102|Drug|Corticosteroids|As prescribed
75630500|NCT00661102|Drug|Placebo|As prescribed
75630501|NCT00661102|Drug|capecitabine [Xeloda]|As prescribed
75630502|NCT00661102|Drug|dexpantenol [Bepantol]|As prescribed
75324239|NCT00248651|Drug|Placebo|Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
75467905|NCT01934361|Drug|placebo|Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
75467906|NCT01934374|Behavioral|Task-Oriented Lower Extremity Strengthening Training|"On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.~The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity."
75467907|NCT01934413|Behavioral|Technology-Enhanced Transitional Palliative Care|The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.
75781835|NCT05293366|Diagnostic Test|Assessment of muscular phenotypes of LO-COCO patients|Questions will be collected regarding the tolerance to physical activity and modifications after diagnosis of Covid. Muscular strength will be assessed by means of tests (Medical Research Council Scale) and dynamometers. Balance will be assessed with a Romberg test, tolerance to stress will be assessed by means of cyclometer.
75467908|NCT01934413|Other|Usual Standard of Care|Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
75630503|NCT05297383|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid.|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA).
75630504|NCT05297383|Dietary Supplement|Safflower Oil|4 grams safflower oil (AlaskOmega®) per day.
75781836|NCT05293366|Diagnostic Test|Assessment of neuropsychiatric phenotypes of LO-COCO patients|Validated questionnaires will be collected to investigate depression (Beck Depression Inventory-II, BDI-II), apathy (Apathy Evaluation Scale, AES), anxiety (Test Anxiety Inventory, TAI), attention and cognitive functions (Montreal Cognitive Assessment and Quick Mild Cognitive Impairment). Fatigue will be assessed by Fatigue Rating Scale (FRS) and Fatigue Severity Scale (FSS). Muscle power will be assessed by six-minute walking test and sit and stand up test. The presence of myopathy will be evaluated by mean electrophysiological study.
75630505|NCT05297383|Behavioral|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
75630506|NCT05297383|Behavioral|Flexibility Training|30 min of stretching 3 days/week for 6 weeks
75630507|NCT00665158|Behavioral|UC (Usual Care Group)|Usual Care Group - Treatment Implementation by Primary Care Physician
75630508|NCT00665158|Behavioral|BI (Behavioral Intervention Group)|Behavioral Intervention Group - Treatment Implementation by Health Educator
75630509|NCT02609347|Other|Manual Therapy Group|The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
75630510|NCT02609347|Other|Control Group|The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
75781837|NCT05293366|Procedure|Muscle biopsy|Muscle biopsy will be performed upon need.
75324240|NCT03839719|Procedure|Group PI|Before rinsing with the mouthrinse, Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
75630511|NCT00911638|Behavioral|Patient decision aid|"Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
75781838|NCT05293366|Diagnostic Test|Assessment of pulmonary phenotypes of LO-COCO patients|Modified Medical Research council questionnaire will be administered for evaluating of the dyspnoea level. Complete respiratory status assessment, including global spirometry, CO lung diffusion capacity and arterial gases analysis will be run. HRCT - high resolution CT scan of the chest - will be performed in selected cases to rule out the eventual sequelae of SARS-Cov2 related pneumonia.
75781839|NCT05293366|Diagnostic Test|Assessment of cardiological phenotypes of LO-COCO patients|Cardiological assessment will be run upon data collected from: Short Form-36 Health Survey (SF36), echocardiogram at rest and during stress tests, six-minute walking test, N-terminal fragment brain natriuretic peptides (NT-proBNP)
75781840|NCT05293366|Diagnostic Test|Assessment of vascular phenotypes of LO-COCO patients|The assessment of the potential post-thrombotic vascular damage will comprise the investigation of prevalence of previously unknown deep venous thrombosis by ultrasonography.
75781841|NCT05293366|Diagnostic Test|Assessment of dermatological phenotypes of LO-COCO patients|Dermatology evaluation will account on: thrichoscopy, dermoscopy, onychoscopy and capillaroscopy, confocal microscopy, skin ultrasonography
75781842|NCT05293366|Procedure|Tissue biopsy|Tissue biopsy will be performed upon need.
76075667|NCT00884806|Device|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
75917182|NCT05619406|Device|Riskometer Application|The intervention group participants at baseline will be assessed by installing a riskometer app on their mobile phones to calculate their global stroke risk score. They will be shown their risk scores and the specific risk factors identified through the screening. They will be counselled and supported to manage their risk factors through lifestyle changes and visit their healthcare provider for appropriate care.
75917183|NCT05619406|Behavioral|Routine Clinic Therapy|After their assessment by the blinded adjudicator, the controls will visit the study doctor to obtain the routine clinic therapy and then will be allowed to go home.
75917184|NCT03435302|Drug|Temozolomide Plus Cisplatin|"Temozolomide is the oral analog of dacarbazine (DTIC), shows potential advantages over dacarbazine.~Cisplatin is an agent that can potentially enhance the activity of temozolomide."
75630512|NCT00911638|Behavioral|Usual care|"Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only"
75630513|NCT02609191|Device|"Whole body exam using the Discovery A"|"Whole body exam using the Discovery A machine made by Hologic."
75781843|NCT01244048|Dietary Supplement|n3 long chain polyunsaturated fatty acids|Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
75630514|NCT02609191|Device|"First whole body exam using the Stratos DR"|"First whole body exam using the Stratos DR machine made by the DMS group."
75324241|NCT03839719|Procedure|Group OC|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
75781844|NCT04399382|Drug|Biologics|The exposure of interest in this observational study is the biological therapy of Tumor Necrosis Factor (TNF) inhibitor, specifically etanercept biosmilar/ infliximab/ adalimumab/ golimumab.
75781845|NCT03621670|Biological|Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)|Bexsero is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group.
75781846|NCT03621670|Biological|Prevnar13|Prevnar13 (PCV13) is to be administered intramuscularly on upper side of the left thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
75781847|NCT03621670|Biological|Pediarix|Pediarix (DTPa-HBV-IPV) is to be administered intramuscularly on lower side of the left thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
75781848|NCT03621670|Biological|Hiberix|Hiberix (Hib) is to be administered intramuscularly on lower side of the right thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
75917185|NCT03435302|Drug|High-Dose IFN-a2b|Interferon belongs to the large class of glycoproteins known as cytokines.
75917186|NCT04807582|Other|PET/MRI|18F-fluoropivalate tracer injection followed by PET/MRI scan
75917187|NCT04973150|Behavioral|To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children.|To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children. Methods A total of 300 preschool-age children who underwent general anesthesia of selective ophthalmic surgery in a 3A grade hospital from August 2019 to July 2020 were selected as the research object, who were divided into experimental group and control group with 150 cases each by random number table. Children in the control group received regular education on cartoon animation videos before surgery; children in the experimental group received eye-covering pretreatment on the basis of cartoon animation videos. The differences in preoperative anxiety degree score, postoperative acute delirium incidence, delirium degree score, and postoperative nursing care difficulty score were compared between the two groups.
75917188|NCT04807192|Radiation|stereotactic body radiotherapy|one administration of SBRT 8 Gy at D1
75917189|NCT04807192|Drug|CMP-001|4 sequential administrations of CMP001 at Day 1 (SC), Day 5 (±1) (IT), Day 9 (±1) (IT) and Day 16 (±1) (IT)
75917190|NCT04451018|Other|evaluation of arterial anomalies in upper limbs|evaluation of arterial anomalies in upper limbs with doppler ultrasound
75917191|NCT04798222|Drug|Treatment A|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
75917192|NCT04798222|Drug|Treatment B|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
75917193|NCT04798222|Drug|Treatment C|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition
75917194|NCT04798222|Drug|Treatment D|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.
75917195|NCT04798222|Drug|Treatment E|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.
75324242|NCT03839719|Procedure|Group CHX|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
75630515|NCT02609191|Device|"Second whole body exam using the Stratos DR"|"Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes."
75630516|NCT04157218|Device|HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)|The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .
75630517|NCT04157218|Device|Threads used in this study are absorbable Aptos|The threads will be inserted to the cheeks
75630518|NCT02609893|Other|modified directly observed therapy (mDOT)|
75630519|NCT02609893|Other|unobserved dosing|
76075668|NCT00884806|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
76075669|NCT05086354|Behavioral|JUMP|Warm-up, stretching, jumping rope, cool-down
76075670|NCT00885742|Biological|FXIII Concentrate (Human)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 [NCT00883090]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion."
76075671|NCT04964440|Device|Pure-EP|Advanced Signal Acquisition and Processing
76075672|NCT05319262|Radiation|Pink noise exposure|Continuous pink noise sound exposure at 45 dBA, throughout the whole night
76075673|NCT05319262|Radiation|Traffic noise|120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.
76075674|NCT00887458|Drug|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
76075675|NCT00887458|Drug|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
75324243|NCT03800251|Dietary Supplement|Nutricia PreOp - a clear, non-carbonated, lemon flavoured, carbohydrate drink that provides 0.5kcal/ml|Fasting parturients at term, admitted for elective cesarean section and consent to partake in the study, will be given the intervention drink
75630520|NCT02609893|Other|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
75630521|NCT00669370|Drug|docetaxel and capecitabine|biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
75630522|NCT04797871|Behavioral|Resistance training|Participants will complete a 2-days-a-week training routine: Resistance training (RT, 50-75% 1RM (one-repetition maximum), 4 sets, 8-12 repetitions, 4 exercises). The warn up include Light Intensity Continuous Training (8-10 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by Physiotherapists and Graduated in Sports Sciences.
75630523|NCT04797871|Behavioral|Standard care|This group will be allocated to standard care and therefore no supervised exercise regimen according to scientific guidelines for general physical activity and return to sport provided by the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease.
75630524|NCT02632006|Biological|PIK-PD-1 cells|"DC cell suspension (1×10*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
75630525|NCT02632006|Biological|DC-PMAT|"DC cell suspension (1×10*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
75781849|NCT03621670|Biological|Rotarix|Rotarix (HRV) is to be administered orally as a 2-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) to all subjects in the MenB+PCV group and Placebo+PCV group.
75781850|NCT03621670|Biological|M-M-R II|M-M-R II (MMR) is to be administered subcutaneously on upper side of the right arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
75781851|NCT03621670|Biological|Varivax|Varivax (VV) is to be administered subcutaneously on upper side of the left arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
75781852|NCT03621670|Biological|Placebo (saline water)|Placebo is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the Placebo+PCV group.
75781853|NCT01145768|Drug|TC-5214|4 mg tablet, oral, BID, group 1
75917196|NCT04798222|Drug|Treatment F|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.
75324244|NCT05464381|Drug|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
75324245|NCT05464381|Drug|Placebo|Placebo
75324246|NCT03800797|Drug|Loxoprofen sodium hydrogel patch|100 mg per day
75781854|NCT01145768|Drug|TC-5214|TBD tablet, oral, BID, groups 2-6
75917197|NCT04798222|Drug|Treatment G|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
75917198|NCT04798222|Drug|Treatment H|Participants will receive oral dose of dapagliflozin capsule in fasted condition.
75917199|NCT03433196|Drug|HS-25 and Atorvastatin|HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily
75917200|NCT03433196|Drug|Atorvastatin|Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily
75324247|NCT03800797|Drug|Loxoprofen sodium tablet|60 mg t.i.d.
75324248|NCT04383067|Procedure|Tumor Infiltrating Lymphocytes (TIL)|Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
75324249|NCT04383067|Drug|Proleukin|high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
75781855|NCT01145768|Drug|Placebo|
75324250|NCT01994109|Drug|MYOBLOC|"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."
75630526|NCT00665236|Other|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
75630527|NCT00665236|Procedure|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
75630528|NCT00669448|Behavioral|Minfulness-based cognitive therapy|Mindfulness Based Cognitive Therapy (MBCT) is a group intervention that integrates elements from primarily Mindfulness-based Stress Reduction programme (MBSR)and cognitive therapy.The MBCT programme includes 2½ hours of training once a week for 8 weeks. In addition participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
75324251|NCT01994109|Other|PLACEBO|
75630529|NCT04790617|Behavioral|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
75781856|NCT01143584|Drug|Cabergoline|"In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point."
75781857|NCT01143584|Drug|cabergoline|"In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~mg twice a week - second week 1.5 mg twice a week - third week~mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also >50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk."
75781858|NCT01145846|Drug|Cytarabine plus Daunorubicin [Arm II (AD regimen)]|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
75781859|NCT03526588|Biological|Autologous umbilical cord blood|6×10^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.
75781860|NCT01238510|Procedure|stent technique: Provisional fKBT|"Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.~Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
75781861|NCT01238510|Procedure|stent technique: Routine fKBT|"Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
75781862|NCT04239274|Device|transcranial direct current stimulation|Subjects in this arm will receive one session of tDCS for 20 minutes at 2.0 milliamps.
75781863|NCT04239274|Device|transcranial pulsed current stimulation|Subjects in this arm will receive one session of tPCS for 20 minutes at 2.0 milliamps.
75324252|NCT03800095|Drug|Early palliative care integration|The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
75324253|NCT01978509|Drug|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
75630530|NCT00669526|Behavioral|BCBT|Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
75630531|NCT00669526|Behavioral|SMHC referral|Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
75630532|NCT02416011|Behavioral|GENERIC|The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
75781864|NCT04239274|Device|Sham-no stimulation|Subjects in this arm will receive one session of sham for 20 minutes.
75781865|NCT03134456|Drug|Pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
75781866|NCT03329404|Device|Mirasol Red Blood Cells (MIR RBCs)|Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
75781867|NCT03329404|Device|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
75781868|NCT05207228|Behavioral|CBT4CBT|Cognitive behavioral treatment through the web CBT4CBT
75781869|NCT01313104|Procedure|colposcopy|Undergo colposcopy
75917201|NCT02792829|Drug|Lenvatinib|All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.
75324254|NCT01978509|Drug|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
75630533|NCT02416011|Behavioral|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
75630534|NCT05075395|Device|PARO therapy seal|PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
75630535|NCT00665314|Drug|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
75630536|NCT00665314|Drug|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
75630537|NCT04154722|Drug|Meropenem Injection|inj meropenum for 10 days
75630538|NCT04154722|Drug|Azithromycin Powder|syp azithromycin for10days
75630539|NCT02631928|Drug|human biphasic insulin|investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
75630540|NCT02631928|Drug|human biphasic insulin, reference|marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
75630541|NCT02609035|Behavioral|Telephonic prompt|
75630542|NCT00632385|Drug|Eletriptan|40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred >2 hours from first dose and within 24 hours of first dose
75630543|NCT05579613|Device|Interactive virtual reality device|The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor.
75630544|NCT00910689|Drug|Propranolol or nadolol|Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
75630545|NCT00910689|Drug|Placebo control|Placebo
75781870|NCT01313104|Other|cervical Papanicolaou test|Undergo cervical Pap smear
75781871|NCT01313104|Procedure|screening method|Undergo anal Pap smear
75781872|NCT01313104|Procedure|screening method|Undergo high resolution anoscopy
75781873|NCT01238744|Dietary Supplement|Flaxseed drink|Drink containing flaxseed mucilage
75781874|NCT01238744|Dietary Supplement|Flaxseed drink|Drink containing flaxseed mucilage
75630546|NCT00910689|Behavioral|Behavioral Migraine Management (BMM)|"Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with basic migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (hand warming) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed"
75630547|NCT00910689|Drug|Optimal Acute Therapy|This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
75781875|NCT01238744|Dietary Supplement|Flaxseed tablet|Tablets containing flaxseed mucilage consumed with a control drink
75781876|NCT01238744|Dietary Supplement|Control drink|Control drink
75781877|NCT01143662|Drug|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
75781878|NCT01143662|Drug|Peginterferon alfa-2a|sc, qw, for 48 weeks.
75324255|NCT01978509|Drug|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
75324256|NCT00248495|Drug|cisplatin|Given IV
75324257|NCT00248495|Drug|pemetrexed disodium|Given IV
75324258|NCT00248495|Procedure|adjuvant therapy|Metastasis prevention/control
75324259|NCT00248495|Procedure|conventional surgery|Undergoing tissue removal
75630548|NCT00807001|Drug|IDX184|oral dose, active or placebo
75781879|NCT01145924|Procedure|EBUS TBNF|Transbronchial needle forceps will be use with the EBUS TBNA scope
75781880|NCT04882150|Drug|BMS-986196|Specified dose on specified days
75781881|NCT04882150|Other|Placebo|Specified dose on specified days
75781882|NCT05173688|Drug|Propofol|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
75781883|NCT01146548|Drug|FLUOXETINE|20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
75781884|NCT03478930|Drug|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
75781885|NCT03478930|Drug|Placebo|Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
75781886|NCT01312714|Drug|Cholecalciferol|3 tablets of 1000 IU daily for 26 weeks
76075676|NCT05310682|Other|Data informed Platfrom for health|The DIPH promotes local data use for decision-making, priority-setting, planning and course correction at the district level by introducing a structured and collaborative process within the administration cadre. The DIPH is delivered as a package of job aids and guidelines. It involves grouping stakeholders who are brought together to deliberate on issues in a virtual platform facilitated by regular meetings. The package facilitates stakeholders' meetings in five steps: Assessment, Engagement, Definition, Planning and Follow-up. Together, these steps make up one whole cycle of the DIPH completed over four months. Each cycle looks at a specific health theme, identified in the early stages of the cycle itself. The package also includes a digital interface where everyone can regularly review data and check on progress. Note: LSHTM has exempted this study from having a sponsor, as DIPH is implemented at the health system administration level.
75324260|NCT00248495|Procedure|neoadjuvant therapy|Tumor Reduction
75630549|NCT04222335|Other|Blood samples|"Each participant will be followed-up regularly as part of the usual practice for imaging and medical consultations. During their visits, from inclusion (T0) to the end of study participation (T progression), each patient will have a blood sampling specifically for the research to analyze tumor DNA and circulating tumor cells: T0, T1month, T3 months, Tn months, T DNA C+, T progression.~This research does not include any other act or intervention specifically required for its purposes."
75630550|NCT02608957|Device|Latella Knee Implant System|
75781887|NCT01312714|Drug|Placebo|3 tablets of 1000 IU daily for 26 weeks
75781888|NCT04188028|Drug|Dextromethorphan 5 MG|dextromethorphan 5 mg po
75917202|NCT04828408|Procedure|Bariatric surgery|Patients with a body mass index (BMI) ˃35, age interval of 18-65, and ASA score II-III undergoing laparoscopic bariatric surgery were included in the study. Patients with neuromuscular, cardiopulmonary, and cerebrovascular diseases, phrenic nerve damage or diaphragm paralysis, those who have undergone thoracic surgery, who could not communicate, who did not want to participate in the study, who used alcohol, those who needed postoperative intensive care, those who had surgical complications during surgery, and those who were switched to open surgery were not included in the study.
75917203|NCT04451096|Dietary Supplement|Probiotics with prebiotic|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
75917204|NCT04451096|Dietary Supplement|Placebo|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
75917205|NCT04828252|Device|Low level laser treatment|The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
75917206|NCT04797676|Procedure|different methods of specimen acquisition|After informed consent, the investigators use two methods to obtain specimens for patients with pancreatic ductal adenocarcinoma, who needs eus-fnb for auxiliary diagnosis and had the opportunity of surgery. One method is EUS-FNB with wet suction technique, the other is surgery (including radical operation and cytoreductive surgery). Both methods are used on the same patient to remove deviations in results caused by tumor heterogeneity.
75917207|NCT02069769|Behavioral|communication with oncology team|Oncology team will contact patients and families via telephone at specific intervals
76075677|NCT03216694|Diagnostic Test|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
76075678|NCT03216616|Behavioral|Cognitive Behavioural Therapy|
76075679|NCT03275662|Behavioral|Dietary Fiber|
76075680|NCT03275662|Behavioral|Fermented Foods|
76075681|NCT03216304|Drug|100 mg safinamide|"Safinamide will be administered as follows:~Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
75324261|NCT03809767|Drug|CS1003 monoclonal antibody|CS1003 will be administered intravenously every 3 weeks.
75324262|NCT03806465|Other|Feasibility survey|A survey questionnaire will be administered at each household. At the baseline household survey, each child aged less than 5 years will be tested for malaria using a rapid malaria test.
75324263|NCT03806465|Other|Sentinel hospital surveillance|Cerebrospinal samples will be collected from all children hospitalised and suspected of having meningitis.
75781889|NCT04188028|Drug|Paroxetine 10Mg Tablet|Paroxetine 10 mg po
75781890|NCT04188028|Drug|Paroxetine 20Mg Tablet|Paroxetine 20 mg po
75781891|NCT04731064|Procedure|HAL (Hemorrhoidal Artery Ligation) - RAR (Recto-Anal Repair)|The patient is operated on in the first perineal position, under general anesthesia or under locoregional or even local anesthesia, after rectal preparation by simple enema. The HAL equipment included a disposable transparent rectoscope fitted near its end with a centimeter window through which wire stitch ligatures will be made. A light source facilitating the exposure of the internal face of the rectum and a Doppler transducer secured to the base of the rectoscope containing the Doppler system. Everything is connected to a generator which transmits Doppler noises to the surgeon. A printer on the generator makes it possible to map ligatures and note the depth of linked arteries. Equipment includes needle holder, knot pusher, scissors and dissecting forceps. The material for HAL is identical, except for the disposable rectoscope which is more indented at its end and on one side.
75324264|NCT03806465|Other|Community mortality surveillance|A verbal autopsy will be performed
75324265|NCT02307123|Procedure|Intubation|HEMS physician prehospital intubation
75324266|NCT03800641|Drug|Dexmedetomidine|oral, intravenous and nasal administration of Dexmedetomidine
75324267|NCT03807011|Drug|fentanyl group|fentanyl 2 μg/kg
75324268|NCT03807011|Drug|remifentanil group|remifentanil 0.2 μg/kg/min
75324269|NCT02986503|Drug|Doxorubicin+cisplatin+ifosfamide|Chemotherapy for Good responder high grade osteosarcoma
75324270|NCT02986503|Drug|Doxorubicin+cisplatin+ifosfamide+methotrexate|Chemotherapy for Poor responder high grade osteosarcoma
75630551|NCT04669717|Drug|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
75630552|NCT04669717|Drug|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
76075682|NCT03216304|Drug|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
76075683|NCT03216304|Drug|20 mg rosuvastatin calcium period 2|- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
75630553|NCT04669717|Drug|1/d 500 mg Azithromycine Pfizer for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
75630554|NCT05755009|Radiation|High- and Low-dose radiotherapy|High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain a total of two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.
75630555|NCT00809341|Biological|Rituximab|375 mg/m^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m^2 on Days 1, 30, and 37 as part of HiCy.
75630556|NCT00809341|Drug|Cyclophosphamide|750 mg/m^2 on Day 1 of each cycle as part of R-CHOP.
75781892|NCT01312792|Other|Amoxycilline, Cephradine followed by follow up on day 3|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
75781893|NCT01312792|Other|Injectable ampicillin followed by urgent referral|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
75781894|NCT03038438|Device|Abre venous self-expanding stent system|venous stent
75917208|NCT04450862|Other|Cognitive Behavioural therapy self help intervention for anxiety|"The intervention will involve five key components:~Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.~Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.~Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.~Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.~Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving."
75917209|NCT02066571|Drug|Droxidopa|Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.
75917210|NCT02066571|Drug|sugar pill|Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
75917211|NCT03433118|Device|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers
75917212|NCT02066649|Drug|Carvedilol|Administering carvedilol to patients diagnosed with large varices on endoscopy
75917213|NCT02066649|Procedure|Variceal band ligation|Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
75917214|NCT04807036|Device|Hypotension Prediction Index|HemoSphere Clinical Platform with Acumen Hypotension Prediction Index Feature
75917215|NCT02070003|Behavioral|Motivational Interviewing and Physician Guided Opioid Weaning|
75917216|NCT04807270|Other|Intra-articular T-LAB / PRP KIT injection|Intra-articular 3 ml T-LAB / PRP KIT injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
75917217|NCT04807270|Other|Intra-articular T-LAB / PRP INJECTION SYRINGE injection|Intra-articular 3 ml T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
76075684|NCT03216460|Device|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
76075685|NCT03216538|Drug|AS101 1% oral solution|0.4 ml daily p.o.
76075686|NCT03216538|Drug|Placebo|0.4 ml daily p.o.
75630557|NCT00809341|Drug|Doxorubicin|50 mg/m^2 on Day 1 of each cycle as part of R-CHOP.
75630558|NCT00809341|Drug|Vincristine|1.4 mg/m^2 on Day 1 of each cycle as part of R-CHOP.
75630559|NCT00809341|Drug|Prednisone|100 mg/day on Days 1-5 of each cycle as part of R-CHOP.
76075687|NCT03217396|Procedure|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
76075688|NCT03218722|Drug|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
76075689|NCT03218722|Drug|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
76075690|NCT03216148|Diagnostic Test|FET-PET|All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
76075691|NCT00888628|Biological|Purified Pancreatic Islets|Islet after kidney transplant in patients with type I diabetes.
75630560|NCT00809341|Drug|Ifosfamide|2000 mg/m^2/day on Days 1-3 of each cycle as part of R-CHOP.
76075692|NCT00888628|Drug|Etanercept|Given as induction for islet cell transplant
75630561|NCT00809341|Drug|Carboplatin|Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.
75630562|NCT00809341|Drug|Etoposide|100 mg/m^2/day on Days 1-3 of each cycle as part of R-CHOP.
75630563|NCT00809341|Drug|High-dose cyclophosphamide|50 mg/kg/day on Days 2-5 of HiCy.
75630564|NCT00809341|Procedure|PET scan|Performed once between Days 16-20 of cycle 3 of R-CHOP.
75630565|NCT04648111|Diagnostic Test|Vital sign measurement|Vital signs measurement will be obtained by the research staff using hospital standard medical devices and the Anura Research App will also be used to measure vital signs. Measurement will take place before surgery and post surgery (1 ±2hrs and 2 ±4hrs after surgery).
76075693|NCT03215992|Device|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
75917218|NCT04807270|Other|Intra-articular SALINE injection|Intra-articular 3 ml SALINE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
76075694|NCT03215680|Other|Climate|Hot and temperate climate
76075695|NCT03838276|Procedure|AL 150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
76075696|NCT03838276|Procedure|AL 100 BPL 150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
76075697|NCT03837886|Dietary Supplement|Sodium bicarbonate|The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.
76075698|NCT03837886|Dietary Supplement|Calcium carbonate|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
75630566|NCT01125800|Drug|LDE225|LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
75630567|NCT04025827|Other|Dietary intake|We will collect detailed data on dietary intake and weight for healthy newborns in four low income countries.
75917219|NCT03432962|Other|no intervention - recoding of food recall only|recoding of food recall
75917220|NCT02070081|Procedure|Roux-en-Y gastric bypass surgery or sleeve surgery|
75467909|NCT01934439|Device|30 PAAD treatments|Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
75630568|NCT05046145|Behavioral|speech therapy for chewing + real tDCS|participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
75781895|NCT03523000|Other|Continuous intrathecal prognostic infusion test|The patient is infused with solution through the percutaneous intrathecal catheter at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
76075699|NCT03219970|Drug|Osimertinib|80mg oral daily
76075700|NCT00889330|Drug|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
75781896|NCT03523000|Drug|Bupivacaine|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
75781897|NCT03523000|Drug|Fentanyl|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
75917221|NCT03435068|Device|Ceramic rotary bur|Gingivoplasties were performed with the same ceramic burs to easily provide a knife-edge appearance with ceramic rotary bur
75917222|NCT03435068|Device|Diode laser|The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power were used in the study.
76075701|NCT00889330|Drug|Placebo|Vehicle without active, one drop in each eye at each of two visits.
75324271|NCT04727983|Device|Electrotherapy|The first group will be given Neuromuscular Electrical Stimulation (NMES) and lifestyle suggestions (LSS) (NMES group)
75324272|NCT04727983|Device|Sham Electrotherapy|The second group will be given sham NMES in addition to LSS (SHAM ES group)
75324273|NCT02986191|Procedure|Mucograft|This method of grafting will be used to treat the gingival recession using coronally advanced flaps.
75324274|NCT02986191|Procedure|Connective Tissue Graft|This will be used in the traditional manner to correct gingival recession
75467910|NCT01934491|Behavioral|Cognitive Training A|
76075702|NCT03219580|Drug|5-Fluorouracil|50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
75324275|NCT03806699|Biological|Placebo|Sterile normal saline
75324276|NCT03806699|Biological|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
75467911|NCT01934491|Behavioral|Cognitive Training B|
75630569|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
75630570|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
75630571|NCT04030351|Other|food - dried fruit|raisins, apricots, figs, and pineapple
75781898|NCT03523000|Drug|Placebo|Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
76075703|NCT03219580|Drug|Normal Saline Flush, 0.9% Injectable Solution|0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
76075704|NCT03215446|Drug|maintenance of anaesthesia with propofol|
75781899|NCT03523000|Device|Intrathecal Drug Delivery System (IDDS)|40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL
75781900|NCT01143740|Drug|RO5045337|orally day 1-10 each 28-day cycle, 3 cycles
75781901|NCT04705480|Drug|Pregabalin 50mg|Patients will receive 50 mg every 8 hours without dose titration. Patients with CrCl < 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if < 7 days post-enrollment).
76075705|NCT03215446|Drug|maintenance of anaesthesia with sevoflurane|
76075706|NCT03215212|Other|eye mask|eye mask administered from 10 pm to 7 am
75917223|NCT03435068|Device|Scalpel|Scalpel surgery were performed as control group (conventioanl group).
75917224|NCT02070159|Drug|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
75917225|NCT02070159|Drug|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
75630572|NCT02609581|Drug|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
75630573|NCT00811135|Drug|bevacizumab [Avastin]|15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
75630574|NCT00811135|Drug|capecitabine [Xeloda]|1000mg/m2 bid po on days 1-14 of each 3-week cycle
75630575|NCT00811135|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
75630576|NCT00811057|Drug|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
75630577|NCT00811057|Drug|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
75630578|NCT00811057|Drug|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
75630579|NCT00879970|Drug|pioglitazone|Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
75630580|NCT00879970|Drug|rosiglitazone|Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
75630581|NCT00879970|Drug|placebo|Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
75630582|NCT00879970|Dietary Supplement|Vitamin D|Vitamin D factor intervention
75630583|NCT00879970|Dietary Supplement|Placebo|Vitamin D factor intervention
75917226|NCT02070159|Drug|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
75917227|NCT03434990|Other|Spinal manipulation/myofascial release|The protocol will be composed by myofascial release followed by spinal manipulation. Paravertebral muscles and gluteus maximus and piriform muscles will be manually checked for tension, stiffness, spasm and painful points. The intervention will be composed by: trigger points release, release of muscle fascia and active release technique. The myofacial release will be done with a constant pressure during 30 seconds, 3x in each point. After this procedure, the spinal manipulation will be performed in high velocity and low amplitude thrust technique, on the lumbar spine and sacroiliac joint.
75917228|NCT03434990|Other|Spinal manipulation|The sacroiliac joint will be test and manually verified for any dysfunction, and the lumbar spine will be also assessed to verify any hypomobility and vertebral rotation. The segments with alterations will be manipulated with a high velocity and low amplitude thrust technique.
75917229|NCT03128762|Biological|ILC2 levels in blood|The levels of circulating ILC2 cells relative to other lymphocytes will be determined via flow cytometry
76075707|NCT03215212|Other|ocean sound|Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
76075708|NCT03215212|Other|ear plug|ear plug administered from 10 pm to 7 am
76075709|NCT03215134|Other|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre & Rimes, submitted) and is now being evaluated in a primary mental-health service.
75630584|NCT00808639|Drug|Methotrexate|intravenously 30mg/m2 over 30 minutes
75630585|NCT00808639|Drug|Doxorubicin|intravenously 30mg/ms over 15 minutes
75630586|NCT00808639|Drug|vinblastine|intravenously 3mg/m2 over 30 minutes
75917230|NCT04797598|Other|Virtual reality group|This will receive Virtual reality sessions and both group will receive conventional physical therapy as base line treatment
75917231|NCT04797598|Other|Cyclic training group|This will receive cyclic training session. both group will receive conventional physical therapy as base line treatment
75630587|NCT00808639|Drug|cisplatin|intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
75630588|NCT00808639|Drug|Pegfilgrastim|Given subcutaneously 24 hours after last chemotherapy dose
75630589|NCT05005195|Radiation|Low dose abdominal computed tomography scan|A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer
75630590|NCT00810901|Behavioral|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
75917232|NCT04827628|Dietary Supplement|Oryza Sativa Extract|The product is a suspension of 5.6 gram/100 mL given once daily, contains 71.9%, purple in color, range pH 3-5. Stored in the darker bottle. The frequency of administration is once-daily after the meal.
76075710|NCT00896038|Drug|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
75324277|NCT01978743|Drug|Raltegravir|Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
75324278|NCT00763061|Drug|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo & 9 PM
75324279|NCT00763061|Drug|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM & 9 PM
75324280|NCT03806335|Other|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%
75324281|NCT03806335|Other|Placebo|Patients will receive 2.5 ml normal saline in each tonsil
75630591|NCT00810901|Behavioral|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
75630592|NCT00910299|Drug|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
75630593|NCT00910299|Drug|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
75917233|NCT04827628|Dietary Supplement|Control|citric acid 0.1g/oz and 1% sorbitol mixture, given once daily after meal
75917234|NCT02066805|Drug|Database assessment of off-label XGEVA use|No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
75917235|NCT03128684|Other|Small Green Lentil Muffin|Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
75630594|NCT00669760|Other|non-interventional study|does not apply
75630595|NCT00671086|Drug|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
75324282|NCT03806335|Other|General anesthesia|All patients will receive general anesthesia prior to infiltration
75630596|NCT00671086|Drug|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
75630597|NCT04024189|Other|Survey|Patients were given a questionnaire/survey to complete in respect of their satisfaction of the consent process for their surgical procedure
75630598|NCT02608723|Device|Standard shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
75630599|NCT02608723|Device|Austere shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
75630600|NCT02608723|Device|Sophisticated shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
75630601|NCT04154566|Other|Aerobic Exercises|Aerobic exercise refers to exercise that involves or improves oxygen consumption by the body. It is the type of activity that uses large muscle groups. Its performance is in a continuous and rhythmic way with a main goal to make the heart and lungs work harder than they do when the person at rest
75630602|NCT00665548|Radiation|X-ray; magnetic resonance imaging|"Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences."
75781902|NCT04705480|Drug|Gabapentin 300mg|Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl < 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if < 7 days post-enrollment).
75781903|NCT04705480|Drug|Neither Pregabalin nor Gabapentin|Patients will receive neither Pregabalin nor Gabapentin.
75917236|NCT03128684|Other|Split Red Lentil Muffin|Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
75917237|NCT03128684|Other|Wheat Muffin|Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes
75917238|NCT03128684|Other|Small Green Lentil Chili|Consumption of small green lentil chili; consumption of ad libitum pizza test meal after 180 minutes
75917239|NCT03128684|Other|Split Red Lentil Chili|Consumption of split red lentil chili; consumption of ad libitum pizza test meal after 180 minutes
75917240|NCT03128684|Other|Rice Chili|Consumption of rice chili; consumption of ad libitum pizza test meal after 180 minutes
75917241|NCT03109340|Other|Supervised treadmill group (Group I)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70% VO2max (moderate-intensity) was determined by the submaximal treadmill test.The participants were instructed walking exercise at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY).During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
76075711|NCT00896038|Drug|Placebo|Non-active placebo
75324283|NCT03806777|Drug|Dexmedetomidine|Highly selective alpha-2 adrenergic agonist with sedative properties.
75630603|NCT03007329|Drug|Exenatide|Exenatide will be combined with Dapagliflozin
75630604|NCT03007329|Drug|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
75630605|NCT03007329|Drug|Dapagliflozin|Dapagliflozin, in both arms
75630606|NCT04072341|Drug|Propolis Period (Green Propolis 250mg/day)|Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.
75630607|NCT04072341|Other|Control Period|In the control period they will only follow standard treatment for their comorbidities.
75630608|NCT00595504|Drug|Ramelteon|Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
75781904|NCT01238978|Drug|Vildagliptin|
75781905|NCT01238978|Drug|"Usual Care"|
75781906|NCT01239134|Biological|TRX518|Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
75781907|NCT03327220|Device|iovera°|The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
75781908|NCT01245608|Drug|Polypill|Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
75781909|NCT00318149|Biological|Fluarix|1 dose administered intramuscularly in the deltoid region of the non-dominant arm
75781910|NCT00318149|Biological|Fluarix-AS25|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
75781911|NCT00318149|Biological|Fluarix-AS50|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
75781912|NCT00318149|Biological|Fluarix-AS01B|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
75781913|NCT00318149|Biological|Fluarix-AS01E|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
75917242|NCT03109340|Device|ECE PEDO pedometer (Group II)|Following a 10-minute rest after treadmill test, the participants were instructed to walk on the treadmill while maintaining their target heart rate. The number of steps taken in a minute was calculated using a criterion pedometer when target HR responses were reached. In this way, we determined the steps per minute required to moderate intensity walking for each participant. Detected individual step numbers were recorded to ECE PEDO for each person. Then participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from the range of steps per minute.During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
75630609|NCT00595504|Drug|Placebo|Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
75917243|NCT02070393|Radiation|Proton|14-24 Radiation treatments using Protons
75917244|NCT03432884|Drug|BGB-3111|Subjects will receive BGB-3111
75917245|NCT03432884|Drug|Placebo|Subjects will receive Placebo
75917246|NCT03432884|Drug|Moxifloxacin|Subjects will receive Moxifloxicin
75917247|NCT04806880|Device|Web-application|support for olfactory coaching consisting of the inhalation of fragrant essential oils.
75917248|NCT03440294|Diagnostic Test|resting standard spirometry|The subject (seated, bust straightened) should perform, after a slow and maximum inspiration, a forced and complete exhalation followed by a new inspiration to the total lung capacity.
75917249|NCT03440294|Diagnostic Test|maximum exercise testing|Incremental exercise on cycle ergometer with 100W start for men (80W for women) for 4 minutes as part of the warm-up. Then, step increment of a 50W power for men (40W for women) lasting 2 minutes each.
75917250|NCT04827784|Procedure|local anaesthetic injection|The head and neck of the condyle were detected by palpating the pretragal area. Then, the needle was inserted anterior to the junction of the tragus and the lobule. After 0.5 ml the solution was subcutaneously infiltrated, the needle was protruded until it touched the neck of the condyle. Aspiration was performed to avoid intravenous injections, and the remaining solution was injected thereafter.
75917251|NCT03986996|Drug|amoxicillin, metronidazole and doxycycline|antibiotics: Patient weight 30-50 kg Patient weight > 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks Metronidazole 250 mg X 2 Day X 2 weeks 375 mg X 2 Day X 2 weeks
75917252|NCT03986996|Drug|amoxicillin and doxycyclin|antibiotics: Patient weight 30-50 kg Patient weight > 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks
75917253|NCT04827472|Drug|Normal saline|100ml
75630610|NCT00808483|Other|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
75630611|NCT03952533|Dietary Supplement|Dav|Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
75630612|NCT02629978|Procedure|CT-guided percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
75630613|NCT04067271|Other|Analyze changes in intestinal microbiome|Descriptive Analysis
75781914|NCT04648696|Drug|Vancomycin CI|The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin
75781915|NCT04648696|Drug|Vancomycin II|Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
75917254|NCT04827472|Drug|DWJ1521|Single dose
75917255|NCT04827472|Drug|DWP14012 Tablet|Single dose, Tablet
76075712|NCT03219346|Other|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
75781916|NCT01236716|Drug|Albumin paclitaxel plus carboplatin|Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
75781917|NCT01236716|Drug|Gemcitabine plus carboplatin|Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
75781918|NCT03440008|Other|Dynamic 3D bone motion capture|Two x-ray systems will image the subjects ankle while they walk, allowing us to calculate ankle joint angle and alignment
75781919|NCT03440008|Device|wedged insole|medial or lateral wedge (appropriate for varus or valgus misalignment) will be applied during 1 data collection session to evaluate effect of wedging on misalignment
75917256|NCT02067117|Drug|GC FLU® Injection, GC FLU® Pre-filled Syringe Injection|
75917257|NCT03440138|Procedure|bariatric surgery (RYGB or SG)|laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity
75917258|NCT04796428|Drug|Canagliflozin|Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.
75917259|NCT04796428|Drug|Dapagliflozin|"Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used."
76075713|NCT03218956|Dietary Supplement|Dietary supplement: Protein intake|"Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.~The last 4 meals will in addition contain labelled labelled 13C phenylalanine."
75630614|NCT04980625|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
75630615|NCT04980625|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
75324284|NCT03809689|Other|68Ga-NODAGA-RGD PET/CT|intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection
75467912|NCT01934530|Procedure|Soft Tissue Grafting|"All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement."
75630616|NCT03753711|Procedure|Multifidus muscle biopsy during minimally invasive back surgery|Bilateral biopsy of the multifidus muscle in patient with a unilateral disc hernia.
75630617|NCT00676000|Procedure|Interrupted vaginal closure|Horizontal mattress closure of vaginal mucosa over mesh
75630618|NCT00676000|Procedure|Continuous vaginal closure|Running closure of vaginal mucosa over mesh
75630619|NCT04030039|Drug|Interferon|chronic hepatitis B patients with interferon therapy
75630620|NCT04030039|Drug|nucleoside analogues|chronic hepatitis B patients with interferon therapy
75630621|NCT04154098|Device|Scapula orthosis assistance|Participants are elevating their arm while their scapula is assisted by the scapula orthosis
75630622|NCT04154098|Procedure|Manual scapula assistance|Participants are elevating their arm while their scapula is assisted by a trained personnel
75630623|NCT04154098|Other|No assistance|Participants are elevating their arm without being assisted
75630624|NCT04154098|Other|Functional Test|Participants perform a functional test once without (NO) and once with (OA) the orthosis
75630625|NCT00810511|Device|Lotrafilcon A contact lens|Silicone hydrogel contact lens
75917260|NCT04796428|Drug|Empagliflozin|"If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used."
75917261|NCT02867592|Drug|Cabozantinib|Given PO
75917262|NCT02867592|Drug|Cabozantinib S-malate|"Given PO~Note: Capsule formulation (Cometriq) not used in this trial."
75324285|NCT03809689|Diagnostic Test|82-Rb PET/CT as part of standard care, not a comparator|2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition
75324286|NCT01979133|Drug|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
75630626|NCT00810511|Device|Comfilcon A contact lens|Silicone hydrogel contact lens
75630627|NCT02628574|Drug|TRX518 monotherapy|comparison of different (ascending) doses of TRX518 monotherapy
75630628|NCT02628574|Drug|TRX518 with gemcitabine|comparison of different (ascending) doses of TRX518 in combination with gemcitabine
75630629|NCT02628574|Drug|TRX518 with pembrolizumab|comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
75630630|NCT02628574|Drug|TRX518 with nivolumab|comparison of different (ascending) doses of TRX518 in combination with nivolumab
75630631|NCT00596362|Drug|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
75630632|NCT00907803|Drug|ST-246 400 mg|Capsules, 400 mg daily for 14 days
75630633|NCT00907803|Drug|ST-246 600 mg|Capsules, 600 mg daily for 14 days
75630634|NCT00907803|Drug|Placebo|Capsules, once daily for 14 days
75630635|NCT00669994|Drug|Ciprofloxacin|Cipro XR 500 mg tablets taken once daily
75630636|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
75630637|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
75630638|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
75630639|NCT00808249|Drug|Placebo|2 tablets taken twice a day for 28 days
75630640|NCT02628262|Procedure|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
75630641|NCT02790723|Drug|sc-rAAV2.5IL-1Ra|Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.
75630642|NCT00676156|Drug|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
75630643|NCT00676156|Drug|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
75630644|NCT00676156|Drug|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
75917263|NCT02867592|Other|Pharmacological Study|Correlative studies
75917264|NCT02070471|Drug|Placebo|Placebo
75917265|NCT02070471|Drug|LC28-0126 Dose A|LC28-0126 Dose A
75917266|NCT02070471|Drug|LC28-0126 Dose B|LC28-0126 Dose B
75917267|NCT02070471|Drug|LC28-0126 Dose C|LC28-0126 Dose C
75917268|NCT03440060|Diagnostic Test|procalcitonin|procalcitonin value will be obtained within 24 hours after ICU admission in both groups and will be taken into account in the procalcitonin group only
76075714|NCT03219112|Other|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
75324287|NCT03800069|Device|Group K Diagnostic point of care device|Arm 1 will have a finger prick sample collected to test the ability of Group K Diagnostic point of care device and app to identify liver function values.
75324288|NCT04675879|Device|Shoulder arm bandage|Three different shoulder-arm bandage types
75324289|NCT04645069|Biological|ADG126 Mono|ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.
75324290|NCT04645069|Biological|ADG126-anti PD1|ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion
75324291|NCT04645069|Biological|ADG126-ADG106|ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion
75324292|NCT05432713|Drug|LP-168 tablet|Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
75630645|NCT05753527|Behavioral|Progressive Relaxation Exercises|Deep abdominal breathing will be done three times and the breath will be given slowly. The fists will be clenched, keep the fists clenched in this way for 7-10 seconds, and then release them for 15-20 seconds. By opening the arms to the side and locking the elbows, the triceps muscle will be stretched and relaxed. The forehead muscles by raising the eyebrows The eyes will be closed and relaxed. The mouth will be opened and closed. The head will be stretched back and relaxed. The shoulders will be lifted and relaxed. Both hips will be tightened and relaxed by bringing them closer together. The thigh muscles will be tightened and relaxed.
75630646|NCT03970629|Device|PERSONA Total Knee|Primary Total Knee Arthroplasty
75630647|NCT00670150|Drug|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
75630648|NCT00670150|Drug|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
75630649|NCT00914017|Drug|Atorvastatin|Atorvastatin, 40 mg daily for 1 year
75630650|NCT00914017|Drug|Placebo|sugar pill daily for 1 year
75630651|NCT00676234|Drug|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
75630652|NCT04036851|Behavioral|Peer support intervention|Peer support groups will meet monthly for the duration of follow-up, with separate groups for pregnant and postpartum women. Groups will be facilitated by women who are living with HIV and have experience of PMTCT services in this setting. Group sessions will include brief information and a structured discussion about a relevant topic, followed by opportunities for unstructured discussion.
75630653|NCT00671320|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
75630654|NCT00671320|Drug|diclofenac|diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
75630655|NCT04229667|Other|Improved Community Health Volunteer (CHV) program|"Multi-modal intervention targeting intensive household monitoring of high-needs patients using monthly visits to measure blood pressure and blood sugar, adherence to treatments and compliance with clinics visits, and motivational interviewing to facilitate behavior change and psychosocial support."
75630656|NCT05753449|Device|Burst-type DBS electrical stimulation programming|Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered.
75917269|NCT02067195|Drug|Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)|No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
76075715|NCT03219190|Behavioral|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
75324293|NCT05432713|Drug|LP-168 Placebo tablet|LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
75324294|NCT00754247|Drug|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
75324295|NCT00754247|Drug|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
75467913|NCT01934543|Other|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
75630657|NCT05753449|Device|Standard of care DBS programming|Standard of care DBS stimulation programming
75630658|NCT00670384|Biological|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Sublingual drops
75630659|NCT00670384|Biological|Placebo|Sublingual drops
75630660|NCT00671398|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
75630661|NCT00671398|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
75324296|NCT00754247|Drug|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
75324297|NCT02305329|Drug|BIA 9-1067|
75324298|NCT01979445|Drug|Cangrelor|Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.
75324299|NCT01979445|Drug|Clopidogrel|Clopidogrel 600 mg single oral dose
75324300|NCT01979445|Drug|Prasugrel|Prasugrel 60 mg single oral dose
75324301|NCT03802565|Drug|Tolperisone|TID
75324302|NCT03802565|Drug|Placebo|Placebo
75630662|NCT00671398|Drug|Placebo|Ramelteon placebo-matching tablets, orally for one night only
75630663|NCT03926247|Behavioral|Immigrant Well-Being Project|The IWP intervention emphasizes a sustainable and replicable partnership model between community-based organizations and universities that involves Mexican immigrants and undergraduate advocates working together to: a) increase immigrants' abilities to navigate their communities; b) improve immigrants' access to community resources; c) enhance meaningful social roles by valuing immigrants' culture, experiences, and knowledge; d) reduce immigrants' social isolation; and e) increase communities' responsiveness to immigrants through changes in policy and practice. The IWP is administered by university students enrolled in a service learning course, and has two elements: 1) Learning Circles, which involve cultural exchange and one-on-one learning opportunities, and; 2) Advocacy, which involves collaborative efforts to mobilize community resources related to health, housing, employment, education, and legal issues.
75630664|NCT00676312|Drug|PTH134|
75917270|NCT02067195|Drug|3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
75917271|NCT02070627|Drug|Indocyanine Green (ICG)|60-30 minutes prior to cholecystectomy, 2.5 mg of indocyanine green (ICG) will be injected intravenously. An additional 2.5 mg of ICG may be injected intraoperatively if the fluorescence fades prior to imaging.
75917272|NCT02070627|Device|Near Infrared Fluorescence Cholangiography (NIRF-C)|Near infrared fluorescence cholangiography will be performed intraoperatively in order to image anatomy.
75630665|NCT00908895|Procedure|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
75324303|NCT02308371|Device|Automated Pulse Pressure Variation|Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
75917273|NCT03432728|Procedure|Dental rehabilitation under general anesthesia|Dental treatment of all teeth affected by dental caries in a single visit under general anesthesia
75917274|NCT04450784|Other|collection of the clinical and biological characteristics of secondary AMLs in children|to record scientific and medical information on cases of secondary Acute Myeloid Leukemias that have occurred in France since 2013
75917275|NCT04450160|Drug|Anhydrous Enol-Oxaloacetate (AEO)|Oral supplementation with AEO along with the Standard of Care (Temozolomide)
75917276|NCT04450160|Other|Standard of Care|Standard of Care Temozolomide
75917277|NCT02067351|Behavioral|Mindfulness|Meditation, body scan, yoga.
75917278|NCT03929952|Other|Neurofeedback treatment|"20 sessions of neurofeedback of 5 minutes each consisting of :~The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain."
75917279|NCT03929952|Other|functional magnetic resonance imaging (fMRI) scans|The patient in alpha synchrony related state and in rating state will undergo an fMRI
75917280|NCT03434756|Other|Propioceptive training of the abdominal wall muscles|At the beginning, patients will be in a supine position, the lower edge of the StabilizerTM will be placed between the posterior superior iliac spines, aligned with the sacral base. Abdominal manoeuvre will be developed by the patients until they reach 40 mmHg and hold steadily for 10 seconds. Prior the examination, each subject practiced the abdominal manoeuvre three times with an ultrasound image feedback.
75917281|NCT04745936|Other|Style curve similar to natural curvature of endotracheal tube|Stylet curvature is made similar to the natural curvature of endotracheal tube for intubation using C-MAC videolaryngoscope.
75917282|NCT04745936|Other|Style curve similar to hockey stick shape|Stylet curvature is made similar to hockey stick shape for intubation using C-MAC videolaryngoscope.
75917283|NCT02070783|Drug|ARA290|
75324304|NCT04382443|Drug|Colchicine|At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
75324305|NCT01980771|Behavioral|BTWB intervention|Men work in groups to complete a intervention that takes approximately two hours to complete.
75324306|NCT01980771|Behavioral|Cancer prevention and screening|Men are provided health education about cancer screening and prevention
75917284|NCT02070783|Drug|Placebo|
75917285|NCT03432572|Drug|Pyridium|a urine discoloration agent
75917286|NCT03432572|Drug|Riboflavin|a urine discoloration agent
75324307|NCT04633213|Drug|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
75467914|NCT01934543|Other|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
75630666|NCT00908895|Procedure|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
75917287|NCT03432572|Drug|Thiamine|active placebo not known to cause urine discoloration
75324308|NCT04633213|Drug|Placebo|Ophthalmic Solution
75324309|NCT01981863|Drug|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
75324310|NCT01981863|Drug|Placebo|Placebo administered in same volume as in experimental arm.
75324311|NCT00245765|Drug|Certolizumab Pegol|"Pharmaceutical Form: solution for injection in pre-filled syringe~Route of Administration: subcutaneous use"
75324312|NCT00245765|Other|Placebo|Matching Placebo to Certolizumab Pegol
75324313|NCT01995045|Drug|Triamcinolone|Retrobulbar anesthesia
75324314|NCT01995045|Drug|Bupivicaine Hydrochloride|Retrobulbar anesthesia
76075716|NCT02804074|Other|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
76075717|NCT02804074|Other|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
75324315|NCT04937725|Diagnostic Test|eye tracking|Eye tracker will be used to evaluate study parameters
75324316|NCT03806075|Behavioral|Second generation sequencing|Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
75467915|NCT01934569|Drug|Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771|PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
75630667|NCT00676390|Other|doubly labelled water and questionnaire|0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
75630668|NCT00676468|Other|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
75630669|NCT00676468|Other|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
75630670|NCT00676468|Other|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
75630671|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
75630672|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
75630673|NCT00591253|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
75781920|NCT01236794|Behavioral|Lifestyle Education Sessions and Youth Exercise Sessions|The intervention will include a ~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
75781921|NCT04154800|Drug|BMS-986209|Specified Dose on Specified Days
75781922|NCT04154800|Other|BMS-986209 Placebo|Specified Dose on Specified Days
75917288|NCT03379077|Behavioral|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
75917289|NCT03439904|Other|Pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
76075718|NCT02639260|Drug|N-acetyl D-mannosamine|dose escalation
76075719|NCT04381234|Device|dialyzer|Asymmetric triacetate dialyzer
76075720|NCT04381234|Combination Product|hemodialysis with citrate-containing dialysate|acetate-free dialysate
76075721|NCT04381234|Other|predilution hemodiafiltration|predilution hemodiafiltration
76075722|NCT03218644|Other|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
76075723|NCT03218644|Other|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
76075724|NCT03218176|Device|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
76075725|NCT03218176|Device|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
76075726|NCT03218176|Device|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
76075727|NCT03218176|Device|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
76075728|NCT03218176|Device|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
76075729|NCT03218176|Device|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
75324317|NCT03806075|Behavioral|16s rRNA gene sequencing|Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
75467916|NCT01934595|Dietary Supplement|Beneprotein|The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
75467917|NCT01934608|Behavioral|Refill synch|
75467918|NCT01934621|Behavioral|Strategy Training|
75467919|NCT01934621|Behavioral|Attention Control|
75630674|NCT02629900|Behavioral|Time restricted feeding|Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
75630675|NCT00676702|Dietary Supplement|Ensure Plus|A high-fat liquid meal of 500 ml of Ensure Plus
75630676|NCT00676702|Drug|Pancrelipase in combination with Ensure Plus|3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
75630677|NCT04152070|Other|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
75781923|NCT04154800|Drug|Itraconazole|Specified Dose on Specified Days
75781924|NCT04154800|Drug|Diltiazem|Specified Dose on Specified Days
75781925|NCT01236872|Dietary Supplement|Beetroot juice|250ml once of beetroot juice
75781926|NCT01236872|Dietary Supplement|Water|250ml once of low-nitrate mineral water
75781927|NCT01048229|Drug|Rasagiline|1 mg rasagiline once daily (plus placebo twice daily)
75917290|NCT02260323|Other|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
75917291|NCT02260323|Other|patient-tailored DMARDs|patient use tailored disease-modifying antirheumatic drugs
75917292|NCT03803592|Behavioral|Dyadic MCS program|"In the first 4 weeks, the dyads will attend the center-based FTF sessions. Each session will last for 1.5 hours. In the first 60 minutes, MCS activities (e.g. reality orientation, calculation and drawing) will be led by an occupational therapist. Skills in delivering the MCS activities will also be taught to equip CG with skills in leading the home-based sessions later. CG will leave in the last 30 minutes to attend a psychoeducation group on caregiving (led by social workers) and the PWD will continue the session.~From week 5 onwards, The home based session (Week 5-15) will be delivered by the CG 3 times weekly at home (30 - 45min/ session).The sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions held on the 8th and 12th week over the period."
75917293|NCT02067429|Procedure|Limbal Relaxing Incisions|
75917294|NCT02067429|Device|Toric Intraocular Lens|
75917295|NCT03434600|Other|Oxford UKA vs Sigma UKA|
75917296|NCT02280954|Drug|Indocyanine Green (ICG)|
75917297|NCT02070861|Other|Ventricular pacing and passive leg raise|Ventricular pacing and passive leg raise
75917298|NCT03432416|Drug|NES-E2 CVR|NES-E2 CVR
75917299|NCT02281032|Other|interRAI PC|"PREPARATORY PHASE~Step 0: Introductory information~Step 1: Training on the interRAI PC and the BelRAI webapplication~Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization~IMPLEMENTATION PHASE~Step 3: Identification of residents with palliative care needs, based on the surprise question~Step 4: Informed consent signature requirements~Step 5: Login to the BelRAI webapplication~Step 6: Definitions of roles and functions~Step 7: Completion of the interRAI PC~Step 8: Interpretation of results~Step 9: Use of results"
75917300|NCT02070939|Drug|PF-06260414|Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
75917301|NCT02070939|Drug|Placebo|Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
75917302|NCT02070939|Drug|PF-06260414|Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
75630678|NCT05753371|Drug|Metformin Hydrochloride 500 MG|Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
75917303|NCT02070939|Drug|Placebo|Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
75917304|NCT02070939|Drug|PF-06260414|Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
75324318|NCT04539457|Behavioral|Desktop helper|The 'Desktop Helper (version 10)' is a user-friendly information sheet developed by the IPCRG. This 'Desktop Helper (version 10)' has been developed in co-operation with several clinicians and experts in the field of COPD. These practical guidance and support are a tool for clinicians working in primary care. The 'Desktop Helper (version 10)' contains specific advice to prevent clashes. The specific advice of the 'Desktop Helper (version 10)' will be elaborated in decision trees. These will be integrated and implemented into the MedicomSmart system by Stichting Healthbase. Subsequently, these decision trees will provide GPs to conduct case-finding of COPD patients with 'medication-comorbidity clashes'. These are based on the 'Desktop Helper (version 10)' . Case finding will be done by the GP or the practice nurse (POH).
75630679|NCT04151836|Other|Exercise education|"weekly telephone or mobile application LINE consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects."
75630680|NCT00671476|Drug|pegylated liposomal doxorubicin hydrochloride|
75917305|NCT02070939|Drug|Placebo|Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
75917306|NCT02805504|Drug|Exparel|This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
75781928|NCT01048229|Drug|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
75781929|NCT04703296|Behavioral|MBAT course|"The MBAT will involve:~(i) 4 weekly 1.5-hour course sessions. The sessions will provide guided exercises, didactic information, and discussions to promote greater mindfulness.~(ii) Daily mindfulness practice that will be facilitated by the Measuring Mindfulness App (MMA) and/or instructor-delivered mindfulness practices. The daily mindfulness practice will require about 15 minutes to complete."
76075730|NCT03218176|Device|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
75324319|NCT04539457|Behavioral|E-learning|The e-learning module will be explanatory to the 'Desktop Helper (version 10)' how to perform the case-finding and in what way the case-finding can be beneficial to the patients with COPD and their (co)morbidities. This e-learning module will include several example cases and how to deal with the case-finding and the next steps in the process to reduce the (co)morbidity clashes with the medications of COPD. Together with the decision trees as inferred from the 'Desktop Helper (version 10)', the e-learning module is aimed at inducing a behavioral change in prescribing medication to a patient suffering from COPD and one or more (co)morbidities.
75917307|NCT02805504|Drug|Marcaine|This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
75917308|NCT04450940|Behavioral|PACV survey|
75917309|NCT04450940|Behavioral|Placebo survey|
75917310|NCT02067507|Behavioral|Tailored education and referral|LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
76075731|NCT03218176|Device|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
76075732|NCT04380844|Other|Beprevent|10 will become part of the intervention group. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
75630681|NCT00671476|Genetic|DNA methylation analysis|
75630682|NCT00671476|Genetic|TdT-mediated dUTP nick end labeling assay|
75630683|NCT00671476|Genetic|fluorescence in situ hybridization|
75630684|NCT00671476|Genetic|loss of heterozygosity analysis|
75630685|NCT00671476|Genetic|polymerase chain reaction|
75917311|NCT02067507|Behavioral|Staff training and patient reminders|AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities
75917312|NCT02067507|Behavioral|Clinic-level reminder systems|Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
75917313|NCT03434522|Device|vBloc Maestro Rechargeable System|vBloc therapy consists of a neuromodulation device that delivers intermittent, controllable electrical blocking algorithms, to the intra-abdominal vagus nerve for the treatment of obesity.
75630686|NCT00671476|Other|immunoenzyme technique|
75630687|NCT00671476|Other|immunohistochemistry staining method|
75630688|NCT00671476|Other|laboratory biomarker analysis|
75630689|NCT00671476|Procedure|breast duct lavage|
75630690|NCT00671476|Procedure|neoadjuvant therapy|
75630691|NCT00671476|Procedure|therapeutic conventional surgery|
75630692|NCT00908583|Drug|plasmapheresis|Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
75630693|NCT00908583|Drug|Bortezomib|Patients will receive bortezomib as described in protocol
75630694|NCT00908583|Drug|Rituximab|Patients will receive rituximab as described in protocol
75630695|NCT00908583|Drug|Methylprednisolone|Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
75630696|NCT04030117|Procedure|ACTIVA Bioactive restoration|Removal of Class II decay in second primary molars and placement of ACTIVA restoration.
75781930|NCT04770376|Other|Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.|Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.
76075733|NCT03215290|Procedure|TCS|"The cutting surface recognized as not good cutting surface was further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
75630697|NCT04030117|Procedure|Compomer restoration|Removal of Class II decay in second primary molars and placement of Compomer restoration.
75781931|NCT05291026|Other|mobile phone-based health information|health education and follow-up messaging, randomly assigned to each participant in the intervention arm using a randomization software, delivered once daily, as short message service (sms)
75781932|NCT00317603|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
75781933|NCT04112602|Other|Sputum|Sputum will be collected after a respiratory physiotherapy session, scheduled as part of routine care.
75781934|NCT04112602|Other|Tracheal aspiration|Tracheal aspirations will be collected in intubated patients (intubation for surgery under general anesthesia).
75781935|NCT01048307|Device|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
75917314|NCT03432338|Other|inquiries|Inquires reported to clinician.
76075734|NCT02537548|Other|Laboratory Biomarker Analysis|Correlative studies
76075735|NCT02537548|Procedure|Retroperitoneal Lymph Node Dissection|Undergo RPLND
76075736|NCT00897676|Drug|Exendin-(9-39)|100-500pmol/kg/min
76075737|NCT00897676|Drug|placebo|placebo (0.9% NaCl)
75630698|NCT04153162|Device|Stereotactic body radiation therapy|Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
75630699|NCT05753293|Other|breathing exercise|"Buteyko breathing technique developed to control hyperventilation and anxiety which leads to shortness of breath. It uses series of exercises to teach patients to breathe less deeply and less rapidly /Bhastrika Bellow Breathing is diaphragmatic breathing - deep breathing involving the diaphragm rather than the accessory muscles. Regulated pranayama exercises require inhalation, maintaining isometric contraction of respiratory muscles and forceful expiration. These techniques will strengthen respiratory muscles"
75630700|NCT00671632|Drug|Ramelteon, triazolam, and placebo (56 possible combinations total)|"Randomized sequence over eight consecutive days to include the following:~Ramelteon 16 mg, tablets, orally, one day only;~Ramelteon 80 mg, tablets, orally, one day only;~Ramelteon 160 mg, tablets, orally, one day only;~Triazolam 0.25 mg, capsules, orally, one day only;~Triazolam 0.50 mg, capsules, orally, one day only;~Triazolam 0.75 mg, capsules, orally, one day only;~Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;~Additional dose of study medication or placebo, tablets or capsules, orally, one day only."
75630701|NCT05754463|Other|The effect of plyometric training on balance and proprioception in athletes in different branches|Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
75630702|NCT03989505|Diagnostic Test|blood-draw for biomarker analyses|Blood will be drawn at three time-points: immediately before catherization, 12-24 hours after catheterization and 4-8 weeks after discharge. Creatinine will be measured for endpoint definition, while the markers urea, CRP (C-reactive protein), NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury marker-1), cystatin C, suPAR (soluble urokinase-type plasminogen activator receptor), and penKid will be measured as biomarkers of interest.
75630703|NCT02628340|Other|Ex-vivo analysis|
75630704|NCT04153708|Behavioral|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
75630705|NCT04153708|Behavioral|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
75630706|NCT00909363|Drug|Promacta|"WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment"
75630707|NCT00909363|Diagnostic Test|blood drawing in patients with WAS|blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
75630708|NCT00909363|Diagnostic Test|blood drawing in healthy controls|blood will be drawn once in healthy children as controls for platelet parameters
75630709|NCT00676936|Drug|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
75630710|NCT00676936|Drug|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
75630711|NCT00810355|Behavioral|Support Group|General support and problem solving for work activity
75630712|NCT00810355|Behavioral|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
75630713|NCT00810355|Behavioral|Cognitive Remediation|Computerized training to enhance cognitive functioning.
75781936|NCT03326518|Diagnostic Test|Lumentin® 44|Contrast agent
75781937|NCT03326518|Diagnostic Test|Diluted Omnipaque®|Contrast agent
75781938|NCT03326518|Diagnostic Test|Movprep®|Contrast agent
75781939|NCT00317369|Drug|OPC-6535(Tetomilast)|
75781940|NCT02049905|Drug|Aldoxorubicin|
75781941|NCT02049905|Drug|Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)|
75781942|NCT03620812|Dietary Supplement|rapeseed or soy protein or no protein|25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
75781943|NCT01062191|Device|Aquacel AG, typical carboxymethylcellulose dressing|"4 X 4, Aquacel silver sheet"
75781944|NCT01062191|Device|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Wound dressing
75781945|NCT02037659|Procedure|DermaBond treatment of Gastric Varices|Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
75781946|NCT03994510|Other|Clinical and biological assessments - a 5 Years follow-up|During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.
75781947|NCT03985787|Behavioral|Resistance Training|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
75781948|NCT03981965|Other|Physical activity|Physical activity as described previously.
75781949|NCT03325894|Drug|SHP465|SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.
75781950|NCT01058759|Drug|Enoxaparin|
75467920|NCT01934634|Drug|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
75630714|NCT02629744|Drug|Etrolizumab|Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
75630715|NCT02629744|Device|Prefilled Auto-injector (Rotaject)|Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
75630716|NCT05326321|Other|Study Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
75630717|NCT00677170|Drug|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
75630718|NCT03917433|Behavioral|Virtual Reality Exposure Therapy|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
75630719|NCT03917433|Behavioral|Tactile Feedback|In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
75630720|NCT03917433|Behavioral|Point-based Rewards|Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
75630721|NCT02629510|Drug|Tachosil|
75630722|NCT02629588|Behavioral|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
75630723|NCT00908349|Drug|Oxcarbazepine XR|Open Label Study
75630724|NCT01125566|Drug|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
75630725|NCT01125566|Drug|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
75630726|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
75630727|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
75781951|NCT01058759|Other|No Enoxaparin|
75781952|NCT01239368|Procedure|Adoptive Immunotherapy|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
75781953|NCT01239368|Biological|Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)|Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
75781954|NCT01239368|Biological|Th1/Tc1 Rapa Cell Therapy|Th1/Tc1Rapa: 5 x 10e(6) cells/kg
75781955|NCT03985709|Other|Probiotic product|Probiotic (Lactobacillus casei) once daily taken by 3 months.
75781956|NCT03985631|Other|Rehabilitation intervention|Rehabilitation sessions based on Tai Chi through telerehabilitation
75781957|NCT01146002|Drug|Guanfacine (sustained release)|Treated with study drug once screening and initial testing is completed (see protocol above)
75781958|NCT05632172|Procedure|implant insertion|bone level dental implant insertion
75781959|NCT01146626|Drug|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
75781960|NCT01146626|Drug|Peg+ Ribavirine|Peg+ Ribavirine
75781961|NCT01245686|Behavioral|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
75781962|NCT01245842|Other|Hand exercise program|Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
75781963|NCT03667586|Behavioral|Group cognitive behavioral therapy|Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
75467921|NCT01934634|Drug|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
75467922|NCT01934634|Drug|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
75467923|NCT01934673|Other|No treatment given|Patients will fill out a questionnaire by interview.
75630728|NCT04031872|Drug|LY3200882|Combination treatment with LY3200882 and capecitabine
75630729|NCT03414255|Biological|Micronized DHACM|1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
75630730|NCT03414255|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
75781964|NCT02924324|Device|propofol|
75781965|NCT02924324|Drug|ropivacaine|
75781966|NCT02924324|Behavioral|Wong-Baker FACES® Pain Rating Scale|Nurses will record patient-reported pain scores.
75324320|NCT03805997|Device|Dietary advice|participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.
75781967|NCT02924324|Behavioral|Post-procedural quality of life (QOL)|
76075738|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
75324321|NCT03805997|Other|Consumption of Bleu-Blanc-Coeur products|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
75324322|NCT03805997|Other|No consumption of Bleu-Blanc-Coeur products|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
75324323|NCT03805997|Biological|Blood sample|the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum
75324324|NCT03805997|Other|Contact|Participants of the group A will be contacted by phone,sms, mail by a technician every 15 days from 7th month of pregnancy to the 8th month of pregnancy and then every week from the 9th month of pregnancy to the 45th postpartum day (except the week of childbirth), in order to collect their consumption data of the delivered food products.
75324325|NCT03805997|Other|food questionnaire|Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum
75324326|NCT03805997|Other|newborn faeces sample|Newborn faeces sample will be collected at 21 Days post partum
75324327|NCT03805997|Other|breast milk sample|Breast milk sample will be collected at 21 days and 45 days post partum
75324328|NCT01995123|Behavioral|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
75467924|NCT01934686|Other|No treatment given|Patients will fill out a questionnaire by interview.
75467925|NCT01934699|Device|Cardiac ultrasound|Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.
75467926|NCT01934699|Device|MRI scanner|Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
75467927|NCT01934712|Drug|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
75467928|NCT01934712|Drug|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
75467929|NCT01934738|Drug|PF-06273340|Tablets, 100 mg TID, 14 days
75630731|NCT00810277|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
75630732|NCT04151758|Drug|Docosahexaenoic Acid Supplementation|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
75630733|NCT04151758|Other|Promotion of physical activity|All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
75630734|NCT04151758|Other|Promotion of healthy food habits|All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
75630735|NCT00670696|Drug|Rapydan|Topical anaesthetic plaster
75781968|NCT01239446|Other|Not relevant (there is no intervention in the present study)|Not relevant (there is no intervention in the present study)
75781969|NCT02528240|Procedure|EMS|
75781970|NCT02528240|Device|+ occlusive membrane|
75781971|NCT02528240|Device|conebeam CT|
75781972|NCT01239524|Procedure|denervation of thoracodorsal nerve or saving the nerve|
76075739|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
76075740|NCT01616459|Biological|Synflorix™|Intramuscular injection
76075741|NCT01616459|Biological|Prevnar 13™|Intramuscular injection
75324329|NCT01995123|Behavioral|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
75467930|NCT01934738|Drug|Placebo|Tablets, TID, 14 days
75630736|NCT00670696|Drug|tetracaine gel|Topical tetracaine gel
75630737|NCT05753137|Other|Acupuncture|The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.
75630738|NCT05753137|Other|Acupuncture placebo|A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.
75917315|NCT02071251|Procedure|Prospective wound complication protocol|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
75917316|NCT02281110|Device|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
75917317|NCT02783508|Drug|IV Meperidine|"Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered."
75467931|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
75781973|NCT05137574|Device|Integrated Pulmonary Index (IPI) monitoring|Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
75781974|NCT05137574|Drug|propofol|propofol
75781975|NCT05137574|Drug|ketamine|ketamine
75781976|NCT01146080|Device|Promus Element|Promus Element implanted to treat coronary artery lesions.
75917318|NCT02783508|Drug|Nitrous Oxide|"Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered."
75917319|NCT03434288|Other|Bone sampling|Bone biopsy in Diabetic patients with foot osteomyelitis
75917320|NCT02071329|Drug|Vaccine FP-01.1|
75917321|NCT02071329|Drug|Placebo|
75917322|NCT02071329|Other|Virus Challenge|
76075742|NCT01616459|Biological|Infanrix hexa™|Intramuscular injection
76075743|NCT03218254|Drug|Methylphenidate|Titration of MTP for treatment of fatigue
75781977|NCT01146080|Device|Promus|Promus stent implanted to treat coronary artery lesions
75781978|NCT05018546|Procedure|Irrigation force|RIRS with different irrigation force
75781979|NCT02852330|Device|SA16 research software|Software for measurement of voltage tomography intraoperatively.
75781980|NCT02852330|Device|CS19 (1.6.2)|Software for measurement of voltage tomography post-operatively.
76075744|NCT03218254|Drug|Placebo|Placebo
76075745|NCT04415801|Diagnostic Test|Repeated removal and re-placement of healing and prosthetic abutments|Repeated removal and re-placement of healing and prosthetic abutments
75324330|NCT01995123|Behavioral|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
75467932|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
75467933|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
75781981|NCT01236950|Drug|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indication
75467934|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
75781982|NCT01236950|Drug|Delmopinol mouthrinse|Commercial mouthrinse with manufacturer's use indication
76075746|NCT03215056|Drug|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
76075747|NCT03215056|Drug|Normal saline|Placebo
75324331|NCT00781079|Behavioral|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
75324332|NCT01982643|Drug|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
75467935|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
75467936|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
75630739|NCT04153630|Biological|mesenchymal stem cells derived from bone marrow (BM-MSCs)|Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
75630740|NCT00677248|Drug|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
75630741|NCT00677248|Drug|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
75781983|NCT04971746|Drug|Pirfenidone|On Days 1 and 13, participants will receive an oral dose of pirfenidone.
75781984|NCT04971746|Drug|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 daily.
75781985|NCT04971746|Drug|Nintedanib|On Days 1 and 13, participants will receive an oral dose of nintedanib.
75917323|NCT00676494|Device|Pathway PV Atherectomy System|The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in lower limb peripheral vasculature during percutaneous interventional procedures.
75917324|NCT03439592|Diagnostic Test|collection of fecal material|in study population we will collect fecal material to analyze the microbiotic flora by genetic techniques.
75630742|NCT05754307|Procedure|Access Flap|Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.
75917325|NCT02071407|Drug|Midazolam|"For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.~Morphine can be used to supply adequate analgesia."
75917326|NCT02071407|Drug|Placebo|
76075748|NCT04626401|Behavioral|Forearm immobilization|Two days of forearm immobilization
76075749|NCT01919801|Drug|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
75781986|NCT00369161|Drug|Everolimus (RAD001)|
75781987|NCT00369161|Drug|Tacrolimus|
75781988|NCT00369161|Drug|Basiliximab|
75781989|NCT00369161|Drug|Corticosteroids|
75781990|NCT01143974|Drug|pemetrexed plus cisplatin|pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
75781991|NCT01239836|Behavioral|Constructivist interactive workshop on urinary incontinence|A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.
75781992|NCT01239836|Behavioral|Evidence-based self-management tool|Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.
75781993|NCT01239836|Behavioral|General health lecture|Participants will attend a lecture on general women's health issues that does not address urinary incontinence.
75781994|NCT04904042|Device|Use of plasma of neutral argon|"Evaluation of the mesentery or peritoneum area infiltrated by miliary implants that is going to be treated. Determination of the PCI. Collection of several samples of the mesenteric peritoneum or parietal peritoneum with tumor involvement (implants between 1-2.5mm of diameter).~It will established a matrix which will be divided into 12 quadrants where the tissue with implants will be placed and it will be treated according to specific power (80-100%), and for an action time of 2-4 seconds or until macroscopic tumor destruction. For each power, application of Plasmajet at 1, 2 and 3 cm from the target tumor tissue.~The in-vivo effect will be evaluated with the use of ball-tip in terms of damage to the serosa or vascularization of the mesentery."
75781995|NCT01146158|Procedure|Axillary dissection for breast carcinomas|surgery Axillary dissection
75781996|NCT02637986|Dietary Supplement|Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|2 capsules will be given per day
75781997|NCT02637986|Other|Placebo - capsule with no active ingredient|2 capsules will be given per day
75781998|NCT02437916|Drug|AMG 228|AMG 228 will be administered intravenously
75917327|NCT03432104|Dietary Supplement|Oxxynea®|Oxxynea® is a blend of polyphenol-rich extracts from olive, grape, pomegranate, green tea, grapefruit, orange and blueberry. Dosage is 1 x 450 mg-capsule.
75917328|NCT03432104|Dietary Supplement|Placebo|Placebo product is 100% maltodextrin. Dosage is 1 x 450 mg-capsule of identical appearance than the verum capsule.
75917329|NCT03434210|Other|LAT-treated Community Model|The subjects in experimental group is on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
75917330|NCT03434210|Other|care as usual|Control group will get usual community care, the treatment is identified by doctors, patients and care-giver as usual.
75630743|NCT05754307|Procedure|Closed Surgical Technique|"Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentionally excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required."
75917331|NCT02281266|Procedure|curative resection|
75917332|NCT02281266|Drug|thymalfasin|1.6mg twice a week, 12 months
75917333|NCT02281266|Drug|nucleoside analog (suggest to use entecavir)|
75630744|NCT00637598|Radiation|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
75917334|NCT02065089|Other|playing the ipad quiz game|Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.
76075750|NCT01919801|Drug|Placebo|
76075751|NCT01919723|Drug|Ticagrelor|Ticagrelor loading dose
76075752|NCT01919723|Drug|Eptifibatide|i.v. infusion
76075753|NCT01919489|Drug|Liraglutide + OADs|Liraglutide subcutaneously daily
76075754|NCT01919489|Drug|Glargine + OADs|Glargine once daily subcutaneously
76075755|NCT01919411|Drug|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
76075756|NCT01919411|Drug|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
76075757|NCT01901393|Drug|IV ibuprofen|
76075758|NCT01901393|Drug|Ketorolac|
75630745|NCT00671710|Drug|Aminolevulinic Acid|Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
75630746|NCT04311476|Other|Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy|Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
75917335|NCT03432026|Device|High resolution computed tomography scan of the chest.|High resolution computed tomography scan of the chest & pulmonary function tests will be done for every patient to classify them.
75917336|NCT00625326|Drug|COL-121|75 µg/g COL-121 Ointment
75917337|NCT00625326|Drug|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment
76075759|NCT01890707|Procedure|General Anesthesia|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
76075760|NCT01890707|Procedure|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
76075761|NCT01900691|Device|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
76075762|NCT01890473|Drug|Abatacept|
76075763|NCT01889069|Drug|Rituximab|Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
75630747|NCT04311476|Drug|0.9% Sodiun Chloride|0.9% Sodiun Chloride in control group
75630748|NCT00911716|Biological|bevacizumab|
75630749|NCT00911716|Drug|cyclophosphamide|
75630750|NCT00911716|Drug|docetaxel|
75630751|NCT00911716|Procedure|adjuvant therapy|
75630752|NCT00912184|Device|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
75630753|NCT00912184|Device|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
75630754|NCT00677326|Biological|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
75630755|NCT00595582|Dietary Supplement|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
75781999|NCT00337571|Drug|Aripiprazole|Tablets, Oral, once daily, 8 weeks
75782000|NCT00337571|Drug|Placebo|Tablets, Oral, once daily, 8 weeks
75782001|NCT01247792|Behavioral|SOPs for decision-making and communication|Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
75782002|NCT01247870|Drug|Metformin|Metformin 1 g twice daily for 28-35 days
75782003|NCT01247870|Drug|Placebo|Placebo
75782004|NCT02528396|Drug|BioChaperone insulin lispro|Injection at t0,or t+15 minutes or t-15minutes with test meal
75917338|NCT00625326|Drug|Placebo|Placebo
75917339|NCT00625326|Drug|COL-121|150 µg/g COL-121 Ointment
75917340|NCT00625326|Drug|COL-121|300 µg/g COL-121 Ointment
75917341|NCT02065167|Biological|Cultured autologous Mesenchymal Cells|Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
76075764|NCT01889069|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
76075765|NCT01889069|Drug|Vincristine|Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
75630756|NCT00677404|Biological|BM-MNC injection|Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
75630757|NCT04031482|Other|No intervention, only standard care|"The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to~analyse disease progression~systematize findings about treatment processes~identify potential influencing factors~review any new diagnostic procedures~identify potential test subjects for further study~evaluate the safety of various treatment concepts"
75630758|NCT04153474|Procedure|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
75630759|NCT04153474|Procedure|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
75630760|NCT00671944|Other|Low protein diet|Low protein diet for 6.5 weeks
75782005|NCT02528396|Drug|Humalog®|Injection at t0,or t+15 minutes or t-15minutes with test meal
75782006|NCT01062347|Biological|Zinc|
75782007|NCT03985319|Drug|YYD601 20mg|Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
75782008|NCT03985319|Drug|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori
75782009|NCT01237028|Drug|Calcitriol|Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
75782010|NCT01146236|Device|Sutures|Orthopedic surgical wounds closed with sutures
75782011|NCT01146236|Device|Staples|Orthopedic surgical wounds closed with metallic staples
75917342|NCT03434054|Drug|Losartan|blood pressure medication
75917343|NCT03434054|Other|Placebo|non-active sham intervention
75917344|NCT02071563|Dietary Supplement|CSB14|
75917345|NCT02071563|Dietary Supplement|RUSF1|
75917346|NCT02071563|Dietary Supplement|SC+|
75782012|NCT04831658|Drug|the dose-escalation phase|"The study adopts the 3+3 design,The dose planned to be explored is the daily oral dose of the BTK inhibitor abutinib, which is 100 mg, 150 mg and 200 mg, respectively.Orelabrutinib continues to be taken orally until the tumor is relieved for 3 months; PD-1 monoclonal antibody is used by intravenous drip, 21 days as a treatment cycle, and a total of 1 year of observation; formustine is used by intravenous drip for 21 days It is a treatment cycle, a total of 6 cycles of observation; after 2 cycles, the efficacy is evaluated, and adverse reactions are recorded. At the same time, MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath, and intrathecal injection once per treatment cycle, a total of 6 times."
75917347|NCT04472988|Behavioral|Eye Movement Desensitization and Reprocessing|"The first session will be assigned to the assessment and the exploration of the personal history and for presenting the method to the client. Then, each case will be conceptualized according to the Model of Two Method Approach and the protocol for the treatment will be used. The procedure will be organized around targeting the most ten disturbing memories which happened before the illness debut, including stressful or traumatic memories from childhood. The rationale behind this approach is that adverse events leave traces in the neural network of an individual in such a way that these cause a variety of emotional or cognitive symptoms. If we consider the illness as being also a symptom of a traumatic past, then we expect that by accessing the dysfunctionally stored memory and stimulating the innate processing system, the symptoms of the illness diminish."
75917348|NCT04472988|Other|Placebo|The participants randomised in this group will receive a protocol focused only on present and future (present symptoms, daily problems, future projects). The psychologist will lead the discussion anywhere except for the past.
75917349|NCT04472988|Drug|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
75467937|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
75630761|NCT00680446|Drug|Immunoglobulin G (Ig NextGen 16%)|Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
75630762|NCT00672022|Drug|Zavesca (Miglustat)|
75782013|NCT01240850|Drug|Methotrexate+Prednisone|Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
75630763|NCT04150666|Dietary Supplement|Hydration|the same with arm descriptions
75782014|NCT01240850|Drug|Prednisone|
75782015|NCT04813016|Drug|Tramal 1|Early intraperitoneal injection of tramal and bupivacaine
75782016|NCT04813016|Drug|Tramal 2|Late intraperitoneal injection of tramal and bupivacaine
75782017|NCT04813016|Drug|Dexmedetomidine 1|Early intraperitoneal injection of dexmedetomidine and bupivacaine
75782018|NCT04813016|Drug|dexmedetomidine 2|Late intraperitoneal injection of dexmedetomedine and bupivacaine
75782019|NCT01146314|Behavioral|Family Focused Lifestyle Intervention|The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
75782020|NCT00368927|Drug|sulindac|Given orally
75782021|NCT00368927|Other|placebo|Given orally
75782022|NCT01146938|Drug|fimasartan|single administration of fimasartan 120mg
75782023|NCT01146938|Drug|fimasartan|single administration of fimasartan 120mg
75782024|NCT01237106|Other|IVM|all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
75782025|NCT01324661|Behavioral|Ostracism|Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
75782026|NCT02686502|Behavioral|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
75917350|NCT03433976|Drug|spinal anesthesia|spinal anesthesia for planned cesarean sections
75917351|NCT03783741|Behavioral|Questionnaire|Interview
75917352|NCT04473144|Drug|Ulinastatin|In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
75917353|NCT04451564|Behavioral|Mindfulness oriented recovery enhancement|8- week psychological program based on mindfulness techniques
75782027|NCT04792112|Behavioral|Decision support tool|Decision support tool for late preterm antenatal corticosteroids
75782028|NCT01242410|Device|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
75917354|NCT02605642|Drug|CT-P13|biosimilar infliximab
75917355|NCT02283450|Drug|Qiliqiangxin Capsule|
76075766|NCT01889069|Drug|Doxorubicin|Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
75467938|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
75467939|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
75467940|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
75630764|NCT00677638|Device|Ventor Embracer|Implantation of Ventor Embracer
75630765|NCT00680602|Behavioral|Group Cognitive Behavior Therapy|Structured protocol described by Cordioli et al., 2003
75630766|NCT00680602|Drug|SSRI (fluoxetine, sertraline, paroxetine, citalopram)|Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
75630767|NCT00677716|Drug|131I-chTNT-1/B MAb (Cotara)|Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
75630768|NCT00677794|Drug|Clear fluids|Clear fluids only after lunch.
75917356|NCT03128450|Biological|human neural stem cell|human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel
75917357|NCT00624858|Drug|naltrexone SR 32 mg/ bupropion SR 360 mg daily|"All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.~During the study, subjects will receive ancillary therapy including advice on diet and exercise"
75917358|NCT02071797|Device|Induced Therapeutic Hypothermia|Head to head, direct comparator of two standard care devices/treatments (RhinoChill versus Blanketroll lll) to assess time to induced therapeutic hypothermia
75917359|NCT03128528|Drug|Empagliflozin 10mg|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
75917360|NCT03128528|Drug|Placebo Oral Tablet|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
75630769|NCT00677794|Drug|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
75917361|NCT02071641|Drug|Sunitinib|
75917362|NCT02253810|Drug|Tranexamic Acid|Medication administered intra-operatively to promote blood clotting.
75630770|NCT00677794|Drug|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
75630771|NCT02628496|Drug|Fluorescein injection, USP 10%|-2.5 ml intravenous 10 minutes before procedure
75917363|NCT02253810|Drug|Placebo|Saline solution
75324333|NCT01996839|Drug|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
75630772|NCT02628496|Device|Confocal laser microlaryngoscopy|
75917364|NCT03128606|Drug|GLPG3067 single dose|GLPG3067 oral suspension, single ascending doses, daily
75917365|NCT03128606|Drug|Placebo single dose|Placebo, oral suspension, daily
75917366|NCT03128606|Drug|GLPG3067 multiple dose|GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
75917367|NCT03128606|Drug|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
75917368|NCT03128606|Drug|GLPG3067 oral suspension|GLPG3067 oral suspension, single dose, daily
75630773|NCT02628496|Procedure|Biopsy (standard of care)|
75917369|NCT03128606|Drug|GLPG3067 oral tablet|GLPG3067 oral tablet, single dose, daily
75917370|NCT03128606|Drug|GLPG3067/GLPG2222 multiple dose|GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
75917371|NCT03128606|Drug|GLPG3067/GLPG2222 Placebo multiple dose|GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
75917372|NCT03128606|Drug|GLPG3067/GLPG2222/GLPG2737 multiple dose|GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
75917373|NCT03128606|Drug|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
75630774|NCT02628496|Procedure|KTP laser photoablation (standard of care)|
75917374|NCT00624390|Device|Sepraspray|
75917375|NCT04411966|Diagnostic Test|18F-fluorothymidine|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
75324334|NCT01996839|Drug|Loteprednol Etabonate Gel (TID)|One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
75324335|NCT01996839|Drug|Vehicle (BID)|One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
75324336|NCT01996839|Drug|Vehicle (TID)|One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
75324337|NCT00797797|Drug|No Treatment Added|No added treatment
75917376|NCT03298893|Drug|Nivolumab Injection|2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks
75324338|NCT00797797|Drug|Milnacipran Added|Milnacipran 100 mg/d added
75324339|NCT01996917|Device|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
75630775|NCT00680680|Drug|Dutasteride|Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months
75630776|NCT04150588|Drug|Efrin drops|The amount that the eyelid rise after Erin drops before surgery
75630777|NCT04150744|Combination Product|radiofrequency ablation|take advantage of RFA to destroy hepatocellular carcinoma by high temperature
75630778|NCT04150432|Device|Edmon|New device for exhaled propofol concentration measurements
75630779|NCT00808015|Drug|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
75630780|NCT00680758|Drug|cisplatin|"Dose Level: -3 20mg/m2/week 3-6 patients~Dose Level: -2 20mg/m2/week 3-6 patients~Dose Level: -1 25mg/m2/week 3-6 patients~Dose Level: 1 25mg/m2/week 3-6 patients~Dose Level: 2 25mg/m2/week 3-6 patients~Dose Level: 3 25mg/m2/week 3-6 patients"
75630781|NCT00680758|Drug|everolimus|"Dose Level: -3 20mg/m2/week 3-6 patients~Dose Level: -2 20mg/m2/week 3-6 patients~Dose Level: -1 20mg/m2/week 3-6 patients~Dose Level: 1 20mg/m2/week 3-6 patients~Dose Level: 2 25mg/m2/week 3-6 patients~Dose Level: 3 30mg/m2/week 3-6 patients"
75917377|NCT03298893|Drug|Cisplatin|40 mg/m2, once a week during radiotherapy
75917378|NCT03298893|Radiation|radiotherapy|"Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.~An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.~An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center."
75917379|NCT04678466|Biological|flotetuzumab|CD123 x CD3 bispecific DART® antibody
75917380|NCT00621894|Drug|LGD-4665|LGD-4665 Thrombopoietin mimetic
75917381|NCT00621894|Drug|Placebo|Placebo
75917382|NCT04806490|Diagnostic Test|the diagnosis for Yin Deficiency Syndrome|The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome
75917383|NCT02065323|Drug|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
75917384|NCT02065323|Drug|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
75917385|NCT02283606|Device|Accuvix SnonAce UGEO|vaginal ultrasonography
75917386|NCT02521454|Behavioral|MBRT|
75782029|NCT04770662|Other|Questionnaires|"Administered Questionnaires:~Dutch version of Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS, Goodman W.K. e.a.)~Dutch version of Eating Disorder Inventory-3 (EDI-3, David M. Garner)~General Questionnaire: demografic , scholar and social information and child psychiatric history~Dutch version of the Child Behavior Checklist (CBCL, T.M. Achenbach)~Anorectic Behavior Observation Scale (ABOS, Vandereycken W., Universitair Centrum Kortenberg, 1992)"
75782030|NCT04742582|Dietary Supplement|Preterm Infants - fed fermented formula|Feeding infants with fermented formula supplemented with the fermentation products of the probiotic L. paracasei CBA L74 (800 mg / 100 ml of milk) (84 kcal and 2.9 g protein per 100 ml)
75782031|NCT04742582|Other|Preterm Infants - fed standard formula|Feeding infants with standard formula with the addition of skimmed milk powder in order to provide the same protein and energy amount of the supplemented formula (84 kcal and 2.9 g protein per 100 ml)
75782032|NCT04742582|Other|Pre-term Infants - breastfed|Breastfeeding infants - Reference group
75782033|NCT02655692|Drug|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
75782034|NCT02655692|Drug|Placebo/Saline|This is a saline placebo/non-active solution.
75782035|NCT02243384|Procedure|Laparoscopic Hepatectomy|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
75782036|NCT02243384|Procedure|Radiofrequency Ablation|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
75782037|NCT01146470|Dietary Supplement|RGC|dosage of Red Grape Cells once a day, during 3 months
75782038|NCT01146470|Dietary Supplement|Placebo|dosage of Placebo once a day, during 3 months
75782039|NCT04696640|Behavioral|Remote Patient Monitoring|Participants' glucose data will be monitored by the study team using population analytic reports. Participants who either have excessive hypoglycemia or hyperglycemia on these reports will be contacted by a pediatric endocrinologist (the principal investigator) to discuss any necessary adjustments to their home diabetes management plans. This intervention will be in addition to their usual care (regular visits at the UC Davis Pediatric Endocrinology clinic).
75782040|NCT01237262|Drug|Adalimumab, etanercept, infliximab|"Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.~Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks."
75782041|NCT03913754|Other|Psycho-social consequences of lupus erythematosus|It will be necessary to take into account the psychosocial experience of the disease [47] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
75782042|NCT03913676|Behavioral|Velibra|"Velibra is grounded in a cognitive-behavioral theoretical orientation and consists of six treatment modules representing different skills and therapeutic techniques. Each of the first five modules is followed by a training session, and contains activities related to training attention biases (CBM-I). All sessions plus trainings are designed to be completed in 1 - 2 hours, depending on the user's reading speed, interest, motivation, and individual path through the program. The modules cover a variety of therapeutic content that is broadly consistent with a cognitive-behavioral perspective. The modules' content draws from therapeutic strategies: (1) Cognitive Modification, (2) Mindfulness, Acceptance, and Relaxation techniques (4) Exposure, (5) Interpersonal Skills, (6) Psychoeducation and Relapse Prevention."
75782043|NCT01147328|Other|Virtual Health Record (VHR)|Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
75917387|NCT02283684|Procedure|Greenlight laser PVP|Vaporization of the prostate adenoma using 532nm laser with 180W XPS system using Moxy fiber
75324340|NCT03496233|Drug|Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]|Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
75917388|NCT02283684|Procedure|Bipolar TUVP|Bipolar energy is used for generation of plasma that ends up by vaporization of the prostate adenoma
75917389|NCT02071953|Device|Experimental adhesive w/out phosphoric acid in post. rest.|Experimental adhesive without phosphoric acid in posterior restorations
76075767|NCT01889069|Drug|Prednisone|Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
75324341|NCT04482673|Drug|Daily Vitamin D3|6000 IU vitamin D3 daily
75324342|NCT04482673|Drug|Daily placebo|Placebo daily
75324343|NCT04482673|Drug|Bolus vitamin D3|Bolus 20,000 IU vitamin D3 daily for 3 days
75324344|NCT04482673|Drug|Bolus placebo|Bolus placebo daily for 3 days
75324345|NCT01984515|Behavioral|Referral Management System|"Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD."
75324346|NCT00245063|Drug|cediranib maleate|Given PO
75324347|NCT00245063|Other|laboratory biomarker analysis|Correlative studies
75324348|NCT00245063|Other|pharmacogenomic studies|Optional correlative studies
75324349|NCT02151487|Drug|Ropivacaine|Ropivacaine alone
75324350|NCT02151487|Drug|Ropivacaine and dexamethasone|Ropivacaine combination with dexamethasone
75917390|NCT02071953|Device|Experimental adhesive with phosphoric acid in post. rest.|Experimental adhesive with phosphoric acid in posterior restorations
75917391|NCT04806256|Behavioral|Clinical Decision Support System|This project is based on the artificial intelligence (AI) algorithm to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the traditional Chinese medicine intervention Clinical Decision Support Systems (CDSS) for dry eye. At the same time, the CDSS is provided to clinicians for their selection.
76075768|NCT01889069|Drug|Bendamustine|Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
75324351|NCT02151487|Drug|Ropivacaine and clonidine|Ropivacaine combination with clonidine
75324352|NCT02151487|Drug|Ropivacaine, dexamethasone and clonidine|Ropivacaine combination with dexamethasone and clonidine
75324353|NCT02148809|Radiation|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
75782044|NCT01329770|Dietary Supplement|Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|"Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)~Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks"
75324354|NCT03805763|Procedure|Large extent of ILM Peeling|The extent of ILM peeling is 4DD
75324355|NCT03805763|Procedure|Small extent of ILM Peeling|The extent of ILM peeling is 2DD
75324356|NCT05318339|Drug|Trastuzumab|"A loading dose of trastuzumab 8mg/kg IV over 90 minutes will be administrated on day 1 of week 1.~For all subsequent doses, trastuzumab 6mg/kg IV over 30 minutes will be administrated every three weeks.~Pyrotinib 400mg PO daily will be administrated at the same time."
75467941|NCT01934751|Other|Delayed Intervention (DI)|Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
75630782|NCT00680758|Drug|paclitaxel|"Dose Level: -3 65mg/m2/week 3-6 patients~Dose Level: -2 70mg/m2/week 3-6 patients~Dose Level: -1 70mg/m2/week 3-6 patients~Dose Level: 1 80mg/m2/week 3-6 patients~Dose Level: 2 80mg/m2/week 3-6 patients~Dose Level: 3 80mg/m2/week 3-6 patients"
75630783|NCT04150198|Device|TEP/IRM|All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
75782045|NCT01329770|Dietary Supplement|Placebo|Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
75782046|NCT03913520|Other|Outcome research|patients will undergo an evaluation of their outcome at 30 days postoperatively
75917392|NCT04806256|Other|Routine intervention|The routine intervention without CDSS is also the clinically common intervention at present.
75917393|NCT03431870|Other|Trans-esophageal echocardiography|Perform a trans-esophageal echocardiography before and after anesthesia.
75324357|NCT00763919|Behavioral|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
75324358|NCT00763919|Behavioral|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
75324359|NCT00763919|Behavioral|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
75324360|NCT00763919|Behavioral|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
75467942|NCT01934751|Other|Rapid Intervention (RI)|Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
75917394|NCT00673062|Drug|SCH 900538|(4X50mg Capsules)
75467943|NCT01934777|Drug|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
75917395|NCT00673062|Drug|Pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
75917396|NCT00673062|Drug|Placebo Capsules|Placebo
75917397|NCT02260245|Behavioral|Team training using the TeamSTEPPS model|Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
75467944|NCT01934777|Drug|placebo pearls|placebo
75467945|NCT01934803|Dietary Supplement|Zinc gluconate|Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
75467946|NCT01934803|Dietary Supplement|Placebo|
75630784|NCT00677872|Drug|PRX-08066|
75917398|NCT00504270|Drug|Placebo|po daily
75917399|NCT00504270|Drug|RG3421 120mg|120mg po daily
75917400|NCT00504270|Drug|RG3421 20mg|20mg po daily
75467947|NCT01934816|Other|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
75630785|NCT00677950|Procedure|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
75782047|NCT03644654|Procedure|Standard care group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. Fluid boluses will be used according to anesthesiologists decision (timing and amount of fluids). In case of drop of mean arterial pressure (MAP) below 65 mmHg norepinephrine will be started (with initial bolus of 5 - 10 ug).
75630786|NCT05754229|Device|AI-assisted colonoscopy|The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
75630787|NCT02628184|Other|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
75630788|NCT00678106|Drug|Dalbavancin|Subjects weighing > 60 Kg: 1 gram IV single dose Subjects weighing < 60 Kg: 15 mg/Kg IV
75630789|NCT00810199|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg IV every 4 weeks.
75630790|NCT00810199|Drug|methotrexate|Approximately 15-17 mg methotrexate capsule orally once a week.
75630791|NCT00810199|Drug|placebo|Placebo matching methotrexate capsule taken orally once a week.
75630792|NCT00877006|Drug|bendamustine|
75630793|NCT00877006|Drug|rituximab|
75782048|NCT03644654|Procedure|Noninvasive monitoring group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. In case of hypotension (defined as a mean arterial pressure below 65 mmHg), the intervention will be led according to a protocol based on cardiac index, systemic vascular resitance and stroke volume variation (SVV) values (ClearSight, Edwards).
75782049|NCT00316589|Biological|IMVAMUNE (MVA-BN)|2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
75782050|NCT03913364|Dietary Supplement|Probiotic|B. bifidum 900791-containing ice cream
75324361|NCT04703335|Drug|Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.
75782051|NCT03913364|Dietary Supplement|Placebo|Placebo ice-cream
76075769|NCT02533180|Biological|Immunosuppression withdrawal|"Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued."
75630794|NCT00877006|Drug|vincristine|
75630795|NCT00877006|Drug|prednisone|
75630796|NCT00877006|Drug|cyclophosphamide|
75782052|NCT01251068|Device|near infrared spectroscopy: invos 5100|duration:six hours
75630797|NCT00877006|Drug|doxorubicin|
75630798|NCT00678184|Drug|Atorvastatin|80 mg atorvastatin on two following days each
75630799|NCT02608255|Other|blood samples|
75782053|NCT01251068|Device|INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
75782054|NCT01251068|Device|near infrared spectroscopy device|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
75782055|NCT01147562|Procedure|Collection of biospecimen|Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
76075770|NCT04381780|Dietary Supplement|Recovery Factors|A unique porcine serum based polypeptide nutritional support
76075771|NCT03218332|Diagnostic Test|Biomarkers for detecting possible CTE invivo|Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
76075772|NCT03218098|Procedure|Lobectomy via UVATS|lobectomy with small skin access 4 cm
76075773|NCT03218020|Other|No intervention assigned, this is an observational study.|No intervention assigned, this is an observational study.
76075774|NCT00898222|Drug|aspirin|81 mg orally daily for two weeks
75630800|NCT00876928|Drug|vitamin D|liquid vitamin D3 dissolved in medium chain triglyceride once a week
75630801|NCT00876928|Drug|placebo|medium chain triglyceride given once per week
75630802|NCT02627950|Drug|Morphinhydrochloricum|5 mg morphine intravenously
75630803|NCT02627950|Drug|Metoclopramide|10 mg MCP intravenously
75630804|NCT02627950|Drug|Ticagrelor|180 mg ticagrelor orally
75630805|NCT02627950|Drug|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
75630806|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
75630807|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
75782056|NCT01048385|Dietary Supplement|Coenzyme Q10 concomitant treatment|Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
75782057|NCT01048385|Dietary Supplement|Placebo|Treated with capsules containing the vehicle (Sesame oil).
75782058|NCT03916640|Drug|ADO09 formulation|Subcutaneous injection of ADO09 formulation
75782059|NCT03916640|Drug|Placebo|Subcutaneous injection of 0.9% NaCl
75782060|NCT03916640|Drug|Symlin®|Subcutaneous injection of pramlintide
76075775|NCT01830556|Drug|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
76075776|NCT03217630|Other|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
76075777|NCT03217942|Drug|NGF|Intramuscular injection
76075778|NCT03217552|Diagnostic Test|Mologic Biomarker Panel|In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
76075779|NCT00903448|Drug|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
76075780|NCT00903448|Drug|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
76075781|NCT01830634|Behavioral|Theraband with strengthening and stretching exercise|"Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day."
76075782|NCT00895180|Biological|olaratumab|Given IV
76075783|NCT00895180|Biological|ramucirumab|Given IV
75630808|NCT00807937|Drug|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
75630809|NCT00807937|Drug|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
75630810|NCT00678340|Device|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
75782061|NCT03916640|Drug|Humulin®|Subcutaneous injection of human insulin
75782062|NCT03916640|Drug|Humalog®|Subcutaneous injection of insulin lispro
75782063|NCT03916250|Drug|PF-06700841 cream|PF-06700841 will be applied topically
75782064|NCT03916250|Drug|White petrolatum|White petrolatum will be applied topically
75782065|NCT01062503|Drug|Zoledronic acid|ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
75782066|NCT02533037|Other|Traditional Instability Tools|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
75782067|NCT02533037|Other|Ankle Destabilization Shoes|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
75782068|NCT03916406|Drug|PF 06835919|300 mg
75782069|NCT03916406|Drug|Midazolam|7.5 mg
75782070|NCT00316277|Behavioral|Standard Medical Management (SMM) of Prescription Opiate Abuse|Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
75917401|NCT04827082|Other|Diacutaneous fibrolysis|Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
75917402|NCT03559803|Drug|Cisplatin|"Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion)."
75917403|NCT03439436|Drug|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
75917404|NCT03439436|Drug|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
75630811|NCT00678340|Device|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
75630812|NCT00681070|Other|Arm 2: Absorbable sutures|use of absorbable catgut sutures in pediatric facial lacerations
75630813|NCT00681070|Other|Arm 1: non-absorbable sutures|Use of non-absorbing sutures
76075784|NCT03214042|Device|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
75467948|NCT01934829|Drug|urea-based cream|"urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator."
75782071|NCT00316277|Behavioral|Enhanced Medical Management (EMM) of Prescription Opiate Abuse|Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
75467949|NCT01934842|Device|TAP20-C|
75782072|NCT01249352|Drug|Nimotuzumab|200 mg, IV Weekly IV dose for up to 26 weeks.
75782073|NCT01249352|Drug|Cisplatin|75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
75782074|NCT01249352|Drug|Fluorouracil|1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
75782075|NCT01249352|Radiation|Radiotherapy|Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day
75917405|NCT04826848|Diagnostic Test|Lactate|We will evauate the lactate clearance of the patients in 6 hours period. Lactate clearance = [(Initial lactate - 6th hour lactate) / Initial lactate] * 100
75917406|NCT00502710|Drug|Placebo|Placebo po daily.
75917407|NCT00502710|Drug|RO4876904|Escalating doses, at a starting dose of 12.5mg po daily.
75917408|NCT03439358|Drug|Magnesium Sulfate|Bolus infusion: 100mL normal saline with 4g MgSO4 over 30 minutes Maintenance infusion: 25mL normal saline per hour with 1g MgSO4
75917409|NCT03439358|Other|Normal Saline|Bolus infusion: 100mL normal saline over 30 minutes Maintenance infusion: 25mL normal saline per hour
75917410|NCT02072031|Drug|Anlotinib|Anlotinib p.o. qd
76075785|NCT01830868|Drug|Zonisamide tablets|The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
75467950|NCT01934842|Device|SAFE-T-FILL|
75467951|NCT01934907|Other|Washing of packed RBC by normal saline|
75467952|NCT01934933|Drug|celebrex|
75467953|NCT01934933|Drug|Enbrel|
75467954|NCT01934933|Drug|Enbrel plus Celebrex|
75630814|NCT00681148|Drug|Botox injection|Intraprostatic injection of Botox (100 units for < 30 cc prostate; 200 units for > 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
75630815|NCT00681148|Drug|Saline injection|Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
75630816|NCT02627716|Procedure|SOS Plan|"It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.~The booklet outlines four avenues to consider:~Contact details / contact person~Treatment and current follow-ups~Medical care in the event of a crisis~Practical aid in the event of a crisis~Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks."
75917411|NCT02072031|Drug|Sunitinib maleate|Sunitinib 50 mg p.o. qd
75467955|NCT01934946|Other|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
75467956|NCT01934946|Other|home rehabilitation|6 times home rehabilitation services within 3 months
75917412|NCT03431792|Device|Long Tail Balloon|s. description of experimental Arm
75917413|NCT05616442|Drug|Ketotifen|Mast cell stabilizer
75917414|NCT05616442|Drug|Vitamin E|Dietary supplement
75917415|NCT00498966|Drug|Perifosine|"Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food."
75917416|NCT03439202|Other|Hypoxia|Subject will conduct low-intensity exercise on a bike in different hypoxic conditions.
75917417|NCT04795570|Procedure|Transurethral resection of the prostate or bladder|All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.
75467957|NCT01934959|Drug|Bifico|
75467958|NCT01935011|Other|PD, DBS|PD DBS frequency on swallowing function
75917418|NCT02065401|Drug|Deferitazole (disodium salt, granule)|Single oral dose of 1500 mg administered on Day 1
75917419|NCT02065401|Drug|Deferitazole (disodium salt, tablet)|Single oral dose of 1500 mg administered on Day 1
75917420|NCT02065401|Drug|Deferitazole (magnesium hydroxide salt)|Single oral dose of 2400 mg administered on Day 1
75917421|NCT00620256|Drug|AL-37807 ophthalmic suspension, 0.1%|
75917422|NCT00620256|Drug|Timolol gel forming solution, 0.5%|
75917423|NCT00620256|Other|AL-37807 ophthalmic solution vehicle|
75917424|NCT00620256|Drug|Latanoprost ophthalmic solution|
75917425|NCT04450082|Procedure|One anastomosis gastric bypass|The linear stapler divides the stomach horizontally at the junction of the corpus and antrum at the level of crow's foot. In cases where the pre-operative study has shown the presence of the gastric fundus, if possible the fundus was dissected and a long, narrow gastric pouch was designed starting from beyond the crow's foot to just lateral the angle of His over a 42-Fr orogastric tube. Gastrojejunostomy was then performed between 200-220 cm distally to the ligament of Treitz using a 45-mm.
75917426|NCT04795414|Biological|SARS-CoV-2 Vaccine(Vero Cell), Inactivated|The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)
75917427|NCT02072187|Dietary Supplement|Active|
75917428|NCT02072187|Dietary Supplement|Placebo|
75917429|NCT04893122|Other|COVID-19 pandemic|Study focuses on the impact of the COVID-19 pandemic on emergency attendances and admissions.
75782076|NCT03916172|Behavioral|The Open Door Approach to Parenting Teenagers (APT)|APT works on a one-to-one or couple basis. It offers 6 weekly 50-minute appointments with an optional 7th review session. The practitioners delivering the intervention have qualifications in psychology, or significant experience of working with adolescent populations, and have undertaken training and supervision in the model. Its aim is to help the parent manage the parenting of their teenager more effectively and establish a more balanced relationship by eliciting their views, feelings, and understanding of their teenager and their relationship, discussing their parental identity and role, carefully examining communication, responses, and information giving, and supporting appropriate boundary making. This is achieved through a collaborative development of strategies, psychoeducation and behavioural experiments.
75782077|NCT03912974|Drug|Escitalopram|see 'arm description'
76075786|NCT03213964|Biological|FATE-NK100|"FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~Dose Level 1: 1 x 10^7 cells/kg IP~Dose Level 2: >1x10^7 cells/kg to ≤3x10^7 cells/kg~Dose Level 3: Complete FATE-NK100 bag (≥3 x 10^7 to ≤ 10 x 10^7 cells/kg)"
75467959|NCT01935024|Other|Personalized Exercise Regimen|All exercise regimens include a stationary bicycle.
75782078|NCT03912974|Drug|Placebo oral capsule|see 'arm description'
75782079|NCT00368849|Drug|atomoxetine|This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.
75782080|NCT00368849|Drug|Matching Placebo|This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
75782081|NCT03912896|Behavioral|Taekwondo|Children will participate in a 7-week taekwondo program.
75917430|NCT00617526|Drug|RDEA806 400 mg|
75917431|NCT00617526|Drug|Placebo|Placebo
75917432|NCT00617526|Drug|RDEA806 1000 mg|
75917433|NCT00617526|Drug|RDEA806 600 mg|
76075787|NCT03213964|Drug|Interleukin-2|"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."
76075788|NCT03214276|Dietary Supplement|Vinitrox polyphenols|Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
75467960|NCT01935050|Behavioral|Guided Cognitive-Behavioral Self-Help|Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
75630817|NCT02608333|Behavioral|ESDM-12|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
75782082|NCT01144676|Drug|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days."
75917434|NCT00617526|Drug|RDEA806 800 mg|
75917435|NCT04805710|Drug|clopidogrel combined with rivaroxaban arm|Patients who have been selected will be randomized to the clopidogrel combined with rivaroxaban arm. clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily
75917436|NCT02076477|Radiation|concurrent chemoradiotherapy|Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
75630818|NCT02608333|Behavioral|control group|"heteregenous as usual community intervention"
75630819|NCT04149652|Diagnostic Test|Lung Elastosonography|Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.
75782083|NCT01144676|Drug|placebo|The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
75917437|NCT02076477|Drug|Docetaxel|Docetaxel:60mg/m2 d1,Given IV
75917438|NCT02076477|Drug|pemetrexed|pemetrexed: 500mg/m2 d1,Given IV
75917439|NCT02076477|Drug|Cisplatin|Cisplatin：25mg/m2 d1-3，Given IV
75917440|NCT03433820|Other|Observation of wound healing|Observation of wound healing after skin biopsy
75917441|NCT04472832|Drug|Placebo for Treatment A|6 tablets matched to mitapivat tablet
75917442|NCT04472832|Drug|Mitapivat 100 mg|Two 50-mg tablets
75917443|NCT04472832|Drug|Placebo for Treatment B|4 tablets matched to mitapivat tablet
75917444|NCT04472832|Drug|Mitapivat 300 mg|Six 50-mg tablets
75917445|NCT04472832|Drug|Placebo for Treatment C|4 tablets matched to mitapivat tablet
75917446|NCT02072265|Device|Infrared thermal images|
75917447|NCT03433664|Device|CO2 laser|Fractional CO2 laser treatment using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping
76075789|NCT03214276|Dietary Supplement|Placebo|Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
75782084|NCT01144676|Drug|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours."
75917448|NCT00615966|Drug|Diannexin|single dose, 200 µg/kg IV
75917449|NCT00615966|Drug|Placebo|Single dose, IV
75917450|NCT00615966|Drug|Diannexin|Single dose, 400 µg/kg IV
75917451|NCT04795492|Behavioral|remote intervention|Medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided. Risk factor modification included lipid control, smoking and drinking cessation, BP monitoring, dietary change keeping a healthy weight and in our trial. There were also a lot of educational materials about coronary heart disease knowledge that were reviewed by cardiologists, and participants were free to provide them whenever and wherever they want.
75917452|NCT04795492|Behavioral|Routine outpatient follow-up|Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention.
75917453|NCT02072343|Device|No-DCCM|
75917454|NCT02072343|Device|DCCM|
76075790|NCT03213808|Other|No intervention: analysis of health data from patients with|No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
75917455|NCT02072343|Other|Water 5ml in tracheal tube|
75917456|NCT02072343|Other|Water 10ml in tracheal tube|
76075791|NCT03217474|Procedure|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
75630820|NCT02627482|Device|Fetal heart rate monitor (Monica AN24)|"The AN24 is a portable, battery powered device, developed in the UK and designed to monitor passively an unborn baby in the antenatal period. The device is CE marked and is attached via a cable assembly which in turn attaches to five standard disposable electrodes placed on the abdomen of a pregnant woman. It is intended for ambulatory use in either the home or hospital environment.~The AN24 has had rigorous checks in the UK and has been used in many European countries. No hazards have been identified that could compromise the safety of, or cause harm to the fetus or the mother. The only potential issue identified is a local reaction under the electrodes. Nonetheless, the electrodes used are the standard disposable ECG electrodes, used routinely for adult ECG measurements."
75782085|NCT01144676|Drug|placebo|The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
75782086|NCT00316199|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
75782087|NCT00316199|Drug|paclitaxel|175 mg/m2, intravenous (IV), every 21 days until disease progression
75782088|NCT01251224|Other|Integrated Pest Management|The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.
75782089|NCT01251224|Other|Education|This group will receive education about mouse IPM.
75782090|NCT01573208|Device|Custom guides|Symbios custom guides for TKA
75917457|NCT03438968|Behavioral|Exercise training|Cardiac Rehabilitation exercise training
75917458|NCT02076555|Behavioral|Education - Diabetes and Social Issues|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Social Issues was created. The module covers specific and detailed aspects of the topic social issues such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible."
75917459|NCT04879550|Diagnostic Test|Antithrombin III|Antithrombin III deficiency causes thrombosis. Is thrombosis in ECMO patients related to Antithrombin III deficiency? Groups with and without thrombosis will be separated and whether it is related to Antithrombin III deficiency will be evaluated.
75917460|NCT02076633|Drug|L19IL2+L19TNF|Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
75782091|NCT03985475|Other|skin sample|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
75782092|NCT01147718|Biological|digoxin plus albiglutide|A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
75917461|NCT00613002|Drug|testosterone gel|once daily transdermal testosterone gel, 300 mcg
75917462|NCT00613002|Drug|placebo gel|once daily transdermal placebo gel
75917463|NCT02076711|Drug|Metoprololsuccinate|
75917464|NCT02076711|Drug|Placebo|Placebo
75917465|NCT00495222|Procedure|Tissue plication|Tissue apposition and plication of a dilated GJ anastomosis with the Endoscopic Suturing System
75917466|NCT00495222|Device|Endoscopic Suturing System|Tissue plication of dilated GJ stoma
75917467|NCT00495222|Device|Tissue Plication|Tissue plication for GJ stoma reduction
75917468|NCT00492960|Drug|larazotide acetate|gelatin capsules
75917469|NCT00492960|Drug|placebo|gelatin capsules
75917470|NCT00492960|Dietary Supplement|900 mg gluten|gelatin capsules
75917471|NCT02076945|Procedure|US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)|
76075792|NCT03217474|Drug|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
76075793|NCT03217474|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
76075794|NCT03217318|Device|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
75917472|NCT03438890|Device|Warm saline|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
75917473|NCT03438890|Device|anti-fog agent|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
75917474|NCT03438890|Device|chlorhexidine|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
76075795|NCT01830946|Other|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
76075796|NCT01830946|Other|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
76075797|NCT01830946|Other|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
76075798|NCT01831024|Device|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
75630821|NCT04029259|Diagnostic Test|Brain MRI|Brain MRI diagnoses tromboembolic lesions or bleeding to the cerebrum and is part of preoperative diagnostic tests before carotid surgery. After surgery brain MRI may present New lesions related to surgery, clinically significant or insignificant. Our goal is to evaluate the relevance of this modality in carotid surgery..
75782093|NCT03985553|Behavioral|Parenting Self-Management Program|
75782094|NCT03913052|Procedure|Intra-articular Viscosupplement Application|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine is performed once when the knee joint was in the supine position and the knee is in the extension.
75782095|NCT01251302|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
75782096|NCT03916016|Behavioral|Enhanced Integrated Behavioral Health Care|The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.
75782097|NCT03916016|Behavioral|Usual Care|A collaborative model where medical and behavioral providers worked with each other episodically
75782098|NCT03915938|Drug|Ketamine|S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml
75917475|NCT03438812|Dietary Supplement|dehydroepiandrosterone (DHEA)|Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.
75917476|NCT02077101|Other|Questionnaire|
75917477|NCT02077101|Other|Interview|
75630822|NCT00681226|Drug|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
75630823|NCT00681304|Other|ultrasound scan|The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
75782099|NCT03915938|Drug|Placebo|Administered in an identical way than ketamine.
75630824|NCT04148950|Other|Kinesio Tape|
75630825|NCT04148950|Other|Compression Stockings|
75630826|NCT04148950|Other|Exercise Program|
75630827|NCT02627014|Other|Manual therapy|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
75782100|NCT03915782|Device|Remote ischemic conditioning|Remote ischemic conditioning (RIC): Four cycles of [5 minutes of brachial cuff inflation at 200 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation] started as soon as possible after Magnetic Resonance Imaging (MRI).
75630828|NCT02627014|Other|Home physical therapy|once a day: 15 minutes
75630829|NCT02627014|Other|Manual therapy in cervical region|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
75630830|NCT02627014|Other|Home physical therapy in cervical region|once a day: 15 minutes
75630831|NCT00678964|Drug|Erlotinib|Erlotinib 150 mg, p.o., once daily
75782101|NCT03915782|Device|Patients with a sham procedure of remote ischemic conditioning|Sham procedure: Four cycles of [5 minutes of brachial cuff inflation at 30 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation] started as soon as possible after Magnetic Resonance Imaging (MRI).
75782102|NCT01237496|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
75630832|NCT00678964|Drug|Vinorelbine and Carboplatin|Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
75630833|NCT05299138|Behavioral|Marriage and Relationship Enhancement Skills (MRES) Intervention|The Intervention group will be assigned a Case Manager and placed in the next available Marriage and Relationship Enhancement Skills (MRES) class that is convenient for their schedule. Intervention participants will attend classes weekly and meet with their Case Manager weekly, bi-weekly, or monthly, as needed. Study measures will be gathered from intervention participants at baseline, 10 weeks after baseline, and then 22 weeks after baseline. The following tools will be utilized at baseline and follow-up assessment: (1) REACH program eligibility screening (only conducted at baseline), (2) Information, Family Outcomes, Reporting, and Management (nFORM) system, (3) Family Environment Scale (FES), (4) Revised Dyadic Adjustment Scale (RDAS), and (5) Economic Self-Sufficiency Scale (ESS).
75917478|NCT02077179|Behavioral|HIP Program|"The entirety of the HIP Program is delivered through an interactive mobile website.~The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.~The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays."
75917479|NCT01109550|Procedure|ERCP|endoscopic retrograde cholangiopancreatography transpapillary biopsies
75917480|NCT02077257|Drug|Rosuvastatin|Rosuvastatin 20 mg/d compared to 10 mg/day
75917481|NCT02732912|Device|Ear plugs|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
75917482|NCT02732912|Device|Eye Mask|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
75630834|NCT04912453|Procedure|Primary anastomosis|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive primary anastomosis
75630835|NCT04912453|Procedure|Enterostomy|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive enterostomy
75630836|NCT04031638|Other|Radioactive Iodine treatment|Patients with a thyroid tumor who received radioactive Iodine treatment.
75782103|NCT03915704|Device|Shotblocker|Injection was administered with ShotBlocker.The Shotblocker application to all children in this group was done by the second researcher. After the injection, the shotblocker was wiped with 70% alcohol.
75917483|NCT02732912|Drug|Zopiclone|This night sedation will be given to any patient requesting it, in either group
76075799|NCT03213886|Drug|Calcifediol (Vitamin D)|"After surgical treatment, participants with vitamin D deficiency (25OHD < 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~Will follow the usual hip fracture rehabilitation pathway.~25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)"
76075800|NCT01831102|Other|none- observational study|
76075801|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
76075802|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
76075803|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
76075804|NCT01739348|Drug|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
76075805|NCT01739348|Drug|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
75630837|NCT02627170|Device|dynamic Scheimpflug analyzer (corneal visualization Scheimpflug technology [Corvis ST], OCULUS, Wetzlar, Germany)|
75630838|NCT02627248|Drug|Huaier Granule|20g tid, orally
75630839|NCT02627248|Drug|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
75630840|NCT02627248|Drug|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
75630841|NCT02627248|Drug|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
75630842|NCT03993535|Drug|selective serotonin reuptake inhibitor|open treatment based on patient preference and treatment availability
75630843|NCT02626936|Other|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
75782104|NCT03915704|Procedure|Control|No intervention was made in the children.
75782105|NCT03915704|Device|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed.The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
75782106|NCT01251458|Drug|Torisel|Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
75782107|NCT01416428|Drug|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
75630844|NCT02626936|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
75782108|NCT00316121|Device|HEALOS and Leopard Cage|Placement in interbody space
75782109|NCT00316121|Device|Leopard Cage and Autograft|Placement in the interbody space
75782110|NCT03912740|Drug|Dexmedetomidine|Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.
75782111|NCT03912740|Drug|sodium chloride|Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)
75630845|NCT02626936|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
75630846|NCT02626936|Device|Dexcom G4 Platinum glucose sensor|
75782112|NCT03912740|Drug|Remifentanil|Both groups will have remifentanil analgesia guided by the Nol-Index
75782113|NCT01058915|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg/day
75782114|NCT01058915|Drug|Rosuvastatin 40mg|Rosuvastatin 40mg/day
75782115|NCT01144754|Drug|Rituximab|Calculated per patient
75782116|NCT00915902|Drug|Omega-3-acid ethyl esters|Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks
76075806|NCT03217084|Drug|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
75630847|NCT02626936|Device|Accu Chek Combo insulin pump|
75630848|NCT00679198|Behavioral|nurse-patient communication|"We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting."
75630849|NCT02627326|Procedure|open flap debridement|periodontal surgery in the form of open flap debridement was done in both the groups
75630850|NCT00912262|Drug|Capsaicin Topical Liquid|
75630851|NCT04151212|Drug|BAT5906 injection|Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
75782117|NCT00915902|Drug|Placebo|Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
75782118|NCT01250132|Other|Biological and behavioral explorations|"Blood dosages:~biochemistry~pituitary gland~somatotropic axis~corticotropic axis~gonadotropic axis~thyrotropic axis~antidiuretic axis~Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)"
75782119|NCT01147796|Device|computed tomography|64 slices CT with iodine injection
75782120|NCT01147796|Device|computed tomography|64 slices CT with iodine injection
75782121|NCT03912116|Other|CLARIX FLO|100mg CLARIX FLO
75782122|NCT03912116|Other|Saline|Saline
75782123|NCT01251692|Procedure|Surgery|The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
75782124|NCT01144832|Drug|ebastine|20 milligram capsule once daily
75630852|NCT00679276|Procedure|Prolift|surgical repair of vaginal prolapse
75630853|NCT02626702|Other|Observational|Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
75630854|NCT02627638|Other|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
75630855|NCT00906945|Drug|G-CSF|
75630856|NCT00906945|Drug|Plerixafor|
75630857|NCT00906945|Drug|Mitoxantrone|
75630858|NCT00906945|Drug|Etoposide|
75630859|NCT00906945|Drug|Cytarabine|
75630860|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
75630861|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
75782125|NCT01144832|Drug|placebo capsule|one capsule once daily
75630862|NCT02627560|Drug|Tranexamic Acid|moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
75630863|NCT02627560|Drug|saline|moisten the surgical wound surface with 20 ml placebo (0.9% saline)
75630864|NCT03784027|Device|CamAPS FX|"CamAPS FX closed loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~Cloud upload system to monitor CGM/insulin data"
75782126|NCT01147952|Behavioral|Structured exercise training|randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
75782127|NCT01251848|Drug|Sitaxentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
75782128|NCT01251848|Drug|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
75782129|NCT01251848|Drug|Sitaxsentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
75782130|NCT01251848|Drug|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
75782131|NCT01251926|Drug|EZN-2208|
75782132|NCT01251926|Drug|Bevacizumab|
75782133|NCT03911882|Dietary Supplement|Celergen Administration|The food supplement Celergen was administered on a daily basis for a total of 3 months (90 days) to participating fibromyalgia patients
75782134|NCT03911648|Drug|0.5 ml.kg-1 bupivacaine 0.25%|Caudally
75917484|NCT02077335|Radiation|HDR brachytherapy monotherapy|"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~V100 > 95%~V150 30-35%~V200 < 15%~D90 > 90% (12,15Gy)~Bladder~• V75 < 1cc~Rectum~• V75 < 1cc~Urethra~V125 = 0cc D10 < 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."
75630865|NCT03784027|Other|Sensor augmented therapy|Study insulin pump and study CGM.
75917485|NCT04134494|Device|Ablative Fractional 2940 nm Laser|"Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.~Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.~Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚."
75917486|NCT02792517|Drug|Erenumab|A single dose of erenumab administered in the abdomen.
75917487|NCT02792517|Drug|Ethynil Estradiol/Norgestimate Oral Contraceptive|Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.
75782135|NCT03911648|Drug|0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1%|Caudally
75917488|NCT00488748|Device|Thymatron|Right unilateral placement, 6x seizure threshold, 3 times per week until clinically appropriate to stop (approximately 2-6 weeks)
76075807|NCT03217084|Drug|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
76075808|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
76075809|NCT00899470|Drug|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
75782136|NCT03915314|Diagnostic Test|Neuropsychological tests|The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.
75782137|NCT01250288|Other|Personal Health Management System|BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients & their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
75782138|NCT02528162|Behavioral|education|Evaluation of education for GDM
76075810|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
75630866|NCT00681460|Drug|human recombined insulin|multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
75630867|NCT00681460|Drug|metformin|pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
75630868|NCT05332119|Device|VR glasses|Patients will watch a virtual world in VR glasses during the painful procedure. They will be able to choose between 3 VR content based on their preferences.
75630869|NCT05332119|Other|Control group|Patients will not receive distraction during chest drain removal
75630870|NCT05749939|Behavioral|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. A goal of ACT is to help people develop psychological flexibility, meaning they can experience and live with difficult thoughts and emotions, and still pursue what matters to them. The current project is an online, self-guided, 6-session intervention. Each session is expected to take about 30 minutes each, and the entire course will take approximately 3-4 weeks to complete, as users are encouraged to take a few days in between sessions. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and care- specific vignettes, and apply ACT concepts to their own lives and care situations. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
75630871|NCT05332041|Other|Predicta Bioactive bulk fil composite restoration|Predicta Bioactive bulk fil resin composite restoration material
75782139|NCT03911804|Procedure|bolus group and infusion group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
76075811|NCT00899470|Drug|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
76075812|NCT01738646|Drug|Vorinostat|
76075813|NCT01738646|Drug|Bevacizumab|
76075814|NCT03213574|Other|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
75782140|NCT01237730|Drug|cefuroxime|Use the cefuroxime as prophylaxis.
76075815|NCT03213574|Other|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
75324362|NCT04382989|Device|Analysis of human milk composition by mid-infrared spectrophotometry|"Analysis of human milk macronutrient content was performed by mid-infrared spectrophotometry using a Miris Human Milk Analyser.~An immune-enzymatic ELISA assays were used to estimate lysozyme and lactoferrin concentrations in human milk."
75324363|NCT03806153|Other|Morphokinetic|The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).
75630872|NCT03653325|Device|ORI measurement|Oxygen (FiO2) will be titrated according to ORI index and Oxygen saturation.
75630873|NCT03653325|Device|oxygen saturation measurement|Oxygen (FiO2) will be titrated according to oxygen saturation
75917489|NCT00488748|Device|Magstim Theta|100% power, vertex placement, 3 times per week, until clinically appropriate to stop (approximately 2-6 weeks)
75782141|NCT01237730|Drug|Tailored antibiotic|Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
75917490|NCT03438734|Device|Regional cerebral oxygen saturation|Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
75917491|NCT03438734|Device|Bispectral Index (BIS)|The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.
75917492|NCT00487656|Drug|ART-123|6mg/ml ampule solution for injection @ .01mg/kg
75917493|NCT00487656|Drug|placebo|6 mg/ml ampule solution for injection at .01mg/kg
75917494|NCT03431714|Drug|Artesunate amodiaquine|Drugs were administered under observation of the study nurse for three days
75324364|NCT04695301|Other|Rehabilitation protocol through a digital platform|During 3 months the patients will participate in a rehabilitation program through a digital platform
75324365|NCT04691635|Other|evaluation of movements with sensors|evaluation of movements with sensors
75630874|NCT05752981|Device|multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)|Participants will be monitored during surgery using the multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS). This study is observational in nature and no intervention will be applied based on the results of the tr-fNIRS device.
75630875|NCT00876694|Drug|Indacaterol 300 µg|Indacaterol 300 µg once daily (od) via SDDPI
75630876|NCT00876694|Drug|Salmeterol 50 µg|Salmeterol 50 µg twice daily (bid) via Diskus®
75782142|NCT01148030|Drug|3M Skin and Nasal Antiseptic|Intra-nasal dosing
75782143|NCT01252082|Procedure|Scaling and Rootplaning|All patients in the test group receive scaling and rootplaning under local anesthesia
75782144|NCT01252160|Drug|QUTENZA|Cutaneous patch
75917495|NCT02077413|Procedure|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
76075816|NCT01831414|Other|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
75782145|NCT00337103|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
75782146|NCT00337103|Drug|Capecitabine|Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
76075817|NCT01831414|Other|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
76075818|NCT03213340|Other|Catechin Cohort 1|- 4 capsules taken with water 1 hour prior to meal
76075819|NCT03213340|Other|Curcuminoid Cohort 2|- 2 capsules taken with water 1 hour prior to meal
75782147|NCT00415532|Drug|Medical Standard of Care for ITP|
75782148|NCT00415532|Biological|Romiplostim|
76075820|NCT03213340|Other|Flavonoid Cohort 3|- ~ 1 oz. serving consumed 30 minutes before meal
76075821|NCT01716104|Drug|Afalaza|Safety and Efficacy
76075822|NCT01716104|Drug|Placebo|Safety and Efficacy
76075823|NCT03837262|Combination Product|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
76075824|NCT03836170|Procedure|Laparoscopic cholecystectomy|A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
76075825|NCT01831492|Device|zeolite + dolomite|Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
76075826|NCT01831492|Device|cellulose|given for 14 weeks
75782149|NCT00315731|Biological|Follicular Lymphoma|For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
75630877|NCT05749159|Behavioral|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
75630878|NCT03778489|Other|Training|10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
75630879|NCT02607007|Other|2% M.F. Milk|
75630880|NCT02607007|Other|White Bread|
75782150|NCT03911570|Drug|Glucosamine Sulfate|Therapy with the prescription formulation of crystalline glucosamine sulfate
75917496|NCT02077413|Procedure|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of ~5 minutes."
75324366|NCT05352529|Device|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
75917497|NCT02077413|Procedure|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
75324367|NCT05352529|Device|Dementia educational videos|Investigators collected publicly available educational videos regarding dementia-related caregiving and support. The videos were made available to participants through compatible tablets.
75324368|NCT00764309|Drug|dasatinib|Tablets, Oral, 100 mg, once daily, 6 months
75324369|NCT04656379|Procedure|spine surgery|Risk factors for postoperative delirium in elderly patients underwent spine surgery will be evaluated.
75324370|NCT02151877|Drug|Inhaled Nitric Oxide|delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
75630881|NCT02607007|Other|Strawberry Jam|
75782151|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once Daily, 7 Days
75630882|NCT02607007|Other|31% M.F. Cheddar Cheese|
75782152|NCT01250366|Drug|INX-08189|Capsule, Oral, 25 mg, Once Daily, 7 days
75782153|NCT01250366|Drug|INX-08189|Capsules, Oral, 50 mg, Single Dose, 1 day
75630883|NCT02607007|Other|2% M.F. Plain Greek yogurt|
75782154|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once daily, 6 days
75782155|NCT01250366|Drug|INX-08189|Capsules, Oral, 50 mg, Once daily, 7 days
75782156|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once daily, 7 days
75782157|NCT01250366|Drug|INX-08189|Capsules, Oral, 100 mg, Once daily, 7 days
75630884|NCT02607007|Other|Soy Beverage|
75630885|NCT02607007|Other|Water|
75630886|NCT00805441|Drug|LY686017|50 milligrams (mg) daily by oral route for 12 weeks
75630887|NCT00805441|Drug|Placebo|Daily by oral route for 12 weeks
75782158|NCT01250366|Drug|Placebo matching with INX-08189|Capsules, Oral, 0 mg, Once daily, 7 days
75782159|NCT01250366|Drug|Ribavirin|Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days
75782160|NCT03915080|Drug|Oktokog alpha|adjusting dose and dose interval according to MyPKFIT
76075827|NCT03213106|Device|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
75630888|NCT00590317|Drug|Prochlorperazine|Patients receiving Prochlorperazine
75630889|NCT00590317|Drug|Ondansetron|Patients receiving Ondansetron
75630890|NCT01139762|Drug|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
75630891|NCT01139762|Drug|Placebo|Administered orally, once daily for 26 weeks
75630892|NCT01139762|Drug|Finasteride|5mg administered orally, once daily for 26 weeks
75630893|NCT00805285|Drug|Combination Oral Budesonide and Rectal Hydrocortisone|Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
75630894|NCT02606773|Drug|Ascorbic Acid|Ascorbic acid in different ways and doses
75782161|NCT03915158|Procedure|bariatric surgery|sleeve gastrectomy
75782162|NCT00062868|Biological|LMP1/2 CTLs (ALCI - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10^7 cells/m2; Day 14: 2 x 10^7 cells/m2~Dose Level Two~Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2~Dose Level Three~Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
75782163|NCT00062868|Biological|LMP1/2 CTLs (ALCI - Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2~Dose Level Two~Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2~Dose Level Three~Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
75782164|NCT00062868|Biological|LMP1/2 CTLs (ALCI - Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2~Dose Level Two~Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2~Dose Level Three~Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
75917498|NCT02077413|Procedure|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
75917499|NCT03431636|Other|immersion|cold water immersion
75917500|NCT03431636|Other|ice pack|ice packs through the body
75917501|NCT03431636|Other|rest|seated rest
75917502|NCT02077491|Other|High-protein diet and resistance training|The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
75917503|NCT00484536|Drug|CDP323|250 mg capsules, 500 mg bid (1000 mg/day)
75917504|NCT00484536|Drug|placebo|capsules, once daily
75630895|NCT05715307|Other|Intensive experiential training in T2DM management|One-week intensive experiential training for endocrinologists, means 1-week hospitalization experience in leading center (Ruijin Hospital) including health examination and results interpretation, and attending integrated training courses for T2DM management. During patient intervention period, endocrinologists will attend the follow-up and experience sharing meeting regularly.
75630896|NCT05715307|Other|Regular training in T2DM management|Regular training and communication implemented by MMC leading center (Ruijin Hospital) under the guidance of T2DM diagnosis and treatment.
75630897|NCT04310774|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug)|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
75917505|NCT00484536|Drug|CDP323|250 mg Capsules, 500 mg, once daily
75630898|NCT01139450|Drug|0417|Topical 0417 test product applied twice daily for 4 weeks
75630899|NCT01139450|Drug|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
75782165|NCT00062868|Biological|LMP2 CTLs (ALSCER - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10^7 cells/m2; Day 14: 2 x 10^7 cells/m2~Dose Level Two~Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2~Dose Level Three~Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
75782166|NCT00062868|Biological|LMP2 CTLs (ALSCER - Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2~Dose Level Two~Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2~Dose Level Three~Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
75782167|NCT00062868|Biological|LMP2 CTLs (ALSCER - Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2~Dose Level Two~Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2~Dose Level Three~Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
75782168|NCT00062868|Biological|LMP1/2 CTLs (ALCI - Expansion - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10^7 cells/m2; Day 14: 2 x 10^7 cells/m2"
75917506|NCT03438422|Dietary Supplement|Pollen extract|1 tablet a day
75917507|NCT02080065|Procedure|living donor liver transplantation|
75917508|NCT03433586|Drug|Aspirin 81 mg|81mg of aspirin to be taken daily for 10-14 days
75917509|NCT03433586|Drug|Placebo|Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days
75917510|NCT02080143|Device|Thermal Adhesion Patch|
75917511|NCT02080143|Device|Thermal Adhesion Patch|
75917512|NCT02273232|Other|Remote Ischemic Preconditioning|Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
75917513|NCT02273232|Other|Supervised Exercise|constructed extra excessive for peripheral vascular diastase patients
75917514|NCT02273232|Other|Standard Care|Standard Care for peripheral vascular disease patients including advises regarding exercises
75917515|NCT03433508|Biological|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
75917516|NCT03433508|Other|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
75917517|NCT02072499|Procedure|KTP Green Light Prostatectomy|
75917518|NCT02072499|Device|Green Light|
75917519|NCT02072499|Procedure|Open prostatectomy|
75917520|NCT03431558|Combination Product|bLF (Bovine lactoferrin)|BLF administration in two different strengths (150 & 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.
75917521|NCT03431558|Drug|Glucon-D 99.4% (Placebo)|This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
75324371|NCT02151877|Drug|placebo|inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
75630900|NCT01139450|Drug|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
75630901|NCT05748067|Procedure|SDF|Silver diamine fluoride
75630902|NCT05748067|Procedure|HVGIC restoration|High viscosity glass ionomer restoration
75630903|NCT05748067|Procedure|SSC|Stainless steel crown
75630904|NCT04021069|Diagnostic Test|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
75630905|NCT00805207|Drug|Progesterone|Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.
75630906|NCT00805207|Drug|testosterone|Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
75630907|NCT00805207|Drug|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
75630908|NCT00805207|Device|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.
75917522|NCT02273622|Dietary Supplement|hydroxytyrosol|Pilot study with 20 participants, each participant will alternately by the two arms of the study (hydroxytyrosol 5 mg and 20 mg) and control, during 6 weeks.
75917523|NCT02273622|Dietary Supplement|placebo|
75324372|NCT04382833|Other|HOT APPLICATION|HOT APPLICATION
75630909|NCT00805207|Drug|Estrogen|Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.
75630910|NCT00805207|Other|Control|No treatment with studies performed 31 to 72 days apart
75630911|NCT05747755|Behavioral|ADEPT Program|Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality and safety personnel in change management, pilot testing and refinement of Safety I and Safety II interventions to reduce systemic causes of diagnostic errors and to increase resilience, thus promoting diagnostic excellence.
75630912|NCT03016351|Other|Aerobic Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
75630913|NCT03016351|Other|Resistance Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
75630914|NCT00805675|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
75630915|NCT00805675|Drug|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
75630916|NCT00805675|Drug|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
75630917|NCT03958201|Combination Product|Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
75630918|NCT04015453|Procedure|Mohs micrographic surgery|All participants will have received Mohs micrographic surgical treatment for a facial skin cancer.
75630919|NCT00589303|Drug|FDA approved rate and rhythm control drugs|"Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.~Rate Control:~Beta-Blocker:~metoprolol~atenolol~carvedilol~Calcium Channel Blocker:~verapamil~diltiazem~Rhythm Control:~procainamide~quinidine~disopyramide~propafenone~flecainide~sotalol~dofetilide~amiodarone"
75630920|NCT00589303|Device|AV Node ablation and device implant|"Pacing Systems:~Enpusle Premarket Approval Number (PMA#) P980035~EnRhythm PMA# P980035~Adapta PMA# P980035~Cardiac Resynchronization Therapy (CRT) Pacing Systems:~- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031~Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:~EnTrust PMA# P980016~Virtuoso PMA# P980016~ICD CRT Pacing Systems:~InSync Maximo PMA# P980016~InSync Sentry PMA# P890003~Concerto PMA# P980016"
75630921|NCT02607943|Drug|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
75630922|NCT02607943|Drug|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
75782169|NCT00062868|Biological|LMP1/2 CTLs (ALCI - Expansion Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2"
75782170|NCT00062868|Biological|LMP1/2 CTLs (ALCI - Expansion Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2"
75782171|NCT00075504|Drug|triapine|Given IV
75782172|NCT00075504|Drug|gemcitabine|Given IV
75782173|NCT01092390|Dietary Supplement|Lovaza (fish oil)|4 grams per day
75782174|NCT01092468|Procedure|Diathermy|flap dissection with conventional diathermy
75324373|NCT04382833|Other|MASSAGE|
75324374|NCT00798577|Drug|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
75324375|NCT00798577|Drug|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
75324376|NCT00799435|Drug|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
75630923|NCT02970877|Biological|Fecal filtrate from 150 g stool from healthy lean donors|150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
75630924|NCT02970877|Biological|Fecal filtrate from 150 g of the recipient's own stool|150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
75630925|NCT03932305|Dietary Supplement|Lutein|Lutein is a common oral supplement that may have neuroprotective effect on the human retina
75630926|NCT03932305|Dietary Supplement|Placebo|Inactive placebo tablet
75630927|NCT02606617|Drug|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
75630928|NCT02606617|Drug|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
75630929|NCT00914095|Drug|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
75630930|NCT00914095|Drug|placebo|tablets of placebo 3 times a day
75630931|NCT05745337|Drug|As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)|Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
75782175|NCT01092468|Procedure|Harmonic Scalpel|flap dissection using harmonic scalpel (FOCUS)
75917524|NCT02077569|Drug|AZD5363|Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
75917525|NCT02273934|Behavioral|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
75917526|NCT02273934|Behavioral|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
75917527|NCT03431402|Drug|Hyperbaric oxygen|- HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition
75917528|NCT02072577|Behavioral|Video|"The student watched the video prepared individually in the ward where they were interned.~After this step, the student demonstrated again the procedure for oral hygiene.~At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially."
75324377|NCT04329091|Drug|Dexmedetomidine|All subjects will receive Dexmedetomidine to induce sedation between their pre-sedation and post-sedation perceptual learning tests.
75917529|NCT00482664|Drug|CP-866,087|Tablets for oral administration
75917530|NCT00482664|Drug|CP-866,087|Tablets for oral administration
75917531|NCT00482664|Drug|CP-866,087|Tablets for oral administration
75782176|NCT01092624|Drug|Solifenacin|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
75917532|NCT00482664|Drug|Placebo|Tablets for oral administration
75917533|NCT02077803|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
75917534|NCT02077803|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
75917535|NCT02077803|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
75630932|NCT05744791|Behavioral|Active Play planned movement program|Teachers will implement an addition two physical activity opportunities that incorporate active play each day for a potential dose of 20-30 minutes per day and 100-150 minutes per week.
75324378|NCT00244751|Drug|GI262570 0.5 mg|GI262570 0.5 mg
75630933|NCT00952380|Drug|dalteparin|dalteparin subcutaneous injection
75630934|NCT03866161|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment
75630935|NCT02856750|Drug|Gabapentin|Gabapentin 300 mg three times daily x30 days
75917536|NCT02077803|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
75917537|NCT03431324|Behavioral|Episodic Future Thinking about Mating Opportunities|"Participants who complete the mating-EFT intervention will be instructed to write about three positive mating-related events that would occur within the course of one year if you successfully quit smoking now. Participants will then be asked to close their eyes and imagine the events that they listed as specifically and vividly as possible (e.g., to imagine the setting and the sequence of the events, as well as the persons and objects that would be present. A period of one minute will be allotted for participants to mentally pre-experience each event.~The general-EFT intervention will be structured similarly to, with the key exception of being instructed to write about and imagine three positive life events."
75917538|NCT03431324|Behavioral|Targeted Mating-EFT Intervention|"This intervention is identical to the Episodic Future Thinking about Mating Opportunities intervention with the exception that in Arm 2 the aim will be to determine whether the Mating-EFT intervention is especially effective when administered to individuals who are single or highly motivated to seek a mate."
75917539|NCT00666900|Drug|Low Strength IDP-107|Once a day for 12 weeks
75324379|NCT00244751|Drug|GI262570 1.0 mg|GI262570 1.0 mg
75917540|NCT00666900|Drug|High Strength IDP-107|Once a day for 12 weeks
75917541|NCT00666900|Drug|Placebo Comparator|Once a day for 12 weeks
75917542|NCT03431246|Biological|Gardasil and Gardasil-9|All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
75917543|NCT03559491|Drug|Intravitreal injection|Long term release steroid injection
75917544|NCT04449848|Other|Sitting after intra tympanic injection|Sitting after intra tympanic injection
76075828|NCT03213106|Device|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
75324380|NCT00244751|Drug|Placebo|Placebo
75324381|NCT04382209|Procedure|Erector spinae plane block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.
75630938|NCT04277832|Diagnostic Test|Questionary|All patients will answer two different questionary (TUPAST, TOPAS 2)
75630939|NCT05751967|Drug|Placebo Combined With Ursodeoxycholic Acid|1 tablet/ day
75630940|NCT05751967|Drug|Fenofibrate Combined With Ursodeoxycholic Acid|200 mg/day
75630941|NCT02857920|Drug|Bevacizumab|7.5 mg/kg, i.v, once every 3 weeks (continuous)
75630942|NCT02857920|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfusion in 3 times, i.v.
75917545|NCT02072655|Procedure|socio-aesthetic care|"care of the face~skin cleansing with cleansing milk to remove impurities~a gentle scrub to exfoliate and cleanse the skin~a relaxing massage~moisturizing mask~application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...~care manicure / pedicure,~massages~makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship."
75630943|NCT03847831|Behavioral|Active School Flag Program|Schools enrolled in the program take part in the 17 actions described in the PPASF.
75917546|NCT00664716|Biological|Baminercept alfa 1|experimental - one dose level
75630944|NCT02858466|Radiation|MRI scan|
75630945|NCT05750953|Behavioral|eHealth@Hospital-2-Home|At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company. MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals. The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices. Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
75782177|NCT01092624|Drug|Placebo|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
75917547|NCT00664716|Biological|Placebo|Placebo comparator
75917548|NCT00664716|Biological|Baminercept alfa 2|experimental - second dose level
75917549|NCT00664716|Biological|Baminercept alfa 3|experimental - third dose level
75324382|NCT04382209|Device|Intravenous meperidine patient controlled analgesia device|Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
75630946|NCT02607631|Drug|Pembrolizumab|treated with Pembrolizumab 200 mg every 3 weeks
75917550|NCT00664716|Biological|Baminercept alfa 4|experimental - fourth dose level
75917551|NCT00664716|Biological|Baminercept alfa 5|experimental - fifth dose level
76075829|NCT00904618|Procedure|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
75630947|NCT02858232|Biological|MASCT-I|Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
75630948|NCT02857842|Drug|Prednisolone|
75630949|NCT00914407|Drug|Oxygen|100% Oxygen inhalation for 30 minutes
75782178|NCT01092624|Device|Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
75782179|NCT01237574|Other|Intervention according to the standard of care.|Every 6 months, patients will have clinical, biological and morphological evaluation according to the standard of care.
75917552|NCT02072733|Other|Comprehensive geriatric assessment|Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
75917553|NCT04449770|Device|double lumen tube|prospective cohort study
75917554|NCT03228069|Procedure|Blood drawn after rabies booster vaccination|Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.
76075830|NCT00904618|Procedure|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
76075831|NCT00904618|Drug|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
75630950|NCT03635437|Drug|Gamma-Aminobutyric Acid (GABA)|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
75782180|NCT03957096|Drug|SGN-CD47M|SGN-CD47M administered intravenously
75917555|NCT00474864|Drug|GW856553|
75917556|NCT05075096|Other|No intervention.|No intervention observational study.
75917557|NCT00472836|Drug|CP-945,598|Administration of CP-945,598 in subjects with normal renal function.
75917558|NCT00472836|Drug|CP-945,598|Administration of CP-945,598 in subjects with severe renal impairment.
75324383|NCT04634071|Drug|Varenicline|Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.
76075832|NCT03213028|Other|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
76075833|NCT03837652|Other|Use of bone-borne palatal expander & maxillary osteotomy|Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae
76075834|NCT01839136|Procedure|Intrauterine transfer of gametes|
75324384|NCT04634071|Drug|Bupropion|Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.
75324385|NCT04634071|Drug|Long-acting nicotine replacement therapy|Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.
75324386|NCT04634071|Behavioral|Low-intensity counseling|A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.
75324387|NCT04634071|Behavioral|High-intensity counseling|A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.
75630951|NCT03635437|Drug|Alprazolam|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
75630952|NCT03796663|Behavioral|Mindful Parenting Program|"The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines."
75782181|NCT00087438|Radiation|stereotactic body radiation therapy|
75782182|NCT00321464|Biological|Denosumab|Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
75782183|NCT00321464|Drug|Zoledronic Acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
76075835|NCT01839136|Procedure|Intrauterine transfer of embryos|
76075836|NCT01839214|Drug|VB-201 160mg|
76075837|NCT01839214|Drug|Placebo|
76075838|NCT01839292|Device|uncovered D-type stent insertion|
75324388|NCT04634071|Other|No nicotine replacement therapy|Participants in this group will not receive per required need nicotine replacement therapy.
75782184|NCT02889796|Drug|Filgotinib|200 mg or 100 mg tablet(s) administered orally once daily
75782185|NCT02889796|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
75782186|NCT02889796|Drug|Adalimumab|40 mg administered via subcutaneous injection once every two weeks
75782187|NCT02889796|Drug|Placebo to match adalimumab|Administered via subcutaneous injection once every two weeks
75782188|NCT02889796|Drug|MTX|Commercially sourced tablet(s) administered orally
75782189|NCT03911258|Procedure|nasopharyngeal swab versus nasal wash|The type of procedure will be determine according to patient collaboration
75782190|NCT01237808|Drug|Cytarabine|in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).
75782191|NCT01237808|Drug|Etoposide|first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).
75917559|NCT05044130|Dietary Supplement|High-fat mixed-meal tolerance test (HF-MMTT)|The test meal consists of a standardized HF-MMTT (791 cal) with 197 g cream (38 % fat), 18 g sugar and 1 g vanilla sugar for taste (75 g fat, 25 g carbohydrate and 4 g protein)
75917560|NCT04472052|Other|appendectomy|Surgical standard treatment for acute appendicitis All patients receive preoperative single-shot antibiosis, usually 2000 mg cefotaxime combined 500 mg metronidazole. Appendectomy is performed usually within 24 h of admission in patients with acute appendicitis. The laparoscopic appendectomy using the 3-trocar technique represents the surgical standard. In uncomplicated or non-perforated appendicitis, drainage is generally not required. Wounds are closed intra-cutaneous with absorbable sutures. Patients without postoperative complications are discharged home two days after surgery.
76075839|NCT01839292|Device|double-layered ComVi stent insertion|
75324389|NCT04634071|Drug|Nicotine Replacement Products|Participants in this group will receive per required need nicotine replacement therapy.
75324390|NCT03417921|Drug|ABTL0812|ABTL0812 in combination with gemcitabine and nab-paclitaxel
75324391|NCT03417921|Drug|Gemcitabine and nab-paclitaxel|Gemcitabine and nab-paclitaxel as standard pattern
75324392|NCT03028935|Behavioral|Exercise Intervention|Undergo instructor-led exercise program
75324393|NCT03028935|Behavioral|Nutritional Intervention|Undergo instructor-led nutritional education program
75917561|NCT02072811|Drug|DAC|"DNR 60 mg/m2 0,5h infusion iv on 1-3 days~2-CdA 5 mg/m2 2h. infusion iv on 1-5 days~Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days"
75782192|NCT01237808|Drug|All-trans retinoic acid (ATRA)|in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
75917562|NCT02072811|Drug|CLAG|"G-CSF 30MU sc, on 0-5 days~Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days~Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days~Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day"
75917563|NCT02072811|Drug|Consolidation, I HAM cycle|"Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days~Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days"
75917564|NCT02072811|Drug|II Consolidation HiDAraC|• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
75630953|NCT03796663|Behavioral|MATCH BPT Program|The MATCH BPT Program consists of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 60 minute individually-implemented sessions.The sessions will consist of the coach obtaining and reviewing weekly assignments completed by the parent, followed by activities and discussions that focus on a particular parenting skill (i.e. praise, active ignoring, giving effective instructions). The discussions will emphasize benefits and possible problems that the parent may encounter throughout the week while implementing the new skill. The coach will assign to the parent a practice assignment to further encourage use of the concept.
76075840|NCT01839370|Device|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
75324394|NCT03935425|Device|FitMi Plus|A set of common objects that couple with a wireless sensor platform to allow the performance of functional exercises to be measured by a motivating software platform.
75630954|NCT05750797|Drug|Oral corticosteroids|The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.
75782193|NCT03911024|Behavioral|HIV|At the completion of each EMA, participants in the intervention group (n=50) will receive messages that address:1) unsafe sexual behaviors, 2) alcohol/drug use, 3) PrEP interest, and 4) HIV testing. In addition, participants will have access to a button in the app that will link them to resources when/if they are the victim of sexual assault. Finally, intervention arm youth will be asked to set a behavioral goal related to HIV prevention during this session. Those goals will include increasing condom use, PrEP use, non-occupational post-exposure prophylaxis (nPEP) use, reducing number of sexual partners, not having sex with using drugs or drinking alcohol, avoiding IV drug use, getting testing for HIV, and testing and treating sexually transmitted infections (STIs) as needed
75917565|NCT02072811|Drug|Consolidation, III HiDAraC cycle|"Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days~2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C"
75917566|NCT02274324|Dietary Supplement|different diets|3 different diets: A\B\C
75917567|NCT04471896|Device|Joovv Mini|Infrared light therapy uses certain wavelengths of light that are delivered to the face. This study will use the Joovv Mini.
75917568|NCT02080299|Procedure|Remote ischemic preconditioning (RIPC)|3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
75917569|NCT02080299|Procedure|Placebo|Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
75917570|NCT03428672|Procedure|total hip arthroplasty|Bone samples from Hip fracture were collected from the femoral head which has been replaced
75917571|NCT02274636|Dietary Supplement|Xylitol|A comparison between discs and gel
75917572|NCT02072889|Other|Neck Angle|Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
75324395|NCT03935425|Device|FitMi Basic|A wireless sensor platform that allows movement subcomponents and point-to-point exercises to be measured by a motivating software platform.
75324396|NCT03389997|Diagnostic Test|nasal swabs|Iterative nasal swabs will be performed to screen for virus shedding
75324397|NCT00799981|Device|A=SpeediCath Compact 7 cm and B=POBE 10 cm|Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
75324398|NCT03378297|Drug|Metformin|Metformin tablets 850 mg x 2 orally
75324399|NCT03378297|Drug|Acetylsalicylic acid|Acetylsalicylic acid tablets 160 mg x1 orally
75324400|NCT03378297|Drug|Olaparib|Olaparib capsules 300 mg x 2 orally
75324401|NCT03378297|Drug|Letrozole|Letrozol tablets 2.5 mg x 1 orally
75630955|NCT05701267|Device|MRI research|3T MRI protocol of ~1 hour
75782194|NCT03911024|Behavioral|General health|Participants in the attention control condition (n=50) will answer the same EMA items as the Intervention group. However, the intervention messages will contain content related to nutrition, physical activity, sleep hygiene, and tobacco use. Finally, control arm youth will be asked to set a behavioral goal related to general health during this session.Those goals will include getting 7+ hours of sleep, eating >= 5 servings of fruits or vegetables, not using tobacco products, exercising at least 60 minutes.
75917573|NCT02521220|Dietary Supplement|L-citrulline|L-citrulline 2 times daily 3 gram (6g/day)
75917574|NCT02521220|Dietary Supplement|Placebo|Maltodextrin 2 times daily 3 gram (6g/day)
75917575|NCT02080377|Drug|Glibenclamide|
75917576|NCT02080377|Drug|Insulin|
75917577|NCT00468000|Biological|Ixmyelocel-T|IM injection
75917578|NCT00468000|Biological|Placebo|IM Injection
75917579|NCT02260479|Procedure|Preheated|Skin disinfection solution is preheated in a warming cupboard
75917580|NCT03428594|Biological|CKD-11101|
75917581|NCT03428594|Biological|NESP|
75917582|NCT02072967|Other|Ribomustin|Routine practice
75917583|NCT02072967|Other|rituximab|Routine practice
75917584|NCT03878810|Behavioral|Exergaming|A video game-based physical activity training applied using a commercial game console.
76075841|NCT01839448|Biological|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
76075842|NCT04380766|Procedure|Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer|Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
76075843|NCT04380532|Biological|V-SARS|Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month
75630956|NCT00803179|Drug|Nutropin AQ|Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
75630957|NCT00914173|Device|Scanlaf Circulator and water bath|Cold Pressor Test
75782195|NCT01252316|Other|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
75782196|NCT01252316|Other|Implementation of an In-Hospital CPR Training Model|UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
75917585|NCT05205564|Other|This is a cross-sectional research design.|No intervention will be involved in the study.
76075844|NCT00906958|Device|Nexus Flow Generator|The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
76075845|NCT00906958|Device|VPAP Flow Generator 25|Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
76075846|NCT01832116|Drug|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
76075847|NCT01839526|Drug|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
75782197|NCT03911180|Device|Proximal femoral nail with straight parallel blade|Petrochanteric fixation with Heracles proximal femoral nail
75917586|NCT02073045|Other|educational intervention|Receive educational handouts
75917587|NCT02073045|Other|lymphedema survey|Ancillary studies
75917588|NCT03877094|Behavioral|Nature virtual reality video|the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy
76075848|NCT03212872|Diagnostic Test|Endoscopy|
75324402|NCT03933475|Device|Virtual reality game|Use of virtual reality games on television screens
75324403|NCT04559659|Other|Respiratory muscle strength|Pimax and Pmax will be performed according to the (ATS) and (ERS). A Manovacuometer (Analog M 120, GlobalMed) with a range between 0-120cmH2O will be used. The elderly should undergo forced inspiration after maximal expiration and forced expiration after maximal inspiration through a mouthpiece with a hole to prevent closure of the glottis to evaluate Pimax and Pmax. The elderly should sustain the inspiration for 1 second. Three measurements will be performed, with a one-minute interval between them, with less difference equal to 10% between them, the higher value will be used.
76075849|NCT01832194|Drug|Botox|
76075850|NCT01832272|Procedure|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
76075851|NCT01832428|Other|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
76075852|NCT00907426|Drug|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
76075853|NCT00907426|Drug|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
76075854|NCT01832662|Other|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
75324404|NCT03367689|Drug|Olaparib|Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
75630958|NCT00914173|Device|Medoc TSA 2000|Thermal stimuli pain
75630959|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension|topical suspension
75630960|NCT00804193|Drug|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
75782198|NCT01148108|Drug|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
75782199|NCT03910946|Drug|Tuberculin, Purified Protein 5Unt/0.1 mL Solution|Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
75917589|NCT02275260|Device|Cerebral Diffusion-Weighted Magnetic Resonance Imaging|Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)
75917590|NCT02275260|Device|Transesophageal Echocardiography|Patients undergo a Transesophageal Echocardiography prior to the ablation itself
76075855|NCT01832662|Other|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
76075856|NCT01832662|Other|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
76075857|NCT00908908|Drug|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
76075858|NCT00909064|Drug|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
75782200|NCT01250444|Other|Inspiratory Muscle Training|Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
76075859|NCT03837340|Other|CMHT|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
75630961|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
75630962|NCT05697211|Drug|Ferric maltol 30 mg (Feraccru®)|In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.
75630963|NCT02607787|Behavioral|Exercise|The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
75630964|NCT02607787|Other|Control|The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
75630965|NCT04115215|Behavioral|Physical exercise (PE)|This arm includes 10 sessions of multi-component exercise sessions (including aerobic, resistance, flexibility, dual-tasking) of 1 hour/week of functional group exercise, directed to foster empowerment for subsequent continuation of exercise in community-dwelling older adults referred by primary care to a geriatrician and an expert physical therapist. Participants will receive a leaflet with instructions to perform five strength-based exercises and instructors will recommend participants to perform the exercises and walk at least 15 minutes daily.
75630966|NCT04115215|Device|Transcranial current stimulation (tCS)|This arm includes 1 application/week for 10 weeks during PE, through an adapted commercial helmet. Transcranial current stimulation (tCS) is a neural stimulation technique based on electrical stimulation of selected parts of the brain with direct or alternated electrical current (tDCS or tACS) of very low intensity of 1,5 milliamps (mA), using one or more electrodes placed on the skull. tCS is non-invasive (no surgical procedures) and it is painless, as applied in the proposed protocols.
75782201|NCT03910790|Device|19 gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
75782202|NCT03908762|Device|iSage App with connected glucometer|Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.
75917591|NCT02275260|Other|Paperbased neurocognitive testing|To assess the impact of PVI on the patient's neurocognitive status
75917592|NCT02073201|Other|High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
75917593|NCT02073201|Other|Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
75917594|NCT02073201|Other|Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
75917595|NCT02073357|Procedure|Light general anaesthesia (BIS = 50)|
75917596|NCT02073357|Procedure|deep general anaesthesia (BIS = 35)|
75782203|NCT03908762|Behavioral|Magnet|Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.
75782204|NCT03910634|Drug|Fluorouracil|1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
75917597|NCT02275494|Procedure|Total hip arthroplasty|Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
75917598|NCT03423446|Drug|Telotristat Ethyl|Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose
75917599|NCT02080533|Other|Slow-paced respiration therapy|The FDA-approved RESPeRATE device contains headphones and a sensor that attaches to the chest to detect inhalation and exhalation. Musical tones synchronize with the respiratory cycle to slowly guide the user to decrease respirations.
75917600|NCT03133962|Other|Adult patients who are candidates for a CAP or long-term central catheter placement|Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
75917601|NCT03430778|Other|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
75917602|NCT03430778|Other|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
76075860|NCT03837340|Other|CAU|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
75917603|NCT02073513|Device|Kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
76075861|NCT01832896|Drug|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
76075862|NCT03212014|Other|LSVT-BIG|LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
75782205|NCT03910634|Radiation|Intensity modulated radiation therapy|Radiotherapy for 5-6 weeks，50-60Gy
75782206|NCT03910634|Drug|carboplatin|Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
75324405|NCT00813319|Behavioral|Girls OnGuard|Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
75917604|NCT02073513|Device|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
75917605|NCT02281578|Behavioral|Community-based combination HIV prevention intervention|The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.
75917606|NCT02281578|Behavioral|Standard of care HIV services|Locally available standard of care HIV prevention, treatment and care services
75917607|NCT03423368|Device|Libramed|Policaptil Gel Retard
75917608|NCT03423368|Device|Placebo|Placebo-comparator
75324406|NCT00243659|Biological|ReFacto AF|
75324407|NCT00814177|Drug|warfarin|No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
75324408|NCT00814177|Drug|warfarin|Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
75630967|NCT04115215|Other|Control|Participants of similar profile, randomized to the control group, will undergo weekly 30 minutes educational sessions on healthy aging, including relevant aspects of nutrition, self-care, physical activity, plus measurement of blood pressure, heart rate and peripheral oxygen Hb saturation. These participants will be offered to join the PE program after the 6-months follow-up (end of the study).
75324409|NCT00243347|Drug|AZD2171|oral tablet
75324410|NCT05335681|Behavioral|WARM SHOWER APPLICATION|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen and groin areas will be applied. Since possible complications may be encountered, pregnant women The researcher will be accompanied and sit safely in the chair. will be provided. VAS scale twice, before and after the intervention will be applied. Birth satisfaction scale before discharge will be applied.
75630968|NCT00957996|Drug|Peramivir|300 mg twice daily
75630969|NCT00957996|Drug|Peramivir|600 mg once daily
75630970|NCT02607553|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
75630971|NCT04017949|Drug|Corticosteroid injection|1 cc (40 mg) of a corticosteroid (kenalog) is given
75917609|NCT02073591|Other|Ceradan Cream|
75917610|NCT02073591|Other|Ceradan Wash|
75917611|NCT02275650|Radiation|nbUVB|2 SED nbUVB exposure will be given every other week
75917612|NCT03423212|Behavioral|Just Do You|Just Do You is an intervention designed to keep young adults connected to their professional behavioral health treatments. It is a brief two-module engagement program that utilizes a hybrid provider team of a licensed clinician and peer to increase young adult engagement in adult outpatient day programs (i.e., New York State Personalized Recovery Oriented Services). The first session consists of the following components: 1) Welcome; Group Guidelines, Purpose, 2) Discuss Recovery Principles; Narrative of Role Model; 3) Video of Celebrity Service User and Discussion, and 4) Recovery Goals (and role of services in that). The second session consists of: 1) What are services & how can they help? 2) Visual art exercise -- Cause of SMI and validation, 3) Maintaining my Medicaid Insurance, and 4) Discussion of Systemic Barriers.
75917613|NCT03423212|Behavioral|Active Control|The active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
75324411|NCT04332601|Behavioral|Fatigue Management Therapy|14 sessions of 1h CBT intervention
75324412|NCT04332601|Other|TAU (Treatment as usual)|No CBT intervention
75782207|NCT03910712|Drug|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
75782208|NCT03910712|Drug|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
75782209|NCT03910712|Drug|Aromatase inhibitor|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
75782210|NCT01250600|Behavioral|Home exercise|Daily home exercise for 3 months
75630972|NCT04115137|Device|pelvic varicose veins plug embolization|pelvic varicose veins plug embolization
75630973|NCT02606539|Procedure|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
75630974|NCT02606539|Drug|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
75782211|NCT02528474|Device|balloon angioplasty with Pantera Lux|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
75917614|NCT02078037|Device|Arctic Sun cooling device|The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.
75917615|NCT02078037|Other|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
75917616|NCT02275728|Other|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
75782212|NCT02528474|Device|balloon angioplasty with SeQuent Please|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
75917617|NCT02275728|Other|Eletromyography Biofeedback|
75917618|NCT03423134|Other|New adhesive strip|This is a strip made of a newly developed adhesive
75630975|NCT00589693|Drug|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
75630976|NCT00589693|Drug|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
75630977|NCT00589693|Drug|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
75630978|NCT05735509|Device|Rubber dam|Intraoral impressions can be taken with rubber dam in place. The care provider will take two impressions, one with the rubber dam in place and one without. The investigator will randomly chose one of the two impressions for crown manufacturing, and the crown will be delivered by the care provider blindly
75630979|NCT02606383|Drug|Dapaconazole|
75630980|NCT02606383|Drug|Ketoconazole|
75630981|NCT02606695|Device|NuvaMap O.R.|Clinical imaging software used to assess intraoperative spinal alignment
75782213|NCT03908606|Procedure|Scaling and root planing|Supra and subgingival scaling and root planing.
75782214|NCT03914924|Behavioral|Exercise Program|"The 12-week program consisting of 16 exercise sessions in a total of supervised and individually prescribed aerobic and muscle-strengthening exercise of approximately 60 minutes duration. The exercise sessions will be delivered as follow:~4 weeks - supervised exercise sessions 2x / week~8 weeks - supervised exercise sessions 1x / week~In addition, they will receive counseling for unsupervised exercise sessions in their community, to accumulate a minimum of 150 min/week."
75782215|NCT03914924|Behavioral|Lifestyle Education Program|"The 12-week program consisting of 18 education classes of 30 minutes duration delivery by a health educator team. Participants receive a comprehensive education workbook to accompany the sessions, containing 20 chapters. The classes will be delivered as follow:~initial class to program introduction~4 weeks - education classes 2x / week~8 weeks - education classes 1x / week~final class to program graduation"
75782216|NCT03910556|Drug|Propofol|intraoperative factors
75782217|NCT03659578|Drug|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
75917619|NCT02073669|Procedure|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)|
75917620|NCT03428516|Device|Fixed CPAP|CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep
75917621|NCT03428516|Device|Auto-adjusting CPAP|Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
75917622|NCT02276742|Behavioral|Social Cognitive Theory|focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
75917623|NCT02276742|Other|Monitoring|Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
76075863|NCT03212014|Other|POWER|Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
76075864|NCT03212014|Other|Traditional rehabilitation|traditional exercise models in currently clinical use
75630982|NCT02606695|Device|NuvaMap|Clinical imaging software used to assess spinal alignment
75630983|NCT05663359|Procedure|EVLA 1940 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1940 nm
75630984|NCT05663359|Procedure|EVLA 1470 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1470 nm
76075865|NCT03211780|Device|General Electric LOGIQ E9 ultrasound system|Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
76075866|NCT03211936|Procedure|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
76075867|NCT03211936|Device|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
75630985|NCT02607475|Device|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
75917624|NCT02073825|Behavioral|Web Brief Intervention (WBI)|4-session WBI
75630986|NCT02607475|Device|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
75630987|NCT02606227|Behavioral|Financial incentive|Vouchers
75630988|NCT02606227|Other|No financial incentive|No financial intervention
75324413|NCT00243269|Behavioral|Acupressure expectancy enhancement|"This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea."
75630989|NCT05660473|Drug|Vincristine|Anti-tumor alkaloids
75630990|NCT05660473|Drug|Daunorubicin|Anthracycline
75630991|NCT05660473|Drug|Cyclophosphamide|Alkylating agent
75917625|NCT02281656|Procedure|Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer|
75630992|NCT05660473|Drug|Pegaspargase|Polyethylene glycol (PEG) conjugated to L-asparaginase
75630993|NCT05660473|Drug|Prednisone|Glucocorticoids
75324414|NCT03364491|Drug|Tranexamic Acid|A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
75782218|NCT03659578|Radiation|split-course radiotherapy|Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost
75782219|NCT03659578|Drug|thymosin alpha 1|subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
75917626|NCT02281656|Procedure|Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.|
75917627|NCT03428438|Other|Rehabilitation at home via SMS|Cardiac rehabilitation
75917628|NCT02281812|Procedure|Radiofrequency ablation|After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
75917629|NCT02073903|Behavioral|Patient Survey|
75917630|NCT02073903|Behavioral|Provider Survey|
75917631|NCT03428282|Procedure|VR Box|Distraction will be made during the injection of the drug using this method.
75917632|NCT03428282|Procedure|Tablet Device|Distraction will be made during the injection of the drug using this method
75324415|NCT03364491|Drug|Placebo|50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
75324416|NCT04311307|Biological|[6,6-2H2]glucose|Each subject will be administered two oral [6,6-2H2]glucose loads (pre-prandial, fed) in the hospital setting and one oral [6,6-2H2]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral [6,6-2H2]glucose load.
75324417|NCT04294069|Drug|Azithromycin 500 mg|500mg azithromycin PO for seven days starting on admission
75782220|NCT03910322|Dietary Supplement|Bif195|Two different doses of the bacterial strain Bif195 is compared to placebo
75917633|NCT03428282|Drug|Anesthesia|Anesthesia will be obtained by injecting the drug into the oral mucosa before performing the dental treatment.
75917634|NCT00463242|Drug|Agomelatine|Either 25 mg or 50 mg agomelatine orally once daily
75324418|NCT04294069|Drug|Azithromycin Oral Product|1000mg azithromycin PO once at admission
75630994|NCT05660473|Drug|Cytarabine|Pyrimidine antimetabolites
75630995|NCT05660473|Drug|6-mercaptopurine|Cell cycle-specific antitumor drug
75630996|NCT05660473|Drug|Dexamethasone|Glucocorticoids
75630997|NCT05660473|Drug|Methotrexate|Antifolate antineoplastic drug
75917635|NCT00463242|Drug|paroxetine|
75917636|NCT00463242|Drug|placebo|
75917637|NCT02078271|Other|FBDG group|The group received food based dietary guidelines for complementary feeding
75630998|NCT05660473|Drug|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
75630999|NCT04013035|Procedure|cervical length measurement|cervical length measurement at second trimester pregnancy termination in nulliparous pregnant women.
75631000|NCT00803101|Biological|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
75631001|NCT00803101|Biological|Fresh frozen plasma|Intravenous infusion, dosage depending on baseline INR and body weight
75631002|NCT03518827|Other|Asymmetry measurement|There is no intervention, the study will prospectively assess associations between asymmetries and injury risk. Asymmetry measurement will be conducted, then injuries will be tracked.
75631003|NCT02607241|Device|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
75631004|NCT02607241|Device|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR > 0.8, residual diameter stenosis < 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis > 40% or FFR < 0.8).
75782221|NCT03910322|Dietary Supplement|Placebo|Placebo
75782222|NCT01148186|Behavioral|knowledge transfer tool|knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
75782223|NCT01252550|Dietary Supplement|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
75917638|NCT02078271|Other|Stimulation|The group received psychosocial stimulation
75917639|NCT02078271|Other|Combinded FBDG and stimulation|The group received both FBDG and psychosocial stimulation
75782224|NCT01252550|Dietary Supplement|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
75782225|NCT01253486|Behavioral|Disease-related Expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
75631005|NCT00801229|Drug|Vyvanse|Vyvanse 30, 50, or 70 mg daily
75631006|NCT00801229|Drug|Placebo|Placebo 30, 50, 70 mg daily
75631007|NCT04114825|Biological|RV001V|RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
75782226|NCT01253486|Behavioral|Active Comparator: Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
75631008|NCT04114825|Other|Placebo|Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
75631009|NCT03444259|Procedure|Cardiac surgery|Open heart surgery
75782227|NCT01253486|Behavioral|Sham Comparator: Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
75782228|NCT02889562|Drug|Apixaban|Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.
75631010|NCT02606149|Behavioral|Truthful information on chemotherapy risks|One of two trained oncologist will meet the patient and inform him following an interview-guideline
75631011|NCT02606149|Behavioral|Standard of information|
75782229|NCT02889562|Drug|Warfarin|Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
75782230|NCT01252706|Behavioral|brief intervention|limit time giving information, motivation, empathy, responsibility, self control
75782231|NCT03914768|Biological|Immunomodulatory DC vaccine to target DIPG and GBM|This study will inject DC vaccine cells near lymphoid tissue close to the tumor. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day. The cells will be repeatedly infused every month for six consecutive months depending on the response and the condition of the patient. The amount of DC vaccine cells per injection is based on prior report at 5-10x106. An initial dose escalation scheme will be imposed.
75782232|NCT03915236|Device|MON4STRAT Strategy|Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.
75782233|NCT03915236|Other|Control group|Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.
75782234|NCT03323164|Drug|Timolol Maleate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
75324419|NCT00782639|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
75631012|NCT04269954|Drug|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin
75631013|NCT02856672|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
75631014|NCT02856672|Device|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
75782235|NCT03323164|Drug|Brimonidine Tartrate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
75782236|NCT03914690|Drug|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
75782237|NCT03914690|Drug|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
75782238|NCT03914456|Other|rehabilitation treatment|
75782239|NCT03323086|Behavioral|Brief Intervention (BI) with Technology Extender|One, 45-60 minute BI, followed by three months of access to technology extenders
75917640|NCT02078271|Other|Control group|
76075868|NCT03211936|Device|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
76075869|NCT03211936|Other|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
76075870|NCT03211936|Other|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
76075871|NCT01830400|Drug|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
75631015|NCT00630630|Drug|Levetiracetam|
75631016|NCT00630630|Other|Placebo|
75631017|NCT02857608|Drug|Lymphoseek|
75631018|NCT04269564|Device|stepwise PEEP|"a PEEP of 4 cmH2O will be used after intubation till 5 minutes after pneumoperitonium, and adjusted in a step wise approach after lung ultrasound by adding 2 cmH2O, repeating ultrasound 5 minutes after every change in peep till no lung collapse is detected by lung ultrasound with a maximal peep of 10 cmH2O, or if hemodynamic instability occurs.~Lung ultrasound examination will be performed at a minimum three times in each patient; the first will be performed 1 min after starting mechanical ventilation of the lungs, 5 minutes after pneumoperitonium, 5 min after every peep increase in stepwise peep group and the last time at the end of the surgery.~We define anaesthesia-induced atelectasis to be significant if any region has a consolidation score of ≥ 2."
76075872|NCT01830478|Drug|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
76075873|NCT01830478|Drug|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
75917641|NCT02074137|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
76075874|NCT01833442|Behavioral|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
76075875|NCT01833442|Behavioral|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
75782240|NCT03323086|Other|Brochure|Brochures provided one time
76075876|NCT01835782|Drug|L-Serine|
75631019|NCT02854722|Drug|Deferasirox and calcium-vitamin D3|"deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy."
75631020|NCT02854722|Drug|Calcium-vitamin D3|Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
75917642|NCT02074137|Drug|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
75917643|NCT02074137|Drug|Prednisolone|Pharmaceutical form:Tablet Route of administration: Oral
75917644|NCT02078349|Drug|KPT-330|Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA >2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
76075877|NCT00909220|Behavioral|Behavioral Activation|Behavioral Activation included up to 16 weekly 50 minute psychotherapy sessions using BA (Addis & Martell, 2004; Martell et al., 2001, 2010). Techniques included functional analyses to identify the antecedent and consequential aspects of low mood, and interventions such as monitoring daily activities, assessing pleasure/satisfaction and competence achieved via activities, assigning tasks that induce mastery or pleasure, and reducing skill deficits. Clinicians included postdoctoral fellows in clinical psychology (n = 2) or licensed clinical psychologists (n = 2).
76075878|NCT04426695|Drug|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
76075879|NCT04426695|Drug|Placebo|Placebo IV Single Dose
76075880|NCT01838200|Biological|Bacillus Calmette-Guérin (BCG) vaccine|BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.
75324420|NCT00782639|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
75324421|NCT03805295|Other|BOKS Program|12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
75631021|NCT00948246|Device|Easyband®|The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
75782241|NCT03908294|Diagnostic Test|Lab tests, non-invasive fibrosis (Fibroscan/ARFI)|Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
75324422|NCT05744219|Drug|Ferric carboxymaltose|Active drug
75324423|NCT05744219|Drug|Placebo|Placebo
75324424|NCT01997229|Biological|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
75631022|NCT00800683|Drug|BI 1356|BI 1356 dosed once daily
75782242|NCT03914534|Drug|Valproic Acid 500 MG|Administration of 500 mg of Valproic Acid
75782243|NCT03914534|Drug|Valcote 500 mg|Administration of 500 mg of Valproic Acid
75782244|NCT03913988|Behavioral|Lucid Dream|Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.
75782245|NCT03913988|Behavioral|Stress Reduction|Stress reduction techniques are a set of strategies designed to reduce anxiety and include meditation and guided imagery.
75782246|NCT03913988|Behavioral|Sleep Hygiene Techniques|Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.
75782247|NCT03914222|Device|CardioSpire (Respirix) Device|Patients will blow into the device through a small tube, which analyzes the signals in the airway patterns.
75782248|NCT03910400|Diagnostic Test|Computation of quantitative flow ratio|"After stents were implanted whenever technically possible in the STEMI patients, the investigators created a temporary artificial stenosis inside the stent by partially inflating a balloon catheter during pharmacologic hyperemia.~Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections with the artifical stenosis, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR."
75782249|NCT02888080|Drug|ACZ885|ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
75917645|NCT03795116|Device|LED-RL phototherapy|The LED-RL treatment device has a 4.7 cm x 6.1 cm rectangular array of LEDs and emits visible red light (633 nm) at a power density of 360.2 W/m2 at room temperature and a distance of 10 mm from the target surface.
76075881|NCT01838200|Drug|Ipilimumab|Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
76075882|NCT01838200|Drug|Isoniazid|Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
76075883|NCT01833754|Drug|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
76075884|NCT01720030|Drug|Levosimendan|Verum therapy
76075885|NCT01720030|Drug|Conventional therapy|Placebo therapy to safeguard blinding
76075886|NCT01720108|Drug|rivaroxaban and ASA|
76075887|NCT01720186|Device|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
76075888|NCT03211468|Behavioral|Clinical intervention program to prevent eating disorders|See previous
76075889|NCT04380220|Diagnostic Test|Blood samples and processing|DSC perfusion technique at 3.0-T MRI only in MS patients
76075890|NCT01832974|Drug|IL-13-PE|IL-13-PE intravenous infusion
75917646|NCT03795116|Device|Mock irradiation|The mock therapy device is designed to sound, look, and feel identical to the LED-RL treatment device (i.e., has the same physical components and thermal output), except it does not emit visible red light.
75324425|NCT01997229|Drug|Placebo|Placebo
75324426|NCT00800839|Drug|Busulfan|Starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
75324427|NCT00800839|Drug|Fludarabine|Dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
75324428|NCT00800839|Drug|Cyclophosphamide|Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
75782250|NCT02888080|Drug|Placebo|Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
75782251|NCT03910088|Drug|Pregabalin 100Mg Oral Cap|giving a drug to relieve post-dural puncture headache
75782252|NCT03910088|Drug|Hydrocortisone|Giving drug to relieve post-dural puncture headache
76075891|NCT01671735|Other|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
75324429|NCT02000583|Other|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
76075892|NCT01720342|Procedure|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
75782253|NCT03910088|Drug|Acetaminophen|giving a drug to relieve post-dural puncture headache
75917647|NCT02277366|Procedure|Fluorescence Bronchoscopy/Narrow Band Bronchoscopy|Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
75917648|NCT02080689|Other|Decipher|
76075893|NCT01671813|Drug|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
76075894|NCT03836404|Device|Iliac crest reconstruction surgery|When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
76075895|NCT03021291|Device|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
75324430|NCT02000583|Other|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
75324431|NCT00814255|Drug|Adalimumab|Adalimumab 24 mg/m^2 (maximum dose 40 mg) sc q 14 days
75324432|NCT00814255|Drug|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
75917649|NCT02281890|Other|Proven sepsis|Exposure is proven sepsis
76075896|NCT01833052|Device|TAVI (Medtronic CoreValve)|
75324433|NCT00814255|Drug|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
75324434|NCT02000973|Drug|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
75324435|NCT02000973|Drug|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
75324436|NCT02000973|Drug|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
75324437|NCT02000973|Drug|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
75324438|NCT02002767|Drug|Velpatasvir|Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
75324439|NCT00815035|Drug|Peanut OIT|Peanut flour that is orally ingested in a graded fashion.
75324440|NCT00815035|Drug|Placebo|Oat flour used as a placebo that is orally ingested a graded fashion
75631023|NCT00800683|Drug|placebo|placebo matching BI 1356 taken once daily
75631024|NCT01124864|Drug|AUY922|AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
75631025|NCT01113710|Drug|Neupro®|Neupro® is the exposure/intervention of interest in this non-interventional study.
75631026|NCT05726773|Procedure|Robot Assisted Therapy|In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.
75631027|NCT05726773|Procedure|Conventional Therapy|In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
75631028|NCT04114591|Procedure|anterior resection|The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
75782254|NCT03910088|Other|oral fluids|giving oral fluids to maintain good hydration
75324441|NCT01985685|Drug|Thiamine|200 mg IV thiamine
75324442|NCT00815347|Drug|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
75782255|NCT03910088|Drug|Caffeine|giving a drug to relieve post-dural puncture headache
75782256|NCT03910088|Drug|Diclofenac|giving a drug to relieve post-dural puncture headache
75782257|NCT03610438|Drug|Inotuzumab Ozogamicin (IO)|"After course 1 MRD will be evaluated:~- patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance."
76075897|NCT01833052|Device|Claret-Filter|
76075898|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
75631029|NCT04008823|Other|Retrospective and observational epidemiological study, by review of clinical histories,|Retrospective and observational epidemiological study, by review of clinical histories,
76075899|NCT01671969|Other|very low calorie diet|medically supervised diet
76075900|NCT03211078|Procedure|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
76075901|NCT01833208|Other|Laboratory Biomarker Analysis|Correlative studies
76075902|NCT01833208|Radiation|Radiation Therapy|Undergo single-fraction radiation therapy
75631030|NCT01124162|Drug|Losartan|100 mg Tablet
75631031|NCT01124162|Drug|Cozaar®|100 mg Tablet
76075903|NCT03210922|Device|Miami cervical collar|Collar group is put on the Miami cervical collar.
76075904|NCT03830398|Drug|Paracetamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
76075905|NCT03830398|Drug|Deksketoprofen trometamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
75324443|NCT00815347|Drug|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
75324444|NCT01985763|Drug|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
75631032|NCT00923533|Drug|Fimasartan|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
75782258|NCT03610438|Drug|Inotuzumab Ozogamicin (IO)|After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
75917650|NCT03127826|Procedure|Risk Stratified Care|"Physical therapists providing care will all have attended live training in PIPT principles and be involved in monthly continuing education on these principles. The use of specific principles is guided by the patient's risk stratification (as determined by the STarT Back Tool).~Medium Risk:~- Reassurance will be provided to address specific concerns related to their LBP and implications on work~High Risk:~- Physical therapy will be psychologically augmented with the assessment of biopsychosocial risk factors and the adoption of cognitive behavioral principles that explore patient concerns and address unhelpful beliefs and behaviors, including tailored education (e.g., stress management and pain neuroscience), graded exercise, & graded exposure"
75324445|NCT04149301|Diagnostic Test|3D gait analysis|Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.
75324446|NCT04149301|Diagnostic Test|MRI scan|The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
75631033|NCT00923533|Drug|Hydrochlorothiazide|Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
75324447|NCT02061969|Drug|linagliptin|5mg linagliptin tablets
75631034|NCT05104112|Other|The M.E.R. program|"The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).~It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or at home."
75631035|NCT04312568|Drug|Fadanafil|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
75631036|NCT04312568|Drug|Placebo|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
75782259|NCT03909932|Other|Observational study : no intervention|Observational study : only exporting data
75782260|NCT03908372|Drug|Docetaxel|Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles
75782261|NCT03908372|Drug|Cisplatin|Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy
75782262|NCT03908372|Radiation|IMRT|IC+IMRT arm:the patients with complete response will receive 60Gy to the gross target volume of nasopharynx, partial response 64Gy, and the absence of response or stable will receive 70Gy. CCRT arm: 70Gy to the gross target volume of nasopharynx.
76075906|NCT03830398|Drug|Placebo|The investigators apply placebo during a week in preoperative room 45 min before ECT
76075907|NCT04405323|Drug|Lu AG06466|hard capsules, orally, single doses
76075908|NCT04405323|Drug|Itraconazole|200 and 300 mg, capsules, orally
76075909|NCT01720498|Drug|remifentanil|The effect site concentration of remifentanil
76075910|NCT01672047|Drug|Vitamin D2|25（OH）D level <12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， >116.75nmol/L stopped.
76075911|NCT01833286|Procedure|TACE+RFA|TACE first, followed by RFA within 2 months
76075912|NCT01833286|Procedure|re-resection|repeat hepatectomy for recurrent small HCC
76075913|NCT01672125|Other|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
76075914|NCT01720576|Drug|REGN1033 (SAR391786)|
76075915|NCT01720576|Drug|Placebo|
75324448|NCT02061969|Drug|insulin glargine|
75324449|NCT02003625|Drug|GCSF|
75917651|NCT03127826|Procedure|Usual Care|Usual care at the general practitioner's discretion
75917652|NCT00664482|Biological|AGS-006|Autologous Therapy for Pancreatic Cancer
76075916|NCT01833364|Procedure|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
76075917|NCT01720654|Behavioral|EPT|Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
76075918|NCT00911326|Drug|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
76075919|NCT01833676|Drug|Sevoflurane|
76075920|NCT01833676|Drug|Desflurane|
75631037|NCT04310306|Device|Thrombectomy using EmboTrap II|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, using a stent retriever, contact aspiration EmboTrap II. The number of thrombectomy attempts is at the operator's discretion. Combination of balloon guide catheter or intermediate catheter is recommended.
75631038|NCT04309604|Biological|IC14|monoclonal antibody directed against CD14
75631039|NCT00906399|Drug|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
75782263|NCT03322462|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
75782264|NCT03322462|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
75782265|NCT03908138|Drug|RDD|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
75782266|NCT03908138|Drug|VDD|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
75782267|NCT05617664|Drug|desmopressin 120 mcg oral tablets|treatment for three months then will stop
75917653|NCT03110666|Biological|Injection of autologous concentrated bone marrow aspirate|Percutaneous injections at the bone-cartilage interface (distal femur and proximal tibia)
75917654|NCT00600288|Drug|diquafosol tetrasodium Ophthalmic Solution, 2%|1-2 drops administered in each eye 4 times a day for 6 weeks
75917655|NCT00600288|Drug|Non-preserved saline solution (Placebo)|1-2 drops administered in each eye 4 times a day for 6 weeks
75917656|NCT03428204|Procedure|Balloon dilation during 180 seconds|Percutaneous angioplasty with balloon dilation during 180 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
75917657|NCT03428204|Procedure|Balloon dilation during 300 seconds|Percutaneous angioplasty with balloon dilation during 300 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
75917658|NCT02284152|Behavioral|infant-led feeding|mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
75917659|NCT03423056|Other|Preoperative exercise program|Individualized aerobic training program developed by physical therapist using Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks. Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed between 50 to 70% of the maximum heart rate and will be carried on a treadmill or in a stationary bicycle.
76075921|NCT01720732|Behavioral|Lifeline NET|Short Version of Narrative Exposure Therapy
75782268|NCT05617664|Drug|Mirabegron 25 MG Oral Tablet, Extended Release|treatment for three months then will stop
75782269|NCT05617664|Behavioral|behavioral therapy alone|no medications will be given to the patient
75782270|NCT03907904|Device|CPOM Optical Neuromonitor|Prior to induction of anesthesia, the CPOM monitor will be secured to the temporal region of the participant's forehead to measure and record the cerebral hemodynamic data before, during, and following intubation. Hemodynamic, respiratory, body temperature, and anesthetic data will be continuously digitally records. The CPOM device will be detached after extubation in the operative room.
75917660|NCT02278224|Behavioral|Group based rumination focused CBT|The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.
76075922|NCT03210844|Procedure|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
76075923|NCT04380376|Drug|Melphalan|Inhalations with low doses of Melphalan for 7-10 consequent days
76075924|NCT04380376|Other|Standard of care|the patients will receive only SOC (standard of care) treatment
76075925|NCT04380298|Drug|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
76075926|NCT04380298|Drug|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
76075927|NCT04380298|Drug|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
76075928|NCT04164849|Drug|5-aminolevulinic acid|5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
76075929|NCT04164849|Procedure|Blue light photopheresis|The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
75324450|NCT02003625|Drug|meloxicam|
75324451|NCT02003625|Drug|Placebo|
75324452|NCT04037683|Drug|Misoprostol Oral Tablet|Misoprostol 25mcg orally given 2-hourly
75324453|NCT04037683|Drug|Oxytocin|Oxytocin infusion
75324454|NCT04251247|Diagnostic Test|D-dimer/fibrinogen ratio|The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
75324455|NCT04768413|Other|Teleconsultation either by phone or by computer consultation. Quantitative and qualitative approaches to analysis|A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.
75631040|NCT00906399|Drug|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
75631041|NCT01111838|Drug|STA-9090|Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
75631042|NCT02562469|Other|ACTIVATE|A home-based computerized brain training intervention for youth.
75631043|NCT00947856|Drug|brentuximab vedotin|Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
75631044|NCT02605525|Biological|SM101|Human soluble recombinant Fcγ Receptor IIB
75631045|NCT02605525|Other|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
75631046|NCT05332977|Device|CAD-CAM fabricated provisional prosthesis|Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla
75631047|NCT05332977|Device|DC (denture conversion) provisional prosthesis|Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
75782271|NCT01252862|Device|iStent|Implantation of two iStents through a small temporal clear corneal incision
75782272|NCT03909776|Drug|Cisplatin|Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
75782273|NCT01253096|Drug|Intratumoral injections of L19IL2|Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
75782274|NCT03913910|Procedure|Lipogems|Autologous micro-fragmented adipose tissue is injected in the internal orifice, mucosal, submucosal and muscular layer, then in the fistula tract and external orifice in addition to anal flap.
75917661|NCT02278224|Behavioral|Group based CBT|The control group is gold standard group based CBT based on Becks manual for CBT for depression.
75917662|NCT03790436|Dietary Supplement|Betaquik|"Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik."
75917663|NCT00594984|Drug|Cetuximab|IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
75917664|NCT00594984|Drug|Irinotecan|IV solution, IV, Q3W, 350 mg/m2, until progression
75917665|NCT00594984|Drug|Brivanib|Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
75917666|NCT00594984|Drug|Brivanib|Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
75917667|NCT00594984|Drug|Brivanib Placebo|Oral, tablet, QD, until progression
75917668|NCT01369485|Device|(VERV™ System)|Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
75917669|NCT01369485|Device|Sham version of (VERV™ System)|Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
75917670|NCT03422978|Drug|Dexmedetomidine|Single dose dexmedetomidine administered over 60 seconds post-induction.
75917671|NCT03422978|Drug|Normal saline|Single dose normal saline administered over 60 seconds post-induction.
75917672|NCT02278692|Dietary Supplement|Vitamin K|Oral vitamin K
75917673|NCT02278692|Other|Placebo|Oral placebo tablet
76075930|NCT04164849|Procedure|Transfusion|The treated cells are transferred back to the patient as a standard blood transfusion
76075931|NCT04164849|Procedure|Continuous Mononuclear Cell Collection (CMNC)|The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
75631048|NCT00947544|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
75631049|NCT00947544|Drug|NaPBA|NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
75631050|NCT00907335|Drug|Retin-A Micro 0.04% facial acne treatment|Retin-A Micro 0.04% facial acne treatment used once daily
75631051|NCT00907335|Drug|Vehicle control|Color-matched facial gel vehicle control used once daily
75631052|NCT00947154|Drug|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
75917674|NCT03430622|Behavioral|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Interpersonal Psychotherapy (IPT). The LTP Plus is a low-literacy; sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Interpersonal Psychotherapy (IPT) intervention is comprised of a supportive element, an educational element, a parenting element and an interpersonal relationship element. Intervention goals include helping mothers feel supported, empowered and confident about their parenting abilities, which would directly influence reduction in depressive symptoms as well as resolution of interpersonal conflicts.
75917675|NCT03430622|Other|TAU|This group will be on their routine care and will not be given any intervention
76075932|NCT01833910|Other|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
76075933|NCT01833910|Other|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
75324456|NCT04768413|Other|Care modalities. Quantitative and qualitative approaches to analysis|Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.
75324457|NCT04383301|Procedure|Intracorneal ring segment implantaion as the first stage|Intracorneal ring segment (ICRS)
75467961|NCT01935063|Behavioral|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
75631053|NCT05490303|Other|recording of the probe position|For each patient, a cardiac ultrasound acquisition will be performed with an optical tracking system (infrared) recording the probe's position in real time.
75631054|NCT02856360|Other|Moderate Stiffness Footwear|Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
75631055|NCT02856360|Other|High Stiffness Footwear|Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
75631056|NCT01124006|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
75782275|NCT03914144|Other|Catheter insertion|A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.
75782276|NCT01148264|Drug|olanzapine|1x10mg per day for three days
75631057|NCT01124006|Other|Water for injection|Sterile water for injection
75782277|NCT01148264|Drug|metoclopramide|3x10mg per day for three days
75782278|NCT03909464|Device|Neurosensory testing with Pressure-Specified Sensory Device|Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device.
75782279|NCT03907358|Procedure|phacoemulsification|
75782280|NCT03909308|Behavioral|Beach Tennis session|The Beach Tennis training session will be composed by a warm up of 5 min of BT in which technical exercises (i.e., serve, volley, forehand and backhand) will be performed After that, 3 BT small games of 12 min with a 2 minute interval between games using the conventional rules of sport will be performed. Before the session and after each small game, data regarding heart rate, blood pressure and rate perceived exertion will be recorded.
75917676|NCT02281968|Drug|Naproxen|Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
75917677|NCT02281968|Drug|Placebo|
75917678|NCT03422900|Dietary Supplement|Diabetes-Specific enteral formula|Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)
76075934|NCT03210610|Diagnostic Test|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
76075935|NCT01720888|Other|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
76075936|NCT01672281|Other|vibrox- vs. resistance training|Comparison between two exercise interventions
76075937|NCT01834066|Biological|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
76075938|NCT03152955|Drug|Ketamine|Ketamine will be applied in patient-controlled analgesia.
76075939|NCT03152955|Other|scalp nerve block|Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
76075940|NCT03152955|Drug|ondansetron|Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
76075941|NCT03152955|Drug|Sufentanil|Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
75324458|NCT04383301|Procedure|ACXL and wafe front guieded TPRK as the second stage|Accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
75324459|NCT03356431|Other|Supervised group exercise|"Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~Sit to stand exercise during 1 min.~Dynamic stepping exercise (walking up and down one step/stair during 1 min).~Standing calf stretch 3 x 20 sec.~Standing quadriceps stretching 3 x 20 sec.~Supine hamstring stretching 3 x 20 sec."
75782281|NCT01253252|Radiation|[18F] Fluorodeoxyglucose PET Scan Imaging|"Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.~The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.~The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations."
75917679|NCT03422900|Dietary Supplement|Standard formula|Complete enteral formula normocaloric hormoproteic without fiber
75917680|NCT02080845|Dietary Supplement|no caffeine|
75917681|NCT02080845|Dietary Supplement|high caffeine|
75917682|NCT02080845|Dietary Supplement|no theobromine|
75917683|NCT02080845|Dietary Supplement|low theobromine|
76075942|NCT01720966|Procedure|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
76075943|NCT05382975|Behavioral|CSPAP-T|"Trauma-adapted CSPAP delivery:~Staffing support~Trauma-sensitive professional development for teachers and staff~Setting specific needs assessment and action planning"
76075944|NCT01676493|Drug|Codeine|
76075945|NCT01721434|Drug|Levosimendan|
75467962|NCT01935063|Other|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
75467963|NCT01935076|Behavioral|Neonatal exposure to maternal obesity|
75467964|NCT01935115|Drug|Propofol|Propofol anesthesia for ECT
75782282|NCT01253252|Radiation|CT scan|Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
75782283|NCT01253252|Biological|Blood sampling for biological investigations|A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
75782284|NCT00086580|Biological|FluCAM [Fludara + Campath]|"Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity."
75917684|NCT02080845|Dietary Supplement|high theobromine|
75917685|NCT02284230|Drug|Liraglutide|
75917686|NCT02284230|Drug|Placebo|
75917687|NCT00663936|Drug|T-817MA|224 mg T-817 MA once daily
76075946|NCT01721434|Drug|Placebo|Similar coloured placebo
76075947|NCT01721512|Other|Breastfeeding|
76075948|NCT01721512|Other|Infant formula|
76075949|NCT02563431|Device|SYSTAM - SP-ED|"Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~Daily passive mobilisation of the upper member by a therapist.~Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
75467965|NCT01935115|Drug|Ketamine|Ketamine anesthesia for ECT
75917688|NCT00663936|Drug|Placebo|Placebo once daily
75917689|NCT02074215|Other|Aerobic exercises|Aerobic exercises + dual task
75917690|NCT02074215|Other|Stretch exercise|Stretch exercise
75917691|NCT02080923|Behavioral|Brief Motivational Interview|The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
75917692|NCT02792088|Drug|Besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
75917693|NCT02792088|Drug|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
75917694|NCT02074293|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
76075950|NCT02563431|Device|Ultrasling ER 15°Donjoy - 4P-ED|"Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~A training of the patient and members of family on pathology, risk, use of material~Daily passive mobilization of the upper member by a therapist.~Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
75467966|NCT01935141|Procedure|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
75467967|NCT01935141|Device|Siemens Sensation 64-MDCT scanner.|The device will be used to perform CT Pulmonary Angiograms
76075951|NCT03210532|Drug|Telmisartan + Amlodipine + Rosuvastatin|Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
76075952|NCT03210532|Drug|Telmisartan + Amlodipine|Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
76075953|NCT03210532|Drug|Telmisartan + Rosuvastatin|Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
75917695|NCT02074293|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
75917696|NCT02074293|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
75917697|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
75917698|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox intramuscularly at Week 12, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
75631058|NCT03593889|Behavioral|Collaborative stepped care and peer support programme|"For at-risk group, 4 weeks of selective prevention group sessions will be provided at the elderly service level by trained peer supporters with registered social worker supervision, on wellness topics tailored to the person's concern as entry point, packaged with mental health information, followed by a review.~For mild group, 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided. For moderate group, 6-8 weeks high-intensity cognitive behavioral therapy (CBT) would be provided. All intervention for depressed elderly would be conducted by registered social workers. The trained peer supporters will be matched to individual older adults to walk them through the process with regular follow-up for 1 year."
75631059|NCT03593889|Other|Treatment as usual|The control group will receive treatment as usual, which will be determined by the responsible workers from NGO units.
75631060|NCT03589989|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
75631061|NCT03589989|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
75631062|NCT01862952|Other|starting of anti-epileptic drug treatment|
75631063|NCT02882516|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
75631064|NCT00952068|Drug|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
75631065|NCT01123850|Device|Copios|Bone Void Filler
75782285|NCT00086580|Biological|fludarabine phosphate|Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
75782286|NCT03908996|Behavioral|Profile by Sanford weight management plan|The purpose of this study is to observe weight changes in patients who completed endometrial cancer treatment, are clinically overweight, and who participate in the Profile by Sanford weight management program. An exploratory purpose is to examine the bacterial content of the patient's gut by examining stool specimens before starting the Profile by Sanford weight management program and after 6 months of participation in the Profile by Sanford weight management program.
75782287|NCT03908840|Biological|TBI 302|TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
75782288|NCT01253330|Other|Text Message Reminders|During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
75782289|NCT03908918|Other|Mindfulness app|Mobile app-delivered mindfulness intervention delivered over 4 weeks.
75782290|NCT03908528|Dietary Supplement|Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..
75782291|NCT03908528|Other|Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.
75917699|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
75917700|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
75917701|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
75917702|NCT02074293|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
75631066|NCT05572047|Device|Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System|Use of coherent sine-burst electroporation to ablate paroxysmal and persistent AF
75917703|NCT02074293|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
75917704|NCT02074293|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
75917705|NCT02074293|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
75917706|NCT02074293|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
75917707|NCT02074293|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
75917708|NCT02074293|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
75917709|NCT00456378|Device|DIAM™ Spinal Stabilization System|Surgical procedure with implantation of the Investigational device
75782292|NCT04850170|Procedure|manual therapy|"release and stretch the muscles and fascia around shoulder girdle、upper arm and forearm;~massage the masseter muscle and temporalis muscle;~mobilization of the temporomandibular joint, the thoracic and cervical spine, shoulder, and elbow."
75782293|NCT04850170|Procedure|Speech therapy|include the stretching of the neck, facial and oral movement training, and swallowing training
75631067|NCT01123382|Device|Intramuscular Electrical Stimulator|A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
75631068|NCT01123382|Other|Outpatient Therapy|Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
75782294|NCT03903458|Drug|Tinostamustine|First-in-human administration of the combination of Tinostamustine and Nivolumab.
75631069|NCT00951912|Dietary Supplement|Placebo|10g soy protein isolated per day
75782295|NCT03584542|Other|No interventional study|No Interventional study - Only one questionnaire will be done for patients and for general practitioners
75631070|NCT00951912|Dietary Supplement|Daidzein|50mg daidzein +10g soy protein isolated per day
75631071|NCT00951912|Dietary Supplement|Genistein|50mg genistein +10g soy protein isolated per day
75631072|NCT05332665|Device|AS-OCT|Anterior segment optical coherence tomography (AS OCT) is an imaging device that can acquire an anterior segment image using a noncontact method with the patient in a sitting position. This device provides reproducible and quantitative measurements of the AC angle and other anterior segment parameters.
75782296|NCT00086502|Drug|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
75782297|NCT00086502|Drug|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
75782298|NCT00086502|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
75782299|NCT00086502|Drug|Metformin|"Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"
75782300|NCT03903302|Drug|CS1-Sodium Valproate|Single and multiple dose evaluation of CS1
75782301|NCT03620656|Diagnostic Test|FibriCheck|Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm
75631073|NCT05332665|Procedure|YAG laser PI|medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block
75631074|NCT03575169|Device|BIS Monitor|Unilateral BIS electrode
75631075|NCT02882594|Behavioral|Observing patient behaviors for anesthesia induction compliance|Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
75782302|NCT02528084|Procedure|yoga|patients watch and follow an online yoga video.
75782303|NCT02528084|Procedure|standard exercises|patients watch and follow an online standard exercises video.
75782304|NCT03907592|Dietary Supplement|L-carnitine supplementation|Supplementation of 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout the study period.
75782305|NCT03907592|Dietary Supplement|Leucine supplementation|Supplementation of 4000 mg L-leucine per day throughout the study period.
75782306|NCT03907592|Procedure|Resistance training|Resistance training at the gym, twice a week for 24 weeks (48 training units in total).
75917710|NCT00456378|Procedure|Conservative care|Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
75917711|NCT02282124|Behavioral|Self-management program with monthly sessions|Patients participate in 9 sessions during the first 8th month after transplantaiton
76075954|NCT03210454|Other|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
75782307|NCT03826667|Device|Polyetheretherketone (PEEK) Shoulder Suture Anchors|"PEEK Suture Anchors, which include:~HEALICOIL™ PK Preloaded Suture Anchors~BIORAPTOR™ 2.3 PK Suture Anchors/BIORAPTOR™ Curved 2.3 PK Suture Anchors~BIORAPTOR™ Knotless Suture Anchors~MULTIFIX™ S Ultra Knotless Fixation System~FOOTPRINT™ Ultra PK Suture Anchors~TWINFIX™ Ultra PK Suture Anchors/TWINFIX™ Ultra Preloaded and with Needles~SPEEDSCREW™ Knotless Fixation System~SpeedLock Knotless Fixation Device"
76075955|NCT03210454|Other|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
76075956|NCT05119413|Drug|New trio de Kligman|Once daily application in addition to the same sunscreen
76075957|NCT05119413|Drug|Trio Kligman|Once daily application in addition to the same sunscreen
75782308|NCT03907436|Other|USDA Diet|Participants will receive counseling and education on USDA Guidelines for Americans, 2010
75782309|NCT03907436|Other|Mediterranean Diet|Participants will receive counseling and education on a Mediterranean diet.
75782310|NCT03001024|Behavioral|Implementation of WayToServe Español|Following baseline assessment and randomization to experimental condition, premises assigned to the intervention condition will be contacted and recruited to the trial. Managers will provide a list of all servers. All servers will be registered by project staff on the WTS-E website and provided a unique identification code, which will track their use of the training and associate it with the premise. Servers will complete a profile on the program during their first login. Servers will be asked to complete the training within four weeks from initial registration; email and text reminders will be sent to those who do not login within one week of initial registration.
75782311|NCT03001024|Behavioral|Usual and Customary RBS Training|The premises randomized to the UC training condition will be, in effect, blind to the investigation. Server training is mandatory for all servers in New Mexico. Server training is voluntary in Texas but heavily incentivized by TABC's Safe Harbor clause. Under this clause, liquor licensees are held harmless for any service infractions if all servers are trained and certified by an approved RBS trainer; instead, the server is cited for the infraction.
75782312|NCT03636542|Drug|liposomal bupivacaine|Experimental
76075958|NCT01834378|Behavioral|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
76075959|NCT01834378|Behavioral|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
75782313|NCT03636542|Drug|bupivacaine|Active comparator
75917712|NCT02282124|Behavioral|Usual Care, containing one session|Session takes place within the first three months after transplantation
75917713|NCT03749252|Drug|P03277|A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
76075960|NCT03152565|Drug|Avelumab|"Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity."
75324460|NCT03356431|Other|Home-based exercise|"Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~Sit to stand exercise during 1 min.~Dynamic stepping exercise (walking up and down one step/stair during 1 min).~Standing calf stretch 3 x 20 sec.~Standing quadriceps stretching 3 x 20 sec.~Supine hamstring stretching 3 x 20 sec."
75467968|NCT01935141|Drug|Visipaque 320 non-ionic isoosmolar contrast agent|Single Dose of Intravenous Iodixanol will be administered per CT scan.
75467969|NCT01935154|Drug|Vx-001|
75467970|NCT01935154|Drug|Placebo|
76075961|NCT01721590|Drug|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
76075962|NCT01721590|Drug|placebo|3 capsules/time，3times/day for 1 year
75467971|NCT01935167|Drug|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
75467972|NCT01935167|Drug|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
75467973|NCT01935167|Drug|Placebo|Placebo 2 tablets b.i.d.
75467974|NCT01935193|Drug|lysine acetylsalicylate|
75467975|NCT01935206|Drug|Naloxone (2 mg/kg)|
75467976|NCT01935206|Drug|Placebo|
75782314|NCT03305770|Device|verofilcon A contact lenses|Daily disposable soft contact lenses
75782315|NCT03305770|Device|delefilcon A contact lenses|Daily disposable soft contact lenses
75782316|NCT03898622|Drug|Levothyroxine|levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels > 1 and normal T4L
75782317|NCT03907514|Behavioral|"FALE Application"|"FALE is a digital tool, in the form of an application for smartphones, which aims to demonstrate empathy and facilitate communication between the adolescent patient and the dentist. The application contains 14 questions regarding dental anxiety, feelings and patient coping preferences regarding dental care."
75917714|NCT02078505|Behavioral|diet|Carbohydrate poor diet
75917715|NCT00451152|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
75917716|NCT00451152|Other|Anecortave Acetate Vehicle|Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
75631076|NCT01123148|Device|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
75631077|NCT02856204|Other|Cytology Specimen Collection Procedure|Undergo collection of blood
75631078|NCT02856204|Other|Laboratory Biomarker Analysis|Correlative studies
75631079|NCT02856048|Drug|Triptorelin (GnRHa) + Chemotherapy|During her chemotherapy, the patient in the experimental arm will have regular injections of Triptorelin (DECAPEPTYL LP 3 mg, IPSEN) in order to preserve her fertility
75917717|NCT02279472|Procedure|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
75324461|NCT03211221|Device|rTMS (repetitive transcranial magnetic stimulation)|rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies < or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
75631080|NCT02854410|Dietary Supplement|Sodium nitrate|Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
75631081|NCT02854410|Dietary Supplement|sodium chloride|Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
75631082|NCT01123070|Biological|TL011, anti CD20, for the treatment of rheumatoid arthritis|TL011 administered by 2 infusions, 2 weeks apart
75631083|NCT01123070|Biological|MabThera infusions|MabThera, administered by 2 infusions, 2 weeks apart
75631084|NCT02857686|Procedure|intravenous regional anaesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
75631085|NCT02857686|Procedure|forearm IVRA|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
75631086|NCT03841929|Other|Hemodynamic report|The multimodal data comprising the clinical, biochemical, NIRS data and TNE where available will be used by the study team in such cases to reach a description of the hemodynamic status of the study infant and will be provided to the Clinical team.
75631087|NCT04275648|Diagnostic Test|AsthmaTuner exercise field test|AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
75631088|NCT05330403|Procedure|Moxibustion|"In this study, suspended moxibustion was performed by holding an ignited moxa stick at a certain distance (about 3-4 cm) over the skin surface, keeping the moxibustion Site warm without burning the skin.~In the heart meridian intervention group, moxibustion was applied over Site 4 (HT3) of the heart meridian.~In the lung meridian intervention group, moxibustion was performed over Site 1 (LU5) of the lung meridian."
75631089|NCT02854254|Device|peripherally inserted central catheter|peripherally inserted central catheter
75782318|NCT00086190|Drug|paroxetine|Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
75782319|NCT00086190|Drug|venlafaxine|Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
75782320|NCT00086190|Other|placebo|an inactive substance
75782321|NCT01256372|Drug|AP214|AP214
75782322|NCT01256372|Drug|Placebo|Placebo; intravenous infusion
75782323|NCT03320824|Device|New Dermal Filler|hyaluronic acid
75782324|NCT03320824|Device|Device: FDA Approved Dermal Filler|hyaluronic acid
75917718|NCT02078583|Drug|Fentanyl|
75324462|NCT02395185|Other|Milk bottle administration|Patients are given a bottle of milk during the casting process.
75324463|NCT02395185|Other|Water bottle administration|Patients are given a bottle of water during the casting process.
75324464|NCT02395185|Other|Sucrose bottle administration|Patients are given a bottle of sucrose during the casting process.
75631090|NCT02854254|Device|peripherally venous access|standard over-the-needle intravenous catheter
75631091|NCT03198741|Drug|Aspirin + clopidogrel|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
75631092|NCT03198741|Drug|Clopidogrel monotherapy|After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
75631093|NCT03198741|Drug|Aspirin monotherapy|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
75631094|NCT01122680|Drug|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
75631095|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
75631096|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
75917719|NCT02078583|Drug|Remifentanil|
75917720|NCT02078583|Drug|Normal saline|
75917721|NCT00449904|Drug|Liprotamase|Administered orally
75917722|NCT02078661|Drug|PG101|A topical gel containing either 1% or 0.25% PG101 active.
75917723|NCT02948660|Drug|Zolpidem Tartrate Tablets|All participants were administered 10 mg of zolpidem tartrate tablets either via a feeding tube (for patients with prolonged disorders of consciousness) or orally.
75917724|NCT02078739|Behavioral|Yoga Program at home using internet technology|
75917725|NCT00448890|Drug|GSK729327|Tablets
75917726|NCT00448890|Drug|Placebo|GSK729327 Matching placebo - Tablets
75917727|NCT02074605|Biological|Interferon alpha|
75917728|NCT00448422|Drug|prulifloxacin|Tablet
75917729|NCT02081235|Procedure|surgery for congenital heart disease|surgery for congenital heart disease
75917730|NCT00583830|Biological|Mapatumumab|30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
76075963|NCT05381181|Biological|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
76075964|NCT01834456|Other|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
76075965|NCT03210142|Procedure|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
75324465|NCT02396511|Biological|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
75324466|NCT02396511|Biological|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
75782325|NCT03898544|Device|Group primary TKA|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors (IR) on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
75782326|NCT03898544|Device|Group TKA revision|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
75782327|NCT01150292|Dietary Supplement|First period DHA|400 mg DHA supplementation by day for 2 weeks during the first study period
75782328|NCT01150292|Dietary Supplement|Second period DHA|400 mg DHA supplementation by day for 2 weeks during the second study period
75782329|NCT01760291|Device|WATCHMAN LAA Closure Technology|
75782330|NCT03903224|Procedure|Combined Modified Pectoralis and Transversus Plane Blocks|"Modified pectoralis nerve block (Pecs II) aims to block at least the pectoral nerves, the intercostobrachial, intercostals III-IV-V-VI. This will cover dermatomes T2, T3 and T4. The probe is positioned under the lateral third of the clavicle .After locating the subclavian muscle, the axillary artery and the axillary vein we move the probe distally towards the axilla, until the pectoralis minor is identified. We start counting the ribs , from r1 under the axillary artery, we move distally and laterally until the lateral border of pectoralis minor is reached. The serratus anterior muscle which covers r2, r3, r4 is the point of entrance into the axilla.~Blocking of multiple anterior branches of intercostal nerves (Th2-6) using a transversus thoracic muscle plane (TTP) block is used as an additive to pecs II to cover the internal mammary region"
75782331|NCT03903224|Procedure|Erector Spinae block|The patient is placed in a sitting position and The T5 spinous process is located by palpating and counting down from the C7 spinous process. Under complete aseptic conditions a linear ultrasound probe is then placed in a transverse orientation at the level of the T5 transverse process. The tip of the transverse process is centred on the ultrasound screen and the probe is then rotated into a longitudinal orientation to produce a parasagittal view. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superficial to the transverse processes.
75917731|NCT00583830|Biological|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
75917732|NCT00583830|Drug|Paclitaxel|200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle
75917733|NCT00583830|Drug|Carboplatin|AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
75917734|NCT03422588|Procedure|Laparoscopic right colectomy|Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally
75917735|NCT02074683|Procedure|Year A Pathway|Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
75917736|NCT02074683|Procedure|Year B Pathway|Standard of Care Followed by Fat Grafting Operative Procedure
75917737|NCT03430544|Drug|Cariprazine Oral Capsule [Vraylar]|Cariprazine Groups (1.5 or 3mg/d): Cariprazine (VRAYLAR) capsules will be administered orally, once per day. Subjects in the 1.5mg group will receive 1 VRAYLAR capsule containing 1.5 mg cariprazine each day that study drug is administered. Subjects in the 3 mg group will be gradually titrated up to full dose: they will receive 1 VRAYLAR capsule containing 1.5mg cariprazine on the first and second days that study drug is administered and will receive 1 VRAYLAR capsule containing 3mg cariprazine each day for the rest of the medication period. The study medication period begins during the inpatient/induction phase and ends on the last day of outpatient treatment week 8 (approx. 10 weeks total). All VRAYLAR capsules will be over-encapsulated by the University of Pennsylvania Investigational Drug Services (IDS).
75917738|NCT03430544|Drug|Placebo oral capsule|PLACEBO Group: Visually identical placebo capsules will be supplied by the University of Pennsylvania Investigational Drug Service, with a dosing regimen matching the cariprazine groups.
75917739|NCT02081313|Other|Biopsy|
75917740|NCT02081313|Other|Blood sample|
76075966|NCT03210064|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
76075967|NCT03210064|Drug|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
76075968|NCT00905554|Procedure|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
76075969|NCT00905554|Procedure|air insufflation|air insufflation during the insertion phase of colonoscopy
76075970|NCT01721902|Device|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
76075971|NCT01721902|Other|Carrier Solution|Intra-myocardial injection of carrier solution
76075972|NCT01721980|Drug|GLPG0974|
75467977|NCT01935219|Behavioral|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
75917741|NCT00583674|Drug|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
75324467|NCT02396745|Device|Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))|"TECR will be performed to resect the entire length and area of BE lesion.~ECM PLACEMENT:~Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA)."
75324468|NCT00816829|Drug|Placebo|Fenofibrate-matching placebo tablet
75324469|NCT00816829|Drug|Fenofibrate|145 mg NanoCrystal tablet
75324470|NCT02062359|Biological|Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|"Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.~On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes."
75631097|NCT01122680|Drug|Placebo|placebo inhalation solution
75631098|NCT03186339|Procedure|TAVI|transfemoral transcatheter aortic valve implantation
75782332|NCT03982355|Device|DRS probe|The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe
75782333|NCT03275350|Drug|Naltrexone Injectable Suspension|Six monthly injections of extended-release naltrexone
75782334|NCT03275350|Other|Treatment as usual|Standard treatment for opioid use disorder provided at each HIV clinic
75917742|NCT00583674|Drug|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
75917743|NCT00583674|Drug|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
75917744|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
75917745|NCT00583674|Drug|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
75917746|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
75324471|NCT02062359|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
75324472|NCT02062359|Drug|Cyclophosphamide|On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
75631099|NCT03186339|Procedure|SAVR|isolated surgical valve replacement
75631100|NCT03186339|Other|MM|management of aortic stenosis by medical treatment only
75631101|NCT00946998|Drug|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
75782335|NCT01148342|Drug|MDMA|
75782336|NCT01148342|Drug|(+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules|0, 1.0 &amp; 1.6 mg/kg
75782337|NCT01254734|Procedure|transoral robotic surgery|Undergo transoral robotic microsurgery
75917747|NCT00583674|Drug|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
75917748|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
75917749|NCT00583674|Drug|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
75917750|NCT03422510|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
75631102|NCT00946998|Drug|placebo|Placebo tablet will be identical and matched to sertraline tablet.
75631103|NCT03147261|Other|Lifestyle intervention|Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
75917751|NCT02074761|Device|SImmetry|"The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
75917752|NCT02930564|Other|CDED + milk fat and gluten|CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)
75917753|NCT03428048|Procedure|Hybrid procedure|Ablation of the posterior aspect of the heart, an area thought to be the origin of chaotic arrhythmias in persistent Afib patients.
75631104|NCT01138826|Drug|Amlodipine - reference|10 mg tablet, single dose, with water
75631105|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
75631106|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
76075973|NCT01721980|Drug|Placebo|
75631107|NCT00906087|Drug|Cosopt (combination eyedrop of dorzolamide and timolol)|One drop in each eye every twelve hours for six weeks
75631108|NCT02854332|Device|tDCS session|Direct current transcranial magnetic stimulation
75631109|NCT02854332|Device|rTMS session|Repetitive transcranial magnetic stimulation.
75631110|NCT03525795|Drug|CPI-1205|Administered orally
75631111|NCT03525795|Drug|ipilimumab|Administered intravenously
75782338|NCT01254734|Other|laboratory biomarker analysis|Correlative studies
75782339|NCT01254734|Procedure|quality-of-life assessment|Ancillary studies
75631112|NCT02883374|Drug|Chidamide|
76075974|NCT05372991|Drug|CBT-009|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
75631113|NCT02855736|Behavioral|Positive Psychology|"Gratitude Journal (Emmons and Stern, 2013)~Every evening, patients have to write down the things they feel grateful about."
76075975|NCT05372991|Drug|Vehicle|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
75917754|NCT03428048|Procedure|Endocardial ablations|ablations occurring inside the heart isolating the pulmonary veins - blocking energy from creating irregular or chaotic heart beats with use of a catheter
75782340|NCT04783714|Dietary Supplement|Swisse Nutra+ Cholesterol Balance|Swisse Nutra+ Cholesterol Balance is a multi-ingredient nutraceutical composition contained in a brown soft-gel capsule format. Three capsules are required per dose.Swisse Nutra+ Cholesterol Balance is a multi-ingredient formulation containing artichoke extract, bergamot juice extract, hydroxytyrosol, an antioxidant derived from olive oil and sunflower oil-derived phytosterols. All ingredients target cholesterol reduction by different and complementing mechanisms, as evidenced by human clinical trials. These ingredients have been chosen to work synergistically to alleviate hypercholesterolemia and/or dyslipidemia through multiple pathways, whereby each ingredient works via a different mechanism to lower LDL-cholesterol in the body.
75917755|NCT03428048|Procedure|left atrial appendage occlusion|A procedure to isolate the left atrial appendage of the heart. this anatomic body is the origin of clot formation which can lead to stroke. the clot formation as a result of Afib
75917756|NCT00583128|Drug|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
75917757|NCT00583128|Drug|Celphere® CP-305|oral, placebo, sachet, 2 grams three times daily for 8 weeks
75917758|NCT03430466|Drug|Durvalmab&Tremelimumab&Fulvestrant|Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks
75324473|NCT02062359|Drug|Fludarabine|On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
75324474|NCT02397291|Drug|Mannose|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
75324475|NCT02397291|Drug|Myoinositol|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
75631114|NCT02855736|Behavioral|Placebo (food journal)|"Food journal (i.e. alimentary list):~Patients have to write down the list of foods eaten during the day."
75917759|NCT02280018|Drug|JNJ-49122944, 5 milligram (mg)|Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
75917760|NCT02280018|Drug|Placebo|Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
75917761|NCT03422432|Procedure|HIPEC|All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.
76075976|NCT05372991|Drug|Atropine Sulfate|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
75324476|NCT02397291|Drug|Placebo|placebo
75631115|NCT02855970|Other|completion of a quality of life questionnaire|
75631116|NCT05318001|Other|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical (Tone-Hz, Stiffness-N/m and decrement) and viscoelastic (creep and relaxation time-ms) properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position."
75631117|NCT05318001|Other|Evaluation of Foot Morphological Characteristics|Foot length and width will be measured.
75631118|NCT05318001|Other|Evaluation of navıcular mobility|The amount of navicular drop of both feet will be measured.
75631119|NCT05318001|Other|Evaluation of Foot Posture|Foot posture will be evaluated according to Foot Posture Index.
75631120|NCT02420574|Drug|albendazole BENDEX|randomized clinical trial with 2 parallel arms
75631121|NCT02420574|Drug|albendazole OVIS|
75631122|NCT02855502|Drug|Prednisolone|
75631123|NCT02855502|Drug|Placebo|
75782341|NCT04783714|Dietary Supplement|Placebo|Matched brown soft-gel capsule placebo containing olive oil and palm olein - no therapeutic benefit.
76075977|NCT01672515|Device|RIPC group|
76075978|NCT01672515|Device|Control group|
76075979|NCT00906178|Behavioral|CyberSenga|Internet-based HIV prevention program
76075980|NCT03152721|Device|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
76075981|NCT03152721|Other|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
75324477|NCT00816907|Drug|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
75324478|NCT00816907|Drug|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
75324479|NCT00817219|Drug|Calcipotriene plus betamethasone dipropionate ointment|Once daily application for 4 weeks
75467978|NCT01935219|Behavioral|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
75631124|NCT05332431|Device|Optical coherence tomography (OCT)|"Patient with different types of migraine and age and sex matched control group will be subjected to OCT in the ophthalmology department in Assiut University Hospital to assess the following parameters:~Optic nerve head parameters and retinal nerve fibre layer thickness and measuring macular thickness in migraine patients will be measured using optical coherence tomography (OCT) after pupillary dilatation. Retinal nerve fiber layer thickness included average thickness (360° measurement), temporal quadrant thickness (316-45°), superior quadrant thickness (46-135°), nasal quadrant thickness (136-225°) and inferior quadrant thickness (226-315°) will be measured by OCT."
75631125|NCT02853864|Drug|0.0 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0 ng/ml
76075982|NCT01722058|Drug|Peptide application|
75917762|NCT03134274|Device|Dip HBDA|Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
76075983|NCT01722136|Behavioral|Low Dosage|Exercise dose of 8kcal/kg/week
76075984|NCT01722136|Behavioral|High Dosage|Exercise dose of 14kcal/kg/week
76075985|NCT03863379|Diagnostic Test|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
76075986|NCT01672593|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
76075987|NCT01672593|Drug|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
76075988|NCT01672593|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
76075989|NCT01672593|Procedure|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
75631126|NCT02853864|Drug|0.4 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4 ng/ml
75782342|NCT03903146|Behavioral|Early Childhood Obesity Risk-Reduction Program in Hispanics|"Sessions Prenatal (40 min): Includes a colorful binder with information about breastfeeding. Set her goals and action plan for breastfeeding. Past experiences with breastfeeding. Benefits of adopting a healthy behavior, describe and discuss infant feeding and qualms about mixed feeding, barriers to EBF and self-efficacy.~Prenatal Calls (10 min.): Discuss strategies available to accomplish mother's breastfeeding goals. Answer questions. Follow-up call until delivery.~Hospital visit (30 min.): PC visit mother at the hospital stay to support the participant in her effort to breastfeeding.~Postpartum home-visit (40 min.) IBCLC performs a home visit to assess infant feeding pattern, breastfeeding techniques with hands-on assistance if needed. Provide supplemental breastfeeding devices as needed. Answer all questions.~Postpartum calls (10 min.): PC/IBCLC ask about problems/concerns and answer questions. Repeat phone calls as needed (at least 1 a month)."
75782343|NCT03557242|Device|TAVR|Transcatheter Aortic Valve Replacement
75782344|NCT03557242|Other|Warfarin plus Aspirin|Subjects randomized to this arm will receive Warfarin plus aspirin for 30- 45 days post TAVR
75782345|NCT03557242|Other|Aspirin Only|Subjects randomized to this arm will receive aspirin only post TAVR
75917763|NCT02280174|Drug|linagliptin|linagliptin 5 mg/d for12 weeks
75917764|NCT03430388|Biological|Yellow Fever vaccine (17D)|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
75917765|NCT00579384|Drug|JNJ-26489112|Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
75917766|NCT00579384|Drug|Placebo|Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
76075990|NCT03678831|Procedure|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
76075991|NCT01834534|Behavioral|CarePartners for depression|Automated telephone calls for depression monitoring and self-management support.
76075992|NCT04764279|Dietary Supplement|OPTIFAST dietary supplement|Participants will use Optifast Nutrition Supplement as previously described
76075993|NCT01834612|Device|CM1500|blood volume monitor
76075994|NCT04404621|Behavioral|Physical exercise (PE) training and computer-based brain (CBB)|18 weeks of PE and CBB.
76075995|NCT03219034|Device|oral appliance - A ; washout; oral appliance B|Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
75631127|NCT02853864|Drug|0.6 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6 ng/ml
75917767|NCT03430232|Drug|Placebo|Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
75917768|NCT03430232|Drug|STR-324 Dose Level 1|Short infusion of a solution for intravenous administration
75917769|NCT03430232|Drug|STR-324 Dose Level 2|Short infusion of a solution for intravenous administration
75917770|NCT03430232|Drug|STR-324 Dose Level 3|Short infusion of a solution for intravenous administration
75631128|NCT02853864|Drug|0.8 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8 ng/ml
75631129|NCT02853864|Drug|Propofol|The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
75631130|NCT04269642|Drug|PT320 2.0mg Placebo|PT320 2.0mg Placebo
75631131|NCT04269642|Drug|PT320 2.0 mg|Exenatide slowly released formulation
75631132|NCT04269642|Drug|PT320 2.5 mg|Exenatide slowly released formulation
75631133|NCT00907257|Drug|benzoyl peroxide wash|5% benzoyl peroxide wash
75631134|NCT00907257|Drug|Tretinoin gel|0.04% tretinoin gel
75631135|NCT01138046|Drug|Lapatinib in combination with weekly paclitaxel|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
75631136|NCT02854176|Procedure|Somatosensory electrical stimulation|
75631137|NCT02854176|Procedure|Control|
75631138|NCT02853942|Biological|Autologous adipose stem cell therapy|
75631139|NCT02853942|Drug|Mecobalamin|
75631140|NCT03484533|Behavioral|HIV self-test kit|We will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits to HIV-positive pregnant women overcomes their male partners' reluctance to be tested in PMTCT clinics. Pregnant women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
75917771|NCT03430232|Drug|STR-324 Dose Level 4|Short infusion of a solution for intravenous administration
75917772|NCT03430232|Drug|STR-324 Dose Level 5|Short infusion of a solution for intravenous administration
75917773|NCT03430232|Drug|STR-324 Dose Level 6|Short infusion of a solution for intravenous administration
75917774|NCT03430232|Drug|STR-324 Dose Level 7|Short infusion of a solution for intravenous administration
75917775|NCT03430232|Drug|STR-324 Dose Level 8|Short infusion of a solution for intravenous administration
75324480|NCT02007369|Behavioral|WhatsApp|Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.
75324481|NCT02007369|Behavioral|Facebook|Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
75324482|NCT00817843|Drug|Simvastatin|6 weeks of treatment with simvastatin 80 mg
75324483|NCT00817843|Drug|Simvastatin/Ezetimibe|6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
75324484|NCT02008149|Other|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
75324485|NCT00817999|Dietary Supplement|Grapefruit juice|Participants received grapefruit juice during 1 of the 2 periods.
75631141|NCT03484533|Behavioral|Standard of Care|In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
75631142|NCT00876460|Drug|BIBF 1120 M + docetaxel M|BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
75631143|NCT00876460|Drug|BIBF 1120 M + docetaxel H|BIBF 1120 Medium dose bid + docetaxel 75mg/m2
75631144|NCT00876460|Drug|BIBF 1120 H + docetaxel H|BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
75917776|NCT03430232|Drug|STR-324 Dose Level A|Long infusion of a solution for intravenous administration
75917777|NCT03430232|Drug|STR-324 Dose Level B|Long infusion of a solution for intravenous administration
75917778|NCT03430232|Drug|STR-324 Dose Level C|Long infusion of a solution for intravenous administration
75917779|NCT03430232|Drug|Placebo|Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
75917780|NCT02284542|Procedure|Awake|Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
75324486|NCT00817999|Drug|Clopidogrel 75 mg/day|
75324487|NCT00817999|Drug|Clopidogrel 300 mg|
75324488|NCT03839485|Drug|Endodontic treatment using Guedes-Pinto Paste|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
75324489|NCT03839485|Drug|Endodontic using Guedes-Pinto Paste without antibiotic|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
75324490|NCT02008617|Drug|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
75324491|NCT02008617|Drug|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
75324492|NCT03839251|Drug|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
75324493|NCT00819403|Drug|simvastatin|Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
75324494|NCT00819403|Drug|ezetimibe/simvastatin|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
75324495|NCT02010021|Drug|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
75631145|NCT00876460|Drug|BIBF 1120 L + docetaxel M|BIBF 1120 Low dose bid + docetaxel 60 mg/m2
75631146|NCT00876460|Drug|BIBF 1120 H + docetaxel M|BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
75631147|NCT00908115|Biological|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
75782346|NCT01150370|Device|The PrePex a novel device for adult male circumcision|The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
75782347|NCT04774666|Behavioral|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening|Oral fluid-based HIV test
75917781|NCT02284542|Procedure|Non-Awake|"The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.~(Falowski et al., 2011)."
75917782|NCT04470492|Combination Product|Doctormate®+Medical Management|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) twice daily and conventional medication for 3 months.
75917783|NCT04470492|Drug|Medical Management|Patients will be treated with conventional medication for 3 months.
75324496|NCT03272737|Procedure|1RM Test|The dynamic force of the lower limb muscles will be evaluated by the maximal repetition of knee extension and leg press exercise, according to the protocol presented in a previous study [37]. The elderly will perform a warm up consisting of 1 series with 10 unloaded repetitions. After the warm up, the mass to be lifted will be progressively increased until the maximum load that can be lifted is reached, with a maximum limit of 5 attempts and a 3 to 5 minutes interval between them. The test will be conducted by a physical education professional who will verbally encourage participants throughout these steps and perform the load adjustment at week 5 and 10 (Radaelli, 2014).
75324497|NCT03272737|Procedure|Speed gait test|To measure the gait speed of participants they will walk 4.6 metres and the time needed to cover this distance is measured. The mean of three attempts is recorded and divided by the distance. The participants included must achieve in the walking test an average of < 0.,9 m/s (Guralnik, 1994).
75631148|NCT05551611|Other|Playgroup|The mobile game will be sent to the students via a link and the students are allowed to install it on their mobile phones with android and ios operating systems. The internet required for the download was provided by the researcher. For the students who did not have a smart phone in the playgroup, the game would be started from the researcher's phone and the game was played sequentially. All students were allowed to use headphones while playing the game. In order to log in to the game, an account was created on behalf of each student, and the game user name and password were sent to the students by e-mail. It was ensured that they did not communicate with anyone and did not receive help during the game with the supervision of the researcher. Waited until each participant completed the game. Then, the mobile game was deleted from the smartphones of all participants, and the download link was inactive until the research process was completed.
75631149|NCT05551611|Other|Control group|The researcher gave a theoretical lesson through the presentation prepared in the powerpoint program about the birth management of a breech-presented fetus in the classroom as in the traditional education method.
75782348|NCT01256528|Procedure|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
75782349|NCT01150448|Drug|Paliperidone palmitate Treatment A|All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
75917784|NCT03422354|Procedure|Ultrasound guided PVB with General Aneasthesia|An 18G Tuohy needle was inserted perpendicularly at L1,2 to hit the transverse process via an out-of-plane approach. This then directed over the top of the bony structure. The deviation of the needle was kept at 15°. The space was identified using loss of resistance without U/S After negative aspiration, Transverse process visualisation was possible. Distances measured using U/S correlated well with needle depth. Injection of local anaesthetic was visualised as turbulence at L1,2 in all patients. The onset time for this block is 15-25 min
75917785|NCT03422354|Device|Ultrasound|Ultrasound
75917786|NCT03422354|Drug|Paravertebral block|Patients will receive single shot L1-L2 PVB before undergoing GA
75917787|NCT03422354|Drug|General Aneasthesia|General Aneasthesia
75917788|NCT00658086|Drug|ALN-RSV01|administered by nebulization once daily for 3 days
75917789|NCT00658086|Drug|normal saline|administered by nebulization once daily for 3 days
75917790|NCT03427970|Behavioral|observation|Control group will receive the standard of care according to the Scoliosis Research Society criteria: observation for patients with curves between 10°- 25°.
76075996|NCT03219034|Device|oral appliance - B; washout; oral appliance A|Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
75467979|NCT01935219|Behavioral|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
76075997|NCT01722370|Drug|Oxygen|
75467980|NCT01935245|Device|Mini extracorporeal circulation|"Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.~The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products."
75467981|NCT01935245|Device|Conventional extracorporeal circulation|
75782350|NCT01150448|Drug|Paliperidone palmitate Treatment B|Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
75782351|NCT03898466|Drug|Fluticasone furoate|Inhaled corticosteroid
75782352|NCT03898466|Other|Matching placebo|Placebo inhaler
75782353|NCT03319732|Drug|Arbaclofen|Arbaclofen is the active R enantiomer of baclofen.
76075998|NCT01722370|Drug|Medical air equivalent|
75917791|NCT03427970|Behavioral|three-dimensionally integrated exercise for scoliosis|Experimental group will receive a modified physiotherapeutic scoliosis specific exercises --the three-dimensionally integrated exercise for scoliosis program, which include auto-correction in 3D, postural correction, breathing training, resistance training, muscle fascia releasing, functional activities, balance training, core stability training, proprioceptive input exercises and patient education. Auto-correction exercise in 3D will combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.
75917792|NCT03128294|Other|Retrospective, cross-sectional descriptive analysis|This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.
76075999|NCT01721668|Behavioral|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
76076000|NCT01721668|Behavioral|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
76076001|NCT04764435|Other|Physician ownership|"The intervention or exposure is whether the dialysis facility was owned by a physician in 2017"
75782354|NCT04531384|Device|robot-assisted rehabilitation intelligent treatment|robot-assisted rehabilitation psychotherapy
75324498|NCT03272737|Device|Venous occlusion plethysmography protocol|A mercury-filled silastic tube, connected to a low-pressure transducer and a plethysmograph (D.E. Hokanson), will be placed around the largest circumference of the calf region. One cuff will be placed around the ankle and another around the thigh. The ankle cuff will be inflated to a supra-systolic pressure 30 seconds before starting the measurements. At 15-second intervals, the cuff around the thigh will be inflated above the venous pressure for a period of seven to eight seconds. Increased tension in the silastic tube reflects an increase in leg volume and vasodilation. The signal of the muscle blood flow wave will be recorded on a polygraph and analysed every minute, averaging three records per minute. The protocol will be performed during 5 minutes of rest, 3 minutes isometric exercise and 2 minutes of recovery (Bahia, 2006).
76076002|NCT04764435|Other|Large dialysis organization ownership|"The intervention or exposure is whether the dialysis facility was owned by a large dialysis organization in 2017"
75324499|NCT03272737|Device|Measurement of Arterial Stiffness - Pulse Wave Analysis and Velocity|"Arterial stiffness will be estimated from the carotid-femoral aortic pulse wave velocity [33]. Carotid-femoral aortic pulse waves will be recorded by tonometry (SphygmoCor, AtCor Medical, Australia). At the same time, an electrocardiogram will be obtained to calculate the wave transit time. Two distances will be measured: the recording point of the carotid artery and the sternal furcula (distance 1) and the sternal furcula and the recording point in the femoral artery (distance 2). The distance travelled by the pulse wave will be calculated as distance 2 - distance 1. The carotid-femoral aortic pulse wave velocity will be calculated as: carotid-femoral aortic pulse wave velocity = ¼ * distance travelled by the pulse wave (m) / transit time(s)."
75782355|NCT04531384|Other|standard psychotherapy treatment|standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions
75631150|NCT01137812|Drug|Sitagliptin 100 mg|One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
75631151|NCT01137812|Drug|Canagliflozin 300 mg|One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
75631152|NCT01137812|Drug|Metformin|Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
76076003|NCT01722448|Dietary Supplement|Choline|4 capsules with 480 mg choline per day
75631153|NCT01137812|Drug|Sulphonylurea|Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
75631154|NCT00679510|Drug|rosuvastatin|tablet 10 mgs once daily
75631155|NCT00679510|Drug|placebo|placebo
75631156|NCT02626858|Device|extra treatment planning CT-scan|Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
75631157|NCT04146220|Drug|Prednisolone|Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
75782356|NCT02870530|Procedure|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
75782357|NCT01150526|Dietary Supplement|CaHMB|CaHMB capsules with each capsule containing 0.8 g of HMB
75782358|NCT01150526|Dietary Supplement|HMB Free Acid Gel|HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid
75782359|NCT01150526|Dietary Supplement|Placebo|Placebo capsules similar in size and color to the CaHMB capsules used in the study
75782360|NCT01150526|Dietary Supplement|Placebo Gel Dosage|A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel
75782361|NCT01150604|Behavioral|Self-help cognitive-behavioral online course|A self-help online course based on cognitive behavioral therapy for major depression.
75917793|NCT04470570|Other|Cross-Education|1) Cross-Education: The effect that exercising the uninvolved upper extremity will have a positive effect on the involved upper extremity.
76076004|NCT01722448|Dietary Supplement|Placebo|
76076005|NCT01834768|Drug|Eplerenone|
76076006|NCT01672671|Drug|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
76076007|NCT01722682|Biological|Human pancreatic islet transplantation|
76076008|NCT02463981|Device|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
76076009|NCT02459457|Drug|Paclitaxel and Cisplatin|patients get Paclitaxel and Cisplatin according to protocol
76076010|NCT02459457|Drug|Paclitaxel and Fluorouracil|patients get Paclitaxel and Fluorouracil according to protocol
75917794|NCT04470570|Other|Blood-Flow Restriction Training|1) Blood Flow Restriction: A type of resistance training using a blood-pressure like cuff that partially occludes venous blood flow to induce various neurohormonal effects and allows strength gains to be achieved at very low loads of resistance.
75782362|NCT02868970|Biological|Meningococcal B|Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
75467982|NCT01935258|Other|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
76076011|NCT02459457|Drug|Paclitaxel and Carboplatin|patients get Paclitaxel and Carboplatin according to protocol
75324500|NCT03272737|Device|Isometric handgrip exercise protocol|In a supine position, the maximal voluntary handgrip force will be determined as the highest force in 3 consecutive attempts using a Jamar hydraulic palmar dynamometer (Asimow Engineering, CAL, USA). For activation of the central command, mechanoreceptors and muscular metaboreceptors the individual will perform, after 5 minutes of rest (baseline records), 3 minutes of exercise at 30% MVC. This manoeuvre isolates the activation of muscle metaboreceptors, observing the selective activation of these. After the isometric handgrip exercise, 2 minutes of recovery will be performed. Throughout the protocol muscle blood flow, blood pressure and heart rate will be recorded.
75324501|NCT03272737|Device|Vasodilatory capacity|The vasodilatory capacity will be calculated as the percentage of increase of the diameter of the brachial artery and femoral post occlusion in relation to its basal values.
75324502|NCT03272737|Device|Basal blood flow and vasodilatory capacity - Flow mediated dilation (FMD)|Images of the brachial artery will be recorded by a two-dimensional ultrasonography device with a spectral Doppler and linear transducer (Ultra-0122, Philips, The Netherlands).
75324503|NCT03272737|Diagnostic Test|Quality of Life EuroQol-5 Domain|This questionnaire is used to estimate the quality of life in participants before and after the study.
75324504|NCT03272737|Other|Anthropometric Assessment|Anthropometric measurements will be made before and after the training program following the standardization of the International Society for Anthropometric Assessments. The body mass will be measured with an accuracy of 0.1 kg (Filizola). The stature will be obtained by means of the stadiometer with an accuracy of 0.5 cm. The BMI will be calculated as body mass divided by height squared. The circumference of the quadriceps will be measured with a tape measure (Seca) with a precision of 0.1 cm.
75467983|NCT01935258|Other|care as usual|usual care of the general practitioner
75467984|NCT01935271|Dietary Supplement|Muscle Armor Supplement|
75631158|NCT00681616|Device|Compartment Monitoring System (CMS)|The CMS consists of an Introducer, Pressure Measurement & Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
75782363|NCT02868970|Biological|High-Dose TIV|Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.
75782364|NCT02868970|Biological|Tdap (tetanus-diphtheria-acellular pertussis)|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
75782365|NCT02868970|Biological|Meningococcal ACWY|Meningococcal ACWY vaccine is indicated for active immunization of individuals up to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitides serogroups A, C, W-135 and Y.
75324505|NCT02062905|Drug|Dexamethasone|
75324506|NCT02062905|Other|Placebo Vehicle|
75324507|NCT00820573|Drug|Sitagliptin|tablet, 100 mg/day, 6 weeks
75324508|NCT00820573|Drug|Metformin|tablet, 1000 mg/ bid, 6 weeks
75782366|NCT02868970|Biological|Herpes Zoster|Herpes zoster vaccine is indicated for the immunization of individuals 50 years of age or older for the prevention of herpes zoster (shingles).
75324509|NCT00820573|Drug|Sitagliptin + Metformin|tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks
75467985|NCT01935271|Dietary Supplement|Placebo|
75467986|NCT01935297|Behavioral|Exercise|endurance and resistance exercise 3x/week for 8 weeks
75631159|NCT00681616|Device|Compartment Monitoring System with Active Fluid Removal|Compartment Monitoring System with Active Fluid Removal
75782367|NCT02868970|Biological|Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever)|Hepatitis A vaccine is indicated for immunization against infections caused by hepatitis A virus; Hepatitis B vaccine is indicated for immunization against infection caused by hepatitis B virus; and typhoid fever vaccine is indicated for active immunization against Salmonella typhi, the organism which causes typhoid fever.
76076012|NCT02459457|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 34Fx
75467987|NCT01935310|Drug|Imiquimod|"From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.~During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved."
75467988|NCT01935323|Other|High Intensity Interval Training|
75467989|NCT01935323|Other|Moderate Intensity Training|
75467990|NCT01935362|Dietary Supplement|Citrus supplement|
75467991|NCT01935362|Dietary Supplement|Placebo|
75467992|NCT01935375|Behavioral|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
75467993|NCT01935375|Behavioral|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
75467994|NCT01935388|Other|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
75324510|NCT00820573|Drug|Placebo|Placebo 6 weeks
75324511|NCT00821041|Behavioral|Cognitive Behavioral Therapy|6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
75324512|NCT00821119|Device|nasal intermittent positive pressure ventilation|Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
75324513|NCT05217355|Drug|MBA-P01 (Botulinum toxin A)|MBA-P01 will be injected into the Glabellar line
75324514|NCT05217355|Drug|Placebo|Placebo will be injected into the Glabellar line
75324515|NCT05236855|Diagnostic Test|Spectoscropy testing of urine specimen|Urine samples will be independently tested by I R Spectroscopy and those results are to be compared with standard testing procedures for HPV
75631160|NCT00681616|Device|Compartment Monitoring System without fluid removal|Compartment Monitoring System without fluid removal
75631161|NCT00681694|Radiation|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
75631162|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
75631163|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
75631164|NCT04145596|Drug|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
75631165|NCT01137578|Procedure|Ultrasound|Ultrasounds to be performed on children with central venous catheters
75631166|NCT01137578|Drug|Magnetic Resonance Imaging with Contrast|Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
75631167|NCT01137578|Procedure|Magnetic Resonance Imaging without Contrast|Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
75631168|NCT00679666|Drug|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
75631169|NCT00679666|Drug|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
75324516|NCT04382599|Behavioral|Text warning with square background|The warning message is in white text on a black square background
75324517|NCT04382599|Behavioral|Text warning with octagon background|The warning message is in white text on a black octagon background
75324518|NCT04382599|Behavioral|Icon warning|The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
75631170|NCT00679744|Drug|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
75631171|NCT00681772|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
75631172|NCT00946920|Drug|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
75631173|NCT00946920|Drug|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
75782368|NCT03902834|Other|Fitbit|Use the wearable technology (Fitbit) and proven behavioural change techniques to precondition patients prior to lung cancer surgery
75324519|NCT04382599|Behavioral|Graphic warning|The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
75324520|NCT02010645|Drug|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
75324521|NCT02010645|Drug|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
75324522|NCT02944747|Behavioral|Education & paper based calendar|The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.
75324523|NCT02944747|Behavioral|Education & SMS system|The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
75782369|NCT03304522|Drug|VX-150|Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.
75782370|NCT03304522|Drug|Placebo|Participants received placebo matched to VX-150 for 6 weeks.
75782371|NCT03902990|Other|Dual task|The patients in the dual task group received cognitive tasks during treadmill training sessions.
75467995|NCT01935440|Behavioral|Prevention & Testing|6 group sessions, 1 individual session, and 1 dyad session
75467996|NCT01935440|Behavioral|Prevention & Testing Control|7 group sessions
75467997|NCT01935453|Biological|Recombinant hGM-CSF Herpes Simplex Virus Injection|
75631174|NCT04145830|Device|Ultrasound Cyclo Plasty (UCP)|Cyclocoagulation using High Intensity Focused Ultrasound
75631175|NCT00946530|Device|Bright light|Participants uses bright light
75631176|NCT00946530|Device|Control|Participants uses dim light
75631177|NCT00946296|Drug|Potassium Iodide|8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
75631178|NCT02853786|Behavioral|LENA and advice|Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
75631179|NCT02853786|Other|LENA without advice|Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
75631180|NCT00679900|Drug|eplivanserin (SR46349)|5 mg/day
75631181|NCT00679900|Drug|lormetazepam|1 mg/day
75782372|NCT03902990|Other|Treadmill Training|Standard treadmill training
75782373|NCT03902990|Other|Standard exercise programme|Standard exercise programme for Parkinson Disease
75917795|NCT03422120|Other|Natural Killer Cell Activity Assay|Subjects had a blood test to measure NK cell activity (NKA) at different time points
75917796|NCT00447954|Drug|NT-501 implant|High Dose
75631182|NCT00945906|Biological|FXIII Concentrate (Human) (FXIII)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion."
75631183|NCT00681928|Drug|anastrozole|As determined by the subject's physician
75324524|NCT02944747|Behavioral|Education & smart-phone application|The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
75631184|NCT00681928|Drug|letrozole|As determined by the subject's physician
75467998|NCT01935479|Drug|AK159|transdermal administration of teriparatide acetate
75631185|NCT00681928|Other|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
75324525|NCT02833207|Drug|Drug Trial 1 (EDD)|"Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description."
75631186|NCT00681928|Procedure|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
75631187|NCT00681928|Procedure|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
75631188|NCT04269252|Other|CHI-907|CHI-907 is a high CBD extract.
75631189|NCT04269252|Other|CHI-804|CHI-804 is the placebo formulation.
75631190|NCT00594646|Drug|TRUVADA + Raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
75782374|NCT03907202|Drug|Daily injection of KBP/placebo for up to 28 days|Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
75782375|NCT03903068|Device|NEXALIN ADI AC stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.
75917797|NCT00447954|Drug|NT-501 implant|Low Dose
75917798|NCT00447954|Other|Sham Procedure|Sham Procedure
75917799|NCT03128060|Other|Home-based palliative care|The HBPC model consists of home visits by an interdisciplinary primary palliative care team (a physician, nurse, social worker, and chaplain). This team provides pain and symptom management, psychosocial support, advance care planning, spiritual counseling, grief counseling, and other services to meet patient and caregiver needs. Within the first week of a patient's enrollment, team members separately visit the patient at home to assess his/her needs as well as the needs of his/her caregiver. Following the patient's initial assessment, subsequent home visits are based on the patient's and caregiver's needs. At a minimum, a core team member visits the patient at home once per week. Additionally, a 24/7 helpline provides access to nurse counseling and after-hours home visits as needed. As a patient's health declines and he/she becomes eligible for hospice care, HBPC clinicians will refer the patient to hospice.
76076013|NCT01835236|Drug|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
75324526|NCT02833207|Drug|Drug Trial 2 (ROV)|"Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description."
75324527|NCT02065479|Drug|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
75467999|NCT01935479|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
75631191|NCT00680134|Drug|AN2690|AN2690 1% Solution, once daily for 180 days
75631192|NCT00680134|Drug|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
75468000|NCT01935479|Drug|Placebo|Placebo AK159
75631193|NCT02855658|Drug|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
75631194|NCT02855658|Drug|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
75631195|NCT00680212|Dietary Supplement|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
75631196|NCT00680212|Dietary Supplement|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
75631197|NCT02855424|Other|the low-intensity exercise group|Totally 20-time training, frequency 2-6 time/week, total 20 times.
75631198|NCT02855424|Other|the moderate-intensity exercise group|Totally 20-time training, frequency 2-6 time/week,total 20 times.
75631199|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
75631200|NCT00682006|Other|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
75631201|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
75631202|NCT02855346|Combination Product|200 mg of DPV + 320 mg LNG|DPV VR, containing 200 mg DPV
76076014|NCT01835236|Drug|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
75631203|NCT02855346|Combination Product|200 mg of DPV|DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
75631204|NCT00682084|Procedure|Surgery|Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
75631205|NCT02855190|Other|68Ga-citrate and 18F-FDG PET scans|68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
75631206|NCT00680290|Procedure|Exercise|Exercise x 8 weeks
75631207|NCT00682162|Device|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
75631208|NCT00682162|Device|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
75631209|NCT02627404|Other|Blood sample|A blood sample is taken at inclusion of patients in the study to perform DNA analysis
75631210|NCT02627404|Device|actometer|To evaluate the quality of sleep, questionnaires are completed and patients wear an actometer for 21 days. They will also complete a sleep diary
75631211|NCT04150978|Other|High Protein Polymeric Formula|Component: 22.4% protein from total calorie Preparation of Peptisol: 5 spoons of Peptisol powder diluted in 200 ml warm water to have 250 ml Peptisol (equal to 250 kcal). Given as written in the group descriptions
75631212|NCT04150978|Other|Oligomeric Formula|Component: Component: 22.4% protein from total calorie Preparation: 5 spoons of Peptamen powder diluted in 165 ml warm water to have 200 ml Peptamen (equal to 200 kcal). Given as written in the group descriptions
75631213|NCT04150978|Drug|5% Dextrose|500 ml of 5% Dextrose administered to a peripheral vein.
75631214|NCT04051138|Other|Voxx socks and sleeves|participants will be tested with a true device as well as with a placebo device
75631215|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - single-session
75782376|NCT03903068|Device|Pseudo-stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.
75782377|NCT03446170|Behavioral|Graphic cigarette warning labels, plain packaging|This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
75782378|NCT04613050|Other|Respiratory Training|"Respiratory training in form of :~Diaphragmatic breathing,Segmental breathing, Incentive spirometer:"
75782379|NCT04613050|Other|Aerobic training|aerobic exercises are customized according to the patient's underlying disease and residual dysfunction. These exercises will include walking on treadmill. After an initial, 5-minute warm-up phase performed on the treadmill at a low load, each endurance training session lasted 30 minutes and ended with 5-minute recovery and relaxation phase. A total of 3-5 sessions are carried out per week. Patients who are prone to fatigue should perform intermittent exercises
75782380|NCT03902678|Procedure|EUS guided fine needle aspiration of portal vein thrombus|endoscopic ultrasound guided fine needle aspiration of portal vein thrombus which did not fulfill criteria of malignancy by imaging technique
75782381|NCT03315286|Device|SHADE Ultraviolet Sensor|Patients will wear device for 6 months in addition to their own method of photo-protection.
75782382|NCT03315286|Behavioral|Standard of care counseling|Patients will use their own method of photo-protection
75324528|NCT02065479|Drug|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
75324529|NCT05236621|Drug|Pomalidomide|4 mg pomalidomide capsules administered orally
75324530|NCT05236621|Drug|Dexamethasone|40 mg dexamethasone tablets administered orally
75631216|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - multi-session
75631217|NCT00682240|Procedure|laser treatment with PASCAL®|grid / focal laser treatment
75631218|NCT00682240|Procedure|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
75631219|NCT00684502|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
75631220|NCT00684502|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
75631221|NCT01111604|Biological|Ramucirumab|8 mg/kg IV Q2W
75631222|NCT01111604|Biological|Icrucumab|15 mg/kg IV Q2W
75782383|NCT01150682|Genetic|RNA analysis|
76076015|NCT01835236|Drug|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
76076016|NCT01835236|Drug|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
75324531|NCT02066727|Drug|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
75324532|NCT02066727|Drug|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
75324533|NCT05235997|Dietary Supplement|Hydrolized Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
75324534|NCT05235997|Other|Placebo|Placebo look alike the experimental product
75324535|NCT04349241|Drug|favipiravir|pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor
75324536|NCT04349241|Drug|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
75324537|NCT05212129|Device|Percutaneous vagal nerve stimulation (pVNS) device|Subjects in Treatment Arm B will enter a six-week, prospective open label treatment trial with the FDA-approved and commercially available device IB-Stim. This is an ambulatory, neurostimulation device which consists of a battery powered, externally affixed generator with 4 wire leads attached to electrode/needle arrays affixed to the outer ear. The device delivers low voltage (3.2V) stimulation in alternating frequencies for a total of 5 days (around the clock).
75917800|NCT03128060|Other|Enhanced usual care|"Usual primary care consists of: 1) appointment-based access to primary care providers (PCPs) as requested by the patient; 2) case management services; and 3) provider support through palliative care consultation. These PCPs provide family/internal medicine services as well as access to specialist care. They also offer disease case management and pain and symptom management.~These usual care services are enhanced through training in palliative care provided to PCPs. The training addresses core elements of palliative care, specifically these 6 topics: a palliative care overview; strategies for improving patient-provider communications; instruction in ACP; instruction in managing patients' pain and symptoms; care coordination; and preventing medical crises."
75917801|NCT00447564|Drug|Probuphine|4 implants
75917802|NCT00447564|Drug|placebo|4 implants
75324538|NCT05212129|Other|Acoustic vagal nerve stimulation (aVNS) treatment|All subjects receiving acoustic therapy via active VNS (aVNS; n=30) or sham VNS (sVNS; n=30) will enter a four-week, randomized, double-blind clinical trial during which they will listen to either computer altered/filtered vocal music (active treatment) that has been designed to stimulate vagal calming vs. regular non-filtered music (sham treatment). The stimuli will mirror the acoustic intervention known as the Safe and Sound Protocol. This protocol has been found to reduce auditory hypersensitivities and calming the autonomic nervous system by increasing vagal regulation of the heart via brainstem ventral vagal complex. The acoustic intervention may be played by an electronic device (i.e. smartphone, tablet, laptop, mp3) and delivered virtually with the help of trained coaches.
75324539|NCT02012283|Other|Food consumption|Cooked vegetables with spices or without spices
75324540|NCT02812615|Dietary Supplement|Egg|After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
75324541|NCT02812615|Dietary Supplement|Milk|After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
75324542|NCT02812615|Drug|Albendazole/Pyrantel Pamoate|As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
75324543|NCT02812615|Behavioral|Nutritional counselling|Parents/caregivers will be given nutritional counselling
75324544|NCT02812615|Dietary Supplement|Micronutrient sprinkles|For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
75631223|NCT01111604|Drug|mFOLFOX-6|"Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W"
75631224|NCT00950742|Drug|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
75631225|NCT00950742|Drug|BIBW 2992|Increased dose cohorts from low dose to MTD
75782384|NCT01150682|Genetic|reverse transcriptase-polymerase chain reaction|
75917803|NCT03430154|Other|No treatment given|No treatment given
75917804|NCT00576810|Drug|sodium picosulphate|
75917805|NCT03427658|Behavioral|Sweet food consumption|Comparison of the impacts of sweet and non-sweet food consumption
75917806|NCT03427580|Behavioral|MERIT|Metacognitive Reflection and Insight Therapy
75324545|NCT02402127|Device|Narafilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
75324546|NCT02402127|Device|Stenfilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
75324547|NCT02402127|Device|Somofilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
75324548|NCT05195749|Drug|101-PGC-005 ('005) + SOC|Three consecutive days of '005 administration
75324549|NCT05195749|Drug|Placebo + SOC|Three consecutive days of placebo administration
75324550|NCT02067039|Device|OraQuick in home & Sure Check HIV tests|Provision of OraQuick in home & Sure Check HIV tests
75631226|NCT04310228|Drug|Favipiravir Combined With Tocilizumab|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
75631227|NCT04310228|Drug|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
75782385|NCT01150682|Other|enzyme-linked immunosorbent assay|
75782386|NCT01150682|Other|immunohistochemistry staining method|
75782387|NCT01150682|Other|laboratory biomarker analysis|
76076017|NCT01835236|Drug|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
75782388|NCT01253720|Behavioral|PACE CALL/Fit4Life|"The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.~The Fit4Life intervention includes:~Web-based weight loss program Text and Picture messages Counseling Calls Health Coach"
76076018|NCT01671891|Radiation|radiation therapy|45-55Gy
76076019|NCT01671891|Drug|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
75782389|NCT03897686|Device|"hydrous biopolymer with silver ions Argiform"|4.0 ml for one injection with one-week interval between injections. Course - 2 injections.
75631228|NCT04310228|Drug|Tocilizumab|The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
75324551|NCT05182489|Device|Medtronic Adaptix™ titanium implants|Patients who will be having a spinal fusion procedure as part of their standard of care treatment will be randomized to receive either the Medtronic titanium or the PEEK cage supplemented with a pedicle screw system and milled local autograft bone supplemented with GRAFTON DBM DBF. In order to assess fusion, patients will undergo a research-only CT Scan at 6 months post-surgery.
75631229|NCT02881502|Other|severe asthma group|No intervention
75324552|NCT05182489|Device|Medtronic CAPSTONE® PEEK cage|Medtronic CAPSTONE® PEEK cage
75631230|NCT00955110|Drug|Oxymorphone ER|15mg or 30mg
75631231|NCT00955110|Drug|Oxycodone CR|30mg or 60mg
75631232|NCT00955110|Drug|Placebo|The placebo was a sugar pill.
75782390|NCT03897686|Device|saline solution|4.0 ml for one injection with one-week interval between injections. Course - 2 injections.
75917807|NCT02282202|Device|Oscillating Positive Expiratory Pressure (Aerobika ®)|"The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.~There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks."
75324553|NCT02067273|Device|Transcranial Magnetic Stimulation (TMS)|
75324554|NCT02151253|Drug|Armodafinil|Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
75324555|NCT02151253|Drug|Placebo|Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
75324556|NCT02151331|Behavioral|External Facilitation|Non-responding sites randomized to receive external facilitation
75324557|NCT02151331|Behavioral|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
75324558|NCT02067585|Dietary Supplement|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
75324559|NCT02308839|Device|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
75324560|NCT02314689|Drug|Intravenous (IV) citrulline|
75324561|NCT02403999|Other|Test shampoo|Participants used Oilatum Soothe & Protect Shampoo at home in place of their usual wash product at least twice weekly for a two week period.
75324562|NCT02403999|Other|Test bath foam|Participants used Oilatum Soothe & Protect Bath Foam at home in place of their usual wash product at least twice weekly for a two week period.
75782391|NCT03897842|Device|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
75782392|NCT02527772|Drug|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
75324563|NCT02403999|Other|Test head to toe wash|Participants used Oilatum Soothe & Protect Head to Toe Wash at home in place of their usual wash product at least twice weekly for a two week period.
75631233|NCT00955110|Drug|Hydromorphone|8 mg
75631234|NCT05056142|Procedure|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL.
75631235|NCT05056142|Procedure|Spinal Analgesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
75782393|NCT02527772|Drug|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
75782394|NCT03273946|Drug|Fluticasone propionate|Fluticasone propionate is an inhaled corticosteroid to be used via a pediatric spacer device with a face mask for prophylactic treatment of asthma.
75631236|NCT00950664|Drug|Dysport® (abobotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
75631237|NCT00950664|Drug|Botox® (onabotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
75631238|NCT02855112|Biological|Adipose derived mesenchymal stem cell|Allogeneic Adipose derived Mesenchymal Stem cell transplant
75782395|NCT01150916|Procedure|BNP, SAAG, ascites total protein, echocardiography|diagnostic tests
75782396|NCT00660218|Drug|paclitaxel poliglumex|Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
75782397|NCT00660218|Biological|cetuximab|400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
76076020|NCT05025111|Device|Entia Liberty|Home monitoring device
75631239|NCT01111526|Drug|Panobinostat (LBH589)|"Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m^2 IV; DL 1: 2.5 mg/m^2 IV; DL 2: 5 mg/m^2 IV; DL 3: 7.5 mg/m^2 IV; DL 4: 10 mg/m^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks."
75631240|NCT02881346|Drug|Enstilar®|Once daily application of cutaneous foam to plaques on body and/or extremities
75631241|NCT00630708|Drug|Benazepril|20 mg per day
75917808|NCT02521610|Drug|Placebo|Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
75917809|NCT02521610|Drug|RG7625|Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
76076021|NCT03152409|Drug|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
76076022|NCT03152409|Drug|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
75631242|NCT00630708|Drug|Losartan|100 mg per day
75324564|NCT02405325|Behavioral|Physical Activity|intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
75917810|NCT00576342|Drug|AL-3862+timolol ophthalmic suspension|
75324565|NCT02069847|Drug|Budesonide|"Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide."
75631243|NCT00630708|Drug|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
75631244|NCT04258878|Procedure|Sternotomy|Procedure: Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.
75324566|NCT02070237|Drug|Enoxaparin|Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
75917811|NCT00576342|Drug|Dorzolamide+timolol ophthalmic solution|
75324567|NCT02406495|Device|filcon IV 1|contact lens
75917812|NCT00574860|Drug|EN3285|Oral rinse
75917813|NCT00574860|Drug|Placebo|Oral rinse
75917814|NCT00574860|Other|Standard of care|This will be the therapy most commonly used the the institution treating the patient
75917815|NCT02282280|Drug|Prilocaine Chlorhydrate|Use of prilocaine in spinal anesthesia
76076023|NCT03835468|Dietary Supplement|Galacto-oligosaccharides|GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
76076024|NCT03835468|Dietary Supplement|Maltodextrin|sugar based placebo
75324568|NCT02406495|Device|ocufilcon D|contact lens
75631245|NCT01111292|Drug|Inositol|Given PO
75631246|NCT01111292|Other|Placebo|Given PO
75631247|NCT04269330|Procedure|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
75631248|NCT02881736|Other|electroencephalographic,magnetic resonance imaging|
75631249|NCT02853630|Drug|Metformin|Participant will be instructed to take Metformin tablets as per instructions given by the physician.
75631250|NCT02853630|Drug|Vildagliptin|Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
75782398|NCT00660218|Radiation|radiation therapy (IMRT or 3D-CRT)|radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
75782399|NCT00314951|Drug|Fidaxomicin|200 mg oral capsules two times daily (q12h regimen)
75782400|NCT00314951|Drug|Vancomycin|125 mg capsules q6hr (4 times a day)
75782401|NCT00314951|Drug|Matching Placebo to Fidaxomicin|Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
75782402|NCT03906734|Procedure|Septal myectomy|Transaortic septal myectomy
75782403|NCT03906734|Procedure|alfieri stich|Transaortic Mitral valve repair using alfieri technique
75782404|NCT03906734|Procedure|Subvalvular intervention|Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release
75782405|NCT00085644|Biological|adalimumab (D2E7)|Adalimumab 40 mg every other week, subcutaneous
76076025|NCT01830088|Behavioral|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
76076026|NCT01830088|Behavioral|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
75631251|NCT04310384|Device|ShuttleScope|Alternative intervention
75631252|NCT04310384|Device|MacIntosh Laryngoscope|Gold Standart
75782406|NCT00085644|Biological|placebo|Placebo every other week, subcutaneous
75917816|NCT01591772|Other|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
75917817|NCT01591772|Other|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
75917818|NCT03429998|Drug|evolocumab|evolocumab 140 mg/biweekly
75631253|NCT04309838|Combination Product|Treprostinil via implanted pump|Patients, diagnosed with PAH classified in stagnating intermediate-risk status after triple therapy including Selexipag for at least three months will receive the implantation of LENUS pro that enables permanent infusion of Treprostinil.
75782407|NCT01048463|Drug|Nutriall|The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
75917819|NCT03429998|Drug|evolocumab and LDL apheresis|evolocumab 140 mg/biweekly LDL-apheresis monthly
75917820|NCT03429998|Procedure|LDL apheresis|LDL apheresis biweekly
75324569|NCT02071095|Drug|Arm A: Poly-ICLC|Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
75324570|NCT02071095|Drug|Arm B: Normal Saline|Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
75631254|NCT05367206|Drug|Albumin-Bound Paclitaxel|260mg/m2 q3w *2 circles
75631255|NCT05367206|Drug|Carboplatin|AUC 5-6 q3w * 2 circles
75782408|NCT01048463|Drug|LDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
75917821|NCT00658008|Drug|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
75631256|NCT00637286|Drug|Zolmitriptan|5mg Nasal Spray
75782409|NCT01048463|Drug|Placebo|The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
75782410|NCT01048463|Drug|HDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
75782411|NCT01048463|Drug|Chemotherapy|Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
75631257|NCT00944658|Drug|Apremilast|10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks
75631258|NCT00944658|Drug|Placebo (sugar pill)|twice a day
75631259|NCT00637364|Procedure|High intensity focused ultrasound, HIFU|"The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).~The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue."
75782412|NCT01256996|Procedure|Air abrasion of the implant surface with a low abrasive powder|Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
75917822|NCT00658008|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
75917823|NCT00658008|Drug|PD 0332334|Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
75917824|NCT00658008|Drug|Paroxetine|Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
75631260|NCT04269798|Other|Traditional Treatment|conventional rehabilitation program for lower limb, balance and gait training
75917825|NCT00658008|Drug|Placebo|Capsules, oral, placebo bid, 8 weeks with 2 week taper
75917826|NCT03427502|Drug|Bupivacaine-epinephrine|10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline
75917827|NCT03427502|Drug|normal saline|normal saline
75917828|NCT04449614|Procedure|Thoracoscopic CPAM resection|Surgical removal of lung lesion
76076027|NCT01830166|Radiation|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
76076028|NCT01830322|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
75324571|NCT02406573|Device|Crest® Sensi-Stop™ Strips|
75324572|NCT02071173|Device|ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead|"The ACUITY X4 leads are intended for chronic left ventricular pacing and sensing. The leads have 3 tip configuration designs (straight tip, short tip spiral, and long tip spiral), which is intended to provide choices for patients with different anatomies.~The RELIANCE 4-FRONT leads are designed for right-side heart applications within the ventricle, atrium, and superior vena cava. It is intended for permanent sensing, pacing, and defibrillation when used with a compatible implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).~Subjects were allowed to receive both the ACUITY X4 and RELIANCE 4-FRONT lead."
75324573|NCT02348359|Drug|X-82|
75324574|NCT02348359|Drug|Anti-VEGF|
75324575|NCT02348359|Drug|Placebo|
75917829|NCT02280330|Dietary Supplement|MNP group|MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.
75631261|NCT01110200|Drug|ADVAIR DISKUS 250/50 mg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
75782413|NCT03897764|Procedure|Intraoperative superior hypogastric plexus block|SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.
75782414|NCT01257074|Drug|Acyclovir 50mg/g|Cream, dose 5 times daily during 5 days
75782415|NCT01257074|Drug|Penciclovir 10mg/g|Cream, dose 5 times daily during 5 days
75782416|NCT03315208|Behavioral|Unified Protocol (UP)|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.
75917830|NCT02280330|Other|Placebo group|The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
75917831|NCT02284620|Procedure|CFNB group|CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
75917832|NCT02284620|Procedure|LWI group|LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
75917833|NCT02886572|Radiation|Stereotactic radiosurgery|Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
75917834|NCT00440388|Drug|AT-101|AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
75917835|NCT00440388|Drug|Rituximab|Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
75917836|NCT03422042|Other|Short duration of antibiotic|Patient will received intravenous antibiotic until the body temperature is less than 37.8 c fir 72, then antibiotic is discontinued.
75631262|NCT01110200|Drug|SEREVENT 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
75631263|NCT04309994|Other|Myocardial protection system (MPS)|cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
75631264|NCT04309994|Other|Cardioplexol|cardioplegia solution
75631265|NCT01108718|Other|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
75917837|NCT03422042|Other|Standard treatment of antibiotic|Patient will received intravenous antibiotic for 7 days, followed by oral antibiotic for 7 days, regardless of the body temperature.
75917838|NCT04449224|Drug|Adalimuab, Etanercept, Tocilizumab, or Abatacept|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
76076029|NCT01830322|Drug|Gemcitabine|
76076030|NCT01830322|Drug|Any non-gemcitabine chemotherapies or best supportive care|
76076031|NCT01835314|Drug|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
76076032|NCT03150069|Other|Interview|In-person or telephone in-depth interview
76076033|NCT01722760|Procedure|measurements|
76076034|NCT03427281|Behavioral|questionnaire|questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
76076035|NCT01722838|Behavioral|B-ME Intervention|B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
76076036|NCT01835392|Procedure|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
76076037|NCT01835392|Other|Control|Sham placement of blood pressure cuff without inflation
75917839|NCT04449224|Drug|Tofacitinib or Baricitinib|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
76076038|NCT01672905|Other|laboratory biomarker analysis|
75324576|NCT02406885|Drug|Apixaban|New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
75324577|NCT02407041|Drug|GR-MD-02|IV infusion
75324578|NCT05235841|Other|acupressure|Acupressure is a complementary and supportive approach used in symptom management.
75917840|NCT00437112|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 weeks
75917841|NCT00437112|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 24 weeks
75631266|NCT01108718|Other|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
75631267|NCT04312646|Device|Elastography .|Performance of US, elastography
75631268|NCT01137110|Other|Brief LEV|Levetiracetam 1000mg BID x 3 days for prophylaxis
75631269|NCT01137110|Other|Extended LEV|Levetiracetam 1000mg BID for length of hospital stay for prophylaxis
75917842|NCT00434850|Biological|Allogeneic Pancreatic Islet Cells|Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
75324579|NCT02206945|Behavioral|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
75917843|NCT00434850|Drug|Deoxyspergualin|An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
75631270|NCT05367050|Behavioral|Lucid Lane Therapy Program|This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.
75324580|NCT02206945|Behavioral|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
75917844|NCT00434850|Biological|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
75324581|NCT05235607|Biological|Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration|subcutaneous administration
75324582|NCT02093455|Dietary Supplement|Chardonnay Seed Flour (CSF)|CSF is made from wine grape skins and seeds.
75324583|NCT02093455|Dietary Supplement|Placebo|
75324584|NCT05235529|Procedure|Aortic valve replacement|Surgery replacement od the aortic valve
75324585|NCT05235529|Device|TAVI|Transcatheter aortic valve implantation
75324586|NCT05164237|Other|nerve flossing technique|subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
75631271|NCT05367050|Behavioral|Surgical Preparedness Course|This intervention is designed to help the participant prepare for their upcoming surgery. Classes will include discussions around managing chronic pain before surgery, building mental resilience, dealing with the uncertainty of a new diagnosis or treatment plan, questions to ask their anesthesiologist before and on the day of surgery, what to expect during their potential stay at the hospital, and how to optimize their recovery after surgery. Sessions will often include expert doctors who focus on surgery and medical management around it.
75631272|NCT01136954|Drug|Zonisamide|Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
75782417|NCT03315208|Other|Treatment as Usual (TAU)|Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
75782418|NCT03906812|Other|Telemetry|Bed type assignment
75631273|NCT01136876|Drug|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
75631274|NCT01136876|Drug|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
75782419|NCT03906812|Other|Unmonitored|Bed type assignment
75782420|NCT03961932|Drug|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
75782421|NCT01326936|Behavioral|Online education|A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
75917845|NCT00434850|Biological|Daclizumab or basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
75631275|NCT02880332|Other|Usual care|During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
75917846|NCT00434850|Drug|Sirolimus|Maintenance immunosuppressive therapy
75917847|NCT00434850|Drug|Tacrolimus|Maintenance immunosuppressive therapy
75917848|NCT00434850|Biological|Etanercept|Blocks TNF-alpha which is toxic to islet cells
76076039|NCT01725646|Drug|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
76076040|NCT01725646|Drug|Placebo|Subjects in placebo group will take this drug
76076041|NCT03293745|Behavioral|Face to Face CBT-I (F2F)|CBT-I delivered in-person by the therapist.
76076042|NCT03293745|Behavioral|Telemedicine CBT-I (TM)|CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
76076043|NCT01835704|Other|Radio-frequency dennervation of facet joint|
76076044|NCT01835704|Other|Diagnostic nerve-blocks performed under direct x-ray vision|
75324587|NCT05164237|Other|multimodal electrotherapy|subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
75324588|NCT05164237|Other|exercises|subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
75324589|NCT02341599|Drug|MK-6183|MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
75782422|NCT03906500|Behavioral|High schools High on Life|"The intervention consist of three main components.~Environmental factors of the school environment~The component targeting the high school environment consisted of two separate elements:~Revision of school alcohol policy~Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student component~The Student components consisted of three main elements:~Online education for the student committees organizing events where alcohol is sold and the student introduction committee~Pocket movie campaign competition~Social norms campaign~Parent component~The parent component consisted of three separate elements:~Parent Information Meeting~Parent Information Folder~Parent Information Website"
75917849|NCT04449302|Procedure|Immediate molar implant with customized healing abutment|"Patients will receive an immediate implant with customized healing abutment~Atraumatic extraction without flap elevation using periotomes and elevators then sectioning of the roots will be performed to preserve the interseptal bone.~The drilling will be performed starting from the pilot drill in the interseptal bone to the twisting drills according to the manufacturer's instructions to the selected implant size. The implant is to be placed immediately then the insertion torque will be measured using a torque wrench. In order to place the customized healing abutment, the insertion torque should be more than 25 ncm.~The gap distance will be filled by xenograft, a plastic abutment will be screwed in place then a flowable composie resin will be applied around into small amounts and cured to take the soft tissue contour then finishing and polishing of the customized healing abutment will be done."
75324590|NCT02408445|Drug|testosterone cypionate 200mg/ml|Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
75324591|NCT01889329|Dietary Supplement|RUTF-1|Made from local food ingredients
75917850|NCT04449380|Drug|Interferon-ß-1a|IFNβ-1a will be administered subcutaneously at a dose of 44 mcg (equivalent to 12 million international units), three times per week at least 48 hours apart, for a total of two weeks. All patients will receive a total dose of 264 mcg (72 million international units) under physician control
75631276|NCT02880332|Other|Pain Neuroscience education|"This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well."
75782423|NCT04177992|Other|Servo control|FiO2 adjustments will be made by one of two respiratory devices depending on the clinical requirements and current ventilatory therapy of the infant
75782424|NCT01150994|Behavioral|Safety Assessment and Follow-up Telephone Intervention (SAFTI).|Mental health evaluation in ED, followed by Post-ED counseling
75782425|NCT01086618|Drug|systemic chemotherapy|
75782426|NCT01086618|Procedure|adjuvant therapy|
75917851|NCT04449380|Combination Product|Standard of Care (SOC)|Any pharmacological (e.g. antibiotics, etc.) and non-pharmacological (e.g. oxygen, ventilation, etc.) treatments prescribed on clinical grounds
75917852|NCT03128216|Procedure|Blind Local Anesthetic infiltration|Patients of this group received blind local anesthetic infiltration on surgical site. Local anesthetic infiltration are performed by surgeon.
75917853|NCT03128216|Procedure|Transversals Fascia Block|Patients of this group received ultrasound guided omolateral Transversals Fascia Block.
75324592|NCT01889329|Dietary Supplement|RUTF-2|Made from local food ingredients
75324593|NCT01889329|Dietary Supplement|Plumpynut|Commercially made from peanut paste
75324594|NCT00426205|Biological|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
75468001|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"st line:~Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~Bevacizumab until PD or unacceptable toxicity~At PD patients will go to the 2nd treatment line.~nd line:~Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
75782427|NCT01086618|Procedure|quality-of-life assessment|
75782428|NCT01086618|Procedure|therapeutic conventional surgery|
75782429|NCT01086696|Drug|FPAC|Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
75782430|NCT01149278|Drug|maintain mean arterial pressure between 80-85 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
75917854|NCT03128216|Procedure|Spinal Anesthesia|Patients of this group received Spinal Anesthesia
75917855|NCT03128216|Drug|Ropivacaine|Local anesthetic used for local infiltration and Transversals fascia block
75917856|NCT03128216|Drug|Bupivacaine|Local anesthetic used for Spinal Anesthesia
75917857|NCT00566202|Drug|Placebo|Form= capsule, route= oral use. Administration once daily for 8 weeks.
76076045|NCT03243669|Diagnostic Test|High-definition|High-definition colonoscopy
76076046|NCT03243669|Diagnostic Test|Virtual chromoendoscopy|Virtual chromoendoscopy
76076047|NCT03243669|Diagnostic Test|Standard|Standard colonoscopy
76076048|NCT00915148|Other|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
76076049|NCT04937127|Behavioral|I-LEARN training|Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
75631277|NCT02880332|Other|Extra care|During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
75782431|NCT01149278|Other|maintain mean arterial pressure between 65-70 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
75782432|NCT00314795|Drug|Peginesatide|Peginesatide injection
75917858|NCT00566202|Drug|Escitalopram|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
75917859|NCT00566202|Drug|JNJ-18038683|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
75917860|NCT04449068|Other|Neurological and neuropsychological Follow-up after deep brain stimulation|Investigation of tic severity, psychiatric co-morbidities, quality of life, and neuropsychologcial measures until the 5-year after deep brain stimulation (DBS)
75631278|NCT02881580|Other|No intervention : descriptive study|
75324595|NCT05235217|Drug|Test product (T) 40 mg Hard Gelatin Capsules|Hard Gelatin Capsules products containing 40 mg Esomeprazole
75324596|NCT05235217|Drug|Reference product (R) 40 mg Hard Gelatin Capsules|Reference product (R) 40 mg Hard Gelatin Capsules
75324597|NCT00388921|Drug|Vitamin A|
75324598|NCT02016885|Drug|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
75324599|NCT02016885|Drug|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
75631279|NCT01105130|Other|Placebo|Given orally
75782433|NCT01086774|Other|Systane Ultra Lubricant Eye Drops|Single drop in both eyes
75782434|NCT03902522|Drug|PRO 140|2 injections of PRO 140 (2 X 2 mL/inj.)
75782435|NCT01092858|Drug|Testosterone Undeconate (Nebido, BAY86-5037)|Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
75782436|NCT01092858|Drug|Placebo|Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
75782437|NCT03902756|Other|Endotracheal cuff inflation|Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.
75782438|NCT01529879|Device|New Abutment Connection implant|New abutment connection implant
75917861|NCT02280486|Drug|Saxagliptin|5 mg/d
75917862|NCT02280486|Drug|Glimepiride|1mg/d, up titrated 1mg if FPG >6.1 mmol/L (110mg/dL) till 6 mg
75917863|NCT00552474|Device|Libra Deep Brain Stimulation System|Active DBS Therapy
75631280|NCT01105130|Drug|Oral L-Arginine|Given orally 3 capsules ArginMax and 3 Placebo capsules
75782439|NCT01529879|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
75782440|NCT01253798|Other|Group training|Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
75917864|NCT00552474|Device|Libra Deep Brain Stimulation System|Implanted system but no stimulation
75782441|NCT03985397|Other|discharge training|Providing planned discharge training according to the level of knowledge about diet, drug and individual monitoring compliance and cardiovascular risk factors of patients with acute myocardial infarction
75782442|NCT03902288|Other|Fresh pomegranate juice|Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG < 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
76076050|NCT04937127|Other|usual care|usual care
76076051|NCT01725724|Procedure|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
76076052|NCT01725724|Procedure|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
75324600|NCT02016885|Drug|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
75324601|NCT02016885|Drug|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
75324602|NCT02016885|Other|Vehicle|Vehicle Topical Wipes
75324603|NCT00802633|Device|Stapling device during radical cystectomy|Hemostasis
75324604|NCT00802633|Device|Ligasure tissue sealing device|Efficacy of tissue sealing device during hemostasis
75324605|NCT00244777|Drug|Hypo-osmolar ORS|
75324606|NCT02016963|Biological|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
75324607|NCT00142285|Drug|Zinc sulphate (20 mg)|
75324608|NCT02018445|Procedure|Posterolateral Fusion|
75324609|NCT02342379|Drug|Bevacizumab|10mg/kg
75324610|NCT02342379|Drug|TH-302|670mg/m2
75324611|NCT02019069|Drug|liposomal cytarabine-daunorubicin CPX-351|Given IV
75324612|NCT00821821|Drug|MCI-186|"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion"
75324613|NCT00821821|Drug|Placebo|"Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo"
75324614|NCT03839875|Drug|Gynomax® XL Vaginal Ovule|tioconazole, tinidazole, lidocaine
75324615|NCT02409459|Drug|Injectafer|
75324616|NCT02409459|Drug|Placebo|Normal saline solution
75324617|NCT05198167|Other|Hyperoxygenated fatty acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
75324618|NCT05198167|Other|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
75631281|NCT01105130|Drug|Oral L-Arginine|Patients will take 6 capsules of ArginMax twice daily
75631282|NCT01108094|Drug|Itraconazole|"Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months"
76076053|NCT01673139|Behavioral|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
76076054|NCT01673139|Behavioral|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
75917865|NCT00434226|Drug|bevacizumab|Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
75917866|NCT00434226|Drug|sunitinib|25 mg/day for 2 weeks, followed by 1 week of rest
75631283|NCT04310072|Device|Neuromuscular electrical stimulation|NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.
75631284|NCT00954174|Drug|Carboplatin|Given IV
75631285|NCT00954174|Drug|Ifosfamide|Given IV
75631286|NCT00954174|Drug|Paclitaxel|Given IV
75631287|NCT00954174|Other|Quality-of-Life Assessment|Ancillary studies
75631288|NCT02854878|Device|The Lucy ultrasonic comb models A and B combined with the LucyGel|
75631289|NCT04312724|Device|Direct Socket TF|"The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day."
75782443|NCT00314327|Drug|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
75631290|NCT04312334|Other|Control|Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.
75782444|NCT03897452|Drug|Fentanyl (5 microgram/ml) prediluted ampoules|"Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation)."
75782445|NCT03906032|Device|TFNA IM Nail|IM nail
75782446|NCT03906032|Device|Sliding hip screw|SHS surgical fixation
75917867|NCT00434226|Drug|carboplatin|On the first day of each cycle for 4 cycles
76076055|NCT01673139|Behavioral|Control|Given information on recommendations for physical activity.
76076056|NCT01725880|Other|Observation|
76076057|NCT04379362|Procedure|Focal laser ablation|Focal laser ablation
75324619|NCT02409927|Dietary Supplement|MCT oil 10g|10 g of pure MCT oil mixed with skim milk in a standardized breakfast
75324620|NCT02409927|Dietary Supplement|MCT homogenate 10g|10g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
75324621|NCT02409927|Dietary Supplement|Control|vehicule (skim milk) with a standardized breakfast
75324622|NCT02409927|Dietary Supplement|MCT oil 20g|20g of pure MCT oil mixed with skim milk in a standardized breakfast
75324623|NCT02409927|Dietary Supplement|MCT homogenate 20g|20g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
75324624|NCT02409927|Dietary Supplement|MCT oil 30g|30g of 100% pure MCT oil mixed with skim milk in a standardized breakfast
75324625|NCT02409927|Dietary Supplement|MCT homogenate 30g|30g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
75324626|NCT00816751|Procedure|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
75324627|NCT00816751|Procedure|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
75782447|NCT01151072|Drug|insulin degludec|Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
75782448|NCT03906266|Diagnostic Test|NRS 2002, nutric, SGA and adductor pollicis|NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
75917868|NCT00434226|Drug|paclitaxel|On the first day of each cycle for 4 cycles
76076058|NCT03153969|Device|SHOFU Beautifil II LS|Placed under manufacturer's instructions
76076059|NCT03153969|Device|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
76076060|NCT01706198|Drug|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
76076061|NCT01706198|Drug|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
76076062|NCT03079323|Radiation|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
76076063|NCT01835860|Procedure|Prostate artery embolization|
76076064|NCT04378972|Other|curcumin, homotaurine, vitamin D3|ELISA tests on supernatants of 25 vitreous biopsies incubated with bioactive molecules at 37 ° C for 20 h. The concentration of soluble mediators was calculated from a calibration curve.
75631291|NCT04312334|Other|Treatment|The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.
75782449|NCT03897140|Diagnostic Test|Diagnostic Test: Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance feedback to users during image acquisition. For this study, RNs will use EchoGPS to perform limited echocardiogram examinations.
75324628|NCT00816751|Drug|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
75782450|NCT01253876|Dietary Supplement|soy milk, Caw's milk|
75917869|NCT02741700|Behavioral|Gout Storytelling Video Intervention|The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.
75917870|NCT00430950|Drug|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
75917871|NCT00430950|Drug|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
75917872|NCT00551148|Drug|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
75324629|NCT00822523|Drug|Botulinum Toxin, Type A|20 units, single dose, intramuscular in right EDB muscle
75324630|NCT00822523|Drug|Botulinum Toxin, Type A|2 units, single dose, intramuscular to right EDB muscle
75324631|NCT00822523|Drug|Saline|Single Dose, Intramuscular into right EDB muscle
75324632|NCT02410707|Drug|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
75468002|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B~st line~Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~Bevacizumab until PD or unacceptable toxicity~At PD < 3 months after last paclitaxel start 2nd treatment line.~At PD ≥ 3 months after last paclitaxel, start another 4 cycles~Bevacizumab until the next PD or unacceptable toxicity~At the next PD start the 2nd treatment line.~nd line:~Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~At PD < 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~At the next PD start 3rd treatment line."
75468003|NCT01935505|Behavioral|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
75631292|NCT04309058|Drug|Vitamin D drops|Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
75782451|NCT03896906|Device|High-flow nasal cannula|Apply high ﬂow heated (34 °C) and humidified nasal oxygen with the OptiFlow System (Thrive, Fisher & Paykel®, Aukland New Zealand) using a ﬂow of 30 liter/minute and an inspiratory oxygen fraction (FiO2) of 1.0. Increase the oxygen flow to 60 liter/minute over the course of the first minute. Ask the patients not to speak during anesthesia induction and keep the mouth closed.
75917873|NCT00551148|Drug|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
75917874|NCT00551148|Drug|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
75917875|NCT00551148|Drug|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
76076065|NCT04378972|Other|control|ELISA tests on supernatants of 25 vitreous biopsies. The concentration of soluble mediators was calculated from a calibration curve.
76076066|NCT04883073|Device|Use of Endo App|Use of Endo App
76076067|NCT01723150|Drug|Ciprofloxacin|
76076068|NCT01723150|Drug|Ceftriaxone|
75324633|NCT02410707|Drug|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
75324634|NCT02410707|Drug|Oxygen|If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
75631293|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
75631294|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
75782452|NCT03896906|Device|simple mask|Perform standard preoxygenation by oxygen insufflation via a face mask using the standard anesthesia ventilators (semicircular system) with 100% oxygen ﬂow of 12 liter/minute. The patients breathe with tidal volume.
75782453|NCT01257386|Drug|Asacol®|400mg tablets
75782454|NCT01257386|Drug|Mesalazine|400mg tablets
75782455|NCT01257464|Drug|Sitagliptin|100mg po one dose
75782456|NCT01257464|Drug|Placebo|Sugar pill po one dose
76076069|NCT01723150|Drug|Trimethoprim/sulfamethoxazole|
75324635|NCT00822757|Biological|Comparator: V710|Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
75324636|NCT00822757|Biological|Comparator: placebo|Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
75631295|NCT01136408|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
75782457|NCT01257620|Dietary Supplement|Probiotic|Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
75782458|NCT01255046|Drug|Donepezil,|10mg/tab, 1 tab/day for 72 weeks
75782459|NCT01255046|Drug|STA-1|300mg/tab, 2 tab/tid for 72 weeks
75324637|NCT02343081|Drug|Temozolomide|
75782460|NCT01255046|Drug|placebo|2 tab/tid for 72 weeks
75782461|NCT02528006|Device|Type 2 Thyroplasty using Titanium Bridges|
75782462|NCT03902054|Biological|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
75782463|NCT03902054|Biological|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
75782464|NCT03902054|Biological|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
75917876|NCT00551148|Other|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
75917877|NCT00549744|Drug|GSK256066|
75324638|NCT02343081|Drug|Temozolomide|
75324639|NCT03839329|Behavioral|Acceptance and Commitment Training|Acceptance and Commitment Therapy is an acceptance- and mindfulness-based psychotherapy that aims to foster psychological flexibility.
75324640|NCT02343627|Drug|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
75324641|NCT02343627|Drug|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
75631296|NCT01136174|Drug|Placebo|Placebo BID for cohort 1,2,3
75782465|NCT03902054|Biological|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
75782466|NCT03902054|Biological|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
75782467|NCT03901976|Device|bed exit detection|bed exit detection to avoid patients fall
75782468|NCT03902210|Behavioral|Online Yoga|60 minutes per week of online yoga through Udaya.com
75917878|NCT02280564|Behavioral|health coaching with technology support|Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
75917879|NCT02081391|Drug|Tapentadol oral solution 4 mg/mL|"Participants aged 6 months to less than 18 years old with a body weight below 20 kg received tapentadol oral solution 4 mg/mL by mouth every 4 hours for up to 72 hours.~Participants from birth to less than 6 months received tapentadol oral solution, diluted 4 fold."
76076070|NCT01723150|Drug|Ertapenem|
76076071|NCT01725958|Dietary Supplement|Nutritional supplement and protein shakes|
76076072|NCT01835938|Drug|1- Erlotinib|"Erlotinib 50 mg tablet by mouth every day for 14 days,~Erlotinib 100 mg tablet by mouth every day for 14 days,~Erlotinib 150 mg tablet by mouth every day for 14 days,"
76076073|NCT01835938|Drug|placebo|"Placebo 50 mg tablet by mouth every day for 14 days,~Placebo 100 mg tablet by mouth every day for 14 days,~Placebo 150 mg tablet by mouth every day for 14 days,"
76076074|NCT01726114|Device|Non-invasive Optical Glucose Monitor™|Test device
76076075|NCT01726114|Device|YSI blood glucose analyzer|Reference device
75324642|NCT00823069|Device|Perlane and Perlane-L|This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
75324643|NCT00823303|Drug|Paricalcitol|1 mcg daily, adjusted to achieve 40-60% PTH suppression
75324644|NCT00823303|Drug|Calcitriol|0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
76076076|NCT01836016|Drug|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
75324645|NCT02344251|Device|MEMS Cap|MEMS Track Cap records when the medication bottle is opened and closed
75324646|NCT02344251|Device|ID-Cap|ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
75468004|NCT01935505|Drug|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
75631297|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
75631298|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
75631299|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
75631300|NCT01135394|Drug|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
75631301|NCT04309760|Other|MRI|Subjects will receive structural and functional (resting state) MRI
75631302|NCT02881190|Drug|RC48-ADC|
75631303|NCT02881034|Drug|Triple therapy|
75631304|NCT00949884|Drug|olmesartan medoxomil|Oral tablets, once daily, at either 20mg or 40mg daily.
75631305|NCT00949884|Drug|Placebo|placebo oral tablets once daily for two weeks
75782469|NCT03902210|Behavioral|Podcast|60 minutes per week of podcasts
75782470|NCT03902132|Other|Core Stability exercises group|Core Stability Exercises were given in addition to the traditional physical therapy treatment as given to the control group. It included moist heat pack (10mins), Transcutaneous Electrical Nerve Stimulation (10 min), and strengthening regimen (2 sets with 15 isometric repetitions each).
75631306|NCT00949884|Drug|losartan potassium|losartan potassium oral tablet at either 50mg or 100 mg daily dose.
75782471|NCT03902132|Other|Traditional low back physical therapy group|The control group was given traditional low backache physical therapy management such as moist heat pack, TENS, and strengthening regimen (2 sets with 15 isometric repetitions each)
75917880|NCT02081391|Drug|Tapentadol oral solution 20 mg/mL|Participants aged from 6 months to less than 18 years with a body weight greater than or equal to 20 kg received tapentadol oral solution 20 mg/mL by mouth every 4 hours for up to 72 hours.
75917881|NCT02081391|Other|Placebo|Matching placebo oral solution was administered by mouth every 4 hours up to 72 hours.
75917882|NCT00549510|Drug|COREG CR and lisinopril (FDC)|
75917883|NCT00430092|Drug|Difluprednate|
75917884|NCT00430092|Drug|Difluprednate|
75917885|NCT00430092|Drug|Placebo|
75917886|NCT02280642|Biological|Both 2nd and 3rd doses on time|
75917887|NCT02280642|Biological|2nd dose late and 3rd dose on time|
75782472|NCT03901898|Behavioral|Training, audit, and reminders|Briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter), and re-audit at 6 months.
75324647|NCT02344407|Biological|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
75324648|NCT02344407|Biological|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
75631307|NCT00949650|Drug|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
75631308|NCT00949650|Drug|BIBW 2992|BIBW 2992 once daily until progression
75631309|NCT00949650|Drug|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
75782473|NCT03901898|Behavioral|Intervention after 6 months (wait list)|After 6 months, practices receive the intervention: briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter).
75631310|NCT00908037|Drug|eltrombopag|thrombopoietin receptor agonist
75782474|NCT03906188|Other|LitEmotion|LitEmotion is a serious video game programmed for helping managing emotions. The experimental group will play during 3 weeks while the control group will not play. The sample will play during 21 days, one session daily, around 45 minutes. After the 21 sessions the group will stop playing during 3 weeks. Therefore, the scales are done three times. In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
75782475|NCT03901742|Other|Protein-enriched nutrition|Protein-enriched enteral nutrition with a polymeric infant formula
75782476|NCT03901742|Dietary Supplement|High Protein-enriched Nutrition|High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement
75631311|NCT00908037|Drug|Placebo|placebo for comparison
75631312|NCT00631098|Procedure|venous cannulation|External jugular and cubital vein cannulation
75631313|NCT03082755|Drug|Gabapentin Enacarbil|1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
75917888|NCT02280642|Biological|2nd dose on time and 3rd dose late|
75917889|NCT02280642|Biological|Both doses late|
75917890|NCT02074917|Procedure|Anatomical ACL reconstruction|Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
75917891|NCT00427440|Drug|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
75631314|NCT03082755|Drug|Placebo Oral Tablet|1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
75917892|NCT00427440|Drug|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
75324649|NCT02344407|Biological|Placebo|
75324650|NCT00823459|Drug|Everolimus|Given PO
75324651|NCT00823459|Other|Archival Tissue Analysis|Correlative studies
75324652|NCT02411565|Drug|Fermented Wheat Germ Extract (FWGE)|5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
75631315|NCT05332353|Drug|Bacillus Calmette-Guerin|Bacillus Calmette-Guerin (BCG) is immunotherapy to prevent recurrence and progression of non muscle invasive bladder cancer.
75631316|NCT05351853|Dietary Supplement|Omnivore|This study will evaluate effects of plant based diets (vegan and vegetarian). 60 omnivore individuals will be included. 20 of the participants will continue their omnivore diet as control group. 20 of the participants will change their diet to vegetarian, and 20 of them will change their diet to vegan.
75782477|NCT03901742|Other|Standard Enteral Nutrition|Cow's milk based infant formula.
75782478|NCT01149356|Drug|Exemestane|Given orally
75782479|NCT01149356|Drug|Gamma-Secretase Inhibitor RO4929097|Given orally
75917893|NCT02081469|Other|TDF|To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
75917894|NCT02284698|Other|Health Education|Heath education will be given through awareness creation & pamphlet distribution
75917895|NCT00650832|Drug|TMC114; darunavir; Prezista|
75917896|NCT00425100|Drug|fesoterodine fumarate|12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
75917897|NCT00546780|Drug|Tanespimycin|Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
75917898|NCT00546780|Drug|Bortezomib|Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
75917899|NCT00545454|Drug|SSR150106|
75917900|NCT00545454|Drug|Placebos|
75917901|NCT03134430|Other|Normal saline|Injection of Normal saline around peripheral nerve
75917902|NCT03134430|Other|peripheral Nerve block|Injection of local anesthetics around peripheral nerve
75917903|NCT00420888|Drug|ABR-217620/naptumomab estafenatox|10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
75917904|NCT00420888|Drug|IFN-alpha|3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
75917905|NCT00420732|Biological|HyperAcute-Lung Cancer Vaccine|300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
75917906|NCT03135132|Behavioral|Control group|Recommend to consume usual diet during 12-week study period
75917907|NCT03135132|Behavioral|LCD group|Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day
75917908|NCT00543582|Drug|MGCD0103 and Azacitidine|"In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.~In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops."
75782480|NCT01149356|Drug|Goserelin Acetate|Given subcutaneously to premenopausal patients
75324653|NCT02411565|Drug|Placebo|Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
75324654|NCT02411565|Other|Standard of Care: Planned Surgery|Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
75324655|NCT02411565|Other|Quality of Life (QoL) Surveys: FACT-O|Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
75324656|NCT03839407|Device|MUSE Meditation Device|The MUSE Meditation Device guides users in mindful meditation using real-time feedback on brain wave activity.
75782481|NCT03905954|Other|Usual care|For this cross sectional survey, participants will be receiving usual care according to there health care systems
75782482|NCT01148576|Drug|entecavir|entecavir 0.5 mg qd for 12 months
75782483|NCT01148576|Drug|entecavir|entecavir 0.5 mg qd for 12 months
75782484|NCT01148576|Drug|essentiale + entecavir|entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
75917909|NCT03134352|Drug|ZL-3101|A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
76076077|NCT01836016|Drug|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
75324657|NCT02020785|Other|Higher phosphorus period|"Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of ~1gm/d by receiving education on avoiding phosphorus-based additives."
75324658|NCT02020785|Other|Lower phosphorus period|"Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of ~1gm/d by receiving education on avoiding phosphorus-based additives."
75631317|NCT05351853|Dietary Supplement|Vegetarian|20 of the participants will change their diet to vegetarian diet. In this group participants will not eat any meat or meat product but can eat/drink milk products, egg and other animal products.
75631318|NCT05351853|Dietary Supplement|Vegan|20 of the participants will change their diet to vegan diet. In this group participants will not eat any kind of animal products.
75782485|NCT01148576|Drug|Vitamin E + entecavir|entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
75782486|NCT03901586|Other|Satisfaction assessment|Patient will be asked to assess their satisfaction concerning the Richter procedure and its long term effect
75782487|NCT03901586|Other|Quality of life|The Quality of life will be assessed with 3 questionnaires (I-Qol / PISQ-12/PFDI-20)
75917910|NCT03134352|Drug|Placebo|A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
75324659|NCT04974775|Diagnostic Test|Blood collection|Sampling on admission to ICU (all patients)
75631319|NCT05332197|Biological|17D Yellow fever vaccine|This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. The exact potency of each batch is released with the certificate of analysis that accompanies each batch and the potency confirmed at time of release closest to internal minimum specification. This vaccine is the same vaccine used by the national EPI program
75631320|NCT00904215|Drug|telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)|
75782488|NCT03901586|Other|Gynecological assessment|An optional gynecological consult is proposed to the patients to better estimate the gynecological long-term impact of the procedure
75917911|NCT00542724|Drug|VIAject™|Dosage as individually required
75917912|NCT00542724|Drug|Regular Human Insulin|Dosage as individually required
75917913|NCT02286492|Drug|TAS-102|At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
75782489|NCT03901508|Device|TDCS|20 minutes, 2 electrodes (C3/FP2)
75782490|NCT03901352|Drug|Placebo|Matching placebo tablets for oral administration
75782491|NCT03901352|Drug|Mirogabalin|Mirogabalin tablets for oral administration
75782492|NCT01149200|Drug|TC-6499|5mg enteric-coated oral hard gelatin capsule, administered twice daily
76076078|NCT01836016|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
76076079|NCT01836016|Drug|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
75782493|NCT01149200|Drug|Placebo|placebo as enteric-coated oral hard gelatin capsule, administered twice daily
76076080|NCT01836016|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
76076081|NCT01836016|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
75324660|NCT04974775|Diagnostic Test|Blood collection, serial sampling|"Additional sampling to admission samples in~the Cardiac Arrest group after 12 and 48 hours~the Covid-19 group on day 2 and 7 while in the ICU~the Covid-19 group after 3 and 12 months."
75324661|NCT00825565|Drug|Alwextin cream|Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
75631321|NCT05234073|Behavioral|SEE Learning Online Training|This intervention includes classes about socioemotional learning theory and practice, topics related to ethics and well-being practices
75631322|NCT05234073|Behavioral|Waiting list|This group will wait for one month to receive SEE Learning Online Training
75631323|NCT05317689|Drug|Psilocin|17.5mg oral psilocin with psychological support and physiological monitoring
75782494|NCT03905486|Drug|Pregabalin 300mg|Group 1: will receive pregabalin as a monotherapy. Pregabalin will be administered according to the treatment recommendations for fibromyalgia in the package insert [Pfizer Inc., 2012] starting by 50 mg twice daily increasing to 300 mg twice daily according to the efficacy and tolerability for 3 months.
75782495|NCT03905486|Drug|Combined pregabalin 300mg and milancipran 100mg|Group 2: will receive a combined pregabalin and milancipran. Pregabalin will be administered as group 1, while milancipran will be administered according to the treatment recommendations for fibromyalgia, starting by 50 mg once daily for 1 week then increased to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 month.
75782496|NCT03901040|Device|endoscopic ultrasound|endoscopic ultrasound with boutlinum toxin injection in the antrum of the stomach to decrease satiety
75782497|NCT03901118|Drug|chiauranib|in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily
75782498|NCT03901118|Drug|etoposide|50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most
75782499|NCT03901118|Drug|paclitaxel|60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
75782500|NCT03896594|Drug|HL237|Experimental
75782501|NCT03896594|Drug|Placebo Oral Tablet|placebo with same properties except for active ingredient
75782502|NCT01151228|Other|Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.|Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
75782503|NCT03896282|Other|Mobilization at a dedicated daycare facility|"All THA's are performed using a standard posterolateral approach with simple posterior soft-tissue repair. No infiltration anesthesia (LIA) is used in THA's. All TKA's are performed with a standard medial parapatellar approach without the use of tourniquet. Physiotherapy is started as soon as possible after surgery in the dedicated day care facility. Time till first mobilization is recorded as is total time mobilized supervised by a physiotherapist before discharge.~Patients are discharged if fulfilling the discharge criteria before 8 pm. Number of hours spent in hospital in total is recorded."
75782504|NCT03895892|Behavioral|20 km time trial|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
75917914|NCT00539136|Drug|GSK561679 tablet or solution|
75324662|NCT02345031|Drug|AUT00063|600 mg, orally, once a day, for 4 weeks
75324663|NCT02345031|Drug|Placebo|orally, once a day, for 4 weeks
75917915|NCT02282436|Other|No specific intervention for this study|No specific intervention for this study
75631324|NCT05317689|Drug|Psilocybin|25mg oral psilocybin with psychological support and physiological monitoring
75631325|NCT05317689|Drug|Sublingual Psilocin|2.18mg - 4.36mg sublingual psilocin with psychological support and physiological monitoring
75631326|NCT03026127|Behavioral|Cognitive Reappraisal Intervention for Suicide Prevention|Cognitive Reappraisal Intervention for Suicide Prevention, or CRISP, is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
75917916|NCT02284776|Behavioral|Therapeutic education|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
75917917|NCT00384852|Drug|rhBMP-2/CPM|
75917918|NCT02284932|Other|No specific intervention for this study|No specific intervention for this study
75917919|NCT00412932|Drug|Olmesartan medoxomil|Tablets
75631327|NCT03026127|Behavioral|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors
75782505|NCT03895892|Behavioral|Wingate test|30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
75782506|NCT03895892|Dietary Supplement|Ketone/Caffeine|Dietary supplement containing ketone salts and caffeine
75917920|NCT00412932|Drug|Olmesartan medoxomil/hydrochlorothiazide|Tablets
75782507|NCT03895892|Dietary Supplement|Ketone|Dietary supplement containing only ketone salts
75782508|NCT03895892|Dietary Supplement|Water Placebo|Dietary supplement containing only water
75782509|NCT03896204|Behavioral|telephone-suppoted joint protection technique|After joint protection technics training, patients will be followed up with telephone support for 1 month.
75917921|NCT00411528|Drug|Patupilone|
75917922|NCT00411528|Drug|prednisone|
75631328|NCT03015753|Behavioral|Tai Chi training|The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
75917923|NCT00411528|Drug|docetaxel|
75917924|NCT00384150|Drug|galiximab in combination with rituximab|galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
76076082|NCT01836016|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
75324664|NCT00803647|Biological|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
75324665|NCT00803647|Drug|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
75782510|NCT03896204|Behavioral|joint protection technique training|Training will be given to individuals about joint protection technique
75324666|NCT00803647|Drug|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
75324667|NCT00803647|Drug|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
75782511|NCT01151306|Drug|Simvastatin|Simvastatin 20mg once daily (in the evening) for 6 weeks
75782512|NCT01151306|Drug|Lactose tablet|One tablet taken each evening for 6 weeks
75782513|NCT01257776|Drug|Autologous adipose derived mesenchymal stem cells|Intra-arterial administration through a selective cannulation of target common femoral artery
75917925|NCT00532038|Drug|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
75917926|NCT00530166|Drug|JNJ-18054478|3(100 mg) tablets once daily for 12 weeks
75917927|NCT00530166|Drug|sham comparator|3(100 mg) tablets once daily for 12 weeks
75917928|NCT02286570|Device|Glidescope|videolaryngoscope used for endotracheal intubation
75917929|NCT02286570|Device|Airtraq|videolaryngoscope used for endotracheal intubation
75917930|NCT02286570|Device|Fastrach|intubating laryngeal mask airway used for blind endotracheal intubation
75917931|NCT02282592|Other|Observation about the presence of metabolic syndrome|
75917932|NCT00408954|Drug|UK-369,003|100 mg MR tablet once daily for 2 weeks
75917933|NCT00408954|Drug|UK-369,003|UK-369,003-100 mg MR formulation for 2 weeks
75324668|NCT00827983|Drug|Progesterone|25 mg, s.c., once à day
75631329|NCT03015753|Other|Waiting list control group|At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
75917934|NCT03133884|Other|acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 30 seconds.
75917935|NCT03133884|Other|superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
75917936|NCT02286648|Drug|Formocresol|pulpotomy with formocresol
75917937|NCT02286648|Drug|Mineral Trioxide Aggregate|pulpotomy with MTA
75324669|NCT00827983|Drug|Progesterone|90 mg, vaginally, once à day
75631330|NCT05166915|Device|UVA Light Emitting Catheter|Experimental Device intended to eliminate microorganisms using UV-A light, thereby reducing the viral burden of SARS-CoV-2
75631331|NCT05166915|Device|Sham Control Catheter|Sham Control Device
75631332|NCT02664207|Procedure|Open Fetal Repair of Myelomeningocele|Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
75631333|NCT05273541|Biological|Coronavirus vaccination|Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
75631334|NCT05293665|Biological|UB-612|UB-612 (100µg), 0.5mL suspension, intramuscular injection
75631335|NCT05293665|Biological|BNT162b2 vaccine|BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection
75631336|NCT05293665|Biological|ChAdOx1-S vaccine|ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection
75631337|NCT05293665|Biological|Sinopharm BIBP|Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection
75917938|NCT03133806|Device|Ultrasept LAA Closure System|The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
75917939|NCT02282670|Drug|DA-5204|
75917940|NCT02282670|Drug|Stillen tab.|
75917941|NCT02282748|Other|No intervention|
75917942|NCT00406458|Drug|SB-509|60 mg dose
76076083|NCT01836016|Drug|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
75468005|NCT01935505|Behavioral|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
75468006|NCT01935505|Behavioral|Consulting+Telephone+Drug intervention|Include all the above interventions
75468007|NCT01935518|Drug|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
75468008|NCT01935531|Drug|3% diclofenac in 2.5% hyaluronic acid gel|
75917943|NCT00406458|Other|Normal Saline|
75631338|NCT03013257|Device|Echopulse|Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
75631339|NCT00905307|Drug|OPC-34712|oral, once daily
75631340|NCT00905307|Drug|Placebo|Placebo
75631341|NCT00905307|Drug|Aripiprazole|oral, once daily
75631342|NCT02988453|Other|MBT-CD|MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
75631343|NCT00907881|Drug|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
75631344|NCT00904917|Behavioral|Prevention Intervention Project|Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
75324670|NCT02412501|Device|Resolute Onyx Stent - 2.0 mm|Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
75324671|NCT02346903|Drug|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
75324672|NCT00844051|Biological|School-based influenza vaccination program|School-based influenza vaccination program
75324673|NCT02347605|Drug|Nicotine lozenge 4 mg|
75468009|NCT01935544|Device|Botulinum toxin injection|
75468010|NCT01935557|Drug|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
75631345|NCT00904917|Behavioral|Psychoeducation|Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
75631346|NCT04735653|Behavioral|Personalized Glaucoma Coaching|This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second session and one phone call after each subsequent session. Participants can elect to receive any of the following type of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
75631347|NCT04735653|Behavioral|Enhanced Standard care|Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
75631348|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
75631349|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
75631350|NCT00904839|Drug|mFolfox|standard i.v chemotherapy
75631351|NCT00904839|Drug|Bevacizumab|100 mg/Kg solution , IV infusion
75631352|NCT00904839|Drug|mFolfox 6|IV standard chemotherapy
75631353|NCT00904839|Drug|bevacizumab|100 mg/4 ml solution
75782514|NCT05543720|Device|Medly|Medly will enable patients with HF, COPD, Hypertension, Mental Health, or Diabetes to input measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
75324674|NCT02347605|Drug|Placebo lozenge|
75324675|NCT02410161|Dietary Supplement|alpha-linolenic acid-rich supplement|each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
75324676|NCT02348619|Drug|JZP-110|
75468011|NCT01935557|Drug|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
75468012|NCT01935570|Drug|Magnesium chloride (ChronoMag Smart Tablet®)|
75468013|NCT01935570|Drug|Magnesium carbonate (Mag2® Tablet)|
75468014|NCT01935583|Behavioral|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
75468015|NCT01935596|Drug|ropivacaïne|spinal anesthesia.
75468016|NCT01935596|Drug|lévobupivacaïne|
75324677|NCT02153671|Biological|A(H5N1) inactivated influenza vaccine (IIV)|Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.
75324678|NCT02153671|Biological|A(H5N2) live attenuated influenza vaccine (LAIV)|Two doses of A(H5N2) live attenuated influenza vaccine (LAIV) administered 28 days apart, approximately 1.5 years prior to receiving A(H5N1) IIV
75324679|NCT02413203|Drug|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
75324680|NCT02413203|Drug|Placebo|Blood and urine collections before and 3 hours after placebo administration.
75782515|NCT02527850|Device|B-cure laser|
75782516|NCT01149590|Procedure|Computer Tomography Angiography|Computed Tomography Angiography
75324681|NCT04382365|Other|Sleep Health Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness|Cognitive-Behavioral Treatment for insomnia (CBT-I) is a non-pharmacological intervention that is effective in treating insomnia in older adults, even when present with comorbid medical and psychological conditions.25 CBT-I focuses on the maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems, and typically consists of five primary treatment components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
75631354|NCT02505711|Behavioral|Homestead Food Production program|Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
75631355|NCT04724265|Biological|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.
75631356|NCT04985955|Drug|Tofacitinib|Tofacitinib tablet will be administered orally.
75631357|NCT02821923|Dietary Supplement|E967-Xylitol|24g xylitol/d
75324682|NCT02021955|Behavioral|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
75631358|NCT02821923|Dietary Supplement|E968-Erythritol|36g erythritol/d
75631359|NCT04713813|Other|Therapeutic exercise program via hippotherapy mechanical stimulator|Patients were planned to complete hippotherapy exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
75631360|NCT04713813|Other|Therapeutic home exercise program|Patients were planned to complete home exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
75631361|NCT02850549|Other|Procedure: physical therapy and Neck Pain Classification|Physical therapists treated patients in phase one as they usually do and in phase two were trained to follow a neck classification and matched intervention system.
75631362|NCT00903357|Drug|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
75782517|NCT03900494|Device|VHC 1|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 1. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
75631363|NCT00903357|Drug|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
75782518|NCT03900494|Device|VHC 2|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 2. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
75782519|NCT03900572|Biological|HPV Vaccine|Intramuscular injection, 3 doses
75782520|NCT03900572|Drug|Placebo|Intramuscular injection, 3 doses
75917944|NCT00379938|Biological|VAI-VP705 (parvovirus B-19 vaccine)|Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
75917945|NCT00379938|Drug|Placebo|Saline control
75917946|NCT00379938|Biological|MF-59|Adjuvant
75631364|NCT02446665|Device|MR Elastography (MRE) and FibroScan|
75631365|NCT02796573|Behavioral|cognitive behavioural therapy|
75631366|NCT05119023|Behavioral|Observational Learning|All participants will complete a computer-based serial response time task intended to measure observational (implicit) learning ability. In this task, participants look at a dot move from one of 4 positions on a computer screen. Unbeknownst to participants, dot movement followed a 12-movement pattern for most experimental blocks. Eye-tracking data is collected and eye fixations within regions of interest trigger trial advancement. Learning ability is evaluated as a comparison of saccadic response times during sequenced trials relative to pseudorandomized trials.
75631367|NCT05119023|Behavioral|Rule-based Learning|All participants will complete a computer-based rule-based learning task intended to measure rule-based (explicit) learning ability. In this task, participants look at sequences of geometric shapes on a computer screen. Through visuals and verbal instruction, they are taught 5 rules that govern sequences. After learning rules, participants are asked to judge via button press whether novel sequences adhere to rules or not.
75782521|NCT05528120|Drug|VC004 Capsules|Oral administration after fasting/high-fat meal
75782522|NCT05528120|Drug|VC004 Capsules|Oral administration after high-fat/fasting meal
75782523|NCT05570786|Drug|Gestrinone|The intradermal gestrinone/placebo pellet will be inserted on the same day as the levonorgestrel intrauterine hormonal device (Kyleena®)
75782524|NCT05570786|Drug|Placebo|Subdermal implant-bioabsorbable placebo pellet (cholesterol)
76076084|NCT04378816|Other|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions.A question prompt list (QPL) is a structured list of questions that serves as a prompt for patients to consider questions to ask their physician.
75324683|NCT02022111|Behavioral|Patient Education and Behavioral Activation|To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
75631368|NCT04651725|Other|Exercises|Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
75631369|NCT04632771|Other|N/A (observational study)|N/A (observational study)
75324684|NCT02022111|Behavioral|Supporting Self-Care (care coordinators)|Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
75631370|NCT02754063|Device|PbtO2 probes|PbtO2/ICP/CPP-directed therapy according to international recommendations
75631371|NCT02754063|Other|No PbtO2 probes|ICP/CPP-directed therapy according to international recommendations
75782525|NCT05561894|Other|pulse pressure variation index guided fluid therapy|maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either >12% or >16%
75782526|NCT03895970|Drug|Lenvatinib plus Pembrolizumab|Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.
75631372|NCT02749305|Other|Collection of patient-reported outcome measures|Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
75631373|NCT02208765|Device|Stress Single Photon Emission Computed Tomography|
75782527|NCT00336479|Drug|Telaprevir|tablet
75782528|NCT00336479|Drug|Ribavirin|tablet
75782529|NCT00336479|Drug|Pegylated Interferon Alfa 2a|Solution for injection
75631374|NCT02847351|Dietary Supplement|Arabinoxylan Diet|"19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).~Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT)."
75917947|NCT00406068|Drug|Mycobacterial cell wall-DNA complex|8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
75917948|NCT02696031|Drug|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
75782530|NCT00336479|Other|Placebo|matching placebo tablet
75782531|NCT03905564|Drug|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
75782532|NCT03905564|Drug|Diclegis (Registered Trademark)|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).
75782533|NCT03895424|Dietary Supplement|IFAC|This intervention will contain the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope 58Fe
75782534|NCT03895424|Dietary Supplement|MIFAC|This intervention will contain the micellarized form of the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope with 57Fe
75782535|NCT03895424|Dietary Supplement|Control Ferrous Sulfate|This intervention will contain ferrous sulfate in the form of a solution labelled with the iron isotope 54Fe. A capsule with the same amount of fat as in the other arms will be administered to the participants
75917949|NCT02696031|Drug|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
75917950|NCT00403416|Drug|AEB071|
75917951|NCT00403416|Drug|Mycophenolic Acid|
75917952|NCT00401388|Drug|Perifosine|Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
75917953|NCT00401388|Other|Loperamide|All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.
75782536|NCT01151384|Drug|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
75782537|NCT01257932|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
75917954|NCT00401388|Other|Allopurinol|Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.
76076085|NCT01723306|Genetic|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
76076086|NCT01836094|Drug|Methylene Blue (USP grade, 280mg oral)|
76076087|NCT01836094|Drug|Placebo|oral, one time
75631375|NCT04202289|Device|Nile Tilapia Fish Skin|In the search of new therapies for burns, the skin of Brazil's most cultivated fish, the Nile tilapia, which was mostly a waste product (although sometimes used as a resistant material for artisanal handicraft), was suggested as a possibility for the development of a low-cost xenograft. Apart from non-infectious microbiota, Nile Tilapia Fish Skin presented histomorphological similarities with human skin in pre-clinical studies. It was shown to have a deep dermis formed by thick collagen fibers organized on parallel/horizontal and transversal/vertical arrangement and composed, in comparison, by larger amounts of type I collagen. Nile Tilapia Fish Skin did not present variations in its microscopic structure and tensile strength after glycerolization, irradiation and posterior rehydration, recovering its natural consistency after glycerol removal.
75917955|NCT00401388|Other|Antiemetics|Antiemetic prophylaxis will be administered at the treating investigator's discretion.
75917956|NCT02282826|Drug|GZ402668|Pharmaceutical form:solution Route of administration: intravenous
75917957|NCT02282826|Drug|placebo|Pharmaceutical form:solution Route of administration: intravenous
75782538|NCT03895190|Behavioral|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
75917958|NCT02282826|Drug|GZ402668|Pharmaceutical form:solution Route of administration: subcutaneous
75324685|NCT02022111|Other|Psychiatrist and Diabetologist Reviews|Senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patients and their usual care providers.
75324686|NCT02022111|Other|Decision-support Electronic Health Record System|The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
75468017|NCT01935609|Behavioral|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
75782539|NCT03905408|Drug|50 mL of 50% Glucose|1st dose
75782540|NCT03905408|Drug|100 mL of 50% Glucose|2nd dose
75782541|NCT03905408|Drug|150 mL of 50% Glucose|3rd dose
75782542|NCT03905408|Drug|200 mL of 50% Glucose|4th dose
75917959|NCT02282826|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
76076088|NCT01705730|Drug|tocilizumab|Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
75782543|NCT01258010|Drug|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
75782544|NCT01258010|Drug|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
75782545|NCT00314249|Drug|Placebo|Placebo, oral administration, twice daily for 12 weeks
75782546|NCT00314249|Drug|Milnacipran 100mg|Milnacipran 100mg per day (50mg BID [twice a day])
75917960|NCT02282826|Drug|acyclovir|Pharmaceutical form:tablet Route of administration: oral
75917961|NCT04471584|Device|Insertion of ILR device|All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.
75917962|NCT00374166|Drug|SSR149415|Oral administration (capsules of 50 and 100 mg)
75917963|NCT00374166|Drug|Placebo|Oral administration (capsules)
75917964|NCT00374166|Drug|Paroxetine|Oral administration (capsules)
75917965|NCT02285088|Drug|GBT440|GBT440 will be administered as oral capsules
75917966|NCT02285088|Drug|Placebo|Matching placebo will be administered as oral capsules
75917967|NCT02081625|Drug|NS-065/NCNP-01|"NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks"
75917968|NCT02286882|Drug|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
75917969|NCT02285244|Drug|sotrastaurin acetate|Given PO
75917970|NCT02285244|Other|pharmacological study|Correlative studies
75917971|NCT02285244|Other|laboratory biomarker analysis|Correlative studies
75917972|NCT02287116|Device|Easy Flow system and INCA® nasal cannulae set|
75917973|NCT02078895|Drug|Botox|Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
75917974|NCT00399906|Drug|BMS-582949|Tablets, Oral, Once daily, 12 weeks
75917975|NCT00399906|Drug|Placebo|Tablets, Oral, Once daily, 12 weeks
75917976|NCT02078973|Drug|15 mg tolvaptan|15 mg pr day for 1 day
75917977|NCT02078973|Drug|30 mg tolvaptan|30 mg pr day for 1 day
75917978|NCT02078973|Drug|45 mg tolvaptan|45 mg pr day for 1 day
75917979|NCT02078973|Drug|Placebo|1 tablet Unikalk pr day for 1 day
75917980|NCT00397254|Drug|rizatriptan|10mg ODT 27 tablets
75917981|NCT00397254|Drug|rizatriptan|10mg ODT 9 tablets
75917982|NCT01369641|Procedure|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
75324687|NCT02022111|Other|Standard of Care|Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
75324688|NCT02022735|Device|Deep Brain Stimulator|DBS will provide brain stimulation.
75631376|NCT04202289|Drug|Silver Sulfadiazine Cream 1%|Topical antibiotic commonly used for the treatment of superficial and deep partial-thickness burns.
75631377|NCT02850003|Drug|IDP-120 Gel|Gel
75631378|NCT01949883|Drug|CPI-0610|
75631379|NCT01730313|Drug|Pyridoxine|
75631380|NCT01730313|Drug|Sodium Valproate|
75631381|NCT01730313|Drug|Phenytoin|
75782547|NCT01255280|Behavioral|Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
75917983|NCT01369641|Drug|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
75917984|NCT01369641|Other|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
75917985|NCT01369641|Drug|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
75917986|NCT02283060|Drug|Stribild|To be administered orally, once daily with food.
75917987|NCT02283060|Drug|Atripla|To be administered orally, once daily at bedtime on an empty stomach
75917988|NCT02079051|Behavioral|Moderate intensity weight loss|A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
75917989|NCT02079051|Behavioral|High intensity medical weight loss|Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
75917990|NCT03559725|Other|VLN menthol cigarettes (A)|0.4mg nicotine / g tobacco king size filter menthol cigarette
75631382|NCT01730313|Drug|Placebo|
75631383|NCT02849925|Drug|Sealants to arrest microcavitated caries.|Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
75917991|NCT03559725|Other|Usual Brand Menthol Cigarettes (B)|Usual brand king size menthol cigarettes
75917992|NCT03559725|Drug|Nicotine gum (C)|4 mg nicotine gum
75917993|NCT00529152|Drug|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
76076089|NCT01726192|Procedure|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
76076090|NCT01726192|Procedure|Placement of a femoral neurostimulating catheter|
75631384|NCT02849769|Device|Implant of an MR-conditional Tachy device system|
75631385|NCT02849379|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
75631386|NCT02849379|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
75631387|NCT02847663|Device|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
75782548|NCT01255280|Behavioral|Information, Motivation, Behavioral skills change approach to sexual risk reduction|The comparison condition will only receive the two IMB risk reduction sessions.
75324689|NCT02153983|Drug|Colchicine 0.6Mg Cap|Colchicine 0.6 mg given twice daily
75324690|NCT02153983|Drug|Placebo capsules given|Placebo capsules given twice daily
75324691|NCT02153983|Drug|Colchicine 0.6Mg Tab|Open-label colchicine
75631388|NCT02847663|Other|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
75782549|NCT03900260|Device|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
75917994|NCT02287194|Device|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
75917995|NCT02079207|Biological|NBP606|13-valent peumococcal conjugate vaccine(13vPnC)
75917996|NCT02079207|Biological|Prodiax-23|23-valent peumococcal polysaccharide vaccine(23vPS)
75917997|NCT03429920|Dietary Supplement|Q CAN PLUS|Active powder with fermented soy , 2 pouches per day, each pouch contains 12-15 gms of fermented soy
75468018|NCT01935635|Biological|HPDCs-T immune therapy|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2*105-1*106 cells per time,total 12 times;
75631389|NCT01104662|Drug|Vancomycin|
75631390|NCT01104662|Drug|Daptomycin|
75631391|NCT01104662|Drug|Semi-Synthetic Penicillin|
75631392|NCT02849301|Device|Arabin cervical pessary|
75631393|NCT02849613|Other|Adipose Derived Stem Cells|
75631394|NCT02849613|Other|Vehicle media|
75782550|NCT03900104|Procedure|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
75782551|NCT03900104|Procedure|Cervical injection of technetium 99 m-labeled human albumin colloid particles|Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
75782552|NCT01258088|Drug|AN2728 Ointment|5mg/cm2, BID
75782553|NCT01258088|Drug|AN2728 Vehicle|5mg/cm2 BID
75782554|NCT03905018|Drug|Tadalafil 20 MG|tadalafil 20 mg orally ,after a single administration
75782555|NCT01589588|Device|Open Hudson Mask|Mask type 1 oxygen
75782556|NCT01589588|Device|Cluster headache mask with 3 L reservoir|Mask type 2 with oxygen
75782557|NCT01589588|Device|Mask 3|Mask type 3 oxygen
75468019|NCT01935648|Drug|Ropivacaine|
75631395|NCT01461291|Device|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
75782558|NCT01589588|Device|Carnét oxygen demand valve|mask type 3 oxygen
75782559|NCT01589588|Device|Carnét oxygen demand valve|mask type 3 placebo
75782560|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 100 mL Spray-dried S/D-treated Plasma
75782561|NCT01589666|Drug|Spray-dried S/D-treated plasma|Infusion of 200mL Spray-dried S/D-treated plasma
75782562|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 500 mL Spray-dried S/D-treated plasma
75782563|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 750 mL Spray-dried S/D-treated Plasma
75917998|NCT03429920|Dietary Supplement|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research, Inc.)
75468020|NCT01935674|Drug|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
75468021|NCT01935674|Drug|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
75782564|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 800 mL Spray-dried S/D-treated Plasma
75782565|NCT01258166|Procedure|Surgery or immobilization|
75782566|NCT03894722|Procedure|Control|During the third molar extraction the saline solution will be used in the control group.
75782567|NCT03894722|Procedure|0.5% concentration of PVP-I|During the third molar extraction 0.5% concentration of PVP-I solution will be used in the test group.
75917999|NCT00570336|Drug|CTS-1027|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
75918000|NCT00570336|Other|Placebo|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
75918001|NCT00527046|Drug|CP-424,391|
75918002|NCT02075151|Procedure|Bronchial Thermoplasty|Bronchial thermoplasty
75918003|NCT00525330|Drug|KRP-104 QD Drug: Placebo Drug: Metformin|KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
75918004|NCT00525330|Drug|Placebo Drug: Metformin|Two tablets 15 to 30 minutes before each meal, morning and evening.
75918005|NCT00525330|Drug|KRP-104 BID Drug: Placebo Drug: Metformin|KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
75918006|NCT02079285|Procedure|EUS-FNA|
75918007|NCT00393120|Drug|INCB009471|100mg SR (sustained release) orally once daily
75918008|NCT00393120|Drug|INCB009471|300mg SR (sustained release) orally once daily
75918009|NCT00393120|Drug|Placebo comparator|Orally once daily
75468022|NCT01935687|Device|Using of instrumented wheel|Using of instrumented wheel
75631396|NCT01461291|Procedure|Cataract surgery|Cataract surgery alone
75631397|NCT02847195|Device|pupillometry|This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
75631398|NCT01104584|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
75631399|NCT05062785|Drug|Intranasal insulin|"This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits."
75782568|NCT03894722|Procedure|1 % concentration of PVP-I|During the third molar extraction 1 % concentration of PVP-I solution will be used in the test group.
75782569|NCT03894722|Procedure|3 % concentration of PVP-I|During the third molar extraction 3 % concentration of PVP-I solution will be used in the test group.
75631400|NCT01407627|Dietary Supplement|Fructose|"Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
75631401|NCT02849535|Behavioral|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
75918010|NCT02079363|Other|No interventions, this is an observational study|
75918011|NCT02287272|Drug|CHF 5993 pMDI|4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
75918012|NCT02287272|Drug|Cimetidine plus CHF5993 pMDI|Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
75918013|NCT00392574|Drug|Prulifloxacin|Tablet
75324692|NCT02348775|Dietary Supplement|GlyNAC (combination of glycine and n-acetylcysteine)|HIV patients will be studied before and after receiving GlyNAC
76076091|NCT01836172|Drug|YJP-14|An 50% ethanolic extract of Lindera obtusiloba stems
75324693|NCT00828061|Drug|Placebo|Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
75782570|NCT03894800|Drug|Methoxyflurane (M)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention inhalation of metoxyflurane 3 ml and NaCl i.v. will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
75782571|NCT03894800|Drug|Fentanyl (F1)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
75782572|NCT03894800|Drug|Fentanyl (F2)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
75782573|NCT03894800|Drug|NaCl (C)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
75918014|NCT00392574|Drug|Placebo|Tablet
75918015|NCT02075229|Device|Cochlear implant|A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
75918016|NCT00391560|Drug|perifosine|Identical intervention in both arms.
75918017|NCT02081781|Procedure|Probing|"A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A Hard resistance could be felt as the probe touched the end of the nasolacrimal duct. A Pop tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner."
75918018|NCT04470414|Diagnostic Test|IgG antibodies immunoassay|Assessment of IgG level will be done by quantitative assessment of IgG in the serum of recovered persons by Chemiluminescence Immunoassay (CLIA).
75324694|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
75468023|NCT01935687|Device|Using of ergometer roller|Using of ergometer roller
75468024|NCT01935752|Other|blood samples|blood samples
75468025|NCT01935752|Other|vascular echotracking|endothelial function study and virtual histology study
75468026|NCT01935765|Other|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
75631402|NCT01103960|Drug|Telmisartan80mg+Amlodipine5mg|combination therapy
75631403|NCT01103960|Drug|amlodipine 5mg|monotherapy
75324695|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
75324696|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
75468027|NCT01935765|Other|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
75468028|NCT01935765|Other|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
75918019|NCT02075307|Dietary Supplement|Blueberry Powder|
76076092|NCT01836328|Drug|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
76076093|NCT01836328|Drug|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
76076094|NCT01726348|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
75468029|NCT01935765|Other|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
75631404|NCT01103960|Drug|Telmisartan80mg+Amlodipine 5mg|combination therapy
75468030|NCT01935765|Other|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
75631405|NCT04413279|Procedure|LipiFlow Thermal Pulsation|To manage patients with dry eye disease secondary to MGD
75782574|NCT03894644|Other|Simulation technology|The intervention involves three consecutive sessions of the PeriopSim™ Instrument Trainer, followed by two consecutive sessions of the PeriopSim™ for Burr Hole Surgery (https://periopsim.com).
75631406|NCT04413279|Drug|Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation|to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
75631407|NCT02847039|Genetic|Blood samples|Blood samples at baseline.
75631408|NCT05006144|Other|sequenced trunk co-activation exercises|"Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~Righting and protective reactions~Functional stretching exercises."
75782575|NCT03900182|Device|Hyperbaric Oxygen Therapy|The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
75782576|NCT03900026|Drug|Evolocumab|REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection
75782577|NCT03900026|Other|Placebo|Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.
75782578|NCT01149668|Drug|PCI-24781|Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
75918020|NCT02075307|Dietary Supplement|Placebo|
75918021|NCT00363636|Drug|Galiximab in combination with rituximab|Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
75918022|NCT00363636|Drug|Rituximab in combination with placebo|Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
75782579|NCT01586234|Procedure|DSAEK with graft shaping and smoothing|"A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~The tissue on the underside of the cornea (endothelium) will be scraped away~The graft from the donor cornea (previously smoothed with a laser) will be inserted through the incision and placed against the endothelium of the host cornea."
75918023|NCT02957253|Other|risk factors|monitoring risk factors due to deterioration of the liver disease
76076095|NCT01726426|Dietary Supplement|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
75918024|NCT02957253|Other|self-care|information and motivation to adherence to self-care instructions and medical treatment
75918025|NCT02957253|Other|nutrition|nutritional assessment and activities to prevent malnutrition
75918026|NCT02957253|Other|lifestyle|motivation of lifestyle changes essential for disease progress and
75918027|NCT02957253|Other|psychosocial needs|psychosocial care.
75918028|NCT02957253|Other|Nurse-led clinic|compensated disease once yearly, decompensated disease twice a month to every third month
75918029|NCT02285400|Procedure|CPAP level|CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
75918030|NCT02605174|Drug|Lasmiditan 50 mg|One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
75468031|NCT01935765|Other|Electrocardiogram (ECG)|Electrocardiogram (ECG)
75468032|NCT01935765|Other|Carotid echography|Carotid echography
75468033|NCT01935765|Other|Blood pressure|Blood pressure
75468034|NCT01935804|Drug|Pioglitazone|30 mg/daily for 12 months
75468035|NCT01935804|Drug|Metformin|850 mg/daily for 12 months
75468036|NCT01935817|Drug|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
75468037|NCT01935817|Drug|Placebo|
75468038|NCT01935830|Radiation|[11c] LAAM|intravenous administration of 15-20 mCi of [11c] LAAM.
75918031|NCT02605174|Drug|Lasmiditan 100 mg|One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
75918032|NCT02605174|Drug|Lasmiditan 200 mg|One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
75918033|NCT02605174|Drug|Placebo|Two placebo tablets to match lasmiditan doses.
76076096|NCT04379128|Other|Attentional tasks|a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control
76076097|NCT04378894|Behavioral|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
75918034|NCT02285556|Behavioral|psychological rehabilitation training|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
75782580|NCT01586234|Procedure|Standard DSAEK|"A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~The tissue on the underside of the cornea (endothelium) will be scraped away~The graft from the donor cornea will be inserted through the incision and placed against the endothelium of the host cornea."
75782581|NCT01149746|Drug|Tamsulosin|Test 0.4 mg Capsule
75918035|NCT02285556|Behavioral|physical and neurological rehabilitation training|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
75918036|NCT02285556|Radiation|rTMS 10HZ high frequency stimulation|Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
76076098|NCT01705652|Drug|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
76076099|NCT01723540|Procedure|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
76076100|NCT01836406|Drug|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
76076101|NCT01723618|Drug|CRD007|
76076102|NCT01836484|Diagnostic Test|Diffusion-weighted MRI|
76076103|NCT01836484|Diagnostic Test|Fluorodeoxyglucose-18-PET/CT|
76076104|NCT01836484|Diagnostic Test|Fluoro-ethyl-coline-PET/CT|
75782582|NCT01149746|Drug|Tamsulosin|Reference Listed 0.4 mg Capsule
76076105|NCT01836562|Biological|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
76076106|NCT01726816|Drug|Probucol 250mg/day|Probucol 250mg + Placebo
76076107|NCT01726816|Drug|Probucol 500mg/day|Probucol 500mg + Placebo
75324697|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
75324698|NCT02023125|Drug|Alectinib|A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
75324699|NCT02023125|Drug|Esomeprazole|Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
75324700|NCT02023125|Other|High Fat and Calorie Meal|High fat and calorie meal served prior to alectinib administration
75782583|NCT01149824|Drug|Salvinorin A|
75782584|NCT01149824|Drug|Placebo|
76076108|NCT01726816|Drug|Placebo|Probucol matching placebo
75782585|NCT01149902|Biological|Cyclophosphamide, Docetaxel, Dendritic cells, OK-432|Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35
75782586|NCT03904940|Device|Total Contact Insole|Ethyl vinyl acetate insole shaped in the cast of the patient's foot.
75782587|NCT03904940|Device|Ethyl vinyl acetate flat insole|Flat insole made of the same material ethyl vinyl acetate
75782588|NCT01151696|Drug|Atarax (Hydroxyzine)|One milligram per 10 kilogram, intramuscular use
75782589|NCT01151696|Drug|Placebo|Placebo
75782590|NCT01254266|Behavioral|inpatient hospitalization and follow up|An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
76076109|NCT01836796|Dietary Supplement|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
76076110|NCT01836796|Dietary Supplement|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
75782591|NCT01254266|Behavioral|inpatient treatment and follow up|one month inpatient treatment followed by a year-long follow up on the inpatient unit.
75782592|NCT01254266|Procedure|bariatric surgery|bariatric surgery.
76076111|NCT01726894|Device|Irreversible Electroporation|
76076112|NCT00915538|Drug|pMDI budesonide/formotrol 160/4.5 is in group 1|The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
75324701|NCT02023125|Other|Standard Meal|Standard meal served prior to alectinib administration
75782593|NCT01254266|Behavioral|inpatient treatment with follow up|1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
75782594|NCT03894176|Other|Plasma PTX3 concentration|Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
75918037|NCT02285556|Radiation|fake rTMS 10HZ high frequency stimulation|Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
75918038|NCT02075385|Procedure|pre, during and pos-treatment swallowing exercises|Speech pathology therapy
75324702|NCT00803959|Other|Office evaluation|Office evaluation
75324703|NCT00803959|Other|UDS|Urodynamics
75324704|NCT02349477|Drug|Gabapentin|gaba potentiating medication
75324705|NCT02349477|Drug|Placebo|a pill that looks exactly like the active medication but does not contain medication
75324706|NCT00828295|Drug|palonosetron|palonosetron IV 1 mcg/kg
75918039|NCT00522990|Drug|AT9283|Three weekly intravenous administration of AT9283
75918040|NCT00522834|Drug|Elesclomol (STA-4783)|213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
75918041|NCT00522834|Drug|Paclitaxel|80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
75918042|NCT02075619|Drug|Amlodipine+Rosuvastatin|Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
75918043|NCT02075619|Drug|GSK3074477 FDC - 1|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
76076113|NCT00915538|Device|Symbicort 160/4.5 plus Aerochamber Plus included in group 2|Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
75631409|NCT05006144|Other|Standard Orthotic Management|A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
75631410|NCT05006144|Other|selective dorsal rhizotomy|All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact. After opening the dura, the posterior nerve roots of L2 to S1 were identified and divided into 3 to 6 rootlets. At L2, from 30% to 50% of the posterior nerve rootlets were sectioned without selective stimulation. Selective electric stimulation of each nerve rootlet was performed from L3 to S1. The percentage of rootlets sectioned at each level (table 3) was determined by the surgical team based on the electromyographic results obtained intrasurgically and knowledge of the presurgical assessment results. The laminae were replaced on the completion of the rootlet stimulation and secured with sutures in the yellow ligament and the supraspinous ligament.
75631411|NCT02880098|Biological|Troponin T blood level|assess Troponin T blood level for every child born from the same sample of blood (after clamping the umbilical cord) used for assessment of pH and lactate.
75631412|NCT04309448|Behavioral|Perturbation-based balance training with functional electrical stimulation|The PBT program will consist of repetitive practice of reactive stepping for one hour. The participants will be equipped with the Odstock 2-Channel stimulator on one or both sides depending on their deficits. One channel of stimulation may be applied to the common fibular nerve to elicit a flexor withdraw reflex and elicit a step. The second channel of stimulation may be applied to the quadriceps muscles to assist with the supporting phase of the reactive step, as required. Participants will experience about 60 perturbations per session during balance exercises. To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness around the participant's trunk. Throughout the hour-long session, participants will complete challenging balance tasks, customized to their ability level, during standing and walking. The training will be supervised by a licensed physiotherapist and administered by a licensed physiotherapist or registered kinesiologist.
75631413|NCT04886505|Device|Electrolytic eCLIPs Bifurcation System|The electrolytic eCLIPs bifurcation system will be implanted into patients with bifurcated saccular intra-cranial aneurysms.
75631414|NCT04975256|Drug|MRTX849|KRAS G12C inhibitor
75631415|NCT04975256|Drug|BI 1701963|SOS1 Inhibitor
75631416|NCT00951951|Procedure|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
75631417|NCT00951951|Procedure|Posterior Approach|
75782595|NCT03894332|Diagnostic Test|Electrical Impedance Tomography (EIT)|"After enrollment, a silicon EIT belt of proper size with 16 electrodes was placed around the patient's chest between the 4th and 6th intercostal spaces, and connected to the EIT device. All patients were ventilated in Pressure Support Ventilation (PSV) mode, with a dedicated ventilator connected to the EIT device.~We acquired 5-min EIT data records at baseline (during PSV), during the first (SBT_0) and the last (SBT_30) 5 minutes of SBT, and, when the patient was extubated, during spontaneous breathing soon after (SB_0) and 30 minutes after extubation (SB_30).~EIT and ventilator data were recorded at a sample of 20 Hz. The last 3 minutes of each record were analyzed.~We measured respiratory rate (RR); Vt changes from baseline, expressed as percent (dVt%); dEELI variations from baseline, expressed in mL; the Global Inhomogeneity index (GI); Impedance ratio (IR) and the Center of Ventilation (CoV)."
75782596|NCT02527928|Other|None intervention|
75918044|NCT02075619|Drug|GSK3074477 FDC - 2|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
76076114|NCT01836874|Drug|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
76076115|NCT01724086|Drug|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
75918045|NCT02079675|Drug|SKI3246 Low Dose|SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
75918046|NCT02079675|Drug|SKI3246 High Dose|SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
75918047|NCT02079675|Drug|Placebo|SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
75918048|NCT02079753|Device|Inogen|single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours
76076116|NCT01724086|Drug|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
76076117|NCT01724086|Drug|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
75324707|NCT00828295|Drug|palonosetron|palonosetron 3mcg/kg IV
75918049|NCT02079753|Device|Combination system of a portable and a stationary device.|"Combination system of a portable and a stationary device (reservoir of liquid oxygen Liberator 30, Caire and a liquid Stroller oxygen pack Caire for patients using previously liquid oxygen, or a VisionAire5 Airsep stationary concentrator and an Inogen One G2 portable Inogen concentrator for patients using previously concentrators)"
75918050|NCT04795102|Combination Product|immediate implant placement with ATBG and L-PRF|immediate implant placement using ATBG as a graft material, with L-PRF
75631418|NCT02849067|Other|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
75918051|NCT04795102|Combination Product|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without L-PRF
76076118|NCT01724086|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
75631419|NCT02849067|Other|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
75631420|NCT02880800|Drug|Morphine as IVPCA|"Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below:~Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours"
75631421|NCT02880800|Drug|Hydromorphone as IVPCA|"Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below:~Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours."
75631422|NCT02880800|Drug|Morphine|IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h)
75782597|NCT01149980|Drug|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
75782598|NCT03904784|Behavioral|school withdrawal teenagers|The teenagers will have 4 interview with medical team alone or with his familly in order to have questionnaries, schools reports, psychological evaluation.
75782599|NCT03899714|Other|Cryotherapy|Crushed ice in a plastic bag will be used, as it is a widely accessible and financially convenient method of cryotherapy. One half of a kilogram of ice will be placed in a plastic bag. The plastic bags will be 17 cm wide and 22 cm long. The air will be squeezed out of the bag and it will be sealed. The bag will be wrapped in a wet towel and applied to the tested area. Every five bags of crushed ice will be kept in an insulated foam container containing one kilogram of dry ice. Dry ice has a temperature of negative 80 degrees Celsius, and is used to keep the bags of crushed ice in a frozen state till the participants are briefed and the testing began.
75782600|NCT01258244|Other|Audiovisual Feedback|EMTs will get audiovisual feedback on CPR technique during CPR
75918052|NCT00517920|Drug|ABT-869|0.25 mg/kg QD
76076119|NCT01724086|Drug|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
76076120|NCT01724086|Drug|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
76076121|NCT00913510|Device|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
76076122|NCT00913510|Drug|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
76076123|NCT01727050|Device|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
76076124|NCT01727050|Device|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
76076125|NCT03836638|Drug|30 Units of botulinum toxin|30 Units of botulinum toxin to upper face
75324708|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.5 mL, Subcutaneous
75631423|NCT02880800|Drug|Hydromorphone|Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h)
75918053|NCT02079831|Behavioral|Energy Restriction|"Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity."
75631424|NCT04383873|Device|Training by means of Armeo Spring device|This patients group receive 40 experimental sessions. Each session is based on 30 min by using Armeo Spring device.
75631425|NCT04383873|Other|Current treatment based on conventional therapy|All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.
75918054|NCT02079831|Behavioral|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
75918055|NCT02079831|Behavioral|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
75918056|NCT04827004|Drug|Anlotinib Hydrochloride Capsules|Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
76076126|NCT03836638|Drug|50 Units of botulinum toxin|50 Units of botulinum toxin to upper face
76076127|NCT01727128|Drug|BKM120|
76076128|NCT01727206|Drug|Tocilizumab|
75631426|NCT04383873|Other|Additional treatment based on conventional therapy|This intevention was added for providing the same amount of therapy than those patients randomly enrolled in the intervention group. So, patients in the control group receive other 30 min of conventional therapy added on current treatment during 40 sessions.
75631427|NCT02849145|Biological|Blood sampling|7,5 ml of patient peripherical blood will be collected at each blood sample.
75631428|NCT02847117|Other|Mastiha|The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
75631429|NCT01107392|Drug|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
75631430|NCT01107392|Drug|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
75631431|NCT04924803|Behavioral|No video|Weekly text messages
75631432|NCT04924803|Behavioral|Video Text|Weekly text messages including links to intervention videos
75631433|NCT05037279|Drug|Bacillus Calmette-Guerin: Strain Russian BCG-I|"Induction: 80 mg weekly for 6 weeks.~Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
75631434|NCT05037279|Drug|Bacillus Calmette-Guerin: Strain TICE|"Induction: 50 mg weekly for 6 weeks.~Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
75631435|NCT01106846|Drug|Group A: Saline Group|Saline continuous infusion
75631436|NCT01106846|Drug|Group B: 1% Ketamine group|Administration of 1% ketamine intravenously.
75631437|NCT05034783|Drug|[68Ga]Ga-HBED-CC-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) [68Ga]Ga-HBED-CC-exendin-4. Tracer doses of [68Ga]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.
75631438|NCT05034783|Drug|[68Ga]Ga-NOTA-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) [68Ga]Ga-NOTA-exendin-4. Tracer doses of [68Ga]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.
75631439|NCT04309526|Drug|NCO-48 Fumarate|NCO-48 Fumarate
75631440|NCT04309526|Drug|Placebo|Placebo
75631441|NCT00902577|Drug|FMISO|FMISO PET scans
75631442|NCT00902577|Other|MRI|Undergo MRI
75631443|NCT00902577|Other|PET|Undergo FMISO PET scan
75631444|NCT00902577|Other|MRS|
75631445|NCT04568889|Behavioral|A $10 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
75631446|NCT04568889|Behavioral|A $20 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
75631447|NCT04568889|Behavioral|Emphasis of Government Involvement|Individuals see a message emphasizing the involvement of the government in the study,
75631448|NCT04568889|Behavioral|Emphasis of Academic Researchers Involvement|Individuals see a message emphasizing the involvement of academic researchers in the study,
75631449|NCT04568889|Behavioral|Cost-Benefit Frame|Individuals will see messaging that emphasizes the public health benefits of answering the survey questions in the baseline survey (cost-benefit frame).
75631450|NCT04568889|Behavioral|Duty Frame|Individuals will see messaging that emphasizes an individual's responsibility to their community in the baseline survey (duty frame),
75631451|NCT04568889|Behavioral|Racial/Ethnic Frame|Individuals will see messaging that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups in the baseline survey.
75631452|NCT04568889|Behavioral|No Messaging|Individuals will see no messaging in the baseline survey.
75631453|NCT04202601|Drug|Sintilimab|"Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight<60Kg: 3mg/kg Q3W Weight>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight<60Kg: 3mg/kg Q3W Weight>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight<60Kg: 3mg/kg Q3W Weight>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
75324709|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Subcutaneous
75324710|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.05 mL, Intradermal
75324711|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Intradermal
75324712|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.15 mL, Intradermal
75324713|NCT02350569|Drug|LDV/SOF|90/400 mg FDC tablet administered orally
75324714|NCT02023515|Behavioral|Emotional brain training|Stress management based program
75918057|NCT00363012|Biological|HER-2/neu intracellular domain protein|300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
75918058|NCT00363012|Other|flow cytometry|This is a laboratory test used to assess the antigen specific T cell population.
75918059|NCT00363012|Other|immunohistochemistry staining method|This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
75918060|NCT00363012|Procedure|biopsy|A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
75918061|NCT00363012|Other|Sterile water placement|100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
76076129|NCT01724164|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
75468039|NCT01935830|Drug|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
75631454|NCT04202601|Drug|IBI310|"Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
75631455|NCT04215315|Other|Retrospective observation|Case note and imaging review
76076130|NCT01724164|Behavioral|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
76076131|NCT01724164|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
75782601|NCT03893708|Behavioral|Prenatal yoga|The prenatal yoga classes will be offered at Urban Wellness (2024 N. 7th St., Phoenix, AZ 85006). Classes will be offered Tuesdays's from 4:15-5:30 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
75918062|NCT02287506|Other|Optimised Diagnostic Strategy|(ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
75324715|NCT02023515|Behavioral|Behavioral weight loss|Standard behavioral weight loss
76076132|NCT01724164|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
76076133|NCT01724164|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
75631456|NCT04202367|Drug|1 mg.kg-1 bupivacaine 0.25%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
75918063|NCT04805476|Device|Non invasive mechanical ventilation|Prophylactic non invasive mechanical ventilation
75918064|NCT04805476|Device|GP|GP subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to team routine and patient need.
75324716|NCT00355017|Procedure|BNP-guided care in addition to multidisciplinary management|
75324717|NCT02350647|Device|Suture Anchor HEALOCOIL|Rotator cuff tears will be repaired intraoperatively using suture anchors
75324718|NCT02350647|Device|Suture anchor Twinfix Ultra HA|
75324719|NCT02350881|Device|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
75324720|NCT02023983|Other|Early discharge|Early discharge (within 72 hours) of selected patients with low risk of complications after myocardial infarction with ST segment elevation, treated with successful percutaneous coronary intervention
75324721|NCT02023983|Other|Standard discharge|Discharge after myocardial infarction with ST segment elevation in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day)
75324722|NCT02351115|Drug|A=Placebo|
75324723|NCT02351115|Drug|B=Inhaled Alprazolam 0.5 mg|
75324724|NCT02351115|Drug|C=Inhaled Alprazolam 1 m|
75631457|NCT04202367|Drug|1 mg.kg-1 bupivacaine 0.125%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
75631458|NCT02846805|Procedure|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
75631459|NCT00119847|Procedure|PCI|
75918065|NCT02283216|Device|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
75324725|NCT02351115|Drug|D= Inhaled Alprazolam 2 mg|
75324726|NCT02351115|Drug|E=Placebo|
75324727|NCT02351271|Device|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
75468040|NCT01935830|Drug|Efavirenz|Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
76076134|NCT01724242|Drug|Vaginal DHEA|
76076135|NCT01724242|Drug|Placebo|
75468041|NCT01935843|Biological|CART-HER-2|
75468042|NCT01935856|Drug|KHK7580|Oral administration
75468043|NCT01935869|Drug|LEO 90100|
75468044|NCT01935869|Drug|Vehicle|
75468045|NCT01935869|Drug|Petrolatum ointment|
75468046|NCT01935882|Drug|Artemether-lumefantrine combination|
75468047|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
75631460|NCT00119847|Drug|Optimal Medical Therapy|Guideline-directed drug therapies after MI
75468048|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
75631461|NCT02846493|Drug|bromocriptine|Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.
75782602|NCT03893708|Behavioral|Pregnancy education|Pregnancy education classes will be offered at the Arizona Biomedical Collaborative Building on ASU Phoenix Campus. Classes will be offered on Tuesday's from 5:30-6:45 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
75918066|NCT02283216|Device|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
75918067|NCT02283216|Device|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
75918068|NCT02075931|Other|Physical activity feedback with group meetings|Physical activity feedback
75918069|NCT02075931|Other|Control|No intervention
75918070|NCT04795180|Drug|Irrigations trough the efferent limb of loop ileostomy|Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
76076136|NCT01724320|Drug|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
76076137|NCT01837030|Dietary Supplement|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
75324728|NCT02351271|Device|Manual capsulorhexis&lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
75782603|NCT02527616|Device|FFR Infusion Microcatheter and standard intra-venous (IV) infusion|Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
75918071|NCT04471116|Dietary Supplement|OMNi-BiOTiC® FLORA plus+|OMNi-BiOTiC® FLORA plus + is a dietary supplement for the treatment of a disturbed vaginal flora (dysbiosis). The product combines probiotic bacterial strains with a special fiber mixture. The product contains the following strains: Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116
75918072|NCT02076087|Procedure|Liposuction/lipectomy|Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
75918073|NCT04471272|Procedure|RFA using gradual RF energy delivery mode with Octopus electrodes|RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
75918074|NCT02081937|Biological|anti-CD19-CAR vector-transduced T cells|
75918075|NCT04805242|Other|Dextrose Prolotherapy Injection|"Subacromial injection: 5 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: Previously marked using a sterile 27 gauge injector (dental needle); A total of 10 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the infraspinatus, teres minor, supraspinatus insertion on the tuberculum majus, the subscapularis insertion on the tuberculum minus, the coracoid process and the long head of the biceps.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
76076138|NCT01837030|Device|Capsule Endoscopy|GIVEN capsule
76076139|NCT01837108|Drug|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
76076140|NCT01837108|Drug|Placebo|
76076141|NCT01727596|Other|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
76076142|NCT01724398|Other|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
75324729|NCT02025075|Drug|Rocuronium|Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
76076143|NCT01724398|Other|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
76076144|NCT01724398|Other|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
76076145|NCT01724398|Other|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
76076146|NCT01724476|Drug|folate with B12|
76076147|NCT01724476|Drug|placebo|
76076148|NCT01724554|Drug|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
76076149|NCT01724632|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
76076150|NCT01727752|Procedure|Decompression|
75324730|NCT02351505|Drug|Selinexor|Given PO
75324731|NCT02351505|Other|Laboratory Biomarker Analysis|Correlative studies
75324732|NCT02351505|Other|Pharmacological Study|Correlative studies
76076151|NCT03835936|Other|High frequency compression of the chest wall group|The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.
75918076|NCT04805242|Other|Saline Injection|"Subacromial injection: 5 cc solution (saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: 5 cc solution (saline + 1% lidocaine solution) will be injected to the attachment areas of the previously marked tendons to the bone using a sterile 30 gauge injector.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
75918077|NCT02285712|Device|Vascular ultrasound system|
75631462|NCT02846493|Drug|dexamethasone|Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
75918078|NCT02082015|Device|Low frequency rTMS|Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
75918079|NCT04805086|Biological|MON002|Autologous monocytes
75918080|NCT02285790|Device|Reflectance confocal microscopy|
76076152|NCT03835936|Other|Manual maneuvers physiotherapy group|20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
75468049|NCT01935895|Behavioral|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
75782604|NCT01258322|Drug|Pioglitazone|The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
75782605|NCT01148732|Procedure|ultrasonography|a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
75918081|NCT02285790|Procedure|Punch biopsy|
75918082|NCT02285790|Procedure|Surgical excision|Excision of the suspected basal cell carcinoma lesion under local anesthetics
75918083|NCT04804852|Other|sarcopenia assessment|evaluation of sarcopenia by CT san at the C3 vertebrae
76076153|NCT01837342|Procedure|Surgical reserction|
76076154|NCT01837342|Other|Radiological percutaneous drainage and washing drainage|
76076155|NCT03835624|Diagnostic Test|interleukin 33|serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
76076156|NCT01727830|Other|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
76076157|NCT01727908|Other|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
76076158|NCT01837420|Drug|VB-201 80mg|
76076159|NCT01837420|Drug|VB-201 160mg|
76076160|NCT01837420|Drug|Placebo|
76076161|NCT01727986|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
76076162|NCT01724788|Drug|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
76076163|NCT01724788|Drug|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
76076164|NCT01837498|Drug|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
76076165|NCT01837498|Drug|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
76076166|NCT01705574|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally with food once daily
76076167|NCT01705574|Drug|ATV|300 mg capsule administered orally with food once daily
76076168|NCT01705574|Drug|RTV|100 mg tablet administered orally with food once daily
76076169|NCT01705574|Drug|FTC/TDF|200/300 mg tablet administered orally with food once daily
75918084|NCT02088021|Device|Portico Transcatheter Aortic Valve|Placement of the SJM Portico aortic valve with a ALC delivery system
75918085|NCT04826380|Procedure|Trapeziectomy|Simple trapeziectomy (without LRTI)
75918086|NCT02285946|Procedure|major spine surgery|
75918087|NCT02083341|Device|Lelo® Siri vibrator|external vibration device
75918088|NCT02083341|Device|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
75918089|NCT02083419|Device|LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
75918090|NCT00358878|Drug|Satavaptan|oral administration once daily
75918091|NCT00358878|Drug|placebo|oral administration once daily
75918092|NCT02082093|Device|Telemedicine System|
76076170|NCT01705574|Drug|E/C/F/TDF Placebo|Tablet administered orally with food once daily
75324733|NCT00242567|Drug|Zoledronic Acid|"Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes."
75324734|NCT00242567|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
75324735|NCT00241631|Drug|Fluticasone Propionate|500 u
75324736|NCT00241631|Drug|placebo|
75324737|NCT00241631|Drug|Theophylline|Theophylline placebo capcule
75468050|NCT01935908|Drug|levetiracetam|
75468051|NCT01935960|Other|Laboratory Biomarker Analysis|Correlative studies
75631463|NCT03636789|Other|Neurological consultation|study of horizontal, vertical, reflex and voluntary saccades, and of horizontal and vertical ocular pursuit by a BrainTracker eye-oculography system
75631464|NCT01106690|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
75631465|NCT01106690|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
75782606|NCT03893786|Device|Robotic Rehabilitation|"Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
75782607|NCT01255358|Drug|Dexamethasone|dexamethasone encapsulated in human erythrocytes. One infusion per month of about 10-15 mg of dexamethasone. The treatment covers 1 month of therapy-
75782608|NCT03899558|Device|Humidified nasal high-flow device|Humidified nasal high-flow device which delivers warmed, humidified air at flow rates of up to 60 litres per minute via a nasal cannula interface. Intended delivery at 30 L/min at 37 degrees Celsius, if tolerated.
76076171|NCT01705574|Drug|ATV Placebo|Tablet administered orally with food once daily
75782609|NCT03904706|Other|Audits only|Formalized audit teams with monthly meetings at each facility.
75782610|NCT03904706|Other|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
75782611|NCT03899480|Biological|Haploidentical Natural Killer (NK) Cells|infusion with N-803 activated NK cells
75782612|NCT03899246|Drug|Eight Percent Topical Capsaicin|See arm description
75918093|NCT05618860|Other|Questionnaire|eligible participants in the radiology department waiting rooms will be asked to complete a questionnaire after taking consent.
75782613|NCT01150058|Genetic|western blotting|
76076172|NCT01705574|Drug|RTV Placebo|Capsule administered orally with food once daily
75782614|NCT01150058|Other|flow cytometry|
76076173|NCT01705574|Drug|FTC/TDF Placebo|Tablet administered orally with food once daily
75468052|NCT01935960|Other|Pharmacological Study|Correlative studies
75782615|NCT01150058|Other|laboratory biomarker analysis|
75782616|NCT03893552|Device|Negative expiratory pressure|Using a cough assist, a negative expiratory pressure will be applied while recording the respiratory flow in patients suffering from sleeping disorders or snoring.
75782617|NCT03893864|Dietary Supplement|Administration of a product with Fitosomed Ubiquinone|Healthy runner athletes, > 50 years old, without any chronic illness, without any other nutritional supplementation or drug intervention, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions.
75468053|NCT01935960|Other|Placebo|Given PO
75918094|NCT02082171|Other|Multidomain intervention|Multidomain preventive intervention designed by a multidisciplinary team on the basis of results of a comprehensive geriatric assessment
75918095|NCT02283372|Drug|nab-Paclitaxel|
75918096|NCT02283372|Drug|Gemcitabine|
75918097|NCT02283372|Radiation|Intensity modulated radiation|
75918098|NCT00507936|Drug|ABT-894|ABT-894 1 mg capsule BID throughout treatment period
75918099|NCT00507936|Drug|ABT-894|ABT-894 2 mg capsule BID throughout treatment period
76076174|NCT01705574|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally with food once daily
75631466|NCT01106690|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
75631467|NCT01106690|Drug|Metformin|The patient's stable dose of metformin background therapy should be continued throughout the study.
75631468|NCT01106690|Drug|Pioglitazone|The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
75631469|NCT02850315|Device|optimal coherence tomography|
75631470|NCT02690805|Device|MR-compatible scinti-mammography (MRI-SMM) system|
75631471|NCT02850393|Other|Functional magnetic resonance imaging|
75918100|NCT00507936|Drug|ABT-894|ABT-894 4 mg capsule BID throughout treatment period
76076175|NCT04378660|Diagnostic Test|Artificial intelligence for polyp detection|Colonoscopy enriched with artificial intelligence tool developed for polyp detection, implemented as a second observer
75631472|NCT02850393|Behavioral|behavioral measures|
75631473|NCT02850393|Other|physiological measurements|
75631474|NCT02880566|Procedure|Scalp block|Full scalp block
75782618|NCT03893864|Procedure|Coenzyme Q10 level in muscle biopsies|Determination of the muscle Ubiquinone concentration, the metabolic and structure characteristics of the muscle before and after one month of supplementation
75782619|NCT03893864|Diagnostic Test|Coenzyme Q10 level in plasma, blood cells, urine cells|Determination of Ubiquinone concentration in different tissues before and after one month of supplementation or not
75782620|NCT03893864|Diagnostic Test|Total antioxidant capacity after strenous exercise|Determination of the Total Antioxidant Capacity after strenous exercise in the Climate Chamber
75782621|NCT03893474|Diagnostic Test|OCT|Optical Coherence Tomography of study eye.
75782622|NCT03893474|Diagnostic Test|Visual Acuity|Visual acuity measured by ETDRS
75782623|NCT01151930|Drug|SCB01A|This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
75782624|NCT03893084|Other|Pregnancy preparation training|Pregnancy preparation education; folic acid use, physical activity, nutrition, addictions counseling issues are included.
75782625|NCT01148888|Drug|Magnesium|Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
75782626|NCT03904394|Other|Exercise|Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery
75782627|NCT03899168|Other|Social Tag Popularity|The relative size of treatment tags in a tag cloud was either larger for antidepressant treatments or psychotherapy treatments.
75782628|NCT03899168|Other|Confidence in Prior Attitudes|Participants thought back of situations in which they were either confident or doubtful about their own knowledge. This should elicit a mindset where participants are more or less confident about their own prior attitudes.
75782629|NCT03899168|Other|Source Credibility|The source credibility of the community that allegedly collected and labelled the blog posts was either high or low in terms of expertise. Either experts (high credibility) or first semester students (low credibility) did allegedly collect blog posts. This was indicated by banners on top of the navigation platform in the internet browser.
75782630|NCT03899324|Drug|Bumetanide white, oblong, scored tablet|Bumetanide with a titration period
75782631|NCT03899324|Drug|Placebo white, oblong, scored tablet|placebo intake identically to group 1
75782632|NCT01258478|Other|Rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
75782633|NCT01258478|Other|Usual care|Usual care
75782634|NCT05507996|Drug|Recombinant adeno-associated virus administration|The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.
75782635|NCT03893006|Device|Level of vehicle automation|From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.
76076176|NCT01837576|Drug|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
75324738|NCT05744141|Procedure|Relaxation Exercises|"Relaxation exercises consist of voluntary, rhythmic and regular stretching and relaxation of large and small muscle groups until the whole body relaxes. For this exercise application, the Relaxation Exercises CD prepared by the Turkish Psychological Association will be used. The CD consists of 30 minutes and relaxation exercises are explained with the sound of a stream accompanied by verbal instructions. This exercise includes rhythmic breathing, muscle relaxation exercises and music (stream sound)."
75324739|NCT02351739|Drug|pembrolizumab|
75324740|NCT02351739|Drug|ACP-196 in combination with pembrolizumab|
75782636|NCT02527538|Device|Pleth|apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
75918101|NCT00507936|Drug|placebo|placebo capsule BID throughout the treatment period
75918102|NCT00507936|Drug|Duloxetine|Duloxetine 60 mg QD throughout treatment period
75918103|NCT02083497|Other|rigid bandage|
75631475|NCT04308356|Behavioral|Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA)|interview 2
75631476|NCT04308356|Other|Autonomy Preference Index (API ) questionnaire - Information|part of interview 1
75631477|NCT04308356|Other|anxiety and depression (HADS) questionnaire|part of interview 1
75631478|NCT04286529|Drug|Calcitriol capsules|0.25micrograms, taken daily for eight weeks, orally
75631479|NCT04286529|Drug|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
75631480|NCT01103180|Drug|Escitalopram|10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
75631481|NCT02848911|Drug|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
75631482|NCT00625898|Drug|Docetaxel|"75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B"
75782637|NCT01258556|Dietary Supplement|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10*9 cfu/ml daily for 30 days.
75782638|NCT01258556|Dietary Supplement|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
75782639|NCT01148966|Drug|aminolevulinic acid|Given PO
75782640|NCT01148966|Other|laboratory biomarker analysis|Correlative studies
75782641|NCT01148966|Procedure|therapeutic conventional surgery|Standard brain tumor surgery with intra-operative frameless MRI stereotactic guidance and intra-operative ultrasound guidance
75782642|NCT01258634|Drug|Dexrazoxane|"Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1"
75918104|NCT02083497|Other|elastic bands|
75918105|NCT02083497|Other|without the use of banding|
75918106|NCT04427020|Dietary Supplement|Milk protein + GBI-30|Both conditions matched flavor, color, and serving size
75324741|NCT05744063|Drug|Emapalumab-Lzsg 5 MG/ML [Gamifant]|iv
75468054|NCT01935960|Drug|Retinoid 9cUAB30|Given PO
75631483|NCT00625898|Drug|Trastuzumab|"First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B"
75782643|NCT01258634|Drug|Doxorubicin|"Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0"
75782644|NCT01258634|Drug|Cisplatin|"Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Poor Responders:~Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol"
75782645|NCT01258634|Drug|G-CSF|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000~Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000"
75782646|NCT01258634|Drug|PEG-filgrastim|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy"
75782647|NCT01258634|Drug|Etoposide|"Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1~Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4"
75782648|NCT01258634|Drug|Ifosfamide|"Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4"
75782649|NCT01258634|Drug|Mesna|"Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)"
75782650|NCT01258634|Drug|Leucovorin|Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is <0.1 uM
75324742|NCT00240071|Drug|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
75324743|NCT00240071|Drug|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
75324744|NCT00240383|Drug|Muraglitazar|
75468055|NCT01935973|Other|Laboratory Biomarker Analysis|Correlative studies
75468056|NCT01935973|Drug|Trametinib|Given PO
75468057|NCT01935973|Drug|Uprosertib|Given PO
75631484|NCT00625898|Drug|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
75918107|NCT04427020|Dietary Supplement|Milk protein|Both conditions matched flavor, color, and serving size
75918108|NCT02083575|Drug|Vitamin C, Defriprone, deferisarox|adjuvant vitamin c with iron chelator.
75631485|NCT00625898|Drug|Bevacizumab|"15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B"
75918109|NCT02083575|Drug|deferiprone , deferesarox|iron chelator
76076177|NCT04378738|Behavioral|survey|all people in the cohort
75468058|NCT01935986|Dietary Supplement|probiotic|
75468059|NCT01935986|Dietary Supplement|placebo|
75324745|NCT02352363|Drug|CVT-301|
75324746|NCT02352363|Other|Observational cohort|
75324747|NCT03805139|Dietary Supplement|Ajwa Date (phoenix dactylifera)|Effect of Ajwa on Dyslipidemia
75324748|NCT00765947|Drug|Aliskiren|Aliskiren 150 or 300 mg
75324749|NCT00765947|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg
75324750|NCT00765947|Drug|Amlodipine|Amlodipine 5 or 10 mg
75324751|NCT05743907|Drug|DA-2811|DA-2811 Group: DA-2811 + Forxiga placebo
75324752|NCT05743907|Drug|Forxiga|Forxiga Group: Forxiga + DA-2811 placebo
75468060|NCT01935999|Device|One piece closed pouch|A one piece closed pouch for the collection of stool from a colostomy stoma
75468061|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
75631486|NCT00625898|Drug|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
75631487|NCT00625898|Drug|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
75631488|NCT00625898|Drug|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
75324753|NCT03805061|Other|'aerobic exercise'|The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed a period of; 8 weeks, 3 days a week, 30-45 minutes each patient.
75631489|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
75631490|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
75918110|NCT04794946|Biological|Covishield|2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.
75631491|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
75631492|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
75631493|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
75631494|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
75631495|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
75631496|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
75631497|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
75631498|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
75468062|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
75468063|NCT01936025|Drug|Dextromethorphan|
75782651|NCT03904628|Drug|TG02 capsules oral administration, BIW in every 28d|TG02 capsules150mg oral administration, BIW in every 28d
75631499|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
75631500|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
75782652|NCT03904628|Drug|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 200mg oral administration, BIW in every 28d
75782653|NCT03904628|Drug|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 250mg oral administration, BIW in every 28d
75324754|NCT03805061|Device|'isokinetic exercise'|Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low exercise and exercise was applied for 5-10 minutes to cool down at the end of the study. were included in a rehabilitation program that they would apply for 3 days per week for 8 weeks.The measuring of isokinetic muscle strength, CSMI Humac Norm isokinetic dynamometer's commonly used angular velocities of 60 ° and 180 ° / sec was used.
75324755|NCT00766649|Drug|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
75324756|NCT02352831|Drug|Tosedostat|
75324757|NCT02352831|Drug|Capecitabine|
75468064|NCT01936025|Drug|Sitagliptin|
75468065|NCT01936025|Drug|Placebo|
75468066|NCT01936038|Other|CPAP|CPAP
75468067|NCT01936038|Procedure|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
75468068|NCT01936064|Dietary Supplement|Jobelyn + Cyclophosphamide-Epirubicin6|Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6
75468069|NCT01936064|Drug|Placebo + Cyclophosphamide - Epirubicin 6|Routine drugs for the treatment of breast cancer to be used with Placebo
75468070|NCT01936077|Drug|Recombinant LH (Luveris)|150 IU recombinant LH daily.
75468071|NCT01936090|Drug|Bortezomib|Given IV
75782654|NCT01258712|Drug|Tocilizumab + methotrexate(MTX)|Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
75782655|NCT01258712|Drug|Tocilizumab placebo + methotrexate(MTX)|Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
75782656|NCT03904160|Behavioral|Weight management|Please see the arm descriptions.
75782657|NCT01258868|Drug|Celebrex|400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.
75782658|NCT01258868|Biological|Tumor cell vaccine|A minimum of 1x10e7 and a maximum of 1x10e8 patient tumor cells that have been exposed to 1 mcM decitabine for 6 days, exposed to 100 Gy radiation and emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections; if subject shows immune response, vaccine will be given every three months from months 9 - 24
75782659|NCT01255514|Drug|high dose dexamethsone|high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
75782660|NCT01254578|Other|Laboratory Biomarker Analysis|Correlative studies
75782661|NCT01254578|Drug|Lenalidomide|Given orally
75782662|NCT01254578|Other|Pharmacological Study|Correlative studies
75782663|NCT03892850|Behavioral|Nurse prescription|Pharmacological nurse prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
75918111|NCT00358722|Drug|Fermagate|Film coated tablet 500mg
75918112|NCT02088099|Other|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
75631501|NCT02853240|Procedure|Muscle biopsy|A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
75631502|NCT02853552|Drug|Misoprostol|800mcg misoprostol taken sublingually
75631503|NCT02850471|Device|electroacupuncture|Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
75631504|NCT04202055|Other|Biomarker analysis|Detection of biomarker in cerebrospinal fluid
75631505|NCT02853396|Other|Cognitive Behaviour Therapy|
75631506|NCT02853396|Other|Psychoeducation|
75631507|NCT02846727|Device|skin perfusion image|Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
75631508|NCT02857296|Other|interview and observation|
75782664|NCT03892850|Behavioral|Medical prescription|Pharmacological medical prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
75918113|NCT02088099|Other|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
75918114|NCT04804462|Device|Virtual Reality Meditation|After donning the VR headset, participants will be able to use a handheld controller to choose from several virtual outdoor settings, three types of meditation, and three session lengths. After choosing their desired option, participants will experience virtual reality meditation in the desired virtual location, of the desired meditation type, and for the allotted duration chosen.
75631509|NCT02846649|Behavioral|PIER|Daily text message queries with tailored support
75782665|NCT01152008|Other|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
75918115|NCT03134040|Behavioral|Incentives (Rebate)|
75631510|NCT02854956|Behavioral|Neuropsychological, cognitive and behavioral assessment|"The assessment includes mainly :~The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient~The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient~The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).~The Vineland adaptive behavioral scale which allow to assess the adaptive behavior~The Nisonger child behavior rating form which allow to assess the behavior disorders~Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.~Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component."
75631511|NCT04258917|Device|Study withdrawn|Study withdrawn
75631512|NCT02857452|Other|SLA Questionnaire|
75918116|NCT03134040|Behavioral|Incentives (Donation)|
75918117|NCT03134040|Behavioral|Feedback|
75918118|NCT02082249|Drug|ABT-SLV187|Dose levels will be individually optimized
75324758|NCT02352831|Procedure|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
75324759|NCT00766727|Device|GLYDe Dressing|Wound dressing intended to minimize scar formation
75631513|NCT02857452|Other|Lupus Qol Questionnaire|
75631514|NCT04268472|Drug|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
75782666|NCT03904082|Procedure|Erector Spinae Plane block ( Group ı)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
75324760|NCT04275479|Diagnostic Test|Oral Glucose Tolerance Test|This is a two step process. Subjects will be asked to fast overnight,(no food and only water to drink for at least 8 hours). Then when subjects arrive for the visit,participants will have blood drawn and be asked to drink a sugary liquid. One hour later, another blood sample will be drawn and after two hours a final blood sample will be drawn.
75468072|NCT01936090|Radiation|Total-Body Irradiation|Undergo TBI
75631515|NCT04268472|Drug|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
75631516|NCT04268472|Drug|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
75631517|NCT04268472|Drug|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
75782667|NCT03904082|Procedure|Serratus Anterior Plane block ( Group ıı)|SAP Block will perform preoperative to all patients in SAP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
75631518|NCT02846337|Procedure|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
75324761|NCT04275479|Other|Modified Oral Glucose Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). There will be no blood drawn during this test, participant will be asked to drink a sugary liquid and to remaining fasting (water only) for the two hour after finishing the drink.
75324762|NCT04275479|Other|Modified Mixed Meal Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.
75468073|NCT01936090|Drug|Melphalan|Given IV
75782668|NCT03904082|Procedure|Control Group (GROUPIII)|Control group will receive no intervetion. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
75782669|NCT05667194|Drug|KH617|KH617 is s freeze-dried powder injection
75468074|NCT01936090|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
75782670|NCT03903926|Biological|5000 volunteers (6-35 months)-EV71 vaccine|two doses EV71 vaccines will be administrated on day 0, 30 respectively
75782671|NCT03903848|Other|Exercise|Single session of treadmill walking and resistance exercise
75782672|NCT01152086|Other|Mountain hiking in the Austrian and Bavarian Alps|"Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~Endurance training (performed within 70-85% of the maximum heart rate)~Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~Stretching after hiking (ca. 5 min)~Short break at half-time (ca. 15 min)"
75782673|NCT03904238|Behavioral|Cognitive-Behavior Therapy for Hypersomnia (CBT-H)|"The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., I cannot live a full life because of my illness), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia."
75782674|NCT01149044|Procedure|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
75782675|NCT03315130|Drug|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
75468075|NCT01936090|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
75468076|NCT01936090|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
75782676|NCT03315130|Drug|Placebo|Daily subcutaneous (SC) injection
75324763|NCT04275479|Device|Continuous Glucose Monitor|The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).
75468077|NCT01936090|Other|Laboratory Biomarker Analysis|Correlative studies
75468078|NCT01936103|Drug|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
75468079|NCT01936103|Drug|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
75782677|NCT01152164|Behavioral|questionnaires|Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
75324764|NCT04275479|Other|Food Diary|The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.
75782678|NCT03892382|Device|rTMS|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.
75782679|NCT03273166|Device|INVSENSOR00001|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
75782680|NCT03273166|Device|Control SpHb sensor|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
75782681|NCT03273166|Procedure|Hemodilution|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers while undergoing a hemodilution procedure.
75468080|NCT01936116|Device|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
75468081|NCT01936116|Device|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
75468082|NCT01936129|Drug|Copaxone|
75468083|NCT01936129|Drug|Placebo (buffered normal saline w/v)|
75468084|NCT01936142|Device|Use of RenalGuard|
75468085|NCT01936155|Device|Custom-built, two-channel stimulator|Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
75468086|NCT01936168|Device|Mechanochemical Endovenous Ablation (MOCA)|Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
75468087|NCT01936168|Procedure|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
75918119|NCT02286258|Drug|Calcium EDTA|"Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
75324765|NCT04275479|Other|Medical History Questionnaires|The participant will be asked to provide detailed medical history
75782682|NCT01152242|Drug|Isoglycemic Clamp|Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
75468088|NCT01936194|Dietary Supplement|DHA+EPA|
75631519|NCT02846337|Procedure|ENHANCED MEDICAL TREATMENT|"Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~Medical care adjustment in order to apply European and American guidance for chronic heart failure care~Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~Physical rehabilitation suggestions by a physiologist~Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
75631520|NCT04269018|Behavioral|Cancer specific Mobile text message|The intervention is cancer specific lifestyle mobile text messages daily for 2 months
75782683|NCT01152242|Drug|Comparator: insulin glargine|Insulin glargine at 0.4 U/kg
75782684|NCT03341806|Drug|Avelumab|Avelumab will be administered intravenously every 2 weeks at a dose of 10 mg/kg for 2 cycles
75782685|NCT03341806|Combination Product|MRI-guided LITT therapy|(Part B) prior to receiving Avelumab 10 mg/kg every 2 weeks + LITT
75468089|NCT01936194|Dietary Supplement|High Olive Oil|
75782686|NCT01255826|Procedure|Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP|After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is < 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
75782687|NCT01255826|Procedure|Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.|After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
75782688|NCT03904004|Procedure|Peroral endoscopic myotomy|Endoscopic myotomy after performing a tunnel to reach the muscular layer through a mucosal incision
75324766|NCT02353299|Drug|Silenor 6 mg|Silenor 6 mg single nighttime dose.
75631521|NCT04269018|Behavioral|General health messages|Daily text related with general health message
75782689|NCT03904004|Procedure|Neumatic dilatation|Inflation of a ballon of specific diameter in the gastro-oesophageal junction
75782690|NCT03904004|Procedure|Botulinum toxin injection|Injection of botulinic toxin to inhibit the contraction of the gastro-oesophageal junction muscular layer
75782691|NCT03904004|Procedure|Laparoscopic Heller Myotomy|Five or six small incisions are made in the abdominal wall and laparoscopic instruments are inserted. The myotomy is a lengthwise cut along the oesophagus, starting above the lower oesophageal sphincter (LOS) and extending down onto the stomach a little way. The oesophagus is made of several layers, and the myotomy only cuts through the outside muscle layers which are squeezing it shut, leaving the inner mucosal layer intact.
75324767|NCT02353299|Drug|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
75918120|NCT02286258|Drug|Gd-DOTA|"Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
75918121|NCT04826146|Device|Validation of qCON versus BIS|Correlation between qCON and BIS values (main outcome) and qNOX and MOAA/S scale are determined
75918122|NCT02088255|Procedure|Static surface|During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
75918123|NCT02088255|Procedure|Dynamic surface|During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
75324768|NCT02353299|Drug|Placebo|placebo single nighttime dose-1.5 hours
75918124|NCT04794556|Device|tight-fitting of KF94 mask with clip|The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method
75324769|NCT02353299|Drug|Placebo|placebo single nighttime dose-4 hours
75324770|NCT00756977|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
75324771|NCT00756977|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
75324772|NCT02027883|Device|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
75324773|NCT02027883|Device|Educated T shock setting|Experimental Parameter Set 2 Programming Values
75324774|NCT00783965|Drug|tazarotene|Applied to the skin
75324775|NCT00783965|Other|placebo|Applied to the skin
75468090|NCT01936194|Dietary Supplement|DHA|
75468091|NCT01936220|Behavioral|Continuity of specialized care|Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
75918125|NCT03133728|Diagnostic Test|Alere Q Testing|Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.
75631522|NCT04308980|Dietary Supplement|Specialized product for medical nutrition (SPP-1)|"Patients randomly allocated to this group will use specialized product for medical nutrition (SPP-1). This product contains: soy protein, whey protein concentrate, microcapsulated rapeseed oil, maltodextrin, inulin, Polydextrose, soy lecithin, potassium citrate, magnesium lactate, ω-3 PUFA (docosahexaenoic acid), sweetener mixture (stevia extract, erythritol), natural flavor Yogurt-vanilla, calcium carbonate, betaine hydrochloride, natural flavor raspberry, vitamin premix (vitamins a, e, C, D3, B1, B2, B6, B12, PP, folic acid, Pantothenic acid, K1, Biotin), beet juice concentrate, carrageenan, mineral premix (iron, zinc, copper, manganese, iodine, selenium, molybdenum, chromium), alpha-lipoic acid. The product is packed in approved by sanitary rules bags by 30 g. The instant drink obtained by the mixture of the bag content with warm (30-60C) water should be used immediately after being prepared. The daily dose is 1 pack TID"
75918126|NCT02088411|Drug|Diclofenac|
75918127|NCT02088411|Dietary Supplement|Wobenzym|
75782692|NCT03903770|Device|Upper extremity rehabilitation|Participants receive the SUPER intervention 3 times per week for 1 hr, during 4 weeks. For participants with a low recovery potential for hand function, the SUPER interventions consists in robot-assisted reaching movements and unilateral and bilateral VR activities. The robot-assisted activity consists of a reaching task to six targets placed at maximal reach distance. For the VR activity, we use a reach and grasp VR activity based on a shopping task. Participants with good potential for hand recovery also receive 30 min of electromyography-triggered muscle stimulation, combined with the VR activity. The muscle stimulation is triggered when the participant attempts to grasp a virtual object and helps with hand opening movements.
75918128|NCT02088411|Other|Placebo|
75918129|NCT04794712|Device|Venous reflux tools (Ultrasound and Photo plethysmography (PPG))|Venous reflux tools Pain assessment tools
75918130|NCT02082327|Drug|IV migalastat HCl|
75918131|NCT02082327|Drug|IV placebo|
75918132|NCT02082327|Drug|oral migalastat HCl|
75782693|NCT01152320|Behavioral|Spirometry Fundamentals™ Training CD|MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
75918133|NCT04469946|Device|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
75918134|NCT03559101|Other|Distilled water|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
75918135|NCT03559101|Other|Medical Food 1|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
75918136|NCT03559101|Other|Medical Food 2|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
75782694|NCT01149122|Drug|Gemcitabine/Oxaliplatin|GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks
75782695|NCT01149122|Drug|Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)|GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
75782696|NCT01152398|Biological|MVA-BN-HER2|experimental vaccine, subcutaneous injection q4weeks x6
75782697|NCT03903614|Behavioral|SML|SML consists of supervised handwriting practice, fitness exercises, and fine motor speed drills that preferentially belabor a participant's right eye, ear, hand and leg during therapy.
75782698|NCT03903614|Behavioral|CON|CON consists of supervised handwriting practice, fitness exercises, and fine motor speed drills on the participant's dominant hand.
75918137|NCT03559101|Other|Pedialyte|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
75918138|NCT03559101|Other|Gatorade|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
75918139|NCT04794244|Behavioral|ASGE-FABES Program|In the control group study, pretest-posttest and experimental design with repeated measurements were used in randomized groups. An overweight and obese adolescent constituted the sample of 250 (125-experiment, 125-control) of the study. Research data Socio-Demographic Features Information Form, Adolescent Nutrition Information Scale, Adolescent Physical Activity Information Scale, Adolescent Lifestyle Scale, Healthy Lifestyle Choice Scale for Adolescents, Beck Anxiety Scale, Daily Food Consumption Form, Beverage Consumption Form, collected using. Data are saved before and after application. ASGEFABES PROGRAM was applied to the experimental group for 10 weeks. Measurements after the training program were collected in four measurements: 1st week, 6th and 12th months.
75918140|NCT04470336|Other|Collagen Supplement|Three capsules post-breakfast Three capsules post-dinner
75918141|NCT04470336|Other|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
75918142|NCT04470336|Other|Placebo|Three capsules post-breakfast Three capsules post-dinner
75918143|NCT02083731|Biological|MSCs|
75782699|NCT01150214|Procedure|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
75631523|NCT04308980|Behavioral|individualized diet|All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine
75324776|NCT02354859|Drug|Gallium nitrate|Study subjects will receive an infusion of either placebo or gallium nitrate.
75324777|NCT02354859|Drug|Normal Saline|Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
75324778|NCT00421551|Drug|Darunavir|during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
75468092|NCT01936220|Behavioral|Parent groups combined with Continuity of Specialized care|Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
75468093|NCT01936220|Behavioral|Discontinuity of care, non specialised care|Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
75468094|NCT01936233|Drug|Aspirin|Aspirin 0.1 QD po
75468095|NCT01936233|Drug|Lamivudine|LAminvudine 0.1 QD po
75468096|NCT01936246|Dietary Supplement|Increased protein|
75918144|NCT04441242|Other|Ambient lighting|Use of ambient lighting (75-150 lux) in endoscopy room.
75918145|NCT04441242|Other|Low lighting|Use of low lighting (<75 lux) in endoscopy room.
75918146|NCT02083887|Biological|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10^10 vp and MVA ME-TRAP 1 x 10^8 pfu
75918147|NCT02604550|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
75918148|NCT02604550|Drug|Percocet 7.5/325|Percocet 7.5/325 will taken as needed up to every four hours.
75918149|NCT02604550|Drug|Naprosyn 500 mg|Naprosyn 500 mg will be taken twice daily.
75468097|NCT01936285|Drug|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
75468098|NCT01936285|Drug|Placebo|
75468099|NCT01936298|Device|A-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
75468100|NCT01936298|Device|P-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
75631524|NCT02844621|Drug|Omeprazole|20mg orally once daily
75631525|NCT02853162|Radiation|ARREST-study|Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
75631526|NCT02844699|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
76076178|NCT01728142|Device|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
76076179|NCT01728142|Other|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
76076180|NCT01837732|Other|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
75324779|NCT00421551|Drug|ritonavir|during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
75324780|NCT02356107|Drug|5-hydroxytryptophan and Creatine monohydrate|
75324781|NCT00767507|Drug|cangrelor|
75324782|NCT00767507|Other|Placebo|Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
75631527|NCT02844699|Drug|Placebo|5% infusion solution of dextrose (glucose)
75782700|NCT03892148|Drug|Furosemide|Protocol for the use of diuretics
75782701|NCT03892148|Drug|Hydrochlorothiazide|Protocol for the use of diuretics
75782702|NCT01152476|Drug|remifentanil|General anesthesia is maintained witn sevoflurane and remifentanil.
75782703|NCT01152476|Drug|normal saline|General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
75918150|NCT00388518|Drug|Actos|45mg po daily
75918151|NCT00388518|Drug|Placebo|po daily
75918152|NCT00388518|Drug|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
76076181|NCT01837732|Other|Relational:|Relational: 10 mn verbal patient's centered exchanges
75918153|NCT02084043|Drug|Nebulization of Amikacin during NIV (RR: 15 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
75918154|NCT02084043|Drug|Nebulization of Amikacin during NIV (RR: 25 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
75918155|NCT04825444|Device|Photoacoustic inspection|Use photoacoustic imaging system to image breast blood vessels
75918156|NCT02084199|Drug|GLPG0634|100 mg oral tablet, intake once daily for 10 days
75918157|NCT04804150|Device|Vacuum suspension system active or inactive|The device will be plugged in, or won't be plugged in, depending of the randomization. The patient and the investigator will not know whether the device is plugged in or not, and if the medical device is active or not
75918158|NCT02286336|Other|brachial plexus block|brachial plexus block with ropivacaine 40ml
75918159|NCT04470258|Other|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The Elmo system will be applied to 10 patients with hypoxemic respiratory failure by COVID-19 and its effectiveness will be assessed by analyzing the physiological variables and the patient's comfort, as well as their clinical outcomes (need for tracheal intubation) and recovery time. Hypoxemic respiratory failure and need for O2.
75324783|NCT02029755|Procedure|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
75324784|NCT02029755|Procedure|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
75631528|NCT02848677|Behavioral|Nutritional counseling|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
75631529|NCT02848677|Behavioral|usual care|usual care of hypertensive patients.
75324785|NCT02029755|Procedure|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
75631530|NCT00941304|Drug|Oxycodone|Single-dose of over-encapsulated oral 5-mg oxycodone capsule
75918160|NCT04470258|Device|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|After testing for the following requirements: offering CPAP, ensuring the maintenance of alveolar ventilation without CO2 rebreathing, monitoring intra-ELMO pressure, minimizing adverse effects of the system such as noise, face temperature, airway dryness and comfort global; tests will be carried out on healthy volunteers using prototypes of the Elmo system and assessing whether their effectiveness in providing positive airway pressure and their usability from the perspective of their primary users (doctor, physiotherapist and nurses) and the volunteer's comfort . With this, realistic simulations will be carried out, centered on the evaluation based on heuristic principles.
75918161|NCT02591290|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular (2 doses with 8-week interval)
75918162|NCT04470102|Procedure|mitral valve repair by edge-to-edge technique|transaortic access for mitral valve repair edge-to-edge
75324786|NCT05743829|Procedure|Tissue excision as part of routine clinical care|Tissue excision
75324787|NCT03804749|Drug|suramin sodium|The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
75468101|NCT01936311|Behavioral|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
75631531|NCT00941304|Drug|Buprenorphine|Single-dose of buprenorphine HCl buccal film
75631532|NCT00941304|Drug|Placebo Film|Single-dose of placebo buccal film
75631533|NCT00941304|Drug|Placebo Capsule|Single-dose of oral placebo capsule
75631534|NCT02845869|Device|THOR Laser LX2 System|Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
75631535|NCT02845869|Device|Sham Therapy|The therapeutic light will be turned off but the system will produce similar noises and mild heat.
75918163|NCT04470102|Procedure|Septal myectomy|isolated extended septal myectomy
75918164|NCT02791893|Device|VNS device|Hand held device to use for self administration of vagus nerve stimulation.
75918165|NCT02791893|Device|Inactive device|Hand held device to use for self administration of simulated vagus nerve stimulation.
75324788|NCT03804749|Other|placebo|Placebo is 0.9% sodium chloride injection.
75324789|NCT03804515|Drug|14C-labeled poziotinib|a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally
75468102|NCT01936337|Drug|DLX105 Hydrogel|topical administration on psoriatic plaque
75631536|NCT02852460|Other|rapid recovery|
75631537|NCT04308824|Other|clipping|a single clip will be placed in every case of polypectomy for large colorectal polyps
75631538|NCT04308824|Other|nebulization of glue|After clipping, a cyanoacrilate glue will be nebulized using a spray catheter
75324790|NCT02029911|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
75324791|NCT05621213|Other|Teleconsultation assisted by a physiotherapist or nurse|"A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions.~This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver."
75631539|NCT02846025|Dietary Supplement|Folate and capsule of oil hazel|rich diet aministracao folate and capsule of oil hazel
75631540|NCT02846025|Dietary Supplement|Folate and placebo|rich diet aministracao folate and placebo
75631541|NCT02846025|Dietary Supplement|antioxidant and placebo|antioxidant diet (90μg folate) and placebo capsule
75631542|NCT02880410|Device|NeuroBlate System|Laser Interstitial Thermal Therapy
75918166|NCT04803682|Behavioral|Preventive Intervention|Participate in ASPIRE and mentorship program
75918167|NCT04803682|Behavioral|Questionnaire Administration|Ancillary studies (pre and post questionnaire)
75631543|NCT02880410|Drug|Radiation therapy and temozolomide|Radiation therapy and temozolomide
75918168|NCT03530670|Other|oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction
75324792|NCT02357043|Device|Dario Blood Glucose Monitoring System|Finger-stick obtained with BGMS
75324793|NCT02357043|Device|YSI|Finger-stick sample obtained by nurse/technician to be tested with YSI
75324794|NCT05743751|Device|Normothermic machine perfusion|XVIVO (perfusion company, Gothenburg, Sweden), functions to be included in perfusion equipment, cardiopulmonary bypass machine and neonatal cardiopulmonary bypass machine, including polyethylene pipeline, heating equipment (perfusion temperature 37 ℃), venous pool (venous pressure is 0 mmHg, adjust the height of perfusion pool), centrifugal pump (arterial pressure is set at initial 75 mmHg, maintain 65 mmHg). The perfusion solution contains 215ml of dextran/albumin solution and 400ml of hematocrit, 2ml of 10% calcium gluconate, 1300u/L heparin and 400mg of cefazolin sodium. The oxygen/carbon dioxide ratio is (95%/5%, 2L/min) for continuous perfusion, and pO2 is maintained at 650mmHg during perfusion. During perfusion, continue to use verapamil, amino acid, glucose and insulin. Lactic acid Ringer solution (10ml/h) was used to supplement the lost circulation volume due to urine production during perfusion.
75324795|NCT05743751|Device|Hypothermic machine perfusion|LifePort Kidney Transporter is designed to integrate with the clinical environment by using readily available supplies, requiring minimal user intervention, and by being easy to use. LifePort Kidney Transporter is a portable, isolated kidney perfusion and transport system, designed to support a donated kidney and to maintain the organ in a near-normal physiologic state under hypothermic aseptic conditions. An insulated plastic housing encloses the kidney and perfusate within a LifePort Kidney Transporter Disposable Perfusion Circuit. LifePort Kidney Transporter components include an Ice Container, Pump Deck, Control Panel, Outer Display, Bubble Detectors, External Connections Panel, sensors, and four lithium-ion batteries. Two handles make the unit easy to lift and carry
75324796|NCT02031627|Device|pneumatic compression - 1 hour per day|Pneumatic compression treatment once per day (1 hour)
75324797|NCT02031627|Device|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day in the AM & PM (2 hours)
75631544|NCT02848755|Device|Cranial ultrasonography|
75918169|NCT03530670|Other|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|"Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction."
75918170|NCT03530670|Other|Playing smartphone game|Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
75468103|NCT01936337|Drug|Placebo|topical administration on psoriatic plaque
75324798|NCT02031627|Device|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM & PM (4 hours)
75918171|NCT04794400|Other|oxygen mask|All patients fulfilling inclusion criteria would be offered to test the intervention as part of their care. The intervention consisted only of a standardised way to evaluate this new clinical routine.
75918172|NCT00120042|Drug|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
76076182|NCT04378582|Other|risk factors|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
75324799|NCT04273295|Other|Abdominal massage|The patients lying in comfortable relaxed supine position and physiotherapist performed slow circular clockwise movements on the abdomen, throw tangential pushing, with digital pulp, slow and gradual pressure, with fingers inclination 45 degree. The pressure applied to the abdomen on each point for 1 min, beginning with the ascending colon, transverse colon, descending colon and sigmoid; this sequence was repeated approximately 15 min. The therapist teaches the parents this technique and asked them to apply at home 3 times / day for 15 min.
75324800|NCT02358135|Other|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
75324801|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
75468104|NCT01936350|Drug|Sildenafil|The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
75468105|NCT01936350|Drug|Placebo|This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
75631545|NCT02879006|Drug|Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT
75631546|NCT02879006|Drug|Placebo|Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
75631547|NCT02879006|Drug|Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
75631548|NCT02879006|Drug|Multi OIT|24 months of multi OIT (maintenance dose of 1gm each food allergen)
75631549|NCT02846181|Drug|[14C]-SK-1405|
75631550|NCT00941070|Drug|triapine|Given IV
75631551|NCT00941070|Drug|cisplatin|Given IV
75918173|NCT00120042|Drug|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
75918174|NCT04426942|Other|survey|survey on sexuality during pregnancy
75918175|NCT02084277|Device|Self-ligating brackets (SLB)|
76076183|NCT01728298|Biological|SLITone ULTRA HDM immunotherapy|
76076184|NCT01737710|Biological|Fluzone® Intradermal Vaccine|A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
76076185|NCT01737710|Biological|Fluzone® (Intramuscular) vaccine|A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
75324802|NCT02032641|Device|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
75468106|NCT01936402|Behavioral|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
75468107|NCT01936415|Device|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
75631552|NCT00941070|Radiation|external beam radiation therapy|Undergo pelvic external beam radiation therapy
75631553|NCT00941070|Procedure|quality-of-life assessment|Ancillary studies
75631554|NCT00941070|Other|questionnaire administration|Ancillary studies
75918176|NCT02084277|Device|Conventional brackets (CB)|
75918177|NCT02084355|Drug|oral oxycodone|
75918178|NCT02084355|Drug|oral hydromorphone|
75918179|NCT02084355|Drug|fentanyl patch|
75324803|NCT02312739|Procedure|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
75324804|NCT02312739|Drug|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
75324805|NCT02312739|Drug|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
75324806|NCT02312739|Drug|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
75324807|NCT02312739|Other|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
75468108|NCT01936415|Device|Regenerex|
75468109|NCT01936428|Other|interview|
75468110|NCT01936441|Behavioral|Cognitive Behavioral Therapy-Insomnia (CBT-I)|See Experimental Arm Description
75468111|NCT01936441|Behavioral|Menopause Education Control (MEC)|See Experimental Arm Description
75468112|NCT01936493|Genetic|DNA analysis|At a future time DNA analysis will be performed
75468113|NCT01936493|Other|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
75468114|NCT01936506|Behavioral|Cognitive Training A|
75468115|NCT01936506|Behavioral|Cognitive Training B|
75468116|NCT01936545|Drug|propofol during liver transplantation.|The anesthesia was maintained with propofol during liver transplantation.
75631555|NCT00941070|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
75324808|NCT02312739|Other|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
75918180|NCT00353574|Drug|Darusentan|Darusentan capsules administered orally once daily
75468117|NCT01936545|Drug|Desflurane during liver transplantation.|The anesthesia was maintained with desflurane during liver transplantation.
75631556|NCT00941070|Procedure|positron emission tomography|Undergo FDG-PET/CT
75631557|NCT00941070|Procedure|computed tomography|Undergo FDG-PET/CT
75631558|NCT02857218|Drug|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
75631559|NCT02857218|Procedure|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
75631560|NCT01098812|Device|Tecnis ZCB00 IOL (control)|Tecnis 1-piece acrylic IOL
75631561|NCT01098812|Device|Toric Intraocular lens|Toric acrylic intraocular lens with various cylinder powers
75631562|NCT00602316|Drug|gadolinium-chelate|
75631563|NCT00602316|Procedure|conventional surgery|
75631564|NCT00602316|Procedure|magnetic resonance imaging|
75918181|NCT02082405|Drug|bortezomib|Given SC or IV
75918182|NCT02082405|Drug|cyclophosphamide|Given PO
75918183|NCT02082405|Drug|dexamethasone|Given PO
75918184|NCT02082405|Other|laboratory biomarker analysis|Optional correlative studies
75918185|NCT02082405|Other|quality-of-life assessment|Ancillary studies
75918186|NCT05618548|Biological|COVID-19 vaccine|COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).
75468118|NCT01936558|Other|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
75631565|NCT00602316|Procedure|magnetic resonance spectroscopic imaging|
75631566|NCT02879786|Other|Posturographic tests|
75468119|NCT06071780|Other|organic product - Virgin Coconut Oil|A commercially available sterilized contact lens was soaked in VCO for 4 hours in a sterile condition to allow absorption of VCO into the contact lens polymer. The contact lens here is a vehicle to transport the VCO into the eye.
75631567|NCT02879786|Other|Questionnaire of motion sickness susceptibility|
75782704|NCT03892304|Other|Self-report written questionnaire|"Patient questionnaire filled-out in presence of clinical nurse. Gynecological options and contraceptive choices were recorded. Close-ended questions used (yes/no): contraception use; contraceptive pill use; contraceptive implant; intrauterine device; tubal sterilization; mechanical contraception; other type of contraception use; previous term delivery; gynecological follow-up; previous Pap smear. If Yes was noted, more details were requested (contraception name, delivery date, gynecological follow-up frequency, last Pap smear date).~Other gynecological history and management data not included in the 2014 questionnaire: age at first menstruation, menstrual cycle regularity without hormonal contraception, age at menopause, previous human papilloma virus vaccination, recurrent vulvovaginal candidiasis, urinary incontinence, fertility/infertility data, and infertility treatment with assisted reproductive technologies. Results were compared with those obtained in 2014 (121 women)."
75782705|NCT03892070|Dietary Supplement|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB will be provided for 12 weeks twice daily
75782706|NCT03892070|Dietary Supplement|Mannitol|1.5 g twice daily for 12 weeks
75782707|NCT03903380|Other|Manual Therapy and Usual care exercise protocol for neck pain|Manual Therapy protocol between four to eight sessions and exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
75918187|NCT02088489|Device|Atrial flutter irrigated catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
75918188|NCT02088489|Device|Atrial flutter porous tip catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
75918189|NCT03530592|Device|Seated Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system over a 6-week intervention period.
75468120|NCT06071728|Dietary Supplement|Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)|Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.
75468121|NCT06071676|Other|conventional impression group|Silicon impression material loaded on plastic tray and inserted inside the patient mouth
75468122|NCT06071676|Other|digital impression group|direct scanning was done using intraoral scanner to the female housing of the attachments on position
75631568|NCT02857530|Drug|rhTPO|rhTPO
75631569|NCT02857530|Drug|placebo|without rhTPO
75631570|NCT02878928|Genetic|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
75782708|NCT03903380|Other|Manual Therapy and Augmented reality exercise protocol|Manual Therapy protocol between four to eight sessions and Augmented reality exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
75782709|NCT03891758|Biological|DPT-IPV-Hib|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
75468123|NCT06071663|Procedure|Single and two visits pulpectomy|Comparison of clinical and radiographic outcome of Single and two visits pulpectomy
75468124|NCT06071650|Behavioral|Exercise to a Heart Rate (HR) Zone|Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration
75468125|NCT06071637|Procedure|Double low-power laser therapy simultaneous applicated|Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
75468126|NCT06071598|Other|Surgical specimens of CRC-affected patients|Specimens of CRC-affected patients will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
75631571|NCT00602394|Drug|Lithium|
75631572|NCT00903201|Drug|SB656933|20 mg
75782710|NCT03891758|Biological|Hib vaccine|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
75631573|NCT00903201|Drug|SB656933|50mg
75631574|NCT00903201|Drug|Placebo|placebo
75631575|NCT04309214|Dietary Supplement|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
75782711|NCT03891758|Biological|DPT-IPV|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
75918190|NCT04428268|Drug|Chloroquine Phosphate Tablets|Orally administered
75918191|NCT02082561|Behavioral|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
75918192|NCT04825600|Diagnostic Test|anti-Toxoplasma gondii IgG and IgM dosage|blood sample performed to check the toxoplasma serological diagnosis
75918193|NCT04825600|Diagnostic Test|cellular test|blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis
75918194|NCT02084433|Procedure|intraosseous anaesthesia using a computerized system|"1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
75324809|NCT05718765|Behavioral|PACES intervention|"The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE."
75631576|NCT04309136|Drug|Anlotinib|All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment
75631577|NCT04309136|Procedure|surgery|Perform surgery if operable after neoadjuvant therapy
75324810|NCT05718765|Other|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
75324811|NCT02351037|Drug|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
75631578|NCT04309136|Procedure|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
75631579|NCT04956302|Drug|Bortezomib|Given SC
75631580|NCT04956302|Drug|Daratumumab and Hyaluronidase-fihj|Given SC
75631581|NCT04956302|Drug|Dexamethasone|Given PO or IV
75631582|NCT04956302|Drug|Panobinostat Lactate|Given PO
75631583|NCT04202133|Behavioral|WW (formerly Weight Watchers)|The WW intervention will consist of weekly group workshops for 16 weeks with WW Coaches and Guides.
75631584|NCT04202133|Behavioral|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered the WW intervention
75631585|NCT02848443|Drug|Trifluridine/tipiracil hydrochloride (S 95005)|Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
75631586|NCT02848443|Drug|Oxaliplatin|Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
75324812|NCT02351037|Drug|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
75468127|NCT06071585|Other|Formalin-fixed Paraffin-embedded (FFPE) tissue samples analysis|We will stain and analyze EoE, GERD, and controls Formalin-fixed paraffin-embedded (FFPE) tissue samples already stored in the pathological laboratory of OSR.
75631587|NCT02848443|Drug|Bevacizumab|Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
75631588|NCT02848443|Drug|Nivolumab|Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
75631589|NCT04954586|Other|Pain Informed Movement|Participants will attend a twice weekly exercise program.
75631590|NCT00632697|Drug|pentoxifylline|800 mg daily for six months
75631591|NCT00632697|Drug|placebo|
75631592|NCT02848209|Procedure|TCA 20% Peeling|TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
75918195|NCT02084433|Procedure|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
75468128|NCT06071572|Other|Biological samples collected specifically for the IBD Biobank|Biological samples will include: material intestinal biological waste (surgical leftover), 30 ml of peripheral blood, one sample stool standards and a saliva sample.
75468129|NCT06071559|Procedure|Laparoscopic Roux-en-y gastric bypass|Obesity surgery
75631593|NCT02848209|Procedure|Phenol/croton oil Peeling|Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.
75631594|NCT02848209|Procedure|TCA 40% Peeling|TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
75631595|NCT05337969|Drug|Metformin and Vildagliptin 850/50 mg|50 mg Vildagliptin + 850 mg Metformin as single-dose per study period
75631596|NCT02844153|Other|modalities of metformin prescription|Metformin prescription or not, in each CKD stage
75631597|NCT02844387|Dietary Supplement|L-arginine hydrochloride solution|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive either oral arginine supplementation one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
75631598|NCT02844387|Other|Placebo|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive oral placebo one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
75631599|NCT02844231|Other|Single-photon emission computed tomography|
75918196|NCT04803760|Other|A self-administered questionnaire|A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
75918197|NCT04427098|Drug|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Subcutaneous enoxaparin 40 mg once daily for 14 days.
75631600|NCT04209465|Drug|BDTX-189|Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle.
75918198|NCT04427098|Drug|Enoxaparin|Subcutaneous enoxaparin for 14 days: 60 mg once daily in case of body weight of 45 to 60 kg; 80 mg once daily in case of weight from 61 to 100 kg; 100 mg once daily in case of bodyweight >100 kg
75918199|NCT00352560|Drug|Irbesartan|Tablets, Oral, 300 mg, once daily, 30 days.
75918200|NCT00352560|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 30 days.
75918201|NCT00115050|Drug|TMC114|
75918202|NCT05616364|Drug|Dexmedetomidine injection|Dexmedetomidine intravenous
75631601|NCT02844075|Drug|MK-3475(pembrolizumab)|"Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery."
75324813|NCT02351037|Drug|Ibrutinib+Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
75324814|NCT02358603|Diagnostic Test|Chronotropic Incompetence Diagnostic Algorithm|
75468130|NCT06071546|Device|MAIA|MAIA is a visual field testing device combining visual field tests, fixation loss correction by a real-time retinal tracker and confocal TrueColor fundus imaging (P/N AHMACME001)
75782712|NCT01259180|Procedure|acupuncture treatment|twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
75782713|NCT01259180|Procedure|Sham acupunture|twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1~2inches away from real acupuncture point
75782714|NCT01259258|Procedure|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
75631602|NCT02844309|Drug|Thalidomide|thalidomide 50-150 mg per night
75631603|NCT02845713|Drug|Ivermectin, Diethylcarbamazine Albendazole (IDA)|To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
75324815|NCT05718609|Drug|Rabeprazole|proton-pump inhibitor (PPI)
75324816|NCT05718609|Drug|Colloidal Bismuth Pectin Granules|Gastric mucosal protective drug with anti-H. pylori effect
75918203|NCT05616364|Drug|Tramadol|Tramadol intravenous
75324817|NCT05718609|Drug|Amoxicillin|Antibiotic for H. pylori eradication
75324818|NCT05718609|Drug|Furazolidone|Antibiotic for H. pylori eradication
75918204|NCT02082639|Biological|Cervarix™|2 doses intramuscularly in the deltoid muscle of the non-dominant arm
75918205|NCT02082639|Biological|Havrix|2 doses intramuscularly in the deltoid muscle of the dominant arm
75918206|NCT00351156|Procedure|Blood sample|
75782715|NCT01259258|Procedure|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
75782716|NCT01152632|Other|manual acupuncture|thirty minutes duration every time, five times per week for one course, a total four courses
75782717|NCT01256216|Device|Total Knee Replacement with Vanguard Total Knee|Patients indicated for a total knee replacement utilizing the Vanguard Total Knee System.
75782718|NCT01259882|Drug|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
75782719|NCT01259882|Drug|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
75324819|NCT05718609|Drug|Clarithromycin|Antibiotic for H. pylori eradication
75324820|NCT02359305|Drug|Acetaminophen|Acetaminophen given by IV
75468131|NCT06071520|Drug|Fostamatinib|Patient treated with fostamatinib in the period described
75918207|NCT00345618|Drug|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
75918208|NCT00345618|Drug|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
75918209|NCT00345618|Drug|Placebo (for idrabiotaparinux sodium)|"0.5 mL pre-filled syringe~Subcutaneous injection"
75918210|NCT00345618|Drug|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
75918211|NCT00345618|Drug|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
75918212|NCT00345618|Drug|Enoxaparin|"Prefilled syringes as locally registered~Subcutaneous injection"
75918213|NCT02476851|Device|POLFA (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
75918214|NCT02476851|Device|Kawasumi (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
75918215|NCT02595970|Drug|Secukinumab|weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
75918216|NCT03530514|Drug|REGN4461|REGN4461
75918217|NCT03530514|Drug|Placebo|Placebo-matching REGN4461
75918218|NCT02287662|Other|Vancouver 3M Clinical Pathway|
75918219|NCT04793932|Drug|PAXG|Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days
75918220|NCT04793932|Drug|mFOLFIRINOX|Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days
75324821|NCT02359305|Drug|Acetaminophen|Acetaminophen suppository given rectally
75631604|NCT05337813|Device|"Storz Medical Extracoporeeal Shock Wave Therapy System"|A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)
75782720|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
75782721|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
75782722|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
75782723|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
75782724|NCT01155440|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
75782725|NCT01155440|Procedure|Thoracic epidural block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
75782726|NCT01261988|Device|VIPER|Comparison of ostomy systems
75782727|NCT01261988|Device|Esteem™ Cut to Fit One Piece Closed End Pouch|Comparison of ostomy systems
75782728|NCT03889262|Other|Hippotherapy|Hippotherapy is a therapeutic method in which a mechanical horse is used for therapeutic purposes.
75782729|NCT03889262|Other|Neurodevelopmental Therapy|Neurodevelopmental therapy (NDT) is a hands-on treatment approach used by physical therapists, occupational therapists, and speech-language pathologists. NDT was developed to enhance the function of children who have difficulty controlling movement as a result of neurological challenges, such as cerebral palsy and head injury. During treatment interventions, repeated experience in movement ensures that a particular pattern is readily accessible for motor performance. The more a patient performs certain movements, the easier these movements becomes.
75782730|NCT03889652|Diagnostic Test|Oct scans|Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups
75782731|NCT01259336|Drug|Itraconazole|Tablet 200 mg twice daily for 6 months
75782732|NCT01259336|Drug|treatment in cavitary pulmonary aspergillosis|Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
75782733|NCT03885986|Radiation|Ultrasound|role of ultrasound in comparison to magnetic resonance imaging in diagnosis of benign cystic lesions of knee
75782734|NCT03891134|Dietary Supplement|Branched Chain Amino Acid|Participants were purposively sampled to receive one sachet enriched BCAA twice a day(7.2g) for 5 weeks.
75782735|NCT03886142|Procedure|radiofrequency|radiofrequency of the genicular nerves
75918221|NCT04793932|Drug|short-course chemotherapy|other two months of chemotherapy after surgery
75918222|NCT04793932|Drug|long-course chemotherapy|other two months of chemotherapy before surgery
75324822|NCT02360319|Drug|Any FDA approved antipsychotic agent|Investigators are free to choose the most appropriate treatment for their clients
75468132|NCT06071481|Drug|Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution|2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol
75468133|NCT06071403|Other|(enteral feeding volume/ total fluid volume)*100%|(enteral feeding volume/ total fluid volume)*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume
75631605|NCT02845557|Other|OGTT and IVGTT tests|
75631606|NCT05243121|Diagnostic Test|MRI|undergoing enhanced MRI
75631607|NCT02845245|Other|3D printed plastic model prototype|
75631608|NCT02845245|Other|3D CT scan|
75631609|NCT02845245|Other|Plain film radiographs|
75631610|NCT00902265|Drug|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
75782736|NCT03886142|Procedure|platelet rich plasma injection|intra articular injection of platelet rich plasma
75782737|NCT01259414|Other|Solvent with specific gravity less than lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)
75918223|NCT03611868|Drug|APG-115+Pembrolizumab|dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
75324823|NCT02360319|Drug|aripiprazole long acting injectable formulation|
75324824|NCT05718531|Drug|Rivaroxaban 2.5 Mg Oral Tablet twice daily|effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.
75324825|NCT05718531|Drug|Clopidogrel 75 Mg Oral Tablet|Used as control group in 2nd arm and 5th arm
75324826|NCT05718531|Drug|Aspirin tablet 75 mg|Used as control group in 2nd arm and 5th arm
75324827|NCT05718453|Combination Product|Laboratory Tests|Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
75631611|NCT04510779|Device|Apple Watch|Apple Watch is a smartwatch developed by Apple Inc. The heart rate variability function will be used.
75631612|NCT02848365|Device|Endotracheal intubation|Endotracheal intubation will be done with any of these equipments
75631613|NCT04490109|Biological|B244|B244 suspension
75631614|NCT04490109|Biological|Vehicle|Vehicle suspension
75631615|NCT02848287|Drug|normal saline|1*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
75631616|NCT02848287|Drug|ropivacaine|1*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
75324828|NCT02360631|Drug|Chantix|A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
75324829|NCT02360631|Drug|Placebo|Health education counseling will be provided to all participants.
75782738|NCT01259414|Other|Solvent with specific gravity equivalent to lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
75782739|NCT03891212|Behavioral|Placed in prone position for at least 16 consecutive hours a day.|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
75782740|NCT03314662|Biological|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
75782741|NCT03314662|Biological|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
75782742|NCT03314662|Biological|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
75782743|NCT03886298|Procedure|radiofrequency splanchnic denervation|the authors will denervate the splanchnic nerves via radiofrequency
75918224|NCT04803838|Other|No intervention|No intervention
75918225|NCT04793854|Other|Measure of the Life habits (MHAVIE)|"Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).~Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,…)."
75918226|NCT00116298|Drug|stavudine, efavirenz, lamivudine|
75918227|NCT04793542|Procedure|lower-limb hot water immersion|For a minimum of 30 minutes, 3 times a week for 8 consecutive weeks, participants will submerge their lower-limbs into 30-32°C (lukewarm) or 39-40°C (hot) water which will be measured with a supplied waterproof thermometer.
75918228|NCT04786678|Behavioral|Cell phone notification|Habitual bed and wake times will be detected using a wearable for 4 weeks. Using habitual wake time, a minimum bedtime to achieve adequate sleep will be calculated (8 hours). If phone usage is detected after this minimum bedtime, participants will receive a notification informing them they are awake past their minimum bedtime and recommend they go to bed to obtain adequate sleep.
75918229|NCT04786834|Procedure|Vesico urethral anastomosis on chicken model|Performance of a vesico urethral anastomosis on a chicken model with Da Vinci robotic system
75918230|NCT01866111|Drug|YKP3089|
75918231|NCT01866111|Drug|Placebo|
75918232|NCT04793230|Diagnostic Test|biopsying|The procedure was carried out under general or local anesthesia. An otolaryngologist conducts the endoscopic intranasal operation, while an eye surgeon removes tissue from the sac and lacrimal tubes using lacrimal probes passed through the canaliculi.
75918233|NCT04803136|Procedure|spine surgeries|all spine surgeries including stabilization and fusion surgeries
75918234|NCT04351204|Radiation|radiotherapy|multiple new techniques and software for MR-guided adaptive radiation therapy.
75918235|NCT02084589|Other|PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
75918236|NCT02084589|Other|PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
75324830|NCT02033499|Behavioral|SMBG|Blood glucose levels are tested once daily.
75324831|NCT02362191|Device|Alternating Current Stimulator|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
75324832|NCT05718375|Drug|CU01-1001|CU01-1001
75631617|NCT02847897|Device|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
75631618|NCT05337657|Drug|GB491+Letrozole|Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
75631619|NCT05242575|Behavioral|The information provided in the iVFT and control book parallel one another.|"An immersive virtual fled trip (iVFT) is a form of virtual reality (VR). The term immersive refers to an experience where the senses become heightened through multisensory input (e.g., visual, auditory, proprioceptive). When adding peripherals such as a head-mounted device (HMD) (e.g., goggles with 3D-lenses), a mobile phone becomes a pseudo-theater providing a 360-degree view that mimics the real world. For example, one can experience a simulated rollercoaster or visit the moon that may otherwise be inaccessible in day-to-day life. Also, a VFT provides for context and aids in background knowledge that is a crucial aspect of learning.~Participants will receive three interventions sessions each last 15-minutes."
75918237|NCT04348552|Other|Primary care professionals reports of potential patient safety incidents, non-COVID-19 related|Primary care professionals reports of potential patient safety incidents, non-COVID-19 related
75918238|NCT03557853|Drug|Golimumab Injection|Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
75918239|NCT04786288|Other|massage with lavender essential oil mixed in a carrier oil|22 elderly participants received a one session M technique hand massage that lasted 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the M technique hand massage
75918240|NCT04786288|Other|massage with odourless baby oil|odourless baby oil was used for the application of one session M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.
75918241|NCT02084823|Biological|cancer stem cell vaccine|
75324833|NCT05718375|Drug|Placebo|Placebo
75918242|NCT04346992|Other|no intervention|no intervention
75918243|NCT02084901|Device|Drug-eluting biodegradable stent Orsiro implantation|Drug-eluting biodegradable stent Orsiro implantation
75918244|NCT02084901|Device|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
75918245|NCT04786522|Diagnostic Test|Bioimpedenziometry, Handgrip strenght evaluation|The measurement of body composition was performed using Bioimpedance (BIA 101, Akern srl, Pontassieve (FI), Italy). The handgrip dynamometer (Jamar, Sammons Preston, Bolingbrook, IL, USA) was used to determine the isometric force of the forearm.
75324834|NCT00355095|Drug|Erythropoietin|intravenous daily 3.3 *10^4 Units, duration 3 days
75631620|NCT02690961|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
75631621|NCT02690961|Drug|placebo multiple doses|
75782744|NCT03886298|Procedure|retrocrural celiac denervation|the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
75918246|NCT04786522|Diagnostic Test|Evaluation on blood specimens|Serum samples were assayed for calcium, phosphorus, magnesium, iron, lactate dehydrogenase (Ldh), creatine phosphokinase (Cpk), creatine kinase myocardial band (Ckmmb), myoglobin, thyroid stimulating hormone (TSH), 25(OH)-Vitamin D, osteocalcin, bone alkaline phosphatase (b-ALP), C-terminal telopeptide of type I collagen (CTX-I), haptoglobin, sclerostin, myostatin, and Irisin. Irisin serum concentrations were detected using a competitive ELISA kit (AdipoGen, Liestal, Switzerland)
75918247|NCT03559023|Procedure|Ultrasound Only|The anesthesia team will use ultrasound to scan on subject's upper back (thoracic spine) to identify a place to begin the epidural procedure. A pen will be used to place markings on subject's back.
75918248|NCT03559023|Procedure|Manometry Only|The anesthesia team will use an extra piece of tubing to confirm the epidural space one the epidural space is established.
75918249|NCT03559023|Procedure|Ultrasound Plus Manometry|The anesthesia team will use both ultrasound and manometry to assist with epidural placement.
75918250|NCT03559023|Procedure|Usual Care/Management|"The epidural will be placed using the usual technique utilized by the anesthesiology department. The the usual care/management group will receive a sham (fake) ultrasound exam of subject's upper back with fake pen markings placed on subject's back. The ultrasound machine will not be turned on."
75918251|NCT02595502|Device|JJVC Marketed Contact Lens (Test)|
75918252|NCT02595502|Device|Competitor Marketed Contact Lens (Control)|
75324835|NCT02366871|Drug|Oral apixaban|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
75324836|NCT02366871|Drug|Subcutaneous enoxaparin|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
75631622|NCT05242107|Dietary Supplement|Omega-3 supplement group|35 Neonates were given Omega 3 in a dose of 40mg/kg/day (8), after establishment of full-feeding and for 2 weeks duration. Omega-300 (Montana pharmaceutical industry) capsule was used which contains 1000mg Omega 3 fatty acids.
75782745|NCT03890978|Other|promotional Exclusive breastfeeding text messages|promotional Exclusive breastfeeding text messages will be send to women via mobile phone
75324837|NCT05718219|Drug|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
75631623|NCT05242107|Other|Full feeding without receiving any supplementation group|35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
75631624|NCT02845167|Other|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods
75631625|NCT05241951|Other|Structured hand-off|A clinical pharmacist will be utilized to provide a structured handoff at the end of the hospital stay between hospital and SNF skilled nursing facility.
75631626|NCT05241951|Other|Medication Management|The clinical pharmacist consults with hospital and SNF teams to reconcile, adjust and monitor medications to provide comprehensive medication management during care transitions.
75631627|NCT05337579|Other|Supplemental Micro Breaks|Supplemental Micro Breaks, of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours
75782746|NCT01262066|Behavioral|Lifeskills Workshop Intervention|Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
75782747|NCT03314272|Device|Space Glucose Control|Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
75918253|NCT02082951|Behavioral|Empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
75918254|NCT02082951|Behavioral|Empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
75918255|NCT04346290|Drug|Dexmedetomidine|Initial infusion dose of dexmedetomidine is 0.4 mcg/kg/min, maintenance infusion dose is 0.1-0.7 mcg/kg/min
75918256|NCT02084979|Behavioral|telepsychiatry evaluation|telepsychiatry evaluation and consultation to primary care
75918257|NCT04793386|Diagnostic Test|carotid ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and pulsatility by ultrasound
75324838|NCT05718219|Drug|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
75631628|NCT05337579|Procedure|Exercise Breaks|Exercise Breaks, of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.
75918258|NCT04803448|Behavioral|Benefit statement|"The participant reads this statement after asked one of eight health questions~What is your height in inches?~What is your weight in pounds?~How many days out of the last 2 weeks did you drink alcohol?~How often a month do you use other substance such as marijuana, cocaine, ecstasy, or other drugs~How often a month do you use Rx or non-Rx medications to excessive amounts?~When was the last time you smoked a cigarette?~How many days in the last 2 weeks did you engage in more than 30 min exercise?~How many times did you engage in sexual activity in the last month with another individual? . The statement reads: Accurately answering this will increase the likelihood of a correct diagnosis.~An example of this with one of the 8 health questions is... What number of days in the last 2 weeks you engaged in >30 minutes of exercise? Accurately answering this will increase the likelihood of a correct diagnosis."
75324839|NCT02036541|Device|AqueSys XEN 45 Glaucoma Implant|Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
75324840|NCT02368431|Drug|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
75468134|NCT06071390|Behavioral|Animated- assisted video|"For the experimental group, 15 minutes prior to the endoscopy, the researcher provided insight into the procedure by showing them a 3-minute animated video titled Endocan. This video, crafted by Köse in 2019 for his doctoral dissertation, offers a succinct overview of the endoscopy procedure."
75782748|NCT01152710|Drug|Capecitabine|Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
75782749|NCT03638050|Other|Functional Capacity Assessment|Individuals will be assessed on the third day after acute myocardial infarction. The six-minute walk test will be performed according to the norms of the American Thoracic Society.
75918259|NCT04803448|Behavioral|Risk Statement|"The participant reads this statement after being asked one of eight health questions.~The statement reads: Inaccurately answering this will increase the likelihood of an incorrect diagnosis."
75918260|NCT04803448|Behavioral|Privacy Statement|"The participant reads this statement after being asked one of eight health question for example. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
75468135|NCT06071377|Other|Biologic Specimen Collection|Participants will have blood and urine collected annually at Baseline, Year 1 and Year 2.
75468136|NCT06071338|Diagnostic Test|Clinical Periodontal Examination|No details will be published from the clinical assessment.
75324841|NCT02368431|Drug|Placebo|Placebo
75324842|NCT00757601|Drug|MK1006|"MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
75324843|NCT00757601|Drug|Placebo|"Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
75468137|NCT06071286|Procedure|Blood samples|Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
75631629|NCT04061577|Device|Transcranial Direct Current Stimulation (tDCS)|20 minutes of Cathodal tDCS after +/- before endovascular thrombectomy (EVT)
75631630|NCT04041921|Procedure|Percutaneous coronary intervention|
75631631|NCT04041921|Procedure|Coronary Artery Bypass Grafting|
75631632|NCT04041921|Drug|Medical treatment|
75631633|NCT04432077|Behavioral|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR) - a parent-mediated cognitive-behavioral treatment modified for young children with ASD
75631634|NCT02690883|Drug|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
75631635|NCT02690883|Drug|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG <10.0mmol/L.
75631636|NCT02942823|Other|"The serious game KOP"|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
75782750|NCT03891056|Procedure|metabolic surgery|The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
75782751|NCT03271528|Drug|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
75782752|NCT03271528|Drug|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
75782753|NCT01262144|Radiation|Radiotherapy|Radiotherapy for cervical cancer
75782754|NCT01153412|Other|Osteopathic Manipulative Treatment|Osteopathic manipulation to determine balance and stability in elderly
75782755|NCT01155596|Behavioral|negative pressure ventilator use|Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
75324844|NCT03809975|Other|Multidisciplinary Community Program|"Patient will undergoes 12 weeks of structured and personalized multidisciplinary community-based program, which consists of Physiotherapy, Dietetics and Psychology sessions. Patients will also attend 2 educational sessions. Physiotherapy and educational sessions are mandatory for all participants, while the need for dietetics and psychological interventions are determine using individual's BMI measurements and psychological questionnaires.~Inclusion criteria:~Dietetics: 23.5 < BMI <32.5; Psychology: PEG > 4 or PHQ-4 > 5 or PAM level < 3"
75918261|NCT04803448|Behavioral|Benefit + Privacy|"The statement reads Accurately answering this will increase the likelihood of a correct diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
76076186|NCT01724944|Procedure|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
75782756|NCT02507596|Biological|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
75782757|NCT02507596|Procedure|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
75324845|NCT03809975|Other|Current model of care|No controlled set of treatment assigned to patient. It is based totally on the discretion of the attending clinicians. It will generally contain an unspecific number of physiotherapy sessions. Other allied health involvement such as dietetics and psychological interventions will be on an ad hoc basis. In some cases, the orthopaedic surgeon may recommend for surgery.
75324846|NCT03836651|Other|Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.
75324847|NCT03836651|Other|Control group|The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
75918262|NCT04803448|Behavioral|Risk + Privacy|"The statement reads Inaccurately answering this will increase the likelihood of an incorrect diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
75918263|NCT04786366|Other|The study does not have an intervention, but observe the AF incidence of the UK disease-free population|The study does not have an intervention, but observe the AF incidence of the UK disease-free population.
75468138|NCT06071234|Procedure|3D printed technology|Preoperative application of 3D printing technology to evaluate the breast blood supply of patients and observe whether the incidence of ischemic complications in the flap and nipple areola complex is reduced compared to conventional non preoperative evaluation.
75631637|NCT05241639|Diagnostic Test|Pentacam|Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar
75631638|NCT02848053|Other|no intervention|
75468139|NCT06071182|Device|Task-oriented Fruit ninja game|The fruit ninja game were played from tablet PC 20 minutes in a day and 2 times in a week for 4 weeks
75468140|NCT06071182|Other|sham-controlled therapy|The fruit ninja game playing video (https://www.youtube.com/watch?v=cAb0cAviA1s) was watched on the same tablet for 3 minutes a day, twice a week, for 4 weeks, and the wrist and wrist exercises were repeated for 2 minutes on a flat and smooth table. movements were made.
75631639|NCT02847975|Dietary Supplement|Sodium nitrate|Sodium nitrate will be ingested orally
75631640|NCT02754375|Procedure|rTMS|
75631641|NCT04210401|Other|Duodenoscope Culture|Culture of reusable duodenoscopes following each use.
75782758|NCT03889184|Other|rehabilitating meals-on-wheels service|the meals-on-wheels service will be specifically targeted for old people discharged from hospital, receiving exercise rehabilitation in the municipality or already receiving meals-on-wheels
75782759|NCT04480372|Drug|Gemcitabine|Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).
75782760|NCT04480372|Drug|Atezolizumab|Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
75782761|NCT03885440|Other|Age|Age<40 years old is chosen as the cutoff value.
75782762|NCT03885440|Other|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
75782763|NCT01153490|Behavioral|Behavioral Intervention|Substance-related
75782764|NCT04462276|Drug|Atezolizumab|fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
75782765|NCT04462276|Radiation|thoracic radiotherapy (TRT)|30 Gy in 10 fractions
75782766|NCT01586390|Other|Functional treatment for ankle sprain using ankle cast|Functional treatment for ankle sprain using ankle cast
76076187|NCT04381000|Other|Exercise Group|The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
75631642|NCT02845011|Device|Audiovisual compression feedback|The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.
76076188|NCT04379674|Other|FACILITATION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
75631643|NCT02845011|Other|Standard Manual Chest Compression|Cardiopulmonary resuscitation according to published international guidelines.
75631644|NCT02384265|Behavioral|IM/SMS + Incentive Condition|See description of Intervention arm protocols above.
75782767|NCT01586390|Other|Ankle sprain treated with removable ankle support|Ankle sprain functionally treated with removable and adjustable ankle support
75782768|NCT04461262|Device|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
75918264|NCT04786132|Other|Cognitive-motor training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
76076189|NCT04379674|Other|INHIBITION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
76076190|NCT04379674|Other|PLACEBO TAPING|Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
75324848|NCT05743439|Behavioral|Early Augmentative and Alternative Communication (AAC) Intervention|Caregivers will receive 24, 50 min intervention sessions twice a week for three months. During each intervention session, the therapist provides instruction and coaching on using AAC and a set of evidence-based language support strategies. Strategies are taught sequentially in three phases: (1) Responding to all Communication, (2) Teaching Words, and (3) Creating Communication Opportunities. Caregivers practice using the AAC intervention strategies during three, five-minute routines with their children. Therapists coach the caregiver on using the targeted strategies during these routines, encouraging caregivers to reflect on their implementation, and developing a plan to use the AAC strategies during activities not practiced during the intervention session. The AAC intervention is provided to families using an evidence-based service delivery model, Family Guided Routines Based Intervention.
75324849|NCT02037555|Biological|AT-III (Human)|AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.
75324850|NCT02037555|Other|Placebo|0.9% Sodium Chloride for Injection, United States Pharmacopeia
75324851|NCT03809819|Procedure|laparoscopic Vecchietti vaginoplasty|Patients who underwent laparoscopic Vecchietti vaginoplasty
75468141|NCT06071169|Other|progressive relaxation exercise|Nurses will be asked to perform relaxation exercises 3 days a week for 5 weeks, 20 minutes in each practice.
75782769|NCT04461262|Device|Standard Care|Uncoated Foley catheter
75782770|NCT03890510|Other|Ringer's Lactate solution|Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.
76076191|NCT01725022|Other|Home Care|This is the interventional arm where patients receive the transplant care in their homes.
76076192|NCT01728532|Device|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
76076193|NCT01728532|Device|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
76076194|NCT01837810|Drug|Ibuprofen|800mg every 8 hours as needed for pain
76076195|NCT04378348|Behavioral|Motivational Interview (MI)|The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey
76076196|NCT04378348|Behavioral|Participatory Group Activity|Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.
76076197|NCT04378348|Behavioral|Control Condition|At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
75631645|NCT02847819|Device|airway ultrasound for vocal cords movement assessment.|Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
75782771|NCT03890510|Procedure|Spine surgery under general Anesthesia in the prone position|The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.
75782772|NCT01152866|Drug|Choriogonadotropin alpha (r-hCG)|Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).
76076198|NCT01725100|Drug|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
76076199|NCT01725100|Drug|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
76076200|NCT01725178|Behavioral|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
75631646|NCT02844855|Behavioral|Cognitive tests|MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
75631647|NCT05337111|Other|Cardiorespiratory fitness test|Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness
75631648|NCT05337111|Other|Resting measure of fat oxidation|Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
75631649|NCT05337111|Other|Maximum fat oxidation test|Progressive exercise test to determine maximum fat oxidation during exercise
75631650|NCT00943722|Biological|V503|Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
75631651|NCT05190237|Dietary Supplement|TMD21-16 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
75631652|NCT05190237|Dietary Supplement|TCD21-55 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
75631653|NCT05190237|Dietary Supplement|TFD21-1 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
75782773|NCT03301714|Behavioral|Oral Health Education|Group-based oral health education vs Individual-based oral health education using motivational interviewing
75782774|NCT01259570|Dietary Supplement|Group 1|Skimmilk enriched with VD encapsulated in CM
75782775|NCT01259570|Dietary Supplement|Group 2|VD will be dissolved in milkfat and homogenized into skimmilk
75324852|NCT03809819|Diagnostic Test|FSFI questionnaire|Completion of FSFI questionnaire
75324853|NCT03809819|Diagnostic Test|UDI-6 questionnaire|Completion of UDI-6 questionnaire
75324854|NCT03809819|Diagnostic Test|IIQ-7 questionnaire|Completion of IIQ-7 questionnaire
75631654|NCT05164731|Biological|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third does was given 3, 4, 5 or 6 months after two doses
75631655|NCT00632775|Drug|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg."
75324855|NCT03804359|Drug|Rituximab|"In the personalized arm, the patient will be treated in function of the CysR activity result during the inclusion visit."
75631656|NCT00632775|Drug|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg."
75631657|NCT02847741|Other|patient's routine care|Interview by psychiatrists, questionnaires, blood analysis
75782776|NCT01259570|Dietary Supplement|group 3|3% fat milk wherein the VD will be in CM
75782777|NCT01259570|Dietary Supplement|Group 4|Placebo: un-enriched skimmilk.
75324856|NCT05743361|Diagnostic Test|Blood sampling|Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
75324857|NCT02369211|Drug|Acetaminophen (Ofirmev)|The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
75468142|NCT06071130|Behavioral|Fit and Strong|Procedure: During Years 3-5, participants will be recruited in waves through our standard recruitment practices to participate in Experiments 4A at the City of Chicago park sites. We will first prescreen them via telephone to verify that potential participants meet the inclusion criteria. F&S! classes will be offered at two pre-determined Chicago park sites. Each of the two sites will host the 8-week-long program once in the spring and once in the fall for two years for a total of four F&S! cycles at each center (totaling 8 F&S! cohorts). Upon consenting to be in E4A, participants will be enrolled in F&S! at the site closest to their home or the wait-list control. In the pre-intervention phase, participants both in F&S! and on the waitlist will come to the lab at DePaul to complete the pre-intervention measurement batter. Within one week after baseline measurements, participants will attend F&S! for 3 sessions a week for 8 weeks.
75468143|NCT06071091|Device|Intracranial stenting|"In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible.~Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication."
75631658|NCT04272918|Behavioral|Caregiver Support Model|Examine the effectiveness of the Caregiver Support Model (CSM) on improving caregivers' well-being.
75631659|NCT04272918|Behavioral|Psycho-education Program|Examine the effectiveness of the Psycho-education Program (PP-E) on capacity building, empowerment, and improving well-being.
75631660|NCT02847585|Dietary Supplement|Water-soluble Ubiquinol|10 mg/kg BW/d, by oral drops
75631661|NCT04420689|Drug|ALM-488|ALM-488 Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
75631662|NCT05047653|Diagnostic Test|RALE score vs. severity score|RALE score vs. severity score and CORADS
75631663|NCT04385589|Drug|Dapagliflozin|Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.
75631664|NCT04385589|Drug|insulin|insulin
75782778|NCT03885752|Drug|chewed mint gum|In the preoperative waiting area before transferring to the operating room, patients in group G chewed mint gum for 2 minutes and then spit it out.
75631665|NCT05032443|Other|Awareness survey|The 33-item questionnaire will sent to pediatric endoscopy nurses in our country. Questionnaires will be delivered to nurses through hospital visits or electronic media.
75631666|NCT04201977|Other|Foam Roller Recovery|Myofascial self-release will be developed through the foam roller (FR), where participants will use a custom-made foam roller constructed from a hollow polyvinyl chloride tube that will have an outside diameter of 10cm and a thickness of 0.5cm and will be surrounded by neoprene foam with a thickness of 1cm. Each volunteer will be shown the technique for the 5 muscle groups involved and the technique used for each muscle group. FR will consist of 45s of rolling for each muscle in the left lower extremity, 15s of rest, 45s in the lower right extremity. They will be instructed to begin with the practice on the most distal portion of the muscle. They will be instructed to place as much tolerable body mass on the FR at all times and to roll their body mass back and forth along the roller as smoothly as possible at a rate of 50 beats per minute (ie , 1 rolling motion for 1 to 2s). The total technique time is estimated at 10 to 15min (PEARCEY et al., 2015).
75918265|NCT04786132|Other|Motor training|A training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups.
75324858|NCT02369211|Other|Placebo|The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
75782779|NCT03885752|Other|swallow twice|asked to swallow twice without any additional treatment.
75782780|NCT03890276|Other|HMS EL&C training module|No additional information
75782781|NCT03890276|Other|Videos used to supplement live trainer|[Cherrie to add]
75782782|NCT01153568|Dietary Supplement|Vitamin D 3|Patients will bew given a single capsule to take once daily
75782783|NCT01153568|Other|placebo|placebo tablets
75918266|NCT04793308|Other|Endodontic files|Engine-driven nickel titanium Ni-Ti instruments
75324859|NCT03804281|Procedure|Test group|The surgery will be done with the use of 4x magnification loop, the knives are micro blades and micro-sutures 7//0 used with the microsurgical instruments kit
75324860|NCT03804281|Procedure|Control group|esthetic crown lengthening with conventional approach with an internal bevel incision, following CEJ anatomy, this will be followed by an intra-sulcular incision, removal of the strip of outlined marginal gingiva and elevation of a mucoperiosteal ﬂap to the level of the alveolar bone crest.
75324861|NCT00759161|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 4 weeks
75918267|NCT04785742|Drug|Almonertinib|Almonertinib
75324862|NCT00759161|Drug|AN2728 Ointment Vehicle|AN2728 Ointment Vehicle, twice daily for 4 weeks.
75324863|NCT02038023|Drug|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
75918268|NCT04426552|Drug|dexmedetomidine|will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
75918269|NCT04426552|Drug|sevoflurane|preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
75324864|NCT04384133|Diagnostic Test|Impulse oscillometry|Impulse oscillometry is a pulmonary function test. During the test, the participant is told to breathe normally.
75918270|NCT04803370|Other|Convalescent Plasma with antibody against SARS-CoV-2.|"Convalescent plasma plus standard treatment for COVID-19. The convalescent plasma is from patients recovered from COVID-19 and negative viremia in the test detection COVID-19.~The infusions will be given on days 1 and 2, of the study, after the positive result for COVID-19 of the recipient patient."
75918271|NCT04803370|Other|Standard treatment for COVID-19|The patients will receive the standard treatment for COVID-19, according to guidelines for COVID-19 (retrovirals drugs, interferon-α / β, anti-IL-6 monoclonal antibody, oxygen therapy, etc..)
75918272|NCT04793074|Combination Product|Transforming nanoparticle dressing|Transforming nanoparticle dressing
75918273|NCT04793074|Combination Product|Conventional compression dressing|Conventional compression dressing
75631667|NCT04201977|Other|Active recovery|Active recovery for 20 minutes (MIKA et al., 2016) will consist of pedaling on a stationary bike at a speed of 50 to 60 rpm. The load (49 ± 9 W) will be adjusted individually so that the heart rate is close to 100 bpm (about 50% of the theoretical maximum heart rate). This effort intensity is similar to that used in the literature (CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010)
75631668|NCT04201977|Other|Immersion in cold water|Immersion in cold water will consist of the individual sitting in a plastic pool with water at the water level of the umbilical scar. Water temperature is between 11 and 15ºC, for a period between 10 and 15 minutes immediately after the exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009). Water temperature will be controlled by adding or removing ice. This method has been applied by studies conducted by our research group (MISSAU; SIGNORI, 2017).
75918274|NCT04786054|Diagnostic Test|BED Questionnaire|BED Questionnaire
75918275|NCT04785664|Other|Community-based pro-Active Monitoring Program|The Intervention provides phone monitoring addressed to all the clients and home visits tailored to the individual needs. Moreover, it activates other formal or informal care resources based on the needs of the patients reported in the Individualized Care Plan (ICP) which derives from the assessment of multidimensional frailty. The main peculiarity of the program is that the operators identify the main problem of the client and try to track down the best solution in agreement with the client. It can be a health or social intervention or a different kind. Interventions may include assistance to make clients' houses safer thereby reducing risk factors for falls or reviewing the therapeutic scheme to improve patient adherence to the treatment in collaboration with the GP.
75324865|NCT04384133|Diagnostic Test|Spirometric pulmonary function test|In the spirometric pulmonary function test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
75324866|NCT04384133|Diagnostic Test|Fractional exhaled nitric oxide (FENO) test|In the FENO test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
75918276|NCT01369329|Drug|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
75918277|NCT01369329|Drug|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).
75918278|NCT01369329|Drug|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
75631669|NCT04201977|Other|Passive recovery|Volunteers will be seated for 20 min after the resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
75631670|NCT05336331|Procedure|SG or a RYGB|operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive
75631671|NCT04995939|Procedure|Laboratory parameters and Scoring systems|Neutrophil/ Lymphocite ratio, albumin level and scoring systems has been evaluated.
75631672|NCT04951401|Other|lipid profile|lipid profile
75918279|NCT04792996|Other|No intervention|No intervention. case - control design.
75324867|NCT04384133|Diagnostic Test|Thorax Computed Tomography|Computed tomography is a radiological examination.
75631673|NCT04951401|Other|ECG|ECG
75782784|NCT03885674|Other|Video Call Reminder Condition|Receive daily video call reminders from Kessler Foundation research staff directly at the time of each medication dose and instructed to take the medication while on the video call.
75782785|NCT03885674|Other|Automated Text Message Reminder Condition|Receive daily automated text messages at the time of each medication dose and will be instructed to take the medication at that time. Each text message reminder will also contain a photo of the medication to be taken. On a weekly basis, study personnel will contact participants in this group to make sure they are receiving the text messages appropriately.
75782786|NCT03885206|Other|Level of healthcare services|Patiens judged to be eligible for admittance to a municipal acute care wrad will be admitted to hospital as an intervnetion, to be able to compare same patient groups.
75782787|NCT01153646|Genetic|pHIV7-shI-TAR-CCR5RZ treated CD4 cells|Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
75918280|NCT04792762|Other|GIP(1-30)NH2|Intravenous administration of the peptide hormone GIP(1-30)NH2 during a stepwise glucose clamp
75918281|NCT04792762|Other|GIP(1-42)|Intravenous administration of the peptide hormone GIP(1-42) during a stepwise glucose clamp
75918282|NCT04792762|Other|Saline|Intravenous administration of saline during a stepwise glucose clamp
75918283|NCT04802980|Drug|HB002.1T|HB002.1T is a vascular endothelial growth factor receptor decoy
75918284|NCT04802980|Drug|Oxaliplatin|Oxaliplatin is an anti-tumor drug
75918285|NCT04802980|Drug|Capecitabine|Capecitabine is an anti-tumor drug
75918286|NCT04802980|Drug|Paclitaxel|Paclitaxel is an anti-tumor drug
75918287|NCT04802980|Drug|Gemcitabine|Gemcitabine is an anti-tumor drug
75918288|NCT04802980|Drug|Cisplatin|Cisplatin is an anti-tumor drug
75918289|NCT04802980|Drug|Carboplatin|Carboplatin is an anti-tumor drug
75918290|NCT02083029|Procedure|Simulated dive reflex|All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
75782788|NCT03890198|Biological|LCAR-C182A cells|Patients receive fludarabine (3×300 mg/ m^2) and cyclophosphamide (3×30 mg/m^2) IV on days -5 to-3, and then Patients receive CAR-T cells. PS：The specific dose of fludarabine and cyclophosphamide is adjusted according to the individual condition of the subject and the judgment of the investigator.
75918291|NCT02085057|Procedure|Functional Magnetic Resonance Imaging|
75918292|NCT05616052|Drug|Semaglutide|treatment with different dosage regimes
75918293|NCT02088567|Procedure|Total Knee Arthroplasty|Total knee arthroplasty, per the usual practice of the physician.
75918294|NCT02088567|Other|Application of dHACM|Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
75918295|NCT03558477|Drug|YYD601 1|YYD601 1
75918296|NCT03558477|Drug|YYD601 2|YYD601 2
75324868|NCT04384133|Diagnostic Test|Chest X Ray|Chest X ray is a radiological examination.
75324869|NCT04384133|Diagnostic Test|Blood eosinophil level|A tube of blood will be drawn from the participant.
75631674|NCT04948359|Other|Group I (The patients intubated with cuffed ETT of ID number 4.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
75782789|NCT01153022|Other|joint mobilization techniques|In the experimental group, ankle joint mobilization was applied for five minutes, using grade II joint traction rhythmic oscillation (Mailland Scale) with the knee in 15° of flexion, subtalar in neutral and ankle in resting position (10º plantarflexion). During the control study, participants were placed under the same conditions as those of the experimental group but only the hands of the evaluator were placed in the foot, in the position of joint traction simulation.
75782790|NCT03889808|Diagnostic Test|Determination of serum anti-toxin Abs for C. difficile|
75918297|NCT03558477|Drug|YYD601 3|YYD601 3
76076201|NCT01837888|Device|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
75782791|NCT03890042|Drug|Dienogest group|VISANNE 2MG Tablet once daily
75324870|NCT04384133|Other|CAT|It consists of 8 questions.
75324871|NCT04384133|Other|mMRC|It is the scale used to measure the severity of shortness of breath.
75782792|NCT03890042|Drug|Gestodene-Ethinyl Estradiol|Gynera tablet once daily
75782793|NCT03890042|Radiation|Ultrasound|ultrasound assessment of uterine volume
75782794|NCT03890042|Other|visual analogue scale|visual analogue scale for assessment of pain
75918298|NCT03558477|Drug|Nexium|Nexium
75918299|NCT04792840|Drug|Femara Pill|study effect on bone
75918300|NCT02085213|Drug|Glyceryl Trinitrate|
75918301|NCT02085213|Drug|Matched Placebo|Matched placebo
75324872|NCT02038179|Drug|Allopurinol|Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.
75324873|NCT02038179|Drug|Placebo|Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
75918302|NCT02088723|Behavioral|Head of bed elevation|head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
75918303|NCT02088801|Device|Airtraq, blade without channel for tracheal tube intubation|Intubation
75918304|NCT02088801|Device|KingVision , blade without channel for tracheal tube intubation|
75918305|NCT02088801|Device|A.P. Advance, blade without channel for tracheal tube intubation|
75918306|NCT02088801|Device|Macintosh|
75918307|NCT04792294|Device|Extracorporeal photopheresis|ECP can be used as second-line treatment in patients unresponsive to azithromycin. ECP has been firstly developed for treatment of cutaneous T cell lymphomas and later used in a variety of other indications including solid organ transplantation. The process starts with leukapheresis, followed by incubation of the isolated cells with 8-methoxypsoralen (8-MOP) and subsequent activation of 8-MOP with ultraviolet A radiation. At the end, the cells are reinfused into the patient. 8-MOP is a biologically inert substance, but in the presence of UVA light it cross-links DNA by forming covalent bonds with pyrimidine bases and causes apoptosis.
75918308|NCT04792450|Device|Thermography|Measure Temperature using Thermal Camera
75918309|NCT04792450|Device|Tympanic Thermometer|Measure Temperature using Tympanic Thermometer
75918310|NCT04792450|Device|Forehead Thermometer|Measure Temperature using Forehead Temperature
75918311|NCT04792450|Device|62 Max + Infra-red thermometer|Measure Temperature using 62 Max + Infra-red thermometer
75918312|NCT02088879|Behavioral|chest compression with kneeling position|
75918313|NCT02088879|Behavioral|chest compression with standing position|
75918314|NCT04802278|Biological|COVID-19 vaccine|Any COVID-19 vaccine
75918315|NCT02085291|Drug|Norepinephrine|Norepinephrine infusion to titrate MAP to usual level
76076202|NCT01725334|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
75324874|NCT00768287|Biological|IB1001|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery
75631675|NCT04948359|Other|Group II (The patients intubated with cuffed ETT of ID number 5.0)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
75782795|NCT01153802|Drug|GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin|"This is an open label, adaptive design, daily dosing, non-randomized PET occupancy study in healthy adult males.A range of doses may be evaluated. The initial dose, given in the study as a single dose was 150mg GSK1360707. The remaining subjects will be dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose will not exceed 150mg per day, the maximum total dose given in the FTIH study.If dosing is conducted as a single dose, the dose will be administered after the baseline scan, If a dosing is performed in a split dose manner, dosing will occur after the baseline scan, and up to 12 hours later. The time period between doses will be determined by emerging PET occupancy data.~Subsequent doses, if any, will be chosen based on the observed scan results. No single dose, or total dose split over 2 dosing sessions, will exceed the maximum dose in the FTIH study."
75782796|NCT03299686|Drug|CJM112|300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.
75782797|NCT03299686|Other|Placebo to CJM112|Placebo to match CJM112 + standard of care treatment
75782798|NCT03889964|Other|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
75782799|NCT03885284|Drug|mFOLFIRINOX|"Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~Irinotecan 150 mg/m2 IV day 1~Oxaliplatin 85 mg/m2 IV day 1~Leucovorin 400 mg/m2 IV day 1~5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3."
75782800|NCT03885284|Radiation|Proton beam radiation|Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7
75918316|NCT02085291|Drug|Crystalloid|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one.
75918317|NCT04792138|Diagnostic Test|VERDICT MRI|Advanced Diffusion Model
75918318|NCT04792138|Diagnostic Test|Luminal Index Imaging|Advanced T2 mapping
75918319|NCT05503641|Other|Cognitive and psychomotor stimulation|"Each cognitive stimulation session aimed to maintain and/or improve cognition through memory, language, executive functions, attention, concentration, and perception activities. All the people in the two groups performed the same cognitive stimulation activities adapted to their cognitive and sensory abilities.~The psychomotricity sessions were aimed at maintaining and/or improving the motor, cognitive, social and affective functioning of the person through activities that work on postural tone, body scheme, laterality, fine and gross motor skills, balance, flexibility, among others, adding a cognitive component. All the psychomotricity activities were adapted to the motor and cognitive abilities of the users."
75918320|NCT04802122|Drug|Sevoflurane inhalant product|Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) will be used for induction to anesthesia and facilitate endotracheal intubation.
75918321|NCT04802122|Drug|Propofol Fresenius|Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% will be for induction to anesthesia and facilitate endotracheal intubation. .
75918322|NCT02089035|Dietary Supplement|MUFA-rich dairy products (UHT milk, cheese and butter)|
75918323|NCT02089035|Dietary Supplement|Conventional dairy products (UHT milk, cheese, butter)|
75918324|NCT04784728|Drug|Lidocaine topical system 1.8%|lidocaine patch
76076203|NCT04378036|Other|Neurodevelopmental Therapy|The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.
75324875|NCT00768287|Biological|nonacog alfa|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
75324878|NCT00768521|Drug|tolterodine tartrate|"Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule"
75631676|NCT04948359|Other|Group III ( The patients intubated with cuffed ETT of ID number 5.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
75631677|NCT02847429|Drug|Crenolanib|
75631678|NCT02847429|Drug|Placebo|
75631679|NCT03959007|Other|Aesthetic therapy sessions|Only for experimental arm at 3 times during hospitalization
75631680|NCT03959007|Other|Questionnaire|Both arm at 3 times during hospitalization
75631681|NCT04827381|Other|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
75631682|NCT04827381|Other|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
75631683|NCT04750005|Other|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing twice a day.
75631684|NCT04750005|Other|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
75782801|NCT01153100|Drug|Glargine|Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
75782802|NCT01262222|Other|endothelial function testing|After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.
75918325|NCT04791982|Behavioral|Educational sessions|Firstly, the literature was scanned and a education booklet prepared after the opinions of 5 academic nurses, who are experts in the field of oncology, was used. The booklet was included colorectal cancer treatment, symptoms that may develop due to chemotherapy and information on their control, psychosocial support of caregiving family members. Interviews and educational sessions with family members who agreed to participate in the study were held in one-on-one and face-to-face meeting room. These interviews lasted approximately 45 to 60 minutes for each family member. In the interviews, a educational booklet containing information on nutrition, exercise, symptom management, physical aspects of care and disease-specific care was used to present information to caregivers. All of educational sessions were performed by the single researcher.
75918326|NCT02085525|Other|Nurse Practitioner Clinic|"The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs."
75918327|NCT05615272|Biological|Bio-PRF|Intervention group
75631685|NCT04750005|Other|Reach Unflavored Waxed Dental Floss|Participants after brushing for 1 minute, rinse mouth with water and FLOSS once a day in first use.
75631686|NCT04750005|Other|American Dental Association (ADA) Ref Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
75782803|NCT03889496|Radiation|indium-111-exendin SPECT/CT|SPECT/CT imaging after injection with In-111-DTPA-exendin-4
75782804|NCT03884738|Other|Concentric Exercise|"Leg Curl Machine: 1st week - 1st day is 10 maximum repeat test. 2nd week - 2 days of training - 2 sets of 6 repeats. %60 percent of maximum load.~3rd week - 3 days of training - 3 sets of 6-8 repeats. %60-80 of maximum load. 4th-8th week - 3 days of training - 3 sets of 8-12 repeats. when 3 sets of 12 achieved, load was increased with 2.5kg."
75782805|NCT03884738|Other|Nordic Eccentric exercise|"st week - 1 day - 2 sets of 5 repeats.~nd week - 2 days - 2 sets of 6 repeats.~rd week - 3 days - 3 sets of 6-8 repeats.~th week - 3 days - 3 sets of 8-10 repeats. 5-8th weeks - 3 days - 3 sets of 12-8 repeats. When achieved 3 sets of 12 repeats with full range, speed was increased."
75918328|NCT05615272|Drug|Alveogyl|Control group
75918329|NCT02085603|Drug|Saracatinib|
75918330|NCT02085603|Drug|Placebo|
75918331|NCT04784572|Other|first injection delay and second injection delay|"During the first injection, the patient will make END scale for 5 seconds, EVAF scale for 10 seconds and insight scale for 5 minutes.~The second injection the patient will make END scale for 5 seconds and EVAF scale for 10 seconds and then a maintenance."
75918332|NCT02090829|Drug|Syntocinon (synthetic oxytocin)|Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
75782806|NCT03884738|Other|Neuromuscular Electrical Stimulation|8 weeks, three times per week, 15 minutes of bilateral hamstring stimulation. 100 Hz. frequency, 600 microsecond duration rectangular current
75918333|NCT02090829|Other|Placebo|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
75918334|NCT04785040|Other|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale
75918335|NCT02791659|Radiation|Automatic beam adjustment function|The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
75918336|NCT04784494|Device|Magnetic Seizure Theapy (MagPro XP MST)|"MST treatment will be administered over the frontal/vertex cortex using 100 Hz stimulation using the MagPro XP MST with Cool TwinCoil. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~MST treatments will be administered twice a week, for up to 16 treatments. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
75918337|NCT02090907|Drug|Levothyroxine|
75918338|NCT02090907|Drug|Placebo|
76076204|NCT04378036|Device|Hippotherapy Simulator|Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
76076205|NCT04378192|Device|Laryngeal mask airway|Insertion of laryngeal mask airway before intubation of a morbidly obese patient
76076206|NCT04378192|Device|face mask|use of face mask before intubation of a morbidly obese patient
76076207|NCT01725412|Dietary Supplement|Thiamine 300mg PO once daily|
76076208|NCT01725412|Dietary Supplement|placebo|
76076209|NCT01725490|Drug|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
75631687|NCT04711083|Diagnostic Test|overnight pulse oximetry|"Wrist worn Overnight oximetry was performed using portable Nonin 2500 (Nonin Medical Inc., USA) pulse oximeters. The test was explained to the subjects and their caregiver by experienced health-care staff from the sleep unit. The recording was done at home and started just before going to bed and ended on awakening; the recommended duration was a minimum of 5 h and a maximum of 7 h. The awake SpO2, mean SpO2. The data were analysed to calculate the overnight minimum SpO2, mean SpO2, dip frequency (defined as a fall in SpO2 of > 4%), the percentage of oximetry sleep time spent with a SpO2 of < 90%, and the total oximetry time. Recordings were classified as normal (< 4.9 desaturation events an hour), equivocal (5 to 14.9 desaturation events an hour), or abnormal (> 15 desaturation events an hour) according to the severity and pattern of nocturnal desaturation observed ."
75782807|NCT01153256|Drug|magnesium sulphate|The patients of group M receive 50 mg/kg of magnesium sulphate in 100 ml of isotonic saline over 10 min immediately before anaesthesia induction. After induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg), rocuronium 0.6 mg/kg is given over 5 s in a running infusion.
75782808|NCT01153256|Drug|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
75782809|NCT01153256|Drug|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
75782810|NCT01153334|Drug|Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)|1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
75782811|NCT01259804|Dietary Supplement|Peanut oral immunotherapy|Daily doses of peanut flour
75918339|NCT04801888|Biological|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
75918340|NCT04801888|Biological|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
76076210|NCT01725490|Drug|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
76076211|NCT01725490|Drug|Placebo|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
75918341|NCT02089503|Other|intravitreal injections of Lucentis|intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
75631688|NCT02845791|Behavioral|Interactive Lifestyle programme workshop|Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).
75918342|NCT02090985|Procedure|Lipomodelling of symptomatic peri-stomal skin contour abnormalities|
75918343|NCT02594098|Drug|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
75782812|NCT03881930|Other|Balance rehabilitation with modified visual input|Patients will perform the exercises alternatively: while keeping their eyes closed or their vision will be obstructed by a opaque mask or disturbed by moving luminous dots projected on the environment in a dark room without any visual reference cues.
76076212|NCT01682876|Biological|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
76076213|NCT01725568|Device|BioMonitor|Implantable cardiac monitor
75324879|NCT00768521|Drug|Comparator: Placebo to tolterodine tartrate|"Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule"
75324880|NCT02038569|Drug|LEO 80185 gel|
75324881|NCT00768599|Drug|Econazole Nitrate Cream 1%|Topical cream, applied once daily for 4 weeks.
75631689|NCT05336721|Drug|Chiauranib|25mg/35mg/50mg orally once daily
75631690|NCT05336721|Drug|capecitabine|1000mg/m2 on Days 1-14 in a repeating 21-day cycle
75631691|NCT04691115|Drug|AM1476|AM1476 Capsules
75631692|NCT04691115|Drug|Placebo|Placebo Capsules
75631693|NCT04080999|Device|r-TMS|The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
75631694|NCT04080999|Device|SHAM|Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
75631695|NCT04210635|Other|ZEN cart|essential oils + relaxing music + dim light
75631696|NCT04573413|Device|Inhibitory repetitive transcranial magnetic stimulation|"r-TMS Parameters: International 10/20 system for the location of the target area (left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
75631697|NCT04573413|Device|Sham Group|Sham stimulation and Visual scanning training Intervention: Device: SHAM
75782813|NCT03881930|Other|Balance rehabilitation with no modified visual input|Patients will perform the exercises while keeping their eyes openned
75782814|NCT01153880|Drug|Retapamulin|Prescription sales claim of retapamulin
75782815|NCT01153880|Drug|Co-prescription of retapamulin and topical mupirocin|Same day prescription sales claims for retapamulin and topical mupirocin
75782816|NCT01260428|Device|threshold PEEP|Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing
75782817|NCT05499338|Procedure|Stretching program|The stretching programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. The final stretching position was that which generated a sensation of moderate-intense tightness in the muscles, but without exceeding the pain threshold. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
75782818|NCT01157156|Drug|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
75782819|NCT03884894|Diagnostic Test|molecular assay|performed with blood culture simultaneously
75782820|NCT03884894|Diagnostic Test|Blood culture|performed with molecular assay simultaneously
75918344|NCT02594098|Drug|Placebo|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
75918345|NCT02091063|Drug|ACY-1215|All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
75631698|NCT05336643|Device|Radiofluorescence|Assessment of pelvic sidewall with Firefly and Sensei
75631699|NCT00723723|Drug|Statin|Statin
75918346|NCT02091219|Drug|Vitamin D|2400 IU/day by mouth for 16 weeks
75918347|NCT02091219|Drug|25(OH)D3|20 micrograms/day by mouth for 16 weeks
76076214|NCT01728610|Dietary Supplement|Probiotic (Active high)|Higher dose of probiotic supplement
76076215|NCT01728610|Dietary Supplement|Probiotic (Active low)|Lower dose of probiotic supplement
75324882|NCT00768599|Drug|Econazole Nitrate Foam 1%|Topical foam, applied once daily for 4 weeks.
75324883|NCT00768599|Drug|Vehicle Foam|Topical foam, applied once daily for 4 weeks.
75324884|NCT03804203|Radiation|standard treatment|3000 cGy in 10 daily fractions
76076216|NCT01728610|Dietary Supplement|Placebo|Placebo
75631700|NCT05335395|Behavioral|SUNRISE radio campaign|"The SUNRISE radio campaign will be promoting responsive caregiving and providing opportunities for early learning to support child development during the first 3 years of life.~The SUNRISE campaign will follow DMI's established intervention approach with:~60-second radio spots, tailored to increase awareness, knowledge, motivation, skills and opportunity regarding the target behaviours, will include scripted dramas and modelling of responsive parent-child interactions. Each spot will be broadcast 10 times a day for a week; the content of the spots will be changed on a weekly basis. This weekly cycle will continue for three years.~Long format 60-minute programmes broadcast 2-3 times a week, incorporating longer dramas, real life testimonials and practical 'how to' advice, with space for listeners to call in, express opinions and uncertainties and ask questions."
75631701|NCT00653913|Drug|SCH 58235|SCH 58235 10 mg (once daily)
75631702|NCT00653913|Drug|pitavastatin|Pitavastatin 2 mg (once daily)
75631703|NCT00652431|Drug|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
75631704|NCT00652431|Drug|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
75631705|NCT00652431|Drug|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
75631706|NCT03372525|Device|HFOV|Infants were randomized to HFOV
75782821|NCT03881774|Biological|CAR-T cells|collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg
75631707|NCT03372525|Device|CMV|Infants were randomized to CMV
75782822|NCT01260506|Drug|VB-111|
75782823|NCT01260506|Drug|Bevacizumab|Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
75782824|NCT01262300|Biological|Varicella Zoster Virus Vaccine (Zostavax)|Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
75782825|NCT01154114|Drug|darapladib|darapladib 40 mg oral dose
75782826|NCT03462758|Device|IUD|Postpartum IUD placement
75782827|NCT01157312|Drug|clomiphene citrate +highly purified uFSH|
75782828|NCT01157312|Drug|clomiphene citrate|
75782829|NCT01157390|Other|Infant formula|Name: Infant formula with high proportion of palmitic acid in the sn-2 position Dosage & frequency: Fed as need Duration: at least 3 months
75782830|NCT01157390|Other|Breast feeding|Breast feeding
75782831|NCT02527304|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo adaptive staged SBRT
75782832|NCT02527304|Other|Quality-of-Life Assessment|Ancillary studies
75631708|NCT04068363|Other|non interventional|non interventional study
75782833|NCT02527304|Other|Questionnaire Administration|Ancillary studies
75782834|NCT02527304|Radiation|Stereotactic Body Radiation Therapy|Undergo adaptive staged SBRT
75782835|NCT03888248|Device|Whole-body vibration|Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week
75782836|NCT03888248|Other|Muscle strengthening exercises|Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
75782837|NCT01262378|Procedure|abdominal plastic surgery|Surgery for ABDOMINAL SUBCUTANEOUS FAT
75782838|NCT03888326|Device|1x1 anodal tDCS|20 minutes of 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
75782839|NCT03888326|Device|Sham tDCS|Sham 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
75782840|NCT03888326|Behavioral|Robotic Rehabilitation|10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
75782841|NCT01154270|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
75782842|NCT03881618|Procedure|electroacupuncture+auricular pressure,|electroacupuncture+auricular pressure for 20 minutes
75782843|NCT03881540|Other|tDNA-MI group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements and motivational interviewing counseling. .
75782844|NCT03881540|Other|tDNA-CC group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements+ 150 min/week of moderate intensity exercise + and conventional counselling.
75918348|NCT02593864|Device|Variable-Stiffness Shoe|A load-modifying variable-stiffness shoe previously shown to reduce joint loading
75782845|NCT03881540|Other|UC group|Meal plan of 1200-1500 kcal/day using conventional foods + 150 min/week of moderate intensity exercise + and conventional counselling
75782846|NCT01157546|Procedure|Normal saline via TAP catheters|A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
75782847|NCT01157546|Procedure|Lidocaine via TAP catheters|A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
75782848|NCT02527460|Drug|Anakinra|Participants will self-administer daily subcutaneous injections of anakinra for 8 weeks. The dose will be increased over the first four weeks to minimize injection site reactions. The target dose after four weeks is 300mg daily.
75782849|NCT01263860|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
75782850|NCT01263860|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
75782851|NCT01263860|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
75782852|NCT01263860|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
75918349|NCT02091297|Drug|TAP Block|This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
75918350|NCT02091297|Drug|Ropivacaine|The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
75631709|NCT00901485|Device|AutoVPAP|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.
75631710|NCT00901485|Device|VPAPIIIST-A|Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.
75631711|NCT04067739|Other|non interventional study|non interventional study
75468144|NCT06071091|Other|Optimal medical care, without additional endovascular procedures|"The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts.~In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion.~The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list):~Nursing~Nursing care~Symptomatic treatments: analgesics for example~Systematic clinical monitoring and control imaging if necessary~Rehabilitation if necessary)"
75631712|NCT04060641|Genetic|Geneticure for RDN Genetic Panel|This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
75631713|NCT02842593|Behavioral|Lower-repetition, heavier-load|8-12 reps/set at ~80% 1 repetition maximum
75631714|NCT02842593|Behavioral|Higher-repetition, lighter-load|20-25 reps/set at ~30% 1 repetition maximum
75782853|NCT03884582|Device|Cova Monitoring System 3|Healthy Volunteers
75631715|NCT02842515|Other|teeth avulsion|
75631716|NCT00896337|Device|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
75631717|NCT00896337|Drug|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
75631718|NCT00896337|Drug|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
75631719|NCT00380523|Drug|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
75631720|NCT04201743|Drug|Acellular amniotic membrane derived allograft injection (NuDYN)|Injectable acellular amniotic membrane derived allograft (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) in the treatment of knee osteoarthritis.
75782854|NCT03881306|Drug|D-TACE|D-TACE with CalliSpheres-Oxaliplatin
75782855|NCT01154348|Drug|S-707106|Tablet, taken once daily with morning meal
75782856|NCT01154348|Drug|Placebo|Placebo tablet, taken once daily with morning meal
75782857|NCT01154348|Drug|Metformin, S-707106 plus metformin|Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily
75782858|NCT01154348|Drug|Metformin, placebo plus metformin|Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
75782859|NCT00075270|Drug|Paclitaxel|Active Comparator
75782860|NCT00075270|Drug|GW572016 (Lapatinib)|Oral GW572016 Lapatinib
75782861|NCT03888638|Procedure|Hepatectomy|Removal of a part of the liver because of tumor
75324885|NCT03804203|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
75324886|NCT03803891|Procedure|Endoscopic full-thickness resection|Endoscopic full-thickness resection (EFTR) with Over-The-Scope-Clip in colorectal lesions
75324887|NCT02370693|Drug|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
75324888|NCT02370693|Drug|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
75631721|NCT00319995|Drug|loratadine; montelukast|
75631722|NCT03832413|Diagnostic Test|DELPhI (TMS-EEG analysis)|We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).
75631723|NCT02842281|Other|Fructan|Short-chain oligosaccharide primarily composed of fructose polymers
75631724|NCT02842281|Other|Maltodextrin|Polysaccharide produced from starch
75631725|NCT00633165|Drug|Brostallicin|Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
75631726|NCT03789513|Diagnostic Test|HPV test with partial genotyping and VIA triage|HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
75631727|NCT02091843|Procedure|DBS of the Basolateral Nucleus of the Amygdala|
75631728|NCT02091843|Device|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
75631729|NCT02842437|Drug|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
75631730|NCT02842437|Other|normal saline|receive matching placebo (equal volume of normal saline)
75631731|NCT00157911|Drug|MK0653; ezetimibe / Duration of Treatment: 12 weeks|
75631732|NCT00157911|Drug|Comparator: simvastatin / Duration of Treatment: 12 weeks|
75324889|NCT02370693|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
75918351|NCT02091297|Drug|Acetaminophen|"Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia"
75918352|NCT02091297|Drug|Morphine|
75918353|NCT04791670|Other|survey study|The surveys will include general data, the type of electronic devices in possession and the purpose of use. eHealth literacy will be assessed with the eHeals questionnaire. Platform's ease of use will be assessed with the System Usability Scale, and participants´ opinion about the digital path utility with six questions. These items will be answered with a Likert-scale. Finally, we added an open question for qualitative analysis.
75918354|NCT02091453|Behavioral|APT training|APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.
75918355|NCT02091453|Behavioral|Multiprofessional rehabilitation|Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
75918356|NCT04760470|Other|Technological-assisted upper extremity rehabilitation|Subjects get 6 weeks of technological-assisted upper extremity rehabilitation
75918357|NCT02091609|Other|dental interproximal brush|use of this to maintain oral hygiene
75918358|NCT02091609|Other|dental floss|use of this to maintain oral hygiene
75918359|NCT04784338|Behavioral|Virtual shared medical visit|a shared medical visit done by zoom in a group, 1.5 hours
75631733|NCT05336175|Drug|Angiotensin 1-7|"A substance, Angiotensin-(1-7) [Ang-(1-7)], is known to decrease inflammation in the brain. This substance is naturally produced in the body and works by activating areas in the brain involved in memory. Previous studies examining the ability of Ang-(1-7) treatment to prevent memory loss post open-heart surgery found that 21 days of treatment with Ang-(1-7) protected memory post-surgery. Participants treated with Ang-(1-7) were protected from post-surgery increase in NfL levels. This clinical sub-project within the existing study will allow us to obtain preliminary data to evaluate the safety and efficacy of treatment with Ang-(1-7) to improve cognitive function and determine if this treatment is associated with changes in plasma levels of NfL protein.30 participants will take 100 micrograms of Ang-(1-7) per day via subcutaneous injection for 90 days."
75631734|NCT05336175|Drug|Saline solution|Saline solution will be given as a placebo intervention to 10 participants. These participants will take 100 micrograms of saline solution per day via subcutaneous injection for 90 days.
75631735|NCT02842125|Drug|Ad-P53|Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
75631736|NCT02842125|Drug|Xeloda|Oral metronomic chemotherapeutic agent
75631737|NCT02842125|Drug|Keytruda|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
75631738|NCT02842125|Drug|Opdivo|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
75631739|NCT03708549|Drug|Berberine|The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
75631740|NCT03708549|Drug|Metformin|The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
75631741|NCT00156117|Drug|asenapine|5 mg BID or 10mg BID
75631742|NCT00156117|Drug|Placebo|Placebo
75631743|NCT00156117|Drug|olanzapine|olanzapine 15 mg QD
75782862|NCT01155752|Drug|Pulmozyme single use ampule|• Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
75782863|NCT01155752|Drug|placebo|identical placebo
75918360|NCT04784338|Behavioral|Nutritional classes|A cooking class done by the teaching kitchen demonstrating cooking skills
75918361|NCT03557073|Behavioral|Postoperative phone call|The intervention is a phone call on the day following surgery.
75631744|NCT00140985|Drug|MK0954, losartan potassium/Duration of Treatment: 20 weeks|
75782864|NCT03888170|Other|No intervention|No intervention
76076217|NCT03835390|Behavioral|SIMDiscovery|The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
76076218|NCT01838434|Drug|lenalidomide|given PO
76076219|NCT01838434|Drug|idelalisib|given PO
75782865|NCT01264094|Drug|Clevudine|clevudine 30 mg qd
75782866|NCT03884348|Drug|proton pump inhibitor, amoxicillin, clarithromycin|non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
75324890|NCT03809507|Other|Qualtrics survey questions|"Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication"
75631745|NCT00140985|Drug|Comparator: amlodipine / Duration of Treatment: 20 weeks|
75782867|NCT03884348|Drug|proton pump inhibitor, amoxicillin, metronidazole|clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
75782868|NCT03881384|Other|ctDNA level during neoadjuant chemotherapy|Draw blood from each enrolled patient every time before chemotherapy and measure the ctDNA level in plasma.
75782869|NCT01264172|Procedure|PCCP|PCCP: an minimal-invasive surgery technique, in wich a special plate is pushed in position and fixed through 2 small approaches only (about 2 cm long)
76076220|NCT01838668|Drug|Placebo|Two placebo capsules orally BID
76076221|NCT01838668|Drug|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
75324891|NCT02039115|Drug|prednisone|6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
75324892|NCT02039115|Drug|placebo|6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
75631746|NCT03255057|Device|Hemolung Respiratory Assist System|Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.
75631747|NCT03255057|Device|Invasive mechanical ventilation|Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
75631748|NCT00140907|Drug|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
75631749|NCT00140907|Drug|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
75782870|NCT01264172|Procedure|DHS|Conventional surgical treatment of proximal femur fracture including one longer approach from lateral
75782871|NCT01264172|Procedure|Osteosynthesis with nails|Osteosynthesis with nails is a minimal-invasive surgery technique for proximal femur fractures.
75631750|NCT00132717|Drug|MK0653A (ezetimibe [+] simvastatin)|
75782872|NCT02527382|Procedure|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
75782873|NCT01154426|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
76076222|NCT01728688|Other|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
75324893|NCT00759473|Drug|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
75324894|NCT00759473|Drug|Placebo|
75324895|NCT02371395|Other|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
75324896|NCT00759707|Drug|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein [arterial] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
75324897|NCT02039817|Drug|IDN-6556|
75324898|NCT02371785|Device|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
75324899|NCT03809273|Drug|Yangxinshi|Yangxinshi pill 3 pills /tid
75324900|NCT03809273|Drug|Trimetazidine|Trimetazidine 20mg/tid
75631751|NCT00132717|Drug|Comparator: atorvastatin|
75324901|NCT03809273|Drug|Yangxinshi mimic|Yangxinshi mimic tablets 3 pills /tid
75324902|NCT03809273|Drug|Trimetazidine mimic|Trimetazidine mimic tablets 20mg/tid
75631752|NCT00132717|Drug|Comparator: fluvastatin|
75324903|NCT04384991|Drug|HU007|Cyclosporine 0.02% with Trehalose 3%
75631753|NCT00132717|Drug|Comparator: lovastatin|
75631754|NCT00132717|Drug|Comparator: pravastatin|
75631755|NCT00132717|Drug|Comparator: rosuvastatin|
75782874|NCT01154426|Drug|Gemcitabine Hydrochloride|Given IV
75782875|NCT01154426|Other|Pharmacological Study|Correlative studies
75782876|NCT01154426|Drug|Veliparib|Given orally
75782877|NCT01589744|Device|Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)|The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
75782878|NCT01154504|Other|clinical treatment|The clinical treatment will be optimized to gold standard international heart failure treatment
75782879|NCT01154504|Procedure|ultrafiltration|The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
76076223|NCT01728688|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
76076224|NCT01728766|Other|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at >37 weeks by and birth weight <2500 g
75324904|NCT04384991|Drug|Restasis eye drop|Cyclosporine 0.05%
75324905|NCT05742893|Diagnostic Test|Measurement of pragmatic and discourse test scores in the two scales.|The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .
75324906|NCT00354627|Drug|TMC125|200 mg b.i.d. till commercially available.
75631756|NCT00132717|Drug|Comparator: simvastatin|
75631757|NCT00127179|Drug|MK0906, finasteride / Duration of Treatment: 48 weeks|
75631758|NCT00127179|Drug|Comparator: placebo / Duration of Treatment: 48 weeks|
75631759|NCT02842047|Behavioral|Stop, Breathe & Think™|online daily meditations delivered using smart phone or other computer based application
75782880|NCT01154504|Procedure|isovolumetric hemofiltration|The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
75782881|NCT01157624|Drug|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
75782882|NCT01157624|Drug|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
75782883|NCT00074958|Biological|Fabrazyme (agalsidase beta)|1 mg/kg every 2 weeks
76076225|NCT01728766|Other|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at >37 weeks and birth weight >2800 g
76076226|NCT04377646|Drug|Hydroxychloroquine|400 mg at day 1 and day 2, then 400 mg weekly up to 2 months
75468145|NCT06071078|Behavioral|Training of professionals according to the DISCUSS announcement protocol|"The emergency services will be divided into 4 clusters (2 or 3 services per cluster). Each cluster will belong successively to the control arm and then to the intervention arm according to a 5 successive steps of 4 months duration (stepped wedge method). The deployment of the training will therefore not be done simultaneously in the different services.~Individuals in this group will have received a decision of withholding and withdrawing life-sustaining treatments according to the DISCUSS announcement protocol, by a professional trained in this procedure."
75468146|NCT06071052|Procedure|TACE and HAIC Combined With Regorafenib|TACE and HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer who failed the second line treatment regimens
75468147|NCT06071039|Combination Product|3D spacer Fabric Based Mattress|For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
76076227|NCT04377646|Drug|Hydroxychloroquine (placebo)|1 pill at day 1 and day 2, then 1 pill weekly up to 2 months
76076228|NCT04377646|Drug|Zinc|15 mg per day up to 2 months
76076229|NCT04377646|Drug|Zinc (Placebo)|1 pill per day up to 2 months
76076230|NCT01728922|Dietary Supplement|5000IU vitamin D|Vigantol Oil
76076231|NCT01728922|Dietary Supplement|10000IU vitamin D|Vigantol Oil
76076232|NCT01728922|Other|Placebo|Placebo Oil
76076233|NCT01682720|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
76076234|NCT01682720|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76076235|NCT01682720|Drug|Placebo to match SOF|Placebo to match SOF administered orally once daily
75468148|NCT06071026|Device|Net Ultra Filtration Rate|The net ultra filtration rate is modified every 6 hours accordingly to randomisation
75468149|NCT06071013|Drug|Nintedanib, gefitinib, erlotinib, afatinib|"Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration.~Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells."
75468150|NCT06071000|Behavioral|Neuro-developmental stimulation (Neuro-vývojová stimulace).|Neuro-developmental stimulation is exercise based intervention program that is focused on repeating reflex movements and thus inhibiting reflexive response.
75631760|NCT02842047|Behavioral|End of Life Planning Videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.
75631761|NCT02842047|Behavioral|Caregiver wellness videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
75782884|NCT01157702|Biological|Inactivated influenza vaccine (split virus, Vero cell-derived)|One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
76076236|NCT01682720|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
76076237|NCT01838902|Drug|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
76076238|NCT01838902|Drug|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
76076239|NCT01838902|Drug|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
76076240|NCT01838902|Drug|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
76076241|NCT03409822|Device|Masimo SpHb™ monitor|Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
76076242|NCT03401086|Other|Kinesio Taping|Kinesio Taping
76076243|NCT03409510|Radiation|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
76076244|NCT04551014|Device|Use of EverLift|Use of EverLift for submucosal injection prior to polypectomy
76076245|NCT04551014|Device|Without use of EverLift|Without use of EverLift for submucosal injection prior to polypectomy
75468151|NCT06070987|Procedure|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 100 units. The dose range of each target muscle is as below:100 units in rectus femoris.
75631762|NCT05334771|Device|Dual band pure tune audiometer|Orbiter 922 Tympanometry
75631763|NCT02841813|Other|No intervention|No intervention
75631764|NCT00953706|Drug|Ivacaftor|Tablet
76076246|NCT01729000|Other|Gloves|All staff must wear gloves for subjects that are in the experimental group.
76076247|NCT01729078|Dietary Supplement|Dietary intervention|three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
76076248|NCT01714544|Drug|Cloderm Cream|
76076249|NCT03401008|Other|Oral manifestations|To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.
76076250|NCT03400696|Behavioral|Lower carbohydrate diet|Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
76076251|NCT03400696|Behavioral|Higher fiber diet|Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
76076252|NCT03400696|Behavioral|Physical activity focused|Focused on aerobic and resistance exercise, while following dietary guidelines <https://www.choosemyplate.gov>
76076253|NCT01729234|Dietary Supplement|Nitrate|Dietary Supplement
76076254|NCT01729234|Dietary Supplement|Placebo|Dietary Supplement
75468152|NCT06070987|Other|BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot after BoNT-A injected in the affected rectus femoris, then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
76076255|NCT03409354|Behavioral|Tele-rehabilitation|There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.
75782885|NCT01092936|Other|Rating Scale administration|Movement Disorder Society_Unified Parkinson's Disease Rating Scale will be submitted to the patient (with the help of the caregiver) in a single visit lasting about 40 minutes.
75918362|NCT04791592|Procedure|Single-injection, ultrasound-guided bilateral PIF block.|"PIF block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
75918363|NCT04791592|Procedure|Single-injection, ultrasound-guided bilateral TTMP block.|"TTMP block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
75918364|NCT02091765|Behavioral|Internet-based cognitive behavioral therapy.|
75918365|NCT04791202|Drug|Dextrose|See arm descriptions
75918366|NCT04791202|Drug|Methylprednisolone Acetate 40 MG/ML|See arm descriptions
76076256|NCT03409354|Behavioral|Usual care|Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
76076257|NCT03400462|Drug|NSAID|Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.
75468153|NCT06070987|Other|None BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot (do not inject BoNT-A in the affected rectus femoris), then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
75468154|NCT06070974|Diagnostic Test|CMR and blood collection|All patients enrolled will undergo 2 CMR examination (within 3-5 days post PCI and after six months), and blood collection at third day after PCI (T0). Patients recruited at Centro Cardiologico Monzino will be subjected to a blood withdrawal also at different time points: 1- 3- 6 months after STEMI (T1, T2, and T3 respectively).
75468155|NCT06070948|Drug|Venetoclax|Oral; Tablet
75631765|NCT00953706|Drug|Placebo|Tablet
75782886|NCT03881462|Procedure|Axillary nerve block for artificial deltoid muscle palsy|"Axillary nerve block block (AXNB):~The ultrasound probe is placed transversally in the infraclavicular region with the arm in 90° abduction. The brachial plexus and its cords are identified l lateral to the brachial artery. The posterior cord is identified by ultrasound and is blocked - or, if the axillary nerve visible too - the axillary nerve is selectively blocked when it leaves the posterior cord and lies on the subscapular muscle accompanied by the posterior circumflex humeral artery. Using an in-plane technique, a short bevel connected to a nerve stimulator with the setting 0.5 mA current intensity, 0.1 ms impulse duration and 2 Hz impulse frequency for dual guidance, will be advanced until its tip is positioned near the nerve without eliciting motor contractions. After careful negative (for blood) aspiration local anesthetic will be applied until the targeted neuronal structure is surrounded by the injected fluid."
76076258|NCT03400462|Device|oral appliance|The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.
75631766|NCT02853084|Drug|HL2351|The dose will be adjusted based on disease activities
75631767|NCT02853006|Biological|Blood and respiratory fluids sampling|In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
75631768|NCT02853006|Procedure|Biopsy|
75631769|NCT02853006|Procedure|Excised tissues|
75631770|NCT02852382|Drug|Bupivacaine|In the scalp block and local infiltration arms; bupivacaine %0,5 will be used.
75631771|NCT02852382|Drug|morphine patient controlled analgesia|End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.
75918367|NCT02085681|Other|Tele-medicine|Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.
75782887|NCT03881072|Other|Ultrasounicelastography|Observing the correlation between endometrial elasticity score, endometrial blood flow index (PI, RI, S/D, endometrial thickness, morphology) and clinical pregnancy rate.
75631772|NCT00630942|Drug|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
75782888|NCT03880916|Drug|Duloxetine|"Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
75324907|NCT03803501|Other|condensed functional restoration program|The condensed functional restoration program (CFRP) is a complex multidisciplinary intervention proposed as usual care according to international guidelines. The program takes place in our department of rheumatology, 6 hours per day, 1 day a week, for 4 weeks. Patients are included during consultation or Hospitalisation and are in groups of 6 maximum per FRP. The CRFP was developed on the basis of therapeutic patient education programs and physical exercises (Van Wambeke 2017, Desthieux 2014). Three hours per day are devoted to physical exercises which were divided into three periods: warming, stretching, and muscular strengthening. Specific exercises adapted to work circumstances (like manutention) are taught. Muscular strengthening is based on isotonic contraction on fitness devices. Education is based on 1 hour long educative session adapted from back school programs once a week. Educative booklets are also given to the patients.
75918368|NCT02085681|Other|Conventional referral|All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
75324908|NCT05742815|Other|No intervention|This is an observational collection of data from purchased donor milk samples
75631773|NCT00602550|Drug|Zidovudine|
75631774|NCT02852148|Device|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
75631775|NCT00604110|Other|Biventricular pacing post cardiac surgery|Determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF<45%), is hemodynamically favourable.
75631776|NCT00602628|Other|questionnaire administration|
75918369|NCT04801342|Radiation|Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Unilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
75324909|NCT00770861|Drug|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
75324910|NCT00770861|Drug|Placebo|Matching placebo tablets, oral administration
75631777|NCT00602628|Procedure|adjuvant therapy|
75782889|NCT03880916|Drug|Placebo|Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
75782890|NCT01155908|Drug|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
75782891|NCT03880760|Other|L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
75631778|NCT00602628|Procedure|biopsy|
75782892|NCT03880760|Other|Placebo|Taking 1 placebo capsule twice a day before meals for six months.
75631779|NCT00602628|Procedure|computed tomography|
75918370|NCT04801342|Radiation|Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Bilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
75631780|NCT00602628|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
75631781|NCT00602628|Procedure|magnetic resonance imaging|
75631782|NCT00602628|Procedure|therapeutic conventional surgery|
75631783|NCT00602628|Procedure|ultrasound imaging|
75631784|NCT00602628|Radiation|radiation therapy|
75918371|NCT04801342|Drug|Memantine Hydrochloride|Start from day 1 of WBRT orally for 24 weeks and escalating doses over the first 4 weeks
75324911|NCT03808805|Drug|Aprepitant 80 mg|oral therapy - daily dose - 14 days
75631785|NCT00602706|Biological|sargramostim|
75324912|NCT03808805|Drug|Hydroxyzine 25mg|oral therapy - daily dose - 14 days
75631786|NCT00602706|Drug|melphalan|
75631787|NCT00602706|Procedure|autologous hematopoietic stem cell transplantation|
75631788|NCT00602706|Procedure|peripheral blood stem cell transplantation|
75631789|NCT00602706|Radiation|samarium Sm 153 lexidronam pentasodium|
75631790|NCT00604344|Drug|insulin detemir|
75631791|NCT00604344|Drug|insulin NPH|
75631792|NCT02852226|Other|Pre Exposure Prophylaxis|Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.
75782893|NCT03880448|Drug|Metronidazole|Metronidazole 500mg/8h/7days
75782894|NCT03880448|Drug|Placebo|Cornstarch 500mg/8h/7days
75782895|NCT03880448|Procedure|periodontal surgery|periodontal surgery
75782896|NCT02527226|Behavioral|Facial exercises|A series of self-administered facial movements and expressions.
75918372|NCT04801264|Drug|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga-PSMA will be used to image lesions of adenoid cystic carcinoma by PET/CT.
75918373|NCT04801264|Drug|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
75918374|NCT02085837|Other|Education|Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
75918375|NCT02085837|Other|Daily weight measurement and monitoring|Monitor weight to avoid problems related to hypervolemia.
75918376|NCT02085837|Other|Universal Dietary education|To improve diet and health
76076259|NCT03400462|Other|dry needling|Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
75631793|NCT02852226|Behavioral|Characteristics of women who enroll|The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
75631794|NCT02852226|Behavioral|referral sources of women who enroll|Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
75631795|NCT00940992|Drug|DER 45 EV|Topical application to face for 12 weeks
75631796|NCT00940992|Drug|Vehicle|Topical application to face for 12 weeks
75631797|NCT02851914|Drug|"Tricyclic Antidepressants (TCA)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
75918377|NCT02085837|Other|Medication review|Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.
75918378|NCT02085837|Other|Focused advanced directive program|Education will be provided to increase awareness and encourage patients to have advanced directive.
75631798|NCT02851914|Drug|"Selective Serotonin Uptake Inhibitors (SSRI)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
75782897|NCT01157780|Drug|Lovaza (fish oil)|Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
75782898|NCT03884192|Drug|Consolidation Sintilimab|Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
75918379|NCT02085837|Other|Countdown to fistula program|To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
75918380|NCT02590588|Drug|Idelalisib|Idelalisib daily until unacceptable toxicity or disease progression.
75631799|NCT00938964|Drug|Lidocaine|Lidocaine versus placebo infusion for 48 hours
75631800|NCT00938964|Drug|Placebo|Lidocaine versus placebo infusion for 48 hours
75631801|NCT04268160|Diagnostic Test|Blood draw to measure GPx activity|Routine blood draw to measure levels of blood markers.
75631802|NCT04268160|Diagnostic Test|Blood draw to measure SOD activity|Routine blood draw to measure levels of blood markers.
75631803|NCT04268160|Diagnostic Test|Blood draw to measure Lp(a) levels|Routine blood draw to measure levels of blood markers.
75631804|NCT00938886|Drug|Naltrexone|Daily 50 mg naltrexone
75782899|NCT03880604|Procedure|Triple tourniquets|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels
75782900|NCT03880604|Drug|TA|1-gram tranexamic acid (10 ml) in 100 ml saline infusion
75782901|NCT03880604|Other|placebo to TA|placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
75782902|NCT01264250|Drug|AZD2927|Single dose of AZD2927
75782903|NCT01264250|Drug|Placebo|Single dose of placebo
75631805|NCT00938886|Drug|Placebo|Matched naltrexone placebo
75782904|NCT03887858|Drug|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration under fasting
75918381|NCT02085915|Other|strip Peri Screen|
75918382|NCT05615896|Device|Imaging Session|Various scans will be captured on both devices
75918383|NCT02086071|Procedure|re biopsy|re biopsy depending on the location of the pathology
75918384|NCT03558399|Other|FET according to ERA|Single euploid FET will be performed at the time indicated by the ERA test results.
75918385|NCT03558399|Other|FET according to standard protocol|Single euploid FET will be performed according to our standard FET protocol.
76076260|NCT01703858|Drug|BI 113608 PIB|powder for oral solution
75324913|NCT03808805|Drug|Placebo of Hydroxyzine|oral therapy - daily dose - 14 days
75324914|NCT03808805|Drug|Placebo of Aprepitant|oral therapy - daily dose - 14 days
75324915|NCT05717829|Procedure|Modified hip capsular incision|modified incision to make re -suturing of the capsule easier with multiple stitches.
75324916|NCT00355173|Device|Lubo cervical collar|
76076261|NCT01703858|Drug|BI 113608|conventional tablet formulation
76076262|NCT01703858|Drug|BI 113608|conventional tablet formulation
76076263|NCT01703858|Drug|BI 113608|conventional tablet formulation
76076264|NCT01703858|Drug|pantoprazole 40 mg STADA|film-coated tablet
76076265|NCT01703858|Drug|BI 113608|conventional tablet formulation
75918386|NCT02086149|Behavioral|Aerobic Exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals. Two month course of the nicotine patch initiated during week 5.
75918387|NCT02086149|Behavioral|Health Education|12-week health education control. Weekly sessions about 12 different topics related to the health effects of smoking, led by an expert in smoking cessation.
75782905|NCT03887858|Drug|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
75918388|NCT02086227|Drug|Glucagon for Injection (Fresenius Kabi USA)|Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
75918389|NCT02086227|Drug|Glucagon for Injection (Bedford Laboratories)|Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
75918390|NCT03558321|Procedure|Hysteroscopic guided fractional curretage|Under general anaesthesia , evaluation of the endometrial cavity was done followed by biopsy of the whole endometrial tissue
75918391|NCT03558321|Procedure|total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection|Through abdominal incision , removal of the whole uterus , both tubes and ovaries and in some cases pelvic lymph nodes removal was done
75918392|NCT02086305|Behavioral|Transitional Care Model|Symptom assessment and management, care goal setting, post-discharge support
75918393|NCT02086305|Behavioral|Usual care|Usual care is the routine practice in the hospital
75918394|NCT02086461|Device|Pneumatic pyloric dilatation|
75631806|NCT04268082|Device|Visual biofeedback with the use of sensorized insoles|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol. The experimental group was re-educated to the correct gait dynamics by wearing the sensorized insoles and by using a specific software's graphical interface as a visual biofeedback.
75631807|NCT04268082|Other|Standard rehabilitation based on physiotherapist's verbal instructions|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol.The Control group did not wear the insoles, but it carried out the rehabilitation programme under the physiotherapist supervision and with his verbal feedbacks.
75918395|NCT02086461|Other|15 mm pyloric balloon dilatation|
75631808|NCT05381688|Procedure|VIM DBS|Stereotactic deep brain stimulation of ventral intermediate nucleus of thalamus
75631809|NCT02852070|Procedure|bronchoalveolar lavage 120ml|120mL sterile saline solution instilled into the distal bronchial tree in 3 times
75782906|NCT03887546|Device|Inspiratory muscle trainer|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
76076266|NCT03409042|Behavioral|Caloric compensation|The investigators have adapted an established within-subject preload paradigm to assess infant's short term caloric compensation. At each studied age, the measure of caloric compensation required two visits at the laboratory on two non-consecutive days. On the first visit, the infants received a fixed amount of a food preload either low or high in energy density. The order of the two preloads was counterbalanced. After a delay (ranging from several hours in the 3-4 months old infants to 25 min in 10.5- and 14.5-month-old infants), the infants were served an ad libitum meal. Weight intakes (g) were assessed by weighing each bottle/bowl before and after consumption.
75631810|NCT02852070|Procedure|bronchoalveolar lavage 60ml|60mL sterile saline solution instilled into the distal bronchial tree in 3 times
75631811|NCT02851836|Behavioral|image visualization and quotation|"two sets of 60 pictures are shown to the adolescents. we ask them to quote for their valence, hedonicity, arousal and to characterize the emotion elicited in each picture.~This evaluation takes approximately 1hour."
75782907|NCT03887546|Procedure|Respiratory exercise|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
75782908|NCT02940574|Drug|Syntocinon (Oxytocin)|Syntocinon nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
75782909|NCT02940574|Other|Placebo (Physiological water (solution of sodium chloride (NaCl) in water))|Placebo nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
75782910|NCT01154582|Dietary Supplement|Egg snack|subject consume 4 cooked whole eggs, providing 380 kcal
75782911|NCT01154582|Dietary Supplement|Cottage cheese|Subjects consume 200 g of cottage cheese, providing 380 kcal
75782912|NCT03880370|Behavioral|Questionnaires / scales|EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)
75782913|NCT03880370|Diagnostic Test|Ultrasound imaging|Rectus abdominis dominant side & non-dominant side external oblique dominant side & non-dominant side internal oblique dominant side & non-dominant side transversus abdominis dominant side & non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side & non-dominant side
75918396|NCT02086539|Other|Large Envelope|
75918397|NCT02086539|Other|Priority Mail|
75918398|NCT02086539|Other|Amazon|
75468156|NCT06070909|Device|The EMG activations|The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions
75631812|NCT00602784|Biological|IC41|
75782914|NCT03880370|Diagnostic Test|FLEXIBILITY|weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test
75782915|NCT03880370|Diagnostic Test|FUNCTIONAL TESTS|Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen
75918399|NCT02086617|Other|ultrasound of aorta|
75918400|NCT02086773|Biological|Red blood cell transfusion|
75918401|NCT02089581|Drug|Active comparator MR2XXX|comparison of two new oral formulations with existing formulation
75918402|NCT02089581|Drug|MRXXX|MRXXX
75631813|NCT02851680|Biological|blood samples|
75918403|NCT02089581|Drug|MR1XXX|
75918404|NCT02089581|Drug|MRXXX and MR1XXX|MRXXX and MR1XXX in fed and fasted state
75918405|NCT02086851|Behavioral|Lifestyle Intervention|
75918406|NCT02086851|Behavioral|Parent Motivational Interviewing|
75918407|NCT02086929|Drug|Trazodone|
75468157|NCT06070883|Procedure|Amniotic membrane transplantation|Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix. It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. Amniotic membrane transplantation will be performed in eye OT under aseptic conditions. The necrotic tissues at the base of the ulcer will be debrided and sent for culture and sensitivity. The rolledup edge of the ulcer or the loosely adhered epithelium adjacent to the ulcer will also be removed. The amniotic membrane will be trimmed to fit the shape of the ulcer and placed with its epithelial side up. Then the amniotic membrane will be secured with 10-0 nylon suture (5 cases with interrupted and 25 cases with continuous suture) with the suture knots buried.
75468158|NCT06070857|Drug|LV232|"Drug: LV232 1mg Group:~6 subjects will receive LV232 1mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 2mg Group:~6 subjects will receive LV232 2mg, orally; 2 subjects will receive placebo, orally.~Other Names: Placebo~Drug: LV232 4mg Group:~6 subjects will receive LV232 4mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 8mg Group:~6 subjects will receive LV232 8mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 20mg Group:~6 subjects will receive LV232 20mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo"
75631814|NCT00602862|Drug|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
75631815|NCT00602862|Drug|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
75631816|NCT00602862|Drug|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
75631817|NCT04268238|Procedure|Hygiene Guidance|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate).
75631818|NCT04268238|Procedure|Sealant Application|Permaseal (Ultradent) is an unloaded resin based on methacrylate and photopolymerizable. The teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal for 5 seconds to the tooth surface and light curing for 20 seconds. After that, it is necessary to evaluate occlusion.
75631819|NCT04268238|Radiation|Low Level Laser Application|Volunteers will receive irradiation with AsGaAl laser, wavelength of 780nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, density of energy of 35 J/cm2 (considering a spot size of 0.028cm2 of this equipment), the dose will be 1 J per point. Irradiation will be performed at a cervical, an apical point, and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
75631820|NCT04257942|Procedure|carotid endarterectomy|carotid endarterctomy that is being used for carotid stenosis disease
75782916|NCT01264328|Drug|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
75782917|NCT01157858|Drug|Everolimus|2.5 mg every day orally
75782918|NCT01157858|Drug|Octreotide LAR|40 mg every 28 days IM
76076267|NCT01729390|Other|Energy density and portion size feeding study|In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
75782919|NCT01157936|Drug|Allopurinol|daily dosage
75324917|NCT03803267|Other|Erector spinae plane block|For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.
75324918|NCT03803267|Other|Quadratus lumborum block|For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect
75782920|NCT01157936|Other|placebo|daily dosage
75782921|NCT01262534|Other|Clinical profile of patients|Comorbidities and associated type of treatments will be collected.
75324919|NCT03803267|Drug|Propofol|Propofol (2 mg/kg)
75324920|NCT03803267|Drug|Fentanyl NCS|Fentanyl (1µg/Kg)
75782922|NCT01262534|Other|Patient Preferences about treatment|Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
75918408|NCT02086929|Drug|Venlafaxine|
76076268|NCT01729468|Drug|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
75324921|NCT03803267|Drug|Atracurium Injectable Product|atracurium (0.5mg/kg)
75324922|NCT03803267|Other|Endotracheal intubation|endotracheal intubation
75324923|NCT03803267|Drug|Anesthesia Maintenance|Inhalational isoflurane in oxygen/air mixture
75324924|NCT03803267|Drug|Muscle Relaxation|atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
75324925|NCT02041221|Drug|SPARC1316 Dose 1|The subjects will receive SPARC1316.
75324926|NCT02041221|Drug|Placebo|
75324927|NCT02041221|Drug|SPARC1316 Dose 2|
76076269|NCT01729468|Drug|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
76076270|NCT04550468|Other|Low-Carb High-Fat breakfast|Participants will receive 8 low-carb high-fat breakfast meal recipes to follow daily during 3 months.
76076271|NCT04550468|Other|"Low fat standard care control breakfast"|Participants will receive 8 low-fat breakfast meal recipes to follow daily during 3 months.
76076272|NCT03400384|Other|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
75631821|NCT00631176|Behavioral|Just-In-Time Training|On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
75631822|NCT02851602|Biological|Blood sample|
75631823|NCT00602940|Procedure|Acupuncture|12 treatments over 8 weeks
75631824|NCT00602940|Procedure|Sham Acupuncture|12 treatments over 8 weeks
75631825|NCT00942708|Drug|Fluoxetine|"Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID"
75631826|NCT05381298|Procedure|Deep Margin Elevation using resin composite|After completion of the root canal treatment of the offended tooth and comprehensive evaluation of the obtained treatment, the randomly allocated patients will undergo deep margin elevation procedure where rubber dam isolation will be accomplished Followed by proper matricing and wedging ) followed by selective enamel etching for 10 seconds then universal adhesive application following the manufacturer instructions followed by application of flowable resin composite for the first 1 mm and light cured for 20 seconds according to the manufacturer recommendations followed by application of packable bulk fill composite to elevate the margins and light cured following the manufacturer instructions.
75631827|NCT05381298|Procedure|Surgical Crown Lengthening|Participants in this group will undergo surgical crown lengthening in which an internal bevel incision will be done buccally and lingually followed by full thickness flap reflection using mucoperiosteal elevator, then interproximal bone removal will be done using end cutting bur to the planned position away from the margins by 3 mm. The flap will be displaced apically with apically positioned sutures. Postoperative instructions will be given to the patient aiming to control postsurgical complications including pain and swelling. Suture removal and assessment of the surgical site will be done after two weeks
75631828|NCT00937950|Other|Gynaecological follow-up|Subjects received a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years in this gynaecological follow-up study (HPV-052 EXT 008). No vaccine was administered in this extension study. Subjects received 3 doses of Cervarix/Havrix vaccine, administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the HPV-008 (NCT00122681) primary study.
75782923|NCT01262534|Other|Quality of Life|The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
75782924|NCT01264484|Device|Advantage Prosthetic Heart Valve|All patients eligible for this study are treated with an Advantage prosthetic heart valve
75782925|NCT01260818|Drug|Tranexamic Acid|1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
76076273|NCT01729546|Device|7 Blood glucose monitoring systems|
76076274|NCT04376788|Biological|exchange blood transfusion from normal donor|IV method
75631829|NCT00942162|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
75631830|NCT02852772|Behavioral|Cognitive function tests|
75631831|NCT00942084|Drug|Acyclovir|"Protocol V2 & up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days)."
75782926|NCT01260818|Drug|normal saline|100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
75782927|NCT01262612|Drug|immediate cediranib|cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
76076275|NCT04376788|Biological|plasma from convalescent patients with COVID-19|IV method
76076276|NCT04376788|Drug|Methylene Blue 5 MG/ML|IV method
76076277|NCT03400228|Dietary Supplement|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
76076278|NCT03400228|Dietary Supplement|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
76076279|NCT01729702|Other|blood sample collection|
76076280|NCT03400072|Other|Unsupervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
76076281|NCT03400072|Other|Supervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
76076282|NCT03408496|Other|Myofascial release|Manual therapy
76076283|NCT03408496|Other|Muscle stretching|Muscle stretching
76076284|NCT03408496|Other|Control|Medical appointment
76076285|NCT03408418|Procedure|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
76076286|NCT01714310|Drug|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
76076287|NCT01714310|Drug|Placebo|Initiated at end of study week 4 and continued to study week 12.
75324928|NCT02041221|Drug|SPARC1316 Dose 3|
75324929|NCT02041221|Drug|SPARC1316 Dose 4|
75324930|NCT02041221|Drug|SPARC1316 Dose 5|
76076288|NCT01714310|Drug|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
75324931|NCT02041377|Device|Karajishi TS Investigational Blood Glucose Monitoring System|Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
75324932|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 1|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
75324933|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 2|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
75631832|NCT00941928|Drug|Epratuzumab|360 mg/m^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
75631833|NCT00941928|Drug|Fludarabine|25 mg/m^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
75782928|NCT01262612|Drug|Start cediranib after 28 days Best Supportive Care|patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
75631834|NCT00941928|Drug|Cyclophosphamide|60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
75631835|NCT00941928|Drug|Mesna|12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
75324934|NCT00354705|Behavioral|Questionnaire|Two questionnaires taking 30 minutes to complete.
75341332|NCT05564845|Diagnostic Test|Neuropsychological assessment|"Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults~Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA)~A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II)~Narrative memory~Word fluency~Route finding NEPSY-II~World Fluency~Additional Questionnaires (6-18 years):~Child Behavior Checklist (CBCL)~Teacher Report Form (TRF)~Youth Self Report (YSR)~Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report)~Conners-3® • Additional Questionnaires (18+ years):~Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ<70)~Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ<70)~Conners' Adult ADHD Rating Scales (CAARS)~Emma toolbox"
75631836|NCT00941928|Procedure|Infusion of NK cells|Transplant of Haploidentical NK cells by vein on Day 0.
75782929|NCT03887390|Behavioral|Depression Medication Choice|The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.
75918409|NCT02249013|Procedure|Cytoreductive Surgery (CRS)|CRS was performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.
75918410|NCT02249013|Procedure|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC was performed according to the closed-abdomen technique using CDDP (25 mg/L of perfusate/m2, total limit of 240mg) for the first 10 patients and thus, using CDDP plus Doxorubicin (15mg/L) thereafter, both for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 4L to 6L) was circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.
76076289|NCT03408262|Biological|Ad4-EnvCN54|Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
75341333|NCT02132936|Drug|LEO 90100 aerosol foam|
75631837|NCT00941928|Drug|Interleukin-2|Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
75631838|NCT02851524|Other|posturography|
75631839|NCT05381064|Device|artificial intelligence assistance system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
75631840|NCT04203966|Diagnostic Test|12-item General Health Questionnaire (GHQ-12)|Structured validated screening tools to assess for the presence of CMDs, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
75631841|NCT04203966|Diagnostic Test|WHO AUDIT (World Health Organization- Alcohol Use Disorders Inventory Tool)|Structured validated screening tools to assess for the presence of alcohol use disorders, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
75631842|NCT00603096|Device|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
75631843|NCT00603174|Device|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
76076290|NCT03408262|Biological|MVA-CN54|Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
76076291|NCT03408262|Biological|CN54gp140/MPLA|Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
76076292|NCT04377802|Diagnostic Test|molecular testing for virus RNA using RT-PCR|Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
75341334|NCT02132936|Drug|Aerosol foam vehicle|
75341335|NCT02132936|Drug|Calcipotriol BDP gel|
75631844|NCT02852616|Behavioral|Narrative Exposure Therapy|8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
75631845|NCT02852694|Drug|Methotrexate|Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children <20kg: 1x 5mg) is recommended.
75782930|NCT01158014|Procedure|Fibrin Glue, Quixil|quixil 0.1 ml
75782931|NCT01158014|Procedure|Suture|vicryl 10/0
75782932|NCT03884114|Other|High-fidelity simulation|The first evaluation modality studied is high fidelity (HF) simulation. In our study, this modality is considered to be the gold-standard assessment method of clinical assessment, because HF simulation corresponds to the modality which reflects the best clinical competence in hospital settings. The HF pediatric manikin used (SimBaby), is able to reproduce all the signs of an asthma exacerbation (coughing, wheezing, tachypnea, chest indrawing, seesaw respiration, cyanosis). In the simulation room, participants can use the same items that those present in the simulation game (a glass of water, paracetamol, short acting beta-agonist, controller treatment (Fluticasone), an asthma spacer with a facial mask, saline nose drops to perform nasal irrigation, oral steroids in tablets (prednisone), and a phone).
75918411|NCT02249013|Drug|Neoadjuvant Chemotherapy (NACT)|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
75918412|NCT02249013|Drug|Adjuvant Chemotherapy|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
75918413|NCT02249013|Procedure|Fast-track recovery strategy|A comprehensive fast-track program was applied to accelerate recovery, reduce morbidity, and shorten convalescence for patients enrolled in our trial.
75918414|NCT03557541|Dietary Supplement|Sardine|They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)
75918415|NCT03557541|Dietary Supplement|Control|They received a common T2D-preventive diet
75918416|NCT02249871|Drug|semaglutide|All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
75918417|NCT02249871|Drug|Omeprazole|Will be given daily with oral semaglutide.
75918418|NCT02087007|Drug|Cilostazol|100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
75918419|NCT02087007|Drug|placebo|100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
75918420|NCT05500209|Behavioral|Personal resources' enhancement: self-efficacy|Participants in this condition are asked to take part in a 7-day psychological intervention delivered through Facebook Messenger chat-bot. Each day one CBT-framed exercise aimed at coping self-efficacy enhancement is delivered. An exercise takes form 5 to 30 minutes to complete.
75918421|NCT02089815|Behavioral|Home based exercise|modified Otago exercise program to simple designed home based exercise program
75918422|NCT02089815|Other|fall prevention education and counseling|
75918423|NCT02087319|Other|hair loss, baldness (patient's own platelet-rich plasma)|hair loss, baldness
75918424|NCT01434602|Drug|everolimus|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation: 5mg to 10mg daily.
75918425|NCT01434602|Drug|sorafenib|Patients will be treated with sorafenib in combination with everolimus (days 1-28); There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation 400mg-600mg twice a day (bid) or 400mg-800mg twice a day, 7 days on and 7 days off.
75341336|NCT02132936|Drug|Gel vehicle|
75341337|NCT01528891|Drug|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
75341338|NCT01528891|Other|Placebo|
75341339|NCT05230628|Device|Active TENS|Active TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
75918426|NCT02087397|Other|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
75918427|NCT02087397|Biological|AD-SVF Cell Injection|Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
75918428|NCT02087475|Drug|Irinotecan|
75918429|NCT02087475|Drug|5-fluorouracil|
75918430|NCT02087475|Radiation|Local radiotherapy|
75918431|NCT02087475|Procedure|R0 resection|
75918432|NCT02087553|Biological|Transfusion of red blood cells|(non-experimental) PRBC transfusion
75918433|NCT02087553|Biological|Infusion of albumin/saline|(non-experimental) albumin/saline infusion
75918434|NCT03427190|Other|APSOM vs Control|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
75918435|NCT02089893|Device|Fundus photography|Non-mydriatic fundus photographs
75918436|NCT03427112|Device|Xin1 Humerus System|"Retrospective assessment of the surgical handling and performance of the X-ray-based tracking and navigation system Xin1 Humerus system evaluated from 10 proximal humerus plate fixations"
75918437|NCT02092545|Other|Ketogenic diet|
75918438|NCT03427034|Device|BladderLight®|Using a cell collection device to look for the presence of bladder cancer cells
75918439|NCT05486949|Drug|AZD4205 and carbamazepine|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
75918440|NCT05486949|Drug|AZD4205 and itraconazole|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
75918441|NCT03429764|Procedure|CISS|continuous independent sling sutures will be placed with minimum two intact contact points at the surgical site
75324935|NCT03803033|Other|Clinical pharmacy-based home medication management review service|A baseline interview by the clinical pharmacist was conducted with patients at their homes to assess their use of treatment and to collect all relevant information needed to identify TRPs. Upon TRP identification at baseline, the clinical pharmacist generated a written report of findings and recommendations, which was delivered directly to the patient's physician in a sealed envelope. Patients were asked to refer back to their physicians if they required confirmation of any changes in treatment. Physicians maintained the blinding of patients with regard to whether changes were based on recommendations by the pharmacist. In both the intervention and the control groups, the clinical pharmacist performed a follow-up interview with patients 3 months after the initial interview, during a regular follow-up visit to their physician at the hospital. Assessments in the follow-up interview, regardless of the study group, involved changes in treatment and number of TRPs.
75631846|NCT02852694|Drug|Adalimumab|Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients < 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
75782933|NCT03884114|Other|Simulation game|"EfficAsthme is a simulation game used on a tablet computer. This simulation game was developed to train parents on the management of asthma exacerbations of their children. For the purpose of the study, EfficAsthme is diverted from its original use to assess students' clinical skills. The training scenario A polluted atmosphere is used in this study. Participants need to observe the signs presented by the child, and to determine the severity of the asthma exacerbation. From a menu on the right of the screen, the participant can choose several actions, especially to provide the short acting beta-agonist."
75782934|NCT03884114|Other|Multiple choice questionnaire|The third evaluation modality corresponds to a multiple choice questionnaire (MCQ) including 15 questions. As for HF-simulation and the simulation game, the MCQ starts with the same briefing and continues with 15 questions regarding the management of a moderate asthma exacerbation.
75782935|NCT01158092|Device|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
75782936|NCT01158092|Other|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
75782937|NCT03884036|Biological|Vitamin D|Vitamine D
75782938|NCT01158170|Radiation|Prophylactic cranial irradiation|25GY/10fraction
75918442|NCT03429764|Procedure|VIMS|internal mattress suture will be placed with minimum two intact contact points at the surgical site
75918443|NCT03429686|Other|DRT Intervention|The digital reminiscence therapy intervention will run 12 sessions twice per week, for six weeks, for up to an hour at a time (this will depend on the participant's ability and willingness to participate). The sessions of reminiscence therapy will be culturally appropriate and based on the key stages in the life which most people will have experienced. These sessions are individual, face-to-face sessions.
75918444|NCT03558243|Procedure|Patent Hemostasis arm|Patent hemostasis with TR BAND
75918445|NCT03558243|Procedure|ULTRA arm|Patent hemostasis protocol plus ipsilateral ulnar compression
75918446|NCT03558243|Device|Hemostatic disc arm|StatSeal disc plus TR Band
75324936|NCT05717751|Procedure|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
75631847|NCT02852694|Drug|Azathioprine / 6 Mercaptopurine|Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
75631848|NCT00604578|Drug|Pioglitazone Hydrochloride|
75631849|NCT00937560|Drug|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
75631850|NCT00937560|Drug|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
75631851|NCT00937560|Drug|Carboplatin|Carboplatin was supplied locally in commercial batches.
75782939|NCT01158170|Drug|Erlotinib /Gefitinib|Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
75782940|NCT03880136|Drug|CTP-543|Once daily dosing
75782941|NCT01260974|Drug|Caspofungin|50mg/dd for 21dd, starting within 24h from Liver Transplantation.
75782942|NCT03879980|Drug|Bilateral QL block|Bilateral lateral Quadratus Lumborum block using 20 ml of 0.25% bupivacaine each injection as preemptive analgesia.
75782943|NCT03879980|Drug|Non-QL block|Only received fentanyl IV during surgery.
75918447|NCT03426956|Dietary Supplement|Glucose|Ingestion of glucose (50 g) dissolved in 200 ml water.
75918448|NCT03426956|Dietary Supplement|Glucose + Canagliflozin|Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.
75918449|NCT03557229|Drug|Melatonin 5 mg|Oral: 50 mg once daily for 5 days
75918450|NCT03557229|Drug|Vitamin C 1 GM Oral Tablet|Oral: 1 GM every 6 hours for 5 days
75918451|NCT03557229|Drug|Vitamin E 400 UNT|Oral: 400 UNT every 8 hours for 5 days
75631852|NCT00603252|Biological|Twinrix|
75631853|NCT00603252|Biological|Engerix-B|
75631854|NCT00603252|Biological|Havrix|
75631855|NCT00603252|Biological|HBVAXPRO|
75918452|NCT03557229|Drug|N-acetylcysteine|Oral: 1200 mg every 12 hours for 5 days
75918453|NCT02521532|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
75918454|NCT02521532|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
75918455|NCT02087631|Drug|Extended-release quetiapine fumarate|Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
75782944|NCT03883958|Procedure|Erector Spinae Plane Block|ESPB will be performed in sitting or lateral decubitus position. The target vertebral level will be correspond to the approximate mid-point of the extent of fractured ribs. The tip of the transverse process of the target vertebra will be identified using the high-frequency linear placed in cephalocaudal orientation about 3 cm to the spinous process. The skin and subcutaneous tissue will be infiltrated with 2-3 ml of 2% lignocaine. With the transducer fixed over the targeted TP, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be advanced in-plane to the ultrasound beam in a cephalo-caudal direction to contact the TP. Correct needle tip position will be confirmed by doing alternating aspiration to confirm lack of inadvertent vascular puncture with injection of 1-2 ml of saline and visualizing linear fluid spread deep to erector spinae muscle, separating it from the TP. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
75468159|NCT06070857|Drug|Placebo|"Drug: LV232 1mg Group:~6 subjects will receive LV232 1mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 2mg Group:~6 subjects will receive LV232 2mg, orally; 2 subjects will receive placebo, orally.~Other Names: Placebo~Drug: LV232 4mg Group:~6 subjects will receive LV232 4mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 8mg Group:~6 subjects will receive LV232 8mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 20mg Group:~6 subjects will receive LV232 20mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo"
75468160|NCT06070844|Behavioral|yoga nidra|Yoga Nidra is a guided meditation technique that involves listening to audio readings. Yoga nidra application will be started at the 6th postoperative hour and will be applied one time. Yoga nidra is expressed as yoga sleep or deep relaxation. In this practice, it will be ensured that the mother will mentally visualise all parts of her body with the commands to be given during controlled breathing and emotionally feel the body parts. The Yoga Nidra application will last 30 minutes.
75631856|NCT00603252|Biological|Vaqta|
75631857|NCT04268394|Drug|CC-99677|CC-99677
75631858|NCT04268394|Drug|Methotrexate|Methotrexate
75631859|NCT04268394|Drug|Sulfasalazine|Sulfasalazine
75631860|NCT04268394|Drug|Itraconazole|Itraconazole
75631861|NCT04268394|Drug|Rifampin|Rifampin
75631862|NCT04268394|Drug|Midazolam|Midazolam
75918456|NCT03426800|Other|Acupuncture and training|Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
75631863|NCT04268394|Drug|Digoxin|Digoxin
75631864|NCT04268394|Drug|Metformin|Metformin
75631865|NCT04268394|Drug|Rosuvastatin|Rosuvastatin
75631866|NCT02851368|Device|near infrared fluorescence imaging (NIFI)|The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.
75631867|NCT02851368|Drug|Indocyanine Green|Indocyanine Green will be administered intravenously 1 day prior to NIFI.
75631868|NCT02851212|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
75918457|NCT03558165|Diagnostic Test|Oncomine Comprehensive Assay|Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay
75918458|NCT00940940|Biological|Zostavax (Live attenuated herpes zoster vaccine)|0.6 mL subcutaneous
75918459|NCT00940940|Biological|Placebo vaccine|0.65 mL subcutaneous
75918460|NCT02092623|Device|Transvaginal posterior mesh|A trocar-free fixation system with low-weight mesh
75918461|NCT03557840|Drug|temocillin|Drug dosing and blood sampling as per the protocol
75918462|NCT02092701|Drug|Cholecalciferol|
75918463|NCT03421262|Diagnostic Test|IADPSG Criteria|One-step: 2 hr 75 gr OGTT
75324937|NCT00771173|Drug|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
75631869|NCT02851212|Drug|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
75631870|NCT02851212|Drug|Canagliflozin|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
75631871|NCT02851212|Drug|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
75918464|NCT03421262|Diagnostic Test|NDDG Criteria|Osullivan test + 3 h 100 g OGTT
76076293|NCT03401788|Drug|Belzutifan|120 mg once daily (three 40 mg oral tablets once daily).
75324938|NCT00771173|Other|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
75324939|NCT05717673|Device|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph
75324940|NCT05717595|Dietary Supplement|fructose|oral ingestion of fructose vs dextrose
75324941|NCT02044419|Drug|lomitapide|
75324942|NCT02045277|Drug|IDP-118 Lotion|Lotion
75324943|NCT02045277|Drug|IDP-118 Monad HP Lotion|Active Comparator
75324944|NCT02045277|Drug|IDP-118 Monad Taz Lotion|Active Comparator
75324945|NCT02045277|Drug|IDP-118 Vehicle Lotion|Vehicle
75324946|NCT02045511|Behavioral|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
75324947|NCT02045511|Device|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
75324948|NCT02378025|Behavioral|Yoga Group|A 10-week yoga course designed to treat pain.
75324949|NCT02378025|Behavioral|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
75918465|NCT03421028|Device|Electromyography Biofeedback|EMG-Biofeedback- assisted training is a method in which electrodes situated on the surface of the skin detect small voltage changes which arise from the working muscles (in this case masseter and temporalis muscles). The voltage is transformed into a visual or sound time-variable signal which gives the patient feedback as he willingly tries to change the muscle tension (in this case to lower the excessive masseter tension)
75918466|NCT03421028|Other|Classic treatment for myogenous TMD|Combination of physiotherapy (manual therapy), stabilization occlusal splint usage and counseling
75918467|NCT02087709|Other|Low-calorie diet|
75918468|NCT03426722|Drug|L-carnitine|"L-carnitine VS Placebo is randomized (1:1)~L-carnitine 500mg TID(PO),~First evaluation will be performed at 8 weeks and then unblinding will be done. If symptoms continue after treatment, dose escalation in L-carnitine group by 1000mg TID (PO). If symptoms continue after treatment in Placebo group, L-carnitine 500mg TID(PO) will be given."
75918469|NCT03426722|Drug|Placebo|Placebo 500mg TID(PO)
75631872|NCT02851134|Genetic|genetic analysis|genetic (Whole Exome Sequencing )
75918470|NCT02087787|Behavioral|BMT Legal Clinic|2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
75918471|NCT03426488|Behavioral|VIP - Västerbotten Intervention Programme|Intervention on CVD (cardiovascular disease) and diabetes
75631873|NCT02851134|Biological|blood and stools samples|biological collection
75782945|NCT03883958|Procedure|Paravertebral Block|TPVB will be performed at a spinal level midway between the uppermost and the lowest fractured rib with the patient in sitting or lateral decubitus position (with patients lying on their unaffected side). The ultrasound-guided technique will be used. A high-frequency linear transducer will be used to confirm the levels of the fractured ribs. The most cephalad and most caudad fractured ribs will be identified first. The fractured rib in the middle will be then identified, and the rib will be then traced back medially. After skin and subcutaneous tissue infiltration with 2-3 ml of 2% lignocaine, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be inserted in a lateral-to-medial direction until the needle tip entered the paravertebral space. 1-2 ml of Saline will be injected into the paravertebral space while observing the pleura being moved deeply. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
75918472|NCT02090049|Dietary Supplement|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
75918473|NCT02090049|Dietary Supplement|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
75631874|NCT02851446|Other|measure dyspnoea> Borg 7|
75631875|NCT00594568|Drug|LY450139|Administered orally once daily
75631876|NCT00594568|Drug|Placebo|Administered orally once daily
75782946|NCT01264640|Drug|Aspirin and Clopidogrel|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
75918474|NCT03426410|Other|Survey|Electronic survey containing a questionnaire regarding knowledge and use of national guidelines of low back pain rehabilitation, type and frequency of cross sectional communication, attitudes and beliefs about back pain and two patient vignettes.
75631877|NCT00684658|Behavioral|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
75782947|NCT01262690|Drug|PF-05230901|Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
75918475|NCT02090127|Drug|ficlatuzumab|humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
75631878|NCT00684658|Behavioral|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
75631879|NCT04144504|Device|Retrievable metallic stenting|Use of retrievable metallic stents for the treatment of biliary anastomotic stricture after liver transplantation
75631880|NCT04144504|Device|Plastic stenting|Use of plastic stents
75324950|NCT00771407|Device|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
75324951|NCT00771407|Other|Standard ostomy creation|Ostomy will be created as routinely performed
75631881|NCT00684892|Device|Chartis System|Assessment of airway flow and pressure
75631882|NCT04143802|Drug|LY3437943|Administered SC
75631883|NCT04143802|Drug|Dulaglutide|Administered SC
75631884|NCT04143802|Drug|Placebo|Administered SC
75324952|NCT03808649|Drug|1500ml of 2.5% mannitol|1500ml of 2.5% mannitol was used in experimental group
75324953|NCT03808649|Drug|different volume of 2.5% mannitol|different volume of 2.5% mannitol based on BMI was used in active comparator group
75324954|NCT03808571|Other|cord blood specimen during the delivery|The cord blood will be taken during the delivery of baby.
75341340|NCT05230628|Device|Sham TENS|Sham TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
76076294|NCT03408184|Drug|Lumbar paravertebral group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
76076295|NCT03408184|Drug|The field block group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
76076296|NCT01713998|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
76076297|NCT03409900|Other|LPB|The LPB will be performed in a lateral position, but modified to utilize ultrasound guidance to enhance our ability to quickly and safely locate the lumbar plexus as well as to avoid unblinding with regard to the traditional landmark LPB technique. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
76076298|NCT03409900|Other|QLB|The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
75324955|NCT00788255|Drug|Final exogenous oxytocin concentration=22.5 μU/mL|Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
75324956|NCT00788255|Drug|Final exogenous oxytocin concentration=30.1μU/mL|Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
75631885|NCT00684970|Drug|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
75631886|NCT00685048|Behavioral|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
75631887|NCT00685048|Behavioral|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
75782948|NCT01262690|Drug|PF-05230901|Single dose SC
75782949|NCT03887468|Device|EvoCit|hemodialysis using the combination of the Evodial dialyzer with a citrate enriched dialysate
75782950|NCT03887468|Device|EvoHep|hemodialysis using the combination of the Evodial dialyzer with a conventional bicarbonate based dialysate and systemic anticoagulation using unfractionated heparin
75782951|NCT01155986|Drug|Lidocaine 5% medicated plaster|Topical hydrogel plaster (700mg lidocaine)
75782952|NCT01155986|Drug|Placebo topical plaster|Topical hydrogel plaster
75782953|NCT01261130|Biological|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
75918476|NCT03426332|Other|No intervention|No intervention
75324957|NCT00788255|Drug|Final exogenous oxytocin concentration=32.9μU/mL|Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
75324958|NCT02379195|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
75631888|NCT00685048|Behavioral|four 50-minute individual therapy sessions of MET & CBT|MET & CBT
75631889|NCT02626546|Procedure|Major surgical procedure|observation of postoperative outcomes
75782954|NCT01261130|Biological|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
75782955|NCT01261130|Biological|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
75782956|NCT01261130|Biological|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
75782957|NCT01261130|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
75782958|NCT01261130|Biological|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
75782959|NCT01261130|Biological|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
75782960|NCT03887312|Behavioral|t-CETA|Cognitive Behavioural Therapy (CBT) based approach delivered over the telephone. Components are available for common problems, including anxiety, depression, PTSD, conduct problems, substance abuse, and safety issues (including self-harm or suicidal ideation), and a tailored treatment package is produced for each child based on the presenting problem(s) and response to treatment. There are components for use with both child and caregiver.
75918477|NCT03420872|Other|Nutrient mixtures|consumption of a mixture of beneficial nutrients
75918478|NCT01767129|Drug|AVP-923-45|One capsule twice daily for 14 days
75918479|NCT01767129|Drug|Placebo|One capsule twice daily for 14 days
75918480|NCT03420716|Dietary Supplement|yogurt|
75918481|NCT04448912|Procedure|Damage control surgery|Surgery for non-traumatic abdominal emergencies using the damage control approach
75918482|NCT04448912|Procedure|Conventional surgery|Conventional surgery for non-traumatic abdominal emergencies
75918483|NCT02095743|Device|implanted port for chemo administration (X-port isp)|
76076299|NCT03408028|Other|Medical File consultation|Medical File consultation
76076300|NCT04549922|Drug|ISIS 721744|1.2 mL of ISIS 721744 subcutaneous once after randomization
76076301|NCT04549922|Drug|Normal Saline|1.2 mL subcutaneous
76076302|NCT03834376|Drug|Pimodivir|Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram [mg]) over a time period of 5 days.
76076303|NCT01681628|Behavioral|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
76076304|NCT04377958|Diagnostic Test|Serum biomarker testing|Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
75918484|NCT02095743|Device|Use of a PICC line for chemo administration (PowerPICC SOLO²)|The description of the device could found on the published marketing authorisation
75918485|NCT04448522|Radiation|reduced dosage IMRT|"Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~IMRT: PTVnx：63.6Gy/30Fr/2.12Gy; PTVnd：63.6Gy/30Fr/2.12Gy; PTV1：54Gy/30Fr/1.8Gy; PTV2：49.2Gy/30Fr/1.64Gy"
75918486|NCT04448522|Radiation|conventional dosage IMRT|"Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~IMRT: PTVnx：69.96Gy/33Fr/2.12Gy; PTVnd：69.96Gy/33Fr/2.12Gy; PTV1：59.4Gy/33Fr/1.8Gy; PTV2：54Gy/33Fr/1.64Gy"
75631890|NCT00912418|Biological|autologous tumor cells plus GM-CSF-in Adjuvant|"Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.~Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods."
75631891|NCT00682474|Behavioral|Counseling Intervention|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
75631892|NCT00682474|Behavioral|Information Intervention|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
75631893|NCT00682552|Procedure|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
75631894|NCT00685204|Drug|Milataxel|Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
75782961|NCT03887312|Behavioral|Médecins du Monde treatment as usual|Case manager-led care, with referral to a psychotherapist or psychiatrist as necessary. Médecins du Monde's approach is based on a joint collaboration between mental health trained case managers (who undergo extensive training by experts in the field on topics including Psychological First Aid, Child Protection, Gender Based Violence, etc.) and psychotherapists from different schools (providing Eye Movement Desensitization and Reprocessing [EMDR] for trauma, Interpersonal Therapy [IPT] for depression, Cognitive Behavioural Therapy [CBT], motivational counselling, familial or systemic therapy, and integrative approaches). Thus the number and content of sessions, and the person delivering treatment (case manager, psychotherapist, psychiatrist) vary.
75782962|NCT03887156|Diagnostic Test|Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test|Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.
75782963|NCT01154660|Other|Tidal Volume|observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
75782964|NCT01158248|Biological|panitumumab|
75782965|NCT01158248|Drug|cisplatin|
75918487|NCT02093013|Other|Integrated care program|Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
75918488|NCT03429374|Device|Liquiband Fix8|LiquiBand® Fix 8™ (Advanced Medical Solutions - Plymouth, UK) is a hernia mesh fixation device providing strong and secure mesh fixation without causing any tissue damage or mechanical trauma. This device is designed to offer precise and controlled delivery of tissue glue (n-butyl-2-cyanoacrylate), resulting in a strong mesh fixation.
75918489|NCT03429374|Device|Absorbable tack|Absorbable tack
75918490|NCT01309191|Other|Minoxidil|Over the counter Rogaine, twice a day for 8 weeks
75918491|NCT01309191|Other|Placebo|
75918492|NCT01094223|Behavioral|Mindfulness Based Relapse Prevention|Meditation based therapy group incorporating relapse prevention skills training
75918493|NCT01094223|Behavioral|Health Education|Psychoeducation group focused on various topics pertaining to physical health
75782966|NCT01158248|Radiation|brachytherapy|
75782967|NCT01158248|Radiation|external beam radiation therapy|
75918494|NCT03420638|Drug|Adjunct Exparel (bupivacaine liposome suspension 1.3%)|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% [13.3 mg/mL] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.
76076305|NCT03405220|Behavioral|Self affirmation, 10 items, written examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
75631895|NCT00682630|Drug|pyronaridine artesunate clinical trial reference tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
75918495|NCT03420638|Other|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
75918496|NCT02090205|Procedure|Non-ventilation during CPB|Patients that will not be ventilated during cardio-pulmonary bypass
75782968|NCT01158326|Drug|Resfenol|"Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours."
75918497|NCT02090205|Procedure|Ventilation with CPAP|These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
75918498|NCT02090205|Procedure|Ventilation with 5 act/minute|These patients will receive mechanical ventilation (5 acts/minute) during CPB
75918499|NCT02090205|Device|CPAP|Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
75918500|NCT02090205|Device|Ventilator: 5 act/minute|Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
76076306|NCT03405220|Behavioral|Self affirmation, 10 items, no examples|"Participants will complete the 10 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
75324959|NCT02379195|Drug|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
75631896|NCT00682630|Drug|pyronaridine artesunate to-be-marketed tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
75918501|NCT03420560|Behavioral|warmer temperature|Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
76076307|NCT03405220|Behavioral|Self affirmation, 10 items, imagined examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
75324960|NCT02379195|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
75324961|NCT02379195|Drug|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
75631897|NCT00685282|Behavioral|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
75631898|NCT00875056|Drug|Vorinostat|Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle
75631899|NCT00682708|Dietary Supplement|PlumpyNut|
75631900|NCT00682708|Dietary Supplement|PlumpyDoz|
75631901|NCT00685594|Drug|cholecalciferol|20.000 IU cholecalciferol per week for 5 years versus placebo
75631902|NCT00685594|Drug|Placebo|Placebo capsule once a week, identical to cholecalciferol capsule
75631903|NCT04139746|Procedure|Scleral Buckling|Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.
75782969|NCT01158326|Other|Placebo|10 ml of oral placebo every 6 hours for 48 hours
76076308|NCT03405220|Behavioral|Self affirmation, 5 items, written examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
75324962|NCT02379195|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
75324963|NCT02379273|Device|Nucleus Hybrid L24 Implant|Subjects have already been implanted with the Nucleus Hybrid L24 implant.
75782970|NCT01586546|Behavioral|Face-to-Face MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
75782971|NCT01586546|Other|Waitlist Control I|No intervention offered during study period. Intervention is offered after completion of study.
76076309|NCT03405220|Behavioral|Self affirmation, 5 items, no examples|"Participants will complete a 5 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
76076310|NCT03405220|Behavioral|Self affirmation, 5 items, imagined examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
75782972|NCT01586546|Other|Waitlist Control II|No intervention offered during study period. Intervention is offered after completion of study.
76076311|NCT03405220|Behavioral|Self affirmation, 3 items, written examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
76076312|NCT03405220|Behavioral|Self affirmation, 3 items, no examples|"Participants will complete a 3 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
75631904|NCT04139746|Procedure|Drainage-Injection-Pneumoretinopexy|According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
75918502|NCT00715988|Drug|Methadone HCl Inject 10 mg/ml (will require dilution)|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)
75782973|NCT01586546|Behavioral|Online MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
75918503|NCT00715988|Drug|Methadone|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
75324964|NCT05715567|Other|Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)|Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)
75324965|NCT05714319|Other|Data collection|"Variables collected will include:~demographics (sex, age)~comorbidities (type 2 diabetes mellitus, familiar history of CAD, smoke habit, dyslipidaemia, hypertension, history of CAD)~echocardiographic (left ventricle ejection fraction at admission, the presence and grade of diastolic dysfunction, and the presence and grade of any valvulopathies)~angiographic data (presence of non-obstructive CAD (any coronary lesion <50% diameter stenosis), the presence of myocardial bridge and, if this latter is present, its localization and length)~laboratory measurements (hematologic variables (haemoglobin and white blood cells), creatinine, high sensitivity cardiac troponin I (hs-cTnI), and C-reactive protein (CRP) at the time of admission)~medical therapy at admission~response to intracoronary provocative test with ACh."
75631905|NCT00685672|Drug|adrenalin|adrenalin 2 microgram pr ml placebo
75631906|NCT00685672|Drug|placebo|Saline instead of adrenaline in the epidural mixture
75631907|NCT04143178|Other|Expressive Writing|The expressive writing is a form of writing therapy developed primarily by James W. Pennebaker in the late 1980s consisting of writing about stressful and traumatic experience for 15-20 min for 3 consecutive days, including one's thoughts and feelings. The expressive writing allows people to express and process emotions, feelings, and thoughts related to the life events and consequent changes and this may favor a mental reorganization of the negative events, a greater expression and regulation of the emotions related to them. This intervention could provoke social, emotional, and consequently, psychophysical changes as is showed in patients with chronic diseases and cancer. In the present study, to all participants in the writing group, 5 days after the transplant, has been asked to write for 3 consecutive days, 20 minutes each days about their deepest emotions and feelings related to the chronic failure, the transplant and their expectations after that.
75631908|NCT04143178|Other|Neutral Writing|Five days after the transplant, to the control group participants has been asked to write for 3 consecutive days 20 minutes a day on an assigned neutral theme (eg. describe 1 object in the room) as objectively as possible, without mentioning their emotions or thoughts related to it.
75782974|NCT03879824|Procedure|Secondary Radial Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
75782975|NCT03879824|Procedure|Secondary Femoral Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
75782976|NCT01264796|Behavioral|culturally tailored diabetes education|lifestyle modification group education
75782977|NCT01156064|Device|Confocal Laser Endomicroscopy (Pentax/Optiscan)|Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
75782978|NCT01156064|Device|Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)|NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
75782979|NCT01264874|Drug|Vitamin D3 ( Colecalciferol)|100000 IU every 50 days for 3 years
75782980|NCT01264874|Other|placebo|For 3 years IU every 50 days
75918504|NCT02093091|Procedure|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano.|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The recent nano-filled RMGI filling (Ketac Nano) was used to fill these cavities.
76076313|NCT03405220|Behavioral|Self affirmation, 3 items, imagined examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
76076314|NCT01728064|Drug|Placebo|Placebo capsules
76076315|NCT01728064|Drug|EPI-743 400 mg|
76076316|NCT01728064|Drug|EPI-743 200 mg|
76076317|NCT03407950|Behavioral|IPT+|Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
76076318|NCT03407950|Behavioral|Treatment as usual|no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
75918505|NCT02093091|Procedure|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The conventional RMGI filling (Vitremer) was used to fill these cavities.
75631909|NCT00683176|Drug|Choline Fenofibrate|135 mg
76076319|NCT03834298|Other|Four Food Elimination Diet|Food allergens are thought to initiate eosinophilic inflammation and dietary elimination of trigger allergens is an effective treatment for EoE. Previous work demonstrates that in both children and adult EoE patients, the food antigens including cow's milk, wheat, egg, soy, peanut/tree nut and fish/shell fish, are the most common food triggers causing esophageal inflammation. Participants will be assigned to single arm treatment / intervention with a diet restricted of the four most common food allergens, milk, soy, wheat and egg, or a four food elimination diet (FFED). With the goal to optimize diet treatment, in Aim 2, eligible participants will undergo sequential food reintroductions based on protocol.
75631910|NCT00683176|Drug|Placebo|Placebo
75631911|NCT02626234|Drug|INC280|
75324966|NCT05714319|Other|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACCE in the past months will be investigated and collected.
75324967|NCT00771875|Drug|Rabbit Antithymocyte Globulin (RATG)|All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
75324968|NCT00771875|Drug|Rituximab|Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
75631912|NCT02626234|Drug|digoxin|
75324969|NCT00771875|Drug|Bortezomib|Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
75631913|NCT02626234|Drug|rosuvastatin|
75631914|NCT00685828|Drug|imatinib mesylate|By mouth
75631915|NCT05298982|Behavioral|Early activity and Mobilisation Intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
75631916|NCT00685906|Drug|AZD6140|90 mg tablet taken by mouth 2 times a day for 21 days per cycle
75631917|NCT00685906|Drug|Levonorgestrel and Ethinyl Estradiol (Nordette®)|1 tablet taken by mouth once a day for 28 days per cycle
75782981|NCT01262768|Behavioral|Portion Size Measurement Aids (PSMAs)|Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
76076320|NCT03400774|Other|Stair-climbing|Short bouts of moderate intensity stair-climbing
76076321|NCT04377178|Device|Dentin grinder|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - dentin grinder from the separated root and these particles are incorporated into the extraction socket
75324970|NCT00771875|Drug|Acetaminophen|Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
75631918|NCT00683488|Behavioral|Focus Group|Focus group using and collecting feedback on the CBT/CM intervention.
75631919|NCT00683488|Behavioral|First Intervention Trial|"Intervention will comprise of approximately 15 weekly sessions.~Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.~Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.~Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility."
75631920|NCT00683488|Behavioral|Intervention Trial 2|Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
75631921|NCT00686062|Other|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
75631922|NCT00686062|Other|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
75631923|NCT04139824|Drug|Xanthine Oxidase Inhibitor|LC350189 200mg qd
75631924|NCT04139824|Drug|nonsteroidal anti-inflammatory drug|Naproxen 500mg BID
75631925|NCT00940602|Drug|Deferasirox|Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
75631926|NCT00940602|Drug|Placebo|Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
75631927|NCT02626390|Other|Frequent instructions/feedback and an Internal Focus of Attention|
75631928|NCT02626390|Other|Minimal instructions/feedback and an External Focus of Attention|
75631929|NCT00686140|Drug|celecoxib|400mg/day, twice a day, 12 weeks
75631930|NCT00686140|Drug|Placebo|twice a day, 12 weeks
75631931|NCT00686218|Drug|imatinib mesylate|Given orally
75631932|NCT00686218|Drug|panobinostat|Given orally
75782982|NCT01586468|Drug|WF10|0.5 mg/kg B.W.
75782983|NCT01586468|Drug|NaCl Solution|NaCl Solution
75782984|NCT01158482|Procedure|IVC Filter Placement or Retrieval|An IVC Filter will be placed or removed using endovascular techniques.
75918506|NCT03429062|Other|Personal training exercises|Personal training: strengthening, stretching, endurance, balance Whole body vibration: strengthening, balance, stretching, endurance, balance
75918507|NCT02093169|Drug|Part A: Lu AF35700|One 30 mg single dose for one day; orally
75918508|NCT02093169|Drug|Part B: Lu AF35700|Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
75918509|NCT03420326|Behavioral|Frailty status assessment|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status
75918510|NCT03556995|Other|bariatric surgery patients|
75631933|NCT00686218|Genetic|polymerase chain reaction|Testing
75631934|NCT00686218|Genetic|protein expression analysis|Testing
75324971|NCT00771875|Drug|Antihistamine|Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
75468161|NCT06070831|Device|Inspiratory muscle training|"Respiratory training, performed through IMT, was carried out with a pressure threshold device (Treshold IMT, Philips-Respironics, Pittsburg, PA, USA). Threshold IMT offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the inspiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
75631935|NCT00686218|Genetic|western blotting|Testing
75631936|NCT00686218|Other|flow cytometry|Testing
75631937|NCT00686218|Other|laboratory biomarker analysis|Testing
75631938|NCT00686218|Other|pharmacological study|Testing
75631939|NCT00683566|Procedure|electrostimulation|Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
75631940|NCT00683956|Device|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
75631941|NCT00683956|Drug|Propofol|
75631942|NCT00686296|Other|Taliderm™|taliderm™ dressing application once
75631943|NCT00686296|Other|Taliderm™|Taliderm™ dressing application up to three applications
75631944|NCT00686296|Other|standard wet to dry dressing with gauze|wet to dry dressing standard of care
75631945|NCT00603486|Device|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
75631946|NCT02850744|Drug|PQR309|80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
75631947|NCT04266834|Other|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the Hikari DX L-FABP test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the L-FABP test at the clinically-appropriate point in each case."
75782985|NCT01262924|Biological|GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine|Intramuscular, single dose
75631948|NCT04139668|Drug|Naltrexone 380 MG [Vivitrol]|Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)
75918511|NCT03420248|Device|Non-spherical polyvinyl alcohol particle or Tris-acryl gelatin microsphere|One of non-spherical polyvinyl alcohol particle or tris-acryl gelatin microsphere is used for embolic materials. All other processes are same.
75324972|NCT00771875|Drug|Methylprednisolone|Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
75324973|NCT02046525|Biological|Autologous fecal microbiota therapy|
75324974|NCT02046525|Other|Placebo|Saline enema
75324975|NCT05742737|Other|Frailty Index|The mFI-5 scoring system used in the current study was developed by Saxton and Velanovich by comparing the five variables in the original CSHA-FI with NSQIP database
75631949|NCT04139668|Behavioral|Motivational Enhancement Therapy and Cognitive Behavioral Therapy|Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
75631950|NCT04266678|Behavioral|Resistance exercise program|Exercise sessions with exercise science professional. Target hypertrophy repetition range and progressive resistance exercise.
75631951|NCT04266756|Drug|Selexipag matrix tablet|Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.
75631952|NCT04266756|Drug|Selexipag encapsulated pellets|Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.
75631953|NCT04266756|Drug|Selexipag Immediate-release (IR) tablet|Participants will receive Selexipag immediate-release tablet orally under fasted condition.
75631954|NCT00606060|Drug|Kogenate (BAY14-2222)|100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
75631955|NCT05379192|Other|Group 1, Group 2, Group 3, Group 4|The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm
75782986|NCT01262924|Biological|GSK Biologicals' reduced-antigen-content acellular pertussis vaccine|Intramuscular, single dose
75782987|NCT01262924|Biological|Tedivax-Adult™/ Td-Rix™|Intramuscular, single dose or 2 doses (in the annex phase)
75782988|NCT01158560|Dietary Supplement|cholecalciferol (vitamin D3)|oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks
75782989|NCT01158560|Behavioral|Gargling|gargling with tap water, twice daily
75782990|NCT01158560|Dietary Supplement|Placebo|matched placebo for active vitamin D
75918512|NCT02791269|Drug|Peginterferon alfa-2a|180 mcg SC injection QW for 48 weeks.
75918513|NCT03556449|Diagnostic Test|High resolution ultrasound|Using a high-frequency linear array transducer (18L6 HD)
75918514|NCT02090361|Procedure|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
75918515|NCT03773289|Other|No intervention|This is a retrospective, observational pharmacoepidemiological study using nationally collected data. There is no intervention.
75918516|NCT03556917|Combination Product|iontophoresis + caffeine|we will use cafeislaine c (caffeine) +galvanic current
75918517|NCT02090439|Drug|Silodosin|
75324976|NCT02047305|Device|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
75782991|NCT03879746|Drug|Tamsulosin|drug will be used in treatment of premature ejaculation
75782992|NCT03879746|Drug|Paroxetine Hydrochloride|drug will be used in treatment of premature ejaculation
75918518|NCT02696564|Drug|Losartan|50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
75918519|NCT02696564|Drug|Placebo|one capsule per day for two weeks, followed by two capsules per day for 46 weeks
75918520|NCT02093325|Drug|Eltrombopag|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
75918521|NCT02093325|Drug|Placebo|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
75918522|NCT02093403|Drug|decitabine|Given IV
75918523|NCT02093403|Drug|selinexor|Given PO
75918524|NCT02093403|Other|pharmacological study|Correlative studies
75324977|NCT00760019|Drug|salsalate|1.5 grams orally 3 times daily
75631956|NCT04266444|Device|Exergaming in virtual environment|"The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty."
75782993|NCT03879746|Other|placebo|tablets without active substance will be given to patients suffering from premature ejaculation
75782994|NCT03879590|Drug|Doxophylline|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
75918525|NCT02093403|Other|laboratory biomarker analysis|Correlative studies
75918526|NCT03426176|Drug|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
75782995|NCT03879590|Drug|Budesonide|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
75782996|NCT01265108|Drug|Iron sucrose.|Volunteers will receive an intravenous infusion of 200 mg iron sucrose, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
75782997|NCT01265108|Drug|Normal saline|Volunteers will receive an intravenous infusion of 100 ml normal saline, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
75782998|NCT01159028|Drug|BP1001|Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
75782999|NCT01159028|Drug|BP1001 in combination with LDAC|Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
75918527|NCT03426176|Drug|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
75918528|NCT03426176|Drug|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
75631957|NCT00875524|Biological|CYD dengue vaccine serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
76076322|NCT04377178|Device|Bone mill|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - Bone mill from the separated root and these particles are incorporated into the extraction socket
76076323|NCT01720420|Device|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
75324978|NCT00760019|Drug|placebo|matching placebo
75324979|NCT02383719|Device|Oro-nasal Mask|
75324980|NCT00789113|Drug|Extended Release Lamotrigine|
75341341|NCT05198102|Biological|Recombinant novel coronavirus vaccine (CHO cells)|At 12 months after the basic immunization (window period ± 3 months), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
75341342|NCT01529203|Drug|Botulinum Toxin Type A (Azzalure)|Powder for solution for injection
75341343|NCT01529203|Device|Restylane ranges|Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
75341344|NCT01529827|Drug|fludarabine phosphate|Given IV
75631958|NCT00875524|Biological|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
75918529|NCT03426176|Drug|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
75918530|NCT02095899|Drug|Rufinamide|2x200mg up to max 2x800mg a day Titration over 20days
75918531|NCT03426098|Device|Secret RF|A series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
75918532|NCT02095977|Procedure|fluoroscopy|Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
75918533|NCT02095977|Procedure|synchronized high-voltage shock|"If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.~For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist."
75631959|NCT04266600|Procedure|Extensive mesentery resection|Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis
75631960|NCT01094288|Drug|Alisertib|Alisertib ECT
75918534|NCT02095977|Procedure|Holter monitor|Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
75918535|NCT03127670|Drug|Solanum melongena peel extract 0.05%|Administered topically twice daily for 12 weeks
76076324|NCT03835000|Procedure|Orthopedic surgery|before and after surgery, patient will need medical imaging to asses their conditions
75918536|NCT03428984|Drug|EXPAREL|EXAPREL 266 mg in 20 mL
75918537|NCT03525002|Drug|Bromocriptine|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
76076325|NCT03409120|Device|Boston Scientific Vercise PC IPG with directional DBS lead|We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
75324981|NCT05714241|Other|Data extraction|"After routine coronary function testing using a diagnostic pressure-temperature sensor guidewire in order to assess Coronary Flow Reserve (CFR) and the Index of Microvascular Resistance (IMR); and/or the acetylcholine (Ach) provocative test to assess the presence of coronary vasomotion disorders, patients will be stratified, accordingly to coronary function testing and Ach provocative test, in four groups/endotypes:~MVA (evidence of CMD defined as any of abnormal CFR [<2.0], IMR [≥25], or microvascular spasm);~VSA (CFR ≥2.0, IMR <25 and epicardial spasm);~both MVA and VSA (evidence of CMD and epicardial spasm);~none/non-cardiac chest pain (CFR ≥2.0 and IMR <25 and neither microvascular nor epicardial spasm)."
75783000|NCT03886844|Dietary Supplement|Human milk fortifier based on human milk (Prolacta)|Intervention is started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity, afterwards a human milk fortifier based on bovine milk is administered until estimated date of birth or 52 weeks corrected for prematurity (weight <10. percentile) according to ESPGHAN(=European Society for paediatric gastroenterology, hepatology and nutrition) guidelines
75783001|NCT03887000|Other|magnesium|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
75783002|NCT03887000|Other|placebo|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
75918538|NCT03525002|Other|Placebo|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
75918539|NCT03426020|Other|Oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before induction
75918540|NCT03426020|Other|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|patients will be watched a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) 20 minutes before induction.
75918541|NCT03426020|Other|Play game (PC fishing game)|Patients will be played a simple PC game (a fishing game) 20 minutes before induction
75324982|NCT05714241|Other|Blood sampling|At the time of this coronary angiography, arterial blood samples through the radial sheath will be collected. If collected at the time of any follow-up visit, venous blood samples will be collected by venipuncture with the same modalities to obtain whole blood, serum and plasma samples after centrifugation.
75918542|NCT03420170|Other|Graded Exercise Integrated Education|"Aerobic exercise Wheelchair propelling, boxing, hand cycling (2 rounds)~3 mins. exercise and 2 mins. rest~Increased to 4.5 mins. and 30 sec. rest~Strengthening exercise:~Vertical chest press, butterfly press; vertical row and wide lattissimus pull down 3 sets, 10 reps. and 2 min rest between sets, moderate to vigorous intensity (50% of 1 RM)~Educational intervention:~The educational intervention for exercise self-efficacy and physical activity level (2 hours a week for 8 weeks during in rehabilitation and once a month for 8 weeks after discharge from rehabilitation)"
75918543|NCT03420170|Other|Conventional Physical Therapy|Normal routine of physical therapy including mobility training, wheelchair skills, resistance exercise, aerobic training, balance exercise, functional exercise
75918544|NCT03428906|Drug|Oxytocin|intranasally administrated
75918545|NCT03428906|Drug|Placebo|intranasally administrated
75918546|NCT02521298|Other|Strength Training|
75918547|NCT02521298|Procedure|Placebo|
75341345|NCT01529827|Drug|melphalan|Given IV
75341346|NCT01529827|Radiation|total-body irradiation|Undergo TBI
75783003|NCT01154738|Drug|Lidocaine|"bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.~start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine"
75783004|NCT01154738|Drug|Placebo|"NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00"
76076326|NCT03405142|Drug|Panitumumab-IRDye800|Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is < 1/12 of the therapeutic dose.
75631961|NCT01094288|Drug|Docetaxel|Docetaxel IV infusion
75631962|NCT02690298|Device|ExSpiron|Non-Invasive respiratory volume monitoring
75631963|NCT00686530|Procedure|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
75631964|NCT00686530|Procedure|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
75631965|NCT02850822|Drug|Demethylation drug|Demethylation drug,such as Decitabine
75918548|NCT02521298|Drug|Cortico-Steroid Injection. Depomedrol 40mg/1ml.|
75918549|NCT02521298|Procedure|Dry Needling|
75918550|NCT00389870|Biological|panitumumab|
75918551|NCT00389870|Drug|cyclosporine|
75918552|NCT00389870|Drug|irinotecan hydrochloride|
76076327|NCT03405142|Drug|Lymphoseek|Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
75631966|NCT02850822|Drug|Chemotherapy regimen|Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
75783005|NCT01263002|Drug|clevudine, Adefovir|"Nucleoside-analogue naive patient : Clevudine 30mg qd~Assess the complete virological response(HBV DNA < 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd~Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd~During medication of Clevudine, virological breakthrough : add adefovir 10mg qd~During treatment period, composite virological response : stop the medication and F/U for 2 years~Recurrence after stopping treatment(HBV DNA > 2,000IU/ml) retreat medication at composite virological response.~complete virological response: HBV DNA < 60 IU/ml~virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously."
75783006|NCT01261286|Drug|verapamil|
75783007|NCT01159106|Other|Pressure Support Ventilation|Spontaneous mode of ventilation whereby the patient initiates the breath and the ventilator delivers support with the preset pressure value
75783008|NCT01159106|Other|Neurally adjusted ventilatory assist (NAVA)|"Gas delivery from the mechanical ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi).~The ventilator is aware of the change in diaphragmatic EMG by the insertion of a specially designed nasogastric tube with EMG electrodes that cross the diaphragm."
75783009|NCT01265186|Device|Bispectral Index|The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.
75783010|NCT01265186|Device|Amplitude-integrated EEG|A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.
75783011|NCT05666882|Other|Non-interventional|Non-interventional
75783012|NCT01263080|Drug|mirtazapine|mirtazapine 30mg QD
75783013|NCT01263080|Drug|folic acid placebo|folic acid placebo 1 tablet QD
75783014|NCT01263080|Drug|mirtazapine placebo|mirtazapine placebo 1 tablet QD
75783015|NCT01263080|Drug|folic acid|folic acid 0.4mg QD
75918553|NCT03127436|Drug|Acarovac|House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
75918554|NCT03425942|Behavioral|Internet Cognitive Behavioral Therapy for insomnia (ICBT-i)|This intervention lasts for five weeks. The intervention is internet-based and mainly consists of the most potent CBT technics i.e. sleep restriction and stimulus control. Weekly feedback is provided by master students supervised by clinical psychologists.
75918555|NCT03425942|Behavioral|Internet Applied Relaxation Techniques (IART-i)|This intervention lasts for five weeks. The intervention is internet-based and consists of different common applied relaxation exercises and treatments. Weekly feedback is provided by master students supervised by clinical psychologists.
75918556|NCT04449146|Diagnostic Test|Scapular positioning in Standing position using Sonography|The localizer ultrasound of the shoulder is performed in an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer.
75631967|NCT00684034|Other|Sampling of blood|A sampling of blood will be made
75631968|NCT00684034|Other|Sampling of blood|A sampling of bood will be made before the dialysis
75631969|NCT00684034|Other|Sampling of blood|A sampling of blood will be made.
75324983|NCT05714241|Other|Clinical Follow-up|"All patients will undergo a final follow-up visit at 12 months from the date of enrollment.~During the visit, the incidence of MACE in the past months will be investigated, the Seattle Angina Questionnaire (SAQ) will be administered and the SAQ summary score will be collected."
75631970|NCT05380986|Drug|Camrelizumab combined with apatinib mesylate|Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
75631971|NCT00684112|Drug|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
75631972|NCT00684112|Drug|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
75631973|NCT04306796|Device|3D printed splints|3D printed made to measure splints
75631974|NCT04306796|Device|Thermoplastic splints|thermoplastic splints individually adjusted by occupational therapists
75631975|NCT00684190|Drug|AZD3355|150 mg bid, oral, 7 days
75631976|NCT00684190|Drug|Esomeprazole|40 mg od, oral, 7 days
75783016|NCT01261364|Behavioral|GeneSightRx|Multi-genetic pharmacogenomic panel
75918557|NCT02640950|Device|NeuroStar TMS|Transcranial Magnetic Stimulation
76076328|NCT03407872|Drug|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
75631977|NCT02877992|Procedure|Ovarian puncture|Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
75631978|NCT05380908|Other|None of any intervention|The patients did not have any intervention.
75783017|NCT01261364|Behavioral|Treatment as usual|Treatment as usual
75783018|NCT01263158|Other|Expectancy of standard oxytocin treatment|
75783019|NCT01261442|Procedure|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
75783020|NCT01263236|Drug|LY2940094|Administered orally
75783021|NCT01263236|Drug|Placebo|Administered orally
75783022|NCT03879356|Drug|N-acetyl cysteine|effect of N-acetyl cysteine in Aluminum phosphide poisoning patients
75631979|NCT02626078|Other|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
75918558|NCT02559830|Genetic|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10^6 transduced CD34+ cells/Kg (maximum 20x10^6) at bedside for infusion.
75783023|NCT01159418|Drug|Panobinostat (LBH589), Carboplatin and Paclitaxel|"Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."
75631980|NCT04307888|Device|Perclose Proglide (Abbott)|Common Femoral Artery percutaneous access closure by means of Perclose Proglide device
75631981|NCT05379036|Drug|prescribing anapproved drug, examination|"Blood test to assess serum zonulin levels;~Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months."
75631982|NCT00686608|Dietary Supplement|glucose|0.3mg/kg of glucose
75783024|NCT03886766|Drug|Hot-melt extruded amorphous solid dispersion of Efavirenz|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
75783025|NCT03886766|Drug|Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
75783026|NCT03886766|Drug|Efavirenz solution|Efavirenz solution, 3 mg, oral administration (product 3)
75783027|NCT01261520|Behavioral|Culturally-tailored video|A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
75783028|NCT01261598|Procedure|Positron Emission Tomography|Positron Emission Tomography
75783029|NCT01265342|Drug|Beclomethasone|Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
75783030|NCT01265342|Drug|Placebo|Placebo nebulised suspension twice a day for 10 days
75783031|NCT03883334|Drug|Metisoprinol|Immunodulator
75783032|NCT01159496|Drug|PF-05212377 (SAM-760)|Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
75783033|NCT01159496|Drug|Placebo|Oral capsule, once daily for 14 days
75783034|NCT01265576|Drug|Sorafenib|Participants will be on sorafenib at least 30 days before randomization into either the Treatment or Control Arms. Sorafenib will be administered according to the package insert unless contraindicated based on physician expertise.
75918559|NCT03420092|Drug|Form 1 of AZD5718 tablets|The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.
75783035|NCT01265576|Drug|VT-122 (propranolol plus etodolac)|Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
75783036|NCT01265576|Drug|Placebo|Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
75783037|NCT01261676|Other|Implementation aids|An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)
75918560|NCT03420092|Drug|Form 2 of AZD5718 tablets|The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.
75918561|NCT03420092|Drug|Form 3 of AZD5718 tablets|The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.
75918562|NCT03420092|Drug|Form 4 of AZD5718 tablets|The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.
75918563|NCT03420092|Drug|Form 5 of AZD5718 tablets|The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.
75918564|NCT03420092|Drug|Selected form (Form 2 - 5) of AZD5718 tablets|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
75631983|NCT00686608|Dietary Supplement|fructose|fructose IV bolus
75783038|NCT03883256|Device|high flow nasal cannula|High flow nasal cannula is a device that delivered heated and humidified high flow gases to at or near body temperature to avoid drying and possible injury to the nasal mucosa. In this study, subjects perform a constant-load exercise test with high flow nasal cannula.
75783039|NCT03883256|Device|nasal cannula|Nasal cannula is a device that delivered oxygen to patients. In this study, subjects perform a constant-load exercise test with nasal cannula.
75783040|NCT01261754|Radiation|99mTc MIP 1404|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
75783041|NCT01261754|Radiation|99mTc MIP 1405|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
75783042|NCT01265732|Drug|PF-04191834|single dose, 100mg, dispersion
75918565|NCT03419936|Diagnostic Test|Endoscopic biopsy|"Pre-operation (initial diagnosis) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~Post-subtotal gastrectomy (After 6 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~Post-subtotal gastrectomy (After 12 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~Post-subtotal gastrectomy (After 24 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy."
75918566|NCT03419858|Behavioral|Mindfulness Meditation|A well-validated brief mindfulness-based mental training regimen [four sessions; 20 min/session] was used to teach patients to independently practice mindfulness meditation.
75918567|NCT03419858|Behavioral|Placebo Meditation|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
76076329|NCT03407872|Drug|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
76076330|NCT03407872|Drug|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
76076331|NCT03407872|Drug|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
75783043|NCT01265732|Drug|PF-04191834|single dose, 100mg, suspension
75783044|NCT01265732|Drug|PF-04191834|single dose, 300mg, suspension
76076332|NCT00016354|Drug|benzoylphenylurea|
75631984|NCT00686608|Dietary Supplement|saline|IV saline
75631985|NCT02879474|Behavioral|Melanoma scale questionnair|
75783045|NCT03883022|Drug|with U-VANCO (vancomycin hydrochloride)|1 gm or 2 gm mixed with autogenous cancellous bone graft
75918568|NCT03419858|Behavioral|Slow-Breathing|Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.
75918569|NCT03419858|Drug|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.
76076333|NCT03834610|Drug|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
76076334|NCT03834610|Drug|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
75631986|NCT02850666|Behavioral|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
75631987|NCT00684268|Drug|Silibinin|"comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion"
75631988|NCT00684268|Drug|Silibinin|20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
75918570|NCT03419858|Other|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
76076335|NCT03834610|Diagnostic Test|serum testosterone level|measurement of serum testosterone level
76076336|NCT03834610|Diagnostic Test|HbA1C|measurement of HbA1C levels
76076337|NCT03834610|Device|penile doppler|penile doppler to measure the degree of erection and penile vasculature
75631989|NCT04302662|Drug|MS1819-SD|Patients will receive increasing doses from the lowest to a maximum dose of MS1819-SD on top of a stable dose of PPEs. The total treatment phase will range from 39 to 51 days.
75631990|NCT04256226|Procedure|Tumor excision|Excision of GIST
75783046|NCT03883022|Drug|without U-VANCO (vancomycin hydrochloride)|no vancomycin added
76076338|NCT01681472|Drug|6R-MTHF (arfolitixorin) 200 mg/m2|i.v. bolus injection
75783047|NCT01159652|Drug|zaleplon|10 mg
75783048|NCT01159652|Drug|zolpidem extended release|12.5 mg
75918571|NCT03417206|Drug|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%
76076339|NCT01681472|Drug|Levoleucovorin 200 mg/m2|i.v. bolus injection
76076340|NCT01681472|Drug|6R-MTHF (arfolitixorin) 60 mg/m2|i.v. bolus injection
76076341|NCT01681472|Drug|Levoleucovorin 60 mg/m2|i.v. bolus injection
75783049|NCT01159652|Drug|bedtime placebo|placebo
75783050|NCT01159652|Drug|middle of the night placebo|placebo
75783051|NCT01159730|Drug|VB-201 or Placebo|
75783052|NCT01159808|Drug|INX-08189|3, 25 and 100 mg capsules; oral administration, single dose
75783053|NCT01159808|Drug|Placebo|matching placebo capsules, oral administration, single dose
75783054|NCT03886532|Other|Medical Marijuana|registry and blood samples
75783055|NCT01261832|Drug|antiplatelet therapy|Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
75783056|NCT03882866|Procedure|3D-printed non-coplanar template|3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
76076342|NCT01040806|Behavioral|Usual care|Patients will receive their usual medical care
76076343|NCT01040806|Behavioral|Health coaching|Peer health coaches will counsel patients with diabetes
75918572|NCT03417206|Device|pupillary dilatation reflex|PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity > 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity <5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity <5%
76076344|NCT01049152|Device|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
75631991|NCT00686764|Other|Observational|"Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36)."
75918573|NCT00003716|Biological|rituximab|
75631992|NCT00604656|Drug|insulin aspart|
75631993|NCT00684346|Other|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
75783057|NCT03882866|Procedure|3D-printed coplanar template|3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
75783058|NCT03883178|Procedure|Minimal-invasive endoscopic transgluteal approach|Every patient, suffering from a pudendopathie or clunealgie, conform the Nantes criteria, and who are candidates for a surgical treatment through the transgluteal open approach, will be asked their permission to perform the procedure through a minimal-invasive endoscopic transgluteal approach.
75783059|NCT01265810|Other|supersaturated calcium-phosphate|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
75783060|NCT01265810|Other|sodium chloride 0.9 %|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
75918574|NCT02593786|Drug|Nivolumab|
75918575|NCT03425864|Procedure|connective tissue graft|patient will receive immediate implant and connective tissue graft
75918576|NCT03425864|Device|immediate implant|patient will receive immediate implant with connective tissue graft.
75918577|NCT03425708|Drug|20mg Febuxostat|Participants take 20mg febuxostat pill once a day for at least six months.
75918578|NCT03425708|Drug|40mg Febuxostat|Participants take 40mg febuxostat pill once a day for at least six months.
75918579|NCT03417128|Behavioral|Peer support|Participants residing in the location selected to be intervene will to form at minimum 4 peer groups. This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering. Two participants from each peer group will be selected as the peer leader (PL). PL will be trained to deliver the content of PERSUADE modules and will be responsible to run a weekly peer gathering with their respective groups for the following three months.
75918580|NCT03417050|Other|No intervention will take place for this retrospective and observational study.|No intervention will take place for this retrospective and observational study.
75918581|NCT05472922|Device|Placement of MiniMizer Gastric Ring|Insertion of MiniMizer Gastric Ring in addition to the normal MGB-OAGB
75341347|NCT01529827|Drug|tacrolimus|Given IV or PO
75341348|NCT01529827|Drug|mycophenolate mofetil|Given IV or PO
75631994|NCT00874120|Drug|Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
75631995|NCT00874120|Drug|Placebo|Placebo taken twice daily (12 hours apart) for 7 days.
75631996|NCT00939822|Drug|Simvastatin|40 mg Simvastatin/day
75631997|NCT00939822|Drug|Placebo|Matching Placebo
75631998|NCT04139512|Procedure|guided surgery|placement of implant with local anesthesia using full guided surgery protocol versus free- hande one
75631999|NCT04139512|Procedure|conventionnel implant placement|placement of dental implant with conventionnal freehand technic
75632000|NCT00687154|Procedure|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
75918582|NCT05472922|Procedure|Normal MGB-OAGB|No insertion of Minimizer Gastric Ring in addition to the normal MGB-OAGB
75918583|NCT05472610|Biological|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
75918584|NCT03425630|Dietary Supplement|Argicolina|8 weeks
75918585|NCT03425630|Dietary Supplement|Normolip|8 weeks
75918586|NCT04791124|Other|Electroencephalography|"EEG evaluation Composed by three consecutive tests~Resting state EEG, with either eyes open or closed~Auditory steady-state response (ASSR)~Auditory evoked potential"
75918587|NCT03416972|Radiation|Standard platinum-based chemoradiotherapy|Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
75918588|NCT03425552|Drug|Paliperidone|Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)
75918589|NCT03425552|Drug|Paliperidone|Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension
75918590|NCT04791046|Drug|antihypertensive therapy|Personalized evidence-based antihypertensive therapy in patients with comorbidities
75918591|NCT03425474|Drug|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
75918592|NCT03425474|Drug|Propofol|Initial dose plus supplemental doses as necessary
75918593|NCT05472454|Other|Ready-to-eat meals|Participant group to consume ready-to-eat meals in accordance with the DASH diet for a period of 4 weeks.
75918594|NCT03419624|Drug|Dapagliflozin 10mg|Dapagliflozin 10 mg tablet once daily
75918595|NCT03419624|Drug|Exenatide 2 mg [Bydureon]|Exenatide 2 mg injection once weekly
75918596|NCT03419624|Drug|Placebo Oral Tablet|Placebo oral tablet once daily
75918597|NCT03419624|Drug|Placebo injection|Placebo injection once weekly
75918598|NCT03419624|Drug|Insulin|daily Insulin injections
76076345|NCT00915928|Drug|Perindopril|2,5 mg daily for 3 months
76076346|NCT00915928|Drug|Placebo|Placebo dayli for 3 months
76076347|NCT03407638|Other|PROUD Intervention|The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
75324984|NCT03808259|Drug|(S)-ketamine Oral Thin Film|(S)-ketamine OTF sublingual formulation at a dose of 7 mg, 14 mg, and 28 mg will be administered in sequential cohorts.
75783061|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM
75324985|NCT03808259|Drug|(S)-ketamine IV Infusion|(S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.
75324986|NCT03808259|Drug|Placebo|Participants will receive matching placebo.
75783062|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
75918599|NCT03419624|Drug|Metformin, if taken before|If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
75324987|NCT05742659|Other|A mobile-based interactive simulation scheme (MISS)|A mobile-based interactive simulation scheme (MISS) was proposed and developed to investigate its effects on facilitating hands-on learning of NG insertion in undergraduate medical students.
75324988|NCT03808181|Device|ChloraSolv|Weekly application of ChloraSolv for 6 weeks
75324989|NCT02386605|Behavioral|Motivational Interviewing and Cognitive Behavioral Therapy|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
75324990|NCT02386605|Behavioral|Relaxation Skills|Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
75324991|NCT03807947|Procedure|Radial TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via left transradial access
75324992|NCT03807947|Procedure|Transfemoral TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
75632001|NCT00687154|Procedure|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
75632002|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
75918600|NCT04342390|Other|High-Intensity Interval Training (HIIT)|The exercise we are studying is called high-intensity interval training, or HIIT. Participants in the exercise group will participate in the exercise program. Each exercise session will last up to 1 hour. All exercise sessions will be directed and monitored by an experienced exercise trainer or exercise physiologist.
75918601|NCT05472376|Other|Retrospective study|Retrospective study
75918602|NCT05472298|Behavioral|self-management intervention|lifestyle modification, goal setting, coaching and peer support, problem-solving
75324993|NCT02387853|Drug|LEO 90100|
75632003|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
75783063|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
75324994|NCT03802331|Drug|BI 1323495,|single oral doses
75324995|NCT05742581|Other|Computed Tomography|In our study, computerized tomography of 24 rotator cuff tears (rotator cuff tear group) and 20 Bankart lesions, and no rotator cuff tears (control group) were examined. CSA and AI were measured on three-dimensional glenohumeral joint models obtained by three-dimensional reconstructions of computed tomography examinations.
75324996|NCT05708079|Procedure|Endovascular thrombectomy|An endovascular thrombectomy is the removal of a thrombus (blood clot) under image guidance. A thrombectomy is most commonly performed for an arterial embolism, which is an arterial blockage often caused by atrial fibrillation, a heart rhythm disorder.
75324997|NCT02145299|Device|TruePath CTO Device|"The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions."
75324998|NCT02145299|Device|CROSSER CTO Device|
75324999|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
75325000|NCT02146001|Other|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
75632004|NCT00685126|Drug|Albuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
75783064|NCT01154894|Other|Aravita including arachidonic acid and docosaheaenoic acid|Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
75918603|NCT03416660|Device|Fractional Carbon Dioxide laser|
75918604|NCT04800952|Other|blood samples and filtered fluid will be collected.|"Arterial blood samples will be collected just before the commencement of continuous venovenous haemofiltration (CVVHF) and 1 h after the termination of CVVHF.~Prefilter and post-filter venous blood samples and filtered fluid will be collected 1 and 3 h after the commencement of CVVHF and at the end of CVVHF."
75918605|NCT03419390|Device|combined Coaxial Optical Coherence Tomography (OCT) System|The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
75918606|NCT04800796|Other|Audiovisual|Receive blended learning before and reading the Standard operating procedure
75918607|NCT03419312|Device|Proclaim™ Elite 5: Burst - Washout - Sham|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
75918608|NCT03419312|Device|Proclaim™ Elite 5: Sham - Washout - Burst|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
75918609|NCT04790500|Other|mobilization technique|Mobilization of sacroiliac joint which will increase the range of motion and reduction in pain and improvement in functional limitation.
75918610|NCT04790500|Other|muscle energy technique|Muscle energy technique it is known as active muscular relaxation technique. It helps in lengthening the shorten muscle and increasing range of restricted muscles
75918611|NCT04790422|Dietary Supplement|Dietary fiber supplement|Dietary fiber
75918612|NCT04790422|Dietary Supplement|Caseine protein hydrolisate|Dietary supplement
75918613|NCT04790422|Dietary Supplement|Maltrodextrine|Placebo comparator
75918614|NCT03425240|Device|Nerve Stimulation|Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
75918615|NCT04790656|Other|Conventional Therapy|Subjects will randomly placed into intervention group and control group . In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
75325001|NCT02146001|Other|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
75341349|NCT01529827|Drug|methotrexate|Given IV
75632005|NCT00606216|Procedure|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
75918616|NCT04790656|Other|Cycle ergometer combine with CPAP|Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days . The maximum exercise time for postoperative day 2 will be 20 min, and 30 min for the third and fourth postoperative days.
75783065|NCT03886376|Other|Deep Massage|The deep massage group received 12 minutes of massage on the legs, arms and the back with three different sliding pressures.
75783066|NCT03886376|Other|Superficial Massage|The superficial massage group received 12 minutes of only one sliding pressure performed on the legs, arms and the back.
75783067|NCT03886688|Drug|HEC53856|oral administration
75783068|NCT03886688|Drug|placebo|oral administration
75632006|NCT00606216|Procedure|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
75783069|NCT01154972|Procedure|Preoperative sentinel lymph node identification and marking|SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
75783070|NCT01261910|Behavioral|Intensive initial education|Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
75783071|NCT01155128|Behavioral|exercise aerobic|The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
75783072|NCT01155206|Drug|glucagon|glucagon 3ng/kg/min
75918617|NCT03425162|Drug|Morphine Sulfate|patient-controlled analgesia (PCA) morphine
75918618|NCT03425162|Procedure|Group P|Group P:patient-controlled analgesia (PCA) morphine
75918619|NCT03425162|Procedure|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 Bupivacaine
75918620|NCT02096133|Drug|Cholecalciferol|Vitamin D3 solution
75918621|NCT02096133|Other|Placebo comparator|Placebo comparator
75918622|NCT04800406|Procedure|Dental Implants|Resorbable blast media surface treated dental implant and Acid etched surface treated dental implant.
76076348|NCT03407404|Combination Product|Ketamine-Midazolam|Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.
75341350|NCT01529827|Other|laboratory biomarker analysis|Correlative studies
75341351|NCT01529827|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
75341352|NCT01529827|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
75632007|NCT00606216|Procedure|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
75632008|NCT00687232|Drug|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
75918623|NCT03416582|Behavioral|Symptom Management Education and Nurse Coaching|"The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the Cancer Treatment Symptom Management Education Toolkit geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration."
75325002|NCT02313597|Procedure|SETON|In seton treatment, initially Hydrogen peroxide will be applied to the external opening with a 10-cc syringe, and the internal opening will be located by direct visualization of the anal canal via proctoscope. A probe will be inserted into the external opening and carefully maneuvered through the internal opening. Silk 1/0 suture will be then tied to the tip of the probe, which will be then squeezed out of the external opening. The suture will be then tied around the sphincter and through fistula tract. Later, the seton will be tightened at four-week intervals under local anesthesia until the suture cut through the sphincter.
75325003|NCT02313597|Procedure|VAAFT|Patients assigned to the VAAFT group will receive the following procedure. The external opening will be widened with a probe, and a fistulascope will be inserted to delineate the primary and secondary tracts and locate the internal opening. The internal opening will be then stitched with Vicryl™ (Polyglactin 910) 2-0 suture through the anal route with the help of a proctoscope. The tract of the fistula will be washed and debrided through the scope and cauterized. Finally, the external opening will be excised and will be sent for biopsy.
75325004|NCT05742503|Other|Depo-Provera|Injectable progesterone
75325005|NCT05742503|Other|Implanon|Etonogestrel implant
75325006|NCT05742503|Other|Norgestrel|Pill containing progesterone
75783073|NCT03675386|Other|Interventional Group|The Transitional Pain Service Program enables targeted, mechanism-based, treatment innovations aimed at reducing the incidence and severity of chronic post-surgical pain, disability and enabling safe opioid prescribing/ weaning after major surgery. The investigator's TPSP intervention uses a variety of methods to support patients to manage pain and wean off opioids. This includes physician-guided opioid and non-opioid pharmacotherapy and tapering, and clinical psychology services specializing in pain education, Acceptance & Commitment Therapy (ACT) and e-mobile self-management tools.
75783074|NCT03675386|Other|Control Intervention|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
75468162|NCT06070831|Device|Expiratory muscle training|"Respiratory training, performed through PEP, was carried out with a pressure threshold device (Treshold PEP, Philips-Respironics, Pittsburg, PA, USA). Threshold PEP offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the expiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
75468163|NCT06070818|Other|Healthy Body & Mind Program|12-week physical activity and lifestyle education program
75783075|NCT03879278|Drug|NPT189|NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
75918624|NCT03416582|Behavioral|Drinks Diary|The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
76076349|NCT03407404|Combination Product|Morphine -Midazolam|Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.
75325007|NCT05742503|Other|Mirena|Levonorgestrel-releasing intra-uterine drug (IUD)
75468164|NCT06070805|Other|depression|The score of Hamilton Rating Scale for Depression (HAMD) is ≥8
75325008|NCT02388321|Drug|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
75632009|NCT00687232|Drug|Placebo|
75632010|NCT05382780|Other|The breather respiratory muscle trainer|The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.
75632011|NCT05382780|Other|Diaphragmatic and localized breathing exercises|"A. Diaphragmatic breathing exercises:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~B. Localized Breathing:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~C. Mild Interval training exercise"
75632012|NCT05382780|Other|interval aerobic training and respiratory training|mild intensity interval aerobic training and respiratory training on treadmill
75632013|NCT04138654|Dietary Supplement|Processed meat product|300 grams per day during 2 weeks
75632014|NCT04138654|Dietary Supplement|White meat wash-out|300 grams per day during 2 weeks
75632015|NCT04138654|Dietary Supplement|Processed meat products enriched with natural compounds|300 grams per day during 2 weeks
75918625|NCT02090517|Device|Pulsed Dye Laser|Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
75632016|NCT04138654|Dietary Supplement|Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds|3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
76076350|NCT03830086|Drug|Midazolam|Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
76076351|NCT03830086|Drug|Sufentanil|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
76076352|NCT03830086|Drug|Propofol|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
75783076|NCT03879200|Other|Group antenatal care|Care will be provided in group sessions in dialogue sensitive to language and cultural issues. Group numbers will be around 8; the woman with partner or other companion welcome. The content of the sessions will be designed in collaboration with midwives and Somali born women, following the present parental education and findings from the focus groups. The sessions will be held at the antenatal clinic led by one or two midwife, assisted by the trained female Somali interpreter.
75468165|NCT06070792|Other|NEURO LINGUISTIC PROGRAM|NEURO LINGUISTIC PROGRAM
75468166|NCT06070792|Other|PROGRESSIVE MUSCLE RELAXATION EXERCISES|PROGRESSIVE MUSCLE RELAXATION EXERCISES
75468167|NCT06070766|Drug|Ketamine|The use of ketamine in chronic conditions.
75468168|NCT06070753|Drug|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of EVT. Daily infusion for 10 consecutive days.
75468169|NCT06070740|Drug|Durvalumab and Chemotherapy(oxaliplatin and capecitabine)|"Combination therapy includes:~Durvalumab: intravenous infusion with a fixed dose of 1500 mg on day 1, repeated every 3 weeks ± 3 days; Chemotherapy: Oxaliplatin 130mg/m2 intravenous infusion on day 1, capecitabine 1000mg/m2, orally, twice a day, from day 1 to day 14; repeated every 3 weeks ± 3 days;~After 6 cycles of combination therapy, maintain with durvalumab 1500 mg every 4 weeks ± 3 days for 2 years. Terminate the trial if confirmed disease progression, initiation of other anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent or other reasons considered by the investigators."
75468170|NCT06070727|Other|Obturator|Evaluation of patient satisfaction and oral healthy related quality of life of Polyetherketoneketone(PEKK) and metal framework for management of maxillectomy cases.
75783077|NCT01159886|Procedure|Ileal intubation|"After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed."
75468171|NCT06070701|Procedure|Superficial Parasternal Block (SIPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the superficial parasternal intercostal plane using real-time ultrasound guidance.
75468172|NCT06070701|Procedure|Erector Spinae Plane Block (ESPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the plane deep to the erector spinae muscle, typically at the level of the 5th thoracic vertebra, under real-time ultrasound guidance.
75468173|NCT06070701|Drug|General anesthetic|During general anesthesia, fentanyl is administered according to NOL monitoring.
75783078|NCT03878888|Drug|Exparel 266 MG Per 20 ML Injection|patients receive Exparel in bilateral TAP blocks for open abdomen surgery
75918626|NCT02090517|Device|Long Pulsed Alexandrite Laser|Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
75918627|NCT02090517|Device|Pulsed Dye Laser Plus Nd:YAG Laser|The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
75918628|NCT02090517|Procedure|Electrodesiccation|A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
76076353|NCT03830086|Drug|Rocuronium|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
76076354|NCT03830086|Drug|Sevoflurane|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
76076355|NCT03830086|Drug|Bupivacaine|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
76076356|NCT03407326|Dietary Supplement|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
75468174|NCT06070701|Drug|Morphine|Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
75468175|NCT06070675|Device|Minze Diary Pod|The automated bladder diary utilized in this study consists of the Minze Diary Pod and Minze Flow app. The Diary Pod is a capacitance-based measuring device, that automatically registers voided volumes and time of void. The Diary Pod connects via Bluetooth to the Minze Flow app to request additional information from the patient, such as urge, drinks and leakages.
75632017|NCT00604734|Device|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
75632018|NCT05380674|Behavioral|The short questionnaire of healthy habits|collects sociodemographic data, weight, height, and physical activity, self-reported.
75632019|NCT00687310|Behavioral|Educational intervention|Tailored asthma education based on needs assessment
76076357|NCT03407326|Dietary Supplement|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
76076358|NCT02240212|Drug|Afuresertib|The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
75632020|NCT00690508|Procedure|Supra-Sternal Tube-Tip Palpation (SSTTP)|The supra-sternal palpation of the tube after tracheal intubation.
75783079|NCT03878966|Device|Inserting polymer free drug eluting stent in the coronary arteries|• Early invasive strategy with percutaneous coronary intervention will be done for the patients presenting with NST ACS who meet the inclusion criteria using Polymer-free drug eluting stents instead of the polymer-permanent drug eluting stents .
76076359|NCT02240212|Drug|Paclitaxel|Paclitaxel sourced locally will be administered IV
76076360|NCT02240290|Drug|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
76076361|NCT02240290|Drug|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
75783080|NCT01266200|Procedure|Mantis|percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
76076362|NCT03407092|Other|ADAPT cohort|Thrombectomy with distal aspiration technique
76076363|NCT03407092|Other|Stentriever Cohort|Thrombectomy with stent retriever
75325009|NCT02388321|Drug|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
75632021|NCT05382624|Procedure|Abdominal circumference was measured at the umbilical level in the standing position at the end of a normal expiration.|The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications, such as nausea or vomiting, the number of patients requiring ephedrine and atropine, the total amount of intravenous fluid used, and the total amount of ephedrine used during surgery were recorded.
75783081|NCT01266200|Procedure|XIA|Treatment of the fracture with Xia and conventional operation technique
76076364|NCT01713686|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
76076365|NCT01047436|Drug|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
76076366|NCT01047436|Drug|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
76076367|NCT02240446|Device|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
76076368|NCT02240446|Device|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
76076369|NCT03406936|Drug|Daily interruption of midazolam|daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
75783082|NCT01159964|Biological|Immunotherapeutic GSK2302032A, different formulations|Intramuscular administration
75783083|NCT01266278|Other|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
76076370|NCT03406780|Biological|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
76076371|NCT03406780|Drug|Placebo|Placebo
76076372|NCT02240524|Procedure|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
76076373|NCT02240524|Procedure|Systemic chemotherapy|
75783084|NCT01266278|Other|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
76076374|NCT02240524|Procedure|HIPEC|
76076375|NCT02240602|Drug|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
76076376|NCT02240602|Drug|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
76076377|NCT02240602|Drug|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
76076378|NCT03406546|Drug|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
76076379|NCT03406546|Drug|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
75325010|NCT05742425|Drug|Serplulimab Combined With FOLFIRI and Bevacizumab|For patients with confirmed failure to reach CC0/1, they should be treated with sullizumab combined with FOLFIRI+bevacizumab for 4-8 cycles within 3 weeks after the exploration operation. After the end of the 4th and 8th cycles, they should be evaluated with imaging and MDT. If the conversion is successful, they should be treated with a second exploration operation within 3-4 weeks, The patients with CC0/1 can be evaluated for tumor reduction surgery (CRS) combined with intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), and the follow-up treatment plan will be selected according to the clinical situation of the patients after surgery; If CC0/1 cannot be evaluated after the second exploration surgery and CC0/1 cannot be performed after the imaging evaluation, other chemotherapy and optimal supportive treatment will be performed according to the situation.
75325011|NCT02313675|Drug|Acetaminophen|
75918629|NCT03419156|Other|Text Message Arm Intervention|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
75918630|NCT02096289|Drug|Thioridazine|
75325012|NCT02313675|Drug|Ketorolac Tromethamine|
75325013|NCT02313675|Drug|Saline|
75632022|NCT04139590|Device|Panda|
75632023|NCT04139590|Device|Visual Analogue Scale - Original|
75632024|NCT05382468|Other|Intradialytic exercise|Intradialytic exercise comprised of a set warm up, aerobic, active,passive & cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month & supervised by principle investigator.
75632025|NCT00603876|Dietary Supplement|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
75783085|NCT01266278|Other|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
75783086|NCT03882710|Drug|Metoprolol XR|Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
75632026|NCT00687388|Drug|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
75918631|NCT04800640|Other|Experimental: Electroanalgesia|The sample will consist of 66 individuals, of both men and women, where they will be randomly included in two groups: Intervention group composed of 33 patients who will effectively receive the treatment through electroanalgesia via TENS;
75632027|NCT00687388|Drug|celecoxib|200mg daily for 8 weeks
75783087|NCT01267838|Procedure|PCI|PCI of bifurcation lesions with double stenting
75918632|NCT03416504|Behavioral|Gradual Exposure (EXP-G)|In EXP-G, exposure proceeded hierarchically from mildly, to moderately, to highly intense stimuli so that exposure intensity gradually built between (but not within) sessions.
75918633|NCT03416504|Behavioral|Variable Exposure (EXP-V)|In EXP-V, exposure stimuli were chosen at random (i.e., pieces of paper with exposure stimuli written on them were pulled randomly from an opaque container) so that mild, moderate, and high intensity exposures could occur in any order during any of the sessions (the participant was not informed which level was coming next). This aimed to maximize (a) uncertainty, (b) variability in exposure intensity, and (c) variability in corresponding physiological arousal.
75325014|NCT02388633|Procedure|Plasmapharesis|Clinically-indicated LDL apheresis
75325015|NCT02389101|Other|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
75325016|NCT02389725|Device|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
75325017|NCT02389725|Device|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
75325018|NCT03801629|Drug|High Morphine Dose|Subjects will receive an intramuscular morphine injection (0.07mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
75325019|NCT03801629|Drug|Low Morphine Dose|Subjects will receive an intramuscular morphine injection (0.04mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
75468176|NCT06070675|Other|Paper bladder diary|The paper bladder diary utilized in this study is a paper timetable that has the patient enter (in the columns of the timetable) drinks in ml, urinations in ml (using a measuring cup) and leakage episodes for the nearest hours (rows of the timetable).
75632028|NCT00687388|Drug|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
75632029|NCT02625688|Other|Delayed cord clamping|We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
75632030|NCT02625688|Other|Cord milking|If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.
75783088|NCT01161602|Drug|Pumosetrag|
75632031|NCT02625688|Other|Early cord clamping|We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
75632032|NCT00939510|Biological|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
75783089|NCT01161602|Drug|Pumosetrag|
75783090|NCT01161602|Other|Placebo|
75783091|NCT01161602|Drug|Pumosetrag|
75325020|NCT03801551|Diagnostic Test|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
75341353|NCT00569192|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
75632033|NCT00939510|Drug|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
75783092|NCT01263392|Device|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria & leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
75783093|NCT03882632|Device|Fat Grafting for Fecal Incontinence|Autologous adiopse tissue harvesting/grafting using Lipogems
75783094|NCT01161758|Other|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
75783095|NCT01161758|Other|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
75783096|NCT01161836|Drug|Iniparib|"Solution for infusion~60-minute intravenous infusion"
75783097|NCT05051306|Other|High-load resistance exercise|Subjects in high-load trial performed 4 sets per exercise, 8 repetitions with load of 85%-8RM with 90 sec of rest between sets.
75918634|NCT02090595|Behavioral|MBCT-C|A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.
75918635|NCT02090595|Behavioral|Waitlist Control|Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
75918636|NCT04778150|Device|VO 100 medical device from Mespere LifeSciences|The investigators want to show a positive relationship between SjvO2 and SvO2 in order to possibly use in the future SjvO2 measured by VO 100 as a noninvasive surrogate of SvO2 in patients undergoing liver transplantation surgery.
75918637|NCT02093481|Other|Test meal|
75918638|NCT02093481|Other|Reference|
75918639|NCT02093481|Other|Priming|The reference or test meal was eaten 3 days prior to measurements of variables.
75325021|NCT05741021|Drug|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
75325022|NCT05741021|Drug|Pemetrexed|A chemotherapy medication used to treat a number of types of cancer.
75325023|NCT05741021|Drug|Carboplatin|A chemotherapy medication used to treat a number of types of cancer.
75632034|NCT00939510|Other|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
75783098|NCT05051306|Other|Low-load resistance exercise|Subjects in low-load trial performed 4 sets per exercise, 15 repetitions with load of 45%-8RM with 90 sec of rest between sets.
75783099|NCT01266434|Drug|Simvastatin|10 mg once daily for 8 weeks
75632035|NCT00687466|Drug|Insulin|"Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour."
75632036|NCT00606372|Procedure|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
75632037|NCT04266288|Drug|Ketamine|Active drug
75783100|NCT01266434|Drug|B1-6-12|1 tablet once daily for 8 weeks
75783101|NCT01266512|Drug|DOCETAXEL|Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
75918640|NCT02093481|Other|No priming|The reference or test meal was eaten 1 days prior to measurements of variables.
75918641|NCT04775342|Device|smartphone|modern technology
75918642|NCT02090673|Drug|Exenatide|
75918643|NCT04758572|Other|Manual Therapy|Mobilization, massage and stretching
75325024|NCT05741021|Drug|Paclitaxel|A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
75632038|NCT04266288|Drug|Sodium Chloride 0.9%|Placebo
75632039|NCT02625532|Procedure|Follicular phase|Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
75783102|NCT01266512|Radiation|Intensity Modulated Radiotherapy (IMRT)|2 Gy per fraction
75918644|NCT04758572|Other|Placebo massage|Kneading and rubbing without intention to treat
75918645|NCT03419000|Genetic|blood sample|Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
75783103|NCT01266512|Drug|CISPLATIN|Pharmaceutical form: solution for infusion Route of administration: intravenous
75918646|NCT03556371|Drug|N-Acetylcysteine|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
76076380|NCT03406546|Device|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
76076381|NCT01681004|Device|iFuse Implant System|Placement of iFuse implant system via surgery
75325025|NCT04383977|Drug|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
75325026|NCT04383977|Drug|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
75325027|NCT03801239|Diagnostic Test|Urodynamic Study|during visit Week 0 patients had urodynamic study
75325028|NCT03801239|Diagnostic Test|OABSS questionnaire fulfilment|during visit Week 0 and Week 2 patients fulfilled OABSS
75325029|NCT03801239|Diagnostic Test|UDI-6 questionnaire fulfilment|during visit Week 2 patients fulfilled UDI-6 questionnaire
75325030|NCT03801239|Diagnostic Test|IIQ-7 questionnaire fulfilment|during visit Week 2 patients fulfilled IIQ-7 questionnaire
75325031|NCT03801161|Biological|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).|Pentavalent vaccine is being recommended to provide infants at 6wk, 10wk and 14wk of age. This vaccine also induces plasma CRP >5 mg/L in infants within 24 hours of immunization.
75632040|NCT02625532|Procedure|Luteal phase|Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
75325032|NCT05561777|Other|Physician-targeted CDS tool for PCN allergy delabeling|This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
75325033|NCT02389881|Drug|TAK-058|TAK-058 Solution
75325034|NCT02389881|Drug|TAK-058 Placebo|TAK-058 placebo-matching solution
75325035|NCT02389959|Drug|Bevacizumab|Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
75325036|NCT02389959|Drug|Placebo (Saline)|4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
75325037|NCT00775931|Procedure|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
75783104|NCT01156454|Procedure|X-ray|surgical specimen taken to radiology and contents x-rayed
75325038|NCT00775931|Drug|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
75468177|NCT06070662|Diagnostic Test|Coronary microvascular disease testing during coronary angiography|During invasive coronary angiography, in addition to coronary angiography performed as per routine clinical care, participants will have angiographic testing for coronary microvascular disease using routine clinical procedures. This will consist of fractional flow reserve (FFR), coronary flow reserve, index of microvascular resistance and vasospasm provocation testing with acetylcholine (Ach).
75632041|NCT00687622|Drug|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
75783105|NCT01158638|Behavioral|Web Mediated Step Intervention|The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
75918647|NCT03556371|Drug|Placebo oral capsule|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
75918648|NCT04789798|Device|TeleDiab (Telemedicine)|"TeleDiab program components consist of:~Electronic transmission of capillary blood glucose measurement results~Electronic transmission of blood pressure measurements~Synchronized video-conferencing, secure messaging~Access to clinical data from patient files when necessary~Reminding of routine follow-up tests and examinations~Providing web-based educational materials to patients."
76076382|NCT01681004|Other|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
75325039|NCT00775931|Radiation|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
75325040|NCT00775931|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
75325041|NCT00775931|Drug|Busulfan|patients<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
75341354|NCT00569192|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
75468178|NCT06070662|Diagnostic Test|Cardiac magnetic resonance scan including exercise|Participants will undergo a cardiac magnetic resonance scan compromising 1) T1 mapping, 2) oxygenation-sensitive MRI and 3) perfusion imaging. All will be obtained at rest and during exercise using a step ergometer.
75468179|NCT06070662|Diagnostic Test|Additional analysis of already acquired CT scan|Previously acquired CTCA images from the main research study will be transferred to Heartflow for computation of coronary blood volume.
75632042|NCT01098266|Drug|NGR-hTNF plus Best Investigator's Choice (BIC)|"NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
75783106|NCT01160042|Drug|Metformin|Metformin Tablets 1000 mg
75783107|NCT01160042|Drug|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
75783108|NCT03882476|Diagnostic Test|InSight|Clinical decision support (CDS) system for sepsis detection
75783109|NCT01267916|Device|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
75783110|NCT01267916|Device|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
75783111|NCT01267916|Device|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
76076383|NCT01046110|Drug|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
76076384|NCT01046110|Drug|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
76076385|NCT01713530|Drug|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
76076386|NCT01713530|Drug|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
75325042|NCT00775931|Drug|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
75325043|NCT00775931|Procedure|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
75325044|NCT02148107|Drug|BI 691751|BI 691751 Dose 1
75325045|NCT02148107|Drug|BI 691751|BI 691751 Dose 2
75783112|NCT01267916|Device|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
75783113|NCT01267916|Device|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
75783114|NCT01267916|Device|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
75783115|NCT01156610|Behavioral|Tobacco Treatment|"Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol)."
75918649|NCT04789798|Other|Usual care|Usual diabetes care, as provided by primary care providers
75918650|NCT03416426|Device|Amplatzer® PFO occluder or Gore® Septal Occluder|The closure procedure was performed under general anesthesia. After achieving femoral venous access, the PFO was crossed with a 5F multipurpose catheter, which was advanced into the left upper pulmonary vein and then exchanged over a 0.035 inch J-tipped stiff guidewire for an 8F or 9F guiding sheath. Procedural anticoagulation was initiated with 5000 units of intravenous heparin. After then additional heparin was administrated throughout procedure to maintain an activated clotting time of ≥250 seconds. Device size was selected based on TEE measurements of the distance between the PFO and the aortic root.
75918651|NCT03906058|Drug|Anlotinib|All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
75918652|NCT04799704|Diagnostic Test|swabbing of conjunctiva|Each eye will be sampled with a single, sterile, nylon, flocked swab
75918653|NCT02096367|Other|Gait analysis|
76076387|NCT01713530|Drug|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
76076388|NCT01045798|Drug|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
76076389|NCT01045798|Drug|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
76076390|NCT02240758|Procedure|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
75325046|NCT02148107|Drug|BI 691751|BI 691751 Dose 3
75325047|NCT02148107|Drug|BI 691751|BI 691751 Dose 4
75325048|NCT02148107|Drug|BI 691751|BI 691751 Dose 5
75325049|NCT02148107|Drug|BI 691751|BI 691751 Dose 6
75325050|NCT02148107|Drug|Placebo|Placebo
75325051|NCT02052141|Biological|CINRYZE 500|500 Units of CINRYZE administered by IV injection
75325052|NCT02052141|Biological|CINRYZE 1000|1000 Units of CINRYZE administered by IV injection
75468180|NCT06070636|Procedure|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
75783116|NCT03882788|Drug|Isoflurane|Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.
75783117|NCT03882788|Drug|Fentanyl (high dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
75783118|NCT03882788|Drug|Fentanyl (low dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
75341355|NCT00569192|Drug|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
75468181|NCT06070636|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75783119|NCT01161914|Drug|Cerezyme®|administered by IV infusion for a dose of 60 U/kg
75918654|NCT02096367|Other|Kinematic gait analysis in lower limb|
75783120|NCT01161914|Drug|ISU302|administered by IV infusion for a dose of 60 U/kg
75325053|NCT02391987|Device|Tele-monitoring and health coaching|"Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.~Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management."
75468182|NCT06070636|Drug|Sintilimab|200mg intravenously every 32 weeks
75468183|NCT06070623|Device|US|We use elastography and color Doppler from US machine and compare results with CT
75468184|NCT06070571|Drug|Yarrow and moringa mixture|yarrow and moringa mixture nano particles loaded on buccal film
75325054|NCT00777179|Drug|Vandetanib|Tablet, oral, daily
75468185|NCT06070558|Device|MRI with Real Time MRI Rapid Flash sequence|MRI examination of temporomandibular joint with Real Time MRI Rapid Flash sequence
75325055|NCT00777179|Drug|Placebo|Placebo
75325056|NCT05507177|Other|communication training programme for healthcare providers|the communication training programme is specifically designed to help Dutch primary care healthcare providers facilitate adequately deprescribing cardiometabolic medication in older patients
75632043|NCT01098266|Drug|Placebo plus Best Investigator's Choice (BIC)|"Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
75783121|NCT01160120|Drug|generic FDC of TDF/3TC/EFV|Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
75783122|NCT03882554|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
75783123|NCT01156688|Drug|Misoprostol|sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
75783124|NCT01156688|Drug|Misoprostol|buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
75783125|NCT03876704|Drug|High dose of fat-Soluble Vitamin|Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion
75783126|NCT03876704|Drug|Conventional dose of fat-Soluble Vitamin|Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion
75783127|NCT03878654|Drug|Tauroursodeoxycholic Acid|Naturally occurirng bile acid
75783128|NCT03878732|Diagnostic Test|Bindex measurement|One time bone density measurement with ultrasound device
75468186|NCT06070545|Other|Modified Supine Position|Among the patients in the control group, for whom consent was obtained, the standard clinical procedure including supine after percutaneous coronary intervention (0 degrees flat on the back) will be provided, and for the patients in the experimental group, care including the modified supine position will be provided. The modified supine position is a position in which patients lie on their back with the head of the bed elevated at a 20-degree angle, with a pillow between the soles of their feet and the end of the bed. Both study groups will be required to lie supine in bed for 6 hours and stay in bed for 12 hours before ambulation is allowed in order not to increase the risk of local bleeding, as required by the clinical procedure.
75468187|NCT06070532|Biological|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
75632044|NCT00687700|Drug|GSK961081|GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
75632045|NCT00687700|Drug|GSK961081 matching placebo|GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
75783129|NCT01266746|Procedure|Vitreous surgery|Vitreous surgery is performed to treat the original disease not for the study.
75632046|NCT00687700|Drug|Propranolol|Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.
75783130|NCT03878576|Other|REFERENCE: white bread - BGL0 [RP]|Determination of glycemic response after consumption of BGL0.
75783131|NCT03878576|Other|TEST: b-glucan enriched bread - BGL2 [IP1]|Determination of glycemic response after consumption of BGL0.
75783132|NCT03878576|Other|TEST: b-glucan enriched bread - BGL3 [IP2]|Determination of glycemic response after consumption of BGL0.
75783133|NCT03878576|Other|TEST: b-glucan enriched bread - BGL4 [IP3]|Determination of glycemic response after consumption of BGL0.
75918655|NCT02096367|Other|Analysis of static posture|
75918656|NCT02096367|Other|Gait on treadmill|Treadmill during 2 minutes
75325057|NCT05734235|Dietary Supplement|Vitamin C|Two Vitamin C tablets daily for 8 days.
75325058|NCT05734235|Dietary Supplement|Vitamin E|One Vitamin E tablet daily for 8 days.
75325059|NCT02392767|Dietary Supplement|Verum|2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.
75468188|NCT06070519|Diagnostic Test|CPET and related variables evaluation|"At the baseline visit ,CPET-related variables, echocardiographic, ECG, therapy and blood chemistry data will be collected. The baseline CPET will be repeated within 2 weeks. Patients will perform 4 follow up visits at 6, 12, 18 and 24 months after the baseline visit. At every study step, it will be performed:~Echocardiography (LVEF)~Blood sample (Na+, MDRD, Hb)~Maximal ramp protocol CPET (peakVO2, VE/VCO2 slope)"
75632047|NCT00687700|Drug|Propranolol matching placebo|Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
75783134|NCT03878264|Drug|CORT118335 Oral|CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
75783135|NCT03878264|Drug|14C-CORT118335 intravenous|14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
75783136|NCT03878264|Drug|14C-CORT118335 oral|14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
75783137|NCT03878186|Other|Usual Care (UC)|Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt
75783138|NCT03878186|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT): Usual Care + Cognitive-behavioral therapy program intervention (AppraHIV). This intervention involves 7 in-person weekly sessions based on Adjuvant Psychological Therapy centered in three areas: cognitive appraisal, affect and adherence and self-care, everyone with different techniques: cognitive techniques, diaphragmatic breathing, scheduling pleasurable activities, use of pillbox, solving problems, planning for the future, etc. The intervention was manualized (according to Template for Intervention Description and Replication TIDieR), piloted and validated.
75783139|NCT03882164|Diagnostic Test|Blood-Bile Ratio of Tacrolimus|Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered
75783140|NCT01160276|Drug|cyclosporine+colchicine|the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
75783141|NCT01160276|Drug|tacrolimus|the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
75783142|NCT01162070|Other|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
75783143|NCT01162070|Other|Standardized strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
75783144|NCT01162148|Behavioral|Conventional or regular pulmonary rehabilitation program alone|Conventional or regular pulmonary rehabilitation program alone
75783145|NCT01162148|Device|very low load IMT (sham IMT) alone|very low load IMT (sham IMT) alone
75783146|NCT01162148|Device|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
75783147|NCT01162148|Device|Targeted inspiratory resistive or threshold IMT alone|Targeted inspiratory resistive or threshold IMT alone
75783148|NCT03882398|Other|Balance|"Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)"
75632048|NCT00935532|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week;
75632049|NCT00935532|Drug|insulin glargine|subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
75632050|NCT04139356|Procedure|Deep breaths|Patients will undergo a 6 minutes protocol. Baseline: 1 minute normal breaths. Intervention: 1 minute with 10 deep breaths, 1 each 6 secs. Pulse-oxymetry will be continuously recorded.
75632051|NCT02878226|Procedure|repair of rupture|
75918657|NCT02096367|Device|Muscle vibration stimulation|Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
75918658|NCT04789876|Other|Phosphate mobile app|The phosphate mobile app has the features of i) matching phosphate binder with dietary phosphate intake, ii) educational videos of phosphate management, iii) food database with local food items, iv) record-keeping and goal setting.
75325060|NCT02392767|Dietary Supplement|Placebo|corn starch
75325061|NCT04384289|Procedure|Nursing care based on the Transitonal Care Model|Nursing care carried out in collaboration with a multidisciplinary team in line with Transitonal Care Model for elderly patients who have undergone open heart surgery
75325062|NCT05732129|Drug|Fluzoparib|150mg,orally, bid (days 1-7) every 2 weeks
75325063|NCT05732129|Drug|Irinotecan|30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
75325064|NCT04384601|Drug|Chemotherapy|Perioperative chemotherapy will be administered according to description in two arms.
75325065|NCT02394951|Drug|Pregabalin|Anticonvulsant
75632052|NCT04138420|Drug|Bevacizumab Injection|Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
75632053|NCT05378646|Drug|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
75632054|NCT01093586|Procedure|double-unit umbilical cord blood transplantation|Undergo transplantation
75632055|NCT01093586|Other|cytogenetic analysis|Correlative studies
75632056|NCT01093586|Procedure|bone marrow aspiration|Correlative studies
75325066|NCT02394951|Drug|Placebo|Identical, matching inactive substance
75632057|NCT01093586|Other|fluorescence in situ hybridization|Correlative studies
75632058|NCT01093586|Drug|busulfan|Given orally
75632059|NCT01093586|Drug|cyclophosphamide|Given IV
75632060|NCT01093586|Drug|anti-thymocyte globulin|Given IV
75632061|NCT01093586|Drug|methylprednisolone|Given IV
75918659|NCT04789876|Behavioral|One-off dietary counselling with a phosphate booklet|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study. Patients received a complimentary phosphate booklet after the counselling session. The phosphate booklet contains similar educational information as per the phosphate mobile app excluding the matching of phosphate binder with dietary phosphate information.
75918660|NCT02827526|Drug|Ketamine|
75632062|NCT01093586|Drug|cyclosporine|Given IV
75632063|NCT01093586|Drug|mycophenolate mofetil|Given orally or IV
75918661|NCT02827526|Drug|Control|
75325067|NCT03838367|Drug|350 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
75468189|NCT06070493|Other|classic physiotherapy program|For individuals of control group, a hot pack was applied to the shoulder area for 15 minutes, while the individuals were in the sitting position. The conventional mode of transcutaneous electrical nerve stimulation was used. Frequency was adjusted in the range of 50-100 Hz, and the amplitude intensity was adjusted between 10-30 milliampere with the intensity of mild tingling without causing any excessive discomfort or contractions. Electrodes were placed at the anterior, posterior, superior, and inferior of the shoulder region. In the exercise program of the patients, joint range of motion exercises, stretching, scapular stabilization, rotator cuff, and shoulder muscle strengthening exercises were given.
75632064|NCT01093586|Other|flow cytometry|Correlative studies
75632065|NCT01093586|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
75783149|NCT03882398|Other|Endurance|"Progressive-cycle program (15-25 minutes)~Warming up Pedalling with 0 resistance (2 minutes)~Main Part* Week 1-2 : 3x2 minutes Week 3-4 : 4x2 minutes Week 5-6 : 5x2 minutes Week 7-8 : 6x2 minutes~Return to resting stage Pedalling with 0 resistance (1 minute)~(*Pedalling with resistance set at 3-4. Rest: 2 minutes between sets or 120 beats/minute. One more set added every two weeks and workout intensity maintained at 70% of heart rate reserve-HRR)"
75783150|NCT01156766|Device|- locking anterior plate|"The number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. Several surgical techniques are described in particular locking plates and intrafocal pinning techniques.~The aim of the study is to compare (X-ray assessments and functional outcome) these two types of treatment by using a prospective, randomised multicentric analysis."
75783151|NCT01266980|Drug|Inhaled FF/ GW642444M (200/25mcg)|All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
75783152|NCT03878420|Device|Valeda PBM treatment|The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.
75783153|NCT03878420|Device|Valeda Sham treatment|The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
75783154|NCT01263548|Drug|lisdexamfetamine dimesylate|Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
75783155|NCT03882086|Other|foot reflexology|Four sessions foot reflexology was applied for 15 minutes in each foot, every other days between postpartum 14th- 20th day
75918662|NCT04799314|Drug|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy
75918663|NCT03425084|Drug|Morphine|The study was designed as an open, non-controlled drug trial, with scientists and participants blinded to the patients OCT1 status. Morphine will be given as a single dosis (0,15 mg/kg) at the end of the Surgery and later as boluses of 0,04mg/kg administrated by patient-controlled analgesia, (PCA). Blood samples with drug concentrations will be used to determine a difference in morphine AUC due to the patients OCT1 status. Questionnaire answers will be used to determine the effect of morphine due to the patients OCT1 status
75632066|NCT04266132|Procedure|General anaesthesia|General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.
75918664|NCT02096445|Device|robot-assisted neurocognitive therapy of hand function|2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.
75918665|NCT02096445|Other|Conventional neurocognitive rehabilitation|Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
75918666|NCT03424928|Drug|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
75918667|NCT03424928|Drug|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
75632067|NCT04266132|Procedure|Ultrasound-guided RLB|The suggested ultrasound transducer orientation is sagittal paramedian (cephalacaudad direction). We begin our ultrasound scanning in a paramedian sagittal plane by finding desired level (T12- L1).The transverse process view, the costotransverse ligament can be visualized above the paravertebral space. Continuing to scan from lateral to medial, the vertebral laminae come into view.
75632068|NCT04266132|Procedure|Ultrasound-guided INB|A high-frequency probe is placed medial to the anterior superior iliac spine with the axis facing the umbilicus. A needle is inserted toward the ilioinguinal nerve as it runs between the transversus abdominis and internal oblique.
75632069|NCT04266132|Drug|Bupivacaine|0.3 ml.kg of 0.25% bupivacaine will be injected under visualization.
75632070|NCT02625454|Drug|Intravenous Acetaminophen|1000 mg Acetaminophen q 6 hours, given intravenously
75325068|NCT03838367|Drug|525 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
75325069|NCT03838367|Drug|700 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
75325070|NCT03838367|Drug|AUC 5 Carboplatin|Carboplatin is an anticancer drug chemotherapy drug.
75632071|NCT02625454|Drug|Oral Acetaminophen|1000 mg Acetaminophen q 6 hours given orally
75325071|NCT03838367|Drug|Maximum Tolerated Dose (MTD) of leronlimab|The decision on the MTD will be made following the results obtained from Phase I studies
75341356|NCT05289206|Other|Vaccine - ChAdOx1-S/nCoV-19 [recombinant]|ChAdOx1-S/nCoV-19 [recombinant] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
75632072|NCT00606450|Drug|CC-10004|20 mg CC-10004 taken 1 time per day for 12 weeks
75632073|NCT00606450|Drug|CC-10004|20 mg of CC-10004 taken 2 times per day for 12 weeks
75632074|NCT00606450|Drug|Placebo|matching placebo taken either 1 or 2 times per day for 12 weeks
75632075|NCT00687934|Drug|STA-9090|This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
75783156|NCT02527070|Device|RESPeRATE (Paced Breathing)|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
75632076|NCT02879552|Procedure|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
75632077|NCT02879552|Procedure|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
75632078|NCT04138888|Drug|Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use|Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
75632079|NCT04138888|Drug|Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use|Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
75632080|NCT04266210|Device|Fuji Bulk|Restorative system
75783157|NCT02527070|Device|Quantum Warp10 (Red LED)|
75783158|NCT02527070|Device|Omnilux new-U (Near Infrared LED)|
75632081|NCT04266210|Device|G-ænial Posterior|Restorative system
75783159|NCT02527070|Other|Heat/cold provocation|Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
75783160|NCT01162226|Behavioral|gait and balance training program|The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
75783161|NCT01160432|Drug|Methadone, naloxone|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient's individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week's periods for four weeks.
75783162|NCT03882242|Behavioral|Facilitation of a school-based program|Participants deliver the prevention program (described in previous research) to school-children.
75783163|NCT03877718|Drug|Arm 1: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)
75783164|NCT03877718|Drug|Arm 2: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
75783165|NCT03877718|Drug|Arm 3: Sumatriptan Succinate 100 mg capsule|One capsule of sumatriptan succinate 100 mg
75783166|NCT03877718|Drug|Arm 4: Promethazine HCl 18.75 mg|One capsule of promethazine HCl 18.75 mg
75783167|NCT03877718|Drug|Arm 5: Promethazine HCl 37.5 mg|One capsule of promethazine HCl 37.5 mg
75783168|NCT03877718|Other|Placebo|One capsule of placebo
75783169|NCT03877952|Drug|14C-CORT125281|14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
75783170|NCT01267058|Biological|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine|Intramuscular, single dose
75468190|NCT06070493|Other|Myofascial release|myofascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the lateral neck and shoulder, pectoral region, scapulothoracic area, and arm regions for 5 minutes for optimum benefit.
75468191|NCT06070480|Other|Spinal Anesthesia Group|Effect of spinal anesthesia on intraocular pressure
75632082|NCT04139044|Procedure|Balance Exercise Training for Stable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
75632083|NCT04139044|Procedure|Balance Exercise Training for Unstable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
75632084|NCT00688012|Drug|SPC3649|
75632085|NCT00937404|Biological|Poliorix|All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
75632086|NCT00688090|Biological|Biological: MKC1106-MT|Cancer Vaccine, Immunotherapy
75783171|NCT01267058|Biological|GSK Biologicals' acellular pertussis vaccine|Intramuscular, single dose
75783172|NCT01267058|Biological|Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine|Intramuscular, single dose
75783173|NCT02526914|Drug|Intranasal Oxytocin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
75783174|NCT02526914|Drug|Intranasal vasopressin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
75632087|NCT00688090|Biological|Biological: MKCC1106-MT|Cancer Vaccine, Immunotherapy
75632088|NCT00688168|Behavioral|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
75632089|NCT00688168|Behavioral|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
75468192|NCT06070480|Other|Desflurane Group|Effect of general anesthesia with desflurane on intraocular pressure
75632090|NCT00688168|Behavioral|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
75632091|NCT05382234|Diagnostic Test|CBC, ESR ,CRP,Liver Function ,renal function ,ABG,Na,K,D-dimmer ,cardiac enzyme,ferritin ,blood and urine culture in negative cases|cllinical and laboratory evaluation of MIS-C,Effectivness of different therapeutic modalities,Outcome of cases (morbidity,mortality)
75632092|NCT00690976|Behavioral|Proyecto SOL|Group intervention
75632093|NCT00690976|Behavioral|HCT|Offer of HIV counseling and testing
75632094|NCT02625142|Other|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
75783175|NCT02526914|Drug|Intranasal placebo|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
75632095|NCT01098110|Drug|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
75783176|NCT03876938|Drug|aprepitant|aprepitant 125 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
75783177|NCT03876938|Drug|olanzapine 10 mg|olanzapine 10 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 10 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
75783178|NCT03876938|Drug|olanzapine 5 mg|olanzapine 5 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 5 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
75783179|NCT03876782|Diagnostic Test|IOLMaster|IOL power calculation will be done with IOLMaster
75783180|NCT03876782|Diagnostic Test|Verion|IOL power calculation will be done with Verion
75783181|NCT03876626|Other|PositiveLinks RX Mobile App|A mobile app designed with tools to facilitate patient self-monitoring, patient-provider communication, medication refills, and social support.
75783182|NCT03876626|Other|PositiveLinks RX Portal|An online portal that interacts with the mobile app to enable users to engage with participants though messaging and medication refill tracking.
75783183|NCT01162460|Drug|Eslicarbazepine acetate (BIA 2-093)|"Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.~Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.~Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.~Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions."
75783184|NCT03882008|Drug|Abatacept|All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
75783185|NCT01267214|Drug|Sodium Hyaluronate (Hyalgan)|1% Sodium Hyaluronate in prefilled syringe
75783186|NCT01267214|Procedure|Osteotomy alone|no injection
75783187|NCT01156922|Drug|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.~Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
75918668|NCT05449821|Diagnostic Test|Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum and saliva samples will be collected from both groups for biochemical analysis.
75632096|NCT01098110|Drug|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
75341357|NCT01571557|Drug|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
75341358|NCT00569660|Drug|Azacitidine|75 mg/m^2 subcutaneous daily for 7 days (every 4 week cycle)
75468193|NCT06070480|Other|Propofol Group|Effect of general anesthesia with propofol on intraocular pressure
75632097|NCT01098110|Drug|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
75632098|NCT04138966|Device|Nol-Index|Multiparametric monitor that studies that establishes an index as a surrogate to nociception
75632099|NCT04138966|Device|Skin Conductance|Measures skin conductance as a surrogate to nociception
75632100|NCT00912496|Biological|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
75632101|NCT00912496|Biological|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal [0.01%(w/v)] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
75632102|NCT00912496|Drug|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
75341359|NCT05129228|Device|OCT-guided saphenous vein CABG|OCT examination of harvested saphenous vein conduits will indicate pathology. Under the surgeon's discretion the conduit segments with pathology will not be grafted.
75341360|NCT01573273|Drug|Oxytocin|intranasal administration, 40 IUs
75341361|NCT01573273|Drug|Saline|intranasal administration, 40 IUs
75341362|NCT01574287|Drug|FACBC|Drug is give intravenously over 2 minutes at time of scan
75632103|NCT02879396|Behavioral|PA4LE Program|"Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~Patient understanding of red flag indicators of worsening condition and appropriate next steps~Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness & Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms"
75632104|NCT04138342|Drug|Quantum dots coated with veldoreotide|The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
75325072|NCT04384211|Other|Computer Assisted Detection Software For Vertebral Fractures|A device named Smart Bone that is using CT image retrospectively acquired to entails a second review of CT images with Vertebral Compression Fractures through an interactive AI program developed by Quanta Computer Inc. was applied to the CT images. The device is a computer-aided detection (CADe) software application and is designed to assist radiologists to analyze Spine CT images. The device uses deep learning methods to perform vertebrae detection and classification of images.
75783188|NCT03877874|Drug|Aironyl syrup(Terbutaline sulfate) + Epidrone syrup(Dexamethone)|Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)
75783189|NCT01160588|Drug|Sertraline|Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
75783190|NCT03876470|Other|Hepatitis C treatment as chosen by provider|Participants' providers will determine the type of HCV treatment as appropriate.
75783191|NCT01162616|Dietary Supplement|labeled iron solutions|labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
75783192|NCT03877562|Drug|Olanzapine|Olanzapine 10 mg oral tablet
75783193|NCT03877562|Drug|CORT118335|CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets
75783194|NCT03877562|Drug|Placebo|Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
75783195|NCT01160666|Drug|Belimumab|Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
75783196|NCT03876548|Device|Cadexomer Iodine Gel|Subjects will apply gel product to keloid scar site every other day for 28 days following keloid scar revision surgery.
75783197|NCT03760250|Drug|Imiquimod 5% cream|Imiquimod 5% Cream application to keloid skin area 5-times per week for 6 weeks, starting 1-week before keloid excision
75632105|NCT04138342|Drug|Topical approved placebo|The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
75783198|NCT01162694|Other|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
75783199|NCT01162694|Other|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
75783200|NCT01157000|Drug|Canagliflozin|On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
75783201|NCT01160900|Procedure|Coronary angioplasty all lesions|treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
75783202|NCT01160978|Drug|Simvastatin 80mg|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
75783203|NCT01160978|Drug|Control Rx|The transplant recipients who have received an organ from non-treated donors.
75783204|NCT01269320|Drug|Femarelle|Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
75918669|NCT01878500|Device|Intraoperative stereotactic imaging with VectorVision|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
75918670|NCT02093559|Behavioral|Brief counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
75325073|NCT00354861|Biological|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
75325074|NCT00354861|Biological|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
75632106|NCT00688402|Drug|AZD3355|Single dose
75783205|NCT01161134|Drug|Meloxicam|Meloxicam Tablets 15 mg
75783206|NCT01161212|Other|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
75783207|NCT01161212|Other|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
75918671|NCT04340284|Biological|autologous adipose tissue derived stromal vascular fraction (SVF)|"liquid and solid portion of lipo-aspirate after non enzymatic processing yields SVF.~This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ ,~, the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC, 20%), plus a wide number of CD34+ hematopoietic cells (40%)."
75918672|NCT04448990|Device|TENS eco 2 Transauricular vagal nerve stimulation|"Auricular electrical stimulation will be applied bilaterally using Transcutaneous Electrical Nerve Stimulation device TENS eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany).~tVNS will be applied bilaterally using electrical square impulses delivered in blocks of 9 impulses with a frequency of 100 Hz and a pulse width of 200 μs emitted twice per second resulting in mixed frequency pattern of 100 Hz/2 Hz with the current intensity, that will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved."
75918673|NCT04448990|Device|Sham TENS eco 2|Sham
75918674|NCT02093637|Other|Placebo acupuncture|Placebo Comparator
75918675|NCT02093637|Other|Battlefield Acupuncture|Experimental
75918676|NCT03424772|Diagnostic Test|Whole genome sequencing|WGS will be performed for the trio
75918677|NCT04799002|Drug|Topotecan|Topotecan intraocular injection for chemotherapy in retinoblastoma
75918678|NCT04799002|Drug|Melphalan|Melphalan intraocular injection for chemotherapy in retinoblastoma
75918679|NCT02250027|Drug|HL301 300mg capsule|2 capsules at once, 3 times a day, for 7 days
75918680|NCT02250027|Drug|Placebo|2 capsules at once, 3 times a day, for 7 days
75918681|NCT03416192|Device|MCO-HD|Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.
75632107|NCT04138264|Other|Preoperative opioid counseling|preoperative counseling consists of education with a brief multi-media presentation in the preoperative area on the day of surgery using a handheld tablet. The message of the preoperative counseling consisted of: 1) Background on the opioid epidemic including basic facts and consequences, 2) Description of risk factors for opioid abuse and how to consume opioids safely, 3) Information on the specific opioid the patient was prescribed and the anticipated amount and duration of use postoperatively, 4) Encouraging the use of non-opioid therapy prior to taking the prescribed opioids or quickly transitioning to non-opioid medications postoperatively, and 5) Contact information and instructions to call if the patient experienced any adverse events and/or if additional pain medication is needed.
75918682|NCT03416192|Device|high-flux HDF|Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter
75918683|NCT04789642|Other|blood pressure measurement whatsapp educational program|educational
75918684|NCT02096523|Other|Blood collection for platelet protein samples|
75918685|NCT04788706|Other|Low level Laser Therapy and Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
75918686|NCT04788706|Other|Placebo Laser and Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation
75918687|NCT04788706|Other|Low level Laser Therapy and Low level Laser Therapy plus Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
75918688|NCT04788706|Other|Placebo Laser and Placebo Laser plus Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
75918689|NCT05615740|Diagnostic Test|Optical coherence tomography (OCTA)|OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time
75918690|NCT02098785|Drug|Caffeine citrate|Oral solution
75918691|NCT04798456|Behavioral|Coma scales|CRS-R and GOSE
75918692|NCT04798456|Diagnostic Test|Imaging, electrophysiology, body signals, and brain stimulation|MRI, fMRI, EEG, TMS-EEG, Olfaction, Respiration, EKG
75918693|NCT04798456|Behavioral|Questionnaires|several questionnaires and an interview with the caregiver
76076391|NCT03406390|Procedure|Pterygium surgery|The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
75325075|NCT00354861|Biological|Engerix B|20 µg hepatitis B antigen absorbed on alum
75325076|NCT04345445|Drug|Tocilizumab|IV infusion
75918694|NCT03556059|Other|Role of EOSS|The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.
76076392|NCT04377256|Procedure|Ridge preservation: Tooth extration and immediat bone grafting in the socket|Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
76076393|NCT03406234|Other|No intervention.|Cross-sectional observation without interventions.
75325077|NCT04345445|Drug|Methylprednisolone|IV infusion
75325078|NCT02056431|Behavioral|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
75341363|NCT00572468|Drug|Simvastatin|40 mg of simvastatin
75341364|NCT00572468|Other|Placebo|placebo
76076394|NCT02240992|Biological|PBSC|
76076395|NCT02240992|Biological|MSCs|
76076396|NCT02982694|Drug|Atezolizumab|Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
76076397|NCT02982694|Drug|Bevacizumab|Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
76076398|NCT04377568|Biological|Convalescent plasma (CP)|Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL
76076399|NCT02156674|Drug|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
76076400|NCT02241070|Behavioral|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
76076401|NCT01712984|Biological|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
75341365|NCT02339246|Drug|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
75341366|NCT02339246|Drug|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
75783208|NCT03874442|Other|CliniPup serious game|"The interactive game is played at home by the children on a computer or tablet before the surgery. The SERES Pain in Children-game is created with realistic scenarios based on scientific literature about perioperative pain and fear in children. The primary goal of the game is to provide the children insight in the impact of their personal choices on their well-being and on their environment by giving the children information about the day of the surgery. The ultimate aim of the game is to create a change in behaviour, enhance children's coping strategies and reduce the burden of pain and fear in the children and parents."
75468194|NCT06070467|Other|Mixed Methods Research (MMR) using quantitative (QUAN) and qualitative (QUAL) tools|"A Mixed Methods Research (MMR) using quantitative (QUAN) Vision Related-QoL (VR-QoL = FVQ-CYP and VQoL-CYP) tools and psychosocial PEM-CY, and qualitative (QUAL) socio-anthropologic investigations can capture reliably children's and teenagers' Patient-Reported Outcome (PRO).~The QUAN study is a cross-sectional study including short-term re-test repetition (children/teenagers only) using the following PROMs for children/teenagers:~Self-reported questionnaires for patients (FVQ-CYP and VQoL-CYP)~For caregivers: PEM-CY questionnaires~The QUAL study will rely on the following instruments:~Semi-directive interviews,~Focus groups,~Field observation."
75468195|NCT06070454|Diagnostic Test|vaginitis panel|vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida
75468196|NCT06070402|Device|DIAL, a voice-controlled virtual assistant|Participants in the experimental group will test in their homes a device called DIAL, a voice-controlled virtual assistant designed to communicate with the elderly and help them in different contexts. They will use it for four weeks. They will receive an individual training session on how to use the device, an instruction sheet for its use and, in addition, they will receive telephone technical support throughout the study. Finally, the device will be uninstalled and all participants will be called back to answer the same survey they answered before the intervention.
75632108|NCT00688480|Drug|Placebo|1 capsule, orally for 9 months
75783209|NCT01267370|Dietary Supplement|Soy polysaccharide fiber|"Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and > 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)"
76076402|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
76076403|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
76076404|NCT01042678|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye
76076405|NCT01042600|Device|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
76076406|NCT01042600|Device|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
76076407|NCT04377412|Other|Pandemic control measures|Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.
76076408|NCT01041976|Behavioral|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
75632109|NCT00688480|Drug|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
75632110|NCT01092728|Drug|Dasatinib|100 mg daily.
75632111|NCT01092728|Procedure|Surgical Resection|Complete surgical resection of tumor(s).
75632112|NCT00688558|Drug|JTT-705 600 mg and simvastatin 40 mg|"JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments"
75341367|NCT05085626|Drug|fluzoparib+chidamide|Arms A will be treated with fluzoparib in combination with cedaramide
75341368|NCT05085626|Drug|fluzoparib+camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
75341369|NCT05041946|Drug|Methylphenidate|Given PO
75341370|NCT05041946|Other|Placebo (Sugar Pill)|Given PO
75341371|NCT00573872|Radiation|Radiosurgery|"Phase I: 20-25 Gy in 5 fractions~Phase II: 9-24 GY in 1 fraction"
75632113|NCT00688558|Drug|Placebo and simvastatin 40 mg|"Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
75918695|NCT03424616|Device|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
75918696|NCT02096757|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
75918697|NCT02096757|Other|Pro-Omega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
75918698|NCT02093871|Device|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
76076409|NCT01041976|Behavioral|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
76076410|NCT00921310|Drug|Pemetrexed|
76076411|NCT00921310|Drug|Temsirolimus|
76076412|NCT04376710|Other|Completion of pre-pandemic survey|Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.
76076413|NCT04376710|Other|Completion of survey after peak of pandemic|Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.
75468197|NCT06070376|Device|Fully Covered Esophageal Prosthesis (FC-SEMS)|The placement of the Fully Covered Esophageal Prosthesis (FC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
75632114|NCT04031326|Behavioral|LENA Home|LENA Home is a 13-week curriculum designed to add an early-language focus to existing home visiting or parent education programs for children ages birth to three. It employs LENA wearable audio recorder technology and targeted content to help parents and other caregivers increase interactive talk. There are 13 weekly one-on-one sessions, including modules on parent-child reading and increasing verbal interaction during typical home activities. Sessions include videos, practical techniques, and feedback from LENA recordings via intuitive reports to help parents talk more with their children. LENA Home reports provide data on adult words spoken to the child (AWC) and conversational turns (CTC). LENA Home has been shown to increase interactive talk and child language ability and informs parents how much they are talking with their children in an objective way.
75632115|NCT01096550|Behavioral|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
75632116|NCT01096550|Behavioral|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
75632117|NCT02625376|Dietary Supplement|Resvega|Dietary supplementation with Resvega BD
75632118|NCT02625376|Dietary Supplement|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
75632119|NCT02625376|Dietary Supplement|placebo|Dietary supplementation with a placebo BD
75632120|NCT00688714|Drug|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
75632121|NCT00688714|Drug|Placebo|
76076414|NCT04376710|Other|Completion of post telemedicine encounter survey|Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
76076415|NCT02241148|Drug|Acetaminophen 500mg|500 mg, tablets every 8 hours
76076416|NCT02241148|Device|Kinesio taping|Taping will be changed every week.
76076417|NCT03405688|Procedure|Blood sampling|Extra blood samples taken for laboratory analysis
76076418|NCT01712516|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
76076419|NCT01712516|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
76076420|NCT01712516|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
75632122|NCT01101542|Biological|Cervarix.|Subjects will receive three doses of the Cervarix vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in routine clinical practice settings.
76076421|NCT01712516|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
76076422|NCT03405610|Behavioral|The Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
76076423|NCT04166240|Behavioral|SAFER TRACKS Intervention|SAFER Change Package delivered using a Virtual Breakthrough Series [VBTS] Collaborative supplemented with automated surveillance data on test results.
76076424|NCT01703000|Device|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
75632123|NCT01101542|Other|Data collection|All adverse events will be recorded by all subjects or the subject's parents/guardians using diary cards.
75632124|NCT04881578|Other|continuous cardiac monitoring before and after transcatheter PFO closure|Data will be assessed from patients with cryptogenic stroke and planned PFO occlusion who undergo the contemporary ICM protocols to search for silent AF
76076425|NCT01040728|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
76076426|NCT01040728|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
76076427|NCT01040728|Drug|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
75632125|NCT04153084|Drug|Polyethylene Glycol 4000 with electrolytes|The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
75468198|NCT06070376|Device|Partially Covered Esophageal Prosthesis (PC-SEMS)|The placement of the Partially Covered Esophageal Prosthesis (PC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
76076428|NCT01040728|Drug|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
75632126|NCT04153084|Drug|PEG-3350 with electrolytes|The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
75632127|NCT04153084|Drug|Sodium picosulfate|"The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night."
75783210|NCT03877328|Other|BiotechCoachForAll|A group of thirty subjects diagnosed with heart failure (HF) of any etiology undergo an experimental procedure in the following order: resting-state (eyes-closed), passively viewing thirty two agents which are grouped with respect to different appearance characteristics and passively viewing combinations of virtual agents. During the experiment, brain activity, heart rate, skin conductance, temperature and eye-gaze biosignals are collected by means of electroencephalography, Empatica E4 and Gazepoint. Subsequently, a prospective cohort study is performed in a subgroup of ten participants which undergo a three additive stage procedure. Stage 1, a wearable monitoring device (Wavelet Health) is given in order to provide objective information on the patient's activity. Stage 2, the FitForAll physical exercise program is introduced. Stage 3, introduces the coaching aspects, where personalized recommendations and suggestions are delivered through home surfaces' projection.
75783211|NCT01162850|Dietary Supplement|Polypodium Leucotomos|Oral capsule at 240 mg taken twice a day for 12 weeks
75632128|NCT00691288|Drug|Omega Pure followed by placebo|Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
75632129|NCT00691288|Drug|Placebo followed by Omega Pure|Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
75632130|NCT00688948|Drug|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
75783212|NCT01162850|Dietary Supplement|Placebo|240 mg Placebo taken orally twice daily created by company which manufactured active ingredient
75783213|NCT01268384|Drug|Gemcitabine plus Capecitabine|Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
75783214|NCT01269398|Device|GO-LIF and SpineAssist SYSTEMS|
75783215|NCT03874598|Procedure|Ear acupuncture|Patients in the intervention group are treated twice a week for five weeks using semi-standardized ear acupuncture.
75783216|NCT03874598|Behavioral|Psychoeducation|Patients of the control group receive a 1,5 h psychoeducation group concerning sleep improving behaviour.
75783217|NCT01161290|Behavioral|synchronous interactive audio/video telecommunication|4 weekly synchronous interactive audio/video sessions on self-care management for dyspnea provided via the Internet and free downloadable software (Skype) on patients' home computer
75783218|NCT01269476|Drug|SNX-001|3.6, 7.2, or 10.8 mg single dose or t.i.w.
75783219|NCT01269476|Drug|Placebo|Same volumes and frequency as active.
75783220|NCT01267526|Device|Easypod™|Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph
75783221|NCT03876392|Diagnostic Test|magnetic resonance imaging|Compare bone marrow biopsy with magnetic resonance imaging to detect bone marrow metastases
75783222|NCT03874676|Other|PEACE Rounds|PEACE Rounds are a routine process for providing self help to clinicians who care for difficult patients from the perspective of ethics and the need for cross-disciplinary communication. PEACE Rounds participants will be interviewed about how they experience the rounds and for their perspective on the effects on their own wellness and resilience.
75783223|NCT03874520|Other|Video triage|The operator will offer the parent calling regarding the sick child to assess the child on video, as compared to the current standard; on the telephone.
75783224|NCT01162928|Drug|Nutriflex Omega special + Oxepa|3-chamber-bag combined with enteral nutrition
75632131|NCT00672334|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
75783225|NCT01162928|Drug|Nutriflex Lipid special + Pulmocare|3-chamber-bag combined with enteral nutrition
75783226|NCT01161368|Drug|Lapatinib, Vinorelbine|"Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle."
75783227|NCT01267682|Behavioral|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
76076429|NCT01040728|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
76076430|NCT01593020|Drug|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
76076431|NCT01593020|Drug|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
75468200|NCT06070337|Device|H-Guard|A novel Haemodialyser primer used for one treatment only
75341372|NCT00574340|Other|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
75468201|NCT06070324|Procedure|Breast surgery|Any surgery involving incisions made along the nipple areolar complex. These would include transgender mastectomy, cisgender female breast reduction/augmentation/reconstruction, and cisgender male gynecomastia correction.
75632132|NCT00672334|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
75632133|NCT00937326|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
75632134|NCT00937326|Drug|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
75783228|NCT01163006|Other|Polydextrose and soluble gluco fibre|Polydextrose and soluble gluco fibre
75783229|NCT01268462|Other|Heliox+PEP|For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
75783230|NCT01268462|Other|Oxygen+PEP|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
75918699|NCT05430100|Other|The effect of usıng breast mılk pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|5 Minutes before the OGT insertion, the camera recording will be started and the preterm newborn will be given a breast milk pacifier. After the breast milk pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with the swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will continue so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
75918700|NCT05430100|Other|The effect of usıng sucrose pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a sucrose-sweetened pacifier. After the sucrose-sweetened pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with a swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
76076432|NCT01593020|Drug|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
76076433|NCT01593020|Drug|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
76076434|NCT01593020|Drug|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
76076435|NCT01593020|Drug|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
76076436|NCT01040260|Other|Counseling|Smoking cessation counseling
75468202|NCT06070324|Device|Suturing of surgical incision|The closing of a surgical incision by using sutures so appose and maintain apposition of two skin edges. Suturing may or may not require knot-tying depending on the material of suture used.
75632135|NCT04152694|Other|Ceftaroline levels in CRRT|Levels of ceftaroline measured in patients receiving CRRT
75632136|NCT00689182|Procedure|monthly phlebotomy x 12 months|All patients will receive monthly phlebotomies.
75632137|NCT04138186|Device|2.0g G-PUR®, oral administration|tid for 12 weeks
75632138|NCT04138186|Device|Placebo, oral administration|tid for 12 weeks
75632139|NCT00691522|Drug|Xerecept|
75632140|NCT02629666|Behavioral|ERS and/or Self-management Strategies|
75632141|NCT00873730|Drug|etanercept|Etanercept 50 mg twice a week (BIW) for 12 weeks
75632142|NCT00873730|Drug|etanercept/placebo|Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
75632143|NCT00689416|Drug|rosuvastatin|40 mg, tablet, once daily for 3 months.
75632144|NCT00689416|Drug|placebo|40 mg, tablet, once daily for 3 months
75341373|NCT05004896|Drug|Ketamine Hydrochloride|50 patients will receive ketamine hydrochloride, over four infusions, flexibly dosed between 0.5 mg/kg to 0.75 mg/kg
75341374|NCT05004896|Drug|Midazolam Hydrochloride|50 patients will receive midazolam hydrochloride, over four infusions, flexibly dosed between 0.02 mg/kg to 0.03 mg/kg
75341375|NCT05005754|Dietary Supplement|Probiotics|During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
76076437|NCT01040260|Behavioral|Contingency management|Use of tangible rewards for abstinence from smoking
75918701|NCT05430100|Other|The effect of usıng pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a pacifier. After the pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's swallowing reflex will be placed by moving the esophagus from there to the stomach. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement.
75918702|NCT03418688|Drug|COR388|COR388 administered for 10 or 28 days.
75918703|NCT03418688|Drug|Placebo|Placebo administered for 10 or 28 days.
75632145|NCT00689494|Other|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
75918704|NCT02521064|Dietary Supplement|Exclusive Enteral Nutrition (EEN)|Patients will be treated with 8 weeks of Exclusive Enteral Nutrition (EEN). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
75918705|NCT02521064|Drug|Prednisone|Patients will be treated with 8 weeks of prednisone (corticosteroid). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
75632146|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.5 mg, single dose, injection
75632147|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.75 mg, single dose, injection
75632148|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.1 mg, Single dose, injection
75783231|NCT01268462|Other|Heliox|For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
75783232|NCT01268462|Other|Oxygen|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
75918706|NCT05395468|Other|photographs of each eye|All subjects included will take 5 photographs of each eye according to a standardised procedure in terms of distance, lighting and framing
75918707|NCT02099097|Other|web-based video game (Quit IT)|
75918708|NCT02099097|Behavioral|Questionnaires|In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
76076438|NCT01040260|Drug|Nicotine patches|Nicotine patches
75341376|NCT05005754|Dietary Supplement|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
75632149|NCT00672568|Drug|Placebo|Solution, single dose, injection
75632150|NCT00922714|Drug|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
75632151|NCT00922714|Drug|saline (placebo)|NaCl 0.9 g/L
75632152|NCT00691834|Biological|Intracoronary delivery of unfractionated bone marrow mononuclear cells|Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
75632153|NCT00691834|Biological|Placebo|Plasma and culture medium (10 ml)
75632154|NCT02629276|Other|neurodynamic testing|
75918709|NCT02099097|Other|Salvia sample|The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
75918710|NCT03424538|Other|Neurorehabilitation|5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
75918711|NCT03424538|Other|Physiotherapy|5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
75918712|NCT02096913|Drug|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period."
76076439|NCT02241226|Behavioral|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
76076440|NCT01046422|Drug|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
75632155|NCT00672724|Drug|Ramelteon|Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
75632156|NCT00672724|Drug|Placebo|Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
75632157|NCT05380596|Behavioral|Telepharmaceutical Care|The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3). In the opportunities, aspects related to pharmacotherapy and health status, non-pharmacological approaches, treatment adherence and evaluation of problems related to pharmacotherapy (PRM) will be discussed.
75632158|NCT00689650|Device|1540 nm fractional laser|
75632159|NCT05382156|Drug|Osilodrostat|oral administration of Osilodrostat tablets at different doses according to patient's need
75632160|NCT00604032|Drug|Atralin (tretinoin) Gel, 0.05%|Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
75632161|NCT00874432|Drug|angiotensin converting enzyme inhibitor|Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
75632162|NCT00874432|Drug|lisinopril|1 x 40 mg per day
76076441|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
76076442|NCT01046422|Drug|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
76076443|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
76076444|NCT01046422|Drug|Placebo|Capsule, Oral, 0mg, Daily, 28 days
75632163|NCT00606528|Other|No intervention|None. This is an observational study.
75341377|NCT01798082|Other|Pelvic organ prolapse decision aid|
75341378|NCT00576680|Drug|RAD001|Given orally once a day
75632164|NCT04138108|Other|Psychoeducation|The parents of each child were educated as couples and each training session lasted 45-60 minutes for each family. Approximately the first five minutes of the training were used for warm-up, 25 minutes were used for basic ADHD knowledge and the last 15 minutes were catechetic and conducted interactively. The psychoeducation included discussion about the causes, symptoms and signs of ADHD, the course and characteristics of the disease according to age, the treatment process, the drugs used in the treatment and their side effects, correct and incorrect information about drugs, the other symptoms which can coexist with ADHD and their treatment, and what the parents can do about these issues.
75632165|NCT00935220|Drug|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
75632166|NCT00691912|Drug|liposomal Doxorubicin|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
75632167|NCT00691912|Drug|Myocet / Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
75632168|NCT00874276|Drug|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
75783233|NCT01269632|Biological|blood sampling, specific biological exams and biobank and self administered questionnaires|"HIV INFECTION at inclusion and annually up to 06 years follow-up~clinical and therapeutic evaluation by physician~biological: blood sampling, specific biological exams and biobank~self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~clinical evaluation by physician~biological: blood sampling, specific biological exams and biobank~self administered questionnaires"
75918713|NCT02096913|Drug|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment."
75341379|NCT00576680|Drug|Temozolomide|Taken orally once a day for one week followed by a one-week break period
75632169|NCT00874276|Genetic|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
75918714|NCT03418610|Drug|Azelaic Acid foam 15%|mild to moderate rosacea
76076445|NCT01046422|Drug|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
76076446|NCT02241382|Device|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
76076447|NCT02241382|Device|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
75632170|NCT05382390|Drug|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count > 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
76076448|NCT01712438|Biological|Human cl rhFVIII|
76076449|NCT03405376|Drug|Intravitreal aflibercept injection|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
75632171|NCT05382390|Drug|Decitabine|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
76076450|NCT02241460|Drug|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
76076451|NCT02241460|Drug|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
76076452|NCT01712204|Drug|Placebo|Placebo Capsule BID for 16 Weeks
75341380|NCT04866602|Drug|Atoguanil|Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
75341381|NCT04866602|Drug|Malarone|Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
75341382|NCT04730648|Drug|PCSK9 inhibitor|For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
75341383|NCT05246540|Other|Data collection|Data collection
75632172|NCT04265820|Device|unilateral implantation of IOL|unilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
75783234|NCT01268540|Device|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
75783235|NCT01268540|Device|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
76076453|NCT01712204|Drug|AC-201|AC-201 50mg Capsule BID for 16 Weeks
76076454|NCT01712204|Drug|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
76076455|NCT01592864|Drug|Stannous Fluoride|dentifice
76076456|NCT01592864|Drug|Sodium Monofluorophosphate|dentifrice
75918715|NCT03031197|Combination Product|Tailored realtime triggered reminder pkg|"Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence."
75918716|NCT04604366|Drug|misoprostol|it stimulates uterine contractions
75918717|NCT02099253|Drug|Dexmedetomidine 01|Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
75325079|NCT03800459|Behavioral|family empowerment program|The empowerment program-nursing interventions were given in 6 sessions in the experimental group Session 1: Individualized training: General information about CF, respiratory system involvement and treatment process, airway cleaning in CF, drug applications (45-50 min) Session 2:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min).Session 3:Phone calls:Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min) Session 4:Individualized training:protection from infections, nutrition and psychosocial support (45 min) Session 5:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min) Session 6:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min)
75325080|NCT00354939|Drug|Insulin glargine|
75325081|NCT04919031|Device|Inspiratory muscle trainer|POWER breathe IMT is a drug-free, hand-held breathing training device. The medical term for this type of breathing training is Inspiratory Muscle Training, or IMT. POWER breathe IMT exercises the main muscles you use to breathe in, primarily your diaphragm and intercostal
75325082|NCT04919031|Other|diaphragmatic release|diaphragmatic release is a manual technique use for restoring the ability of the diaphragm to go through a full range of motion
75325083|NCT05713877|Drug|Melatonin|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
75783236|NCT01268618|Dietary Supplement|Probiotic|"2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of:~Lactobacillus acidophilus NAS, 30 billion CFU~Bifidobacterium bifidum Malyoth, 120 billion CFU~Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU"
75783237|NCT01268618|Dietary Supplement|Placebo|2 capsules, 3x/day placebo capsules
75783238|NCT01267760|Device|Multipass hemodialysis|8-hour dialysis using a recycled dialysis bath of 25-30 l
75632173|NCT04265820|Device|bilateral implantation of IOL|bilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
75783239|NCT03877250|Diagnostic Test|Pre-Treatment Biopsy|Participants screened for participation will include those with a diagnosis of advanced NSCLC who have undergone a pre-treatment biopsy prior to start of therapy with a PD-(L)1 inhibitor or who are medically able to undergo a biopsy if (1) no pre-treatment biopsy has been obtained and (2) no PD-(L)1 inhibitor has been started.
75918718|NCT02099253|Drug|Dexmedetomidine 02|Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
76076457|NCT01592786|Drug|Memantine Hydrochloride (HCl)|Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
75325084|NCT05713877|Drug|Placebo|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
75783240|NCT03877250|Diagnostic Test|On-Treatment Biopsy|All participants who receive at least 1 dose of PD-(L)1 inhibitor will be referred for a biopsy. The biopsy should be obtained within 4 weeks of first on-treatment imaging (usually performed ~6-9 weeks after beginning therapy) and will be performed in participants regardless of radiologic response.
75783241|NCT03877250|Diagnostic Test|Biopsy at Disease Progression|All participants who develop disease progression after initial response to PD-(L)1 blockade will be considered for an additional, optional biopsy. Biopsies at disease progression are often obtained per standard of care within 4 weeks of documented progression on imaging and prior to the initiation of further systemic therapy.
76076458|NCT01711736|Biological|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
75325085|NCT05545371|Biological|immunization procedures|The subjects were vaccinated with rabies vaccine according to different immunization procedures
75632174|NCT05378412|Behavioral|3Cs|The 3Cs program is an educational strategy aimed at fostering resilience and compassion in people. It is based on improving the mental well-being of the participants by transforming their attitudes and behaviors through increased consciousness.
75632175|NCT00689806|Drug|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not > 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
75783242|NCT03877250|Diagnostic Test|Peripheral Blood-Based Studies|All participants will have peripheral blood obtained on Day 1 of cycles 1-4 (0, 3, 6, and 9 weeks). At each time point, peripheral blood sample will be collected pre-treatment and used for analysis of T cell subsets and TCR sequencing.
75783243|NCT03877172|Device|High-flow nasal cannula|To provide high-flow nasal cannula in the immediate postoperative period after lung resection surgery as compared to conventional face-mask therapy, in a randomized sequence, for 30 minutes.
75632176|NCT00689806|Drug|Placebo|Placebo by mouth once daily for weeks 1-4.
75632177|NCT00606606|Other|Clinical Decision Support|
75918719|NCT05818449|Other|DigiNet intervention|"Patients with initial diagnosis of NSCLC stage IV in the model region receiving the following interventions:~broad NGS-based molecular diagnostics and, based thereupon, personalized treatment information within the national Network Genomic Medicine (nNGM) lung cancer~regular clinical follow-up visits and data documentation in the shared central digital database by participating physicians~monthly assessment of patient-reported outcomes (PRO) on quality of life, anxiety, and depression~incorporation of PROs into treatment by physicians~treatment monitoring and counseling in the case of critical conditions by expert committee"
75918720|NCT05818436|Procedure|Procedure: prosthetic functioning|Prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts
75918721|NCT05818436|Device|Conventional dental prosthesis|: conventional prosthetic treatment new prosthesis
76076459|NCT01711736|Biological|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
75325086|NCT05664945|Behavioral|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera.~Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint).~Specific exercises are evidence-based; been used in several intervention studies on patients with COPD.~Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations.~The education sessions consist of dialogue, reflections around empowerment and better living with COPD.~Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
75468203|NCT06070311|Combination Product|Thymoquinone (0.5%) and Olive oil ointment|"Preparation of the Thymoquinone and Olive oil ointment:~Thymoquinone Oleaginous base ointment containing olive oil will be prepared for intranasal administration. The ointment will be prepared using the fusion method as follows:~Anhydrous lanolin and white soft paraffin will be melted at 70°C and then olive oil will be added with continuous stirring, Thymoquinone will be added to the congealing mixture as it is being cooled and stirred finally, the congealing mixture is left to cool at room temperature tell solidification and sterilized using UV radiation. The final product will be characterized for spreadability, drug content, drug release and stability."
75468204|NCT06070155|Other|Aerobic Exercise three time a week|The participants will receive mild to moderate aerobic exercise for three weeks for 12 sessions.
75632178|NCT05380362|Other|Venous Angioplasty|venous angiogram to look for lesions or flaps and then plastying vessels open.
75632179|NCT05380362|Other|Sham Angioplasty|Patients will be brought to the angio suite and will not know if they are having the venous angioplasty or not.
75632180|NCT05381922|Other|blood laboratory investigation(coagulation profile- platelet function test)|blood laboratory investigation including ( complete blood count, coagulation profile, platelet function test, level of factor decrease
75632181|NCT00594958|Biological|IC51|6 mcg, intramuscularly [i.m.], 0.5 mL
75632182|NCT04204044|Drug|Metformin Hydrochloride|Metformin Hydrochloride is used in PCO
75632183|NCT04204044|Drug|Myo-inositol|Myo inositol used in PCO
75632184|NCT02625064|Other|Blood samples collection before treatment|
75632185|NCT02625064|Other|Blood samples collection after treatment|
75783244|NCT01165034|Other|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
75783245|NCT01166906|Device|pain blocking|pain blocking
75783246|NCT01280162|Drug|Dihydroartemisinin piperaquine|40/320 mg tablets, 9 tablets total
75632186|NCT02625064|Other|laboratory biomarker proteomic analysis|
75632187|NCT05378256|Other|Clinical scales of CIPN|Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).
75632188|NCT00672802|Drug|Ramelteon and Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
75918722|NCT05818371|Diagnostic Test|Sonographic determination of the optic nerve sheath diameter|Ultrasound-based determination of the optic nerve sheath diameter
75918723|NCT05818306|Drug|BL-001|Live biological product BL-001
75918724|NCT05818306|Drug|Placebo|Placebo
75918725|NCT05818241|Procedure|Treatment of fracture by forearm cast|Patient that are not surgically treated for DRF
75918726|NCT05818241|Procedure|Surgical treatment of fracture|Patients that are surgically treated for DRF
75918727|NCT05818215|Other|NO intervention|NO intervention
75918728|NCT05818202|Other|Questionannire|The questionannaires for both physiotherapists and stroke patients were formed in this study. The perspectives of the participants were recorded.
75918729|NCT05818163|Device|electroencephalography spectral analysis|"Before inducing general anesthesia in the patient entering the operating room, an anesthesia depth monitoring patch is attached to the forehead, and EEG data during anesthesia is collected using the currently used anesthesia depth monitoring device.~The EEG data is transformed into a frequency and energy distribution and density spectral array (DSA) graph using Fourier transform (FFT) for spectral analysis."
75918730|NCT05818111|Drug|steroid|triamcinolone 40mg 4cc
75918731|NCT05818111|Drug|Xylocaine 2 % Injectable Solution|xylocaine 2% 4cc
75918732|NCT05818111|Drug|Normal saline 2cc|normal saline 2cc
75918733|NCT05818111|Drug|normal saline 12cc|normal saline 12cc
75918734|NCT05818098|Device|Intravascular Lithotripsy System of Shanghai MicroPort Rhythm|The Intravascular Lithotripsy System is a single-use, sterile, disposable balloon angioplasty catheter that contains a series of unfocused, electrohydraulic lithotripsy emitters, which convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within vascular plaque.
75918735|NCT05818059|Diagnostic Test|Diagnosis of Tuberculosis with computer-aided detection (CAD) software|"After enrolment, each subject will be assessed according to ARM 1 (assessment by clinician #1 without CAD) or ARM 2 (assessment by clinician #1 with CAD). Allocation to sequence ARM 1 or ARM 2 will be performed using a computer-generated random assignment list (with a 1:1 ratio), and assignments will be included in sealed opaque envelopes sequentially numbered.~Clinicians cannot be masked to the assessment method (with or without CAD) and cannot be masked to the further assessment (referral for microbiological diagnosis with stool and sputum Xpert) due to care process. However, the statistician will be masked to the assessment during data analysis."
75918736|NCT05818033|Device|CARE1.02|Participants in the intervention group will wear CARE1.02 and receive the follow-up checks.
76076460|NCT01592708|Other|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
75918737|NCT05818033|Device|Single-vision spectacle lens|Participants in the control group will wear single-vision spectacle lens and receive the follow-up checks.
75918738|NCT05818007|Drug|Hyaluronic acid|The main function of HA appears to be in tissue healing, by activating and modulating inflammatory responses, stimulating cellular proliferation, migration, and angiogenesis, inducing basal keratinocyte proliferation and re-epithelization by reducing collagen deposition and scarring
75918739|NCT05818007|Drug|Sodium bicarbonate|sodium bicarbonate solution
76076461|NCT01042522|Biological|Bleomycin Sulfate|Given IV
76076462|NCT01042522|Drug|Carboplatin|Given IV
76076463|NCT01042522|Drug|Cisplatin|Given IV
76076464|NCT01042522|Drug|Etoposide Phosphate|Given IV
76076465|NCT01042522|Other|Laboratory Biomarker Analysis|Correlative studies
75632189|NCT00691990|Procedure|Total thyroidectomy|Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
75632190|NCT00689962|Device|Linvatec 4.5 mm Smart Screw|Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
75783247|NCT01167062|Drug|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
76076466|NCT01042522|Drug|Paclitaxel|Given IV
75325087|NCT05664945|Behavioral|home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint).~Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook.~The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
75325088|NCT05664945|Behavioral|Control|"Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department.~Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.~If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation)."
75325089|NCT03800147|Drug|"Mutaflor Suspension (E. coli Nissle 1917)"|"Inoculation of Mutaflor Suspension (E. coli Nissle 1917)"
75468205|NCT06070129|Procedure|surgical pulmonary embolectomy|open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus
75632191|NCT00689962|Device|Synthes 4.0 mm steel screw|Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
75632192|NCT00692146|Drug|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
75632193|NCT00692146|Drug|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
75783248|NCT01167062|Other|Placebo|One tablet OD for a maximum of 28 days
75783249|NCT01280240|Drug|Monofer(R)|Intravenous bolus injection given over app. 2 minutes only once
75783250|NCT01165268|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
75783251|NCT03876158|Device|Prometra II Programmable Pump system(Flowonix Medical)|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
75783252|NCT01280318|Procedure|head and neck surgery|Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.
75783253|NCT01165346|Radiation|Fiducials|Implantation of fiducials
75783254|NCT01165346|Radiation|CyberKnife|3 fractions over 8 to 10 days, 15 Gy/fraction
75783255|NCT03874364|Device|Lidocaine gel|10 ml 2% lidocaine gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
75783256|NCT03874364|Other|Counselling|Patients receive a brochure in the waiting room explaining the procedure in details.
76076467|NCT01702844|Drug|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
76076468|NCT01702532|Drug|Nicotine|Comparison of different dosage forms of nicotine
76076469|NCT02241616|Drug|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
76076470|NCT03400306|Drug|Veliparib, capsule|capsule; 50 mg or 100 mg
76076471|NCT03400306|Drug|Veliparib, tablet|tablet; 400 mg
76076472|NCT03400306|Drug|Carboplatin|Intravenous
76076473|NCT03400306|Drug|Paclitaxel|Intravenous
76076474|NCT03405298|Behavioral|Educational Material|Educational material is in the form of a brochure
75918740|NCT05817981|Other|Semi-structured interview|Before the questionnaire survey, 30 cancer survivors and 30 clinical oncology medical staff will respectively participate in different semi-structured interview individually.
75918741|NCT05817981|Other|Questionnaires set|Except for participants who participated in semi-structured interviews, other cancer survivors who met the inclusion criteria will be asked to respond to the demographic information sheet, the cancer related sexual and reproductive health knowledge and attitudes questionnaire, and the access methods and demand for cancer-related fertility information.
75918742|NCT05817955|Drug|Azacitidine (AZA) with Ruxolitinib|"Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened.~Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture."
75918743|NCT05817916|Procedure|ESP block|ESP block: ultrasound guided erector spina plane block
75918744|NCT05817916|Procedure|LP block|LP block: ultrasound guided lumbar plexus block
76076475|NCT03405298|Behavioral|Supplemental Collaborative Care|Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider
76076476|NCT03405064|Drug|Oral Levonadifloxacin/Linezolid Tablet|oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
76076477|NCT03405064|Drug|Intravenous Levonadifloxacin/Linezolid Infusion|IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
76076478|NCT01702454|Biological|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
76076479|NCT02241694|Other|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
76076480|NCT02241772|Drug|TA-8995|
76076481|NCT02241772|Drug|Placebo|
75325090|NCT03800147|Other|Blood samples|Blood samples will be collected and analyzed at different study time points
76076482|NCT02241850|Other|High intensity training|9 weeks of supervised high intensity training
76076483|NCT04413656|Other|ablation|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
75632194|NCT04152928|Diagnostic Test|PET/MR scan|The patient will be positioned in the PET/MR with the field of view of the PET including the abdomen, and IV administration of 68Ga-DOTATATE will take place, with initiation of dynamic PET simultaneous with start of IV injection. Dynamic PET imaging will consist of 22 time frames of increasing durations (6 x 10, 3 x 20, 3 x 60, 5 x 180, and 5 x 300 s). The dynamic PET examination will be followed by a whole-body PET/MR scan ranging from the proximal femur to the base of the skull (3 min per bed position) starting at 60 min after injection. MR will be used for attenuation correction of the PET images of the abdomen/pelvis and whole-body. MR protocol will include three plane fast spin echo T2 weighted, DWI, DCE and ASL. The addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
75632195|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 180 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
76076484|NCT04413656|Other|surgery|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
75325091|NCT03800147|Other|Stool samples|Stool samples will be collected and analyzed at different study time points
75325092|NCT03800147|Other|Clinical information|Clinical information will be collected at different study time points using questionnaires
75325093|NCT03800303|Behavioral|Family-based treatment|2-week family-based treatment
75325094|NCT03800225|Procedure|Repair|Anterior ligament repair with internal brace.
75632196|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 90 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
75632197|NCT00690118|Drug|pioglitazone|45 mg/day, 18 months
75632198|NCT00690118|Drug|placebo|once daily, 18 months
75632199|NCT04139278|Other|Observational|Observational retrospective study
75632200|NCT00694252|Drug|Lapatinib|Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
75632201|NCT00871858|Drug|anastrozole|Given orally
76076485|NCT01702298|Drug|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
76076486|NCT01702298|Drug|Metformin|Participants will continue pre-study dose of metformin tablet(s) >=1000 per day
76076487|NCT03404752|Drug|Peg-Filgrastim|
75325095|NCT00795275|Drug|Sitagliptin Phosphate|Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
75325096|NCT05713565|Device|A digital care solution for patients with Coronary Artery Disease|A digital care solution that provides remote patient monitoring and a patient support program specifically developed for CAD patients. The digital care solution empowers self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
75325097|NCT05713565|Other|Standard of care for patients with Coronary Artery Disease|Follow-up and continuous care as usual in outpatient care (i.e., Standard of Care). The participants in the Standard of Care - control group will also receive an information leaflet about relevant lifestyle modifications for CAD.
75325098|NCT00777335|Drug|Panobinostat - LBH589|Solution for infusion - 25mg/5ml
75325099|NCT00777335|Drug|Panobinostat - LBH589|Hard gelatine capsules - 5mg and 20 mg
75632202|NCT00871858|Drug|fulvestrant|Given intramuscularly
76076488|NCT04377022|Other|Combined Therapy (Aerobic Exercise in addition to conventional therapy)|"There are two intervention arm in the study~Combined therapy~Conventional Therapy"
75918745|NCT05817864|Diagnostic Test|Capnography|"Index test: Capnography, which monitors ETCO2, the percentage concentration, or partial pressure of CO2 at the end of exhalation, will serve as the index test. It will be performed by connecting the end of the nasogastric tube with the sensor of the bedside sidestream capnography device. Placement within the airway is defined as detecting a capnogram waveform or an ETCO2 level > 10 mmHg.~Reference standard: This study will use radiography (chest/abdominal X-ray) as the reference standard for determining the correct placement of nasogastric tubes. Radiology will be performed as soon as possible and interpreted by a physician. A repeat radiography will be performed if necessary. We will also use pH-Fix-4.5-10 to determine the pH value, and its accuracy is +/- 0.2 pH with minimum increments of 0.5. A pH of 5.5 or below indicates gastric placement."
75918746|NCT05817838|Behavioral|Financial Incentives|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocery store
76076489|NCT03405532|Diagnostic Test|DM-ECC|Diabetes mellitus CPB
76076490|NCT03401710|Drug|Erythropoietin|Erythropoietin 4000 UI will be administered every other day subcutaneously
76076491|NCT02241928|Biological|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
75783257|NCT03874364|Other|Monitor|Patients are allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
76076492|NCT02242006|Other|serial serum sampling for quantification of drug concentration|
76076493|NCT03409978|Device|in-Motion app|mobile phone application for recording fidgety movements at home
76076494|NCT02242084|Drug|Intravenuse Alteplase|
76076495|NCT01701362|Drug|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
75783258|NCT03874364|Device|Lubricating gel|10 ml plain lubrificant gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
75783259|NCT03874364|Other|No counselling|Patients won't receive a brochure in the waiting room explaining the procedure in details.
76076496|NCT01701362|Drug|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
76076497|NCT01673295|Drug|RTX infusions|RTX + Standard of Care
76076498|NCT01673295|Other|Standard of Care|Standard of Care only
76076499|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
76076500|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
76076501|NCT00919126|Drug|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
76076502|NCT03404440|Other|L.Reuteri|
76076503|NCT04375540|Procedure|Upper first premolars extractions|Fixed orthodontic treatment with upper first premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
75783260|NCT03874364|Other|No monitor|Patients are not allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
76076504|NCT04375540|Procedure|Upper second premolars extraction|Fixed orthodontic treatment with upper second premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
76076505|NCT03833908|Device|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
76076506|NCT04375618|Drug|RhEGF|The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
76076507|NCT04375618|Drug|Plain Collagen|A collagen membrane without FGF-2 will be used.
75783261|NCT01167296|Device|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
75783262|NCT01163396|Drug|Bevacizumab|
75783263|NCT01163396|Drug|Irinotecan|
75783264|NCT01163396|Drug|Oxaliplatin|
75783265|NCT01163396|Drug|5-fluorouracil/leucovorin|
75783266|NCT01163552|Procedure|Surgical debulking and Intrathoracic Hyperthermic Chemotherapy|Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
75783267|NCT01269788|Drug|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
75918747|NCT05817838|Behavioral|Financial Incentives and Multilevel Multicomponent|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocer store, in-person, group-based nutrition education with other Southeast Asian families, text messages and motivational interviewing
76076508|NCT01710800|Drug|Esomeprazole|
76076509|NCT01710800|Drug|placebo|
76076510|NCT03404284|Behavioral|Family planning and infant immunization service integration|The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
76076511|NCT03833986|Other|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
75918748|NCT05817838|Other|School Engagement|For six months, families will attend in-person, group-based school engagement education with other Southeast Asian families designed to improve youths' academic outcomes. Families will receive text messages and motivational interviews. At the end of the six months, families will receive the equivalent of the six months worth of weekly, $15 financial incentives.
75918749|NCT05817799|Drug|L-Carnitine 500Mg thrice daily|L-Carnitine 500mg oral thrice daily
75918750|NCT05817799|Drug|1g L-Carnitine IV three times a week|1g IV L-Carnitine three times a week
75918751|NCT05817760|Procedure|Z-scrotoplasty|Z shape incision of the penoscrotal web and closure
75918752|NCT05817760|Procedure|Heineke-Mikulicz scrotoplasty|Transverse incision of the penoscrotal web with vertical closure
75918753|NCT05817747|Other|Dialogue support tool|The dialogue support tool will be used as a support for the participant and surgeon to decide on which treatment arm is optimal for the participant.
75918754|NCT05817695|Device|Leadless pacemaker|To observe the effect of pacemaker implantation at different sites on cardiac synchronization and tricuspid regurgitation
75918755|NCT05817682|Other|Interprofessional education|"The study will be conducted among students of the Krakow Academy. The experimental group will consist of 35 students participating in the Interdisciplinary Circle of Medical Simulation from the following faculties: medicine, nursing and medical rescue.~Students will be divided into 7 interprofessional teams, in which they will take classes planned for small groups."
75918756|NCT05817630|Other|Silicone oil Tamponade for Retinal Detachment|eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed
75325100|NCT00790673|Drug|CF 102|Oral capsules
75325101|NCT00790673|Drug|Placebo|Matching placebo capsules
75325102|NCT05644587|Drug|buprenorphine/naloxone|Buprenorphine/naloxone will be used to begin each patient's treatment for opioid use disorder.
75918757|NCT05817604|Radiation|SBRT|SBRT dose 13Gyx3 fraction-squeme
75918758|NCT05817578|Device|Quantitative Sensory Testing / Dynamometry / Goniometry|Testing procedures that follow previously used protocols of the literature for all the Quantitative Sensory Testing, Dynamometry & Goniometry
76076512|NCT03404128|Other|Questionnaires|Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
75325103|NCT00355329|Procedure|Tongue Acupuncture (Procedure)|
75325104|NCT00355407|Drug|Darbepoetin alfa|
75325105|NCT00355251|Drug|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
75325106|NCT03832127|Drug|18F-Fludarabine|Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
75325107|NCT04880265|Device|BraveHeart wearable life sensors|Collection of EKG data
75325108|NCT04876131|Drug|Benzylpenicillin - single dose|"Participants will receive a single dose of IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours."
75325109|NCT04876131|Drug|Benzylpenicillin - three days|"Participants will receive three days of this IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours. For severe infections, use up to 60 mg/kg (maximum 2.4 g) every 4-6 hours."
75325110|NCT04876131|Drug|Gentamicin - single dose|"Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children >10 years old: 6-7 mg/kg (maximum dose 560 mg)"
75632203|NCT00692224|Drug|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
75632204|NCT00692224|Drug|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
75632205|NCT00694330|Biological|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
75632206|NCT04136938|Other|Social marketing campaign|A social marketing campaign of prevention workshop sessions will be performed.
75632207|NCT00673036|Other|Blood sample|60 ml of whole blood
75632208|NCT00692302|Behavioral|SAFETY|Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
75632209|NCT00692302|Behavioral|Enhanced usual care|Enhanced usual care will include treatment as usual enhanced by study support.
75632210|NCT00673192|Procedure|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
75918759|NCT05817565|Device|Ultrasound (Phyaction 190 I); with a frequency of 3 MHz was used|Intermittent cervical traction (traction force equal 8% of body weight) was applied with the patient lying supine and the head in neutral position.
75918760|NCT05817513|Other|Myofascial release.|Myofascial release (MFR) is a therapeutic treatment that uses gentle pressure and stretching to facilitate the release of fascial restrictions caused by accidents, injury, stress, repetitive use, and traumatic or surgical scarring. The fascial restrictions are palpated by the practitioner and the techniques are applied directly to the skin of the patient without lotions or oils. The pressure is applied into the direction of the restriction just until resistance is felt or the tissue is perceived to stop moving. The pressure is sustained at this point of resistance, without sliding over the skin or forcing the tissue, for a minimum of 90-120s. As the tissue begins to release, the practitioner maintains the same amount of pressure and follows the release three dimensionally through multiple releases.
75918761|NCT05817513|Other|Traditional exercises for scoliosis treatment.|"The exercises are:~Pelvic tilt.~Arm and leg raises.~Cat-cow.~Bird dog.~Latismus dorsi stretch.~Abdominal press.~Practice a good posture."
75918762|NCT05817487|Behavioral|high-intensity interval training (HIIT)|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The training sessions in the HIIT group involved five high-intensity intervals of 4 minutes each (running or walking on a treadmill) at 85% VO2max interspersed with 3 minutes of low-intensity walking.
76076513|NCT01710020|Drug|CP-690,550|CP-690,550 10 mg oral powder for constitution
75918763|NCT05817487|Behavioral|crossover point(COP) exercise training|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The COP exercise training sessions involved 45 minutes of continuous exercise at the COP on a treadmill.
75918764|NCT05818176|Device|NAVIRFA® Navigation System|radiofrequency ablation by NAVIRFA® Navigation System.
75918765|NCT05818176|Device|ultrasound|radiofrequency ablation by ultrasound
75918766|NCT05817435|Biological|efgartigimod PH20 SC as a prefilled syringe presentation|efgartigimod PH20 SC as a prefilled syringe presentation
76076514|NCT03833830|Diagnostic Test|Optical Coherence Tomography angiography (OCTA)|There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group >20 injections and shortterm treatment group < 5 injections).
76076515|NCT02982850|Drug|Dabigatran|
75325111|NCT04876131|Drug|Gentamicin - three days|"Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children >10 years old: 6-7 mg/kg (maximum dose 560 mg)"
75632211|NCT00692380|Radiation|Fractionated radiation therapy followed by chemotherapy|Increasing doses of radiation therapy
75632212|NCT00673270|Drug|Fludrocortisone|50 µg of fludrocortisone per os
75783268|NCT01269788|Drug|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
75783269|NCT01269788|Drug|placebo|oral , daily 30 mins before breakfast, for 6 weeks
75783270|NCT01269788|Drug|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
76076516|NCT02982850|Drug|Acetylsalicylic acid|
75325112|NCT04876131|Drug|Cefalexin - post single dose of IV antibiotics for the remaining two days|Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
75632213|NCT00673270|Drug|Hydrocortisone|50 mg of intravenous hydrocortisone
75325113|NCT04852497|Procedure|Ventricular tachycardia ablation|patients having undergone ventricular tachycardia radiofrequency ablation using of pace mapping strategy to identify the critical isthmus
75325114|NCT00355875|Procedure|titration of oxygen during resuscitation|
75632214|NCT00673270|Drug|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
75632215|NCT00673270|Drug|Placebo of Hydrocortisone|2 ml of isotonic saline solution
75632216|NCT04152850|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and Traditional Chinese Medicine
75632217|NCT00871780|Drug|BG00002 (natalizumab)|
75632218|NCT00694408|Drug|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
75783271|NCT01269788|Drug|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
75783272|NCT01269788|Drug|placebo|oral , daily 30 mins before breakfast, for 6 weeks
75783273|NCT01163630|Drug|esomeprazole/ASA Fixed Dose Combination (FDC)|esomeprazole 20 mg/ASA 81 mg oral capsule
75783274|NCT01280708|Other|Capture data|Capture and standardization of data of patients aged over 18 years received a kidney transplant or a simultaneous pancreas-kidney transplant from data sources will be performed by clinical research associates.The quality of data will be validated by cross annual audits. The statistical analysis will be made on a case by case according to clinical objectives.
75783275|NCT03871946|Diagnostic Test|oral glucose tolerance test (OGTT)|Implementation of OGTT: The patient was seated in a quiet room after 10-12 h of overnight fasting, and blood samples were drawn. Thereafter, 75 g glucose solution dissolved in 300 mL of water was administeredwithin 5 min. Two hours after this,another blood sample was drawn. During the test, the patient wasn't allowed to rest and eat, but not smoke.
75783276|NCT03874130|Drug|Scopolamine|IV Scopolamine
75783277|NCT01280786|Drug|Elesclomol Sodium|Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
75783278|NCT01163708|Device|Prophecy Technique|Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
75783279|NCT01163708|Device|Navigation System|
75918767|NCT05817435|Biological|efgartigimod PH20 SC as a vial + syringe presentation|efgartigimod PH20 SC as a vial + syringe presentation
75918768|NCT05817409|Drug|Intrathecal Baclofen Pump|intrathecal baclofen treatment
75918769|NCT05817396|Behavioral|Promotion of Physical Activity-related Health Competence (PAHCO)|"Intervention for the curriculum content PAHCO at nursing schools in Bavaria"
75918770|NCT05817357|Device|Rensair Compact air purifier unit|Installation of Rensair Compact air purifier (Rensair Ltd.) in the homes of children/young people participating in this study
75918771|NCT05817331|Other|Carer Treatment Preference Myelodysplasia Questionnaire|Caregiver-reported outcome measure in MDS
75918772|NCT05817331|Other|Clinician Treatment Preference Myelodysplasia Questionnaire|Clinician-reported outcome measure in MDS
75918773|NCT05817331|Other|Patient Treatment Preference Myelodysplasia Questionnaire|Patient-reported outcome measure (PROM) in MDS
76076517|NCT02982850|Drug|Warfarin|
76076518|NCT01700348|Device|Airflosser|Use of Philips Airflosser
76076519|NCT01700348|Device|Manual Floss|Active Comparator
76076520|NCT02242162|Procedure|phrenic nerves magnetic stimulations|
76076521|NCT03404050|Other|Music and dance movement therapy|Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
76076522|NCT02242240|Drug|Formoterol twice daily|
76076523|NCT02242240|Drug|Formoterol once daily|
76076524|NCT02242240|Drug|Tiotropium once daily|
76076525|NCT02242240|Drug|Placebo|
76076526|NCT03403972|Drug|Vancomycin 250Mg Capsule|Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
76076527|NCT02242318|Drug|Telmisartan|
76076528|NCT02242318|Drug|Valsartan|
76076529|NCT02242318|Drug|Placebo|
76076530|NCT01700192|Biological|MK-8237 tablets|MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
75918774|NCT05817305|Other|Medical history and functional evaluation|During each session, physical parameters are measured and data on medical history and physical activity are collected. To assess cardiorespiratory fitness, all patients complete a submaximal, moderate, and perceptually regulated treadmill walking test (1k-TWT). Patients unable to complete the test at a walking speed ≥ 3.0 km/h perform the test over 500m or 200m.
75918775|NCT05817305|Other|Health education|Patients receive recommendations for risk factor management as well as continuous motivational counselling in order to develop and maintain a stable active lifestyle.
76076531|NCT01700192|Biological|Placebo tablets|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
75325115|NCT00791219|Drug|SUBA-itraconazole|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
75632219|NCT00694408|Other|No steroids|Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
75632220|NCT04136782|Drug|Albumin-bound paclitaxel combined with carboplatin|Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
75783280|NCT01269866|Drug|Cymbalta|Cymbalta 60 to 120 mg PO QD
75783281|NCT03757988|Behavioral|Exercise Intervention- PACE-Life|Subjects will be provided with a Fitbit wristband and instructed how to use it. During the first group session, subjects will be taught how to use their heart rate (on the Fitbit) to determine how fast subjects should walk (to achieve the appropriate exercise dosage). Information on proper care, usage, and how to determine the appropriate heart rate from the watch, which will be used to guide the intensity of the walk will be provided to subjects and reviewed at each group session. For all clinic based group sessions, subjects will arrive at the STEP clinic to meet the entire group and leaders and be reminded of the HR that corresponds with the intensity of that group session. Next, the group will go outside and walk for 30 minutes.
75783282|NCT05387642|Drug|10 mg PRAX-114, 20 mg PRAX-114, and Placebo|Single dose with a washout period between doses
75918776|NCT05817292|Dietary Supplement|Probiotics|Assumption of commercial probiotics
75918777|NCT05817292|Other|No intervention|No assumption of probiotics
75918778|NCT05817279|Diagnostic Test|Optical coherence tomography|"Optical coherence tomography: OCT is a non-invasive CE-certified diagnostic modality based on light interferometry. An OCT scan visualizes an area with a diameter of 6mm thereby revealing the skin and adnexal structures with a depth of approximately 1.5mm.~3mm punch biopsy: the patients included in this study underwent a 3mm punch biopsy conform regular care. The subsequent histopathological examination of the biopsy specimen serves as ground truth diagnosis of the lesions (gold standard)"
75918779|NCT05817253|Behavioral|Portrait|In the context of audit and feedback interventions, Portrait is document produced by the physician organization 'Therapeutics Initiative' that provides personalized prescribing feedback for BC family physicians (FPs). Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual physician's prescribing practice, alongside the mean and median levels of their peers (other BC physicians), a succinct review of the best-available evidence on the topic, and recommendations for future action.
75918780|NCT05817253|Behavioral|Therapeutics Letter|The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and help provide reference for the data presented in the Portraits.
75918781|NCT05817214|Drug|Cadonilimab|All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1
75918782|NCT05817214|Drug|Anlotinib|All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.
75918783|NCT05817201|Drug|Toripalimab|Toripalimab 240mg day7 and day 28，every 3 weeks 1month after radiotherapy，until progression or 1 years or intolerant.
75918784|NCT05817201|Drug|Tegafur|Tegafur 70mg/m2/day day 1 to day 14，and day 29 to day42.
75918785|NCT05817201|Radiation|IMRT|PGTV 54Gy/2.16Gy/25F/5W, PTV 45Gy/1.8Gy/25F/5W
75918786|NCT05817149|Procedure|Blood samples|Blood samples
75918787|NCT05817136|Diagnostic Test|Eko DUO|Acquisition of a single-lead ECG via patients self-examine themselves twice a week for 12 months.
75918788|NCT05817123|Other|Questionnaires|"Administration of the following questionnaires:~Mutuality scale~Pittsburgh Sleep Quality Index (PSQI)~Epworth Sleep Scale (ESS)~Sleep Condition Indicator (SCI)~International Physical Activity Questionaire (IPAQ)~Mediterranean diet score (MDS)~Quality of Life SF 12~Hospital Anxiety and Depression Scale (HADS)"
76076532|NCT01700192|Drug|Rescue Medication: Self-Injectable Epinephrine|Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
76076533|NCT01700192|Drug|Rescue Medication: Loratadine tablets|Loratadine tablet 10 mg administered orally as needed for rescue medication.
75325116|NCT00791219|Drug|Itraconazole|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
75325117|NCT00791219|Drug|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
75783283|NCT05387642|Drug|10 mg PRAX-114 or 20 mg PRAX-114|Once daily oral treatment for 28 days
75783284|NCT05382026|Dietary Supplement|Nutritional supplementation during a 6 month resistance training program|1% chocolate milk
75783285|NCT05382026|Dietary Supplement|Nutritional supplementation during a 6 month resistance training program|Pea-based beverage
75783286|NCT05382026|Dietary Supplement|Nutritional supplementation during a 6 month resistance training program|Maltodextrin placebo
75783287|NCT01587404|Device|THERMOCOOL® SMARTTOUCH™ Catheter (including Surround Flow)|Variable contact force as measured at the catheter tip within the left atrium
75783288|NCT01165502|Drug|CM3.1-AC100|MAD study with repeated subcutaneous (sc) doses
76076534|NCT01700192|Drug|Rescue Medication: Olopatadine ophthalmic drops|Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
75325118|NCT04822545|Other|referral to comprehensive weight management clinic|"Patients will receive a referral for outpatient CWM clinic, with a message sent to the CWM clinic scheduler, prior to hospital discharge.~At six months after discharge, the patient will receive a phone call from the investigators to ascertain whether they were able to go to the CWM clinic and about their experience."
75632221|NCT04136782|Drug|Epirubicin combined with docetaxel|Epirubicin (Pfizer Pharmaceutical (Wuxi) Co., Ltd., China; National Drug Approval Number: H20000496) will be intravenously administered at 90 mg/m2 for 120 minutes on day 1 of each 21-day session of treatment. At the same time, docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; National Drug Approval Number: J20150083) will be intravenously administered at 75 mg/m2 for 120 minutes. Drug administration will be performed once every other 3 weeks for four times.
75918789|NCT05817032|Behavioral|Telerehabilitation|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have a hybrid approach (10-12 in person, 24-26 virtual) or fully virtual.
75918790|NCT05817032|Behavioral|Standard rehabilitation care|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have 10-12 in person exercise.
75918791|NCT05817019|Drug|Sugammadex Sodium|Sugammadex Sodium 2mg/kg when TOF >= 2, postoperative period
75918792|NCT05817019|Drug|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg when TOF >= 2, postoperative period
75632222|NCT04137874|Diagnostic Test|eSTROKE model|The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician
75783289|NCT01165502|Drug|Placebo|Placebo for compound CM3.1-AC100 s.c.
75783290|NCT01281098|Procedure|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
75918793|NCT05817006|Other|Device|research of the long-COVID-19 in the children
75918794|NCT05816980|Radiation|Hyperfractionated external beam radiation|40.8Gy/34 fractions (1.2Gy BID 5/7 days with minimum 6 hours interval) Concurrent capecitabine (825 mg/m2 BID 5/7 days)
75783291|NCT01281098|Drug|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
75783292|NCT03871400|Procedure|Anterior cervical discectomy and fusion|primary, 2-level, contiguous
75918795|NCT05816967|Procedure|Medication review and discharge counseling|Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.
75918796|NCT05816902|Other|The location of the patient's treatment|The location of the patient's treatment
75918797|NCT05816863|Drug|pabolizumab|pabolizumab IV every 3 weeks (q3w)
75918798|NCT05816772|Drug|Endosequence Bio ceramic Sealer|Brasseler,USA, a nano-particulate injectable premixed bioceramic sealer that contains Calcium Silicates, Calcium Phosphate, Calcium Hydroxide and Zirconium Oxide
75918799|NCT05816772|Drug|Sealapex Calcium hydroxide Based Sealer|KERR Dental, an original eugenol-free root canal sealant based on calcium hydroxide.
75918800|NCT05816720|Drug|Lutetium-177 DOTATATE|Intravenous administration
75918801|NCT05816707|Biological|PRF|"Teeth will be extracted a-traumatically as possible to avoid any soft tissue or bony damage.~The extracted sockets will be debrided by bone curettes and saline. The three extraction sockets will be divided into three groups: control group, curcumin group, and PRF group.~After curcumin/ PRF placement, all sockets will be closed by simple interrupted suture"
75918802|NCT05816707|Biological|Curcuma Longa gel|Curcuma Longa gel
75918803|NCT05816707|Other|extraction socket|extraction socket
75918804|NCT05816694|Drug|NAB-Paclitaxel plus Cisplatin|NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
76076535|NCT01700192|Drug|Rescue Medication: Mometasone furoate nasal spray|Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
75325119|NCT00797459|Device|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
75783293|NCT03874208|Other|MRI sequence|An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).
75632223|NCT04137874|Other|Control|Conventional prehospital care
75783294|NCT03874208|Other|MRI|MRI exam
75783295|NCT03871322|Dietary Supplement|Vitamin D and K2 supplementation|if supplementation of vitamin D and K2 changes the time to fracture healing
75783296|NCT03871322|Dietary Supplement|Vitamin D supplementation|if supplementation of vitamin D alone changes the time to fracture healing
75783297|NCT03871322|Dietary Supplement|Placebo|Placebo control group
75783298|NCT00313781|Drug|CP-751,871|CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
76076536|NCT00924118|Drug|Sodium Nitrite|Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
76076537|NCT02242396|Drug|Telmisartan|
75325120|NCT05614401|Other|functional and medical information|1) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.
75325121|NCT04817553|Other|exposure to COVID19|Observational study of IgG4 patients with pancreatobiliary involvement who were diagnosed with COVID19
75325122|NCT04807101|Drug|midazolam alone|elimination of fentanyl from conscious sedation
75468207|NCT06070064|Other|Effect of music on the manifestation of strength|"After the first 1RM visit, described above, each participant will complete 2 additional randomised, counterbalanced visits, each with one condition: Music (MUS) and No Music (No-MUS). The participants will be instructed to attend the laboratory to perform the screening test in different environmental conditions that do not impact on their health status.~During the MUS session, participants will perform a back squat test and a CJM test while listening to music. The chosen songs will be at least 120 beats per minute (BPM) 15. The tempo of the music for each of the tracks will be calculated using bpm software (Tangerine!v.1.4). The music will be played using an iPhone X (Apple Inc., Cupertino, CA, USA) connected to a portable speaker (Sony MHC-V02, Sony Co., Tokyo, Japan). The sound intensity will be adjusted and standardised for all participants to 75 dB (at ear level) using the Decibel X-dBA sound level meter. Trap and reggaeton music will be played before, during and after the test."
75632224|NCT04137640|Drug|palbociclib combined with letrozole|Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.
75632225|NCT04137640|Drug|epirubicin combined with cyclophosphamide and sequential docetaxel|Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
75783299|NCT00313781|Drug|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
75783300|NCT00313781|Drug|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
75783301|NCT00313781|Drug|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
75783302|NCT00313781|Drug|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
75918805|NCT05816694|Drug|Cisplatin plus Epirubicin plus Cyclophosphamide|Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
75632226|NCT04137718|Other|nonIntervention|nonIntervention
75632227|NCT00692458|Drug|Comparator: odanacatib|odanacatib; 5mg oral, once daily for approximately 60 months.
75632228|NCT00692458|Drug|Comparator: placebo|placebo; oral, once daily for approximately 60 months
75632229|NCT00911794|Other|Disclosure Writing (Written Disclosure Therapy)|Patients write about a stressful life experience
75918806|NCT05816668|Drug|Tranexamic acid|Patients with prostate cancer and radical video laparoscopy prostatectomy indication will receive 1,0g of Tranexamic Acid solution IV in bolus 20 minutes before of anesthetic induction, followed by a maintenance hose of 1,0mg/kg/h of surgery.
75632230|NCT00911794|Other|Neutral (Sham) Writing|Patients write about neutral subjects
75632231|NCT00692536|Behavioral|NNR (Nordic Nutrition Recommendations)|Diet with equal amounts of fat, protein and carbohydrates
75632232|NCT00692536|Behavioral|MPD (Modified paleolithic diet)|A diet high in protein and fat, but low in carbohydrates
75918807|NCT05816668|Other|Placebo|Patients randomized to placebo group will receive physiological saline and will undergo to the radical video laparoscopu prostatectomy normally
75783303|NCT03871478|Drug|Lidocaine|See Arm Description
75783304|NCT03871478|Drug|Bupivacaine|See Arm Description
75783305|NCT03871478|Drug|Lidocaine and Bupivacaine|See Arm Description
75783306|NCT01281332|Device|Menopod|The mechanism of action of the device will not be revealed in advance.
75783307|NCT01281332|Device|Inactive device|
75783308|NCT01281410|Procedure|Inspiratory Muscle Training|Inspiratory Muscle Training with Respifit (5 times per week)
75783309|NCT01281410|Other|inspiratory muscle training|Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)
75783310|NCT01281488|Procedure|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
75918808|NCT05816642|Drug|sunitinib or pazopanib|Single targeted therapy
75918809|NCT05816642|Drug|PD-1 inhibitor combined with axitinib|targeted therapy combined with immunotherapy
75918810|NCT05816629|Diagnostic Test|Multiparameter ultrasound based-AI|Multiparameter ultrasound based-AI for the diagnosis of thyroid nodules
75918811|NCT05816577|Dietary Supplement|EcN Colibactin knockout|E coli Nissle strain with ClbP-gene removed and therefore not producing colibactin
75918812|NCT05816577|Dietary Supplement|E Coli Nissle|E Coli wildtype strain
76076538|NCT02242396|Drug|Telmisartan hydrochlorothiazide|
75918813|NCT05816564|Behavioral|Attention Bias Modification (ABM) for depression|"Both groups will be asked to engage in mindfulness activities but only one group will receive the train-positive ABM task. The control group will receive a sham task that is not programmed to train attention towards positive stimuli."
76076539|NCT03403816|Behavioral|Before School Physical Activity Program|BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
76076540|NCT03403738|Behavioral|Bounce Back Now|web/smartphone-based intervention for disaster victims
76076541|NCT03403738|Behavioral|enhanced usual care|enhanced usual care with list of resources
75783311|NCT01281488|Procedure|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
75341384|NCT05246462|Other|Logotherapy|In this study, the experimental group received seven-session logotherapy-based interviews on making sense of life, while the control group received only routine nursing care. In this study, Personal Meaning Oriented Psychotherapy (PMOP) was used to structure interviews on making sense of life based on Logotherapy and enhance the sense of meaning in cancer patients, share their concerns, experiences, and feelings about diagnosis-treatment, have their difficulties defined, maintain, and develop their sense of purpose and responsibility.
75632233|NCT00911872|Device|collagen (EVOLENCE)|injectable collagen
75632234|NCT00694642|Biological|Selected CD 133+ cells|Endothelial progenitor cell CD 133
75632235|NCT02624830|Drug|Sulfonylurea|See Arm description.
75632236|NCT00912652|Behavioral|lifestyle intervention|Three doses of lifestyle intervention will be compared to an education control condition.
75918814|NCT05816564|Behavioral|Sham Attention Bias Modification (ABM)|The sham intervention will be given to the control group (but they will still receive mindfulness exercises).
75918815|NCT05816538|Procedure|Paravertebral nerve block (PVB)|PVB is a regional anesthetic technique applied at the thoracic (Th) level of Th2, Th3, and Th4 at a dose of 0.3ml/kg 0.5% levobupivacaine total, divided into levels. Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
76076542|NCT04374994|Drug|Avanafil 50 MG|Oral phosphodiesterase type 5 inhibitors
76076543|NCT04374994|Drug|Placebo oral tablet|lactose and maize starch, Egypt
76076544|NCT02242474|Drug|Anti-TNF suspended perioperatively|
75783312|NCT01281488|Drug|indocyanine green|Given IV
75918816|NCT05816538|Procedure|Pectoralis and Serratus Plane Nerve Blocks (PECS 2)|Pectoralis and Serratus Plane Nerve blocks (PECS 2) is a regional anesthetic technique applied in the space between the large and small pectoral muscles (10 ml of 0.5% levobupivacaine), and in the space between the small pectoralis muscle and the serratus anterior muscle (with 15 ml of 0.5% levobupivacaine). Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
75918817|NCT05816538|Device|Regional anesthetic technique with ultrasound guidance|The device that will be used is an ultrasound with an 8 Hz ultrasonic linear probe for both regional anesthetic techniques.
76076545|NCT02242474|Drug|Anti-TNFα continued perioperatively|
76076546|NCT03403660|Other|non White coat|Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
76076547|NCT03833752|Diagnostic Test|Diagnostic Flexible Cystosocpy|Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
76076548|NCT03833752|Diagnostic Test|Diagnostic Rigid Cystoscopy|Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
76076549|NCT03403582|Other|Raspberries|250g frozen whole red raspberries
75341385|NCT00578552|Drug|Placebo|Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
75341386|NCT00578552|Drug|Gabapentin - 1800 mg/day|gabapentin - 1800 mg/day for 12 weeks.
75632237|NCT00912652|Behavioral|Health Education Control|Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
75632238|NCT02624752|Dietary Supplement|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
75783313|NCT01281566|Drug|Placebo|liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
76076550|NCT04374916|Device|Premaquick®|Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
75783314|NCT01281566|Drug|Cisapride|0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
76076551|NCT04374916|Device|PARTOSURE®|An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
76076552|NCT01709864|Drug|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
75783315|NCT01163942|Drug|G-CSF|Yes/no addition of G-CSF
75783316|NCT01163942|Drug|Early retreatment with ATG|Yes/no early retreatment with ATG
75783317|NCT03876002|Drug|[18F]PBR06|Subjects will undergo PET imaging using 1 single intravenous (IV) injection of [18F]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
75783318|NCT01164020|Dietary Supplement|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
75783319|NCT01164020|Other|Placebo (Dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
75783320|NCT01164020|Other|Resistance training|resistance training twice a week for 24 weeks
75783321|NCT00368537|Drug|Tigecycline|Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
75783322|NCT00368537|Drug|ampicillin-sulbactam|"Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.~A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued."
75918818|NCT05816538|Device|Regional anesthetic technique with peripheral nerve stimulation.|The 22G neurostimulator needle (Stimuplex D®, B. Braun Melsungen AG)], and neurostimulator (Stimuplex HNS 12, B. Braun, Melsungen AG, Germany) will be used for both regional anesthesias.
75918819|NCT05816538|Drug|Levobupivacaine 0.5%|Local anesthetic levobupivacaine 0.5% will be used for regional anesthetic technique with ultrasound guidance and peripheral nerve stimulation. For the paravertebral block at a dose of 0.3ml/kg total, applied at the thoracic (Th) level of Th2, Th3, and Th4 and divided into levels. For the PECS 2 block levobupivacaine 0.5% 10 ml will be applied in the space between the large and small pectoral muscles and 15 ml in the space between the small pectoralis muscle and the serratus anterior muscle.
75918820|NCT05816538|Procedure|General anesthesia|In both groups for induction of general anesthesia we will use 1% propofol 2 - 2.5 mg/kg (10 mg/ml, Fresenius), sufentanil (Sufentanil® Altamedics) 0.2 μg / kg, rocuronium [Zemuron®, Schering - Plow] 0.8 mg/kg. We will use a laryngeal mask (I - gel supraglottic airway) of appropriate sizes for airway maintenance. All subjects will be ventilated by controlled mechanical ventilation with a volume of 8 ml/kg, a frequency of about 12 breaths per min with a mixture of oxygen and air in a 40: 60% ratio. Maintenance of anesthesia and sedation in group 1 will be performed with continuous infusion of 1% propofol (10 mg / ml, Fresenius) (25 - 150 mcg / kg / min.) and rocuronium [Zemuron®, Schering - Plow] 0.01 mg / kg / min per perfusor.
76076553|NCT01709864|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
76076554|NCT04878315|Drug|Capoten|Capoten will be administered per the treatment sequence
76076555|NCT04878315|Drug|Captopril|Captopril will be administered per the treatment sequence
76076556|NCT02242708|Behavioral|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
75918821|NCT05813990|Other|recostructive ear surgery|recostructive ear surgery in pediatric population
75918822|NCT05810285|Device|GKS Prime Flex Mobile knee|Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis
75918823|NCT05810220|Device|Electrode-Neural Interface|Measurements taken from the electrode-neural interface will be used to guide elimination of poorly functioning ABI electrodes and improve speech perception outcomes.
75918824|NCT05809583|Drug|Ozanimod|Patients with established diagnosis of UC starting ozanimod therapy as part of their clinical care
75918825|NCT05806775|Behavioral|Low-load resistance training with blood flow restriction|A licensed physical therapist, will deliver intervention to all participants (2x/wk, 8 wks) using an FDA-cleared BFR system, the Delfi PTSII (Delfi Medical Innovations). The pressure cuff will be placed at the most proximal portion of the limb and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with a minimum of 60% and a maximum of 80% limb occlusion pressure. At 60-80% limb occlusion pressure there is diminished venous outflow to induce the necessary metabolic effect while still allowing arterial flow for safety. Individual limb occlusion pressures will be determined at the beginning of each session automatically by the Delfi PTSII device.
75632239|NCT02629042|Procedure|Partial endodontic treatment under local and/or locoregional anesthesia|The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
75632240|NCT02629042|Drug|prednisolone|The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
75918826|NCT05805813|Combination Product|peritoneal rest|Change continuous ambulatory peritoneal dialysis to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month. In this way, give a chance of peritoneum rest.
75918827|NCT05803629|Diagnostic Test|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq(2-4 mCi) 68Ga-FAPI.
76076557|NCT04374604|Diagnostic Test|Placental growth factor|On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
76076558|NCT01706835|Drug|aldoxorubicin|
76076559|NCT01651533|Behavioral|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
76076560|NCT01651533|Behavioral|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
76076561|NCT03403348|Drug|JNJ-64417184|Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
76076562|NCT03403348|Drug|Placebo|Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
76076563|NCT02242786|Radiation|External beam radiation therapy|
75632241|NCT02624674|Device|Multi-spectral Imaging Device (MSID)|
75783323|NCT01165580|Drug|valganciclovir [Valcyte]|oral dose, Days 1 and 2
75783324|NCT01268852|Device|Damon self ligating orthodontic bracket|Orthodontic treatment with Damon self ligating bracket
75918828|NCT05803629|Diagnostic Test|18F-FDG|Intravenous injection of one dosage of 7.4MBq/kg(0.2mCi/kg) 18F-FDG. 18F-FDG PET/CT is performed within one week from 68Ga-FAPI PET/CT scan.
75918829|NCT05803434|Drug|Cannabidiol oral solution|"Cannabidiol will be administered orally twice daily into equally divided doses. The starting dose is 2.5 mg/kg twice daily. The dose can be gradually increased to 5 mg/kg twice daily, which is the recommended maintenance dose, up to a maximum dose of 10 mg/kg twice daily, according to tolerability and clinical response.~Following titration, subjects will continue treatment over a 20-week maintenance period. The total treatment duration from the beginning of the titration period till the end of the maintenance period will be 24 weeks."
75918830|NCT05787873|Drug|SIPS-2209-1|QD, PO
75918831|NCT05787873|Drug|SIPS-2209-2, SIPS-2209-3|QD, PO
75918832|NCT05785676|Device|Filter implantation|Implantation of OATF ALN vena cava filter
75783325|NCT01268852|Device|Insignia self ligating orthodontic bracket|Orthodontic treatment with Insignia self ligating bracket
75918833|NCT05777226|Drug|Epalrestat|Patients in the treatment group are intervened with Epalrestat tablets.
75918834|NCT05777200|Behavioral|Supportive psychotherapy|Counselling patients, providing supportive psychotherapy to help them detox their illicit drug usage, and help them rehabilitate again into society.
75918835|NCT05773209|Device|RLRL device|Crossover device (RLRL of 5% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
75918836|NCT05769920|Drug|TTHX1114(NM141) Ophthalmic Solution|Eye drop twice daily
75918837|NCT05766462|Other|Pacemaker lower rate setting|Pacemaker lower rate is set by physician and may be adjusted according to the physician diagnosis.
75918838|NCT05757245|Genetic|GMCN-508A Drug Product|Transplant of autologous hematopoietic stem and progenitor cells transduced with GMCN-508A lentiviral vector.
75918839|NCT05747963|Device|software-delivered CBT-I|The automated software called 'resleep' incorporates all core elements of CBT-I: sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene and education, tailoring content based on each participant's reported baseline sleep function and sleep progress. The 6-week treatment includes 42 times of intervention.
75918840|NCT05747963|Other|online PE|Subjects in the control group will receive non-tailored information about insomnia and sleep health education content using the Wechat Official Account.
75918841|NCT05747261|Genetic|ANB-004, dose 1|Adeno-associated viral vector carrying the SMN gene single infusion at dose 1. The duration of the infusion is about 60 minutes.
75918842|NCT05747261|Genetic|ANB-004, dose 2|Adeno-associated viral vector carrying the SMN gene single infusion at dose 2. The duration of the infusion is about 60 minutes.
75918843|NCT05747261|Genetic|ANB-004, dose 3|Adeno-associated viral vector carrying the SMN gene single infusion at dose 3. The duration of the infusion is about 60 minutes.
75632242|NCT00692614|Drug|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
75918844|NCT05740059|Other|Adjusted Transfusion|Patients assigned to the SvO2 group will be transfused if Hb concentration is lower than 7-9 g/dL and central SvO2 ≤ 65%. Transfusion will be repeated whenever Hb concentration is lower than 7-9 g/dL and central SvO2 ≤ 65% during surgery and in the ICU (until day 5). Central SvO2 will be measured on a blood sample obtained from the distal lumen of the central venous catheter. Oximetry will be used for measurement with a point-of-care of gas analysis.
75918845|NCT05738304|Procedure|Retrograde intrarenal surgery with external ureteral catheter|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, an external ureteral catheter will be placed for 24 hours.
76076564|NCT01673451|Drug|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
75632243|NCT00694720|Drug|AVE0657|capsules once a day at bedtime
75632244|NCT00694720|Drug|placebo|capsules once a day at bedtime
76076565|NCT01673451|Drug|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
76076566|NCT02242864|Drug|Micardis®|
76076567|NCT02242864|Drug|MicardisPlus®|
76076568|NCT01709708|Drug|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
75341387|NCT00578552|Drug|Gabapentin - 2700 mg/day|gabapentin - 2700 mg/day for 12 weeks.
75632245|NCT04136470|Biological|Collection of stool, blood (PBMC) and biopsy (FFPE)|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
75632246|NCT04136392|Device|ABIOMED, Inc. hemodynamic support devices|ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
75632247|NCT04137250|Procedure|Hamstring|The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
76076569|NCT01709708|Drug|Saline|Saline
76076570|NCT01673529|Drug|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
75341388|NCT01532089|Biological|Bevacizumab|Given IV
75341389|NCT01532089|Drug|Erlotinib|Given PO
75341390|NCT01532089|Drug|Erlotinib Hydrochloride|Given PO
75341391|NCT01532089|Other|Laboratory Biomarker Analysis|Correlative studies
75918846|NCT05738304|Procedure|Retrograde intrarenal surgery with double J internal ureteral stent|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, a double-J internal ureteric stent will be placed for 2 weeks.
75918847|NCT05730842|Drug|EDG-5506 Tablet|Single Oral Dose - Tablet
75918848|NCT05730842|Drug|Radiolabeled EDG-5506 Suspension|Single Oral Dose
75341392|NCT04640792|Procedure|Screening or Surveillance Conventionall colonoscopy|Patients in Group A (CC) will undergo Screening or Surveillance Conventual Colonoscopy, Patients in Group B (MEAC) will undergo Screening or Surveillance Colonoscopy with ME-ADPS Device
75918849|NCT05730842|Drug|Radiolabeled EDG-5506 Intravenous|Single Intravenous Dose
75918850|NCT05720078|Radiation|Adaptive, two-phase RT|Participants in this arm will be treated with an adaptive, two-phase radiation therapy approach
75632248|NCT04137250|Procedure|Quadriceps tendon|orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
75632249|NCT04136236|Diagnostic Test|The diagnosis of Artificial Intelligence and endoscopist|When suspected esophageal mucosal lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
75918851|NCT05716607|Drug|OD dual-release Hydrocortisone|Treatment with once-daily dual-release hydrocortisone
75918852|NCT05716607|Drug|TID Hydrocortisone|Treatment with thrice-daily conventional immediate-release hydrocortisone
75918853|NCT05713201|Procedure|Percutaneous Coronary Intervention|Treatment of coronary stenoses with a drug-eluting stent or balloon
75918854|NCT05709340|Other|proprioceptive neuromuscular facilitation exercises|PNF exercises will be done for Masseter, Temporalis, Lateral pterygoid and medial pterygoid muscles. Each contraction will be held for 10 seconds, and each stretch (relaxation phase) will be allowed to continue as long as the muscle tension continued to give away.
75918855|NCT05709340|Other|traditional physical therapy treatment|"Ultrasound: Continuous ultrasound at 1MHZ to temporomandibular joint at 1.0-1.25 W/CM2 for 5 min over each affected TMJ and masseter area, with the mouth in a slightly open position.~Forward head posture correction exercises including: chin tuck exercise, Strengthening shoulder retractors, stretching of sternocleidomastoid muscle, and Stretching of pectoralis muscle."
75918856|NCT05699343|Procedure|InterOss Collagen (Bone xenograft) and InterOss Collagen Guide (Collagen membrane)|Group will receive InterOss Collagen and InterOss Collagen Guide during surgical intervention visit.
75918857|NCT05699343|Procedure|InterOss Collagen (Bone xenograft)|Group will only receive InterOss Collagen during surgical intervention visit.
75918858|NCT05688579|Drug|Mineralocorticoid Receptor Antagonists(MRAs)|Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
75783326|NCT01048619|Drug|ON 01910.Na|In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
75918859|NCT05688579|Other|Blank control|Participants will be treated with the original antihypertensive drugs for 48 months.
75918860|NCT05688267|Other|Continuous Mobility Training|The continuous mobility training adopted 5 grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists.
75632250|NCT00694798|Biological|Mycobacterium w|Immunomodulator
75632251|NCT00594178|Device|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
75783327|NCT03875924|Other|VWD treatments|Modalities and types of treatments in VWD patients for severe hemorrhagic events: INN, quantities, duration of treatment
75918861|NCT05688267|Other|Usual Care|Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training.
75918862|NCT05688072|Other|trunk oriented exercise|trunk oriented exercises include: stretching exercises, stabilization exercises (active or active-assisted), arm exercises in fixed trunk position, trunk-oriented exercises (active or active-assisted), trunk mobilization (sitting and lying position), and functional reaching exercises with different ranges of motion in shoulder elevation
76076571|NCT01673529|Drug|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
76076572|NCT02243098|Drug|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
75341393|NCT05563987|Behavioral|ACT-DE|The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
75341394|NCT05563987|Behavioral|DE|DE
75325123|NCT04793217|Behavioral|Improving AIDS Care After Trauma +|ImpACT+ integrates skills for HIV treatment adherence and coping with trauma, tailored to the South African context. This includes exploration of values informing care engagement, recognizing the synergistic stress of sexual trauma and HIV, understanding the contribution of stressors to maladaptive coping, and developing adaptive methods for coping as alternatives to avoidance. ImpACT+ will be delivered in private spaces at the primary care clinic and will consist of 6 individual sessions followed by 6 maintenance check-ins. Individual sessions focus on coping, adherence, and care engagement during an early critical period, while maintenance check-ins reinforce positive change and support ongoing implementation of skills. Evidence supports a 6-session format in low-resource settings. Individual sessions will begin within 2 weeks after the baseline survey and be completed by the 4-month assessment. Maintenance check-ins will begin following the 4-month assessment.
75918863|NCT05688072|Other|whole body vibration|WBV application technique. The children assume a full squatting position on a vibration platform. The apparatus will set at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 min. The children were instructed to remain in squatting position after the vibration started and to report any discomfort that arose. At the end of 5 min, the vibration turned off automatically. Thereafter, the children rested for 1 min. They were then asked to stand on the vibration platform while supported by the therapist for 5 min, with the same parameters as those used in the squatting position. The total time of application of WBV in each session was 10 min.
75325124|NCT04793217|Behavioral|Adapted Problem-Solving Therapy|Participants will receive three weekly individual sessions of adapted PST. The goal of PST is to identify problems that interfere with daily activities and address them through problem-orientation work. We anticipate stressors will include (a) relationship difficulties, including family stress, (b) financial stress and unemployment, (c) general impact of HIV infection, and (d) overall chronic stress. Thus, PST may indirectly address stressors that may impact care engagement, but will not address the intersection of HIV and trauma specifically.
75918864|NCT05675501|Drug|Encapsulated Benzoyl Peroxide Cream|"Subjects will use a pea-size amount for each area of the face"
75325125|NCT05452031|Behavioral|Care2Sleep|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
75325126|NCT05452031|Behavioral|Sleep Education|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
75325127|NCT00355953|Drug|Genistein|
75918865|NCT05673603|Drug|Brensocatib|Oral tablet
75918866|NCT05662111|Drug|Etidronate|The dosage of etidronate is 20 mg/kg for twee weeks and ten weeks off. Etidronate is given in capsules of 200 mg. Etidronate capsules are administered orally. During the study, participants will receive etidronate in four periods of two weeks during the twelve months of follow-up.
75918867|NCT05662111|Drug|Placebo|Placebo is given in capsules and are administered orally. During the study, participants will receive placebo in four periods of two weeks during the twelve months of follow-up.
75918868|NCT05659927|Drug|MG-ZG122 Humanized Monoclonal Antibody Injection|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
75325128|NCT05416073|Drug|Esketamine|"PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
75325129|NCT05416073|Drug|Sufentanil|"PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
75325130|NCT02979171|Device|Laryngeal Mask Airway Classic|
75325131|NCT05481801|Biological|Covid-19 vaccination|"Correct Covid19 vaccination status was considered in the following situation:~Received at least two Covid-19 vaccine doses being the last in the last 6 months."
75632252|NCT05298826|Drug|recombinant factor VIIa|using recombinant factor VIIa
75632253|NCT00673426|Biological|Enoxaparin sodic|
76076573|NCT02243098|Drug|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
76076574|NCT02243098|Drug|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
75632254|NCT00673504|Drug|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
76076575|NCT03403114|Behavioral|Questionnaire|a 15min questionnaire
75632255|NCT00673504|Drug|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
75632256|NCT00673582|Drug|Rosuvastatin|10 mg/day rosuvastatin
75632257|NCT00673582|Drug|Placebo|Placebo, 10 mg a day for 96 weeks
75632258|NCT00694954|Device|Diagnostic Test - Given Imaging Pillcam|"Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.~Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)"
75632259|NCT00694954|Other|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
75632260|NCT04137094|Behavioral|Persuasive Health Communication Intervention|A persuasive health communication intervention will be performed
76076576|NCT01673607|Procedure|Biopsie liver|
75918869|NCT05659927|Drug|Placebo|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
75632261|NCT00912574|Drug|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
75918870|NCT05659823|Drug|Bupivacaine-fentanyl-morphine elective group|Guideline recommended analgesia in elective caesarian section.
76076577|NCT00920374|Biological|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
75325132|NCT05481801|Biological|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
75783328|NCT01281800|Procedure|Gemcitabine in long infusion|"TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid [Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT], vitamin B-12 [OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy."
75632262|NCT00912574|Drug|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
75325133|NCT05481801|Biological|Pneumococal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year. One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years. One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
75325134|NCT05481801|Biological|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
75325135|NCT05601687|Procedure|Direct Endoscopic Necrosectomy|Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS).After placement of the LAMS, EN shall be performed during the same procedure (Direct EN). After DEN, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS. Endoscopic necrosectomy and VARD shall be repeated as often as clinically indicated and logistically possible with a minimum of one day between procedures
75632263|NCT00912574|Biological|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
75783329|NCT01586858|Other|Observational|Observational study of subjects previously enrolled in the RAVE trial
75325136|NCT05601687|Procedure|Step-up Approach|"Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS). After placement of the LAMS, a 7-Fr/4cm double pigtail stent and a 7-Fr nasocystic catheter shall be placed through the LAMS.~The effect of the index drainage procedure shall be evaluated every 72 hours and next treatment step will depend on whether the patient's condition improves.~If clinical improvement is observed, the drainage regime continues, and no further therapeutic action shall be taken.~In absence of clinical improvement after 72 hours and if supplementary drainage is impossible, the patient shall proceed to endoscopic necrosectomy (EN) or video-assisted retroperitoneal debridement (VARD). Absence of clinical improvement due to causes not related to the WON treatment, e.g., urinary tract or pulmonary infection or iv catheter sepsis, shall not influence the treatment algorithm of the WON."
75325137|NCT05664971|Biological|Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection|200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
75325138|NCT05664971|Biological|Toripalimab|240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
75783330|NCT01059149|Device|repetitive transcranial magnetic stimulation|MagPro x100 (MagVenture A/S, DANEMARK)
75783331|NCT03870932|Other|Motor Imagery physical therapy|
75918871|NCT05659823|Drug|Bupivacaine-fentanyl elective group|Current analgesia in elective caesarian section.
75918872|NCT05659823|Drug|Bupivacaine-fentanyl emergency group|Current analgesia in emergency caesarian section.
75918873|NCT05640453|Drug|Pregabalin|Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
76076578|NCT03159039|Other|Conventional Physiotherapy|
76076579|NCT03159039|Other|Prolonged slow exhalation technique|Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
76076580|NCT01673685|Device|Portable Oxygen|
75468208|NCT06070038|Behavioral|Integrated Behaviour Change Based Intervention Materials|The intervention will be delivered over a three-month period as a series of four zoom hosted workshops, online content, and a moderated social support group. Zoom workshops will last 45 minutes and will target key constructs from the integrated behavior change model. Main topics of the workshops are autonomy Supportive parenting (Week 1), goal setting and outcome beliefs (Week 3), physical activity norms (Week 5), and encouraging self-efficacy and maintenance (Week 8). Following each workshop, participants will receive links to online content that builds on workshop themes, such as messages, worksheets, and reflection tasks. Throughout the trial, participants will be able to participate in social support chat groups to discuss their progress with other members of the intervention group and intervention facilitators.
75783332|NCT03870932|Other|Conventional physical therapy|
75783333|NCT03982121|Drug|FOLFOX regimen|Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
76076581|NCT04374292|Behavioral|Family intervention|"Topics covered in each session with intervention group mothers.~Dietary and physical activity habits and their link to obesity and cardio-metabolic diseases. Children learn about healthy eating habits and health risks at home.~Food-preparation processes. Selecting and purchasing food and beverages; importance of food groups and their impact on health; importance of fruit and vegetables. Balance between food groups, source of foods, organic or industrialized. Family menu preparation.~Habits and behaviors surrounding eating processes identified as health or risk factors, such as energy density, portion-size control, controlling emotional eating.~Beverages. Water versus sugar-sweetened drinks prepared at home or purchased at the store.~Preventing the risk of cardiovascular diseases by learning healthy eating habits and practicing these habits at home.~Integration. Practicing the skills learned during the intervention in each stage of preparing food and eating"
75325139|NCT05664971|Drug|Docetaxel|60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression
75325140|NCT05664971|Drug|Pemetrexed|500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed
75325141|NCT05664971|Drug|Cisplatin|75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
75468209|NCT06070012|Drug|Tebentafusp|An anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.
75468210|NCT06069986|Procedure|coronary artery bypass graft CABG|comparison between onpump and off pump CABG
75468211|NCT06069960|Procedure|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
75468212|NCT06069947|Procedure|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
75468213|NCT06069908|Other|Complex Decongestive Treatment|Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach. It will be applied 5 days a week for 3 weeks
75468214|NCT06069908|Other|Sham transcutaneous vagus nerve stimulation|In sham transcutaneous vagus nerve stimulation application, the device electrode will be placed in the superior scapha region of the outer ear, where the vagus nerve has no innervation, and no current will be given.Complex Decongestive Therapy and sham transcutaneous vagus nerve stimulation.It will be applied 5 days a week for 3 weeks.
75468215|NCT06069908|Other|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation will be applied in addition to Complex Decongestive Therapy.It will be applied 5 days a week for 3 weeks.
75468216|NCT06069908|Other|Exercise|Patients will undergo lymphedema-specific exercises 5 days a week for 3 weeks.
75783334|NCT03982121|Drug|Nivolumab|Nivolumab 240 mg
75783335|NCT03982121|Drug|Ipilimumab|Ipilimumab 5 or 10 or 25 mg
75918874|NCT05640453|Drug|Dexmedetomidine|Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)
75783336|NCT03982121|Drug|GLA-SE|GLA-SE 1 or 2 or 5 or 10 or 20 μg
75325142|NCT05664971|Drug|Carboplatin|AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
75783337|NCT03871010|Device|Midline catheter|Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.
75783338|NCT01167530|Drug|Everolimus|First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 10, 20 and 50 mg of RAD001 per week.Second phase of the study:RAD001 (everolimus) will be administered per os every day one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 2.5, 5 and 10 mg of RAD001 per day.The two phases of the study may be conducted independently and in parallel.
75783339|NCT01167686|Dietary Supplement|Gardemont Goldtrain Plus (GT+)|Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
75325143|NCT05664971|Drug|Paclitaxel|175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
75325144|NCT05664971|Drug|Etoposide|100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles
75468217|NCT06069856|Dietary Supplement|Iron Folic Acid Tablets with 60 mg of iron|IFA with 60 mg iron is an intervention group. IFA with 60 mg of iron will be taken orally once daily from the time of randomization
75468218|NCT06069856|Dietary Supplement|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization.
75468219|NCT06069830|Drug|4 cycles of ESA regimen with sandwiched radiotherapy|Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
75918875|NCT05637333|Diagnostic Test|Contrast Stress Echocardiography|Dipyridamole will be infused at 0.56mg/kg of body weight over 4mins. After 2 minutes, if the patient has tolerated the infusion well, a further 0.28mg/kg will be infused over 2 minutes. Tolerance will be determined by the absence of 1) myocardial ischaemia (significant chest pain with ECG ST depression or T wave inversion or wall motion abnormality on ECHO) 2) a significant drop in blood pressure 3) significant arrhythmia and 4) intolerable symptoms. One minute after completion of Dipyridamole infusion Sonazoid will be infused at the same rate as was used during acquisition of the rest images. After 45 seconds when steady state is reached, the ultrasound images will be acquired as stated below in contrast imaging. If the Dipyridamole is not well tolerated by one minute after the 0.56mg/kg infusion, we will move straight to the infusion of Sonazoid with no extra 0.28mg/kg infusion.
75918876|NCT05635851|Drug|Glyceryl Trinitrate Only Product in Oromucosal Dose Form|Glyceryl trinitrate will be administered via sublingual spray.
75918877|NCT05635851|Other|Placebo sublingual spray|A placebo sublingual spray will be administered.
75918878|NCT05633836|Procedure|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreduction surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
75632264|NCT00912574|Drug|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
75918879|NCT05611255|Procedure|Systematic Intermittent Catheterization|A strategy that consists of draining urine only once, in all patients, after surgery (in the operating room).
75918880|NCT05611255|Procedure|Bladder Scan Guided Catheterization|A strategy of standardized and reproducible assessment of bladder volume before discharge from the post anesthesia care unit, and draining urine only in patients who require it.
75918881|NCT05599789|Drug|Pembrolizumab in Combination with Plinabulin and Docetaxel|Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 and 8 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.
75918882|NCT05594134|Other|Automatic toothbrush with nylon bristle|The automatic toothbrush with nylon bristles will be used for 10 seconds per dental arch
75918883|NCT05594134|Other|Automatic toothbrush with silicone bristle|The automatic toothbrush with silicone bristles will be used for 10 seconds
75918884|NCT05594134|Other|Manual toothbrush used for 2 minutes|A conventional manual toothbrush will be used for 2 minutes
75783340|NCT03871088|Dietary Supplement|Omega-3 fatty acids|12-week double-blind, randomized controlled trial
75783341|NCT03871244|Procedure|Less red blood cell transfusions|The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.
75918885|NCT05594134|Other|Manual toothbrush used for 45 seconds|A conventional manual toothbrush will be used for 45 seconds
75918886|NCT05591989|Device|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
75918887|NCT05582018|Device|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
75918888|NCT05581901|Drug|Methadone (Dose1)|Dose: 0.10mg/kg
75918889|NCT05581901|Drug|Methadone (Dose 2)|Dose: 0.15mg/kg
75918890|NCT05581901|Drug|Methadone (Dose 3)|Dose 0.20mg/kg
75918891|NCT05570344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
75918892|NCT05570344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support|"rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.~Text4Support:~Text4Support is one of the ResilienceNHope suites of supportive text messaging programs delivered by the Global Psychological eHealth Foundation [80]. The program allows users to receive daily supportive text messages which have been written by a team of cognitive-behavioral therapists and mental health professionals in collaboration with users of mental health services. The aim of this Text4Support depression program is to enhance positively the mood of patients with clinical depression. The program operates through the use of positive reinforcement to correct distorted or negative thought patterns."
75325145|NCT04848077|Behavioral|Step count increase with the use of a motivational smartphone application|All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
75468220|NCT06069830|Drug|2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
75783342|NCT03871244|Procedure|More red blood cell transfusion (standard transfusion strategy in PICU)|The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice
75783343|NCT01167764|Drug|tranexamic acid, placebo|tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
75783344|NCT01164176|Drug|everolimus|
75783345|NCT01164176|Other|laboratory biomarker analysis|
75632265|NCT00692848|Other|Procalcitonin dosage PCT-Q test (Brahms, Germany)|Procalcitonin result available to the attending physician
75632266|NCT00695032|Drug|cisplatin|
75632267|NCT00695032|Drug|ifosfamide|
75632268|NCT00695032|Other|laboratory biomarker analysis|
75918893|NCT05568316|Dietary Supplement|Preoperative Immunonutrition|"Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
76076582|NCT04374292|Other|Usual nutritional consultation|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
76076583|NCT05289063|Drug|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
76076584|NCT05289063|Drug|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
76076585|NCT05289063|Other|Continuous Positive Airway Pressure Therapy|CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
75325146|NCT05591313|Behavioral|LI-40|Participants were asked to complete a volume-matched light-intensity exercise for 30-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
75325147|NCT05591313|Behavioral|MI-30|Participants were asked to complete a volume-matched moderate-intensity exercise for 20-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
75468221|NCT06069830|Drug|2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|PD-1 monoclonal antibody, 200mg, i.v. d1
75632269|NCT04137172|Procedure|laparoscopic (IPOM) hernioplasty without repair|"Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap ."
75632270|NCT04137172|Procedure|aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS|"Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation"
75632271|NCT04137172|Procedure|laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0|The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
76076586|NCT04374526|Biological|COVID-19 Convalescent Plasma|ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
76076587|NCT05284305|Other|Pregnancy|DT with a history of concomitant or subsequent pregnancy.
75632272|NCT04137328|Drug|Liraglutide|0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months
75783346|NCT01164332|Other|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
75783347|NCT03875846|Diagnostic Test|Intraoperative Hemodynamic Pressures|Secondary analyses will examine the Ankle-Brachial Index, and the absolute limb pressures. In addition, the changes in flow rate of contrast before- and after- intervention will be examined as an indicator of perfusion.
75783348|NCT03875846|Diagnostic Test|Contrast Flow Rate|A secondary analysis will examine the rate of contrast flow during pre-intervention and post-intervention angiograms, and correlate these findings with hemodynamic measurements recorded during surgery.
75783349|NCT02526992|Device|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
75783350|NCT00313313|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term [ST], 12 months long-term [LT])
75783351|NCT00313313|Drug|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
75783352|NCT00313313|Drug|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
75783353|NCT00313313|Drug|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
75783354|NCT00313313|Drug|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
75783355|NCT00313313|Drug|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
75783356|NCT01586936|Drug|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
75632273|NCT04137328|Drug|insulin|Add or adjust insulin (when basic insulin is preferred for those who do not use insulin, such as those who have already used insulin, adjust the dosage or program according to the condition, inject subcutaneously) for 3 months
75632274|NCT00692926|Biological|ALDHbr Umbilical Cord Blood Cells|ALDHbr sorted Umbilical Cord Blood Cells
75632275|NCT00693004|Drug|PRX-03140|
75632276|NCT00693004|Drug|Donepezil|
75632277|NCT00693004|Drug|Placebo|
75632278|NCT04152538|Other|not intervention but investigation|possible differences in quadriceps muscular activity
75632279|NCT00695344|Drug|everolimus|Everolimus 2 times per day, v.o., 2 years treatment.
75632280|NCT00695344|Drug|azathioprine or mycophenolate mofetil|2 times per day during 2 years
75325148|NCT05591313|Behavioral|HI-16|Participants were asked to complete a volume-matched high-intensity exercise for 16-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
75918894|NCT05568316|Dietary Supplement|Perioperative Immunonutrition|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
75918895|NCT05566067|Other|Survey|There will be no interventions for study participants. Participants will be asked to complete a survey.
75918896|NCT05561426|Other|Ad libitum breakfast and dinner meals for 12 days|Ad libitum portions of breakfast and dinner meals served at the eating behaviour lab
75325149|NCT05590299|Other|Fish oral immunotherapy (codfish)|Codfish in mixture of potato prepared under food manufacturing regulations provided in varying doses
75632281|NCT00693082|Dietary Supplement|flaxseed|1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
75632282|NCT04047550|Diagnostic Test|Ventilatory chemosensitivity|Using this technique, the patient first voluntarily hyperventilates to a PETCO2 value of 20-25 mmHg, then undergoes a rebreathing test allowing the PCO2 to rise to 55-60 mmHg while PETO2 is maintained at 150 mmHg. The procedure is then repeated with PETO2 clamped at 50 mmHg. Parameters derived from this method include slopes of the ventilatory response during hyperoxia and hypoxia.
75632283|NCT00693316|Drug|ORM-12741|Alternating panel single dose escalation.
76076588|NCT04374058|Other|less-frequency hemodialysis|Patients of treatment group would be evaluated quarterly
76076589|NCT02590809|Drug|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
75325150|NCT05590299|Other|Placebo oral immunotherapy|Placebo in potato mixture prepared under food manufacturing regulations provided in varying doses
75325151|NCT05458713|Device|Laser acupuncture|Irradiate acupoints with low power laser
75325152|NCT00355485|Device|microdermabrasion|"Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.~Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart."
75325153|NCT05660915|Procedure|Intermediate approach|The area between superior mesenteric vein and superior mesenteric artery was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.
75325154|NCT05660915|Procedure|Standard approach|The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
75325155|NCT04812509|Drug|MW032|The active ingredient of MW032 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
75325156|NCT04812509|Drug|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
75632284|NCT00933270|Device|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
75632285|NCT00695422|Genetic|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
75783357|NCT01167920|Other|Virtual Hypertension Clinic|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals until the end of the study.
75783358|NCT03873974|Diagnostic Test|DualDur dark-field microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Manual evaluation.
76076590|NCT02590809|Drug|Placebo|Placebo will be given for 30 days
75325157|NCT05647655|Device|Ultrasonography|Bedside thoracic ultrasound for patients complaining of acute dyspnea.
75325158|NCT00810095|Device|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
75632286|NCT00695422|Other|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
75632287|NCT00695422|Other|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
76076591|NCT02590809|Other|Walk distance test|Walk distance test during 6 minutes
75918897|NCT05555186|Device|BWL classrooms (Experimental)|Adolescents in the BWL classrooms will be exposed to the circadian stimulating bright light (600-1000lx) to maintain alertness. The programming of the LED lighting system in the intervention group (BWL) will be tuned to provide equal stimuli to the cone and melanopsin-containing photoreceptors measured at the eye height (1.2 m above floor level for sitting position) approximately in the range 4500 -5500 K (cool white light) or between 600 and 1000 lx.
76076592|NCT02590809|Other|Exercise echocardiography|
75325159|NCT05446623|Drug|Dexmedetomidine|Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.
75632288|NCT00695422|Procedure|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
75632289|NCT04137016|Other|Mobile application|
75783359|NCT03873974|Diagnostic Test|DualDur dark-field automatic microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Software evaluation.
75783360|NCT03873974|Diagnostic Test|Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
75783361|NCT03873974|Diagnostic Test|Bózsik Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
76076593|NCT01709318|Drug|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
76076594|NCT01709318|Drug|Etonogestrel (ENG)|Daily release of 75, 100, 120 or 125 μg
76076595|NCT01709318|Drug|Ethinyl estradiol (EE)|Daily release of 15 μg
76076596|NCT01709318|Drug|Estradiol (E2)|Daily release of 300 μg
76076597|NCT02243254|Drug|high dose remifentanil|high dose remifentanil
76076598|NCT02243254|Drug|Ibuprofen|intravenous ibuprofen
76076599|NCT02243254|Drug|low dose remifentanil|low dose remifentanil
75325160|NCT05446623|Drug|Sufentanil|The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
75632290|NCT02624362|Behavioral|Therapeutic Suggestion|suggestions about potential beneficial effects of the odor are given
75632291|NCT02624362|Behavioral|Asthmogenic Suggestion|suggestions about potential negative effects of the odor are given
75783362|NCT03873974|Diagnostic Test|enzyme-linked immunosorbent assay (ELISA) IgM and IgG|Standard ELISA test for Lyme borreliosis.
75783363|NCT03873974|Diagnostic Test|DualDur Polymerase chain reaction|DualDur PCR test for Lyme borreliosis.
76076600|NCT03402880|Biological|Pembrolizumab|Given IV
76076601|NCT03402880|Drug|Epacadostat|Given PO
76076602|NCT03402880|Other|Laboratory Biomarker Analysis|Correlative studies
75632292|NCT02624362|Other|Phenylethyl Alcohol odor|Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
75632293|NCT00607542|Drug|baclofen|2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
75632294|NCT00605046|Drug|SPECT scan|AV151-01: Evaluation of [123I] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
75632295|NCT04265898|Device|The Digital Virginia Tech Carilion Cognitive Examination|Completion of a newly developed digital cognitive screen
75632296|NCT00936858|Drug|RAD001|
75632297|NCT00606762|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
75632298|NCT00605124|Other|Knee muscle exercises|Home exercises three times a week, control every three months
75783364|NCT01268930|Procedure|Bipolar electrocautery for ovarian hemostasis|after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.
75632299|NCT00693550|Other|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
75783365|NCT01268930|Procedure|hemostatic matrix (FloSeal)|after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.
75632300|NCT02624440|Drug|Standard myeloma treatment|The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
75632301|NCT02624440|Drug|Clarithromycin|P.o. clarithromycin 250 mg twice daily
75632302|NCT02624440|Drug|Sulfamethoxazole/trimethoprim|P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
75783366|NCT01165658|Radiation|Proton Therapy|The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
76076603|NCT01673763|Device|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
76076604|NCT03402802|Drug|monitoring of adherence with medication|persons taking routine postoperative eye drops will have their frequency of drop taking monitored
76076605|NCT01673841|Procedure|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
76076606|NCT03402724|Other|echographic|Patients are called for an echographic evaluation in the implanting center in case of the usual care
76076607|NCT04374214|Procedure|Complete Pulpotomy using Mineral Trioxide Aggregate|Inflammed coronal pulp tissue will be removed till the canal orifices and mineral trioxide aggregate placed over the amputated pulp stump.
76076608|NCT04374214|Procedure|Complete Pulpotomy using Simvastain -alphatricalcium phosphate|Inflammed coronal pulp tissue will be removed till the canal orifices and Simvastatin -alpha tricalcium phosphate placed over the amputated pulp stump.
76076609|NCT03153345|Device|bedside respiratory muscle training|The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
75918898|NCT05555186|Device|DWL classrooms (Comparison)|Participants in DWL classrooms will receive conventional light from the same kind of equipment as used for the intervention group, only not applying high circadian stimulation(300lx). In order to replicate conventional lighting in the classrooms, the programming of the new LED lighting system in the control group (DWL) will meet the minimum requirements according to EN12464-181, or at least 300 lx measured at table height for a light source rated at 3000 K (warm white light).
76076610|NCT03153345|Behavioral|conventional stroke rehabilitation program|The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
76076611|NCT01673997|Drug|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
76076612|NCT04373824|Drug|Ivermectin|Ivermectin 200 to 400 mcg per kg body weight
76076613|NCT01676571|Drug|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
76076614|NCT04373980|Device|phototherapy|estimate CD4 and CD8 subsets in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
75632303|NCT02624440|Drug|Observation|Observation without prophylactic antibiotic
76076615|NCT01699178|Drug|Oral testosterone undecanoate|Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
75632304|NCT04136704|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
76076616|NCT01699178|Drug|Transdermal testosterone gel (AndroGel)|Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
75632305|NCT00606840|Behavioral|large changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
75783367|NCT03870542|Procedure|kidney transplantation|Kidney transplant for end-stage renal disease from deceased kidney donors
75783368|NCT01168154|Dietary Supplement|Lactobacillus Reuterii|Lactobacillus Reuterii 10000000000 CFU per day
75783369|NCT01168154|Dietary Supplement|placebo|placebo
76076617|NCT02243332|Device|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
76076618|NCT03402646|Behavioral|Reminder module (SMS and Phone call)|Same as described under arm/group descriptions
75632306|NCT00606840|Behavioral|small changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
75632307|NCT00673972|Radiation|gastric scintigraphy|"All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window."
75632308|NCT04152616|Other|Instrumental evaluation of posture|"After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®)."
75783370|NCT03873662|Diagnostic Test|Blood sample|Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
75783371|NCT02526758|Drug|beclomethasone|
75783372|NCT02526758|Drug|formoterol|
75783373|NCT02526758|Drug|budesonide|
75783374|NCT01168466|Behavioral|QEEG-based Neurofeedback Training|EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.
75783375|NCT01281878|Drug|Vitamin B 6|Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
75783376|NCT01164488|Drug|danoprevir|Repeated daily doses
75918899|NCT05549713|Procedure|Upper blepharoplasty|Upper eyelid surgery in local anesthesia performed by removing excess skin folds and closing with sutures placed on the skin crease.
75918900|NCT05546125|Other|as per Physician's prescription|Participants need to take the Revatio as per Physician's prescription
75918901|NCT05520294|Other|High-performance liquid chromatography-tandem mass spectrometry assays|Paraffin blocks will be requested for slide creation, and at least 12 mL of whole blood will be collected in 2 green top tubes, centrifuged, and plasma transferred for storage at -80 C until further processing
76076619|NCT03402646|Behavioral|Photovoice|Same as described under arm/group descriptions
76076620|NCT02077959|Drug|lenalidomide|Given PO
76076621|NCT02077959|Biological|pidilizumab|Given IV
76076622|NCT02077959|Other|pharmacological study|Correlative studies
76076623|NCT02077959|Other|laboratory biomarker analysis|Correlative studies
76076624|NCT01683409|Drug|Baricitinib|Administered orally
76076625|NCT01683409|Drug|Placebo|Administered orally
75632309|NCT04265352|Other|No intervension|There is intervention at all.
75918902|NCT05516927|Diagnostic Test|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
75918903|NCT05508061|Drug|Insulin Lispro Cartridge [Lyumjev]|Administration of Lyumjev in combination with the AP system
76076626|NCT04548518|Biological|GPO Tri Fluvac vaccine|Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).
76076627|NCT04548518|Biological|Licensed influenza vaccine|The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020
76076628|NCT02243488|Device|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
76076629|NCT01699022|Drug|Injection Cyclofem|"Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
76076630|NCT01670175|Drug|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
76076631|NCT03402490|Behavioral|Motivational interviewing|
75783377|NCT01164488|Drug|ketoconazole|Repeated daily doses
75783378|NCT01164488|Drug|ritonavir|Repeated daily doses
76076632|NCT01674231|Other|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
76076633|NCT01674231|Other|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
76076634|NCT02243566|Drug|MicardisPlus®|
76076635|NCT01670253|Behavioral|Group 1|"6 hour fast from all solid foods and milk beverages~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
75325161|NCT04383899|Other|Questionnaire|All patients testing positively for COVID-19, with completed questionnaires. As appropriate, the duration of the study will be at least the time to complete the questionnaire for non-hospitalized patients, and for those who are hospitalized, they will be followed until hospital discharge or death to ascertain outcome.
75632310|NCT04136080|Other|vasopressors|control the mean arterial pressure with vasopressors
75325162|NCT00792077|Drug|Lenalidomide|5 mg daily for 56 days.
75325163|NCT02979015|Drug|alirocumab SAR236553 (REGN727)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
75325164|NCT02979015|Drug|placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
75783379|NCT01164566|Procedure|endoscopic procedure|
75783380|NCT01164566|Other|questionnaire administration|Ancillary studies
75632311|NCT05380128|Genetic|Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms|Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).
75632312|NCT00693862|Drug|levodopa, carbidopa, entacapone|
75632313|NCT00693862|Drug|levodopa, carbidopa|
75783381|NCT01269008|Device|Medtronic ePID 2.0|Closed loop system is an automated insulin delivery system based on body blood sugar. It consists of an Insulin pump, glucose sensor, and a device presently a laptop with all the algorithms.
75783382|NCT01272362|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
75783383|NCT01282034|Procedure|Marrow stimulation - Drilling or Microfractures|"Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.~Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective."
75918904|NCT05508061|Drug|Insulin Lispro Cartridge|Administration of Humalog in combination with the AP system (standard therapy)
75918905|NCT05504642|Drug|Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)|Two weeks before start of Chemo-radio-immunotherapy one administration of Nivolumab 3 mg/kg and Ipilimumab 1 mg/kg IV over 30 minutes, with a 30 minute break between Nivolumab and Ipilimumab.
75918906|NCT05504642|Drug|Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab)|In week 1-7, standard administration of concurrent Cisplatin mono 40mg/m2 body surface area d1, 8, 15, 22, 29 (Monday of each treatment week) during radiotherapy. Simultaneous application of Nivolumab 3mg/kg week 1, 3, 5, 7 (on Thursday) and Ipilimumab 1mg/kg in week 5 (on Thursday).
75918907|NCT05504642|Procedure|Maintenance Treatment (Nivolumab/Ipilimumab)|For six months after Chemo-radio-immunotherapy, Nivolumab 3mg/kg every two weeks x12 (week +2, +4, +6, +8, +10, +12, +14, +16, +18, +20, +22, +24 (twelve applications), each application over 30 minutes and Ipilimumab every six weeks x4 (week +6,+12, +18, +24).
75632314|NCT05377788|Drug|Lazertinib|Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR
75918908|NCT05490953|Drug|Pentoxifylline|Patients will be treated pentoxifylline during the first two chemotherapy cycles of their respective treatment.
75918909|NCT05490953|Drug|Placebo|Patients will be treated with placebo during the first two chemotherapy cycles of their respective treatment.
75632315|NCT00631254|Procedure|Allergen challenge|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
75632316|NCT00631254|Procedure|Allergen challenge|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
75632317|NCT02624206|Dietary Supplement|Juice A|Subjects to be given juice daily for 3 weeks.
75632318|NCT02624206|Dietary Supplement|Juice B|Subjects to be given juice daily for 3 weeks.
75632319|NCT04135924|Other|Rehabilitation|physical exercise and respiratory muscle training
75632320|NCT05379894|Procedure|Percutaneous nephrolithotripsy|Extraction of kidney stones through skin using nephroscope
75783384|NCT01282034|Device|MaioRegen Surgery|MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
75632321|NCT00607776|Drug|(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400|Drops
75783385|NCT00312845|Drug|Bortezomib + Rituximab|VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
75783386|NCT00312845|Drug|Rituximab|rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
75783387|NCT01282190|Behavioral|Motivational interview|Motivational interview
75783388|NCT01282268|Drug|arbaclofen|orally disintegrating tablet
75783389|NCT01282268|Drug|placebo|orally disintegrating tablet
75632322|NCT00607776|Drug|Systane|Drops
75632323|NCT00674050|Drug|Technosphere Insulin (TI) Inhalation Powder|3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
75783390|NCT01165736|Drug|PF-05186462|single intravenous infusion of 100 microgram
75783391|NCT01165736|Drug|PF-05186462|single oral administration of 100 microgram
75783392|NCT01165736|Drug|PF-05089771|single intravenous infusion of 100 microgram of PF-05089771
75783393|NCT01165736|Drug|PF-05089771|single oral administration of 100 microgram PF-05089771
75783394|NCT01165736|Drug|PF-05150122|single intravenous administration of 100 microgram PF-05150122
75783395|NCT01165736|Drug|PF-05150122|single oral administration of 100 microgram PF-05150122
75783396|NCT01165736|Drug|PF-05241328|single intravenous infusion of 100 microgram PF-05241328
75632324|NCT00674050|Drug|Albuterol (Salbutamol)|2 puff= 200ug total dose
75632325|NCT00674050|Drug|Fluticasone|2 puffs= 500ug total dose
75632326|NCT04267458|Other|evaluation of sofuspovir containing DAA regien expected insult on kidney|to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV
75632327|NCT02628652|Dietary Supplement|GOS|
75783397|NCT01165736|Drug|PF-05241328|single oral administration 100 microgram PF-05241328
75783398|NCT03870308|Diagnostic Test|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
75783399|NCT01168544|Dietary Supplement|loading dose Vitamin D and 50.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
75783400|NCT01168544|Dietary Supplement|loading dose and 25.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
75783401|NCT01168544|Dietary Supplement|Vitamin D 800 IU /day|800 IU vit D3/day
75783402|NCT03985241|Diagnostic Test|Functional Assessment of Myocardial Ischemia by icECG|
75783403|NCT03875066|Other|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
75918910|NCT05489822|Device|VERTICALE® Cervical System|"All measures and devices mentioned in the study protocol correspond to routine clinical practice with the exception of the following questionnaires:~NDI (Neck Disability Index) NRS (Numerical Rating Scale) neck pain (cervical spine) and NRS arm pain mJOA (modified Japanese Orthopaedic Association) Score"
75918911|NCT05475483|Drug|SOM3355 capsules|Treatment will be blind for the whole duration of the study.
75918912|NCT05475483|Drug|Placebo capsules|Treatment will be blind for the whole duration of the study.
75918913|NCT05474729|Drug|minocycline|minocycline capsule 100mg per day orally
75918914|NCT05474001|Drug|Fentanyl|10mg bubivacain intrathecal ( 2ml ) with 20microgram intrathecal fentanyl
75918915|NCT05474001|Drug|Bupivacain|10mg bubivacain intrathecal (2ml) with 0.5 ml saline with no intrathecal fentanyl
75918916|NCT05474001|Drug|intravenous graniseton|10mg bubivacain intrathecal ( 2ml ) with 0.5 ml saline with no intrathecal fentanyl with 1mg iv granisetron
75632328|NCT02628652|Dietary Supplement|GLOS|
75632329|NCT02628652|Dietary Supplement|FOS|
75632330|NCT04152460|Device|Viscalor Bulk (VOCO,Cuxhaven)|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
75632331|NCT04152460|Other|Grandioso x-tra|Nanohybrid Bulk Resin Composite
75783404|NCT03875066|Other|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
75632332|NCT00872170|Drug|Sildenafil|"Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"
75632333|NCT00936702|Drug|carboplatin|Given IV
75783405|NCT00368069|Drug|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
75783406|NCT00368069|Drug|Placebo|oral tablets, 2 tablets once daily
75783407|NCT01165814|Drug|Naproxen Tramadol|
75918917|NCT05471232|Genetic|Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
75783408|NCT01269086|Behavioral|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
75783409|NCT00367991|Drug|Recombinant human erythropoietin alfa (drug)|200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
75783410|NCT00367991|Drug|Placebo|Normal saline to match active drug (rHuEpo)
75783411|NCT01168700|Drug|aged garlic extract|Aged garlic extract, 1.2 g per day for 12 weeks
75783412|NCT01168700|Drug|Placebo|Placebo 1.2 g per day for 12 weeks.
75632334|NCT00936702|Drug|everolimus|Given PO
75783413|NCT01165892|Drug|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
75783414|NCT00367835|Drug|SPD503 (Guanfacine hydrochloride)|Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
75918918|NCT05471232|Other|EHR-Based Network Model|EHR-based network will be created to predict psychiatric outcomes in youth with IDDs
75325165|NCT04693767|Other|Mechanical thrombectomy|"Clot specimen collection~Extracranial blood collection"
75783415|NCT00367835|Drug|Placebo|Placebo
75783416|NCT02526446|Behavioral|Self-administered acupressure|"The intervention consists of a total of 28 hours over a period of 8 weeks:~i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.~ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).~iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours)."
75783417|NCT02526446|Other|wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
75783418|NCT01168778|Behavioral|Physician Workshop|Physicians that were assigned to the intervention group attended a 3.5 hour intervention workshop where they were trained in skills to communicate information about physical examination findings, treatment, and follow-up that will ultimately facilitate appropriate antibiotic prescribing and increase parent satisfaction with care.
75918919|NCT05451199|Drug|ICP-488|ICP-488 will be administered as tablet
75918920|NCT05451199|Drug|Placebo|Matching placebo will be administered as tablet
75918921|NCT05446584|Device|High Definition Transcranial Direct Current Stimulation|HD-tDCS for this study is not intended to be a treatment, and will be applied continuously for 30 minutes at sham (0 mA) or 2 mA for active conditions across 3 consecutive daily sessions to probe neural circuit integrity. This specific HD-tDCS device is completely computer driven, running on a laptop using specialized software. Circular electrodes (12-mm in diameter) filled with conductive gel will be placed in a 4x1 ring configuration with the central electrode being the anode surrounded by four cathodes.
75918922|NCT05445232|Drug|LY3437943|Administered SC.
75918923|NCT05445232|Drug|Midazolam|Administered orally.
75325166|NCT04693767|Other|Minimally invasive surgery|"Clot specimen collection~Arterial blood collection"
75325167|NCT05583123|Device|restored abutment (OPZAs)|The restorations will be restored by the OPZAs
75325168|NCT05583123|Device|restored abutment (TPZAs)|The restorations will be restored with the TPZAs with friction-fitted titanium bases.
75325169|NCT04382417|Other|Observational study|Not required
75325170|NCT00799643|Drug|Salsalate|Salsalate 3.5 g/d orally, divided dosing
75325171|NCT00799643|Drug|Salsalate Placebo|
75325172|NCT03835013|Drug|Saline 0.9%|Intravenous infusion of 0.9% saline
75325173|NCT03835013|Drug|Glucagon (25ng/kg/min)|Intravenous infusion of glucagon 25ng/kg/min
75325174|NCT03835013|Drug|Glucagon (50ng/kg/min)|Intravenous infusion of glucagon 50ng/kg/min
75632335|NCT00936702|Drug|paclitaxel|Given IV
75632336|NCT00693940|Behavioral|Group mediated cognitive behavioral (GMCB) sessions|GMCB will include weekly group exercise sessions, lasting approximately 60 to 75 minutes each for a 6 month period. During these sessions, participants will be asked to exercise by walking around a track. There will also be a group discussion, led by a facilitator, who will help participants find ways to increase the frequency of their walking exercise at home. After completing the GMCB sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
75783419|NCT03874832|Drug|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
75783420|NCT01273688|Behavioral|Eccentric training (Flex-Bar)|6x15 repetitions of supination and pronation daily over 12 weeks
75783421|NCT01273688|Device|EpiHit elbow brace|daily wearing of the EpiHit elbow brace
75632337|NCT00693940|Other|Health education sessions|Health education will include weekly educational sessions on a health-related topic, lasting approximately 60 minutes each. After completing the health education sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
75632338|NCT02623894|Other||No intervention study is an observational study
75632339|NCT00696046|Procedure|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical & steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
76076636|NCT04373590|Behavioral|Decision aid|The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
76076637|NCT01683019|Device|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
75918924|NCT05445232|Drug|Warfarin|Administered orally.
76076638|NCT01683019|Device|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
75468222|NCT06069804|Drug|The TR group|Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
75632340|NCT00674518|Behavioral|One on one counseling|Motivational Interviewing
75632341|NCT00674518|Behavioral|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
75632342|NCT00674518|Behavioral|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
75918925|NCT05445232|Drug|Caffeine|Administered orally.
75918926|NCT05439291|Procedure|Regular Epilation Regimen|Epilation using laser device
75632343|NCT00607854|Drug|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
75918927|NCT05439291|Procedure|Surgical excision|Excision of pilonidal pit with trephine
75632344|NCT00694174|Drug|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
75783422|NCT01164800|Drug|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
75783423|NCT01164800|Drug|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
75783424|NCT01169012|Drug|Clofarabine|Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)
75783425|NCT03873896|Diagnostic Test|Stimulated skin wrinkling test|Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)
75783426|NCT03873896|Procedure|Digital Nerve Block|A digital nerve block is performed by injecting a total of 3 millilitres of 2% Lidocaine at the base of the ring finger of randomized hand of the volunteer. The effect of the block is confirmed clinically before proceeding with the study data collection. Please see the description for more details on the procedure
76076639|NCT03861507|Device|Prostate Brachytherapy|High dose - rate (HDR) brachytherapy
76076640|NCT02243644|Drug|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
76076641|NCT02243644|Drug|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
76076642|NCT01988883|Drug|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
76076643|NCT01988883|Drug|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
76076644|NCT01988883|Drug|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
76076645|NCT04373356|Device|Resin Infiltration|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
76076646|NCT04373356|Device|Sodium Fluoride Varnish|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
76076647|NCT03402412|Other|narrow-band UVB|Standard established treatment for atopic dermatitis with narrow-band UVB will be used in this study but initially only on a small amount of skin to assess what changes takes place in the skin.
75632345|NCT00694174|Drug|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
75632346|NCT00607932|Behavioral|behavioral dietary intervention|
75783427|NCT01169090|Drug|SK-0403|SK-0403
75783428|NCT01169090|Drug|Placebo|Placebo
75783429|NCT01169090|Drug|Sitagliptin|Sitagliptin
75783430|NCT01282502|Drug|Midostaurin|50 mg BID for 8 cycles
75783431|NCT01282580|Dietary Supplement|Lovaza-Omega 3 fatty acid capsules|The study will require monthly visits at 0, 1, 2 and 3 months of study intervention. At each visit a fasting serum sample will be obtained, self-report diaries (adverse events, record of omega 3 supplement doses or fish servings taken/missed) will be collected, and pill count / labels from cans of fish will be recorded. Medications and supplements will be reviewed with participants at each monthly visit. At clinic visits at 0 and 3 months, a history and physical examination and breast adipose fine needle aspiration (FNA)will be performed.Omega 3 supplements will be dispensed in monthly amounts.
75783432|NCT01282580|Other|Dietary fish (canned salmon, albacore)|Participants randomized to dietary fish will be asked to incorporate fish in the form of canned albacore and salmon into their diets at four 6 oz servings per week for 3 months. Participants on the dietary fish arm of the study will receive recipes using canned salmon and/or albacore. Sufficient canned salmon/albacore will be available for subjects who wish to prepare a meal for the family/household. Dietary intake will be assessed via 3 day diet records (0 and 3 months) and food frequency questionnaires (0 and 3 months). Verbal and written instructions on how to keep diet records, with food measured or weighed, will be given.
75783433|NCT01269242|Drug|bindarit|300 mg bid, that is one 300 mg tablet twice a day for 6 months;
75783434|NCT01269242|Drug|bindarit|600 mg bid, that is two 300 mg tablets twice a day for 6 months
75783435|NCT01269242|Drug|placebo|bindarit-matching placebo tablets for 6 months.
75783436|NCT01169714|Drug|0.1 mg PF-04995274|0.1 mg PF-04995274, qd, for 14 days or placebo
75783437|NCT01169714|Drug|1 mg PF-04995274|1 mg PF-04995274, qd, for 14 days or placebo
75918928|NCT05436366|Device|Soleus loading response in able-bodied participants|Able-bodied participants are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
76076648|NCT01745757|Drug|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
76076649|NCT01745757|Drug|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
75783438|NCT01169714|Drug|10 mg PF-04995274|10 mg PF-04995274, qd, for 14 days or placebo
76076650|NCT03402178|Drug|E2082|Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
76076651|NCT03402178|Drug|Placebo|Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
76076652|NCT01709162|Biological|Ipilimumab|
76076653|NCT01709162|Drug|Chemotherapy|
75632347|NCT00607932|Dietary Supplement|Brassica vegetable|
75632348|NCT00607932|Drug|indole-3-carbinol|follow up at 2,4,6 months post baseline.
75632349|NCT00607932|Other|counseling intervention|2, 4, 6 months post baseline
75632350|NCT00607932|Other|medical chart review|2,4,6 months post baseline
75632351|NCT00607932|Other|questionnaire administration|
75783439|NCT01169714|Drug|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
75783440|NCT01169714|Drug|1.0 mg PF-04995274|1.0 mg PF-04995274, qd, for 14 days or placebo
75632352|NCT00607932|Procedure|adjuvant therapy|
75632353|NCT00674596|Drug|ramipril|ramipril 10 mg/day during 3 months
75632354|NCT00674674|Drug|Topotecan|"Induction (4 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 3.~The Induction period is the first 4 weeks of therapy."
75783441|NCT01169714|Drug|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
75783442|NCT01274702|Other|Visual Reconstitutions Therapy|
75783443|NCT01274702|Other|Saccadic Eye Movement Training|
75783444|NCT01169792|Drug|tamoxifen|
75783445|NCT01169324|Other|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
75783446|NCT05343494|Behavioral|Lifestyle Intervention|"The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom."
75783447|NCT01169402|Drug|Fluconazole|25mg/kg intravenously once weekly while on ECMO
75783448|NCT01169480|Behavioral|Give a massage|Participants in this arm will give a 50-minute Swedish massage to a volunteer.
75783449|NCT01274780|Drug|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
76076654|NCT04764201|Drug|HIP2001|Test drug
76076655|NCT04764201|Drug|HGP2001|Reference drug
76076656|NCT02243800|Other|cholecalciferol versus placebo|
76076657|NCT04764123|Diagnostic Test|AVNRT mapping|AV annuli mapping during AVNRT
76076658|NCT03402100|Drug|eye drops|children who received daily eye drops for myopia
76076659|NCT01674309|Drug|FOLFORINOX|INTRAVENOUS administration
76076660|NCT02243956|Other|Flavanol rich food product|polyphenol rich test product
76076661|NCT04764045|Drug|Ropivacaine|Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
76076662|NCT01698554|Drug|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
76076663|NCT01698554|Drug|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
75325175|NCT03835013|Drug|Exenatide|Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes
75632355|NCT00674674|Drug|Topotecan|Consolidation (6 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 4. The Consolidation period is 6 weeks in duration. Consolidation begins immediately after completion of the 4th week of Induction.
75632356|NCT00674674|Drug|Topotecan|Maintenance (4 weeks for 11 courses): Patients will receive IT topotecan for 5 consecutive days during week 1. Each course of Maintenance is 4 weeks in duration. Maintenance begins immediately after completion of the 6th week of Consolidation.
75918929|NCT05436366|Device|Soleus loading response in participants with hemiparesis|Participants with spastic hemiparesis due to a stroke are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
75783450|NCT01274780|Drug|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
75783451|NCT01169870|Drug|Genexol-PM|Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
75918930|NCT05427344|Other|Water exercise group|Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi.
76076664|NCT01698554|Drug|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
76076665|NCT01698554|Drug|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
76076666|NCT03401944|Drug|TPN|
75325176|NCT05568303|Behavioral|CBT techniques|through CBT sessions , the participants apply problem solving process in managing their stressors . examining the role of cognitions, emotions, and behaviors to form cause and effect relationship of participants psychological distress
75325177|NCT04546737|Other|Magnetic Resonance Spectroscopy (MRS).|This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal allowing to measure under curves areas, amplitudes, ratios and concentrations of various metabolites contained in a biological tissue, in addition to water and lipids. This offers the possibility, in addition to the contribution of MRI imaging, to better characterize pathological processes (inflammatory, infectious, etc.) through spectral and metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will be carried out with a mono-voxel spectroscopy using a PRESS [Point RESolved Spectroscopy] sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE of 288 ms.
75325178|NCT05553561|Procedure|IPRL device|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
75325179|NCT05553561|Procedure|pharmacological therapy & Eyelid hygiene|traditional methods of MGD treatment as Eyelid hygiene, topical preservative free lubricant, topical & systemic antibiotics & anti-inflammatory agent
75325180|NCT00421629|Behavioral|After-sales service and supportive supervision (AfterSS)|
75632357|NCT00606996|Behavioral|Group interpersonal psychotherapy (IPT-G)|
75632358|NCT00606996|Behavioral|Psychoeducation on co-occurring disorders (PSYCHOED)|
75632359|NCT02628730|Device|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
76076667|NCT03401944|Other|Control|
76076668|NCT04404855|Other|NGS + Antibiotic Recommendation|NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist
76076669|NCT04404855|Procedure|Standard of Care treatment|Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.
76076670|NCT03401866|Diagnostic Test|DSC-MRI|"The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes."
75783452|NCT01169870|Drug|Paclitaxel|
75783453|NCT03873428|Other|FES PET|FES injection
75783454|NCT01169948|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
75783455|NCT01165970|Drug|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
75632360|NCT02628730|Device|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
75632361|NCT00605436|Behavioral|Restorative yoga therapy|3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
75783456|NCT01165970|Device|Saliva natura|Saliva substitute without restriction to be used
75632362|NCT02628886|Biological|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
75632363|NCT02628886|Biological|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
75632364|NCT02628886|Other|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
75918931|NCT05427344|Other|Land exercise group|Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land.
75918932|NCT05427344|Other|Control group|Control group who will not perform additional physical activity or receive any extra treatments.
75918933|NCT05421715|Other|TELEDUC-DIAB|"Systematic monthly remote monitoring between traditional face-to-face consultations by a medical researcher using Kidia and My Diabby digital devices:~With downloading by the adolescent of all data on My Diabby platform (clinical data from diabetes monitoring)~Evaluation of adverse events related to the treatment of diabetes (hospitalizations and concomitant treatment)~Analysis of data collected via My Diabby and Kidia: glycemic balance, captured data, connection frequency, alerts and alarms, diabetes knowledge)~The proposal of a therapeutic education session according to the needs of the adolescent via the Kidia application~Treatment adaptation~A follow-up in case there is an alert identified by the teenager, the relative or My Diabby/caregiver~The medical orientation of the patient according to the needs identified~A proposal for a therapeutic education session according to the needs of the adolescent via the Kidia application"
75632365|NCT04265508|Other|Assessment of hemostatic profile|To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
76076671|NCT04763733|Other|laparoscopic splenectomy|surgical
76076672|NCT04376866|Drug|Toripalimab|anti-PD-1 antibody
76076673|NCT00895791|Device|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
75632366|NCT02623738|Drug|Placebo ophthalmic solution|
75632367|NCT02623738|Drug|DE-117 ophthalmic solution low|
75632368|NCT02623738|Drug|DE-117 ophthalmic solution high|
75632369|NCT02623738|Drug|Latanoprost ophthalmic solution 0.005%|
75632370|NCT00607074|Drug|Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
75632371|NCT00607074|Drug|Anti-Giardia treatment only (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
75325181|NCT00421629|Behavioral|Prospective reimbursement (PR)|
75325182|NCT00421629|Behavioral|Both (AfterSS and PR)|
75632372|NCT00607074|Drug|Control group (placebo)|Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
75632373|NCT02623582|Biological|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
75632374|NCT02623582|Drug|Cyclophosphamide|Given IV
75783457|NCT01282736|Behavioral|Integrative Response Therapy|A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
75783458|NCT01282736|Behavioral|Cognitive Behavioral Therapy|A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
76076674|NCT00895791|Device|culotte stenting (Xience V)|implantation of stent
75325183|NCT04499157|Drug|MEMOPTIC|Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
75325184|NCT04499157|Drug|usual treatment of glaucoma|Patients will receive only their usual treatment of glaucoma.
75783459|NCT01166048|Drug|Duloxetine|"Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)~day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg~day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg"
75783460|NCT01166048|Drug|Duloxetine|2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
75783461|NCT01282892|Procedure|excess of visceral fat|excess of visceral fat
75783462|NCT01282892|Procedure|patients with NAFLD|patients with NAFLD
75325185|NCT04481061|Genetic|Electronic Decision Tool|Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.
75632375|NCT04264416|Device|WB-EMS|16 weeks of WB-EMS
75632376|NCT02623660|Device|ODIN1|"Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.~All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges."
75632377|NCT02623660|Other|Standard Care|Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
75632378|NCT02623660|Device|Diagnostic Device Testing|Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
75632379|NCT04264494|Procedure|PRP intra articular injection|Fifty RA patients were injected intra-articularly with 3 doses of PRP at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6 months post the last injection regarding the same evaluating tools.
75632380|NCT04264494|Procedure|NACL intra articular injection|and 50 patients who serve as a control and injected intra-articularly with 3 doses of placebo (NaCl saline) at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6months post last injection regarding the same evaluating tools.
75918934|NCT05420805|Dietary Supplement|ALAC, inulin, FOS, and sodium butyrate|Pre- and post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
75918935|NCT05420805|Dietary Supplement|Sodium butyrate and zinc oxide|Post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization, as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
75468223|NCT06069804|Drug|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
75632381|NCT04047316|Device|Digital dermoscopy|Acquire skin images with a new digital dermatoscope
75468224|NCT06069739|Behavioral|Guided physical activity|To achieve the European guidelines of 150 minutes by week of moderate intensity physical activity, participants randomized to the GPAG condition were prescribed three 60 minutes exercise sessions (five minutes of warm-up and five minutes of cool-down for a total of sixty minutes per session) per week for 12 weeks. Exercise consisted of brisk walking in urban and rural open spaces during which heart rate monitors were worn and participants were instructed to stay within their moderate intensity range. The incentives were different proposals for specific exercises to train the different musculoskeletal areas more comprehensively. Autonomous exercise was monitored offside the sessions through a series of weekly checkpoints.
75632382|NCT00696124|Biological|VM202 2mg|2mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
75632383|NCT00696124|Biological|VM202 4mg|4mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
75468225|NCT06069739|Behavioral|Standard physical activity|"Participants randomised to the SPAG performed their usual daily activities and continued with their daily routine.~Both conditions were matched for duration of physical activity. Participants in both conditions were required to attend three on-site sessions by week over 12 weeks that served as checkpoints. Moreover, both conditions were provided with brief healthy lifestyle counseling at baseline."
75632384|NCT00696124|Biological|VM202 8mg|8mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
75632385|NCT00696124|Biological|VM202 16mg|16mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
75632386|NCT04264650|Behavioral|an mHealth intervention|The Care & Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
75632387|NCT05379660|Device|transcutaneous electrical acupoint stimulation|Basing on the theory of traditional Chinese medicine, bilateral Zusanli (ST 36), Shangjuxu (ST 37) and Sanyinjiao (SP 6) are elected as the acupuncture points,the electrode pads with wire are attached to the corresponding acupoints, which are connected with Hwato electric acupuncture treatment instrument,TEAS stimulation uses a dense-dispersed wave with frequencies of 2 and 100 Hz alternating every 3 s, and the intensity 5 ~ 12mA,on the first and second days after surgery, the doctor who is responsible for acupuncture will arrive at the ward in the morning and afternoon to administer TEAS stimulation at the same acupoints for 30 min in the TEAS groups
75783463|NCT03869762|Drug|Xgeva|Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer induced bone destruction.
75783464|NCT03869762|Drug|Xtandi|"Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.~Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression."
75632388|NCT00605514|Drug|VRC-EBODNA023-00-VP|
75632389|NCT00605514|Drug|VRC-MARDNA025-00-VP|
75632390|NCT04135534|Drug|group A|mutonpain 0.05 mg/kg
75632391|NCT04135534|Drug|group B|mutonpain 0.1 mg/kg
75632392|NCT04135534|Drug|group C|mutonpain 0.2 mg/kg
75632393|NCT00696202|Drug|Mirena (BAY86-5028)|Intrauterine levonorgestrel containing device (market product)
75632394|NCT00608010|Procedure|Vitrification|Embryos were vitrified according to a previously described technique
75632395|NCT00608010|Procedure|Slow freezing|Embryos were frozen with slow freezing technique
75783465|NCT01283126|Procedure|euglycemic and hypoglycemic clamp|Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
75783466|NCT03873350|Other|Consumption of kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of living kombucha daily for three weeks.
75632396|NCT00608088|Behavioral|Usual Care|"The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls."
75918936|NCT05395533|Drug|Recombinant CD20 monoclonal antibody-MMAE conjugte for injection|The dose of the enrolled subjects was increased according to the following 7 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg. (according to the data of the previous study, when the dose climbs to 1.5 mg / kg, there is a serious decline of neutrophils, which shall be subject to the principle of 3 + 3.
75468226|NCT06069700|Other|Non-pharmacological Individualized rehabilitative therapy|Treatments will be standardized but components of the treatments will be individualized to the participants based on what subgroup they're classified into at baseline based on their initial clinical examination and self-reported dominant impairment. *Physiological group - Participants will receive supervised sub-symptom aerobic exercise 20-minutes twice per week and mindfulness-based training 20-minutes twice per week. *Cervical group - Participants will receive physical therapy to the cervical spine. Physical therapy will include soft tissue therapy directed to the cervical myofascial tissues, and graded cervical spine facet mobilizations. *Vestibulo-Ocular group - Patients classified to vestibulo-ocular subgroup will receive bi-weekly 30-minute individualized oculomotor, vestibular and balance exercises including adaptation exercises, gaze stability exercises, visual-vestibular integration exercises, habituation exercises, static and dynamic balance exercises.
75468227|NCT06069700|Other|Non-pharmacological Usual care therapy|"All participants in the active control group will receive 'usual care', (twice a week for 6 weeks), which will consist of reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour. Additionally, participants will be afforded weekly 20-minute supervised progressive sub-symptom aerobic exercise sessions at the KITE clinic under the supervision of study coordinator NM. They will be instructed to also perform daily 20-minutes of subsymptom aerobic exercise outside the supervised exercise sessions."
75632397|NCT00608088|Behavioral|Community Health Nurse/Peer Councelor Team|"Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months."
75632398|NCT00674752|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
75632399|NCT00674752|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
75632400|NCT00674752|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
75632401|NCT05370456|Device|Local application of a HA gel for the treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction and HA gel will be applied.
75632402|NCT05370456|Procedure|Treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
75632403|NCT05298514|Other|Not applicable - qualitative research study|We are not delivering interventions. This is a qualitative study in the form of focus groups.
75632404|NCT00674830|Behavioral|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
75783467|NCT03873350|Other|Consumption of heat-sterilized kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of heat-sterilized kombucha daily for three weeks.
75783468|NCT01282970|Drug|BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
75783469|NCT01282970|Drug|Placebo to BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
75468228|NCT06069674|Diagnostic Test|Serum dosage of GFAP and UCH-L1|blood test execution as per usual care in the ED
75468229|NCT06069661|Device|Aortic Stenosis|F2 Filter and Delivery system to cover the 3 great cerebral vessels
75468230|NCT06069648|Behavioral|printed screening decision aid|a booklet form of screening decision aid containing information of cervical cancer screening options
75468231|NCT06069648|Behavioral|a leaftlet|a leaflet containing information about healthy lifestyles
75632405|NCT00674830|Behavioral|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
75632406|NCT00674830|Behavioral|placebo|usual care
75632407|NCT05379582|Other|Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound|Once the critical ill patients is stable, enteral nutrition was initiated following a procedure assisted by gastrointestinal ultrasound.
75632408|NCT02623270|Device|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
75783470|NCT03869918|Other|Exercise Program|Exercise at home or through a class as chosen by the subject.
75783471|NCT01283048|Drug|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
75783472|NCT03873740|Biological|EV71 inactived vaccine（Vero cells）|The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.
75918937|NCT05395351|Drug|rt-PA|Recombinant Tissue Plasminogen Activator
75918938|NCT05387551|Device|CGM|Dexcom G6 sensor, transmitter and supplies will be provided to family for use. Participants will wear G6 and have real-time glucose data throughout the study.
76076675|NCT01674387|Device|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
76076676|NCT01674387|Other|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
75632409|NCT02623270|Device|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
75918939|NCT05378724|Device|Hospital Fit 2.0, HFITAPP0, release 05, Maastricht Instruments B.V., the Netherlands|Hospital Fit consists of a smartphone app combined to the MOX accelerometer. Hospital Fit provides patients and physiotherapists direct feedback on patients' physical activity behavior. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. Hospital Fit also gives patients insight into their own recovery process. During every treament, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
75632410|NCT00605592|Procedure|Pancreatic Islets of Langerhans Cell Transplant|Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
75632411|NCT00594100|Device|GORE Flow Reversal System (GFRS)|Carotid artery angioplasty and stenting with embolic protection
75918940|NCT05375643|Behavioral|SURGE|Video with or without person to person guidance to support decision making around genetic testing
76076677|NCT03401632|Other|Enteral nutrition|Enteral nutrition support
76076678|NCT01698320|Drug|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
75325186|NCT05364879|Behavioral|Prehabilitation Exercise Intervention|The exercise intervention will consist of light-to-moderate intensity aerobic, resistance, and mobility exercises. These exercises will be performed in a circuit type manner. Participants will perform similar exercises that are modified to meet their individual abilities. Exercise intensity, modifications and substitutions will be determined for each participant based on their medical history, 6 minute walk test results, and baseline frailty scores. Exercise sessions will be performed 3x/wk beginning at 30 min and progressing to 60-min as tolerated for a minimum of four weeks but will continue up until the time of the participants surgery. A hybrid approach will be used for the exercise sessions whereby the participant must attend the first exercise session in person and subsequent sessions will be delivered virtually. Sessions will be overseen by the study Clinical Exercise Physiologist.
75325187|NCT00800345|Drug|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
75325188|NCT00800345|Drug|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
76076679|NCT01698320|Drug|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
76076680|NCT03401554|Procedure|titanium mesh|closing the lateral window for maxillary sinus floor elevation with titanium mesh
75632413|NCT00607152|Drug|Rasburicase|0.20mg/kg per day IV
75468232|NCT06069648|Behavioral|mobile screening decision aid|a mobile app format of screening decision aid containing information of cervical cancer screening options
75632414|NCT00607152|Drug|Allopurinol|100mg tablets
75632415|NCT00696748|Drug|Nebido (testosterone undecanoate)|Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
75632416|NCT00696748|Drug|Placebo|Placebo 4 mL intramuscular
75632417|NCT00605670|Behavioral|questionnaires|patients will fill out two questionnaires post surgery
75632418|NCT00605670|Behavioral|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
75632419|NCT00696280|Behavioral|Functional Living Index - Emesis|
75783473|NCT03873740|Biological|EV71 inactived vaccine（Human diploid cells）|The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
75783474|NCT01172756|Drug|Riociguat (BAY63-2521)|0.5 mg single oral dose
75783475|NCT01172756|Drug|Riociguat (BAY63-2521)|1 mg single oral dose
75783476|NCT01172756|Drug|Riociguat (BAY63-2521)|2 mg single oral dose
75783477|NCT01172756|Drug|Placebo|single oral dose
75783478|NCT02525822|Drug|IDP-123 Lotion|Investigational Product: IDP-123 Lotion
75783479|NCT02525822|Drug|Tazorac Cream, 0.1%,|Comparator Product: Tazorac Cream, 0.1%
75783480|NCT02525822|Drug|Vehicle Cream|Comparator Product: Vehicle Cream
75783481|NCT02525822|Drug|Vehicle Lotion|Comparator Product: Vehicle Lotion
75783482|NCT01172834|Behavioral|Health Coaching|A manual-driven group Health Coaching intervention. Once a week for 3 months.
75783483|NCT01172912|Biological|filgrastim|
75783484|NCT01172912|Biological|pegfilgrastim|
75783485|NCT01172912|Drug|carboplatin|
75783486|NCT01172912|Drug|cisplatin|
75783487|NCT01172912|Drug|dexamethasone|
75783488|NCT01172912|Drug|etoposide|
75783489|NCT01172912|Drug|ifosfamide|
75783490|NCT01172912|Other|high-dose chemotherapy with autologous stem cell rescue|
75783491|NCT01172912|Other|laboratory biomarker analysis|
75783492|NCT01172912|Procedure|autologous hematopoietic stem cell transplantation|
75325189|NCT04479111|Procedure|laparoscopic ileocecus-sparing right hemicolectomy|The ileocecal artery(ICA) is skeletonized. The colic branch of ICA is divided and ligated. Preserve anterior cecal artery, posterior cecal artery and ileocecal branch of ICA. Divide and ligate the right colic artery(RCA) and middle colic artery(MCA) at their roots. Dissect the lymph nodes surrounding the ICA, RCA and MCA accordingly. Head-to-Head colocolic anastomois is done, with circular stapler via making an opening at the bottom of cecum.
75632420|NCT05363124|Other|PEWS calculation by parents using AI-based smartphone app|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. Explanations will be given to the parents regarding the use of the application and the way to calculate the PEWS through a very brief and standardized education. Parents should then proceed to the calculation of PEWS, as far as possible before the intervention of the nurse, using the Caducy® appl with a smartphone dedicated to the study .
75632421|NCT05363124|Other|PEWS calculation by nurse using conventional procedure|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. the nurse proceed to the calculation of PEWS in blind of parents and to triage process by priorityzing patient in 5 level of gravity (from 1-vital emergency to 5-nonurgent patient). If the medical examination was not proceeded directly after the triage process, nurses were asked to proceed a new triage if the optimal delay of the medical examination was passed.
75783493|NCT01172912|Procedure|peripheral blood stem cell transplantation|
75783494|NCT01283204|Drug|SP|"<Every 3 weeks>~Day 1~14 : TS-1 80mg/m2/day (PO),~Day 1 : CDDP 60mg/m2/day IVF 2hours,~Day 15~21 : Rest."
75468233|NCT06069635|Other|Fatigue protocol (repeated sprint ability)|The test performed on an outdoor field (artificial grass carpet) in the form of 6 repetitions of maximal 2× 15 m shuttle sprints interspersed with 20 seconds of passive recovery , Before the RSA protocol, all players perform a brief standardized warm-up (approximately 20 minutes long), in 1at submaximal speed (followed by 40 seconds of passive recovery The fatigue index (FI) used to characterize the RSA performance was calculated in terms of percentage decrement score At the end of the RSA protocol , usually the time elapsed between the end of the last sprint and the beginning of the measurements was no more than 20 seconds, to avoid masking effects related to progressive recovery from fatigue.
75783495|NCT01283204|Drug|FL/Tax|"<Every q 3 weeks>~Day1 : Paclitaxel 175mg/m2 IVF for 2hours~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
75783496|NCT01283204|Drug|FL/Doc|"<Every q 3 weeks>~Day1 : Docetaxel 75mg/m2 IVF for 1hour~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
75783497|NCT01283204|Drug|FOLFOX|<Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
75783498|NCT03869528|Drug|5 sprays of 10% lignocaine|5 sprays of 10% lignocaine
75783499|NCT03869528|Drug|10 sprays of 10% lignocaine|10 sprays of 10% lignocaine
75783500|NCT01166204|Radiation|Radiotherapy|Radiotherapy
75783501|NCT03869294|Drug|GS|Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
75783502|NCT01283360|Other|HEC Placebo Gel|The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
75783503|NCT01283360|Drug|Tenofovir 1% Gel|Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
75783504|NCT01172990|Procedure|Immediate Invasive Management|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
75783505|NCT01172990|Procedure|Conventional Management|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
75632422|NCT00674908|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
75632423|NCT00674908|Biological|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
75632424|NCT00607230|Biological|BCG|BCG vaccination at 0 and 4 weeks
75632425|NCT00607230|Biological|Saline|Saline vaccination at 0 and 4 weeks
75783506|NCT01173068|Drug|Ertapenem|Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.
75783507|NCT03267940|Drug|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arms.
75783508|NCT03267940|Drug|CIS|CIS will be administered as per the schedule specified in the respective arms.
75783509|NCT03267940|Drug|GEM|GEM will be administered as per the schedule specified in the respective arms.
75783510|NCT03267940|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arms.
75783511|NCT01284452|Drug|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
75783512|NCT01284452|Drug|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
75783513|NCT03873506|Drug|transplantation of hUC-MSCs|Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
75325190|NCT04788797|Drug|Prolyl Endopeptidase|Two capsules three times a day.
75325191|NCT04788797|Other|Placebo|Two capsules three times a day
75325192|NCT03806751|Drug|[O-15]Water|All study participants with undergo brain imaging with [O-15]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
76076681|NCT03401554|Procedure|collagen membrane|closing the lateral window for maxillary sinus floor elevaion with collagen membrane
76076682|NCT01674465|Biological|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m^2 two-three hours prior to their standard of care biopsy
75632426|NCT02621710|Other|Questionnaire 3 months post-operatively|
75632427|NCT04265118|Device|Sidewards Tilting Bed|Sidewards tilting of the bed is hypothesized to induce a body position change in sleeping subjects.
75468234|NCT06069635|Other|Sham Comparator: Control group|approximately 20 minutes long), which consisted of : 6 minutes of incremental running from 60% to 80% of maximal aerobic speed; 6 minutes of dynamic flexibility exercises; 2 minutes of forward, backward, and lateral jogging and high-knee and ''butt-kick'' runs; 2 minutes of shuttle sprints (5 m in 1 direction and 5 m in the opposite direction, repeated for 2 minutes) at submaximal speed (followed by 40 seconds of passive recovery); and 2 minutes of RSA protocol simulation at submaximal speed (2 repetitions), again followed by 40 seconds of passive recovery. take apenalty of water and rest
75468235|NCT06069622|Diagnostic Test|24-hour ambulatory blood pressure|24-hour ambulatory blood pressure, blood, and urine will be obtained prior to semaglutide therapy and after 20 weeks of semaglutide therapy.
76076683|NCT03401476|Drug|Morphine Sulfate|Morphine Sulfate Tablets
75632428|NCT02621632|Device|(Socknleg)To done of a novel compression system|To done a novel compression system.
75632429|NCT04264104|Other|neural mobilization|This is a type of mobilization that uses a specific combination of joint movements
75632430|NCT00696358|Radiation|308nm excimer lamp|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
75632431|NCT00696358|Radiation|308nm excimer laser|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
75632432|NCT05269212|Other|Usual Care trajectory|Usual care after Spinal Cord Stimulation implantation
75632433|NCT05269212|Other|A biopsychosocial rehabilitation program|A personalized biopsychosocial rehabilitation program specifically targeting return to work.
75632434|NCT02621554|Dietary Supplement|resveratrol supplementation|6 months of resveratrol supplementation
75632435|NCT02621554|Dietary Supplement|Placebo|6 months of placebo intake
75632436|NCT02623036|Drug|Equivalent dose enalapril|Chronotherapy with enalapril.
75783514|NCT03378128|Procedure|Diagnostic laparoscopy|The patient will initially undergo a diagnostic laparoscopy by a minimally invasive approach and entry method. The decision of which approach and entry to perform will be dictated by the primary surgeon of record's preference and their assessment of pre-operative patient factors. Once the primary surgeon determines the areas of macroscopic disease, he/she will make an assessment as to the need to convert to a laparotomy or continue laparoscopically. At the completion of the procedure, it will be noted whether an optimal cytoreduction (≤ 1 cm residual disease) or a sub-optimal cytoreduction (>1 cm residual disease) was performed.
75783515|NCT03866720|Other|Carbohydrate rich breakfast|A porridge breakfast meal fed at a carbohydrate delivery rate of 7.3 mg/kJ of each participants resting metabolic rate.
75783516|NCT03866720|Dietary Supplement|Whey protein enriched breakfast|A porridge breakfast meal in which 15 grams of whey protein is substituted in place of carbohydrate and a small portion of fat.
75783517|NCT03866876|Other|Eucapnic pH|Collection of Biological marker (proposed by Racinet): eucapnic pH
75783518|NCT04590430|Drug|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
75783519|NCT04590430|Other|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
76076684|NCT03884673|Drug|DTG+ 3TC|It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
75325193|NCT03806751|Drug|Acetazolamide|The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
75632437|NCT02623036|Drug|Equivalent dose lisinopril|Chronotherapy with lisinopril
75918941|NCT05355974|Drug|Norepinephrine|Norepinephrine continuous infusion at 0.10 mcg/kg/min
75325194|NCT04383275|Drug|capecitabine and trastuzumab|In IRIS-A cohort, patients who met the inclusion criteria(ER，PR<10%, T≤2cm or ER,PR ≥10% 1cm<T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
75325195|NCT04383275|Drug|endocrine therapy and trastuzumab|In IRIS-B cohort, patients who met the inclusion criteria(ER,PR ≥10% T≤1cm) would be given endocrine therapy (premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane) combined with standard trastuzumab for 1 year and complete endocrine therapy for 5 years.
75325196|NCT00355563|Device|PAS-Port Automated Proximal Anastomosis System|
75325197|NCT04453059|Drug|Iopamidol|Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)
75325198|NCT04383197|Behavioral|Endurance exercise training|Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
75325199|NCT04383197|Drug|Semaglutide|3 months of therapeutic treatment with semaglutide
75632438|NCT00696826|Drug|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
75632439|NCT01092182|Drug|EPOCH-R|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
75918942|NCT05355974|Drug|Lactated Ringers, Intravenous|500mL infusion run at 999mL/hr
75918943|NCT05355974|Drug|normal saline|500mL infusion run at 999mL/hr
75918944|NCT05355974|Drug|Plasma-lyte|500mL infusion run at 999mL/hr
75918945|NCT05348044|Other|Res-ET intervention|Remote IMST delivery on Resilience
75918946|NCT05340413|Drug|Olaparib|300mg twice daily
76076685|NCT04376944|Other|Survey|questionnaire on their symptoms and their exposures
76076686|NCT04548206|Other|Pilates training|The program consisted of core-based Pilates exercises on the mat for 60 minutes.
76076687|NCT04548206|Other|control|The program consisted of progressive relaxation exercises at home.
75468236|NCT06069622|Dietary Supplement|Liberal salt diet|Participants will be on a liberal salt (about 200 mEq sodium/day) diet for 7 days.
75468237|NCT06069609|Device|Kalifilcon a Contact Lens for Astigmatism|Kalifilcon A Daily Disposable Toric Contact Lens for Astigmatism
75632440|NCT01092182|Drug|EPOCH-RR|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 3 cycles
75325200|NCT04445493|Device|MindRhythm Harmony|Passive recording of the head pulse
75325201|NCT04009811|Device|Suersen and membraneous obturators evaluation|"The patient will wear one month each obturator prothesis (Suersen and membraneous obturators). The order of evaluation will be randomized in two arms.~Half of patient will first wear one month the membranous obturator then one month the Suersen, the other half of patient will first wear one month the Suersen obturator and one month the membranous obturator."
75325202|NCT03796065|Behavioral|FSI-R Treatment|The FSI-R involves a series of separate and joint meetings with parents and children to discuss challenges the family has faced and the strengths that helped them make it through past challenging times. Additional psychoeducation on mental health and promoting resilience along with coaching to enhance parenting skills is provided throughout and may be tailored to family needs. The FSI-R provides a shared space for refugee families both to recognize their strengths and to problem-solve in a more collective way on family challenges and shared hopes for the future. The FSI-R is delivered in the home, by a trained interventionist, over the course of 10-modules.
75632441|NCT02623192|Other|Patients who have performed the ARDS pulmonary function test|
75632442|NCT04135378|Drug|ascorbic acid|Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
75632443|NCT04135378|Other|placebo|:- included 30 students given placebo for one week before presentation.
75632444|NCT02878772|Drug|vinpocetine|30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
75783520|NCT01170026|Behavioral|Family Check-up/ Individual MI|The 2-session intervention protocol consists of an individual motivational interview plus the Family Check-Up (Dishion & Kavanagh, 2003), a family based motivational interview. The experimental protocol provides a thorough assessment of both individual and family strengths and weaknesses with respect to substance use prevention and school attendance/performance.
75783521|NCT01170026|Behavioral|Individual and family psychoeducation|Families in PE will return for the same number of visits as the IMI and FCU sessions of the IMI/FCU condition. An interventionist will review a set of educational materials with the parents regarding teen SU use, truancy and risk behaviors and parenting a teenager. A similar set of materials will be reviewed with the adolescent
75325203|NCT04441983|Diagnostic Test|7 Tesla MRI of the foot|7 Tesla MRI
75918947|NCT05333796|Behavioral|gait with leg length discrepancy|After attaching the surface electromyography(EMG) to bilateral back muscles, participants walk at a comfortable speed. The investigators will evaluate the effects of leg length discrepancy on the back muscle activation during gait.
75325204|NCT03973229|Drug|Estradiol patch|Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
75325205|NCT03973229|Other|Placebo patch|Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
75325206|NCT05236595|Other|Individualized drug matching per genetic disease|Patient phenotype and samples will be evaluated for individualized therapeutic drug development
75325207|NCT03782103|Drug|ZuraPrep Clear Solution|Apply topically.
75325208|NCT03782103|Drug|ChloraPrep|Apply topically.
75325209|NCT03782103|Drug|ZuraPrep Vehicle|Apply topically.
75325210|NCT05319015|Drug|Neoadjuvant Lenvatinib|20 mg PO daily for 12 weeks prior to surgery
75325211|NCT05319015|Drug|Neoadjuvant Pembrolizumab|200 mg IV every 3 weeks for 4 doses prior to surgery
75468238|NCT06069609|Device|Acuvue Oasys 1-Day for Astigmatism|Commercially available contact lenses: Acuvue Oasys 1-Day for Astigmatism
75632445|NCT02878772|Drug|Aspirin|100mg, once daily, oral medication
75632446|NCT02623114|Drug|methylphenidate|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
75632447|NCT02623114|Drug|atomoxetine|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
75632448|NCT00932646|Drug|BI 1744 (Olodaterol) Low Dose|BI1744 Respimat low dose once daily and placebo Foradil
75918948|NCT05328947|Other|Modified Functional Reach and Functional Reach|Establishment of Modified Functional Reach Test (mFRT) and Function Reach Test (FRT) values for individuals with no functional impairments.
75918949|NCT05323955|Drug|Trastuzumab|Administer per current package insert based on site standard of care guidelines
75918950|NCT05323955|Drug|Trastuzumab Emtansine (T-DM1)|Administer per current package insert based on site standard of care guidelines
75918951|NCT05323955|Drug|Pertuzumab|Administer per current package insert based on site standard of care guidelines
75918952|NCT05323955|Drug|Tucatinib|300 mg orally twice daily (21 Day Cycle)
75918953|NCT05322824|Drug|standard medical treatment|standard medical treatment
75632449|NCT00932646|Drug|BI 1744 (Olodaterol) Medium Dose|BI1744 Respimat medium dose once daily and placebo Foradil
75632450|NCT00932646|Drug|Placebo|Placebo Respimat once daily and placebo Foradil
75632451|NCT00932646|Drug|Foradil|12 mcg twice daily and placebo Respimat
75632452|NCT02878460|Other|monitoring with ORI + SpO2|"If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is < lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
75918954|NCT05322824|Procedure|Interventional stenting|Interventional stenting
75325212|NCT05319015|Procedure|Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection|Resection of locally advanced RCC with IVC tumor thrombus
75632453|NCT02878460|Other|monitoring with SpO2|"If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is < lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
75918955|NCT05322408|Drug|HCW9218|HCW9218 at the assigned dose level is administered as a subcutaneous injection once every 3 weeks for a minimum of 2 treatment cycles unless medically contraindicated.
75918956|NCT05316519|Other|Transcutaneous Vagus Nerve Stimulation|Visuomotor task training with transcutaneous stimulation targeting landmark that activates biomarker
75632454|NCT00871234|Drug|Etravirine|Two one-hundred mg tablets orally twice daily for four weeks
75632455|NCT04941482|Behavioral|Periodic health check program for post-stroke|The stroke survivors will be assessed their physical and mental health, recurrence risks, and harmful behaviors at 0, 1, 3, and 6 months by specific scales.
75632456|NCT04941482|Behavioral|Guiding the appropriate rehabilitation exercises|The appropriate rehabilitation exercises will be designed and guided for each patient and they will be followed up by the daily online report.
75632457|NCT04941482|Behavioral|Motivational Interviewing|Motivational Interviewing will carry out on post-stroke patients in the first three months (one time per week in the first month and one time per the second and third month). This intervention method aims to discover and resolve patient's conflicts by a standardized communication skill to improve their mental health and change negative behaviors.
75632458|NCT04941482|Device|Functional near-infrared spectroscopy|The fNIRS devices as an effective monitoring and therapeutic tool, evaluating the evolution of neural activity and stroke rehabilitation and recovery. Moreover, the cortex hemodynamic measure by fNIRS may detect early various mental disorders such as depression, anxiety, schizophrenia... through cognitive tasks.
75918957|NCT05316051|Device|Inverted foot orthoses|Inverted functional orthoses will be used in this study based on Blake (1986) inverted orthotic technique. Two groups of foot orthosis will be fabricated with two different inverted angles: 25° inverted angle and 15° inverted angle.
75783522|NCT03296566|Behavioral|Patient Liaison|An experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy report will inform the referring provider that these patients will be informed of the results. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients. She will forward any patient questions beyond her scope to the patient's colposcopist who may then provide answers to the patient liaison or to the patient directly depending on the complexity and nature of the question.
75918958|NCT05312385|Drug|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
75918959|NCT05312385|Drug|Propofol|Intravenous infusion of propofol
75468239|NCT06069583|Behavioral|Support platform|"The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar.~Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D."
75468240|NCT06069505|Diagnostic Test|Aspergillus PCR|Aspergillus PCR will be performed on different volumes of serum and plasma of patients with hematological malignancies with suspicion for invasive fungal infection.
75783523|NCT01170104|Drug|Sorafenib|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
75783524|NCT01170104|Procedure|TACE (Transcatheter arterial chemoembolization)|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
75918960|NCT05309031|Other|Water Immersion|Participants will enter the pool, which has a thermoneutral temperature of 33°C (92°F), warm enough to be comfortable, but cool enough to avoid an increase in HR with similar ambient air temperature. A maximum depth of 4 to 4 feet 6 inches allows ample room participants to be immersed to the chest, float vertically and move in the pool. During 45 min of immersion, they will be instructed to stand, walk and move ad lib. Noodles will be available to hang or rest on in a vertical position. Taller participants will remain at the pool's deep end. The timeframe was chosen to approximate our previous immersion intervention length.
75918961|NCT05296590|Diagnostic Test|Monocyte Distribution Width (MDW) , observation|Observation of MDW performance blinded to treating clinical teams
75918962|NCT05293405|Diagnostic Test|18F-DPA-714 PET|TSPO expression are quantitatively analyzed in all brain regions or spinal cord using 18F-DPA-714 PET
75918963|NCT05289193|Diagnostic Test|PET Scan|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
75918964|NCT05289193|Drug|Nivolumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
75918965|NCT05289193|Drug|Ipilimumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
75325213|NCT05319015|Drug|Adjuvant Pembrolizumab|200 mg IV every 3 weeks for up to 13 doses after surgery
75325214|NCT00810719|Drug|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
75468241|NCT06068075|Other|FoundationOne Liquid CDx|a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center
75632459|NCT04135612|Other|Smartphone based communication|Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles.
75632460|NCT02877914|Other|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
75632461|NCT00675064|Drug|GSK369796|Anti-malarial
75325215|NCT00810719|Drug|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
75632462|NCT00675064|Drug|Placebo|Placebo matching GSK369796
75918966|NCT05289193|Procedure|Surgical Resection of Melanoma|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
75918967|NCT05283811|Device|NEUROPACE RNS SYSTEM|This device is indicated as a therapy in reducing the frequency of seizures in individuals
76076688|NCT04372810|Procedure|High Velocity Low Amplitude manipulation (HVLA)|The thrust manipulation technique was used, which consists of high speed and small amplitude manipulation. The therapeutic intervention was performed through decompressive maneuvers for the tibiotarsal joints. The choice of the place of application of the manipulation technique was delimited by the identification of the area or areas with compressive compartmental impairment and joint restriction. The use of the method depended directly on the identification of one or more regions of joint restraint.
75632463|NCT02879240|Other|Animated Cartoon|An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.
75468242|NCT06067594|Diagnostic Test|Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement|Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
75468243|NCT06067113|Procedure|Supraaortic and transcranial duplex|Ecographic evaluation of supraaortic and transcranial arteries, including presence of plaques, flow velocities and pulsatility index
75632464|NCT02879240|Other|Black screen|A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.
75632465|NCT04267224|Drug|Ticagrelor 90mg|Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.
75632466|NCT00675142|Procedure|Intrauterine Insemination|Changing the time span between ovulation induction and IUI during fertility treatment.
75632467|NCT04267068|Behavioral|Growth Mindset and Modifiable Risk Factor Information|15 minute interactive article describing neuroplasticity followed by 15 minute interactive article describing modifiable risk factors for depression and anxiety
75632468|NCT04267068|Behavioral|Control|30 minute interactive article describing symptoms of depression and anxiety, common concerns of college student
75632469|NCT00675220|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75918968|NCT05283811|Behavioral|EMU|Patients are admitted to the Epilepsy Monitoring Unit for observation of seizure activity prior to further treatment
75918969|NCT05274152|Device|Immersive Virtual Reality Lower Limb and Knee Rehabilitation|Patients wore a VR headset while undergoing their rehabilitation session
76076689|NCT04372810|Procedure|Care assessment and guidance|Evaluation and care guidelines on glycemic control and diabetic foot care.
75325216|NCT03835845|Device|PICO7Y|The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
75468244|NCT06066918|Drug|Pregabalin 75mg|Pregabalin 75 mg twice a day
75468245|NCT06066866|Other|endoscopic sampling of luminal fluid|We will collect luminal fluid via endoscopic sampling
75468246|NCT06066775|Other|Observation study without intervention|Observation study without intervention
75468247|NCT06066489|Other|educational program about VAP|An educational program about VAP that includes VAP bundle from CDC as core measures , equipment related measures and general measures.
75632470|NCT00608400|Dietary Supplement|Clarinol CLA|0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
75632471|NCT04152304|Other|Sinex program (neuromuscular training program)|The SINEX program is a three months neuromuscular training program aiming to increase neuromuscular stability of the shoulder
75632472|NCT04152226|Drug|J. Lividum|Investigational Product
75632473|NCT00607308|Biological|PF-04360365|Single dose of 0.1 mg/kg IV on Day 1
75632474|NCT00607308|Biological|PF-04360365|Single dose of 0.5 mg/kg IV on Day 1
75632475|NCT00607308|Biological|PF-04360365|Single dose of 1 mg/kg IV on Day 1
75632476|NCT00607308|Biological|PF-04360365|Single dose of 5 mg/kg IV on Day 1
75632477|NCT00607308|Drug|Placebo|Single dose of placebo IV on Day 1
75632478|NCT00607308|Biological|PF-04360365|Single dose of 10 mg/kg IV on Day 1
75918970|NCT05269407|Device|Peripheral perfusion index|"The study aimed to generate a model relating pre-spinal perfusion index to the likelihood and severity of the reduction in blood pressure in the first 20 min after spinal injection.~A correlation between the delta PI and the delta SBP (the difference between the baseline maternal systolic blood pressure and the lowest blood pressure)will be investigated to establish a predictive model to define cut-off values at which perfusion index variation indicated a low risk (no or mild hypotension groups) or a high risk (moderate, severe groups) of reduction in blood pressure.. The incremental change of a measure PI, the ΔPI will be calculated as the absolute change in PI between supine and sitting positions, ΔPI=PIsupine-sitting. The relative change in PI the rPI, will be expressed as the percentage of change in PI, rPI=ΔPI/PIsitting× 100."
75918971|NCT05269238|Other|performing lumbar punctures by students with standard training|performance of the puncture by the student have been previously trained with standard training
75325217|NCT04369443|Procedure|Large volume Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
75325218|NCT03761277|Device|Medtronic SynchroMed™ II infusion system|Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).
75325219|NCT03761277|Drug|Preservative-free morphine sulfate (PFMS)|The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
75632479|NCT04135144|Other|Group 1 (printed materials)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
75632480|NCT04135144|Other|Group 2 (video phone reminder)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
75632481|NCT00605748|Procedure|Segmental PV-Isolation of the arrhythmogenic vein(s)|isolation of pulmonary veins for curing atrial fibrillation
75783525|NCT01283672|Other|Controlled diet with whole grain barley, whole grain oats, or low grain diet|Participants will consume a standardized diet for 3 days prior to the treatment intervention meal. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. Participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
75783526|NCT00455104|Other|No intervention|This is an observational, voluntary registry.
75783527|NCT01284764|Drug|Mosapride|Mosapride 10mg, one dosage, once evening of the day before the endoscopy
75783528|NCT03866330|Biological|Intraarticular injection of WJMSC|ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure
75783529|NCT01166516|Device|Treatment with HUD IBV Valve System|Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
75918972|NCT05269238|Other|training students augmented reality simulator|performance of the puncture by the student have been previously trained using the augmented reality simulator
75325220|NCT04348929|Other|Self-administered questionnaires|Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
75325221|NCT03720795|Behavioral|Stepped Care CBT|"Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions."
75325222|NCT00810797|Drug|exemestane|Given orally
75325223|NCT00810797|Other|laboratory biomarker analysis|One year after completion of study treatment
75325224|NCT00810797|Procedure|quality-of-life assessment|One year after completion of study treatment
75632482|NCT00605748|Procedure|Segmental PV-Isolation of all veins|isolation of pulmonary veins for curing atrial fibrillation
75632483|NCT01091246|Biological|Q/LAIV (MEDI3250)|10 ^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
75783530|NCT01173224|Drug|Placebo|Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
75783531|NCT01173224|Drug|DAS181|DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
75783532|NCT01283750|Behavioral|care coordination|dementia-related care coordination
75783533|NCT01278212|Radiation|accelerated hypofractionated radiotherapy (AHF-RT)|30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
75783534|NCT03755882|Device|ACUVUE® DEFINE™ Vivid Style|TEST Lens
75783535|NCT03755882|Device|LACELLE™ Sparkling Brown|CONTROL Lens
75918973|NCT05269108|Procedure|Fluoroscopy-free RIRS|RIRS for renal stone under direct visualization, without fluoroscopy
75918974|NCT05269108|Procedure|Standard RIRS|RIRS for renal stone under fluoroscopy-guidance
75632484|NCT01091246|Biological|FluMist/B/Yamagata|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
75632485|NCT01091246|Biological|FluMist/B/Victoria|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
75325225|NCT00810797|Other|immunohistochemistry staining method|Correlative studies
75325226|NCT04340505|Drug|Fluocinolone Acetonide|Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.
75325227|NCT03677739|Other|Informational Intervention|Receive information focusing on skin cancer
75325228|NCT03677739|Other|Informational Intervention|Receive information on healthy lifestyle
75325229|NCT03677739|Other|Survey Administration|Ancillary studies
75632486|NCT02622958|Drug|PH94B|"PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
75632487|NCT02622958|Other|Placebo|"Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
75632488|NCT05260086|Device|Neuronavigated aiTBS|Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)
75632489|NCT02622880|Dietary Supplement|immunomodulatory supplement|Experimental Group (immunomodulatory supplement STUDY)
75918975|NCT05259137|Drug|Intralesional enalaprilat injection|1.0 mL of 1.25 mg/mL enalaprilat
75918976|NCT05258383|Other|3D maps of physical doses|3D maps of physical doses delivered to organs by positioning imaging will be calculated based on the patient's CT image used by the treatment planning system (dosimetric calculation performed by Monte Carlo method).
75918977|NCT05258370|Other|Dosage|Evaluation of circulating C-terminal FGF23 (FGF23Ct) rate, circulating intact FGF23 (FGF23i) rate and Erythropoietin
75918978|NCT05258370|Other|Cardiac echography|12 months after patient enrollment
75918979|NCT05256134|Drug|Gantenerumab|Gantenerumab will be administered as per the dosing schedule described in the Arm description.
75918980|NCT05256134|Drug|Placebo|Placebo will be administered as per the dosing schedule described in the Arm description.
75918981|NCT05255250|Behavioral|PLAYshop|The intervention includes: 1. Educational Training - the 60 min virtual workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be sent physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
75918982|NCT05245656|Drug|RB/RBAC alternating|"Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~Rituximab 375mg/m2, IV, D1~Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~Rituximab 375mg/m2, IV, D1~Bendamustine 70mg/m2, IV, D2-3~Cytarabine 500mg/m2, IV, D2-4"
75632490|NCT02622880|Dietary Supplement|IMPACT|IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
75632491|NCT04267146|Drug|Nivolumab|"Solution for intravenous injection 10 mg/ml. Initial dose : 3 mg/kg Nivolumab will be given at 3 mg/kg/injection every two weeks from the first day of radiotherapy to the last day of chemotherapy.~One de-escalation dose : 1 mg/kg"
75632492|NCT04267146|Drug|Temozolomide|Capsules: 5, 20, 100, 140, 180 and 250 mg orally. Temozolomide will be given at 75mg/m2/day from the day of start of radiotherapy to the last day of radiotherapy, then, after one month rest at 200mg/m2/day for five consecutive days for 12 cycles (28 days cycle).
75632493|NCT04267146|Radiation|Radiotherapy|Total dose of 54 Gray(Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation period.
75468248|NCT06066307|Other|Olfactory training|Olfactory training will be performed by sniffing four specific essential oils twice daily for 30 seconds each. Participants are encouraged to visualize the item they are smelling, while they perform the procedure, in a quiet room, with their eyes closed. The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol).
75468249|NCT06066294|Biological|Regimen 1|WHO Pre-qualified rabies vaccine (Rabivax-S), WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7
75325230|NCT03955913|Other|Archival Tumor Tissue Sample|Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue.
75325231|NCT00355641|Drug|Ropinirole Extended Release (XR)|Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
75468250|NCT06066294|Biological|Regimen 2|WHO Pre-qualified rabies vaccine (Rabivax-S), Government of India approved vaccination schedule, 3 visits, 0.1ml 1 site on day 0, 7 and 28
76076690|NCT01674543|Other|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
76076691|NCT01674543|Other|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
76076692|NCT01674543|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
75632494|NCT00912106|Other|Synovial fluid composition and lubrication analysis|Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
76076693|NCT01674699|Device|EXCOR Pediatric|Ventricular Assist Device
76076694|NCT01674777|Drug|ASP1941|oral
76076695|NCT03876717|Drug|Colesevelam Hydrochloride|Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
75325232|NCT04624763|Procedure|Left bundle branch pacing|"LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~One of the following should be met:~Selective LBBP with an iso-electrical window between the pacing spike and QRS onset;~If using dual-lead method with one at His-bundle and the other at LBB region, a retrograde His-bundle potential is recorded from His-bundle lead during LBBP;~LVATs at lead tip pacing of 1.5V/0.5ms and 10V/0.5ms are ≤ 80ms and the difference is < 10ms;~A discrete LBB potential is recorded from lead tip and LVAT at tip pacing of 3V/0.5ms is ≤ 80ms19.~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
76076696|NCT03876717|Drug|Placebo oral capsule|Inactive placebo tablets over-encapsulated with DB caps AAA
75325233|NCT04624763|Procedure|Right ventricular pacing|Implantation of a RV pacing lead is attempted using the standard-of-care technique first.
75632495|NCT04263324|Behavioral|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care.
75632496|NCT05258214|Other|Mulligan Bent Leg Raise|Mulligan's bent leg raise, as well as the extreme Straight Leg Raise, can be used to relieve Low Back Pain. It can be used to treat leg discomfort that is above the knee. Bent Leg Raise methods are used where there is a restricted range of motion in the hip flexion joint, as well as low back pressure with or without referred leg pain.
75632497|NCT05258214|Other|Mulligan Traction Straight Leg Raise|Mulligan traction leg raise exercises are a non-invasive treatment that has been shown to help people with low back pain and reduced hip flexion range. Conservative sciatica therapy focuses on pain relief, but increasing Straight Leg Raise range will help restore normal mobility and reduce the severity of low back disability.
76076697|NCT01674855|Drug|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
75632498|NCT05258214|Other|Neural Mobilization|These techniques are designed to mobilize a nerve with as little pressure down, resulting in a larger longitudinal excursion than techniques that actually lengthen the nerve bed, such as tensioning procedures.
75632499|NCT00626132|Dietary Supplement|Eucommia|two capsules three times a day orally for 2 weeks
75783536|NCT01585688|Drug|hLL1-DOX (IMMU-115)|hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
75783537|NCT01170182|Drug|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
75783538|NCT01170182|Device|Prilosec® 40 mg|Prilosec® 40 mg
75783539|NCT01170260|Behavioral|INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion
75783540|NCT01170260|Behavioral|SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion
75783541|NCT01170260|Behavioral|SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION|Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
75783542|NCT01284842|Other|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
76076698|NCT01674855|Drug|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
75783543|NCT01284920|Drug|MDV3100|oral
75783544|NCT01173302|Biological|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
75783545|NCT00312377|Drug|Docetaxel|infusion
75783546|NCT00312377|Drug|Vandetanib|oral
75783547|NCT01173380|Other|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
75468251|NCT06066281|Behavioral|Neuropsychological assessment|All participants who will meet the inclusion criteria will be adminstered a pencil-paper neuropsychological tests battery including: the Digit Span Backward Task, the Brief Repeatable Battery of Neuropsychological Tests and the CST. After 15 days from the baseline evaluation the CST will be re-administrated to all subjects.
75632500|NCT02622646|Drug|Recombinant VIII factor|"Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~Describe PK parameters in patients on prophylaxis treatment with Advate®~Analyze differences in PK parameters in non-controlled vs well controlled patients~Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence)."
75632501|NCT02621320|Dietary Supplement|Vitamin D|Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
75632502|NCT02621320|Dietary Supplement|Placebo|alcohol-based solution 1.3ml daily over a period of 12 weeks.
75468252|NCT06065670|Drug|Clemastine Fumarate|12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
75632503|NCT01097330|Procedure|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
75783548|NCT01173380|Other|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
75918983|NCT05245656|Drug|RB|"Every 4 weeks for 6 cycles~Rituximab 375mg/m2, IV, D1~Bendamustine 90mg/m2, IV, D1-2"
75918984|NCT05243212|Biological|CAR-BCMA|CAR-BCMA T-cells are genetically modified autologous T-cells directed to the B-cell maturation antigen (BCMA). CAR-BCMA T-cells identify and eliminate BCMA-expressing malignant plasma cells. Upon binding to BCMA-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, persistence and elimination of malignant plasma cells.
75918985|NCT05243108|Dietary Supplement|dietary nucleotides|1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;
75918986|NCT05243108|Dietary Supplement|placebo|placebo
75918987|NCT05242744|Drug|[18F]FluorThanatrace|Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
75468253|NCT06065670|Drug|Placebo|Matched sugar tablet
75918988|NCT05231408|Other|High-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
75918989|NCT05231408|Other|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
75783549|NCT01173536|Drug|GDC-0449|Oral repeating dose
75783550|NCT01173536|Drug|moxifloxacin|Oral single dose
75783551|NCT01173536|Drug|placebo|Oral repeating dose
75468254|NCT06065592|Drug|Palbociclib|Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.
75783552|NCT01580891|Drug|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% applied topically once a day for 28 days.
75468255|NCT06065592|Drug|Rivaroxaban|Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.
75468256|NCT06065592|Genetic|SNP|diagnostics of patients' carriers or not of the risk allele(s)
75468257|NCT06063538|Combination Product|CardiaMend in Combination with Amiodarone|"The first three patient will receive 600 mg amiodarone into the intact pericardial space. Amiodarone serum levels will be tested at post operative days 2 and 6. The study will only proceed if there is a serum amiodarone level less than 25% of the normal therapeutic level. This should insure lack of systemic toxicity. After the first 3 patients have demonstrated low amiodarone blood levels, a total of up to 60 patients will be enrolled in the study.~The CardiaMend patch will saturated per the instructions and be sutured into place. Amiodarone will be dripped directly over the heart."
75632504|NCT01097330|Drug|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
75783553|NCT01580891|Drug|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.
75783554|NCT01580891|Drug|Placebo topical cream|Placebo topical cream applied topically once a day for 28 days.
75783555|NCT01059383|Drug|VECAM 40/300|1 capsule, orally, once daily at bedtime.
75783556|NCT01059383|Drug|Esomeprazole 20 mg|1 capsule, orally, once daily 30-60 min. before dinner
75783557|NCT03295318|Biological|Non-adjuvanted study formulation NmCV-5|Non-adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A&X conjugated to tetanus toxoid and C,Y&W conjugated to CRM protein. The diluent contains Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
75918990|NCT05231395|Other|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
75468258|NCT06062602|Drug|TAK-676|Intratumoral microdose injection by the CIVO device.
76076699|NCT00924352|Drug|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.
75783558|NCT03295318|Biological|Adjuvanted study formulation NmCV-5|Adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A&X conjugated to tetanus toxoid and C,Y&W conjugated to CRM protein. The diluent contains Alum as adjuvant with Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine
75468259|NCT06062602|Drug|Carboplatin|Intratumoral microdose injection by the CIVO device.
75783559|NCT03295318|Biological|Menactra|Menactra is available as ready to used solution containing polysacchride antigens A,C,Y&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine.
75468260|NCT06062602|Drug|5-FU|Intratumoral microdose injection by the CIVO device.
75783560|NCT03311230|Behavioral|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
75783561|NCT03311230|Behavioral|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
75783562|NCT03311230|Behavioral|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
75783563|NCT01285232|Drug|Anakinra|150 mg sc once daily during four weeks
75783564|NCT03866018|Other|Adapted physical activity|12 sessions of one hour of adapted physical activity.
75783565|NCT01173770|Drug|ADC3680B|Escalating single doses ADC3680B or Placebo over 5 study periods
75783566|NCT01173770|Drug|ADC3680B|ADC3680B or Placebo for 7 days
75783567|NCT01173770|Drug|ADC3680B|Single doses ADC3680B over 2 study periods under fasted and fed conditions
75783568|NCT03868826|Procedure|Orthopaedic surgery and/or rehabilitation|The avulsion is repaired and hereafter the patient follows rehabilitation. Some are treated conservatively and only follow rehabilitation.
75918991|NCT05231395|Other|Control Group|"Control group will be given breathing exercises 120 times/day, 7days/week, for 8 weeks as home program.~Control group will be followed-up by telephone once a week"
75918992|NCT05229562|Drug|BIIB122|Administered as specified in the treatment arm.
76076700|NCT00924352|Drug|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
75468261|NCT06062602|Drug|Paclitaxel|Intratumoral microdose injection by the CIVO device.
75918993|NCT05216887|Biological|Aducanumab|Administered as specified in the treatment arm.
75918994|NCT05182697|Drug|SCI-210|Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily
75918995|NCT05182697|Drug|Oral CBD oil|CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
75918996|NCT05179200|Procedure|Plasmapheresis|Plasma donation
75918997|NCT05179200|Procedure|Whole blood donation|Blood donation
75918998|NCT05175599|Other|Water Birth|The water birth group will use a tub of a water to labor and give birth.
75918999|NCT05164887|Procedure|Laparoscopic colorectal resection|the patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics
75919000|NCT05159830|Drug|Cannabidiol Cap/Tab|The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Sublingual tablet contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed tablet.
75468262|NCT06062602|Combination Product|TAK-676 + Carboplatin|Intratumoral microdose injection by the CIVO device.
75468263|NCT06062602|Combination Product|Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
75919001|NCT05159830|Drug|Placebo Cap/Tab|Placebo of similar cannabidiol galenic form
75468264|NCT06062602|Combination Product|Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
75919002|NCT05148481|Drug|BIIB104|Administered as specified in the treatment arm
75919003|NCT05148481|Drug|Placebo|Administered as specified in the treatment arm
75468265|NCT06062602|Combination Product|TAK-676 + Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
75468266|NCT06062602|Combination Product|TAK-676 + Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
75632505|NCT02622490|Other|two test meals with two different macronutrient compositions|Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
75632506|NCT02878616|Drug|LFG316|LFG316 single dose
75632507|NCT02878616|Drug|IVIG|IVIG single dose
75632508|NCT04016194|Diagnostic Test|Lung function testing|Multiple-breath washout (MBW) is a safe, easy and sensitive lung function test using inert gases such as Nitrogen (N2) to assess efficiency of ventilation distribution. The latter can be estimated by the lung clearance index (LCI), an established study end-point in patients with CF
75468267|NCT06062472|Dietary Supplement|Probiotics|Both live and heat-treated of Lactobacillus paracasei will be used in this study
75468268|NCT06062446|Procedure|Modified Lumbar Puncture|The Investigator will perform the modified LP procedure using the 22 Gg needles Quincke spinal needle (namely, without reinsertion of stylet into the spinal needle after cerebrospinal fluid (CSF) collection before spinal needle removal).
75919004|NCT05147545|Other|Moderate intensity physical effort|Pedaling 15 minutes at 75 Watt then 100 Watt of the ergometer
75919005|NCT05147545|Other|Low intensity physical effort|Pedaling 3 minutes at the 30 Watt level of the ergometer
75468269|NCT06062290|Device|Electromyography (EMG)|Measurement of the compound muscle action potential for the assessment of neuromuscular function
75468270|NCT06062290|Device|Kinemyography (KMG)|Measurement of the muscle velocity for the assessment of neuromuscular function
75468271|NCT06061393|Drug|Venofer 200 MG Per 10 ML Injection|treat anemia with venofer up to 5 doses
75468272|NCT06061393|Drug|Ferinject|ferinject 500 mg, once a week for 2 weeks
76076701|NCT01674933|Drug|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
76076702|NCT01674933|Behavioral|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
76076703|NCT03852693|Other|Histopathological review|Histopathological review
76076704|NCT04373044|Drug|Baricitinib|Given PO
75632509|NCT00934440|Drug|Bevacizumab|"First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles)."
75632510|NCT00934440|Drug|Azacitidine|"Dose level 1: 35 mg/m2/day for 7 days.~Dose level 2: 55 mg/m2/day for 7 days.~Dose level 3: 75 mg/m2/day for 7 days.~mg/m2/day = dose based on height and weight"
75632511|NCT02622802|Drug|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
75783569|NCT03869138|Behavioral|Virtual-reality based dance training|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
75783570|NCT03869060|Biological|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
75919006|NCT05147545|Other|Hyperlipidic meal|Eating an hyperlipidic meal 60 minutes after a physical effort
75919007|NCT05147545|Diagnostic Test|Measure of circulating DNA|"Multiple measure of circulating DNA: on an empty stomach, at the end of the physical effort, after 15, 30 and 60 minutes of rest, 120 minutes after an hyperlipidic meal.~An additional measure will occur for subjects free of malignancy during the effort."
75919008|NCT05147519|Behavioral|Novel interventions to achieve HIV remission|To establish a group of well-characterized people living with HIV who initiated ART during acute or early HIV transmission that can serve as a source population for future studies, including those designed to test novel interventions to achieve HIV remission.
76076705|NCT04373044|Drug|Hydroxychloroquine|Given PO
76076706|NCT04373044|Drug|Placebo Administration|Given Po
75632512|NCT02622802|Drug|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
75632513|NCT02622802|Drug|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
75632514|NCT04134988|Other|Medimoov|The Medimoov game platform (created by NaturalPad©) is a physio-gaming medical device, which comes in the form of functional and postural rehabilitation software. Associating movement capture and videogames, Medimoov contributes to the older adults' motivation and engagement and offers adapted physical activities.
75632515|NCT04134988|Other|Standard psychomotor therapy|Psychomotor therapists are among the professionals recommended by the French national health authority. They intervene on psychomotor dimensions of falls, namely the motor, sensory and cognitive aspects.
75632516|NCT05158374|Drug|Aspirin tablet|75mg Aspirin once per day
75632517|NCT05158374|Drug|Metformin|500mg Metformin once per day
75919009|NCT05143021|Other|Multidisciplinary Sickle Cell Disease- Obstetric Team|Modified multidisciplinary teams for pregnant women with sickle cell disease including members from an obstetrics team and sickle cell disease team.
76076707|NCT03851991|Drug|Arbidol|oral
75632518|NCT05158374|Drug|Aspirin and Metformin|75mg Aspirin and 500mg Metformin once per day
75632519|NCT00675532|Behavioral|Primary Care Counseling|Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
76076708|NCT03851991|Drug|Placebos|controle
76076709|NCT01675089|Drug|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
76076710|NCT01675245|Drug|No intervention|This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
76076711|NCT03850431|Behavioral|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
76076712|NCT03850431|Behavioral|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
75325234|NCT00356733|Drug|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
75325235|NCT04591925|Device|Control Device insulin infusion devcie|Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula
75325236|NCT04591925|Device|Investigative insulin infusion devcie|Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
75325237|NCT04542473|Drug|Pancreatic Enzyme|CREON micro 5000
75325238|NCT04542473|Drug|Ursodeoxycholic acid|Ursodiol C24H40O4 suspension
75325239|NCT04542473|Other|Pancreatic Enzyme placebo|Microcrystalline Cellulose,Macrogel 4000, Iron Oxide Yellow, Iron Oxide Red, Activated Charcoal.
75783571|NCT03872804|Procedure|Autologous punch mini grafts:|"Under local anesthesia, multiple 1mm holes will be made in the depigmented treatment area using 1mm punch graft instrument inserted to a depth of 2-4 mm to remove a small column of depigmented skin that is to be discarded. The punches will be situated at or very close to the border of the lesion to avoid leaving an achromic fissure and will be separated by 5-8 mm distance from each other.~On the donor area mostly is the gluteal area, punches will be harvested using the same sized punches very close to each other so that maximum number of grafts can be taken from a small area.~Then the harvested-punch minigrafts will be inserted into the recipient chambers, pressed firmly by saline soaked gauge for hemostasis and secured by sterile strips or a compression bandage if applicable."
75783572|NCT03872804|Procedure|Transverse needling|Needling will be done for selected treatment patch using a 30 G disposable insulin syringe, going from the pigmented margins of the lesion into the vitiliginous patch, Position of the needle will be kept close to the dermoepidermal junction and movement will be from normal skin towards the lesion. Needle pricks may lead to oozing of a small drop of blood which will be managed by physical pressure. No dressings will be needed. The procedure will be repeated for selected lesions weekly for a duration of 3 months.
76076713|NCT03850431|Behavioral|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
76076714|NCT03850431|Behavioral|Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions|A letter with all four types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
76076715|NCT01697696|Drug|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
75783573|NCT03872804|Procedure|Punch minigrafts followed by transverse needling|In a third lesion, punch minigrafts will be done as mentioned in line 1 and will be left to stabilize for 3 months then transverse needling will be done weekly for the margins of the lesion as well as the areas of the punch grafts toward the vitiliginous area.
75783574|NCT03872804|Other|Oral pulse steroid with narrow band|"A fourth lesion will be chosen as a control lesion, to which no surgical treatment will ba attempted.~All lesions will receive NB-UVB therapy according to standard protocol twice weekly and the patients will continue on the oral mini pulse dexamethasone at 2.5 mg dose for two consecutive days weekly all through the study period"
75783575|NCT01170338|Drug|Varenicline 100 mg by mouth twice daily|this is an active drug to help smoking cessation
75783576|NCT01170338|Drug|control|this is the placebo that will help us maintain a blinded study
75783577|NCT03866096|Other|Experimental|The player will perform exercises of balance, stability, and strengthening of the abdomen, back and gluteus. All these exercises will be carried out in first instance on flat surfaces and later on unstable surfaces to increase the difficulty of it. The training will be done in different levels of difficulty, once the participant managed to master the initial level, advance to the next level to complete the three levels of difficulty during the 6 weeks of training. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of the intervention of the experimental group will last 20 minutes
76076716|NCT01697696|Drug|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
76076717|NCT01697696|Drug|Placebo|Placebo to match QAB149
75325240|NCT04542473|Other|Ursodeoxycholic acid placebo|Sodium Citrate Dihydrate, Aspartame, Carboxymethylcellulose Sodium, Citric Acid Monohydrate, Dispersible Cellulose, Glycerol, Polysorbate-80, Saccharin Sodium,Sodium Benzoate, Sodium Methylparaben, Sodium Propylparaben
75325241|NCT05249907|Other|Massage|"Stroking (stroking) movement will be performed on the soft tissue parallel to the muscle fibers on the origo and insertion lines. Vaseline will be preferred as an intermediate to increase the lubricity of the instrument. The frequency of patting and friction movements will be 60 repetitions per minute.~Starting from the medial side of the gastrocnemius (calf) muscle in both legs and moving it longitudinally from distal to proximal and from back to distal in a straight line within 20 seconds, for 2.5 minutes. Then this treatment will be applied to the lateral side of the gastrocnemius muscle for 2.5 minutes."
75783578|NCT03866096|Other|Control|Neuromuscular training will be applied through balance and stability exercises on both flat and unstable surfaces. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of each session of the control group is 10 minutes.
75783579|NCT00312221|Drug|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
75783580|NCT00312221|Drug|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
75783581|NCT00312221|Drug|oxycodone immediate-release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
75783582|NCT03872570|Drug|Phenylephrine|intravenous administration
75783583|NCT03872570|Drug|Norepinephrine|intravenous administration
76076718|NCT04764903|Other|No intervention|There is no intervention in this study
76076719|NCT04404543|Drug|SYHA1807|Escalation Cohort Administration: Orally
76076720|NCT04404543|Drug|SYHA1807|Dose Expansion Cohort Administration: Orally
76076721|NCT03849807|Other|Experimental group|the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
76076722|NCT03849807|Other|Control group|Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
76076723|NCT01569152|Drug|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
76076724|NCT01569152|Drug|Dose-Matched Placebo|Dose-matched placebo dosed orally BID
75632520|NCT00675532|Behavioral|Cognitive-behavioral psychotherapy|Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
75468273|NCT06061107|Behavioral|Handbook for Geriatric Prearranged Medical Care Consultation|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention."
75468274|NCT06060938|Other|Risk stratified arm|"Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~Measurement of height and weight (baseline)~Complete a mammography (baseline and every 1-4 years according to the risk-group)~Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)~Provide a blood sample for analysis of 313 common genetic variants associated with risk of breast cancer (baseline)~Receive a screening schedule recommendation."
75632521|NCT02621086|Dietary Supplement|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
75783584|NCT03865862|Other|Experimental|The athletes will perform an intervention of 4 weeks, with two weekly sessions, in which the intervention will be performed during the training, with these sessions lasting 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series. This intervention will be performed adding 50% of his OR as external load during the first two weeks, 55% of his MR during the third week, and 60% of his MR in the fourth week of the intervention. During the exercise you can help the physiotherapist who will accompany you to perform the concentric phase without load.
75783585|NCT03865862|Other|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 squat repetitions on a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a 15-second rest between series. The subjects of this group will perform the protocol using only their own weight as a load.
75783586|NCT01062737|Drug|ASU|
75783587|NCT01170416|Other|12-lead body surface mapping|An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
75783588|NCT01173926|Drug|insulin degludec|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
75783589|NCT01173926|Drug|insulin degludec/insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
75783590|NCT01173926|Drug|insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
75919010|NCT05134103|Behavioral|Mindbeacon Therapist Guided, Internet Cognitive Behavioral Therapy for Depression|"The treatment consists of 11 depression modules delivered approximately once per week (at therapists' discretion) over a period of 12 weeks. Additionally, the therapist typically tailors treatment to client's individual needs by including supplementary modules for a variety of issues such as generalized anxiety, panic, social anxiety, post-traumatic stress, insomnia, pain, and relationships etc. Clients can complete the readings, exercises, and worksheets at any convenient time, using their web-enabled smartphone, tablet, or computer. Access to the modules and all messaging is provided through the secure platform. Messaging is asynchronous meaning participants can message their therapist as often as they choose and expect a response within 1-2 business days. After 12 weeks of active treatment, they will have unguided access (without therapist support) to the treatment materials that were covered for an additional 40 weeks."
75919011|NCT05134103|Other|Waitlist Control Group|Participants assigned to this arm will wait for 12 weeks before receiving active treatment condition
75919012|NCT05128786|Biological|CCT301-38|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT301-38. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single or multiple dose of CCT301-38 via intravenous injection.
75919013|NCT05120570|Drug|VIC- 1911|25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.
75919014|NCT05119868|Other|Nutritional intervention based on Mediterranean Diet|A personalized nutritional counseling and a tailored diet, according to Mediterranean dietary pattern, designed on the pre-pregnancy weight, height and trimester of pregnancy provided by certified dietitians.
75919015|NCT05112211|Drug|Doxycycline Hyclate|patients administrated with doxycycline tablets 100mg orally per day
75919016|NCT05110040|Drug|immunosuppressive agent|patients with TAO recruited in this study will administrated with immunosuppressive agent per day
75919017|NCT05107427|Drug|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
75919018|NCT05107427|Biological|Avelumab 20 mg/mL Intravenous Solution (IV)|"Avelumab is an IV administered monoclonal antibody that blocks the interaction of programmed death ligand-1 (PD-L1) with its receptors PD-1 and B7.1 on T cells and antigen-presenting cells, and has been shown to activate adaptive and innate immune functions.~The study dosing regimen is 800 mg (four 20mL vials of 20mg/mL solution) for IV infusion once every two weeks"
76076725|NCT01569152|Drug|Methotrexate|MTX dosed at the stable dose receive upon study entry
76076726|NCT03870009|Other|ARDS patients|"The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation"
76076727|NCT01675557|Dietary Supplement|Vitamin D3|a single oral dose of vitamin D3
75632522|NCT00934362|Drug|Lucinactant first|lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
75632523|NCT00934362|Drug|Placebo first|6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
75632524|NCT00675610|Behavioral|communication training|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
75632525|NCT00675688|Drug|Bazedoxifene/Conjugate Estrogens (CE)|
75632526|NCT00675688|Drug|Raloxifene|
75632527|NCT00675688|Drug|Placebo|
75632528|NCT00934128|Device|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
75632529|NCT00934128|Device|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
75783591|NCT02526602|Procedure|Preservation (endopelvic fascia)|Robotic assisted radical prostatectomy with preserving of endopelvic fascia
75783592|NCT02526602|Procedure|Opening (endopelvic fascia)|Robotic assisted radical prostatectomy with opening of endopelvic fascia
75783593|NCT03349268|Device|Pulsed xenon ultraviolet (PX-UV) Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
75783594|NCT03349268|Device|Sham Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
75783595|NCT01170494|Drug|ergocalciferol 2000 IU orally, daily|ergocalciferol 2000 IU orally, daily
75919019|NCT05103423|Drug|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
76076728|NCT01675557|Dietary Supplement|Vitamin D2|a single oral dose of vitamin D2
75919020|NCT05103423|Drug|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
75919021|NCT05103423|Drug|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
75919022|NCT05099263|Device|Vivaer Arc Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal airway in a single study session.
76076729|NCT01675557|Dietary Supplement|Placebo|a single oral dose of placebo
76076730|NCT03028454|Dietary Supplement|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
76076731|NCT03028454|Dietary Supplement|Placebo|Capsules containing rice flour powder.
76076732|NCT01675791|Biological|ALK tree AIT 0.5 DU|
76076733|NCT01675791|Biological|ALK tree AIT 1 DU|
76076734|NCT01675791|Biological|ALK tree AIT 2 DU|
76076735|NCT01675791|Biological|ALK tree AIT 4 DU|
76076736|NCT01675791|Biological|ALK tree AIT 7 DU|
76076737|NCT01675791|Biological|ALK tree AIT 12 DU|
75632530|NCT02622334|Drug|Latanoprost|Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.
75632531|NCT02622334|Drug|Placebo|Matching placebo formulation will be administered in Part A.
75632532|NCT02622334|Drug|RO5093151|RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
75632533|NCT00696514|Dietary Supplement|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
75632534|NCT00696514|Dietary Supplement|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
75632535|NCT02621164|Biological|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
75632536|NCT02621164|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
75632537|NCT04263870|Drug|sintilimab|oral capecitabine 1000mg per m2 bid d1-14, intravenous oxaliplatin 130mg d1 per m2, sintilimab 200mg (every 3 weeks)
75632538|NCT02620930|Device|All market approved CRT-D or ICD systems endowed with the APNEA Scan algorithm|
75632539|NCT05247606|Device|Mobile application|Lifestyle intervention through web-based mobile application
76076738|NCT01675791|Biological|ALK tree AIT Placebo|
76076739|NCT04410068|Device|WARMTAC|Randomization to one of the arms previous to surgery.
76076740|NCT04410068|Device|3M Bair Hugger|Randomization to one of the arms previous to surgery.
76076741|NCT03869307|Other|Exercise|The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
76076742|NCT01675869|Behavioral|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
76076743|NCT01675869|Behavioral|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
76076744|NCT01675947|Drug|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
76076745|NCT01675947|Drug|Lidocaine|Lidocaine 2%
76076746|NCT01676025|Procedure|PRA|
75632540|NCT02622412|Other|Multi-professional breathlessness service (MBS)|Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
75783596|NCT01170494|Drug|ergocalciferol 25000 IU oraly every 2 weeks|ergocalciferol 25000 IU oraly every 2 weeks
75783597|NCT01170494|Drug|ergocalciferol 50000 IU orally every 4 weeks|ergocalciferol 50000 IU orally every 4 weeks
75783598|NCT01170494|Drug|ergocal1000 IU & cholecal 1000 IU orally daily|ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
76076747|NCT01676025|Procedure|LA|
75783599|NCT01170494|Drug|cholecalciferol 2000 IU orally daily|cholecalciferol 2000 IU orally everyday
75783600|NCT01170494|Drug|Cholecalciferol 25000 IU orally every 2 weeks|Cholecalciferol 25000 IU orally every 2 weeks
75783601|NCT01170494|Drug|Cholecalciferol 50000 orally every 4 weeks|Cholecalciferol 50000 orally every 4 weeks
75783602|NCT01170494|Drug|placebo orally everyday|placebo orally everyday
75783603|NCT01587326|Drug|Escitalopram|escitalopram 10 mg/d to 20 mg/d
76076748|NCT04640259|Other|Online Survey|Epidemiological Survey (approx 200 questions)
75325242|NCT05158595|Other|Exergaming low intensity group|wobble board-based Exergame balance training, the game intensity will be low for this group (Size of goal will be kept small for 3 times a week, 30 minutes per day for 8 weeks.
75783604|NCT03294538|Drug|Generic Estradiol Vaginal Cream USP, 0.01%|Vaginal cream, generic formulation of the brand product.
75783605|NCT03294538|Drug|Estrace® Vaginal Cream USP, 0.01%|Vaginal cream, brand product.
75783606|NCT03294538|Drug|Vehicle Vaginal Cream|Vaginal cream, placebo. Has no active ingredient
75783607|NCT03872336|Drug|Experimental labetalol dose|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
75325243|NCT05158595|Other|Exergaming moderate intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept medium).for 3 times a week, 30 minutes per day for 8 weeks.
75325244|NCT05158595|Other|Exergaming high intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept high).for 3 times a week, 30 minutes per day for 8 weeks.
75325245|NCT05158595|Other|control group exergaming|Exer games training with soccer heading and penguin slide games(Wii Fitt balance games) for 3 times a week, 30 minutes per day for 8 weeks.
75783608|NCT03872336|Other|Current standard of care|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the standard dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
75783609|NCT01170572|Other|No intervention|No intervention
75783610|NCT01170728|Device|Coloplast Virtue® Male Sling|The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
75783611|NCT02987530|Drug|Dolutegravir|Oral use, 50mg/day
75783612|NCT02987530|Drug|Darunavir-cobicistat|Oral use, 800-150mg/day
76076749|NCT02082717|Drug|potassium chloride replacement|
76076750|NCT02082717|Drug|Experimental - 4% Sodium Bicarbonate|
76076751|NCT03660189|Other|Two bag system|The two IV fluid bags have identical fluids and electrolytes, except one has 10% dextrose and the other has no dextrose. The two fluid bags run simultaneously and their rates are adjusted according to the patient's blood sugar.
76076752|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
76076753|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
76076754|NCT01569074|Drug|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
76076755|NCT01569074|Drug|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
76076756|NCT01569074|Drug|Placebo|Placebo twice daily for 12 weeks
76076757|NCT03842241|Device|Non-custom made foot orthoses|Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
76076758|NCT03752775|Device|Robot assisted upper limb rehabilitation|The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
76076759|NCT04348773|Procedure|Dehydration|Dehydration of the natural tooth by tooth isolation
76076760|NCT04348773|Procedure|Rehydration|Rehydration
76076761|NCT04403685|Drug|Tocilizumab|Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
75632541|NCT02622412|Other|Delayed MBS Intervention|Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
75632542|NCT04262700|Device|LifeScan's new BGMS|LifeScan new Blood Glucose Monitoring System (BGMS)
75632543|NCT05317182|Other|Occlusal Splints Analogic-Analogic|Take a conventional impression to the patient and conventional fabrication of the splint.
75632544|NCT05317182|Other|Occlusal Splints Analogic-Digital|Take a conventional impression to the patient and digital fabrication of the splint.
75632545|NCT05317182|Other|Occlusal Splints Digital-Digital|Take a digital impression to the patient and digital fabrication of the splint.
75632546|NCT00871000|Biological|Boostrix Polio™ 711866|Single dose, intramuscular administration.
75632547|NCT00871000|Biological|Priorix Tetra TM 208136|Single dose, subcutaneously.
75632548|NCT00871000|Biological|Tetravac TM|Single dose, intramuscular administration.
75919023|NCT05097352|Behavioral|High Intensity Interval Training (HIIT)|Twenty minutes of HIIT will be completed three days a week for six weeks.
75325246|NCT04290689|Drug|Botulinum Toxin-A injection|Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.
75632549|NCT05157828|Other|No intervention|No intervention
75632550|NCT01096784|Drug|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
75632551|NCT02621008|Other|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
75632552|NCT02622256|Behavioral|Health System: HTN Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team & may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
75325247|NCT04290689|Procedure|Serial casting stretching|Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
75632553|NCT04016038|Other|a psycho-social investigation|The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.
75632554|NCT00696592|Drug|Bevacizumab (Avastin), Verteporfin (Visudyne)|
75632555|NCT02617108|Device|Foley balloon|a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
75632556|NCT02617264|Procedure|SPOT|Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
75632557|NCT02617420|Device|Propeller Health Monitoring Device|
75783613|NCT02987530|Drug|Emtricitabine-Tenofovir|Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
75783614|NCT03865550|Drug|Isotonic saline|Placebo
75783615|NCT03865550|Drug|Ketamine Injectable Solution|Active comparator
75783616|NCT01285388|Drug|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
75783617|NCT01174316|Device|AutoVPAP™|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
75919024|NCT05097352|Other|Waitlist|Waitlist participants will be tested on the outcomes at the same time points as the treatment group.
75919025|NCT05091034|Behavioral|Controlling Asthma Program for Adolescents (CAMP Air)|Controlling Asthma Program for Adolescents (CAMP Air) is an e-health intervention grounded in social cognitive theory and motivational interviewing to guide teens through asthma self-care and how to navigate the health care system. It makes use of various interactive and personalized approaches.
76076762|NCT03746925|Procedure|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
76076763|NCT03746925|Procedure|SuperPATH|SuperPATH approach surgery to replace the hip.
75632558|NCT02620696|Drug|netazepide|
75632559|NCT02622022|Drug|Morphine hydrochloride|
75632560|NCT02622022|Other|Placebo|
75632561|NCT02621866|Device|Ultraviolet A radiation|Twice daily with 10 Joules/cm2. Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)
75783618|NCT01174316|Device|VPAPIIIST-A™|Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
75783619|NCT01285466|Drug|BEZ235 + paclitaxel|
75783620|NCT01285466|Drug|BKM120 + paclitaxel|
76076764|NCT01604408|Biological|LY2495655|Administered SC
76076765|NCT01604408|Drug|Placebo|Administered SC
75325248|NCT00801827|Drug|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
75632562|NCT02621866|Device|Sham irradiation|As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of <500nm, but permits visible light to pass.
75632563|NCT00934050|Drug|ELND005 (scyllo-inositol)|"Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks"
75632564|NCT02620618|Drug|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
75632565|NCT00607464|Device|Polyethylene occlusive skin wrap|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
75632566|NCT01091168|Drug|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
75783621|NCT01285466|Drug|BEZ235 + paclitaxel + trastuzumab|
75783622|NCT01285466|Drug|BKM120 + paclitaxel + trastuzumab|
75783623|NCT01166828|Behavioral|TELLEPUPPS|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
75783624|NCT03265600|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.
75783625|NCT03265600|Behavioral|60-minute Introduction to Mindfulness|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
75783626|NCT01285544|Drug|Atorvastatin (Lipinon)|treatment of dyslipidemia administration : PO, qod
75325249|NCT00802685|Drug|Early ibuprofen|"IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen."
76076766|NCT04404231|Radiation|Delivery of infrared light to the head|Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.
76076767|NCT04404231|Other|No Infrared treatment|This is sham treatment. No light is actually given.
75468275|NCT06060938|Other|Control arm|"Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~Measurement of height and weight (baseline)~Complete a mammography (baseline and every second year)~Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)"
75632567|NCT01091168|Drug|Alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
75632568|NCT04135768|Procedure|Wrist joint haematoma washout|After plating of the distal radius is performed, a small incision is made on the wrist joint capsule. This is the portal for fluid efflux. An intravenous cannula is used to puncture the wrist joint capsule adjacent to the first incision and normal saline is infused through this cannula into the wrist joint. The infusion continues until the fluid efflux from the first portal is clear and no longer blood stained. This will be the point at which the washout is considered to be complete.
75632569|NCT04135768|Procedure|Volar locking plate insertion of the distal radius|An anatomical locking plate is applied to the distal radius fracture using screws
75632570|NCT02621788|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
75632571|NCT05321576|Procedure|Erector spinae plane block (ESPB) technique without opioid use|Local anesthetic injection to the erector spinae muscle plane at T5 level on the operation side.
75783627|NCT01285544|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
75783628|NCT01174394|Procedure|DCEAS (Hwato®/ Dongbang®)|Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
75783629|NCT01174394|Procedure|Body electro-acupuncture (Hwato®/ Dongbang®)|Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
76076768|NCT04413578|Device|Dexcom G6|Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.
76076769|NCT04413578|Device|Contour NextOne|A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
75783630|NCT01174394|Procedure|n-CEA (Strietberger®)|Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
75919026|NCT05091034|Behavioral|Attention Control Asthma Education Intervention|Using Asthma Plus, an asthma education program, teens learn about asthma and other conditions relevant to asthma and adolescents.
75919027|NCT05084274|Behavioral|Lifestyle program|If the patient is allocated to the interventional group, the lifestyle modification program will be planned/started immediately after the intake at the fertility clinic. The lifestyle modification program has a duration of 12 weeks in which the subject will receive follow-up by the endocrinologist/diabetologist and dietitian to re-ceive an active dietary intervention plan, follow-up by the physiotherapist where sessions to start with physical exercise will be given. Monthly follow-up visits with the coordinating PCOS-midwife will be planned to enhance the subject's knowledge about PCOS and give emotional support. At the moment of randomization, the PCOS coordinating midwife will immediately plan all necessary appointments, with the endocrinologist and dietitian, physiotherapist and PCOS-coordinator, for the 12-week lifestyle program. This way, patients will have a clear overview of the following 12 weeks.
76076770|NCT01677429|Device|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
76076771|NCT01677429|Device|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
76076772|NCT01677429|Behavioral|Cognitive Behavioral Therapy|For the treatment of panic disorder
76076773|NCT03658707|Other|questionnaire|Shoulder questionnaire
76076774|NCT01567826|Drug|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor [any dose] and Crestor [less than 40mg]"
76076775|NCT01567826|Drug|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
75325250|NCT00802685|Other|Late ibuprofen expectant group (placebo)|"Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to late ibuprofen expectant group will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV."
75632572|NCT00864916|Drug|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
75325251|NCT03535857|Device|PTNS|Use of PTNS on the ankle for 30 minutes
75325252|NCT00802919|Drug|Varenicline|Varenicline 1-2 mg/day
75325253|NCT00802919|Drug|Placebo for varenicline|Placebo
75632573|NCT00864916|Drug|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
75632574|NCT00864916|Drug|Placebo|Participants will receive placebo three times per day for 48 weeks.
75325254|NCT00802997|Device|Sinergy|radiofrequency denervation
75325255|NCT00802997|Device|Placebo sham|sham procedure
75325256|NCT04383041|Other|No intervention|Completing questionnaires via ePRO app from their own mobile devices
75325257|NCT04480385|Other|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch
75468276|NCT06060171|Procedure|Aortic valve intervention|Surgical or transcatheter aortic valve intervention
75632575|NCT04130386|Behavioral|Motivational Interviewing|Participants receiving MI
75632576|NCT04130386|Behavioral|e-education|Participants receiving e-education
75632577|NCT00864682|Drug|Saline|3.3 mL normal saline
75632578|NCT00864682|Drug|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
75632579|NCT00864682|Drug|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
75632580|NCT00698386|Dietary Supplement|Zinc supplement|Zinc miconutrient supplements have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.Each micronutrient capsule contains 50mg zinc (as zinc sulphate) in a lactose matrix.In this clinical trial one tablet of zinc as oral supplement will be given everyday during the entire course in line with the directly observed treatment, short-course (DOTS) strategy recommended by the World Health Organization.
75632581|NCT00698386|Dietary Supplement|Placebo|Placebo have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.The placebo consisted of lactose alone. Supplement and placebo capsules were indistinguishable in appearance both externally and internally.
75632582|NCT04130308|Other|Retrun to run protocol|Progressive return to run protocol for patients after ACL-R
75632583|NCT00931944|Drug|KNS-760704|150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
75632584|NCT02614378|Procedure|air insufflation|modulated air insufflation of the ear canal
75632585|NCT02614378|Procedure|placebo|no air will be introduced in the ear canal
75632586|NCT02614456|Drug|interferon-gamma and nivolumab|
75632587|NCT04130230|Drug|Neostigmine|Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.
75632588|NCT04130230|Drug|Standard therapy|Standard therapy for sepsis and septic shock
75632589|NCT00929994|Behavioral|Cardiac Rehabilitation|Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
75632590|NCT02614300|Other|Pulmonary Rehabilitation and Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 1h15min
76076776|NCT03657459|Other|Danger Signs of Heart Failure Videos|Short (under 3 minutes each) videos on (a) recognition of dyspnea, fatigue and edema and (b) self-management of each (based on diet, fluid management and activities)
76076777|NCT03653481|Dietary Supplement|Oligofructose-enriched Inulin OI|Consumed as a powder, 8g/d for children <50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
76076778|NCT03653481|Dietary Supplement|Maltodextrin|Consumed as a powder, 8g/d for children <50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
76076779|NCT03743025|Drug|Dulaglutide Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
75783631|NCT01174394|Drug|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
76076780|NCT03743025|Other|Saline Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
75632591|NCT02614300|Other|Pulmonary Rehabilitation|The patient will come 3 times per week during 12 weeks Each session 45min
75783632|NCT05275816|Other|Comparing the appropriateness of our practice and the usability of the AUC through comparing the actual management provided at our institution with that recommended by the AUC.|"The AUC application for carpal tunnel syndrome management requires four patients' variables to generate appropriateness ratings for six different treatment options. Each procedure is rated as appropriate, maybe appropriate, or rarely appropriate. The six procedures include splint, steroid injection, carpal tunnel release, oral steroids or Ketoprofen phonophoresis, investigation of alternative diagnoses, and further investigation using an electro-diagnostic study.~To judge the usability of the AUC for the management of carpal tunnel syndrome, the required parameters of each patient were collected and entered into the AUC application by two independent authors to generate the appropriateness rating of the provided treatment for each patient. Afterwards, the agreement between the AUC recommendations and the actual treatment that was provided at our institution was assessed."
75783633|NCT01174472|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of the novel paclitaxel eluting balloons
75783634|NCT01174472|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of conventional angioplasty balloons
75783635|NCT00335153|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
75783636|NCT00335153|Device|CADD-Legacy® 1400 ambulatory infusion pump|
75919028|NCT05080751|Behavioral|Eating Behaviors|Materials to be weekly available for intervention group, following a schedule of sessions (six in total): videos, audios, booklets, films, books and other presentations. The intervention will be based online, in a asynchronous modality. Members will self-manage activities.
75919029|NCT05061095|Other|Assessment Surveys|Patients will complete surveys in three periods. An initial baseline survey, longitudinal assessments completed every 2 weeks over the course of the first three months on study (6 times maximum), and extended assessments that will happen every 3 months after the initial longitudinal period up to 2 years on the study (7 times maximum). Baseline questionnaire will collect demographic and background medical record information. Longitudinal assessments will consist of a BWS questionnaire (patients rate importance of 7 treatment goals), decisional conflict scales, EQ-5D-5L, distress thermometer, and items from PRO-CTCAE. Extended assessments will use same questionnaires as longitudinal assessments.
76076781|NCT02986022|Behavioral|Resilience|Self-efficacy, optimism, altruism, goal setting
76076782|NCT02986022|Behavioral|Information|Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
76076783|NCT03742167|Other|Telemedicine|The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
75468277|NCT06059196|Behavioral|ARCHES (Addressing Reproductive Coercion in Health Settings)|ARCHES (Addressing Reproductive Coercion in Health Settings) includes training existing contraceptive providers to (1) provide contraceptive clients with education on reproductive coercion and methods/ways to use contraceptive methods covertly if desired, (2) provide screening for reproductive coercion and intimate partner violence, (3) provide a referral to specialized services for those disclosing intimate partner violence, (4) and offer a palm-sized mini-booklet with educational information on reproductive coercion and intimate partner violence. A mobile application was developed to guide contraceptive providers through the counselling protocol.
75632592|NCT02614300|Other|Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 30min
75632593|NCT05148702|Drug|Antibiotic - standard duration|Clinician decided antibiotic and duration of treatment
75632594|NCT05148702|Drug|Antibiotic - fixed-extended-duration|Clinician decided antibiotic for a fixed duration of 28 days.
75632595|NCT05058768|Diagnostic Test|The lungs causes and extrapulmonary factors|Acute lung injury due to internal and external pulmonary causes can be used as intervention items in this study, and intervention items can be excluded according to inclusion criteria and exclusion criteria.
75632596|NCT02616874|Drug|MVA.HIVconsv vaccine|Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
75632597|NCT02616874|Drug|Romidepsin|Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
75632598|NCT04263636|Procedure|Phacoemulsification with bilateral trifocal diffractive IOLs|Uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs
75632599|NCT02616718|Radiation|Repeated computed tomography scan of abdomen|Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
75632600|NCT01090310|Drug|AIN457|AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
75632601|NCT01090310|Drug|Placebo|Matching placebo to AIN457
75783637|NCT00335153|Device|PEG tube|percutaneous endoscopic gastrostomy tube
75783638|NCT00335153|Device|J-tube|jejunal tube
75783639|NCT01170806|Drug|Orlistat|Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
75783640|NCT03868436|Drug|Methoxyflurane 3mL|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
75468278|NCT06059196|Behavioral|BCS+ (Balanced Counseling Strategy Plus)|BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
75468279|NCT06058182|Diagnostic Test|blood draws|Pre-procedure, post-procedure (12-24 h), 6-month, and 12-month blood draws
76076784|NCT01337505|Drug|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
75632602|NCT02616952|Dietary Supplement|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
76076785|NCT03648645|Device|Self measurement of blood pressure|"Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient."
75325258|NCT04382729|Other|Neuromuscular Electrical Stimulation|The intervention group, in addition to the daily routine physical therapy, receives NMES for 15 days (5 days per week for 3 weeks). NMES is applied bilaterally using an electrical stimulator with pairs of electrodes placed transversally on the quadriceps muscles and on the gastrocnemius muscles. The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 µs). Stimulation intensity is adjusted daily by the physical therapist to elicit a visible twitch in each muscle. The total duration of the NMES session is 30 min for the first week and 45 min for the second and third week. Stimulation (on) time is 5 s and relaxation (off) time is 15 s, thus eliciting a total of 90 evoked contractions per day during the first week and 135 contractions per day during the second and third week.
75632603|NCT02616952|Behavioral|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
75783641|NCT02965690|Procedure|Zimmer Biomet NexGen CR|Total Knee Replacement
75783642|NCT02965690|Procedure|Medacta International GMK Sphere|Total Knee Replacement
75783643|NCT01280006|Other|Intermittent hypoxia|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
75919030|NCT05061095|Other|Qualitative Interviews|Patients will participate in 2 interviews (1 initial interview, 1 follow up). These will be cognitive interviews focusing on establishing content validity for BWS questionnaire. Will establish patient understanding of questions asked in BWS, understanding of how preferences affect treatment decisions, expected outcomes, and feedback from patients on other potentially important attributes not included in BWS.
75919031|NCT05058846|Procedure|Biospecimen Collection|Undergo blood, tissue, and saliva collection
75919032|NCT05058846|Procedure|Magnetic Resonance Cholangiopancreatography|Undergo MRCP
75468280|NCT06056869|Drug|hyoscine butylbromide|will be given during first stage of labor intravenously
75783644|NCT01280006|Drug|Indomethacin|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Indomethacin: 50 mg, Oral, three times per day for five days."
75783645|NCT01280006|Drug|Celecoxib|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses."
75468281|NCT06056869|Other|normal saline|placebo
75919033|NCT05058846|Procedure|Magnetic Resonance Imaging|Undergo MRI
75919034|NCT05058846|Procedure|Endoscopic ultrasound|Undergo endoscopic ultrasound
75919035|NCT05058846|Other|Questionnaires|Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire
76076786|NCT00003459|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
76076787|NCT03829215|Device|CAERVest cooling device|The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.
76076788|NCT04763811|Other|Focus groups|discussion between participants about representations of health, dependance, fragility, and new technologies
76076789|NCT04763811|Other|Individual interviews|Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors
76076790|NCT02083107|Drug|Misoprostol|Comparison of different routes of administration of 400 micro gram misoprostol
76076791|NCT02083107|Other|Placebo|
75632604|NCT04133428|Drug|Sacubitril-Valsartan|"Evaluation of the Sacubitril-Valsartan treatment effectiveness.~As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment.~Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made."
75783646|NCT01280006|Drug|Placebo|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Placebo: Oral, three times per day for five days."
75632605|NCT02878070|Behavioral|Calls from a Peer Health Coach for 6 months|Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
75632606|NCT04133350|Behavioral|Active Patient Engagement|The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
75632607|NCT01090076|Dietary Supplement|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
75632608|NCT00869050|Drug|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
75783647|NCT02526836|Procedure|Conventional Surgery|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
75783648|NCT02526836|Procedure|Complete mesocolic excision with central vascular ligation|excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
75919036|NCT05055661|Other|Pharmaceutical Teleconsultation|The pharmacist will apply the teleconsultation according to the elaborated workflows and will follow in seven steps: scheduling the teleconsultation; pre-consultation, in which the pharmacist will make a checklist of the adequacy of the teleconsultation environment; presentation of the professional and the objectives of the teleconsultation to the patient; search for information about the patient and their pharmacotherapy; identification of problems related to pharmacotherapy; elaboration of a care plan and appointment for the re-consultation.
75919037|NCT05053451|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporarily affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (20 minutes) to stimulate the targeted brain area (e.g. the DLPFC, TPJ, Occipital Cortex) depending on the phase of the study.
75919038|NCT05041049|Device|Comparing Visual Reality to High-fidelity mannequin Stimulation|"This is a prospective, randomized, non-inferiority study. VR will be compared to HFS, which will be considered the a priori gold standard for residents simulation training.~The study will be divided into two phases. In the pre-test phase, participants will be randomly allocated to receive either a VR or HFS scenario (scenario 1, see below). In the post-test phase, all participants (regardless the initial grouping) will undergo a HFS scenario (scenario 2, see below).~All scenarios have been chosen from critical events published by the Society of Pediatric Anesthesia48 and adult sources49.~The study will be conducted at the McGill University Health Center - Research Institute (MUHC-RI)."
75919039|NCT05036226|Combination Product|Hydroxychloroquine, Metformin, Sirolimus|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily
75468286|NCT06050707|Radiation|Radiotherapy - Low risk group|20 fractions completed in 4 weeks
75468287|NCT06050707|Radiation|Radiotherapy - Standard risk group|25 fractions completed in 5 weeks
75632609|NCT00869050|Drug|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
75783649|NCT03265132|Biological|anakinra|sub cutaneous injection
75783650|NCT03265132|Drug|Placebo|sub cutaneous injection
75919040|NCT05036226|Combination Product|Hydroxychloroquine, Metformin, Sirolimus, Dasatanib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Dasatinib 20mg daily
76076792|NCT04403997|Procedure|Chromoendoscopy|Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.
76076793|NCT00925054|Drug|rAvPAL-PEG 0.001 mg/kg|In Part 1, the planned starting dose levels is 0.001 mg/kg
76076794|NCT00925054|Drug|rAvPAL-PEG 0.003 mg/kg|In Part 1, the planned starting dose levels is 0.003 mg/kg
76076795|NCT00925054|Drug|rAvPAL-PEG 0.01 mg/kg|In Part 1, the planned starting dose levels is 0.01 mg/kg
76076796|NCT00925054|Drug|rAvPAL-PEG 0.03 mg/kg|In Part 1, the planned starting dose levels is 0.03 mg/kg
76076797|NCT00925054|Drug|rAvPAL-PEG 0.1 mg/kg|In Part 1, the planned starting dose levels is 0.1 mg/kg
76076798|NCT02335905|Drug|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
75632610|NCT02878148|Device|Diagnostic imaging modalities for suspected renal colic|"All patients with suspected acute uncomplicated renal colic included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.~Imaging examination will be performed according to current guidelines.~Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol."
75632611|NCT04133506|Drug|Aspirin 300mg|see earlier (only half of healthy volunteers receive aspirin)
75783651|NCT02533193|Procedure|ERAS perioperative cares|"Patient's preoperative counseling & education before surgery~No Bowel preparation~Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery~Fluid restriction & Management by pulse contour analysis or transesophageal doppler~Early mobilization~Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)~Intravenous patient controlled analgesics (no opioids analgesics)~Postoperative Nausea Active Control~No nasogastric tube~No drain insertion~Patients will be discharged at POD#4 if there's no problem"
75919041|NCT05036226|Combination Product|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily
75919042|NCT05036226|Combination Product|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily Dasatanib 20mg daily
75919043|NCT05036226|Combination Product|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily
75919044|NCT05036226|Combination Product|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily Dasatanib 20mg daily
75919045|NCT05035745|Drug|Talazoparib|Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)
75919046|NCT05035745|Drug|Selinexor|Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)
75919047|NCT05033964|Combination Product|Percutaneous Coronary Intervention with drug eluting stents|Coronary drug eluting stent implantation
75919048|NCT05030454|Device|ETHOS|Ring-gantry CT-guided radiotherapy unit, pairing a linear accelerator within a ring-gantry imaging unit.
75919049|NCT05030454|Radiation|CT-guided stereotactic adaptive radiotherapy|All participants will be initially planned to at least 35 Gy in 5 fractions, subject to hard constraints based on the treatment site.
76076799|NCT00925756|Drug|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
75325259|NCT04382729|Other|Physical Therapy Exercise|The control group is subjected to a protocol of physical therapy exercises, applied once a day for 30 minutes (5 days per week for 3 weeks) by the staff physical therapists. It starts with global passive range of motion exercises, followed by active and resistive exercises (including controlled breathing exercises and respiratory muscle training), transfer to the edge of the bed or to a chair, standing and walking.
75632612|NCT04872218|Drug|Abatacept|24 week treatment of IV abatacept following recommended dosages from the monograph
75919050|NCT05024708|Other|Cardiac exercises and tests|Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)
75632613|NCT04872218|Drug|Placebo|24 week treatment of IV placebo following recommended dosages from the abatacept monograph
75632614|NCT04872218|Other|Peanut oral immunotherapy|Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.
75632615|NCT04308746|Behavioral|Online Individualistic Prime (statement writing)|Participants write 3 statements each about (1) themselves, (2) why they are not like others, and (3) why it is beneficial to stand out from others
75632616|NCT04308746|Behavioral|Online Collectivistic Prime (statement writing)|Participants think about a social group and write 3 statements each about (1) their social group, (2) why they are like others, and (3) why it is beneficial to blend in with others
75919051|NCT05023655|Drug|Tazemetostat|800mg po twice daily
75919052|NCT05011552|Behavioral|Self-Compassion, Health, and Empowerment (SHE)|The SHE intervention includes 8 weekly sessions and 24-hour access to the intervener for any additional support needed. The first and last sessions will be delivered over the phone with the woman based on a brochure. The brochure describes the four major components: a) IPV information, b) Danger Assessment, c) Safety Planning, and d) Resources. It will be discussed with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Session 2-7 focus on providing mental health self-care resources, which are deep breathing, progressive muscle relaxation, visualization, general introduction and overview of self-compassion, mindfulness, and loving-kindness.
75919053|NCT05011552|Behavioral|The Control Condition|Women randomized to the control group will be provided with the same brochure and mental health care resources.
75919054|NCT05005897|Biological|Cyanocobalamin|Intramuscular injection of 400 µg cobalamin to children with elevated thcy at enrollment
75919055|NCT04994977|Drug|Melphalan|Given at 0.5 mg/ml.
75919056|NCT04994977|Drug|Carboplatin|Given at 5 mg/ml.
75919057|NCT04994977|Drug|Topotecan|Given at 0.2 mg/ml.
75919058|NCT04963465|Diagnostic Test|Ferning on microscopy|Amniotic fluid ferning will be assessed in the cohort before known rupture of membranes and after known rupture of membranes
76076800|NCT03736005|Other|Exposure of significant critical illness|Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
76076801|NCT04372966|Device|Total hip arthroplasty|Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
76076802|NCT04372654|Device|Electroducer Sleeve|The device's safety will be assessed at the radial and femoral puncture site
76076803|NCT03731013|Behavioral|Mediterranean diet (MedDiet)|Participants randomized in the Mediterranean diet group without physical activity will be instructed and supported towards adhering to principles of the Mediterranean diet, without changes in physical activity habits.
75468288|NCT06050707|Radiation|Radiotherapy - Intermediate risk group|30 fractions completed in 6 weeks
75468289|NCT06050707|Radiation|Radiotherapy - High risk group|35 fractions completed in 7 weeks
75325260|NCT00803543|Drug|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
75468290|NCT06048328|Behavioral|Game Changers for Family Planning|Game Changers for Family Planning (GC-FP) intervention. The intervention will consist of 7 group sessions. The sessions will focus on stigma reduction, disclosure decision making, knowledge, and building skills for advocacy. The 2-hour, weekly sessions will be facilitated by 2 trained peers who are MC users, and conducted in Luganda using a structured manual, and group format to facilitate: sharing of experiences to build support, modeling and motivation; group problem solving and role playing to build skills and self-efficacy; and homework between sessions to practice skills and generate experiences to be processed in the group.
75468291|NCT06046950|Other|Treatment target DAS28CRP-LDA|Aiming for DAS28CRP-low disease activity
75468292|NCT06046950|Other|Treatment target SDAI-remission|Aiming for SDAI-remission
75632617|NCT00698464|Drug|Pasireotide|Single subcutaneous injection of 600 µg of Pasireotide.
75632618|NCT04938050|Diagnostic Test|Ultrasound|Ultrasound evaluation, with grayscale and color Doppler imaging.
75632619|NCT00696904|Drug|ABT-333|Capsule, see arms for intervention description
75468293|NCT06046300|Diagnostic Test|Investigation of the relationship between trunk position sense and muscle activation, balance and quality of life in individuals with transtibial amputation.|It is aimed to investigate whether the trunk position sense, including the trunk right and left sides of the individuals with transtibial amputation, is affected and the relationship between trunk position sense and muscle activation, balance and quality of life.
75468294|NCT06041282|Procedure|manipulation under anesthesia|After the anesthesia took effect, the patient was placed in the supine position, and the experienced surgeon stood at the head of the bed to release the affected limb by four angles of forward flexion, abduction, external rotation and internal rotation. After the operation is completed, 1ml de Bosson (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) is injected once.
75468295|NCT06041282|Procedure|supervised home rehabilitation|The doctor instructs the patient in exercise training at the outpatient clinic. At each clinic visit, the doctor will guide the different stages of the movement. At the first visit, the doctor guides the patient through the first phase of the rehabilitation program to improve the patient's basic mobility. At the first month of follow-up, the second phase of rehabilitation program was guided, and the recovery of mobility was accompanied by muscle training, including wall climbing and muscle resistance exercises. 1ml Debossone (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) was injected once at the clinic. All the training required patients to do their best at home to complete 3 sets of 5 each. At the end of each day, the patient will upload a video to the platform, and the doctor will evaluate whether the patient's recovery is in place.
75325261|NCT00803543|Drug|Placebo|Dosage: Two tablets once a day for 24 weeks
75468296|NCT06038032|Behavioral|My Viva Plan (www.myvivaplan.com)|A web-based platform based on preventive self-care that contains tools to monitor nutrition, physical activity, and mental wellbeing will be accessed daily for 24 weeks.
75468297|NCT06038032|Behavioral|Online healthcare professional support|Individual and group sessions with a Registered Dietitian, Qualified Exercise professional, and Mental Health Professional for 16 weeks.
75325262|NCT04099641|Drug|Bavituximab|Bavituximab IV infusion
75325263|NCT04099641|Drug|Pembrolizumab Injection|Pembrolizumab IV Infusion
75325264|NCT05051735|Drug|Paracetamol|Paracetamol 500 mg
75632620|NCT00696904|Drug|Placebo|Capsule, see arms for intervention description
75632621|NCT04933682|Drug|ALXN2050|Oral tablet.
75632622|NCT04933682|Drug|Fluconazole|Oral tablet.
75632623|NCT04933682|Drug|Rifampin|Oral capsule.
75632624|NCT04306718|Procedure|membrane peeling|ERM and ILM are peeled routinely during surgery
75632625|NCT04307966|Behavioral|The CIrCLE of Life Initiative|HIV and obesity prevention programme delivered directly to Grade 6 preadolescents and indirectly to their parents.
75632626|NCT00625976|Behavioral|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
75632627|NCT00625976|Behavioral|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
75632628|NCT04308200|Other|CO-OP approach|"There are 3 stages in the CO-OP approach. Stage I, the Preparation Stage, is primarily concerned with establishing the goal. Before the first interview, the child was contacted, the family and the child were informed, and it was checked whether they met the prerequisites. At this stage, 3 targets were selected and the basic performance level was determined. Stage II, the Acquisition Stage, is essentially the plan and do stage, in which the work of using strategies to acquire skills is done. This stage originally comprised 10 sessions. At this stage, the first session enabling principles were implemented and the global strategy goal-plan-do-check was introduced. The family attended this process with observation. Parents / caregivers were encouraged to make observations to generalize strategies. Stage III, the Verificatíon stage usually consists of only one session in which control is performed; the progress made was revised as learned strategies."
75919059|NCT04942613|Behavioral|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
75325265|NCT05051735|Drug|Placebo|Placebo
75325266|NCT05220033|Other|Informational intervention|Receive information focusing on coping skills for patients diagnosed with gynecologic cancer
75325267|NCT05220033|Other|survey administration|Ancillary studies
75325268|NCT00803777|Device|Investigational Blood Glucose Monitoring System|Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
75325269|NCT00356343|Device|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
75325270|NCT00356343|Other|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
75325271|NCT03466125|Procedure|Cardiac surgery|Retrospective cohort study
75919060|NCT04942613|Other|Physical Therapy Interventions|strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise
76076804|NCT03731013|Behavioral|Physical activity (PA)|Participants randomized in the group physical activity without Mediterranean diet will participate in a structured, supervised PA program to achieve 150 min of moderate PA per week, without changes in dietary habits.
76076805|NCT03731013|Behavioral|Mediterranean diet and physical activity|The combination group (MedDiet + PA) will receive the combination of both interventions.
76076806|NCT04372888|Behavioral|choice decision frame|active choice for genetic testing
75783652|NCT02533193|Procedure|Conventional perioperative cares|"No Patient's preoperative counseling & education before surgery~Bowel preparation~No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~Conventional Mobilization~Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~IV PCA~Postoperative Nausea Control if needed~No Thromboembolism prophylaxis~No or Low Content Oxygen therapy~Drainage tube insertion if needed"
75468298|NCT06037135|Drug|dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery. The research nurse, who did not participate in the study other than the management and preparation of the study medication, prepared 50mL of 0.9% normal saline for the control group and a mixture of dexmedetomidine 2 mL and 0.9% normal saline 48 mL (at a concentration of 4 μg/mL) for the dexmedetomidine group.
75325272|NCT03839147|Behavioral|Education and counseling|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
75468299|NCT06037135|Drug|0.9% normal saline|In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
75632629|NCT04308200|Other|NDT|All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.
75632630|NCT04927598|Device|plasmapheresis|patients of Gullian Barrie syndrome undergo plasmapharesis
75783653|NCT03865160|Drug|Atropine eye drops, 0.01%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
76076807|NCT04372888|Behavioral|opt-in decision frame|"gain frame for genetic testing"
76076808|NCT04372888|Behavioral|opt-out decision frame|"loss frame for genetic testing"
76076809|NCT04372888|Behavioral|enhanced choice (context) decision frame|consequences of genetic testing
75632631|NCT04307108|Device|Magic Glass|MAGIC-GLASS is a VR-based home system for stroke rehabilitation, developed by Ulster University (UK) in collaboration with Tech4Care srl (Italy) and miThings AB (Sweden) in the context of the EU-funded Project Magic (grant agreement No 687228). It includes a number of mini-games grounded on rehabilitation paradigms such as mirror therapy [29] and can adapt to the capability of a person. In addition, the games will include an automatic coaching system for giving feedback both on rehabilitation results (e.g. achievement of exercise goals) and performance (during the exercise itself, the system will give real time advice on the execution of the exercise).
75783654|NCT03865160|Drug|Atropine eye drops, 0.02%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
75783655|NCT03865160|Drug|Placebo (NaCl 0.9%) eye drops|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
75783656|NCT01059461|Drug|Cerebrolysin®|injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
75783657|NCT01324739|Drug|human BNP-32|3pmol/kg/min infusion
75783658|NCT01285700|Drug|Lamazym|ERT, infusion weekly
75919061|NCT04942613|Other|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene
75919062|NCT04942613|Other|Qualitative Interview|Qualitative interview to explore patient perspectives of the multicomponent telerehabilitation program (physical therapy, biobehavioral interventions, technology, and social support interventions) and how they contribute to program engagement and participation as well as changes in physical activity.
75919063|NCT04924153|Other|No Intervention|Administered as specified in the treatment arm.
75919064|NCT04915300|Drug|Apabetalone|Apabetalone 100mg p.o. (tablets) BID for 24 weeks treatment period.
76076810|NCT04372888|Behavioral|enhanced choice (norms) decision frame|social norms for genetic testing
76076811|NCT04372888|Behavioral|enhanced choice (affect) decision frame|commitments for genetic testing
76076812|NCT04372732|Diagnostic Test|Serum tumor autoantibody detection|All enrolled patients will be tested for ten kinds of tumor autoantibodies using peripheral blood before PD-1 bloackade treatment.
76076813|NCT02245126|Drug|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
76076814|NCT02245126|Drug|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
76076815|NCT04347382|Drug|Honey|1gm/Kg/Day
76076816|NCT04347382|Drug|Nigella Sativa / Black Cumin|80mg/Kg/day
76076817|NCT04347382|Drug|Placebos|Empty capsule with 250ml of distilled water
75919065|NCT04915300|Drug|Placebo|Placebo p.o. (tablets) BID for 24 weeks treatment period.
75632632|NCT00927186|Drug|Teriparatide|"20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
75783659|NCT01171040|Other|Echocardiography, including the measurements of left atrial (LA) distensibility|The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
75783660|NCT01062815|Dietary Supplement|Parenteral Nutrition|Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
75783661|NCT02939950|Device|Bausch + Lomb Samfilcon A Soft Contact Lens|soft contact lenses
75783662|NCT02939950|Device|Bausch + Lomb Pure Vision Soft Contact Lens|soft contact lenses
75783663|NCT03992105|Other|prospective cohort|"topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively"
75919066|NCT04910997|Other|Aerobic exercise training|Combination of supervised and home-based aerobic exercise training
75919067|NCT04909710|Other|Mobile Game System for Potential Treatment of Developmental Delays|This mobile game system is designed to generate valuable data from video, image, and usage data for measuring progress and building novel artificial intelligence models while delivering impactful education for and treatment of children with developmental delays such as autism.
75919068|NCT04909203|Device|iKinnect2.0|iKinnect2.0 is a paired mobile phone app for use on both Android and iOS operating systems by youth with conduct disorders and their parents.
75919069|NCT04909203|Device|Active Control App|Mobile phone app for use on both Android and iOS operating systems for GPS tracking of other persons.
75919070|NCT04904419|Diagnostic Test|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
75919071|NCT04888481|Drug|68Ga-HA-DOTATATE|Tracer injection
75468300|NCT06031974|Behavioral|DISCO Intervention|optimal medical management in accordance with European Society of Cardiology recommendations + dietary intervention based on Dietary Approaches to Stop Hypertension (DASH diet) + strict monitoring of eating and lifestyle behaviors
75632633|NCT00927186|Drug|Zoledronic Acid|"5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
75632634|NCT02877602|Device|MRI|
75632635|NCT02877602|Device|Transient Elastography|
75632636|NCT00593554|Radiation|Total Body Irradiation|8 Gy on Day -9
75783664|NCT01286246|Drug|Vaginal progesterone|Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
75783665|NCT01286246|Drug|Placebo|Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
75783666|NCT01324817|Device|Kai Spot (v 2.1)|The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.
75783667|NCT01324817|Device|Kai Continuous (v 1.0)|The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
75919072|NCT04879745|Other|MyVoice:Rheum|Participants will be given access to MyVoice:Rheum, a web-based decision aid (DA).
75919073|NCT04879745|Other|Pamphlet|Participants in this arm will be given a copy of an existing patient pamphlet
75919074|NCT04879745|Other|Provider Experience|Rheumatologists will take a survey to assess their experiences with MyVoice and/or the pamphlet
75919075|NCT04878367|Behavioral|Five active practices of living rules for responding to fine dust.|"Check the fine dust weather forecast~Check the operation time and filter of the air purifier~Window ventilation~Inhalant is used or not~Bad fine dust: Refrain from going out"
75919076|NCT04866706|Device|Visiol|VISIOL is a 2.0% (m/v) SH viscoelastic solution used for ocular surgery.
75919077|NCT04866069|Biological|SARS-CoV-2 vaccine|Adjuvanted inactivated vaccine
75919078|NCT04866069|Biological|Placebo|0.9% NaCl
75919079|NCT04846478|Drug|Talazoparib|capsule, taken by mouth, once a day
75632637|NCT00593554|Drug|Thiotepa|5 mg/kg/d on Day -8 to -7
75632638|NCT00593554|Drug|Fludarabine|40 mg/m2/d on Day -6 to -3
75632639|NCT00593554|Biological|Rabbit ATG|2.5 mg/kg/d on Day -5 to -2
75632640|NCT00593554|Drug|Palifermin|60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2
75632641|NCT04129918|Behavioral|light and sound modification (earplugs and eye masks)|In the experimental group，the patients used earplugs and eye masks during nighttime sleep.
75632642|NCT01101308|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
75632643|NCT01101308|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
75632644|NCT02616328|Other|No intervention|No intervention administered in this study
75632645|NCT02620462|Device|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
75632646|NCT02877524|Other|Adaptive support ventilation|ASV during NIV
75632647|NCT02877524|Other|Pressure support ventilation|PSV during NIV
75632648|NCT00697606|Device|Seprafilm®|Seprafilm® placed at time of primary cesarean
75632649|NCT00697606|Other|Control|no Seprafilm® used at primary cesarean
75325273|NCT05205369|Behavioral|10-week home-based Yi Jin Bang exercise program|Each participant in this group will do a home-based Yi Jin Bang exercise program four times a week for ten consecutive weeks, which consists of ten minutes of warm-up, 18 minutes of Yi Jin Bang exercise (ten exercises), and ten minutes of cool-down. To learn how to conduct the home-based exercise session, each participant will be invited to one introductory session before starting the prescribed exercise program. Two experienced Yi Jin Bang instructors will lead the introductory session. Besides, in order to monitor participants' adherence and help them to conduct self-training, we will use the Zoom Meeting application. Zoom can capture and record participants' movements through the webcam. During the introduction sessions, we will teach participants how to use Zoom. Furthermore, we will provide support for adherence to the home exercise sessions through telephone calls or e-mail every two weeks.
75632650|NCT04306640|Other|Sagittal Cervical Posture Corrective Orthotic Device|The subjects in the traction group will receive the deneroll extension traction. The subjects will be asked to lie supine on the ground with their legs straight, upper arms by their sides and forearms gently folded across their trunk. The therapist will place the apex of the denneroll either in the mid cervical region or the lower cervical region depending on the apex of cervical curvature deformity of each subject. Initially, participants begin with three minutes of sustained denneroll extension traction and progressed to the goal of 20 min per session with one to two additional minutes per session
76076818|NCT03726489|Device|Daavlin 7 series 3 panel narrow band phototherapy home units|"Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors"
76076819|NCT03726489|Device|narrow band phototherapy clinic units|Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
76076820|NCT04372342|Drug|nalbuphine|Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
76076821|NCT04372342|Drug|remifentanil|remifentanil
76076822|NCT04372264|Drug|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
76076823|NCT04372264|Drug|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
76076824|NCT04372264|Drug|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
76076825|NCT04366570|Other|clinical assessment of the shoulder and the cervical spine includes stress guideline tests|As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol
75632651|NCT04128358|Diagnostic Test|Serological assay for blood born viral hepatitis|Qualitative PCR for patients with hepatitis C antibody positive
75632652|NCT04128358|Diagnostic Test|Quantitative microbiological test for HCV|Quantitative PCR in those with proven HCV infection
75632653|NCT00626054|Drug|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
75632654|NCT00626054|Drug|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
75632655|NCT04262622|Device|Group TEA: thoracic epidural analgesia group|in this group TEA will be performed by the insertion of transthoracic epidural catheter before induction of general anesthesia. Analgesia will be started on wound closure by injecting local anesthetic mixture into the epidural catheter
75632656|NCT04262622|Device|Group RSB: rectus sheath block group|Two sets of epidural catheters which have multiple perforations at the end of the tubing will be surgically applied bilaterally into the rectus sheaths for each patient in this group on wound closure. By the end of surgery,injection of local anesthetic mixture will be started.
75632657|NCT04134676|Drug|Conditioned Media|Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
75632658|NCT02878694|Biological|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections No treatment in the second eye
75632659|NCT05009316|Other|Questionnaires|Online-based questionnaires
75632660|NCT02620540|Device|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
75632661|NCT00926796|Drug|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
75783668|NCT05275660|Drug|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.
75783669|NCT05275660|Other|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
75783670|NCT03753542|Other|Multimedia education, booklet Providence and tele-nursing follow-up|Multimedia education, booklet and weekly tele-nursing follow-up is about chemotherapy and side effects management
76076826|NCT02083809|Drug|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
76076827|NCT02083809|Drug|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
76076828|NCT02244112|Drug|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
75783671|NCT03981887|Drug|Nafithromycin|Nafithromycin 200 mg as IV infusion
75783672|NCT03981887|Other|Placebo|placebo administered as IV infusion
75783673|NCT01063127|Other|Study on insulin sensitivity after diet or bariatric surgery|Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
75468301|NCT06030050|Behavioral|Animal-assisted intervention|The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Therapy dogs are trained and certified animals who are leashed at all times and under direct care of their dog handler, NOT companion animals, personal pets, nor emotional support animals.
76076829|NCT02244112|Drug|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
76076830|NCT03723681|Drug|Quizartinib|Quizartinib is provided as 20 mg tablets for oral administration
76076831|NCT04366180|Dietary Supplement|Probiotic|The probiotic group will received one capsule with Lactobacillus K8 per day (3x10^9 cfu/day) during 2 months
76076832|NCT04366180|Dietary Supplement|Control|The control group will received one placebo capsule per day during 2 months
76076833|NCT03722589|Biological|Flublok|0.5 mL intramuscular dose of Flublok
75632662|NCT00926796|Drug|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients >45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
76076834|NCT03722589|Biological|Flucelvax|0.5 mL intramuscular dose of Flucelvax
76076835|NCT03722589|Biological|Fluarix|0.5 mL intramuscular dose of Fluarix
75632663|NCT00926796|Drug|Gemifloxacin|One 320 mg tablet administered orally.
76076836|NCT03722589|Biological|Fluzone|0.5 mL intramuscular dose of Fluzone
76076837|NCT03722589|Biological|Fluzone High-Dose|0.5 mL intramuscular dose of Fluzone
76076838|NCT04372420|Drug|RhBMP-2 absorbable sponge in grade II furcation|The collagen sponge is impregnated with rhBMP-2 at a concentration of 0.5 μg/ml/1cm3 and were stored at 4°C. This rhBMP-2 impregnated collagen sponge was then dispensed at grade II furcation site
76076839|NCT04372420|Procedure|PLATELET RICH FIBRIN in grade II furcation|For preparation of PRF, patient's venous blood is collected into 10ml glass tube or glass-coated plastic tube and centrifuged at 2700 rpm for 12min which leads to two different layers in the test tube, the upper platelet rich fibrin and the lower RBC portion. The formed PRF clot could then be removed from the glass tube and used in grade II furcation
75632664|NCT00696982|Drug|sitagliptin|sitagliptin 100 mg once daily for 3 months
75632665|NCT00696982|Drug|glibenclamide|glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
75632666|NCT01087736|Drug|Topiramate|After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
75632667|NCT01087736|Other|Placebo administration|Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
75783674|NCT01063127|Other|gastric bypass|Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
75783675|NCT03868280|Procedure|Antegrade femoral nailing Supine Position|Antegrade femoral nailing in Supine Position using a Fracture Table
75783676|NCT03868280|Procedure|Antegrade Femoral Nailing Lateral Position|Antegrade femoral nailing in Lateral Position using a Free drape
75783677|NCT03984773|Behavioral|Nudge|Oncology practices will be randomly assigned to receive an intervention, in which individual clinicians will receive a weekly audit email detailing how many serious illness conversations (SIC) they have had compared to the recommended level, and a link to a list of their patients scheduled in clinic next week at high risk of short-term mortality as identified by a mortality prediction algorithm. Clinicians will have the chance to review the opt-out list and pre-commit to a serious illness conversation with appropriate patients. Clinicians will receive nudge on the day of the patient visit via text message reminding them of their pre-commitment to conduct a serious illness conversation.
75919080|NCT04846478|Drug|Tazemetostat|orally as a tablet twice daily.
75919081|NCT04835844|Device|CARTO|Redo-ablation of paroxysmal AF with high density mapping system, CARTO, in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
75919082|NCT04835844|Device|RHYTHMIA|Redo-ablation of paroxysmal AF with high density mapping system, RHYTHMIA, in conjunction with the 64-electrodes ORION mini-basket catheter.
75919083|NCT04834973|Drug|tigilanol tiglate|"Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
75919084|NCT04834973|Drug|pembrolizumab|"Three weekly 200 mg intravenous pembrolizumab treatment.~Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy."
76076840|NCT04372576|Diagnostic Test|Assessment of ventilator-associated pneumonia criteria|Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.
76076841|NCT02244190|Drug|Tipranavir|New oral solution (back up) formulation
76076842|NCT02244190|Drug|Tipranavir|
76076843|NCT02244190|Drug|Ritonavir|
76076844|NCT00954915|Biological|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
76076845|NCT00926380|Drug|denosumab|denosumab: 60 mg SC every 6 months
76076846|NCT00926380|Drug|teriparatide|teriparatide: 20 mcg SC QD
75919085|NCT04829331|Device|Restrata|Restrata is a sterile, single use device intended for use in local management of wounds
75468302|NCT06024486|Diagnostic Test|fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)|measurement of serum albumin, fibrinogen and CRP
75468303|NCT06016907|Behavioral|Internet-delivered cognitive behavioral therapy (ICBT)|Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.
76076847|NCT04366414|Other|hook breathing removing nose-clip|"Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.~The experimental breathing protocol consisted on to remove nose-clip previous to surface and then perform hook breathing during 20 seconds."
76076848|NCT04366414|Other|usual breathing (UB)|Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.
76076849|NCT02244268|Drug|ALNA®|
75632668|NCT04262388|Biological|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
75468304|NCT06016907|Behavioral|In-person cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.
75632669|NCT04262388|Biological|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
75632670|NCT04262076|Other|Pulpine with Polyamidoamine Dendrimer|Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
75632671|NCT04262310|Other|Small Bowel and Colonic Permeability Test|small bowel and colonic permeability based on oral probe molecules and urine excretion in 60 healthy white, female and male adults aged 18-70y
75632672|NCT00608712|Drug|Esomeprazole|Esomeprazole 20mg oral tablet
75632673|NCT01079936|Drug|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
75783678|NCT03292588|Biological|Mepolizumab|"Mepolizumab administered every 4 weeks by subcutaneous injection at a dose of:~100 mg for participants ≥12 years of age and~40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
75919086|NCT04800809|Other|This study does not entail offering any intervention; all data collected will be based on standard of care.|This study does not entail offering any intervention; all data collected will be based on standard of care.
75919087|NCT04797520|Device|Eko CORE Stethoscope|Eko CORE stethoscope will be used as a visual and auditory means of confirming placement of ETT
75919088|NCT04797520|Device|Point of care ultrasound|"Point of care ultrasound will be used as a means of confirming placement of ETT. This is the gold standard used in standard of care"
75919089|NCT04782193|Biological|CD19 and CD22 targeted prime CAR- T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
75632674|NCT01079936|Drug|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
75632675|NCT01079936|Procedure|Stem Cell Infusion|Stem cell infusion on Day 0.
75632676|NCT00931710|Drug|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
75468305|NCT06012149|Behavioral|Braining|A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
75919090|NCT04781634|Biological|CD19 and CD22 targeted prime CAR-T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
75919091|NCT04776330|Biological|BCMA targeted prime CAR-T cells|BCMA targeted prime CAR-T cell therapy
76076850|NCT04366492|Other|Prevalence of blood borne viral infections (HBV/HCV/HIV)|rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire
75468306|NCT06012149|Behavioral|Structured advice on physical activity|A 12 week program where participants are encouraged to engage in physical exercise
75468307|NCT06001762|Drug|Abemaciclib|CDK4 and CDK6 inhibitor, tablet taken orally
75468308|NCT06001762|Drug|Tamoxifen|Selective estrogen receptor modulator, taken orally per institutional standard of care
75468309|NCT06001762|Drug|Anastrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
75468310|NCT06001762|Drug|Letrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
75468311|NCT06001762|Drug|Exemestane|Steroidal aromatase inhibitor, taken orally per institutional standard of care
75468312|NCT06001762|Drug|LHRH Agonist|Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
75468313|NCT06001671|Drug|BEBT-109|"BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd"
75468314|NCT05994482|Other|adenoma vs no adenoma|For Aim 1, the investigators will examine colorectal cancer risk among older adults with prior removal of a precancerous polyp (adenoma) vs a prior normal colonoscopy
75468315|NCT05994482|Other|colonoscopy vs no colonoscopy|For Aim 2, the investigators will examine colorectal cancer risk among older adults with prior history of polypectomy, exposed vs unexposed to subsequent surveillance colonoscopy
75919092|NCT04764825|Drug|Methadone|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients <65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients > 65 years of age."
75632677|NCT00931710|Drug|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
75632678|NCT01100528|Biological|recombinant interferon alfa-2b|Given subcutaneously (SC) 3 times a week for 24 weeks
75632679|NCT01100528|Drug|dacarbazine|Given IV on days 1 and 29
75632680|NCT01100528|Other|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
75919093|NCT04764825|Drug|Morphine|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients <65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients > 65 years of age."
76076851|NCT04365946|Procedure|Gastroscopy|Upper GI endoscopy and biopsy
75632681|NCT04306406|Other|Raspberries|Red raspberry smoothies drink
75632682|NCT04306328|Device|Neurostimulation|Implantation of 2 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
75632683|NCT01079234|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily
75783679|NCT03292588|Drug|Placebo|"Placebo administered every 4 weeks by subcutaneous injection at a dose of:~100 mg for participants ≥12 years of age and~40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
75783680|NCT03752528|Diagnostic Test|Blood sample collection|Determination of buprenorphine and norbuprenorphine plasma concentrations
75783681|NCT03752528|Diagnostic Test|Urine sample collection|Urine sample for determination of free buprenorphine and free norbuprenorphine concentrations, qualitative UDS for opioids, quantitative UDS for buprenorphine, norbuprenorphine and naloxone, and determination of creatinine concentration
75783682|NCT03865004|Drug|Paracetamol+Morphine|1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
75783683|NCT03865004|Drug|Dexketoprofen plus Morphine|Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
75783684|NCT03865004|Drug|Placebo plus Morphine|100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
75783685|NCT00334295|Drug|Fulvestrant|A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.
76076852|NCT03823209|Behavioral|Social Network|Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.
75632684|NCT01079234|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
75632685|NCT01079234|Drug|insulin aspart|At least three daily doses at meal-time
75632686|NCT00931632|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
75632687|NCT00931632|Drug|Placebo|Nitrogen gas will be administered in the same manner as the experimental drug.
75632688|NCT02877758|Other|Tomorrowlabs cosmeceutical formulation|
75632689|NCT02877758|Other|Sham cosmeceutical formulation|
75632690|NCT04306484|Diagnostic Test|FDOPA-TEP|FDOPA-TEP performed as part of the normal management of a suspected brain tumour
75632691|NCT04261998|Other|Service-learning program|Intervention group will perform a service-learning program with real patients with heart transplantation, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
75632692|NCT00608790|Drug|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
75632693|NCT00608790|Drug|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
75783686|NCT01285778|Drug|panitumumab, mytomicin C, 5-FU, radiation|"Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:~First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks~Then Mitomycin C, 10mg/m2 on days 1 and 29~Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32~Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy."
75783687|NCT03292432|Behavioral|TERA Intervention (TERA)|"A sequence of adherence support strategies implemented at care visits and as needed on the basis of EDM data. Components include: (1) remote education/preparation with an adherence coach conducted with VSee software (video conferencing) at site at baseline, week 4 and week 12; (2) one-way text alert at dose time when bottle has not yet been opened for that dosing window (users can disable this on request); (3) missed dose two-way outreach text asking What's the plan? which gets sent to both the participant's phone and a study phone; and (4) implementation of the coach-outreach (phone, text, remote counseling) triggered by missed doses or as a check-in to inquire about the well-being of the youth (once per week when no other contact with coach occurred the week prior)."
75919094|NCT04763772|Diagnostic Test|Body Fat Distribution Imaging Report|Those randomized to body fat distribution imaging will be scanned on a 1.5 Tesla Siemens Aera MRI scanner (Siemens, Erlangen, Germany), located in the Center for Advanced Heart and Vascular Care using a 6-minute dual-echo Dixon Vibe protocol providing a water and fat separated volumetric data set covering neck to knees, and a multiecho Dixon acquisition for proton density fat fraction assessment in the liver. Images of the liver will be acquired using a 16-channel SENSE extra large Torso coil and images from the rest of the body will be acquired using the body coil. Volumetric imaging datasets of the body derived by MRI will be generated and adipose tissue/fat depots will be quantified: abdominal subcutaneous compartment (ASAT), visceral compartment (VAT), and hips and buttocks (lower body fat); proton density fat fraction of the liver (i.e. hepatic steatosis) as well as the quality of lean (skeletal muscle) including muscle volume and degree of fat infiltration.
75919095|NCT04763772|Diagnostic Test|Basic Weight Information|Body weight and body mass index
75919096|NCT04763772|Behavioral|Patient Provided|Body weight/fat distribution information will be provided directly to the patient
75325274|NCT05205369|Behavioral|10-week home-based usual exercise therapy program|Among exercise therapy in the treatment of SAPS, stretching and strengthening protocols are often used . Therefore, participants in this group will do a standardized home-based stretching and strengthening exercise program four times per week for ten weeks, which is set up according to a previous study. This program has been demonstrated that can be effective in reducing pain and improving function in patients with SAPS. For strengthening exercises, elastic bands will be used. To learn how to conduct the self-training program, each participant in this group will also be invited to one introductory session before starting the prescribed exercise training. Two certificated physiotherapists will lead the introductory session. In addition, a video demonstration clip will be given to each participant to provide a home reference, and the Zoom Meeting application will be used to help monitor the exercise.
76076853|NCT03823209|Behavioral|Brief HIV Prevention Counseling|Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
75632694|NCT01078922|Drug|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
75783688|NCT03292432|Behavioral|Standard of Care (SOC)|Cell-phone reminders, patient-education, adherence planning (medication management), and checking-in on adherence at clinical care visits, as well as Viral load (VL) monitoring with patient feedback on VL, are used at sites. Less common, but available as a general service at some sites, on several websites, and at many pharmacies, youth may also receive text messages at dose times, for appointment reminders, and for refill reminders.
75632695|NCT04305938|Diagnostic Test|Minimally invasive and non-invasive blood analyte measurement|Rapid point-of-care minimally invasive blood analyzer consisting of a spectrometer and a computer loaded with Kaligia software that controls the data acquisition and signal processing to interpret blood analyte measurement.
75632696|NCT04259580|Procedure|Endoscopic retrograde pancreatography (ERCP)|Endoscopic procedure to access biliary and/or pancreatic structures
75783689|NCT01285856|Other|hair and saliva samples|"Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling."
75919097|NCT04763772|Behavioral|Physician Provided|Body weight/fat distribution information will be provided directly to the physician
76076854|NCT00870051|Device|Endurant Stent Graft|Endurant Stent Graft implantation
75632697|NCT00609570|Dietary Supplement|NanoGreens|fruits and vegetables
75632698|NCT00609570|Dietary Supplement|Whey protein|Whey
75632699|NCT00609570|Dietary Supplement|Calcium pills|CA
75632700|NCT00863746|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
75632701|NCT00863746|Drug|Placebo|Placebo - 2 tablets twice daily (BID)
75632702|NCT04259814|Behavioral|Speech-language therapy (SLT)|Age-appropriate play activities with speech-language pathologist (SLP) to elicit speech, using stimulation strategies including but not limited to recasts, expansion, parallel talk, interactive modeling, communication temptations, and phrase completions. Activities will include an age-appropriate story, pretend play (i.e., house with people, playing with a baby doll), an assembly task (i.e., building blocks, making pretend pizza), and a highly motivating, clinician-controlled activity (i.e., blowing bubbles, swing, pushing cars down a ramp).
75632703|NCT04259814|Behavioral|Modified constraint-induced movement therapy (mCIMT)|Participants will wear a removable cast and an occupational therapist will be present during therapy to focus on facilitating play with the affected arm.
75783690|NCT01063205|Drug|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
75783691|NCT01063205|Drug|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
75783692|NCT01063205|Drug|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
75919098|NCT04760743|Biological|NBP2001 adjuvanted with alum (RBD 30μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.
75919099|NCT04760743|Biological|NBP2001 adjuvanted with alum (RBD 50μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 50μg/dose) on Days 0 and 28.
75919100|NCT04760743|Other|Normal Saline|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
76076855|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
76076856|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
76076857|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
76076858|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
76076859|NCT03630315|Drug|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
76076860|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
75325275|NCT03454347|Dietary Supplement|Profile Perform|The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.
75325276|NCT03454347|Other|Lower Limb Suspension|This group will complete two weeks of lower limb suspension.
75325277|NCT03867305|Device|MOBIDERM|Use of a MOBIDERM mobilizing band after total knee prosthesis
75325278|NCT04940897|Other|Use of CareSens ketone meter|Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
75325279|NCT04938869|Other|Educational Intervention|Receive basic diabetes mellitus education
75325280|NCT04938869|Other|Medical Device Usage and Evaluation|Use CGM device and app
75325281|NCT04938869|Other|Survey Administration|Ancillary studies
75325282|NCT05192655|Other|Observation|Observation Study
75325283|NCT03361371|Device|Battery operated nasal aspirator|Suctioning prior to every feed with battery operated nasal aspirator for three days in addition to the routine standard of care.
75632704|NCT05330910|Procedure|Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
75632705|NCT05330910|Procedure|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
75632706|NCT04992156|Drug|Palbociclib|Palbociclib 125mg/d
75632707|NCT04259268|Other|Quality of preoperative information register|Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)
75632708|NCT04259268|Other|Suitability of information contained in the informed consent|Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)
75632709|NCT00608946|Dietary Supplement|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
75919101|NCT04756700|Diagnostic Test|DigiCog (BCCAMS app)|Administered as specified in the treatment arm.
75919102|NCT04756700|Diagnostic Test|Konectom Application|Administered as specified in the treatment arm.
75919103|NCT04742738|Biological|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
75325284|NCT03361371|Device|Suction bulb|Suctioning prior to every feed with bulb nasal aspirator for three days in addition to the routine standard of care.
75325285|NCT03359733|Drug|TAK-659|TAK-659 tablet.
75325286|NCT03357627|Drug|TAK-659|TAK-659 tablets.
75325287|NCT03357627|Drug|Venetoclax|Venetoclax tablets.
75632710|NCT00608946|Dietary Supplement|placebo|placebo
75632711|NCT02613832|Other|EPAP|The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.
75632712|NCT02613832|Other|Breath Stacking|The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
75783693|NCT01175096|Drug|RAD001 (everolimus, Afinitor®)|"RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.~2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days."
75783694|NCT02532959|Device|Diagnostic Breath Analysis|Conduct exhaled breath samples
75783695|NCT01174706|Behavioral|Information prescriptions|One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.
76076861|NCT03630315|Drug|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
76076862|NCT00929344|Drug|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
76076863|NCT00929344|Drug|Duloxetine|40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
76076864|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
76076865|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
76076866|NCT00929344|Drug|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
76076867|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
76076868|NCT03820557|Other|Educational Intervention|Undergo Decision Counseling Program
75919104|NCT04742738|Other|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
75919105|NCT04742738|Biological|GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
75919106|NCT04742738|Other|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
75919107|NCT04742738|Biological|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
75919108|NCT04742738|Biological|GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
75919109|NCT04742738|Other|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
75919110|NCT04775784|Diagnostic Test|Determination of SARS-CoV2 presence in CNS|Brain tissue sampling
75919111|NCT04725435|Behavioral|Kangaroo care|Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.
75325288|NCT03834701|Device|EUS guided radiofrequency ablation|The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
75632713|NCT00609648|Behavioral|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
75632714|NCT00609648|Behavioral|Pamphlet|A pamphlet reassuring patients about dental injections.
75632715|NCT02616016|Device|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
75919112|NCT04725435|Behavioral|Facilitated Tucking Position|"Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
75919113|NCT04706910|Drug|18F-DOPA|All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
75919114|NCT04706910|Drug|Furosemide Injection|Some participants will receive an intravenous injection of furosemide (40mg, single dose)
75919115|NCT04705805|Behavioral|Self-assessment of olfactory disorders through two questionnaires.|"Assessment of sense of smell or loss of smell using an Analogue Visual Scale~Carrying out the objective smell test (Sniffin' sticks test) (gold standard)~Information from two self-questionnaires translated into French: a quality of life questionnaire (The Questionnaire Olfactory Disorders (QOD)) and a self-assessment questionnaire of his olfactory capacities (Self-Mini Olfactory Questionnaire (Self-MOQ))"
75919116|NCT04704271|Drug|Inhaled THC|4 mg inhaled THC
75632716|NCT00609102|Drug|Placebo|one capsule BID
75632717|NCT00609102|Drug|n-aceylcysteine|450 mgm BID
75632718|NCT02620228|Device|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
75632719|NCT04259502|Procedure|Rhomboid intercostal block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
75632720|NCT04259502|Procedure|Erector spinae plane block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
75632721|NCT02615938|Drug|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
75632722|NCT02615938|Other|Placebo|Apply Placebo not to modify lysosomal pH
75632723|NCT00926328|Drug|Triclosan, fluoride|Six Month study, brush twice daily
75632724|NCT00926328|Drug|Fluoride|twice daily usage
75632725|NCT04203732|Procedure|Anesthesia Type|The anesthetic type either general anesthesia or neuraxial anesthesia is the intervention type for patients undergoing primary total joint arthroplasty of the knee or hip.
75632726|NCT00863512|Drug|cisplatin|Given IV
75632727|NCT00863512|Drug|docetaxel|Given IV
75632728|NCT00863512|Drug|gemcitabine hydrochloride|Given IV
75919117|NCT04704271|Drug|Placebo|Inhaled placebo (no active cannabinoids)
75919118|NCT04685850|Other|sequela evaluation|clinical and neurological examination, psychological evaluation (cognitive performance), an auditory, speech and visual assessment and an evaluation of the child's school performance
75919119|NCT04680286|Drug|Methadone Hydrochloride|Single dose, intravenous bolus, 0,1 mg/kg administered at induction of anesthesia.
75919120|NCT04680286|Other|Placebo|Single dose, intravenous bolus. Administered as the experimental arm.
75919121|NCT04678284|Behavioral|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide brief diabetes education as needed.
75919122|NCT04675762|Drug|Fingolimod|Patients randomized to fingolimod will also receive fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
75919123|NCT04675762|Other|Placebo|Patients randomized to fingolimod will also receive placebo once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
75919124|NCT04674722|Drug|Injection of 99mTc-NM-02|A Patient will be injected with microdose (<100ug) of 99mTc-NM-02 radiotracer
75919125|NCT04674722|Drug|Injection of 188Re-NM-02|A Patient will be injected with microdose (<100ug) of 188Re-NM-02 radionuclide therapy
75632729|NCT00863512|Drug|pemetrexed disodium|Given IV
75919126|NCT04672018|Other|Houtou Jianweiling tablet|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
76076869|NCT03630159|Biological|Tisagenlecleucel|Gene modified autologous T cells
75325289|NCT03839225|Other|Community intervention|"Community intervention will be built depending on contextual factors and will contain the following elements:~Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions."
75325290|NCT04923113|Diagnostic Test|Histology，13C urea breath test，Stool antigen test，Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori|The above 5 detection methods will be performed in patients who meet the inclusion criteria to detect H. pylori infection
75325291|NCT04923113|Drug|Rabeprazole，Minocycline，Amoxicillin and Colloidal bismuth pectin|Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days
75632730|NCT00863512|Drug|vinorelbine tartrate|Given IV
75919127|NCT04672018|Drug|Omeprazole Tablet|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
75919128|NCT04657458|Biological|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
75919129|NCT04649983|Biological|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
75919130|NCT04648475|Biological|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
75919131|NCT04638881|Drug|Magnesium sulfate|Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.
75919132|NCT04638881|Drug|Normal Saline|Placebo. Bolus and infusion administered similarly under general anesthesia.
76076870|NCT03630159|Drug|Pembrolizumab|anti PD-1
75325292|NCT05143047|Behavioral|Medication counseling|"Participants will receive a customized written medication instruction sheet which includes a picture of an oral dosing syringe indicating the patient's dose as well as a chart showing medication name, dose, route, frequency, duration, next dose due, side effects, and storage information. In addition, participants will be shown how to draw up their child's dose using an oral syringe and then will be asked to practice this task (show-back). Teach-back will be used to ensure participant's understanding of medication details."
75632731|NCT00863512|Procedure|standard follow-up care|Standard care
75632732|NCT04261920|Drug|Huangqi Guizhi Wuwu decoction|"The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)."
75632733|NCT05330832|Diagnostic Test|Thrombodynamics test|Thrombodynamics test is a global hemostasis test that allows to register the dynamics of fibrin clot formation in time and space. It requires whole blood samples from included patients.
75632734|NCT02619994|Drug|Linezolid|
75632735|NCT02619994|Drug|Delamanid|
75783696|NCT01285934|Biological|Autologous Hematopoietic Stem Cell Transplantation|All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation
75632736|NCT02619994|Drug|Levofloxacin|
75632737|NCT02619994|Drug|Pyrazinamide|
75632738|NCT02619994|Drug|Locally-used WHO-approved MDR-TB regimen in Korea|
75783697|NCT01285934|Drug|intensive insulin therapy|The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
75632739|NCT04263402|Drug|Methylprednisolone|Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).
75632740|NCT04263402|Drug|Methylprednisolone|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).
75632741|NCT04261374|Diagnostic Test|Measurement of sublingual microcirculation|Measurement of sublingual microcirculation
75632742|NCT04124458|Device|Radiofrequency ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
75783698|NCT01063361|Dietary Supplement|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
75783699|NCT01063361|Dietary Supplement|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
75783700|NCT03291808|Behavioral|Weight loss intervention|"This 6-month intervention will include restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate changes in dietary habits and activity patterns will be introduced, promoted and reinforced throughout the program. Weekly group meetings in a synchronous chat (i.e., in real time) led by a facilitator will be the venue for the group process. Extensive web-based resources to support behavior changes will be offered. Group chat sessions will meet online weekly for 6 months."
75919133|NCT04631198|Other|Thoracoabdominal rebalancing|the patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
75919134|NCT04630795|Device|ViscoTurf insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest.
75919135|NCT04630795|Device|Control insole|Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
75919136|NCT04627753|Drug|Rituximab, lenalidomide|Maintenance for 2 years
75919137|NCT04623853|Device|Variable Stiffness AFO|The Dynamic AFO is able to adjust in stiffness depending on activity.
75325293|NCT03925311|Procedure|endometrial biopsy and blood sampling|patient will be performed endometrial biopsy and collected blood samples at particular time points
75325294|NCT03923907|Behavioral|EIM intervention group|As in arm description
75325295|NCT02152085|Device|Narrow pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
75325296|NCT02152085|Device|Wide pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
75325297|NCT03250923|Drug|silver citrate complex and acemannan|Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan
75325298|NCT00805493|Drug|Riluzole|
75325299|NCT03236649|Drug|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
75632743|NCT04123834|Procedure|Patella tendon & bone block autograft + press-fit femoral technique|Implantless Arthroscopic ACL reconstruction using press-fit femoral technique The investigator's study uses the press-fit graft fixation technique by Edgar Michael. A midline skin incision was made that extends from inferior pole of patella up to anterior tibial tuberosity. Patella tendon with tibial tuberosity bone block were harvested, patella bone was left intact. The tendon was fixed together with non-absorbable suture.
75632744|NCT04123834|Procedure|Arthroscopic ACL reconstruction|Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)
75632745|NCT04123834|Device|Hamstring tendon autograft + implant fixation|Arthroscopic ACL reconstruction with implant (using hamstring tendon autograft fixed with bioscrew and endo-button)
75632746|NCT05298280|Device|Pendulum appliance|In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires. The 0.032-inch TMA wires were activated 45 degrees to produce a force of 200-250g per side. On average, intraoral reactivation of the distalizing springs was performed twice during the procedure. When a super Class I molar relationship was obtained, pendulum was replaced by a Nance holding arch. The average treatment duration was 8 months followed by bracket conventional therapy.
75632747|NCT05298280|Device|clear aligners|The standardized orthodontic intervention was represented by the maxillary molar distalization protocol proposed by Align Technology: it was planned in order to obtain a sequential distalization on the upper arch, and the staging was set at 0.25 mm per aligner. During sequential distalization aligners are set up to distalize one tooth at a time. The attachments were engineered by Align Technology to achieve predictable tooth movements. Each couple of aligners was worn for 7 days.
75632748|NCT02615704|Device|Active group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
75632749|NCT02615704|Device|Active group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
75632750|NCT02615704|Device|Control group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
75632751|NCT02615704|Device|Control group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
75632752|NCT02619916|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
75632753|NCT02619916|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
75632754|NCT00868192|Drug|Pemetrexed|
75632755|NCT00868192|Drug|Bevacizumab|
75632756|NCT02615782|Drug|CKD-397|CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
75919138|NCT04617951|Dietary Supplement|Ishige Okamurae extracts group|Ishige Okamurae extracts 300 mg/day for 12 weeks
75919139|NCT04617951|Dietary Supplement|Placebo group|Placebo 300 mg/day for 12 weeks
75919140|NCT04608773|Other|Remineralizing Extreme Dry Mouth Spray with Xylitol|oral hydrating spray
75919141|NCT04608773|Device|Alcohol-Free Moisturizing Dry Mouth Spray|oral hydrating spray
75919142|NCT04605718|Drug|RO7223280|For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.
75919143|NCT04602546|Device|BIS Complete Monitoring System|The BIS™ EEG complete monitoring system is intended for use under the direct supervision of a licensed healthcare practitioner or by personnel trained in its proper use. The system and its associated parameters are intended for use on adult patients within a hospital or medical facility, providing patient care to monitor the state of the brain by data acquisition of EEG signals.
75919144|NCT04591366|Other|Barrier dressing|A barrier dressing will be applied either pre or post implant prior to a culture swab and closing the incision.
75325300|NCT03236649|Drug|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
75919145|NCT04582149|Device|EyeControl Eye-tracking Device|The EyeControl is a new, wearable, eye-tracking device that facilitates communication by means of internal feedback to the patients with a bone-conducting speaker. In this way, the device can ask the patient what he or she wants to say, and the patient replies by eye gestures such as blinking or moving the eyes in a certain direction. Once the patient is able to operate the device, it will stay on the patient for as long as she or he would like it on, or until the patient is successfully extubated or discharged from the ICU, whichever is earliest.
75919146|NCT04577209|Device|Disposable oxygen face tent|Disposable oxygen face tent used to minimize aerosol particles (through suction) during aerosol generating anesthesia procedures.
75919147|NCT04571424|Drug|BIIB133 (Dapirolizumab pegol)|Administered as specified in the treatment arm
75919148|NCT04571424|Drug|Placebo|Administered as specified in the treatment arm
76076871|NCT04371874|Drug|Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin|The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
76076872|NCT04371796|Drug|Sintilimab injection|Sintilimab injection 200mg, 2cycles of treatment before surgery
76076873|NCT02244346|Drug|Secotex®|
76076874|NCT04365712|Device|Piezoelectric tool|
75325301|NCT00807209|Drug|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
75325302|NCT00807209|Drug|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
75325303|NCT00807209|Drug|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
75632757|NCT02615626|Procedure|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
75632758|NCT04122352|Other|Ischemic compression|Ischemic compression was performed 3 times ; after the initial evaluation, after the first week evaulation and after the second week evaulations.
75632759|NCT04122352|Other|Exercises (Rocabodo's 6x6 exercises and posture exercises)|Rocabodo's 6x6 exercises exercise was shown to be administered for 4 weeks. After the first week evaluation, posture exercises are added to the exercise programs of the patients.
75632760|NCT00930930|Drug|cisplatin|Given IV
75632761|NCT00930930|Drug|everolimus|Given orally
75632762|NCT00930930|Drug|paclitaxel|Given IV
75783701|NCT03864770|Device|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy is a mechanical sound wave that generates energy by extremely high-frequency vibration to compress the medium. Low-energy extracorporeal shock waves can be used for cell regeneration and pain control therapy; medium-high energy can be used to treat patients with poor bone healing; high-energy can be used to lithotrite. In recent years, extracorporeal shock waves have been applied on the musculoskeletal diseases, such as: epicondylitis, plantar fasciitis, chronic pelvic pain, chronic heel pain syndrome, lymphedema, burns, pressure sores, calcific tendinitis and myofascial pain syndrome. This treatment is a non-invasive and safe treatment.
75919149|NCT04569864|Procedure|Hypothermic circulatory arrest with unilateral selective anterograde cerebral perfusion|Hypothermic circulatory arrest provides protection to cerebral and visceral organs.
75325304|NCT00807209|Drug|Fentanyl via PCA|Fentanyl via PCA
75783702|NCT03864770|Procedure|General physical therapy|The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
75325305|NCT00807209|Drug|Bupivacaine via epidural|Bupivacaine via epidural
75632763|NCT00930930|Other|placebo|Given orally
75632764|NCT00930930|Procedure|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
75632765|NCT00698776|Drug|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
75632766|NCT00698776|Biological|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
75632767|NCT04259112|Procedure|high pressure|High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
75919150|NCT04564612|Drug|BIIB091|Administered as specified in the treatment arm
75919151|NCT04564612|Drug|Rabeprazole|Administered as specified in the treatment arm
76076875|NCT04365712|Device|Oscillating Saw|
76076876|NCT04366024|Other|other|clinical diagnosis
76076877|NCT04376554|Drug|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) PO q8h [±1 hour] for 10 days
75632768|NCT04259112|Drug|deep neuromuscular block|Deep neuromuscular block is defined as PTC 1-2.
76076878|NCT04376554|Drug|amoxicillin-clavulanate|amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h [±1 hour] for 10 days
76076879|NCT03627741|Drug|Triamcinolone Acetonide|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
76076880|NCT04371718|Drug|JKB-122|JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
76076881|NCT04371718|Other|Placebo|A capsule has same component but active drug
76076882|NCT03712839|Other|Cognitive-functional evaluation|The participants will be evaluated with a set of tools within the context of meaningful ADL.
76076883|NCT04376164|Radiation|low level laser therapy|mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months
75632769|NCT04259112|Procedure|low pressure|Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
75632770|NCT04259112|Drug|moderate neuromuscular block|Moderate neuromuscular block is defined as TOF twitch 1-2.
75632771|NCT04122040|Drug|Roxithromycin 300 MG|Roxithromycin 300 mg oral per day
75632772|NCT04122040|Drug|Placebo|Placebo one table oral once dialy
75632773|NCT04134364|Drug|Sodium alginate|3 days oral administration of sodium alginate after gastric biopsy
75632774|NCT04259034|Other|diagnosis of periodontitis in oral lichen planus patients|diagnosis of periodontitis in oral lichen planus patients
75632775|NCT04259034|Other|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
75632776|NCT04120948|Device|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
75919152|NCT04564612|Drug|Itraconazole|Administered as specified in the treatment arm
75919153|NCT04539470|Drug|Efmarodocokin Alfa|Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.
75919154|NCT04534907|Combination Product|The combination of exposure and response prevention (ERP) and VR|The combination of exposure and response prevention (ERP) and VR aimed to investigate the combination of an immersive virtual reality environment (VRE) alongside therapist delivered CBT to reduce anxiety when the OCD patients were induced by virtual scene.Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get VR+ERP session twice a week. From the fourth week to the seventh week, patients weill get VR+ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
75919155|NCT04534907|Behavioral|Traditional ERP|Patients will achieve the exposure based CBT for total 10 times excluding 8 sessions of ERP. Structured protocol described by Foa et al., 2012. Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get ERP session twice a week. From the fourth week to the seventh week, patients weill get ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
75632777|NCT04120948|Device|Tongue scraper|mechanical scraping of the dorso-posterior surface of the tongue
75919156|NCT04521062|Device|Dilapan S|Placement of Dilapan S
75919157|NCT04518319|Drug|Omega-3 polyunsaturated fatty acids|Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.
75919158|NCT04518319|Behavioral|Xbox aerobic exercise|Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.
75919159|NCT04518319|Device|transcranial direct current stimulation,tDCS|Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.
75919160|NCT04518319|Drug|Olanzapine|Patients will take only olanzapine pills.
76076884|NCT04365322|Other|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
76076885|NCT03719937|Device|weight on the anterior chest of the patient|The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
75325306|NCT03372317|Drug|18F-MK-6240|Results of the 18F-MK-6240 PET scan will be correlated with other observations.
75325307|NCT00807989|Drug|Carbamazepine|
75325308|NCT00807989|Drug|Lamotrigine/Valproate|
75632778|NCT00609882|Other|Nasal CPAP|"Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation"
75632779|NCT00609882|Other|Humidified High Flow Nasal Cannula (HHFNC)|HHFNC
75919161|NCT04516226|Other|Vaginal cleansing with chlorhexidine gluconate solution|Cleansing of the vaginal walls with chlorhexidine gluconate solution for women diagnosed with PPROM
76076886|NCT03818217|Device|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
76076887|NCT03818217|Device|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
75632780|NCT04259190|Behavioral|interoceptive exposure|Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
75632781|NCT04258956|Drug|Axitinib|"Avelumab 10 mg/kg will be administered every two weeks. Avelumab is administered as a 1-hour iv infusion, diluted with 0.9% saline solution; Axitinib 5 mg should be taken orally twice daily approximately 12 hours apart with or without food. They should be swallowed whole with a glass of water. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~The duration of treatment cycle is 28 days."
75919162|NCT04511871|Biological|CCT303-406|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.
76076888|NCT03626337|Drug|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
76076889|NCT02244658|Drug|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
75919163|NCT04503941|Device|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
75919164|NCT04503941|Device|False Needle treatment|False Needle treatment treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
75632782|NCT00862654|Drug|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
75919165|NCT04495868|Drug|Bacteriostatic Normal Saline|A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
76076890|NCT03718845|Behavioral|Mind-Body Medicine Curriculum|The Mind-Body Medicine curriculum consists of presentations on different mind-body techniques as well as the research supporting the use of these techniques.The mind-body technique is then practiced in a supportive small group setting. Mind-body techniques will include guided imagery, relaxation techniques, several forms of meditation, autogenic training and biofeedback.
76076891|NCT02982616|Dietary Supplement|Dodecanoic acid|The middle chain saturated fatty acid that can be widely found in daily food.
75919166|NCT04495868|Drug|1% Lidocaine|A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
75325309|NCT05131191|Diagnostic Test|CT-FFR measurement|Patients were scanned with ≥ 64 row CT according to standard operating specifications. The software obtains the coronary CT angiography image file through the data communication interface. Based on the image processing algorithm, the centerline and contour of the target vessel can be extracted, and then the target vessel can be reconstructed to obtain the three-dimensional size information of the vessel; Based on hydrodynamics calculation and analysis, the fractional flow reserve (FFR) of each position of the target vessel is measured.
75919167|NCT04483544|Drug|pembrolizumab|PD-1 inhibitor pembrolizumab, 200mg intravenously (IV) every 3 weeks
75919168|NCT04483544|Drug|olaparib|PARP inhibitor olaparib 300 mg orally, twice daily (BID)
75325310|NCT05131191|Procedure|invasive FFR|Insert the pressure guide wire into the finger guide tube and push the pressure guide wire until the pressure sensor just comes out of the orifice of guiding catheter; Equalize PD and PA values;Push the pressure guide wire to the distal end of the lesion, and record the measured blood vessel and position;Record the resting Pd / PA of the pressure guide wire;Nitroglycerin and adenosine triphosphate were administered intravenously according to standard catheter laboratory specifications to achieve maximum hyperemia;Record the FFR value of the in-stent lesions.
75325311|NCT05124327|Other|QI project- usage of RPM|close monitoring through RPM to analyze feasibility and compare readmission rates
75325312|NCT05124249|Diagnostic Test|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
75632783|NCT00862654|Drug|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
75919169|NCT04475029|Drug|Methadone|One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
75632784|NCT00862654|Drug|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
75919170|NCT04475029|Drug|Morphine|One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
75919171|NCT04466735|Dietary Supplement|Active group|2 x 12 g of EKS/day
75919172|NCT04466735|Dietary Supplement|Placebo group|Isocaloric placebo supplement with similar salt load but no EKS
75919173|NCT04466111|Device|Intellis neurostimulator system|The study will use the commercially available IntellisTM neurostimulator and compatible SCS system components from Medtronic using stimulation parameters within the specifications approved for use in the approved indications. The study will stimulate the cervical dorsal columns of the spinal cord.
75919174|NCT04457089|Drug|Simvastatin 40mg|Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
76076892|NCT02982616|Behavioral|Positive emotion|Positive emotion induced by facial expressions and classic music.
76076893|NCT02982616|Dietary Supplement|saline|saline
76076894|NCT02982616|Behavioral|neutral emotion|Neutral emotion induced by facial expressions and classic music.
76076895|NCT04403841|Other|patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control|The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence
75325313|NCT05124249|Procedure|PCI|Patients who undergoing PCI
75325314|NCT04744558|Other|Low carb high fat ketogenic dieting|Macronutrient ratios for low carb high fat ketogenic diet were 20 %, 5 %, 75 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
75632785|NCT00862654|Drug|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
75632786|NCT00609180|Behavioral|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
76076896|NCT04403841|Other|Usual diabetes care alone|Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
75919175|NCT04456881|Other|Patients with patellar dislocation undergo patellar femoral medial reconstruction|Arthroscopic double-beam anatomical reconstruction of medial patellofemoral ligament
75632787|NCT00609180|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
75325315|NCT04744558|Other|Low carb high fat non-ketogenic dieting|Macronutrient ratios for low carb high fat non-ketogenic diet were 20 %, 15 %, 65 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
75632788|NCT00609180|Dietary Supplement|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
75632789|NCT00609180|Dietary Supplement|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
75632790|NCT00867490|Drug|Candesartan+HCTZ - Phase 1|4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.
75632791|NCT00867490|Drug|Aliskiren+HCTZ - Phase 2|Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
75632792|NCT00867490|Drug|Aliskiren+HCTZ+amlodipine - Phase 3|The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
75783703|NCT05275348|Behavioral|Tele-Enhance Fitness|"Tele-Enhance Fitness (tele-EF) is a community-based exercise program for older adults. It is a supervised group exercise program that will meet virtually 3 times a week for 1 hour for 4 months. Each tele-EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Tele-EF classes will be led by an instructor trained in administering EF through a virtual format. EF instructors will be able to monitor and correct participant's movements through videoconference. All tele-EF classes are monitored by a spotter who watches participants exercise using gallery mode."
75632793|NCT04263012|Other|collection of patient data|assess mortality rate, rehospitalization and survival rate of patients after receiving an artificial heart implant
75632794|NCT00697060|Drug|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
75632795|NCT00930774|Device|FM system|Frequency modulation assistive device
75632796|NCT00930774|Behavioral|Auditory training|Participation in computerized auditory training program for eight weeks
75632797|NCT04248504|Other|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
75632798|NCT04261530|Behavioral|Self-hypnosis/self-care|
75325316|NCT04745247|Procedure|RSS|"Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours~Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS"
75919176|NCT04441047|Drug|AlloStim|Living, activated allogeneic Th1-like memory immune cells
75325317|NCT05111392|Biological|Placebo|Ingestion of one (1) liter of beverage with observation for 2 h
75632799|NCT04261530|Behavioral|Music/self-care|
75325318|NCT05111392|Biological|Oral Rehydration Solution 1|Ingestion of one (1) liter of beverage with observation for 2 h
75325319|NCT05111392|Biological|Oral Rehydration Solution 2|Ingestion of one (1) liter of beverage with observation for 2 h
75632800|NCT04261530|Behavioral|Self-care|
75632801|NCT04261530|Behavioral|Psycho-education|
75632802|NCT00867334|Drug|Imatinib mesylate and panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
75632803|NCT00867334|Drug|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
75632804|NCT04120324|Other|Eligible for Same Day Discharge|Preoperative Physiotherapy and Anesthesia Criteria met.
75632805|NCT04120324|Procedure|Primary Single Joint Total Hip Arthroplasty|Total Hip Replacement Surgery
75919177|NCT04417205|Other|Carbohydrate Rich Breakfast|Participants will be asked to consume the provided carbohydrate rich breakfast before 1000h daily for 28 days.
75919178|NCT04417205|Dietary Supplement|Whey protein enriched breakfast|Participants will be asked to consume the provided whey protein enriched breakfast before 1000h daily for 28 days.
76076897|NCT03624621|Behavioral|Functional Remediation|Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
76076898|NCT03624621|Device|Computerized Cognitive Training (CCT)|12 add-on sessions (20-minute long) after each group session to train cognitive domains.
75783704|NCT05275348|Behavioral|In-person Enhance Fitness|Enhance Fitness is a community-based exercise program for older adults. It is a supervised group exercise program that will meet in person 3 times a week for 1 hour for 4 months. Each EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning/walking, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Classes will be led by an instructor trained in administering Enhance Fitness.
75632806|NCT04120324|Other|Discharge Same Day|Postoperative criteria for Same Day Discharge met.
75632807|NCT00925704|Drug|Calcitriol|Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
75783705|NCT01060163|Drug|Tranexamic Acid|A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
75919179|NCT04404101|Procedure|1). EUS-FNA plus MFB|The cyst will be punctured using a 19-G EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed and the wall of the cyst biopsied using the micro forceps passed through the 19 G needle under direct EUS visualization. A minimum of 4 cyst wall biopsies will be obtained to procure at least 4 visible tissue fragments. Cyst fluid will be aspirated and sent for CEA and cytology.
75325320|NCT00364234|Device|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
75783706|NCT01060163|Drug|Saline|Saline served as placebo
75919180|NCT04404101|Procedure|2). EUS-FNA Alone|The cyst will be punctured using an EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed, and cyst fluid will be aspirated and sent for CEA, and cytology.
75919181|NCT04364958|Other|A web based-Patient Decision Aid (PtDA) (shown on the computer)|Patient decision aids (PtDAs) are tools that assist patients in making health decisions, when there is uncertainty about treatment choice, incorporating their personal preferences and values about the available treatment options. This PtDA will include information about GAD symptoms, diagnosis, causes, and benefits and risks associated to psychological and pharmacological treatments for GAD (based on the Clinical Practice Guidelines-GAD). It will also include a values clarification exercise, in which patients will have to rate the importance attributed to the different aspects of treatments (e.g., mode of administration, benefits, risks, time to improvement, probability of relapse).
75919182|NCT04364958|Other|A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care.|Patients in the control group will receive a fact sheet (one page) with general information on mental health as a part of usual care provided by the Canary Islands Health Service.
75919183|NCT04354402|Other|No intervention|No intervention
75919184|NCT04348643|Biological|CEA CAR-T cells|CEA-CAR-T cells will be administered intravenously.
75325321|NCT03210675|Diagnostic Test|Polysomnography (PSG)|PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
75919185|NCT04340661|Dietary Supplement|BIOintestil|Ginger ryzoma powder and Palmrose essential oil (Cymbopogon Martinii)
75919186|NCT04340661|Dietary Supplement|PLACEBO|Cornstarch
75325322|NCT04928872|Combination Product|Predefined meal|Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
75325323|NCT00357591|Device|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
75325324|NCT04905628|Device|Dexcom CGM System|Dexcom CGM System
75632808|NCT00925704|Drug|Lanthanum carbonate + Calcitriol|Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
75632809|NCT00925704|Drug|Sevelamer carbonate + Calcitriol|Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
75632810|NCT00697138|Drug|d-Amphetamine; Atomoxetine|Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
75632811|NCT02615548|Other|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
75632812|NCT02615548|Other|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
75632813|NCT04263168|Diagnostic Test|Continuous Glucose monitoring in the perioperative period|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
75632814|NCT02619604|Other|Education Intervention|Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
75632815|NCT00609960|Behavioral|clowns present|clowns present during the proccess of induction of anesthesia
75783707|NCT03864380|Diagnostic Test|Color retinography|Non mydriatic color retinography within 1 month before and within 1 hour after the marathon
75783708|NCT03864380|Diagnostic Test|OCT-A|Optical Coherence Tomography - Angiography within 1 month before and within 1 hour after the marathon
75783709|NCT03864380|Diagnostic Test|Blood pressure measurement|Blood pressure measurement within 1 month before and within 1 hour after the marathon
75783710|NCT01063439|Drug|Busulfan, Etoposide, Cytarabine, Melphalan|Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
76076899|NCT03624621|Behavioral|Psychoeducation|12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.
75325325|NCT03218891|Behavioral|Cardiac Rehabilitation|"The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~5 minutes warm up~30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~10 minutes of localized exercises;~5 minutes of relaxation."
75468316|NCT05994482|Other|survey and expert panel|The investigators will conduct 44 semi-structured one-on-one qualitative interviews with VA patients (older adults) and providers (primary care, GI, geriatrics) to understand perspectives on CRC risk, and potential benefits and harms of surveillance (Aim 3a). The investigators will then convene an expert panel with key stakeholders including Veterans, primary providers, geriatricians, gastroenterologists, VA leaders, and policy makers to present Aim 1, 2, and 3a findings (Aim 3b). The primary outcome will be specific recommendations regarding use of surveillance colonoscopy in older adults, ranked by priority and feasibility, that can guide VA policy around future implementation (or de-implementation) of surveillance among older adults.
75325326|NCT05722977|Drug|Surufatinib + envafolimab|Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks
75468317|NCT05994313|Dietary Supplement|Habitual potato consumption|Potatoes are to be consumed in the evening meal, every evening for 12-weeks.
75468318|NCT05994313|Dietary Supplement|Habitual non-nutrient-dense staple consumption|White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.
75468319|NCT05988164|Other|Eye Mask|Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier.
75468320|NCT05986149|Behavioral|Conversation about arts and culture|intergenerational conversation about arts and culture between older adults and international students who native language is not English.
75468321|NCT05984524|Behavioral|Gamma-Music Based Intervention|Gamma or Control lights with Music-Based Intervention for 8 week period
75632816|NCT00609960|Drug|midazolam|midazolam
75468322|NCT05982184|Other|Music|Patient preferred music listened to through earpieces or headphones using patients' own hardware and software.
75468323|NCT05979519|Behavioral|Fresh Funds for Mom's|"Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.~Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks."
75632817|NCT00697840|Biological|Engerix™-B|Intramuscular injection, 2 doses
75632818|NCT00697840|Biological|HBV-MPL 208129|Intramuscular injection, 2 doses
75632819|NCT00697840|Biological|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
75632820|NCT04879134|Drug|Apomorphine Injectable Solution|"Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo"
75783711|NCT03263806|Diagnostic Test|CTFFR-Guided Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.
75632821|NCT04879134|Drug|Placebo|"0.9% saline placebo injection~Other Names:~• Saline"
75632822|NCT00697216|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
75632823|NCT00697216|Biological|Engerix™-B|3-dose intramuscular injection
75632824|NCT04879056|Diagnostic Test|PIPS 5.1|Description: Scanning glass slides on PIPS 5.1. This intervention will be applied in the arm of intra-system and the arm of inter-system.
75632825|NCT04134130|Drug|Degarelix 120 MG [Firmagon]|Two doses of degarelix, 240 mg, subcutaneously once, at study start.
75632826|NCT04134130|Drug|Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector|Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
75632827|NCT04134130|Drug|Testosterone Undecanoate|One dose 1000 mg testosterone once, after 3 weeks.
75632828|NCT04258644|Drug|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Combination therapy of 4 drugs, 21 days for one cycle.
75632829|NCT02619448|Drug|Carboplatin|chemotherapy
75632830|NCT02619448|Drug|Paclitaxel|chemotherapy
75632831|NCT02619448|Radiation|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
75783712|NCT03263806|Diagnostic Test|SOC Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
75919187|NCT04324268|Drug|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
75919188|NCT04324268|Other|Placebo|Placebo
76076900|NCT03624621|Device|Online games|Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
76076901|NCT00929500|Behavioral|MAST program|MAST program: twice a week for 4 months
76076902|NCT03816111|Behavioral|TEACH-PD Training Curriculum|The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.
76076903|NCT03816111|Behavioral|Current standard PD training|Current PD training materials and plan
75632832|NCT00610038|Drug|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
75919189|NCT04300153|Procedure|ESP Block|At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process
75468324|NCT05979519|Behavioral|Standard Medical care|Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks or be provided the medically tailored meals for 12 weeks.
75632833|NCT02876588|Other|Unrestricted|Users may open up to 4 patient records at a time.
75783713|NCT03741959|Procedure|Experimental group|"Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015)."
75783714|NCT03741959|Procedure|Control group|Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
75632834|NCT02876588|Other|Restricted|Users are restricted to open 1 patient record at a time.
75783715|NCT03751280|Device|PEAR-004|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
75783716|NCT03751280|Device|Sham|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
75783717|NCT05275270|Other|oxytocin gel|The active oxytocin gel (A) consisted of oxytocin dissolved in a gel-based on hypromellose with a pH of 3.8. 1 ml of gel contained 600 IU of oxytocin
75919190|NCT04300153|Other|Global Quality of Recovery-15 score|Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.
75919191|NCT04300153|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.
76076904|NCT00929578|Drug|Fluphenazine|Intralesional injection of Fluphenazine
75783718|NCT05275270|Other|placebo gel|The placebo gel (B) consisted of the gel alone
75632835|NCT04970472|Biological|collection of blood, urines, stool and tumor samples|blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
75632836|NCT04031248|Device|Whole body vibration|In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices [Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
75632837|NCT04031248|Other|EXERCISE group|The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
75632838|NCT01076036|Device|CorPath 200|CorPath™ 200 robotically-assisted percutaneous coronary intervention
75632839|NCT01076036|Device|CorPath 200|CorPath PCI - robotic-assisted percutaneous coronary intervention
75632840|NCT04119856|Other|Affiliation with the outgoing lung team|"The work of the outgoing lung team takes place in the patient's home and involves the following:~The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call."
75632841|NCT04258800|Device|Music during colonoscopy|Music during colonoscopy
75632842|NCT02619526|Drug|Nebivolol|Nebivolol 10mg, once a day
75632843|NCT02619526|Drug|Carvedilol|Carvedilol 25mg, twice a day
75783719|NCT01060241|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
75783720|NCT01048931|Procedure|single-port LAVH|single-port LAVH
76076905|NCT00929578|Drug|Placebo|Intralesional injection of placebo
75468325|NCT05979519|Behavioral|Medically Tailored Frozen Meals|Participants will enroll in the MTM program. Once enrolled participants will receive 10 frozen meals delivered by Door Dash to their home each week for 12 weeks.
75468326|NCT05977023|Drug|NMDAE|Use of an NMDA enhancer for the treatment of bipolar depression
75919192|NCT04298216|Diagnostic Test|Ultrasound Analysis of Inferior Vena Cavae (IVC)|Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
75325327|NCT00843713|Drug|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
75325328|NCT00843713|Drug|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
75919193|NCT04289467|Drug|Fenfluramine|Open-label
75919194|NCT04283097|Drug|KPG-818|The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.
75919195|NCT04279574|Device|Lithium disilicate onlays (IPS emaxCAD/Ivoclar)|Restoration of posterior teeth
75919196|NCT04279574|Device|Chairside zirconia crowns (3M)|Restoration of posterior teeth
75919197|NCT04278157|Behavioral|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|The SCBT-SB is a manualized and flexible intervention that uses a modular approach to the treatment of adolescent suicidality. After the first mandatory module (Crisis module), and at the end of each subsequent module, the therapist works with the teen and caregivers to determine the next one. The Crisis Module is fixed and represent the intervention core skills with 9 sessions. The optional coping skills modules include Thoughts, Emotional Regulation, Family Communication, Social Interaction, Activity, Trauma, and Substance Use.
75919198|NCT04278157|Behavioral|Treatment as Usual|Therapy that typically consist of eclectic individual therapy including CBT, emphasizing psychoeducation and providing support, with occasional conjoint parent sessions or individual caregiver sessions. The treatment as usual primarily focuses on generating solutions to the adolescent and caregivers most urgent concerns.
75632844|NCT04261140|Other|EQUIA Forte Fil|"Apply cavity conditioner (20% polyacrylic acid) 10 s on enamel and dentine, rinse Mix 10 s and apply bulk-fill Apply EQUIA coat and light cure for 20 s~unit"
75632845|NCT04261140|Other|Clearfil Majesty Esthetic|Apply in 2-mm increment, light cure for 20 s
75632846|NCT04261140|Other|NexComp Flow|Apply in 2-mm increment light cure for 20 s
75632847|NCT04261140|Other|3M Espe Bulk-fill|Apply in single increment up to 4 mm; light curing for 20 s
75783721|NCT03865784|Other|Experimental|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done, proceed to ask the subject to lean forward applying the rest of the strip, except the distal edge, with a tension of between 15 and 25%, finally requesting the subject to rejoin straining the distal base without tension, on the twelfth dorsal spinous process.
75919199|NCT04272151|Biological|BCMA CAR-T cells|A single infusion of BCMA CAR-T cells will be administered intravenously.
75919200|NCT04272125|Biological|CD123 CAR-T cells|A single infusion of CD123-CAR-T cells will be administered intravenously
75919201|NCT04271800|Biological|CD19 CAR-T cells|A single infusion of CD19-CAR-T cells will be administered intravenously.
75919202|NCT04271644|Biological|BCMA CAR-T cells|BCMA CAR-T cell therapy
75325329|NCT04845490|Drug|Mitomycin|Mitomycin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
75325330|NCT04845490|Drug|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Lobaplatin 50mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
75325331|NCT00356967|Drug|dianicline|
75325332|NCT00357045|Drug|Paroxetine|
75325333|NCT04819360|Drug|VESIcare 10Mg Tablet|"Vesicare® 10 mg per day for 12 weeks~Vesicare 10mg 12 weeks"
75325334|NCT04819360|Drug|Botox 100 UNT Injection|1 injection of Botox® 100 UNT
75325335|NCT04585204|Diagnostic Test|Oral glucose tolerance test|Oral glucose tolerance test
75632848|NCT04119622|Drug|Toripalimab|toripalimab 240 mg d1; q3w, up to two cycles.
75632849|NCT04119622|Drug|oxaliplatin|oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
75783722|NCT03865784|Other|Control|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. The objective of the application of the technique based on this type of exercise is to improve muscle strength, endurance and neuromuscular control. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done the tape will be placed without tension and sn movement of the subject.
75783723|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|Decision Aid
75783724|NCT02872558|Other|Usual Care|Usual Care
75325336|NCT05722899|Other|Football training|10-week progressive football training with small-sided games, 2x/week, 45min-1h sessions
75325337|NCT04341220|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation.
75468327|NCT05977023|Drug|Placebo Cap|Use of placebo as a comparator.
75783725|NCT05275192|Device|Videoscope-assisted periodontal regeneration minimally invasive surgery|Use of a videoscope to improve visualization of periodontal defect during minimally invasive surgery
75468328|NCT05968586|Other|Body positioning|Body positioning of infants prone vs supine.
75632850|NCT04119622|Drug|capecitabine|apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
75632851|NCT04261452|Diagnostic Test|isokinetic dynamometer|"Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. Positioning of the subjects (sitting with hips flexed to 75°) was standardized based on the length of the thigh and leg to minimize individual differences. Correction for the effect of gravity on neuromuscular performance was accomplished by incorporating limb mass into the calculation of torque production. Previous warm-up was repeated five time with an angular velocity of 400°/s. All patients randomly performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.~Measurements of torque, work (J), power (W) maximum (peak), and fatigue index were obtained in both tests. In addition, data were analysed at percent of prediction (percent pred) by reference values previously described for the Brazilian population, corrected by muscle mass and peak values."
75632852|NCT04261452|Diagnostic Test|Cardiopulmonary Exercise Test|"All exercise tests were performed on an electronically braked cycle ergometer. Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system.~The incremental exercise test started with 2-min unloaded cycling and increments of 3-10 Watts per min until exhaustion. The anaerobic threshold was estimated by the ventilatory equivalents and V-slope methods and it was determined in agreement by a cardiologist and pulmonologist. Heart rate was determined using the 12-lead electrocardiogram. Throughout the experiment, the pulse hemoglobin saturation (SpO2) was assessed with a pulse oximeter and the 'shortness of breath' was asked at exercise cessation using the 0-10 Borg category ratio scale. All measurements were expressed as percentage predicted for the Brazilian population."
75632853|NCT04261452|Diagnostic Test|Functional Capacity Tests|"The six-minute walk test (6MWT) was in accordance with the American Thoracic Society (ATS). The four-minute step test (4MST) consisted of going up and down a 20-cm high, 40-cm wide and 40-cm long step for 4 minutes.~The investigators measured the heart rate and pulse hemoglobin saturation at rest before each test and every minute of both tests. The investigators assessed dyspnoea and leg fatigue at rest and with the modified Borg scale immediately after finishing the test."
75632854|NCT04261452|Diagnostic Test|Lung Function Test|"Spirometry, gas transfer, and static lung volumes were measured in all patients, and airflow was measured using a Pitot-tube based on the American Thoracic Society/European Respiratory Society guidelines. Measurement of maximal inspiratory and expiratory pressures was performed from the residual volume and total lung capacity. Resting blood gases were obtained by samples from the radial artery."
75783726|NCT05275192|Procedure|Periodontal regeneration minimally invasive surgery|Conventional periodontal regeneration minimally invasive surgery without use of a videoscope
75783727|NCT05275192|Procedure|Guided tissue regeneration surgery|Conventional guided tissue regeneration surgery for periodontal regeneration without use of a videoscope
75783728|NCT01283906|Device|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
75783729|NCT01283906|Device|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
75783730|NCT05253898|Procedure|Pelvic floor Physical Therapy|Purpose of pelvic floor muscle education program is reduce the symptoms of stress urinary incontinence and improving quality of life.
75783731|NCT05253898|Procedure|Therapeutic Yoga Training|Purpose of this group show the effectiveness of yoga therapy on stress urinary incontinence and quality of life.
75325338|NCT04341220|Other|Balance exercises|Specific balance exercises, focused on balance, postural control and control of the center of gravity within the support base.
75325339|NCT00357123|Drug|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
75325340|NCT04436458|Drug|Niclosamide Oral Tablet|Continued SOC therapy together with niclosamide TID for 14 days
75325341|NCT04436458|Drug|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
75325342|NCT03834753|Biological|bevacizumab|1.25 mg, intravitreal injection
75325343|NCT03834753|Biological|ranibizumab|0.5mg, intravitreal injection
75325344|NCT04271878|Other|RespirAct™ system (Thornhill Research Inc., Toronto, Canada)|"HUTT with Normal Breathing in Room Air (No gas interventions will be applied)~HUTT with Normal Breathing and ETCO2 clamped at baseline levels~HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg )~HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg)~HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied~HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels."
75325345|NCT00845039|Biological|Cetuximab|Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
75325346|NCT00845039|Drug|Irinotecan|180 mg/m² every 14 days until disease progression or participant intolerance
75325347|NCT00845039|Biological|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
75325348|NCT05098821|Other|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
75325349|NCT03879616|Behavioral|An Enhanced Reminder|"This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure."
75325350|NCT00845195|Drug|Olopatadine HCl Nasal Spray, 0.6%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
75325351|NCT00845195|Drug|Azelastine HCl Nasal Spray, 0.1%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
75325352|NCT00845507|Drug|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
75325353|NCT00845507|Drug|Placebo|Placebo: Sterile solution in equivalent doses as Exenatide
75325354|NCT03782506|Behavioral|Interactive Music Therapy|Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.
75632855|NCT04261452|Diagnostic Test|Doppler Echocardiography|The same medical doctor performed all echocardiograms and all patients underwent comprehensive echocardiography.
75632856|NCT04261452|Diagnostic Test|Anthropometry and Body Composition|"Body composition was assessed using a body composition analyzer. Percent body fat was estimated from the resistance and reactance values.~Resistance values and the subject's height (meters), weight (kg), sex, and age (years) were entered into a computer program to estimate percentage of fat, fat mass (FM), and muscle mass (MM)."
75468329|NCT05946824|Radiation|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields
75632857|NCT01096316|Behavioral|Depression Care Management|The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
75632858|NCT00699166|Drug|DNK333|25 mg and 100 mg oral doses, each taken twice daily
75468330|NCT05946824|Radiation|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields
75468331|NCT05945940|Other|no intervention|no intervention
75783732|NCT03868202|Drug|Estradiol Transdermal Product|Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
75783733|NCT00311363|Drug|GEn (XP13512)|1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
75783734|NCT00311363|Drug|GEn (XP13512)|1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
75783735|NCT00311363|Drug|Placebo|Placebo, orally, once daily for 12 weeks following single blind 24-week phase
75783736|NCT03867968|Behavioral|TIPS Intervention|Web-based training for family member.
75783737|NCT03867968|Behavioral|Control|Traumatic Brain Injury website for family members.
75783738|NCT03868358|Device|transcranial magnetic stimulation|"The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks"
75783739|NCT01171274|Behavioral|Hatha Yoga|"9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~One class of 90 minutes per week, 10 minutes training at home each day."
75783740|NCT01171274|Behavioral|Information regarding exercises and behaviour|"9 weeks of exercises practiced at home.~Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
75468332|NCT05945641|Behavioral|Low Load Resistance training|Performing single leg knee extension exercise with using equivalent to ~30%1-RM to failure,
75468333|NCT05945641|Behavioral|Sprint/High Intensity Interval Training|Performing repeated submaximal/maximal 30second-60 seconds (1-3 minute rest between) aerobic intervals on a Kicking ergometer (modified bike that allows cycling to be performed with one leg using a kicking motion).
75632859|NCT04119700|Procedure|Muco-muscular endorectal advancement flap after fistulectomy|After fistulectomy muco-muscular flap of the rectal wall will be mobilized. The muscular defect is sutured with separate interrupted sutures (Vicryl / Polysorb 2/0, 0/0, 3/0). The muco-muscular flap is fixed to the anoderm without tension by interrupted sutures (Vicryl / Polysorb 4/0). The wound of the perianal area is not sutured.
75783741|NCT03863756|Radiation|EOS|The new EOS-technology (EOS imaging, Paris, France) based on a low-dose X-ray system allows 3D modeling of the spine based on 2-dimensional
75783742|NCT00333983|Device|Robotic Upper Extremity Neurorehabilitation|Upper extremity exercise using a planar robot Upper extremity exercise using a planar and vertical robot
75783743|NCT00333983|Other|Traditional Upper Extremity Exercise Group|Upper extremity stretching, skateboard reaching activities, and arm ergometer
75783744|NCT01171352|Procedure|Transpulmonary Thermodilution|A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
75783745|NCT01171430|Device|Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)|"3 Whole Body Dynamic Contrast Enhanced MRI:~1 WB-DCE-MRI before induction of chemotherapy(initial MRI).~1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).~1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI)."
75783746|NCT01175252|Other|Database analysis|Review and collect data from database
75783747|NCT01171508|Device|Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA|Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
75783748|NCT01171508|Device|Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
75919203|NCT04271410|Biological|CD19 CAR-T cells|CD19 CAR-T cell therapy
75325355|NCT03782506|Behavioral|Verbal-based support|Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
75632860|NCT04119700|Procedure|Primary sphincter reconstruction after fistulectomy|Fistulectomy will be performed. The affected gland is visualized and removed. If there are secondary extensions, they are excised also. Sphincter defect with stitches (suture material Vicryl / Polysorb 2/0, 0/0, 3/0) with restoration of the anal canal profile (suturing of the anodermal-skin border). The skin is not suturing.
75468334|NCT05944133|Other|No intervention, observational retrospective study|No intervention
75632861|NCT04132726|Other|Massage therapy|Massage therapy performed by a physiotherapist
76076906|NCT04371484|Other|ICD-10|A collection of ICD-10 codes used within the PMSI that relate to physical abuse.
76076907|NCT04371016|Other|Verticalization (bed)|"The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes.~At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method"
76076908|NCT04371406|Drug|Hydroxychloroquine and Azithromycin|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
75325356|NCT05078541|Procedure|Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor|"The Procedure~Injection of local subcutaneous and pericapsular anaesthesia~Needle radiofrequency ablation under ultrasound guidance~Patients should communicate with operating surgeon upon excessive heat or pain~The procedure usually lasts 30-45 minutes"
75325357|NCT03761914|Biological|galinpepimut-S|Galinpepimut-S will be administered as monotherapy, then galinpepimut-S will be co-administered with pembrolizumab. After that, there will be un-paired administration of pembrolizumab and galinpepimut-S according to the schedule described in the protocol and described in the arm/group descriptions on ClinicalTrials.gov.
75325358|NCT03761914|Drug|Pembrolizumab|Galinpepimut-S will be administered as monotherapy, then galinpepimut-S will be co-administered with pembrolizumab. After that, there will be un-paired administration of pembrolizumab and galinpepimut-S according to the schedule described in the protocol and described in the arm/group descriptions on ClinicalTrials.gov.
75325359|NCT00845663|Drug|Certolizumab pegol|Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
75783749|NCT01171508|Device|Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)|Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
75783750|NCT01171508|Procedure|Urine 6-sulphatoxymelatonin (aMT6s)|Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
75783751|NCT01171508|Other|Karolinska Sleepiness Scale|Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
75783752|NCT01171508|Other|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
75783753|NCT01171508|Other|Sleep-diary|Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
75783754|NCT01171586|Behavioral|mDiet|"The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics."
75783755|NCT03863678|Other|Neurodevelopemental therapy (NDT)|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).
75919204|NCT04265963|Biological|CD123 CAR-T cells|CD123 CAR-T cell therapy
75325360|NCT00845663|Drug|Certolizumab pegol|Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
75468335|NCT05936632|Other|Discrete Choice Experiment (DCE)|DCE survey experiment
75632862|NCT04132726|Other|non-effective treatment|non-effective treatment
75632863|NCT02615392|Behavioral|Park Prescription|Please refer to the information included in the arm description.
75919205|NCT04254705|Procedure|Rectal Biopsy|Suction biopsy or forceps biopsy
75919206|NCT04253561|Drug|Ipatasertib|Ipatasertib will be administered orally once a day, beginning on Cycle 1, Day 1 through Day 21 of each 28-day cycle.
75919207|NCT04253561|Drug|Trastuzumab|600 mg every 3 weeks
75919208|NCT04253561|Drug|Pertuzumab|420 mg every 3 weeks
75919209|NCT04240171|Drug|Dapagliflozin 5Mg Tab|Dapagliflozin 5mg tablets daily
75919210|NCT04240171|Drug|Glimepiride 4Mg Tab|Glimepiride Tablets daily
76076909|NCT04371406|Dietary Supplement|Azinc|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
76076910|NCT04370938|Behavioral|Coping strategies video|No additional description
76076911|NCT03716739|Drug|Testosterone Cypionate 100 MG/ML|100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
75632864|NCT00925548|Biological|Tecemotide (L-BLP25) and Hormonal Treatment|"Investigational Arm:~Pretreatment (Single Dose) 300 mg/m^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~*calculated as mass of lipopeptide (antigen)"
75783756|NCT03863678|Other|Neurodevelopemental therapy (NDT) and dry needling|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.
75325361|NCT00364312|Behavioral|diet and physical activity|
75325362|NCT00364390|Drug|Anginera, a human tissue replacement therapy|
75632865|NCT00925548|Biological|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|"Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD)."
75632866|NCT00925548|Drug|cyclophosphamide|300 mg/m^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
75632867|NCT00925548|Drug|sodium chloride (NaCl)|NaCl 9 g/L infusion
75632868|NCT00866788|Drug|omalizumab|Administered by subcutaneous injection
75632869|NCT00866788|Drug|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
75783757|NCT01171664|Drug|Placebo|Tablet, one BID
75919211|NCT04221958|Device|Electrocardiogram|"An electrocardiogram measures the electrical activity of the heartbeat. This intervention will be used on healthy adult volunteers whom are part of the staff at the institution."
75919212|NCT04212091|Biological|PGT121.414.LS|Administered via IV infusion or SC infusion, depending on the arm
75919213|NCT04212091|Biological|VRC07-523LS|Administered via IV infusion or SC infusion, depending on the arm
75325363|NCT03416998|Other|phototherapy|Phototherapy will be performed using clusters of 12 diodes (Table 1); four 905 nm diodes (mean power of 0.3125 mW and peak power of 12.5 W for each diode; 250 Hz), four 875 nm diodes (mean power of 17.5 mW for each diode) and four 640 nm diodes (mean power of 15 mW for each diode). The device manufactured by Multi Radiance Medical® (Solon, OH, USA) will be used due to its high quality, ample use in clinical practice and due to the fact that no national companies manufacture diode clusters with the characteristics required for the proposed project.
75632870|NCT00866788|Drug|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
75632871|NCT00866788|Drug|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
75325364|NCT03267238|Biological|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
75632872|NCT04132570|Drug|Budesonide|Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\- 3 Days.
75919214|NCT04207333|Behavioral|Mental Arithmetic Test|The researcher will call out a four-digit number and ask the participant to subtract either 7 or 13. Each minute, a new four-digit number will be called out and the participant must subtract the 7 or 13 from the number. The test will last approximately 5 minutes
75919215|NCT04170738|Drug|Adderall|3 weeks of Adderall
75632873|NCT04132570|Other|Placebo|Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\- 3 Days.
75632874|NCT02619370|Behavioral|Conversation card game|
75632875|NCT02619370|Behavioral|Active Control|
75783758|NCT01171664|Drug|STAHIST|STAHIST in tablet form dosed one BID
75783759|NCT01175330|Drug|Omega-3 fish oil emulsion (Omegaven)|Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
75783760|NCT01175330|Drug|Intralipid|Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
75783761|NCT02526056|Other|Physiotherapists|This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.
75783762|NCT02526056|Other|elderly people|In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
75919216|NCT04158817|Drug|68Ga-Labeled PSMA|All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.
75919217|NCT04158817|Drug|Non-labeled PSMA|Patient will be injected with microdose (<100 ug) of THP-PSMA
75919218|NCT04158375|Behavioral|Resistance Exercise|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Participants will complete 2 progressing to 4 sets of 8 to 12 repetitions per exercise, with 1 minute rest between sets. Participants will warmup for 5 minutes on a treadmill, cycle ergometer or elliptical at ~50% VO2 peak then begin resistance training. Resistance will be performed 4 days per week with lower body exercise on Monday and Thursday, and upper body on Tuesday and Friday. Wednesdays are a rest day. Participants will begin at 2 sets per exercise on weeks 1 and 2, then 3 sets for week 3, and 4 sets for weeks 4 to 12.
75919219|NCT04154618|Device|Continuous wireless vital sign monitoring|Infants will receive wireless vital sign monitoring throughout their birth hospitalization.
75783763|NCT01171742|Procedure|Intermittent hepatic inflow occlusion (IHIO)|Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
75783764|NCT03864458|Drug|KHK7791|oral administration
75783765|NCT03864458|Drug|Placebo|oral administration
75783766|NCT03262012|Drug|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
75632876|NCT00697294|Dietary Supplement|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
76076912|NCT03716739|Drug|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks.
76076913|NCT03716661|Procedure|ORIF|Open Reduction Internal Fixation
76076914|NCT02245204|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
76076915|NCT03611907|Device|"Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)"|In this intervention a 17-Gauge needle is used to aspirate the follicles
75632877|NCT02619292|Behavioral|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
75632878|NCT00699244|Procedure|Peripheral placement of local anesthesia|Peripheral placement of local anesthesia
75632879|NCT00699244|Procedure|Central placement of local anesthesia|Central placement of local anesthesia
75632880|NCT02619214|Drug|30% of oxygen concentration.|30% oxygen concentration during one hour of general anesthesia.
75632881|NCT02619214|Drug|60% of oxygen concentration.|60% oxygen concentration during one hour of general anesthesia.
75783767|NCT03262012|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
75783768|NCT03262012|Drug|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
75632882|NCT00699322|Drug|Sitagliptin|100mg P.O. per day for 1month
75632883|NCT00699322|Drug|Glimepiride|2mg P.O. per day for 1 month
75632884|NCT04119466|Behavioral|Stabilizing training|The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.
75632885|NCT00860470|Dietary Supplement|Iron (27 mg) - folic acid (600 ug)|"Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
75919220|NCT04150991|Other|Fiber intervention|Each subject will supplement his/her normal dietary intake with 35 grams of dietary fiber daily for three consecutive weeks.
75919221|NCT04150991|Other|Placebo treatment|Each subject will supplement his/her normal dietary intake with an 18.53-g maltodextrin placebo daily for three consecutive weeks.
75919222|NCT04135261|Drug|HBM4003|Intravenous (IV) administration
75632886|NCT00860470|Dietary Supplement|Multiple micronutrient|"Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
75632887|NCT00923364|Drug|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
75632888|NCT00923364|Drug|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
75632889|NCT00923364|Procedure|Total Body Irradiation (TBI)|200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
75919223|NCT04134910|Procedure|Physical Therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
76076916|NCT03611907|Device|"Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)"|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
76076917|NCT04365010|Drug|Sodium Bicarbonate Ringer's Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
75325365|NCT03006016|Drug|Omega-3 Fatty Acid|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
75783769|NCT03262012|Drug|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
75919225|NCT04107298|Device|SUNDANCE™ Drug Coated Balloon|Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter
75919226|NCT04105660|Other|Training for EEG monitoring|Training for reading EEG curves during anaesthesia
76076918|NCT04365010|Drug|0.9% Sodium Chloride Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
76076919|NCT03609801|Behavioral|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
76076920|NCT03609801|Behavioral|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
76076921|NCT02244814|Behavioral|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
75325366|NCT03006016|Other|Placebo|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
75632890|NCT00923364|Procedure|Allogeneic Hematopoietic Stem Cell (HSC)|stem cell transplant
75783770|NCT01174940|Drug|extracorporeal photopheresis|"Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient."
75783771|NCT01283984|Drug|AZD2115|Single dose, oral inhalation (nebuliser solution)
75919227|NCT04105660|Other|Standard monitoring|Standard monitoring including clinical parameters and BIS index
75919228|NCT04094142|Drug|Acalabrutinib|"Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission."
75919229|NCT04089514|Drug|Adalimumab|Administered as specified in the treatment arm
75919230|NCT04088409|Drug|Baricitinib|Administered orally
75919231|NCT04088409|Drug|Adalimumab|Administered SC
75919232|NCT04084314|Biological|Erenumab|pre-filled pen (auto-injector)
75325367|NCT04292561|Drug|Low MAC|To maintain a target of sevoflurane inhalation concentration 0.8 MAC.
75325368|NCT04292561|Drug|High MAC|To maintain a target of sevoflurane inhalation concentration 1.0 MAC.
75325369|NCT02871934|Genetic|SLCO1B1 Genotype|Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
75325370|NCT03123393|Drug|TAK-659|TAK-659 Tablets
75325371|NCT04340830|Procedure|Free gingival graft|Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
75325372|NCT04743076|Procedure|Endovascular treatment|Endovascular treatment
75632891|NCT00923364|Drug|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
75632892|NCT02613676|Device|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
75632893|NCT02613676|Other|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
75783772|NCT01283984|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
75919233|NCT04074109|Combination Product|Teleyoga|the yoga protocol will be delivered via a tablet computer to groups of participants
75919234|NCT04074109|Behavioral|In-person yoga|the yoga protocol will be delivered by a yoga instructor in the room to group of participants
75919235|NCT04073706|Procedure|TH BSO with SNB Note: If participants (≤45 years of age) wish to retain their ovaries a BSO may be omitted.|"Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the sentinel node. These one or two nodes are thought to be first involved with cancer spread."
75919236|NCT04073706|Procedure|TH BSO without retroperitoneal node dissection Note: If participants (≤45 years of age) wish to retain their ovaries a BSO may be omitted.|Removal of uterus, tubes and ovaries without retroperitoneal node dissection
75919237|NCT04057820|Other|Finnegan Neonatal Abstinence Scoring Tool|The FNAST is a scoring system used in neonatal units to initiate and guide therapy in infants of opiate-dependent mothers.
75919238|NCT04057820|Other|Eat, Sleep, Console (ESC) care tool|The ESC care approach emphasizes parental involvement, simplifies the assessment of infants with NOWS and focuses interventions on non-pharmacologic therapies.
76076922|NCT02244814|Behavioral|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
75325373|NCT04743076|Other|Standard medical treatment|Standard medical treatment
75919239|NCT04056689|Drug|DNL151|Oral repeating dose
75919240|NCT04056689|Drug|Placebo|Oral repeating dose
75919241|NCT04045353|Behavioral|Low carbohydrate diet education|A 200 page informational document that connects with an online application will be provided to subjects.
75919242|NCT04045353|Behavioral|Low carbohydrate diet education with behavioral component|A 12 week course taught be a certified instructor will teach subjects about a low carbohydrate document. Subjects will also be given a 200 page informational document that connects with an online application.
75919243|NCT04028700|Biological|G6PD Deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
75919244|NCT04028700|Biological|Non-G6PD deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
75919245|NCT04024761|Biological|CIML NK|CIML NK cells have enhanced ability to recognize and kill leukemia targets
75919246|NCT04024761|Drug|Fludarabine|Fludarabine is a chemotherapy agent
75919247|NCT04024761|Drug|Cyclophosphamide|Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent
75919248|NCT04008901|Drug|BST-104 (Lonicera Flos Extract)|175 mg of Lonicera Flos extract in 1 tablet (300 mg)
75632894|NCT01096160|Drug|MK-8226 BID, 1 mg|MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
75783773|NCT01175408|Other|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
75783774|NCT01175408|Other|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
75783775|NCT01175408|Other|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
75325374|NCT00848237|Device|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
75325375|NCT03115203|Other|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
75325376|NCT03115203|Other|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
75325377|NCT03092895|Biological|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
75919249|NCT04008901|Drug|Placebo oral tablet|0 mg of Lonicera Flos extract in 1 tablet (300 mg)
76076923|NCT03707691|Behavioral|Listening tests. Pitch training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of ~20 minutes performed at home over a period of 15 weeks.
75325378|NCT03092895|Drug|Apatinib|Subjects receive Apatinib orally every day with a dose escalation
75325379|NCT03092895|Drug|FOLFOX4|Subjects receive FOLFOX4 treatment every 2 weeks
75325380|NCT03092895|Drug|GEMOX|Subjects receive GEMOX treatment every 2 weeks
75632895|NCT01096160|Drug|MK-8266 BID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
75632896|NCT01096160|Drug|MK-8266 TID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
75632897|NCT01096160|Drug|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
75783776|NCT01175408|Other|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
75919250|NCT04004988|Drug|Tirzepatide|Administered SC
75919251|NCT04004988|Device|Prefilled syringe (PFS)|PFS used to administer tirzepatide
75919252|NCT04004988|Device|Auto-injector (AI)|AI used to administer tirzepatide
75919253|NCT03971513|Procedure|Trans abdominal plane|"Trans abdominal plane block is performed with ultra sound guidance.~- The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen).~- When the needle is visualised in the plan separating the muscle internal oblicum and transversal of the abdomen, 20 ml of ropivacaïne 5mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
76076924|NCT03707691|Behavioral|visuo-spatial training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of ~20 minutes performed at home over a period of 15 weeks.
76076925|NCT03707691|Behavioral|EEG/MEG/MRI recordings.|Listening tests. EEG/MEG/MRI recordings
76076926|NCT02156908|Drug|D-serine|D-serine 60 mg/kg
76076927|NCT04763265|Biological|"Botulinum toxin A BoNT/A-DP"|To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
76076928|NCT04763265|Biological|"Botulinum toxin A Botox Cosmetics"|To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
75632898|NCT01096160|Drug|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
75632899|NCT01096160|Drug|Placebo BID (Panel A)|Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
75919254|NCT03966092|Procedure|Quadratus lumborum block|"Bilateral Quatratus lumborum block is performed with ultra sound guidance. The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). Laterally, these three are merging to from fascia transversalis. Under fascia transversalis, we can see quadratus lumborum muscle. Punction point in lateral, 1cm in the plan separating quadratus lumborum block and fascia transversalis~20 ml of ropivacaïne 3.75mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
75919255|NCT03961347|Drug|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
75919256|NCT03961347|Drug|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
75325381|NCT03084731|Dietary Supplement|Microbiota Directed Complementary Food (MDCF)|"For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period."
76076929|NCT02244970|Other|Mindfulness|Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
76076930|NCT02244970|Other|Psychoeducation|Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
75325382|NCT02589808|Device|Full TTE|Full transthoracic echocardiogram, with Doppler.
75632900|NCT01096160|Drug|Placebo BID (Panel B)|Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
75325383|NCT02589808|Device|GE Vscan|Handheld echo.
75325384|NCT03839771|Drug|AG-120|250mg tablets
75325385|NCT03839771|Drug|Placebo for AG-120|250mg tablets
75325386|NCT03839771|Drug|AG-221|100mg tablets
75632901|NCT01096160|Drug|Placebo TID (Panel C)|Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
75632902|NCT01096160|Drug|Placebo TID (Panel D)|Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
75632903|NCT01096160|Drug|Placebo TID (Panel E)|Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
75919257|NCT03958890|Drug|HLX10 100 mg in 10 ml Injection|3mg/kg IV（HLX10+cis-platinum+5FU）
75919258|NCT03958890|Drug|Placebos|3mg/kg IV（placebo+cis-platinum+5FU）
75919259|NCT03935568|Drug|PU-AD|3 cohorts receiving a single oral dose of PU-AD at one time.
75919260|NCT03935568|Drug|Placebo|3 cohorts receiving a single oral dose of Placebo at one time
75325387|NCT03839771|Drug|Placebo for AG-221|100mg tablets
75632904|NCT00860158|Drug|Dasatinib|Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
75632905|NCT00860158|Drug|Leuprolide Acetate (LHRH Analogue)|Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
75632906|NCT00860158|Procedure|Radical Prostatectomy|Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
75783777|NCT03637894|Dietary Supplement|Feeding infants with fermented formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
75783778|NCT03637894|Other|Feeding infants with standard formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
75783779|NCT03637894|Other|Breastfeeding infants|Reference group
75783780|NCT03863600|Behavioral|Midwife-led continuity of care|Midwives from governmental hospitals provide antenatal and postnatal case-load-care in rural villages governmental clinics
75919261|NCT03935568|Drug|Placebo|2 cohorts receiving multiple oral dose of Placebo at one time
75919262|NCT03935568|Drug|PU-AD|2 cohorts receiving multiple oral dose of PU-AD at one time
75919263|NCT03934840|Drug|Cabazitaxel|20 mg/m2 Q 21 days
75919264|NCT03934840|Drug|Carboplatin|AUC 4 Q21 Days x 6 cycles with ADT
75919265|NCT03934840|Drug|Abiraterone|1000 mg PO daily
75919266|NCT03934840|Drug|Prednisone|5 mg PO daily on chemotherapy completion
75919267|NCT03913715|Other|Ostomy Self-Management Training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
75919268|NCT03898700|Behavioral|strength based coaching|strength based and solution focused coaching
75919269|NCT03897036|Drug|CX-4945|API powder-in-capsule in 200 mg strength
75919270|NCT03888989|Biological|Quadrivalent inactivated influenza vaccine (IIV)|Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
75919271|NCT03879538|Drug|Nitrous Oxide|a total of three treatments (6 total exposure hours) over one week with 2 or 3 days between each session.
75919272|NCT03879538|Drug|Oxygen|a total of three treatments (6 total exposure hours) over one week with 2 or 3 days between each session.
75919273|NCT03867006|Dietary Supplement|Protein|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.
75632907|NCT02615314|Procedure|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
75919274|NCT03867006|Dietary Supplement|Protein and Carbohydrate|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.
75919275|NCT03863457|Drug|Fluoroglutamine [18F]F-GLN|Evaluate the kinetics and biodistribution of [18F]F-GLN in primary and metastatic breast cancer.
75632908|NCT02615236|Device|perineal ultrasound|transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
75632909|NCT02615236|Procedure|Clinical diagnosis|diagnosis of OASIS clinically
75919276|NCT03861858|Behavioral|DBT-A|DBT-A is a multimodal therapy which consists of weekly individual therapy, weekly multifamily skills groups, as needed phone coaching, and weekly consultation team for the therapists.
75325388|NCT02591056|Device|Erchonia® Verju™ Laser|There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.
75325389|NCT02591056|Device|Green PRESS 8|There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
75325390|NCT02997033|Other|No intervention|No intervention
75783781|NCT03864302|Behavioral|Motor Imagery|Motor imagery (MI) is a psychological technique for improvement of motor skills.(24) MI skill training (MIST) has been used and explored in several disciplines including Sports, Music, Education, Psychology and Medicine.(18) The literature has found positive effects on performances in professional athletes but also on rehabilitation of stroke patients.(25,26) MI is a cognitive imagery of a physical performance, e.g. a high jumper imagine a high jump, prior to performance. MI is not as effective as physical practice, but more effective compared to no training.(27) Further, MI combined with physical practice has been found to be more effective in skill performance in sports compared to physical practice alone.(18) MIST has shown promising results on surgical performances in flexible cystoscopy performed by doctors.(28)
75783782|NCT03288142|Other|Hypertension Coaching Application and Home Monitor|The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD
75783783|NCT03288142|Other|Control: Tracking Application and Home Monitor|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
75783784|NCT01286090|Drug|Cisapride|One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
75783785|NCT01286090|Drug|Placebo|One tablet taken orally 4 times a day for up to 8 weeks.
75919277|NCT03838289|Radiation|multimodal magnetic resonance imaging or computed tomography|multimodal magnetic resonance imaging including T1 Flair,T2 Flair, magnetic resonance angiography (MRA), perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), enhanced gradient echo T2 star weighted angiography (ESWAN); multimodal computed tomography including non-contrast CT, volume perfusion CT
75919278|NCT03781765|Drug|Methylphenidate|stimulant medication
75919279|NCT03781765|Drug|Atomoxetine|non-stimulant medication
75919280|NCT03781752|Drug|Methylphenidate|study to determine dose
75325391|NCT02953587|Procedure|Oral Glucose Tolerance Test (OGTT)|Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.
75325392|NCT02953587|Drug|Human Ghrelin|Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.
75919281|NCT03772457|Drug|Rivaroxaban|new oral anticoagulant molecules which is the selective factor Xa inhibitor
75325393|NCT02953587|Drug|Saline|Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
75325394|NCT00814697|Device|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
75325395|NCT00814775|Device|Fastrach Laryngeal Mask|Intubation of difficult airway using Fastrach Laryngeal Mask
75783786|NCT00310817|Biological|MenACWY-CRM conjugate vaccine, adjuvanted|
75783787|NCT00310817|Biological|MenACWY polysaccharide vaccine|
75783788|NCT00310817|Biological|MenACWY-CRM conjugate vaccine, unadjuvanted|
75783789|NCT03783286|Drug|Ivacaftor|Ivacaftor (Kalydeco®, Vertex Pharmaceuticals Inc.) was the first of a new class of drugs that improved CFTR gating dysfunction (2, 3, 4). For such mutations (G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D) that permit CFTR expression at the cell membrane but compromise its activity.
75919282|NCT03765892|Other|Questionnaire (Adult)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the distribution of socio-professional categories.~Answering the questionnaires will take 45 minutes."
75919283|NCT03765892|Other|Questionnaire (Children)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the proportion of subjects having repeated grades.~Answering the questionnaires will take 45 minutes."
75919284|NCT03714958|Drug|HDM201|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
75919285|NCT03714958|Drug|Trametinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
75919286|NCT03708315|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride
75919287|NCT03708315|Drug|Placebos|Placebo
75919288|NCT03682575|Other|Enrollment|All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.
75325396|NCT00814775|Device|CTrach Laryngeal Mask|CTrach Laryngeal Mask intubation
75632910|NCT02878538|Drug|Deferiprone|Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
75632911|NCT02878538|Other|Placebo phase|Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
75632912|NCT04134598|Radiation|Breast irradiation (RT)|Irradiation of volume's portion Index quadrant) or whole volume of the residual breast.
75632913|NCT04134598|Drug|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).
75783790|NCT03863912|Other|Disney movie|Disney movie on portable DVD Player.
75632914|NCT00929526|Procedure|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
75632915|NCT00929526|Procedure|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
75632916|NCT04307342|Procedure|MIPO with Extra-articular Distal Humeral Anatomical Plate|MIPO with Extra-articular Distal Humeral Anatomical Plate
75632917|NCT02618902|Biological|tolerogenic dendritic cells (tolDC)|dose-escalation
75632918|NCT04134052|Drug|ketamine sedation versus midazolam sedation|Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
75632919|NCT04258176|Other|Multidisciplinary outpatient pathway|Coordinators, assigned to improve the care flow, review and align the patient's appointments and tests in agreement with the patient's wishes. Outpatient consultations are arranged to take place the same day and schedules for care providers are coordinated. The patients' attendance in outpatient clinics are planned sequentially where the delivering specialty writes a summary to the subsequent specialty. Afterwards, the involved physicians and nurses attend an interdisciplinary conference, resulting in a joint treatment plan, with feedback and notice of modifications, which is delivered to the patient and general practice.
75783791|NCT03863912|Other|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
75783792|NCT03863990|Drug|PAH medication|Any PAH-targeted medication
75783793|NCT03863366|Drug|Prucalopride|1mg prucalopride tablet, encapsulated in white capsule
75919289|NCT03636386|Device|Percutaneous microelectrolysis|284/5000 Application of Direct Current through an acupuncture needle with intensities in microamps (μA) in the PGm of the upper trapezius muscle. The acupuncture needle will correspond to the negative electrode or cathode. The intensity of work will be 610μA at the myofascial trigger point.
75919290|NCT03636386|Device|Ultrasound therapy|Application of conventional ultrasound (US) on PGm with a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
75919291|NCT03612583|Procedure|Lung- and Diaphragm-Protective Ventilation|Ventilation and sedation will be progressively modified according to the LDPV algorithm to achieve targets. Patients will be crossed-over to the opposite PEEP strategy. LDPV titration will then be repeated to achieve LDPV targets. After establishing a combination of ventilation and sedation settings at which LDPV targets are achieved, the targets will be maintained over a 24-hour period.
75919292|NCT03586973|Drug|Cabozantinib|Cabozantinib tablet
75632920|NCT04307420|Procedure|Sonic Fill Restoration|Kerr's Sonic Fill is the only sonic-activated, single-step, bulk-fill composite that starts out as a low-viscosity composite.
75783794|NCT03863366|Other|Placebo|Lactose placebo tablet, encapsulated in white capsule
75783795|NCT01060397|Behavioral|Extended Brief Intervention|Frames motivational interviewing approach
75783796|NCT01060397|Behavioral|Control|Usual care
75783797|NCT01175486|Drug|Actos (Pioglitazone)|Actos 30 mg for 6 months
75783798|NCT01175486|Drug|Acarbose|Acarbose 50 mg tid for 6 months
75783799|NCT01049087|Radiation|Plasma volume determination (99mTc-albumin)|The test is performed using 5MBq technetium-labeled albumin (99mTc-albumin-Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
75783800|NCT01049087|Radiation|Plasma volume determination (125I-albumin)|The test is performed using 0.2MBq 125iodine-labeled albumin (125I-albumin) with several postinjection samples for accurate zero-time extrapolation.
75783801|NCT02526134|Device|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
75632921|NCT04307420|Procedure|Composite Resin Restoration|Composite resins are polymer-based materials used in dentistry for aesthetic repairs.Polymerization is accomplished typically with a hand held curing light that emits specific wavelengths keyed to the initiator and catalyst packages involved.
75632922|NCT02615080|Drug|CRD007|
75632923|NCT02615080|Drug|Placebo|
75632924|NCT04903730|Drug|AER-901 Solution for Nebulization|"Part A: participants will be enrolled into 1 of up to 5 sequential cohorts (A1 to A5). Inhaled AER-901 doses of 5, 10, 20, 40, and 80mg are planned.~Part B: participants will be enrolled into 1 of up to 3 cohorts (B1 to B3).~Cohorts B2 and B3 will commence following Part D of the study and following SRC review of safety, tolerability, and PK data. A decision to dose with either a propylene glycol formulation or a sterile water formulation will be made by the SRC at the time of the review of the Part D data.~Part D has a three-part design (Treatment Periods 1 & 2 separated by a Washout period) and will compare placebo to a single-dose of AER-901 (5 mg/mL QD) followed by two doses of AER-901.~Each cohort will consist of 8 participants (6 receiving AER 901 and 2 receiving placebo)."
75632925|NCT04903730|Drug|Placebo|0.45% sterile saline for injection delivered via the FOX MOBILE device.
75632926|NCT04203654|Behavioral|cognitive-behavior group therapy|cognitive-behavior group therapy Frequency: thrice a week Treatment duration: 16 week
75632927|NCT04203654|Behavioral|Individual supportive psychotherapy|Individual supportive psychotherapy 3 sessions during the 16-week treatment period
75632928|NCT04260906|Device|Vagus nerve stimulator|Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears (Figure 1). The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
75783802|NCT02747498|Procedure|Procedure with circumferential pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
75919293|NCT03579966|Drug|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
75325397|NCT02593396|Drug|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
75632929|NCT04260906|Other|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
75632930|NCT00859456|Drug|Sunitinib|"Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.~A small molecule, multi-targeted receptor tyrosine kinase inhibitor that selectively targets and intracellularly blocks the signaling pathways of receptor tyrosine kinase (RTKs)."
75919294|NCT03578380|Procedure|Surgery|Lymphovenous anastomosis
75919295|NCT03578380|Other|Compression and drainage therapy|Treatment with compression stockings and manual drainage (massage therapy)
75919296|NCT03533985|Behavioral|Song of Kin|Music therapists will assess meaningful song/theme (of choice/culture) and provide musical elements in a way that nurtures parents. They will then develop a simplified part of the theme into a soothing lullaby for their infants to be utilized directly by the parent/s and/or the music therapist to comfort, engage or sedate.
75919297|NCT03533985|Other|Gato box|Depending on the time of intervention and need of the infant the music therapist will provide rhythmic entrainment that follows the heart rate or suck patterns of the infant
75919298|NCT03533985|Other|Ocean disc|Depending on the time of intervention and needs of the infant the music therapist will provide a whoosh sound using the Remo Ocean disc. It will be entrained to the infant's respiratory rate.
75325398|NCT02593396|Drug|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
75632931|NCT01075646|Drug|ropivacaine|"Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.~Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.~Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h."
75919299|NCT03533985|Other|Contingent singing|Depending on the state of the infant, the music therapist will provide short segments of conversant prosody, to enhance quiet-alert, or stimulate relaxation/sleep
75919300|NCT03533985|Other|Tonal Vocal holding|Music therapist will provide a vowel, long held tone, sung without vibrato
75919301|NCT03533985|Other|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
76076931|NCT00004143|Drug|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
75919302|NCT03533764|Behavioral|ASMA|ASMA, grounded in social cognitive theory and utilizing motivational interviewing techniques, guides adolescents in their transition to being consumers and teaching them to navigate the health system, including overcoming challenges to health care access. Briefly, it consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
76076932|NCT04364542|Procedure|Suprascapular nerve block|The patient lies supine in beach chair position with surgical drapes on. The anatomical landmarks are outlined and the infiltration spot is identified. The block is performed with 10 ml ropivacaine 0.75%.
76076933|NCT04364542|Procedure|Interscalene Nerve Block|The patient lies supine position with the head turned to the contralateral side to the block. A linear high-frequency ultrasound probe is used for identifying the roots of supraclavicular brachial plexus using the traceback technique. The block is performed with 15 ml ropivacaine 0.5%.
75783803|NCT02747498|Procedure|Procedure with linear ablation in addiction to pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
75783804|NCT01175564|Drug|TC-5214|Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet
75919303|NCT03520374|Diagnostic Test|Ultrasonography|Ultrasonography use for the evaluation of gastric contents
76076934|NCT04364542|Procedure|Arthroscopic rotator cuff repair|Conventional arthroscopic rotator cuff repair.
76076935|NCT03705429|Drug|TC-H x Paclitaxel (P) + Trastuzumab(T)|chemotherapy
76076936|NCT04370782|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
76076937|NCT04370782|Drug|Azithromycin|Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
75632932|NCT01075646|Drug|saline solution|"Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.~Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.~Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h"
75632933|NCT01075412|Drug|[F18]Fluorothymidine|FLT PET scan 5 mCi (+/- 10%)
75632934|NCT00799903|Drug|Darapladib|Lp-PLA2 inhibitor administered in addition to standard therapy
75632935|NCT00799903|Drug|Placebo|Placebo administered in addition to standard therapy
76076938|NCT04370782|Drug|Zinc Sulfate|Zinc sulfate 220mg once daily for 5 days
76076939|NCT04370782|Drug|Doxycycline|Doxycycline 200 mg once daily for 5 days
75632936|NCT01075256|Device|5% calcium sodium phosphosilicate toothpaste|Low concentration calcium sodium phosphosilicate tubule occlusion agent
75632937|NCT01075256|Device|7.5% calcium sodium phosphosilicate toothpaste|High concentration calcium sodium phosphosilicate tubule occlusion agent
75632938|NCT01075256|Device|Placebo toothpaste|Placebo toothpaste
75632939|NCT02876432|Device|Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
76076940|NCT03604653|Device|HIPEC|Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
75632940|NCT02876432|Drug|Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
75783805|NCT01175564|Drug|Placebo|Placebo tablet, single dose and 6 days repeated dose
75783806|NCT01177826|Procedure|Sample collection|Stool sample
76076941|NCT03604653|Drug|Mitomycin c|MMC 30mg@ T0, 10mg@T45 min
76076942|NCT03604653|Drug|CDDP 50|50mg/m2@T0
76076943|NCT03604653|Drug|CDDP 75|75mg/m2@T0
76076944|NCT03604653|Drug|Doxorubicin|15mg/m2@T0
76076945|NCT04376320|Device|customised ceramic sheets (Group 1)|guided bone regeneration
76076946|NCT04376320|Combination Product|modified sausage technique (Group 2)|guided bone regeneration
76076947|NCT04376086|Procedure|Epidural anesthesia|Segmental epidural analgesia
76076948|NCT04376086|Procedure|general anesthesia|general anesthesia
76076949|NCT04375852|Diagnostic Test|Detection of autoantibodies|Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
76076950|NCT03805659|Device|HD-tDCS|High-Dose transcranial Direct Current Stimulation
76076951|NCT03805659|Device|Sham|Sham sessions (no electric current)
76076952|NCT03603795|Drug|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
76076953|NCT03603795|Drug|Placebo|Placebo concomitant with induction chemotherapy patients with AML
76076954|NCT04370314|Other|Dental prosthetics|Implant-supported crowns
76076955|NCT04364464|Drug|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
76076956|NCT04746885|Dietary Supplement|DHA|Oral supplement
76076957|NCT04375774|Device|FFP2|Face Fit test of the FFP2 with the PortaCount® PRO+ 8038 from TSI
76076958|NCT04375774|Device|Facial mask|Face Fit test of a conventional respirator facial mask with the PortaCount® PRO+ 8038 from TSI
76076959|NCT04375774|Device|MFS|Face fit test of a MFS with the PortaCount® PRO+ 8038 from TSI
75325399|NCT02593630|Device|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
75325400|NCT00848783|Drug|Irinotecan|
75325401|NCT00848783|Drug|Cisplatin|
75325402|NCT00848783|Procedure|Surgery|
75325403|NCT00848783|Drug|Floxuridine|
75325404|NCT00848783|Drug|Capecitabine|
75632941|NCT02876432|Other|Sham electroacupuncture|The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
75632942|NCT02876276|Procedure|Hyaluronic acid filler|Papillary augmentation with HA dermal fillers was considered as the test group
75919304|NCT03508869|Drug|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
75632943|NCT00923130|Drug|Bevacizumab|Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
75783807|NCT01177904|Other|Cease progsterone at 5|Cease administration of progsterone at first US at 5 weeks
75783808|NCT01177904|Other|control group: progesterone 8|Control group: progesterone until 8 weeks of pregnancy
75919305|NCT03508869|Drug|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
75919306|NCT03508869|Drug|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
75325405|NCT05372536|Other|parent-led home-administered low-dose Cytarabine|Parents to the included participants are offered to administer the protocolized low-dose bolus (injection) Cytarabine in their children's CVCs at home. The administration procedure is developed as a simple and safe non-touch technique. The parents receive a video and paper-based guideline and information material followed by a 3-step nurse-led education program. The parents can administer the Cytarabine at home when they (and the child/adolescent) feel safe and comfortable managing the procedure and when the nurses are sure that the parents can manage the procedure at home. The first dose of Cytarabine is always administered at the hospital.
75919307|NCT03507699|Radiation|Liver radiation therapy|21 Gy in three fractions to one liver metastasis
75325406|NCT05371990|Other|Determination of Eating habits|Questionnaire
75325407|NCT00849251|Drug|cyclophosphamide|Given IV or PO
75632944|NCT00923130|Drug|Ixabepilone|Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
75632945|NCT04258098|Drug|Oral antibiotics ( Streptomycin ,metronidazole )|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
75783809|NCT02940886|Drug|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
75919308|NCT03507699|Drug|Nivolumab Injection [Opdivo]|administered IV at a dose of 3mg/kg every 2 weeks
75919309|NCT03507699|Drug|Ipilimumab Injection [Yervoy]|administered IV at a dose of 1mg/kg every 6 weeks
75919310|NCT03507699|Drug|CMP-001|A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
75325408|NCT00849251|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
75325409|NCT00849251|Drug|bortezomib|Given IV
75325410|NCT00849251|Drug|dexamethasone|Given IV or PO
75325411|NCT05371912|Device|Trans Cranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.
75783810|NCT02940886|Drug|Iron sucrose|"Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial.~Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended."
75783811|NCT03863132|Device|TAVR|Repair of defective aortic valve by microsurgical Intervention.
76076960|NCT03700047|Device|GAL1704|new dermal filler
76076961|NCT03700047|Device|Juvederm Voluma|hyaluronic acid
76076962|NCT00924040|Drug|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
76076963|NCT04363996|Other|New Bioactive Restorative Material|Filling material
76076964|NCT04363918|Device|bioelectric stimulation|bioelectric stimulation
76076965|NCT03598413|Dietary Supplement|Omega-3|200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
76076966|NCT01592240|Drug|PBO|Placebo Q28d
76076967|NCT01592240|Drug|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
76076968|NCT01592240|Drug|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
76076969|NCT01592240|Drug|PBO|Placebo, Q14d
76076970|NCT01592240|Drug|PF-04950615|PF-04950615 50mg, Q14d
76076971|NCT01592240|Drug|PF-04950615|PF-04950615 100 mg, Q14d
76076972|NCT01592240|Drug|PF-04950615|PF-04950615 150mg, Q14d
76076973|NCT04370158|Other|disease history|Clinical progression and prognosis of patients with interstitial lung diseases
75325412|NCT00364468|Drug|pegfilgrastim|
75783812|NCT03860714|Diagnostic Test|Neuropsychological tests|We do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Clinical Dementia Rating(CDR),Quality of Recovery Score - 40 (QoR-40),Geriatric Depression Scale (GDS),CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
75919311|NCT03507647|Behavioral|Mindfulness Based Cognitive Therapy|"MBCT is a manualised group skills-training program (Segal, Williams & Teasdale 2012) consisting of eight weekly sessions of 2.5 hours, plus one day of silent practice. The program includes both formal and informal meditation exercises. Cognitive techniques that are part of the program are education, monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan.~The MBCT treatment will be adapted to address the needs of patients with a bipolar disorder. A few examples of these adaptations are: (more) psychoeducation about manic symptoms in addition to the psychoeduction about depression; introducing the 3-minute breathing space earlier in the programme and more often during sessions, especially when strong emotions are present; repeatedly bringing the focus to self-care; and making use of the mindful movement (yoga) exercises more frequently."
75919312|NCT03507647|Other|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse). Usual care will not be restricted, except for proscribing high-frequency psychological interventions such as (group) cognitive behavioral therapy, for practical and methodological reasons.
75919313|NCT03497923|Drug|Magnesium Sulfate|After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.
75919314|NCT03494478|Other|Neuropsychological testing|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up
75919315|NCT03494478|Other|Actimetry|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
75632946|NCT04260750|Behavioral|Internet-administered Cognitive behavioral therapy (ICBT)|"The intervention consists of fifteen modules, each having a specific focus on a problem (e.g. comorbid worry alongside the depression) or containing a specific strategy or element (e.g. behavioral activation).~The fifteen modules are:~Introduction/Psychoeducation about depression, Behavioral activation 1, Behavioral activation 2, Cognitive restructuring, Acceptance, Psychoeducation about emotions, Anxiety and exposure, Comorbid social anxiety, Comorbid worrying and generalized anxiety, Comorbid panic disorder, Sleep problems, Perfectionism, Stress management, Relaxation, and Relapse prevention.~The first and last module are assigned to all participants. The rest is picked either by the participants themselves or by the therapist conducting the intake interview."
75783813|NCT01177982|Behavioral|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
75325413|NCT00850031|Device|AcuFocus Corneal Inlay|Inlay implanted in cornea for improvement of near vision
75919316|NCT03494478|Other|Self-questionnaires on emotional topics|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
75919317|NCT03457935|Other|blood samples|Blood samples
75783814|NCT01177982|Behavioral|Reduced RBT (r-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
75783815|NCT01177982|Behavioral|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
75783816|NCT01177982|Behavioral|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job Club Recovery housing CAP housing admission Recovery sponsor
76076974|NCT05620654|Drug|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
76076975|NCT04357834|Other|Equipment with smartwatch throughout hospital stay on the general ward|Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
75325414|NCT05371678|Other|Therapeutic motor control interventions|Treatment duration will be 8 weeks, two sessions a week. Each session will take approximately 60 minutes. This intervention includes education, dietary advices, core stabilization exercises and pelvic floor muscle training with surface Electromyographic-Biofeedback. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Core stabilization exercises will be performed 2 days a week with a physiotherapist and the session will be approximately 50 minutes. Diaphragmatic breathing will be taught to children in breathing exercises. The pelvic floor muscles exercises will be do by surface Electromyographic-Biofeedback. The Electromyographic-Biofeedback teaches the child how to relax the external anal sphincters with visual and auditory feedback techniques.The child will learn to relax the pelvic floor muscles during defecation by monitoring the recorded electromyographic activity.
75783817|NCT01177982|Behavioral|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
75783818|NCT01177982|Behavioral|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
76076976|NCT04357522|Biological|15-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
75919318|NCT03437395|Device|Balloon Brachytherapy|The balloon brachytherapy catheter method uses one tube with a small balloon on the end placed where the tumor had been. The balloon is filled with salt water so it fits this space. The end of the tube will extend from the side of the breast and will be connected to a special machine for treatments. The RT dose is delivered by a radioactive seed that travels through the tube into the center of the balloon. The seed will be removed at the end of each treatment. The tube and the balloon filled with salt water will stay in the breast until the 10 RT treatments are done. The radiation oncologist will decide if this type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10-15 minutes.
75919319|NCT03437395|Radiation|3D Conformal External Beam Irradiation|3D conformal external beam irradiation uses a beam of radiation to deliver the radiation therapy dose to the place in the breast where the cancer was removed. The Radiation Oncologist will decide which type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10 to 15 minutes.
75919320|NCT03429205|Other|No external heating used during surgery|Deviation from external heating for all surgery standard
75919321|NCT03429205|Other|External heating blanket used during surgery|Standard external heating plan used in all surgery types
75919322|NCT03377387|Drug|Capecitabine|Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
75632947|NCT05085678|Device|Co'moon (online website to support women with AET)|"The tool contains three parts:~e-learning based on the brochure on adjuvant endocrine therapy (AET) in the University Hospital Leuven,~serious game where patients are confronted with scenes of their daily life and motivational guidelines to stimulate their self-management,~a patient-reported-outcome questionnaire (PROMs), reported in the patient medical file.~The tool is designed to stimulate patients self-management of their menopausal AET-related complaints and to discuss them with their health care professionals ."
75919323|NCT03377387|Drug|Neratinib|Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Phase II The MD has been determined as 240mg of neratinib
75919324|NCT03377387|Behavioral|EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30|Questionnaires Every Cycle (+/- 3 days) (For phase II)
75919325|NCT03372837|Drug|Rituximab|The administration of rituximab at 375 mg/m^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
75632948|NCT05330208|Drug|SHR-1816|SHR-1816
75632949|NCT05330208|Drug|Placebo|Placebo
75632950|NCT00610194|Drug|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
75783819|NCT01177982|Behavioral|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
75919326|NCT03371420|Drug|PU-AD|
75919327|NCT03371420|Device|PET Scan|
76076977|NCT04357522|Biological|13-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
75632951|NCT02473003|Behavioral|high intensity exercise|high intensity exercise 80-90%
75632952|NCT02473003|Behavioral|low/medium intensity exercise|low/medium intensity exercise 40-50%
75632953|NCT02473003|Behavioral|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
75632954|NCT02605915|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
75632955|NCT02605915|Drug|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter*min (mg/mL*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
75632956|NCT02605915|Drug|Docetaxel|Docetaxel 75 mg/m^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.
75632957|NCT02605915|Drug|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
75632958|NCT02605915|Drug|Trastuzumab|Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
75783820|NCT01177982|Behavioral|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
75919328|NCT03371420|Other|Blood Draws|
75919329|NCT03349502|Drug|MG4101|Administration of study drug (MG4101) for the patients with refractory or relapsed acute myeloid leukemia (Single arm)
75919330|NCT03324191|Dietary Supplement|Placebo|Placebo will be matched for flavour, odour, and colour, to a tea beverage, without any active ingredient (tea extract).
75919331|NCT03324191|Dietary Supplement|Tea beverage|Tea beverage
75919332|NCT03324191|Dietary Supplement|Tea extract (medium concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a medium concentration of tea extract.
75919333|NCT03324191|Dietary Supplement|Tea extract (high concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a high concentration of tea extract.
75919334|NCT03324191|Other|High fat liquid meal challenge|"A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
76076978|NCT00937378|Drug|SER120|Nasal Spray, once a day
76076979|NCT00937378|Drug|Placebo|Nasal Spray
76076980|NCT00005901|Drug|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
76076981|NCT04369768|Procedure|restoration of permanent molars affected with MIH|restore MIH affected molars using direct composite or preformed metal crowns
75919335|NCT03314974|Biological|HSCT with TBI Regimen|Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
75919336|NCT03314974|Biological|HSCT with Non-TBI Regimen|Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
76076982|NCT03800199|Other|Perceptive rehabilitation|The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.
76076983|NCT04369534|Drug|Clopidogrel|Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI
76076984|NCT04369534|Drug|Ticagrelor|Administration of standard dose of ticagrelor during 12 months after PCI
76076985|NCT04369456|Other|blood sample|a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms
75468336|NCT05936177|Other|Patient education|The intervention in this osteoporosis education research will consist of a concise and informative educational session delivered by a physiatrist, utilizing slides prepared based on information from reputable sources such as the International Osteoporosis Foundation website and the World Health Organization (WHO) health education booklet. The session will cover various topics including the definition of osteoporosis, its causes, risks, complications, dietary options, and specific exercise recommendations, with a focus on raising awareness and promoting informed decision-making regarding prevention and treatment options.
75632959|NCT02605915|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).
75783821|NCT02525978|Behavioral|Video Task|Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.
75325415|NCT05371678|Other|Conventional treatment|Treatment duration will be 8 weeks. This intervention includes education, dietary advices and laxative therapy. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Laxative therapy will be adjusted at different doses according to the child's age and weight. Laxative therapy will be administered to children by a specialist doctor.
75468337|NCT05936008|Behavioral|Exercise MICT|Standard of care, exercise recommendations for people with stroke
75632960|NCT02605915|Drug|Doxorubicin|Doxorubicin will be administered at 60 mg/m^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
75325416|NCT05371522|Radiation|[18F]DPA-714 positron emission tomography (PET) scan|60 minute dynamic brain [18F]DPA-714 positron emission tomography (PET) scan followed by a 30 minute static whole body positron emission tomography (PET) scan
75325417|NCT02153099|Drug|TAK-058 (ENV8058)|TAK-058 (ENV8058) oral solution
75325418|NCT02153099|Drug|Placebo|TAK-058 (ENV8058) placebo-matching oral solution
75325419|NCT00850889|Device|Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
75325420|NCT00850889|Device|A gel of hyaluronic acid (concentration of 20 mg/mL)|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
75325421|NCT05254288|Other|Chlorhexidine|In-office and domiciliary use of chlorhexidine for 14 days.
75325422|NCT05254288|Other|Ozoral gels|In-office administration of Ozoral Pro and domiciliary use of Ozoral gel for 14 days.
75468338|NCT05936008|Behavioral|Exercise HIIT|The HIIT protocol consists of Short Interval, High Volume exercise at 1-minute exercise bouts followed by 1-minute active recovery for 25 minutes.
75468339|NCT05934331|Drug|LM302+Toripalimab|LM-302 in combination with Toripalimab.
75468340|NCT05931380|Drug|Orforglipron|Administered orally
75468341|NCT05931380|Drug|Placebo|Administered orally
75632961|NCT02605915|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
75632962|NCT02606071|Device|CRT-D|HF patients treated in clinical practice with a CRT-D device
75632963|NCT04028323|Drug|Terlipressin|Terlipressin should be administrated intravenously while monitoring heart rate and blood pressure daily.
75632964|NCT04028323|Drug|Octreotide|Octreotide should be continuously intravenously administrated while monitoring heart rate and blood pressure daily.
75632965|NCT04114201|Procedure|PSI|Implantation of a Total Knee Arthroplasty patient-specific instrumentation using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
75632966|NCT04114201|Procedure|Conventional|Implantation of a Total Knee Arthroplasty with conventional using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
75783822|NCT02525978|Other|Imaginal Task|Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
75783823|NCT03863444|Other|Prenatal Preparation Education|Intervention, provided by researchers, includes video, counseling, and skill practices. Video contains (1) Newborn Reaction, including rooting reflex, correct latch-on posture, assuring newborn having enough milk intakes; (2) Newborn Care, including holding, dipper-changing, clothes-changing, and swaddle the newborn; and (3) Partner Support, including the importance of partner support and the content how partner provide support to the postpartum women. After watching the video, the researcher will provide participants counseling, and then each pair of participants will have skill practice.
75919337|NCT03312699|Biological|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
75919338|NCT03312699|Biological|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
76076986|NCT03590457|Device|Airvo 2; High-Flow nasal cannula system|Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
75632967|NCT03253627|Behavioral|Health Enhancement Program|The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition-without mindfulness instruction-using similar modalities to MBSR training for a matched schedule.
75632968|NCT03253627|Behavioral|Mindfulness-Based Stress Reduction|The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
75783824|NCT03863444|Other|Routine care|Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
75468342|NCT05928910|Device|SmileyScope VR|The SmileyScope Virtual Reality Headset is a VR headset to reduce pain and anxiety undergoing medical procedures. The device comes pre-loaded with a static virtual reality scenario. Participants will use the device in person when coming to clinic during an in-person, one time PNE procedure.
75783825|NCT01172054|Biological|VAX128|one IM injection
75919339|NCT03312699|Biological|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
75919340|NCT03312699|Biological|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
75919341|NCT03312699|Biological|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
76076987|NCT04363762|Behavioral|Internet-based multimodal pain program|A guided internet-based multimodal pain program for chronic TMD pain
76076988|NCT04363762|Device|Occlusal splint|Occlusal splint, standard
76076989|NCT04763187|Procedure|Tooth extraction|Tooth extraction and alveolus regeneration with autologous blood concentrate.
75325423|NCT00851279|Device|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
75325424|NCT04742764|Combination Product|Standard medical therapy|Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
75325425|NCT04742764|Device|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours|Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.
75325426|NCT04742764|Device|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours|The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
75468343|NCT05928910|Other|Standard of Care Treatment|Participants in this group will receive standard of care treatment during an in-person, one time PNE procedure.
75468344|NCT05925608|Combination Product|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter (treatment)
75632969|NCT04114435|Other|Echocardiography|Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures
75632970|NCT02607163|Drug|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
75632971|NCT02607163|Drug|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
75632972|NCT00799825|Biological|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
75632973|NCT05719909|Behavioral|Cognitive Training|8 sessions of web-based cognitive training
75632974|NCT05719909|Behavioral|Sham Training|8 sessions of web-based sham training
75783826|NCT01172054|Biological|Placebo|One IM injection
75325427|NCT00851357|Drug|Nicotine Patch|Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
75325428|NCT00851357|Behavioral|Telephone Counseling|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling."
75468345|NCT05919589|Other|Care Integration for Children With Special Health Care Needs|The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
75468346|NCT05918692|Drug|BMF-500|Investigational Product
75325429|NCT00851357|Drug|Placebo|Placebo nicotine patch
75325430|NCT00851357|Other|Self-Help Materials|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day."
75325431|NCT05105074|Drug|Intrathecal Morphine|Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
75632975|NCT00799591|Other|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
75919342|NCT03312699|Biological|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm [temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)] drink on alternate days, e.g., days 1, 3, 5 and 7.
75325432|NCT05105074|Drug|Placebo|Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
75325433|NCT00815087|Device|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
75325434|NCT00815087|Behavioral|Exercise home program|Daily exercise training
75325435|NCT04978324|Biological|leukocyte platelet rich fibrin (L-PRF)|Participants blood will be spun to obtain L-PRF strips and liquid L-PRF. Pockets will receive insertion of small L-PRF strips followed by liquid L-PRF injections to fill the 5-8mm pockets of the test side.
75325436|NCT04978324|Procedure|Scaling and Root Planing|Scaling and root planing, which is the standard of care, will be performed on the control side using Cavitron and hand scalers on test and control sides under local anesthesia.
75468347|NCT05917938|Drug|NNC0194-0499|NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
75468348|NCT05916560|Drug|LY3437943|Administered SC.
75468349|NCT05907616|Behavioral|Produce purchase incentive|Participants will be provided with a specific incentive amount per month for 10 months to purchase produce, nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
75325437|NCT04946968|Drug|Oral Dacomitinib|All subjects will receive the open-label Dacomitinib as tablets for oral self-administration on a continuous daily basis at a dose of 30 mg for one cycle. For subjects eligible for dose titration after Cycle 1, and after shared patient and investigator decision, these subjects will receive Dacomitinib 45 mg orally on a continuous daily basis.
75468350|NCT05906706|Drug|dupilumab|Subcutaneous (SC) administration
75632976|NCT01075100|Drug|Ixabepilone|20 mg/m2 on Days 1 and 8
75919343|NCT03261284|Diagnostic Test|D-dimer-guided adjustment stratege|D-dimer-guided adjustment stratege
75919344|NCT03261284|Diagnostic Test|Thepeautic-heparin therapy|0.3-0.7U/ml of anti-Xa activity or APTT 1.5-2.5 times of control
75919345|NCT03223727|Diagnostic Test|Blood tests|Blood tests for several bone markers (see summary)
75919346|NCT03221244|Device|VR Treatment|Distractors
75919347|NCT03221244|Device|VR Active Control|No distractors
75919348|NCT03219450|Drug|NeoVax|It stimulates the immune system to attack cancer cells.
75919349|NCT03219450|Drug|Cyclophosphamide|It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
75919350|NCT03219450|Drug|Pembrolizumab|Is a monoclonal antibody that helps the immune cells to be better at attacking cancer cells.
75919351|NCT03199196|Device|Activity Tracker|"Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.~Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker."
75919352|NCT03199196|Device|Smartphone Application|"Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.~Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application."
75632977|NCT01075100|Drug|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
75632978|NCT02876354|Drug|Menaquinone|Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
76076990|NCT04363450|Drug|Hydroxychloroquine|Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
76076991|NCT04363450|Drug|Placebo|Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
75783827|NCT03285958|Behavioral|STEPS Intervention|Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
75783828|NCT01178060|Other|Personalized Heart Attack and Stroke Risk|Personalized assessment of heart attack and stroke risk based on 10yr predictors with individual risk factors.
75783829|NCT01178060|Other|Standard Education|Patients received a general handout describing risk factors for heart attack and stroke.
75783830|NCT01288196|Drug|Placebo IV|A single 30-minute IV infusion of placebo
75783831|NCT01288196|Drug|CNTO 6785 1 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 1 mg/kg
75919353|NCT03199196|Behavioral|Questionnaires|Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
75919354|NCT03199196|Behavioral|Focus Group|Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
75919355|NCT03199196|Behavioral|Electronic Newsletters|Participant emailed electronic newsletters to read that may help participant be more physically active.
75919356|NCT03199196|Behavioral|Telephone Counseling|Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
75919357|NCT03172689|Device|CardioQ|comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
75325438|NCT02856269|Dietary Supplement|Zinc gluconate|Participants will take a daily dose of zinc gluconate.
75325439|NCT03663023|Procedure|Intestinal obstruction|
75919358|NCT03142841|Other|RESCUE Problem Solving Intervention|This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
75325440|NCT04839250|Procedure|heads-up method|3D surgical video system, which includes Alcon NGENUITY 3D visualization system (Alcon, Fort Worth, TX) and Leica M822 and M844 microscopes (Leica Microsystems, Wetzlar, Germany),can be used to perform head-up phacoemulsification combined with intraocular lens implantation surgery.
75919359|NCT03127267|Drug|Masitinib (6.0)|Masitinib (titration to 6.0 mg/kg/day)
75325441|NCT04382573|Genetic|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
75919360|NCT03127267|Drug|Riluzole|Riluzole 50 mg tablet, treatment per os
75325442|NCT00364702|Drug|methylphenidate|
75325443|NCT00852137|Drug|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
75325444|NCT00852137|Drug|Vehicle Gel|Vehicle Gel once daily for 2 consecutive days
75919361|NCT03127267|Drug|Placebo|treatment per os
75919362|NCT03127267|Drug|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
75919363|NCT03123198|Behavioral|Dialectical Behavior Therapy|DBT is a multimodal comprehensive psychosocial treatment.
75919364|NCT03092466|Procedure|femoral nerve catheter|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
75919365|NCT03092466|Drug|femoral group|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
75919366|NCT03092466|Drug|control group|infusion of saline solution (15ml) in femoral catheter
75919367|NCT03089463|Diagnostic Test|Observation|The primary objective is to employ the measurements of neuropathy, micro/macro-perfusion, and biomechanics of the foot mainly tissue stiffness and plantar pressure to determine the vulnerability of foot to mechanical trauma and ulceration. From the data collected it is proposed that a prognostic risk stratification system will be developed based on the range of parameters collected to identify those that are at highest risk of ulceration incident. Those that are classed as high risk are to be sub-stratified to increase the accuracy of the system in predicting ulceration. This will allow a patient-specific approach to be taken in the prevention of ulcers by providing adequate information to predict ulceration incident.
75325445|NCT04765306|Device|Traditional Direct Fascial Closure|Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
75325446|NCT04765306|Device|Fascial Closure Device|Fascial closure using a fascial closure device under direct laparoscopic guidance.
75468351|NCT05903885|Other|On-site Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home based Fecal Immunochemical Test (FIT) kit directly at the DMV site by the research staff.
75783832|NCT01288196|Drug|CNTO 6785 3 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 3 mg/kg
75783833|NCT01288196|Drug|CNTO 6785 10 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 10 mg/kg
75783834|NCT01288196|Drug|CNTO 6785 SC|A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
75783835|NCT01288196|Drug|Placebo SC|A single SC dose of placebo administered in up to 3 SC injections
75783836|NCT01175642|Behavioral|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
75783837|NCT01175642|Behavioral|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
75783838|NCT05216614|Drug|Fluvoxamine|Fluvoxamine is an SSRI used for depression and anxiety disorders. This study will investigate the efficacy of fluvoxamine for improvement of olfactory dysfunction in subjects with post-Covid-19 parosmia.
75783839|NCT05216614|Drug|Placebo|lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind
75783840|NCT03860636|Diagnostic Test|Endometrial Pattern on Ultrasound at ET|Ultrasound scan
75783841|NCT03860636|Diagnostic Test|Endometrial Pattern on Ultrasound at HCG|Ultrasound
75919368|NCT03066440|Drug|Normal saline|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
76076992|NCT03685149|Drug|Flecainide Pill|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
75919369|NCT03066440|Drug|Lactated Ringers|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
76076993|NCT03685149|Drug|Placebo|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
76076994|NCT04370080|Device|Silver Diamine Fluoride 38%|Dental caries arrest medication
75325447|NCT04652362|Behavioral|Growth Mindset Online Single-Session Intervention|During the self-administered single session intervention participants are provided with basic information about the brain and are introduced to the concept of neuroplasticity. The concept of neuroplasticity is applied to personal traits, such as shyness, anxiety and sadness, and young people are taught that these traits are the result of thoughts and feelings in our brain and are amenable to change. Participants are presented with scientific information and research evidence to support the idea that people have the potential to change and are given vignettes from older children detailing how they have used a growth mindset to overcome difficulties. The intervention takes approximately 20-30 minutes to complete.
75325448|NCT04652362|Behavioral|Supportive Therapy Online Single-Session Intervention (Control)|The single session supportive therapy intervention was designed to be structurally comparable to the growth mindset intervention, including the same number of reading and writing activities. Participants were provided with information about emotions and the benefits of expressing emotions. Vignettes from older children described times they had shared their emotions with friends and family members.
75632979|NCT00626678|Drug|Azathioprine|It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
75632980|NCT00626678|Drug|Prednisone|Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
75632981|NCT00626678|Drug|Placebo|Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
75632982|NCT00803023|Drug|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
75783842|NCT03860636|Diagnostic Test|Endometrial Pattern on Ultrasound at TVOR|Ultrasound
75783843|NCT03860636|Diagnostic Test|Endometrial Pattern on Ultrasound at co-ordination scan|Ultrasound
75632983|NCT00803023|Drug|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
75632984|NCT00803023|Drug|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
75632985|NCT00803023|Drug|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
75632986|NCT02877290|Device|non-invasive ventilation (NIV)|
75783844|NCT03860636|Diagnostic Test|Endometrial thickness at HCG|Ultrasound
75783845|NCT03860636|Diagnostic Test|Endometrial thickness at TVOR|Ultrasound
75783846|NCT03860636|Diagnostic Test|Endometrial thickness at ET|Ultrasound scan
75919370|NCT03038568|Diagnostic Test|CT scan|Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
75783847|NCT03860636|Diagnostic Test|Endometrial thickness at coordination scan|Ultrasound scan
75783848|NCT03860636|Diagnostic Test|Endometrial volume at HCG|Ultrasound scan
75783849|NCT03860636|Diagnostic Test|Endometrial volume at TVOR|Ultrasound scan
75783850|NCT03860636|Diagnostic Test|Endometrial volume at ET|Ultrasound scan
75783851|NCT03860636|Diagnostic Test|Endometrial volume at coordination scan|Ultrasound scan
75783852|NCT03860636|Diagnostic Test|Blood test for progesterone at HCG|Blood test
75783853|NCT03860636|Diagnostic Test|Blood test for progesterone at TVOR|Blood test
75919371|NCT03017872|Drug|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
75919372|NCT03017872|Drug|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
75919373|NCT03017872|Drug|Darunavir|800mg tablet by mouth once daily for 96 weeks.
75783854|NCT03860636|Diagnostic Test|Blood test for progesterone at ET|Blood test
75783855|NCT03860636|Diagnostic Test|Blood test for progesterone at coordination scan|Blood test
75783856|NCT03860636|Diagnostic Test|Change in endometrial pattern between TVOR and ET|Ultrasound scan
75783857|NCT03860636|Diagnostic Test|Blood test for estradiol at HCG|Blood test
75783858|NCT03860636|Diagnostic Test|Blood test for estradiol at TVOR|Blood test
75783859|NCT03860636|Diagnostic Test|Blood test for estradiol at ET|Blood test
75783860|NCT03860636|Diagnostic Test|Blood test for estradiol at coordination scan|Blood test
75783861|NCT03860636|Diagnostic Test|Endometrial blood flow (doppler) at HCG|Ultrasound scan
76076995|NCT03588585|Procedure|Tension|Tension applied to catheter and taped firmly to leg.
76076996|NCT03588585|Procedure|NO TENSION|Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same
76076997|NCT01591616|Drug|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
76076998|NCT03681873|Diagnostic Test|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
76076999|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
75919374|NCT03017872|Drug|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
76077000|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
75632987|NCT04306172|Other|An US Readmission Risk Prediction Model|Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
76077001|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
76077002|NCT00938314|Drug|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
75783862|NCT03860636|Diagnostic Test|Endometrial blood flow (doppler) at TVOR|Ultrasound scan
76077003|NCT04370392|Procedure|intraperitoneal local anaesthetic instillation|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
75783863|NCT03860636|Diagnostic Test|Endometrial blood flow (doppler) at ET|Ultrasound scan
75783864|NCT03860636|Diagnostic Test|Endometrial blood flow (doppler) at coordination scan|Ultrasound scan
75783865|NCT03860636|Diagnostic Test|Contractility at embryo transfer on a subgroup of participants|Ultrasound scan
76077004|NCT04369378|Behavioral|Meditation app usage|Investigators will confirm eligibility of applicants, enroll participants in the study and provide an identification number for de-identification of the data, and provide a list of mental health resources to participants. Participants will then be sent a link to a Google Form for the pre-intervention survey, to be completed prior to first use of the mindfulness app. Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period, participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
75325449|NCT04742530|Behavioral|Fasted Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after a 7-hour period of fasting. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
75325450|NCT04742530|Behavioral|Fed Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
75632988|NCT04306172|Other|LACE+ score|The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
75632989|NCT04306172|Other|SQLAPE model|The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
75632990|NCT04305860|Dietary Supplement|Modified starch without flavoring|Each patient of this group receives the thickener during three days of hospitalization
75632991|NCT04305860|Dietary Supplement|Mofidied starch with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
75632992|NCT04305860|Dietary Supplement|Xanthan gum without flavoring|Each patient of this group receives the thickener during three days of hospitalization
75783866|NCT03860636|Diagnostic Test|Change in endometrial pattern between coordination scan and ET|Ultrasound scan
75783867|NCT03860636|Diagnostic Test|Change in endometrial pattern between HCG and ET|Ultrasound scan
75632993|NCT04305860|Dietary Supplement|Xanthan gum with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
75783868|NCT03860480|Procedure|ESP with Bupivacaine 0.5%|Regional anesthesia procedure with Bupivacaïne 0.5%
75783869|NCT03860480|Procedure|ESP with Saline 0.9%|Regional anesthesia procedure with Normal Saline
75783870|NCT01288274|Other|Community Based administration of DMPA|Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
75783871|NCT05666648|Other|Sitz Bath|Individual patients were randomized to either receive 'sitz baths' or 'no sitz baths' treatment for 4 weeks. Patients were asked to have 'sitz bath' once in morning and again at bedtime, after each week pain scores and healing of fissure were assessed. Main outcome measures were validated
75783872|NCT03285646|Drug|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
75783873|NCT03285646|Drug|Placebo|Subcutaneous (SC) every 4 weeks (Q4W)
75783874|NCT03860402|Other|Temperature|temperature of drug
75919375|NCT03000205|Device|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain at Week0
75919376|NCT03000205|Device|Normal saline and Lidocaine.|Normal Saline injection for chronic shoulder pain at Week0 (Arms:Placebo Comparator: Placebo)
75919377|NCT02982876|Procedure|Dynamic Flexible Bronchoscopy|The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuvers will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle
75919378|NCT02982876|Procedure|Rigid Bronchoscopy|Under general anesthesia, a rigid bronchoscope (Bryan-Dumon Series II; Bryan Corporation; Woburn, MA) will be introduced, and respiration will be maintained through jet ventilation.
75919379|NCT02982876|Device|Stent placement|Silicone Y stent or uncovered self-expanding metallic stent will be placed in the standard fashion and good fit will be confirmed visually.
75919380|NCT02956902|Other|Clinician supported smartphone application intervention|
76077005|NCT03798327|Behavioral|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
76077006|NCT04357678|Other|Qi Gong Programme|"Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week."
76077007|NCT04357678|Other|Short Form Sun Style Tai Chi|"Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session."
76077008|NCT04357444|Drug|1: ILT101|Subcutaneous injections, once-daily administration for 10 consecutive days.
76077009|NCT04357444|Drug|2: Placebo Comparator|placebo in Subcutaneous route
76077010|NCT04369144|Other|Dynamic Scapular Recognition exercise|The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session
76077011|NCT03679689|Dietary Supplement|artificially sweetened beverages|artificially sweetened beverages restriction
75325451|NCT04742530|Behavioral|Fed Morning Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 10:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
75325452|NCT04479826|Device|Advanced hybrid closed loop system|Free living follow-up of meal handelling
75325453|NCT00852761|Drug|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
75325454|NCT00852761|Drug|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
75325455|NCT03839537|Other|Exposure measurement|"2 measurements per subject (in warm season and in cold season)~Devices placed inside taxi vehicles on the passenger seat in a sampling bag"
75632994|NCT04114279|Procedure|Performance of laparoscopic duodenal atresia repair|completion of laparoscopic duodenal atresia repair in a surgical simulator
75632995|NCT00859222|Drug|LBH589|
75632996|NCT00859222|Drug|bevacizumab|
75632997|NCT01072448|Drug|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
75632998|NCT01072448|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
75632999|NCT00922974|Radiation|External beam radiation therapy|Single fraction dose of 8 Gy external beam radiation therapy
75783875|NCT01175720|Procedure|Periodontal surgery to gingival recessions|Test and control technique to treat gingival recessions.
75468352|NCT05903885|Other|Mailed Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home based Fecal Immunochemical Test (FIT) kit directly by mailing without any personal (face-to-face) contact.
75783876|NCT01288352|Other|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~Optimal antiarrhythmic drug therapy~Catheter ablation with the aim of pulmonary vein isolation (PVI),~Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
76077012|NCT04369222|Other|Observational|Maternal consumption of mild analgesics
75325456|NCT03839537|Other|Spirometry test|"2 measurements per subject - before and after the work shift - in warm and cold seasons~Subject will inhale and exhale in the device"
75468353|NCT05900401|Other|Bone Marrow Transplant|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
75633000|NCT00922974|Radiation|Radiosurgery/SBRT|Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.
75633001|NCT00858988|Drug|Rifaximin|100mg of rifaxin for 7 consecutive days, twice daily
75783877|NCT03867656|Other|GLP-2|GLP-2 injection
75783878|NCT03867656|Other|GIP|GIP injection
75783879|NCT03867656|Other|Placebo|Placebo injection
75783880|NCT03309202|Drug|PF-05221304|25 mg dose
75633002|NCT00858988|Drug|Placebo|twice daily for 7 consecutive days
75633003|NCT00858832|Drug|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
75783881|NCT03860324|Procedure|Single-shot erector spinae plane block|Single-shot Erector Spinae Plane block with 30ml of ropivacaine 0,5% + adrenaline 150mcg.
75783882|NCT03860324|Procedure|Single-shot fascia iliaca block|Single-shot Fascia Iliaca block with 40ml of ropivacaine 0,2%
75633004|NCT01071512|Drug|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
75919381|NCT02942095|Drug|Ixazomib|"Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase"
75919382|NCT02942095|Drug|Erlotinib|Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.
75919383|NCT02879708|Other|Information Only|Households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village (such as the VHSNC meetings and Village Health and Nutrition Days). Information will be disseminated through an initial visit to all households, and from then on either through (1) broadcast messages sent to households via mobile phone, (2) central individuals in the village social network who will be asked to spread that information, or (3) public officials charged with spreading the information throughout the village.
75919384|NCT02879708|Other|Information and Facilitation|In addition to the information interventions described above, this intervention will provide trained facilitators to help community members engage in a participatory process with VHSNCs and identify key deficiencies for improvement in health services that most concern community members. The facilitators are trained to help organize meetings and are provided a detailed checklist of activities to be undertaken prior to the the meetings. The three key health workers at the village level (ASHA, ANM, and AWW) report to the local (village level) elected representatives and block level authorities, who receive feedback from the community in the accountability interventions.
75919385|NCT02872467|Drug|Syntocinon treatment|24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
75919386|NCT02872467|Other|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
75919387|NCT02781519|Drug|THC|Active THC (0.015mg/kg) administered over 10 minutes
75919388|NCT02781519|Drug|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
75919389|NCT02669212|Behavioral|Cardiopulmonary Exercise Test (CPET)|All participants will undergo an exercise stress test
75468354|NCT05900401|Procedure|Peripheral Blood Stem Cell Collection|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.
75468355|NCT05900401|Drug|Fludarabine|Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)
75783883|NCT01175876|Device|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
75633005|NCT00858442|Procedure|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width & length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width & length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
75633006|NCT04256148|Biological|ALXN1830|Administered via intravenous (IV) infusion
75633007|NCT04256148|Other|Placebo|Matching placebo (sterile liquid diluent) administered via IV infusion
75783884|NCT01175876|Procedure|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
75919390|NCT02616094|Device|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
75919391|NCT02616094|Device|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
75633008|NCT00626834|Drug|Vigabatrin|Dose 1 BID
75919392|NCT02610959|Other|Intervention group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
76077013|NCT04363294|Diagnostic Test|PYP scan|99mTc-labeled pyrophosphate
75468356|NCT05900401|Drug|Cyclophosphamide|Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
75633009|NCT00626834|Drug|Vigabatrin|Dose 2 BID
75633010|NCT00626834|Drug|Vigabatrin|Dose 3 BID
75783885|NCT03860012|Drug|Folic Acid|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
75783886|NCT02525198|Dietary Supplement|fatty acid/flavonoid blend|see arm description
75783887|NCT02525198|Dietary Supplement|Placebo|see arm description
75783888|NCT03860090|Device|Pacemaker implant|Implantation of endovenous cardiac stimulation device.
75783889|NCT03860090|Device|Defibrillator implant|Implantation of endovenous cardiac defibrillation device.
75783890|NCT03860090|Procedure|AXILLARY VEIN ACCESS|Fluoroscopy-guided axillary puncture to get vein access
75783891|NCT03860090|Procedure|CEPHALIC VEIN ACCESS|Optimized cephalic vein cutdown to get vein access
75783892|NCT03859934|Drug|Melatonin|Melatonin treatment
75783893|NCT03859934|Drug|Placebo Oral Tablet|Placebo treatment
75633011|NCT00626834|Drug|Matching placebo|Matching placebo BID
75919393|NCT02610959|Other|Control group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
75919394|NCT02580201|Biological|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
75919395|NCT02536664|Drug|Rituximab|
75919396|NCT02483988|Device|NUsurface® Meniscus Implant|The NUsurface® Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network that supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
75633012|NCT04861116|Behavioral|Intervention program for test anxiety|12-week ICT-based manualized, targeted and facilitated individual intervention for adolescent students, that aims to promote compassion, acceptance and mindfulness, in order to help improve test anxiety's regulation (and consequently symptom reduction), as well as increase general and school-related well-being, while promoting valued life action.
75633013|NCT04119076|Other|Classroom-based physical activity|
75783894|NCT03867812|Other|SOBAR|SOBAR is a high protein nutrition bar optimized to delay gastric emptying
75783895|NCT03867812|Other|Control food|Chexmix (General Mills Inc.), Honey Nut Flavor
75783896|NCT03867812|Other|Full meal|Stouffer's Bistro Crostini 5 cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie
75783897|NCT01178372|Drug|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
75919397|NCT02438111|Genetic|metagenome|metagenome
75919398|NCT02426892|Biological|ISA 101|100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
75919399|NCT02426892|Drug|Nivolumab|3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
75325457|NCT03839537|Diagnostic Test|Exhaled carbon monoxide test|"2 measurements per subject - before and after the work shift - in warm and cold seasons~Subject will exhale in the device"
75325458|NCT03839537|Diagnostic Test|Skin allergy test|- Performed by a physician during the inclusion clinical examination
75783898|NCT01178372|Drug|Probiotics(VSL#3)|will receive VSL#3 (110 billion CFU)three times a day
75783899|NCT01178450|Procedure|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
75919400|NCT02332161|Other|surveys, evaluative tests for leg function|See outcome measures
75919401|NCT02312687|Biological|KRN23|solution for SC injection
75919402|NCT02304367|Biological|Burosumab|Solution for subcutaneous injection
75919403|NCT02179359|Drug|Reduced Toxicity Ablative Regimen|"Anti-thymocyte Globulin (ATG)~Fludarabine~Busulfan~Stem Cell Infusion Day 0"
75919404|NCT02179359|Drug|Reduced Intensity Preparative Regimen|"Alemtuzumab~Cyclophosphamide~Fludarabine~Total Body Irradiation (TBI)~Stem Cell Infusion Day 0"
75919405|NCT02179359|Drug|Myeloablative Preparative Regimen|"Alemtuzumab~Cyclophosphamide~Busulfan~Stem Cell Infusion Day 0"
75919406|NCT02094625|Drug|N-Acetylcysteine|"NAC will be administered intravenously over ~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC."
75919407|NCT02054520|Drug|HyperAcute®-Melanoma (HAM) Immunotherapy|
75325459|NCT03839537|Diagnostic Test|Spirometry test|- Performed by a physician during the inclusion clinical examination
75325460|NCT03839537|Diagnostic Test|Fractional Exhaled Nitric Oxide Testing|- Performed by a physician during the inclusion clinical examination
75325461|NCT00364936|Procedure|Palliative care service|
75325462|NCT04222751|Device|Ankle Splint|Ankle splint will be slightly modified from the commercial form to include a pneumatic air cell secured under the forefoot below the splint's padded lining. This replaces the foam wedge provided by the manufacturer, allowing a gradual adjustment of the forefoot/toe region.
75325463|NCT04084756|Behavioral|Couples Crisis Response Plan|The CCRP is a single session therapist-facilitated suicide prevention intervention conducted with a dyad
75633014|NCT04119076|Other|Control Group|
75633015|NCT04255992|Dietary Supplement|Calcium Arm|1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
75633016|NCT04255992|Dietary Supplement|Vitamin D/Calcium|1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
75783900|NCT01178450|Drug|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
75783901|NCT00074490|Drug|Rituximab|Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).
75783902|NCT00074490|Drug|Fludarabine|Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
75325464|NCT04084756|Behavioral|Mental Health Education|The Mental Health Education session is a single session therapist-facilitated mental health psychoeducation session conducted with a dyad
75325465|NCT04082806|Drug|GHB|50 mg/kg GHB at one experimental night
76077014|NCT01591460|Drug|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
76077015|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
75919408|NCT02054520|Drug|Ipilimumab|
75633017|NCT02618824|Drug|Histidine Tryptophan Ketoglutarate Solution|Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
75325466|NCT04082806|Drug|Trazodone|1.5 mg/kg trazodone at one experimental night
75633018|NCT02618824|Other|Terminal Warm Blood Cardioplegia|Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
75633019|NCT00610272|Radiation|Radiotherapy|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
75919409|NCT02054520|Drug|Pembrolizumab|
76077016|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
76077017|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
75633020|NCT00610272|Radiation|Radiotherapy|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
75633021|NCT00610272|Radiation|Radiotherapy|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
75633022|NCT00610272|Radiation|Radiotherapy|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
75783903|NCT00074490|Drug|Etoposide|Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.
75783904|NCT00074490|Drug|Doxorubicin|Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
75783905|NCT00074490|Drug|Vincristine|Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.
75783906|NCT00074490|Drug|Cyclophosphamide|Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
75919410|NCT02054520|Drug|Nivolumab|
76077018|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
75783907|NCT00074490|Procedure|Peripheral blood stem cell (PBSC) transplantation|PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.
75783908|NCT00074490|Genetic|T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells|The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).
75783909|NCT00074490|Drug|Prednisone|Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
75919411|NCT02049827|Other|participation in the study|
75919412|NCT01922921|Biological|HER-2/neu Intracellular Domain Protein|Given ID
75919413|NCT01922921|Other|Laboratory Biomarker Analysis|Correlative studies
76077019|NCT03584295|Device|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation
76077020|NCT03584295|Other|Conventional Care|Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
76077021|NCT04363216|Drug|Ascorbic Acid|Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
76077022|NCT04363372|Drug|MRx-4DP0004|MRx-4DP0004 is a lyophilised formulation of a proprietary strain of bacteria.
76077023|NCT04363372|Drug|Placebo|Placebo capsules will be identical in appearance to active product.
76077024|NCT04357210|Procedure|fistula tract excision and anal sphincter reconstruction|The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
76077025|NCT03678675|Drug|Ketorolac|The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
75325467|NCT04082806|Drug|Placebos|placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
75325468|NCT05656222|Drug|VIA combination treatment|a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
75325469|NCT05635786|Drug|Alteplase (0.9mg/kg)|Intravenous thrombolysis with Alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
75325470|NCT05635786|Drug|Tenecteplase (0.25mg/kg)|Intravenous thrombolysis with Tenecteplase (0.25mg/kg, maximum 25 mg) with 100% of the dose given as a bolus.
75919414|NCT01922921|Biological|Pertuzumab|Given per standard of care
75919415|NCT01922921|Other|Placebo|Given PO
75919416|NCT01922921|Biological|Polysaccharide-K|Given PO
75919417|NCT01922921|Biological|Trastuzumab|Given per standard of care
75919418|NCT01807715|Other|survey|Survey before procedure to obtain demographic information and contraceptive information
75919419|NCT01778777|Device|Universe Reverse Prosthesis|Implantation of an universe reverse prosthesis
76077026|NCT04363060|Combination Product|Azithromycin with amoxicillin/clavulanate|Patients will receive azithromycin 500 mg on day 1 followed by 250mg per day for the next four days with amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
75783910|NCT00074490|Procedure|Allogeneic hematopoietic stem cell transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant.
75783911|NCT00074490|Drug|Filgrastim|Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) > 1000, two values; or ANC > 5000 cells/ul on one occasion).
75919420|NCT01682980|Other|Strength training|The strength training will be delivered 2-3 times per week for 12 weeks, 5-8 repetitions maximum in 3 series. The patients must warm up 5 minutes on an ergometer cycle. The following muscle groups will be trained: Quadriceps and hamstrings, hip muscles (abductors and extensors), calf muscles. A home exercise program will be delivered including one leg exercises and balance exercises. Progression will follow a 2+ principle. For instance, when the study participant is able to perform 2 more repetitions, more loads are required.
75919421|NCT01682980|Other|Aerobic exercise|The aerobic exercise program include ergometer cycling for at least 45 minutes 2-3 times a week on 75-80% of max heart rate will be required.
75919422|NCT01546987|Drug|GnRH agonist|LHRH agonists are administered with a variety of techniques. The manufacturer's instructions should be followed. Begins within 6 weeks after registration (if not started prior) at same time as anti-androgen and TAK-700 (if applicable).
75633023|NCT00858208|Drug|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
75325471|NCT00854087|Drug|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
75325472|NCT00854087|Drug|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
75325473|NCT00365950|Drug|Duration of anticoagulation|
75325474|NCT00365950|Drug|Warfarin duration|
75325475|NCT02487797|Drug|Oxytocin|
75633024|NCT00610350|Drug|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
75919423|NCT01546987|Drug|Anti-androgen|Starts at same time as GnRH agonist, ends at end of radiation therapy. Either flutamide (orally 250 mg three times a day) or bicalutamide (orally 50 mg once a day).
75783912|NCT00074490|Genetic|T-Rapa cell Donor Lymphocyte Infusion (DLI)|The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).
75783913|NCT01286636|Other|computer model|Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
75783914|NCT01286636|Other|Polysomnogram|Diagnosis of sleep apnea will rely on polysomnogram
75783915|NCT03862976|Diagnostic Test|computerized cardiotocography|computerized cardiotocography (C-CTG)
75783916|NCT03859856|Other|hormone panel and ultrasonography|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH, LH, E2 and AMH hormone levels and ultrasonography for antral follicle count and ovarian volume measurement will be done.
75919424|NCT01546987|Drug|TAK-700|300 mg twice daily (BID) (600 mg per day) orally, continuously for 2 years starting with ADT.
75919425|NCT01546987|Radiation|Radiation therapy|Starts 8-10 weeks after initiation of ADT. Initially 45 Gy (1.8 Gy / fraction) to prostate and pelvic lymph nodes delivered with 3DCRT/IMRT, then a boost using intensity-modulated radiation therapy (IMRT), low dose rate (LDR) brachytherapy, or high dose rate (HDR) brachytherapy.
75919426|NCT01494324|Other|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
75919427|NCT01018654|Behavioral|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
76077027|NCT04363060|Drug|amoxicillin/clavulanate|Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
75325476|NCT02487797|Other|Sodium Chloride 0.9%|
75325477|NCT00422266|Drug|Omega 3 fatty acids and plant sterol enriched drink|
75325478|NCT00422266|Dietary Supplement|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
75325479|NCT01733693|Drug|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
75325480|NCT01733693|Drug|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
75325481|NCT00855413|Drug|Darunavir|800 mg orally once daily
75325482|NCT00855413|Drug|Ritonavir|100 mg orally once daily
75325483|NCT00855413|Drug|Etravirine|200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
75325484|NCT05599204|Other|schroth exercise|the patients will receive the Schroth three-dimensional exercise. patient first assumes a posture in the cervico-cranial and shoulder girdle and the thoracic region is held in the correct posture. The patient inspires air into the concave side and during the exhalation phase isometric and isotonic muscle tensing occur. While the patient is breathing, the therapist should observe the posture and movement of the thoracic cage and diaphragm. Basic posture correction in sitting and walking and Sensorimotor training by the ball will be applied
75468357|NCT05900401|Drug|Rituximab|Rituximab on study day -6
75468358|NCT05900401|Drug|Siplizumab|Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.
75468359|NCT05898594|Procedure|Low-dose Computed Tomography|Per standard care
75633025|NCT00610350|Drug|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
75919428|NCT01018654|Behavioral|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
75919429|NCT00809991|Radiation|hypofractionation|3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T
75783917|NCT03867266|Procedure|Ablation with radiofrequency|Ablation point by point on the cavo tricuspid isthmus guided by an index lesion
75919430|NCT00788307|Biological|Ad5-CMV-NIS|
75325485|NCT05599204|Other|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push up- plus, head-neck-retraction, and Kibler squeeze
75325486|NCT00816101|Other|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
75325487|NCT00816101|Other|Mepilex® Border Lite|Self-adherent foam dressing
75633026|NCT01071200|Drug|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
75633027|NCT01071200|Drug|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
75633028|NCT04255836|Drug|Durvalumab|Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months
75633029|NCT04255836|Drug|the first line chemotherapy for metastatic NSCLC|paclitaxel+carboplatin or pemetrexed+cisplatin
75633030|NCT04255836|Radiation|stereotactic body radiotherapy (SBRT)|SBRT total doses of 50-60Gy/≤10F
75633031|NCT04257786|Procedure|1ry cyto-reductive surgery|1ry surgery then chemotherapy
75783918|NCT03961152|Behavioral|PainCoach app|In response to the patient's input of the pain experienced (no pain, bearable pain, unbearable pain, or untenable pain), the app gave advice on pain medication use, exercises/rest and when to call the clinic from day 1 until day 14 after surgery.
75919431|NCT00788307|Drug|liothyronine sodium|
75919432|NCT00788307|Genetic|reverse transcriptase-polymerase chain reaction|
75919433|NCT00788307|Other|laboratory biomarker analysis|
76077028|NCT01591382|Drug|Ketamine|Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
75325488|NCT00816101|Device|Adhesive Bandage|Adhesive bandage
75325489|NCT05504434|Device|Single-use gastroscope|Adults patients are treated with a single use gastroscope instead of a reusable gastroscope
75325490|NCT00366262|Drug|PLA-695|
75325491|NCT00366262|Drug|Naproxen|
75325492|NCT00366262|Drug|Placebo|
75468360|NCT05893082|Device|F2 Filter and Delivery System|Placement of F2 device in aorta to cover the great cerebral vessels.
75783919|NCT02525900|Procedure|Wound Infiltration|Wound Infiltration with 0.25% Bupivacine
75468362|NCT05888506|Dietary Supplement|Ketone Ester|Participants will consume the ketone ester beverage produced by KetoneAid prior to bedtime. Participants will consume 60 mL (30 grams ketones) of the ketone beverage.
75633032|NCT04257786|Combination Product|Neoadjuvant chemotherapy followed by surgery|chemotherapy then surgery
75633033|NCT00699478|Drug|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
75633034|NCT04919148|Behavioral|Heat risk and pro-environment behavior message|Eligible participants will be randomized to either a control condition to receive a standardized heat health warning or an intervention condition to receive a heat health warning plus figures depicting heat risk and pro-environment behavior via their preferred and accessible channel (WhatsApp, WeChat or the text message) each time when a Very Hot Weather Warning is issued by the Hong Kong Observatory.
75633035|NCT04119232|Behavioral|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
75633036|NCT02615002|Drug|Piromelatine|
75633037|NCT02615002|Drug|Placebo|
75633038|NCT02207569|Device|CoreValve Evolut R TAVR system|
75783920|NCT02525900|Procedure|TAP Blocks|bilateral TAP block with 0.25% Bupivacaine
75783921|NCT02525900|Procedure|TAP Catheters|bilateral TAP Catheter with repeat bolus of 0.25% Bupivacaine
75919434|NCT00788307|Radiation|iodine I 131|
75919435|NCT00708760|Behavioral|paper based training|read selected material, test skills learned in simulator lab
75919436|NCT00708760|Behavioral|web based training|read and view selected web based material, test skills learned in simulator lab
75919437|NCT00614211|Procedure|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
75919438|NCT00614211|Procedure|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
75919439|NCT00588185|Drug|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone|Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.
76077029|NCT01591382|Drug|Placebo|Patients who received ketamine-matching placebo were given saline infusions
76077030|NCT01591382|Drug|Hydromorphone PCA|Intravenous hydromorphone PCA
76077031|NCT04362904|Other|acupressure|
76077032|NCT03678441|Behavioral|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
76077033|NCT03678441|Procedure|Cognitive Assessment|Receive pen and paper cognitive assessment
76077034|NCT03677817|Drug|Lidocaine|regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h
76077035|NCT03677817|Drug|NaCl 0,9%|IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
75325493|NCT05452018|Other|Intervention group|In healthy volunteers, activity measurement of muscles of interest by intramuscular electromyography during predefined swallowing tasks
76077036|NCT00931996|Drug|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
75325494|NCT00818363|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
75919440|NCT00268476|Drug|Celecoxib|
75633039|NCT02619058|Biological|NKT cells|autologous natural killer T cell
75633040|NCT01070888|Drug|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
75633041|NCT01070888|Drug|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
75633042|NCT04114513|Dietary Supplement|Maltodextrin|NOVAPRODUKT, white powder 5 weeks intervention
76077037|NCT04348305|Drug|Hydrocortisone|Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
75633043|NCT04114513|Dietary Supplement|Inulin|BENEO-Orafti, white powder 5 weeks intervention
75633044|NCT04114513|Dietary Supplement|Pectin|BANG & BONSOMER GROUP OY, white powder 5 weeks intervention
75633045|NCT04114513|Dietary Supplement|Beta-glucan|Tate & Lyle, white powder 5 weeks intervention
76077038|NCT04348305|Drug|Sodium Chloride 9mg/mL|Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
75633046|NCT04114513|Dietary Supplement|Galactooligosaccharides|FrieslandCampina, white powder 5 weeks intervention
75633047|NCT05683639|Other|warming of the follicular aspiration needle|the follicular aspiration needle will be heated overnight before the ovarian aspiration procedure.
75633048|NCT05683249|Drug|NRCT-101-SR|NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects < 50kg LBM receive a total of four 375 mg tablets per day.
75633049|NCT05683249|Drug|Placebo|Matching placebo
75633050|NCT00914329|Drug|Gelsemium Sempervirens|5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
75633051|NCT00914329|Drug|Gelsemium Sempervirens|15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
75919441|NCT00268476|Drug|Docetaxel|
75919442|NCT00268476|Drug|Prednisolone|
76077039|NCT00928174|Drug|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
76077040|NCT01696214|Drug|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
76077041|NCT01696214|Drug|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
76077042|NCT01696214|Drug|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
76077043|NCT01696214|Drug|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
75325495|NCT00818363|Drug|SABER-Placebo|Injectable Solution; 5.0 mL SABER-Placebo/Once
75325496|NCT00828841|Drug|Cetuximab|Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
75325497|NCT00828841|Drug|Paclitaxel|Paclitaxel 200 mg/m2 Day 1 every 21 days
75325498|NCT00828841|Drug|Carboplatin|Carboplatin AUC 6 Day 1 every 21 days
75325499|NCT00828841|Drug|Gemcitabine|Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
75325500|NCT00828841|Drug|Cisplatin|Cisplatin 75 mg/m2 Day I every 21 days
75325501|NCT00486551|Behavioral|Anger control training|
75325502|NCT05445310|Drug|Furmonertinib|Furmonertinib 80mg/d
75468363|NCT05888506|Dietary Supplement|Placebo|Participants will consume the placebo supplement prior to bedtime. The placebo supplement will be a ketone ester-free, taste and viscosity-matched, beverage produced by KetoneAid.
75633052|NCT00914329|Drug|Placebo|placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
75633053|NCT00857896|Drug|Fesoterodine|4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
75633054|NCT04112485|Procedure|Microdiscectomy|
75633055|NCT00857818|Drug|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
75919443|NCT00268476|Drug|ADT|
75919444|NCT00268476|Drug|Zoledronic Acid|
75919445|NCT00268476|Drug|Abiraterone|
75919446|NCT00268476|Radiation|Radiotherapy to the prostate|
75919447|NCT00268476|Drug|Enzalutamide|
75919448|NCT00268476|Drug|Metformin|
75919449|NCT00268476|Drug|Transdermal Oestradiol|
75919450|NCT00261443|Drug|Lithium or Valproate with placebo (PBO)|"Tablets, Oral, once daily~lithium 250-2100 mg/day~valproate 250-2500mg/day~Placebo once daily"
76077044|NCT02083263|Device|Bilevel|3 months
76077045|NCT02083263|Device|PEP mask|3 months
76077046|NCT04356898|Other|No intervention|No intervention
76077047|NCT05347875|Other|ICanWALK© App.|"App containing educational and instructional videos on crutch fitting and walking with key components of these skills highlighted. App video records individual using the taught skills to enable them and their care providers to review their usage of the walking aids."
76077048|NCT04369300|Behavioral|Registery Data Collection|Observational Data Collection
76077049|NCT03794037|Drug|dydrgesterone 10 mg( tab)/12hs/14 days|Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
76077050|NCT03794037|Combination Product|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days|montelukast 10 mg(tab) once daily oral for 7 days & dydrgesterone 10 mg (tab) twice daily oral for 14 days &
76077051|NCT04356508|Drug|Nivolumab|Single dose at 0.3mg/kg
76077052|NCT04362280|Behavioral|ReCHARGE|During their PE class, all participants (both arms) participate in an intensive lifestyle intervention with established efficacy among this population for the academic fall semester. The following semester, participants are randomized to different treatment arms. ReCHARGE increases the intensity of treatment provided in the first semester by increasing social support and addressing common barriers youth have to adhering to intervention.
76077053|NCT04362280|Behavioral|TAU|PE class as usual led by PE teacher.
76077054|NCT04362202|Other|Water-based Sequential Preparatory Approach|"The experimental training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises followed a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e., catching a ball thrown by the therapist).~The control aquatic therapy consists of water-based exercises, in line with suggestions of the Hydrotherapy Association of Chartered Physiotherapists Guidance on Good Practice in Hydrotherapy.~These consisted of warm-up exercises, stretching exercises for the lower limbs, recruitment exercises and walking exercises during each phase of gait (single stance, swing and double stance)."
76077055|NCT04762641|Drug|ABL503|ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
76077056|NCT01543087|Procedure|blood sampling|Blood sample collection at different time points
76077057|NCT01543087|Drug|bivalent rLP2086|A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
75633056|NCT00857818|Drug|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
75633057|NCT02618668|Drug|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
75783922|NCT01094028|Drug|Oxytocin|20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
75783923|NCT01288508|Dietary Supplement|Supra Fiber|2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
75783924|NCT01288508|Dietary Supplement|Psyllium|1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
75633058|NCT02618668|Drug|Propofol|2 mg/kg I.V
75633059|NCT02618434|Drug|SPN-810|
75783925|NCT03960762|Other|ESP block (Group ESP)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block
75919451|NCT00261443|Drug|Lithium or Valproate with Aripiprazole|"Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)~lithium 250-2100 mg/day~valproate 250-2500mg/day~aripiprazole 15-30 mg/day"
75919452|NCT00093379|Drug|Capecitabine|825 mg/m^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
75919453|NCT00093379|Drug|Oxaliplatin|50 mg/m^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
75919454|NCT00093379|Radiation|Radiation Therapy (XRT)|Undergo radiotherapy* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. *Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
75633060|NCT02618434|Drug|Placebo|
75633061|NCT01074944|Drug|Eliglustat tartrate|Oral Capsule in 50 mg or 100 mg dosages
75633062|NCT02613520|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
75633063|NCT02613520|Other|Normal Saline|0.9% Sodium chloride
75783926|NCT03960762|Other|SAP block (Group SAP)|In group B, after lateral positioning, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be enjected for correction. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
75783927|NCT03863054|Device|NATROX™ Topical Oxygen Therapy System|"A small battery-powered electrochemical oxygen generator to concentrate atmospheric oxygen and feed to wound site through a dressing-like oxygen distribution system"
75783928|NCT01175954|Drug|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.
75783929|NCT01175954|Drug|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
75783930|NCT01288586|Device|Scandinavian Total Ankle Replacement System (STAR Ankle)|Total Ankle Replacement
75783931|NCT01286714|Device|CLIP OST|
75919455|NCT00000524|Drug|cyclosporine|
75919456|NCT00000524|Drug|prednisone|
75919457|NCT02593318|Drug|Oxaloacetate (OAA) 1g|Pills to be taken orally in 500mg dose two times per day
75919458|NCT02593318|Drug|Oxaloacetate (OAA) 2g|Pills to be taken orally in 1000mg dose two times per day.
75919459|NCT04583852|Other|AIVÍA, Ultra-Brightening Spot Micro-needle Patch|a dissolving micro-needle patch, contains active ingredients
75919460|NCT04583852|Other|Placebo Micro-needle Patch|matching placebo will be provided as a dissolving micro-needle patch
76077058|NCT04368598|Drug|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
76077059|NCT04368598|Drug|Acetylcysteine|Acetylcysteine, po, 400mg tid, for 4 weeks
76077060|NCT05347641|Drug|Penpulimab|"Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine * (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5"
76077061|NCT01696058|Drug|Tiotropium|marketed product
76077062|NCT01696058|Drug|Placebo matching Olodaterol|one dose
76077063|NCT01696058|Drug|Tiotropium|marketed product
76077064|NCT01696058|Drug|Olodaterol|one dose
75325503|NCT03611621|Drug|Imlifidase|This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects who have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.
75325504|NCT05443906|Behavioral|Home exercise|Exercise to address limitations impacting walking
75325505|NCT00858689|Drug|Minocycline|50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
75783932|NCT01288664|Drug|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
75919461|NCT02094027|Behavioral|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
76077065|NCT04368520|Dietary Supplement|Vitamin D3|800 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
75325506|NCT05415592|Device|DePuy Synthes Radial Head Replacement System|DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.
75633064|NCT02613520|Biological|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
75325507|NCT00830791|Drug|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
75325508|NCT00830791|Drug|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
75783933|NCT03859778|Other|survey|French pharmacy students will be contacted by email thanks to the student associations and scolarity departments. Answer to the survey will be done online
75783934|NCT03285490|Drug|KX2-391 Ointment 1%|Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical
75783935|NCT03285490|Drug|Placebo|Dosage form: Ointment; Route of administration: Topical
75783936|NCT03859544|Other|Retrospective study|Retrospective study to search mutations associated with Central nervous system lymphoma and study of the prognostic impact (overall survival and progression-free survival) of these mutations.
75919462|NCT02094027|Other|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
75919463|NCT02099331|Drug|Melatonin|
75325509|NCT04741360|Other|Modified Story Memory Technique|10-session computerized program to improve new learning and memory
75325510|NCT00820235|Device|OsseoSpeed™|OsseoSpeed™ implant
75325511|NCT00820235|Device|NobelSpeedy™ Replace®|NobelSpeedy™ Replace® implant
75919464|NCT02099331|Drug|Placebo (for Melatonin)|Sugar pill manufactured to mimic Melatonin 20 mg
75919465|NCT02250105|Drug|ARI-3037MO|Lipid lowering
75633065|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q14 day schedule
75919466|NCT02250105|Drug|Placebo|Inactive
75919467|NCT05615584|Diagnostic Test|Quantitative mass spectrometry assay|ORX-A determination by quantitative mass spectrometry
75919468|NCT02099409|Device|FLORENCED2|FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
76077066|NCT04368520|Dietary Supplement|Vitamin D3|3,200 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
76077067|NCT04368520|Other|Placebo|Hypromellose capsules, given daily for 3 months
75633066|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q21 day schedule
75633067|NCT02618746|Other|Telerehabilitation|
76077068|NCT04762797|Other|Non|This is a retrospective study, without intervention.
75633068|NCT02618746|Other|Hospital based Rehabilitation|
75633069|NCT04012801|Diagnostic Test|C13 breath test|C13 breath test for patients of acute myocardial infarction who need dual- antiplatelet after PCI.
76077069|NCT04762563|Other|IASTM application|IASTM application .
76077070|NCT04762563|Other|Kinesio Tape® Tex Gold)|Kinesio Tape® Tex Gold)
76077071|NCT04356820|Other|acupressure|Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room
76077072|NCT04356274|Other|Participatory System Dynamics (PSD)|Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
76077073|NCT04356274|Other|Audit and Feedback (AF)|Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
75325512|NCT00820235|Device|NanoTite™ Certain® PREVAIL®|NanoTite™ Certain® PREVAIL® implant
75325513|NCT05353816|Device|Intervention/treatment:|Implantation of left ventricular assist device for hemodynamic support.
75633070|NCT04119310|Other|Lumbar-thrust mobilization|The intervention group will receive passive spinal rotational grade V thrust-mobilization, based on Maitland's approach. The intervention will be performed with the subject in right sidelying and left sidelying. The operator's palpating hand is placed over the L2-3 intervertebral space, and the other hand bends both legs of the participant up to the range at which the L2-3 midposition is found. The participant is then asked to straighten the lower leg and hook the upper leg over it with the upper leg's knee positioned over the side of the plinth. While the lower component is kept still, the participant's trunk is rotated until the hip starts to lift off from the plinth. The bottom hand and uppermost hand rest under a pillow and the chest wall, respectively. With the starting position settled, the operator stands behind the participant, takes up the slack within the spine and then provides a grade V thrust- mobilization while stabilizing the uppermost shoulder.
75633071|NCT04119310|Other|Sham thrust-mobilization|Subjects are positioned in right sidelying. The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension passive range of motion without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
75633072|NCT01074554|Drug|Antibiotic Regimen|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
75633073|NCT01074554|Drug|Placebo Regimen|lactose control tablets; one for each antibiotic with equivalent pills
75633074|NCT00857584|Drug|Extended release quetiapine (quetiapine XR)|"Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.~Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study."
75633075|NCT00857584|Drug|Sertraline|"Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study."
75919469|NCT03418454|Diagnostic Test|Buccal mucosa samples for Extraction of BACTERIAL DNA|"Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome)."
75919470|NCT05328388|Dietary Supplement|Lycomato|Lycomato sof gels
75919471|NCT02099487|Radiation|Radiation|hypofractionated IMRT
75325514|NCT05026099|Other|Boxing training|Boxing training: warm-up. Mitt hitting, sandbag hitting, in sitting, cool down, Assessment after 4 weeks boxing training: warm-up. Mitt hitting, sandbag hitting, below hips, cool down, Assessment after 6 weeks Boxing training: warm-up. Mitt hitting, sandbag hitting, both inn sitting and standing, cool down, Post assessment
75325515|NCT05026099|Other|Task Oriented Training|Task-oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 4 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 6 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Post assessment
75325516|NCT00821795|Drug|NPH/Regular 70/30 mix|injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
75325517|NCT00821795|Drug|insulin aspart protamine/insulin aspart 70/30 mix|injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
75325518|NCT05322304|Dietary Supplement|Almond|Intervention (almond supplementation) and Isocaloric diets (control)
75325519|NCT04382131|Other|NaCl Solution|NaCl Solution prepared by participants at home using water and salt
75325520|NCT04382261|Procedure|Scaling and root planing|Full mouth or quadrant SRP
75325521|NCT00833365|Drug|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
75919472|NCT02096991|Other|Can 1|drink the beverage in a can and a glass bottle
75919473|NCT02096991|Other|Can 2|Consume two canned beverage
75919474|NCT02096991|Other|Glass|consume two glass bottled beverage
75325522|NCT00833365|Drug|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
75325523|NCT00821951|Drug|Vorinostat|200 mg, 300 mg, 400 mg, once per RT fraction
75325524|NCT00821951|Radiation|Radiotherapy|Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
75919475|NCT04788160|Other|Cervical SNAGs along with conventional therapy|"cervical SNAG half rotation technique will be performed with the patient sitting on a chair in the erect posture. The therapist placed his thumb over thumb over the transverse process of C1. Then, he glided ventrally with active rotation of the restricted site 10 times holding for 10 seconds with overpressure at end of the rotation with 30 second rest in between each repetition and 3 session/week for 4 weeks.~Conventional therapy will include:~Hot pack over the cervical region for 10 minutes.~TENS for 10 minutes.~Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions with 3 sessions/week for 4 weeks.~Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~Cervical flexor strengthening will be done 10 times in sitting position."
75325525|NCT00852631|Drug|Quetiapine fumarate (Seroquel)|600mg Extended release tablet, oral, once daily
75325526|NCT00860015|Drug|Alimta|"500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer."
75325527|NCT00860015|Drug|Gemcitabine|"1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy."
75325528|NCT00853333|Drug|dexmedetomidine|
75325529|NCT00853333|Drug|midazolam|
75325530|NCT00853333|Drug|propofol|
75325531|NCT05237063|Biological|Blood and urine samples|Additional Blood and urine samples will be collected at inclusion, 1, 3 and 5 years follow up visits
75325532|NCT00853645|Device|Subcutaneous Implantable Defibrillator (S-ICD) System|
75325533|NCT00822107|Drug|Hydrochlorothiazide|50 mg one time
75919476|NCT04788160|Other|Conventional Therapy|"Patients in this group will undergo only conventional therapy which will include:~Hot pack for 15 minutes.~TENS for 10 minutes.~Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions each 3 sessions/week for 4 weeks.~Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~Cervical flexor strengthening will be given to the patient by the therapist, 10 times in sitting position."
75919477|NCT02097069|Dietary Supplement|Folic acid|Folic acid 400 mcg/day
76077074|NCT04104763|Behavioral|study of osteofibrous dysplasia features|obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.
76077075|NCT01695746|Drug|C.E.R.A.|Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
76077076|NCT03790137|Drug|Fenfluramine Hydrochloride|Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
76077077|NCT04795076|Dietary Supplement|Infant formula|Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
75325534|NCT05218408|Biological|CYNK-001 systemic and Intra cavity administration|"Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10^9 or 3.6 x10^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a"
75325535|NCT05236907|Drug|Melatonin|The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.
75325536|NCT05236907|Other|No intervention|No intervention was used.
75325537|NCT05236907|Drug|Midazolam|7.5 mg of Midazolam orally.
75325538|NCT05217706|Drug|Ketamine|The treatment group will receive Ketamine 0.2mg/kg IV once
75633076|NCT00857584|Drug|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
75633077|NCT02876120|Other|Implementation|Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.
75633078|NCT04132024|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
75919478|NCT02097069|Dietary Supplement|Myo-inositol|myo-inositol 2000 mg twice a day
75633079|NCT00798967|Drug|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
75633080|NCT00798967|Drug|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
75919479|NCT02097069|Dietary Supplement|D-Chiro-inositol|D-chiro inositol 250 mg twice a day
75919480|NCT02097069|Dietary Supplement|Myo-inositol plus D-chiro inositol|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
75919481|NCT05294770|Other|Optisource® Plus: Very Low Calorie Diet treatment|Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)
75325539|NCT05217706|Drug|normal Saline|The placebo group will receive normal saline IV in a matched syringe
75468364|NCT05883358|Drug|Clonidine, Buprenorphine|Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
75468365|NCT05882916|Device|HIV self-testing|Oral fluid-based HIV self-test kits for secondary distribution
75633081|NCT02876198|Device|Gonioscopy|Study of the trabecular structure by gonioscopy
75633082|NCT04132102|Drug|Afatinib|Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
75633083|NCT02618356|Drug|Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage <1.25 m2 80 mg/d~1.25m2 - <1.5 m2 100 mg/d~1.5 m2 120 mg/d"
75633084|NCT00697996|Drug|Rituximab for transplant rejection|
75633085|NCT04112251|Dietary Supplement|Cocoa Flavonols Supplement|Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
75633086|NCT04118842|Drug|Savolitinib|Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
75633087|NCT04118842|Drug|Rifampicin|Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
75633088|NCT00699634|Drug|Nabilone|Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
75633089|NCT02618278|Other|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
75633090|NCT00698074|Device|Cardiac Resynchronisation Therapy|Biventricular Pacemaker Implant
75919482|NCT05294770|Other|Hypocaloric Mediterranean Diet|Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
75633091|NCT02618200|Device|3D prostate ultrasound|
75633092|NCT04131868|Behavioral|Typical sleep opportunity|Typical sleep opportunity with consistent sleep timing for 1 week
75633093|NCT04131868|Behavioral|Extended sleep opportunity|Extended sleep opportunity by 90 min per night with consistent sleep timing for 1 week
75633094|NCT04131790|Behavioral|Tele-Behavioral Activation|Five 1-hour sessions of BA delivered by a trained interventionist via video-conferencing
75633095|NCT04131790|Behavioral|Tele-Friendly Visiting|Five 1-hour FV sessions delivered by a trained interventionist via video-conferencing
75633096|NCT04131634|Radiation|Stereotactic Ablative Radiation|A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy
75633097|NCT00798889|Drug|Sunitinib|Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
75633098|NCT04113889|Drug|Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)|72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.
75633099|NCT04113889|Drug|Metformin, pioglitazone and placebo|72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
75783937|NCT02525276|Behavioral|exercise|The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
75919483|NCT03424226|Drug|Acetazolamide|a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
75325540|NCT00833443|Drug|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
75325541|NCT05215912|Drug|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
75325542|NCT05215912|Drug|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
75325543|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
75325544|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
75468366|NCT05882916|Behavioral|Behavioral economic 'nudges'|Salient information for men included with the self-test kit on clinic location and hours within their cluster, and pilot-tested messaging on the importance of early ART initiation, and the availability and benefits of PrEP
75633100|NCT00796861|Drug|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
75633101|NCT04112017|Device|YVOIRE Y-Solution 360|Hyaluronic acid
75633102|NCT02605057|Drug|LEO 80185 gel|
75633103|NCT02605057|Drug|Dovobet(r) Ointment|
75783938|NCT02525276|Drug|Hormone treatment|"Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat"
75783939|NCT02939716|Other|Rhubarb|300gm rhubarb
75783940|NCT02939716|Other|Bread|2 slices bread
75783941|NCT02939716|Other|Lettuce|300g lettuce
75919484|NCT03555513|Procedure|living kidney transplantation|receiving kidney transplantation from living donor
75919485|NCT04353856|Other|quality of life assessment|quality of life assessment using the EQ5D questionnaire once a month
76077078|NCT04368286|Behavioral|pulmonary rehabilitation|Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
75325545|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
75325546|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
75325547|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
75325548|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
75325549|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
75325550|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
75783942|NCT01176110|Device|LMA Perfect Temp|The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
75325551|NCT05213338|Device|Wear-documentation microchip|Microchip embedded in the appliance
75325552|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
75325553|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
75325554|NCT05207722|Biological|CYNK-101|CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to express a variant of CD16, Fc gamma receptor III (FcγRIII).
75325555|NCT05207722|Drug|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
75325556|NCT05207722|Drug|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
75468368|NCT05881473|Diagnostic Test|pain assessment after clavicular fracture repair|This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
75468369|NCT05875129|Device|VAVA prototype|Cognitive behavioral therapy for insomnia
75325557|NCT05207722|Drug|Recombinant Human Interleukin-2|6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.
75325558|NCT05207722|Drug|Cyclophosphamide|Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
75325559|NCT05207722|Drug|Fludarabine|Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
75468370|NCT05872022|Other|No Intervention|This is a non-interventional study, therefore no intervention is used.
75783943|NCT01172444|Drug|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
75783944|NCT01172444|Drug|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
75783945|NCT01172444|Drug|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
75783946|NCT01288742|Drug|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
75783947|NCT01288742|Drug|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
75783948|NCT01288742|Drug|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
75783949|NCT01288742|Drug|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
75919486|NCT03416036|Biological|TetraVax-DV-TV003 (TV003)|TV003 contains 10^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10^3.3 PFU/mL of rDEN2/4Δ30(ME), 10^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm
75919487|NCT03416036|Biological|rDEN2Δ30-7169 (DENV-2)|Administered at a dose of 10^3 PFU by subcutaneous injection in the deltoid region of the upper arm
75919488|NCT03416036|Biological|rDEN3Δ30 (DENV-3)|Administered at a dose of 10^3 PFU by subcutaneous injection in the deltoid region of the upper arm
75919489|NCT03416036|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
75919490|NCT02250729|Other|intradermal pholcodine allergy test in cases|
75919491|NCT02250729|Other|Blood sampling|
75468371|NCT05870176|Behavioral|Enhanced Referral|The enhanced referral uses an electronic referral and patient decision aid to provide choices to 3 different physical activity programs.
75468372|NCT05870176|Behavioral|Standard Referral|"The standard referral period will serve as the usual care comparator. Patients will receive a paper referral and Fitbit monitor."
75468373|NCT05867407|Device|Anumana Low EF AI-ECG Algorithm|Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.
75468374|NCT05867407|Other|Care-as-Usual|Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.
75783950|NCT01288742|Drug|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
75783951|NCT01178840|Device|WC then FC2|4 uses of WC followed by 4 uses of FC2
75783952|NCT01178840|Device|FC2 then WC|4 uses of WC followed by 4 uses of FC2
75783953|NCT01178996|Biological|Thymosin alpha 1|Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
75783954|NCT01178996|Drug|Ribavirin|Ribavirin 1000 mg (<75 kg) or 1200 mg (>75 kg) daily with food divided in two doses orally for 48 weeks
75919492|NCT04788472|Drug|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
76077079|NCT01694420|Drug|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
76077080|NCT04347148|Procedure|SNAGs Treatment|a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.
75919493|NCT04788082|Diagnostic Test|3D Printed Heart Model|Prior to surgical intervention, the surgeon will be exposed to clinically-indicated images and a patient-specific 3D printed model of the subject's heart anatomy.
75919494|NCT03424070|Other|Shoulder Roll|The POGO score assesses the percent of the glottic opening that can be seen with and without the shoulder roll.
76077081|NCT04347148|Procedure|Sham Laser Treatment|A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
76077082|NCT03580317|Other|EA+ Carbamazepine|"Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily."
76077083|NCT03580317|Other|EA+Placebo|In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
75919495|NCT03424070|Other|No shoulder roll (placebo)|Placebo
75919496|NCT02097147|Drug|Vilazodone 20 mg|Oral administration, once per day.
75919497|NCT02097147|Drug|Vilazodone 40 mg|Oral administration, once per day.
76077084|NCT03580317|Other|sham EA+Carbamazepine|"Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part."
76077085|NCT03580317|Other|sham EA+Placebo|The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
76077086|NCT04362124|Biological|vaccine BCG|Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.
76077087|NCT04362124|Other|Placebo|A single dose intradermal application of normal saline solution.
75633104|NCT05638945|Behavioral|ED Delirium Screening and Detection Program (ED-DDP)|The intervention arm will have standardized delirium screening by nurses using the brief confusion assessment method (bCAM) in the EHR and will receive the ED-DDP. The ED-DDP will consist of: 1) a multicomponent 1-day delirium champion workshop; 2) real-time direct observation/training via telehealth (tele-training); and 3) training of nurses by champions. Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses.
75325560|NCT05207722|Drug|Mesna|MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.
76077088|NCT04361968|Other|Animal-assisted placebo condition|Participants receive the same verbal information as in the Placebo condition. Additionally, participants will receive the same verbal information as in the Dog only condition.
76077089|NCT04361968|Other|Placebo condition|"Participants receive verbal information that they are receiving an analgesic cream (i.e. Antidolor, containing Lidocain), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
75325561|NCT00860171|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Autologous stem cells given via central catheter
75325562|NCT00860171|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV
75919498|NCT02097147|Drug|Paroxetine 20 mg|Oral administration, once per day.
75325563|NCT00860171|Other|Laboratory Biomarker Analysis|Correlative studies
75325564|NCT05206240|Other|Radial extracorporeal shock wave therapy and conventional physical therapy|"The conventional physical therapy program will consist of verticalization strategies, range of motion exercises, muscle stretching and strengthening exercises, stance and balance training, core stability exercises, gait training, functional training, cryotherapy or local heat for 1h/day, 5 days/week for 2 weeks.~Regarding the rESWT delivery, 2000 shots will be applied on the triceps surae myotendinous junction with a frequency of 10 Hz and an energy density of 60 mJ, 7 min/session, 1 session/week for 2 weeks."
75325565|NCT00366418|Drug|Rituximab|
75919499|NCT02097147|Drug|Placebo|Oral administration, once per day.
75919500|NCT02094105|Procedure|Endoscopy examination with iodine staining|Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
75919501|NCT03423992|Biological|chimeric antigen receptor T cells|chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
75919502|NCT03423914|Behavioral|Expressive writing|The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system
75919503|NCT03423914|Other|Only Writing|Participants write about knowledge related to infant care during four days
75325566|NCT03839303|Device|Infra-zygomatic Mini Implant Supported Appliance|"leveling and alignment of the four maxillary incisors~infra zygomatic mini-implant will be placed bilaterally~wire frame work that is designed resembling the inner bow of headgear will be adapted to the upper arch~a heavy arch wire engaging the 4 incisors will be attached to the wire frame work~orthopedic force will be delivered from the mini-implants to the wire frame work"
75325567|NCT03839303|Device|high pull head gear|"acrylic maxillary splint is made with flying tubes~high pull head gear is adapted to be inserted in the flying tubes"
75919504|NCT05425095|Other|Buteyko Breathing Technique|Group A will be treated with Buteyko Breathing Technique. Patient in a relaxed sitting position will ask to take a gentle breath in (2 sec), breath out (3sec) followed by pinching the nose with hands to hold the breath. The therapist will count the no. of seconds the patient can comfortably hold the breath until feels the need to breathe in again. Followed by releasing the nose and continue breathing.
75919505|NCT05425095|Other|Corpse-Pose Technique|Group B will be treated with Corpse-Pose Technique for 15-20 min.
75919506|NCT03418298|Behavioral|Prehabilitation group|Subjects will performed an internet-based exercise program before surgery
75919507|NCT03418220|Other|blood and aqueous humor sampling|The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).
75919508|NCT02633150|Other|Supplementation with red grapes polyphenol|
75919509|NCT03415802|Drug|Nab-paclitaxel and S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-14, q3w)
75919510|NCT02094183|Other|GLP-1|GLP-1
75919511|NCT02094183|Dietary Supplement|low calorie diet|low calorie diet
75325568|NCT05184088|Drug|[18F]florbetaben|All enrolled patients will undergo [18F]florbetaben PET imaging.
75325569|NCT00860795|Biological|Echinacea purpurea|Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
75919512|NCT03127202|Device|Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)|Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.
75919513|NCT02099877|Drug|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
75919514|NCT02097381|Drug|Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir|"Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day)."
75325570|NCT00860795|Drug|placebo|placebo 25 ml daily in 2 divided doses for 10 days
75468375|NCT05867186|Behavioral|Exercise training|Exercise training during intensive cancer treatment, maintenance therapy and aftercare. Training mainly consists of age-appropriate and personalised endurance, strength, flexibility, balance/coordination and gait training. Exercise is provided 3 to 5 times a week lasting for 45 to 60 minutes under supervision during inpatient and outpatient stays, as well as at home. At home, patients train independently according to the exercise recommendations of the exercise professionals, receive supervised telemedical exercise sessions and/or combine their training with digital tools.
75633105|NCT00914563|Device|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
76077090|NCT04361968|Other|Dog only condition|"Participants will get a therapeutic rationale for the presence of the dog. The rationale is supported in the literature and therefore not invented for the purpose of this study. Participants will be told that: Studies have shown the presence of an animal can affect pain perception because the presence and the interaction with an animal can increase our Oxytocin level. Therefore, the investigators want to examine if the presence of a dog has an impact on your pain perception. While participants have to wait for the action time of the cream they are allowed to pet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Participants will still be able to see the dog."
76077091|NCT04361968|Other|Control Condition|Participants in this condition will receive no intervention. All instructions will be conveyed in a standardized manner to ensure that the participant-experimenter relationship is comparable in terms of friendliness and attention across all four conditions.
75325571|NCT00823043|Drug|timolol hemihydrate|timolol hemihydrate 0.5% solution
75325572|NCT00823043|Drug|timolol maleate|timolol maleate in sorbate
75325573|NCT05115760|Dietary Supplement|Dietary Supplement|Given Kate Farms pea protein oral nutrition supplement PO
75325574|NCT05115760|Other|Quality-of-Life Assessment|Ancillary studies
75325575|NCT05115760|Other|Questionnaire Administration|Ancillary studies
75325576|NCT05103514|Other|Online Survey|There are no interventions planned for this study. This is an observational study only.
75325577|NCT00861263|Device|overtube use during enteroscopy|use of overtube for the regular scheduled enteroscopy
75325578|NCT05083390|Drug|norUrsodeoxycholic acid|500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
75325579|NCT05074030|Behavioral|Personalized Normative Feedback|Normative Feedback on drinking behaviors.
75325580|NCT05074030|Behavioral|Coping-Motive Specific Personalized Feedback Intervention plus an Ecological Momentary Intervention (PFIcope+EMI)|An EMA plus EMI intervention to decrease drinking to cope behaviors among emerging adults receiving psychiatric treatment.
76077092|NCT04356118|Drug|Recombinant Human Endostatin|endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.
76077093|NCT04356118|Drug|intrathcal methotrexate|Intrathecal chemotherapy specified dose on specified days.
76077094|NCT04356118|Drug|Targeted drugs for non-small cell lung cancer|EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .
75325581|NCT00862745|Drug|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
75325582|NCT00862745|Drug|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
75325583|NCT02150759|Drug|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
75325584|NCT02150759|Drug|Fentanyl|add dexmedetomidine during position change
75325585|NCT02150759|Drug|Ketamine|add dexmedetomidine during position change
75325586|NCT02150837|Other|5 & 2 & 2 Plan|Medifast has developed the 5 & 2 & 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 & 2 & 2 Plan consists of 5 Medifast meal replacements, 2 Lean & Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, >72g protein, >100g of carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
75325587|NCT02150837|Other|4 & 2 & 1 Plan|Medifast has developed the 4 & 2 & 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 & 2 & 1 Plan consists of 4 Medifast meal replacements, 2 Lean & Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, >72g protein, >100g carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
75468376|NCT05866315|Drug|Remimazolam|Administer remimazolam
75468377|NCT05866315|Drug|Desflurane|administer desflurane
75468378|NCT05866315|Drug|Remifentanil|administer remifentanil
75633106|NCT00914563|Other|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
75325588|NCT04991350|Drug|Intravitreal ranibizumab|Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.
75468379|NCT05863052|Biological|Immunotherapy|immunotherapy
75468380|NCT05860504|Diagnostic Test|Echocardiography|All patients in the study will be examined with echocardiography
75468381|NCT05860504|Diagnostic Test|Cardiac magnetic resonance imaging|Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
75468382|NCT05860504|Diagnostic Test|Coronary CT|Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
75783955|NCT01178996|Biological|PEGinterferon alfa2a|180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
75783956|NCT01178996|Drug|Placebo|Placebo
75468385|NCT05843799|Drug|ILB-202|Single i.v. infusion
75468386|NCT05843799|Drug|Placebo|Single i.v. infusion
75468387|NCT05841212|Other|DBT for ADHD|See information included in arm/group description.
75783957|NCT03862898|Other|Lumbar stabilization exercises|Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
75783958|NCT01179074|Procedure|oesophageal stenting with self expandable metal stent|oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer
75783959|NCT01179074|Procedure|Oesophageal stent followed by external beam radiotherapy|30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
75783960|NCT03862586|Drug|N-acetyl cysteine|
75783961|NCT03862586|Drug|Placebos|
75783962|NCT01180946|Dietary Supplement|ergocalciferol|ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
75783963|NCT01180946|Other|placebo pill|placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
75783964|NCT01179152|Drug|Budesonide turbuhaler, Budesonide+Formoterol turbuhaler|Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
75783965|NCT01179230|Other|SPECT imaging|Dipyridamole stress testing 0.57 mg/kg
76077095|NCT04361734|Other|Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)|"Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body."
75325589|NCT04991350|Drug|Intravitreal bevacizumab|Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
75633107|NCT00802867|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
75633108|NCT04113967|Other|Biodanza program|Biodanza is a form of intervention aimed at promoting health and well-being through the promotion of self-expression and self-regulation through interaction through music and dance. The music accompanied by the movement of the body induces some experiences that present the ability to modify the organism itself both at an organic level, as affective-motor and existential. This intervention constitutes a means for the correct development of human qualities, whose purpose is to integrate the potentials of bond, health and harmony, as well as to develop new alternatives for the life of each individual.
76077096|NCT04361578|Diagnostic Test|Magnetic resonance elastography|All patients enrolled will receive magnetic resonance elastography of the brain.
75633109|NCT00914797|Drug|inhaled and oral terbutaline|"Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954."
75633110|NCT02604901|Behavioral|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR*S (BI). BI was considered an active intervention method.
75633111|NCT02604901|Behavioral|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
75633112|NCT04114045|Dietary Supplement|Experimental:Whey protein|Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.
75633113|NCT04114045|Dietary Supplement|Active Comparator: Isoenergetic control - Carbohydrate|Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.
75633114|NCT04114045|Other|Placebo|Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
75633115|NCT00798655|Drug|Panitumumab|"Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight"
75633116|NCT00798655|Drug|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
75633117|NCT00798655|Radiation|Radiation Therapy|"Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day."
75633118|NCT04111783|Device|POU protocol ultrasound|The evaluation method performed a preoperative examination of the patient within 10 minutes by a heart scan and a standard scan of the face, a large vascular scan under the xiphoid, a body cavity scan, and a standard scan of the face and a lung scan. Preparation, providing anesthesia and surgeons with a fast, comprehensive and accurate preoperative judgment with important clinical and social significance.
75633119|NCT00593983|Behavioral|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
75633120|NCT00593983|Behavioral|Time-matched health education|Health education and standard of care treatment
76077097|NCT04361812|Drug|HS632|Subcutaneous injection of HS632
75325590|NCT00366496|Device|Acrysof single piece (SA60AT)|
75325591|NCT00366496|Device|Acrysof IQ (SN60WF)|
75783966|NCT01179230|Other|PET imaging|Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
75783967|NCT01286948|Drug|Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
75783968|NCT01179308|Other|General-epidural anesthesia|General anesthesia combined with epidural anesthesia
75325592|NCT00857545|Other|Laboratory Biomarker Analysis|Correlative studies
75325593|NCT00857545|Biological|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
75325594|NCT00857545|Biological|Saponin-based Immunoadjuvant OBI-821|Given SC
75325595|NCT04952194|Drug|Stalevo|The dose of Stalevo initially ranges from (Levodopa/Carbidopa/Entacapone) 50/12.5/200 mg 3 times a day to a target dose of 100/25/200 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
75325596|NCT04952194|Drug|Carbidopa and Levodopa Controlled Release Tablets|The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
75468388|NCT05839119|Drug|Degarelix|initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)
75783969|NCT01179308|Other|Balanced general anesthesia and postoperative opioids|General anesthesia alone
76077098|NCT04361812|Drug|Omalizumab (Xolair®)|Subcutaneous injection of Omalizumab Xolair®)
75919515|NCT03418142|Behavioral|Priovi|Priovi is an Internet intervention for people with BPD. Content is continuously adapted to patients' concerns and needs. Priovi is a comprehensive program, which is conceptually and substantially based on the schema therapeutic approach used in BPD patients. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audios and motivating text messages. Techniques to cope with borderline symptoms (e.g., psychoeducation about modes, schemas and basic emotional needs in addition to relevant strategies to weaken, reduce and/or heal maladaptive schemas and modes) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
75919516|NCT03418142|Other|CAU|Care as Usual: In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Priovi after 12 months post-baseline (i.e., wait list with respect to Priovi access).
75919517|NCT03127280|Other|Fast Track foley removal|Foley catheter is removed at 4 hours after surgery
75919518|NCT02099955|Drug|Vitamin D3|4000 IU/day or 2000 IU/day for 12 weeks
75919519|NCT02097459|Drug|Anastrozole|
75919520|NCT02097459|Drug|Tamoxifen|
75919521|NCT02097459|Drug|Toremifene|
76077099|NCT04368208|Other|Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery|The Edinburgh questionnaire is a self questionnaire validated for postnatal depression between 4 and 6 weeks postnatal
75325597|NCT04930354|Drug|ECP-1014|Patients will be selected who (1) have failed all standard of care therapy (relapsed/refractory) or (2) have relapsed and are not a candidate for an available standard of care therapy as assessed by the investigator (such as, but not limited to, colorectal cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), head and neck, etc.) with COX-2 overexpression, ultimately resulting in elevated production of prostaglandin E2 (PGE2).
75325598|NCT00835159|Drug|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
75325599|NCT00835159|Other|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
76077100|NCT04368052|Diagnostic Test|Mini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein|Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
76077101|NCT04355962|Drug|Sevoflurane|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
76077102|NCT04355962|Drug|Intravenous drug|Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
76077103|NCT04367662|Procedure|blood sampling|blood sampling in hospitalized patient for COVID-19 infection
76077104|NCT04367584|Other|Clinical and laboratory examination|Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
75633121|NCT04113655|Biological|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
75919522|NCT02343302|Device|Jackson-Pratt Drain|"A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain"
75325600|NCT04927156|Device|BALT medical devices|"Includes, but is not limited to, the following:~Access devices~Aneurysm treatment devices~Ischemic Stroke and peripheral occlusive diseases treatment devices~Arterio-Venous Malformations/fistulas treatment devices"
75468389|NCT05839119|Combination Product|Gemcitabine/Cisplatin|"SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle)."
75919523|NCT02343302|Device|Non-suctioning drainage|"A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain"
75919524|NCT02097615|Procedure|chlorhexidine gluconate|chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
75919525|NCT02097615|Other|deionized water|application every 24 hours six weeks
75919526|NCT02590432|Drug|Linaclotide|Linaclotide capsules, orally, once daily.
76077105|NCT04361890|Diagnostic Test|perineal ultrasound|all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
75919527|NCT02094339|Procedure|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
76077106|NCT04361500|Device|Seraph 100|Seraph 100 therapy during a COVID-19 infection
76077107|NCT00705081|Drug|ezetimibe|10 mg once daily
76077108|NCT00705081|Drug|statin|
76077109|NCT04361110|Radiation|Computerized tomography scan of the abdomen|Non-specific abdominal ct´s with different phases and contrast +/-.
76077110|NCT00704769|Drug|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
76077111|NCT00938548|Drug|Pregabalin|Pregabalin 75 mg orally
76077112|NCT00938548|Drug|Vitamin Complex (placebo)|Vitamin Complex orally
76077113|NCT00932620|Drug|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
75919528|NCT02094339|Procedure|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
76077114|NCT00932620|Drug|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
76077115|NCT04361188|Procedure|MAC anesthesia|Patients receives DBS under monitored anesthesia care.
75468390|NCT05832086|Behavioral|Fasting Mimicking Diet (FMD)|Consume the FMD (Xentigen, L-Nutra, Los Angeles, CA) for 5 days every monthly cycle for 6 cycles total in 6 months.
75468391|NCT05832086|Behavioral|Standard Anti-Cancer Diet|Will receive standard of care diet and exercise recommendations from the study dietitian. The diet advice will be consistent with the American Cancer Society for cancer survivors and exercise recommendation of a goal of 150 minutes/week of cardiovascular exercise and weight resistance training at least twice a week.
75633122|NCT04113655|Biological|Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
75633123|NCT04113655|Biological|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202"
75633124|NCT00914641|Drug|Apixaban IR|immediate release tablet, 10 mg, single dose
75633125|NCT00914641|Drug|Apixaban MR1|modified release tablet 1, 10 mg, single dose
75633126|NCT00914641|Drug|Apixaban MR2|modified release tablet 2, 10 mg, single dose
76077116|NCT04361188|Procedure|AAA anesthesia|Patients receives DBS under asleep-awake-asleep anesthesia.
76077117|NCT00003453|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
76077118|NCT04367818|Procedure|Peri-anal local anaesthetic infiltration|postoperative pain relieve, among pediatrics patient
75468392|NCT05831735|Behavioral|Physical activity|"The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed)."
75633127|NCT00914641|Drug|Apixaban MR3|modified release tablet 3, 10 mg, single dose
75633128|NCT05632393|Drug|Daridorexant|Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
75633129|NCT00796549|Drug|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
75633130|NCT00856492|Biological|bevacizumab|Given IV
76077119|NCT04367818|Procedure|Caudal anaesthesia|Regional anaesthesia for postoperative pain relieve, among pediatrics patient
76077120|NCT01677273|Dietary Supplement|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
75633131|NCT00856492|Biological|pegfilgrastim|Given subcutaneously
75633132|NCT00856492|Drug|cyclophosphamide|Given IV
76077121|NCT01677273|Dietary Supplement|Intact casein|30 g protein/supplement, 4 supplements/visit
76077122|NCT01677273|Dietary Supplement|Intact whey protein|30 g protein/supplement, 4 supplements/visit
76077123|NCT04355806|Drug|PD-1/PD-L1 inhibitors|Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
76077124|NCT04355806|Biological|Inactivated trivalent influenza vaccine|Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
76077125|NCT01677351|Drug|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
76077126|NCT01677351|Drug|placebo|
75633133|NCT00856492|Drug|doxorubicin hydrochloride|Given IV
75633134|NCT00856492|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
75633135|NCT04113265|Device|SUNEKOS ® Body|SUNEKOS ® Body is a medical device (class III). The study product was injected at level of the inner thighs, knees and arms by needle (29 G) using the interstitial fluid technique (IFT)
76077127|NCT00938704|Drug|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
76077128|NCT00938704|Drug|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
76077129|NCT03668379|Behavioral|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
76077130|NCT03668379|Behavioral|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT & mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
75919529|NCT02094339|Procedure|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
75325601|NCT04860856|Drug|0.5% ropivacaine|The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.
75325602|NCT04860856|Drug|Normal Saline|20ml of normal saline
75919530|NCT02094339|Drug|ropivacaine|0.2% ropivacaine
75633136|NCT04113577|Other|usability survey|usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.
75633137|NCT04113343|Drug|Remimazolam|Remimazolam via oral administration
75633138|NCT04113343|Other|Alcohol|Alcohol
75919531|NCT02094339|Drug|ropivacaine|0.2% ropivacaine
75919532|NCT02094339|Drug|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
75919533|NCT03415724|Procedure|Inferior alveolar nerve block|Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars
75919534|NCT04447664|Device|Inclouded telespirometry system|Components of the system: Portable digital ultrasonic spirometer (Uscom SpiroSonic MOBILE), android mobile application, clinical web cloud application
75919535|NCT04447586|Other|Pressure measurement during exhalation through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer|"Participants performed exhalation attempts through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer, following the instructions of Command A and B (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) in a specific order for each group. Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study."
75633139|NCT04111471|Drug|Prebiotics|Enrolled patients will receive 10 grams of inulin daily for 21 days
75633140|NCT04111471|Drug|Placebos|Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
75633141|NCT04111393|Procedure|transoral specimen extraction|transoral specimen extraction during laparoscopic gastric resection
75919536|NCT04447586|Other|Pressure measurement during exhalation through an alternative PEP device/soft drink straw.|"Participants were requested to exhale as indicated by the right command (Command A or B), for 3 sets of 10 repetitions. This procedure included short breaks between sets."
75919537|NCT02100033|Device|acupuncture|
75633142|NCT04113031|Behavioral|Flywheel squats versus free weight high load squats for explosive actions in football|Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
75919538|NCT03415646|Other|Erector Spinae Plane Block|erector spinae plane block with double level injection will be administered before the surgery
75633143|NCT04111159|Drug|HSK3486|Subjects < 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
75919539|NCT03415646|Device|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
75919540|NCT02097771|Device|LMA SupremeTM|
75919541|NCT02097771|Device|AuraOnceTM|
76077131|NCT03668379|Behavioral|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT & mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
75325603|NCT00827099|Biological|anti-thymocyte globulin|anti-thymocyte globulin
75325604|NCT00827099|Drug|fludarabine phosphate|fludarabine phosphate
75325605|NCT00827099|Drug|Melphalan|melphalan
75325606|NCT00827099|Drug|mycophenolate mofetil|mycophenolate mofetil
75919542|NCT05170100|Behavioral|NUIG OAB App|An interactive software-delivered 8-week intervention accessed through the patients' mobile device. It provides best-practice behavioural therapy, and delivers evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
75919543|NCT04787770|Other|non-intervention|non-intervention
75919544|NCT02250495|Device|Sympara Therapeutic System|Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension
75325607|NCT00827099|Drug|tacrolimus|tacrolimus
75325608|NCT00827099|Procedure|umbilical cord blood transplantation|umbilical cord blood transplantation
75325609|NCT00366574|Device|Amadeus Microkeratome|
75325610|NCT00366574|Device|IntraLase|
75325611|NCT00366652|Drug|desvenlafaxine SR|
75325612|NCT00366652|Drug|desipramine|
75325613|NCT00366652|Drug|duloxetine|
75325614|NCT00366730|Drug|Nitazoxanide|
75325615|NCT02617888|Radiation|CCTA ~ BREAST SHIELDS|Breast shield placement (randomized) among women.
75325616|NCT02618512|Drug|SBC-103|SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
75325617|NCT00857857|Drug|GW870086X|Investigational product
75325618|NCT00857857|Drug|FP|Positive control
75633144|NCT04111159|Drug|Propofol|Subjects < 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
76077132|NCT03668379|Behavioral|Augment w/BAT & mHealth|"Non-responders to the BAT & mHealth intervention may be re-randomized to receive an additional dose of BAT & mHealth in the form of an additional session of BAT."
76077133|NCT00938782|Device|Sedline|
75633145|NCT04111081|Other|Auricular pressure|Select related auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
75633146|NCT04111081|Other|Shame auricular pressure|Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
75633147|NCT02605291|Other|Diet with a different macronutrient content A|A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.
75325619|NCT00857857|Drug|Placebo|Placebo control
75325620|NCT02622178|Diagnostic Test|Optical Coherence Tomography|Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
75325621|NCT02622178|Diagnostic Test|Visual evoked potential|Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white checkerboard pattern reversal stimulus. Electrodes are placed on the head and face to monitor Electroencephalogram (EEG) activity during testing. Output parameters from VEP system include amplitude and latency measures for each stimuli.
75325622|NCT02623348|Behavioral|pedometer|pedometer-based physical activity recommendations
75325623|NCT02625298|Device|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
75325624|NCT02625298|Device|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
75325625|NCT02625844|Other|No intervention|No intervention administered in this study.
75325626|NCT00858013|Drug|Nateglinide|Nateglinide 90~120mg three times a day
75325627|NCT00858013|Drug|Glimepiride|Glimepiride 1~2mg once a day
75633148|NCT02605291|Other|Diet with a different macronutrient content B|A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.
75633149|NCT02605291|Other|Diet with a different macronutrient content C|A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.
75633150|NCT02605291|Other|Interval treadmill running exercise|Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
75633151|NCT02605291|Other|Steady state treadmill running exercise|Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.
76077134|NCT03666351|Drug|Amlodipine 5mg|Amlodipine 5 mg
76077135|NCT03666351|Drug|Losartan|Losartan Potassium 50 mg
76077136|NCT03666351|Drug|Losartan and Amlodipine|Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
76077137|NCT03666351|Drug|Amlodipine/Losartan/Chlorthalidone|Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
75325628|NCT02626156|Device|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
75325629|NCT02626156|Device|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
75325630|NCT00835861|Drug|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
75325631|NCT00835861|Drug|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values <90 and one hour post prandial values <130.
75633152|NCT05297227|Procedure|Non surgical periodontal Therapy|Non-surgical periodontal therapy comprising oral hygiene instruction and motivation, professional mechanical plaque removal, and subgingival instrumentation will be performed. It consists in the use of an ultrasuond (piezoeletric device) and manual curettes.
76077138|NCT03666351|Drug|current treatment|treatment is done by maintaining the current treatment
76077139|NCT00928642|Drug|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
76077140|NCT00928642|Drug|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
76077141|NCT04361422|Drug|Isotretinoin Only Product in Oral Dose Form|assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
75919545|NCT03417908|Procedure|PNF|The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.
75919546|NCT03417908|Procedure|Sham|Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
75633153|NCT00697372|Device|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
75633154|NCT00697372|Device|Everolimus eluting stent|Implantation of Everolimus eluting stent
75633155|NCT04118686|Other|CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)|CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
75633156|NCT04118686|Other|CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)|CT program with Computerized cognitive training (CoRe) plus sham stimulation
75633157|NCT04111003|Procedure|local anesthesia|administering local anesthesia in the region of the planned restorative procedure
75783970|NCT01289366|Device|Endocytoscopy|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
75919547|NCT02250573|Biological|Replenine®-VF (High Purity Factor IX)|
75325632|NCT04339660|Biological|UC-MSCs|1*10E6 UC-MSCs /kg body weight suspended in 100mL saline
75325633|NCT04339660|Other|Placebo|100mL saline intravenously
75325634|NCT02627794|Device|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
75325635|NCT02627794|Device|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
75325636|NCT00804973|Drug|LY2590443|200 milligrams (mg) as four 50-mg capsules, oral, once
75325637|NCT00804973|Drug|Placebo injection|saline solution, injection, once
75325638|NCT00804973|Drug|Sumatriptan|6 milligrams (mg) injection (0.5 milliliter [mL] of 12 mg/mL solution), once
75325639|NCT00804973|Drug|Placebo capsule|4 capsules, once
75325640|NCT02628106|Drug|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
75325641|NCT02628964|Device|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
75325642|NCT00836017|Other|No Intervention|No intervention was administered as part of the study.
75325643|NCT02629354|Drug|Ibuprofen|
75325644|NCT02629354|Drug|Caffeine|
75325645|NCT02629354|Drug|Ibuprofen|
75633158|NCT04111003|Procedure|Tooth restored using SFRC filling|Restoration of an endodontivally treated molar using a shor-fiber base filling and veneering composite
75633159|NCT04111003|Procedure|Tooth restored using Ceramic indirect endocrown|Restoration of an endodontically treated molar using a ceramic indirect restoration
75633160|NCT04110847|Drug|JING CEIH SHERN YUAN EXTRACT PILL|Oral use, 3#BID
75633161|NCT00699712|Drug|CD-NP (Chimeric natriuretic peptide)|Infusion of CDNP at two of four doses
75633162|NCT02605135|Device|Continued Pessary Use|Pessary Fitting
75633163|NCT00856180|Drug|Bevacizumab|
75633164|NCT00856180|Drug|Cyclophosphamide|
75633165|NCT02605213|Drug|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
75633166|NCT02605213|Drug|Placebo|Placebo for control Group of primary sclerosing vhlangitis
75633167|NCT04112563|Procedure|exploration in white light (WLI)|Exploration of the right colon done in white light (WLI)
75633168|NCT04112563|Procedure|Exploration in LCI|Exploration of the right colon in linked color imaging (LCI)
75633169|NCT04131478|Genetic|Pharmacogenetic testing|Pharmacogenetic testing for TNF alfa
75633170|NCT00900627|Drug|AZD8931|Tablet Oral bid
75783971|NCT03858296|Behavioral|Internet-delivered emotional awareness training|Emotional awareness training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
75783972|NCT03858296|Behavioral|Internet-delivered Cognitive reappraisal training|Cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
75783973|NCT03858296|Behavioral|Internet-delivered awareness and reappraisal training|Emotional awareness and cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
75783974|NCT03088826|Drug|Morphine Sulfate|15mg PO morphine sulfate
75783975|NCT03088826|Drug|Oxycodone|10mg Oxycodone
75783976|NCT03088826|Drug|Acetaminophen|650 mg Acetaminophen
75783977|NCT01289444|Behavioral|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
75919548|NCT03415568|Dietary Supplement|LCT oil|LCT muffin was provided to the study participants. The LCT muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was LCT.
75783978|NCT01289444|Behavioral|Healthy Living Control|"Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides."
75783979|NCT00367133|Procedure|Standard of Care Group|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
75919549|NCT03415568|Dietary Supplement|MCDG oil|MCDG muffin was provided to the study participants. The MCDG muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was MCDG.
75919550|NCT02250261|Behavioral|KÄPY|
75919551|NCT03417596|Other|Control|Routine treatment
75919552|NCT03417596|Behavioral|Vestibular Rehabilitation|Exercise and rehabilitation programme was individualized
75919553|NCT02590354|Other|ART interruption|
75919554|NCT03417518|Drug|Desflurane Inhalant Product|General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane
75633171|NCT00900627|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off (repeated cycles)
75633172|NCT00900627|Drug|Placebo|Oral bid (twice daily)
75919555|NCT03417518|Drug|Propofol|General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode
75919556|NCT03415490|Other|Folded technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. Then, after the second circuit, the bandage is brought on the cheek and up over the eye to the forehead, where it was passed between the eyebrows but not wrapped around the head. Instead, the bandage is folded and then first passed back on the cheek of the affected side then back to the forehead a total of four times. Finally, the bandage is wrapped completely around the head once
75919557|NCT03415490|Other|Classic technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. After the second circuit, the bandage was brought below the ear, up over the eye and around the head of the non-affected side and then wrapped around the head in the same manner four times. The bandage is then brought around the head once.
75919558|NCT04342234|Other|data collection of palatal casts and palatal images of cleft patients routinely treated at the institution|data collection of palatal casts and palatal images of cleft patients, using routinely taken intraoral/palatal photographs and palatal casts of infants with cleft lip and palate deformity
75919559|NCT03417362|Other|Animation|3 minute video describing and explaining early medical abortion, followed by questionnaire
75919560|NCT03555903|Other|Endometriosis cohort|"The investigator record data on risks factors, symptoms (pain), quality of life (using standardized quality of life questionnaires), infertility history, and management of the disease with a 5-years follow up.~Different surgical procedures exist to treat DIE and are they are described in the database, to allow comparison."
75919561|NCT03771183|Other|Patients in long response during Halaven® treatment|Data collection
75325646|NCT02834247|Drug|TAK-659|TAK-659 Tablets.
75325647|NCT02834247|Drug|Nivolumab|Nivolumab intravenous infusion.
75633173|NCT04010773|Other|collective and psycho-social intervention|The intervention duration is 1 year. It combine (1) In each unit, working groups aimed at improving QWL, (2) counseling and training of directors and frontline managers, and (3) in each unit, concertation meeting between workers, front-line managers and directors.
75783980|NCT00367133|Drug|1mg triamcinolone acetonide|Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
75919562|NCT04787458|Device|abdomen binder (Sejung Korea, Seoul, Republic of Korea)|abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea)
75919563|NCT05169632|Device|Computerized Gaming Rehabilitation Program 1|Brain training games with physical exercise component.
75919564|NCT05169632|Device|Computerized Gaming Rehabilitation Program 2|Cognitive training games with physical exercise component.
75325648|NCT00859027|Drug|risedronate|35 mg/week by mouth
75325649|NCT00859027|Drug|Placebo risedronate oral tablet|One tablet by mouth every week as directed
75325650|NCT02630992|Drug|Amoxicillin-Clavulanate potassium|
75325651|NCT05071131|Dietary Supplement|Inulin|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
75325652|NCT05071131|Dietary Supplement|Placebo|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
75325653|NCT00836407|Drug|Ipilimumab|Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
75633174|NCT00866320|Drug|sorafenib tosylate|Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
75633175|NCT04115449|Drug|Dexmedetomidine|Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes
75633176|NCT04115449|Drug|normal saline|Normal Saline as a placebo will be infused over a period of ten minutes
75919565|NCT03555747|Other|Canine distalization|GCF was sampled from the mesial (tension) and distal (pressure) sides of maxillary right and left canines immediately before appliance placement (baseline) and after force application (24 hours and 28 days)
75919566|NCT05151562|Behavioral|Virtual Music Therapy|Each study participant will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be delivered by a board-certified music therapist (using Zoom as a primary platform). These individualized therapeutic encounters will use music that is personally meaningful and familiar to the participant and the participant's loved ones to facilitate reminiscence. Decision-making processes made by the music therapist will reflect a flexible session structure and series of intervention choices contingent on each participant's cultural identity, expressive and receptive communication, fine and gross motor ability, affect, orientation to time and place, and personal preferences on any given day.
75633177|NCT04133974|Behavioral|methadone induced memory retrieval-extinction procedure|Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
75633178|NCT04110925|Genetic|Genetic Mutations|DNA sequencing for mutations to be obtained by bloodwork within 6 months of diagnosis, or by accessing diagnostic bone marrow aspirate slides.
75919567|NCT02097927|Behavioral|Mango-flavour beverage|The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
75919568|NCT02098005|Other|usual care evidence-based physiotherapy|Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
75919569|NCT02098005|Other|modern neuroscience approach|Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
75919570|NCT04058860|Device|NIRS monitoring|Cerebral and somatic near-infrared spectroscopy (rScO2) measurements
75919571|NCT04058860|Device|Cox monitoring|Cerebral autoregulation monitoring
75633179|NCT04110925|Other|Inflammatory and lipid markers|Bloodwork to be done for lipid profile, c-reactive protein (CRP), and multiplex chemokine/cytokine analysis.
75633180|NCT04110925|Other|Computed Tomography (CT) of the heart|Sunnybrook Patients with no history of cardiovascular disease [ex: past/present coronary artery disease (CAD), peripheral vascular disease (PVD), angina, myocardial infarction (MI), stroke, transient ischemic attack (TIA), or stents], not pregnant, and able to undergo CT will receive a CT of the heart to look for and quantify any occult coronary artery disease.
75633181|NCT02841735|Device|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
75633182|NCT02841735|Device|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
75783981|NCT00367133|Drug|4mg triamcinolone acetonide|4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
76077142|NCT03579615|Device|FIASP + closed loop device|Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
75325654|NCT00836407|Biological|Pancreatic Cancer Vaccine|The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
76077143|NCT03579615|Device|Insulin aspart (standard of care insulin) + closed loop device|Participants will be advised to maintain their usual insulin 24 hours prior to admission.
76077144|NCT04367428|Biological|Administration of probiotics|Patients will receive the previously mentioned combination of probiotics before and after surgery
76077145|NCT04367272|Procedure|First Arthroplasty|First Knee
76077146|NCT04367272|Procedure|Second Arthroplasty|Second Knee
75325655|NCT02631772|Drug|Sofosbuvir/Ledipasvir x 12 weeks|
75325656|NCT02631772|Drug|Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks|
75325657|NCT02633488|Drug|Placebos|A 12 week single blind placebos
75325658|NCT02633488|Drug|metformin|A 12 week single blind metformin
75325659|NCT00859339|Drug|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
75325660|NCT00859339|Drug|Cisplatin|Cisplatin (70 mg/m2) IV day 1
75325661|NCT00859339|Drug|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
76077147|NCT04367194|Behavioral|Neurorehabilitation|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
75325662|NCT00859339|Procedure|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
75468393|NCT05831735|Behavioral|Physical activity and education|"In addition to the intervention in physical activity, the people participating in this program will benefit from 6 months of educational activity (EA). The EA program includes 6 sessions scheduled according to the patients' availability in groups and by videoconference.~Following their entry into the study and their allocation to the programs (1 month maximum), the patients will be invited to a first individual EA session, in order to establish an educational diagnosis (1 hour). This session will allow for an assessment of their needs and the presentation of the workshops. Then, between the second and the sixth month following randomization, patients will benefit from 5 collective EA sessions per group of 6 patients maximum (1h30 to 2h). These sessions will be about PA, nutrition, pain management. An individual session will be held at the end of the intervention and will allow for an educational assessment."
75468394|NCT05824767|Drug|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Giapreza) was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
75325663|NCT05032599|Biological|CD5 CART|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
75325664|NCT00859495|Drug|Doxorubicin|A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
75325665|NCT00859495|Drug|Cisplatin|Platinum-based antineoplastic
75468395|NCT05824351|Device|Tanzanian beeswax-pine resin|Thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
75468396|NCT05824351|Device|Domestic beeswax-pine resin|Thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
75468397|NCT05824351|Device|Hollister's AdaptTM Barrier Rings|Thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
75325666|NCT00859495|Drug|Pemetrexed|Folate Analog Metabolic Inhibitor
75325667|NCT00859495|Radiation|Radiotherapy|Standard procedure given 3 weeks after last dose of chemotherapy
75325668|NCT05722041|Procedure|Immediate dental implant placement|Placement of one dental implant immediately after tooth extraction.
75325669|NCT05029635|Drug|HMPL-523|HMPL-523 will be oral administrated once daily for 24 weeks
75325670|NCT05029635|Drug|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .
75325671|NCT00355719|Drug|Atazanavir (Reyataz)|Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
75325672|NCT00355719|Drug|Ritonavir (Norvir)|Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
75325673|NCT00355719|Drug|Nevirapine (Viramune)|Nevirapine (Viramune): tablets 200 mg (1 tablet/12h*)
75325674|NCT00859651|Drug|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
75325675|NCT00859651|Drug|Placebo capsule|Matching placebo capsules
75325676|NCT02815761|Other|NO intervention, just observation|No intervention.
75325677|NCT02811705|Other|Quality of life|Quality of life
75325678|NCT02633956|Drug|Obeticholic Acid|Once a day (QD) by mouth (PO)
75325679|NCT02633956|Drug|Atorvastatin|"Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated."
75325680|NCT02633956|Drug|Placebo|Once a day (QD) by mouth (PO)
75325681|NCT02800161|Drug|Trehalose|Trehalose 70g/die
75468398|NCT05823688|Device|Electrical Impedance Tomography|Measure of regional ventilation by Electrical Impedance Tomography (EIT) before and during pneumoperitoneum
75468399|NCT05823376|Drug|Avatrombopag|Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10^9/L; Drug administration will be stopped when PLT≥100×10^9/L.
75468400|NCT05822791|Diagnostic Test|Prolonged cardiac monitoring|Prolonged cardiac monitoring
75325682|NCT02800161|Drug|Maltose|Maltose 70g/die
75325683|NCT00836641|Biological|prevenar|7-valent pneumococcal conjugate vaccine
75325684|NCT00836641|Biological|pneumovax|23 valent pneumococcal polysaccharide vaccine
75325685|NCT05721963|Diagnostic Test|No interventions.|No interventions.
75325686|NCT02693067|Drug|Rose bengal disodium|Percutaneous intralesional injection to NET tumor
75325687|NCT00806221|Drug|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
75325688|NCT02634814|Device|Transcutaneous Electrical Nerve Stimulation|TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
75325689|NCT02634814|Other|Therapeutic Exercise|Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
75468401|NCT05822791|Diagnostic Test|ECG|Electrocardiogram
75468402|NCT05819242|Diagnostic Test|Angulus|Smartphone app
75468403|NCT05816655|Drug|Fulvestrant plus AI plus ribociclib|Fulvestrant + AI + ribociclib +/- GnRH agonist
75468404|NCT05816655|Drug|AI plus ribociclib|AI + ribociclib +/- GnRH agonist
75919572|NCT04058860|Device|Sublingual microscopy|Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
75325690|NCT02634814|Device|Sham Transcutaneous Electrical Nerve Stimulation|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day."
75325691|NCT04345029|Dietary Supplement|Dietary supplement consumption|"The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days."
75919573|NCT03415334|Behavioral|behavioral development for change|"Social Marketing Principles (4 Ps) Product, price, place and promotion~Communication for Behavior Development Approach 1. Interpersonal communication campaigns (IPC) 2. Mass media and public gathering awareness campaigns 3. Public health awareness campaigns 4. A village hotline and local satellite channel 5. School awareness raising events"
75325692|NCT02635828|Drug|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
75325693|NCT02635828|Drug|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
75325694|NCT02635828|Drug|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
75325695|NCT00836719|Drug|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
75325696|NCT05721885|Behavioral|nutrition management|Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score > 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
75325697|NCT02638168|Drug|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
75325698|NCT02638168|Drug|Placebo|inert placebo ingredient
75633183|NCT02841735|Device|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
75325699|NCT00837031|Drug|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
75919574|NCT02094651|Drug|divalproex sodium|The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.
75325700|NCT00837031|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
75325701|NCT02973880|Drug|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
75468405|NCT05811039|Device|Remo-Wax® Oil|Remo-Wax® Oil (abbreviated RWO; GMDN (Global Medical Device Nomenclature) code 46259, Earwax softening oil), is a CE-marked, non-sterile fluid mixture, used for prevention of impacted earwax. Remo-Wax® Oil also moisturizes the skin in the ear canal and reduces itching and irritation caused by the ear canal dryness
75468406|NCT05802004|Device|Acoustic Stimulation (STIM)|During the in-lab overnight, the Dreem 2 Headband will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power). Tones are phase-locked to the up-phase of the delta wave. Tone delivery is paused when an arousal is detected.
75468407|NCT05802004|Device|No Acoustic Stimulation (SHAM)|During the in-lab overnight, the participant will wear the Dreem 2 Headband, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
75919575|NCT02094651|Other|Placebo|The placebo is an inactive substance that looks like the active drug.
75633184|NCT04133896|Diagnostic Test|IL-6, Clusterin, Irisin Level|Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
75633185|NCT04112875|Dietary Supplement|L-arginine|Handled powdered supplement to be mixed with water, has orange flavor for oral use.
75633186|NCT04112875|Dietary Supplement|Maltodextrin|hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.
75633187|NCT03679611|Drug|Sugammadex Sodium|Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery
75633188|NCT03679611|Drug|Neostigmine|neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
76077148|NCT03778515|Diagnostic Test|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
76077149|NCT04355416|Drug|curcumin Oral gel|application of curcumin oral gel after scaling and root planing
75919576|NCT03411200|Behavioral|Multimodal and exercise-based intervention|"The multimodal and exercise-based intervention is comprised of:~Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session."
75919577|NCT03411122|Drug|napabucasin|Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.
75633189|NCT04131244|Procedure|In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator|After laparoscopic unilateral oophorectomy, ovarian medulla would be dissected from cortex. After fragmentation of 2 cm square ovarian cortex into smaller pieces they would be incubated PTEN inhibitor and AKT stimulator for 48 hours. Finally we will auto graft these fragments beneath to the fallopian tube peritoneal surface.
75919578|NCT03411122|Drug|cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate|CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.
75919579|NCT04787224|Other|immediate implant with vestibular socket therapy|A 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth. The socket orifice and the vestibular access incision were connected by a subperiosteal tunnel that was created using a periotome and a micro-periosteal elevator. Implants were installed using a CADLCAM surgical guide. A flexible cortical membrane shield of heterologous origin, 0.6 mm in thickness was prepared by hydrating and trimming it. It was then tucked through the vestibular access incision, till it extended 1 mm below the socket orifice, and stabilized using a membrane tack ( to the apical bone. The gap between the implant and the shield/the labial plate was then filled with particulate bone graft [75% autogenous bone chips harvested form local surgical sites and 25% inorganic bovine bone mineral matrix.
75919580|NCT02094807|Drug|NSAID|Will be used if other drugs are not tolerated.
75633190|NCT04112719|Other|supine position|The patient will be placed in a supine position. Changes in cardiac output will be measured.
75919581|NCT02094807|Procedure|thoracic epidural anesthesia|Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
75325702|NCT02973880|Drug|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
75468408|NCT05802004|Device|Daily acoustic stimulation (STIM2)|During the ~2 weeks at home, the Dreem 2 Headband will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power). Tones are phase-locked to the up-phase of the delta wave. Tone delivery is paused when an arousal is detected.
75633191|NCT04112719|Other|15 degrees lateral tilt|The patient will be placed in 15 degrees lateral tilt position. Changes in cardiac output will be measured.
75633192|NCT04112719|Other|30 degrees lateral tilt|The patient will be placed in 30 degrees lateral tilt position. Changes in cardiac output will be measured.
75633193|NCT02841891|Device|Sylys® Surgical Sealant|Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant
75633194|NCT02841891|Procedure|Stapled Anastomosis Colectomy Procedure|Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
75633195|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
75633196|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
75633197|NCT02604667|Other|Blood tests|"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
75633198|NCT02604667|Other|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
75633199|NCT00914953|Drug|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
75633200|NCT00869518|Drug|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
75633201|NCT00869518|Drug|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
75919582|NCT02094807|Drug|opioids|During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
75919583|NCT02094807|Drug|paracetamol|100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
75325703|NCT04344483|Drug|2% Lidocaine and 1:100,000 Adrenaline|Topical application of 2% Lidocaine and 1:100,000 Adrenaline in the form of dressing will be applied over skin graft donor site of thigh for 10 minutes.
75325704|NCT04344483|Drug|Normal saline|Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.
75325705|NCT02639494|Device|Self-Centering Guide Catheter|
75919584|NCT02094807|Procedure|operative fixation of rib fractures|Fractures will be stabilized on the outside of of the ribs.
75919585|NCT05139472|Drug|Empagliflozin 10 MG|Daily Empagliflozin
75325706|NCT02154763|Drug|Ropivacaine|
75919586|NCT04757090|Drug|89Zr-trastuzumab|"-To minimize uptake of the 89Zr-trastuzumab in normal tissues, immediately prior to planned 89Zr-trastuzumab injection patients will receive a 50 mg dose of cold unlabeled trastuzumab intravenously (IV). The administration of a fixed small dose of unlabeled antibody to improve tumor-to-normal-tissue (T/N) uptake of the radiolabeled antibody is standard in this type of imaging procedure."
75919587|NCT03397862|Drug|Donepezil TDS|Donepezil patch
75919588|NCT03397862|Drug|Vehicle TDS|Placebo patch
75919589|NCT02100267|Drug|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
75919590|NCT05614726|Dietary Supplement|575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase|A multi-strain probiotic blend
75919591|NCT02094963|Drug|Ticagrelor|180mg loading and 90mg bid
75919592|NCT02094963|Drug|Clopidogrel|600mg loading and 75mg qd
75919593|NCT03985696|Other|blood sample|1 blood volume (5-7 ml EDTA)
75919594|NCT03415256|Other|passive vibration|The passive vibration is delivered using a Physio Plate (Domino S.R.L, San Vendemiano, Italy). The frequency delivered is 50 Hz for a total number of ten cycles for a period of ten minutes approximately (one cycle= 60seconds working time with 2 seconds rest time).
75919595|NCT03415256|Other|no passive vibration|The control group will not receive any treatment and continue their usual lifestyle.
75919596|NCT03982810|Drug|Antibiotics|Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
75919597|NCT02098239|Drug|G17DT|
75919598|NCT02098317|Drug|DHA plus Vitamin D|DHA 500 mg plus Vitamin D 800 IU
75919599|NCT02098317|Drug|Placebo|Placebo pearls mimicking pearls with DHA and Vitamin D
75919600|NCT03410966|Procedure|trans cateheter ablation|All AF patients will receive trans catheter ablation by radiofrequency, to destroy arrhythmic atrial cells, and to isolate arrhythmic atrial firing around pulmonary veins' ostia.
75919601|NCT03410888|Procedure|Popliteal approach|"Popliteal approach:~Under ultrasound guidance a 50 to 90 mm 22 G needle is inserted in and advanced to contact the target nerve until nerve movement is detected. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
75919602|NCT03410888|Procedure|Infragluteal approach|Infragluteal approach: The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
75919603|NCT02100423|Drug|curcumin|Given PO
75919604|NCT02100423|Dietary Supplement|cholecalciferol|Given PO
75919605|NCT02100423|Other|laboratory biomarker analysis|Correlative studies
75919606|NCT02100423|Other|pharmacological study|Correlative studies
75919607|NCT04787146|Other|No intervention|Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.
75919608|NCT03415100|Biological|CAR-NK cells targeting NKG2D ligands|The infusion of CAR-NK cells will be performed in the Third Affiliated Hospital of Guangzhou Medical University. Following infusion of CAR-NK cells, interleukin-2 (IL-2) will be injected subcutaneously into some patients to support the in vivo survival of CAR-NK cells. The subject will be observed for any side effects during this time and all the adverse events will be recorded.
75919609|NCT02098551|Other|SPT and APT|"All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone."
75919610|NCT03410732|Biological|activated DCs|autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.
75919611|NCT03410732|Procedure|radical surgery only|Only radical surgery is given to the control group
75919612|NCT03556605|Other|OneTouch Reveal® Mobile APP system|Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).
75919613|NCT03556605|Other|Current Blood Glucose Monitor|Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.
75325707|NCT02154763|Drug|Normal Saline|
75325708|NCT05721807|Other|functional magnetic stimulation|"When applying functional magnetic stimulation, the stress urinary incontinence program P2 stress was chosen. The first 20 min. current frequency was 35 Hz, modulation - rising amplitude (from 0 to maximum per second), total wave duration 12 s. active time 6 s., pause time 6 s. After 20 min. current frequency changed to 5 Hz, modulation and wave remained the same. After 2 min. current frequency changed to 35 Hz, modulation - amplitude, one-sided sinusoidal, wave remained the same. The total duration of the procedure was 30 min. A magnetic spring is installed at the bottom of the chair. During the treatment, each subject was instructed to sit on a chair so that the perineum was centered on the spring and that the subjects felt the contraction of the muscles. The intensity of the magnetic field was adjusted so as to feel comfortable during the study procedure (Vadalà et al., 2017)."
76077150|NCT04355416|Procedure|subgingival scaling and root planing|subgingival scaling and root planing without application of curcumin gel
75325709|NCT05721807|Other|pelvic floor muscle training program|The program consisted of two parts. From procedures 1 to 6, 6 exercises were performed, after 6 times the exercises were adjusted, and from procedures 7 to 12, another 5 exercises were performed. The program consists of breathing, pelvic floor muscle strength, endurance, speed training exercises and exercises to strengthen the thighs, buttocks, deep back and deep abdominal muscles. Exercises were performed in 2 sets of 10 repetitions at an intensity from various positions: lying on the back, side, sitting, quadruped (Oliveira et al., 2017; Walton et al., 2019).
75325710|NCT02629731|Device|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
75325711|NCT02639884|Device|SedLine EEG|
75325712|NCT02639884|Device|RRa monitoring|
75325713|NCT02641522|Drug|Siltuximab|Single infusion of siltuximab (11 mg/kg)
75919614|NCT02520830|Dietary Supplement|Blueberry Group|22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
75919615|NCT02520830|Dietary Supplement|Placebo Group|Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
75325714|NCT02641834|Other|Vegetarian diet|7-days dietary profile with an isocaloric Vegetarian diet for 3 months
75325715|NCT02641834|Other|Mediterranean diet|7-days dietary profile with an isocaloric Mediterranean diet for 3 months
75325716|NCT05721495|Other|freeze all strategy embryo transfer|criopreservation of all viable embryos in order to transfere the best one in a posterior cycle
75325717|NCT05721495|Other|fresh embryo transfer strategy|transfer of the best embryo two or three days after the fecundation technique
75633202|NCT00794781|Drug|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
75325719|NCT04964427|Drug|Methylphenidate|A single dose of 5-10 mg of immediate release MPH (Ritalin®) will be administered in line with NICE and AIFA (Agenzia Italiana del Farmaco) guidelines for ADHD treatment.
75325720|NCT04964427|Device|anodal tDCS|Anodal electrode will be positioned over the left dlPFC, according to the 10-20 EEG on the sites corresponding F3, whereas the reference electrode will be placed above the contralateral supraorbital area, corresponding to Fp2. In the active tDCS condition, the current will increase slowly during the first 30 seconds to 1 mA (ramp-up) and, at the end of the stimulation, the current will decrease slowly to 0 mA during the last 30 seconds (ramp-down). Between the ramp-up and ramp-down constant current will be delivered for 20 minutes, with a density of 0.04 mA/cm2.
75325721|NCT04964427|Device|sham tDCS|In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.
75325722|NCT05721417|Procedure|Tricuspid valve surgery|Surgical treatment of tricuspid regurgitation, that may be performed by repair or replacement
75325723|NCT05721339|Behavioral|Acceptance and Commitment Therapy|"ACT will be applied through 8 sessions by the psychological flexibility processes, which were grouped into three response styles: open, aware, and active. Openness is reflected by acceptance, which means the conscious embrace of psychological events without unnecessary attempts to change their frequency. Defusion means untangling unhelpful thoughts and responding to mental experiences as experiences rather than guides to action. The awareness set, which is reflected by applying self-as-context, which means a continuous and secure I from which events are experienced but distinct from those events. A present moment means ongoing, nonjudgmental contact with internal and external events as they occur in the present moment. The active set, which was reflected by making the intern nurses embrace their desired and chosen life values directions, and commit action to selected values."
75325724|NCT00357669|Drug|Brivaracetam 25 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Tablet~Concentration: 25 mg~Route of Administration: Oral use"
75325725|NCT00357669|Drug|Brivaracetam 50 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Tablet~Concentration: 50 mg~Route of Administration: Oral use"
75325726|NCT00357669|Other|Placebo|"Active Substance: Placebo Pharmaceutical Form: Tablet~Concentration: 25 mg and 50 mg~Route of Administration: Oral use"
75325727|NCT00861601|Drug|eltrombopag 12.5 milligrams (mg) tablet|eltrombopag 12.5 mg tablet once a day
75325728|NCT00861601|Drug|eltrombopag 25 mg tablet|eltrombopag 25 mg tablet once a day
75325729|NCT05715723|Drug|Reamberin|Reamberin® in the average daily dose of 10 ml/kg daily
75325730|NCT02641912|Other|Biotene mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
75633203|NCT04112329|Behavioral|Exergaming|will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks.
75919616|NCT04787068|Behavioral|Occupational Therapy support|Intervention include (a) didactic education about diseases; (b) the use of errorless techniques to improve assistance for CR's Activities of Daily Living (ADL), Instrumental ADL, and communication tasks; (c) the use of incentives (e.g., providing a favorite scented shampoo); (e) use of a schedule/calendar on a computer, cell phone and/or blackboard in CR's home to coordinate caregiving tasks for family members; (f) suggesting more frequent PACE daycare visits or use of a nearby PACE, having a snack or short game to prevent going to bed right after dinner); (d) use of the Buffalo Functional Exercise for strengthening ( a home-based exercise developed for PACE by the PI and shown to be effective in preventing falls)
75919617|NCT02094729|Drug|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
75919618|NCT02094729|Drug|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
75783982|NCT03862508|Other|Plyometric exercises|"Jump Drop Jump, dropping the subject from a height of 30cm and then make a vertical jump.~Long jumps asking the athletes to take momentum and make a leap forward trying to reach the greatest possible distance.~Jump Countermovement jump unilaterally, alternating the lower extremities. Jumps 180º with the athletes maintaining a semi-squat position. Jump Countermovement jump repeatedly starting from an upright position and the upper extremities in both hips.~All the exercises will be done through 8 repetitions per session during the first two weeks, increasing two repetitions every two weeks (until reaching 12 repetitions at the end of the intervention).~For the realization of each one of the exercises, the ballasted weight will be used (Powerinstep® model)."
75325731|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
75325732|NCT00861913|Other|Laboratory Biomarker Analysis|Correlative studies
75325733|NCT00861913|Drug|Pazopanib Hydrochloride|Given orally
75325734|NCT00861913|Other|Pharmacological Study|Correlative studies
75325735|NCT00862537|Device|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
75325736|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
75783983|NCT03859310|Device|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
75325737|NCT00863551|Drug|Trospium Chloride|Extended release, 60 mg, oral daily
75325738|NCT03838575|Drug|2% alcoholic chlorhexidine skin prep (SKIN PREP)|This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
75325739|NCT03838575|Device|Iodophor Antimicrobial Incise Drapes (DRAPE)|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied."
75325740|NCT03838575|Device|Gentamicin-impregnated implants/ sponges (SPONGE)|This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
75325741|NCT03838575|Other|NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
75325742|NCT02642536|Behavioral|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
75325743|NCT02642536|Behavioral|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
75783984|NCT01287026|Procedure|Cardiac Real-time MRI RHC (Right Heart Catheterization)|
75783985|NCT01176188|Other|Comfort Care|The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
75325744|NCT02620774|Drug|Ceftolozane/tazobactam|3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
75325745|NCT02620774|Procedure|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
75468409|NCT05802004|Device|No daily acoustic stimulation (SHAM2)|During the ~2 weeks at home, the participant will wear the Dreem 2 Headband, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
75783986|NCT01176188|Other|Usual care|Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
75783987|NCT01179464|Drug|Aminobiphosphonate|Patients will receive standard intravenous biphosphonate treatment
75783988|NCT01179464|Drug|Simvastatin|40 mg once daily
76077151|NCT05620810|Behavioral|neuropsychiatric symptoms|neuropsychiatric symptoms
75325746|NCT03540355|Drug|Cipros 20 association|oral, once a day
75325747|NCT03540355|Drug|Crestor 20 mg|Oral, once a day
75325748|NCT00357201|Drug|Food supplement (T1675)|
75325749|NCT04339816|Drug|Azithromycin|orally or into nasogastric tube for 5 days
75325750|NCT04339816|Drug|Hydroxychloroquine|orally or into nasogastric tube for 5 days
75468410|NCT05799209|Device|Float Pool|Participant floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
75468411|NCT05799209|Device|Float Chair|Participant floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
76077152|NCT04355494|Biological|eculizumab|Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)
75325751|NCT04339816|Drug|Placebo|orally or into nasogastric tube for 5 days
75325752|NCT02978703|Drug|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
75325753|NCT02643004|Device|Senofilcon A|contact lens
75325754|NCT02643004|Device|Stenfilcon A|contact lens
75325755|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)|100 mg subcutaneous (s.c) once
75325756|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)|200 mg subcutaneous (s.c) once
75325757|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)|300 mg subcutaneous (s.c) once
75325758|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
75325759|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
75325760|NCT05588908|Drug|Compound Betamethasone Injection (phase II)|1 mL i.m. once on Day 1
75633204|NCT00797563|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
75783989|NCT03859076|Behavioral|MB-BP|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions & a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, & specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, & stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
75325761|NCT05588908|Other|Placebo (phase II)|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
75919619|NCT02094729|Drug|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
75919620|NCT02094729|Drug|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
75325762|NCT05588830|Drug|Belimumab|Belimumab, 10mg/kg, was administered intravenously on the 0, 14 and 28 days, and then once every 28 days until the 24th week
75919621|NCT02520752|Drug|INC280|
75325763|NCT05588830|Drug|Telitacicept|Telitacicept is injected subcutaneously, 160mg/time, once a week, for a total of 24 weeks
75325764|NCT04740190|Drug|Talazoparib|low dose whole brain radiation, followed by combination talazoparib and carboplatin
75325765|NCT00865969|Drug|Belinostat|
75325766|NCT05588596|Behavioral|Trauma Resiliency Mindfulness-Informed Intervention|The total duration of the intervention was once a week for eight weeks. The aim of the intervention was to teach patients a range of trauma recovery mindfulness skills
75325767|NCT05588518|Combination Product|desensitizing agents -10% Propolis|"10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives."
75325768|NCT05588362|Other|Fitz Frames 3-D Printed Glasses|The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
75325769|NCT05588206|Radiation|Hypofractionated Stereotactic Radiotherap|A standard 3+3 statistical design was employed. Three patients will initially be treated at dose level 1, 6 Gy in 5 fractions, 3 fractions a week. Dose limiting toxicities (DLT) were defined as any grade 3-5 radiation injury or any non-hematologic toxicity felt to be possibly, probably, or definitely related to radiation, identified within the evaluation period of 3 months following the completion of radiotherapy.
75325770|NCT05587972|Other|survey|Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic PRO surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks.
75325771|NCT00866749|Drug|Daunorubicin|Starting Dose 25 mg/m^2 by vein weekly
75325772|NCT00866749|Drug|Vincristine|Starting Dose 2 mg by vein weekly
75325773|NCT00866749|Drug|PEG-asparaginase|Starting Dose 2000 International units/m2 by vein in week 1
75325774|NCT00866749|Drug|Intrathecal Methotrexate|Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
75633205|NCT00869440|Drug|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
75633206|NCT00869440|Drug|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
75633207|NCT00895947|Drug|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
75633208|NCT00895947|Other|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
75919622|NCT02520752|Drug|Midazolam|
75919623|NCT02520752|Drug|Caffeine|
75919624|NCT05199922|Drug|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 40 ml (20 ml for each side) of %0,25 bupivacaine.
76077153|NCT02982460|Other|Isoinertial + eccentric exercise|A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
75919625|NCT02095119|Drug|Nimotuzumab|Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
75919626|NCT02095119|Drug|Cisplatin|Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is >/= 60. The administration form will be intravenously.
76077154|NCT02982460|Other|Eccentric exercise|A session of eccentric exercise covers the strength of scapular muscles.
76077155|NCT03777735|Procedure|human bone graft screw|All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
75325775|NCT00866749|Drug|Cyclophosphamide|Starting Dose 1g/m2 by vein in weeks 1 and 5
75633209|NCT02604823|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.
76077156|NCT04355260|Procedure|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).
75468412|NCT05799092|Diagnostic Test|Invasive coronary angiography|As alternative to non-invasive functional testing, invasive coronary angiography will be performed.
76077157|NCT04347304|Dietary Supplement|Dark chocolate (20 grams) per day providing 508 mg of polyphenols|subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
75468413|NCT05799092|Diagnostic Test|Non-invasive functional test|Standard non-invasive functional testing will be performed.
75468414|NCT05787379|Behavioral|Concordant Care Training|Concordant Care training has four components. 1. Clinicians will complete ~3 hours of online, asynchronous training that will teach them practices including validate Veterans' experiences with Long-COVID, develop shared understanding with patients about Long-COVID, and develop patient-centered action plans. Clinicians will be provided with handouts, case examples, video demonstrations, and practice exercises to help them integrate these practices into care. 2. Tele-mentoring groups will be offered ~bi-weekly and be open to all clinician participant in the Concordant Training arm. Content will include review of specific cases, didactics on specific Concordant Care practices, role-play exercises, and review of session recordings. At least two sessions are required. 3. Clinician Pocket Card that serves as a reminder of the Concordant Care process. 4. An electronic prompt will be sent to enrolled Veterans encouraging them to speak with their clinician about their Long-COVID concerns.
75633210|NCT00869362|Other|Diabetes management team|MD evaluation followed by NP education and and medication titration
75783990|NCT03859076|Other|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
75783991|NCT01179620|Drug|Certoparin|Certoparin
75783992|NCT01179698|Procedure|Navigation surgery|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
75919627|NCT02095119|Drug|Gemcitabine|Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation < 60). The administration form will be intravenously.
75919628|NCT02095119|Procedure|CT Scan|A CT Scan will be performed in all patients prior to the beginning of treatment to assess any measurable tumor found by this method. The CT Scan will be repeated once the patient completes the induction phase with Nimotuzumab (4 once a week doses), when the patient has completed 3 full cycles of combination therapy with Nimotuzumab (every 2 weeks)and Gemcitabine or Cisplatin (every 21 days)and once more when the patient has completed 6 full cycles of the aforementioned therapy.
76077158|NCT04347304|Dietary Supplement|white chocolate (20 grams) with no polyphenols|subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
76077159|NCT00928720|Device|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
75325776|NCT00866749|Drug|Cytarabine|75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
75325777|NCT00866749|Drug|Mercaptopurine|Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
75325778|NCT00866749|Drug|Methotrexate|"Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3"
75325779|NCT00866749|Drug|Doxorubicin|25 mg/m2 by vein in weeks 1, 2 and 3
75325780|NCT00866749|Drug|Thioguanine|60 mg/m2 by mouth daily for two weeks
75633211|NCT00915187|Drug|CCS/C|Adjuvant to influenza vaccine
75633212|NCT00915187|Biological|Influenza Vaccine|Influenza vaccine
75633213|NCT04131400|Diagnostic Test|Visual Acuity Testing and Retinal Imaging|All clinical and para- clinical tests including visual acuity assessment, perimetry, optical coherence tomography (OCT), enhanced depth- OCT, OCT angiography, color fundus, autofluorescence and infrared fundus photography will be performed
75633214|NCT02841579|Drug|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
75783993|NCT01179698|Procedure|Navigation system|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
75919629|NCT03410576|Procedure|Carotid artery stenting|Patient undergo elective carotid artery stenting. In this patient group blood sampling was performed at three time points: T1, at the time of the insertion of the arterial line; T2, 60 min after stent insertion; and T3: the first postoperative morning.
75919630|NCT03410576|Procedure|Carotid endarterectomy|Patient undergo elective carotid endarterectomy. Group samples were collected at the following four time points: T1, at the time of the insertion of the arterial line; T2, 60 min after cross-clamp release; T3, the first postoperative morning; and T4, the third postoperative morning. A matched subgroup of patients from the previously obtained data served as a historical control.
76077160|NCT00928720|Device|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
76077161|NCT00934024|Drug|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
76077162|NCT04360954|Diagnostic Test|Diagnostic test|There is no intervention. This study will test deidentified archived biosamples.
76077163|NCT04361032|Drug|Tocilizumab Injection|Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
75633215|NCT00588445|Drug|Gefitinib|"Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
76077164|NCT04361032|Drug|Deferoxamine|Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
75633216|NCT04118218|Other|Rhizolysis pain analysis|"Definition of the subgroup of good clinical outcome after rhizolysis (called effective rhizolysis) by lumbar VAS or lower extremity pain VAS or Oswestry index decreased at 6 weeks after rhizolysis.~The efficiency criterion based on the decrease in the dolorimeter or the Oswestry index corresponds to a decrease of at least 50% [1, 2, 3, 4]."
75325781|NCT04740112|Other|Foods with beta-glucan from oats and barley|Breakfast bars made with varying levels of total dietary fiber and beta-glucan, with or without claims on package image
75325782|NCT05587660|Procedure|Fully threaded cannulated screws|The most popular method in undisplaced neck of femur fracture include internal fixation by cannulated screws in which screws can be inserted relatively simply and atraumatically as compared to other methods. Screws can be used partially threaded or fully threaded; however studies on fully threaded screw fixation method are inconclusive.
76077165|NCT04747119|Other|muscle energy technique|the patient was supine and the therapist fix the lower limb of the affected side then ask the patient to perform isometric contraction for abductors maintained for 3-5 seconds, then the patient was instructed to stop, exhale and relax then the therapist perform further adducted the patient's knee of the affected side as a stretching exercise for Three to five repetitions of these directions were performed.
75325783|NCT00866905|Drug|Ixabepilone|40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
75325784|NCT00866905|Drug|Cyclophosphamide|600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
75633217|NCT00092781|Drug|MK0663, etoricoxib|
75633218|NCT00092781|Drug|Comparator: celecoxib|
75633219|NCT04118296|Drug|Anti-Acne Preparations for Topical Use|Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
75633220|NCT00092703|Drug|MK0663, etoricoxib|
75919631|NCT02100735|Other|Sedation protocol|Nursing driven sedation protocol
75919632|NCT02520596|Other|Bioavailability of Raspberry polyphenols|
75325785|NCT05587426|Dietary Supplement|SFF|Ingestion of 20g of SFF after 10-14 hours of fasting
75325786|NCT05587426|Dietary Supplement|Glucose|Ingestion of 20g of glucose after 10-14 hours of fasting
75325787|NCT05587426|Dietary Supplement|SFF chocolate chips|Ingestion of 50g of chocolate chips made with SFF after 10-14 hours of fasting
75325788|NCT05587426|Dietary Supplement|Regular chocolate chips|Ingestion of 50g of regular chocolate chips after 10-14 hours of fasting
75325789|NCT00867139|Drug|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
76077166|NCT04747119|Other|conventional selected physical therapy|"life style modification~Transcutaneous electrical nerve stimulation (TENS)~Flexibility stretching exercises to the hip flexors"
75325790|NCT00867139|Drug|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
75325791|NCT00867139|Other|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
75325792|NCT05441878|Drug|20% albumin|Albumin arm for resuscitation fluid
75325793|NCT05441878|Drug|Balanced salt solution|Only Balanced salt solution will be used.
75325794|NCT05342818|Drug|Neostigmine|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
75633221|NCT00092703|Drug|Comparator: Diclofenac sodium|
75633222|NCT00699946|Drug|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
75633223|NCT00699946|Drug|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
75633224|NCT00796315|Drug|Doxylamine Succinate USP|One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
75633225|NCT00855166|Drug|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
75633226|NCT00855166|Drug|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
75633227|NCT00855166|Drug|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
76077167|NCT04360798|Other|Unilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants exercises will only be done for 60 minutes with the affected lower extremities.
75919633|NCT03738202|Behavioral|Multifaceted intervention package|"Multifaceted intervention package will comprise following strategies:~Initial training for all workers and managers on occupational health and safety (OHS)~Follow-up refresher sessions every three months~Formation of workplace committees (including worker representatives) to draw up, agree and promote a health and safety plan that includes wet mopping, safe disposal of cotton dust, and the use of simple face masks, as well as further publicity about the risks from cotton dust.~Provision of adequate supplies of face masks to support the health and safety plan"
75919634|NCT05168852|Other|Formlabs Permanent CB Resin|Tooth-colored, ceramic-filled permanent resin that can be fabricated with a 3D printer
75919635|NCT05168540|Other|no intervention|Children will be included on the occasion of an admission to pediatric unit, the emergency room, the intensive care unit or a consultation in a specialized unit for children at risk of abuse. Their primary care pathway will be analyzed.
75919636|NCT01667224|Dietary Supplement|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
75919637|NCT01667224|Dietary Supplement|Placebo|Amount and calorie of placebo are same with Actiponin.
76077168|NCT04360798|Other|Bilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants will complete their exercises with both lower extremities for 30 minutes.
75325795|NCT05342818|Drug|Ondansetron 8mg|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
75325796|NCT05342818|Drug|Metoclopramide Injection|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
75325797|NCT05342818|Other|Enteral feeding nutrition|The type and rate of enteral feeding nutrition will be the same for all patients (180ml/3h). All patients have a 30-degree head-up position
75325798|NCT05342818|Other|Sequential Organ Failure Assessment (SOFA) score|SOFA score will be performed on all patients before the beginning of the study
75325799|NCT00867217|Dietary Supplement|High Dose Vitamin D|High Dose Vitamin D3 (3 capsules of 10,000 IU) weekly for 24 weeks.
75325800|NCT00867217|Dietary Supplement|Placebo|Placebo comparator
75325801|NCT00867217|Dietary Supplement|Standard Dose Vitamin D3|Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)
75325802|NCT00867217|Drug|Letrozole 2.5mg|All subjects received letrozole as standard of care.
75325803|NCT05337592|Drug|BI 1815368 formulation 1|BI 1815368 formulation 1
75325804|NCT05337592|Drug|Placebo|Placebo
75633228|NCT00855166|Drug|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
75783994|NCT01288820|Drug|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
75783995|NCT01288820|Drug|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
76077169|NCT03552003|Other|Treatment for clinical practise|Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
75325805|NCT05337592|Drug|BI 1815368 formulation 2|BI 1815368 formulation 2
75325806|NCT00867451|Behavioral|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
75325807|NCT00867451|Drug|Melatonin|Body Weight <40mg will be given 3mg at bedtime for two weeks Body Weight >40mg will be given 6 mg at bedtime for two weeks
76077170|NCT00928954|Drug|gabapentin|increasing to 1200 mg/day
75325808|NCT05302414|Other|board game-based teamwork training|Using board game-based learning to develop resuscitation teamwork competency in PGY doctors and nurses.
75325809|NCT05302414|Behavioral|simulation-based teamwork training|Using board simulation-based learning to develop resuscitation teamwork competency in PGY doctors and nurses.
75633229|NCT00587587|Device|Apligraf|Application at Day 0, potential re-application at Week 4
75633230|NCT00587587|Other|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
75633231|NCT02843841|Other|Blood and fecal sample.|Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
75633232|NCT04117828|Dietary Supplement|Dates|Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
75783996|NCT01181024|Drug|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
75325810|NCT05302414|Other|lecture-based teamwork training|Using board lecture-based learning to develop resuscitation teamwork competency in PGY doctors and nurses.
75325811|NCT05239156|Device|Janesse|"Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan."
75325812|NCT00867529|Biological|rituximab|Given IV
75325813|NCT00867529|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
75325814|NCT00867529|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
75325815|NCT00867529|Other|pharmacological study|Correlative studies
75325816|NCT00867529|Other|laboratory biomarker analysis|Correlative studies
75783997|NCT01181024|Drug|RO5303253|Cohorts receiving single ascending doses
75783998|NCT01181024|Drug|RO5303253|Single dose
75783999|NCT01181024|Drug|RO5303253|Multiple doses
75784000|NCT00367055|Drug|rosiglitazone-metformin|
75784001|NCT00367055|Drug|Metformin|
75784002|NCT00367055|Drug|metformin+ gliclazide|
75784003|NCT01181180|Dietary Supplement|water consumption|The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
75919638|NCT04709354|Diagnostic Test|Dermoscopic examination|The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.
75919639|NCT02098629|Drug|Milrinone|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
75919640|NCT02098629|Drug|Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
75919641|NCT02098629|Drug|Saline Infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
75919642|NCT03397472|Device|magnetic field modulation device|use the device with magnetic field modulation to treat insomnia
75919643|NCT03397472|Device|placebo device|use the sleep pillow without magnetic field modulation treatment
75919644|NCT05176912|Other|Exercise|Reformer Pilates exercises will given for 8 weeks, 3 days in a week
75919645|NCT03397316|Procedure|xenograft placement .|immediate implant placement in upper esthetic zone with xenograft placement between residual labial bone and implant surface.
76077171|NCT00928954|Drug|memantine|increasing to 40 mg/day
75633233|NCT04107259|Diagnostic Test|Blood sample|Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
76077172|NCT04355026|Drug|Bromhexine Oral Tablet and/or hydroxychloroquine tablet|bromhexine 16 mg TID hydroxychloroquine 200 mg BID
75633234|NCT02841501|Genetic|Analysis of genetic polymorphisms|An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
76077173|NCT04762485|Biological|Humanized CD7 CAR-T cells|Split intravenous infusion of CD7 CAR-T cells [dose escalating infusion of (0.5-10)x10^6 CD7 CAR-T cells/kg
76077174|NCT04347070|Other|Phsyiotherapy|To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time
75325817|NCT05199220|Other|Questionnaire|Participant must complete a questionnaire about injury during crossfit practice
75325818|NCT05197270|Biological|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
76077175|NCT04762173|Device|Online self-help intervention|Access to two online, self-guided programs available on the SilverCloud Health website.
76077176|NCT04367350|Diagnostic Test|laboratory biomarkers|creatine kinase, troponin, urine myoglobin, and autoimmune antibodies
75468415|NCT05787379|Behavioral|Education Packet Training|Clinicians randomized to the control arm will receive a comprehensive information packet with the latest understanding of Long-COVID. Clinicians will also be provided a packet directing them to relevant VA trainings for Long-COVID. Whole Health trainings which focus on wholistic integrated approaches to care will be highlighted. Whole Health is important for all Veterans, and it is thought to be particularly relevant for poorly understood conditions that don't easily fit in traditional medical model.
75325819|NCT05197270|Biological|Aflibercept IVT|Commercially available Active Comparator Other Name: Eylea
75633235|NCT00854620|Drug|Sorafenib|Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
75325820|NCT02417779|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
75468416|NCT05787119|Other|Conventional therapy|The CT consists of 1 session of 30 minutes of physical therapy (type of re-education established according to the pain at rest and during movement assessed every day) and 1 session of 30 minutes of occupational therapy (type of re-education established according to the pain at rest and during movement assessed every day). CT is performed 5 days a week.
75633236|NCT02178657|Drug|Autologous bone marrow mononuclear cell intra-arterial injection|
75633237|NCT00793585|Drug|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level < 6mg/dl , the dosage changed to 200mg/d.
75325821|NCT02417779|Device|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
75633238|NCT00793585|Other|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
75633239|NCT02013141|Drug|Telavancin|
75784004|NCT00057330|Biological|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
75784005|NCT00057330|Biological|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
75784006|NCT01181336|Biological|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
75784007|NCT01181336|Biological|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
75784008|NCT03283696|Drug|Olaratumab|Administered IV
75784009|NCT03283696|Drug|Doxorubicin|Administered IV
75784010|NCT03283696|Drug|Ifosfamide|Administered IV
75784011|NCT03283696|Drug|Mesna|Administered per standard of care
76077177|NCT04367350|Diagnostic Test|muscle ultrasound|Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)
76077178|NCT04762329|Other|Manage My Pain (MMP) digital pain app group|To evaluate the extent of patient engagement with the Manage My Pain (MMP) digital application when used in a clinical setting
75325822|NCT00367588|Behavioral|Low bacterial diet|
75633240|NCT04107103|Drug|Combination Product: Nivolumab with Pemetrexed|Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.
75633241|NCT04133818|Behavioral|Multidisciplinary education and exercise therapy program|"Multidisciplinary program: one and a half day of education and exercise therapy about low back pain :~Lectures and explanations about low back pain~Physical activity~Relaxation"
75633242|NCT02841423|Procedure|neuropsychological test battery|
75633243|NCT02841345|Other|behavioral and fMRI|"The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants."
75633244|NCT02617810|Drug|JNJ-42847922|Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
75784012|NCT01176344|Drug|Vitamin D|50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
75784013|NCT01176344|Drug|Placebo|Inert placebo capsules once monthly for 2 years.
75784014|NCT03857906|Device|Intra-Aortic Ballon Pump insertion|The IABP (Ultraflex IAB 7.5F, 2.5mm; Arrow International, Reading, PA) was inserted percutaneously through the right femoral artery in the previous 1 - 6 hours before the scheduled surgery. Positioning of the IABP was guided by radioscopy. The balloon size was based on the patient's height (30, 40 or 50 cc). Transesophageal echocardiography was used to confirm correct IABP placement before and after CABG
75919646|NCT03555357|Other|Platelet Rich Fibrin|Platelet Rich Fibrin (PRF) is the next generation of PRP and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. Due to a lack of anticoagulant in the tube, PRF becomes a gel after 15-20 minutes of being isolated. These properties make PRF useful in reconstructive and aesthetic medicine but may also be beneficial for scar therapy in the same way PRP is currently used.
75919647|NCT03555357|Other|Platelet Rich Plasma|Platelet Rich Plasma (PRP) has been used in surgical settings to stimulate healing and promote tissue regeneration. In the field of cosmetic medicine, PRP has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss therapies, laser treatments, and microneedling. Harvested PRP has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis
75919648|NCT03397160|Behavioral|Decision Support Intervention (DSI)|"A question list (QL) that includes areas of patient concern are created by the health coach for use by the patient and the urologist at their first consultation visit where they discuss the extent of their cancer and consider treatment options. The coach uses the Prostate Cancer SCOPED model to complete a Prostate Cancer SCOPED Model Form. The SCOPED model uses concepts such as the situation, choices (treatment), objectives (personal goals and priorities), people (involved in supporting a treatment decision), evaluation and decisions (clarifying which choice is best and next steps)."
75919649|NCT02098707|Other|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
75919650|NCT04649918|Other|pulmonary rehabilitation|COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
76077179|NCT04367038|Other|Warm Acupressure, Cold Acupressure , Conventional Acupressure|Acupressure is non-invasive, safe and effective.
75784015|NCT02939560|Device|NeuroStar® TMS device (Neuronetics, Atlanta, GA)|Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
76077180|NCT04360642|Other|singing|Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities:
76077181|NCT04403451|Behavioral|True North|Love Notes, Financial Stability, Jobs
76077182|NCT03549351|Other|Measurable residual disease measured by flow cytometry|Measurable residual disease measured by flow cytometry
75325823|NCT05028946|Drug|Foralumab|Foralumab will be administered per dose and schedule specified in the arm description.
75325824|NCT04814212|Device|Percutaneous coronary intervention using drug-coated balloon|"SeQuent Please (BBraun) + tailored antithrombotic regimen:~Stable patients without OAC: perioperative SAPT (preferably) or perioperative DAPT followed by lifelong SAPT~Stable patients with OAC: perioperative SAPT (preferably) or perioperative DAPT and lifelong OAC~ACS patients without OAC: 1-month DAPT followed by lifelong SAPT~ACS patients with OAC: perioperative DAPT followed by 1-month SAPT and lifelong OAC"
75468417|NCT05787119|Other|ARMT|The ARMT consists of 1 session of 30 minutes (type of rehabilitation established according to the pain at rest and during movement evaluated daily). ARMT is performed 5 days a week for 1 month.
75633245|NCT02617810|Drug|Midazolam|Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
75633246|NCT02617810|Drug|Warfarin|Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
75633247|NCT04111237|Behavioral|Two Finger technique|two finger method for chest compression provuision
75633248|NCT04111237|Behavioral|Two Thumb Technique|Two thumb technique
75633249|NCT00898443|Other|Epidural anesthetic|Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
75633250|NCT00898443|Other|Spinal anesthetic|This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
75633251|NCT02614612|Drug|Itacitinib (200 mg)|
75633252|NCT02614612|Drug|Itacitinib (300 mg)|
75919651|NCT05053672|Device|ReOxy|"ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session.~The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min.~During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control)."
75325825|NCT04814212|Device|Percutaneous coronary intervention using drug-eluting stent|"Biofreedom (Biosensors), Synergy (Boston Scientific), Ultimaster Tansei (Terumo) and Integrity Onyx (Medtronic), Xience Pro S (Abbott) or Promus Elite (Boston Scientific) or any other DES can also be used provided that it has a CE mark for 1-month DAPT, combined with tailored antithrombotic regimen:~Stable patients without OAC: 1-month DAPT followed by lifelong SAPT~Stable patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and life-long OAC~ACS patients without OAC: 3-month DAPT followed by lifelong SAPT~ACS patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and lifelong OAC"
75325826|NCT00889915|Drug|Methylphenidate transdermal system|Not specified in protocol; determined by local standard of care.
75633253|NCT02614612|Drug|prednisone or methylprednisolone (corticosteroids)|All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
75325827|NCT00889915|Drug|Lisdexamfetamine dimesylate|Not specified in protocol; determined by local standard of care.
75325828|NCT00889915|Drug|Osmotic-release oral system methylphenidate (OROS MPH)|Not specified in protocol; determined by local standard of care.
75325829|NCT00889915|Drug|Mixed amphetamine salts extended release|Not specified in protocol; determined by local standard of care.
75633254|NCT00900159|Drug|eszopiclone|3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
75325830|NCT00841087|Drug|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
75325831|NCT00841087|Drug|insulin detemir|Injection subcutaneously at bedtime
75325832|NCT00841087|Drug|insulin aspart|Injection subcutaneously immediately before each meal.
75325833|NCT02685436|Drug|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
75633255|NCT00900159|Drug|matching placebo|matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
75633256|NCT02843997|Genetic|Endophenotype and sequencing|Draw an endophenotype and genetic study
75784016|NCT02530788|Drug|Selenium Supplement (sodium selenite)|"On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
75325834|NCT04338958|Drug|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment
75784017|NCT02530788|Drug|Placebo|"On the evening before operation the patient receives the first dosage of placebo orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
75325835|NCT00841555|Drug|temozolomide|"Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.~Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment"
75325836|NCT00841555|Radiation|Hypofractionated radiation therapy|Patients will undergo HIMRT
75325837|NCT00841555|Radiation|Intensity-modulated radiation therapy|Patients undergo HIMRT
75325838|NCT02686138|Drug|Tenapanor|
75325839|NCT02686138|Drug|Placebo|
75633257|NCT05334693|Biological|Expanded haploidentical NK cells|Two doses of expanded haploidentical NK cells (30-100 x 10^6 cells /kg).
75633258|NCT02840955|Device|Staphefekt SA.100|
75633259|NCT02840955|Other|Placebo|
75633260|NCT01689909|Drug|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
75784018|NCT01288898|Drug|ASP1941|Oral
75784019|NCT01288898|Drug|Placebo|Oral
75784020|NCT01313806|Device|Resonator|Treatment group vs. Placebo group
75784021|NCT01313806|Device|Placebo|Inactive Resonator Device
75325840|NCT00842023|Drug|Nesiritide|Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
75633261|NCT01689909|Drug|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
75633262|NCT00854308|Drug|Erlotinib HCl|Erlotinib 150 mg oral dose once daily.
75919652|NCT05053672|Device|Sham ReOxy|Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions. Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve. The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.
76077183|NCT04360408|Other|Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis|The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
76077184|NCT03548571|Biological|Dendritic cell immunization|Intradermal injection
76077185|NCT03548571|Drug|Adjuvant temozolomide|After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
75325841|NCT00842023|Drug|Nitroglycerin|5-10 mcg/min titrating per protocol based on blood pressure
75325842|NCT00868309|Biological|Anavip|Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
75633263|NCT00854308|Drug|MetMAb|MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
75633264|NCT00854308|Drug|placebo (0.9 % saline)|Placebo Intravenous infusion every 3 weeks.
75633265|NCT02617498|Device|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.
75325843|NCT00868309|Biological|CroFab|CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
75633266|NCT02617498|Device|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
75784022|NCT01089192|Drug|Metformin|
75784023|NCT03748706|Drug|PTI-125, 100 mg tablets|PTI-125, 100 mg tablets taken twice a day for 28 days
75919653|NCT02095509|Drug|Enoxaparin|Drug class: Low-molecular weight heparin
75325844|NCT02693704|Device|Hearing Aids|The only intervention consists in applying a specific processing on some recorded speech signals, and comparing the performance obtained with such processed samples with ones that have not been processed. The applied processing is a binaural spatialization method that consists in filtering an original audio signal to get a left and right versions (for the two ears). The binaural rendering gives the impression that the speech signal (and thus the speaker) is located in a desired position in the environment.
75325845|NCT00368134|Drug|Vildagliptin|
75325846|NCT02696200|Device|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
75325847|NCT02697214|Device|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device compared to ECG and Polar H7
75325848|NCT02697214|Device|Apple Watch|Apple Watch heart rate monitoring device compared to ECG and Polar H7
75325849|NCT02697214|Device|Mio Fuse|Mio Fuse heart rate monitoring device compared to ECG and Polar H7
75325850|NCT02697214|Device|Basis Peak|Basis Peak heart rate monitoring device compared to ECG and Polar H7
75325851|NCT02697292|Drug|Intravenous Immunoglobulin|GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day [week 1 day 1], then will receive 1g/kg not exceeding 80 grams daily for 1 day [week 1 day 2]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks [week 3 and 5] for 2 infusions.
75325852|NCT02697292|Drug|Placebos|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Dose will be determined based on ideal wt. with not to exceed 80 grams. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day [week 1 day 1], then will receive 1g/kg not exceeding 80 grams daily for 1 day [week 1 day 2]. Then once every 2 weeks subjects will receive 0.6g/kg for 4 weeks [week 3 and 5] for 2 infusions.
75633267|NCT04201587|Other|Henna application|Henna application was performed to the patients in the intervention group. The patient was instructed to apply henna before going to bed at night, and after waking up in the morning (for an average of 8-10 hours) was instructed to wash with only water. The patient was asked to do this application at home after the second and third chemotherapy cycles. Thus, the patient applied henna twice in total (fifteen days apart).
75784024|NCT02564380|Drug|Pembrolizumab|
75784025|NCT02564380|Drug|Placebo|
75784026|NCT01093092|Dietary Supplement|Calcitriol|Given PO
75784027|NCT01093092|Drug|Cisplatin|Given IV
75784028|NCT01093092|Drug|Gemcitabine Hydrochloride|Given IV
75784029|NCT01093092|Other|Pharmacological Study|Correlative studies
75784030|NCT01289054|Drug|Tasigna|
75784031|NCT01289054|Drug|Gleevec|
75784032|NCT01179776|Drug|Ilomedin|Ilomedin
75784033|NCT01179776|Drug|Placebo|i.v saline
75784034|NCT01179776|Drug|Ilomedin|
75784035|NCT01179776|Drug|Ilomedin and standard low dose treatment|
75784036|NCT01179854|Drug|Remegal|Drug/ placebo
75784037|NCT01289600|Device|Mechanical ventilation|The mechanical ventilator is set to different ventilation modes as described in the individual arms.
75784038|NCT01181414|Procedure|Atrio ventricular junction ablation with radio-frequency|Atrioventricular junction ablation by using radiofrequency energy.
75919654|NCT03397082|Drug|Lidocaine gel|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.
75919655|NCT03397082|Drug|Placebo|5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
75919656|NCT05164276|Other|Head position|Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
75325853|NCT02697292|Drug|Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
75633268|NCT05334537|Other|Aromatherapy|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of >37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
75633269|NCT05334537|Other|Placebo oil (odorless baby oil- jojoba and almond oil)|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of >37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
75919657|NCT02101047|Drug|Phenylephrine|
75919658|NCT03396848|Other|SHAReClinic|Online clinic with educational modules
75919659|NCT02095587|Drug|IPI-145|25 mg single oral capsule
75325854|NCT00842335|Drug|JI-101|JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
75919660|NCT03396536|Other|Evaluation of KM|"KM will be evaluated. The alveolar mucosa will be stained with Lugol's solution, by means of a cotton swab. A cotton roll will be soaked in the solution and gently applied on the mucosa around the implant. Since Lugol's solution is selective to the glycogen present in AM, the muco-gingival junction as the borderline between the blue-stained alveolar mucosa and KM can be easily identified.~A manual periodontal probe with 1 mm markings will measure the distance from the peri-implant margin and the muco-gingival junction.~Mucosal thickness (MT) will be measured after topical application of the anesthetics. MT will be evaluated inserting a 27G needle with a rubber stop 1 mm below the peri-implant mucosal margin at the mid-buccal aspect, until the abutment is engaged. The needle will be removed and the distance between the rubber stop and the point of the needle will be measured with a manual periodontal probe."
75325855|NCT02700334|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
75325856|NCT02700334|Drug|Placebo|one per day before breakfast during 12 weeks.
75325857|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
75325858|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-7
75325859|NCT00868699|Drug|Placebo|Placebo Comparator
75325860|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
75468418|NCT05787119|Other|cortical reactivity|An electroencephalogram was taken at the start and end of the study to study cortical reactivity during the performance of 3 different tasks repeated 30 times: a resting task (consisting of looking at a cross on a screen), a motor imagery task (consisting of imagining performing wrist flexions/extensions) and a motor execution task (consisting of performing wrist flexions/extensions).
75633270|NCT00592852|Drug|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
75784039|NCT01181414|Drug|Beta blocker/digoxine/amiodarone|Ventricular rate control by using drug treatment.
75784040|NCT01093170|Drug|RNA-144101|Intravitreous administration of RNA-144101
75784041|NCT03747302|Other|Social Media Message about HPV and HPV vaccine|Messages educate parents with facts about HPV vaccination.
75325861|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
75325862|NCT02701270|Dietary Supplement|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
75325863|NCT02701270|Dietary Supplement|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
75325864|NCT02701582|Drug|Phenylephrine|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) < 13 and Cardiac Index is >=2.2 Phenylephrine is administered
75325865|NCT02701582|Drug|Epinephrine|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) < 13 and Cardiac Index is < 2.2 Epinephrine is administered
75325866|NCT02701582|Other|Albumin|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
75325867|NCT02701582|Other|Voluven|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
75468419|NCT05787119|Other|Fluidity of movement|Motion capture at the start and end of the study to study the fluidity of movement during 3 different tasks repeated 30 times: a resting task (looking at a cross on a screen), a motor imagery task (imagining wrist flexions/extensions) and a motor execution task (performing wrist flexions/extensions).
75784042|NCT03747302|Other|Social media message about risk of electronic cigarettes.|Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.
75919661|NCT02095665|Drug|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
75784043|NCT01094340|Drug|Thalidomide|fixed dose over 8 clinic visits
75784044|NCT03858920|Device|Fibroscan of Liver|A non-invasive diagnostic device used to measure liver scarring
75919662|NCT02095665|Drug|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
75325868|NCT02701582|Other|Normal Saline|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
75919663|NCT02095665|Drug|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
75919664|NCT03414944|Radiation|SMART-Brain|"Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10 fractions/2 weeks.~OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy."
75633271|NCT04117906|Behavioral|STAGE training for anxiety|STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
75919665|NCT02101125|Drug|BMS-986020|
75919666|NCT02101125|Drug|Rosuvastatin|
75919667|NCT04602182|Procedure|music therapy intervention|Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
75633272|NCT00895245|Drug|fosaprepitant dimeglumine|Given IV
75633273|NCT00895245|Drug|cisplatin|Given IV
75633274|NCT00895245|Drug|palonosetron hydrochloride|Given IV
75633275|NCT00895245|Drug|dexamethasone|Given IV and orally
75633276|NCT00895245|Other|Functional Living Index-Emesis Questionnaire|Ancillary studies
75919668|NCT02101203|Drug|Placebo|
75325869|NCT02701582|Other|Packed Red Blood Cells|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
75325870|NCT02701582|Device|FloTrac Monitor|FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.
75325871|NCT00869167|Drug|Ramelteon|melatonin agonist
75325872|NCT02013583|Other|No intervention|This is an observational registry. No interventions are required or provided.
75919669|NCT02101203|Drug|0.5 mgTestosterone + 10 mg Buspirone|"A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days)."
75919670|NCT04583384|Diagnostic Test|1H-Spectroscopy MRI|"PRESS asymetric monovoxel  PROBE , TE 144 ms, TR 2500 ms, 768 or 1024 averages"
75919671|NCT03414866|Behavioral|EQ-5D-5L QOL questionnaire|Written questionnaire
75919672|NCT05110846|Drug|Placebo|Placebo
75919673|NCT05110846|Drug|CT-868|CT-868
75325873|NCT00843349|Drug|Lanthanum Carbonate|Phosphorus binder
75919674|NCT02101593|Drug|ADI-PEG 20|
75633277|NCT00895245|Behavioral|Emesis Diary|Ancillary studies
75633278|NCT00895245|Radiation|Radiotherapy|Undergo radiotherapy
75784045|NCT03858920|Procedure|Low-dose non-contrast CT|CT scan as part of routine research care
75784046|NCT00056862|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 90 mcg/week
75784047|NCT00056862|Drug|Peginterferon alfa-2a|180 mcg/week
75784048|NCT00056862|Drug|Ribavirin|800 mg/day
75784049|NCT03858842|Other|epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD|epidemiology, characteristics, healthcare resources and associated costs of patients diagnosed with non-IPF PF-ILD and SSc-ILD
76077186|NCT00939562|Drug|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
76077187|NCT00939562|Drug|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
75325874|NCT00843349|Other|900 mg Phosphate Diet|Amount of phosphorus consumption in a day kept below 900 mg.
75325875|NCT00843349|Drug|LC Placebo|Placebo for Lanthanum Carbonate
75325876|NCT00843349|Other|Ad Libitum Diet|Patients continued to eat their usual diet.
75325877|NCT03839017|Device|SIMMAXMARCHERYAN2|Digital cognitive aid during the management of simulated war wounded.
75325878|NCT00869791|Drug|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
75325879|NCT00869791|Drug|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
75325880|NCT02704702|Drug|Fimasartan|
75633279|NCT02617732|Drug|Tianqi capsule|"The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day"
75633280|NCT02617732|Drug|placebo|"The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day"
75633281|NCT03172377|Other|Lengthening adalimumab dosing interval|Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
75633282|NCT00865306|Behavioral|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|"This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments."
75633283|NCT02843919|Other|Electroencephalography and Electrocardiography|
75633284|NCT02617654|Drug|Liraglutide|Treatment with liraglutide for 52 weeks
75633285|NCT02617654|Drug|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
75633286|NCT00700024|Drug|Testim|50 mg/dose7day
75633287|NCT00700024|Behavioral|Strength training|three times a week
75784050|NCT01287182|Drug|Ateronon|Ateronon daily for 3 months
75633288|NCT00700024|Drug|placebo|placebo
75784051|NCT00056316|Behavioral|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
75784052|NCT00056316|Behavioral|Behavioral Skills Training: Experimental|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
75325881|NCT02704702|Drug|Rosuvastatin|
75633289|NCT03033771|Device|Implantation with the Multilayer Flow Modulator (MFM)|Endovascular implantation with the MFM
75633290|NCT00697450|Drug|insulin detemir|Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
75325882|NCT02704702|Drug|Fimasartan + Rosuvastatin|
75325883|NCT04382287|Procedure|Remin Pro® and MI Paste Plus®|Te toothastes were applied at home twice a day over the six anterior upper primary teeth
75325884|NCT00869947|Device|Powered ankle-foot prosthesis|The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.
75325885|NCT00869947|Other|No device|
75325886|NCT02707432|Behavioral|Heart Matters|"Heart Matters is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at two different stages."
75633291|NCT00896649|Other|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
75633292|NCT00896649|Procedure|digital mammography|standard screening mammogram
75325887|NCT03216655|Other|phone call|Investigators give a regular follow-up to participants: phone call monthly
75325888|NCT03216655|Other|wechat group|Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
75325889|NCT02708212|Procedure|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
75325890|NCT00871819|Device|Precision Spinal Cord Stimulation (SCS)|Various SCS device programming parameters
75325891|NCT02708290|Other|MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time|"Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.~MITA verbal activities start with simple vocabulary-building exercises and progress toward exercises aimed at higher forms of language, such as noun-adjective combinations, spatial prepositions, recursion, and syntax. All exercises are deliberately limited to as few nouns as possible since the aim is not to expand a child's one-word vocabulary, but rather to teach him/her to integrate mental objects in novel ways by utilizing prefrontal synthesis (PFS). MITA activities outside of the verbal domain aim to provide the same PFS training visually through implicit instructions."
75325892|NCT00895531|Drug|Depodur|7.5 mg Depodur via the epidural catheter
75325893|NCT00895531|Procedure|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
75633293|NCT00896649|Procedure|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
75633294|NCT00796003|Drug|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
75633295|NCT00796003|Drug|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
75633296|NCT04110535|Drug|Remimazolam|IV administration over 1 minute
75633297|NCT04110535|Drug|Midazolam|IV administration over 1 minute
75633298|NCT04110535|Other|Saline|IV administration over 1 minute
75633299|NCT05562895|Device|Ion Endoluminal System and Cios Spin|Integrated version of the Ion Endoluminal System and Cios Spin
75784053|NCT01180010|Procedure|Low Dose CT|"A chest CT uses special radiographic equipment using x-rays to capture images of the chest, and with the aid of a computer, processes the images to create cross-sectional pictures or slices of the areas of interest. The images can then be printed out or examined on a monitor. The CT scanner is a large unit with a hole running directly through its center, giving the appearance of a doughnut. During the scanning, patients will lie flat on their back on a table, and they are periodically asked to hold their breath. The table will first move through the scanner to determine the correct starting position. The rest of the scans are made as the table moves more slowly through the cavity in the scanner."
75784054|NCT01180088|Procedure|RIGHT HEPATECTOMY WITH CLASSIC APPROACH|The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
76077188|NCT04355104|Behavioral|Education|"A one hour educational session per week for 4 weeks. In a total of 4 sessions of education, the content based on LBP Clinical Practice Guidelines which recommended that education and counseling strategies for patients with low back pain.~Education session will be through video lecturing as a motivated tool of education for all subject who are in experimental group, this video will repeated the same in every educational session and will be sent for all participants.~The neuroscience education will be by the therapist using interactive slide show and hand-drawing images.~In addition to the education video, slide show, we will specify the education for every patient to give him all that he need, questions and details, mention his case on real spine to explore it and to determine the expected goal from what he need and what we have."
75468420|NCT05760521|Other|Provider Educational Intervention|Following the informed consent (10 min) and sociodemographic survey (5 minutes), the providers in Arm A will be offered education of two days, six hours each day, with support and follow-up. They will also be asked to complete brief knowledge and confidence surveys pre-post-intervention (30 minutes total).
76077189|NCT04355104|Behavioral|Standard physical therapy|Two session physical therapy per week for 4 weeks. The physical therapy will be based on patients case.
75325894|NCT02709694|Other|No intervention|No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
75468421|NCT05754398|Behavioral|six independent and interconnected educational training sessions|"Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach."
75468422|NCT05741502|Drug|Clozapine|We will assess inflammatory/immune marker labs
75633300|NCT05335785|Device|High-intensity lazer therapy|Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
75633301|NCT05335785|Other|Exercises|Exercise program including Codman, Range of motion and streightening exercises three times in a week.
76077190|NCT04359940|Diagnostic Test|Cardiac MRI|For clinical surveillance
75325895|NCT02710240|Drug|Indocyanine Green (ICG)|
75325896|NCT02710240|Radiation|Intraoperative near-infrared (NIR)|
75325897|NCT01603225|Procedure|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
75325898|NCT03215875|Drug|Fed- 60mg ER Torsemide|60mg ER Torsemide will be given after high fat, high-calorie meal
75325899|NCT03215875|Drug|Fasting- 60mg ER Torsemide|60mg ER Torsemide will be given after overnight fasting
75325900|NCT02710630|Drug|Dabigatran etexilate tablet E1|
75325901|NCT02710630|Drug|Dabigatran etexilate tablet D1|
75325902|NCT02710630|Drug|Dabigatran etexilate tablet C1|
75325903|NCT02710630|Drug|Dabigatran etexilate tablet B1|
75325904|NCT02710630|Drug|Dabigatran etexilate tablet A1|
75325905|NCT02710630|Drug|Dabigatran etexilate capsule|
75325906|NCT02715076|Other|Ambient Temperature 19°C|Ambient Temperature 19°C
75468423|NCT05741502|Drug|Antipsychotics,Other (non-Clozapine)|We will assess monitor inflammatory/immune marker lab
75325907|NCT02715076|Other|Ambient Temperature 21°C|Ambient Temperature 21°C
75325908|NCT02715076|Other|Ambient Temperature 23°C|Ambient Temperature 23°C
75325909|NCT02715076|Device|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
75325910|NCT02715076|Other|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
75325911|NCT00873457|Drug|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
75325912|NCT02715700|Drug|Methadone|Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
75325913|NCT02715700|Drug|Doravirine|Doravirine 100 mg oral tablet once per day.
75325914|NCT03215953|Device|cast shoe|ankle-high, custom-made, well-moulded cast shoe
75468424|NCT05729022|Device|Ultrasound microendoscopic technique|Ultrasound-guided microendoscopic lumbar transforaminal epidural steroid injection
75633302|NCT04025203|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
76077191|NCT04359862|Drug|Sevoflurane|25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
75325915|NCT03215953|Device|removable walker|Prefabricated especially designed for relieving load on the foot
75325916|NCT02716324|Behavioral|Care Manager CM)|The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
75468425|NCT05729022|Radiation|Fluoroscopy|Fluoroscopy-guided lumbar transforaminal epidural steroid injection.
75468426|NCT05725070|Drug|212Pb-NG001|"212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.~Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001."
75468427|NCT05716217|Other|Arm training|Daily arm training program
75325917|NCT02716324|Other|ADHD Portal|The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
75325918|NCT00875641|Other|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
75325919|NCT04338724|Drug|CS1002|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
75325920|NCT03216031|Behavioral|Gardening programme|3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the falls prevention growing site. Each participant will attend the programme 8 times.
75325921|NCT00895921|Drug|Olanzapine|Single intramuscular 10-mg dose
75325922|NCT00895921|Drug|Aripiprazole|Single intramuscular 9.75-mg dose
75325923|NCT02716714|Drug|ingenol mebutate gel 0.015%|-Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days
75325924|NCT02716714|Drug|ingenol mebutate gel 0.05%|-Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
75325925|NCT02719366|Device|comfilcon A Extended Range test lens|contact lenses
75325926|NCT02719366|Device|comfilcon A control lens|contact lenses
75325927|NCT00368212|Behavioral|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
75325928|NCT00368212|Behavioral|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
76077192|NCT04359862|Drug|Propofol|25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
75325929|NCT05319457|Other|The radon app|Participants will be asked to use the radon app.
75325930|NCT05319457|Other|Print brochure|Participants will receive print brochures.
75325931|NCT03215329|Procedure|abdominal or vascular surgery|Intermediate or high risk abdominal or vascular surgery
75325932|NCT02720224|Drug|Estetrol|15 mg [14C]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
75325933|NCT05312827|Behavioral|Training Intervention and Program of Support (TIPS) for fostering the adoption of family-centred telehealth interventions in pediatric rehabilitation|The proposed pre-post study will evaluate the implementation and effectiveness of a Training Intervention and Program of Support (TIPS) to enhance the adoption of family-centred telehealth in pediatric rehabilitation centres across Canada. TIPS is a multifaceted intervention, comprised of the following: 1) a 10-hour intensive training program offered to participating therapists at each site over a one-month period, including 4 hours of self-paced learning modules and a 6-hour mandatory interactive webinar; and 2) an 11-month program of support which is composed of monthly mentoring meetings at each site led by the local therapist champion, and a national virtual community of practice facilitated by 3 national knowledge brokers - an occupational therapist, a physiotherapist and a speech-language pathologist - experienced in family-centred telehealth in pediatric rehabilitation, offered simultaneously to all participating therapists across Canada.
75468428|NCT05706727|Drug|Intravenous bolus dose of Mephentermine and mephentermine|intravenous bolus dose of mephenteramine 6mg
75633303|NCT04025203|Drug|Ibuprofen Arginine|Oral tablets
75633304|NCT04025203|Drug|Gabapentin|oral capsules
75633305|NCT02843607|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
75784055|NCT03308968|Drug|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
75784056|NCT03308968|Drug|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
75784057|NCT01289132|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 12 weeks.
75784058|NCT01289132|Drug|Azilsartan|Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
75784059|NCT01289132|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
75784060|NCT01289132|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
75633306|NCT02843607|Biological|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
75633307|NCT02843685|Drug|Drotrecogin alfa activated|
75633308|NCT04106947|Other|Questionnaires|Questionnaires
75633309|NCT00915577|Drug|Interferon beta-1a|30mcg, IM once-a-week
75633310|NCT00915577|Device|Single-use autoinjector|Single-use autoinjector with Avonex 30mcg pre-filled syringe
75633311|NCT00895011|Drug|Placebo|One dose 30 minutes prior to initiation of sexual activity
75633312|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
75633313|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
75633314|NCT02604355|Other|Matching Placebo|Oral dosing with placebo capsules to match RO7020322.
75784061|NCT01289132|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
75784062|NCT01289132|Drug|Azilsartan|Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
75784063|NCT01289132|Drug|Candesartan cilexetil|Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
75784064|NCT01287260|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg twice daily (BID)
75784065|NCT01287260|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg once daily (OD)
75784066|NCT03857516|Device|Multipolar left ventricular lead implantation|Multipolar left ventricular lead implantation with measurements of pacing thresholds in varrious pacing configurations.
75919675|NCT04523246|Biological|SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|The Shingrix vaccine is a subunit vaccine that contains the recombinant varicella zoster virus (VZV) glycoprotein E (gE), adjuvanted with the proprietary Adjuvant System (AS01B). The AS01B Adjuvant system consists of two immune-stimulants, the saponin, Quillaja saponaria Molina, fraction 21 (QS21), and the toll-like receptor 4 (TLR4) agonist, MPL (3-O-desacyl-40-MPL) that enhance the release of interferon gamma (IFNϒ), which in turn stimulates activation and recruitment of blood monocyte-derived and resident lymph node dendritic cells to take up and present gE to cluster of differentiation 4 (CD4+) T cells.
75919676|NCT04523246|Drug|Normal Saline|Sterile normal saline, inactive control.
75633315|NCT02604355|Drug|RO7020322|Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
75633316|NCT00899847|Procedure|Autologous peripheral blood stem cells (auto-PBSC) transplantation|"Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective"
75325934|NCT02722330|Device|Baha 5 SuperPower on Baha Attract System|The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
75325935|NCT05314777|Procedure|Low dose ESWT application|Patients trained for low dose ESWT application.
75633317|NCT00899847|Procedure|Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
75633318|NCT00899847|Drug|Filgrastim|"Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection."
75325936|NCT05314777|Procedure|High dose ESWT application|Patients trained for high dose ESWT application.
75325937|NCT05314777|Procedure|Sham ESWT|Patients trained for sham ESWT.
75919677|NCT04753450|Other|No intervention|No intervention
75784067|NCT01181570|Drug|Adalimumab|Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
75325938|NCT05314777|Procedure|Exercise Training|Patients trained for exercise training.
75325939|NCT00881647|Other|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
75325940|NCT00882661|Device|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
75325941|NCT00882661|Device|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
75325942|NCT00883675|Drug|Docetaxel-Carboplatin|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
75325943|NCT00884065|Other|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
75325944|NCT00884065|Other|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
75325945|NCT03215407|Drug|Intra-articular Tocilizumab|Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
75325946|NCT03215407|Drug|Intra-articular Compound Betamethasone|Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
75325947|NCT02722408|Drug|Gemcabene|300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
75633319|NCT00899847|Drug|Cyclophosphamide|Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
75633320|NCT00899847|Drug|Melphalan|Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
75633321|NCT00899847|Drug|Cyclosporine|Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
75784068|NCT01181570|Drug|Placebo|Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
75784069|NCT05200312|Drug|Zanubrutinib|160 mg capsules administered by mouth twice daily (21-day cycles).
75784070|NCT05200312|Drug|Lenalidomide|25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)
75784071|NCT05200312|Drug|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
75784072|NCT05200312|Drug|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
75919678|NCT02102607|Other|age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
75919679|NCT03414788|Biological|PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and [124I]IB PF 06687234 simultaneously
75919680|NCT03414788|Biological|[124I]IB PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and [124I]IB PF 06687234 simultaneously
75919681|NCT03410264|Behavioral|CR-EXP|See arm/group descriptions
76077193|NCT04354948|Behavioral|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
75325948|NCT00884611|Device|Predictive Low Glucose Suspend Algorithm ON|The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.
75325949|NCT00884611|Device|Predictive Low Glucose Suspend Algorithm OFF|
75325950|NCT05310331|Combination Product|Donafenib combined with paclitaxel and platinum ± PD-1 antibody|Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate > 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min < creatinine clearance rate < 60ml/min) ± PD-1 antibody every 3 weeks.
75633322|NCT00899847|Radiation|Total lymphoid irradiation|Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
75325951|NCT00891319|Device|Electrical stimulator|"• 12-week intervention~Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home."
75633323|NCT00899847|Biological|Rabbit anti-thymocyte globulin|ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
75325952|NCT00885079|Drug|OPC-12759 Ophthalmic suspension|OPC-12759 Ophthalmic suspension 2%
75784073|NCT05200312|Drug|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
75784074|NCT05200312|Drug|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
75784075|NCT05200312|Drug|Prednisone (or equivalent)|40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
75633324|NCT00899847|Drug|Mycophenolate Mofetil 250mg|MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
75468429|NCT05706727|Drug|intravenous bolus dose of phenylephrine 50 mcg|intravenous bolus dose of phenylephrine 50 mcg
75784076|NCT01180166|Drug|nimotuzumab|200 milligram (mg) of nimotuzumab per week during radiation period
75784077|NCT03862196|Behavioral|Tailored text messages to improve retention in HIV care|Trained counselors will deliver the text messages. After a block randomization, the trained counselor (a nurse) will send the first welcoming message to participants in the intervention arm. The nurse will send 2 tailored text messages per week. In addition 2 to 4 days before an appointment, the nurse will send a message reminder. In addition, the nurse will have bilateral communication with participants using text messages according to their needs. The participants of the intervention arm will interact with the nurse during 3 months with a semi-structured strategy, that is, with template text messages (predesigned) and open messages (for which the nurse will be trained). Three and six months after started the intervention the variables of interest will be assessed.
75919682|NCT03410264|Behavioral|EXP-CR|See arm/group descriptions
75919683|NCT03410264|Behavioral|Stress Management|See arm/group descriptions
75468430|NCT05705648|Dietary Supplement|medium chain triglyceride oil|Medium chain triglyceride oil
75468431|NCT05705648|Dietary Supplement|Safflower oil|Safflower oil
75468432|NCT05701280|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of the dentate nucleus area of the cerebellum plus motor rehabilitation to improve upper-extremity function.
75468433|NCT05701280|Other|Rehabilitation|Motor rehabilitation to improve upper-extremity function.
75468434|NCT05700032|Diagnostic Test|high MI impulses|patients will receive intermittent high MI impulses(>1.0) in addition to low MI imaging. LVOT VTI will be measured at different times per protocol.
75633325|NCT00899847|Drug|Solumedrol|Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
75633326|NCT00899847|Drug|Diphenhydramine|Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
75633327|NCT00899847|Drug|Acetaminophen|Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
75919684|NCT02102685|Procedure|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
75325953|NCT00885079|Drug|Hyalein Mini Ophthalmic solution|Hyalein Mini Ophthalmic solution 0.1%
75325954|NCT00896779|Drug|ranibizumab|"Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months"
75325955|NCT03214939|Biological|Immunotherapy based on dendritic cells|Intravenous injection of cells
75468435|NCT05700032|Diagnostic Test|low MI impulses|patients will receive low MI imaging only. LVOT VTI will be measured at different times per protocol.
75468436|NCT05695742|Other|Active Smoking|Being active smoker
75468437|NCT05695742|Other|Passive smoker|Being exposed to secondhand smoke
75468438|NCT05695742|Other|Non-smoker|Not being an active or passive smoker.
75468439|NCT05679388|Drug|Relugolix Pill|A medication used to treat prostate cancer. Relugolix comes as a tablet to take by mouth. It is usually taken with or without food once daily.
75468440|NCT05679388|Drug|Ritonavir|HIV antiviral It can treat HIV infection, which causes AIDS. It does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease and prolong life.
75468441|NCT05679388|Drug|Itraconazole|A drug used to treat fungal infections.
75468442|NCT05678101|Device|transcutaneous electrical nerve stimulation (TENS)|Chattanooga Physio TENS (DJO Global, Vista, CA)
75325956|NCT03376477|Biological|GM-CSF vaccine|Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
76077194|NCT04354948|Behavioral|No pain (Hypotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
76077195|NCT03540927|Behavioral|PM+ for entrepreneurs|The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
76077196|NCT03540927|Other|Cash transfer to the Entrepreneurs|The entrepreneurs in the control arm will receive cash transfer only for their businesses.
75325957|NCT03376477|Drug|Lenalidomide|Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
75325958|NCT03376477|Drug|Prevnar13|Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
75325959|NCT03376477|Other|Placebo Prevnar13|Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
75325960|NCT03376477|Other|Placebo GM-CSF Vaccine|Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
75325961|NCT02726620|Procedure|Attending real-time decision support|Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
75468443|NCT05678101|Device|Sham transcutaneous electrical nerve stimulation (TENS)|Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
75325962|NCT02726620|Procedure|In-room real-time decision support|Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
75919685|NCT02102685|Procedure|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
75325963|NCT02726620|Procedure|Attending feedback emails|Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
75325964|NCT02726620|Procedure|In-room provider feedback emails|In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
75325965|NCT02726620|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
75325966|NCT02726620|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.
75468444|NCT05655182|Biological|PIV5-vectored RSV Vaccine (BLB-201) Low Dose|BLB201 10^6 PFU
75633328|NCT00899847|Drug|Hydrocortisone|Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
75633329|NCT04106479|Device|NIRS evaluation|NIRS will be used for measurement of cerebral and renal saturation.
75633330|NCT05558605|Diagnostic Test|AI-guided echo|AI-guided echocardiography
75633331|NCT05558605|Diagnostic Test|Standard echo|Standard echocardiography
75633332|NCT04106791|Device|closed-loop system for vasopressor administration|The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
75919686|NCT05083078|Drug|Guselkumab|Guselkumab will be administered subcutaneously.
75919687|NCT05083078|Drug|Risankizumab|Risankizumab will be administered subcutaneously.
76077197|NCT04354714|Drug|Ruxolitinib|For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
76077198|NCT04354714|Procedure|Peripheral blood draw|-Screening, Day 2, Day 4, Day 8, Day 15, and Day 29
76077199|NCT04366960|Drug|Enoxaparin|Subcutaneous enoxaparin
76077200|NCT03539445|Drug|Butylphthalide|This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
76077201|NCT03539445|Drug|Butylphthalide Placebo|This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
75325967|NCT02726620|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
75325968|NCT02726620|Device|Pager system|The mobile pager system through which alerts can be sent
75325969|NCT02726620|Procedure|Central neuraxial anesthesia|Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
75468445|NCT05655182|Biological|PIV5-vectored RSV Vaccine (BLB-201) High Dose|BLB201 10^7 PFU
75468446|NCT05655182|Drug|Placebo|The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10^6 PFU).
75919688|NCT02520674|Other|optic nerve head ophthalmoscopy|Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
75784078|NCT03637738|Radiation|RIOP-Intrabeam® system|The radiation source is inserted at the immediately on surgical resection bed after tumorectomy and started for 20 to 55 minutes to perform intraoperative radiotherapy precisely targeting the tissues that present the greatest risk of local recurrence. The applied dose will be 20 Gy on the applicator surface.
75784079|NCT03637738|Radiation|conventional surgery +RTE|Conventional EBRT, 5 to 10 weeks after surgery, according to the usual recommendations, 2 Gy per session, 5 sessions per week, with a total dose on the mammary gland of 50 Gy + a boost of 16 Gy on surgical resection bed .
75325970|NCT02726620|Procedure|Non-cardiac surgery|Any surgical intervention that is not aimed at surgical correction of the heart
75325971|NCT02726620|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
75919689|NCT05068024|Drug|FWD1509 MsOH|FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
75919690|NCT03414710|Behavioral|Health education booklet plus video plus brief counseling|Participants in the intervention group will receive a health education booklet, watch a 10-minute video and receive counseling provided by the clinicians
75919691|NCT03414710|Behavioral|Health education booklet only|Participants in the intervention group will only receive a health education booklet
75784080|NCT02940730|Drug|Dalbavancin via Intravenous Administration|Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
75919692|NCT03555201|Other|Manual therapy|protocol of soft tissues techniques
76077202|NCT04360876|Drug|Dexamethasone injection|Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days
75325972|NCT02726620|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
75784081|NCT02940730|Drug|Dalbavancin via Intraperitoneal Administration|Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
75784082|NCT03741062|Device|J. Morita AdvErl Evo Er:YAG laser|"Er:YAG laser perimeters:~Energy = 80 mJ Pulse Rate = 25 Hz Duration = 30 s"
75784083|NCT03741062|Device|Control|Sham treatment with laser unit turned off
75325973|NCT02726620|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
75325974|NCT02726620|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
75325975|NCT02726620|Drug|Ephedrine|Cardiovascular drug used to treat intraoperative hypotension
75325976|NCT02726620|Drug|Phenylephrine|Cardiovascular drug used to treat intraoperative hypotension
75325977|NCT02726620|Drug|Norepinephrine|Cardiovascular drug used to treat intraoperative hypotension
75325978|NCT02726620|Drug|Epinephrine|Cardiovascular drug used to treat intraoperative hypotension
75325979|NCT02726620|Drug|Dobutamine|Cardiovascular drug used to treat intraoperative hypotension
75325980|NCT02726620|Drug|Dopamine|Cardiovascular drug used to treat intraoperative hypotension
75325981|NCT02726620|Drug|Isoproterenol|Cardiovascular drug used to treat intraoperative hypotension
75325982|NCT02726620|Drug|Milrinone|Cardiovascular drug used to treat intraoperative hypotension
75325983|NCT02726620|Drug|Atropine|Cardiovascular drugs used to treat intraoperative hypotension
75325984|NCT02726620|Drug|Glycopyrrolate|Cardiovascular drug used to treat intraoperative hypotension
75325985|NCT02726620|Drug|Vasopressin|Cardiovascular drug used to treat intraoperative hypotension
75468447|NCT05634447|Drug|Drug: CKD-391, QD, PO|Drug: CKD-331, D337 QD, PO
75468448|NCT05628038|Drug|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w
75784084|NCT01587560|Device|PyroTITAN, Ascension Orthopedics, Inc.|All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
75919693|NCT03555201|Other|Regular treatment control.|Regular treatment control.
75919694|NCT03396458|Diagnostic Test|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg, anti-HBs and anti-HBc).
75468449|NCT05628038|Drug|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
75468450|NCT05628038|Drug|5FU|400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
75919695|NCT03396458|Other|Questionnaire|Participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g. sharing toothbrushes, HBV infected family member) and HBV vaccination status.
76077203|NCT04360876|Drug|Placebos|Placebo delivered intravenously on the same dosing schedule as dexamethasone
76077204|NCT04403529|Drug|Traditional Chinese Medicine Formulation|"The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption."
75468451|NCT05628038|Drug|folinic acid|400 mg/m2 q2w
75633333|NCT00853762|Drug|Atacicept 25 mg|Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
75633334|NCT00853762|Drug|Atacicept 75 mg|Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
75633335|NCT00853762|Drug|Atacicept 150 mg|Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
75633336|NCT00853762|Drug|Atacicept 150 mg|Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
75633337|NCT00789529|Device|Opti-Free® RepleniSH® MPDS|soft contact lens disinfecting solution
75633338|NCT00789529|Device|ReNu MultiPlus®|soft contact lens disinfecting solution
75784085|NCT01587560|Device|TITAN, Ascension Orthopedics, Inc.|
75784086|NCT03281668|Behavioral|High intensity interval training (HIIT)|Each training session for High Intensity Interval Training will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
75784087|NCT01181648|Behavioral|questionnaire and semi-structured interviews|Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
75325986|NCT02726620|Drug|Terlipressin|Cardiovascular drug used to treat intraoperative hypotension
75325987|NCT02726620|Drug|Sodium Chloride 0.9%|Intravenous fluid used to treat intraoperative hypotension
75325988|NCT02726620|Drug|Ringer's lactate|Intravenous fluid used to treat intraoperative hypotension
75325989|NCT02726620|Drug|Hydroxyethyl starch solutions|Intravenous fluid used to treat intraoperative hypotension
75325990|NCT02726620|Drug|Fresh Frozen Plasma|Intravenous fluid used to treat intraoperative hypotension
75325991|NCT02726620|Drug|Packed Red Blood Cells|Intravenous fluid used to treat intraoperative hypotension
75468452|NCT05628038|Drug|Oxaliplatin|130 mg/m² q3w or 85 mg/m² q2w
75325992|NCT02726620|Drug|Albumin solutions|Intravenous fluid used to treat intraoperative hypotension
75325993|NCT02726620|Drug|Plasma-Lyte|Intravenous fluid used to treat intraoperative hypotension
75468453|NCT05628038|Drug|Irinotecan|180 mg/m² q2w and 200 mg/m² q3w
75468454|NCT05628038|Drug|Raltitrexed|2 mg/m² q2w and 3 mg/m² q3w
75633339|NCT02840565|Drug|BIA 5-453|Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
75633340|NCT02840565|Drug|Placebo|The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
75633341|NCT04117750|Dietary Supplement|cholecalciferol (vit D3)|42,000 IU oral vitamin D per week and 500 mg calcium carbonate
75784088|NCT01587638|Drug|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
75784089|NCT01587638|Drug|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
75784090|NCT01176422|Genetic|Blood sample|Blood samples will be collected before and after treatment completion.
75784091|NCT03858452|Procedure|Muscles exercises program|
75784092|NCT01287338|Drug|Olopatadine|low dose
75784093|NCT01287338|Drug|Olopatadine|high dose
75784094|NCT01289288|Behavioral|Mailed printed materials and in-office training|"Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~Two sessions of in-office training with two standardized patients"
75784095|NCT01176500|Drug|(18)Fluciclatide|
75919696|NCT04940884|Behavioral|Supervised exercise training|SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session
75919697|NCT04940884|Behavioral|Aerobic exercise training|All recruited subjects were instructed to walk >=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.
75919698|NCT02102841|Procedure|Skin biopsy|
75919699|NCT02102841|Procedure|Skin suction blister|
75919700|NCT02102841|Biological|Mantoux test|
75468455|NCT05628038|Radiation|Radiation|"25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence tumor.~35-60Gy/5-8Fx irradiation for distance metastasis tumor."
75633342|NCT02603653|Device|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
75633343|NCT00894933|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
75633344|NCT02614846|Drug|Hetrombopag Olamine|
75633345|NCT04131322|Drug|Amgevita 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
75633346|NCT04131322|Drug|HUMIRA 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
75633347|NCT02843373|Device|TMS|
75468456|NCT05626829|Drug|Tranilast|Tranilast capsules 100mg 3 times per day when reradiation
75468457|NCT05626088|Other|No Intervention|This is a non-interventional study.
75468458|NCT05621018|Device|Maze Out|Play for 15 weeks, at list once a week the serious game: Maze Out
76077205|NCT04403529|Drug|Placebo Formulation|"Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption."
75633348|NCT04581759|Device|RIPC device (IPC-906X)|Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.
75325994|NCT02726620|Drug|Lidocaine|Local anesthetic used for central neuraxial anesthesia.
75325995|NCT02726620|Drug|Bupivacaine|Local anesthetic used for central neuraxial anesthesia.
75325996|NCT02726620|Drug|Levobupivacaine|Local anesthetic used for central neuraxial anesthesia.
75325997|NCT02726620|Drug|Ropivacaine|Local anesthetic used for central neuraxial anesthesia.
75325998|NCT02726620|Drug|Mepivacaine|Local anesthetic used for central neuraxial anesthesia.
75325999|NCT02726620|Drug|Tetracaine|Local anesthetic used for central neuraxial anesthesia.
75326000|NCT02726620|Drug|Prilocaine|Local anesthetic used for central neuraxial anesthesia.
75326001|NCT02726620|Drug|Procaine|Local anesthetic used for central neuraxial anesthesia.
75468459|NCT05619146|Device|Motor-assisted arms and legs cycling|The participants will complete 60min of active cycling training paradigm, 5 times a week, for 12 weeks. The cycling ergometer will be used to provide motorized assistance during simultaneous arms and legs cycling to the participant while they are seated.
75468460|NCT05617781|Behavioral|Questionnary|The primary outcome of this study is to analyze the post-traumatic stress disorder's repercussions on empathy by passing the Interpersonal Reactivity Index (IRI)
75468461|NCT05617625|Drug|Busulfan|0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant
75468462|NCT05617625|Drug|Melphalan|70 mg/m^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant
75468463|NCT05617625|Drug|Fludarabine|25 mg/m^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant
75468464|NCT05617625|Device|CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)|CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.
75468465|NCT05615714|Other|Paresthesia-free Peripheral Nerve Field Stimulation|High frequency and sub-paresthesia threshold intensity parameters will be used for paresthesia-free stimulation of trigeminal nerve branches.
75326002|NCT02726620|Drug|Chloroprocaine|Local anesthetic used for central neuraxial anesthesia.
75326003|NCT02726620|Drug|Benzocaine|Local anesthetic used for central neuraxial anesthesia.
75468466|NCT05615714|Other|Sham stimulation|Stimulation will be turned off.
75633349|NCT04581759|Drug|foundational treatment|foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
75468467|NCT05612061|Behavioral|Indigenous Recovery Planning|"The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future."
75633350|NCT04133740|Drug|Oxygen|Liberal versus conservative oxygen therapy.
75633351|NCT00792805|Drug|Indacaterol 150 µg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
75633352|NCT00792805|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
75633353|NCT00792805|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
76077206|NCT04354324|Drug|Radioiodine|The test group: low dosage (30mci). The control group: high dosage (100mci).
76077207|NCT04403373|Behavioral|Waitlist control|waitlist control
75633354|NCT02840175|Drug|etanercept|will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
75633355|NCT02840175|Drug|adalimumab|will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
76077208|NCT04403373|Behavioral|Moderate-intensity walking exercise|walking exercise
76077209|NCT04403373|Behavioral|Vigorous-intensity walking exercise|walking exercise
75326004|NCT02726620|Drug|Articaine|Local anesthetic used for central neuraxial anesthesia.
75326005|NCT04381585|Device|A MINI DISTRACTOR WITH A SUBMERGED ACTIVATION COMPONENT|Mini distractor is used to regenerate alveolar bone which is resorbed due various reasons. The distractor uses a winch-like submucosal activation component which is buried in the tissue; Flicking the winch turns the screw which moves the segment upwards in the direction of black arrow increasing height.
75326006|NCT00887575|Drug|Paclitaxel|IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2
75326007|NCT00887575|Drug|Carboplatin|IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4
75326008|NCT00887575|Drug|Sunitinib|By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
75326009|NCT03214783|Other|Facial characteristics|The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
75326010|NCT03352843|Drug|Primaquine|All patients will be administered with a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen, and then followed-up for 28 days for clinical and laboratory assessment to assess safety and efficacy.
75326011|NCT03215173|Behavioral|Fit After Baby|Mobile application
75326012|NCT03215173|Behavioral|Text4Baby Control Group|Receive free text messages
75919701|NCT05613634|Device|Repetitive transcranial magnetic stimulation|A high frequency (10 Hz) rTMs on the dominant dorsolateral prefrontal cortex (DLPFC) was applied with the Magstim Rapid Magnetic Stimulator, Magstim Company. Patients were seated in a chair, arms and legs relaxed, head stable, and no movement was allowed during the procedure. Motor threshold (MT) was determined before each session and was defined as the percent intensity output of the stimulator that generated a 50µV motor evoked response in the abductor pollicis brevis (APB) muscle in five out of 10 trials. The DLPFC of dominant hemisphere was localized on the scalp 5.5 cm anterior to the hot spot for the contralateral APB muscle along the parasagittal plane. The average MT was 50 % (range, 45-55%) of the maximal output of the stimulator. The initial mapping procedure was completed with the coil oriented at 45° lateral diagonal orientation roughly perpendicular to the central sulcus and the center of the coil applied tangentially to the scalp.
75919702|NCT05613634|Other|Cawthorne Cooksey exercises|Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.
75919703|NCT03396380|Drug|Vitamin D with calcium and clomiphene citrate|"Vitamin D ( ossofortin®, EVA PHARMA) 10000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~Induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily) starting from the third day of menstrual cycle and for five days ."
75919704|NCT03396380|Drug|Placebo Oral Tablet with calcium and clomiphene citrate|"The placebo tablet twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily)starting from the 3rd day of menstrual cycle and for five days"
75919705|NCT02102919|Device|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
75919706|NCT02102919|Device|Virtual Games (VG)|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
75919707|NCT02102919|Other|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
75919708|NCT02102919|Device|Aktiv Tramp (Swiss Frei AG, Switzerland)|Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
75919709|NCT03464110|Behavioral|Communication Intervention|. The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
75919710|NCT04449926|Biological|Bacillus of Calmette and Guerin (BCG)|Prime and boost vaccination
75919711|NCT03414632|Drug|99mTc-PYP|Radioisotope used in the SPECT/CT imaging
75919712|NCT02103075|Device|Neuromuscular electrical stimulation|All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.
75919713|NCT04921618|Other|2 online self-administered questionnaires on|"Participant profile~Spontaneous partner notification practices collected one month after STIs diagnosis"
75919714|NCT04921618|Other|2 online self-administered questionnaires on|"Participant profile~Experiences with partner notification and use of STI testing following notification"
75919715|NCT03554577|Device|Hearing Aid without NR|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
75919716|NCT03554577|Device|Hearing Aid with NR_A|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
76077210|NCT04354636|Drug|Silver modified atraumatic restorative treatment|Silver diamine fluoride that will be applied during atraumatic restorative treatment
76077211|NCT04354636|Other|Atraumatic restorative treatment|Using atraumatic restorative treatment without applying silver diamine fluoride
75326013|NCT03214549|Procedure|gull wing preparation of laminates veneers|preparation involving mesial and distal extension further lingualy.
75326014|NCT03214549|Procedure|conventional preparation of laminates veneers|preparation not involving mesial and distal extension further lingualy.
75326015|NCT03238027|Drug|SNDX-6352|Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)
75326016|NCT03238027|Drug|Durvalumab|Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
75326017|NCT00887653|Drug|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
75326018|NCT00887965|Drug|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
75326019|NCT05312749|Other|progressive relaxation exercises|progressive relaxation exercises
75633356|NCT02840175|Drug|Abatacept|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
75919717|NCT03554577|Device|Hearing Aid with NR_B|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
75326020|NCT02729038|Drug|Gepotidacin|Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
75919718|NCT03554577|Device|Hearing Aid with NR_C|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
76077212|NCT04354090|Drug|JY09|Subcutaneous injection
76077213|NCT04359550|Biological|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
75326021|NCT05311813|Drug|Enoxaparin, Hydroxychloroquine|To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy
75326022|NCT03214627|Device|Anemia Control Model (ACM)|The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
76077214|NCT04359550|Other|placebo|placebo
75326023|NCT03214627|Drug|IV iron|IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
75326024|NCT03214627|Drug|Erythropoiesis-Stimulating Agent (ESA)|ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
75326025|NCT00888511|Drug|Tarceva|Tarceva 150 mg/day
75326026|NCT00888511|Radiation|Radiotherapy|66 Gy/33 F/5 F per week for 5 weeks
75326027|NCT05311111|Procedure|distal radial artery approach|Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
75468468|NCT05597748|Device|Modified Herbst Approach|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
75468469|NCT05597748|Device|Conventional Herbst Approach|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
75326028|NCT05311111|Procedure|conventional radial artery approach|Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
75326029|NCT03214393|Diagnostic Test|Doppler|Doppler will be done to pregnant women with Pre-Eclampsia
75326030|NCT03214393|Diagnostic Test|serum antibodies|serum antibodies will be measured for pregnant women with Pre-Eclampsia
75326031|NCT02730988|Behavioral|Weight Stable Group|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
75326032|NCT03214315|Procedure|Visceral adipose tissue specimen|specimen
75326033|NCT02731300|Device|tDCS|brain stimulation by cathodal electrode at motor cortex
75633357|NCT02840175|Drug|Tocilizumab|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
75633358|NCT04133662|Behavioral|Sleep Manipulation Protocol|A structured sleep duration intervention will be taught to patients
76077215|NCT04354480|Biological|RSV Vaccine|Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.
76077216|NCT04354480|Other|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
76077217|NCT03567525|Procedure|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels|After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection
76077218|NCT03567525|Procedure|Standard surgical approach|After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
76077219|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
76077220|NCT02084511|Drug|BI 1026706|BI 1026706
76077221|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
75326034|NCT05315089|Other|Virtual reality games +conventional exercises|Virtual reality games +conventional exercises
75919719|NCT03396302|Other|Educational intervention|The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
75919720|NCT04972630|Behavioral|Pal-Care|"Pal-Care intervention participants will receive a 6-month intervention based upon the WHO toolkit and it will be delivered by the community health workers (CHWs). The goal of this pragmatic clinical trial is to test and evaluate a home-based palliative care intervention for utilizing community health workers to facilitate the delivery of palliative care to cancer patients in rural India. More details provided in the intervention arms section. After the intervention, clinicians, CHWs and a purposefully selected set of patients/caregivers, who were involved in the Pal-Care will be interviewed to understand their experiences, needs, expectations, barriers, facilitators and strategies."
75919721|NCT04972630|Behavioral|Control-Usual Care|"The control group will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency."
76077222|NCT02084511|Drug|Celecoxib|Celecoxib capsule
76077223|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
76077224|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
76077225|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
75326035|NCT05315089|Other|Conventional exercises|Conventional exercises
75326036|NCT00368368|Drug|GK Activator (2)|100mg po
75326037|NCT00888979|Drug|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
75326038|NCT02734498|Device|Electroconvulsive Treatment (ECT) Right Unilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed unilateral on the right side.
75326039|NCT02734498|Device|Electroconvulsive Treatment (ECT) - Bilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed Bilateral.
75326040|NCT03142867|Other|non-applicable|non-applicable
75326041|NCT02734576|Device|Venous Sinus Stenting with the Precise Pro Stent|Enrolled patients will undergo a minimally invasive procedure that involves placement of a stent in the cerebral venous sinuses (large veins of the brain).
75326042|NCT03214237|Other|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
75326043|NCT03214159|Drug|Ritonavir Tablet 100mg|Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
75326044|NCT03214159|Drug|NORVIR tablet 100mg|NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
75633359|NCT04031092|Device|Wearable tech with feedback|An armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone.
75326045|NCT03213925|Radiation|Radiation therapy|"Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region.~Techniques: 3D conformal radiation therapy or intensity modulated radiation therapy (IMRT).~Standard systemic treatment for patients with hormonal positive receptor (hormone therapy for at least 5 years) and HER2 positive (trastuzumab for 1 year)"
75633360|NCT04031092|Device|Wearable tech without feedback|An armwrist device measuring physical activity level, no reporting back to the user.
75633361|NCT04031092|Behavioral|Rehabilitation program|traditional inpatient rehabilitation program.
75633362|NCT05334225|Other|Training Program|An in-person urethral catheterization training program that utilizes training videos (demonstrating procedures, providing examples of ordinary and difficult cases, utilizing animation techniques as well)
75633363|NCT04106635|Procedure|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
75784096|NCT01180322|Drug|Cytarabine|"Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)~Consolidation therapy:~Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).~Elderly patients (>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2)."
76077226|NCT00942448|Other|Placebo s.c.|1 single injection at day of dental surgical extraction
75784097|NCT01180322|Drug|Idarubicin|"First induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.~Arm B:~12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.~Second induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)~Arm B:~12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups)."
76077227|NCT02982148|Device|methylene blue intradermal injection|Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
76077228|NCT02982148|Device|methylene blue subcutaneous injection|Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
76077229|NCT04697758|Drug|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye
76077230|NCT04697758|Drug|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye
76077231|NCT04697758|Drug|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye
75326046|NCT03213847|Device|Superb microvascular imaging (SMI) (Toshiba)|to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
75633364|NCT04106635|Procedure|Cricoid pressure|To apply cricoid pressure, the cricoid cartilage is compressed by 30N force with a single-handed three finger maneuvre towards the vertebral bodies.
75919722|NCT02106273|Device|Bronchial blocker (Coopdech, Arndt)|Using bronchial blocker with LMA
75326047|NCT03838705|Procedure|hypoxia|It was accepted that hypoxia developed in patients with SpO2< 92 or falling over 20% compared to preoperative values.
75326048|NCT03838705|Procedure|normooxy|It was accepted that patients with SpO2 between 100-92 mmHg
75326049|NCT03213613|Behavioral|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
75326050|NCT03213613|Behavioral|Active Control|Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move an object to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
75919723|NCT02106273|Device|LMA-ProsealTM|
75919724|NCT03414476|Other|Hair follicles sampling|The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath
75919725|NCT04893616|Other|Integration of vaccination services into delivery services|The purpose of the work is to integrate readily available birth dose vaccinations (Oral Polio and the Tuberculosis vaccine) currently given in a separate clinic into the maternity delivery services through improved training, checklist, and job aides.
75919726|NCT03396146|Other|12 ml total blood tubes volume|12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
75919727|NCT03396146|Other|Fecal sample|Fecal sample at inclusion
75919728|NCT03414320|Other|Gathering data|Gathering data about sleep, heart rate, carbohydrate intake, insulin pump, continuous glucose sensor, meals.
75919729|NCT05614414|Procedure|tracheal intubation by Videolaryngoscope|The investigators performed laryngoscopy using a McGrath video-laryngoscope with a number 4 blade.
75919730|NCT05614414|Procedure|tracheal intubation by direct laryngoscope|The investigators performed laryngoscopy using either a Macintosh laryngoscope using a number 4 blade.
75919731|NCT04866862|Drug|Combination of Fruquintinib and Camrelizumab|Fruquintinib 5mg d1-21+Camrelizumab 200 mg d1
75919732|NCT04855942|Device|Focused Extracorporeal Shock Wave Therapy (ESWT)|2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
75919733|NCT04855942|Device|physiotherapy|therapeutic ultrasound, 12 times in 3 weeks
75919734|NCT03414164|Dietary Supplement|procyanidine|natural antioxidants
75919735|NCT05613478|Drug|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
75919736|NCT05613478|Drug|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
75468470|NCT05595551|Behavioral|"The intervention Aan Tafel in 1, 2, 3 euro"|"The participants in this group are clients of Colruyt who are subscribed to the program Aan Tafel in 1 2 3 euro. They will receive two-weekly recipe booklets with 6 balanced and child-friendly recipes in each booklet. They are guaranteed a fixed price for each recipe, that will be given at the checkout counter, based on their loyalty card."
75326051|NCT03213613|Behavioral|Low-dose Adaptive Attention Training|Participants in the low-dose training group will play a reduced number of sessions as the Adaptive Attention Training group. Specifically, they will train for two 30-minute sessions at the start and middle of a six-week period. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
75468471|NCT05593770|Drug|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
75633365|NCT02747589|Procedure|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
75633366|NCT02603497|Drug|ASP015K|oral
75633367|NCT04250961|Other|postoperative early shower|The shower group showered in 48-72 hours after median sternotomy with tap water.
75919737|NCT05613478|Procedure|Postoperative TACE treatment|TACE treatment after radical surgery
75919738|NCT05613478|Procedure|Radical surgery|Radical surgery
75919739|NCT05613478|Procedure|Preoperative TACE treatment|TACE treatment before preoperative camrelizumab combined with apatinib mesylate
75919740|NCT04412018|Drug|Icosapent ethyl|Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
75919741|NCT04426474|Drug|LY3502970|Administered orally.
75919742|NCT04426474|Drug|Placebo|Administered orally.
75919743|NCT03406988|Procedure|Autologous fat grafting|Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU
76077232|NCT03562455|Other|VRSim 3.0|VRSim 3.0 is a virtual reality training module.
75919744|NCT03406988|Procedure|Sham procedure|Local injection of 0.5ml saline solution after a simulated liposuction procedure.
75919745|NCT03297424|Drug|PLX2853|tablets
75919746|NCT03406832|Drug|Nitroprusside Sodium|Intracoronary infusion 50~100μg each time (repeated)
75919747|NCT03406832|Drug|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
75919748|NCT03406832|Drug|Heparinized saline|Intracoronary infusion 2ml for single time
76077233|NCT03562455|Behavioral|In-Person Wheelchair Training|A therapist will be used to train power wheelchair users.
75326052|NCT03838315|Other|Neural Mobilization with Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints. Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization. Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.~•Post isometric relaxation technique"
75326053|NCT03838315|Other|Neural Mobilization without Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack~Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute."
75326054|NCT02737072|Drug|LY2510924|Administered SQ
75919749|NCT04836442|Other|Alcohol-PTSD-PFI (AP-PFI)|Integrated computer-based personalized feedback intervention to specifically target anxiety sensitivity in the context of hazardous drinking and PTSD symptoms. The AP-PFI will focus on feedback about alcohol behavior in the context of PTSD symptoms, AS, and coping-oriented alcohol use.
75784098|NCT01180322|Drug|Etoposide|"Induction therapy:~Arm A, C, D:~100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.~Arm B:~100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 6+8."
75919750|NCT04836442|Other|Active Comparison Condition (C-PFI)|Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
75919751|NCT03414008|Drug|BI 1291583|Single dose
75919752|NCT03414008|Drug|Matching placebo: Tartaric acid|Single dose
75919753|NCT04960306|Biological|Fecal filtrate transplantation|"Patients will receive 5-8 encapsulated lyophilized fecal filtrate transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
75919754|NCT04960306|Biological|Conventional fecal microbiota transplantation|"Patients will receive 5-8 encapsulated lyophilized conventional fecal microbiota transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
75919755|NCT03406442|Procedure|Transpterygoid approaches|All patients will be operated by transpterygoid approaches which is classified into 5 major types.Type A involves thinning of the pterygoid process to access to Pterygopalatine fossa. Type B involves the removal of the medial and anterior aspect of the base of the pterygoid process to access the lateral recess of sphenoid sinus. Type C involves removing the base of the pterygoid plates to reach the petrous apex, Meckel's cave, or cavernous sinus. Type D requires removal of the pterygoid plates to access the infratemporal fossa. Type E requires the removal of the medial pterygoid plate or the entire pterygoid process, and the medial third of the Eustachian tube to acessof the lateral nasopharynx
75919756|NCT03406052|Behavioral|Smartphone-Assisted MB-CBT|Experimental subjects will receive a mindfulness-based CBT online software program workbook (in collaboration with Nex J Systems, Inc.) accessible online. Exposure to and interaction with the online workbook is combined with health coaching (duration of 24 total hours) primarily delivered in phone and software interactions. In addition, each participant will be given a Fitbit-HR Charge, a wearable bracelet that assesses physical steps and 24 hour heart rate in 5 second (averaged) durations (with related access to software that permits daily tracking).
75919757|NCT03405974|Drug|Aspirin|Aspirin (acetylsalicylic acid)
75919758|NCT03405974|Drug|Placebo|Placebo
75326055|NCT02737072|Drug|Durvalumab|Administered IV
75919759|NCT04802668|Device|Patients were ventilated with assist-control ventilation（A/C） mode at different tidal volume|Ventilation mode was set to assist-control volume ventilation with different tidal volume, respiratory frequency 15 times/min, PEEP 5 centimeter water column.
76077234|NCT04359082|Dietary Supplement|CocoaVia supplement|CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine
76077235|NCT04359082|Other|Placebo Pill|Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
76077236|NCT04359316|Drug|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
75326056|NCT02834065|Device|Cardiopulmonary bypass machine|Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
75326057|NCT05446558|Procedure|Intracorporeal anastomosis|"Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.~Device:~Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis."
75919760|NCT04802668|Behavioral|spontaneous breathing and no spontaneous breathing|Data were recorded when patients had and did not have spontaneous breathing
76077237|NCT04359316|Drug|Azithromycin|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
76077238|NCT03762135|Other|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
76077239|NCT03762135|Other|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
76077240|NCT00939796|Device|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
76077241|NCT00939874|Drug|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
76077242|NCT04359160|Device|Orthense, Orthense, Digikare Inc. Blagnac, France|Mobile-app follow-up care, with questions and score
75326058|NCT05446558|Procedure|Extracorporeal anastomosis|"A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.~Device:~Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis."
75468472|NCT05593770|Drug|Placebo|Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
75633368|NCT04518891|Behavioral|Cognitive Functional Therapy (CFT)|Cognitive functional therapy (CFT) is an intervention that deals with potentially modifiable multidimensional aspects of pain (e.g. provocative cognitive, movement and lifestyle behaviours). Treatment with CFT will be individualised, the physiotherapist will listen to the complete patient pain history and the intervention will be focused on individual needs. A detailed examination will be crucial in identifying the modifiable multidimensional mediators of pain and disability (provocative cognitive, pain, movement and lifestyle behaviors) of each participant.
75633369|NCT04518891|Device|Sham intervention|Due to the impossibility of applying placebo exercise, the control intervention in this study will be based on successful reports of placebo intervention in patients with chronic low back pain in the literature (Placebo photobiomodulation + neutral talking control)
75633370|NCT02840487|Biological|VRC-ZKADNA085-00-VP|VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
75633371|NCT00915265|Other|Multilobed catheter (group CPA)|- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia
75633372|NCT00915265|Other|Multilobed catheter (group EA)|EA group : thoracic epidural infusion of 0.2 % ropivacaine
75633373|NCT02843217|Behavioral|Lifestyle, screening|
75633374|NCT02840331|Drug|St. John's Wort|Single oral doses (900 milligram) 2-4 hours before laparoscopy
75633375|NCT02840331|Device|Photodynamic diagnostic and therapy|Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
75633376|NCT02840409|Drug|Vinblastine|
75633377|NCT02840409|Drug|Bevacizumab|
75633378|NCT02839941|Drug|Iguratimod|Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
75633379|NCT02839941|Drug|Mycophenolate mofetil|All subjects will receive mycophenolate mofetil for consecutive 52 weeks
75633380|NCT02839941|Drug|Tacrolimus|All subjects will receive tacrolimus for consecutive 52 weeks
75633381|NCT02839941|Drug|Glucocorticoids|All subjects will receive glucocorticoids for consecutive 52 weeks
75326059|NCT03213379|Device|Actimetry measures|The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
75326060|NCT05446480|Drug|Desloratadine|Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
75326061|NCT05446480|Drug|Placebo|Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.
75326062|NCT05446480|Other|No Intervention|No pill ingestion during the trial - to discern the presence of a placebo effect from baseline inflammatory response
75326063|NCT03213145|Drug|intraconazole|Subjects will receive itraconazole once daily from Day 5 through Day18
75326064|NCT03213145|Drug|Rifampin|Subjects will receive rifampin once daily from Day 5 through Day 16
75326065|NCT03213145|Drug|EDP 305|Subjects will receive EDP 305 once daily on Day 1 and Day 14
75326066|NCT02722564|Behavioral|self estimation of breath alcohol content|
75326067|NCT02722564|Device|breath alcohol content as measured by Alco Sensor IV device|
75633382|NCT02842983|Drug|Esmolol|conventional management plus esmolol infusion
75633383|NCT02839785|Drug|Ibuprofen|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
75633384|NCT02839785|Drug|Placebo|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
75326068|NCT02722564|Other|drink a beer|drink a beer, repeat until breath alcohol content 0.1
75326069|NCT05446246|Procedure|Bariatric surgery|Sleeve gastrectomy
75326070|NCT02598817|Other|Standard Infant Formula|Standard Infant Formula containing High Sn-2
75326071|NCT05446090|Diagnostic Test|Spirometry including peak flow|Spirometry including peak flow to assess the degree of airway obstruction. Spirometry will be conducted according to a study SOP. The Global Lung Function (GLI) 2012 equations will be used. Reversibility testing will not be routinely performed. Thus, asthma medications will not normally be withheld for study visits and patients should take their inhalers as usual. The same type of device will be used at each visit.
75468473|NCT05576350|Behavioral|Smartphone Based Alcohol Monitoring (SAM)|Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.
75633385|NCT02843295|Other|blood samples|
75633386|NCT02843061|Drug|Rituximab|
75633387|NCT02843061|Biological|NK immunotherapy|Each time 10 billion cells, 4 times in all,i.v.
75633388|NCT02838147|Device|FreeStyle sensors.|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
75633389|NCT02838147|Device|Glucometer|Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value
75633390|NCT02839473|Device|Castalie water spray|
75633391|NCT02839473|Device|Hydrogel Hydrosorb®|
75784099|NCT01180322|Drug|Azacitidine|"Induction therapy:~Arm B and C:~100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Arm D:~100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Maintenance therapy:~Arm B, C, D:~50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)"
76077243|NCT04359160|Other|Questionnaire|Paper questionnaire follow-up, with questions and score
75326072|NCT05446090|Diagnostic Test|Fractional Exhaled Nitric Oxide (FeNO)|Fractional Exhaled Nitric Oxide (FeNO) to assess the degree of airway inflammation. FeNO will be measured using a standard device (NIOXX Vero®) in accordance with the manufacturer's guidelines. The same type of device will be used at each visit. FeNO should be performed prior to any other respiratory assessment if possible.
75326073|NCT05446090|Diagnostic Test|Forced Oscillation Technique (FOT)|FOT is a non-invasive method that evaluates resistance and reactance in the respiratory system during tidal breathing. It should be performed after FeNO, but prior to Spirometry and will be conducted according to a study SOP.
75468474|NCT05576350|Behavioral|Tracking and Reducing Alcohol Consumption (TRAC)|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage drinking. It requires four 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the four sessions of intervention content, participants will complete smartphone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
75919761|NCT03404882|Behavioral|Supportive/reminder text messaging plus peer support|Regular supportive/reminder text message will be delivered to patients who will also receive face to face and interactive text message support from peer support workers
76077244|NCT03557385|Drug|Iopamidol|"aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~Rate of 4 mL/sec, volume of 10 cc (left coronary system)~Rate of 3 mL/sec, volume of 6 cc (right coronary system)."
75468475|NCT05576350|Behavioral|TRAC-ER|Ecological momentary interventions (EMI) use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use.
76077245|NCT03557385|Drug|adenosine|FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
76077246|NCT03557385|Device|Navvus® Catheter|the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
75633392|NCT02613741|Other|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
75633393|NCT02608203|Drug|[68Ga]-DOTANOC PET/CT|
75633394|NCT02839239|Dietary Supplement|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
75633395|NCT02839239|Dietary Supplement|Drops with vitamin D3|Oil suspension with vitamin D3
75326074|NCT05446090|Procedure|Sputum Induction|Sputum Induction for the assessment of airway inflammation and microbiology. Sputum induction will be performed according to an SOP, which includes measures to protect the safety of participants. These consist of pre-treatment with Salbutamol, a short acting bronchodilator, stipulated levels of lung function in order to perform the test and stopping criteria. If the participant is unable to undergo the procedure, due to safety reasons, they will be asked to produce a spontaneous sputum sample. Sputum samples will be collected for a differential cell count, bacterial culture and sensitivity and storage for future research. Procedures for sampling and processing will be detailed in a study SOP.
75468476|NCT05566639|Biological|mRNA-1010|Sterile liquid for injection
75633396|NCT02837835|Drug|ceftazidime|20 mg/kg of body weight followed by 60 mg/kg/day
75633397|NCT02837835|Drug|ceftazidime|20 mg/kg over 30 min every 8 h
75633398|NCT02839161|Biological|Na-GST-1/Alhydrogel|
75633399|NCT02839161|Biological|Na-APR-1 (M74)/Alhydrogel|
75633400|NCT02839161|Biological|Hepatitis B Vaccine|
75633401|NCT02837991|Drug|CDX-014|
75919762|NCT03404882|Behavioral|Supportive/reminder text messaging|Regular supportive/reminder text message will be delivered to patients who will NOT receive any face to face or interactive text message support from peer support workers
75919763|NCT03404882|Behavioral|Peer support only|face to face support from peer support workers but no interactive or daily supportive/reminder text messages
75633402|NCT00925002|Drug|Tafamidis|20 mg oral Fx-1006A daily
75633403|NCT02842905|Other|Fitting Audiologist completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist
75919764|NCT03116074|Behavioral|Interactive Digital Health Tools|Discharge checklist, discharge video, safety dashboard enhanced with discharge preparation indicator, secure patient-provider messaging, condition-specific educational videos
75919765|NCT03035422|Drug|Sequential Packaging (SET)|"Sequential chemotherapy:~Thiotepa 5 mg / kg / day for 1 day (D-13)~Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)~Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)~Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)~Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)~Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)"
75919766|NCT03035422|Drug|Transfusion graft|Graft of peripheral stem cells is preferred at D0
76077247|NCT03557385|Device|CVi® Contrast Delivery System|The CVi® Contrast Delivery System will be used to deliver the contrast medium
76077248|NCT03528213|Drug|Sodium Lactate light dose|bolus 2.5ml/kg then 0.25ml/kg/h
76077249|NCT03528213|Drug|Sodium Lactate high dose|bolus 2.5ml/kg then 0.5ml/kg/h
76077250|NCT03528213|Drug|Normal saline|normal saline at physician discretion
76077251|NCT05620030|Other|Univentricular Heart|Prevention of complications when discovered
76077252|NCT03758001|Drug|IBI101|0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
76077253|NCT03758001|Drug|IBI101|1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
76077254|NCT03758001|Drug|Sintilimab|200mg iv infusion day 1 of every 21 days
75919767|NCT03035422|Drug|Prevention of GVHD|"Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5~Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)~Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)"
76077255|NCT05346861|Drug|Trastuzumab plus chemotherapy|Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
76077256|NCT05346861|Drug|Trastuzumab in combination with pyrotinib plus chemotherapy|Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
76077257|NCT04358614|Drug|Baricitinib 4 MG Oral Tablet|Baricitinib+antiviral therapy administration for 2 weeks
75919768|NCT03035422|Drug|Care supports|According to the protocols of each center
75919769|NCT03035422|Drug|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II"
76077258|NCT01670409|Radiation|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
75326075|NCT05446090|Diagnostic Test|Bloods|Blood will be collected for laboratory analysis, including Vitamin D, Haematology, WCC differential, C-Reactive protein.
75326076|NCT05446090|Diagnostic Test|Nasal lavage|Nasal lavage samples will be taken at the baseline (attack) visit. Samples will be obtained by injecting 5ml of sterile normal saline into the participant's nostrils via a nasal adaptor and then immediately aspirated. These will be placed in a sterile container and transported to the laboratory for viral identification. This procedure will be detailed in a study SOP.
75468477|NCT05566639|Biological|Licensed quadrivalent inactivated seasonal influenza vaccine|Sterile suspension for injection.
75468478|NCT05555017|Procedure|PSMA-radioguided surgery|Approximately 15-24 hours prior to surgery, 400-600 Megabecquerel (MBq) of 99mTc-PSMA-I&S will be intravenously administered to the patient at the Nuclear Medicine department. Following this injection patients will be allowed to return home, and then present for their 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery the next day.
75468479|NCT05555017|Drug|ADT|Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.
75468480|NCT05540275|Drug|Tislelizumab plus Bevacizumab|200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks
75468481|NCT05539391|Other|Data patient|Medical History and characteristic of patient
75468482|NCT05539391|Other|Physical examination|Arterial pressure, arterial oxygen saturation, heart rate
75919770|NCT04337060|Procedure|Single-injection ultrasound-guided bilateral erector spinae plane (ESP) block-Sham|"With the patient in the sitting position, 20 ml normal saline will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: after anesthesia induction, paracetamol 1 gr intravenous (IV)+ tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV morphine patient-controlled analgesia (PCA) of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
76077259|NCT01670409|Drug|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
75468483|NCT05539391|Procedure|Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB|Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.
76077260|NCT05619562|Diagnostic Test|Device for CTC/DTC detection|The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.
76077261|NCT04761705|Drug|JV-GL1|Experimental Treatment
76077262|NCT04761705|Drug|Latanoprost 0.005% Ophthalmic Solution|Active Control
76077263|NCT04358692|Device|Aixplorer Mach30|To measure myocardial stiffness by ShearWave elastography on not beating heart
76077264|NCT04403217|Other|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
76077265|NCT04358926|Device|Hyperbaric oxygen therapy|8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
75326077|NCT05446090|Diagnostic Test|Throat swab|A throat swab will be taken at the baseline (attack) visit for viral identification.
75326078|NCT05446090|Diagnostic Test|Nasal Brush.|Nasal brushings samples may be taken at baseline (attack) and at second visits for RNA and DNA extraction. This will be optional and specific consent from participants will be sought. Procedures for sampling and processing will be detailed in a study SOP.
75326079|NCT05446090|Diagnostic Test|Nasal absorption|Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.
75468484|NCT05539391|Procedure|Rapid sequence intubation (RSI) : Recommendations for emergency intubation|Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
75784100|NCT01180322|Drug|Lenograstim|"Consolidation therapy:~subcutaneously daily beginning on day 10 until neutrophil count > 0.5 x 109/l."
75784101|NCT01287494|Drug|Sertraline|dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
75784102|NCT03858218|Other|questionnaires set|questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)
76077266|NCT04358770|Drug|Clocortolone Pivalate|Cream, 0.1%
75326080|NCT05446090|Other|Medical History, Demographic, and Concomitant Medications|Medical history will include clinically significant diseases and prior surgeries and smoking history. A specific respiratory history will also be recorded. Demographic data will include age, sex and self- reported race/ethnicity. Medication use will also be collected.
75326081|NCT05446090|Other|Sino-nasal Outcome Test|The incidence of upper airway symptoms will be assessed using Sino-nasal Outcome Test (SNOT).
75326082|NCT05446090|Other|Gastroesophageal Reflux Disease Questionnaire|The incidence of Gastroesophageal Reflux Disease will be assessed using GERDQ questionnaire.
75326083|NCT05446090|Other|Pittsburgh Vocal Cord Dysfunction Index|The incidence of vocal cord dysfunction will be assessed using Pittsburgh Vocal Cord Dysfunction (VCD) Index
75326084|NCT05446090|Other|Nijmegen Questionnaire.|The incidence of dysfunctional breathing will be assessed using Nijmegen dysfunctional questionnaire.
75326085|NCT05446090|Other|Hospital Anxiety and Depression Scale|The incidence of anxiety and depression will be assessed using Hospital Anxiety and Depression Scale (HADS).
75326086|NCT05446090|Other|Compliance and adherence|In order to assess adherence as a factor in exacerbations, a participant's beliefs and attitudes towards medicines will be explored using the Medicines Adherence Report Scale (MARS) questionnaire. Non-intentional non-compliance with usual treatment will be assessed by checking inhaler technique; poor inhaler technique will be reported to the participant's clinical team. Also, GP records will be reviewed for information on medications prescribed in the last 12 months.
75326087|NCT05446090|Other|Acute Asthma Quality of Life Questionnaire|The impact of acute asthma on quality of life will be assessed using Acute Asthma Quality of Life Questionnaire at baseline and follow up.
75326088|NCT02547883|Drug|Cessation of statin|The intervention evaluated is the cessation of statin
75326089|NCT05445700|Device|Patient-controlled analgesia pump (PCA)|Each patient will receive a PCA pump with intravenous (i.v.) morphine.
75326090|NCT04381975|Behavioral|Move in Mind Program|Each of the six Move in Mind sessions will take place once a week for approximately 1.5 hours, with 12-17 individuals participating per class. The material and exercises taught will include physical floor exercises, breathing exercises, as well as awareness training.
75326091|NCT04381975|Behavioral|6 Week Waitlist Control|The waitlist control group will receive the Move in Mind program after 6 weeks.
75326092|NCT05445622|Other|learning spinal mobilization with a force sensor|Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
75326093|NCT05312203|Other|the App|The App provides content for mobile-based stress relief that can be used on most Android and iOS-based mobile devices. Content for stress relief consists of three modules; meditation, cognitive approach, and relaxation sounds. Additionally, the App includes the module for objective stress monitoring. The APP was originally designed and developed in Korean, but English, Chinese, and Japanese versions are also available. For use in the treatment environment, the manufacturer also provides a service that allows therapists to check their patients' application usage and their stress level measured by the stress monitoring module.
75633404|NCT02842905|Other|Participant's Physician completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
75633405|NCT02839395|Other|No intervention- base line|the subject will sited in a dim light room. No screen light illumination.
75633406|NCT02839395|Other|Acute|The subject will be sited in front of computer screen light illumination for 2 hours.
75633407|NCT02839395|Other|Chronic|The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
75633408|NCT02842671|Other|Assigned Ambassador|If assigned to the intervention group, participants will be contacted by the assigned medical student ambassador at least 1 day prior to the procedure. A brief discussion will take place to review the child's history and survey results. The family will be met by the Ambassador at the hospital and stay with the family until the patient is in the post anesthesia recovery unit. The ambassador is expected to make accommodations for the child as determined by the accommodations survey results. The family will be required to allow the Ambassador to stay through check-in and the procedure.
75633409|NCT04206033|Other|Observational study|Observational study
75326094|NCT05445388|Device|Aurisvue|OCT imaging of the middle ear
75326095|NCT03213301|Drug|Lurbinectedin|3.2 mg/m2 i.v. every 3 weeks
75326096|NCT05445154|Drug|SKLB1028 Dose Escalation|Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin
75326097|NCT04381819|Diagnostic Test|SARS-CoV-2 PCR|SARS-CoV-2 E gene
75633410|NCT04249713|Drug|Brodalumab|Interleukin 17 Receptor A Antagonist
75633411|NCT04249869|Drug|VGH-AD1|VGH-AD1 includes Yi-gan-san 3.0g, Huan-shao-dan 1.0g, Danshen(Radix et Rhizoma Salviae Miltiorrhizae) 0.75g, Tian-ma(Rhizoma Gastrodiae) 0.75g, Gou-teng(Ramulus Uncariae Cum Uneis) 0.375g, and Ba-ji-tian(Radix Morindae Officinalis) 0.375g, two times per day, each serving a small packet of 7.5 grams of concentrated granules.
75633412|NCT00610506|Drug|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
75326098|NCT05444998|Drug|Intuzumab, pyrrolidone, nab-paclitaxel|"Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~The patient's postoperative adjuvant therapy was 4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy.~Multiple drug interruptions for adverse events were allowed throughout."
75326099|NCT05444842|Other|insulin iontophoresis|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent). after cleaning the wound the insulin ions and oleic acid will be injected into the electrode of iontophoresis device (Phoresor_ IIAuto, ModelPM850, IOMED) then The device was set to the required dose of 40 mA-min, and the current intensity was gradually increased based on the subject's tolerance (ranging from 1 to 4 mA). The device computed the required time for the selected dose automatically.
75468485|NCT05535257|Device|Sequential Compression Device|Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary. The device will inflate and deflate.
75326100|NCT05444842|Other|topical insulin|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of the wound, patients will get ten units (0.1 mL) of insulin crystal in solution with 1mL saline (0.9 percent). An insulin syringe needle was used to spray the solution twice daily on the wound area.
75326101|NCT05444842|Other|conventional treatment|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of wound 1mL 0.9 percent saline was given.
75919771|NCT04337060|Procedure|Single-injection ultrasound-guided bilateral erector spinae plane block-Lidocaine/Bupivacaine|"With the patient in the sitting position, 10 ml 1% lidocaine + 10 ml 0.5% bupivacaine will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: After anesthesia induction, paracetamol 1 gr IV + tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV PCA of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
75919772|NCT04337060|Other|Pain follow-up and monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 15th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours with two different conditions which are at rest and while couching.If NRS score becomes ≥4 Dexketoprofen 50 mg will be administered (max 4 times).
75919773|NCT05611996|Behavioral|Peers plus|Peer support intervention in which peer mentors who have experiential knowledge of depression deliver social support through video chats and texting to older adults with depression.
75919774|NCT03413930|Procedure|Transanal total mesorectal excision|Patients undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
75919775|NCT03413930|Procedure|Laparoscopic total mesorectal excision|Patients undergo Laparoscopic total mesorectal excision.
75919776|NCT03413852|Device|SQUID non-adhesive liquid embolic agent|AVM embolization using SQUID non-adhesive liquid embolic agent
76077267|NCT04402983|Other|Physiotherapy|Program content Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
75326102|NCT04381741|Biological|CD19-7×19 CAR-T plus PD1 monoclonal antibody|Three different doses of CD19-7×19 CAR-T (1×106/kg、2×106/kg、3×106/kg) plus 200mg Tislelizumab every 3 weeks for 6 times
75784103|NCT02524964|Drug|sodium tanshinone IIA sulfonate|eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)
75326103|NCT03838003|Procedure|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
75326104|NCT05444686|Diagnostic Test|99mTc-FAPI|inject the tracer to subjects and perform SPECT/CT scans
75784104|NCT02524964|Other|control|equivalent volume of sodium chloride solution
75326105|NCT05444452|Device|Implanatation of Genoss DES sirolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Genoss stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
75326106|NCT05444452|Device|Implanatation of Xience DES everolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Xience stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
76077268|NCT04564300|Procedure|Training|Both groups will perform a standardized training protocol
76077269|NCT04525144|Drug|Tebonin Forte|Dietary supplement: Gingko biloba EGb 761
76077270|NCT05619484|Device|Smart AFO|Diagnostic ankle-foot orthosis with AFO stiffness and range of motion settings adjusted using a mobile application
76077271|NCT05618470|Drug|Wumeiwan Jiawei Fang|orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.
76077272|NCT05618470|Drug|botulinum toxin A|Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
76077273|NCT04358536|Device|CovX|Convolutional neural network for classification of COVID-19 from chest X-rays
75326107|NCT04380571|Device|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
75326108|NCT04380571|Device|Electrical stimulation|A positive auto adhesive electrode was applied above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Both electrodes were linked to an electrical stimulation device ( EMS physio Ltd, OX129 F, England) with a low frequency current (10 Hz), and adjustable intensity.
75468486|NCT05534750|Drug|Tedizolid arm (SIVEXTRO®)|Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
75784105|NCT01289756|Drug|Clomiphene|clomiphene once 100 mg oral
75784106|NCT01289756|Drug|clomiphene and paroxetine|clomiphene 100mg and paroxetine 3x40mg
75784107|NCT01289756|Drug|clomiphene and clarithromycin|clomiphene 100mg and clarithromycin 9x500mg
75784108|NCT01181882|Dietary Supplement|Fish Oil and Aspirin|4 grams of fish oil each day for 28 days and 81 mg aspirin
76077274|NCT04358146|Other|Experimental Infant formula|Exclusive formula feeding with the new infant formula thickened with fibers
75784109|NCT01181960|Drug|Risperidone long acting injectable - New Starts|Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
75784110|NCT01181960|Drug|Risperidone long acting injectable - Continuous Users|Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
75326109|NCT04380571|Other|Traditional treatment|Conventional treatment through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
75919777|NCT05614336|Biological|Blood sample|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
75468487|NCT05534750|Drug|Linezolid arm (ZYVOXID®)|Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
75326110|NCT05444374|Drug|Serplulimab|Recombinant anti-PD-1 humanized monoclonal antibody injection
75326111|NCT05444374|Drug|Bevacizumab|Humanized anti-VEGF monoclonal antibody injection
75326112|NCT05312359|Device|Transcranial alternating current stimulation-true stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.
75326113|NCT05312359|Device|Transcranial alternating current stimulation-sham stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.
75919778|NCT04267640|Biological|AMG0001|AMG0001 is a DNA Plasmid encoding hepatocyte growth factor (HGF) administered intramuscularly
75919779|NCT04267640|Biological|Placebo|Matching placebo
75919780|NCT04447274|Drug|Camrelizumab and Apatinib|Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles
75919781|NCT02977156|Biological|Pexa-Vec|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
75919782|NCT02977156|Drug|Ipilimumab|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
75919783|NCT03413774|Procedure|vaginal swab|high vaginal and Endocrvical swabs for bacterial, protozoal and chlamydial infection- examined by PCR
76077275|NCT04358146|Other|Infant formula thickened with locust bean gum|Exclusive formula feeding with the formula thickened with locust bean
76077276|NCT05620498|Drug|tislelizumab+lenvatinib+GMOX|tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2
76077277|NCT05620498|Drug|tislelizumab+GEMOX|tislelizumab+GEMOX
75326114|NCT05312281|Device|Device : Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo|Wear for 6 weeks post-surgery
75326115|NCT05444218|Procedure|Open flap debridement|After local anesthesia (2% lidocaine with1:100,000 epinephrine), intrasulcular incisions will be performed to create a horizontal flap extending beyond the adjacent teeth and/or implants. Buccal and lingual full-thickness flaps will be dissected, and granulation tissue will be removed to expose the implant threads and bone defect. The flap will be repositioned in its original position and stabilized with interrupted sutures, which will be removed after 10 days.
75468488|NCT05534750|Drug|Standard quadruple therapy arm|"Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms."
75468489|NCT05526924|Radiation|Chemoradiation|A combination of chemotherapy and radiation given at the same time to treat cancer.
75468490|NCT05526924|Drug|Pamiparib|An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).
75468491|NCT05526924|Drug|Hydroxyurea|A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.
75468492|NCT05526924|Drug|Fluorouracil (5FU)|A chemotherapy drug used to treat different types of cancer.
75784111|NCT01181960|Drug|Paliperidone Palmitate -New and Continuous Users|Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
75784112|NCT01181960|Drug|Other Antipsychotics - New Starts|Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
75784113|NCT03858374|Device|transferred by air-suspending mattress|Put mattress in advance on the bed. When patients need to be transferred from bed to bed, fill the mattress with gas and keep it inflated, then pull the mattress .
75784114|NCT03858374|Device|transferred by slide board|When patients need to be transferred from bed to bed, insert slide board under patient, then pull the slide board.
75784115|NCT03858374|Device|transferred by bedsheet|When patients need to be transferred from bed to bed, just lift the bedsheet.
75784116|NCT01180556|Dietary Supplement|Probiotics|Daily oral supplementation for four weeks
75784117|NCT01180556|Dietary Supplement|Placebo|Placebo administration
75919784|NCT05168072|Device|m-Health app|M-Health app is used to set weight loss targets and record body weights online. Participants learn the calories they consumed by using the m-Health APP and follow the APP for physical exercise
75919785|NCT05168072|Other|conventional outpatient obesity management|Diet and exercise guidance
75919786|NCT02419846|Other|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
76077278|NCT01670565|Drug|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
76077279|NCT01670565|Drug|Mycophenolate Mofetil|Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at <2,000 mg/day for <3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
75468493|NCT05526924|Drug|Tislelizumab|An anti-cancer drug.
75468494|NCT05526300|Device|Intelligent Hypertension Management System|The intelligent hypertension management system is used to remotely detect the blood pressure of hypertensive patients
75468495|NCT05526300|Other|The standard care|The standard care
75468496|NCT05522244|Diagnostic Test|extended CTA|Extending the standard CTA 3 cm below the carina.
75633413|NCT04250649|Procedure|subcutaneous tissue disinfection|"Skin and subcutaneous incision (up to the muscular fascia) with superficial blade scalpel, disinfection of the subcutaneous tissue with 3cc of Betadine solution, placement of the retractors, dissection and development of the delto-pectoral interval with deep blade scalpel.~When the joint is opened, bacteriological smears are taken from 5 sites in the two groups. 1) exposed subcutaneous tissue, 2) surgeon's gloves (distal end of fingers), 3) superficial blade, 4) deep blade, 5) retractors.~The rest of the shoulder surgery procedure does not differ from what is commonly performed.~The samples are sent to bacteriology for bacterial culture. Anaerobic research is done specifically for P. acnes. The results are considered negative after 10 days."
75784118|NCT03861884|Diagnostic Test|Cognitive assessments|Cognitive assessment and MRI at 3T and/or 7T
75784119|NCT03858062|Device|Insulin pump therapy (with or without glucose sensor)|Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor
75784120|NCT03858062|Device|Artificial pancreas (Inreda Diabetic)|Bi-hormonal reactive closed loop system without mealtime announcement
75784121|NCT01182038|Device|BirthRite birthing seat|Randomization takes place on admission to the labor ward when the participants are in active labor.Participants in this arm were to sit on the seat for 20 minute periods.After these 20 minutes, the participant should stand and mobilize during two to three contractions, before resuming the birth seat position. If progress of the descent of the fetal head was obvious the participant was not asked to mobilize.
75784122|NCT01180712|Dietary Supplement|Mirtoselect|"Male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days."
75784123|NCT03857438|Drug|Ongoing treatment for bipolar mania|Prescribed by the following doctor during hospitalization and after discharge
75919787|NCT02419846|Procedure|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
75919788|NCT02419846|Other|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
75468497|NCT05517122|Dietary Supplement|Nicotinamide (NAM)|500 mg a day
75468498|NCT05517122|Dietary Supplement|Nicotinamide Riboside (NR)|1000 mg a day
75919789|NCT02419846|Other|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
75919790|NCT02419846|Other|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
75468499|NCT05517122|Dietary Supplement|Nicotinamide Mono Nucleotide (NMN)|1000 mg a day
75468500|NCT05517122|Dietary Supplement|Microcrystalline cellulose|500 mg a day
75919791|NCT02419846|Other|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
75919792|NCT04114292|Drug|Tauroursoursodeoxycholic acid, brand name Tudcabil|Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
75919793|NCT02413138|Drug|Somavaratan (VRS-317)|Long acting recombinant human growth hormone
76077280|NCT01670565|Other|Placebo Infusion|Infusion of normal saline
75468501|NCT05516940|Other||
75468502|NCT05515991|Other|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|"SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.~Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals."
75919794|NCT05167994|Drug|Anlotinib hydrochloride|Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT
75919795|NCT04690426|Biological|PRV-101|Coxsackie Virus B vaccine
75919796|NCT04690426|Other|Placebo|Placebo
76077281|NCT03088215|Device|shock-waves|Application of shock-waves (radial and focused)
76077282|NCT01675479|Device|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
76077283|NCT01678755|Drug|ABT-126|ABT-126 Low Dose
76077284|NCT01678755|Drug|ABT-126|ABT-126 High Dose
76077285|NCT01678755|Drug|Placebo|Placebo
76077286|NCT04358380|Other|Liver injury|LFTs elevation or liver decompensation
76077287|NCT04358302|Behavioral|Pillsy|"The electronic pill bottle cap, Pillsy, and its accompanying software application provides reminders to take a scheduled dosage of medication via bottle cap alerts and smartphone push notifications, text messages, and/or automated phone calls. The Pillsy application records dosing dispense date and time when the user opens the bottle. During the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls).~The electronic pill bottle cap, Pillsy, is a commercially available device marketed to consumers. The electronic pill bottle cap does not capture or store PHI. Quick tips on how to use Pillsy can be found at https://www.pillsy.com/instructions"
76077288|NCT01670799|Drug|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
76077289|NCT02404935|Drug|Cetuximab|
76077290|NCT02404935|Drug|FOLFIRI and cetuximab|
76077291|NCT00943150|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
76077292|NCT00943150|Procedure|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
75468503|NCT05515991|Other|SUPPORT-DIALYSIS Only|SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.
75468504|NCT05515575|Drug|Niraparib|Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
75468505|NCT05501366|Dietary Supplement|Ketone Supplement|Four different exogenous ketone products at two serving sizes or a non-ketogenic placebo (one study product per test day). 1) Monoester of BHB (R)-1,3 butanediol (BHB Mono-ester), 2) diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) 3) diester of AcAc and (R,S)-1,3 butanediol (AcAc Di-ester) & 4) (R) -1,3 butanediol only (BDO). All products will be delivered in 2 different dosages 180mg/kg and 360mg/kg on separate testing days.
75468506|NCT05501366|Behavioral|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
75468507|NCT05501366|Biological|Blood Draw|IV cannula will be inserted at the start of each Test Day, and removed at the end of each Test Day, Blood samples will be collected according to the schedule in Figure 1. Cannula will be flushed with a small volume of saline after each sample to maintain patency. We will draw 504 mL of blood, which is about 2.1 cups throughout the 4-week intervention
75468508|NCT05501366|Other|Breath Reading|Participants will breathe into a commercially available handheld breath acetone analyzer according to the schedule. Participants will wear a fitted face mask attached to a metabolic cart for a 10-minute period every 60 minutes
75468509|NCT05501366|Other|Heart Rate Variability|Participants will wear a Bluetooth heart rate monitor chest strap throughout the test day.
76077293|NCT03511131|Behavioral|Queer Sex Ed|Comprehensive sexual health education program condition (Informational)
76077294|NCT03511131|Behavioral|Keep It Up|Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)
76077295|NCT03511131|Behavioral|Keep It Up-Control|HIV knowledge control condition, attention-matched to KIU (Informational)
76077296|NCT03511131|Behavioral|Young Men's Health Project|Motivational enhancement video interviewing condition (Motivational/behavioral)
76077297|NCT03509025|Drug|Jointstem|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
76077298|NCT04320940|Drug|Phenobarbital Sodium Injection|The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
76077299|NCT03422523|Drug|Atezolizumab|Intravenous drip
75468510|NCT05501366|Other|CGM/CKM|Continuous Ketone Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at ~2- week intervals during the study. The sensor will be removed at the end of the final test day
75468511|NCT05501366|Radiation|DXA|Lean Body Mass will be assessed once via DXA
75468512|NCT05501366|Other|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting <1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
75468513|NCT05496491|Radiation|Neoadjuvant Chemoradiotherapy|5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
75784124|NCT03857438|Diagnostic Test|Audiovisual recording during guided presentation|Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
75784125|NCT03861650|Other|Bone Marrow Aspirate Concentrate|A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow
75784126|NCT03861650|Other|Saline|Physiological saline is added in control group to act as placebo
75784127|NCT03857360|Dietary Supplement|Pentabiocel|Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.
75784128|NCT03857360|Dietary Supplement|Placebo|Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.
75326116|NCT05444218|Other|Er: YAG irradiation|An Er:YAG laser (Lite Touch, Light Instruments, Israel) will be used, with an irradiation energy of 20 mJ, frequency of 20 Hz, output power of 0.4 W, and an energy density of 2.76 J/cm2. An 8 mm long sapphire tip will be used in the respective handpiece and not in contact with the titanium surface, with concomitant water spray irrigation, under air 6 and water spray 6, the irradiation angle will be 90 degrees, at a focal distance of 2 mm, with spot size diameter of 1.3 mm
75468514|NCT05496491|Drug|Adjuvant Chemotherapy|8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)
75468515|NCT05496491|Drug|Consolidation Chemotherapy|CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
75468516|NCT05492266|Device|Expiratory Muscle Strength Training|At visit 1, participants will be block randomized based on PWSS score (3-6 or 7+) to Expiratory Muscle Strength Training (EMST) for 6 to 8 weeks or no exercises. Participants in the EMST-150 group will perform 5 sets of 5 resistive expirations once a day with a 10-15 second rest between each repetition and a 1-2 minute rest between each set of 5 repetitions.
75468517|NCT05492266|Device|Maintenance Training|"At visit 2, participants with improved (decreased) PWSS of 2 or more points, for whom the family and/or surgeon is not currently considering surgical intervention for VPI, will be further randomized to continue maintenance EMST exercises or no exercises for 6 months. Participants in the maintenance group will complete 3-5 sessions exercise sessions each week (rather than daily training), with 2 sets of 5 resistive expirations (rather than 5 sets)"
75468518|NCT05488522|Biological|SBRT + atezolizumab and bevacizumab|"Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT.~Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks.~Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks."
75633414|NCT04914078|Drug|Mepolizumab 100 MG|The patients will treated with subcutaneous Mepolizumab at 100 mg every 30 days. Patients will be recruited among those eligible to Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco) guidelines who will accept to participate to the study. In particular inclusion criteria will be: severe (Step 4 and 5 GINA) asthma with at least blood eosinophilic count above 300 cells/mcl at least once in the previous year and ≥150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. In addition, one of the following conditions will be required: 1) ≥2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.
75633415|NCT02837601|Device|AirSeal® Insufflation System (AIS)|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
75633416|NCT04257708|Diagnostic Test|ultrasound|Transvaginal us to assess the cavity
75633417|NCT02837679|Other|Geriatric Follow up|
75633418|NCT05329974|Other|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
75633419|NCT02837055|Device|VivaSight intubation|patients are intubated with an endotracheal tube with an integrated camera
75633420|NCT02837055|Device|conventional intubation|patients are intubated with a conventional endotracheal tube
75633421|NCT04255758|Other|Cycle Ergometer Exercise|25 minutes, 70% VO2max steady state cycle ergometry exercise
75633422|NCT02837133|Behavioral|integrated yoga program|the program as a one-time session for 3 hours as a component of a Stress Management Education program
75633423|NCT02837289|Other|Therapy taping|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
75633424|NCT02837289|Other|Placebo taping|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
76077300|NCT03422523|Drug|Rituximab|Intravenous drip/or Subcutaneous from cycle 2
75633425|NCT04260828|Drug|Aspirin 100mg|Daily active drug administered orally for 3 months.
75633426|NCT04260828|Other|Placebo|Sugar pill administered orally for 3 months.
75633427|NCT00928746|Device|Ipratropium bromide|
75633428|NCT02834871|Device|Electromyogram|
75633429|NCT02834715|Dietary Supplement|Stevia rebaudiana liquid extract|Sweetener made of liquid stevia self administered daily for 30 days
75326117|NCT05444218|Drug|Metronidazole|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
76077301|NCT03422523|Drug|Gemcitabine 1000 mg|intravenous drip
75326118|NCT05444218|Drug|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
75468519|NCT05480605|Behavioral|Occupational Therapy|Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
75633430|NCT04468815|Drug|BMS-986278 Tablet|Specified dose on specified days
75633431|NCT04468815|Drug|Esomeprazole|Specified dose on specified days
75633432|NCT04468815|Drug|BMS-986278 suspension|Specified dose on specified days
76077302|NCT03422523|Drug|Oxaliplatin 100 MG|intravenous drip
75326119|NCT05444218|Drug|Placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (beginning after open flap debridement).
76077303|NCT02406729|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
76077304|NCT02406729|Other|Placebo|Route:subcutaneous
75468520|NCT05469204|Drug|Midazolam oral solution|2 mg single-dose before and during estradiol treatment.
75468521|NCT05469204|Drug|Digoxin Oral Tablet|0.25 mg single-dose before and during estradiol treatment.
75468522|NCT05469204|Drug|Acetaminophen Oral Tablet|500 mg single-dose before and during estradiol treatment.
75468523|NCT05469204|Drug|Midazolam Injectable Solution|1 mg intravenous single-dose before and during estradiol treatment.
75633433|NCT00610584|Procedure|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
75633434|NCT00610584|Procedure|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
75633435|NCT00610584|Drug|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
75326120|NCT01830361|Drug|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
75326121|NCT05444140|Behavioral|Health coaching|The health coaching programme includes four monthly health coaching sessions for three months.
75919797|NCT05167916|Procedure|Outpatient check cytoscopy|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
76077305|NCT03032536|Drug|AL-3778|AL-3778 tablets or capsules
75326122|NCT01830439|Drug|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
75326123|NCT01830439|Drug|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
75326124|NCT05443828|Other|Breakfast Control Meal|The participants consumed extruded puff with added vitacel (cellulose) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
75468524|NCT05464836|Drug|CB-103|Given by PO
75468525|NCT05464836|Drug|Venetoclax|Given by PO
76077306|NCT03032536|Drug|Entecavir|Entecavir once daily for 14 days
75468526|NCT05456958|Other|MRI Biofeedback|We will use state-of-the-art fMRI and neurofeedback of brain signals in order to teach patients with PTSD to self-regulate pathological brain activity that is associated with their symptoms. Indeed, feedback information is crucial for learning, where rt-fMRI-based neurofeedback makes information about brain activity accessible to our consciousness (Ros et al., 2014; Sitaram et al., 2017). It thus provides a reinforcement signal to induce personalized learning mechanisms, allowing individuals to search for appropriate cognitive strategies to voluntarily control brain activity. The feedback signal will come from activity within either the amygdala or PCC.
76077307|NCT03032536|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
75468527|NCT05456958|Other|Sham-MRI Biofeedback|In the sham-control arm (N=20), individuals will receive fake neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
75468528|NCT05454488|Other|Focal Cryoablation|Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
75468529|NCT05454488|Other|Standard of Care|Participants will receive a prostate biopsy.
75468530|NCT05454488|Other|Quality-of-life Questionnaires|Participants will fill out questionnaires.
75468531|NCT05450731|Other|12-week supervised exercise based cardiac rehabilitation program|12-week exercise-based cardiac rehabilitation intervention on the recurrence of atrial fibrillation (AF) in patients at six- and twelve-months post-ablation procedure.
75468532|NCT05445726|Device|CPM Device|CPM device used in tangent with reference ECG for validation
75468533|NCT05445492|Device|CPM Device|The CPM device and reference device are used simultaneous to validate the CPM device.
75468534|NCT05445206|Device|CardioPulmonary Management Device (CPM)|CPM device is used in tangent with reference capnography device.
75468535|NCT05433025|Device|Cervigard Neck Collar|A device used to treat neck pain caused by forward head posture
75468536|NCT05422235|Other|Routine Medical Treatment|Subjects will continue their routine medical treatment.
75468537|NCT05422235|Other|Aerobic Exercise|Symptom-limited peak heart rates of subjects will be determined using the modified Bruce Protocol. For aerobic training, subject will be carried out on the treadmill according to the results of exercise tests. Initially, 40-60% of the peak heart rate will be trained and progression will be made in subject training programs every 2 weeks. Training will consist of warm-up, main exercise and cool-down periods. Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks. The room temperature will be fixed at 25°C in order to keep the impact of environmental factors at a minimum. In addition, individuals will be asked to come with appropriate shoes and clothes for the training.
75468538|NCT05422235|Other|Aerobic Exercise+ Foot-Related Exercise|In addition to walking training specific to the subject in the aerobic exercise group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
75468539|NCT05396794|Behavioral|Standard weight loss education|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider.
75468540|NCT05396794|Behavioral|Standard weight loss education + Educational Video|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider followed by a 15-minute educational video detailing the benefits of weight loss.
75468541|NCT05392608|Drug|Alpelisib 150 MG Oral Tablet [Piqray]|Alpelisib 300mg once daily (may be reduced to 1dd250 or 1dd200mg in case of toxicity)
75468542|NCT05392608|Drug|Fulvestrant|Fulvestrant 300mg 1x/four weeks
75468543|NCT05373719|Other|No intervention; observational|No intervention; observational
75468544|NCT05369390|Drug|NNC0487-0111 A|Participants will receive NNC0487-0111 A tablet once daily.
75633436|NCT00894543|Drug|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
75633437|NCT00894543|Other|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
75633438|NCT02838849|Dietary Supplement|Fiber|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men), keeping the usual liquid intake
75633439|NCT02838849|Dietary Supplement|Fiber and Water|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men) plus 2 liter of water/day
75468545|NCT05369390|Drug|NNC0487-0111 B|Participants will receive NNC0487-0111 B tablet once daily.
75468546|NCT05369390|Other|Placebo B (NNC0487-0111 B)|Participants will receive placebo matched to NNC0487-0111 B tablet once daily.
75784129|NCT03855410|Behavioral|S4E|The face-to-face version of S4E (i.e., Storytelling for Empowerment) is registered as a best-practice with the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-Based Practices and Programs.The S4E mHealth app was developed in collaboration with youth in Southeast Michigan. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol and drug use, HIV and STIs. We now propose to develop modules focused on tobacco prevention and cessation. S4E aims to increase self-efficacy and communication about health risk behaviors. The face-to-face version of S4E has been shown to prevent and reduce substance use, including cigarette use, as well as increase (1) substance use prevention knowledge, (2) communication about health risk behaviors, and (3) perception of harm and self-efficacy in refusing licit and illicit substances.
75919798|NCT05167916|Diagnostic Test|Urine cytology|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
75919799|NCT01896778|Procedure|Hyperthermia Treatment|Undergo B-WARM
75919800|NCT01896778|Other|Laboratory Biomarker Analysis|Correlative studies
75919801|NCT03413540|Other|Jump|Drop jump from step
75633440|NCT02834325|Procedure|mechanical ventilation|
75633441|NCT04249791|Procedure|Transplantation of the uterus from live donor.|Laparoscopic-robotic hysterectomy for uterine transplantation in live-donor patient.
75633442|NCT04249635|Dietary Supplement|DHA|Women received supplementation of Based on Schizochytrium oil, 100% DHA (DSM) from 14 weeks of pregnancy until delivery.
75919802|NCT01648894|Procedure|Surgery after 11 weeks of delay after chemoradiotherapy.|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
75468547|NCT05369390|Other|Placebo A (NNC0487-0111 A)|Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
75633443|NCT02838771|Other|Water drinking test|Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
75633444|NCT02838771|Other|Dysphagia screening questionnaire|Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
75784130|NCT03855410|Behavioral|Attention-Matched Control Group|Participants in the Attention-Matched Control group will receive a PDF version of the tobacco module material, an enhancement to the usual care they would receive should they not join the study. Participants in this group will also receive usual care. The Clinic's usual care includes standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services.
75784131|NCT01290770|Other|blood sample|blood sample at inclusion and 1 month after inclusion
75468548|NCT05368025|Device|Mobili-T/Noona|Use of two mobile health systems over a period of 6 months
75468549|NCT05360160|Drug|SNDX-5613|Given by PO
75468550|NCT05360160|Drug|Venetoclax|Given by PO
75468551|NCT05360160|Drug|ASTX727|Given by PO
75468552|NCT05356936|Dietary Supplement|Vitamin K2 (MK-7)|Participants will receive Vitamin K2 (MK-7) daily by mouth.
75468553|NCT05356936|Dietary Supplement|Vitamin D3|Participants will receive Vitamin D3 daily by mouth.
75468554|NCT05355051|Drug|Azacytidine|Given by Vein (IV)
75468555|NCT05355051|Drug|Pembrolizumab|Given by Vein (IV)
75468556|NCT05353738|Biological|Blood sample for research of anti-xoprs netralizing anti spike|"The evaluation of the ex vivo efficacy of the Moderna vaccine by the search for anti Spike AcN at 6,24, 40 and 52 or 64 weeks after the second injection of the vaccine.~The effectiveness of vaccination of CANNEMUSS patients will be evaluated by comparing the antibodies anti-S neutralizers from patients in the CANNEMUSS study to those from patients whose sample was carried out before the pandemic (negative control group) and those of patients infected with the omicron virus (positive control group)."
75468557|NCT05353738|Other|Questionnaire|Evaluation of vaccine efficacy in real life by filling out questionnaires
75326125|NCT05443828|Other|Breakfast Test Meal|The participants consumed bread with added arabynoxylans (AX) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
75468558|NCT05339451|Diagnostic Test|Blood biomarkers|Blood biomarkers in plasma and serum.
75468559|NCT05337826|Device|Continuous Glucose Monitor|Participants will enroll in a series of remote educational visits conducted by CDCES to assess readiness and barriers to CGM initiation and utilization, with the goal to sustain use of CGM Technology over time in older populations on complex insulin regimen.
75468560|NCT05329792|Drug|L19IL2/L19TNF|Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks
75326126|NCT05443828|Other|Breakfast Test Meal|The participants consumed extruded puff with added wheat bran as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
75326127|NCT01830517|Drug|Amlodipine, Losartan|
75468561|NCT05322343|Other|Questionnaires|"Participants will complete a series of three questionnaires at the V1 visit (at home, by a trained interviewer):~A general questionnaire, with collection of general health history and exposure data~A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5 visits.~An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety."
75468562|NCT05322343|Other|Fasting blood sampling.|In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.
75468563|NCT05322343|Other|Saliva collection and nasal or nasopharyngeal swab|On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
75326128|NCT04380415|Diagnostic Test|Single lead ambulatory ECG patch|Single lead ambulatory ECG patch worn on the chest
75468564|NCT05322343|Other|Urine samples|During the V2 visit, the nurse will collect urine samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator.
75326129|NCT05443672|Device|Yizhun BUSMS|During the breast scanning, Yizhun BUSMS uses different color box to identify the breast lesion, and the box color indicates the risk grade of the lesion.
75326130|NCT03837457|Drug|Cobomarsen|At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
75633445|NCT02837211|Behavioral|Tapered Low Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period."
75326131|NCT03212833|Diagnostic Test|fasting serum insulin|fasting serum insulin in chronic hepatitis C patients
75326132|NCT05443360|Dietary Supplement|DENSITY™ (Amorphous calcium carbonate, ACC)|"Dosage form: tablet~Dose(s): 1000 mg /tablet, comprising 500 mg amorphous calcium carbonate per tablet (calcium element 200mg)~Dosing schedule: The usual dose for oral use is 2 ACC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
75919803|NCT01648894|Procedure|Surgery after 7 weeks of delay after chemoradiotherapy|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
75919804|NCT04014920|Device|Oxygen group|The control group will receive oxygen (first randomization), HFNO oxygen or standard oxygen (second randomization)
75919805|NCT04014920|Device|NIV Group|The experimental group will receive NIV (first randomization) alternated with HFNO or standard oxygen (second randomization)
75326133|NCT05443360|Dietary Supplement|Crystalized calcium carbonate (CCC)|"Dosage form: tablet~Dose(s): 1000 mg /tablet, comprising 500 mg crystalized calcium carbonate per tablet (calcium element 200mg)~Dosing schedule: The usual dose for oral use is 2 CCC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
75326134|NCT01830751|Other|Restrained Sitting Treatment|Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
75326135|NCT05443282|Diagnostic Test|Prolidase Level|Measurement of venous blood serum level of prolidase enzyme level by ELISA method.
75326136|NCT05443282|Diagnostic Test|Follicle Stimulating Hormone Level|Measurement of venous blood serum level of follicle stimulating hormone level.
75326137|NCT05443282|Diagnostic Test|Estradiol Level|Measurement of venous blood serum level of estradiol hormone level.
75326138|NCT05443282|Diagnostic Test|Proline Level|Measurement of venous blood serum level of proline level.
75326139|NCT05443282|Diagnostic Test|Hydroxyproline Level|Measurement of venous blood serum level of hydroxyproline level.
75326140|NCT05443282|Diagnostic Test|Anti-mullerian Hormone Level|Measurement of venous blood serum level of anti-mullerian hormone level.
75468565|NCT05322343|Other|Hair and a tonenail (or hand nail) sampling|During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope
75633446|NCT02837211|Behavioral|Traditional Low-Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level."
75633447|NCT02837367|Dietary Supplement|Administration of supplements containing methyl-donors|Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)
75784132|NCT01290848|Behavioral|Take TIME Health Campaign|"Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.~Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.~Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children."
75919806|NCT05167604|Drug|Adjuvants, Pharmaceutic|Patients with stage IB-IIA NSCLC after curative surgery were treated with adjuvant chemotherapy. The blood samples of the patients before and after adjuvant chemotherapy will be collected to examine the MRD status
75784133|NCT05668520|Diagnostic Test|Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system|"Consent Paperwork~Nutritional assessment using MNA and MUST questionnaires~24-hour dietary recall assessment Body weight, height, waist circumference, mid upper arm and calf circumference"
75633448|NCT00922272|Drug|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
75633449|NCT00922272|Drug|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
75633450|NCT00853372|Drug|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.
75633451|NCT00853372|Drug|Trebananib|Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
75633452|NCT02836977|Drug|tegafur-uracil|Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
75633453|NCT00913042|Other|sample blood|"Early culture~Bacterial DNA tests in blood"
75633454|NCT00848536|Drug|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
75919807|NCT05611684|Drug|Polyethylene Glycol Losenatide|Treatment 0.2mg QW for 12 weeks
75919808|NCT03413462|Drug|HS-25|HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.
75919809|NCT03413462|Drug|Placebo of HS-25|Placebo HS-25 10mg/tablet, 20mg,once daily,for 12 weeks,and then HS-25 20mg once daily for 40 weeks.
75784134|NCT01184534|Behavioral|Video|5 minute multimedia presentation (video)
75633455|NCT00848536|Drug|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
75633456|NCT00922116|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
75633457|NCT04117282|Other|gait training|training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
75919810|NCT01058512|Drug|NOV-205|"There will be 4 treatment Groups with 10 patients in each group:~Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"
75919811|NCT05167292|Other|Observational study|Routine clinical care was provided to all AKI cases presenting to the TTM Hospital in Samoa. This prospective observational study reviewed incidence, aetiology and outcomes for these cases.
75919812|NCT05167214|Device|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain
75919813|NCT01014598|Drug|Cisplatin|Given intra-arterially via isolated lung suffusion
75919814|NCT01014598|Other|Pharmacological Study|Correlative studies
76077308|NCT03032770|Device|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
75326141|NCT05443282|Diagnostic Test|Antral Follicle Count|Ultrasonographic evaluation of antral follicle count to determine ovarian reserve.
75326142|NCT05443282|Diagnostic Test|Prolactine Level|Measurement of venous blood serum prolactine hormone level.
75326143|NCT05443282|Diagnostic Test|Thyroid Stimulating Hormone Level|Measurement of venous blood serum thyroid stimulating hormone level.
75326144|NCT05443048|Device|Ivoclar Ivotion Denture System|Fabrication of maxillary and mandibular complete removable dental prosthesis with the Ivoclar Ivotion Denture System
75468566|NCT05322343|Other|Nasal microbiota|Nasal or nasopharyngeal swab
75633458|NCT04255524|Device|Optic coherence tomography angiography (OCTA)|Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map
75633459|NCT04260516|Drug|N-acetyl cysteine|Mucolytic and antioxidant drug
75633460|NCT00921024|Drug|CXA-101|intravenous
75633461|NCT00921024|Drug|Ceftazidime|intravenous
75633462|NCT04260594|Drug|Arbidol|Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
75326145|NCT00904345|Drug|Cetuximab|Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.
75919815|NCT03413306|Drug|Eltrombopag|Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.
75919816|NCT03413306|Drug|IST (ATG + CsA)|
75919817|NCT03404804|Drug|Amoxicillin|Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
75919818|NCT05611450|Other|disease self-management application|The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.
75326146|NCT00904345|Radiation|50-60 Gy and 70 Gy|Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.
75326147|NCT05442892|Procedure|Multicomponent exercise training programme|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individuals functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 30-60% of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L. Torrejón de Arroz, Madrid, Spain) combined with balance and gait retraining exercises that progressed in difficulty and functional exercises such as rises from a chair.
75326148|NCT05442736|Drug|Ciprofloxacin|studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
75326149|NCT03212911|Biological|Hepatitis B vaccine|Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
75326150|NCT05442502|Procedure|The overlap guiding tube(OGT) method|The overlap guiding tube(OGT) is used to assist the anvil fork placed into the esophageal cavity.
75326151|NCT05442502|Procedure|The conventional overlap method|After firing the stapler, two openings were converted into a single entry hole to create an end-to-side esophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
75326152|NCT01830829|Drug|Jalyn|study drug
75326153|NCT01830829|Drug|Placebo|Placebo
75326154|NCT03212755|Diagnostic Test|serum immunoglobulin G level|measurement of the serum level as a marker of diabetic complications
75468567|NCT05322343|Other|Measurements|"In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit.~Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes."
75633463|NCT04260594|Other|basic treatment|basic treatment
75468568|NCT05322343|Other|Neuroimaging|"A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes.~The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed"
75633464|NCT04203888|Other|Swedish Massage|60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.
75633465|NCT04203888|Other|Yoga|"60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005)."
75633466|NCT04260438|Drug|CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T|single oral administration under fed condition
75633467|NCT04260438|Drug|CKD-393 0.5/100/1000mg formulation 1 Tab. 1T|single oral administration under fed condition
75633468|NCT04260438|Drug|CKD-393 0.5/100/1000mg formulation 2 Tab. 1T|single oral administration under fed condition
75633469|NCT00928668|Drug|Placebo|Placebo device for comparison
75633470|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
75784135|NCT01184534|Behavioral|Questionnaires|2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
75633471|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
75633472|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
75633473|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
75784136|NCT01184612|Behavioral|Motivational Interviewing; MI|"MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client."
75784137|NCT01182116|Procedure|J Pouch|Comparing J pouch, side to end coloanal surgery
75919819|NCT03403946|Device|Macintosh blade|Laryngoscopy with C-MAC PM in combination with Macintosh blade
75919820|NCT03403946|Device|D-Blade|Laryngoscopy with C-MAC PM in combination with D-Blade
75919821|NCT03403946|Device|Intubation|Intubation with C-MAC PM in combination with D-Blade
75919822|NCT04523584|Device|Magnetic Resonance Imaging (MRI)|Participants will undergo MR imaging of the liver. Liver PDFF will be measured.
75326155|NCT05440084|Procedure|Chronic total occlusion percutaneous coronary intervention|Chronic total occlusion percutaneous coronary intervention
75468569|NCT05322343|Other|Medical visit|For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.
75326156|NCT01831063|Behavioral|Simulation|The experimental group received a simulation based seizure teaching session in addition to the traditional seizure teaching
75468570|NCT05313204|Other|Moderate-intensity cardiovascular exercise|The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.
75468571|NCT05311904|Other|Survey|1 initial questionnaire and 1 monthly follow-up questionnaire for 11 months
75468572|NCT05305144|Procedure|Vascular and ophthalmological examinations|"Part. 1 - Vascular checkup examinations:~After collecting classic clinical parameters (weight, height, waist circumference), the in-depth vascular workup of each participant will include the following measurements:~Measurement of central arterial pressure,~Measurement of arterial stiffness,~Continuous blood pressure measurement (beat-to-beat),~Heart rate measurement,~24-hour blood pressure measurement with QKD (holter).~Part. 2 - Ophthalmological examinations:~After dilating the pupil, a series of examinations will be conducted on the participant:~Auto-refractometry~Measurement of the axial length of the globe~Color retinophotography of the retina,~Adaptive Optics Exam~SS-OCT-A exam"
75468573|NCT05304936|Drug|HCW9218|Bifunctional TGF-β antagonist/IL-15 protein complex
75468574|NCT05298709|Other|Hyperventilation and CO2 challenge|Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators as described in study arm.
75633474|NCT05056428|Behavioral|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
75633475|NCT05329818|Device|high definition transcranial direct current stimulation|"Non-invasive brain stimulation neuromodulation using HD (3,14cm^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down."
75468575|NCT05294081|Behavioral|Exposure therapy|10 sessions based on an individualized pain hierarchy
75633476|NCT00592774|Drug|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
75919823|NCT04523584|Device|Ultrasound Imaging|Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.
75919824|NCT03403244|Procedure|US-MR image fusion-guided PTED|patients diagnosed with lumbar disc herniation undergoing US-MR image fusion-guided PTED
75919825|NCT03403244|Procedure|fluoroscopy-guided PTED|patients diagnosed with lumbar disc herniation undergoing fluoroscopy-guided PTED
75468576|NCT05294081|Behavioral|Cognitive behavioral therapy|10 sessions with graded activity, relaxations techniques and cognitive interventions
75633477|NCT00592774|Drug|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
75919826|NCT05611372|Drug|Rasagiline|1 mg rasagiline
75919827|NCT03923738|Drug|Tocilizumab|TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
75919828|NCT05475184|Drug|JPI-547|"Poly-(ADP-ribose) polymerase (PARP) & tankyrase (TNKS) inhibitor.~The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal."
75468577|NCT05291923|Other|no intervention|no intervention
76077309|NCT03032614|Drug|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
75326157|NCT04381507|Device|endovascular repair|Endovascular repair of descending thoracic aneurysms or PAU using a stent graft.
75468578|NCT05280600|Other|Not applicable - non-interventional study|Not applicable - non-interventional study
75468579|NCT05275075|Other|Pancreatic cancer microRNA and messenger RNA expression.|Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
75468580|NCT05265325|Drug|AND017|Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 4 mg and 2-weeks interval according to Hb levels
75633478|NCT04131010|Device|single operator video cholangioscopy|The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
76077310|NCT03032614|Drug|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
75326158|NCT05437822|Drug|Tranexamic acid|2 g of tranexamic acid in 50 mL of saline
75326159|NCT05437042|Other|Medial calcaneal wedge|Immediate effect of medial calcaneal wedge for static balance and weight distribution
75326160|NCT03212599|Drug|Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
75326161|NCT05448040|Procedure|Socket preservation|Tooth extraction and preservation with a biomaterial
75326162|NCT03212443|Procedure|Suprascapular nerve- axillary nerve block combination|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
75326163|NCT03212443|Procedure|Subacromial infiltration|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
75326164|NCT05447962|Behavioral|Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)|Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.
75326165|NCT05447962|Behavioral|Barbershop-Based Facilitation (BF)|Trained and qualified facilitators assist community health workers (CHWs) to: 1) increase their confidence in delivering CLIP; 2) understand participants' concerns and beliefs about hypertension (HTN); and 3) develop skills in lifestyle counseling to help the men initiate lifestyle modification.
75326166|NCT05311423|Diagnostic Test|QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra|Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
75468581|NCT05265325|Drug|AND017|Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg and 2-weeks interval according to Hb levels
75468582|NCT05265325|Drug|epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars|Dose regimen and adjustment rules according to the USPI or SmPC or local practice
75326167|NCT03212053|Biological|biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)|Patients will have blood samples at each consultation (2 or 3 sampling tubes) in order to carry out systematically three biological tests
75633479|NCT05603260|Behavioral|Imagery intervention for voice hearing (meta-cognitive imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of meta-cognitive imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
75633480|NCT05603260|Behavioral|Imagery intervention for voice hearing (Imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
75633481|NCT05603260|Behavioral|Imagery intervention for voice hearing (promoting positive imagery de novo)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of promoting positive imagery de novo.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
75784138|NCT05275556|Device|Computer-Assisted Detection (CADe) Device|The CADe Device uses artificial intelligence to aid in identifying colorectal polyps during High Definition White Light Endoscopy (HD-WLE) based colonoscopies. This device connects the Gastroenterologist's colonoscopy video output source to the main monitor and highlights the regions of interest where the device detects a potential lesion. The CADe Device overlays graphical markers onto video from the endoscope camera and does not perform further processing to the endoscope video signal. This device is not intended to replace clinical decision making.
75784139|NCT03857282|Other|Aerobic Exercises|5 to 10 min warm up exercises than 30min bicycle exercise and 5 to 10 min cool down exercises
75784140|NCT03857282|Other|Tai Chi Exercises|5 to 10 min warm up exercises and 30 min Tai Chi exercises and than than 5 to 10 min cool down exercises.
75784141|NCT03307174|Drug|Bupivacaine|
75784142|NCT03307174|Drug|Fentanyl|
75784143|NCT01184690|Procedure|Single-operator double-balloon endoscopy|Single-operator double-balloon endoscopy
75919829|NCT05611294|Device|Topography Guided LASIK Surgery|LASIK surgery, using corneal topography data in treatment profile, to correct myopia or myopia with astigmatism refractive error.
75326168|NCT05447260|Drug|Ruxolitinib|Dosage based on platelet count
75326169|NCT05447104|Behavioral|Mastication|Chewing sugar-free gum for 20 min
75326170|NCT05311267|Other|Action observation training|Subject is asked to observe videos with motor contents
75468583|NCT05255900|Drug|Metyrapone Capsules|Exposure to 24 weeks of treatment with metyrapone
75468584|NCT05252442|Other|Pre-COVID-19|Pre-COVID-19 period
75468585|NCT05252442|Other|COVID-19|COVID-19 period
75468586|NCT05252442|Other|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out period
75468587|NCT05245500|Drug|MRTX1719|MRTX1719 is a potent PRMT5-MTA inhibitor
75468588|NCT05243641|Drug|Neratinib|Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.
75468589|NCT05243641|Drug|Capmatinib|Capmatinib will be supplied at 200 mg and 150 mg tablets
75633482|NCT05603260|Behavioral|Imagery intervention for voice hearing (visuospatial working memory tasks)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of visuospatial working memory tasks.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
75919830|NCT05611294|Device|Small Incision Lenticule Extraction Surgery|Corneal lenticule formation using a femtosecond laser, with subsequent lenticule extraction, to correct myopia or myopia with astigmatism refractive error.
75633483|NCT00700960|Drug|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
75633484|NCT00700492|Drug|progesterone|vaginal capsules 3X200mg daily
75326171|NCT05311189|Drug|HLX10, Trastuzumab and Chemotherapy|HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
75326172|NCT01831297|Device|measurement of blood pressure|measurement of pulse wave velocity
75326173|NCT01831375|Behavioral|Speak Up|Intervention group_treatment group
75326174|NCT01831375|Behavioral|Get connected|Participants will learn to be connected with social resources in the community.
75468590|NCT05229679|Diagnostic Test|HPV testing|All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
75784144|NCT01184690|Procedure|dual-operator double-balloon endoscopy|dual-operator double-balloon endoscopy
75784145|NCT03448978|Biological|Descartes-08|autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
75468591|NCT05224336|Drug|Psilocybin|25mg oral psilocybin
75784146|NCT03448978|Drug|Fludarabine|intravenous fludarabine
75784147|NCT03448978|Drug|Cyclophosphamide|intravenous cyclophosphamide
75919831|NCT04447508|Behavioral|Participants receive one on one motivational interviewing and participate in a group exercise class virtually.|Participants have one group exercise class over zoom per week and an online one on one motivational interviewing session every second week.
76077311|NCT03032614|Drug|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
75633485|NCT04116190|Behavioral|Telerehabilitation|Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.
75633486|NCT04116190|Behavioral|Conventional inpatient rehabilitation|Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
75633487|NCT00700648|Drug|insulin aspart|Intravenous NovoRapid dose & frequency as decided by treating physician
75633488|NCT00703300|Drug|bortezomib|Given IV
75633489|NCT00703300|Drug|decitabine|Given IV
75633490|NCT00703300|Other|pharmacological study|Correlative studies
75633491|NCT00703300|Other|laboratory biomarker analysis|Optional correlative studies
75633492|NCT04116034|Device|alfapump DSR system|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
75784148|NCT03857204|Device|SAMPL plain wave algorithm|SAMPL's plain-wave algorithm allowing portable US or Wireless Probe scanning - thus enabling clinicians with more flexible point-of-care locations when performing US scans for fetal weight assessment.
75784149|NCT01587716|Drug|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
75784150|NCT01587716|Other|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
75784151|NCT01587716|Drug|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
75784152|NCT01587716|Other|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
75784153|NCT03258814|Behavioral|Active Supervised Training (AST)|The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.
75919832|NCT04447196|Other|MDP|Multi dimensional dyspnea profile scores at rest and during non invasive ventilation
75919833|NCT03395834|Device|O3|O3 TM and INVOS® monitoring simultaneously in single patient during 3 min of vascular occlusion test
75919834|NCT04448288|Other|Static stretching|Static stretchings were performed by subjects that involved varied repetitions of 30-s static-stretches and 20-s relax period.
75919835|NCT03395756|Drug|Depot-Medroxyprogestereone Acetate|Administration of 150 mg intramuscular depot medroxyprogesterone acetate
76077312|NCT04182490|Biological|LMN-101|VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
76077313|NCT04182490|Drug|Placebo|Identical appearing placebo
76077314|NCT03032458|Drug|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
76077315|NCT03032458|Drug|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
76077316|NCT03032458|Drug|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
75326175|NCT05446402|Combination Product|Geologie Acne Regimen - one side of face|"Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three levels over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes:~Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid)~Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide)~Repairing Night Cream -~Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)"
75326176|NCT05446402|Combination Product|Proactive Acne Regimen - other side of face|"ProActiv is an over-the-counter cosmetic regimen with three products. The~Proactiv Solution 3-Piece System regimen includes:~Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)~Revitalizing Toner (Glycolic Acid)~Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)"
75326177|NCT01831453|Drug|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
75326178|NCT01831453|Drug|placebo|soft gelatinous capsules filled with isopropylmyristate oil
75326179|NCT00369772|Drug|darbepoetin alfa|
75633493|NCT00703378|Drug|Docetaxel (Taxotere®)|Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
75326180|NCT03212209|Device|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
75326181|NCT00369850|Other|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
75326182|NCT00369850|Procedure|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
75326183|NCT00369850|Procedure|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
75633494|NCT00703456|Behavioral|Balance Training|balance training three days per week for 4 weeks during single limb standing
75633495|NCT00852202|Drug|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
75919836|NCT05558254|Other|Robert - intervention to enhance muscle strength|"Intervention:~Training will be conducted with the robot ROBERT®. 3 times a week for 8 weeks the patient will conduct 60 repetitions of hip flexion of one leg. The patient is lying supine. ROBERT is attached to the patient's lower leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. The ROBERT is attached to the patient's lower leg and thereby eliminating the gravity of the leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. ROBERT is set in active or guided mode and will be individually adjusted. When practice starts the patient get visual feedback to the range of movement of the hip flexion plus the amount of repetitions conducted and persisting."
75919837|NCT03395678|Device|Microneedling|The exact microneedling settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
75326184|NCT01831531|Drug|S-1|S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA >1.6 m2) p.o bid d1-28
75326185|NCT01831531|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
75468592|NCT05224336|Drug|Placebo Niacin|100mg oral niacin
75468593|NCT05222620|Other|Questionnaire Administration|Ancillary studies
75633496|NCT00852202|Drug|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
75633497|NCT00852202|Drug|placebo|placebo capsules, oral administration, once daily dosing
75633498|NCT01074008|Drug|ABT-450|50 mg capsules co-administered with ritonavir
75633499|NCT01074008|Drug|ABT-072|50 mg tablet
75633500|NCT01074008|Drug|ABT-333|400 mg tablet
75633501|NCT01074008|Drug|Ritonavir|100 mg capsules co-administered with ABT-450
75633502|NCT01074008|Drug|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
76077317|NCT02245438|Drug|Tipranavir low dose|
75633503|NCT01074008|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
75633504|NCT01074008|Other|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
75633505|NCT04117048|Device|LabPad® point-of-care|All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
75633506|NCT04117204|Other|Fruits and Vegetables|Fruits and Vegetable delivery, once a week for 12 weeks.
75633507|NCT02613052|Drug|normal saline|10 mL of normal saline agitated prior to IV administration
75633508|NCT02613052|Drug|human albumin|10 mL of 5% albumin agitated prior to IV administration
75633509|NCT02613052|Drug|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
75784154|NCT03258814|Behavioral|Standard of Care (SOC) Physiotherapy|Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.
75784155|NCT01184924|Behavioral|Evaluation of the Arthritis Foundation Tai Chi Program|The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
75784156|NCT01290926|Drug|chemotherapy|sorafenib 600mg/day capecitabine 1250 mg/m²/day
75784157|NCT04922866|Other|no intervention|no intervention
75468594|NCT05222620|Radiation|Stereotactic Radiosurgery|Undergo single fraction SRS
75468595|NCT05222620|Radiation|Stereotactic Radiosurgery|Undergo fractionated SRS
75468596|NCT05191719|Procedure|Botox injection|Comparator, current gold standard
75468597|NCT05191719|Procedure|Neurotomy|Surgical procedure
75468598|NCT05179785|Device|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely that can decrease the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
75468599|NCT05179785|Device|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely to increase the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions.
75468600|NCT05174065|Drug|Apremilast|Oral tablets
75468601|NCT05174065|Drug|Placebo|Oral tablets
75633510|NCT01073930|Drug|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
75633511|NCT01073930|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
75468602|NCT05166499|Dietary Supplement|Hydroxy Methyl Butyrate|Hydroxy Methyl Butyrate
75468603|NCT05166499|Dietary Supplement|Balanced Amino Acids|Balanced Amino Acids
75468604|NCT05160675|Other||No intervention
75633512|NCT01073930|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
75633513|NCT01073618|Drug|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
75633514|NCT02875964|Device|electroencephalogram|Implanting electrode to measure brain activity
75633515|NCT02875964|Device|magnetoencephalogram|Implanting electrode to measure brain activity
75633516|NCT00789373|Drug|Pemetrexed|Induction therapy: 500 mg/m^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
75919838|NCT03395678|Device|Fractional non-ablative 1,540nm laser|The exact laser settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
75468605|NCT05157100|Drug|Ingrezza Pill|Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
75468606|NCT05149937|Other|interprofessional, person-centered care concept|interprofessional, person-centered care concept
75468607|NCT05144555|Other|Fixed orthodontic treatment with stainless steel brackets|"Stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
75468608|NCT05144555|Other|Fixed orthodontic treatment with ceramic brackets|"Ceramic brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
75468609|NCT05143619|Other|Survey Administration|Complete surveys
75468610|NCT05134142|Other|Electronic Health Record Review|Undergo medical record review
75468611|NCT05134142|Other|Physical Performance Testing|Undergo physical performance testing
75468612|NCT05134142|Other|Quality-of-Life Assessment|Complete assessments
75468613|NCT05134142|Other|Questionnaire Administration|Complete questionnaire
75468614|NCT05133804|Drug|Methylphenidate|Ritalin 10mg
75468615|NCT05133804|Drug|Reboxetine|Reboxetine 4mg
75468616|NCT05133804|Drug|Placebo|Placebo matched to Reboxetine
75468617|NCT05133804|Drug|Placebo|Placebo matched to Ritalin
75468618|NCT05131321|Procedure|Primary ankle arthrodesis (fusion)|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
75919839|NCT05475106|Biological|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of ~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.
75919840|NCT05167136|Behavioral|Awareness Level|"Demands and expectations about the green hospital were measured with a questionnaire applied to 287 people, consisting of health professionals and employees in a small private hospital that does not have a green hospital certificate in the province of Istanbul."
75919841|NCT04448132|Biological|IPV-Al|adjuvanted reduced dose inactivated polio vaccine
75919842|NCT05475028|Other|RRBS|Reduced Representation Bisulfite Sequencing
76077318|NCT02245438|Drug|Tipranavir high dose|
75468619|NCT05131321|Procedure|ORIF (open reduction and internal fixation)|ORIF: ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
75468620|NCT05127421|Drug|Ruxolitinib cream|"Ruxolitinib cream 1.5% applied twice a day (BID)"
75468621|NCT05127421|Drug|Vehicle|Vehicle cream applied twice a day (BID) to affected areas
75468622|NCT05126797|Other|Questionnaire Administration|Ancillary studies
75468623|NCT05126797|Device|Stent Device|Wear customized 3D printed oral stent
75633517|NCT00789373|Drug|Cisplatin|Induction therapy: Cisplatin: 75 mg/m^2, IV, on Day 1 of each 21-day cycle for 4 cycles
75326186|NCT03211897|Drug|Haloperidol Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
75326187|NCT03211897|Drug|Ziprasidone Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
76077319|NCT02245438|Drug|Ritonavir low dose|
75633518|NCT00789373|Drug|Placebo|Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
75633519|NCT00789373|Drug|Pemetrexed|Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
75326188|NCT03211897|Drug|OLANZapine Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
75633520|NCT00789373|Other|Best Supportive Care|Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
75633521|NCT00851890|Drug|ABT-333|50 mg capsules
75633522|NCT00851890|Other|Placebo for ABT-333|Capsule
75326189|NCT03211897|Drug|Midazolam injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
75633523|NCT00851890|Drug|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
75326190|NCT00422500|Behavioral|Questionnaire|Surveys about symptoms, mood, and quality of life.
75326191|NCT00422500|Behavioral|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
75326192|NCT00422500|Other|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
75326193|NCT01831687|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
75326194|NCT01831687|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
75326195|NCT05444296|Other|Superficial Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
75326196|NCT05444296|Other|Non-thrust Mobilizations only|Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
75633524|NCT00851890|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
76077320|NCT02245438|Drug|Ritonavir high dose|
75326197|NCT05441254|Drug|Camrelizumab; Nab-paclitaxel; S-1|"Camrelizumab: 200 mg, intravenous infusion, d1, q3w;~Nab-paclitaxel: 130 mg/m2 intraperitoneal and 130 mg/m2 intravenously, d1, q3w;~S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w;~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
75326198|NCT00904813|Radiation|Short-course RT|Preoperative radiotherapy (RT) given 5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
75326199|NCT00904813|Radiation|Long-course RT|Preoperative radiotherapy (RT) given 2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
75326200|NCT04016428|Behavioral|OPTIMISM|Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.
75326201|NCT04016428|Behavioral|Sleep Education|Six-week online program that provides education on sleep during pregnancy.
75633525|NCT00626756|Device|LiDCO technology|non invasive monitoring of cardiac output
75633526|NCT02877368|Other|Computed tomography|
75633527|NCT02877212|Drug|Eltrombopag|Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
75633528|NCT04299230|Device|Cortium C3|
75784158|NCT01185002|Other|PillCam® COLON 2 procedure using MgC boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.
75784159|NCT01185002|Other|PillCam® COLON 2 procedure using Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts
75784160|NCT01185002|Other|PillCam® COLON 2 procedure using reduced dose of Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
75784161|NCT01176734|Device|tVNS-Device|Active treatment with the t-VNS device.
75784162|NCT02940080|Other|Dietary|
75784163|NCT01185236|Drug|simvastatin/ezetimibe|simvastatin/ezetimibe 10/20mg once daily for 12weeks
75784164|NCT01185236|Drug|atorvastatin 20mg|atorvastatin 20mg once daily for 12weeks
75784165|NCT05222672|Other|His Bundle Pacing|Pacing of the His bundle
75326202|NCT03211585|Device|Perfecta V-Beam laser|This s a single study and a prototype of the FDA-cleared, flashlamp-pumped pulsed-dye laser, that is currently on the market, that has evolved over almost 25 years of continuous development. The broad-spectrum flashlamp pumps energy into a cavity containing liquid dye. The dye is excited resulting in the emission of 595 nm orange light.
75326203|NCT04738864|Diagnostic Test|ultrasound|extracranial and intracranial ultrasound assessment
75326204|NCT01832077|Device|90 D|rural doctors exam eye fundus by 90 D
75468624|NCT05117931|Drug|Amivantamab|Patients will receive amivantamab weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (<80kg) or 1400mg (>80kg). The first day of dosing is considered Cycle 1 Day 1. Each cycle is 28 days in duration. The initial dose will be administered over 2 days to prevent infusion reactions. For patients who weigh <80 kg, amivantamab 350mg IV will be given on Cycle 1 Day 1, and the remaining 700mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1050mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle. For patients who weigh ≥ 80 kg, 350mg IV amivantamab will be given on Cycle 1 Day 1 and 1050mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1400mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle.
75468625|NCT05115656|Behavioral|Online group 1|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
75326205|NCT01832077|Device|fundus camera and grader|taking fundus pictures and graded by graders in ZOC
75919843|NCT04448444|Behavioral|Motor Program Activating Therapy|Patients undergo ambulatory physiotherapy - Motor Program Activating Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
75326206|NCT00369148|Drug|nateglinide(drug) mitiglinide(drug)|
75326207|NCT00369304|Drug|pharmacokinetic (how the body absorbs and eliminates) interaction|
75326208|NCT04380493|Diagnostic Test|hepatic transient elastography using S probe and M probe|
75326209|NCT03777202|Procedure|High-flow nasal oxygen|High-flow nasal oxygen will be applied to the patients using Optiflow system through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
75326210|NCT03777202|Procedure|Low-flow nasal oxygen|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
75326211|NCT01832233|Procedure|Renal Denervation|The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
75326212|NCT01832467|Drug|cetuximab-containing chemotherapy|
75326213|NCT03211351|Drug|Liposic|one eye of the participant recieved Lipoic
75326214|NCT03211351|Drug|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
75919844|NCT04448444|Behavioral|Vojta reflex locomotion|Patients undergo ambulatory physiotherapy - Vojta Reflex Locomotion Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
75468626|NCT05115656|Behavioral|Online group 2|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
75919845|NCT03413228|Other|Questionnaire|An interview to collect some informations will be done: demographic informations, medical history, vaccination against influenza status, symptoms and virological informations. Then, a nasal swab was performed in order to identified the influenza virus.
75326215|NCT05442658|Other|Microbiota|
75326216|NCT01832623|Other|Exploration of Vitamin D roles|"Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
75326217|NCT03708640|Other|Digital Activity Tracker|Group wears physical activity tracker and receives physical activity feedback information informed by the tracker
75468627|NCT05112133|Dietary Supplement|Mulberry leaf extract|Oral administration
75468628|NCT05112133|Dietary Supplement|Water|Oral administration
76077321|NCT02245438|Drug|Norethindrone-Ethinyl Estradiol|
75326218|NCT03708640|Other|Smart Text Messaging|"Group receives personalized, health coaching via smart text messages"
75633529|NCT04106713|Behavioral|Individual Psychotherapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
75633530|NCT04106713|Behavioral|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven [behaviours] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing [behavioural] and emotional awareness, and situational and interoceptive exposure to emotion cues."
75326219|NCT03708640|Other|Physical Activity Counseling|Group receives baseline counseling on physical activity
75326220|NCT01832701|Other|Coffee|coffee versus placebo
75468629|NCT05109364|Drug|Terazosin therapy|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
75468630|NCT05106257|Behavioral|Self-management education (short)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The short condition consists of two calls (30-45 minutes each) to introduce patient education topics and refer to the booklet for further information.
75919846|NCT05613166|Drug|Everolimus|Everolimus will be administrated orally based on seizure events, with an administration interval longer than 24 hours. Participates with a body surface area (BSA) of <= 1.2 m^2, the dosage was 2.5 mg/time; for BSA 1.3-2.1 m^2, the dosage was 5 mg/time; and for BSA >=2.2 m^2, the dosage was 7.5 mg/time.
75919847|NCT05613166|Drug|Placebo|Vitamin C
75919848|NCT05166668|Drug|Letrozole 2.5mg tablet|letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
75326221|NCT01832701|Other|Placebo comparator|maltodextrine with caffeine
75468631|NCT05106257|Behavioral|Ground-based walking training|Participants randomized to this condition will be mailed a pedometer (3DFitBud Simple Step Counter) and instructed on its use to establish baseline steps/ day for 7 days. They will then receive a booklet with instructions to establish a walking program and three brief (10-15 minute), bi-weekly calls from a trained staff member to review step count values and engage in setting personal activity goals over the course of 6 weeks, following established exercise guidelines for individuals with COPD.
75633531|NCT04106713|Behavioral|Group Cognitive Behavioural Therapy (group CBT)|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
75633532|NCT02875652|Biological|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
75326222|NCT03617926|Device|X92001666|the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
75326223|NCT03617926|Other|RID shampoo|Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
75919849|NCT05558176|Drug|Sildenafil citrate|The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer Inc, NewYork, NAFDAC Reg NO: 04 - 1509, Batch No: 477209; Exp date: 11 - 2024) will be used in the course of the study.
75919850|NCT03401138|Other|Preoperative Stroke Volume(SV)-guided fluid optimization|"Preoperative SV-guided hemodynamic optimization will be commenced with patients receiving 250ml fluid challenges over five minutes aiming to maximize SV. Maximal SV is defined as absence of a sustained rise in SV by at least 10% in response to a fluid challenge.~PPI will be obtained from the Masimo Radical 7 (Masimo, Irvine, CA, USA) and NIRS from Invos 5100C (Medtronic, Minneapolis, MN, USA).~BV measurements will use pulse dye densitometry (PDD) with Indocyanine Green (ICG). We will use the Dye Densitogram 3300 analyser Nihon Kohden (Tokyo, Japan) for registration of the spectrophotometrical absorption of ICG and calculation of BV."
75919851|NCT04748224|Drug|Bupivacaine 0.25% Injectable Solution|a local anesthetic drug
75326224|NCT03837613|Procedure|tumor resection and neck dissection|Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.
75326225|NCT03610984|Other|type 1 diabetes structured education|The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
75326226|NCT03836911|Other|serious game|Effect of serious game on elderly in comparison of the physical activity adapted meeting
75326227|NCT03836911|Other|classic program|Effect of serious game on elderly in comparison of the physical activity adapted meeting
75326228|NCT05438446|Procedure|Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)|"The ReCor Medical Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark, but Investigational in the USA.~The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney."
75326229|NCT05318209|Other|Exercise|Closed-chain Shoulder Girdle Scapular Depression Exercise
75633533|NCT00788827|Biological|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
75633534|NCT02875574|Drug|Any treatment regimen|Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
75919852|NCT04748224|Drug|bupivacaine plus dexmedetomidine|bupivacaine is a local anesthetic drug plus dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative and analgesic sparing effects
75919853|NCT03399968|Device|ESWT|at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right
76077322|NCT04761939|Combination Product|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~Stent - a pre-mounted Cobalt Chromium (CoCr) alloy based stent - 2.25 mm Diameter and 8mm, 12mm, 15mm, 17mm, 20mm, 24mm, 28mm and 33mm length~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0"
75633535|NCT02875574|Other|Bacterial mutation|Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
75633536|NCT02612974|Biological|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
76077323|NCT03032146|Procedure|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
76077324|NCT03087669|Device|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
75633537|NCT04304924|Other|The personalized telephone based intervention|"The personalized telephone based intervention:~Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
75633538|NCT00592072|Dietary Supplement|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
75633539|NCT00592072|Other|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
75633540|NCT02875418|Device|EUM|"STUDY DESIGN~Explanation regarding the study and assessing eligibility criteria.~Signing an informed consent.~Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
75326230|NCT02470312|Procedure|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
75633541|NCT02875418|Device|Tocodynamometry|"STUDY DESIGN~Explanation regarding the study and assessing eligibility criteria.~Signing an informed consent.~Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
75326231|NCT02470312|Device|MediGuide|
75633542|NCT04742972|Radiation|SABR|SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.
75326232|NCT02470312|Procedure|EP|
75326233|NCT03211195|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
75326234|NCT02470390|Drug|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
75326235|NCT00363532|Drug|infusion of calcitonin gene related peptide (CGRP)|
75633543|NCT04742972|Other|SOC|"Three options:~Continuation of Enzalutamide~Observation~Switch to next line treatment"
75633544|NCT00626288|Drug|Mesalazine|Mesalazine 800mg t.i.d. 12 weeks
75326236|NCT05311501|Other|Non-surgical periodontal treatment|Non-Surgical periodontal Treatment was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments. Oral Hygiene Instructions (OHI) were provided throughout the experimental period. Local anesthesia was performed only when needed.
75633545|NCT00626288|Drug|Placebo|Placebo cpr, t.i.d. 12 weeks
75633546|NCT00792571|Drug|Beraprost Sodium Modified Release|
75633547|NCT04108975|Procedure|Rectus muscle reapproximation during CS|Reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures.
75633548|NCT04108975|Procedure|Rectus muscle non reapproximation during CS|During CS rectus muscle non reapproximation will be done.
75919854|NCT03399968|Device|Placebo ESWT|the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group
75919855|NCT03395600|Drug|B1S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
75919856|NCT03395600|Drug|B125S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
75919857|NCT03395600|Drug|B1S10|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
76077325|NCT03087669|Drug|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
76077326|NCT00939952|Drug|ertapenem|500 mg IV once
76077327|NCT02401815|Drug|PLX9486|PLX9486 will be administered per dose and schedule specified in the arm.
75326237|NCT03505996|Biological|CS1001|Monoclonal antibody
75633549|NCT01069484|Other|Postpartum pelvic floor muscle training|Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
75633550|NCT04110223|Genetic|next generation sequence|targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
75633551|NCT04109989|Device|HominisTM Surgical System|Trans-vaginal gynecological procedures
75633552|NCT00794365|Drug|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
75633553|NCT01067144|Drug|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
75633554|NCT01067144|Drug|Lorazepam (active control)|0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
75919858|NCT04736758|Drug|GP681 tablet|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
75633555|NCT01067144|Drug|Placebo (inactive)|2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
75633556|NCT04749758|Biological|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
75633557|NCT02603185|Drug|Hemay007|
75633558|NCT02603185|Drug|placebo|
75633559|NCT04003129|Other|questionnaire|"Data will be obtained through a written questionnaire for assessing knowledge, practice and attitude of paediatricians regarding early childhood caries.~Data collected will be saved and tabulated on computer and finally statistically analysed."
75633560|NCT05610943|Procedure|ultrasound-guided quadratus lumborum nerve block|The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
75633561|NCT05610943|Procedure|ultrasound-guided Ilioinguinal Iliohypogastric Nerve Block|The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
75633562|NCT01078298|Drug|varenicline|varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
75633563|NCT01078298|Drug|placebo|placebo tablets matched in appearance and dosage to varenicline tablets
75633564|NCT00788593|Drug|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
75784166|NCT02524886|Device|GPi DBS with Medtronic electorde and Activa PC pulsegenerator|The electric stimulation of 2 leads implanted in the Globus Pallidus internus
75784167|NCT02524652|Drug|Ropivacaine 0.5% 20 mLs|Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
75784168|NCT01182272|Drug|sorafenib tosylate|
75919859|NCT04736758|Drug|GP681 Simulant|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
75919860|NCT03413150|Drug|Amiodarone|Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent AT during their hospitalization in the ICU.
75784169|NCT01182272|Other|laboratory biomarker analysis|
76077328|NCT02401815|Drug|Pexidartinib|Pexidartinib capsules will be administered per dose and schedule specified in the arm.
75784170|NCT01182272|Procedure|neoadjuvant therapy|
75784171|NCT01182272|Procedure|therapeutic conventional surgery|
76077329|NCT02401815|Drug|Sunitinib|Sunitinib will be administered per dose and schedule specified in the arm.
75468632|NCT05106257|Behavioral|Inhaler training|Participants randomized to this condition will receive two sessions of inhaler technique education using a virtual teach-to-goal (TTG) method in which individuals are observed using their inhaler, provided feedback, and then observed again.
75468633|NCT05106257|Behavioral|Caregiver support|Participants randomized to this condition will identify an informal caregiver who is involved in their healthcare (i.e., spouse, family member, or friend), who will receive a mailed copy of the Respiratory Health Association's COPD Caregiver's Toolkit, a comprehensive informational resource to support the care of the person living with COPD. Caregivers will receive two brief (10-15 minute) check-in calls from a trained staff member. The structured content of these sessions will include providing an overview of toolkit content, identifying goals for sections(s) to review and incorporate into caregiving activities, and addressing any questions.
75468634|NCT05106257|Behavioral|Self-management education (long)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The long condition consists of five, weekly calls (30-45 minutes each) following a structured curriculum of patient education topics.
75784172|NCT03855254|Behavioral|communication type|Positive and negative communication types are the way that the practitioner communicates to the participant about the potential effectiveness of the osteopathic treatment. The control is a neutral communication condition.
75633565|NCT00788593|Drug|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
75633566|NCT00788593|Drug|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
75633567|NCT04305080|Other|Anodic oxidation|Abutments will undergo anodic oxidation process after etching with Hydrofluoric acid & Nitric acid mixture for 10 minutes for debridement in a bath of distilled water with citric acid for 5 minutes to turn the abutment collar into pink color. The stainless steel plate will be connected to the cathode (-) and titanium abutments will be connected to the anode (+) end of the DC Power Supply. After then abutments will be left in distilled water for 10 minutes and sterilized before insertion in patient mouth.
75468635|NCT05097716|Drug|Ritlecitinib|Ritlecitinib 200 mg provided as four 50 mg oral capsules
75468636|NCT05097716|Drug|Tolbutamide|Tolbutamide 500 mg provided as one 500 mg oral tablet
75633568|NCT04305080|Other|Untreated abutment|Abutment will be left untreated with its gray color.
75633569|NCT04106011|Drug|Gabapentin|Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).
75919861|NCT03395444|Device|pulsed shortwave therapy|Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength
75633570|NCT04106011|Diagnostic Test|BTACT|Cognition measure: Brief Test of Adult Cognition by Telephone
75633571|NCT04106011|Diagnostic Test|BPI|Pain severity and interference at baseline using the Brief Pain Inventory
75633572|NCT04106011|Diagnostic Test|HADS|Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale
75633573|NCT04106011|Diagnostic Test|SLP9|Assessment of Sleep
75633574|NCT04106011|Diagnostic Test|NPSI|Assessment of neuropathic components
75633575|NCT02877056|Procedure|Endoscopy|Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
75633576|NCT02603029|Other|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
75633577|NCT02603029|Other|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
75784173|NCT03861416|Drug|L-arginine 1.4% 500 ml|Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
75784174|NCT03861416|Drug|L-arginine 1.4% 250 ml + placebo 250 ml|Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
75784175|NCT03861416|Drug|Placebo solution|Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
75784176|NCT01185314|Procedure|Testing for mutation status|EGFR mutation test
75919862|NCT03399890|Diagnostic Test|Neurological physical exam|Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
75919863|NCT03399812|Dietary Supplement|Animal protein|The animal protein intervention is a smoothie containing 40 grams of whey protein isolate.
75919864|NCT03399812|Dietary Supplement|Plant protein|The animal protein intervention is a smoothie containing 40 grams of pea protein isolate.
75468637|NCT05086016|Device|Catheterized Stenting|Catheterized stenting of vascular narrowings.
75468638|NCT05084963|Drug|IRL201104|lyophilised powder for reconstitution for IV dosing
75468639|NCT05084963|Drug|Placebo|Matching placebo for IRL201104
75468640|NCT05071703|Drug|Trilaciclib|"Carboplatin combined with Etoposide (ES-SCLC patients)~plus Topotecan (second/third line ES-SCLC patients)"
75468641|NCT05071300|Drug|Eplontersen|Eplontersen will be administered by SC injection.
75919865|NCT05474716|Drug|Brimonidine tartrate 0.2% ophthalmic solution|Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.
75919866|NCT03399734|Drug|Perampanel|Single oral dose of 1 x 4-mg perampanel tablet
75633578|NCT02876744|Other|ophthalmologic examination|ophthalmologic examination including optical coherent tomography with angiography module
75633579|NCT02875886|Drug|Amiloride|Combined with hydrochlorothiazide
75468642|NCT05058989|Diagnostic Test|Advanced ultrasound measurements (Duplex ultrasound (DUS) and Vector flow imaging (VFI)|PPG is a non-invasive method used to evaluates the severity venous reflux by measuring the venous refiling time (VRT).The principal of PPG works by using a small light source and a photoelectric cell attached to the skin in the medial supramalleolar area of the leg (the distal lower medial area of the leg).
75326238|NCT01832857|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
75326239|NCT00363610|Drug|Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma|
75919867|NCT03399734|Drug|Perampanel|Single 4-mg dose of perampanel fine granules
76077330|NCT00947752|Drug|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
76077331|NCT00947752|Drug|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
75326240|NCT03837535|Procedure|Surgery|Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
76077332|NCT03032692|Device|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
75468643|NCT05058989|Other|Clinical interventions and procedures|"First trimester (0-13 weeks):~Consent~Clinical data collection~Blood samples (genomic+ hormonal)~Duplex ultrasound~Vector flow imaging (advanced ultrasound software)~Truncated cone tool (measuring leg circumference using a tape measure)~PPG~AVVQ (Aberdeen varicose veins questionaire)~Second trimester (14-26 weeks):~Clinical data collection~Blood sample (hormonal only)~DUS~VFI~Truncated cone tool~PPG~AVVQ~Third trimester (27-40 weeks):~Same as second trimester~Three months after giving birth:~Same as second trimester"
75784177|NCT01176890|Drug|GLP-1|"1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
75326241|NCT03837301|Procedure|NESS-EFTR with sentinel lymph node navigation|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
75326242|NCT00363688|Drug|Penicillin test and challenge|
75326243|NCT01832935|Drug|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
75468644|NCT05055843|Procedure|Magnetic Resonance Imaging|Undergo 3D MRI
75784178|NCT01176890|Other|Saline|"Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
76077333|NCT03032692|Other|Exercise with biofeedback|
76077334|NCT03032692|Other|exercise without biofeedback|
75326244|NCT01832935|Drug|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
75326245|NCT02471326|Biological|VRC-HIVMAB060-00-AB (VRC01)|A potent HIV-specific monoclonal antibody
75326246|NCT01833013|Other|live birth date and quality of life assessment|
75326247|NCT05406778|Device|SPARK Test|Twenty (20) minutes of resting state EEG data collection.
75468645|NCT05054998|Radiation|Fludeoxyglucose F-18|Given IV
75468646|NCT05054998|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
75468647|NCT05054998|Procedure|Positron Emission Tomography|Undergo PET/MRI
75633580|NCT02875886|Drug|Hydrochlorothiazide|Combined with amiloride
75633581|NCT02875886|Other|Low-sodium diet|
75633582|NCT00793819|Drug|silodosin|α1-adrenergic antagonist
75633583|NCT04109833|Drug|ABT|any antibiotic therapy in the first week of life
75633584|NCT00894387|Drug|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
75633585|NCT00894387|Drug|Placebo|Placebo
75633586|NCT02839005|Other|Continuous suture with polyglecaprone 25|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyglecaprone 25
75633587|NCT02839005|Other|Continuous suture with polyamide (nylon)|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyamide (nylon)
75784179|NCT03257410|Device|Theranova 400 dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
75784180|NCT03257410|Device|Elisio-17H dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
75784181|NCT02524574|Procedure|cardiac Rehabilitation|
75784182|NCT02524574|Other|Tomography Positron Emission|
75919868|NCT03126578|Drug|LEO 32731|LEO 32731 is being developed by LEO Pharma.
75919869|NCT03126578|Drug|Midazolam|Benzodiazepine
75919870|NCT03412994|Drug|Apatinib|Apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer
75919871|NCT03412994|Drug|standard second-line chemotherapy|The second line standard chemotherapy regimen recommended by the NCCN
76077335|NCT03457155|Other|VS-I dosing in plasma samples|"VS-I dosing in plasma samples using ELISA protocol :~At intensive care admission time~24h after admission time~In case of FA occurrence~In case of sinusal rhythm recovery (in patients with new onset FA)"
76077336|NCT03087747|Procedure|Percutaneous cholecystostomy|Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
76077337|NCT03032224|Procedure|Resection of the esophagus and the gastroesophageal junction|
75633588|NCT02836665|Procedure|Telemedicine for dermatological emergency patients|"Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site."
75468648|NCT05053555|Device|high dose rate brachytherapy|diagnostic workup, staging, and treatment per the institution standard of care
75468649|NCT05053555|Device|high dose rate brachytherapy|reviewing historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021
75468650|NCT05047302|Device|BlueLeaf Procedure|The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
75468651|NCT05046067|Procedure|Computed Tomography|Undergo CT
75326248|NCT01833091|Other|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand & arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
75326249|NCT03411382|Other|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
75326250|NCT03411382|Other|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
75468652|NCT05046067|Procedure|Therapeutic Conventional Surgery|Undergo surgery per standard of care
75326251|NCT03411382|Other|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
75326252|NCT03411382|Other|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
75326253|NCT03210805|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acids Supplementation|28 days of a commercially available supplement. 4 capsules per day.
75468653|NCT05041153|Drug|Lenvatinib|Given by PO
75633589|NCT04249479|Other|CM Temperature (20° C)|CM will be administered at 20° C (room temperature).
75633590|NCT04249479|Other|CM Temperature (37° C)|CM will be administered at 37° C (pre-heated).
75784183|NCT03861026|Device|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
75326254|NCT04380181|Drug|dobu|Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
75326255|NCT02472262|Dietary Supplement|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
75784184|NCT01185470|Device|Implantation of Morphine Sulfate delivering programmable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
75326256|NCT02472262|Dietary Supplement|Corn soy flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
75326257|NCT02472262|Dietary Supplement|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
75468654|NCT05041153|Biological|Pembrolizumab|Given by IV
75468655|NCT05035706|Procedure|Biopsy|Undergo biopsy
75468656|NCT05035706|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
75468657|NCT05035706|Other|Electronic Health Record Review|Medical records reviewed
75468658|NCT05035706|Other|Photography|Photographs taken
75468659|NCT05035667|Other|Questionnaire Administration|Complete questionnaires
75468660|NCT05032105|Device|Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
75784185|NCT00056160|Drug|CC-5013|Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
75468661|NCT05006248|Device|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.
75468662|NCT05006248|Device|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
75633591|NCT04249479|Other|Weight|The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.
75633592|NCT02836821|Drug|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
75633593|NCT02836821|Drug|Rifampicin Capsules|rifampicin was administered in the morning 2 hours after breakfast
75468663|NCT05006248|Device|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
75468664|NCT04989959|Drug|[18F]PT2385|[18F]PT2385 infusion
76077338|NCT03456687|Drug|Exenatide|Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
75468665|NCT04989959|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after [18F]PT2385 infusion
76077339|NCT03497013|Device|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
75326258|NCT03210727|Behavioral|Ready to CARE program|"The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion."
75468666|NCT04989959|Procedure|Biopsy|CT-guided tumor biopsy
75468667|NCT04973852|Device|Ekso|Exoskeleton walking
76077340|NCT03497013|Device|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
76077341|NCT03495375|Dietary Supplement|Treatment with a probiotic|All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
76077342|NCT03495375|Other|Treatment with placebo|All participants will take the placebo once daily for 10 weeks.
75326259|NCT01833559|Dietary Supplement|Dietary control|
75468668|NCT04971200|Drug|Tildrakizumab|2 100mg subcutaneous injections Q4W
76077343|NCT00948298|Drug|Vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
75326260|NCT01833559|Drug|Insulin|If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
75784186|NCT00056160|Drug|Dexamethasone|Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
75784187|NCT01185626|Other|SCP care|
75784188|NCT03857126|Other|Signal acquisition|ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).
76077344|NCT00948298|Drug|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
76077345|NCT05346783|Drug|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
75326261|NCT03253120|Other|Water|Patient/ Healthy volunteer will drink 5dl of Water
75326262|NCT03210649|Drug|CKD-519|Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1~D14
75326263|NCT03210649|Drug|Placebo|Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1~D14
75326264|NCT01833637|Other|APN Intervention|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
75326265|NCT03215485|Behavioral|Nutrition lessons|Face-to-face interactive group lessons delivered in the classroom.
75468669|NCT04931225|Drug|Landiolol|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
75468670|NCT04930991|Drug|Omeprazole|Treatment will consist of Omeprazole 2 weeks prior to surgical therapy of pancreatectomy.
75468671|NCT04906824|Device|great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing|VascuCel implantation in order to perform great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
75468672|NCT04906512|Device|3M™ Tegaderm™ CHG I.V. Securement Dressing|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
76077346|NCT05346783|Other|Placebo (vehicle)|1 drop 6 times a day
76077347|NCT05346783|Drug|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
76077348|NCT00948610|Drug|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
76077349|NCT02245750|Device|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
76077350|NCT03032302|Dietary Supplement|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
76077351|NCT03032302|Dietary Supplement|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
75468673|NCT04906512|Device|3M™ Tegaderm™ Transparent Film Dressing 1626W|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
75468674|NCT04905277|Drug|Atenolol 50 MG|50 mg Atenolol daily
75326266|NCT03215485|Behavioral|Virtual world learning environment|Every participant has their own unique avatar in the virtual world learning environment named Rippleville. They can choose to complete quests, watch archived nutrition video lessons, explore, and socialize with other avatars. They receive rewards (Rippleville dollar and badges) for their efforts.
75326267|NCT03215485|Other|Newsletter|All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.
75468675|NCT04905277|Drug|Placebo|one placebo daily
75468676|NCT04893278|Other|Virtual reality|Use of Virtual reality goggles during procedure
75468677|NCT04892472|Device|NovoTTF-200T|All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.
75326268|NCT05394142|Drug|Placebo|Comparator arm with placebo
75468678|NCT04892472|Drug|Pembrolizumab (MK-3475) 200 mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
75468679|NCT04889911|Behavioral|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
75633594|NCT02836587|Behavioral|Balance training|The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
75633595|NCT02834169|Other|Non interventional|Data collection
75633596|NCT00633321|Biological|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
75633597|NCT00633321|Biological|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
75326269|NCT05394142|Drug|Pioglitazone|Pioglitazone 7.5 mg/day
75326270|NCT05394142|Drug|Spironolactone|Spironolactone 50 mg/day
75326271|NCT05394142|Drug|Metformin|Metformin 850 mg/day
75326272|NCT00901225|Drug|G-CSF plus Plerixafor|"On Day 5 of G-CSF mobilization,~if the patient's peripheral CD34+ cell count is < 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is < 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."
75468680|NCT04889911|Other|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
75468681|NCT04888312|Biological|CD40 agonist mitazalimab in combination with chemotherapy|Mitazalimab administered intravenously every 14 days in combination with standard of care chemotherapy modified FOLFIRINOX.
75468682|NCT04880083|Dietary Supplement|Commercially Available Starter Infant Formula|Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
75468683|NCT04857671|Drug|Botulinum Toxin Type A in saline water|"100 Allergan units Botulinum toxin A in a total of 2 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 100 IU per 20 injections points."
75468684|NCT04857671|Drug|Isotone saline water|2ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 20 injections points
75468685|NCT04856046|Procedure|Biospecimen Collection|Undergo collection of blood sample
75633598|NCT02839083|Other|Thoracic Paravertebral group|Thoracic paravertebral block is performed using bupivacaine 0.25% in a total volume of 30 ml
75633599|NCT02839083|Other|Pecs II group|Ultrasound guided ipsilateral Pecs II block is performed using bupivacaine 0.25% in a total volume of 30 ml
75633600|NCT02834091|Procedure|Hypnoanalgesia|
75633601|NCT02836743|Drug|Circadin|Slow-release melatonin
75633602|NCT02836743|Drug|Placebo|
75633603|NCT00928512|Drug|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
75633604|NCT00928512|Drug|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
75784189|NCT01290146|Drug|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
75633605|NCT04249089|Behavioral|Relaxation video and pamplet|This group will be asked to watch a video and perform relaxation techniques twice a day following surgery
75326273|NCT02472730|Device|Distal Attachment Cap|Colonoscopies are performed under the supervision of board certified attending gastroenterologists experienced in colonoscopy. Attending physicians will provide assistance at their discretion or at the request of the trainee. All close examinations for polyps will be carried out on withdrawal of the colonoscope.
75468686|NCT04856046|Other|Electronic Health Record Review|Review of medical records
75468687|NCT04855864|Other|Follow-up of BCR TKA|Pre- and postoperative follow-up of patients treated with the BCR design by measuring PROMs, and clinical- and radiographic evaluation
75468688|NCT04855864|Other|Follow-up of BCS TKA|Pre- and postoperative follow-up of patients treated with the BCS design by measuring PROMs, and clinical- and radiographic evaluation
75468689|NCT04855864|Other|Follow-up of PS TKA|Pre- and postoperative follow-up of patients treated with the PS design by measuring PROMs, and clinical- and radiographic evaluation
75326274|NCT05393050|Drug|Colquhounia Root Tablet|Colquhounia Root Tablet is a tripterygium preparation
75468690|NCT04853004|Diagnostic Test|SARS-CoV2 antibody measurement|Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
75633606|NCT04255368|Other|Water-soluble choline|600 mg choline as choline bitartrate
75784190|NCT01290146|Drug|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~SBP ≥100 mmHg: 0.1 mcg/kg/min"
75468691|NCT04836637|Dietary Supplement|Maltodextrin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
75784191|NCT01177124|Behavioral|MBSR 6 Weeks Program|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
75326275|NCT05393050|Drug|Methotrexate tablets|Methotrexate is a drug used to treat rheumatoid arthritis
75326276|NCT03210415|Other|Observational Study Model|There is no intervention for the study.
75468692|NCT04836637|Dietary Supplement|Calcium-carbonate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
75468693|NCT04836637|Dietary Supplement|Calcium-enriched permeate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
75326277|NCT03166228|Drug|Normal Saline 0.9% Infusion Solution Bag|0.9% saline as distension medium as long as diathermy is not in use
75326278|NCT03166228|Drug|1.5% Glycine only|1.5% Glycine alone during hysteroscopy as long as diathermy is in use
75326279|NCT01833793|Drug|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
75468694|NCT04836637|Dietary Supplement|Calcium-enriched permeate with Inulin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
75468695|NCT04828083|Drug|Lidocaine IV|Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
75468696|NCT04828083|Drug|Saline IV|Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
75468697|NCT04826068|Behavioral|Emotional Processing|Processing Emotions of others based on photographs of faces
75468698|NCT04825678|Drug|Erenumab|Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
75633607|NCT04255368|Other|Fat-soluble choline|600 mg choline as phosphatidylcholine
75633608|NCT04255368|Other|No choline control|No choline
75633609|NCT04257240|Procedure|selective hepatic vascular exclusion|major hepatectomy with vascular control of blood inflow and outflow of the whole liver
75633610|NCT04257240|Procedure|semielective hepatic vascular exclusion|major liver resection by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
75633611|NCT00610818|Other|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
75633612|NCT04255290|Other|Leg Squat Lounge|The players assigned to the experimental group will receive an intervention through plyometric and eccentric hamstring exercises
75633613|NCT04255290|Other|Control group|The subjects included in the control group will perform an eccentric work protocol
75633614|NCT04255446|Device|Thora3DiTM|Not international
75633615|NCT04255680|Diagnostic Test|Buccal Swabs and Blood Draws|Buccal Swabs - Frataxin & specific RNA markers Blood Draws - Lipid panel, Uric Acid, Protein Marker Analysis and PAX Gene RNA Analysis
75633616|NCT00787891|Drug|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
75633617|NCT00787891|Drug|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
75633618|NCT00892437|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
75633619|NCT00892437|Drug|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
75633620|NCT00892437|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
75326280|NCT01833949|Procedure|Unilateral laparoscopic drilling|Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume
75326281|NCT01833949|Procedure|Bilateral laparoscopic drilling|Bilateral laparoscopic drilling with fixed doses energy
75633621|NCT00892437|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
75784192|NCT00061932|Drug|bortezomib|Given IV
75784193|NCT00061932|Drug|irinotecan|Given IV
75468699|NCT04808713|Behavioral|Treatment|The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
75468700|NCT04808700|Other|Follow-up of Episealer implant|Follow-up and radiographic evaluation in patients who received an Episealer implant
75468701|NCT04808505|Biological|Cipaglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
75468702|NCT04808505|Drug|Miglustat|65 mg oral capsules
75468703|NCT04805346|Device|autoRIC®|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada).17 The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol
75468704|NCT04788654|Drug|Celebrex, acetaminophen, and dexamethasone|Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.
75919872|NCT03412916|Behavioral|GetActive|GetActive is a comprehensive, multimodal treatment that was designed to increase quality of life, resiliency and ability to cope with medical symptoms and stress. This program is rooted in the elicitation of the relaxation response, a non-judgmental state of focused attention and increased awareness.
76077352|NCT04053166|Device|individualized home-based physical activity|Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.
75326282|NCT03154996|Drug|Topotecan|"Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)"
75326283|NCT03154996|Drug|Gadolinium|Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
75326284|NCT03154996|Device|Synchromed II infusion pumps|Implanted subcutaneously to facilitate chronic infusion.
75326285|NCT03219307|Combination Product|NOVOCART 3D|Matrix associated autologous chondrocyte implant
75326286|NCT05389306|Diagnostic Test|MRI Scanning|MRI scanning will be performed with a 3.0-T magnetic resonance imaging system with a head and neck-combined coil employing spin-echo technique. The range of the MRI scanning will be from the suprasellar cistern to the inferior margin of the sternal end of the clavicle. The section thicknesses for the axial plane, the sagittal plane and the coronal plane will be 5 mm, 3 mm and 2 mm, respectively. The intersection gaps will be 1 mm. Before the intravenous injection of the MRI contrast agents, T1 weighted images, T2 weighted images and diffusion weighted images will be obtained in the axial planes, while only T1 weighted images will be obtained in the sagittal and coronal planes. After the intravenous injection of the MRI contrast agents, T1-weighted axial sequence, T1-weighted sagittal sequences and T1-weighted fat-suppressed coronal sequence will be performed.
75919873|NCT03412916|Behavioral|Get Active with Fitbit|The GetActive Program for Pain with a Digital Monitoring Device (GetActive Fitbit) is identical to the GetActive with the addition of a FitBit for recording of physical activity.
75919874|NCT02588248|Drug|Peppermint Oil|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640 mg of L-Menthol).
76077353|NCT04053166|Other|MRI|An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).
76077354|NCT04053166|Biological|blood sampling|Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.
75326287|NCT05389306|Diagnostic Test|Contrast-Enhanced Ultrasonography|A sonographer equipped with a 6-15 MHz linear array probe will be adopted for contrast-enhanced ultrasonography examination. Conventional high-frequency ultrasonography will be performed firstly before the intravenous injection of the ultrasound contrast agents. Then the ultrasound contrast agents will be injected intravenously, and contrast-enhanced ultrasonography examination will be performed. The mechanical index of contrast-enhanced ultrasonography examination will be 0.23. The wash-in and wash-out process within the lymph node will be dynamically observed during the arterial phase. During the Kupffer-phase, the degree of enhancement will also be observed.
75326288|NCT05389306|Diagnostic Test|Ultrasound-guided Lymph Node Aspiration|After the conventional high-frequency ultrasonography and contrast-enhanced ultrasonography examination was finished, ultrasound-guided aspiration of the target lymph node will be performed. The lymph node tissue obtained from ultrasound-guided lymph node aspiration will be subjected to pathologic evaluation. And the diagnostic performance of MRI and contrast-enhanced ultrasonography will be evaluated using the pathologic diagnosis of the lymph node as the gold standard.
75468705|NCT04788654|Procedure|Saline irrigation, aspiration of pneumoperitoneum, and low pressure penumoperitoneum|Surgical intervention will be performed. Saline irrigation, aspiration of pneumoperitoneum, and low pressure pneumoperitoneum will be performed.
75468706|NCT04781647|Drug|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily
76077355|NCT04053166|Other|Questionnaires|sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.
76077356|NCT04053166|Other|6-minute walk test|The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.
75326289|NCT04380259|Behavioral|Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)|"MBTR-R is a mindfulness-based group intervention of nine 2.5-hour weekly sessions. MBTR-R format and structure parallel MBSR (mindfulness-based stress reduction) and MBCT (mindfulness-based cognitive therapy). MBTR-R includes systematic training in formal and informal mindfulness practices with trauma-sensitive adaptations and home practice. Trauma-sensitive adaptations include a safe place practice, psychoeducation about posttraumatic stress, stress reactivity, as well as self-compassion practices to cope with fear, self-judgement, guilt and shame. Socio-cultural adaptations include real-time linguistic translation of each session by a cultural mediator from the refugee community and use of socio-culturally specific metaphors. MBTR-R groups were conducted for men and women separately and delivered in an accessible, safe space in the local refugee community. Group meetings included a shared meal of traditional Eritrean food and female participants were offered free child care."
75468707|NCT04781647|Drug|ETV|Participants will receive ETV 0.5 mg tablets orally once daily
76077357|NCT05430958|Drug|INO-4800|INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
75326290|NCT02475070|Drug|Vildagliptin|Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
75326291|NCT02475070|Drug|Dapagliflozin|Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
75633622|NCT00892437|Drug|COBI placebo|Placebo to match COBI administered orally once daily
75919875|NCT02588248|Other|Placebo|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 80 ml of Solution B, also has 0 mg of L-Menthol).
76077358|NCT05430958|Drug|INO-9112|INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
75326292|NCT05381506|Drug|Orelabrutinib and Gemox|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin"
75326293|NCT00902161|Drug|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
75326294|NCT00902161|Drug|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
75326295|NCT00902161|Drug|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
75326296|NCT01834105|Drug|Liuwei Dihuang Pills|
75326297|NCT03095170|Behavioral|Computerized brain fitness training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program.
75468708|NCT04781647|Biological|Peg-IFNα|Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
75468709|NCT04777084|Drug|IBI318|IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 20 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
75468710|NCT04770246|Drug|TAS-117|TAS-117 will be dosed orally every day on a 21-day cycle
75919876|NCT03412838|Procedure|graft surgery|A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants
75326298|NCT03095170|Behavioral|Yoga|Will use adapted Hatha Yoga where participants sit on armless chairs placed on sticky mats for some asana (poses) and use the chair for support throughout. This adapted Hatha Yoga style is appropriate for older adults including those who have limited mobility, use walkers or are in wheelchairs. The appropriately sequenced yoga practice meets the American College of Sports Medicine recommendation for older adults for muscle strengthening and flexibility. Instructions are modeled for the participants
75326299|NCT03095170|Behavioral|Wellness Education|The education component will involve daily 60-minute group sessions with topics such as Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
75468711|NCT04770246|Drug|TAS-117|TAS-117 will be dosed intermittently on a 21-day cycle
75468712|NCT04770246|Drug|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
75468713|NCT04770246|Drug|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
75468714|NCT04768569|Drug|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
75468715|NCT04768569|Drug|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
75468716|NCT04759664|Drug|LUT014 Gel (Dose 1)|Topical gel
75468717|NCT04759664|Drug|LUT014 Gel (Dose 2)|Topical gel
75468718|NCT04759664|Drug|Placebo|LUT014 matching placebo topical gel
75468719|NCT04743791|Drug|Dupilumab|Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.
75633623|NCT00892437|Drug|RTV placebo|Placebo to match RTV administered orally once daily
75633624|NCT04108585|Procedure|HFO therapy|HFO therapy from mechanical ventilation
75633625|NCT04108585|Procedure|CPAP therapy|CPAP therapy from mechanical ventilation
75633626|NCT02838537|Drug|Exposure to Triptan|
75633627|NCT02838537|Drug|Exposure to Ergot|
75633628|NCT04108507|Procedure|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
75633629|NCT02836509|Drug|Paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
75919877|NCT05557396|Other|Internal Tube Length Measurement Procedures for Nazogastric Tube|Different Internal Tube Length Measurement Procedures will used for the correct placement of nasogastric tube.
75919878|NCT05239442|Other|Taste Commission|"Evaluation of the daily meal once a week:~Introduction on the different sensory dimensions of the food, hedonic rating for each component, indicate what pleases/what could be improved in the recipe."
75326300|NCT03095170|Behavioral|Support Group (patient and partner)|Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
75326301|NCT03095170|Behavioral|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
75326302|NCT01834183|Drug|Tivozanib|
75633630|NCT02836509|Drug|Ibuprofen|800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
75633631|NCT00792103|Drug|NP101|NP101 study patch 4 hour application
75326303|NCT01834183|Drug|Gemcitabine|
75326304|NCT04379947|Procedure|Fractional Flow reserve|Measurement of fractional flow reserve in the preoperative work-up for oronary artery bypass surgery
75326305|NCT02478580|Drug|Nuvigil|Patients will receive Nuvigil before the surgery
75326306|NCT02478580|Drug|Placebo|Placebo will be given before surgery
75326307|NCT03838081|Behavioral|Spielberger State Anxiety Inventory (STAI-S),|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
75326308|NCT03838081|Behavioral|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
75326309|NCT03838081|Behavioral|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
75633632|NCT02836197|Behavioral|Communication skills training|The general aim of the communication skills training program is to help physicians learn effective communication skills in contexts of high uncertainty. The training will last 30 hours, will be spread over 4 months. The training will be conducted by group of 3 subjects. The training will include mainly role-plays, theoretical information and modeling techniques. A training manual has been developed to increase content standardization and reduce potential group or trainee biases. The role-plays will be based on clinical cases brought up by the participants.
75919879|NCT05239442|Other|Evaluation of the taste commissions|"At 0, 3, 6 months:~Food intake measurement, satisfaction measurement, and food waste measurement performed on 2 days (same week but not necessarily consecutive)~Assessment of nutritional status using the Mini-Nutritional Assessment (MNA)"
75919880|NCT05239442|Other|Entretien SWOT|Individual semi-guided face-to-face interview with an experimenter. They will allow us to identify the positive and negative effects of the taste commissions in the establishment as well as the levers and difficulties encountered during the implementation of the taste commissions. These interviews will be recorded using an audio device (dictaphone). Their content will then be transcribed in full.
75919881|NCT05557318|Device|Vaginal swab for RT-PCR|Screening for Bacterial vaginosis (BV) / Trichomonas / Chlamydia trachomatis / Candida albicans
75919882|NCT05557318|Device|Vaginal swab for culture|Screening for Group B streptococcus / Neisseria gonorrhoeae / Escherichia coli
76077359|NCT05430958|Device|CELLECTRA® 2000|Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
75326310|NCT03838081|Behavioral|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
75326311|NCT03210181|Other|Superficial cervical plexus block|A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
75326312|NCT03210181|Other|Placebo|Patients will receive an equivalent volume of normal saline
75326313|NCT05345470|Other|140 calories per 30 gram test meal|Food
75633633|NCT04108663|Behavioral|Effect of tDCS on cognitive control task performance|Added verum or sham tDCS while working on a cognitive control task.
75633634|NCT05306379|Drug|Simvastatin|Oral dose 40 mg
75633635|NCT05306379|Drug|Voclosporin|Oral dose 23.7 mg twice daily
75633636|NCT05304663|Drug|Onfekafusp alfa|Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26
75633637|NCT05304663|Drug|Lomustine|"Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles."
75919883|NCT05557318|Device|Metabolic gas signatures detected by Ainos Flora (operated by participant)|The participant operates the Ainos Flora to collect signatures of metabolic gases in the vagina by herself.
75919884|NCT05557318|Device|Metabolic gas signatures detected by Ainos Flora (operated by medical staff)|The medical staff operates the Ainos Flora to collect signatures of metabolic gases in the participant's vagina.
75919885|NCT03412682|Drug|Budesonide (6 mg)|Budesonide (6 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
75919886|NCT03412682|Drug|Budesonide (9 mg)|Budesonide (9 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
76077360|NCT05428930|Drug|CKDB-501B|Intramuscular injection CKDB-501B
76077361|NCT05428930|Drug|Botox®50U|Intramuscular injection Botox®50U
76077362|NCT03031834|Drug|Quinapril|
75633638|NCT04109755|Drug|Pembrolizumab|5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
75326314|NCT03210493|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
75326315|NCT03210025|Drug|BF-Methyldopa 250mg Tablet|BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
75326316|NCT03210025|Drug|Metopa Tab 250mg|Metopa Tab 250mg is manufactured by APT
75326317|NCT03219853|Dietary Supplement|selenium enriched parsnips|Parsnips which have been grown in a selenium enriched environment
75326318|NCT03219853|Dietary Supplement|Conventional parsnips|Parsnips which have been grown in a conventional environment
75326319|NCT01834417|Device|TexiMat|
75326320|NCT04338412|Device|ProSeal-LMA™|It is a second generation LMA that is commonly used among all other LMAs
75326321|NCT02480998|Biological|IL-YANG Flu Vaccine QIV 0.5mL|
75326322|NCT02480998|Biological|IL-YANG Flu Vaccine TIV 0.5mL|
75326323|NCT03218995|Drug|Eteplirsen|Infusion for intravenous use.
75326324|NCT01834495|Device|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
75326325|NCT01834495|Device|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
75326326|NCT00905125|Biological|Fluzone®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
75326327|NCT00905125|Biological|Fluarix®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
75326328|NCT00905827|Behavioral|CAMS|Collaborative assessment management in suicidality
75326329|NCT03219541|Behavioral|Interventional Automated mobile phone text|Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
75326330|NCT03219541|Behavioral|Control Automated mobile phone text|Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
75326331|NCT03219073|Device|Active tDCS using tDCS device|Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.
75326332|NCT03219073|Device|SHAM tDCS using tDCS device|SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
75633639|NCT04248387|Drug|Toripalimab|Toripalimab, intravenous drip infusion, a dose of 3 mg / kg once every 2 weeks for a total of two cycles
75326333|NCT00894127|Device|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
75326334|NCT03216499|Drug|HIF-2alpha Inhibitor PT2385|Given PO
75326335|NCT03216499|Other|Pharmacological Study|Correlative studies
75633640|NCT02838693|Procedure|Not applicable. This is an observational study.|Not applicable. This is an observational study.
75633641|NCT04248309|Drug|intramuscular progesterone 20-40mg from D3 until pregnancy test|serum progesterone <7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
75633642|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
75633643|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
75326336|NCT03216499|Other|Laboratory Biomarker Analysis|Correlative studies
75326337|NCT03216499|Other|Pharmacogenomic Study|Correlative studies
75326338|NCT03215797|Drug|phenylephrine|phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
75326339|NCT03215797|Drug|Norepinephrine|Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
75326340|NCT03219463|Dietary Supplement|Ginger|3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
75326341|NCT01834573|Behavioral|physical exercise|10 weeks physical exercise; three times a week
75326342|NCT03211507|Other|Computer-assisted telephone interview|Occupational history
75326343|NCT03211507|Genetic|Genetic analysis|To include analysis of known susceptibility markers
75326344|NCT01830049|Other|Take blood|
75633644|NCT02836275|Other|Diffusion/Perfusion-weighted Magnetic Resonance Imaging|
75633645|NCT02836353|Drug|Somatostatin|Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
75633646|NCT02836353|Drug|Rifaximin|1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
75633647|NCT05333757|Other|Questionnaire|Adults with spinal deformities were asked to complete two questionnaires assessing quality of life
76077363|NCT02982382|Other|Manipulative Therapy|Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.
75326345|NCT02485834|Procedure|FDG-PET|
75326346|NCT02485834|Procedure|surgery|
75326347|NCT02485834|Drug|5-FU|200 mg/m^2/day IV
75633648|NCT02836431|Drug|Dexmedetomidine 1mcg/kg Intranasal|DEX 1 mcg/kg Intranasal
75633649|NCT02836431|Drug|Dexmedetomidine 2mcg/kg Intranasal|DEX 2 mcg/kg Intranasal
75633650|NCT02836431|Drug|Dexmedetomidine 1mcg Intravenous|DEX 1 mcg/kg Intravenously
75633651|NCT02833779|Other|Individual exercises|
75633652|NCT02833779|Other|Group exercises|
75326348|NCT02485834|Drug|capecitabine|oral 800 mg/m^2 BID
75633653|NCT02833545|Device|Ozone gas|Injection of ozone gas intra articularly
75326349|NCT02485834|Drug|docetaxel|30 mg/m^2 IV
75326350|NCT02485834|Drug|Irinotecan|50 mg/m^2 IV
75326351|NCT02485834|Radiation|3D-CRT|
75326352|NCT02485834|Radiation|IMRT|
75919887|NCT03412682|Drug|Mesalazine (3,600 mg)|Mesalazine (3,600 mg) administered once a day plus three mesalazine 400 mg three times a day, over an 8-week treatment period.
75326353|NCT01830283|Biological|varicella vaccine|The providers would get varicella vaccine
75326354|NCT01834885|Drug|QVA149|QVA149 via inhaler twice a day
75326355|NCT01834885|Drug|fluticasone/salmeterol|fluticasone/slameterol via inhaler twice a day
75633654|NCT02833545|Drug|Steroid injection|Injection of steroids (diprospan) intra articularly
75326356|NCT01834963|Drug|Interferon Alfa、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
75326357|NCT01834963|Drug|Cisplatin、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
75326358|NCT03219385|Device|Mirabilis System|The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
75326359|NCT03219151|Device|eMAR game|The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process
75326360|NCT03219151|Other|Normal pre-work|Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
75326361|NCT04380103|Drug|XELOXIRI/Bevacizumab|bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
75326362|NCT01954966|Drug|Progesterone|Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.
75326363|NCT01954966|Drug|Placebo|Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
75326364|NCT01835119|Drug|gum|gum
75326365|NCT01839019|Drug|ODM-102|Single dose escalation
75326366|NCT01839019|Drug|Placebo for ODM-102|Single dose escalation
75326367|NCT01835275|Behavioral|Enhanced Audio|
75326368|NCT01835275|Behavioral|Audio|
75326369|NCT01835353|Drug|Prasugrel 100mg loading dose|
75326370|NCT01835353|Drug|Prasugrel 60mg loading dose|Prasugrel 60mg loading dose
75326371|NCT05210608|Behavioral|Working Memory Training (Active Intervention) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
75326372|NCT05210608|Behavioral|Control Training (CT) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Control Condition Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
75326373|NCT03836365|Other|Preoperative counseling office visit|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have an in person preoperative counseling office visit.
75633655|NCT04250181|Other|RF ablation of atrial fibrillation|Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation
75633656|NCT05326425|Drug|lazertinib(YH25448)|- lazertinib 240mg(3tablets, 80mg/1tablet), once a day, oral, before disease progression
76077364|NCT02982382|Other|Pain Education|Individuals will receive pain education based in a biopsychosocial approach
76077365|NCT02982382|Other|Sham|The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
75633657|NCT02836041|Behavioral|questionnaires|"Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):~In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total)."
75633658|NCT02836041|Device|actigraph|This device reliably measures sleep by monitoring the child's motion.
75633659|NCT00784693|Biological|Tanezumab|15 mg IV single dose
75633660|NCT00784693|Drug|Placebo|Placebo IV single dose
75633661|NCT02835885|Device|Digitmer High Voltage Stimulator model DS7A TENS unit|
75633662|NCT00893763|Procedure|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
75633663|NCT00893763|Procedure|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
76077366|NCT00944554|Drug|Varenicline|Varenicline given twice a day or five weeks.
76077367|NCT00944554|Drug|Placebo|Placebo given twice a day or five weeks.
76077368|NCT03031990|Behavioral|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
75468720|NCT04743791|Other|Placebo|Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).
75468721|NCT04737330|Drug|Secukinumab|Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
75468722|NCT04737330|Drug|Placebo|Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
75468723|NCT04734210|Drug|0.02% Betamethasone Sodium Phosphate|topical corticosteroid solution
75326374|NCT03836365|Other|Preoperative counseling phone call|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have a preoperative counseling phone call.
75633664|NCT04105933|Other|CS-CBT|Culturally sensitive Cognitive Behavioural Therapy was delivered individually, focused on potential cultural beliefs and attitudes that might collide with core values of CBT.
75633665|NCT04105933|Other|CBT|CBT was delivered at an individual level, dealing with thoughts, feelings and behaviours in the present. Thoughts are identified and then challenged, to make them more objective and rational.
75468724|NCT04734210|Drug|0.04% Betamethasone Sodium Phosphate|topical corticosteroid solution
75326375|NCT03836521|Device|Transcatheter aortic valve replacement|
75326376|NCT01835509|Behavioral|Intervention, Camp plus reunions|
75326377|NCT02485912|Biological|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
75326378|NCT02485912|Biological|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
75326379|NCT03836599|Drug|Verinurad|Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.
75326380|NCT03836599|Drug|Allopurinol|Participants will receive allopurinol 300 mg once daily.
75326381|NCT03836599|Drug|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
75326382|NCT01839097|Drug|Belinostat|"Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:~Cohort 1: belinostat 1000 mg/m2 IV on Day 1~Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2~Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3~Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4~Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5"
75468725|NCT04734210|Drug|Placebo|topical vehicle solution
75468726|NCT04732130|Behavioral|Time-Restricted Feeding|Participants are instructed to limit food intake to maximum 8 hours per day.
75468727|NCT04732130|Behavioral|Alternate Day Fasting|Participants are instructed to fast every other day.
75468728|NCT04727528|Drug|Sodium zirconium cyclosilicate|Investigational medicinal product
75633666|NCT00915811|Drug|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
75784194|NCT01177202|Biological|HAC1 Vaccine|Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
75784195|NCT03856970|Drug|Microgestin®|30 μg/1500 μg tablets for oral administration
75326383|NCT01839097|Drug|CHOP|"Cyclophosphamide - 750 mg/m2 - IV - Day 1~Vincristine - 1.4 mg/m2 - IV - Day 1~Doxorubicin - 50mg/m2 - IV - Day 1~Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat."
75468729|NCT04727528|Drug|Placebo|Plabeco comparator
75468730|NCT04724980|Drug|PRGN-2012|"In the Phase 1, 3+3 dose escalation clinical trial evaluating PRGN-2012 at two dose levels (1x10^11 and 5x10^11 particle units (PU)) administered as adjuvant therapy prior to standard-of-care debulking surgery.~In the Phase 2 segment, PRGN-2012 is evaluated at the RP2D."
75468731|NCT04716998|Biological|MesenCure|Three administrations of MesenCure in addition to standard care
75468732|NCT04714450|Behavioral|Experimental: MMST+|The format of the MMST will remain the same; however, the white noise, images and math task will be modified to mitigate habituation effects.
75784196|NCT03856970|Drug|Levothyroxine|600 μg tablets for oral administration
75784197|NCT03856970|Drug|Glyburide|5 mg tablets for oral administration
75468733|NCT04711837|Drug|HSK3486|HSK3486 for induction of general anesthesia.
75468734|NCT04711837|Drug|Propofol|Propofol for induction of general anesthesia.
75468735|NCT04693377|Procedure|Cryosurgery|Undergo cryoablation
75468736|NCT04693377|Other|Quality-of-Life Assessment|Ancillary studies
75468737|NCT04693377|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
75468738|NCT04682678|Procedure|Implantation of electrodes for Spinal cord stimulation|The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
75468739|NCT04680611|Other|no study intervention. Patients receive standard clinical care|no intervention. observational study
75468740|NCT04676425|Drug|MK-8189|Administered at a dose of 4 mg via oral tablet
75468741|NCT04674189|Biological|CVnCoV Vaccine|Intramuscular injection
75633667|NCT00915811|Drug|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
76077369|NCT03031990|Behavioral|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
76077370|NCT03031990|Behavioral|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
76077371|NCT03031756|Device|glycine powder air-polishing (Air-Flows)Perio Powder|
75326384|NCT02488018|Biological|Provision of experimental honey|"Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.~25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight."
75633668|NCT00915811|Drug|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
75633669|NCT00915811|Procedure|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
75633670|NCT00892047|Drug|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
75633671|NCT00892047|Drug|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
76077372|NCT03031756|Device|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
76077373|NCT00944710|Drug|Atropine|Weekend atropine 1%
76077374|NCT00944710|Device|Plano lens|plano lens over the sound eye
76077375|NCT00944710|Drug|Atropine|Weekend atropine 1%
76077376|NCT00945100|Device|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
75326385|NCT01835665|Drug|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
75326386|NCT01839175|Biological|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
75326387|NCT01839175|Biological|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
75326388|NCT01839175|Biological|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
75633672|NCT05549011|Other|PENG Block|PENG block for analgesic purposes performed before hip surgery
75784198|NCT03856970|Drug|Digoxin|0.25 mg tablets for oral administration
75784199|NCT03856970|Drug|IW-3718|500-mg film-coated tablets for oral administration
75784200|NCT02530710|Drug|Q203|
75784201|NCT02530710|Drug|Placebo|
75784202|NCT06193967|Behavioral|Caregiver Praise|Caregivers will provide praise for child's engagement in dietary self-monitoring behaviors as a form of positive reinforcement
75784203|NCT06193967|Behavioral|Gamification|DSM logs will include gamification (points, levels, virtual pets) as positive reinforcement for child's engagement in dietary self-monitoring behaviors
76077377|NCT00945100|Device|Eye Patch|2 hours patching daily
76077378|NCT05384236|Other|kinesiology taping|To apply kinesiology taping in plantar fascia
75326389|NCT01839175|Biological|RotaTeq|2 mL oral administration at 2, 3 and 4 months
75326390|NCT01839175|Biological|Nimenrix|0.5 mL intramuscular injection at 12 months
75326391|NCT01839175|Biological|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
75326392|NCT01582048|Drug|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
75326393|NCT01835821|Device|prosthetic crowns|prosthetic crowns
75326394|NCT01839253|Drug|b-blocker(Atenolol)|
75326395|NCT01839253|Drug|ACE inhibitor(Enapril)|
75326396|NCT01839253|Other|control|
75326397|NCT00404170|Drug|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
75326398|NCT01839409|Behavioral|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
75326399|NCT01835977|Device|Irreversible Electroporation (Nanoknife)|
75326400|NCT01839565|Device|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
75326401|NCT01836211|Other|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
75326402|NCT01836211|Other|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
75633673|NCT05549011|Other|SIFI compartment block|SIFI compartment block for analgesic purposes performed before hip surgery
75633674|NCT05549011|Diagnostic Test|Numeric Rating Scale|Self-reported pain intensity score between 0-10
75784204|NCT06193928|Drug|Maralixibat|The recommended dosage is 380 mcg/kg once daily.
75784205|NCT06193915|Device|Ultrasound guided hematoma block.|Patients with a dislocated fracture of the distal radius will receive ultrasound guided hematoma block with 10mL lidocaine 2% to get real-time guidance of the given anesthesia into the fracture site before closed reduction of a distal radius fracture.
75784206|NCT06193915|Procedure|Blind hematoma block|Patients with a distal radius fracture will receive standard treatment; hematoma block with 10mL 2% lidocaine performed with palpation of the fracture site (blind hematoma block) before closed reduction of dislocated distal radius fractures.
75784207|NCT06193902|Biological|LEU011|Immunotherapy
76077379|NCT05384236|Other|taping or Low-dye taping|To apply taping or Low-dye taping in plantar fascia
75326403|NCT04379869|Drug|NNZ-2591|Single dose of NNZ-2591
75326404|NCT04379869|Drug|Placebo|Comparator for double-blind MAD
75468742|NCT04674189|Drug|Placebo|Intramuscular injection
75633675|NCT05549011|Diagnostic Test|Angle of sitting|Measurement of sitting angle in degrees with a protractor
75633676|NCT02602561|Dietary Supplement|HMB|
75633677|NCT02602561|Dietary Supplement|Placebo|
75633678|NCT02835729|Drug|Idarubicin|Chemotherapy
75633679|NCT02835729|Drug|Cytarabine|Chemotherapy
75326405|NCT01836289|Drug|High-dose Cyclophosphamide|
75326406|NCT03218839|Device|PrePex male circumcision device|PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
75326407|NCT01839643|Drug|Meloxicam 2.4 g|2.4 g in Vaginal Ring
75326408|NCT01839643|Drug|Meloxicam 3.0 g|3.0 g in Vaginal Ring
75326409|NCT01839721|Drug|Bifilact®|placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
75326410|NCT01839721|Other|placebo|
75326411|NCT01836367|Drug|Ingenol Mebutate 0.015%|Picato
75326412|NCT04379557|Procedure|Catheter Ablation|Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
75341395|NCT05563285|Behavioral|Exercise and Mindfulness-Based Intervention|"1.Exercise Intervention~1st-2nd week: 15 min for Brisk walking. Intensity: HRmax (60%-65%); CR10 (5-6). 3rd-4th week: 20 min for Brisk walking. Intensity:HRmax (65%-70%); CR10 (6-7). 5th-6th week: 25 min for Brisk walking. BW: Intensity: HRmax(70%-75%); CR10 (6-7). 7th -8th week:30 min for Brisk walking.~Exercise Intervention basic content:~(1) Gradually increase the walking speed; (2) Slowly reduce the speed; (3) Rest for 5 min.~2. Mindfulness-Based Intervention~1st-2nd week: 30 min for mindfulness training. 3rd-4th week: 35 min for mindfulness training. 5th-6th week: 40 min for mindfulness training. 7th-8th week: 45 min for mindfulness training.~Mindfulness-Based Intervention basic content:~(1) Yoga; (2) Mindful breathing; (3) Mindfulness meditation; (4) Body scan; (5) Mindfulness awareness; (6) RAIN technique; (7) Mindful Stretching; (8) Mindful walking; (9) Mindful running"
75341396|NCT05563285|Behavioral|Control Group|The control group maintained their classes as usual, usual physical education sessions, and usual daily life.
75341397|NCT01746056|Device|Occlusive Heat Patch|The heat patch will be applied for 2 hours every day for a period of 12 weeks.
75633680|NCT02835729|Drug|Indoximod Freebase|IDO pathway inhibitor
75633681|NCT02835729|Drug|Indoximod HCL F1|IDO pathway inhibitor
75633682|NCT02835729|Drug|Indoximod HCL F2|IDO pathway inhibitor
75633683|NCT02835651|Dietary Supplement|Palmitic acid|Experimental products are enriched with C16:0
75633684|NCT02835651|Dietary Supplement|Stearic acid|Experimental products are enriched with C18:0
75633685|NCT02833623|Behavioral|Short-message-based Re-education|
75633686|NCT02833623|Behavioral|conventional education|
75633687|NCT00787267|Drug|Dasatinib|70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
75633688|NCT02838615|Procedure|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
75341398|NCT05246228|Other|Peripheral blood sampling in order to evaluate changes in the circulating immune population|Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)
75341399|NCT01533259|Drug|Stribild|Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
75341400|NCT05246072|Drug|Ivermectin + colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
75341401|NCT05246072|Drug|Colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
75341402|NCT02135432|Drug|Ivacaftor|
75341403|NCT02135432|Drug|Placebo|
75341404|NCT01576003|Drug|Glutamine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
75468743|NCT04670198|Behavioral|Youth Empowerment Skills|The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional
75468744|NCT04670198|Behavioral|Waiting-list control|Usual care for 6 months, followed by the YES programme.
75633689|NCT04104061|Other|iron profile|blood test
75633690|NCT05324319|Drug|Ad26COVS1|Heterologous vaccination
75633691|NCT05324319|Drug|ChAdOx1 SARS2 Vaccine|Heterologous vaccination
75633692|NCT05324319|Drug|BNT162B2|Homologous vaccination
75633693|NCT05324319|Drug|mRNA-1273|Homologous vaccination
75633694|NCT02603263|Other|Social Norms Poster|"A poster containing a social norms message: Most people here choose to eat vegetables with their lunch"
75633695|NCT04104295|Diagnostic Test|Ultrasound following X-ray|A short (less than 10 minutes) ultrasound (US) scan of the abdomen within 2 hours of the routine X-ray (XR). The performer will be a physician who received a focused training on relevant US views, blinded to the XR image and report.
75633696|NCT02838225|Drug|Docetaxel, Doxorubicin|
75633697|NCT02838225|Drug|Docetaxel, Doxorubicin, Cyclophosphamide|
75633698|NCT00928434|Drug|Degarelix|Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.
75633699|NCT00928434|Drug|Degarelix|Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).
75633700|NCT00928434|Drug|Leuprolide|Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
76077380|NCT03031600|Diagnostic Test|Radiodilution via Daxor BVA-100|The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).
75326413|NCT04380025|Dietary Supplement|Experimental: Oral Mirtogenol|The experimental arm is Oral Mirtogenol dietary supplement, one capsule daily in addition to bimatoprost ophthalmic drops with primary open angle glaucoma
75326414|NCT04380025|Dietary Supplement|Placebo of oral Dietary supplement|This is the oral placebo of the supplement (control) un daily capsule in addition to the bimatoprost ophtalmic drops
75633701|NCT02604121|Device|Orcellex® Rovers brush|transepithelial brushing
75633702|NCT02831595|Device|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
75633703|NCT04248699|Dietary Supplement|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
75919888|NCT05557084|Procedure|laparoscopic vertical clip gastroplasty (LVCG) with Bariclip.|The investigator performed laparoscopic vertical clip gastroplasty, This procedure consists of a nonadjustable clip that is vertically placed around the stomach, parallel to the lesser curvature, mimicking the effect of sleeve gastrectomy. The clip restricts oral intake, the anatomy of the stomach is not permanently changed, the small bowel remains untouched, the digestive pathway is not diverted, no stapling or resection are required and the magnitude of restriction is supposed to remain constant during the years. The vertical clip is thus placed without risks of staple line leak, malabsorption side effects, changes in anatomy, and is potentially reversible [9]. creating a 4-cm window to enter the lesser sac while lifting the stomach to create sufficient space to be able to suture. Plication of the antrum for 3-5 cm is performed. Fluid testing for patency is performed with methylene blue or normal saline and the procedure is terminate.
75919889|NCT05166434|Procedure|trans-crestal sinus lifting|this study will be divided in to three different groups, each group will receive a same technique of Crestal maxillary sinus lifting and implant placement at 2,4,6 mm heights.
75919890|NCT03412526|Drug|Fludarabine|Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)
76077381|NCT03031600|Diagnostic Test|Hemodilution via hematocrit measurement|Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
76077382|NCT00949078|Drug|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
76077383|NCT00945256|Other|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
76077384|NCT00945256|Drug|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
76077385|NCT00945256|Dietary Supplement|Amino Acid Drink|7.5 gram Amino Acid drink
76077386|NCT00940576|Dietary Supplement|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
76077387|NCT00940576|Other|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
76077388|NCT05354752|Drug|VC005 tablets|VC005 groups repeat administration for 7 days
76077389|NCT05354752|Drug|VC005 Placebo tablets|VC005 placebo groups repeat administration for 7 days
76077390|NCT03854032|Biological|Nivolumab|Given IV
76077391|NCT03854032|Biological|IDO1 Inhibitor BMS-986205|Given PO
76077392|NCT03854032|Procedure|Therapeutic Conventional Surgery|Undergo Surgery
76077393|NCT03854032|Other|Questionnaire Administration|Ancillary studies
76077394|NCT02982226|Other|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
76077395|NCT02982226|Other|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
75326415|NCT00908791|Drug|Conjugated Linoleic Acid (CLA)|Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
75326416|NCT01836601|Behavioral|Family-centered nighttime communication bundle|
75326417|NCT03218371|Procedure|chandelier-assisted peripheral vitrectomy under air|chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
75633704|NCT00787189|Device|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
75633705|NCT00787189|Device|Placebo Laser|inactive low level laser light therapy with no therapeutic output
76077396|NCT03031288|Device|A|standard bottle
76077397|NCT03031288|Device|B|vented base bottle
76077398|NCT03031522|Radiation|18F-IRS|According to experiment, 18F-IRS was non-toxic and stable in serum.
76077399|NCT03031444|Drug|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
76077400|NCT03031444|Drug|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
76077401|NCT05320042|Device|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
76077402|NCT05320042|Device|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
75326418|NCT01836679|Drug|Chidamide|Given orally
75468745|NCT04661891|Other|Isometric contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of applying joint torque to reach a pre-defined torque level based on the subject's maximal voluntary contraction (i.e., 25%, 60%, 70%, 80%, 90%). The participant will control torque intensity by responding to a biofeedback displayed on a screen. The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
75919891|NCT03412526|Radiation|Radiation|Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day
76077403|NCT02982304|Device|Deep Brain Stimulation|Deep Brain Stimulation Electrode
76077404|NCT02980198|Biological|IFN-Kinoid|IM administration
75326419|NCT01836679|Drug|Paclitaxel|Given IV
75326420|NCT01836679|Drug|Carboplatin|Given IV
75633706|NCT04248621|Drug|Leuprorelin|LHRH agonist
75633707|NCT04248621|Drug|Goserelin|LHRH agonist
75633708|NCT04248621|Drug|Triptorelin|LHRH agonist
75633709|NCT04248621|Drug|Degarelix|LHRH antagonist
75633710|NCT04248621|Drug|Bicalutamide|Antiandrogen
75633711|NCT04248621|Drug|Flutamide|Antiandrogen
75633712|NCT04248621|Drug|Maximum androgen blockade|Combination therapy with LHRH agonist and antiandrogen
75633713|NCT00784459|Drug|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
75919892|NCT03412526|Biological|TIL administration|TIL Administration
75919893|NCT03412526|Drug|IL-2|bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.
76077405|NCT02980198|Other|Placebo|IM administration
75326421|NCT01836679|Drug|Placebo|Given orally
75326422|NCT03218293|Device|RIPC device (IPC-906X)|Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
75326423|NCT02489110|Behavioral|Webnovela|
75326424|NCT02489110|Behavioral|Information|
75326425|NCT05452252|Diagnostic Test|functional mandibular evaluation|Active mandibular movements including depression, protrusion, and left-right deviation, facial anthropometry was measured on facial shape on photograph, and phenotype and asymmetry
75326426|NCT05452096|Behavioral|Education program and ergonomic schedulling|"The duration: six months. The explicit choice for a multimodal intervention to be tested as a whole is in line with the assertion of other experts that workplace interventions using a single approach will not be effective.~Multimodal intervention~Implementing healthy scheduling. This will imply fast forward-rotating shift schedules, being adapted to chronotype, allowing for adequate resting times between shifts and series of shifts, allowing for napping at work, in particular during the first two days of an early shift.~Education program for drivers: psychoeducation on the sleep-wake cycle chronotypes, based on the cognitive-behavioral treatment of insomnia (CBT-i), information on the impact of light on wakefulness and sleep, information on napping and creating awareness on daytime sleepiness, tools for stress reduction, physical exercise, information on healthy eating in the context of shiftwork The education program will consist of a one-day, 8-hour session."
75633714|NCT00784459|Drug|Placebo|Treatment with Placebo, IV
75633715|NCT04257006|Device|oXiris membrane|Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
75633716|NCT02831517|Drug|BIIB074|Administered as specified in the treatment arm
75633717|NCT02831517|Drug|Placebo|Matched Placebo
75633718|NCT04256928|Procedure|Preoperative electrical clipping|Body hair in the operative field will be clipped with an electrical clipper by hospital personnel during preparation to planned surgery.
75633719|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|"Omega-3's are administered in the form of an orange pudding made by Coromega~1 mg of omega-3 fatty acid 2 times per day"
75633720|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|"Omega-3 Fatty Acids in orange pudding form~1 packet two times per day"
75633721|NCT04248777|Other|standardised OCT-guided intervention|The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
75784208|NCT06193876|Other|Petitgrain and ylang-ylang essential oil|Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.
75784209|NCT06193850|Other|Observation during time|Evaluation through clinical investigation and questionnaires useful for evaluating the patient's psycho-physical conditions
75784210|NCT06193837|Drug|Augmentin|Use of prophylactic antibiotics in lap cholecystectomy
75784211|NCT06193785|Other|Hypnosis|hypnosis realised by expert practitioner, before and during the electromyogram procedure
75784212|NCT06193772|Behavioral|Internet-delivered psychodynamic therapy (IPDT)|"IPDT consists of 8 therapist-supported self-help modules delivered over 10 weeks on a secure online platform. Modules consist of texts and video followed by assignments which they send to their therapist and receive feedback within a few days. The intervention IPDT adapted starts with therapist feedback about the patient's predicted progress and continues with adapting the treatment to the individual adolescent, for example adding text chat sessions."
76077406|NCT02980198|Other|ISA 51|adjuvant
76077407|NCT05258734|Other|COVOS app|In this study, the patients in the experimental group will be followed up with the COVOS app and nursing interventions (videos, information messages) to manage their symptoms will be directed with the COVOS app.
76077408|NCT05258734|Other|Standard Care|In this study, the patients in the control group will not receive any intervention, the standard follow-up and health care provided by the family health center of the patients will continue.
76077409|NCT02980432|Other|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
76077410|NCT03031132|Behavioral|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
75784213|NCT06193759|Biological|Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)|Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse. In this study, individualized TSA-T cells will be generated against proteogenomically determined tumor-specific antigens after standard of care treatment in children less than 4 years of age with embryonal brain tumors.
75326427|NCT00369460|Other|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
75326428|NCT00369538|Drug|losartan, hydrochlorothiazide|Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months
75326429|NCT00369538|Drug|hydrochlorothiazide, losartan|One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
75326430|NCT02489734|Drug|sevoflurane|extubation when end-tidal concentration of sevoflurane < 0.5%
75326431|NCT02489734|Drug|Sevoflurane|extubation when end-tidal concentration of sevoflurane >= 0.5%
75326432|NCT05124262|Other|Low- FODMAPdiet group intervention|Diet intervention
75326433|NCT02490670|Drug|Cephalexin|Administered orally
75326434|NCT00908947|Device|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
75326435|NCT02492854|Device|PICO Single-Use Negative Pressure Dressings|Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
75326436|NCT02492854|Other|Sterile Gauze Dressings|Current standard-of-care dressings used to cover surgical wounds post-operatively.
75326437|NCT05451706|Behavioral|Mental help-seeking self-persuasion|Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
75326438|NCT01836757|Drug|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
75326439|NCT01836757|Drug|Placebo|
75326440|NCT05451472|Diagnostic Test|thyroid function tests|Thyroid function tests:thyroid stimulating hormone (TSH), total thyroxine (T4), free thyroxine (FT4), total triiodothyronine (T3), and free triiodothyronine (FT3)
75326441|NCT05451472|Diagnostic Test|complete blood count|complete blood count
75326442|NCT05451472|Diagnostic Test|serum creatinine|serum creatinine
75326443|NCT05451472|Diagnostic Test|blood urea|blood urea
75326444|NCT05451472|Diagnostic Test|serum electrolyte|serum electrolyte
75326445|NCT05451472|Diagnostic Test|serum calcium|serum calcium
75326446|NCT05451472|Diagnostic Test|serum phosphorus|serum phosphorus
75326447|NCT05451472|Diagnostic Test|parathyroid hormone level|parathyroid hormone level
75468746|NCT04661891|Other|Isokinetic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of moving a joint to completing a set of contractions (10-20 contractions) at various velocities (i.e., 10 degrees per second, 30 degrees per second, 60 degrees per second). The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
76077411|NCT03031132|Behavioral|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
76077412|NCT03031132|Behavioral|Breakfast Skipping|Participants will skip breakfast each morning.
75326448|NCT05451472|Diagnostic Test|liver function test|ALT_AST_Total biliruin_total protein _serum albumin
75326449|NCT05451472|Diagnostic Test|arterial blood gases|PH_PCO2_PO2_HCO3_base deficit
75326450|NCT05451472|Diagnostic Test|complete urine analysis|complete urine analysis
75326451|NCT01836835|Other|Pregnancy Unique Questionnaire of Emesis (PUQE)|For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
75326452|NCT01836835|Other|24 hours self-reported nutritional intake form|A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
76077413|NCT03031054|Procedure|Sono-guided injection with hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
75326453|NCT01839877|Drug|HIA DEBIRI + systemic FOLFOX|
75326454|NCT05451394|Other|ROAF|"Use of the method Ressource Optimisation of Armed Forces (ROAF). 6 one-hour workshops"
75326455|NCT05451394|Other|Active Comparator|6 one-hour workshops on cognitive process
75326456|NCT03218059|Procedure|Methotrexate Combined With Transvaginal Surgery|The methods of treatment of CSP
75326457|NCT05107492|Drug|450mg|following a single subcutaneous dose of PF-06480605 450 mg
75326458|NCT05107492|Drug|150mg|following a single subcutaneous dose of PF-06480605 150 mg
75326459|NCT05107492|Drug|Placebo|following a single subcutaneous dose of placebo
75326460|NCT01839955|Drug|erlotinib hydrochloride|"Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally"
75341405|NCT01576003|Dietary Supplement|L-alanine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
75326461|NCT01839955|Drug|quinacrine dihydrochloride - Escalation dose|Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 [starting dose]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
75326462|NCT01839955|Other|laboratory biomarker analysis|Correlative studies
75633722|NCT02834949|Behavioral|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
75326463|NCT01839955|Other|pharmacological study|Correlative studies
75326464|NCT01839955|Drug|quinacrine dihydrochloride - Extension dose|Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
75468747|NCT04661891|Device|Dynamic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Multi-joint tasks (i.e. walking, squatting, cycling) will be performed at a given frequency. A motion capture system will be used to record the joint angles and ground reaction forces simultaneously.
75468748|NCT04661891|Device|Isometric contraction with muscle fatigue|"An identical experiment will be performed as stated in Isometric contraction with the addition of induced muscle fatigue by repeatedly maintaining 40% of muscle torque until failure to maintain a contraction for 5 seconds."
75468749|NCT04661891|Device|Multi-joint functional activities while wearing exoskeleton|Participants will be measured and fitted with the bilateral exoskeleton, and sufficient range of motion to used exoskeleton will be confirmed. HD-EMG grids will be applied to the lower limb muscles of interest. The participant will perform single-joint movements to calibrate the decoder parameters. The participant will then perform multi-joint activities (e.g., standing, squatting, walking overground or on a treadmill, cycling, or stair climbing) in a movement analysis laboratory
75468750|NCT04661891|Other|Clinical Assessments|Subjects may complete a 10 meter walk test (10MWT) overground or over a pressure-sensitive walkway, 6 minute walk test (6MWT), Berg Balance scale (BBS), and/or Functional Gait Assessment (FGA). They may also complete step ups or squats.
75468751|NCT04660539|Drug|satralizumab|Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
75468752|NCT04660539|Drug|azathioprine (AZA)|Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
75633723|NCT02834949|Behavioral|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
75633724|NCT02834949|Behavioral|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
75919894|NCT05130710|Procedure|staging laparoscopy|All patients of both groups underwent staging laparoscopy by the same two attending onco-surgeon, using the same technique and the same laparoscopic device. Under general anesthesia and in supine position SL was performed. A 10 mm optic laparoscopic port was inserted via the midline incision below the umbilicus using Hasson technique. All four quadrants of the abdomen as well as pelvis were inspected during laparoscopy and biopsy was taken from any suspicious lesion through insertion of 5mm port. All specimens underwent cytological evaluation by two independent pathologists. The presence of any malignant cells, regardless of the number, confirmed the positive cytology. In the event of discordant reports between two pathologists, specimens were sent for the third review by a pathologist who was blinded to the previous results. Laparoscopic evaluation was considered positive as if adjacent organ involvement, omental involvement or peritoneal seeding were seen.
76077414|NCT03031054|Procedure|Sono-guided injection with normal saline|Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
75468753|NCT04660539|Drug|mycophenolate mofetil (MMF)|Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
75468754|NCT04660539|Drug|oral corticosteroids|Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
75468755|NCT04652765|Drug|Camostat Mesilate|Camostat 600mg by mouth four times a day, for a total of 7 days
75468756|NCT04652765|Drug|Bicalutamide 150 mg|Bicalutamide 150mg by mouth once daily, for a total of 7 days
75468757|NCT04642430|Drug|Apixaban|Refer to Apixaban group
75468758|NCT04642430|Drug|Rivaroxaban|Refer to Rivaroxaban group
76077415|NCT03031366|Other|3d roadmap guidance|TIPS was established using 3d roadmap
76077416|NCT03031366|Other|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
76077417|NCT00945334|Drug|Neomycin|500 mg po bid for 14 days
76077418|NCT00945334|Drug|Placebo|placebo for 14 days tid
76077419|NCT00945334|Drug|Rifaximin|550 mg po tid
75468759|NCT04630431|Other|Best Practice|Undergo standard of care follow-up
75468760|NCT04630431|Other|Educational Intervention|Undergo clinical trial education via a video and educational booklet
75633725|NCT00786565|Device|Advanced Akreos Adapt in one operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
75633726|NCT00786565|Device|Akreos Adapt in fellow operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
75919895|NCT04447430|Device|bright light|treat patients with bright light, 30 min per day, 7 times per week, over 6 weeks
75919896|NCT04447430|Device|dim red light|treat patients with dim red light, 30 min per day, 7 times per week, over 6 weeks
75919897|NCT05117684|Procedure|Novel|Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
75326465|NCT02493088|Other|Antisocial personality recording of behavior and contextual elements|aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
75919898|NCT05117684|Procedure|Conventional|Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
75919899|NCT05238818|Biological|Autologous Tumor Infiltrating Lymphocyte Injection (GT202)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. T cells then are manufactured to express mbIL-12. After lymphodepletion, patients are infused with GT202 followed by IL-2.
75326466|NCT01831843|Device|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
75326467|NCT01831843|Device|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
75326468|NCT01831843|Device|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
75326469|NCT02494102|Drug|Modafinil|Atypical Psychomotor stimulant
75326470|NCT02494102|Drug|Placebo|
75633727|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
75784214|NCT06193746|Device|non-invasive laser therapy|(diode laser, continuous output, in skin contact mode, 0.005W,0.2cm,beam spot area 0.03cm2, 288j/cm ,1800s) in the morning session, we measured lipid profile and kidney function before and after treatment to measure improvement
75919900|NCT05238662|Procedure|pedicle screw fixation on one side and intervertebral cage on the other sided|pedicle screw fixation on one side and intervertebral cage on the other sided
75919901|NCT05238662|Procedure|pedicle screw fixation and interbody cage on the same side|pedicle screw fixation and interbody cage on the same side
76077420|NCT00087789|Genetic|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10^10 vg, CERE-110 1.0 x 10^11 vg, CERE-110 2.0 x 10^11 vg
75468761|NCT04630431|Other|Electronic Health Record Review|Review of medical record
75468762|NCT04630431|Behavioral|Patient Navigation|Undergo clinical trial navigation
75468763|NCT04630431|Other|Questionnaire Administration|Complete questionnaire
75468764|NCT04627948|Diagnostic Test|Stockholm3 test|Diagnostic test: Stockholm3-test. Men from the study sites, diagnosed with prostate cancer and currently on AS and planned for rebiopsies will be invited to the study.
75468765|NCT04624750|Drug|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to < 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2 - (patients aged 6 to < 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study."
75784215|NCT06193733|Biological|Autologous Dendritic Cell|Biological: Immunotherapy with dendritic cells
75784216|NCT06193720|Drug|Arnica montana|Assess the effect of arnica montana on pain, swelling ans trismus after impacted third molar surgery
75326471|NCT01836991|Procedure|surgery|
75326472|NCT03219619|Device|Cap-EGD|Undergoing cap-assisted endoscopy
75326473|NCT03219619|Device|Duo|Undergoing side-viewing duodenoscope
75326474|NCT05451160|Device|steep pulse therapy system|The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation
75326475|NCT05451160|Device|RF Ablation System|RF Ablation System
75326476|NCT00894517|Biological|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
75326477|NCT00894517|Drug|Placebo (saline)|Saline injected into the prostate on Day 1.
75468766|NCT04619797|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
75468767|NCT04619797|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
75468768|NCT04619797|Drug|Pemetrexed|Pemetrexed 500 milligrams per square meter (mg/m^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
75468769|NCT04619797|Drug|Carboplatin|Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
75468770|NCT04619797|Drug|Cisplatin|Cisplatin 75 mg/m^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
75784217|NCT06193720|Other|Placebo|Patients will take placebo drug after surgeries
75919902|NCT05238428|Behavioral|Trust boost|The investigators adapt the wording of the vaccination invitation to foster trust and increase vaccination acceptance.
75919903|NCT05238272|Device|Transcranial random noise stimulation (tRNS)|There will be 20 minutes of stimulation (real tRNS or sham tRNS), 40 minutes of MT (unilateral or bilateral) and 30 minutes of functional task training.
75919904|NCT05238272|Device|sham tRNS|the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds
76077421|NCT03578224|Procedure|Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)|Undergo EUS-FNA
76077422|NCT03578224|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
76077423|NCT03578224|Procedure|Fine-Needle Aspiration|Undergo FNA
76077424|NCT03578224|Drug|Sonazoid (Perflubutane)|Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance
75326478|NCT01833871|Other|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
75326479|NCT01833871|Other|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
75326480|NCT05059210|Behavioral|Coach McLungs Intervention|Practices have received implementation of Coach McLungs
75633728|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
75633729|NCT02835105|Drug|Surotomycin|A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
75633730|NCT02835105|Drug|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
75633731|NCT02835027|Procedure|Open versus endovascular surgery|Treatment for acute ischemia
75633732|NCT05285514|Diagnostic Test|Comparison of macro- and microcirculatory parameters|"Microcirculation examination using sublingual videomicroscopy, tissue O2 saturation (StO2) by NIRS and transcutaneous CO2 pressure (tcpCO2) monitoring, in conjunction with macrocirculatory parameters measures including cardiac output, arterial pressure and pulsed O2 saturation, in order to establish the relationship between the macrocirculatory changes in blood pressure and cardiac output and the microcirculatory flow and capillary density during vasoactive agent use. . Participants receive interventions as part of routine medical care to restore Cerebral Perfusion pressure (CPP) to appropriate levels (60-70 mmHg)"
75633733|NCT04257084|Diagnostic Test|chromoendoscopy with target biopsy; NBI with target biopsy|"Chromoendoscopy with target biopsy: 0.03% indigo carmine solution based chromoendoscopy (using high-definition colonoscopy) will be fulfilled and target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.~NBI with target biopsy: After inserting a high definition colonoscopy up to cecum, endoscopists observe the colon in combination of white light and NBI (white light first and then NBI). Target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia."
75326481|NCT01838395|Drug|Ara-C|IV
75633734|NCT02835183|Device|iDECIDE|The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.
75633735|NCT02835183|Device|Insulin pump|Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.
75633736|NCT02602483|Drug|Ibuprofen|
75633737|NCT02602483|Drug|Magnesium|
75633738|NCT02602483|Drug|Ascorbic Acid|
75633739|NCT02602483|Drug|Placebo|
75633740|NCT04245813|Behavioral|Interdisciplinary educational program|Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
75326482|NCT01838395|Drug|BL-8040|SC
75326483|NCT05051176|Diagnostic Test|2D usg and 3D/4D usg|IRD distance measured by a linear probe 2D usg. Pelvic floor muscle morphometry measured by 3D/4D usg
75326484|NCT01837147|Behavioral|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
75326485|NCT01837147|Behavioral|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
75326486|NCT00422578|Drug|tadalafil|
75326487|NCT01837303|Procedure|Pap smear|"A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.~These slides will be processed so that they may be reviewed by a single board certified pathologist.~There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo."
75326488|NCT05048056|Drug|Placebo|Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1
75326489|NCT05048056|Drug|AK120|AK120 Regimen 1- subcutaneous injection every 2 weeks.
75326490|NCT05048056|Drug|AK120|AK120 Regimen 2- subcutaneous injection every 2 weeks
75633741|NCT04256694|Diagnostic Test|Rapid Antigen Test for Group A Streptococcus|Rapid strep tests will be performed by throat swab of healthy adult volunteers.
75633742|NCT02828943|Behavioral|IMT with High Resistance EMT|
76077425|NCT03559114|Drug|Dalteparin|Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
76077426|NCT03559114|Drug|Saline|Saline in prophylactic doses administered daily if screening criteria are satisfied.
76077427|NCT03492021|Other|Diet Intervention_AP-CPT|Adequate Protein_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
75326491|NCT03217981|Other|Sepsis protocol|Adherence to the sepsis protocol
75326492|NCT02494180|Drug|fentanyl|arm A receiving iv fentanyl
76077428|NCT03492021|Other|Diet Intervention_PP-PPT|Optimal Protein_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
75326493|NCT02494180|Drug|pethidine|arm B receiving iv pethidine
75326494|NCT02494180|Drug|Diazepam|arm B receiving iv diazepam
75326495|NCT02494180|Drug|Midazolam|arm A receiving iv midazolam
75468771|NCT04619797|Drug|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
75468772|NCT04619797|Drug|Pembrolizumab|Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.
75326496|NCT05032690|Drug|Bosutinib capsule|Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast
75326497|NCT05032690|Drug|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast
75326498|NCT05032690|Drug|Bosutinib|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours
75326499|NCT05032690|Drug|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast
75326500|NCT02494336|Procedure|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
75326501|NCT02494336|Procedure|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
75326502|NCT02494336|Drug|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
75468773|NCT04614467|Biological|CLBS16|GCSF-mobilized autologous CD34+ cells
75468774|NCT04614467|Biological|Placebo|isotonic solution (no CD34+ cells)
75468775|NCT04604509|Drug|Bupropion Hydrochloride Controlled-release|Given PO
75468776|NCT04604509|Drug|Nicotine Replacement|Given via nicotine patch, lozenges, or gum
75633743|NCT02828943|Behavioral|IMT with Low Resistance EMT|
75784218|NCT06193707|Other|the Remote Intervention|Remote health intervention refers to the use of big data, artificial intelligence and 5G technology to provide healthcare services and interventions to individuals at a distance. This approach allows healthcare providers to deliver medical care, monitor patients' health, offer consultations, provide education, and offer support without the need for in-person interaction.
75468777|NCT04604509|Other|Questionnaire Administration|Ancillary studies
75784219|NCT06193707|Other|the Traditional Intervention|Ultrasound follow-up review is recommended. If there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
75919905|NCT05238272|Behavioral|the unilateral MT|For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task.
76077429|NCT05198908|Other|VR group|"Women in this group will wear virtual reality glasses (15-20 minutes) until the episiotomy repair begins and ends. At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
75326503|NCT01839331|Biological|4 mL injection of Ampion|4 mL Injection of Ampion
75326504|NCT01839331|Biological|10 mL Injection of Ampion|10 mL Injection of Ampion
75326505|NCT01839331|Drug|4 mL Injection of Placebo|4 mL Injection of Placebo
75326506|NCT01839331|Drug|10 mL Injection of Placebo|10 mL Injection of Placebo
75326507|NCT01837381|Procedure|TEA|Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol [absolute alcohol], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
75468778|NCT04604509|Other|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
75468779|NCT04604509|Drug|Varenicline|Given PO
75468780|NCT04595422|Other|Educational Intervention|Undergo training consisting of a 60-minute educational session
75468781|NCT04595422|Other|Educational Intervention|Receive lung cancer screening educational materials
75468782|NCT04595422|Other|Questionnaire Administration|Complete questionnaire
75468783|NCT04595422|Other|Survey Administration|Ancillary studies
75468784|NCT04594005|Drug|abemaciclib+paclitaxel|"Phase 1b: About 3-6 patients enrollment is expected at dose level 1, -1 and -2. Dose reduction will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.~level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 100mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks level-2: abemaciclib 50mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks~Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study."
75468785|NCT04591977|Device|HPV Self-Sampling Kit (Evalyn Brush)|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
75468786|NCT04580732|Device|MiniStim PNS|MiniStim PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
75633744|NCT04256382|Other|dementia pain care education|Participants are educated about dementia pain care.
75633745|NCT04256382|Other|dementia care education|Participants are educated about dementia pain care.
75633746|NCT02833389|Drug|Placebo|UTTR1147A matching placebo will be administered SC.
75633747|NCT02833389|Drug|UTTR1147A|UTTR1147A will be administered SC.
75633748|NCT00784147|Drug|Ibalizumab|Ibalizumab 800 mg IV every 2 weeks
75633749|NCT00784147|Drug|Ibalizumab|Ibalizumab 2000 mg IV every 4 weeks
75326508|NCT02495038|Drug|10% reduction of combination of Esmeron® and Nimbex®|Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
75326509|NCT02495038|Drug|20% reduction of combination of Esmeron® and Nimbex®|The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
75468787|NCT04578665|Behavioral|Behavioral Interaction Conditions|The participants will be single-blinded and complete a tracking task as either: solo task, collaboration task (both participants work on a common task synchronously to achieve a goal; this is a summative effort to achieve the goal), competition task (each participant has to achieve a goal at the expense of his or her partner, therefore maximizing effort or error of the partner in reaching the goal), or cooperation task (an asymmetric partnership with an active partner and a passive partner working towards a goal).
75468788|NCT04578665|Device|Haptic Impedance Level|The subjects will complete their task at 3 impedance levels: high (a virtual stiffness 160-200 N/m and damping 0~10 Nm/s; this will be a stiff connection in which the subjects feel like they are connected via rigid links and each subject will perceive the other partner's movement directly), medium (a virtual stiffness 100-140 N/m and damping 0~10 Nm/s; this will be a spring like-connection in which the subjects feel like they are connected with a spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two participants), and soft (a virtual stiffness 40-80 N/m and damping 0~10 Nm/s; this will be a spring like connection in which the subjects feel like they are connected with a loose spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two subjects, however, this force will be smaller than that of the medium impedance).
75468789|NCT04578665|Behavioral|Skill Level of Partner|There will be two skill levels: novice (a participant who has no prior experience with the trajectory tracking experiment; in testing with the clinical populations, the investigators will assign this condition to the clinical participant) and expert (a participant who is experienced with the trajectory tracking experiment and who can achieve a tracking error [difference of the desired trajectory and actual trajectory] below a certain threshold; in testing with the clinical population, the investigators will assign this condition to the therapist). Participants will start experimentation paired as novice-novice, and at the end of the session may be invited to continue additional sessions to be paired as the expert in a novice-expert dyad.
75468790|NCT04578665|Device|Robot Controller Showcase|The subjects will complete 10 training sessions per assistive robot for the researchers to observe motor learning and functional outcomes.
75468791|NCT04574635|Procedure|Biospecimen Collection|Undergo collection of blood samples
75468792|NCT04574193|Device|digital therapeutic for substance use disorders|The Continuing Care application (app) is a HIPAA-compliant, mobile-friendly, software program designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration.
75326510|NCT01834339|Biological|AlloDerm|
75468793|NCT04574193|Other|Treatment As Usual|12-weeks of weekly group cognitive behavioral therapy
75326511|NCT01834339|Biological|EVPOME|
75468794|NCT04570761|Device|Dreem headband|acoustic stimulation
75468795|NCT04570761|Device|Dreem headband|acoustic stimulation
75326512|NCT01830985|Drug|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
75326513|NCT05450614|Other|Thrive app|The application has already been developed using the Flutter framework and provides users with the main CBT-based strategies to reduce depressive symptoms. In order to engage users, gamification strategies were also implemented. Some examples are 1) development and achievement: quiz on psychoeducation with rewards; 2) epic sense: like the messages in the psychoeducation session; 3) unpredictability: surprise quiz. An avatar will also be available for the participant, who will gain experience as he interacts with some of the application's functions. Finally, participants will receive weekly videos of less than 5 minutes with tips on how to use the app. There will be a total of 12 videos with psychoeducation tips and how to use the application.
75326514|NCT05450614|Behavioral|TCCG|In the literature, there is no single protocol for the treatment of depression through CBCT, therefore, a systematized protocol was developed for this study, aiming to structure and unify this intervention. Participants selected for the TCCG group will be randomly divided into 10 groups of 10 members each. The TCCG will be held through weekly meetings, exclusively online. Twelve sessions lasting 90 minutes each will be applied. The structuring of the sessions is based on the cognitive-behavioral model, starting with psychoeducation about the disorder and self-knowledge, starting with cognitive restructuring and relapse prevention. Homework will be part of the protocol. The sessions will be held on a digital platform (Google Meet) and access instructions will be provided to the participants of this group in the evaluation interview.
75326515|NCT00370006|Biological|Towne CMV vaccine|
75326516|NCT00422110|Drug|Seletracetam|
75326517|NCT01837615|Device|Photopill treatment|
75326518|NCT01837693|Procedure|Experimental: immediate colposcopy|A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
75326519|NCT04993144|Device|continuous theta burst stimulation|stimulatory protocol
75468796|NCT04564963|Other|Cryotherapy|Application of cryotherapy (e.g. ice in resealable zipper storage bags, gel packs, ice packs) over largest closed incision in the post-operative period every 4 hours, at minimum, for up to 72 hours (while participant is awake and admitted to hospital). The cryotherapy should not be placed in direct contact with skin.
75326520|NCT03837769|Device|Aktiia OBPM PulseWatch wrist device|The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
75326521|NCT04956484|Biological|Belimumab|Belimumab 10 mg/kg
75326522|NCT04956484|Drug|Standard of care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
75326523|NCT03217435|Procedure|Corneal epithelial allograft|A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
75919906|NCT05238272|Behavioral|the bilateral MT|For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task. The activities practiced during MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen).
75326524|NCT03217435|Procedure|Limbal conjunctival allograft|A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
75326525|NCT03217435|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
75633750|NCT04260360|Drug|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
75633751|NCT04256616|Other|This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.|"urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC."
75784220|NCT06193694|Behavioral|Coaching|Formal coaching program followed by the Coaching Fidelity Tool, to be taken by the study group after program completion contains 12 questions, predominantly multiple choice and yes/no, although there is one question that requires a short answer as well as a place to write additional comments. These questions are meant to elicit responses about their experience with their assigned coach during their one-on-one coaching sessions.
75326526|NCT03217435|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
75326527|NCT05450458|Drug|KNEE JOINT INFILTRATION WITH HYALURONIC ACID WITH SORBITOL SYNOLIS VA|KNEE INFILTRATION WITH HYALURONIC ACID WITH SORBITOL IN SPORTSMEN
75326528|NCT01837771|Device|Diaphragmatic stimulation|
75633752|NCT04254822|Procedure|Transjugular intrahepatic portosystemic shunt|The TIPS procedures will be performed by experienced interventional radiologists. polytetrafluroethylene-covered stents were used with initial balloon dilatation to 8 mm, aiming for a decrease in portal-venous pressure gradient to less than 12 mm Hg.
75784221|NCT06193681|Other|Pedi@ctivity Exercise Mobile Application Exercise Program|The first group of the study received a mobile application (Pedi@ctivity) based exercise program. With the Pedi@ctivity exercise mobile application, the selected exercises and exercise program will be offered personalized to each adolescent for 12 weeks. After 12 weeks, the effectiveness of the Pedi@ctivity mobile application-based exercise program on the evaluation parameters will be investigated.
75784222|NCT06193681|Other|Supervised Exercise Group|In the physiotherapist-supervised personalized exercise program, the exercises selected through the Pedi@ctivity exercise mobile application will be applied to adolescents under the supervision of a physiotherapist (2 sessions face-to-face, 1 session online/synchronous).
75784223|NCT06193668|Behavioral|High-fat overnutrition|Overnutrition: 40% higher lipid consumption per day than required
75919907|NCT03412448|Other|observation|Observation,
75326529|NCT05449912|Other|Collection of environmental exposure data|noise pollution air pollution proximity and accessibility to green spaces, blue spaces
75326530|NCT01720615|Drug|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
75326531|NCT01720615|Drug|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
75326532|NCT01837927|Drug|NVA237|Once daily for 52 weeks
75326533|NCT01837927|Drug|Tiotropium Respimat®|Once daily for 52 weeks
75326534|NCT02503852|Device|Puregraft System|The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
75326535|NCT02503852|Device|Celution System|The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
75326536|NCT02503852|Procedure|Kerastem Therapy|The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
75326537|NCT02503852|Procedure|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
75326538|NCT01838005|Behavioral|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
75326539|NCT01838083|Drug|Insulin glargine new formulation HOE901|Pharmaceutical form: solution Route of administration: subcutaneous
75326540|NCT05441644|Device|Bispectral index|A new placemewnt to monitor intraoperative BIS
75326541|NCT01838161|Behavioral|Part II|Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
75326542|NCT01838161|Behavioral|Part III|•video educational
75919908|NCT03126422|Drug|Dexmedetomidine|Pretreatment of different doses of dexmedetomidine
75919909|NCT03399422|Biological|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
75919910|NCT03399422|Procedure|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
75919911|NCT03399344|Other|MRI|In addition to the standard diagnostic work-up patients will receive an additional MRI scan 0-21 days prior to their scheduled surgery.
75326543|NCT01838161|Behavioral|Part I|Parental Interviews
75326544|NCT04943926|Other|Energy restricted diet|Nutritional complete formula diet followed by an energy restricted diet
75326545|NCT04943926|Other|Low carbohydrate high fat diet|Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
75468797|NCT04560595|Behavioral|Caffeine Reduction Manual|We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.
75326546|NCT01838239|Dietary Supplement|Fish Oil|Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
75633753|NCT04254822|Drug|Carvedilol|Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease <90 mmHg.
75633754|NCT04254822|Procedure|Endoscopic variceal ligation|For endoscopic variceal ligation, the first elective session will be carried out within 7 days of randomisation. Then EBL sessions were scheduled every 10-14 days until variceal eradication (disappearance of varices or being too small to be sucked in the banding device).
75919912|NCT03412370|Other|Cognitive Assessment|Complete cognitive assessments
75919913|NCT03412370|Other|Questionnaire Administration|Complete questionnaires
75326547|NCT01720693|Procedure|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
75326548|NCT02504554|Drug|oral Vancomycin|an antibiotic
75326549|NCT02504554|Drug|MoviPrep|a bowel cleanse
75326550|NCT02504554|Drug|Prilosec|a stomach acid suppressan
75326551|NCT02504554|Biological|human fecal material; processed, frozen administered orally|human fecal material; processed, frozen, administered orally
75326552|NCT02504554|Biological|human fecal material; processed, frozen; administered orally and rectally|human fecal material; processed, frozen; administered orally and rectally
75326553|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
75326554|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
75326555|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
75326556|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
75326557|NCT03217123|Device|Deep Brain stimulation|Electrical stimulation at subcortical level
75326558|NCT04937452|Drug|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
75468805|NCT04549311|Drug|Antibiotic 1 arm (amoxicillin + clavulanic acid)|Prescription of antibiotics (amoxicillin + clavulanic acid) after incision and drainage of perianal abscess.
75468806|NCT04549311|Drug|Antibiotic 2 arm (ciprofloxacin + metronidazole)|Prescription of antibiotics (ciprofloxacin + metronidazole) after incision and drainage of perianal abscess.
75468807|NCT04547868|Other|Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
75633755|NCT00891813|Drug|Zemplar (paricalcitol)|Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
75633756|NCT05528575|Dietary Supplement|Blueberry, cranberry, green tea extract, cocoa|tablet supplements, available readily.
75633757|NCT05528575|Dietary Supplement|GOS, Inulin, RS2|Prebiotic combination, Inulin, GOS and RS2
76077430|NCT05198908|Other|Skin to skin group|"For women in this group, a warm sterile operating room towel will be placed on the newborn until the episiotomy repair begins and ends, so that her naked body remains on the mother's chest.At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
76077431|NCT03087435|Device|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
75326559|NCT04937452|Drug|Rotigotine 6Mg/24Hrs Patch|Rotigotine 6 mg/24Hrs administration for 24 weeks
75326560|NCT04937452|Drug|Placebo|Placebo administration for 24 weeks
75326561|NCT03216811|Drug|nutraceutical|8-week administration of nutraceutical compound
75326562|NCT01720771|Dietary Supplement|probiotic tablet|Intake of one probiotic lozenge tablet per day
75326563|NCT01720771|Dietary Supplement|sugar pill|one tablet daily
75326564|NCT01838707|Drug|0.125% Bupivacaine HCL @ 4-5 ml/h|
75326565|NCT01838707|Drug|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
75326566|NCT01838707|Drug|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
75326567|NCT01720849|Drug|Fampyra|The will be given as per normal patient treatment plan
75326568|NCT04379479|Drug|Dialyzable Leukocyte Extract|Experimental Intervention. Dialyzable Leukocyte Extract
75326569|NCT04379479|Drug|Placebo oral|Placebo
75468808|NCT04547868|Other|Decaffeinated Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of decaffeinated coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
75326570|NCT00914485|Behavioral|Provider Communication Skills Training|"Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity."
75326571|NCT02506114|Biological|PROSTVAC V/F|PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
75468809|NCT04547868|Other|Warm water|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of warm water will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
75468810|NCT04537429|Drug|Eptinezumab|up to four iv infusions of eptinezumab
75468811|NCT04528719|Biological|mRNA-1345|Formulation for injection
75468812|NCT04528719|Drug|Placebo|0.9% sodium chloride (normal saline) injection
75468813|NCT04521764|Biological|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Given IT
75468814|NCT04517643|Other|Therasphere Therapy|TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
75468815|NCT04512911|Procedure|Endocardial ablation|Endocardial ablation of VT
75468816|NCT04512911|Procedure|Endocardial- Epicardial ablation|Epicardial ablation of VT in addition to endocardial ablation
75468817|NCT04512911|Drug|Antiarrhythmic medications|Addition of anti arrhythmic medication or dose increase
75468818|NCT04501133|Device|Peripheral electrical stimulation|Electrical stimulation will be delivered to forearm muscles with an electrical stimulator (Digitimer Ltd., Hertfordshire, UK) so that they generate forces opposed to those arising from the tremorgenic input.
75633758|NCT05528575|Dietary Supplement|prebiotics and polyphenols|combination of the same prebiotics and polyphenols as above
75919914|NCT03399266|Device|Double Balloon catheter for induction of labor|With the patient in lithotomy position or lying supine in bed, a speculum is inserted to visualise the cervix. The device is inserted into the cervix using long forceps until both balloons enter the cervical canal. Then, the uterine balloon is inflated with 20 ml of saline (by means of a 20 ml syringe). The device is then pulled out until stopped by the uterine balloon covering the internal cervical os. At this point the cervico-vaginal balloon located at the external os is inflated with 20 ml of saline and the speculum is removed. Then both balloons are additionally inflated with alternate increments of 20 ml normal saline to a total volume of 80 ml in each balloon. The device is loosely taped to the patient's inner thigh.
75326572|NCT02506114|Drug|Ipilimumab|
75633759|NCT05528575|Dietary Supplement|Maltodextrin|maltodextrin, 10g per day
75919915|NCT03395132|Drug|Fucicort® Lipid cream|The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
75919916|NCT03395132|Drug|Fucidin® cream|The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
75919917|NCT03395132|Drug|Fucicort® Lipid cream vehicle|The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
75326573|NCT00915031|Device|UroCool|Hypothermia Endorectal Device
75326574|NCT00370084|Drug|Itopride|oral, three times daily
75326575|NCT00370084|Other|Placebo|oral, three times daily
75326576|NCT04923256|Behavioral|AAT-APP: A novel smart-phone approach-avoidance bias modification intervention|Participants allocated to the intervention group will be required to upload photos of drinks they wish to avoid, as well as activities they wish to engage in more, and be trained to avoid and approach by repeatedly 'swiping' images away from and towards themselves, respectively.
75326577|NCT04923256|Behavioral|Sham training control|Complete an AAT on a weekly basis for four weeks
75326578|NCT01725685|Drug|FF 400 mcg|FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
75326579|NCT01725685|Drug|UMEC 500 mcg|UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
75326580|NCT01725685|Drug|FF/UMEC 400/500 mcg|FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
75633760|NCT04254900|Other|evaluating energy availability|energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass
75468819|NCT04501133|Device|Single pulse TMS|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
75633761|NCT02833311|Behavioral|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
75468820|NCT04492540|Other|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
75633762|NCT02833311|Behavioral|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
75326581|NCT01721083|Procedure|Procedure: Z-track|Subject received immunization by z-track
75326582|NCT01721083|Procedure|Procedure: Bunch|Subject receives immunization by bunch method.
75468821|NCT04492540|Other|MIND diet program|control group will receive diet program for 12 weeks
75468822|NCT04489589|Drug|Midodrine|10mg PO/NG q8h
75468823|NCT04489589|Drug|Placebo|10mg PO/NG q8h
75468824|NCT04471987|Drug|IL12-L19L19|"Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications."
75326583|NCT05449054|Procedure|Anterior colporrhaphy|All patients will be operated by the vaginal route. They are prepared under strict aseptic conditions in the dorsal lithotomy position. The bladder is emptied preoperatively with a thin disposable catheter and antibiotic prophylaxis (cefazolin) is administered before incision. A vasoconstricting solution (combination of vasopression and NaCl) is administered and a vertical anterior vaginal incision is made from the apex to two centimeters short of the external urethral meatus using an electric cautery or a scalpel. The vaginal epithelium is grasped on both sides and the fibromuscular layer of the anterior vaginal wall is sharply dissected laterally to the inferior pubic ramus. The bladder is completely dissected from the apex and up to 4 to 6 cm from the pubic ramus. The anterior colporrhaphy is defined as a native tissue repair and rows of absorbable sutures (2/0 vicryl) are used.
75784224|NCT06193668|Behavioral|Normocaloric macronutrient-balanced nutrition|"Normocaloric, macronutrient-balanced nutrition:~Calories requirement for weight maintenance [(kcal/d) 55% carbohydrates, 15% proteins, 30% fat]"
75919918|NCT03395132|Drug|betamethasone (Lianbang Beisong®) cream|The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
75919919|NCT03395054|Other|cervical stabilization exercises|cervical stabilization exercises
75326584|NCT04920994|Procedure|M-TAPA block|A high-frequency linear ultrasound probe will be used, probe will be placed on the costochondral angle in the sagittal plane and angled deeply to view the lower aspect of the chondrium in the midline, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced into the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
75468825|NCT04471987|Drug|IL12-L19L19|Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
75468826|NCT04466371|Other|Questionnaire|A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
75468827|NCT04464785|Device|CentriMag Circulatory Support System|The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
75468828|NCT04464473|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
75468829|NCT04460352|Radiation|Neoadjuvant radiotherapy (arm A)|1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
75468830|NCT04460352|Drug|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
75468831|NCT04460352|Procedure|Esophagectomy|Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
75468832|NCT04460352|Radiation|Neoadjuvant radiotherapy (arm B)|"Two alternative schemes:~1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy."
75468833|NCT04460352|Drug|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
75633763|NCT02833311|Behavioral|Contact Control Group|Participants are prescribed an exercise program and given information on healthy eating.
75633764|NCT04255056|Drug|Pyrotinib|"Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
75919920|NCT03395054|Other|conventional exercises|conventional exercises
75633765|NCT00783835|Drug|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
75633766|NCT04248075|Device|Electroencephalogram|Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.
75919921|NCT03127124|Drug|NANT-008|Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI)
75468834|NCT04460352|Drug|Cisplatin, paclitaxel|Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.
75633767|NCT05031546|Drug|Difelikefalin|IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)
75633768|NCT04254744|Drug|Sevoflurane|Sevoflurane inhalation for anesthesia
75326585|NCT04920994|Procedure|SCTAP block|A high-frequency linear ultrasound probe will be placed obliquely on the upper abdominal wall, along the subcostal margin near the midline. After identifying the rectus abdominis muscle, the ultrasound probe will be gradually moved laterally along the subcostal margin until the transversus abdominis muscle will be identified lying posterior to the rectus muscle, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced medially and directed towards the transversus abdominis plane until its tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles on entering the neurofascial plane. The same procedure will be repeated on the contralateral side.
75326586|NCT04920994|Drug|Bupivacaine Hydrochloride|20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
75326587|NCT03409939|Dietary Supplement|Aromatic Amino Acid Intake|Intakes will be randomly chosen from a list of 8 doses of aromatic amino acids. Each intake will will be repeated approximately 4 times.
75326588|NCT01721395|Dietary Supplement|Agave Syrup|
75326589|NCT02506660|Drug|Bupivacaine|
75633769|NCT05274711|Other|Whole body vibration training|The participants will be instructed to stand on the vibration platform bare footed and distribute their weight evenly on both feet (fig 3). Next, they will be asked to do a head and neck retraction while looking forward with their knees at 30 degrees of flexion. In order to prevent fatigue in the subject's cervical area due to holding their head and neck in retraction, they will be asked to hold this position for 15 seconds then rest for 5 seconds. Since each set will last 60 second this allowed the subjects to do 3 retractions in each set. In total each subject will perform 15 retractions during the training. The subjects will experience a vertical vibration at a frequency and amplitude of 30 Hz and 4 mm during the sets (Salami et al., 2018).
75633770|NCT05274711|Other|Conventional physical treatment|Posturalcorrectionexercisesintheformofstretchingandstrengthening exercise. Manual stretching exercises as passive stretch to (upper trapezius, levator scapulae, sub occipitalis, scalene, sternocleidomastoid, and pectoralis major muscles), 30 seconds of 3-5 repetitions for each muscle, followed by 30 seconds of rest, as well as isotonic exercises (to strength deep neck flexors and scapular retractor muscles) 3 sets of 12 repetitions each with a 6 second hold in between, with a 1-2-minute rest between sets (Kisner. and Colby 2012).
75633771|NCT04103827|Other|usability assessment|"Usability of Le Qoos will be assessed using a validated usability questionnaire"
75326590|NCT02506660|Drug|Perineural dexamethasone|Dexamethasone in nerve block
75326591|NCT02506660|Drug|Intravenous dexamethasone|
75784225|NCT06193642|Other|experimental|Subjects diagnosed with OI will undergo a series of assessments using sensor imaging and Gait-Analysis; we will proceed with a careful and detailed collection, analysis and evaluation of functional data typical of Gait-Analysis studies, aimed at identifying that subset of parameters that will prove most interesting and useful for the purposes of the study, thus identifying the sensors and algorithms that can precisely produce the most usable synthetic information for defining the quality of motor function in these patients.
75919922|NCT03127124|Drug|Fluorouracil Injectable Product|5-fluoro-2,4 (1H,3H)-pyrimidinedione.
75919923|NCT03127124|Drug|Avastin Injectable Product|Recombinant humanized monoclonal IgG1 antibody
75326592|NCT02506660|Drug|Intravenous saline|
75326593|NCT02506660|Drug|Perineural saline|Saline in nerve block
75326594|NCT04377607|Other|File scanning|RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
75326595|NCT01725997|Procedure|hook plate|Surgery with hook plate followed by physiotherapy
75326596|NCT01725997|Other|Physiotherapy|Patients will be following a program specific for AC joint dislocations
75326597|NCT02509624|Drug|Selonsertib|6 mg tablets administered orally in fed state
75326598|NCT01726075|Drug|COLIRIOBCN070660|One drop per eye twice a day during 24 months
75326599|NCT01726075|Drug|Placebo|One drop per eye twice a day during 24 months
75326600|NCT01726075|Drug|Brimonidine|One drop per eye twice a day during 24 months
75326601|NCT01726153|Behavioral|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
75326602|NCT04338334|Other|Manual drainage & arm therapeutic exercise|See arm/group descriptions.
75326603|NCT04338334|Other|Cohesive bandaging & arm therapeutic exercise|See arm/group descriptions.
75326604|NCT01721629|Procedure|Sudden wean of nasal CPAP|
75633772|NCT02831361|Drug|Gemigliptin|
75633773|NCT02831361|Drug|Gemigliptin placebo|
75633774|NCT02831361|Drug|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
75633775|NCT02831361|Procedure|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25"
75633776|NCT00611052|Behavioral|the Adolescent Coping with Stress|A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
75633777|NCT00611052|Behavioral|Treatment as usual|The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
75326605|NCT01721629|Procedure|Gradual wean of nasal CPAP|
75326606|NCT05448898|Drug|Traditional Chinese Medicine CU Xiu Tang|Oral Traditional Chinese Medicine CU Xiu Tang once a day and repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
75326607|NCT05448898|Other|Olfactory Training|repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
75326608|NCT00369616|Biological|CYT002-NicQb|
76077432|NCT05153590|Drug|Saxenda®|"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."
75326609|NCT00369694|Drug|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
75633778|NCT00611052|Other|usual health education|usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
75633779|NCT04103905|Drug|Recombinant Humanized Monoclonal Antibody MIL62 Injection|The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
75326610|NCT00369694|Drug|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
75633780|NCT02828631|Device|Macintosh laryngoscope|
75633781|NCT02828631|Device|McGrath videolaryngoscope|
75633782|NCT02828631|Device|Pentax videolaryngoscope|
75326611|NCT01721707|Drug|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
75326612|NCT01721707|Drug|Latanoprost|1 drop in each eye, 1x/day, at 9PM
75326613|NCT03409783|Device|ENSO Device|An active ENSO device that delivers neuromodulation therapy.
75633783|NCT02828709|Device|Irreversible Electroporation|Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
75633784|NCT05036148|Other|Data analysis|MH registry data will be screened for MH positive diagnosis
75633785|NCT05240937|Behavioral|mindfulness-based self-compassion will be applied|A mindfulness-based self-compassion program will be applied to this group of patients who have had breast cancer and have fully completed their treatment.
75633786|NCT05014620|Other|Semi-directive interview|semi-structured exploratory interview
75633787|NCT02831205|Device|everolimus-eluting bioresorbable vascular (Absorb) scaffold|
75633788|NCT02831205|Device|everolimus-eluting cobalt-chromium (Xience) stent|
75633789|NCT04253340|Diagnostic Test|Bone mineral analyser|high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12
75919924|NCT03127124|Drug|Leucovorin Calcium Injection|Calcium N -[p -[[[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1).
75326614|NCT03409783|Device|Sham Device|Sham Device
75326615|NCT03409705|Dietary Supplement|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
75326616|NCT03409705|Dietary Supplement|Control group|2,000 mg of starch was orally administered per day for 12 weeks.
75326617|NCT05448586|Drug|Opioid|Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
75326618|NCT01726465|Drug|Methylprednisolone|Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
75633790|NCT04260204|Procedure|Pediatric cardiac surgery|
75633791|NCT02831439|Behavioral|Basic public reporting|The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
75633792|NCT02831439|Behavioral|Enhanced intervention|The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
75633793|NCT02831439|Behavioral|Control group - observational|"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."
75633794|NCT04254432|Device|remote ischemic conditioning|RIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 4 weeks.
75919925|NCT03127124|Drug|Eloxatin Injectable Product|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum.
75919926|NCT03399188|Procedure|Fecal microbiome transplantation|Fecal microbiota transplantation will be performed through colonoscopy to the IBD patients. Donor feces will be extensively screened for other diseases. Colonoscopy will be done at FMT center of Severance Children's Hospital twice with a month of duration. Recipients will be admitted the day before colonoscopy, and they will be discharged after a day of observation.
75468835|NCT04460352|Drug|Oxaliplatin, calcium folinate, 5-fluorouracil|FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
75326619|NCT01726465|Drug|N-acetylcysteine|Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°-110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
75468836|NCT04460352|Procedure|Esophagectomy|Esophagectomy only in case of residual or recurrent locoregional cancer.
75468837|NCT04445831|Biological|ACI-35.030|Administration of a Low dose of ACI-35.030
75468838|NCT04445831|Biological|ACI-35.030|Administration of a Medium dose of ACI-35.030
75468839|NCT04445831|Biological|ACI-35.030|Administration of a High dose of ACI-35.030
75468840|NCT04445831|Other|Placebo|Administration of Placebo
75468841|NCT04445831|Biological|JACI-35.054|Administration of a Low dose of JACI-35.054
75633795|NCT02828553|Other|Aggressive planned ambulation with a mobility aide|A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
75633796|NCT05331534|Behavioral|Eye-tracking assisted attention control training (ACTo)|"ACT is made of 8 sessions of a Dot-Probe Task (DPT). The DPT is a computerized task in which two visual stimuli (one emotional stimulus and one neutral stimulus) are displayed simultaneously on the left and right side of the screen. AB towards or away from emotional stimuli is respectively inferred by faster or slower responses to detect a probe replacing an emotional stimulus than a probe replacing a neutral stimulus. In the ACT therapy, the probe replaces the negative and neutral stimuli with equal frequency.~ACTo will combine ACT with eye tracking methodology, allowing to directly record eye movements of the participants during the task. At each trial, images will be displayed for 2s and the negative image will be replaced by the neutral image (and vice versa) if the patient continues to explore the negative image beyond the first fixation, in order to block any additional attentional engagement."
75633797|NCT05331534|Behavioral|Attention control training (ACT)|Patients will benefit from the ACT as described above; at each trial, images will remain on screen for 2s.
75633798|NCT00783289|Other|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
75633799|NCT00783289|Biological|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
75633800|NCT00783289|Biological|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
75919927|NCT03399110|Drug|Oxaliplatin|oxaliplatin 130 mg/m2
75919928|NCT03399110|Drug|Capecitabine|Capecitabine 1000mg/m2
75326620|NCT02509936|Behavioral|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
75326621|NCT02509936|Dietary Supplement|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
75326622|NCT01720303|Drug|repaglinide|2 mg (tablets) before each main meal
75784226|NCT06193629|Drug|Lang Qingata|Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
75784227|NCT06193629|Drug|placebo|Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use
75468842|NCT04445831|Biological|JACI-35.054|Administration of a Medium dose of JACI-35.054
75468843|NCT04419181|Drug|Docetaxel|Dose: 75 mg/m2 q3w
75468844|NCT04419181|Drug|Carboplatin|Dose: area under the concentration-time curve [AUC] 6 q3w
75468845|NCT04419181|Drug|Trastuzumab|Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
75633801|NCT00783289|Biological|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
75784228|NCT06193616|Drug|Octreotide|All consenting patients treated with octreotide LAR according to Determina AIFA n. 1264 del 3 August 2018 and fulfilling the selection criteria will be collected at prespecified time-points according to the routine visits scheduled for these patients and the periodic follow-up visits till dialysis initiation as described in the AIFA indication on GU Serie Generale n.5 del 08-01-2020.
75919929|NCT03127046|Drug|Aceclofenac|Oral single dose administration of aceclofenac 200mg
75919930|NCT03127046|Drug|Esomeprazole|Oral single dose administration of aceclofenac 200mg
75919931|NCT03127046|Drug|Aceclofenac and Esomeprazole|Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
75919932|NCT03412214|Device|Perfusion index detected by pulse oximeter|Perfusion index detected by pulse oximeter
75326623|NCT01720303|Drug|isophane human insulin|Injection s.c. (under the skin) at bedtime
75326624|NCT01720303|Drug|insulin|Injection s.c. (under the skin) twice daily
75468846|NCT04419181|Drug|Pertuzumab|Dose: 840-mg loading dose, 420-mg maintenance dose q3w
75468847|NCT04419181|Drug|Trastuzumab emtansine|Dose: 3.6mg/kg q3w
75468848|NCT04396340|Biological|XMT-1592|XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
75468849|NCT04388852|Biological|Ipilimumab|Given IV
75468850|NCT04388852|Drug|Valemetostat|Given PO
75326625|NCT03216889|Behavioral|Cognitive Behavioral Therapy for Insomnia|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
75919933|NCT03412214|Device|AAI|The AEP Monitor/2 (Danmeter A/S, Odense, Denmark), a commercialized system for depth of anesthesia monitoring, extracts the middle latency auditory evoked potentials (MLAEP) from the EEG-signal by using an autoregressive model with an exogenous input adaptive method.
75633802|NCT02828787|Other|MRI|"The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night."
75919934|NCT03394898|Other|body mass index, eating behaviour|The patients' weights and heights will be measured and the body mass index will be calculated from the measured values.Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
75919935|NCT05105672|Drug|Sintilimab|IV infusion
75326626|NCT03216889|Behavioral|Control|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
75919936|NCT05105672|Drug|Cisplatin|IV infusion
76077433|NCT03490864|Dietary Supplement|Melatonin 1 mg|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
76077434|NCT03490864|Dietary Supplement|Placebos|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
76077435|NCT03490864|Other|Meal Timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
76077436|NCT03490864|Other|NON Meal Timing|Subjects are instructed to maintain their habitual meal timing.
75326627|NCT00912301|Drug|Sodium chenodeoxycholate (NaCDC)|500 or 1000 milligrams NaCDC per day each for a period of 4 days
75326628|NCT00912301|Other|Placebo|Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
75326629|NCT04341766|Other|No special intervention|No special intervention : Ultrasound data will be collected
75326630|NCT01726543|Procedure|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
75326631|NCT01726543|Procedure|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
75919937|NCT05105672|Radiation|External Beam Radiotherapy (EBRT)|Undergo pelvic EBRT
75919938|NCT05105672|Radiation|brachytherapy|brachytherapy
75919939|NCT03394820|Drug|Dexamethasone|The intervention is the time when dexamethasone is administered
75919940|NCT01328054|Drug|lapatinib|lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
75919941|NCT01328054|Drug|placebo matching lapatinib|placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
75919942|NCT03394742|Behavioral|Peer support|Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
76077437|NCT03030898|Diagnostic Test|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
76077438|NCT00089973|Drug|Ispinesib|Given intravenously at a dose of 18 milligram (mg)/ meter square (m^2).
76077439|NCT03030820|Procedure|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
75326632|NCT03409627|Biological|INXN-4001|Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)
75326633|NCT04862416|Biological|R0.6C transmission blocking vaccine|Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.
75326634|NCT01721863|Other|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
75326635|NCT04850638|Drug|SHR4640 tablets and furosemide tablets|SHR4640 tablets and furosemide tablets
75326636|NCT01721941|Drug|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
75326637|NCT01721941|Drug|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
75326638|NCT01721941|Drug|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
75326639|NCT01721941|Drug|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
75326640|NCT05448508|Device|Automatic lancet|An automatic lancet, which can reach a depth of 2.4 mm-3 mm, was used for safe piercing in babies.
75326641|NCT05448430|Device|Theta burst stimulation|a new paradigm of high frequency repetitive transcranial magnetic stimulation
75326642|NCT03409549|Radiation|Fluciclovine PET/CT|Fluorine-18 Fluciclovine PET/CT scan of the brain
75326643|NCT01726387|Behavioral|Psychosocial Counseling|Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
75326644|NCT01726387|Behavioral|Usual Care|Depending on the conditions, patients get usual care of their general practitioner
75326645|NCT01722175|Procedure|ALPPS surgery|
75633803|NCT04358445|Other|Magnesium-Rich Artificial Cerebrospinal Fluid|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
75468851|NCT04387435|Other|A change or titration in the current or frequency settings of the VNS therapy system.|The study treatment involves changing the output current or frequency of the default device settings in a FDA approved device for VNS therapy. The proposed frequency changes in this study are within the FDA approved output current and frequency levels.
75468852|NCT04386317|Drug|Terazosin|Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
75468853|NCT04380857|Drug|Dexamethasone ophthalmic insert 0.4 mg|intracanalicular dexamethasone insert
75919943|NCT05067920|Diagnostic Test|Levels of SARS-COV-2 antibodies|Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)
75326646|NCT01722175|Procedure|PVO surgery|
75633804|NCT05591053|Device|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted esophagectomy.
75633805|NCT04245579|Other|Multifactorial Memory Training Program (UMAM method)|
75633806|NCT02828319|Drug|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
75633807|NCT04025281|Other|Extra Virgin Olive Oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
75784229|NCT06193603|Other|True dry cupping therapy|In the intervention group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. The therapist will perform 5 minutes of dry cupping therapy, moving the cups up and down using both hands. Participants will also receive routine physiotherapy, including a 20-minute session of transcutaneous electrical stimulation with a frequency of 100 pulses per second and a duration of 60 microseconds. The stimulation intensity will be adjusted for sensory stimulus. Stabilization exercises like abdominal hollowing and bridging will be included. The treatment will consist of 10 sessions, three times per week.
75633808|NCT04025281|Other|Refined Olive Oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
75326647|NCT04308096|Drug|KRN23|The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.
75919944|NCT05067920|Diagnostic Test|rRT-PCR SARS-Cov-2|Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th
75919945|NCT05067920|Diagnostic Test|Hematological and immunological biomarkers|Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.
75919946|NCT05067920|Diagnostic Test|Mitochondrial DNA|One time quantification mitochondrial DNA haplogroup.
75919947|NCT05067920|Diagnostic Test|SARS-CoV-2 Viral Culturing|Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.
75919948|NCT05067920|Diagnostic Test|Sequencing COVID-19|Sequencing viral protein spike (S) COVID-19 related to CT value below 15.
75633809|NCT02828163|Other|Autologous Platelet rich plasma|Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
75468854|NCT04380857|Drug|Topical Prednisolone Acetate Ophthalmic Drops|"Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue"
75468855|NCT04327570|Other|Patient sampling|Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
75468856|NCT04307836|Device|Renal Denervation|Renal Denervation: DENEX system
75468857|NCT04307485|Drug|Ticagrelor|90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
75633810|NCT02828163|Drug|Triamcinolone Acetonide|10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
75633811|NCT04245189|Other|Endoscopic ultrasound for detection of Chronic pancreatitis|Presence of Chronic pancreatitis in alcoholic cirrhosis patients.
75633812|NCT04107805|Drug|BI 1323495|Tablet
75633813|NCT04107805|Drug|Placebo|Tablet
75633814|NCT04107805|Drug|Midazolam|Oral administration
75919949|NCT05171036|Other|Adapted Physical Activity|"Group 1 Maintenance of autonomy: Patients in group 1 have no cardiovascular disorders, possibly some cognitive deficits but do not reside in a protected unit.~Group 2 Prevention of the risk of falls: Patients in group 2 have no cardiovascular problems, possibly some cognitive problems, but can finally follow the indications of the cognitive assessment in the form developped for the study.~Group 3 Prevention of the risk of falls and monitoring of cardiovascular disorders in the absence of cognitive impairment: Patients in group 3 have had a recent, and currently stabilised, cardiovascular event that may justify exercise reconditioning.~Group 4 Prevention of the risk of falls and disorientation in a context of cognitive deficit: Patients in group 4 have moderate to severe cognitive disorders, or have Alzheimer's disease or a related disease at a stage of the disease requiring special attention."
75326648|NCT02512276|Behavioral|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
75326649|NCT00915499|Device|VPAP Adapt SV|Comparison of ASV and CPAP modes
75326650|NCT01726777|Dietary Supplement|Control|Normal cheddar cheese
75326651|NCT01726777|Dietary Supplement|Vitamin D|Vitamin D3 supplemented cheddar cheese
75326652|NCT04833088|Other|Focus group discussions|Focus group discussions will be organized to investigate the needs and requirements of the participants in terms of three pre-defined user scenarios.
75326653|NCT03409471|Device|Flocked Swab|At the colposcopy clinic, vaginal self-sample will be collected with the Flocked Swab (Noble Bioscience, Inc., Korea).
75326654|NCT03409471|Device|Cervical Brush|Physician collected cervical sample will be collected also at the colposcopy center with the Cervical Brush (Noble Bioscience, Inc., Korea).
75468858|NCT04299620|Device|Digital Image Analysis|Analysis of images
75468859|NCT04299620|Procedure|Radical Prostatectomy|Undergo standard of care radical prostatectomy
75468860|NCT04299620|Procedure|Transrectal Ultrasound|Undergo transrectal ultrasound
75633815|NCT02828475|Other|CALYPSO|Software platform of machine-learning based predictive models of surgical complication.
75633816|NCT02828475|Behavioral|Standard Care|Previous standard of care based on surgeon judgement alone.
75468861|NCT04284267|Device|Transcranial Magnetic Stimulation|TMS is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study will use intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
75468862|NCT04271488|Drug|Tasurgratinib|Tasurgratinib oral tablet.
75633817|NCT02833155|Drug|Entinostat|Given PO
75633818|NCT02833155|Drug|Exemestane|Given PO
75633819|NCT04105387|Procedure|Early Tracheostomy Change|The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
75633820|NCT04247841|Other|Visual Aid|The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual discription stating the anticipated risk. For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS.
75633821|NCT04247841|Other|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
75633822|NCT02875730|Procedure|Pulse Sequence|Cylindrical Navigator Preparatory Pulse Sequence
75633823|NCT02875730|Procedure|CMRI|Cardiac Magnetic Resonance Imaging
75468863|NCT04271488|Drug|Tasurgratinib|Tasurgratinib oral capsule.
75468864|NCT04265274|Drug|Disulfiram|dosing 400mg daily
75468865|NCT04265274|Drug|Vinorelbin|25mg/m2 day 1 and 8,
75468866|NCT04265274|Drug|Cisplatin|75mg/m2 day 1
75468867|NCT04265274|Drug|Copper|2 mg of elementary Copper daily
75468868|NCT04264260|Drug|Colchicine Tablets|three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
75468869|NCT04255199|Behavioral|Control|Clinicians randomized to the control group will receive a single visit with a standardized patient instructor (SPI) scheduled during usual office hours. SPIs will portray a patients with acute back pain but will deliver no formative training or feedback to the primary care physicians randomized to the control arm.
75633824|NCT02876666|Behavioral|SCI Virtual Coach|Participants are given a computer with the SCI Virtual Coach program and are asked to interact with the Coach daily for 2 months.
75633825|NCT04672460|Drug|TALZENNA capsule|Current commercial talazoparib formulation 1 mg once daily given under fasting condition
75468870|NCT04255199|Behavioral|Intervention|Clinicians randomized to the intervention group will receive 2-3 visits with a standardized patient instructor (SPI) scheduled during usual office hours over ~3 month period. For intervention physicians, SPIs will portray patients with acute back pain and will provide formative feedback to physicians and specific instruction in communication techniques to facilitate patient acceptance of a watchful waiting strategy with respect to spinal imaging. The specific communication techniques and sequence will be determined based on pre-trial literature review, patient focus groups, and interviews of primary care physicians who will not participate in the trial.
75326655|NCT03409471|Diagnostic Test|HPV assay|The hrHPV assay used, will be the Roche Cobas® 4800 HPV test, Anyplex™ II HPV HR detection kit and Realtime HPV HR-S Detection kit.
75326656|NCT05532306|Drug|Ribavirin 400 mg film coated tablet (1*400mg)|an immediate release film-coated tablet containing 400 mg Ribavirin
75326657|NCT05532306|Drug|Copegus® 200 mg film coated tablet (2*200mg)|an immediate release film-coated tablet containing 200 mg Ribavirin
75326658|NCT01722253|Procedure|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
75633826|NCT04672460|Drug|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
75326659|NCT05320614|Other|Web-Based Education|Web-Based Education Information about the operation that the child will undergo; animation films about the hospital, the operating room and the medical equipment to be used; training with presentation including methods of coping with anxiety, fear and pain, postoperative wound care, possible complications in nutrition and nursing care; educational games Education with Therapeutic Play Method Training with the therapeutic game method for 30-45 minutes in the game room in the service one day before the surgery
75326660|NCT05320614|Other|Routine maintenance Training|Explaining the routine care given to the child and parent in the control group by the pediatric surgery nurse in the service.
75326661|NCT02512900|Drug|MEDI9929, 140 mg|On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
75468871|NCT04254094|Other|Neuropsychological scales|Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
75468872|NCT04247542|Drug|Ibezapolstat|Investigational antibacterial agent
75468873|NCT04247542|Drug|Vancomycin|Active comparator
75633827|NCT04672460|Drug|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
75633828|NCT02874950|Other|office exercise training|The exercise group, did 6 months office exercise training.
75633829|NCT02874950|Other|ergonomic modification|The ergonomic modification group, followed 6 months modified office ergonomic modification.
75633830|NCT02874950|Other|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
75633831|NCT02874950|Other|Control|Control group did not do any exercise and did not follow any ergonomic modification.
75633832|NCT00847912|Drug|5-fluorouracil|"Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped."
75784230|NCT06193603|Other|Sham cupping therapy|In the control group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. However, unlike the intervention group, the cups in the control group will not be moved and will remain stationary for 5 minutes. The cups will have small holes (<2mm in diameter) to release negative pressure quickly. Double-sided tapes will be used to secure the cups and maintain contact with the skin.
75633833|NCT00847912|Drug|Placebo, vehicle control|"Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped."
75326662|NCT05602038|Procedure|Quadratus laborum block|quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side
75633834|NCT04116892|Procedure|the Cover group|The internal limiting membrane around the MH was left to cover the hole
75633835|NCT04116892|Procedure|the Fill group|The internal limiting membrane around the MH was left to fill the hole
75326663|NCT05602038|Drug|Intrathecal morphine|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
75326664|NCT05602038|Drug|intrathecal bupivacaine|intrathecal bupivacaine 0.5% 15mg and fentanyl
75326665|NCT01722409|Drug|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
75326666|NCT01722409|Drug|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
75326667|NCT01726933|Drug|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
75326668|NCT01726933|Drug|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
75326669|NCT01726933|Drug|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
75326670|NCT04707586|Other|Cold Application|Created by the researcher; A bandage with 3 pieces of 13x10 cm cold gel and a cold gel container in which they are placed will be used, which can be adjusted according to the head circumference of the patient between 60-80 cm in length. The ability of the cold gel cups of the bandage to be moved on the bandage will allow comfortable cold application to the patient's bilateral frontotemporal and occipital areas at the same time. After waiting for 20 minutes in the freezer part of the refrigerator, the temperature and temperature of the gels applied and the cold application area before and after each application will be measured and recorded. An Infrared Non-Contact Food Thermometer will be used for temperature measurement of cold gel packs, and an Infrared Non-Contact Thermometer device will be used for temperature measurement of the cold application area.
75468874|NCT04240392|Behavioral|Collaborative Care (CC)|"The sites randomized to CC will have 4-6 on-site support visits at the outset of the study. These visits will occur during the first 3 months of the project. During these visits, study staff will again review buprenorphine induction procedures (heretofore referred to as initiation rather than induction) and dosing of buprenorphine as well as therapeutic behavioral treatments. The investigators will provide the center with forms and educational materials as well as an app that can be run to help dosing during initiation procedures. At the same time, the investigators will teach obstetricians, nurses and support staff the principles of motivational interviewing. The investigators will set up visits for the CM to meet with a recovery coach trainer provided by the investigators' community partner."
75468875|NCT04240392|Behavioral|Extension for Community Healthcare Outcomes (ECHO)|The Weitzman Institute (WI), a community partner and provider for the ECHO condition, is a research and innovation center focused on improving care for medically underserved and special populations. Since 2013, CHCI/WI has provided education and technical assistance through an established video conference and online learning platforms to over 800 primary care providers and over 200 care team members who treat patients with chronic pain and opioid addiction. WI partners with national experts in pain care, substance abuse disorder, and MAT to create and deliver a robust training program for clinicians across the country through Project ECHO ®. The WI will work with the study team to develop and staff the sessions.
75468876|NCT04225806|Device|BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)|The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
75326671|NCT01722565|Procedure|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
75468877|NCT04218708|Other|Nicotine patch and gum|Nicotine patch and gum will be given to subjects in the Nicotine replacement therapy cohort every visit after providing exhaled CO/Saliva cotinine test.
75633836|NCT04116892|Procedure|the peeling group|the internal limiting membrane was discarded
75633837|NCT00701194|Behavioral|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
75326672|NCT04735198|Procedure|Primary tumor surgery|Large bowel resection.
75326673|NCT04735198|Procedure|Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy|Large bowel resection combined and cholecystectomy.
75633838|NCT04116424|Other|nurse training of the patient|visit + telephone follow-up
75633839|NCT04116424|Other|neurologist accompaniement|presentation during consultation by neurologist
75633840|NCT00850564|Drug|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
75633841|NCT04030858|Behavioral|Plant-based diet + nutrition education|The intervention group will adopt a nutrient-dense dietary pattern and receive nutrition education sessions specific to that lifestyle. The diet protocol is comprised of minimally-processed plant foods such as fruits, vegetables, legumes, beans, nuts and seeds. No refined sugars, added salt, or oil will be included. Dietary fat intake limited to 20% of total calories or less per day. Animal products will be eliminated. This dietary pattern is expected to improve resilience, mood, inflammation, microbiome, spirituality, and overall general health (as measured by weight, cholesterol, blood pressure). The treatment group will also receive weekly nutrition education sessions to support the diet.
75633842|NCT04030780|Dietary Supplement|spore-forming probiotic|spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks
75784231|NCT06193577|Dietary Supplement|Phaseolus Vulgaris L. Dry Extract|Extracts of Phaseolus vulgaris (beans) in association with a balanced diet are known to reduce glycaemia and food intake in rodents and humans thus promoting weight loss.
75326674|NCT01727401|Drug|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
75326675|NCT05532228|Procedure|Adenotonsillectomy|adenotonsillectomy by cold dissection
75326676|NCT02513212|Device|Potassium Oxalate|Professionally applied liquid
75326677|NCT02513212|Drug|Stannous fluoride paste|SnF2 Paste
75326678|NCT02513212|Device|Manual toothbrush|Marketed manual toothbrush
75326679|NCT02513212|Device|Power toothbrush|Marketed power toothbrush
75326680|NCT03409081|Drug|gilteritinib|oral
75326681|NCT05591508|Dietary Supplement|Ketogenic Diet|Ketogenic diet will be in the form of artificial powder which can be diluted and given through NG tube. It will be started at a ratio of 1:1 followed by daily increment (2:1,3:1 and 4:1) till a urine ketone of 2+ is seen
75326682|NCT02513446|Drug|BI 1026706|Single dose of BI 1026706 on Day 1
75326683|NCT02513446|Drug|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
75326684|NCT00363844|Drug|Sitagliptin phosphate|50 mg QD or 100 mg QD for 12 months
75468878|NCT04218708|Behavioral|Minnesota Nicotine Withdrawal Scale (MNWS)|The MNWS assesses symptoms associated with nicotine withdrawal (i.e., craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia).
75326685|NCT04703062|Behavioral|Experimental group 1|It is planned to do exercises for 50 minutes a day, 2 days a week during 8 weeks with physiotherapist. It will be planned individually according to the needs of the patients. Exercises will progress in the following weeks by changing the number of repetitions, the amount of resistance and the amount of time. Counseling about physical activity and the suggested sports activity will be provided. In daily living activities ergonomics and joint protection principles will be taught. Informing Family.
75468879|NCT04218708|Behavioral|ASSIST (the Alcohol, Smoking and Substance Involvement Screening)|The ASSIST is the Alcohol, Smoking and Substance Involvement Screening Test. It is a brief screening questionnaire to find out about people's use of psychoactive substances (alcohol, smoking and substance involvement).
75633843|NCT04030780|Other|Placebo|similar capsules administered twice daily
75326686|NCT04703062|Behavioral|Experimental group 2|Counseling about physical activity and the suggested sports activity will be provided.Patients make aerobic and strengthening exercises by himself based on physiotherapist's suggestions. Informing Family about; Why are the exercises necessary To what extent the families should be protective The harmful effects of inactivity There will be information about the resting-activity cycle when there is bleeding.
75326687|NCT04687800|Drug|Dextenza 0.4mg intracanalicular Insert|intracanalicular insert delivery system
75326688|NCT04687800|Drug|Durezol 0.05% Ophthalmic Emulsion|Standard therapy, topical steroid drop
75326689|NCT00864383|Drug|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|"Moxifloxacin 400 mg Rifampicin < 45 kg 450 mg > 45 kg 600 mg Isoniazid 300 mg Pyrazinamide < 40 kg 25 mg/kg rounded to nearest 500 mg* 40-55 kg 1000 mg > 55 kg - 75 kg 1500 mg > 75 kg 2000 mg Ethambutol < 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg > 55 kg - 75 kg 1200 mg > 75 kg 1600 mg *For pyrazinamide dosing in patients < 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
75326690|NCT05532072|Drug|Rapamycin|Rapamycin plus Methylprednisolone
75633844|NCT00703612|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
75633845|NCT00837148|Drug|Sorafenib and Dacarbazine|"Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance."
75633846|NCT00703690|Drug|MK0767|MK0767 2.5, 5, and 10 mg/day supplied as tablets
75326691|NCT05532072|Drug|Methylprednisolone|Methylprednisolone Alone
75326692|NCT03216772|Device|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
75326693|NCT02514070|Drug|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
75633847|NCT00703690|Drug|Comparator: fenofibrate|fenofibrate 200 mg supplied as capsules
75633848|NCT00703690|Drug|Comparator: Placebo (unspecified)|matching placebo will be supplied as tablets/capsules.
75633849|NCT05297968|Drug|Oseltamivir Phosphate For Oral Suspension/Tamiflu|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension/Tamiflu 75mg (6mg/ml,12.5ml)
75633850|NCT05297968|Drug|Oseltamivir Phosphate For Oral Suspension|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension 75mg (6mg/ml,12.5ml)
75633851|NCT00849940|Device|CAS NIRS FORE-SIGHT oximeter|Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
75633852|NCT02613130|Drug|Stannous fluoride toothpaste|
75468880|NCT04218708|Behavioral|Counseling|At each study visit, participants will receive counseling protocol that will be based on effective counseling manuals. The PI will train the research assistant who will assist the PI in tailoring the manual to the target group: counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects known to contribute to smoking among PLWHA (e.g., tips on dealing with depression and feeling stigmatized particularly in relation to HIV).
75633853|NCT02613130|Drug|Potassium nitrate toothpaste|
75633854|NCT00849472|Drug|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
75633855|NCT00849472|Drug|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
75633856|NCT00849472|Procedure|surgery|neoadjuvant surgery for breast cancer
75633857|NCT00849472|Drug|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
75784232|NCT06193577|Dietary Supplement|Placebo|The placebo control does not contain active ingredients.
75326694|NCT02514070|Drug|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
75326695|NCT00864539|Dietary Supplement|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
75326696|NCT00864539|Dietary Supplement|plain milk|daily intake of 200 ml plain milk
75326697|NCT00864539|Dietary Supplement|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
75468881|NCT04218708|Other|NIDA Standardized Research E-cigarettes (SREC)|"NIDA SREC has a case with a liquid tank. The e-liquid is supplied in sealed disposable cartridges that deliver >300 puffs / cartridge. The SREC uses a battery recharged via a micro USB port. A single charge is designed to outlast the capacity of an e-liquid cartridge. The e-liquid is tobacco flavored and contains nicotine."
75468882|NCT04189588|Drug|Cetirizine HCl 10 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
75633858|NCT04116580|Other|RAAP - for Raw Apple in connection with re-contact with the raw apple according to an Ultra-Rush protocol|
75326698|NCT00864539|Dietary Supplement|plain orange juice|daily intake of 250 ml plain orange juice
76077440|NCT03030742|Other|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~Satisfaction with pain control 2-4 weeks postpartum~Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~Patient characteristics associated with high opioid use~Methods of storage and disposal of unused opioids"
75326699|NCT00864539|Dietary Supplement|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
76077441|NCT04402203|Drug|Favipiravir|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
75326700|NCT00864539|Dietary Supplement|Placebo|daily placebo
75468883|NCT04189588|Drug|Diphenhydramine 50 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
75633859|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
75633860|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
75633861|NCT00782509|Drug|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
76077442|NCT04402203|Drug|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
75633862|NCT04116346|Other|Oral intake allowed|Oral intake (food and fluids) allowed up to the time of the procedure
75633863|NCT05598112|Biological|FMT capsules|FMT capsules containing extensively screened donor stool.
75919950|NCT05018780|Other|Muscle Energy Technique|"Post isometric relaxation: Patient will be asked to perform isometrics on piriformis, iliopsoas and erector spinae muscles one by one. Each isometric contraction will be held for 10 seconds. After 10 seconds, contraction will be released with an exhalation. These contractions will be repeated for 5 times in one session.~Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Muscle Energy Technique."
75326701|NCT05460312|Diagnostic Test|prostate biopsy|trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.
75326702|NCT03143920|Combination Product|Hyperbaric Oxygen Therapy-|Hyperbaric oxygen therapy provides 100% medical grade oxygen at 2.4 atmospheres of absolute pressure with a Class A multiple person chamber or Class B single person chamber. Hyperbaric chambers are classified as a Class II medical device and have been FDA cleared.
75326703|NCT00827255|Drug|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
75326704|NCT02442102|Behavioral|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
75326705|NCT05235503|Drug|Medicinal cannabis in combination with oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with oxycodon
75326706|NCT05235503|Drug|Medicinal cannabis in combination with placebo oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
75326707|NCT02153489|Drug|Aclidinium bromide|
75326708|NCT02153489|Drug|Placebo|
75633864|NCT05598112|Other|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug.
75633865|NCT00701428|Drug|Losartan|Losartan 50 mg daily during 6 + 6 weeks
75633866|NCT00701428|Other|CPAP|CPAP during the second 6 week-period
75633867|NCT00927810|Drug|Canakinumab|
75633868|NCT00848926|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous infusion
75633869|NCT02602951|Other|Pilot MRI program|Pilot MRI program
75633870|NCT02602951|Other|MRI with 4D Flow sequence|MRI with 4D Flow sequence
75633871|NCT00847132|Behavioral|Collaborative Care Treatment|Depression education, treatment recommendations, coordination of care
75633872|NCT00847132|Behavioral|Usual Care Treatment|Treatment as usual, providers are notified of diagnoses
75633873|NCT04254510|Other|Myofascial relaxation technique|"Before the intervention, the number of days of the last menstrual cycle of all participants, the number of painful days throughout the cycle, pain intensity values according to the Visual Analogue Scale will be recorded, and the scores will be recorded in the participants.~Technique of direct relaxation of fascia of both psoas muscles to the participants in the myofascial relaxation group since the end of the last cycle, 90-120 sec. It will be applied by the physiotherapist twice a week."
75633874|NCT00706888|Dietary Supplement|Vitamins B6, B9 and B12 and polyphenols|
75633875|NCT00706888|Dietary Supplement|placebo|
75633876|NCT05019534|Drug|Vemurafenib Oral Tablet [Zelboraf]|Vemurafenib 960mg qd or 960mg bid (2 cohorts)
75633877|NCT05019534|Drug|Cetuximab Injection [Erbitux]|Cetuximab 500mg/m2 Q2W
75633878|NCT05019534|Drug|Camrelizumab|Camrelizumab 200mg Q2W
76077443|NCT03030976|Drug|cyclophosphamide|Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
76077444|NCT03030976|Drug|anti-CD19-CAR-T cells|A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
76077445|NCT03454425|Device|Exablate Subthalamotomy|ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
76077446|NCT03454425|Device|Sham Exablate Subthalamotomy|Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
75326709|NCT04634344|Drug|DZD2269|A single dose of DZD2269 starting at 5 mg will be given on Cycle 0 and then followed by a wash-out period. Multiple doses of DZD2269 at the same dose level will be given once daily after the wash-out period.
75326710|NCT04627012|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75326711|NCT04627012|Drug|Opdivo|3mg/mg intravenously every 3 weeks
75326712|NCT04627012|Drug|Camrelizumab|200mg intravenously every 3 weeks
75326713|NCT04627012|Drug|Keytruda|200mg intravenously every 3 weeks
75919951|NCT05018780|Other|Sacral Manipulation|"To manipulate an iliac anterior rotation displacement sacroiliac joint dysfunction and to restore posterior rotation of the ilium, participant will be positioned in side lying. Therapist will place one hand at Anterior superior iliac supine (ASIS) and the other at Ischial tuberosity. A quick thrust will be applied and ASIS will be pushed posteriorly while Ischial tberosity anteriorly. This will be maintained for 10 to 30 seconds.~To manipulate an iliac posterior rotation displacement sacroiliac joint dysfunction and to restore anterior rotation of the ilium, participant will be in prone position. One hand of therapist will be at Posterior superior iliac supine (PSIS) and the other one at pubic rami. A quick thrust will be delivered and PSIS will be moved anteriorly while pubic rami posteriorly. This will be maintained for 10 to 30 seconds.~Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Sacral Manipulation."
75326714|NCT04627012|Drug|Toripalimab|240mg intravenously every 3 weeks
75326715|NCT04627012|Drug|Sintilimab|200mg intravenously every 3 weeks
75326716|NCT04627012|Drug|Tislelizumab|200mg intravenously every 3 weeks
75326717|NCT04600102|Device|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
75326718|NCT00866879|Drug|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
75326719|NCT00866879|Other|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
75326720|NCT00866879|Procedure|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
75633879|NCT00707044|Procedure|Control group (usual care)|control group, care as usual, 24 hours intensive care stay
75633880|NCT00707044|Procedure|Short-Stay Intensive Care treatment (SSIC)|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
75326721|NCT00866879|Procedure|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
75468884|NCT04189588|Drug|anti-CD20 such as Rituximab or Paclitaxel|Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
75468885|NCT04176419|Drug|Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
75633881|NCT04254120|Behavioral|Cognitive-behavioral therapy|Psychological treatment focusing on changing cognitions and behaviors using information processing theory and learning theory approaches.
75633882|NCT04254120|Behavioral|Integrated motivational interviewing and cognitive-behavioral therapy|Motivational interviewing is a psychological treatment approach focusing on increasing motivation by eliciting patient talk favoring behavior change and resolving patient ambivalence about change.
75919952|NCT05002244|Drug|CTL0801 (Azilsartan)|CTL0801 (Azilsartan), single dose, daily, repeated oral administration
75919953|NCT05002244|Drug|CTL0802 (Rosuvastatin)|CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
75919954|NCT05002244|Drug|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
75919955|NCT05170880|Procedure|Primary endodontic treatment|Primary non surgical endodontic treatment will be provided to patients in treatment group.
75326722|NCT00866879|Procedure|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
75326723|NCT00866879|Other|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
75326724|NCT00866879|Procedure|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
75326725|NCT02311920|Biological|Ipilimumab|Given IV
75468886|NCT04176419|Drug|Placebo Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
75468887|NCT04176419|Drug|Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
75919956|NCT03412136|Dietary Supplement|Control|Participants were given 5 minutes to ingest the non-caloric beverage which contained 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water and sweetened with 0.2g sucralose (Tate & Lyle, Stoney Creek, Ontario, Canada) in order to match sweetness with the glucose beverage.
75919957|NCT03412136|Dietary Supplement|Glucose|Participants were given 5 minutes to ingest the beverage which contained either 1g of protein (plain whey-protein isolate; BiPro USA., Eden Prairie, Minnesota, U.S.A) per kg of bodyweight and was flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
75326726|NCT02311920|Other|Laboratory Biomarker Analysis|Correlative studies
75326727|NCT02311920|Biological|Nivolumab|Given IV
75326728|NCT02311920|Drug|Temozolomide|Given PO
75326729|NCT02153723|Drug|Glatiramer Acetate|
75326730|NCT04388878|Drug|PF-07054894|Participants will receive oral ascending doses
75326731|NCT04388878|Drug|Placebo|Participants will receive matching placebo
75326732|NCT00828191|Drug|Progesterone|25 mg, once a day, SC
75919958|NCT03412136|Dietary Supplement|Protein|Participants were given 5 minutes to ingest the beverage which contained 1g of glucose monohydrate (BioShop Canada Inc., Burlington, Ontario, Canada) per kg of bodyweight and flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
76077447|NCT00949234|Drug|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance <30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
76077448|NCT02984787|Procedure|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
75919959|NCT04446884|Biological|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution
75919960|NCT04446884|Other|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
76077449|NCT02984787|Procedure|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
75326733|NCT00828191|Drug|Progesterone|100 mg, twice a day, vaginally
76077450|NCT03090880|Drug|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
75326734|NCT04571320|Behavioral|Summer STRIPES|See arm description.
75326735|NCT04571320|Other|Enhanced School Services as Usual|see arm description.
75326736|NCT05531838|Device|Fu Lishan instant sense hospital dynamic glucose monitoring system|Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
75326737|NCT04375306|Procedure|RFR guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.
75468888|NCT04176419|Drug|Placebo Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
75468889|NCT04176419|Drug|Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
75468890|NCT04176419|Drug|Placebo Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
75633883|NCT00707122|Other|Albumin and Crystalloids|"From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:~1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:~if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;~if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;~if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted."
75326738|NCT04375306|Procedure|Angio guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
75326739|NCT00867659|Drug|Cetrotide acetate|cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
75326740|NCT00912925|Biological|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
75326741|NCT00912925|Biological|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
75468891|NCT04176419|Drug|Gabapentin|600 mg orally at time of check in to the preoperative unit
75633884|NCT00707122|Other|Crystalloids|"Volume replacement will be performed in both the treated and the control group according to the early-goal directed therapy.~control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed."
75633885|NCT04254042|Drug|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
75326742|NCT05531058|Behavioral|AI-driven Vaccine Communicator|The intervention will include six modules web-based psychoeducation programme (two module sessions weekly, each module lasts for 15-20 minutes). And the content of the intervention includes six modules sessions, including Module 1- What is COVID-19, Module 2- Basic knowledge of vaccine; Module 3- Risk and benefit; Module 4- Fear & myth; Module 5- Vaccine policy; Module 6- Review the intervention and end the programme. Also with an MI communication skills-based AI, digital assistant.
75326743|NCT05531058|Behavioral|Self-learning of COVID-19 vaccine knowledge|Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge (using multiple choices questions similar to the intervention group), and this is to ensure that participants from the control group also use time to search relevant information of covid-19 vaccines, also this is to control the time effects.
75326744|NCT04549870|Drug|Roflumilast|Treatment according to national roflumilast guidelines
75326745|NCT00828347|Drug|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
75326746|NCT00828347|Drug|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
75633886|NCT04254042|Drug|Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer|30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
75633887|NCT00918138|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
75633888|NCT00918138|Drug|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
75326747|NCT05531760|Procedure|Descemet Membrane Endothelial Keratoplasty|DMEK-operated eyes
75326748|NCT03835663|Diagnostic Test|No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes|Standard upper GI endoscopy with biopsies
75326749|NCT00829049|Drug|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
75326750|NCT00829049|Drug|Adapalene|1 pea-size amount, QD x 16 weeks
75326751|NCT03835429|Device|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, Airway Management Inc.(AMI), Dallas Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared.
75919961|NCT04446494|Procedure|Identification and preservation of arm lymphatics (DEPART)|Indocyanine green was utilized to identify arm sentinel nodes, and 0.1 ml MB was injected into the arm sentinel nodes to reveal the subsequent-echelon nodes and lymphatics. Gross arm lymph nodes were examined by intraoperative partial frozen section and were removed if positive.
75919962|NCT03398876|Drug|Oromucosal Nicotine Spray (ONS)|Participants will receive oral dose of oromucosal nicotine spray (ONS).
75919963|NCT03398876|Drug|Nicotine Gum|Participants will chew nicotine gum for 30 minutes.
75919964|NCT03398876|Other|Cigarette|Participants will smoke one cigarette as 10 puffs for 3 minutes.
75919965|NCT03411980|Drug|Vilaprisan (BAY1002670)|Single oral dose (1 x 2 mg immediate-release, film-coated tablet)
75919966|NCT03398720|Drug|HTI-1066 dose level 1|Starting dose level
75919967|NCT03398720|Drug|HTI-1066 dose level 2|2nd dose level
75919968|NCT03398720|Drug|HTI-1066 dose level 3|3rd dose level
75468892|NCT04176419|Drug|Placebo Gabapentin|600 mg orally at time of check in to the preoperative unit
75468893|NCT04176419|Drug|Celecoxib|200 mg orally at time of check in to the preoperative unit
75468894|NCT04176419|Drug|Placebo Celecoxib|200 mg orally at time of check in to the preoperative unit
75468895|NCT04171219|Biological|Pembrolizumab|Given IV
75633889|NCT00918138|Drug|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
75633890|NCT00918138|Drug|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
75633891|NCT00918138|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
75468896|NCT04171219|Drug|Talabostat Mesylate|Given PO
75468897|NCT04163172|Procedure|Surgical treatment of distal humeral fracture with elbow hemiarthroplasty|Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)
75468898|NCT04163172|Procedure|Surgical treatment of distal humeral fracture with double plating.|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)
75633892|NCT04244136|Device|contrast CT|contrast CT abdomen fir measurement of the volume of expected residual normal renal tissue before surgery
75633893|NCT04253574|Diagnostic Test|Imaging with 18F-FDG PET/CT and/or Ultrasound|All patients were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)) in the search of primary tumors or metastases of their malignant melanomas.
75633894|NCT00782275|Drug|bevacizumab|
75633895|NCT00782275|Drug|temsirolimus|
75633896|NCT04107571|Procedure|A type of operation for coranary heart disease patients.|A type of operation for coranary heart disease patients.
75919969|NCT03398720|Drug|HTI-1066 dose level 4|4th dose level
75919970|NCT04971668|Other|Aromatherapy|Three drops of the designated blend aromatherapy (ginger & lavender) will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient will be asked to inhale deeply and simulate like chewing gum for 5 minutes.
75919971|NCT04971668|Other|Gum Chewing|Patients will chew gum (sugar free) and inhale deeply with inert gauze for 5 minutes.
75919972|NCT04971668|Other|Controlled|Patients will inhale deeply with inert gauze and simulate like chewing gum for 5 minutes.
75326752|NCT04303702|Drug|Continue Oxytocin|The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
75326753|NCT04303702|Other|Discontinue Oxytocin|Patients will have their oxytocin discontinued in the second stage of labor. The patient will receive routine maintenance IV fluids per the discretion of the provider.
75326754|NCT01727479|Other|Ribose|After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
75326755|NCT01727479|Other|Placebo|
75326756|NCT00868751|Biological|tocilizumab|"Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.~Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16."
75468899|NCT04162210|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered.
75633897|NCT02602873|Other|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
75784233|NCT06193564|Other|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) A constant current of 2 mA was applied to the experimental group for 20 minutes.
75326757|NCT01727557|Procedure|regional anesthesia|Regional anesthesia will be compared to local anesthesia
75326758|NCT01727557|Procedure|local anesthesia|Regional anesthesia will be compared to local anesthesia
75326759|NCT04529044|Drug|Lutetium Lu 177 Dotatate|Given IV
75326760|NCT01821144|Behavioral|Salt reduction|Salt reduction
75326761|NCT01821144|Other|Control|No salt awareness education
75326762|NCT00913003|Drug|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
75326763|NCT00913003|Drug|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
75326764|NCT00869141|Drug|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
75326765|NCT05530902|Other|Multidisciplinary Primary Rehabilitation Care|As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
75326766|NCT01722799|Device|Drug elluting Balloon (DEB)|Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.
75633898|NCT00791557|Drug|Infliximab|IV drug given at weeks 1,2,14,22
75326767|NCT01722799|Device|Drug elluting coronary stent (DES)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
75326768|NCT01727635|Other|body-mind-spirit group therapy|8-session therapy
75326769|NCT03408925|Other|Exercise program|The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
75326770|NCT02828254|Drug|PRI-724|
75326771|NCT01722955|Other|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
75326772|NCT01722955|Other|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
75468900|NCT04162210|Drug|Pom/dex (Pomalidomide plus low dose Dexamethasone)|Pomalidomide and Dexamethasone will be administered.
75633899|NCT04107337|Other|Vocal work session with straw exercises|"Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath in the straw ; (1 minute) Phonation in the straw ; (2 minutes) Make a siren in the straw ; (4 minutes) Vocalizations in the straw on the arpeggio of Rossini.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
75633900|NCT04107337|Other|Vocal work session with open mouth exercises|"Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath on a [f] with open mouth ; (1 minute) Phonation on the vowel [a] with open mouth ; (2 minutes) Make a siren on the vowel [a] with open mouth ; (4 minutes) Vocalizations on the vowel [a] on the arpeggio of Rossini with open mouth.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
75326773|NCT04216420|Device|MERM-observed self-administered therapy|The MERM device has an electronic module and a medication container that records adherence, stores medication, emits audible and visual on-board alarms to remind patients to take their medications on time and refill, and enables providers to download the data and monitor adherence. It is manufactured by Wisepill Technologies, South Africa.
75468901|NCT04157101|Behavioral|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
75468902|NCT04157101|Behavioral|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
75633901|NCT00920790|Biological|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
75633902|NCT04253886|Device|Ovassapian Fibreoptic Intubating Airway|The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).
75919973|NCT03398642|Behavioral|French Lifestyle Redesign|Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
75919974|NCT03394664|Behavioral|Feeding Study|Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
75326774|NCT00829985|Biological|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
75326775|NCT00829985|Biological|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
75326776|NCT01606176|Drug|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
75326777|NCT01606176|Drug|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
75326778|NCT00913081|Dietary Supplement|Quercetin|Quercetin 500, 1000, or 2000 mg PO one time
75326779|NCT00913081|Dietary Supplement|Placebo|Placebo PO one time
75326780|NCT04198792|Other|No intervention|No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest
75326781|NCT03408769|Other|Medical questionnaire|"Brief Index of Sexual Functioning for Women questionnaire~Quality of life questionnaire (EORTC QLQ-BR23)~Partnership questionnaire (partnerschaftsfragebogen; PFB)~Short interview about their sexual intimacy"
75326782|NCT04077424|Biological|Fluzone-High Dose Quadrivalent|Seasonal influenza vaccination with FDA approved vaccines for this age group.
75326783|NCT04077424|Biological|Fluad|Adjuvanted (MF59) inactivated influenza vaccine
75326784|NCT04077424|Biological|Flublock|Recombinant hemagglutinin vaccine
75468903|NCT04154488|Drug|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
75633903|NCT00781963|Behavioral|Manual-based cognitive behavioral therapy for insomnia|Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.
75633904|NCT00781963|Behavioral|Non-directive sleep education|Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
75633905|NCT05176314|Drug|Rosuvastatin|Administered Orally.
75633906|NCT05176314|Drug|Pirtobrutinib|Administered Orally.
75633907|NCT04017325|Other|no intervention (post study follow up)|No intervention (post study follow up)
75919975|NCT03394586|Drug|Exposure to golimumab|retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
75919976|NCT03411824|Other|no intervention|Non applicable
75633908|NCT00920556|Drug|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
75919977|NCT03394430|Drug|Placebos|Patients in Group A receive intranasal normal saline before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
76077451|NCT03490695|Other|Practice Facilitation|Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.
76077452|NCT03490695|Other|Usual Care|Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
75326785|NCT05597592|Procedure|Feasability of a personalised physical rehabilitation program at home|Monitoring of the realization of a personalised physical rehabilitation program at home by patients with neuromuscular and neurodegenrative disease
75326786|NCT00869375|Device|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
75326787|NCT01727869|Drug|REGN1400|
75326788|NCT01727869|Drug|Erlotinib|
75326789|NCT01727869|Drug|Cetuximab|
75326790|NCT04425330|Other|physiotherapy exercises|The evidence on the effectiveness of physical therapy in children with myelomeningocele is limited. The International Classification of Functionality, Disability and Health for Children and Youth is a useful tool to assist therapists in analyzing problems about the focus of the intervention. The evidence in physical therapy practice for individuals of all ages with neurological disorders, focuses on 5 Ps: prevention, prediction, participation, personalized and plasticity. Thus, neurological physiotherapists must perform the care with a focus on preventing the patient's disabilities, predicting the ideal response of an intervention, through measures of results of the movement system. In addition, it is of paramount importance that the goal of rehabilitation is that people with neurological disabilities are fully included and participate in life activities that are important to them and that their care is personalized. All of these measures facilitate the process of positive plasticity.
75326791|NCT04425330|Other|PBM|Photobiomodulation occurs from the application of low intensity light such as low intensity laser and light emitting diode (LED). The therapeutic effectiveness of phototherapy is based on the absorption of photons by photoreceptors or chromophores. Studies on the experimental model of spinal cord injury have shown that both wavelengths have the potential to be an effective and non-invasive means of therapy, promoting axonal appearance, increased concentration of glial cells and nerve connections, in addition to functional and sensitive. The findings of a clinical trial involving individuals diagnosed with spinal cord injury demonstrate that PBM exerted positive effects on motor function, especially during isotonic contraction of stimulated muscles assessed by electromyography, and there was a recovery in sensory perception and muscle strength.
75326792|NCT04425330|Other|SHAM PBM|SHAM PBM
75326793|NCT02684266|Drug|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
75326794|NCT00869609|Behavioral|GLB Traditional Maintenance (TM)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
75326795|NCT00869609|Behavioral|GLB-Carb-focused Maintenance (CF)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
75326796|NCT00370864|Biological|H5N1 pandemic influenza vaccine|
75326797|NCT04379167|Drug|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
75633909|NCT00920556|Drug|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
75633910|NCT00781885|Drug|Beraprost sodium modified release|Tablets 60mcg
75633911|NCT04901676|Drug|Leronlimab|Leronlimab 700 mg (first dose) followed by weekly 350 mg
75633912|NCT04901676|Drug|Placebo|Placebo
75633913|NCT04843176|Diagnostic Test|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
75919978|NCT03394430|Drug|Midazolam|Patients in Group B receive intranasal 0.25mg/kg midazolam before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
76077453|NCT03489993|Diagnostic Test|Ang II and Ang-(1-7)|Measured in plasma and urine using radioimmunoassays.
76077454|NCT03489993|Diagnostic Test|FGF23 and klotho|Measured using ELISA's.
75633914|NCT04843176|Diagnostic Test|LI-RADS|The Liver Imaging Reporting and Data System (LI-RADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
75326798|NCT01603368|Dietary Supplement|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
75326799|NCT01603368|Dietary Supplement|Placebo|Oil drops without Lactobacillus reuteri
75633915|NCT04831086|Drug|Steroid Drug|Steroids doses will be optimized in the intervention group according the risk based on predictive models
75326800|NCT00370942|Drug|GW823093C A|A=45 mg
75633916|NCT04831086|Drug|Tocolytic Agents|Tocolysis duration will be optimized in the intervention group according the risk based on predictive models
75326801|NCT00370942|Drug|GW823093C B|B=30 mg
76077455|NCT00951808|Biological|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
75919979|NCT03394430|Drug|Dexmedetomidine|Patients in Group C receive intranasal 1μg/kg dexmedetomidine before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
75326802|NCT00370942|Drug|GW823093C C|C=25 mg
75326803|NCT01727947|Other|MSOME|A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied > 13% of nuclear area) in each sample will be assessed.
75919980|NCT04951310|Behavioral|Philly Vax Sweepstakes|"The Philly Vax Sweepstakes is a citywide sweepstakes designed to motivate Philadelphians to get vaccinated against COVID-19. A total of 36 vaccinated Philadelphians will win among three cash prize packages, distributed from the total cash pool. These 36 will be chosen over three drawings, with 12 residents chosen in each drawing."
75326804|NCT01728103|Device|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
75326805|NCT00371020|Drug|low molecular weight heparin, 5-FU|
75326806|NCT04476628|Drug|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
75326807|NCT04476628|Device|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
75919981|NCT03411668|Other|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
75326808|NCT04476628|Device|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
76077456|NCT00951808|Behavioral|Standard care|Participants will receive standard care for ACS while in the hospital.
76077457|NCT03030508|Other|No intervention|
76077458|NCT03030430|Biological|BAT1706 injection|1mg/kg, IV on day 1
75326809|NCT01728181|Drug|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
76077459|NCT03030430|Biological|EU-sourced Avastin|1mg/kg, IV on day 1
75326810|NCT01728181|Drug|Erlotinib|150 mg/day for 28 day cycle. No rest period.
75326811|NCT01728181|Other|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
75326812|NCT04378231|Drug|Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension|dry suspension of amoxicillin clavulanate potassium
75326813|NCT04475302|Biological|BCG vaccine (Freeze-dried)|single dose of BCG vaccine (Freeze-dried) manufactured by Serum Institute of India, Pune. The composition of BCG vaccine is Live, attenuated BCG (Bacillus Calmette-Guerin Strain). (Each 1 ml contains between 2 x 106 and 8 x 106 Colony Forming Units (C.F.U.) with Diluent: Sodium Chloride Injection I.P.)
75326814|NCT04378309|Behavioral|ePREP|6-session online psychoeducational program with supporting coach calls
75326815|NCT01728571|Dietary Supplement|Vitamin D3|
75326816|NCT01728571|Dietary Supplement|fish oil|
75326817|NCT01728571|Dietary Supplement|Vitamin D3 placebo|
75326818|NCT01728571|Dietary Supplement|Fish oil placebo|
75326819|NCT00832637|Drug|Cisplatin|Cisplatin is administered intravenously at 40 mg/m2 on day 1 and day 15, every 28 days. Cisplatin is administered following Gemcitabine. Cisplatin administration should occur with hydration with normal saline at 250 mL/ hour for at least 4 hours before and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
75326820|NCT00832637|Drug|Erlotinib|100 mg orally daily. For grade 3 or 4 skin rash, erlotinib should be held until resolution of the rash to no more than grade 1 before resumption of erlotinib.
75326821|NCT00832637|Drug|Gemcitabine|Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
75326822|NCT03408457|Procedure|Blood sampling after antibiotic administration|Sampling of 6 x 8 mL (in sum 48 mL) via the central venous line (established for the surgical procedure) until postoperative day 2
75326823|NCT04338490|Device|Feedback mannequim|The intervention group received rcp training with their performance being evaluated in real time so that they could correct themselves
75633917|NCT02603965|Radiation|Copper Cu 64 TP3805|Given IV
76077460|NCT03030430|Biological|US-sourced Avastin|1mg/kg, IV on day 1
76077461|NCT00089661|Drug|Placebo|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
76077462|NCT00089661|Drug|AMG 162 / Denosumab|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
76077463|NCT00941668|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
76077464|NCT00941668|Drug|sodium monofluorophosphate toothpaste|Twice daily usage
75326824|NCT05191901|Other|Stress Ball|Reducing pain and fear by squeezing a stress ball during the blood draw procedure.
75326825|NCT03408301|Procedure|Tourniquet deflation|Tourniquet deflation
75326826|NCT05186285|Drug|CM338|CM338 : a humanized monoclonal antibody.
75326827|NCT05186285|Drug|Placebo|Placebo.
75326828|NCT03408223|Radiation|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
75326829|NCT03408223|Radiation|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
75326833|NCT00370162|Drug|lactoserum|
75633918|NCT02603965|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
75633919|NCT02603965|Procedure|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
75919982|NCT03398564|Procedure|Erector Spinae Plan Block|The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.
75326834|NCT00918229|Device|balloon implant|Absorbable perirectal spacer implantation
75326835|NCT00918229|Procedure|Balloon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
75326836|NCT00370240|Drug|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
75326837|NCT00370240|Other|placebo|The PCB group received saline solution in equal volume.
75326838|NCT05116475|Drug|Darolutamide 300 mg|Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
75326839|NCT05116475|Drug|Placebo of Darolutamide|Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
75326840|NCT03408145|Device|Hyaluronic Acid|Injection of 3x 2.5ml of Hyaluronic Acid
75326841|NCT03408145|Device|Amniotic Tissue Allograft|Injection of 1x 1ml of Amniotic Tissue Allograft
75326842|NCT03408145|Drug|Saline|Injection of Saline
75633920|NCT02603965|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
75633921|NCT02603965|Other|Laboratory Biomarker Analysis|Correlative studies
75919983|NCT03398564|Procedure|Oblique subcostal TAP|ultrasound-guided bilateral oblique subcostal TAP block with bupivacaine 0.25% (20ml on each side)
75919984|NCT03398486|Diagnostic Test|Kinesiotaping|Dynamic adhesive taping is a method that involves the application of specific tapes to the surface of the patient's skin in order to use the natural self-healing processes of the body. It is often used as an element that sustains the therapeutic effect. Its action is based mainly on the action normalizing muscle tone, supporting the work of joints, improving the function of weakened muscles, increasing microcirculation at the site of application.
75919985|NCT03398486|Diagnostic Test|inactivation of trigger points (TrP)|A procedure for releasing trigger points using physiotherapy using the ischemic compression method, which involves applying pressure to the active trigger point, until it is switched off, i.e. pain ceases.The location of the trigger point is done palpatively, with a pliers grip, covering the strained tissue on the inside and outside of the cheek with the thumb and index finger.
76077465|NCT03488121|Behavioral|Poster|Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
75633922|NCT02602795|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.
75633923|NCT02602795|Behavioral|Information Motivation Behavioral Model|This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
75633924|NCT04103047|Other|SAD|The patients who have an SAD inserted as part of their normal Anaesthetic plan will be consented prior to their Anaesthetic and then have a questionnaire to fill out post operatively.
75633925|NCT00918684|Drug|Escitalopram|10mg tab daily
75633926|NCT05543707|Drug|PBI-0451 (Pomotrelvir)|2 × 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
75633927|NCT05543707|Drug|Placebo|2 × placebo to match PBI-0451(Pomotrelvir) tablets administered orally BID with food for 5 days (10 total doses)
75326843|NCT01663896|Device|OCT stent guidance|Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT
75633928|NCT04105465|Device|PlasmaJet|The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
75326844|NCT02475772|Drug|Cisplatin and doxorubicin|The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
75326845|NCT02475772|Procedure|Cisplatin and doxorubicin|intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
75468904|NCT04149171|Drug|with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.|The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
75468905|NCT04149171|Drug|conventional treatment|standard treatment based on crystalloid fluid and tranexamic acid (TXA)
75468906|NCT04147585|Other|Intermittent Reduced Calorie Diet (IRCD)|Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
75468907|NCT04144894|Diagnostic Test|Shear Wave Elastography|Advanced ultrasound technique
75919986|NCT03398408|Behavioral|Training|The intervention group will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
75919987|NCT03394352|Other|Activity on Board|During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.
75633929|NCT04105309|Behavioral|Implementation Intentions|"Implementation intentions aid in pre-planning and habitualization of behaviors, as they serve to identify the when, where, and how of behaviors leading to goal attainment. Often taking the form of If/when situation x arises, then I will do y!, implementation intentions can be conceptualized in two parts, namely, an environmental or internal retrieval cue and a goal-directed behavioral response. Implementation intentions are effective because they 1) create a strong association between a retrieval cue and a goal-aligned behavior, increasing the likelihood that the goal-aligned behavior will be retrieved and utilized when the cue is encountered, and 2) increase attention for and cognitive accessibility of the retrieval cue, increasing opportunities for goal-aligned action ."
75919988|NCT03394352|Other|Usual Diabetes Care|Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.
75919989|NCT03411590|Other|Fortified milk Powder|Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
75919990|NCT03394274|Other|restrictive and liberal transfusion|hemoglobin threshold value was accepted 8g/dl. restrictive blood transfusion group was defined that if perioperative transfusion was started equal or under hemoglobin level 8 g / dL. Liberal blood transfusion group was defined as perioperative transfusion was started over hemoglobin level 8 g / dL .
75919991|NCT02520440|Biological|Monitoring of plasmatic levels of Citrulline|Measured plasma amino-acids levels
75919992|NCT02520440|Device|Intra-abdominal pressure monitoring|Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
75919993|NCT02520440|Biological|Monitoring of plasmatic levels of Arginine and Glutamine|Measured plasma amino-acids levels
75468908|NCT04111822|Drug|red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate|Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
75468909|NCT04111822|Drug|on crystalloid fluid and Tranexamic acid|Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
75468910|NCT04088370|Other|Blood Draw|Blood Draw Only
75633930|NCT04105309|Behavioral|Fluency Training|Fluency training is a learning strategy that requires an individual to perform a skill or demonstrate knowledge repeatedly for both accuracy and response rate; the goal is to enhance automaticity of the response and promote endurance and retention of skills and knowledge over time and in the face of distractors. Participants completed 1 minute fluency training protocol 4 times throughout the study.
75919994|NCT03394196|Diagnostic Test|HIV-2 Genotypic Drug Resistance Testing using DBS|Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.
76077466|NCT03488121|Behavioral|Thank-you Letter|Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
76077467|NCT05056792|Other|Isometric strength training for 8 week|Plyometric training for 8 week
75468911|NCT04086264|Drug|Azacitidine|Commercially available formulation given subcutaneously (SC) or intravenous (IV)
75468912|NCT04086264|Drug|IMGN632|Study formulation given intravenously (IV)
75468913|NCT04086264|Drug|Venetoclax|Commercially available formulation administered orally
75919995|NCT03394196|Drug|2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)|1. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
76077468|NCT05056792|Other|Conventional training|Conventional training for 8 week
76077469|NCT03487887|Device|continuous glucose monitoring (CGM) iPro™2 Medtronic|A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
75633931|NCT04105309|Behavioral|Text Messages|SMS reminders sent to phone of implementation intentions 16 times throughout the study.
76077470|NCT01597414|Drug|Pertuzumab + trastuzumab|"Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks."
75633932|NCT04105309|Behavioral|Goal Intentions|Intentions to complete a goal that do not specify a plan about how to do so (compared to implementation intentions, that do)
76077471|NCT01597414|Drug|Pertuzumab + trastuzumab + metronomic chemotherapy|Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
75633933|NCT04883424|Behavioral|Diabetes Education Program Based on Health Belief Model|After the application, increase in family support and decrease in blood sugar levels are expected in diabetic patients. Family members' diabetic attitudes are expected to increase.
75633934|NCT00786409|Biological|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
76077472|NCT04984330|Drug|Selinexor|Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
75326846|NCT04338256|Behavioral|Wellness and Resilience for College and Beyond (Undergraduate College Course)|"The course, Wellness and Resilience for College and Beyond was originally developed by James Mazza, PhD and colleagues at the University of Washington as a 10-week course. The course developers adapted their course materials to fit the needs of a 16-week semester for the purpose of this study. The Wellness Course teaches students evidence-based skills for improving mental health from dialectical behavior therapy, acceptance and commitment therapy, and the field of positive psychology. Classes meet for 2.5 hours weekly with approximately half of class time spent on teaching new content (lecture) and the other half spent with students working in small groups on practice and discussion exercises."
75633935|NCT05150886|Diagnostic Test|rox index|After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.
75633936|NCT04583982|Other|T-Detect™ SARS-CoV-2 Assay|T-Detect™ SARS-CoV-2 Assay is an investigational device that is indicated to assess T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19. These results will not be shared with the participant.
75633937|NCT04881396|Biological|Evaluation of the immunogenicity of the vaccine in haemodialysis patients|The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)
75919996|NCT03394196|Drug|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )|2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
75919997|NCT03394196|Drug|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)|3. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
75919998|NCT03398174|Behavioral|Motor Control Exercise|"Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
75326847|NCT00915655|Drug|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
75326848|NCT00915655|Drug|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
75326849|NCT00915655|Drug|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
75326850|NCT00915655|Drug|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
75633938|NCT00919854|Drug|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
75468914|NCT04082520|Radiation|Gallium Ga 68-DOTATATE|Given IV
75633939|NCT00919854|Drug|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
75326851|NCT00915655|Drug|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
75326852|NCT05531682|Drug|HB0017|HB0017 in different dosing regimens
75326853|NCT05531682|Other|Placebo|Subjects will receive several injections of Placebo
75326854|NCT03622138|Other|Impact|Impact is an easy to use, cost- and time-efficient technology platform that is capable of (a) gathering relevant process and outcomes data in a feasible way within real-world service settings; (b) producing real-time analytics (e.g., graphical displays) and meaningful reports at the provider, service setting, and broader levels (e.g., state-wide); and (c) linking data analytics to continuous quality improvement (CQI) feedback to help providers achieve best practices and targeted youth outcomes.
75326855|NCT04379323|Diagnostic Test|YuWell YE900 Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE900 Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer.
75326856|NCT01728649|Other|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
75919999|NCT03398174|Behavioral|Patient Education|"Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
75920000|NCT03398096|Device|Cardiac shock wave therapy|Ultrasound guided cardiac shock wave therapy (CSWT) is a new treatment method offering an alternative to revascularization by stimulating angiogenesis. Subsequent clinical trials showed that CSWT could reduce symptoms of myocardial ischemia and improve cardiac function in patients with severe coronary artery disease.
76077473|NCT04984330|Drug|Dexamethasone|Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
75326857|NCT03835507|Drug|recombinant human erythropoietin(rhEPO)|Injection of erythropoietin every months (total 12 months)
75326858|NCT03835195|Other|Diabetes Disease Management Program|The attention is carried out in a single physical place, in the city of Medellin. The scheme of intervention in the comprehensive Diabetes Clinic is based on the concept of disease management. The intervention is composed of 5 phases, which apply to all the patients cared for in the institution (access, reception, entry, clinical consultation, management plan, education, pharmaceutical care). The healthcare team consists of 5 endocrinologists, an endocrinologist pediatrician, 7 general practitioners trained in diabetes, 5 pharmacists trained in diabetes and certified in education for patients with diabetes and 3 nutritionists.
75326859|NCT03835195|Other|Usual Care Process|The patients are treated in the cardiovascular risk clinic (general practitioners) of their Primary Healthcare Provider Institution or by specialists in internal medicine, pediatrics or endocrinology in the different Provider Institutions of Health Services of the insurance service network of health or in private doctors' offices assigned to the insurer. In some cases there is assisted consultation (general practitioner - specialist). There is no defined periodicity for follow-up; Appointments are assigned to need, according to the criteria of the treating physicians. In some cases there is remission to educational activities, not necessarily focused on type 1 diabetes.
75633940|NCT04698720|Behavioral|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot).The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds.The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
75633941|NCT04698720|Behavioral|Hypnosis with Guided Imagery|"In the beginning of the first session we apply the Eye-Roll Test for Hypnotizability of Herbert Spiegel. Each session follows the Hypnotic Protocol with the following steps:Pre-talk/Absortion/Ratification/Aliciation/Dissociation/Awakening.~The four sessions train the participants in visual, auditory and kinesthetic perception on ulcer healing. The protocol also promotes medical treatment acceptance."
75326860|NCT03581656|Device|ChordArt System|The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
75326861|NCT02195440|Drug|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
75326862|NCT03834805|Other|lung and liver elastography measurement of fetus|Other: lung and liver elastography measurement of fetus
75326863|NCT05525052|Other|Trans-Facet fixation|Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
75920001|NCT03398018|Drug|repository corticotropin injection|80 units twice per week as a subcutaneous injection
75326864|NCT03834259|Procedure|sitting position|keeping the patient in a sitting position after spinal anaesthesia
75326865|NCT03834259|Procedure|supine position|keeping the patient in supine position after spinal anaesthesia
75920002|NCT03411434|Drug|Methylphenidate Oral Tablet|cf arm group description
75920003|NCT03411278|Device|Deep Oscillation (DO)|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2).The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
75920004|NCT03126656|Drug|Testosterone Undecanoate|just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
76077474|NCT03030352|Behavioral|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
75326866|NCT05524974|Drug|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
75326867|NCT05524974|Drug|Oxaliplatin|Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.
75326868|NCT05524974|Drug|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
75326869|NCT05524974|Drug|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.
75633942|NCT04698720|Behavioral|Neutral Guided Imagery|This placebo consists of neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends, and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, positive or negative, which occurred before patient has the current DFU. Then, the patient is asked about a number of questions regarding the chosen episode in order to promote a more detailed reconstruction of the event. The patient is asked to imagine according to the instructions given by the Psychologist. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered regarding each of the questions.
75633943|NCT04678518|Diagnostic Test|Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF|1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours)
75633944|NCT04669782|Dietary Supplement|Vitamin K (MK7)|MK-7 will be administered at a dose of 375 microg / day
75633945|NCT04669782|Drug|Teriparatide|Teriparatide will be administered as standard of care
75633946|NCT04667754|Behavioral|Internet-delivered Cognitive Behavioural Therapy|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend ~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
75633947|NCT04253028|Device|NERv's Inline Device|NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
75633948|NCT04252872|Drug|HCP0605|
75633949|NCT04252872|Drug|HGP1405|
75633950|NCT04252872|Drug|HCP1401|
75633951|NCT04252482|Device|CPAP|CPAP useg 3month
75633952|NCT00891735|Drug|Ranibizumab|Sterile solution for intravitreal injection.
75784234|NCT06193564|Other|Cervical Stabilization Exercises|"Before initiating the stabilization exercises, individuals included in the study were instructed on correct postural alignment. Cervical chin tuck movement was taught during the exercise along with postural alignment and craniocervical flexion movement was requested. After teaching craniocervical flexion exercises in all positions (supine, lying on the side, prone, crawling, sitting, and standing), participants were instructed to perform the movement slowly.~The purpose of this phase was to establish the relationship between vision and motor learning using the Pressure Biofeedback Stabilizer device. The device was positioned on the neck area and inflated to 20 mmHg. The pressure level gradually increased in 2-mmHg increments from 20 to 30 mmHg. For each pressure value (22, 24, 26, 28, 30 mmHg), participants were asked to maintain craniocervical flexion for 10 seconds, and this exercise was repeated ten times."
75326870|NCT05524974|Drug|Nab paclitaxel|nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.
75326871|NCT03321682|Other|Functional Training|Exercises performed in circuit, using weights, elastic bands, suspension tapes, cones and on unstable surfaces.
75326872|NCT03321682|Other|Strength Training|Exercises carried out using weights and involving the main muscle groups.
75326873|NCT00870467|Biological|Double-blind adalimumab|Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
75326874|NCT00870467|Drug|Double-blind Placebo|Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
75326875|NCT00870467|Biological|Open-label Adalimumab|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
75920005|NCT03126734|Other|Infant Massage course|"Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.~This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually."
75920006|NCT03385382|Drug|Dexamethasone intravitreal implant 0.7 mg|Intravitreal Implant of dexamethasone
75633953|NCT04252248|Drug|Dacogen|Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.
75920007|NCT03385382|Drug|Ranibizumab Injection|Injection of ranibizumab
75326876|NCT00870467|Biological|Open-labelAdalimumabRescue|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
75326877|NCT05209932|Behavioral|Online New Beginnings Program (eNBP)|The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group-based NBP that can be used on a smart phone, tablet or computer. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations.
75326878|NCT01728727|Other|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
75326879|NCT01728727|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
75326880|NCT01723267|Other|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
75326881|NCT01723267|Other|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
75326882|NCT00370318|Biological|10 valent pneumococcal conjugate vaccine|
75326883|NCT00370318|Biological|Infanrix Hexa|
75633954|NCT04252326|Other|Survey|Doctors, Nurses and Dentists filled survey about adverse drug reractions
75633955|NCT04833192|Diagnostic Test|experimental group|DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group
75633956|NCT04251858|Procedure|Dental Scaling|The individuals will be treated by a single periodontist and the scaling and root planing procedures will be performed on all teeth as follows: local anesthetic infiltrative type of the areas to be treated, dental and root scaling using Grace 5/6 carbon steel curettes, 11/12, 13/14 and MacCall 13/14, 17/18 curettes, according to their therapeutic indications. Polishing the quadrants treated with abrasive paste; oral hygiene instructions including Bass toothbrushing, dental floss and sometimes inter-dental brush.
75633957|NCT04251858|Other|Oral hygiene instruction|Oral hygiene instructions should be given to all study participants. Guidance on the most appropriate toothbrush, toothpaste and interproximal cleaning method.
75633958|NCT00891657|Device|SprayShield™|Anti-adhesion barrier
75633959|NCT04814082|Device|MicroPort Evolution Medial-Pivot Knee System (Cruciate-substituting)|Medial Pivot Knee System
75633960|NCT04814082|Device|Stryker Triathlon Tritanium Knee System (Condylar Stabilizing)|Single Radius Design Total Knee System
75633961|NCT04252170|Device|Rehabilitation Therapy, Experimental on the BrightArm Compact device|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.
75633962|NCT05238129|Other|No intervention - standard care is assessed|No intervention - standard care is assessed
75784235|NCT06193564|Other|Sham-Transcranial Direct Current Stimulation (tDCS)|tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) (Figure 2). As shown in the figure, a constant current of 2 mA was applied to the experimental group for 20 minutes. For the sham group, electrodes were placed in the same areas and a current of 0 mA was applied.
75784236|NCT06193551|Device|Ovitex LPR|Robotic assisted laparoscopic repair of hiatal hernia using permanent sutures with Ovitex mesh as reinforcement.
75326884|NCT00370318|Biological|Rotarix|
75784237|NCT06193538|Drug|Recombinant NV-A01 adenovirus injection|Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
75784238|NCT06193525|Drug|Talazoparib|Talazoparib is administered daily as single agent, 1 mg orally until unacceptable toxicity or progression of disease.
75784239|NCT06193512|Device|SwishKit + Oral care treatment as usual|SwishKit + Oral care Treatment as usual (TAU) group, instillation of chemical antimicrobial agents care and tooth brushing will be performed as in Oral Care TAU, but SwishKit care will be conducted after other oral care interventions, and prior to instillation of the chemical antimicrobial agent.
75326885|NCT00370318|Drug|Paracetamol|
75326886|NCT01723345|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
75326887|NCT04289116|Behavioral|We Test|This design tests the added benefits of adjunct intervention components delivered prior to receipt of CHTC-Assertive Communication Training (ACT) videos viewed by the couple separately and individually delivered Motivational Interviewing-based Communication Skills Training (MI-CST). These target the development of communication skills necessary to participate fully in HIV prevention and sexual safety discussions inherent to CHTC.
75326888|NCT04289116|Behavioral|IHTC|Individual HIV Testing and Counseling
75326889|NCT01728883|Device|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
75326890|NCT04288336|Other|Food Diary|Ancillary studies
75326891|NCT04288336|Other|Preventative Dietary Intervention|Follow intermittent fasting
75326892|NCT04288336|Other|Questionnaire Administration|Ancillary studies
75326893|NCT01728961|Drug|Artemether/Lumefantrine (AL)|
75326894|NCT00870545|Behavioral|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
75326895|NCT05524896|Device|ElucidVivo|Plaque morphology characterization for predicting non-invasive fractional flow reserve (FFR)
75326896|NCT01723501|Drug|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
75633963|NCT02831127|Other|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
75326897|NCT01723501|Drug|sterile water|Sterile water wipes (placebo)
75326898|NCT05524818|Diagnostic Test|the Computerized Adaptive Testing System of the Functional Assessment of Stroke (CAT-FAS)|The CAT-FAS comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper Limb, 11 items from the Fugl-Meyer Assessment-Lower Limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. The CAT-FAS assesses all these functions simultaneously. Results are automatically reported as Rasch scores. A higher score indicates greater physical functions. In the previous study, results indicated that the CAT-FAS had sufficient efficiency (< 10 items on average), reliability (Rasch reliability ≥ 0.88), concurrent validity (Pearson r ≥ 0.91), and responsiveness (SRM ≥ 0.65) in persons with stroke.
75326899|NCT01729117|Other|Meal Replacement|5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
75326900|NCT01729117|Other|Standard Care|Standard Care only
75326901|NCT00872027|Drug|Escitalopram|10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents
75326902|NCT00872027|Drug|Placebo|Placebo pills for 8 weeks
75326903|NCT01854814|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
75633964|NCT02831127|Other|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
75633965|NCT02828397|Drug|REGN2222|
75326904|NCT01854814|Drug|Losartan|Maximum tolerated labeled dose of Losartan
75326905|NCT01723657|Drug|Ara-C|"Intermediate dose during induction phase to remission.~High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."
75326906|NCT01723657|Other|Autologous peripheral blood stem cell transplantation.|"In patients with favorable cytogenetics with a Leukocyte index above 20.~Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."
75326907|NCT01723657|Other|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
75633966|NCT05237505|Device|Bi-Level Positive Airway Pressure|6 months of Bi-Level positive airway pressure therapy starting at 8cmH2O inspiratory pressure/4 cmH2O expiratory pressure titrated until subject until the subject reaches a minimum, stable breathing pattern and blood oxygen saturation of 88%. If stability in blood oxygen content is not met using these parameters, supplemental oxygen may be added.
75633967|NCT05237505|Drug|Oxygen gas|6 Months of Oxygen starting a minimum flow of 2 litres per minute, titrated up until the subject reaches a minimum, stable blood oxygen saturation of 88%
75784240|NCT06193512|Procedure|Oral care treatment as usual|Oral care will be delivered per standard operating procedure of the ICU, which may include the instillation of chemical agents for the purpose of reducing bacterial load, will be administered at 4-hour intervals, and tooth brushing performed twice daily (morning and evening).
75784241|NCT06193486|Biological|MSGV1-PSCA-8T28Z|Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.
75784242|NCT06193486|Drug|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
75326908|NCT01723657|Drug|G-CSF|"Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."
75326909|NCT01723657|Other|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
75326910|NCT01723657|Other|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
75326911|NCT02576652|Other|Tetracycline|Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
75326912|NCT02576652|Other|Demeclocycline|Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
75326913|NCT02576652|Procedure|Total Hip Replacement|Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
75326914|NCT03407911|Other|Harvested|Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis
75633968|NCT05137353|Behavioral|Music Training (RitMoZ Training)|This training is inspired by intervention concepts followed in SUVAG Polyclinic in Zagreb, Croatia and Kodaly pedagogy in Hungary. RitMoZ Training programme consists of 6 main activities: matching activity, nursery rhymes, rhythmic stimulations, music shapes, music writing and music reading. The training focuses on the perceptual overlap between language and music, embodiment and entrainment. The aim of the training is to improve characteristic features of reading disorders such as phonological awareness, perception of rhythm, phonological working memory and perception of speech sounds.
75633969|NCT05137353|Behavioral|Spelling Training|This training consists of activities which focus on practicing spelling words in a computer task; the aim is to train orthographic processing which is suggested to improve phonological awareness and phonological working memory.
75633970|NCT04251468|Device|GEPII|Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)
75633971|NCT04251468|Device|Ion-selective electrodes|Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.
75633972|NCT04247373|Drug|Ropivacaine|According to previous patient's response, the investigators will allocate the concentration of ropivacaine of next patient during Co2 insufflation. And, for this allocation of concentration of ropivacaine the investigators use biased coin design up-and-down method.
75633973|NCT02828007|Device|NIV Group|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
75326915|NCT01850758|Procedure|Regenexx SD|stem cell treatment
75633974|NCT04251234|Other|Light intensity, ~30 lux|~30 lux compared to very dim light baseline condition <1 lux
75633975|NCT04251234|Other|Baseline light intensity, <1 lux|Very dim light condition
75633976|NCT04795596|Procedure|secondary cytoreductive surgery|resection of isolated recurrent ovarian carcinoma in platinum resistant disease
75633977|NCT04795596|Drug|Chemotherapy|second line chemotherapy according to investigator's choice
75633978|NCT04245267|Behavioral|DIABEMPIC|Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
75633979|NCT04250766|Procedure|Echo-guided uterine biopsy|"Echo-guided uterine biopsy will be performed by a specialized radiologist by transvaginal and exclusive transuterine approach. 4 to 5 samples will be made.~Local anesthesia will be performed. A pain assessment will be performed during the biopsy (visual or verbal scale)."
75633980|NCT02832921|Behavioral|cognitive training by virtual reality|
75633981|NCT02832921|Behavioral|watching a scientific TV documentary|
75633982|NCT02832921|Device|treadmill|"VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking-i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill-places greater demand on cognitive resources than a single task."
75633983|NCT00917124|Device|INVOS|"Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.~None of the interventions are outside the range of good clinical practice."
75633984|NCT02832765|Radiation|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
75784243|NCT06193486|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
75326916|NCT01850758|Other|Exercise Therapy|exercise therapy control
75326917|NCT01812304|Other|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
75326918|NCT01812304|Other|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
75326919|NCT01729273|Other|Diet and Exercise Intervention|Remote Dietary and Exercise Intervention Program
75326920|NCT04645134|Behavioral|Brain Health Assessments|The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.
75326921|NCT01743742|Drug|Vitamin E, Vitamin C|
75326922|NCT01723735|Drug|Alirocumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75326923|NCT01723735|Drug|Ezetimibe|"Pharmaceutical form: overencapsulated tablet~Route of administration: oral"
75326924|NCT01723735|Drug|Ezetimibe Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
75326925|NCT01723735|Drug|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
75326926|NCT00872729|Drug|Cystagon®|"Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H."
75468915|NCT04082520|Drug|Lutetium Lu 177 Dotatate|Given IV
75468916|NCT04082520|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
75326927|NCT00872729|Drug|RP103|"Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product."
75326928|NCT01729429|Behavioral|HPV brochure, recall, reminders|"HPV-vaccine specific brochure mailed before clinic visit~Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
75920008|NCT03394118|Drug|Osimertinib|A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
75784244|NCT06193473|Behavioral|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients within 24-48 hours after hospitalization were recorded. A detailed medication review will be conducted by the clinical pharmacist during the participants' hospitalization.As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
75784245|NCT06193460|Device|low-level laser therapy|photobiomodulation mode of diode laser (low-level laser therapy).
75633985|NCT02832765|Radiation|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
75326929|NCT01729429|Behavioral|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
76077475|NCT04951102|Behavioral|Electronic Asthma Shared Decision-Making App|The electronic Asthma SDM App will ask questions related to medicine-related, non-medicine-related, and COVID-19-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment. They may also use the Asthma SDM app to find information about asthma, medication management, COVID-19 and COVID-19 vaccines.
76077476|NCT04951102|Behavioral|Shared Decision Making Physician Training Video|Training video to educate physicians on Shared Decision-Making and the use of Shared Decision-Making tools.
75326930|NCT04640376|Drug|Paracetamol Uniflash 125mg|Oromucosal solution 1.25 mL for buccal use
76077477|NCT04951102|Behavioral|Electronic Asthma Shared Decision-Making App- Patient Data|Data from the pre-visit electronic Asthma SDM app completed by the patients. Data includes medicine-related, non-medicine-related, and COVID-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment.
76077478|NCT04951102|Behavioral|Standard Care|Standard Care for asthma.
75326931|NCT04640376|Drug|Panadol 500 MG Oral Tablet X1|Tablet masked in capsule
75326932|NCT04640376|Drug|Panadol 500 MG Oral Tablet X2|Tablet masked in capsule
75326933|NCT04640376|Drug|Placebo|Dummy treatment
75326934|NCT03320200|Other|CNS-focused treatment|The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
75326935|NCT03320200|Other|Standard Care Treatment|The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
75326936|NCT03407755|Procedure|Intraocular gas|Participants randomized to either air or SF6 gas in the anterior chamber.
75633986|NCT02832765|Radiation|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
75920009|NCT03389672|Procedure|spinal anesthesia|For conventional spinal anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
76077479|NCT03030196|Drug|Denosumab|NaCl 0.9% injection is used as placebo
76077480|NCT03029962|Behavioral|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
76077481|NCT03035578|Drug|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
75326937|NCT00832871|Drug|Mifepristone|Mifepristone 200 mg will be administered orally
75326938|NCT01723813|Biological|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
75633987|NCT02832765|Radiation|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases
75633988|NCT02832999|Drug|sub cutaneous liraglutide|Liraglutide 1.2mg/day
75633989|NCT02832999|Drug|Oral Vildagliptin|Vildagliptin 50mg/day
75784246|NCT06193421|Drug|Ambroxol Hydrochloride|75mg slow release (SR), X16/day or 300mg X4/day oral capsules.
75784247|NCT06193395|Other|Questionnaire|No intervention, only clinical testing of questionnaire
76077482|NCT03035578|Drug|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
76077483|NCT04933942|Drug|Lomustine|Oral administration of Lomustine
75326939|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 systemic injections|Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
75326940|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration|GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
75468917|NCT04082520|Procedure|Positron Emission Tomography|Undergo PET/MRI
75468918|NCT04082520|Other|Quality-of-Life Assessment|Ancillary studies
75326941|NCT05081297|Other|Qigong|Qigong as a traditional chinese medicine technique, composed of several types of exercises: Baduanjin, taijiquan, yijinjing, baojiangong.
75468919|NCT04082520|Other|Questionnaire Administration|Ancillary studies
75326942|NCT03307018|Procedure|Postoperative systematic bronchial aspiration.|Postoperative flexible bronchoscopy and systematic bronchial aspiration.
75326943|NCT01729507|Other|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
75326944|NCT01729507|Behavioral|standardised behavioural therapy|"The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session."
75326945|NCT05530200|Radiation|Hypofractionated radiotherapy|24Gy/8Gy/3f
75326946|NCT05530200|Drug|PD-L1 inhibitor|q3w
75326947|NCT05530200|Drug|GM-CSF|200μg, D1-D7
75468920|NCT04079465|Device|O2matic|O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
75468921|NCT04066114|Biological|lulizumab pegol|25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
75633990|NCT05230095|Behavioral|social cognition tests|"The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene.~Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery.~Healthy volunteers will be evaluated only one time."
75326948|NCT05530200|Drug|IL-2|at a dose of 2 million IU, D8-D14
75633991|NCT05230095|Behavioral|Quality of life self-questionnaire|Quality of life will be assessed using a self-administered questionnaire in the patients group only.
75633992|NCT04245033|Drug|Dihydroartemisinin-Piperaquine (DP)|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment of malaria in school children (IPTsc).
75633993|NCT02830971|Procedure|Doing Different ICU techniques and skills|
75633994|NCT04244799|Behavioral|Behavioral nudges|"Behavioral nudges include the following:~Colorful pathway overlaid with footprints leading from the toilet to the handwashing station~Rotating posters in toilet areas with messages targeting behavioral motivators for handwashing (disgust, social affiliation)~Sticker of a pair of eyes placed above the handwashing station~Soap dish with an arrow beside it on the sink or counter to remind children to wash their hands with soap"
75784248|NCT06193382|Behavioral|PCIT|Participants will receive the adapted Pocket PCIT Online via a web-based learning platform for up to 5 weeks. Participants will engage in this intervention weekly for about 1 hour per week. During engaging with the adapted Pocket PCIT Online version of PCIT, caregivers will learn positive parenting skills to increase the warmth of the parent-child relationship as well as strategies to effectively set limits. Participants will also participate in 15-minute check-in phone calls with a therapist each week throughout the course of treatment.
75326949|NCT05044949|Other|Probiotic|The study product is a probiotic strain
75326950|NCT05044949|Other|Placebo|The study product is a placebo to the probiotic strain
75326951|NCT01729585|Procedure|Massage Therapy|The Massage Therapy protocol consists of a series of 5 massages administered over 10 (+2) weeks. Length of time for each visit will be approximately 1.5 - 2 hours Typically, a series of treatments over time allows the body time to integrate tissue related changes and potentially maintain a more healthy musculoskeletal state. Based on expert opinion in the field of MT, following a series of massage treatments administered over time, one can anticipate tissue changes. By adding time between treatments, data will describe the ability of subjects to maintain changes over progressively longer periods of time. Treatment protocol will be based on the application of myofascial trigger point therapy (Timberlake, 1999) to musculoskeletal areas of the body often affected by disease progression in CF.
75633995|NCT04244799|Behavioral|National WASH policy|"The Philippines' Department of Education National WASH in Schools (WinS) policy promotes correct hygiene and sanitation practices among school children and a clean environment in and around schools and includes initiatives related to infrastructure, knowledge, and behavior change, but does not include other programs with an explicit focus on handwashing promotion."
75633996|NCT02830737|Procedure|Traditional RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center
75920010|NCT03389672|Procedure|epidural anesthesia|For conventional epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
75326952|NCT03301168|Biological|BPX-501 T cells|T cells transduced with CaspaCIDe® safety switch
75468922|NCT04066114|Biological|antithymocyte globulin (rabbit)|1.5 mg/kg intravenously (IV) on Day 0 (day of transplantation) and the day following (Day 1)
75468923|NCT04066114|Drug|methylprednisolone|500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
75468924|NCT04066114|Biological|tocilizumab|8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
75326953|NCT03301168|Drug|Rimiducid|administered to inactivate BPX-501 cells in the event of GVHD
75326954|NCT01723891|Drug|Surfolase capsule|
75326955|NCT01723891|Drug|HT-002-01|
75326956|NCT04981301|Drug|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the convex probe will be covered with a sterile sheath and a 22G, 100 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles with the anterior approach, the needle will be punctured in the Petit triangle and 5 ml of saline will be injected into the anterolateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
75468925|NCT04066114|Drug|Prednisone|"Beginning on Day 3 post transplantation, taken orally: 60 mg daily~Days 4 through 10: 30 mg daily~Days 11 through 17: 20 mg daily~Days 18 through 24: 10 mg daily~After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol"
75468926|NCT04066114|Drug|everolimus|Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
75468927|NCT04066114|Biological|belatacept|5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
75633997|NCT02830737|Procedure|No-touch RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
75633998|NCT04244643|Other|data collection|"Data collected from patient records~Demographic data: date of birth, sex, city of birth~Contact lenses: laboratory, brand, model, wearing time before the exam, opening date of the blister, solution of contact lenses, material, renewal time~Refraction~Dry eye disease: Ocular Surface Disease Index (OSDI) score~LACRYDIAG data: Non-Invasive Break-Up Time (NIBUT), interferometry and tears meniscus height"
75633999|NCT00889863|Drug|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
75784249|NCT06193369|Behavioral|Digital Peer Navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for cancer. Participants will be matched through a digital app with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Patients will communicate with their peer navigator through digital direct messaging, videoconference or by telephone. Participants will also have access to a health resource library on the digital app that contains local and national resources about cancer.
75784250|NCT06193356|Other|Learning tool|Video based learning tool about detection of endoscopic resection scars and recurrence.
75920011|NCT03389672|Procedure|combined spinal-epidural anesthesia|For conventional combined spinal-epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
75920012|NCT01941446|Drug|Eravacyline, Moxifloxacin, and placebo|
75920013|NCT03393962|Biological|OC-EIEs|2 to 4 infusions, once a week, 0.1~4x10^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
75920014|NCT01907360|Drug|HLD200 (methylphenidate hydrochloride)|
75920015|NCT03126032|Other|GlycoCheck™-System|"Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay."
75920016|NCT03126188|Drug|Sertraline|Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
75920017|NCT03126188|Drug|Dosulepin|Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
76077484|NCT04933942|Drug|Romiplostim|Subcutaneous administration of Romiplostim
76077485|NCT00089583|Drug|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
75326957|NCT01729663|Biological|CSF470 vaccine, BCG, Molgramostim|
75326958|NCT01729663|Drug|interferon alpha 2b|
75326959|NCT05530122|Biological|infliximab, adalimumab, golimumab, vedolizumab, ustekinumab|
75326960|NCT03407677|Device|ROTO track®|An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
75326961|NCT03070600|Other|Universal PrEP Counseling|Counseling at universal sites, will use a standardized counseling script to state that PrEP is available for women at risk for HIV, explain that HIV prevalence in the region is high, and will note that women with HIV positive partners or who don't know their partner's status may be at risk. Counseling will specify that women may have their own reasons to feel at risk or to want PrEP. Following standardized counseling, women will select PrEP at the same visit or will be allowed to deliberate on the decision and come back at the next visit with a decision. Women will be informed that it is advisable to use PrEP if they know their partner is HIV positive or if they do not know their partner's status and will be encouraged to bring untested partners to clinic if status is unknown.
75468928|NCT04066114|Drug|mycophenolate mofetil|"An option for participants who do not tolerate everolimus: to be switched to either~mycophenolate mofetil 1000 mg administered orally twice daily or~mycophenolic acid"
75468929|NCT04066114|Drug|mycophenolic acid|"An option for participants who do not tolerate everolimus: to be switched to either~mycophenolic acid 720 mg taken orally twice daily or~mycophenolate mofetil"
75468930|NCT04060862|Drug|Ipatasertib|Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
75468931|NCT04060862|Drug|Placebo|Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
76077486|NCT00089583|Drug|Ritonavir|Ritonavir solution bid
75468932|NCT04060862|Drug|Palbociclib|Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
75634000|NCT00889863|Drug|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
75326962|NCT03070600|Other|Targeted PrEP Counseling|"Following enrollment, the targeted PrEP clinics will provide two inter-related innovations over two ANC visits. In the targeted PrEP clinics, any of the following three criteria can trigger enhanced PrEP counseling. A participant that meets any one of these criteria will receive PrEP counseling during the study visit where the criteria is met:~Risk Score >6 (Risk score includes male partner status known/unknown, syphilis infection, and lifetime number of male partners) or any National AIDS and STI Control Programme (NASCOP) risk factors~participant declines partner self-tests regardless of partner HIV status, and/or~their partner declines self-testing or tests positive."
75468933|NCT04060862|Drug|Fulvestrant|Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
75468934|NCT04040881|Behavioral|Remote monitoring using smartphone accelerometer|"Patients will be instructed to carry the smartphone around their hips during waking hours, regardless of whether they are at home or outside (a nylon hip holster will be provided) and to keep it turned on at all times.~Daily steps will be recorded for at least seven days before the start of chemotherapy, and the median baseline number of daily steps will be calculated for each patient.~On the first day of chemotherapy, patients will receive side effect education as per standard of care. Patients will be instructed to continue carrying the smartphone daily as indicated for the entire duration of the first three chemotherapy cycles.~At the end of the follow-up period (or sooner in cases of early interruption of chemotherapy due to toxicity or disease progression; a change in chemotherapy regimen; or hospitalizations lasting ≥3 days), patients will rate their satisfaction with the intervention using a Likert-scale questionnaire and open-ended questions."
75634001|NCT02832453|Behavioral|Lifestyle|The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
75468935|NCT04040569|Radiation|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
75468936|NCT04010461|Device|TMS|Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex
75634002|NCT02832453|Behavioral|Aerobic interval training|The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
75920018|NCT03126188|Drug|Venlafaxine|Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
75326963|NCT00873821|Drug|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
75326964|NCT00873821|Drug|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
75468937|NCT04010461|Behavioral|n-back working memory task|Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)
75468938|NCT03995108|Drug|Mavorixafor|Mavorixafor provided as 100 mg capsules.
75468939|NCT03995108|Drug|Placebo|Placebo matching to mavorixafor capsules
75468940|NCT03985423|Drug|Emapalumab-Lzsg|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day [SD] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
75468941|NCT03978793|Device|MyTPill, a digital pill|MyTPill is a digital pill containing an approved medication
75468942|NCT03971734|Drug|Regadenoson 0.05mg|Regadensoson 0.05mg administered prior to MRI
75634003|NCT02832453|Behavioral|Traditional continous training|The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
75784251|NCT06193343|Behavioral|Adaptive Daily Step Promotion|"Participants will wear a Fitbit monitor on their non-dominant wrist during a 10 to 14 day run-in screening to capture daily steps reported by the Fitbit but no daily step goals will be sent to the participant. The Fitbit monitor will be worn during all waking hours except water activities, and compliance will be considered as a day with ≥1,000 steps. Next, participants will undergo a 16-week intervention wearing the Fitbit monitor on their wrist and receive a text message each morning with a personalized, adaptive daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day. Goals will not exceed 10,000 daily steps."
75920019|NCT03389594|Other|Surgical guide|Surgical Guide for this group will designed from 0.4mm voxel size
75326965|NCT01724047|Behavioral|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
75326966|NCT01724047|Behavioral|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
75326967|NCT03407599|Drug|Faster aspart|An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.
75326968|NCT03407599|Drug|Insulin aspart (NovoRapid®)|An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.
75326969|NCT04974359|Drug|Lu AG06466|Lu AG06466 - capsules
75326970|NCT04974359|Drug|Placebo|Placebo - capsules
75920020|NCT03389516|Other|Polymem|wound care dressings
75920021|NCT03389516|Other|Lanolin|wound care oinment
75326971|NCT05529888|Drug|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
75326972|NCT01724125|Other|personal electronic medical record|
75326973|NCT05524272|Other|This study aims to evaluate the effects of colour by number mandala in decreasing the stress of children hospitalized due to their chronic disease.|Colour by number Mandala in different sizes includes pictures and numbers. The child has to find the colour specified in the number and colour it with the specified colour. Colourful pictures emerge as a result of colouring
75326974|NCT05524194|Drug|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
75326975|NCT03407365|Behavioral|10 Week Exercise Program|Subjects will complete a 10 week exercise program using DVD with instructions provided. Participants will have to do one session of exercise on 5 different days each week for a total of 5 sessions per week, for 10 weeks.
75784252|NCT06193330|Procedure|antibiotic-coated plate|A plate for fixing long bone fractures is coated with antibiotics cement prepared in theatre
75784253|NCT06193330|Procedure|external fixator|external fixators are applied to participants with severe long bone fractures
75784254|NCT06193304|Drug|Eliglustat|Pharmaceutical form:solution -Route of administration: Oral wihtout ingestion
75784255|NCT06193265|Procedure|Discectomy|Discectomy is the surgical removal, total or more often partial, of an intervertebral disc
75784256|NCT06193239|Diagnostic Test|OWL-EVO1|EVOC probe
75920022|NCT01849250|Drug|Docosahexaenoic Acid|Given PO
75920023|NCT01849250|Other|Placebo|Given PO
75920024|NCT03385148|Drug|68Ga-Sgc8|underwent a standard routine 18F-FDG PET/CT first, and then injected 10~20 MBq 68Ga-Sgc8
75920025|NCT04446338|Diagnostic Test|Antibody Test|Presence and Titer of Anti-Sars-CoV-2 Antbodies
75920026|NCT03389360|Diagnostic Test|procalcitonin|assessing the frequency of rising procalcitonin associated with infectious complications in immunosuppressed LDLTRx.
75920027|NCT03389282|Diagnostic Test|Tear Sampling|comprehensive eye exam, Schirmer test, break-up time, tear sampling
75920028|NCT03389204|Other|PHYSICAL THERAPY|EXERCISES AND EDUCATION TO FOLLOWING AFTER DISCHARGE PHYSICAL TREATMENT
75326976|NCT03407365|Behavioral|DVD Program After 10 Weeks|If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
75326977|NCT05518578|Drug|SPN-817|oral capsule
75326978|NCT05518500|Biological|Flu Vaccine (Year 1)|Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.
75326979|NCT05518500|Biological|Flu Vaccine (Year 2)|Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.
75326980|NCT05518500|Biological|Flu Vaccine (Year 3)|The flu vaccine to be administered in the 2024-2025 flu season is to be determined. Researchers are hoping that by the 2024-2025 flu season an mRNA-based influenza vaccine will be approved by the FDA and available for use in this study. In the event an mRNA vaccine is not available, researchers will reassess the vaccine to be administered in Year 3.
75468943|NCT03971734|Drug|Regadensoson 0.1mg|Regadensoson 0.1mg administered prior to MRI
75920029|NCT03393728|Drug|Propanolol|72-hour propanolol before specific treatment of hyperthyroidism
75920030|NCT03393650|Other|Exercise + Placebo group|1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo
75920031|NCT03393650|Other|Exercise + Protein group|1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.
75920032|NCT03393572|Drug|Bupivacaine 0.25%|Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%
75920033|NCT03393572|Drug|Magnesium sulphate.|Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.
75920034|NCT03393572|Drug|nalbuphine|Patients will receive intraperitoneal 5 mg nalbuphine
75920035|NCT03393416|Biological|MASCT-I|The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
76077487|NCT04902664|Behavioral|Patient education materials|Patients receive a text-message and email with educational materials about medical testing.
75326981|NCT05205174|Device|depth electrodes|The study will be conducted at a single center, in TBI patients requiring neurosurgical intervention in the form of EVD placement. During neurosurgical intervention at the bedside in the Intensive Care Unit (ICU), a single depth electrode will be placed in the brain adjacent to the EVD catheter in the same burr hole. After EVD and depth electrode placement, continuous recording of ECoG activity as well as relevant physiological parameters will be performed for the duration of clinically indicated invasive neuromonitoring in accordance with the standard of care for TBI patients. A single recording station is currently available for data collection, therefore, with an anticipated average recording period of 14 days, the study will take greater than 210 days to complete for a total of 15 patients.
75326982|NCT05518344|Device|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."
75634004|NCT00915018|Drug|Neratinib|Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
75634005|NCT00915018|Drug|Trastuzumab|Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
75634006|NCT00915018|Drug|Paclitaxel|Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
75326983|NCT05518266|Procedure|US-guided Parasternal block|Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance
75326984|NCT05518266|Procedure|Surgeon-delivered parasternal block|Just before wiring of the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
75326985|NCT03058978|Device|Etonogestrel Implant|Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period.
75634007|NCT02830425|Other|No intervention|
75326986|NCT05523960|Procedure|No MBP|No mechanical bowel preparation before operation
75634008|NCT04247295|Device|Traditional Cast|Application of a traditional cast
75326987|NCT05529576|Drug|Omega 3 fatty acid|Omega-3 fatty acids complementation according to the patient's CRP level
75326988|NCT00212134|Device|Contact lens correction of aphakia|optical correction of infant surgical aphakia with Contact lens
75326989|NCT00212134|Device|Intraocular lens implantation|optical correction of surgical aphakia with intraocular lens
75326990|NCT05517876|Device|Vascular abdominal or peripheral surgery|"replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes abdominal aorto-aortic and/or aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral)."
75326991|NCT02575950|Drug|LEO43204|
75326992|NCT02575950|Drug|Placebo|
75326993|NCT02477878|Biological|BPX-501|Biological: T cells transduced with CaspaCIDe suicide gene
75326994|NCT02477878|Drug|Rimiducid|Rimiducid administered to treat GVHD
75326995|NCT00371098|Biological|Influenza vaccination: Influvac (SolvayPharma)|
75920036|NCT03393416|Drug|PD1 antibody|"Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study."
75326996|NCT00371098|Biological|placebo influenza vaccine|
75326997|NCT04114708|Diagnostic Test|Anterior cruciate ligament Reconstruction (ACLR)|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.
75326998|NCT04114708|Diagnostic Test|ACLR with lateral extra-articular tenodesis (LET)|All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
75326999|NCT05523804|Procedure|interval cytoreductive surgery|cytoreductive surgery after 3-4 cycles of chemotherapy
75634009|NCT04247295|Device|Woodcast|Application of a woodcast
75634010|NCT04246905|Drug|sulforaphane|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
75634011|NCT04246905|Other|placedo|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
75634012|NCT04246905|Drug|selective 5 - HT reuptake inhibitors (SSRI)|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
75634013|NCT02830503|Procedure|Feeding tube daily replacement|Feeding tubes replaced once a day in the first week of life.
75327000|NCT05523804|Procedure|delayed cytoreductive surgery|surgery after >5 cycles of chemotherapy
75327001|NCT05523804|Other|no surgery|no cytoreductive surgery (>5 cycles of chemotherapy alone)
75327002|NCT00913627|Drug|ibuprofen|
75634014|NCT05251740|Device|Altimate Medical EasyStand Bantam|The child will stand in the device for 60 min per day, 5 days per week for 2 months.
75634015|NCT02832219|Dietary Supplement|Molecular hydrogen|
75634016|NCT02832219|Dietary Supplement|Placebo|
75634017|NCT02827695|Behavioral|SMASK|Medication adherence and BP monitoring
75634018|NCT02827695|Behavioral|EnhancedSC|Standard care without med reminder functions with healthy lifestyle texts
75634019|NCT04528446|Radiation|Dual-energy X-ray absorptiometry|DXA whole body, hip, spine, and radius at baseline, and 12-month visit.
75920037|NCT05172674|Diagnostic Test|ultrasound according routine antenatal care|ultrasound examinations at 11-14, 19-22 and 33-35 weeks
75920038|NCT04445948|Drug|Esomeprazole 40 milligrams Oral Tablet|Proton Pump inhibitor
75468944|NCT03971734|Drug|Regadensoson 0.2mg|Regadensoson 0.2mg administered prior to MRI
75920039|NCT04445948|Drug|Amoxicillin 1000 milligrams tablets|Penicillin derivative antibiotic
75920040|NCT04445948|Drug|Clarithromycin 500 milligrams Tablets|Macrolide antibiotic
75920041|NCT04445948|Drug|MetroNIDAZOLE 500 milligrams Oral Tablet|Antiprotozoal
75920042|NCT04445948|Drug|Lactoferrin Bovine sachets 200 milligrams|a protein found naturally in milk from humans and cows
75920043|NCT02479646|Biological|MYL-1401H|
75920044|NCT02479646|Biological|EU-Neulasta|
75327003|NCT00913627|Drug|ibuprofen|
75327004|NCT00913627|Drug|naproxen|
75327005|NCT00913627|Drug|Placebo|
75327006|NCT05517798|Procedure|Alveolar ridge preservation|Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
75327007|NCT05529498|Behavioral|Moderate paced continuous gait training|walking continuously for 20 minutes at a moderate pace
75634020|NCT04528446|Radiation|High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)|HR-pQCT of the radius and tibia at baseline, and 12-month visit.
75634021|NCT04528446|Other|Blood draw and Urine collection|The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
75327008|NCT05529498|Behavioral|High Intensity Interval gait training|20 minutes of interspersing 30 seconds of fast walking with 1 minute of rest
75327009|NCT04297176|Drug|Vancomycin-traditional dosing|The dose is calculated based on 2 vancomycin serum levels
75327010|NCT04297176|Drug|Vancomycin- Trough-only based dosing|The dose is calculated based on 1 vancomycin serum level (i.e. trough)
75468945|NCT03971734|Drug|Regadensoson 0.4mg|Regadensoson 0.4mg administered prior to MRI
75468946|NCT03971734|Drug|Regadensoson 0.7mg|Regadensoson 0.7mg administered prior to MRI
75468947|NCT03971734|Drug|Regadensoson 1.0mg|Regadensoson 1.0mg administered prior to MRI
75468948|NCT03971734|Drug|Regadensoson 1.4mg|Regadensoson 1.4mg administered prior to MRI
75634022|NCT04528446|Other|Questionnaires|Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
75634023|NCT02830347|Drug|Amoxicillin|Extraction
75634024|NCT02830347|Procedure|Extraction|Extraction of third molars
75920045|NCT02479646|Biological|US-Neulasta|
76077488|NCT04902664|Behavioral|Physician peer-comparison email|Physicians receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals.
76077489|NCT04902664|Behavioral|Physician education materials|Physicians receive reference materials on medical test interpretation and incidental findings.
75327011|NCT05529420|Other|measurement of the depth of neuromuscular blockade|time of TOF 1 measurement (= clinical effect, stimulation of the ulnar nerve - adductor pollicis muscle tension) will be documented in the CRF and if there is no need to add further doses of the muscle relaxant, TOF 2, TOF 3, TOF 4, and TOF-R ≥ 0,9 (= time to full recovery from the effect of the non-depolarizing muscle relaxant) will also be registered.
75327012|NCT05454592|Behavioral|Stress and Coping Online Outreach Program|3 videos and a resource library disseminated over the course of 9 weeks.
75327013|NCT04142034|Behavioral|the iAmHealthy Behavioral Intervention|"iAmHealthy Behavioral Intervention Arm~Child/caregiver pairs in the iAmHealthy behavioral intervention arm will receive:~usual care at their clinic for all issues, including overweight and obesity;~a monthly newsletter that focuses on general child health. The child/caregiver pairs will receive six newsletters (one per month) during the six month intervention period (same newsletter provided to the newsletter-only intervention participants);~weekly group sessions for the first three months, followed by monthly group sessions during the next three months, for a total of 15 group sessions. The trial's iAmHealthy behavioral intervention psychologist or social worker (one team per clinic) will deliver these group sessions via an electronic tablet that the trial sponsor will supply;~11 hours of individual homework sessions with the iAmHealthy behavioral intervention dietician"
75327014|NCT04142034|Behavioral|Newsletter only arm|Newsletter arm participants will receive a monthly newsletter on maintaining a healthy weight through diet and exercise
75468949|NCT03875092|Biological|Pembrolizumab|IV infusion
75468950|NCT03875092|Drug|Paclitaxel|IV infusion
75468951|NCT03875092|Drug|Nab-paclitaxel|IV infusion
75468952|NCT03875092|Drug|Carboplatin|IV infusion Carboplatin dose should not exceed 900 mg.
75468953|NCT03875092|Drug|Saline placebo for pembrolizumab|IV infusion
75468954|NCT03863041|Other|Additional sequence performed during MRI scan|An additional sequence will be performed during the MRI scan.
75468955|NCT03862833|Drug|IL2|"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"
75468956|NCT03862833|Drug|Zoledronic Acid|4 mg at day +15 post graft
75634025|NCT05253456|Procedure|Derma -Dartos Flap for second layer closure|usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients
75634026|NCT04246749|Drug|[14C]-CRN00808|Investigational drug
75634027|NCT04246749|Drug|CRN00808|Investigational drug
75920046|NCT02467868|Biological|MYL-1401H|During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
75920047|NCT02467868|Biological|Neulasta|During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
75920048|NCT02791191|Drug|LY3202626|Administered orally
75920049|NCT02791191|Drug|Placebo|Administered orally
75920050|NCT02101749|Biological|trivalent inactivated influenza|intradermal or intramuscular injection in the deltoid area.
75920051|NCT02106585|Drug|JTT-251 or Placebo|Subjects will receive JTT-251 or Placebo
76077490|NCT04902664|Behavioral|General visit preparation materials|Patients receive a text-message and email with general visit preparation tips.
76077491|NCT03030040|Behavioral|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
75634028|NCT05253300|Other|Positioning the patient|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group."
75920052|NCT02103387|Behavioral|Cognitive Behavioral Training|Cognitive Behavioral Training [CBT] (stress awareness, cognitive restructuring, coping skills training, interpersonal skills training)
75920053|NCT02103387|Behavioral|Relaxation Training|Relaxation Training [RT] (muscle relaxation, deep breathing, guided imagery, meditation)
75920054|NCT02103387|Behavioral|Health Education Control|Health Education control condition (information about breast cancer diagnosis and treatment, side-effect management, recurrence, physical activity and nutrition, and life after breast cancer)
75920055|NCT02102061|Other|multidisciplinary intervention|"a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size."
75920056|NCT02103465|Drug|Rotigotine|transdermal patch
75920057|NCT02103465|Drug|Placebo|transdermal patch
75920058|NCT02106663|Procedure|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.
75920059|NCT02106663|Procedure|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.
75634029|NCT02830269|Device|Transcranial Doppler ultrasonography measurements|Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
76077492|NCT03029494|Device|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
75920060|NCT02106741|Behavioral|Relaxation acupressure|"The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
75327015|NCT04142034|Other|Consecutive Recruitment|Recruitment of study participants through identifying potential participants through their medical records
75327016|NCT04142034|Other|Traditional Recruitment|Recruitment of potential participants through flyers and advertisements
75327017|NCT02231710|Biological|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
75327018|NCT05523648|Drug|Chronic Hepatitis B|92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
75327019|NCT02115100|Procedure|procedure|Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
75920061|NCT02106741|Behavioral|Stimulating acupressure|"The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
75920062|NCT02102139|Drug|DXM + Propofol|"After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP > ±20% from baseline), the target concentration was increased by 0.5 ng mL-1."
75920063|NCT02102139|Drug|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
76077493|NCT03029494|Drug|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
76077494|NCT03029494|Device|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
75327020|NCT05529108|Dietary Supplement|control biscuits|Consumption of plain biscuits everyday during intervention period.
75327021|NCT05529108|Dietary Supplement|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits everyday during intervention period.
76077495|NCT03029494|Dietary Supplement|Vitamin C|1000 mg
75327022|NCT05529108|Dietary Supplement|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits everyday during intervention period.
75327023|NCT05523258|Behavioral|Computerized cognition training|The researchers distribute tablet computers for the patients. The patients in this group receive cognitive function training under the guidance of a full-time cognitive function trainer. The training time is about 45-60 minutes every time, and the frequency is twice a day until the operation. After the operation, cognitive function training should be started as soon as possible when the patient meets the following conditions including Glasgow score ≥ 12, no mechanical ventilation and no sedative drugs. The training intensity is the same as that before operation, generally starting from the 2nd to 3rd day after operation and continuing to discharge or the 7th day after operation.
75920064|NCT02106819|Behavioral|Testing of emotional communication ability|Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.
75920065|NCT02106819|Procedure|magnetic resonance imaging (MRI) of the brain|Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
75920066|NCT02103543|Other|physical therapy|physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
75920067|NCT02103543|Procedure|lumbar interlaminar epidural steroid injection|single lumbar interlaminar epidural steroid injection
75784257|NCT06193213|Procedure|measurement of train of four ratio (TOFR) to assess residual neuromuscolar block|Upon arrival of the spontaneously breathing patient in the Post-Anesthesia Care Unit, a researcher will evaluate the TOFR to detect any residual neuromuscular block using the acceleromyographic method at the level of thumb adductor.2 TOFR measurements will be performed 30 seconds apart. If the difference between the two measurements will be ≤ 0.1, the average value will be considered for the purposes of the analysis. In case of a difference > 0.1, a third measurement will be taken and the average of the two closest results will be considered. If a residual block is detected sugammadex will be administered (2 mg/kg in the case of at least 2 contraction responses to TOF stimulation or 4 mg/kg in the case of no contraction response) to restore normal neuromuscular function , assessed by subsequent TOFR measurement.
75784258|NCT06193187|Drug|Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg|Test (T)
75784259|NCT06193187|Drug|Entresto 50 mg|Reference (R)
75784260|NCT06193148|Drug|Jaktinib|Participants will receive Jaktinib orally for single dose
75327024|NCT05523258|Behavioral|Basic training based on tablet computer|The researchers distribute the same tablet computer to the patients. The patients in this group receive basic training under the guidance of a full-time cognitive function trainer. The training duration is the same as that of the test group.
75327025|NCT04047160|Drug|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724
75327026|NCT05517720|Other|Aria Trio complete Facial System|Renew Serum, Brighten Serum, and Refine Serum.
75327027|NCT01724203|Dietary Supplement|Lactobacillus rhamnosus|
75327028|NCT01724203|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
75327029|NCT01724203|Dietary Supplement|Placebo|
75920068|NCT02103543|Drug|epidural steroid injection|Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
75920069|NCT02102217|Procedure|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
75327030|NCT02738086|Behavioral|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
75327031|NCT02738086|Behavioral|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning
75634030|NCT05253222|Diagnostic Test|retrograde image by colonic TET|"Delivery of contrast fluid by colonic TET Each participant will receive one delivery of 200 ml contrast fluid by colonic TET to the distal portion of the lesion.~One group will be taken CT investigation, another group will be taken X-ray fluoroscopy.~Imaging parameters will be collected and evaluated."
75634031|NCT02832609|Other|Supine|measurements after 30 minutes in complete supine position
75327032|NCT04054882|Biological|Sabin-IPV and DTaP|simultaneously administration of Sabin-IPV and DTaP
75327033|NCT04054882|Biological|Sabin-IPV|administration of Sabin-IPV only
75634032|NCT04201899|Dietary Supplement|No intervention - pure observation|Phosphate administration (yes or no)
75634033|NCT00916578|Radiation|Radiation Therapy|50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
75634034|NCT00916578|Drug|Capecitabine|During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
75634035|NCT02832297|Other|Vectra DA|
75920070|NCT02103621|Behavioral|Unified Protocol (UP)|
75634036|NCT02832297|Other|Usual Care|
75327034|NCT04054882|Biological|DTaP|administration of DTaP only
75920071|NCT02103621|Behavioral|Taper and Monitoring (TAP-M)|
75920072|NCT03555123|Drug|Simdax|Levosimendan2.5mg/ml
75920073|NCT03554499|Procedure|Bichectomy with hydrodissection|Intraoral removal of buccal fat pads using hydrodissection technique
75920074|NCT03554499|Procedure|Bichectomy|Intraoral removal of buccal fat pads using conventional technique
75920075|NCT02102295|Drug|Experimental toothpaste|Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
75327035|NCT05523102|Drug|Paracetamol|Intravenous paracetamol/acetaminophen
75327036|NCT05523102|Drug|Ketorolac|Intravenous ketorolac/NSAID
75920076|NCT02102295|Drug|Control toothpaste|Control toothpaste was containing 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
75327037|NCT03407287|Procedure|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV
75327038|NCT03407287|Procedure|Standard of care invasive vascular monitoring|Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.
75327039|NCT03407287|Procedure|Standard noninvasive vascular monitoring|Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.
75327040|NCT05523024|Dietary Supplement|Probiotic|The probiotic group will receive one capsule of the probiotic mixture (dose:1x109 colony forming units (CFU) per day in one dose (before breakfast). The PRO preparation will contain the following bacterial strains: 50% Lactococcus lactis Rosell® - 1058, 25% Lactobacillus casei Rosell® - 215, 12,5% Lactobacillus helveticus Rosell® - 52, 12,5% Bifidobacterium bifidum Rosell® - 71). Probiotics will be administered orally.
75327041|NCT05523024|Dietary Supplement|Berberine|The berberine group will receive 1500 mg of Berberine (Berberine hydrochloride 97% extract of Berberis aristata) per day in 3 doses. Berberine will be administered orally, before breakfast, dinner, and before supper.
75468957|NCT03859063|Behavioral|Intervention|Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
75634037|NCT05253144|Radiation|Radiotherapy|Radiotherapy
75327042|NCT05523024|Dietary Supplement|Placebo|The placebo group will receive a placebo. Placebo will contain only the excipients and will be administered orally for 24 weeks. Placebo in no way: color, taste, smell, form of taking, the dosage will not differ from the preparations tested. However, it will not contain probiotcs or berberine. Placebo will be orally administered three times a day: before breakfast, dinner, and supper (6.00-7.00 p.m.). To meet the GCP conditions, subjects from all groups will receive the same number of capsules (six) per day.
75327043|NCT05523024|Dietary Supplement|Probiotc and Berberine|Probiotics and Berberine groupwill receive both: a probiotics mixture (as in PRO group: 1x109 CFU/day; in one dose) and 1500 mg/day of Berberine (Berberine hydrochloride 97% extract of Berberis aristata; in 3 doses). Probiotcs and berberine will be administered orally before breakfast, before dinner, and before supper.
75327044|NCT00877877|Procedure|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
75327045|NCT01724281|Other|No intervention, only follow up|
75634038|NCT05253144|Procedure|Surgery|Surgery
75634039|NCT04801056|Drug|TB006|TB006 monoclonal antibody
75327046|NCT02739100|Drug|Triferic|
75327047|NCT04378543|Biological|ART352-L|recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures
75327048|NCT03407209|Other|consumption of local anesthetic measurement|consumption of local anesthetic measurement in both groups
75327049|NCT05453734|Procedure|Progressive Muscle Relaxation Exercises|Before data collection, one of the researchers received training and certification from a psychotherapist specialist in this field to be able to apply the PMR exercises. The guidelines on the PMR exercises were prepared in line with the literature and training received by the researcher. In the guidelines, the person is asked to be in a comfortable place and position, to reach the face by following the large muscle groups gradually, starting from the feet, to tense the muscles in each step, and then to release them. It is necessary to take a deep breath after each muscle group, to stop for a while, and release it slowly
75327050|NCT01724515|Other|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
75468958|NCT03859063|Behavioral|Control|Community based follow-up as usual
75468959|NCT03856892|Other|High Dose Yoga|"Participants engage in an intensive full yoga practice of hatha breath-based practices and inner meditative techniques along with body-based asana. Intensive level uses breath, management of abdomen, inner focus in all practices. The high dose of yoga is an interpretation of the Translational Model of Yoga (TMY) and Yoga Process formula, both developed in this study's cultural research: a systematized psycho-physical yoga method of Hatha Zone (HZ) focus (below-navel, exhale, inner focus), incorporating key components of practice-focus-surrender (PFS) approach and repeat-engage-trust (RET) elements."
75468960|NCT03856892|Other|Medium Dose Yoga|"The medium dose of yoga is a regular practice of primarily body-posture training with minimal reference to the breath, but with a longer period of time duration in training prior to intervention commencement. Participants have 5 months of pre-training before initiating the intervention."
75468961|NCT03847467|Drug|2'-Fucosyllactose|Human milk oligosaccharide prebiotic dietary supplement
75634040|NCT04801056|Other|Placebo|Placebo i.v. infusion
75634041|NCT02830113|Procedure|non-surgical periodontal treatment|One session of complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution
75634042|NCT04457154|Device|Inspire Upper Airway Stimulation System|Implant of the Inspire Upper Airway Stimulation System
75634043|NCT02830035|Procedure|Real-time Ultrasound-guided|Real-time ultrasound guided paramedian spinal anesthesia
75634044|NCT02830035|Procedure|Anatomical Landmark Technique|Conventional anatomical landmark technique for paramedian spinal anesthesia
75634045|NCT04247529|Other|Exposure to conflicting health information|At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.
75634046|NCT04247529|Other|No exposure to conflicting health information|At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
75784261|NCT06193148|Drug|Placebo|Participants will receive Placebo orally for single dose
75327051|NCT05528640|Other|Mental Health Literacy Program|Six educational sessions will be delivered on a private YouTube channel which consists of information about mental health literacy (knowledge about priority mental illnesses, attitude/ stigma related to mental illnesses, and help-seeking efficacy). There will be six-weeks unrestricted access period. Afterwards, the round-up session which consists of problem-based learning and group sharing will be delivered in person. Two vignettes based on the clinical scenarios will be given for discussion. Furthermore, participants are encouraged to share their opinion on mental health literacy, strategies for dealing with difficulties of caring for patients with mental illnesses in general hospitals, way to promote mental health literacy of healthcare professionals in general hospitals
75327052|NCT03407131|Procedure|Joint replacement surgery|Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.
75634047|NCT02827539|Device|LessRay|A software device has been developed that combines the benefits of reduced radiation associated with low-dose and/or pulse settings while preserving and possibly offering enhanced resolution. LessRay is a software device that is viewed on a separate monitor next to the fluro screen of the C-arm.
75634048|NCT02827539|Device|Standard Fluoroscopy|For control arm, patients will receive the standard fluoroscopy for imaging.
75468962|NCT03847467|Other|Placebo|Dextrose
75634049|NCT04675866|Other|Camrelizumab, Albumin-bound paclitaxel, S-1|Camrelizumab: 200mg, iv, Q3W, d1; Albumin-bound paclitaxel: 125mg/m2, iv, d1, 8, Q3W; S-1: According to the patient's body surface area, the dosage is set to 40, 50, 60 mg/time, bid, po, taking 2 weeks, and stopping the drug for 1 week as a cycle.
75634050|NCT04635930|Other|Taping plus Traditional exercises|The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.
75327053|NCT03407131|Procedure|Intramedullary nail fixation|Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
75327054|NCT01721239|Other|Standardized Followup program|Standardized written information, patient photos and three followup consultations.
75327055|NCT03999268|Behavioral|I-START|Designed as a supplementary educational tool for patients on insulin therapy, I-START includes an injection plan to reinforce the knowledge and behaviors that users have been taught by their health care provider. This is done through eight modules created for the benefit of new and experienced insulin users, and those using pens or vial/syringes. The modules address a variety of topics pertinent to insulin therapy, including overcoming psychosocial barriers, injection techniques and best practices, managing hypo- and hyperglycemic events, monitoring blood glucose and troubleshooting and problem solving. At the end of each module, users can self-evaluate their confidence in mastering the information presented. This gives them the ability to move forward into the next module, repeat material already presented and/or save features of the modules that they would like to revisit at another time.
75327056|NCT03999268|Behavioral|Standard Insulin Administration Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
75327057|NCT05522712|Device|Acapella user|"The exercise session will include three sets of deep breaths. Each set will include 10 repetitions which were fol¬lowed by 30 to 60 seconds pause in between. Patients will be instructed to perform slow maximal inspiration, while expiration was done through acapella in a prolonged manner to minimize airway closure and alveolar collapse. In the Acapella device, resistance was increased continuously on each successive day. The technique will be applied for 15 minutes.~Components of Acapella® treatment will include :~Breathing control~10 breaths through the Acapella® device~Inhaling up to approximately three - quarter maximum breathing capacity~2-3 second breath hold~Active exhalation to Functional residual capacity but not too forcefully (3-4 second)~The patient did 2-3 huffs at the end of the session, Cough or forced expiration in a set cycle."
75468963|NCT03829319|Biological|Pembrolizumab|IV infusion Q3W
75468964|NCT03829319|Drug|Carboplatin|IV infusion Q3W
75468965|NCT03829319|Drug|Cisplatin|IV infusion Q3W
75634051|NCT00889707|Drug|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
75634052|NCT00889707|Drug|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
75920077|NCT02102373|Device|polyethylene glycol 3350|Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
75468966|NCT03829319|Drug|Pemetrexed|IV infusion Q3W
75468967|NCT03829319|Drug|Lenvatinib|Oral capsule once daily
75468968|NCT03829319|Drug|Placebo matching lenvatinib|Oral capsule once daily
75468969|NCT03824652|Other|walnuts|2 ounces of walnuts daily for 4-10 weeks
75468970|NCT03824652|Other|usual diet|Subject continues usual diet
75468971|NCT03824652|Other|phone counseling with dietitian|Weekly calls with dietitian
75468972|NCT03800823|Behavioral|Parent group|In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
75634053|NCT02829801|Behavioral|AAT and cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with a 15 minute introductory activity allowing the establishment of the relationship with the dog and between the participants. Activities with the dog will be offered: games, caresses, brushing.~Then, a 40 minute cognitive stimulation will be offered. Finally, 5 minutes will be devoted to the closing of the session and to say goodbye to participants and the dog (pet him, play with him ...)."
75920078|NCT03555045|Procedure|conducting the slanted recession technique on the superior and inferior poles|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
75920079|NCT03555045|Procedure|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
75920080|NCT02110017|Other|fMRI social cognition task|fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
75920081|NCT02103699|Drug|No intervention|This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
75920082|NCT02103777|Drug|Caffeine citrate|Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
76077496|NCT03087279|Behavioral|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
75327058|NCT05522712|Device|Incentive spirometer user|"Sit upright in a chair or in bed. Hold the incentive spirometer at eye level, hold a pillow to help splint or brace the incision to decrease pain at incision.~Put the mouthpiece in mouth and close lips tightly around it. Slowly breathe out (exhale) completely.~Breathe in (inhale) slowly through mouth as deeply as possible. As taking the breath, the ball will rise.~Try to get the ball as high as possible.~When getting it, hold breath for 10 seconds, or as long as possible.~Then, breathe out slowly through mouth. Then, Rest for a 30-60 seconds.~Repeat 10 times. Try to get the ball to the same level or higher with each breath.~repeat 10 times for 3 sets."
75327059|NCT05522712|Procedure|Control|This group is a control group will not receive new intervention just traditional chest physiotherapy and mobilization
75327060|NCT04378465|Other|Enhanced Recovery Program (ERP)|An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
75634054|NCT02829801|Behavioral|Cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with an introductory activity of 15 minutes that will establish the relationship between the participants. Different topics will be proposed to foster communication and exchange.~Then, the same cognitive stimulation in the AAT arm will be offered."
75634055|NCT02827383|Behavioral|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
75634056|NCT02829879|Drug|8% arginine/1450ppm sodium monofluorophosphate dentifrice|
75634057|NCT02829879|Drug|5% potassium nitrate/2500ppm sodium fluoride dentifrice|
75634058|NCT04441008|Device|Accelerated Intermittent Theta Burst (aiTBS)|High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.
75634059|NCT04441008|Device|Electroconvulsive therapy (ECT)|ECT as per standard clinical care and management.
75634060|NCT05249283|Other|Questionnaire Measures|Patients will complete the following questionnaires: CDS questionnaire, Niigata PPPD questionnaire, HAD (Hospital Anxiety and Depression) scale and DHI (Dizziness Handicap Inventory)
75634061|NCT05246007|Drug|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
75327061|NCT00370474|Device|Bi-ventricular lead placement|
75327062|NCT05528406|Drug|HLX208|900mg bid po
75634062|NCT05246007|Drug|Normal Saline|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
75634063|NCT00914940|Drug|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
75920083|NCT02104011|Drug|Propranolol|
75920084|NCT02104089|Device|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
75920085|NCT03554889|Biological|NK Cell adaptive transfer|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
75920086|NCT03554889|Drug|Nimotuzumab|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
75920087|NCT03554421|Procedure|Percutaneous tibial nerve stimulation|A 20Hz electrical current is given via an electrode inserted through the skin over the posterior tibial nerve above the medial malleolus of the foot and the nerve is stimulated until a motor reflex of the big toe is acheived. Treatment is then continued for 30 minutes at this level. The treatment is then repeated for a total of 10 sessions within a 2 week period.
76077497|NCT03035266|Other|Blood Flow Restriction|Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
76077498|NCT03035266|Other|Standard rehabilitation|Standard of care for post-operative condition
76077499|NCT05346705|Behavioral|New individualized upper airway muscle functional training|The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.
75634064|NCT00914940|Drug|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
75327063|NCT05453422|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
75920088|NCT02251041|Drug|Antithrombin-III|
75634065|NCT00914940|Drug|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
75920089|NCT02251041|Drug|Infliximab|
75920090|NCT02251041|Drug|Apotransferrin|
75634066|NCT00914940|Radiation|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
75634067|NCT00914940|Other|Magnetic Affinity Cell Sorting|Device
75634068|NCT00914940|Procedure|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
75920091|NCT02251041|Drug|Human recombinant erythropoietin|
75634069|NCT00914940|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
75634070|NCT00914940|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
75634071|NCT02829567|Behavioral|Motivational interviewing|
75634072|NCT04244721|Other|Preschool Autism Communication Therapy (PACT)|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
75634073|NCT04244721|Other|Treatment As Usual (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
75327064|NCT01729897|Drug|Etomidate|
75634074|NCT00631800|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
75634075|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
75784262|NCT06193122|Device|Ultrasound imaging 3D and Spectroscopy|Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
75784263|NCT06193109|Other||the patients with sepsis and septic shock were performed echocardiography for detecting right ventricular systolic function
75784264|NCT06193083|Other|Semi-directed individual interviews|Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)
75920092|NCT02251041|Drug|C1-Inhibitor|
75327065|NCT01729897|Drug|Fentanyl|
75634076|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + placebo dose titration (blinded)
75784265|NCT06193083|Other|The self-administered questionnaires, rPATD and BMQ|"rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.~This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal)~BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .~The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.~It comprises 10 items relating to specific beliefs about prescribed treatments:~A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief."
75920093|NCT02251041|Drug|Glutathione|
75920094|NCT02251041|Drug|Alfa-tocopherol|
75920095|NCT02251041|Drug|Melatonin|
75920096|NCT02251041|Drug|Epoprostenol|
75634077|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label)
75634078|NCT02831907|Procedure|Cardiac surgery|All cardiac surgery procedures with the use of cardiopulmonary bypass
75634079|NCT02832141|Procedure|Mobilization anterior|Participant in prone position. Central thoracic mobilization from posterior-to-anterior.
75634080|NCT02832141|Procedure|Mobilization posterior|Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
75920097|NCT02251041|Drug|Sodium chloride solution|
75920098|NCT02106897|Drug|BIIB059 (litifilimab)|See Arm Descriptions
75327066|NCT01729897|Drug|Propofol|
75327067|NCT01048177|Drug|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
75327068|NCT05517096|Other|E-Health|In the intervention phase asthma care is provided on an at-needed-basis via online communication and is always available during working hours.
75327069|NCT02740582|Drug|Tolcapone|
75327070|NCT02740582|Drug|Placebo|
75920099|NCT02106897|Drug|Placebo|See Arm Descriptions
75920100|NCT02107053|Dietary Supplement|PJ|
75920101|NCT02107053|Drug|IV iron|IV iron is routinely administered to dialysis patients worldwide to correct anemia
75920102|NCT02110251|Behavioral|Supervised Exercise Therapy|
75920103|NCT02107209|Procedure|Bronchoscopic Lung volume reduction|Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
75920104|NCT02104323|Drug|Endostatin|Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
75634081|NCT04247685|Device|12-lead ECG monitoring device (MiRTLE Medical)|12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical is the experimental device;
75634082|NCT04247685|Device|3-lead ECG gating system|3-lead ECG gating system is the placebo/standard of care
75634083|NCT02829645|Other|Clinical assessment|Clinical assessment with questionnaires
75634084|NCT00701506|Device|Patterned Electrical Neuromuscular Stimulation|"20-minute session, to each affected knee, 3 times per week for 12 weeks.~PENS for 20 minutes:~Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~Minimal twitch for 5 minutes.~Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~Electrodes placed on quadriceps and hamstrings"
75634085|NCT00701506|Device|Placebo PENS|"20-minute session, to each affected knee, 3 times per week for 12 weeks.~Placebo PENS for 20 minutes:~Electrodes placed on quadriceps and hamstrings."
75920105|NCT02104401|Device|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
75920106|NCT03770715|Device|Respiratory polygraphy|The respiratory polygraphy consisted of continuous polygraphical recordings for a whole night from 22:00 h to 07:00 h with standardised equipment
75920107|NCT02107287|Radiation|IMRT Technique|
75634086|NCT04246827|Behavioral|Enhanced Lifestyle Weight Management|The Enhanced Lifestyle Weight Management program was a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors were integrated into a lifestyle behavioral weight loss intervention.
75634087|NCT00704002|Procedure|antegrade intramedullary splinting|antegrade intramedullary splinting with 2 to 3 small K-wires
75920108|NCT02110329|Genetic|evaluation of the recurrence rate according to molecular analysis|
75920109|NCT02107365|Drug|Asunaprevir|Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
75920110|NCT02107365|Drug|Daclatasvir|Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
75634088|NCT00704002|Procedure|conservative treatment|conservative treatment with 2-finger splint for one week
75920111|NCT02107365|Drug|Ribavirin|Ribavirin tablets or capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
75634089|NCT02831829|Other|water-based exercise training|Water-based training will be performed in upright position, in waist to xyphoid process deep thermo-neutral water at temperature of 32,8 C. The immersed exercise will include two session of aerobic and calisthenic exercise per day, six days of a week, both lasting 30 minutes
75327071|NCT05453266|Procedure|Application of Tranexamic acid in arthroscopic irrigation solution|Application of Tranexamic acid in arthroscopic irrigation solution
75634090|NCT02831829|Other|land-based exercise training|Land-based training will include two aerobic and calisthenic exercise session per day, six days of a week, both lasting 30 minutes
75468973|NCT03800823|Behavioral|mHealth component|After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
75634091|NCT02829411|Behavioral|Workforce Readiness Program|job readiness workshops, organized into ten daily sessions over two weeks.
75634092|NCT02829411|Behavioral|Relationship education|"25-hours of Within My Reach curriculum and relationship skills education sessions"
75784266|NCT06193083|Other|The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)|"FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )~Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :~Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations"
75327072|NCT05453266|Procedure|No application of Tranexamic acid in arthroscopic irrigation solution|No application of Tranexamic acid in arthroscopic irrigation solution
75920112|NCT02107365|Drug|Pegylated Interferon alpha-2a|Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
75920113|NCT02110407|Device|tDCS|transcranial direct current stimulation (tDCS)
75920114|NCT02110407|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
75920115|NCT03554343|Diagnostic Test|test for SMN1 exon 7 deletion|Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers
75920116|NCT02104635|Behavioral|Delivery of a Post-Partum Package|
75327073|NCT01724827|Device|ceramic (Empress CAD, Ivoclar Vivadent)|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
75327074|NCT01724827|Device|composite (Lava Ultimate, 3M Espe)|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
75468974|NCT03800823|Behavioral|Standard care|Standard care for overweight and obesity.
75468975|NCT03776318|Drug|Long-Term Safety Follow-up|STX-015-18-01 long-term safety follow-up
75468976|NCT03774485|Device|G-Tech Gutcheck Myoelectric recording device|Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
75634093|NCT00914628|Genetic|HSV-Tk|Infusion of approximately 1±0.2 x 10^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
75327075|NCT03406663|Behavioral|Group 1|"Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose, > 4.4 and ≤ 5.6 mmol/L, no change, < 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
75327076|NCT03406663|Behavioral|Group 2|"Fasting SMPG (median of the last 3 days including current day) in the range of~7.8 mmol/L, increase 6 units of Gla-300 dose, > 5.6 and < 7.8 mmol/L, increase 3 units of Gla-300 dose, > 4.4 and ≤ 5.6 mmol/L, no change,~3.3 and < 4.4 mmol/L, reduce 3 units of Gla-300 dose, < 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
75327077|NCT05187702|Other|Functional exersize|Participants will be given balance and strengthening exercises covering the balance exercise protocol.
75634094|NCT00914628|Other|T-cell depleted or T-cell replete strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
75920117|NCT02104713|Biological|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose~Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.~Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.~Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.~Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.~Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
75920118|NCT02110563|Drug|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.1mg/kg/dose~Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.~Number of cycles: until progression or unacceptable toxicity develops."
75920119|NCT02104791|Drug|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
75920120|NCT02104869|Biological|Trivalent influenza vaccine (inactivated and fragmented).|
75920121|NCT02107521|Other|Intracytoplasmic morphologically selected sperm injection|Sperm selection for injection will be performed at 6600x magnification
75920122|NCT02107521|Other|Intracytoplasmic sperm injection|sperm selection for injection will be performed under 400x magnification
75920123|NCT02250885|Drug|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
75920124|NCT02110719|Drug|Celebrex|
75920125|NCT02110719|Drug|Gabapentin|
75920126|NCT02110719|Drug|IV acetaminophen|
75920127|NCT02110719|Drug|oral acetaminophen|
75920128|NCT02110719|Drug|oral ibuprofen|
76077500|NCT04832230|Other|Hearing test|"The hearing test is composed of several examinations:~pure tone audiogram~otoscopy~tympanometry~Healthy individuals: The hearing test will be performed at enrollment (Day 0). Patients: The hearing test will be performed at Day 1, Day 3, Day 7 and Day 30."
75920129|NCT02110719|Drug|percocet|
76077501|NCT04832230|Other|Questionnaire about previous noise exposure|The participant will have to fill in a questionnaire about his/her previous noise exposure at enrollment (Day 0).
76077502|NCT04832230|Other|Otoacoustic emission measurement|"Healthy individuals: Otoacoustic emission will be measured at enrollment (Day 0).~Patients: Otoacoustic emission will be measured at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
75920130|NCT02110719|Drug|vicodin|
76077503|NCT04832230|Other|Electrocochleography|"Healthy individuals: Electrocochleography will be performed at enrollment (Day 0).~Patients: Electrocochleography will be performed at Day 30."
75327078|NCT05187702|Other|Aerobic exersize|60% of the maximum heart rate is given 3 walking eccentricity per week
75327079|NCT01049581|Procedure|aquatic therapy|two hours per week, one hour per time, total 12 weeks
75327080|NCT05522400|Behavioral|Virtual Reality (VR) and human computer interaction system|The experimental group used VR technology and human-computer interaction system for exercise, while the control group used traditional exercise program
75327081|NCT05522322|Other|COPD scoring ststems in ICU|SAPS & APACH scoring systems in COPD ICU pts
75327082|NCT01724905|Dietary Supplement|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
75327083|NCT01724905|Dietary Supplement|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
75327084|NCT02740660|Drug|Caffeine 100mg / Albuterol 4mg|
75327085|NCT02740660|Drug|Placebo|
75920131|NCT02110719|Drug|Oxycodone|
75920132|NCT02110719|Drug|dilaudid|
75920133|NCT02110719|Drug|Dexamethasone|
75920134|NCT02110719|Drug|zofran|
76077504|NCT04832230|Other|Speech audiometry in noise|"Healthy individuals: Speech audiometry in noise will performed at enrollment (Day 0).~Patients: Speech audiometry in noise will performed at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
76077505|NCT04832230|Other|Multi-frequency impedance measurement|"Healthy individuals: Multi-frequency impedance will be measured at enrollment (Day 0).~Patients: Multi-frequency impedance will be measured at Day 30."
76077506|NCT04832230|Other|Assessment of tinnitus severity|Tinnitus severity will be assessed using a visual analogic scale at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
75327086|NCT02740660|Behavioral|Family weight management counseling|
75634095|NCT00922792|Drug|activated recombinant human factor VII, long acting|Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
75634096|NCT00922792|Drug|activated recombinant human factor VII, long acting|Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
75468977|NCT03771716|Behavioral|African Dance|Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.
75634097|NCT05493904|Procedure|OCT-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using OCT.~OCT Reference site: Most normal looking segment, No Lipidic plaque. Operator can decide 1 of 2 methods for stent sizing.~By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane [EEL] can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25mm (Ex> mean external elastic membrane reference diameter 3.35mm, 3.25mm stent diameter will be chosen).~By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25mm (Ex> mean distal reference lumen diameter 2.55mm, 2.75mm stent diameter will be chosen)."
75327087|NCT03929068|Drug|carbidopa-levodopa|Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.
75468978|NCT03771716|Behavioral|African Cultural Immersion|The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
75468979|NCT03755388|Device|Episealer|Placing Episealer device
75784267|NCT06193057|Procedure|Total ankle arthroplasty|Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
75784268|NCT06193031|Drug|C16TR|Administered as inhalation using a Philips Micro device inhaler.
75327088|NCT03929068|Drug|Placebo Oral Tablet|Placebo will be given to maintain blinding of participants and study team.
75784269|NCT06193031|Drug|Placebo|Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.
75784270|NCT06193031|Drug|Tyvaso®|Administered as inhalation.
75327089|NCT03925636|Dietary Supplement|Specific Carbohydrate Diet|The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
75327090|NCT05528094|Dietary Supplement|GeniusDrops|"The active ingredients listed below are safe and the study sponsor has noted there are no known side effects of the supplement. The main ingredients are:~Hibiscus flower- Has been shown to boost oxygenation to the brain and vital organs. Has also demonstrated efficacy for boosting the immune system.~Gingko leaf- Has been shown to stimulate memory by increasing mental sharpness and clarity.~Rhodiola- Helps regulate energy and stress level. Gotu kola- Has been shown to have impacts on reducing anxiety. Licorice Root- Helps boost the key brain neurotransmitter called Brain Derived Neurotrophic factor which can help with cognitive development Peppermint Leaf- Reduces fatigue while helping improve cognitive abilities. Has also been shown to promote immune system function."
75327091|NCT05516784|Drug|Clopidogrel|Comparison of platelet reactivity between clopidogrel and ticagrelor
75327092|NCT05516784|Drug|Ticagrelor|Comparison of platelet reactivity between clopidogrel and ticagrelor
75327093|NCT04337788|Other|telehealth applications|telehealth applications during 30 days/patient
75327094|NCT05528016|Procedure|Upper Eyelid Blepharoplasty|Blepharoplasty is a procedure that the skin, orbicularis oculi muscle, and fat pads are excised to treat visual field loss caused by dermatochalasis.
75327095|NCT05516706|Other|Dynamic stretching|Participants in this group performed a 10 minutes warm-up followed by 15 minutes of dynamic stretching exercises which included arm cross-over, scapular scaption, upper body twist walking lunges, cat and cow pose, and rotator cuff movements.
75327096|NCT05516706|Other|Plyometric push up|Participants in this group performed 10 minutes of warm-up followed by 15 minutes of plyometric push training which included one-arm push-ups and depth push up
75327097|NCT05522166|Other|Digital Stories and Face-to-face Basic Life Support Trainings|In this study, digital storytelling and face-to-face applied techniques will be given to teacher candidates via social media (Whatsapp) and the impact of these trainings on the knowledge and skill levels of teacher candidates will be evaluated comparatively.
75468980|NCT03747159|Drug|Belimumab Injection|Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
75468981|NCT03735628|Drug|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
75468982|NCT03735628|Drug|Nivolumab|Nivolumab: concentrate for solution for infusion
75468983|NCT03727100|Combination Product|Clonidine Micropellets|Injection
75468984|NCT03727100|Other|Sham|Injection
75784271|NCT06193005|Other|no intervention|no intervention
75784272|NCT06192992|Other|Peripheral heating of 2 feet|Heating of both feet
75784273|NCT06192992|Other|Sham|No heating
75784274|NCT06192979|Drug|Daratumumab|"Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice."
75327098|NCT02571972|Drug|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
75327099|NCT03694288|Procedure|Implant removal|Surgical Implant removal
75327100|NCT04996134|Drug|Domperidone Oral Product|10-30 mg of oral domperidone administered QID.
75327101|NCT05435872|Device|The Artificial intelligence Cloud Platform|The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.
75327102|NCT04994496|Behavioral|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
75327103|NCT04994496|Behavioral|Two-week web-based text messages containing fun facts|"The web-based sham intervention consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham intervention, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
75327104|NCT05377840|Behavioral|Cognitive Behavioral Therapy|CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. standard CBT Participants will have individual weekly sessions lasting 60 minutes each over an 8-week period with 1 follow-up maintenance session at week 12.
75468985|NCT03720275|Genetic|Systematic screening of TTR mutations|The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
75634098|NCT05493904|Procedure|Angiography-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using angiography only.~The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 30% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended."
76077507|NCT04832230|Biological|Blood sample collection|Healthy individuals: A blood sample will be collected at enrollment (Day 0). Patients: A blood sample will be collected at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
75634099|NCT05493904|Device|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
75634100|NCT01077518|Drug|Ofatumumab|Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.
75634101|NCT01077518|Drug|Bendamustine infusion|Bendamustine 100 mg/vial, injection
75784275|NCT06192979|Drug|Bortezomib|All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
75920135|NCT02105103|Device|Accu-Chek® Insight Insulin Pump|A new insulin pump, the Accu-Chek® Insight insulin pump, will be used by all subjects enrolled in this study. The usability of the Accu-Chek® Insight insulin pump for the intended use has already been investigated in a Human Factor study. The study subjects may encounter the following potential risks of CSII therapy while participating in the study: Possible hypoglycemia; Possible hyperglycemia which might progress to ketosis and DKA; Infusion site reactions (bleeding, bruising, discomfort, pruritus, pain, plaster reactions, inflammation, infection etc.)
75920136|NCT02110797|Other|biological markers and evaluation of the mineral density at the lumber spine using DEXA|
75920137|NCT03012165|Drug|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
75920138|NCT03012165|Drug|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
75920139|NCT03012165|Drug|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
75784276|NCT06192979|Drug|Dexamethasone|All patients received 20-40 mg oral or intravenous dexamethasone
75784277|NCT06192979|Drug|Venetoclax|All patients received venetoclax 400mg daily.
75784278|NCT06192953|Other|Functional Proprioceptive Stimulation|Orthoses with a system of 12 stimulators producing mechanical oscillations are attached to the joints of the upper limbs (wrist, elbow and shoulder) or lower limb joints (ankle, knee, hip). These stimulators, which are all synchronized, deliver mechanical oscillations (FPS) that give the illusion of complex movements, while the patient is bedridden, neither moving nor producing effort.
75784279|NCT06192940|Behavioral|Counseling home caregivers|Advice on the proper use of insulin therapy will be given, if necessary, to caregivers. Patients are reviewed at 1 month of this first visit with a collection of the same data
75784280|NCT06192927|Drug|TenoMiR|Single intralesional injection
75784281|NCT06192927|Drug|0.9% Sodium Chloride Injection|Single subcutaneous injection
75784282|NCT06192875|Other|Non-Interventional Study|Non-interventional study
75920140|NCT02107755|Biological|ipilimumab|Given IV
75920141|NCT02107755|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
75920142|NCT02107755|Other|laboratory biomarker analysis|Blood and tissue samples will be collected for research purposes.
75920143|NCT02110953|Combination Product|irinotecan-eluting beads|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
75327105|NCT05377840|Behavioral|Sudarshan Kriya Yoga|SKY Breath Meditation is a deep breathing and meditation technique that enables physiological changes leading to improved mental and physical health. Participants will first attend a 3-day online workshop (2.5 hours each day) delivered live by a certified instructor to learn the SKY Breath Meditation practice. Participants will then practice SKY 25 minutes daily for 6 weeks and 3-4 times per week up to 12 weeks.
75327106|NCT05516550|Drug|Treamid|Participants will receive Treamid 25 mg once a day daily during 4 weeks
75327107|NCT05516550|Drug|Treamid twice a day|Participants will receive Treamid 25 mg in the morning and in the evening daily during 4 weeks
75634102|NCT01077518|Drug|Ofatumumab and Bendamustine infusions (Arm A)|Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
75634103|NCT01077518|Drug|Bendamustine infusion (Arm B)|Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
75634104|NCT04203186|Drug|atovaquone-proguanil|Malaria standard treatment regimen
75634105|NCT00835120|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
75634106|NCT00914316|Drug|Ranolazine|Ranolazine, 1000 mg, capsule, twice daily, by mouth.
75634107|NCT00914316|Drug|Placebo|twice daily
75634108|NCT00701740|Drug|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
75634109|NCT00701740|Drug|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
75634110|NCT04938882|Drug|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
75634111|NCT04938882|Drug|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
75634112|NCT04938882|Drug|Compound lidocaine at low concentration|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
75634113|NCT04938882|Drug|Compound lidocaine at high concentration|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
75634114|NCT00704080|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
75634115|NCT00704080|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
75920144|NCT02110953|Procedure|hepatic artery embolization|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
75920145|NCT03554109|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
75920146|NCT03554109|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
75327108|NCT05516550|Drug|Treamid once a day|Participants will receive Treamid 50 mg in the morning daily during 4 weeks
75327109|NCT05516550|Drug|Placebo|Participants will receive Placebo in the morning and in the evening daily during 4 weeks
75327110|NCT04382339|Drug|SOF/RBV/PegINFα-2|SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
75327111|NCT00371332|Drug|Minocycline HCL Microspheres|
75327112|NCT05516472|Drug|Microbial Transplant Therapy|Participants will take microbial capsules, 2 capsules daily for 7 days
75634116|NCT05253066|Drug|Chidamide combined with exemestane (+/- goserelin)|Chidamide combined with exemestane (+/- goserelin)
75634117|NCT05253066|Drug|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
75634118|NCT04797858|Behavioral|COVID-19 self-test|5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19. Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.
75634119|NCT04797858|Behavioral|COVID-19 test referral|5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19. These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites. Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.
75634120|NCT04303442|Procedure|TEP|Total extraperitoneal laparoendoscopic hernia repair with one or three skin incisions.
75634121|NCT00827632|Drug|Low dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."
75634122|NCT00827632|Drug|High dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."
75634123|NCT02874638|Dietary Supplement|BASE egg protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
75634124|NCT02874638|Dietary Supplement|BCAA-enriched egg protein|BCAA-enriched egg protein provided as crystalline amino acid.
75634125|NCT02874638|Dietary Supplement|small amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
75634126|NCT02874638|Dietary Supplement|large amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
75920147|NCT03554109|Drug|Aldoxorubicin HCl|albumin-binding prodrug of doxorubicin HCl
75634127|NCT04303598|Drug|FNC|3mg, 1 tablet，QD
75634128|NCT04303598|Drug|3TC|300mg, 1 tablet，QD
75920148|NCT03554109|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
75327113|NCT05516472|Drug|Placebo|Participants will take placebo capsules
75327114|NCT05257564|Device|Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)|Fingerstick capillary blood will be collected according to each manufacturer's Instructions for use. The fingerstick capillary blood samples will be used immediately on the point-of-care assays. The venous blood will be collected in specific tubes for plasma (GLU), for whole blood (HbA1c) and for serum (CREP, CHOL). Plasma will be separated by centrifugation at the PHC facility and health post and aliquots will be prepared. Serum will be left to clot prior to centrifugation and serum aliquots will be prepared at the PHC facility and health post. The samples will be stored until transfer to the BPKIHS reference lab.
75327115|NCT00842075|Drug|pramlintide|subcutaneous injection (15 mcg initial dose)prior to meals
75327116|NCT04382105|Other|Observation of salivary IL-6 levels|Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
75327117|NCT05522010|Procedure|Cervical spine surgery|A standard anterior approach was made with discectomy sparing the cartilage, and with foraminal decompression. Complete excision of the posterior longitudinal ligament was routinely performed to complete neural decompression. Trial inserters were used to identify the proper implant size. Device under sizing may lead to poor ﬁxation and implant migration. The largest possible device that can be safely placed should be selected to maximize device- endplate contact and to gain support from the apophyseal rim. The teeth of the implant were optimally ﬁxated to the endplate via Caspar pin compression following device insertion. The device may be replaced or changed using the same insertion instrument if ﬁnal imaging demonstrated suboptimal positioning. Rinsing the implanted disc space removes rests of blood and bone dust, all potentially promoting HO
75327118|NCT05521932|Other|endometrium collected|endometrium tissue collected following adhesiolysis surgery
75468986|NCT03694938|Device|Magnetic resonance imaging|Annually magnetic resonance imaging
75634129|NCT04303598|Drug|TDF|300mg, 1 tablet，QD
75634130|NCT04303598|Drug|EFV|200mg, 1 tablet，QD
75634131|NCT04303598|Drug|FNC placebo|1 tablet，QD
75468987|NCT03694691|Diagnostic Test|Liver Biopsy|For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
75468988|NCT03685331|Drug|Palbociclib|Combination of palbociclib, olaparib, and fulvestrant.
75468989|NCT03685331|Drug|Olaparib|Combination of palbociclib, olaparib, and fulvestrant.
75468990|NCT03685331|Drug|Fulvestrant|Combination of palbociclib, olaparib, and fulvestrant.
75468991|NCT03634488|Drug|hydroxyurea (20mg/kg/day)|Treatment of severe malnutrition in children with SCA in northern Nigeria
75634132|NCT04303598|Drug|3TC placebo|1 tablet，QD
75634133|NCT02874716|Other|Tuberculosis Program (PPIA)|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.
75634134|NCT00704236|Drug|Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)|50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
75634135|NCT00704236|Drug|Placebo|
75634136|NCT04748718|Other|Exercise-based injury prevention program|~10-minute, 4+ times/week exercise-based injury prevention program. Includes flexibility, strengthening, balance, agility and plyometric exercises.
75784283|NCT06192862|Behavioral|Assessment of screening intention and Transtheoretical Model stages for CRC screening|"Screening Intentions will be measured by asking the subject, How much do you agree or disagree: I am intending to have colon cancer screening within the next 6 months. Subjects who strongly disagrees or somewhat disagrees are considered not having screening intention. Subjects who somewhat agrees or strongly agrees are considered having screening intention. For subjects who has screening intention, they will be asked if they have plan to arrange a consultation with primary care physician to collect FIT kits in next 3 months."
75784284|NCT06192849|Drug|Furmonertinib|This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
75784285|NCT06192836|Procedure|Manual Removal 1|"Placenta will be removed manually~Uterine incision will be repaired as double layered~No uterine massage will be performed"
75784286|NCT06192836|Procedure|Manual Removal 2|"Placenta will be removed manually~Uterine incision will be repaired as double layered~Uterine massage will be performed for one minute duration, after uterine incision is closed"
75784287|NCT06192836|Procedure|Controlled Cord Traction 1|"Placenta will be delivered via controlled cord traction~Uterine incision will be repaired as double layered~No uterine massage will be performed"
75784288|NCT06192836|Procedure|Controlled Cord Traction 2|"Placenta will be delivered via controlled cord traction~Uterine incision will be repaired as double layered~Uterine massage will be performed for one minute duration, after uterine incision is closed"
75920149|NCT03554109|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
75468992|NCT03634488|Dietary Supplement|Ready-to-use therapeutic food|Treatment of severe malnutrition in children with SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeautic food
75920150|NCT03554109|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
75327119|NCT05233150|Behavioral|PriCARE/CARIÑO|PriCARE/CARIÑO is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE/CARIÑO uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE/CARIÑO includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. CARIÑO is the culturally adapted version of PriCARE for Spanish speaking participants.
75327120|NCT00879359|Drug|carboplatin, paclitaxel, and bevacizumab|All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
75327121|NCT05516394|Procedure|Laparoscopic liver resection|Liver tumors are resected with minimally invasive approach, laparoscopically.
75327122|NCT05146726|Other|BARMER anemia treatment|BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.
75784289|NCT06192836|Procedure|Controlled Cord Traction+Uterine Massage 1|"Placenta will be delivered via controlled cord traction plus uterine massage~Uterine incision will be repaired as double layered~No uterine massage will be performed after placental delivery"
75784290|NCT06192836|Procedure|Controlled Cord Traction+Uterine Massage 2|"Placenta will be delivered via controlled cord traction plus uterine massage~Uterine incision will be repaired as double layered~Additional uterine massage for one minute duration will be performed after uterine incision is closed"
75784291|NCT06192810|Procedure|Laparoscopic/open adrenalectomy|
75327123|NCT05146726|Other|NON-BARMER anemia treatment|Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
75327124|NCT00880919|Drug|quetiapine extended-release|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
75327125|NCT00880919|Drug|Placebo|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
75327126|NCT02741284|Drug|Room air|
75327127|NCT02741284|Drug|10L Oxygen by nonrebreather mask|
75327128|NCT00880997|Drug|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17."
75634137|NCT04745520|Device|Rib fixation|"Rib fixation is performed by a senior surgeon. The patient is under general anesthesia. A thoracotomy focused on the fracture is performed to optimize access to the rib to be repaired. Video-assisted thoracic surgery (VATS) can be performed to better localize rib fractures. Significant muscle division is avoided. Removal of the periosteum is not required. The broken rib segments are approximated with forceps and the medical devices are used to fix the fracture. The medical devices are implemented according to the manufacturers' recommendations. The goal is to stabilize the chest wall. It is not useful to fix all fractures to stabilize the wall. A chest tube can be placed at the end of the operation.~Medical devices~The following medical devices can be used:~MatrixRIB™, De Puy Synthes Companies, Zuchwill, Switzerland~STRATOS™, MedXpert GmbH, Heitersheim, Germany~NiTi Fixing PlatesTM, IAWAI, Yandzhou, China"
75784292|NCT06192797|Procedure|HAIC|administration of gemcitabine and oxaliplatin via the tumor feeding arteries every 3 weeks.
75468993|NCT03634072|Procedure|PVR|Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
75327129|NCT00880997|Other|Placebo|Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
75468994|NCT03622749|Device|Transcranial Magnetic Stimulation (TMS)|Non-Invasive neuromodulation
75784293|NCT06192797|Drug|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
75920151|NCT03554109|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
75920152|NCT03554109|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
75920153|NCT03554109|Biological|GI-6207|CEA yeast vaccine
75920154|NCT03554109|Biological|GI-6301|Brachyury yeast vaccine
75920155|NCT03554109|Drug|Avelumab|Avelumab
75920156|NCT03554109|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
75920157|NCT03554109|Biological|haNK|NK-92 [CD16.158V, ER IL-2]
75920158|NCT03554109|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75920159|NCT03554109|Drug|Doxorubicin HCL|Doxorubicin HCL
75920160|NCT03554109|Drug|paclitaxel|paclitaxel
75920161|NCT02107833|Drug|OPRX-106|
75920162|NCT02105181|Device|Placement of a FCMS in the biliary tract of the patients|During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
75327130|NCT05521620|Behavioral|The father-friendly NICU|"Fathers have skin-to-skin contact with their infants~Fathers participate in important situations~Fathers receive information and guidance directly~Both parents participate in meaningful conversations~The department organize mother and father groups~The families have the opportunity to have a close family member to support them~Older siblings have the opportunity to stay overnight.~The department offer counseling by a social worker"
75327131|NCT00881465|Behavioral|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
75634138|NCT04745520|Drug|Analgesia|Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
75327132|NCT00881465|Behavioral|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
75327133|NCT00883103|Drug|2% Lidocaine jelly|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
75327134|NCT00883103|Drug|Plain aqueous gel|Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
75634139|NCT04636086|Drug|Cholecalciferol|Vitamin D supplementation
75634140|NCT04636086|Other|Placebo|Placebo comparator
75634141|NCT04336410|Drug|INO-4800|INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.
75634142|NCT04336410|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.
75634143|NCT00827242|Drug|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
75634144|NCT00827242|Drug|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
75634145|NCT01077362|Drug|placebo|SC injections
75634146|NCT01077362|Drug|ustekinumab 45 mg|SC injections
75634147|NCT01077362|Drug|ustekinumab 90 mg|SC injections
75634148|NCT00846586|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
75634149|NCT00846586|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
75634150|NCT00846586|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
75634151|NCT00785785|Drug|Nilotinib (AMN107)|
75327135|NCT02742532|Drug|Oxytocin|Intranasal oxytocin 40 IU
75327136|NCT02742532|Drug|Placebo|Intranasal saline solution
75327137|NCT03573544|Drug|OBI-888|For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
75327138|NCT03573544|Drug|OBI-888|For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
75327139|NCT03573544|Device|Globo H IHC Assay|This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
75327140|NCT05521386|Drug|Caffeine|Single pill in an acute dose of 5 mg per kg of body mass
75327141|NCT05521386|Drug|Placebo|Single pill in an acute dose of 5 mg per kg of body mass
75327142|NCT00370630|Drug|Avastin (Bevacizumab) and triamcinolone|
75327143|NCT05521230|Drug|Placebo Mouthwash|Application of mouthwashes
75327144|NCT05521230|Drug|Cymenol mouthwash|Application of mouthwashes
75327145|NCT00370708|Procedure|Oral Intake following admittance to the postpartum ward|
75327146|NCT04984980|Drug|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
75327147|NCT00370786|Drug|bevacizumab|
75327148|NCT03437356|Other|Pulmonary vein isolation using CLOSE protocol|'CLOSE' protocol: Ablation index > 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index > 550 at the anterior wall, and inter-lesion distance < 6.0mm
75327149|NCT03437356|Drug|Antiarrhythmic drug therapy (ADT)|"During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.~Preferred dosages:~Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or <70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men < 70 years, Cr <1.5mg/dl, >70kg, except 80 mg OD if female >70 years or Cr >1.2mg/dl~In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT."
75327150|NCT05516160|Diagnostic Test|diagnostic of optical aberrations|diagnostic of optical aberrations with new device
75327151|NCT03387670|Drug|Simvastatin|"One (1 = 40mg) simvastatin tablet once daily at night for 1 month~Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 months"
75634152|NCT00785785|Drug|imatinib (STI571)|
75634153|NCT02612818|Device|Coelioscopy|
75634154|NCT00707278|Radiation|Radiation Therapy|Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
75634155|NCT00707278|Drug|Capecitabine|Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
75634156|NCT00707278|Drug|Oxaliplatin|Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
75634157|NCT01077284|Drug|Febuxostat|Febuxostat capsules
75634158|NCT01077284|Drug|Allopurinol|Allopurinol capsules
75634159|NCT01077284|Drug|Placebo|Placebo-matching capsules
75327152|NCT03387670|Drug|Placebo|"One (1) placebo tablet once daily at night for 1 month~Two (2) placebo tablets once daily at night, for the next 35 months"
75468995|NCT03621540|Device|active tDCS|Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.
75468996|NCT03621540|Device|sham tDCS|Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.
75468997|NCT03621540|Behavioral|Adaptive working memory training|Adaptive spatial n-back training.
75327153|NCT04979832|Drug|GM-CSF, fosfomycin and metronidazole|GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch
75327154|NCT02740114|Drug|Bupivacaine|150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
75327155|NCT02740114|Drug|Liposomal Bupivacaine|266 mg injected on each side of the wound at the end of surgery before wound closure.
75327156|NCT02740114|Drug|Oxycodone|1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
75327157|NCT02740114|Behavioral|Pill Diary|Participants complete a pill diary every day for 30 days after hospital discharge.
75327158|NCT02740114|Behavioral|Symptom Questionnaire|Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
75327159|NCT05527158|Behavioral|Yi Jin Jing exercise|Yi Jin Jing of The General Administration of Sport of China, which consists of twelve operational processes as the standard intervention
75468998|NCT03605719|Drug|Carfilzomib|Given IV
75468999|NCT03605719|Drug|Dexamethasone|Given IV
75920163|NCT03554031|Drug|Recombinant Human Growth Hormone (rhGH) Injection|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.
75920164|NCT02111109|Device|Side Stream Dark Field Microscopy|
75920165|NCT02111265|Drug|Remifentanil|"Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~Remifentanil is stopped before skin closure"
75920166|NCT02111265|Drug|Cisatracurium|"Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~Cisatracurium is stopped before skin closure."
75920167|NCT02111265|Drug|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
75327160|NCT03356470|Other|F-FDG PET/CT|F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
75327161|NCT05520996|Behavioral|Cyberball|Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence
75327162|NCT05515926|Procedure|Cranial manipulation group, or cranial osteopathic techniques (OMM)|"Cranial OMT procedure:~Subjects were relaxed and lying on the back for entire time of the research protocol (approximately 30 min). Osteopathic physician performed the osteopathic manipulations using his hands. The physician gently applied a small amount of force to the neck and head to release tissue tension until feeling a softening and warmth of tissues. Subjects experienced a sensation of slight pulling, releasing, or relaxing of the tissue."
75327163|NCT05515926|Procedure|Sham manipulation|The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
75327164|NCT05527080|Other|physiotherapy|Some infants will receive physiotherapy as a part of their clinically indicated care.
75327165|NCT05527080|Device|brace|Some infants in the hip dysplasia group will receive brace and/or cast as a part of their clinically indicated care
75327166|NCT04745104|Drug|SHR-1707|SHR-1707 will be administered through IV infusion
75327167|NCT04745104|Drug|Placebo|Placebo will be administered through IV infusion
75327168|NCT00371410|Procedure|vitrectomy|
75327169|NCT00371410|Drug|intravitreal triamcinolone acetonide|
75469000|NCT03605719|Biological|Nivolumab|Given IV
75469001|NCT03605719|Biological|Pelareorep|Given IV
75469002|NCT03602391|Behavioral|SCP Plus|The primary goal of the proposed project is to develop an in-home psychoeducational intervention (Senior Companion Program Plus, or SCP Plus) that is accessible, affordable, and sustainable for low-income African American ADRD caregivers. A weekly, 60 minute psychoeducational module will be delivered face-to-face across 9 weeks and will focus on education about ADRD, behavior management, communication skills, and aspects of providing care that enhance meaning such as spirituality. In order to provide an accessible intervention that is potentially sustainable, Senior Companions will be trained to provide the intervention in the homes of the African American ADRD caregivers.
75469003|NCT03593993|Procedure|Surgical Cohort|Blood, cerebrospinal fluid, and surgical tissue collected during procedure
75469004|NCT03547050|Other|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
75920168|NCT02111265|Device|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
75920169|NCT02251119|Drug|Tipranavir|
75920170|NCT02251119|Drug|Ritonavir|
75920171|NCT02251119|Drug|Loperamide|
75327170|NCT00371410|Procedure|macular focal laser photocoagulation|
75634160|NCT00704314|Drug|Simvastatin|80 mg Simvastatin daily for 8 weeks
75920172|NCT02105493|Drug|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
75920173|NCT02105493|Drug|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
75784294|NCT06192771|Behavioral|ESSI-SURG|Patients will receive 3 face-to-face sessions with a speech-language pathologist (SLP), each with a specific goal, namely: pre-surgical educational, a post-operative day 3 therapy, and post-operative day 7 therapy. Following discharge from hospital, participants will be seen by an SLP for 4 weekly sessions, offered via telehealth or face-to-face depending on the patient's clinic schedule and/or availability.
76077508|NCT03029026|Other|Baseline assessment|Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
76077509|NCT03029026|Procedure|Transthoracic echocardiography|"Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.~Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus."
75327171|NCT04296474|Drug|ALK Alutard 5-grasses and birch|Intralymphatic injections
75327172|NCT04296474|Drug|ALK Diluent|intralymphatic injections
75634161|NCT00704314|Drug|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
75784295|NCT06192771|Behavioral|Standard-of-Care|Participants will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
75327173|NCT04295850|Drug|Aspirin 81 mg|Aspirin 81mg daily PO
75327174|NCT05520918|Diagnostic Test|the LIT test|The retained functional capacity of leukocytes (primarily neutrophils) to produce ROS in response to PMA in whole blood samples could provide a rapid 10-minute detection method for objectively determining onset or occurrence of severe COVID-19 and monitoring progression and treatment of COVID-19.
75784296|NCT06192758|Device|TheraSphere PCa|Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
75784297|NCT06192745|Behavioral|no screen control with dim light and calming activities|Non-screen-based quiet activities for 1 hour before bed in room lighting 40-50 lux
75327175|NCT04738240|Diagnostic Test|Intra-operative endoscopy|Intra-operative endoscopy to assess rectal anastomosis
75784298|NCT06192745|Behavioral|unfiltered Bright tablet screen|Bright light screen media exposure will be delivered on an iPad Pro provided by the research team which will be set to the brightest light intensity setting for 1 hour before bed in room lighting 40-50 lux
75784299|NCT06192745|Behavioral|Filtered dim tablet screen|Filtered dim light screen media exposure will be delivered for 1 hour before bed in room lighting 40-50 lux on an iPad Pro provided by the research team. A blue light filter will be used to alter the spectral distribution of the emitted light and the screen brightness will be dimmed to the lowest possible setting
75784300|NCT06192745|Behavioral|Exciting content|We will create a 1-hour recording of movie clips containing exciting content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
75920174|NCT02105571|Behavioral|Intervention|
75634162|NCT04103437|Diagnostic Test|Maximal incremental running test|"Maximal incremental running test with measures of metabolic, spatio-temporal parameters and video recording with camera in the frontal plane.~video recording of frontal view, metabolic and spatio-temporal measures of three (self-selected speed, + and - 20 percentage of self-selected speed) 6 minutes running test monthly (12 months) follow-up questionnaire"
75634163|NCT04103437|Diagnostic Test|Metabolic and movement analysis of running|Running analysis of three six minutes running test (self-selected speed, + and - 20% of the self-selected speed) by video recording with camera in the frontal plane, and acquisition of the metabolic and spatio-temporal parameters
75920175|NCT02105649|Other|Strengthening exercise + Electrical stimulation of calf muscle|
75920176|NCT02105649|Other|selected physical therapy program|
75327176|NCT05520840|Diagnostic Test|blood sampling for screening of biomarkers|Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
75327177|NCT05527002|Other|Satisfaction of patients after medical and surgical treatment for thoracic endometriosis|"It is a retrospectively evaluation of cases of thoracic endometriosis in our clinic over the last 20 years, based on the review of medical records and on outpatient follow-up visits.~The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period.~If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study."
75327178|NCT02166905|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
75327179|NCT02166905|Drug|Epacadostat|Given PO
75327180|NCT02166905|Other|Laboratory Biomarker Analysis|Correlative studies
75327181|NCT02166905|Other|Pharmacological Study|Correlative studies
75327182|NCT02166905|Drug|Poly ICLC|Given SC
75327183|NCT02743078|Drug|Bevacizumab|10 mg/kg every 2 weeks intravenously over 30 minutes.
75634164|NCT04103437|Other|Questionnaires|Monthly follow-up questionnaire (12 months) about training habits and injuries
75634165|NCT00704392|Drug|XL647|Tablets supplied at 50-mg strength administered orally daily
75634166|NCT00704392|Drug|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
75327184|NCT02743078|Device|TTFields Therapy|Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.
75327185|NCT04294368|Dietary Supplement|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid|The control group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF.
75327186|NCT04294368|Dietary Supplement|Similac Liquid Protein Fortifier|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
75327187|NCT04294368|Dietary Supplement|Nestle Microlipid|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
75327188|NCT04294368|Dietary Supplement|Medica Nutrition SolCarb|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU.
75327189|NCT04294368|Dietary Supplement|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)|The experimental group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF. For participants in the experimental group, the investigators will continue to add fortification. Two packets of HMF per day will be added until goal fortification is reached.
75327190|NCT04294368|Dietary Supplement|Similac Liquid Protein Fortifier (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base protein content in the donor breast milk for each particular batch of donor breast milk.
75327191|NCT04294368|Dietary Supplement|Nestle Microlipid (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base fat content in the donor breast milk for each particular batch of donor breast milk
75634167|NCT00704470|Other|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
75634168|NCT00704470|Other|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
75327192|NCT04294368|Dietary Supplement|Medica Nutrition SolCarb (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base carbohydrate content in the donor breast milk for each particular batch of donor breast milk
75327193|NCT04294368|Other|Analysis with Miris (AB) Human Milk Analyzer|For participants in both the control and the experimental arms, each batch of donor milk will be analyzed using the Miris Human Milk Analyzer. Manufacturer recommendations for milk analysis will be strictly followed.
75327194|NCT03323398|Biological|mRNA-2416|mRNA encoding human OX40L
75327195|NCT03323398|Biological|Durvalumab|PD-L1 inhibitor
75327196|NCT05526846|Behavioral|Plant-based diet education|"Participants will attend a virtual kick-off introductory session and will receive weekly emails with information about plant-based diets and a goal/task for each week.~There will be a 'core curriculum' that will be sent to all participants, as well as additional information according to the participant's stage of change and food choice preferences.~All information will be available on a website that will be created for this study. The website will feature curated information about plant-based diets, that is tailored to patients who had recent colorectal operations and may have a colostomy or an ileostomy.~Bi-weekly office hours will be held for patients to have the opportunity to discuss questions or concerns that may arise."
75327197|NCT00890981|Procedure|high-resolution peripheral quantitative computed tomography (HR-pQCT)|Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
75920177|NCT02111343|Other|Computer-based auditory training (CBAT)|"There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.~Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day."
75920178|NCT02105727|Behavioral|Community-based salt reduction|
75327198|NCT00890981|Procedure|Dual energy X-ray absorptiometry (DXA)|Bone densitometry assessments of the forearm by DXA on day 1.
75327199|NCT00890981|Biological|Denosumab|Denosumab 60 mg subcutaneously every 6 months in the previous study
75327200|NCT00890981|Drug|Placebo|Placebo to denosumab subcutaneously every 6 months in the previous study
75327201|NCT05515770|Drug|Cabotegravir Injection|Long action cabotegravir injection
75784301|NCT06192745|Behavioral|Calming Content|We will create a 1-hour recording of movie clips containing calming content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
75784302|NCT06192732|Behavioral|A more plant-based diet during weight loss|Participants receive dietary counseling on a more plant-based diet during weight loss. They will be counseled by a dietician to increase their plant-based protein intake up to 60%, focusing on 1.2 grams of protein per kg body weight.
75327202|NCT05520684|Diagnostic Test|urine culture and urinalysis|urine culture and urinalysis
75327203|NCT04480138|Drug|Pegylated Interferon-α2b|1 mcg/kg on day 1 and day 8 after safety evaluations.
75469005|NCT03547050|Other|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
75784303|NCT06192719|Other|None, observational study.|Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.
75784304|NCT06192706|Device|Foldax Tria Aortic Valve|Aortic Valve Replacement
75920179|NCT02105805|Behavioral|Dietetic group sessions|Group sessions to improve dietary adherence
75920180|NCT02105883|Other|Use of identification badge during scenarios|
75327204|NCT04480138|Other|Standard of Care|Standard of care as per local authority
75327205|NCT01610843|Other|Survey|Longitudinal surveys
75920181|NCT02111421|Drug|Dexmedetomidine 01|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,after the umbilical cord was clapped.The wight used to calculate the dose of dexmedetomidine would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.
75327206|NCT00371488|Drug|GW572016 oral tablets|Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
75327207|NCT02743312|Device|Torso Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
75920182|NCT02111421|Drug|Dexmetomidine 02|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
76077510|NCT03029026|Procedure|99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy|Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
75327208|NCT02743312|Device|Sham Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
75327209|NCT02743312|Device|Fitbit Flex|Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
75327210|NCT01501955|Device|Metaphyseal Hip Prosthesis|Metaphyseal Hip Prosthesis (MHP) hip replacement
75327211|NCT01501955|Device|Stanmore|Stanmore hip prosthesis
75327212|NCT02743702|Other|RESPIRATORY PHYSIOTHERAPY|"The protocol designed was composed of the following exercises:~supine position: inhalation and exhalation with abdominal and thoracic pressures. 5 times~lateral decubitus, with incentive spirometer lung inflation are made on right/left sides. 3 sets on each side~sitting position, with the body leaning slightly forward, head and shoulders bent inwardly directed. It inspire called for 3 times, sent off in air through the mouth, after that the child was coughing~diaphragmatic breathing in a sitting position: after a slow exhalation requested, child should steam a mirror with his mouth slightly open. 3 replications~in a sitting position, with help of an ambu bag, we made inflations. Repeated 3 times~exercises of upper member coupled to respiratory rhythm: shoulder flexion and extension was carried out during the inspiratory phase and the extension and adduction of them during expiration. 3 times"
75469006|NCT03483337|Other|MRI examinations|Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
75327213|NCT02743702|Other|USUAL THERAPIES|
75327214|NCT04335760|Combination Product|Modified Bruce protocol on treadmill|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
75327215|NCT05520606|Procedure|pancreatoduodenectomy|Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
75327216|NCT00883415|Drug|Darbepoetin alfa|Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
75327217|NCT02743936|Device|Nasal cannula|Placement of nasal cannula under non-invasive positive pressure ventilation mask
75327218|NCT02743936|Device|Non-invasive positive pressure ventilation|Non-invasive positive pressure ventilation
75469007|NCT03483337|Other|MRI examinations|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
75469008|NCT03477175|Drug|E7080|Oral Administration.
75634169|NCT04103125|Device|Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.|The subjects will receive at baseline the first IMD by the Investigator in accordance with the CIP
75920183|NCT02106039|Procedure|intensive monitoring|
75920184|NCT02111499|Drug|LAS41004-IMP1|daily topical application
75920185|NCT02111499|Drug|LAS41004 IMP2|daily topical application
75920186|NCT02111499|Drug|LAS41004 IMP3|daily topical application
75920187|NCT02111499|Drug|LAS41004 IMP4|daily topical application
75920188|NCT02111499|Drug|LAS41004 IMP6|daily topical application
75920189|NCT02111499|Drug|LAS41004 IMP5|once daily, topical
76077511|NCT03029026|Radiation|CT 3-5-minute post-contrast research sequences|Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
76077512|NCT03029026|Procedure|Cardiac Magnetic Resonance|CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
76077513|NCT03029026|Procedure|Endomyocardial biopsy|Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
75469009|NCT03477175|Drug|Comparator Drug|Per parent study.
75469010|NCT03477175|Drug|Comparator Drug: Sorafenib|Per parent study.
75327219|NCT00842231|Other|Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
75327220|NCT00372034|Device|Temporary Collagen Inserts|
75920190|NCT03554811|Device|Functional electrical stimulation assisted supine cycling (FESC)|A supine cycle ergometer attached to a six-channel stimulator will be used for FESC. Surface electrodes will be applied to the hamstrings, quadriceps, and calf muscles on both legs. Muscles will be stimulated at specific stages throughout the cycling phase. Each session will start with a 1 minute motor-driven passive cycling warm-up at a rate of 20 revolutions per minute. Patients will continue with passive, active-assisted, or active cycling, according to their level of participation. If the patients stop cycling actively, the ergometer will revert to passive cycling.
75327221|NCT04337632|Drug|Doxorubicin Hydrochloride Liposome Injection+carboplatin|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.
75784305|NCT06192693|Drug|Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution|"1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion <7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion >8%."
75920191|NCT03554811|Other|Conventional early exercise and mobility interventions|These interventions will be based on the patient's alertness and medical stability, and includes activities to maintain or increase limb range of motion and strength, in and out of bed mobility, sit to stand, and transfer training, as well as assisted ambulation.
75920192|NCT03554733|Behavioral|ReInventing Yourself after SCI|6-week, manualized, cognitive-behaviorally based group educational intervention
75920193|NCT03553953|Device|BIS device|Recording data from BIS device from patients who undergo elective surgery under general anesthesia
75920194|NCT02111655|Device|Second generation surveillance of AVF|"Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound."
75920195|NCT02111655|Procedure|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
75920196|NCT02111655|Procedure|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
75920197|NCT02111655|Procedure|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
75920198|NCT02111655|Procedure|urea method|Quarterly recirculation with urea method.
75920199|NCT02108145|Procedure|bilateral metal stent insertion|
75920200|NCT02108145|Procedure|unilateral metal stent insertion|
76077514|NCT03029026|Other|Follow-up assessment|1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
75920201|NCT02111733|Other|Hs-TNT dosage|Bloodwork before and after hemodialysis for high sensibility troponins T blood level
75327222|NCT04337632|Drug|paclitaxel +carboplatin|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
75327223|NCT05526612|Other|Group 1 Motor imagery and Bobath Therapeutic Approach (BTA+MI)|Motor imagery (MI) is the mental rehearsal of motor abilities to improve function. Without revealing any movement in the body, the representation of the movement is created in the mind, the person imagines that he/she is performing the movement. Eating activity will be applied in motor imagery. Individualized therapy sessions in the Bobath Therapeutic Approach will also be received by the Physiotherapist along with Motor imagery. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
75920202|NCT02108301|Drug|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
75920203|NCT02111889|Other|[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.|[11C] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and [15O]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
75634170|NCT04103203|Diagnostic Test|PathoRobot/ Patho-Doc Test result|Test results of the new diagnostics will be available to the treating physician.
75634171|NCT00826618|Drug|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
75784306|NCT06192693|Drug|Capsulized placebo transfer containing dilution solution|"1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion <7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion >8%."
75920204|NCT02113839|Procedure|Spirometry|Before re-breathing (if the patient not performed one 6 months in advance).
75920205|NCT02113839|Procedure|CO Exhaled breath|In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).
75920206|NCT02113839|Procedure|P01|P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
75920207|NCT02113839|Procedure|FeNO|The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
75920208|NCT02111967|Other|Questionnaire administration|
75920209|NCT02111967|Other|Laboratory biomarker analysis|
75634172|NCT05579197|Device|Lower-limb robotic intervention|"The intervention proposed in this study involves the use of an exosuit for lower limbs, the Myosuit. The selection of the tasks has been done in order to replicate typical activities of daily living in a structured environment, i.e. a rehabilitation hospital.~Specifically, the tasks involve walking, sit to stand, balance and stair climbing.~During the phases of assessment (session 2 and session 10), other devices are be used. Specifically:~The Optogait system; for a markerless gait analysis;~The Gyko sensor; an inertial sensor that will be used at the beginning of the training for the synchronisation of the signals recorded by the Myosuit and the signal recorded by the Optogait.~Finally, during all the sessions, the Polar heart rate sensor is used to constantly monitor the cardiac frequency of the patients."
75469011|NCT03471182|Behavioral|Psychiatric and Cognitive Testing|Interviews, questionnaires, and computer testing.
75920210|NCT02113995|Other|ACERTO protocol vs Traditional care|Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.
75469012|NCT03471182|Drug|Cocaine Self-adminstration|The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
75469013|NCT03471182|Radiation|Positron Emission Tomography|PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of [18F]FPEB.
75634173|NCT02876822|Dietary Supplement|Vitamin D|
75634174|NCT04304222|Device|3D Printed Denture Framework|The Denture Framework is 3D printed from the digital image obtained from the denture mold.
75920211|NCT02108379|Device|Rhinix Nasal Filters|
75920212|NCT02112123|Drug|Icariin|
75920213|NCT02112123|Dietary Supplement|Matching placebo|
76077515|NCT04402047|Other|Electroacupuncture|We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.
76077516|NCT04402047|Drug|Topical diclofenac sodium gel|The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
75920214|NCT02108535|Drug|Nanocrystalline silver|Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
75920215|NCT02108535|Drug|Silver Sulfadiazine|This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
75784307|NCT06192654|Procedure|Small intestinal submucosa (SIS) graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the small intestinal submucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
75784308|NCT06192654|Procedure|Autologous oral bucal mucosa graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. The autologous oral bucal mucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
75327224|NCT05526612|Other|Group 2 Motor imagery, Bobath Therapeutic Approach and Physical practice (BTA+MI+PP)|Individualized therapy sessions in the Bobath Therapeutic Approach with motor imagery will be performed by the physiotherapist, and in addition to these, 5 repetitions of the eating activity used in motor imagery will be practiced. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
75920216|NCT02108613|Behavioral|Exercise Sessions|8 weeks of weekly exercise classes taught by a certified exercise physiologist.
75920217|NCT02108613|Behavioral|Nutrition Education|Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.
75920218|NCT02108613|Behavioral|Peer Support Volunteer|Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
75327225|NCT05349058|Drug|Immune Checkpoint Inhibitors|Patients receive Immune Checkpoint Inhibitor as per oncology protocol
75327226|NCT05348980|Drug|Phenylephrine Hydrochloride 4 mg|Intramuscular Phenylephrine HCL 04 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
75327227|NCT05348980|Drug|Phenylephrine Hydrochloride 8 mg|Intramuscular Phenylephrine HCL 08 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
75327228|NCT00884585|Drug|Cyclosporine Vehicle|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
75327229|NCT00884585|Drug|Cyclosporine 0.010%|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
75327230|NCT05520372|Combination Product|Autologous immune enhancement therapy (AIET) for cancer patients|Autologous NK cell and CD8 T cell therapy for cancer patients
75327231|NCT05079516|Other|Theta burst transcranial magnetic stimulation|Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
75327232|NCT05348902|Other|In this study, only cases were collected and reported without any intervention or adverse reactions|In this study, only cases were collected and reported without any intervention or adverse reactions
75327233|NCT05526456|Procedure|Esophagectomy|McKeown, Ivor-Lewis, and Sweet procedure
75327234|NCT00884897|Drug|Oxytocin|Oxytocin given as 20 IU BID
75327235|NCT00884897|Drug|Placebo|Placebo given as 20 IU BID
75469014|NCT03471182|Other|Magnetic Resonance Imaging|Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
76077517|NCT03028714|Behavioral|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
76077518|NCT03028168|Other|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
76077519|NCT03028168|Other|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
76077520|NCT03028168|Other|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
76077521|NCT03027778|Other|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
76077522|NCT03035110|Behavioral|Dialectical Behavioural Therapy (DBT) based skills groups|Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
76077523|NCT03017638|Other|Questionaire|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
75634175|NCT04030624|Device|Remote Electronic Patient Monitoring|The Remote Patient Monitoring intervention is a remote monitoring system intended for use by healthcare professionals for the collection of physiological data in home and healthcare settings. Patient information is displayed on a computer located at the medical institution. Throughout the day, patient data from the remote monitoring system are presented on the clinician user interface (e.g., temperature, blood pressure, heart rate, respiration rate). Data are transmitted from sensors to the patient's smart phone.
75634176|NCT00627146|Drug|ChAgly CD3|6 days treatment 8mg/d intravenous
75634177|NCT00627146|Drug|Placebo|6 days
75634178|NCT02874872|Behavioral|OASIS Collaborative|OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
75920219|NCT02114073|Drug|Cyclosporine|In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
75920220|NCT02114073|Drug|Betamethasone|In control arm, betamethasone eye drop will be prescribed in postoperative period.
75920221|NCT03553407|Device|Low Level Laser - Pulse|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
75920222|NCT03553407|Device|Low Level Laser - continuous|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
75920223|NCT03553407|Device|Low Level Laser - placebo|placebo will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
76077524|NCT03017248|Drug|Ketamine|ketamine
75634179|NCT00826540|Drug|sorafenib tosylate|Given orally
75634180|NCT00826540|Biological|bevacizumab|Given IV
75634181|NCT01077050|Device|SciBase III Electrical Impedance Spectrometer|SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
75469015|NCT03467919|Biological|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
75469016|NCT03467919|Biological|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
75920224|NCT02114463|Procedure|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
75920225|NCT02114463|Procedure|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
75920226|NCT02114463|Drug|ropivacaine|0.2% ropivacaine
75920227|NCT02114463|Drug|flurbiprofen|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
75920228|NCT02112201|Behavioral|Integrated intervention for parents and adolescent girls|The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
75920229|NCT02114619|Drug|Low dose of I-131|We wil administer 100 micro currie of iodine per thyroid gram
75920230|NCT02114619|Drug|Intermediate dose|We will administer 150 micro currie of iodine per thyroid gram
75920231|NCT02114619|Drug|High dose|We will administer 200 micro currie of iodine per thyroid gram
75920232|NCT02112279|Biological|Donor microbiota applied via colonoscopy.|"B. Preparation of donor sample 1. Instillation via Colonoscopy~1. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.~Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe."
75920233|NCT02114697|Drug|Statin therapy|Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years. Participants may also receive a different type of statin as prescribed by their cardiologist based on clinical judgement.
75920234|NCT02114697|Behavioral|Lifestyle modification|Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.
75920235|NCT02251197|Drug|BIII 890 CL|
75784309|NCT06192641|Drug|Melatonin 3 MG|patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).
75920236|NCT02251197|Drug|Placebo|
75784310|NCT06192628|Behavioral|Parkinson's Exercise and Education Programme|"A 12 week programme of exercise and education~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist only)"
75798481|NCT03867474|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The intervention group will be delivered in a group-based format, for one three-hour session per week for an 8-week period. Each session will consist of mindfulness practice (e.g. lying down body scan, sitting meditation, mindful eating, mindful movements such as walking and light hatha yoga movements) along with an inquiry about the practice. Strategies on stress reactivity, responding to stress, and some basic content on cognitive behaviour therapy principles will also be taught. Participants will be placed in dyads during the group. Homework practice will be given to complete on a daily basis for approximately 30-45 minutes. During week six participants will attend an all-day silent meditation retreat on a Saturday (Total of 10 sessions = 8 sessions, 1 orientation, and 1 all-day retreat).
75920237|NCT02112435|Device|Somnyx ®|Active mandibular advancement splint
75920238|NCT02112435|Device|Narval ORM ® or SomnoDent ®|Mandibular advancement splint
75920239|NCT02108769|Behavioral|Yogic Breathing|"Chanting Om~Sharp deep inhalation through nostrils~Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~Yogic Breathing:~Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~Hold breath in this position for about 16 seconds.~Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~Go to step a)."
75920240|NCT02108769|Behavioral|Attention Control|The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
75920241|NCT02114775|Drug|Growth Hormone|0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months
75920242|NCT02114775|Drug|Sildenafil|50 mg by mouth daily
76077525|NCT03017248|Drug|Placebos|0.9% normal saline
76077526|NCT03017248|Drug|Morphine|Morphine
75469017|NCT03467789|Drug|Dietary Vitamin D3 pre-treatment|The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is < 31 ng/mL, and 5 days if the D3 level is > 31 ng/mL
76077527|NCT03035344|Other|Metabolome study|Metabolome study in ALL patients compared to healthy controls
75327236|NCT02753842|Device|5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms|"Fitted condoms are available in 56 sizes based on combinations of length (approximately 10mm increments) and circumference (approximately 2 mm increments). Fitted condom thickness is 70 microns ± 10 microns. Appropriate condom size is user-determined with a paper template fitting tool graduated with non-sequential numbering and lettering for maximum privacy. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Thin condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 50 microns ± 5 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Standard condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
75634182|NCT04303052|Device|Angiodynamic Bioflo Picc IR-KIT (145 cm guidewire) or|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
75327237|NCT05515146|Diagnostic Test|near infra red fluorescence lymphatic imaging|ICG (0.2 ml from 25mg of ICG diluted by 5.0 ml of aqua ad injectabilia) was injected intradermally at the basis of the tattooed cutaneous area and at one point chosen so that the tracer had to flow under this area directly towards the root of the limb
75327238|NCT03216473|Drug|Neuronox|Clostridium Botulinum Toxin A 100 U
75327239|NCT03216473|Drug|Botox|Clostridium Botulinum Toxin A 100 U
75327240|NCT00886145|Device|Vibration: Right Leg and No Vibration: Left Leg.|"Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month."
75327241|NCT02753920|Other|voiding trial|1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
76077528|NCT03034720|Behavioral|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
75327242|NCT02753920|Device|Foley catheter|If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
75327243|NCT00887471|Procedure|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
75469018|NCT03467789|Radiation|Photodynamic therapy|Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
75634183|NCT04303052|Device|Angiodynamic Bioflo Picc MST-KIT (70 cm guidewire)|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
75798482|NCT01172730|Device|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
75798483|NCT01278888|Procedure|Anterolateral thoracotomy|Standard anterolateral thoracotomy
75798484|NCT01278888|Procedure|Posterolateral thoracotomy|Standard muscle sparing posterolateral thoracotomy
75798485|NCT01278888|Procedure|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
75798486|NCT01278888|Procedure|Anterolateral Thoracotomy|Standard anterolateral thoracotomy
75798487|NCT01172262|Procedure|MRI|This is an observational study, no intervention will occur.
75798488|NCT03872622|Other|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.
75798489|NCT01172340|Behavioral|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
75920243|NCT02114775|Drug|Placebo|Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
75920244|NCT02108847|Drug|.2% Ropivacaine|
75920245|NCT02108847|Drug|Saline|
75920246|NCT02108847|Procedure|Fascia Iliaca Block|Ultrasound-guided regional anesthesia block to the groin area.
75920247|NCT02251353|Procedure|intervention|hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery
75920248|NCT02251353|Drug|systemic treatment|Systemic therapy
75920249|NCT02108925|Drug|Oxygen|supplementary oxygen during exercise
75920250|NCT02109003|Device|Pressure easy® device|Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
75327244|NCT05520216|Device|Spinal mouse (idiag m360)|A noninvasive Spinal Mouse device will be used to measure the thoracic kyphosis and lumbar lordosis angle of the spinal column in the sagittal plane. It will be displayed on the computer aided software screen where the thoracic and lumbar region angles are calculated by swiping over the spinal processes from top to bottom with the Spinal Mouse (IDIAG m360) device. Measurements will be taken while standing on a flat surface. The volunteer will take off his upper clothes and shoes during the examination. Relax your arms and torso will be positioned next to you. The distance between the feet will be approximately waist width and parallel to each other, the knees will be straight and face motionless. He will stand where he feels comfortable. A Spinal Mouse examination will be performed and data will be recorded.
75634184|NCT04303130|Drug|Camrelizumab|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes (the overall infusion time including the flushing time is not shorter than 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days)."
75920251|NCT02109003|Device|Manual control of Pcuff followed by continuous control.|Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
75920252|NCT03553329|Drug|dabrafenib|Monthly biological assessment which included: blood count, a blood electrolytes, an creatininemia, a dosage of urea, a dosage of transaminases, of gammaGT, of phosphatases alkaline, of LDH and of albumin.
75634185|NCT00626600|Drug|Oxycodone Hydrochloride|
75920253|NCT02112591|Procedure|transobturator subtrigonal tape S-TOT|Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.
75920254|NCT02112591|Procedure|Transobturator suburethral tape (TOT)|Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
75920255|NCT02115087|Procedure|ultrasound guided rectus sheath block|the application of rectus sheath block with ultrasound guidance
75920256|NCT02115087|Drug|Morphine|
75920257|NCT02115165|Drug|Cabazitaxel|On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
75920258|NCT02115243|Drug|Ipilimumab|
75920259|NCT02109237|Procedure|Assessment of sleep disorders and treatment if required|Assessment of sleep disorders and treatment if required
75920260|NCT03004053|Device|Reflectance Confocal Microscopy (RCM) endoscope device|
75920261|NCT02109315|Drug|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
75634186|NCT00707356|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
75920262|NCT02109315|Drug|Liraglutide 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
75920263|NCT02112669|Device|VasQ|
75920264|NCT02112747|Other|Patient Navigator|Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
75920265|NCT02115477|Procedure|Lymphadenectomy|Pelvic and/or paraaortic lymphadenectomy
75920266|NCT02112825|Behavioral|Exercise|Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
75920267|NCT02115555|Behavioral|HIT-aided approach|Subjects randomized to this approach will be using the HIT-aided monitor.
75920268|NCT02115555|Behavioral|Contracted conflict management system|Subjects randomized to this arm will be using the behavioral contracted conflict management system.
75920269|NCT02115555|Behavioral|HIT plus contracted conflict management|Subjects randomized to this arm will use both the HIT-aided approach and the behavioral contract conflict management system.
75920270|NCT02112903|Drug|Encapsulated vortioxetine IR tablet, 20 mg|
75920271|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 5.5)|
76077529|NCT03034486|Drug|D930, D565|Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
75920272|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 6.0)|
75920273|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 7.0)|
75920274|NCT02115711|Behavioral|Community health worker|The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
76077530|NCT00088881|Biological|rituximab|Given IV
76077531|NCT00088881|Drug|prednisone|Given orally
76077532|NCT00088881|Drug|cyclophosphamide|Given IV
76077533|NCT00088881|Drug|doxorubicin|Given IV
76077534|NCT00088881|Drug|vincristine|Given IV
76077535|NCT00088881|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
76077536|NCT00088881|Radiation|radiation therapy|Undergo radiotherapy
75469019|NCT03467789|Drug|Serum Maintenance Vitamin D3|2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.
75634187|NCT04304456|Other|Treatment|Antimicrobial and other treatment modalities such as source control, vasoactive medications, dialysis
75634188|NCT02612740|Biological|Deproteinized bovine bone|cyst removal followed by heterologous bone grafting
75920275|NCT02109393|Other|MIRT|"It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.~All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks."
76077537|NCT00088881|Procedure|positron emission tomography|Undergo PET scans
76077538|NCT02981914|Drug|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
76077539|NCT02981680|Procedure|Remote Ischemic Preconditioning (RIPC)|Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.
76077540|NCT02981680|Procedure|sham-RIPC|
76077541|NCT03026452|Procedure|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
76077542|NCT03025750|Biological|IPV-Al SSI|Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age
76077543|NCT03025750|Biological|IPV SSI|Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
76077544|NCT03024892|Procedure|ICG GB|ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
76077545|NCT03024892|Procedure|ICG IV|ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
75469020|NCT03455725|Device|CardiAMP Cell Therapy System|The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
75634189|NCT02612740|Device|granules of deproteinized bovine bone (Bio-Oss)|
75634190|NCT04799990|Drug|Risankizumab|Subcutaneous Injection
75634191|NCT04799990|Biological|Comparator 1|Subcutaneous or Intravenous Injection
75634192|NCT04799990|Drug|Comparator 2|Oral, Opthalmic, Subcutaneous or Intravenous Injection
75798490|NCT01172340|Behavioral|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
76077546|NCT03024892|Procedure|LC conventional|simple laparoscopic cholecystectomy was performed under white light image.
76077547|NCT03024892|Procedure|LC conventional and IOC|simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
76077548|NCT03024658|Other|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
76077549|NCT00952120|Device|GSUC|Gauze-based wall suction negative pressure wound therapy
76077550|NCT00952120|Device|VAC|Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
76077551|NCT03017482|Device|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:~Questionnaires about the utility and impact of the device~Use of the device in children younger than the current FDA approval range"
75469021|NCT03455725|Other|Sham Treatment|Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
75634193|NCT00707512|Drug|natalizumab|Administered as specified in the TOUCH Prescribing Program
75634194|NCT02611726|Other|Acupuncture|Acupuncture
75634195|NCT00704548|Drug|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
75634196|NCT00704548|Drug|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
75798491|NCT03867240|Drug|Gabapentin|Gabapentin (10 mg/kg up to 600 mg) will be given 30 minutes prior to being transported to the operating room. The gabapentin will be in the standard liquid with a concentration of 250mg/5mL. Starting postoperative day 1, patients in the experimental group will receive gabapentin three times daily. Dose of gabapentin will be 100 mg for patients <50 kg and 200 mg for patients > 50 kg. Gabapentin will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with gabapentin for the remainder of their doses upon discharge.
76077552|NCT04353544|Other|delayed cord clamping|delayed cord clamping
76077553|NCT03017404|Drug|Doxorubicin Hydrochloride Liposome Injection|
76077554|NCT03017404|Drug|Cyclophosphamide|
76077555|NCT03017404|Drug|docetaxel|
76077556|NCT00953212|Drug|beta blockers|metoprolol 25mg by mouth every 6 hours
75634197|NCT00592384|Drug|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
75634198|NCT00592384|Drug|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
75634199|NCT00707590|Drug|BMS-767778 or Placebo|
75634200|NCT05473468|Drug|Famitinib|a single oral dose of [14C]famitinib (25 mg/150 uCi suspension)
75634201|NCT00846040|Other|Reduced fat diet|RF (selective reduction of 85% of baseline fat calories per day)
75634202|NCT00846040|Other|Reduced carbohydrate diet|RC (selective reduction of 60% of baseline carbohydrate calories per day)
75327245|NCT05520216|Behavioral|chest circumference measurement|Measurements will be taken from the axillary (4th rib level - two fingers below the axilla), epigastric (xiphoid process level) and subcostal (9th rib level) regions at the time of normal, maximal inspiration, and maximal expiration using a tape measure while the patient is in a sitting position. The tape measure will be placed in the area to be measured. Care will be taken that there is no folding or horizontal level difference in the tape measure and that the fingers are not under the tape measure. Normal respiration will be measured first and recorded in centimeters (cm). The patient will then be asked to take a deep, long breath towards the bottom of the tape measure. The value obtained will be recorded as the deep inspiration value. Immediately after deep inspiration, the patient will be asked to make a deep and long expiration. The obtained value will be recorded as deep expiration.
75469022|NCT03454646|Drug|cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)|"The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
75469023|NCT03441061|Biological|Inotuzumab Ozogamicin|Given IV
75634203|NCT00846040|Drug|Drug: f-18 fallypride|Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound [18F] fallypride which binds competitively with dopamine to the D2 receptor.
75634204|NCT00846040|Device|fMRI|Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
75634205|NCT00846040|Device|PET|Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
76077557|NCT00953212|Drug|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
75634206|NCT02611336|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
75798492|NCT03867240|Other|Placebo|Placebo will be given 30 minutes prior to being transported to the operating room. Placebo will be identically appearing to gabapentin. Starting postoperative day 1, control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group. It will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with placebo for the remainder of their doses upon discharge.
75920276|NCT02109393|Other|MIRT+Lokomat|It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
75920277|NCT02112981|Device|Sirolimus Eluting Coronary Stent|BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.
75920278|NCT02112981|Device|Everolimus-eluting Coronary stent|Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
75634207|NCT04115722|Other|IBD ACTIVIT|Effect of IBD disease and activity of disease on coagulation parameters
76077558|NCT00953212|Drug|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
75634208|NCT00704704|Drug|5-aza-cytidine and Thalidomide|5-AZA-Cytidine 75mg/m2 5 days a month. 12 months. Thalidomide 50mg orally daily for 6 months.
76077559|NCT00953290|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
76077560|NCT03024190|Other|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
76077561|NCT03024190|Other|stretching exercise|15- min stretching exercise for upper extremity twice daily
75634209|NCT00707824|Drug|nalbuphine|nalbuphine 5 mg epidural
75634210|NCT00707824|Drug|nalbuphine|nalbuphine 10 mg epidural
75634211|NCT00707824|Other|NSS|NSS
76077562|NCT03024190|Other|OT rehabilitation program|regular rehabilitation program for 3 weeks
76077563|NCT03024268|Device|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
76077564|NCT03034408|Drug|Nalmefene|
75634212|NCT00826228|Drug|teriparatide|teriparatide 20ug daily sc for 6 months
75798493|NCT03468660|Behavioral|Auditory training with feedback|Experimental group receives phoneme-level and sentence-level training with feedback
75798494|NCT03468660|Behavioral|Listening paradigm with no feedback|Active controls listen to acoustic stimuli with no feedback
76077565|NCT03034408|Drug|Baclofen|
76077566|NCT03034408|Drug|Placebo Oral Capsule|
76077567|NCT03034252|Procedure|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
75634213|NCT00826228|Other|weight-bearing|device assisted walking
75634214|NCT00825994|Drug|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA]), PO [by mouth], qd [every day]
75327246|NCT05520216|Behavioral|Maximum Breath Hold Test|During the breath-hold measurement, the subject will sit in a chair with a backrest. He will take a deep breath through his nose. We do not want maneuvers (Valsalva and Müller) and diaphragm contractions that will affect the breath-hold time, so volunteers will be observed throughout the test. The test will be terminated as soon as involuntary diaphragm contractions are seen. This test will be applied 3 times by resting the volunteer with breaks for 5 minutes. The average of 3 test results will be taken (Lin, Y. C.: Effect of O2 and CO2 on breath hold breaking point. In The Physiology of Breath Hold Diving. (eds): CEG Lundgren, M Ferringo, Undersea and Hyperbaric Medical Society Inc, Bethesda, Maryland, p: 75-87 1987.).
75327247|NCT05520216|Behavioral|Sit and Reach|While the participant is sitting on the floor with his back to the wall and his legs are fully extended in front of him, his knees should be in full contact with the floor. The box will be placed on the sole of the participant's feet (without shoes) in full contact with the volunteer's feet. The participant will be instructed to lean forward as slowly as possible, keeping their fingertips level with each other and their legs straight on the floor. He will be asked to slowly lie down along the ruler three times, and on the third attempt the volunteer will be instructed to reach out as far as possible and hold for 2 seconds. This value will be saved
75920279|NCT02115789|Behavioral|Visual Analog Scale|"Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being normal skin and 10 being the worst scar imaginable."
76077568|NCT03017092|Behavioral|Tablet-guided tobacco intervention|This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
76077569|NCT03016858|Procedure|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
75920280|NCT02115867|Dietary Supplement|Probiotic|Symprove probiotic
75920281|NCT03553485|Device|Transcutaneous vagus nerve stimulation|The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.
75327248|NCT02754310|Other|Variation of scenarios|Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
75327249|NCT02754310|Other|Repeated scenarios|The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
75920282|NCT03553485|Device|Sham|Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.
76077570|NCT03023020|Drug|Aspirin|Dosing per current guidelines and local practice
75327250|NCT03384563|Drug|Dexmedetomidine|Dexmedetomidine 9 arms
75634215|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
75634216|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
75634217|NCT00825916|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
75634218|NCT00791479|Drug|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
75634219|NCT00791479|Drug|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
75920283|NCT03553485|Radiation|Radiotherapy|Standard treatment for included patients
76077571|NCT03023020|Drug|P2Y12 inhibitor|Dosing per current guidelines and local practice
76077572|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
75327251|NCT03375437|Genetic|Blood and tumor samples|"FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2*10mL EDTA)"
75327252|NCT04946526|Dietary Supplement|Broccoli seed extract|2 capsules, one dose
75327253|NCT04946526|Dietary Supplement|Broccoli seed extract with mustard seed powder|2 capsules, one dose
75920284|NCT02115945|Other|DN4 test|The DN4 test was used to evaluate neuropathic pain.
76077573|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
76077574|NCT00087555|Drug|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
76077575|NCT03016780|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.
76077576|NCT03016780|Other|Normal Saline|Normal saline and the traditional treatments for ulcerative colitisin in part 2.
76077577|NCT03022318|Drug|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
76077578|NCT01677897|Drug|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
76077579|NCT03033940|Radiation|Observational use of fluoroscopy|
76077580|NCT03483363|Drug|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure.
75634220|NCT00890097|Drug|AL-8309B Ophthalmic Solution|
75634221|NCT00890097|Drug|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
75634222|NCT02831751|Biological|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
76077581|NCT03483363|Drug|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
76077582|NCT03483363|Drug|intravenous (IV) prophylactic antibiotic|All groups with receive standard parenteral (IV) prophylactic antibiotic.
75920285|NCT02115945|Other|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
75634223|NCT02831751|Biological|60 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
75634224|NCT02831751|Biological|FluLaval® Tetra (15 µg/strain)|Single dose of a licensed quadrivalent vaccine
75634225|NCT02831751|Biological|Fluzone® High-Dose (60 µg/strain)|Single dose of a licensed trivalent vaccine
75634226|NCT00913458|Drug|etanercept|
75634227|NCT05208333|Drug|Albenza 200Mg Tablet|"Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection"
75920286|NCT02115945|Other|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
75920287|NCT02115945|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
75634228|NCT04201041|Procedure|pudendal nerve pulsed radiofrequency|received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach
75634229|NCT04309773|Drug|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose
75920288|NCT02115945|Procedure|femoral block|
75920289|NCT02115945|Procedure|epidural block|
75920290|NCT02113137|Drug|group 1: drug: chlorine dioxide|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
75469024|NCT03407469|Behavioral|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
75469025|NCT03401762|Behavioral|MCI|EMG-controlled game
75634230|NCT04309773|Drug|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose
75634231|NCT02827305|Drug|Gotukola|10 ml of mouthwash to be rinsed for duration of 60 seconds
75634232|NCT02827305|Procedure|Scaling|Ultrasonic scaling was performed in one visit on both upper and lower arches.
75798495|NCT01172964|Drug|flucytosine|Given orally
75798496|NCT01172964|Other|polymerase chain reaction|Correlative studies
76077583|NCT03033628|Device|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
76077584|NCT03033628|Device|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
75798497|NCT01172964|Other|immunohistochemistry staining method|Correlative studies
75798498|NCT01172964|Biological|gene therapy|Injected at the time of the surgery to resect the tumor
75798499|NCT01172964|Other|pharmacological study|Correlative studies
75920291|NCT02113137|Device|group 2: device: small tooth brush for tongue cleaning|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 2 - additional practice of tongue cleaning by a small tooth brush two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
75920292|NCT02116023|Other|Orange flavored beverage|
76077585|NCT01677975|Procedure|FNA (fine needle aspiration)|
76077586|NCT03016702|Other|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
75920293|NCT02113215|Procedure|Stable Isotope Infusion|9-hour infusion of stable isotope tracers
75920294|NCT02116101|Dietary Supplement|Bright Momchilovtsi Yogurt|"Oral consumption of Bright Momchilovtis Yogurt containing 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus~Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo."
76077587|NCT03016702|Other|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
76077588|NCT00956020|Biological|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
76077589|NCT03086733|Drug|Metformin|850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
76077590|NCT03017170|Drug|Dried Cranberry|"Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit."
76077591|NCT03017170|Drug|Placebo Oral Capsule|Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
75798500|NCT01172964|Other|3-Tesla magnetic resonance imaging|Correlative studies
75798501|NCT01172964|Other|laboratory biomarker analysis|Correlative studies
75798502|NCT01172964|Procedure|therapeutic conventional surgery|Surgery to resect the tumor
75327254|NCT02748070|Drug|Prednisone|
75327255|NCT02748070|Drug|Flonase|
75327256|NCT03216629|Behavioral|"Saying sorry"|"The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?"
75327257|NCT05514756|Device|Active t-VNS|Active t-VNS at 8 Hz for up to 60 minutes will be applied to the left cymba conchae
75327258|NCT05514756|Device|Sham t-VNS|Sham t-VNS at 8 Hz for up to 60 minutes will be applied to the left earlobe
75327259|NCT05514756|Other|Baseline assessments|Baselines assessments with no stimulation will serve as control in this three-part crossover design
75469026|NCT03401762|Behavioral|Sham MCI|Sham control game
76077592|NCT05346549|Behavioral|High energy preload|Tests the extent to which participants reduce their food intake at a meal following ingestion of a high energy preload drink.
76077593|NCT05346549|Behavioral|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
75469027|NCT03336268|Behavioral|POINT|A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
75920295|NCT02116101|Dietary Supplement|Bright Dairy Beverage|Oral consumption of Bright Dairy Beverage Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
75327260|NCT05311709|Drug|sotorasib|single group, all patients receive sotorasib
75327261|NCT02748928|Device|UltraShape Power|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
75469028|NCT03328026|Biological|SV-BR-1-GM|SV-BR-1-GM inoculation intradermally at 4 sites.
75469029|NCT03328026|Drug|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
75327262|NCT05310383|Combination Product|Tislelizumab plus radiotherapy|During the period of radiotherapy, patients receiveTislelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Tislelizumab 200mg q3W was administered for up to 35 cycles (up to approximately 2 years) after radiotherapy until disease progression or toxicity.
75327263|NCT02574312|Device|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
75469030|NCT03328026|Drug|Interferon Inoculation|Post-inoculation low dose Interferon into the vaccination sites ~2 days after SV-BR-1-GM inoculation.
76077594|NCT03033862|Device|Bioresorbable Vascular Scaffold|Bioresorbable Vascular Scaffold
76077595|NCT03033862|Device|Drug Eluting Stent|Drug Eluting Stent
76077596|NCT00086619|Drug|synthetic hPTH 1-34|Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
75327264|NCT02574312|Device|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
75469031|NCT03328026|Drug|retifanlimab|retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
75634233|NCT02827227|Biological|lymphocytes immunophenotyping|"The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded."
75634234|NCT02827929|Behavioral|Education|3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
76077597|NCT00945958|Drug|SPARC0913|One drop of SPARC0913 in affected eye once daily for 24 weeks
75327265|NCT05310305|Combination Product|Radiotherapy for targeted lesions and PD-1 antibody|Radiotherapy for targeted lesions in all enrolled participants, with concurrent PD-1 antibody. Patients may or may not accept subsequent PD-1 as maintenance therapy.
75327266|NCT04424784|Biological|5% O2|5% oxygen will be used during oocyte retrieval, fertilization check and embryo grading
75469032|NCT03324932|Drug|Denosumab Injection|AI intake + denosumab injection per 6 months VS only AI intake
75469033|NCT03297645|Behavioral|School|CHWs will ensure that families submit required health paperwork (e.g., asthma action plan, medication release form) and confirm with school nurses that children have the appropriate medications. School nurses will be given a standardized protocol to follow with clear guidelines for caring for students with asthma. The CHW assigned to the family will work with the school nurse to ensure that communication with the medical provider is occurring.
75634235|NCT02827851|Procedure|Liposuction|
75920296|NCT02113293|Drug|CyclASol®|Cyclosporine A Solution
75920297|NCT02113293|Drug|Placebo (vehicle)|Vehicle Solution
75920298|NCT02116179|Behavioral|DVD Intervention|Participants will be randomly assigned, with a baseline and 3 month follow up assessments
75920299|NCT02116257|Drug|Propacetamol|total 4g of Propacetamol added to patient's PCA regimen
75920300|NCT02116257|Drug|PCA regimen|
76077598|NCT00085917|Drug|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
76077599|NCT00085917|Drug|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
76077600|NCT03416283|Behavioral|Remote Monitoring|Remote BP monitoring and medication adherence
76077601|NCT03416283|Behavioral|Remote Monitoring + Social Support|"Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)"
76077602|NCT03416049|Device|PEMF therapy with a high-power PEMF device|The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
76077603|NCT03416049|Device|PEMF therapy with a medium PEMF power device|The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
76077604|NCT03416049|Device|PEMF therapy with a low-power PEMF device|The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
75920301|NCT02109627|Drug|Ficlatuzumab|5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
75327267|NCT05519826|Device|Vascular surgery|"POLYMAILLE® EXTRA THIN vascular prostheses are indicated for replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral) and/or femoro-popliteal bypass above the knee."
75327268|NCT05519670|Drug|Niraparib Oral Product|Niraparib + capecitabine treatment
75634236|NCT02827851|Other|SVF isolation|SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
75634237|NCT02827851|Other|Intraarticular administration of autologous SVF|
75327269|NCT05519592|Drug|Ropivacaine injection|Intramuscular ropivacaine injection (gluteus maximus and rectus femoris)
75327270|NCT05519592|Drug|Sodium Chloride Injection|Intramuscular sodium chloride injection (gluteus maximus and rectus femoris)
75327271|NCT05519514|Drug|Cortiment|Budesonide 9 mg prolonged release tablets
75327272|NCT05519514|Drug|Budesonide|Experimental (Budesonide 9 mg prolonged release tablets)
75327273|NCT02756572|Drug|Cladribine|Given IV
75327274|NCT02756572|Drug|Cyclosporine|Given PO
75327275|NCT02756572|Drug|Cytarabine|Given IV
75634238|NCT02829333|Other|general anesthesia and patient controlled intravenous analgesia|Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation
75634239|NCT02829333|Other|spinal anesthesia and continuous postoperative epidural analgesia|Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation
75327276|NCT02756572|Biological|Filgrastim|Given SC
75327277|NCT02756572|Drug|Fludarabine Phosphate|
75327278|NCT02756572|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
75327279|NCT02756572|Other|Laboratory Biomarker Analysis|Correlative studies
75327280|NCT02756572|Drug|Melphalan|Given IV
75327281|NCT02756572|Drug|Mitoxantrone Hydrochloride|Given IV
75327282|NCT02756572|Drug|Mycophenolate Mofetil|Given PO
75634240|NCT05251662|Drug|Sintilimab|200mg IV d1 Q3W
75784311|NCT06192628|Behavioral|Parkinson's Exercise and Education Programme and Behavioural Change|"A 12-week programme of exercise, education and behavioural change techniques to support exercise adherence and exercise self-efficacy~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist and participant)~Additional techniques addressing behavioural regulation include firstly, an exercise diary completed independently at home, secondly, the rationale and the intended functional benefit and expectations of the exercise programme clearly explained, thirdly individual weekly conversations to reflect on progress, expectations, solutions to barriers, and goals. Finally, peer support is strongly encouraged through the in-class support, and a social media networking group."
75784312|NCT06192615|Drug|Intravenous Dexmedetomidine|Intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg)
75784313|NCT06192615|Drug|Sublingual Dexmedetomidine|Sublingual dexmedetomidine (120 μg)
75784314|NCT06192615|Drug|Intravenous Placebo|Intravenous placebo of 0.9% saline administered over 40 minutes
75327283|NCT02756572|Other|Questionnaire Administration|Ancillary studies
75327284|NCT02756572|Drug|Sirolimus|Given PO
75327285|NCT02756572|Radiation|Total-Body Irradiation|Undergo TBI
75327286|NCT02756572|Drug|Melphalan Hydrochloride|Given IV
75634241|NCT05251662|Drug|IBI305|7.5mg/kg IV d1 Q3W
75634242|NCT05251662|Drug|GEMOX|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
75634243|NCT02829177|Drug|Allopurinol|
75634244|NCT02829177|Drug|Placebo|
75634245|NCT00631878|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
75634246|NCT05112081|Drug|Botulinum toxin type A|The group will receive a solution of 100 units BTX with 10 ml sterile saline close to the superficial inguinal ring.
75634247|NCT05112081|Other|Sterile saline|The group will receive a solution of 10 ml sterile saline close to the superficial inguinal ring.
75634248|NCT00913380|Radiation|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
75634249|NCT00913380|Radiation|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
75920302|NCT02109627|Drug|Cytarabine|2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.
75920303|NCT02113371|Behavioral|Intervention|
75920304|NCT02116413|Procedure|Fluid challenge|The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.
75920305|NCT02116413|Procedure|Cardiac ultrasound|Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.
75327287|NCT01049035|Biological|Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate|0.5 milliliter (mL), Intramuscular (IM) injection
75327288|NCT01049035|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)|0.5 mL, IM injection
75327289|NCT01049035|Biological|M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live|0.5 mL, Subcutaneous (SC) injection
75327290|NCT01049035|Biological|Varicella Virus Vaccine Live|0.5 mL, SC injection
75327291|NCT01049035|Biological|Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
75327292|NCT01049035|Biological|Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
75327293|NCT01049035|Biological|Rotavirus Vaccine|oral
75327294|NCT01049035|Biological|Hepatitis B Vaccine|0.5 mL, IM injection
75327295|NCT05134272|Device|Neuromuscular electrical stimulation|Neuromuscular Electrical Stimulation will be applied by the therapist to infant's finger flexors and extensor for 15 min./day, 3x/week.
75327296|NCT05134272|Behavioral|Modified constraint induced movement therapy|Modified CIMT will consist of constraint 24 hours/day using a splint in addition to therapy two hours/day, 3x/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week.
75327297|NCT05134272|Behavioral|Standard care for infant with asymmetrical hand function|Infants will receive one hour of therapy, one time/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week. In addition the infant will wear a sock on their preferred hand during the hour of therapy/home program activity.
75327298|NCT05131698|Combination Product|Tislelizumab and Lenvatinib|"TACE therapy: For transarterial infusion chemotherapy before or after TACE embolization, each drug will generally be diluted with 0.9% sodium chloride solution or 5% dextrose solution 150-250 mL and injected slowly into the target artery for ≥20 min. Subsequent TACE therapy will be administered on an as-needed basis as assessed by the clinician, with each treatment interval exceeding 6 weeks and no more than 6 treatments in total.~Lenvatinib: The starting dose of lenvatinib will depend on the patient's baseline weight: if baseline weight ≥ 60 kg, patients will receive 12 mg of lenvatinib administered once daily; if baseline weight < 60 kg, patients will receive 8 mg of lenvatinib once daily. TACE therapy will be given 3 days apart.~Tirelizumab: Tirelizumab 200 mg , intravenous infusion on the same day as the first dose of lenvatinib, once every three weeks.~Translated with www.DeepL.com/Translator (free version)"
75327299|NCT00371722|Procedure|Appendectomy|
75327300|NCT01724983|Drug|ketamine|
75327301|NCT01724983|Drug|fentanyl|
75920306|NCT02116491|Device|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
76077605|NCT03416049|Device|PEMF therapy with the sham PEMF device|The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
76077606|NCT00084747|Drug|bortezomib|
76077607|NCT04402671|Other|non-cross-linked porcine skin collagen membrane|non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.
76077608|NCT04402671|Other|glutaraldehyde cross-linked bovine collagen membrane|glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.
76077609|NCT01678287|Drug|ASP1941|oral
75327302|NCT02973958|Drug|Bupivacaine|See active comparator description
75327303|NCT02973958|Drug|Sevoflurane|See active comparator description
75327304|NCT02973958|Drug|Acetaminophen|See active comparator description
75327305|NCT02973958|Drug|Ibuprofen|See active comparator description
75327306|NCT02973958|Drug|Ketorolac|See experimental arm description
75634250|NCT04244097|Drug|Bupivacaine Hydrochloride|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
75634251|NCT04244097|Drug|Neostigmine|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
75634252|NCT02827773|Other|Talking Pill Bottle|Made by Talking Rx
75784315|NCT06192615|Drug|Sublingual Placebo|Inert sublingual film
75327307|NCT05519280|Behavioral|the Biopsychosocial-Spiritual Group Intervention|The Experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
75327308|NCT01048333|Drug|Formoterol|Formoterol Turbuhaler 9 μg and Placebo Diskus
75327309|NCT01048333|Drug|Salmeterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler
75634253|NCT04681872|Procedure|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
75327310|NCT01048333|Drug|Placebo|Placebo Diskus and Placebo Turbuhaler
75327311|NCT05513976|Drug|SHR4640 tablet|SHR4640 tablet 5mg
75784316|NCT06192602|Behavioral|AIM_AT|The program consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team.
75784317|NCT06192602|Behavioral|CPG|Psychoeducation group program (12-18 members/group) consists of 10 two-hour sessions, weekly/biweekly (similarly, 4-month duration) and is guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psychoeducation programs for psychosis.
75784318|NCT06192602|Behavioral|TAU|Routine/Usual care only (control) group participants (and the two treatment groups) will receive usual community mental healthcare services.
76077610|NCT01678287|Drug|Placebo|oral
76077611|NCT01678365|Drug|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
75327312|NCT05513976|Drug|SHR4640 tablet|SHR4640 tablet 10mg
75327313|NCT05513976|Drug|febuxostat tablet|febuxostat tablet 40mg or 60mg or 80mg based on prior medication
75327314|NCT05513976|Drug|SHR4640 placebo tablet|SHR4640 placebo tablet 5 or 10mg
75327315|NCT04335526|Drug|Cholestyramine Resin|Change bile acid pool by cholestyramine treatment
75327316|NCT05525832|Other|Normal saline|Nasopharyngeal washes with NaCl 0.9%
75327317|NCT05348746|Other|Advanced Analysis of Polymorphism|Assessment of Plasmodium falciparum drug resistance. Target P. falciparum drug resistance genes: Pfk13 propeller, Pfdhfr and Pfdhps. The polymorphisms analysis of the propeller domain of the Pfk13 gene will be performed by PCR amplifications and subsequent sequencing. Analysis of Pfdhfr gene at codons 51, 59, 108 and Pfdhps gene at codon positions 436, 437, 540, 581, 613 will be done by means of amplifications and subsequent Sanger sequencing. Molecular studies will be performed only for research purposes and will have no impact on the clinical management of study patients.
75327318|NCT01725295|Other|NST|A form of physical therapy
75634254|NCT04681872|Procedure|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
75469034|NCT03297645|Behavioral|Asthma education|CHWs will deliver evidence-based asthma education to parents and children. Content is drawn from existing asthma management programs, and adapted for families in Richmond. Between sessions, CHWs will call parents at least monthly to check in and assess family asthma management, including healthcare utilization since the last contact.
76077612|NCT00946270|Drug|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
75634255|NCT04681872|Procedure|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus
75634256|NCT02826993|Device|CCE in incomplete Colonoscopies|When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
75634257|NCT02829255|Other|altitude exposure|altitude exposure
75634258|NCT04244331|Diagnostic Test|CCO|Determination of COO in tumor biopsies from patients with GBDD using the Lymph2Cx assay using NanoString tectology
75634259|NCT02829021|Device|FLIR ThermaCAM P-65|Women recalled for assessment after positive screening mammography were offered dynamic infrared thermography before clinical mammography and further tests.
75634260|NCT00785629|Drug|Calcium acetate|
75634261|NCT00785629|Drug|Lanthanum Carbonate|
75634262|NCT00785629|Drug|Sevelamer Carbonate|
75784319|NCT06192576|Drug|Olipudase alfa|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
75784320|NCT06192550|Device|Profound Matrix™ System|Study subjects will be treated with the Profound Matrix System
76077613|NCT00946270|Drug|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
75920307|NCT02116569|Drug|Daratumumab|Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.
75920308|NCT02116647|Behavioral|Psychoanalytic therapy|
76077614|NCT00946270|Drug|CC-4047|3.0 mg capsules daily by mouth day 1 through 21.
76077615|NCT03478293|Device|iStent inject surgery|Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
75634263|NCT00785629|Drug|Placebo|
75469035|NCT03297645|Behavioral|Home environmental remediation|Healthy Homes will complete home-based environmental assessments using evidence-based protocols. Healthy Homes will provide real-time education and share information about their findings and recommendations for action. Families are provided with low-cost intervention materials (e.g., filters, pillow covers), as well as behavioral modifications to aid in the reduction of asthma triggers in the home.
75469036|NCT03297645|Behavioral|Informational mail|Family will be mailed publicly available asthma information every 3 months.
75920309|NCT02109783|Dietary Supplement|Caffeine 2mg|Caffeine 2 mg versus 4 mg/kg or placebo
76077616|NCT03021850|Procedure|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
76077617|NCT03475641|Drug|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
76077618|NCT03475641|Procedure|The current standard treatment|Tumescent anesthesia.
75327319|NCT01725295|Other|Hydrotherapy|
75634264|NCT05097183|Procedure|Accurate Commissural Alignment (ACA)|Software based, computed tomography analysis that allows planification of accurate commissural alignment of TAVR by inserting the delivery system in a patient-specific degree of rotation.
75634265|NCT00916344|Device|EVIA Pacemaker|patient has standard indication for pacemaker therapy
75469037|NCT03266783|Drug|Apixaban|Refer to Apixaban group
75469038|NCT03266783|Drug|Rivaroxaban|Refer to Rivaroxaban group
75469039|NCT03242343|Device|VasQ|An external support device for AV fistula
75634266|NCT00915733|Drug|cilostazol|100 mg twice daily for at least 1 month
75634267|NCT00915733|Drug|clopidogrel (Plavix)|150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
75920310|NCT02109783|Dietary Supplement|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
76077619|NCT01678521|Procedure|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
76077620|NCT03021616|Other|energy drink|32oz of commercially available energy drink
76077621|NCT03021616|Other|Moxifloxacin 400mg|400mg moxifloxacin active control drink
76077622|NCT03021616|Other|Placebo|Placebo drink
76077623|NCT03021694|Dietary Supplement|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
75798503|NCT01172964|Biological|E. coli CD-expressing genetically modified neural stem cells|Injected at the time of the surgery to resect the tumor
75798504|NCT03866928|Drug|Stiripentol|1500 mg of stiripentol b.i.d.
75798505|NCT03435354|Behavioral|Physical activity counselling|Clinician counselling about physical activity using standardized tools to promote daily physical activity.
75634268|NCT00915733|Genetic|CYP2C19|CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19*2 (rs4244285, c. 681G>A, p.P227P), and CYP2C19*3 (rs4986893, c. 636G>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
75327320|NCT05525754|Procedure|computed tomography-guided nasotracheal intubation|Before intubation, the lower part of the nasal valve region, aka the narrowest area of the nasal passage, was measured by calculating the distance between the anterior border of the inferior concha and the septal cartilage
75327321|NCT05348434|Procedure|3D printed polyether ether ketone facial implants in repairing maxillofacial deformities|All patients underwent Computed Tomography (CT) scans under the condition of providing a large number of slices (more than 200 slices) per axis, and the thickness of each slice is less than 1 mm with 64-bit resolution, Then the design of the required facial implant was carried out in coordination between the designer and the surgical team. The final form of the facial implant was printed from PolyEther Ether Ketone (PEEK), and then surgical work was performed for patients under general anaesthetic according to the appropriate surgical entrance. The implants were fixed in place using titanium screws
75327322|NCT05348278|Drug|Urea cream|apply 10% urea cream at both hands and feet twice daily
75327323|NCT02323113|Drug|TAK-659|TAK-659 tablets.
76077624|NCT03086187|Device|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
75327324|NCT05519202|Drug|S-1,Oxaliplatin, Penpulimab|S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
76077625|NCT02245828|Drug|QCC374|Single and multiple ascending doses of QCC374
75469040|NCT03231735|Device|Mid frequency ventilation|Mechanical ventilator used at rates > 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
75634269|NCT00915733|Drug|aspirin (Acetylsalicylic acid)|aspirin 100 mg qd
75634270|NCT04245969|Device|Experimental: 448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the shoulder and thoracic area
75634271|NCT04245969|Other|Sham comparator|A simulation of 448kilohertz capacitive resistive monopolar radiofrequency will be carried out to make believe the patient to be treated through this equipment.
75634272|NCT04245969|Other|No intervention|These participants will be assessed at the same time than the rest of participants. They will not receive any kind of treatment.
75634273|NCT02828865|Device|Irreversible Electroporation (IRE) System|
76077626|NCT02245828|Drug|Placebo|Placebo comparator
75327325|NCT05519124|Device|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
75327326|NCT05519046|Device|Cardiac Contractility Modulation (CCM)|Cardiac Contractility Modulation (CCM) implantation
75327327|NCT05519046|Device|CRT|Cardiac Resynchronization Therapy
75327328|NCT04934670|Drug|T-Guard|T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
75327329|NCT04934670|Drug|Ruxolitinib|Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
75634274|NCT02604043|Other|pH monitoring|After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.
75634275|NCT02604043|Other|accelerometer monitoring|Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
75327330|NCT02759146|Other|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
75327331|NCT02759146|Other|Meditative Practices|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
75634276|NCT00913770|Behavioral|Brief Negotiation Interview (BNI)|Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
75634277|NCT00913770|Drug|Buprenorphine Initiation|
75920311|NCT02109783|Dietary Supplement|Caffeine 0|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
75920312|NCT02109861|Drug|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
75920313|NCT02109861|Drug|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
75920314|NCT02109861|Drug|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
75920315|NCT02113605|Other|Cognitive behavior therapy|Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
75920316|NCT02118753|Drug|Eplerenone|eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
75920317|NCT02118909|Drug|Pracinostat|
75920318|NCT02118909|Drug|Itraconazole|
75920319|NCT02118909|Drug|Ciprofloxacin|
75920320|NCT02116725|Other|Shower gel with zinc|Standard shower gel (Sanex) supplemented with zinc sulfate.
75920321|NCT02116725|Other|Plain shower gel|Standard shower gel (Sanex).
75920322|NCT02116725|Other|Distilled water|Sterile distilled Water.
75920323|NCT02118987|Drug|Omalizumab|
76077627|NCT00956254|Drug|Fentanyl sublingual spray|Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
76077628|NCT03021148|Other|Questionnaire|Administration of questionnaire.
75327332|NCT02281383|Biological|Bacillus Calmette-Guérin (BCG)|
75327333|NCT01047553|Drug|Formoterol (OT)|9 μg/dose, Inhaled, twice daily for 52 weeks
75327334|NCT05525442|Procedure|percutaneous cholecystostomy|Transhepatic gallbladder drainage was performed under ultrasound guidance after local anesthesia was administered by interventional radiology to patients with acute cholecystitis. Subsequently, an 8-10 Fr pigtail catheter was inserted into the gallbladder using a guide wire under fluoroscopy.
75327335|NCT04337398|Behavioral|Exercise training for 12 weeks (wearables)|Activity trackers with adaptive weekly step goals, weekly walking groups and coaching.
75327336|NCT04337398|Behavioral|Exercise training for 12 weeks (wearables and exergames)|Activity trackers with adaptive weekly step goals, weekly walking groups, coaching and exercise programme based on exergames (aerobic, resistance and stretching training three weekly group sessions).
75634278|NCT02602639|Device|Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)|Participants will strengthen their quadriceps and hamstrings using electrical stimulation for up to 12 weeks (using an Odstock 4 channel neuromuscular stimulator). Then participants will use a seated rower (Concept 2 Rower, fitted with a backrest that allows those with spinal cord injury to engage in rowing) in conjunction with the electrical stimulation for 12-24 weeks.
75634279|NCT04617366|Other|Individualized rTMS strategy|It will adjust the rTMS parameters based on the results of fNIRS.
75634280|NCT04617366|Other|Traditional rTMS strategy|The patients will always be given low-frequency rTMS to contralesional M1.
75784321|NCT06192537|Behavioral|A role-playing exercise by utilizing an obesity suit in a simulation scenario|All participants will be asked to wear an obesity simulation suit (Unisex obesity Simulation suit, Erler-Zimmer, Germany) and to participate in a standardized scenario that simulates meetings between a person with obesity and a 'registered dietitian'. The 'registered dietitian' will be presented by a professional role-player and the scenario will encompass different levels of weight bias through dialogue and the use of inappropriate equipment.
75327337|NCT00372346|Procedure|Transplantation of autologous endothelial progenitor cells|
75327338|NCT05120232|Behavioral|Unified Protocol|A transdiagnostic, cognitive behavioral therapy.
75327339|NCT05120232|Behavioral|Modified Unified Protocol (UP+)|A transdiagnostic, cognitive behavioral therapy.
75327340|NCT03837717|Behavioral|Holding|Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.
75327341|NCT03837717|Other|Saliva collection|Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin
75327342|NCT03837717|Behavioral|No Holding|Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.
75327343|NCT02760862|Drug|hydrocortisone 100mg.|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
75327344|NCT02760862|Drug|mannitol 20% intravenous fluid|group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
75469041|NCT03231735|Device|Standard frequency ventilation|Mechanical ventilator used at rates < 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
75634281|NCT00780559|Behavioral|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
75634282|NCT00780559|Behavioral|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
75634283|NCT02826291|Device|RD-100i, OSNA|quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
75634284|NCT02826057|Other|Targeted temperature management (33 degree Celsius)|
75634285|NCT02602249|Biological|MUC1-gene-DC-CTL|MUC1-gene-DC-CTL will be used against tumor cells.
75634286|NCT02602249|Biological|MUC1-peptide-DC-CTL|MUC1-peptide-DC-CTL will be used against tumor cells.
75634287|NCT00912912|Drug|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
75634288|NCT00889005|Other|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
75634289|NCT04104997|Drug|5% GLH8NDE|5% GLH8NDE as eye drops
75634290|NCT04104997|Drug|Placebos|Placebo as eye drops
75634291|NCT02824653|Biological|Mesenchymal Stem Cells|Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
75634292|NCT04714944|Dietary Supplement|Placebo|Supplementation period 12 weeks
75920324|NCT02119143|Dietary Supplement|vitamines and minerals|given for 24 weeks, after 4 week wash out of all supplements and dietetic products
75920325|NCT02119143|Dietary Supplement|placebo|given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
75920326|NCT02116881|Procedure|Colorectal Surgery|Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
75920327|NCT02122965|Other|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
75920328|NCT02119221|Drug|Copanlisib (BAY80-6946)|Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of [14C]
75920329|NCT02116959|Drug|Melphalan|
75920330|NCT02116959|Drug|Carboplatin|
75920331|NCT02116959|Drug|Etoposide|
75920332|NCT02116959|Drug|Vincristine|
75327345|NCT05720637|Drug|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
75634293|NCT04714944|Dietary Supplement|Whole fiber product|Supplementation period 12 weeks
75634294|NCT00779857|Device|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
75634295|NCT04104919|Drug|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
75634296|NCT04104919|Drug|Placebo 6 mL|Single preoperative intrathecal injection
75634297|NCT04102891|Other|Microbiota modulation diet|The Collect&Go shopping carts of the 400 participants will be adapted by replacing food products by healthier alternative ones based on the Flemish food-based dietary guidelines and the microbiota modulation diet guidelines for the control and study arm respectively. Based on these guidelines, and the habitual dietary pattern and level of food literacy of the participant, personalized dietary advice will be provided. A dietitian helpline will be available for further nutritional issues as well.
75634298|NCT04241913|Behavioral|Mom Power Intervention|Mom Power is a 10-week therapeutic intervention for at-risk families that incorporates elements of several evidence based practices. It combines didactic material with mindbody self-care skills and in vivo practice to improve the quality of attachment between parent and child, and to reduce the psychopathology of at-risk parents. The child team component provides each child with one-on-one care focusing on meeting the child's social-emotional needs and providing attachment-related experiences within a developmental framework.
75634299|NCT04201275|Drug|HEC74647PA capsule|Capsule administered orally once daily
75634300|NCT04201275|Drug|placebo|HEC74647PA capsule matching placebo administered orally once daily
75634301|NCT00913692|Drug|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
75634302|NCT00913692|Drug|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
75327346|NCT05720637|Device|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
75327347|NCT05720637|Device|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20*1.5mm or φ0.20*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
75327348|NCT03838107|Behavioral|observation and measure of trajectory of recovery in CRPS|Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
75327349|NCT05720559|Drug|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area
75327350|NCT05720559|Drug|S1|Orally on d2-d15 at 20 mg three times daily
75327351|NCT05720559|Drug|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
75327352|NCT05720559|Drug|Metronidazole|Metronidazole 0.4g/time, qd
75469042|NCT03219359|Procedure|Autologous stem cell transplant|Hematopoietic stem cell transplantation
75327353|NCT05720559|Drug|Vitamin A|Vitamin A 25,000 units/time, qd
75327354|NCT05720559|Drug|Folic acid|Folic acid 0.4 mg/time, qd
75469043|NCT03219359|Drug|Cyclophosphamide|Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ >20x104/ml then leukapheresis daily to collection goal
75634303|NCT04710108|Other|Health Communication|Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.
75634304|NCT04242303|Procedure|Total knee replacement|"Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts."
75920333|NCT02123043|Behavioral|Motor learning-based training|The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
75327355|NCT05720559|Drug|Capecitabine|Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.
75327356|NCT05720247|Diagnostic Test|Fibroscan|Fibroscan is a safe and effective test using ultrasound to measure liver elasticity and can detect early signs of liver disease even before a patient shows symptoms.
75327357|NCT05720247|Behavioral|Brief Intervention|Short counselling session to discuss drinking behavior, risks to health and available sources of treatment and support.
75327358|NCT02761252|Drug|Bilastine 20mg|
75327359|NCT02761252|Drug|Montelukast 10mg|
75327360|NCT02761252|Drug|Placebo Bilastine 20mg|
75327361|NCT02761252|Drug|Placebo Montelukast 10mg|
75634305|NCT04810026|Behavioral|Education|Healthy-lifestyle and diabetes-related virtual education (text and videos)
75634306|NCT04810026|Behavioral|Meal delivery|breakfast, lunch, and dinner adhering to the longevity diet macro-nutrient profiles
75634307|NCT04810026|Behavioral|Lifestyle coaching|calls with coach and/or nutritionist, access to Facebook community support group
75634308|NCT04787328|Drug|HA121-28 tablets|HA121-28 450 mg, po, QD×21 days, every 4 weeks (28 days)
75634309|NCT00784927|Biological|rituximab|
75327362|NCT05714475|Procedure|Pancreas surgery|"Criteria~Inclusion Criteria:~Isolated pancreatic metastases from Colorectal cancer~Previous surgery for colorectal cancer~Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas~pancreaticoduodenectomy total-pancreatectomy distal-pancreatectomy other metastases resection"
75327363|NCT00357357|Drug|HF0220|comparison of different dosages of drug
75327364|NCT05448742|Device|Biplanar PSI slope-reducing MOWHTO.|High tibial osteotomy (HTO) is a widely performed procedure in case of varus knee with medial compartment osteoarthritis (OA), with medial-opening wedge version performed more often than lateral-closing wedge one. While in most cases the goal of medial-opening wedge HTO (MOWHTO) is isolated correction of coronal limb alignment, intentional or unintentional increase of posterior tibial slope (PTS) after MOWHTO can occur, however its extent is usually limited and depends on accurate hinge axis placement. One of the ideas developed to improve accuracy of hinge axis placement and accuracy of biplanar correction are Patient-Specific Instruments (PSI). Our intervention is novel, biplanar, medial-opening wedge, posterior tibial slope-reducing high tibial osteotomy aided by PSI, with tibial tuberosity serving as hinge axis.
75327365|NCT01046695|Device|TENS Unit|TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
75327366|NCT05443984|Drug|JP-1366 20mg|1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
75327367|NCT05443984|Drug|Esomeprazole 40mg|1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
75327368|NCT01725607|Drug|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
75327369|NCT01725607|Procedure|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
75327370|NCT02763124|Procedure|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
75327371|NCT03304379|Drug|Fasinumab|Solution for injection in pre-filled syringe
75327372|NCT03304379|Other|Diclofenac|NSAID active comparator (capsule)
75327373|NCT03304379|Other|Celecoxib|NSAID active comparator (capsule)
75327374|NCT03304379|Drug|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
75327375|NCT00915967|Drug|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
75327376|NCT00915967|Drug|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
75327377|NCT05327842|Device|New training simulator|Participants receive training with new simulator
75327378|NCT05327842|Device|Traditional simulator|Participants receive traditional training
75327379|NCT02763826|Device|transcranial direct current stimulation|brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
75634310|NCT00784927|Drug|cyclophosphamide|
75634311|NCT00784927|Drug|dexamethasone|
75327380|NCT05032560|Drug|ABX464|Drug: ABX464 ABX464 is a new anti-inflammatory drug
75327381|NCT05032560|Drug|Placebo|Drug: Matching Placebo placebo matching with ABX464
75327382|NCT02766244|Device|ICG/SPY|indocyanine green fluorescence imaging
75327383|NCT02766244|Drug|Antibiotic Ointment|Antibiotic ointment
75327384|NCT05031078|Biological|Gardasil|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap."
75327385|NCT05031078|Drug|Lidocaine injections|"1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg."
75327386|NCT03406117|Drug|HAT1|All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
75327387|NCT03406117|Other|Saline Solution|Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
75327388|NCT05513664|Drug|Osimertinib|80 or 160 mg/qd
75327389|NCT03216395|Device|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
75634312|NCT00784927|Drug|lenalidomide|
75634313|NCT00637884|Drug|Fexofenadine HCl|
75634314|NCT00915421|Procedure|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
75634315|NCT04785378|Device|Medical mask|Participants will carry out field tests one day wearing a medical mask and the other day without a mask.
75634316|NCT04785378|Other|Field tests|Participants will perform 6 MWT and ISWT tests to determine their exercise capacity, and a 30-second sit and stand test to determine lower extremity endurance.
75634317|NCT00779779|Biological|Rotarix™|Two oral doses, with at least 4 weeks interval in-between
75920334|NCT02123043|Behavioral|Practice wheeling|The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
75920335|NCT02119377|Other|questionnaire|
75327390|NCT03216395|Device|Hemo-clipping|Hemo-clipping <=20 clips
75327391|NCT03216395|Device|thermo-coagulation|contact thermo-coagulation < = 8 pulses
75327392|NCT03216395|Drug|Epinephrine|epinephrine injection (diluted 1:1000) beneath peptic ulcer <20 mls
75327393|NCT03401125|Other|Medical file data collection|The information described in the 'outcome measures' section will be collected from the medical files of the patients.
75634318|NCT04203342|Drug|Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
75634319|NCT04203342|Drug|Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
75327394|NCT04337086|Device|T4k Appliance|The pre-fabricated, hard, polyurethane, pink T4K™ (Myo functional research Co., Australia) was used in the study. It consisted of: facial bows, lingual bows / tongue guard, lingual tag / tongue tag, dental channels with a pre-determined bite position and a lip bumper. In the first week, the patients were instructed to gradually increase the wearing time of the appliance during the daytime. By the second week, the patients were instructed to wear the appliance achieving at least 8 hours during sleeping. The Trainer usually needs no adjustments. The patients were asked to place it themselves inside their mouths. The distal ends of the appliance were trimmed 2-3 mm with an acrylic bur on a straight hand piece if they were too long or the patient could not keep his lips together. By the end of the first 4 weeks, the patients were wearing the appliances minimum of 1 hour during the day plus the overnight wear following the manufacturer's instructions.
75327395|NCT04337086|Device|Twin block appliance|The twin block was used, and instructions were given to wear the appliance nearly full-time. Selective sequential inter-occlusal trimming was done monthly after the 2nd month in the occlusal surface of the maxillary bite blocks to clear over the mandibular molars allowing their eruption in a more favourable mesial direction and to increase the vertical dimension. Trimming was done in the fitting surface over the maxillary and mandibular premolars whenever needed to allow their full eruption and to level the occlusal plane
75327396|NCT03405961|Device|Carestream 3600 intra oral scan|"Carestream 3600 is CE marked intra oral scanner manufactured by Carestream Dental. It is already licensed for use in dentistry to produce digital study models. The scanner is 220 x 38 x 58 mm large and operates using video capture technology. It emits no radiation.~Carestream 3600 is connected to a computer via a USB port and a computer software (CS Model +) converts the scan into digital study models using trigonometric calculations. The software is then used to take measurements on the digital models and calculate PAR scores"
75327397|NCT03838835|Behavioral|Augmented equine-facilitated CBT group program|Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
75327398|NCT03838835|Behavioral|TAU is equine-facilitated group therapy|TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
75327399|NCT03838835|Other|WLC|WLC consists of youth who are not yet receiving any services at Gallop NYC.
75327400|NCT02767492|Device|BioD Restore|Investigational product, BioD Restore, will be injected into the articular space of the knee.
75327401|NCT02767492|Drug|Kenalog|Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
75327402|NCT05525208|Biological|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
75327403|NCT05525208|Biological|Active Comparator|The Pfizer-BioNTech® COVID-19 vaccine or BNT162b2, is an mRNA vaccine encoding a P2 mutant spike protein (PS 2) and formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA (modRNA).
75634320|NCT04203342|Drug|Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)|Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
75634321|NCT00915889|Behavioral|telephone-based intervention|Either 6 or 8 telephone educational sessions
75634322|NCT00915889|Other|counseling intervention|counseling and communications studies
75634323|NCT00915889|Other|questionnaire administration|Ancillary studies
75784322|NCT06192511|Behavioral|Educational Website and Video|The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.
75784323|NCT06192472|Procedure|Chemical sclerotherapy|Sclerosant will be retained within the vein
75784324|NCT06192472|Drug|1% Sodium Tetradecyl Sulphate|1% Sodium Tetradecyl Sulphate
75784325|NCT06192472|Drug|3% Sodium Tetradecyl Sulphate|3% Sodium Tetradecyl Sulphate
75920336|NCT03553173|Other|So-Lo-Mo|So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).
76077629|NCT03085953|Behavioral|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
75920337|NCT03553173|Behavioral|Psychological advice|Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
75327404|NCT05310149|Device|Prosthetic intervention with maxillary obturator prosthesis|Prosthetic intervention with maxillary obturator prosthesis is necessary to restore the contours of the resected palate and to recreate the functional separation of the oral cavity and sinus and nasal cavities. Followings are the objectives of maxillary obturator Restoration of esthetics or cosmetic appearance of the patient, Restoration of function, Protection of tissues, Therapeutic or healing effect and psychological therapy.
75920338|NCT03553173|Drug|Bupropion Pill|Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
75920339|NCT03553173|Drug|Varenicline Pill|Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
76077630|NCT03085953|Other|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
75327405|NCT01044433|Drug|lapatinib ditosylate|Given orally
75327406|NCT01044433|Drug|capecitabine|Given orally
75327407|NCT04336774|Device|Caption AI|Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.
75327408|NCT04336930|Diagnostic Test|Pupillary pain index (PPI)|Measurement of PPI with a pupillometer
75327409|NCT03400969|Device|Glycerol 17%|Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.
75327410|NCT03400969|Device|Aequasyal (OGT)|Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.
75327411|NCT03400969|Device|Salient (new product)|Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
75634324|NCT00915889|Other|study of socioeconomic and demographic variables|Ancillary Studies
75327412|NCT04381871|Dietary Supplement|Acacia Senegal|Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
75634325|NCT00915889|Procedure|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
75634326|NCT04572438|Procedure|Tracheostomy|Tracheostomy is a procedure that creates a surgical airway in the windpipe to improve oxygenation of the lungs.
75634327|NCT04102969|Behavioral|Benson Relaxation Technique|Benson relaxation technique will be performed two times a day for 10 minutes during the study period ( two months) for the intervention group.
75634328|NCT04102969|Other|Nutrition Package Session|A nutrition package session will be given to the control group.
75784326|NCT06192472|Drug|0.5% Polidocanol|0.5% Polidocanol
75920340|NCT02117037|Other|blood sample|
75920341|NCT01330017|Drug|Phenylephrine HCl|10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
76077631|NCT03020680|Dietary Supplement|Coenzyme Q10|To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
75327413|NCT04381871|Dietary Supplement|Pectin|Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
75327414|NCT04337008|Other|blood draw|20 mL blood draw will be performed at J1 et J7
75327415|NCT03400813|Behavioral|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.
75469044|NCT03219359|Drug|Cyclophosphamide|Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
75469045|NCT03219359|Drug|Thymoglobulin|Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
75469046|NCT03219359|Drug|Methylprednisolone|Day -3 to -1: 1 gram prior to each ATG dose
75469047|NCT03219359|Drug|Vedolizumab|Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
75634329|NCT04203108|Drug|ATG|In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
75634330|NCT04203108|Drug|CsA|In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
75634331|NCT04203108|Drug|MTX|In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
75634332|NCT04203108|Drug|MMF|In both groups, MMF will be administrated at a dose of 1.0g/d.
75784327|NCT06192472|Drug|3% Polidcanol|3% Polidcanol
75784328|NCT06192459|Device|Modality physical therapy|Magnetotherapy, low-energy laser, electrotherapy, etc.
75920342|NCT01330017|Drug|Placebo|Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
75920343|NCT01330017|Drug|Loratadine|10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
75920344|NCT02117115|Radiation|Dynamic contrast-enhanced computed tomography|CT scan performed between Day +7 and Day +14.
75920345|NCT02117115|Drug|Ioversol|To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
75327416|NCT03262415|Device|LabPatch Continuous Glucose Monitoring (CGM)|"The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides.~The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm [0.618] x 15.7 mm [0.618]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.~A wire that connects the chip to a laptop that continuously captures glucose data."
75327417|NCT05518890|Other|Diet Only|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks
75327418|NCT05518890|Other|Diet plus Exercise|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks. Participants will also be asked to perform 5x30 minute cycling exercise sessions at home. Each week the intensity of exercise will be increased (week 1 = RPE 12, week 2 = RPE 13, week 3 = RPE 14, week 4 = RPE 15)
75327419|NCT04336696|Procedure|Total thyroidectomy and central neck dissection|
75327420|NCT02758210|Device|Use of a Tablet|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using Tablet and while using the Tablet. The measured position of the Tablets tested will be normal routine position (noting at least 6 inches/15 centimeters from their pacemaker).
75469048|NCT03180034|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
75469049|NCT03180034|Other|Questionnaire Administration|Ancillary studies
76077632|NCT03086109|Other|Risk factors|Risk factors associated bone degenerative diseases
75469050|NCT03180034|Biological|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
75469051|NCT03180034|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
75784329|NCT06192459|Other|Combined therapy:|Muscle strength and joint mobility training, provided twice a week for a duration of three weeks (with assessment on the second session of the third week), totaling six rehabilitation sessions. Additionally, patients are required to engage in daily home-based rehabilitation. During the hospital-based training sessions, a therapist provides guidance and conducts the training. This process encompasses progressive muscle strength training, manual joint mobilization, and active and passive joint movement training to achieve effective rehabilitation outcomes. Each rehabilitation session in the hospital lasts approximately 30 minutes. For home-based training, patients must follow the therapist's instructions and complete 20-30 minutes of home rehabilitation every day. Modality physical therapy are are carry out as usual.
76077633|NCT03020212|Drug|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
75798506|NCT03866694|Behavioral|BRIGHT|Dyadic therapeutic parenting intervention (BRIGHT) beginning in third trimester of pregnancy through six months postpartum focusing on child-parent relationship, mental health, infant social-emotional development, and recovery. Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic.
76077634|NCT01678599|Drug|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients > 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
76077635|NCT03445221|Dietary Supplement|IV Immunonutrition|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
76077636|NCT03445221|Dietary Supplement|Conventional Diet|patients will continue preoperative oral conventional diet.
76077637|NCT03019822|Drug|LSD|100ug per os, single dose
76077638|NCT03019822|Drug|MDMA|125mg per os, single dose
76077639|NCT03019822|Drug|Amphetamine|40.3mg per os, single dose
76077640|NCT03019822|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs
75469052|NCT03169712|Behavioral|Cognitive Behavioral Therapy for PTSD|Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
75469053|NCT03169712|Behavioral|Imagery Rehearsal Therapy|IRT protocol published by Nappi and collaborators (2010)
75469054|NCT03158805|Drug|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
75469055|NCT03158805|Other|Placebo|Placebo injection
75469056|NCT03126331|Drug|Nivolumab|"Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more."
75327421|NCT02758210|Device|Use of a Smart Phone|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using a Smart phone and while using the Smart phone. The position of the Smart phone tested will be normal position at the ear and while texting (noting at least 6 inches/15 centimeters from their pacemaker).
75327422|NCT04334512|Drug|Hydroxychloroquine|Treatment with hydroxychloroquine
75327423|NCT04334512|Drug|Azithromycin|Treatment with azithromycin
75327424|NCT04334512|Dietary Supplement|Vitamin C|Treatment with vitamin C
75327425|NCT04334512|Dietary Supplement|Vitamin D|Treatment with vitamin D
75469057|NCT03126331|Drug|Ipilimumab|Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
75469058|NCT03121352|Drug|Carboplatin|AUC 4.5 IV day 1 of 21-day cycle
75327426|NCT04334512|Dietary Supplement|Zinc|Treatment with Zinc
75327427|NCT01043185|Drug|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
75327428|NCT01043185|Drug|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
75327429|NCT01043185|Drug|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
75327430|NCT01043185|Drug|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
75920346|NCT02123199|Drug|Indacaterol (Onbrez®) /QAB149|
75920347|NCT02123277|Device|Balloon catheter for the Eustachian tube|Balloon catheter is inserted in the Eustachian tube to dilate it.
75920348|NCT02251899|Behavioral|Disease-Management intervention|The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
75920349|NCT02117271|Device|continuous positive airway pressure|device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
75920350|NCT02117271|Other|Breathe Right ®|Nasal dilator strip treatment used during sleep to open the nasal airway
75327431|NCT01043185|Drug|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
76077641|NCT01678677|Biological|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
76077642|NCT01678677|Biological|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
76077643|NCT01678677|Biological|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
76077644|NCT01678677|Biological|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
75327432|NCT05207254|Diagnostic Test|Ultrasonic test|Ultrasonic test to the patient's head, neck and jaw area.
75327433|NCT02769442|Device|Terumo SurFlash Plus catheter|
75327434|NCT02769442|Device|BD Insyte Autoguard catheter|
75327435|NCT01042093|Drug|Ropivacaine|Ropivacaine 5mg/ml (49.25 ml)
75784330|NCT06192433|Device|High-frequency repetitive transcranial magnetic stimulation (40Hz)|Participants in this group receive high-frequency TMS at 40 Hz. The TMS intervention is applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient undergoes this TMS treatment for a course of 10 consecutive working days. The specific parameters for TMS include pulses at 40 Hz with an intensity set at 40% of the maximum intensity. Each pulse lasts for 2 seconds, followed by a 58-second rest period. On each treatment day, patients receive 30 sets of stimulation, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
75920351|NCT02119845|Device|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
75920352|NCT02117505|Drug|Formulation 2|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
75920353|NCT02117505|Drug|Formulation 1|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5*30 mg tablet=150 mg) in one of the treatment periods.
75920354|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions
75920355|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions
75920356|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions
75920357|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
75920358|NCT02117661|Dietary Supplement|L-carnitine capsules|Oral
75327436|NCT01042093|Drug|Toradol|Toradol 30mg/ml (1 ml)
75327437|NCT01042093|Drug|Clonidine|Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
75327438|NCT01042093|Drug|Epinephrine|Epinephrine 1 mg/ml (0.5 ml)
75327439|NCT03400735|Combination Product|Cefdinir/clavulanic acide 300/125 mg film-coated tablets|Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.
75327440|NCT03400735|Drug|Cefdinir 300Mg Capsule|Cefdinir is used as comparator
75327441|NCT03400657|Procedure|Multi-disciplinary Treatment|due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
75327442|NCT02770846|Procedure|Immediate loading|
75327443|NCT02770846|Procedure|Delayed loading|
75327444|NCT04737928|Drug|Latanoprost|latanoprost 0.05%(one drop, once daily)
75327445|NCT04737928|Drug|tafluprost|tafluprost 0.015% (one drop, once daily)
75327446|NCT04336540|Other|Menu configuration (presence of energy labelling)|Restaurant menus are altered to accommodate energy labelling intervention
75327447|NCT04336540|Other|Menu configuration (more lower energy options added)|Restaurant menus are altered to include more lower energy options
75469059|NCT03121352|Drug|Nab-paclitaxel|75mg/m2 IV days 1, 8 and 15 of 21-day cycle
75469060|NCT03121352|Drug|Pembrolizumab|200 mg IV every 21 days
75920359|NCT02117661|Dietary Supplement|Cellulose capsules|oral
75920360|NCT02117739|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
75920361|NCT02117739|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
76077645|NCT01678677|Biological|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
76077646|NCT01678677|Biological|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
76077647|NCT01678677|Biological|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
76077648|NCT01678677|Biological|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
76077649|NCT01678677|Drug|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
75920362|NCT05293587|Behavioral|Physical Activity|Physical activity sessions will take place 3x/week over six weeks and will take between 45 and 60 minutes for each session. The sessions will be led by a Serenity Behavioral Health CPS as part of the PEERS program and will be supervised by research staff. Sessions will occur at public parks. Transportation to the park will be provided by Serenity Behavioral Health. Structured activities will include a warm-up, a mix of simple exercises requiring minimal supplies (such as walking, basic aerobic movements, and body weight resistance exercises), and cool-down. Sessions will be held in green park environments with shade, restrooms, and level walking paths.
75327448|NCT04336462|Device|oxyhydrogen|Hydrogen-Oxygen Generator with Nebulizer Model: AMS-H-03 Gas production: 2.0 L/min, 2.5 L/min, and 3 L/min, three gears in total (in this study, the gas production of each machine is 3 L/min, two sets are connected and used together by three-way connection, and the total gas production is 6 L/min.) Manufacturer: Shanghai Asclepius Meditech Co., Ltd.
75920363|NCT02251509|Drug|Carvedilol|
75920364|NCT02251509|Drug|Metoprolol tartrate|
76077650|NCT03019978|Other|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
76077651|NCT03443193|Other|Exercise training|Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
75327449|NCT04336462|Device|Oxygen|oxygen inhaled,3 L/min . 6 hour a day.
75327450|NCT00372502|Procedure|Modified EGDT|Early goal directed therapy with lactate clearance
75327451|NCT00372502|Procedure|Standard EGDT|Early goal directed therapy
75327452|NCT00371800|Drug|cinnamon|
75634333|NCT04102657|Other|Intermittent Fasting|Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
75634334|NCT04102657|Other|Free-Living Diet|Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.
75634335|NCT04102657|Other|Left Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
75784331|NCT06192433|Device|Moderately high-frequency repetitive transcranial magnetic stimulation (10Hz)|Participants in this group receive moderately high-frequency TMS at 10 Hz. Similar to the high-frequency group, the TMS intervention targets the bilateral dorsolateral prefrontal cortex (DLPFC) and is administered for a course of 10 consecutive working days. The TMS parameters for this group involve pulses at 10 Hz with an intensity set at 90% of the maximum intensity. Each pulse lasts for 4 seconds, followed by a 56-second rest period. As in the high-frequency group, patients in this group also receive 30 sets of stimulation per treatment day, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
76077652|NCT03019900|Procedure|Red blood cells transfusions|The survey was designated to assess the practices of blood transfusion, specifically about the threshold and factors that can modify this threshold.
76077653|NCT03019432|Behavioral|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
76077654|NCT00946348|Drug|Dronabinol|Dronabinol 10 mg or 15 mg
76077655|NCT00946348|Drug|Cannabis|Cannabis cigarette
76077656|NCT00081159|Drug|Doxorubicin hydrochloride|Doxorubicin 20 mg/m^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
75634336|NCT04102657|Other|Right Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
75784332|NCT06192420|Drug|Traumeel®|3g of gel three times daily for 7days (+1 day visit window)
75784333|NCT06192420|Drug|Diclofenac sodium gel 1%|3g of gel three times daily for 7days (+1 day visit window)
75784334|NCT06192420|Drug|Placebo|3g of gel three times daily for 7days (+1 day visit window)
75920365|NCT03553017|Device|Binocular OCT|Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
76077657|NCT00081159|Drug|Goserelin acetate|
76077658|NCT00081159|Drug|Leuprolide acetate|
76077659|NCT00081159|Drug|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
76077660|NCT00081159|Procedure|orchiectomy|
76077661|NCT00081159|Radiation|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
76077662|NCT03033550|Behavioral|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
76077663|NCT03033706|Procedure|Pulse pressure variation guided fluid therapy|Pulse pressure variation obtained from invasive blood pressure waveform
76077664|NCT03033706|Procedure|Traditional fluid therapy|4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
76077665|NCT03033706|Procedure|Brain tumor excision|Brain tumor excision under general anesthesia
76077666|NCT03033472|Drug|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
76077667|NCT03033472|Drug|Oral Placebo|Oral Placebo 30 minutes before treatment
76077668|NCT01679067|Procedure|colonoscopy with endoscopic biopsies|
76077669|NCT02981836|Biological|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
76077670|NCT02981836|Biological|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
75327453|NCT01041859|Drug|Tapentadol extended release (ER)|Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
75327454|NCT01041859|Drug|Placebo|Form= tablet, route= oral use. Matching placebo twice daily.
75920366|NCT02119923|Behavioral|Working memory training|The WM consisted of two tasks; the Number-letter task (Rogers & Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.
76077671|NCT03033004|Device|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
75327455|NCT04827550|Other|STUDY|Fibromyalgia Patient
75327456|NCT03405805|Biological|13-valent pneumococcal conjugate vaccine (PCV13)|Vaccination with PCV13
75327457|NCT00371878|Biological|7-valent pneumococcal conjugate vaccine (Prevnar)|
75327458|NCT03400423|Drug|Caffeine|Oral administration of 1.2mg/kg of powdered caffeine with water.
75327459|NCT03400423|Behavioral|Moderate Intensity Exercise|Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)*0.6.
75634337|NCT04834206|Drug|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
75634338|NCT04834206|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
75634339|NCT04834206|Drug|Nedaplatin|Concurrent chemotherapy. nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
75327460|NCT04336072|Behavioral|RFPP|
75327461|NCT04336072|Behavioral|TFCBT|
75634340|NCT02602717|Other|lymph nodes cyto-punction|
75327462|NCT04377139|Procedure|Prophylaxis|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
75327463|NCT04377139|Procedure|Preemptive|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
75327464|NCT00372580|Procedure|blood test|
75327465|NCT03405727|Dietary Supplement|Oral dietary supplements|Protein enriched diet
75634341|NCT04107415|Other|yoga|A total of 12 yoga sessions, 2 sessions a week for 6 weeks, was applied to the patients in the experimental group.
75634342|NCT05227248|Dietary Supplement|Dark chocolate|Patients were administered 20 grams of dark chocolate
75634343|NCT05227248|Dietary Supplement|Milk Chocolate|Patients were administered 7.5 grams of milk chocolate
75634344|NCT00631722|Drug|Quatiapine Fumarate|600-750mg/day
75784335|NCT06192407|Dietary Supplement|High Oleic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.
75784336|NCT06192407|Dietary Supplement|High Palmitic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.
75798507|NCT03866694|Other|STAR/TAU+|Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic
76077672|NCT03033004|Device|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
76077673|NCT03033004|Device|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
76077674|NCT03085641|Device|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
76077675|NCT03033082|Other|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used."
76077676|NCT03033160|Drug|Estradiol Ring|
75327466|NCT05349994|Other|Extended physiotherapy|At admission to the surgical ward after ICU care, participants received an individual rehabilitation plan developed in collaboration with the participants and the ward-based physiotherapist. The rehabilitation plan included specified exercises for 1- 2 sessions of approximately 30 minutes a day. For example breathing exercises, practicing transfer in and out of bed and from sitting to standing, stairclimbing, and walking with or without walking aids.
75327467|NCT01040845|Drug|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
75327468|NCT01040845|Drug|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
75327469|NCT01040845|Drug|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
75327470|NCT05349916|Other|Control|300 g rice porridge + 150 ml drinking water
75634345|NCT00631722|Drug|Haloperidol|12-20mg/day
75634346|NCT00845728|Drug|Indacaterol 150 µg|Indacaterol 150 µg o.d. delivered via SDDPI
75634347|NCT00845728|Drug|Tiotropium|Tiotropium 18 µg o.d. delivered via handihaler®
75634348|NCT00779467|Drug|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
75634349|NCT00779467|Drug|Bupivacaine|
75634350|NCT00779467|Drug|fentanyl|fentanyl 2 mcg/ml
76077677|NCT03019354|Device|high-flow nasal oxygen|Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.
76077678|NCT03019354|Device|Oxygen mask|Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
75327471|NCT05349916|Other|Isomaltodextrin Low Dose|300 g rice porridge + (5 g IMD in 150 ml drinking water)
75327472|NCT05349916|Other|Isomaltodextrin High Dose|300 g rice porridge + (10 g IMD in 150 ml drinking water)
75327473|NCT05349916|Other|GPC partially digestible maltodextrin|300 g rice porridge + (15 g GPC fiber in 150 ml drinking water)
75327474|NCT05349916|Other|Resistant Starch Type 4|300 g rice porridge + (15 g RS4 starch in 150 ml drinking water)
75327475|NCT00371956|Drug|raloxifene|60mg/day
75634351|NCT04203030|Behavioral|Physical Activity|Participants will meet in a weekly group session to discuss a topic related to physical activity and physical function and participate in group-based physical activity. Participants will also have instructions to participate in physical activity outside of the weekly sessions, incrementally increasing their total physical activity over the intervention period.
75327476|NCT00371956|Drug|placebo|tab 1 daily
75327477|NCT04334200|Behavioral|Cultivate yourself: support for caregivers of dementia persons|The Chinese cultural values, including philosophical thoughts, will be included in the intervention. Chinese philosophical thoughts including the concepts of moderation, improving oneself, and harmony with nature will be used in the intervention. Confucianism, Taoism and Buddhism are the foundation for Chinese for concepts of health and illness, health promotion, and health-seeking behavior. Therefore, it is necessary to incorporate such philosophies in the sessions of the program.
75327478|NCT05349604|Dietary Supplement|Garlic extracts|One intake in total
75327479|NCT05349604|Dietary Supplement|Placebo|One intake in total
75327480|NCT04335838|Other|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
75327481|NCT01040689|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
75327482|NCT01040689|Drug|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
75327483|NCT01040689|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
75327484|NCT01040689|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
75327485|NCT01040689|Drug|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
75327486|NCT04133584|Biological|EV71 +SIV|Give 2 doses of EV71 +SIV, get 2 blood samples before the first dose and 28-43 days after the last dose.
75327487|NCT04133584|Biological|EV71|Give 2 doses of EV71 , get 2 blood samples before the first dose and 28-43 days after the last
75327488|NCT04133584|Biological|SIV|Give 2 doses of SIV , get 2 blood samples before the first dose and 28-43 days after the last
75327489|NCT00372658|Drug|1% Lidocaine intracervical injection|
75327490|NCT01048255|Drug|VX-765|300mg Oral Tablet, 900mg TID
75634352|NCT04273230|Other|Microalbuminuria detection|Detection of microalbumin in urine
75634353|NCT04559100|Radiation|chest radiography|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
75634354|NCT04559100|Radiation|thoracic computed tomography scan|6 and 12 months after hospital discharge, if the patient had a CT scan upon admission to the hospital. If the study is normal at 6 months it will not be repeated at 12 months.
75634355|NCT04559100|Diagnostic Test|spirometry|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
75798508|NCT02526576|Biological|Stromal Vasular Fraction|The stromal vascular fraction obtained from adipose tissue will be added to the graft
75798509|NCT02526576|Procedure|Biopsy|A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
75798510|NCT01172496|Drug|treprostinil diethanolamine|Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
76077679|NCT04348539|Other|Balance training|32 sessions will be held twice a week, with each session taking an average of 45 minutes
76077680|NCT00958282|Drug|lisdexamfetamine/Behavior Therapy|
76077681|NCT00958282|Other|placebo|
75327491|NCT04109638|Device|Endonovo SofPulse|The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
75327492|NCT03400189|Drug|Sulthiame|Single dose (50, 100, 200 mg)
75327493|NCT04429048|Device|Acupressure elastic band (Sea-Band)|The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy
75327494|NCT04429048|Device|General elastic band (no bud)|general elastic band was put over bilateral PC6 acupoints
75327495|NCT01043263|Drug|EN3324 (axomadol)|twice daily dosing
75327496|NCT01043263|Drug|Placebo|twice daily dosing
75327497|NCT04334434|Other|Telerehabilitation|15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist
75327498|NCT04087174|Drug|Capivasertib|Patients will receive multiple oral dose of capivasertib.
75327499|NCT04087174|Drug|Enzalutamide|Patients will receive 160 mg oral dose of enzalutamide.
75327500|NCT04087174|Drug|Abiraterone|Patients will receive 1000 mg oral dose of abiraterone.
75327501|NCT01043029|Drug|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
75327502|NCT01043029|Drug|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
75327503|NCT04065958|Behavioral|Yoga-mindfulness|Body-mind therapy
75920367|NCT02119923|Behavioral|Placebo training|Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers & Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
75920368|NCT02117895|Procedure|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
75327504|NCT04065958|Behavioral|Patient education and physiotherapy|Lectures and physiotherapy
75327505|NCT04294342|Behavioral|Active Comparator: Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program. Each session consisting of warm-up, balance, strength, power and break fall exercises. There is clear a progression within the 10 week program in three main blocks. Block 1: learning the exercises and principle movements, Block 2 more resistance and advance falling techniques, Block 3 Power training and falling strategies from stand up positions.
75327506|NCT04282954|Drug|JP-1366|JP-1366, QD
75327507|NCT04282954|Drug|JP-1366 placebo|JP-1366 placebo, QD
75634356|NCT04559100|Diagnostic Test|Diffusing capacity of carbon monoxide|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
75327508|NCT04282954|Drug|Esomeprazole 40mg|Esomeprazole 40mg, QD
75327509|NCT04282954|Drug|Esomeprazole placebo|Esomeprazole placebo, QD
75634357|NCT04559100|Diagnostic Test|6 minute walk test|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
75327510|NCT04791358|Diagnostic Test|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
75920369|NCT02117895|Procedure|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
75920370|NCT02117973|Procedure|iAssist Technique using Persona system vs. the conventional technique using Persona system|
75327511|NCT03881800|Other|titration- blood sample|Ceftazidime titration
75327512|NCT05337436|Biological|Lymphatic drainage|Biological determination in plasma:
75327513|NCT05337436|Biological|Total and ionized magnesium|Total and ionized magnesium
75327514|NCT05337436|Biological|Total and ionized calcium|Total and ionized calcium
75327515|NCT04755712|Drug|Rachianesthesia|Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
75327516|NCT04755712|Drug|Sodium Chloride Injection|"Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2)."
75327517|NCT04755712|Drug|Morphine|Morphine via pump (patient controlled analgesia)
75327518|NCT04746274|Behavioral|Online large-group one-session multicomponent positive psychological intervention|The intervention is aimed at enhancing positive mental health by using components from positive psychology or positive psychotherapy. These include for exapmle using character strengths, savoring the moment, goal setting and goal attainment. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
75327519|NCT04746274|Behavioral|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|The intervention is aimed at reducing dysfunctional thoughts by applying strategies known from the cognitive therapy of depression. These include for example identification of automatic thoughts and cognitive biases as well as evaluating evidence for and against automatic thoughts. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
75327520|NCT04733638|Device|Viz ICH VOLUME|Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.
75634358|NCT04559100|Diagnostic Test|saint george respiratory questionnaire|6 and 12 months after hospital discharge.
75634359|NCT00778921|Drug|Amlodipine 10 mg|Amlodipine 10 mg
75634360|NCT00778921|Drug|Aliskiren 150|Aliskiren/Amlodipine 150/10 mg
75634361|NCT00778921|Drug|Amlodipine 300|Aliskiren/Amlodipine 300/10 mg
75634362|NCT04173312|Combination Product|Bupivacaine infusion|Local systemic Infusion of anesthetic
75634363|NCT04173312|Combination Product|Saline|Local systemic infusion of saline
75634364|NCT00915876|Drug|Paricalcitol|paricalcitol 1 mcg QD x 8 weeks
75920371|NCT02118051|Drug|Ganirelix 0.25 mg.|Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle> 14mm.
75920372|NCT02118051|Drug|Recombinant choriogonadotropin alfa|Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles> 17 mm are observed
75920373|NCT02118051|Drug|Micronized natural progesterone.|Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
75920374|NCT02118129|Behavioral|an educational video|
75920375|NCT02118129|Other|wait listed|
75920376|NCT02123355|Drug|Induction of anesthesia|Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
75327521|NCT05330026|Combination Product|Diaphragm´s study during yoga breathing|Study and compare the activation of the diaphragm during different breaths: rest, ujjayi and pursed lips
75920377|NCT02123355|Procedure|Intubation|After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35~40 mmHg，pulse oxygen saturation is more than 95%.
75327522|NCT05285488|Other|"focused attention group"|"focused attention group: adult subjects practicing focused attention meditation.~contemplation group: adult subjects practicing contemplation meditation."
75920378|NCT02123355|Drug|Sevoflurane, remifentanil ,vecuronium|Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
75327523|NCT04334044|Drug|Ruxolitinib Oral Tablet|Ruxolitinib 5 mg twice a day
75327524|NCT03576976|Behavioral|Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
75469061|NCT03114501|Behavioral|Yoga|Participants receive yoga sessions up to 5 days per week, based on the patient's schedule, over the course of patients' Radiation Therapy (up to 15 sessions, 45-60 min. each). Yoga sessions audio and video recorded.
75784337|NCT06192394|Other|Chewing Gum|Patients will be asked to chew xylitol gum for 20 minutes every 2 hours (17.00-19.00, 19.00-21.00, 21.00-23.00) after drinking the X-M Diet syrup prescribed the day before the colonoscopy procedure. After the enema is given on the day of the colonoscopy, they will be asked to chew gum for 20 minutes every 2 hours until one hour before the scheduled procedure time. Xylitol is a naturally occurring five-carbon sugar alcohol (C5H12O5) found in fruits and vegetables such as plums, strawberries, cauliflower, and pumpkin. It is similar in taste to sucrose but contains 40% fewer calories than other carbohydrates (1 gram of xylitol = 2.4 calories). Xylitol has positive effects on dental health and may also have beneficial impacts on other systems such as immunity, respiratory, and digestive systems. Since xylitol is not digested by human enzymes, it has a laxative effect. In the study, sugar-free gum with xylitol will be used.
75327525|NCT04335448|Other|No intervention is planed|No intervention is planed
75798511|NCT01279824|Behavioral|swallowing therapy|Standardized behavioral swallowing intervention
75469062|NCT03114501|Behavioral|Yoga Questionnaire|Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
75469063|NCT03114501|Behavioral|Symptom Questionnaires|Symptom questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
75634365|NCT00915876|Drug|Placebo|Placebo for Paricalcitol 1 mcg QD x 8 weeks
75327526|NCT05220670|Other|HIIT|It will be carried out after a 10-minute warm-up period with joint mobility exercises and dynamic stretching. The intervention will consist of a training in which intense work intervals and active rest periods are combined using a cycle ergometer. The session will be divided into 4 intervals of 4 minutes duration at an intensity of 85-95% of the maximum heart rate [MHR], individually controlled during all sessions (Polar Team pro®), followed by active rest intervals of 3 minutes duration at 50-70% FCM. After training, a 10-minute cool-down of gentle pedaling and joint range exercises will be carried out.
75327527|NCT05220670|Other|MICT|Heating phase identical to the previous one. Subsequently, the participants will perform training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be individually controlled (Polar Team pro®). The session will conclude with a cool-down phase identical to the previous one.
75469064|NCT03113929|Radiation|MRI|Research MRI
75634366|NCT04079244|Behavioral|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children."
75634367|NCT04079244|Behavioral|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
75634368|NCT04550988|Other|feasibility study|The aim of this study is to evaluate the possibility of establishing a patient-based ultrasound monitoring of the knee (representing a target joint accessible with any hand) with a handheld device.
75634369|NCT00776659|Other|Aromasin|Non-Interventional study design.
75920379|NCT02123355|Drug|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
75920380|NCT02123355|Drug|Placebo|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
75920381|NCT02123433|Biological|pneumococcal conjugate 13 valent vaccine|"Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm."
75920382|NCT02120313|Other|inpatient rehabilitation|
76077682|NCT03019276|Drug|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
76077683|NCT03032926|Behavioral|Open Trial|Behavioral Intervention
76077684|NCT03033316|Drug|Dexamethasone|
76077685|NCT03032848|Drug|Conjugated Estrogen|use of 1 gram per day
76077686|NCT03032848|Drug|Promestriene|use of 1 gram per day
76077687|NCT03032848|Drug|Estriol|use of 1 gram per day
76077688|NCT03032848|Drug|Vaginal Moisturizer - Cream|use of 1 gram per day
75469065|NCT03108456|Device|Orbital Atherectomy|Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation
75634370|NCT04235712|Other|Harmonized Depression Outcome Measures|This is an observational study where outcome measures will be extracted from patients' medical records and from questionnaires to provide information back to the clinician.
75634371|NCT00825682|Other|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
75327528|NCT04334122|Other|Instrument-assisted soft tisue mobilization|"All patients in the experimental group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~In addition to the traditional physiotherapy program, the patients in the experimental group were subjected to tool-assisted soft tissue mobilization 3 times a week (12 sessions with 1 day interval).~All evaluations were repeated to all patients in the experimental and control groups after four weeks."
75634372|NCT00632268|Drug|RAD001; Cisplatin; 5-FU; Leucovorin|RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
75327529|NCT04334122|Other|Traditional physiotherapy|All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
75784338|NCT06192394|Device|Vibration|Patients will be asked to apply abdominal vibration for 5 cycles one hour after drinking the prescribed . A vibrating massage belt will be used for vibration applications. It will be stated that patients should wear the vibration belt on the abdominal area and use it at low intensity initially. They will then be explained that they can increase or decrease the intensity according to their comfort level. When they want to change the vibration level, they will be able to adjust the level they can tolerate. The belt is primarily utilized in the fitness industry for the purpose of weight loss. The intensity of the vibration application can be gradually increased on the belt. Additionally, the belt has both automatic and manual modes. When used in automatic mode, it has an automatic shutdown feature after 10 minutes.
75920383|NCT02120313|Other|outpatient rehabilitation|
76077689|NCT00080223|Drug|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
75327530|NCT00372814|Behavioral|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
75327531|NCT00372814|Behavioral|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
75327532|NCT04544800|Device|Use of Splint for UADT Visualization|The use of a splint to assist the patient and the surgeon with UADT procedures.
76077690|NCT03472443|Other|acupuncture|Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
76077691|NCT04402359|Drug|meropenem|meropenem one gram slowly IV infusion every 8 hours for 14 days
75784339|NCT06192394|Other|Control|Patients will undergo standard bowel preparation determined by the hospital.
75798512|NCT03863886|Procedure|Endoscopic ultrasound catheter (UM-2R/3R, Olympus)|A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.
76077692|NCT04402359|Drug|ceftazidime 2 grams and avibactam 500|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).
75469066|NCT03108456|Device|Balloon|Vessel preparation with conventional and/or specialty balloons
75634373|NCT05469568|Other|Circuit training followed by telerehabilitation|Patients participate in an ambulatory rehabilitation program (12 weeks) and then gain access to mobile application to record their movement activities. This application will aslo inlude a library with exercise vidoes from the ambulatory program. These videos should inspire patients to do the exercises at home.
75634374|NCT05469568|Other|Usual care|Patients have usual information about importance of regular movement activities and recommendation of proper exercises
75634375|NCT04145076|Drug|Placebo|Two oral doses of placebo.
75798513|NCT01284582|Biological|ATH03|4 vaccinations
75920384|NCT02120391|Other|iPhone Application|All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
75920385|NCT02123589|Drug|Deep sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
75920386|NCT02123589|Drug|Deep and daily interruption of sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
76077693|NCT04402359|Device|ventilator|all patients selected to be ventilated for 14 days
76077694|NCT00088179|Drug|pexelizumab in conjunction with CABG|
76077695|NCT00959764|Drug|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
76077696|NCT00959764|Drug|Intranasal Calcitonin|Intranasal Calcitonin Spray
76077697|NCT00959764|Drug|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
75327533|NCT03223714|Drug|Conbercept Ophthalmic Injection|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
75327534|NCT03223714|Drug|sham injection|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
75920387|NCT02123589|Drug|Light sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl,continuous intravenous infusion ; The target level of sedation,RASS score between -2 and +1;
75920388|NCT02120547|Drug|Cenicriviroc in mild liver impaired|Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
75327535|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.
75327536|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
75327537|NCT05113498|Dietary Supplement|(-)-Epicatechin|Administration of a capsule with 150 mg of pure (-)-epicatechin after 48h low-flavanol diet.
75327538|NCT04501822|Diagnostic Test|Evaluation of clinical, instrumental and laboratory diagnostics tests|During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
75920389|NCT02120547|Drug|Cenicriviroc in moderate liver impaired|Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
75920390|NCT02118207|Other|Aerobic running exercise|60 min of aerobic intervals completed prior to SCUBA diving
75920391|NCT03552861|Device|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
75920392|NCT02120703|Drug|Pregabalin|Pregablin 75 mg per oral two times a day
75634376|NCT04145076|Drug|Citalopram|Single oral dose of citalopram (20mg) and single oral dose of placebo.
75634377|NCT04145076|Drug|Tianeptine|Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
75920393|NCT02120703|Drug|Gabapentin|Gabapentin 200 mg twice daily per oral
75920394|NCT02118285|Drug|Fludarabine|Fludarabine 25 mg/m^2 IV on days -6 through -2 from NK cell infusion
75920395|NCT02118285|Drug|Cyclophosphamide|Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
75327539|NCT05457088|Other|1.5 protein|dietary plan having dietary protein of 1.5 gr/kg/day
75327540|NCT05457088|Other|0.8 protein|dietary plan having dietary protein of 0.8 gr/kg/day
75634378|NCT00707902|Drug|chlorhexidine/lidocaine|
75634379|NCT00707902|Drug|echinacea/sage|
75920396|NCT02118285|Biological|NK cells|CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
75920397|NCT02118285|Biological|IL-2|IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
75920398|NCT02118285|Drug|INCB024360|INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
75920399|NCT02251587|Other|Standard Weight Management Program|Standard Diet program based on diet and exercise.
75920400|NCT02251587|Other|Sensible Weigh Program|Weight loss program designed for low income women.
75920401|NCT02118519|Biological|Autologous Mesenchymal Stem Cells|Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
75327541|NCT02415712|Drug|Fomepizole|The first dose of fomepizole is administered at a dose of 15 mg/kg, followed by the second to fifth doses administered at a dose of 10 mg/kg. The sixth and subsequent doses are administered at a dose of 15 mg/kg. The interval of the intravenous doses is 12 hours with one administration lasting more than 30 minutes.
75327542|NCT04485754|Other|Telemedicine FU|Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
75327543|NCT04485754|Other|Office FU|Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
75327544|NCT05441098|Other|Neoadjuvant therapy|Preoperative systemic therapy for breast cancer patients
75634380|NCT04107025|Other|HELP|Individual counseling were given to each intervention group participant. They were assisted with safety, emotional and mental support and referrals for health and financial assistance. Participants were also given handout to manage anxiety and panic situations during the legal procedures.
75634381|NCT00704860|Other|Open label pharmacotherapy|"Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"
75634382|NCT03360942|Device|SCC DBS|Deep Brain Stimulator
75634383|NCT00833794|Drug|Tramadol Once a day|
75634384|NCT00833794|Drug|Placebo|
75634385|NCT00912288|Drug|Dimebon 20 mg po TID|Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
75634386|NCT00912288|Drug|Placebo po TID|Placebo (matched to Dimebon) po for 26 weeks
75327545|NCT05456698|Drug|Inotuzumab ozogamicin|"Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.~Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity."
75327546|NCT04383340|Behavioral|Mother-Infant Transaction Program|Parent sensitivity training for mothers of premature infants
76077698|NCT01005706|Drug|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
76077699|NCT01005706|Drug|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
75327547|NCT04383340|Behavioral|Treatment as usual|Standard hospital care and parental support
75327548|NCT02973724|Drug|Remifentanil|The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
76077700|NCT05346471|Device|Multimodal neuromonitoring|Multimodal neuromonitoring accounts for intraparenchymatous ICP probe, brain tissue oxygen probe and/or cerebral microdialysis device
75634387|NCT00778375|Drug|Clofarabine|20 mg/m^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
75634388|NCT00778375|Drug|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
75634389|NCT00778375|Drug|Decitabine|20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
75634390|NCT04102267|Drug|Bupivacaine liposome injectable suspension|Liposomal bupivacaine 266 mg via injection
75634391|NCT04102267|Drug|Bupivacaine HCl without epinephrine via continuous infusion|Bupivacaine HCl 300 mg via continuous infusion
75920402|NCT02118675|Other|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
75920403|NCT02118675|Other|Body Composition and Circumference measurements|This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
75920404|NCT02118675|Other|Whole Body DXA scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
76077701|NCT01679379|Procedure|Absorbable suture group|Skin is closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture]
75327549|NCT02973724|Drug|Propofol anesthesia|Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
75327550|NCT05456464|Other|Reiki|Reiki is applied touching the energy centers of the body (chakras). There are seven main and many small chakras on a body. Chakras are located on the front and back sides of the body in a vertical line that runs along the middle of the body in humans. A complete Reiki therapy includes all the chakras and organs.
75634392|NCT02602171|Other|Oldenburger sentence test, localization test|
75634393|NCT04202718|Diagnostic Test|VitalPatch Device|The VitalPatch® is an IRB (791130) and FDA approved wearable device that allows for the constant monitoring of biometric measurements and may have utility in the health management of individuals at high-risk for poor health outcomes and in the detection or prevention of adverse events within settings where more traditional telemetry monitoring devices are not currently in use.
75634394|NCT04498104|Other|Psychological assessment|Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.
75798514|NCT01166880|Device|Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
75798515|NCT01284660|Dietary Supplement|DHA|DHA ingested orally by heavy smokers
75798516|NCT01284660|Dietary Supplement|Oral ingestion of 5 placebo tablets|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
75327551|NCT03216005|Device|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
75327552|NCT05315687|Device|Y-90 SIR-Spheres|Y-90 SIR-Spheres
75327553|NCT05315687|Procedure|Yttrium-90 Microsphere Radioembolization|Undergo Y90 radioembolization
75327554|NCT05315687|Other|Systemic Therapy|Systemic Therapy
75327555|NCT03215615|Procedure|Periodontal surgery|Coronally advanced flap for root coverage
75327556|NCT03215615|Procedure|Total Etch adhesive|Total-etch adhesive system (two step)
75634395|NCT00777829|Drug|zolpidem|Participants will receive one dose of 10 mg before each nap.
75634396|NCT00777829|Drug|Placebo|Participants will receive a dose of placebo before each nap.
75634397|NCT00632190|Other|fluorophotometry|
75634398|NCT00632190|Procedure|colposcopic biopsy|
75634399|NCT00632190|Procedure|colposcopy|
75634400|NCT00632190|Procedure|light-scattering spectroscopy|
75634401|NCT00916045|Drug|Thiotepa|
75634402|NCT00916045|Drug|Fludarabine|
75798517|NCT01175070|Drug|Intravitreal injection of pegaptanib sodium|Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen [TM]) 0.3mg every 6 weeks over a 30 week period.
75327557|NCT03215615|Procedure|Universal Adhesive|One-step self-etching adhesive system
75920405|NCT02118675|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
75920406|NCT02118675|Other|BodPod|This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
75920407|NCT02118675|Other|Circumferences|This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
75920408|NCT02118675|Other|Ultrasound|An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
75634403|NCT00916045|Drug|Intravenous busulphan|
75634404|NCT00916045|Drug|Thymoglobulin|
75634405|NCT00916045|Drug|Ciclosporin|
75634406|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
75327558|NCT03215615|Procedure|Nanofilled Composite|Partial nanofilled-resin composite restoration
75327559|NCT03215615|Procedure|Micro-Hybrid Composite|Partial micro-hybrid composite restoration
75327560|NCT04264000|Drug|platelet-rich plasma|Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
75634407|NCT00916045|Drug|Fludarabine|
75634408|NCT00916045|Drug|Cyclophosphamide|
75634409|NCT00916045|Radiation|Radiotherapy|
75920409|NCT02126709|Drug|Repigel|Repigel will be used as the intervention in the treatment group
75920410|NCT02126787|Behavioral|Intensive Group Analytic Psychotherapy|The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes & Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.
76077702|NCT01679379|Procedure|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
75634410|NCT00916045|Drug|Thymoglobulin|
75634411|NCT00916045|Drug|Ciclosporin|
75327561|NCT04264000|Drug|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
75327562|NCT05455996|Drug|MDMA|MDMA-assisted therapy
75327563|NCT05455918|Drug|TIP treatment (paclitaxel/ifosfamide/cisplatin)|Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2~5 (total 6g/m2) Cisplatin 25mg/m2/day D2~5 (total 100mg/m2)
75634412|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
75634413|NCT00916045|Drug|Fludarabine|
75634414|NCT00916045|Drug|Melphalan|
75634415|NCT00916045|Drug|Thymoglobulin|
75634416|NCT00916045|Drug|Ciclosporin|
75634417|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
75327564|NCT04334902|Device|mPDia|Clinical decision support system for diagnosing neurodegenerative parkinsonism
75327565|NCT02958748|Other|taking blood sample|
75327566|NCT05455762|Other|Exercise|The intervention consists of 8 week of combined resistance and aerobic exercise. Patients will exercise 6 days a week;3 days aerobic ones and 3 days resistance ones. The aerobic exercise include 20 minutes of walking divided into three parts. In the first five minute the patients walks slowly to warm up, in the next 10 minutes the patient will speedup to reach the intensity described by the physiotherapist. In the last 5 minutes the patient walks like the first five minutes. The middle 10 minutes may be increased or not based on patient's weekly report. The resistance training consists of 5 exercise; hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
75327567|NCT00889187|Radiation|Neoadjuvant Short-Course Photon Radiation|
75327568|NCT00889187|Drug|Capecitabine|
75634418|NCT00916123|Drug|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
75634419|NCT00916123|Drug|Prednisone|10 mg per day starting on cycle 1, day 1
75634420|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
75327569|NCT04334824|Drug|Hydrochlorothiazide|Exposure to hydrochlorothiazide will be defined as a prescription for hydrochlorothiazide alone or in combination with non-ACE inhibitor antihypertensive drugs at cohort entry date.
75327570|NCT04334824|Drug|Angiotensin-converting enzyme (ACE) inhibitors|Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
75327571|NCT03215537|Behavioral|comprehensive intervention|preoperative and postoperative exercise program
75327572|NCT05314127|Drug|Tazarotene 0.1% Gel,Top|once daily topical application at night with a cotton tipped applicator on every lesion
75327573|NCT05314127|Drug|Imiquimod|Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.
75920411|NCT02126787|Behavioral|Intensive transdiagnostic cognitive-behavioral group therapy|GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, & Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, & Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
75634421|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
75327574|NCT05314127|Drug|Fluorouracil Cream|5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
75327575|NCT05314127|Drug|Petrolatum|applied once daily at night
75469067|NCT03086421|Behavioral|Questionnaires|Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
75634422|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
75634423|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
75784340|NCT06192381|Other|Web-Based Learning Module (WBL)|To ensure a uniform starting point, the participants were recruited via faculty website and students' academic counseling services. At the baseline, after the initial assessment, the participants were randomized at a 1:1 allocation ratio into the following groups: 1) traditional health education group (control group) (n = 68) who received health education with traditional face-to-face method; 2) web-based health education group (intervention group) (n = 68) who received health education with Web-Based Learning Module (WBL).
75784341|NCT06192368|Device|INSPIRE|Virtual reality application for relaxing.
75920412|NCT03551925|Behavioral|Treatment as Usual Plus Occupational Therapy|The IMeds consists of a three-step process that leads the client from the reflection of past performance, to goal setting, and onto strategy identification and implementation. This intervention guides the client through identifying strategies in the following six areas: altering the medication management activity, advocacy, assistive technology, environmental modifications, and securing refills on time (Schwartz et al., 2017).
75784342|NCT06192368|Device|Tablet|Gaming tablet
75784343|NCT06192355|Device|Esophagogastroduodenoscopy|performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
75327576|NCT04932850|Biological|MAD0004J08|Human mAb 100 mg / 2.5 mL solution for injection
75327577|NCT04932850|Other|Placebo|Placebo matching to MAD0004J08 2.5 mL solution for injection
75327578|NCT03130127|Drug|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
75327579|NCT05455528|Diagnostic Test|estimated GFR calculation|The estimated GFR is computed with Modification of Diet in Renal Disease (MDRD) formula
75327580|NCT03215459|Device|Cardiopulmonary Exercise Test|Cardiopulmonary Exercise Test
75327581|NCT04225078|Drug|Loperamide|Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.
75327582|NCT04225078|Other|Placebo|Matching loperamide placebo capsules will be administered orally.
75327583|NCT04225078|Drug|Moxifloxacin|Moxifloxacin tablets will be administered orally.
75327584|NCT04380935|Biological|Convalescent plasma|Convalescent plasma of recovered COVID-19 patients (donor)
75327585|NCT04380935|Drug|Standard of care|"According to national or hospital guidelines COVID-19 Management Protocol"
75327586|NCT00373048|Drug|mefloquine|tablet, once weekly
75327587|NCT00373048|Drug|placebo|tablet, once weekly
75327588|NCT05455372|Drug|PPI quadruple therapy|PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
75327589|NCT00372892|Drug|Rituximab|375mg/m2 per week for 4 consecutive weeks
75634424|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
75634425|NCT00775021|Device|etafilcon A|Contact Lens
75634426|NCT00775021|Device|nelfilcon A|Contact Lens
75634427|NCT00916201|Drug|URB597|10 mg / d for 5 days, orally
75634428|NCT00916201|Drug|intranasal Insulin|160 IU / d for 5 days, intranasal
75634429|NCT00916201|Drug|Cannabidiol CR|320 mg / d for 5 days, orally
75634430|NCT02601781|Procedure|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
75327590|NCT00372892|Drug|Placebo|Saline IV placebo once per week for 4 consecutive weeks
75327591|NCT04127656|Other|Amino Acid-Based Experimental Study Formula|Amino Acid-Based Formula; fed ad libitum
75327592|NCT00895817|Drug|Swallowed fluticasone|440 µg twice daily for 8 weeks
75327593|NCT00895817|Drug|Esomeprazole|40 mg once daily for 8 weeks
75327594|NCT03020303|Drug|Spironolactone 25Mg Tablet|Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.
75327595|NCT03020303|Drug|Placebo Oral Tablet|Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
75327596|NCT04825522|Drug|Vancomycin|During spinal surgery, participants will receive intrawound vancomycin powder in their wound before closure.
75634431|NCT02601781|Device|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
75634432|NCT00777205|Behavioral|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
75634433|NCT00777205|Behavioral|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
75634434|NCT00833638|Drug|Placebo|One tablet orally daily
75634435|NCT00833638|Drug|Tadalafil|Orally once daily
75784344|NCT06192329|Behavioral|Hot water therapy|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 105°F water for ~30 min, followed by immersion to the hip level for ~60 min (total immersion time of 90 min).
75784345|NCT06192329|Behavioral|Warm water immersion|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 97°F water for ~30 min, followed by immersion to the hip level for ~60 min (total immersion time of 90 min).
75798518|NCT03863964|Diagnostic Test|blood test|13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.
75327597|NCT00373204|Drug|Motexafin Gadolinium|"On Day 1 of each 3 week cycle for up to 12 cycles:~MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour."
75327598|NCT00373282|Drug|Triamcinolone acetonide|
75327599|NCT01047319|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
75327600|NCT00373438|Procedure|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
75327601|NCT03838679|Diagnostic Test|Best-corrected Visual acuity testing (BCVA)|Best-corrected visual acuity (BCVA) will be measured using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts at 4 meters and 1 meter, respectively.
75327602|NCT03838679|Diagnostic Test|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
75327603|NCT03838679|Diagnostic Test|Color fundus photography (CFP)|Color fundus photography is a non-invasive, fast and reliable imaging method providing a true-to-life depiction of the ocular fundus.
75920413|NCT03551925|Behavioral|Treatment as Usual|A clinical pharmacist counsels participants on proper medication adherence.
75327604|NCT03838679|Diagnostic Test|Optical coherence tomography angiography (OCTA)|OCTA, an extension of conventional OCT, offers noninvasive imaging of the retinal and choroidal vasculature.
75327605|NCT03838679|Diagnostic Test|Polarization-sensitive optical coherence tomography (PS-OCT)|PS-OCT, a functional exten- sion of conventional OCT technology, enables differentiation of retinal layers based on their distinct interference with the polarization state of the probing light beam, as opposed to mere light intensity.
75327606|NCT03838679|Diagnostic Test|Microperimetry (MP)|Microperimetry allows testing of retinal sensitivity at specific locations in the area of the fovea, parafovea or even more peipheral areas of the macula.
75327607|NCT03838679|Diagnostic Test|Adaptive-optics optical coherence tomography (AO-OCT)|AO-OCT, an extension of conventional OCT, offers non-invasive imaging of the retina with improved lateral resolution of up to 2-3 μm.
75327608|NCT03838679|Diagnostic Test|Fluorescein angiography (FA)|FA imaging is a standard imaging technique used for the diagnosis of vascular pathologies of the retina such as choroidal neovascularization.
75327609|NCT02911805|Behavioral|Aerobic exercise|Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
75327610|NCT02911805|Behavioral|Balance exercise|Instructor-led exercises done in a group setting for strengthening, balance, flexibility
75327611|NCT03215225|Procedure|Root canal orthograde treatment|
75634436|NCT01041404|Drug|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
75634437|NCT01041404|Drug|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
75634438|NCT01041404|Drug|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
75634439|NCT01041404|Drug|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
75327612|NCT01123018|Behavioral|Memtrax Memory screening test|Memory Screening test
75327613|NCT03405649|Behavioral|Group A|Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.
75920414|NCT02123901|Other|Walking Meditation|"Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week."
75920415|NCT02123901|Other|Walking|Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
75634440|NCT00777049|Drug|Panobinostat|Hard gelatine capsule - 5mg and 20mg
75634441|NCT00774787|Drug|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
75920416|NCT02123901|Other|No exercise|Sedentary life style.
75920417|NCT02123979|Drug|Neupro® transdermal patch/placebo|8mg transdermal patch Neupro® transdermal patch/placebo
75327614|NCT03405649|Behavioral|Group B|Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
75327615|NCT02884414|Device|Cutaneous stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
75327616|NCT04382027|Dietary Supplement|Omega-3 + vitamin K2 (monoacylglycerol form)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
75469069|NCT03073577|Drug|Antiaging Glycopeptide|Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
75327617|NCT04382027|Dietary Supplement|Omega-3 + vitamin K2 (ethyl ester)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
75634442|NCT00888927|Biological|KW-0761|The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.
75327618|NCT01044901|Procedure|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
75634443|NCT01040780|Drug|Icotinib|125 mg three times daily (375 mg per day) by mouth
75634444|NCT01040780|Drug|Gefitinib|250 mg every 24 hours by mouth
75920418|NCT03552315|Dietary Supplement|Carbonated water with amino acids and chromium|The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
75920419|NCT03552315|Dietary Supplement|Placebo Carbonated Water|The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
75920420|NCT02120859|Device|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis < 40% and FFR > 0.8.
75327619|NCT02884492|Drug|18F-THK-5351|18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
75469070|NCT03069469|Drug|DCC-3014|CSF1R inhibitor
75469071|NCT03066206|Drug|Poziotinib|Given PO
75920421|NCT02120859|Device|Provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
75920422|NCT02126865|Drug|Placebo to BI 1060469|tablet
75920423|NCT02126865|Drug|BI 1060469 Healthy|tablet
75920424|NCT02126865|Drug|Placebo to BI 1060469 asthmatics|tablet
75469072|NCT03051659|Drug|Eribulin Mesylate|Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
75634445|NCT00888849|Procedure|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
75634446|NCT00888849|Procedure|Suturing|Suturing
75634447|NCT04303832|Other|eye exercises|Eye exercises for correcting eye deviation
75634448|NCT04303832|Device|eye glasses|Eye glasses for correcting eye deviation
75327620|NCT02884492|Procedure|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
75327621|NCT00896441|Drug|Citalopram|"Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI."
75469073|NCT03051659|Drug|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
75469074|NCT03051074|Behavioral|Floating|Floating supine in a pool saturated with Epsom salt for up to 90 minutes
75634449|NCT04241991|Radiation|Active laser|Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
75634450|NCT04241991|Radiation|Placebo laser|Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
75634451|NCT04243317|Behavioral|Lifestyle & diet|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans.
75634452|NCT04243317|Behavioral|Lifestyle, diet & sleep|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans. The experimental group will additionally receive a sleep improvement program based on CBTi.
75634453|NCT04303988|Drug|Pyrotinib|PO
76077703|NCT03085251|Device|Blood glucose monitoring systems for self-testing (BGMS)|"Measurement procedure~Subjects will be asked to wash and dry their hands before the measurements.~The measurement procedure for each reagent system lot of a BGMS will be as follows:~Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~The sample will be applied to the reagent system units following specifications in the manufacturer's labelling."
75327622|NCT02885350|Drug|Spinal analgesia for labour pain|Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
75327623|NCT02885350|Drug|Epidural analgesia for labour pain|Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
75327624|NCT02790515|Drug|Anti-thymocyte globulin (rabbit)|Given intravenous (IV) prior to transplant on Days -14, -13, -12.
75327625|NCT02790515|Drug|Blinatumomab|Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
75634454|NCT04303988|Drug|Temozolomide Injection|IV
75634455|NCT04303988|Drug|SHR-1316|IV
75634456|NCT04303988|Drug|Bevacizumab|IV
75634457|NCT04303988|Drug|Cisplatin/Carboplatin|IV
75634458|NCT04682600|Device|Liver Incytes System|The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method. The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them. A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver. Ultrasound imaging through the patient ribs is used to track the displacements of these waves. Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated. The use of volumetric multi-frequency imaging increases the amount of liver scanned
75634459|NCT01059812|Drug|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
75920425|NCT02126865|Drug|BI 1060469 asthmatics|tablet
75327626|NCT02790515|Drug|Cyclophosphamide|Given by IV infusion prior to transplant on Day -9.
75327627|NCT02790515|Drug|Fludarabine|Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
75327628|NCT02790515|Drug|G-CSF|Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
75327629|NCT02790515|Drug|Melphalan|Given IV prior to transplant on Days -2 and -1.
75327630|NCT02790515|Drug|Mesna|Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
75327631|NCT02790515|Drug|Rituximab|Given IV prior to transplant on Day -1.
75469075|NCT03051074|Behavioral|Comparison|Watching a relaxing film for up to 90 minutes
75469076|NCT03050671|Device|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
75469077|NCT03050671|Device|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
75469078|NCT02975882|Drug|Irinotecan Hydrochloride|Given PO
75469079|NCT02975882|Other|Laboratory Biomarker Analysis|Correlative studies
75469080|NCT02975882|Other|Pharmacological Study|Correlative studies
75469081|NCT02975882|Drug|Sirolimus Albumin-bound Nanoparticles|Given IV
75327632|NCT02790515|Drug|Tacrolimus|Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
75327633|NCT02790515|Drug|Thiotepa|Given IV prior to transplant on Day -3.
75327634|NCT02790515|Biological|HPC,A Infusion|Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
75327635|NCT02790515|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
75327636|NCT02790515|Drug|Sirolimus|Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
75327637|NCT03400111|Radiation|low-level laser therapy|low-level laser therapy will be used to relieve pain and discomfort during orthodontic treatment at specific time points.
75327638|NCT03400111|Drug|Panadol-extra|Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort
75920426|NCT02120937|Behavioral|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
75920427|NCT02126943|Drug|Opsumit (macitentan)|10 mg tablets
75920428|NCT02121015|Behavioral|Share|
75327639|NCT03404791|Drug|TAR-200|TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
75327640|NCT03215381|Drug|[11C]AZD1390|[11C]AZD1390
75327641|NCT03406039|Behavioral|Integrated Online CBT and MI|The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
75327642|NCT03839069|Procedure|minor salivary gland transplantation|The investigators will harvest the autologous labial salivary gland tissue and transplant to the upper and lower conjunctival fornix of the lesion eye.
75327643|NCT03834415|Dietary Supplement|Lactobacillus reuteri DSM17038|Oil drops of L. reuteri containing 1x10>8 CFU
75327644|NCT03834415|Other|Placebo for Probiotics|Oil drops mimicking in consistency and flavor to experimental product
75327645|NCT03834649|Procedure|partially de-epithelized connective tissue graft|graft procedures to obtain simultaneous tissue augmentation in the horizontal and vertical dimensions. The donor site was prepared with a full-thickness coronal dissection and a partial-thickness apical dissection.The objectives were to use a single procedure to achieve simultaneously apico-coronal and buccolingual augmentation,to have a smaller open wound in the donor site and less patient discomfort, and to guarantee better revascularization of the onlay section aided by the submerged connective tissue section of the graft.
75920429|NCT02121015|Behavioral|Self-Directed|
75920430|NCT02121093|Procedure|vibration|
75920431|NCT02127021|Drug|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
76077704|NCT03085407|Procedure|early cholecystectomy|cholecystectomy was done within 48 after admission
75327646|NCT03834649|Procedure|Mucograft|"For preprosthetic defects, a standard mucosal augmentation procedure, which is well reported in the literature, was performed. The surgical site produced by the surgery leaves a denuded area supraperiosteally that is addressed by grafting with a xenogeneic collagen membrane (Mucograft).~purpose of the surgery is to improve the quantity of attached mucosa to facilitate the final dental reconstruction"
75327647|NCT03405571|Other|No intervention|No intervention
75327648|NCT04380623|Behavioral|Mobile Phone-Based Web-Page: HPV vaccine|Website to be accessed via mobile phone to deliver tailored educational material
75327649|NCT00918931|Drug|Obatoclax Mesylate|30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
75327650|NCT04381715|Genetic|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
75469082|NCT02975882|Drug|Temozolomide|Given PO
75634460|NCT01059812|Drug|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
75634461|NCT00888615|Drug|Elesclomol Sodium|Given IV
75920432|NCT02127021|Drug|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
75920433|NCT03551847|Drug|Antibiotic|The intervention involves giving an infected patient antibiotics.
75920434|NCT03551847|Drug|No antibiotics|The intervention involves not giving an infected patient antibiotics.
75920435|NCT02121171|Device|Ologen Collagen Matrix|Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
75920436|NCT02121171|Procedure|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
76077705|NCT03085407|Procedure|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
76077706|NCT01679691|Other|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
75327651|NCT03405493|Behavioral|Wake and Light Therapy|Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.
75327652|NCT03405493|Behavioral|Sleep and Light Therapy|Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
75920437|NCT02127177|Device|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
75920438|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 1|Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.
75920439|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 2|Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
75920440|NCT03551223|Biological|Neuron specific enolase (NSE)|5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.
75920441|NCT02121249|Device|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
75920442|NCT02121249|Procedure|free hand technique|"No specific device is necessary in the free hand technique"
75920443|NCT02121327|Other|disease management|disease management program include self management education
75920444|NCT02121327|Other|usual care|usual care group receive regular outpatient treatment
75920445|NCT02121561|Behavioral|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
75920446|NCT00150462|Drug|Carfilzomib|Administered as an IV bolus dose
75920447|NCT00150462|Drug|Dexamethasone|Administered orally prior to carfilzomib
75327653|NCT02885506|Drug|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
75327654|NCT02885506|Drug|Oral administration of P218 matching placebo|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
75327655|NCT03214913|Other|Early Goal Directed Therapy|EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
75784346|NCT06192316|Behavioral|3x3 between-subjects experimental exposure|"Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, Tobacco Free, Synthetic Nicotine) between-subjects design. We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions. Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to. Within each condition, pack images will vary by 4 brands and 4 flavors per brand. While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking."
75920448|NCT02287740|Behavioral|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
75634462|NCT00888615|Drug|Paclitaxel|Given IV
75634463|NCT02824497|Other|No intervention. It's a description study|
75634464|NCT00845650|Biological|AIGIV 3.5 mg/kg|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
75634465|NCT00845650|Biological|Gamunex 90 mg/kg|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
75634466|NCT00845650|Biological|AIGIV 7.0 mg/kg|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
75634467|NCT00845650|Biological|Gamunex 180 mg/kg|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
75634468|NCT00845650|Biological|AIGIV 14.0 mg/kg|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
75634469|NCT00845650|Biological|Gamunex 360 mg/kg|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
75469083|NCT02965755|Other|Treatment recommendation|Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
75920449|NCT02287740|Behavioral|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
75920450|NCT02287740|Behavioral|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
75920451|NCT00095550|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
75920452|NCT00095550|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
75920453|NCT00095550|Drug|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
75920454|NCT00095394|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
75920455|NCT00095394|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
75920456|NCT00093132|Drug|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
76077707|NCT03470805|Drug|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
76077708|NCT03084549|Drug|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
76077709|NCT03084549|Drug|Administration of placebo|Administration of placebo in the margins of the episiotomy
76077710|NCT03082521|Behavioral|Improving the antibiotic prescribing quality|The goal is to improve the antibiotic prescribing quality of GPs in a GPC by setting up a participatory action research. The interventions will be co-designed with the GPs.
76077711|NCT03080259|Behavioral|Stimulant Diversion Prevention (SDP)|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
76077712|NCT03081351|Procedure|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
76077713|NCT03081351|Procedure|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
76077714|NCT03084861|Drug|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
76077715|NCT03084861|Drug|Conventional treatment|"Artificial tears: Lubristil ®~Therapeutic Contact lens: Air Optix Night&Day"
76077716|NCT01006252|Drug|Tasisulam-sodium|Administered intravenously on Day 1 of a 28-day cycle, until disease progression.
76077717|NCT01006252|Drug|Paclitaxel|80 mg/m^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
76077718|NCT03081897|Drug|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
76077719|NCT03081897|Drug|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
75469084|NCT02938130|Other|Wellness Programs|Wellness Programs delivered in the Community Partners and Community LIFE programs
75469085|NCT02916550|Behavioral|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
75634470|NCT05086809|Device|Device A|Participant wear Device A and evaluate the performance of the device.
75634471|NCT05086809|Device|Device B|Participant wear Device B and evaluate the performance of the device.
75920457|NCT00093054|Drug|Cranberry juice|TID dosage for UTI treatment
75920458|NCT00093054|Dietary Supplement|Placebo cranberry juice|TID placebo dosage to match active comparator
75920459|NCT00089466|Drug|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
75920460|NCT00080106|Biological|MRK Ad5 HIV-1 gag vaccine|MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
75920461|NCT00080106|Other|Vaccine placebo|MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
75920462|NCT00335244|Drug|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
75920463|NCT00335244|Drug|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
76077720|NCT03089931|Procedure|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
76077721|NCT03084705|Device|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
75634472|NCT00888381|Biological|Inactivated Influenza Vaccine (2009 / 2010 formulation)|A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
75634473|NCT00887913|Device|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
75634474|NCT02825745|Dietary Supplement|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
75327656|NCT03214913|Other|Ruijin Strategy|"Ruijin Strategy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%~35%."
76077722|NCT02245906|Dietary Supplement|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
75327657|NCT03215147|Diagnostic Test|Confirmation of Airway Disease combined with IPF|To confirm the airway disease combined with IPF, PFT+BDR+DLCO, MBPT, Induced sputum exam, MAST, Total IgE, serum Eosinophil count, FENO will be done at the time of registration and 6~8 weeks later.
76077723|NCT02245906|Dietary Supplement|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
75327658|NCT03404011|Other|Propylene glycol and Glycerol intake|Intake of 1 gram of propylene glycol/Glycerol mix (50:50). Blood sample before, 5 minutes and 20 minutes after intake.
75327659|NCT03404011|Device|Mimicking intake|Mimicking propylene glycol/glycerol intake with the device turns off. Blood sample before, 5 minutes and 20 minutes after intake.
75327660|NCT04381949|Procedure|positive pressure extubation|"Two arms:~the first with classic extubation with disconnection of the ventilator and the second with an extubation without disconnection of the respiratory positive pressure"
75327661|NCT03840382|Behavioral|Tele-PrEP Intervention|Telemedicine conferences with PrEP-specialists
75327662|NCT03214835|Device|Endo CDx Brush biopsy|In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
75327663|NCT05312099|Other|Case control|Case control study
75327664|NCT03214757|Other|treatment of anemia.|drug treatment of anemia.
75327665|NCT05311865|Other|Club event|Participate in a club event without a mask, indoors, with vaccinated people.
75327666|NCT05311787|Procedure|esophagectomy with simultaneous reconstruction|Subtotal resection of esophagus and simultaneous reconstruction by gastric pull-up or colon conduit
75327667|NCT02895100|Drug|PTG-100|Daily dosing of PTG-100 by subject for a 12 week treatment period.
75634475|NCT02826135|Procedure|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output or decreased central venous pressure, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
75327668|NCT02895100|Drug|Placebo|Daily dosing of Placebo capsules by subject for a 12 week treatment period.
75327669|NCT01830491|Drug|Clopidogrel|
75327670|NCT01830491|Drug|aspirin 100mg|
75327671|NCT03837275|Procedure|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique) and implant placement
75634476|NCT02825823|Dietary Supplement|Ketone Salt|
75798519|NCT01280136|Behavioral|It's Your Game Tech|An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
76077724|NCT02245906|Dietary Supplement|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
76077725|NCT03080649|Device|excavated with rotary bur|One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
76077726|NCT03080649|Device|Er:YAG laser|One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
76077727|NCT00959842|Drug|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
75327672|NCT03837275|Procedure|closed maxillary sinus lift|transdcrestal sinus lift and immediate implant placment
75327673|NCT00904007|Other|Interactive Spaced Education (ISE) --- online education|"ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions."
75327674|NCT02777944|Behavioral|Motivate: a web-based intervention|A web-based intervention focuses on managing expectations of assessment, addressing ambivalence and increasing users' motivation and confidence to attend their initial appointment. This is achieved through the use of information, motivational tools, interactive activities and stories from other individuals with EDs spread across four 15-20 minute modules.
75327675|NCT01830569|Behavioral|The EBMeDS system|"The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.~The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group."
75327676|NCT01830569|Other|Evidence Linker|The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
75634477|NCT02825823|Dietary Supplement|Placebo|
75634478|NCT04949295|Device|ocular surface analyzer|Using ocular surface analyzer for Inspection
75327677|NCT02778880|Drug|Ketamine|
75327678|NCT02778880|Drug|Fentanyl|
75327679|NCT05311319|Drug|HAIC+TQB2450+Anlotinib|HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
75327680|NCT05311163|Procedure|MitraClip|Transcatheter Mitral Edge-To-Edge Repair
75327681|NCT05310929|Drug|Labetalol and Glyceril trinitrate|for control of blood pressure
75327682|NCT03214133|Other|Epicatechin-rich cocoa dose response|Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
75327683|NCT03214133|Other|Epicatechin-rich cocoa vs placebo on performance|An optimized dose of epicatechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
75327684|NCT00891995|Device|Closed loop|Closed loop therapy for up to 4 to 6 days
75327685|NCT00891995|Device|Home glucose monitoring|Standard diabetes management using a home glucose meter.
75327686|NCT00891995|Device|Insulin pump|Insulin pump use for 2 years
75327687|NCT00891995|Device|Continuous glucose monitor|Continuous glucose monitor use for 2 years
75327688|NCT02781454|Drug|Mexiletine|
75327689|NCT02781454|Drug|Placebo|
75469086|NCT02911064|Behavioral|Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
75634479|NCT00833560|Drug|Cyclophosphamide|In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
75327690|NCT00892697|Drug|Telaprevir|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
75327691|NCT00892697|Drug|Peginterferon alfa-2a|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
75327692|NCT00892697|Drug|Ribavirin|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
75327693|NCT04381403|Other|Bio-descaling D-Tart toothpaste|Patients received Bio-descaling D-Tart toothpaste, which is a new dentifrice (Visionaturolab Inc., QC) that contains a natural bio-descaler powder of cuttlefish bone
75327694|NCT04381403|Other|Crest® toothpaste|Patients received Crest toothpaste; Anti-tartar toothpaste
75327695|NCT04381793|Dietary Supplement|Recovery Factors|Porcine serum amino acid/peptide
75634480|NCT00833560|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
75634481|NCT00833560|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
75634482|NCT04242927|Drug|Nicotinic acid +Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
75327696|NCT01830959|Drug|Roflumilast|Roflumilast
75327697|NCT01830959|Drug|Placebo|Placebo one a day
75327698|NCT02155465|Drug|Ruxolitinib|"Ruxolitinib 10mg PO BID~Ruxolitinib 15mg PO BID~Ruxolitinib 20mg PO BID"
75327699|NCT02155465|Drug|Erlotinib|Erlotinib 150mg PO QD
75327700|NCT01831193|Drug|Curcumin|
75327701|NCT01831505|Drug|Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them|
75327702|NCT02781610|Drug|Standard of care IV antibiotic(s)|IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
75327703|NCT01831583|Device|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
75327704|NCT01831583|Device|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
75327705|NCT02155543|Drug|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
75327706|NCT02155543|Drug|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
75327707|NCT02155543|Drug|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
75327708|NCT02155543|Drug|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
75327709|NCT03214055|Drug|Mannitol|The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
75327710|NCT03405337|Drug|FVIII products|Adynovate, Eloctate, Afstyla, Kovaltry
75327711|NCT03405337|Drug|Conventional FVIII replacement therapies|Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
75327712|NCT01831661|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
75327713|NCT01831661|Drug|GLUCOPHAGE®XR|GLUCOPHAGE®XR 750 mg once a day
75327714|NCT03403387|Dietary Supplement|GlutenShield|combination probiotic, prebiotic, and enzyme supplement
75327715|NCT03403387|Other|Placebo|Avicel (cellulose) and bentonite powder
75634483|NCT04242927|Drug|Routine care|Routinely apply urea ointment and provide best supportive care.
75327716|NCT03799432|Other|COAST-IS|COAST-IS has been designed to equip organizations with the knowledge, motivation, and skill needed to thoughtfully match implementation strategies to identified determinants by applying intervention mapping. The COAST-IS intervention will include four different modes of delivery: 1) dissemination of educational materials; 2) five web-based interactive education sessions on the need for tailoring implementation strategies and the application of intervention mapping; 3) site visits to discuss change objectives necessary to successfully implement trauma-focused cognitive behavioral therapy; and 4) organizational coaching related to using an intervention mapping approach.
75327717|NCT03799432|Other|TF-CBT Learning Collaborative|The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
75327718|NCT03405181|Other|Training with additional weight|The infants will be positioned in a reclined position. A bracelet with an additional weight (20% of the total mass of the upper limb) will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches it. After reaching, the object will be carefully removed and resubmitted in order to elicit a new movement. The interval between each presentation will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
75327719|NCT03405181|Other|Training without additional weight|The infants will be positioned in a reclined position. A bracelet without the additional weight will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches the object. After reaching, the object will be carefully removed (or picked up) and resubmitted in order to elicit a new movement. The interval between each presentation of the object will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
75327720|NCT04375501|Other|Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail|If fit for anaesthesia patients may undergo relevant procedure for fractured neck of femur as per NICE guidelines within limitations of resources as defined by BOAST
75327721|NCT00373516|Drug|Vehicle (Placebo) applied BID|
76077728|NCT03080805|Drug|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/ m^2 BID)
75327722|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied QD|
75327723|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied BID|
75327724|NCT04375579|Other|Comprehensive geriatric assessment (CGA)|Questionnaires on nutritional status, autonomy and quality of life
76077729|NCT03080805|Drug|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
76077730|NCT00959920|Procedure|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
76077731|NCT00959920|Procedure|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
75469087|NCT02908672|Drug|Atezolizumab|Will be administered as per the schedule described in individual arm.
76077732|NCT03018964|Procedure|Solo surgery|Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
75469088|NCT02908672|Drug|Atezolizumab Placebo|Will be administered as per the schedule described in individual arm.
75469089|NCT02908672|Drug|Cobimetinib|Will be administered as per the schedule described in individual arm.
75469090|NCT02908672|Drug|Vemurafenib|Will be administered as per the schedule described in individual arm.
75634484|NCT00708136|Behavioral|water based training program to improve balance|
75920464|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
76077733|NCT03018964|Procedure|operation with a camera operator in SILC|conventional single incision laparoscopic cholecystectomy with a scopist
76077734|NCT03089775|Drug|BBI-2000|Experimental
76077735|NCT03089775|Drug|Vehicle|Vehicle Comparator
76077736|NCT03089775|Other|Multiple treatments|BBI-2000, Vehicle, Clobetasol Propionate, No treatment
76077737|NCT04401735|Drug|Polydeoxyribonucleotides|PDRN injection to epidural space
76077738|NCT04401735|Drug|Normal saline|Normal saline
76077739|NCT01007110|Dietary Supplement|DHA|Docosahexaenoic Acid (DHA) from algal oil
75469091|NCT02908672|Drug|Vemurafenib Placebo|Will be administered as per the schedule described in individual arm.
75634485|NCT04948047|Diagnostic Test|Pathological examinations as the golden diagnosis criteria|Pathological diagnosis, as the golden standard for diagnosing pulmonary nodules, is achieved by two experienced pathologists and validated by the third senior pathologist.
75920465|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
75920466|NCT00333216|Other|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
75920467|NCT05715372|Behavioral|Mediterranean diet|12-week structured program for Mediterranean diet.
75920468|NCT05715372|Behavioral|AHA walking program|12-week structured AHA walking program.
75920469|NCT05715372|Behavioral|Mindfulness-based stress reduction|8-week structured mindfulness-based stress reduction (Cabot).
75920470|NCT05715372|Behavioral|Unstructured Mediterranean diet|Unstructured 12-week program with basic outline for Mediterranean diet.
75469092|NCT02871921|Behavioral|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
75469093|NCT02827032|Device|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
75469094|NCT02818283|Dietary Supplement|Soy Pretzel|Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides ~280 calories (16% fat, 54% total carbohydrates, and 30% protein).
75469095|NCT02818283|Other|Wheat Pretzel|Each packet (5oz.) of wheat pretzel contains high gluten wheat flour, vital wheat gluten, shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides ~290 calories (16% fat, 54% total carbohydrates, and 30% protein).
75634486|NCT04948047|Diagnostic Test|Breath test combined with computed tomography|"Exhaled breath of each participant will be collected with Tedlar bags. The volatile organic compounds will be detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).~The Imaging markers of pulmonary nodules, including the size, three-dimensional shape, and appearance characteristics, are derived from the chest computed tomography within 2 weeks before surgery resection."
75634487|NCT02824419|Drug|Methionine|Subject undergoes imaging studies with FDG and with methionine.
75634488|NCT02824419|Drug|DOTANOC|Subject undergoes imaging studies with FDG and with DOTANOC.
75327725|NCT03402217|Behavioral|Patient Centered Postpartum Contraception App|This is a theory-based smart phone-based application designed to provide immediate postpartum contraception information to young women aged 15-25.
75327726|NCT03796468|Other|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies. The rescue MT may be performed in case of deterioration within the 24 hours
75327727|NCT03796468|Procedure|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus medical, the MT is performed immediately after the randomization
75327728|NCT04375423|Behavioral|Ecological momentary assessment and intervention: Behaviorally-dependent messaging|In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks
75327729|NCT04375423|Behavioral|Ecological momentary assessment only|Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
75327730|NCT03709732|Other|no intervention|observational study
75327731|NCT03405103|Behavioral|Striving|
75327732|NCT03405103|Behavioral|Boning-Up|
75327733|NCT03405103|Behavioral|Personal Choice|
75634489|NCT05660343|Drug|Ozonized Olive Oil Solutions|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, 100 ml bottle.
75634490|NCT05660343|Device|Low Level Laser LLL Therapy|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, Ozonated olive oil, 100 ml bottle, and 810 nm diode laser, 3.4 j/cm2 energy density, 0.5w power, CHEESE DEN7A/DEN4A 810, 2 min for each side
75634491|NCT02825667|Other|Physiotherapy sessions|Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
75327734|NCT03400267|Drug|Paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
75327735|NCT03400267|Drug|Fentanyl|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
75327736|NCT04375345|Device|hip arthroplasty|complex primary total hip arthroplasty or revision total hip arthroplasty performed through anterolateral or posterolateral approach
75327737|NCT01831973|Drug|Lipotecan|
75469096|NCT02811133|Drug|Inositol|Subjects will receive inositol
75469097|NCT02790021|Procedure|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
75469098|NCT02784119|Procedure|temporary porto-caval shunt|temporary porto-caval shunt
75469099|NCT02775435|Biological|Pembrolizumab|IV infusion
75469100|NCT02775435|Drug|Paclitaxel|IV infusion
75469101|NCT02775435|Drug|Nab-paclitaxel|IV infusion
75469102|NCT02775435|Drug|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
75469103|NCT02775435|Drug|Saline placebo for pembrolizumab|IV infusion
75469104|NCT02685826|Drug|Durvalumab|single use vials administered via intravenous infusion
75469105|NCT02685826|Drug|Lenalidomide|capsules for oral administration
75469106|NCT02685826|Drug|Dexamethasone|tablets for oral administration
75634492|NCT00887679|Drug|Escitalopram|10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
75469107|NCT02684162|Biological|Donor Lymphocytes|Given IV
75469108|NCT02684162|Drug|Guadecitabine|Given SC
75469109|NCT02684162|Other|Laboratory Biomarker Analysis|Correlative studies
75469110|NCT02662907|Procedure|Barium Swallow|Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
75469111|NCT02662907|Behavioral|Questionnaires|Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
75634493|NCT04241523|Drug|Lenvatinib 4 mg Oral|"Planned doses of 8 mg of lenvatinib per day for patients with body weight <60 kg, and 12 mg for those with body weight ≥60 kg.~In case of treatment-related adverse effects, interruption or reduction is allowed."
76077740|NCT01007110|Other|Placebo|Placebo capsule
75469112|NCT02662907|Device|Expiratory Muscle Strength Training (EMST) Device|Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
75920471|NCT05715372|Behavioral|Unstructured walking program|Unstructured 12-week walking program.
75920472|NCT05715372|Behavioral|Unstructured stress reduction|Unstructured program using mobile application for stress reduction.
76077741|NCT03019120|Drug|Vitamin D|"Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery."
75327738|NCT03213821|Other|protein intake|For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
76077742|NCT03080337|Other|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
76077743|NCT00960622|Drug|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
76077744|NCT00960622|Drug|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
75327739|NCT01832051|Drug|89Zr-trastuzumab injection|
75327740|NCT00898937|Genetic|microarray analysis|tumor specimen will be assessed by microarray analysis
75327741|NCT00898937|Procedure|breast biopsy|A breast biopsy will be done to obtain a tumor specimen
75469113|NCT02662907|Device|Digital Manometer|Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
75634494|NCT04242459|Radiation|Adaptive Radiotherapy|Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning
75327742|NCT02785432|Device|Sham low level laser|Sham laser will be administered using the same time and contact exposure as delivered for the active group, but without any energy delivered.
75327743|NCT02785432|Device|Active low level laser|Active treatment will be delivered using the time, contact, and energy exposures described in the arm description.
75327744|NCT01832129|Drug|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
75327745|NCT01832129|Drug|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
75327746|NCT02786134|Radiation|PET scan|A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.
75327747|NCT02786134|Radiation|Echocardiogram|An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
75634495|NCT02825589|Device|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
75920473|NCT00332748|Drug|Oral Taxane|
75920474|NCT00329082|Drug|LY2062430|"100mg QW IV for 12 weeks~100mg Q4W IV for 12 weeks~400mg QW IV for 12 weeks~400mg Q4W IV for 12 weeks"
75920475|NCT00329082|Drug|Placebo|5: Placebo QW IV for 12 weeks
75920476|NCT03530436|Dietary Supplement|Native turmeric extract|207 mg curcumin
76077745|NCT00960622|Drug|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
76077746|NCT03430947|Drug|Vemurafenib|Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
76077747|NCT03430947|Drug|Cobimetinib|Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
75327748|NCT02903446|Drug|Denosumab|Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
75327749|NCT01832285|Drug|fluvoxamine|100mg/day, PO(in the mouth) each day during 6 weeks
75469114|NCT02662907|Behavioral|Neurocognitive Exams|Participants given neurocognitive exams at baseline.
75469115|NCT02662907|Drug|Barium|Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
75469116|NCT02659800|Other|Laboratory Biomarker Analysis|Correlative studies
75469117|NCT02659800|Biological|NT-I7|Given IM
75469118|NCT02659800|Other|Placebo|Given IM
75469119|NCT02658981|Biological|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
75469120|NCT02658981|Biological|Anti-PD-1|Given IV
75469121|NCT02658981|Other|Pharmacological Study|Correlative Studies
75920477|NCT03530436|Dietary Supplement|Native turmeric extract with 7-9% volatile turmeric oils|207 mg curcumin
75920478|NCT03530436|Dietary Supplement|Turmeric extract plus mixture of phytochemicals|207 mg curcumin
75920479|NCT03530436|Dietary Supplement|Cyclodextrin complex of curcuminoids|207 mg curcumin
75920480|NCT03530436|Dietary Supplement|Turmeric oleoresin|207 mg curcumin
75920481|NCT03530436|Dietary Supplement|Liposomal curcumin|207 mg curcumin
75920482|NCT03530436|Dietary Supplement|Phytosomal curcumin|207 mg curcumin
75920483|NCT03530436|Dietary Supplement|Micellar turmeric extract|207 mg curcumin
75920484|NCT03530280|Drug|pregabalin (lyrica)|preoperative pregabalin and the postoperative sham block will perform.
75920485|NCT03530280|Drug|Placebo oral tablet|The preoperative placebo oral tablet and the postoperative sham block will perform.
75920486|NCT03530280|Drug|adductor canal block including bupivacaine|The preoperative placebo oral tablet and adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
75327750|NCT01832363|Drug|HXe MRI guided treatment sequence for BT|HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
76077748|NCT00960778|Drug|nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
75327751|NCT01832363|Other|Standard treatment sequence for BT (control)|Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
75327752|NCT02903836|Drug|Nafithromycin 800 mg 3 days|
75327753|NCT02903836|Drug|Nafithromycin 800 mg 5 days|
75327754|NCT02903836|Drug|Moxifloxacin 400 mg|
76077749|NCT00960778|Other|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
76077750|NCT03392649|Device|Parasym|Tragus stimulation was done using the Parasym device.
76077751|NCT03019042|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
75920487|NCT00079482|Drug|CEP-701|
75327755|NCT01832441|Other|Intra thecal transplantation of autologous MNC|Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
75327756|NCT00014911|Procedure|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
75327757|NCT00014911|Drug|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
75634496|NCT00833482|Drug|Voriconazole|Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
75798520|NCT03863652|Procedure|Percutaneous coronary intervention via snuffbox approach|After local anesthesia on left or right anatomical snuffbox with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by an insertion of the 5Fr. or 6Fr radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan). The selection of puncture device is at physician discretion.
75798521|NCT01178034|Genetic|Calculate warfarin dose using demographic/genetic algorithm|Age, body weight and genetic to calculate warfarin dosage
75920488|NCT00079482|Drug|high-dose cytarabine|Chemotherapy
75920489|NCT00079482|Drug|Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)|Chemotherapy
75920490|NCT00073866|Drug|celecoxib|
75920491|NCT00073866|Drug|docetaxel|
76077752|NCT03019042|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
75327758|NCT00014911|Drug|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
75327759|NCT00014911|Drug|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
75327760|NCT00014911|Drug|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
75920492|NCT00073866|Drug|irinotecan hydrochloride|
76077753|NCT03080571|Biological|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
76077754|NCT03080571|Other|standard care|
76077755|NCT00961402|Behavioral|Wellness Control|6-month wellness control
76077756|NCT00961402|Behavioral|Exercise Intervention|6 month exercise intervention
76077757|NCT03080181|Drug|Pasireotide 0.6 MG/ML|The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
76077758|NCT03018886|Other|GHRH plus arginine test|One ug/kg GHRH [GHRH(1-29), GEREF Serono, Italy] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
75327761|NCT00014911|Drug|Ganciclovir|An antiviral used to kill viruses and stop viral replication
75327762|NCT00014911|Drug|Trimethoprim|An antibacterial used to prevent opportunistic infections
75327763|NCT00014911|Drug|Pentamidine|An antiprotozoal used to prevent disease
75327764|NCT01832675|Drug|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
75327765|NCT01832675|Drug|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
75327766|NCT03213587|Drug|Apatinib|500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
75327767|NCT00013897|Drug|Atazanavir|
75327768|NCT00013897|Drug|Lamivudine/Zidovudine|
75634497|NCT00833482|Drug|Atazanavir|Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
75634498|NCT00833482|Drug|Ritonavir|"Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.~Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal."
75634499|NCT04196049|Procedure|fragmatome|Patients with massive subretinal hemorrhage from age related macular degeneration and organized subretinal blood clot were managed by inferior retinectomy. The subretinal organized blood clot was dragged to the preretinal space and removed by fragmatome. The retinal was reattached with perfluorocarbon liquid and laser was applied at the margin of retinectomy. Silicon oil was infused at the end of surgery.
75634500|NCT02824107|Biological|blood sample|
75634501|NCT02824107|Behavioral|questionnaires for psychosocial factors|
75798522|NCT01286298|Procedure|Laser gingivectomy|Gingivectomy by diode laser
76077759|NCT03080025|Behavioral|CBCT® (Cognitively Based Compassion-Training)|"The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.~The therapeutic tools are based on systemic approaches & techniques, which contains a resource- & solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).~Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):~a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression."
76077760|NCT01007656|Dietary Supplement|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
76077761|NCT03089385|Other|Hypertension tool|An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
75327769|NCT00013897|Drug|Efavirenz|
75327770|NCT03219983|Drug|Ropivacaine|Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
75327771|NCT03219983|Drug|liposomal bupivacaine|A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
75327772|NCT03219905|Device|Therapeutic Kinesio-taping|"The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees."
75327773|NCT03219905|Device|Sham Kinesio-taping|"The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg."
75327774|NCT03219749|Behavioral|exercise training|Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
75327775|NCT04347577|Drug|duloxetine|open-label study
75327776|NCT02240017|Drug|Carboplatin|Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
75327777|NCT02240017|Drug|Fractionated Cisplatin|Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
75327778|NCT02240017|Drug|Gemcitabine|Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
75327779|NCT00899717|Procedure|Occlusal adjustment|modification of occlusal surfaces
75327780|NCT00899717|Procedure|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
75327781|NCT04374955|Dietary Supplement|Activia Probiotics Shot|The product contains Actiregularis - at least 2x106 cfu / g.
75327782|NCT04374955|Other|Routine care|Routine care of the hospital will be provided.
75798523|NCT01286298|Procedure|Laser gingivectomy|Diode laser gingivectomy for gingival enlargement
75798524|NCT03863418|Dietary Supplement|Lactobacillus rhamnosus GG|PROBIOTIC
75798525|NCT03863418|Other|placebo|placebo
75798526|NCT01286376|Dietary Supplement|Symbiotic Lactofos|Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
75798527|NCT01286376|Dietary Supplement|Maltodextrin|Maltodextrin
75920493|NCT00073398|Biological|Drug: Hyperacute Lung Cancer Cell Vaccine|At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
75327783|NCT03219593|Drug|Apatinib mesylate tablets|Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
75634502|NCT04906239|Procedure|Erector Spinae Plane Block|A high-frequency ultrasound linear probe, covered with a sterile sheath, will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After showing the T 4-5 transverse process and the erector spinae muscle on top of it, a 22-gauge, 80 mm insulated quincke type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal, using the in-plane technique. When the transverse process is touched, the needle will be pulled out and after a negative aspiration test with 0.5 mL of normal saline and after the demonstration of a hypo-echogenic image and hydro dissection, a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.
75634503|NCT05659953|Drug|LMT503|Subjects will receive one of several different oral doses of LMT503 once daily
75634504|NCT05659953|Drug|Placebo|Subjects will receive one of several different oral doses of Placebo once daily
75634505|NCT00845182|Drug|Pioglitazone|Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months
75327784|NCT02240095|Behavioral|Intervention A - Online Clinical Questions Recorder|Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
75327785|NCT02240095|Behavioral|Intervention B - Online Evidence Retrieval Coach|Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
75327786|NCT02240095|Behavioral|Intervention C - Online Audit and Feedback|Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
75327787|NCT03836807|Drug|Ketoprofen|40 mg KLS granules (corresponding to 25 mg ketoprofen)
75327788|NCT03836807|Other|Placebo|0 mg KLS granules
75327789|NCT03404713|Behavioral|Pathways to Health|Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.
75327790|NCT03404713|Behavioral|Be4U|This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
75327791|NCT03213197|Other|CPR video|Patient watches a short CPR video
75327792|NCT02240173|Dietary Supplement|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
75327793|NCT02240173|Drug|Haloperidol|Conventional drug normally used for psychotic problems
75327794|NCT01832909|Other|Walnut Diet|Controlled diet with 1.5 oz/d of walnuts.
75327795|NCT01832909|Other|Control Diet|Controlled diet without walnuts.
75327796|NCT02240641|Drug|Lacidipine|
75327797|NCT02240641|Drug|Diuretics|
75327798|NCT02240641|Drug|antihypertensive drugs|
75327799|NCT02240641|Drug|alpha blockers|
75327800|NCT02240641|Drug|Angiotensin-Converting Enzyme Inhibitors|
75327801|NCT02240641|Drug|beta blockers|
75327802|NCT03219671|Drug|Nivolumab|nivolumab 240mg every 2 weeks
75327803|NCT03219671|Drug|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks
75634506|NCT00845182|Drug|Exenatide|Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
75634507|NCT00845182|Drug|Pioglitazone and Exenatide|Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months
75920494|NCT00325650|Drug|Rimonabant|Tablet, oral administration
75920495|NCT00325650|Drug|Placebo (for Rimonabant)|Tablet, oral administration
75327804|NCT03404635|Drug|Apixaban|Apixaban as standard of care for VTE
75327805|NCT03404635|Drug|Rivaroxaban|Rivaroxaban as standard of care for VTE
75327806|NCT03213275|Other|Microbiome Sequencing, Neurophysiologic Assessment, Immunological test|Stool sampling, aEEG, VEP, NIRS, ydTCR, Treg, biomarker
75327807|NCT03404557|Other|Proteomic analysis|Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
75327808|NCT01832987|Drug|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
75327809|NCT03404479|Drug|Diacerein|For 12 weeks, administered twice a day by oral.
75327810|NCT03404479|Drug|Celecoxib|For 12 weeks, administered twice a day by oral.
75327811|NCT03837665|Biological|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
75327812|NCT03219203|Biological|Hepatitis B vaccine|Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
75327813|NCT04374643|Other|Slef questionnaires fulfilment|Questionnaires to assess the psychological impact of confinement and its evolution over 6 months
75327814|NCT04374487|Drug|Convalescent Plasma|200 ml of ABO compatible plasma transfusion will be done to the subject randomized for the test arm therapy
75327815|NCT04374487|Other|Standard Care Therapy|Subjects randomized to control group will be on standard care treatment according to Institutional Protocols.
75327816|NCT04380467|Dietary Supplement|Vitamin D (cholecalciferol)|(aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
75327817|NCT03218735|Procedure|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
75327818|NCT03218735|Procedure|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
75327819|NCT04374409|Dietary Supplement|High-flavanol cocoa powder|Non-alkalized fat-reduced cocoa powder (Natural Acticoa)
75327820|NCT04374409|Dietary Supplement|Low-flavanol cocoa powder|Alkalized fat-reduced cocoa powder (10/12 DDP Royal Dutch)
75327821|NCT03218579|Dietary Supplement|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
75634508|NCT04934553|Behavioral|Amplification of Positivity Training|12 90-minute, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
75634509|NCT04934553|Behavioral|Cognitive-behavioral Therapy|12 90-minute, clinician-administered treatment sessions focused on strategies to alter cognitions and behavior related to alcohol use.
75920496|NCT03133572|Device|Supraglottic airway|Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
75327822|NCT03218579|Biological|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
75327823|NCT04374331|Other|video-assisted training|The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
75920497|NCT03133572|Device|Face-mask|In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
75327824|NCT03218657|Drug|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
75327825|NCT03218657|Drug|Androgens|Androgens take orally 80mg qd
75327826|NCT03218657|Drug|Cyclosporins|Cyclosporines take orally 3-5mg/kg*d qd
75920498|NCT00317694|Drug|Fermagate|Film coated tablet 500mg
75920499|NCT00317694|Drug|Placebo|Oral administration, film coated tablet, 0mg
75327827|NCT02240719|Drug|everolimus|Given PO
75327828|NCT02240719|Drug|bendamustine hydrochloride|Given IV
75327829|NCT01833299|Procedure|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
76077762|NCT03089229|Drug|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
75327830|NCT01833299|Procedure|TACE|
75327831|NCT02240797|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
75327832|NCT01833377|Dietary Supplement|caraway sample|
75327833|NCT01833377|Dietary Supplement|placebo|
75327834|NCT03213041|Drug|Carboplatin|Given IV
75327835|NCT03213041|Other|Laboratory Biomarker Analysis|Correlative studies
75327836|NCT03213041|Biological|Pembrolizumab|Given IV
75327837|NCT02240875|Biological|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
75327838|NCT02240875|Biological|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
75327839|NCT02240875|Biological|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
75327840|NCT02240875|Biological|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
75327841|NCT02240875|Biological|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
75327842|NCT02240875|Biological|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
75327843|NCT01833611|Drug|Entecavir|entecavir 0.5mg qd
75327844|NCT01833611|Drug|placebo|placebo qd
75634510|NCT00833248|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
75634511|NCT00833248|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
75920500|NCT00070590|Drug|Bosentan|
75920501|NCT00067782|Drug|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
75920502|NCT00067782|Drug|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
75920503|NCT00058266|Dietary Supplement|genistein|Given orally
75920504|NCT00058266|Procedure|conventional surgery|Patients undergo surgery
75469122|NCT02658981|Other|Laboratory Biomarker Analysis|Correlative Studies
75327845|NCT02240953|Drug|Warfarin|Only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
75327846|NCT02240953|Drug|Warfarin + ASA 100 mg + PPI|100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
75920505|NCT03530202|Drug|Creatine monohydrate|Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
75327847|NCT02240953|Drug|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
75469123|NCT02658981|Biological|Anti-CD137|Given IV
75327848|NCT02240953|Drug|Observational Warfarin|This is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
75327849|NCT03218813|Behavioral|Intervention cohort ('after' group)|"The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.~After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose')."
75327850|NCT03212729|Radiation|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
75634512|NCT00833248|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
75327851|NCT03212729|Procedure|Conventional endodontic treatment|After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
75327852|NCT03218501|Drug|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
75469124|NCT02592291|Device|MHealth|The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
75469125|NCT02575794|Drug|Terameprocol|Given PO
75920506|NCT03530202|Drug|Maltodextrin Powder|Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
75920507|NCT03530046|Combination Product|High SID fluid|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
75920508|NCT03530046|Combination Product|Hartmann's solution|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
75920509|NCT00313794|Drug|CP-675,206|15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
75920510|NCT03529968|Procedure|esophagectomy|Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
75920511|NCT00040404|Drug|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
75920512|NCT00040404|Drug|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
75920513|NCT00040404|Drug|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
75469126|NCT02575794|Other|Pharmacological Study|Correlative studies
75469127|NCT02481349|Other|Best Practice|Undergo standard of care
75469128|NCT02481349|Other|Informational Intervention|Receive DVD for home practice
75469129|NCT02481349|Other|Quality-of-Life Assessment|Ancillary studies
75469130|NCT02481349|Other|Questionnaire Administration|Ancillary studies
75469131|NCT02481349|Other|Yoga|Complete couple-based Hatha yoga program
75469132|NCT02419339|Procedure|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
75469133|NCT02403505|Biological|9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use|"By the percutaneous route with the multiple puncture device~9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix"
75469134|NCT02240472|Procedure|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
75469135|NCT02236910|Other|Lu-DOTA-TATE|
75469136|NCT02140021|Procedure|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
75469137|NCT02140021|Other|Laboratory Biomarker Analysis|Correlative studies
75469138|NCT02107105|Other|Quality-of-Life Assessment|Complete quality of life questionnaire
75327853|NCT03218501|Drug|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
75327854|NCT03218501|Drug|Placebo|Placebo is to be administered orally once daily for 2 weeks
75920514|NCT00040404|Other|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
75327855|NCT02241031|Biological|MPs|MPs are generated from cord blood using a combination of cytokines.
75327856|NCT02241031|Drug|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
75634513|NCT02612506|Drug|Hepalatide|There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
75634514|NCT02612506|Drug|Placebo|There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
75327857|NCT02156167|Device|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
75327858|NCT03212807|Drug|Durvalumab|Investigational Medicinal Product
75327859|NCT03212807|Drug|Lenalidomide|Investigational Medicinal Product
75920515|NCT00313248|Drug|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
75920516|NCT00313248|Drug|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
75920517|NCT00310830|Drug|Bosentan|Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
75920518|NCT00035568|Drug|Glucovance (metformin HCl/glyburide)|
75327860|NCT03212417|Other|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
75327861|NCT01833767|Drug|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
75327862|NCT01833923|Drug|anlotinib|oral medicine.
75327863|NCT01834079|Biological|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
75327864|NCT03213353|Drug|Tablet paracetamol, guaifenesin and phenylephrine HCL|Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
75327865|NCT03213353|Drug|Vicks Active SymptoMax Plus powder for oral solution|Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
75327866|NCT04381013|Device|Emergency Ventilator Splitter|Device to enable oxygen delivery to two patients independently from a single ventilator.
75327867|NCT03218267|Other|Static Posturography|The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.
75327868|NCT03218267|Other|One-leg standing test (OLS)|During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).
75634515|NCT02612584|Device|Pinhole Soft Contact Lens apply for presbyopia|
75634516|NCT00833092|Dietary Supplement|Sugar Pill|Sugar pill supplementation for 9 weeks
75920519|NCT00035568|Drug|or Metformin HCl alone|
75920520|NCT00035568|Drug|or Glyburide alone.|
75920521|NCT00031512|Drug|Placebo|Placebo.
75920522|NCT00031512|Drug|Pleconaril (VP63843)|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
76077763|NCT03089229|Drug|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
75327869|NCT03218111|Other|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
75327870|NCT03218111|Other|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
75327871|NCT03212573|Combination Product|ERAS protocol|ERAS protocol includes early oral intake and deambulation and multimodal analgesia
75327872|NCT03212573|Combination Product|Standard care|Oral intake and deambulation 24h after surgery and only intravenous analgesia.
75327873|NCT03218189|Other|Country characteristics|Observational study of country characteristics
75327874|NCT03218033|Behavioral|Social Media|
75327875|NCT03217955|Behavioral|CBT-SA|Info has been included in arm description
75327876|NCT03217955|Behavioral|Standard Treatment|Info has been included in arm description
75634517|NCT00833092|Dietary Supplement|magnesium|300 milligrams daily for 8 weeks
75634518|NCT00708370|Other|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
75634519|NCT00708370|Other|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
75634520|NCT00702130|Drug|Pravastatin|pravastatin 40mg per os once daily
75920523|NCT00030186|Drug|CEP-701 60mg|60mg orally 2 times a day for 28 days
75920524|NCT00030186|Drug|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
75634521|NCT02611414|Device|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
75634522|NCT02611414|Device|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
75327877|NCT01834235|Drug|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
75327878|NCT01834235|Drug|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
75327879|NCT01834235|Drug|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
75327880|NCT03212339|Other|Therapeutic intervention|Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.
75327881|NCT03217799|Device|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
75327882|NCT03211871|Drug|Dexmedetomidine|Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
76077764|NCT03089307|Device|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
75327883|NCT03211871|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Intraoperative intravenous normal saline infusion
75469139|NCT02107105|Other|Questionnaire Administration|Complete quality of life questionnaire
75469140|NCT02046057|Procedure|PNB of SLN|Percutaneous biopsy of sentinel node
75469141|NCT01993810|Drug|Carboplatin|Given IV
75469142|NCT01993810|Drug|Cisplatin|Given IV
75634523|NCT00823264|Drug|Activated Charcoal|50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
75920525|NCT00030186|Drug|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
75920526|NCT03529812|Behavioral|CBCT-informed training|Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
75920527|NCT02287974|Drug|Stem cell infusion|Unique stem cell infusion of the randomized group
75920528|NCT03529734|Other|12 min running|This was already explained in the description of arm
76077765|NCT03088293|Drug|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
75327884|NCT01834469|Drug|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
75327885|NCT03217487|Procedure|Corneal epithelial autograft|Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
75327886|NCT03217487|Procedure|Limbal conjunctival autograft|A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
75327887|NCT03217487|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
75327888|NCT03217487|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
75327889|NCT03838133|Drug|TLC590|TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
75327890|NCT03838133|Drug|Naropin®|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
75327891|NCT03838133|Drug|Normal Saline|Normal Saline (0.9% sodium chloride, 10ml)
75327892|NCT03838133|Drug|Bupivacaine|Bupivacaine 50 mg (0.5%, 10 mL)
75327893|NCT03217409|Drug|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg
75327894|NCT03217409|Drug|Rosuvastatin|Rosuvastatin 5Mg Tablet
75327895|NCT00895193|Other|Apple pectin|Apple pectin 2000mg
75327896|NCT00895193|Drug|Aspirin 325 mg|Aspirin 325 mg
75327897|NCT00895193|Other|Placebo|Placebo
75469143|NCT01993810|Biological|Durvalumab|Given IV
75634524|NCT00708604|Procedure|Islet Transplantation|Islet Transplantation
75634525|NCT00708604|Biological|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
75469144|NCT01993810|Drug|Etoposide|Given IV
75469145|NCT01993810|Drug|Paclitaxel|Given IV
75469146|NCT01993810|Drug|Pemetrexed Disodium|Given IV
75469147|NCT01993810|Radiation|Photon Beam Radiation Therapy|Undergo photon beam radiation therapy
75469148|NCT01993810|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
75469149|NCT01993810|Other|Quality-of-Life Assessment|Ancillary studies
75469150|NCT01993810|Other|Questionnaire Administration|Ancillary studies
75920529|NCT03529734|Other|Local strengthening exercises|This was already explained in the description of arm
75920530|NCT03529656|Behavioral|Early rehabilitation program for liver transplantation|Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
75327898|NCT01834547|Drug|Drugs use: methylphenidate|40 mg tablets
75634526|NCT00832780|Radiation|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
75920531|NCT00307398|Drug|Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg|One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.
75920532|NCT00307398|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
75920533|NCT01368081|Drug|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
76077766|NCT03088293|Drug|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
75634527|NCT02824341|Device|fMRI|
75634528|NCT04241055|Behavioral|Values affirmation exercise|In the experimental values affirmation condition, participants spend 10-15 minutes completing a guided reflection regarding values that are personally important (see Logel and Cohen, 2012; Brady, Griffiths, & Cohen, in prep).
75634529|NCT04241055|Behavioral|Active control exercise|In the active control condition, participants spend 10-15 minutes completing a guided reflection regarding values that are not personally important but could be important to someone else (see Logel and Cohen, 2012; Brady, Griffiths, & Cohen, in prep).
75634530|NCT04241211|Drug|Forsteo|Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.
75634531|NCT04241211|Drug|Denosumab Prefilled Syringe [Prolia]|Patients were administered 60mg of denosumab (Prolia) subcutaneously once 6months from the day on before 3months to after 3months about surgery.
75920534|NCT01368081|Drug|BI 10773|BI 10773 low dose tablet once daily
75920535|NCT01368081|Drug|Placebo (low dose)|Placebo tablets once daily
76077767|NCT03089151|Behavioral|Community Garden Intervention|"The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~A garden plot in a Denver Urban Garden~Seeds and plant starts~Introductory gardening workshop~Social events including garden-specific events and garden mentoring.~The non-gardening group will remain on the DUG wait lists and will not receive these resources.~Duration of the intervention is 1 year."
75920536|NCT01368081|Drug|BI 10773|BI 10773 high dose tablet once daily
75920537|NCT01368081|Drug|Placebo (high dose)|Placebo tablets once daily
75327899|NCT01834547|Drug|Drug use: modafinil|40 mg tablets
76077768|NCT03084003|Dietary Supplement|Almonds|
75920538|NCT02127411|Behavioral|Mindfulness-Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
75920539|NCT02127489|Drug|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
76077769|NCT03084003|Dietary Supplement|Graham crackers|
75920540|NCT02127645|Procedure|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
75920541|NCT02127645|Procedure|LRT-TEM|TEM following 46 Gy RT
75920542|NCT02127645|Procedure|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
75920543|NCT02127645|Procedure|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
75920544|NCT02124135|Behavioral|Diet/Nutrition Education|"As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant."
75920545|NCT02124213|Drug|30 mg PF-06412562|Subject will receive a single dose of 30 mg PF-06412562
75920546|NCT02124213|Drug|PF-06412562|The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
75920547|NCT02124213|Drug|PF-06412562|"The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional."
75327900|NCT01834547|Drug|caffeine|400 mg
75327901|NCT01834547|Drug|placebo|placebo
75327902|NCT03211637|Combination Product|Wounds Protocol|Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
75469151|NCT01962415|Drug|Hydroxyurea|Oral administration at 30 mg/kg/day.
76077770|NCT03703401|Diagnostic Test|Hysterosalpingo-contrast-sonogram|A contrast ultrasound scan to examine fallopian tube pathology and blockage
76077771|NCT01008280|Drug|baclofen|baclofen 10 mg tid
76077772|NCT01008280|Drug|placebo|placebo pill tid
76077773|NCT03084159|Behavioral|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
75327903|NCT03217253|Other|Laboratory Biomarker Analysis|Correlative studies
75327904|NCT03217253|Other|Pharmacological Study|Correlative studies
75327905|NCT03217253|Drug|Tazemetostat|Given PO
75469152|NCT01962415|Drug|Alemtuzumab|"Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection.~Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 30 mg); Stratum 3: No treatment dose, test dose only."
75327906|NCT03212105|Behavioral|60 Second Video|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
75327907|NCT03212105|Other|Educational Brochure|The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
75327908|NCT01834703|Procedure|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
75920548|NCT00303498|Drug|Sitexsentin sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
75920549|NCT00303498|Drug|Placebo|placebo identical to the study drug in description, dose and duration
75920550|NCT02124291|Device|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
75920551|NCT02588092|Drug|ADCT-301|Intravenous infusion
75920552|NCT02121717|Drug|Chiglitazar|Take orally
75920553|NCT02121717|Drug|Placebo|Take orally
75634532|NCT00591838|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
75920554|NCT03529578|Procedure|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
75327909|NCT01834703|Procedure|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
75327910|NCT03211559|Other|Exercise|clinical pilates on mat
75327911|NCT01834781|Device|Pulsed electromagnetic fields|
75327912|NCT01834781|Device|w/o pulsed electromagnetic fields|
75634533|NCT02611648|Other|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
75634534|NCT02611648|Other|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
75798528|NCT01284738|Other|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~the dosages of MP carried out by the UMR 608 in Marseille,~the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.~In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units."
75327913|NCT03217331|Drug|CRD-102|14 mg CRD-102 capsules administered twice daily orally for 14 days.
75327914|NCT03211715|Other|questionnaire|Rectal cancer patients who received sphincter saving surgery will be asked to fill up questionnaire related to bowel dysfunction
75327915|NCT03216863|Other|Respiratory rehabilitation|It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
75469153|NCT01962415|Drug|Fludarabine|IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.
75634535|NCT00702442|Drug|Droperidol|0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
75920555|NCT00004914|Biological|epoetin alfa|
75327916|NCT01834937|Device|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
75469154|NCT01962415|Drug|Melphalan|IV administration at 70 mg/m2/dose.
75469155|NCT01962415|Drug|Thiotepa|IV administration at 200 mg/m2/dose
75634536|NCT00702442|Drug|Saline solution|Saline solution administrated i.v 30 min prior surgery
75920556|NCT00004914|Procedure|physical therapy|
75920557|NCT00286806|Drug|AT-101|
75920558|NCT02124447|Drug|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
75469156|NCT01950351|Other|Laboratory Biomarker Analysis|Correlative studies
75634537|NCT02612272|Drug|Ketorolac|intra-articular ketorolac
75798529|NCT01284738|Other|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~the dosages of MP carried out by the UMR 608 in Marseille,~the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat."
75798530|NCT01284816|Procedure|bariatric surgery|The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
75798531|NCT01173198|Device|WAVEFRONT Optimized LASIK|30 patients
75634538|NCT02612272|Drug|Betamethasone|intra-articular betamethasone
75327917|NCT03211169|Procedure|Biopsies of bile duct stricture with pediatric biopsy forceps|Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
75920559|NCT02124447|Drug|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
75920560|NCT02124447|Drug|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
76077774|NCT04279665|Device|Virtual Reality (VR)|20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
75798532|NCT01173198|Device|WAVEFRONT GUIDED LASIK|30 patients
75327918|NCT03211169|Procedure|Biopsies of bile duct stricture with cholangioscopy-directed biopsies|Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
75327919|NCT04380389|Diagnostic Test|hypoxia|Brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.
75920561|NCT02124447|Drug|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
75920562|NCT00004908|Drug|cyclophosphamide|
75327920|NCT03217019|Procedure|Guidewire-assist|catheter insertion with guidewire-assist(catheter over guidewire)
75327921|NCT03217019|Procedure|Direct|catheter insertion without guidewire assist(catheter over needle)
76077775|NCT03088995|Diagnostic Test|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
76077776|NCT03089073|Drug|Desmopressin|60μg or 120μg once daily at bedtime
76077777|NCT00963430|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
76077778|NCT03083925|Device|TIPS|Transjugular Intrahepatic Portosystemic Shunt
75327922|NCT03211403|Drug|SHR4640|SHR4640 or placebo once daily for a week
75327923|NCT03211247|Biological|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
75327924|NCT03211247|Biological|Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
75327925|NCT03211247|Biological|Placebo|Placebo patch, once daily
75327926|NCT03216941|Drug|Ketamine|"study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication."
75327927|NCT03216707|Device|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
75327928|NCT03216707|Device|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
75469157|NCT01950351|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
75327929|NCT03216707|Device|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
75327930|NCT03216707|Other|Capsaicin cream|Capsaicin cream
75327931|NCT01835093|Drug|Tipepidine Hibenzate|
75327932|NCT01835249|Other|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP <120 mmHg.
75469158|NCT01950351|Other|Quality-of-Life Assessment|Ancillary studies
75469159|NCT01919619|Biological|Ipilimumab|Given IV
75920563|NCT00004908|Procedure|peripheral blood stem cell transplantation|
75920564|NCT00004908|Radiation|radiation therapy|
75920565|NCT03551769|Drug|tricaprilin|Tricaprilin formulated as AC-SD-01
75920566|NCT03551769|Other|standard meal|standard meal
75920567|NCT03551769|Other|high-fat meal|high-fat meal
75920568|NCT03551769|Other|overnight fast|fasting for at least 9 hours
75920569|NCT00004902|Drug|tocladesine|
75920570|NCT04426162|Other|Multi-domain Intervention|Intervention includes neurofeedback, heart rate variability biofeedback, memory and cognitive training, and one-on-one coaching to encourage behavior change in diet, sleep, physical fitness, and stress reduction.
75920571|NCT02127801|Drug|REGN1908-1909|
75798533|NCT01173276|Other|Sperm Washing with Intrauterine Insemination (IUI)|For semen samples, seminal fluid will be separated from sperm using a density gradient/swim-up separation technique. The purified sperm sample will be washed, and screened for HIV RNA using sensitive real-time RT-PCR. Samples with detectable traces of HIV RNA will not be used for insemination. Samples with no detectable traces of HIV RNA will be used for a standard intrauterine insemination of the female partner.
75798534|NCT03866304|Device|Device: S2 Picosecond laser|Each subject will receive up to 16 laser treatments.
75798535|NCT03866616|Behavioral|Brain Builders Parenting Class|Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting
75920572|NCT02127801|Drug|placebo|
75634539|NCT04040218|Procedure|Dry Needling|Dry needling is utilized by multiple practitioners to address impairments in neuromusculoskeletal function, often related to pain and loss of mobility. Dry needling, according the American Physical Therapy Association (APTA), is defined as a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
75327933|NCT01835249|Other|Standard BP arm|Participants in the Standard BP arm have a goal of SBP <140 mmHg.
75327934|NCT01838993|Drug|Lidocaine inhalation|Lidocaine inhalation before intubation
75327935|NCT01838993|Drug|Placebo|
75327936|NCT03211013|Drug|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
75327937|NCT03211013|Drug|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
75327938|NCT03836495|Dietary Supplement|lysine and phosphorus|addition of lysine and essential amino acid and/or phosphorus an essential mineral
75327939|NCT03836573|Behavioral|Smoking Cessation iPad Decision Aid Tool|Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.
75327940|NCT01835405|Device|LiquiBand Flex|
76077779|NCT03426423|Other|Behavioral smoking cessation intervention|"The intervention consists in a behavioral smoking cessation intervention combined with pharmacotherapy. The intervention is tailored it to specificities of participants based on findings from the previous phase of our study (DISCGO-MIX, Swissethics ID PB_2016-01459).~Counseling will cover topics such as assessing ambivalence and enhancing motivation with motivational interviewing methods, identifying barriers to quit, coping with cravings and intensive relapse prevention strategies. Participants will be advised to use over the counter nicotine replacement bi-therapy (NTR). A 2-week starting kit, consisting of nicotine transdermal patch and a short acting NRT (lozenge, gums, inhaler or mouth spray) will be provided to participants for free, if they wish to take NRT.~The behavioral intervention will last 30-45 minutes, and will be conducted by a research nurse using an interview guide."
75327941|NCT01835405|Device|Dermabond Advanced|
75327942|NCT01835405|Device|Sutures (Prolene)|
75327943|NCT03210857|Other|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
75634540|NCT00832624|Drug|sitagliptin|Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
75469160|NCT01919619|Drug|Lenalidomide|Given PO
75327944|NCT01835561|Drug|Pomalidomide|Single oral dose of 4-mg capsule
75634541|NCT00832078|Device|SpeediCath Compact Male|CH 12 hydrophilic coated intermitten compact catheter
75634542|NCT00832078|Device|Speedicath|CH 12 hydrophilic coated intermittent coated catheter
75798536|NCT03866616|Behavioral|Control (Usual care)|"This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
75327945|NCT01835561|Drug|Pomalidomide|4-mg capsule
75327946|NCT01835639|Dietary Supplement|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
75327947|NCT01839071|Procedure|biopsy|
75327948|NCT03210623|Device|stent retriever(TonbridgeMT)|mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
75469161|NCT01918527|Drug|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
75634543|NCT00913120|Drug|YM150|oral
75327949|NCT03210623|Device|Solitaire™|mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
75327950|NCT01839149|Drug|TI-001|TI-001 is intranasal oxytocin
75327951|NCT01839149|Drug|Placebo|
75327952|NCT01839383|Other|different dialysate calcium concentration|
75327953|NCT01835795|Device|Swiss DolorClast® CLASSIC applicator|Radial Extracorporeal Shock Wave applicator use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
75469162|NCT01918527|Drug|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
75634544|NCT00913120|Drug|Placebo|oral
75634545|NCT00913120|Drug|Enoxaparin|injection
75634546|NCT00913198|Drug|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
75634547|NCT00822172|Dietary Supplement|Levocarnitine tartrate|Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
75634548|NCT00822172|Drug|cilostazol|"Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days."
75798537|NCT01284894|Device|Conventional manometry|Conventional esophageal manometry
75798538|NCT01284894|Device|High resolution manometry|High resolution esophageal manometry
75798539|NCT01288170|Drug|Nebcinal Tobi|
75798540|NCT01288170|Drug|Tobi Nebcinal|
75798541|NCT01178112|Drug|Trientine|Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
75798542|NCT01178112|Drug|Carboplatin|Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
75920573|NCT05725590|Procedure|External pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The external pancreatic duct stent left the other end exteriorized through the proximal jejunum via a small enterotomy that was fixed in the abdominal wall.
75327954|NCT01835795|Device|Swiss DolorClast® CLASSIC placebo applicator|Placebo applicator, use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
75327955|NCT00906425|Device|Straumann Bone Level Implant|Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
75327956|NCT01835873|Other|Lactated Ringer's|
75634549|NCT00702598|Behavioral|Telephone-based Cognitive Behaviour Therapy (CBT)|Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
75327957|NCT01835873|Other|HES 130/0.42|Balanced colloid solution
75327958|NCT01835951|Other|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
75327959|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
75327960|NCT01839539|Biological|dendritic and cytokine-induced killer cells|
75327961|NCT00901199|Drug|Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
75327962|NCT01839617|Dietary Supplement|Early parenteral nutrition|
75327963|NCT01839617|Dietary Supplement|Late parenteral nutrition|
75469163|NCT01851369|Drug|TRC102|TRC102 has been shown to potentiate the activity of temozolomide by preventing BER and allowing cleavage of TRC102 bound DNA, which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with TMZ and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
75469164|NCT01792531|Behavioral|Parent training group|The More & Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More & Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
75469165|NCT01792531|Behavioral|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
75784347|NCT06192303|Diagnostic Test|Bronchoalveolar lavage and pathogen metagenomic sequencing|After the patient is enrolled, traditional pathogen testing will be improved, and the clinical physician will make a preliminary diagnosis based on routine pathogen testing, clinical manifestations, infection indicators, and imaging. Within 24 hours of initial diagnosis, bronchoalveolar lavage and pathogen metagenomic sequencing were performed, and BALF mNGS results were fed back to clinical physicians (without interfering with clinical decision-making). Clinical treatment data of patients were collected at 72 hours, 7 days, 14 days, and 28 days after the start of treatment, and follow-up and efficacy evaluation were conducted. Finally, a review committee consisting of two senior respiratory physicians and one imaging physician conducted a systematic review of cases to make the final diagnosis of enrolled patients (as the gold standard), analyzing the accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of BALF mNGS in diagnosing CIP.
75798543|NCT01178112|Drug|Trientine MTD|Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
75327964|NCT01836341|Drug|Afatinib|
75327965|NCT01836341|Drug|Cisplatin|
75327966|NCT01836341|Drug|Carboplatin|
75327967|NCT01836341|Drug|Pemetrexed|
75327968|NCT01836341|Radiation|Radiation therapy|
75469166|NCT01792531|Behavioral|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
75327969|NCT01836419|Procedure|classic LMA insertion|
75327970|NCT00906503|Drug|dexamethasone|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
75327971|NCT00906503|Procedure|PET/Computed Tomography (CT)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
75327972|NCT00906503|Radiation|fludeoxyglucose (18F)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
75327973|NCT01836575|Drug|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment [dexamethasone + vitamin B12 + folic acid, as per pemetrexed label] + Antiemetic therapy at investigator's discretion.
75327974|NCT01836575|Drug|Carboplatin|Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle].
75327975|NCT01836653|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75920574|NCT05725590|Procedure|Internal pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The internal pancreatic duct stent, a silicone catheter with multiple side pores, was inserted into the main pancreatic duct and the other end was placed in the jejunum cavity.
76077780|NCT03426423|Other|Control|"Participants assigned to the control group will receive a less intensive and non-tailored intervention for smoking cessation.~For this arm the structured 3 steps AAR approach will be used:~Ask for smoking status. Advise to quit in a clear manner. Refer to external help: participants will receive a booklet with information on smoking cessation (non specific to diabetes and gender) and links to support facilities (national quitline, smoking cessation clinic, websites, self-help).~This unique intervention of 5-10 minutes will be performed by the research nurse."
75327976|NCT01836653|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75327977|NCT01836653|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75327978|NCT01836653|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75327979|NCT01836653|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75327980|NCT01836653|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
75327981|NCT01836731|Behavioral|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
75327982|NCT01836731|Behavioral|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
75327983|NCT03836885|Drug|Apremilast|Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.
75327984|NCT03836885|Drug|Placebo|Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
75327985|NCT03837119|Other|pregnancy outcome|descriptive statistics of variables
75327986|NCT00920647|Other|Control|3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
75327987|NCT00920647|Drug|Idursulfase IT (1 mg)|The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
75634550|NCT00702598|Behavioral|Telephone reminder calls|Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
75634551|NCT00832000|Drug|Mexiletine|200 mg three times a day; in pill form
75634552|NCT00832000|Drug|Placebo|Placebo three times a day; in pill form
75634553|NCT00911508|Device|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
75798544|NCT01178112|Drug|Carboplatin MTD|Maximum tolerated dose found in MTD Dose Escalation Group
75798545|NCT01178112|Other|PK Testing|Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
75798546|NCT01173354|Dietary Supplement|Free balanced amino acid mixture|7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
75798547|NCT01173354|Dietary Supplement|Free essential amino acid mixture|7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
75327988|NCT00920647|Drug|Idursulfase IT (10 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
75327989|NCT00920647|Drug|Idursulfase IT (30 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
75327990|NCT01836887|Dietary Supplement|Very low polyphenol fruit based drink (control)|
75327991|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
75327992|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
75327993|NCT01836965|Behavioral|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
76077781|NCT01009762|Biological|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
76077782|NCT05688813|Procedure|Regional anesthesia intervention|Ultrasound-guided caudal and sacral erector spinae blocks were administered
75327994|NCT04373395|Procedure|D-CLAG|Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor
75327995|NCT01837043|Drug|Belatacept|
75634554|NCT00911508|Drug|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
75634555|NCT04202796|Procedure|Catheter ablation|Catheter ablation of arrhythmia
75327996|NCT01837043|Drug|Calcineurin Inhibitor|
75634556|NCT04202952|Drug|HEC110114 Tablet|administered orally once daily
75634557|NCT04202952|Drug|Sofosbuvir Tablet|administered orally once daily
75327997|NCT01839773|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
75327998|NCT01839773|Drug|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
75327999|NCT04373239|Procedure|Assisted Reproductive Technology|Assisted reproductive technology includes IVF and IVF+ICSI.
75328000|NCT04373161|Device|Home Pulse Oximetry Monitoring|Patients to check their home oxygen saturation three times daily and return to the ED for sustain oxygen <92% or for worsening symptoms.
75328001|NCT00909155|Drug|Venlafaxine ERT|Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
75328002|NCT00909155|Drug|Fluoxetine|Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
75328003|NCT01839851|Drug|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
75328004|NCT01839851|Drug|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
75651719|NCT05800028|Behavioral|Learning new information|The purpose of this study is to test the effects of different social contexts when learning new information. Participants in the AD, SPPA, and HC experimental groups will be given tests to learn verbal information (location of drawings in a grid). The learning phases of these tests are presented in the form of a memory game in which participants are asked to make pairs of drawings by finding the second copy of the proposed pair by trial and error in a grid. After learning, a task of recognizing the position of the drawings in the grid is performed. Each participant will carry out this learning in three different conditions: 1) learning alone, 2) learning by observation of the reconstruction of the pairs of images by a partner, and 3) collaborative learning in which the two game partners discover and reconstruct the pairs together.
75920575|NCT05474482|Other|kinesio taping with exercises|Kinesio taping with full stretch of 75 to 100 % for 2 days session per week and exercises for 3 days session per week for total 8 weeks.
75920576|NCT05474482|Other|Kinesio taping without exercises|Kinesio taping with a full stretch of 75 to 100 % for 2 days session per week without exercises for 8 weeks.
75920577|NCT05474482|Other|Kinesio taping without stretch as control|kinesio taping without any stretch for 2 days session per week for total 8 weeks.
75920578|NCT02127879|Device|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
75920579|NCT02127879|Device|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
76077783|NCT01009918|Drug|Coreg CR®|Given orally
76077784|NCT01009918|Drug|lisinopril|Given orally
76077785|NCT01009918|Other|placebo|Given orally
76077786|NCT03088683|Device|Nathanson Retractor|Liver will be retracted with Nathanson retractor
76077787|NCT03088683|Device|Reveel Retractor|Liver will be retracted with Reveel retractor
76077788|NCT04401657|Diagnostic Test|Fractional flow reserve with adenosine stress testing|ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
76077789|NCT03019198|Drug|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
76077790|NCT03019198|Drug|Placebo - Concentrate|
76077791|NCT04401501|Other|Manual Therapy and Exercises|Combination of physiotherapy (manual therapy) techniques and exercises for cervicogenic headache
76077792|NCT04401501|Other|Exercise|Exercises for cervicogenic headache
75328005|NCT01839929|Drug|Prograf|oral
75328006|NCT01839929|Drug|Advagraf|oral
75920580|NCT03529500|Diagnostic Test|Caries detection - dmtf index|"Dental caries experience was recorded using the dmft index, which was employed following the recommendations of the WHO to establish the prevalence and severity of caries. Active visible white spots were also recorded. The examinations were performed in duplicate for each child with the aim of establishing inter-examiner agreement using the Kappa statistic which demonstrated good agreement (K = 0.81).~The criteria adopted for the determination of prevalence followed by guidelines of the Oral Health Surveys - Basic Methods, 4th edition (WHO, 1997) described in the examiner's manual and annotator's manual produced by the coordination team of the Brazil Oral Health Project. The severity and prevalence of dental caries were determined based on the dmft index."
76077793|NCT03018808|Other|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
76077794|NCT03018808|Other|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
76077795|NCT03018808|Other|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
75634558|NCT04276740|Dietary Supplement|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis)~MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
75634559|NCT04276740|Other|Placebo|Placebo
75328007|NCT03403855|Device|Rocket® IPC- Long External Length|Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
75328008|NCT03403855|Device|Rocket® IPC- Short External Length|Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
75328009|NCT04373083|Drug|Cemiplimab|Administered in 3-week intervals
75328010|NCT04373083|Radiation|Involved-site radiotherapy (IS-RT)|Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
75328011|NCT03210545|Drug|Betamethasone|A cross-over study where patients with Addison´s disease will undergo two treatment periods where their usual hydrocortisone replacement therapy will be replaced by the glucocorticoid betamethasone in physiological and supra physiological doses. A wash-out period of 2-5 weeks in-between the treatment periods will be carried out where participants intake their usual hydrocortisone replacement therapy.
75634560|NCT04394286|Genetic|SHP648|Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
75634561|NCT04378296|Other|Teledermatology|The experimental group will be made up of dermatological patients monitored asynchronously.
75634562|NCT04054674|Procedure|Abutments with flat occlusal scheme preparation restored by lithium disilicate crowns|Clinical trials lacks information about flat occlusal preparation design in case of endodontically treated teeth. Therefore, this is tested during preparation when compared to planer occlusal preparation while the final restoration in both arms is lithium disilicate (e.max) crowns.
75328012|NCT04372849|Other|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
75328013|NCT04372849|Other|Placebo|Single dose of placebo solution as nasal spray
75328014|NCT03210389|Drug|Lobaplatin|Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
75634563|NCT00774397|Drug|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
75328015|NCT03403777|Drug|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks.
75328016|NCT01837121|Other|the SMS reminder message|the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
75634564|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
76077796|NCT03018808|Procedure|Blood test|Blood samples will be collected at indicated time points
76077797|NCT03018808|Other|anthropometric measures|Anthropologic measures will be performed.
76077798|NCT03018808|Other|Oximetry|Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
76077799|NCT03083613|Drug|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
76077800|NCT03083613|Drug|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
75328017|NCT02241421|Drug|Amoxicillin|
75328018|NCT02241421|Drug|Vancomycin|
75328019|NCT02241421|Other|Placebo|
75328020|NCT01837199|Drug|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
75328021|NCT03210233|Procedure|Blood test, skin testing and challenge testing.|Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy
75328022|NCT01837355|Dietary Supplement|Lactobacillus rhamnosus|
75328023|NCT01837355|Dietary Supplement|Placebo|
75328024|NCT03210311|Device|compression|a compression stocking is worn, a garment compression class 2, flat knitted
75328025|NCT00926185|Drug|Lifitegrast|Ophthalmic Solution
75920581|NCT03529500|Diagnostic Test|Saliva flow rate|Samples of non-stimulated saliva were collected from the participants for five minutes using two aspirator tubes connected to a 15-ml Falcon tube. One aspirator tube was positioned under the child's tongue and the other was attached to the aspirator device. After five minutes, the amount of saliva was measured for the determination of salivary flow. Collections were performed between 9 and 11 am and the time of the last meal was recorded. At least a one-hour interval was required between the last meal and the collection of the saliva sample. The volume of saliva was measured. The salivary flow volume was calculated and expressed as ml/min. The following categories were considered in the analysis of salivary flow: < 0.1 ml/min = xerostomia; 0.1 to 0.6 ml/min = very low flow; 0.7 to 0.9 mL/min low flow; 1.0 to 2.0 ml/min = normal flow; and > 2.0 ml/min = high flow.
75920582|NCT03529500|Diagnostic Test|Saliva Buffering Capacity|an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC). The saliva/acid solution was shaken in a q 220 vortex tube agitator (Quimis, Diadema, SP, Brazil) for 15 seconds. Next, pH was determined in a portable pH meter (KASVI K39-0014P, Curitiba, PR, Brazil) for the determination of the SBC. The following categories were considered: ≥ 5.5 = very good buffering capacity; 5.4 to 5.0 = good buffering capacity; 4.9 to 4.5 = medium good buffering capacity; 4.4 to 4.0 = low buffering capacity; and ≤ 3.9 very low buffering capacity.
75920583|NCT03551145|Other|Acellular collagen matrix|3D collagen matrix consists of the collagen porcine type I and III
75920584|NCT03551145|Other|Autogenous free gingival graft|Autogenous graft harvested from the posterior palate
75328026|NCT00926185|Drug|Placebo|Ophthalmic Solution
75328027|NCT01837511|Other|Data acquisition and analysis|Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
75920585|NCT04441476|Other|Questionnaires|"An online questionnaire (Limesurvey platform) will be made available at 4 different times (M0, M1, M2 and M6).~The first questionnaires (M0 and M1) will include a component for professional characterization. Generic and specific stress factors related to ICU and the current pandemic and collective and individual defensive strategies will also be collected in M0 and M1.~At M2 and M6, the traumatic impact of the crisis, burnout, signs of depression and recourse to internal or external support in the department (occupational medicine, support unit) will be collected."
75920586|NCT04441476|Other|psychological and sociological interviews|"conducting semi-directive psychological interviews (40 interviews in M2, 40 interviews in M6).~sociological interviews: 40 (20 in M1-M2 then 20 in M6) in order to understand the consequences of the epidemic on daily life, both intra-family and micro-social."
75328028|NCT00921895|Device|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
75328029|NCT03210077|Device|Monitoring|Monitoring
75634565|NCT00774397|Drug|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
75634566|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
75634567|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
75634568|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
75920587|NCT05474326|Device|intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System)|application of intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System) on lower limbs and its effect on fetal and maternal doppler and amniotic fluid index in women with oligohydramnios. the compression system will be applicated on lower limbs for one hour in which it will produce intermittent compression on lower limbs. amniotic fluid amnout assessment will be done after this including doppler studies in order to detect any change in amniotic fluid amount or dopper.
75920588|NCT02127957|Other|Exercise|Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
75920589|NCT04441398|Drug|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
75328030|NCT04372771|Other|Curves Circuit|The Curves Circuit consists performing 13 hydraulic resistance exercise machines that utilize bidirectional resistance that work all major muscle groups. These are interspersed with floor-based calisthenic exercises designed to maintain an elevated heart rate.
75328031|NCT04372771|Other|Weight Watchers|The Weight Watchers program encourages one to increase physical activity.
75328032|NCT01837589|Other|QCT|
75328033|NCT01837589|Other|DXA|
75328034|NCT02241499|Radiation|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
75328035|NCT02241499|Drug|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
75328036|NCT01837667|Drug|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
75328037|NCT01837667|Drug|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
75328038|NCT02241577|Procedure|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
75328039|NCT02241577|Procedure|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
75328040|NCT04372303|Behavioral|Compassion Fatigue Resiliency Program (CFRP)|The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.
75469167|NCT01731236|Dietary Supplement|Carnitine|Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
75634569|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
75634570|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
75634571|NCT00774397|Drug|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
75634572|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
75634573|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
75920590|NCT04441398|Drug|Placebo|Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
75920591|NCT02128035|Procedure|With Lead Shield|"A pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
75920592|NCT05474248|Behavioral|Experimental group|Diaphragmatic Breathing Training
75920593|NCT03551067|Drug|Dexmedetomidine|Dexmedetomidine mixed with juice was given to the child orally preoperatively.
75469168|NCT01731236|Dietary Supplement|Choline|Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
75328041|NCT03217877|Diagnostic Test|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9~15 months after the procedure according to the practice pattern of each participating center.
75634574|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
75634575|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
75634576|NCT00774397|Drug|Placebo|Placebo
75920594|NCT03551067|Combination Product|Midazolam/Ketamine|Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
75634577|NCT03576144|Drug|BI 1265162|Multiple rising inhaled doses
75634578|NCT03576144|Drug|Placebo|Multiple rising inhaled doses
75920595|NCT05474170|Other|AHA resuscitation sequence|Starting the cardiopulmonary resuscitation by following the AHA guideline, meaning starting with 15 chest compressions, followed by 2 ventilations
75634579|NCT04454736|Behavioral|"Amateur Group Singing"|45-minute singing session led by a professional choirmaster without a therapeutic background once a week
75920596|NCT05474170|Other|ERC resuscitation sequence|Starting the cardiopulmonary resuscitation by following the ERC guideline, meaning starting with 5 initial ventilations, then alternating 15 chest compressions with 2 ventilations
76077801|NCT00963508|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
75634580|NCT04454736|Behavioral|"Professional Group Singing"|120-minute singing session led by a professional choirmaster without a therapeutic background three times a week. Assessments take place twice a week.
75634581|NCT00632034|Other|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
75328042|NCT03217877|Diagnostic Test|No Routine stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
75469169|NCT01731236|Drug|Antibiotics|Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
75469170|NCT01731236|Drug|Choline and Aspirin|Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
75634582|NCT05491369|Other|Epilepsy application|Nanacara is an epilepsy application which helps people with epilepsy to self-manage their conditions.
75634583|NCT04166292|Device|Stylage® XL Lidocaïne|"On V1 (D0), a total volume of 8 mL maximum can be used per subject on the whole face.~On V2 (M1), a possible touch-up can be made according to the injector and subject's opinion which cannot exceed 4 ml."
75920597|NCT02288052|Behavioral|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
75920598|NCT02288052|Behavioral|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
75920599|NCT03552237|Dietary Supplement|dietary fiber|We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
75920600|NCT03529266|Biological|Porcine Fibrin Sealant (PFS)|2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
75920601|NCT03529266|Procedure|Surgery|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
75920602|NCT02128191|Drug|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
75469171|NCT01731236|Drug|Carnitine and Aspirin|Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
75469172|NCT01627093|Other|Medical Chart Review|Review of medical records
75920603|NCT02128191|Drug|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
76077802|NCT00963508|Drug|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
76077803|NCT03088371|Drug|Bupivacaine 0.25%|For psoas sciatic block.
76077804|NCT03088371|Other|Pajunk Needle|For local anaesthesia application in psoas sciatic block
76077805|NCT03088371|Other|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
76077806|NCT03088371|Drug|Lidocaine 1%|For psoas sciatic block.
76077807|NCT03088371|Drug|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
75469173|NCT01627093|Other|Questionnaire Administration|Complete questionnaires
75469174|NCT01590069|Biological|Aerosolized Aldesleukin|Breathe aerosolized aldesleukin
76077808|NCT03088371|Drug|Lidocaine 2 %|For psoas sciatic block in the post-operative period
75634584|NCT04099771|Drug|Ketamine|Ketamine infusion
76077809|NCT03088371|Drug|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
75328043|NCT04379531|Diagnostic Test|Low-dose Chest CT|Patients referred by the primary care physician with suspected pneumonia.
75634585|NCT04273620|Behavioral|Optokinetic stimulation and cueing-based reading therapy (OKS-READ)|"Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy)."
75920604|NCT04393636|Other|Digital cardiac Counseling|"Screening for reduced physical fitness and digital counseling.~Screening for smoking and digital counseling.~Screening for malnutrition and obesity and digital counseling.~Screening for anxiety and depression and digital counseling.~Screening for elevated pulmonary risk score and digital counseling."
75920605|NCT00004896|Drug|busulfan|
75920606|NCT00004896|Drug|cyclophosphamide|
75328044|NCT03833947|Drug|lignocaine+bicarbonate|ETT cuff was filled with mixture of 2% lignocaine with bicarbonate
75328045|NCT03833947|Drug|lignocaine+dexamethasone|ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
75328046|NCT03219437|Drug|risankizumab|subcutaneous (SC) injection
75328047|NCT03219437|Drug|methotrexate|capsule
75328048|NCT00920023|Drug|Superparamagnetic Iron Oxide Magnetic Resonance Imaging|Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
75328049|NCT03212963|Drug|Halobetasol Topical Lotion|Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
75328050|NCT03403309|Drug|1) Inosine 5'-monophosphate|1) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
75328051|NCT03403309|Drug|Placebo|2) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
75920607|NCT00004896|Procedure|allogeneic bone marrow transplantation|
75469175|NCT01590069|Other|Laboratory Biomarker Analysis|Optional correlative studies
76077810|NCT01010854|Drug|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
76077811|NCT05685537|Drug|Levosimendan|Initiation of levosimendan 48 hours before surgery
75328052|NCT04347499|Other|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
75328053|NCT03218969|Drug|Ecopipam|oral drug in subjection currently experiencing dopamine agonist induced augmentation
75328054|NCT03218969|Drug|Placebo|matching placebo
75920608|NCT00004896|Procedure|bone marrow ablation with stem cell support|
75328055|NCT02982499|Device|magnetic resonance image (MRI)|Radiographic imaging that takes about 30-45 minutes
75328056|NCT02982499|Device|Optical Coherence Tomography (OCT)|Images taken from the back of the eye (retina)
75328057|NCT03214523|Behavioral|Sleep Education|The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
75328058|NCT04372537|Behavioral|hypnosis|use of hypnosis.
75328059|NCT04372537|Behavioral|standard care|standard clinical procedure
75328060|NCT04372225|Other|analysis of hypocalcemia|analysis of postoperative calcium and PTH levels
75328061|NCT03214289|Biological|Fecal Microbiota Transplantation|Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
75341406|NCT05245994|Drug|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy. Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide [80 to 100mg/m2] via intravenous infusion and carboplatin [ The area under the curve (AUC) is 5-6] by intravenous infusion or cisplatin [75-80 mg/m2] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator. The initial dose of olaparib is 300mg twice daily. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.
75469176|NCT01529593|Drug|Temsirolimus|"Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
75920609|NCT00004896|Radiation|radiation therapy|
75920610|NCT02121951|Procedure|Local Anesthetic infiltration|Lignocaine infiltration through the nephrostomy track
75920611|NCT02121951|Procedure|Quadratus Lumborum block|A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
75328062|NCT04372459|Behavioral|Online integrated and stepped psychosocial care|"This program features four levels of care, increasing in intensity of psychosocial care as patients move from one level to the next one.~Step 1: Screening and monitoring of several psychosocial variables through the central mobile application of the program (App ICOnnecta't).~Step 2: Online guided and self-help psychoeducation Campus in which patients can consult videos and online resources, co-constructed between health professionals and patients, containing reliable and rigorous information related to the oncological process.~Step 3: Online community of psychosocial support. Participants can choose from 12 cancer-related discussion forums and share with the community any health-related question that worries them fostering, thus, debate and stimulating peer-support.~Step 4: Intensive online group psychotherapy (App ICOnnecta't Videoconsultation), based on the Group Positive Psychotherapy program for cancer survivors (Ochoa, Sumalla, Maté, Castejón, Rodríguez et al., 2010)."
75328063|NCT04372459|Behavioral|Usual psychosocial care|This active control group will receive the standard psychosocial treatment for cancer survivors in the participating centers, led by a clinical psychologist and consisting of 8 individual, 45/60-minute sessions, each of which every 1-2 months, focused on providing emotional support and psychoeducation during the first year of primary cancer treatment.
75328064|NCT01830023|Device|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
75469177|NCT01529593|Drug|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
75469178|NCT01504789|Behavioral|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
75469179|NCT01504789|Behavioral|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
75469180|NCT01504789|Behavioral|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
75469181|NCT01504789|Behavioral|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
75634586|NCT04273620|Behavioral|General neuropsychological treatment|As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
75634587|NCT03378570|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
75634588|NCT00909870|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
75634589|NCT00909870|Device|Profore|Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
75328065|NCT01830101|Drug|TMZ plus concurrent re-irradiation|
75328066|NCT01830101|Drug|Temozolomide|low-dose temozolomide daily for one year
75328067|NCT01838603|Other|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
75328068|NCT01830257|Other|sending message|Sending the suggestive short message
75328069|NCT01834625|Diagnostic Test|PET scan|
75328070|NCT01830335|Drug|Indomethacin|
75328071|NCT01830335|Drug|Placebo|
75328072|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
75328073|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
75328074|NCT00926263|Biological|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
75328075|NCT01838915|Dietary Supplement|Prebiotics+Glutamine|"Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function."
75328076|NCT01838915|Dietary Supplement|Placebo|Maltodextrin, 20 g.
75469182|NCT01446133|Drug|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
75469183|NCT01446133|Drug|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
75328077|NCT01725659|Other|Motor Learning|training of the hemiplegic upper limb with motor learning
75328078|NCT01725659|Other|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
75328079|NCT01725659|Other|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
75469184|NCT01349881|Drug|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
75920612|NCT02121951|Drug|MAC|Incremental doses are given to the targed sedation and analgesia
75634590|NCT00768469|Drug|Neratinib|Administered orally, continuous, once daily.
75634591|NCT00768469|Drug|Paclitaxel|Administered IV, on days 1, 8, 15 of 28 day cycle.
75328080|NCT00926497|Other|Procalcitonin-guided decision making|Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
75328081|NCT00916643|Device|HELP Secura (apheresis treatment)|Process is described in Arm (above).
75328082|NCT04372147|Procedure|MMA embolization|Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
75328083|NCT03409913|Radiation|FDG PET/CT|Conventional FDG PET/CT including head in order to asses cranial arteries.
75328084|NCT03403075|Behavioral|ETAF|Therapeutic education and Physical activity
76077812|NCT04279509|Procedure|Tumor Core Biopsy|"Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses."
75328085|NCT03403075|Behavioral|Usual care|Usual care
75328086|NCT04378361|Device|endovascular repair|Endovascular repair of complicated acute, subacute or chronic type B aortic dissection with double lumen
75328087|NCT03833869|Procedure|Assisted hatching|Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
75469185|NCT01349881|Drug|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
75328088|NCT01725737|Drug|GlyTI-M|
75469186|NCT01349881|Drug|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
75469187|NCT01349881|Drug|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
76077813|NCT04279509|Procedure|Blood sampling|Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
75469188|NCT01340742|Procedure|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
75634592|NCT00886821|Biological|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
75634593|NCT03319368|Other|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
75634594|NCT02825433|Other|No intervention, only ventilation monitoring|
75634595|NCT02823795|Behavioral|Motivational Interviewing|Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
75328089|NCT01725737|Drug|Placebo|Placebo Comparator: starch
75328090|NCT04371991|Diagnostic Test|blood test|blood test (serum samples) for biochemical examination
75328091|NCT02242279|Drug|BEA 2180 BR|
75328092|NCT02242279|Drug|Tiotropium|
75328093|NCT02242279|Drug|Placebo|
75328094|NCT04371757|Drug|α1-adrenergic block|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
75328095|NCT04371757|Other|Placebo|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
75469189|NCT01340742|Procedure|Control|Cuff placed on arm uninflated for 30 minutes.
75328096|NCT00917735|Drug|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
75328097|NCT00917735|Other|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
75328098|NCT04371601|Drug|Oseltamivir|Oseltamivir capsules
75469190|NCT01295645|Drug|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
75469191|NCT01295645|Other|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
75469192|NCT01254903|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
75920613|NCT05473858|Drug|OraVerse Injectable Product|injection of oraverse,
75920614|NCT05473858|Device|diode laser|patient exposed to diode laser
75920615|NCT00004584|Drug|Atazanavir|
75920616|NCT00004584|Drug|Ritonavir|
75920617|NCT00004584|Drug|Saquinavir|
75920618|NCT04363528|Other|Doppler Echo|2 doppler echo will be done at patients hospitalized in ICU and with SARS-CoV-2 pneumopathy at 7 days apart
75920619|NCT03552159|Behavioral|Behavioral activation|Activity scheduling, monitoring, review and re-scheduling
75920620|NCT03552159|Other|Psychoeducation|Education on dementia, caregiving stress, event scheduling and communication skills
75920621|NCT00004230|Drug|captopril|
75920622|NCT00004230|Drug|cyclophosphamide|
75920623|NCT00004230|Procedure|autologous bone marrow transplantation|
75920624|NCT00004230|Procedure|peripheral blood stem cell transplantation|
75920625|NCT00004230|Radiation|radiation therapy|
75920626|NCT02252367|Drug|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
75920627|NCT02252367|Other|Placebo|Placebo tablet once daily for 12 weeks.
75920628|NCT00004182|Drug|irinotecan hydrochloride|
75920629|NCT02122029|Behavioral|Lifestyle counselling|Behavioral techniques for weight management
75328099|NCT04371601|Drug|hormones|a moderate amount of hormone
76077814|NCT00964444|Device|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
75634596|NCT04242693|Behavioral|Mobile goal-setting intervention|This intervention applied two constructs from the goal setting theory-self-monitoring and goal setting. Briefly, all participants were asked to take photos of all their meals and upload them with descriptions to an online platform. The participants in the experimental group were taken through two additional processes that represented these two constructs. Self-monitoring was operationalized by asking those in the experimental group to count the number of times they ate red/orange vegetables using a counting checklist. Goal setting was operationalized as asking them to set a goal to eat red/orange vegetables one more time tomorrow.
75328100|NCT04371601|Device|oxygen therapy|oxygen therapy,mechanical ventilation and other supportive therapies
75328101|NCT04371601|Procedure|mesenchymal stem cells|mesenchymal stem cells
75328102|NCT01832207|Device|Transcutaneous electrical nerve stimulation|
75328103|NCT01832207|Device|Placebo transcutaneous electrical nerve stimulation|
75328104|NCT04371523|Drug|Apo-Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.
75634597|NCT04242381|Other|Cold Application|At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.
75328105|NCT04371523|Drug|Matched Placebo|Matching Placebo
76077815|NCT05685459|Other|Standard patient simulation model|Nursing students were trained with a standard patient simulation model for position and communication skills education.
75328106|NCT03402997|Diagnostic Test|Resistivity measurement|To measure and compare the tissue impedance values obtained by analysing ex vivo non-neoplastic (healthy and peritumoral) and neoplastic breast tissues
75328107|NCT01837979|Procedure|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
75328108|NCT02242357|Drug|Micardis®|
75328109|NCT02242357|Drug|Micardis® Plus|
75328110|NCT03409835|Drug|Ramosetron|Ramosetron 0.3 mg is administered after induction of general anesthesia.
75920630|NCT02122029|Procedure|Bariatric Surgery|Vertical Banding Gastroplasty
76077816|NCT04400721|Drug|Erector spinae plane block with ropivacaine 3.75mg/ml|Single shot erector spinae block
76077817|NCT01010932|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
76077818|NCT01010932|Other|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
76077819|NCT03018652|Drug|Intravenous immunoglobulin|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
75328111|NCT03409835|Drug|Normal saline|Normal saline 2 ml is administered after induction of general anesthesia.
75328112|NCT02242513|Device|Pulsed radiofrequency (PRF)|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.
75328113|NCT02242513|Drug|Xylocaine|
75328114|NCT03409757|Drug|Velphoro|4 weeks
75328115|NCT03409757|Other|saliva collection|2 samples
75328116|NCT03409757|Other|Supragingival biofilm collection|2 samples
75328117|NCT03409757|Other|stool collection|2 samples
75328118|NCT03409757|Other|blood collection|2 samples
75328119|NCT03402763|Behavioral|Educational Video|The intervention is an educational video presented to patients in the ED with the intent to promote ACP among older adults.
75328120|NCT03402763|Behavioral|Primary Care Provider Email|For intervention patients, an email will be sent to primary care providers explaining that the patient has seen a video about advance care planning, providing a synopsis of the video, and giving instructions about how to document end-of-life care preferences in the electronic health record.
75328121|NCT03409679|Drug|Murepavadin|Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
75328122|NCT03409679|Drug|Two anti-pseudomonal antibiotics|Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
75328123|NCT00926887|Device|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
75328124|NCT00926887|Device|Placebo Laser|Inactive light
75328125|NCT04371367|Biological|avdoralimab|intravenous administration of avdoralimab
75328126|NCT04371367|Other|Placebo|intravenous administration of placebo
75328127|NCT02242591|Drug|Ropivacaine 7,5 mg/ml|
75328128|NCT02242591|Drug|Saline|
75328129|NCT03409601|Other|100% Portion Size|Meal portion size at baseline
75328130|NCT03409601|Other|125% Portion Size|Meal portion size 125% of baseline
75328131|NCT03409601|Other|150% Portion Size|Meal portion size 150% of baseline
75328132|NCT03409601|Other|175% Portion Size|Meal portion size 175% of baseline
75328133|NCT01726127|Other|Broccoli and Brussels Sprouts|
75328134|NCT01726127|Dietary Supplement|Cruciferous Complete|
75328135|NCT01726127|Other|Placebo|
75328136|NCT02982577|Drug|Pilocarpine|Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
75920631|NCT05556460|Device|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
75920632|NCT05201742|Other|Inspiratory muscle training|Threshold inspiratory muscle training was performed for 6 weeks with device.
75920633|NCT05201742|Other|Incentive Spirometry|Incentive spirometry was performed for 6 weeks with device.
75920634|NCT02124525|Drug|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
76077820|NCT03018652|Drug|Normal Saline|5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
75920635|NCT02124681|Drug|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
75920636|NCT02124681|Other|Placebo|Placebo PO for 13±1 weeks
75920637|NCT05611060|Behavioral|Building Healthy Life Skills Program|The intervention provides education and training in the long-term mental and physical health consequences of childhood adversity and emotion regulation skills.
76077821|NCT04353700|Behavioral|Yoga group|During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
76077822|NCT04353466|Procedure|quantitative chemical shift imaging (QCSI)|"Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered bone at risk"
76077823|NCT04353466|Drug|Elelyso|intravenous (IV) infusions of Elelyso
75634598|NCT04242381|Other|Kinesiotaping Application|KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)
75634599|NCT04242381|Other|Exercise treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Before starting the exercise program, the patients were instructed to not perform the movements exceeding 90° overhead. The exercise program was initiated using codman pendulum, passive joint motion range (with a 1-m stick), and posterior capsule stretching exercise. Shoulder wheel, finger ladder, and shoulder strengthening exercise with theraband were added to the exercise programs of patients with full or near total range of motion and pain relief. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
75634600|NCT04242381|Other|Sham Kinesio taping application|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
75920638|NCT03551613|Dietary Supplement|honey supplementation|honey supplementation
75920639|NCT05556304|Other|assessment in the 8th month of pregnancy and during delivery|"Day 0: presentation of the study~During pregnancy between Day 0 and 36-38SA: inclusion~During pregnancy: collection of pelvic MRI data if performed during pregnancy for maternal or fetal reasons~Between 36 and 38 WG: collection of demographic, obstetrical, fetal ultrasound and clinical data / Perineal elastographic recording / Recording of the perineal deformation by stereovision camera~In the delivery room, at the beginning of labor and before pushing: collection of clinical data / Collection of obstetrical ultrasound data / Perineal elastographic recordings / Recording of the perineal deformation by stereovision camera~In the delivery room, during expulsion : recording of the perineal deformation by stereovision camera~In the delivery room, after childbirth: collection of obstetrical, clinical and neonatal data / Perineal elastographic recordings / Cephalic and shoulder measurements of the newborn with a tape measure"
76077824|NCT03018496|Dietary Supplement|Beta-Hydroxy-Beta-Methylbutyrate|
75328137|NCT02982577|Other|Spray without Pilocarpine|Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
75328138|NCT03409445|Other|no intervention|no intervention (observational study)
75328139|NCT02242747|Drug|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
75634601|NCT04242615|Other|Prognostic score|
76077825|NCT03018496|Other|Placebo|
76077826|NCT00966238|Biological|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
75328140|NCT02242747|Drug|5% 5-FU|two applications a day for four weeks in a pre-determined area
75328141|NCT04371133|Diagnostic Test|Adropin (ng/L)|Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).
75328142|NCT01726205|Drug|Pregabalin and normal saline infusion, PRG|
75634602|NCT02825121|Device|Monitoring Neuromuscular Blockade the Flexor Hallucis|
76077827|NCT01012336|Drug|Aprepitant/Ramosetron/Dexamethasone|"Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.~Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.~Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg."
75328143|NCT01726205|Drug|Pregabalin and ropivacaine 02% infusion|
75328144|NCT01726205|Drug|Placebo drug, normal saline infusion|
75328145|NCT02242825|Drug|Micardis®|
75328146|NCT02242825|Drug|MicardisPlus®|
75328147|NCT04370743|Other|No intervention|
76077828|NCT00966550|Other|Tomato|Tomato with high carb/fat meal
76077829|NCT00966550|Other|Non-tomato|Non-tomato with high carb/fat meal
76077830|NCT03387501|Drug|Plasma rich in growth factors (PRGF-Endoret)|Intrauterine administration of PRGF
76077831|NCT01012492|Drug|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
76077832|NCT05688345|Drug|Remimazolam|The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
76077833|NCT05688345|Drug|Propofol|Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
76077834|NCT05688345|Drug|Dexmedetomidine|The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
76077835|NCT03016624|Device|OCT guided PCI|oct guided
76077836|NCT03016624|Device|Angiography guided PCI|angio guided
75328148|NCT04370977|Drug|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to <15kg, two tablets per dose for those 15 to <25kg, and three tablets per dose for those 25 to <35kg.
76077837|NCT03083457|Drug|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
75328149|NCT04370977|Drug|Winthrop™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children <9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children >18-35kg.
75920640|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
76077838|NCT03083457|Drug|General anesthetic|Total intravenous anesthesia with a standard protocol
75328150|NCT01726283|Device|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
75920641|NCT05556070|Other|Arm 1|: Local retailer produce vouchers ($25 value) will be distributed to the families biweekly over a 32-week period for a total of 16 vouchers. The vouchers can be redeemed for fresh produce at the grocery store that issued the vouchers.
75920642|NCT05556070|Other|Arm 2|Boxes of fresh fruits and vegetables (F&V), each containing approximately 50 servings of F&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F&V boxes will be distributed to families every 2 weeks over 32 weeks.
75920643|NCT05556070|Other|Arm 3|subjects in this arm will receive the usual standard of care at the clinic for the study period
76077839|NCT03083457|Drug|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
76077840|NCT03083457|Procedure|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
76077841|NCT03083457|Procedure|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
76077842|NCT04348227|Behavioral|Enhanced hygiene measures|Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
75634603|NCT02825121|Device|Monitoring Neuromuscular Blockade adductor of the thumb.|
76077843|NCT00967486|Procedure|Carotid endarterectomy with routine shount|
76077844|NCT00967486|Procedure|Carotid endarterectomy with selective shunt|
75328151|NCT01726283|Drug|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
76077845|NCT04348461|Drug|Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells|Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
75469193|NCT01234025|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
75634604|NCT02825199|Dietary Supplement|Caffeine|capsule: 300mg caffeine
76077846|NCT04348617|Other|Moderate exercise|50 minutes of moderate exercise on treadmill
75634605|NCT02825199|Dietary Supplement|Non caffeine|capsule: placebo (maize starch)
75634606|NCT02824965|Drug|Pembrolizumab|Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
75634607|NCT02824965|Biological|CVA21|CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
75634608|NCT04919343|Behavioral|BBC Education Tiny Happy People videos|This intervention involves regular texting of BBC Education Tiny Happy People videos to parents
75634609|NCT04919343|Behavioral|Physical health control intervention|This intervention involves regular texting of publicly available videos about supporting infant physical and dental health to parents
76077847|NCT04348617|Other|Rest|50 minutes of rest or sedentary activity
76077848|NCT01013194|Other|Human Fetal Liver Cell Transplantation|"Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10^8 cells. Number of sessions: up to 2."
75328152|NCT02243683|Drug|AX-024.HCl|
75328153|NCT02243683|Other|Placebo|
75328154|NCT03409211|Dietary Supplement|PEVCO|All subjects will receive PEVCO for 6 more weeks.
75469194|NCT01234025|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
75328155|NCT03409211|Dietary Supplement|Dietary Supplement Capsules without Coconut Oil|All subjects will receive placebo (PBO) for 3 weeks
75469195|NCT01234025|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
75469196|NCT01234025|Drug|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
75469197|NCT01234025|Drug|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
75469198|NCT01187199|Drug|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
75920644|NCT05556070|Other|Brighter Bites app|"Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
75920645|NCT02128425|Drug|FOLFOXIRI|"irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~*reduced in UGT1A1 7/7 patients"
75920646|NCT02128425|Drug|FOLFOX|oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
75920647|NCT05555992|Device|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
76077849|NCT04761237|Drug|Goal-directed fluid therapy (GDET)|Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV < 13%.The infusion was stopped when the SVV < 10%.If the increase of SV was less than 10% or CI < 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
76077850|NCT05684835|Procedure|Excision|All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.
76077851|NCT03018184|Other|MRI and Muscle Dynamometer|
75328156|NCT04370899|Other|lifestyle assessment|"A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex).~The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year.~Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco."
75341407|NCT05547529|Procedure|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
75634610|NCT04242537|Device|High flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a high flow nasal cannula with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
75634611|NCT04242537|Device|Low flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a low flow nasal cannula coupled with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
75634612|NCT00886743|Drug|oprelvekin|injection, 50 mg/kg, once daily
75634613|NCT02826915|Device|Near Infra Red Spectroscopy (NIRS)|
75920648|NCT02122419|Other|lateral|spinal anesthesia performed during lateral position
75920649|NCT02122419|Other|sitting|spinal anesthesia performed during sitting position
75920650|NCT05639790|Combination Product|Electronic cigarettes + Health Counselling|Ad libitum use of electronic cigarettes for 1 month
75920651|NCT05639790|Other|Health Counselling|Health Counselling from a licensed mental health counselor
75920652|NCT05555680|Other|Ferriman-Gallwey Score|The Ferriman-Gallwey score is used to evaluate hirsutism. The examiner scores the subjects on a scale of 0-4 for terminal hair growth on eleven different body areas according to the Ferriman-Gallwey scoring system. A Ferriman-Gallwey score of 8 or more was considered diagnostic of hirsutism
75920653|NCT02122497|Procedure|abdominal aortic surgery|
75920654|NCT02128503|Other|HBV DNA level monitoring|HBV DNV level being monitoring regularly
75920655|NCT02128581|Drug|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
75920656|NCT02128581|Other|Saline|
75920657|NCT03532620|Drug|Pitavastatin Calcium|"In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
75920658|NCT03532620|Drug|Atorvastatin Calcium|"In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
75920659|NCT05612854|Procedure|Mechanical embolectomy: by hydromechanical defragmentation by pigtail|Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation
76077852|NCT00968032|Device|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
76077853|NCT04401345|Drug|Glycopyrrolate 0.2 MG/ML|In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
76077854|NCT04401345|Drug|Normal saline|In this group, the patients will receive 1 ml of 0.9% normal saline
76077855|NCT00968344|Dietary Supplement|Leucine|3-4g Leucine added to daily meals
76077856|NCT00968344|Dietary Supplement|Alanine|Powered amino acid
75328157|NCT01720121|Other|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
75328158|NCT04370431|Drug|TTYP01 single ascending doses|TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)
75328159|NCT04370431|Drug|Placebo|Placebo control for Part A of the study
75328160|NCT04370431|Drug|TTYP01, 60 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
75328161|NCT04370431|Drug|TTYP01, 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
75328162|NCT04370431|Drug|Radicut® (ampoule), 30 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes
75328163|NCT04370431|Drug|Radicut® (bag) , 60 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes
75328164|NCT04370431|Drug|TTYP01, up to 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
75634614|NCT02826915|Device|Electroencephalogram (EEG)|
75634615|NCT00886587|Device|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
75328165|NCT01726361|Behavioral|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
75328166|NCT01726361|Behavioral|Treatment as usual|Other kinds of out of home placement
75328167|NCT04370353|Dietary Supplement|Cocoa flavanols|Flavonoid-rich cocoa powder, containing 100mg total flavanols per 316mg.
75328168|NCT04370353|Dietary Supplement|Placebo supplement|Microcrystalline filler, containing 0mg total flavanols.
75634616|NCT00886587|Device|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
75328169|NCT04369963|Procedure|Esophagogastroduodenoscopy and Colonoscopy with Biopsies|Participants will have an esophagogastroduodenoscopy and colonoscopy with biopsies. Biopsies from esophagogastroduodenoscopy will not exceed 16 pinch biopsies, biopsies from colonoscopy will not exceed 16 pinch biopsies. Participants will have anesthesia for both procedures.
75328170|NCT02245165|Biological|L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV|
75328171|NCT02245165|Biological|saline|
75634617|NCT00886119|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
75328172|NCT03408977|Other|probe meal|The probe meal will be served in 150 Kcal portions (10 g foie, 10 g cheese, 5 g chips, 2 g peanuts, 3 g toast, and 27 mL soft drink) up to the level of maximal satiation.
75328173|NCT03835871|Drug|Placebo|Intervention: Drug: placebo
75328174|NCT03835871|Drug|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg HFA per day
75328175|NCT03835871|Drug|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg HFA per day
75920660|NCT05612854|Device|Suction embolectomy by the Penumbra Indigo aspiration system|"The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries.~510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX"
75634618|NCT00886119|Device|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
75328176|NCT03835871|Drug|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg HFA per day
75634619|NCT02823873|Device|Pulsewave oscillometric wrist cuff blood pressure monitor|Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
75634620|NCT02826759|Other|diabetes|the exposure of interests are obesity, diabetes and insulin-resistance
75920661|NCT02122653|Other|Weight training|Participants will perform 4 weeks of Weight training for lower extremities.
75920662|NCT02122653|Device|Electronic muscle stimulator|Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
75920663|NCT05612776|Other|HIIT|HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.
76077857|NCT03083301|Other|Medical Files data extraction|Medical Files data extraction
75328177|NCT03402373|Dietary Supplement|Lycoderm|soft gel contains nutritional supplement
75328178|NCT03402373|Dietary Supplement|Placebo|soft gel without active ingredients
75328179|NCT03402295|Drug|Bortezomib, cyclophosphamide, thalidomide, dexamethasone|Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
75328180|NCT03836183|Diagnostic Test|Pleuropulmonary ultrasound with clinical examination|Pleuropulmonary ultrasound associate with a clinical examination
75328181|NCT02243761|Other|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
75328182|NCT02243839|Drug|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
75328183|NCT02243839|Procedure|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
75328184|NCT03402061|Dietary Supplement|nutrient enhanced recipes|normal ingredients will be substituted to promote nutrient density of products
75328185|NCT04369495|Other|BAFF serum levels|BAFF levels in serum in visit 0,1,2 during induction therapy
75328186|NCT02243917|Drug|CB-5083|
75341408|NCT05547529|Procedure|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
75634621|NCT02824887|Other|Electro-acupuncture|Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
75634622|NCT02824887|Other|Conventional treatment of Western Medicine|Routine non operative treatment of Western Medicine
75634623|NCT02823951|Drug|Rebif|
75634624|NCT02823951|Drug|Tecfidera|
75328187|NCT03401983|Other|Pelvic Floor Muscle Training and Abdominal Training|Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.
75328188|NCT03401983|Other|Pelvic Floor Muscle Training|Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
75920664|NCT05612776|Other|HRV|The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.
75920665|NCT02288130|Drug|GnRHa|
75920666|NCT02288130|Drug|Ulipristal|
75920667|NCT02128659|Behavioral|SHE Project|Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
75920668|NCT03529032|Drug|Methadone|methadone for control postoperative pain
75920669|NCT02128737|Behavioral|Sleep|
75920670|NCT02122731|Drug|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
76077858|NCT05684679|Other|Incentive spirometer plus Chest physiotherapy|Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
75328189|NCT02243995|Other|Physical training|
75328190|NCT02243995|Behavioral|Physical training|
75328191|NCT03401905|Procedure|Low frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a low frequency TENS is applied, at 2 Hz frequency and 120 microseconds of pulse width.
75328192|NCT03401905|Procedure|High frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a high frequency TENS is applied, at 12o Hz frequency and 200 microseconds of pulse width.
75328193|NCT02244073|Drug|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
75634625|NCT02826837|Drug|LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab|"The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
75634626|NCT02826525|Drug|AZD4076|Investigational product
75328194|NCT02244151|Drug|Decapeptyl® diario|Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
75328195|NCT02244151|Drug|Decapeptyl® daily|Decapeptyl® daily OPU 36 hrs after GnRH administration
75328196|NCT03401827|Drug|Chemotherapy (Gemcitabine + nab-paclitaxel)|"Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15"
75328197|NCT03833791|Behavioral|education and modifying diet|The control group maintains a sedentary lifestyle and is only subjected to follow a hypocaloric diet
75341409|NCT05245604|Drug|TJO-087|Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
75469199|NCT01187199|Drug|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
75469200|NCT01187199|Drug|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
75920671|NCT05458726|Drug|Osimertinib|Osimertinib or chemotherapy
75920672|NCT01367847|Behavioral|Helping the Noncompliant Child (HNC)|Well-established behavioral parent training program (McMahon & Forehand) for parents of 3 to 8 y.o. children with externalizing problems
75920673|NCT01367847|Behavioral|Technology-Enhanced Helping the Noncompliant Child (TE-HNC)|Standard HNC program plus technology-enhancements (see description under Arm)
75920674|NCT05612698|Behavioral|Aerobic training|Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax. Due to any form of aerobic exercise involving large muscle groups and causes sustained increases in HR is likely to be beneficial, the type of aerobic exercise will be agreed with each group of patients, varying from 4 to 8 people. There will be a choice of ex-ercises and participants will be able to choose a combination of up to 2 different exercises. The participants' choice of the type of activity to be performed is expected to encourage greater adherence. The range of exercises will be brisk walking or running, swimming, and/or aerobic dancing.
76077859|NCT05684679|Other|Diaphragmatic breathing exercise plus Chest physiotherapy|Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
76077860|NCT04761003|Device|Thoracoscopy forceps|take pleural biopsy
76077861|NCT01015534|Drug|Temozolomide|
76077862|NCT01015534|Radiation|Whole brain irradiation|
76077863|NCT05688033|Radiation|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
76077864|NCT03083145|Dietary Supplement|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
75469201|NCT01187199|Drug|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
75634627|NCT02826525|Drug|Placebo|Control
75634628|NCT04243083|Drug|TLL018 tablet, placebo|Oral QD
75328198|NCT03833791|Behavioral|education, modifying diet and physical activity prescription|"One group, in addition to fulfilling a hypocaloric diet identical to the control group, is subjected to prescribe moderate physical activity.~Other group, in addition to fulfilling a hypocaloric diet identical to the control and moderate group, is subjected to prescribe intense activity."
75328199|NCT03833401|Procedure|Autologous tissue transplantation|Root canal disinfection and revascularization with patient's own minced pulp tissues
75328200|NCT03833401|Procedure|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation
75328201|NCT03833635|Other|osteopathic manipulative treatment|OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect
75328202|NCT03833635|Other|Sham|the sham intervention consists in a stable skin-to-skin contact with the participant
75328203|NCT04376671|Device|Electroencephalography|The patients underwent EEG recordings according to previously published methods (Bonanni et al., 2008). . EEG recordings were analyzed with methods described in our previous work (Bonanni et al., 2008) by 2 experimenters unaware of the clinical conditions of the subjects. Briefly, quantitative EEGs (QEEGs) were recorded from 21 scalp derivations. Ag/AgCl disk scalp electrodes (19) were placed according to the international 10-20 system, EEG was recorded from Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T 4, T5, T6, O1, and O2. Two additional electrodes were placed on A1 and A2. EEG activity was analyzed from single or multiple leads grouped to define the following scalp regions: anterior (Fz, Fp2, F7, Fp1, F3, F4, and F8), central (Cz, C3, and C4), posterior (Pz, P3, P4, O1, and O2), and temporal (T3, T4, T5, and T6).
75328204|NCT00909545|Drug|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
75328205|NCT00909545|Drug|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
75634629|NCT04877847|Device|Low-frequency therapeutic ultrasound (LOTUS)|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on per normal operating instructions.
75328206|NCT00909545|Drug|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
75634630|NCT04877847|Device|LOTUS System with Ultrasound Disabled|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on and set to Control Setting.
75328207|NCT00909545|Drug|Placebo|4 Placebo to Match (PTM) tablets once daily
75328208|NCT02244229|Drug|Tamsulosin|
75328209|NCT02244229|Drug|Finasteride|
75634631|NCT02825277|Device|Doppler|acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
75634632|NCT02823639|Procedure|Transcranial direct current stimulation|
75328210|NCT02244229|Drug|Placebo|
75328211|NCT04369027|Diagnostic Test|passive leg raising|"passive leg raising: to raise the legs of the patients by adjusting the angle of the patient's bed during one minute.~Tidal volume challenge: an increas by 2ml/Kg of the tidal volume during one minute"
75328212|NCT04368793|Behavioral|Remote pulmonary rehabilitation|The pulmonary rehabilitation intervention includes respiratory exercise, barehanded aerobic training, exercise prescription of elastic band impedance training, respiratory muscle strength training, etc.
75328213|NCT04369339|Other|Colposcopy|
75328214|NCT02157103|Drug|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
75328215|NCT00924001|Drug|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10^9 and 1 x 10^11 lymphocytes) after expansion in interleukin-2 and OKT-3
75328216|NCT00924001|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
75328217|NCT00924001|Drug|Fludarabine|25 mg/m^2/day intravenously x 5 days
75328218|NCT00924001|Drug|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
75328219|NCT02244307|Drug|alpha-adrenergic blocker|
75328220|NCT00910481|Device|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
75328221|NCT03401593|Drug|midazolam with fentanyl|Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
75328222|NCT03408821|Other|Problem Solving Therapy (PST)|Participants will attend 8 weekly session of Case Manager (CM) implemented PST, a form of group talk therapy.
75328223|NCT04376359|Procedure|hyperbaric oxygen therapy|Hyperbaric oxygen therapy is the patient put in airtight oxygen tank, by increasing the air pressure in the environment (1.5 to 3.0) under atmospheric pressure, to give 100% oxygen, the patient treatment time is approximately 60 minutes to 120 minutes in this way, can achieve the purpose of greatly increase the oxygen partial pressure in the organization, so as to achieve reverse brain edema, reduce lipid peroxidation, inhibiting leukocyte hyperactivity, rebuild the blood brain barrier.
75328224|NCT03408743|Behavioral|Knowledge Alone|Increase knowledge relate d STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing & treatment services.
75328225|NCT03408743|Behavioral|Self-efficacy alone|Increase self-efficacy to us e protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75328226|NCT03408743|Behavioral|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75328227|NCT03408743|Behavioral|Benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75469202|NCT01187199|Drug|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
75469203|NCT01177683|Drug|Bendamustine|"Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4"
76077865|NCT03083145|Dietary Supplement|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
76077866|NCT03083145|Behavioral|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
76077867|NCT05683353|Other|None intervention|None intervention.
76077868|NCT00968890|Biological|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
76077869|NCT00968890|Biological|Fluarix™|Intramuscular injection, 1 dose
76077870|NCT00968890|Biological|Placebo|Intramuscular injection, 1 dose
75328228|NCT03408743|Behavioral|Injunctive norms alone|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
75328229|NCT03408743|Behavioral|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75328230|NCT03408743|Behavioral|Injunctive norms and benefits|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75328231|NCT03408743|Behavioral|Injunctive norms, benefits, self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75469204|NCT01177683|Drug|Doxorubicin|"Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4"
75634633|NCT04240977|Behavioral|"HOBSCOTCH: Home-Based Self-Management and Cognitive Training Changes Lives"|Home-Based Self-Management and Cognitive Training Changes Lives (HOBSCOTCH) is a novel phone-based intervention that is enables acquisition of cognitive skills in line with problem solving therapy (PST), and is well suited for PWRE who have failed all other treatment alternatives. Sessions #2 through #7 focus on building patient's awareness for their own day-to-day memory problems, brainstorming, implementing and reviewing the outcomes of potential solutions they generate themselves using the PST framework. In each of these sessions, providers will assist patients in generating alternative solutions, in thinking through what the implementation of each strategy would entail, and in helping them review outcomes for adopted strategies to refine their approach for optimized adoption and generalization.
75328232|NCT03408743|Behavioral|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
75328233|NCT03408743|Behavioral|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75798548|NCT01175460|Drug|S-1, Nedaplatin|nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
75798549|NCT01175538|Drug|Lactulose|In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
76077871|NCT03082833|Drug|AZD2014|AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
75328234|NCT03408743|Behavioral|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75328235|NCT03408743|Behavioral|Descriptive norms, benefits, self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75341410|NCT05245604|Drug|Cyclosporine ophthalmic solution 0.05%|Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
75469205|NCT01177683|Drug|Bortezomib|"Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11"
75469206|NCT01177683|Drug|Bendamustine|"Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4"
76077872|NCT03082989|Device|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
75469207|NCT01177683|Drug|Filgrastim|"Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC >1000"
75469208|NCT01084252|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75469209|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
75798550|NCT01175538|Drug|Lactulose|lactulose will be used in 30-60ml/day
75798551|NCT03860688|Drug|TED + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
76077873|NCT03082989|Other|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
76077874|NCT00970216|Drug|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
76077875|NCT03017950|Drug|CKD-330|
76077876|NCT03017950|Drug|D086|
76077877|NCT03017950|Drug|CKD-330 + D086|
76077878|NCT00971620|Biological|Botulinum toxin type A|Given as an intralesional injection.
76077879|NCT00971620|Other|Placebo|Given as an intralesional injection
75328236|NCT03408743|Behavioral|Descriptive norms and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
75634634|NCT04875507|Behavioral|Positive Psychology|This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
75634635|NCT04243161|Other|Experimental|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.~The intensity of the treatment will be 50% of the PIM and PEM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
75328237|NCT03408743|Behavioral|Descriptive and injunctive norms, self-efficacy|orrect misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75328238|NCT03408743|Behavioral|Descriptive and injunctive norms, and benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75328239|NCT03408743|Behavioral|Descriptive & injunctive norms, benefits, efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75634636|NCT04243161|Other|Control|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.~The intensity of the treatment will be 30% of the PIM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
75634637|NCT02822547|Drug|Peginterferon alfa-2a|Patients will receive Peginterferon alfa-2a according to the standard medical practice
75634638|NCT05040009|Behavioral|integrated foot care program|"Regular foot care and examination by an adequately trained professional: -~Structured education:~Educational modality will be provided to patients in a structured way. This will take many forms: one-to-one verbal education session last around 30 min motivational interviewing, video education, booklets, pictorial education via animated drawing or descriptive images structured foot care education consists of information on:~Foot ulcers and their consequences~Preventative foot self-care behaviors~Wearing adequately protective footwear~Undergoing regular foot checks~Practicing proper foot hygiene~Seeking professional help in a timely manner after identifying a foot problem~3-Adequate footwear 4-Foot-related exercises and weight-bearing activity 5-Foot examination and screening 6- Instructions about foot self-management"
75634639|NCT05660889|Other|Blood sampling.|Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
75634640|NCT02823483|Other|Sunscreen Lotion (BAY987521)|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
75634641|NCT02823483|Other|Untreated Skin|This site is patched without treatment as irradiated control
75634642|NCT04848597|Drug|Recombinant humanized anti-PD-1 monoclonal antibody injection|200mg , once every 3 weeks
75634643|NCT04240041|Diagnostic Test|Transcerebellar diamater|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.
75634644|NCT04240041|Diagnostic Test|Placental thickness|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
76077880|NCT05687565|Dietary Supplement|Control group placebo|Dietary suplementation
76077881|NCT05687565|Dietary Supplement|Experimental group 1 lauric acid|Lauric acid 1.5 grams once daily
76077882|NCT05687565|Dietary Supplement|Experimental group 2 lauric acid|Lauric acid 3 grams once daily
75328240|NCT03408743|Behavioral|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
75328241|NCT03408743|Behavioral|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75341411|NCT01576471|Biological|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
75634645|NCT02822313|Drug|Coppertone (BAY987518)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-76_V27-006)
76077883|NCT01884922|Drug|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
75634646|NCT04239495|Other|Observational study: range of clinical and lifestyle factors|Medical conditions and medications. Educational and occupational history. Lifestyle exposures, assessed using reduced Food Frequency Questionnaire, Rapid Assessment of Physical Activity questionnaire and objectively-measured physical activity levels over 7 days using a GeneActiv wrist-worn accelerometer (Activinsights, Cambridge, UK).
76077884|NCT01884922|Drug|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
76077885|NCT03083223|Other|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
75634647|NCT04803669|Procedure|Intrument-assisted soft tissue mobilization technique|This technique; It is applied with the help of a tool made of stainless steel. The instrument is rubbed on the skin at an angle of about 30 degrees, creating a massage-like effect on the soft tissue (2 sessions per week and 5 minutes per session, 8 sessions in total for 4 weeks).
75634648|NCT04803669|Procedure|Conventional Treatment|Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
75634649|NCT04239729|Behavioral|ACT Website and Coaching|The ACT website includes sixteen sessions and is designed to teach a series of skills from ACT applied to hoarding. The intervention also includes brief supportive coaching (an initial phone call and weekly support over email).
75634650|NCT02826369|Other|3.0 Tesla in Magnetic Resonance Imaging|"Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.~The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition."
75469210|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
75920675|NCT05612698|Behavioral|Aerobic training plus resistance training|Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action. In each session, between 5 and 10 exercises will be worked on, per-forming 10-15 repetitions, and progressing to 8-10 lifting as the weight increases, involving the major muscle groups from the core, lower body and upper body. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session.
75634651|NCT05660811|Drug|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
75634652|NCT05660811|Drug|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
75634653|NCT05660811|Drug|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
75634654|NCT05660811|Drug|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
76077886|NCT01610908|Other|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.~Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
75328242|NCT03408743|Behavioral|Expectancies and perceived benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75634655|NCT02823561|Dietary Supplement|Garcinia mangostana|
75328243|NCT03408743|Behavioral|Expectancies, benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75328244|NCT03408743|Behavioral|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
75328245|NCT03408743|Behavioral|Expectancies, injunctive norms, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75634656|NCT02823561|Behavioral|Control group|
75634657|NCT02823405|Drug|X4P-001|X4P-001 100 mg capsules, administered orally, continuous daily dosing
75634658|NCT02823405|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg, administered by IV infusion every 3 weeks
75634659|NCT02823249|Dietary Supplement|1.56 g L-Tryptophan|
75920676|NCT05612698|Behavioral|High intensive interval training|Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO. Starting with 4 intervals lasting 1 minute keeping in a range of 85-90% HRMax, separated by 1 minute of low intensity activity (no static) (4 × 1 min intervals.) A progression will be followed by increasing the number of circuits, up to 10 (10 × 1 min intervals) [25, 78, 79]. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session. Although the target popula-tion is a sedentary population, we expect the HIIT approach, despite being high intensity, to be well received, due to its growing popularity, as demonstrated by a study in which 62% of inactive participants preferred HIIT to other types of exercise.
75328246|NCT03408743|Behavioral|Expectancies, injunctive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75328247|NCT03408743|Behavioral|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75328248|NCT03408743|Behavioral|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
75634660|NCT02823249|Dietary Supplement|1.56 g L-Leucine|
75634661|NCT02823249|Dietary Supplement|50 g Xylitol|
75634662|NCT02823249|Dietary Supplement|75 g Erythritol|
75920677|NCT05612620|Diagnostic Test|coulture|Samples from the vagina, fornix and cervical canal will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
75784348|NCT06192290|Behavioral|Home-based transitional Cardiac Telerehabilitation|This comprehensive series is divided into 16 parts, each addressing crucial aspects of open-heart surgery recovery. Part 1 introduces open-heart surgery, heart disease symptoms, and preoperative preparations for elderly patients. Part 2 delves into cardiac rehabilitation, defining objectives and detailing recovery stages. Part 3 covers care for surgical incisions and infection signs. Part 4 explores sleep and rest, while Part 5 guides patients on a healthy post-surgery diet. Part 6 focuses on nursing interventions for dyspnea, and Part 7 addresses post-surgery cough. Part 8 discusses nursing interventions for thrombosis prevention
75920678|NCT02122809|Drug|Chiauranib|Take orally
75920679|NCT05610982|Behavioral|Yoga Program|The yoga program involves two weekly 60-minute group-based classes. Participants can attend in-person or online (via Zoom). In total, 24 classes will be offered across 12 weeks. The program structure has been developed and approved by certified yoga instructors (n=12) and adults diagnosed with gynecologic cancer (n=6). The classes will follow a flexible base class that the instructor can then adapt as they see fit to promote participants' comfort, safety, and engagement. The program will also include group discussions and journaling that participants may participate in, if they choose. Finally, participants will be encouraged to access an online database of pre-recorded short-duration yoga practices to support their at-home practice.
76077887|NCT01610908|Other|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
75920680|NCT02124837|Behavioral|Park walk during lunch break|
75920681|NCT02124837|Behavioral|Relaxation during lunch break|
76077888|NCT05687409|Drug|Entecavir 0.5 mg|Orally administered Entecavir 0.5 mg, once a day. For six months
76077889|NCT05687409|Drug|A 10-g packet of lactulose oral solution and three capsules of probiotics|"A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing > 4.2×106 CFU Clostridium butyricum and > 4.2×105 CFU Bifidobacterium longum infantis).~Participants orally administered the contents three times daily after meals. For six months."
75328249|NCT03408743|Behavioral|Expectancies, descriptive norms, & self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75634663|NCT02823249|Dietary Supplement|75 g Glucose|
75634664|NCT02823249|Dietary Supplement|Tap water|
75341412|NCT01576471|Biological|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
75341413|NCT05245448|Drug|Tetrandrine|Administered orally
75634665|NCT02823249|Dietary Supplement|Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)|
75634666|NCT02823249|Device|Nasogastric Tube|
75634667|NCT04240743|Device|cephalomedullary nail|For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.
75784349|NCT06192277|Other|Screening|Patients are screened to confirm they are low risk for a penicillin allergy
75328250|NCT03408743|Behavioral|Expectancies, descriptive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75634668|NCT04240743|Device|sliding hip screw|For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.
75328251|NCT03408743|Behavioral|Expectancies, descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75328252|NCT03408743|Behavioral|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
75328253|NCT03408743|Behavioral|Expectancies, descriptive & injunctive norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75328254|NCT03408743|Behavioral|Expectancies, descriptive & injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
75328255|NCT03408743|Behavioral|Expectancies, descriptive & injunctive, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
75328256|NCT03401515|Drug|Propranolol Hydrochloride 1 MG/ML|Propranolol 1 mg every 6 hrs in the first 24 hrs after isolated blunt traumatic brain injury
75328257|NCT03401515|Other|Normal saline|Normal Saline 1 ml every 6 hrs
75328258|NCT04368715|Device|Laser-assisted frenectomy with 2780 nm Er:Cr;YSGG and 940 nm diode laser|
75784350|NCT06192277|Drug|Low dose Penicillin|Low risk participants are given a low-dose of oral penicillin followed by 60 minutes of observation
76077890|NCT05687409|Dietary Supplement|A 10-g packet of glucose oral solution and three capsules of starch|A 10-g packet of glucose oral solution and three capsules of starch. Participants orally administered the contents three times daily after meals. For six months.
75328259|NCT01726829|Device|MD-Logic Artificial Pancreas (MDLAP) system|
75328260|NCT01726829|Procedure|sensor augmented pump therapy|
75328261|NCT02244385|Other|no intervention|
75328262|NCT03408509|Behavioral|Computerized cognitive training|Posit Science Inc. will supply the software for the computerized cognitive training through the platform BrainHQ, which is available on line. The training program consists of a set of computerized exercises designed to improve the speed and accuracy of sensory information processing while engaging neuromodulatory systems involved in attention and reward. The rationale is that, in order to understand and remember information, the brain must first generate precise and reliable neurological responses that represent the sensory stimuli. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations. The goal is to increase the effectiveness with which these stimuli engage and drive plastic changes in brain systems. Engagement is monitored by electronic data upload following each training session.
75328263|NCT02244541|Drug|ANAVEX2-73 Oral|
75328264|NCT02244541|Drug|ANAVEX2-73 Intravenous|
75634669|NCT02821845|Behavioral|Untrained and Trained SCI Hip or Knee|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of hip control or knee control, members of this group will be trained at slow to moderate gait speeds,
75784351|NCT06192277|Drug|Standard dose Penicillin|Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.
75784352|NCT06192277|Other|Remove allergy label|Participants who have no reaction after 28 days have their penicillin allergy label removed from their electronic medical record and hospital record.
75784353|NCT06192264|Drug|ASC40|ASC 40 tablets orally once daily
75784354|NCT06192225|Behavioral|pre-trained guided slow paced breathing (~6 breaths per minute)|Slow PACE breathing
75798552|NCT01173432|Device|continuous positive airway pressure|an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
75328265|NCT02244541|Drug|ANAVEX2-73 Oral|30 mg hard gelatin capsule
75328266|NCT02244541|Drug|ANAVEX2-73 Oral|50 mg hard gelatin capsule
76077891|NCT05679063|Other|Physiotherapy|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group
76077892|NCT05679063|Other|Sham, Control|Talks about healthy habits
76077893|NCT02162680|Drug|1% lidocaine|
76077894|NCT02162680|Drug|bacteriostatic normal saline (BNS)|
76077895|NCT02162992|Other|No intervention|Observational
75920682|NCT03552081|Other|Fragmented DNA evaluation in blood and semen samples|The objective will be to evaluate the decrease in the percentage of sperm with spermatic DNA fragmentation by the TUNEL technique following the evolution of this rate to 3 months, 6 months and 12 months after cessation of smoking by blood and semen samples.
75920683|NCT00150618|Drug|SPD503 (1 mg)|
76077896|NCT05687331|Procedure|knee arthrocentesis|arthrocentesis of the knee joint to gather a synovial fluid sample
76077897|NCT05687331|Procedure|venipuncture|Peripheral venipuncture to gather a blood sample
75328267|NCT01720433|Procedure|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
75328268|NCT04368325|Diagnostic Test|Serum creatinine levels|Comparison of treatment length using mechanical ventilaton, length of stay in ICU, survival between two groups
75634670|NCT04240431|Diagnostic Test|Probing /irrigation of lacrimal passages|Probing of the lacrimal passage was done using #00 Bowman's lacrimal probe which can reveal any narrowing (resistance) or obstruction (soft stop) of the canaliculi during its advancement from punctum towards the lacrimal sac.
75634671|NCT00633711|Device|Automatic (variable, automatically controlled) pressure CPAP|"CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.~Home nocturnal usage. Two-month treatment."
75634672|NCT00633711|Device|fixed continuous positive airway pressure (CPAP)|"CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.~Home nocturnal usage. Two-month treatment."
75634673|NCT00768079|Other|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
75634674|NCT00768079|Biological|Benralizumab|A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
75634675|NCT02820675|Other|structured case analysis|implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.
75634676|NCT02820675|Other|"strucured screening every patient, every shift"|implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
76077898|NCT05687331|Diagnostic Test|MRI-scan|MRI-scan of the knee
76077899|NCT05687331|Diagnostic Test|Physical examination|Physical examination of the injured knee
76077900|NCT05687331|Other|KOOS questionnaire|KOOS questionnaire of the injured knee
75634677|NCT04753047|Other|No intervention|No intervention
75634678|NCT02603575|Drug|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
76077901|NCT00972088|Device|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
76077902|NCT05677815|Procedure|Underwent Surgery from 2019 to 2022|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia
75634679|NCT02603575|Drug|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
75784355|NCT06192199|Diagnostic Test|2018 edition of the Guidelines for Diagnosis|According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group
76077903|NCT01017250|Radiation|Stereotactic Radiosurgery (SRS)|Tumor Volume < 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
76077904|NCT01017250|Drug|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
75784358|NCT06192147|Dietary Supplement|protein restricted diet combined with vitamin D intervention|On the basis of conventional treatment, a protein restricted diet combined with vitamin D intervention plan is given
75920684|NCT00150618|Drug|SPD503 (2 mg)|
75920685|NCT00150618|Drug|SPD503 (3 mg)|
75920686|NCT00150618|Drug|SPD503 (4 mg)|
75920687|NCT00150618|Drug|Placebo|
75920688|NCT05610904|Diagnostic Test|Prediction model evaluation|a machine learning based anastomotic leakage prediction model
75328269|NCT01720511|Dietary Supplement|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
75328270|NCT01720511|Dietary Supplement|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
75920689|NCT02124993|Other|Questionnaire|Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
75920690|NCT02128815|Other|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
75920691|NCT03532464|Drug|azithromycin|The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
75328271|NCT01720589|Dietary Supplement|Melt (test oil)|
75328272|NCT01720589|Dietary Supplement|Corn oil (control)|
75328273|NCT03401359|Genetic|tissue biopsy, blood sample|At baseline, 100 tumor/blood samples will be banked. Only ~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.
75634680|NCT02603575|Drug|Sulfanilamides|1.92g q8h
75634681|NCT02601859|Drug|Lithium Carbonate|
75634682|NCT04097587|Behavioral|experimental group|This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.
75634683|NCT04097587|Other|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
75634684|NCT02822703|Device|rTMS Active 20Hz|Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
75651720|NCT05796401|Behavioral|Cognitive training|"Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks~+/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score >110s))"
75784359|NCT06192134|Device|CPM device|CPM brace
75784360|NCT06192121|Other|Web Based Education|In this research, a reminder message will be sent 3 times a week along with web-based training.
75328274|NCT01726907|Device|Robotic SMG resection|The surgical procedure and the considerations for surrounding neurovascular structures were similar to that of the endoscope-assisted SMG resection. The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA) including a 30° dual channel endoscopic arm and two instrument arms was introduced. The SMG was retracted using the 5-mm Maryland forceps on the left and the dissection was conducted using a 5-mm spatula monopolar cautery or a Harmonic curved shears on the right. A Yankauer suction handled by a bed-side assistant could be used for counter traction of the gland which facilitated the dissection procedure.
75328275|NCT01726907|Device|Endoscopic SMG resection|An assistant held a 10-mm 30° rigid endoscope allowing the operating surgeon to use both hands. Surgical resection tools such as dissector and Harmonic scalpel (Harmonic Ace 23E®; Johnson & Johnson Medical, Cincinnati, OH, USA) was held in the right hand and a Yankauer suction or a Debakey forcep was held on the left for traction of the SMG. The dissection plane between the capsule of the SMG was conducted under magnified endoscopic view using the the blade of the Harmonic scalpel and the endoscopic dissector. Routine identification of the marginal mandibular branch of the facial nerve was unnecessary in SMG resection, since the dissection plane was always deep to the middle layer of the deep cervical fascia which includes the fascia of the gland. The Wharton's duct, facial artery and vein were ligated using the Harmonic scalpel or vascular clip.
75328276|NCT03401281|Other|Coconut oil|50g extra virgin coconut oil daily for four weeks
75328277|NCT03401281|Other|Butter|50g butter daily for four weeks
75328278|NCT03401281|Other|Olive oil|50g extra virgin olive oil daily for four weeks
75328279|NCT03408431|Device|Ambu® AuraGain™|Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
75328280|NCT03408431|Procedure|neck extension|Patients' neck will be maximally extended (~60°) during blind intubation.
75328281|NCT04368169|Dietary Supplement|Teramune Botanical Extract|Combination blend of aromatic plant extracts in an emulsifier carrier.
75328282|NCT04368169|Other|Placebo|Emulsifier carrier without active supplement ingredients.
76077905|NCT03082443|Other|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
76077906|NCT00812032|Drug|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
76077907|NCT00812032|Drug|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
75328283|NCT03408275|Other|None - observational|None - observational
75328284|NCT04368247|Diagnostic Test|Skin Fluorescent Imaging|Application of reagents, then imaging and scoring
75328285|NCT02244775|Device|SR™MCP|
75328286|NCT00911495|Drug|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
75328287|NCT03834103|Behavioral|Self-rehabilitation program and protein supplement|"Participants follow a home-based self-rehabilitation program consisting of the realisation of a set of physical exercises using an elastic band. The exercises have to be performed 3 times a week, and are associated with a protein supplementation.~The rehabilitation follow-up by the physician is planned once a week, by phone, and with face-to-face appointments at inclusion, 6 weeks and 3 months follow-up."
76077908|NCT04352764|Diagnostic Test|CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test|The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19
75469211|NCT00993044|Drug|Irinotecan|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
75328288|NCT03408197|Device|EasyWarm|Perioperative warming with EasyWarm to prevent inadvertent hypothermia during anaesthesia
75328289|NCT03408197|Device|BairHugger|Perioperative warming with BairHugger to prevent inadvertent hypothermia during anaesthesia
75328290|NCT01726985|Other|Parameter Based Clinical Disposition|"Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~NT-ProBNP reduction of > 23% from peak value during admission~Fluid Reduction of > 1.3L (orders for I/O q8h required)~Serum Sodium of > 135 mmol/L the day of planned discharge"
75634685|NCT02822703|Device|rTMS Sham|The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
75634686|NCT02601079|Device|Endodrill Biopsy|Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
75651721|NCT05796401|Drug|Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC|"Personalised neuroprotective medication adapted to the individual's biological profile :~Vitamin B12 : 500 micrograms per day~Folinic acid : 50 mg per day~Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks"
75920692|NCT03532464|Drug|doxycycline|The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
75920693|NCT02128893|Drug|Isavuconazole|oral
75328291|NCT04367701|Diagnostic Test|Hemolysis|Authors measured free plasma hemoglobin concentration in gram
75328292|NCT01727063|Procedure|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
75328293|NCT02244931|Device|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
75920694|NCT02128893|Drug|Esomeprazole|oral
75920695|NCT02124369|Drug|Abraxane|125mg/m2, IV, on days 1,8 & 15 of each 28 day cycle, up to 6 cycles.
75328294|NCT02244931|Device|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
75328295|NCT02244931|Device|Standard manual Wheelchair|Standard manual Wheelchair
75328296|NCT00918671|Other|No new specific intervention|No new specific intervention
75328297|NCT04366297|Device|Intravenous access|obtaining intravascular access using a standard intravenous cannula
75328298|NCT04366297|Device|Intraosseous access|obtaining intravascular access using a ready intravenous NIO needle set
75920696|NCT02124369|Drug|Gemcitabine|1000mg/m2, IV, on days 1,8 & 15 of a 28 day cycle, up to 6 cycles.
75920697|NCT05555602|Device|Cold-air cooling|Cryo 6 works with a compressor system like those in refrigerators and uses ambient air to generate a permanent stream of cold air with a maximum flow to 1000 L/min and a temperature as low as -30°C, depending on the cooling delivery system and the desired cooling level (range 1-9).
75920698|NCT05447728|Diagnostic Test|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
75920699|NCT05447728|Diagnostic Test|PRESTO|The PRESTO study is a group of 8 pre-hospital stroke scales used to detect large vessel occlusion strokes.
75328299|NCT03408041|Other|Medical file data extraction|Medical file data extraction
75328300|NCT04366375|Diagnostic Test|PTX-3|Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
75328301|NCT01720823|Device|home polysomnography (GETEMED)|
75328302|NCT01720823|Device|standard polysomnography (BRAINNET II)|
75328303|NCT02245009|Procedure|Cardioversion|
75328304|NCT04379453|Procedure|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention
75328305|NCT04376047|Other|Reverse Trendelenburg position|The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.
75328306|NCT04376047|Other|Semi-recumbent position|The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
75341414|NCT05245448|Drug|Placebo|Administered orally
76077909|NCT05687175|Other|Questionnaire|Questionnaire administration (PDQ-M, NRS, SF-36)
75328307|NCT04379609|Other|Masticatory efficiency|"Two-color chewing gum mixing ability test was used to measure masticatory efficiency in the control group, before and after treatment in the experimental group.21 Commercial two-color chewing gum was used.The gum was left on the patient's tongue and he/she was asked to chew 20 times naturally.~After chewing, the gum was put in a transparent plastic bag and squeezed to 1 mm. Both sides of the sample were scanned at 300 dpi resolution on a desktop scanner (HP Deskjet, California, USA) in the same day to prevent the colors from deteriorating due to saliva. For each patient, two sides of scanned images were processed in ViewGum software (version 1.4, Dhal Software, Kifissia, Greece, www.dhal.com) using the method of Halozenitis et al. (2013).22 The value of VOH (variance of hue) was taken as the value of chewing activity. The highness of this value indicates low masticatory efficiency."
75328308|NCT04366141|Device|COVID-19 barrier box|Attending anesthesiologists will use a plastic proprietary barrier enclosure for intubating patients in the intervention group to protect spreading aerosolized droplets from patient to health care provider.
75328309|NCT04366453|Procedure|echocardiography|Four measurements in echocardiography performed in addition to standard care
75328310|NCT04379375|Behavioral|Nudge|Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
75328311|NCT03834233|Drug|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
75634687|NCT02601079|Device|Conventional Biopsy forceps|Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
75469212|NCT00993044|Drug|Vincristine|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
75920700|NCT05725356|Other|Basic body awareness therapy|Participants were instructed to focus on maintaining good posture, balance, uninterrupted breathing, increased awareness, and decreasing unnecessary muscle tension.
75920701|NCT05299905|Procedure|Virtual reality using Semi-CAVE|The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.
75328312|NCT04367389|Behavioral|Physical activity promotion|Physical activity promotion activities consist of two phone or video calls with a therapists, two group video calls with a therapist, a complementary e-learning course and a fitness tracker that was provided.
75634688|NCT04240275|Device|Reliability of the G-Walk device in children with Cerebral Palsy|"The purpose of this study was to confirm the test-retest reliability of a commercially available body-worn sensor-G-Walk® sensor system-for spatiotemporal gait parameters in children with CP.~The children will be assessed with the G-Walk on two separate occasions.For the reliability analysis, the second measurement tests will be repeated 3 days after the first assessment.~The device is placed on an elastic belt and worn on the waist of the person being evaluated, with the center of the device at the fifth lumbar vertebrae. To ensure correct placement of the device, the L4-L5 intervertebral space will be palpated via the posterior superior iliac spines (SIPS).~After the accelerometer is placed, the children are asked to walk calmly at normal speed, on a 10 m track, whose boundaries will be determined with colored lines and to return to the starting position."
75328313|NCT04367389|Behavioral|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for persons with MS. However, they can be adjusted according to participants prior physical activity level and their time for exercise during the week.
75341415|NCT00580502|Device|LAP-BAND® Adjustable Gastric Band (LAGB®)|Bariatric surgery for patient whose BMI is between 30 and 40 kg/m^2
75634689|NCT02822157|Drug|Olaparib|
75634690|NCT02822157|Drug|carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly|physician's choice chemotherapy
75634691|NCT00767455|Device|HP828-101|21 day patches
75634692|NCT02822781|Other|No intervention|There is no intervention. The patients will receive common questionnaire usually used by doctors (SNOT 22). Some Data to describe the population are collected then.
76077910|NCT04746651|Other|Guided Self Help|Guided self help appointments with prison staff - 4x 30 minute appointments.
76077911|NCT02159872|Drug|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
76077912|NCT00417664|Drug|Dexmedetomidine|Dexmedetomidine administered as part of anesthesia in cardiac surgery patients
76077913|NCT00417664|Drug|Propofol|Propofol administered as part of anesthesia in cardiac surgery patients
76077914|NCT00417664|Drug|Midazolam|Midazolam administered as part of anesthesia in cardiac surgery patients
76077915|NCT05687019|Combination Product|Intravesical instillations of Ialuril® Prefill|5 injections of Ialuril® Prefill on D0 or D1, D7, D14, D21 and D28 after Holmium laser surgery for prostate adenoma
75784361|NCT06192095|Device|Skin barrier film|Preventive use of skin barrier film after insertion of a vascular indwelling catheter before covering with transparent dressing +/- gauze
75920702|NCT05299905|Procedure|Virtual reality using the HMD|The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
76077916|NCT03400059|Device|Chordate System S211 in treatment mode|Chordate System S211 in treatment mode
76077917|NCT03400059|Device|Chordate System S211 in placebo mode|Chordate System S211 in placebo mode
76077918|NCT01021306|Device|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
75634693|NCT02822937|Drug|Methylphenidate|Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
75784362|NCT06192082|Procedure|The conscious sedation group|The conscious sedation group (Group A) received sufentanil 0.05-0.1 5 minutes before examination μ G/kg, administration time 30 seconds, 1-2 mg of midazolam administered 2 minutes before examination; Evaluate the patient's MOAA/S score, insert a digestive endoscope at 2-3 minutes, and add 1-2mg of midazolam if the patient is unable to tolerate coughing or movement during the examination. Reevaluate the MOAA/S score, and continue the operation after 2-3 minutes;
75328314|NCT01727375|Other|Circadian light|"Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation."
75328315|NCT04367545|Diagnostic Test|Saliva collection|Saliva collection will be done in addition to standard diagnosis collection (nasopharyngeal collection using swab)
75920703|NCT02128971|Dietary Supplement|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
75920704|NCT02128971|Dietary Supplement|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
76077919|NCT01021306|Device|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
75634694|NCT02822937|Drug|Triazolam|Triazolam is a benzodiazepine similar to Valium. Triazolam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia). Triazolam is used to treat insomnia (trouble falling or staying asleep).
75920705|NCT02128971|Dietary Supplement|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
76077920|NCT01021306|Other|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
76077921|NCT01021306|Other|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
75634695|NCT02822937|Other|Project: EVO|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
75634696|NCT02822937|Drug|Placebo|Sugar pill
75634697|NCT04200885|Drug|Dexketoprofen Trometamol|Patients were instructed to record the number of drugs they used until the second and seventh postoperative days.
76077922|NCT03082287|Device|Fecal Calprotectin Level|Measurement of calprotectin in feces
75920706|NCT02128971|Dietary Supplement|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
75920707|NCT02128971|Dietary Supplement|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
75920708|NCT02128971|Dietary Supplement|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
75920709|NCT05555446|Dietary Supplement|Bovine colostrum|Subject will receive bovine colostrum with gluten.
75920710|NCT05555446|Dietary Supplement|Placebo|Subject will receive a placebo with gluten.
75920711|NCT02288208|Drug|Antiviral Therapy (tenofovir or entecavir)|
75920712|NCT02288208|Drug|Birinapant|
75328316|NCT03407963|Procedure|Embolization|Embolization by microparticles (300-500 microns)
75634698|NCT04200885|Drug|Dexamethasone 21-Phosphate|Injections were administered in the immediate preoperative period as a single shot.
75634699|NCT04200885|Device|Therapeutic Elastic Bandage|The bands' lengths were individually measured and divided into five equal parts up to 2/3 of their lengths to obtain fan-type shape.
75634700|NCT05659251|Combination Product|Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy|Serplulimab 4.5mg/kg, IV, Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 2-4 cycles, one cycle every 21 days.
75634701|NCT05659251|Procedure|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
75634702|NCT00766831|Drug|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram [mg] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
75634703|NCT02821689|Drug|Pirfenidone|Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
75634704|NCT02822859|Device|Wright nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
75634705|NCT02822859|Device|Bennett-Twin nebulizer|Puritan Bennett Corp., Carlsbad, CA, USA
75634706|NCT02822859|Device|Aeroneb Solo|Aerogen Ltd., Galway, Ireland
75634707|NCT02821533|Procedure|TACE|TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
75634708|NCT02821533|Drug|Cisplatin|Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
75784363|NCT06192082|Procedure|Intravenous general anesthesia group|Intravenous general anesthesia group (Group B): sufentanil 0.05-0.1 μ G/kg, administration time 30 seconds, 1mg/kg of propofol administered 2 minutes before examination. Depending on the patient's sleep status, 10mg of propofol can be administered every 30 seconds; Evaluate the patient's MOAA/S score. At 0-1 points, a digestive endoscope is inserted. If there is coughing or physical activity during the examination that the patient cannot tolerate, propofol 10-20mg can be administered multiple times. Evaluate the MOAA/S score again, and continue the operation after 0-1 points.
75784364|NCT06192069|Other|Sustainable Heat Strain Prevention Program for Agricultural Elderly Workers (SHiP-AEW)|The SHiP-AEW is a 4-week multifaceted intervention program focused on evidence-based heat strain prevention strategies for agricultural workers over 60 years old. Delivered through weekly 1-hour sessions, the program incorporates the following primary components:
75784365|NCT06192056|Behavioral|RNT Focused Web- Based Self-Help Program|This 10 day long intervention contains psychoeducational contents, experimental exercises, monitoring behavior and committed action strategies. Each step of the intervention aims to develop a specific psychological flexibility skill like cognitive defusion etc.
75784366|NCT06192043|Behavioral|Behavioral Psychoeducational Intervention|Psychoeducational Program would be used as an intervention strategy for individuals with smoking cessation to provide understanding and insight to the participants about the problem. Furthermore, this program would deal with interventions like motivation, cognitive conceptualization, coping skills and training, craving management, and relapse prevention among individuals with smoking cessation
75784367|NCT06192030|Other|Prediction model|We develop and validate clinical models to predict patient survival and gene signatures in ovarian metastases of colorectal cancer.
75784368|NCT06192004|Other|None (Observational Study)|Not applicable since Observational Study
75784369|NCT06191991|Drug|Atorvastatin|40 mg
75784370|NCT06191991|Drug|ALG-055009|0.9 mg
75784371|NCT06191991|Drug|Rosuvastatin|10 mg
75784372|NCT06191978|Drug|ASTX727|Given by PO
75920713|NCT02288208|Drug|Placebo (for birinapant)|
75920714|NCT05700682|Device|Shoulder/Hip/Knee Embolization with Embozene Microspheres|Fluoroscopically-guided arterial embolization of synovitis in the painful shoulder, hip or knee.
75920715|NCT03550833|Behavioral|Questionnaire|Questionnaire
75920716|NCT03550833|Biological|blood sample|7 ml whole blood for Peripheral blood
75920717|NCT02129049|Other|educational intervention|Participate in the Enhancing Connections Telephone Program
76077923|NCT01021618|Drug|Regadenoson|Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
75328317|NCT04367155|Drug|Tranexamic acid injection|hemostatics use
75328318|NCT01727453|Drug|warfarin|Warfarin in anticoagulant dose
75328319|NCT01727453|Drug|Bemiparina|"Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.~Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer."
75920718|NCT02129049|Behavioral|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
75920719|NCT02129049|Other|questionnaire administration|Ancillary studies
75920720|NCT02125071|Other|Blood Sample Collection|Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
75920721|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
75920722|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
75920723|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
75920724|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
76077924|NCT01021618|Other|Symptom-limited exercise|Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
75328320|NCT04376125|Other|Suboccipital inhibition in tension headache|Deep maneuver of myofascial induction in the suboccipital muscles
75634709|NCT05659407|Drug|Belimumab in SLE patients / Rituximab in RA patients|Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
75634710|NCT04240353|Other|COPD digital support service|Use of COPD digital services to record patient symptoms, integrate physiology monitoring, communicate with the clinical team and track interaction
75634711|NCT00766675|Drug|Tramadol hydrochloride|Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
75634712|NCT00766675|Drug|Acetaminophen|Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
75634713|NCT04101799|Behavioral|For Our Children's Sake|Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
75784373|NCT06191978|Drug|Venetoclax|Given by PO
75784374|NCT06191939|Behavioral|Mindful Self-Compassion for Lung Cancer (MSC-LC)|"The overall goal of this 10-week, group-based, virtually-delivered, psychosocial intervention is to enhance recognition and responsiveness to difficult thoughts and emotions and to build self-compassion skills that facilitate patients' ability to turn inward to those thoughts and feelings with mindfulness, connectedness, and self-kindness. Each weekly session is designed to be 90 minutes and follows an agenda with highly structured scripts covering self-compassion topics (e.g., pain of disconnection, listening with compassion), which are carefully organized to build upon one another. In each session, didactic topics (e.g., What is self-compassion?) taught by trained interventionists lead into guided experiential learning practices (e.g., guided meditation), which are then followed by inquiry into the participants' direct experiences of the practices. The treatment manual is adapted based on the Mindful Self-Compassion Teacher Guide (from the Center for Mindful Self-Compassion)."
75920725|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
75920726|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
75920727|NCT02251977|Drug|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
75920728|NCT02251977|Drug|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
75920729|NCT02251977|Drug|mFOLFOX6 or XELOX|"mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient."
75920730|NCT03528954|Drug|Propofol|Those who received intravenous propofol
75920731|NCT02252055|Biological|ATDC_Nantes|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"
76077925|NCT03082053|Drug|varlitinib|IMP
76077926|NCT03082053|Drug|capecitabine|Companion Medication
76077927|NCT01022242|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
75634714|NCT04101799|Other|Active control|Participating in everyday activities that may include parenting activities in the control prisons
75634715|NCT02821611|Behavioral|Meditation Group|twice daily 20 minute mantra-based meditation practice for 8 weeks
75920732|NCT03532386|Procedure|ICSI|ICSI for both couples
75920733|NCT02131077|Biological|ALLO-ASC-TI|
75920734|NCT02131077|Drug|Placebo|
75920735|NCT05612464|Other|No intervention|No intervention
76077928|NCT01022242|Drug|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
76077929|NCT05686941|Other|Trans-cutaneous Laryngeal ultrasound (TLUS)|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords
75328321|NCT04377347|Other|Time|Exposure is the time from patients call the Emergency Medical Coordination Center to they are admitted to a neurosurgiocal department.
75328322|NCT04375969|Other|whole body cryostimulation treatment|The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
75328323|NCT04375969|Other|Connection WBC treatment and HIIT training|WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions
75634716|NCT00766597|Drug|Vicriviroc|Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
75634717|NCT02820441|Drug|Zopiclone|
75328324|NCT04375969|Other|Control Group|This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study
76077930|NCT05686941|Other|TLUS and simultaneous laryngoscopy|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords with simultaneous video laryngoscopy (usual care)
76077931|NCT03358563|Drug|Docetaxel|Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
75328325|NCT04375969|Other|HIIT training group|This group will do the training program without cold exposure
75328326|NCT04377425|Diagnostic Test|COVID-19 swap test PCR|COVID-19 swap test PCR performed according to hospital standard operating procedures
75634718|NCT02820441|Drug|Placebo|
75634719|NCT04097431|Behavioral|Response Blocking|Physically preventing the response (i.e., precursor) from occurring.
75634720|NCT00910962|Drug|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
76077932|NCT03358563|Drug|Degarelix|Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
75634721|NCT00910962|Drug|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
75328327|NCT04376203|Procedure|Thyroidectomy|Typical Thyroidectomy
75634722|NCT00910962|Drug|Placebo|Placebo
75784375|NCT06191939|Other|Enhanced standard of care with waitlist|Participants in the enhanced standard of care control condition will be provided with an information sheet from the NCI about how to find helpful organizations and resources in their community. Self-report will be used to describe any supportive care services pursued by the participant. Additionally, control participants will be added to a waiting list for receiving the MSC-LC intervention program. After completing all questionnaire assessments (18 weeks following study entry), the study team will offer the MSC-LC intervention program to participants on the waiting list.
75634723|NCT02822391|Other|observation|
75784376|NCT06191913|Device|Near-infrared spectroscop|Before the induction of anesthesia, INVOS pediatric SomaSensor probe (Coviden, Dublin, Ireland) was placed on the patient's forearm and then connected to a monitor, which was used to continuously measure and assess the dynamic changes in the StO2
76077933|NCT03358563|Drug|Bicalutamide|The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
75634724|NCT02690571|Other|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
75634725|NCT04200807|Device|Ultrasound Cardiac Output Monitor (USCOM 1A)|doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)
75634726|NCT05659095|Other|autologous hair follicle derived mesenchymal stem cell suspension|Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point. The follow-up duration was 9 months.
75634727|NCT02821065|Device|Remote Patient Monitoring|
75634728|NCT02820285|Other|Evaluation of the staging of fibrosis liver|The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
75920736|NCT02288442|Other|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
75920737|NCT02125227|Drug|Rosuvastatin, Metformin, YH14755|single dose
75920738|NCT02125227|Drug|YH14755|single dose
75920739|NCT03532230|Procedure|Osteopathic Manipulative Treatment (OMT)|No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
75328328|NCT01720901|Drug|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
75328329|NCT04357561|Behavioral|Exercise group (Schroth best practice)|Exercise program will be structured with scoliosis specific exercises (schroth best practice). Schroth best pratice is a pattern spesific scoliosis rehabilitation concept which aimes active self correction during curve pattern specific curve activities of daily life. Exercises for rotational breathing, everyday activities, spinal mobilization and corrective exercises will be specified based on the curve type and applied under the supervision of a physiotherapist.
75328330|NCT01727531|Drug|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
75634729|NCT02820285|Other|Determine the expression level of semaphorin|The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
75634730|NCT02820285|Other|Determination of the composition of immunity cells|"The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)"
75784377|NCT06191900|Biological|Autologous tumor infiltrating lymphocyte injection（GT201）|GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
75784378|NCT06191887|Biological|Autologous BAFFR-targeting CAR T Cells|Given IV
75784379|NCT06191887|Drug|Bendamustine|Given IV
75784380|NCT06191887|Procedure|Biopsy|Undergo biopsy
75920740|NCT02129127|Device|Paclitaxel Coated Chocolate Balloon Angioplasty|Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
75328331|NCT02982343|Behavioral|Falls management plus exercise training|Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.
75634731|NCT04239807|Device|Group 1 GALILEO WBV|3 month home based WBV training
76077934|NCT03358563|Radiation|Ferumoxytol-enhanced MRI imaging|Ferumoxytol-enhanced MRI imaging will evaluate immune micro-environment in the prostate. Three subjects enrolled to the study will undergo the first ferumoxytol-enhanced MRI imaging within 21 days prior to start of hormonal therapy followed by second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
75784381|NCT06191887|Procedure|Biospecimen Collection|Undergo blood sample collection
75784382|NCT06191887|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy/aspirate
75784383|NCT06191887|Procedure|Computed Tomography|Undergo CT scan
75634732|NCT04239807|Other|Group 2 Control|Training on the floor without WBV
75634733|NCT00773461|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
75634734|NCT00773461|Drug|Placebo|iv every 4 weeks for 24 weeks
75784384|NCT06191887|Drug|Cyclophosphamide|Given IV
75634735|NCT02821377|Drug|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
75634736|NCT02821377|Drug|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
75784385|NCT06191887|Procedure|Echocardiography|Undergo echocardiography
75784386|NCT06191887|Drug|Fludarabine|Given IV
75784387|NCT06191887|Procedure|Leukapheresis|Undergo leukapheresis
75784388|NCT06191887|Procedure|Magnetic Resonance Imaging|Undergo MRI
75784389|NCT06191887|Procedure|Positron Emission Tomography|Undergo PET scan
75784390|NCT06191874|Other|Standard-of-care (SOC) surgery plan|Use of SOC clinical planning tools to prepare for DBS (deep brain stimulation) surgery
76077935|NCT01018420|Drug|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
75634737|NCT02821377|Procedure|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
75784391|NCT06191874|Other|HoloDBS hypothetical surgery plan|Use of next generation visualization tools and surgical targeting models to hypothetically prepare for DBS (deep brain stimulation) surgery
75784392|NCT06191861|Behavioral|Most hoped for future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for future self for 20 minutes.
75784393|NCT06191861|Behavioral|Most feared future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most feared future self for 20 minutes.
75784394|NCT06191861|Behavioral|Control (trip to zoo)|Participants in this condition think and write about a future trip to the zoo
75784395|NCT06191861|Behavioral|Balanced future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for and feared future self for 20 minutes.
75784396|NCT06191822|Other|Nutrition|Interact with mobile app and work toward personalized nutrition goals
75784397|NCT06191822|Other|Fitness|Interact with mobile app and work toward personalized fitness goals
75784398|NCT06191822|Other|Sleep|Interact with mobile app and work toward personalized sleep goals
75920741|NCT05555134|Behavioral|educational intervention|will also have an extra educational intervention, a group intervention (4-6 people) through a one-hour training session via zoom, which will be given by the PI (extensive experience in the subject) a week after discharge from the ER. Information will be reinforced and doubts will be solved
75328332|NCT02982343|Behavioral|Falls management only|Participants will undergo a session of falls management and education.
75328333|NCT01721135|Drug|GSK2190915 100mg|Film coated oral tablet
75328334|NCT01721135|Drug|GSK2190915 200mg|Film coated oral tablet
75328335|NCT01721135|Drug|moxifloxacin 400mg|Film coated oral tablet
75634738|NCT02820987|Drug|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
75634739|NCT02820987|Drug|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
75634740|NCT02820987|Drug|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
75651722|NCT05796401|Other|Treatment as usual (TAU)|Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
75784399|NCT06191809|Procedure|Controlled Ovarian Stimulation Protocol|"Ovarian Stimulation Process:~Stimulate ovaries with FSH & hMG (150-375 IU) starting day 2-3 of menstruation.~Monitor response with ultrasound & hormones (E2, LH, P4).~GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.~PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.~Trigger ovulation when ≥2 follicles >17mm (Triptorelin, hCG, or rhCG).~Oocyte retrieval 36-38 hours later (>10mm follicles aspirated).~Embryo Culture & Monitoring:~Fertilize with ICSI.~Culture & evaluate embryos (43-45 hours, day 3/5).~Freeze all embryos."
75784400|NCT06191796|Drug|zanzalintinib|Specified doses on specified days
75784401|NCT06191796|Drug|AB521|Specified doses on specified days
75784402|NCT06191796|Biological|Nivolumab|Specified doses on specified days
75784403|NCT06191770|Procedure|Morphine,|Nalbuphine along multimodal analgesia(Paracetamol and Ketamine)
75784404|NCT06191744|Drug|Epcoritamab|Subcutaneous (SC) Injection
76077936|NCT01018420|Drug|Moxifloxacin|400 mg capsule at the 6 hour point
76077937|NCT04401033|Behavioral|Telephonic medical visit|The patient will receive a telephonic call passing a medical visit
76077938|NCT04401033|Procedure|Gastrointestinal endoscopy|Upper or lower GI endoscopy according to clinical practice and current guidelines
75634741|NCT04052490|Other|Abutment with flat occlusal reduction with feather edge finish|Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.
75328336|NCT01721135|Drug|moxifloxacin placebo|Film coated oral tablet
75634742|NCT04041258|Procedure|pseudoarthrosis of clavicle|Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
75328337|NCT01721135|Drug|GSK2190915 placebo|Film coated oral tablet
75328338|NCT02982421|Behavioral|Group art therapy|Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
75328339|NCT02982421|Behavioral|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
75634743|NCT02820363|Device|"CERAMENT|G"|"Surgical repair of tibia fracture, CERAMENT™|G applied to bony voids."
75634744|NCT02820363|Procedure|SOC treatment|surgical repair of tibial fracture
75634745|NCT03652272|Behavioral|EMC2|"Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~Patients will receive a Medication Guide + Summary with their After Visit Summary~Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
75651723|NCT05792813|Drug|LGYY|LGYY = Linggui Yangyuan paste
75784405|NCT06191744|Drug|Prednisone|Oral Tablet
75784406|NCT06191744|Drug|Rituximab|Intravenous (IV) Infusion
75784407|NCT06191744|Drug|Lenalidomide|Oral Capsule
75784408|NCT06191744|Drug|Doxorubicin|IV Injection
75784409|NCT06191744|Drug|Vincristine|IV Injection
75920742|NCT03532152|Device|Pure Purr VR technology|"The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.~The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate."
76077939|NCT04401033|Procedure|Abdominal ultrasound|Diagnostic abdominal ultrasound according to the current guidelines
75328340|NCT03407885|Other|Bundled payments for knee and hip replacement|"The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices."
75784410|NCT06191744|Drug|Cyclophosphamide|IV Injection
75784411|NCT06191744|Drug|Obinutuzumab|IV Infusion
75784412|NCT06191744|Drug|Bendamustine|IV Infusion
75784413|NCT06191484|Behavioral|WELL Behavioral Probe|Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
75784414|NCT06191315|Drug|Dupilumab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
76077940|NCT03081975|Device|HD white light or NBI|Use of NBI or HD white light
76077941|NCT03082131|Dietary Supplement|Resistant Starch Wheat|The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
76077942|NCT03081819|Drug|SH003|Herbal medicine for cancer treatment
76077943|NCT00974350|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once
75328341|NCT00929071|Device|Evolence|Injectable collagen
75328342|NCT00929071|Device|Lidocaine|admix anesthetic
75328343|NCT00929071|Drug|topical anesthetic|
75784415|NCT06191315|Drug|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
75784416|NCT06190717|Device|EchoMark/EchoSure|Subjects assigned to the Diagnostic Arm will have the EchoMark implanted at the time of AVF creation. The subject will return every 2 weeks for a follow-up assessment to include an EchoSure scan until fistula maturation and/or permanent access use is achieved. The EchoSure scans are to be reviewed by the investigator(s) or delegated study staff and aid in the determination when a further assessment, including a physical exam, is required to determine cannulation clearance or if an intervention(s) may be required to prevent failure of fistula maturation. All physical exams will include assessing the fistula for bruit and thrill. The subject's medical history will be reviewed at each visit and will include all interventions, cannulation attempts, and adverse event reporting.
76077944|NCT00974350|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
76077945|NCT00974350|Drug|SABER-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
75920743|NCT03532152|Device|Sham VR technology|The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
75920744|NCT03550599|Other|Patients accessing to Radiotherapy Unit|No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment
75920745|NCT03528876|Drug|FOLFOX and FOLFIRI|a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
76077946|NCT05633901|Other|Educational Video|Patients will be given the link to the educational video and able to view it as many times as they want
76077947|NCT05633901|Other|Standard Counseling|Current standard of care verbal counseling from a clinic nurse
76077948|NCT05633511|Procedure|Split Mouth Design|PRF on one side of mouth and CTG on the other side of participant's mouth.
76077949|NCT05395702|Drug|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
76077950|NCT03016546|Behavioral|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
75328344|NCT04378205|Procedure|0.014-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.014-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
75328345|NCT04378205|Procedure|0.016-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.016-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
75634746|NCT02820909|Procedure|venous and arterial catheter set-up using ultrasound guidance|The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than > 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
75651724|NCT05792813|Drug|LGYY mimetic|LGYY = Linggui Yangyuan paste
75651725|NCT05792813|Drug|WZYZ|WZYZ= Wuzi Yanzong oral solution
75651726|NCT05792813|Drug|WZYZ mimetic|WZYZ= Wuzi Yanzong oral solution
75328346|NCT00929305|Device|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
75784417|NCT06190717|Procedure|Standard of Care|Subjects are assessed using standard of care per KDOQI guidelines, which includes a physical exam at the 2-week follow-up visit and at the 4-6-week follow-up visit. All follow-up visits will include an assessment of adverse events and medical history review to include all interventions, cannulation attempts, and laboratory results. If evaluation yields an abnormal finding, subjects will undergo a Duplex ultrasound assessment and treatment under the institution's standard of care. All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.
75784418|NCT06190340|Drug|TNP-2092 capsules|Subjects received TNP-2092 capsules orally twice daily at the dose of 100 mg, 300 mg, and 600 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.
75784419|NCT06190340|Drug|Placebo|Subjects received Placebo orally twice daily in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.
75784420|NCT06189859|Procedure|endoscopic submucosal dissection using SPRAY COAG mode|After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Spray coag mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
75920746|NCT03550755|Biological|V3-Cervix|Oral tableted preparation containing hydrolyzed tumor antigens derived from peripheral blood and tumor tissue
75651727|NCT05771402|Drug|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
76077951|NCT03016546|Behavioral|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
75784421|NCT06189859|Procedure|endoscopic submucosal dissection using Precisect mode|After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Precisect mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
76077952|NCT01023178|Drug|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
76077953|NCT01023178|Drug|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
75328347|NCT00929305|Device|Placebo laser|Inactive laser light
75328348|NCT01727687|Behavioral|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
75328349|NCT04347265|Other|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
75328350|NCT01721525|Drug|Afatinib, Ribavirin, and weekly carboplatin/paclitaxel|Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects > 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
75328351|NCT04366063|Biological|Cell therapy protocol 1|Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment.
75634747|NCT02820909|Procedure|Anatomical guidance.|"In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (> 3 punctures), a conversion to ultrasound guidance will be done.~In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than > 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit."
75634748|NCT04148118|Biological|BW-1010: 50 µg - sprayer - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
75634749|NCT04148118|Biological|BW-1010: 50 µg - pipette - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
75634750|NCT04148118|Biological|BW-1010: 100 µg - sprayer - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart"
75634751|NCT04148118|Biological|BW-1010: 100 µg - pipette - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
75634752|NCT04148118|Biological|Saline (Placebo) - sprayer - IN|"Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
75634753|NCT04148118|Biological|Saline (Placebo) - pipette - IN|"Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
75634754|NCT04148118|Biological|BioThrax (positive control) - SC|"BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart."
75634755|NCT04595721|Behavioral|Hidden object|Participant will be instructed to look at the hidden object image on the overhead light to look for a number of objects and observe the image.
75634756|NCT04595721|Behavioral|Stress ball|Participants will be handed a single-use, squeezable stress ball and instructed to squeeze the stress ball.
75634757|NCT04146636|Diagnostic Test|e-LIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT), liver biopsy if necessary (elstometry ≥ 8 kPa and < 15 kPa)
75634758|NCT02820129|Device|Medication Wallet Card|A medication wallet card will be given to the intervention group. This will be personalized for each patient and will include the patient's medications, dosages, and medical conditions. It will be personally given to a patient after a medical appointment with their family physician.
75634759|NCT02820129|Device|Reminder Card|"A reminder card will be given to this group. The card will not be personal and will be mailed to patients. It will state, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
75634760|NCT00773383|Drug|RG1507|iv 9mg/kg weekly
75634761|NCT00773383|Drug|erlotinib [Tarceva]|150mg oral daily
75634762|NCT04239417|Other|Graduated abdominal strengthening exercises|"Exercise mat and inflatable Swiss ball~Wall bar, wedges, elastic tubing"
75634763|NCT04239417|Device|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
75634764|NCT04239417|Combination Product|Graduated abdominal strengthening exercises and the Russian current stimulation|Combination between The Russian current and abdominal exercises
75634765|NCT04101409|Other|Decision aids|Shared decision making with decision aids
75634766|NCT02818881|Other|High-speed yoga|
75634767|NCT02818881|Other|Low-speed yoga|
75784422|NCT06188728|Dietary Supplement|effect of 10 gm psyllium husk fiber twice a day, 30 minutes before breakfast and dinner|comparing the effect of psyllium husk fiber and lifestyle modification alone with the combined effect of psyllium husk fiber on metabolic health of centrally obese school teachers
75784423|NCT06188728|Behavioral|Effect of life style modification (Diet, Behavior and physical activity)|To assess the effect of life style modification (Diet, Behavior and physical activity) on centrally obese school teachers
76077954|NCT01023178|Drug|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
75328352|NCT04366063|Biological|Cell therapy protocol 2|Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.
75651728|NCT05771402|Drug|NAs|Once/day, 1 capsule/time, oral
75651729|NCT05771402|Drug|Peg-IFNα|Once/week, 180μg/time, subcutaneous injection
75651730|NCT05769816|Drug|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
75651731|NCT05769816|Drug|NAs|Once/day, 1 capsule/time, oral
75784424|NCT06188728|Combination Product|Combined effect of 10 gm Psyllium husk fiber and lifestyle modification|To evaluate the combined effect of 10 gm psyllium husk fiber in gel form, 30 minutes before breakfast and dinner along with dietary, behavioral and physical activity modification on centrally obese school teachers
75784425|NCT06188728|Other|Control|No intervention
75784426|NCT06188585|Device|UI-EWD|Hemostatic powder administered at index endoscopy
76077955|NCT01023178|Drug|Progesterone, micronized|Given starting at 18 months
75920747|NCT05554900|Procedure|preventive regenerative peripheral nerve interface reconstruction|Each RPNI unit consists of nerve stump and free autologous muscle graft that is cut off from healthy muscle of the amputated limb. The muscle graft is approximately 30×15×5 mm.The ends of the transected nerve are placed within the muscle belly of the free muscle grafts in an orientation that is parallel to the muscle fibers. Next, the nerve is secured distally with 6-0 non-absorbable monofilament sutures in an epimysial-to-epineurial fashion. The nerve is then wrapped around completely via muscle graft and epimysial securing sutures. All RPNI units are placed in areas remote from the surgical incision and from the weight-bearing surface of the limb.
75920748|NCT02129283|Behavioral|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
75920749|NCT00264732|Drug|Amolimogene|1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
75920750|NCT00264732|Drug|Amolimogene|3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
75920751|NCT00264732|Other|Placebo|Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
75920752|NCT05554822|Drug|Aspirin 100mg|Single antiplatelet therapy with aspirin 100 mg OD for 6 months after the procedure
75920753|NCT05554822|Drug|Aspirin 100 mg OD plus clopidogrel 75 mg OD|Double antiplatelet therapy with Aspirin 100 mg OD plus clopidogrel 75 mg OD for 3 months, followed by 3 months of single antiplatelet therapy with aspirin 100 mg OD.
75328353|NCT01727843|Drug|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
75328354|NCT01727843|Other|placebo|applied topically to surgical site in OR.
75634768|NCT04097665|Device|indocyanine green angiography|All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
75328355|NCT04365751|Procedure|Percutaneous microwave ablation, Laparoscopic hepatectomy|For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.
75328356|NCT01727921|Device|22 gauge ProCore needle biopsy|22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
75328357|NCT01727921|Device|25 gauge ProCore needle biopsy|25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
75328358|NCT04365907|Drug|Zafatek tablets|Once weekly new anti-diabetic drug approved only in Japan
75634769|NCT04097509|Biological|AFG application on palatinal wound healing|9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.
75784427|NCT06188585|Device|Conventional therapy|Conventional endoscopic therapy (bipolar electrocoagulation or clips, with or without epinephrine injection) administered at index endoscopy
75798553|NCT01288248|Device|Airway laryngeal mask classic|"This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.~The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned"
75920754|NCT02125305|Drug|Metformin|
75920755|NCT02125383|Procedure|Active tDCS|Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
75920756|NCT02125383|Procedure|Sham tDCS|Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
75651732|NCT05760898|Behavioral|Blood pressure intervention arm|The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.
75328359|NCT04357639|Other|No intervention|No intervention: Usual care for nasopharyngeal sampling and blood sampling for COVID-19 detection
75328360|NCT00937105|Device|lotrafilcon A contact lenses|FDA approved soft contact lenses
75328361|NCT00937105|Device|Renu Multiplus|
75328362|NCT00937105|Device|Clear Care|
75328363|NCT04367077|Biological|MultiStem|intravenous infusion
75328364|NCT04367077|Biological|Placebo|intravenous infusion
75328365|NCT01721915|Drug|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
75328366|NCT01721915|Drug|Placebo|
75920757|NCT05554744|Procedure|EUS-guided fine-needle injection|Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.
75920758|NCT02131389|Device|Iconacy Hip System|
75920759|NCT04469322|Diagnostic Test|Mental Health DNA Insight Test (Pathway Genomics)|Pharmacogenetic report based on the patients DNA profile at ~45 SNP markers covering 16 genes
75920760|NCT04469322|Diagnostic Test|Sham Test|"Names of 53 medications listed with use as directed"
75328367|NCT04357483|Drug|flowable thrombin containing collagen hemostat matrix|A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.
75920761|NCT04330222|Diagnostic Test|7 Tesla Magnetic Resonance Imaging|Diagnostic Imaging
75920762|NCT04330222|Other|Brief Memory and Executive Test|Cognitive Assessment
75920763|NCT04469400|Dietary Supplement|Low fat diet intensive intervention|education and Compound protein solid beverage
75328368|NCT04357483|Drug|thrombin coated L-dopa contained collagen patch|A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
75328369|NCT01721993|Drug|T121|
75328370|NCT01721993|Drug|Zoledronic acid|
75634770|NCT04097509|Biological|i-PRF application on palatinal wound healing|10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.
75634771|NCT04097509|Other|control|no application
75634772|NCT02818803|Other|Propolis|
75634773|NCT02818803|Drug|Miconazole|
75634774|NCT04238403|Behavioral|Behavioral Parent Training (MATCH Protocol)|BPT. Behavioral Parent Training (BPT) is a well-established psychosocial intervention for the treatment for ADHD and related behavioral difficulties (e.g., oppositional problems). BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods (e.g., praise, effective communication, reward systems, time-out from positive reinforcement) to facilitate positive behaviors in their child (e.g., compliance) and reduce challenging behaviors (e.g., opposition). BPT comes in several manualized, commercially available manuals. The version of BPT that we will be utilizing is from the MATCH protocol (Chorpita and Weisz, 2009), which consists of 10 components, delivered with individual families, typically over the course of 10-16 weekly individual meetings (total meetings depends upon parent availability and acquisition of BPT skills).
75634775|NCT04350060|Other|Retro-fitted room with technological enhancements|Reconstructing and retrofitting a currently existing memory care room at Samaritan Bethany Arbor Terrace Senior Living with integrated technologies specifically to accommodate the needs of persons with dementia to enhance sensory stimulation in sight, sound and sleep.
75634776|NCT00757003|Device|Endovascular Stent-graft repair of descending thoracic aorta|A TAG device will be used to repair the pathology in the thoracic aorta
75634777|NCT02817009|Behavioral|Social Support|The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.
75634778|NCT02817009|Behavioral|Nutrition Session|Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.
75634779|NCT02817009|Behavioral|Physical Activity Session|45 minutes physical activity session to promote healthy behaviors
75634780|NCT04203264|Diagnostic Test|Real-time artificial intelligence identification system|The patients swallowed the MCE with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. The magnetic steering time for passing through the pylorus was not allowed more than 15 min. The real-time auxiliary system implemented real-time processing for the output image of MCE system. Professional operators guarantee the integrity of the examination and the diagnostic results of professional endoscopist was used as the gold standard. The system diagnosis results was recorded at the same time. The sensitivity, delay time, specificity of lesions and anatomical landmarks will be analyzed.
75634781|NCT02818647|Procedure|Tonsillectomy|Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
75651733|NCT05745142|Drug|Sunitinib|as provided in real world practice
75920764|NCT04469400|Other|Low-Carbon Water Diet Intensive Intervention|education and Nutrition bar
75328371|NCT04366609|Drug|Methylphenidate|Treatment with methylphenidate through dose escalation
75328372|NCT03407339|Other|Shared Oral Care intervention|"One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level."
75328373|NCT04366843|Other|chair massage|Chair massage was performed useing only traditional methods of Swedish massage were used, consisting of stroking (smooth, continuous movements to relax and calm the sympathetic nervous system), kneading (consisting of wringing, squeezing muscles, compressing pressure points for the relaxation of soft tissues, i.e. muscles, tendons, fascia), stretching combined with swaying and passive movements of the upper limbs (to mobilize the joints of the upper limbs) and final stroking combined with slapping and shaking percussion, vibration.
75469213|NCT00993044|Drug|Temozolomide|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
75798554|NCT01288248|Device|endotracheal tube|"This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.~The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age."
75328374|NCT04366843|Other|the exercise program|The original set of exercises was developed based on the knowledge and clinical experience of the authors of the study and based on EBP (Evidence Based Practice). The program consisted of 14 strengthening and stretching exercises involving the muscles of the trunk and limbs whose main goal was to mobilize the joints and strengthen the weakened muscles and relax overloaded muscle groups.
76077956|NCT03373851|Device|Zalviso Device|"The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program."
75634782|NCT04203420|Other|screening and confirmatory tests|screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test
76077957|NCT03373773|Procedure|Foley catheter removal|After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
75328375|NCT03407261|Procedure|micro-osteoperforations|Three vertical micro-osteoperforations, using Excellerator, in the buccal extracted site were executed following the aseptic procedure and local anesthesia
75920765|NCT02125539|Behavioral|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
75634783|NCT04339452|Device|Impella 5.0 and Impella 5.5 with SmartAssist Supported OPCABG|Subjects will undergo insertion of an axillary or ascending aortic Impella 5.0 Device or Impella 5.5 with SmartAssist, followed by Impella supported OPCABG using a sternotomy approach with shunting of the coronary arteries to achieve myocardial protection.
75634784|NCT05658939|Other|Phone/Internet survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone/internet for patients.
75634785|NCT04116372|Behavioral|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
75634786|NCT02818725|Drug|Chemotherapy|METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2
75634787|NCT02818725|Drug|Panitumumab|PANITUMUMAB: 6 mg/kg on day 2
75634788|NCT02817165|Dietary Supplement|Probiotic (BioK+)|Probiotic (BioK+) with 3 stains of Lactobacillus
76077958|NCT01023568|Device|Macintosh blade|Intubation with Macintosh blade laryngoscope
75634789|NCT02817165|Other|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
75634790|NCT02820051|Device|Transcutaneous CO2 monitor|Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.
75798555|NCT01288326|Drug|liraglutide|Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
75798556|NCT01173510|Drug|Raltegravir plus Truvada|Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
75798557|NCT01173510|Drug|Atripla|Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
75920766|NCT02125539|Behavioral|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
75920767|NCT05554588|Procedure|Intrathrombus Thrombolysis During Primary PCI|Intrathrombus Thrombolysis During Primary PCI
75328376|NCT04366687|Behavioral|Smart Parents - Safe and Healthy Kids|Smart Parents - Safe and Healthy Kids (SPHSK) is a module designed to be added to existing evidence-based parent education programs. Because the module builds off of the core parenting skills developed in existing parent education programs, the module can be delivered in one session. SPSHK is comprised of three key CSA-prevention components: healthy child sexual development, parent-child communication about sex and sexual behaviors, and CSA-specific safety strategies such as vetting a babysitter and monitoring one-on-one time with adults. Behaviorally based, the module presents developmentally comprehensive information to parents of children 0-13 and utilizes role-playing scenarios and activities to maximize parents' use of learned skills.
75920768|NCT05554588|Procedure|Aspiration Thrombectomy During Primary PCI|Aspiration Thrombectomy During Primary PCI
76077959|NCT01023568|Device|Glidescope|Intubation with Glidescope laryngoscope.
75328377|NCT04366687|Behavioral|Parents as Teachers|Parents as Teachers (PAT) is a parent-support program delivered to parents of children under five and focuses on improving parenting skills through parent-child interactions, development centered parenting, and general well-being. PAT has demonstrated positive effects on child and parent outcomes related to school readiness.
75328378|NCT03407183|Procedure|intradetrusor injection of botulinumtoxinA (Botox)|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.
75328379|NCT03407105|Biological|MDX-010|Specified dose on specified days
75328380|NCT01728233|Drug|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
75328381|NCT01722149|Genetic|Adoptive Transfer of re-directed T cells|Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
75328382|NCT01722227|Drug|Liraglutide|
75634791|NCT02820051|Drug|Midazolam|The initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
75634792|NCT02820051|Drug|Propofol|The initial dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
75328383|NCT01722227|Drug|Placebo|
75634793|NCT02820051|Drug|Nalbuphine|The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
75634794|NCT02820051|Drug|Lidocaine|Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
75634795|NCT02819817|Drug|Aloe Vera Gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
75634796|NCT02819817|Other|Ultrasound gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
75634797|NCT02817243|Drug|SP2086|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
75784428|NCT06188247|Device|NightOwl home-monitoring|The NightOwl™ system consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl™ software. The sensor is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl™ sensor acquires accelerometer data and reflectance-based photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
75784429|NCT06187805|Device|OSSIX Volumax|OSSIX Volumax is used in combination with autogenous bone collected during preparation of the implant osteotomy.
75784430|NCT06187285|Drug|Empagliflozin 25 MG|Patient will get Empagliflozin 25
75784431|NCT06187285|Drug|Sitagliptin 100mg|Patient will get Sitagliptin 100 mg
75784432|NCT06187077|Behavioral|DHA-Enhanced FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Weekly educational modules provide information on components of cardiovascular health (CVH). Participants are given a Fitbit to track physical activity, which will automatically synch to the app and will be asked to track their daily fruit and vegetable intake on the app. DHAs will promote CVH and digital health readiness as peer mentors by guiding participants through the educational modules and encouraging use of the additional interactive app features. During the guided intervention phase, they will facilitate weekly visits with participants in their church, which will follow the FAITH! App modules and integrate a digital health topic. Following the 11-week guided intervention, participants will have a 12-month maintenance phase with access to use the app as they wish.
75798558|NCT01173588|Other|yogurt added with bifidobacteria and soluble fiber (YBF)|Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
75920769|NCT05329324|Other|Questionnaire for study group|Demographic features, Stage and Type, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
76077960|NCT01023568|Device|Truview PCD|Intubation with Truview PCD laryngoscope.
76077961|NCT03372291|Other|Usual Care|Usual leukemia care with all the supportive care measures instituted by the leukemia team
76077962|NCT03372291|Other|Psychological intervention|Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
76077963|NCT01023724|Drug|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
76077964|NCT01023724|Drug|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
75920770|NCT05329324|Other|Questionnaire for control group|Demographic features, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
75920771|NCT05725278|Behavioral|Tiko Platform Behavioural cum mHealth Intervention|Tiko platform is a mix of social franchising and social marketing concepts to promote health behaviours through rewards to health promoters (pro agents), healthcare providers (doctors and pharmacies), Beneficiaries (women needing FP and/or ANC services), and shop keepers and life-style service providers where beneficiaries, providers and promoters could use their rewards points. The health promoters could purchase from wholesale retailers products such as sanitary napkins, condoms and then resale these at profit. Beneficiaries were given discounts and their rewards points can be used as cash to avail certain lifestyle services at participating locations, and so did the health care providers. Pro agents also got incentives for recruiting the beneficiaries and after beneficiaries reached certain service access/use milestones. All this was integrated on a mHealth platform using smart phones and smart cards (for those without access to Tiko card).
75920772|NCT05725278|Other|Standard of Care / Business as Usual|Non-Users of Tiko did not use Tiko platform but they could access any health care provider or pharmacy to avail same services related to Family planning, antenatal care, postnatal care
75328384|NCT01722305|Drug|Dexamethasone|Given PO
75784433|NCT06187077|Behavioral|FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Each week, an educational module is completed in the app, which provides information on a component of cardiovascular health. Participants will be given a Fitbit to track their physical activity, which will automatically synch to the app, and will be asked to track their daily fruit and vegetable intake on the app as well. Following the 11-week guided intervention, participants will have a 12-month maintenance phase in which they will have access to use the app as they wish.
75328385|NCT01722305|Other|Laboratory Biomarker Analysis|Optional correlative studies
75634798|NCT02817243|Drug|Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
75634799|NCT00766363|Drug|EVP-6124 (0.1 mg/day)|EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
75784434|NCT06186934|Drug|the standard-dose group (4 g/day)|Patients with chronic kidney disease undergoing hemodialysis and controlling hyperphosphatemia
75920773|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
75920774|NCT00254904|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
75920775|NCT00254904|Drug|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
75920776|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
75920777|NCT00254904|Drug|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
75328386|NCT01722305|Other|Pharmacological Study|Optional correlative studies
75328387|NCT01722305|Drug|Pomalidomide|Given PO
75328388|NCT04365595|Other|Questionnaires, spirometry|Questionnaires targeting health-related quality-of-life, symptoms, anxiety and depression
75328389|NCT04365517|Drug|Sitagliptin|We propose a randomized controlled open label intervention study. Patients with type 2 diabetes admitted to COVID-19 and randomized to the study group will be treated with sitagliptin at an adjusted dosage for estimated glomerular filtrate: 100 mg once daily (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2 ) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
75328390|NCT03406871|Drug|Regorafenib|One course will last 28 days. Oral administration at a dose of 80 mg/day, 120mg/day or 160 mg/day for 21 consecutive days, with a 1-week washout period.
75634800|NCT00766363|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
75920778|NCT04329988|Other|questionnaire|A questionnaire will be made available to all eligible patients in general practitioners waiting rooms. This questionnaire will be composed by the single question, followed by the AUDIT and FACE questionnaires, and three socio-demographic questions. This questionnaire will be anonymous. Patients who agree to fill out a questionnaire will place it in a sealed box once completed.
75920779|NCT05295082|Procedure|guided trephination-based drilling protocol|the implant site preparation in this group will be done by guided trephination protocol which uses the surgical guide to trephine the implant site then remove the guide and continue the drilling in a freehand manner
75920780|NCT05295082|Procedure|guided Conventional drilling-based protocol|the implant site preparation in this group will be done by a guided conventional drilling protocol which uses the surgical guide to guide the sequential drills up to the final drill
75920781|NCT05554510|Other|Observational|No interventions planned. Observational data collection only.
75920782|NCT05725122|Procedure|Extracorporeal shock wave lithotripsy|Extracorporeal shock wave lithotripsy will given to the patients
75920783|NCT05725122|Procedure|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy.|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy will be given to the patients
75920784|NCT03880396|Radiation|hypofractionated Rth with platinol|hypofractionated Rth with weekly cisplatin 40mg/m2
75920785|NCT03532074|Diagnostic Test|assessment of bowel symptoms before surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery
75328391|NCT03406871|Drug|Nivolumab|One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.
75634801|NCT00766363|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
75634802|NCT00766363|Drug|Comparator: Placebo|Matching placebo was administered as one capsule per day for 28 days.
75920786|NCT03532074|Diagnostic Test|assessment of rectosigmoid during laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. A near-infrared camera-head (KARL STORZ Gesellschaft mit beschränkter Haftung & Co., Tuttlingen, Germany) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
75920787|NCT03532074|Diagnostic Test|follow up and assessment of bowel symptoms after surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery
75469214|NCT00993044|Drug|Bevacizumab|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
75634803|NCT00766363|Drug|Donepezil|Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
75328392|NCT04365439|Biological|Blood plasma|Convalescent plasma after COVID-19
75634804|NCT00766363|Drug|Rivastigmine|Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
75328393|NCT04365283|Procedure|New Bioactive Restorative Material (ACTIVA Presto)|New Bioactive Restorative Material
75328394|NCT04365283|Other|High Viscosity Glass Hybrid Reinforced Glass Ionomer (EQUIA Forte)|High Viscosity Glass Hybrid Reinforced Glass Ionomer
75634805|NCT02636946|Drug|Bimatoprost SR|Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
75798559|NCT01175616|Drug|Creatine|Oral Creatine 5 grams daily.
75920788|NCT03532074|Diagnostic Test|assessment of rectosigmoid perfusion during robot-assisted laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. The robotic Firefly imaging system (daVinciXi surgical platform; Intuitive Surgical, Sunnyvale, CA) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
75920789|NCT04441164|Other|Observation of Virtual Actions|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
75920790|NCT04441164|Other|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
75634806|NCT02636946|Drug|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
75634807|NCT02636946|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
75920791|NCT04441164|Other|Acceptability questionnaire|It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
75920792|NCT04441164|Other|Observation of Virtual Actions (step 4)|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
75920793|NCT04441164|Other|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
75328395|NCT01728311|Drug|BAY1082439|BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
75328396|NCT04357093|Other|Grape seed extract mouthwash|Mouthwash 15% grape seed extract
75328397|NCT04357093|Other|Sodium fluoride mouthwash|Sodium fluoride mouthwash
75634808|NCT02636946|Procedure|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
75634809|NCT02819895|Other|A customized windows® software application|A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.
75328398|NCT03406793|Dietary Supplement|Standard MNP|Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.
75328399|NCT03406793|Dietary Supplement|High zinc, low iron MNP|Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.
75798560|NCT03863340|Behavioral|interruptions of work tasks|"During each activity two interruptions/breaks were selected randomly from a set of ten predetermined actions:~Active break types:~Move shoulder and upper back~Swing arms near the body~Three slow but forceful elevations of the shoulders, a relaxation exercise based on the principles developed by Jacobson~Stand up and stretch~Slowly turn head in all possible directions.~Passive break types:~Tell a couple of jokes~Stand up and have a drink~Relaxing the trapezius~Questions on actual posture and feelings of comfort / discomfort.~A short rest on the couch"
75798561|NCT01286610|Device|ProMedVi Vibrosphere|vibration therapy
75784435|NCT06186687|Behavioral|Myofunctional therapy exercise|Myofunctional therapy involves various exercises to train muscles in the soft palate, tongue, face, and pharynx. Vocal letters are used to train the palatopharyngeus, palatoglossus, uvula, tensor veli palatine, and levator veli palatine muscles. Tongue exercises involve sliding the tongue to the upper and side surfaces of the teeth, placing the tip in front of the palate, and pressing and sucking the tongue up to the palate. Face exercises involve inflating the cheeks, gargling, and sucking the cheeks to exercise the orbicularis oris muscle and the buccinator muscle. Icing stimulates the mouth, producing a cold, chilling, and numbing effect, causing reflexive contraction of the palate, tongue, and pharyngeal muscles.
75920794|NCT04441164|Other|Haptic stimulation|According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
75920795|NCT04441164|Other|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
75920796|NCT01359046|Device|silver SPC|subject randomized to receive silver alloy impregnated catheter
75920797|NCT01359046|Device|standard SPC|subject randomized to receive standard catheter
76077965|NCT00974818|Drug|Mitomycin C (MMC)|Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
76077966|NCT00974818|Biological|Bacillus Calmette-Guerin (BCG)|Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
75634810|NCT00766051|Other|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
75784436|NCT06184867|Diagnostic Test|Relational Agent|Alex was developed as an interactive and personalized education and decision support intervention for smart devices, and guides participants through the key primary stages of assessing personal risk of hereditary cancer, providing genetic education, cancer family tree, patient testimonials, asks and answers questions and for those who choose, facilitates genetic testing, and streamlines disclosure of test results.
75920798|NCT00253968|Drug|Eplivanserin|oral administration
76077967|NCT05395546|Other|dCBT-I|"Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~Scale assessment needs to be completed at the end of treatment~One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation"
76077968|NCT00977704|Device|Restylane and Perlane|
76077969|NCT05395390|Behavioral|Exercise (Resistance Training|Resistance Training done both at home and on site using either dumbells or keiser pneumatic exercise machines respectively
75328400|NCT03406793|Dietary Supplement|High zinc, low/no iron on alternating days|Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.
75328401|NCT03406793|Dietary Supplement|Dispersible zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.
75328402|NCT03406793|Dietary Supplement|Intermittent zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.
75784437|NCT06184867|Other|Clinical Letter|Letter will be signed by Dr. Toppmeyer and contain a recommendation to contact the Life Center for a cancer genetic risk assessment and to consider GT.
75784438|NCT06184750|Procedure|Biopsy|Undergo biopsy
75784439|NCT06184750|Procedure|Biospecimen Collection|Undergo collection of blood samples
75328403|NCT03406793|Dietary Supplement|Placebo powder|Daily provision of a placebo powder for 24 weeks.
75328404|NCT04365127|Drug|Progesterone 100 MG|Subcutaneous administration twice daily
75328405|NCT01728467|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
75634811|NCT00909792|Device|Lotrafilcon B|Silicone hydrogel, soft, multifocal contact lens
75784440|NCT06184750|Procedure|Mammography|Undergo mammography
75784441|NCT06184750|Other|Questionnaire Administration|Ancillary studies
75784442|NCT06184750|Drug|Tamoxifen|Given PO
75920799|NCT00253968|Drug|placebo|oral administration
75328406|NCT01728467|Drug|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
75328407|NCT03406637|Device|BPK-S Integration|primary total knee endoprosthesis
75469215|NCT00955045|Drug|istradefylline|
75469216|NCT00887302|Procedure|Gastric Band|Places a band over the upper portion of the stomach.
76077970|NCT05395234|Behavioral|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura & McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction & flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
75784443|NCT06182839|Drug|Canagliflozin 300Mg Tab|Patients will get 1 pill of Canagliflozin 300 mg daily for one year.
76077971|NCT03371667|Drug|Methotrexate|"Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
75328408|NCT00929383|Device|Wingspan Stent System with Gateway PTA Balloon Catheter|"The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.~The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion."
75328409|NCT03406559|Other|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion,
75328410|NCT01722461|Device|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
75328411|NCT01722461|Device|Sham treatment|Ulthera System delivering no ultrasound energy
75634812|NCT00909792|Device|Senofilcon A|Silicone hydrogel, soft, multifocal contact lens
75634813|NCT02819739|Drug|medical oxygen|
75784444|NCT06182839|Drug|Placebo|Patients will get 1 pill of placebo daily for one year.
75784445|NCT06182384|Drug|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：1mL AI, injection two needles. Second period: 2mL AI, injection one needle).
75784446|NCT06182384|Drug|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：2mL AI, injection one needle. Second period: 1mL AI, injection two needles).
75784447|NCT06181929|Diagnostic Test|Low dose CT|A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent
75328412|NCT00929773|Device|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
75784448|NCT06181734|Drug|Ivosidenib|inhibitor of mutant IDH1
75784449|NCT06181487|Other|High Intensity Functional Training|12 weeks of high-intensity functional training, 3 times/week. Each class lasts 60 minutes, including warm-up, physical training, and cool down.
75328413|NCT00929773|Device|Placebo laser|Inactive laser light.
75328414|NCT01722539|Drug|Sulfadoxine-pyrimethamine|Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
75328415|NCT01722539|Drug|Piperaquine|Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
75634814|NCT03104868|Behavioral|TAKE IT Strategy|"The TAKE IT Strategy includes:~Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.~SMS text-messaging to remind patients when to take all their medicine.~A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.~EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond."
75634815|NCT02819661|Device|SOMNOTOUCH RESP|Ventilatory effort recorder
75634816|NCT02819661|Procedure|Caesarean section|Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
75634817|NCT02819661|Drug|Spinal anesthesia with intrathecal morphine|is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
75651734|NCT05737069|Drug|Ibuprofen arginine granules 400 mg|Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
75784450|NCT06181279|Procedure|Individualized PEEP group|Individualized PEEP group: Recruitment Maneuver (RM) is performed first. In pressure control mode, PEEP and airway plateau pressure are increased to 20 cmH2O and 35 cmH2O at a rate of 5 cmH2O every 30s, and driving pressure is maintained at 15 cmH2O throughout. Subsequently, in volume-controlled ventilation mode, PEEP decreases from 20 cmH2O to 4 cmH2O at gradient of 2 cmH2O, and each PEEP level is maintained for 30s. The PEEP corresponding to the lowest driving pressure is the individualized PEEP we need. If multiple PEEP levels showed the same lowest driving pressure, the lowest PEEP value as the individualized PEEP. The above procedures are performed three times during the surgery (5 minutes after intubation,5 minutes after the beginning of pneumoperitoneum, and 5 minutes after the end of pneumoperitoneum).
75784451|NCT06181279|Procedure|Fixed PEEP group|After the same RM, PEEP is fixed at 8 cmH2O.
75784452|NCT06179290|Other|Ploom HTP Menthol HTS; MX3 (681)|Menthol heated tobacco product
75634818|NCT02816541|Other|Pelvis Retroverted|Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
75634819|NCT02816541|Other|Pelvis in Neutral Position|Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
76077972|NCT03371667|Drug|Placebo|"Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
76077973|NCT01024738|Drug|Fluoride|Brush half mouth twice daily for four days.
76077974|NCT01024738|Drug|Triclosan, fluoride|Brush twice daily
76077975|NCT01024738|Drug|Chlorhexidine Gluconate|Rinse mouth twice a day
76077976|NCT05613153|Dietary Supplement|Peppermint Oil|Participants weighing more than 40 kg will receive 2 peppermint oil capsules 3 times a day. Smaller children who weigh between 30 kg and 40 kg will receive 1 capsule of peppermint oil 3 times a day. All subjects will receive 8 weeks of treatment.
76077977|NCT04279041|Procedure|root canal preparation|root canal preparation
76077978|NCT01024972|Drug|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
76077979|NCT01024972|Drug|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
76077980|NCT03370809|Radiation|Brain PET/CT step|a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
76077981|NCT05686395|Procedure|Ultrasound-guided Interscalene Block group|ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery
75328416|NCT01722539|Drug|Albendazole|One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
75634820|NCT02816541|Other|Aerobic exercise|Aerobic exercises (walking) performed on a treadmill.
75328417|NCT01722539|Drug|Praziquantel|Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
75634821|NCT00765817|Drug|placebo|subcutaneous injection, twice a day
75634822|NCT00765817|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
75634823|NCT02818491|Drug|Placebo|Normal saline 0.9% in 2 mls
75784453|NCT06179290|Other|Ploom HTP Tobacco HTS; R8 (120)|Non-menthol heated tobacco product
75784454|NCT06179290|Other|Smoking Abstinence (menthol)|No smoking or other tobacco product use for duration of the study, menthol group comparator
75784455|NCT06179290|Other|Smoking Abstinence (non-menthol)|No smoking or other tobacco product use for duration of the study, non-menthol group comparator
75798562|NCT01286610|Device|schwa-medico MUSKELaktiv|Electrical muscle stimulation
76077982|NCT05686395|Procedure|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block
75328418|NCT01722617|Other|Questionnaire|Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
75328419|NCT03406403|Device|Laryngeal mask airway|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
75634824|NCT02818491|Drug|Dexamethasone 1 mg|Dexamethasone 1 mg in 2 mls
75634825|NCT02818491|Drug|Dexamethasone 2 mg|Dexamethasone 2 mg in 2 mls
76077983|NCT05686395|Drug|Bupivacaine|bupivacaine 0.25%.
76077984|NCT01025830|Drug|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
76077985|NCT01025830|Drug|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
76077986|NCT03081039|Drug|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
76077987|NCT03081039|Drug|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
75634826|NCT02818491|Drug|Dexamethasone 3 mg|Dexamethasone 3 mg in 2 mls
75634827|NCT02818491|Drug|Dexamethasone 4 mg|Dexamethasone 4 mg in 2 mls
75634828|NCT02818491|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 20 mls
75634829|NCT02818179|Radiation|THERMOGRAPHY IMAGING|
75634830|NCT02816853|Drug|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
75634831|NCT02816853|Drug|Placebo|Matching placebo will be administered.
75798563|NCT01286610|Device|Galileo Home Plus (ICU)|vibration therapy
75798564|NCT03863106|Other|Metastatic gastroenteropancreatic and lung neuroendocrine tumors|Patients with metastatic GEP and lung NETs will be selected via the Cancer Database on NEN of the Hospices Civils de Lyon. Data from this database will be matched with the French nationwide claims and hospitalization database (SNDS database), allowing access to the corresponding healthcare resources use and their related costs. Data regarding clinical and tumour characteristics and treatments patterns will be collected via the database between 1 January 1990 and 31 of December 2017.
76077988|NCT03081039|Drug|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
75634832|NCT02816853|Drug|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
75634833|NCT04101097|Other||
75634834|NCT02818257|Other|Strip A|Adhesive strip A
75634835|NCT02818257|Other|Strip B|Adhesive strip B
75784456|NCT06178757|Drug|TAPB|As soon as the surgical procedure is completed, TAPB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed at the level of the anterior axillary line between the 12th rib and the iliac crest, and the external oblique abdominal muscle, internal oblique abdominal muscle, and transverse abdominis muscle will be visualized. Then, using the in-plane technique, the needle will be advanced with the help of ultrasound until the needle tip reaches the space between the internal oblique and transversus abdominis muscles. After negative pressure aspiration, 5ml saline will be injected and the block location will be confirmed. Once the block location is confirmed, 20ml 0.25% bupivacaine (40ml total for each side) will be injected bilaterally.
75784457|NCT06178757|Drug|EOIB|As soon as the surgical procedure is completed, EOIB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath in the supine position, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the 6th rib in the mid-axillary line, at the line between the anterior superior iliac spine and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected between, the external oblique muscle and the rib, and the block location will be confirmed. After confirming the block location, 20 ml 0.25% bupivacaine will be applied to the plane between 6.,7., and 8. ribs and the muscles. The same procedure will be applied to the other side (a total of 40 ml 0.25% bupivacaine).
75784458|NCT06177392|Procedure|Secondary TAVI access|The randomization will determine whether radial or femoral artery puncture will be employed as the secondary access in the TAVI procedure.
75784459|NCT06176495|Diagnostic Test|Educational Text Messages|"The educational content will be targeted about Diabetes Education and will be guideline based with what complies to the standards of care instituted by the American Diabetes Association.~They text messages will comprise content related to general diabetes knowledge, diabetes management and control, coping with diabetes, and guidance on adopting a healthy lifestyle."
75784460|NCT06175026|Behavioral|Health messages|Participants view messages about the health impacts of certain dietary substitutions.
75784461|NCT06175026|Behavioral|Environmental messages|Participants view messages about the environmental impacts of certain dietary substitutions.
75784462|NCT06175026|Behavioral|Health and environmental messages|Participants view messages about the health and environmental impacts of certain dietary substitutions.
75784463|NCT06175026|Behavioral|Neutral messages|Participants view neutral messages unrelated to the health and environmental impacts of certain dietary substitutions.
75784464|NCT06173544|Behavioral|Standard of Care (SOC)|Participants randomized to this arm will received enhanced standard of care.
75784465|NCT06173544|Behavioral|Adapted Friendship Bench (AFB)|Participants randomized to this arm will receive the Adapted Friendship Bench protocol delivered by a trained counselor.
75784466|NCT06173544|Behavioral|Enhanced Friendship Bench (EFB)|Participants randomized to this arm will receive the Enhanced Friendship Bench protocol delivered by a trained counselor and a peer supporter.
75469217|NCT00887302|Procedure|Gastric Sleeve|Stapling stomach vertically to reduce size of stomach and removal of larger curve portion of the stomach
75469218|NCT00887302|Procedure|Gastrostomy Tube|Tube is inserted into the stomach that delivers nutrition directly into the stomach.
75469219|NCT00761618|Procedure|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
75784467|NCT06173024|Biological|TAK-577|TAK-577 as IV injection at dose calculated based on the participant's body weight.
75784468|NCT06172335|Dietary Supplement|Cetoleic acid|Very long monounsaturated fatty acid (C22:1n-11)
75784469|NCT06172335|Dietary Supplement|Control oil|Mix of oils with low cetoleic acid content
75634836|NCT02818257|Other|Strip C|Adhesive strip C
75784470|NCT06163794|Other|Nutritional postprandial test|Metabolic responses to several test meals
75784471|NCT06162221|Drug|RMC-6291|Oral tablet
76077989|NCT01026844|Drug|erlotinib|Taken orally once a day
76077990|NCT01026844|Drug|hydroxychloroquine|Taken orally once a day
76077991|NCT04278963|Drug|YinHu QingWen Decoction|YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
76077992|NCT04278963|Drug|YinHu QingWen Decoction(low dose)|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
76077993|NCT04278963|Other|Chinese medicine treatment|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.
76077994|NCT04278963|Other|standard western medicine treatment|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
75634837|NCT02818335|Drug|LY3023414 Reference Fasted|Administered Orally
75784472|NCT06162221|Drug|RMC-6236|Oral tablet
75784473|NCT06162221|Drug|Pembrolizumab|IV Infusion
75469220|NCT00761618|Procedure|IPC Placement|IPC placed in chest cavity to drain excess fluid
75634838|NCT02818335|Drug|LY3023414 Test Fasted|Administered Orally
75634839|NCT02818335|Drug|LY3023414 Test Fed|Administered Orally
75634840|NCT02818413|Other|Biospecimen collection and questionnaires|Biospecimen collection and questionnaires
75634841|NCT02819583|Biological|PCAR-019 (anti-CD19 CAR-T cells)|
75651735|NCT05737069|Drug|Ibuprofen arginine granules 400 mg (Spedifen)|Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
75784474|NCT06162221|Drug|Cisplatin|IV Infusion
75784475|NCT06162221|Drug|Carboplatin|IV Infusion
75784476|NCT06162221|Drug|Pemetrexed|IV infusion
75920800|NCT05612308|Other|Vertical Oscillatory Pressure (VOP)|The VOP involves a pressure from the posterior aspect of the body while patient lye prone. the pressure is exacted directly on the spine, The sustained Natural Apophyseal Glides involves pressure as well when the patient sits down on a chair. The movement is done from the posterior to the anterior as well
75469221|NCT00761618|Radiation|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
75920801|NCT05612230|Other|Data analysis|Data analysis is based on a single database from the National Health Medical Data (North Center).
75920802|NCT05543304|Diagnostic Test|radiological evaluation|All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.
75920803|NCT05612152|Other|Referral to Quitline|An electronic referral to the state quitline is placed. This prompts the quitline to proactively call the patient to enroll in counseling services.
75634842|NCT02819349|Behavioral|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
75920804|NCT05612152|Other|Choose2Quit|An electronic referral to the Choose2quit tobacco cessation navigator is placed. This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.
75920805|NCT05549986|Other|Observational|Observational
75920806|NCT05549830|Other|Patient Positioning|"In the preoperative period, the patient/patient relative will be informed about the possible surgical position and the importance of placing the patient in a different position before and after surgery.~İn the postoperative period, the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals."
76077995|NCT00979732|Dietary Supplement|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
76077996|NCT00979732|Dietary Supplement|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
75469222|NCT00579644|Drug|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
75634843|NCT00772603|Drug|Placebo|Non-active tablet identical to study drug tablets
75634844|NCT00772603|Drug|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
75634845|NCT00772603|Drug|1200mg SPN-804|two active tablets and two non-active tablets, all identical
75634846|NCT02819427|Device|Near Infra Red Spectroscopy (NIRS)|
75634847|NCT02819427|Device|Electroencephalography (EEG)|Electroencephalography (EEG) in a simultaneous High-Resolution (HR) recording.
75634848|NCT02819505|Dietary Supplement|beta-alanine|
75634849|NCT02819505|Dietary Supplement|Placebo|
75634850|NCT04237779|Biological|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in micro testicular sperm extraction (TESE) material.
75634851|NCT04239105|Device|Microfluidic and Raman spectrum|Detection of Circulating Tumor Cells
76077997|NCT03368781|Device|AcQMap Imaging and Mapping System|3D Cardiac Imaging and Mapping during ablation procedures
76077998|NCT03353181|Device|Endoscopic scissors|Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.
76077999|NCT03353181|Device|Biliary stent|Standard placement of biliary stent
76078000|NCT05686239|Drug|RL-007|investigational study drug
76078001|NCT05686239|Drug|Placebo|placebo capsules matching the appearance and size of the active drug
75634852|NCT02819271|Drug|CXL-1427 Ascending Dose|
75634853|NCT02819271|Other|Placebo|
75634854|NCT02819271|Drug|CXL-1427 Descending Dose|
75634855|NCT02816463|Device|Ambu AuraGain|
75634856|NCT02816463|Device|LMA Supreme|
75634857|NCT02818101|Behavioral|Hypnosis session|
75634858|NCT02816619|Behavioral|Personalized Physical Activity coaching program|
75634859|NCT02816619|Behavioral|Free practice of physical activity|
75634860|NCT00772447|Drug|Daptomycin|4mg/kg IV ; Q 24 hr (once every 24 hours)
75798565|NCT03435640|Drug|NKTR-262|"During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262."
75798566|NCT03435640|Drug|bempegaldesleukin|"During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles."
76078002|NCT05686161|Biological|SW-BIC-213;SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
75634861|NCT00772447|Drug|Vancomycin|"Vancomycin - 1g per 12 hrs, for 7-14 days~Or switch to~Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:~- 1 g every 6 hours or 2 g every 8 hours"
75634862|NCT00765037|Device|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
75634863|NCT02817867|Device|tDCS|Transcranial direct current stimulation (tDCS)
75328420|NCT03406403|Drug|Magensium sulphate|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
75634864|NCT02817867|Device|TMS|Transcranial magnetic stimulation
75784477|NCT06161753|Behavioral|Cognitive Functional Therapy|"CFT is an individualised, combined physical and behavioural approach specifically developed to target the multidimensional complexity of persistent LBP. CFT utilises a multidimensional clinical reasoning framework that enables the clinician to identify both modifiable and non-modifiable biopsychosocial factors (i.e. physical, cognitive, emotional, social, lifestyle and health comorbidities) underlying an individual's LBP. CFT targets these factors by: (1) helping the patient 'make sense of their pain' from a biopsychosocial perspective, (2) build confidence to engage in valued activities through functional movement training and (3) adopt positive lifestyle behaviours (O'Sullivan et al., 2018).~Participants will receive approximately 7 treatment sessions over a 13-week period, although this will vary depending on participant needs, in line with the individualised nature of the intervention. Participants will be provided a booster session at 26 weeks to reinforce self-management."
75920807|NCT05700526|Device|Planning of multiplanar and/or multifocal osteotomies in children by using VSP, PSIs and customized structural bone allograft|Preoperative VSP is performed starting from 3D digital models obtained from DICOM data of CT-scan with a segmentation process. If applicable, a model of the contralateral limb is obtained and used as reference for the correction. The surgeon and the engineer together define the surgical strategy, establishing the correction, the design of Patient-Specific Instruments (PSIs) and the hardware to implant. Then, through VSP, an ideal model of the bone graft is designed.
75920808|NCT05700526|Device|Routine preparation of bone graft according to standard protocols|The size dimensions obtained through VSP are used by the tissue bank to manually cut a structural bone graft according to the standard protocols.
75920809|NCT05700526|Device|Preparation of bone graft with virtual bone-matching and GSIs|The best donor bone is identified by matching the 3D models provided by bone bank with the planned graft, considering not only the size but also the most suitable configuration of cortical and medullary bone. Then GSIs are designed and 3D printed to perform the exact cut on the donor bone according to the experimental protocol.
75920810|NCT05700526|Procedure|Corrective osteotomy|The acute surgical correction is performed according to VSP using PSI and the customized bone graft. Preoperative variables (age, sex, disease, deformity), intraoperative variables (operation time, intraoperative complications, use of fluoroscopy, intraoperative bleeding) are registered.
75920811|NCT03544606|Drug|isosorbide mononitrate|isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction
75920812|NCT03544606|Drug|Placebos|70 patients induced by placebo (pyridoxine) administered in the posterior vaginal fornix.
75920813|NCT02741310|Drug|Placebo|Administered by intravenous infusion
75328421|NCT03406403|Other|Control group (closure of anesthetics)|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
75328422|NCT04378517|Other|psychosocial education in parents groups|psychosocial education
75634865|NCT02817867|Device|tDCS + TMS|Association between tDCS and TMS.
75920814|NCT02741310|Drug|Sumatriptan|Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
75920815|NCT02741310|Drug|Erenumab|Administered by intravenous infusion
75920816|NCT03531684|Dietary Supplement|MMFS-205-SR|Twice daily, oral, 500 mg tablets
75328423|NCT04378517|Other|psychosocial parents support, interviews with APN|Family strength-oriented therapy conversation
75328424|NCT04357171|Procedure|Low anterior resection with protective loop ileostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning ileostomy is performed.
75634866|NCT04238169|Drug|Bevacizumab|7.5mg/kg once every three weeks
75634867|NCT04238169|Drug|Toripalimab|240 mg once every three weeks
75634868|NCT04238169|Radiation|SBRT|30-50Gy/5F（2-4 lesions）
75634869|NCT04687371|Other|Proprioceptive vestibular exercise|To assess effects of proprioceptive vestibular exercises training in patients with peripheral vestibular hypofunctions
75634870|NCT04687371|Other|Standard vestibular rehabilitation exercises|To assess effects of standard vestibular rehabilitation exercises in patients with peripheral vestibular hypofunctions
75634871|NCT04687371|Other|Controlled|First and last measurement will be taken. There will be no intervention. study will include 9 patients.
75634872|NCT04200573|Drug|Ampreloxetine|The study drug will be administered orally as a single Dose A tablet
75651736|NCT05732311|Device|intermittend theta burst stimulation|intermittend theta burst stimulation
75784478|NCT06159647|Behavioral|Mouth cancer warning|Participants will view messages about the risk of mouth cancer from alcohol consumption.
75784479|NCT06159647|Behavioral|Throat cancer warning|Participants will view messages about the risk of throat cancer from alcohol consumption.
75328425|NCT04357171|Procedure|Low anterior resection with protective loop transverse colostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning transverse colostomy is performed.
75634873|NCT00831844|Biological|cixutumumab|Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
75634874|NCT00831844|Other|laboratory biomarker analysis|Correlative studies
75634875|NCT02816073|Device|Pan-retinal photocoagulation using pattern scanning laser|Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
75328426|NCT03406169|Drug|Sildenafil 25 MG Oral Tablet|twice a day dosing
75634876|NCT02816229|Device|Insertion of endobronchial valve|One or more endobronchial one- way valves will be inserted into the appropriate lung regions
75634877|NCT00764881|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose
75634878|NCT00764881|Drug|Microgynon|Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
75920817|NCT03531684|Dietary Supplement|Placebo|Twice daily, oral
76078003|NCT05686161|Biological|Sinopharm (BIBP);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
75920818|NCT00243906|Drug|Recombinant tissue plasminogen activator|Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
75328427|NCT03406169|Drug|Pentoxifylline|400mg twice a day
75634879|NCT00764881|Drug|Placebo|Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
75634880|NCT02816385|Procedure|Antegrade cardioplegia|Injection of the cardioplegia in the coronary arteries
75634881|NCT02816385|Procedure|Retrograde cardioplegia|Injection of the cardioplegia in the venous system
75634882|NCT04044196|Procedure|Rotator cuff repair|Rotator cuff repair performed arthroscopically
75634883|NCT02819193|Other|raw mother's own milk|Infants receive mother's own milk before day 7.
75634884|NCT00705328|Behavioral|Primary Health Care Model (PRMHLTH)|Primary health care service delivery
75634885|NCT00705328|Behavioral|Recreation Coordination Model (REC)|Recreation coordination service delivery
75634886|NCT00705328|Behavioral|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of PRMHLTH plus REC.
75634887|NCT00922870|Device|Cascade|Cascade treatment over 48h
75634888|NCT00922870|Other|Standard treatment|Standard therapy
75634889|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
75634890|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
75634891|NCT04609215|Other|ALECSAT|"Patients will receive concurrent chemotherapy with carboplatin/gemcitabine with cycles repeated every 3 weeks.~During the loading phase, patients will receive ALECSAT at 28 days intervals at weeks 5, 9, and 13. Hereafter (the maintenance phase), ALECSAT will be administered every 12 weeks until disease progression, death, unacceptable toxicity, investigator/patient decision or EOT visit at 18 months."
75784480|NCT06159647|Behavioral|Voice box (larynx) warning|Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.
75784481|NCT06159647|Behavioral|Esophagus cancer warning|Participants will view messages about the risk of esophagus cancer from alcohol consumption.
75784482|NCT06159647|Behavioral|Liver cancer warning|Participants will view messages about the risk of liver cancer from alcohol consumption.
75784483|NCT06159647|Behavioral|Colon and rectum cancer warning|Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.
75920819|NCT00243906|Procedure|Low-intensity ultrasound|Delivery of additional IA rt-PA (up to 22 mg) in the setting of low-energy ultrasound via the EKOS microinfusion catheter at the site of IA occlusion in acute ischemic stroke patients with large strokes (NIHSS >/= 10) treated within 3 hours of symptoms onset.
75920820|NCT03532360|Other|Oral immunotherapy|Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
75328428|NCT03406169|Other|Placebo|placebo twice a day
75328429|NCT04346875|Procedure|Regularly changing of dressing|Conventional dressing
75328430|NCT04346875|Procedure|No application|No dressing change
75328431|NCT01722695|Other|Dialyzer comparison|"Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization."
75328432|NCT04357327|Diagnostic Test|rapid salivary test|a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay
75328433|NCT03835793|Diagnostic Test|CAC-score|Testing for possible unfavourable health effects of early surgical menopause
75328434|NCT04357015|Drug|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
75634892|NCT05384548|Behavioral|Problematic smart phone use course|A 6 session, online, group-based, psychological course targetting problematic smart phone use.
75634893|NCT02817477|Drug|Ketamine Hydrochloride|Delivered intranasally using an atomizer
75634894|NCT02817477|Drug|Morphine|Delivered either as an IM injection or a slow IV bolus
75634895|NCT00844558|Other|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
75634896|NCT00844558|Other|Control|There is no intervention associated with this arm of the study
75634897|NCT02819115|Biological|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Butantan Fragmented Inactivated Trivalent Influenza Vaccine
75634898|NCT02818959|Device|JenaValve Pericardial TAVR System|The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
75634899|NCT04101175|Procedure|Evaluation of the procedure of abortion|Observational study using questionnaires
75634900|NCT02815839|Drug|SHR4640|
75634901|NCT02815839|Drug|Placebo|
75634902|NCT04099069|Procedure|anesthesia|patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
75634903|NCT00709072|Behavioral|SMS (Short Message Service) reminders|SMS reminders sent every 2 weeks
75634904|NCT04097197|Behavioral|Brief educational intervention|same as before
75634905|NCT00821236|Device|Excimer Laser|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
75634906|NCT00821236|Device|AMO/VISX CustomVue™|Excimer Laser
75634907|NCT00821236|Device|LADARVision 4000 excimer laser|Excimer Laser
75634908|NCT02816151|Drug|full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
75634909|NCT02816151|Drug|half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
75328435|NCT04357015|Drug|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
75328436|NCT04357015|Drug|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
75634910|NCT00756457|Device|Bracing|Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
75634911|NCT00756457|Other|Strengthening exercises|"Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a warm up."
75634912|NCT00756457|Other|Stretching exercises|Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
75634913|NCT02814123|Other|24-hour inpatient intervention|Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
75634914|NCT04101019|Drug|Lidocaine|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.
75634915|NCT04101019|Drug|Saline Solution|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
75634916|NCT02817321|Procedure|single-injection TPVB + continuous TPVB|Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.
75634917|NCT02817321|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning
75634918|NCT02817321|Device|PAJUNK Contiplex S Catheter|
75634919|NCT02817321|Drug|single dose ropivacaine|"2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~given immediately after the correct position of the tip of the needle has been confirmed"
75784484|NCT06159647|Behavioral|Breast cancer|Participants will view messages about the risk of breast cancer from alcohol consumption.
75784485|NCT06159647|Behavioral|Cancer (generic, not site-specific)|Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.
75784486|NCT06159647|Behavioral|Addiction and neurological changes|Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.
75784487|NCT06159647|Behavioral|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
75784488|NCT06159647|Behavioral|Liver damage|Participants will view messages about the risk of liver damage from alcohol consumption.
75328437|NCT03835637|Drug|ORIC-101|Capsule or oral suspension
75328438|NCT04364893|Other|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
75328439|NCT01722773|Device|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
75328440|NCT04356703|Other|Neuropsicomotor developmental test|Children will be evaluated trough Bayley III and PEDI scale. They also will be examined by pediatrician, neurosurgeon, orthopedics and phisiatry
75634920|NCT02817321|Drug|continuously infusion of ropivacaine|"0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~given through the catheter inserted in the T8 paravertebral space following the single dose"
75784489|NCT06159647|Behavioral|Harm to fetus|Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.
75784490|NCT06159647|Behavioral|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
75920821|NCT03531606|Drug|Mechnicov probiotics|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
75920822|NCT03531606|Drug|Placebo|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
75920823|NCT01367457|Other|Temsirolimus (Non-Interventional Study)|There is not any intervention in this study.
75920824|NCT05553652|Dietary Supplement|ASTARTE™ oral capsules|1 Capsule daily for 6 months
75920825|NCT05553652|Dietary Supplement|Placebo oral capsules|1 Capsule daily for 6 months
75920826|NCT05553496|Drug|Rituximab|Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
75920827|NCT05553496|Drug|Dexamethasone|Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
75920828|NCT00239694|Biological|Pneumococcal Vaccine|One time preventative vaccine
75920829|NCT00239694|Biological|Meningococcal Vaccine|One time preventative vaccine
75920830|NCT02129361|Behavioral|Adapted Screening and Brief Intervention (Adapted SBI)|
75328441|NCT03406091|Drug|Plerixafor|Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) [3]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
75634921|NCT02817321|Drug|Morphine given as IPCA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
75634922|NCT00844480|Drug|zoledronic acid|zoledronic acid, 5mg, iv
75634923|NCT00844480|Drug|placebo|iv
75634924|NCT00771901|Drug|tauroursodeoxycholic acid|1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
75634925|NCT00771901|Other|placebo|7 pills daily for 4 weeks
75634926|NCT00771901|Drug|sodium phenylbutyrate|20g/day for four weeks.
75634927|NCT05349682|Diagnostic Test|dynamic contrast enhanced MRI|An MRI study of the knee will be done to check the degree of osteoarthritis and blood flow to the affected knee. This scan will take about 1-2 hour(s).
75784491|NCT06159647|Behavioral|Impaired sleep|Participants will view messages about the risk of impaired sleep from alcohol consumption.
75784492|NCT06159647|Behavioral|Drinking guidelines|Participants will view messages about guidelines for alcohol consumption.
75784493|NCT06159647|Behavioral|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
75920831|NCT02129361|Behavioral|Screening & Education Attention Control|
75920832|NCT02129439|Drug|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation."
75920833|NCT02129439|Drug|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
75920834|NCT05549440|Device|Orsiro Mission|Percutaneous intervention using Orsiro Mission stent
75920835|NCT05549440|Device|Resolute Onyx|Percutaneous intervention using Resolute Onyx stent
75784494|NCT06159647|Behavioral|Road injuries|Participants will view messages about the risk of road injuries from alcohol consumption.
75798567|NCT03435640|Drug|nivolumab|During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
75328442|NCT04364815|Drug|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine and standard preventive measures
75328443|NCT04364815|Drug|Placebo plus standard preventive measures|Placebo tablet plus standard preventive measures as defined by PGH-HICU
75328444|NCT03406013|Behavioral|Written Information|Receive written information on diet and exercise relevant to older men with prostate cancer
75328445|NCT03406013|Behavioral|Prescription|Participants receive tailored exercise prescription and tailored diet recommendations
75328446|NCT03406013|Behavioral|Technology|Participants receive motivational text messages and can electronically log and track their exercise and diet habits
75328447|NCT03406013|Behavioral|Coaching|Participants receive access to an exercise and diet coach to provide advice by phone and/or email
75328448|NCT04673383|Drug|SPL026|Intravenous solution
75328449|NCT04673383|Drug|Placebo|SPL026-matched placebo
75784495|NCT06159088|Dietary Supplement|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
75784496|NCT06159088|Dietary Supplement|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
75784497|NCT06159088|Other|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
75784498|NCT06158659|Dietary Supplement|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
75784499|NCT06158659|Dietary Supplement|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
75784500|NCT06158659|Other|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
75784501|NCT06154421|Procedure|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
75920836|NCT02131467|Drug|Perampanel|oral drug
75920837|NCT05549284|Drug|Orelabrutinib,Rituximab and Methotrexate|Orelabrutinib, Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma. The response will be evaluated every 2 cycles. Patients who achieved complete remission (CR) or partial remission (PR) will receive further treatment, and there are 6 cycles of RMO regimen for the induction. The patients with stable disease (SD) or progressed disease(PD) will withdraw from the trial and receive salvage regimens. After total 6 induction cycles, the investigators evaluate the efficiency again. After 6 cycles, the patients who receive CR or PR, can tolerate Autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be candidates of high-dose chemotherapy and stem rescue. The patients who achieve CR or PR, cannot tolerate AHSCT will go to whole brain radiotherapy or Orelabrutinib maintenance. The patients with SD or PD will receive salvage regimen.
75920838|NCT03531528|Other|Diet|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
75920839|NCT02129517|Other|IMPACT intervention|Tailored, web-based educational short video clips
75920840|NCT02129517|Other|Online education materials|Online NCI-based educational materials
75920841|NCT02129517|Other|survey administration|Ancillary studies
75920842|NCT03065218|Drug|99mTc sestamibi|The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.
75920843|NCT00232752|Device|4.0 CYPHER Sirolimus-Eluting Coronary Stent|4.0 CYPHER Sirolimus-Eluting Coronary Stent
75920844|NCT02125617|Drug|Abiraterone|1000 mg/day
75328450|NCT01728701|Biological|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
75328451|NCT01728701|Biological|Normal Saline (NS)|Normal saline
75328452|NCT03405857|Other|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
75328453|NCT04356625|Diagnostic Test|MEPic|"patient in the supine position sitting 45° to 60°,~closed suction catheter was removed~a 90° elbow was placed and a bacterial filter in series with endotracheal tube~adapter was also coupled to the aneroid pressure gauge~in series an inspiratory unidirectional valve was placed that did not allow expiration~2 ml of physiological solution was slowly instilled through the port in the 90º elbow to cause induced cough"
75328454|NCT04377269|Other|Taping and Bandaging|Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
75328455|NCT04652713|Other|Protein-rich breakfast|"High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.~1 glas of water (150 ml)"
75784502|NCT06154421|Procedure|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
75784503|NCT06152575|Drug|Elranatamab|Elranatamab will be administered subcutaneously
75784504|NCT06152575|Drug|Elotuzumab|Elotuzumab will be administered intravenously
75784505|NCT06152575|Drug|Pomalidomide|Pomalidomide will be administered orally
75784506|NCT06152575|Drug|Dexamethasone|Dexamethasone will be administered orally
75784507|NCT06152575|Drug|Bortezomib|Bortezomib will be administered subcutaneously or intravenously
75784508|NCT06152575|Drug|Carfilzomib|Carfilzomib will be administered intravenously
75784509|NCT06148272|Drug|LY3971297|Administered SC
75784510|NCT06148272|Drug|Placebo|Administered SC
75798568|NCT01175694|Radiation|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
75920845|NCT02125617|Drug|Prednisolone|10 mg/day
75328456|NCT04652713|Other|Carbohydrate-rich breakfast|"Low protein breakfast containing approx. 2 g protein per 100 g. Participants will be asked to consume ~60 g bread, 20 g jam and 250 ml juice for breakfast.~1 glas of water (150 ml)"
75920846|NCT05553262|Behavioral|Behavioral support|Behavioral support as described under 'Arm description'.
75328457|NCT04652713|Other|No breakfast|1 glas of water (150 ml)
75328458|NCT04377191|Other|exergame|Microsoft Xbox 360 Kinect The exercises were advanced from simple to complex. The program started with exercises in a sitting position. In the next stage, the games requiring weight transfer and use of upper limbs in standing position were continued. The program ended with games that require more complex movements such as lunge and mini squats.
75920847|NCT02288598|Device|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
75328459|NCT04377191|Other|exergame|ALDA In the training, games that could be controlled by balance swing, trunk movements and weight transfer in sitting or standing position were used.
75328460|NCT04377191|Other|exercise|Standard Exercise Program The program included warm-up, main exercise and cooling. Warm-up and cooling included neck, trunk, upper-lower extremity range of movement (ROM) exercises and stretching exercises. Main exercise included postural alignment, strengthening for trunk and lower extremity, balance and walking exercises.
75634928|NCT05349682|Procedure|geniculate artery embolization|The physician will perform a diagnostic angiography, where they will take pictures of vessels near the knee that will be treated. Once the artery to be treated is identified, the doctor will guide a thin wire called a microwire, and a plastic tube called a microcatheter to the targeted artery, and more pictures of vessels at the knee will be taken. This picture will be used to see if there are any abnormal vessels at the knee, such as abnormal blood flow, abnormal vessel connections (between the veins and arteries), or new blood vessel growth. Once the targeted artery at the knee is confirmed, the doctor will inject enough particle embolic (Embozene) to slow or stop the blood flow in the geniculate artery. Once all vessels are treated, a final angiogram (pictures of blood vessels) will be performed to ensure that the blood flow has slowed.
75634929|NCT04099147|Other|This is an observational study.|This is an observational study. No intervention is planned outside of usual clinical practice.
75634930|NCT00705562|Other|milk protein formulas, varying carbohydrate/protein sources|ad lib for 0-8 days of age until 28 days of age
75634931|NCT02814201|Behavioral|SRT|"simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )"
75634932|NCT04098991|Drug|Levothyroxine|All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
75634933|NCT00843856|Drug|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
75634934|NCT00843856|Drug|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
75634935|NCT04480125|Drug|Azacitidine|100mg D1-7
75634936|NCT04480125|Drug|Chidamide|30mg BIW PO
75634937|NCT00764491|Device|Structural Allograft Spacer|Following disc space preparation the spacer is placed in accordance with cleared labeling and supplemental instrumentation is provided as an adjunct to fixation.
75634938|NCT00764491|Device|OptiMesh 1500S|Following disc space preparation the OptiMesh is deployed and filled in accordance with study surgical technique and supplemental instrumentation is provided as an adjunct to fixation.
75784512|NCT06138951|Other|Endurance exercise|On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.
75784513|NCT06132724|Other|Signal acquisition|"Synchronized signals from cardiac, respiratory and movements non invasive measurements.~One acquisition is 20 minutes long, and each subject participate to two sessions, separated by 1 to 15 days."
75920848|NCT02288598|Behavioral|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
75920849|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
75920850|NCT02131545|Drug|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
75634939|NCT00705640|Biological|incomplete Freund's adjuvant|Given subcutaneously and intradermally
75634940|NCT00705640|Biological|multi-epitope melanoma peptide vaccine|Given subcutaneously and intradermally
75798569|NCT03860298|Device|NaviFUS System|Using NaviFUS System treatment for 10 minutes in drug resistant epilepsy. The site of the NaviFUS exposure is where the future surgery will be removed. Patients will concomitant use of anti-epileptic drugs (AEDs).
75798570|NCT01175772|Drug|Cytophosphan, Celecoxib, Methotrexate|"Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~Cytophosphan tab 50 mg -1x1 per day, continuous~Celecoxib tab 200 mg - 1x2 per day, continuous~Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly"
75920851|NCT02131545|Drug|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
75328461|NCT01728857|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
75328462|NCT02245243|Drug|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
75634941|NCT00705640|Biological|tetanus toxoid helper peptide|Given subcutaneously and intradermally
75634942|NCT00705640|Procedure|biopsy|Patients undergo surgical biopsy at replicate vaccine site
75634943|NCT02813733|Procedure|Thyroid surgery|Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
75634944|NCT00705796|Drug|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
75634945|NCT00705796|Drug|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
75634946|NCT02811081|Procedure|Passive Deflation|In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
75920852|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
75920853|NCT00229008|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
75920854|NCT00229008|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
75920855|NCT02125695|Procedure|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
75920856|NCT02125695|Procedure|Blood Sampling|Sampling for biomarker and basic research in CLE and AD
75920857|NCT02125695|Procedure|Skin Biopsy|As described in the treatment arm
75920858|NCT03551535|Behavioral|Monitored, At-Home Exercise Intervention|Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
75920859|NCT05549128|Device|Photobiomodulation|The red laser (DMC) will be applied with the aim of reducing the anxiety of children during the dental consultation. It will be continuously and directly with 60J of energy, wavelength of 660nm and 100mW/cm2 of power. The application will be located in the unilateral radial artery for 10 minutes. The laser will be transmitted through an appropriate bracelet where the laser tip fits perfectly. It is a painless, non-invasive method that does not cause any discomfort during application.
75920860|NCT05549128|Device|Photobiomodulation sham|The red laser (DMC) will be applied off. I
75634947|NCT02811081|Procedure|Normal Saline Instillation|In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
75634948|NCT02811081|Procedure|Normal Saline Instillation + Pulmonary Recruitment|In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
75634949|NCT04021693|Other|Handheld Ultrasound Devices|Interns in the handheld ultrasound device arm shall carry a personal handheld ultrasound device to be used for self-directed learning
75634950|NCT02813967|Radiation|Radiotherapy 54 Gy|Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.
75634951|NCT02813967|Radiation|Radiotherapy 60 Gy|Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.
75634952|NCT02813967|Drug|S-1|S-1 70mg/m2 was administered on days 1-14 and 29-42.
75634953|NCT00913432|Drug|masitinib|3 mg/kg/day oral route
75634954|NCT00913432|Drug|masitinib|masitinib 6 mg/kg/day oral route
75634955|NCT02600689|Behavioral|Physical exercise training|
75634956|NCT02600689|Behavioral|Cognitive exercise training|
75634957|NCT02811315|Other|Observational. Non interventional study|Observational. Non interventional study
75634958|NCT00702832|Behavioral|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
75784514|NCT06132659|Other|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with the real neurofeedback. Visit 4 will take place one month after visit 3 and will include a follow-up interview with a trainer assessor as well as questionnaires. Additionally, 2 weeks after visit 3 participants will also complete some questionnaires online.
75920861|NCT03528564|Drug|Iron sucrose|Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)
75920862|NCT03528564|Drug|Epoetin Alfa|Erythropoietin to be administered to half of study participants (40,000 IU x 1-2 subcutaneous injections)
75920863|NCT03528564|Drug|Placebo|Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
75328463|NCT03405701|Procedure|IVM|Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
75634959|NCT00702832|Other|standard treatment|treatment as usual
75634960|NCT02811237|Other|HESTIA|"Management based on the HESTIA rule:~If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
75634961|NCT02811237|Other|sPESI|"Management based on the simplified PESI score:~If the sPESI score =0, the proposed management will be outpatient care.~In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
75634962|NCT04257123|Device|Gelesis100|Participants will administer Gelesis100 before lunch and dinner meals.
75634963|NCT04257123|Other|Placebo|Participants will administer a placebo before lunch and dinner meals.
75651737|NCT05732103|Drug|CTX-712|CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
75798571|NCT01173666|Procedure|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
75328464|NCT03405701|Procedure|IVF|Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
75634964|NCT02810847|Device|I-Bit plus|The study will treat amblyopia (lazy eye) using 3-D computer technology and active shutter glasses. Computer games and DVD's are viewed through the active shutter glasses and are specially prepared to preferentially stimulate the lazy eye; the child can only play the game accurately if they are using their lazy eye.
75634965|NCT00843778|Biological|Certolizumab Pegol|"200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 [NCT00674362], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks."
75634966|NCT04251507|Device|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments.Non pharmacological technique to reduce pain and anxiety during a procedure.
75634967|NCT02813343|Device|BlueStar app|BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
75634968|NCT02815371|Procedure|Needle Acupuncture|See above
75634969|NCT02815371|Procedure|Laser Acupuncture|See above
75634970|NCT02815371|Procedure|Sham Laser Acupuncture|See above
75634971|NCT02810769|Dietary Supplement|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
76078004|NCT05686161|Biological|Pfizer(BNT162b2);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
76078005|NCT03368313|Device|Circaid|Circaid is a velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
75920864|NCT03028792|Behavioral|Attention Modification Program|"Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe."
75920865|NCT03028792|Behavioral|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus."
75920866|NCT00207168|Behavioral|Compliance|
75920867|NCT02131701|Behavioral|Physical activity|
76078006|NCT04279743|Dietary Supplement|omega-3 phospholipids|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
75634972|NCT02810769|Dietary Supplement|Control|Sugar matched control containing berry flavouring and no phytochemicals
75651738|NCT05723432|Drug|KD6001|KD6001 will be administered intravenously.
75798572|NCT01173666|Drug|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
75798573|NCT01536964|Drug|morphine|2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later
75798574|NCT01536964|Drug|saline|2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
75798575|NCT01288404|Drug|Fluorometholone|topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
75634973|NCT02810769|Dietary Supplement|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
76078007|NCT04279743|Dietary Supplement|omega-3 Triglycerides|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
75328465|NCT04364971|Procedure|singleradius and multiradius total knee arthroplasty|singleradius and multiradius total knee arthroplasty
75784515|NCT06132659|Other|fMRI with Sham-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with feedback that looks similar to real neurofeedback, but is computer generated. Visit 4 will take place 2 weeks after visit 3 and participants will complete more questionnaires.
75920868|NCT05724810|Device|Active deep transcranial magnetic stimulation (dTMS)|"First, we find the position of the right abductor pollicis brevis (APB) motor cortex, finding the minimal motor threshold (MT) required for its activation, which determines the strength of the pulses. After determining the MT, dTMS stimulation is applied 6 cm anterior to the motor hot spot, at 120% of the MT. The target threshold is built toward gradually. During the first treatment, participants receive stimulation at 100% of the MT. During the second treatment, stimulation intensity increases to 110% of the MT. Beginning at the third treatment and continuing onward, participants receive treatment at 120% of the MT for the course of the treatment."
75920869|NCT05724810|Device|Sham dTMS|Sham group will go through the same procedure. The only difference is that the sham card does not deliver stimulation.
75920870|NCT03550521|Behavioral|Mindfulness|Participants will be instructed to focus on the sensations of breathing. Subsequently, whenever their minds wander to distressing thoughts or emotions, they will be instructed to acknowledge those thoughts or emotions, and then bring their attention back to the sensations of breathing.
75920871|NCT02926768|Drug|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
75920872|NCT03531372|Device|Mipolixin®|1.55g chewable tablet 5 times a day for 2 weeks
75920873|NCT03531372|Device|Poliprotect®|1.55 g chewable tablet 5 times a day for 2 weeks
75328466|NCT01728935|Drug|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
75328467|NCT03834311|Device|isokinetic strengthening|isokinetic upper extremity (forearm) strengthening for 4 weeks 3d/w
75328468|NCT03834311|Other|exercise band strengthening|upper extremity (forearm) strengthening with exercise band 4 weeks 3d/w
75328469|NCT04356547|Device|Fiberoptic intubation with laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator.
75920874|NCT02129595|Dietary Supplement|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
75328470|NCT04356547|Device|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator.
75328471|NCT03833999|Drug|Ondansetron 8mg|ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
75328472|NCT03833999|Diagnostic Test|abdominal MRI|serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
75328473|NCT03833999|Drug|Lactulose|Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
75634974|NCT02810691|Dietary Supplement|Soluble fiber supplementation|Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.
75634975|NCT02810691|Dietary Supplement|Placebo (for fiber supplementation)|Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
75634976|NCT00910728|Drug|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
75798576|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 1.25 mg/0.05mL
75798577|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 2.5 mg/0.1mL
75798578|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 3.75 mg/0.15mL
75920875|NCT02129595|Dietary Supplement|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
75920876|NCT00207012|Drug|BMS-599626|
76078008|NCT03345615|Diagnostic Test|30-day ambulatory cardiac event monitor|SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
75328474|NCT03833999|Drug|Placebo oral capsule|overcoated placebo tablet, identical to the ondansetron
75328475|NCT04356313|Device|GORE® EXCLUDER® Iliac Branch Endoprosthesis|Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component
75328476|NCT04379219|Drug|Methotrexate|giving methotrexate at least 1 w week before surgery
75634977|NCT04235517|Other|Temporary hemi-epiphysiodesis or epiphysiodesis|Tension band plate (eight-plate, pedi plate), staple or locking plate
75634978|NCT02813499|Other|CARE Rule|Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
75634979|NCT02332200|Other|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
75784516|NCT06131281|Procedure|E-TORe|The E-TORe utilizes ESD in addition to APC prior to endoscopic suturing. In this approach, a standardized solution of normal saline or hetastarch mixed with methylene blue and epinephrine is injected into the gastric rim of the GJA outlet. The mucosa is then carefully incised to expose the underlying muscular layer for a width of approximately 1cm around the GJA circumference. Following ESD, APC is then applied to the inner and outer mucosal margins of the ESD tract. Finally, endoscopic sutures are then placed in purse string fashion and cinched closed around a 6mm TTS balloon.
75784517|NCT06131281|Procedure|c-TORe|The c-TORe will be completed utilizing APC prior to endoscopic suturing. In this approach, the gastric rim of the anastomosis is circumferentially ablated using APC (forced APC, flow of 0.8 L/min and power of 30-70 watts) extending an average of 1-2 cm from the outlet. Following ablation, endoscopic sutures are placed in a purse string fashion within the ablated area and the outlet cinched closed over a 6mm through-the scope (TTS) balloon.
75784518|NCT06125054|Drug|Ketamine|single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)
75784519|NCT06125054|Drug|Placebo|single dose of placebo (0.9% saline solution i.v. over 40 minutes)
75328477|NCT04364659|Behavioral|Food-Specific Inhibitory Control Training (FoodT App)|FoodTrainer (FoodT) is a simple game that aims to train individuals to 'stop' to certain unhealthy foods. Repeatedly playing this game is hypothesised to help build associations between certain foods (such as chocolate) and stopping, putting the brakes on unhelpful eating behaviour.
75784520|NCT06125054|Behavioral|real-time fMRI neurofeedback training|Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated twice.
75784521|NCT06125054|Behavioral|sham real-time fMRI neurofeedback training|Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated twice.
75634980|NCT05631249|Drug|Sotorasib 120Mg Tab|Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
75784522|NCT06120283|Drug|BGB-43395|Planned doses administered orally.
75920877|NCT02648620|Device|SurVeil Drug Coated Balloon|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
75920878|NCT02648620|Procedure|Angioplasty|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
75920879|NCT02131857|Behavioral|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
75920880|NCT05548894|Device|stabilization splint|upper acrylic splint rest on the maxillary teeth and had flat surface
75634981|NCT02810925|Procedure|PENS T6|Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
75634982|NCT02810925|Procedure|TENS T11/T12|Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.
75634983|NCT02810925|Dietary Supplement|Hypocaloric 1200 Kcal/day diet|Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
75634984|NCT02810925|Dietary Supplement|Normocaloric 2000 Kcal/day diet|Patients follow a Normocaloric 2000 Kcal/day diet during 12 weeks.
75634985|NCT04248894|Other|Exercise training of High Intensity|High intensity
75920881|NCT05548894|Device|laser therapy|The laser apparatus had a hand piece on which either a specially designed optic prism was attached to transfer laser energy to the tip of the prism
75920882|NCT05548894|Device|stabilization splint and laser therapy|the stabilization splint used in combination of treatment with laser therapy
75920883|NCT02129673|Drug|VS101 Insert Dose A|Sustained release of latanoprost into the eye
75920884|NCT02129673|Drug|VS101 Insert Dose B|Sustained release of latanoprost into the eye
75920885|NCT02129673|Drug|VS101 Insert Dose C|Sustained release of latanoprost into the eye
75920886|NCT02129673|Drug|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
75920887|NCT05724732|Biological|GT201|Autologous tumor infiltrating lymphocyte injection
75328478|NCT04356079|Diagnostic Test|International Headache Society Test|Thorough History of Patients and families
75469223|NCT00579644|Drug|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
75634986|NCT04248894|Other|Exercise training of Moderate Intensity|Moderate intensity
75634987|NCT04248894|Other|Untraining|Sedentary
75634988|NCT02813187|Biological|cellular and tissue based therapy|
75920888|NCT02125773|Behavioral|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
75920889|NCT05552872|Diagnostic Test|mNGS, IDSeq UltraTM|pathogen detection
75634989|NCT02813187|Procedure|debridement|
75634990|NCT02813187|Procedure|advanced wound therapy|
75634991|NCT02813187|Dietary Supplement|Nutritional screening|
75634992|NCT04419207|Diagnostic Test|Breath test|Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).
75634993|NCT02815527|Other|Fresubin intensive|Enteral nutrition containing a high protein concentration
75634994|NCT02810379|Procedure|written informed consent|
75634995|NCT02810379|Procedure|video+written informed consent|
75784523|NCT06120283|Drug|Fulvestrant|Standard dose administered via intramuscular injection.
75328479|NCT03658096|Device|pressure monitor ultrasound system|Patients and healthy volunteers will be tested sitting with the elbow flexed and the forearm pronated. The forearm of the examinee will be secured to the table. The hand will be positioned on an adjustable block such that the forearm will be in a horizontal position. At the distal radioulnar joint level, the transducer will be maintained perpendicular to the longitudinal axis of the ulna. The dorsal surface of the distal radius and the center of the ulnar head will be displayed on a monitor.To determine the same measurement level in each volunteer, the highest aspect of the ulnar head will be taken. The DRUJ motion during cyclic loading toward the palmar direction at the distal ulna will be recorded. The compression-release cycles will be applied with the pressure-monitor ultrasound system. The cycle will be set to 1.5Hz. The pressure in the palmar direction will be applied with different levels of transducer displacements, i.e. 1 mm, 2 mm, and 3 mm.
75634996|NCT05629923|Drug|tixagevimab-cilgavimab(AZD7442, AstraZeneca)|In the case of antibody level <100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).
75634997|NCT02810535|Other|Observation|"Visit 1:~Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~Completion of a Health Questionnaire~Lung function testing with spirometry~Skin prick test~Visit 2:~Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~Measurement of nitric oxide in expired air (FeNO)~Taking nasal secretion samples with a cotton carrier for 15 min~Nasal provocation test with dust mite~Blood sample collection to define blood count, IgE and specific IgE"
75784524|NCT06120283|Drug|Letrozole|Standard dose administered orally as a tablet.
75784525|NCT06118086|Drug|REM-422|"REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~REM-422 will be administered orally once daily"
75634998|NCT02810223|Biological|CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
75634999|NCT02810301|Other|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
75635000|NCT02810301|Other|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
75635001|NCT00820222|Drug|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
75635002|NCT00820222|Drug|lapatinib|oral medication; daily dose taken once a day
75635003|NCT00820222|Drug|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
75635004|NCT04181151|Other|Electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
75635005|NCT02810067|Procedure|Tunnel + AlloDerm|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm).
75635006|NCT02810067|Procedure|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
75784526|NCT06109909|Device|Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation|The EEG interface device is a J&J Engineering 1-330 C2 box. The software used to determine LIP-tES feedback patterns was developed by Neurogen High Performance Neurofeedback. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+,A-,B+,B-), with respect to the Common Neck Reference. During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scale to record EEG signals. All four (A+,A-,B+,B-) electrodes are involved in applying weak electrical pulses back to the brain (feedback process). The brief feedback pulse (~100mV) is adaptive and determined based on the offset of the frequency spectrum recorded across the left and right hemisphere (A vs. B) electrodes in the time window immediately prior to stimulation.
75920890|NCT02125851|Other|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
75920891|NCT02125851|Other|Honey|esophageal mucosal contact time of honey vs sucralose slurry
75920892|NCT02260557|Drug|Selexipag|Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily
75920893|NCT02260557|Drug|Placebo|Placebo matching selexipag 200 μg tablets to be administered orally twice daily
75920894|NCT04469166|Procedure|tourniquet|Use of tourniquet
75920895|NCT04469166|Procedure|No tourniquet|No use of tourniquet
75920896|NCT02553616|Behavioral|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
75920897|NCT02125929|Procedure|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
75920898|NCT02125929|Procedure|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
75920899|NCT02125929|Procedure|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
75920900|NCT04468854|Dietary Supplement|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
75920901|NCT04468854|Other|Placebo|mannitol formulated for oral administration (capsules)
75920902|NCT02129829|Drug|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
75635007|NCT02815449|Other|Meals prepared with iron fortified cube with Low stabilizer level|Meals prepared with iron fortified cube with Low stabilizer level
75635008|NCT02815449|Other|Meals prepared with iron fortified cube with Medium stabilizer level|Meals prepared with iron fortified cube with Medium stabilizer level
75784527|NCT06108141|Behavioral|Resident Education And Counseling on Household Firearm Safety|An intervention that includes a self-directed online curriculum and virtual reality simulations, designed to teach firearm screening and counseling among clinicians.
75635009|NCT02815449|Other|Meals prepared with iron fortified cube with High stabilizer level|Meals prepared with iron fortified cube with High stabilizer level
75635010|NCT02815215|Procedure|Minimally Invasive Carroll's Technique|Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
75635011|NCT02815215|Procedure|Ponseti method|As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
75920903|NCT02288754|Diagnostic Test|Blood test|No intervention except to collect blood for diagnostic test development
75635012|NCT02814825|Other|ViviGen|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
75635013|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
75920904|NCT04468698|Other|Peritoneum insufflation|Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.
75920905|NCT02129985|Drug|Exenatide|Exenatide (10 ug/bid for 3 months)
75920906|NCT02129985|Drug|Metformin|Metformin 850 mg/bid for 3 months
75920907|NCT01730638|Drug|• TF2 and 68 Ga-IMP-288|
75920908|NCT05724576|Biological|OmniMSC-AMI|10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10^7 OmniMSC-AMI, n=5).
75920909|NCT02126007|Behavioral|Sleep and Rhythm Intervention|
75920910|NCT02126007|Behavioral|Dietary Modifications|
75920911|NCT05700136|Behavioral|MOMENT|Prenatal and postnatal factors including maternal, environment, and infant circadian rhythm were studied to determine its effect on infant growth and temperament.
75920912|NCT00162942|Device|Adacolumn|"Ten apheresis sessions:~One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9)."
75920913|NCT00162942|Device|Sham|Sham, ten apheresis sessions within 9 weeks
75920914|NCT02132013|Behavioral|Intervention SUBLIME|Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
75635014|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
75635015|NCT01039688|Drug|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
75635016|NCT02815137|Other|Digital Polymerase Chain Reaction|Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
75635017|NCT02237508|Drug|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
75651739|NCT05723432|Drug|Toripalimab|Toripalimab will be administered intravenously.
75784528|NCT06108141|Behavioral|Modified American Academy of Pediatrics Safer|An intervention that includes a self-directed online curriculum.
75784529|NCT06108076|Drug|Ketone Monoester (KE)|Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits
75920915|NCT05548504|Radiation|Photon|50-66Gy/ 24 fractions, inhomogeneous dose distribution photon therapy
75920916|NCT05548504|Radiation|Proton|50-66Gy/ 24 fractions, inhomogeneous dose distribution proton therapy
75920917|NCT02252523|Drug|Dexmedetomidine|
75920918|NCT05552170|Other|day-case surgery|Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
75920919|NCT02132091|Other|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
75920920|NCT02132091|Dietary Supplement|400 IU Vitamin E|once each day in morning; oral pill form
75920921|NCT02132091|Dietary Supplement|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
75920922|NCT05552014|Behavioral|Natural Psychotherapy|"Natural psychotherapy is based on Morita therapy and is a psychotherapy that fully reflects the characteristics of Chinese culture, taking into account the Chinese cultural background and actual clinical characteristics."
75920923|NCT05552014|Behavioral|Mental Health Education|Mental Health Education Seminar
75920924|NCT02130141|Dietary Supplement|Dark chocolate|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
75920925|NCT02130141|Other|Dietary counselling|Usual snacks are limited.
75920926|NCT05548348|Drug|Furmonertinib 160 mg, Q.D.|Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.
75920927|NCT03550365|Other|Rye bran bread intervention|4 week dietary intervention rich in rye bran bread
75920928|NCT03550365|Other|Rye bread intervention|4 week dietary intervention rich in rye bread
75920929|NCT03550365|Other|Wheat bread diet|4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
75920930|NCT02130219|Device|Non-invasive intracranial pressure measurement|The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
75920931|NCT02130219|Device|Brain MRI/CT|"1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume."
75920932|NCT02130219|Procedure|Lumbar puncture and cerebrospinal fluid pressure measurement|Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
75920933|NCT02130375|Procedure|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
75920934|NCT02126085|Procedure|Endovascular recanalisation|"Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept"
75469224|NCT00116272|Drug|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
75469225|NCT00080886|Biological|rituximab|
75635018|NCT02237508|Drug|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).
75635019|NCT02237508|Drug|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
75635020|NCT02237508|Drug|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
75635021|NCT04175847|Drug|RC88|"Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration"
75635022|NCT02813031|Other|Functional meat products|
75635023|NCT02813031|Other|Traditional meat products|
75635024|NCT02812875|Drug|CA-170|"Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer."
75784530|NCT06106984|Device|Graded motor imagery mobile app|The Graded Motor Imagery mobile app is a mobile app designed for intervention in phantom limb pain.
75784531|NCT06105151|Drug|VV119(SAD)|VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 4 mg Group:6 subjects will receive VV119 4 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;
75635025|NCT00909090|Dietary Supplement|12 mg Lutein + Zeaxanthin|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year
75635026|NCT00909090|Dietary Supplement|Visually identical placebo|Visually identical placebo, taken once daily for one year
75784532|NCT06105151|Drug|VV119 Placebo(SAD)|VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 4 mg Group:2 subjects will receive VV119 Placebo 4 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;
75798579|NCT01285206|Device|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
75469226|NCT00080886|Drug|carmustine|
75469227|NCT00080886|Drug|cytarabine|
75469228|NCT00080886|Drug|etoposide|
75469229|NCT00080886|Drug|melphalan|
75469230|NCT00080886|Procedure|autologous bone marrow transplantation|
75469231|NCT00080886|Procedure|peripheral blood stem cell transplantation|
75635027|NCT04243746|Behavioral|Time Restricted Feeding|Subjects practise TRF (2-3 meals) as an adjunct to the QQH healthy plate diet. Subjects of the intervention group can eat during the pre-determined 8-12 hours eating window, but they are only allowed to drink water and calorie-free drinks for the remaining 12-16 hours. Subjects are allowed to decide the time of their first and the last meal of the day as long as they eat within the 8-12 hour window period. However, skipping breakfast and having late dinner are discouraged.
75920935|NCT03528330|Device|Rehabilitation with dental implant with internal hexagon connection|"All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
75920936|NCT03528330|Device|Rehabilitation with dental implant with conical connection|"All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
75784533|NCT06105151|Drug|VV119(FE)|A：4 mg VV119, following an overnight fast of at least 10 hours for Period 1; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 2; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 3; B: 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1; 4 mg VV119, following an overnight fast of at least 10 hours for Period 2; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 3; C: 4mg VV119, administered 30 minutes after the start of a standard meal for Period 1; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2;4 mg VV119, following an overnight fast of at least 10 hours for Period 3.
75920937|NCT03550053|Device|3D mandibular plate|Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.
75920938|NCT02126163|Behavioral|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
75920939|NCT04440852|Behavioral|TEACCH|The Treatment and Education of Autistic and Communication Handicapped Children
75920940|NCT02126241|Other|NICaS guided CRT optimization|"Baseline CO measurement by NICaS~AV delay optimization:~AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~The AV delay yielding the maximal CO, will be considered the optimal AV delay~The device will be programmed using the optimal AV delay~VV delay optimization:~After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~The VV delay yielding the maximal CO, will be considered the optimal VV delay~The device will be programmed using the optimal VV delay"
75920941|NCT04469010|Dietary Supplement|Iron Bis-Glycinate Chelate and Vitamin C|28 mg iron 240 mg vitamin C
75920942|NCT04469010|Dietary Supplement|Iron Bis-Glycinate Chelate|28 mg iron
75920943|NCT04469010|Dietary Supplement|Placebo|Matched placebo
75920944|NCT02130531|Drug|Emixustat HCl Tablet|Tablet for oral administration
75920945|NCT02130531|Other|Placebo Tablet|Tablet for oral administration
75920946|NCT01121224|Device|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
75920947|NCT01121224|Device|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
75920948|NCT01121224|Drug|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
76078009|NCT05685849|Device|Echocardiography|Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
75784534|NCT06101329|Drug|Lenacapavir Tablet|Tablets administered orally without regard of food
75784535|NCT06101329|Drug|Lenacapavir Injection|Injection administered subcutaneously
75784536|NCT06101329|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)|200/300mg fixed dose combination (FDC) tablets administered orally
75784537|NCT06101238|Dietary Supplement|supplementation with low dose elemental iron|65mg daily
75328480|NCT04347031|Drug|Mefloquine|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
75635028|NCT04243746|Behavioral|Standard Care|Subjects practice the QQH healthy plate diet as per guidelines set by the Health Ministry the guidelines.QQH refers to a normal food plate (23cm in diameter), divided into a quarter of rice (carbohydrates), a quarter of meat (protein) and a half plate of vegetables and fruits. Additionally, no calories specification is required and snacks are discouraged.
75635029|NCT04220034|Biological|Blood sample|Blood sample will be collected to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time
75920949|NCT01121224|Drug|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
75920950|NCT01121224|Drug|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
75920951|NCT00138762|Drug|torcetrapib/atorvastatin|
75920952|NCT00138762|Drug|atorvastatin|
75920953|NCT00138762|Drug|placebo|
75920954|NCT02130609|Device|Skintel|
75920955|NCT02252601|Other|HFDT test|
75920956|NCT02252601|Other|Pure tone Audiogram|
75920957|NCT02132325|Behavioral|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
75920958|NCT02130843|Device|INSERTION OF URETEHRL CATHETER|USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
76078010|NCT05471349|Behavioral|Flyer and video|Participants will view a flyer and video
75469232|NCT01936571|Other|Blood samples|Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
75469233|NCT01936584|Procedure|TAPP repair for inguinal hernias|
75469234|NCT01936584|Procedure|TEP repair for inguinal hernia|
75469235|NCT01936584|Other|EuraHS-QoL questionnaire|questionnaire administration
75635030|NCT03955302|Behavioral|Exercise|There will be an intervention for 12 weeks. For exercises in the water, there will be an expert physiotherapist in the field of hydrotherapy that will guide the exercises in controlled sessions of approximately 45 minutes. Exercises of joint mobility, balance, strength and coordination with / without aquatic material will be included. At all times, qualified health personnel will monitor any symptom or sign that advises the removal of the subject of the study.
75635031|NCT02809755|Drug|4% Lidocaine|
75635032|NCT02809755|Other|Saline|
75635033|NCT02812719|Drug|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
75635034|NCT02812719|Drug|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
75784538|NCT06101043|Procedure|Pectoral nerve block|An ultrasound probe was placed obliquely over the second and third ribs below the lateral one-third of the clavicle. After identification of the anatomical structures, the needle was advanced along a superior-medial-to-inferior-lateral passage to the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL ropivacaine (0.375% w/v) was injected at the level of the third rib. The anesthetic spread around the axilla, and the needle was withdrawn to the point in the plane between the pectoralis major and minor muscles. A second injection of 20 mL ropivacaine (0.375% w/v) was then delivered (PECS II).
75784539|NCT06090669|Drug|imatinib|Imatinib at 100-400 mg PO QD based on arm assignment/dose level
75784540|NCT06090669|Device|TruSight Oncology|Assay sequencing platform to identify pathogenic genetic mutations in DNA and RNA
75920959|NCT02126397|Procedure|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
75469236|NCT01936584|Other|Carolina Comfort Scale|questionnaire administration
75469237|NCT01936597|Other|Therapeutic and preventive strategies|Single set (control Arm)
75469238|NCT01936597|Other|Therapeutic and preventive strategies|Controller
75920960|NCT02126397|Procedure|polyps resection with bipolar electrode|
75920961|NCT03531294|Drug|Aflibercept Injection|intravitreal 2mg aflibercept injection
75920962|NCT05551702|Behavioral|CBT-txt|Cognitive Behavioral Therapy delivered via automated text messaging.
75920963|NCT03549975|Drug|Botulinum Toxin Type A 100 unit/Vial (Product)|Botulinum toxin type A injection followed by functional electrical stimulation
75920964|NCT05482152|Behavioral|Nurse-led care by a nurse specialist in pain|A nurse pain specialist consultation in patients in the experimental arm before they receive standard care by a physician.
75920965|NCT05551624|Drug|Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet|Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
75920966|NCT00134238|Drug|torcetrapib/atorvastatin|
75920967|NCT00134238|Drug|atorvastatin|
75920968|NCT02786901|Drug|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
75920969|NCT02786901|Drug|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
75920970|NCT02786901|Drug|Vehicle Gel|Gel
75920971|NCT02130921|Behavioral|Intervention to Address Drug Use and HIV in Vietnam|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
76078011|NCT03345537|Other|Non interventional study|Non interventional study - only data collected and one blood sample additional
76078012|NCT03344913|Behavioral|Walking|walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
76078013|NCT03321981|Drug|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
76078014|NCT03321981|Drug|Trastuzumab|humanised IgG1 monoclonal antibody
76078015|NCT03321981|Drug|Vinorelbine|antineoplastic drug of vinca alkaloid family
75635035|NCT04236765|Other|TB infection-screening benefiting group|The children who participate in the study will be recruited during a programmed visit to a traveler health clinic or a primary care center. During the first visit the parents or legal guardian will be interviewed, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit. A new interview will be carried out with the parents or legal guardian and a questionnaire will be completed with epidemiological and clinical data. The child will undergo a new TST and QFT-Plus test.
75635036|NCT02876978|Genetic|CAR-GPC3 T Cells|Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
75635037|NCT02876978|Drug|Fludarabine|30 mg/m^2/day x 4 days
75635038|NCT02876978|Drug|Cyclophosphamide|500 mg/m^2/day x 2 days
75328481|NCT04347031|Drug|Hydroxychloroquine|"st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
75635040|NCT04782596|Procedure|Posterium nasal septum resection|Posterium nasal septum resection is required to ensure approach during transnasal endoscopic pituitary surgery in patients with pituitary adenoma.
75635041|NCT00909480|Drug|insulin detemir|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
75635042|NCT00909480|Drug|insulin glargine|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
76078016|NCT03321981|Drug|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
75635043|NCT05642715|Behavioral|EX+|All participants, regardless of study arm, will be offered: BecomeAnEX, an online tobacco treatment with support community PLUS Positively Smoke Free on the Web (an intervention targeting people with HIV who smoke) integrated into the BecomeAnEX site.
75635044|NCT05642715|Drug|Varenicline|All participants, regardless of study arm, will be offered: A 12-week course of varenicline dosed according to product label.
75635045|NCT05642715|Behavioral|HR|Participants allocated to the EX+/HR arm will be offered: 30-minute video urging smokers who cannot or will not quit to cut down on cigarettes, and also to control their risk for lung cancer and cardio or cerebrovascular disease by undergoing low-dose CT screening for lung cancer (for those meeting prespecified criteria), and referral to Cardiometabolic Clinic (for those meeting prespecified criteria).
75635046|NCT05642715|Behavioral|TAU|Participants allocated to the EX+/TAU arm will be offered: Medical treatment as usual from their regular providers after completing Stage 1 of the study
75635047|NCT02874170|Other|Spectroscopy magnetic resonance of phosphorus 31|
75635048|NCT04368039|Device|Normobaric Oxygen|40% FiO2 for 4 weeks
75635049|NCT04368039|Device|Placebo|21% FiO2 for 4 weeks
75635050|NCT02874326|Drug|Octreotide LAR|
75784541|NCT06083987|Behavioral|Intersectionality and Identity|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of intersectionality and identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
75469239|NCT01936597|Other|Therapeutic and preventive strategies|Audio
75469240|NCT01936610|Other|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
75784542|NCT06083987|Behavioral|Confidentiality|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on Confidentiality for caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
75798580|NCT01307878|Drug|chemotherapy ± targeted therapy|Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
75798581|NCT03860220|Drug|NEWSTATIN TS|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
76078017|NCT05685693|Procedure|Robotic-assisted total knee arthroplasty (raTKA)|Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.
75328482|NCT04347031|Combination Product|Mefloquine + azithromycin + / - tocilizumab|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
75469241|NCT01936610|Other|lecture|Describe advantages and disadvantages in one 90-min session
75920972|NCT03550677|Procedure|general anesthesia|The patient will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10-20 mg rocuronium and proper size Laryngeal mask airway will be placed securely the airway.
75328483|NCT04347031|Combination Product|Hydroxychloroquine + azithromycin + / - tocilizumab|"st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
75784543|NCT06083987|Behavioral|Educating Your Community|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of the education of family and friends about identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
75920973|NCT03550677|Procedure|ankle block|ankle nerve block will be performed in group ankle block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5% bupivacaine and same amount placebo (saline) in groups placebo under the guidance of peripheral nerve stimulator the anesthesia will be discontinued and LMA will be removed. The patients will be transferred from postoperative care unit to the ward after they are eligible for discharge according to modified Aldrete scoring system.
75469242|NCT01936636|Drug|Fentanyl|
75635051|NCT00627302|Drug|PEG-400|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
75635052|NCT00627302|Drug|Systane|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
75635053|NCT02812641|Drug|BPF-CCRT (run-in)|Six patients will be enrolled in run-in phase. If <= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If > 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
75635054|NCT02812641|Drug|BPF-CCRT (randomized)|Twenty-two patients will be planned to assign to the experimental arm
76078018|NCT05685693|Procedure|conventional total knee arthroplasty|total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
75635055|NCT02812641|Drug|PF-CCRT (randomized)|Twenty-two patients will be planned to assign to the active control arm
75635056|NCT02812563|Other|genetic|Galilee exam - Corn analysis with Optiwave Refractive Analysis
75635057|NCT02809365|Device|FreeStyle Libre|Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections
75635058|NCT02809365|Device|personal glucometer|Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
75635059|NCT01058096|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
75798582|NCT03860220|Drug|CADUET|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
75798583|NCT01568476|Procedure|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
75798584|NCT01568476|Procedure|Interneural|Sciatic nerve blockade at the site of bifurcation
75798585|NCT01173744|Device|Gamma-3 Nail|Gamma-3 Nail (stryker)
75920974|NCT02132403|Drug|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
75920975|NCT02132403|Drug|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
75920976|NCT02132403|Drug|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
75920977|NCT05700058|Other|Dietary protein supplement|3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants
75328484|NCT02906566|Drug|Retinol|Retinol in the form of vitamin A lotion
75328485|NCT02906566|Drug|Placebo|Placebo of Retinol
75328486|NCT00913133|Drug|Desirudin|Desirudin SC 15mg q12h
75328487|NCT00373126|Drug|transdermal nicotine patch|
75469243|NCT01936675|Other|Genetic Risk Score|Patients in this arm will receive their genetic-informed risk for having a heart attack.
75635060|NCT01058096|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
75635061|NCT05581134|Device|Virtual Reality intervention|Virtual reality (VR) is a powerful tool to create an illusory state in which the user can feel that they have been transported to a new location (place illusion), that events happening are real (plausibility illusion), and even that bodies have been substituted by an avatar (embodiment illusion). VR illusions are driven by the same neurological mechanisms of everyday perception of the body in the world and induce realistic responses to VR.
75635062|NCT05581134|Behavioral|Control Group intervention|Treatment will follow general treatment principles in physiotherapy for FMDs: (1) education; (2) exploration of how symptoms affect movement and posture; (3) retraining movement using strategies based on redirection of attention; and (4) development of a self-management plan.
75635063|NCT02809287|Procedure|Jackknife posture|patients with left lateral position plus jackknife position when perform laparoscopic hepatectomy
75651740|NCT05723328|Behavioral|Group Music Therapy Advocacy Recording Intervention (MTAR)|Music Therapy Advocacy Recording Intervention (MTAR) is a sequence of group music therapy song-writing and recording sessions framed as a mental health awareness project to be shared with the general public.
75651741|NCT05722964|Drug|SHR-1906|Intravenous injection
75651742|NCT05722964|Drug|SHR-1906|Intravenous injection
75651743|NCT05722964|Drug|Placebo|Placebo，Intravenous injection
75651744|NCT05716165|Device|proprioceptive knee braces|The patient will perform the tests with the knee braces.
75798586|NCT01173744|Device|DHS|DHS (Zimmer)
75920978|NCT04264806|Drug|Azacitidine|Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m^2.
75328488|NCT04356235|Procedure|A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
75635064|NCT04219839|Behavioral|SOC + Educational Videos Designed Especially for post-transplant patients|Patient focused videos (3-5 minutes each) with topics that will include: What to Expect After Transplant, What is the Kidney, Understanding your Labs, Transplant Medications, General Medical Care Post-Transplant, When to Call your Coordinator, and Self-Management/Sick Day protocols. Video curriculum will be offered in two ways. First, tablet computers with active links to each video will be available in kidney transplant clinic. At provider/coordinator discretion, study participants may also view videos while waiting for other appointments. In addition, for patients with smartphones who consent to this, a desktop link will be provided to the transplant video curriculum webpage (mobile friendly view).
75635065|NCT02814747|Other|quantitive study: 500 patients likely to be candidates for HTS|
75635066|NCT02814747|Other|qualitative study: 30 patients who have benefited from HTS|
75635067|NCT02812017|Behavioral|Thirty Million Words- Well Baby|Through evidence-based strategies, the TMW-WB curriculum teaches parents how to harness the power of their words to build their child's brain and impact their child's learning trajectory.
75635068|NCT02812017|Other|Safety Starts at Home|A portion of the Safety Stars at Home set is shown. Demonstrating proven childproofing techniques and accident-prevention strategies, which unifies safety guidelines and shows caregivers how to take proactive measures at home. Many no- or low-cost safety alternatives are offered.
75635069|NCT01057862|Drug|Naltrexone|Targeted dosage of 50mg PO daily
75635070|NCT01057862|Other|Placebo|Sugar pills daily PO
75635071|NCT02812251|Drug|JNJ-61393215|JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
75635072|NCT02812251|Drug|Placebo|Matching placebo will be administered.
75635073|NCT01038128|Drug|Memantine|Drug: Memantine, 10-40 mg daily
75635074|NCT02812329|Behavioral|HIV prevention videogame|Assess acceptability and efficacy of a HIV prevention videogame
75635075|NCT04303520|Biological|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
75635076|NCT04303520|Drug|Fludarabine|30mg/m2/d
75635077|NCT04303520|Drug|Cyclophosphamide|500mg/m2/d
75798587|NCT01285284|Other|Music|A previously defined list of songs will be administered by headphones to these patients.
75920979|NCT04264806|Drug|Cusatuzumab|Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
76078019|NCT01027468|Drug|Bevacizumab|intraocular bevacizumab injection
75635078|NCT02812095|Procedure|Refeeding|when amount of feeding reach to 120mL/kg a day,
75635079|NCT02812407|Device|Mucosal Impedance|"During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~And at 20 cm"
75635080|NCT02809599|Behavioral|DIZZTINCT|The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
75635081|NCT02562378|Drug|Trastuzumab and non-pegylated liposomal doxorubicin|"3 Cohorts (3+3 design):~Cohort 1- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2) IV~Cohort 2- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (50 mg/m2) IV~Cohort 3- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (60 mg/m2) IV"
75635082|NCT04141137|Device|TricValve® System|The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
75635083|NCT00842530|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
75635084|NCT00842530|Biological|Inactivated rabies virus vaccine|0.5 mL, Subcutaneous
75920980|NCT02132481|Other|EMA Only|The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
75328489|NCT04356235|Procedure|B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
75635085|NCT00842530|Biological|Placebo|Sodium chloride 0.9%
75798588|NCT01285284|Other|No music|No music will be administered by the headphones connected to the MP3 device.
75798589|NCT03862872|Dietary Supplement|Anti-Aging Formula|Anti-Aging Formula contains 1050 mg of EPA and 350 mg of DHA from anchovies, sardines, and/or mackerel whole body oil, 120 mg of GLA from Borage (Borago officianalis) seeds, 2.5 mg of zeaxanthin from Capsicum annuum L. fruit, 5 mg of lutein from Tagetes erecta flower, and 25 μg (1000 IU) of vitamin D3 (cholecalciferol) from lanolin per 4 capsule daily dose. This dosage form is the same as is commercially marketed in Canada under license Natural Product Number (NPN) 80077254.
75328490|NCT04356235|Procedure|C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
75920981|NCT02132481|Other|EMI Only|The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
75920982|NCT02132481|Other|EMA+EMI|"The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current risk of use in the next 7 days ."
75328491|NCT04356235|Procedure|D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
75328492|NCT04356235|Procedure|E: unilateral simple mastectomy|unilateral simple mastectomy
75328493|NCT04356235|Procedure|F: after bilateral SSM, ASM, NSM, expander-implant exchange|after bilateral SSM, ASM, NSM, expander-implant exchange
75328494|NCT02787694|Other|Factor Targeted Walking Training|Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches
75328495|NCT02787694|Device|treadmill|
75328496|NCT04378283|Drug|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%)|The study is designed to evaluate topical anesthetics
76078020|NCT01027780|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
76078021|NCT05102799|Other|No intervention|No intervention
75635086|NCT04190238|Other|Super inductive system (high frequency electromagnetic field)|Super inductive system (high frequency electromagnetic field)
75635087|NCT04190238|Other|Physical therapy|specific for spasticity
75635088|NCT04236921|Drug|DopaSnap®|immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
75635089|NCT04236921|Drug|RDL of CD-LD|(immediate release CD/LD 25/100mg; Merck Sharp & Dohme Corp., USA),
75635090|NCT05580510|Drug|Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator."
75635091|NCT05580510|Drug|Empagliflozin 10 MG OD|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug."
75784544|NCT06083987|Behavioral|How to find Affirming Caregivers|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of finding affirming caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
75784545|NCT06083987|Behavioral|Control Group - No Interventions|Control Group - Will be given no interventions
75784546|NCT06079879|Drug|Bomedemstat|Oral Capsule
76078022|NCT05395156|Device|Transcutaneous electrical nerve stimulation (TENS)|Control group will receive TEAS on sham acupoint daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles Study group will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles
76078023|NCT03320343|Other|MRI|3D morphological MRI and diffusion tensor imaging
76078024|NCT05395000|Behavioral|Videos|A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.
75328497|NCT04378283|Drug|EMLA plus infiltration as anesthetic for wound repair.|EMLA plus infiltration as anesthetic for wound repair.
75328498|NCT04356157|Behavioral|Behavioural change interventions|"The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive."
75328499|NCT04355845|Drug|Sumatriptan|25 milligrams (mg) single dose tablet
75328500|NCT04355845|Drug|PF-06651600|PF-06651600 400 mg single dose
75635092|NCT02811627|Drug|Memantine|Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
75784547|NCT06079879|Drug|Anagrelide|Oral Capsule
75784548|NCT06079879|Drug|Busulfan|Oral Capsule
75784549|NCT06079879|Drug|Interferon alfa/pegylated interferon alfa|Oral Capsule
75784550|NCT06079879|Drug|Ruxolitinib|Oral Capsule
75784551|NCT06078436|Device|Pulmonary artery catheter|Pulmonary artery catheter monitoring or not
75784552|NCT06076135|Radiation|Intestinal Low Dose Radiotherapy-1Gy|ILDR will be administered as single fractions every 3 weeks (Q3W). The total dose of radiotherapy was 1 Gy in 1 fractions. The radiation treatment volume included the jejunum and ileum.
75635093|NCT02811627|Device|Magnetic Resonance Imaging|The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
76078025|NCT05395000|Behavioral|Simulation|An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.
76078026|NCT05395000|Behavioral|Interview|At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.
76078027|NCT04278807|Procedure|Regional Anesthesia - Nerve Blocks|Regional Anesthesia and ultrasound-guided nerve blocks
76078028|NCT00980278|Procedure|Sinus lift augmentation and dental implant|transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
75328501|NCT02789410|Drug|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
75328502|NCT02789410|Drug|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
75328503|NCT01723241|Drug|XAF5, concentration A|
75328504|NCT01723241|Drug|XAF5, concentration B|
75328505|NCT01723241|Drug|XAF5, concentration C|
75328506|NCT01723241|Drug|Placebo|
75784553|NCT06076135|Radiation|Intestinal Low Dose Radiotherapy-2Gy|ILDR will be administered as single fractions every 3 weeks (Q3W). The total dose of radiotherapy was 2 Gy in 2 fractions. The radiation treatment volume included the jejunum and ileum.
75784554|NCT06076135|Radiation|Intestinal Low Dose Radiotherapy-3Gy|ILDR will be administered as single fractions every 3 weeks (Q3W). The total dose of radiotherapy was 3 Gy in 3 fractions. The radiation treatment volume included the jejunum and ileum.
75784555|NCT06076135|Drug|PD-1 Inhibitors|The immunotherapy regimen is determined by the physician in charge. PD-1 inhibitors were given on the day after each ILDR, with a treatment frequency of once every 3 weeks（Q3W） until progression.
75328507|NCT04356001|Procedure|Socket preservation|'One-Piece' autologous tuberosity graft combining hard and soft tissue, harvested from the maxillary tuberosity, placed in extraction sockets.
75328508|NCT01729325|Behavioral|Preventive Narrative Exposure Therapy|During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
75328509|NCT01729481|Drug|Gemcitabine|1000 mg/m² iv weekly
75328510|NCT01729481|Drug|Erlotinib|100mg, once per day
75328511|NCT01729481|Drug|Oxaliplatin|85mg/m², q2weeks
75635094|NCT00634413|Drug|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
75635095|NCT00634413|Drug|Placebo|Inhaled matching placebo administered twice daily for 28 days
76078029|NCT00980278|Biological|Aastrom BRCs|sinus augmentation, BRC application, dental implant
76078030|NCT03344211|Drug|Enzalutamide|Given PO
76078031|NCT03344211|Other|Laboratory Biomarker Analysis|Correlative studies
75328512|NCT01729481|Drug|Folinic Acid|400 mg/m², q2weeks
75328513|NCT01729481|Drug|Irinotecan|180 mg/m², q2weeks
75328514|NCT01729481|Drug|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
75328515|NCT03405077|Behavioral|IPT Online Training|"First, college mental health clinicians will complete baseline online questionnaires and deliver their usual treatment to 1 or 2 clients with symptoms of eating disorders. Then, they will complete the guided online training program and post-training assessments. Next, they will treat 1 or 2 different clients with eating disorders and complete post-training assessments. As part of the baseline and post-training assessments, clinicians will complete a telephone-based simulation assessment with staff raters, in which the investigators will recreate a client session and rate how well the clinicians adhere to IPT in treating the simulated client. The guided on-line training program will ultimately be compared to the gold standard training."
75328516|NCT00939211|Drug|AZD9164|Solution for inhalation through nebulization, single dose
75635096|NCT00634413|Drug|Budesonide|Inhaled budesonide twice daily for 28 days
75651745|NCT05716165|Device|No knee brace|The patient will perform the tests without the knee brace.
75784556|NCT06075589|Behavioral|Education for Intervention|Participants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.
75784557|NCT06075589|Behavioral|Best Practice|Patients receive enhanced treatment as usual and receive a mental health resource information sheet on study.
76078032|NCT03344211|Radiation|Radium Ra 223 Dichloride|Given IV
76078033|NCT05394454|Procedure|Bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins.
76078034|NCT03274401|Device|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
76078035|NCT03274401|Device|5 day ECG patch|Selection of device for monitoring clinicians' choice
76078036|NCT05086107|Drug|BV100|Rifabutin for infusion
75328517|NCT00939211|Drug|Tiotropium|Dry powder for inhalation, single dose
75784558|NCT06073067|Radiation|GRID therapy|GRID therapy delivers a high dose of radiation to small areas of tumor interleaved with areas that intentionally receive a low dose
75784559|NCT06070649|Drug|0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion|Infusion
75784560|NCT06070649|Drug|0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion|Infusion
75784561|NCT06070649|Drug|25 mg Diphenhydramine (5 min) + Normal Saline|Infusion
75920983|NCT02132481|Other|Neither - RSAU|"The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens."
75328518|NCT00939211|Drug|Placebo|Placebo
75328519|NCT03404999|Other|clinical decision support|Decision support system (see description of hypertension decision support system alerts and order sets for details)
75635097|NCT05758792|Other|Muscle Quality Index|Evaluations are applied to older adults to compare the results of muscle quality.
75635098|NCT02815059|Drug|Ibrutinib|Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.
75635099|NCT02815059|Drug|Dasatinib|Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.
75784562|NCT06064981|Behavioral|Text message nudges|"Fourteen text message nudges, tailored to address specific barriers and concerns regarding naloxone acquisition and carrying. These barriers were identified using qualitative interviews conducted by the authors in prior studies. Examples included: optimism bias (e.g., beliefs that participants were unlikely to encounter someone who had overdosed in their daily lives), and identity bias (e.g., beliefs that participants were not the type of people who could save a life)."
75328520|NCT02791906|Drug|ISMN|
75784563|NCT06064981|Behavioral|Commitment contract|"In addition to the training, participants in the third arm were asked to sign commitment contracts, which had language in which they committed to carrying/acquiring naloxone."
75784564|NCT06064604|Other|Control|The stroke survivors will serve as their own control group. The participants will complete the required tasks without an exoskeleton device.
75328521|NCT02791906|Dietary Supplement|Vitamin C|
75328522|NCT03404921|Procedure|ESTD|During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.
75328523|NCT03404921|Procedure|ESD|The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
75920984|NCT05699902|Procedure|PECs block during mastectomy|The patients were randomised to receive a PECS block consisting of 30 ml of levobupivacaine 0.25% after induction of anaesthesia (PECS group) or a saline mock block (control group). The patients answered a 40-item QoR questionnaire (QoR-40) before and 1 day after breast cancer surgery. MAIN OUTCOME MEASURES
75920985|NCT05699902|Procedure|Sham block|Female undergone mastectomy and have received conventional analgesic methods
75328524|NCT01729715|Behavioral|Internet|
75328525|NCT01729715|Behavioral|DVD|
75328526|NCT04466293|Behavioral|Choice Architecture|"Providers will receive general training on TPT benefits, indications, and contra-indications.~Providers will be provided with updated ART and TPT prescribing approach. This will be adapted to the country context and may include a pre-printed prescription pad (Mozambique), adaptations in clinical stationary (Zimbabwe), or adaptations to an electronic prescribing system (Malawi).~The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
75328527|NCT03404765|Behavioral|Tai Chi|
75328528|NCT01723319|Device|HBLPADD coil deep TMS|20 daily deep TMS treatment
75328529|NCT01723319|Device|Sham|inactive treatment
75635100|NCT02815059|Drug|Prednisone|Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
75635101|NCT05638269|Other|no intervention|Observational studies, no intervention
75635102|NCT03735732|Behavioral|prime|groups be confronted with health or palatability aspects of food items
75635103|NCT03918720|Behavioral|Trekkers Family Health Empowerment Programme|Health Assessment, Health Enablement and Health Literacy provided to empower participants awareness towards a healthier life style
75635104|NCT02811393|Other|Assess muscle function|Assess muscle function with hand grip test and sit and stand test
75635105|NCT00819910|Drug|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
75635106|NCT00819910|Drug|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
75635107|NCT00819910|Drug|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
75635108|NCT00819910|Drug|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
75784565|NCT06064604|Device|Hip Exoskeleton|The Georgia Tech Hip Exo is a wearable robotic device for hip extension/flexion assistance. This device will be used to study the lower limb movement and how to effectively assist users. It makes use of a responsive controller that considers information such as joint angles to understand the user's state and assists with the appropriate level of power accordingly.
75784566|NCT06064604|Device|Ankle Exoskeleton|The Dephy Exoboot is a lower limb exoskeleton which attaches to the user below the knee through a cuff at the proximal calf and a provided shoe. This investigational device is used to make it easier for able-bodied and impaired individuals to walk and run under a variety of conditions. The exoskeleton provides assistance at the ankle joint during movement. The purpose is to assist the user in lower limb movements such as ground level walking, climbing stairs/ramps, and sit-to-stand.
75784567|NCT06060977|Drug|IMG-007|Intravenous Infusion
75328530|NCT01729793|Dietary Supplement|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
75328531|NCT01729793|Other|Placebo|Capsule containing microcrystalline cellulose
75920986|NCT02135991|Behavioral|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
75920987|NCT02135991|Behavioral|Project CHOICE|Sites will receive standard training for Project CHOICE.
75920988|NCT02132559|Drug|DHEA|
75635109|NCT04197843|Device|NaviCam (ANKON)|The NaviCam (ANKON) is a miniaturised wireless endoscope in a single use capsule. It can be remotely controlled with the patient in a magnetic console. The operator to the magnetic-driven NaviCam sits in a computer workstation and manipulates the capsule suspended in a waterfilled stomach. After careful examination of the stomach, the capsule is then allowed to passed through the pylorus into duodenum and small bowel. The patient wears harness with small bowel imaging capabilities.
75920989|NCT05551468|Behavioral|StayFine guided app-based personalised intervention modules|Participants work on guided app-based personalised intervention modules in the StayFine app over the course of three months. The modules are selected by the participant based on shared decision making and a personalized advice. The intervention is based on Preventive Cognitive Therapy (PCT) with elements of Cognitive Behavioral Therapy (CBT) and Positive Psychology. Modules are: psycho education (mandatory), cognitive restructuring (mandatory), positive affect, behavioral activation, exposure, wellness, sleep and a relapse prevention plan (mandatory).
75920990|NCT05551468|Behavioral|StayFine app-based monitoring|Monitoring six times per day for two weeks in the StayFine app.
75920991|NCT00126984|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
75328532|NCT02793154|Drug|Exenatide|Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate >=6 hours apart)
75328533|NCT02793154|Drug|Albiglutide|Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
75328534|NCT03404687|Radiation|ultrasound|for assessment of adnexal masses size and pattern
75635110|NCT02808117|Dietary Supplement|MNP|"Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency."
75784568|NCT06052306|Drug|BAY3546828|Intravenous (IV) infusion on Day 1 of each cycle.
75784569|NCT06052306|Drug|BAY2616505|Each participant in the substudy will receive the BAY2616505 administered at baseline (Day 1) by intravenous (i.v.), after completion of the screening period and before the first dose of BAY3546828 in Cycle 1.
75784570|NCT06052306|Drug|BAY2315493|If the planned dose of total antibody is more than 1 mg, BAY2315493 will be administered by intravenous (i.v.), starting one hour prior to the i.v. injection of BAY2616505.
75784571|NCT06052293|Drug|ANG003|To evaluate four possible combinations of lipase, protease and amylase.
75328535|NCT03404687|Diagnostic Test|cancer antigen 125 level|for prediction of malignancy
75328536|NCT03404687|Radiation|Doppler|for detection of blood flow
75328537|NCT01729949|Dietary Supplement|Active Treatment Beverage|Strawberry and Blackcurrent extract
75328538|NCT01729949|Dietary Supplement|Placebo Treatment Beverage|without active components
75328539|NCT03404531|Behavioral|Social Media Messages Intervention Group|The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
75328540|NCT03404531|Behavioral|Website Only Group|The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
75328541|NCT01723553|Drug|C-11 PiB|One time intravenous administration of ~740 megabecquerel (MBq) of [N-methyl-C-11]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
75784572|NCT06051357|Drug|HRS-5965 tablets|HRS-5965 tablets for 12 weeks
75920992|NCT00126984|Biological|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
75920993|NCT00126984|Biological|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
75920994|NCT00126984|Biological|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
75920995|NCT05700370|Diagnostic Test|MyProstateScore|MyProstateScore is a urine-based biomarker test used to predict the risk of clinically significant prostate cancer
75920996|NCT05551390|Other|one-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
75469244|NCT01936701|Procedure|bilateral cataract surgery|same-day bilateral cataract surgery with implantation of intraocular lens
75784573|NCT06047379|Drug|NEO212 Oral Capsule|NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
75784574|NCT06047379|Drug|Ipilimumab|Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
75635111|NCT04237311|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as following: after greater curvature dissociating, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using linear cutting stapler of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
75635112|NCT04237311|Procedure|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass is performed as following: a gastric pouch of approximately 30mL was obtained using linear cutting stapler, the sum of the length of the alimentary limb and the biliopancreatic limb> 200 cm (can be adjusted according to the incidence of the patient's BMI, type 2 diabetes mellitus and the specific situation).
75635113|NCT02808897|Device|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (FR) to 32 FR shall be used for the single anterior mediastinal chest tube.
75635114|NCT02808897|Device|Active Clearance Technology drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum with one (1) standard chest tube. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 FR to 32 FR shall be used for the single anterior mediastinal chest tube.
75635115|NCT02808039|Other|Platelet reactivity testing|assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
75635116|NCT04321395|Drug|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.
75635117|NCT02807961|Drug|ELX-02|Synthetic aminoglycoside
75635118|NCT02807961|Drug|Placebo|Placebo comparator
75635119|NCT02814669|Drug|Atezolizumab|Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
75635120|NCT02814669|Drug|Radium-223 Dichloride|Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
75635121|NCT04237389|Procedure|Ablation Index Guided endocardial catheter radiofrequency ablation|Ablation Index (AI) guided catheter RF ablation with circumferential ablation around the right and left PVs and 2 additional lines between the lower and upper PVs (endoBox-lesion).
75635122|NCT04237389|Procedure|minimally invasive thoracoscopic surgical epicardial ablation.|"Description: minimally invasive thoracoscopic surgical epicardial ablation using Box-lesion set, which includes isolation of the right and left PVs, roof and posterior wall lines and removal of the LAA."
75920997|NCT05551390|Other|three-times umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
75920998|NCT02132715|Behavioral|Resistance Exercise|
76078037|NCT05085015|Other|Functional Exercise Training Group|"Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. The training will be given on the treadmill Treadmill Technogym. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end."
75469245|NCT01936714|Procedure|cataract surgery|
75635123|NCT02808741|Drug|F901318 SDD|Pharmacokinetics area under curve
75784575|NCT06047379|Drug|Pembrolizumab|Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
75635124|NCT02808741|Drug|F901318 IR|Pharmacokinetics area under curve
75635125|NCT02808741|Drug|F901318 IR Fasting|Pharmacokinetics area under curve
75635126|NCT02808741|Drug|F901318 IR Fed|Pharmacokinetics area under curve
75635127|NCT02808663|Biological|fecal calprotectin concentration|
75635128|NCT02808663|Biological|blood collection|
75635129|NCT05571189|Behavioral|Daily Activity Text|Participants will receive a text each day with instructions about the daily activity they should complete for that day.
75635130|NCT05571189|Behavioral|Control Text|"Participants will receive a text each day with no instructions about daily activity. It will have messages like have a nice day."
75784576|NCT06047379|Drug|Nivolumab|Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
75784577|NCT06047379|Drug|Regorafenib|Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
75784578|NCT06047379|Drug|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
75920999|NCT02132715|Behavioral|KAATSU exercise|
75469246|NCT01936727|Procedure|cataract surgery|
75469247|NCT01936740|Procedure|cataract surgery|
75635131|NCT02807727|Drug|Intralipid 20%|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
75921000|NCT05558722|Drug|Anlotinib|Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles) Combined TAC×6 cycles: albumin-bound paclitaxel (200mg/m2, 1d Q3W) + pirarubicin （50mg/m2, 1d Q3W) + cyclophosphamide (500mg/m2, 1d Q3W);
75921001|NCT03551379|Device|Double Balloon Endoluminal Platform|A DBA platform will be use din this registry study to facilitate ESD
75921002|NCT05699746|Drug|Capecitabine tablets|Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
75635132|NCT02807727|Drug|Modified Ringers Lactate|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
75921003|NCT05699746|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
75921004|NCT02136225|Behavioral|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
75635133|NCT05561907|Procedure|Surgical gastrojejunostomy (SGJ)|Laparoscopic gastrojejunostomy
75635134|NCT05561907|Procedure|Endoscopic gastrojejunostomy (EGJ)|Endoscopic ultrasound (EUS) guided gastrojejunostomy
75635135|NCT02807649|Dietary Supplement|Experimental: Nutrilite® Low dose|Two tablets consume daily with meal.
75784579|NCT06047379|Drug|Paclitaxel|Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
75784580|NCT06047379|Drug|FOLFIRI Protocol|"FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating."
75784581|NCT06047379|Drug|Bevacizumab|Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
75784582|NCT06046209|Device|Control Contact Lens|Daily disposable contact lens for 90 minutes
75784583|NCT06046209|Device|Test Contact Lens|Monthly replacement contact lens for 90 minutes
75635136|NCT02807649|Dietary Supplement|Experimental: Nutrilite® High dose|Two tablets consume daily with meal.
75784584|NCT06042270|Dietary Supplement|Betaine|3 grams per day for ~4 weeks
75784585|NCT06042270|Dietary Supplement|Placebo|3 grams per day for ~4 weeks
75784586|NCT06039384|Drug|INCB099280|Administered as specified in the treatment arm description
75784587|NCT06039384|Drug|adagrasib|Administered as specified in the treatment arm description
75784588|NCT06038227|Procedure|Robotic Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using RATS.
75921005|NCT05551312|Other|Virtual Essential Newborn Care (vENC) training|Essential Newborn Care Mobile Virtual Reality Simulation
75921006|NCT02136303|Dietary Supplement|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
75921007|NCT02136303|Other|S2: Kale extract versus kale purée|
75328542|NCT03404453|Diagnostic Test|Difficult airway incidence and prediction|Paediatric patients scheduled for surgery under general anaesthesia will be examined and a set up of airway prediction tests will be performed to predict the possibility of difficult airway
75328543|NCT02907268|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
75328544|NCT02907268|Drug|abobotulinumtoxinA|AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
75635137|NCT02807649|Dietary Supplement|Placebo Comparator: Placebo|Two tablets consume daily with meal.
75635138|NCT02814435|Other|Questionnaire|The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
75635139|NCT02814435|Other|Computerised contrast sensitivity function test|This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
75635140|NCT02814513|Device|ANDAGO|Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
75635141|NCT02814513|Device|ANDAGO|Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
75635142|NCT02814513|Device|ANDAGO|Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
75635143|NCT02814513|Device|ANDAGO|Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
75635144|NCT02814513|Device|ANDAGO|To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
75635145|NCT02814357|Other|Control (market standard)|
75635146|NCT02814357|Other|wheat flour|
75635147|NCT02814357|Other|chickpea flour|
75784589|NCT06038227|Procedure|Video Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using VATS.
75784590|NCT06036927|Drug|TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
75784591|NCT06036927|Drug|TQC2731 matching placebo|It'a a placebo injection without active substances.
75921008|NCT02136303|Other|S3: Kale extract: AMD-patients|
75784592|NCT06036914|Drug|Bumetanide|Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.
75784593|NCT06036914|Drug|Furosemide|"Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID."
75469248|NCT01936753|Behavioral|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
75635148|NCT02814357|Other|guar gum|
75921009|NCT05558332|Behavioral|Youth-Nominated Support Teams for CHR|"Intervention for adolescents aimed at preventing, reducing, and/or managing suicidal thoughts and behaviors. YST-CHR is an add on to the treatment and therapy they are already receiving. Study clinicians will administer the adapted YST treatment manual to participants, aimed at improving suicidal risk."
75328545|NCT04376957|Behavioral|Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool|"This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise."
75328546|NCT04376957|Behavioral|Standard of care consisting of standard counselling|Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
75635149|NCT02814357|Other|barley|
75328547|NCT02907814|Device|Optical Coherence Tomography (OCT)|The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.
75328548|NCT02907814|Other|Eye Exam|This is a brief, non-contact ocular exam.
75328549|NCT02909140|Drug|Topical phenylephrine 2.5%|
75328550|NCT02909140|Drug|Topical cyclopentolate 1%|
75328551|NCT02909140|Drug|Intracameral Lidocaine 1%|
75635150|NCT02807337|Drug|Caphosol|
75635151|NCT02807337|Drug|0,9% NaCl|
75635152|NCT02807415|Drug|Lumacaftor plus Ivacaftor|Oral treatment with lumacaftor/ivacaftor tablets according to the prescribing information
75635153|NCT02804841|Dietary Supplement|Cholecalciferol -Vitamin D3|
75635154|NCT02804841|Other|Placebo -gel capsule containing no vitamin D.|
75469249|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of n-3 fatty acids for 8 weeks
75469250|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of olive oil for 8 weeks.
75635155|NCT05529537|Other|manual lymphatic drainage|In addition to conventional treatment for 4 weeks, manual lymph drainage will be applied to the patients.
75635156|NCT05529537|Other|excersize|upper extremity normal joint range of motion exercise, strengthening exercise, tendon gliding exercises
75635157|NCT02808273|Drug|Bemiparine|Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
75328552|NCT02909140|Drug|Intracameral 0.2- 0.3ml of epinephrine 1:10,000|
75328553|NCT01723631|Device|Trap Myelin Test|
75328554|NCT02909764|Other|Low Sodium Group|Breakfast Cereal
75328555|NCT01724879|Drug|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
75328556|NCT04348435|Biological|HB-adMSCs|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
75635158|NCT00634491|Drug|sodium bicarbonate|150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
75635159|NCT00634491|Drug|Acetazolamide|Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
75635160|NCT00634491|Drug|normal salin|1 cc/kg/hr 6 hour before and after angiography
75635161|NCT02807103|Drug|Rituximab|1 g intravenous pulse at day1 and day15
75328557|NCT04348435|Other|Placebos|Saline
75328558|NCT03404141|Other|Parent craft|Midwife-guided classes for pregnant women about pregnancy and childbirth
75469251|NCT01936805|Drug|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
75469252|NCT01936922|Device|GaitAid®|Provides visual and auditory cues for walking.
75469253|NCT01936961|Drug|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
75469254|NCT01936961|Radiation|Hypofractionated Radiotherapy|
75635162|NCT02807103|Drug|Placebo-rituximab|intravenous pulses at day1 and day15
75635163|NCT02807103|Drug|Cyclophosphamide|intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
75635164|NCT02807103|Drug|Placebo-cyclophosphamide|intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
75635165|NCT02806791|Drug|FILGRASTIM|
75635166|NCT00830518|Drug|Alisertib|Alisertib capsules
75635167|NCT02804685|Other|exercise protocol|The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
75635168|NCT00908544|Other|PHI-patients|Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
75784594|NCT06034392|Device|CHAMP App|CHAMP® App is a downloadable software mobile Application with a Software Platform. CHAMP® App is an electronic version of data entry for children with conditions that require close monitoring from their homes. The primary Intended Use is to relay monitoring information from homes to the health care team. This monitoring includes data options that can facilitate the collection of monitoring data of children in the home setting to improve communications between parents at home and remote caregivers. The CHAMP® App itself does not do home monitoring of the child's medical condition. It is not designed to alert parents if data entered has reached a red flag (problem) level. Users of the CHAMP App are advised in writing and in the informed consent process that urgent medical conditions should not be managed through the CHAMP App, and that appropriate emergency care should be obtained directly rather than through the CHAMP App.
75784595|NCT06033898|Behavioral|12 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1000 steps. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
75921010|NCT04324372|Drug|HEC68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
75921011|NCT02132793|Behavioral|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
76078038|NCT05085015|Other|Home Exercise Training Group|Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. They will walk at least 30 minutes, 3 days a week for 8 weeks at outdoor. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end.
75921012|NCT02132793|Behavioral|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
75921013|NCT05551234|Other|Regular exchanges|The seniors and childrens will meet once a week, for 7 months, over a period of one and a half hours, outside school hours (4:30 p.m. to 6:00 p.m.) and school holidays.
75921014|NCT03549897|Drug|Placebo|Placebo Product
75921015|NCT03549897|Drug|90 mcg Reference Product|90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE [TEVA RESPIRATORY, LLC]
75921016|NCT03549897|Drug|180 mcg Reference Product|180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE [TEVA RESPIRATORY, LLC]
76078039|NCT05075109|Device|High Frequency TENS|30 minutes of high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
76078040|NCT05075109|Device|Low Frequency TENS|30 minutes of low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks. And combined with 30 minutes of TRT.
75635169|NCT00908544|Other|CHI-patients|Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
75635170|NCT02804607|Other|questionnaire|
75328559|NCT03404141|Behavioral|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy to reduce stress levels among pregnant women
75635171|NCT00830440|Device|EndoBarrier Device|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks
75635172|NCT00830440|Behavioral|Diet & Lifestyle Counseling|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
75635173|NCT04115865|Device|Endotracheal sonde or laryngeal mask|Healthy subjects ; requiring general anesthesia with endotracheal or endobuccal device
75635174|NCT00913354|Device|Acupuncture (Carbo®)|The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
75651746|NCT05709483|Drug|Aspirin|Platelet assays including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, Thromboxana A2 levels- will be measured at baseline and 1 hour after administration of single-dose enteric-coated 81 mg aspirin
75921017|NCT03549897|Drug|90 mcg Test Product|90 mcg Test Product - ALBUTEROL SULFATE HFA [AMNEAL IRELAND LIMITED]
75921018|NCT05551078|Biological|thrombophilia screening|In the IUGR group systematic thrombophilia screening had already been performed.
75921019|NCT02132871|Device|Impedance cardiography Physioflow ®|
75921020|NCT02136381|Behavioral|LEAP intervention|"LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.~Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.~Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.~Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles"
75921021|NCT02136381|Behavioral|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.~Participants in the control group will be assessment after two months."
75635175|NCT00913354|Device|Placebo acupuncture (Strietberger®)|"The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.~Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger."
75921022|NCT05547802|Biological|BBIBP-CorV and/or BNT162b2 vaccine|Booster immunization was carried out at least 4 months after the first two doses of basic immunization.
75921023|NCT03551301|Other|Transitional Case Management|"TCM program is a type of very flexible community treatment in terms of frequency and intensity of care. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialised in SUD treatment. The intervention begins during hospitalisation and lasts around 4 weeks after discharge from the hospital.~The main aim of this intervention is to accompany the patient in the difficult phase of transition between hospital and outpatient care and ensure their adherence to the treatment program. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs. Another important aim is to reduce the number of (unplanned) hospitalizations and emergency room visits."
75635176|NCT05523687|Drug|[14C]-PC14586|Single, oral dose of [14C]-PC14586
75635177|NCT00702910|Drug|Placebo|comparator
75921024|NCT02133027|Procedure|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
75635178|NCT00702910|Drug|GW642444|investigational drug or placebo
75921025|NCT02133027|Device|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
75635179|NCT00702910|Drug|Magnesium Stearate|Magnesium Stearate
75635180|NCT02806635|Behavioral|OurRelationship|
75635181|NCT02806635|Behavioral|PREP Online|
75921026|NCT05700838|Behavioral|Cough Skill Training - with Variable Practice|"Variable practice will involve three targets that reflect a range of cough airflows, including strong, moderate, and weak coughs."
75921027|NCT05551000|Other|Experimental, comparator and control|"To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group."
75635182|NCT00908310|Drug|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
75635183|NCT02804529|Device|Veress needle|
75635184|NCT03896334|Behavioral|Supervised Isometric Handgrip Training|The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.
75635185|NCT03896334|Behavioral|Sham comparator - stretching and relaxation exercises|The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
75784596|NCT06033898|Behavioral|24 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 24 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
75784597|NCT06033898|Behavioral|36 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 36 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
75635186|NCT00830128|Drug|pregabalin (Lyrica)|Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
75635187|NCT03906357|Drug|Pemigatinib|
75635188|NCT04034550|Other|Blood and urine sampling and blood banking|In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.
75635189|NCT05580120|Behavioral|Online-supervised exercise group|Participants in the online-supervised exercise group were provided with an online-supervised exercise program by using the video conferencing method three times a week for 6 weeks on the Zoom application. The exercise program was carried out synchronously
75635190|NCT05580120|Behavioral|Unsupervised-exercise training group|The unsupervised-exercise training group was informed about how to do the same exercises by another researcher, a nurse academician, on the online platform by using the lecturing method. Each training intervention took approximately 30 minutes.
75635191|NCT05498103|Drug|Methazolamide 25 MG|25 mg tablets
75635192|NCT05498103|Drug|Methazolamide 50 MG|50 mg tablets
75784598|NCT06032767|Other|observational group|patients initially diagnosed with nasopharyngeal carcinoma treated with IMRT
75921028|NCT02136459|Other|Small Tube size|An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
75921029|NCT02136459|Other|Large Tube size|An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
75921030|NCT02136537|Device|Bilateral NMES legs|Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
75921031|NCT02136537|Other|Best medical therapy|Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
75921032|NCT05451264|Diagnostic Test|blood pressure measurement|Completion of the physical activity and quality of life questionnaire (PedSQL adapted to the age of the child), measurement of weight and height; Measurement of VOP (Pulse wave velocity), AI (increase index) and ECG (electro cardiogram) collection at rest lying down; Stimulation test by slow breathing at 6 cycles/min for three minutes; Continuation of the measurements in a standing position for 5 minutes; Installation of blood pressure holter (MAPA) which will be kept for 24 hours and then returned by post.
75635193|NCT00841906|Device|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
76078041|NCT05075109|Other|Task Related Training|"Each session of TRT would include:~1. postural control, 2. shoulder mobilization, 3. weight bearing exercises 4. Functional activities that will comprise of simple tasks to more advanced movement patterns as follows:~Reaching activities~Forward supported reach with cane on tabletop~Reaching against gravity~Reaching overhead with active wrist/hand movements~Dynamic reaching to target e.g. catch a ball~Grasping, holding and release~Grasp, hold and release objects with gravity minimized~Pick up and move/release small objects on table~Pick up and move/release large objects without proximal support~Incorporate pinch grips in hold and release including stacking, lifting and overhead activity~Upper limb ADL~Brushing hair, putting on scarf~Opening bottles, turning off water tap~Writing, drawing~Folding of towels, hanging towels and setting table~Self-feeding"
76078042|NCT01029730|Drug|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
76078043|NCT01029730|Drug|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
75635194|NCT00841906|Device|Alice PDx with written and verbal instructions|Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
75635195|NCT05557227|Other|1-hour cycling|60 % VO2 max
76078044|NCT01029730|Drug|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
75469255|NCT01937013|Drug|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
75635196|NCT00771667|Drug|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
75635197|NCT00771667|Drug|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
75635198|NCT00771667|Drug|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
75784599|NCT06023862|Drug|Dostarlimab|Intravenous (IV) infusion
75784600|NCT06023862|Drug|Bevacizumab|Intravenous (IV) infusion
75784601|NCT06023862|Drug|Doxorubicin|Intravenous (IV) infusion
75784602|NCT06023862|Drug|Gemcitabine|Intravenous (IV) infusion
75784603|NCT06023862|Drug|Paclitaxel|Intravenous (IV) infusion
75784604|NCT06023862|Drug|Pegylated liposomal doxorubicin|Intravenous (IV) infusion
76078045|NCT05552235|Device|Elbow SOFT 300|15 patients will be included in this group and will used the medical device ElbowSOFT 300 during sport practice (at least 2 sport sessions per week), for 6 weeks.
75784605|NCT06013462|Procedure|Descemet Membrane Endothelial Keratoplasty|DMEK (Descemet Membrane Endothelial Keratoplasty) is a surgical technique used to treat primary or secondary corneal endothelial decompensation.
76078046|NCT05552235|Other|Control group|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device), for at least 2 sport sessions per week during 6 weeks.
76078047|NCT05066997|Drug|Active treatment arm: OCS-01 (dexamethasone)|The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit
76078048|NCT05066997|Drug|Vehicle|The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit
76078049|NCT05345535|Other|Trampoline exercise|45 minutes of exercises that includes upper and lower extremity movements a trampoline with music
75635199|NCT00771667|Drug|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
75784606|NCT06008782|Device|HEARS-SLP device|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
75784607|NCT06008782|Behavioral|HEARS-SLP program|Tailored aural rehabilitation for participant and communication partner
75784608|NCT06008080|Device|Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System
75784609|NCT06003556|Diagnostic Test|PSMA-1007 Positron Emission Tomography (PET) scan|Additional staging PET scan prior to focal therapy to focal therapy.
75635200|NCT00771667|Drug|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
76078050|NCT05345535|Other|Walking|45 minutes of moderate tempo walking
76078051|NCT03273621|Procedure|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
75921033|NCT04468620|Behavioral|Assistive Soft Skills & Employment Training (ASSET)|The ASSET curriculum covers six key social skill areas: (a) Communication; (b) Networking; (c) Attitude & Enthusiasm; (d) Teamwork; (e) Problem Solving & Critical Thinking; and (f) Professionalism, as well as new content added based on our pilot findings (Mental Health; Stress Management and Self-Advocacy; and Awareness of Self & Others). The schedule includes two sessions for Communication and Professionalism, and a graduation session; thus, bringing the total number of sessions to 13. The structural elements of the training format include didactic lecture, experiential activities, group discussions, role-plays, performance feedback,and weekly take-home assignments. A key element is a social hour following each 90-minute session, in which participants practice learned skills while sharing a meal.
76078052|NCT05025033|Drug|PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate|PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
76078053|NCT00980746|Drug|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
76078054|NCT00980746|Drug|Placebo|oral route
76078055|NCT05424783|Other|Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate|The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
76078056|NCT02984631|Procedure|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
76078057|NCT05201157|Other|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch
76078058|NCT05201157|Other|Control Group|No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
76078059|NCT00981214|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
76078060|NCT03308565|Biological|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
75341416|NCT01576939|Radiation|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to < 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
75635201|NCT00771667|Drug|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
75784610|NCT06003465|Drug|LY3437943|Administered SC
75784611|NCT06003465|Device|Test|Used to administer LY3437943 SC
75784612|NCT06003465|Device|Reference|Used to administer LY3437943 SC
75784613|NCT06001385|Drug|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
75784614|NCT06001385|Drug|Fludarabine|Given IV pre-transplant as part of conditioning regimen
75341417|NCT00581048|Drug|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
75635202|NCT00771667|Drug|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
75784615|NCT06001385|Procedure|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
75784616|NCT06001385|Drug|Post-Transplant Cyclophosphamide|Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.
75784617|NCT06001385|Drug|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post cyclophosphamide.
75784618|NCT06001385|Drug|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
75784619|NCT06001385|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
75784620|NCT06001385|Other|Patient Reported Outcomes|Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
76078061|NCT01031134|Behavioral|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
75921034|NCT05550844|Radiation|Chest HRCT|A chest HRCT to identify emphysema
75921035|NCT05550844|Genetic|blood analysis|If emphysema is identified, a blood analysis will be performed to exclude known causes of emphysema (Alpha-1 antitrypsin deficiency, PTPN6 mutation)
75921036|NCT05550844|Other|Lung function tests|Lung function tests will be performed in accordance with ATS/ERS technical standard
75921037|NCT02133105|Drug|Levosimendan|
75921038|NCT02133105|Drug|Dobutamine|
76078062|NCT01031134|Other|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
76078063|NCT05415657|Drug|Denosumab|Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
76078064|NCT05415657|Drug|Placebo|Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
75341418|NCT01577329|Behavioral|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
76078065|NCT03016234|Drug|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
75635203|NCT00771667|Drug|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
75341419|NCT04391504|Procedure|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
75341420|NCT05233280|Other|Oral liquids and soft food 2 hours postoperative|Early versus delayed oral liquid feeding after ceasarean section
75341421|NCT05222360|Other|Education|3 educational sessions about body image and nutrition
75635204|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
75784621|NCT06001385|Drug|Melphalan|Given IV pre transplant as part of conditioning regimen
75784622|NCT06001385|Radiation|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
75921039|NCT04468464|Other|Occlusal Splint Treatment|Occlusal splint is used by a dentist during sleep or day time to protect the teeth and temporomandibular joint. Manufactured individually by the technicians according to the dentists measurement procedure.
75635205|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
75635206|NCT02801175|Procedure|Pulmonary vein isolation|
75635207|NCT04039360|Combination Product|self-expanding metallic stent placement followed by neoadjuvant chemotherapy|Neoadjuvant chemotherapy was administered 1 week after successful SEMS placement and decompression for patient with obstructing left-sided colonic cancer. Patients received either three cycles of mFOLFOX6 repeated every 2 weeks or two cycles of CAPOX repeated every 3 weeks. Elective surgery was performed 2 weeks after completion of chemotherapy by experienced colorectal surgeons.
75784623|NCT06001385|Drug|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
75798590|NCT03862872|Dietary Supplement|Control Fish Oil|The control fish oil is a soft gelatin capsule containing 1,106 mg of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil. A four capsule per day dose provides 816 mg EPA and 572 mg DHA, which is only slightly less EPA+DHA than is provided within a four capsule per day dose of Anti-Aging Formula. This minor difference would not be expected to alter clinical outcomes.
75798591|NCT03862872|Other|Inert Placebo|The inert placebo is a soft gelatin capsule containing 1040 mg of corn oil.
75921040|NCT04468464|Other|Osteopathic Manual Treatment|Osteopathy treats the body as a whole and applied by hands over the related structures of the body. TMJ, Cervical, Thoracal, Lumbar vertebra mobilization was applied as well as the fascial and visceral mobilization. Patients also used occlusal splint for 6 weeks during the intervention.
75921041|NCT02136693|Drug|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
75921042|NCT02136693|Drug|Placebo|3.5 g /day of inert compound for 180 days after STARR
75921043|NCT05726136|Drug|acetated Ringers|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
75921044|NCT05726136|Drug|albumin 5%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
76078066|NCT03016234|Drug|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
76078067|NCT03695679|Behavioral|Interactive computer-based intervention|"There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~Perceived Susceptibility and Perceived Severity~Perceived Benefits and Perceived Barriers~Cue to Action~Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information."
75921045|NCT05726136|Drug|albumin 20%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
75921046|NCT05547334|Behavioral|Inference Based Approach (IBA)|The Inference Based Approach (IBA) (as described by Visser et al., 2015 and adapted for use in adolescents by L. Webers)is a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly and carried out as specified in a Dutch session-by-session IBA protocol, containing standardized forms for exercises and homework assignments. Each session has a standard format, starting with agenda setting and evaluating homework assignments, followed by determining and executing a new exercise and determining new homework. The IBA model is based on the assumption that adolescents with OCD and poor inside misjudge the actual state of affairs. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the childs attention from observable reality.
76078068|NCT04353388|Diagnostic Test|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
76078069|NCT01031914|Device|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
76078070|NCT05404893|Diagnostic Test|Fecal calprotectin measurement|Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
76078071|NCT02167204|Procedure|Computed Tomography|Undergo 18F-FLT PET/CT
76078072|NCT02167204|Radiation|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
76078073|NCT02167204|Procedure|Positron Emission Tomography|Undergo 18F-FLT PET/CT
76078074|NCT05404737|Other|transthoracic echocardiography (TTE)|In order to evaluate the interchangeability of RV-LSF, a TTE will be performed just after the placement of general anesthesia, when the patient is under mechanical ventilation
76078075|NCT05404737|Other|transoesophageal echocardiography (TEE).|During cardiopulmonary bypass surgery patients is monitored by a TEE as recommended.
76078076|NCT04992429|Procedure|SphinkeeperTM|The SphinkeeperTM includes up to 10 self-expandable prostheses, which get inserted into the intersphincteric place. They are made of inert Hyexpan (polyacrylonitrile)
76078077|NCT05538585|Drug|Galicaftor|Oral
76078078|NCT05538585|Drug|Navocaftor|Oral
75635208|NCT02800395|Procedure|Malnutrition screening and perioperative nutritional support|"Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~Implementation of an adapted nutritional support based on ESPEN Guidelines"
75921047|NCT05451186|Other|Eye patch and headphones|Patients in the experimental group will be asked to use an eye mask and earplugs from 22:30 to 6:30 in the morning on the 1st, 2nd and 3rd nights.
76078079|NCT00982072|Drug|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
76078080|NCT00982072|Drug|prednisolone|Prednisolone 1mg/kg maximum 60mg od
76078081|NCT05537571|Drug|SLN360|SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
76078082|NCT05537571|Drug|Placebo|Sodium chloride, solution for injection
76078083|NCT05343195|Other|Task-oriented exercise|Task-oriented exercise program for patients after total hip replacement.
75341422|NCT01578031|Device|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
75341423|NCT01578031|Other|Usual Care|Usual care.
75341424|NCT01798472|Procedure|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
75635209|NCT04236063|Other|WHODAS 2.0 Questionnaire|36-item WHODAS 2.0 questionnaire will be used for each patient to identify difficulty faced by patient over past 30 days from the day of interview
75635210|NCT02804451|Device|Macintosh laryngoscope|intubation with standard macintosh larygoscope; gold standard
75635211|NCT02804451|Device|TruView EVO2 laryngoscope|A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),
75469256|NCT01937013|Drug|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
75469257|NCT01937065|Other|No treatment|
75635212|NCT02804451|Device|TruView EVO2 PCD laryngoscope|A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),
75635213|NCT02804451|Device|ETView SL|An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube
75921048|NCT02133339|Drug|TRN-157|
76078084|NCT05343195|Other|Control|Control intervention: conventional physiotherapy after hip replacement
76078085|NCT01899053|Drug|TAK-228|TAK-228 Capsules
75328560|NCT04377893|Device|Eye gaze AT intervention|"The eye-gaze AT intervention includes eye-gaze AT and service delivery to support the participants using this technology in daily life. The Tobii PCEye Mini (Tobii, Danderyd, Sweden) and specialized software are applied with adaptation to meet each child's individual needs.~To ensure the consistency of service delivery, two-day courses are conducted before the intervention. The participant's teachers or parents are invited as the main interventionist to facilitate the child's usage of eye-gaze AT in daily life under team support. The service delivery involves parents in joint goal-setting, planning, and jointly review the progress of the usage of eye-gaze AT as a family-centered practice. Individual meetings and individual supports are provided during intervention periods. The collaborative team will perform biweekly follow-up contacts during intervention periods.~The researcher will conduct the fidelity checklist every month to determine the extent of treatment integrity."
76078086|NCT01899053|Drug|TAK-117|TAK-117 Capsules
75328561|NCT01722929|Device|Skin sensor|
75328562|NCT02982031|Procedure|shamrock|This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
75635214|NCT04008537|Device|Ring gantry kV-CBCT combined with linear accelerator|Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
75635215|NCT05579808|Procedure|Epidural Analgesia|Using an aseptic technique while the patient is in sitting position, an epidural catheter was placed at the L2-L3 or L3-L4 interspace. Analgesia was established with the epidural administration of a low dose of local anaesthetic, plus a lipid-soluble opioid (ropivacaine 0.1% and sufentanyl 0.5%, 20 mL). Analgesia was maintained with a top-up regimen, using intermittent manual epidural boluses of increasing concentrations of ropivacaine, with up to 0.15% at full dilation, according to specific needs of individual participants.
75635216|NCT05520879|Dietary Supplement|Sharnali 1|"The intervention is food product, made from locally available food ingredients in Bangladesh.~Sharnali 1 made from rice, lentil, dried skimmed milk, sugar, vegetable oils and micronutrient premix."
75635217|NCT05520879|Dietary Supplement|Sharnali 2|Sharnali 2 made from chick peas, dried skimmed milk, sugar, vegetable oils and micronutrient premix.
75635218|NCT03893175|Drug|Ibuprofen|400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
75635219|NCT03893175|Drug|Acetaminophen|500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
75635220|NCT03893175|Drug|Placebo|By mouth
75635221|NCT03893175|Drug|Oxycodone|5 mg by mouth every 6 hours as needed for pain
75328563|NCT02982031|Procedure|paramedian transverse scan|The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
75328564|NCT03404063|Drug|Cardiac Drug|"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
75635222|NCT02235792|Device|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
75635223|NCT04236453|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
75635224|NCT04236453|Drug|Darunavir|Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
75328565|NCT03404063|Drug|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
75784624|NCT06000046|Device|Automatic image analysis|After referral for suspected prostate cancer, the patient is scanned with magnetic resonance imaging (MRI) in accordance with guidelines of the standardized healthcare pathway. For consenting patients, the images are interpreted in two ways: first, in the conventional manner, i.e., manually by a radiologist, to determine whether clinically significant cancer is suspected. If so, the radiologist will delineate the suspicious lesions. In the second approach, the software will perform the same task as the radiologist, but automatically. If either or both interpretations point to significant cancer, the patient will be sent for targeted biopsy sampling. Histopathologic evaluation of the samples will then determine whether significant cancer is present in each of the targeted lesions (delineated by the radiologist, software, or both).
76078087|NCT05396235|Biological|MT-3921|Solution for infusion; Intravenous (IV)
75328566|NCT04347109|Diagnostic Test|Non invasive epicardial mapping|Non invasive mapping using Cardio Insight system is performed in all included patients.
75328567|NCT02793856|Drug|Cyclophosphamide|To deplete Tregs before collecting peripheral blood
75328568|NCT02793856|Other|PD-1 Knockout T Cells|Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
75635225|NCT04236453|Drug|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
75635226|NCT04236453|Drug|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally on Day 1.
76078088|NCT05396235|Biological|Placebo|Solution for infusion; Intravenous (IV)
75635227|NCT02801019|Other|E-poly|comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
75635228|NCT02801019|Other|ArComXL|comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
75635229|NCT02800473|Device|Strorz (commercial)|
76078089|NCT05532423|Drug|Beetroot Juice - Active|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
76078090|NCT05532423|Drug|beetroot juice - Placebo|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
76078091|NCT01032694|Drug|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
75635230|NCT02800473|Device|CyPaM2 (experimental)|
75635231|NCT00770965|Biological|AIN457|
76078092|NCT01032694|Drug|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
76078093|NCT05391945|Diagnostic Test|polysomnography|Patient will be assessed by home Polysomnography(PSG), one night, Pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function.
75328569|NCT03403985|Drug|Calcium Hydroxide (Ca(OH)2)|Ca(OH)2 will be used in this group
75328570|NCT03403985|Drug|Mineral Trioxide Aggregate|MTA will be used in this group
75635232|NCT00770965|Biological|Placebo|
75784625|NCT05999968|Drug|Abemaciclib|Administered orally.
75328571|NCT04364425|Drug|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide
75328572|NCT04364425|Drug|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
75784626|NCT05999968|Drug|Darolutamide|Administered orally.
75784627|NCT05999968|Drug|LHRH agonist/antagonist|Physician's choice. Administered in accordance with the prescribing information.
75784628|NCT05997446|Device|Left atrial appendage occlusion (LAAO)|Implantation of an Amplatzer Amulet left atrial appendage occluder
76078094|NCT01032850|Drug|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
76078095|NCT04399707|Device|Transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
76078096|NCT04399707|Device|Placebo transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
76078097|NCT05390944|Drug|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
75328573|NCT04364425|Drug|Normal saline|Ultrasound guided injection using 15ml or 12 ml of normal saline
75328574|NCT01723943|Other|educational intervention|"Receive the What's Happening to the Woman I Love? booklet"
75328575|NCT01723943|Other|counseling intervention|Undergo Helping Her Heal educational counseling program
75328576|NCT01723943|Other|educational intervention|Undergo Helping Her Heal educational counseling program
75328577|NCT01723943|Other|psychosocial support for caregiver|Undergo Helping Her Heal educational counseling program
75784629|NCT05996198|Device|Oculus Rift headset|The Oculus Rift is a commercially-available virtual reality (VR) headset. It is used to present the visual environment in which participants perform the reaching task.
75328578|NCT04355377|Other|Non intervention|Non intervention
75328579|NCT04378829|Diagnostic Test|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
75328580|NCT02911324|Drug|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
75635233|NCT04096651|Other|gait recordings|gait recordings
75784630|NCT05996198|Device|Exoskeleton Device|The exoskeleton was designed and constructed to provide either gravity assistance or gravity resistance. It applies a torque to both shoulders. Torque values do not exceed 50% of the torque due to gravity. The device is mounted to a testing chair and attached to the participant using Velcro straps.
75784631|NCT05996003|Drug|NS-089/NCNP-02|"Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1"
75798592|NCT03862794|Behavioral|new social norm feedback letter with bar chart|letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
76078098|NCT05390944|Drug|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
76078099|NCT04911309|Other|functional exercise training|12 weeks functional exercise training twice per week, each session lasting 60 min
75635234|NCT04096651|Other|brain magnetic resonance imaging|brain magnetic resonance imaging
75635235|NCT04096651|Other|oculomotor movement recordings|oculomotor movement recordings
75635236|NCT02806557|Device|Home finger-prick capillary blood count monitoring|A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
75635237|NCT05461339|Drug|TAB014 Monoclonal Antibody Injection|intravitreal injection at 1.25mg once every 4 weeks
75635238|NCT05461339|Drug|Ranibizumab Injection [Lucentis]|intravitreal injection at 0.5mg once every 4 weeks
75635239|NCT02806479|Other|Observational: Arrhythmogenic Substrate|
76078100|NCT04911309|Other|standard therapy / treatment|12 weeks standard therapy / treatment
76078101|NCT04909437|Dietary Supplement|Mycobiotic|2 sachet/day, 21 days, oral
76078102|NCT04909437|Dietary Supplement|Placebo|2 sachet/day, 21 days, oral
76078103|NCT01032928|Behavioral|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
76078104|NCT04278261|Procedure|Focal therapy(high-frequency irreversible electroporation)|High-frequency irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with localized prostate cancer
76078105|NCT04278261|Procedure|laparoscopic radical prostatectomy|Laparoscopic radical prostatectomy
76078106|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
76078107|NCT00983242|Drug|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
76078108|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
76078109|NCT04278105|Device|HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
76078110|NCT04278105|Device|Sham HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
76078111|NCT04278105|Other|Upper extremity rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
75635240|NCT02800629|Dietary Supplement|Modified Citrus Pectin|MCP versus placebo
75635241|NCT02800629|Dietary Supplement|Placebo|
75635242|NCT03854682|Procedure|Radiofrequency microtenotomy|A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
75635243|NCT03854682|Behavioral|Strength training|Non-surgical treatment consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
75635244|NCT02806245|Other|Biventricular pacing|"Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~Atrial sensing- right ventricular pacing 10 min.~5 min no pacing (washout).~Atrial sensing - biventricular pacing 10 min.~5 min no pacing (washout).~Intrinsic rhythm~5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped."
75635245|NCT05562414|Behavioral|HIIT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will perform six high-intensity intervals (95% HRmax) at high pedalling rates of 80-100 rounds per minute (rpm) for 60-90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20 watts, 60-80rpm) aimed to return to 60% HRmax (approximately 1.5-2 min). The duration of the HIIT bout is approximately 21 minutes."
75635246|NCT05562414|Behavioral|MCT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will continuously train at 60% HRmax and pedal at 60-80 rounds per minute. The duration of the MCT bout is 26 minutes."
75635247|NCT02800707|Other|Sucralose|Sweetner
75635248|NCT02800707|Other|Stevia|Sweetner
75635249|NCT02800239|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
75635250|NCT03409848|Drug|Nivolumab|Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)
75635251|NCT03409848|Drug|Nivolumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
75635252|NCT03409848|Drug|Ipilimumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
75635253|NCT02806323|Other|Yoga practice|
75784633|NCT05981794|Device|Electrical heating pad|A powered heating pad
75784634|NCT05981794|Device|Sham heating pad|A heating pad that is not powered on
75328581|NCT02911324|Behavioral|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
75784635|NCT05981703|Drug|BGB-26808|Planned doses administered orally as a tablet daily.
75921049|NCT02133339|Drug|Placebo|
75328582|NCT04355299|Behavioral|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
75328583|NCT04355299|Behavioral|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
75328584|NCT04355299|Behavioral|aerobic exercise|Aerobic exercise is any activity that gets your blood pumping and large muscle groups working. It's also known as cardiovascular activity.
75328585|NCT04355299|Behavioral|usual care|received usual care
75328586|NCT01729403|Drug|aleglitazar|150 mcg orally daily, 16 weeks
75328587|NCT01729403|Drug|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
75635254|NCT02804295|Other|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
75635255|NCT00763555|Drug|CD 2027|Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
75635256|NCT00763555|Drug|Calcitriol Vehicle|Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
75635257|NCT02804373|Drug|Oxytocin (OXT) continuous|Administration of 24 IU of oxytocin daily during 28 days
75635258|NCT02804373|Drug|Placebo|Placebo daily during 28 days
75635259|NCT02804373|Drug|Placebo continuous|Placebo administration the following 2 days after each OXT administration, during 28 days.
75635260|NCT02804373|Drug|Oxytocin|Administration of 24 IU of oxytocin every 3 days during 28 days.
75784636|NCT05981703|Drug|Tislelizumab|Planned doses administered by intravenous infusion.
75784637|NCT05964569|Other|model-guided optimization of treatment plan|original treatmant plans are optimized based on model-based NTCP
75784638|NCT05964569|Other|standard treatment plan, no optimization|original treatment plans are not optimized
75784639|NCT05962125|Other|periodic alveolar recruitment maneuvers|A stepwise increment of tidal volume was used for each ARM.
75784640|NCT05962125|Other|positive end-expiratory pressure|a PEEP of 6 to 8 cm H2O
75784641|NCT05957276|Other|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
75784642|NCT05955534|Device|TPUG|Tracheostomy shall utilize any FDA approved device for the performance of percutaneous dilatational tracheostomy. PUG shall be performed using the only FDA-cleared device for ultrasound gastrostomy, the PUMA-G System.
75784643|NCT05955534|Procedure|PEG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
75921050|NCT02136771|Dietary Supplement|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
75328588|NCT01729403|Drug|placebo|orally daily, 16 weeks
75328589|NCT04355611|Other|Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)|Epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
75328590|NCT01724645|Dietary Supplement|Korean traditional diets|"The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.~The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods."
75328591|NCT01724645|Dietary Supplement|Control group|"Told to  eat as usal diets."
75328592|NCT02914132|Device|Seraph 100 Filter|Treatment of renal replacement therapy patients with bacteremia.
75328593|NCT01724099|Drug|Euiiyin-tang|Korean medicinal herbal drug
75328594|NCT01724099|Drug|Placebo|Placebo drug, same odor and formula as Euiiyin-tang
75328595|NCT04281667|Drug|Oral Antibiotics|Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
75328596|NCT04281667|Drug|Placebo|Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
75651747|NCT05709197|Procedure|Braun anastomosis|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. In addition to the reconstruction technique used, a side-to-side anastomosis will be created between the afferent and efferent jejunal limbs of the gastrojejunostomy (GJ) at 20 cm distance from the GJ. The anastomosis will be hand-sewn with monofilament PDS 3-0 one-layer running suture.
75784644|NCT05955534|Procedure|PRG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
75784645|NCT05950464|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
75784646|NCT05950464|Procedure|Biopsy|Undergo biopsy
75784647|NCT05950464|Procedure|Biospecimen Collection|Undergo collection of blood samples
75921051|NCT02136771|Dietary Supplement|Placebo|
75921052|NCT00125970|Biological|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
75921053|NCT00125970|Biological|VRC-HIVADV014-00-VP|1 x 10^10 PU administered in deltoid
75921054|NCT00125970|Biological|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
75921055|NCT00125970|Biological|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
75921056|NCT05579457|Other|Short Physical Performance Battery|The SPPB was applied to determine the physical performance levels of the elderly. This test is a valid and reliable test that measures the performance of the lower extremities and can be applied for elderly. The SPPB included three sections: getting up from a chair, standing balance, and walking speed. At the end of these tests, the scores of the three sections were calculated and higher scores were evaluated as reflecting higher levels of physical performance
75328597|NCT04281667|Drug|Mechanical Bowel Preparation|Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
75328598|NCT04378985|Device|Wearing a Wearable device (Fitbit inspire HR)|"'Wearing a wearable device (the smart watch) for 8 weeks~The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'"
75328599|NCT02914210|Device|Virtual physical therapy rehabilitation program|Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
75328600|NCT02914210|Other|No intervention|Traditional physical therapy delivered in clinic or via home-health visits
75328601|NCT04355455|Drug|Citalopram|40 mg citalopram intravenously
75328602|NCT04355455|Drug|Placebo|Saline solution
75328603|NCT00913913|Biological|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
75328604|NCT00913913|Drug|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
75328605|NCT00913913|Biological|IL-2|IL-2 18 MiU/m2 CI 5 days
75328606|NCT00913913|Biological|IFN|IFN 6 MiU subc TIW
75328607|NCT00373594|Drug|Rituximab|
75469258|NCT01937078|Drug|Famotidine|Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
75469259|NCT01937104|Drug|Desflurane|"Anesthesia with desflurane in both Group 1 and Group 2~- adjust MAC to maintain BIS between 40-60"
75784648|NCT05950464|Procedure|Computed Tomography|Undergo CT
75921057|NCT03528252|Other|Written advice LDL Cholesterol|One A4 paper with written information on both sides
75469260|NCT01937104|Drug|Remifentanil|"Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%"
75921058|NCT03528252|Other|Written advice Triglycerides|One A4 paper with written information on both sides
75921059|NCT02133417|Device|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
75921060|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
75921061|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
75921062|NCT01561521|Drug|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
75921063|NCT03531216|Other|Rosemary essential oil|Topically-applied oil to both dorsal and palmar aspects of the hands
75328608|NCT00373594|Drug|Fludarabine|
75328609|NCT03403829|Drug|Gemcitabine|Gemcitabine maintenance chemotherapy
75328610|NCT03403829|Radiation|standard chemoradiotherapy|standard chemoradiotherapy
75328611|NCT04355221|Procedure|pulsed radiofrequency|Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
75328612|NCT03403673|Other|Frailty assessment tools|There is evidence to suggest that patients who are frail have a higher risk of developing complications after major surgery. Our aim is to ask you simple questions about your physical ability to perform daily life activities, assess your general health condition and ask you to do simple tasks such as drawing a clock or walking for a short distance to assess your speed of walking. Our main aim is to identify a tool that will assist us to identify patients who are at risk of frailty
75328613|NCT04364113|Other|Usual Protein Diet|The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus
75328614|NCT04364113|Other|Low Protein Diet|The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus
75328615|NCT04364113|Other|Very Low Protein Diet|The very low protein diet contains 0.28 g/kg/day or protein, mg/kg/day of Phosphorus and a keto acid mixture.
75651748|NCT05709197|Procedure|Standard Child reconstruction|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. The surgeon is able to perform the PD as normally would be done (antecolic, retrocolic, pylorus-preserving or with distal gastric resecting).
75651749|NCT05706441|Other|Point-of-Care Ultrasound|Ultrasonographic scans of the lung and right hemidiaphragm were acquired after 30 min from the beginning of the SBT, or immediately before reconnecting the patient to the ventilator in the case of SBT failure occurring before
75651750|NCT05697198|Diagnostic Test|OmniSeq Test|Genomic and immune profiling assay for all solid tumors
75784649|NCT05950464|Procedure|Electrocardiography|Undergo ECG
75784650|NCT05950464|Procedure|Magnetic Resonance Imaging|Undergo MRI
75784651|NCT05950464|Drug|Tuvusertib|Given PO
75784652|NCT05950464|Procedure|X-Ray Imaging|Undergo x-ray
75784653|NCT05948878|Device|Novel Taping Method|Subjects will be asked to have the novel taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
75798593|NCT03862794|Behavioral|standard social norm feedback letter|social norm feedback letter used as standard practice, without specific information about the prescribing percentile
75921064|NCT03531216|Other|Placebo|Topically-applied oil to both dorsal and palmar aspects of the hands
75921065|NCT02253303|Other|midline incision or off-midline incision|Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
75921066|NCT03531138|Other|Pulmonary Rehabilitation|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week and fill out the exercise follow-up form. Supervised exercise sessions consist of aerobic(treadmill walking, bicycle training, arm ergometer training) and strengthening training(free weights). A 6-min walk test, a 10-meter walking speed test and a 5 times sit to stand test will be performed to determine the exercise capacity of the patient. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed sequentially by the same physiotherapist, giving 20 minute rest periods within the same day.
75328616|NCT04364113|Drug|Medications needed to maintain usual blood pressure|The MAP goal for the usual blood pressure group is <=107 mm Hg for ages 18-60 and <=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
75635261|NCT05514678|Behavioral|Cognitive Stimulation Therapy|CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.
75635262|NCT02806401|Device|landmark|
75635263|NCT02806401|Device|US_Ax|
75635264|NCT02800083|Drug|Pitolisant (BF2.649)|
75921067|NCT03531060|Drug|IRL790|IRL790 capsule 10 mg
75921068|NCT03531060|Drug|Placebo|Placebo capsule
75921069|NCT02136927|Drug|SPARC1210|
75921070|NCT02136927|Drug|Reference1210|
75921071|NCT03527784|Device|Parietene Macro|Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.
75635265|NCT02800083|Drug|Placebo|
75635266|NCT02806167|Other|Clinical algorithm|Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
75635267|NCT00763321|Drug|ABT-712|ABT-712 extended-release tablet
75635268|NCT00763321|Drug|Placebo|Placebo tablet
75635269|NCT02799927|Procedure|Indirect Pulp Treatment with Bioactive Dentin Substitute|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Biodentine and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
75635270|NCT02799927|Procedure|Indirect Pulp treatment with Calcium hydroxide|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Ultra-Blend plus, and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
75784654|NCT05948878|Device|BCH Emergency Department Taping Method|Subjects will be asked to have the BCH emergency department taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
75784655|NCT05948878|Device|Chevron Taping Method|Subjects will be asked to have the Chevron taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
75921072|NCT03527784|Device|Parietex Parastomal|Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.
75921073|NCT03527784|Device|Dynamesh IPST|Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
75921074|NCT02133495|Procedure|Non Cadaveric Human Acellular Dermal Tissue|
75921075|NCT05723952|Other|Barcelona scoliosis physical therapy school|procedure for treating Adolescent Idiopathic scoliosis
75921076|NCT05723952|Other|International scoliosis schroth therapy|procedure for treating Adolescent Idiopathic scoliosis
75921077|NCT02260713|Biological|autologous bone marrow cell|Transplantation of 200 million cells in 1.8 ml of autologous plasma in a single sitting. In case of intralesional route, the cells were delivered in one sitting at six sites ( 2 above the lesion, 2 at the lesion and 2 below the lesion) as 0.3 ml aliquots each. In case of Intrathecal route, the cells were delivered as a single injection of 1.8ml via lumbar puncture.
75921078|NCT03133494|Other|ABG analysis|ABG analysis was performed and compared between two groups
75798594|NCT03859986|Drug|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle
75798595|NCT03859986|Drug|ALX-101 Gel 5%|ALX-101 Gel 5%
75798596|NCT01175928|Device|Sham device|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
75921079|NCT05723796|Procedure|nasal endoscopy|nasal endoscopy and mucosal biopsy
75921080|NCT03549663|Drug|Tacrolimus|Tacrolimus capsules: 0.5mg/pill, 50 pills/box, AstellasPharma (China) Co., Ltd.; Tacrolimus capsules: 1mg/pill, 50 pills/box, Hangzhou ZhongmeiHuadong Pharmacy Co., Ltd. Start to administer on the randomized grouping day (D0) with an initial dose by weight: initial dose of 0.05-0.075mg/kg/d (bid) following a strict administration interval of 12 hours or fasting or 2 hours after meal. Adjust TAC dose according to 24-hour urine protein, plasma concentration and eGFR changes. It is recommended that plasma trough concentration should be remained at 5-8ng/ml and TAC dose during the whole therapy stage should not be lower than 0.5mg/d. Drugs should be stopped if the 6-month therapy is ineffective. After 6-month therapy, for those whose urine protein achieved complete remission (CR) or partial remission (PR), TAC dose should be reduced gradually with a total therapy duration of 48 weeks.
75328617|NCT04364113|Drug|Medications needed to maintain low blood pressure|The MAP goal for the low blood pressure group is <=92 mm Hg for ages 18-60 and <=98 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
75921081|NCT03549663|Drug|Prednisone|Glucocorticoid (prednisone): 5mg/pill, 100 pills/bottle: Shanghai Sine Pharmaceutical Factory Co., Ltd. The initial dose of prednisone should be 0.5mg/kg/d orally (maximum dose of 40mg/d) and administration should be continued for 8-12 weeks; then reduced by the monthly decreased amount of 0.1mg/kg/d till to 0.2mg/kg/d (5-10mg) to maintain. Prednisone should be stopped after administration for the entire 48 weeks.
75921082|NCT02137083|Drug|Docetaxel|75mg/m2 D2 every 21 days
76078112|NCT04278027|Behavioral|Cognitive Remediation Therapy|"CIRCuiTS is a web-based computerised CR therapy, delivered by a therapist but supplemented with independent sessions to facilitate massed practice. It targets metacognition, particularly strategy use, in addition to providing massed practice of basic cognitive functions. The therapist facilitates motivation, metacognitive and strategy development and generalisation of learning by encouraging the participant to learn about and regulate their cognitive performance and to transfer this learning to meet real-world goals. Therapists provide additional scaffolding for CR tasks to ensure consistent successful performance. Independent sessions involve carrying out cognitive tasks allocated by the therapist to ensure scaffolded learning (Reeder et al.2017)"
76078113|NCT00984334|Drug|Naloxone SR 5 mg capsules|
76078114|NCT00984334|Drug|Placebo|
75328618|NCT03403595|Drug|177Lu-EB-PSMA-617|accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
75635271|NCT02800005|Device|AFA group (successive patients)|The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.
75635272|NCT02800005|Other|BMI group (successive patients)|The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
75635273|NCT02804139|Other|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization.
75635274|NCT02804139|Other|Standard Care|Standard Care after C-section with no additional physical therapy.
75635275|NCT02806089|Device|Handheld dynamometer|Evaluation of muscle strength
75921083|NCT02137083|Drug|Fulvestrant|500mg D1, D15, D29, D57, every 28 days later
76078115|NCT00984334|Drug|Naloxone SR 10 mg capsules|
76078116|NCT00984334|Drug|Naloxone SR 20mg capsules|
76078117|NCT00984334|Drug|Naloxone SR 2.5 mg capsules|
76078118|NCT02168062|Behavioral|Behavioral Dietary Intervention|Receive individualized nutrition counseling
76078119|NCT02168062|Other|Counseling|Receive individualized symptom management service counseling
76078120|NCT02168062|Other|Educational Intervention|Review educational modules
76078121|NCT02168062|Behavioral|Exercise Intervention|Receive individualized exercise counseling
75328619|NCT04354987|Drug|CKD-391 10/10mg|Drug T: CKD-391 10/10mg(Other Name: Test Drug)
75328620|NCT04354987|Drug|D090, D337|D090 and D337 co-administration(Other Name: Reference drug)
75328621|NCT03835091|Other|BRASS score|Brainstem response on neurologic examination
75328622|NCT03834935|Drug|Elidel (pimecrolimus 1%)|topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
75328623|NCT03834935|Drug|Cold Cream|Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
75328624|NCT01724255|Other|questionnaire|
75635276|NCT02806089|Biological|Creatinine index|Evaluation of muscle mass using plasma creatinine level
75635277|NCT02806089|Device|Electrical bioimpedance analysis|Evaluation of lean body mass
75921084|NCT05428800|Behavioral|Progressive Relaxation Exercises|Progressive muscle relaxation (PMR) is a relaxation technique that tenses and relaxes muscles in an unprompted, regular, and consecutive manner until the whole body is relaxed.
75921085|NCT02137161|Drug|Dexamethasone+Tobramycin eye drop|dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
75921086|NCT02137161|Drug|Bromfenac eye drop|bromfenac ophthalmic solution 0.09%
76078122|NCT02168062|Drug|Goserelin Acetate|Given SC
76078123|NCT02168062|Other|Laboratory Biomarker Analysis|Correlative studies
76078124|NCT02168062|Drug|Leuprolide Acetate|Given SC or IM
76078125|NCT02168062|Other|Quality-of-Life Assessment|Ancillary studies
76078126|NCT02168062|Drug|Triptorelin Pamoate|Given IM
76078127|NCT05334459|Radiation|radiotherapy|"Oligometastatic disease (defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems)~Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc) (if there is, based on institutional practice)~o ER / PR /Her2 /Ki67 study)~Collection of CTC.~Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~o Denosumab, Biphosphonate for bone metastasis~RT to metastatic side (if visible). Continue Systemic therapy~12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~ST will be continued until progression and/or unmanageable toxicity.~Radiologic evaluation every 3-6-month based on institutional practice."
76078128|NCT05373615|Drug|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
76078129|NCT03304587|Diagnostic Test|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
75635278|NCT02806089|Other|"Voorrips score questionnaire"|Evaluation of physical activity
75784657|NCT05947149|Other|questionnaires administration|"Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H&N43, HADS, Brief COPE, BRCS.~Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS.~Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H&N43."
75784658|NCT05941442|Drug|Darigabat|Oral tablets
75784659|NCT05941442|Drug|Placebo|Oral tablets
75784660|NCT05940012|Other|Manual Therapy|Hands on treatments including manipulation, mobilization and soft-tissue mobilization with therapeutic intent.
75784661|NCT05935098|Drug|BGB-A3055|Administered intravenously
75784662|NCT05935098|Drug|Tislelizumab|Administered intravenously
75921087|NCT02252991|Other|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
75921088|NCT05211999|Behavioral|Precede-Proceed Model Based Simulation Experience|The program was created on the basis of the PRECEDE-PROCEED Model.The program consists of eight phases. It will be carried out with theoretical training and simulation experience in the experimental group. In the control group, theoretical training will be given. Results will be followed.
75921089|NCT05211999|Behavioral|Control Group|No intervention in control group just theoretical education was done for them.
75921090|NCT05401266|Procedure|mild hypercapnia|Ventilation parameters were adjusted to achieve and maintain ETCO2 50-55 mmHg until spontaneous respiration was restored
75921091|NCT02253069|Device|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
75921092|NCT02253069|Device|Applying Placebo to tie-over dressings|Placebo control
75635279|NCT02806089|Biological|Inflammatory and nutritional status|Evaluation of C reactive protein and albumin
75635280|NCT04099017|Other|Mulligan Joint mobilization|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~Mulligan joint mobilization in Non-weight bearing (NWB) to weight-bearing (WB) 6 -10 Reps and 3 sets/ session.~Procedural detail:~Joint mobilization will be performed in sagittal, frontal and transverse direction, following glide will be preferred will depend on patient adherence to the joint mobilization. Mobilization will be progress from NWB to WB according to patient compliance 27~Knee strengthening Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~Kinesiotaping:"
75784663|NCT05935033|Drug|Emraclidine|Tablet
75784664|NCT05932446|Drug|LY3819469|Administered SC.
75921093|NCT03528096|Device|Somnomat B|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
75921094|NCT03528096|Other|Sound|Sound of the moving bed was recorded and played back during the baseline night.
75784666|NCT05923359|Other|Apple Watch|Apple Watch
75784667|NCT05909280|Other|Pressure-volume loop measurements|Pressure-volume loop measurements using a conductance catheter
75784668|NCT05906836|Drug|Rosuvastatin|Administered orally.
75784669|NCT05906836|Drug|Selpercatinib|Administered orally.
75784670|NCT05904496|Drug|BGB-30813|Specified dose administered on specified days
75784671|NCT05904496|Drug|Tislelizumab|Specified dose administered on specified days
75784672|NCT05900570|Diagnostic Test|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
75784673|NCT05895955|Biological|TetraFluvac TF vaccine|"The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine [A/Sydney/5/2021(H1N1) pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus] produced by The Government Pharmaceutical Organization (GPO), Thailand.~Each prefilled dose of TetraFluvac TF contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
75784674|NCT05895955|Biological|Vaxigrip vaccine|"Vaxigrip vaccine is commercially available seasonal quadrivalent inactivated split virion influenza vaccine [A/Sydney/5/2021(H1N1) pdm09-like strain and A/Darwin/9/2021 (H3N2)-like strain and B/Austria/1359417/2021-like strain and B/Phuket/3073/2013-like strain, manufactured by Sanofi Pasteur, Ltd. France.~Each prefilled dose of Vaxigrip vaccine contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
75921095|NCT05362656|Device|VX1+ dispersion mapping|Careful biatrial high density dispersion mapping is performed as the first step of the procedure. Operators map each region of both atria carefully by moving the mapping catheter slowly. If VX1+ application detects dispersion regions, the corresponding dipoles location will be automatically tagged on the 3D-map. Accuracy and relevance of dispersion regions should be confirmed by the operator by checking EGMs visually.
75784675|NCT05889715|Other|Green Wellness Program: Plants-2-Plate|A 6-month, intensive interprofessional program focused on a WFPB predominant eating pattern
75784676|NCT05878717|Biological|Belimumab|Belimumab will be administered.
75921096|NCT03528018|Device|REACt system|The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements
75921097|NCT03528018|Other|Physical therapy|Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
75921098|NCT03530982|Other|Intensive goal training|Intensive goal training : 30 hours during 2 weeks
75921099|NCT05723718|Other|Observational Survey|Evaluation of the nutritional status and body composition on tumor regression grade in gastric cancer patients scheduled for multimodal treatment. Nutritional status assessment will include: selected clinical variables evaluation (weight, BMI, nutritional status scales), bioelectrical impedance analysis and selected laboratory parameter assessment. After inclusion in the study, each patient will have four consecutive nutritional status assessments: (1) one day prior staging laparoscopy or during qualification to neoadjuvant chemotherapy, (2) one day before the gastrectomy, (3) one month after the gastrectomy, (4) after the last cycle of adjuvant chemotherapy.
75921100|NCT03527628|Drug|Adriamycin|25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
75921101|NCT03527628|Drug|Cyclophosphamide|400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
75784677|NCT05878717|Other|Placebo|.Placebo will be administered.
75784678|NCT05877508|Drug|AER002|Intravenous infusion of AER002
75921102|NCT03527628|Drug|Vinblastine|6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
75921103|NCT03527628|Drug|Dacarbazine|375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
75784679|NCT05877508|Other|Placebo|Placebo infusion
76078130|NCT03304587|Diagnostic Test|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
75921104|NCT03527628|Drug|Brentuximab Vedotin|1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
75328625|NCT02796352|Drug|High dose bolus interleukin-2 (HD IL2)|"Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).~The planned treatment consists of 3 courses (6 cycles) of HD IL-2."
75784680|NCT05875896|Procedure|Total wrist fusion|Observation after implantation of Medartis Aptus Wrist Arthrodesis Plate
75784681|NCT05875493|Drug|JAB-21822|2 discrete single doses
75921105|NCT03527628|Drug|ABVD|All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
75921106|NCT03530904|Other|mobilization|Early mobilization after CIED implantation
75921107|NCT03530826|Other|No intervention|No Intervention
75328626|NCT00939367|Drug|Zolpidem Tartrate Tablets 10 mg|
75784682|NCT05875493|Drug|JAB-21822|2 discrete single doses
75784683|NCT05873582|Device|Robotic-assisted inguinal hernia repair|Primary transperitoneal unilateral or bilateral inguinal hernia repair with the Dexter robotic system
75784684|NCT05871970|Biological|TARA-002|All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
75328627|NCT00939367|Drug|'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg|
75328628|NCT04347187|Drug|Anticoagulants|oral anticoagulants, dual or triple antithrombotic theraphy
75328629|NCT01724411|Other|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
75328630|NCT02797054|Behavioral|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
75784685|NCT05871307|Radiation|Preoperative Radiotherapy|Resection of brain mestases following
75784686|NCT05871307|Radiation|Intraoperative Radiation|While Resection
75784687|NCT05871307|Radiation|Postoperative Radiotherapy|After resection
75921108|NCT03530748|Procedure|Endovascular therapy and Imaging Acquisition|"Endovascular repair for renal artery stenosis;~Parenchymal Blood Volume(PBV) acquisition and analysis for target kidney"
75921109|NCT04466748|Drug|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.
75921110|NCT04466748|Drug|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
75921111|NCT04466670|Drug|acetylsalicylic acid|acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
75921112|NCT04466670|Drug|Unfractionated heparin nebulized|unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
76078131|NCT03304587|Other|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
75921113|NCT04468542|Drug|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
75784688|NCT05871008|Other|Assessment tool IA3-CP with SDoH|Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.
75921114|NCT04468542|Drug|Superior laryngeal nerve block - Placebo (saline)|2-cc injection of saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
75328631|NCT02797054|Behavioral|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
75921115|NCT04468308|Other|Questionnaire|Patients complete the National Eye Institute Visual Function Questionnaire 25 pre-operative, 1 month and 3 month postoperatively.
75921116|NCT04615260|Device|NanoBone|Nanobone® Synthetic Bone Graft is a nanocrystalline hydroxyapatite imbedded in a silica gel matrix. The nanocrystalline structure accurately replicates autologous hydroxyapatite and the silica gel matrix that rapidly transforms into an osteogenic matrix post-implantation. NanoBone promotes remodeling by acting as a strong osteoinductive material. NanoBone® is available as a putty.
76078132|NCT03304587|Other|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
75328632|NCT02797054|Behavioral|Usual care|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
75328633|NCT00920075|Drug|Alendronate (Fosamax)|Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
75328634|NCT04364035|Biological|ChAdOx1.HTI|ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection
75328635|NCT04364035|Biological|MVA.HTI|MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection
75328636|NCT04364035|Drug|GS-9620|GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
75328637|NCT04364035|Biological|Placebo|Saline placebo delivered as one 0. 5 mL IM injection
75328638|NCT04364035|Drug|Placebo Oral Tablet|Unit-dose placebo tablet delivered as two 3-mg placebo tablets
75635281|NCT04099017|Other|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Trunk stabilization Area: Trunk Type of exercise: Stabilization exercise Intensity: 6-8 reps Frequency: 3 sets per session and 30 second duration break between sets~Procedural detail:~i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~Iv. lateral step up:~Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~Procedural detail:~i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~Kinesiotaping:"
75784689|NCT05871008|Other|Assessment tool IA3-CP without SDoH|Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.
75784690|NCT05869955|Drug|CC-97540|Specified dose on specified days
75784691|NCT05869955|Drug|Fludarabine|Specified dose on specified days
75784692|NCT05869955|Drug|Cyclophosphamide|Specified dose on specified days
75784693|NCT05862285|Drug|Ipatasertib|Ipatasertib will be administered as a monotherapy or in combination with other agent(s) or comparator agent(s) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
75784694|NCT05859412|Other|Neurodynamic exercises|The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
75921117|NCT03525522|Device|Nd:YAG Laser|Three sessions of Nd:YAG treatment every two weeks.
76078133|NCT03304587|Diagnostic Test|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
75328639|NCT00920231|Device|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
75328640|NCT00920231|Device|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
75328641|NCT04737538|Other|Experimental Dentrifrice|Toothpaste containing sodium bicarbonate, sodium hyaluronate and sodium fluoride
75328642|NCT04737538|Other|Positive control dentifrice|Dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride
75328643|NCT04737538|Other|Negative control dentifrice|Dentifrice containing 1100ppm fluoride as sodium fluoride (Crest Cavity Protection)
75328644|NCT03403439|Drug|BI 1015550|Reference and Test Treatment
75469261|NCT01937104|Device|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
75784695|NCT05859412|Drug|Steroid injection (Depomedrone 40mg)|Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
75784696|NCT05859412|Other|Advice|Group receiving advice but no additional treatment
75469262|NCT01937104|Procedure|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
75635282|NCT04099017|Other|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~Procedural detail:~i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~Kinesio-taping:~Muscle stretch method will be applied which involves one Y and two I straps: The Y-shaped tape base will be affixed over the top of patella then pulls up his/her knee to its maximum bending capacity then both end of Y strip is placed around the patella ending on the tibial tuberosity. Then reinforcing I-tape will be affixed at the origin and insertion of MCL and LCL. Tape will be change in every session."
75635283|NCT02799849|Other|Sleep and metabolism assessment|
75635284|NCT00770653|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
75635285|NCT00770653|Drug|Glimepiride and Metformin|Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
75784697|NCT05858515|Drug|Baricitinib 4 MG|Nonproprietary name: Baricitinib
75784698|NCT05858515|Drug|Placebo|Placebo
75784699|NCT05851547|Radiation|Prostate SBRT with Focal Boost|Prostate stereotactic body radiotherapy delivered to 27 Gy in 3 fractions on alternating days to uninvolved regions with up to 39 Gy in 3 fractions delivered to mpMRI-defined intraprostatic lesions
75784700|NCT05851547|Drug|Triptorelin Injection|Six months of androgen deprivation therapy for intermediate-risk localized prostate cancer and 24 months for high-risk localized prostate cancer
75784701|NCT05844423|Biological|0.5 ml dose of 1.1 mcg VAX-24|24 valent pneumococcal conjugate vaccine
75784702|NCT05844423|Biological|0.5 ml dose of PCV20|20 valent pneumococcal conjugate vaccine
75784703|NCT05844423|Biological|0.5 ml dose of 2.2 mcg VAX-24|24 valent pneumococcal conjugate vaccine
75328645|NCT03403439|Drug|itraconazole|Test treatment
75635286|NCT04185207|Other|no intervention|There is no intervention.
75784704|NCT05844423|Biological|0.5 ml dose of 2.2/4.4 mcg VAX-24|24 valent pneumococcal conjugate vaccine
75784705|NCT05837975|Device|FREE Walk Exoskeleton|Using a robotic exoskeleton to help with lower limb activities that are difficult due to neurological diseases. Used at home for individual patient training.
75784706|NCT05837975|Other|Traditional Rehabilitation|Traditional rehabilitation refers to the use of conventional therapeutic methods.
75784707|NCT05833087|Behavioral|Schema therapy|30 sessions of schema therapy. The therapy was developed by Jeffrey Young and others and encompasses elements from cognitive behavioral, psychodynamic, and gestalt therapies, as well as attachment theory.
75784708|NCT05833087|Behavioral|Other psychotherapy|In this arm, psychotherapy can be psychodynamic, cognitive behavioral, interpersonal or other evidence-based psychotherapies, aimed at changing cognitions, behavior, improve social relations and uncover unconstructive psychological patterns.
75784709|NCT05833087|Other|Standard care package content|"The patient is offered prescription and monitoring of psychopharmacological treatment of up to 5 hours by a psychiatrist, when appropriate.~Additionally, patients have up to 3 hours of preparatory and diagnostic sessions and up to 4 hours of meetings with the participation of next-of-kin and/or collaboration partners in other public instances."
75784710|NCT05831540|Other|Discussion|Participate in focus group
75328646|NCT04346797|Drug|Eculizumab|"Intravenous administration as follows:~Induction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22"
75784711|NCT05831540|Other|Educational Activity|Undergo training to use CDS tool
75784712|NCT05831540|Behavioral|Healthcare Activity|Utilize CDS tool
75328647|NCT02798380|Drug|HTS-519 Insert|Maximum feasible dose of HTS-519 Insert per diseased nail
75328648|NCT04377815|Other|General Public cohort|No intervention is being tested
75328649|NCT04355065|Behavioral|Cognitive Traning with The Secret Trail of Moon|Patients are pharmacologically stable and receive a cognitive intervention with our videogame once a week in the hospital.
75328650|NCT04355065|Behavioral|Cognitive Traning with Therapeutic Chess|This group is pharmacologically stable. This group performs cognitive training through a therapeutic chess protocol designed by a chess psychologist. The training is done from home and we contact them weekly to correct the exercises done and to follow up.
75328651|NCT04355065|Drug|Control Group|"These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group."
75469263|NCT01937104|Procedure|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
75784713|NCT05831540|Other|Survey Administration|Complete survey
75784714|NCT05824871|Drug|Sudapyridine|Two weeks of loading dose followed by twenty-two weeks of maintenance dose Drug: Background regimen (BR) for RR-TB Background regimen (BR) for RR-TB selected according to WHO and local guidelines for up to 72 weeks.
75784715|NCT05824871|Drug|Bedaquiline|"Two weeks of loading dose followed by twenty-two weeks of maintenance dose~Drug: Background regimen (BR) for RR-TB Background regimen (BR) for RR-TB selected according to WHO and local guidelines for up to 72 weeks."
76078134|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.
76078135|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.
76078136|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84
75784716|NCT05823142|Behavioral|CB Sleep|The CB-sleep intervention is a cognitive behavioral intervention guided by principles and practices from motivational interviewing and the psychology of behavior change, primarily drawing on self-efficacy and action planning theory. The goals of CB-sleep are for participants to achieve adequate sleep duration (7-9 hours per night), adequate sleep efficiency (≥ 85%), and regular sleep timing (<60-minute differences in bed and wake times). The intervention components include improving sleep knowledge (hygiene), developing a nightly routine, addressing competing activities, modifying environmental conditions, lifestyle (avoiding caffeine and vigorous exercise before bed), technology (limiting or avoiding screens for at least one hour before bed), basic stress-management (progressive muscle relaxation and guided imagery), and self- monitoring.
75784717|NCT05799872|Behavioral|Positive Affect Treatment for Anorexia Nervosa (PAT-AN):|PAT-AN is an adaptation of the cognitive-behavioral outpatient individual therapy for anhedonia (17, 68). The overarching aim of PAT-AN is to enhance reward sensitivity (reward anticipation, experiencing, and learning) to non-eating disorder experiences and to decrease or replace reward sensitivity to weight-loss experiences (26). PAT-AN includes 6 sequential modules, each designated to target specific reward sensitivity disturbances (26, 68). Homework and experiential practice during sessions are essential components of PAT-AN, and participants are provided a workbook to assist with this practice. During each session, collaborative homework review is followed by skill development and homework assignments.
75635287|NCT02799615|Drug|Infliximab|No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician
75784718|NCT05799872|Behavioral|Psychoeducational and Behavioral Therapy (PBT)|The comparison treatment is modeled off of educational and behavioral interventions used in prior clinical trials for AN and common elements of standard behavioral eating disorder treatments. The treatment is structured to parallel the modular format of PAT-AN.
75921118|NCT03525522|Drug|Topical corticosteroid Diprosone|3 months of topical corticosteroids Diprosone
75921119|NCT03228732|Drug|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
75921120|NCT03228732|Drug|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
75921121|NCT03228732|Drug|Fluoxetine|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
75635288|NCT04079907|Dietary Supplement|Ketone|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
75921122|NCT03228732|Drug|DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
75921123|NCT03228732|Drug|Fluoxetine and DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
75921124|NCT04466436|Other|tryptophan|measurement of tryptophan in serum
75921125|NCT04466514|Drug|ASTX029|Form: tablet; Route of Administration: oral
75921126|NCT04500834|Biological|Metal Panel T.R.U.E. Test|Diagnostic patch test
75921127|NCT04467450|Drug|botulinum toxin type A|ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
75635289|NCT04079907|Dietary Supplement|Placebo|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
75635290|NCT04036773|Dietary Supplement|Fruit and vegetable deliveries|Weekly home deliveries of approximately 15 pounds of fresh fruits & vegetables
75635291|NCT00819052|Drug|Nevirapine XR|Nevirapine XR
75635292|NCT00819052|Drug|Nevirapine XR|Nevirapine extended release
75635293|NCT00819052|Drug|Nevirapine IR|Nevirapine Immediate Release
75635294|NCT02799537|Other|Randomized clinical study|Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
75921128|NCT04467450|Drug|Methyl Prednisolonate|ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
75635295|NCT00763009|Drug|dipyridamole|0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
75921129|NCT03525366|Other|Radiofrequency ablation|Radiofrequency Ablation (RFA) as an intervention is part of standard of care at Memorial Herman Hospital, Houston.
75921130|NCT03008382|Drug|Metoprolol Tartrate Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
75635296|NCT04098757|Dietary Supplement|Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
75921131|NCT03008382|Drug|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
75328652|NCT03403127|Diagnostic Test|PET/CT Scans|PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).
75921132|NCT02137239|Drug|Thymoglobulin|
75921133|NCT02137239|Drug|Belatacept|
75328653|NCT02917642|Device|Ultrasonic Irrigation|Passive Ultrasonic Irrigation is based on the transmission of acoustic energy through the irrigant by a stainless steel wire or endodontic file
75328654|NCT02917642|Device|Non-Ultrasonic Irrigation|Syringe and needle irrigation with no-ultrasonic activation
75328655|NCT04364581|Drug|Letrozole|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
75469264|NCT01937104|Procedure|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
75469265|NCT01937143|Behavioral|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
75635297|NCT02799459|Procedure|General anaesthesia|the patient will receive a general anaesthesia do proceed at her conization
75921134|NCT02137239|Drug|mycophenolate mofetil(MMF)|
75921135|NCT02137239|Drug|Corticosteroids|
75328656|NCT04364581|Drug|Placebo|Women will be treated with placebo for 10 days before hysteroscopic intervention
75469266|NCT01937143|Behavioral|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant
75469267|NCT01937143|Behavioral|Control|General information about infant immunizations at birth of a newborn infant
75469268|NCT01937169|Behavioral|Motor Task|A motor task executed for 30 minutes after drug adminidtration
75635298|NCT02799459|Procedure|Hypnosis in conization|this is the experimental treatment which is allocated to the experimental group
75635299|NCT02803983|Procedure|Pediatric hip plate|Children were treated with pediatric hip plate.
75635300|NCT02803983|Procedure|Cannulated screw|Children were treated with cannulated screw.
75798597|NCT01175928|Device|NormaTec PCD (Peristaltic Pulse PCD)|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
75798598|NCT02525640|Device|Hearing Aid|Hearing aid comparison
75921136|NCT02137239|Drug|Everolimus(EVL)|
75921137|NCT02137239|Drug|Tacrolimus(TAC)|
75328657|NCT04363723|Other|Pulmonary Rehabilitation|Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.
75328658|NCT01049009|Drug|Nebivolol|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
75328659|NCT01049009|Drug|Metoprolol XL|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
75328660|NCT04363645|Other|Multicontext (MC) approach|The Multicontext approach is a metacognitive intervention designed to improve awareness, strategy use, and executive functioning.
75328661|NCT02918656|Other|Infographic presentation of health information|"The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs."
75328662|NCT02918656|Other|PLS presentation of health information|The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
75469269|NCT01937169|Drug|Levodopa tablet|
75469270|NCT01937169|Behavioral|Sham non-motor task|A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration
75469271|NCT01937169|Drug|Placebo pill|
75469272|NCT01937182|Drug|Citalopram|Citalopram 10-40 mg per day administered orally
75328663|NCT02918656|Other|Scientific abstract presentation of health information|The students in scientific abstract group will read the the text written for the academic population and practitioners.
75469273|NCT01937182|Drug|Placebo|1/2-2 tablets per day with no intrinsic drug activity
75469274|NCT01937208|Radiation|intensity modulated radiation therapy in both arms|
75469275|NCT01937208|Drug|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
75469276|NCT01937221|Other|spectral-domain optical coherence tomography (SD-OCT)|Intervention same to all groups.
75469277|NCT01937234|Drug|Metoclopramide|"Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses."
75798599|NCT01178346|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
75798600|NCT01178346|Biological|Placebo|Placebo vaccine given 6 times over 6 months
75798601|NCT01173822|Other|Ultrafiltration of residual blood|The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
75798602|NCT01286688|Drug|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
76078137|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
76078138|NCT03304587|Other|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
76078139|NCT03304587|Other|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
76078140|NCT03304587|Other|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
76078141|NCT03304587|Other|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
75635301|NCT02612350|Genetic|ctDNA Analysis for the Detection of Genetic Mutations|Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
75635302|NCT02805777|Device|CPAP mask|A new vent CPAP mask system will be used in this trial
75635303|NCT05477589|Drug|busulfan, cyclophosphamide and melphalan, BuCyMel|a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)
75784719|NCT05799586|Behavioral|Traditional Chinese Medicine health preservation group|The traditional Chinese medicine health preservation intervention for depression was developed based on a previous systematic review and meta-analysis of Traditional Chinese medicine based integrated health interventions for depression, traditional Chinese medicine health preservation textbooks, clinical practice guidelines related to traditional Chinese medicine health preservation and traditional Chinese medicine treatment for depression. The content and structure of traditional Chinese medicine health preservation for depression was achieved among Hong Kong traditional Chinese medicine experts via a Delphi study.
75921138|NCT05229354|Biological|TV005|The TV005 admixture is comprised of four monovalent dengue vaccine candidates representing each of the four DENV serotypes: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30.
75921139|NCT05229354|Biological|rDEN2Δ30-7169 attenuated virus strain|based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified
75921140|NCT05227794|Behavioral|Compassion Cultivation Training (CCT)|CCT is a secular, empirically supported 8-week program that integrates meditation practices, interactive discussions, and educational lectures to improve self-compassion and other-oriented compassion, emotion and stress management, and happiness and well-being. It includes a weekly 2-hour educational lecture with discussion and in-class exercises, a recommendation of 15-30 minutes of daily meditation, and real-world assignments to practice compassion. The program is taught by a certified instructor with more than 5 years experience.
76078142|NCT03304587|Other|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue & sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
76078143|NCT04352920|Other|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
75328664|NCT02850874|Procedure|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
75635304|NCT05477589|Drug|clofarabine, fludarabine and busulfan, CloFluBu|combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)
75784720|NCT05799586|Behavioral|Waitlist control group|Usual care
75784721|NCT05799495|Drug|PF-07817883|Arm 1: low dose Arm 2: medium dose Arm 3: high dose
75784722|NCT05799495|Drug|Placebo|Placebo
75798603|NCT01178424|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
75635305|NCT05758636|Behavioral|Emotional Freedom Technique|"Before starting the EFT session, the participants were asked to identify the problem that aroused their anxiety. After the common point of the problems was determined, the ORDS level of all participants was determined. Next, the EFT session explained traditional acupressure meridian points on the head, face, neck, chest, and hands. Next, they were asked to repeat the phrase, Even though I have this feeling of stress and anxiety, I accept myself deeply and completely, while gently applying to the acupuncture points with their index and middle fingers. While using this expression, the participants hit each acupuncture area seven times. After the first round of hits accompanied by this phrase, participants were asked to abbreviate this feeling of anxiety, stress with another short phrase. The participants then repeated rounds of this process until they noticed that their anxiety had decreased"
75784723|NCT05793255|Behavioral|Social Phone Calls|Following the collection of baseline data, the study participant will be randomly assigned to a student volunteer to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6weeks. Each phone call is expected to last around 1 hour with flexibility to be shorter or longer. The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer. If the stroke survivor and student volunteer wish to speak more than the designated one call a week, that will be allowed if both parties agree. The same student volunteer will conduct all six sessions
75784724|NCT05791201|Drug|VX-264|Allogeneic human stem cell-derived islets.
76078144|NCT05387356|Other|prone position|thirty-one patients who had a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. Medical datas of the patients will be obtained from patients' files which are strictly filled during pandemic. Prone position indication of intensive care unit (ICU) is in case of severe ARDS with PaO2/FiO2 <150 despite a PEEP >10 cmH2O.
76078145|NCT01888367|Drug|DFA-02 Antibiotic Gel|
75328665|NCT02850874|Procedure|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
75469278|NCT01937234|Drug|Placebo|"Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses."
75469279|NCT01937325|Drug|ivacaftor|active arm
75635306|NCT00841672|Drug|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
75635307|NCT00841672|Drug|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
75635308|NCT05549115|Drug|clarithromycin-sensitive(first-line)|esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
75635309|NCT05549115|Drug|clarithromycin-resistant(first-line)|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
75635310|NCT05549115|Drug|empirical therapy group first-line|esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
75635311|NCT05549115|Drug|levofloxacin-sensitive(rescue treatment)|esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
75635312|NCT05549115|Drug|levofloxacin-resistant(rescue treatment)|esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
75784725|NCT05776056|Drug|Methylphenidate|Methylphenidate 10mg will be taken twice daily.
75469280|NCT01937325|Drug|placebo|active arm
75784726|NCT05776056|Drug|Placebo|An inactive pill (placebo) will be taken twice daily.
75921141|NCT05227794|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|MBSR is among the most studied mindfulness-based interventions in the literature and is a secular, 8-week psycho-educational group-based intervention. The program structure (slightly modified to match CCT) includes a weekly 2-hour class, a prescription of 15-30-minutes of daily mindfulness practice, and a one-day optional retreat (6 hours) between week six and seven. The program is taught by a certified instructor with more than 5 years experience.
75635313|NCT05549115|Drug|empirical therapy group rescue treatment|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
75784727|NCT05772169|Drug|Mifepristone 300 MG [Korlym]|Mifepristone tablets for once daily oral dosing
75784728|NCT05772169|Drug|Placebo for mifepristone|Placebo tablets for once daily oral dosing
76078146|NCT01888367|Drug|DFA-02 Placebo Gel|
76078147|NCT05386732|Device|Micro needling|All patients were treated with a 16 needle, 3mm, 33-gauge surgical grade stainless steel needle cartridge. The operator began treatment using a depth of (1mm) and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occured, the minimum and maximum depth used to create pinpoint bleeding was recorded. The operator began treatment using a minimum depth of 1mm and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occurred.
75635314|NCT02805699|Drug|Baofeikang Granule|To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
75328666|NCT02850874|Drug|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
75635315|NCT02805699|Drug|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
75328667|NCT01047683|Drug|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
75635316|NCT04236219|Drug|ALLN-346|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
75635317|NCT04236219|Drug|Placebo|Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
75635318|NCT00908232|Drug|Cyclophosphamide|500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
75635319|NCT00908232|Drug|Bortezomib|1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
75635320|NCT00908232|Drug|Dexamethasone|20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
75635321|NCT00908232|Drug|Lenalidomide|10 mg orally daily, days 1-14 for cycles 5 to 8
75635322|NCT05545761|Other|music therapy|Feedback will be received via WhatsApp that the participants have listened to the maqam conveyed to them.Before applying music therapy in the experimental group, they will be asked to fill out the questionnaires.At the end of the music therapy application, the questionnaires made at the beginning will be applied to the experimental group again.No application will be made to the control group, and data collection forms will be applied twice with an interval of 4 weeks.
75635323|NCT00770341|Drug|Daptomycin 4 mg/kg|MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
75635324|NCT00770341|Drug|Comparator: vancomycin|vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
75635325|NCT00770341|Drug|Daptomycin 6 mg/kg|MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
75635326|NCT03813420|Behavioral|Pittsburgh Sleep Quality Index (PSQI)|"The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month. It has seven components as subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction.~Each component is scored from 0 to 3, and the Global Pittsburgh Quality of Sleep (PQS) score is the sum of the scores of the seven components that is between 0 and 21. The higher Global PQS scores indicate poor sleep quality and the cut off score for poor sleep is 5 and over."
76078148|NCT00988000|Other|telephone consultation|alternative to face to face consultation for new referrals
75784729|NCT05770102|Drug|Atezolizumab|"Adult participants will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric participants will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
75784730|NCT05770037|Drug|Alectinib|"Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
75784731|NCT05767658|Behavioral|Safe Sleep|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for infant safe sleep and b) an online community and social network of other pregnant WIC clients and new parents.
75784732|NCT05767658|Behavioral|Breastfeeding|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for breastfeeding and b) an online community and social network of other pregnant WIC clients and new parents.
75784733|NCT05767658|Behavioral|Early Brain Development and Parent-Child Relationships|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for early brain development and parent-child interactions (control intervention) and b) an online community and social network of other pregnant WIC clients and new parents.
75784734|NCT05762198|Device|Rezūm|In the REZUM arm, water vapour treatment is performed for all subjects under local anaesthesia.
75328668|NCT01047683|Drug|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
75328669|NCT01047683|Drug|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
75784735|NCT05762198|Device|TURP|In the TURP arm, all men will receive TURP operation under general or spinal anaesthesia
76078149|NCT00988000|Other|No intervention|no alternative to face to face consultation
76078150|NCT05343117|Drug|Palbociclib based-therapy as initial endocrine therapy|Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)
76078151|NCT05343117|Drug|Palbociclib based-therapy after chemotherapy|Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)
76078152|NCT01898195|Drug|Varenicline|Varenicline will be provided for three months.
76078153|NCT01898195|Behavioral|Text Message|Text messages will be developed twice daily for three months
75784736|NCT05755386|Drug|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
75784737|NCT05755386|Drug|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
76078154|NCT01898195|Behavioral|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
75921142|NCT04468152|Behavioral|Dietary habits and intake|Optical coherence tomography (OCT) withdrawals and central foveal thickness (CFT) evaluations of those included in the study were made by the doctor and directed to the dietician (researcher). The dietary intake of participants was assessed using a validated quantitative food frequency questionnaire (QFFQ) (21). The total food intake was then converted to total nutrient intake based on the food's nutrient profile. Standardized food recipes for Turkey and the Nutrition Information System (BEBIS) program, which is a food composition database for nutrient estimation, were used to determine the average daily energy and nutrient intake for each participant.
76078155|NCT04348071|Drug|Ruxolitinib|Participants will receive 10 mg ruxolitinib twice daily.
75635327|NCT03813420|Behavioral|International Physical Activity Questionnaire (IPAQ)|The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as low, moderate and vigorous physical activity that they engaged in during the last seven days prior to survey. Vigorous physical activity, defined by the questionnaire, referred to intense exercise that resulted in very rapid breathing and an elevated heart rate (e.g. intense weight lifting, aerobics, running, and cycling). Moderate physical activity was defined as less intense exercise that slightly heightened breathing and heart rate (e.g. less exertive cycling, fast walking, and light weight lifting).
75635328|NCT03813420|Behavioral|The Short Form 36 Health Survey (SF-36)|The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Additionally, the psychometric evaluation of the SF-36 generated two summary scores as the Mental Health Component Score and the Physical Health Component Score that the higher scores indicate better HRQOL.
75469281|NCT01937338|Drug|AZD7624|nebuliser solution; 20 mg/mL for inhalation
75784738|NCT05750056|Drug|lidocaine|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
76078156|NCT05242666|Diagnostic Test|3T MR Imaging of the cervical spinal cord|Patients will undergo either Magnetic Resonance Imaging of the Spinal Cord
75328670|NCT02919826|Behavioral|Adapted Dialectical Behaviour Therapy|12 weekly sessions of DBT group therapy
76078157|NCT05242666|Other|Positron Emission Tomography using [11C]PIB|Patients will undergo combination MRI/PET using a [11C]PIB radiotracer
75328671|NCT02920918|Drug|Canagliflozin|
75328672|NCT02920918|Drug|Sitagliptin|
75328673|NCT03403049|Radiation|Carbon Ion|Study subjects will receive carbon ion radiotherapy (CIRT), with daily fraction sizes of 3 GyE. The total CIRT dose will increase with each dose level. Subjects in dose level 1 and 2 will receive photon radiotherapy as well.
75328674|NCT03403049|Drug|Gemcitabine + Cisplatin|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
75341425|NCT01798472|Procedure|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
75469282|NCT01937338|Drug|Placebo|nebuliser solution for inhalation
75784739|NCT05750056|Drug|0.9% saline|Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
75784740|NCT05750056|Drug|Propofol|An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
75784741|NCT05750056|Drug|Sufentanil|Sufentail 0.1 ug/kg was administered for sedation induction.
75784742|NCT05741164|Procedure|Biopsy|Undergo tumor biopsy
75784743|NCT05741164|Procedure|Biospecimen Collection|Undergo blood sample collection
75784744|NCT05741164|Procedure|Computed Tomography|Undergo CT scan
76078158|NCT05242666|Other|3T MR Imaging of the Brain|3T MR Imaging of the Brain
76078159|NCT05242666|Other|7T MR Imaging of the Spinal Cord|7T MR Imaging of the Spinal Cord
75784745|NCT05741164|Biological|Pembrolizumab|Given IV
75784746|NCT05741164|Drug|Propranolol|Given PO
75784747|NCT05741164|Other|Questionnaire Administration|Ancillary studies
75798604|NCT01178424|Behavioral|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
76078160|NCT03696927|Device|Active Powered Prosthesis (APEX) for Spinal Cord Injury|The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
76078161|NCT01897727|Drug|Spironolactone|
75921143|NCT02137317|Device|LAPPE (locally adapted personal protective equipment)|"Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes."
76078162|NCT01897727|Drug|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
76078163|NCT04352998|Dietary Supplement|One dose pre-workout condition|one dose of a multi-ingredient pre-workout supplement
76078164|NCT04352998|Dietary Supplement|Two dose pre-workout condition|two doses of a multi-ingredient pre-workout supplement
75328675|NCT03403049|Drug|Gemcitabine + Capecitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
75784748|NCT05736692|Behavioral|Brief Sleep Intervention|A ~50-minute semi-structured intervention based on the behavioral sleep medicine literature, particularly for adolescent insomnia, focused on key elements that can be addressed in one session. Treatment elements include engaging motivation, goal setting, barrier identification, problem-solving, pre-planning, self-monitoring, and setting rewards. The interventionist will be sensitized to barriers to sleep quality and quantity particularly relevant during adolescence, including job/work, homework, and social obligations, use of nicotine and caffeine, and social media and electronic devices. The interventionist will converse primarily with the adolescent, but parents will remain in the room as a support in problem-solving and executing therapeutic plans.
75328676|NCT03403049|Drug|Gemcitabine + Erlotinib|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
75341426|NCT01798472|Procedure|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
75784749|NCT05732831|Drug|TNG462|TNG462, a selective PRMT5 inhibitor, will be administered orally
75784750|NCT05731973|Procedure|Intercostal nerve cryoablation|Intercostal nerve cryoablation is applied during Nuss procedure.
75784751|NCT05731973|Drug|Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Thoracic epidural is placed prior to Nuss procedure
75784752|NCT05731973|Drug|Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))|Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
75784753|NCT05731973|Drug|Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)|Opioids
75784754|NCT05728502|Drug|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
75784755|NCT05728502|Drug|Standard of Care (SoC)|Dosage at the discretion of the treating physician.
75784756|NCT05725902|Drug|Etavopivat|The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
75784757|NCT05724615|Behavioral|Outreach + Bulk ordering|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening.
75784758|NCT05724615|Behavioral|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening. They will also receive text messages to remind them to have their lab completed as well as a link to schedule the lab and inform them of walk-in hours.
75784759|NCT05722418|Biological|CB-011|CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
75921144|NCT03522792|Other|Neurotensin|Intravenous infusion of neurotensin
75921145|NCT03522792|Other|Saline|Intravenous infusion of saline
75921146|NCT03522792|Other|Ad libitum meal|Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
75921147|NCT03522792|Other|Liquid meal|A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
75921148|NCT02137395|Drug|Dexamethasone|dexamethasone administration, intravenously
75921149|NCT02137395|Drug|Placebo|saline administration intravenously
76078165|NCT04352998|Dietary Supplement|Placebo condition|one dose of a placebo
76078166|NCT05593744|Other|no intervention|This is an observational study so not involved intervention
76078167|NCT01897493|Drug|Evacetrapib|Administered orally
76078168|NCT01897493|Drug|Digoxin|Administered orally
76078169|NCT04353076|Other|Simulated heatwave exposure|Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.
76078170|NCT04353076|Other|Simulated heatwave exposure with mid-day cooling|Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
76078171|NCT03264027|Drug|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
75784760|NCT05721248|Other|Cessation of anti-HER2 treatment|Cessation of anti-HER2 treatment with standard treatment described as trastuzumab (Herceptin) with or without pertuzumab (Perjeta) continued as long as it is working or significant side effects occur.
75921150|NCT02137551|Other|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
75921151|NCT02137629|Drug|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
75921152|NCT02137707|Drug|Gilenya|All patients will receive Gilenya
75921153|NCT02253381|Procedure|Right|Right lateral decubitus position during spinal anesthesia
75921154|NCT02253381|Procedure|Left|Left lateral decubitus position during spinal anesthesia
75921155|NCT04252014|Behavioral|Hookah tobacco messages|Messages communicating the risks of hookah tobacco use in 4 thematic areas: health harms, addictiveness, social use, flavorings.
75921156|NCT02261025|Drug|acetylsalicylic acid|75-100mg,per day
75921157|NCT05579067|Procedure|ACL Reconstruction using an autograph of the peroneus longus tendon, folded twice.|The use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
75328677|NCT03403049|Drug|Gemcitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
75328678|NCT03403049|Radiation|Photon|During this study, the prescribed dose shall be administered according to the dose escalation shown in the table, starting with dose level 1. The carbon ion dose shall be gradually escalated while gradually reducing the dose of photons until eventually administering a full dose of 56 GyE/14 Fx carbon ions (fractional dose of 4 GyE). Dose escalation will be performed in parallel for two patient groups: patients whose pancreatic tumors are greater than 5 mm from the duodenum (Group A) and those whose tumors are within 5 mm of the duodenum (Group B). Enrolled patients will be monitored for 90 days after radiotherapy starts for any acute toxic reaction and to explore the maximum tolerated dose, in addition to being observed for any related long-term toxic reactions in accordance with the protocol.
75328679|NCT00944047|Drug|nab-paclitaxel|100 MG/M2 IV over 30 minutes once a week for 12 weeks
75921158|NCT05579067|Procedure|ACL Reconstruction using an autograph of Hamstrings muscle tendons.|The use of Hamstring muscle tendon autograft (Semitendinus and slender muscle) taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
75921159|NCT05578989|Device|Virtual reality glasses|watching a video with music with virtual reality glasses.
75921160|NCT05578833|Diagnostic Test|HPV DNA test with selective HPV 16/18 genotyping (cobas® 4800 HPV Test, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
75328680|NCT00944047|Drug|trastuzumab|4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
75328681|NCT00944047|Drug|Doxorubicin|60 MG/M2 every two weeks for a total of 4 cycles
75635329|NCT02803905|Biological|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
75784761|NCT05718583|Dietary Supplement|Butyrate|"Participants will self-administer the oral Short Chain Fatty Acid (SCFA) Butyrate supplement three times daily with meals for up to 2 months. The minimum duration necessary for an evaluable participant will be 2 weeks of SCFA supplementation."
75784763|NCT05704361|Drug|RO7121932|Participants will receive a single dose of RO7121932 administered as IV infusion.
75784764|NCT05702229|Drug|Rilvegostomig|an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion
75921161|NCT05578833|Diagnostic Test|p16 and Ki-67 biomarker detection in the form of dual cytological staining (CINtec Plus, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
76078172|NCT03264027|Drug|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
75784765|NCT05702229|Drug|Volrustomig|an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion
75784766|NCT05702229|Drug|FOLFOX|5-fluorouracil 400 mg/m^2 IV, oxaliplatin 85 mg/m^2, leucovorin 400 mg/m^2 (or levoleucovorin 200 mg/m^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m^2 IV 24 h day 1-2
75784767|NCT05702229|Drug|XELOX|capecitabine 1000 mg/m^2 BID, days 1 to 14, oxaliplatin 130 mg/m^2, day 1
76078173|NCT03264027|Drug|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
76078174|NCT04415411|Other|Nursing care based on the Theory of Human Caring|Planned nursing care based on 10 caritas processes of Theory of Human Caring.
75635330|NCT02601547|Device|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
76078175|NCT01887353|Drug|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
76078176|NCT01887353|Drug|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
76078177|NCT05352711|Device|active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand con|VR is mainly created by generating visual effects through head-mounted display (HMD) systems. An HMD is a device worn on the head or as part of a helmet with a built-in display and lenses, allowing the user to experience the virtual world with the help of a wide viewing angle, head and hand movements tracking as well as objects interacting by controllers.
75784768|NCT05702229|Drug|AZD7789|an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion
75784769|NCT05702229|Drug|AZD0901|an anti Claudin18.2 ADC; IV infusion
75784770|NCT05702229|Drug|5-Fluorouracil|5-FU, IV infusion, Q3W
75921162|NCT05578833|Diagnostic Test|standard conventional cytology PAP test|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
76078178|NCT05352711|Other|active assisted range of motion exercise|Patients were treated active assisted ROM physical therapy 2 sessions per week for 4 weeks.
75328682|NCT00944047|Drug|cyclophosphamide|600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
75921163|NCT03527082|Other|Questionnaire|"Questionnaire of 20 items evaluating attitudes and perception of mesh use in gynaecological surgery. Questionnaire will take 10 minutes to complete. For non-English speaking patients a translator will be sought, where feasible to help women complete the questionnaire.~Participation will be entirely voluntary and also the questionnaire will be piloted to ensure that questions asked are clear and concise. Questionnaire is anonymised and does not contain patient identifying information thereby eliminating breach of confidentiality."
75784771|NCT05702229|Drug|Capecitabine|Oral take, Q3W
75784772|NCT05701995|Drug|Deucravacitinib|Specified dose on specified days.
75784773|NCT05701995|Other|Placebo|Specified dose on specified days.
76078179|NCT00988156|Drug|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
75328683|NCT00944047|Biological|Growth Factor Support|"All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.~Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician."
75635331|NCT02804217|Other|Genetic: mutation profile|
75635332|NCT02691000|Device|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
75635333|NCT02691000|Device|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
75784774|NCT05688111|Drug|Tranexamic acid injection|Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours
75784775|NCT05688111|Other|Glucose water 5%|Placebo group 30ml will be received 12 hourly for 48 hours
75784776|NCT05687344|Drug|Nifedipine ER|Postpartum BP treatment to <140/90 mmHg
75784777|NCT05686551|Drug|Tominersen 60 mg|60 mg tominersen administered intrathecally every 16 weeks
75784778|NCT05686551|Drug|Placebo|Matching placebo administered intrathecally every 16 weeks
75784779|NCT05686551|Drug|Tominersen 100 mg|100 mg tominersen administered intrathecally every 16 weeks
75784780|NCT05685303|Device|Alleviant ALV1 System|Creation of interatrial shunt
75784781|NCT05685303|Other|Sham-Control|Cardiac imaging
75784782|NCT05678634|Behavioral|Declarative learning with immediate feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 500 ms following a response (button press)
75784783|NCT05678634|Behavioral|Declarative learning with delayed feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 5000 ms following a response (button press)
75798605|NCT03859518|Other|blood and skin samples|To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
75921164|NCT02137863|Drug|Dexmedetomidine|"Intravenously 1μg/kg/10min administered just before the procedure.~1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography."
76078180|NCT00988156|Drug|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
76078181|NCT02160730|Drug|R-roscovitine|See Arm Description
76078182|NCT01896869|Drug|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
76078183|NCT01896869|Biological|Vaccine|5x10^8 cells administered in 6 intradermal injections
76078184|NCT01896869|Drug|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
76078185|NCT03329001|Drug|Niraparib Tablet|Niraparib tablet formulation
75635334|NCT04097041|Procedure|Tympanomastoidectomy|Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).
75635335|NCT04097041|Procedure|Non-Surgery|"Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing."
75635336|NCT04236687|Device|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
75784784|NCT05678634|Behavioral|Probabilistic learning with immediate feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 500 ms following a response (button press)
75784785|NCT05678634|Behavioral|Probabilistic learning with delayed feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 5000 ms following a response (button press)
75784786|NCT05678634|Behavioral|Word learning task with active feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names through trial and error guided by feedback. Each response will be followed by feedback either indicating that the response is correct or prompting the child to try again (i.e., to correct an error)
75921165|NCT02137863|Drug|0.9 % NaCl|During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
75784787|NCT05678634|Behavioral|Word learning task with passive feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names. Regardless of response accuracy on each trial, each response will be followed by a visual presentation of the correct response.
75798606|NCT03863028|Other|Simulation training|It is not a randomized trial - all three groups are exposed to simulation training.
75798607|NCT01176084|Behavioral|low carbohydrate diet|
76078186|NCT03329001|Drug|Niraparib Capsule|Niraparib capsule formulation
76078187|NCT04872465|Device|TBS|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
76078188|NCT04872465|Device|sham|Participants will receive sham (placebo) TBS treatment the same as experimental group
76078189|NCT01896557|Drug|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
75328684|NCT00944047|Procedure|Surgery|"After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.~All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection."
75798608|NCT01176084|Behavioral|low carbohydrate diet and exercise|
75798609|NCT01173900|Biological|Gardasil® HPV vaccine|0.5 ml given at 0, 2, 6 months
75328685|NCT03402971|Diagnostic Test|echocardiography|echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
75328686|NCT02921386|Drug|Oral Testosterone Undecanoate|All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
75635337|NCT04236687|Procedure|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate
75921166|NCT02137863|Drug|0.9 % NaCl|"100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure"
75921167|NCT02137941|Behavioral|techniques to optimize potential (TOP)|The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
76078190|NCT01896557|Drug|Ranitidine|Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
76078191|NCT01896557|Drug|Clopidogrel|Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
76078192|NCT02160808|Drug|Secretin|Drug to stimulate pancreatic secretion
76078193|NCT02160808|Drug|Placebo|
76078194|NCT01886105|Drug|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
76078195|NCT01886105|Other|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
76078196|NCT01886105|Radiation|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
75635338|NCT02803827|Other|Rapid diagnostics|Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
76078197|NCT03327909|Behavioral|TAKE vs. HOLD|All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
75784788|NCT05677269|Procedure|Laparoscopic excision of endometriosis, including colorectal endometriosis|Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.
76078198|NCT00989014|Drug|CD07805/47|0.5% Topical Gel
75784789|NCT05677269|Procedure|In vitro fertilisation or intracytoplasmic sperm injection|IVF/ICSI treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill. One IVF/ICSI cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.
75635339|NCT02803827|Biological|Probiotic|The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
75635340|NCT02803827|Other|Placebo|The placebo will be the vegetable oil vehicle and look identical to the probiotic.
75635341|NCT02799303|Device|Multi-parametric MRI|Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
75635342|NCT02799303|Other|PSA testing|Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
75784790|NCT05675046|Device|Ultrasound Guided Carpal Tunnel Release (CTR-US)|The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically < 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.
75784791|NCT05654220|Behavioral|Text Messaging Intervention|A text messaging intervention will be conducted that includes prompts to call trained BenePhilly enrollment specialists to submit applications for benefits programs. Text message prompts will be sent on days 2, 4, 7, 14, and 21 post-discharge from a Penn Medicine emergency department.
75784792|NCT05654116|Behavioral|Caregiver Interaction Profile (CIP) training|The CIP training aims to boost six interactive skills in daycare providers: sensitive responsiveness, respect for children's autonomy, structuring and limit setting, verbal communication, developmental stimulation, and fostering positive peer interactions. The training takes place with 1 or 2 daycare providers at a time, and consists of 5 or 6 weekly sessions, respectively. In individual trainings, sessions 1-3 focus on two skills each, session 4 is a recap of two skills the daycare provider chooses, and the final session is shared with a colleague. In pairwise sessions, session 1 focuses on the first two skills, sessions 2-5 each focus on one skill, and the last session serves as a recap of two skills the daycare providers choose. The training uses a video-feedback method: daycare providers are filmed in interactions with children in daycare, the CIP trainer preselects relevant fragments of video recordings to discuss with the daycare provider(s) during the training sessions.
75784793|NCT05649969|Behavioral|Consultations with Moffitt Dietician|Participants will have an initial consultation with a dietician and then biweekly follow-up visits (in person or virtually) for 12 weeks.
75784794|NCT05649969|Behavioral|Daily Food Intake Diary with Fitbit smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone application and wear a Fitbit for 12 weeks
75784795|NCT05649969|Behavioral|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at week 4, 8, 12 and 16.
75784796|NCT05644977|Drug|Emraclidine|Oral tablets
75784797|NCT05644977|Drug|Placebo|Oral tablets
76078199|NCT00989014|Drug|CD07805/47|0.18% Topical Gel
76078200|NCT00989014|Drug|CD07805/47|0.07% Topical Gel
76078201|NCT00989014|Drug|CD07805/47 placebo|Vehicle Topical Gel
76078202|NCT05095012|Other|Pediatric Acute Care Concussion Clinical Pathway|MD assessment will be partially standardized to assess for patients at higher risk of becoming persistently symptomatic. These patients scoring as 'high risk' will be referred to one of three specialty clinics. High risk is defined as scoring 9 or higher out of 12 on the 5P score.
76078203|NCT03262779|Biological|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
75635343|NCT03793608|Drug|Dupilumab|Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)
75784798|NCT05643235|Device|Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)|Patients initiating BTK inhibitors will be offered the option of monitoring using the Medtronic Insertable Cardiac Monitor (ILR). The device will be implanted by a certified and credentialed electrophysiologist to enable monitoring to begin at least 24 hours prior to the first administration of the BTK inhibitor. Monitoring data will be collected prospectively until the patient withdraws consent, the device is removed, or up to 60 months
75635344|NCT02798991|Drug|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
75784799|NCT05643066|Drug|0.1 mg/kg esketamine|Esketamine 0.1 mg/kg was intravenously injected first.
75784800|NCT05643066|Drug|0.2 mg/kg esketamine|Esketamine 0.2 mg/kg was intravenously injected first.
75784801|NCT05643066|Drug|0.9% saline|0.9% saline was intravenously injected first.
75784802|NCT05643066|Drug|Propofol|Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
75784803|NCT05642000|Behavioral|SASEA HUB|SASEA HUB website, an intervention tool to increase COVID-19 testing
75784804|NCT05632757|Behavioral|Psychological assessments|The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.
75784805|NCT05632575|Behavioral|Virtual Promotoras Program|"Participants will receive a unique participant code from the virtual promotoras (i.e., patient educators and navigators), to access the VIP mobile phone app intervention. This will give them access to the three main components of the VIP intervention:~Educational Modules (8 evidence-based educational modules made by the VPs),~Sexual and Reproductive Health Plan (SRHP): Quiz-style instrument to help the participant set goals for her sexual health and develop a set of questions to ask her provider.~Virtual Promotora's (VP) chat room.: Opportunity for participant to ask any questions that she may have about sexual health (SH) or sexual healthcare access (SHCA), refine her SRHP. The VP will also help her make her appointment for her clinical visit with one of the local free clinics which do not require insurance and are youth-friendly, and practice having the conversation that she wants to have with her clinical provider."
75784806|NCT05630066|Drug|60 mg QD Alogabat|"Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.~I"
75784807|NCT05630066|Drug|40 mg QD Alogabat|Participants aged 10-14 years receiving the equivalent of the adult 60 mg alogabat dose.
75784808|NCT05630066|Drug|7 mg QD Alogabat|Participants aged 5-9 years receiving the equivalent of the adult 20 mg alogabat dose.
75784809|NCT05630066|Drug|Part 2 Adult Alogabat High Dose (aged 15-17)|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
75784810|NCT05630066|Drug|Alogabat|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
75921168|NCT02137941|Behavioral|heart coherence (HC)|The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
75921169|NCT02133729|Other|Blood sampling and OGTT|
75921170|NCT03522558|Behavioral|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
75921171|NCT03522558|Behavioral|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
75921172|NCT02138019|Procedure|Fibrin Glue assisted external eye surgery|
76078204|NCT05593120|Diagnostic Test|CT-FFR|"In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR. In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels. CT-FFR will be evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour. The data derived from this test will determine their management strategy."
75784811|NCT05630066|Drug|Alogabat|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, additional participants may be recruited in any of the of the 3 age-groups in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2."
75635345|NCT02798991|Drug|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
75635346|NCT03787836|Behavioral|Maintained Exercise|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
75921173|NCT02138019|Device|Fibrin glue|
75921174|NCT02252757|Device|CoVa|
75921175|NCT02133807|Procedure|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
75328687|NCT03402815|Drug|Maraviroc 300 mg|Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.
75328688|NCT02245555|Drug|Tamsulosin|
75328689|NCT03402737|Radiation|Stereotactic body radiotherapy|"The range of dose-painting will be escalated in following levels:~2x 6-8Gy (day 1-4)~3x 6-8Gy (day 1-4-7)~3x 6-10Gy (day 1-4-7)~3x 6-12Gy (day 1-4-7)~Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks.~Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide."
75328690|NCT04378673|Other|not interventional|This randomized controlled trial included data from 120 cases in the pediatric health and diseases department.
75635347|NCT03787836|Behavioral|Increased Intensity|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
75635348|NCT05472753|Dietary Supplement|Experimental Treatment, DCOOP Product, Hydroxytyrosol extract|Intervention group will receive a nutritional formula from DCOOP (Spain).
75635349|NCT05472753|Dietary Supplement|Experimental Treatment,Indukern product, Curcumin and selenium extract|Intervention group will receive a nutritional formula from Indukern (Spain).
75784812|NCT05630066|Drug|Part 2 Optional Cohort|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, participants from any of the 3 age-groups may enroll in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2"
75784813|NCT05627245|Drug|Belinostat|Given IV
75784814|NCT05627245|Procedure|Biopsy|Undergo biopsy
75784815|NCT05627245|Procedure|Biospecimen Collection|Undergo blood sample collection
75784816|NCT05627245|Procedure|Computed Tomography|Undergo CT scan
75784817|NCT05627245|Other|Pharmacokinetic Study|Pharmacokinetic study
75784818|NCT05627245|Procedure|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT
75784819|NCT05627245|Drug|Tazemetostat|Given PO
75784820|NCT05627232|Drug|Tazemetostat|Given PO
75784821|NCT05627232|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
75921176|NCT02138331|Biological|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
75921177|NCT02133885|Drug|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
75921178|NCT02133885|Other|Placebo Group|These subjects will start with placebo (tablet looking just like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
75921179|NCT05578521|Drug|Cerebralcare pills|a dose of 2 packages, twice a day of Cerebralcare pills
75921180|NCT05578521|Drug|Cerebralcare pills placebo|Cerebralcare pills placebo will be administrated at the same rate with experimental group
75921181|NCT03548649|Device|exoskeleton robot training|subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
75921182|NCT02138409|Drug|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
75921183|NCT02138409|Drug|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
75784822|NCT05627232|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
75784823|NCT05627232|Procedure|Biospecimen Collection|Undergo blood sample collection
75921184|NCT02138487|Other|liberal postoperative activity|Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.
75921185|NCT02138487|Other|Restricted postoperative activity|Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
75921186|NCT02134041|Other|traumatic brain injury|mild TBI, GCS >/=13 after traumatic brain injury
75328691|NCT03904771|Behavioral|Nutrition counselling + peer support|Behavioral nutrition counselling and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by a nutrition therapist.
75328692|NCT03904771|Behavioral|Social activation + peer support|Social activation and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by group leader.
75784824|NCT05627232|Drug|Palbociclib|Given PO
75784825|NCT05614102|Drug|BAY2965501|Daily oral application
75635350|NCT05472753|Other|Control Treatment|Control group will receive a placebo (product loading substance)
75784826|NCT05614102|Drug|Pembrolizumab|In combination group 200mg as infusion every 3 weeks
75784827|NCT05595642|Drug|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W
75784828|NCT05595642|Drug|Placebo|Participants will receive SC placebo Q2W
75784829|NCT05592223|Drug|BCG Vaccine USP|2x10^6 cfu Tice® BCG (ID)
75784830|NCT05592223|Drug|Isoniazid|INH in the dose of 300 mg for three days post BCG injection.
75784831|NCT05592223|Drug|Rifampin|RIF in the dose of 600 mg for seven days post BCG injection.
75921187|NCT02134197|Drug|Lupartumab Amadotin (BAY1129980)|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
75921188|NCT02138565|Procedure|Gastric by-pass surgery|
75635351|NCT02799147|Procedure|Allogeneic stem cell transplantation|
75921189|NCT02138643|Procedure|Endoscopic surgery|These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
76078205|NCT05593120|Diagnostic Test|Routine care|All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital. The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
75328693|NCT01724801|Radiation|whole brain radiation(WBI)|WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
75635352|NCT02799147|Drug|Fludarabine monophosphate|
75635353|NCT02799147|Drug|Busulfan|
75635354|NCT02799147|Drug|Bendamustine|
75635355|NCT03394326|Behavioral|family-based obesity prevention lifestyle intervention|A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
75635356|NCT02798913|Drug|Short DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
75328694|NCT01724801|Drug|Icotinib|administered orally at a dose of 125 mg 3 times daily
75635357|NCT02798913|Drug|Long DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
75635358|NCT03388476|Diagnostic Test|Capnography|Measuring of the exhaled air, especially endtidal co2, through capnography.
75328695|NCT04354441|Drug|hydroxychloroquine sulfate 200 MG|Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days. Participants will be couriered the medication upon giving consent and will start taking the medication immediately.
75328696|NCT04354441|Drug|Placebo oral tablet|Placebo that is identical in appearance to the study medication will be taken twice a day for 10 days. It will be couriered to participants upon giving consent. They will start taking the medication immediately.
75784832|NCT05590689|Drug|Gliolan|A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)
75784833|NCT05590689|Radiation|Radiodynamic therapy|Radiotherapy will be performed in combination with Gliolan administration
75784834|NCT05588102|Drug|Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）|Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)
75784835|NCT05587764|Diagnostic Test|Standard of Care|Standard of care for emergency events per local guidelines.
75784836|NCT05582811|Drug|Dose Riociguat 2,5 or 5mg|A selective stimulator of soluble guanylate cyclase (sGC)
75784837|NCT05582811|Drug|Riociguat|A selective stimulator of soluble guanylate cyclase (sGC)
75784838|NCT05582811|Drug|Placebo|Placebo
75328697|NCT04378595|Other|During COVID-19 Pandemic|Assessing status of food insecurity during the COVID-19 pandemic
75328698|NCT04378595|Other|After COVID-19 Pandemic|Assessing status of food insecurity after the COVID-19 pandemic
75328699|NCT02802514|Drug|Albiglutide 50mg|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
75784839|NCT05562934|Biological|Experimental drug|SC injection
75921190|NCT02138643|Procedure|Laparoscopic surgery|These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
76078206|NCT03262467|Procedure|Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)|In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
75328700|NCT02802514|Drug|Albiglutide matching placebo|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm
76078207|NCT00990964|Device|Attain Success Lead|Attain Success Lead
75635359|NCT02805543|Device|Color doppler imaging|
75635360|NCT04016025|Behavioral|Adherence to topical standard therapy assessed|Adherence defined as percentage of patients applying at least aimed daily dose
75635361|NCT03327636|Device|Echopulse|This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
75635362|NCT05331924|Procedure|IPL therapy|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
75635363|NCT05331924|Procedure|Punctal plugs|Silicone punctal plugs are small pieces of silicone designed to block tear drainage through occluding the lacrimal punctum.
75635364|NCT02805387|Dietary Supplement|Treatment|Bicarbonate was ingested
75635365|NCT05333094|Other|Brackets|"Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)"
75635366|NCT00762463|Drug|Celecoxib|capsule, 200 mg QD, 6-12 weeks
75635367|NCT00762463|Drug|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
75635368|NCT02805465|Device|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
75635369|NCT02805465|Device|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
75784840|NCT05562934|Other|Placebo|SC injection
75921191|NCT02138799|Drug|enzalutamide|oral
75921192|NCT02138799|Drug|rifampin|oral
75921193|NCT02138877|Procedure|After coming stent after dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.
75921194|NCT02138877|Procedure|Stentless dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. No stents are inserted
75635370|NCT03638700|Device|VisiGlide™ angled tip|Arm A: Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
75921195|NCT02134275|Behavioral|Whole body vibration training|Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.
75921196|NCT02134275|Behavioral|Control group|Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
75328701|NCT02802514|Drug|Exenatide 10microgram|It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
75328702|NCT02802514|Drug|Exenatide placebo (saline)|It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
75328703|NCT00944671|Drug|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
75328704|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
75328705|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
75328706|NCT03875131|Other|Biomarkers of Dementia and Cognitive Decline|"Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.~The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.~Mini-Mental Status Evaluation~Hachinski Ischemic Scale~Cognitive Subscale of Alzheimer's Disease Assessment Scale~Disability Assessment for dementia~Quality of life improvement as assessed by:~Minnesota Living with Heart Failure Scale~Anti-Clot Treatment Scale (ACTS) Quality of Life Survey"
75635371|NCT03638700|Device|VisiGlide2™ angled tip|Arm B: Primary use of VisiGlide2™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (straight tip) resp. to VisiGlide™ (tip according to the examiner)
75635372|NCT03638700|Device|VisiGlide™ straight tip|Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
75635373|NCT03638700|Device|VisiGlide2™ straight tip|Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
75635374|NCT00762385|Device|galyfilcon A|galyfilcon A
75784841|NCT05562245|Other|Motivational Interviewing-Based Breastfeeding Education|"Motivational interviewing is basically a directive and client-centered psychosocial intervention used to help individuals discover and analyze ambivalent emotions related to their health behaviors, to learn new skills and to improve their existing skills. One of the main guiding principles in motivational interviewing is self-support and empowerment. The interviews consist of one to four sessions lasting between 7.5-60 minutes.~A total of four motivational interviews will be held with the mothers in the experimental group."
75784842|NCT05560750|Procedure|Frenotomy|Releasing the tongue-tie with scissors
75784843|NCT05560750|Procedure|Oral physiotherapy|Gentle parental activation of the mouth area and the tongue for 1 month
75328707|NCT02922868|Device|EndoSheath CST-5000 Scope|Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.
75921197|NCT02975271|Drug|Serlopitant|
75328708|NCT02922868|Device|Olympus Visera Elite OTV-S190 Scope|Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
75328709|NCT00944749|Drug|h-ATG (ATGAM )|
75328710|NCT00944749|Drug|Cyclosporine (Gengraf )|
75328711|NCT02763202|Other|CHS Transition Services|"The CHS Transition Services (CHS-TS) pathway includes the following seven components:~(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge"
75921198|NCT02975271|Drug|Placebo|Matching placebo
75921199|NCT02741076|Drug|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
75341427|NCT01798472|Procedure|uncemented hemiarthroplasty|"Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel."
75635375|NCT00762385|Device|comfilcon A|comfilcon A
75921200|NCT02741076|Drug|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
75328712|NCT01047293|Drug|RAD001|"RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~Directly on the tumor cells by inhibiting tumor cell growth and proliferation~Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells."
75921201|NCT02973633|Device|Diffusion Tensor MRI (DTI)|Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
75921202|NCT02973633|Drug|Gadolinium DOTA Meglumine|Late Gadolinium enhancement
75635376|NCT00906282|Drug|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
75469283|NCT01937416|Biological|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
75784844|NCT05554627|Drug|Esketamine|Intranasal spray; a dissociative hallucinogen drug used as a general anesthetic and an antidepressant for treatment of depression.
75784845|NCT05554627|Drug|Aripiprazole|Atypical antipsychotic; used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. Taken by mouth or injection into a muscle.
75784846|NCT05554159|Behavioral|Standard Fitbit Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
75784847|NCT05554159|Behavioral|Virtual Exercise Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
75784848|NCT05550714|Drug|general anesthesia|The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.
75921203|NCT02139033|Drug|Retaine™|
75469284|NCT01937429|Device|Colonoscopy with blue Indigo Carmin®|
75469285|NCT01937429|Device|Standard colonoscopy with insufflation of air|
75921204|NCT01666444|Drug|pegylated liposomal doxorubicin (PLD)|
75921205|NCT01666444|Drug|VTX-2337|TLR8 Agonist
75921206|NCT01666444|Drug|Placebo|
75921207|NCT02134431|Device|flexible sigmoidoscopy or colonoscopy with biopsies|Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
75921208|NCT02253225|Other|Functional Magnetic Resonance Imaging (fMRI)|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
75921209|NCT02134509|Behavioral|Experimental App|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules
75635377|NCT00906282|Drug|Carboplatin|AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
75635378|NCT02798445|Other|TAPIRS|Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
75635379|NCT02798445|Other|CONTROL|Multilayer bandages and wound care
75921210|NCT02134509|Behavioral|Active Comparator App|It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
75469286|NCT01937442|Drug|Thalidomide Celgene™|200mg once daily and by mouth
75469287|NCT01937455|Biological|rAAV1-PG9DP|4x10^12 vg administered intramuscularly
75635380|NCT02798757|Drug|Dapagliflozin|Urine samples will be collected for 1HNMR spectroscopies
75635381|NCT04100863|Other|No Intervention|There is no intervention for this study.
75635382|NCT05200806|Other|Non-Narcotic ERAS Post-Operative Pain Management|As described previously.
75635383|NCT02798367|Behavioral|CBT-I plus placebo|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
75635384|NCT02798367|Drug|CBT-I plus Melatonin 3 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
75635385|NCT02798367|Drug|CBT-I plus Melatonin 5 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
75635386|NCT00762229|Drug|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
75635387|NCT00762229|Drug|Ezetimibe 5 mg|"Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half"
76078208|NCT03299751|Biological|Diagnostic performances of biomarkers combination|"A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.~The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results."
75784849|NCT05550714|Drug|Conscious sedation|A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
75784850|NCT05546866|Drug|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
76078209|NCT05022394|Biological|Nivolumab|Given IV
76078210|NCT05022394|Drug|Sapanisertib|Given PO
76078211|NCT01895777|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
76078212|NCT01895777|Drug|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
76078213|NCT05005936|Procedure|Ultrasonography|Undergo ABUS
76078214|NCT05005936|Procedure|Ultrasonography|Undergo WBUS
75328713|NCT01047293|Drug|FOLFOX|FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
75328714|NCT01047293|Drug|Bevacizumab|Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
75328715|NCT01045967|Drug|Lansoprazole|30 mg delayed-release Capsule
75328716|NCT01045967|Drug|Prevacid®|30 mg delayed-release Capsule
75328717|NCT02808052|Drug|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
75635388|NCT00907374|Drug|benazepril|benazepril 10 mg orally once daily
75635389|NCT00907374|Drug|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
75635390|NCT02805153|Drug|PEG-rhG-CSF|
75328718|NCT01724957|Procedure|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
75328719|NCT03402581|Device|c-mac laryngoscope|type of laryngoscopes
75328720|NCT02808130|Other|hyperlipidemia, periodontitis, gingivitis|GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
75635391|NCT02805153|Drug|rhG-CSF|
75635392|NCT04096339|Other|Colonoscopy followed by EGD|Colonoscopy is done first followed by EGD
75635393|NCT04096339|Other|EGD followed by Colonoscopy|Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
75635394|NCT04100707|Procedure|Genicular block was applied|This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
75635395|NCT02805231|Other|Vitamin D receptor polymorphic analysis|
75635396|NCT02803671|Device|TFU-NIRS|
75635397|NCT02803671|Device|NIRS|
75635398|NCT02803671|Device|EEG|
75635399|NCT02805075|Other|Fructooligosaccharide|Given PO
75635400|NCT02805075|Other|Laboratory Biomarker Analysis|Correlative studies
75635401|NCT02803515|Biological|peripheral venous blood samples|peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
75784851|NCT05537753|Device|Encore PFO closure device|The Encore PFO closure device comprises an implant component and a single-use delivery system.
75784852|NCT05537753|Device|FDA-approved PFO closure device|Chosen by the investigator
75784853|NCT05536037|Drug|Metformin|Given PO
75784854|NCT05536037|Procedure|Biopsy|Undergo biopsy
75784855|NCT05518032|Procedure|Biopsy|Undergo biopsy
75784856|NCT05518032|Biological|Pembrolizumab|Given IV
75784857|NCT05518032|Biological|Therapeutic Autologous Dendritic Cells|Given intratumorally
75784858|NCT05508074|Drug|IFB-088 50mg/day|Tested product
75784859|NCT05508074|Drug|Placebo|Placebo
75784860|NCT05508074|Drug|Riluzole 100mg/day|Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo
75784861|NCT05503550|Drug|Talquetamab|Talquetamab will be administered subcutaneously (SC).
75784862|NCT05503056|Other|art therapy|six sessions of art therapy with licensed therapists
75784863|NCT05503056|Other|nothing|no intervention to this group
75784864|NCT05496374|Drug|Placebo|Placebo-matching capsules will be administered orally.
75921211|NCT05159622|Behavioral|Water Up! at Home|1: Addressing physical barriers to replace SSB with water at home: Participants will receive a personal, reusable bottle of water, a National Sanitation Foundation-certified water filter pitcher and one additional filter cartridge 2: Addressing sociocultural barriers to change individual perceptions: The curriculum has 6 topics delivered in 12 sessions: a) water for your health (diabetes/obesity among Latinos); b) health benefits of water vs. SSB, c) sugar content of SSB, d) safety & affordability of filtered tap water vs. bottled beverages, e) access and promotion of SSB vs. water in your community, f) tips for improving water taste, perceived susceptibility, severity, costs and benefits. 3: Addressing sociocultural barriers to increase skills: During each session, participants will be asked to perform hands-on learning activities (e.g., measure sugar content in SSB, take pictures of themselves explaining to their family members the key messages of various lessons).
76078215|NCT03291951|Behavioral|Resistance training|The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
76078216|NCT00992602|Drug|methotrexate|Given IV
76078217|NCT00992602|Drug|liposomal cytarabine|Given IT or via LP
75469288|NCT01937455|Biological|rAAV1-PG9DP|4x10^13 vg administered intramuscularly
76078218|NCT00992602|Other|quality-of-life assessment|Ancillary studies
76078219|NCT00992602|Other|laboratory biomarker analysis|Correlative studies
76078220|NCT00993226|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
76078221|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
75328721|NCT02677870|Drug|saproterin dihydrochloride|The drug will be given as described in the arm/group descriptions.
75469289|NCT01937455|Biological|rAAV1-PG9DP|8x10^13 vg administered intramuscularly
75469290|NCT01937455|Biological|rAAV1-PG9DP|1.2x10^14 vg administered intramuscularly
75469291|NCT01937481|Behavioral|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
75469292|NCT01937494|Drug|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
76078222|NCT00993226|Drug|Bupivacaine HCl Treatment 1c|40 ml
75469293|NCT01937533|Procedure|Magnetic Resonance Imaging using an endovaginal receiver coil|
75635402|NCT03240978|Behavioral|exercise intervention|A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
75328722|NCT02677870|Other|Diet treatment|Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
75328723|NCT02809846|Device|Quell|
75328724|NCT02809846|Device|Sham Quell|
75328725|NCT00945061|Radiation|intracavitary balloon brachytherapy|Patients undergo brachytherapy
75784865|NCT05496374|Drug|SPR720 500 mg|SPR720 500 mg (250 mg × 2 capsules) will be administered orally.
75784866|NCT05496374|Drug|SPR720 1000 mg|SPR720 500 mg (250 mg × 4 capsules) will be administered orally.
75784867|NCT05487768|Other|EEG measurement|"EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~Knee extension while sitting (10x left - right)~Bipodal squatting (10x)~Unipodal stance (5x30 seconds left-right)"
75784868|NCT05485155|Drug|Alpha-proteinase inhibitor|Intravenous infusion at 120 mg/kg body weight dose/week for 12 weeks for a total of 12 infusions.
75784869|NCT05467891|Drug|Ribociclib|600 mg orally once daily Days 1-21 (28 day Cycle)
75784870|NCT05467891|Drug|Fulvestrant|500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
75784871|NCT05467891|Drug|Anastrozole|1 mg orally once daily
75784872|NCT05467891|Drug|Letrozole|2.5 mg orally once daily
76078223|NCT00993226|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
76078224|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
76078225|NCT00993226|Drug|Bupivacaine HCl Treatment 2c|40 ml
75328726|NCT00945061|Radiation|intraoperative radiation therapy|Patients undergo radiotherapy
75341428|NCT04378166|Device|Smart glass|Practitioner wears smart glasses connected to ultrasound machine during central venous catheterization
75469294|NCT01937546|Procedure|Primary delivery of anterior shoulder|
75635403|NCT05461209|Drug|Talquetamab|Talquetamab will be administered as subcutaneous injection.
75635404|NCT05461209|Drug|Belantamab Mafodotin|Belantamab Mafodotin will be administered as intravenous infusion.
75635405|NCT03230604|Device|Filtek Bulk Fill Composite and Tetric N Ceram Bulk Fill Composite|Restorative cavities one, two and five with material Filtek Bulk Fill Composite
75635406|NCT03230604|Device|Z 350 Xt Composite|Restorative cavities one, two and five with material Z 350 XT Composite
75635407|NCT02798055|Drug|Bosentan group|
75635408|NCT03223194|Genetic|AT342|AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
75635409|NCT02804919|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
75784873|NCT05467891|Drug|Exemestane|25 mg orally once daily
75784874|NCT05465005|Behavioral|Torque Generation|Relaxed, or flexing about the elbow to 25% or 50% of the maximum elbow torque that one can generate.
75469295|NCT01937546|Procedure|Primary delivery posterior shoulder|
75635410|NCT05331768|Combination Product|banding ligation plus terlipressin infusion|Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
75635411|NCT04235595|Other|Connective Tissue Manipulation|The application was delivered with the participant in a sitting position, with the entire back and sacral regions left exposed. The treatment was administered to the sacral, lower thoracic and pelvic regions.
75469296|NCT01937572|Other|Visionaire system (Knee MRI)|
75635412|NCT04235595|Other|Transcutaneous Electrical Nerve Stimulation|TENS was administered with the participant lying face down with a flat cushion underneath the abdomen. TENS was administered via 2 channels of electrodes placed with the sacral region in the middle. The intensity of the current was increased until the participant felt it.
75469297|NCT01937572|Other|No Knee MRI|
75784875|NCT05458882|Behavioral|"living with food allergy educational booklet"|An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
75784876|NCT05443412|Diagnostic Test|Diagnostic test for prostate cancer|All recruited patients will undergo investigations including urine for spermine, blood for miRNA, TRUS, and MRI prostate. Patients with high suspicion of Clinically significant prostate cancer in any one step (urine, blood, ultrasound, OR MRI) will be offered an image-guided prostate biopsy.
75784877|NCT05442203|Device|Zio Patch Monitor|Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.
75921212|NCT02139111|Drug|Placebo|Oral placebo capsule
75784878|NCT05442203|Device|Echocardiogram|Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.
75921213|NCT02139111|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
75921214|NCT02139111|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
75921215|NCT02139111|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
75921216|NCT02139111|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
75469298|NCT01937585|Behavioral|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
75469299|NCT01937585|Behavioral|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
75469300|NCT01937611|Drug|Dexmedetomidine|Dexmedetomidine
75784879|NCT05417100|Drug|Methadone|methadone 0.2 mg/kg IV.
75784880|NCT05413486|Other|Observational|"Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.~Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups."
75784881|NCT05407961|Drug|LY3532226|Administered SC.
75784882|NCT05407961|Drug|Placebo|Administered SC.
75784883|NCT05407961|Drug|Dulaglutide|Administered SC.
75784884|NCT05398796|Biological|mRNA -1215|mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.
75784885|NCT05398744|Other|Group Exercise Program|At-home, aerobic group exercise program facilitated by exercise physiologist via video format, 3 times a week for 16 weeks.
75469301|NCT01937611|Drug|Midazolam|Midazolam
75921217|NCT03522480|Device|Jamboxx Respiratory Therapy Device|The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
75921218|NCT03522480|Other|Autogenic Draining Training|A respiratory therapist will teach children how to conduct the autogenic draining technique (a series of exhalations and inhalations) by demonstrating the technique to them, and having them practice in their office. Children will also receive an informational packet and short video about the technique for reference
75921219|NCT02139189|Device|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
75921220|NCT05120934|Drug|Amitriptyline 25 MG|25 mg orally for 4 weeks
75921221|NCT05120934|Drug|Amitriptyline 50 MG|50 mg orally for 4 weeks
75469302|NCT01937637|Behavioral|Cognitive Behavioral Intervention for Breathlessness|Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
75469303|NCT01937650|Drug|Radiotherapy plus metronidazole|Metronidazole was added to the standard radiotherapy that is routinely used.
75469304|NCT01937663|Drug|KWA-0711|
75921222|NCT05120934|Drug|Duloxetine 30 MG|30mg orally for 4 weeks
75921223|NCT05120934|Drug|Duloxetine 60 MG|60mg orally for 4 weeks
76078226|NCT04889248|Other|Inspiratory Muscle Training with Powerbreath IMT device.|"Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax."
76078227|NCT01885559|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
76078228|NCT01885559|Drug|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
76078229|NCT01885559|Drug|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
75921224|NCT05120934|Drug|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
76078230|NCT01884545|Behavioral|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
76078231|NCT01884545|Genetic|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
75635413|NCT03609762|Behavioral|EQ-5D-5L HRQOL results be available to the attending doctor|all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
75921225|NCT05120934|Drug|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
75921226|NCT03548493|Drug|Magnesium sulphate|Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h
75469305|NCT01937689|Drug|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
75921227|NCT03548493|Drug|Fentanyl|Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
75635414|NCT04235439|Drug|Gan & Lee Insulin Lispro Injection|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
75635415|NCT05119686|Drug|AR882 Dose 1|Solid Oral Capsule
75635416|NCT05119686|Drug|AR882 Dose 2|Solid Oral Capsule
76078232|NCT01884545|Behavioral|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
76078233|NCT01895543|Drug|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
75921228|NCT03548493|Drug|Propofol|In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
75921229|NCT05550610|Behavioral|Mindfulness Based Attention Training (MBAT) and Yoga|Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Participants also completed 15 minutes of group mindfulness practice 6 days/week and received information on embedded practice during the duty day. Yoga was delivered 6 days/week, 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
75921230|NCT03525132|Procedure|Laser Doppler Velocimetry + Optic Adaptative Camera|Fluxometry measure while subject is sitting in front of the optic adaptative camera
75921231|NCT02139267|Biological|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
75921232|NCT02139345|Device|TC-A PS Total Knee Replacement System|Subject will be implanted with the TC-A PS Total Knee Replacement System
75921233|NCT02139345|Device|TC-PLUS Solution PS Total Knee Replacement System|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
75921234|NCT03549819|Drug|Cannabidiol (CBD) Oil Capsules|"200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)"
76078234|NCT00994318|Drug|FCM (Ferric carboxymaltose) high ferritin target|
76078235|NCT00994318|Drug|FCM (Ferric carboxymaltose) low ferritin target|
75469306|NCT01937702|Other|0.9% NaCl (sodium chloride)|
75635417|NCT05119686|Drug|Placebo|Matching Solid Oral Capsule Placebo
75635418|NCT02798133|Procedure|OLA|PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
75635419|NCT02798133|Procedure|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
75635420|NCT02797743|Other|Whole blood|"Adults ≥18 yrs of age: up to 50 mL (5 tubes)~Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)~Children 0-11 yrs of age: single tube (1 tube, 10 mL)"
76078236|NCT00994318|Drug|Oral Iron (Ferrous sulphate)|
76078237|NCT04695808|Behavioral|yoga|Yoga practice will be done two days a week for 10 weeks.
76078238|NCT04525456|Dietary Supplement|Reduxium|Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
76078239|NCT00995722|Drug|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
76078240|NCT00995722|Drug|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
75921235|NCT03549819|Drug|Sunflower Lecithin Oil in Capsule|Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
75921236|NCT02139423|Other|CMV PCR|
75921237|NCT01665430|Drug|Tocilizumab|Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
75921238|NCT03524976|Device|Squid|"SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter."
75921239|NCT05578053|Drug|Dalpiciclib|a new, orally administered, selective CDK4/6 inhibitor
75921240|NCT02134743|Procedure|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
76078241|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
76078242|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
75328727|NCT02924350|Other|Stannous fluoride|"Supervised direct application (Day 0): Participants applied a pea-sized dose of test dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and Home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed each of the 2 qualifying test teeth first, followed by their whole mouth for at least 60 sec. Participants were permitted to rinse with 5 mL tap water (room temperature) for 5 sec. maximum after brushing on supervised brushing (Day 0) and were also permitted to rinse with tap water after brushing on home use (3 days)."
75328728|NCT02924350|Other|Sodium monofluorophosphate|"Supervised direct application (Day 0): participants applied a pea-sized dose of control dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed their whole mouth thoroughly for at least 60 sec. Participants were permitted to rinse with 5mL tap water (room temperature) for 5 sec. maximum after brushing in supervised brushing on Day 0 and were also permitted to rinse with tap water after brushing on home use (3 days)."
75328729|NCT00374062|Behavioral|relaxation therapy 1|relaxation therapy 1
75635421|NCT02640222|Drug|VKA|
75635422|NCT02640222|Drug|Apixaban|
75635423|NCT02640222|Drug|dabigatran|
75635424|NCT02640222|Drug|rivaroxaban|
75635425|NCT03868605|Device|EMR and ESD|Endoscopic mucosal resection using a resection snare Endoscopic submucosal dissection using an electrosurgical knife
75635426|NCT03868605|Device|Over- the- scope full- thickness resection device|Endoscopic resection of neoplastic lesions of the colon using the over- the- scope full- thickness resection device
75635427|NCT02795871|Behavioral|Neuropsychological and cognitive assessment|
75635428|NCT02795715|Device|tDCS|
75635429|NCT02795715|Behavioral|training|
75635430|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
75635431|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
75921241|NCT04466202|Other|Music with Structured Verbal Training|Structured verbal training on prostate biopsy was given to the intervention group before the procedure, and then patients in this group listened to the music they preferred during the procedure with headphones.
75921242|NCT05542888|Procedure|Sacroiliac joint mobilization|Sacroiliac joint mobilization will be performed with the patient in side lying position in which grade I,II pain relief mobilization will be given in PA direction.It will be given as 1 set of 30 oscillations per session, 3 times per week for 4 weeks.
75921243|NCT05542888|Procedure|Standard therapy|Postural education, Hot pack, Antenatal exercises
75635432|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
75635433|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
75784886|NCT05393388|Drug|[18F]AV-1451|[18F]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.
75921244|NCT03549741|Drug|Clomiphene Citrate 50mg|oral tablets
75921245|NCT03549741|Drug|Cabergoline Oral Tablet|oral tablets
75921246|NCT03549741|Drug|Placebo Oral Tablet|oral tablets
76078243|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
75635434|NCT02797899|Device|Platelet Rich Fibrin|Native growth factors
75635435|NCT03983031|Drug|Rituximab|Infusion
75635436|NCT03970005|Behavioral|Step-Based Care Model|Care model comprised of psychosocial and pharmacological interventions in which individuals start with low-intensity interventions and progress onto progressively higher-intensity interventions until their reach remission criteria.
75635437|NCT00903786|Drug|perampanel|Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
75635438|NCT02795637|Drug|dasotraline|dasotraline 8mg capsule/day
75784887|NCT05384470|Drug|Marihuana|Two doses of marijuana given.
75921247|NCT05542810|Combination Product|Use sports drinks as polyethylene glycol solvents|Using sports drinks as a polyethylene glycol solvent and water as a polyethylene glycol solvent in the control group, the effectiveness of intestinal preparation in the two groups was compared, and the adverse reactions, the acceptability of the solution taste, the timing of oral laxatives, and the willingness to repeat the same intestinal preparation or the willingness to recommend the same intestinal preparation to others were compared.
75784888|NCT05384470|Device|BID2 Instrument - breathalyzer|The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
75921248|NCT03522402|Drug|Sevoflurane|38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
75784889|NCT05384444|Other|Fasting mimicking diet|The fasting mimicking diet consists of a 5 day regimen: day 1 diet of the diet supplies ~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
75784890|NCT05378633|Radiation|SRS|Stereotactic Radiotherapy (SRS)
75469307|NCT01937728|Drug|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA < 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
75784891|NCT05378633|Radiation|Whole Brain Radiotherapy|Whole Brain Radiotherapy (WBRT)
76078244|NCT03016468|Drug|Parenteral Remodulin (treprostinil) injection|Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
75328730|NCT00374062|Behavioral|relaxation therapy 2|relaxation therapy 2
75328731|NCT00374062|Behavioral|relaxation therapy 3|relaxation therapy 3
75328732|NCT02469220|Dietary Supplement|Low FODMAP|Blinded food supplements containing only items with a low content of FODMAPs
75635439|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|three doses of 30µg of GMZ 2 vaccine,
75635440|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|100 µg of GMZ 2 vaccine
75328733|NCT02469220|Dietary Supplement|Standardized FODMAP|Blinded food supplements containing FODMAPs
75328734|NCT00374218|Drug|High Fructose Corn Syrup|
75328735|NCT00374218|Drug|Sucromalt|
75469308|NCT01937728|Drug|B: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks."
75469309|NCT01937728|Drug|C: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
75469310|NCT01937728|Drug|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
75469311|NCT01937728|Drug|E: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
75469312|NCT01937728|Drug|F: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks."
75469313|NCT01937754|Dietary Supplement|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
75469314|NCT01937754|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
75469315|NCT01937767|Drug|Remimazolam|
75469316|NCT01937767|Drug|Propofol|
75635441|NCT00703066|Biological|Rabies vaccine|3 doses of Rabies vaccine
75635442|NCT02803359|Procedure|Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold|
75635443|NCT00762073|Drug|budesonide|oral suspension
75635444|NCT00762073|Drug|placebo|oral suspension matching budesonide
75328736|NCT00945139|Drug|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
75328737|NCT00945139|Drug|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
75635445|NCT04030468|Other|Educational intervention addressed to general practitioners|"feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~Continuous Medical Education (CME) course"
75635446|NCT04030468|Other|Informative intervention addressed to patients|• leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
75469317|NCT01937767|Drug|Sevoflurane|
75921249|NCT05577975|Device|The Aspara @ smart grower|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
76078245|NCT03016468|Drug|Oral Treprostinil|Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
75328738|NCT02812342|Drug|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
75328739|NCT02254642|Procedure|Ischemic preconditioning during aortic clamping|Ischemic preconditioning during aortic clamping
75328740|NCT02254642|Procedure|Procedure/Surgery: usual surgery|Procedure/Surgery: usual surgery
75635447|NCT02795793|Drug|Non-operative management group (NOM)|With intravenous Piperacillin with Tazobactam (Tazocin)
75328741|NCT03871465|Drug|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
75328742|NCT03871465|Procedure|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
75328743|NCT03871465|Drug|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
75328744|NCT02125864|Procedure|intravitreal injection|collecting blood samples
75328745|NCT04363489|Device|Wearable Medical Device (Empatica E4)|A wearable medical device (Empatica E4) which is a smart wristband that detects skin temperature, heart rate and sleep. It is CE and FDA approved.
75328746|NCT04363489|Diagnostic Test|COVID-19 PCR Swab|COVID-19 PCR Swab will be self-taken by doctors every day. Fischer nasopharyngeal PCR Swabs
75328747|NCT04363489|Diagnostic Test|Pulse Oximeter|Participants will measure their oxygen saturations every day, and report them on the survey. Pulmolink A310 pulse oximeters
75469318|NCT01937767|Drug|Remifentanil|
75921250|NCT05542732|Device|CardioWatch 287-2|CardioWatch 287-2 (CW2 Test Device or CW2). This medical device is based on the precursor CardioWatch 287-1 approved by EU-MDR under number 20M00011CRT01, CW2 has two red, two infrared and two green LEDs, and two photosensors compared to its precursor.
75328748|NCT02814448|Device|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
75328749|NCT02814448|Device|CO2 standard cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
75469319|NCT01937767|Drug|Fentanyl|
75635448|NCT02795793|Procedure|Appendectomy group (Operative management, OM)|
75469320|NCT01937767|Drug|Rocuronium|
75635449|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)|
75635450|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)|
75328750|NCT02814448|Device|Thermocoagulator|The use of heat produced by high-frequency electric current to bring about local destruction of tissues
75469321|NCT01937793|Other|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
75469322|NCT01937793|Other|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
75469323|NCT01937806|Drug|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
75469324|NCT01937806|Drug|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
75469325|NCT01937819|Device|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
75469326|NCT01937832|Drug|Faropenem|dosage form: Injection dosage:1200 mg frequency: Three times a day
75469327|NCT01937832|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
75469328|NCT01937897|Other|Bi-lateral massage|Unilateral massage on the left side of the body.
75635451|NCT00913588|Drug|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)|
75635452|NCT02803281|Other|Frailty Assessment|Various physiologic and frailty assessment tests
75635453|NCT02610946|Behavioral|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
75635454|NCT02610946|Behavioral|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
75784892|NCT05369819|Drug|Midazolam|. Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room
75784893|NCT05369819|Drug|Saline|Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room
75784894|NCT05358587|Other|Ultrasound guided PENG block with 20 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
75784895|NCT05358587|Other|Ultrasound guided PENG block with 30 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
75635455|NCT04100785|Behavioral|Internet-delivered Cognitive Behavioural Therapy|The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
75921251|NCT05698966|Other|we will use reduced dose of acceptable corticosteroids treatment for preterm birth|the two different group will differ in the doses of corticosteroids
75635456|NCT02797665|Drug|corticosteroids|prednisone 0.6mg/kg/d
75784896|NCT05357729|Device|MultiSense® remote monitoring|At hospital, the patient will be monitored with conventional monitoring devices as well as the MultiSense® solution (at least one hour with a reference monitor). After hospital discharge, the patients will be remotely monitored by their healthcare professional using the MultiSense® solution.
75784897|NCT05348785|Drug|BIIB122|Administered as specified in the treatment arm
75784898|NCT05348785|Drug|BIIB122-Matching Placebo|Administered as specified in the treatment arm
75921252|NCT02139501|Drug|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
75921253|NCT02134821|Procedure|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
75921254|NCT03527004|Other|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.
75921255|NCT03527004|Other|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in IQOS users residing in Italy.
75921256|NCT05577897|Other|Education|"A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet COPD Guide on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method."
76078246|NCT00997204|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
76078247|NCT00997516|Procedure|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
76078248|NCT00997516|Procedure|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
76078249|NCT04263610|Drug|Dimethyl fumarate (DMF) standard scheme|Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.
76078250|NCT04263610|Drug|Dimethyl fumarate (DMF) simplified scheme|Participants will receive DMF gastro-resistant tablet orally at a dose of 60, 120, 180, 240, 360 mg daily in Week 1, Week 2, Week 3, Week 4, Week 5 respectively, and 480 mg daily from Week 6 to Week 8. If a PASI is greater than or equal to (>=) 30% at Week 8, no dose increase will be done and if PASI is less than (<) 30% at Week 8, participants will receive 600 mg daily in Week 9 and 720 mg from the Week 10 onwards.
75635457|NCT02797665|Procedure|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
75635458|NCT05297149|Behavioral|Hippotherapy|The hippotherapy program consisted of 6 weekly sessions that varied in duration between 20 and 30 minutes depending on the weekly program and the participant's condition. Each session started with brief greetings and contact with the horse.
76078251|NCT04263610|Drug|Tildrakizumab|Participants who achieve PASI less than (<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg [(as per the Summary of Product Characteristics (SmPC)] at Weeks 16, 20 and 32 up to Week 40.
75784899|NCT05348486|Radiation|Dose escalation|Dose escalation 75,9 - 79,2 Gy in 33 fractions for GTV hypoxic or any hypoxic LN > 2cm
75784900|NCT05347693|Drug|Sodium Zirconium Cyclosilicate (SZC)|"White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement.~Label text will be translated into local language."
75784901|NCT05347693|Drug|Local standard of care|Local SoC in the country to be used as per local label
75784902|NCT05345171|Genetic|DTX301|non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector
75784903|NCT05345171|Other|Placebo|normal saline infusion
75784904|NCT05345171|Drug|Oral Corticosteroids|Participants who receive DTX301 solution will receive oral corticosteroids.
75784905|NCT05345171|Drug|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind
75784906|NCT05345171|Drug|Sodium Acetate|A tracer for the Ureagenesis Rate Test (URT)
75784907|NCT05344157|Biological|XSTEM-OA|XSTEM-OA is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of osteoarthritis.
75921257|NCT05542654|Other|Foot Massage|Pregnant women in the intervention group were given a foot massage for 15 minutes each, for a total of 30 minutes for three days, while the control group did not receive foot massage.
75921258|NCT02134899|Drug|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
75921259|NCT02134899|Drug|Calcineurin inhibitors maintenance|Usual treatment
75921260|NCT02135055|Other|blood sample collection|Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
75921261|NCT02135055|Drug|Midazolam|The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
75635459|NCT05297149|Behavioral|Home exrecises|The home exercise program consisted of the following balance training exercises: one leg standing on foam with eyes open and closed, double leg standing on foam with eyes open and closed, walking in tandem with eyes open and closed, balance exercises on an inclined surface, balance exercises in squat, and jumping over an obstacle on the ground. All participants performed the exercises under parental supervision, 3 times per week for 6 weeks. The physiotherapist made video calls to the children and parents to ensure their adherence to the home exercise program.
75635460|NCT02795091|Other|manual cleaning|manual clean the rag and floor towel
75635461|NCT02795091|Device|machine clean|machine clean the rag and floor towel
76078252|NCT00997594|Procedure|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
75635462|NCT02797587|Drug|Varenicline|1 week starter kit followed by 1mg twice daily for 12 weeks.
75921262|NCT02135055|Drug|Morphine|Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
75921263|NCT02135055|Procedure|Sedation interruption|Sedation interruption is performed at 8 am every morning.
76078253|NCT04225390|Drug|Dacarbazine (DTIC)|Dacarbazine powder for IV solution
75635463|NCT02797587|Drug|Cytisine|Multi-daily dosing, range 3-9 mg daily for 25 days.
75328751|NCT00931489|Drug|ranibizumab (Lucentis(R))|0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
75921264|NCT02139579|Drug|Bevacizumab|7.5 mg/kg every 3 weeks
75921265|NCT04425928|Procedure|occupational therapy based activity training programs|Occupational therapy based activity training programs in which exercises based on physiotherapy are put into the purposeful activities at vestibular rehabilitation.
75921266|NCT04425928|Procedure|Physiotherapy based exercise training programs|Cawthorne-cooksey exercises were performed at vestibular rehabilitation
75921267|NCT02139657|Biological|RIG-C|
75921268|NCT05550064|Other|Structured contraceptive counseling|"Educational video - healthcare providers (Medical doctors and nurse-midwives)present available contraceptives that could be used after delivery, with emphasis on effectiveness, how they should be used, mechanism of action and health benefits.~The four key questions are to be asked to all pregnant women to make them reflect on factors that highly affects choice of contraceptives.~A tiered effectiveness chart will be used to visualize the effectiveness of different contraceptives, and guide the prospective user in her choice depending on the answers to the key questions~The box of contraceptive models are used for the prospective user to inspect, hold, feel the different contraceptives, as this has been shown to decrease fear regarding specific methods."
75921269|NCT03526926|Drug|CPX-351|VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
75635464|NCT02797587|Drug|Nicotine Replacement Therapy|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
76078254|NCT00997672|Drug|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
76078255|NCT00997672|Drug|Placebo|
75635465|NCT02797587|Drug|Varenicline Placebo|1 week starter kit followed by 1 pill twice daily for 12 weeks.
75328752|NCT04363333|Diagnostic Test|Home Sleep Apnea Testing or In-hospital Polysomnography|Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis
75328753|NCT02816710|Drug|Conbercept|Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
75328754|NCT04363411|Other|finger prick screening for BBV infections and questionnaires by outreaching methodology|Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.
75328755|NCT04363255|Drug|Etoposide Injection|Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
75328756|NCT04363255|Drug|Carboplatin Injection|Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
75635466|NCT02797587|Drug|Cytisine Placebo|Multi-daily dosing for 25 days.
75328757|NCT04363255|Drug|Cisplatin injection|Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
75635467|NCT02797587|Drug|Nicotine Replacement Therapy Placebo|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
75635468|NCT04098601|Behavioral|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
75635469|NCT02797509|Behavioral|Psychosocial Skills-Based Intervention|Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
75635470|NCT04100941|Diagnostic Test|standard suction|After the needle is inserted in the mass, removing the stylet before performing EUS-FNA. Then attach a 10mL syringe to the end of needle. 20 times of for-backward Suction was applied after the lesion was punctured.
75921270|NCT02135211|Behavioral|Lifestyle counseling|
75328758|NCT04363255|Drug|Toripalimab|After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.
75921271|NCT04076826|Drug|Dexmedetomidine|Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
75328759|NCT04363255|Drug|Anlotinib hydrochloride|After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
75328760|NCT02818114|Behavioral|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
75635471|NCT04100941|Diagnostic Test|slow pull|After the needle is inserted in the mass, slowly pull the stylet out while performing EUS-FNA with 20 times for-backward.
75635472|NCT04100941|Diagnostic Test|wet suction|After removing the stylet, the needle was flushed with 5mL of saline solution to replace the column of air with saline. A 10mL syringe was attached to the end of the needle. 20 times of for-backward Suction was applied after the lesion was punctured.
75635473|NCT02795325|Drug|DCR-PH1|IV infusion of DCR-PH1
75921272|NCT04076826|Drug|Propofol or Midazolam|Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
75921273|NCT04076826|Diagnostic Test|Blood sampling|In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
75921274|NCT02139735|Other|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
75921275|NCT02139735|Other|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
75921276|NCT02139735|Other|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
75921277|NCT05535634|Diagnostic Test|Sound Ear Check|Hearing test, measurement of the input impedance of the middle-ear transmission system
75921278|NCT05577585|Drug|Ketamine 50 MG/ML|See also Arm description
75921279|NCT05577585|Drug|Midazolam|See also Arm description
75921280|NCT04465968|Drug|Cisplatin|Cisplatin 60 mg/m2, IV, day 1
75921281|NCT04465968|Drug|S1|80 - 120 mg/day, PO, day 1-14
75921282|NCT04465968|Radiation|concurrent radiotherapy|66 Gy/33 Fr
75921283|NCT04465968|Drug|Durvalumab|preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
75921284|NCT04465968|Procedure|Surgery|Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
75921285|NCT04465968|Drug|Durvalumab|"(For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1"
75328761|NCT02930824|Genetic|CYP2C19 genotyping|All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
75328762|NCT00931879|Drug|omega-3-ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients.
75328763|NCT00931879|Drug|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
75328764|NCT02930980|Device|Investigational Software loaded on Micra device|Subject will receive an investigational software loaded on subject's Micra device
75328765|NCT03001258|Other|Presbyopia screening training|The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
75635474|NCT02795325|Other|Placebo|
75635475|NCT00761761|Drug|Sensoril|
75635476|NCT00761761|Other|Placebo|
75635477|NCT02803047|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation number - SR15-61-Z15-034).
75635478|NCT02795403|Other|blood draw of 150ml, twice|
75635479|NCT04235361|Diagnostic Test|Differential RPA tests|The mobile diagnostic suitcases will be deployed at Ebola Treatment centres in DRC. Samples of patients refered for diagnostic testing will be tested by PCR by existing diagnostic teams, and will be additionally tested by the mobile suitcase laboratory using differential RPA tests for 6 parameters.
75635480|NCT04235283|Device|Primary total knee replacement by pinless navigation (Orthomap Express,Stryker, Michigan)|The varus/valgus, extension/flexion, thickness of distal cut of femur was determined and done by pinless navigation system. After cutting, the instant information of resection level can show on the display screen. If the alignment is satisfying, the anterior/posterior femoral cut, chamfer cut and box resection were done by conventional jig
75635481|NCT04235283|Procedure|Primary total knee replacement by traditional jig and minimally invasive technique|The femoral alignment was determined by intramedullary guide. The femoral alignment jig was set to 5-7 degree valgus dependent on the preoperative radiograph. A bone plug is impacted into the entry hole of femoral medullary canal before prosthesis placement.
75635482|NCT00761605|Drug|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
75784908|NCT05342597|Drug|MT-1186|A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.
75784909|NCT05322941|Drug|AEF0117|AEF0117 (1.0, 0.3, and 0.1 mg) capsules
75784910|NCT05322941|Drug|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
75784911|NCT05322226|Behavioral|Addiction follow-up before and after liver transplantation|Addiction consult and follow-up
75635483|NCT02797431|Drug|Interleukin-7|IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR>2.5 or platelet count < 35,000
75635484|NCT02797431|Drug|Placebo|IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count < 35,000
75635485|NCT00761527|Drug|Desloratadine Syrup|"Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg [milligrams] of desloratadine)~Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)"
75635486|NCT00770029|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
75635487|NCT00770029|Drug|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
75635488|NCT02797353|Other|Maternal Neonatal and Child Health Interventions|Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
75635489|NCT02794935|Other|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
75635490|NCT02794935|Other|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
75635491|NCT04095949|Dietary Supplement|Artichokes|Approximately 200 g of cooked artichokes
75784912|NCT05315947|Drug|brivaracetam|Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.
75784913|NCT05315947|Drug|brivaracetam|Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.
75784914|NCT05308875|Biological|PD1-BCMA-CART|Single infusion of PD1-BCMA-CART administered intravenously (i.v.)
75784915|NCT05300256|Device|Peripheral Heating|Peripheral heating of the feet
75784916|NCT05300256|Device|Sham|Sham
75784917|NCT05296096|Other|Protein dosage and rehabilitation team delivered exercise prescription|"The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years.~The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions."
75784918|NCT05294471|Device|Non-contrast MRI with novel MRI software|The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.
75784919|NCT05293496|Biological|vobramitamab duocarmazine|Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.
75784920|NCT05293496|Biological|lorigerlimab|Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
75784921|NCT05289037|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
75784922|NCT05289037|Biological|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
75784923|NCT05289037|Biological|BNT162b2 (B.1.1.529)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
75635492|NCT04096183|Other|Ventilation of healthy volunteers|Ventilation of healthy volunteers in different clinical situations
75635493|NCT04235985|Combination Product|Chlorhexidine Gluconate with HUBS|4% CHG soap will be applied to HUBS following manufacturers recommendation and applied to skin for different application times as dictated by the randomization of the marked sites on the forearm. Followed by a HUBS moistened with water.
75635494|NCT00817414|Drug|LCI699-matching placebo|LCI699-matching placebo oral capsules
76078256|NCT04160650|Behavioral|Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer|"This is an educational intervention which aims to answer the questions:~In patients with CRC what is the effect of empowering education versus standard education on knowledge level in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on activation level related to nutrition impact side effects' self-care in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on malnutrition risk in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on QoL in 4 months follow-up?"
75784924|NCT05289037|Biological|BNT162b2 (B.1.351)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
75784925|NCT05289037|Biological|BNT162b2 bivalent (wildtype and Omicron BA.1)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
75784926|NCT05289037|Biological|BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
76078257|NCT04828161|Drug|ensovibep|IV on day 1 only.
75328766|NCT00945295|Drug|Botulinum toxin type A, BoNT-A|Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
75328767|NCT00945295|Other|Rehabilitation Therapy|Rehabilitation therapy
76078258|NCT04828161|Drug|Placebo|IV on day 1 only.
75328768|NCT03772873|Procedure|minimally invasive pilonidal excision|MIPE procedure with trephine excision of pits and sinuses
75328769|NCT03706027|Device|radiation therapy-3 fractions|Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
75328770|NCT03706027|Device|Radiation therapy-5 fractions|Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
75328771|NCT03634813|Device|High Blood Pressure Monitor|High Blood Pressure Monitoring device (Omron MX3 model BP742, Omron, Shaumberg, IL)
75328772|NCT03634813|Procedure|Usual Care|Usual Care
75635495|NCT00817414|Drug|LCI699|LCI699 oral capsules
75635496|NCT03944187|Diagnostic Test|Transvaginal sonography|Transvaginal sonography for measurement of cervical length, fetal head circumference and fetal head to cervix angle .
75635497|NCT00769561|Behavioral|Biofeedback-Based Cognitive Behavioral Treatment|The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
75784927|NCT05289037|Biological|CoV2 preS dTM [B.1.351]|Is a liquid formulation made of recombinant protein placed in a formulation buffer that contains the spike protein sequence of the B.1.351 (Beta) variant SARS-CoV-2 strain.
75784928|NCT05289037|Biological|CoV2 preS dTM/D614|Is a liquid formulation made of recombinant protein placed in a formulation buffer. The antigen solution contains the spike protein sequence of the ancestral strain of SARS-CoV-2.
75784929|NCT05289037|Biological|CoV2 preS dTM/D614+B.1.351|Is a liquid formulation made of recombinant protein placed in a formulation buffer contains the spike protein sequences of the ancestral and B.1.351 (Beta) variant SARS-CoV-2 strains
75921286|NCT02139813|Procedure|Laparoscopic Mini-gastric bypass|"The laparoscopic Omega Loop Bypass will consist of:~a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His~a narrow gastric tube will be calibrated to be approximately 1.5 cm wide~an Omega loop of 200 cm~a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler"
75921287|NCT02139813|Procedure|Procedure of reference in bariatric surgery|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~a small gastric pouch (about 30cc)~an antecolic alimentary limb~a gastro-jejunal anastomosis using a linear stapler~a 150cm long alimentary limb~a 50cm biliary limb~a latero-lateral jejuno-jejunal anastomosis~closure of the mesenteric defects"
75328773|NCT04354363|Other|Platelet rich plasma|Giving women PRP before ICSI
75328774|NCT03490825|Dietary Supplement|Melatonin 1 mg|Melatonin (1mg) will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
75921288|NCT03526770|Other|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink without any intervention
75328775|NCT03490825|Dietary Supplement|Placebos|Placebo will be administered daily during the intervention. The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
75328776|NCT03490825|Other|Meal timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
75328777|NCT03490825|Other|Non-Meal timing|Subjects are instructed to maintain their habitual meal timing.
75328778|NCT04363099|Other|observational|observational management of outpatients COVID 19
75328779|NCT04354207|Diagnostic Test|Peripheral vein punction|Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood
75635498|NCT00769561|Device|Dental treatment with occlusal splint (OS)|Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
75635499|NCT02797041|Drug|Bortezomib|Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
75921289|NCT03526770|Other|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
76078259|NCT01000324|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
75328780|NCT04354207|Diagnostic Test|Stool collection|Gut microbiome will be investigated in stool samples.
75328781|NCT04362787|Device|High pressure non invasive ventilation in acute hypercapnic respiratory failure|Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
75328782|NCT04354051|Drug|Sodium Nitrite|Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
75635500|NCT02794779|Drug|Oxytocin|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
75784930|NCT05289037|Biological|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
75469329|NCT01937910|Behavioral|TRAIT Task|Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
75469330|NCT01937936|Behavioral|Cognitive Behavioral Therapy (CBT)|Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
75784931|NCT05289037|Biological|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
75784932|NCT05289037|Biological|mRNA-1273.529|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
75784933|NCT05289037|Biological|mRNA-1273.617.2|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.617.2 (Delta) variant SARS-CoV-2 strain.
75784934|NCT05289037|Other|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
75784935|NCT05286242|Biological|COVID19 vaccine|All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.
75328783|NCT04362943|Drug|Baricitinib or Anakinra|Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.
75328784|NCT03317899|Procedure|Hematopoietic Cell Transplantation|Undergo auto HSCT
75328785|NCT03317899|Drug|Tbo-filgrastim|Given subcutaneously
75328786|NCT03317899|Other|Laboratory Biomarker Analysis|Correlative Studies
75784936|NCT05285553|Device|MiSight 1 Day|Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.
75784937|NCT05285553|Device|Proclear 1 day|"Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.~Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year."
75784938|NCT05285527|Device|MiSight 1 Day|Subjects will wear MiSight 1 day lenses for three years.
75784939|NCT05282758|Other|Free Movement Dance|Free Movement Dance as a physiotherapy intervention
75784940|NCT05282758|Other|Modified person-centred progressive resistance exercise|Modified person-centered progressive resistance exercise as a physiotherapy intervention
75784941|NCT05273827|Drug|neoadjuvant immunotherapy|Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.
75784942|NCT05273827|Drug|Neoadjuvant chemotherapy|Cis-platinum combined with paclitaxel or pemetrexed
75784943|NCT05272631|Device|Retrograde Femoral Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with RFNA based on the surgeon's decision and the site's SOC.
75784944|NCT05272631|Device|Tibial Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with TNA based on the surgeon's decision and the site's SOC.
75921290|NCT03526770|Drug|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention
76078260|NCT01000324|Biological|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
76078261|NCT01000324|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
76078262|NCT04399629|Behavioral|PCIT-ED|12 sessions of PCIT-ED therapy
76078263|NCT04399629|Behavioral|Parenting Wisely|Teaches parents how to set more effective limits
75328787|NCT04353505|Drug|Ketorolac|Intra-arterial delivery of Ketorolac in the internal maxillary artery, once
75328788|NCT04353505|Drug|Dexamethasone|Intra-arterial delivery of Dexamethasone in the internal maxillary artery, once.
75784945|NCT05270356|Other|MRI|Magnet Resonance Imaging of the Brain without Contrast
75784946|NCT05265520|Procedure|His-CRT implantation|The pathophysiological process is utilized in His-Bundle corrective pacing, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular endocardial lead.
75784947|NCT05265520|Procedure|BIV-CRT implantation|Biventricular cardiac resynchronization therapy has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
75784948|NCT05265169|Device|Microwave ablation|Microwave ablation of colorectal liver metastases (CLM)
75921291|NCT03526770|Other|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
75921292|NCT03526770|Other|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing gum as an intervention."
75921293|NCT03526770|Other|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
75921294|NCT02135367|Biological|PRP|injections of Platelet rich Plasma
75921295|NCT05699512|Behavioral|Multiprofessional, tailored rehabilitation|Patients receive individual, tailored, multiprofessional rehabilitation
75635501|NCT00817336|Drug|D Serine|60 mg/kg/day
75635502|NCT00817336|Drug|Placebo|oral
75635503|NCT02802657|Procedure|Treat-and-Extend regimen|For the T&E regimen,investigators recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.
75635504|NCT02802657|Procedure|Pro Re Nata|For the PRN group, investigators recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
75921296|NCT04189458|Other|Multimodal exercise program|Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (30 min), cool-down (5 min), and finishing ritual (5 min). At the initial stage, the activation of different muscle groups will be performed. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities and will privilege IPS. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation - physical fitness (strength, balance and agility) - alternating with exercises mainly focused on cognitive stimulation - CF (planning ability, solving-problems, IPS, attention and DT performance). At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants sign an attendance sheet regarding the session, including perceived exertion (Borg Scale) and satisfaction (Caregiver Treatment Satisfaction questionnaire).
75921297|NCT02139891|Device|Cardiac Resynchronization Therapy with MultiPoint Pacing|
75921298|NCT02135523|Radiation|involved-field radiation therapy|Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
75921299|NCT05577507|Drug|Cholestyramine Resin 4000 MG [Questran]|cholestyramine 4 gram sachets (questran) will be administered orally on 150 ml water three times daily for 8 weeks period trial
75921300|NCT05577507|Drug|Calcium Carbonate 500 MG Oral Tablet|control group will administer standard therapy calcium carobonate as calcium based phosphate binder 500 mg three times daily within meals
76078264|NCT04606797|Drug|Nicotine patch|Nicotine transdermal patches as per product monograph
76078265|NCT02164240|Drug|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
75635505|NCT02802657|Drug|Conbercept|
75635506|NCT04039438|Other|No intervention|No intervention will be provided during the study nor participants will be receiving any intervention anywhere else.
75635507|NCT00761215|Drug|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
75635508|NCT00761215|Drug|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
75635509|NCT00761215|Drug|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
75784950|NCT05240677|Procedure|Upper GIT endoscopy|Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
75784951|NCT05238740|Other|ViviGen®|It will investigate the radiological and clinical outcome of stand-alone ALIF procedure L5/S1 using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
75784952|NCT05238740|Other|rhBMP-2|It will investigate the radiological and clinical outcome of stand-alone ALIF procedure L5/S1 using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
75784953|NCT05237453|Radiation|Photons|MR-guided adaptive radiotherapy
75784954|NCT05236114|Other|Observation|No intervention
75921301|NCT05535400|Behavioral|Physical-Psychological Integrative Intervention|The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program. And the content of the intervention includes eight different sessions, including Session 1- Orientation and engagement, Session 2- Awareness and Acceptance; Session 3- Non-judgement; Session 4- Stay present and let go; Session 5- Our thoughts are not real & Response without reacting; Session 6- Empowerment of self-management and discuss pain management; Session 7- Seek out pleasant things and social support and Session 8- Review the intervention and end the programme.
75921302|NCT05535400|Device|Brief online didactic education|Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
75921303|NCT05577429|Other|Low-moderate intensity exercise under normoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 20.9%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
75921304|NCT05577429|Other|Low-moderate intensity exercise under moderate hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 16.5%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
75635510|NCT04235751|Behavioral|Professional Coaching|6 individualized professional coaching sessions via phone
76078266|NCT02164240|Drug|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
76078267|NCT02164396|Device|Spectacle Lens|Spectacle Lens Only
75341429|NCT01578577|Behavioral|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
76078268|NCT02164396|Device|Habitual Soft Contact Lens|subject's own contact lens
75635511|NCT02794857|Drug|NP001|
75635512|NCT02794857|Drug|Placebo|
75635513|NCT04100629|Behavioral|digital support: text messages|In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
75635514|NCT05805293|Device|High-Velocity Nasal Insufflation Therapy|"Parameter settings for the HVNI apparatus are as follows:~The flow of HVNI will initially be set at 30-40 L/min, and inspiratory flow rate could be increased to 45-60 L/min.~FIO2 will be adjusted to maintain a SaO2 more than 90 % and relative humidity of 30-34%.~Temperature range of 35-37°C."
75784955|NCT05234177|Other|Observation|No intervention
75784956|NCT05227924|Device|Total hip arthroplasty (primary or revision)|Total hip arthroplasty with at least one medical device from the SYMBOL range
76078269|NCT02164396|Device|Test Lens|senofilcon A or narafilcon A
76078270|NCT02169466|Drug|BIA 9-1067|OPC, Opicapone
76078271|NCT02169466|Drug|Placebo|PLC, Placebo
76078272|NCT02169466|Drug|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
75784957|NCT05223868|Drug|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
75784958|NCT05223868|Drug|Placebo|Placebo tablet will be administered orally.
75784959|NCT05223647|Procedure|Thoracic radiotherapy|30Gy/10 fractions thoracic radiotherapy given between 2nd and 3rd course of chemo-immunotherapy.
75784960|NCT05223647|Drug|Chemo-immunotherapy|Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
75784961|NCT05218057|Procedure|Ureteroscopic lithotripsy|Ureteroscopic lithotripsy is one of the surgical procedure options for ureteric stone less than 1.5 cm. While many energy systems has been used for stone fragmentation during ureteroscopy, laser energy is the most commonly used approach for stone fragmentation.
75784962|NCT05215262|Behavioral|Treat Act Know Engage (T.A.K.E.) Steps|Intervention sessions will consist of psychoeducation, HIV/STI goal identification, referral to HIV testing and PrEP, and communication skill building.
75921305|NCT05577429|Other|Low-moderate intensity exercise under high hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 14.8%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
75921306|NCT05542186|Procedure|Kinesiotaping|Biomechanical correction for discogenic low back pain using kinesiotaping
75328789|NCT03005899|Drug|SyB P-1501|"After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed"
76078273|NCT05440396|Diagnostic Test|Photographs collection phase|"Three medical experts have been selected to review the photo collected. Each expert medical assesses the presence of local signs of infection on the photographs by annotating them directly via a dedicated software. They will annotate local signs: redness, perfusion extravasation, necrosis, hematoma, edema, non-purulent discharge, and purulent discharge.~A convolutional neural network model will determine the probability of local sign presence. Each picture will be annotated to determine the main characteristics of the catheter. A dataset preparation with photo cropping will be performed for modelling."
76078274|NCT01001806|Drug|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
76078275|NCT01001806|Drug|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
76078276|NCT01001806|Drug|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
76078277|NCT05322993|Device|GI Genius|The use of artificial intelligence during colonoscopy to improve polyp detection.
76078278|NCT05322993|Device|Standard white light colonoscope|Standard colonoscopy.
76078279|NCT04021264|Drug|Ropivacaine-Sufentanil|Local anesthetic injection
76078280|NCT04021264|Drug|Dextrose 5|Sham injection
75635515|NCT05805293|Device|Non-Invasive Ventilation|Patients will be put on inspiratory/expiratory pressure 10/5 cmH2O (11). The inspiratory and expiratory pressures will be titrated with increments of 2 cmH2O based on improvement of oxygen saturation by continuous pulse oximetry and arterial blood gases values, alleviation of dyspnea and a decrease of respiratory rate and heart rate. The maximum allowed inspiratory pressure was 20 cm H2O. The maximum allowed expiratory pressure was 10 cm H2O.
75635516|NCT05805228|Other|Sexual Counseling|Pregnancy and postpartum period-specific sexual counseling was given to pregnant women and their spouses.
75635517|NCT05805189|Procedure|pulmonary vein (PV) isolation|The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
75635518|NCT05805163|Behavioral|FABI tailored COVID-19 testing pamphlet|FABI adapted COVID-19 educational pamphlet
75784963|NCT05215262|Behavioral|Standard or Care|S.O.C. arm will receive treatment as usual. After the baseline interview, participants will be referred to their PCP for management of any clinical issues that arise. Their clinic visit schedule will follow their clinical needs and recommendations of their clinic provider
76078281|NCT01002118|Drug|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
76078282|NCT01002118|Drug|Placebo|4 capsules each day for 16 weeks
75784964|NCT05202301|Drug|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
75784965|NCT05202301|Drug|Enzalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
75784966|NCT05202301|Drug|Apalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
75784967|NCT05198843|Drug|Dasatinib|Given PO
76078283|NCT05322369|Other|periodontal charting only|Periodontal charting only
75784968|NCT05198843|Dietary Supplement|Icosapent Ethyl|Given PO
75921307|NCT01565655|Drug|peficitinib|oral
75921308|NCT01565655|Drug|Placebo|oral
75921309|NCT05535322|Drug|GLP-1RA|All T2D adults treated with Glucagon-like peptide-1 receptor agonists (GLP-1RA) or initiating a GLP-1RA during the study period
75921310|NCT05535322|Drug|SGLT2i|SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
76078284|NCT05311839|Other|Exercise|Hot packs, active range of motion exercises, pendular exercises, wall climb exercises, mobilization exercises, and shoulder capsular stretching
76078285|NCT05311839|Other|Thera band|graded Thera band exercises for shoulder flexion, abduction, internal, and external rotation
76078286|NCT01003288|Biological|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)~* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
76078287|NCT04759365|Drug|ASN51|ASN51 formulation for oral capsule
76078288|NCT04759365|Drug|Placebo|Placebo formulation for oral capsule
76078289|NCT05364112|Device|Compreflex|The Compreflex standard calf and foot (with basic liner) from Sigvaris (St. Gallen, Switzerland) is an easy-to-use interlacing Velcro wrap device with adjustable compression levels.
76078290|NCT04757571|Drug|Paroxetine|Paroxetine 20 mg tablet plus standard therapy
76078291|NCT04757571|Drug|Placebo|Placebo tablet plus standard therapy
75328790|NCT03005899|Drug|SyB P-1501 placebo|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
75921311|NCT05535322|Drug|Insulin|Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i
75635519|NCT05805163|Behavioral|Standard COVID-19 home-based test kit|Standard COVID-19 home-based test kit
75921312|NCT05535322|Drug|Miscellany|Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
75921313|NCT05592574|Other|Blood sample|Blood samples required to performe IL-17 Dosage
76078292|NCT03232593|Drug|Atezolizumab|Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
76078293|NCT02162446|Drug|satoreotide trizoxetan|
76078294|NCT01895309|Drug|Enbrel (etanercept)|
75635520|NCT05805098|Drug|Venetoclax|Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
75784969|NCT05186415|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.
75784970|NCT05185037|Device|Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)|The purpose of this study is to compare measurements of NIBP taken by the study device and measurements taken by the current FDA-approved algorithm included in Rev. N.0 software for the IntelliVue patient monitors during motion artifact in patients undergoing caesarian section deliveries under epidural anesthesia
75921314|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
75921315|NCT05577273|Drug|Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)|single dose of P.O. Cefuroxime Axetil 500 mg. For penicillin allergy patients, single dose of P.O. Trimethoprim/Sulfamethoxazole 160mg/800mg
75921316|NCT02252913|Drug|Volitinib|oral administration
76078295|NCT01895309|Drug|SB4 (proposed biosimilar to etanercept)|
75328791|NCT02929927|Procedure|Rubber dam isolation|tooth was isolated using a rubber dam in order to avoid the outside microbe
75328792|NCT02929927|Device|aPDT|Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60 s,then irradiation 120 s.
75921317|NCT02252913|Drug|Docetaxel|intravenous injection
75921318|NCT05698030|Other|Food allergy|Oral immunotherapy to pistachio
75921319|NCT03548259|Procedure|Platelet-rich plasma|Platelet-rich plasma injection
75921320|NCT03548259|Procedure|Platelet-poor plasma|Platelet-poor plasma injection
75921321|NCT05542108|Behavioral|Multisensory Stimulation and Family Education Group|Bedside intervention directly with infant with trained healthcare providers and parents. Includes two parts: twice daily multisensory stimulation sessions and separate family education meetings completed with individual infant parent/s and trained operator.
76078296|NCT04738071|Device|PFO closure|PFO closure after stroke or transient ischemic attack
76078297|NCT01884311|Biological|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
75469331|NCT01937936|Behavioral|Health Education|Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
75469332|NCT01937988|Other|Doula Arm|
75469333|NCT01938027|Procedure|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
75635521|NCT05805098|Drug|Homoharringtonine|On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
75921322|NCT05542108|Behavioral|Family Education Only Group (FEG)|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
76078298|NCT01004770|Drug|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
76078299|NCT01004770|Drug|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
76078300|NCT04399317|Device|Flow controlled ventilation (Evone-ventilator)|The new ventilation technique will be applied
76078301|NCT03230877|Device|Toffee full face mask with 'Improved Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Improved Seal in this treatment arm.
76078302|NCT03230877|Device|Toffee full face mask with 'Normal Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Normal Seal in this treatment arm.
75328793|NCT02929927|Drug|1% iodine tincture|use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe
75328794|NCT02929927|Drug|2.5%NaClO|use 2.5% NaClO as irrigants
75469334|NCT01938053|Other|Call when test results are ready|Patients are called when the test results are ready
75921323|NCT05698576|Device|TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT)|A perineal local anesthesia block is performed with patient on lithotomy. The ultrasound probe is advanced, secured to digital stepper. The live ultrasound image feed is visible on the FOCALYX® Fusion device. Image co-registration (MR/US) will be performed. The FOCALYX® Fusion device shows outline of the prostate on the MRI and the target area(s) in real-time. The urologist advances laser fiber introducer, temperature probes to indicated coordinates. Target treatment - applying TRANBERG® laser energy over the treatment area and controlling delivery with a pedal. Treatment is monitored using FOCALYX® Fusion device in real-time. One laser fiber will be used and a single or multiple applications may be required. The fiber will be relocated to other targets if present. Patient will be dismissed to the MRI center where a multiparametric MRI will be conducted. After this study is completed, the patient will be discharged home with instructions and contact information.
75921324|NCT02135835|Drug|Shenfu Zhusheye|
75921325|NCT02135835|Drug|5% glucose injection|
75921326|NCT05546008|Device|Multislice CT|all patient will be subjected to echocardigraphy and multislice ct and compare thier results
75921327|NCT02253459|Drug|UTD1 Injection plus capecitabine|
75635522|NCT05805098|Drug|Cytarabine|On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
75921328|NCT02253459|Drug|Capecitabine|
75635523|NCT05804994|Device|Elgydium Clinic Sensileave Gel (V063B - DP3003)|Tested product is applied/used only once a day before whitening tray wear.
75635524|NCT05804981|Other|PRO-CS|4 questions about cognitive function added to annual wellness visit protocol
75635525|NCT05804968|Other|Digital HIV Self Disclosure Intervention|This project will develop a digital HIV disclosure intervention, drawing from the HEADSUP manual (Evangeli et al., 2020), which consists of four modules, including a HIV disclosure planning component. A SCED will be used to explore HIV disclosure intention, amongst other variables throughout baseline, intervention and follow up phases. Participants will further be asked to complete a participant experiences questionnaire to explore how they found the digital intervention and assess acceptability. This project will recruit a diverse sample of Sub-Saharan Africa adults living with HIV and residing in the U.K.
75635526|NCT02795559|Other|Glucose|75g glucose dissolved in 300ml water
75921329|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV|0.25mL, subcutaneous injection
75921330|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV|0.5mL, subcutaneous injection
75921331|NCT02140047|Biological|Haemophilus influenza type b conjugate vaccine + DPT-IPV|0.5mL, subcutaneous injection
75921332|NCT02135913|Dietary Supplement|Vitamin D|All subjects enrolled into the study will be prescribed standard of care Vitamin D
75921333|NCT02140125|Drug|ASP2408|subcutaneous administration
75921334|NCT02140125|Drug|Placebo|subcutaneous administration
75921335|NCT02140203|Other|Yoga Training|one-year experimental training (three times per week and one hour per session)
75921336|NCT05576961|Drug|RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-6 to D-3 RX-af01: 2 capsules, bid, po, D-2 to D0 Treatment (Every 3 weeks) RX-af01: 1 capsule, bid, po, every day Toripalimab: 240mg, ivdrip, D1, every 3 weeks.
75921337|NCT05576961|Drug|Mixed bacteria|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
75921338|NCT05576961|Drug|High dose RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
75921339|NCT05592496|Procedure|Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.|After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
75921340|NCT05592496|Device|Catheter insertion technique by using special tube t|By using special tube, it is possible to locate the catheters in retromuscular space, where they are close to cutaneous nervs
75921341|NCT05592496|Procedure|"Connection of catheters bilateraly to easy pump system,"|"Connection of catheters, which are inserted in to retromuscular space, to ensure continuous receiving of Bupivacaine fluid for analgesia. Easy pump system provides continous receiving of bupivacaine fluid infusion speed - 5ml per hour"
75921342|NCT05592496|Diagnostic Test|VAS scale for pain control|By using Visual Analog scale of pains, the pain score is fixed
75635527|NCT02795559|Other|Inulin|75g glucose plus 24g inulin dissolved in 300ml water
75921343|NCT05576727|Other|Unruptured intracranial aneurysms|Extensive clinical, biological and imaging data of unruptured intracranial aneurysm patients will be recorded during a 5 years follow-up.
75921344|NCT05697796|Procedure|Two different surgical methods|SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension
75921345|NCT03548181|Behavioral|Virtual Autonomous Physiotherapist Agent (VAPA)|A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
75635528|NCT02795559|Other|Resistant starch|75g glucose plus 28g resistant starch in 300ml water
75635529|NCT05804942|Behavioral|High glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:>70), 20% fat and 20% protein.
75635530|NCT05804942|Behavioral|Medium glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:55-70), 20% fat and 20% protein.
75635531|NCT05804942|Behavioral|Low glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:<55), 20% fat and 20% protein.
75635532|NCT05804929|Other|Observation without intervention|Observation of food intake, body composition, microbiota, genetics, metabolic rate, metabolomics.
75635533|NCT05804916|Device|Surface Guided Radiation Therapy (SGRT)|SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection
75635534|NCT05804903|Device|(ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Plus Transcatheter Heart Valve in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
75784971|NCT05184556|Behavioral|Family-based treatment (FBT)|FBT is a structured behavioral treatment focused on empowering caregivers to take charge of the adolescent's eating behavior and return him/her to a normative weight and developmental trajectory. FBT involves three consecutive phases: 1) caregivers are fully in control of the adolescent's eating; 2) control of eating is gradually returned to the adolescent; and 3) developmental issues are explored. In the current study, FBT is adapted for delivery in the home setting in the following ways: intensified dose of treatment (2-6 hours of therapy per week over 10 - 32 weeks); use of clinician as an additional support to the family; multiple family meals in the home and community; sociocultural tailoring; and inclusion of supplemental individual work with the adolescent to improve emotion regulation/distress tolerance.
75921346|NCT05541718|Behavioral|Reiki|Reiki will be provided by a trained Reiki master with the aim of balancing the flow of energy in the patient's body.
75328795|NCT02929927|Procedure|root canal preparation|mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer
75328796|NCT02929927|Procedure|root canal obturation|filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation
75328797|NCT02693665|Behavioral|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
75635535|NCT05804877|Behavioral|mindfulness-based cognitive therapy|Participants in the experimental group would be arranged to attend online mindfulness-based cognitive programs for eight weeks. Each week was divided into 3 parts, which were detailed mindfulness-based skills training with pictures or short videos, techniques application in different scenarios, and concepts consolidation through a web-based assignment.
75635536|NCT05804877|Other|Mental health education|The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
75635537|NCT05804864|Drug|KM501|1a: The program evaluated six dose levels, i.e., 0.1, 0.3, 0.6, 1.2, 1.8, 2.4 mg/kg, An accelerated titration was performed in the 0.1 and 0.3 mg/kg dose groups, and then a Bayesian optimal interval design was used to determine MTDS for four subsequent dose levels. Ib: The antitumor activity of KM501 monotherapy in subjects with specific types of tumors that are HER2-positive or express, amplify, or mutate will be evaluated at the RP2D dose level
75635538|NCT05804799|Diagnostic Test|Contrast-enhanced liver CT scan|"The contrast-enhanced liver CT scans were obtained from all of the participants.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction."
75784972|NCT05184556|Behavioral|Integrative family therapy|The integrated family therapy approach includes psychoeducation, supportive family therapy, and elements of cognitive-behavioral interventions. Families may be referred for additional nutritional counseling and prescribed a meal plan as indicated. Typical strategies include educating families on the presentation and prognosis of adolescent AN; identifying dysfunctional family structures/alliances and communication patterns; using reflective listening to engage and validate family members; challenging maladaptive beliefs about eating and weight; and supporting families in developing strategies for management of both general and eating disorder-specific distress. Treatment is generally non-directive.
75921347|NCT05541718|Behavioral|Sham Reiki|Sham Reiki will be delivered by an individual trained to simulate the Reiki interventionist's movements, but they will not visualize patient healing
75921348|NCT05541718|Behavioral|Mindfulness Meditation|The mindfulness meditation intervention will be adapted from a standardized mindfulness induction script validated in prior research. The mindfulness practice will guide patients to focus attention on breath and body sensations while monitoring and accepting discursive thoughts, negative emotions, and pain. The MM interventionist will be a trained mindfulness provider and have experience using MM in medical settings.
75921349|NCT05545696|Device|AI on algorithm|The mandibles of the participants were scanned with ''AI on'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
75921350|NCT05545696|Device|AI off algorithm|The mandibles of the participants were scanned with ''AI off'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
76078303|NCT04469374|Other|Jumping exercise|Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.
76078304|NCT04469374|Other|Balance exercise (sham control)|Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
75328798|NCT00932035|Procedure|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
75328799|NCT00932035|Drug|isosulfan blue based lymphatic mapping|
75328800|NCT00932035|Procedure|axillary lymph node dissection|Undergo standard axillary lymph node dissection
75328801|NCT00932035|Procedure|quality-of-life assessment|Ancillary studies
75328802|NCT00932035|Other|Questionnaire administration|Ancillary studies
75328803|NCT04362397|Behavioral|FoCo|This is an attention, care and self-care training.
75328804|NCT04362397|Behavioral|No intervention|This is a waiting list
75328805|NCT04362241|Drug|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|Prednisolone Acetate 1% ophthalmic drops
75921351|NCT05541640|Drug|normal saline group|normal saline infusion at the start of surgery
75328806|NCT05620069|Other|Music listening|Participants are asked to select one of four music playlists and listen to it for appr. 30 minutes at bedtime during the intervention period.
75921352|NCT05541640|Drug|lidocaine group|lidocaine infusion at the start of surgery
75328807|NCT05619757|Behavioral|Compliance with medical treatment for endometriosis|"During their scheduled consultation at the Hôpital Femme Mère Enfant (HFME), women who meet the eligibility criteria will be presented with the study and given the written information note. If they agree to participate, the investigator will give them a QR code redirecting them to the online self-questionnaire.~Patients will be included once they log in and complete the questionnaire."
75635539|NCT05804760|Diagnostic Test|Measurement of implant parameters|"Examination of the inclusion criteria~Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption."
75328808|NCT04362319|Diagnostic Test|Questionnaire forms|Assessment of demographics, burnout, depression and self-perceived medical errors
75635540|NCT05804734|Drug|Vitamin K Antagonist - Drug|"Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment."
75328809|NCT01384513|Drug|Fludarabine|Given IV
75469335|NCT01938053|Other|Text message when test results are ready|Patients receive a text message when results are ready
75469336|NCT01938053|Other|Call and text message when test results are ready|Patients receive both a call and a text message when test results are resay
75469337|NCT01938092|Drug|Diazepam|
75469338|NCT01938092|Drug|Placebo|
75469339|NCT01938105|Other|Nimotuzumab+chemoradiotherapy|"Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.~--------------------------------------------------------------------------------"
75635541|NCT05804721|Drug|Apipe (Aripiprazole10 mg)|Test drug
75635542|NCT05804721|Drug|Abilify (Aripiprazole10 mg)|Reference drug
76078305|NCT01884077|Device|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
75635543|NCT05804695|Procedure|Arthroscopic TMJ disc repositioning under GA|a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
76078306|NCT01884077|Device|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
75921353|NCT05492643|Biological|one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)|all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
75921354|NCT05492643|Other|Cellular Immunity|the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
75921355|NCT05492643|Other|Humoral Immunity|the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
75921356|NCT05492643|Other|Safety|all the 500 participants enrolled will undergo safety observation
75921357|NCT02739594|Drug|Ibandronate|Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
75328810|NCT01384513|Drug|Busulfan|Given IV
75328811|NCT01384513|Radiation|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
75328812|NCT01384513|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
75328813|NCT01384513|Drug|Cyclophosphamide (CY)|Given IV
75328814|NCT01384513|Drug|Tacrolimus|Given IV or PO
75328815|NCT01384513|Drug|Mycophenolate mofetil|Given IV
75469340|NCT01938118|Behavioral|Obesity Prevention Group|
75469341|NCT01938118|Behavioral|Injury Prevention Group|
75921358|NCT02739594|Drug|Zoledronate|Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
75921359|NCT05545618|Diagnostic Test|CCTA and 18F-FDG-PET/CT|18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days
76078307|NCT04614311|Drug|Triamcinolone Hexacetonide 20 MG/ML|JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints
76078308|NCT03922204|Drug|MCLA-145|full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137
76078309|NCT04717791|Device|Vivaer® ARC Stylus|The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
75469342|NCT01938131|Device|repeated Muscle Vibration (rMV) (Cro ® System)|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
75469343|NCT01938144|Drug|Advil Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.
75784975|NCT05180344|Behavioral|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
75921360|NCT05541562|Diagnostic Test|clinical laboratory tests, and imaging characteristics|Data included the demographic status, etiology of the liver disease, clinical laboratory tests, and imaging characteristics. Clinical laboratory tests included D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin III, international normalized ratio (INR), thrombin time (TT), albumin (Alb), serum creatinine, hemoglobin, platelet count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, model for end-stage liver disease (MELD) score, and Child-Pugh score. Imaging characteristics included splenic vein diameter, splenic vein velocity, portal vein diameter, and portal vein velocity.
75921361|NCT03548025|Device|BTL-703 (Treatment group)|Treatment with BTL-FR2000 Device
75921362|NCT02140281|Drug|Treatment A (cefadroxil alone)|A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
75921363|NCT02140281|Drug|Treatment B - AZD1722 followed by cefadroxil|15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
75921364|NCT05592106|Diagnostic Test|T1 mapping on gadoxetic acid-enhanced MRI|All subjects underwent 1.5T Gd-EOB-DTPA-enhanced MRI including pre-contrast and hepatobiliary-phase T1 mapping.
75921365|NCT05489133|Behavioral|Modified prolonged exposure|Imaginary and in vivo expo, in addition to psychoeducation
75921366|NCT05592028|Device|transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy|XDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy.
75921367|NCT05541328|Other|Tisagenlecleucel|The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
75921368|NCT05545462|Drug|Doxycyclin|THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
75921369|NCT05545462|Other|COMMON SALT|THE USE OF COMMON SALT IN TREATMENT OF UMBILICAL GRANULOMA
75921370|NCT05541172|Drug|Testosterone Undecanoate|Testosterone undecanoate (1000 mg/4 ml) will be administered at a dose of 1 ml every 12 weeks for 6 months, 2 ml every 12 weeks for 6 months, 3 ml every 12 weeks for 6 months and 4 ml every 12 weeks for 6 months.
75469344|NCT01938144|Drug|Advil Allergy and Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.
75635544|NCT05804682|Procedure|Fascial Neck Dissection|Central and lateral neck dissection with the fascial technique
75635545|NCT05804682|Procedure|Standard Neck Dissection|Central and lateral neck dissection with the standard technique
75921371|NCT05478993|Drug|SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone|"Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.~If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events."
75921372|NCT05699356|Other|Non Surgical treatment|Non Surgical
75921373|NCT05699356|Procedure|laparoscopic drilling|Surgical intervension
75921374|NCT05699356|Behavioral|Treatment of Poly cystic ovary for infertility by Life style modification|Non Surgical
75921375|NCT05699356|Procedure|Treatment of Poly cystic ovary for infertility by Assisted reproductive technique|Surgical intervention
76078310|NCT04713579|Other|No intervention - observational study|There is no intervention in this study as it is purely observational.
75328816|NCT01384513|Device|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
75635546|NCT05804656|Drug|CKDB-501A|Intramuscular injection CKDB-501A
75635547|NCT05804656|Drug|Botox®|Intramuscular injection Botox®
75635548|NCT05804630|Drug|Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)|As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
75784976|NCT05180344|Behavioral|Treatment as Usual + Ecological Momentary Assessment (TAU + EMA)|Safety Planning Intervention; ecological momentary assessment only
75784977|NCT05180318|Drug|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
75784978|NCT05180318|Drug|0.9% saline|0.9% saline
75784979|NCT05169437|Drug|Niraparib|Eligible participants will receive daily dosing of Niraparib.
75921376|NCT05478447|Procedure|Vibration|whole-body vibration, and tendon vibrations will be applied to the human body
75921377|NCT05591872|Drug|LD+I+TRB|Same as in the arm description
75328817|NCT01384513|Procedure|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
75328818|NCT05613907|Other|CLTI Clinic|This is a specialist clinic designed to assess and manage patients with CLTI.
75328819|NCT03035617|Drug|Bupivacaine|Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .
75328820|NCT03035617|Other|Saline|In control arm mesh will be soaked in normal saline solution as is routinely done.
75328821|NCT02933320|Biological|BI-1206 single agent dose escalation phase|BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.
75469345|NCT01938144|Drug|Paracetamol|Acetaminophen 500 mg, 4x/day, up to 8 doses.
75921378|NCT02140359|Behavioral|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
75921379|NCT03989232|Drug|Semaglutide|Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
75635549|NCT05804617|Procedure|Dome-type (Modified C-incision) manual morcellation|Morcellation performed by surgeon or trainee
75921380|NCT03989232|Drug|Placebo (semaglutide)|Semaglutide placebo injected once-weekly from week 13 to week 40.
75921381|NCT02140437|Drug|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
75635550|NCT05804591|Drug|Pregabalin 150mg|Single dose of pregabalin 150mg in a capsule per os 1 hour before start of the operation.
75635551|NCT05804591|Drug|Placebo|1 capsule containing placebo per os 1 hour before start of the operation.
75921382|NCT02140437|Drug|Anastrozole|standard endocrine therapy
75921383|NCT05697640|Drug|Vericiguat Oral Tablet|The treatment period includes ten weeks of daily vericiguat or placebo intake (depending on randomization) and a 30-day follow-up period (no vericiguat/placebo intake).
75921384|NCT03549195|Procedure|ICG|The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
75469346|NCT01938157|Procedure|Diffusion-weighted MR imaging|An addition 90 seconds of DWI will be added to a clinical breast MRI for all patients agreeing to participate in the study.
75635552|NCT05804565|Procedure|Bone Saw|The surgeon will use an oscillating microsaw to transect the metatarsal shaft
75635553|NCT05804565|Procedure|Bone Cutter|The surgeon will use a manual bone cutter to transect the metatarsal shaft
75635554|NCT05804539|Behavioral|Manual therapy|The therapist checks the range of motion of the cervical joints and gives manual treatment to the restricted joints. Throughout the examination, the subject lied in a supine position on a professional rehabilitation bed with the seventh cervical vertebra (C7) on the edge of the bed and the other the body above the C7 were placed off the bed. The therapist held the subject's occipital bone with one hand and the radial aspect of the second metacarpophalangeal joint of the other hand to grip the spinous process of the sixth cervical vertebra and slowly pushed the occiput downward to check the joint mobility of the fifth cervical vertebra and the sixth cervical vertebra. After the examination, the restricted joint was accurately located and treated with targeted manual therapy. For example, stretching was performed with the right side of C4-C5 flexed, closing only the right side of the subject's C4-C5 as much as possible to increase joint mobility on the right side of C4-C5.
75635555|NCT05804539|Behavioral|Tai Chi|Based on the characteristics of young people and the need to correct their FHP, the classic Yang's 24 Forms of Tai Chi has been improved. The movements are mostly upper limb movements and the lower limb movements have been simplified to make the movements easy to learn. The modified Tai Chi exercise retains the traditional Tai Chi movements but is simple and easy to learn; at the same time, it increases the movement of the shoulder and neck joints. The subjects performed each exercise session in a group setting at the school gymnasium, with a professional Tai Chi instructor guiding them through a warm-up session, followed by a Tai Chi exercise session.
75635556|NCT05804539|Behavioral|Tai Chi and Manual therapy|Intervention content of MSG included 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy.
75635557|NCT05804474|Other|Observational study|Observational study
75921385|NCT03549195|Procedure|ICG-CP|The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
75921386|NCT03549195|Procedure|ICG-TMTP1|The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
75921387|NCT05697562|Procedure|Rubber band ligatures (RBL)|This instrumental technique is realized during consultation. A rubber band is applied on top of each hemorrhoidal complex via a proctoscope. This banding causes an ulceration which heals with resulting fibrosis. The patient can receive a maximum of 3 RBL during each session, which can be repeated up to 3 times at a 6 weeks interval.
75328822|NCT02933320|Biological|Combination of BI-1206 with rituximab escalation phase|An investigation of combination treatment of BI-1206 with rituximab.
75328823|NCT02933320|Biological|BI-1206 single agent expansion phase|BI-1206 single agent expansion phase at the RP2D.
75469347|NCT01938183|Procedure|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
75469348|NCT01938183|Drug|Metronidazole tablet|750 mg metronidazole tablets
75469349|NCT01938183|Drug|placebo gel|semi-solid suspension containing carbopol
75469350|NCT01938183|Drug|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
75328824|NCT02933320|Biological|Combination of BI-1206 with rituximab expansion phase|BI-1206 in combination with rituximab at the RP2D.
75328825|NCT05613829|Other|Burn surgery|Patients underwent burn surgery
75328826|NCT04361773|Radiation|Photobiomodulation|Treatment with a device with 144 light emitting diodes (LEDs) at wavelengths of 420, 660 and 850nm, 3J per point for 10 minutes.
75469351|NCT01938196|Drug|KWA-0711|
75469352|NCT01938196|Drug|Placebo|
75469353|NCT01938209|Other|seated thoracic manipulation|seated general thoracic spine manipulation
75469354|NCT01938209|Other|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
75784980|NCT05161819|Device|Repetitive transcranial magnetic stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses
75784981|NCT05161819|Device|Sham stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses (with sham coil)
75784982|NCT05155111|Diagnostic Test|Telemedicine consult|A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
75328827|NCT04361773|Other|Sham Photobiomodulation|Simulation of the LED application, with a device with external characteristics identical to that of the PBM group, for the same period of time.
75784983|NCT05153083|Procedure|Open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Each participating center will be able to use its preferred European Conformity marked device, for cryoablation according to their normal clinical practice and according to the instructions for use.
75328828|NCT02933476|Device|Vibrotactile Stimulation|The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
75328829|NCT04361695|Procedure|Hemorrhoidectomy|The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
75328830|NCT04361695|Drug|Ketoprophenum|Ketoprophenum
75328831|NCT04361695|Drug|Placebo|Placebo
75469355|NCT01938222|Procedure|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
75469356|NCT01938235|Drug|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
75469357|NCT01938235|Drug|Placebo|Intravenous bolus and 24-hour infusion of placebo
75635558|NCT05804422|Dietary Supplement|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
75784984|NCT05151328|Drug|Plecanatide|Plecanatide or Placebo; Route of Plecanatide/placebo administration: tablet; dosage: 30mg, dosage form oral; Frequency of administration: QD
75921388|NCT05697562|Procedure|Superior Rectal Artery Embolization (SRAE)|"This technique is realized under local anesthesia during a one-day hospitalization. The interventional radiologist will perform the procedure in the angiography room. After local anesthesia right femoral artery puncture is performed and a 4 F or 5 F introducer sheath is placed using the Seldinger technique. With an appropriate 4 or 5 F catheter the superior rectal artery is catheterized. With a microcatheter the different branches are selectively occluded with microcoils. The endpoint of embolization is reached when all SRA branches above the pubic ramus are embolized, with cessation of flow distally or a static column of contrast.~The procedure can be repeated with addition of the embolization of the middle rectal wall artery (MRA) in case of failure after 12 weeks."
75784985|NCT05146830|Other|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
75784986|NCT05145452|Dietary Supplement|Fish-oil derived n-3 polyunsaturated fatty acids|4.2 g/d (7 pills with 600 mg each)
75784987|NCT05145127|Drug|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
75469358|NCT01938274|Other|Educational intervention|A 30-minute discussion and slide presentation with a trained member of the research team.
75469359|NCT01938287|Device|SENSIMED Triggerfish|
75469360|NCT01938300|Drug|Magnesium Sulfate|
75469361|NCT01938300|Drug|Normal saline|
75328832|NCT03035773|Behavioral|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
75469362|NCT01938313|Procedure|ERAS perioperative cares|"Patient's preoperative counseling & education before surgery~No Bowel preparation~Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~Fluid restriction & Management by pulse contour analysis or transesophageal doppler~Early mobilization~Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))~Epidural patient controlled analgesics (no opioids analgesics)~Postoperative Nausea Active Control~Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)~Perioperative High content Oxygen therapy~No drain insertion~No Levin tube~Patients will be discharged at POD#4 if there's no problem."
75635559|NCT05804422|Dietary Supplement|Placebo|Placebo
75635560|NCT05804409|Diagnostic Test|FECAL ELASTASE|screening for pancreatic exocrine insufficiency in MAFLD patients
75635561|NCT05804370|Drug|Gleolan|Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength [λ] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.
75635562|NCT05804357|Behavioral|Manual Therapy|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion
75635563|NCT05804357|Behavioral|Exercise|It is an approach that is combined with diaphragmatic breathing, activating the passive-active musculoskeletal and neural systems. In this approach, transversus abdominis and multifudus muscles are activated as deep core muscles.
75635564|NCT05804344|Device|Anodal speech motor tDCS|tDCS montage set for Anode: C5; Cathode: Fp2
75635565|NCT05804344|Device|Cathodal speech motor tDCS|tDCS montage set for Anode: Fp2; Cathode: C5
75784988|NCT05140902|Device|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
75784989|NCT05138510|Behavioral|Focus Group|"Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred.~We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material.~Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison."
75328833|NCT03035773|Behavioral|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
75784990|NCT05130775|Other|Transesophageal echocardiograpgy|3D acquisition of the right ventricle regurgitation volume
75784991|NCT05119907|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
75784992|NCT05109234|Drug|Brivaracetam Film-coated tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Brivaracetam film-coated tablet [10, 25 or 50 mg] will be administered twice per day in equal doses."
75784993|NCT05109234|Drug|Brivaracetam oral solution|"Pharmaceutical form: Oral solution~Route of administration: Oral use~Brivaracetam oral solution [10 mg/mL]) will be administered twice per day in equal doses."
75328834|NCT03035773|Behavioral|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
75328835|NCT03035149|Other|Weight Management Program|Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
75328836|NCT03035383|Procedure|Purse string technique|Thyroidectomy closure is performed using purse string suturing technique.
75328837|NCT03035383|Procedure|Conventional technique|Thyroidectomy closure is performed using conventional suturing technique.
75328838|NCT05563675|Drug|Long acting muscarinic antagonists (LAMAs) at bedtime|LAMAs administered at bedtime (approx 8-10pm)
75328839|NCT02933866|Drug|DSXS topical|topical treatment
75328840|NCT02933866|Drug|Vehicle topical|topical treatment
75469363|NCT01938313|Procedure|Conventional perioperative cares|"No Patient's preoperative counseling & education before surgery~Bowel preparation~No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~Conventional Mobilization~Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~IV PCA~Postoperative Nausea Control if needed~No Thromboembolism prophylaxis~No or Low Content Oxygen therapy~Routine drain insertion~Levin tube insertion if needed"
75328841|NCT05555251|Drug|BI-1607|administered at different doses in Phase I by intravenous infusions every 3 weeks.
75469364|NCT01938339|Device|PET/MR|Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
75469365|NCT01938352|Biological|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
75469366|NCT01938352|Biological|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
75784994|NCT05096442|Device|GENOSS® DCB|Drug Coated Balloon
75784995|NCT05096442|Device|SeQuent® Please NEO|Drug Coated Balloon
75784996|NCT05090709|Other|Spinal Mobilisation Intervention|30 minutes spinal mobilisations, rate = 0.37Hz, 22 beats per minute, force = less than grade 1, threshold of 80N, location = L1-L5.
75784997|NCT05090709|Other|General Massage|30 minutes manual touch with no specifications or recordings on rate, pressure or location of touch.
75469367|NCT01938404|Biological|Octaplas|Octoplas infusion solution for IV administration
75469368|NCT01938404|Drug|Standard Plasma|Plasma given as replacement fluid
75469369|NCT01938417|Drug|tobramycin|
75469370|NCT01938443|Drug|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
75469371|NCT01938443|Drug|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
75784998|NCT05087875|Behavioral|TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. Participants set goals for reducing their drinking and learn strategies to help them achieve those goals. It requires four 30-minute sessions with a counselor using mobile phones.
75784999|NCT05087875|Other|No intervention|The comparison group will be evaluated based on daily self-monitoring data.
75785000|NCT05085977|Biological|TARA-002|Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
75785001|NCT05073237|Other|Placebo|Daily placebo tablet
75785002|NCT05073237|Drug|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20mg.
75785003|NCT05059327|Drug|Basimglurant with crossover to Placebo|Basimglurant with crossover to Placebo
75921389|NCT05697562|Procedure|Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL)|The procedure is performed in lithotomy position with a modified proctoscope including a Doppler transducer (THD device) under anesthesia during a one-day hospitalization. This transanal Doppler guidance enables accurate detection and targeted suture ligation of the SRAs Following gel lubrication, the proctoscope is inserted through the anal canal reaching the low rectum, about 6-7 cm from the anal verge. After identification of the best place for artery ligation, the Doppler system is turned off. The artery will be directly ligated with a Z-stitch at the site of the best Doppler signal.
75921390|NCT05697484|Device|educational game|"Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, an access to the mobile game after a simple training for game usage. Both groups will be followed for a period of 3 months.~The mobile game is planned to have the following design:~Game will be presented in Arabic language.~The game will consist of four levels. a. At the beginning of each level there will be an educational video that the patient must watch in order to be allowed to start the level."
75921391|NCT05545228|Behavioral|Link work intervention|Intervention from a link worker to support participants to access dental services.
75921392|NCT03547401|Device|Ankle Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the arm (model IntelliVue M8105a MP5 Phillips, calibrated).
75921393|NCT03547401|Device|Arm Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the ankle (model IntelliVue M8105a MP5 Phillips, calibrated).
75921394|NCT03526692|Behavioral|Neurofeedback|Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
76078311|NCT04579029|Procedure|Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging|Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
76078312|NCT04705545|Device|transpalatal arch group|transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.
75785004|NCT05059327|Drug|Placebo with crossover to Basimglurant|Placebo with crossover to Basimglurant
75785005|NCT05057858|Drug|co-formulated 300 mg TDF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
76078313|NCT04705545|Device|Nance button|Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
76078314|NCT05066698|Biological|ST266|Topical ocular application: one drop four times a day for eight weeks
75798610|NCT03866070|Other|Experimental|Two exercises will be done to strengthen the external rotation (using elastic bands): standing with 90 degrees of shoulder abduction and elbow flexion and also in standing with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. Dumbbell exercises will be performed through 4 exercises: flexion in the horizontal plane of 135º, external rotation in lateral decubitus, horizontal abduction with external rotation, and extension in prone position. There will be 5 repetitions each exercise of 3 seconds each, with 2 minutes of rest between exercises.
75328842|NCT05555251|Drug|BI-1607|administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
76078315|NCT05066698|Other|0.67% Sodium Chloride Ophthalmic Solution|Topical ocular application: one drop four times a day for eight weeks
75328843|NCT05555251|Drug|Trastuzumab|administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
75328844|NCT03035305|Dietary Supplement|Lipid-based Nutrient Supplement (LNS)|"For each round of SMC distribution (total of 4 rounds):~For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks~For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks"
75328845|NCT03035305|Drug|Seasonal malaria chemoprevention|"For each round of SMC distribution (total of 4 rounds):~For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine"
75328846|NCT02935036|Drug|ADPS topical product|topical product
75328847|NCT02935036|Drug|Placebo Control|topical product
75328848|NCT03035071|Procedure|minimally invasive esophagectomy|In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.
75328849|NCT03035071|Procedure|open esophagectomy|in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.
75921395|NCT03940872|Diagnostic Test|Self-questionnaire 3PDQ|"Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire.~- An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once."
75798611|NCT03866070|Other|Control|Two exercises will be done to strengthen the external rotation, using elastic bands. The first, standing, with 90 degrees of shoulder abduction and elbow flexion. The second, also in standing, with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. The band will be subject to a surface, at an equal distance from the subject's elbow to the ground. The repetitions will last one second in concentric external rotation and two seconds in eccentric external rotation, with a rest of 30 seconds between series.
75328850|NCT03034837|Drug|resin sealant|Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.
75328851|NCT03034837|Drug|ART sealant|"Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once."
75328852|NCT03034759|Other|individualized insulin sensitivity index (ISind)|"The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads."
75328853|NCT02158273|Drug|Sugar Pill|145 mg/day, oral pill, 9 days
75328854|NCT02158273|Drug|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
75328855|NCT02819284|Drug|KPI-121 0.25% Ophthalmic Suspension|
76078316|NCT05066698|Biological|Open-label ST266|Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
75328856|NCT02819284|Drug|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
75328857|NCT04361461|Drug|Hydroxychloroquine Sulfate|400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
75328858|NCT04361461|Drug|Hydroxychloroquine Sulfate + Azythromycin|400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
76078317|NCT04277793|Behavioral|Monitored self-guided problem solving|Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
76078318|NCT05058742|Device|AuriStim|Auricular vagal nerve Stimulator, which Targets the auricular branches of the vagal nerve
75328859|NCT03002506|Drug|Ceftolozane/tazobactam|Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
75328860|NCT03034993|Behavioral|Text Messaging|"Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response."
75328861|NCT02822950|Drug|Ceftazidime/avibactam|Ceftazadime/avibactam dosing in ICU patients
75469372|NCT01938456|Drug|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
75328862|NCT03034681|Other|Physiotherapy technique: TENS|
75328863|NCT03034681|Other|Physiotherapy technique: Vojta Therapy|
75328864|NCT02935738|Drug|Prednisolone treatment|Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
75328865|NCT00932659|Device|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
75469373|NCT01938456|Drug|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
75635566|NCT05804344|Device|Anodal IFG tDCS|tDCS montage set for Anode: F3; Cathode: Fp2
75635567|NCT05804344|Device|Cathodal IFG tDCS|tDCS montage set for Anode: Fp2; Cathode: F3
75635568|NCT05804344|Device|Sham tDCS|tDCS device set in Sham mode
75635569|NCT05804305|Drug|Misoprostol|Misoprostol is a prostaglandin E1 analogue
75635570|NCT05804305|Drug|Placebo|Placebo contained substance that has no therapeutic value.
75635571|NCT05804292|Other|Questionnaire administration|Questionnaire administration
75635572|NCT05804279|Drug|BPDO-1603|donepezil/mematine
75635573|NCT05804253|Procedure|Maxillary sinus augmentation|Maxillary sinus grafting with 2 different xenogenic materials
75635574|NCT05804149|Device|acupuncture|study group take acupuncture Acupuncture was applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.
75328866|NCT03034447|Other|Questionnaire|Children and parents are going to inform data regarding socioeconomical status, asthma and rhinitis diagnosis, asthma and rhinitis control, medications, sleep complaints, and sleep habits
75469374|NCT01938456|Drug|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter^2 or 75 mcg/body
75469375|NCT01938469|Other|Liquid Meal|
75921396|NCT05451069|Diagnostic Test|Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells|"Serum and CSF levels assay of NfL and CHI3L1 using the enzyme linked immunosorbent assay kits (ELISA).~Peripheral blood mononuclear cells (PBMC) will be obtained by Ficoll-Hypaque gradient. plasmacytoid dendritic cells will be identified in (CSF) and (PBMN) based on their selective expression of surface antigen (cluster of differentiation 303) CD303, named blood dendritic cells antigen 2 (BDCA-2).Antihuman antibodies: BDCA-2, HLA-DR , CD274 , HLA-G and CCR7 for identification of tolerogenic plasmacytoid dendritic cells using flowcytometry."
75921397|NCT05575635|Drug|fruquintinib + concurrent radiotherapy + chemotherapy|"mFOLFOX6: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days, continuous infusion.~fruquintinib: 3mg/d, qd po, for 7 weeks continuously.~Radiation Therapy: radiation 45.0~50.0 Gy (1.8-2.0 Gy/day or 25 fractions weeks 3-7)"
75921398|NCT05591560|Drug|Itraconazole capsule|Oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group II
75921399|NCT05591560|Drug|Placebo|4 placebo capsules for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group I
75921400|NCT05540470|Drug|PART|"Chloroquine(150mgs tablets) weight-adjusted dosage ; An 8-aminoquinoline drug~Primaquine (PQ) (15 mg tablets): weight-adjusted dosage. (Rationale: this short-course posology has been chosen to facilitate the adherence to treatment for asymptomatic individuals participating to the Module A, Primaquine will be administered to all participants to Module A during the induction phase of the intervention.~OR tafenoquine (TQ) (150 mg tablets): 2 tablets as a single dose (orally), (Rationale: the posology chosen corresponds to that used in phase III trials for the radical cure of P. vivax and the therapeutic recommendation in Brazil). Tafenoquine will only be administered during the full implementation phase to participants who do not meet exclusion criteria."
75921401|NCT05540470|Drug|Malakit|"delivery of a sturdy, lightweight, waterproof plastic involucre that contains:~1 laminated sheet with illustrated instruction~1 complete anti-malarial treatment targeting P. falciparum, but also effective in acute forms of P. vivax with association with artemisinin derivatives~A blister of 24 tablets of Artemether 20 mg + lumefantrine 120 mg of generic medication~Two 15 mg tablets of primaquine, to be given as a single dose (145)~1 symptomatic treatment (analgesic, antipyretic): a blister pack of 10 paracetamol 500 mg tablets~3 Malaria rapid diagnostic tests (RDTs) in individual packs and with easy-to-use retractable lancets. Three tests will be included, taking into account the possibility of having one or two negative or invalid tests before returning to a distribution site for further supplies."
75921402|NCT05540470|Other|CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS|Surveys will include the collection of a detailed questionnaire on recent malaria and mobility history, a clinical examination, and a venous blood sample
75328867|NCT03034447|Other|Lung Function Test|Children are going to blow in a machine that measures how the lung is working
75328868|NCT03034447|Other|Home Sleep Study|Children are going to sleep at home with a device that tells if they stop breathing during sleep
75469376|NCT01938469|Other|Solid Meal|
75785006|NCT05056415|Other|Everyday Life Rehabilitation (ELR)|"Everyday Life Rehabilitation (ELR) is an intervention model for integrated occupational therapy in close collaboration with housing staff in sheltered and supported housing facilities (Lindström, 2007; 2011), aiming at personal recovery and engagement in meaningful everyday activities for persons with SPD. The mediators are: personcentred, motivational, recovery- and activity-based methods, negotiation of user goal priority and expected outcome; methods for training in real-life situations; devices for collaboration; support from staff on an everyday basis; and an educational package including web-sections, manuals, and collegiate tutorial.~The language and actions of professionals promote hope, self-discovery and shared-decision making, shaped in partnership with residents. The resident is also encouraged to access different resources outside of health and social care such as family, peer and social support, out-of-housing strategies, and sources in the open society."
75328869|NCT00939991|Drug|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
75328870|NCT03034369|Other|Access to Care|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.
75328871|NCT03034369|Other|Depression Screening|Analysis of health care claims data for depression screenings at baseline and 12 months.
75328872|NCT03034369|Other|Patient-Provider Relationship|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.
75469377|NCT01938482|Drug|0.3% GSK1940029 gel|Will be supplied as gel for topical application
75469378|NCT01938482|Drug|1% GSK1940029 gel|Will be supplied as gel for topical application
75469379|NCT01938482|Drug|0.3%/1% vehicle gel only|Will be supplied as gel for topical application
75469380|NCT01938508|Drug|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
75469381|NCT01938521|Dietary Supplement|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
75469382|NCT01938521|Dietary Supplement|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
75328873|NCT03034369|Other|Patient-Clinic Interactions|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.
75328874|NCT03034369|Other|Stigma|Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.
75328875|NCT03034369|Other|Provider Continuity|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.
75328876|NCT03034369|Other|Symptom Severity|Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.
76078319|NCT03832101|Behavioral|MATB|MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
75328877|NCT03034369|Other|Diagnoses|Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.
75328878|NCT03034369|Other|Social support|Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.
75328879|NCT03034369|Other|Preventive Screening|Analysis of health care claims data for preventive screenings at baseline and 12 months.
75469383|NCT01938534|Drug|Helicobacter pylori eradication|
75469384|NCT01938560|Other|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
75635575|NCT05804149|Drug|Thyroxine|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine
75635576|NCT05804149|Dietary Supplement|low caloric diet|Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
75469385|NCT01938586|Other|Steri-Strip|
75469386|NCT01938586|Other|Superficial sutures|
75469387|NCT01938612|Drug|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
76078320|NCT03685318|Device|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
76078321|NCT03685318|Device|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
76078322|NCT03617302|Drug|Experimental: Nitrate-containing|Experimental
75469388|NCT01938612|Drug|tremelimumab|tremelimumab is administered by IV infusion every 4 weeks
75469389|NCT01938638|Drug|BAY1143572|
75785007|NCT05056415|Other|Treatment as usual (TAU)|No standardized instructions about the efforts is given to staff at the accommodations. Usually, only short terms efforts are offered to residents, such as prescribing technical aids.
75785008|NCT05055050|Drug|UGN-201|Intravesical 200 mg /50 ml x 1 dose
75785009|NCT05053503|Device|Sparrow Ascent Therapy System|Transcutaneous auricular neurostimulation (tAN)
75785010|NCT05053503|Drug|Lofexidine|Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
75785011|NCT05053503|Drug|Extended-release injectable naltrexone|Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
75328880|NCT03034369|Other|Inpatient Hospitalization Utilization|Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.
75328881|NCT03034369|Other|Inpatient Readmissions|Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.
75328882|NCT03034369|Other|Post-Admission follow-up|Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
75328883|NCT05375695|Other|Time-restricted eating|"The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.~Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care."
75328884|NCT03034213|Device|Gentrix™ Surgical Matrix (Treatment)|Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
75469390|NCT01938651|Procedure|high field strength magnetic resonance imaging|Undergo 7T MRI
75469391|NCT01938651|Procedure|magnetic resonance spectroscopic imaging|Undergo 31P MRS
75469392|NCT01938651|Procedure|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
75469393|NCT01938651|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
75469394|NCT01938651|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
75469395|NCT01938690|Device|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
75469396|NCT01938729|Procedure|Liver resection and placement of hepatic artery infusion pump|
75469397|NCT01938729|Drug|FLOXURIDINE|
75469398|NCT01938729|Drug|DEXAMETHASONE|
75469399|NCT01938729|Drug|GEMCITABINE|
75469400|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 60 mg dextrose
75469401|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 80 mg dextrose
75469402|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 100 mg dextrose
75469403|NCT01938781|Drug|entecavir|antiviral therapy
75469404|NCT01938781|Drug|Peg-IFN|antiviral and antifibrosis therapy
75469405|NCT01938807|Behavioral|CareCoach mobile application to assist in diabetes management|
75469406|NCT01938820|Drug|entecavir|anti-viral therapy
75469407|NCT01938820|Drug|Thymosin-α|antiviral and antifibrosis therapy
75469408|NCT01938859|Drug|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
75328885|NCT03034213|Device|Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)|A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
75785012|NCT05047055|Drug|Isoniazid|Intensive Phase for 2 months and Continuation phase for 2 months dose: 75 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
75921403|NCT05540470|Other|QUALITATIVE STUDY|Systematic mapping of stakeholders in the pre-intervention period Semi-structured interviews and focus groups. Observational techniques Participatory approach. Participatory design of a community-based adverse event surveillance system
75635577|NCT05804110|Other|Mindful Caring Education Program|A four-session education plan was prepared under the nature of action research. The Theory of Unitary Caring Science is transferred to practice through Caritas processes. In this context, ten Caritas processes and caring-healing modalities (meditation, reflection, etc.) were used in the study. The pilot study was carried out with six nurses face-to-face. The education program was conducted on an online platform. Each education took approximately 2.30-3 hours. The evaluation process in action research is an essential part of the change.
75328886|NCT03034291|Dietary Supplement|Cacao 70%|Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.
75328887|NCT03034291|Dietary Supplement|White chocolate|
75328888|NCT04361305|Drug|Dapoxetine|30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
75328889|NCT04361305|Drug|Tadalafil|5 mg tablets every day for 8 weeks
75328890|NCT04361305|Drug|Tadalafil|5 mg tablets every day for 8 weeks
75785013|NCT05047055|Drug|Rifampicin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 150 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
75921404|NCT05429073|Drug|RGLS8429|solution for subcutaneous injection
75921405|NCT05429073|Drug|Placebo volume-matching RGLS8429 dose|solution for subcutaneous injection
75469409|NCT01938859|Drug|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
75469410|NCT01938859|Drug|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
75635578|NCT05804097|Drug|Hyperbaric oxygen|90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA
75785014|NCT05047055|Drug|Pyrazinamide|Intensive Phase for 2 months only dose: 400 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
75785015|NCT05047055|Drug|Ethambutol|Intensive Phase for 2 months and Continuation phase for 2 months dose: 275 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
75785016|NCT05047055|Drug|Moxifloxacin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 400 mg for 30 to 64 yrs AND 600 mg for 65 and above years of age.
75921406|NCT05591482|Procedure|mesh repair|mesh repair of diaphragmatic hernia
76078323|NCT03617302|Drug|Placebo: Nitrate-depleted|Placebo
75785017|NCT05047042|Behavioral|Advanced Cancer Support in Virtual Rehabilitation and Exercise|The study intervention will consist of an individualized 8-week program of online exercise modules, supervised interactive group class and one-to-one consultations with an exercise or rehabilitation specialist and a pain and symptom physician, delivered via secure live Zoom sessions.
75785018|NCT05031897|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
75921407|NCT05575323|Other|Same-day SBRT and spinal surgery|SBRT and surgical stabilization with or without decompression within 24 hours
75921408|NCT05575323|Other|Standard of care|Surgical stabilization with or without decompression followed by cRT or SBRT as soon as the wound is healed sufficiently
75328891|NCT04361383|Other|control group|the patient will receive general anesthesia
75328892|NCT04361383|Procedure|quadratus lumborum block type 3|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
75469411|NCT01938872|Procedure|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
75469412|NCT01938898|Other|Invitation letter randomisation|"There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~Male & Study & Confidentiality~Male & Study~Male & Project & Confidentiality~Male & Project~Female & Project & Confidentiality~Female & Project~Female & Study & Confidentiality~Female & Study~Neutral & Study & Confidentiality~Neutral & Study~Neutral & Project & Confidentiality~Neutral & Project"
75469413|NCT01938911|Drug|Syntocinon-Spray|Intranasal oxytocin (24 IU)
75469414|NCT01938911|Drug|Placebo of syntocinon|Intranasal administration
75469415|NCT01938911|Behavioral|Social support|Social support from the best friend
75328893|NCT04361383|Procedure|erector spinae plane block|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
75328894|NCT04361071|Device|stent|stent
75328895|NCT04361071|Device|plaque excision system|plaque excision system
75328896|NCT05351437|Drug|MTx-COVAB36|MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
75328897|NCT05351437|Drug|Placebo|0.9% saline
75328898|NCT04361149|Drug|Capsaicin Topical Cream (0.075%)|Capsaicin cream will be administered as a topical skin cream
75328899|NCT04361149|Device|Delsys Trigno Galileo System|A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.
75469416|NCT01938924|Device|GekoTM|electrical neuromuscular stimulation
75469417|NCT01938937|Device|Transcranial bright light device|
75635579|NCT05804071|Drug|Niferex|"Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions"
75785019|NCT05031897|Drug|Mycophenolate Mofetil|Given IV
75785020|NCT05031897|Drug|Tacrolimus|Given IV
75469418|NCT01938937|Device|Transcranial sham device|
75785021|NCT05031897|Drug|Cyclophosphamide|Given IV
75328900|NCT04361149|Device|Excaliber, Natus Medical|Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.
75635580|NCT05804058|Procedure|Revision surgery|Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)
75635581|NCT05804019|Behavioral|Nutritional and physical interventions|The intervention is developed with a focus on nutritional needs and physical activities. The Plan-Do-Study-Act (PDSA) model is used to redefine issues and relevant actions together with residents, relatives, care staff, and nursing home management. The intervention will be developed based on new knowledge from sub-study 1, previous studies, practical experiences, the participant's experiences and wishes as well as the staff's experiences and wishes. Together they will form an implementation catalog, from here, the intervention nursing homes can select a relevant number of components, which will be tested and implemented in practice. The implementation duration is 6 months and the PDSA model is repeated at two-month intervals to strengthen and qualify the intervention. The PDSA model is known to the city's staff in advance and is additionally used in connection to continuing education. The Usual Care Group will continue the usual care.
75785022|NCT05031897|Radiation|Total-Body Irradiation|Undergo TBI
75785023|NCT05031897|Procedure|Donor Lymphocyte Infusion|Undergo DLI
75469419|NCT01938950|Other|Aerobic Exercise|
75635582|NCT05804006|Other|Conventional physiotherapy followed by HIIT-REC program|The experimental protocol will be preceded by 30 minutes of conventional physiotherapy followed by 15 min the rest period; then the HIIT-REC procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload at 50 rpm for weeks 1-2 and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (4 to 6 repetitions). The training intensity will progress similarly by 5% peak workload two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5
75635583|NCT05803993|Procedure|Fecal microbiota transplantation (FMT) Single FMT infusion|Single FMT infusion via colonoscopy
75635584|NCT05803980|Procedure|Fecal microbiota transplantation (FMT)|Single FMT infusion via colonoscopy
75921409|NCT02140515|Drug|Lutropin alfa|Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
75328901|NCT04361149|Other|Placebo Cream|Placebo cream will be administered as a topical skin cream
75328902|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
75469420|NCT01938950|Other|Resistance Exercise|
75469421|NCT01938950|Other|Aerobic and Resistance Exercise|
75469422|NCT01938963|Behavioral|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
75469423|NCT01938976|Behavioral|TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge|Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
75785024|NCT05031897|Drug|Fludarabine|Given IV
75785025|NCT05031897|Drug|Melphalan|Given IV
75785026|NCT05028205|Behavioral|Prevention Plus|Families will receive a behavioral intervention for childhood obesity provided by a BHC. This will consist of three, in-person meetings (months 1, 3, and 5), and three, 20-minute phone calls (months 2,4, and 6). During in-person visits, child height and weight will be taken, and BMI will be plotted on the BMI-for-age growth chart. During these sessions, families will receive feedback on child growth and weight status. Prevention Plus materials and child and caregiver energy balance behavior goals will be reviewed. The phone calls will be with the caregiver, where caregivers will be asked to measure the height and weight of their child, calculate BMI, and plot on the BMI-for-age growth chart. The BHC will discuss the family's progress on achieving child and caregiver goals and implementation of behavioral parenting strategies. Families will receive a fruit and vegetable prescription (FVx) in addition to the standard Prevention Plus family-based behavioral weight loss treatment.
75469424|NCT01939015|Device|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
75921410|NCT02140515|Drug|Follitropin alfa and Lutropin alfa|Administration of (rFSH) and (rLH)
75921411|NCT05544838|Device|LMA insertion with standard technique|"Standard LMA insertion technique; LMA held like a pen and index finger placed at the junction of LMA tube and cuff. Index finger used to press LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of hypopharynx. LMA then held with non- dominant hand and index finger removed.~Rotational LMA insertion; LMA inserted like guedel airway insertion: LMA proximally grasped close to anaesthesia circuit attachment. Insertion was conducted with LMA cuff facing towards nose, hard palate and then advanced into the base of hypopharynx until resistance was felt. At this point, LMA rotated at 180 degree anti-clockwise and LMA tube black line positioned and confirmed on the nasal side."
75921412|NCT05579535|Other|gait training exercises|walking exercises in different directions
75635585|NCT05803967|Behavioral|Baduanjin exercising|baduanjin will be applied 5 times per the week, under supervision, for 12 weeks,
75635586|NCT05803915|Drug|Toripalimab|The participants will receive Toripalimab 240mg intravenous infusion every 3 week, and Nimotuzumab 150mg/㎡ every 2 week for 2 cycles
75785027|NCT05027880|Behavioral|Web-based single-session growth mindset intervention for adolescent anxiety|This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
75328903|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
75635587|NCT05803902|Drug|Experimental drug 9MW1911|Experimental drug administered with IV infusion
75635588|NCT05803902|Drug|Placebo|Placebo administered with IV infusion
75785028|NCT05027711|Radiation|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)
76078324|NCT04334980|Biological|bacTRL-Spike|Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
75328904|NCT04360915|Drug|ASK120067|Take ASK120067 tablets orally in first day at 160 mg in fast condition.
75328905|NCT04360915|Dietary Supplement|ASK120067 in fed condition|Take ASK120067 tablets orally in first day at 160 mg in fed condition.
75635589|NCT05803863|Drug|Myatro|myopia control with 0.01% atropine drops
75635590|NCT05803863|Drug|Myatro XL|myopia control with 0.05% atropine drops
75635591|NCT05803746|Drug|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
75635592|NCT05803720|Behavioral|Provider Intervention on Addressing Intersectional Stigma and Medical Mistrust in Patients with HIV|The intervention will consist of psychoeducation and skills-building for HIV care providers to gain knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
75635593|NCT05803707|Behavioral|Home-based Adapted Physical Activity|There will be 8 weekly sessions at a time defined in advance for the same group and for the 8 sessions
75635594|NCT05803681|Device|Capacitive Coupled Electric Fields (CCEF)|In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.
75635595|NCT05803681|Other|Calssic clinical protocol|(1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
75785029|NCT05027711|Radiation|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)
75785030|NCT05020587|Behavioral|Open pilot trial of a group therapy manual.|Open pilot trial of a group therapy manual.
75785031|NCT05015439|Drug|Cannabidiol|The study intervention will be supplied as a softgel capsule containing cannabidiol.
75785032|NCT05015439|Drug|Placebo|The study intervention will be supplied as a softgel capsule containing inert filler.
76078325|NCT05003908|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75785033|NCT05015218|Diagnostic Test|Vacular Ultrasound|To visualize the internal jugular veins ( IJVs) a linear transducer with a 5-10 MHz linear probe was placed over the neck, and the IJV was measured just below the bifurcation of the sternal and clavicular heads of the muscle. The IJV measurements were performed on the transverse axis over a single respiratory cycle. Patients with evidence of IJV thrombosis were excluded. IJV measurements included the antero-posterior maximum diameter at the end of expiration (IJVmax), the antero-posterior mimimum diameter at the end of inspiration (IJVmin), the IJV collapsibility index (IJV-CI) during spontaneous, quiet, breathing, [(IJVmax - IJVmin diameter)/IJVmax] and the ratio (R) of IJVmax-to-IJV-CI.
75785034|NCT05006794|Drug|GS-9716|Tablet(s) administered orally
75785035|NCT05006794|Drug|Docetaxel|Administered intravenously
75785036|NCT05006794|Drug|sacituzumab govitecan-hziy|Administered intravenously
75785037|NCT05006521|Drug|KN-002|KN-002 dry powder inhaler
76078326|NCT04323748|Drug|rituxan|"The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2"
76078327|NCT03015298|Device|PET/MRI|The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
75328906|NCT05329675|Dietary Supplement|Sinphar Lipucan Capsule|oral Sinphar Lipucan Capsule 1# (Arm A), 2# (Arm B), or 3# (Arm C)/day for 90 days
75328907|NCT05290987|Device|nasal spray|2 sprays in each nostril, 6 times a day
75328908|NCT05147389|Diagnostic Test|AI model classification|AIWorks is an artificial intelligence model for real-time cholangioscopic detection of neoplastic and non-neoplastic bile duct lesions. It allows you to choose using a video file or a USB camera input as the detection source. Once the input source has been selected, the software performs real-time detection by surrounding the area of interest (i.e., the area with malignancy features) inside a bounding box. All detections made are displayed on the right side of the screen and can also be reviewed afterwards.
75341430|NCT01578577|Behavioral|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
75341431|NCT04361396|Other|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy.
75328909|NCT05147389|Diagnostic Test|DSOC endoscopist experts' classification|"Six endoscopists with high DSOC expertise will observe and classify a set of videos among neoplastic or non-neoplastic bile duct lesions following a Bernoulli distribution; blinded to clinical records and should have never attended said patients.~Gastroenterologists from each center, with non-DSOC responsibility, will select DSOC videos and corresponding baseline data. DSOC videos and data will be gathered in one set. Each video represents a full DSOC for a single patient. The patient will be the unit of this study.~The neoplastic bile duct criteria are in accordance with the Robles-Medranda et al and the Mendoza classifications (ie. Irregular mucosa surface, Tortuous and dilated vascularity, Irregular nodulations, Polyps, Ulceration, Honeycomb pattern, etc.). The experts will assess neoplastic bile duct by presence or absence of disaggregated criteria. Likewise, by Boolean logical operators, the statistical software will compute disaggregated answers."
75785038|NCT05004727|Drug|Guselkumab|Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
75635596|NCT05803642|Drug|Olanzapine|intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.
75785039|NCT05004727|Drug|Placebo|• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
75785040|NCT04998305|Drug|TJ-68|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of TJ-68 for three times per day before meals. It will be administered by dissolving 2.5 g of TJ-68 powder in 1 oz. of lukewarm water.
75785041|NCT04998305|Drug|Placebo|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of placebo for three times per day before meals. It will be administered by dissolving 2.5 g of the placebo powder in 1 oz. of lukewarm water.
75785042|NCT04994938|Other|Diet Intervention|Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.
75785043|NCT04994938|Other|Exercise Intervention|Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
75785044|NCT04986046|Other|Home Plate Lite|Home Plate Lite comprises electronic educational content (e.g. recipes, instructional videos) disbursed at least weekly.
75785045|NCT04986046|Other|Virtual Home Plate|Virtual Home Plate comprises two, 45-minute weekly sessions where parents work together with a study staff member to discuss the themes and prepare the components of a meal, including entrees, side dishes, and desserts.
75921413|NCT05591326|Procedure|i-PRF application procedure|Local anesthesia will be applied to the area with gingival recession. Before the procedure, the venous blood taken from the patient will be centrifuged at 700 RPM for 3 minutes in glass and non-addition tubes to obtain i-PRF. i-TZF will be taken into a 2 cc injector. In 2020, Özsağır et al. Decortication, that is, microneedling, will be performed with insulin needle tips according to the protocol defined by Dr. Then the prepared i-PRF will be infected to the apical mucogingival junction of the keratinized gingival area. This process will be repeated once a month for 3 months. After the 3rd month, the horizontal and vertical gingival recession values will be evaluated and recorded at the end of 6 months and 1 year.
75921414|NCT02260947|Drug|PF-06273340|PF-06273340 50 mg
75921415|NCT02260947|Drug|PF-06273340|PF-06273340 400 mg
75921416|NCT02260947|Drug|Pregabalin|Pregabalin 300 mg
75921417|NCT02260947|Drug|Ibuprofen|Ibuprofen 600 mg
75921418|NCT02260947|Drug|Placebo|Matching Placebo
75328910|NCT03033667|Dietary Supplement|G group|patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
75635597|NCT05803642|Drug|Haloperidol|intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.
75635598|NCT05803590|Drug|Green tea mouthwash|effictive against caries and periodontal diseases
75635599|NCT05803590|Drug|Chlorhexidine mouthwash|the gold standard against which other anti-plaque and gingivitis agents are measured
75635600|NCT05803538|Device|SMS, telephone interview or diary card|SMS, telephone interview or diary card
75785046|NCT04986046|Other|Fruit and Vegetable prescription|All families will receive FVRx over two months; FVRx can be redeemed for fresh, frozen, or canned produce at participating retailers in Philadelphia
75785047|NCT04984889|Drug|TAK-662|Lyophilized, sterile concentrate of human protein C
75785048|NCT04983238|Drug|BYON5667 & SYD985|Ocular administration: BYON5667, Intravenous administration: SYD985
75785049|NCT04983238|Drug|Placebo & SYD985|Ocular administration: Placebo, Intravenous administration: SYD985
75921419|NCT05698498|Other|Guaranteed Income|Guaranteed income payments will be disbursed monthly for a total of 24 months to participants who are randomized to the guaranteed income intervention group. Participants will be given the choice to select from one of two different payment strategies (equal monthly payments of $1,000/month vs hybrid payment schedule with initial amount of $6,500 the first month followed by $500/month x 11 months); payment strategy preferences will be re-assessed after 12 months. The choice of payment strategy will be strictly left to participants to specify.
76078328|NCT03015298|Device|PET/CT|At the next day of PET/MRI examination,A PET/CT examination will be performed.
76078329|NCT04296838|Drug|intravitreal injection of Conbercept|patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.
75635601|NCT05803525|Other|Intra-canal medication protocol|"Copious gentle irrigation will be provided without canal instrumentation using 20 mL 1.5% NaOCl in a slow flowing rate by a 27-gauge irrigating side vented needle positioned 2 mm from the root end followed by 20 mL saline.~After root canal dryness using paper points , double antibiotic paste (DAP) containing 500 mg of metronidazole and ciprofloxacin mixed with 0.5 mL polypropylene glycol giving a creamy paste will transported into root canal via lentulo spiral filler positioned 2 mm shorter than the WL apically and to level just below the cement-enamel junction (CEJ) coronally. Access cavity will be sealed response to the initial treatment will be assessed after 3 weeks.(21) In the next visit, If the patient is asymptomatic, the DAP will be removed using 10 mL of NaOCl according to the concentrations mentioned in each study group, followed by copious irrigation with 10 mL of 17% EDTA (22) and normal saline then drying the canals with sterile paper points."
75635602|NCT05803499|Behavioral|Targeted Cognitive Behavior Therapy for Insomnia|This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.
75635603|NCT05803499|Other|Information-Only Control|The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.
75635604|NCT05803460|Behavioral|Stage 1 Experimental A group: actual natural environment|Participants will go to the park and sit still for 20 minutes.
75635605|NCT05803460|Behavioral|Stage 1 Experimental B group: virtual reality natural environment|Participants will experience the virtual reality natural environment by the researcher for 20 minutes
75921420|NCT05698498|Other|Public Benefits Information Session|All participants (both the control and intervention groups) will be offered the option of attending a Public Benefits Information Session during which they will receive a comprehensive resource directory of public benefit, assistance, and social service programs available to residents of Santa Clara County, have the opportunity to ask questions about enrolling in those programs, and also have the opportunity to seek additional benefits navigation assistance from our community partner, Sacred Heart Community Service. This session is intended to be optional, with the decision to attend and participant to be left to the discretion of each study participant. Attendance is not required for study participation.
75921421|NCT05415423|Behavioral|Developing an objective measure of experienced pain|"At the beginning of each study, participants are randomly allocated into one of two groups.~Within each group all participants are exposed to the same painful stimulus. One group experiences a painful stimulus of higher intensity compared to that of the other group. The painful stimuli are physically identical for every subject within the same group and within the standard of previous pain research.~Participants are then asked to evaluate the painful stimulus they just received according to a self-reported scale (NRS, VAS, gLMS, NRS-MB). Participants are also asked to decide multiple times whether they prefer a larger amount of money and experience the same or more painful stimulus they received before or a smaller amount of money and no (or a less) painful stimulus. The smaller amount of money is progressively increased across choices until it matches the larger amount, similar to multiple price-list methods (MPL) which are standard in economics."
75921422|NCT05540236|Other|auricular acupressure|The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points
75785050|NCT04970368|Procedure|Sentinel node procedure|Excision of ALL mapped nodes and other suspicious nodes regardless of mapping and label by anatomic location
75785051|NCT04970368|Procedure|Selective staging|Intraoperative consultation (IOC)
75785052|NCT04969315|Drug|TT-10|TT-10 orally administered BID starting at 10 mg and will be increased to 200 mg (additional dose levels maybe explored, if appropriate based on emerging safety, PK or PD data).
75921423|NCT05540236|Other|sham auricular acupressure|The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
75921424|NCT05544448|Other|Blood sample taken at a single time point|At inclusion, a blood sample will be taken for research purpose
75921425|NCT05589532|Device|Prosthetic single-tooth prosthesis using PEEK|A single tooth implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis.
75921426|NCT03547791|Drug|Betamethason Sodium Phosphate|The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.
75921427|NCT03547791|Drug|Normal saline|Intramuscular injection of normal saline 3ml twice 24hours apart
75921428|NCT04819113|Biological|Nimenrix|MenACWY-TT vaccine
75635606|NCT05803460|Behavioral|Stage 1 Control group: city environment|Participants will sit still for 20 minutes in a city environment.
75635607|NCT05803460|Behavioral|Stage 2 group|tree element virtual natural environment and tree and water element virtual natural environment experiences
75921429|NCT04818177|Drug|Institutional standard intravenous immune globulin treatment|No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.
75921430|NCT04809129|Device|Weighted vest|Patients will wear a weighted vest following bariatric surgery with weight increased incrementally to maintain baseline weight. This vest will be worn for a minimum of 8 hours a day for three months postoperatively.
75921431|NCT05544370|Behavioral|Intensive high intensity intervallic training group|The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
75328911|NCT03033667|Dietary Supplement|group L|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
75921432|NCT05544370|Behavioral|Extensive high-intensity intervallic training|The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
75328912|NCT03033667|Dietary Supplement|Group C|Over night fasting with no supplementation
75785053|NCT04969146|Behavioral|Dyadic Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Dyadic Intervention. The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
75785054|NCT04969146|Behavioral|Patient Only Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Patient Only Intervention. The patient in the Patient Only Intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
75785055|NCT04946357|Radiation|Protons|proton irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
75921433|NCT04799691|Procedure|Invasive ventilation strategy|Use of an invasive ventilatory support strategy
75921434|NCT04799691|Procedure|Non-invasive ventilation strategies|Use of non-invasive ventilatory support strategies
75921435|NCT05544292|Other|Antiinflammatory/DMARDs|Antiinflammatory/DMARDs
75921436|NCT04776057|Other|catarct surgery with toric intra ocular lenses|rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation
75921437|NCT05539768|Biological|HS-IT101|Adoptive transfer of 1x10^9-6x10^10 autologous TIL to patients i.v. in 30-60 minutes.
75921438|NCT04775745|Drug|LP-168|For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.
75921439|NCT04775745|Drug|LP-168|For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
75921440|NCT05544058|Other|Retrospective study|Retrospective study
75328913|NCT03033433|Drug|DCB-DM101|determination of optimal dose for Stage 2
75328914|NCT00947167|Drug|pertuzumab|840 mg, 420 mg, iv
75635608|NCT05803460|Behavioral|Stage 3 Experimental group: virtual reality natural environment|virtual reality natural environment programs for 2 time a week (40 mins/ every week) and 8weeks.
75785056|NCT04946357|Radiation|carbon ions|carbon ion irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
75785057|NCT04940689|Drug|Dexmédétomidine 0.5 g/kg + lidocaine 1.5 mg/kg|The patient will be anesthetized with Dexmedetomidine 0.5 g / kg + lidocaine 1.5 mg / kg for the induction instead of morphin.
75785058|NCT04940689|Drug|Remifentanil|The patient will be anesthetized with morphin.
75785059|NCT04925583|Radiation|Stereotactic body radiotherapy (SBRT)|"level 0 (de-escalation): 10 x 5.0Gy~level 1 (start): 10 x 5.5Gy~level 2: 10 x 6.0Gy~level 3: 10 x 6.5Gy"
75921441|NCT04425460|Drug|Favipiravir|Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
75921442|NCT04425460|Other|Placebo|Placebo combined with supportive care recommended in the current National/Local guidelines. Placebo dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
75921443|NCT03547323|Device|Theranova 400 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
75328915|NCT00947167|Drug|erlotinib|150 mg, PO
75328916|NCT04360759|Drug|Chloroquine or hydroxychloroquine|Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.
75921444|NCT03547323|Device|FX80 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
75921445|NCT03547713|Behavioral|Social feedback|Social feedback regarding performance of a public speech is delivered to participants
75921446|NCT03547713|Behavioral|Self-referential paradigm|Exposure to traits varying in valence (positive vs. negative) and social domain (power vs. affiliation)
75328917|NCT04360993|Radiation|Radiotherapy|Patients have received radiotherapy as a treatment modality for Head and neck cancer
75328918|NCT00940771|Drug|Boosted Atazanavir|Boosted Atazanavir, once a day dose adjusted for child's weight for 6 months.
75635609|NCT05803460|Behavioral|Stage 3 Control group: routine care|Control group received routine care last for 8 weeks.
75635610|NCT05803447|Other|Interview questionnaire|"An Interview questionnaire concerning an assessment of the intensity suicidal behavior, M.I.N.I. 7.0.2 was used.~M.I.N.I. interview was conducted with each patient to verify the intensification of suicidal behaviour."
75635611|NCT05803447|Diagnostic Test|biochemical parameters|"The concentrations of the following parameters were determined from the:~blood serum: vitamin D3, B12, folic acid, sodium, potassium, calcium, magnesium, chlorine, total cholesterol, LDL and HDL fractions, TG~plasma: metabolites of the oxidative stress"
75328919|NCT04360603|Device|27G|using 27G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
75635612|NCT05803447|Diagnostic Test|cognitive function|The participants completing cognitive function were assessed using computer CogState Test. The following cognitive functions were assessed: psychomotor drive (DET), metastability of attention (IDN), verbal memory, retrieval of learned material (ISLR) and verbal learning and memory (ISL), visual learning and memory (OCL), processing speed (GMCT), visual memory including deferred retrieval (GMR), executive functions (SETS and GML), working memory (ONB, TWOB).
75328920|NCT04360603|Device|25G|using 25G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
75328921|NCT03033277|Biological|Placebo transplantation|Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
75635613|NCT05803369|Behavioral|Regulating Together (RT)|Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
75635614|NCT05803369|Behavioral|Achieving Independence and Mastery in School (AIMS)|AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.
75635615|NCT05803330|Drug|Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma|Abandonment of intravenous volume expansion with alpha-blockers during preoperative preparation in patients with pheochromocytoma
75328922|NCT03033277|Biological|HUC-MSCs transplantation|Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
75635616|NCT05803278|Other|Online enhancement training|"Online enhancement training lasting 3 months, using the InTempo app system (Gea-Metaphonology-Athena-reading/Ermes-writing) three times a week for twenty minutes. The training will include: Metaphonological Enhancement; Reading Enhancement; Writing Enhancement."
75635617|NCT05803252|Behavioral|Focused Acceptance and Commitment Therapy|"FACT aims to increase one's psychological flexibility so that one will not generate feelings of distress and suffering when confronted with painful life situations. The intervention of this study will follow the FACT principles laid out by Strosahl, Robinson and Gustavsson to increase parents' psychological flexibility. Three core processes influence one's psychological flexibility: awareness, openness, and engagement.~The key objectives of each core process are:~Awareness: Able to experience the present moment, able to take perspective on self~Openness: Able to detach distressing private experiences and associated rules, able to take a non-judgemental, accepting stance towards painful material~Engagement: Exhibits strong connection with values, able to sustain values-consistent action"
75635618|NCT05803252|Other|Waitlist Control|The waitlist control group participants will commence their FACT intervention immediately after they complete their follow-up assessment.
75635619|NCT05803239|Device|EBUS-TBNA|Participants would undergo EBUS-TBNA(NA-201SX-4022, OLYMPUS MEDICAL SYSTEMS CORP, JAPAN).
75635620|NCT05803239|Device|EBUS-TBCB|Participants would undergo EBUS-TBCB(20402-401, ERBE Elektromedizin Gmbh, Germany).
75635621|NCT05803226|Behavioral|Slow Art Plus|Slow Art Plus involved a full 90-minute engagement, one that is built upon the existing Slow Art programme with added layers of mindfulness and self-compassion practices, as well as a response art activity that fosters symbolic dialogue and an emotional aesthetic experience between participants and the selected artwork.
75635622|NCT05803213|Other|Virtual Reality 360 interactive video|Clinical scenarios revised and presented with 360 video, and interactive design on the learning platform that is available anytime and anywhere to the medical students
75635623|NCT05803213|Other|Traditional mini-lecture|Clinical scenario described according to the script as a mini-lecture to the medical students
75635624|NCT05803174|Diagnostic Test|blood sample|"Blood collection Circulating serum concentrations of melatonin and dopamine were determined from fasting blood samples. Participants were required to fast from 10 pm the previous evening. A 5 mL serum blood sample was collected from the antecubital vein between 8.30 am and 10 am.~Tear collection Tear samples were collected using Schirmer's strip without anesthesia between 8:30-10:00am. Tears were extracted in 200 μl of 1 X Phosphate Buffered Saline with 0.1% Tween-20 (PBST).~Saliva collection Saliva samples were collected via the passive drool method with subjects in a seated position. Subjects were asked to rinse their mouth with water 10 minutes prior to saliva collection and to refrain from using lip makeup during the sampling period."
75635625|NCT05803161|Drug|Congrong Runtong oral liquid|"Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola"
75635626|NCT05803161|Drug|Placental Congrong Runtong oral liquid|Placental Congrong Runtong oral liquid
75798612|NCT01288482|Device|AeroEclipse II breath-actuated nebulizer|The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
75798613|NCT01288482|Device|English-Wright continuous-mode nebulizer|The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
75328923|NCT03033355|Drug|Intradetrusor injection of Botulinum Toxin-A|Using cystoscopy, Botulinum Toxin-A is injected into the bladder.
75328924|NCT03033121|Drug|Growth Hormone|
75328925|NCT03033199|Drug|Probiotic Agent|probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
75328926|NCT03033199|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
75328927|NCT02245711|Biological|Stem Cell|
75328928|NCT04360525|Other|Reasons|Causes of sigmoid volvulus
75635627|NCT05803135|Drug|Iguratimod combined with Tofacitinib;|Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)
75921447|NCT03547713|Behavioral|Reward vs. punishment task|Reception of monetary gains vs. losses
75328929|NCT04360291|Other|Eye tracker|In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
75635628|NCT05803122|Other|Uniform Data Set (UDS) neuropsychological battery|Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease
75328930|NCT00934141|Other|Learning Session|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
75785060|NCT04919330|Behavioral|Family Acceptance and Commitment Therapy-based Eczema Management Programme|"The parent-child dyads will receive four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP). In each session, a group of 6-8 parent-child dyads will receive 90 minutes of ACT, followed by 30 minutes of education related to eczema management. Throughout the sessions, ACT strategies will help the dyads achieve the following therapeutic processes: To weaken the rumination cycle and fused thoughts related to eczema with body-image concern, shame and self-criticism for extending kindness and understanding to oneself; to build self-perspective-taking when seeing one's experience as part of the larger human experience; to strengthen their stands for their values related to self-kindness with acceptance of one's experience; and to take steps to act on values while practising kindness and compassion. Same as the waitlist control, the dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation."
75921448|NCT03547713|Behavioral|Emotional reactivity task|Exposure to emotional faces vs. shapes
75328931|NCT00934141|Other|Interest Circle Calls|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
75328932|NCT00934141|Other|Coaching|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
75469425|NCT01939015|Device|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
75469426|NCT01939041|Device|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
75785061|NCT04919330|Behavioral|Wait-list Control Group|The parent-child dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation. To ensure equity of access to potentially effective treatment (i.e., family ACT-based eczema management programme), the dyads in the wait-list control group will receive the same programme after the completion of all assessments of the intervention arm.
75785062|NCT04909411|Other|OPHTHALMOLOGICAL ASSESSMENT|assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination
75785063|NCT04909411|Other|NEUROPSYCHOLOGICAL ASSESSMENT|completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire
75785064|NCT04887792|Drug|Acetazolamide|ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
75921449|NCT05576272|Drug|QL1706|5 mg/kg#D1#Q3W IV, 4-6 cycles
75921450|NCT05576272|Drug|Carrelizumab|200mg#D1#Q3W IV, 4-6 cycles
75921451|NCT05576272|Drug|Gemcitabine|1000mg/m2#D1&D8#Q3W IV, 4-6 cycles
75635631|NCT05803070|Drug|Topical Cetirizine 1 %|topical cetirizine belongs to anti histamines group
75921452|NCT05576272|Drug|Cisplatin|80mg/m2#D1#Q3W IV, 4-6 cycles
75921453|NCT05576116|Procedure|Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)|"Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure."
75921454|NCT05576116|Procedure|Combined Sleeve Gastrectomy and Pancreas transplantation|Simultaneous SG and pancreas transplantation
75921455|NCT05381025|Dietary Supplement|Kava (Piper methysticum) extract|Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
75921456|NCT05539690|Behavioral|Balance training|"Step-by-step training (5 levels)~30 minute per training~3 times per week~4 weeks"
75921457|NCT03758313|Other|CO2 measurements|Distal etCO2, tcCO2 and paCO2 values will be recorded simultaneously in ventilated preterm infants. We will measure etCO2 in a distal position using a double lumen tube connected to an external side-stream capnometer.
75921458|NCT05504512|Other|No intervention|No intervention
75469427|NCT01939041|Device|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
75635632|NCT05803070|Drug|Topical betamethasone valerate 0.1%|topical betamethasone valerate belongs to corticosteroids group
75635633|NCT05803031|Drug|Melaleuca Alternifolia Oil|"Tea tree oil 5% gel (Sigma Aldrich® Steinheim, Germany) for local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy.~The gelling agent; Carbopol 940 (1% w/v) was first soaked in distilled water for 2 h then TTO dissolved in an appropriate amount of propylene glycol was added to the Carbopol dispersion. Methyl paraben 0.2% w/v dissolved in preheated water was used as a preservative. The gel mixture was then magnetically stirred for 30 min. Finally, pH was adjusted using 1 N NaOH added dropwise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110 °C for 20 min."
75328933|NCT00934141|Other|Website|The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
75785065|NCT04887792|Drug|Placebo|Identical gelatin capsules will be prepared by filling with inert excipients.
75635634|NCT05803031|Procedure|Non-surgical periodontal debridement|Scaling and root surface debridement
75635635|NCT05803005|Other|inflammatory marker in autism spectrum disorder|Evaluate some Inflammatory markers [IL-6, IL-8, TNF_alpha] in children with autism spectrum disorder
75635636|NCT05802992|Drug|Colchicine|"The investigational drug colchicine was used at a daily dose of 0.5-1 mg. In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.~If the patient needs to be treated with the investigational drug colchicine on the day of dexamethasone administration, he should take dexamethasone orally within 3 hours before the administration of colchicine."
75785066|NCT04880031|Drug|BOS-580|BOS-580 will be administered by subcutaneous injection
75921459|NCT05478460|Other|Hookwire localization|Patients were performed CT -guided hook wire localization(20G×120mm, PAJUNK medizintechnologie, Geisingen in Germany). patients were placed on a CT table in a suitable position(supine, prone, lateral) to obtain the shortest needle insertion route for their initial CT scan. Local anesthesia of the skin and planned puncture tract was performed using 10ml Lidocaine 1%. Next, the needle was inserted into or near the pulmonary nodule.
75921460|NCT05337501|Other|Collecting data|Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
75328934|NCT00940927|Drug|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
75328935|NCT00941005|Device|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
75921461|NCT05543980|Device|Sham device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 33ºC.
75328936|NCT00934375|Drug|Aricept (donepezil hydrochloride)|5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
75328937|NCT00934375|Drug|placebo|
75785067|NCT04880031|Drug|Placebo|Placebo will be administered by subcutaneous injection
75785068|NCT04878510|Drug|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
75785069|NCT04878510|Other|Placebo|Normal saline placebo will be given as continuous infusion.
75328938|NCT05105425|Dietary Supplement|NUTRIOSE®|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
75785071|NCT04857905|Procedure|Microsurgical resection|Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.
75785072|NCT04857905|Procedure|Gamma Knife radiosurgery|Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.
75785073|NCT04855786|Procedure|Thoracic duct drainage|drain placement into the thoracic duct
75785074|NCT04851925|Other|MR Fingerprinting|Specific Magnetic Resonance Imaging protocol
75328939|NCT05105425|Dietary Supplement|GLUCIDEX® IT21 (Placebo)|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
75328940|NCT03002974|Drug|Anakinra 100 mg|100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
75328941|NCT03002974|Drug|Triamcinolone Acetonide 40 mg|1 mL intramuscular injection of a 40 mg/mL injectable suspension
75328942|NCT03002974|Drug|Placebo to Anakinra 100 mg|sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
75921462|NCT05543980|Device|Leg heat therapy device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 42ºC.
75921463|NCT04725981|Procedure|Total laparoscopic hysterectomy|Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
75921464|NCT05543902|Behavioral|Breastfeeding Problems Management Model (BPMM)|The BPMM was composed of interventions with the leadership of a nurse and included topics of the early postpartum period; postpartum 1st, 2nd, 6th, and 8th weeks; increasing breastfeeding motivation and breastfeeding success; and preventing and eliminating breastfeeding problems. The components of the model included meeting women face-to-face, giving education using a booklet, providing breastfeeding consultancy on the phone, and home visits.
75921465|NCT05334849|Device|Circulating exosomal lncRNA-GC1 detection|"Collect peripheral blood sample of 80 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect circulating exosomal lncRNA-GC1. Tumor response evaluation will be performed after two cycles of immunotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
75921466|NCT05543824|Drug|Levobupivacaine|Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize
75921467|NCT05698420|Device|Dialysis using the Theranova-400 device.|Patients receive hemodialysis treatment using the Theranova-400 dialyzer.
75921468|NCT05698420|Device|Dialysis using the FX80 device.|Patients receive hemodialysis treatment using the FX80 dialyzer.
75328943|NCT03002974|Drug|Placebo to Triamcinolone Acetonide 40 mg|1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
75328944|NCT02245477|Device|obstetric Ultrasound|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
75921469|NCT04703673|Drug|Cineole|self administration according to directions for use
75921470|NCT04703673|Drug|Nasal Decongestant|self administration according to directions for use
75921471|NCT05543746|Drug|Brexanolone|Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.
75921472|NCT03526536|Drug|IV Novolin R human insulin|Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
75921473|NCT05543590|Drug|Plasmapheresis|5 sessions of plasma exchanges
75921474|NCT05543590|Other|Blood collection|Blood collection to assess biological markers at baseline, M3 and M12
75921475|NCT05543590|Other|Stool samples|Stool samples will be collected from participants at baseline,M3 and M12
75921476|NCT05543590|Other|PET scan|PET scan at baseline and M6
75921477|NCT05543590|Other|Cycle ergometer stress test|Cycle ergometer stress test at M6
75921478|NCT05543590|Other|Questionnaires at baseline|Questionnaires at baseline, M3 and M6
75921479|NCT05543590|Other|Medical consultations|Medical consultations
75328945|NCT02245477|Other|serum Vascular Endothelial Growth Factor|Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
75328946|NCT03833557|Procedure|Nanohydroxyapatite Pulpotomy|Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic
75328947|NCT03833557|Procedure|MTA pulpotomy|Angleus grey MTA
75328948|NCT03833557|Procedure|Formocresol Pulpotomy|Buckley's Fromocresol. diluted full strength foromocresol
75785075|NCT04851873|Genetic|OAV101|Gene Therapy - 1.1e14 vector genome (vg)/kg as a one-time IV infusion was administered over approximately 60 minutes.
75785076|NCT04822688|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
75785077|NCT04821089|Biological|IPN10200|Several different doses will be administrated in a dose-escalation manner. One single injection will be injected locally into several sites across the glabellar region.
75785078|NCT04821089|Biological|IPN10200 Placebo|One single injection of study intervention will be injected locally into several sites across the glabellar region.
75785079|NCT04821089|Biological|Dysport|Single administration of study intervention in stage 1 / step 2 only
75785080|NCT04816721|Drug|EDP-938|Oral suspension
75785081|NCT04816721|Drug|Placebo|Placebo oral suspension to match EDP-938
75785082|NCT04814446|Biological|Vaccination|Intramuscular injections of 0,5 ml will be administered at M0, M2 and M6
75798614|NCT03859830|Device|Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
75635637|NCT05802992|Drug|Lenalidomide|In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.
75328949|NCT04360447|Device|Reformer Pilates|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
75328950|NCT04360447|Other|Home Exercise|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
75328951|NCT04360057|Other|PMD|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance used on the initial visit.
75328952|NCT04360057|Other|PMDPlus|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance on follow up visits
75635638|NCT05802979|Drug|Adjuvants, Anesthesia|testing the effect of adding ketamine versus neostigmine to the analgesic efficacy of serratus anterior plane block in modified radical mastectomy surgeries
75328953|NCT03032887|Behavioral|voice prompts|voice prompts on disinfectant dispenser
75328954|NCT03032887|Behavioral|agitation|Education, reminders and optimising materials
75328955|NCT02825212|Drug|Harvoni|12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
75328956|NCT02825212|Drug|Epclusa|once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
75328957|NCT03032809|Other|Vessel Wall MR imaging|Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
75635639|NCT05802888|Drug|Tetracycline 500mg tid|Amoxicillin 1000mg bid +Tetracycline 500mg tid +Bismuth+Esomeprazole 40mg bid
75635640|NCT05802888|Drug|Tetracycline 500mg qid|Amoxicillin 1000mg bid +Tetracycline 500mg qid +Bismuth+Esomeprazole 40mg bid
75635641|NCT05802875|Behavioral|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
75785083|NCT04807803|Diagnostic Test|Assessment of Minimal hepatic encephalopathy (MHE)|Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
75785084|NCT04805736|Procedure|Microwave Ablation|Image-guided microwave ablation 7-10 days prior to surgery
75785085|NCT04805736|Drug|Camrelizumab|Camrelizumab 200 mg was given a few days after microwave ablation
75785086|NCT04805736|Procedure|Breast Surgery|Standard of care breast conserving surgery or radical mastectmoy
75798615|NCT03859830|Device|AK200 Ultra S, extracorporeal circulation conduct of blood purification|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
75798616|NCT01286766|Drug|DCS (docetaxel with cisplatin with TS-1)|"S-1: 70 mg/m2 #2 bid PO, D1-14~Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks."
75921480|NCT03512184|Behavioral|YMCA class|The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
75921481|NCT05573529|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
75328958|NCT02825680|Other|Enhanced NCP Support|NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
75328959|NCT02825680|Other|LEAP|The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model for Improvement, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool.
75328960|NCT04983043|Drug|Low dose Qishenyiqi Dripping Pills 3 bags|Low dose Qishenyiqi Dripping Pills contain Qishenyiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishenyiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
75328961|NCT04983043|Drug|High dose Qishenyiqi Dripping Pills 3 bags|High dose Qishenyiqi Dripping Pills contain Qishenyiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
75328962|NCT04983043|Drug|Qishenyiqi Dripping Pills placebo 3 bags|Qishenyiqi Dripping Pills placebo contain Qishenyiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
75328963|NCT00373672|Drug|armodafinil (Nuvigil)|armodafinil (Nuvigil)150 mg qd
75328964|NCT00373672|Drug|placebo|identical in appearance to active comparator
75328965|NCT03032731|Behavioral|Website and pedometer intervention|Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
75328966|NCT03032731|Other|Control|Standard, publicly available NHS resources for healthy lifestyles.
75328967|NCT03032653|Other|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
75469428|NCT01939041|Behavioral|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
75635642|NCT05802875|Behavioral|Progressive Muscle Relaxation|"Progressive Muscle Relaxation is a representative relaxation technique used in a wide scope of disorders. Developed by the American physician E.Jacobson in the late 1920s, it is based on the finding that anxiety states are usually accompanied by increased muscle tension, while in resting states the muscles are relaxed. By applying this technique, an individual learns how to relax several muscle groups in the body.~In the context of the current project, PMR is chosen as the active control condition because it is a broadly accepted and easy-to-implement relaxation exercise that can be offered as a (group) online course and does not include specific contents of RASMUS."
75785087|NCT04805554|Other|Joint Insights decision aid|The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.
75785088|NCT04793776|Behavioral|Manage Emotions to Reduce Aggression|MERA begins with education about the adaptive nature of emotions, how childhood and military experiences can influence emotion regulation, and how combat requires different emotion regulation strategies than most civilian environments. MERA use modeling and practice with feedback to teach cognitive-behavioral and acceptance-based emotion regulation skills.
75921482|NCT05573529|Device|intraocular lens implantation|intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
75469429|NCT01939054|Drug|Nimotuzumab|
75921483|NCT03546309|Device|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
75328968|NCT03032653|Other|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
75921484|NCT03546309|Device|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
75328969|NCT03004534|Drug|darolutamide|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
75328970|NCT02826694|Genetic|Well infant, whole exome sequencing|Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
75328971|NCT02826694|Genetic|Diagnosed, whole exome sequencing|In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
75469430|NCT01939054|Drug|docetaxel|
75469431|NCT01939054|Drug|capecitabine|
75635643|NCT05802862|Drug|Insulin Degludec and Insulin Aspart|administered subcutaneously, once a day
75328972|NCT02939170|Device|Delefilcon A Multifocal Contact Lenses with Molded Mark|
75328973|NCT02939170|Device|Delefilcon A Multifocal Contact Lenses|
75469432|NCT01939067|Device|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
75469433|NCT01939067|Device|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
75469434|NCT01939080|Procedure|Exercise training with supervised sessions|
75469435|NCT01939093|Drug|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
75469436|NCT01939093|Dietary Supplement|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
75469437|NCT01939093|Drug|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
75469438|NCT01939132|Drug|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
75469439|NCT01939171|Drug|Thymoglobulin|
75469440|NCT01939210|Other|Educational Intervention|Participate in breathing training sessions
75469441|NCT01939210|Other|Meditation Therapy|Participate in breathing training sessions
75469442|NCT01939210|Other|Questionnaire Administration|Ancillary studies
75635644|NCT05802823|Other|Standardized Simülation Patient|There are preliminary information, information, application and analysis sessions in the research. A rehearsal will be made 10 days before the application and arrangements will be made if necessary. The students will be given the resources 1 week before the application and the scenario 5 minutes before the application and informed consent will be obtained. Just before the application, information about the simulation process and analysis will be given. Students will be divided into 6 groups with the random numbers table and the application will be made on different days and times. The application time is 10-15 minutes and the camera will be recorded during the interview. At the end of the application, standard patient feedback will be given for each student. At the end of the application, analysis sessions will be held with the students as a group and feedback will be given by peers and trainers about their own performances. Analysis sessions will take between 30-45 minutes.
75635645|NCT05802810|Drug|[14C]JT001|Subjects will receive approximately 300 mg/100 µCi of [14C]JT001 orally.
75635646|NCT05802771|Procedure|surgical resection|surgical resection of the lung cancer
75785089|NCT04793776|Behavioral|Present Centered Psychotherapy|PCT will serve as the comparison group. PCT assists Veterans in understanding and coping with current difficulties, such as aggression, but does not provide systematic training in emotion regulation skills.
75328974|NCT04346953|Behavioral|Video based exercise|Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.
75328975|NCT03004846|Drug|GSK2981278 ointment|"GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas ."
75469443|NCT01939236|Drug|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
75635647|NCT05802745|Other|Reintubation|Patients requiring re-intubation for acute respiratory failure.
75635648|NCT05802563|Device|fitness tracker|Study subjects will wear a Fitbit fitness tracker
75635649|NCT05801406|Device|Tornado (Cook)|Fiducial marker endobronchial positioning under augmented fluoroscopy to mark ground glass opacities.
75635650|NCT05800574|Radiation|Radiation therapy (5 days for 7 weeks)|Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)
75785090|NCT04783558|Behavioral|Mobile-based NAS Caregiving Tool|The information and skills training in the adapted NAS caregiving tool will be largely based on elements of Eat Sleep Console. Therefore, the NAS mobile tool intervention will incorporate non-intrusive caregiving skills and strategies that encompass providing a low stimulating environment (e.g., dimmed light and low noise), swaddling, continuous comfort and contact with caregiver, skin-to-skin contact, frequent breastfeeding/feeding, as well as novel components identified in the key informant interviews (e.g., preparing for stigma during delivery, CPS involvement, etc.).
75785091|NCT04777799|Device|URGOnight|"URGOnight is a daytime brain training solution (CE marked) aim at improve the quality of sleep. The device consists of an electroencephalographic (EEG) measuring strip connected to a mobile application. The latter is available free of charge on Android and iOS in various mobile application stores (Google Play Store and App Store).~URGOnight is a wireless device, it connects via Bluetooth® Low Energy (BLE) to the URGOnight mobile application running on a smartphone. The EEG data is broadcast via a BLE protocol, and the standard Bluetooth® operating distance has a range of 10 meters.~To use the URGOnight solution, the user must authorize the application to access his phone's memory to store his usage data and must also authorize the geolocation of his phone to enable BLE connection. This data is not recorded but is necessary for the proper functioning of the solution."
75785092|NCT04769739|Other|CO2|using CO2 insufflation to help insertion
75921485|NCT05439850|Procedure|arthroscopic rotator cuff repair|This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
75921486|NCT05439850|Biological|Bioinductive implant|A bioinductive implant that is designed to promote healing of the torn rotator cuff tendon after surgery.
75921487|NCT05439850|Diagnostic Test|Ultrasound Imaging|An ultrasound will be performed on each patient one year postoperatively.
75635651|NCT05800574|Radiation|Radiation therapy (5 days for 6 weeks)|Mon-Fri (5 days for 6 weeks), total 35 fractions over 30 treatment days of RT (two doses 6 hours apart except for the last 6th Friday of the 6 weeks )
75785093|NCT04769739|Other|Water|using water instead of traditional gas to help insertion
75785094|NCT04769739|Other|50% saline|using 50% saline solution instead of traditional gas to help insertion
75785095|NCT04769739|Other|25% saline|using 25% saline solution instead of traditional gas to help insertion
75921488|NCT03524586|Procedure|Ipsilateral rotation of head|Ipsilateral rotation of head against fixed tube
75921489|NCT03524586|Procedure|Contralateral rotation of head|Contralateral rotation of head against fixed tube
76078330|NCT03228459|Diagnostic Test|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
75328976|NCT03004846|Drug|Vehicle ointment|It will be supplied as white to off-white vehicle ointment for topical application.
75635652|NCT05800574|Drug|Cisplatin|Cisplatin, 40mg/m2 (weekly for 7 weeks)
75635653|NCT05796063|Diagnostic Test|gastric point of care ultrasound|Patients will receive a gastric point of care ultrasound to evaluate for delayed gastric emptying. Gastric POCUS studies will be obtained using Kosmos, a handheld portable ultrasound that is FDA approved for clinical use. This product has already been validated for use, and this is not a novel application of the technology.
75635654|NCT05795205|Behavioral|Normal dinner|Participants will consume breakfast at 0830-0855 am, lunch at 1230-1255 pm, followed by dinner at 1800-1825 pm. Snacks will be consumed at 2130-2140 pm.
75635655|NCT05795205|Behavioral|Delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Dinner will be consumed at 21:30-21:55 pm.
75328977|NCT03032497|Device|EEG-based BCI analysis of fear avoidance|Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
75785096|NCT04760288|Drug|Pralsetinib|Participants will receive pralsetinib at a dose of 400 mg, as per the dosing schedule described above.
75469444|NCT01939236|Drug|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
75635656|NCT05795205|Behavioral|Exercise with delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Participants will exercise for 45 min at moderate-intensity 45 min prior to the delayed dinner at 21:30-21:55 pm.
75635657|NCT05791812|Device|home-based transcranial direct current stimulation (tDCS)|2mA of tDCS for 20 min every weekday for six weeks
75785097|NCT04760288|Drug|Cabozantinib|Adult participants will receive cabozantinib at a dose of 140 mg, as per the dosing schedule described above.
75785098|NCT04760288|Drug|Vandetanib|Adult participants will receive vandetanib at a dose of 300 mg and adolescent participants will receive vandetanib as per the dosing schedule described above.
75785099|NCT04752280|Radiation|Proton irradiation|proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)
75785100|NCT04752280|Radiation|Photon irradiation|proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy
75785101|NCT04751942|Device|Non-compressive Bioactive Garment|patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty
75785102|NCT04751942|Device|thrombo-embolic deterrent|patients will be randomized to wear the gold standard TED hose following total knee arthroplasty
75921490|NCT05306301|Drug|Ponatinib|Ponatinib is a novel, synthetic, orally-active TKI discovered using a computational and structure based drug design approach. Ponatinib was specifically designed to inhibit all clinically relevant variants of BCR-ABL1, including the T315I mutant (15-17). In vitro assays have demonstrated that Ponatinib potently inhibits the kinase enzymatic activity of the T315I ABL kinase domain, as well as that of the native (unmutated) enzyme. In leukemia cell lines expressing these BCR-ABL1 variants, Ponatinib potently inhibited BCR-ABL1 signaling, leading to the reduction of cellular proliferation and induction of apoptosis. Ponatinib also inhibits the proliferation of cell lines expressing other major clinically-observed Imatinib-resistant mutants of BCR-ABL1.
75921491|NCT03526380|Behavioral|Behavioral: the OPT-IN Intervention|A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
75921492|NCT05539222|Other|Food vouchers and education|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group. Family food purchases were assessed using electronically recorded supermarket-obtained transactions.
75785103|NCT04750278|Drug|FP-025 100 mg|FP-025 100 mg BID
75921493|NCT05543434|Drug|Hyaluronic acid|anti-inflammatory, anti-edematous, osseoinductive.
75921494|NCT04963140|Other|Optimized self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device
75921495|NCT04963140|Other|Conventional self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms
75328978|NCT04359667|Drug|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]|1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)
75469445|NCT01939106|Device|One Piece Drainable Pouch|
75469446|NCT01939249|Device|Abbott Laboratories Xience|
75469447|NCT01939249|Device|Biotronik Orsiro|
75469448|NCT01939262|Other|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
75635658|NCT05791448|Procedure|Biospecimen Collection|Undergo collection of blood samples
75635659|NCT05791448|Procedure|Computed Tomography|Undergo CT scan
75635660|NCT05791448|Procedure|Magnetic Resonance Imaging|Undergo MRI
75785104|NCT04750278|Drug|FP-025 300 mg|FP-025 300 mg BID
75785105|NCT04750278|Drug|Placebo|Placebo BID
75785106|NCT04746924|Drug|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
75785107|NCT04746924|Drug|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
75328979|NCT00373750|Procedure|Family Spirit Intervention|The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
75328980|NCT03008590|Drug|Naltrexone|One 4.5 mg capsule each evening
75469449|NCT01939262|Other|Control|Participants assigned to the control group will be instructed to follow their usual diets.
75328981|NCT03008590|Drug|Placebo|One capsule each evening
75328982|NCT04359511|Drug|Prednisone|prednisone 0.7 mg/kg/d (PO)
75785108|NCT04746924|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
75328983|NCT04359511|Drug|Hydrocortisone|hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
75785109|NCT04746924|Drug|Placebo|Placebo infusions will consist of a sterile, normal saline solution.
75785110|NCT04743362|Diagnostic Test|Dermoscopic imaging|The skin lesion will be imaged before application of alcohol (spray/wipe) and after application of alcohol (spray/wipe). The dermatoscope/camera with dermoscopy imaging capabilities, including but not limited to VEOS® SLR (Canfield Scientific, Inc.), will be placed on/near the area(s) of interest. Images will be captured in polarized and/or nonpolarized modes and contact and/or non-contact modes.
75328984|NCT03032419|Biological|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
75635661|NCT05791448|Drug|RNA Transcription Modulator AU-409|Given PO
75469450|NCT01939327|Drug|Lenalidomide/Rituximab|
75469451|NCT01939379|Drug|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
75785111|NCT04743362|Diagnostic Test|3-dimensional total body photography|Participants will stand in the center of an imaging station consisting of 92 high-resolution cameras. Image capture by all cameras will occur simultaneously, (approx. 3 milliseconds). Within a few minutes, specialized software will process and assemble the images into a 3D avatar - a digital model of the patient's skin - showing all his or her lesions.
75785112|NCT04743362|Diagnostic Test|Confocal microscopy|CM imaging (Vivascope®, Caliber Imaging and Diagnostics, Rochester, NY) will be performed using an arm-mounted CM device (Vivascope1500, Caliber I.D., Inc.) or using a handheld CM device (Vivascope3000, Caliber I.D., Inc.).
75785113|NCT04743362|Diagnostic Test|Optical Coherence Tomography imaging|OCT subsurface imaging shows structural-level morphology (epidermal and dermal layers) in skin down to the deeper reticular dermis.
75785114|NCT04743362|Diagnostic Test|Ultrasound|US imaging allows assessment of depth, Doppler vascular imaging, and elastography features of skin lesions.
75469452|NCT01939379|Drug|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
75469453|NCT01939392|Device|Renal Denervation (OneShot™ Renal Denervation System)|
75469454|NCT01939418|Drug|RAD001|Afinitor 5mg qd. po.
75635662|NCT05787990|Diagnostic Test|Diabetes Microvascular Complication Tests|Continuous glucose monitoring using Freestyle Libre Pro, Foot examination with monofilament and neurothesiometer, HbA1c and Urine Microalbumin Creatinine Ratio, Corneal confocal microscopy, Fundal photography, Optical coherence tomography, Optical cohere
75635663|NCT05787288|Biological|Extracellular Vesicles from Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cell-derived extracellular vesicle preparation; Specification: 5ml, with extracellular vesicle concentration of 1 × 109 particles/ml in the preparation;
75469455|NCT01939418|Drug|Gemcitabine|gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
75469456|NCT01939418|Drug|Cisplatin|cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
75469457|NCT01939444|Drug|naloxone intranasal|If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
75469458|NCT01939444|Drug|naloxone intravenous|The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
75469459|NCT01939457|Drug|Misoprostol|
75469460|NCT01939483|Drug|irinotecan hydrochloride|Given IV
75469461|NCT01939483|Other|laboratory biomarker analysis|Correlative studies
75469462|NCT01939509|Drug|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
75469463|NCT01939509|Drug|Bisoprolol|
75469464|NCT01939522|Biological|13-valent pneumococcal conjugate vaccine (PCV13)|
75469465|NCT01939535|Other|No intervention|Evaluation of an imaging technique ic MRI
75469466|NCT01939561|Drug|Lamotrigine|
75469467|NCT01939561|Drug|Placebo|Placebo is tablets identically with the Lamotrigine tablets.
75469468|NCT01939574|Other|Chemoradiation Therapy|"Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight."
75469469|NCT01939574|Other|Adjuvant Therapy|"Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight."
75635664|NCT05783999|Device|vibra plus|the device is applied to the patient's lower limbs and generates an active flow of vibrations that may reduce fatigue
75635665|NCT05783583|Device|Remote Digital Slit Lamp|Slit Lamp Examination
75635666|NCT05781412|Device|tDCS|Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
75785115|NCT04743362|Diagnostic Test|Hyperspectral imaging|Hyperspectral imaging shows biochemical information regarding the distribution of skin melanin and hemoglobin50. SkinSpect™ is a form of a hyperspectral dermatoscope.
75328985|NCT03032419|Biological|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
75328986|NCT00373906|Drug|Bortezomib (Velcade)|
75921496|NCT05289141|Device|Use of high flow nasal oxygen therapy|Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).
75469470|NCT01939587|Drug|PBF-680 5 mg|
76078331|NCT03228459|Diagnostic Test|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
75635667|NCT05776290|Biological|Hyaluronic Acid|This material will be injected into the prepared impact socket prior to inserting the implant. This injection will be done inside the socket as well as on the periphery of the socket.
75635668|NCT05776264|Behavioral|Music Condition|During one of the sessions, participants will listen to music while walking on the treadmill for 10 minutes.
75635669|NCT05776264|Behavioral|Podcast Condition|During one of the sessions, participant will listen to a podcast for 10 minutes while walking on the treadmill.
75635670|NCT05776069|Drug|VGA039|Single doses of VGA039
75635671|NCT05776069|Other|Placebo|Single doses of Placebo
75921497|NCT05289141|Device|Use of other non-invasive ventilation or high concentration oxygen masks|Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
75921498|NCT05539144|Radiation|Delineation for organs at risks (OARs) in IMRT plan|An adaptive contouring brush within the planning software was used to create a new structure: the air cavity within oral cavity, oropharynx, larynx and hypopharynx, and the new structure was expanded and shrunk uniformly 2 mm to create the oral cavity, oropharynx, larynx and hypopharynx
75921499|NCT01858896|Drug|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
75921500|NCT01858896|Other|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
75921501|NCT04675047|Other|no intervention for healthy control|observational study - no intervention
76078332|NCT03228459|Diagnostic Test|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
75469471|NCT01939587|Drug|PBF-680 20 mg|
75469472|NCT01939587|Drug|Placebo|
75469473|NCT01939600|Other|Starch-free breakfast|Starch-free breakfast alone
75635672|NCT05774782|Device|Cerebral flow diverter|The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.
75635673|NCT05772390|Radiation|Partial breast re-irradiation|partial breast re-irradiation
75635674|NCT05770726|Dietary Supplement|Probiotics administration|A total of 10 grams of probiotics was administered in both group, but the routes were different. One group were per colonoscopic spray, and the other was per oral.
75785116|NCT04743362|Diagnostic Test|Electrical impedance spectroscopy|Electrical impedance spectroscopy (EIS) measures skin's resistance to the flow of alternating electric currents to differentiate benign and malignant lesions.
75785117|NCT04743362|Diagnostic Test|Patient self-imaging|Clinical and dermoscopy self-imaging by patients can be accomplished using mobile phone technology. In the case of dermoscopy, this requires a small dermatoscope attachment for the phone.
75785118|NCT04732429|Drug|HST5040|Liquid solution
75469474|NCT01939600|Other|Hi-Maize 260|Starch-free breakfast plus 55.3g Hi-Maize 260
75469475|NCT01939600|Other|Hylon VII|Starch-free breakfast plus 56.9g Hylon VII
75469476|NCT01939600|Other|Amioca|Starch-free breakfast plus 56.4g amioca starch
75785119|NCT04732429|Drug|Placebo|Liquid solution
75469477|NCT01939613|Drug|colloids|TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
75469478|NCT01939626|Device|Single-step medium|This medium will allow in vitro culture of human embryos for 5/6 days
75469479|NCT01939626|Device|Standard culture medium|This culture system needs media change on day 3 of culture.
75469480|NCT01939639|Drug|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
75635675|NCT05765227|Device|Lehfilcon A multlifocal contact lenses|Investigational silicone hydrogel multifocal contact lenses
75635676|NCT05765227|Device|Lotrafilcon B multifocal contact lenses|Commercially available silicone hydrogel multifocal contact lenses
75635677|NCT05765227|Device|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
75635678|NCT05761444|Drug|Atozet 10/40 mg or 10/80 mg|Atozet 10/40 mg or 10/80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
75635679|NCT05761444|Drug|Lipitor 40 mg or 80 mg|Lipitor 40 mg or 80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
75785120|NCT04731610|Other|Radiotherapy|postoperative radiotherapy after complete resection of thymoma
75785121|NCT04731610|Other|Surveillance after resection|Surveillance after tumour resection
75785122|NCT04729179|Drug|Cannabidiol|Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
75785123|NCT04729179|Drug|Placebo|Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
76078333|NCT03228459|Diagnostic Test|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
76078334|NCT03228459|Diagnostic Test|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
76078335|NCT03228459|Diagnostic Test|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
75921502|NCT05539066|Device|AI health assistant|To study the advantages of AI health assistant management group compared with conventional management group in terms of comprehensive compliance rate, metabolic index level, hypoglycemia incidence rate, and mastery of diabetes related knowledge.
75635680|NCT05758948|Diagnostic Test|NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue|In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants
75635681|NCT05757791|Drug|Empagliflozin|The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
75635682|NCT05730101|Other|Cognitive-behavioral treatment (CBT)|In the first individual session (CBT1), together with the therapist, participants develop a behavioral and conditional model of their procrastination behavior. In the next 2 group sessions (CBT2 and CBT3), participants receive psychoeducation on procrastination. The focus is on learning the method of starting on time. In the 3 group session (CBT4), participants identify key procrastination-promoting thoughts and are supported to develop alternative thoughts; deepened in the second individual session (CBT5). In the next 2 group sessions (CBT 6 and CBT7), participants are informed about action planning with focus on learning to plan realistically. The last group session is a concluding session: Experiences with the methods learned and an outlook on further steps and goals are discussed. At the end of both individual sessions (CBT1 and CBT5), participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
75921503|NCT05538988|Drug|Cemiplimab|Cemiplimab is a recombinant human IgG monoclonal antibody known as a programmed cell death 1 (PD-1) immune checkpoint inhibitor. The PD-1 pathway is an immune system checkpoint that may be exploited by tumour cells to escape active T-cell surveillance. Cemiplimab binds to PD-1 on T cells and blocks the interaction with its ligands, PD-L1 and PD-L2. Inhibition of the receptor/ligand signaling restores the anti-tumour immune response
75921504|NCT04467060|Drug|Anaprazole Sodium|2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg，fasting oral administration.
76078336|NCT03228459|Diagnostic Test|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
76078337|NCT03228459|Other|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
76078338|NCT03228459|Other|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
75328987|NCT02981797|Other|Blood Collection During Standard of Care Treatment|Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
75328988|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
75328989|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
75328990|NCT00955513|Drug|Placebo|Placebo
75328991|NCT02939326|Drug|EB-001 injection|
75921505|NCT04467060|Drug|Placebo|single dose, fasting oral administration
75921506|NCT04667637|Drug|edaravone dexborneol|Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
75921507|NCT03871894|Other|Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)|Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day
75921508|NCT03871894|Other|Standard and fixed nutritional intervention till patient in ICU|Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
75921509|NCT01511328|Other|HPV testing|Testing for Human Papilloma Virus
75921510|NCT02253927|Drug|BILR 355 - D1|
75921511|NCT02253927|Drug|BILR 355 - D2|
75921512|NCT02253927|Drug|BILR 355 - D3|
75921513|NCT02253927|Drug|BILR 355 - D4|
76078339|NCT03228459|Diagnostic Test|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
76078340|NCT03258177|Other|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
76078341|NCT03015064|Other|Myocardial Infarction|Observational study of myocardial Infarction patients
75328992|NCT02939326|Drug|Placebo injection|
75328993|NCT03032185|Device|Transcutaneous Elevtrical Nerve Stimulation|
75328994|NCT02943226|Device|Becton Dickinson Nexiva Diffusics System|Becton Dickinson Nexiva Diffusics System will be used to inject IV contrast and will be compared to a single hole catheter to see if it improves image quality in the main vessels in the abdomen and pelvis because of its novel design.
75328995|NCT02943226|Device|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to a novel 3 hole catheter to see which catheter provides the best image quality.
75328996|NCT00935311|Drug|ABT-712 Extended-release|ABT-712 extended-release tablet
75328997|NCT00935311|Drug|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
75921514|NCT02253927|Drug|Ritonavir|
75921515|NCT02253927|Other|high fat breakfast|
75328998|NCT00935311|Drug|Placebo|Placebo tablet
75635683|NCT05730101|Other|Imaginary pill treatment (IP)|In the first session (IP1), participants will be asked about the nature of their procrastination behavior and receive a procedure to take an imaginary pill following a rationale of 5 steps. In the second IP session (IP2), experiences with taking the IP are discussed and the procedure of taking the IP is adapted according to previous experiences and current needs. The rationale of the second session encompasses the same five steps with small modifications: 1) discussing IP sensitive problem and adapting it if necessary, 2) building trust/belief/reality of the IP, 3) discussing the personally meaningful IP and adapting it if necessary, 4) taking the IP, 5) adapting the procedure for self-administering the IP in real life on daily basis if necessary and building adherence. At the end of both sessions, participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
75328999|NCT03019744|Device|MeCFES-assisted task-oriented upper limb rehabilitation|
75329000|NCT03019744|Other|Usual Care task-oriented upper limb rehabilitation|
75635684|NCT05728775|Drug|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia.
75635685|NCT05728775|Drug|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia.
75329001|NCT03031951|Behavioral|Lifestyle Intervention Group|The intervention group will start the lifestyle intervention with a 60-minute nutrition appointment given by a certified dietitian. This meeting is intended to provide a well-balanced personalized diet plan, calculated to create a moderate reduction from ~300 to 500kcal/day according to each participant's energy requirements and preferences. Two additional follow-up appointments are also planned to adjust the individual energy requirements throughout the intervention. Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Weight will be monitored weekly.
75785124|NCT04728607|Device|Compression device.|A compression device is a device that uses circumferential compression to reduce swelling around a stuck ring. The device is used by placing it near, but not overtop, the offending ring, and then is inflated compressing the finger. The device is applied, and the hand elevated, for approximately five minutes. The device is then removed, and with a small amount of lubricant, the ring is removed.
75785125|NCT04716686|Drug|Niraparib|Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.
75785126|NCT04714164|Behavioral|Group Cognitive Behavioral Therapy|Therapy will be delivered weekly for 8 weeks by Zoom.
75785127|NCT04706208|Behavioral|Cognitive Multisensory Therapy|Cognitive multisensory rehabilitation (CMR) is a type of physical therapy that incorporates conscious perception of body positions and movements during (multi)sensory discrimination exercises. The treating therapists will give 40 minutes of discrimination exercises embedded in functional movements followed by 5 minutes of applying the learned strategies during activities of daily living. CMR uses several types of discrimination exercises: Participants discriminated shapes, length, weight, distance, resistance, textures or compare kinesthetic information with visual information for integration of multisensory information. Solving the discrimination task is combined with reflection and a learning process, prompted by the therapist on how the limb (was) moved or was positioned.
75785128|NCT04706208|Other|Usual Care|Standard of care treatment for neuropathic pain after spinal cord injury
75785129|NCT04706208|Behavioral|Clinical Assessment|Clinical assessments are detailed below. Screening will include demographic and general health data; mini mental state evaluation (MMSE)-short version; Edinburgh handedness inventory; and the kinesthetic and visual imagery questionnaire (KVIQ).
75785130|NCT04706208|Behavioral|Magnetic Resonance Imaging (MRI)|The MRI scanning will include structural scans, resting-state functional MRI, and 4 task-based functional MRI.
75785131|NCT04706208|Other|OPTIONAL: blood draw|This part is OPTIONAL: 38ml of blood will be taken one time (for able body adults) or at 3 time points (for adults with spinal cord injury and neuropathic pain.
75785132|NCT04702776|Drug|Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%|Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.
75785133|NCT04702776|Drug|Sodium hyaluronate 0.15%|Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.
75785134|NCT04702776|Drug|Sodium hyaluronate 0.4%|Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
75785135|NCT04696822|Drug|Epinephrine Nasal Product, 1.6 mg|Single dose Nasal powder spray without allergen challenge
76078342|NCT03187054|Procedure|anterior or posterior colporrhaphy|will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
75329002|NCT02946034|Drug|Viekira Pak ± ribavirin|12 weeks treatment with AbbVie Viekira Pak ± ribavirin
75329003|NCT02946034|Drug|Mavyret|8 or 12 weeks treatment with AbbVie Mavyret
75329004|NCT00955747|Drug|Tagatose|powder; 15 grams three times daily; one year
75329005|NCT00955747|Drug|Sugar Substitute Splenda|1.5 g powder tid
75329006|NCT02946892|Drug|Carvedilol|Carvedilol will be given for 12 weeks and then an exercise test will be performed
75329007|NCT02946892|Drug|Placebo|Placebo will be given for 12 weeks and then an exercise test will be performed
75329008|NCT03017521|Drug|TAS-117|TAS-117 16mg, daily
75329009|NCT00935857|Device|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
75329010|NCT00935857|Device|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
75469481|NCT01939639|Drug|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
75469482|NCT01939652|Procedure|Restrictive VS Standard Fluid Regime|
75469483|NCT01939652|Drug|Drag: Crystalloids and Colloids|
75469484|NCT01939691|Drug|Difluprednate|Difluprednate 0.05% - corticosteroid eyedrop
75469485|NCT01939691|Drug|Nepafenac|Nepafenac 0.1% - NSAID eyedrop
75469486|NCT01939691|Drug|Prednisolone acetate|prednisolone acetate 1% - corticosteroid eyedrop
75635686|NCT05721209|Device|C-Mill with AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training. The AR/VR feedback will include computer generated obstacles and objects projected as images on the treadmill. Participants will be asked to use these projections as stepping cues and step on some images of objects while avoiding stepping on the images of obstacles.
75329011|NCT03017599|Device|20-gauge ProCore FNB needle|"The investigators will prospectively collect data base including patients who underwent EUS-guided biopsy with the 20-gauge ProCore histology needle for the evaluation of Pancreatic solid mass.~EUS procedures will be performed under sedation with linear echoendoscopes. Once the lesion will be penetrated, the stylet will be removed, and suction will be applied for 10 to 20 seconds by using a 10-ml syringe while moving the needle to and fro. All samples will processed at the pathology departments for histological analysis with documentation."
75329012|NCT01045421|Drug|MLN8237 (Alisertib)|"Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."
75635687|NCT05721209|Device|C-Mill without AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.
75635688|NCT05721209|Device|Zeno 3-Layer Walkway|Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.
75635689|NCT05721209|Device|Hunova|Used to conduct fall-risk assessment.
75635690|NCT05717023|Behavioral|Online guided self-help intervention for sexual distress following sexual assault|4 Sessions of guided self-help will be shared with the participants. These will be in the form of handout and video recordings that participant access through Qualtrics. The intervention is based on research on sexual trauma, psychosexual difficulties and materials developed by Bart's NHS Foundation Trust Sexual Wellbeing Service. It has been made in collaboration with clinicians within the service, experts by experience and the chief investigator.Within the document there are scripts for each session which are read out in the video recordings. The handouts depict the visual images for the video and the materials provided to participant.
75635691|NCT05715671|Drug|esketamine|The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
75785136|NCT04696822|Drug|Epinephrine nasal product, 1.6 mg + allergen|Single dose Nasal powder spray with allergen challenge
75785137|NCT04696822|Drug|Epinephrine Injection 0.3 mg|Intramuscular injection
75785138|NCT04696822|Drug|Epinephrine Nasal Product, 3.2 mg|Twice dose Nasal powder spray without allergen challenge
75785139|NCT04696822|Drug|Epinephrine Nasal Product, 3.2 mg + allergen|Twice dose Nasal powder spray with allergen challenge
75785140|NCT04694586|Drug|rifampicin|rifampicin 35 mg/kg
75785141|NCT04694586|Drug|pyrazinamide|pyrazinamide 40 mg/kg
75785142|NCT04694586|Drug|HRZE|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg combination tablets
75785143|NCT04694586|Drug|HR|isoniazid 75 mg + rifampicin 150 mg combination tablets
75921516|NCT03745144|Drug|Cladribine|Participants will receive cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
75921517|NCT03745144|Drug|Placebo|Participants will receive placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
75921518|NCT03745144|Drug|Microgynon®|Participants will receive Microgynon® tablet once daily for 21 days in treatment period 1 and 2.
75785144|NCT04690348|Procedure|Craniotomy|Craniotomy
75785145|NCT04690348|Radiation|Cesium-131 brachytherapy|Intracavitary Cesium-131 brachytherapy
75785146|NCT04685928|Diagnostic Test|MRI and MRI-guided prostate biopsy|Multiparametric MRI prostates in the MRI arm will be performed using 1.5 or 3.0 Tesla scanner with a pelvic phased array coil and contrast injection. T2-weighted, diffusion weighted and dynamic contrast enhanced scans will be included and the reporting of MRI finding will be done according to PI-RADS (Prostate Imaging-Reporting and Data Systems) v2.1 recommendations. MRI-guided targeted biopsy will be performed by Urologists experienced in MRI-guided biopsy for men with PI-RADS score 3-5.
75921519|NCT05571657|Behavioral|Reminder/Recall Sent Via Preferred Method of Communication|Parents of 12-17 year-old patients due for COVID-19 booster dose will receive a one-time vaccine reminder/recall via the parent's preferred method of communication (mailed letter, text message, email)
75921520|NCT05697016|Drug|Sivelestat Sodium for Injection|Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl]amino-acetate tetrahydrate]
75921521|NCT05697016|Drug|The Placebo|Excipients used for the sivelestat sodium
75921522|NCT02253771|Device|shockwave therapy|Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
75921523|NCT02253771|Device|placebo shockwave therapy|sham shockwave therapy by an identically looking device without any function
75921524|NCT05538442|Other|Physiological recordings|Physiological, cognitive, biological measurments
75921525|NCT04664907|Other|Videomusic listening|Patients will attend a 8 min videomusic session and questionnaires will be performed before and after this session.
75329013|NCT02947984|Radiation|Standard Treatment|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
75329014|NCT02947984|Radiation|Higher Dose|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
75329015|NCT03031717|Procedure|Transjugular intrahepatic portosystemic shunt|
75329016|NCT03031639|Procedure|Endoscopic approach thyroidectomy|Thyroid surgery using endoscopy.
75329017|NCT03402425|Diagnostic Test|18F-FET PET|Patient are investigated with an 18F-FET PET
75329018|NCT02981641|Radiation|Intraoperative radiotherapy (IORT)|Total dose: 18~22 Gy; Single dose: 18~22 Gy; Frequency: 1
75329019|NCT02981641|Drug|Sequential chemotherapy|Sequential chemotherapy
75329020|NCT02981641|Radiation|Three dimensional conformal radiation therapy (3D-CRT)|Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30
75329021|NCT02981641|Drug|Concurrent chemotherapy|Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
75635692|NCT05714605|Behavioral|THRIVE Intervention|The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals following hospitalization.
75635693|NCT05707897|Drug|TS-142 10 mg|Single-dose of 10 mg of TS-142
75921526|NCT05696860|Device|Capnography Monitoring|Capnography monitoring
75921527|NCT04425772|Drug|FNC+Standard of Care|FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
75921528|NCT04425772|Drug|FNC dummy tablet+Standard of Care|FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
75635694|NCT05705453|Device|Epidural Spinal Cord Stimulation|Stimulation of the spinal cord from the epidural space.
75921529|NCT03327376|Device|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
76078343|NCT04760457|Procedure|Implant placement with flapped surgery|Four mini implants will be placed reflecting a flap.
75635695|NCT05705089|Drug|Rivaroxaban 15 MG|Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
75635696|NCT05705089|Drug|Warfarin|Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
75785147|NCT04685928|Diagnostic Test|TP-arm Systematic biopsy|Transperineal 24-core biopsy using a free-hand technique under local anaesthesia will be performed under transrectal ultrasound guidance for men in this arm
75785148|NCT04684797|Behavioral|Virtual T-maze task|Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
75921530|NCT05134714|Device|CAD/CAM zircon band and loop space maintainer|Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
75921531|NCT05134714|Device|Conventional metal band and loop space maintainer|Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.
75921532|NCT01567995|Drug|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
75921533|NCT01567995|Drug|Vehicle (base cream)|Vehicle (base cream)
75921534|NCT05277909|Other|The expert assessment of shoulder impairments and individualised treatment plan|The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
75921535|NCT05277909|Other|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
76078344|NCT04760457|Procedure|Implant placement with flapless surgery|Four mini implants will be placed without reflecting a flap.
75329022|NCT04377737|Diagnostic Test|RT-PCR Covid-19|estimation of the prevalence of positive rt-PCR in school children during the pandemic period
76078345|NCT04760457|Procedure|Implant immediate loading|Four mini implants will be immediately loaded.
76078346|NCT04760457|Procedure|Implant delayed loading|Four mini implants will be loaded after a 6-week healing period.
75329023|NCT02981563|Other|Time Together|For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
75329024|NCT03402347|Radiation|Non-ionising radiation|Laser regimes will be applied to ex vivo skin samples.
75329025|NCT03017365|Other|Stable Resistance Training|traditional machine-based resistance training
75329026|NCT03017365|Other|Unstable Resistance Training|free weight resistance training using unstable devices
75635697|NCT05682495|Drug|ARM A|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.
75635698|NCT05682495|Drug|ARM B|Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2.
75635699|NCT05682495|Drug|ARM C|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2.
75635700|NCT05682495|Drug|ARM D|Subjects will receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg*2.
75635701|NCT05682495|Drug|ARM E|Subjects will receive treatment HR20031 FDC 5/50/750 mg*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3 followed by 7 days washout and then receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3.
75635702|NCT05682495|Drug|ARM F|Subjects will receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg*2 followed by 7 days washout and then receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3.
75635703|NCT05672901|Device|StrataMGT|StrataMGT is a 100% medical grade film-forming silicone gel for the treatment of cutaneous skin lesions and Genitourinary Syndrome of Menopause. StrataMGT is a flexible wound dressing used on compromised skin. It dries to form a thin, flexible wound dressing which hydrates and protects affected areas. StrataMGT is used to relieve low grade inflammatory changes such as dry, itching, flaking, peeling and irritated skin. StrataMGT is designed for partially epithelized skin and is suitable for children and patients with sensitive skin.
75921536|NCT04627389|Procedure|orbicularis oris muscle Z- plasty modification of modified millard technique|After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
75921537|NCT04627389|Procedure|modified millard technique|no z-plasty modification
75921538|NCT03547557|Device|Exablate 2000 strappable system|
75921539|NCT03547479|Behavioral|VDOT|In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
75635704|NCT05672901|Drug|Estrace 0.01% Vaginal Cream|Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
75635705|NCT05671822|Drug|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 1A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 1B) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1C) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1D) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
75921540|NCT03547479|Behavioral|VDOT + mobile money|The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
75635706|NCT05671822|Drug|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 2A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 2B) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 2C) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
75635707|NCT05671679|Other|SNAQ app|SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image. The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g. foods, ingredients, sauces, herbs or seasonings). Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database. Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function. The user can always adapt proposed nutritional contents at their own discretion. Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices. The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
75635708|NCT05671679|Other|Traditional carbohydrate counting|Patients will follow their traditional methods of carbohydrate counting during the control period. In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
75635709|NCT05666167|Behavioral|Group Telehealth Exercise Sessions with text messaging plus booster sessions|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.
75635710|NCT05650515|Other|Co-creation|The development of a technology-based exercise intervention based on ideas of older adults and experts in the field of geriatric rehabilitation/research/medicine
76078347|NCT02991586|Behavioral|Dialectical Behaviour Therapy|Group of families
76078348|NCT04898296|Other|Questionnaire, Interview|During the stay, a study visit is arranged with the patient after the 6-minute walk test has been performed. This consists of filling out the questionnaire and an interview, which lasts about 45-60 minutes. This is carried out by the investigator on at least 5 subjects. After each interview, a list of influencing factors is kept. If new aspects continue to appear in the 5th interview, the interviews are continued (up to a maximum of the 10th subject). If no new aspects appear in the interviews from number 6 onwards, the interviews are discontinued and no further patients are recruited. The conversations are recorded with an audio recording.
76078349|NCT04898296|Other|Focus Group|The focus group is carried out first in order to identify influencing variables that may be relevant for the interview (duration 60-90 minutes).
75635711|NCT05649540|Drug|Vonoprazan|Potassium-competitive acid blocker
75635712|NCT05649540|Drug|Amoxicillin|Antibiotic for H. pylori eradication
75785149|NCT04675476|Behavioral|Provider Prompt & Patient Outreach and Education|To target lack of provider-prompted discussion about lung screening, an electronic medical record (EMR) message will be sent to primary care providers prior to scheduled visits with screening-eligible patients to notify them of the patient's eligibility and to encourage discussion of the benefits and limitations of the test. To target patient-level knowledge about lung screening, an outreach specialist will educate screening-eligible patients about the benefits and limitations of the test prior to their visit.
75798617|NCT01286766|Drug|DCF (docetaxel with cisplatin with 5-FU)|"5-FU: 1,000 mg/m2 CI, D1-3~Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~treatment is repeated until 4 cycles"
75921541|NCT05567523|Drug|Dexmedetomidine|In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.
76078350|NCT04550013|Other|Heavy-Slow Resistance training|Resistance training for knee extensors. The exercise will be performed at 80% of 1 RM and slowly (6 s/repetition).
75921542|NCT05567523|Drug|Normal saline|normal saline
75921543|NCT05567523|Drug|Midazolam|midazolam
76078351|NCT04550013|Other|Low-Load Blood Flow Restriction training|Resistance training for knee extensors. The exercise will be performed at 30% of 1 RM and with a relative Artery Occlusion Pressure of 80%
75785150|NCT04672681|Behavioral|Play-based physical activity intervention|The intervention group will participate in a six-month play-based physical activity intervention starting from their initiated treatment. The intervention combines hospital and home-based physical activity. Three days a week, there will be 45 minutes of group-based physical activity at the hospital during admissions or appointments at the outpatient clinic, supervised by an exercise professional or pediatric physiotherapist. Children who are isolated during treatment are offered supervised individual 45 min. training sessions 3 times a week as a substitute. During the other four days a week, or on days where the family is at home, the parents administer the play-based physical activity. At inclusion, the parents receive education and supervision on conducting play-based physical activity with their child in the hospital room or at home. They will receive inspiration material containing numerous different plays, games, and activities in different intensities.
75635713|NCT05646693|Dietary Supplement|Drusen Mega®|It consists of a dietary supplement composed of Vitamin C 60.0mg, Vitamin E 30.0mg, Zinc 12.5mg, Copper 1.0mg, Astaxanthin 4.0mg, Zeaxanthin 2.0mg, Lutein 10.0mg and Omega 3 Acids 500.0mg. It is suggested to consume one capsule per day, preferably with food. This supplement is indicated for nutritional deficiencies and in patients with ophthalmological pathologies.
75785151|NCT04668872|Radiation|Y90 TARE|Y90 TARE will be performed as standard of care (SOC)/clinically indicated: 1) in a lobar or sub-lobar fashion (depending on tumor involvement and location; also targeting the tumor as selective as possible and sparing as much as possible of non-involved liver parenchyma), for participants with extensive bilobar disease or 2) in a radiation segmentectomy approach, intending to deliver 190 Gy radiation dose to target tumor: for patients with limited liver metastatic disease, not amenable for surgery or ablation.
75785152|NCT04668872|Diagnostic Test|PET/CT|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
75785153|NCT04668872|Diagnostic Test|PET/MRI|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
75785154|NCT04665037|Drug|Posaconazole IV 6 mg/kg|POS 6 mg/kg body weight by IV infusion
75635714|NCT05646693|Drug|Sertraline|It consists of a drug capsule composed of Sertraline Hydrochloride 50mg. In adults it is suggested to consume one to four capsule(s) per day, administering (preferably) the highest dose in the evening, before going to bed. This drug is indicated in the treatment of depressive states with anxiety or moderate to severe agitation, which are accompanied by tension, excitement, insomnia, obsessive and hypochondriac traits. It is also indicated in obsessive-compulsive disorder, panic attacks, stress disorder, post-traumatic disorder, social anxiety disorder and used to relieve the symptoms of premenstrual dysphoric disorder.
75635715|NCT05646693|Drug|Placebo|It consists of a placebo capsule composed of Magnesium Oxide 100mg. This component is inert in the dose at which it will be administered.
75785155|NCT04665037|Drug|Posaconazole PFS 6 mg/kg|POS nominal 6 mg/kg body weight based on weight bands taken orally
75921544|NCT02584504|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
75921545|NCT02584504|Drug|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
75921546|NCT02584504|Drug|Atorvastatin|Atorvastatin 5 mg tablet orally.
75785156|NCT04662619|Other|B. infantis|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU), will be provided to infants once daily for 12 weeks."
75785157|NCT04662619|Other|Lactose Placebo|Powdered infant formula grade lactose will be provided to infants once daily for 12 weeks.
75921547|NCT02584504|Drug|Non-statin Lipid-Modifying Therapy|Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
75921548|NCT02584504|Other|Diet Alone|Stable cholesterol-lowering diet as background therapy.
75921549|NCT04607889|Other|Survey|Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.
75785158|NCT04661137|Drug|Selinexor 60 MG|Selinexor 60 mg PO on days 1, 8 and 15
75785159|NCT04661137|Drug|Selinexor 80 MG|Selinexor 80 mg PO on days 1, 8 and 15
75785160|NCT04661137|Drug|Selinexor 100 MG|Selinexor 100 mg PO on days 1, 8, 15 and 22
75785161|NCT04661137|Drug|Carfilzomib|56 mg/m2 IV on days 1, 8 and 15
75785162|NCT04661137|Drug|Pomalidomide|4 mg PO daily for 21 days
75785163|NCT04661137|Drug|Daratumumab|16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on
75785164|NCT04661137|Drug|Dexamethasone|20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22
75785165|NCT04649385|Drug|BGB-15025|Administered orally once or twice daily (QD or BID)
75921550|NCT04599777|Drug|TACE combined with sorafenib and tislelizumab|Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
75921551|NCT02253615|Other|Machines exercises|Resistance training in pneumatic machines.
75921552|NCT02253615|Other|Elastic exercises|Resistance training with elastic tubes.
75921553|NCT05698264|Device|concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
75785166|NCT04649385|Drug|Tislelizumab|Administered 200 mg intravenous (IV) infusion
75785167|NCT04643431|Diagnostic Test|Perflutren|The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.
75329027|NCT03017365|Other|Adductor/Abductor Resistance Training|machine-based adductor/abductor resistance training
75635716|NCT05624463|Behavioral|Modified intubation protocol|1. Turn on the electromyography (EMG) monitor and connect the EMG monitor to the patient as the patient is anesthetized; 2. View the vocal cords with video laryngoscope and intubate the patient with the EMG endotracheal tube; 3. Check the EMG monitor to confirm the correct contact between the electrodes and vocal cords; 4. Adjust the tube to achieve proper and stable contact between the electrodes and vocal cords; 5. Tape the EMG endotracheal tube at the midline and position the patient.
75635717|NCT05624463|Behavioral|Conventional intubation protocol|1. Intubate the patient with the EMG endotracheal tube and note depth; 2. Position patient and verify the position via Glottic Exam or Respiratory Variation; 3. Fix tube position.
75635718|NCT05624463|Behavioral|Early resumption of oral intake|Patients will drink 30-50ml of normal temperature water after Steward scores ≥ 4 at PACU. If patients swallow successfully and have no significant discomfort symptoms, physicians will guide patients to resume drinking and eating gradually.
75635719|NCT05624463|Behavioral|Delayed resumption of oral intake|Patients will resume drinking water 6h after the operation at ward. Before patients resume oral drinking, they will be provided 10ml/kg 5% glucose saline intravenously.
75635720|NCT05616624|Drug|ADI-PEG 20|-Given 60 minutes (+/- 15 minutes) prior to docetaxel
75785168|NCT04633811|Dietary Supplement|Low Oxalate Diet before Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 6 days. 2 x 24 hour urines will be collected on days 3 and 4.
75785169|NCT04633811|Dietary Supplement|Oral load of oxalate and sucralose before Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 5 of the 6-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
75635721|NCT05616624|Drug|Gemcitabine|-Given over the course of 90 minutes (+/- 10 minutes)
75635722|NCT05616624|Drug|Docetaxel|-Given over the course of 60 minutes (+/- 10 minutes)
75635723|NCT05609487|Other|As usual|Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period.
75785170|NCT04633811|Dietary Supplement|Optifast VLCD Program|Subjects will go on a 10-week Intestive level Optifast VLCD weight loss program
75785171|NCT04633811|Dietary Supplement|Optifast VLCD Transition Phase|After completion of the 10-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 4 weeks.
75785172|NCT04633811|Dietary Supplement|Low Oxalate Diet after Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 11 days and collect 2 x 24 hour urines on days 8 and 9
76078352|NCT04894162|Other|Questionnaire|Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a research questionnaire about research preferences.
75785173|NCT04633811|Dietary Supplement|Oral load of oxalate and sucralose after Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 10 of the 11-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
75785174|NCT04633330|Drug|AHCC®capsules|AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
75785175|NCT04633330|Drug|Simulation of AHCC®capsules|TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
75798618|NCT01286844|Drug|GSK2190915A 5mg|Oral powder for dispersion in water
75798619|NCT01286844|Drug|GSK2190915A 10mg|Oral powder for dispersion in water
75798620|NCT01286844|Drug|GSK2190915A 25mg|Oral powder for dispersion in water
75798621|NCT01286844|Drug|GSK2190915A 50mg|Oral powder for dispersion in water
76078353|NCT04134520|Device|ProLung System|Non-invasive bioconductance measurements
76078354|NCT02808364|Biological|Personalized cellular vaccine|Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
76078355|NCT02709616|Biological|Personalized cellular vaccine|Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
75329028|NCT03402191|Drug|L-arginine|l-arginine for thalassemia with pulmonary hypertension
76078356|NCT02468752|Drug|Oxygen|
75329029|NCT03402191|Drug|Sildenafil|Sildenafil for thalassemia with pulmonary hypertension
75329030|NCT03031561|Device|Ultrasound|Undergo standard ultrasound
75329031|NCT03031561|Device|MicoPure ultrasound|Undergo MicoPure ultrasound
75329032|NCT03031561|Procedure|Biopsy of Breast|Undergo breast biopsy or surgical resection
75329033|NCT03402113|Drug|Dexmedetomidine|consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.
75329034|NCT03402113|Drug|Midazolam|consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
75329035|NCT04359355|Device|Artificial Intelligence System for Detection of colorectal polyps|In this group, an artificial Intelligence System will be used for computer-aided diagnosis of colorectal polyps. Diagnostic Performance of the artificial intelligence System for detection of polyps will be compared against Operator-based detection in the same group
75329036|NCT03017209|Dietary Supplement|Locally-prepared bar|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
75329037|NCT03017209|Dietary Supplement|USAID Corn Soy Blend Plus|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
75785176|NCT04625465|Behavioral|CBT Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).
75921554|NCT05698264|Device|concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
75921555|NCT05695924|Device|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
75921556|NCT05695924|Procedure|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
75921557|NCT05061160|Other|Interval Aerobic Exercise training Group|"Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
75635724|NCT05609487|Device|Protection plan|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
75635725|NCT05606367|Device|Non-slip Balloon Catheter of Shanghai MicroPort Rhythm|The principle of Non-slip Balloon Catheter in dilating stenotic lesions is mechanical extrusion of the vessel through the balloon, resulting in irregular rupture of atheromatous plaque and enlargement of the lumen.
75635726|NCT05606367|Device|NSE Coronary Dilatation Catheter|The Lacrosse® NSE is an angioplasty catheter with 3 longitudinal elements attached directly proximal and distal to the balloon that produces 3 endovascular surgical incisions during balloon dilation.
75921558|NCT05061160|Other|Continuous Aerobic Exercise training Group|"Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
76078357|NCT02468752|Other|Air|
75635727|NCT05601817|Behavioral|Vita|Vita is developed by this study team based on Attention Restoration Theory. The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.
75785177|NCT04625465|Behavioral|Attention Control Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.
75785178|NCT04622696|Diagnostic Test|Ultrasound imaging|Subjects in the performance cohort will undergo ultrasound imaging to assess the visibility of the HydroMARK Breast Biopsy Marker at 6-12 weeks post-implant. There is no intervention in the safety cohort (retrospective chart review).
75785179|NCT04613388|Other|Assesment of Effectiveness and side effects|Case Report forms, Quality of life questionaire
75785180|NCT04609878|Drug|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
76078358|NCT04817956|Drug|Atezolizumab|drugs used outside indication, based on biomarker
75785181|NCT04609878|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
75785182|NCT04609878|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
75785183|NCT04609878|Drug|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
75921559|NCT05007262|Drug|Tangningtongluo tablets|Four pills each time and three times a day after meals.
76078359|NCT04672239|Behavioral|"Smartphone app Smiling instead of Smoking (SiS) Version 3"|Participants will be onboarded to the smartphone app SiS and will be asked to use it for 7 weeks to support them in quitting smoking.
76078360|NCT04672239|Behavioral|"Smartphone app QuitGuide (QG)"|Participants will be onboarded to the NCI smartphone app QG and will be asked to use it for 7 weeks to support them in quitting smoking.
76078361|NCT04672239|Behavioral|"Brochure Clearing the Air (CTA)"|"Participants will be onboarded to the brochure Clearing the Air and will be asked to use it for 7 weeks to support them in quitting smoking."
75785184|NCT04603898|Dietary Supplement|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days
75785185|NCT04603898|Dietary Supplement|Carbon-13 Ascorbic Acid Oral Load|Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.
76078362|NCT01894919|Biological|Bexsero® vaccine (1 dose at study month zero)|
76078363|NCT01894919|Biological|Bexsero® vaccine (2 doses 1 month apart)|
76078364|NCT04418206|Other|patients COVID 19|Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
76078365|NCT04130698|Behavioral|Distress Tolerance|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
76078366|NCT04130698|Drug|transdermal nicotine patch|Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
75785186|NCT04598529|Other|A2 milk|a variety of cow's milk that contains only A2 beta-casein (and therefore lacks of A1 beta-casein).
75469487|NCT01939704|Other|Pediatric Primary Care Intervention|30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.
75469488|NCT01939704|Other|Pediatric Urgent Care Intervention|3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
75469489|NCT01939717|Other|Dance group|"Participants will attend ten weeks of set dancing classes. Each class will be one and half hours. Family members will be invited to partner each participant with Parkinson's disease during the class. Set dancing steps and sets will be thought and progressed in line with the participants abilities. Frequent rests will be taken during the classes.~Participants will be given a home exercise programme which will involve chair based exercises, mental rehearsal, listening music, watching a dance DVD and practicing dance material thought in class."
75469490|NCT01939730|Drug|Rituximab|375 mg/m^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
75469491|NCT01939730|Drug|GM-CSF|250 mcg subcutaneously 3 times a week for 8 weeks.
75785187|NCT04598529|Other|Conventional milk|cow's milk with a mixture of A1 and A2 beta-casein.
75785188|NCT04597437|Drug|Zanamivir|Intravenous zanamivir
75785189|NCT04597437|Other|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
75798622|NCT01286844|Drug|GSK2190915A 100mg|Oral powder for dispersion in water
75921560|NCT05007262|Drug|Calcium dobesilate capsules|1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.
75921561|NCT05150613|Other|No Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible & distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed & inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale & post-exercise exhaustion scale will be assessed upon completion of exercise testing.
75469492|NCT01939743|Drug|Diclofenac suppository plus lidocaine gel|
76078367|NCT04130698|Behavioral|Active Health Control|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
76078368|NCT05306223|Drug|Bedaquiline|Bedaquiline uncoated tablets will be administered orally.
76078369|NCT05306223|Drug|Levofloxacin|Levofloxacin filmcoated will be administered orally
75329038|NCT03017209|Other|Placebo|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
75329039|NCT01725191|Other|Laboratory Biomarker Analysis|Correlative studies
75329040|NCT01725191|Other|Pharmacological Study|Correlative studies
75469493|NCT01939743|Drug|Lidocaine gel only|
75635728|NCT05601817|Behavioral|Com|Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity. The com intervention involves doing game-like training on a iPad.
75798623|NCT01288638|Other|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
75329041|NCT01725191|Drug|Tivantinib|Given PO
76078370|NCT05306223|Drug|Linezolid|Linezolid tablets will be administered orally
76078371|NCT05306223|Drug|Cycloserine|Cycloserine capsules will be administered orally.
76078372|NCT05306223|Drug|Clofazimine|Clofazimine capsules will be administered orally.
76078373|NCT05306223|Drug|Pyrazinamide|Pyrazinamide tablets will be administered orally.
76078374|NCT05306223|Drug|Protionamide|Protionamide enteric-coated tablets will be administered orally.
75469494|NCT01939756|Device|Intravesical baobab oil|Intravesical baobab oil
75469495|NCT01939769|Other|Exercise - Low-intensity exercise|
75469496|NCT01939769|Other|Exercise - High-intensity exercise|
75469497|NCT01939782|Other|No Breakfast (NoB)|In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
75469498|NCT01939782|Other|Yes Breakfast (YesB)|In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
75469499|NCT01939795|Other|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
75469500|NCT01939808|Other|Splint Neutral|
75469501|NCT01939808|Other|Splint Extended|
75635729|NCT05601817|Behavioral|Vita+Com|Vita+Com intervention is a combination of both Vita and Com interventions. Participants will be asked to complete Vita first and then Com intervention.
75635730|NCT05597397|Device|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
75635731|NCT05590065|Device|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
75921562|NCT05150613|Other|Surgical Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible & distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed & inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale & post-exercise exhaustion scale will be assessed upon completion of exercise testing.
75921563|NCT05150613|Other|N95 Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible & distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed & inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale & post-exercise exhaustion scale will be assessed upon completion of exercise testing.
75921564|NCT03546153|Behavioral|Aerobic exercise program|Exercise program consists of training for 60 minutes, three times per week for 12 weeks. Participants will use a treadmill, Nu stepper/bike or elliptical to exercise.
76078375|NCT03016000|Drug|Thalidomide|Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
76078376|NCT03016000|Other|Observation|Just observation
76078377|NCT04130152|Drug|Palbociclib|Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle
76078378|NCT04130152|Drug|Letrozole|Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
76078379|NCT03224481|Other|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
76078380|NCT01894841|Behavioral|Coping Long Term with Active Suicide (CLASP)|6 month behavioral telephone-based intervention. Calls assess risk, problem solve any immediate issues, and case management
76078381|NCT01894841|Other|Safety Assessment and Follow Up Evaluation|enhanced risk monitoring with full assessment protocol at 3, 6, 9, and 12 month follow up. Results sent as a note to the patient's VA mental health provider
75798624|NCT01288638|Other|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
76078382|NCT04106674|Procedure|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
76078383|NCT03254589|Drug|Methotrexate|See arm descriptions
76078384|NCT03254589|Drug|Sulfasalazine|See arm description
76078385|NCT03254589|Drug|Other DMARDs|See arm
75329042|NCT03017443|Behavioral|Nutrisystem Turbo 10|Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.
75635732|NCT05585372|Other|CT guided opening mobilization of cervical intervertebral foreman|"the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
75635733|NCT05568043|Behavioral|COPD Transitions of Care Intervention Bundle: Virtual Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal [V-TTG] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.
75635734|NCT05568043|Behavioral|COPD Transitions of Care Intervention Bundle: In-Person Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.
75798625|NCT03862638|Other|Yoga Therapy|Yoga therapy is therapeutic application of yoga, specifically designed to treat the condition using physical posture, breathing exercises, guided relaxation and meditation.
75798626|NCT02525484|Drug|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
75785190|NCT04592627|Other|Simulated home environment visit|During the simulated home environment visit participants will 1) participate in a simulated University of Texas (UT) Physicians Stroke Outpatient Clinic telemedicine visit using an iPAD during which participants will be audio- and visually-recorded in order for the research team to collect raw facial expression data; 2) be instructed to complete a series of activities of daily living (e.g., sitting down and brushing hair) during which participants will be audio- and visually-recorded in order for the research team to collect raw body motion tracking data; and 3) complete a participant satisfaction survey via a REDCap link and participate in an audio-recorded, semi-structured interview (e.g., asking the participants thoughts on privacy considerations related to future use of the facial expression and body motion technology in a home environment) with members of the research team.
75469502|NCT01939821|Behavioral|Educational and counselling program|"Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
75635735|NCT05566886|Device|Continuous measurement of photoplethysmography at the wrist|Patients receive a wristband that uses multi-color LEDs to measure pulsations at the wrist.
75329043|NCT03017443|Behavioral|Nutrisystem My Way|The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (~50% kcal from carbohydrate, ~25% from protein, ~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.
75329044|NCT03017443|Behavioral|Nutrisystem DASH|The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included < 30% fat (< 7% saturated fat), < 150 mg/d of cholesterol, and < 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu [7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.
75329045|NCT03017443|Behavioral|Dieting on Your Own (DIY) - DASH|The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
75921565|NCT04549857|Behavioral|aromatherapy|"The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~The placebo group only used base oil (sweet almond oil).~The control group did not provide any interventional measures and only received conventional treatment."
75635736|NCT05563831|Other|national registry|The investigators will collect demographic, clinical, biological and imaging characteristics of patients with PROS.
75635737|NCT05561335|Device|hearing aid -novel program|novel microphone configuration
75635738|NCT05561335|Device|hearing aid - standard program|standard microphone configuration
75635739|NCT05554926|Drug|AEF0117|2 mg AEF0117 containing approximately 100 μCi of [4-14C]AEF0117
75635740|NCT05550857|Other|eccentric resistance exercise|The subject will lying prone on a treatment table. One end of eccentric resistance band will tie around the mid of the foot of indvidual, the other end of the resistance band will be attach to the table and the band is adjusted so that it will tight and there will be no slack present in it. It will provide a smooth eccentric resistance throughout the dorsiflexion range
75785191|NCT04574882|Other|Survey|Interested participants may complete the informed consent online. After informed consent, the participant will be asked to share the digital data types that they use (Facebook, Instagram, Twitter, Google search, step data) and then participants will complete a cross-sectional survey.
75798627|NCT01173978|Behavioral|Steroid hormone|Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
75635741|NCT05550857|Other|myofascial release|The subject will lye prone on a treatment table. Deep longitudinal massage with the help of both thumbs reinforcing eachother will be given on the subject's calf muscles.
75635742|NCT05541913|Other|Tele nursing|The intervention group in the study will be the parents of children who received routine care in the surgical service and who received tele-nursing service, who had undergone circumcision operation.After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
75798628|NCT01173978|Other|No intervention|
75921566|NCT03547089|Device|Viveve®|A single treatment using Viveve® with 110 pulses administered to the vaginal introitus at 90 J/cm2
75921567|NCT03546075|Dietary Supplement|Resveratrol|
75921568|NCT03546075|Other|Placebo|
75921569|NCT04535895|Radiation|Simultaneous integrated boost|Adjuvant breast cancer irradiation including simultaneous integrated boost
75921570|NCT05515107|Device|Videolaryngoscope size 1 Miller blade|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
75329046|NCT04359043|Behavioral|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC is an intervention that focuses on increasing the caregiving capacity of the caregiver by enhancing a set of emotional and cognitive components that collectively, sensitizes the caregiver to the emotional and cognitive needs of the child.
75329047|NCT04359043|Behavioral|Treatment as Usual|Treatment as Usual was delivered by community-based organization caseworkers. It consists of a nutritional curriculum of the same dosage and time commitment as the experimental condition, but with no caregiving component.
75329048|NCT00914069|Device|RIVS vascular access|Access to peripheral vasculature
75329049|NCT00914069|Device|Conventional vascular access|Vascular access using conventional venous access device
75329050|NCT03031405|Drug|Oxytocin nasal spray|
75329051|NCT03031405|Drug|Placebos|Placebo nasal spray
75469503|NCT01939821|Behavioral|Educational program|"Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals."
75635743|NCT05526144|Drug|Synthroid|Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.
75635744|NCT05526144|Drug|Placebo|Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
75469504|NCT01939834|Device|AAA control|"AAA control is a method to determine insulin dosing to keep glucose in range. AAA control is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the AAA control and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.~AAA control will be tested in 40 hours sessions and 5 consecutive overnight sessions."
75469505|NCT01939834|Other|CGM + insulin pump at home|The subject will be on their home insulin pump and using a CGM per their usual care.
75635745|NCT05526066|Biological|ARCT-810|ARCT-810 is messenger RNA (mRNA) coding for Ornithine Transcarbamylase (OTC) formulated in a lipid nanoparticle (LNP) under development.
75785192|NCT04570150|Drug|Sugammadex|Subjects who are randomized to into the sugammadex arm (Arm I) will receive sugammadex for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm II (neostigmine group).
75921571|NCT03547011|Procedure|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
75921572|NCT03547011|Procedure|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
75921573|NCT05537584|Drug|Sertraline|Subjects will receive 8 weeks of sertraline while monitored by the study physician
75329052|NCT03031249|Drug|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
75329053|NCT03031249|Drug|all-trans retinoic acid|ATRA at a dose of 30mg/㎡/d on day 1-14.
75469506|NCT01939847|Other|Treatment suggestion|Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
75469507|NCT01939860|Other|Written and verbal patient education on hypertension and its treatment|
75469508|NCT01939873|Behavioral|KRISTELLER|
75635746|NCT05526066|Other|Placebo|Normal Saline
75635747|NCT05513469|Drug|Lutathera|regulair PRRT of 4 cycles with 7.4GBq
75635748|NCT05492396|Device|Standard gluteus medius repair with Tapestry Biointegrative implant|Patients will undergo standard gluteus medius repair utilizing augmentation.
75635749|NCT05484349|Drug|Tizanidine Hydrochloride|Tizanidine Hydrochloride 1 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
75785193|NCT04570150|Drug|Neostigmine|Subjects who are randomized into the neostigmine arm (Arm II) will receive neostigmine for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm I (sugammadex group).
75798629|NCT03865758|Device|IN2L computer system|Therapists will use the IN2L computer system to choose videos, music, games and exercise specific to the rehabilitation needs and personal preferences of patients.
75329054|NCT03031249|Drug|Arsenic Trioxide|ATO at a dose of 10mg/d on day 1-14
75329055|NCT02980315|Other|CAR-T cells|the patients treat with CAR-T cells
75329056|NCT02980393|Behavioral|Lifestyle intervention|The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
75785194|NCT04565899|Other|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
75785195|NCT04544449|Drug|Fenebrutinib|Participants will receive fenebrutinib.
75785196|NCT04544449|Drug|Ocrelizumab|Participants will receive ocrelizumab.
75785197|NCT04544449|Drug|Placebo matched to ocrelizumab|Participants will receive ocrelizumab-matching placebo.
75785198|NCT04544449|Drug|Placebo matched to fenebrutinib|Participants will receive fenebrutinib-matching placebo
75785199|NCT04542733|Drug|Everolimus|Everolimus will be given with tacrolimus.
75785200|NCT04542733|Drug|reduced dose tacrolimus|Reduced dose tacrolimus will be given with or without leflunomide
75785201|NCT04540900|Biological|KB301|non-integrating HSV-1 vector expressing human type III collagen
75785202|NCT04540900|Other|Placebo|sterile isotonic saline
75785203|NCT04527315|Other|Questionnaires|Various questionnaires will be used to assess short and long-term impacts of depression, anxiety, and other indicators of overall mental health and quality of life
75785204|NCT04520126|Dietary Supplement|Olivomed (capsules containing hydroxytyrosol)|patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.
75785205|NCT04520126|Dietary Supplement|OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).|patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.
75785206|NCT04506866|Device|InterStim Micro|Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use
75785207|NCT04493853|Drug|Capivasertib|400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
75785208|NCT04493853|Other|Placebo|matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
75785209|NCT04493853|Drug|Abiraterone Acetate|Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
75785210|NCT04474821|Other|Educational Intervention|Receive educational materials on HPV
75785211|NCT04474821|Other|Survey Administration|Ancillary studies
75921574|NCT05537584|Drug|Bupropion|Subjects will receive 8 weeks of bupropion while monitored by the study physician
75921575|NCT03546933|Device|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
75329057|NCT03016663|Procedure|Technique of Breast Lipofilling|"Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.~Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.~Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).~Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.~Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided."
75329058|NCT01042535|Biological|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
75329059|NCT01042535|Drug|1-methyl-d-tryptophan|Given orally (PO)
75329060|NCT01042535|Other|Laboratory biomarker analysis|Correlative studies
75785212|NCT04465838|Other|NIS|This is a non-interventional study (NIS).
75785213|NCT04450914|Behavioral|CV Prevention Choice Tool|The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.
75785214|NCT04450914|Behavioral|Implementation Facilitation Strategies|During the active implementation stage, health systems will deploy tailored implementation facilitation and other tailored implementation strategies aimed at increasing adoption and use of shared decision making using CV Prevention Choice.
75329061|NCT03031327|Device|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
75329062|NCT03031327|Device|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
75329063|NCT03031327|Device|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
75785215|NCT04448678|Behavioral|Health Insurance Education Program (HIEP)|[See arm/group descriptions]
75785216|NCT04448678|Other|Usual Care|[See arm/group descriptions]
75785217|NCT04437030|Device|MSOT Acuity Echo device|The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.
75785218|NCT04428866|Diagnostic Test|Continuous Glucose Monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed during visit 1 in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
75785219|NCT04428866|Diagnostic Test|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days to assess activity, concurrent with CGM sensor wear.
75785220|NCT04428866|Diagnostic Test|Mixed meal tolerance test|After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
75785221|NCT04428866|Diagnostic Test|Glucagon Sensitivity Testing|After baseline blood sampling, glucagon will be administered by injection, and blood samples will be collected for analysis of glucose and hormone responses. This will allow us to assess whether sensitivity to glucagon is altered in PBH.
76078386|NCT01894607|Procedure|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
76078387|NCT01894607|Drug|DEFINITY|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier."
75785222|NCT04428866|Diagnostic Test|Hypoglycemic Hyperinsulinemic Clamp|This test will assess hormonal responses to hypoglycemia. Participants will arrive after an overnight fast. After baseline blood sampling, an infusion of insulin and glucose will be started, and infusions will be adjusted to allow glucose levels to drop very gradually. Blood samples will be collected for measurement of hormonal responses to lowering of glucose. This test will allow us to determine whether secretion of hormones which counteract hypoglycemia (counterregulatory hormones) is reduced in patients with PBH as compared with other groups.
75635750|NCT05484349|Drug|Tizanidine Hydrochloride|Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
75785223|NCT04428866|Diagnostic Test|analysis of fecal microbiome|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
75785224|NCT04428723|Other|Entry of demographic and medical history data into a deidentified database|Entry into repository for analysis.
75785225|NCT04428723|Genetic|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.
75785226|NCT04428723|Diagnostic Test|Stool sample for microbiome analysis|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
75785227|NCT04428723|Diagnostic Test|Mixed meal tolerance test|For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
75785228|NCT04428723|Diagnostic Test|Continuous glucose monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
75785229|NCT04428723|Diagnostic Test|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.
75785230|NCT04423718|Drug|Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|Solution in Vial, intravitreal (IVT) injection
75785231|NCT04423718|Drug|Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)|Solution in Vial, 2 mg, intravitreal (IVT) injection
75785232|NCT04419168|Other|cCBT|A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both cCBT.
75785233|NCT04419168|Other|m-Education|A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both m-Education.
75785234|NCT04409288|Drug|Apalutamide|Androgen receptor inhibitor.
75785235|NCT04409288|Drug|Enzalutamide|Androgern receptor inhibitor
75921576|NCT05537506|Device|Bracket slot 0.018|That includes12 patients who will be treated using the bracket slot 0.018×0.025-inch system.
75921577|NCT05537506|Device|Bracket slot 0.022|Includes12 patients who will be treated using the bracket slot 0.022×0.028-inch system
75921578|NCT04007523|Behavioral|Family Support System|Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.
75921579|NCT04007523|Behavioral|HELP Support System|A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
76078388|NCT01894607|Behavioral|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
76078389|NCT04399395|Drug|Naltrexone/bupropion|Approved drug for obesity treatment
75329064|NCT01725503|Dietary Supplement|Creatine and Amino Acid supplement|
75329065|NCT03031171|Behavioral|Screening patient navigation|The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
75329066|NCT03031171|Behavioral|Non-Navigated|Randomly matched sample of non-navigated clinic patients
75329067|NCT01725581|Procedure|Observed Structured Assessment Tool in Pelvic Examination|Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
75329068|NCT03031015|Device|Cemented K-wire Fixation|Fractures were reduced and then fixed with cemented K-wires.
76078390|NCT04399395|Other|Lifestyle|Lifestyle
75329069|NCT03031015|Device|Plating|Fractures were reduced and then fixed with Plate.
75635751|NCT05484349|Drug|Tizanidine Hydrochloride Placebo|Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks
75635752|NCT05482906|Other|eGait|IMU sensor (as part of eGait device) worn at the hip during T25FW
75635753|NCT05470244|Other|Routine Physical Therapy and Intra-venous analgesic regimen|ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
75798630|NCT01174056|Drug|Zileuton|600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation
75798631|NCT01174056|Drug|Pioglitazone placebo|Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
76078391|NCT01883453|Device|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
76078392|NCT01883453|Device|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
76078393|NCT02000596|Drug|Trastuzumab plus Pertuzumab|
76078394|NCT02000596|Drug|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
76078395|NCT02000596|Drug|Chemotherapy with Eribulin|
75785236|NCT04402125|Behavioral|TargEted MAnageMent Intervention (TEAM)|"TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows:~A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning.~Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED.~Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers."
75921580|NCT04459377|Drug|S-Ketamine|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
76078396|NCT03223779|Drug|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
76078397|NCT03223779|Radiation|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
75329070|NCT03401957|Drug|Cetuximab|Cetuximab-based infusional 5-FU regimen as the 1st line treatment.
76078398|NCT04613297|Other|Baseline and during hospitalization blood samples|"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~at day 3~day 5 and~In case of aggravation~At the discharge from hospital"
75635754|NCT05470244|Other|Transcutaneous Electrical Nerve Stimulation along with Routine Physical Therapy and Intra-venous analgesic regimen|High frequency stimulations via Transcutaneous Electrical Nerve Simulator will be applied. ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
75635755|NCT05455476|Behavioral|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.
75635756|NCT05455476|Behavioral|CBT for Chronic Pain|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
75635757|NCT05452551|Other|Myotonometric measurement|MyotonPRO is a non-invasive myotonometer used to evaluate the viscoelastic properties of soft tissues. Data collection will be carried out by three researchers experienced in the use of myotonometer. Before the evaluations, participant and repeated measurement information for both researchers will be recorded on the device. All assessments will be made bilaterally. The first researcher will perform two measurements 30 minutes apart from the measurement point standardized with MyotonPRO to evaluate the plantar mechanical properties. Then, the second researcher will take two measurements with MyotonPRO from the same point with 30 minutes intervals. One day later, the first researcher will measure again from the same reference point once.
75329071|NCT03401957|Diagnostic Test|liquid biopsy|The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
75329072|NCT04358965|Drug|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
75635758|NCT05449548|Drug|Lenalidomide 10 mg|All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
75635759|NCT05438264|Drug|Donepezil|acetylcholinesterase inhibitor
76078399|NCT04613297|Other|Baseline blood sample|Blood sample will be performed at the inclusion visit only
76078400|NCT05168865|Drug|Letrozole 2.5mg|Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
75635760|NCT05438264|Drug|Placebo|placebo
75469509|NCT01939886|Drug|Mefloquine - Artesunate|
75635761|NCT05425797|Other|In-Person Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place in-person at the PP's office.
75329073|NCT04358965|Drug|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
75329074|NCT04358965|Drug|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
75469510|NCT01939886|Drug|Artemether-lumefantrine combination|
75469511|NCT01939912|Drug|Adenosine|Antiarrhythmic agent.
75635762|NCT05425797|Other|Video-Call Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place virtually via a secure video system.
75635763|NCT05425797|Other|Phone Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place via telephone.
75635764|NCT05424341|Other|Muscle Energy Technique|For Gastrocnemius muscle, subject will be in supine position keeping knee fully extended and therapist on affected side in walking position. The subject's ankle joint will be dorsiflexed until a resistance feel and will ask to hold this position and exert 20% of force towards plantar flexion for a period of 5 to 7 seconds. Resistance will be released and relaxation of 5 seconds will be given during which the ankle will was passively dorsiflexed to a new barrier. 5 repetitions will be given.
75785237|NCT04401904|Drug|Dapagliflozin 10 mg|10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth
75785238|NCT04401904|Behavioral|Nutritional counseling|10 participants randomized to receive 12 weeks of weekly counseling on nutrition
75921581|NCT04459377|Drug|Sodium Chloride 0.9% Inj|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
75921582|NCT00748618|Dietary Supplement|vitamin D3|10,000 I.U./wk of vitamin D3 orally for 6 months
75921583|NCT00748618|Dietary Supplement|vitamin D3|50,000 I.U./wk of vitamin D3 orally for 6 months
75329075|NCT04358653|Other|fall prevention exercise program|The intervention protocol was starting with a 10 minute warm up (5 minutes circular walking combined with neck rotation in clockwise and counterclockwise fashion and 5 minutes upper and lower limp stretching exercises) and was followed by 30 minutes of exercises that were aiming to muscle strengthening, balance improvement and functionability enhancement. The muscle strengthening routine consisted of exercises both from standing and sitting position using an elastic band, heel and toe standing, upper limb strengthening using dumbbells. Balance training consisted of standing on one leg, shifting weight laterally from one foot to the other, staggered stance, side stepping. Functionalibility improvement was promoted through walking upstairs and downstairs, standing up from sitting to upright position. At the end a 5 minute cool down procedure was following consisting of circular walking, mild head movements and upper and lower body stretching.
75921584|NCT04450563|Drug|14-day outpatient intervention|The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.
75785239|NCT04396873|Drug|11C-MC1|Injected IV followed by PET scanning
75785240|NCT04396873|Drug|11C-PS13|Injected IV followed by PET scanning
75921585|NCT04425694|Device|e-EWS system|The e-EWS system is connected to a physiological monitor, which takes various physiological measurements. The system has an auto-charting module, which automatically captures patients' physiological measurements in an electronic chart (e-chart) and calculates their EWS. All the information in the auto-charting module is then wirelessly transferred to a central display in the ward's nurses station. The central display shows patients' status in terms of EWS and issues alerts when any EWS has exceeded a set threshold. The e-EWS system is not only capable of auto-charting but also provides an alert mechanism to help nurses detect early deterioration.
75921586|NCT04731922|Drug|TAK-510|TAK-510 solution.
75921587|NCT04731922|Drug|TAK-510 Placebo|TAK-510 placebo-matching solution.
75329076|NCT01041287|Drug|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is >125/80 for the remaining 8 weeks
75329077|NCT01041287|Drug|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is >125/80 for the remaining 8 weeks
75635765|NCT05424341|Other|Counterstrain Technique|Therapist places thumb on tender point at plantar fascia insertion while patient in supine position with ipsilateral knee flexed. Plantar flex the toes and ankle while monitoring sore site with thumb, curling around tender point until monitoring thumb feels symptomatic relief. Supination/pronation of foot will be added if necessary. The position of ease will be maintained for 90 secs until tissues beneath monitoring thumb softens. Tender spot is re-evaluated once the foot is returned to neutral without moving the thumb. It will be repeated 3 times for 30 secs resting interval in-between
75635766|NCT05418413|Device|CTB|conventional Twin-block (CTB) will be comprised of maxillary and mandibular removable appliances having the labial bows, adam's clasps, and with no incisal capping.
75635767|NCT05418413|Device|ETB|will be comprised of maxillary and mandibular removable 1.5-mm biocryl sheet will be adapted separately on maxillary and mandibular casts with help of vacuum machine, and Acrylic bite blocks with the inclined plane will be fabricated on biocryl sheets sim
75785241|NCT04396873|Drug|18f-florbetaben|Injected IV followed by PET scanning
75785242|NCT04384757|Procedure|Distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
75921588|NCT05537350|Dietary Supplement|Lumenato|Supplementation of 12 weeks
75785243|NCT04381936|Drug|Lopinavir-Ritonavir|Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.
75785244|NCT04381936|Drug|Corticosteroid|Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or >44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
75785245|NCT04381936|Drug|Hydroxychloroquine|Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).
75785246|NCT04381936|Drug|Azithromycin|Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
75785247|NCT04381936|Biological|Convalescent plasma|Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).
75785248|NCT04381936|Drug|Tocilizumab|Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)
75785249|NCT04381936|Biological|Immunoglobulin|Intravenous immunoglobulin (IVIg) for children >44 weeks gestational age and <18 years with PIMS-TS only (see Protocol for dosage)
75921589|NCT04404387|Drug|Administration of vitamin C|"The intervention is intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).~The other name of the drug: Ascorbic acid."
76078401|NCT02165722|Behavioral|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit [chronic and acute] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
76078402|NCT04654143|Drug|BVL-GSK098 capsule, placebo|Oral QD
76078403|NCT01882985|Drug|Docetaxel|Given IV
76078404|NCT01882985|Dietary Supplement|Lycopene|Given PO
75635768|NCT05415813|Other|Ischemic Compression|It includes conventional Physical therapy, hot packs (75°C) for 20 minutes, and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold, and 10-second relaxation between two repetitions) as a baseline treatment. For the Ischemic compression, the patient will be in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position physiotherapist will apply gradually increasing pressure to the Trigger points until the subject perceived the first noticeable pain. At that moment, the pressure will be maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure will be increased until the discomfort appears again. This process will be maintained for 90 seconds.
75329078|NCT04358731|Biological|NmCV-5|"The NmCV-5 is a fixed-combination available as the lyophilized powder containing meningococcal groups A and X polysaccharides conjugated to tetanus toxoid and meningococcal groups C, W and Y polysaccharides conjugated to CRM197 protein. The vaccine will be reconstituted with normal saline just prior to administration.~The NmCV-5 lyophilized powder component contains sucrose, sodium citrate and trometamol as excipients. This component is presented as a freeze-dried powder in a single dose vial. No preservative or adjuvant is present in the vaccine.~The normal saline diluent is a sterile clear colorless liquid in a single dose glass ampoule."
75329079|NCT04358731|Biological|Menactra|The control vaccine is the licensed meningococcal serogroups ACYW conjugate vaccine (Menactra), manufactured by Sanofi Pasteur Incorporated. Menactra is supplied as a single 0.5 mL dose formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4 mcg each of meningococcal A, C, Y, and W polysaccharides conjugated to approximately 48 mcg of diphtheria toxoid protein carrier. No preservative or adjuvant is added during manufacture.
75329080|NCT03401801|Procedure|Stellate ganglion block|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.
75635769|NCT05415813|Other|Ischemic compression with Muscle Energy Technique|The Participants will receive all the treatments given to the active comparator group and they will also receive the Muscle Energy Technique treatment in supine position and the practitioner will stabilize the shoulder of the affected side with one hand, while the ear/mastoid area of the affected side will be held by the opposite hand. The head and neck were then bent towards the contralateral side, flexed, and ipsilaterally rotated. The subjects will then shrug the stabilized shoulder towards the ear at a sub-maximal pain-free effort (20% of the available strength). The isometric contraction will be held for 7-10s. This position will be maintained for 30 seconds and repeated three to five times per treatment session. Treatment sessions will be given on alternate days.
75785250|NCT04381936|Drug|Synthetic neutralising antibodies|Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation
75785251|NCT04381936|Drug|Aspirin|150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.
75785252|NCT04381936|Drug|Colchicine|1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only
75785253|NCT04381936|Drug|Baricitinib|UK [age ≥2 years with COVID pneumonia] and India [age ≥18 years with COVID-19 pneumonia]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.
76078405|NCT04648761|Biological|OPTIMAL algorithm|The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.
76078406|NCT04277481|Other|10 minute cold pack|10 min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
76078407|NCT04277481|Other|12 minute cold pack|12 min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
76078408|NCT04277481|Other|15 minute cold pack|15, min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
76078409|NCT04277481|Other|20 minute cold pack|20 min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
75329081|NCT03401723|Other|3D-Colonoscopy Progression Score|3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
75469512|NCT01939925|Other|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
76078410|NCT02166346|Drug|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
75921590|NCT04404387|Drug|Administration of placebo|Administration of placebo. Patients (in the control arm) will receive dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C. Placebo will be infused over 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute as per the infusion instructions of vitamin C.
75785254|NCT04381936|Drug|Anakinra|For children ≥1 <18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children <10 kg in weight.
75785255|NCT04381936|Drug|Dimethyl fumarate|Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).
75785256|NCT04381936|Drug|High Dose Corticosteroid|Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.
75635770|NCT05409651|Behavioral|Time restricted eating|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
75635771|NCT05396768|Other|Assessment using the ACTION-tool.|Participants will be assessed using the ACTION-tool while they are performing a CTI on a porcine rib model and Thiel embalmed human cadavers.
75785257|NCT04381936|Drug|Empagliflozin|Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).
75785258|NCT04381936|Drug|Sotrovimab|UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.
75469513|NCT01939925|Other|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
75635772|NCT05393440|Biological|BS-006|BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
75635773|NCT05386875|Diagnostic Test|rK28|"rK28 RDT (Index): The Leishmania Ab Rapid Test is a rapid immunochromatographic test that uses the recombinant antigen rK28 to detect antibodies against Leishmania species in human serum, plasma, or whole blood samples intended for primary VL diagnosis. It is a Research Use Only product commercialized by CTK Biotech, Inc. (USA).~IT-Leish rK39 RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by Bio-Rad (France). This is currently the recommended RDT for VL diagnosis in Kenya.~Kalazar Detect rK39, RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by InBios (United States)."
75785259|NCT04381936|Drug|Molnupiravir|Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.
75635774|NCT05383144|Other|Complete Positioning scans|Entire treatment zone imaging at mi-treatment and at end of treatment
75635775|NCT05361356|Radiation|Spectral CT scanning|Volunteer accept spectral CT scanning
75635776|NCT05355857|Diagnostic Test|brain PET-MRI with 18F-FDG|Realisation of a brain PET-MRI with 18F-FDG in 39 healthy volunteers
75785260|NCT04381936|Drug|Paxlovid|UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.
75921591|NCT05698186|Drug|Thero2-01S22|Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
75921592|NCT05698186|Drug|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
75921593|NCT05698186|Drug|Thero2-01S22|Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
75921594|NCT05698186|Drug|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
75635777|NCT05350280|Device|electric current|Electric current will be applied in this group of patients using removable device.
75635778|NCT05350280|Device|Traditional treatment|No acceleration method will be performed in this group.
75785261|NCT04381936|Drug|Baloxavir Marboxil|"Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4."
75785262|NCT04381936|Drug|Oseltamivir|"Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)"
75785263|NCT04381936|Drug|Low-dose corticosteroids: Dexamethasone|Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations <92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
75785264|NCT04381936|Drug|Low-dose corticosteroids: Dexamethasone|≥18 years old) with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
75798632|NCT01174056|Drug|Zileuton placebo|Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
75921595|NCT03546855|Drug|Apatinib|Apatinib 500mg/d po,28 days as one cycle
75921596|NCT04675606|Behavioral|Regular diet|Patients in the regular diet arm (which is the experimental arm) will not have any diet limitations and will be recommended to consume a healthy balanced diet for American adults as recommended by the United States Department of Agriculture (USDA) and US Food and Drug Administration (FDA).
76078411|NCT02166346|Drug|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
75798633|NCT01174056|Drug|Pioglitazone|PPAR-gamma agonist
75798634|NCT01174134|Other|Nutritional beverage|
75785265|NCT04379830|Dietary Supplement|Very Low Energy Diet|Optifast 900 is an FDA approved commercial nutritionally complete meal replacement product manufactured and marketed in the United States. Optifast 900 will be employed as part of the VLED in the present study in the following manner: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
75785266|NCT04370301|Drug|Cyclophosphamide|Given IV
75785267|NCT04370301|Drug|JAK Inhibitor|Given PO
75635779|NCT05350085|Drug|Remimazolam besylate|① initial dose: use a micro injection pump to pump remimazolam at the rate of 50mg/h, and observe for 4 ~ 8 minutes until Ramsay Sedation grade III，then start dental operation ; ② Maintenance dose: maintain the pump speed at 5 ~ 10mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
75635780|NCT05350085|Drug|Midazolam|① initial dose: use a micro injection pump to pump remazolam at the rate of 30mg/h, and observe for 4 ~ 8 minutes until Ramsay Sedation grade III，then start dental operation; ② Maintenance dose: maintain the pump speed at 3 ~ 6mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
75635781|NCT05322629|Behavioral|PrEP adherence biofeedback|Services for women in the intervention arm includes bio-feedback adherence counseling based on urine lateral flow assays of tenofovir to measure adherence with rapid PrEP delivery .
75785268|NCT04370301|Drug|Fludarabine|Given IV
75785269|NCT04370301|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
75785270|NCT04370301|Drug|Melphalan|Given IV
75785271|NCT04370301|Drug|Mycophenolate Mofetil|Given PO
75785272|NCT04370301|Procedure|Peripheral Blood Stem Cell Transplantation|Given IV
75785273|NCT04370301|Drug|Tacrolimus|Given IV and PO
75785274|NCT04370301|Radiation|Total-Body Irradiation|Undergo TBI
75785275|NCT04370301|Procedure|Computed Tomography|Undergo CT
75921597|NCT04675606|Behavioral|Low fiber diet|Patients in the low fiber diet arm (which is the control arm) will be recommended to consume foods that are low in fiber content per United Ostomy Associations of America Recommendations
75921598|NCT05679310|Dietary Supplement|Hydroxytyrosol/Essential oils|A dietary supplement containing 10 mg of hydroxytyrosol, synthesised using genetically modified Escherichia coli strains and equal amounts (8.33 μL) of essential oils from oregano vulgaris, sage officinalis and crithmum maritimum.
75921599|NCT05537272|Drug|Tadalafil 5mg|Administration of Tadalafil 5mg once daily seven days before and seven days after prostate biopsy
75921600|NCT05537272|Drug|Tamsulosin Hydrochloride 400 Microgram Prolonged-Release Oral Capsule|Administration of Tamsulosin 0.4mg once daily seven days before and seven days after prostate biopsy
75921601|NCT05537272|Other|Placebo|Administration of placebo ( Vitamin C [ascorbic acid] 500mg tablet) once daily seven days before and seven days after prostate biopsy
75921602|NCT03546777|Device|magnetic resonance imaging|magnetic resonance imaging of shoulder
75921603|NCT04634110|Drug|Brigatinib|At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated.
75921604|NCT05059353|Device|Digitally based multidomain intervention|"Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.~Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.~Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.~Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed."
75921605|NCT05537194|Drug|dihydropyridine calcium channel inhibitors use|administration of dihydropyridine calcium channel inhibitors
75921606|NCT05696704|Other|Behavioral: Mindfulness Based Cognitive Therapy|Individual tele-therapy 12 to 16 weeks
75921607|NCT05696704|Other|Behavioral: Behavior Activation|Individual therapy 12 to 16 weeks
75921608|NCT05536882|Drug|Benzoyl peroxide|See arm description
75921609|NCT05536882|Drug|Adapalene Gel|See arm description
75469514|NCT01939951|Dietary Supplement|Activation Energy Serum|7 drops or 21 drops twice daily
75469515|NCT01939964|Other|Activation Mist|Activation Mist topical spray
75469516|NCT01939990|Drug|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
75469517|NCT01939990|Drug|Nebivolol|5 to 10mg per day
75921610|NCT03956355|Drug|Tapinarof|Tapinarof cream, 1%, applied once daily
75635782|NCT05322629|Behavioral|Standard of care counseling|Adherence counseling based on self report and following national guidelines
75635783|NCT05320939|Drug|Mepolizumab 100 MG|30 subjects (≥ 300 eosinophils/ul) will receive mepolizumab 100 mg subcutaneously every 4 weeks for 5 complete doses.
75635784|NCT05313308|Drug|Midazolam|Midazolam oromucosal solution
75635785|NCT05278091|Other|None, pure observationnal study|None, pure observationnal study
75785276|NCT04370301|Procedure|Magnetic Resonance Imaging|Undergo MRI
75785277|NCT04370301|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
75785278|NCT04370301|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
75785279|NCT04370301|Procedure|Biospecimen Collection|Undergo blood sample collection
75785280|NCT04370301|Procedure|Echocardiography|Undergo ECHO
75785281|NCT04370301|Procedure|Multigated Acquisition Scan|Undergo MUGA
75921611|NCT03956355|Drug|Vehicle Cream|Vehicle cream applied once daily
75785282|NCT04356612|Other|Chart Review|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
75785283|NCT04355897|Biological|Convalescent COVID 19 Plasma|Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma
75785284|NCT04354467|Diagnostic Test|urine neutrophil gelatinase -associated lipocalin|urine biomarker is measured and batched procesessed
75635786|NCT05276180|Other|Arm A) Multifactorial intervention strategy|"Implementation of the multifactorial intervention strategy will be supported by the following components:~1) An implementation team at each intervention unit consisting of 5-6 HCWs is responsible for informing and engaging all HCWs at the unit. For implementing the various components of the strategy. They will have the role of planning regular workplace meetings. 2) One or two internal facilitators will be the link between the external facilitator and the care unit. The internal facilitator will give support with material, information and will be able to ask questions of the external facilitator.~3) External facilitator will ensure that the implementation process works according to plan. The research team will present the results of SMET to the implementation team.~4) The research group will be project leaders and support the external facilitators. They will provide workshops and will also be responsible for data collection."
75785285|NCT04353687|Device|Robotic-assisted inguinal hernia repair|Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.
75921612|NCT03931161|Drug|Evolocumab Auto-Injector [Repatha]|Auto-Injector, 140 mg every two weeks.
75921613|NCT03931161|Drug|Placebo Auto-Injector|Matching Placebo for the active comparator (Evolocumab)
75329082|NCT03401723|Other|Endoscopy Training System|"The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~Loop Management - The management of a standard alfa-loop.~Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal."
75329083|NCT03401723|Other|3D-Colonoscopy Retraction Score|3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
75329084|NCT00955903|Behavioral|Exercise|Participants will participate in supervised exercise sessions
75329085|NCT00955903|Behavioral|Reduced Calorie Diet|Participants will follow a reduced calorie diet
75329086|NCT00955903|Behavioral|Weight Maintenance Diet|Participants will follow a weight maintenance diet
75785286|NCT04348045|Drug|Arm A - Olaparib|"300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued."
75785287|NCT04348045|Drug|ARM B - durvalumab plus selumetinib|"Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily"
75785288|NCT04348045|Drug|ARM C FOLFIRI|FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
75921614|NCT05037123|Drug|Continuous ketamine infusion|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
75921615|NCT05037123|Drug|Ketamine + Saline|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
75329087|NCT04376879|Other|Data monitoring for 48h within the first 24 hours of admission for COVID-19|The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )
75785289|NCT04337710|Procedure|Exclusive Enteral Nutrition|Mom's milk or donor milk at 60-80 ml/kg/day after randomization within the first 24 hours.
75785290|NCT04337710|Procedure|Progressive Enteral Nutrition|Mom's milk or donor milk at 20-30 ml/kg/day after randomization within the first 24 hours.
75921616|NCT05037123|Other|Placebo|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
75921617|NCT05536648|Other|Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial|To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.
75921618|NCT03892005|Procedure|Total Hip Arthroplasty using MOTIVATION HIP Total Hip System|To systemically document the clinical safety and performance of the commercially available MOTIVATION HIP Total Hip System in primary THA.
75921619|NCT05695612|Other|Novaloc Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Novaloc attachments. The proper Novaloc abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
75329088|NCT03016585|Other|Tai Chi Training|Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.
75921620|NCT05695612|Other|Locator Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Locator attachments. The proper Locator abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
75921621|NCT04366167|Other|Cardiac surgery|Cardiac surgery during the COVID-19 pandemic
76078412|NCT01893905|Drug|CS+SG|Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
75785291|NCT04317274|Behavioral|Good high cholesterol video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around treatment of high cholesterol.
75785292|NCT04317274|Behavioral|Poor high cholesterol video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around treatment of high cholesterol.
75785293|NCT04317274|Behavioral|Good colon cancer screening video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around screening for colorectal cancer.
75785294|NCT04317274|Behavioral|Poor colon cancer screening video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around screening for colorectal cancer.
75921622|NCT05695534|Other|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
75921623|NCT04365075|Device|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
75921624|NCT04365075|Device|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
75921625|NCT05678920|Other|patient-administered questionnaires|patient-administered questionnaires (MEOWS): Obstetric early warning systems are recommended to provide timely recognition, treatment and early referral of critically ill or developing patients. The development of early warning systems from simple bedside observation charts arose from the knowledge that physiological disturbances precede critical illness. Thanks to these charts, the fact that the patient's findings are in the risky value ranges allows the clinician to evaluate the patient earlier and in detail. MEOWS is a simple screening tool for maternal morbidity.
75921626|NCT05678842|Other|Descriptive|Descriptive
75329089|NCT03401021|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
75329090|NCT04358887|Procedure|piezoelectric surgery|after flap reflection bone and root end cutting are done with piezoelectric surgical insert
75635787|NCT05276180|Other|Arm B) Single intervention strategy|No further interventions other than access to the Swedish guideline for patient handling and movement and the results from the SMET questionnaire will be presented to the manager. Arm B will be assigned an external facilitator who provides information, is present at the start-up meeting and will be the contact person during the study period. No further support will be given to the care units in arm B.
75635788|NCT05275127|Other|changes of gingival crevicular fluid miRNA|Evaluation of changes of gingival crevicular fluid miRNA after periodontal treatment
75635789|NCT05273359|Drug|Benralizumab|15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
75635790|NCT05273359|Other|Benralizumab placebo|15 subjects (>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.
75785295|NCT04299464|Drug|Placebo|Participants will receive oral placebo for approximately 12 weeks.
75921627|NCT04354155|Drug|Enoxaparin Prefilled Syringe [Lovenox]|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
75329091|NCT04358887|Procedure|conventional bur|after flap reflection bone and root end cutting are done with surgical bur
75329092|NCT03400865|Drug|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
75329093|NCT03031093|Radiation|inhalation protocol|technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
75329094|NCT03031093|Device|High Flow Nasal Cannula|aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.
75635791|NCT05273359|Other|Comparison (control) group; no intervention|15 subjects (<150 eosinophils/microliter) will not receive any intervention.
75635792|NCT05272059|Drug|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
75785296|NCT04299464|Drug|RO7017773|Participants will receive oral RO7017773 for approximately 12 weeks.
75785297|NCT04296409|Other|Turkish Deglutition Handicap Index|Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.
75785298|NCT04295759|Drug|INCB7839|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
75785299|NCT04291612|Other|Physical exam|Part 2 participants will be prospectively followed clinically for relapse for 30 months from the date of surgery for physical examination at post-ops visits.
75785300|NCT04277637|Drug|BGB-11417|Film-coated tablets administered once daily at a dose as specified in the treatment arm
75785301|NCT04277637|Drug|Zanubrutinib|320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
75785302|NCT04277637|Drug|obinutuzumab|Given as an intravenous infusion administered per label.
75798635|NCT03859596|Procedure|MGB/OAGB|BARIATRIC PROCEDURE INVOLVED CREATION OF SLENDER GASTRIC POUCH OF 12-15CM IN LENGTH AND BILIO-PANCREATIC LIMB OF 150-200 CM
75798636|NCT01174212|Procedure|Prophylactic Antibiotics|Preoperative Antibiotics
75798637|NCT01174212|Procedure|Control Antibiotics|Antibiotics will be held until intraoperative cultures have been obtained.
75785303|NCT04270019|Drug|Polyethylene Glycol 3350|In order to prepare PEG 3350 50% weight/volume, 25 grams of the sterilized PEG 3350 will be measured out and placed into a sterilized glass bottle then 25 mL of sterile water will be added. The solution will be allowed to rest for 10 minutes so that dissolution may occur. More sterile water will then be added so the total volume is 50mL. This solution will then be sterilized by the Halifax Health Infirmary pharmacy department using a liquid autoclave cycle of 120 degrees Celsius for 20 minutes in a glass vial. The 50 mL solution will be portioned into 2mL sterilized glass vials using a standard aseptic technique. The solutions will be kept at a solid frozen state between negative 25 degrees Celsius and negative 10 degrees Celsius for a maximum of 45 days. The solutions will be removed from storage on the day of surgical utilization in order to ensure storage guidelines are kept to the highest standards.
75329095|NCT01040351|Procedure|ultrasound guided aspiration of hydrosalpingeal fluid|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
75921628|NCT05032833|Drug|5-MeO-DMT|A single dose of 5-MeO-DMT will be administered intranasally
75635793|NCT05272059|Drug|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
75635794|NCT05266144|Procedure|radiofrequency ablation|Bilateral pulmonary vein isolation, a kind of radiofrequency ablation, is performed in atrial fibrillation patients for atrial arrhythmia therapy.
75785304|NCT04270019|Drug|Normal Saline|Standard solution of sterile normal saline.
75921629|NCT05032833|Other|Placebo|A single dose of placebo will be administered intranasally
75921630|NCT04450654|Drug|Gamunex-C|Gamunex-C IVIG will be given at week 0 and week 4
75785305|NCT04257773|Behavioral|REACH Forgiveness Workbook Intervention|Participants will be asked to complete the REACH Forgiveness Workbook
75785306|NCT04249843|Drug|BGB-3245|administered orally (PO)
75785307|NCT04247958|Procedure|Colorectal resection|Robotic-assisted resection of the colon or rectum in subjects with benign or malignant colon or rectal disease, where SureForm™ Staplers are utilized for transection and/or creation of anastomosis.
75785308|NCT04245176|Behavioral|Standard Genetic Counseling|Standard genetic counseling: Standard of care discussion
75921631|NCT04450654|Drug|Albumin|1% albumin solution dosed at equivalent volume to the corresponding weight-based Gamunex-C IVIG dose will be given at week 0 and week 4
75921632|NCT05536570|Drug|IncobotulinumtoxinA 100 UNT|Scalene injection
75921633|NCT05001165|Other|Proactive Panel Management Clinics for HFrEF|Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.
76078413|NCT01893905|Drug|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
76078414|NCT04460235|Drug|Prevenar13 Pneumo-23|Vaccination according national guidelines
75329096|NCT03016741|Biological|GnRH agonist/antagonist|Given GnRH agonist/antagonist therapy
75635795|NCT05264129|Drug|Atogepant|Oral Tablet
75635796|NCT05264129|Drug|Ubrogepant|Oral Tablet
75635797|NCT05259345|Procedure|Bilateral SE-TAP|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the internal oblique and transversus abdominis muscles toward the lateral border of the semilunar along the costal margin.
75635798|NCT05259345|Procedure|Bilateral M-TAPA|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given into the layer between the transverse abdominal muscle and the inferior plane of the costal cartilage at the midclavicular line, in the sagittal plane.
75635799|NCT05259345|Procedure|Bilateral RSB|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the rectus muscle and posterior rectus sheath bilaterally.
75635800|NCT05248178|Behavioral|CO-OP Procedures|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
75785309|NCT04245176|Behavioral|Quantitative Genetic Counseling|Quantitative genetic counseling: Discussion is guided by tables and graphs.
75785310|NCT04239703|Diagnostic Test|MMDx|Portion of kidney transplant indication biopsy
75785311|NCT04239703|Diagnostic Test|Prospera|Transplant patient blood sample
75785312|NCT04239703|Diagnostic Test|HLA antibody|Transplant patient blood sample
75921634|NCT04376008|Procedure|Standard prostate biopsy|Transperineal TRUS guided standard prostate biopsy (SB).
75921635|NCT04376008|Procedure|Targeted and standard prostate biopsy|Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
75921636|NCT05678764|Device|Conversational Information Collection Tool|Conversational Information Collection Tool that facilitates the self-referral to talk therapy.
75921637|NCT03877965|Drug|Digoxin|Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
76078415|NCT01050946|Biological|Haploidentical/cord transplant|"Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion"
75635801|NCT05248178|Device|tDCS|Each session will begin with 20 minutes of anodal tDCS applied to the ipsilesional dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. The cathode will be placed over the contralesional supraorbital area. Direct current will be applied through two saline soaked sponges placed on the scalp. The tDCS device contains software for double-blinded delivery.
75785316|NCT04224987|Drug|Azithromycin|"Azithromycin will be administered as a directly observed dose in oral suspension form for children:~Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~For children 1-11 months of age, weight or age-based dosing will be used~For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
75921638|NCT02586064|Behavioral|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
75921639|NCT02586064|Behavioral|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
75635802|NCT05248178|Behavioral|Computer Cognitive Training Procedures|Individuals receiving computerized cognitive training will receive an equal dosage of 12, 45-minute sessions directly following the assigned tDCS condition. The online training software of BrainHQ will be used. BrainHQ is a well-recognized cognitive training program that targets the areas of attention, memory, processing speed, people skills, intelligence, and navigation. BrainHQ tracks progress and automatically grades difficulty as appropriate.
75785317|NCT04224987|Other|Placebo|"Placebo will be administered as a directly observed dose in oral suspension form for children:~Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~For children 1-11 months of age, weight-based dosing will be used~For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
75921640|NCT02253849|Drug|Carbamazepine|
75921641|NCT02253849|Drug|Tipranavir|
75635803|NCT05248178|Device|sham tDCS group|Sham tDCS will involve the same preparation as in tDCS, but the current will ramp up for only 30 seconds and then return to zero. This method allows for sensations on the scalp associated with tDCS without inducing any neural changes.
75635804|NCT05214170|Device|Electroanatomic mapping with the NeuTrace System|Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
75635805|NCT05192148|Other|Patients|On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
75635806|NCT05188612|Combination Product|Observational (registry)|Observational (Patient Registry)
75635807|NCT05183763|Behavioral|STAR-MAP health coaching|Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
75635808|NCT05183763|Behavioral|Medication reminder tools|Medication-taking reminder app and pillbox
75635809|NCT05181995|Drug|NYX-783|NYX-783
75635810|NCT05181995|Drug|Placebo|Placebo for 50 mg NYX-783
75635811|NCT05175170|Behavioral|Decision-aid|The decision aid consists of domains related to human reproduction, fertility, and fertility preservation. The domains address priority learning objectives in each domain to increase knowledge on the impact of gender-affirming medical interventions on fertility and fertility preservation options.
75635812|NCT05171790|Drug|QL1706 injection|5 mg/kg, IV, Q3w
75785318|NCT04222972|Drug|Pralsetinib|Administered orally
75921642|NCT02253849|Drug|Ritonavir|
75921643|NCT04981197|Behavioral|Baduanjin exercise|Patients in the intervention group underwent a 12-week Baduanjin exercise programme consisting of 12 weeks of Baduanjin exercise, a 35-min Baduanjin exercise demonstration video, a picture-based educational brochure, and a performance record form.
75921644|NCT04233489|Behavioral|Family Nurture Intervention (FNI)|"FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a physician.~The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU)."
75921645|NCT03545997|Drug|Montelukast 10mg|The capsules will be presented in box of 95 capsules packaged in unit blister
75921646|NCT03545997|Drug|Placebo|Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
75921647|NCT05678608|Procedure|surgical excision|posterior midline approach and total excision for spinal cord tumors
75921648|NCT05696548|Drug|Lenvatinib|Lenvatinib will be administered at a dose of 24mg as oral dose, one a day
75921649|NCT05696548|Drug|Nivolumab|Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
75921650|NCT05536024|Diagnostic Test|Prediction of glioma grading and molecular subtype|Prediction of WHO grading(II/III/IV), IDH gene mutation status, ATRX deletion status, 1p/19q deletion status, CDKN2A/B homozygous deletion status, TERT gene mutation status, epidermal growth factor receptor (EGFR) mutation status, chromosome 7gain and chromosome 10 less status, H3F3A G34 (H3.3 G34) mutation status, H3 K27M mutation status
75329097|NCT03016741|Drug|Prednisone|Given by mouth
75785319|NCT04222972|Drug|Carboplatin|Administered IV
75785320|NCT04222972|Drug|Cisplatin|Administered IV
75785321|NCT04222972|Drug|Pemetrexed|Administered IV
75329098|NCT03016741|Drug|Abiraterone Acetate|Given by mouth
75921651|NCT05696470|Device|DePuy Synthes Conduit 3D printed titanium cages|DePuy Conduit 3D printed titanium cages supplemented with SKYLINE Anterior Cervical Plate System and 1 CC DBM
76078416|NCT03677661|Other|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
75635813|NCT05169905|Combination Product|RSV MAT vaccine|"Single dose of the RSV MAT vaccine reconstituted with NaCl solution was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~RSV MAT vaccine was no longer administered to participants at Day 31. No vaccine was administered in the dTpa_RSV-P Group, since there were no participants assigned to it."
75635814|NCT05169905|Combination Product|dTpa vaccine|"Single dose of the dTpa vaccine was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~Two formulations of dTpa vaccine are licensed in the US and outside of the US (ex-US), respectively. dTpa-US formulation was administered to participants in centers located in the US, while dTpa-ex-US formulation was planned to be administered to participants in centers ex-US. The dTpa-ex-US formulation was not applicable in this study anymore as no non-US sites were initiated before the decision to stop the study.~The participants in RSV_dTpa-P and RSV_dTpa-A study groups were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.~No vaccine was administered in the dTpa_RSV-P Group, since there were no participants assigned to it."
75635815|NCT05167955|Behavioral|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy|An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
75635816|NCT05163223|Biological|AST-301(pNGVL3-hICD)|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
75635817|NCT05163223|Drug|rhuGM-CSF|Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
75635818|NCT05163223|Drug|Placebo|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
75635819|NCT05163223|Drug|Pembrolizumab|Q3W; IV infusion
75785322|NCT04222972|Drug|Pembrolizumab|Administered IV
75785323|NCT04222972|Drug|Gemcitabine|Administered IV
75785324|NCT04222972|Drug|Paclitaxel|Administered IV
75329099|NCT03016741|Drug|Enzalutamide|Given by mouth
75785325|NCT04222972|Drug|Nab-Paclitaxel|Administered IV
75785326|NCT04219202|Radiation|Proton radiation|Therapeutic radiation Treatment with Protons
75785327|NCT04219202|Radiation|Carbon Ion radiation|Therapeutic radiation Treatment with Carbon Ions
75785328|NCT04218019|Device|TTFields|The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
75785329|NCT04213469|Biological|PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells|Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1
75785330|NCT04211480|Biological|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression
75785331|NCT04205630|Drug|SYD985|SYD985 powder for concentrate for solution for infusion
75785332|NCT04199104|Drug|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
75921652|NCT03810729|Diagnostic Test|Smartphone assessment|The smartphone app will be performed on participants randomly assigned to receive this test.
75921653|NCT03810729|Diagnostic Test|Modified Allen's Test|The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
75921654|NCT03810495|Drug|naltrexone implant|1.8 g implant containing 60% naltrexone
75921655|NCT04980885|Drug|AK117|Subjects receive AK117 intravenously.
75329100|NCT03401645|Other|Wrist Alarm|Wrist device with alarm timer
75329101|NCT03401645|Behavioral|Home-based Arm and Hand Exercise|Repeated visuomotor tasks, unilateral arm and hand movements, bilateral arm and hand movements
75329102|NCT04358809|Drug|Suspension of heat killed (autoclaved) Mycobacterium w|Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
75329103|NCT04358809|Other|Placebo|Placebo along with Standard of care (SOC) treatment for COVID-19
75921656|NCT04980885|Drug|Azacitidine|Subjects receive Azacitidine subcutaneously.
75921657|NCT03545685|Other|specific memory and attention realtime training|The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
75921658|NCT03545841|Other|HIT|Participants completed 6 weeks of HIT
75921659|NCT03545841|Other|MICT|Participants completed 6 weeks of MICT
75635820|NCT05163223|Drug|Capecitabine|On days 1-14 (Q3W), BID ; Oral administration,
75785333|NCT04199104|Biological|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
75785334|NCT04199104|Drug|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
75785335|NCT04197492|Radiation|Hypofractionated Stereotactic Radiotherapy|Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)
75785336|NCT04197492|Drug|Anlotinib|Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
75785337|NCT04194268|Radiation|Carbon Ion|12 x 4 Gy (RBE)
75921660|NCT04184505|Drug|Azacitidine|75mg/mq/day subcutaneously for 7 days every 28 days
75921661|NCT04184505|Drug|Standard Chemotherapy|"cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)"
75921662|NCT04184505|Procedure|Allogeneic stem cell transplantation|Allogeneic stem cell transplantation
75921663|NCT03754023|Diagnostic Test|Urine-TIMP-IGFBP7 biomarker for AKI|Urine-TIMP-IGFBP7 biomarker for AKI
75921664|NCT03546543|Procedure|Position change|Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone
75921665|NCT02782923|Device|STISIM driving simulator|This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
75635821|NCT05142384|Behavioral|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later."
75635822|NCT05142384|Combination Product|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies
75921666|NCT03546465|Drug|ropeginterferon alfa-2b|6 subjects in each cohort will receive a single dose by subcutaneous injection
75921667|NCT02148003|Procedure|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
75921668|NCT02148003|Procedure|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
75921669|NCT02148003|Device|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
75921670|NCT03760458|Drug|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets|Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
75921671|NCT03760458|Drug|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)|Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
75921672|NCT02066415|Biological|Erenumab|Administered once a month subcutaneously by authorized investigational site study staff.
75921673|NCT02066415|Drug|Placebo|Administered once a month subcutaneously by authorized investigational site study staff.
75921674|NCT02583256|Biological|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
75921675|NCT02583256|Biological|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
75921676|NCT03745794|Other|Best Practice|Given standard of care
75921677|NCT03745794|Drug|Quadratus Lumborum Block|Undergo QL block
75921678|NCT03745794|Other|Quality-of-Life Assessment|Ancillary studies
75921679|NCT03745794|Other|Questionnaire Administration|Ancillary studies
75329104|NCT01042925|Drug|XL147 (SAR245408)|administered orally once daily as tablet(s)
75329105|NCT01042925|Biological|trastuzumab|administered by IV once every 3 weeks
75921680|NCT04467918|Drug|Cannabidiol|Already described
75921681|NCT04467918|Other|PLACEBO|Already described
75921682|NCT03133104|Other|Antenatal corticosteroids|Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
75921683|NCT03522090|Diagnostic Test|lower neck CT|Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
76078417|NCT03677661|Other|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
76078418|NCT03015922|Drug|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
76078419|NCT03015922|Biological|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
76078420|NCT01893827|Drug|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
75921684|NCT03522012|Drug|Tocilizumab|Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.
75921685|NCT05698108|Device|Instrument Assisted Soft Tissue Mobilization (IASTM)|Tools designed for soft tissue mobilization
75921686|NCT05698108|Other|Conventional Physical Therapy|Moist Hot pack, Ultrasound, Deep Friction Massage, Stretching and Strengthening Exercises.
75921687|NCT05695456|Other|personalized exclusion diet based on CLE|personalized exclusion diet based on CLE
75635823|NCT05130944|Behavioral|Entre Nosotras|"A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women."
75635824|NCT05130944|Behavioral|Doing What Matters in Times of Stress|The stress management components are derived from the World Health Organization Doing What Matters in Times of Stress illustrated guide for coping with adversity (World Health Organization, 2020). The illustrated guide and accompanying audio files are publicly available: https://www.who.int/publications/i/item/9789240003927. During five sessions, the intervention involves 15-20 minute exercises covering a range of stress management and coping skills.
75635825|NCT05123963|Behavioral|High-intensity interval training|3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.
75635826|NCT05101122|Drug|Dosing 1: Atomoxetine|Oral administration at bedtime
75785338|NCT04190628|Drug|ABM-1310|"Part A: Starting dose at 25 mg by mouth twice daily.~Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A.~Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
75921688|NCT05695456|Other|empiric exclusion diet|exclusion diet with milk or gluten-containing grains
75921689|NCT05535868|Other|SPN3 innoculation|Healthy adult participants aged 18-50 (inclusive) will be inoculated with pure culture of well-characterised, fully sequenced amoxicillin-sensitive SPN3. They will be observed for safety and development of pneumococcal colonisation
75921690|NCT04720612|Biological|Omalizumab|Single subcutaneous dose of 375mg of omalizumab and standard of care.
75921691|NCT04720612|Other|Placebo|Single subcutaneous dose of normal saline in a syringe identical to that of the omalizumab arm and standard of care.
75921692|NCT02584660|Drug|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
75921693|NCT02584660|Drug|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
75921694|NCT04862286|Drug|Risankizumab|Subcutaneous (SC) injection.
75921695|NCT02254083|Drug|BIBT 986 BS - low|
75921696|NCT02254083|Drug|BIBT 986 BS - high|
76078421|NCT01893827|Drug|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
75635827|NCT05101122|Drug|AD313|Escalating dose of AD313; Oral administration at bedtime
75635828|NCT05090774|Behavioral|Adapted Otago Exercise Program (OEP)|A modified version of the 8- week evidence-based Otago Exercise Program (OEP), adapted for integration into supervised exercise therapy (SET). The OEP exercises will include 12 static and dynamic standing balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking). The OEP also contains additional behavior change techniques embedded within the intervention protocol (i.e. feedback on behavior, self-monitoring of behavior, biofeedback).
75635829|NCT05087771|Drug|injectable naltrexone|360 mg dose to be given prior to hospital discharge
75635830|NCT05087771|Drug|oral naltrexone|50 mg tab dispense 30 day supply to be given at hospital discharge
75635831|NCT05087329|Behavioral|Virtual Mindfulness Meditation|Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
75635832|NCT05084235|Drug|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
75635833|NCT05084235|Drug|Placebo|Placebo matches the active drug in appearance, odor and labelling
75635834|NCT05062252|Device|Mirror Medacta Shoulder System|Anatomic total shoulder arthroplasty system
75785339|NCT04190628|Drug|Cobimetinib|"Part B: orally administered once daily.~Part C-3 and C-4: Continuous once daily oral dose from Part B, administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Dose formulation is 60 mg capsules."
75921697|NCT02254083|Drug|Placebo|
75921698|NCT03576573|Device|PROCOTYL® C|Hip Arthroplasty
75921699|NCT04467138|Drug|Omegaven|Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
75921700|NCT05535790|Other|Naturalistic LED light|Naturalistic LED light (bright light therapy) which affects Melanopic Equivalent Daylight Illuminance.
75921701|NCT05535790|Other|Standard/traditional lighting|Standard/tradtional lighting environment with fluorescent tubes
75921702|NCT02143323|Drug|Augmentin tablet|
75921703|NCT04467216|Device|Computerised cognitive training using virtual reality|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong.The VR systems available in the market for older people are only for non-interactive activities (e.g., watching movies) to provide unusual experiences for disabled older people who cannot travel too far from home.
75921704|NCT05689762|Behavioral|Healthy lifestyle|Promotion of healthy lifestyle behaviors
75921705|NCT04043650|Behavioral|HeartSteps|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
75921706|NCT04466826|Other|Headache Journal|Phase 1 of study to determine a baseline for headache frequency, headache intensity and medication usage patterns
75921707|NCT04466826|Drug|Sphenopalatine Block|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
75635835|NCT05062252|Device|Medacta Shoulder System|Anatomic total shoulder arthroplasty system - standard configuration
75635836|NCT05049694|Device|zirconia crowns|esthetic crowns for capping permanent molars with caries
75635837|NCT05049694|Device|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
75329106|NCT01042925|Drug|paclitaxel|administered by IV once every week
75635838|NCT05048901|Drug|Cabozantinib|Oral Cabozantinib 40-60 mg daily .every 4 weeks as a cycle
75635839|NCT05048901|Drug|Lanreotide|Lanreotide 120 mg deep SC on day 1 every 4 weeks.every 4 weeks as a cycle
75785340|NCT04188678|Other|Bone Marrow Transplant (BMT)|Bone marrow transplantation will be conducted according to the investigators' institution's standard of care, or else according to research protocol (if applicable).Study visits that include the performance of assessments will occur prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. All dates are +/- 7 days. The initial study visit will take place during standard of care pre-transplant evaluations, which typically span 3-4 days. The post-BMT visits will take place before or after regularly-scheduled BMT follow up.
75785341|NCT04185974|Radiation|C12 re-irradiation|51 Gy(RBE) or 54 Gy
75921708|NCT04466826|Device|Tx360|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
75921709|NCT05678452|Procedure|HOLEP for treating BPH|HoLEP will be performed using 100W Versapulse, Luminis Inc., with 2J/25Hz for LP-HoLEP and 2J/50Hz for HP-HoLEP.
75921710|NCT04841616|Procedure|Endoscopic Ultrasound -Guided Fine Needle Biopsy|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
75329107|NCT03017053|Radiation|Radiotherapy|Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor
75635840|NCT05042973|Drug|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
75635841|NCT05042973|Drug|Placebo|Placebo matches the active drug in appearance, odor and labelling.
75329108|NCT03017053|Procedure|Elective neck dissection|Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor
75329109|NCT03401567|Other|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
75329110|NCT03400709|Drug|N Acetylcysteine|Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.
75635842|NCT05038163|Other|Nutrition Facts|The nutritional information label for each beverage is enlarged.
75635843|NCT05038163|Other|Text Warning|The health risks of sugary beverages are communicated to subjects using words/text and simple images.
75635844|NCT05038163|Other|Graphic Warning|The health risks of sugary beverages are communicated to subjects using a combination of words/text and graphic images/photographs.
75635845|NCT05034003|Device|Zirconia crown|Esthetic crowns for capping primary incisor with caries
75635846|NCT05034003|Device|composite strip crown|Esthetic resin restoration for primary incisor with caries
75635847|NCT05030272|Device|"Quit on the Go App (formerly Learn to Quit  App)"|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
75635848|NCT05030272|Behavioral|Brief advice|Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt.
75785342|NCT04185974|Radiation|Photon re-irradiation|54 Gy(RBE) or 60 Gy
75785343|NCT04171089|Behavioral|Child- Safety Plan Intervention|The intervention includes recognizing and knowing the individual's warning signs for a suicidal crisis, their personal coping/distraction skills, people to contact, as well as a restriction of the means to hurt oneself.
75785344|NCT04165772|Drug|TSR-042 or Dostarlimab|Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
75635849|NCT05030272|Drug|Nicotine patch|All participants will receive an 8-week course of transdermal nicotine patches. The first 4 weeks of use will be 21mg/24 hours, followed by 2 weeks of 14mg/24 hours patches, and finally 2 weeks of 7mg/24 hours patches.
75785345|NCT04165772|Drug|capecitabine or 5-FU|Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
75785346|NCT04165772|Radiation|Intensity Modulated Radiation Therapy (IMRT)|The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
75921711|NCT04841616|Procedure|Contrast-Enhanced Harmonic Endoscopic Ultrasound|After initial evaluation, 2.5ml of second-generation contrast media, SonoVueTM (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
75921712|NCT03544593|Device|Revolve System|Fat grafting system
75921713|NCT04466904|Drug|IBI362|Administrated by subcutaneous injection
75921714|NCT04466904|Drug|Placebo|Administrated by subcutaneous injection
75635850|NCT05030272|Behavioral|Smartphone coaching|Participants randomized to the smartphone app intervention will receive 4 weeks of smartphone coaching given by research staff. The coaching is meant to be a time to address any issues that may rise with the participants' study smartphone or app.
75921715|NCT04466904|Drug|Dulaglutide|Administrated by subcutaneous injection
75921716|NCT03524274|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
75921717|NCT03524274|Procedure|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
75635851|NCT05030272|Drug|Nicotine gum|Each participant enrolled will be given NRT gum (5-10week course) to be taken orally as nicotine cravings arise. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) gum pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
75921718|NCT02143479|Drug|Tacrolimus|oral
75921719|NCT03524196|Other|Manage Your Life Online (MYLO)|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
75635852|NCT05030272|Drug|Nicotine Lozenges|In cases where participants are unable to chew nicotine gum, lozenges will be sent as a replacement of Nicotine gum. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) lozenge pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
75635853|NCT05020496|Drug|Diphenylcyclopropenone (DPCP)|Drug will be applied topically on the skin. It will cause contact hypersensitivity in patients
75635854|NCT05017233|Device|Spectral CT|Using Spectral CT to scan Breast
75635855|NCT05013333|Device|AED 3 with Uni-padz|Use of AED 3 with Uni-padz by lay rescuer
75635856|NCT05002803|Other|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
75921720|NCT03521778|Other|Fascial Distortion Model|"Patients will receive manual treatment according to FDM procedures:~Triggerbands - therapist put a pressure by the thumb along the presented pathway.~Continuum Distortions - therapist put a pressure by the thumb at the exact place of feeling of pain.~Folding Distortions - therapist conduct traction or compression of the affected joint.~Herniated Triggerpoint - therapist put a pressure by the thumb at the place where HTP occurs.~Cylinder Distortions - therapist compress and stretch by the hands affected area.~Tectonic Fixation - Therapist compress and stretch affected area by the hands or tools like vacuum bubble."
75921721|NCT03521778|Other|Mulligan Concept|"Patients will receive manual treatment according to Mulligan Concept procedures:~MWM- Mobilization With Movement- application can be defined as the application of a sustained passive force/glide.~NAG - Natural Apophyseal Glide - application can be defined as the oscillatory mobilization techniques from the middle to the end of the range of motion.~SNAG- Sustained Natural Apophyseal Glide- They are weight bearing techniques: all procedures are done with the patient sitting or in standing. They are mobilisations with active movement followed by passive over pressure."
75921722|NCT03521778|Other|Traditional physiotherapy|"Patients will receive traditional physiotherapy:~Exercises, laser treatment, magnetic field therapy, ultrasound treatment, light treatment"
75921723|NCT02143557|Other|Fat-Modified Breast Milk|
75921724|NCT02143557|Other|MCT formula|
75921725|NCT02254239|Drug|Brentuximab Vedotin|Given IV
75329111|NCT03400709|Drug|Placebo Oral Tablet|Placebo treatment
75635857|NCT04998149|Device|Peanut Ball positioning device|Peanut Ball manufactured by Clinton industries at graylinemedical.com https://www.graylinemedical.com/products/clinton-industries-peanut-ball-peanut-ball-40-cm-yellow-8540?_pos=3&_sid=d6e52e63c&_ss=r
75785347|NCT04140708|Behavioral|Exercise--Rock Steady Boxing class|Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
75785348|NCT04107831|Other|Pulmonary rehabilitation|Pre-post test design
75785349|NCT04094454|Device|special tampon with a diameter of 28mm|patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy
75785350|NCT04094454|Device|standard tampon with a diameter of 12-13mm|patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
75785351|NCT04084431|Radiation|Radiation|WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain
75785352|NCT04084431|Other|OSC|optimal supportive Care (OSC) alone
75921726|NCT02254239|Drug|Everolimus|Given PO
75921727|NCT02254239|Other|Laboratory Biomarker Analysis|Correlative studies
75921728|NCT02254239|Other|Pharmacological Study|Correlative studies
75635858|NCT04976257|Procedure|Angiogram|Undergo angiogram
75329112|NCT00956761|Biological|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
75921729|NCT05581732|Dietary Supplement|Nutrinidrink with Dietary Fiber|Nutrinidrink with Dietary Fiber is a specialized nutrition for children during illness and recovery period, as well as with increased protein and energy needs: mental and / or physical stress, chronic diseases, growth and / or weight deficiency
75635859|NCT04976257|Procedure|Catheterization|Undergo prostatic arterial catheterization
75921730|NCT02254317|Dietary Supplement|0 mg placebo|Not containing GSE (Placebo)
75921731|NCT02254317|Dietary Supplement|300 mg GSE|300 mg GSE
75921732|NCT02254317|Dietary Supplement|600 mg GSE|Containing 600 mg of GSE
75921733|NCT02254317|Dietary Supplement|900 mg GSE|Containing 900 mg of GSE
75921734|NCT05088369|Drug|HM201|HM201 will be administered intravenously.
75921735|NCT05088369|Drug|Placebo|Placebo will be administered intravenously.
75921736|NCT05088369|Drug|HM201|HM201 will be administered intravenously.
75921737|NCT05088369|Drug|Placebo|Placebo will be administered intravenously.
75921738|NCT02143635|Drug|HDM201|
75635860|NCT04976257|Drug|Gallium Ga-labeled PSMA-11|Given IV and IA
75635861|NCT04976257|Procedure|Positron Emission Tomography|Undergo PET scan
75635862|NCT04969783|Other|Ventilated Cigarette Filter|Ventilated Cigarette Filter
75635863|NCT04969783|Other|Unventilated Cigarette Filter|Unventilated Cigarette Filter
75785353|NCT04084366|Drug|OBI-999|For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
75785354|NCT04084366|Drug|OBI-999|For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
75921739|NCT02143635|Drug|ancillary treatment|
75921740|NCT05262582|Procedure|Sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
75921741|NCT05262582|Procedure|Two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
75329113|NCT01042769|Drug|Aleglitazar|aleglitazar 150 micrograms po daily
75329114|NCT01042769|Drug|Placebo|placebo control po daily
75329115|NCT02049957|Drug|Sapanisertib|Sapnisertib capsules
75635864|NCT04955691|Other|low carbohydrate diet|Participants will engage in a diet that limits carbohydrate intake to 15% of total daily calories for 2 weeks.
75635865|NCT04955691|Other|standard carbohydrate diet|Participants will engage in a diet that recommends standard carbohydrate intake with respect to total daily calories for 2 weeks.
75635866|NCT04954365|Drug|Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)|Rescue Post-Operative Nausea and Vomiting (PONV) treatment
75635867|NCT04954365|Drug|Amisulpride|Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
75635868|NCT04937647|Other|collection of endoscopic images and videos|collection of endoscopic images and videos
75635869|NCT04936009|Behavioral|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
75635870|NCT04923685|Other|Trier Social Stress Test|The TSST is a standardized test to induce acute psychological stress in humans. Participants will abstain from caffeine for 12 hours and nicotine for 2 hours prior to the test. An IV butterfly catheter will be placed in an arm vein and flushed with saline. Participants will rest for 15 minutes. A 10ml baseline blood sample will be drawn. They will perform the TSST task and then have 10ml of blood drawn at 0, 15, 30, 60, and 90 minutes post-TSST.
75635871|NCT04920617|Drug|DPX-Survivac|SC injection on D7 and D28, then every 8 weeks
75635872|NCT04920617|Drug|Pembrolizumab|IV infusion every 3 weeks
75635873|NCT04920617|Drug|CPA|50 mg twice daily, week on then week off
75635874|NCT04913766|Behavioral|Problem Management Plus|Five session psychological intervention focusing on problem management skills.
75635875|NCT04913766|Behavioral|Services as Usual|Mental health services provided by a mental health specialists according to their standard practices of care
75785355|NCT04083937|Radiation|Hypofractionated radiotherapy with photons|hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)
75785356|NCT04083937|Radiation|Hypofractionated radiotherapy with protons|hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)
75785357|NCT04083937|Radiation|Normofractionated radiotherapy with photons|normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
75921742|NCT05678062|Diagnostic Test|Point-of-care ultrasound|An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
75921743|NCT04467528|Device|Electroacupuncture|"Experimental: Electroacupuncture combined with conventional drug therapy~Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days"
75921744|NCT04467528|Drug|Conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
75921745|NCT05681182|Combination Product|CardiaMend with the Addition of Amiodarone|The CardiaMend patch will be saturated with Amiodarone prior to being sutured into place.
75921746|NCT02143791|Procedure|Burst stimulation|
75921747|NCT02143791|Device|Prodigy system|
76078422|NCT03015766|Other|auricular acupressure therapy|Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
75469518|NCT01940003|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
75469519|NCT01940016|Behavioral|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
75469520|NCT01940016|Behavioral|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
75785358|NCT04060303|Procedure|Perioperative surgical care|The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.
75785359|NCT04053062|Biological|LIGHT-PSMA-CART cells|LIGHT-PSMA-CART cells will be given IV at split doses
75785360|NCT04029688|Drug|Idasanutlin|Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.
75785361|NCT04029688|Drug|Venetoclax|Venetoclax will be administered orally at the adult dose equivalent (adjusted by body weight) of 400 milligrams (mg) in participants with neuroblastoma and the adult dose equivalent of 600 mg in participants with leukemia.
75785362|NCT04029688|Drug|Cyclophosphamide|Cyclophosphamide will be administered once daily on Days 1-5 of each 28-day cycle at 250 milligrams per meter squared of body surface area (mg/m^2) as an intravenous (IV) infusion.
75785363|NCT04029688|Drug|Topotecan|Topotecan will be administered once daily on Days 1-5 of each 28-day cycle at 0.75 mg/m^2 as an IV infusion.
75785364|NCT04029688|Drug|Fludarabine|Fludarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 30 mg/m^2 as an IV infusion.
75785365|NCT04029688|Drug|Cytarabine|Cytarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 2000 mg/m^2 as an IV infusion.
75921748|NCT04823286|Other|Virtual reality health platform during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis. The game will also aim at providing nutritional advice, and improving psychological wellbeing and cognitive function.
75921749|NCT04770324|Device|Interposition supraciliary implant|Surgical placement of 2 interposition supraciliary implant in the supraciliary space
75921750|NCT02143869|Device|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
75921751|NCT04311970|Device|EsoCheck|All patients with known diagnosis of EoE will be administered the EsoCheck device prior to standard of care endoscopy
75921752|NCT03545139|Biological|NeoMTA nusmile|A new formulation of MTA was developed in which bismuth oxide was omitted.
75921753|NCT03545139|Biological|White MTA|Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
76078423|NCT03015766|Other|sham auricular acupressure therapy|The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
76078424|NCT03222843|Drug|Hetrombopag Olamine|once daily
76078425|NCT03222843|Drug|matching placebo|once daily
75329116|NCT02049957|Drug|Fulvestrant|Fulvestrant IM injection.
75469521|NCT01940042|Behavioral|CO2 was removed by means of trandelenburg positions|
75635877|NCT04874233|Drug|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
75635878|NCT04874233|Drug|Placebo|Non-active study drug N = 20
75329117|NCT02049957|Drug|Exemestane|Exemestane tablets.
75329118|NCT03030937|Drug|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
75635879|NCT04861714|Device|Regeneten|Augmentation of standard subscapularis repair with regeneten patch
75635880|NCT04861714|Procedure|Standard repair|Standard subscapularis repair
75785366|NCT04029688|Drug|Intrathecal Chemotherapy|All participants with leukemia, irrespective of arm, will receive intrathecal chemotherapy on Day 1 of each 28-day treatment cycle. Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate age-based dosing as specified in the protocol.
75785367|NCT04007055|Diagnostic Test|Point of care screening for HPR|HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234
75785368|NCT04007055|Drug|Ticagrelor 90mg|Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
75329119|NCT03030937|Drug|Irinotecan|Irinotecan was used as second line treatment with AGC.
75329120|NCT00950365|Drug|Erlotinib Hydrochloride|Given PO
75329121|NCT00950365|Other|Laboratory Biomarker Analysis|Correlative studies
75329122|NCT00950365|Drug|Pemetrexed Disodium|Given IV
76078426|NCT03015688|Radiation|x-ray images|
75329123|NCT01980147|Behavioral|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
75329124|NCT01908465|Drug|Ebastine|
75921754|NCT03521700|Drug|Rosuvastatin|For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was < 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, <3.3mmol/L.
75469522|NCT01940055|Behavioral|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
75469523|NCT01940055|Behavioral|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
75469524|NCT01940068|Dietary Supplement|Amino acid based formula|
75469525|NCT01940081|Other|Transthoracic echocardiography|
75469526|NCT01940081|Other|Exercise test|
75469527|NCT01940081|Other|24-hour Holter electrocardiogram|
75785369|NCT04003805|Drug|Standardized Research E-cigarette (SREC)|The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
75785370|NCT04003805|Drug|Nicotine Mini-Lozenge|We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
75785371|NCT03995173|Device|repetitive transcranial magnetic stimulation|rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
75921755|NCT02144025|Drug|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
75921756|NCT03524040|Device|SEB-250|Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
75921757|NCT05567224|Other|Access to primary care services|Those in the pilot group will be referred to primary care services and allowed to utilize them for at least two years. Primary care services include access to a primary care physician, medical management, and other tasks typically performed by a general practitioner. Those referred to primary care services will not have access to other VUMC outpatient services.
75921758|NCT04748094|Device|Compression belt|The abdominal belt is fastened around the lower abdomen and inflated (like an inner tube) to apply pressure to the belly and reduce the motion associated with respiration (breathing)
75921759|NCT04748094|Other|Visual Guided Breath-hold|A small tracer will be place on the lower abdomen that will feedback to a computer screen that will have graphics to show you if the participant is in breath-hold or not.
75329125|NCT01908465|Drug|Placebo|
75329126|NCT00950833|Biological|Pneumococcal vaccine GSK1024850A|1 or 2 intramuscular injections
75469528|NCT01940081|Other|Contrast-enhanced magnetic resonance imaging|
75329127|NCT01766739|Biological|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
75469529|NCT01940081|Other|123-iodine metaiodobenzylguanidine imaging|
75469530|NCT01940081|Other|Blood samples|
75469531|NCT01940081|Genetic|Genetic analysis|
75469532|NCT01940081|Procedure|Invasive electrophysiological study|
75469533|NCT01940081|Procedure|Endomyocardial biopsy|
75469534|NCT01940081|Procedure|Intraoperative biopsy|
75785372|NCT03974503|Behavioral|Exposure, Relaxation, and Rescripting Therapy|ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.
75785373|NCT03974503|Behavioral|Sleep and Nightmare Management|This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
75921760|NCT03523884|Other|Exercise Program plus Education|Rotator cuff exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
75469535|NCT01940081|Procedure|Intraoperative mapping and/or ablation|
75329128|NCT05711901|Device|Efferon LPS|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 12h immediately following admission to the intensive care unit
75329129|NCT05711745|Procedure|Calf myofascial technique|A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
75469536|NCT01940107|Other|evaluations|Only evaluations
75469537|NCT01940107|Procedure|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
75635881|NCT04860804|Drug|Aspirin and Ketamine|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
75635882|NCT04860804|Drug|Oral Ketamine|Proprietary oral formulation of 0.5mg/kg of ketamine
75635883|NCT04817345|Drug|Plerixafor|Subcutaneous
75785374|NCT03954236|Drug|topical ruxolitinib 1.5% cream|Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
75785375|NCT03954236|Other|Topical vehicle/moisturizer cream|Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
75785376|NCT03949127|Other|Exercise Group|The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
75785377|NCT03917238|Radiation|gallium-68-exendin injection followed by PET/CT scan|After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended
75785378|NCT03915769|Drug|Ozanimod|Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5
75785379|NCT03915769|Other|Placebo|The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.
75785380|NCT03913949|Drug|APG-2575|Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
75635884|NCT04812080|Device|EXPLORER PET/CT|FDG PET Scans on the total body EXPLORER PET/CT scanner
76078427|NCT01882907|Drug|vildagliptin|vildagliptin 50mg bid for 16 weeks
75469538|NCT01940133|Drug|PQR309|Dosing will be orally, once a day for the duration of the trial.
75469539|NCT01940159|Drug|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
75785381|NCT03910972|Biological|Sm-TSP-2/Alhydrogel® vaccine|The Sm-TSP-2/Alhydrogel® candidate vaccine contains recombinant Sm-TSP-2 adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10mM imidazole buffer containing 2mM phosphate and 15% sucrose, with pH 7.4 ± 0.1. The final concentrations of Sm-TSP-2 and Alhydrogel® in the drug product are 0.1mg/ml and 0.8mg/ml respectively.
75469540|NCT01940159|Drug|Placebo|single oral dose placebo
75785382|NCT03910972|Biological|Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701|The Sm-TSP-2/Alhydrogel® candidate vaccine co-administered with the immunostimulant, AP 10-701. b) AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist. Point-of-injection formulations with this immunostimulant will be prepared immediately prior to vaccination by adding an appropriate volume of AP 10-701 to Sm-TSP-2/Alhydrogel® and withdrawing an appropriate volume to administer the desired amount of Sm-TSP-2 plus 5µg GLA-AF.
75785383|NCT03910972|Biological|ENGERIX-B Hepatitis B Vaccine|Recombinant hepatitis B vaccine containing 10 mcg recombinant hepatitis B surface antigen per dose
76078428|NCT01882907|Drug|Pioglitazone|Pioglitazone 15mg bid for 16 weeks
76078429|NCT04073823|Device|Flexitouch Plus|Flexitouch Plus full arm and core treatment
75469541|NCT01940172|Drug|Birinapant|"Dose Escalation:~Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );"
76078430|NCT04073823|Device|Flexitouch Plus FT with software modification|Flexitouch Plus full arm and trunk/chest treatment
76078431|NCT04049955|Procedure|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
76078432|NCT01051570|Drug|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
76078433|NCT01051570|Drug|RAD 001|5 mg orally starting on Day 2 then continuous
75469542|NCT01940172|Drug|Conatumumab|10 mg/kg IV on Day 1 and 15 of each cycle
75469543|NCT01940224|Drug|Pregabalin|Preoperative administration of pregabalin 300mg
75469544|NCT01940224|Drug|Placebo|Preoperative administration of placebo
75469545|NCT01940224|Drug|Morphine|Postoperative administration of morphine via PCA pump for 48h
75635885|NCT04773834|Other|Digital diabetes prevention program (dDPP)|The digital diabetes prevention program is through the Noom app, and the three devices (Fitbit physical activity tracker, Fitbit weight scale, and self-check hemoglobin a1c kit). This is a one year diabetes prevention program where participants will be expected to participate in 5 to 7 interviews over a 18 month period.
75635886|NCT04773834|Other|Adapted dDPP-EHR tool|This is a product of Phase 1 and 2 of this study where participants will receive detailed text messaging regarding their engagement levels in Noom app.
75635887|NCT04764396|Combination Product|Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)|The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.
75635888|NCT04764396|Drug|Saline|FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
75635889|NCT04763317|Genetic|Prostate cancer risk gene panel|A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
76078434|NCT01051570|Drug|prednisone|5 mg orally twice a day starting on Day 1 then continuous
75635890|NCT04742712|Device|CoronaCheck Device|All participants breath normally into the device for up to 6 minutes
75785384|NCT03910166|Procedure|drug-coated balloon catheter（Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
75785385|NCT03910166|Procedure|Intracranial artery stent system（APOLLO）|stent assisted angioplasty
75921761|NCT03523884|Other|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
75921762|NCT01099761|Biological|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
76078435|NCT01051570|Other|laboratory biomarker analysis|Samples will be collected from archival tissue.
75329130|NCT02246023|Device|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
75469546|NCT01940237|Behavioral|Psychotherapy|Interpersonal psychotherapy in the treatment of major depressive disorder.
75469547|NCT01940250|Drug|Magnesium Sulphate|MgSO4 IV infusion
75921763|NCT01099761|Biological|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
75921764|NCT01099761|Other|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
75469548|NCT01940250|Drug|Sterile water|H2O IV infusion
75635891|NCT04731051|Drug|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
75635892|NCT04731051|Drug|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
75635893|NCT04706923|Drug|BCV|BCV 0.2 mg/kg BIW, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW via IV infusion for 2 hours
75635894|NCT04684589|Drug|Tadalafil 20 MG|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
75635895|NCT04684589|Drug|Placebo|Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
75635896|NCT04682509|Drug|Glecaprevir/pibrentasvir|Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
76078436|NCT01051570|Other|pharmacological study|Samples will be collected Cycle 1, day 1, 2 & 8 and Cycle 2, Day 1 & 2
76078437|NCT04046601|Device|impedance|After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
75635897|NCT05443438|Behavioral|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
76078438|NCT01893281|Drug|Topical Testosterone Solution|Administered topically to axillae.
76078439|NCT02981446|Drug|DE-117|DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
76078440|NCT02981446|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
76078441|NCT01893203|Drug|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
75329131|NCT02246023|Device|Oxygen saturation|Continuous measurement of oxygen saturation;
75635898|NCT05443438|Behavioral|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
75785386|NCT03907566|Other|The Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals|Swallowing function will be evaluated by the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
75785387|NCT03906708|Other|Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)|Infant lung function testing
75329132|NCT02246023|Device|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
75329133|NCT02246023|Device|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
75329134|NCT02246023|Device|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
75329135|NCT05720091|Drug|ZX-7101A 80mg|a drug to treatment influenza in Chinese adults
75469549|NCT01940263|Dietary Supplement|Anthocyanin|
75469550|NCT01940263|Dietary Supplement|Placebo|
75469551|NCT01940289|Device|Algometric meter readings for perception of pain|
75635899|NCT05443438|Behavioral|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
75785388|NCT03891732|Diagnostic Test|MRI prostate|plain biparametric MRI prostate
75785389|NCT03875911|Drug|Mitomycin C|Three delivery methods of Mitomycin-C in Trabeculectomy
75921765|NCT05566444|Device|Heat stimulus|Contact heat pain stimulus with a termode set at 46 degrees and contact warm stimulus with a termode set at 40 degrees
75921766|NCT03523650|Drug|Propranolol Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.
75921767|NCT03523650|Drug|Placebo Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
75329136|NCT05711277|Dietary Supplement|Standard milkshake ONS (Fortisip Compact Protein)|Two 125ml bottles of standard ONS administered a day for two days
75635900|NCT04632654|Behavioral|A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)|A total of 7 weekly intervention sessions will occur in a period of 6 weeks. Week 0 is a setup session conducted at the participant's home, including equipment set up, safety instruction, personalized exergame prescription development, exergame physical activity practice, discussion of barriers and strategies, and Q&A session. Weeks 1 and 2 are coaching sessions delivered by the interventionist using the FaceTime application in iPad, including exergame minutes and prescription review, exergame physical activity practice, discussion of barriers and strategies, and Q&A session. Week 3 is a progress session conducted at the participant's home. The personalized exergame prescription will be adjusted. This session also will include exergame minutes review, exergame physical activity practice, discussion of barriers and strategies, and Q&A session. Weeks 4 and 5 are the same as weeks 1 and 2. Week 6 is the final session. Exergame platform will be picked up at the participant's home.
75329137|NCT05711277|Dietary Supplement|High protein, fortified, ice cream|Two 80g servings of N-ICE CREAM administered a day for two days
75329138|NCT04358263|Device|Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
75329139|NCT04358263|Device|Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
75329140|NCT01041677|Drug|R256918|10 mg capsule twice daily
75329141|NCT01041677|Drug|placebo|placebo capsule twice daily
75635901|NCT04607668|Drug|Trilaciclib|Trilaciclib or placebo
75329142|NCT01041677|Drug|R256918|15 mg capsule twice daily
75329143|NCT03401411|Behavioral|Survey|Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.
75329144|NCT03401411|Behavioral|Algorithm-based Triage Tool|Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
75329145|NCT00358137|Behavioral|Aerobic Conditioning Program|
75329146|NCT00358137|Behavioral|Strength Training Program|
75469552|NCT01940302|Dietary Supplement|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
75635902|NCT04607668|Drug|Placebo|dextrose 5% in water or normal saline (sodium chloride solution 0.9%)
75469553|NCT01940315|Biological|rBV A/B|0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
75469554|NCT01940315|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
75635903|NCT04606095|Diagnostic Test|EEG|EEG with QST (evoked Pain and Visual Stimulation Assessment)
75635904|NCT04606095|Diagnostic Test|Neuroimaging EEG/fMRI|This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then will return to the fMRI scanner for a few additional scans.
75635905|NCT04606095|Device|HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
75635906|NCT04606095|Device|Sham HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
75635907|NCT04597086|Other|Best Practice|Receive standard of care
75635908|NCT04597086|Procedure|Bright White Light Therapy|Receive BWLT
75785390|NCT03854019|Drug|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
75785391|NCT03854019|Drug|Placebo|Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
75785392|NCT03838419|Radiation|intraoperative radiotherapy|IORT with 21 Gy prescribed to the 90% isodose line
75921768|NCT01025505|Drug|Nilotinib|The dose of NIL is 800 mg daily (400 mg twice daily). It must be adapted according to specific guidelines in case of adverse events (AE). It cannot be increased.
75921769|NCT01025505|Drug|Imatinib|The dose of IM is 600 mg daily (300 mg b.i.d.). It must be adapted according to specific guidelines in case of AE. It cannot be increased.
75921770|NCT02582632|Drug|ombitasvir/paritaprevir/ritonavir|Tablet
75921771|NCT02582632|Drug|dasabuvir|Tablet
75329147|NCT03401333|Behavioral|Text Messaging and Brief Negotiation Interview|An in-person brief motivational intervention coupled with 4 weeks of motivational text messages
75329148|NCT04375475|Dietary Supplement|Bright Changyou probiotic flavored yogurt|Oral consumption of Bright Changyou probiotic flavored yogurt 100 g at a time and twice per day for 28 days. The experimental product has similar package and taste as the comparators.
75785393|NCT03838419|Radiation|whole breast irradiation|hypofractionated WBI Total dose 40.05 Gy (15 x 2.67 Gy)
75921772|NCT02144103|Other|Subtenon administration of autologous ADRC|
75921773|NCT02144103|Procedure|Liposuction|
75329149|NCT04375475|Dietary Supplement|Bright Changyou lactobacillus flavored yogurt|Oral consumption of Bright Changyou lactobacillus flavored yogurt 100 g at a time and twice per day for 28 days.
75329150|NCT04375475|Dietary Supplement|Bright flavored yogurt|Oral consumption of Bright flavored yogurt 100 g at a time and twice per day for 28 days.
75469555|NCT01940328|Device|Transchoracic ultrasound Doppler|
75635909|NCT04597086|Other|Survey Administration|Ancillary studies
75921774|NCT02144103|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
75921775|NCT05677672|Biological|Human TH-SC01 Cell Injection|Single injection of 0.6×10^7,1.2×10^8, 1.8×10^8 cells/kg
75469556|NCT01940367|Device|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
75785394|NCT03836053|Drug|AMG 420|28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks
75635910|NCT04582617|Dietary Supplement|Cocoa Extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
75785395|NCT03816163|Drug|zolbetuximab|Administered as an intravenous infusion.
75921776|NCT05677672|Other|Saline solution|saline solution will be given at the same quantity and following the same schedule
75921777|NCT05399836|Behavioral|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants.
75921778|NCT00307476|Device|Rusch Nasopharyngeal Airway|For placement of rectal trumpet (Rusch nasopharyngeal airway-32FR): Patient's skin is cleansed with Smith and Nephew Personal cleanser and rinsed thoroughly with water to remove any soap residue and dried. Apply 3M no sting barrier film to provide skin protectant. Attach the shaft end of the trumpet to a urinary drainage bag. Using hemostats, clamp the tubing beneath the sample port of the drainage bag. Instill 5cc of mineral oil through the flange end of the trumpet, being careful not to over fill or spill mineral oil onto flange. Release the clamp and allow the mineral oil to drain into urinary drainage bag. If possible, place patient into side-lying position with knees drawn toward the chest. Fold flange into quarters, insert into the rectum. Pull back gently until there is slight resistance. Secure the drainage bag to the bed frame. Drainage tubing should be positioned to prevent tension or pull on trumpet.
76078442|NCT01893203|Drug|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
75635911|NCT04582617|Dietary Supplement|Cocoa Extract Placebo|Cocoa extract placebo
75785396|NCT03816163|Drug|nab-paclitaxel|Administered as an intravenous infusion
75785397|NCT03816163|Drug|gemcitabine|Administered as an intravenous infusion
75635912|NCT04582617|Dietary Supplement|Multivitamin|Multivitamin
76078443|NCT04023435|Other|PNE edcuation|The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
75341432|NCT04333082|Other|Data collection|"collection of patient data~Data collection (demographics, prehospital management, duration of ICU and hospital stay, destination at discharge, date(s) of seizure(s), electroencephalographic (EEG) data, seizure history and etiology, number and duration of SE episodes, medication, types of SE according to the current guidelines from the International League of Epilepsy (ILAE), neuroimaging features, comorbidities, laboratory parameters, complications during and after SE , laboratory testing, vital signs, fluid balance) will be performed from the digital medical records, the electroencephalographic and microbiologic database of patients"
75341433|NCT01579045|Device|senofilcon A|bilateral daily use soft contact lens
75635913|NCT04582617|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
75635914|NCT04527289|Drug|Amantadine (100mg) as add on therapy.|Amantadine (100mg) as add on therapy to the management regimen of traumatic brain injury - 100mg twice daily Oral or feeding tube
75635915|NCT04527289|Drug|Placebo|patients will be managed with placebo as add on to the standard regimen.
75785398|NCT03804788|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, & Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
75785399|NCT03804788|Behavioral|Sleep Hygeine|All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
75635916|NCT04516746|Biological|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
75635917|NCT04516746|Biological|Placebo|Commercially available 0.9% (n/V) saline for injection.
75635918|NCT04505735|Drug|11C-PiB|Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.
75785400|NCT03803904|Other|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
75329151|NCT05719857|Procedure|Hepatic vein pressure gradient measurement|HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.
75785401|NCT03780829|Behavioral|hypoxia|intermittent cycles of normoxia-hypoxia
75785402|NCT03780829|Behavioral|sham hypoxia|intermittent cycles of sham hypoxia
75785403|NCT03780829|Drug|D-cycloserine|NMDA agonist treatment
75785404|NCT03780829|Drug|sham-NMDA agonist|sham-NMDA agonist treatment
75785405|NCT03780829|Behavioral|exercise training|bimanual massed practice training
75785406|NCT03728673|Drug|Escitalopram Oral Capsules|Active capsules will contain 10 mg escitalopram oxalate.
75785407|NCT03727061|Biological|Nivolumab|Immunotherapy - Standard of care
75469557|NCT01940367|Device|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:~Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~Mode: Burst~Cycle: 10 seconds~Frequency: 10 Hz~Pulse Width: 250 µs~Intensity: to subject comfort level"
75469558|NCT01940393|Drug|Cetirizine|Drug administration
75341434|NCT01579045|Device|etafilcon A|bilateral daily use soft contact lens
75341435|NCT01579045|Device|nelfilcon A|bilateral daily use soft contact lens
75341436|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lens
75635919|NCT04502524|Behavioral|Smoking Cessation Intervention (New website)|Complete the new website smoking cessation program
75635920|NCT04502524|Behavioral|Smoking Cessation Intervention (Standard of care website)|Complete the standard of care website smoking cessation intervention
75921779|NCT04683354|Drug|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. It will be given twice or three times daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative antitumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
75341437|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lenses
75469559|NCT01940393|Drug|Desloratadine|Drug Administration
76078444|NCT05263947|Drug|Bevacizumab and Icotinib|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
75469560|NCT01940393|Drug|Fexofenadine|Drug administration
75469561|NCT01940393|Drug|Ebastine|Drug administration
75469562|NCT01940393|Drug|Bilastine|Drug administration
75469563|NCT01940406|Procedure|Stimulation procedure|Device
75469564|NCT01940419|Drug|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
75469565|NCT01940419|Drug|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
75635921|NCT04502524|Behavioral|Health Education|Receive information about the cost of smoking, benefits of quitting, ways to prepare for quitting, ways to handle triggers and withdrawal symptoms, and available medications to help with quitting. And will receive additional resources available at the VA handout via email at the end of the study.
75635922|NCT04502524|Other|Health Promotion and Education|Receive motivational and reminder text messages
75785408|NCT03727061|Drug|Porfimer Sodium|Given IV
75785409|NCT03727061|Procedure|Interstitial Illumination Photodynamic Therapy|Undergo I-PDT
75785410|NCT03727061|Biological|Pembrolizumab|Immunotherapy - Standard of care
75785411|NCT03727061|Drug|Cisplatin|Standard of Care
75635923|NCT04502524|Other|Questionnaire Administration|Ancillary studies
75635924|NCT04492215|Behavioral|Interaction between patient and trained general practitioners in motivational interviewing|Impact of the medical interview on the patient
75785412|NCT03727061|Drug|Carboplatin|Standard of Care
75785413|NCT03727061|Biological|Cetuximab|Standard of Care
75785414|NCT03727061|Other|Quality of Life Assessment|Ancillary Studies
75785415|NCT03727061|Drug|Fluorouracil|Standard of Care
75785417|NCT03711058|Drug|Copanlisib|"Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV"
75785418|NCT03711058|Drug|Nivolumab|"Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV"
75785419|NCT03704480|Drug|Durvalumab|1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
75785420|NCT03704480|Drug|Tremelimumab|300mg by IV infusion on D1 at cycle 1 only
75635925|NCT04487886|Drug|Duvelisib|Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.
75329152|NCT05719857|Procedure|Ultrasound-guided percutaneous liver biopsy|Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.
75329153|NCT05719857|Diagnostic Test|Multiparametric Abdominal Magnetic Resonance with Elastography|The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
75329154|NCT00924053|Drug|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
75635926|NCT04487886|Drug|Placebo|A placebo to match duvelisib will be taken orally twice per day for 14 days.
75635927|NCT04460872|Drug|Testosterone Enanthate|Subjects receive testosterone (100 mg/week) by intramuscular injection
75635928|NCT04460872|Behavioral|Locomotor Training|Subjects receive locomotor training (4 sessions/week for 2-3 months)
76078445|NCT04415567|Drug|Lenvatinib|The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW <60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
75329155|NCT00924053|Drug|Placebo|Placebo capsules to match EGT0001474
75329156|NCT05707845|Drug|Medical treatment.|Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
75635929|NCT04457401|Dietary Supplement|Probiotic|This probiotic is commercially available and contains Bifidobacterium (3 x 10^9 colony forming units/capsule) as the active ingredient and potato starch, magnesium stearate and ascorbic acid as excipients.
75329157|NCT05707845|Behavioral|weight reduction|weight reduction in the form low caloric diet program for 12 weeks.
75635930|NCT04457401|Dietary Supplement|Placebo|The placebo contains potato starch, magnesium stearate and ascorbic acid.
75635931|NCT04437602|Diagnostic Test|Contrast Enhanced Mammography (CEM)|Additional CEM in preoperative staging
75785421|NCT03697876|Drug|PRO-165|PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
75785422|NCT03697876|Drug|Artelac|Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch & Lomb México, S.A. de C.V.
75785423|NCT03695315|Device|Continuous Positive Airway Pressure|CPAP is a noninvasive treatment for sleep apnea
75785424|NCT03681561|Drug|Ruxolitinib|"Phase I: Ruxolitinib at assigned dose* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~Dose Levels:~(starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop."
75329158|NCT05707845|Other|exercise|aerobic exercise in the form of walking on treadmill for 30 minutes 3 times a week for 12 weeks.
75329159|NCT04375319|Device|OCT|OCT can provide clear in vivo imaging and evaluate the vascular repair after stent implantation by measuring the optical echo of near-infrared light reflection
75635932|NCT04428905|Other|Quality-of-Life Assessment|Ancillary studies
75635933|NCT04428905|Other|Questionnaire Administration|Ancillary studies
75635934|NCT04428905|Other|Survivorship Care Plan|Receive personalized care plan/resource manual
75635935|NCT04428905|Other|Telemedicine|Participate in telehealth sessions
75635936|NCT04422795|Device|External thermomechanical device delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings frozen and the vibration mechanism switched on, delivering vibration and cold stimuli to the area for 30 seconds before the intramatricial injection and until needle withdrawal
75635937|NCT04422795|Device|External thermomechanical device without delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings at unfrozen and the vibration mechanism switched off, for 30 seconds before the intramatricial injection and until needle withdrawal
75635938|NCT04422795|Drug|Ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion
75635939|NCT04413617|Drug|PF-06650833|400 mg
75635940|NCT04413617|Drug|PF-06651600|100 mg
75635941|NCT04413617|Drug|Tofacitinib|11 mg
75635942|NCT04405115|Behavioral|Geriatric Assessment|Geriatric Assessment Visit
75635943|NCT04343274|Drug|Tozuleristide|
75635944|NCT04244123|Combination Product|integrated information and nurse led telephone clinic|combining web-based information from easypod connect with nurse led telephone clinic
75635945|NCT04242446|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
75635946|NCT04242446|Other|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
75635947|NCT04233086|Other|No intervention, observational only|No intervention, observational only
75921780|NCT02178722|Drug|MK-3475|IV infusion
75921781|NCT02178722|Drug|INCB024360|Oral daily dosing
76078446|NCT04723576|Behavioral|Stress First Aid|"Stress First Aid (SFA) is an evidence-based intervention to mitigate the psychosocial impact of COVID-19 on Health Care Workers (HCWs). SFA was initially developed for the United States Navy and Marine Corps as a framework of actions for peer support delivered by individuals without mental health training. SFA is designed to teach simple, supportive actions that can be seamlessly integrated into work environments. SFA training focuses on five essential principles: cover (restore and support a sense of safety), calm (encourage simple strategies such as breathing), connect (engage in and promote social support), competence (improve ability to address crucial needs and concerns), and confidence (increase hope and limit self-doubt and guilt). In this study, we are adapting the SFA model to include HCW-specific examples of SFA actions and case scenarios specific to the COVID-19 pandemic and will implement SFA using a train-the trainer model."
76078447|NCT03280251|Drug|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
76078448|NCT03280251|Drug|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
76078449|NCT03280251|Other|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
75329160|NCT00833313|Procedure|Atrial biopsy|Biopsy of left atrial free wall and possibly left atrial appendage
75329161|NCT03400397|Other|Cool Kids programme|A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
75329162|NCT03834389|Behavioral|Case- based Learning|critical thinking, self efficacy, focus group interview
75635948|NCT04218565|Biological|Golimumab (GOL)|Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.
75329163|NCT00357825|Drug|[S,S]-Reboxetine|
75329164|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product A
75635949|NCT04193449|Diagnostic Test|colonoscopy|colonoscopy procedure
75785425|NCT03681561|Drug|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
75785426|NCT03678545|Drug|Dupilumab (blinded)|Subcutaneous injection every two weeks as follows: 600 mg initial dose, and 300 mg subsequent doses for a total of 6 injections.
75785427|NCT03678545|Drug|Placebo (blinded)|Placebo is matched to the active drug (dupilumab), and is given in the same manner: a subcutaneous injection every two weeks for a total of 6 injections.
75785428|NCT03678545|Drug|Dupilumab (open-label)|After completing 6 doses of blinded study drug (dupilumab or placebo), participants can continue into the open-label portion of the study, in which all subjects will receive 12 doses (every 2 weeks for 24 weeks) of dupilumab.
75921782|NCT03523572|Drug|Trastuzumab deruxtecan|The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
75921783|NCT03523572|Drug|Nivolumab|Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
75921784|NCT00972309|Biological|T-cell receptor alternate reading frame protein (TARP) peptide vaccine|Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
75921785|NCT00972309|Biological|T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine|Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
76078450|NCT03280251|Other|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
75635950|NCT04145635|Device|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
75635951|NCT04129502|Drug|TAK-788|TAK-788 capsule
75635952|NCT04129502|Drug|Pemetrexed|Pemetrexed IV infusion
75635953|NCT04129502|Drug|Cisplatin|Cisplatin IV infusion
75635954|NCT04129502|Drug|Carboplatin|Carboplatin IV infusion
75329165|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product B
75329166|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product C
75329167|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Spiriva 18 Mcg/capsule inhaled via HandiHaler
75635955|NCT04112940|Other|Starch-based Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
75635956|NCT04112940|Other|Xanthan-gum Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
75635957|NCT04112576|Device|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
75785429|NCT03670069|Drug|Itacitinib|Given PO
75785430|NCT03670069|Other|Laboratory Biomarker Analysis|Correlative studies
75785431|NCT03656549|Drug|Pemetrexed|3+3 dose escalation study of pemetrexed in patients with impaired renal function
75921786|NCT03133026|Device|Single operator cholangioscopy, Endoscopic biliary RFA|Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
75921787|NCT03526224|Drug|Dimethyl Fumarate|Individuals with MS treated with dimethyl fumarate (Tecfidera)
75921788|NCT03526224|Drug|Teriflunomide|Individuals with MS treated with teriflunomide (Aubagio)
75921789|NCT03748329|Device|Ultrasound|Will deposit local anaesthetic intra-orally with the aid of ultrasound to guide the location of the final deposition.
75921790|NCT03639246|Drug|AVB-S6-500|AVB-S6-500 is experimental drug
75921791|NCT03639246|Drug|Paclitaxel (Pac)|Paclitaxel is active comparator
75469566|NCT01940432|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhong Liao (BL33) Hui Yang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50一60mm with 30一45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50一60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with dilatational wave,50 Hz and electric current 1一5mA(milliampere).Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
75921792|NCT03639246|Drug|Pegylated liposomal doxorubicin (PLD)|PLD is active comparator
75921793|NCT03639246|Other|Placebo|Placebo comparator
75921794|NCT00594620|Dietary Supplement|Flav-ein capsules|Soy/isoflavone supplementation
75635958|NCT04055116|Drug|Buffered Lidocaine|Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
75635959|NCT04045028|Drug|Tiragolumab|Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)
75635960|NCT04045028|Drug|Daratumumab/rHuPH20|Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression
75635961|NCT04045028|Drug|Rituximab|Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).
75635962|NCT04045028|Drug|Atezolizumab|Administered by IV infusion at a fixed dose of 1200 mg Q3W
75635963|NCT04010747|Behavioral|Motivational Interviewing for Loved Ones (MILO)|4 sessions of behavioral coaching in motivational interviewing communication techniques
75635964|NCT04010747|Behavioral|Mental Health Services Consultation and Waitlist|1 session of individualized consultation on relevant mental health services for the IP and participating PCSO and 6 weeks on a waitlist, followed by opportunity to participate in MILO sessions.
75651751|NCT05683119|Other|Exercise and blood draw|This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle [MC] and oral contraceptive pill [OCP] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
75785432|NCT03651752|Drug|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
75785433|NCT03647137|Other|Detailed motor testing, including FoG, in PD subjects|"Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state."
75785434|NCT03646357|Other|Non-betablocker|No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.
75921795|NCT00594620|Drug|Placebo|Placebo
75921796|NCT03544515|Device|Er,Cr:YSGG laser|Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing
75921797|NCT03544515|Procedure|Scaling|Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
75921798|NCT03544515|Device|Inactive Er,Cr:YSGG|Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
75921799|NCT03550170|Behavioral|Teleconference|This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
75921800|NCT03550170|Behavioral|Internet|The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.
75921801|NCT03550170|Behavioral|1-to-1, in-person|Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
75921802|NCT00545324|Drug|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
75921803|NCT00545324|Drug|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
75785435|NCT03646357|Drug|Betablocker|"A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be:~Metoprolol succinate up to a total dose of 200mg daily~Bisoprolol up to a total dose of 10mg daily~Carvedilol up to a total dose of 50mg daily~The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care."
75785436|NCT03623113|Behavioral|BCC intervention|Structured training and education i basic carbohydrate counting principles
75785437|NCT03623113|Behavioral|ABC-ACC intervention|Structured training and education i advanced carbohydrate counting principles including the use of a automated bolus calculator carbohydrate
75921804|NCT02582242|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
75921805|NCT04467684|Drug|CB-0406 100 mg|Single oral dose
76078451|NCT01882829|Drug|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
75785438|NCT03623113|Behavioral|Standard dietary education|Personalized individual dietary counselling based on overall meal planning, dietary guidelines and the patient's need and preferences
76078452|NCT04399005|Other|after-each-case room disinfection|After-each-case room disinfection was defined as after completing each case.
75785439|NCT03615326|Biological|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
75635965|NCT04007900|Behavioral|Positive Affect Treatment|PAT was designed as a 15-week intervention delivered in 3 modules. Module 1 (Pleasant Events Scheduling) uses behavioral activation methods to enhance positive experiencing before, during, and after rewarding events. Module 2 (Attending to the Positive) applies cognitive training techniques to promote shifting attention towards rewarding aspects of daily situations and to learn behavior mood associations. Module 3 (Cultivating the Positive) uses mindfulness approaches to foster reward experiencing. Treatment length has been expanded to 20 sessions to enhance the suitability of the intervention for AN and target the reward mechanisms that characterize AN. Additional adaptations include: 1) An emphasis on a mindful balance between reward and inhibition; 2) Additional module on shifting attention away from AN-specific rewards; 3) Addition of exercises to work towards long-term life goals and enhance healthy experiences; and 4) Further focus on navigating social rewards.
75785440|NCT03615326|Biological|Placebo|Solution for IV infusion on Day 1 of each 3-week cycle.
75329168|NCT05706987|Drug|Lidocaine|continuous lidocaine infusion perioperatively
75469567|NCT01940432|Behavioral|pelvic floor muscle training group|Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
75785441|NCT03615326|Drug|Cisplatin|80 mg/m^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
75785442|NCT03615326|Drug|5-FU|800 mg/m^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
75785443|NCT03615326|Drug|Oxaliplatin|130 mg/m^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
75921806|NCT04467684|Drug|CB-0406 200 mg|Single oral dose
75921807|NCT04467684|Drug|CB-0406 400 mg|Single oral dose
75921808|NCT04467684|Drug|CB-0406 800 mg|Single oral dose
75921809|NCT04467684|Drug|CB-0406 1,000 mg|Single oral dose
75329169|NCT05706987|Drug|Normal saline|normal saline
75329170|NCT03400007|Device|Dynamic floor magnetic resonance imaging|Dynamic floor magnetic resonance imaging (MRI)
75329171|NCT03400007|Device|Colpocystodefecography|Colpocystodefecography (CCD)
75329172|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
75329173|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
75329174|NCT00729573|Drug|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
75329175|NCT00729573|Drug|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
75329176|NCT03405389|Procedure|MatrixWAVE MMF System|Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion
75329177|NCT02951182|Drug|TEZ|
75329178|NCT02951182|Drug|IVA|
75329179|NCT02951182|Drug|VX-440|
75329180|NCT02951182|Drug|Matched Placebo|
75921810|NCT04467684|Drug|Matched placebo|Color and size matched placebo
75921811|NCT05004038|Biological|BCG Vaccine AJVaccines|Single intradermal injection of BCG Vaccine according to published Summary of Product Characteristics
75921812|NCT00663351|Device|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
76078453|NCT04399005|Other|daily room disinfection|Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
76078454|NCT04760301|Drug|local tranexamic acid injection|local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
76078455|NCT04760301|Other|local normal saline injection to cervix|local normal saline injection to the cervix- 20 ml saline
76078456|NCT04760301|Drug|IV 1 g tranexamic acid|IV 1 g tranexamic acid diluted in 100 ml saline
76078457|NCT04760301|Other|IV 1 g normal saline|IV 100 ml normal saline
76078458|NCT02170870|Drug|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
75469568|NCT01940445|Device|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
75785444|NCT03615326|Drug|Capecitabine|1000 mg/m^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
75635966|NCT04000256|Behavioral|Activity based rehabilitation|Activity based rehabilitation for the upper extremity involves various gross and fine movements, reach and object transportation, and object manipulation. The rehabilitation equipment used during training will include gaming and instrumented training equipment, conventional table-top tasks, and exercise aids.
75921813|NCT00663351|Device|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
75921814|NCT02288988|Procedure|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
76078459|NCT02170870|Drug|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
76078460|NCT02170870|Drug|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
75785445|NCT03615326|Drug|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): <1.25 m^2 BSA =40 mg, 1.25 to <1.5 m^2 BSA=50 mg, ≥1.5 m^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.
75469569|NCT01940445|Device|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
75469570|NCT01940536|Drug|Tranexamic Acid|antifibrinolytic
75469571|NCT01940536|Drug|Placebo|Placebo
75469572|NCT01940549|Device|Trauma Focused Therapy + tDCS|
75469573|NCT01940562|Drug|eltrombopag|"Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children < 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
75469574|NCT01940575|Device|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
75635967|NCT03998527|Device|Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)|TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.
75635968|NCT03990623|Radiation|Computed Tomography Perfusion Imaging|Undergo perfusion CT
75785446|NCT03615326|Biological|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
75785447|NCT03599635|Drug|liposomal bupivacaine|Experimental
75785448|NCT03599635|Drug|Bupivacaine|Active Comparator
75785449|NCT03540420|Drug|Atezolizumab|atezolizumab 1200 mg intravenous every 3 weeks in 12 months
75785450|NCT03527485|Diagnostic Test|11UCB-J PET Scan|11UCB-J PET Scan
75785451|NCT03521154|Drug|Osimertinib 80mg/40mg|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
75785452|NCT03521154|Drug|Placebo Osimertinib 80mg/40mg|"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
75785453|NCT03519464|Biological|Gardasil 9|Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
75921815|NCT04976270|Drug|GLPG3667|GLPG3667 capsules
75921816|NCT04976270|Drug|Placebo|Matching placebo capsules
75921817|NCT03526146|Behavioral|Behavioral: Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
75921818|NCT05677516|Procedure|ablation- pulmonary vain isolation- crioablation|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
76078461|NCT04400097|Procedure|suture|suture methods of autograft conjunctival transplantation
76078462|NCT04678648|Drug|RSC-1255 Dose Escalation|Phase 1a will enroll 24-34 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
75635969|NCT03990623|Procedure|Liver Biopsy|Undergo liver biopsy
75329181|NCT02959359|Drug|Ledipasvir 90mg/Sofosbuvir 400 mg|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
75329182|NCT02959359|Drug|Ribavirin|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
75329183|NCT04375163|Other|Isokinetic intense exercise protocol|The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.
75329184|NCT04375163|Other|Massage treatment|"Massage consisted of stroking (30) and petrissage (50) for muscle relaxation, then friction (10), pincement and clapping (30) to prepare muscles for the next set."
75329185|NCT04347551|Other|High velocity/low amplitude cervical spine manipulation|The participants will receive a single cervical spine rotary manipulation to the previously identified palpable cervical segmental fixation. During the performance of the manipulation, the supine participant will rest their arms at the sides of their body. Next, the index finger of the chiropractor's contact hand will be placed on the lamina of the restricted cervical segment. The chiropractor will then rotate the participant's head contralaterally until the barrier of the cervical segments volitional end range is reached. The chiropractor's other hand will be placed behind the participant's head to induce gentle neck rotation contralateral to the chiropractor's thrusting hand. The chiropractor will deliver a manual thrust, with the thrust vector directed towards the participant's opposite eye.
75329186|NCT05705661|Device|HIGH FREQUENCY CHEST WALL OSCILLATION|The HFCWO device used a triangular wave form which increases the airflow velocity more than other devices. Therefore, clearing sticky airway mucus and alveolar exudates and maintaining airway patency has become currently the most urgent issue in the ventilatory management of patients with severe COVID-19.
75635970|NCT03950973|Behavioral|CareAvenue|CareAvenue is an e-health tool providing information about diabetes management and low-cost resources. Participants in this group have access to CareAvenue and receive a weekly automated phone call and text messages related to CareAvenue and its resources as well as diabetes management.
75635971|NCT03950973|Behavioral|Guest Assistance Program|The Guest Assistance Program (GAP) is a resource, which provides assistance with medical and non-medical needs and resources to patients receiving medical care at University of Michigan health system. Participants in this group are provided with GAP information and receive text messages related to diabetes management.
75635972|NCT03929315|Behavioral|OLV technique on tracheo-bronchial model|Models will range in size from 6 yrs to 6 weeks.
75635973|NCT03929120|Biological|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)|Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.
75785454|NCT03509909|Behavioral|Hatha yoga|Manualized hatha yoga
76078463|NCT04678648|Drug|RSC-1255 Dose Expansion|Phase 1b will enroll 48-104 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
75329187|NCT02829034|Drug|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
75329188|NCT02829034|Drug|Placebo|Placebo by mouth twice per day for a total of 26 weeks
75329189|NCT00924209|Drug|Gemcitabine|1250 mg/m^2 dose for two doses on days 1 and 8
75329190|NCT00924209|Drug|Cisplatin|80 mg/m^2 on day 1
75329191|NCT00924209|Drug|Bevacizumab|7.5 mg/m^2 on day 1 every 21 days for first two cycles only
75329192|NCT00924209|Procedure|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
75635974|NCT03924102|Drug|Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT|A rest and stress imaging study will be conducted on the PET/CT scanner with [11C] Acetate.
75329193|NCT00924209|Drug|Etoposide|100 mg/m^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
75329194|NCT05719467|Drug|Buscopan 20 MG/ML Injectable Solution|1 mL intravenously
75329195|NCT05719467|Drug|Sodium bicarbonate|4 g orally
75329196|NCT05719467|Drug|Placebo|4g orally
75329197|NCT05719467|Drug|Nacl 0.9%|1 mL intravenously
75329198|NCT02830438|Device|Shear wave elastography|Ultrasound technique of the kidneys to assess wave elastography.
75329199|NCT03408119|Dietary Supplement|Dried Plum|Dried plum fruit, 100g or 50g depending on treatment group randomized to
75329200|NCT03408119|Dietary Supplement|800 IU vitamin D and 450mg elemental calcium|Supplemental vitamin D and calcium to protect against further bone loss
75329201|NCT03837405|Behavioral|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
75329202|NCT03837405|Behavioral|Mindfuless|Mindful eating app use plus group sessions to learn mindfulness
75329203|NCT02832154|Other|Internet-Based Intervention|Complete online PA program
75329204|NCT02832154|Procedure|Quality-of-Life Assessment|Ancillary studies
75329205|NCT02832154|Other|Questionnaire Administration|Ancillary studies
75635975|NCT03916328|Drug|B/F/TAF|A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
75635976|NCT03916328|Drug|TDF/3TC/EFV or DTG or NVP|A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.
75635977|NCT03916328|Other|DMPA|Two thirds of the women will be on DMPA for contraception.
75635978|NCT03916146|Behavioral|Parent Training Intervention|Adapted version of the Family Check-Up/Everyday Parenting intervention
75635979|NCT03901638|Drug|Tllsh2910|Tllsh2910 80mg twice per day orally for 12 weeks
75635980|NCT03901638|Drug|Placebo|Placebo
75785455|NCT03509909|Behavioral|Supportive physical activity|Manualized stretching and strengthening
75785456|NCT03500731|Biological|CD3/CD19 negative hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation
75785457|NCT03500731|Drug|Rituximab|Transplantation Conditioning
75785458|NCT03500731|Drug|Alemtuzumab|Transplantation Conditioning
75785459|NCT03500731|Drug|Fludarabine|Transplantation Conditioning
75785460|NCT03500731|Drug|Thiotepa|Transplantation Conditioning
75785461|NCT03500731|Drug|G-CSF|Transplantation conditioning
75785462|NCT03500731|Drug|Hydroxyurea|Transplantation Conditioning
76078464|NCT03015454|Other|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
75635981|NCT03896438|Device|Transcranial Direct Current Stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
75635982|NCT03870217|Behavioral|Site selection|Turning off electrodes on the electrode array based on imaging and psychophysical measures
75635983|NCT03867500|Drug|Niacin|All participants will receive intravenous Niacin and each participant will serve as their own saline control on the second study
75635984|NCT03867500|Other|Saline|All participants will serve as their own controls with a saline infusion study day.
75635985|NCT03867136|Drug|PZA sensitivity guided ultra-short all Oral Regimen|Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, >50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, >50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
75635986|NCT03867136|Drug|Standardized Shorter Regimen|Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, >50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, >50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
75635987|NCT03867058|Behavioral|Electrode selection/electrode configuration|Electrodes will be chosen based on their spatial tuning curves. Focused stimulation will be applied to electrodes with good temporal processing acuity.
75635988|NCT03867032|Behavioral|Auditory training|Training with psychophysical tests (amplitude modulation detection on single electrodes) for improving speech recognition
75635989|NCT03866850|Behavioral|Phase duration|We will vary the phase duration in the stimulation, and examine detection threshold, spatial spread of neural excitation, and speech recognition as the outcomes.
75635990|NCT03862014|Device|SDF only|Molar with MIH will be treated with SDF
75635991|NCT03862014|Device|SDF+ARR|Molar with MIH will be treated with SDF+ARR
75635992|NCT03857048|Other|Weight Loss|12-wk weight loss intervention using a meal replacement strategy (Health & Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal
75635993|NCT03857048|Other|Exercise training|16-wk supervised endurance exercise training program
75785463|NCT03498638|Behavioral|Couples Therapy|Couples in the intervention group will receive couples therapy for 8 weekly sessions. Each therapy session will last approximately an hour. All therapies will be conducted by the PI, Dr. Gunnur Karakurt. Dr. Karakurt is a Licenced Marriage and Family Therapist and AAMFT (American Association of Marriage and Family Therapy) approved clinical supervisor. All therapies will be conducted as a couple. Training on stress management and safety planning will be performed as individuals. There will not be any group sessions. The goal of couple therapy is to help and improve couples' capacity to regulate emotions, solve problems, and communicate through therapy with the couple together.
75921819|NCT05677516|Procedure|ablation- pulmonary vain isolation- pulsed field ablation (PFA)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the pulsed field ablation (PFA) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a PFA electrode. PFA procedures are performed under general anesthesia. The procedure is performed using X-ray fluoroscopy.
76078465|NCT03015454|Other|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
75341438|NCT00582998|Procedure|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
76078466|NCT04760379|Other|Conventional therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
75635994|NCT03857048|Other|Overfeeding|3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements
75635995|NCT03840434|Diagnostic Test|MyotonPRO|Each patient will perform a stress test to trigger the painful. Measurements will be done by intramuscular punction as usually, and by non invasive tool : MyotonPRO
75635996|NCT03824496|Diagnostic Test|Cranial Accelerometry Measurement|Measuring the HeadPulse using cranial accelerometry
75635997|NCT03781986|Drug|APG-115|APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
75635998|NCT03781986|Drug|Carboplatin|Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
75635999|NCT03743402|Behavioral|Pain self-management training|"This intervention will have 4 components:~telephone-delivered evidence-based pain self-management training,~web-based video of successfully tapered patients with motivational interviewing debriefing,~a voluntary, self-paced opioid taper~opioid and non-opioid prescribing guidance for the patient's primary care provider."
75636000|NCT03743402|Behavioral|video education, motivational interviewing|web-based video of successfully tapered patients with motivational interviewing debriefing
75636001|NCT03743402|Behavioral|voluntary self-paced opioid taper|Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they will negotiate details with their primary care provider.
75636002|NCT03743402|Behavioral|prescribing guidance for primary care provider|Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper. All prescriptions will be written by the primary care provider.
75785464|NCT03498638|Other|Control|Couples in the control group will be taught safety planning, given information on local resources to help victims of violence, and will be instructed in stress and anger management strategies. Following this 8 week period, they will receive 8 weeks of couple therapy unless they choose not to.
75921820|NCT05677516|Procedure|ablation- pulmonary vain isolation- radiofrequency ablation (RF)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the radiofrequency ablation (RF) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a RF electrode. RF procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
75329206|NCT05719389|Drug|CT-P13|CT-P13 is a biosimilar of infliximab approved by EMA since 2015, and it is administered intravenously (i.v.) at a standard dose of 5 mg/kg at week 0, 2, 6 and then every 8 weeks, although the scheduled maintenance regimen can be optimized by administering the drug every 4-6 weeks or increasing the dose up to 10 mg/kg2.The safety profile of CT-P13 SC was comparable to that of CT-P13 i.v.; There were also fewer patients with positive anti-drug antibodies with CT-P13 SC than with CT-P13 i.v.3 At the moment, no data are available on the effectiveness, safety and immunogenicity in a real-world population of patients who have been switched from i.v. to s.c. infliximab.
75785465|NCT03481660|Drug|Brolucizumab|Intravitreal injection
75785466|NCT03481660|Drug|Aflibercept|Intravitreal injection
75785467|NCT03467373|Drug|Glofitamab|Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
75785468|NCT03467373|Drug|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
75921821|NCT05677516|Procedure|Electrophysiological study (EPS)|"In the electrophysiological study (EPS), electrophysiological parameters such as the recovery time of sinus rhythm (SNRT), Wenckebach's point, AH and HV intervals are measured. The examination begins with venous access through the femoral vein. Then, diagnostic electrodes are inserted into the right atrium, right ventricle and coronary sinus, with which electrophysiological tests are performed. The SNRT is measured after 60 seconds of atrial pacing with a 600ms cycle. The Wencjabach point is determined by stimulation in the incremental protocol. AV and HV intervals are measured during sinus rhythm using an electrode placed on the bundle of His. EPS is performed under local anesthesia. EPS will be performed both before and after pulmonary vein isolation. In patients with atrial fibrillation, during ablation, only the HV interval will be measured.~The procedure is performed using X-ray fluoroscopy."
75921822|NCT05677516|Diagnostic Test|Holter EKG|Holter ECG is a 24-hour, non-invasive ECG recording using a portable recorder and electrodes placed on the patient's chest. The Holter ECG will be performed three times: on the day preceding and on the first day after pulmonary veins isolation, and after 3 months of observation.
75921823|NCT05677516|Other|Questionnaire|The survey will be conducted after 3 months of observation and will include questions about the number of hospitalizations due to atrial fibrillation, heart palpitations, changes in pharmacotherapy.
75921824|NCT04971512|Drug|EDP-721|Oral administration (Part 1)
75329207|NCT04366193|Diagnostic Test|Oximetry|Validation of a high-resolution wireless oximeter for OSA diagnosis comparing with a well established and validated method (home sleep test).
75329208|NCT04374929|Device|StealthTrac Temporary Pacing Lead Plus Negative Pressure Wound Therapy|Following fixation of the StealthTrac Lead, Negative Pressure Wound Therapy is applied over the incision site.
75469575|NCT01940575|Device|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
75469576|NCT01940588|Behavioral|Neuropsychoanalytic therapy|Psychotherapy, medication management
75469577|NCT01940601|Drug|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
75469578|NCT01940601|Drug|Filgrastim|Filgrastim 5 μg/kg
75341439|NCT00582998|Device|Vacuum Assisted Closure Device|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
75341440|NCT05208476|Procedure|Osteopathic manipulative medicine|A set of hands-on techniques used by osteopathic physicians to help diagnose, treat and prevent illness or disease.
75341441|NCT01579513|Drug|Methylprednisolone|Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
75469579|NCT01940614|Other|Water deprivation test|Classical water deprivation test alone
75469580|NCT01940614|Other|Water deprivation test|classical water deprivation test plus plasma copeptin cut-off levels
75469581|NCT01940614|Other|Hypertonic saline infusion|hypertonic saline infusion test plus plasma copeptin measurement
75469582|NCT01940627|Dietary Supplement|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
75785469|NCT03467373|Drug|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
75785470|NCT03467373|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
75785471|NCT03467373|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m^2 administered IV on Day 1 of each 21-day cycle
75785472|NCT03467373|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle
75469583|NCT01940627|Dietary Supplement|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
75785473|NCT03467373|Drug|Vincristine|Vincristine 1.4 mg/m^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
75785474|NCT03467373|Drug|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
75785475|NCT03467373|Drug|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
75921825|NCT04971512|Drug|Placebo (Part 1)|Placebo to match EDP-721, oral administration (Part 1)
75469584|NCT01940640|Dietary Supplement|DHA|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
75469585|NCT01940640|Dietary Supplement|control|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
75636003|NCT03743402|Other|usual care|Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses
75469586|NCT01940653|Drug|Progesterone|"Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred."
75921826|NCT04971512|Drug|EDP-721 (Part 2)|Oral administration (Part 2)
75921827|NCT04971512|Drug|Placebo (Part 2)|Placebo to match EDP-721 (Part 2)
75636004|NCT03735433|Drug|162mg aspirin dose|2 pills of 81mg aspirin
75636005|NCT03734861|Device|BreatheSmart System|"BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~HeroTracker sensor that counts dosage and monitors real-time medication adherence~CoheroConnect provider portal that allows the Investigator to monitor adherence"
75636006|NCT03734861|Other|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
75636007|NCT03727438|Behavioral|Tele-Self CBTI|The tele-self intervention is comprised of two treatment components: 1) self-management via a workbook with weekly readings, and 2) weekly telephone-based nurse support over 6 weeks
75636008|NCT03727438|Other|Health Education Control|6 weekly phone calls from a study nurse on a range of health topics (non-sleep), similar call duration to intervention phone calls. At the end of the study, participants will be offered assistance through the Durham Behavioral Sleep Medicine clinic.
75636009|NCT03714334|Drug|DNX-2440 injection|DNX-2440 virus will be injected stereotactically
75636010|NCT03712527|Other|Injection of Platelet rich plasma|The blood of the PRP patients group will be centrifuged by the nurse using the dedicated device. A single centrifugation is required to separate the red and white blood platelets and plasma. This method of centrifugation is carried out using specific kits (Mini-GPS System III, Zimmer Biomet Company). The PRP is then collected by the nurse into a syringe that will be provided to the injector physician. Duration of preparation: 20 to 25 minutes. After a standardized sterile preparation, a local anaesthesia will be performed. Then, the injector will inject a volume of 2 mL of PRP into the median portion of the suspected disc under radiographic guidance.
75785476|NCT03465644|Drug|Tailored antithrombotic strategy|Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
75785477|NCT03465644|Drug|Conventional antithrombotic strategy|Clopidogrel + aspirin for 12months
75785478|NCT03454893|Drug|AVR-RD-01|Single IV infusion of between 3 - 20 x 10^6 CD34+ cells/kg.
75785479|NCT03408613|Procedure|Positive Airway Pressure|See arm/group description
75785480|NCT03408613|Procedure|Supplemental Oxygen|See arm/group description
75785481|NCT03408613|Procedure|Sham|See arm/group description
75785482|NCT03406351|Other|Observational|Observational deep phenotyping physiological readouts
75921828|NCT04971512|Drug|EDP-514|Oral administration
75785483|NCT03404193|Drug|Decitabine|Given IV
75785484|NCT03404193|Other|Laboratory Biomarker Analysis|Correlative studies
75921829|NCT04971512|Drug|Placebo (Part 2)|Placebo to match EDP-514
75921830|NCT03523260|Device|Tunneled dialysis catheter placement.|Placement of high-flow tunneled catheter for hemodialysis
75921831|NCT03526068|Device|SafeZoneUVC|SafeZoneUVC® uses a Krypton Chloride (Kr-Cl) excimer lamp as its light source. The Kr-Cl excimer lamp emits UVC light having a main wavelength of 222 nm when the Kr-Cl exciplex is deactivated to non-excited state molecule in the lamp. This 222 nm UVC light can inactivate bacteria, while the Kr-Cl excimer lamp also emits UVC light having a wavelength of 230 nm or more. SafeZoneUVC® effectively eliminates UVC light with a wavelength of 230 nm or more by incorporating an appropriate optical filter inside the unit and also utilizing an opaque guide to ensure that light is not dispersed beyond the target area.
75921832|NCT04217356|Biological|Hematopoietic stem cell transplant|Intravenous infusion of hematopoietic stem cells from a donor.
76078467|NCT04760379|Other|vibration therapy|Focal muscle vibrator (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
75785485|NCT03404193|Drug|Venetoclax|Given PO
75785486|NCT03393975|Biological|BAX930|Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg BAX 930 ORT during Period 1 and Period 2 and switch to BAX 930 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of BAX-930.
75785487|NCT03393975|Biological|Standard of care|Participants will receive Investigator-recommended Standard of care (SoC).
75785488|NCT03381183|Drug|Durvalumab|Phase 1 and Phase 2: 1500 mg every 4 weeks (Q4wks).
75921833|NCT04217356|Drug|Ruxolitinib|Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).
75921834|NCT04217356|Drug|Hydroxyurea|Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).
76078468|NCT03014908|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
75469587|NCT01940679|Dietary Supplement|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
75785489|NCT03381183|Drug|IRX-2 Regimen|"Phase 1 and Phase 2 - Every 12 weeks - IRX-2 Regimen:~Cyclophosphamide 300 mg/m^2 - intravenously.~IRX-2: 460 units daily (4 injections of 115 units)."
76078469|NCT01054768|Drug|alpha-lipoic acid and acetyl-L-carnitine|none to report
76078470|NCT01054768|Drug|Control|none to report
76078471|NCT04387617|Drug|Cannabidiol|The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.
75329209|NCT04374929|Device|StealthTrac Temporary Pacing Lead Plus Anti-Inflammatory Glucocorticoid|"• Methylprednisolone 125 mg administered over 30 minutes beginning at least 30 minutes prior to the incision and StealthTrac Lead insertion procedure. This intravenous dose can be repeated every 8 hours on day one of the insertion from 1-3 doses depending on the patient's ability to take oral medications. It can be administered daily thereafter until the patient is able to take oral dosing. In normal circumstances, post op day 2, commence oral glucocorticoid (see below for recommended oral dosing).~Oral (PO) glucocorticoid preparations and dosing:~Prednisone 40-60 mg orally daily based on BMI category. BMI categories: Low (<18); Medium (18-30); High (>30). Low and medium are assigned 40 mg daily. High BMI is assigned 60 mg daily dose. This while the StealthTrac lead remains in place.~Methylprednisolone 16-32 mg daily based on BMI (low, medium and high) while the StealthTrac Lead remains in place."
75636011|NCT03712527|Other|Injection of NaCl|The placebo will be a single-dose of saline solution which corresponds to NaCl 0,9% ProAmp 10 ml (Laboratoire Aguettant). The vials will be kept at room temperature (≤ 25°C) within the local pharmacy of each centre. 2 mL of this solution will be intra-discal injected.
75636012|NCT03703765|Device|lower limb volume estimation|"The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort."
75785490|NCT03371407|Other|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
75921835|NCT03389126|Drug|Avelumab|Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
75341442|NCT01579513|Drug|Placebo|Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
75469588|NCT01940692|Drug|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
75469589|NCT01940692|Drug|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
75469590|NCT01940718|Drug|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
75636013|NCT03646487|Dietary Supplement|Probiotic LP299v 10x10 colony forming units in capsule form|Daily lactobacillus plantarum (LP299v) 10x10 colony forming units in capsule form
75636014|NCT03646487|Other|Placebo in capsule form|Daily placebo in capsule form
75785491|NCT03370133|Drug|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
75785492|NCT03370133|Drug|Ustekinumab|Ustekinumab will be provided as dose 1 for subjects weighing <=100 kg and as dose 2 for subjects weighing >100 kg at pre-specified time intervals.
75921836|NCT04446104|Drug|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
75785493|NCT03370133|Other|Placebo|Subjects will receive Placebo at pre-specified time points.
75921837|NCT04446104|Drug|Ivermectin 3mg Tab|Ivermectin tablet 12mg single dose
75785494|NCT03312569|Procedure|Right Colectomy with Intracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. The right mesocolon is mobilized and the ileal mesentery is divided. The transverse colon and ileum are then divided with the stapler. Next, attention is turned to constructing the anastomosis. For this purpose, the terminal ileum and the transverse colon stump are brought together. A colotomy and ileostomy is created to form a common channel. The common enterotomy is then closed as per the surgeon's standard of care. The specimen is extracted through an off-midline incision (muscle splitting transverse incision, Pfannenstiel).
75921838|NCT04446104|Drug|Zinc|Zinc tablet 80 mg/vitamin C 500mg daily for 42 days
75921839|NCT04446104|Drug|Povidone-Iodine|Povidone-iodine throat spray (3 times daily) for 42 days
75921840|NCT04446104|Dietary Supplement|Vitamin C|Vitamin C tablet 500mg daily for 42 days
75921841|NCT03385070|Diagnostic Test|Lens examination|The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.
76078472|NCT04387617|Drug|Placebo|The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
76078473|NCT03014830|Drug|Alirocumab|150 mg SQ every 2 weeks
76078474|NCT03014830|Drug|Placebos|Placebo injections SQ every 2 weeks
76078475|NCT05237193|Diagnostic Test|The level of CIN|The extracted DNA from bile will be analyzed by UCAD to determine the level of CIN. And the patient will be followed for up to 2 years.
76078476|NCT03984669|Diagnostic Test|The Juvenile Disease Activity Score (JADAS)|The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.
75636015|NCT03634397|Behavioral|Less-Impaired Arm Training|Participants receive virtual reality and manipulation training in their less impaired arm.
75636016|NCT03634397|Behavioral|Contralesional Arm Comparison|Participants receive therapy in their paretic arm, based on the best-practices framework for arm recovery post stroke.
75785495|NCT03312569|Procedure|Right Colectomy with Extracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. Intracorporeal devascularization may be performed at the surgeon's discretion. The gastrocolic ligament is taken down and the hepatic flexure is mobilized. After complete mobilization of the right colon, the midline incision is extended to serve as the extraction site. The specimen is delivered through the midline extraction incision and the anastomosis is conducted in a standard open technique. The two cut ends of the bowels are aligned for extracorporeal anastomosis.
76078477|NCT03984669|Biological|(1-3)-ß-D-Glucan (BDG) assay (Fungitell)|Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers
75469591|NCT01940731|Drug|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
75636017|NCT03606421|Radiation|SRS and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
75636018|NCT03606421|Radiation|WBRT and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
75636019|NCT03582189|Other|MRI|Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
75636020|NCT03562416|Drug|Nintedanib|Nintedanib (BIBF 1120, Ofev)
75636021|NCT03562416|Drug|Placebo Oral Tablet|Placebo
75636022|NCT03518736|Behavioral|Supporting Play Exploration and Developmental Intervention (SPEEDI)|Physical Therapy intervention
75636023|NCT03512262|Drug|Abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
75785496|NCT03304717|Drug|Tenofovir (TDF) and Emtricitabine (FTC)|"Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.~Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase."
75785497|NCT03304717|Other|Placebo|Placebo for Tenofovir and Placebo for Emtricitabine
75921842|NCT05346718|Other|Ragweed pollen, birch pollen, clean air (placebo)|Participants are exposed for 4 hours in the Fraunhofer Allergen Challenge Chamber with varying pollen concentrations of ragweed or birch pollen and once with clean air, serving as a placebo exposure.
75921843|NCT03389048|Device|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
75921844|NCT03389048|Diagnostic Test|SLR|With the patient lying down on his/her back, the examiner lifts the patient's leg while the knee is straight.
75921845|NCT03388970|Drug|Vitamin K 1|Research group use Vitamin K1
75636024|NCT03512262|Drug|Placebo|Abaloparatide-matched placebo.
75636025|NCT03499600|Behavioral|Clinical Assessment and CFI|CA and CFI families will participate in the Cultural Formulation Interview prior to their standard intake.
75636026|NCT03499600|Behavioral|Clinical Assessment|CA families will participate their standard intake procedures.
75636027|NCT03494153|Other|Non applicable - Non interventional study|Non interventional study
75636028|NCT03481777|Device|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.
75636029|NCT03481777|Device|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
75636030|NCT03396211|Drug|Apatinib|Apatinib tablets
75636031|NCT03396211|Drug|Nivolumab|Fixed dose of nivolumab given intravenously every 2 weeks
75636032|NCT03326167|Other|Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)|Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
75636033|NCT03301896|Drug|LHC165|LHC165 intratumoral injection
75636034|NCT03301896|Biological|PDR001|PDR001 infusion
75636035|NCT03269084|Other|No intervention. DIPP is an observational study.|
75636036|NCT03268993|Dietary Supplement|Avmacol|Avmacol is a dietary supplement available over the counter
75636037|NCT03260322|Drug|ASP8374|intravenous
75636038|NCT03260322|Drug|Pembrolizumab|intravenous
75636039|NCT03233256|Procedure|Feasibility of measuring 2H:1H and 18O:16O in saliva and breath.|The investigators propose to demonstrate the feasibility of measuring 2H:1H and 18O:16O in saliva and breath. The natural abundances of 2H:1H and 18O:16O of urine, saliva, and breath samples will be determined from samples obtained simultaneously from 50 relatively healthy human subjects. We will also measure 2H:1H and 18O:16O enrichments in urine, saliva, and breath of 10 relatively healthy human subjects obtained after consuming a standard DLW dose and compare the estimates of TDEE using these different matrices.
75636040|NCT03229551|Drug|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
75921846|NCT03388970|Drug|normal saline|Placebo group use normal saline
75636041|NCT03229551|Drug|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
76078478|NCT04277403|Radiation|Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.
76078479|NCT04277403|Radiation|Single session or hypofractionated stereotactic radiosurgery|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
76078480|NCT03014596|Other|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
76078481|NCT04365465|Device|NSS-2 Bridge|The NSS-2 BRIDGE (Appendix 1) is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs.
76078482|NCT04365465|Device|Inactive NSS-2 Bridge|This is a sham device which is identical to the active NSS-2 Bridge, but will not provide percutaneous auricular nerve field stimulation when applied.
75636042|NCT03218085|Drug|Tenofovir|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
75636043|NCT03218085|Drug|Emtricitabine|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
75636044|NCT03197077|Procedure|blood sampling|comparison between corifollitropin alfa and follitropin beta in IVM cycles
75636045|NCT03197077|Procedure|transvaginal ultrasound scanning|comparison between corifollitropin alfa and follitropin beta in IVM cycles
75636046|NCT03197077|Procedure|oocyte retrieval for IVM|comparison between corifollitropin alfa and follitropin beta in IVM cycles
75636047|NCT03197077|Drug|Corifollitropin Alfa|Single injection of 100 micrograms of corifollitropin alfa
75636048|NCT03197077|Drug|Follitropin beta|Daily injection (three days) of follitropin beta
75636049|NCT03197077|Drug|oral contraceptive pill pretreatment (Marvelon)|Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
75921847|NCT04799210|Device|Eximis CS (Contained Segmentation) System|Containment, segmentation and extraction of uterine tissue in pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.
75921848|NCT04735094|Diagnostic Test|Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope|A small balloon made of latex can be attached to the tip of echo-bronchoscope which is then inflated with water or saline for better apposition of the echo-endoscope and the airway wall. This may improve ultrasound image quality and aid better visualization of the lymph nodes.
75921849|NCT00616941|Biological|NY-ESO-1 OLP4|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of 5% dextrose in water (D5W) and administered subcutaneously as a single injection.
75921850|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of D5W, mixed with 0.5 mL of Montanide, and administered subcutaneously as a single injection.
75921851|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) and 1.4 mg of poly-ICLC were emulsified in 1.0 mL of Montanide and administered subcutaneously as two injections.
76078483|NCT04365465|Other|Active control|Active control will include standard of care pain management during the postoperative period. Participants in this intervention arm will not receive or wear a device.
75636050|NCT03165487|Other|Breast tissue collection|During Breast Conservation Surgery, one sample will be collected before and after IORT.
75636051|NCT03165487|Other|Blood sample collection|Blood will be collected before and after IORT, and at the two week follow-up.
75636052|NCT03158922|Genetic|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
75636053|NCT03158922|Other|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
75636054|NCT03158922|Procedure|Prostate biopsy|Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
75636055|NCT03136562|Diagnostic Test|Synacthen test|250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
75636056|NCT03112369|Behavioral|Narrative Exposure Therapy (NET)|An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
75636057|NCT03112369|Behavioral|Motivational Interviewing w/Skills Training (MIST)|Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
75636058|NCT03096509|Other|MISSION ABC Integrated Care clinic|The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs.
75636059|NCT03078855|Dietary Supplement|Vitamin D|vitamin D3 2,000 IU daily
75636060|NCT03078855|Biological|Rituximab|Administered weekly x 4
75921852|NCT00105560|Radiation|radiation therapy|Radiation therapy with proton beam to standard doses
75921853|NCT05695066|Procedure|Preoperative fasting instruction|Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
75921854|NCT05694988|Device|Efferon CT|Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.
75329210|NCT04374929|Device|Two StealthTrac Temporary Pacing Leads (Increased Electrode Spacing)|"Once the first StealthTrac Lead is placed using the procedure described in the AtaCor Temporary Pacing System Instructions for Use (DOC-10085), load a second StealthTrac Lead into the same MACH I Delivery Tool, unless it was damaged during insertion of the first StealthTrac Lead, in which case a new MACH I Delivery Tool should be used.~Insert the second StealthTrac Lead through (1) a different intercostal muscle path within the same intercostal space or (2) within an adjacent intercostal space. Increased electrode spacing is achieved by pacing between the leads."
75329211|NCT04374929|Device|StealthTrac Lead Only (Control)|A single StealthTrac Lead is placed with no additional treatment.
75636061|NCT03078855|Other|Placebo|methylcellulose
75921855|NCT03393104|Behavioral|Motor Control Exercise|Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.
75921856|NCT03393104|Behavioral|Patient Education|Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
75921857|NCT03388892|Device|paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)|Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
75636062|NCT03066349|Other|Questionnaires|FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires
75636063|NCT03055923|Device|The Inflammacheck Device|A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
75636064|NCT03007979|Drug|Palbociclib|Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule
75636065|NCT03007979|Drug|Letrozole|Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
75636066|NCT03007979|Drug|Fulvestrant|Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
75785498|NCT03297788|Radiation|SRS|"For SRS the dose prescription to the PTV will be as follows:~20 Gy to the 70%-isodose (lesions < 2 cm max. diameter)~18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~6 x 5 Gy to the conformally surrounding isodose (lesions > 3 cm max. diameter)"
75785499|NCT03297788|Radiation|WBRT|WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
75785500|NCT03242161|Diagnostic Test|LabPatch-alcohol|a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
75785501|NCT03240614|Device|Non-rebreather oxygen mask|This intervention will be preoxygenation using a Non-rebreather that will be placed upon the participant for preoxygenation. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After 3 minutes, an ABG will be taken and labeled as Intervention A.
75921858|NCT03388892|Device|Plain Balloon|Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
76078484|NCT04398615|Device|Wearable watch device|Every study participant will be given a wearable watch device at the beginning of the study and will be instructed on how to use the device and to wear it continuously throughout the duration of the study (6 months total follow-up). The device will register biometric data and automatically archived. During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.
76078485|NCT01055704|Drug|Methylnaltrexone only|0.30 mg/kg subcutaneous injection daily
76078486|NCT01055704|Drug|Codeine only|30 mg taken orally four times daily for 5 days
75329212|NCT05717361|Drug|ketamine-lidocaine|"In the KL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine at predefined concentrations.~As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution"
75329213|NCT05717361|Drug|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
75636067|NCT03007979|Procedure|Optional research biopsy|Patients may consent to paired tumor biopsies at baseline and time of progression.
75636068|NCT03007979|Drug|Goserelin|Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.
75636069|NCT03007979|Procedure|Research blood draw|"-Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~Baseline~C1D15~C2D1~Every 2-3 months thereafter (to coincide with imaging studies)~Time of progression"
75636070|NCT03007979|Procedure|Circulating tumor cell blood draw|-Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression
75636071|NCT03007979|Procedure|Tumor biopsy (optional)|-Baseline and progression
75636072|NCT02960893|Drug|Troriluzole|Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
75636073|NCT02960893|Drug|Placebo|Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
75636074|NCT02960893|Drug|Troriluzole|Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
75636075|NCT02912572|Drug|Avelumab|Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment
75785502|NCT03240614|Device|Bag-valve-mask|This intervention will be preoxygenation using a BVM apparatus for preoxygenation for 3 minutes. At the end of 3 minutes an ABG will be obtained.
75921859|NCT02577718|Drug|Nitroglycerin-citrate-ethanol (NiCE)|Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
75785503|NCT03240614|Device|High Flow Nasal Cannulae|This intervention will be preoxygenation using High Flow Nasal Cannulaes at an FiO2 of 100%. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After the 3 minutes, an ABG will be taken and labeled as Intervention C.
75785504|NCT03227991|Behavioral|Safety Planning Intervention|The Safety Planning Intervention is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings. It involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis.
75785505|NCT03227991|Behavioral|Risk factors and Warning signs|Printed information sheet listing suicide risk factors and crisis hotlines
75785506|NCT03227757|Device|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
75921860|NCT00520533|Biological|Chimeric monoclonal antibody cG250|"First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st & 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (124I-cG250).~Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No 124I-cG250 will be used in the 2nd cycle.~Up to 2 cycles available."
75921861|NCT00520533|Drug|Sunitinib malate|"First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.~Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.~Up to 2 cycles available on-study."
75636076|NCT02912572|Drug|Talazoparib|Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days
75921862|NCT03388814|Drug|Local infiltration of bupivacaine|Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
75636077|NCT02912572|Drug|Axitinib|Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days
75636078|NCT02867813|Biological|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
75636079|NCT02829606|Other|small scotoma using Head Mounted Display No re-mapping|re-mapping software turned off
75636080|NCT02829606|Other|Large scotoma using Head Mounted Display PLUS re-mapping|re-mapping software turned on
75636081|NCT02813083|Other|No intervention (observational)|No intervention (observational)
75636082|NCT02737787|Biological|WT1 Vaccine|
75636083|NCT02737787|Drug|Nivolumab|Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
75636084|NCT02737787|Biological|NY-ESO-1 Vaccine|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.
75636085|NCT02701712|Radiation|Magnetic resonance - guided radiation therapy (MRgRT)|Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
75636086|NCT02494570|Drug|nab-Sirolimus|Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
75785507|NCT03224000|Procedure|Modified Barium Swallow (MBS)|Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
75785508|NCT03224000|Behavioral|Swallowing Questionnaire|Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
75785509|NCT03224000|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
75785510|NCT03224000|Procedure|Video-Strobe Procedure|Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
76078487|NCT01055704|Drug|Methylnaltrexone + codeine|Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
76078488|NCT01055704|Drug|Placebo + placebo|Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
76078489|NCT03280017|Drug|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
76078490|NCT03280017|Drug|Normal saline|normal saline infusion
75329214|NCT02951884|Procedure|Aspiration|A needle is placed into the knee joint and all of the blood that is in the joint is removed.
75636087|NCT02437071|Drug|Pembrolizumab|Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
75636088|NCT02437071|Radiation|Radiotherapy|
75636089|NCT02437071|Procedure|Radiofrequency ablation|
75785511|NCT03224000|Procedure|MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned with MRI guidance.
75785512|NCT03224000|Procedure|Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned by standard-of-care.
76078491|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 6 months
76078492|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 6 months
75329215|NCT02951884|Drug|Bupivacaine|An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
75329216|NCT05701683|Drug|Lactobacillus Reuteri Probiotic|Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy
75329217|NCT05700591|Drug|rhPro-UK|35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes
75921863|NCT03388814|Drug|Pectoralis Nerve block|Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
75785513|NCT03224000|Radiation|Intensity Modulated Radiotherapy (IMRT)|Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
75329218|NCT05700591|Drug|rt-PA|0.9 mg/kg (maximum 90 mg), with 10% administered intravenously as a bolus, followed by 90% infusion within 1 hour
75921864|NCT04680988|Drug|SHR-1210|SHR-1210 intravenously every 3 weeks
75329219|NCT03021538|Device|Extracorporeal Membrane Oxygenation|ECMO is used during lung transplant procedure
75329220|NCT03021538|Device|Cardiopulmonary Bypass|CPB is used during lung transplant procedure
75329221|NCT00374374|Behavioral|Administration of probiotic|
75329222|NCT02834806|Device|BioNIR Ridaforolimus Eluting Coronary Stent System|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
75329223|NCT02835274|Device|BSC Deep Brain Stimulation System with Directional Lead|
75329224|NCT05577663|Other|Routine treatment of the extraction socket|Suturing of the extraction socket with resorbable suture PGA 5/0 in order to protect the blood clot
75329225|NCT05577663|Procedure|Socket seal technique by a free gingival graft|Placement of a free gingival graft in the socket opening in order to protect and stabilize the blood clot followed by suturing
75329226|NCT05577663|Procedure|Socket seal technique using a synthetic resorbable membrane|Placement of a synthetic barrier in the socket opening in order to protect and stabilize the blood clot followed by suturing
75329227|NCT02836990|Device|Prevena Incision Management System|A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
75329228|NCT02836990|Device|Dermabond|A surgical skin adhesive used to prevent surgical wound infections
75329229|NCT05697393|Device|Shaker Pressure Band|
75329230|NCT02841046|Device|cardiac index|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.
75329231|NCT02841046|Device|Stroke Volume Variation|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
75469592|NCT01940744|Procedure|Prescriptive Mobilization|"The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits."
75785514|NCT03221751|Drug|prazosin hydrochloride|Prazosin is an oral capsule. It is an alpha-1 antagonists.
75785515|NCT03221751|Drug|placebo|Placebo is an inert oral capsule identical in appearance to prazosin capsules.
75785516|NCT03221517|Other|Standardized meal with a glucose challenge test|Postprandial glucose and insulin response
75785517|NCT03182296|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
75329232|NCT05717127|Behavioral|Time restricted feeding|Restricted feeding with 20 hours of fasting and a 4 hour window of feeding (between 4 and 8 PM or between 5 to 9 PM).
75785518|NCT03157674|Other|Non-Interventional|Non-Interventional
75785519|NCT03149549|Drug|CX-2009|CX-2009 Monotherapy
75785520|NCT03127722|Procedure|Blood draw|Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
75785521|NCT03127722|Device|ESSURE (BAY1454032)|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
75785522|NCT03127722|Procedure|Laparoscopic tubal sterilization|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
75785523|NCT03125070|Other|Best Practice and Internet site with links to existing resources|Receive usual care
75785524|NCT03125070|Other|Internet, Mobile app and Telehealth Intervention|Receive INSPIRE and survivorship care plan
75785525|NCT03125070|Other|Survey Administration|Ancillary studies
75785526|NCT03093116|Drug|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005) capsules.
75921865|NCT04680988|Drug|SHR-1020|SHR-1020 Orally once daily
75921866|NCT04680988|Drug|Physician's choice chemotherapy|Investigators will declare one of the following regimens:Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection
75921867|NCT05174390|Diagnostic Test|Coala Heart Monitor Pro|thumb- and chest-ECG
75329233|NCT05717127|Behavioral|Standard lifestyle|Standard lifestyle recommendations
75329234|NCT05694273|Procedure|Radiofrequency catheter ablation|Catheter ablation has traditionally been used primarily in isolated Supraventricular tachycardias (SVT), atrioventricular nodal reentry tachycardias (AVNRT) are the most common paroxysmal SVTS. In recent years, the pathophysiological understanding of SVTS and catheter ablation have steadily advanced. Radiofrequency catheter ablation currently dominates AVNRT due to the high recurrence rate after cryoablation.
75329235|NCT05716971|Procedure|Densiron-68 (heavy silicone oil) tamponade for retinal detachment|pars plana vitrectomy using Densiron-68 at thee end of surgery
75329236|NCT03022396|Biological|High Dose Fluzone® (intramuscular)|Licensed seasonal High dose trivalent inactivated influenza
75329237|NCT03022396|Biological|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza
75636090|NCT02396823|Behavioral|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
75636091|NCT02389387|Other|Intensive Intervention|I.A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX):1) real-time communication between staff across healthcare settings, documenting the use of transplant education materials, 2) sending/receiving electronic referrals for transplant specific to a transplant center's requirements and 3) tracking patients' status in the transplant process (e.g., patient interest in transplant, referral for transplant, evaluation start/completion, waitlist status, and transplant) II. Educational webinars/seminars for staff, III. Facility-specific performance feedback reports, IV. Assistance with and review of center-specific action plans to increase transplant referral, V. Scheduled bi-annual phone calls with an SETC member to monitor progress, VI. Patient education on transplant via creation of an Education Station in facility lobby, VII. Development of a Peer Mentor program.
75636092|NCT02341274|Drug|Tacrolimus|Bioequivalence study
75329238|NCT05694117|Behavioral|self-determine sequence exercise program|The Taichi exercise utilized the simplified eight styles of Taichi. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
75329239|NCT05694117|Behavioral|resistance training|The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions). Participants in the RTG completed four sets of each movement, with two to three minutes of rest between each set.
75329240|NCT05694117|Behavioral|Taichi exercise and resistance training|The training of the Taichi exercise and resistance training group consisted of two cycles, the first cycle was aimed at learning and consolidating Taichi exercise, and the second cycle was aimed at improving and consolidating. The Taichi exercise and resistance training group was scheduled for 30 min of Taichi exercise per training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
75636093|NCT02327481|Procedure|3D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
75469593|NCT01940744|Procedure|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
75636094|NCT02327481|Procedure|2D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
75636095|NCT02278055|Drug|Radium-223|
75636096|NCT02231879|Drug|Plerixafor|Twice daily low dose injection for 14 months.
75636097|NCT02231879|Drug|G-CSF|Twice daily low dose injection for 14 months.
75636098|NCT02118649|Behavioral|Game|
75636099|NCT02111018|Device|CytoSorb Device|
75636100|NCT02111018|Procedure|CVVH|
75636101|NCT01968460|Drug|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
75636102|NCT01968460|Drug|Placebo|placebo
75636103|NCT01968460|Drug|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
75636104|NCT01863056|Other|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
75636105|NCT01833806|Device|ExAblate MRgFUS|Focused Ultrasound Ablation
75636106|NCT01761929|Radiation|Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
75636107|NCT01712490|Drug|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
75636108|NCT01712490|Drug|doxorubicin|Doxorubicin: 25 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
75636109|NCT01712490|Drug|bleomycin|Bleomycin: 10 units/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
75636110|NCT01712490|Drug|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
75636111|NCT01712490|Drug|dacarbazine|Dacarbazine (DTIC): 375 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
75636112|NCT01527747|Drug|Saxagliptin|5 mg daily
75636113|NCT01439802|Device|Copper IUD placement at time Cesarean Delivery (Copper T 380A)|Placement of Paragard IUD at time of Cesarean Delivery
75636114|NCT00932581|Other|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
75636115|NCT00932581|Other|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
75636116|NCT00646230|Drug|fenretinide|
75636117|NCT00646230|Other|high performance liquid chromatography|
75636118|NCT00646230|Other|pharmacological study|
75636119|NCT00544414|Drug|cisplatin|
75636120|NCT00544414|Drug|docetaxel|
75636121|NCT00544414|Drug|fluorouracil|
75636122|NCT00544414|Drug|gemcitabine hydrochloride|
75636123|NCT00544414|Drug|leucovorin calcium|
75636124|NCT00544414|Genetic|gene expression analysis|
75636125|NCT00544414|Genetic|protein expression analysis|
75636126|NCT00544414|Other|laboratory biomarker analysis|
75636127|NCT00544414|Procedure|adjuvant therapy|
75636128|NCT00544414|Procedure|biopsy|
75636129|NCT00544414|Procedure|conventional surgery|
75785527|NCT03058796|Device|Contralaterally Controlled Functional Electrical Stimulation (CCFES)|The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
75785528|NCT03058796|Device|Hand Therapy Video Games|The use of video games with CCFES to encourage therapeutic hand movement at home
75921868|NCT02289144|Drug|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
75636130|NCT00544414|Procedure|neoadjuvant therapy|
75636131|NCT00544414|Procedure|quality-of-life assessment|
75636132|NCT00544414|Radiation|radiation therapy|
75636133|NCT00261456|Behavioral|PSA test|Patients tested for their level of Prostate Specific Antigen.
75636134|NCT00261456|Procedure|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
75636135|NCT00816556|Drug|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
75636136|NCT00816556|Drug|Estradiol valerate|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
75636137|NCT00816556|Drug|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
75636138|NCT04100473|Drug|Inhaled Human Insulin|Dance 501 administered using the Dance 501 Inhaler
75636139|NCT04100473|Drug|Insulin Lispro (Humalog U-100)|Lispro
75636140|NCT02797197|Procedure|handgrip strength test|
75636141|NCT02797197|Drug|chemotherapy|
75636142|NCT04235127|Other|sociodemographic variables, somatic conditions, mental disorders, treatment and drug use|"sociodemographic variables~history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.~prescriptions for psychopharmacological products~the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide"
75636143|NCT02796807|Drug|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
75636144|NCT02796729|Procedure|Magnetic resonance imaging|MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.
75785529|NCT03014167|Drug|Albendazole|All eligible individuals will receive a single dose of 400 mg albendazole.
75785530|NCT02984735|Other|Evaluation|Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
75785531|NCT02931695|Other|evaluation of QT interval duration|ECG to evaluation of QT interval duration
75921869|NCT03388736|Behavioral|Supplementary Medicine|A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
76078493|NCT01882439|Other|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
75785532|NCT02931695|Other|circulating sex hormones levels sample|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
75785533|NCT02918435|Behavioral|WE CARE|The WE CARE (Well-child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) survey consists of 12 questions used to identify six unmet material needs (education, employment, food security, housing, childcare, household utilities). It will be administered at health supervision visits during the WE CARE phase at each study site. The Family Resource Book will contain resource information sheets for each of these needs listing available community resources. A physician champion will conduct regular booster sessions every 4 months and train new providers should there be staff turnover.
75921870|NCT03544983|Behavioral|Web + Streamlined Telephone Genetic Counseling|Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
75921871|NCT05340244|Device|Investigational ultrasound exam|"Eligible subjects will be enrolled into the study and positioned for their ultrasound exam. Standard clinical practice procedures will be followed using the standard of care device at the site to complete the clinically indicated exams.~After the clinically indicated exam, portions of the TTE and/or TEE exam will be repeated with the investigational ultrasound device."
75921872|NCT03393026|Drug|Lurasidone|Lurasidone 40-160 mg/day for 6 weeks
75921873|NCT03384992|Other|Diaphragmatic breathing and relaxation|Education on physiological effects of anxiety, instructions in diaphragmatic breathing and relaxation techniques, and audio-recordings 5-15 minutes in length that provide guided relaxation exercises (autogenic, imagery-based and progressive muscle relaxation).
75636145|NCT02796729|Drug|Gadovist (Gadobutrol)|Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
75921874|NCT03384992|Other|Cognitive restructuring|Education on the thought-emotion connection and exercises designed to better understand cognitions associated with increased anxiety and tools to evaluate and replace anxiety-generating cognitions. Includes an interactive tool (thought record) participants complete to facilitate this process.
75921875|NCT03384992|Other|Scheduled worry practice|Education on the association between avoidance and increased anxiety, and instructions on actively thinking about feared events to reduce avoidance and engage healthy coping strategies. Interactive tool includes a video-based guided worry practice session and an interactive worksheet and timer.
75921876|NCT03384992|Other|Telephone coaching|BCS will receive 5 TeleCoaching calls over a period of 4 weeks, to include one introductory phone call, followed by 4 calls focused each week on the current CSM; if the participant is not randomized to a CSM, TeleCoaching will provide reflective listening and encouragement.
75921877|NCT03384992|Other|Usual care|Includes general health, diet-general information and diet-BCSS (breast cancer survivor-specific) information.
75921878|NCT02144415|Drug|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
75921879|NCT02144415|Drug|EB-1020 800 mg|8 x EB-1020 100-mg capsules
75921880|NCT02144415|Drug|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
75329241|NCT05694117|Behavioral|Randomly selected exercise program|Participants in the randomly selected exercise program group who chose Yijinjing exercise were required to complete one hour of Yijinjing exercise training, and those who chose Yijinjing exercise hybrid strength training had to complete half an hour of Yijinjing training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
75329242|NCT05574387|Drug|Metformin|Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver.Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)
75636146|NCT02796729|Drug|50% dextrose solution|50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
75785534|NCT02914899|Behavioral|Surveys|"Intake surveys recorded demographics, workplace profile, financial profile, health care access, cancer screening behavior, medical history, etc.~Exit surveys asked whether drivers received shared decision making (SDM) counseling, completed LCS (low-dose computed tomography [LDCT] scan), had barriers, felt satisfied, etc."
75636147|NCT00760747|Drug|Atomoxetine|1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
75636148|NCT02802579|Radiation|standard protocol|tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
75636149|NCT02802579|Radiation|enhanced protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
75785535|NCT02914899|Behavioral|Navigation|CHWs facilitated SDM and LCS for drivers, providing navigation ( finding a PCP, scheduling appointments, assisting with insurance, etc.), following up on results and next steps.
75785536|NCT02914899|Behavioral|Focus groups|Gained drivers' perspectives on adapting the community health worker (CHW) model to facilitate lung cancer screening (LCS).
75921881|NCT02144415|Drug|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
75921882|NCT02144415|Drug|Placebo|8 x matching placebo capsules
76078494|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 3 months
75636150|NCT02802579|Radiation|enhanced obesity protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
75785537|NCT02914899|Behavioral|In-depth interviews|"Interviews with Chinese livery bases elicited perspectives on adapting the CWH model for the drivers' occupational environment.~Interviews with PCPs, clinic directors, etc. serving Chinese communities provided insight into adapting the CHW model within the health care context."
76078495|NCT01882439|Other|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
76078496|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 3 months
76078497|NCT05236491|Biological|COVID-19 vaccine|Participants are to receive a booster dose of a COVID-19 vaccine.
75785538|NCT02909127|Other|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
75921883|NCT01664104|Drug|Tocilizumab|Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
75921884|NCT03392870|Other|Integrative interventional programme|The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.
75921885|NCT03392870|Other|As usual|The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.
75636151|NCT02794467|Drug|Epelsiban|Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing
75921886|NCT02739984|Biological|Evolocumab|Administered by subcutaneous injection with an automated mini doser
75921887|NCT02739984|Drug|Placebo to Evolocumab|Administered by subcutaneous injection with an automated mini doser
75636152|NCT02794467|Drug|Placebo|A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.
75636153|NCT02796417|Behavioral|REHACOP|REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas
75636154|NCT02796417|Behavioral|Occupational activities|Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
75636155|NCT02796495|Device|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
75636156|NCT00760669|Drug|Infliximab; observational study|This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
75921888|NCT03545529|Other|Innovativ supported|addition of connected tools and stronger accompaniment to prevent falls
75921889|NCT02254161|Drug|Matching placebo|Tablet
75921890|NCT02254161|Drug|BI 1181181 healthy elderly|Tablet
75921891|NCT02254161|Drug|BI 1181181 Healthy young|Tablet
75921892|NCT02140749|Dietary Supplement|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
75921893|NCT02140749|Dietary Supplement|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
75921894|NCT02140749|Dietary Supplement|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
75921895|NCT02140749|Dietary Supplement|Placebo|Chewing tablets without short-chain Fructooligosaccharides
75921896|NCT00496730|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
75921897|NCT00496730|Drug|Comparator: atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
76078498|NCT02246686|Drug|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
76078499|NCT02246686|Drug|Placebo|Application over 12 weeks 20 drops three time daily
75329243|NCT03023176|Biological|Fluzone® standard IIV3|Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
75469594|NCT01940783|Radiation|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
76078500|NCT04400019|Drug|Hydroxychloroquine Only Product in Oral Dose Form|The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
76078501|NCT01055782|Device|Endoguide|Use of endoguide to facilitate completion of endoscopy
76078502|NCT05225805|Drug|Lefamulin|Antibiotic
75329244|NCT03023176|Biological|Fluzone® standard IIV3 Pediatric Dose|Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
75329245|NCT03839745|Other|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
75329246|NCT04366505|Behavioral|Treatment as usual (TAU) and neurofeedback (NFB)|This group will receive Treatment as usual (TAU) and neurofeedback (NFB). During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as target region.
75785539|NCT02909127|Other|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
75921898|NCT02140827|Other|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
75921899|NCT04467372|Dietary Supplement|Tart cherry juice concentrate|Two 8oz bottles of tart cherry juice concentrate daily for 30 days
75921900|NCT04467372|Dietary Supplement|Juice placebo|Two 8oz bottles of placebo juice daily for 30 days
75329247|NCT04366505|Behavioral|mindfulness-based relapse prevention (MBRP) and NFB|This group will receive MBRP and neurofeedback (NFB). MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as a target region.
75329248|NCT04366505|Behavioral|TAU and sham NFB|This group will receive TAU and sham NFB. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
75329249|NCT04366505|Behavioral|MBT and sham NFB|This group will receive MBRP and sham NFB. MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
75329250|NCT03023488|Procedure|flexible ureteroscopy|Flexible ureteroscopy is an endourological procedure performed for kidney stones. The flexible ureteroscope is a device used to reach the renal cavities through the natural urinary tract in a retrograde fashion. During the operation, irrigation fluid is used to expand the cavities to provide space for movement of the device and also to provide clear vision.
75921901|NCT04467372|Dietary Supplement|Freeze dried tart cherry powder|Two freeze dried tart cherry powder capsules daily for 30 days
75921902|NCT04467372|Dietary Supplement|Capsule placebo|Two placebo capsules daily for 30 days
75329251|NCT03023488|Device|Doppler Ultrasound examination|peak systolic velocities (PSV) and end diastolic velocities (EDV) of the arteries will be measured and then resistive index (RI) and pulsatility index (PI) will be calculated.
75329252|NCT03023488|Device|laser lithotripsy|The laser fiber extending into the cavities through the working channel of the ureteroscope is used to fragment the stones. Laser energy is generated by the laser machine and transmitted to the stones via the laser fiber.
75329253|NCT04376645|Procedure|Mandibular Setback with maxillary impaction|Occlusal bite force will be measured after surgery to correct vertical disproportions
75329254|NCT04376645|Procedure|Mandibular setback only|Occlusal bite force will be measured after surgery without changing vertical disproportions.
75329255|NCT02977923|Device|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
75469595|NCT01940783|Device|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
75636157|NCT00760669|Drug|Methotrexate; observational study|Participants with RA will receive methotrexate based on physician's clinical judgement.
75636158|NCT02802267|Drug|Inecalcitol|vitamin D receptor agonist
75785540|NCT02909127|Other|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
75636159|NCT02802267|Drug|Placebo Oral Tablet|placebo
75636160|NCT02794623|Device|Tinnitus masking|Tinnitus masking via CI system
75636161|NCT04235049|Drug|Glecaprevir/pibrentasvir|Treatment for HCV Infection
75636162|NCT02802189|Other|Exercise programme|"Endurance and Resistant training exercise program (Duration: 45 minutes)~Muscle retraining of longus colli and endurance training of the deep cervical flexors.~Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~Active ROM exercises for the neck muscles~Upper limbs exercises with resistant bands~Stretching exercises for the neck and upper limbs muscles"
75785541|NCT02883530|Procedure|Bronchoscopy|Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
75785542|NCT02879617|Drug|durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
75921903|NCT00446186|Drug|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
75921904|NCT00446186|Drug|Comparator: placebo / Duration of Treatment: 2 Weeks|
75921905|NCT02140983|Drug|Liraglutide|90 days of liraglutide up to 1.8mg/day.
75921906|NCT02140983|Drug|Placebo|Placebo medication
75921907|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation A|
75921908|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation B|
75921909|NCT00394160|Drug|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
75921910|NCT02144493|Other|The existence of periampullary diverticulum|Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
75921911|NCT02144493|Other|CBD angle|Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
75921912|NCT03392792|Drug|tissue plasminogen activator|role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
75921913|NCT03392792|Procedure|thrombectomy|role of thrombectomy in patient with acute ischemic stroke
75329256|NCT02977923|Other|Standard pharmacological treatment|according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
75329257|NCT04374851|Device|Polaris miniRITE BTE|The Polaris device is programmed with computer software to match the Hearing loss of the participant.
75636163|NCT02802189|Other|Integrated Neuromuscular Inhibition Technique application.|"Integrated Neuromuscular Inhibition Technique application.~(Duration: 15min)~The protocol was applied to the following muscles:~Upper border of the trapezius muscle~sternocleidomastoid~levator scapulae muscle~splenius capitis muscle~Integrated Neuromuscular Inhibition Technique includes the combination of the following technique:~Ischemic compression~Muscle energy technique~Strain-counterstrain technique"
75636164|NCT02796339|Dietary Supplement|Mastiha|
75636165|NCT02796339|Dietary Supplement|Placebo|
75636166|NCT02796183|Drug|Subconjunctival bevacizumab (Altuzan)|Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
75636167|NCT02796105|Drug|Progevera|
75636168|NCT02796105|Drug|Orgalutran|
75636169|NCT02794701|Other|People with silicosis|
75636170|NCT02794545|Procedure|cART course|The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
75636171|NCT02795949|Drug|Antipseudomonal beta-lactam antibiotic|Pharmaceutical form: solution for infusion
75636172|NCT02795949|Drug|De-escalation(short-spectrum antibiotic)|Pharmaceutical form: solution for infusion
75636173|NCT00769483|Drug|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
75636174|NCT00769483|Drug|Gemcitabine|1000 mg/m^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
75636175|NCT00769483|Drug|Erlotinib|100 mg by mouth daily.
75785543|NCT02874365|Procedure|Endoscopic biopsies|intestinal biopsies
75785544|NCT02836067|Behavioral|Counseling|Smoking cessation counseling
75785545|NCT02836067|Other|Smoking Cessation drugs|Medication to aid smoking cessation
75785546|NCT02836067|Procedure|Bronchoscopy|Bronchoscopy
75785547|NCT02836067|Procedure|Blood Draw|Screening and research blood draws
75921914|NCT02739828|Biological|Adalimumab|Adalimumab
75329258|NCT04374851|Device|Viron miniRiTE BTE|The Viron Hearing device is programmed with computer software to match the Hearing loss of the participant.
75329259|NCT03024112|Device|Heated humified high-flow nasal cannula Oxygen|
75329260|NCT03024112|Other|Standard oxygen therapy|
75785548|NCT02836067|Behavioral|Questionnaires|Behavioral questionnaires
75329261|NCT04374383|Drug|Phthalocyanine Dye|following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed
75329262|NCT04374383|Drug|LASER assisted SRP|LASER assisted SRP will be carried
75329263|NCT02978001|Other|Stabile Isotope tracers|Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
75329264|NCT02978079|Device|Automated pupillometry|Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
75329265|NCT04366427|Combination Product|L-HBO|as previously described.
75636176|NCT02794389|Drug|N-acetyl cysteine|
75636177|NCT02794389|Drug|Placebo|
75636178|NCT02601703|Drug|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
75636179|NCT02601703|Drug|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
75636180|NCT02601703|Drug|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
75636181|NCT02790489|Dietary Supplement|Valedia|
75636182|NCT04098913|Behavioral|Reduced screen-based media use|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
75636183|NCT04234191|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
75636184|NCT04234191|Drug|Hydromorphone|Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
75636185|NCT02790567|Other|HEP score|"The HEP score is a clinicobiological score evaluating the probability of the HIT diagnosis.~The HEP score is based on the blood platelet count, the timing of the platelet decrease, the existence of clinical manifestations of HIT (thrombosis, haemorrhage, skin necrosis) and the existence of an other cause of thrombocytopenia."
75636186|NCT02790567|Other|4Ts score|The 4Ts score is a clinicobiological score evaluating the probability of the HIT diagnosis. The 4Ts score is based on the change in blood platelet count during heparin therapy, the timing of platelet decrease, the existence of a thrombosis, and the existence of an other cause of thrombocytopenia.
75636187|NCT02790567|Other|ID-PaGIA test|The ID-PaGIA test is a particle gel immunoassay that detects immunoglobulins (Ig) G, A and M specific to the heparin/PF4 complexes.
75785549|NCT02831335|Other|MRI|Perform MRI studies
75785550|NCT02831335|Other|MRI|Perform MRI studies
75785551|NCT02831335|Other|MRI|Perform MRI studies
75785552|NCT02831335|Other|Group 4|Perform MRI studies
75921915|NCT02141139|Drug|NSAIDS (ketorolac and ibuprofen)|
75921916|NCT03392714|Drug|R-B(O)AD|rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
75329266|NCT04366427|Combination Product|HBO|as previously described.
75329267|NCT04366427|Combination Product|30% O2|as previously described
75329268|NCT04366427|Combination Product|50% O2|as previously described
75921917|NCT02144571|Behavioral|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
75921918|NCT05673538|Drug|TT-00973-MS tablets treatment|The dose levels to be tested in the dose escalation cohorts are 2, 5, 10, 17, 25, 32, 40 and 50mg QD. All the subjects will receive TT-00973-MS tablets QD until disease progression or occurrence of intolerant adverse reactions.
75921919|NCT03392636|Procedure|Herniotomy|In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
75921920|NCT03384758|Device|Compression Therapy|Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
75921921|NCT02289300|Drug|DCB-BO1202|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
75921922|NCT02289300|Drug|Placebo|"The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
75921923|NCT02289300|Drug|DCB-BO1202+Placebo|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
75785553|NCT02823262|Other|Breast Cancer Treatment Decision Aid for women 70+|We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
76078503|NCT01056016|Other|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
75921924|NCT02144649|Dietary Supplement|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
75329269|NCT02842060|Behavioral|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
75329270|NCT02842060|Behavioral|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
75921925|NCT02144649|Dietary Supplement|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
76078504|NCT01056328|Device|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
76078505|NCT01056328|Device|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
75329271|NCT02978313|Drug|Cetuximab|anti-EGFR monoclonal antibody
75785554|NCT02823262|Other|Usual Care|
75469596|NCT01940796|Drug|Brentuximab Vedotin|Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
75469597|NCT01940848|Drug|STW5 (Iberogast, BAY98-7411)|Applied orally over 28 days, 20 drops STW 5 three times daily
75469598|NCT01940848|Drug|Placebo|Applied orally over 28 days, 20 drops placebo three times daily
75785555|NCT02785120|Drug|TF0023|TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
75785556|NCT02780492|Other|Set of assessment tools|
75785557|NCT02777281|Behavioral|Shoulder pain and SCI|Shoulder pain and SCI
75785558|NCT02777281|Behavioral|Shoulder pain and able bodies|
75785559|NCT02773498|Procedure|conventional TESE|usual procedure for sperm extraction
75329272|NCT02978313|Drug|mFOLFOX6|Oxaliplatin+LV5FU2
75329273|NCT02978313|Drug|FOLFIRI|Irinotecan+LV5FU2
75785560|NCT02773498|Procedure|Micro TESE|procedure of extraction is performed under the operating microscope
75785561|NCT02764138|Behavioral|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
75636188|NCT02790567|Other|HIT-Ab(PF4-H) test|The HIT-Ab(PF4-H) test consist in the incubation of plasma samples with latex beads coated PF4/polyvinylsulfate complexes. After binding of the plasma antibodies a monoclonal antibody recognizing PF4/heparin complexes is added. In the presence of human anti-PF4/heparin antibodies, binding of the monoclonal antibody and subsequent agglutination of latex beads is inhibited. Inhibition of agglutination is quantified and reported in arbitrary units (U/ml). A value equal or higher than 1.0 u/ml may indicate the presence of HIT antibodies.
75636189|NCT02801799|Drug|Varying infusion rates of Ropivacaine 0.2%|"Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.~The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.~The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).~We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter."
75785562|NCT02749552|Behavioral|Acceptance and Commitment Therapy|weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
75329274|NCT00958477|Biological|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
75636190|NCT02690103|Drug|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
75469599|NCT01940913|Dietary Supplement|Probiotic capsules|
75636191|NCT02690103|Dietary Supplement|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
75329275|NCT02958826|Other|Questionnaire|Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
75636192|NCT02690103|Drug|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
75636193|NCT00760513|Drug|OMACOR|4 grammes daily, oral capsule
75636194|NCT00760513|Drug|Placebo oral capsule|4 grammes daily, oral capsule (olive oil)
75636195|NCT02794311|Other|Alcoolpredict|psychological (personality), neuropsychological (executive functions, memory), genetic (snp polymorphisms) and neuro-anatomical (fMRI)
75636196|NCT02689947|Device|Restylane Silk|
75785563|NCT02734602|Drug|Ketamine|Ketamine will be administered after the initial PET scan for subjects participating in the ketamine aim.
75785564|NCT02710435|Device|Reducer System|An aid in the management of chronic refractory angina pectoris
75329276|NCT05716737|Radiation|Irradiation|3 Gy in 6 fractions to the TMJ, every other day, LINAC based
75469600|NCT01940913|Dietary Supplement|Placebo capsules|
75785565|NCT02706561|Behavioral|questionnaires|
75785566|NCT02706561|Behavioral|three in-person sessions|
75785567|NCT02706561|Behavioral|monthly phone calls|
75785568|NCT02706561|Behavioral|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
75785569|NCT02706561|Behavioral|Enhanced Monitoring and Education (EME)|
75785570|NCT02681328|Other|Afirma GEC|Afirma GEC molecular test on collected thyroid tissue
75785571|NCT02681328|Other|ThyroSeq v.2|ThyroSeq v.2 molecular test on collected thyroid tissue
75785572|NCT02681328|Other|Afirma GSC|Afirma GSC molecular test on collected thyroid tissue
75785573|NCT02681328|Other|ThyroSeq v.3|ThyroSeq v.3 molecular test on collected thyroid tissue
76078506|NCT04358913|Device|MR scan with the Alberta linac-MR P3 system|Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
75921926|NCT02144649|Other|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
75329277|NCT05620459|Procedure|Ridge augmentation using chin bone ring with simultaneous implant placement|surgical guides are to be used to harvest chin bone ring, the rings are to be used for bone augmentation in extraction sockets (salama and salama classsification type II),simultaneously implant placement.
75329278|NCT00014495|Biological|filgrastim|
75329279|NCT00014495|Drug|cytarabine|
75329280|NCT00014495|Radiation|bismuth Bi213 monoclonal antibody M195|
75469601|NCT01940926|Drug|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
75469602|NCT01940952|Drug|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|
75469603|NCT01940952|Drug|Placebo + Donepezil 5mg or 10mg|
75469604|NCT01940952|Drug|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg|
75469605|NCT01940965|Drug|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
75469606|NCT01940965|Drug|biguanide|Pharmaceutical form:tablet Route of administration: oral
75469607|NCT01940965|Drug|TZD|Pharmaceutical form:tablet Route of administration: oral
75921927|NCT02144649|Other|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
75921928|NCT05297032|Dietary Supplement|Quercetin Phytosome|All participants will ingest 1 capsule of Quercetin Phytosome (250 mg) three times daily with meals for 90 days.
75636197|NCT04100239|Behavioral|Mindfulness-based stress reduction (MBSR)|MBSR is designed to complement any existing medical treatments, and focuses on the development of mindfulness meditation practice to alleviate psychological distress. MBCL is designed as a follow-up intervention to MBSR and aims to help individuals to turn towards suffering and developing a kind attitude to the self.
75785574|NCT02627092|Other|Copper linen exposure|Subjects will use hospital linens (top sheet, bottom sheet, pillow case, gown) made with copper to see if this helps reduce infections during their hospital stay.
75785575|NCT02566668|Other|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
75785576|NCT02562235|Drug|Riociguat (Adempas, BAY63-2521)|For children with body-weight <50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
75329281|NCT02978469|Other|Life style changing: reducing sedentary behavior|"The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities."
75785577|NCT02555280|Device|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
75785578|NCT02555280|Procedure|Decompression|Decompression alone
76078507|NCT01892657|Drug|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
75636198|NCT02794233|Other|Impedance measurements|Refer to study description
75921929|NCT03388580|Procedure|bronchoalveolar lavage (BAL)|clinically indicated, elective BAL
75921930|NCT03525912|Drug|Ketamine|continuous infusion of low dose ketamine for postoperative pain
75921931|NCT03388502|Other|Automated Text Messaging (SMS) Bot (intervention group)|Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.
75921932|NCT03388502|Other|Routine perioperative education & teaching (control group)|Patients will receive the 'Routine perioperative education & teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
75329282|NCT03017287|Device|GlucoMe App|Assessment of the the GlucoMe App
75329283|NCT04366271|Biological|Mesenchymal cells|1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
75329284|NCT04366271|Drug|Standard of care|Best treatment option for COVID-19 according to investigator criteria
75329285|NCT05566041|Drug|RRx-001 + eLOOP Device|"RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device~Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy"
75329286|NCT05566041|Drug|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
75469608|NCT01940965|Drug|alpha-GI|Pharmaceutical form:tablet Route of administration: oral
75636199|NCT04098289|Procedure|Hysteroscopic septum resection|Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.
75921933|NCT02289378|Drug|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
75921934|NCT03392558|Other|Burt's Bees Skin Care Regimen|Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)
75921935|NCT03392558|Other|Control Regimen|Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
75921936|NCT03851614|Biological|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
76078508|NCT04351581|Other|Discontinuation of ACEi/ARB|Discontinuation of ACEi/ARB
76078509|NCT04351581|Other|Continuation of ACEi/ARB|Continuation of ACEi/ARB
76078510|NCT01057888|Other|Autodialer|Autodialer telephone calls
75469609|NCT01940965|Drug|glinide|Pharmaceutical form:tablet Route of administration: oral
75636200|NCT04098289|Procedure|In vitro fertilization|Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
75636201|NCT02790333|Procedure|traditional reloads|Blue cartridge with3.0mm height staple was used for pancreatic stump
75785580|NCT02468024|Procedure|Lung Surgery|Sublobar Lung Resection
75785581|NCT02468024|Radiation|Radiation therapy|Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
75785582|NCT02404870|Drug|Placebo|Placebo
75785583|NCT02404870|Drug|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
75785584|NCT02359565|Procedure|Biospecimen Collection|Undergo CSF and blood sample collection
75785585|NCT02359565|Procedure|Conventional Magnetic Resonance Imaging|Undergo standard MRI
75785586|NCT02359565|Procedure|Diffusion Tensor Imaging|Undergo DTI
75785587|NCT02359565|Procedure|Diffusion Weighted Imaging|Undergo MR diffusion imaging
75785588|NCT02359565|Procedure|Dynamic Contrast-enhanced MR Perfusion|Undergo DCE permeability MRI
75785589|NCT02359565|Procedure|Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging|Undergo DSC perfusion MRI
75785590|NCT02359565|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
75785591|NCT02359565|Biological|Pembrolizumab|Given IV
75921937|NCT03851614|Drug|Olaparib|Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.
75921938|NCT03851614|Drug|Cediranib|Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.
75921939|NCT03133416|Other|PRP preparation|
75469610|NCT01940978|Drug|Methylphenidate ER|Watson generic, starting dose 18mg QD
75921940|NCT03133416|Device|Physiotherapy|
75785592|NCT02316340|Drug|Vorinostat|400mg by mouth daily
75921941|NCT03133416|Other|PRP and physiotherapy|
75329287|NCT03030547|Device|SenseWear activity monitor|Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
75636202|NCT02790333|Procedure|Tri-Staple reloads|Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
76078511|NCT01057888|Other|Letters|Mailed reminder letters
75469611|NCT01940978|Drug|Cyproheptadine|cyproheptadine hydrochloride
75469612|NCT01941004|Drug|fingolimod|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
75636203|NCT04096105|Drug|CC-93538|a single dose CC-93538 SC
76078512|NCT01881737|Drug|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
75785593|NCT02316340|Drug|Hydroxychloroquine|600mg by mouth daily
75785594|NCT02316340|Drug|Regorafenib|160 mg by mouth daily
75329288|NCT04374617|Diagnostic Test|Duplex ultrasound and Computed Tomography Angiography|All venous thromboembolisms suspected will diagnosed with ultrasound and CT-angiography
75329289|NCT04366037|Other|Routine training|Training will be defined by each club coach
75469613|NCT01941004|Drug|Placebo (6mos) + open label fingolimod (6 mos)|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
75469614|NCT01941056|Biological|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
75469615|NCT01941056|Other|laboratory biomarker analysis|Correlative studies
75469616|NCT01941069|Behavioral|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
75469617|NCT01941069|Behavioral|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
75636204|NCT02790099|Drug|Bupivacaine|Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.
75636205|NCT02790099|Drug|Morphine|0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.
75636206|NCT04100005|Other|No intervention|There is no intervention for this study.
75636207|NCT02790177|Drug|Hyaluronic Acid|
75636208|NCT02790177|Drug|NORMAL SALINE|
75785595|NCT02260505|Drug|Imatinib maintenance|Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
75785596|NCT02207114|Other|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
75785597|NCT02143401|Other|Laboratory Biomarker Analysis|Correlative studies
75785598|NCT02143401|Biological|Navitoclax|Given PO
75785599|NCT02143401|Other|Pharmacological Study|Correlative studies
75785600|NCT02143401|Drug|Sorafenib|Given PO
75785601|NCT02143401|Drug|Sorafenib Tosylate|Given PO
75785602|NCT02107989|Device|MRI|MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.
75921942|NCT03521622|Behavioral|brief counseling|Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
75921943|NCT04565600|Drug|Etoricoxib|Etoricoxib 60 Mg Oral Tablet
75921944|NCT03444714|Drug|RiMO-301|"Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks"
75921945|NCT04486898|Other|Music group|Music group will be given music intervention or listen to music for 30 minutes ,3 times a week for the period of 5 week duration. Music will be selected as per participant's preference
75636209|NCT04100083|Drug|Spironolactone 50 MG|"Study visit timeline: initial visit [consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
75785603|NCT02107989|Device|MEG|MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.
75636210|NCT04100083|Drug|Spironolactone 100mg|"Study visit timeline: initial visit [consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
75921946|NCT03523182|Dietary Supplement|Spirulina|"Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.~Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.~We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend."
75921947|NCT03523182|Dietary Supplement|Control|Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.
75921948|NCT04435808|Drug|Hydroxychloroquine|"Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria. Subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).~Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily"
76078513|NCT01109056|Drug|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
76078514|NCT01109056|Drug|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
75785604|NCT02063724|Biological|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
76078515|NCT04760145|Other|Multicomponent Exercise with Blood Flow Restriction|"10 minutes of initial warm-up.~20 minutes of strength exercises.~10 minutes of resistance exercises.~10 minutes of coordination and balance exercises.~5 minutes of flexibility.~5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed with blood flow restriction."
76078516|NCT04760145|Other|Multicomponent Exercise without Blood Flow Restriction|"10 minutes of initial warm-up.~20 minutes of strength exercises.~10 minutes of resistance exercises.~10 minutes of coordination and balance exercises.~5 minutes of flexibility.~5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed without blood flow restriction."
75921949|NCT03133338|Device|pelvic binder|The requirement of angioembolization can be predicted by the presence of intravenous contrast extravasation (ICE) on computed tomography (CT)
75921950|NCT04674748|Drug|INCB086550|Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
75921951|NCT02290080|Drug|Oxygen|see arm description
75921952|NCT03388424|Diagnostic Test|quantification of microbiota|For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis
75469618|NCT01941082|Drug|RO6867461|Single or multiple ascending dose by intravitreal injection
75469619|NCT01941121|Behavioral|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
75469620|NCT01941134|Drug|ethinyl estradiol-levonorgestrel|Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
75469621|NCT01941147|Device|pulsed ELF-MF|(75 Hz, 1,8 mT)
75785605|NCT01997840|Drug|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
75921953|NCT03388346|Drug|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
75921954|NCT02289612|Other|Yellow Mustard Gum Fibre|
76078517|NCT03870399|Drug|Tamoxifen|The treatment to be used will be tamoxifen 20mg orally once daily.
75469622|NCT01941160|Dietary Supplement|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
75921955|NCT02289612|Other|Soluble Flaxseed Gum Fibre|
75921956|NCT02289612|Other|Fenugreek Gum Fibre|
75921957|NCT05646004|Device|Cataract surgery|Implantation of 621 lens
75469623|NCT01941160|Dietary Supplement|Placebo|Placebo capsule twice daily
75469624|NCT01941173|Biological|ziv-aflibercept|Given IV
75469625|NCT01941173|Drug|leucovorin calcium|Given IV
75921958|NCT03521544|Other|Self-myofascial release|The subjects roll a foam roller under a determinated part of the body to self-massage that area.
75921959|NCT03388112|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5*10^7CFU for 2 weeks
75329290|NCT04366037|Other|Routine training + proprioceptive exercise in warm-up|"Training will be defined by each club coach, adding four proprioceptive exercises in warm-up:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
75329291|NCT04366037|Other|Routine training + proprioceptive exercise in cool-down|"Training will be defined by each club coach, adding four proprioceptive exercises in cool-down:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
75329292|NCT03030391|Other|PET|
75329293|NCT03030391|Other|MRI|
75329294|NCT04374227|Procedure|Osteopathic Manipulative Treatment|Body regions that were treated included head, cervical, thoracic, ribs, lumbar, pelvis, sacrum, lower extremity, and upper extremity.
75636211|NCT04100083|Drug|Spironolactone 200 mg|"Study visit timeline: initial visit [consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
75329295|NCT00960505|Other|Alternate day fasting|
75785606|NCT01972919|Radiation|Radiation Therapy|Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.
75785607|NCT01972919|Drug|Concurrent chemotherapy (Gemcitabine, Capecitabine)|Gemcitabine 400mg/m^2 IV weekly x 6 doses. Capecitabine 825 mg/m^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.
75329296|NCT00960505|Other|Calorie restriction|
75329297|NCT00960505|Other|Control diet|
75329298|NCT04374071|Drug|Methylprednisolone|IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
75329299|NCT02958982|Drug|RP3128|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
75329300|NCT02958982|Drug|Placebo|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
75329301|NCT02244749|Other|skin specimen|skin specimen
75329302|NCT00357981|Drug|ORTHO EVRA, the contraceptive patch|
75329303|NCT03030703|Dietary Supplement|phytic acid|350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
75329304|NCT02157623|Drug|Levulan|Levulan application followed by Red or Blue light PDT
75785608|NCT01948882|Device|ESS505 (BAY1454033)|
75785609|NCT01782599|Other|Dual nicotine patch and electronic cigarette|
75785610|NCT01765140|Drug|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
75785611|NCT01758328|Drug|busulfan|
75785612|NCT01758328|Drug|melphalan|
75785613|NCT01758328|Drug|fludarabine|
75785614|NCT01758328|Biological|anti-thymocyte globulin (ATG)|
75329305|NCT02157623|Other|Red Light PDT|Aktilite™ (red lamp) after Levulan application on lesions
75785615|NCT01758328|Procedure|a T cell depleted stem cell transplant|
75785616|NCT01746849|Biological|Palifermin|
75329306|NCT02157623|Other|Blue Light PDT|Blu-U® (blue lamp) after Levulan application on lesions
75329307|NCT03030469|Other|Change in electronic health record default for new opioid analgesic prescriptions|
75329308|NCT03028324|Device|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
75329309|NCT00358059|Behavioral|Behavioral Family Systems Therapy for Diabetes|
75785617|NCT01746849|Biological|Lupron|
75921960|NCT05631730|Drug|Flecainide|Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
75921961|NCT05631730|Drug|Metoprolol|Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
75921962|NCT03521388|Behavioral|Take care of your mood (CUIDA TU ANIMO in Spanish)|The adolescents will be registered in the Website www.cuidatuanimo.org
75469626|NCT01941173|Drug|irinotecan hydrochloride|Given IV
75469627|NCT01941173|Drug|fluorouracil|Given IV
75469628|NCT01941199|Drug|DA-1229|
75469629|NCT01941199|Drug|metformin|
75469630|NCT01941199|Drug|DA-1229 + metformin|
75785618|NCT01746849|Procedure|peripheral blood stem cell transplantation|
75785619|NCT01746849|Radiation|Total-Body Irradiation (TBI)|
75785620|NCT01746849|Drug|Thiotepa|
75785621|NCT01746849|Drug|Cyclophosphamide|
75785622|NCT01746849|Drug|Degarelix|
75785623|NCT01722266|Drug|Liraglutide|"Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards."
75785624|NCT01722266|Drug|Placebo|"Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards."
75636212|NCT02794155|Drug|HDV Insulin Lispro|HDV Insulin Lispro: ~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
75636213|NCT02794155|Drug|Insulin LISPRO|Insulin Lispro: no bound insulin
75636214|NCT03798015|Other|mitral valve surgery|assessment of ischemic or hemorrhagic stroke subsequent to mitral valve surgery
75636215|NCT02790255|Other|Cold air|
75469631|NCT01941212|Behavioral|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
75785625|NCT01468896|Biological|Cetuximab|Given IV
75785626|NCT01468896|Biological|Edodekin alfa|Given SC
76078518|NCT01109602|Other|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
75329310|NCT00952081|Drug|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
75636216|NCT02790255|Other|Cold water|
75329311|NCT04365881|Other|Cross-sectional observational study|Survey
75469632|NCT01941225|Drug|Inhaled iloprost 5.0 mcg|Single administration
75469633|NCT01941225|Drug|Placebo|Single administration
75636217|NCT04234581|Dietary Supplement|Lysulin|Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
75636218|NCT02801955|Procedure|gastrectomy|radical total/subtotal gastrectomy with D2 lymph node dissection
75785627|NCT01468896|Other|Laboratory Biomarker Analysis|Correlative studies
75785628|NCT01425866|Behavioral|Structured self-management group education during 2 years|After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
75785629|NCT01261728|Drug|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
75469634|NCT01941264|Other|community based screening and treatment|Already described in intervention arm description.
75636219|NCT02801955|Procedure|sampling of peritoneal washing aspirate|After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
75636220|NCT02793843|Drug|Ondansetron (Zofran)|Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
76078519|NCT02175472|Device|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
76078520|NCT02175472|Device|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
75329312|NCT05716347|Biological|the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine|one booster dose intramuscularly in the deltoid muscle of the upper arm.
75469635|NCT01941316|Drug|Carfilzomib|20/36 * mg/m2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
75469636|NCT01941316|Drug|Irinotecan|125 mg/m2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
75469637|NCT01941329|Procedure|Panretinal Photocoagulation (PRP)|
75469638|NCT01941329|Drug|Intravitreous injection of ranibizumab|
75469639|NCT01941342|Procedure|Pancreatoduodenectomy|
75469640|NCT01941342|Procedure|ENBD and Pancreatoduodenectomy|
75469641|NCT01941342|Procedure|EBD and Pancreatoduodenectomy|
75469642|NCT01941342|Procedure|PTCD and Pancreatoduodenectomy|
75469643|NCT01941355|Behavioral|Exercise training component|The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
75636221|NCT02793843|Drug|Dexamethasone (Decadron)|Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
76078521|NCT03014752|Other|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
75785634|NCT01166321|Radiation|Carbon Ion Radiotherapy|Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E
75785635|NCT00953771|Drug|Danazol|Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
75785636|NCT00862433|Drug|Alpha tocopherol|intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
75785637|NCT00862433|Other|Vitamin E|Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
75785638|NCT00862433|Other|Vitamin C|Oral vitamin C, one gram daily.
75785639|NCT00711490|Drug|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
75921963|NCT03521388|Other|Control|The adolescents will visit the Website www.cuidatuanimo.org, but they can not register
75329313|NCT02959840|Device|Acupressure Point P6 stimulator|This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
75636222|NCT02793843|Other|Spinal anesthesia|Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
75636223|NCT02793687|Drug|MEXIDOL® (ethylmethylhydroxypyridine succinate)|
75636224|NCT02793687|Other|Placebo|
75636225|NCT02801487|Radiation|Carbon ion radiotherapy (CIRT)|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3~5mm.
75636226|NCT02801487|Drug|Cisplatin|Cisplatin (40mg/m^2) monotherapy will be given weekly along with radiotherapy.
75785640|NCT00673816|Drug|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
75785641|NCT00589654|Other|Questionnaire|Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
75785642|NCT00582257|Behavioral|questionnaires|Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
75785643|NCT00582231|Other|Questionnaires.|Questionnaires.
75785644|NCT00533117|Drug|Fluoxetine|Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
75785645|NCT00533117|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
75785646|NCT00533117|Behavioral|Supportive psychotherapy|Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
75921964|NCT00092144|Drug|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
75921965|NCT00092144|Drug|Comparator: placebo / Duration of Treatment: 4 weeks|
75785651|NCT00362843|Drug|[15-O]water|
75785652|NCT00026312|Biological|Aldesleukin|Given IV
75921966|NCT02289768|Drug|5-fluorouracil/salicylic acid|
75921967|NCT02289768|Drug|Vehicle|
75921968|NCT03125876|Drug|CT053PTSA|receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
75921969|NCT03712514|Other|Destabilization of the upper cervical spine by Cervistab|Simulate a situation of destabilization of the cervical spine with Cervistab
75921970|NCT03125954|Other|standardized exercise treatment for knee OA in Denmark (GLAiD)|objective measurement of physical activity before, during af after the GLAiD intervention
76078522|NCT03014752|Other|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
75329314|NCT02959840|Drug|Metoclopramide|10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
75785653|NCT00026312|Biological|Dinutuximab|Given IV
75785654|NCT00026312|Drug|Isotretinoin|Given PO
75785655|NCT00026312|Other|Laboratory Biomarker Analysis|Correlative studies
75785656|NCT00026312|Other|Pharmacological Study|Correlative studies
75785657|NCT00026312|Other|Quality-of-Life Assessment|Ancillary studies
75785658|NCT00026312|Biological|Sargramostim|Given IV or SC
75785659|NCT03280264|Drug|KHK7580|oral administration
75785660|NCT01094418|Other|Nerve conduction studies ( NCS) of the peripheral nerves|"Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.~NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves."
75785661|NCT01291238|Behavioral|Healthier, Smarter, Happier|Increased physical activity and decreased sugar and fat intake during school hours
75921971|NCT03523026|Device|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. The program will continue for 6 weeks.
75785662|NCT01089348|Drug|Lactofiltrum + Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os
75785663|NCT01089348|Drug|Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days per os
75785664|NCT01291316|Drug|Clonazepam|clonazepam, 1 mg, single oral dose
75329315|NCT02959840|Drug|Ondansetron|8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
75329316|NCT04358341|Drug|Irinotecan|150 mg/m2 ivdrip every 14 days
75785665|NCT01291316|Drug|Tolterodine|Tolterodine 1,37mg, single oral dose
75636227|NCT04234503|Behavioral|Ethics Quarter|"In the intervention, nurse managers have two educational packages per week, one taking 15 minutes (one quarter).The structure of the whole intervention is made according to the dimensions of ethical activity profile of nurse managers (Laukkanen et al. a2016; Laukkanen et al b2016) consisting of managers:~Developing of own ethics knowledge,~Influencing ethical issues,~Conducting/implementing ethics research,~Identifying and~Solving ethical problems.~Intervention includes also orientation and summary, in total 12 educational packages.~After every dimension, NMs have to make self-reflection and development plans, in total five times. This provides them the opportunity to link their everyday experience with ethical theory."
75921972|NCT03523026|Other|Inspirator Muscle Training|Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.
75636228|NCT02801565|Drug|Conventional controlled ovarian stimulation proctol|Conventional controlled ovarian stimulation proctol without rhGH.
75636229|NCT02793765|Drug|Docetaxel|
75785666|NCT01291316|Drug|clobazam|clobazam 20 mg, single oral dose
75785667|NCT01587872|Procedure|Fujinon EC-450BI5 double-balloon colonoscope|Colonoscopy with the test instrument
75469644|NCT01941355|Behavioral|Psycho-educative component|The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
75785668|NCT01287728|Drug|Treatment BY METROMIDAZOLE|Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
75921973|NCT03523026|Other|Peripheral Muscle Training|Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
76078523|NCT01892501|Procedure|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
76078524|NCT01892501|Device|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
76078525|NCT04333407|Drug|Aspirin 75mg|• If patient not on aspirin, add aspirin 75mg once daily unless contraindicated.
76078526|NCT04333407|Drug|Clopidogrel 75mg|• If patient not on clopidogrel or equivalent, add clopidogrel 75mg once daily unless contraindicated
76078527|NCT04333407|Drug|Rivaroxaban 2.5 MG|"If patient not on an anticoagulation, add rivaroxaban 2.5mg bd unless contraindicated~If patient on DOAC then change to rivaroxaban 2.5mg unless contraindicated"
75329317|NCT04358341|Drug|DOXOrubicin Liposome Injection|25 mg/m2 ivdrip every 14 days
75329318|NCT04358341|Drug|5fluorouracil|400mg/m2 iv bolus and 2400 mg/m2 civ 46h every 14 days
75329319|NCT02978547|Drug|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
75329320|NCT00929357|Drug|DMARDs or Biologics|
75329321|NCT00961051|Device|Investigational MPS|Multi-purpose solution
75329322|NCT00961051|Device|Opti-Free|Multi-purpose solution
75469645|NCT01941368|Dietary Supplement|Placebo|
75469646|NCT01941368|Dietary Supplement|HMB-FA|
75785669|NCT03855176|Drug|Vaqta Injectable Product|Inactive vaccine against hepatitis A virus
75785670|NCT00060840|Drug|Nitric Oxide|40 ppm of Nitric Oxide continuously administered for 48 hours
75785671|NCT00060840|Drug|Nitrogen|Nitrogen (N2) administered at 40 ppm for 48 hours
75785672|NCT03854864|Other|survey|to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
75785673|NCT01185860|Drug|danoprevir|oral doses
75785674|NCT01185860|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly
75785675|NCT01185860|Drug|placebo|oral doses
75785676|NCT01185860|Drug|ribavirin|1000-1200mg/day po
75785677|NCT01185860|Drug|ritonavir|oral doses
75785678|NCT01089426|Drug|Omegaven™|1 g/kg/d of Omegaven until discontinuation of PN
75785679|NCT01089426|Other|Historical Controls|Standard of Care
75785680|NCT01290302|Drug|Luitpold Azacitidine|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
75785681|NCT01290302|Drug|Vidaza®|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
75785682|NCT01089660|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.3 mL, Intramuscular (IM)
75785683|NCT01089660|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular (IM)
75785684|NCT03861104|Other|medical educational video|information based on visual and auditory communication
75329323|NCT02240303|Procedure|Quantitative Sensory Testing (QST)|Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
75469647|NCT01941368|Procedure|High Intensity Interval Training|
75636230|NCT02793765|Biological|Sipuleucel-T|
75636231|NCT02793609|Other|Intervention is to let patient to go home.|Intervention is to let patient to go home.
75636232|NCT02793609|Other|Intervention is to observe women in the ward.|Intervention is to observe women in the ward.
75785685|NCT03280108|Device|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision
75636233|NCT02793531|Other|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
75785686|NCT03280108|Device|AcrySof Monofocal IOL|AcrySof Monofocal IOL Model SN60AT for single vision
76078528|NCT04333407|Drug|Atorvastatin 40mg|• If patient not on a statin, add atorvastatin 40mg once daily unless contraindicated
75329324|NCT02240303|Procedure|Physical Performance|Participants in both groups will have a Physical Performance test.
75785687|NCT01093404|Procedure|Thrombus aspiration|Aspiration of thrombus material before angioplasty
75921974|NCT04330430|Drug|T-VEC|The treatment schedule is based on 4 courses of intralesional T-VEC and 3 courses of intraveneous Nivolumab. T-VEC first, in order to achieve the best synergistic effect with influx of CD8+ T-cells prior to the first Nivolumab dose. T-VEC monotherapy with the dose 10^8 PFU/mL is given every 2 weeks after 3 weeks of the first T-VEC dose (with the first dose of T-VEC 10^6 PFU/mL to allow for seroconversion), and Nivolumab will be given every 2 weeks.
75921975|NCT03387956|Drug|Intrathecal atropine|100ug intrathecal atropine will be injected with spinal anesthesia
75921976|NCT03387956|Drug|dexamethasone|intravenous 8 mg dexamethasone (2ml).
75329325|NCT02240303|Procedure|Magnetic Resonance Imaging (MRI)|Participants in both groups will have an magnetic resonance imaging (MRI).
75329326|NCT02240303|Procedure|Blood Sample|Participants in both groups will have blood samples taken.
75329327|NCT05556291|Drug|Combinations of Oral Blood Glucose Lowering Drugs|Combination of Ertugliflozin and Sitagliptin
75636234|NCT02793453|Other|periodontal smears|
75636235|NCT02793219|Biological|Sipuleucel-T|
75636236|NCT02793219|Drug|Docetaxel|
75921977|NCT03817606|Device|Tritanium Posterior Lumbar Cage|Placement of Tritanium Posterior Lumbar Cage via TLIF procedure
75329328|NCT02959996|Drug|Liposomal bupivacaine|liposomal bupivacaine injection in the Pfannenstiel incision
75469648|NCT01941381|Procedure|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
75636237|NCT02801721|Other|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
75636238|NCT02801409|Drug|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
75785688|NCT01182662|Other|Human umbilical cord-derived MSCs and cyclosporin A|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
75785689|NCT01182662|Other|cyclosporin A|cyclosporin A 5mg/kg po for 12 months
75785690|NCT01185938|Drug|Rosuvastatin|One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
75785691|NCT03855098|Other|Biomarkers of Fruit and Vegetable Intake|"Cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). The following definition of portion sizes will be used; green beans (120g), lettuce (20g), spinach (90g), strawberries (96g) and blueberries (75g).~For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption."
75785692|NCT00059202|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses
75785693|NCT00059202|Drug|Placebo|Placebo for Urso
75921978|NCT03817606|Device|AVS UniLIF PEEK Posterior Lumbar Cage|Placement of AVS UniLIF PEEK Posterior Lumbar Cage via TLIF procedure.
75921979|NCT02290158|Other|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
76078529|NCT04333407|Drug|Omeprazole 20mg|• If patient not on a proton pump inhibitor, add omeprazole 20mg once daily.
76078530|NCT04398225|Drug|Centanafadine|Extended release capsule
76078531|NCT04398147|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
76078532|NCT04398147|Biological|Placebo|Intramuscular administration
75469649|NCT01941394|Biological|Mesenchymal stem cells|Mesenchymal stem cells infusion
75469650|NCT01941407|Drug|Eribulin|Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
75329329|NCT02959996|Drug|Placebo|placebo injection in the Pfannenstiel incision
75329330|NCT00929981|Drug|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
75329331|NCT00961441|Drug|Keppra XR|"Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days"
75329332|NCT02240381|Procedure|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
75469651|NCT01941433|Behavioral|Arthritis Health Journal|
75469652|NCT01941511|Drug|Rivipansel|Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
75469653|NCT01941524|Drug|Poractant alfa instillation|aEEG and NIRS monitoring during poractant alfa instilation
75785694|NCT01177358|Drug|Botulinum Toxin Type A|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy."
75785695|NCT01177358|Drug|Normal Saline|0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
75921980|NCT04465656|Diagnostic Test|Serology test for COVID-19|"In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed in two parts:~ELISA test~Rapid Diagnostic tests (only if ELISA test is positive)"
75785696|NCT03854942|Drug|Placebo|Placebo oral tablet daily
75921981|NCT03384524|Drug|Bromocriptine 2.5 MG|Administered daily
76078533|NCT04398927|Drug|Folfirinox|Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
75636239|NCT02801409|Drug|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
75921982|NCT03384524|Drug|Metoprolol 25 MG|Administered daily
75921983|NCT03384524|Drug|Tamsulosin 0.4 MG|Administered daily
76078534|NCT04398927|Drug|Sintilimab|Sintilimab
76078535|NCT03203889|Behavioral|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
75921984|NCT03384524|Other|Placebo|Three pills, matching active drugs to be administered daily
75921985|NCT05194228|Behavioral|Ecologial Momentary Assessment settings|Various settings for ecological momentary assessments
75921986|NCT03387800|Behavioral|Basic health education messages|Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.
75636240|NCT00907296|Biological|Romosozumab|Administered by subcutaneous injection
75636241|NCT00907296|Drug|Placebo|Administered by subcutaneous injection
75921987|NCT03387800|Behavioral|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
76078536|NCT03203889|Behavioral|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
76078537|NCT03203187|Other|Mango|330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening
76078538|NCT03203187|Other|No intervention|No mango intake for two weeks.
75636242|NCT03787251|Drug|Apatinib|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
75636243|NCT03787251|Drug|The chemotherapeutic drug chosen by the investigator.|"The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice."
75636244|NCT02789865|Drug|Ertapenem, Levofloxacin and Metronidazole|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
75785697|NCT03854942|Drug|Naltrexone|Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days
75785698|NCT03854786|Dietary Supplement|Oxyjun|Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
75921988|NCT02294136|Behavioral|Prep-C|PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
75921989|NCT02294136|Behavioral|Educational Control|Attention Control
75921990|NCT04465578|Procedure|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
75921991|NCT04465578|Procedure|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
75921992|NCT05599282|Drug|Amino Acid Supplement|Four capsules of Amino Acid Supplement will be taken once a day for 90 days.
75921993|NCT05599282|Other|Placebo|Four capsules of Placebo will be taken once a day for 90 days.
75921994|NCT02290236|Device|Pulseoximetry|Peripheral saturation will be recorded continuously
75921995|NCT03387644|Drug|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
75921996|NCT03387644|Drug|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
76078539|NCT05194059|Behavioral|Home-based physical activity|Participants will follow a personalized activity pacing program
76078540|NCT01059682|Drug|Dalcetrapib|Dalcetrapib 600 mg orally once daily
76078541|NCT01059682|Drug|Placebo|Placebo orally once daily
76078542|NCT04398693|Dietary Supplement|Prebiotic|It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of SCFA (acetate and butyrate) in a sachet with a powder that must be dissolved in a glass of liquid to your choice, during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study.
75329333|NCT02240381|Procedure|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
75636245|NCT02789865|Procedure|Endoscopic retrograde appendicitis therapy (ERAT)|The procedures of ERAT will be performed as below：1.Cannulation of the appendiceal lumen. 2.Endoscopic retrograde appendicography (ERA). 3.Irrigation and appendicolith removal. 4.Stenting for drainage.
75636246|NCT02789865|Procedure|Appendectomy|The patients will receive laparoscopic appendectomy according to standard routines.
75329334|NCT02240381|Other|laboratory biomarker analysis|Correlative studies
75921997|NCT02290002|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
75329335|NCT05716113|Drug|RD13-02 cell infusion|CAR-T cells
75636247|NCT02789943|Procedure|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
75636248|NCT02793297|Other|refined wheat crisp bread|Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
75469654|NCT01941524|Drug|Beractant instillation|aEEG and NRs monitoring during beractant instillation
75469655|NCT01941550|Drug|Cabazitaxel chemotherapy|given in 6 cycles
75636249|NCT02793297|Other|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
75636250|NCT02793297|Other|unfermented rye crisp bread|Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
75636251|NCT02793141|Other|No intervention|No intervention will be administered
75636252|NCT02591706|Device|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
75921998|NCT02290002|Other|coasting|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
75636253|NCT02793063|Other|Web-based Survey|This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
75636254|NCT00816400|Drug|MEDI-575|MEDI-575 as an IV infusion
75785699|NCT03854786|Dietary Supplement|Pacebo|Methyl Crystalline Cellulose
75785700|NCT03956472|Procedure|Osteopathic protocol for improving drainage of LCS|Osteopathic intervention improving drainage of LCS and cerebral blood flow through opitmizing veinous circulation
75921999|NCT05172830|Device|Ovation Alto™ Abdominal Stent Graft System|Single occurrence permanent implantation of AAA device
75922000|NCT02294214|Device|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
75922001|NCT02294214|Device|Active ingredient|Transfluthrin (Active ingredient)
75329336|NCT02961946|Drug|Nitroglycerin|Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
75329337|NCT02240459|Drug|fesoterodine 4mg|7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
75329338|NCT02240459|Drug|Oxybutynin|5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
75329339|NCT02240459|Drug|placebo|placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
75785701|NCT03956472|Device|PEEP 10cmH2O|Breathing through a 10 cmH2O expiratory resistance for 10 min every 2 hours during 10h at 3842m high
75329340|NCT02240459|Drug|fesoterodine 8mg|2, 4mg fesoterodine capsules taken together in the morning
75785702|NCT03956472|Other|Fake Osteopathic protocol|Placebo intervention
75785703|NCT03956472|Other|PEEP-Sham|PEEP 0 cmH2O (hidden)
75785704|NCT03278626|Drug|Nivolimumab+Carboplatin/paclitaxel+Radiation|In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
75922002|NCT02294214|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
75329341|NCT02978235|Drug|TAS4464|Intravenous (IV) Infusion
76078543|NCT04399083|Dietary Supplement|Caffeine|"Caffeine will be administered to each participant following an individualized optimal dosing schedule created by the 2B-Alert app. Individualized caffeine dosing schedules will be created by the 2BAlert app on the smartphone the participant uses to do Smart-PVT tests. Study staff will run the optimization at 1900 on Day 15. The algorithm will recommend caffeine dosing to optimize performance during the Peak Alertness window (e.g. from 0300-0900 on Day 16, 44-50 hours of continuous sleep loss). Doses could be recommended at any hour from 2000 on Day 15 to 0800 on Day 16. HOWEVER, the algorithm will not exceed 800 mg of caffeine across the entire study AND it will not dose more than 300 mg of caffeine at a time. Gum will be chewed for a total of 10 minutes by each participant and then discarded.~As there will be no placebo in this protocol, randomization and blinding procedures are not necessary. IT IS IMPORTANT TO NOTE THAT SOME PARTICIPANTS MAY NOT RECEIVE CAFFEINE AT ALL."
75636255|NCT02792985|Behavioral|Multisensory stimulation protocol|"Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.~An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room."
75636256|NCT02792985|Behavioral|Control protocol|"Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.~Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends)."
75329342|NCT02846740|Device|Alpha-Stim®.|cranial electrical stimulation
75329343|NCT02846740|Behavioral|Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale|A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
75329344|NCT02240537|Drug|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
75329345|NCT02240537|Drug|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
75636257|NCT02789631|Other|assessment|
75636258|NCT02789709|Procedure|Surgery|Segmental resection for colon cancer and anterior resection in patients with rectal cancer
75636259|NCT02789787|Procedure|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
75636260|NCT02789787|Procedure|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
75636261|NCT03935607|Diagnostic Test|Transvaginal sonography|Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
75636262|NCT02792751|Device|Bispectral Index Monitorisation (BIS)|Standard monitoring was performed with electrocardiography, pulse oximetry and non invasive blood pressure. Additionally, Bispectral index (Aspect Medical Systems, Natica, MA) electrodes were connected to Group B patients
75636263|NCT02792751|Other|Ramsey Sedation Scale|Propofol administration was done to keep the Ramsey Sedation scale of 3 or 4
75636264|NCT02690025|Drug|ZP1848|
75636265|NCT02792907|Device|Compressive stocking|"After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.~Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking."
75636266|NCT02792673|Other|embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)|
75636267|NCT02792673|Other|embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)|
75636268|NCT02792673|Other|a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid|
75636269|NCT02792673|Device|Labotect embryo transfer catheter|
75329346|NCT02240537|Drug|Montanide|"Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration."
75329347|NCT02240615|Device|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
75636270|NCT02792595|Other|Negative Control|Untreated area
75636271|NCT02792595|Other|Positive Control|High SPF Standard P3/SPF 15
75636272|NCT02792595|Other|Test Product A|Yosemite Falls (Forte Day SPF upgrade) Variant A
75636273|NCT02792595|Other|Test Product B|Yosemite Falls (Forte Day SPF upgrade) Variant B
75636274|NCT02792595|Other|Test Product C|Yosemite Falls (Forte Day SPF upgrade) Variant C
75636275|NCT02792595|Other|Test Product D|Yosemite Falls (Forte Day SPF upgrade) Variant D
75636276|NCT02792595|Other|Test Product E|Yosemite Falls (Forte Day SPF upgrade) Variant E
75636277|NCT02792595|Other|Test Product F|Yosemite Falls (Forte Day SPF upgrade) Variant F
75329348|NCT05676333|Drug|Secukinumab|
75785705|NCT01327092|Other|Injury Intervention Group|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
75785706|NCT03856736|Other|MIAT|Moderated aerobic exercise
75922003|NCT03654092|Behavioral|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
75922004|NCT04132804|Behavioral|Tai Chi|Tai Chi Chuan (taijiquan) or Tai Chi is a mind-body practice borne of Chinese philosophy and martial arts which has been practiced for centuries to promote deep relaxation, strengthened health, and to prevent injuries and illness.
75922005|NCT02294292|Drug|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
75922006|NCT02294292|Drug|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
75922007|NCT02294292|Procedure|Endoscopic Variceal Ligation|
75636278|NCT02792595|Other|Test Product G|Yosemite Falls (Forte Day SPF upgrade) Variant G
75785707|NCT03856736|Other|Control|Weekly body relaxation and sham group
75636279|NCT02792595|Other|Test Product H|Yosemite Falls (Forte Day SPF upgrade) Variant H
75636280|NCT00906204|Biological|Single-dose rabbit Anti-thymocyte Globulin induction|6 mg of rATG administered in a single dose on the day of kidney transplantation
75636281|NCT00906204|Biological|Divided-dose rabbit Anti-thymocyte Globulin induction|6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
75636282|NCT02792361|Procedure|Standard Suction Drain|The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
75785708|NCT01177436|Biological|Taking of urines|Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
75922008|NCT03387566|Drug|HB002.1M|HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
75922009|NCT03387488|Device|StingrayTM, Medtronic®|Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
75922010|NCT02290314|Procedure|minimally invasive MID-line Lumbar Fusion (MIDLF)|
75922011|NCT02290314|Procedure|Posterior lumbar interbody fusion (PLIF)|
75329349|NCT02240771|Procedure|Transarterial chemotherapy|"Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes."
75636283|NCT00638001|Device|custom-molded insoles and custom-molded shoes|"custom-made insoles in PELITE foam (hypoallergenic prosthesis grade foam) or leather top cover cork insoles for patients suffering of mild to moderate ankle arthropathy~custom-molded shoes in leather for patients suffering of end-stage ankle arthropathy"
75636284|NCT03554148|Other|No intervention|This is purely an observational study. Groups SSI/No SSI are defined by the occurence of a surgical site infection.
75636285|NCT02792127|Behavioral|Online Program for Social Anxiety|This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
75785709|NCT03277846|Device|Nexalin Based Trans-Cranial Electrical Stimulation|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
75785710|NCT01186094|Device|Cypher|Sirolimus-eluting stent
75785711|NCT01186094|Device|Endeavor Resolute|Zotarolimus-eluting Stent
75785712|NCT04902976|Other|CPC+ZN|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the solution for 30 s
75785713|NCT04902976|Other|CPC|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the proposed solution for 30 s;
75785714|NCT04902976|Other|Negative Control|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of distilled water for 30 s.
75469656|NCT01941576|Drug|recombinant human brain natriuretic peptide (rhBNP)|Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
75922012|NCT03391856|Drug|N-acetyl-L-cysteine (NAC)|NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
75922013|NCT03391856|Other|supportive therapy|prophylactic platelet transfusion was given when platelet count <20000/ul
75785715|NCT05571436|Behavioral|iCan Diabetes Self-management and Prevention Support Group|"Participants will be asked to attend six weekly sessions and complete pre-and post-assessments with an optional focus group.~The intervention will cover the following topics: 1) Yes, iCan! - Affirmations and Empowerment, 2) The Language of Diabetes - Diabetes Synopsis, 3) Diabetes and Me - Management Strategies, 4) Extraordinary Health - Dream Team, 5) Food for Thought - Food Conscious, and 6) Discussion - Stories/Goals.~Each session is composed of a Check-in, Affirmation/Empowerment Activity, Short Presentation, Q&A and Discussion, Goal setting, and Testing Healthy Snacks."
75922014|NCT03514758|Procedure|several virtual 3-D complex audio environments|The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
75922015|NCT04176614|Other|cereal-legume snack|cereal-legume biscuit
75329350|NCT02240771|Drug|Oral chemotherapy|"Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count & Platelet count would be monitored every 15 days"
75636286|NCT03124212|Other|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
75922016|NCT04176614|Other|cereal snack|cereal biscuit
75922017|NCT01664494|Drug|Capecitabine|Capecitabine will be given according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
75329351|NCT02848222|Device|Bruder Moist Heat Compress|
75329352|NCT02848222|Other|Washcloth|
75329353|NCT05715957|Other|No intervention|No intervention
75329354|NCT02240849|Device|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
75329355|NCT02240849|Device|Placebo general pillow|
75329356|NCT00962065|Drug|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
75785716|NCT03169894|Drug|MDGN-002|MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
75329357|NCT00962065|Drug|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
75329358|NCT00962065|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days
75329359|NCT02240927|Drug|Low Molecular Weight Heparine : Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
75329360|NCT02240927|Drug|Enoxaparine and 2.5 mg Warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4)
75329361|NCT02240927|Drug|Enoxaparine and 4mg Warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
75329362|NCT02240927|Drug|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
75329363|NCT03038308|Drug|Ropinirole|0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
75329364|NCT04358497|Device|Medtronic® Concerto® detachable coil system|coil embolization of the reflux pathways
75329365|NCT04358497|Procedure|sclerosis|Pelvic varices sclerosis with polidocanol foam
75329366|NCT04358497|Drug|Diosmin / Hesperidin|Best chronic medial treatment
75636287|NCT02794077|Drug|Cyclophosphamide|Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
75636288|NCT02792283|Biological|whole blood collection|
75785717|NCT01287806|Drug|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days
75785718|NCT01287806|Drug|blank group|standard treatment
75651752|NCT05678478|Other|semi-directed interview concerning the experience of adolescents and their parents on Lyme borreliosis and on the tick.|"semi-structured interview on the experience of adolescents and their parents on Lyme borreliosis and the tick.~The interviews will be semi-directed in physical presence. Three interviews will be conducted.~The minor will be questioned first, then the parent(s). And finally, the whole family in one interview. All interviews will be audio recorded with parallel note taking in order to best transcribe the visual expressions. The interviews will be transcribed in writing and pseudonymised."
75785719|NCT01186172|Drug|Ethanol-lock therapy|Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
75785720|NCT01186172|Drug|Antibiotic-lock|Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
75922018|NCT02290470|Drug|Olanzapine|"Drug: Olanzapine 10 mg oral~Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy)."
76078544|NCT01892345|Drug|Eculizumab|Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
76078545|NCT01892345|Drug|Placebo|Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
75329367|NCT04358497|Drug|Ibuprofen 400 mg|NSAID treatment
75329368|NCT05545683|Biological|VLA 2001|VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine
75329369|NCT04373291|Biological|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
75636289|NCT02791971|Behavioral|SpeakOut|"SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~Printed materials for recipients to keep and/or share with friends.~Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic."
75636290|NCT02791971|Behavioral|Alcohol Control Intervention|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
75636291|NCT02791737|Behavioral|Exercise Intervention|Complete individualized exercise program
75636292|NCT02791737|Other|Laboratory Biomarker Analysis|Correlative studies
75636293|NCT02791737|Procedure|Physical Therapy|Complete individualized exercise program
75636294|NCT02791737|Other|Quality-of-Life Assessment|Ancillary studies
75636295|NCT02791737|Other|Questionnaire Administration|Ancillary studies
75636296|NCT02535936|Procedure|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
75636297|NCT02788539|Behavioral|Our Whole Lives Website|OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
75636298|NCT05332470|Drug|Lamivudine and Dotiravir Sodium Tablets|3TC (300 mg p.o. q 24 h) plus DTG (50 mg p.o. q 24 h)
75636299|NCT02789319|Device|Blood Glucose Meter Systems|
75636300|NCT04222374|Procedure|Intervention in the UroCCR sites|"Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)~DNA extraction:~For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:~1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,~1 aliquot for the UroCCR biobank.~For patients from other UroCCR centers, only 1 aliquot will be constituted:~1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.~Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux."
75636301|NCT04222374|Procedure|Intervention in the CRB of Bordeaux University Hospital|"Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.~Overall packing of GWAS samples for shipment to the NCI.~Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study."
75636302|NCT04222374|Procedure|Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital|Transfer of the data associated with the samples to the NCI.
75636303|NCT04222374|Procedure|Subsequent intervention at the NCI (for information)|"Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.~GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples."
75785721|NCT03861182|Biological|Biological functionalization of the prosthetic materials by PRF|The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.
75785722|NCT03860948|Drug|Savolitinib Test Preparation|Test preparation (T): dry granulation savolitinib tablets.
75785723|NCT03860948|Drug|Savolitinib Reference Preparation|Reference preparation (R): wet granulation savolitinib tablets.
75329370|NCT04373291|Biological|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
75329371|NCT02849938|Device|TytoCare Device|Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
75329372|NCT04373447|Procedure|lap fundus-calot cholecystectomy|use laparoscopic fundus-calot approach
75329373|NCT04373447|Procedure|open cholecystectomy|use open approach
75329374|NCT05715801|Procedure|hyperbaric oxygen therapy|The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
75329375|NCT05715801|Procedure|conventional oxygen therapy|Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
75329376|NCT04373213|Diagnostic Test|Pleth variability index|The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19
75636304|NCT02791815|Drug|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
75636305|NCT02791815|Drug|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
75636306|NCT02389374|Drug|chloroquine|standard dose
75636307|NCT02389374|Drug|Artemether-lumefantrine combination|standard dose
75636308|NCT02389374|Drug|Primaquine|single dose
75636309|NCT02389374|Drug|Primaquine|14 days
75922019|NCT02290470|Drug|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
76078546|NCT01059760|Behavioral|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
76078547|NCT01059760|Behavioral|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
75329377|NCT04373135|Behavioral|Brief educational video|A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.
75329378|NCT05671107|Diagnostic Test|NET|Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep
75329379|NCT02851108|Drug|Methylene Blue|50 patients will receive methylene blue
75329380|NCT02851108|Drug|Primaquine|50 patients will receive primaquine
75329381|NCT04372667|Behavioral|Community score card approach|"The CSC intervention is a participatory community approach. Health care workers (HCWs), PMTCT clients identified the issues that most impacted PMTCT service quality and uptake, and came together to implement actions for improvement. The core implementation strategy is using dialogue in a participatory forum that engages both service users and service providers. The CSC consists of five core phases, repeated on a regular basis (called rounds), for the life of the project. The five core phases include:~Phase I: Planning and preparation~Phase II: Conducting the Score Card with the community~Phase III: Conducting the Score Card with service providers~Phase IV: Interface meeting and action planning~Phase V: Action plan implementation and follow-up"
75329382|NCT00358995|Behavioral|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
75636310|NCT02789475|Drug|Amlodipine|Amlodipine administration
75636311|NCT02789475|Drug|Rosuvastatin|Rosuvastatin administration
75636312|NCT05379777|Drug|Remimazolam|Remimazolam The starting dose of remimazolam is 1 mg/kg/hr. If sedation does not proceed successfully, increase the infusion rate by 0.2 mg/kg/hr in the next patient. (However, if the infusion rate is less than 0.6mg/kg/hr, the dose is increased by 0.1mg/kg/hr.) If sedation has progressed successfully until the end of surgery, the next patient will use the same dose with a probability of 0.89 or 0.11 It is reduced by 0.2 mg/kg/hr with a probability of (However, if the infusion rate is 0.6mg/kg/hr or less, reduce it by 0.1mg/kg/hr.)
75636313|NCT03649347|Behavioral|Augmented reality exposure therapy|Exposure therapy via utilization of augmented reality. Virtual objects will be placed on the patient's real environment for exposure therapy.
75636314|NCT02791347|Other|Nutrition Intervention|
75636315|NCT04202484|Drug|Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules|Toripalimab: 240mg IV Q3W;Tegafur,Gimeracil and Oteracil Porassium Capsules: 40mg/m2 Bid PO×14d Q3W;Oxaliplatin: 130mg/m2 IV Q3W
75636316|NCT02791425|Device|Brain Computer Interface (BCI) device|A BCI system to facilitate communication in intubated patients. Patients use the device in the ICU for communication for 2 hours a day for 3 consecutive days.
75636317|NCT02791425|Other|Communication picture board|The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
75785724|NCT03854708|Drug|3 pmol/kg*min pancreatic polypeptide|PP 3 pmol/kg*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
75922020|NCT03387410|Drug|Intravenous IRDye 800BK|Fluorescence of the ureter using IRDye 800BK
76078548|NCT05179551|Procedure|Proximal Medial Gastrocnemius Recession|. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied
75636318|NCT04225650|Other|Pulmonology consultation|In case of functional respiratory signs, a consultation with a pulmonologist will be booked. At the end of this consultation, if the doctor deems it necessary, other investigations will be proposed and/or regular follow-up will be organised.
75651753|NCT05672134|Diagnostic Test|Iohexol measurement|Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.
75785725|NCT03854708|Drug|10 pmol/kg*min pancreatic polypeptide|PP 10 pmol/kg*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
75922021|NCT04314388|Other|Intervention: Outdoor Walking Rehabilitation Programme|Participants in the intervention group will take part in an instructor led outdoor walking rehabilitation programme which will last for 3 months. Alongside this participants will also be asked to complete a home exercise programme.
75922022|NCT04314388|Other|Control: The light Stretches Programme|Participants in the control group will be asked to keep to their normal activities of daily living, and given 10 targeted active stretches of the upper and lower body.
76078549|NCT04399785|Other|Camrelizumab and SBRT|Camrelizumab: 200mg every 3 weeks; SBRT
76078550|NCT01059994|Drug|Placebo sildenafil|Oral, daily, 1 week.
76078551|NCT01059994|Drug|Sildenafil|oral, 25mg, daily for 1 week
76078552|NCT01061476|Device|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
75636319|NCT02380404|Procedure|Implants-supported locators placement|Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
76078553|NCT01061476|Other|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
75329383|NCT00358995|Behavioral|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
75329384|NCT04347395|Procedure|Respiratory Bundle & Prevention|The respiratory care bundle intervention comprised of: bed tilt, swallow screen, mouth wash and vaccinations. The bed tilt was a 30-degree whole bed-up positioning both day and night throughout the hospital stay and is shown in Figure 1. Swallow screen was undertaken within 48 hours of admission. Chlorhexidine mouth wash was prescribed initially four times daily. The protocol was amended to twice daily chlorhexidine mouth wash in August 2017 due to poor compliance with four times daily administration. Mouthwash administration was monitored in the intervention group only and deemed non-compliant if missed more than 3 times during the admission. Pneumococcal and influenza vaccination was offered at discharge or within 2-4 weeks post discharge, at no charge to the patient. Post discharge advice was to use pillows in bed to minimize the time the patient laid flat and to avoid lying down for an hour after meals.
75636320|NCT05375565|Other|weight bearing exercises|"Standing knee raise 10 rep x 2sets~Standing knee bend 10 rep x 2sets~Standing hip extension 10 rep x 2sets~Shallow squats 5 rep x 2 sets After 4 week gradually restricting the use of assistive device when patient become able to walk and stand for 10 mins then add stair climbing and descending with a step height not higher than 7 inch.~The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
75636321|NCT05375565|Other|non weight bearing exercises|"Seated knee flexion 10 rep x 2sets~Seated knee extension 10 rep x2sets~Use of stationary bicycle 10 mins~Side lying leg lift 10 rep x2sets~Straight leg raise 10 rep x 2sets The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
75785726|NCT03854708|Drug|Placebo|Placebo (saline solution) was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. The placebo consists of a 0.9 % saline solution containing 5 % albumin.
75785727|NCT03861260|Procedure|Rigid cystoscopy with urethral dilatation|Patients will have a general anaesthetic and a rigid cytoscopic examination of the bladder dilated with sterile water. The urethra will be dilated from FR20 in incremental diameter increases of 2 to French 32 if possible.
75785728|NCT03861260|Procedure|Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)|Patients will undergo flexible cystoscopy and intravesical installations of Hyaluronic acid (HA) + Chondroitin Sulphate (CS) (GAGs) weekly for 4 weeks and then at 8 weeks and 12 weeks.
75785729|NCT03860870|Drug|Clenbuterol Oral Product|Subjects ingest 4x20 microgram clenbuterol tablets
75785730|NCT03860870|Drug|Placebo|Subjects ingest placebo tablets
75785731|NCT01588262|Other|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
75785732|NCT01177514|Drug|Gabapentin|Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
75922023|NCT05172518|Drug|Taxane plus Intermittent Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 ~8 cycles(for the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
75922024|NCT05172518|Drug|Utidelone plus Intermittent Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 ~8 cycles(for the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
76078554|NCT01061476|Other|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
76078555|NCT01111162|Biological|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
76078556|NCT04398303|Biological|ACT-20-MSC|1 million cells / kg body weight in 100 ml in conditioned media
76078557|NCT04398303|Biological|ACT-20-CM|100 ml of conditioned media only
75329385|NCT02854540|Device|Hydrogel electrode-based iontophoresis|Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
75636322|NCT02791113|Other|Fractional Flow Reserve (FFR) Measurement|FFR is defined as the distal pressure to coronary lesion divided by the proximal coronary pressure. FFR is measured through a standard diagnostic catheter during coronary angiogram. FFR is used to guide whether to perform angioplasty or stenting or not in patients with coronary stenosis.
75636323|NCT02790957|Drug|Plerixafor|Single injection of 0.24 mg/kg Plerixafor
75636324|NCT02790957|Drug|Placebo|Single injection of an equal volume of NaCl solution
75636325|NCT00905424|Drug|Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
75785733|NCT01177514|Drug|Sugar pill|Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
75329387|NCT00930293|Behavioral|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
75329388|NCT00930293|Behavioral|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
75469657|NCT01941576|Drug|Placebo (0.9% sodium chloride)|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
75636326|NCT00905424|Drug|Antidepressant + placebo|Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
75636327|NCT04234269|Other|Assessment|Evaluation forms will be applied to the patients who meet the inclusion criteria by face to face interview method.The sociodemographic information of the patients and the time taken to answer the questions in the questionnaires will vary according to each patient, but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1 week intervals.
75785734|NCT00073008|Drug|GW572016 (lapatinib)|tyrosine kinase inhibitor
75785735|NCT01186484|Drug|JNJ-212082|250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
75785736|NCT01182974|Drug|paracetamol|1 gr of paracetamol PO/PZ/PR
75785737|NCT01182974|Drug|dypirone|1 gr PO/PZ/PR/IM
75785738|NCT03856502|Drug|8 mg of dexamethasone|Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.
75785739|NCT03856502|Drug|12,5 mg of 0,5 % of levobupivacaine|Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
75785740|NCT03960684|Device|Levita Magnetic Surgical System|Levita Magnetic Surgical System
75785741|NCT01094652|Dietary Supplement|Whole grain diet|Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.
75785742|NCT01094652|Dietary Supplement|Refined grain diet|The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
75785743|NCT01287884|Other|Venous Blood Gas|patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
75785744|NCT03741192|Device|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
75785745|NCT03856346|Diagnostic Test|Biometry|Biometry for phaco-vitrectomy procedures pre- and postoperatively
75785746|NCT01583478|Biological|incobotulinumtoxinA|Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
75785747|NCT01183052|Other|Training|20 sessions of training
75785748|NCT01327014|Drug|XueZhiKang (XZK), a botanic product with multiple components|4 capsules of study drug twice a day for 12 weeks.
75785749|NCT01327014|Drug|Placebo|4 capsules twice a day for 12 weeks.
75785750|NCT03854630|Drug|Engerix-B|The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.
76078558|NCT04398303|Biological|Placebo|100 ml of MEM-α
76078559|NCT03784287|Drug|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
75329389|NCT00930293|Drug|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
75329390|NCT02977767|Procedure|Conversational hypnosis|Conversational hypnosis starts since the enter of the nurse in patient's room and last since the nurse leaves the room. Change of canula is performed under conversational hypnosis.
75329391|NCT02855086|Biological|Cetuximab|Administered intravenously (IV)
75329392|NCT02855086|Drug|Cetuximab-IRDye 800CW|Administered intravenously (IV)
75469658|NCT01941602|Drug|prophylactic enoxaparin|enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
75469659|NCT01941602|Procedure|non-prophylactic|no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
75469660|NCT01941654|Radiation|preemptive local ablative therapy|
75636328|NCT02791035|Drug|Oral administration of Ipragliflozin|
75636329|NCT03753243|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
75636330|NCT03753243|Drug|Enzalutamide|Patients will receive daily oral doses of study drug (enzalutamide 160 mg/day), which will be administered as four capsules/day to be taken at or near the same time each day.
75636331|NCT02788617|Device|Diafert|The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
75636332|NCT02790879|Other|Transition pediatric - adult|
75785751|NCT01093560|Dietary Supplement|fat feeding|Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
75785752|NCT01177592|Device|VerifyNow, Verigene|Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
75785753|NCT03955848|Biological|Alloreactive NK cell infusion|Alloreactive NK cell infusion
75636333|NCT02790801|Other|observation|observation
75785754|NCT01291394|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
75922025|NCT05172518|Drug|Taxane plus Metronomic Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 ~8 cycles(For the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
75922026|NCT05172518|Drug|Utidelone plus Metronomic Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 ~8 cycles(for the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
75785755|NCT01089738|Drug|PF-03382792 0.5mg|0.5 mg PF-03382792, qd, for 14 days or placebo
75785756|NCT01089738|Drug|PF-03382792 1.5 mg|1.5 mg PF-03382792, qd, for 14 days or placebo
75922027|NCT02298270|Behavioral|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
75922028|NCT03724084|Drug|Cytarabine|Given IV
75922029|NCT03724084|Drug|Daunorubicin|Given IV
76078560|NCT03772743|Other|Culprit-only revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
76078561|NCT03772743|Other|Complete functionally-guided revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
76078562|NCT01111318|Drug|BI 10773|2 tablets BI 10773 25 mg single dose
76078563|NCT04760067|Other|Sports Injury Anxiety Scale|Sports Injury Anxiety Scale
76078564|NCT03571048|Behavioral|Reduced Calorie Diet (RCD)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
75329393|NCT02855086|Procedure|Tumor resection|Standard of care treatment
75636334|NCT02790645|Other|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
75785757|NCT01089738|Drug|PF-03382792 5 mg|5 mg PF-03382792, qd, for 14 days or placebo
75922030|NCT03724084|Drug|Daunorubicin Hydrochloride|Given IV
75922031|NCT03724084|Drug|Pinometostat|Given IV
75922032|NCT03621488|Other|Efficacy of Behavioral Self-Activation with virtual reality|Efficacy of Behavioral Self-Activation with virtual reality
75329394|NCT05368857|Drug|Afamelanotide|Up to 10 adult healthy volunteers will be enrolled in this study in which small areas of their skin will be exposed to UVR and skin samples taken. UV-induced DNA damage and repair will be analysed.
75329395|NCT02241005|Other|Theraworx™ bath wipes|Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
75329396|NCT02241005|Other|Standard bath wipes|Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
75469661|NCT01941654|Drug|Oral TKI|
75636335|NCT02790645|Other|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
75636336|NCT02790645|Other|Group 1b.Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
75636337|NCT02790645|Other|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
75636338|NCT00632580|Drug|intraarticular injection with ropivacaine|
75636339|NCT00632580|Drug|extraarticular injection with ropivacaine|
75785758|NCT01089738|Drug|PF-03382792 15 mg|15 mg PF-03382792, qd, for 14 days or placebo
75785759|NCT03854396|Drug|Prasterone|Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.
75922033|NCT03621488|Other|Efficacy of Behavioral Self-Activation without virtual reality|Efficacy of Behavioral Self-Activation without virtual reality
75636340|NCT02787993|Behavioral|Cognitive Behavioral Mult-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
75636341|NCT02789397|Drug|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
75785760|NCT03854396|Drug|Placebo|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.
75922034|NCT03133182|Drug|Polypharmacy|Patients who are taking >=5 unique prescription drugs in the 3 months prior to surgery
75922035|NCT02290548|Device|high flow nasal cannula|High flow nasal cannula used in postextubation patients
75922036|NCT03387332|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
75922037|NCT02290626|Drug|Elmental diet|elemental diet is administered using PEG.
75922038|NCT02290626|Drug|Semi-solid diet|Semi-solid diet is administered using PEG.
75329397|NCT05541081|Diagnostic Test|Point-of-care STI testing|"Testing for:~Chlamydia and gonorrhoea using the GeneXpert platform (Cepheid)~Trichomoniasis using the OSOM Trichomonas Rapid Test (Sekisui Diagnostics)~HIV and syphilis using the SD BIOLINE HIV/Syphilis Duo (Abbott Diagnostics Medical Co. Ltd)~Hepatitis B using the HBsAg2 rapid test (Abbott Diagnostics Medical Co. Ltd)"
75329398|NCT04347005|Drug|Cohort 1: AR882|Single dose of AR882 or matching placebo
75329399|NCT04347005|Drug|Cohort 2: AR882|Single dose of AR882 or matching placebo
75329400|NCT04347005|Drug|Cohort 3: AR882|Single dose of AR882 or matching placebo
75329401|NCT04347005|Drug|Cohort 4: AR882|Single dose of AR882 or matching placebo
75329402|NCT04347005|Drug|Cohort 5: AR882|Single dose of AR882 or matching placebo
75329403|NCT04347005|Drug|Cohort 6: AR882 Food Effect|Single dose of AR882 or matching placebo in a fed state
75329404|NCT04347005|Drug|Cohort 7: AR882 Solid Oral Formulation|Single dose of AR882 or matching placebo
75636342|NCT02789397|Drug|Placebos|IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
75636343|NCT03286725|Behavioral|Physical Education (PE) Programme|"A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.~The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons."
75636344|NCT05301972|Drug|BET Inhibitor|Bromodomain and Extra-Terminal Inhibitor
75785761|NCT03956160|Other|A co-design phase aims to ensure the feasibility and relevance of the proposed intervention and evaluation.|"4 participatory co-design workshops lasting 4 hours each that will follow a user-centered design approach: identification of end-user needs, prototyping/development of the intervention (case-management procedures and platform), iterative improvement, end-user testing.~Based on the cognitive social theory underpinning the intervention, scientific literature, an overview of existing organizations and the results of the Stroke 69 and Arthur Tybra studies (patient needs following the acute phase), the advisory committee will:~Define the case-manager's profile, and required knowledge and skills~Identify the resources and tools to be proposed on the Internet platform~Test the tools and content~Refine the program evaluation criteria~Test and validate the study procedures."
75785762|NCT01183130|Device|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
75785763|NCT01093638|Biological|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with infant formula
75785764|NCT01093638|Biological|Placebo|Oral formulation of placebo fed concomitantly with infant formula
75785765|NCT03856034|Device|Fetoscopy|Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).
75785766|NCT01183208|Drug|Intervention A|A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
75922039|NCT02294448|Drug|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
75329405|NCT04347005|Drug|Cohort 8: AR882 in combination with allopurinol|Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
75329406|NCT04347005|Drug|Cohort 9: AR882 in combination with febuxostat|Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
75329407|NCT02856490|Device|vSculpt|A genital vibration device that operates in two modes, vibration only or vibration and light, to help tone and tighten pelvic floor muscles.
75329408|NCT02856490|Device|InTone|A genital device using electric muscle stimulation to treat incontinence.
75922040|NCT04446572|Biological|Lactobacillus salivarius CECT5713|Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
75469662|NCT01941667|Behavioral|Daily Messages, Virtual Home Visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
75636345|NCT02789163|Device|Ultrasound|breast ultrasound; hand held and automated volume breast scanner
75636346|NCT05134428|Device|ADAM System|The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.
75329409|NCT00358293|Drug|Tizanidine (sublingual or oral)|
75329410|NCT02241083|Drug|Dopamine|
75329411|NCT02241083|Drug|Norepinephrine|
75329412|NCT02241083|Other|no medication|
75329413|NCT05367531|Device|Autoinjector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
75469663|NCT01941667|Other|Usual Care|Usual care as defined by by the Cardiology Department.
75636347|NCT02789241|Biological|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
75329414|NCT05367531|Device|Standard Injector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
75329415|NCT05367531|Device|Prefilled|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
75329416|NCT04376723|Other|Mental Health Mobile Application|Mobile phones will not be provided to participants, but app subscriptions will be provided.
75469664|NCT01941693|Behavioral|Integrated care|Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
75469665|NCT01941693|Behavioral|Usual care|Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
75636348|NCT02789241|Other|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
75636349|NCT04233411|Other|Mycoprotein ingestion|
75636350|NCT00816166|Device|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
75636351|NCT00816166|Drug|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
75636352|NCT02788851|Drug|Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine|Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
75636353|NCT02788851|Behavioral|Aerobic Exercise|Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
75636354|NCT03479580|Other|Patients with a cardiomyopathy|Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.
75636355|NCT05758324|Dietary Supplement|Nutri PNEA|4 sequences of 10 tablets (one intake)
75636356|NCT05758324|Dietary Supplement|Placebo|4 sequences of 10 tablets (one intake)
75636357|NCT02787915|Biological|DC1-CTL|Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
75636358|NCT04200027|Procedure|total mesorectal excision|Total Mesorectal Excision Total Mesorectal Excision is currently the standard technique for surgical treatment of RC. It was first described in 1982 by Bill Heald, and relies on the excision of the whole mesorectum within an intact mesorectal fascia, with the contained lymphatic system along with the tumour bearing bowel segment Total mesorectal excision
75636359|NCT05326594|Procedure|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
75636360|NCT05326594|Procedure|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
75636361|NCT05326594|Device|Inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
75636362|NCT05326594|Procedure|Heat Therapy|superficial heating for 20 minutes
75636363|NCT02786823|Dietary Supplement|Folic acid|tab. Folic acid 5 mg
75636364|NCT02786823|Dietary Supplement|Vitamin B12|tab. Vitamin B12 500 mcg
75922041|NCT03384368|Device|fractured level screws-distraction|four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
75922042|NCT05661292|Diagnostic Test|Fecal inmunochemical test|A fecal inmunochemical test will be performed prior to colonoscopy.
75341443|NCT04266392|Drug|[18F]-DCFPyl Ligand|To assess the performance of [18F]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
75636365|NCT02786823|Drug|Oral hypoglycemic agents [Metformin +/- Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~Sulfonylurea~Metformin~Metformin plus Sulfonylurea"
75636366|NCT05332314|Drug|NSAIDs|The patients will be given NSAIDs with a reduced dose of the standard opioids treatment.
75636367|NCT00815308|Drug|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8)
75636368|NCT00815308|Drug|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m^2,(Day1 in every week for Weeks 2-8)
75636369|NCT00815308|Drug|Cisplatin|Cisplatin,injection,loading dose 20 mg/m^2,(Day1 in every week for Weeks 2-8)
75636370|NCT00815308|Radiation|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
75636371|NCT05261958|Other|SAQ training|interventions listed above were applied on the players which will improve running mechanics and impove speed power and agility in football players
75636372|NCT03251313|Combination Product|JS001 120mg+GP|In this arm, JS001 120mg will be given at d1; Gem 1000mg/m2 d2,9; DDP(cisplatin) 75mg/m2 d2
75636373|NCT03251313|Combination Product|JS001 240mg+GP|In this arm, JS001 240mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
75636374|NCT03251313|Combination Product|JS001 480mg+GP|In this arm, JS001 480mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
75636375|NCT03251313|Combination Product|GP followed by JS001|In this arm,Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
75636376|NCT01039376|Biological|Ofatumumab|Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.
75636377|NCT01039376|Other|Observation|Observation/Safety Evaluation
75636378|NCT04729686|Other|Pericapsular Nerve Block|Per Standard Institutional Practice
75636379|NCT04729686|Other|Fascia Iliaca Nerve Block|Per Standard Institutional Practice
75636380|NCT04200183|Behavioral|iACTwithPain (ACT+compassion)|This intervention will deliver a eHealth ACT and compassion-based therapy (iACTwithPain) designed for chronic pain
75636381|NCT04200183|Behavioral|ACT-only intervention|This intervention will deliver the iACTwithPain intervention but without the delivery of explicit compassion.
75636382|NCT02610712|Drug|Ketamine|
75636383|NCT02789085|Device|ULF TENS stimulation|
75636384|NCT00705952|Other|Lifestyle intervention|Diet, exercise and behavioural change intervention.
75636385|NCT00905034|Drug|Methotrexate|200 mg/m^2 by vein on days 1 and 15.
75636386|NCT00905034|Drug|Vincristine|1.4 mg/m^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
75636387|NCT00905034|Drug|PEG-l-asparaginase|2500 International units/m^2 by vein on days 2 and 16
75636388|NCT00905034|Drug|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and 15-18.
75636389|NCT00905034|Drug|Rituximab|Rituximab 375 mg/m^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
75922043|NCT05661292|Diagnostic Test|Colonoscopy|A colonoscopy will be performed. Any polyp identified will be resected (polypectomy) and analyzed histologically. NOTE: The subject and colonoscopist will be blinded to FIT test results and risk category.
75636390|NCT02611804|Drug|Diclofenac sodium|
75636391|NCT02611804|Drug|Diclofenac sodium|
75636392|NCT02611804|Drug|Placebo|
75636393|NCT04233333|Device|method of fixation of the orogastric tube|Methods of fixation of the orogastric tube will be randomized
75636394|NCT02157636|Drug|CPI-0610|
75636395|NCT00706108|Behavioral|Observational study|Observational (descriptive) study of technical and non-technical performance
75636396|NCT00706186|Drug|Sodium Oxybate|The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient.
75636397|NCT04232865|Device|Biop System|"Stage 1 - Training:~Up to 320 women in whom a complete procedure with the Biop System will be performed. Biopsies will be taken solely based on colposcopy examination. Enrolled participants will include at least 80 participants Histopathology identified with a high-grade lesion and at least 80 participants Histopathology identified as normal or with a low-grade lesion.~Stage 2 - Validation:~Up to 330 HIV negative women in whom a complete procedure with the Biop System will be performed.~Validation stage will also include up to 165 HIV positive participants. All participants will be enrolled in up to 3 sites in South Africa."
75636398|NCT02611492|Drug|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
75636399|NCT02611492|Drug|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
75636400|NCT02611492|Drug|Aracytine (Ara C)|Age<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
75636401|NCT02611492|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils > 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
75636402|NCT02611492|Drug|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
75636403|NCT02611492|Drug|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
75636404|NCT02611492|Drug|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
75636405|NCT02611492|Drug|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
75636406|NCT02611492|Drug|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
75636407|NCT00706576|Drug|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
76078565|NCT03571048|Behavioral|Time Restricted Feeding (TRF)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
75341444|NCT01534897|Drug|GSK2118436|150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
75341445|NCT05121350|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.
75636408|NCT02788071|Dietary Supplement|FMT capsules|25 capsules per day for 12 days
75636409|NCT02788071|Dietary Supplement|FMT placebo|25 capsules per day for 12 days
75636410|NCT00828568|Drug|Imiquimod 5% manufactured by Taro|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
75636411|NCT00828568|Drug|Aldara - Imiquimod 5%|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
75636412|NCT00828568|Drug|Imiquimod Vehicle manufactured by Taro|Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
75636413|NCT01038752|Drug|Suramin Drug:Docetaxel Drug: Carboplatin|Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
75636414|NCT01038752|Drug|Placebo Drug: Docetaxel Drug: Carboplatin|Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
75636415|NCT00627380|Behavioral|Yoga lifestyle intervention|Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
75636416|NCT00627380|Other|Standard of care|Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
75636417|NCT00903630|Drug|Lenalidomide|administered by mouth at the assigned dose daily for each 28 day cycle
75636418|NCT00903630|Drug|liposomal doxorubicin|administered at a fixed dose of 40 mg/m^2 intravenously (IV) on day 1 of each 28 day cycle
75636419|NCT04302584|Drug|norepinephrine / Vasopressin|• The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
76078566|NCT01892189|Drug|Ketamine|Ketamine intravenous administration.
75785767|NCT01183208|Drug|Intervention B|A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
75636423|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
75636424|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
75636425|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
75636426|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
76078567|NCT01892189|Drug|TAK-063|TAK-063 tablets
76078568|NCT01892189|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
75341446|NCT05121350|Drug|Epirubicin|Epirubicin can inhibit the synthesis of DNA and RNA.
75785768|NCT01183208|Drug|Intervention C|A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
75785769|NCT01183208|Drug|Intervention D|A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
75785770|NCT01183208|Drug|Intervention E|A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
76078569|NCT04746729|Other|No intervention|No intervention
75341447|NCT05121350|Drug|Arotinib hydrochloride capsule placebo|Placebo of Anlotinib hydrochloride capsule
75341448|NCT01534975|Diagnostic Test|contrast agent|we are randomizing patients to different contrast agents.
75341449|NCT00583622|Drug|Bevacizumab|5 mg/kg by vein daily over 90 minutes for 2 Days
75341450|NCT00583622|Drug|Carboplatin|333 mg/m^2 by vein over 2 hours for 3 Days
75922044|NCT05661292|Biological|Optional collection of tissue, blood and urine for future biomedical research|Subjects may optionally participate in the collection of tissue, blood, and urine samples for future biomedical research. This procedure consists of taking a 15 ml sample of venous blood and 20 ml of urine. The tissue samples to be used will be those that have been taken for diagnostic purposes during the colonoscopy. Additional biopsies not required for medical care will not be taken. These samples will be used as long as they are no longer required to establish a diagnosis.
75922045|NCT02294526|Other|Sardine diet|Diet rich in sardine: 100g/day of sardine 5 times a week
75922046|NCT05172440|Drug|tislelizumab combined with axitinib|Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
75922047|NCT02290860|Procedure|Type 2 diabetes diagnosis test|Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
75922048|NCT02298426|Behavioral|Health Management|We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
75922049|NCT02298426|Behavioral|General Management|We provide general information about health. Information is provided through telephones and materials.
75922050|NCT02298426|Other|Placebo|We use placebo to replace the health product.
76078570|NCT03750201|Device|Direct Selective Trabeculoplasty|Laser surgery by automated direct automated SLT device to lower intraocular pressure
76078571|NCT03750201|Device|Selective Trabeculoplasty|Laser surgery by standard SLT device to lower intraocular pressure
75636427|NCT02875106|Device|12-point-ECG|routine recording will be 300 seconds
75636428|NCT02875106|Device|Polar V800|routine recording will be 300 seconds
75636429|NCT02875106|Device|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
75636430|NCT02875106|Device|Adidas Micoach smart run|routine recording will be 300 seconds
75636431|NCT02875106|Device|TomTom Runner Cardio HRM|routine recording will be 300 seconds
75636432|NCT00703144|Drug|piperacillin/tazobactam|piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
75636433|NCT00703144|Procedure|Pharmacokinetic|
75636434|NCT02788929|Device|Fitbit Charge HR|Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
75636435|NCT01037114|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
75636436|NCT01037114|Biological|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.
75636437|NCT01037114|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
75636438|NCT02979366|Drug|S64315 once a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
75636439|NCT02979366|Drug|S64315 twice a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
75636440|NCT03114033|Other|Targeted therapeutic mild hypercapnia|Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg
75636441|NCT03114033|Other|Targeted normocapnia (Standard care)|Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg.
76078572|NCT01062568|Drug|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
75636442|NCT02850198|Device|scalp electroacupuncture|
75636443|NCT02850198|Device|sham scalp electroacupuncture|
75341451|NCT00583622|Drug|Docetaxel|300 mg/m^2 by vein over 2 hours for 1 Day
75341452|NCT00583622|Drug|Gemcitabine|1,800 mg/m2 by vein over 3 hours for 4 Days
75636444|NCT00840970|Device|non-coated Intranasal Splint|placement of non-coated intranasal splint following FESS
75636445|NCT00840970|Device|Sinexus Intranasal Splint|placement of Sinexus Intranasal Splint placed following FESS
75636446|NCT04232475|Other|1 minute of stair climbing and descending|1 minute of stair climbing and descending
75636447|NCT04232475|Other|3 minute of stair climbing and descending|3 minute of stair climbing and descending
75341453|NCT00583622|Drug|Melphalan|50 mg/m^2 by vein over 15 minutes for 3 Days
75636448|NCT04232475|Other|10 minute of stair climbing and descending|10 minute of stair climbing and descending
75636449|NCT01054820|Drug|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
75785771|NCT01287962|Drug|apatinib|750 mg，po，QD； 28 days every cycle
75636450|NCT02062164|Procedure|bariatric surgery|The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.
75636451|NCT02062164|Other|conservative care|Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
75636452|NCT05343819|Drug|AON-D21|AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
75636453|NCT05343819|Drug|Placebo|Isotonic glucose solution identical in appearance to AON-D21.
75636454|NCT00840658|Behavioral|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
75636455|NCT00840658|Behavioral|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
75636456|NCT00840658|Behavioral|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
75636457|NCT00840658|Behavioral|Lecture-format presentation|60 minute lecture-format presentation on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). There are no theory-driven active skill building elements oriented towards safer sex or safer injection.
75636458|NCT02874248|Drug|15 mg E4/3 mg DRSP|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
75636459|NCT02874248|Drug|30 mg E4/6 mg DRSP|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
75636460|NCT02874248|Drug|60 mg E4/12 mg DRSP|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
75636461|NCT02874248|Drug|Visually matching placebo|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
75785772|NCT01287962|Drug|placebo|po，QD； 28 days every cycle
75785773|NCT03855956|Other|KB174|KB174 is a novel mixture of oligosaccharides.
75785774|NCT03855956|Other|Maltodextrin|Maltodextrin is a commercially available easily digestible polysaccharide.
75785775|NCT00058422|Biological|darbepoetin alfa|
75785776|NCT00058422|Biological|filgrastim|
75785777|NCT00058422|Biological|rituximab|
75785778|NCT00058422|Drug|cyclophosphamide|
75785779|NCT00058422|Drug|doxorubicin hydrochloride|
75922051|NCT02298426|Dietary Supplement|SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®|We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
75341454|NCT00583622|Procedure|Stem Cell Transplant|"Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest~Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen"
75341455|NCT01535365|Other|Heat|Application of heat pack to the back or neck sprain.
75785780|NCT00058422|Drug|prednisone|
75785781|NCT00058422|Drug|vincristine sulfate|
75785782|NCT00058422|Radiation|indium In 111 ibritumomab tiuxetan|
75785783|NCT00058422|Radiation|yttrium Y 90 ibritumomab tiuxetan|
75785784|NCT01183286|Behavioral|CFFONE|A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
75785785|NCT01183286|Behavioral|CF website|A CF-related educational website which has some areas of CF information and services relevant to adolescents.
75785786|NCT03854240|Other|Classic block (Group C) and modified block (Group M) groups|Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position by using ultrasound device
75329417|NCT05360667|Other|Standard care plus plus Exergame-based multicomponent training program|"The program contains PRT and functional movement of the four extremities but mainly upper limbs. We will use the commercialized exergame Ringfit Adventure (RFA) to deliver the program.~RFA is a ﬁtness action role-playing game. The player advances the story while exercising as the movement of the player is linked to the main character on the screen. The movements of the player and battle actions are based on performing certain physical activities using the Ring-Con and Leg Strap. RFA itself could estimate the optimal exercise intensity for each player and performs ﬁne-tuned up-and downregulation based on these physiological feedbacks. Therefore, it has become possible to provide an appropriate amount of exercise for all generations from children to the elderly.~The standard care is applied as usual in our LTCF. (descriped as the below in the control group)"
75785787|NCT03956628|Behavioral|stay safe program|Prevention consist of 5-6 lessons having topics about learning safety skills which includes identifying touch, safe and unsafe environment/events, bullying, the good or bad secrets and strangers.
76078573|NCT01062568|Drug|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
75636462|NCT02874248|Drug|75 mg E4/15 mg DRSP|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
75636463|NCT02787603|Other|Interruption of antibiotic treatment due to PCT measurement|In group A at day 5, if the patient shows no clinical signs of infection and PCT levels < 0,25ng/mL OR PCT > 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
75636464|NCT02788305|Drug|Misoprostol|Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
75636465|NCT01036724|Device|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX[TM]) and measuring the amount of radiation exposure duration for each.
75636466|NCT05758012|Drug|oxytocin|Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders
75636467|NCT05758012|Drug|Carbetocin|Participants will be randomized to receive Cabetocin after delivery of the baby's head and shoulders
75785788|NCT01089816|Biological|Local/Regional Public Health Notification|For any H5 positive results, notification of the result to the site's local/regional public health authorities.
75785789|NCT01288040|Behavioral|Split Belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
75785790|NCT02530866|Other|Lower glycemic targets|Women will be randomized to either standard or lower glycemic targets.
75636468|NCT05013528|Other|Bal-A-Vis-X training|"Bal-A-Vis-X training Performed thrice a week for 10 minutes after baseline assessment Standard Physical therapy treatment along with following exercises.~ball Rectangle~ball rectangle and 2 ball drop/pass/catch two-foot jumping forward, tandem walking on ground and tandem walking on the balance beam. ."
75922052|NCT02298582|Drug|intranasal fentanyl|During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
75922053|NCT02298660|Drug|BOTOX|"BOTOX® Total dose per patient: 200U Number of cycles:1 cycle~200 units of BOTOX® will be injected per procedure. BOTOX® will be diluted in 15mL saline to 20U/mL. BOTOX® injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX® will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia."
76078574|NCT03739281|Diagnostic Test|PET/MR|The included patients are imaged with PET/MR as part of the research protocol.
75329418|NCT05360667|Other|Standard care|The standard care in the control group is applied as usual in our LTCF, in the way of group activity, including calisthenics (that could be done in sitting position), horticultural therapy, and group activity of peace (like tabletop games). The programs are performed twice per week, about 30 to 60 minutes (depends on different activity), leading by a therapist.
75341456|NCT01535365|Other|Cold|Application of ice pack to the back or neck sprain.
75636469|NCT05013528|Other|Aerobic Training Group|"Aerobic training group performed exercises thrice a week for 10 minutes after baseline assessment.~Standard Physical therapy treatment along with aerobic training as Running is performed"
75636470|NCT02786667|Drug|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
75636471|NCT02786667|Drug|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
75636472|NCT00913276|Drug|Propofol|
75636473|NCT00913276|Drug|Sevoflurane|
75785791|NCT01094964|Biological|BCG solution|
75785792|NCT01094964|Biological|recombinant interferon alfa|
75785793|NCT01094964|Drug|epirubicin hydrochloride|
75785794|NCT01094964|Drug|mitomycin C|
75785795|NCT01094964|Other|laboratory biomarker analysis|
75785796|NCT01094964|Procedure|hyperthermia treatment|
75785797|NCT01094964|Procedure|quality-of-life assessment|
75785798|NCT01186952|Behavioral|Caloric restriction|The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.
75922054|NCT04446806|Drug|Ruxolitinib|Ruxolitinib as second treatment in patients with severe DS failed in responding to hormone.Furthermore
76078575|NCT03739281|Diagnostic Test|PET/CT|The included patients are imaged with PET/CT as part of normal clinical routine.
75329419|NCT04372901|Procedure|Digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
75329420|NCT04372901|Procedure|Digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement.
75636474|NCT04302116|Drug|Combination therapy with vigabatrin and prednisolone|High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
75636475|NCT04302116|Drug|Vigabatrin Tablets|Vigabatrin (50-150 mg/kg/day) twice daily for 4 months
75922055|NCT05575414|Behavioral|Didactic dietary sessions|Three one-hour online nutrition group classes will be scheduled at 17, 21 and 29 weeks gestation (± 1 week). Nutrient dense foods and beverages and limiting the intake of added sugars, sodium and saturated fat will be encouraged, as well as reading the nutrition facts label, individual goal setting and self-monitoring. Physician recommended physical activity will be encouraged. Food and beverage intake data will be measured by 24-hour dietary recalls collected on three non-consecutive days. Data will be collected by telephone interview by a registered dietitian or dietary technician on four separate occasions: 16, 20 and 28 weeks gestation (± 1 week) and 36 weeks of gestation. Details on portions consumed will be estimated using standard measuring cups and household utensils. Nutrient intake will be generated using Vision Software Nutrient Analysis Software and the United States Department of Agriculture Food Composition Database, Food Data Central.
75922056|NCT05575414|Behavioral|Education Tool|The standard patient education tool will take the form of a leaflet which will include 1. A definition of body mass index 2. A list of measures to be taken to limit weight gain in pregnancy. 3. A description of the major nutrients required in pregnancy (folate, iron, calcium, vitamin D and protein). and 4.A description of the six food groups with recommendations for the number of servings per day.
75922057|NCT03387254|Device|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
75922058|NCT03387254|Device|VR + sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
75922059|NCT03517878|Behavioral|Comprehensive CHW Program|"The comprehensive CHW Cohort will receive home visits from CHWs recruited, trained, and supervised by the Philani organization. Philani has a 30-year history of non-stigmatizing home-based support for women and children in Cape Town. The organization has been operating their comprehensive CHW program in the rural Eastern Cape since 2010; however, in the research areas, CHWs have only been active for one year prior to initiation of the study. Philani recruits CHWs that are positive peer deviants to serve as role models in the community. The CHWs then receive training, materials, and skills to address major community health challenges of HIV, TB, malnutrition, alcohol use, and depression. The CHWs also receive ongoing monitoring and supervision as well as support for difficult cases."
75922060|NCT03387176|Other|Implementation of a gluten-free diet|Patients will be placed on gluten free diet for 9-12 months.
75922061|NCT03384290|Drug|PRS-060|Drug
75636476|NCT02786511|Drug|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
75922062|NCT03384290|Drug|Placebo|PRS-060 Matching Placebo
76078576|NCT03014518|Other|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
75785799|NCT01186952|Behavioral|Diet intervention and structured exercise training program|Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
75785800|NCT01291472|Drug|Ketorolac Tromethamine|After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
75329421|NCT02963974|Device|Cochlear implant|Implantation
75341457|NCT00583700|Drug|Pentoxifylline|Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
75341458|NCT00583700|Drug|Vitamin E|Vitamin E (Over-the-counter) 400 I.U. once daily
75341459|NCT05540743|Drug|biologic DMARDs|follow up the clinical response in Egyptian population to the drug
75636477|NCT05756998|Device|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) (classic technique)|During CS , placement of CuT380 IUD at the top of the uterine fundus with ring forceps or manually; before closing the uterine incision, the strings were placed in the lower uterine segment. If the cervix was closed, dilatation from above with ring forceps or manually. Strings passed through the cervix with ring forceps, then checking that IUD remains at the fundus of the uterus prior to closing the uterine incision. The surgeon took a good care not to include IUD strings within the sutures. Six weeks postpartum; Patients will be questioned for any symptoms of complications or side effects. Pelvic examination (per speculum) and transvaginal ultrasound will be performed. Patient satisfaction will be assessed: pain using (VAS score), missed threads.
75651754|NCT05672134|Drug|Geranylgeranylacetone (GGA)|13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.
75651755|NCT05672134|Diagnostic Test|Echocardiography|The investigators will perform echocardiography to find changes in cardiac function.
75651756|NCT05672134|Diagnostic Test|6-minute walking distance test|6 minute walking distance test to compare exercise tolerance in participants.
75651757|NCT05672134|Diagnostic Test|EndoPAT|Use of EndoPAT to measure endothelial function.
75341460|NCT00584402|Drug|perflutren lipid microspheres|perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
75636478|NCT05756998|Device|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) ( New technique)|During CS, the plunger will be removed, the introducer remains in place and the arms of the IUD were released to be in a transverse position. The introducer will be inserted in the cervical canal through the uterine incision, threads might be shortened if needed or if couldn't be advanced into the cervical canal, The introducer containing the IUD will be then pushed upwards , towards the uterine fundus.The IUD will be placed at the uterine fundus and the IUD will be stabilized at its fundal position by grasping the fundus between the thumb anteriorly and the other fingers posteriorly. The uterine incision was closed while the introducer is in situ , then the introducer will be removed vaginally at the end of CS. Six weeks postpartum; Patients will be followed as in the classic technique group.
75636479|NCT05756998|Procedure|cesarian section|Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment & the fetus is extracted , followed by the placenta & membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis & closure of the abdomen in layers .
75636480|NCT04202562|Procedure|Ab interno trabeculectomy|Ab interno trabeculectomy performed after pupil contraction and 90 degrees ablation of the nasal trabecular meshwork
75636481|NCT04202562|Procedure|Cataract|Cataract surgery with minimal clear cornea incision and phacoemulsification
75922063|NCT02290938|Behavioral|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
75922064|NCT02290938|Other|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
75922065|NCT03571334|Drug|IncobotulinumtoxinA (Xeomin®, Merz) (INA)|IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
76078577|NCT03014518|Other|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
76078578|NCT05155137|Drug|Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)|Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
76078579|NCT05155137|Behavioral|Stroke Riskometer|the primary care units will be randomized to use Stroke Riskometer App together with health community workers to help in the lifestyle modifications
75636482|NCT04302194|Dietary Supplement|phenylalanine restricted diet|Infants with hyperphenylalaninemia on special formula and diet
75636483|NCT05756920|Drug|ABL301|single dose, IV infusion
75636484|NCT05756920|Drug|Placebo|single dose, IV infusion
75636485|NCT04219176|Diagnostic Test|Spectral optical coherence tomography|Swept-source optical coherence tomography (SS-OCT) is the latest milestone in retinal and choroidal imaging. Because its wavelength of 1050 nm, which is superior to the 840 nm of spectral domain optical coherence tomography (SD-OCT), it is able to overcome ocular opacities such as cataracts and vitritis, wich allows retinal and choroidal visualization of eyes whose fundus is not clearly visible. Consequently , SS-OCT allows visualization of the retinal and choroidal vascular networks, even in eyes with medium opacity
75636486|NCT04198077|Drug|Oxygen|Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
75636487|NCT04301960|Other|Single task training|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
75636488|NCT04301960|Other|Dual task training|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
75636489|NCT02890212|Dietary Supplement|selenium supplementation|administration of selenium pills (400 micrograms) for randomized subjects
75636490|NCT02890212|Dietary Supplement|placebo|administration of placebo pills for randomized subjects
75785801|NCT03960528|Procedure|Erector spinae plane block|Bilateral 20 ml Bupivacaine 0.25% + lidocaine 1% injected between erector spinae muscles and transverse process under direct vision.
75785802|NCT03960528|Procedure|Control group|20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
75341461|NCT01537315|Drug|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
75636491|NCT02850432|Procedure|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
75636492|NCT02850432|Other|Conservative treatment|rehabilitation with medical therapy
75798638|NCT01174290|Drug|Haloperidol decanoate|"IV q6h.~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~The patient is discharged from the ICU at Tufts MC.~10 days of study drug administration occurs.~The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
75341462|NCT01537315|Other|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
75469666|NCT01941706|Behavioral|Project UPLIFT|Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
76078580|NCT01881425|Procedure|Glaucoma Surgery|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure."
75922066|NCT03571334|Drug|Normal saline|Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
76078581|NCT01881425|Device|InnFocus MicroShunt|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure."
75922067|NCT02291094|Drug|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
75922068|NCT02291094|Drug|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
75636493|NCT05387577|Drug|Estradiol Tablets|Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
75636494|NCT05387577|Drug|Transdermal patch|Estradiol patch therapy for 8 weeks
75636495|NCT05387577|Drug|Estradiol Tablets|Oral estradiol 1 mg BID for 8 weeks
75798639|NCT01174290|Drug|Placebo|"D5W 0.2mL IV q6h~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~The patient is discharged from the ICU at Tufts MC.~10 days of study drug administration occurs.~The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
75636496|NCT02850354|Other|anti-g maneuvers|investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
75636497|NCT02787759|Other|Hands-Free Walking|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
75636498|NCT02787759|Other|Challenge Based plus Hands-Free'|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
75636499|NCT01052714|Behavioral|Lifestyle Balance|Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
75798640|NCT03859440|Device|DSiHy Silicone hydrogel soft contact lens|•Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.
75922069|NCT03384056|Device|Self Pressurized Airway Device with Blocker|used in adult low risk females undergoing elective gynecological operations
75922070|NCT03384056|Device|Proseal Laryngeal Mask Airway|used in adult low risk females undergoing elective gynecological operations.
75922071|NCT03387098|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
75922072|NCT03387098|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
75922073|NCT03387098|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
75922074|NCT03387098|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
75922075|NCT03387098|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
75922076|NCT03387098|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
75922077|NCT03387098|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
75636500|NCT02786433|Other|conventional physiotherapy|
75636501|NCT02786433|Other|Virtual Reality with X- Box Kinect®|
75636502|NCT03573609|Device|Supranav|Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
75922078|NCT03387098|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75922079|NCT03387098|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75922080|NCT03387098|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
76078582|NCT04165473|Behavioral|Training Program for Developing Social- and Personal Resources|"The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants."
75636503|NCT04702620|Device|Ventica® device from Revenio|Measurement of expiratory flow variability for the detection of bronchospasm in infants
75636504|NCT05385393|Procedure|Arthroscopic posterior capsulotomy of the knee|"The arthroscopic posterior capsulotomy of the knee is performed according to the predefined surgical technique, which was described in detail in the following publication:~Malinowski K, Góralczyk A, Hermanowicz K, LaPrade RF, Więcek R, Domżalski ME. Arthroscopic Complete Posterior Capsulotomy for Knee Flexion Contracture. Arthrosc Tech. 2018 Oct 15;7(11):e1135-e1139. doi: 10.1016/j.eats.2018.07.008. PMID: 30533360; PMCID: PMC6262078."
75469667|NCT01941732|Drug|Sildenafil|
75469668|NCT01941758|Biological|trivalent influenza vaccine|
75469669|NCT01941758|Other|laboratory biomarker analysis|Correlative studies
75636505|NCT02850120|Procedure|Tension-free vaginal tape (TVT)|Surgical insertion of Tension-free vaginal tape (TVT) polypropylene mesh in the treatment of stress urinary incontinence.
75469670|NCT01941771|Drug|Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
75636506|NCT02850120|Procedure|Trans-obturator tape (TOT)|Surgical insertion of Trans-obturator tape (TOT) polypropylene mesh in the treatment of stress urinary incontinence.
75785803|NCT03854162|Device|SMART Guide|The device manufactured according to a digital plan based on patient anatomy. Guiding sleeves are used, through which bone drills are applied. These sleeves sit in a plastic template that is a negative of the patient's dentition, so that the guide is properly stabilized during the operation. The position of the sleeves is calculated from the surgical plan in a way that they guide the drills in the planned position.The material of the template is medical plastic, the sleeves are made of medical steel.The device is applied by the dentist during the implant surgery. The template is placed on the remaining dentition of the patient and stabilized this way. By this, the sleeves are also stabilized in their planned position. Access through the soft tissue can be prepared through the given sleeve with a circular trephine, but the system also supports flap surgery. As access has been established, the dentist performs the surgical protocol as planned.
75785804|NCT02530632|Drug|Propofol|General anesthesia maintained with intravenous propofol infusion
75785805|NCT02530632|Drug|Sevoflurane|General anesthesia maintained with inhalational sevoflurane
75785806|NCT02530632|Procedure|General anesthesia induction|Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
75785807|NCT01183364|Drug|STA-9090 (ganetespib) with Docetaxel|One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
75785808|NCT00072384|Drug|liposomal vincristine sulfate|Given IV
75785809|NCT00072384|Procedure|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
75785810|NCT00072384|Procedure|laser surgery|Surgery using a laser (instead of a scalpel) to cut tissue
75922081|NCT03387098|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
76078583|NCT01064284|Drug|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
75469671|NCT01941771|Drug|Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
75469672|NCT01941784|Other|educational intervention|Undergo health education program
75469673|NCT01941784|Other|counseling intervention|Undergo health education program
75636507|NCT02850120|Procedure|Suprapubic sling (SS)|Surgical insertion of Suprapubic sling (SS) polypropylene mesh in the treatment of stress urinary incontinence.
75636508|NCT05383677|Drug|Anifrolumab|Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
75636509|NCT05383677|Drug|Placebo|Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
75636510|NCT02850042|Behavioral|Occupation-based practice (OBP)|
75636511|NCT02850042|Behavioral|Modified-constraint induced therapy (m-CIT)|
75651758|NCT05672134|Diagnostic Test|Para-amino Hippuric Acid test|PAH-measurement to measure ERPF.
75651759|NCT05672134|Diagnostic Test|Electrocardiogram|12-lead Electrocardiogram
75651760|NCT05664100|Drug|FX-345|Single intratympanic injection of FX-345
75651761|NCT05664100|Drug|Placebo|Single intratympanic injection of placebo
75785811|NCT00072384|Drug|carboplatin|Given IV
75785812|NCT00072384|Drug|etoposide|Given IV
75636512|NCT03742635|Other|General Movements Assessment|Prechtl's Assessment of General Movements (GMA) is a tool used in early infancy to identify infants at high risk of cerebral palsy and neurodevelopmental impairment. General movements are complex motor patterns that involve the entire body, moving fluidly in different directions through the arms, legs, and trunk with variable speed, amplitude, force and intensity. During fetal development, spontaneously generated motor patterns, including general movements, can already be observed. The GMA is a functional assessment of the maturing nervous system that takes advantage of the fact that typically developing infants will have a progression in their general movements. This pattern is characterized by a writhing pattern in the early weeks post-term, followed by the emergence of fidgety movements at 3-5 months of age.
75636513|NCT02785575|Other|HeProCalc algorithm|Heparin and protamine dosage calculated by the algorithm HeProCalc
75785813|NCT00072384|Biological|filgrastim|Given subcutaneously
75785814|NCT01183442|Drug|vitamin D|orally administered 2800 IU of vitamin D or placebo daily
75785815|NCT02525120|Device|Triojection|Triojection is system intended to deliver a specific amount of ozone to a herniated disc.
75785816|NCT02525120|Procedure|Surgical discectomy|Patients will receive surgery to remove the herniated disc material.
75785817|NCT01183598|Drug|tocilizumab [RoActemra/Actemra]|maintenance dose
75785818|NCT01095042|Behavioral|emotion|Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
75636514|NCT05058144|Dietary Supplement|Drinkable solution|the volunteer will consume the volume 300 ml of water with
75636515|NCT04232709|Other|Shared electronic patient record|MedChart allows access to a shared electronic patient record that contains selected information related to a patient's cancer treatment. If a patient contacts the after-hours telemedicine service, the oncology nurse will have access to this shared record
75636516|NCT04232241|Drug|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
76078584|NCT01064284|Drug|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
75922082|NCT03387098|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
75636517|NCT01372254|Behavioral|Standard Treatment|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
75636518|NCT01372254|Behavioral|BAD-AS|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
75636519|NCT01372254|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
75785819|NCT01187108|Drug|N-acetylcysteine|NAC 600 mg oral once daily
75469674|NCT01941784|Behavioral|telephone-based intervention|Receive follow-up phone calls
75329422|NCT04372589|Drug|Heparin|"Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement."
75329423|NCT05537493|Other|Telerehabilitation|It will be followed by exercising on whatsapp
75469675|NCT01941784|Other|questionnaire administration|Ancillary studies
75785820|NCT01187108|Drug|Acetazolamide|Acetazolamide 250 mg oral once daily
75469676|NCT01941784|Procedure|quality-of-life assessment|Ancillary studies
75785821|NCT01187108|Drug|Placebo pills|1 (or 2 in the placebo group) empty gel capsules
75922083|NCT03387098|Drug|lovaza|Omega-3-acid ethyl esters
75922084|NCT03387098|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
75922085|NCT03387098|Procedure|SBRT|Stereotactic Body Radiation Therapy
75329424|NCT05537493|Other|Face to face|It will be followed by face to face
75329425|NCT04364399|Biological|Mumps vaccine|One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50
75469677|NCT01941797|Behavioral|interruption of oral hygiene|
75469678|NCT01941810|Dietary Supplement|bovine lactoferrin supplement|Given PO
75469679|NCT01941810|Other|questionnaire administration|Ancillary studies
75469680|NCT01941810|Procedure|quality-of-life assessment|Ancillary studies
75469681|NCT01941810|Other|laboratory biomarker analysis|Correlative studies
75469682|NCT01941849|Drug|Vandetanib|100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
75922086|NCT02298972|Behavioral|Nurse support and selfmanagement intervention|
75922087|NCT02577016|Drug|Sitagliptin|50 mg tablet administered orally
75922088|NCT02577016|Drug|Placebo|Placebo to sitagliptin administered orally
75922089|NCT02577016|Drug|Ipragliflozin|50 mg tablet administered orally as background medication
76078585|NCT04611815|Procedure|Total knee arthroplasty|Participant will undergo robotic-assisted or conventional total knee arthroplasty
75922090|NCT03520010|Behavioral|Externally-facilitated implementation|NHs randomized to the externally-facilitated arm will attend the same kickoff meetings and have access to the same online resources as the control arm but will also be assigned a clinical coach and will have the opportunity to participate in a series of hosted peer-to-peer learning opportunities. The clinical coach will meet regularly with NH staff to guide the facility through implementation of the Wisconsin UTI Improvement Toolkit.
76078586|NCT04611815|Diagnostic Test|Computer tomography scan|CT scans of the affected knee joint before and after the surgical procedure
76078587|NCT04611815|Diagnostic Test|biomechanical assesment|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
75636520|NCT02785653|Drug|Sevoflurane|Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
75636521|NCT02785653|Drug|Rocuronium|rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
75636522|NCT01052480|Biological|Anti-Influenza Immune Plasma|2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
75636523|NCT01052480|Drug|Standard Care|All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
75636524|NCT02758860|Procedure|Colonoscopy|Patients will be submitted to diagnostic colonoscopy
75636525|NCT02787447|Drug|TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
75636526|NCT02787447|Radiation|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
75636527|NCT02787447|Drug|Thymosin Alpha 1|Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
75636528|NCT00904722|Drug|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
75636529|NCT00904722|Drug|Rituximab|Administered intravenously at the standard dose of 375 mg/m^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
75636530|NCT02909361|Drug|Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
75636531|NCT02873858|Other|smell and taste tests|
75636532|NCT02787525|Other|Questionnaire|"A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone."
75636533|NCT04301024|Other|assessing the nitrous oxide misuse|assessing the nitrous oxide misuse among teenagers consulting in an addioctology center dedicated to young drug users in montpellier
75636534|NCT02849886|Drug|T lymphocytes iCASP9 ΔCD19|Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene
75636535|NCT02849886|Drug|Dimerizer drug AP1903|"AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~Grade ≥3 toxicity attributable to GMC."
75636536|NCT02785497|Other|Control group|will be turn on the equipment, positioning the patient but no put intensity
75636537|NCT02785497|Other|Treatment group|This group will receive electrostimulation
75785822|NCT01095120|Drug|Tesetaxel|"For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.~For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.~For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2."
75785823|NCT01187888|Drug|Rasagiline|tablet once daily 1 mg 1 year
76078588|NCT01891721|Behavioral|Brain Fitness Program (BFP)|"This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session."
75329426|NCT04364399|Biological|measles, mumps and rubella combined vaccine, live|One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50
75329427|NCT02982551|Drug|Insulin|Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity
75329428|NCT02982551|Other|Taste Task|Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.
75469683|NCT01941849|Radiation|131I-mIBG|Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
75785824|NCT01187888|Drug|Sugar pill|tablet once daily one year
75922091|NCT03520010|Behavioral|Internally-driven implementation|Study NHs randomized to the control arm will participate in kickoff meetings introducing the different UTI toolkit components. The meeting will also cover topics on how to assemble a change team, how to use the different tools in the UTI toolkit, and how to track process and outcome measures to monitor progress. NHs assigned to the control arm will have access to a web-based data tracking tool that will allow them to trend a number of study outcomes (e.g., number of monthly urine cultures and UTI treatment events) in their facility over time. Instructions and educational tools will be made available as an online resource but otherwise NHs in the control arm will be expected to implement the Wisconsin UTI Improvement Toolkit using existing internal resources.
76078589|NCT01891721|Behavioral|Cognitive Package (Cogpack)|"This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises."
75329429|NCT02982551|Other|Magnetic Resonance Imaging|Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.
75329430|NCT02982551|Drug|Dextrose|During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.
75636538|NCT01340430|Drug|Trastuzumab|neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
75636539|NCT01029782|Drug|IV cefazolin plus oral probenecid and placebo cephalexin|Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
75329431|NCT04745481|Device|Trunk stabilization training device|"Conventional rehabilitation 30min daily, 20times 4weeks~+Trunk stabilization training device 30min daily, 20time 4weeks"
75636540|NCT01029782|Drug|Oral cephalexin and saline IV plus probenecid placebo|Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
75636541|NCT04232319|Behavioral|Sleep Hygiene Training|"The intervention will last approximately 45 minutes, and will be provided once/week for 3 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge regarding sleep hygiene strategies and examples on how to apply these strategies to improve sleep quality."
75636542|NCT01146990|Drug|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
75636543|NCT04232007|Device|closed-loop system for vasopressor administration|closed-loop system for vasopressor administration
75636544|NCT02785419|Behavioral|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
75636545|NCT04583748|Behavioral|Sahaj Samadhi Meditation|Sahaj Samadhi Meditation (SSM) is a form of automatic self-transcending meditation that involves relaxed attention to a precise sound (mantra), to allow stress reduction and deep relaxation. This technique is easy to learn and offers the support of a group and facilitator.
75469684|NCT01941862|Behavioral|Psychoeducation and Cognitive Bias Modification|
75469685|NCT01941888|Drug|Propofol|
75636546|NCT04583748|Behavioral|Health Enhancement Program|The Health Enhancement Program (HEP) is a standardized program used to teach participants about health promotion, including the benefits of a lifestyle of healthy diet, music, recreation, and exercise. In HEP, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes.
75636547|NCT02785341|Other|questionnaires every 6 weeks (T0, T1, T2, T3 and T4)|Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals
75922092|NCT04465110|Dietary Supplement|Grape Seed Extract|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
75922093|NCT03391700|Drug|Rocuronium(deep)|In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).
75922094|NCT03391700|Drug|Rocuronium(moderate)|In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
75922095|NCT02294760|Device|Subsensory|The stimulation is set to 90% of the sensory threshold.
75922096|NCT02294760|Device|OFF|The stimulation is turned OFF.
75922097|NCT02294838|Device|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
75922098|NCT02294838|Other|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
75469686|NCT01941888|Drug|Midazolam|
75469687|NCT01941888|Device|Target Controlled Infusion|
75469688|NCT01941901|Drug|Calcium electroporation|Intratumoral injection, once only treatment.
76078590|NCT01891721|Behavioral|Commercial Computer Games (Sporcle)|"Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours."
76078591|NCT01064362|Drug|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
76078592|NCT01064362|Drug|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
75785825|NCT01187186|Drug|ASP1941|oral
75785826|NCT00054132|Biological|Bevacizumab|Given IV
75636548|NCT02785341|Other|6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)|
75636549|NCT02785341|Other|leptin level with a blood test every 12 weeks (T0, T2 and T4)|blood sample
75636550|NCT02901717|Drug|Mino-Lok|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
75636551|NCT02901717|Drug|Antibiotic lock|Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
75636552|NCT02849730|Device|Fentanyl/ropivacaine based Epi-PCA|Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.
75636553|NCT02786043|Drug|Propionyl-L-Carnitine Hydrochloride|1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
75785827|NCT00054132|Drug|Erlotinib Hydrochloride|Given PO
75785828|NCT00054132|Other|Laboratory Biomarker Analysis|Correlative studies
76078593|NCT03646461|Drug|Ibrutinib 560mg PO daily (Imbruvica)|BTK inhibitor combined with PD-1 inhibitor
76078594|NCT03646461|Drug|Cetuximab|Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
76078595|NCT03646461|Drug|Nivolumab|Nivolumab 3mg/kg biweekly 28 day cycle
76078596|NCT03013738|Behavioral|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
75785829|NCT01093716|Device|Magstim Rapid® (rTMS)|Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
75922099|NCT02294838|Other|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
75922100|NCT03391544|Procedure|V4c toric ICL implantation surgery|The size and power of the V4c toric ICL were determined following the manufacturer's guidelines using a modified vertex formula. Emmetropia was the target refraction following surgery in all cases. Before surgery, three centration points were marked using the slit lamp while the patient, in sitting position, fixated on the center of the slit-lamp beam, which was narrowed as much as possible.
75922101|NCT03383822|Drug|Intranasal insulin|Humalog lispro 40 IU intranasally
76078597|NCT03013738|Other|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
76078598|NCT01880957|Drug|Lithium|
76078599|NCT01880957|Drug|Lamotrigine|
75636554|NCT03530163|Device|Respiratory Muscle Training|Subjects will breathe through a custom isocapnic Respiratory Muscle Training method developed in-house. The initial breathing frequency will be 30 breaths per minute. Subsequent sessions will begin with 20 minutes of breathing at the highest rate attained on the previous training day. During the last 10 minutes of each session, breathing rate will increase by 1-2 breaths/min.
75636555|NCT03530163|Device|Sham Breathing Training|Each subject in the sham group will be prompted to hold his breath for 10 seconds every 30 seconds (two times each minute) while breathing on a circuit visibly identical to that used in Respiratory Muscle Training. The subject will breathe ambient air normally after each breath hold. Each sham session will last 30 minutes total.
75636556|NCT02847546|Device|True™ Flow Valvuloplasty Perfusion Catheter|Balloon Aortic Valvuloplasty as preparation step in implantation of a Tanscatheter Aortic Valve Implantation (TAVI).
75785830|NCT01588340|Procedure|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
75785831|NCT01588340|Procedure|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
75785832|NCT01093872|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Upon recruitment, all patients will undergo a 1 week treatment consisting of 5 rTMS sessions~Repetitive TMS consists of 1000 stimulations/ day at 1 Hz and 110% of the motor threshold, for five consecutive days over the left AC."
75785833|NCT03853850|Behavioral|Mobile phone text messages|From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (***) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
75785834|NCT01187264|Drug|Methotrexate|once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
75798641|NCT03859440|Device|CE-marked Silicone hydrogel soft contact lens|"・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay"
75922102|NCT03383822|Drug|Intranasal placebo|Diluent intranasally
75922103|NCT02294916|Device|AWS|Video-laryngoscopy 1
75922104|NCT02294916|Device|Intubrite|Video-laryngoscopy 2
75922105|NCT02294916|Device|AirTraq|Optical-laryngoscopy
75922106|NCT02294916|Device|MIL|Direct-laryngoscopy
76078600|NCT04152837|Drug|Lixivaptan|Oral vasopressin V2 receptor antagonist
76078601|NCT01064830|Drug|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
76078602|NCT01064830|Drug|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
75636557|NCT02785965|Device|electroacupuncture|Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
75636558|NCT02785965|Behavioral|lifestyle modification|The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
75636559|NCT04682028|Other|professional care|The trained nurses provide professional care for the patients.
75636560|NCT04682028|Other|coventional care|nurses provide coventional care for the patients.
75636561|NCT04232397|Drug|Anlotinib|anlotinib 8mg qd po
75636562|NCT02785887|Other|Geriatrician review|In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
75636563|NCT02849340|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
75636564|NCT02849340|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
75785835|NCT03854084|Other|The cranial osteopathic techniques|Technique of the temporal bones in favor of the free movement. Ear Pull technique: the hands of the osteopath holds the auricle of the individual with the thumb, index and the middle finger in a tweezer shape and with the elbows resting over the stretcher. Ruddy technique: The osteopath puts the thumbs on the eyelid of each eyeball.
75785836|NCT03854084|Other|Control group|Simulation of the techniques was used in the interventional group
75785837|NCT01183676|Drug|DEPAKOTE® Tablets, 500 MG|1 x 500 mg Tablet, under fed conditions
75785838|NCT01183676|Drug|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 x 500 mg Tablet, under fed conditions
76078603|NCT01879553|Biological|TIV|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
76078604|NCT01115452|Drug|5% Potassium nitrate|5% potassium nitrate solution
76078605|NCT01115452|Drug|2.5% Potassium nitrate|2.5% potassium nitrate solution
75329432|NCT04745481|Device|Conventional rehabilitation|"Conventional rehabilitation 30min daily, 20times 4weeks~+Conventional rehabilitation 30min daily, 20times 4weeks"
75329433|NCT02964910|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
75329434|NCT02156687|Device|Y mesh|Y mesh
75329435|NCT02156687|Device|Dual flat mesh|Dual flat mesh
75329436|NCT02965144|Other|no treatment|no treatment
75329437|NCT04376411|Diagnostic Test|Flow-cytometric assay|100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.
75329438|NCT04376411|Diagnostic Test|2D Echocardiographic analysis|Trans thoracic echocardiographic examination was performed through (PHILIPS -33) echocardiography device with broadband S5-1 transducer
75469689|NCT01941901|Drug|Electrochemotherapy with bleomycin|Intratumoral injection, once only treatment
75469690|NCT01941914|Drug|Calcium chloride|
75636565|NCT02785731|Procedure|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
75636566|NCT02785731|Procedure|Blood draw|Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
75636567|NCT02785731|Procedure|laparotomy or laparoscopy|A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
75636568|NCT03936192|Drug|glucosamine sulphate 1500mg and meloxicam 15mg|glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
75636569|NCT03936192|Drug|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
75636570|NCT03936192|Drug|Placebos|Placebo administered once daily for 12 weeks.
75785839|NCT03856112|Drug|Dexamethasone|Given PO
75785840|NCT03856112|Drug|Ixazomib|Given PO
75785841|NCT03856112|Drug|Ixazomib Citrate|Given PO
75785842|NCT03856112|Drug|Venetoclax|Given PO
75798642|NCT03862560|Other|Strength training program|Strength training program in female soccer players
75798643|NCT03862404|Drug|Bupivacaine-epinephrine|See previous description
76078606|NCT01115452|Other|Sterile water|Sterile water
76078607|NCT04126551|Other|Methylation status|Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
76078608|NCT01890785|Drug|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
75922107|NCT05101252|Device|senofilcon A C3|TEST Lens
75922108|NCT05101252|Device|Dailies Total 1 Multifocal Contact Lenses|CONTROL Lens
75636571|NCT02845635|Other|Personal history of multiple sclerosis|Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
75469691|NCT01941953|Drug|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
75469692|NCT01941966|Drug|Capecitabine|Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
76078609|NCT03571971|Other|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
76078610|NCT03571971|Other|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
75469693|NCT01941966|Drug|Mitomycins|15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
75636572|NCT02847390|Other|Education intervention|The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes superuser educational curriculum focused on delivering safe, evidence-based diabetes care in the hospital setting. The physician educational curriculum will consist of 10 case-based modules taught to internal medicine residents at two academic hospitals and taught to hospitalists at two academic hospitals and one community hospital. The nursing educational curriculum will consistent of 12 case-based modules taught to unit-based nurses at two academic hospitals and one community hospital. These educational interventions will be delivered over a 6-month time frame from August 2016-April 2017.
75636573|NCT02787135|Behavioral|emotion-oriented Cognitive Behavior Therapy|Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
75636574|NCT01029704|Drug|EGT0001442|"Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days."
75636575|NCT01029704|Drug|Placebo capsules to match EGT0001442|"Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days."
75636576|NCT02786979|Drug|Beraprost|Oral
75636577|NCT02786979|Drug|Aspirin|Oral
75785843|NCT03853070|Device|ED Coil / Electro-detach Generator v4|The ED Coil is used for vascular embolization with a platinum coil at the target lesion in a patient's blood vessel. The ED Detach Generator is intended to for use solely to detach the platinum coil from the delivery catheter of the ED Coil.
75785844|NCT01290380|Drug|ASA404, DMXAA, DXAA|ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
75785845|NCT03854006|Procedure|Cryoballoon pulmonary vein isolation|During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.
75798644|NCT03862404|Drug|Normal saline|See previous descreption
75922109|NCT03391310|Other|Honey (medicated)|Honey (medicated) dressing will be used in the experimental group
75922110|NCT02291172|Behavioral|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
75922111|NCT03514524|Other|PET-MR imaging|Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)
75922112|NCT03514446|Drug|Antibiotic therapy duration for 7 days|Antibiotic therapy for seven days
75922113|NCT03386786|Behavioral|Health Partner|Health Partner is a combination of a mobile application and a web-based portal.
75922114|NCT03386786|Behavioral|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
75922115|NCT03383744|Dietary Supplement|vitamin A supplementation|Each child received one capsule of 200,000 IU of vitamin A
75469694|NCT01941966|Radiation|Radiotherapy|Dose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks
75469695|NCT01941979|Drug|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
76078611|NCT03306862|Dietary Supplement|Whole yellow pea soup|Soup containing whole yellow peas
75469696|NCT01941992|Drug|SAMITAL®|
75469697|NCT01941992|Drug|Placebo sachets|
75469698|NCT01942018|Procedure|POEM|Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
75469699|NCT01942031|Behavioral|structured collegial feed back|Collegial feed back to primary care physicians at randomized primary care centers
75636578|NCT02689869|Drug|Ibrutinib|Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research & Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
75636579|NCT02689869|Drug|GA 101|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
75636580|NCT02847312|Other|High avenanthramide, phenolic acid|High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
75636581|NCT02847312|Other|Low avenanthramide, medium phenolic acid|Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
76078612|NCT03306862|Dietary Supplement|Split yellow pea soup|Soup containing split yellow peas
75785846|NCT03853928|Dietary Supplement|Probiotics|"Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII)."
75785847|NCT05167682|Other|Prehabilitation program|Patient will be asked to follow to catalog of procedures till surgery. Procedures catalog contains behavioral changes, physical training, nutritional counseling, conditioning of pulmonary function and optimization of drug of underlying diseases.
75469700|NCT01942044|Device|Promus element, Xience prime, and Nobori|
75785848|NCT01187576|Behavioral|Multi-professional team intervention with PAR, lifestyle brochure|Multi-professional team intervention with PAR, lifestyle brochure
75785849|NCT01187576|Behavioral|Ordinary recommendations on health behaviours, lifestyle brochure|Ordinary recommendations on health behaviours, lifestyle brochure
76078613|NCT03306862|Dietary Supplement|Potato soup|Soup containing potatoes
75329439|NCT04376411|Diagnostic Test|Two-Dimensional speckle tracking echocardiography|Two-Dimensional speckle tracking echocardiography was performed on grey scale images of the left ventricle. For offline analysis digital storage software (Qlab 10.4) was used. The frame rate was adjusted to be 60-90 frame/second.
75329440|NCT04364243|Other|Digitally supported home exercises|The training will comprise of 9 sessions (3 weekly) Each of the training sessions will last 20 minutes. This will result in a cumulative total intervention exercise time of 180 minutes.
76078614|NCT03564015|Other|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
75469701|NCT01942070|Device|Bioresorbable vascular scaffold|
75469702|NCT01942070|Device|Durable polymer everolimus-eluting metallic stent|
75469703|NCT01942083|Drug|OPB-111077|
75469704|NCT01942109|Drug|Furosemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
75469705|NCT01942109|Drug|Torasemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
75636582|NCT02847312|Other|Control|Control are matched with energy and insoluable fibre.
76078615|NCT03564015|Other|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
75329441|NCT02965534|Device|Spectacle/Glasses|
75636583|NCT02785809|Other|Pausing oral contraceptive|
75636584|NCT02847156|Other|Physical assessment|1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
75636585|NCT04405830|Procedure|Renal replacement therapy|Renal replacement therapy (RRT) refers to modalities of treatment that are used to replace the waste filtering functions of a normal kidney.
76078616|NCT04616651|Behavioral|Online Survey|Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
76078617|NCT04616651|Behavioral|Chatbot prototype|An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
75469706|NCT01942174|Biological|Prevenar 13|Vaccination at the beginning of the study (day 0)
75469707|NCT01942174|Biological|Pneumo23 / Pneumovax|Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company
75469708|NCT01942174|Drug|Methotrexate - Immediate|concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
75469709|NCT01942174|Drug|Methotrexate - Delay|"For period group, methotrexate is Initiated & month after the antipneumococcal vaccination by prevenar 13"
75469710|NCT01942187|Drug|Aripiprazole|Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.
75636586|NCT00221988|Drug|Levetiracetam (Keppra)|
75636587|NCT04200105|Device|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 22G EBUS needle
75636588|NCT04200105|Device|Acquire TBNB|Mediastinal and hilar lymph node sampling using the Acquire TBNB needle
75636589|NCT02849262|Drug|Omiganan (CLS001) topical gel|
75636590|NCT02849262|Drug|Vehicle topical gel|
75636591|NCT02341911|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
75636592|NCT02341911|Drug|Gemcitabine,carboplatin|Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
75651762|NCT05640583|Device|Hygieacare System|The device is an FDA cleared colon irrigation device, it will be used according to clearance. The sampling of the colon effluent sampled is the are of study.
75785850|NCT01183910|Dietary Supplement|Citrus Bioflavanoid Blend|Pill Taken Twice a Day
75785851|NCT01183910|Dietary Supplement|Calcium Carbonate|Oral Tablet Taken Twice a Day
75785852|NCT01588574|Biological|MT10109|Botulinum toxin type A
75785853|NCT01588574|Biological|BOTOX(Registered trade mark)|Botulinum toxin type A
75798645|NCT03865680|Drug|CPP-ACP|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
75922116|NCT02291250|Dietary Supplement|Blackcurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
75922117|NCT02291250|Dietary Supplement|Greencurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
76078618|NCT04616651|Behavioral|Open to Options (O2O) Program|Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
75329442|NCT04372511|Device|Binaural Beats|Device: Sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
75329443|NCT02965924|Drug|Phenylephrine 2.5%|Instilling phenylephrine 2.5% eye drop
75329444|NCT04364477|Procedure|transversus abdominis plane (TAP) block|The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.
75329445|NCT02241395|Biological|Intrathecal autologous bone marrow mononuclear cell transplantation|
75636593|NCT00152334|Drug|Botox|All patients meeting the inclusion criteria will undergo manipulation and casting until hindfoot stall is encountered. Hindfoot stall is defined as forefoot abduction to 60 degrees but persistence of hindfoot equinus. At hindfoot stall, subjects received Botox injections at 10 IU/kg into the gastrosoleus muscle complex. Following injections, subjects were recasted.
75785854|NCT03852914|Device|Sodium hyaluronate 2%|Each patient will receive a single injection of SH 2% and will be followed for 6 months. At 6 months follow up visit patients could be offered a second injection whenever and when they comply with the criteria established for re-treatment and will be followed for additional 6 months.
75785855|NCT01184066|Behavioral|ACTS Intervention|ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.
75636594|NCT02849028|Behavioral|sleep disorder|The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
75636595|NCT04200261|Drug|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
75785856|NCT01184066|Behavioral|Usual Care|Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
75329446|NCT02967016|Behavioral|Actigraph|following delivery a ActiGraph will be offered to patients to track their steps
75785857|NCT03853538|Drug|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one hemiface.
75785858|NCT03853538|Other|Semisolid vaseline|Product is applied to one hemiface.
75785859|NCT03853382|Behavioral|Cognitive analytic informed brief therapy|"The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings."
75329447|NCT04372277|Drug|Enstilar|topical Enstilar foam
75329448|NCT04372355|Drug|WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.
75636596|NCT04200261|Drug|sodium chloride|sodium chloride
75785860|NCT01188122|Device|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
75785861|NCT01187654|Biological|AC133|intra coronary injection of bone marrow derived AC133+ cells
75785862|NCT01187654|Biological|MNC|intra coronary injection of bone marrow derived MNC
75469711|NCT01942187|Drug|Bupropion|Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.
75469712|NCT01942187|Behavioral|Problem Solving Therapy|Weekly specialized psychotherapy
75469713|NCT01942239|Device|real time continuous glucose monitoring|
75469714|NCT01942291|Drug|Niacin|The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
75469715|NCT01942304|Procedure|Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation|
75469716|NCT01942304|Procedure|Anorganic bovine bone mineral in direct sinus augmentation|
75651763|NCT05635799|Other|Analysis of walking on flat ground|Analysis of walking on flat ground under different environmental conditions (visit 1)
75785863|NCT01187654|Biological|CONTROL|autologous serum injection
75329449|NCT05620667|Dietary Supplement|immature ponkan (Citrus reticulate) extract|Drink 25mL for once, and once a day.
75469717|NCT01942317|Other|Balneotherapy|
75636597|NCT02847000|Drug|Tetrahydrouridine|"Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
75636598|NCT02847000|Drug|Decitabine|"Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested ~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested ~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested ~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
75636599|NCT02784327|Drug|PRF110|
75636600|NCT03362541|Behavioral|MS INFoRm|MS INFoRm incorporates principles of self-management and adult learning theory. The contents address the sources of fatigue, ways of monitoring fatigue, and strategies to reduce fatigue.
75636601|NCT03362541|Behavioral|Usual Care Control Group|The usual care webpage will contain content from widely available resources about MS fatigue.
76078619|NCT01066624|Drug|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
76078620|NCT01066624|Other|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
76078621|NCT01066624|Device|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
75636602|NCT02849106|Procedure|biopsy to obtain a chemogram|All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
75636603|NCT04231149|Device|Test product 2|Test catheter 2
75636604|NCT04231149|Device|Test product 3|Test catheter 3
75636605|NCT04231149|Device|Comparator|SpeediCath Flex
75651764|NCT05635799|Other|Hospital Anxiety Disorder Questionnaire|performed during the inclusion visit
75785864|NCT04938284|Device|PAS|Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)
75922118|NCT02291250|Dietary Supplement|Blackcurrants with glucose OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
76078622|NCT01878383|Device|Genexpert assay|
76078623|NCT04123197|Other|Stress Challenge|The stress challenge will assess how different parts of the body react to stress. Participants will be given no specific details about the contents of the test before administration.
76078624|NCT05132907|Biological|HDT-301|HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))
76078625|NCT04398771|Drug|Rosuvastatin/Valsartan|Rovatitan QD for 12 weeks
76078626|NCT05117151|Diagnostic Test|hypotension prediction index|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
76078627|NCT01067716|Device|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
76078628|NCT01863953|Drug|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
76078629|NCT01863953|Drug|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
76078630|NCT01863953|Drug|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
75469718|NCT01942330|Procedure|Laparoscopic-Assisted Natural Orifice Surgery|Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
75785865|NCT04938284|Device|VNS|Non-invasive vagus nerve stimulation delivered through cymba concha & cymba cavum of the ear.
75329450|NCT05620667|Dietary Supplement|placebo|Drink 25mL for once, and once a day.
75329451|NCT05620667|Behavioral|time restricted feeding|Controlling a shortened period of time for eating within 8 hour each day.
75329452|NCT02968420|Biological|Human Papillomavirus 9-valent Vaccine, Recombinant|All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
75329453|NCT04364321|Drug|Clonazepam 0.5 MG|Clonazepam 0.02 mg/kg only one dose
75329454|NCT04364321|Drug|Diazepam Tablets|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)
75785866|NCT01290458|Dietary Supplement|Antioxidant vitamins|Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
75785867|NCT01184144|Drug|Pioglitazone|Pioglitazone, 30 mg, by mouth daily for 2 weeks
75785868|NCT03852680|Procedure|aneurysm clipping|treatment of wide necked intracranial aneurysms using different modalities as open surgery by clipping or endovascular techniques as coiling and flow diversion
76078631|NCT01863953|Drug|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
76078632|NCT01068964|Drug|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
75329455|NCT03039088|Other|Follow-up after 12 weeks after TNF alpha blockers initiation|
75329456|NCT05528913|Drug|Fasenra Prefilled Syringe|Fasenra 60mg s.c. administration at weeks 0,4 and 8
75329457|NCT05528913|Other|Matching Placebo Solution|Placebo s.c. administration at weeks 0,4 and 8
75329458|NCT02241473|Other|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
75329459|NCT05337345|Drug|Cendakimab|Specified Dose on Specified Days
75329460|NCT04364009|Drug|Anakinra plus oSOC|"Anakinra plus Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.~The patients will receive intraveinous injection of Anakinra 400mg from Day 1 to Day 3 (two injections of 100 mg each 12 hours) and 200mg the remaining 7 days. The total duration of Anakinra is 10 Days. Efficient dosage of Anakinra as previously described will be continued until Day 10"
75329461|NCT04364009|Drug|oSOC|Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.
75469719|NCT01942343|Drug|Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration|
75469720|NCT01942356|Procedure|TIVA - Hypotension|"Defined as: MAP < 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~Give 200 mL Fluid Bolus~If not successful, give ephedrine 5 mg bolus~Repeat from 1.) if even is not resolved after 3.)"
75636606|NCT04202250|Procedure|CEMP (closed-ended multiport catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously.A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
75636607|NCT04202250|Procedure|OESP (open-ended single port catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the open-ended catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously. A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
75636608|NCT02784249|Procedure|Goniotomy|Procedure: Goniotomy and trabecular excision with a novel ophthalmic knife in combination with planned cataract extraction via Phaco and PCIOL implant.
75636609|NCT02784249|Device|Trabecular Micro-Bypass Stent|Procedure: Trabecular Micro-Bypass stent implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
75636610|NCT02784249|Procedure|Cataract Extraction|Cataract extraction via Phaco and PCIOL implant.
75636611|NCT04908462|Drug|AL01211 or Placebo (Part A)|Five dose groups with doses ranging from 2mg to 60 mg
75636612|NCT04908462|Drug|AL01211 or Placebo (Part B)|Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days
75636613|NCT04218006|Genetic|Mutation Analysis|Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.
75651765|NCT05635799|Other|Analysis of walking on slopes|All assessments will be identical to the flat walking analysis: flat walking will be replaced by slope walking for all environmental conditions
75922119|NCT02291250|Dietary Supplement|Sugar matched water with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
75922120|NCT05662358|Drug|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
75922121|NCT05662358|Drug|Alendronate|oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
75922122|NCT05662358|Drug|Placebo|oral placebo weekly
75922123|NCT02299128|Other|Physical Therapy Treatment|
75469721|NCT01942356|Procedure|TIVA - Hypertension|"Defined as: SBP > 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1.) Labetalol 5 mg IV will be administered"
75469722|NCT01942356|Procedure|TIVA - Bradycardia|"Defined as: Heart rate < 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
75922124|NCT05082454|Device|Open repair|Open repair of the aortic heart valve and ascending thoracic aorta
76078633|NCT01068964|Drug|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
75329462|NCT04344015|Other|Plasma Donation|Previously infected COVID-19 patients will be recruited to donate convalescent plasma.
75329463|NCT03040414|Device|MedtronicMinimed 670G 3.0 hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
76078634|NCT03217162|Drug|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
75922125|NCT03383510|Other|Climate friendly diet|Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.
75922126|NCT03383510|Other|Organic diet|Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.
76078635|NCT03217162|Drug|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
76078636|NCT00768274|Drug|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
76078637|NCT00768274|Drug|Placebo|Placebo twice daily (b.i.d.) for 28 days
75329464|NCT03040414|Device|Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
75636614|NCT02850510|Behavioral|Brief Incredible Years parent training|The IY parent training programme (3-8 years) developed by Webster-Stratton at the Parenting Clinic, University of Washington, is a manualised and video-based training programme for parents of young children with conduct problems (Webster-Stratton and Reid, 2003a). Parents assigned to the short IY Basic (S-IY) condition were divided into groups of 10-12 parents. The S-IY was led by two experienced group leaders and parents met weekly for two-hour sessions at a public health care center in the community. The group leaders led discussions regarding central aspects of parenting on the basis of the video vignettes, role play and homework.
75329465|NCT02241629|Drug|placebo|placebo of levo phencynonate hydrochloride
75329466|NCT02241629|Drug|levo phencynonate hydrochloride|levo phencynonate hydrochloride
75329467|NCT04372043|Other|Questionnaire|"Sleep Hygiene Index and demographic questions."
75922127|NCT03383510|Other|Climate friendly and organic diet|The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.
75922128|NCT03383510|Other|Control group (Control diet)|"A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy."
75922129|NCT03517800|Other|Arterial embolization and/or surgical management.|Arterial embolization and/or surgical management.
75922130|NCT02291328|Other|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
75922131|NCT02291328|Other|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
75922132|NCT03391154|Drug|levothyroxin|90 female received levothroxine
75922133|NCT03391076|Diagnostic Test|FilmArray Respiratory Panel|An Multi-PCR method which can detect 20 pathogens in 45 minutes.
76078638|NCT01116466|Device|ActiGait|ActiGait - implantable drop foot stimulator
76078639|NCT04352842|Other|Echocardiography|An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography
75329468|NCT02863198|Device|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
75329469|NCT02959281|Other|Providing caring physicians with hemodynamic variables|NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
75329470|NCT04371965|Drug|Povidone-Iodine|Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.
75329471|NCT02959125|Other|NutFish Based Food Supplementation|Cookies contain 500 Calories and 15 gram protein make from nut and ocean fish
76078640|NCT02984475|Drug|Metformin|
76078641|NCT01069354|Device|Radiesse® Injectable Dermal Filler with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)
76078642|NCT01069354|Device|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
76078643|NCT03517917|Other|Tumour tissue collection|Collection of tumour tissue and blood
76078644|NCT01069510|Drug|Spironolactone 25mg|Spironolactone 25 mg daily for 12 months
76078645|NCT01069510|Other|Placebo|Placebo daily for 12 months
75636615|NCT02845050|Drug|Vinflunine|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
75922134|NCT02294994|Drug|tirofiban|
75922135|NCT03386630|Drug|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
75922136|NCT03386630|Drug|Hyperbaric bupivacaine+Morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
75922137|NCT03514290|Radiation|Low-lever laser|Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.
75922138|NCT03514290|Other|Tooth bleaching|Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
75922139|NCT03514290|Other|Placebo|The laser tip was positioned similarly to experimental group but without light irradiation
75922140|NCT03386552|Drug|Isifera+|Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer
75922141|NCT03386552|Drug|Buffer|Pertubation solution of Ringer-Acetate buffer
75922142|NCT02291406|Procedure|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
75922143|NCT02291406|Procedure|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
75922144|NCT03383432|Device|Intrauterine device|Copper T 380 A
75922145|NCT03383432|Radiation|Ultrasound|Transabdominal ultrasound
75922146|NCT03383432|Procedure|uterine sounding sparing technique|we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
75922147|NCT03132714|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
75922148|NCT03132714|Drug|Amoxicillin 500mg|Administration of Amoxicillin 500mg tid for 7 days
75922149|NCT03132714|Drug|Metronidazole 400mg|Administration of Metronidazole 400mg tid for 7 days.
75922150|NCT03132714|Drug|Clarithromycin 500mg|Administration of Clarithromycin 500mg bid for 7 days
76078646|NCT04398069|Procedure|hemodynamic optimisation aiming to achieve normal cerebral perfusion|hemodynamic optimisation aiming to achieve normal cerebral perfusion: titration of catecholamin infusion.
76078647|NCT03013660|Other|Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
75636616|NCT02845050|Drug|Cisplatin|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
75636617|NCT02845050|Procedure|Radical cystectomy|max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
75636618|NCT02690922|Drug|Dasatinib|100mg (d1-d84)
75636619|NCT02690922|Drug|prednisone|60mg/m2 d1-24
75636620|NCT02690922|Drug|dexamethasone|10mg/d 3-7days
75636621|NCT02690922|Drug|methotrexate|3g/m2 1day
75636622|NCT04636944|Other|web-based COMPASS intervention|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). COMPASS is tailored to gain an understanding of the difficulties that LTC patients experience and provide information and tools on how to manage these. This qualitative study will explore participants' perspectives on using COMPASS for managing depression and anxiety in heart failure.
75636623|NCT03890718|Procedure|Photorefractive keratectomy in mile keratoconus|Topo-guided photorefractive keratectomy will be performed using an excimer laser (Allegretto Wave Topolyzer, Alcon, Inc.) with a 6 mm optical area and a transition area of 2 mm in all eyes. At that point, the partial topography-guided photorefractive keratectomy laser treatment will be finished. The arrangement will be to treat 70% of the cylindrical and spherical part to not surpass 50μm of stromal expulsion. The estimation of 50μm as the most extreme removal depth recommended by Kanellopoulos in Athens protocol will be chosen
75922151|NCT03132714|Procedure|Single application of PDT|Single application of photodynamic therapy (PDT) at day 0.
75922152|NCT03132714|Procedure|Repeated application of PDT|Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.
75922153|NCT03386318|Drug|Oxycodone|Serum concentration per hour from 1 to 5 h
75922154|NCT03514212|Behavioral|ProActiveS|A 12-week behaviour change intervention, during which time participants met with the researcher weekly and used a pedometer to measure step count and completed an activity diary to monitor progress, set goals and plan how to cope with identified barriers.
75922155|NCT03339284|Drug|Dexamethasone sodium phosphate|Dexamethasone injection
75922156|NCT03339284|Drug|Ropivacaine Hydrocloride|Ropivacaine injection
75922157|NCT03339284|Drug|Sodium Chloride 9mg/mL|Sodium Chloride injection
75922158|NCT02295072|Behavioral|A 5-months physical exercise-based program|"The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus exercise homework in the weekends, and will focus on high-intensity aerobic exercise mainly."
75922159|NCT03517644|Other|DP|Participants are informed that they are about to receive an effective analgesic cream. They are instructed to apply the cream using a cotton pad.
75922160|NCT03517644|Other|OLP Hope|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. Therefore, participants are supposed to evaluate the subjective probability for a positive effect of the cream as rather low. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect for them because this placebo cream did have a positive among some former participants who were similar to the current participant. The emphasis of this similarity (regarding age and sex) aims to induce a feeling of connectedness to previous participants who reported positive effects of the placebo cream.
75922161|NCT03517644|Other|OLP Expectation|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, participants are told that placebos have been shown to contribute substantially to clinical outcomes such as pain intensity/unpleasantness. This positive effect of placebos is reasoned by explaining learning mechanisms such as classical conditioning. We anticipated that after hearing this instruction, participants would consider it to be likely that the placebo has a positive effect for them.
75922162|NCT03517644|Other|Placebo cream|The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).
75922163|NCT03517644|Other|Heat pain|Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
75922164|NCT02291484|Device|Cardiac CT scan|CT-guided management
76078648|NCT04746261|Behavioral|ASSIP + treatment as usual|"ASSIP:~First session: Videotaped narrative interview focusing on the background to the suicidal crisis.~Second session: Video playback. The patient and the therapist watch the recorded interview together, stopping the film regularly to add information. The patient is given a psychoeducational text to read and comment on as homework.~Third session: Compilation of a written case formulation of the individual's vulnerability and triggering events that preceded the suicidal crisis. Individual preventive measures are developed by the patient and the therapist together and written down in a document that the patient keeps and which is attached to the patient's medical record.~Fourth session (optional): Mini-exposure.~Standardized letters: The therapist contacts the patient by letter during two years, every three months the first year and every six months the second year.~Treatment as usual: As described bellow"
75785869|NCT03853460|Procedure|epidural catheter|ultrasound low frequency probe will be used to determine the depth of the posterior complex to assists placement of midline thoracic epidural
75922165|NCT02291562|Drug|Tetrahydrocannabinol|10 mg Tetrahydrocannabinol (capsule, once) oral intake
75329472|NCT02959125|Dietary Supplement|Multiple micronutrients|Vitamin A 5000 iu, vitamin D 400 iu, vitamin C 100 mg, vitamin B1 7.5 mg, vitamin B2 3 mg, vitamin B6 10 mg, vitamin B12 10 mcg, fluoride 1 mg, Fe fumarate 91 mg, niacinamide 20 mg, Ca pantothenate 7.5 mg, folic acid 400 mcg, Zn 5 mg, Ca lactate 250 mg, copper 0.1 mg, iodine 0.1 mg
75636624|NCT00840034|Drug|LY2216684|Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
75785870|NCT03853460|Procedure|nerve block catheter|ultrasound guided placement of bilateral quadratus lumborum catheters
75329473|NCT02959125|Behavioral|Health Education in Pregnancy Class|Health education on pregnancy, complication, and breastfeeding by research team members
75922166|NCT02291562|Drug|Cannabidiol|600 mg Cannabidiol (capsule, once) oral intake
75922167|NCT02291562|Drug|placebo|placebo (capsule, once) oral intake
75922168|NCT03514056|Diagnostic Test|group 1:Patients diagnosed with Behcet disease|Frequency and severity of fibromyalgia will be investigated in patient diagnosed with Behcet disease
75922169|NCT03514056|Diagnostic Test|group 2: Patient diagnosed with fibromyalgia without Behcet disease|Severity of fibromyalgia will be investigated in patient diagnosed with fibromyalgia
75329474|NCT02959125|Other|Government Food Supplementation|Cookies contain 500 Calories and 5 gram protein make from flour and egg
75922170|NCT03316586|Drug|Nivolumab|Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
75922171|NCT03316586|Drug|Cabozantinib|Cabozantinib may help to shrink or stabilize breast cancer
75922172|NCT02291640|Device|MIL|direct laryngoscopy
75329475|NCT02959125|Dietary Supplement|Fe Supplementation|Ferrous Fumarate 60mg and folic acid 0.400 mg
75329476|NCT04347473|Drug|Ilumya Injectable Product|IL-23 injection
75636625|NCT00840034|Drug|Placebo|3 tablets PO QD for up to 12 weeks
75636626|NCT02848950|Drug|Metformin|Supplementation of the study group with Metformin till the day of pregnancy confirmation
75636627|NCT00813904|Biological|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
75785871|NCT01188200|Other|Experimental nutritional formula #M979|One two hundred and forty mL serving at test time, taken orally
75785872|NCT01188200|Other|Standard food|Standard meal prior to test time
75785873|NCT01291628|Device|socks containing copper-oxide fibers|The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
75785874|NCT04934462|Procedure|physiotherapy|Six months physiotherapy aimed at hip stability.
75785875|NCT04934462|Procedure|arthroscopy|Arthroscopic plication of hip joint capsule.
75785876|NCT01184222|Device|great occipital nerve stimulation|"Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted."
75785877|NCT00053898|Drug|anastrozole|1 mg/day and placebo for 5 years
75785878|NCT00053898|Drug|tamoxifen citrate|20 mg/day and placebo for 5 years
75785879|NCT00053898|Radiation|Radiation Therapy|Adjuvant radiation therapy
75636628|NCT04202406|Drug|Acetaminophen and codeine and caffeine|The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
75636629|NCT04202406|Drug|Acetaminophen|The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
75636630|NCT04202406|Drug|Placebo|The patient will receive placebo (starch) 1hour before treatment.
75785880|NCT03855488|Behavioral|Standard cognitive bias modification|Participants will be asked to repeatedly listen to descriptions of ambiguous scenarios that resolve positively and answer one question following each scenario that reinforces the positive interpretation; participants will listen to 60 scenarios/day for 7 days.
75785881|NCT03855488|Behavioral|Imagery enhanced cognitive bias modification|Participants will be asked to imagine themselves as though they are actively involved in the scenarios that they listen to. This condition will be required to answer two questions following each scenario; one that reinforces the positive interpretation and another that promotes engagement with imagery. Participants will listen to 60 scenarios/day for 7 days.
75785882|NCT03855488|Behavioral|Neutral Control Condition|Participants will be asked to listen to descriptions of neutral (i.e., non-emotional) scenarios. This condition will also be required to answer one comprehension question following each scenario. Participants will listen to 60 scenarios/day for 7 days.
75636631|NCT02846766|Drug|Lenvatinib|Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
75636632|NCT00839956|Drug|Bortezomib|Given IV
75922173|NCT02291640|Device|CoPilot|video laryngoscopy
75922174|NCT03513978|Other|IAI Exercises Protocol|Progressive exercises to improve the strength and propioception of the male soccer players.
75636633|NCT00839956|Drug|Vorinostat|Given PO
75636634|NCT04905732|Device|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
75636635|NCT04905732|Device|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
75636636|NCT04545528|Behavioral|Dietary recommendations|The test group will be seen by a nutritionist and will receive specific dietary recommendations according to their specific comorbidities and drugs
75922175|NCT03513978|Other|FIFA 11+|"Progressive exercises protocol to prevent injuries in male soccer players which has been created by FIFA. It is based in different body wieght exercises to improve the neuromuscular control and stabilization."
75922176|NCT03390920|Other|Umbilical Allograft|The umbilical allograft is regulated by the FDA and comes from a lab that is FDA registered.
75922177|NCT03383276|Drug|IL-1Ra|custom eye drop to be applied to the left eye.
75922178|NCT02295150|Drug|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
75922179|NCT03517410|Other|Smart phone use|Patients will be asked to use the smart phone while seated for either: (1) 10 minutes or (2) 30 minutes.
75329477|NCT03040804|Radiation|Low dose Radiotherapy|Subjects in this protocol will only receive radiotherapy directed at one region, typically the region that is most bothersome to the patient. Patients will receive a total radiotherapy dose 7.5 Gy in five daily fractions of 1.5 Gy.
75922180|NCT03386084|Device|microwave diathermy|Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
75329478|NCT02958891|Other|Data collection|Collection epidemiological dental measures
75329479|NCT04364165|Behavioral|Standard invitation to free HIV testing at mobile clinic|Participants receive standard invitation to same day HIV testing at mobile clinic.
75329480|NCT04364165|Behavioral|U=U messaging and invitation to free HIV testing at mobile clinic|Participants receive messaging about being undetectable equals untransmittable (U=U) and invitation to same day HIV testing at mobile clinic.
75636637|NCT02844738|Biological|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 [StroMed + platelet rich plasma (PRP)], Days 7 and 14 [PRP]
75636638|NCT02844426|Drug|bifid triple viable capsule and pectin|
75636639|NCT02844426|Drug|maltodextrin|
75636640|NCT00839800|Drug|Symbicort Turbuhaler|160/4.5 µg
75636641|NCT00839800|Drug|Terbutaline Turbuhaler|0.4 mg
75636642|NCT00867321|Biological|bevacizumab|Given IV
75636643|NCT00867321|Drug|sorafenib tosylate|Given orally
75636644|NCT00753415|Biological|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10^9 vector genomes/mL) or a HD (1 x 10^11 vector genomes/mL).
75636645|NCT00753415|Biological|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
75636646|NCT00913666|Drug|Interferon beta-1a (Avonex)|30 mcg by intramuscular injection once a week
75922181|NCT03390608|Drug|Endocrine therapy|Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
75922182|NCT03390608|Radiation|Radiotherapy|Radiotherapy versus no radiotherapy.
75922183|NCT03390608|Drug|Herceptin|Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
75922184|NCT03390608|Drug|Chemotherapy|Chemotherapy versus no chemotherapy.
75922185|NCT03390608|Procedure|Type of breast cancer surgery|Type of surgery (partial mastectomy, mastectomy, other).
75922186|NCT03390608|Other|Age at diagnosis|Age at diagnosis (<35, 35-<50, 50-<70, ≥70).
75922187|NCT03390608|Other|Screen detected tumor|Screening detected tumor (yes, no).
75636647|NCT05194137|Other|a proprioception protocol associated with vaginal palpation and feedback|A total of 13 previously established examples of voice commands can be used by the physiotherapists to help women understand how to perform a PFM contraction.
76078649|NCT04746261|Other|Treatment as usual and patient safety|"All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records."
75636648|NCT05194137|Other|a proprioception protocol associated with biofeedback|The software has five different interfaces for visualize PFM contraction: sign itself and signal transformed into the movement of a balloon; an airplane; a fairy; or a bird. Positive reinforcements will be verbalized after each PFM contraction using one of 4 previously established examples of voice commands.
75636649|NCT02782611|Behavioral|ENHANCE: Enduring Happiness and Continued Self-Enhancement|ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
75636650|NCT00754741|Behavioral|Adherence information|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
75636651|NCT00754741|Behavioral|Adherence information plus motivational interviewing|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
75636652|NCT05342649|Procedure|P-CTG|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
75636653|NCT05342649|Procedure|CTG|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
75636654|NCT05308095|Other|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Initially, a euglycaemic state (5.0 - 8.0 mmol/L) is established and blood glucose is then declined to hypoglycaemia (3.0 - 3.5 mmol/L) by administering insulin. Thereafter, blood glucose is raised again to euglycaemia (5.0 - 8.0mmol/L). During the procedure, driving data is recorded. Additionally, eye movement, head pose, facial expression, heart rate, skin conductance, and CGM values are recorded throughout the glycemic trajectory. Participants are blinded to the blood glucose values during the procedure.
75785883|NCT01187732|Device|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
75785884|NCT01291706|Device|Transcranial Doppler|Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
75785885|NCT03849950|Other|SMARTCare|"Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.~An education program for patients in the intervention arm that targets training in core self-management skills and is comprised of an introduction and 5 education modules.~An introductory call from a health coach prior to initiating treatment and 5 subsequent calls: prior to the first dose of treatment; 7-14 days following the first dose of treatment; within 2 weeks of coaching session 2; and timing is flexible for the last 2 sessions, but to be completed within 4 months following the first dose of treatment.~Optional sub-study: A sub-set of patients will participate in an end of study interview to gain further insight into SMARTCare."
75785886|NCT03849950|Other|Control|1. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.
75785887|NCT01293656|Other|No intervention.|There is no study intervention. Participants will be treated locally per site standards.
75922188|NCT03390608|Other|Menopausal status at diagnosis|Menopausal status (premenopausal, postmenopausal).
75922189|NCT03390608|Other|Tumor size|Tumor size (≤5 mm, 6-≤10 mm).
75922190|NCT03390608|Other|Estrogen receptor (ER) status|ER-status (positive, negative).
75922191|NCT03390608|Other|Tumor grade|Tumor grade (1, 2, 3).
75922192|NCT03390608|Other|HER2-status|HER2-status (positive, negative).
76078650|NCT04278495|Drug|Cozaar (Losartan Potassium 25mg)|Cozaar (Losartan Potassium 25mg)
76078651|NCT04278495|Drug|Placebo|Placebo
75922193|NCT03390608|Other|Intrinsic subgroups of breast cancer|Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
75922194|NCT03390608|Other|Nodal status|N-status (N0, N1).
75922195|NCT02295228|Other|No intervention|There are no interventions. This is an observational trial.
75922196|NCT03521076|Device|Virtual Reality|Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
76078652|NCT04276545|Drug|IV administration of DEX to investigate the effects for functional nasal endoscopic surgery|IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
76078653|NCT04276545|Drug|IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery|IV administration of midazolam (0.05mg/kg) after induction.
76078654|NCT01117948|Drug|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
75329481|NCT00963157|Drug|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
75636655|NCT02601391|Behavioral|Adapting STEPPS within forensic inpatient services.|This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
75636656|NCT02538861|Diagnostic Test|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
75785888|NCT01293734|Other|warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum|warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
75922197|NCT05171582|Procedure|Surgery 1 (Test group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the test group will be full-filled either with bovine bone substitute with hyaluronic acid (Cerabone plus). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
75636657|NCT02538861|Diagnostic Test|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
75785889|NCT01293734|Other|clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum|clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
75785890|NCT01293734|Other|securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum|securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
75785891|NCT01293734|Drug|Theophylline Sustained-release Tablets and budesonide suspension|Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
76078655|NCT01117948|Drug|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
76078656|NCT02445027|Device|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
76078657|NCT01118338|Device|Redesigned Purevision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
76078658|NCT01118338|Device|PureVision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
76078659|NCT03014440|Drug|Cannabidiol|
76078660|NCT03013036|Device|Ultrasonography|
76078661|NCT03013036|Drug|Sevoflurane|
76078662|NCT03013036|Drug|intravenous midazolam|
76078663|NCT03013036|Drug|Propofol|
76078664|NCT03013036|Drug|fentanyl and rocuronium|
75329482|NCT00963157|Biological|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
75329483|NCT02972554|Drug|Propanolol hydrochloride|One-time dose of 40mg of propranolol
75329484|NCT02972554|Other|Placebo|Outside casing matching that of active drug
75329485|NCT04371731|Other|Care4todayheart failure platform|Platform allowing patients to enter information about their health at home, namely weight and BP and medications
75329486|NCT05643807|Device|Flexible cystoscopy|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
76078665|NCT01071538|Drug|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
76078666|NCT03346395|Behavioral|Problem solving based intervention|Problem solving based intervention
76078667|NCT03346395|Behavioral|Care as usual|Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
75329487|NCT05643807|Device|Urinary catheter|Urinary cytology will be collected through a Ch14 urinary catheter after the cystoscopy
75329488|NCT00921947|Biological|VAX102|Universal M2e influenza vaccine
75329489|NCT02241941|Drug|Daptomycin|
75636658|NCT02538861|Diagnostic Test|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
75636659|NCT02601157|Drug|3-months DAPT|Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
75636660|NCT02601157|Drug|1-year DAPT|Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
75636661|NCT02785107|Behavioral|M-PAC Group|Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
76078668|NCT04352686|Drug|Buspirone|Administration of buspirone to assess esophageal sensitivity
76078669|NCT04352686|Drug|Placebo|Administration of placebo to assess differences in esophageal sensitivity
76078670|NCT03146091|Other|Nonantibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
76078671|NCT03146091|Other|Antibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
75922198|NCT05171582|Procedure|Surgery 2 (Control group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the control group will be full-filled either with bovine bone substitute (Cerabone). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
76078672|NCT01119040|Procedure|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
76078673|NCT04275687|Radiation|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4~7 daily fractions as a boost."
75636662|NCT02784873|Other|High intensity interval training|High intensity interval training within a standard cardiac rehabilitation programme
76078674|NCT04275687|Drug|Concurrent chemotherapy|For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.
76078675|NCT02172742|Drug|BIA 2-093|BIA 2-093 1200 mg once-daily
76078676|NCT02172742|Drug|Placebo|matching placebo
76078677|NCT02172742|Drug|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
76078678|NCT03831633|Drug|Akynzeo|"1 single oral dose of NEPA (capsule) on Day 1 to be administered approximately 1 hour prior chemotherapy (containing 300 mg netupitant and 0.5 mg palonosetron).~- Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
76078679|NCT03831633|Drug|Standard of Care|"oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~IV ondansetron 8 mg on Day 1~Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
75329490|NCT03041896|Device|coflex® Interlaminar Technology|Interlaminer Technology
75329491|NCT03834051|Drug|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation Enema Open Label
75636663|NCT04230993|Other|Sea water solution|Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
75636664|NCT04230915|Other|Intraoperative nerve monitoring|This group will determine as those who were administered 0.3 mg/kg rocuronium,
75329492|NCT04363541|Device|Electric pad for human external pain therapy|An electric pad for local heat production will be put on the back of the patient for two hours
75636665|NCT00752791|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
75636666|NCT04230603|Procedure|Hyperspectral imaging|Photos were taken with the hyperspectral camera of the human tissue
75636667|NCT04230603|Diagnostic Test|Lactate acid measurement|At the marked regions of the specimen, a lactate acid measurement was performed.
75636668|NCT04230603|Diagnostic Test|pathological examination|At the marked regions of the specimen, the pathological examination was performed.
75636669|NCT05261529|Dietary Supplement|Extra Virgin Olive Oil (EVOO)|Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.
75785892|NCT01184300|Genetic|Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers|Patients found to carry the CYP2C19*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
75651766|NCT05635799|Other|Group interview with a sociologist|Virtual reality feedback, accompanied by a confrontation of the patients' subjective experiences (group of 5 to 10 people)
75785893|NCT03849872|Drug|ONO-5788|Investigational Drug
75785894|NCT03849872|Drug|[14C]-ONO-5788|Investigational Drug
75785895|NCT03138538|Drug|Part 1: M8891|Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
75785896|NCT01188278|Drug|Imatinib|Drug being observed but not provided
75651767|NCT05631470|Diagnostic Test|MR screening|This study is to compare the results of MR-FFR with pressure-wired-based FFR measurement.
75785897|NCT01184378|Dietary Supplement|dairy lipids and soluble milk proteins|one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
75785898|NCT04325230|Device|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
75785899|NCT03852602|Drug|Preemptive Analgesics|Analgesic application15 minutes before the treatment
75785900|NCT03852602|Drug|Control|Analgesic application15 minutes before the end of the treatment
75922199|NCT02141373|Device|Glubran 2|
76078680|NCT04396509|Behavioral|Maternal Attachment Inventory Score|three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken.
76078681|NCT02216175|Other|SLIT to cow's milk|Sublingual immunotherapy
76078682|NCT02216175|Other|Low dose OIT|Oral Immunotherapy (low dose)
76078683|NCT02216175|Other|Conventional OIT to cow's milk|Oral Immunotherapy
76078684|NCT03145857|Drug|[68]Ga-HA-DOTATATE|All participants will be injected with [68]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
76078685|NCT02172820|Behavioral|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
76078686|NCT03086889|Other|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
76078687|NCT03086889|Other|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
76078688|NCT02393079|Device|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
76078689|NCT02393079|Device|Sham|A SHAM identical helmet will be used in the control group.
76078690|NCT01074034|Device|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
76078691|NCT02173522|Device|Prostate artery embolization (PAE)|Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
75329493|NCT03043534|Other|shave gel|"Non marketed pre-shave gel with the following INCI list of ingredients:~WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE"
75636670|NCT05261529|Behavioral|Physical Exercise Program|Besides the EVOO supplementation in the same conditions as the 'Intervention 1 Group', participants will add the follow-up of a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, 3 days per week, online and face-to-face group sessions on non-consecutive days. Continuous and intervalic cardiovascular exercise at moderate-intense intensity, controlled by the HR in reserve, with a duration of 15-45 minutes, also including sympathetic modulation exercises (stretching, breathing and meditation) and methods to promote recovery, with a duration of 10-30 minutes.
75329494|NCT03043534|Other|Brush|All subjects randomized to brush will use the brush with each shave
75329495|NCT04363775|Device|The standard Macintosh laryngoscope|intubation with the standard Macintosh laryngoscope and endotracheal tube 7.0 internal diameter with standard tube stylet
75636671|NCT02782299|Other|Decision Aid|Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
75469723|NCT01942356|Procedure|TIVA - Tachycardia|"Defined as: Heart Rate > 90 beats/min~If associated with normal NIBP (MAP > 60 mmHg and SAP < 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required.~If associated with hypertension (SAB > 140 mmHg): proceed with the management of the hypotention during maintenance protocol.~If associated with hypotension (MAP < 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol."
75469724|NCT01942356|Procedure|INH - Hypotension|"Defined as: MAP < 70 % of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~give a 200 ml fluid bolus (crystalloid).~If not successful, give ephedrine 5 mg bolus.~If not successful decrease volatile by 0.1 MAC.~Repeat from 1) if event is not resolved after step 3) for maximum of 2 iterations"
75785901|NCT02459392|Other|Epiduroscopy|"Epiduroscopy has two main uses in the pain clinic:~Releasing epidural adhesions for the relief of chronic sciatica. Adhesions can form around the lower lumbar nerve roots after decompressive surgery for disc disease or after a bad bout of inflammatory sciatica in the absence of surgery. Epidural adhesions can usually be identified on an enhanced magnetic resonance scan using intravenous gadolinium. They also cause uneven spread of X-ray contrast when performing an epidurogram.~Injecting mixtures of local anesthetic and depot steroid around inflamed nerve roots when epidural injections / nerve root blocks have been unsuccessful. The presence of adhesions can prevent epidurally injected drugs from reaching the inflamed nerve roots."
75785902|NCT02459392|Drug|Hyaluronic Acid|Drug administration
75922200|NCT02144727|Procedure|D2 distal subtotal gastrectomy|D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
75922201|NCT02144727|Procedure|D1+ distal subtotal gastrectomy|D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
75922202|NCT03296696|Drug|AMG 596|Drug
76078692|NCT01075204|Drug|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
76078693|NCT01120834|Drug|azacytidine|"Dose level 1: azacitidine 55 mg/m2 on days 1-5~Dose level 2: azacitidine 75 mg/m2 on days 1-5~Dose level 3: azacitidine 55 mg/m2 on days 1-5~Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles."
75329496|NCT04363775|Device|The Vie Scope laryngoscope|intubation with the Vie Scope laryngoscope with bougie stylet and endotracheal tube 7.0 internal diameter
75329497|NCT00359151|Drug|Celecoxib|7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
75469725|NCT01942356|Procedure|INH - Hypertension|"Defined as: SBP > 130% of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~increase Sevoflurane by 0.1 MAC~If not successful after 3 minutes (SBP >130% of baseline), increase Sevoflurane again by 0.1 MAC. Maximum of 1.2 allowed.~If still not successful (SBP >130% of baseline), Labetolol 5mg IV will be administered."
75636672|NCT02784093|Drug|Gastrograﬁn|
75636673|NCT02784093|Procedure|enemas|
75785903|NCT02459392|Drug|DepoMedrol|Drug administration
75922203|NCT03296696|Drug|AMG 404|Drug
75922204|NCT03513822|Drug|Ketamine 10 MG/ML|Ketamine infusion 1mg/kg with electric syringe during 2 hours.
76078694|NCT01120834|Drug|vorinostat|"Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles."
75922205|NCT03513822|Drug|Placebos|Sodium chloride infusion with the same rate, electric syringe during 2 hours.
75922206|NCT03513822|Drug|Midazolam 1 MG/ML|Bolus of Midazolam 1mg before each perfusion.
75922207|NCT02990091|Drug|Omega 3 fatty acid|LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
76078695|NCT01120990|Other|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
75329498|NCT00359151|Drug|Placebo|Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
75329499|NCT02242097|Drug|ibrutinib|Given PO
75329500|NCT02242097|Other|laboratory biomarker analysis|Correlative studies
75329501|NCT00374686|Drug|Valganciclovir|
75329502|NCT04371575|Drug|Carbamazepine|There is no actual intervention as the study is observational. First choice tratment is Carbamzepine and Oxcarbazepine. In medically refractory patients, first choice surgery is microvascular decompression
75329503|NCT00359229|Drug|Zolpidem|Administration of Zolpidem 5mg
75469726|NCT01942356|Procedure|INH - Bradycardia|"Defined as: Heart Rate < 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
75469727|NCT01942356|Procedure|INH - Tachycardia|"Defined as: Heart rate > 90 beats/min~if associated with normal NIBP (MAP > 70% of baseline and SBP <130% of baseline) : give fluid bolus of 200 ml, repeat once if required. (look for bleeding and treat if required).~If associated with hypertension (SBP >130% of baseline) : proceed with the management of the hypertension during maintenance protocol.~If associated with hypotension (MAP < 70% of baseline) : proceed with the management of the hypotension during maintenance protocol."
75469728|NCT01942369|Drug|Triptorelin Acetate 3.75mg intramuscular injection|"Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks."
75636674|NCT04229589|Other|Clinic follow-up|Patients are regularly evaluated to asses the occurrence of syncopal relapses
75329504|NCT02979262|Behavioral|Fathers for Change|
75636675|NCT02163681|Drug|Hyperpolarized Helium-3 MRI of the chest|hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
75329505|NCT02979262|Behavioral|Parent Education|
75636676|NCT05342571|Other|Behavioral, Psychological or Informational Intervention|Participate in ABC session
75636677|NCT05342571|Procedure|Biospecimen Collection|Undergo blood sample collection
75329506|NCT04363931|Procedure|Manual Therapy|Participants in this group received 4 weeks of manual therapy and massage of the masticatory muscles intra and extra orally together with massage of the cervical muscles. Massage and Manual Therapy brings about benefits by increasing local circulation and decreasing muscle tonus . Additionally, stretching exercises aiming to decrease pain and elongate shortened masticatory muscle fibers by autogenic inhibition of the masseter muscle were performed.
75636678|NCT05342571|Other|Electronic Health Record Review|Medical records reviewed
75636679|NCT05342571|Other|Informational Intervention|Receive patient guidebook
75329507|NCT04363931|Procedure|Kinesio Taping|Participants in this group had an application of Kinesio Taping on the masseter muscles. The material used for bruxism Kinesio Taping application was Kinesio Tex Gold Finger Prints (Kinesio Holding Corporation, Albuquerque, USA), a 100% cotton, latex-free, 5-cm wide, elastic tape. Kinesio Taping placement was chosen according to principles described by Kase et al. Tapes were cut 2.5 cm in width (cut in half vertically from 5 cm width). Two strips of Kinesio Tape were crossed over the masseter muscle area with 0-5% tension in maximum stretched epidermis position. Web-cut strips epidermis-dermis-fascia technique were used. Tape was applied bilaterally after every session of manual therapy.
75329508|NCT02980978|Behavioral|Coaching|Focus on nutrition, activity and appropriate medication use and adherence
75329509|NCT04363229|Other|maslach burnout inventory questionnair|The Maslach Burnout Inventory (MBI) is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout
75636680|NCT05342571|Other|Survey Administration|Complete surveys
75636681|NCT02784717|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
75785904|NCT03852368|Other|Exercise|The effects of exercise with different intensity on the executive functions of adolescents
75785905|NCT02417272|Device|Surgical treatment of cervical degenerative disc disease (CP ESP®)|
75785906|NCT02417272|Device|Surgical treatment of cervical degenerative disc disease (Axelle®)|Axelle®
75785907|NCT02359084|Behavioral|Family Navigation|
75785908|NCT02359084|Behavioral|Conventional Care Management|
75798646|NCT03865680|Drug|Duraphat|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
75798647|NCT01288716|Drug|Arbaclofen|
75798648|NCT01285596|Drug|Mirabegron|oral
75798649|NCT03862248|Drug|6EH³RZ|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
75798650|NCT03862248|Drug|6EHR³Z|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
75922208|NCT02990091|Dietary Supplement|Safflower seed oil|Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
75922209|NCT02299284|Other|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
75785909|NCT01095198|Device|offer of vaginal self collection|Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing. They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study. The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing. Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff. The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.
75922210|NCT03383120|Device|Laser treatment|Laser treatment of the peri-implantitis lesion includes mechanical debridement of the implant using an ultrasonic device and plastic curettes followed by diode laser sub-mucosal application for 90 seconds. This is repeated two more times at one-week intervals.
75922211|NCT03383120|Procedure|Surgical treatment with adjunctive systemic antibiotics|Mechanical debridement of the implant will be done in a similar manner to the test group (without laser application) followed by open flap debridement 2 weeks after, and post-operative prescription of Amoxicillin and Metronidazole systemic antibiotics 3 times per day for a period of 1 week
76078696|NCT04346836|Behavioral|Low-intensity, general-fitness exercises|"24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination."
75329510|NCT05639517|Other|Augmented Reality Based Telerehabilitation Application|Spinal stabilization training with augmented reality-based telerehabilitation will be applied twice a week for 8 weeks.
75636682|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
75636683|NCT00902304|Drug|Valsartan and amlodipine|From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
75636684|NCT00902304|Drug|Usual care|As directed by investigator
75636685|NCT00902304|Drug|Valsartan|Valsartan 160mg per day to 320mg per day orally
76078697|NCT04346836|Behavioral|Psychoeducation|A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
75636686|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - combination arm|Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
76078698|NCT02798224|Behavioral|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
75329511|NCT05639517|Other|Training face-to-face|Spinal stabilization training will be applied face-to-face twice a week for 8 weeks.
75329512|NCT04371341|Procedure|erector spinae block by 0.25% bupivacaine|A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.
75329513|NCT00374764|Drug|Risperidone|
75329514|NCT00374764|Behavioral|ABA|
75469729|NCT01942382|Drug|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
75922212|NCT03545451|Device|Videogames|Videogames
75922213|NCT03175328|Procedure|continuous renal replacement therapies|The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
75636687|NCT02784795|Drug|LY3039478|Administered orally
75636688|NCT02784795|Drug|Taladegib|Administered orally
75636689|NCT02784795|Drug|Abemaciclib|Administered orally
75636690|NCT02784795|Drug|Cisplatin|Administered IV
75636691|NCT02784795|Drug|Gemcitabine|Administered IV
75636692|NCT02784795|Drug|Carboplatin|Administered IV
75636693|NCT02784795|Drug|LY3023414|Administered orally
75636694|NCT04230837|Device|Inmediate abutment height|The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.
75636695|NCT00759109|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
75636696|NCT00759109|Other|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
75785910|NCT01095198|Other|2nd reminder letter for Pap testing|Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
76078699|NCT02798224|Behavioral|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
76078700|NCT01122160|Drug|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
76078701|NCT01122160|Drug|placebo|Placebo with berries (blackberries + strawberries)
76078702|NCT02623816|Drug|Optimal Dosing of Omeprazole|Omeprazole 20 mg
75329515|NCT05297643|Device|Ekstracorporeal Shock Wave Therapy (ESWT)|Extracorporeal Shock Wave Therapy (ESWT); It is a treatment method in which high-intensity pressure waves are applied to the desired point in the body. It has been used in the treatment of kidney stones in previous years, and changes in bone tissue have been observed (12). Today, it is used in musculoskeletal system diseases such as plantar fasciitis, epicondylitis, achiltendinitis, osteoarthritis
75329516|NCT05297643|Other|complex decongestive therapy|Complex decongestive therapy consists of manual lymphatic degeneration, compression therapy, skin care and remedal exercise.
75329517|NCT04371185|Drug|BAT2206|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
75469730|NCT01942395|Behavioral|DASH/sodium-restricted diet (DASH/SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
75636697|NCT04214340|Other|evaluation of practices|Study of the management and follow-up of patients presenting with appendicitis in France.
75636698|NCT03982927|Other|Laparoscopic skills workshop|One day laparoscopic skills workshop was offered to the surgical residents
75636699|NCT02848794|Drug|Apatinib and Irinotecan|Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
75329518|NCT04371185|Drug|Stelara(US-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
75636700|NCT04096027|Drug|Cabergoline Pill|0.5 mg cabergoline pill taken orally
75636701|NCT04095481|Device|Obalon Navigation/Touch System|The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon
76078703|NCT02180230|Device|Shorty implants|Dental implant insertion to maxilla or mandible
75469731|NCT01942395|Behavioral|Control Diet|The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
75469732|NCT01942408|Procedure|Repeat PVI|Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
75636702|NCT02846454|Other|inulin|Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
75636703|NCT02846454|Other|arabinoxylan|Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
75329519|NCT04371185|Drug|Stelara(EU-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
75636704|NCT04216134|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
75636705|NCT04216134|Procedure|Positron Emission Tomography|Undergo 68GA-PSMA-11 PET
75636706|NCT00916825|Behavioral|"rehabilitation programme getting better together"|Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
75636707|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
75636708|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
75636709|NCT00759031|Drug|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
75636710|NCT00759031|Drug|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
75636711|NCT02844504|Behavioral|Low Intensity Exercise Training 1|Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
75636712|NCT02844504|Behavioral|Low Intensity Exercise Training 2|Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
75785911|NCT03855722|Procedure|RIPC|Remote Ischaemic Preconditioning
75329520|NCT03834077|Other|Tissue flossing|Electrotherapy (transcutaneous electrical nerve stimulation) and Ultrasound in addition to tissue flossing.
75785912|NCT03855722|Procedure|Sham-RIPC|Sham procedure
75785913|NCT03955926|Dietary Supplement|preoperative oral carbohydrate loading|Carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg) 800 mL is given to the NO-NPO group until 2 hours before surgery
75785914|NCT01293812|Drug|88% sucrose po solution|"88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
75785915|NCT01293812|Drug|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
75922214|NCT03544437|Procedure|extraperitoneal laparoscopic extended retroperitoneal lymph node dissection|"All patients underwent extraperitoneal laparoscopic RNU with bladder cuff excision with concomitant extended RPLND performed by one of two urology surgeons at Renji Hospital.~The anatomical boundaries of the lymph node dissection were deﬁned by the ipsilateral side of UUT-UC. In patients with right-sided UUT-UC, the template of dissection consisted of (i) right perihilar lymph nodes, (ii) paracaval lymph nodes, (iii) interaortocaval lymph nodes and (iv) right pelvic lymph nodes (common, external and obturator lymph nodes).~In patients with left-sided UUT-UC, the template of dissection included (i) left perihilar lymph nodes, (ii) para-aortic lymph nodes, and (iii) left pelvic lymph nodes (common, external and obturator lymph nodes ). Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
75329521|NCT03834077|Other|Placebo comparator|Conventional physiotherapy in addition to flossing without tension
75329522|NCT03834155|Other|Hospital-based CR + Movn Application|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.
75329523|NCT03834155|Other|Choice of Hospital or home-based CR + Movn Application|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.
75469733|NCT01942421|Procedure|Cultivated mucosal epithelial transplantation|cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
75469734|NCT01942447|Biological|FMT|
75785916|NCT01191164|Procedure|Partial Breast Irradiation Utilizing Permanent Breast Seed Implant|"Target Volumes: The surgical cavity will be assessed with US & CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.~Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.~Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre."
75785917|NCT03256552|Drug|Glycopyrronium MDI 28.8 micrograms|Glycopyrronium MDI 28.8 micrograms
75785918|NCT03256552|Drug|Glycopyrronium MDI 14.4 micrograms|Glycopyrronium MDI 14.4 micrograms
75785919|NCT03256552|Drug|Glycopyrronium MDI 7.2 micrograms|Glycopyrronium MDI 7.2 micrograms
75785920|NCT03256552|Drug|Placebo MDI|Placebo Inhalation Aerosol
75785921|NCT01291862|Device|Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.
75785922|NCT03852446|Drug|Indoximod HCL (F2) tablets|The doses will be ascending per cohort from 600 mg to 2400 mg
75785923|NCT03852446|Drug|Indoximod base formulation|Single oral administration of 1200 mg
75785924|NCT03852446|Other|Placebo|The matching placebo doses will be ascending per cohort from 1 to 4 tablets
75922215|NCT02144805|Procedure|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
75329524|NCT03834155|Other|Hospital-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.
75329525|NCT03834155|Other|Choice of Hospital or home-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.
75469735|NCT01942447|Drug|Vancomycin|
75469736|NCT01942460|Drug|Ferumoxytol|
75469737|NCT01942473|Device|Automated FiO2 Control|Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
75469738|NCT01942499|Other|Community-based exercise program|
75922216|NCT02144805|Procedure|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
75922217|NCT00153036|Drug|rt-PA 0.9 mg/kg verum or placebo Intravenous|
75469739|NCT01942512|Device|Endovascular treatment of intracranial aneurysm|
75469740|NCT01942525|Other|aEEG|The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
75469741|NCT01942538|Device|rTMS|one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
75469742|NCT01942538|Device|sham rTMS|same session as defined with the real rTMS, but with a coil not delivering magnetic field.
75469743|NCT01942551|Drug|Tadalafil|
75469744|NCT01942551|Drug|Dutasteride|
75469745|NCT01942278|Other|BHOMA|A complex health systems, clinical care, and community intervention to improve outcomes
75469746|NCT01942577|Device|NoSting|Each participant with get both interventions. The infant's NoSting treated thigh will be sprayed with NoSting following delivery and again at 7 days of age. A quarter 1.5 x 3 inch silicon patch that is applied to the infant's thighs will be used for data sampling.
75329526|NCT01005355|Biological|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
75922218|NCT02915445|Biological|EpCAM CAR-T cells|Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
75922219|NCT02144883|Behavioral|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
75922220|NCT02144883|Behavioral|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
75922221|NCT02141529|Procedure|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
75785925|NCT03852446|Drug|Indoximod HCL (F2) tablets|Single oral administration of 1200 mg
75785926|NCT05111236|Other|Routine physical therapy|Rehabilitation strategies in management of children with spastic CP
75785927|NCT05111236|Other|Traditional massage|Rehabilitation strategies in management of children with spastic CP
75785928|NCT03849560|Biological|Grippol® Quadri|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Quadri into the upper third of the outer surface of the shoulder (the deltoid muscle).
75785929|NCT03849560|Biological|Grippol® Plus, trivalent (Yamagata lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Yamagata lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
75785930|NCT03849560|Biological|Grippol® Plus, trivalent (Victoria lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Victoria lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
75922222|NCT02141529|Procedure|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
75329527|NCT02242175|Device|Glucose breath test (hydrogen breath test)|Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
75329528|NCT05498649|Device|DT1fA|DT1fA contact lenses
75329529|NCT04363151|Other|No intervention.|
75469747|NCT01942629|Other|their will be no intervention in any of the groups, the study is retrospective|
75785931|NCT00071058|Drug|XR9576 (Tariquidar)|
75785932|NCT01089972|Device|22 gauge catheter|radial artery cannulation using 22 gauge catheter
75785933|NCT01089972|Device|20 gauge catheter|radial artery cannulation using 20 gauge catheter
75922223|NCT03513432|Dietary Supplement|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day during 4 weeks
75922224|NCT03513432|Dietary Supplement|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
75922225|NCT03513432|Dietary Supplement|Non-alcoholic beer with 0.00 % alcohol|330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
75922226|NCT02145117|Behavioral|MBSR|Behavioral
75329530|NCT03030313|Device|Reassure Non-Contact Respiration Monitor|Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
75329531|NCT02981368|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
75469748|NCT01942655|Other|Blood sample and recto-colic biopsies|
75469749|NCT01942681|Drug|Propiverine Hydrochloride|Administrate Propiverine Hydrochloride for 12 weeks
75636713|NCT04197219|Drug|Pembrolizumab|200 mg IV day 1 of each cycle every 21 days
75636714|NCT04197219|Drug|Axitinib|5 mg PO BID continuously
75651768|NCT05627492|Behavioral|Dialectical behavioral therapy|DBT will be conducted over 2 years. Participants and their treatment providers will decide on the frequency of sessions collaboratively. This may include individual and/or skills sessions in addition to phone coaching for those who attend individual sessions at least once per month. DBT consultation will also remain a component of the treatment. Participants may choose skills training, conducted in approximately 60 minute meetings, and individual therapy conducted in approximately 60 minute sessions. Family participation in skills training is highly encouraged. Skills training may include: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets.
75785934|NCT03637582|Drug|lidocaine gel|Lidocaine (4%) gel from Quest Products, Inc.
75785935|NCT03637582|Other|Plain aqueous gel|KY jelly lubricant from Reckitt Benckiser
75785936|NCT03849482|Diagnostic Test|Multiparametric Magnetic Resonance Imaging|Multiparametric MRI evaluation includes Conventional MRI, Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI
75329532|NCT02981368|Diagnostic Test|PET/CT imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
75785937|NCT03849482|Diagnostic Test|Fine Needle Aspiration Cytology|Ultrasound-Guided Fine Needle Aspiration Cytology
75785938|NCT03849482|Diagnostic Test|Clinical Evaluation|Patient's history and physical examination, reporting signs and symptoms suggestive of malignancy (pain, facial nerve weakness, fixation to skin and surrounding tissues, trismus, skin ulceration, lymphadenopathy, numbness, weight loss)
75329533|NCT02242253|Drug|Tiotropium|administered via HandiHaler®
75922227|NCT03513354|Other|Soil group|Exercises in soil.
76078704|NCT03012958|Other|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
75329534|NCT02242253|Drug|Salmeterol|administered via metered dose inhaler (MDI)
75329535|NCT02242253|Drug|Placebo-MDI|
75329536|NCT02242253|Drug|Placebo HandiHaler®|
75329537|NCT05285943|Drug|Olive oil cream|Olive oil prepared in a base cream to be applied to irradiated areas.
75785939|NCT03849482|Diagnostic Test|Final Histopathological Diagnosis|Final Diagnosis of the Disease from the Pathology Report after Surgical Resection of the Lesion
75785940|NCT02258594|Other|Web-Based Patient Centered Toolkit (PCTK)|"The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via patient-facing tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The provider-facing PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the patient thread; and 5) discussing patient's plan of care with other providers via the provider thread."
75785941|NCT02258594|Behavioral|The Patient-SatisfActive® Model|The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
75785942|NCT00053352|Procedure|conventional surgery|
75785943|NCT00053352|Drug|cisplatin|Given IV
75922228|NCT03513354|Other|Pool group|Exercises in pool.
75922229|NCT02299440|Other|Baseline evaluation|Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
75469750|NCT01942746|Dietary Supplement|Blueberry Juice S2|Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.
75785944|NCT00053352|Drug|etoposide|Given IV
75785945|NCT00053352|Biological|bleomycin sulfate|Given IV
75785946|NCT00053352|Other|laboratory biomarker analysis|Correlative studies
75922230|NCT02299440|Drug|1st perfusion of ketamine|A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
75922231|NCT02299440|Drug|1st perfusion of saline|A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
75922232|NCT02299440|Other|Follow-up between perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
75922233|NCT02299440|Drug|2nd perfusion of ketamine|A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
75329538|NCT05285943|Drug|Betamethasone Valerate Cream|Betamethasone valerate prepared in a base cream to be applied to irradiated areas.
75329539|NCT05285943|Other|Base Cream|The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.
75329540|NCT03030001|Biological|PD-1 antibody expressing mesothelin specific CAR-T cells|Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
75329541|NCT02242331|Drug|Micardis®|
75329542|NCT00963859|Procedure|Robotic-assisted laparoscopic surgery|During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
75785947|NCT03637504|Behavioral|MedActionPlan®|web-based, mobile medication management application [MedActionPlan® (MAP)]
75922234|NCT02299440|Drug|2nd perfusion of saline|A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
75785948|NCT01193816|Drug|loxapine|Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
75922235|NCT02254395|Device|Deep Brain Stimulation|
75922236|NCT02141763|Drug|UCB4940 40 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
75922237|NCT02141763|Drug|UCB4940 80 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
75922238|NCT02141763|Drug|UCB4940 160 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
75469751|NCT01942746|Dietary Supplement|Blueberry Capsules S2|Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.
75922239|NCT02141763|Drug|UCB4940 240 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
75922240|NCT02141763|Drug|UCB4940 320 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
75922241|NCT02141763|Drug|UCB4940 560 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
75922242|NCT02141763|Other|Placebo|"Pharmaceutical Form: solution~Concentration: 0.9 % sodium chloride~Route of Administration: intravenous"
75922243|NCT02295384|Other|Retrospective Audit|Retrospective Audit
75329543|NCT04370717|Other|telehealth consultation|"A telehealth consultation will be scheduled and conducted without modifications from the routine clinic protocol. The case report will include ICD-10 code and plan of care.~After one week, patients will receive an electronic satisfaction survey. An in-person follow-up and/or procedural visit will be subsequently scheduled. During this visit, the same physician will complete physical examination, document the diagnosis and proceed with either the same or modified plan of care. The research coordinator will enter diagnostic and procedural codes in the case report form."
75329544|NCT04370951|Procedure|Erector Spinae Plane Block - Ultrasound guided|20mls 0.25% Levobupivicaine ultrasound guided bilaterally
75329545|NCT03030157|Drug|pirarubicin(THP)|
75329546|NCT00359385|Drug|Alendronate 70mg weekly|70mg weekly
75469752|NCT01942746|Dietary Supplement|Placebo Capsule S2|Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.
75469753|NCT01942746|Dietary Supplement|Placebo Juice L1|Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.
75469754|NCT01942746|Dietary Supplement|Blueberry Juice L1|Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
75469755|NCT01942772|Device|Ankle-Foot Orthosis|
75469756|NCT01942798|Device|Nintendo Wii|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
75469757|NCT01942798|Device|Wii Big Brain Academy Degree program|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
75651769|NCT05623943|Procedure|Endovascular treatment|Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.
75651770|NCT05623267|Drug|Sugemalimab|Recombinant anti-PD-L1 fully human monoclonal antibody
75651771|NCT05623267|Drug|Placebo|Placebo of Sugemalimab
75651772|NCT05622864|Drug|HRS-9821|HRS-9821
75651773|NCT05622864|Drug|HRS-9821|HRS-9821
75651774|NCT05617092|Other|Physiotherapy treatment|physiotherapy individualized treatment according to the needs of the patient and clinical findings and symptoms
75785949|NCT01193816|Drug|Placebo|Placebo
75785950|NCT05571202|Procedure|General anesthesia plus local infiltration|The eligible patients underwent anorectal surgery under general anesthesia (GE, GM, IVG) plus locally injected analgesics.
75785951|NCT05571202|Procedure|Spinal anesthesia|The eligible patients underwent anorectal surgery under spinal anesthesia alone.
75785952|NCT03847688|Device|Transcranial Magnetic Stimulation|Patient receive Transcranial Magnetic Stimulation for treatment resistant depression as part of their routine care.
75922244|NCT02145195|Dietary Supplement|Vitamin D3 (cholecalciferol)|
75922245|NCT03517020|Drug|Torrent's Nebivolol Tablets|
75922246|NCT03517020|Drug|Forest Pharmaceuticals Inc's Bystolic Tablets|
75922247|NCT02145273|Behavioral|Interpersonal Psychotherapy for Depression -Group|
75922248|NCT02295462|Other|Person-centered Care|Medication Review + Person-centered Care
75922249|NCT02295462|Other|Optimised Treatment|Medication Review only
75922250|NCT03516864|Device|MIMOSA Imager|The MultIspectral MObile tiSsue Assessment (MIMOSA) Imager acquires digital images to calculate anatomical details of chronic wounds (e.g. diameter, surface area, and perimeter). The device can be worn from a lanyard, and clips onto a smartphone, using natural ambient lighting to capture images of a wound. The MIMOSA also uses up to 6 near-infrared LEDs to illuminate tissue with different wavelengths of light to assess tissue oxygenation.
75922251|NCT03516864|Device|Kent Camera|The Food and Drug Administration (FDA) has previously approved a near-infrared device called the Kent camera for the assessment of tissue oxygenation.
75922252|NCT02254629|Drug|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
75922253|NCT02254629|Drug|Laxative Polyethylene Glycol|laxative：2000 ml.
75922254|NCT02145585|Device|Test of pharmacologic anesthesia robot (labVIEW® software)|
75922255|NCT02291796|Drug|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration >500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
75785953|NCT05671250|Combination Product|PRP gel and SOC-treatment|Platelet-lysate loaded sustained release thermo-gelling formulation
75922256|NCT03544827|Drug|Atropine|Atropine 0.01% then atropine 0.1%
75922257|NCT03544827|Drug|Atropine|Atropine 0.1% then atropine 0.01%
75785954|NCT05671250|Combination Product|EPO/ISDN/UFH cryogel dressing|Erythropoietin/Isosorbide dinitrate loaded cryogel scaffold
75785955|NCT05671250|Procedure|Standard of Care|Sharp debridement, saline washing and regular saline dressing
75329547|NCT04371029|Other|PSG|Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
75329548|NCT00966433|Procedure|Spontaneous ventilation|The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
75785956|NCT03245398|Drug|Treatment with one of the two regimens of mebendazole|Once in the morning and once in the evening for 3 consecutive days
75785957|NCT01291940|Other|Pediatric Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
75785958|NCT01291940|Other|Adult Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
75785959|NCT01188434|Behavioral|ITSAN|integrated behavioral intervention for substance abuse, parenting skills, and basic needs
75785960|NCT01188434|Behavioral|Services as Usual|Services as usual referred by child welfare
75329549|NCT00966433|Device|Pressure support Ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
75329550|NCT00966433|Device|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
75329551|NCT05279547|Other|Constant-load bed-cycling exercise|Patients will actively cycle for a minimum duration of 10 minutes and a maximum duration of 20 minutes without breaks.
75636715|NCT04093687|Other|Endoscopist's training|"The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator."
75329552|NCT05279547|Other|Interval bed-cycling exercise|Patients will cycle for the same duration as during constant-load exercise. Interval bed-cycling session will consist of 30 seconds of high intensity exercise alternated by 30 seconds of passive cycling designed so that volume of training will be equal.
75329553|NCT05628129|Other|smartphone application service and phone reminder|smartphone application service and phone reminder for appointments of parents of congenital ectopia lentis patients
75636716|NCT04834908|Biological|Equine COVID-19 Antiserum|Equine COVID-19 antiserum is a polyclonal antibody and it contains Equine COVID-19 immune globulin G.
75636717|NCT04834908|Drug|Standard of care|Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
75785961|NCT03244618|Device|CSSP Toothpaste|Toothpaste containing calcium silicate, sodium phosphate and sodium monofluorophosphate
75785962|NCT03244618|Device|Fluoride Toothpaste|Toothpaste containing sodium monofluorphosphate
75785963|NCT00052962|Procedure|Cytoreductive surgery|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m^2 on day 1 only, leucovorin 200 mg/M^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
75785964|NCT00052962|Procedure|Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m^2 and paclitaxel 125 mg/m^2.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m^2 on day 1 only, leucovorin 200 mg/M^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
75922258|NCT02295618|Device|Standard tracheal tube|Intubation using Macintosh laryngoscope and standard tracheal tube
75922259|NCT02295618|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
75922260|NCT00107991|Drug|etanercept|etanercept 50 mg/week subcutaneous injection
75922261|NCT02299674|Other|Level overground ambulation|
75922262|NCT03513276|Drug|100cc of 2% ropivacaine|Multimodal analgesia + Local infiltration anesthesia
75785965|NCT01193894|Other|Profermin|Medical Food (food for special medical purposes)
75922263|NCT03513276|Drug|Saline Solution|Multimodal analgesia + Saline solution
75922264|NCT03513276|Drug|Adrenaline 10mcg/ml|
75922265|NCT02299752|Procedure|single-gloving system|single-gloving system was used during Catheterization
75636718|NCT02512497|Drug|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
75636719|NCT02512497|Drug|Busulfan|Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI >4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
75922266|NCT02299752|Procedure|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
75922267|NCT02291874|Drug|Ipragliflozin|oral
75922268|NCT02145819|Drug|hCG|
75922269|NCT02145819|Other|LH peak|
75636720|NCT02512497|Drug|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
75636721|NCT02512497|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
75636722|NCT02512497|Drug|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
75636723|NCT00916669|Drug|Etoposide|Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
75329554|NCT03029455|Drug|VX-659|
75329555|NCT03029455|Drug|Tezacaftor|
75329556|NCT03029455|Drug|Ivacaftor|
75785966|NCT01193894|Other|Fresubin|Medical food (food for special medical purposes)
75922270|NCT02299830|Procedure|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
75922271|NCT02299830|Procedure|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
75329557|NCT03029455|Drug|VX-659 Matching Placebo|
75636724|NCT00916669|Drug|Cisplatin|Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
75329558|NCT03029455|Drug|Triple Combination (TC) Matching Placebos|
75329559|NCT02983552|Other|iPad®|Binocular therapy using a Dig Rush application on an iPad®
75329560|NCT02983552|Other|Spectacle correction|Spectacle correction for all waking hours, 7 days per week
75329561|NCT04370405|Drug|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
75329562|NCT04370561|Procedure|ORIF non-locking|Open reduction and internal fixation using 1/3 tubular plate
75636725|NCT00916669|Drug|enoxaparin sodium|Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
75785967|NCT01193972|Other|Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period
75785968|NCT03852212|Other|Manipulation|Thrust technique application
75785969|NCT01294280|Other|Laboratory Biomarker Analysis|Correlative studies
75329563|NCT04370561|Procedure|ORIF locking|Open reduction and internal fixation using active ankle polyaxial locking plate
75329564|NCT02245789|Procedure|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
75329565|NCT02245789|Drug|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
75329566|NCT04370639|Device|AccuFlow sensor|AccuFlow sensor will be worn and survey completed
75785970|NCT04946266|Procedure|Surgical intervention|Surgical intervention with collection of tissue material
75798651|NCT03862248|Drug|6EHRZLfx|WHO levofloxacin-strengthened regimen (6EHRZLfx)
75922272|NCT02299830|Procedure|stent placement|use stent placement to open the airway compressed by out neoplasm
75922273|NCT02299830|Procedure|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
75922274|NCT03747705|Other|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (>18) male and female with, intractable epilepsy, on stable doses of antiepileptic drugs (AEDs), will participate in a 4-week observation period during which no change in the drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window. Between 6:00-22:00 During the study, patients will fill a seizure diary daily.
75922275|NCT02291952|Behavioral|Meal schedule|
75922276|NCT02145897|Biological|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
75922277|NCT02145897|Biological|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
75922278|NCT02145897|Other|Control|
75922279|NCT03516630|Drug|Trazodone 20 mg|Oral drops
75922280|NCT03516630|Drug|Trazodone 60 mg|Oral drops
75922281|NCT03516630|Drug|Trazodone 140 mg|Oral drops
76078705|NCT01122238|Drug|Nicotine Patch|"If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks."
75636726|NCT02689557|Other|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
75636727|NCT02844348|Other|Hypnosis session|
75329567|NCT04370639|Other|Survey|Patients will be asked to complete a survey regarding device tolerability after completing their cesarean section.
75329568|NCT05484141|Other|Rehabilitation with blood blow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
75329569|NCT05484141|Other|Rehabilitation without blood flow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
75329570|NCT04370171|Other|care modalities|For these patients the consultation has been postponed for 6 months. No specific intervention for this group of patient.
75329571|NCT04370171|Other|Teleconsultation either by phone or by computer consultation|Management of diabetic patients by telemedicine with a teleconsultation either by phone or by computer consultation
75636728|NCT04093453|Other|Placebo (Sodium Chloride)|Participant receive Placebo (Sodium Chloride)
75636729|NCT04093453|Other|Exercise|1 hour exercise
75636730|NCT04093453|Dietary Supplement|Sodium Propionate|Participant receive Sodium Propionate
75636731|NCT02784015|Drug|Cisplatin|
75636732|NCT02784015|Drug|Etoposide|
75785971|NCT03849404|Biological|Adalimumab|Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
75785972|NCT04226794|Device|a-tDCS|Anodal Transcranial direct current stimulation (tDCS) stimulation. Anode will be allocated at DLPFC right and cathode at DLPFC left. The stimulation will occur for 20 min in the intensity of 2 milliampere (mA).
75785973|NCT04226794|Behavioral|Nutritional Counseling|Presentation delivered through video clip during 20 minutes based on Cognitive Behavioral Therapy interventions
75785974|NCT04226794|Combination Product|a-tDCS and nutritional counseling|a-tDCS + Nutritional Counseling
76078706|NCT01122238|Drug|Nicotine Gum|"If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks."
75785975|NCT04226794|Combination Product|s-tDCS and nutritional counseling|s-tDCS + Nutritional Counseling
75922282|NCT03516630|Drug|Placebo|Oral drops
75922283|NCT03516630|Drug|Moxifloxacin 400mg|Tablet
75922284|NCT02142075|Drug|Daptomycin|
75922285|NCT03544749|Device|Ambu® AuraGain™|After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.
75922286|NCT03544749|Device|I-gel|After induction of anesthesia, I-gel will be inserted for the mechanical ventilation.
75922287|NCT02292030|Drug|HTEA|usually high thoracic epidural anesthesia
76078707|NCT01122238|Behavioral|Motivational Interviewing|"Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking."
75636733|NCT02784015|Drug|Doxorubicin|
75636734|NCT02784015|Drug|Cyclophosphamide|
75636735|NCT02784015|Drug|Ifosfamide|
75636736|NCT02784015|Drug|Carboplatin|
75636737|NCT02784015|Radiation|Radiotherapy|
75636738|NCT02784015|Drug|Thiotepa|
75636739|NCT02784015|Drug|Melphalan|
75636740|NCT02601235|Drug|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
75636741|NCT02601235|Drug|Afrin|2 pumps in each nostril every 12 hours.
75636742|NCT02783937|Biological|Filgrastim|"Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:~Phase A:~Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.~Phase B:~Injection of saline SC injection twice daily for five consecutive days."
75636743|NCT02783937|Drug|Saline|Injection of saline SC injection twice daily for five consecutive days
75636744|NCT00758485|Drug|Sugammadex|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
75636745|NCT00758485|Drug|0.9% sodium chloride (NaCl)|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
75636746|NCT02782455|Drug|Flavonoids|Daflon is administered
75636747|NCT02782455|Drug|CDobi|Calcium dobesylate is administered
75636748|NCT02846220|Behavioral|Overcoming Immunity to Change health coaching|
75785976|NCT01188512|Biological|BPZE1|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
75785977|NCT01188512|Biological|Placebo|Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
75785978|NCT04190524|Other|Application of cricoid pressure|The study first involves recording a baseline image of the neck anatomy using ultrasound, which is a non-invasive, non-irradiating, non-painful imaging modality. Once the baseline anatomy has been imaged, conventional cricoid pressure will be applied with fingers and/or with the ultrasound probe itself and an image will be recorded. The force applied to the cricoid cartilage will be 30 newtons, as determined by a thin force measurement sensor (Tekscan flexiforce sensor) placed in between the patient's skin and the finger (or ultrasound probe).
75922288|NCT02145975|Drug|Fentanyl|The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
75922289|NCT02145975|Drug|Morphine|The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
75922290|NCT02295696|Behavioral|EMMA|Consultations using dialogue tools
75922291|NCT02146053|Dietary Supplement|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
75922292|NCT02146053|Dietary Supplement|Placebo|placebo capsules: methyl cellulose
76078708|NCT01122238|Behavioral|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
76078709|NCT01122238|Other|No Intervention|No Intervention
75636749|NCT02783781|Procedure|Cardiac surgery (extracorporeal circulation; beating heart)|"Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.~Blood sample collection Urine sample collection"
75636750|NCT03505554|Drug|Lorlatinib|100 mg QD
75636751|NCT04810416|Other|Texting- 10 minutes|Participants will practice texting for 10 minutes using smart phone.
75636752|NCT04810416|Other|Writing- 10 minutes|Participants will practice writing on notebook for 10 minutes.
75636753|NCT04810416|Other|Texting- 15 minutes|Participants will practice texting for 15 minutes using smart phone.
75922293|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
75636754|NCT04810416|Other|Writing- 15 minutes|Participants will practice writing on notebook for 15 minutes.
75636755|NCT05342415|Other|Internally Focused Exercise|While performing the exercises participants will be instructed to focus on the muscle itself.
76078710|NCT01122238|Drug|Nicotine Patch + Nicotine Gum|"If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks."
76078711|NCT01122316|Drug|Metformin|3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
76078712|NCT01076452|Device|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
76078713|NCT01076686|Drug|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
75329572|NCT04370015|Drug|Hydroxychloroquine|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
75329573|NCT04370015|Drug|Placebo oral tablet|• Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
75469758|NCT01942811|Behavioral|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
75469759|NCT01942824|Behavioral|Text Messages|
75636756|NCT05342415|Other|Externally Focused Exercise|While performing the exercises participants will be instructed to focus on the external target (towel, target line, etc.)
75636757|NCT02846142|Drug|PTI-428|
75636758|NCT02846142|Other|Placebo|
75636759|NCT02846142|Drug|ethinyl estradiol and levonorgestrel|
75922294|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID DIET|2. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
75636760|NCT02783703|Dietary Supplement|Medium chain triglycerides (MCT)|Subjects will consume 30 grams per 2000 kilocalories daily of medium chain triglyceride oil by mouth
75785979|NCT04190524|Other|Application of Left lateral paratracheal pressure|Next, left lateral paralaryngeal pressure will be applied at the level of the cricoid cartilage with fingers and/or the ultrasound probe itself, and the image will again be recorded. Left lateral paralaryngeal pressure will be 30 newtons, as determined by a thin force measurement sensor placed in between the patient's skin and the finger (or ultrasound probe).
75785980|NCT00051636|Drug|Zoledronic Acid|Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
75922295|NCT02295930|Other|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
75922296|NCT02295930|Other|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
75922297|NCT02142231|Device|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
76078714|NCT03049449|Biological|Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.3x10^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0
76078715|NCT03049449|Drug|Cyclophosphamide|300 or 500 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
76078716|NCT03049449|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
76078717|NCT04396431|Behavioral|education|"The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat."
75636761|NCT05243160|Other|medication review|The intervention consist of a medication review by a clinical pharmacologist.
75636762|NCT05243277|Other|Oculomotor tests|"There will be four visits. Each visit is associated with a different exposure in terms of level of oculomotor conflict.~At each visit, several oculomotor tests will be performed, followed by a comfort questionnaire. The oculomotor tests are subjective tests during which the participant will be asked to fix his/her eyes on one or more targets that can move in space and to indicate the way he/she perceives this/these target(s). Depending on the test, lenses may be inserted between the participant and the target to modify his/her perception.~The comfort questionnaire consists to rate on a scale of 1 (not at all) to 5 (very much) the presence of visual symptoms, such as burning, watering or dryness.~The participant will then have to perform four different perceptual tasks. His/her level of accommodation (i.e. focus) will be monitored throughout the tasks.~Each exposure is followed again by eye tests and a comfort questionnaire."
75636763|NCT02848482|Device|Photodynamic therapy|Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
76078718|NCT02399943|Drug|Trametinib|
76078719|NCT02399943|Drug|Panitumumab|
75469760|NCT01942863|Procedure|water exchange single balloon enteroscopy|Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.
75636764|NCT02848482|Procedure|Mechanical debridement|Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
75636765|NCT02848482|Drug|Irrigation|0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
75636766|NCT02782533|Device|Deep Brain Stimulation V3|
75636767|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
75636768|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
75636769|NCT00757783|Drug|darunavir|800 mg tablet once daily for 48 weeks
75785981|NCT00051636|Drug|Risedronate|Oral risedronate 30 mg capsules.
75785982|NCT00051636|Drug|Placebo to Risedronate|Oral placebo of risedronate capsules.
75785983|NCT00051636|Drug|Placebo to Zoledronic Acid|5 mL of sterile water one dose intravenous infusion.
75329574|NCT05482581|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,awareness of e-cigarettes sheet;,willingness to use e-cigarettes sheet, knowledge, attitudes and cognitions related to e-cigarettes sheet, awareness of new regulations on e-cigarette control sheet.
76078720|NCT03186027|Dietary Supplement|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect"
76078721|NCT03186027|Dietary Supplement|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo"
76078722|NCT04397913|Drug|Paracetamol|15 mg/kg, q6h
75329575|NCT04369781|Diagnostic Test|transcutaneous oxygen pressure recording at rest|Recording of limb and chest transcutaneous oxygen pressure
75636770|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg tablet once daily for 48 weeks
75785984|NCT00051636|Dietary Supplement|Calcium and Vitamin D|Calcium and vitamin D supplements were supplied.
75469761|NCT01942863|Procedure|CO2 insufflation single balloon enteroscopy|Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.
75922298|NCT02142231|Device|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
75469762|NCT01942863|Other|Procedural Requirements|SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
75636771|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg once daily for 48 weeks
75785985|NCT01188590|Device|TOSCA 500 monitor|transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
75922299|NCT02142309|Drug|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
76078723|NCT04397913|Drug|Ibuprofen|10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
76078724|NCT04397523|Biological|anti-SARS-CoV-2 convalescent plasma|Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
75329576|NCT01006369|Drug|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
75469763|NCT01942876|Behavioral|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
75469764|NCT01942876|Behavioral|Health behavior maintenance|This attention-control arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
75785986|NCT01294826|Drug|AUY922|Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
75785987|NCT01294826|Drug|Cetuximab|Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
75329577|NCT03046966|Procedure|Intervention: Receives Training|"• Complete a Hands-on Intubation in the Simulation Lab with PI instructing:~Using state of the art technology, a Storz C-MAC video laryngoscope~Identifying anatomical landmarks~Practice on the manikin until intubation occurs within 15 seconds"
75329578|NCT03046966|Other|Intervention: Control No Training|• Does not receive simulation training with PI. Only standard training.
75636772|NCT00757783|Drug|atazanavir|300 mg capsule once daily for 48 weeks
75636773|NCT01770249|Procedure|Per-oral Endoscopic Esophagomyotomy (POEM)|The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
75636774|NCT05242926|Drug|ModraDoc006/r|One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
75785988|NCT03956004|Other|OM1 Dell Shared Decision Making Tool|Decision aid meant to improve shared decision making among patients and providers.
75922300|NCT02142309|Drug|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) <45 mL/min
75922301|NCT02142309|Drug|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
75922302|NCT02142309|Drug|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
76078725|NCT02176408|Behavioral|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
76078726|NCT02176408|Behavioral|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
75922303|NCT03516474|Device|MIMOSA Diagnostics|"The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing."
75785989|NCT03956004|Other|Education material from OM1 Dell Shared Decision Making Tool|Investigator-written educational material and quiz to test knowledge of osteoarthritis and treatment options.
76078727|NCT02176408|Behavioral|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
75469765|NCT01942889|Dietary Supplement|Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program|Vit E, Vit C, Selenomethionine, Zinc gluconate
75469766|NCT01942902|Device|Continuous Glucose Monitoring System|
75636775|NCT02782221|Drug|Growth Hormone|Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
75636776|NCT02782221|Drug|Pegisomant|One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
75636777|NCT02781987|Other|chronic pancreatitis|patients with chronic pancreatitis
75636778|NCT02846064|Procedure|Autograft of cryopreserved ovarian tissue|Orthotopic transplantation
75636779|NCT04231617|Drug|glibenclamide|Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
75636780|NCT04231617|Drug|CGRP infusion|CGRP infusion
75636781|NCT04231617|Drug|Placebo|placebo
75636782|NCT04810104|Drug|AZD0328|Active study drug
75636783|NCT04810104|Drug|Placebo|Non-active study drug
75785990|NCT03847922|Drug|Nitrous Oxide + Oxygen Gas (Product)|Self-administered 50% nitrous oxide / 50% oxygen mixture will be given to the intervention group, starting just before the beginning of the urethral bulking procedure.
75922304|NCT02146209|Drug|Metronidazole benzoate|Single oral dose of 400 mg
75636784|NCT00757705|Drug|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
75785991|NCT03847922|Drug|lidocaine gel 2%|6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.
75785992|NCT03847922|Other|Room air|Room air will be administered via the Pro-Nox machine to participants in the control group, starting just before the beginning of the urethral bulking procedure.
75785993|NCT03955770|Combination Product|High-flow oxygen therapy (HFOT)|HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher&Paykel, New Zealand).
75922305|NCT02146209|Drug|Flagyl 125 mg/5 ml oral suspension|Single oral dose of 500 mg (20 ml suspension)
75922306|NCT02146209|Drug|Flagyl 400 mg Tablets|Single oral dose of 400 mg
75922307|NCT02299908|Drug|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
75922308|NCT02299908|Drug|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
75785994|NCT03955770|Combination Product|Low-flow oxygen therapy (LFOT)|LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).
75922309|NCT02142543|Drug|2-DeNT powder|powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
76078728|NCT02176486|Drug|Ixazomib|Ixazomib capsules.
75469767|NCT01942915|Biological|Umbilical Cord Blood Mononuclear Cells|Participants will be transplanted with umbilical cord blood mononuclear cells.
75636785|NCT02845908|Drug|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
75636786|NCT02845908|Drug|FOLFOX|Oxaliplatin plus Leucovorin plus 5-FU
75636787|NCT02845908|Drug|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally PAC
75636788|NCT04197531|Other|Irrigation Method|Irrigation Method
75636789|NCT05242614|Behavioral|The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)|The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.
75785995|NCT01095276|Drug|Pulmozyme (nebulized dornase alpha)|nebulized dornase alpha: 2.5 mg by in-line nebulizer BID
75922310|NCT02142543|Drug|Placebo Comparator|
75922311|NCT02299986|Other|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
75922312|NCT03749265|Other|Ultrasound test|patients need to undergo an ultrasound test for detecting the presence or abscence of peroneus tertius tendon
75922313|NCT02142621|Other|transpyloric feeding|
75922314|NCT02142621|Other|gastric feeding|
75785996|NCT01095276|Drug|Saline|Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).
75785997|NCT01194128|Behavioral|Psychoeducational Support|The intervention is comprised of three modules, each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
75329579|NCT05260515|Behavioral|Staying Sharp intervention|"In the Staying Sharp online program, participants have the opportunity to select which health pillars they are most interested in improving (Be social, Engage your brain, Manage stress, Ongoing exercise, Restorative sleep, and Eat right). After selecting the health pillars, participants can set plans and goals. There are designated activities in each health pillar for participants to complete, including watch videos, read articles, or play games. Participants will follow a step-by-step guide to achieve these goals. The website tracks the status of these goals.~Participants will use Staying Sharp program for 4 months. Research staff will call participants to encourage participants to use the program. Right after the completion of the 4-month program, we will send out a survey to understand user experiences. We will follow participants for another 4 months. After 4 months follow-up, an exit study survey will be conducted either via videoconferences or in-person visits."
75922315|NCT03120806|Procedure|Interrupted subcuticular skin closure|skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section
75922316|NCT03120806|Procedure|continuous subcuticular skin closure|skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
75922317|NCT02142699|Drug|Heme arginate|
75922318|NCT03390452|Behavioral|Mobile Phone Messaging|"Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits."
75922319|NCT03390374|Drug|Nystatin Oral|Nystatin oral suspension
75922320|NCT03545373|Drug|Azithromycin|Azithromycin tablet taken orally
75922321|NCT03545373|Drug|Amoxicillin|Amoxicillin tablets taken orally
75636790|NCT05242614|Behavioral|Psychoeducation educational program|This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
75636791|NCT02784483|Drug|Atezolizumab (1200mg via IV infusion)|Patients will get atezolizumab every 21 days for up to 1 year
75636792|NCT05242536|Other|Nurse- led program|A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
75636793|NCT02784561|Drug|Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|busulfan (3.2 mg/kg/day intravenously [i.v.], days -10 to -8)
75922322|NCT00492856|Drug|mercaptopurine|Given orally
75922323|NCT00492856|Drug|methotrexate|Given orally
75636794|NCT02784561|Drug|Cytarabine(Actavis Italy S.p.A)|cytarabine (1.6 g/m2/day, days -7 to -3)
75636795|NCT02784561|Drug|Fludarabine (Bayer)|fludarabine (30 mg/m2, day -7 to -3),
75922324|NCT00492856|Drug|tretinoin|Given orally
75329580|NCT05476419|Other|Direct intra-oral scanning technique for the post space.|scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
75636796|NCT02784561|Drug|granulocyte colony-stimulating factor (KirinKunpeng)|granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
75636797|NCT02784561|Drug|rabbit ATG（Sanofi/Genzyme）|ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
75922325|NCT02146287|Other|Cycled Light|"Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.~Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630)."
75922326|NCT05161910|Other|Biomarkers|Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).
75922327|NCT05152550|Other|Non-severe pre-eclampsia|Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features.
75922328|NCT03545295|Procedure|Quadratus Lumborum Block type 2|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle
75922329|NCT03545295|Procedure|Quadratus Lumborum Block type 3|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle
75329581|NCT00374530|Drug|PGE2|
75329582|NCT02242877|Drug|Telmisartan|
75636798|NCT00757627|Drug|etoricoxib|etoricoxib 60 mg QD for 4 weeks.
75636799|NCT02848248|Drug|SGN-CD123A|Intravenous infusion in 3-week cycles
75636800|NCT02600455|Drug|Orencia|
75636801|NCT02599987|Device|POWERbreathe® Classic Light|Inspiratory Muscle Training
75922330|NCT04446026|Drug|teneligliptin|teneligliptin 20mg PO qd for 24weeks
75922331|NCT04446026|Drug|Placebo|teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
75922332|NCT03383042|Drug|Cohort 1 (JP-1366 A mg)|Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
75922333|NCT03383042|Drug|Cohort 2 (JP-1366 B mg)|Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
75922334|NCT03383042|Drug|Cohort 3 (JP-1366 C mg)|Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
75922335|NCT03383042|Drug|Cohort 4 (JP-1366 D mg)|Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
75922336|NCT03383042|Drug|Cohort 5 (JP-1366 E mg)|Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
75922337|NCT03383042|Drug|Cohort 6 (JP-1366 F mg)|Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
75922338|NCT03383042|Drug|Cohort 7 (JP-1366 G mg)|Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
75636802|NCT05342181|Other|Static exercises|"Participants will be treated with static core muscle exercises that are traditional group of exercises :~supine bridge~plank~oblique crunch~side lying with Abduction~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
76078729|NCT02176486|Drug|Placebo|Ixazomib placebo-matching capsules.
76078730|NCT01124188|Drug|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
75636803|NCT05342181|Other|Dynamic exercises|"Participants will be treated with dynamic core muscle exercises that were swiss ball exercises~bridging~straight leg raise in prone lying~straight leg raise with hand raise in prone lying~pelvic tilts~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
75636804|NCT01023308|Drug|Panobinostat|Panobinostat was administered 3x week ( 2 weeks on 1 week off)
75636805|NCT01023308|Drug|Bortezomib|Bortezomib was administered 2 x week ( 2weeks on 1 week off)
75636806|NCT01023308|Drug|Dexamethasone|Dexamethasone was adminstered on day of Bortezomib and the day after Bortezomib administration
75785998|NCT01194128|Behavioral|Information only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition. Also provided will be a resource guide containing local contact information."
75785999|NCT01096836|Other|macronutrient and energy manipulation|
75798652|NCT00655876|Drug|cetuximab|Weekly with external beam radiation therapy for a total of six doses. The initial dose of cetuximab is 400 mg/m^2 intravenously administered over 120 minutes on day 1, followed by weekly infusions of 250 mg/m^2 intravenously over 60 minutes on days 8, 15, 22, 29, and 36. The infusion rate of cetuximab must never exceed 5 mL/min.
75922339|NCT03383042|Drug|Cohort 8 (JP-1366 H mg)|Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
75922340|NCT03383042|Drug|Cohort 9 (JP-1366 I mg)|Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
75922341|NCT02142777|Drug|S -Equol|We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
75922342|NCT02142777|Drug|Placebo|The placebo has no active ingredients but is made to look like the study drug.
75922343|NCT02142855|Behavioral|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
75922344|NCT02142855|Behavioral|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
76078731|NCT01124188|Behavioral|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
75329583|NCT02242877|Drug|Telmisartan combined with hydrochlorothiazide|
75469768|NCT01942928|Other|Usual NHS Care|Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.
75922345|NCT03390218|Behavioral|Therapy Assistance Online|protocoled on-line educational modules, with brief therapist interaction and practice support with a mobile app.
75922346|NCT03390218|Behavioral|Treatment as usual|Individual and group therapy, generic in nature
75922347|NCT02146443|Other|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
75922348|NCT02146443|Other|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
75922349|NCT02146443|Device|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
76078732|NCT01124188|Behavioral|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
76078733|NCT02220478|Device|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
75636807|NCT01023308|Drug|Placebo|Placebo was administered 3x week ( 2 weeks on 1 week off)
75786000|NCT01194206|Radiation|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
75786001|NCT01096914|Procedure|percutaneous radiofrequency ablation|"Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
75636808|NCT04230525|Diagnostic Test|non invasive whole body bioimpedence system|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia. The whole-body bioimpedance method will be used to monitör the hemodynamic changes non invasively. This method can evaluate such as cardiac output, cardiac index, stroke volüme, stroke index, stroke volüme variations, cardiac reserve, etc. Parameters with a completely noninvasive method by using only electrots. The device consists of a laptop, a software which calculates cardiac parameters and two electrodes. The measurement is done by the following process: one of these electrodes, which looks like ECG electrodes, is stuck to the wrist and the other one to the opposite ankle or each one to two wrists.
75636809|NCT02784639|Other|Plasma Analysis of circulating cell free DNA|
75786002|NCT01096914|Procedure|percutaneous laser ablation|Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
75798653|NCT00655876|Drug|cisplatin|Weekly with external beam radiation therapy for a total of six doses. Patients receive 25 mg/m^2 as an intravenous infusion over 30-60 minutes on days 1, 8, 15, 22, 29 and 36.
75636810|NCT02784639|Other|Tumor tissue analysis of circulating cell free DNA|
75922350|NCT02142933|Other|vagino-perineal swab|
75922351|NCT02143011|Other|orange juice|intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement
75922352|NCT02143011|Other|sucrose|intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
75922353|NCT02143089|Device|Foley's Catheter|Urinary tract infection inpatient catheterized versus non catheterized
75922354|NCT02143167|Drug|SR-fampridine|"One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks."
76078734|NCT01125202|Behavioral|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
75636811|NCT02783391|Device|ECoG and intracortical electrodes|
76078735|NCT01125202|Behavioral|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
76078736|NCT03013114|Drug|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
75636812|NCT02781909|Drug|Ibuprofen|Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
75636813|NCT02781909|Drug|Standard of Care TB treatment|Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
75798654|NCT00655876|Drug|paclitaxel|Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.
75469769|NCT01942928|Other|Osteopathic Manipulative Therapy|Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
75469770|NCT01942941|Device|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
75798655|NCT00655876|Radiation|radiation therapy|1.8 Gy daily for 28 days (over 5-6 weeks) for a total dose of 50.4 Gy.
75922355|NCT02143167|Drug|Placebo|
75922356|NCT05150132|Device|Oral-B Genius® 8000 power toothbrush with CrossAction brush head with smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone was activated in the PTB with the app group
76078737|NCT01077310|Drug|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
76078738|NCT01077310|Drug|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
76078739|NCT02989857|Drug|AG-120|Tablet administered orally
76078740|NCT02989857|Drug|Placebo|Tablet administered orally
75922357|NCT05150132|Device|Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone were not activated in the PTB without the app group.
75922358|NCT05150132|Device|Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. They were instructed to brush with the Modified Bass technique.
76078741|NCT02393937|Drug|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
75922359|NCT03544671|Dietary Supplement|Vitamin D|
75922360|NCT05144750|Behavioral|Fruit and Vegetable Prescription|"The intervention adds a $50 monthly fruit and vegetable voucher, and text reminder and educational text messages (recipes/tips) to the Standard of Care for patients.~Standard Care for Patients at OCH: Patients will be able to regularly meet with their healthcare team.~Fruit and Vegetable Incentive: During the 8-month intervention period, registered program participants can receive $50 monthly through the reloadable Walmart gift card, which can only be used to purchase fresh fruits and vegetables. The total incentive will be $400 for the eight-month program.~Text Communication: Wholesome Wave will share text reminders to shop and utilize incentives. Wholesome Wave will also share text messages that are consistent with the messages that the OCH dietitians are offering in their standard care, including recipes and tips."
76078742|NCT02393937|Drug|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
76078743|NCT02393937|Drug|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
75329584|NCT01007071|Drug|Human Growth Hormone (1-134)|Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
76078744|NCT01877915|Drug|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
76078745|NCT01877915|Drug|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
75329585|NCT01007071|Drug|Placebo|Subjects randomized to placebo
75636814|NCT02781831|Procedure|Standard rehab|Standard hospital based rehabilitation for patients with stroke
75636815|NCT02781831|Device|Robot-assisted gait rehabilitation|An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
75329586|NCT05475639|Other|Axillary Diclofenac phonophoresis|axillary diclophenac phonophoresis (voltaren gel) will be received three times per week for four weeks
75636816|NCT04302038|Dietary Supplement|Protein|Additional daily protein provided by potato protein.
75636817|NCT04302038|Dietary Supplement|Placebo control|No additional dietary protein (outside of 0.8 g/kg/day as provided by diet)
75636818|NCT02783313|Device|Pathogen reduced plasma-stored platelet concentrates|Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
75636819|NCT02783313|Other|Plasma-stored platelet concentrates|Platelet concentrates stored in plasma
75636820|NCT04229823|Diagnostic Test|Video-oculography|Eye movement parameters will be measured in all of the subjects using video-oculography device (EyeSeeCam, InterAcoustics). Measurement sessions consist of the study subject wearing a goggle attached to a camera that detects the pupil and eye position and velocity. Evaluation start with vestibulo-ocular reflex testing, with video head impulse test. Afterwards, saccades, smooth pursuit and fixation are evaluated.
75636821|NCT04229823|Diagnostic Test|Clinical Scales|All subjects are examined by an investigator in order to score clinical scales for ataxia, including Scale for the Assessment and Rating of Ataxia (SARA), International Co-operative Rating Scale (ICARS), Neurological Examination Scale for SCA (NESSCA), Inventory of Non-ataxia Symptoms (INAS), SCA Functional Index (SCAFI) and Composite Cerebellar Functional Severity Score (CCFS).
75636822|NCT04229823|Diagnostic Test|Genotyping|Individuals at 50% risk (offspring of subjects with molecular diagnosis of SCA3/MJD) will be genotyped in a double-blind manner so that they can be divided into pre-ataxic carriers and related controls (non carriers)
75636823|NCT02783079|Behavioral|CBT|
75636824|NCT02783079|Behavioral|MBSR|
75636825|NCT04229511|Diagnostic Test|Detection of CRKp colonization|Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
75922361|NCT03382964|Biological|VLA1553|I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
75922362|NCT05081037|Device|Wearable Care Group|"Continous glucose monitoring sensor: Study participants wear the sensor on the back of either right or left upper arm for up to 14 days. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning.~Exercise tracker: A FitBit watch will be given to the participants for use to track physical activity levels."
75922363|NCT02877836|Other|magnetic resonance imaging (fMRI)|To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
75922364|NCT03545217|Behavioral|Lifestyle Intervention|a 6-month intensive lifestyle intervention program led by a multidisciplinary team of diabetes nurses and dieticians, and a follow up at 12 months for these participants. This will be a group-based activity adapted from the Diabetes Prevention Program -Thailand project
75922365|NCT02430987|Diagnostic Test|Female sexual function index questionnaire|"Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese with 19 items measuring female sexual function. Cut-off points of >23 and > 26.5 were adopted to define a diagnosis of Female Sexual Function based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM -IV- TR) by the American Psychiatric Association, duration criteria > 24 weeks.~A score of 5 or less on the combination of items comprising the desire domain of the FSFI questionnaire was used to define the diagnosis of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women We consider that a score of 6 or more the woman does not present with HSDD."
75469771|NCT01942967|Other|Echocardiography|"Measurement of:~Left ventricular output (LVO).~Right ventricular output (RVO).~Assessment of the Mesenteric Artery Flow."
75636826|NCT03411915|Biological|XmAb18087|monoclonal bispecific antibody
75922366|NCT02430987|Diagnostic Test|Evaluation of presence of metabolic syndrome|The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol < 50mg/dL; (3) triglycerides > 150mg/dL; (4) arterial blood pressure (SAH) > 130/85mmHg; and (5) fasting glucose > 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.
75636827|NCT01521039|Procedure|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
75798656|NCT01176318|Drug|Erdosteine|capsule 300mg twice daily for 10 days
75922367|NCT02430987|Diagnostic Test|Evaluation of the body mass index|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group
75922368|NCT03385850|Other|enteral nutrition|early enteral nutrition group or delayed enteral nutrition group
75636828|NCT01022996|Drug|Everolimus (RAD001)|Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
75636829|NCT02781597|Drug|Tranexamic Acid|Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
75636830|NCT02781597|Drug|Placebo|Patients will receive 0.9% normal saline
75636831|NCT02783235|Other|cervical cancer screening|for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
76078746|NCT01877915|Other|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
76078747|NCT01876979|Device|IMF Screws|stainless steel screws placed in bone
76078748|NCT01876979|Device|Erich Arch Bars|Surgical braces wired around teeth
76078749|NCT04397601|Drug|Folfiri/Bevacizumab|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.
76078750|NCT04397601|Drug|Folfiri/Aflibercept|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
76078751|NCT01860989|Drug|KAE609|KAE609 75mg single dose
76078752|NCT01860989|Drug|KAE609|KAE609 150mg single dose
76078753|NCT01860989|Drug|KAE609|KAE609 225mg single dose
76078754|NCT01860989|Drug|KAE609|KAE609 300mg single dose
76078755|NCT02906241|Behavioral|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
75469772|NCT01942967|Other|Near Infrared Spectroscopy Monitoring|Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
75469773|NCT01942980|Radiation|Radiation therapy Brain metastasis in breast cancer|Radiation
75469774|NCT01943006|Drug|Hirudoid cream 0.3 % Mucopolysaccharide polysulfate|Hirudoid cream
75798657|NCT01176318|Drug|Placebo|placebo capsule, twice daily for 10 days
75469775|NCT01943006|Drug|Placebo cream without active substance|
75469776|NCT01943019|Drug|Linagliptin|
75469777|NCT01943045|Biological|NGM282|
75798658|NCT01178658|Drug|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
75798659|NCT01178736|Procedure|Breast Cancer Screening and Diagnosis|Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
75798660|NCT01178736|Procedure|Cervical Cancer Screening and Diagnosis|Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
75636832|NCT00757237|Drug|Aztreonam for Inhalation Solution (AZLI)|Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
75636833|NCT00757237|Drug|Tobramycin Inhalation Solution (TIS)|Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
75922369|NCT03390062|Drug|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
75786003|NCT03847532|Genetic|Sanger sequencing method|Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.
75786004|NCT03953430|Other|Gait analysis|
75786005|NCT01194284|Drug|Mifamurtide|Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
75922370|NCT02410629|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
75922371|NCT02410629|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
75922372|NCT03382886|Drug|Nivolumab|"Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
75922373|NCT03382886|Drug|Bevacizumab|"Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:~Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks~Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
76078756|NCT02906241|Behavioral|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
76078757|NCT01860677|Device|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
75329587|NCT05475639|Other|Post isometric facilitation|Post isometric facilitation exercise will be received three times per week for four weeks
76078758|NCT02870829|Drug|menaquinone-7|Oral supplement given post dialysis 3x/week
75329588|NCT05475639|Other|Traditional physiotherapy|Traditional physiotherapy will be received three times per week for four weeks
75329589|NCT02242955|Drug|Diazepam|40 mg per day.
75469778|NCT01943045|Other|Placebo|
75469779|NCT01943058|Drug|megestrol acetate|Given PO
75469780|NCT01943058|Device|levonorgestrel-releasing intrauterine system|Given IUD
75329590|NCT02984644|Drug|Dapagliflozin|Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
75329591|NCT02984644|Drug|Placebo|Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
75786006|NCT03255382|Drug|Fumaderm|Fumaderm tablet administered orally
75786007|NCT03255382|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
75469781|NCT01943058|Other|laboratory biomarker analysis|Correlative studies
75786008|NCT03960450|Drug|BOS-475|topical cream
75786009|NCT03960450|Drug|Vehicle|topical cream
75786010|NCT03847454|Combination Product|REACH|The intervention consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity.
75329592|NCT00358605|Device|The Klearway™ oral appliance|See Detailed Description.
75469782|NCT01943058|Other|questionnaire administration|Ancillary studies
75469783|NCT01943071|Behavioral|Day care for patients with dementia|Day care centres designed by the local authorities for patients with dementia
75469784|NCT01943084|Drug|Norditropin® FlexPro® pen|Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
75469785|NCT01943084|Drug|Genotropin Pen®|Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
75636834|NCT01029392|Drug|Vitamin D|2000iu once a day
75636835|NCT02781753|Biological|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0
75786011|NCT03847454|Other|Standard of care|Standard of care for rehabilitation treatment for musculoskeletal patients.
75798661|NCT01178736|Procedure|Ovarian Cancer Screening and Diagnosis|Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
75798662|NCT01178736|Procedure|Endometrial Cancer Screening and Diagnosis|Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
76078759|NCT02861391|Device|CO2 AcuPulse Laser|Each subject will receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
75636836|NCT02781753|Biological|Peginterferon 180 μg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
75786012|NCT01095354|Drug|Sodium Chloride Inhalation|"Spirometry: all subjects Plethysmography and exhaled nitric oxide: >6 years Multiple Breath Washout: Tidal breathing using a facemask <9 years or mouthpiece >9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches <0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects >10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum."
75786013|NCT03847298|Other|Physical activity and physical fitness assessment|Physical fitness was assessed using Munich Physical Fitness Test (MFT). The SenseWear Armband metabolic holter device was used to record the physical activity level for consecutive 7 days. The functional exercise capacity of the individuals was assessed by the six-minute walking test (6MWT) and cardiorespiratory capacity was assessed by maximal exercise test on the treadmill.
75786014|NCT03955692|Device|tDCS|Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
75786015|NCT01194518|Behavioral|Lifestyle Intervention Program|
75922374|NCT03385772|Procedure|Sphenopalatine ganglion block|The patient will be placed supine, with head in sniffing position. Two long cotton-tipped applicators will be soaked in 4% lidocaine for 30 seconds. An anesthesia provider, after visually inspecting each nostril for any sign of deformity or blockage, will perform the block. A cotton tipped applicator will be inserted into one nostril at an angle perpendicular to the face, and will be advanced to the back of the nasopharynx until resistance is met. The procedure will be repeated in the other nostril. If the patient experiences any pain or discomfort, the physician will stop and redirect the applicator. The applicators will be left in place for 10 minutes, and then removed by the anesthesia provider.
75922375|NCT03389984|Diagnostic Test|cutaneous|SKIN BIOPSY
75922376|NCT02855918|Other|Blood sample for genetic purpose|"All the participants will performed the same evaluations and blood analysis :~A clinical assessment by psychiatrist~Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits…~A neuropsychological assessment for the evaluations of cognitive performances~A routine blood sampling to the realization of a standard blood test~A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript."
75922377|NCT03382808|Behavioral|SEE Training|Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.
75922378|NCT03382808|Behavioral|GAZE Training|Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
75786016|NCT01296386|Biological|IC84|IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
75786017|NCT03960294|Other|DOZE Sleep App|DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
75922379|NCT02853812|Other|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
76078760|NCT02861391|Device|Sham Laser|Each subject will receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
75786018|NCT03849170|Behavioral|Stress Inoculation Technique|Teaches athletes to use cognitive-behavioral techniques to reduce their stress response during sporting events.
75329593|NCT03026959|Behavioral|Mindfulness|The mindfulness intervention follows the structure described by Short, Mazmanian, Ozen, & Bédard, (2015).
75329594|NCT02243111|Radiation|Doppler ultrasound|Detecting Doppler signals from the lungs on the right chest wall
75636837|NCT00903006|Drug|Fulvestrant|Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
75636838|NCT00903006|Drug|MK-0646|Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
75636839|NCT00903006|Drug|Dasatinib|Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
75786019|NCT03849170|Other|Health Intervention|Will provide basic dietary and lifestyle guidelines that athletes should follow in their daily lives to maintain their health
75636840|NCT02873312|Device|StimRouter|"The StimRouter System is a neuromodulation system consisting of the following components and accessories:~An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories."
75636841|NCT02781675|Other|Dietary Intervention|3 wk dietary intervention with prescribed menus and ~50% foods provided.
75786020|NCT03849014|Procedure|Dynamic Hip Screw|Dynamic Hip Screw fixation: Fracture will be reduced under image intensifier. The incision will be made 7-10 cm with a lateral approach. The fascia lata will be incised and the vastus lateralis muscle will be splited along the axis of the femur, without stripping the periosteum. A135° angle guide will be inserted in the lower half of the femoral neck. The barrel of the plate will be guided to the hip screw by direct palpation to minimize the soft-tissue injury. After the insertion of the cortical screw, soft tissue will be protected with 4.5mm drill sleeve during drilling and tapping.
75922380|NCT03389906|Other|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
75329595|NCT05621577|Device|MANDIBULAR ADVANCEMENT DEVICE|orthodontically treating obstructive sleep apnea
75329596|NCT02243189|Drug|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
75636842|NCT04229121|Other|nonintervention|nonintervention
75636843|NCT05242224|Other|Evolutionary Nutrition Package|The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
75329597|NCT02243189|Drug|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
75329598|NCT02243189|Drug|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
75786021|NCT03849014|Procedure|Proximal Femoral Nail|Proximal Femoral Nail fixation: Fracture will be reduced under image intensifier. The incision 2-3 cm with a lateral approach that extended from the cranial part to the tip of the greater trochanter. After palpating the greater trochanter tip, the nail will be then introduced manually into the femoral shaft. The guide wire of the anti-rotational hip blade then introduced. The hip blade should be introduced in the direction of the lower half of the femoral neck. Drilling will be performed under soft-tissue protection with a retractor. The blade will be inserted, and a distal static locking screw and end cap will be inserted under soft tissue protection with a drill sleeve.
75786022|NCT01294982|Drug|AOBO-001|AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
75922381|NCT04927208|Other|exercise and nutritional support|"resistance exercise and protein supplementation including branched chain amino acids for 12 weeks~Other: Combined exercise and nutrition intervention resistance exercise and nutritional supplementation for 12 weeks"
75922382|NCT03125486|Drug|SC belimumab 200 mg|Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.
75329599|NCT00966823|Device|Fetal tracheal obstruction with detachable balloon (device)|"Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.~- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation."
75329600|NCT02977845|Behavioral|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
75469786|NCT01943123|Dietary Supplement|probiotic drink|comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
75469787|NCT01943123|Dietary Supplement|Placebo Comparator: plain, unsweetend, unflavored pasturised milk|comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
75469788|NCT01943136|Drug|papaya 1% extract ointment|
75469789|NCT01943136|Drug|mupirocin 2% ointment|
75469790|NCT01943162|Behavioral|CPT|
75469791|NCT01943188|Radiation|stereotactic body radiation therapy|Undergo SBRT
75469792|NCT01943188|Drug|cyclophosphamide|Given PO
75469793|NCT01943188|Biological|therapeutic autologous lymphocytes|Undergo autologous PBMC infusion
75469794|NCT01943188|Other|laboratory biomarker analysis|Correlative studies
75469795|NCT01943201|Device|new bedsheet|sleeping 5 nights on the new bedsheet
75469796|NCT01943201|Device|conventional bedsheet|sleeping 5 nights on the conventional bedsheet
75636844|NCT04229277|Diagnostic Test|optical coherence tomography|comparison of four imaging technologies in skin tumour diagnosis
75636845|NCT05242068|Device|Veinlite|Use of vein imaging device for visualization of veins during peripheral IV placement
75636846|NCT05242068|Other|Standard care|Patients received standard intravenous catheterization.
75469797|NCT01943240|Drug|Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels|
75469798|NCT01943240|Drug|10 cc of 0.375% ropivacaine pectoral nerve block|
75469799|NCT01943253|Device|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
75329601|NCT02984878|Device|Revanesse Ultra|Nasolabial Fold correction
75329602|NCT05469867|Device|CorNeat EverPatch|The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.
75469800|NCT01943253|Device|Hybridknife ESD|Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
75469801|NCT01943266|Dietary Supplement|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
75636847|NCT04097899|Other|implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients|"Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~Antibiotics cost.~Appropriates of antibiotic use (initiation, duration & time of discontinuation).~Rate of resistance~Clinical outcome, infection rate &length of stay."
75786023|NCT01294982|Drug|AOBO-001|AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
75786024|NCT01294982|Drug|Placebo|Placebo Oral Capsules twice daily
75786025|NCT01191554|Drug|Tranexamic Acid|High and low dosage. Loading dose followed by continuous infusion in operation.
75786026|NCT01188746|Behavioral|McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire|Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
76078761|NCT02843529|Other|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
76078762|NCT01876901|Procedure|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|"2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
76078763|NCT01876901|Procedure|Colo-anal anastomosis (CAA)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
75329603|NCT04370249|Other|pulmonary ultrasound|pulmonary ultrasound on admission
75329604|NCT05260437|Biological|CV2CoV (2 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75329605|NCT05260437|Biological|CV2CoV (4 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75329606|NCT05260437|Biological|CV2CoV (8 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75329607|NCT05260437|Biological|CV2CoV (12 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75329608|NCT05260437|Biological|CV2CoV (16 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75469802|NCT01943279|Other|Remote Follow-up (RFU)|Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
75469803|NCT01943279|Other|Standard Follow-up (SFU)|Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
75469804|NCT01943305|Biological|Japanese Encephalitis vaccine|IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
75469805|NCT01943305|Biological|Yellow Fever vaccine|STAMARIL, 1 dose (0.5 ml)
75636848|NCT04201938|Combination Product|Symbiter-Omega|Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.
75636849|NCT04201938|Dietary Supplement|Placebo|Placebo
75469806|NCT01943357|Behavioral|Diabetes Self Management Program|The interventions include modeling and action-planning to enhance self-efficacy.
75469807|NCT01943370|Other|Early saline irrigation|Initiation of post-operative saline irrigation earlier during the post-operative course
75469808|NCT01943370|Other|Routine Irrigation|Routine initiation of saline irrigation
75469809|NCT01943383|Genetic|iPSC|Single blood draw for the production of induced pluripotent stem cells.
75786027|NCT01296464|Drug|Carbidopa|Capsules
75798663|NCT03862326|Behavioral|Exercise|From lying to sitting to active exercises with focus on the pelvic floor
75798664|NCT00585832|Behavioral|DASH-4-Teens|24-week behavioral nutrition intervention emphasizing a diet high in fruits, vegetables and low fat dairy foods and that is low in fat and sodium
76078764|NCT01876823|Drug|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
75329609|NCT05260437|Biological|CV2CoV (20 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
75636850|NCT02599831|Device|Electrical pudendal nerve stimulation|Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
75922383|NCT02252211|Drug|DS-8895a 1 mg/kg|Patients received infusions with ^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and ^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
75636851|NCT02599831|Device|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
75329610|NCT02986282|Device|ABI measurement using both doppler and oscillometric method|
75329611|NCT04362605|Procedure|Endoscopic Negative Pressure Therapy|"In patients with suspected insufficiency of the esophagojejunostomy first an index endoscopy under general anesthesia with endotracheal intubation was indicated. Standard gastroscopes with outer diameter of 9.8mm were used with carbon dioxide insufflation.~Definition of a anastomotic leak were endoscopic or radiological dehiscences at the esophagojejunostomy with extravasation of fluids and gas. In cases of insufficiencies start of endoluminal ENPT were indicated.~Decision criteria for placement of OPD or OFD were the defect size, radiological findings and clinical situation of the patient. A CT scan in patients with suspected EJAL was done in all cases.~For endoluminal ENPT, the open-pore drainage system is placed within the lumen of the digestive tract at the entrance to the cavity."
75329612|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
75329613|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
75329614|NCT05252949|Dietary Supplement|Oleoylethanolamide (OEA)|Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.
76078765|NCT01876823|Drug|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
75636852|NCT02599831|Device|Transanal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
75636853|NCT05132361|Device|SELUTION SLR™ 018 DEB|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
75922384|NCT02252211|Drug|DS-8895a 3 mg/kg|Patients received infusions with ^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and ^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
76078766|NCT01876511|Drug|MK-3475|MK-3475 10 mg/kg every 14 days
76078767|NCT01993719|Drug|Aldesleukin|720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
76078768|NCT01993719|Drug|Fludarabine|25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days
76078769|NCT01993719|Drug|Fludarabine|30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.
75636854|NCT05132361|Device|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
75636855|NCT02845986|Procedure|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
75636856|NCT02845986|Drug|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
75798665|NCT00585832|Other|Routine Care|individual in-person counseling sessions on guidelines consistent with the Fourth Pediatric Report of the National High Blood Pressure Education Program.
75798666|NCT03092752|Drug|oral antidiabetic drugs|OADs usage conditions and dose selection in T2DM patients
75798667|NCT03750552|Drug|ampreloxetine|Oral tablet, QD
76078770|NCT01993719|Drug|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV)
76078771|NCT01993719|Drug|Cyclophosphamide|Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
75798668|NCT03750552|Drug|Placebo|Oral tablet, QD
75798669|NCT03750240|Diagnostic Test|Sodium (Na) Magnetic Resonance Imaging (MRI)|"Two Na data will be acquired:~FLORET without Inversion Recovery (IR), and~FLORET with IR"
75798670|NCT03750240|Diagnostic Test|Dynamic Contrast- Enhanced (DCE) MRI|DCE MRI will be acquired subsequent to Na MRI to prevent influence of the contrast agent on 23 Na data
75922385|NCT02252211|Drug|DS-8895a 10 mg/kg|Patients were to receive infusions with ^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and ^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
75329615|NCT05252949|Dietary Supplement|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.
75636857|NCT02598739|Other|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
75329616|NCT04369391|Drug|SEP363856 150 mg|SEP363856 tablet 150 mg
75922386|NCT02173353|Device|Ultrasound|Ultrasound to be done just before standard radiation therapy treatment
76078772|NCT01993719|Drug|Cyclophosphamide|Days -5 to -3 (low-dose arm): 300 mg/m^2 IV over 60 minutes.
75636858|NCT02598739|Other|Waiting list for the exercises|
76078773|NCT01993719|Biological|Young TIL|Day 0: Cells will be infused intravenously (IV)
76078774|NCT01993719|Drug|Pembrolizumab|2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
75329617|NCT04369391|Drug|Placebo|Placebo tablet
75329618|NCT04369391|Drug|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
75329619|NCT02873104|Device|truSculpt rf device|radiofrequency device
75329620|NCT04369313|Procedure|delayed cord clamping|umbilical cord clamping more than 30 seconds after birth
75636859|NCT05340933|Other|Voice registration|Voice registration
75636860|NCT04095325|Device|Ultrasound guided erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
75636861|NCT00839332|Drug|LY2603618|
75636862|NCT00839332|Drug|Gemcitabine|
76078775|NCT00638235|Device|AMS Apogee™ with IntePro|Mesh implant for posterior wall pelvic organ prolapse
75636863|NCT04180917|Other|Survey|survey
75636864|NCT03325452|Biological|venous lactate|value of venous lactate
75636865|NCT05341947|Biological|Activated T cells|Activated T cells (ATC) administered intravenously at one timepoint
75329621|NCT04369313|Procedure|early cord clamping|umbilical cord clamping within 15 seconds after birth
75329622|NCT00358683|Drug|Certolizumab pegol|
75329623|NCT00967369|Drug|Bortezomib|Given IV
75329624|NCT00967369|Drug|Carboplatin|Given IV
75636866|NCT04095169|Diagnostic Test|Complement C3d test (blood sample)|Evaluation of C3d levels in EDTA samples from participants
75636867|NCT04230057|Dietary Supplement|Antitumor B|Single dose 2400 mg
75636868|NCT00917215|Device|Disposable stainless steel acupuncture (0.2mmx4mm)|"For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks."
75786028|NCT05146466|Behavioral|E-MATVR|It involves using computer software uploaded onto wireless virtual reality (VR) technology (similar to downloading an app on a mobile phone) and will be delivered using a headset, handheld controllers, and voiceover (all wireless). E-MATVR comprises three serious gaming levels aimed at familiarising men with the normal look and feel of the testes, common testicular symptoms and diseases, and the importance of early help-seeking.
75786029|NCT05146466|Behavioral|E-MATE|It involves using the same information as EMATVR delivered as plain text (e.g., PDF) with still images from E-MATVR. Participants will be given approximately 10 minutes to read the text/look at images using a tablet (e.g., iPad).
75786030|NCT03254602|Device|Intense Therapeutic Ultrasound Treatment|
75786031|NCT02524262|Dietary Supplement|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
75786032|NCT00038142|Drug|Vincristine|2.0 mg/m^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
75786033|NCT00038142|Drug|Doxorubicin|90 mg/m^2 IV over 30 min x 1 repeated every 3 weeks X 6.
75786034|NCT00038142|Drug|Cyclophosphamide|2.0 g/m^2 IV daily x 2 days repeated every 3 weeks X 6.
75786035|NCT00038142|Drug|Dexrazoxane|900 mg/m^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
75922387|NCT02146677|Other|Osteopathic manipulative treatment|
75922388|NCT02146677|Other|Sham therapy|
75329625|NCT00967369|Drug|Etoposide|Given IV
75329626|NCT00967369|Drug|Ifosfamide|Given IV
75329627|NCT04361981|Other|Deep Venous Disease Diagnostic|Clinical and/or echographic diagnosis of Deep Venous Disease in a patient with COVID-19 infection
75329628|NCT02876926|Behavioral|"Smart home-based test for HIV"|A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.
75329629|NCT02876926|Behavioral|Home-based testing only|A standard home-based HIV test kit.
75329630|NCT02876926|Behavioral|Reminder letters for clinic-based testing|Letters reminding patients to get tested at a free clinic location
75329631|NCT04369235|Device|tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. tCES will be applied for 20 minutes at an intensity of 1.0 -1.5 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 6 weeks.
75329632|NCT04369235|Device|Sham tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham tCES will consist of a 5-second ramp up to 1.0-1.5 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
75922389|NCT02146677|Other|Usual care|
75922390|NCT02147847|Behavioral|Video game based training 1|32 one-hour, home-based training sessions over 8 weeks
75636869|NCT05340777|Device|Training Obstetric staff on Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to ensure staff are trained on the newly registered and provided medical device. We will gather feedback on how to improve the training curriculum from participants. We will also gather information from the healthcare workers immediately post-use of an Ellavi UBT device following their management of a refractory PPH case. These surveys will help us to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of PPH care.
75786036|NCT00038142|Biological|ImmTher|900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
75922391|NCT02147847|Behavioral|Video game based training 2|32 one-hour, home-based training sessions over 8 weeks
75922392|NCT02147925|Drug|Liraglutide combined with metformin|Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
75922393|NCT02147925|Drug|Insulin glargine combined with metformin|The initial dose will be 0.2 unit/kg/d
75636870|NCT04494594|Behavioral|Drinks:Ration app|Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.
75922394|NCT02147925|Drug|Sitagliptin combined with metformin|The dose throughout the study will be 100mg per day.
75922395|NCT03544047|Drug|Paclitaxel|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).
75922396|NCT03544125|Biological|Durvalumab|Given IV
75922397|NCT03544125|Drug|Olaparib|Given PO
75922398|NCT02151357|Drug|DCBCI0901|DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
75922399|NCT02146911|Drug|Bupropion|
75636871|NCT02780973|Other|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
75636872|NCT03203460|Behavioral|High-intensity aerobic interval training (HIIT)|A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
75636873|NCT00922948|Procedure|Cryoablation|Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
75786037|NCT01292096|Other|Provision of extra (care coordination and management) services|The pilot intervention begins at the patient's bedside in the hospital and continue after his/her discharge into the community, utilizing a flexible and intensive care management model with a multi-disciplinary team approach. Community Based Care Managers (CBCMs) overseen by a social worker, will connect patients to needed community services including housing for homeless patients, accompany patients to appointments and facilitate transportation to medical, benefits enrollment, and perform other services based in the hospital and community.
75786038|NCT00366899|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
75922400|NCT02146911|Drug|Varenicline|
75922401|NCT02146911|Behavioral|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
75922402|NCT02148159|Device|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
75786039|NCT00366899|Biological|7 valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
75786040|NCT05570968|Procedure|C-arm device|Percutaneous Transluminal Angioplasty
75922403|NCT02148159|Device|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
75469810|NCT01943396|Procedure|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
75469811|NCT01943409|Drug|Intralipid|soybean oil-based lipid emulsion
75922404|NCT02146989|Other|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
75922405|NCT02148315|Behavioral|garden|
75922406|NCT02776683|Drug|BI 695502|
75922407|NCT02776683|Drug|Avastin|
75922408|NCT02731742|Biological|MK-1966|MK-1966 administered as an intravenous (IV) infusion
75922409|NCT02731742|Drug|SD-101|SD-101 administered as an intratumoral (IT) injection
75922410|NCT02254707|Drug|BILB 1941 ZW|
75922411|NCT02254707|Drug|Placebo|
75922412|NCT03543891|Other||
75922413|NCT02963714|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
75922414|NCT02963714|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
75922415|NCT02148393|Procedure|Vitrification with subsequent-cycle embryo thawing/transfer|"The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).~In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation."
76078776|NCT00638235|Device|AMS Apogee™ with Intexen LP|Graft implant for posterior wall pelvic organ prolapse
76078777|NCT00638235|Device|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
75469812|NCT01943409|Drug|ClinOleic|olive oil-based lipid emulsion
75786041|NCT03847376|Drug|Rilpivirine Long Acting (RPV LA)|Participants will receive RPV LA injectable suspension containing 300 milligram per milliliter (mg/mL) of RPV by intramuscular (IM) injection. A starting dose of 900 milligram (mg) RPV LA (3 milliliter [mL] suspension) will be administered with subsequent doses of 600 mg RPV given at 4-week intervals.
75786042|NCT01090128|Drug|Nanoparticle Albumin Bound Paclitaxel|IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
75786043|NCT01090128|Drug|doxorubicin|50 mg/m2 every 3 weeks
75636874|NCT00922948|Procedure|Radiofrequency ablation|Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
75636875|NCT03167892|Device|Oral screen|Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
75636876|NCT02845284|Behavioral|enhanced group support|Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
75636877|NCT02845284|Behavioral|enhanced individual support|Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
75786044|NCT01090128|Drug|cyclophosphamide|500 mg/m2 given every 3 weeks
75786045|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg
75922416|NCT02148393|Procedure|Intensified luteal phase support for fresh embryo transfer|A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
75922417|NCT02148393|Drug|Pregnyl®|1500 IU
75922418|NCT02148393|Drug|Utrogestan®|200 mg tid
75922419|NCT02148393|Drug|Progynova®|2 mg bid
75922420|NCT02148393|Device|CryoBioSystem®|CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
75469813|NCT01943422|Drug|High-dose Interferon alfa-2b|•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
75636878|NCT04229433|Drug|SHR2285 tablet|Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.
75636879|NCT04229433|Drug|Placebo|Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.
75636880|NCT02845206|Procedure|Patient specific cutting blocks|'MyKnee' Instrumentation
75636881|NCT02845206|Procedure|Conventional cutting blocks|Standard Instrumentation
75636882|NCT02783157|Device|Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)|Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
75636883|NCT02783157|Device|Sham LLVNS|A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
75636884|NCT02845362|Other|Sydney Swallow Questionnaire|The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
75636885|NCT02782689|Device|Kit Biflex|Two-layer reusable compression system
75636886|NCT02782689|Device|Profore|Four-layer compression system
75636887|NCT05341713|Biological|inactive SARS-Cov-2 vaccine|We included epilepsy patients who were vaccinated with inactive SARS-CoV-2 vaccines
75636888|NCT05241912|Drug|Dobutamine|administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
75786046|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg
75786047|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
75922421|NCT03385694|Diagnostic Test|Assessment|Pelvic coronal X-ray, proprioceptive test with Delos system, questionnaires administration, orthopaedic, physiatric and prosthetic assessment
75922422|NCT03125252|Other|Bundle|"Awakening and Breathing Coordination Delirium monitoring and management (detection and management of delirium) Early mobility~Factors of environment:~thirst~noise~pain and well-being~sleep~isolation"
75922423|NCT03125252|Other|Standard Paramedical and Medical practices|"The current recommendations recommend the following scheme:~Identification and correction of an organic cause / factors (sepsis, metabolic disorders, withdrawal syndrome, pain)~Use of non-pharmacological means (early mobilization, correction of sensory deficits, temporo-spatial reorientation strategies)~Use of reference antipsychotic pharmacological means"
75922424|NCT02416154|Procedure|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
75922425|NCT03382184|Device|Fraxel Dual laser|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.
75636889|NCT05212545|Dietary Supplement|Placebo|maltodextrin taken daily for 4 weeks with water
75636890|NCT05212545|Dietary Supplement|Prebiotic supplement|Prebiotic supplement taken daily for 4 weeks with water
75636891|NCT05212545|Dietary Supplement|Prebiotic combination|prebiotic oligosaccharides mixture taken daily for 4 weeks with water
75786048|NCT01090206|Dietary Supplement|Vitamin D and calcium|Doses will be based on Vitamin D levels
75786049|NCT05570890|Device|electrical noise stimulation|The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.
75922426|NCT03382184|Device|Halo laser|The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
75786050|NCT05570890|Device|Sham stimulation|Participants will not receive stimulation.
75786051|NCT05570890|Device|Foam|The foam will be used to make an unstable surface.
75786052|NCT01296620|Drug|Ulimorelin Intravenously (IV)|160 µg/kg daily (QD)
75786053|NCT01296620|Drug|Ulimorelin Invtravenously (IV)|480 µg/kg daily (QD)
75786054|NCT01296620|Drug|5% dextrose in water|Placebo
75636892|NCT05212545|Dietary Supplement|Prebiotic oligosaccharides|Prebiotic oligosaccharides taken daily for 4 weeks with water
75786055|NCT04728646|Drug|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
75922427|NCT02324816|Device|The Zeltiq CoolSculpting System|The CoolSculpting System delivers non-invasive cooling for the reduction of subcutaneous fat.
76078778|NCT00638235|Device|AMS Perigee™ with IntePro Lite|Mesh implant for anterior wall pelvic organ prolapse
76078779|NCT00638235|Device|AMS Apogee™ with IntePro Lite|Mesh implant for posterior wall pelvic organ prolapse
75786056|NCT04728646|Device|Regular dissolvable intracanalicular plug|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
75786057|NCT03637192|Other|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
75786058|NCT03637192|Other|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
75786059|NCT01296776|Other|wellness control group.|Light physical exercise and relaxation program once a week in blocks of 10 weeks with breaks of 10 weeks between the blocks. The low-intensity, low-volume program was designed to avoid impact on our endpoints.
75786060|NCT01296776|Device|whole-body electromyostimulation|3 sessions of 18 min/14 (1,5 x week)days over 12 months. 10 low-intensity/low amplitude exercises with electromyostimulation equipment with 85 Hz with periods of 6 sec of current and 4 sec of rest.
75636893|NCT04210830|Diagnostic Test|Quantra-Device|Point of Care Coagulation Monitoring System
75636894|NCT05241756|Device|FLACS using FEMTO LDV-Z8|Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
75786061|NCT04674826|Drug|Tralokinumab administered as 1 × X mL with Device A|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
75786062|NCT04674826|Device|Tralokinumab administered as 2 × Y mL with Device B|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
75636895|NCT05121129|Device|iTBS|25 active iTBS sessions (5 sessions of 9.5 minutes/day, 1,800 pulses per session, 90% of resting motor threshold, placed over the left DLPFC)
75636896|NCT05340543|Procedure|Confocal optical coherence tomography - OCTAVE|"An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function"
75636897|NCT05341635|Diagnostic Test|Swab sampling|Collection of three nose-pharyngeal and oral swabs
75636898|NCT05234034|Other|online survey|participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.
75636899|NCT02781441|Behavioral|Question prompt list (QPL)|
75786063|NCT01295138|Drug|Lactulose|Lactulose liquid. 15mls twice daily
75786064|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
75922428|NCT02314364|Radiation|SBRT with protons or photons|
75922429|NCT03385616|Device|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
75922430|NCT00104871|Drug|Bortezomib|Administered IV at the dose of 1.3 mg/m^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
75922431|NCT03385538|Drug|Clopidogrel|increasing doses of clopidogrel depending on PRU values (75-300 mg)
75922432|NCT03385460|Other|ESWL BOTOX|ESWL after intrravesical BOTOX
76078780|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntePro Lite|Mesh implant for apical and posterior wall pelvic organ prolapse
76078781|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntXen LP|Graft implant for apical and posterior wall pelvic organ prolapse
76078782|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Mesh implant for anteiror and apical wall pelvic organ prolapse
76078783|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)|Mesh implant for anteiror and apical wall pelvic organ prolapse
76078784|NCT01848171|Drug|L-thyroxine|
75636900|NCT02781441|Behavioral|Education brochure of Groupe Français des Myélodysplasies|
75636901|NCT04229043|Dietary Supplement|Sports drink|Drink that will be ingested
75636902|NCT04229043|Dietary Supplement|Water|Drink that will be ingested
75636903|NCT04230291|Behavioral|Verbal consultation|Verbal consultation only without written information before receiving written action plan
75786065|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
75786066|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
75786067|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
75786068|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
75786069|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
75786070|NCT01049165|Drug|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
75786071|NCT01049165|Drug|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
75786072|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
75786073|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
75798671|NCT01174524|Drug|gestoden 60 mcg|gestoden 60 mcg, once a day, administered in 24/4 regimen.
76078785|NCT02758665|Drug|ibrutinib|
76078786|NCT02758665|Drug|obinutuzumab|
76078787|NCT02758665|Drug|venetoclax|
75329633|NCT04369001|Behavioral|Community-Based Exercise|Participants will complete 150 minutes of exercise per week for 12 weeks. Exercise per week will be documented using exercise logs. The exercise protocol will be a culturally-tailored community-based exercise intervention based on the aerobic exercise goals used in the Program ACTIVE study and psychoeducational materials adapted from Program ACTIVE based on feedback from Black men with T2D. Exercise in Program ACTIVE will be obtained through individualized community-based activities that participants in the focus groups indicate as feasible rather than the highly controlled laboratory environment. Exercise goals will be adapted to accommodate the physical and medical restrictions of an older-adult diabetes population.
75922433|NCT03543033|Drug|Corticosteroid injection|These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
75922434|NCT03380702|Procedure|whitening photoactivation gel|35 subjects in active comparator group
75329634|NCT04369001|Behavioral|Cognitive Behavioral Therapy|Participants will receive 10 sessions of CBT using a manualized approach based on Beck's model of cognitive therapy. Sessions are to be completed once weekly in conjunction with weekly exercise. The Program ACTIVE CBT intervention includes: presentation of CBT model; thought records, cognitive distortions, counterarguments, cognitive reframing, automatic thoughts, core beliefs, and relapse prevention. Session goals will be tailored to the needs of men so that the order of topics may vary. Each session will begin with the designation of session goals, review of previously assigned homework, and introduction of new concepts and skills. Individually-tailored homework assignments designed to provide practice with the concepts/skills of the session will be assigned.
75922435|NCT03380702|Procedure|placebo|35 subjects in placebo comparator group
75922436|NCT04723160|Diagnostic Test|Software assisted imaging diagnosis|In the test group, diagnoses are given with the help of the software.
75636904|NCT04230291|Behavioral|Written Action Plan|Written handout of treatment plan and disease management strategies
75786074|NCT03849092|Behavioral|Financial incentives|Cessation programs in municipalities will offer a financial incentive of 1200 DKK to smokers who achieve continuous abstinence from smoking when attending a group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
75786075|NCT03849092|Behavioral|Campaigns|Municipalities will design anti-smoking campaigns targeting smokers, recommending to use a municipal free group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
75922437|NCT02147223|Dietary Supplement|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
75922438|NCT02147223|Dietary Supplement|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
75329635|NCT03050320|Other|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
75329636|NCT03050320|Other|No Exercise|A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
75329637|NCT05467605|Dietary Supplement|probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),|therapeutic intervention, Children will be randomized into two groups using sealed envelopes on admission after meeting inclusion criteria, group ONE will receive multi strain probiotic product which contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
75329638|NCT05467605|Other|maltose dissolved in distilled water|the other group placebo (GROUP TWO ) will receive maltose dissolved in 10 ml distilled water .
75636905|NCT05217654|Drug|Dapagliflozin 10mg|Daily orally administration of 10mg dapagliflozin
75636906|NCT05217654|Drug|Placebo|Daily orally administration of 10mg dapagliflozin-placebo
75636907|NCT05340231|Drug|TACE protocol|"Transarterial infusion chemotherapy: Oxaliplatin(85mg/m^2)+Raltitrexed(3mg) Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)，The endpoint for embolization was defined as stagnation of blood flow of the posterior mesenteric artery.~Intervention cycle：4W; Treatment times: 2. followed by mFOLFOX6"
75922439|NCT02147379|Drug|Lurasidone|
76078788|NCT03182673|Drug|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
75329639|NCT00967993|Drug|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
75329640|NCT04369157|Procedure|Elective surgery|Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.
75636908|NCT05340231|Drug|Neoadjuvant Chemotherapy|mFOLFOX6, Q2W
75786076|NCT04647604|Drug|Omegaven®|A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.
75786077|NCT04647604|Drug|Sodium chloride|intravenously administered 2 mL/kg/day
75786078|NCT01188824|Drug|Cilostazol|100 mg, bid p.o.
75786079|NCT01188824|Other|placebo|1 tablet, bid
75786080|NCT01060475|Drug|LIM-0705 and tacrolimus|Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
75786081|NCT01060475|Drug|LIM-0705 and tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
75922440|NCT02148549|Drug|FIRINOX|FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
76078789|NCT03182673|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
76078790|NCT03182673|Drug|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
76078791|NCT00638157|Drug|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
75786082|NCT01060475|Drug|Placebo LIM-0705 and tacrolimus|Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
75786083|NCT01060475|Drug|Drug LIM-0705 and placebo tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
75786084|NCT01191632|Radiation|one time radiation|"Radiation: one time Radiation with an intensity of~0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery"
75786085|NCT01191632|Radiation|No Radiation|Control group with 0Gy
75329641|NCT04362215|Diagnostic Test|Subjective accomodation amplitude measurement|ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
75786086|NCT01060631|Device|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
75786087|NCT01060631|Device|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
75636909|NCT04202016|Procedure|Piezocision Surgery|After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.
75786088|NCT01296854|Other|Spa therapy|3 weeks of spa therapy
75922441|NCT04690400|Other|Experimental: Active care group|Stretching exercise program remotely supervised. Total of approximately 40 minutes per session by WhatsApp, individually and supervised by a professional (physiotherapist or physical education teacher). As recommended for flexibility improving, 30 seconds of stretching in each exercise will be perform fractionated (3 series of 10 seconds of static position at the point of moderate discomfort, with 10 seconds interval between series). There will be two stretching protocol models with exercises variations, but for the same muscle groups, intensity, volume, and duration. The position at the point of moderate discomfort will be self-adjusted by subjective perception over 12 weeks of intervention. The protocol model will change after seven weeks. In order to make the interventions more similar, the guide and videos of control group will be also sent to experimental group
75786089|NCT03851978|Behavioral|Pharmacist Vaccine Education|When an eligible patient presents to the pharmacy for prescription pick up or drop off, the pop-up note will notify the technician to get a pharmacist for education. The pharmacist will educate the patient on the vaccine and then recommend that the patient receives the vaccine.
76078792|NCT00638157|Drug|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
76078793|NCT00637377|Drug|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
76078794|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
76078795|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
75786090|NCT03254134|Drug|Warfarin|patients treated with warfarin
75786091|NCT03254134|Drug|Dabigatran|patients treated with Dabigatran
75786092|NCT01188902|Dietary Supplement|walnut|walnut consumption 48 g/d
75786093|NCT00037830|Drug|GM1 ganglioside|100 mg twice per day by subcutaneous injection
75786094|NCT00037830|Drug|Placebo|Twice per day subcutaneous injection, equal volume as active drug
75786095|NCT05282810|Other|tympanoplasty|use of cartilage versus tempotalis fascia in tympanoplasty for recuurent perforation
75786096|NCT05179642|Other|OPTIM-EHPAD tool|"This is a randomized, cluster stepped wedge study. Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents."
75329642|NCT02878486|Device|Jawbone Up|Jawbone Up is a wrist wore water resistant activity monitor.
75329643|NCT02878486|Behavioral|Physical Activity Education|A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
75636910|NCT04229355|Drug|DEB-TACE plus Sorafenib|Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
75636911|NCT04229355|Drug|DEB-TACE plus Lenvatinib|Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
75636912|NCT04229355|Drug|DEB-TACE plus PD-1 inhibitor|Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
75636913|NCT02848170|Drug|CS-3150|CS-3150 2.5mg, oral
75636914|NCT02848170|Drug|olmesartan medoxomil|olmesartan medoxomil 10 mg, oral
75786097|NCT05568862|Diagnostic Test|Doppler ultrasound, Urodynamic assessment.|The patients included in the study group were given 600 cc of water in the morning and the Doppler ultrasound was performed 30 minutes later
75786098|NCT05568862|Diagnostic Test|Urodynamic assessment.|A transurethral double lumen catheter was used to measure intravesical pressure in the urodynamic unit for the patients in the study group immediately after the use of the Doppler USG
75786099|NCT03848936|Other|Survey|Survey includes age, gender, cerebral palsy type, education, mental status, working status, living conditions, comorbidities, pain, spasticity, contractures, deformities, mobility status and gross motor function classification system level
75922442|NCT04690400|Other|Active Comparator: Self-care group|The participants will receive counseling to stretching by guide and explanatory video that will be send by WhatsApp. The stretching exercise protocols will be the same performed by the experimental group. In addition, participants will receive recommendation to perform the protocol with the same weekly frequency, intensity, volume, and duration perform by the experimental group After the guide and explanatory video are sent, participants will receive a call for clarification. As well as in the experimental group, the protocol model will change after seven weeks; so, other guide and explanatory video will be sent for participants.
75922443|NCT05044767|Device|total hip arthroplasty|hip replacement surgery
75922444|NCT03375476|Diagnostic Test|collection of cardiovascular risk scores and intraoperative cardiovascular parameters|collection of preoperative cardiovascular risk scores and intraoperative cardiovascular parameters
75786100|NCT03953196|Biological|Imvanex|Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
75922445|NCT03375476|Diagnostic Test|cardiac troponin assay|plasmatic concentration of high sensitive cardiac troponin will be measured at baseline and on postoperative day 1, 2 and 3
75922446|NCT03375476|Diagnostic Test|Electrocardiogram|12 derivations ECG will be made at baseline and on postoperative day 1, 2, and 3
75922447|NCT03375398|Dietary Supplement|Rice|Test food #1: White Rice <63.0 g (dry) Jasmine rice consumed together with 250 mL water
75922448|NCT03375398|Dietary Supplement|Sugardown™|Test food #2: White Rice < 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice < 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water
75922449|NCT04868942|Other|Assisting to the event|"Participant will attend a concert respecting the Following measures :~Individual protection kit: disposable FFP2 masks (3), Hydroalcoholic solution, disposable tissues, garbage bag, water bottle~Health mediation, information on barrier measures~Physical distancing (sitting participation)~Person flow management"
75922450|NCT02147535|Drug|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
75922451|NCT02148627|Drug|LY3041658 (SC)|Administered SC
75922452|NCT02148627|Drug|LY3041658 (IV)|Administered as slow IV infusion
75922453|NCT02148627|Drug|Placebo|Administered as slow IV infusion
75922454|NCT03487796|Behavioral|MySTYLE|Youth and parents will receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
75922455|NCT03487796|Other|Waitlist Control|Youth and parents will not receive intervention materials for the first four months of participation. At the completion of the 4-month follow-up assessment, youth and parents will be eligible to receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
75922456|NCT02151825|Dietary Supplement|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
75922457|NCT02151825|Other|Placebo|3 capsules of Maltodextrin per day
75922458|NCT02155569|Procedure|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
75922459|NCT02155569|Procedure|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
75922460|NCT02148705|Drug|NexoBrid|
75636915|NCT05341479|Procedure|Surgery for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery (e.g., CO2 laser resection), and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., extranodal extension, perineural invasion or vascular invasion)."
75786101|NCT03953196|Biological|Shingrix|Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
75786102|NCT03953196|Biological|LPS|LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
75786103|NCT03953196|Biological|Candin|Candin 0.1 mL solution for injection will be administered as one intradermal injection.
75786104|NCT03953196|Other|Skin Biopsy|3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
76078796|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
75786105|NCT03953196|Other|Saline Control|Saline control solution for injection will be administered as one intradermal injection.
75786106|NCT05179564|Diagnostic Test|iohexol administration|IV injection of weight-dependent low dose of iohexol at time 0
75786107|NCT05179564|Diagnostic Test|iohexol blood sampling|Blood sampling will be performed through an arterial (preferred) or venous line, other than the iohexol infusion line. In the first 30 minutes after iohexol injection, a blood sample of 2 ml will be obtained for iohexol concentration measurement and determination of renal biomarkers serum creatinine, cystatin C, betatrace protein. Subsequently, 2 up to 5 additional blood samples of 0,5 ml will be obtained for iohexol determination at 60,120 ,180, 240 and 360 minutes after iohexol injection to calculate iohexol plasma clearance from the plasma disappearance curve
75786108|NCT03848624|Device|Cycling Group|Electrical pulses from a stimulator can stimulate the target muscles to generate muscle contraction to support a continuous cycling motion
75786109|NCT03851900|Other|Teethmate Desensitizer (TM)|Desensitizing agent will be applied to sensitive teeth.
75922461|NCT02148705|Procedure|Standard of Care (SOC)|
75329644|NCT02878486|Device|ActivPAL|Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
75786110|NCT03851900|Other|Clearfil SE Bond 2|Desensitizing agent will be applied to sensitive teeth.
75469814|NCT01943422|Drug|Vemurafenib|"Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene."
75469815|NCT01943487|Drug|EC905|Oral
75786111|NCT03851900|Other|Distilled water|Placebo will be applied to sensitive teeth as a negative control.
75786112|NCT01097070|Drug|Bevirimat|
75786113|NCT05179252|Drug|Shen-Fu injection|Chinese patent medicine made by modern technology
75786114|NCT05179252|Drug|normal saline|0.9% normal saline, used for sham control
76078797|NCT00636987|Device|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
75329645|NCT02245295|Procedure|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
75329646|NCT02245295|Procedure|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
75329647|NCT01009333|Device|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
75329648|NCT01009333|Device|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
75329649|NCT01009333|Device|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
75329650|NCT04344093|Device|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
75636916|NCT05341479|Radiation|RT for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with RT."
75636917|NCT05341479|Radiation|CRT for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with CRT."
75786115|NCT01295294|Drug|Tranexamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
75329651|NCT04362371|Device|Ainara|1 g at each administration
75329652|NCT02981875|Other|oculomotor training|a sequence of vision training exercises which focused mainly in oculomotor skill
75329653|NCT02981875|Other|placebo|placebo vision training exercises involving minimal accommodation and vergence eye movement.
75329654|NCT04369079|Other|manual myofascial techniques|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side.
75329655|NCT04369079|Other|conventional therapy consisting of exercise and massage.|Underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area.
75329656|NCT00359463|Drug|eltrombopag|Subjects will be administered a single oral dose of 50 mg eltrombopag.
75329657|NCT02880514|Device|PROPEL Mini Sinus Implant|Sinus implant with 370 mcg of mometasone furoate released over 30 days
75329658|NCT02880514|Procedure|Balloon Sinus Dilation Alone|
75469816|NCT01943487|Drug|verapamil|Oral
75786116|NCT01295294|Drug|Mefenamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
75786117|NCT01295294|Drug|Placebo|3 times daily per oral during bleeding/spotting episodes
75786118|NCT01295294|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|In vitro release rate 20 microgram/24 hours. Intrauterine system
75798672|NCT01174524|Drug|ethinylestradiol 15 mcg|ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
75922462|NCT02148705|Drug|Gel Vehicle|
75922463|NCT02254785|Drug|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
75469817|NCT01943513|Biological|BIIB023|Intravenous (IV) infusions
75469818|NCT01943513|Biological|Placebo|Matched placebo
75469819|NCT01943526|Biological|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
75469820|NCT01943604|Other|Nutella Breakfast|Breakfast composed of bread and Nutella, milk and apple slices
75469821|NCT01943604|Other|Waffle Breakfast|Breakfast composed of waffles and syrup, milk, and apple slices
75469822|NCT01943617|Drug|Entecavir|anti-viral therapy
75469823|NCT01943617|Drug|Thymosin-α|anti-viral and antitherapy
75469824|NCT01943630|Drug|15% AS101 gel|Administration of Topical 15% AS101 once a day (overnight)
75922464|NCT02254785|Drug|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
75922465|NCT02254785|Drug|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
75922466|NCT03446612|Drug|Daprodustat|Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.
75786119|NCT04502914|Procedure|Open-to-air strategy|In open-to-air management, the wound will be washed with a chlorhexidine solution and leave the wound open, or portion of the wound assigned to OTA, to the environment. An electric heat lamp (model no. 53103, 250W, Brandt Industries LLC, Bronx, NY) will be placed at as close to 1 yard (0.91 m) as possible from the wound after daily wound care for 24 hours (+/- 6 hours) to promote drying. However, to prevent excessive drying an hourly spritz of topical solution, e.g., DuoDERM® Hydroactive® gel (ConvaTec Oklahoma City, OK) will be used at the bedside.
75786120|NCT04502914|Procedure|Traditional closed-wound management|In traditional closed-wound management, once a day the wound will be washed with a chlorhexidine solution and closed with a non-adherent dressing such as ADAPTIC® (Acelity, San Antonio, TX) soaked in topical antimicrobial solutions, ointments, and creams designed to promote wound healing.
75922467|NCT03446612|Drug|Darbepoetin alfa|Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.
75922468|NCT03446612|Drug|Acetylcholine|Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
75922469|NCT03446612|Drug|Sodium nitroprusside|Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
75922470|NCT03446612|Drug|L-N-monomethyl arginine acetate (L-NMMA)|L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
76078798|NCT01475110|Drug|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
75329659|NCT04361747|Behavioral|nursing counseling|The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
75329660|NCT05605431|Diagnostic Test|Polysomnography|over nightSleep study
75786121|NCT01191710|Other|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
75786122|NCT04367740|Diagnostic Test|To assess for development of IgG antibodies against SARS-CoV2|Swabs will be collected to assess for COVID-19 if PPE supplies allow.
75786123|NCT03846986|Dietary Supplement|Apple Juice1|Apple Juice1
75786124|NCT03846986|Dietary Supplement|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
75786125|NCT03846986|Dietary Supplement|Raw Apple|Raw Apple
75786126|NCT05565040|Procedure|Circumcision in concealed penis|comparison of three surgical techniques (as described in the arms) in the management of concealed penis in pediatrics
75922471|NCT02148783|Drug|methylphenidate|This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with [11C]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
75922472|NCT02148783|Drug|Placebo|
75922473|NCT02155803|Drug|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
75922474|NCT02148861|Drug|Insulin icodec|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
75922475|NCT02148861|Drug|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
75922476|NCT02148861|Drug|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
75922477|NCT02149017|Radiation|SNUBH-NM-333(18F)|5-10 mCi
75922478|NCT02152059|Drug|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
75922479|NCT03124316|Behavioral|Anticipated regret|Induce awareness of future regret about the unwanted behaviour
76078799|NCT01080118|Device|Airtraq|Subjects were taught with the Airtraq video laryngoscope
76078800|NCT01080118|Other|Control group, taught with a standard Macintosh laryngoscope|Subjects were taught how to use the Mackintosh blade first
76078801|NCT03013582|Biological|Amnion Tendon Wrapping|Tendon is wrapped with the allograft
76078802|NCT03013582|Procedure|Surgical Tenolysis|Surgical release of peritendinous scarred tissue
76078803|NCT05307796|Behavioral|Strategy training|The strategy training of focus in this study is metacognitive strategy training intended to build awareness of naming and methods to overcome instances of difficult naming. Strategy training involves (a) teaching the participant to identify instances in which they are unable to name objects, (b) learn a 6-feature framework (e.g. group, use, action) that has been identified to support semantic feature activation in aphasia, (c) learn and practice strategies to utilize the framework in instances of word finding difficulty
75329661|NCT00968071|Drug|Decitabine|20 mg/m^2 IV over an hour and half daily for 5 days.
75329662|NCT00968071|Drug|Gemtuzumab Ozogamicin|3 mg/m^2 IV on day 5.
75329663|NCT04368923|Device|Oxygen Therapy|Patients receive oxygen therapy
75329664|NCT04368923|Procedure|Physical Therapy|Patients receive physical therapy
75329665|NCT02987374|Biological|2011-2012 Fluzone IIV3 (IM)|2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
75329666|NCT04368611|Procedure|start with fundus|fundus first dissection then complete cholecystectomy as usual
75329667|NCT04368611|Procedure|calot first dissection|start dissection by calot approach
75922480|NCT03124316|Behavioral|Material incentive|Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours
75922481|NCT03124316|Behavioral|Problem solving|Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
75922482|NCT02149095|Drug|TransCon PEG treprostinil|
75922483|NCT04925739|Other|Self-questionnaire on the comfort and general appreciation of a nasal mask|Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use
75922484|NCT04925739|Other|Self-questionnaire on the appearance of CPAP side effects related to the mask|Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use
76078804|NCT05307718|Drug|Oral Anticoagulant, Direct-Acting|Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.
75329668|NCT00968227|Biological|Red blood cell transfusion|Transfusion of 1 unit of packed red blood cells over 1 hour.
75329669|NCT04368767|Behavioral|Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, usually in the afternoon. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. After pre-intervention measures of axillary temperature, heart rate, respiratory rate, and oxygen saturation by pulse oximetry (SPO2) are obtained; cotton balls placed in the diaper for urine collection will be removed and stored in an appropriate container. Salivary oxytocin and cortisol will be collected per protocol below. Mothers will be requested to sit in reclining chairs with a front opened blouse or hospital gown. Infants will be removed from the incubator and placed naked except for a diaper and hat directly onto the skin between the mother's breasts and covered with a blanket. All infants will be monitored. After the two hours of SSC is completed, the infant will be returned to the incubator.
75329670|NCT02988856|Device|Magnetic lid system|Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
75469825|NCT01943630|Drug|Vehicle|Administration of Vehicle once a day (overnight)
75469826|NCT01943656|Device|Tobii™ Eyegaze System|Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
75636918|NCT05341479|Other|Surgery for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery, and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., pT3 or pT4 primary, pN2 or pN3 nodal disease, extranodal extension, or vascular invasion)."
75636919|NCT05341479|Procedure|Neoadjuvant treatment for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with neoadjuvant treatment. The subsequent treatments include RT, system therapy/RT, and surgical resection with or without postoperative adjuvant therapy."
75786127|NCT03852056|Drug|MFP Fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
75786128|NCT03852056|Drug|Stannous fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
75786129|NCT03242434|Other|Lactulose and Mannitol solution|Participants will receive 100 milliliter (mL) oral solution of Lactulose [5 grams (g)]/ Mannitol (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
75786130|NCT03242434|Other|Sucralose|Participants will receive 3 capsules of Sucralose (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
75922485|NCT04925739|Other|Self-questionnaire on the patient's appreciation of the mask headgear,|Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.
75329671|NCT04361903|Drug|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours
75786131|NCT03848702|Device|Distal radius fracture brace|The distal radius fracture brace is constructed from biocompatible materials (like polylactic acid; PLA) and the skin is protected by commercially available and approved waterproof padding (like Aquacast®). The major brace components are connected and reinforced with carbon rods and plastic bolt-nut connections. PLA is extensively used, for example in surgical implants, but also as biological alternative for plastics. Aquacast® is approved and used as waterproof padding in swim plaster. The biomechanical function of the distal radius brace has been tested successfully in an ex vivo setting (results to be published). The DRFB includes the distal forearm, wrist an base of the hand. The thumb and fingers are free and the DRFB provides more movement than classical casting.
75922486|NCT04925739|Other|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.
75922487|NCT04925739|Other|Self-questionnaire Epworth on the daytime sleepiness|"Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion.~To study the parameters of the CPAP treatment."
76078805|NCT05307562|Other|Interval training + analytical strength|Patients will receive a training program
76078806|NCT05307562|Other|Interval training + analytical strength and IMT|Patients will receive a training program + IMT
75329672|NCT02989246|Other|Ventilator protocol|Open loop ventilator management by a computer based protocol
75329673|NCT02989246|Device|Esophageal Catheter|Esophageal manometry measurements of patient effort of breathing will be used to guide the protocol recommendations
75329674|NCT00971737|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
75469827|NCT01943669|Device|ReWalk™ device|Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
76078807|NCT05307484|Other|Serious game|This is a serious game in the form of a mobile application, designed to educate adults on dengue prevention.
75922488|NCT04925739|Other|To study the CPAP compliance|To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
75329675|NCT00971737|Biological|trastuzumab|Given IV
75636920|NCT04202172|Procedure|Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction|"The 6-month scheduled coronary angiography will perform 3 interventions:~Endothelial function assessment with intracoronary acetyl-choline infusion.~Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~Stent healing assessment using optical coherence tomography"
75636921|NCT02848404|Device|Categorical Language Fluency Smartphone Application|4 weeks' training
75636922|NCT02782767|Other|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
75922489|NCT04925739|Other|To study the unintentional leakage|To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.
75329676|NCT00971737|Drug|cyclophosphamide|Given IV
75329677|NCT04368377|Drug|Tirofiban Injection|Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
75329678|NCT04368377|Drug|Clopidogrel|Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
75636923|NCT02782767|Other|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
75636924|NCT02782845|Drug|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
75786132|NCT01191866|Behavioral|psychosocial intervention|The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
75786133|NCT01292330|Procedure|nutritional support before operation|nutritional support before operation for more than 4 days
75786134|NCT04222426|Other|89Zr-atezolizumab PET scans|Patients receive a total amount of 10 mg unlabeled atezolizumab, this will be added to the tracer to prevent rapid clearance during imaging. A labeled dose of 37 Megabequerell (MBq) 89Zr-atezolizumab (±10%; 1 Millicurie) will then be administered. The tracer will be administered intravenously (i.v.). All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. After each tracer injection, 89Zr-atezolizumab PET scans will be performed on day 4 (96 ± 6h after tracer administration).
75786135|NCT03852134|Procedure|MOCC Group|After 30 seconds of DCC, the cord will be clamped and cut 5 cm from the introitus in vaginal delivery or abdominal incision in the case of cesarean section before passing the infant with the long umbilical cord segment to the pediatric provider who will milk the cord one time towards the baby during resuscitation.
75786136|NCT03852134|Procedure|DCC Group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
75786137|NCT01292408|Drug|Hydrochloroquine|800 mg per os once, and then 400 mg per day
75922490|NCT04925739|Other|To study the therapeutic pressures of CPAP|To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
75922491|NCT02520050|Behavioral|Traditional MNT|Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
75922492|NCT02520050|Behavioral|Structured MNT|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
75922493|NCT02520050|Behavioral|Structured MNT plus Weekly Support|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
75329679|NCT04368377|Drug|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
75329680|NCT04368377|Drug|Fondaparinux|Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
75636925|NCT02782845|Drug|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
75636926|NCT02782845|Drug|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
75636927|NCT05341401|Drug|Budesonide MMX|Budesonide MMX is a second generator corticosteroid with prolonged colonic release used for management of ulcerative colitis
75922494|NCT02149251|Genetic|Pre-genetic diagnosis|
75922495|NCT02149329|Drug|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
76078808|NCT05307484|Other|Dengue prevention website|This is a website containing information regarding dengue prevention.
75329681|NCT02243267|Other|sample collection|
75329682|NCT05223699|Biological|MGTA-117|MGTA-117 will be administered as an IV infusion
75636928|NCT05341401|Drug|Prednisolone|It is a corticosteroid used as a standard therapy for management of ulcerative colitis
75636929|NCT05337072|Diagnostic Test|Microbiome study|Investigation of the vaginal and endometrial microbiome
75922496|NCT03255512|Drug|Vericiguat (BAY1021189)|2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet
75922497|NCT03255512|Drug|Placebo|Matching placebo
75922498|NCT03255512|Drug|Isosorbide mononitrate (ISMN)|30 mg/tablet or 60 mg/tablet
75922499|NCT02149407|Drug|Glycerin|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
75636930|NCT05340153|Drug|Artemether-Lumefantrine Drug Combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
75636931|NCT05340153|Drug|Dihydroartemisinin-Piperaquine drug combination|Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
75922500|NCT02149407|Procedure|Rectal stimulation|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
75922501|NCT02149407|Other|Control|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
75922502|NCT03380312|Procedure|rTARUP technique|robot-assisted rTARUP technique
75469828|NCT01943682|Drug|CPX-351|Comparison of Different doses of drug
75469829|NCT01943708|Device|SPAP|Novel Auto-algorithm for Auto-CPAP device
75636932|NCT00902850|Device|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
75636933|NCT00902850|Device|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
75636934|NCT05078502|Dietary Supplement|Vitamin D3|One capsule of vitamin D3(40000IU) weekly for 8 weeks
75786138|NCT03637426|Other|Laser|GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours.
75786139|NCT03637426|Other|nano-hydroxyapatite|The GnHAP volunteers were submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications
75786140|NCT03637426|Other|Laser + nano-hydroxyapatite|GLASERnHAP first received laser application and subsequently the application of nanohydroxyapatite according to the manufacturer's recommendations.
75786141|NCT03637426|Other|PLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
75786142|NCT01295372|Drug|Zicronapine|7.5 mg/day; orally
75786143|NCT01295372|Drug|Risperidone|5 mg/day; orally
75786144|NCT05179174|Genetic|blood sample examination|droplet digital PCR in blood sample for research of mutations of GNA11 and GNAQ genes and the following microRNAs: miR - 506-514 cluster, hsamiR - 592 and hsa - miR - 199a - 5p.
75786145|NCT05179096|Behavioral|Mindfulness-based intervention|The program consists of a series of awareness practices: the exercises are presented in progression, starting from the awareness of the external environment, then the self-awareness in the environment, the awareness of the body and the five senses, the awareness of the interconnection among the various forms of life and, eventually, meditation exercises that characterize the awareness of the cognitive processes
75786146|NCT05283278|Drug|Lactoferrin Bovine|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A
75786147|NCT05283278|Combination Product|Lactoferrin Bovine and probiotics|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day in combination with the probiotic Lactobacillus Delbrueckii and Lactobacillus Fermentum (Lacteol fort®) given in a dose of 5 billions starting from birth to the 30th day of life for neonates in group B
75922503|NCT03543657|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).
75922504|NCT03543657|Drug|Darbepoetin alfa|Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.
75922505|NCT03543657|Drug|Placebo of Molidustat (BAY85-3934)|Matching placebo of Molidustat.
75922506|NCT03543657|Drug|Placebo of Darbepoetin alfa|Matching placebo of Darbepoetin alfa.
75922507|NCT04404998|Other|Lower Energy Density|Test meal with lower energy density
75922508|NCT04404998|Other|Higher Energy Density|Test meal with higher energy density
75922509|NCT04404998|Other|Lower Satiation|Information on lower satiation
75922510|NCT04404998|Other|Higher Satiation|Information on higher satiation
75469830|NCT01943708|Device|CPAP|Standard CPAP therapy
75469831|NCT01943721|Drug|VISION5 Product|
75469832|NCT01943734|Behavioral|Information passed on anthropometric assessment|Information passed on worker's anthropometric assessment.
75469833|NCT01943760|Drug|tramadol|The volume of the solution was adequate to maintain the concentration of 2% tramadol
75469834|NCT01943760|Drug|0.9% saline|
75786148|NCT05283278|Other|Placebo|Placebo will be given starting from birth to the 30th day of life for neonates in group C.
75922511|NCT03380234|Other|Worksheets|Worksheets will be distributed to students for them and their parents to complete together. During the first 3 months, the teachers will distribute 1 worksheet every two weeks to the intervention grades, and 1 worksheet in the 4th and 5th months as boosters. The worksheets will deliver information about tobacco smoke, SHS and THS, inviting students and their family members to complete other interesting tasks together.
75922512|NCT03380234|Other|Whatsapp messages|A mobile phone number of this study is also provided on the worksheets, through which participants can receive WhatsApp/WeChat/instant messages (1-2 times every week) designed to encourage behavioural change [15]. They can then forward selected messages to other members of their household, especially smokers.
75329683|NCT04361513|Drug|Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)|3 point genicular nerve block
75329684|NCT04361513|Drug|triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)|intra-articular injection of triamcinilone
75329685|NCT05595993|Drug|Cilostazol|Study participants will be allocated to receive oral administration of 200 mg cilostazol.
75329686|NCT05595993|Drug|Placebo|Study participants will be allocated to receive oral administration of placebo.
75329687|NCT02243501|Behavioral|Intervention Group|The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
75786149|NCT05179018|Diagnostic Test|Ribosomal p2 Autoantibodies as a Serum marker|Using serum marker
75329688|NCT00972205|Drug|paclitaxel|Paclitaxel 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
75329689|NCT00972205|Drug|CBT-1(Registered Trademark)|CBT-1 500 mg/m^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
75786150|NCT01295450|Drug|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
75786151|NCT01295450|Drug|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
75329690|NCT00972205|Radiation|Tc 99m sestamibi|20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
75786152|NCT05178394|Device|Weightlifting belts and wrist straps|"The participants wore a weightlifting belt (Heavywear Nylon Contour Belt H9, North Carolina, USA) for the with weightlifting belt conditions and/or put on a pair of wrist straps (Versa Gripps Professional Series, Versa Gripps, Maine, USA) for the with wrist strap conditions. The steps involved in completing a conventional deadlift have been detailed in Holmes."
75329691|NCT00928421|Drug|Polidocanol Endovenous Microfoam 0.125%|Polidocanol Endovenous Microfoam 0.125%, single dose
75329692|NCT00952315|Device|Cyberwand|Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
75329693|NCT00952315|Device|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
75329694|NCT00952315|Device|Lithoclast Select|Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
75329695|NCT00932321|Drug|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
75329696|NCT00932321|Drug|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
75329697|NCT00952393|Drug|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
75469835|NCT01943773|Procedure|Functional Assessment|"Both arms of the study will undergo functional assessments at three points during the study progress.~BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.~ASSESSMENT OF INTERVENTION EFFECTIVENESS:~Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.~POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation."
75329698|NCT01011829|Drug|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
75329699|NCT01011829|Drug|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
75469836|NCT01943773|Procedure|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions.
75636935|NCT02780739|Behavioral|Cognitive Training - 48 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
75329700|NCT05591157|Device|CSF-3 watch, designed to monitor a user's heart rate based on ECG (electrocardiogram) and PPG (Photoplethysmograph) readings|The subjects will be connected to an ECG Holter, and an investigational Device will be placed simultaneously on the subject's wrist. All subjects in this phase will be asked to participate in a single continuous data recording measurement for seven (7) minutes
75329701|NCT00932477|Drug|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
75329702|NCT00932477|Drug|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
75329703|NCT00932477|Drug|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
75329704|NCT00972439|Drug|Oral Contraceptive: Ortho-Novum® 1/35|
75329705|NCT00972439|Drug|Oral Contraceptive: Ovcon Fe®|
75329706|NCT00358371|Drug|flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
75636936|NCT02780739|Behavioral|Fitness|Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills & Skills; and Cool-down/stretch.
75329707|NCT00358371|Drug|flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
75329708|NCT02989714|Drug|Interleukin-2|600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
75329709|NCT02989714|Drug|Nivolumab|Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
75636937|NCT02780739|Behavioral|Active Control|The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
75636938|NCT02780739|Device|active tDCS|Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
75786153|NCT01297010|Drug|Dexamethasone and ondasetron|Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo
75922513|NCT03380234|Other|Online quizzes|At the end of each worksheet, a QR code is inserted. By scanning this code, students or parents will be invited to answer 2-3 simple quizzes which allow us to assess students' knowledge obtained from the intervention materials and their avoidance of environmental tobacco smoke.
75922514|NCT03380234|Other|Leaflet|A leaflet on smoking and SHS published by the Department of Health will be mailed to the control grades.
75922515|NCT02152215|Procedure|Acellular dermal matrix membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
75786154|NCT01297010|Drug|Dexamethasone|Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
75786155|NCT03851432|Drug|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
75786156|NCT03851432|Drug|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
75786157|NCT03851432|Device|Placebo plus metformin|Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
75786158|NCT01194986|Other|[11C]AZ12807110|Radioligand
75922516|NCT02152215|Procedure|Polylactic acid membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
75922517|NCT03380156|Device|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
75922518|NCT03380156|Device|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
75329710|NCT02243657|Drug|ASP3652|oral
75329711|NCT02243657|Drug|Placebo|oral
75469837|NCT01943786|Drug|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
75469838|NCT01943812|Drug|Estradiol and progeterone|Estradiol and progesterone
75469839|NCT01943838|Drug|SAR245408|Pharmaceutical form: tablet Route of administration: oral
75469840|NCT01943877|Procedure|scaling root planing|scaling root planing
75469841|NCT01943877|Drug|Propolis|experimental
75786159|NCT01194986|Drug|AZD5213|
75786160|NCT01297088|Drug|BAY86-9596|One single dose administration of a diagnostic agent
75786161|NCT03846908|Other|MCT|patients will receive fat load with MCT
75786162|NCT03846908|Other|SFA|patients will receive fat load with SFA
75786163|NCT03846908|Other|MUFA|patients will receive fat load with MUFA
75636939|NCT02780739|Device|sham tDCS|Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
75786164|NCT01192490|Drug|Lidocaine|5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena
75329712|NCT05213013|Other|inhaler treatment with the toy-type nebulizer and training on on the use of a nebulizer/mask|"The children (experimental group), will receive training and inhaler treatment with the toy-type nebulizer. The training topics is as follows:~For effective nebulization, it should be ensured that the parts of the mask are assembled completely and correctly.~The child should be in an upright sitting position during nebulization.~During the procedure, normal breathing should be given into the mask.~As the medicine is finished, a sizzling sound is heard from the device.~After the nebula is over, the face should be washed and the mouth should be rinsed to remove the drug residues accumulated on the face and mouth."
75786165|NCT01192490|Drug|Lubricant|KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
75786166|NCT01295528|Device|Comparison test|Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
75786167|NCT01295606|Drug|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
75922519|NCT02155959|Device|toric intraocular lens|toric intraocular lens
75922520|NCT02730728|Drug|20ml bolus of 0.5% ropivicaine|Local anesthetic
75922521|NCT02730728|Drug|0.2% Ropivicaine at 8 milliliter/hour|Local anesthetic
75922522|NCT02730728|Drug|5ml bolus of 0.5% ropivicaine|Local anesthetic
75922523|NCT04925193|Drug|Selinexor|Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).
75922524|NCT04925193|Drug|Pomalidomide|Oral Table
75329713|NCT02991820|Device|Miller|Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope
75329714|NCT02991820|Device|Macintosh|Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
75329715|NCT02991820|Device|C-MAC|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope
75329716|NCT02991820|Device|GlideScope|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope
75469842|NCT01943890|Device|Hypertonic saline|1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily
75469843|NCT01943890|Procedure|Physiotherapy|
75469844|NCT01943942|Drug|Montelukast 10 mg|Reference product
75469845|NCT01943942|Drug|Montelukast 10 mg|Test product
75469846|NCT01943955|Behavioral|home-based computer gaming|A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
75469847|NCT01943968|Other|Blood test|
75786168|NCT01292564|Device|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
75469848|NCT01944007|Drug|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 9 consecutive days.
75786169|NCT01292564|Device|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
75469849|NCT01944033|Drug|Bricanyl/Iprovent|5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
75786170|NCT01192646|Behavioral|HBLSS|Home Based life saving skills training will be done in the intervention cluster while in the control group no training
75786171|NCT03848546|Behavioral|PDA|"Subjects receive personal dietary fiber advice to increase their fiber intake. This advice will be provided using an online web-portal, where subjects can choose high-fiber alternatives that closely match their own intake. The aim is to swap product for low in fiber for a high fiber alternative (such as white bread, whole wheat bread)."
75786172|NCT03848546|Other|Control (no intervention)|No intervention
75786173|NCT01189058|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
75922525|NCT04925193|Drug|Daratumumab|Injection
75922526|NCT04925193|Drug|Carfilzomib|Injection
75922527|NCT04925193|Drug|Dexamethasone|Oral tablet or injection
75922528|NCT02156037|Behavioral|Diabetes Dashboard Intervention|The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.
75922529|NCT02156037|Behavioral|Usual Diabetes Care|The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
75922530|NCT03379922|Behavioral|Stress balls|Squeezing stress balls while receiving ESWL treatment
75922531|NCT03379922|Behavioral|Headphones|Listening to music while receiving ESWL treatment
75922532|NCT03381794|Procedure|Corneal transplantation|PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
75922533|NCT02156193|Procedure|Prophylactic clip|Prophylactic clipping
75922534|NCT02156193|Procedure|No prophylactic management|No prophylaxis
75329717|NCT02991898|Biological|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion."
75786174|NCT01189058|Procedure|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for >90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
75329718|NCT04361435|Procedure|Chest physiotherapy using a non-invasive oscillating device|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated, particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the mid-clavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is pre-specified on the machine.
75329719|NCT05584995|Procedure|Control group|Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)
75329720|NCT05584995|Procedure|BUAL group|"Bilateral Uterine Artery Ligation Technique:~All uterine surgeries will be conducted by externalizing the uterus as much as possible and holding it by the fundus. The BUAL will be done using absorbable suture no. 1 Vicryl (Vicryl 1, Ethicon, France, Neuvilly-sur-Seine, France) will be placed through an avascular space in the broad ligament and tied from the anterior to posterior aspects of the myometrium 2-3 cm medial to the descending portion of the uterine vessels. In all patients, the suture will be carried from the anterior to the posterior at 1 cm to the myometrium medial to the Uterine artery and will be knotted after passing it through the avascular region at 1 cm to the wide ligament section adjacent to the uterus in both sides. All patients will be examined for uterotonics during and after the surgery. The ovarian arteries will be assessed at the level of the ovarian hilum."
75329721|NCT02881840|Drug|14C-APD421|
75329722|NCT05583201|Biological|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
75636940|NCT02780739|Behavioral|Cognitive Training - 20 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
75636941|NCT05026164|Dietary Supplement|CHI-202|Blend of cannabinoids & other ingredients
75636942|NCT05026164|Dietary Supplement|CHI-101|Placebo
75786175|NCT01192724|Drug|Cilostazol|100 mg BID, for 3 months
75786176|NCT01192724|Drug|Aspirin|Aspirin 100 mg QD, for 1 year
75786177|NCT01192724|Drug|Clopidogrel|Clopidogrel 75 mg QD, for 1 year
75786178|NCT01192802|Drug|albendazole|1 tablet of 400 mg of albendazole per day for three consecutive days
75786179|NCT01192802|Drug|albendazole|single 1 tablet of 400 mg of albendazole
75469850|NCT01944033|Drug|Bricanyl|5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
75469851|NCT01944072|Other|Aerobic exercise training intensity|
75636943|NCT05340075|Procedure|Patients who underwent percutaneous nephrolithotomy|Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation
75786180|NCT01192802|Drug|albendazole|1 tablet of 400 mg of albendazole per day for two consecutive days
75786181|NCT01292720|Drug|Cholecalciferol|Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)
75922535|NCT03379766|Device|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants indivudal hearing loss.
75922536|NCT03379766|Device|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
75922537|NCT02149563|Device|oxygen-enriched air -Normobaric hyperoxia treatment for depression|Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
75922538|NCT03381716|Drug|drug|Application bracket
75922539|NCT03381716|Procedure|Surgery|Surgery
75636944|NCT02844894|Drug|Dexmedetomidine|
75636945|NCT02844894|Drug|Esmolol|
75636946|NCT02844894|Drug|Placebo|normal saline
75636947|NCT04196439|Procedure|continuous epidural analgesia|injection of local anaesthetic into epidural space
75636948|NCT04196439|Procedure|supra-inguinal fascia iliaca compartment block|ultrasound guided injection of local anaesthetic into fascia iliaca compartment
75786182|NCT01292720|Drug|Placebo|Placebo in matching volumes
75786183|NCT01193036|Behavioral|Part 1: Interview + Questionnaires|Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
75786184|NCT01193036|Behavioral|Part 2: Multiple Questionnaires|Questionnaires to be repeated about every 2 weeks for 1 year.
75786185|NCT02939014|Drug|Brentuximab Vedotin|Brentuximab vedotin IV infusion
75798673|NCT01178892|Dietary Supplement|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
75922540|NCT02149641|Radiation|Intensity modulated radiotherapy with chemotherapy|
76078809|NCT01376596|Behavioral|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
76078810|NCT01376596|Behavioral|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
76078811|NCT01033864|Drug|MMF|1 g per day b.i.d. p.o. for at least 1 month
75636949|NCT02847780|Device|Active Comparator :C-Mac Videolaryngoscope|Real time assessment of Glottic aperture at the time of extubation by videolaryngoscope
75329723|NCT04367597|Device|Home-based Neuromuscular Electrical Stimulation (NMES) therapy|A home-based NMES treatment applied by the subjects daily
75329724|NCT05582499|Drug|Dalpiciclib|an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
75329725|NCT05582499|Drug|Pyrotinib|an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
75636950|NCT02847780|Device|Experimental: Airway ultrasound,|Airway ultrasound using portable ultrasound machine to assess vocal cords movement.
75636951|NCT02780193|Drug|Omegaven|Therapy with Omegaven® will be initiated and maintained at 1 g/kg/day. It will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If additional non-protein calories are needed, they will be provided as carbohydrates. No other parenteral form of fat emulsion will be used during Omegaven® therapy.The Omegaven® dose may be discontinued if the subject is receiving adequate enteral nutrition to meet metabolic and growth needs.
75636952|NCT05025540|Diagnostic Test|ultrasonic imaging|Two-dimensional ultrasound images of the patient's kidneys were obtained by ultrasound imaging.
75636953|NCT05338203|Other|tandem breastfeedıng|mother mılk wıll collected from mothers and they wıll be analyzed in laboratuar.
75636954|NCT05341245|Procedure|Graphene oxide and open flap debridement|Using Graphene oxide with open flap debridement in management of periodontal intrabony defects in dogs
75636955|NCT05341245|Procedure|Open flap debridement|Using Open flap debridement in management of periodontal intrabony defects in dogs
75922541|NCT03379610|Diagnostic Test|Nasopharngeal brush|"Baseline nasopharngeal brush before treatment~Post-treatment reassessment of residual NPC"
75329726|NCT05582499|Drug|SHR-A1811|an anti-HER2 antibody-drug conjugate (ADC)
75329727|NCT05582499|Drug|SHR-1316|an anti-programmed death ligand 1 (PD-L1) antibody
75329728|NCT05582499|Drug|Camrelizumab|an anti-programmed death-1 (PD1) antibody
75329729|NCT05582499|Drug|Trophoblast cell-surface antigen 2 (TROP2) ADC|anti-TROP2 ADC
75329730|NCT05582499|Drug|Pertuzumab|Pertuzumab
75329731|NCT05582499|Drug|Trastuzumab|Trastuzumab
75469852|NCT01944085|Drug|Acetaminophen|Syrup
75786186|NCT03851354|Other|Ultrasound meal acommodation test|to observe their tolerance a 500 ml of solution with glutamine, or Caseinate and the protocol will be carried out will be given. Ultrasound measures will be performed and observing changes in Cross Sectional Area of the gastric antrum of the first measurement at the time after administration. Gastric residue will be measured.
75786187|NCT05178160|Other|PEEP Standard Protocol|All the patients treated with CPAP receive a PEEP standard of 10 cmH2O with a fixed FiO2
75786188|NCT01195220|Behavioral|HIV testing|This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
75922542|NCT04319822|Other|blood sample and muscular biopsy|blood sample and muscular biopsy
75922543|NCT02152449|Dietary Supplement|Oral nutritional supplementation|
76078812|NCT01033864|Drug|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
76078813|NCT01033864|Drug|Prednisone|5 mg per day p.o.
76078814|NCT03012568|Device|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
75329732|NCT05582499|Drug|Goserelin|goserelin
75329733|NCT05582499|Drug|Letrozole|letrozole
75329734|NCT05582499|Drug|Nab paclitaxel|Albumin paclitaxel
75329735|NCT05582499|Drug|Carboplatin|Carboplatin
75329736|NCT05582499|Drug|Epirubicin|Epirubicin
75329737|NCT05582499|Drug|Cyclophosphamide|Cyclophosphamide
75329738|NCT05582499|Drug|Fluzoparib|an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
75329739|NCT05582499|Drug|HER2 ADC|anti-HER2 ADC
75329740|NCT02881996|Drug|IV tylenol|IV tylenol given scheduled in addition to standard PCA
75329741|NCT02881996|Drug|No IV tylenol|No additional IV Tylenol given
75329742|NCT02881996|Drug|Ketorolac|both groups receive as part of our standard postop pain protocol after all operations
75469853|NCT01944085|Drug|Ibuprofen|Syrup
75469854|NCT01944085|Other|Vitamin C|Syrup
75636956|NCT04778904|Biological|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine
75636957|NCT04778904|Biological|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine
75636958|NCT04778904|Biological|Nivolumab|Human immunoglobulin G4 monoclonal antibody
75636959|NCT04228887|Diagnostic Test|Respiratory Muscle Strength|Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
76078815|NCT05307016|Diagnostic Test|Two dimensional ultrasonography power and color doppler|"transabdominal and transvaginal two-dimensional power Doppler ultrasound volumes of the placental bed were obtained according to a predefined protocol with the participant in a semi-recumbent position and a full bladder using a RAB4-8-D 3D/4D curved array abdominal transducer (4-8.5 MHz) on a Voluson E8. Predetermined machine settings were used. To allow for differences in attenuation of the power Doppler signal resulting from variation in placental site and maternal adiposity.~Intraoperative staging of degree of placental invasion will be done according to clinical grading system by Collins et al., 2015.~Specimens obtained from patients who underwent hysterectomy or resection of segment of anterior uterine wall in cases with anterior placenta previa will be immersed in formalin 10% concentration and will be sent for histopathological evaluation that will be done by the same pathologist."
75329743|NCT04367831|Drug|Enoxaparin Prophylactic Dose|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~BMI < 40 kg/m2: Enoxaparin 40 mg SC daily~BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~BMI > 50 kg/m2: Enoxaparin 60 mg SC q12h"
75329744|NCT04367831|Drug|Heparin Infusion|Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
75329745|NCT04367831|Drug|Heparin SC|Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
75329746|NCT04367831|Drug|Enoxaparin/Lovenox Intermediate Dose|If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
75329747|NCT02243891|Procedure|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
75329748|NCT02243891|Procedure|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
75636960|NCT04228887|Device|Balance Training|Balance training will provide with Biodex® Balance Training System
75786189|NCT01195220|Behavioral|STI/HIV-T|This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
75786190|NCT01195220|Behavioral|STI/HIV-Plus|This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
75636961|NCT04228887|Device|Inspiratory Muscle Training|15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device
75636962|NCT03986502|Other|Media Intervention|Watch web-based financial literacy video
75636963|NCT03986502|Other|Informational Intervention|Receive information on financial counseling and medical cost assistance
75786191|NCT05177926|Drug|antiviral prophylaxis with Tenofovir Alafenamide Fumarate|All participants will receive antiviral prophylaxis with Tenofovir Alafenamide Fumarate for preventing of Mother-to-child transmission of HBV
75786192|NCT03848390|Behavioral|Conventional diet|The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.
75786193|NCT03848390|Behavioral|Modified Time-restricted Feeding|The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.
75922544|NCT02520128|Radiation|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
76078816|NCT01082380|Drug|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of [14C]PF 02341066
76078817|NCT01083628|Behavioral|Group CBT for Depression with MoodText|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
76078818|NCT01083628|Behavioral|Group CBT for Depression|Standard group CBT for depression using BRIGHT manual
75329749|NCT03051646|Drug|Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
75329750|NCT03051646|Drug|Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit|Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
75636964|NCT03986502|Other|Best Practice|Utilize usual clinic procedures and clinic or community-based financial resources
75636965|NCT03986502|Other|Questionnaire Administration|Ancillary studies
75786194|NCT03848390|Behavioral|Physical activity|At least 30 minutes of physical activity per day 5 times per week.
75922545|NCT03542955|Device|ActiPatch|A Pulsed Shortwave Therapy Device
75329751|NCT02243969|Dietary Supplement|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
75329752|NCT02243969|Dietary Supplement|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
75636966|NCT03986502|Other|Quality-of-Life Assessment|Ancillary studies
75786195|NCT03848390|Behavioral|Restricted consumption of sweetened beverages|Restricted consumption of juice, soda, and other sweetened beverages.
75786196|NCT01193192|Other|Neevo®|"A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid"
75786197|NCT01193192|Other|Prenatal vitamins|for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
75786198|NCT01313962|Drug|Flufirvitide-3 0.05 mg single dose|Nasal Spray
75329753|NCT03110458|Drug|SENS-111 100mg|SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
76078819|NCT01083706|Drug|azacitidine|Given SC or IV
75329754|NCT03110458|Drug|SENS-111 200mg|SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
75636967|NCT02780895|Drug|Human Stem Cells|"MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery."
75636968|NCT02780817|Other|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
75636969|NCT02780817|Other|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
75636970|NCT04229199|Behavioral|simulation|Dyads allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
75786199|NCT01313962|Drug|Flufirvitide-3, 0.1 mg single dose|Nasal spray
75786200|NCT01313962|Drug|Flufirvitide-3, 0.2 mg single dose|nasal spray
75329755|NCT03110458|Drug|Placebo Oral Tablet|Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
75329756|NCT04361357|Other|whey protein|whey protein powder was added on the basis of standardized enteral nutrition preparation.
75786201|NCT01313962|Drug|Flufirvitide-3, 0.4 mg single dose|Nasal spray
75786202|NCT01313962|Other|Placebo|Nasal spray
75786203|NCT01193270|Drug|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
76078820|NCT01083706|Other|laboratory biomarker analysis|Correlative studies
75329757|NCT04344405|Drug|Vitamin D|vitamin D supplementation
75329758|NCT04344405|Drug|Steroid Drug|control
75329759|NCT05187429|Drug|Nivolumab 10 MG/ML [Opdivo]|Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.
75636971|NCT05098197|Biological|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
75636972|NCT02847936|Procedure|vicryl plus suture|episiotomy with triclosan-coated sutures
75636973|NCT02847936|Procedure|vicryl suture|episiotomy with non antibacterial coated suture
75636974|NCT05329233|Device|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
75636975|NCT00634725|Drug|capecitabine|
75636976|NCT00634725|Drug|erlotinib hydrochloride|
75636977|NCT00634725|Drug|gemcitabine hydrochloride|
75636978|NCT00634725|Other|laboratory biomarker analysis|
75636979|NCT00634725|Radiation|radiation therapy|
75636980|NCT04228809|Device|tDCS|transcranial direct current stimulation
75786204|NCT01193270|Drug|Placebo|Sterile water in volume equal to that of the comparator drug
75786205|NCT01193426|Other|Ascite liquid puncture|Ascitic fluid obtained by paracentesis
75786206|NCT01189214|Drug|Memantine|Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
75786207|NCT01193504|Drug|Pred Forte|Pred Forte BID for 4 weeks postop
75786208|NCT01193504|Drug|Lotemax|Lotemax BID for 4 weeks postop.
75786209|NCT01295684|Other|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
76078821|NCT03014128|Other|Clinical examination and data processing of questionnaires|xy
76078822|NCT01035346|Drug|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
76078823|NCT01035346|Drug|Placebo|Single dose of a placebo
76078824|NCT03186729|Drug|Antithrombotic Agent|Anticoagulant or antiplatelet drugs
76078825|NCT03012802|Procedure|Colorectal Surgery|Postoperative Audit
75786210|NCT01295684|Other|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
75786211|NCT03848468|Procedure|Hemorrhoidectomy|excision of 3rd and 4th degree hemorrhoids
75786212|NCT01295762|Other|Immunological analyses|Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
75786213|NCT03848780|Drug|Desflurane|
75786214|NCT05599802|Biological|SARS-CoV-2 variant mRNA vaccine low dose|50μg/dose
75786215|NCT05599802|Biological|SARS-CoV-2 variant mRNA vaccine high dose|100μg/dose
75786216|NCT00051558|Drug|Teriparatide|20 micrograms/day, injection, 36 months
75786217|NCT00051558|Drug|Alendronate Sodium|10 mg/day, oral, 36 months
75786218|NCT00051558|Drug|Placebo|Oral placebo, daily, 36 months
75786219|NCT00051558|Drug|Placebo|Injection placebo, daily, 36 months
75329760|NCT05187429|Drug|Nivolumab 10 MG/ML [Opdivo]|Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.
75329761|NCT05187429|Drug|Saline|Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.
75922546|NCT03542955|Drug|Etoricoxib 60 mg|nonsteroidal anti-inflammatory drug used as standard therapy
75329762|NCT02993302|Drug|1α-D3|patients were given PTU and 1α-D3
75329763|NCT02993302|Drug|Placebos|patients were given PTU and placebos
75329764|NCT03052972|Drug|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie [mCi]) single dose
75329765|NCT03052972|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain
75329766|NCT00359853|Drug|Oral norfloxacin|
75329767|NCT02994238|Device|Remote Health Management Sensor Platform|The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
75329768|NCT05181189|Drug|DAOIB+Omega-3|The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.
75636981|NCT05327673|Other|questionnaire|"quality of life score: FACT-BMT~decisional conflict scale~Discreet Choice Experiment questionnaire"
75636982|NCT05325489|Drug|Nebulized Budesonide|use 0.5mg/2ml Pulmicort Respules BIS QD and oral montelukast sodium chewable tablets 4mg QD
75786220|NCT03848234|Drug|Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
75786221|NCT03848234|Device|Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
75786222|NCT05671640|Device|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
75786223|NCT01295918|Dietary Supplement|L reuteri in children on antibiotics|Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.
75922547|NCT03542331|Drug|Lipiodol|Endometrial flushing with Lipiodol between day 6 and 8 of the cycle
75922548|NCT03542331|Device|Mock catheter|Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle
75329769|NCT05181189|Drug|DAOIB+Placebo|Placebo
75329770|NCT02244203|Drug|BI 60732|
75329771|NCT02244203|Drug|Placebo|
75329772|NCT05168709|Biological|Tozinameran|Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
75329773|NCT03110692|Behavioral|Default initiation|A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
75636983|NCT05325489|Drug|Intranasal Budesonide Spray|nasal spray 100μg QD and oral montelukast sodium chewable tablets 4mg QD
75636984|NCT00902538|Drug|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
75636985|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
75786224|NCT01195298|Drug|Capecitabine and Bevacizumab|"Drugs will be administered in 3-week cycles as follows:~Bevacizumab 15mg/kg via i.v. infusion on day 1~Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14."
75786225|NCT03851276|Radiation|Multi-sliced computed tomography (MSCT)|Surgery planning done based solely on MSCT.
75786226|NCT03846752|Procedure|radial artery access for complex PCI|Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
75786227|NCT03846752|Procedure|femoral artery access for complex PCI|Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
75922549|NCT03381638|Device|Blink Reflexometer|The device uses 5 light puffs of air to the side of the eye causing a blink reflex that is captured by the high-speed camera tracking the eyelids.
76078826|NCT05306392|Device|Moderate Hypothermia|moderate hypothermia will be induced using the heat controller of the VV-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 48 hours followed by a progressive reheating (0.2±0.1°C/h) to reach 36 °C. Temperature at 36°C will be maintained during 48 hours after having reached 36 °C.
76078827|NCT05306392|Device|Normothermia|Temperature at 36°C will be maintained during 48 hours after having reached 36 °C
76078828|NCT05306314|Dietary Supplement|TREATAPROST|oral administration before meals 30 minutes
76078829|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
75786228|NCT03848078|Device|Optical Coherence Tomography|"OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. In such ways, microscopic details of lesions and tissues can be visualized. This information can be used to identify a lesion as BCC, and to specify the subtype. Therefore, we assume that the use of the OCT might reduce the number of biopsies and the accompanying morbidity.~The investigator scans 6mm of skin with the OCT (30 seconds) and decides whether the lesion is a BCC or not."
76078830|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
76078831|NCT01085500|Behavioral|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
76078832|NCT01085500|Procedure|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
76078833|NCT01035658|Drug|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
76078834|NCT01035658|Drug|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
75636986|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
75636987|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
75636988|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
75922550|NCT03543501|Device|Real-time ultrasound imaging feedback|Participants will be taught about the anatomy of abdominal wall muscles and the general functioning of RUSI (5 mins). Then, they will be invited to take the supine position, knees flexed. The feedback will consist of an ultrasound image transmitted to a brightness (B)-mode. Participants will receive the necessary education to understand the image and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions held 10 seconds of the TrA with a visible thickening of the TrA on the RUSI monitor exceeding the measurement at rest (visible on the monitor). Forty-five seconds rest will be allowed between each contraction to avoid fatigue. Participants will have to watch the RUSI monitor during the 15 tests.
76078835|NCT05306236|Other|LLL therapy , postural correction ex|"study group: will receive low level laser therapy 2 sessions per week for 6 weeks in addition to posture correction exercises.~control group: will be treated by posture correction ex only."
76078836|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
76078837|NCT01037452|Drug|Lansoprazole|Tablet
75636989|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
76078838|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide|Tablet
76078839|NCT01037452|Drug|Placebo|Tablet
75329774|NCT04367441|Drug|608|recombinant humanized anti-IL17A monoclonal antibody injection
75329775|NCT04367441|Drug|Placebo|auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
75329776|NCT04367363|Behavioral|Social media & news consumption|Daily reports of social media use and consumption, including reports on receiving and disseminating news articles related to the COVID-19 situation (e.g., how many messaging groups shared news on the outbreak, how many items related to the outbreak they forwarded to others, etc).
75329777|NCT03111316|Drug|Cervidil 10 MG Vaginal Insert|Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
75636990|NCT02779335|Other|Enteral Formula|pediatric subjects will be fed a standard pediatric enteral formula tube feeding
75636991|NCT04228185|Procedure|sleeve gastrectomy|Comparison of banded and not-banded sleeve gastrectomy
75636992|NCT05339763|Radiation|chemoradiotherapy|exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery
75636993|NCT04228653|Device|Renishaw Drug Delivery System|Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.
75636994|NCT02780037|Behavioral|Regulatory frame: prevention|Exercise program presented as preventing deterioration.
75636995|NCT02780037|Behavioral|Regulatory frame: promotion|Exercise program presented as promoting improvement.
75636996|NCT02780037|Behavioral|Regulatory frame: not implied|Exercise program presented without implied consequences.
75786229|NCT01296074|Drug|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
76078840|NCT03012646|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
76078841|NCT05289856|Drug|combination of Avelumab and Cabozantinib|Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
76078842|NCT01085968|Behavioral|PC based training|Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
76078843|NCT01087918|Device|RAGT|16 sessions / 4 times/week / 45 minutes Lokomat training
76078844|NCT01087918|Other|Strength Training|16 sessions / 4 times/week / 45 minutes lower extremity strength training
75786230|NCT03851042|Device|Virtual Reality Head set in PACU|Use of VR headset to determine post op satisfaction in PACU, decreased pain reduction and opioid consumption
75786231|NCT03851042|Other|No intervention|Routine post laparoscopic hysterectomy management (no VR headset)
75636997|NCT02780505|Drug|vitamin c|"In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples."
75786232|NCT01193738|Procedure|osteopathic compression of Pterygopalatine node|osteopathic compression of Pterygopalatine node
75786233|NCT01189448|Drug|Pyrimethamine/Sulfadiazine|"Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.~Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy."
75786234|NCT01189448|Drug|Spiramycine|"Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures"
75922551|NCT03543501|Device|PBU feedback|Participants will receive the same instruction on the anatomy of abdominal wall muscles and general information about the PBU device. They will be invited to take the same position as for the RUSI group (supine, knees flexed). The feedback will be to visualize the intensity of pressure on the dial of a STABILIZER PBU (Chattanooga Group, Hixon, TN). Participants will receive the education necessary to understand the tool and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions of the TrA with a duration of 10 seconds while maintaining the constant pressure at 40 mmHg ± 2 mmHg. Forty-five seconds of rest will be allocated between each contraction. Participants will have to watch the PBU dial during the 15 tests.
76078845|NCT00636441|Drug|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
75786235|NCT03848156|Other|biopsy|Biopsy of nasal polyp for RNA sequencing
76078846|NCT01087996|Biological|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
75329778|NCT03111316|Device|Foley Catheter|The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
75786236|NCT05671328|Other|Biological examinations performed on blood and BAL|Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL
75786237|NCT01195376|Drug|BEZ235|
75786238|NCT01189526|Drug|Ranibizumab|Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
75786239|NCT01189526|Procedure|macular laser photocoagulation|Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
75922552|NCT04312828|Procedure|Orthopedic management of the Z-foot|Orthopedic treatment with femoropedic plasters and slotted splints in 1st intention
75922553|NCT02149797|Procedure|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
76078847|NCT01087996|Biological|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
76078848|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - Rub Care|Daily care for contact lenses - rub care regimen
76078849|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - No Rub Care|Daily care for contact lenses - no rub care regimen
76078850|NCT00636363|Device|Ciba Vision Aquify Multipurpose Solution|daily care for contact lenses
76078851|NCT02984397|Drug|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
76078852|NCT02984397|Drug|Placebo|
76078853|NCT02984397|Other|Standard of Care|
76078854|NCT01922427|Drug|RNS60|
75329779|NCT04360733|Other|Blood draw|serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis
75329780|NCT03833687|Device|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride.
75329781|NCT03054844|Drug|Lidocaine|Lidocaine will be administered before administration of midazolam.
75636998|NCT02780505|Drug|placebo|"Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement."
75636999|NCT02690844|Drug|Clonazepam mixed with Mucolox®|1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.
75637000|NCT02690844|Drug|Mucolox® alone|5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.
75637001|NCT02690844|Drug|Clonazepam|1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.
75637002|NCT04201860|Diagnostic Test|Arterial blood gas analyses and haemostasis measures|Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.
75637003|NCT05075889|Drug|Indocyanine Green|Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment
75637004|NCT02848014|Behavioral|Writing task|
75637005|NCT04972929|Other|Spinal Manipulation|Diversified (i.e. crossed bilateral hypothenar contact) chiropractic technique will be administered at levels of identified spinal joint restriction/dysfunction (derived from thoracic spine x-rays, static and motion palpation, and confirmed or provoked localized tenderness in paraspinal soft tissues).
75637006|NCT04972929|Other|Sham Spinal Manipulation|Sham-SM will be delivered by setting the expansion control knob on an Activator II (Activator Methods®, Phoenix AZ) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician (no actual instrument contact with study participant). At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted to the participant.
75786240|NCT01296230|Procedure|Hormone and semen measurements before varicocelectomy|Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
75786241|NCT01296308|Other|inpatient integrative treatment|two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
75786242|NCT01189682|Procedure|Tegaderm, Tegaderm HP, Tegaderm CHG|dressings on catheters
75786243|NCT03846206|Dietary Supplement|mediterranean diet|a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
75786244|NCT03845972|Procedure|SSFTB|Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
75786245|NCT05388266|Other|Mask ventilation|Mask ventilation is performed under paratracheal pressure or no pressure in a randomized, crossover manner.
75786246|NCT05671016|Procedure|MRI scans and questionnaires|Extra baseline MRI scan performed and questionnaires (EORTC validated questionnaires involving EORTC QLQ C-30, EORTC BN20 and EORTC ELD14) to assess quality of life at baseline, 4 weeks and 8 weeks after treatment
75922554|NCT02149797|Procedure|SILC-Pick'n roll-Beginning (group I)|"SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided"
75922555|NCT02149797|Procedure|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
75922556|NCT05431426|Drug|CH6001|CHF6001 will be administered using the NEXThaler® DPI device
75922557|NCT04988074|Drug|Cemiplimab|Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
75922558|NCT00104637|Drug|sildenafil citrate|sildenafil citrate 25 mg by mouth thrice daily (po tid)
75922559|NCT00104637|Drug|Placebo|25 mg po tid
75329782|NCT03054844|Drug|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
75329783|NCT03054844|Drug|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
75329784|NCT04360967|Other|Standard Formula|Standard Formula
75329785|NCT04360967|Other|Nutrient-enriched Formula|Nutrient-enriched Formula
75329786|NCT05405595|Drug|ADG126|ADG126 and Pembrolizumab combination treatment both will be dosed until progressive disease (PD), intolerable toxicities, withdrawals of consent, or up to 35 cycles.
75329787|NCT00359697|Drug|Hypertonic Saline, Mannitol|
75329788|NCT03111550|Device|Investigational Intraocular Lens Device #1: TECNIS Model ZHR00|Intraocular lens replaces the natural lens removed during cataract surgery.
75637007|NCT02847702|Drug|VM902A 200-mg Capsules|Taken orally with food twice daily
75637008|NCT02847702|Drug|VM902A 400-mg Capsules|Taken orally with food twice daily
76078855|NCT01600131|Behavioral|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
76078856|NCT01600131|Other|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
76078857|NCT01088464|Biological|IMC-11F8|600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
75637009|NCT02847702|Drug|Naproxen 500-mg Capsules|Taken orally with food twice daily
75637010|NCT02847702|Drug|Placebo|Capsules to match VM902A and/or naproxen taken orally with food twice daily
75786247|NCT01580696|Biological|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
75786248|NCT01580696|Other|Non-vaccine clinically matched control group|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
76078858|NCT01088464|Biological|IMC-11F8|800 mg intravenously, every 2 weeks
75922560|NCT03379142|Behavioral|Faith-Based messages|We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
76078859|NCT01088464|Biological|IMC-11F8|800 mg intravenously, Days 1 and 8 every 3 weeks
76078860|NCT01090180|Drug|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
76078861|NCT01090180|Drug|Placebo (sugar pill)|inactive
75922561|NCT05534776|Other|Investigator Global Assessments (IGAs)|5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.
76078862|NCT00636207|Drug|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
75329789|NCT03111550|Device|Investigational Intraocular Lens Device #2: TECNIS Model ZQR00|Intraocular lens replaces the natural lens removed during cataract surgery.
75329790|NCT03111550|Device|TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00|Intraocular lens replaces the natural lens removed during cataract surgery.
75329791|NCT05447013|Biological|Coronavirus-2-specific T cells|Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors
75329792|NCT05447013|Other|standard of care (SOC)|standard of care (SOC)
75786249|NCT01580696|Biological|E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
75922562|NCT04810208|Drug|Docetaxel|Docetaxel in NanoZolid formulation, for intratumoural injection
75922563|NCT05428774|Other|Test product 1|Participants will receive TP1 during one experimental visit.
76078863|NCT00636207|Drug|Placebo|Placebo dry powder inhaler
76078864|NCT01922505|Drug|PPI triple therapy|
75469855|NCT01944111|Device|Plication|Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
75637011|NCT05236881|Device|ANíMATE mobile application|mHealth tool ANíMATE (Adherence, Nutrition, PhysIcal Activity, Motivation, medicAtion, Technology and Empowerment) allows the recording of data related to diet and exercise and feedback on behavior through an intelligent data analysis system.
76078865|NCT04395885|Other|Electronic questionnaire|Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index
76078866|NCT01091116|Drug|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
76078867|NCT01091116|Drug|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
75329793|NCT03111628|Drug|Omalizumab|omalizumab 300 mg every 4 weeks by subcutaneous injection
75637012|NCT02779413|Drug|insulin degludec|Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
76078868|NCT01091116|Drug|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
76078869|NCT01091116|Drug|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
76078870|NCT01091116|Drug|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
76078871|NCT03013426|Drug|NVX-508|Administration of NVX-508 emulsion intravenously
75637013|NCT04887402|Drug|Clomiphene Citrate|"All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles >10mm, follow up till ovulation"
75329794|NCT00359775|Behavioral|Coping Skills Training|6 session behavioral program
75469856|NCT01944124|Behavioral|Mobile Health|Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
75637014|NCT05336916|Behavioral|Buddy|Mindfulness-based Cognitive Behavioural Therapy
75329795|NCT03111940|Procedure|Optimisation of the result of intracoronary stenting according to specific algorithm|
75329796|NCT05120505|Drug|Metformin|The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.
75329797|NCT05120505|Drug|Placebo|The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
75637015|NCT04793568|Drug|Recombinant Interferon gamma 1b (IMUKIN®)|100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)
75637016|NCT04793568|Drug|Recombinant Interferon gamma 1b placebo|5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).
75329798|NCT03113656|Other|Weighted Blanket|Weighted blanket placed on infant for 30 minutes
75637017|NCT01979211|Drug|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
75637018|NCT01979211|Radiation|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
75637019|NCT05339217|Drug|Telitacicept|160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.
75637020|NCT05339217|Drug|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
75637021|NCT04793490|Procedure|Sphenopalatine ganglion block|Patients will receive the SPGB via the transnasal approache by a cotton tipped applicator soaked in lignocaine 2% with 4 mg dexamethasone
75637022|NCT04793490|Drug|paracetamol|patients will receive paracetamol 1 g thrice daily intravenously
75329799|NCT03113656|Other|Non-Weighted Blanket|Non-Weighted blanket placed on infant for 30 minutes
75329800|NCT05118711|Diagnostic Test|Cardiorespiratory fitness|Cardiopulmonary exercise testing
75637023|NCT00779532|Drug|Moxifloxacin|Capsules containing 400 mg moxifloxacin, on Day 14 only
75637024|NCT00779532|Drug|NOMAC-E2 (Org 10486-0 + Org 2317)|Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
75637025|NCT00779532|Drug|Moxifloxacin placebo|Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
75469857|NCT01944124|Behavioral|Exercise Prescription|An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
75637026|NCT00779532|Drug|NOMAC-E2 placebo|Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
75922564|NCT05428774|Other|Test product 2|Participants will receive TP2 during one experimental visit.
75329801|NCT05118711|Diagnostic Test|Lung function|Body plethysmography
75329802|NCT05118711|Diagnostic Test|Muscular strength and balance tests|Handgrip strength test, mid-thigh pull test and standing balance test in static tandem stance
75329803|NCT05118711|Diagnostic Test|Micro- and macrovascular endothelial function and cardiac function|Measurement of flow-mediated dilation, static and dynamic retinal vessel analysis, echocardiography
75329804|NCT05118711|Diagnostic Test|Blood sampling and analysis|Blood sampling by venepuncture
75329805|NCT05118711|Diagnostic Test|Physical activity|Physical activity surveillance using accelerometers
75637027|NCT01036022|Drug|GSK1399686|Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
75637028|NCT05055297|Device|SELUTION SLR™ DEB 014|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
75637029|NCT05055297|Device|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
75329806|NCT05118711|Diagnostic Test|Questionnaires|Global physical activity questionnaire (GPAQ), short-form 8 health survey (SF-8), barriers to physical activity, fatigue assessment scale (FAS), modified medical research council dyspnea scale (mMRC), depression, anxiety, and stress scale (DASS21), post-COVID-19 syndrome symptoms
75922565|NCT05428774|Other|Placebo|Participants will receive placebo during one experimental visit.
75922566|NCT02156349|Device|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
75786250|NCT01580696|Biological|E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
75329807|NCT05118711|Diagnostic Test|Body composition|Dual-energy x-ray absorptiometry (DXA)
75469858|NCT01944137|Other|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
75469859|NCT01944150|Behavioral|Transcutaneous electrical nerve stimulation|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse during 30 minutes lasting session
75329808|NCT03114124|Device|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
75469860|NCT01944150|Behavioral|Transcutaneous electrical nerve stimulation and hypnosis|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse. Following informations are collected by the second nurse: pain representation and its relief thoughts about a quiet place. TENS and hypnosis are associated in a unique 30 minutes session
75786251|NCT01580696|Biological|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
75786252|NCT01580696|Biological|E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
75469861|NCT01944163|Other|Applying a referral model|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
75469862|NCT01944176|Drug|simvastatin, placebo|
75922567|NCT02156349|Device|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out of blood glucose meter devices
75922568|NCT03125330|Behavioral|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
75469863|NCT01944189|Dietary Supplement|Food|"Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (> 5 to >15 kg receive 1 tablet and 15 to > 25 kg receive 2 tablets)~Food arms:~Standard arm = Milk~Experimental arm = maize porridge plus oil~Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)~Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)"
75922569|NCT03420118|Procedure|Tumour tissue collection|"Depending on the status of disease when participants join the study, a sample of tumour tissue may be collected from:~A previous surgery for the disease,~A biopsy for diagnosing the disease,~Other surgical procedures done for clinical management or possible cancer related complications (e.g., bowel obstruction).~In addition:~Patients undergoing pre-screening prior to diagnosis will have tumour sample collected at the time of surgery.~At anytime participants require a biopsy as a part of their cancer care, a sample of that tumour tissue will be collected.~New biopsies will be done to collect fresh tumour tissue each time participants' disease worsens."
75922570|NCT03420118|Procedure|Blood draws|"Blood samples will be collected at the following different times points:~All patient undergoing pre-screening for histological diagnosis will have blood samples collected.~Before starting a new line of treatment for the disease,~One week after starting a new line of treatment for the disease,~During treatment, at each radiological assessment (imaging scan) that will be done to check the status of the disease,~At the time the disease worsens or relapses (comes back)~During observation/follow-up, at the time of any radiological assessments that will be done to check the status of the disease"
75922571|NCT04445636|Drug|Dexmedetomidine|Caudal block with Dexametomedine as an adjuvant to bupivacaine.
75469864|NCT01944202|Behavioral|Educational intervention|Educational and feedback intervention, as described in the Arm Description.
75922572|NCT04445636|Drug|Morphine|Addition of morphine as adjuvant to bupivacaine during caudal block.
75922573|NCT03542253|Procedure|Surgery|After surgical treatment, pathological specimens were extracted to obtain pathological results
75922574|NCT03744273|Procedure|breast capsule biopsy|
75922575|NCT04445480|Procedure|Popliteal block|Sciatic nerve block at popliteal fossa would perform before the participant undergoing angioplasty in experimental arm.
75329809|NCT03114124|Device|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
75329810|NCT02977533|Drug|GZ402668|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75329811|NCT02977533|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75329812|NCT02977533|Drug|Acyclovir|"Pharmaceutical form: tablet~Route of administration: oral"
75329813|NCT02997904|Device|Apply Liquid Then Comb Out|Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
76078872|NCT01092364|Behavioral|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
75637030|NCT04172766|Behavioral|Advanced|"Advanced group users will receive prompts when an acutely high headphone audio level exposure (LEQ equivalent to >97 dBA for >30 minutes) occurs. Those in the WatchOS arm will be prompted when their weekly environmental sound level (7-day LEQ equivalent to >80 dBA for >40 hrs) is high. Either prompt will occur via notification, and will request that the participant review exposure data in the Research app and answer questions related to their exposure. The survey will ask for confirmation that they reviewed the exposure data and perceive it as accuracy, whether or not they used any hearing protection (e.g., ear plugs worn at a rock concert), and any intended listening behavior change resulting from their data review. To minimize notification burden for participants, exposure notification events will occur no more than twice per month. At this same frequency, they will be asked to take an abbreviated audiogram to test for temporary threshold shifts in their hearing level."
75637031|NCT04227795|Device|Artificial intelligence-Assisted real time colonoscopy|The colonoscopy was performed under artificial intelligence assistance
75637032|NCT05321901|Other|Biopsychosocial Exercise Therapy approach (BETY)|The BETY intervention is grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.
75637033|NCT05321901|Other|Control group|The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
75637034|NCT04156230|Drug|[18F]GP1 positron emission tomography/computed tomography|A radioactive dose of 250 MBq of the study drug with a total quantity of ≤ 10 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 120 ± 15 min after the administration of [18F]GP1.
75637035|NCT02779023|Behavioral|Cognitive-Behavior Therapy for Insomnia (CBT-I)|
75637036|NCT05319093|Drug|Ozanimod|Three-months, longitudinal observational period
75637037|NCT03817086|Behavioral|Hand coordination and mental practice|"20 chronic (>1year) moderate to severe TBI patients, with upper extremity movement deficits, will be randomly and equally assigned to two groups.~In the experimental group, participants undergo 5 weeks (3 hrs/week) of physical practice training combined with mental practice (MP group)."
75637038|NCT03817086|Behavioral|Hand coordination and action observation|In the control group 2, participants undergo 5 weeks (3 hrs/week) of physical training (PP group).
75637039|NCT04693182|Other|Shift schedule without quick returns|The intervention entails implementing a shift schedule which abolishes or substantially reduces the number of quick returns (less than 11 hours of rest between two shifts) for a six-month intervention period.
75637040|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
75637041|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
75637042|NCT00752557|Drug|bisphosphonates, calcium, and vitamin D|Oral bisphosphonate therapy
75637043|NCT04228029|Device|Carboxytherapy|Carbon dioxide (CO2) gas in injection form
75637044|NCT04228029|Drug|Intralesional Steroid Injection|triamcinolone acetonide 8 mg/mL
75637045|NCT04683978|Other|Position|Neck extension
75637046|NCT04570176|Procedure|adrenalectomy for adrenal adenoma|adrenalectomy， cystectomy and nephrectomy
76078873|NCT01092442|Procedure|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
76078874|NCT01092676|Drug|Ibuprofen Regular Dosing|Regular dosing
76078875|NCT01092676|Drug|PRN dosing Ibuprofen|PRN dosing Ibupofen
76078876|NCT01092910|Device|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
76078877|NCT05289622|Device|Polyurethane expandable valve stent implant|The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
75637047|NCT00751218|Drug|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
76078878|NCT05271994|Procedure|endoscopic biliary drainage|endoscopic biliary drainage
75469865|NCT01944215|Dietary Supplement|Meal|effect of meal
75469866|NCT01944215|Other|Exercise|effect of exercise
75469867|NCT01944215|Radiation|Sestamibi|reduce radiation dose
75469868|NCT01944215|Drug|Caffeine Tablet|effect of caffeine
75469869|NCT01944215|Other|External Heating|Heating Pad and warm blanket robe
75637048|NCT00751218|Drug|placebo|placebo, once daily for 28 days
75469870|NCT01944228|Device|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
75469871|NCT01944228|Device|Sham Stimulation|Catheter placed in the IJV without stimulation
76078879|NCT05190640|Dietary Supplement|De-Stress Gummies|one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies
75469872|NCT01944254|Procedure|Cardiac output measurement at random to respiration|Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
75469873|NCT01944254|Procedure|Cardiac output measurement synchronised at start of expiration|Cardiac output measurement obtained by PAC TD
76078880|NCT05106244|Other|Real-Time Guidance of Home Care for Patients with PICC or PORT|the experimental group adopted the family self-nursing mode, mainly by the patients' family members to observe the catheter and do regular nursing, and the specialist nurses provided remote real-time online guidance to monitor the family nursing of central venous catheter. The procedures are as follows: (1) make nursing videos recorded by central venous catheter specialist nurses; (2) evaluate the nursing operation ability of the patients' family members and carry out relevant training and health education, repeat until they are qualified; (3) distribute nursing guidance prescriptions and maintenance manuals for central venous catheters; (4) provide online simulated realistic nursing video materials; (5) provide real-time telephone audio and video connection to complete remote nursing guidance. (6) set up a home nursing volunteer service group, establish a doctor-patient exchange group by using Wechat and other media.
76078881|NCT05088148|Other|. Pesticide and Pharmaceutical analysis|Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
76078882|NCT01039792|Drug|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
76078883|NCT01039792|Dietary Supplement|Placebo|placebo
76078884|NCT03013816|Behavioral|Organ Donation Education: Testimonial Messaging|The testimonial messaging video intervention will be shown
76078885|NCT03013816|Behavioral|Organ Donation Education: Informational Messaging|The informational messaging video intervention will be shown
76078886|NCT03013816|Behavioral|Organ Donation Education: Blended Messaging|The blended messaging video intervention will be shown
76078887|NCT03012724|Device|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
76078888|NCT03012724|Device|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
76078889|NCT05023720|Other|nonintervention|
76078890|NCT01041274|Drug|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
76078891|NCT01041274|Drug|Placebo|Placebo by mouth daily for 12 months.
75637049|NCT00751218|Drug|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
75786253|NCT01580696|Biological|E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
75922576|NCT04445480|Other|Control|Sciatic nerve at popliteal fossa would be scanned with the ultrasound. The toothpick would be applied to simulate the procedure of nerve block.
75922577|NCT05649124|Behavioral|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4, SP6 and ST36 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
76078892|NCT01041274|Behavioral|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
76078893|NCT01041274|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
76078894|NCT01041274|Radiation|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
76078895|NCT00635427|Biological|VPRIV®|Intravenous infusion, every other week (EOW)
75469874|NCT01944254|Procedure|Cardiac output measurement timed to instructed exhalation|Cardiac output measurement obtained by PAC TD
75329814|NCT05160753|Procedure|Laparoscopic gastric function preserving surgery combined with resection of the anterior lymphatic drainage area|A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method., and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed.
75329815|NCT04343625|Behavioral|Modified yoga class|Modified yoga was used to see if it would improve pain, fatigue, depression and anxiety, as well as improve sleep quality.
75329816|NCT01012297|Biological|Bevacizumab|Given IV
75329817|NCT01012297|Drug|Docetaxel|Given IV
75329818|NCT01012297|Biological|Filgrastim|Given SC
75329819|NCT01012297|Drug|Gemcitabine Hydrochloride|Given IV
75329820|NCT01012297|Biological|Pegfilgrastim|Given SC
75329821|NCT01012297|Other|Placebo|Given IV
75637050|NCT05318079|Behavioral|Virtual Reality Gaming|Peer-to-peer gaming.
75637051|NCT02600533|Procedure|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
75637052|NCT02779569|Drug|decitabine|
75637053|NCT04095013|Drug|Bupivacaine, fentanyl|Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,
75469875|NCT01944267|Procedure|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
75922578|NCT02768103|Behavioral|task-based training|The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
75329822|NCT02998684|Device|Active Transcranial Direct Current Stimulation|
75329823|NCT02998684|Device|Sham Transcranial Direct Current Stimulation|
75329824|NCT02998684|Behavioral|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
75637054|NCT04095013|Drug|Bupivacaine, dexmedetomidine|Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
75786254|NCT03846518|Device|Hyrax|Rapid maxillary expansion using the Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars.The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
75922579|NCT02152839|Behavioral|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
76078896|NCT00635349|Drug|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
76078897|NCT00635349|Drug|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
76078898|NCT00635349|Drug|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam [7.5 mg or 15 mg once daily] or aceclofenac [100 mg twice daily]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
76078899|NCT00634803|Behavioral|CBT|Cognitive behavioral therapy
76078900|NCT00634803|Drug|Buprenorphine|buprenorphine/naloxone
75329825|NCT03000010|Device|Incisional Wound Vac|
75329826|NCT03000010|Other|Standard Bandage|
75922580|NCT03375086|Drug|APX3330|APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
75922581|NCT02152917|Drug|Tranexamic acid|
75922582|NCT02152917|Drug|Floseal®|
75922583|NCT03111212|Drug|Iloprost|Iloprost nebulized
75329827|NCT00358839|Drug|CGRP|
75637055|NCT05336526|Device|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Bilateral brest augmentation in primary intention
75922584|NCT03111212|Drug|control|sodium chloride 0,9% nebulized
76078901|NCT00634803|Other|Educational Counseling|Didactic, lecture-discussion format to supplement information and advice provided by physicians
76078902|NCT00634803|Other|Physician Management|Brief physician counseling
75329828|NCT03000088|Device|intubate with 60° angled stylet|
75329829|NCT03000088|Device|intubate with 60° angled stylet|
75329830|NCT03000166|Behavioral|Step-Up Intervention|Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
75329831|NCT00923117|Drug|Sutent (sunitinib)|Oral dose 37.5 mg daily on a continuous 4 week cycle
75637056|NCT02600299|Behavioral|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
75637057|NCT02600299|Behavioral|Usual Care|Usual Care
76078903|NCT01401699|Device|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
76078904|NCT01042288|Drug|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
76078905|NCT01042288|Drug|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
76078906|NCT01042288|Drug|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
75637058|NCT04107246|Device|use of the KaliJAR box|"KaliJAR® : validated device for single-dose eye drops collection. the patient will be asked to discard each single dose of eye drops in the KaliJAR box. The patient returns with the KaliJAR box at each consultation as part of normal practice. The KaliJAR box will be emptied at each consultation by the doctor and then returned to the patient.~No further examination or visit."
75786255|NCT03846518|Device|mini Hyrax|Rapid maxillary expansion using the mini Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars. The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
75786256|NCT03846440|Other|No intervention|Cross-sectional
76078907|NCT01217385|Procedure|DOSI|Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
75637059|NCT05316441|Behavioral|psychoeducation|Positive Psychotherapy is a recently emerged therapy method that works on talents. In the study, success skill development psychoeducation based on positive psychotherapy will be applied.
75637060|NCT02779881|Dietary Supplement|Extensively hydrolyzed casein formula plus LGG|
76078908|NCT01042366|Biological|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
76078909|NCT01043146|Drug|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
75329832|NCT04737070|Biological|Prenatal test for Trisomy 21 screening|prenatal routine test for Trisomy 21 screening (blood test + nuchal translucency test)
75637061|NCT00651378|Drug|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
75637062|NCT00651378|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
75637063|NCT00651378|Drug|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
76078910|NCT01043146|Drug|placebo|intravenous 0.9 % NaCl
76078911|NCT04906018|Device|Ultrasound scans|Each subject will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
75637064|NCT00747643|Drug|varenicline|Participants in this group received varenicline according to the schedule in the Arm Description.
75637065|NCT00747643|Drug|placebo|Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
75637066|NCT02780271|Behavioral|In-person education|Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
76078912|NCT04880668|Device|Aerosol Box (Splashguard)|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
75329833|NCT00953173|Device|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
75329834|NCT03054922|Drug|Normal Saline|IV infusion of 0.9% NaCl throughout surgery.
75329835|NCT03054922|Drug|Lactated Ringer|IV infusion of lactated ringer throughout surgery.
75637067|NCT02780271|Behavioral|E-communication|11 months of motivational text messages, emailed newsletters, and access to a website.
75329836|NCT03054922|Drug|Normosol-R Inj|IV infusion of Normosol throughout surgery.
75329837|NCT02977611|Drug|Iron sucrose|Iron sucrose will be infused at dose of 500 mg over a one hour period
75637068|NCT02780271|Behavioral|Control|Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
75637069|NCT05336292|Behavioral|Meaningful life-focused intervention|The intervention works different skills to increase the meaningful life in the general population and specifically in the army.
75637070|NCT05336292|Behavioral|Meaningful life and emotional regulation-focused intervention|The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.
75637071|NCT05336292|Behavioral|Control Group|This group does not do any intervention
75786257|NCT01197014|Drug|Amlodipine plus Losartan|Amlodipine/Losartan high dose
75786258|NCT01197014|Drug|Amlodipine, Losartan|Amlodipine, Losartan
75786259|NCT01197092|Dietary Supplement|Mitochondrial preparations|"Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:~ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)"
75786260|NCT01197092|Dietary Supplement|Infusion therapy|Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
75786261|NCT01197092|Device|Webermedical device|Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
75922585|NCT03170206|Drug|Binimetinib|Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
75922586|NCT03170206|Drug|Palbociclib|It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
76078913|NCT01043926|Drug|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
76078914|NCT04801810|Other|Normobaric hypoxia|Low oxygen exposure to mimic ~8500 feet elevation (experimental).
75469876|NCT01944267|Procedure|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
76078915|NCT04801810|Other|Normobaric normoxia|Normal oxygen exposure to mimic sea level conditions (sham comparator).
75469877|NCT01944267|Procedure|apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
75469878|NCT01944280|Other|massage|
75469879|NCT01944384|Drug|aldactone|aldactone 25 mg for 6 months
75469880|NCT01944410|Biological|PRP injection|injection of PRP to traumatic bone cyst defect
75637072|NCT00627692|Drug|Prucalopride|0.5 mg o.d.
75637073|NCT00627692|Other|Placebo|o.d.
75786262|NCT01197092|Behavioral|Nutritional therapy|"Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts."
75329838|NCT05405764|Dietary Supplement|Porcine protein supplement|Porcine protein supplementation
75329839|NCT05405764|Dietary Supplement|Control product maltodextrin supplement|Maltodextrin supplementation
75786263|NCT01195454|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: Lantus solution for injection~Route of administration: subcutaneous"
75786264|NCT01195454|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: New insulin glargine formulation solution for injection~Route of administration: subcutaneous"
75786265|NCT03851666|Dietary Supplement|12 weeks daily administration Cereal 1|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
75786266|NCT03851666|Dietary Supplement|12 weeks daily administration Cereal 2|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
76078916|NCT01044706|Drug|Bicalutamide|50 mg Oral Tablet
75329840|NCT04360655|Procedure|bronchoscopic microwave intervention|bronchoscopic microwave intervention
75329841|NCT04360655|Drug|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
75329842|NCT03116230|Device|Cutaneous Stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
75329843|NCT03116230|Device|Knee Sleeve|Commercially-available knee sleeve.
75329844|NCT04367129|Diagnostic Test|ECG|12 lead electrocardiogram
75637074|NCT00627692|Drug|Prucalopride|1 mg o.d.
76078917|NCT04447534|Drug|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine
76078918|NCT04447534|Drug|zinc|Zinc tablets
76078919|NCT03014050|Device|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
76078920|NCT01044862|Drug|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
75329845|NCT00375232|Drug|Administration of montelukast or placebo|
75469881|NCT01944436|Drug|Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)|
75469882|NCT01944449|Dietary Supplement|Whey Protein (WPC) at breakfast|The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.
75469883|NCT01944449|Dietary Supplement|Other Protein Sources at breakfast|The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.
75637075|NCT00627692|Drug|Prucalopride|2 mg o.d.
75637076|NCT00627692|Drug|Prucalopride|4 mg o.d.
76078921|NCT01044862|Drug|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
75329846|NCT04347317|Procedure|Low Intensity IMT|"The control group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 30% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
76078922|NCT01044862|Drug|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
75469884|NCT01944449|Dietary Supplement|Low Protein at breakfast|The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
75329847|NCT04347317|Procedure|High Intensity IMT|"The experimental group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 60% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
75329848|NCT00975637|Drug|70 mg SC|70 mg SC
76078923|NCT01045174|Device|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
75329849|NCT00975637|Drug|210 mg SC|210 mg SC
75329850|NCT00975637|Drug|140 mg SC|140 mg SC
75329851|NCT00975637|Drug|280 mg SC|280 mg SC
75329852|NCT00975637|Drug|Placebo|Placebo SC
75786267|NCT03851666|Other|12 weeks daily administration Placebo|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of placebo.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation."
75786268|NCT03846596|Biological|Additional blood tube|Additional blood tube during care
75786269|NCT01187966|Drug|Safinamide|
75329853|NCT04376567|Other|randomization|subjects scheduled to have a BBAVF will be randomized to either the One-stage or the Two stage BBAVF
75329854|NCT04360343|Drug|Film-coated tablet|uncoated tablet
75329855|NCT04343703|Behavioral|Telephone-based management|The intervention consists of a series of phone calls aimed at providing follow up care of individuals at risk. At each phone call the case manager collects information regarding the current treatment, adherence to mental health services, and current life stressors.
75469885|NCT01944488|Drug|GnRH agonist|100 µg/m2 body surface max 100 µg i.v.
75469886|NCT01944501|Procedure|Transcranial Magnetic Stimulation|TMS over the left temporoparietal cortex
75469887|NCT01944501|Procedure|Transcranial Direct Current Stimulation|TDCS over the left temporoparietal cortex
75637077|NCT05436301|Other|Pain Catastrophizing Scale|"Personal and disease-related inquiries of the participants will be recorded in the demographic registration form. To assess the validity of the Pain Catastrophizing Scale-Child (PCS-C) scale, the Pediatric Quality of Life Questionnaire (PEDSQL) 3.0 Arthritis Module, Childhood Health Assessment Questionnaire (CHAQ), and Juvenile Idiopathic Arthritis Disease Activity Score (JADAS) will be administered to the participants. In this way, the consistency of the developed scale with similar questionnaires that were previously reported to be valid will be examined. In order to determine the reliability of the Pain Catastrophizing Scale-Child (PCS-C) scale, test-retest will be performed at one week intervals for the participants whose treatment has not undergone any change. The consistency of the scale will be determined by the data of the participants who have the first and second scale scores. Interviews will be conducted by face-to-face method."
75786270|NCT01187966|Drug|Safinamide|
75786271|NCT01187966|Drug|Placebo|
75786272|NCT01292954|Dietary Supplement|Blueberries|low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period
76078924|NCT04365478|Procedure|Radial Extracorporeal Shock Wave Therapy|rSWT group: One radial shock wave therapy session a week for 8 weeks (parameters: 1.5 bar, 10 Hz, 2000 shots for each muscle group treated) administered daily during the morning for 40 minutes of conventional rehabilitation treatment.
76078925|NCT04365478|Procedure|Conventional physiotherapy|Control group: 40-minutes of conventional rehabilitation treatment 5 days per week in the morning (strength exercise, trunk control exercise, stretching exercise, occupational therapy, and neurodevelopmental facilitation techniques) for 8 weeks
76078926|NCT04361656|Drug|PEG-ELS current standard of care|Standard of care for inpatient colonoscopy
76078927|NCT04361656|Drug|PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)|The dose of Lubiprostone will be 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy if it is BEFORE 11 a.m., and Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS if colonoscopy is scheduled AT or AFTER 11 a.m..
75786273|NCT01195610|Behavioral|Dietary intervention|Instruction to diet for 6 month
76078928|NCT04242394|Procedure|ERCP|Routine ERCP procedures with gallbladder in situ patient
76078929|NCT04238338|Other|monocyte / lymphocyte ratio|The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average
76078930|NCT01047358|Drug|Aromasin|25 mg table QD
75329856|NCT04343703|Behavioral|iFightDepression for Suicide|The iFD-Survive is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iDF tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. The iFD-S also provides telephone guidance (2h per participant).
75786274|NCT01197170|Drug|Anastrozole|1 mg by mouth daily of a 28 day cycle.
75922587|NCT02156427|Device|VITICELL|graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid
75922588|NCT02156427|Device|PLACEBO|hyaluronic acid alone
75922589|NCT03060746|Other|Newly Diagnosed|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
75922590|NCT02156505|Procedure|placement of double bare stent|
75922591|NCT02156505|Device|DoubleBare stent|
75922592|NCT03381014|Drug|Chemotherapy, Cancer, Anthracyclines|follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin
76078931|NCT01047358|Drug|Aromasin|25 mg table QD
76078932|NCT01048606|Behavioral|Placebo + exercise|"Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
75329857|NCT04343703|Behavioral|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
75329858|NCT04343703|Behavioral|Self Awareness of Mental Health|The SAM consist of five, face-to-face, individual sessions designed to raise awareness about depression, anxiety and suicidal behaviors as well as to enhancing skills to effectively cope with stressful life events and mood.
75329859|NCT03024229|Device|LifePort® perfusion machine|Renal perfusion on LifePort® machine
75329860|NCT02244437|Drug|Ibuprofen|
75922593|NCT05649046|Device|thoracic scan Low dose|within 3 months after the V0 visit
75786275|NCT01197170|Drug|Bevacizumab|Starting dose 10 mg by vein on day 1 of a 21 day cycle.
75786276|NCT01197170|Drug|Everolimus|Starting dose 5 mg by mouth daily for a 28 day cycle.
75786277|NCT01197170|Drug|Sorafenib|Starting dose 200 mg by mouth twice a day of a 28 day cycle.
75786278|NCT01197170|Drug|Erlotinib|Starting dose 75 mg by mouth daily for a 28 day cycle.
75786279|NCT01197248|Procedure|Cystocele plication|placement of sutures over the pubocervical fascia during the cystocele repair
75922594|NCT05649046|Biological|BLOOD SAMPLE|within 3 months after the V0 visit
75922595|NCT05649046|Biological|FECES SAMPLE|within 3 months after the V0 visit
75922596|NCT03543423|Other|Oral glucose tolerance test|Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG
75922597|NCT03543423|Other|Liquid mixed meal test|A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).
75922598|NCT03375008|Diagnostic Test|Imaging diagnostic and biopsy|Liver biopsy and MRI scan
75786280|NCT01197248|Procedure|No Plication|Avoid sutures over pubocervical fascia during cystocele plication
75786281|NCT01197404|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
75786282|NCT01197404|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics.
75922599|NCT02149953|Dietary Supplement|Glycine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
75922600|NCT03380936|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
76078933|NCT01048606|Dietary Supplement|Phytoestrogens without exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions."
75329861|NCT02244437|Drug|Acetaminophen|
75637078|NCT00634881|Biological|Alemtuzumab i.v.|"Alemtuzumab will be administered once per week as a 2 h infusion~Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
75637079|NCT00634881|Biological|Alemtuzumab s.c.|"Alemtuzumab will be administered once per week subcutaneously~Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
75786283|NCT01195688|Drug|BI 638683 or placebo|oral doses given to 6 subjects per dose group
75786284|NCT01195688|Drug|Placebo solution|oral doses given to 2 subjects per dose group
75786285|NCT05516966|Drug|HRS9531|Administrated SC
75922601|NCT03380936|Other|Plasma Exchange and IVIG (Intravenous Immunoglobulin )|Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
75786286|NCT05516966|Drug|Placebo|Administrated SC
75786287|NCT05516966|Drug|Dulaglutide Injection|Administrated SC
75786288|NCT01195766|Drug|Ofatumumab|Ofatumumab in addition with ESHAP therapy
75329862|NCT05448495|Other|Posterior TAP block|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine [0.5 mcg\kg] + 2ml dexamethasone [0.1mg\kg)] will be injected at the plane between internal oblique and transversus abdominis near the aponeurosis at the posterior axillary line.
75329863|NCT05448495|Other|ESPB|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine [0.5 mcg\kg] + 2ml dexamethasone [0.1mg\kg)] will be injected at T9 erector spinae plane
75329864|NCT04346927|Other|Telerehabilitation|15 volunteers diagnosed with coronavirus will be included in experimental group. An online exercise program has been created for individuals who will participate in the study. This program is planned to continue 3-4 days a week, in a 30-minute session and for 6 weeks. Treatment sessions will include breathing exercises, posture exercises, peripheral muscle exercises and light aerobic exercises. Individuals were asked to participate in the research via telerehabilitation connection system and were told that they would do their exercises with a physiotherapist.
75329865|NCT04346927|Other|exercise brochure|15 volunteers diagnosed with coronavirus will be included in control group.The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
75329866|NCT03023527|Drug|Nivolumab|
75786289|NCT03850886|Dietary Supplement|Niacinamide Oral Tablet|Nature's Life Niacinamide 1000 mg
75922602|NCT02150031|Drug|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
75922603|NCT02150031|Drug|1% Chlorhexidine|subgingival irrigation
75922604|NCT02150031|Drug|1% Chlorhexidine|supragingival irrigation
75922605|NCT02150031|Procedure|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
75329867|NCT03023527|Drug|Pomalidomide|
75329868|NCT03023527|Drug|Dexamethasone|
75329869|NCT03023527|Drug|Elotuzumab|
75329870|NCT04359875|Behavioral|Phone-call screening and management by a medical student/general practitioner tandem|"Systematic phone contact of the patient by a medical student, under the indirect supervision of the general practitioner. This phone contact will be standardized with 3 questions to ask to the patient:~How are you doing? (with a Likert scale from 1=very bad to 10=very well)~Would you have made an appointment with your general practitioner if there had not been COVID19 epidemic and containment?~Would you like an appointment with your doctor and / or has your doctor ever contacted you? In view of the answers to these 3 questions, the general practitioner will decide whether it is necessary to propose a consultation or a teleconsultation to the patient, taking into account his/her medical background."
75469888|NCT01944540|Procedure|Optimized ESD with snaring|
75637080|NCT04301882|Drug|interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
75786290|NCT03850886|Drug|Antidiabetic|Metformin or Sulphonylurea
75786291|NCT03251482|Drug|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion as a single dose on Day 1.
75786292|NCT03251482|Drug|JNJ-64179375 0.6 mg/kg|JNJ-64179375 0.6 mg/kg IV infusion as a single dose on Day 1.
75786293|NCT03251482|Drug|JNJ-64179375 1.2 mg/kg|JNJ-64179375 1.2 mg/kg IV infusion as a single dose on Day 1.
75786294|NCT03251482|Drug|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
75786295|NCT03251482|Drug|JNJ-64179375 A mg/kg|JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
75786296|NCT03251482|Drug|JNJ-64179375 B mg/kg|JNJ-64179375 Dose B mg/kg IV as a single dose on Day 1.
75786297|NCT03251482|Drug|JNJ-64179375 C mg/kg|JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
75786298|NCT03251482|Drug|JNJ-64179375 D mg/kg|JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
75786299|NCT03251482|Drug|Placebo JNJ-64179375|Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.
75786300|NCT03251482|Drug|Apixaban placebo|Matching apixaban placebo administered orally twice a day for 10 to 14 days.
75786301|NCT03251482|Drug|Apixaban 2.5 mg|Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.
75798674|NCT01178892|Dietary Supplement|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
75922606|NCT02150031|Drug|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
75922607|NCT02150031|Procedure|Tooth extraction|dental extraction
75786302|NCT05355584|Other|Cryotherapy application|The temperature sense test was applied on the dominant side shoulder of the participants against the risk of sensory loss or decreased sensation. In order to test cold intolerance, a cold pack was placed on the forearm of the individuals. After waiting 2-3 minutes, the region was evaluated. Individuals meeting the inclusion criteria were assigned to the groups according to the randomization list created by the computer. Then, the participants' shoulder isometric muscle strength, shoulder flexibility, shoulder endurance and shoulder balance was evaluated. Except for shoulder endurance, all measurements were repeated three times, with a 30-second rest period between each repetition. A 2-3-minute rest period was given after each test. Then, the cold pack was wrapped in a thin and wet cloth on the shoulders of the participants. The treated area was checked every 5 minutes and the participants were asked to say when they felt any unusual symptoms.
75637081|NCT04301882|Drug|direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
75469889|NCT01944540|Procedure|Conventional ESD|
75469890|NCT01944553|Device|The ROSA™ robot|"The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.~Stabilisation in treatment for spine degenerative disease"
75469891|NCT01944579|Other|Blackberries|Participants will receive blackberries as part of a controlled diet.
75469892|NCT01944579|Other|Control|Participants will receive a control food (jello) as part of a controlled diet.
75637082|NCT04300322|Device|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
75637083|NCT04300322|Drug|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
75637084|NCT05457673|Device|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
75469893|NCT01944592|Behavioral|Gynaecology Teaching Associates (GTA's)|Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
75637085|NCT04517136|Behavioral|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
75786303|NCT01196000|Procedure|conventional laparoscopic surgery|operation using conventional laparoscopic techniques
75637086|NCT04517136|Biological|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: Dehydroepiandrosterone (DHEA), cortisol and chromogranin A levels
75637087|NCT04517136|Device|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
75637088|NCT04517136|Behavioral|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
75637089|NCT04228341|Other|Glucose Reference 1|50 g of glucose dissolved in 250 ml of water (First glucose control visit)
75786304|NCT01196000|Procedure|robotic-assisted laparoscopic surgery|operation that involves use of laparoscopic assistance with robotic assistance
75786305|NCT01196000|Procedure|quality-of-life assessment|Ancillary studies
75786306|NCT01196000|Other|questionnaire administration|Ancillary studies
75786307|NCT01189916|Procedure|Endoscopically assisted Appendectomy Surgery|Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
75786308|NCT01189994|Procedure|Acupuncture|Needling of acupoints, some of them receiving electrostimulation
75329871|NCT04367285|Other|Sensor-based Training|Sensor-based Training consists of twelve sessions of upper limb training with PABLO®-Tyromotion. For each session the training consists in interactive-games based on virtual reality which allowed a task-oriented approach and a neurocognitive feedback. The exercises require precision tasks and one-dimensional and bidimensional reaction, allowing to train the attention, the strength control and movement control, the coordination and the movement precision. The interactive-games were chosen from those proposed by the Tyromotion PABLO® System.
75329872|NCT04367285|Other|Upper limb motor training|Upper limb motor training, without robotic support. Subjects performed specific exercises aimed to recovery global upper limb functions, to control hand grasp and to improve hand's fine movements.
75329873|NCT02977689|Drug|IDH305|study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
75329874|NCT04366661|Diagnostic Test|low dose CT|Invited participants from institutes exposed to a high level of smoke pollution such as employees of Transport and Oil Ministries are inquired for their personal history of cigarette smoking then subjected to low dose CT
75329875|NCT04878627|Drug|Cannabidiol|patients receive cannabidiol at various doses for 3 weeks
75329876|NCT04878627|Drug|Placebo|patients receive placebo for 3 weeks
75329877|NCT02244515|Drug|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
75922608|NCT03374852|Drug|CPI-613|500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port
75922609|NCT03374852|Drug|mFOLFIRNOX|mFOLFIRNOX (given immediately after CPI-613 administration):
75922610|NCT04655170|Drug|Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).
75469894|NCT01944592|Behavioral|Manikin (conventional) training|Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
75637090|NCT04228341|Other|Glucose Reference 2|50 g of glucose dissolved in 250 ml of water (Second glucose control visit)
75786309|NCT01189994|Behavioral|Orientation|Orientation sessions focusing in fibromyalgia
75786310|NCT03249454|Device|Anodal tsDCS|During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
75786311|NCT03249454|Device|Cathodal tsDCS|During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
75329878|NCT03833375|Other|Decision Aid|Shared-decision making tool
75329879|NCT05095935|Other|N/A observational registry|N/A observational registry
75922611|NCT04655170|Drug|Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)|Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
75922612|NCT03378986|Procedure|Unilateral total hip arthroplasty|Replacement of one hip joint through a mininvasive surgical procedure
75329880|NCT04360031|Drug|Tacrolimus|Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen
75329881|NCT00953719|Device|36 mm ceramic head on a ceramic acetabular liner|Total hip replacement with a 36 mm ceramic head on a ceramic liner
75637091|NCT04228341|Other|Glucose Reference 3|50 g of glucose dissolved in 250 ml of water (Third glucose control visit)
75637092|NCT04228341|Other|Brown Rice|Unpolished brown rice containing 50 g of available carbohydrate was cooked using a rice cooker (Toyomi) at a ratio of rice to water of 1: 2
75637093|NCT04228341|Other|3 % polished rice|3% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
75922613|NCT03378986|Procedure|Simultaneous bilateral total hip arthroplasty|Replacement of both hip joints through one-stage mininvasive surgical procedure
75329882|NCT00953719|Device|28 mm ceramic head on a polyethylene acetabular liner|Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
75329883|NCT04366739|Drug|CHLORPROMAZINE (CPZ)|"Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum"
75329884|NCT04366739|Combination Product|Standard of Care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm"
75329885|NCT03023059|Drug|Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet|See Arm description
75637094|NCT04228341|Other|6 % polished rice|6% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
75637095|NCT04228341|Other|9 % polished rice|9 % polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
75637096|NCT04228341|Other|20 % Polished rice|White rice (20% polished rice), containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2.
75637097|NCT02600377|Other|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
75786312|NCT03249454|Device|Sham tsDCS|During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.
75786313|NCT03732248|Drug|Rapamycin|Immunosuppressive drug
75786314|NCT03732248|Drug|Placebo|Inert drug
75922614|NCT02156661|Drug|Oxytocin|
75922615|NCT04797026|Other|Letters to increase social connection with goal to alleviate loneliness|Our hypothesis is that a social program connecting patients in residential care facilities with high school students through monthly letter writing would positively impact quality of life for both, reducing quantitative and qualitiative measures of loneliness
75922616|NCT03065062|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.
75922617|NCT03065062|Drug|Gedatolisib|Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
75922618|NCT04310488|Other|The Centre of excellence self-administered (CESAM) questionnaire items|Complete a self-administered questionnaire within two days of their museum visit.
75922619|NCT02150187|Dietary Supplement|HCap Formula|Pill should be taken every other day during the treatment phase.
75922620|NCT02150187|Dietary Supplement|Placebo|Similar pills without active ingredients
75786315|NCT03963778|Behavioral|Improving nutritional care|The interventions will be co-designed with the action research team
75637098|NCT04496310|Procedure|Telemedicine|Telemedicine versus usual care (face to face visit)
75637099|NCT02842788|Procedure|Prone positioning|Turning the patient face down for several consecutive hours
76078934|NCT01048606|Other|Phytoestrogens + exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
76078935|NCT04224766|Procedure|Suprascapular Nerve Block with 5ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
75637100|NCT01022762|Drug|repaglinide|Individually adjusted dose for 16 weeks
75637101|NCT01022762|Drug|gliclazide|Individually adjusted dose for 16 weeks
75637102|NCT04093141|Procedure|IRE|in situ irreversible electroporation
75637103|NCT00311844|Drug|desloratadine|
75786316|NCT01586000|Drug|10 µg/day E2 with NES 200® µg/day|10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
75786317|NCT01586000|Drug|20 µg/day E2 with NES 200® µg/day|20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
75786318|NCT01586000|Drug|40 µg/day E2 with NES 200® µg/day|40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
75798675|NCT01178892|Behavioral|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
75922621|NCT03374774|Drug|BIAsp 30|Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
75922622|NCT02156817|Other|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
75922623|NCT03374696|Behavioral|SAFETY|
75922624|NCT03374696|Behavioral|Standard education|
75329886|NCT03022513|Other|Gluten free diet|The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
75329887|NCT02244827|Drug|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
75329888|NCT00360789|Behavioral|Conventional UK physical therapy|
75637104|NCT05338515|Drug|Selpercatinib|Administered orally.
75637105|NCT01028378|Device|T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser|
75637106|NCT00747565|Device|Tecnis ZM900 Multifocal Intraocular Lens|Investigational intraocular lens
75637107|NCT00747565|Device|CeeOn 911A monofocal IOL|Monofocal Control IOL
75637108|NCT04227561|Procedure|Pudendal nerve block|"Pudendal nerve block will be performed under general anesthesia and guided by neurostimulation.~The local anesthetic solution (chirocaine 2.5mg/ml) will be injected in the ischiorectal fossa with a needle (a BBraun Stimuplex Ultra 360 22G 50mm needle) connected to a neurostimulator (Stimuplex HNS 12 neurostimulator). The neurostimulator will be used to determine the localization of pudendal nerve and to identify the precise site of injection. The contraction of the anal sphincter or bulbocavernosus muscle occurs when the pudendal nerve is reached.~These procedure will be performed bilaterally."
75637109|NCT04227561|Procedure|Penile nerve block|"The local anesthetic solution (chirocaine 2.5mg/ml) will be injected under the fascia of Scarpa with a real-time ultrasound guidance.~These procedure will be performed bilaterally."
75637110|NCT02599675|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
75637111|NCT02599675|Dietary Supplement|Placebo|Olive oil, encapsuled
75637112|NCT01028300|Device|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
75637113|NCT03741972|Drug|iSGTL2|Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
75922625|NCT02150265|Behavioral|SMART manual cognitive behavioral therapy|
75922626|NCT03380858|Device|colectomy|colectomy resection
75637114|NCT02778789|Drug|Tocilizumab|Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label
75922627|NCT03124472|Procedure|uterine artery ligation|Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
76078936|NCT04224766|Procedure|costoclavicular Block 10ml bupivicaine 0.5%|transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
75637115|NCT02778789|Drug|TNF-alpha Inhibitor|Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
75637116|NCT04228497|Device|gastric ultrasound|Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.
75786319|NCT03898648|Other|Waiting room task|"The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed."
76078937|NCT04224766|Procedure|Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
75637117|NCT04228497|Other|the clear fluid intake|the clear fluid intake
75637118|NCT00212784|Drug|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
75637119|NCT00212784|Drug|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
76078938|NCT04210882|Behavioral|Moderate-Intensity Exercise|See description of study arm.
75329889|NCT00360789|Behavioral|Increased intensity of UK conventional physical therapy (PT)|
75637120|NCT00752089|Drug|NaF/ KNO3/isopentane Dentifrice|Experimental toothpaste
75786320|NCT05124548|Diagnostic Test|Sleep diagnostics|On study day 4, all participants perform a single night sleep assessment in a sleep lab via Polysomnography (PSG) and WHOOP strap, a digital Fitness and health Coach.
75786321|NCT00310037|Drug|bortezomib|Given IV
75786322|NCT03708094|Diagnostic Test|molecular diagnosis|whole exome sequencing and data analysis to elucidating molecular diagnosis
75786323|NCT01197872|Other|Preimplantation Genetic Diagnosis|Genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia).
75786324|NCT05670626|Procedure|Refractive Surgery|Phakic implantable contact lens ( ICL)
75637121|NCT00752089|Drug|NaF/KNO3 Dentifrice|Experimental toothpaste
76078939|NCT03012256|Other|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
75922628|NCT03124472|Procedure|Lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~Closure of the anterior abdominal wall in layers"
75922629|NCT05386966|Other|questionnaire|Patient demographic data ( age, gender, residence , work ,Level of education) .Detailed history about the trauma (type, site , manner , mechanism of injury , actual cause of assault , post traumatic period till arrival to hospital ) .Clinical assessment ( Rapid neurological assessment , assesment of Scalp injury ,Presence of other body trauma ,Degree of severity of head injury according to GCS , Radiological finding. Treatment (Conservative or operative intervention ) .Follow up and outcome at the time of discharge by using the GOS .Expected time for healing (<20 day or >20 day ).Expectance for permanent infirmity
75922630|NCT03125408|Diagnostic Test|HCV Assay|Molecular diagnostic test to detect Hepatitus C
76078940|NCT04128514|Device|Panoptix Toric|Cataract surgery and IOL implantation
75637122|NCT00752089|Drug|NaF Dentifrice|Active comparator
76078941|NCT01049776|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
76078942|NCT01772004|Drug|Avelumab|Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
76078943|NCT02930044|Other|Early administration of subcutaneous insulin glargine dose|DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units.
76078944|NCT02930044|Other|IV insulin infusion|All patients will receive the standard of care which is a protocol based continuous insulin infusion
76078945|NCT02930044|Drug|IV fluid repletion|0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
75329890|NCT00360789|Behavioral|UK conventional PT plus functional strength training|
75637123|NCT00752089|Other|Placebo Dentifrice|Placebo comparator
75637124|NCT02779179|Procedure|Periodontal treatment|"Mechanical debridement (scaling, root planning, subgingival curettage)~Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~Antiseptic mouthrinses, gel or dentifrice~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
75637125|NCT02842554|Other|EPT|
75637126|NCT02842554|Drug|Drug Placebo Administration|
75637127|NCT02842554|Other|C|No Intervention
75637128|NCT05295147|Other|Palmar Grasp Reflex Stimulation|The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
75637129|NCT04227405|Behavioral|Connection to community services through case management|Case managers met with couple and conduct a needs assessment for the couple and their family. Then they developed an Individual and Couple Development Plan to take care of those needs, usually by accessing community services. Case managers met every 5 weeks with the couple to check on progress toward meeting the goals of the plan and assess for the present of any new needs.
75922631|NCT03374618|Other|Blood sample|Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
75786325|NCT03631654|Drug|Ivabradine|Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
75637130|NCT04227405|Behavioral|TOGETHER Workshop|Couples were required to participate in a 20 hour workshop (8 sessions of 2 1/2 hours each)in groups of 3 to 8 couples. These groups were facilitated by a financial expert and a couples' expert. The workshop is interdisciplinary and psycho-educational. Couples learn about skills to improve their communication about stress and money problems, conflict resolution, individual and couple stress management in general and about money stress in particular, and financial management
75786326|NCT03631654|Drug|Placebos|Placebo
75637131|NCT04227405|Behavioral|Employment Support Services|Only for those participants that were in need of employment support services. If the needs assessment conducted by the case manager indicated an employment or career need. After completion of the TOGETHER workshop, an employment case manager met with the participant, conducted an employment needs assessment and connected the participant with a workforce agency or one-stop employment centers. After doing so, the employment case manager followed through the various steps that the participant had to complete as part of the employment services for a period of 6 months
75786327|NCT03477916|Biological|FMT|fecal microbial transplantation (FMT)
75922632|NCT02767323|Device|rTMS|excitatory 5Hz rTMS will be used
76078946|NCT02181400|Device|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
76078947|NCT04352218|Device|"PTA + Stenting using Petalo stent"|PTA and Petalo's Stenting are a minimally invasive endovascular procedures, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
76078948|NCT04352218|Procedure|Percutaneous Transluminal Angioplasty (PTA)|PTA is a minimally invasive endovascular procedure, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
76078949|NCT03012178|Procedure|Mitral valve surgery|ACC/AHA guideline directed mitral valve repair or replacement
76078950|NCT03012412|Behavioral|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
76078951|NCT02666638|Other|Control Volunteers|MRI on up to a 7T scanner without contrast.
76078952|NCT02666638|Other|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
76078953|NCT03683524|Drug|Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
76078954|NCT03683524|Drug|Current ART|To continue with their current ART
75786328|NCT03477916|Biological|Placebo FMT|Placebo fecal microbial transplantation (FMT)
75786329|NCT03477916|Dietary Supplement|Prebiotic Fiber|combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
75786330|NCT03477916|Dietary Supplement|Cellulose|Cellulose
75786331|NCT01196234|Drug|Paclitaxel/Carboplatin/Gefitinib|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
75786332|NCT01196234|Drug|Paclitaxel/Carboplatin|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
75786333|NCT02937376|Drug|N-acetyl cystein|A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.
75786334|NCT02937376|Other|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
75786335|NCT01196468|Other|HIV test (serological or salivary)|"An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition"
75786336|NCT01196468|Other|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
75786337|NCT05324930|Device|Piscean collagen dressing|Piscean collagen dressing
75786338|NCT05324930|Device|Saline infused dressing|Saline infused dressing
75786339|NCT00309959|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
75786340|NCT00309959|Other|Laboratory Biomarker Analysis|Correlative studies
75922633|NCT02767323|Device|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
75922634|NCT03370094|Diagnostic Test|Audio-video-streaming of suspected stroke symptoms and signs|The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
75922635|NCT05534698|Procedure|PCI|Revascularization by PCI
75922636|NCT05534698|Procedure|CABG|Revascularization by CABG
75922637|NCT03374540|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
76078955|NCT02246842|Biological|D-Gam® (human anti-D immunoglobulin)|
76078956|NCT02246842|Biological|Rhophylac® (human anti-D immunoglobulin)|
76078957|NCT02617342|Behavioral|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
75786341|NCT03845192|Device|ORI measurement by Radical 97|"ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®."
75786342|NCT03981419|Biological|GRF6021|for IV infusion
75922638|NCT03374540|Drug|Vitamin K antagonist (VKA)|Individually adjusted dose
75637132|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral + oats|"Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months."
75637133|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
75922639|NCT04304950|Drug|Evening Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 pm and 11:00 pm.
75922640|NCT04304950|Drug|Morning Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
75469895|NCT01944618|Drug|Forxiga|FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor [DPP 4 inhibitor] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
75637134|NCT00751933|Dietary Supplement|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
75637135|NCT00751933|Other|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
75637136|NCT01701570|Behavioral|Placebo Attention Control|The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
75637137|NCT01701570|Other|Supervised Exercise Training|The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
75637138|NCT04195269|Drug|Test Article|10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
75786343|NCT03981419|Other|Placebo|for IV infusion
75786344|NCT03238924|Drug|Oxytocin|40 IU oxytocin nasal spray, self-administered
75922641|NCT03374462|Behavioral|Telemedicine Intervention|Home-based telemedicine visits
75922642|NCT03374384|Other|No drug intervention|This study will be performed in Al-Arish Central Hospital and will include all patients from 2 months up to 18 years of age with seizures admitted to Al-Arish Central Hospital
75922643|NCT02780115|Drug|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
75922644|NCT02780115|Drug|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
75922645|NCT02780115|Drug|AGN-199201 Vehicle|Vehicle to AGN-199201
75922646|NCT02780115|Drug|AGN-190584 Vehicle|Vehicle to AGN-190584
75786345|NCT03238924|Drug|Placebos|Saline nasal spray, self-administered
75786346|NCT01190384|Other|Couscous plus fiber|Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.
75786347|NCT01190384|Dietary Supplement|Grape seed extract|300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.
75786348|NCT01190384|Other|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
75922647|NCT03378752|Procedure|HFJV|On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
75922648|NCT02808208|Biological|Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.
75922649|NCT02808208|Drug|Placebo|5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.
75922650|NCT02808208|Biological|Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)|Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery
75786349|NCT02532413|Drug|Poly IC|Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
75786350|NCT02532413|Drug|Entecavir|Entecavir can inhibit the replication of HBV.
75922651|NCT04736446|Device|I-gel® supraglottic device|Use of an i-gel® supraglottic device to deliver ventilations
75922652|NCT04736446|Device|Face mask ventilation|Use of a face mask to deliver ventilations
75922653|NCT03369938|Other|exercise training intervention|structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
75786351|NCT03844958|Other|Red Furu|"50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day"
75786352|NCT03844958|Other|Tofu|"50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day"
75922654|NCT02156973|Other|Video information|A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
75922655|NCT03378674|Drug|Remifentanil Injectable Product|remifentanil: 0,15 mcg/kg/min
75922656|NCT02157207|Dietary Supplement|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
75922657|NCT02157207|Other|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
75637139|NCT04093063|Other|Micro-stellated Icosahedron|A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
75637140|NCT03258138|Behavioral|Health and wellness learning sessions|The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
75637141|NCT03258138|Behavioral|Brainstorming group sessions|The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
75637142|NCT03258138|Behavioral|Individual sessions with a multidisciplinary health team|Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
75651775|NCT05617001|Device|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V1 and V2 in a sequential fashion along with the V4 and Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 5 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
75786353|NCT05253248|Dietary Supplement|OMIS|This is an open-label micronutrient supplementation trial in healthy adult volunteers. We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days.
75786354|NCT01190462|Biological|cetuximab|
75786355|NCT01190462|Drug|simvastatin|
75786356|NCT01190462|Other|laboratory biomarker analysis|
75786357|NCT01198106|Drug|scopolamine|0.6 mg
75786358|NCT01198106|Drug|cinnarizine|50 mg
75786359|NCT02918500|Drug|Nicoderm Patch|Nicotine replacement therapy patch
75786360|NCT03850652|Dietary Supplement|Prebiotic (Synergy-1) + Iron supplement|In addition, participants will be required to take one 7 g sachet of prebiotic food supplement daily. In addition, participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
75786361|NCT03850652|Dietary Supplement|Placebo (Maltodextrin) + Iron Supplement|participants will be required to take one 7 g sachet of placebo (maltodextrin) daily. In addition, participants will be required to take an iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
75922658|NCT04178408|Other|No intervention|No intervention
75922659|NCT02261103|Drug|Pramipexole ER tablets|
75922660|NCT02261103|Drug|Pramipexole IR tablets|
75922661|NCT02261103|Drug|Placebo matching Pramipexole ER tablets|
75922662|NCT02261103|Drug|Placebo matching Pramipexole IR tablets|
75922663|NCT02261103|Other|Standard high-fat breakfast|
75922664|NCT03378596|Dietary Supplement|L-citrulline + L-arginine|L-citrulline + L-arginine - sachet dissolved in water
75922665|NCT03378596|Dietary Supplement|L-arginine|L-arginine - sachet dissolved in water
75922666|NCT03378596|Dietary Supplement|L-citrulline|L-citrulline - sachet dissolved in water
75922667|NCT03378596|Dietary Supplement|Placebo|Placebo (corn starch) - sachet dissolved in water
75922668|NCT03543345|Diagnostic Test|echocardiography study|"Patients with right coronary artery occlusion lesion will be subjected to:~Written consent.~Complete history.~Complete physical examination.~Trans-thoracic echocardiography assessment of the right ventricular function before PCI to the RCA~Follow up Trans-thoracic echocardiography assessment of the right ventricular function four weeks after the PCI."
75922669|NCT02153151|Other|Cytology specimen|Correlative studies
75922670|NCT02153151|Other|Laboratory biomarker analysis|Correlative studies
75922671|NCT04525742|Other|Difficulties lived by disabled children's parents in the period of COVID-19 pandemic|It will be a cross sectional study to obtain the information on difficulties lived by disabled children's parents during recent pandemic period
75922672|NCT04833465|Other|No Intervention|No Intervention
75922673|NCT05475340|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
76078958|NCT02550886|Other|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
75922674|NCT03369860|Behavioral|Interactivity of Experimental Condition|The neurofunctional correlates of motor control will be compared between a collaborative and non-interactive condition.
75922675|NCT02766777|Drug|Lubiprostone|12 or 24 mcg soft capsules for oral administration.
75922676|NCT05534308|Procedure|Transoperative taping|The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, on intraoperative period associated with compression with elastic stockings.
75329891|NCT02244905|Behavioral|Positive Deviance|The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
75329892|NCT02244905|Other|Standard-of-Care Infection Control approach|Standard-of-Care Infection Control approach
75329893|NCT01012921|Device|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
75329894|NCT01012921|Device|MembraGel|Device application at surgery
75637143|NCT03258138|Behavioral|Health goal development|Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
75637144|NCT03258138|Behavioral|Physical activity and nutrition journals|Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
75637145|NCT05338437|Device|Neuromuscular electrical stimulation|Bilateral quadriceps muscle stimulation
75637146|NCT04093375|Procedure|Radical Prostatectomy|Radical prostatectomy with or without androgen deprivation therapy
75637147|NCT04093375|Other|Radical Radiotherapy|Radical Radiotherapy with adjuvant androgen deprivation therapy
75637148|NCT05338359|Biological|Blood sample|Blood sample of 34 mL
75637149|NCT05338359|Other|Phone-call|Phone-call to the participant 15 days after recruitment to fix the final diagnosis
75922677|NCT05534308|Other|No trasoperative taping|Patients will received only compression stockings after surgery
75786362|NCT01190540|Behavioral|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
75786363|NCT01190540|Behavioral|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
75786364|NCT01190540|Behavioral|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
75786365|NCT01190540|Behavioral|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
75922678|NCT03374306|Drug|Atropine (0.01%)|tropical application
75922679|NCT03374306|Drug|Artificial tear|tropical application
75922680|NCT05534230|Drug|Dexmedetomidine Injectable Solution|Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
75329895|NCT01012921|Other|Bio-Gide® membrane|Device application at surgery
75329896|NCT04360499|Other|Low- weight-high-repetitions training|LWHR refers to a specific form of resistance exercise which utilizes low weights and very high repetitions
75329897|NCT04360499|Other|Pilates training|Pilates style exercise training
75329898|NCT04359485|Procedure|Glycolic acids peel 70%|Glycolic acid peel 70% applied in 3 coats medium depth
75329899|NCT04359485|Other|Saline|Sodium chloride
75922681|NCT05534230|Drug|Saline|Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
75922682|NCT03369782|Drug|Rocuronium|rocuronium is administered in bolus and continuous infusion
75329900|NCT03055000|Biological|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
75329901|NCT03055000|Biological|AGS-v + adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
75329902|NCT03055000|Other|Placebo|WFI (0.5mL) on Day 0 and Day 21
75329903|NCT02245061|Other|paired pulses cortical electrical stimulation|
75637150|NCT04090255|Procedure|Renal puncture|The use of a needle for entering pelvicalyceal system of the kidney and put a guide wire for further pcn
75637151|NCT04094857|Drug|HBN-1|Intravenous infusion
75637152|NCT02842398|Behavioral|Balance Master|
75637153|NCT02842398|Behavioral|Customary Care|
75637154|NCT04988997|Drug|Vurolenatide 50mg/PBO|Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
75637155|NCT04988997|Drug|Vurolenatide 100mg/PBO|Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
75637156|NCT04988997|Drug|Vurolenatide 50/50 mg|Vurolenatide - 50 mg weekly SC administration
75637157|NCT04988997|Drug|Placebo|PBO - weekly SC administration
75637158|NCT04092751|Drug|PRA|Single oral 20-mg dose of PRA on Day 1 AM
75637159|NCT04092751|Drug|SCY-078 plus PRA|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later
75637160|NCT05334810|Drug|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
75637161|NCT02842008|Behavioral|Exercise group|This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
75637162|NCT02598505|Drug|Indacaterol|
75637163|NCT02598505|Drug|Placebo|
75637164|NCT02778945|Drug|Rocuronium 0.9 mg/kg|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
75637165|NCT02778945|Drug|Rocuronium 0.6 mg/kg|Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
75637166|NCT02721342|Drug|Ramipril, Irbesartan and Atorvastin|
75637167|NCT02779101|Drug|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
75637168|NCT05336058|Other|No intervention|In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.
75637169|NCT02779959|Drug|Prochlorperazine|
75637170|NCT05335278|Drug|Nintedanib 150 milligrams [Ofev]|All patients will be given nintedanib 150 milligrams orally twice daily
75637171|NCT05173233|Device|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
75637172|NCT00751621|Biological|IgPro20|
75637173|NCT02778477|Drug|PF-06423264|Multiple ascending dose of PF-06423264
75637174|NCT02778477|Other|Placebo|Multiple dose of placebo
75637175|NCT00092898|Drug|MK0653, ezetimibe|
75637176|NCT00092898|Drug|Comparator: placebo|
75329904|NCT04376099|Diagnostic Test|Transcutaneous oxygen pressure measurement during the treadmill test|"Calculation of the decrease from rest of oxygen pressure (DROP) throughout the period of rest exercise and recovery.~The DROP is calculated as chanegs on each limb probe minus changes on a chest reference probe from rest.~Analysis of the recovery period of the recordings will be done to seach for recovery 50% and 90% from the minimal DROP observed Evaluation of calf and non calf pain during the tests. Evaluation of calf and non calf (buttock or thigh) ischemia during the tests. Ischemia being defined as a monimal DROP lower than minus 15 mmHg."
75329905|NCT04376021|Behavioral|Babywearing|Increase mother-infant physical contact through babywearing
75637177|NCT04094467|Drug|Cetrorelix|0.25 mg subcutaneous injection daily for 6 days
75786366|NCT03963622|Other|Respiratory Mechanics|"Different maneuvers based on respiratory mechanics will be assessed at the bedside and will be used to individualize ventilator parameters. Recruitability will be assessed with a one breath decremental PEEP maneuver, and search for airway closure with a low-flow pressure volume or pressure-time curve. If the patient has airway closure, the minimal PEEP will be set at the airway opening pressure to avoid closure. If the patient is considered recruitable, the goal is to set PEEP at or above 15cmH20 to maximize alveolar recruitment, until the plateau pressure reaches the safety limit. Volume control ventilation at 6ml·kg-1 will be used.~Once spontaneous breathing has started, the occlusion pressure (P0.1) will be maintained within targets."
75786367|NCT03963622|Other|Standard Ventilation Strategy|Patients randomized to the control arm will receive standard care. The PEEP is adjusted for oxygenation based on a PEEP-FiO2 table, either the low PEEP-FiO2 or the high PEEP-FiO2 table. Volume targeted ventilation with initial VT 6 mL·kg-1 and Plateau pressure at 30 cmH2O or below, targeting PaO2 60-80 or SpO2 90-95%, adjusted as per the protocol. Pressure-support ventilation is at physician's discretion, but recommended when FiO2 <60%, and is titrated VT 6-8 mL·kg-1.
75786368|NCT01198184|Drug|temsirolimus|Given IV or PO
75786369|NCT01198184|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
75786370|NCT01198184|Other|laboratory biomarker analysis|Correlative studies
75329906|NCT00922883|Drug|Eltrombopag|
75329907|NCT03055156|Device|Low rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
75329908|NCT03055156|Device|High rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
75329909|NCT04357613|Drug|Experimental drug|Imatinib 800mg/d during 14days
75329910|NCT02976987|Drug|Cidofovir|
75329911|NCT02244281|Drug|tamsulosin hydrochloride|
75329912|NCT02244281|Drug|Placebo|
75329913|NCT04376177|Diagnostic Test|Ultrasound|Echodoppler imaging of upper limbs performed by trained operators at rest and during provocative maneuvers for TOS diagnosis.
75329914|NCT04376177|Diagnostic Test|angiography|Angiography (arterial and/or venous) of upper limbs performed by trained operators at rest and during provocative maneuvers such for TOS diagnosis.
75637178|NCT04094467|Drug|Leuprolide Acetate|0.1 mg subcutaneous injection daily for 12 days
75637179|NCT02842476|Device|Disposable Sensor|Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
75637180|NCT02842476|Device|Reusable Sensor|Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
75637181|NCT02842476|Device|Control Pulse Oximetry|A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
75637182|NCT04227249|Procedure|no lymph node dissection|do not undergo lymph node dissection
75637183|NCT02599597|Behavioral|Therapist-assisted iCBT|13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
75786371|NCT01198184|Other|pharmacological study|Correlative studies
75329915|NCT04376177|Diagnostic Test|questionnaires|Use of standard questionnaires (MASC, DASH, SF36) for the evaluation of upper limb symptoms self-completed by the patients at admission.
75329916|NCT04376177|Diagnostic Test|Transcutaneous oximetry|Mesurement of transcutaneuos oxygen pressure on both forearms performed at rest and during provocative maneuversfor TOS diagnosis.
75329917|NCT04376177|Diagnostic Test|plethysmography|Photoplethysmography of the forearms or fingers performed at rest and during provocative maneuvers for TOS diagnosis
75329918|NCT04376177|Diagnostic Test|Electromyogram|Electromyography of the upper limbs with encoding of the physician for the presence or abnsence of signs of plexis compression (impairment of the response on C8 T1 erea
75637184|NCT02599597|Behavioral|Monthly screening with feedback|Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
75637185|NCT02842164|Other|Tension group|
75637186|NCT02842164|Other|No tension group|
75637187|NCT02842164|Other|Foley catheter Balloon|
75637188|NCT02778711|Drug|secukinumab|anti-IL-17
75637189|NCT04209582|Device|measurement of TcPO2 with skin electrode|measurement of TcPO2 with skin electrode
75786372|NCT00333359|Drug|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
75786373|NCT03844880|Behavioral|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
75786374|NCT03844880|Behavioral|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
75786375|NCT03246724|Drug|Triazolam|"This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg"
75329919|NCT04376177|Diagnostic Test|Standard X-Ray|Standard X-Ray performed for the research of apophysomegaly or additionnal cervical rib.
75786376|NCT03246724|Drug|Midazolam|"This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1.0 mg~Dose for BMI greater than or equal to 35: 2.0 mg"
75786377|NCT03246724|Drug|Microcrystalline Cellulose|"This will be used for the oral placebo. This capsule or a triazolam capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1 capsule~Dose for BMI greater than or equal to 35: 2 capsule"
75786378|NCT03246724|Drug|Sodium chloride 0.9%|"This will be used for the intravenous placebo.This injection or midazolam will be administered depending on the randomized treatment group.~Dose for BMI less than 35: volume to match volume of active intravenous medication~Dose for BMI greater than or equal to 35: volume to match volume of active intravenous medication"
75786379|NCT05484440|Other|Psychological|
75329920|NCT04499781|Behavioral|ACCESS II mHealth Intervention|Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
75329921|NCT04499781|Behavioral|ACCESS II control condition|Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
75329922|NCT00361413|Drug|Alefacept (AMEVIVE®)|Alefacept
75329923|NCT00361413|Drug|control group|these patients will receive the same treatment as group A, without alefacept
75786380|NCT03984227|Genetic|Taking peripheral blood samples|quantitative real-time polymerase chain reaction
75786381|NCT01196546|Drug|vildagliptin/metformin|
75786382|NCT01196624|Device|rapid TMS, EXPOSURE TO TRAUMATIC STIMULI|RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
75786383|NCT01196624|Device|rapid TMS, EXPOSURE|apid TMS, EXPOSURE
75786384|NCT04609228|Other|Non-acceptance of blood-transfusions|Patients who do not accept blood products transfusions
75786385|NCT04609228|Other|Acceptance of blood-transfusions|Patients who accept blood products transfusions
75922683|NCT03369782|Drug|Sugammadex|Sugammadex is administered just before reduction of the joint
75329924|NCT03062488|Drug|IV acetaminophen|multi-modal analgesia with IV acetaminophen
75329925|NCT03062488|Drug|Fentanyl|single modal analgesia
75329926|NCT03062488|Drug|PO acetaminophen|multi-modal analgesia with PO acetaminophen
75329927|NCT00936299|Drug|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
75329928|NCT00936299|Other|Placebo|
75637190|NCT02599753|Drug|18-FDTBZ|"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
75637191|NCT00092820|Drug|MK0653, ezetimibe|
75637192|NCT00092820|Drug|Comparator: placebo|
75637193|NCT04094623|Other|Dialectical behavior therapy|15 patients in a group are treated by 2 psychotherapist by DBT including mindfulness skills, distress tolerance skills, emotional regulation skills and interpersonal effectiveness skills.
75637194|NCT04094623|Other|Social support group therapy|15 patients in a group are treated by 2 psychotherapist by SSGT.(Giving support to each other.)
75637195|NCT00092742|Drug|MK0663, etoricoxib|
75637196|NCT00092742|Drug|Comparator: Diclofenac sodium|
75637197|NCT04094389|Other|Orthotic continuous wear group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
75786386|NCT01293266|Drug|Propofol|Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
75786387|NCT03246646|Behavioral|Coaching|Telephone coaching was provided in a series of telephone based sessions with CSO participants
75786388|NCT03948646|Drug|Sofpironium Bromide, 15%|Active
75637198|NCT04094389|Other|Orthotic wear during waking hours only group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
75637199|NCT04094389|Other|Orthotic wear only while sleeping group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~In the night-wear group, participants will be told to wear their orthosis only at night. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated"
75786389|NCT03948646|Drug|Vehicle|Vehicle gel
75786390|NCT05474066|Device|ERP Testing|"Attention & Concentration:~Continuous Visual Memory Test (CVMT):~Flanker Task:~Hayling Test:"
75786391|NCT01198340|Procedure|PC-FNB with basal administration of local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
75786392|NCT01198340|Procedure|PC-FNB without basal local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
75786393|NCT05670548|Other|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
75786394|NCT01347112|Drug|Varenicline|varenicline 1.0 mg dose, twice daily for 12 weeks
75786395|NCT01347112|Drug|placebo|sugar pill twice daily for 12 weeks
75786396|NCT05083598|Other|6 Minute walking test|The patient is asked to repetitively walk along a 15 m track, at their best speed, in six minutes. Before and after the exercise, blood arterial pressure and dyspnea level (via Borg scale) are assessed. Cardiac frequency and peripheral Oxygen saturation are assessed before the test, and every minute and in the two minutes following the exercise.
75786397|NCT05083598|Other|Frailty questionaires|Clinical Frailty Score, Metabolic Equivalent of Task, DUKE Activity Status Index
75786398|NCT05572216|Procedure|Robot assisted partial nephrectomy with 3D image guidance|patient have a partial nephrectomy for renal complex tumor
75786399|NCT01293344|Other|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
75922684|NCT03369782|Drug|Placebo|"Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex"
75922685|NCT00157014|Drug|Tacrolimus|Oral
75329929|NCT04375943|Drug|Antidiabetic|Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
75329930|NCT04375865|Drug|AD-2111|celecoxib 200mg
75329931|NCT04375865|Drug|AD-2112|Tramadol 150mg
75329932|NCT01014091|Biological|GSK pandemic vaccine GSK2340272A|2 intramuscular injections
75637200|NCT04587648|Other|NA, observational study|NA, observational study
75637201|NCT04092985|Device|iECG recording|iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smart watch (Apple Watch Series 4) with the ECG application
75922686|NCT00157014|Drug|Cyclosporine|Oral
75922687|NCT00157014|Drug|Mycophenolate mofetil|Intravenous and Oral
75637202|NCT04195035|Device|Air-Q intubating laryngeal airway|Air-Q intubating laryngeal airway will be used for ventilation & intubation through fiberoptic bronchoscope.
75637203|NCT04195035|Device|Ambu-Aura intubating laryngeal mask|Ambu-Aura intubating laryngeal mask will be used for ventilation & intubation through fiberoptic bronchscope.
75329933|NCT03117634|Drug|Treat and Extend with Aflibercept 2mg|Drug treatment regime which allows extension of treatment interval based on disease activity
75637204|NCT02844270|Device|Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
75637205|NCT05261763|Other|Dry Needling|abc
75637206|NCT05261763|Other|Sham Dry Needing|xyz
75922688|NCT00157014|Drug|Methylprednisolone|Intravenous
75922689|NCT00157014|Drug|Prednisone|Oral
75329934|NCT03117634|Drug|Fixed Dosing with Aflibercept 2mg|Fixed 8 weekly dosing regime throughout the study duration
75637207|NCT02843958|Device|HEMOPTIC|
75922690|NCT03374228|Drug|BMS-986205|Specified Dose on Specified Days
75922691|NCT02778867|Other|1 Food Elimination Diet Therapy|
75922692|NCT02778867|Other|6 Food Elimination Diet Therapy|
75922693|NCT02778867|Other|6 Food Elimination Diet (after 1FED failure)|
75922694|NCT02778867|Drug|Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)|
75469896|NCT01944657|Device|Supplemental TMS|Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.
75469897|NCT01944657|Drug|Standard Medication Monotherapy|These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
75469898|NCT01944683|Other|Placebo|
75637208|NCT02779647|Behavioral|The intervention consisted of physical activity based on play|The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). The total of sessions was 144, the minimum number of sessions to consider valid that a child has completed the intervention was 115 (80%) in order to perform the minimum level of physical activity recommended for their ages. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
75637209|NCT04931823|Drug|CPO-100|Docetaxel albumin-bound
75637210|NCT04092517|Other|Control Corn Soya Diet|Ingredients (% by weight): Maize (78.30); Whole soya beans (20.00); Vitamin/Mineral FBF-V-13 (0.20); Dicalcium Phosphate anhydrous (1.23); Potassium chloride (0.27)
75469899|NCT01944683|Drug|GGF2|
75637211|NCT04092517|Other|Test Corn Moringa Diet|Ingredients (% by weight): Maize (78.30); Moringa (20.0)
75329935|NCT04375709|Other|Physical exercise|The intervention consists out of combined aerobic and strength exercise supervised and guided by specialized physical therapists; additional methods like functional electrical stimulation or oxygen supplementation are added during the main training if indicated.
75637212|NCT04094233|Dietary Supplement|Beetroot extract|Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
75329936|NCT04375709|Behavioral|Education sessions|Sessions include information on physical activity (behaviour), coping with stress and anxiety, dyspnoe, or fatigue; Professional support is given in case of risk for nutritional deficits or post-traumatic stress; sessions are conducted by medical specialists or specialized physiotherapists. All sessions are individually-tailored. In case of nutrition or psychological issues individual sessions are guided by specific health-professionals.
75637213|NCT04094233|Other|Placebo|Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
75637214|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
75637215|NCT00634959|Drug|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
75329937|NCT05071365|Other|Early access to virtual resources|Single arm study. Participants are given access to self help videos for the management of plantar fasciitis while they are on the waiting list
75329938|NCT01014169|Behavioral|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.
75637216|NCT00634959|Drug|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
75786400|NCT01293344|Other|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
75786401|NCT00308711|Drug|Misoprostol vaginal insert 100 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
75786402|NCT00308711|Drug|Misoprostol vaginal insert 50 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
75786403|NCT00308711|Drug|Dinoprostone vaginal insert (Cervidil)|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
75329939|NCT00937235|Drug|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
75637217|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
76078959|NCT02249650|Drug|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
75329940|NCT00937235|Behavioral|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
75469900|NCT01944683|Drug|Midazolam|
75469901|NCT01944696|Other|phototherapy|Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
75469902|NCT01944709|Biological|Dendritic cell application|
75469903|NCT01944735|Drug|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
75637218|NCT00634959|Other|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
76078960|NCT02182492|Drug|Clarithromycin|Clarithromycin 250 mg tablet once daily for 3 months
75786404|NCT05170568|Biological|T cell injection targeting CD7 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.
75637219|NCT02598427|Drug|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
75786405|NCT01190696|Procedure|titanium elastic nailing|we inserted titanium nail in femoral fractures retrogradely
75329941|NCT00937235|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
75786406|NCT01190696|Device|Hip spica casting|we applied cast for three weeks in patients with femoral shaft fracture
75786407|NCT04655716|Drug|Sodium Bicarbonate 150Meq/L/D5W Inj|Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.
75786408|NCT01198418|Behavioral|Experimental|Internet-based intervention that assesses transmission risk and provides prevention messages
75786409|NCT04653688|Device|The FeetMe® Evaluation|The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.
75786410|NCT04653688|Device|the PKG® Watch,|The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® system consists of a wrist-worn movement recording device known as the PKG® Watch,
75922695|NCT03374150|Behavioral|diet counseling|Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
76078961|NCT02182492|Drug|Glucocorticoid|Fluticasone propionate nasal spray 200 μg/d for 3 months
75637220|NCT02598427|Drug|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
75637221|NCT02776215|Drug|tasimelteon|Melatonin receptor agonist
75637222|NCT04226001|Other|Quality of life questionnaire|Quality of life questionnaire
75637223|NCT04092439|Dietary Supplement|Watermelon Juice|100% Watermelon Juice
75637224|NCT04094077|Drug|AGuIX|2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
75786411|NCT04653688|Radiation|MRI|"an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~anatomical registration~automated segmentation~volumetric~texture analysis"
75637225|NCT04092595|Drug|PF-06651600|PF-06651600: 200 mg dose provided as four 50 mg oral tablets
75786412|NCT04653688|Radiation|DaTSCAN|"quantify nigrostriatal dopaminergic depletion~correlate its impact on the type and severity of gait disorders in Parkinson's disease."
75786413|NCT02532725|Procedure|Cardiopulmonary Exercise Stress Test|Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.
76078962|NCT02182804|Device|Olympus|narrow band imaging with magnification
76078963|NCT02182804|Device|Cellvizio|probe-based confocal laser endomicroscopy
76078964|NCT01668082|Procedure|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
76078965|NCT03010306|Other|CASITA|
76078966|NCT03010384|Other|Rehabilitation program|
76078967|NCT01163656|Device|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
76078968|NCT01163656|Device|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
76078969|NCT01129804|Behavioral|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
76078970|NCT01165840|Drug|Dapsone|100 mg PO x 1 dose
76078971|NCT04351854|Other|Retrospective data collection|Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
75329942|NCT01014403|Drug|enoxaparin|Enoxaparin 30 mg sq q 12 hours
75329943|NCT01014403|Drug|placebo|vehicle
75329944|NCT03120832|Biological|PAN-301-1|
75329945|NCT00937859|Drug|SER120|SER120
75329946|NCT00937859|Drug|Placebo|Placebo
75329947|NCT05405608|Drug|Ondansetron|hemodynamic stability in orthopedic surgeries
75329948|NCT01014871|Drug|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
75469904|NCT01944735|Drug|Placebo|Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
75637226|NCT04092595|Drug|Rosuvastatin|10 mg oral tablet
75637227|NCT04092205|Drug|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
75637228|NCT04226157|Device|Home Blood Pressure Monitoring Device (Qardio Arm)|The Home Blood Pressure Device with telemonitoring capability will allow the participants and physician to monitor blood pressure over time and titrate blood pressure medications as needed for persistently elevated blood pressure.
75637229|NCT04226157|Other|Primary Care Provider Blood Pressure Management|Participant will follow up as would normally do with primary care provider for blood pressure management.
75469905|NCT01944748|Behavioral|Families Able To Resolve Situations (FARS)|Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
75922696|NCT04232072|Other|Group ESPB|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
75469906|NCT01944787|Other|Routine|IV Hydration at 125 cc hour
75637230|NCT05117853|Drug|Autofluorescent detection + Injection of indocyanine green|"All four parathyroid glands will be actively sought for in every case selected for the use of AF/ICG, with AF verification of parathyroid tissue.~The timepoints of AF will be:~1 = after lateral dissection side 1 (side 1)~2= after lateral dissection side 2 (side 2)~The timepoints of ICG injection will be:~1 = after the first thyroid lobectomy (side 1)~2 = after the second thyroid lobectomy (side 2)~Scoring of the viability of parathyroid glands (adapted from Vidal Fortuny et al., 2016):~1 = black = not viable/vascularized~2 = grey = moderately viably/ moderately vascularized~3 = white = viable/well-vascularized"
75637231|NCT05117853|Procedure|Gold standard of visual identification and evaluation of viability of the parathyroid glands.|Gold standard of visual identification and evaluation of viability of the parathyroid glands.
75786414|NCT02532725|Procedure|Climatic-Controlled Cardiopulmonary Exercise Stress Test|Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.
75786415|NCT02532725|Procedure|Body Composition Evaluation|Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.
75922697|NCT04232072|Other|Group Ibuprofen|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period. In Group Ibuprofen, patients will be administered ibuprofen 800 mgr IV every 8 hours in the postoperative period.
76078972|NCT00952692|Biological|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.~For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:~One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.~One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
75786416|NCT02532725|Procedure|Pre-Exercise Risk Assessment|Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
76078973|NCT00952692|Drug|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
75786417|NCT03844490|Other|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontanous pulsation stops.~At this time, cord clamping will be made."
75786418|NCT03844490|Other|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivey)
75786419|NCT00308555|Drug|Cannabis|
75786420|NCT05153044|Other|severe acute respiratory syndrome CoV-2 serology|diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.
75922698|NCT02157285|Behavioral|Peer Mentor Counseling|Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
75922699|NCT03369626|Behavioral|FareWell Program|The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
75329949|NCT01014871|Drug|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
75329950|NCT04357769|Other|PSS (Perceived Stress Scale)|Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks
75329951|NCT04357769|Other|GAD-7 (7-item Generalized Anxiety Disorder)|Self-administered scale for the evaluation of anxiety symptoms in the last weeks
75329952|NCT04357769|Other|PHQ-9 (9-item Patient Health Questionnaire)|Self-administered scale for the evaluation of depressive symptoms in the last weeks
75469907|NCT01944787|Other|IV Hydration at 250cc hour|IV Hydration at 250 cc hour
75469908|NCT01944813|Behavioral|ACp conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
75469909|NCT01944826|Other|Registry of patients with Tako-Tsubo cardiomyopathy|
75469910|NCT01944852|Drug|Icodextrin|
75637232|NCT02776371|Drug|Modified non-clarithromycin triple therapy|H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
75469911|NCT01944865|Other|Interval Training|The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
75469912|NCT01944865|Other|Intermittent Training|The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
75469913|NCT01944904|Dietary Supplement|Sugar Pill|The placebo is identical in appearance to the XOS and contains 505mg maltodextrin
75469914|NCT01944904|Dietary Supplement|XOS 2.8|2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
75469915|NCT01944943|Drug|Vismodegib|150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
75469916|NCT01944982|Biological|Expanded haploidentical natural killer cells (NKAEs)|
75786421|NCT01198496|Drug|Losartan, Losartan and HCTZ, Amlodipine , Spironolactone|<Study drugs and treatment steps> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
75786422|NCT01066013|Other|Antimicrobial de-escalation strategy|The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
75786423|NCT05137834|Other|Exercise|Post-surgical exercise
75786424|NCT01066091|Other|Mashed potatoes|Mashed potatoes: Potatoes + Skim milk powder
75786425|NCT01066091|Other|Mashed potatoes + Oleic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
75786426|NCT01066091|Other|mashed potatoes + Palmitic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
75786427|NCT03846284|Drug|Bupivacaine|caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
75922700|NCT02300064|Other|Knee-extensor exercise test|Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes
75922701|NCT02300064|Other|Exercise test with restricting/releasing blood flow|10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.
75329953|NCT04357769|Other|SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks
75786428|NCT03846284|Drug|Magnesium sulfate 50mg|caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.
75786429|NCT03846284|Drug|Magnesium sulfate 30 mg|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
75786430|NCT01066169|Biological|Foceteria® (Novartis)|This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.
75922702|NCT02300064|Other|Exercise test with variable oxygen concentration and MRI|Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine
75922703|NCT02300064|Other|Exercise test with oral antioxidant or placebo cocktail|Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort
75329954|NCT04357769|Other|Zaritt Burden Interview|Self-administered scale for the evaluation of severe mental disorder patients' caregiver burden
75922704|NCT05473390|Other|functional electrical stimulation|functional electrical stimulation on back muscles
75922705|NCT05473390|Other|kinesotaping|no intervention
75922706|NCT02778555|Behavioral|Questionnaires|
75329955|NCT00375466|Drug|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
75329956|NCT00375466|Drug|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
76078974|NCT01168024|Device|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
75329957|NCT04357691|Behavioral|Conventional training|Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model
75329958|NCT04357691|Behavioral|AI-led training|Participants will perform an AI-led training for 4 weeks
75329959|NCT00976183|Drug|Vorinostat|Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
75329960|NCT00976183|Drug|Vorinostat|Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
75469917|NCT01944995|Device|glasses broadband|
75469918|NCT01944995|Device|nasal CPAP|
75469919|NCT01945021|Drug|Crizotinib|
75469920|NCT01945047|Drug|Ketamine|Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
75469921|NCT01945047|Drug|Midazolam|Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
75469922|NCT01945060|Device|heart rate Control to Range System (hrCTR) using DiAs Platform|"Diabetes Assistant (DiAs) Medical Platform System~A smart-phone medical platform (DiAs);~Continuous Glucose Monitor;~Insulin pump;~Bluetooth connection;~Remote Monitoring Server."
75469923|NCT01945060|Other|DiAs Control-to-Range System not informed for heart rate|Not informing system of heart rate during exercise.
75469924|NCT01945073|Behavioral|Educational Booklet (BK)|The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
75469925|NCT01945073|Other|Formal Counselling (CB)|The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
75469926|NCT01945099|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
75329961|NCT00375544|Device|Low level light therapy|
75469927|NCT01945099|Drug|hyaluronidase|
75469928|NCT01945099|Drug|Lispro-PH20|
75469929|NCT01945125|Other|rhTSH Group|Patients receiving rhTSH for RIT stimulation
75329962|NCT04357535|Drug|Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)|ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.
75329963|NCT03121144|Device|Masimo Centroid System|Noninvasive positional monitoring device
75469930|NCT01945151|Other|Group 2 (G2) NMES is applied in the spastic muscle (gastrocnemius).|The G2 apply NMES in the gastrocnemius motor point and the rest will be done during stretching of the gastrocnemius muscle (autogenic inhibition). Five consecutive sessions will be held in the morning and afternoon in the laboratory of Sensory Motor Rehabilitation Engineering.
75469931|NCT01945164|Drug|XL999|The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.
75798676|NCT01178892|Behavioral|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
76078975|NCT01168024|Other|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
76078976|NCT05389566|Diagnostic Test|Quantative Sensory Testing|Evaluation of small fiber neuropathy
76078977|NCT05389566|Diagnostic Test|NCStat-DPN-Check|Evaluation of large fiber neuropathy
76078978|NCT05389566|Diagnostic Test|Composite Autonomic Symptom Score 31|Evaluation of autonomic neuropathy
76078979|NCT05389566|Diagnostic Test|Computerized dynamic posturography|Evaluation of dynamic postural control
75329964|NCT01015807|Drug|Bupivacaine Placebo|2 x 20mL 0.9% NaCl
75329965|NCT01015807|Drug|Clonidine Placebo|2 x 1mL 0.9% NaCl
75329966|NCT01015807|Drug|Bupivacaine|2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
75329967|NCT01015807|Drug|Clonidine|2 x 1ml Clonidine = 150 µg Clonidine
75329968|NCT03067948|Behavioral|Patient Designated Positive Screen Shared with Provider|Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
75469932|NCT01945177|Device|narrow band imaging|narrow band imaging
75469933|NCT01945177|Device|white light endoscopy|white light endoscopy
75469934|NCT01945190|Device|Electroacupuncture|
75469935|NCT01945268|Drug|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
75469936|NCT01945268|Other|Sterile saline|0.5 ml dose injected intramuscularly
75469937|NCT01945333|Behavioral|Cognitive remediation|Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
75469938|NCT01945346|Drug|PRX167700|Oral capsule
75469939|NCT01945346|Drug|Placebo|Oral capsule
75469940|NCT01945372|Other|EEG NeuroFeedback|
75469941|NCT01945385|Behavioral|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
75637233|NCT02776371|Drug|Sequential therapy|H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
75637234|NCT01028222|Drug|Nilotinib|Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
75637235|NCT01028222|Drug|DTIC|DTIC was supplied locally as sterile powder for i.v. infusion.
75637236|NCT00586495|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
75637237|NCT04226079|Diagnostic Test|Collection of exhaled breath|Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
75637238|NCT04225143|Procedure|urostim bilateral|Treatment by bilateral neurostimulation of the tibial nerve
75329969|NCT04784429|Device|Kenevo or C-Leg 4|Kenevo fitted to subjects walking slower than 0.8 m/s as measured by the 2-minute Walk Test. C-Leg 4 fitted to subjects walking faster than 0.8 m/s.
75469942|NCT01945398|Other|Inspiratory Muscle Training|Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
75469943|NCT01945398|Other|SHAM|Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
75469944|NCT01945411|Device|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
75469945|NCT01945411|Device|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
75469946|NCT01945424|Biological|Quadrivalent Influenza Vaccine (QIV)|No Intervention as part of this protocol
75469947|NCT01945437|Drug|Magnesium Sulfate|The magnesium group receive intravenous magnesium sulfate.
75469948|NCT01945450|Drug|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
75469949|NCT01945450|Drug|Ampicillin|
75637239|NCT04225143|Procedure|urostim unilateral|Treatment by unilateral neurostimulation of the tibial nerve
75637240|NCT02776137|Drug|Docetaxel|Docetaxel: 20mg/m2/w for 6 weeks
75637241|NCT02776137|Radiation|Intensity-modulated radiotherapy|a total dose of 60Gy in 30 fractions over 6 weeks
75798677|NCT01178892|Behavioral|Usual Activity|"Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership."
75798678|NCT03865368|Other|Whole Body Vibration Training|Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
75798679|NCT01178970|Behavioral|Resistance training|
75329970|NCT04784429|Device|Non microprocessor controlled knee (NMPK)|NMPK consistent with current standards of care
75922707|NCT03513198|Diagnostic Test|Endoscopic ultrasound (including fine needle aspiration)|"EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.~Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.~Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~EUS-FNA will be performed in all pancreatic masses with at least four passes."
75922708|NCT03513198|Other|Contrast-enhanced endoscopic ultrasound (CE-EUS)|"CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.~The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).~The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.~All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box"
76078980|NCT05389566|Diagnostic Test|Video Head Impulse Test|Evaluation of vertigo and the vestibular organ
76078981|NCT05389566|Diagnostic Test|Accelerometer|Evaluation of gait pattern
76078982|NCT05389566|Diagnostic Test|Handgrip strength|Evaluation of muscle strength
75469950|NCT01945450|Drug|Gentamycin|
75469951|NCT01945450|Drug|Clindamycin|
75469952|NCT01945476|Drug|midazolam premedication|"On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total."
75329971|NCT04827225|Behavioral|questionnaires|Questionnaires (EPDS, HADS, PPQ, MIBS, etc.) will have to be completed by the parents at different stages of their child's development (38 weeks of amenorrhea, 3 months and 24 months).
75637242|NCT04093999|Procedure|Sensory nerve coaptation|A recipient sensory nerve branch of the 11th-12th intercostal nerve was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
75637243|NCT01027754|Drug|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
75637244|NCT01027754|Drug|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
75637245|NCT02773017|Drug|Dexmedetomidine A|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
75637246|NCT02773017|Drug|Dexmedetomidine B|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
75637247|NCT02773017|Drug|Dexmedetomidine C|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
75637248|NCT02776293|Behavioral|Relaxation|
75469953|NCT01945515|Device|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
75637249|NCT02776293|Behavioral|Music|
75637250|NCT04301648|Other|STAR Nurse|"This intervention will consist in that the nurse who is in the hemodynamic nurse's office will do the STAR Nurse's tasks and competences.~Although the intervention will be detailed through phase 1 (integrative review) and 2 (Delphy methodology).~It is expected that the main STAR nurse's competencies and tasks in the nurse's office will be:~To guarantee a comprehensive evaluation and appropriate triage to candidates for an interventional procedure of structural heart disease, coordinating the request for complementary tests and previous visits.~Make education to the patient and family.~Make communication bridge with cardiologists.~Establish specific patient-centered care processes.~Promote continuity of care after discharge, follow up after discharge, and reevaluate quality of life and fragility."
75637251|NCT04301648|Other|Common Practice|Common practice will consist in that the nurse who is in the hemodynamic nurse's office will do her usual task that is exclusively health education.
75637252|NCT04833309|Procedure|pharmacopuncture therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and dosage will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
75786431|NCT05572060|Drug|Metformin|Patient screening will be done using SOFA scoring and NEWS Supplemental oxygen will be supplied. Intubation and mechanical ventilation may be required Venous access will be established.CBC, chemistries, liver function tests,coagulation studies ,Peripheral blood cultures, urinalysis, microbiological cultures from suspected sources (eg, sputum, urine,etc),(ABG) and serum lactate will be obtained Crystalloids will be given at 30 mL/kg, started by one hour and completed within three hours Empiric antibiotic therapy is targeted at the suspected organism(s) In patients with lactic acidosis and severe acidemia, Sodium bicarbonate will be used to maintain the arterial pH above 7.15 In patients having persistent hypoperfusion vasopressors will be added Evaluation of volume status will be done using straight leg raising test and ultrasound guided IVC collapsibility index Plasma rennin, serum lactate and IL6 concentrations will be measured on admission and at one week.
75786432|NCT05572060|Other|standardized protocol|standardized protocol
75786433|NCT05431244|Drug|Antiviral treatment in combination with low-dose gemcitabine|-maximun 6 cycles Gemcitabine; 30mg/m2 or 100mg/m2 or 300mg/m2 D1,D8, D15 (Q 1 week,3 times, rest for 1 week, every 4 weeks ) 1,2 cycle Valganciclovir; 900mg D8~D28 (from 1 week after Gemcitabine iv started, qd, PO, 21days) 3~6cycle Valganciclovir; 900mg D1~D28 (from Gemcitabine start date, PO, 28days)
75922709|NCT03513198|Other|Endoscopic ultrasound elastography (EG-EUS)|"EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD~The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided~The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.~SR and SH will be measured; with three measurements made and recorded on the embedded HDD."
75329972|NCT04825743|Drug|zalunfiban|zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
75922710|NCT03513198|Diagnostic Test|Contrast-enhanced computed tomography (CT)|"Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.~A template will be used to report the imaging results.~The template includes morphologic, arterial, venous, and extrapancreatic evaluations.~Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)."
75922711|NCT03369548|Other|Apple|2 Renetta Canada apples and 2 placebo capsules/ day
75922712|NCT03369548|Other|Oats|40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules / day
75329973|NCT04825743|Drug|Placebo|A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
75329974|NCT01575925|Drug|4 mg Oral POM + 40 mg Oral DEX|
75469954|NCT01945515|Device|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
75469955|NCT01945528|Drug|US-guided tenotomy with PRP|"Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure"
75329975|NCT01575925|Drug|2 mg Oral POM + 40 mg Oral DEX|
75329976|NCT03121612|Device|CPAP|CPAP therapy
75329977|NCT00978445|Other|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
75329978|NCT04818645|Device|Confirm Rx Insertable Cardiac Monitor|Subjects will be subcutaneously implanted with an Abbott Confirm Rx ICM with the device implant procedure per standard of care and current labelling. Data related to subjects' arrhythmias, via the Merlin.net Patient CareNetwork will be transmitted on a monthly basis to the treating physician and subsequently to the study coordination and database center (CCRC) at the University of Rochester. Data on the frequency/types of symptomatic (patient triggered) versus ICM detected (asymptomatic) arrhythmic events will be collected and adjudicated. Clinical data on medication, device interventions, cardiovascular events will be collected at follow-up visits.
75329979|NCT04818645|Other|Conventional Management and monitoring|Subjects randomized to the conventional management arm of the trial will undergo arrhythmia monitoring based on clinical indications and per standard available modalities including periodic electrocardiograms (ECG), Holter and/or event monitoring.
75329980|NCT00936377|Drug|Dexmedetomidine|Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
75469956|NCT01945528|Drug|US-guided tenotomy with lidocaine|Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
75469957|NCT01945541|Device|Body Composition Monitoring|Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
75469958|NCT01945554|Procedure|Cervical nerve root infiltration|4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.
75469959|NCT01945554|Procedure|Lumbar nerve root infiltration|40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.
75469960|NCT01945554|Drug|Mephamesone|
75637253|NCT04833309|Procedure|physical therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and body part will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
75637254|NCT02872766|Device|CXL Myopia|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
75329981|NCT00936377|Other|Placebo|Normal saline for five days.
75329982|NCT03022357|Other|Patient assessment|Clinical examination, Examination, Questionnaires
75329983|NCT03022357|Radiation|DATScan|In small subgroup
75329984|NCT03022357|Radiation|Orbital X-Ray|If foreign body in eye needs exclusion
75329985|NCT03022357|Other|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
75329986|NCT03123874|Device|Sterile pump set-up|Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
75329987|NCT03123874|Device|Mother's Own pump set-up|Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
75329988|NCT03124342|Other|VANDERBILT ICU RECOVERY PROGRAM|"10-component ICU Recovery Program intervention, including:~Nurse Practitioner In-Person Visit at the time of transfer from the ICU~Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources~Performance of formal medication reconciliation at the time of transfer from the ICU~Access to a dedicated 24-hour a day, 7-day a week contact line~ICU Recovery Clinic Visit Medical Examination.~ICU Recovery Clinic Medication Reconciliation and Counseling~ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist~ICU Recovery Clinic Case Management. A brief case management consultation~ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician~Directed Subspecialty Referrals"
75329989|NCT04359095|Drug|Emtricitabine/tenofovir|Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.
76078983|NCT05389566|Diagnostic Test|Dual Energy X-ray Absorbtimetry scan|Evaluation of body composition
75329990|NCT04359095|Drug|Colchicine Pill|Generic drug distributed by the Colombian Health System as an insurance treatment for Gout. It has been suggested that colchicine would be useful in SARS Covid 19 becouse its antiinflammatory effects through reduction of cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome
75329991|NCT04359095|Drug|Rosuvastatin|Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses
75469961|NCT01945554|Drug|0.5% bupivacaine (Bupivacain®)|
75469962|NCT01945554|Drug|Kenacort®|
75637255|NCT02772861|Dietary Supplement|Amino Acid Supplement - One dose|20gr
75637256|NCT02772861|Dietary Supplement|3-Methylhistidine|120mgr
75637257|NCT01034540|Drug|POM3|4 g/day
76078984|NCT05389566|Diagnostic Test|Force Plate Platform|Evaluation of balance while standing still
76078985|NCT01168726|Behavioral|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
76078986|NCT01168726|Behavioral|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
76078987|NCT01168726|Behavioral|Alcohol Education|Educational information about harms associated with heavy drinking.
75469963|NCT01945567|Device|Up to 3 mA, 60 us, 130 Hz deep brain stimulation|
75469964|NCT01945567|Device|Empirical unblinded deep brain stimulation programming|
75469965|NCT01945606|Drug|Placebo (treatment 1)|Oral administration of placebo tablets
75469966|NCT01945606|Drug|BAY1067197 (treatment 2)|Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
75469967|NCT01945619|Biological|Trivirus-Specific CTLs|Patients will receive up to 2 x 10^7 CHM-CTL/m2 as a single infusion and may receive up to 4 additional infusions at intervals of at least 2 weeks.
75469968|NCT01945632|Device|conventional gracey curettes|
75469969|NCT01945632|Device|Vertically oscillating ultrasonic device|
75469970|NCT01945632|Device|piezoelectric ultrasonic scraper|
75469971|NCT01945645|Behavioral|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
75637258|NCT01034540|Drug|Placebo|matching placebo capsule, 4 g/day
75637259|NCT02775981|Drug|RX0041-002|
75637260|NCT02776059|Drug|Standard of care + pegfiltrastim|prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
75637261|NCT02776059|Drug|Standard of care|Oral prednisolone or pentoxifyline for 28 days only
75637262|NCT02772627|Drug|Nebicapone|Nebicapone 100 mg tablets; oral route.
75637263|NCT02772627|Drug|Placebo|Placebo tablets; oral route.
75637264|NCT00774930|Drug|Lanreotide|deep s.c. injection, 120 mg, every 4 weeks (±3 days).
75798680|NCT01287234|Other|Echocardiogram/SonR|All patients will have an echocardiograph and SonR sensor readings
75922713|NCT03369548|Dietary Supplement|Lactobacillus reuteri NCIMB 30242|2 probiotic capsules and 40g cornflakes with semi-skimmed milk / day.
75329992|NCT04359095|Other|Standard treatment|Standard treatment n, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient. No viral therapies are included.
75329993|NCT05402956|Behavioral|Aerobic exercise|Moderate aerobic exercise training
75469972|NCT01945684|Drug|Botulinum toxin type A|Maximum dose 360 U
75469973|NCT01945736|Drug|Methadone|To determine the PK of enteral methadone in children > or = 90 days and <18 years treated for opiate withdrawal per routine medical care.
75469974|NCT01945749|Drug|Intraarticular steroid|1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided.
75469975|NCT01945749|Drug|Intraarticular saline|1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
75469976|NCT01945749|Other|Exercise therapy|"The exercise is commenced 2 weeks after injection.~The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.~In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities."
75637265|NCT00774930|Drug|Placebo|deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
75637266|NCT02775825|Other|survey|
75637267|NCT02772471|Device|HS-1000|
75651776|NCT05608057|Other|Vitamin C mesotherapy|Vitamin C intra-mucosal injection; in which the site of interest will be anesthetized using a topical anesthetic agent (lidocaine gel or xylocaine gel) or infiltration anesthesia, followed by intra-mucosal field injections of 1-1.5 ml Cevarol (L-Ascorbic acid 1000 mg/5 ml
75651777|NCT05608057|Radiation|Diode laser|Diode laser ablation: in which the site of interest will be anesthetized using infiltration anesthesia, followed by laser ablation. 980nm Diode laser will be applied using the following setting parameters: continuous mode with 980nm wavelength at 1.5 W output power.
75786434|NCT05571982|Procedure|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
75786435|NCT05571982|Procedure|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
75786436|NCT01314040|Other|Run in diet|Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other
75786437|NCT01314040|Other|High meat protein diet|Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.
75329994|NCT05345080|Behavioral|Exposure-Reduction Intervention|The customized exposure-reduction intervention includes a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), and a customized asthma self-management and exposure-reduction plan developed using motivational interviewing techniques, support, and exposure-reduction supplies.
75329995|NCT04359251|Other|Gas exchanges at different PEEP|Gas exchanges measurement at different PEEP
75329996|NCT04359251|Other|lung mechanics at different PEEP|lung mechanics measurement at different PEEP
75329997|NCT04359251|Other|Hemodynamics changes at different PEEP|Hemodynamics changes measurement at different PEEP
75329998|NCT02163421|Drug|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
75329999|NCT02163421|Drug|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
75330000|NCT05320510|Dietary Supplement|Se-yeast|The participants will be asked to take Se-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
75469977|NCT01945762|Drug|Vandetanib 300 mg|Vandetanib commercial tablets
75469978|NCT01945788|Drug|Teriparatide (rDNA origin)|
75651778|NCT05602402|Other|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
75786438|NCT01314040|Other|High dairy protein diet|Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy
75786439|NCT01314040|Other|High grain protein diet|Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
75786440|NCT03850184|Diagnostic Test|The Exercise in Mental Illness Questionnaire (EMIQ)|Questionnaire assessing prescription behaviour, knowledge, barriers and behaviour of physical activity in mental health professionals
75786441|NCT05425888|Other|Hemophilia group|Evaluation of the study variables: dorsal flexion; dorsiflexion strength; tibialis anterior muscle activation; biomechanical analysis of gait and balance; and functionality.
75786442|NCT04923308|Other|Triage results disclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will be communicated to the specialist using a standardized clinical note, prior to the patient's consultation and without further discussion.
75786443|NCT04923308|Other|Triage results undisclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will not be communicated to the specialist.
75786444|NCT03182972|Other|Medication reconciliation|Pre-post intervention
75922714|NCT03369548|Other|Cornflakes|40g cornflakes with semi-skimmed milk and 2 placebo capsules/ day.
75330001|NCT05320510|Dietary Supplement|Placebo|The participants will be asked to take placebo-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
75469979|NCT01945801|Drug|Lasilactone|Active drug (spironolactone 100 mg plus furosemide 20 mg).
75922715|NCT02150577|Behavioral|Evidence Based Quality Improvement|Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
75469980|NCT01945801|Other|Sodium-Restricted Diet|The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.
75330002|NCT02982317|Procedure|Manual palpation identification lumbar spine|
75330003|NCT02982317|Procedure|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
75330004|NCT02982317|Procedure|Lumbar level identification gold standard ultrasound|
75330005|NCT04737148|Other|Mortality scores|Revised Baux, BOBI and FLAMES scores
75469981|NCT01945801|Drug|Placebo|The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
75469982|NCT05410990|Diagnostic Test|eosinophil and other hematological parameters|
75469983|NCT05410769|Behavioral|Compassion Focused Therapy|This pilot study aims to propose for the first time a Compassion protocol (Compassion Program for Parkinson) to a group of patients with PD and a group of caregivers and to evaluate its feasibility and effectiveness. The investigators aim to assess whether the program is effective in improving the quality of life and psychiatric symptoms of the patients and caregivers. The Compassion program is a healthy form of self- acceptance, which involves being touched by one's own suffering, along with the desire to alleviate it and treat oneself with understanding and kindness. The duration of the protocol will be 6 weeks (1 meeting/ week of 2 hours). The investigators will recruit 40 patients and 20 caregivers who will be assessed pre and post intervention (Compassionate Mind Training) with interviews, self reports and measurement of the heart rate variability.
75469984|NCT05410717|Biological|Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells|"Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy."
75637268|NCT04201626|Procedure|Adapted ERAS|"Each woman in the intervention group will attend a preoperative counseling session with nurse and doctors. In addition to the standard preoperative counseling, explaining the purpose, process, and the importance of ERAS protocol compliance will be added to the session. Preoperative nutrition and laboratory assessment will be done according to adapted ERAS protocol on that same visit.~During admission, the intervention group participants are provided with care according to adapted ERAS protocol including no bowel preparation, no extended fasting before surgery, balanced intravenous crystalloid, thromboprophylaxis, multimodal pain control reducing opioid usage, multimodal anti-emetics medications, stepping diet up to regular diet within 24 hours, chewing gum for post-operative ileus prevention, early removal of Foley's catheter, and promote early ambulation using care checklist plan."
75637269|NCT02775747|Biological|platelet rich plasma gel|Platelet rich plasma is prepared from fresh whole blood which is collected from a peripheral vein stored in acid citrare dextrose solution A (ACD-A)anticoagulant and processed to increase platelets by separating various components of blood
75922716|NCT03373994|Diagnostic Test|18F-FDG PET/CT initial-time imaging|18F-FDG intravenous bolus injection after a fasting perid of more than 6 hours, simultaneously,PET/CT imaging using one bed lasting 5 minutes was underwent.
75922717|NCT03373994|Diagnostic Test|18F-FDG PET/CT balanced-time imaging|18F-FDG intravenous injection after a fasting perid of more than 6 hours. After 60 minutes, PET/CT imaging using 6-7 bed positions each lasting 2 minutes was underwent.
75330006|NCT02982395|Drug|Nanoxel®M|Intravesical
75330007|NCT02982395|Drug|Mitomycin-C|Intravesical
75469985|NCT05410704|Other|exercises|Pelvic floor muscle exercises and diaphragmatic breathing exercise
75469986|NCT05410691|Device|Handheld US device|Handheld US-guided AVF/AVG cannulation
75469987|NCT05410678|Drug|Renal stent|renal stent implantation in ectatic/aneurysmatic coronary arteries
75637270|NCT02775747|Biological|saline|64 controlled women with recurrent cesarean section and fullfit to all inclusion and exclusion craiteria will reseve saline injection at time of wound closure
75922718|NCT03520764|Dietary Supplement|New infant formula with synbiotics|Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.
75922719|NCT03520764|Dietary Supplement|Standard infant formula with prebiotics|Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.
75922720|NCT03369470|Behavioral|App Dexterity|App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)
75922721|NCT03369470|Behavioral|Theraband|Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
75469988|NCT05410665|Procedure|Standard treatments for sepsis|Standard treatments for others
75922722|NCT04640038|Drug|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
75330008|NCT00979069|Behavioral|Aerobic group|12 weeks of aerobic exercise 3 times a week
75330009|NCT03124966|Device|Pulse Oximeter sensor|
75330010|NCT02982005|Drug|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 62.
75330011|NCT02982005|Drug|Placebo|Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
75330012|NCT00979303|Device|Intracardiac echocardiography and 3D navigational system|Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
75330013|NCT04333264|Procedure|suction drainage|After primary total hip arthroplasty closed suction drainage will be used.
75330014|NCT04333264|Procedure|no suction drainage|After primary total hip arthroplasty closed suction drainage won't be used.
75330015|NCT04736836|Drug|Rifaximin|locally absorbed antibiotic
75922723|NCT02296008|Device|3D high resolution anorectal manometry|"Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.~3D picture of pressures of anorectal will be recorded."
75330016|NCT03021109|Device|Measurement of inferior vena cava diameters with ultrasound|The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
75469992|NCT05410639|Other|online education program|The training we provided was to give exercises and advice to parents according to the age of the baby in order to stimulate the motor and social development of the baby,and then, an improvement in the stress state of the parents by their participation in the care of their baby.The training, which began with the discharge of the baby from the hospital, was in the form of slide presentations and videos.
75469993|NCT05410639|Other|no online education program|Parents and their infants in the control group did not receive any online education program
75637271|NCT05335200|Diagnostic Test|(S)-[18F]FBFP PET/CT|Patients will be intravenously injected with 185-370MBq (S)-[18F]FBFP and undergo serial whole-body PET/CT scans at multiple time points (5min, 15min, 30min, 45min, 1h, 2h, 4h). Safety assessment and tolerability of the study will be conducted.
75637272|NCT02841774|Drug|Pravastatin|40mg daily (Weeks 2 - 14)
75637273|NCT02841774|Drug|Rosuvastatin|20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK <+1.5 x ULN, and LDL-c is >60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
75637274|NCT02772315|Other|omics|diagnostic procedures applying omics results
75637275|NCT02841384|Other|taping patellar McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
75637276|NCT02841384|Other|Placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
75637277|NCT02772237|Biological|Riboflavin|Riboflavin 400mg daily
75637278|NCT02772237|Biological|Placebo|
75637279|NCT02841306|Drug|Ursodeoxycholic Acid|
75637280|NCT04225689|Other|CD-TREAT diet|Dietary intervention
75786445|NCT05571826|Behavioral|telerehabilitation|No specific treatments will be applied. The persons who experienced telerehabilitation interventions will be included.
75786446|NCT05072288|Other|Remote activity program|Participant will have to do exercise at home everyday (15min/day)
75922724|NCT03378284|Drug|Tegoprazan|Tegoprazan QD for 7 days
75922725|NCT03378284|Drug|Revaprazan|Revaprazan QD for 7 days
75922726|NCT03516396|Behavioral|Training Plus|Training plus enhanced community development activities
75922727|NCT03516396|Behavioral|Training Only|Training Only (livestock management and child nutrition) for 24 months then add community development inputs
75922728|NCT03516396|Behavioral|No Inputs then Community development and training|No inputs for 24 months then add community development and training
75330017|NCT03126370|Drug|TDF with a boosted protease inhibitor|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment"
75330018|NCT03126370|Drug|TAF with a boosted protease inhibitor|"Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment"
75637281|NCT01027364|Drug|Factor IX (rFIXFc)|
75637282|NCT01027364|Drug|rFIX|
75637283|NCT01316250|Drug|Nilotinib|Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
75637284|NCT02771925|Drug|Gabapentin 2g/day divided in two doses for 24 weeks|"Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.~All patients will receive standard of care treatment."
75637285|NCT02771925|Drug|Placebo 2g/day divided in two doses for 24 weeks|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
75786447|NCT04916912|Procedure|coronary artery bypass grafting|Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
75786448|NCT03850106|Dietary Supplement|Placebo|Placebo
75786449|NCT03850106|Dietary Supplement|Indus810|Active product
75786450|NCT01199432|Drug|5-FU（intravenous infusion）+epirubicin+cyclophosphamide|5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
75922729|NCT03369392|Other|Panda application|A smartphone-based postoperative pain management tool
75922730|NCT02617550|Drug|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
75637286|NCT03205956|Drug|Levodopa|"At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above."
75786451|NCT01199432|Drug|5-FU（intravenous bolus）+epirubicin+cyclophosphamide|5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
75637287|NCT02840994|Biological|CV301|
76078988|NCT01170754|Drug|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
75922731|NCT02617550|Drug|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets [o.d.].
75330019|NCT03126370|Drug|TAF with a boosted protease inhibitor and LDV/SOF|"After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment"
75637288|NCT02840994|Biological|Pembrolizumab|
75637289|NCT02840994|Biological|Nivolumab|
75637290|NCT02775591|Drug|DA-9701|DA-9701 30mg Tablet
75637291|NCT02775591|Drug|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
75786452|NCT01199432|Drug|epirubicin+cyclophosphamide|epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
75922732|NCT02617550|Drug|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat [trough] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat [peak] or placebo) on day 13, day 27 and day 41
75922733|NCT03512886|Other|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
75922734|NCT03512886|Other|Single task training|An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
75922735|NCT03369314|Drug|octaplasLG®|Data will be collected in all patients who have received at least one infusion of octaplasLG®
75922736|NCT05533840|Diagnostic Test|ultra-high-resolution computed tomography exams|Participants in the age groups undergo ultra-high-resolution computed tomography exam
75922737|NCT03520530|Device|Mouth Guard|Patient will wear mouth guard while pushing in the second stage of labor
75922738|NCT03378206|Device|hinged 8-figure plate|Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.
76078989|NCT01170754|Drug|Golytely 4 liters|Golytely 4 liters
76078990|NCT02522832|Other|Titre 1|Virus infection
75330020|NCT00979459|Drug|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
75330021|NCT00979459|Drug|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
75637292|NCT02771847|Behavioral|survey|anonym survey is given to people
75637293|NCT02844036|Procedure|Percutaneous angioplasty|
75637294|NCT02844036|Procedure|Balloon angioplasty|
76078991|NCT02522832|Other|Titre 2|Virus infection
76078992|NCT02522832|Other|Titre 3|Virus infection
75330022|NCT03126448|Diagnostic Test|Highly Sensitive Assays|Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.
75637295|NCT02844036|Procedure|Right heart catheterization|
75637296|NCT02844036|Procedure|Echocardiography|
75637297|NCT02844036|Other|A six-minute walking test|
75637298|NCT02844036|Procedure|Functional respiratory investigations|
75637299|NCT02844036|Procedure|Pulmonary tomography or pulmonary angiography|
75637300|NCT02844036|Other|Biological parameters|
75637301|NCT02771457|Drug|Infliximab at weeks 0,2, and 6|
75637302|NCT02771457|Drug|Infliximab at weeks 0,4, and 8|
75637303|NCT02771457|Drug|Infliximab at weeks 0 and 8|For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
75637304|NCT01027286|Device|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
75786453|NCT05064020|Drug|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.
75786454|NCT05058560|Drug|Tislelizumab|tislelizumab, 200 mg IV Q3W, up to one year.
75786455|NCT01293422|Drug|Rifampicin|Rifampicin 600 mg daily for a week
75786456|NCT01190774|Behavioral|Information to health provider without patient knowledge|The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
75786457|NCT01190774|Behavioral|dentist behaviour and patient expectancy|patient give information about their dental anxiety to the dentist
75798681|NCT03859284|Other|flowable resin composite|gold standard
76078993|NCT05166330|Drug|Ketofol equal ratio|5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine
76078994|NCT05166330|Drug|Ketofol 1:3 ratio|15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
76078995|NCT01378104|Drug|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
75637305|NCT02771769|Other|blood draw|Participants will have a venous blood draw of ~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
75786458|NCT03850262|Radiation|MRI|"The study will be done on 1.5T MR unit (Siemens) and 1.5T MR unit (Philips) at Assuit University Hospital, or 1.5T MR unit (G.E.) at Eman General Hospital.~The field of view varied between 14 cm and 16 cm, and slice thickness varied between 3 and 4 mm, with 0.5 mm intersection gap.~Imaging sequences included sagittal PD proton density, T2 and STIR, axial PD, coronal STIR and coronal oblique."
75922739|NCT03378206|Device|conventional 8-figure plate|Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
75922740|NCT03512808|Drug|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
75637306|NCT02843802|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
75637307|NCT02843802|Biological|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
75637308|NCT02771379|Drug|Idebenone|Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
75637309|NCT00627770|Device|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
75637310|NCT01026870|Drug|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
75637311|NCT01026870|Drug|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
75637312|NCT02771535|Behavioral|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
75637313|NCT02771535|Behavioral|Health Training|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
75637314|NCT02771691|Other|Mentalization-Based Group Therapy for Adolescents|
75637315|NCT02696811|Dietary Supplement|White carrots|White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
75922741|NCT03512808|Drug|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
75922742|NCT05533762|Device|arch insole and sham insole|children wear insoles on feet
75922743|NCT03520452|Other|Green coffee extract|Reconstituted in water and given to subjects
75637316|NCT02696811|Dietary Supplement|Oat biscuits|The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
75922744|NCT03520452|Other|Placebo|Placebo
75922745|NCT02519582|Drug|Niclosamide|2 g per day orally
75922746|NCT03512730|Device|Titanium brush|a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis
75922747|NCT03512730|Other|Classic decontamination|Classic decontamination will be performed by means of H2O2 3% and plastic curettes
75922748|NCT03378050|Behavioral|HEART|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training."
75922749|NCT03378050|Other|Usual Care|"Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
75922750|NCT05167968|Other|No intervention (Observational cohort)|"For each patient, evaluation and adhesion to diuretics at inclusion are recorded:~Self-questioning of medication adherence: Girerd questionnaire~Assessment of the Medication Possession Ratio~Social and demographic data~Comorbidities~PH characteristics"
75922751|NCT03516318|Behavioral|SMART Connections|SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
75637317|NCT02841228|Radiation|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
75637318|NCT02844114|Drug|Ganoderma lucidum spore|G 300mg, 5 tablets by mouth
75637319|NCT02844114|Drug|Placebo|Sugar pill manufactured to mimic tramadol 1500mg tablet
75637320|NCT02844114|Drug|Chemotherapy|iv.30 minutes
75637321|NCT04810143|Device|Mitra Microsampler|an FDA Class I medical device for direct specimen collection of blood or other biological fluids
75637322|NCT05334498|Other|Motor dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed tossing and catching the ball, rehanging loops on hoops, buttoning and unbuttoning the shirts, holding the cup in water without the spilling and receiving with returning the water. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
75786459|NCT01198886|Other|Successful Aging Program|Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.
75798682|NCT03859284|Other|self adhering flowable|moist bonding self adhering flowable composite
75469994|NCT05410626|Drug|prolong-release methylphenidate|This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
75922752|NCT05467462|Drug|I.V carbetocin administration|Group I: carbetocin was intravenously administered immediately after birth of the baby.
75922753|NCT05467462|Drug|I.V Oxytocin administration|Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
75922754|NCT05467462|Drug|I.V carbetocin and tranexamic acid administration|Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
75922755|NCT05467462|Drug|I.V Oxytocin and tranexamic acid administration|Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
75469995|NCT05410613|Combination Product|electromagnetic field and a plantar resistance exercise|"Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz.~a plantar resistance exercise therapy by the StepIt rocker pedal, the overall exercise program will be to exercise on the pedal with the index leg for 1 min - then rest it for 1min - and to repeat this 10 times (20 minutes). This regime will be done twice daily (e.g .morning and evening)."
75922756|NCT03373838|Other|Census|Survey and interview
75922757|NCT03516240|Other|Biofreeze|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.
75922758|NCT03516240|Other|Placebo|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
75330023|NCT01019707|Drug|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
75469996|NCT05410613|Device|Pulsed electromagnetic field|Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz
75637323|NCT05334498|Other|Cognitive dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed sharp coloring, subtraction, counting, verbal analogical reasoning and backward spelling. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
75330024|NCT01019707|Drug|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
75469997|NCT05410613|Other|usual care|standard general advice according to hospital protocol
75469998|NCT05410535|Drug|Patients who continued UDCA 300mg medication|patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
75469999|NCT05410535|Other|Patients who discontinued UDCA 300mg prescription|patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
75470000|NCT05410522|Device|EMS Program|Lower limb electrostimulation therapy is scheduled for lung transplant patients. The therapy consists in the application of 2 daily 30-minute sessions that begin in the first 48 hours post-transplantation and are maintained daily until discharge from the hospital.
75470001|NCT05410483|Drug|Docetaxel|Hyperthermic Intraperitoneal Docetaxel
75470002|NCT05410470|Drug|Ruxolitinib|
75637324|NCT02775357|Behavioral|Measurement and communication of HIV risk|Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling
75637325|NCT02775357|Behavioral|Standard HIV testing and counseling|Participants received HIV testing and counseling following standard Ministry of Health guidelines
75637326|NCT05335980|Device|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
75637327|NCT05335902|Diagnostic Test|ultrasound measurement of the optic nerve sheath diameter|ultrasound measurement of the optic nerve sheath diameter
75922759|NCT03516162|Other|There is no study-specific intervention|There is no study-specific intervention
75922760|NCT03369002|Drug|seladelpar|Oral single dose 10 mg
75922761|NCT03520296|Other|Questionnaire|Questionnaire evaluating well-being in relation to diet and nutrition
75470003|NCT05410444|Device|Clean Intermittent Catheterization|Under clean conditions, the method of regularly inserting the urinary catheter into the bladder through the urethra and emptying the urine regularly is called clean intermittent catheterization.
75922762|NCT03373526|Other|Inspiratory Muscle Training|The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.
75637328|NCT05335902|Diagnostic Test|MoCA test|MoCA test is a short bedside test for measuring cognitive disfunction
75637329|NCT02696733|Device|Ultrasound|Ultrasound-guided obturator nerve localization
75330025|NCT04457271|Behavioral|Goal Management Training (GMT)|GMT is a structured, short-term cognitive remediation program with an emphasis on mindfulness and practice in planning and completion of goal-oriented behaviours. The main objective of GMT is to help participants regain executive control in order to better define goals and monitor performance in achieving them. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Mindfulness meditation is also incorporated for the purpose of developing the skill of bringing one's mind to the present to monitor ongoing behaviour, goal states, and the relationship between them, and for the development of attentional control. The program incorporates real-life examples to illustrate goal attainment failures and successes, as well as in-session practice of complex tasks that mimic real-life tasks - typically a challenge for individuals with executive function deficits (e.g., planning and set-shifting tasks).
76078996|NCT01378104|Drug|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
75330026|NCT00979615|Drug|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
75330027|NCT00979615|Drug|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
75637330|NCT02696733|Drug|lidocaine 2%|local anesthetic used to block the obturator nerve
75637331|NCT02696733|Drug|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
75637332|NCT02771613|Other|Multi professional in situ simulation|After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
75637333|NCT02771613|Other|Large diffusion of information|After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
75637334|NCT02771301|Biological|dendritic cells|Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
75637335|NCT02771067|Procedure|Fluid infusion|Fluid infusion will be performed using 6% hydroxyethyl starch. Pulse pressure variation and stroke volume will be measured before and after fluid infusion.
75637336|NCT02775123|Device|Cytosorb|A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
75637337|NCT02770989|Procedure|Vimecon Laser CAI percutaneous cardiac ablation|The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
75637338|NCT02775201|Procedure|Plantaris release under ultrasound guidance|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
75330028|NCT03126682|Drug|Wellbutrin SR 300Mg Extended-Release Tablet|Wellbutrin SR 300Mg Extended-Release Tablet
75637339|NCT02775201|Procedure|Plantaris excision surgically|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
75637340|NCT01026974|Biological|rMenB|
75330029|NCT05236738|Drug|Atazanavir|Specified dose on specified days
75330030|NCT05236738|Drug|Cobicistat|Specified dose on specified days
75637341|NCT01026974|Biological|rMenB+OMV NZ|
75637342|NCT02770911|Procedure|"without Dog Ear group"|a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection
75637343|NCT02770911|Procedure|"with Dog Ear group"|a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
75637344|NCT04225299|Drug|TOOKAD®|TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
75637345|NCT02775045|Other|Observation Period|8 week observational period
75922763|NCT03373526|Other|Aerobic Training|The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
75330031|NCT05236738|Drug|Atazanavir/Cobicistat Mini-tablet|Specified dose on specified days
75470004|NCT05410444|Device|Indwelling catheterization|A catheter is inserted into the bladder through the urethra to drain urine. The catheter has been left in the patient's body.
75470005|NCT05410431|Other|clinical and radiologic manifestations of rare presentations of Dermoid cyst|
75637346|NCT02774967|Procedure|root coverage|Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
75637347|NCT00897390|Drug|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
75637348|NCT00897390|Drug|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
76078997|NCT03344250|Drug|EGFR BATs with TMZ following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
75470006|NCT05410405|Procedure|implant site preparation|piezoelectric bone surgery osseodensification drills
75637349|NCT00897390|Drug|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
75922764|NCT02778399|Drug|Placebo|Placebo tablets for oral administration once daily
75922765|NCT02778399|Drug|OBE2109|OBE2109 tablets for oral administration once daily
75922766|NCT03520218|Device|Performance of R-PEM|R-PEM imaging will produce high-sensitivity images with low levels of F-18 FDG and optional subsequent scans performed will display reduced levels of the injected radiotracer.
75922767|NCT03377894|Procedure|blunt uterine incision expansion|blunt uterine incision expansion
75922768|NCT03377894|Procedure|sharp uterine incision expansion|sharp uterine incision expansion
75637350|NCT01034462|Drug|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
76078998|NCT03344250|Drug|Weekly EGFR BATs following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
76078999|NCT01130740|Behavioral|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
76079000|NCT05397288|Behavioral|Resistance exercise (R)|"A 6-month program led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) sessions (45 mins each) are delivered in a tapering schedule:~1st month: group practice (1 time/week), home visits (2 times/week)~2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~3rd month: group practice (1 time/week), phone calls (2 times/week)~4th month: phone calls (2 times/week)~5th month: phone calls (1 time/week)~6th month: weaning period"
75330032|NCT00980395|Drug|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
75330033|NCT00980395|Drug|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
75330034|NCT00980395|Drug|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
75330035|NCT03072550|Device|RenewalNail™ Plasma Treatment System|application of cold atmospheric plasma to a fungal infected toenail
75330036|NCT01021111|Device|Activity Training with Feedback|The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
75637351|NCT01034462|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
75637352|NCT04176627|Device|Lung ultrasound|One-time lung ultrasound study completed on peritoneal dialysis patients at monthly clinic visit
75330037|NCT02976597|Drug|Bupivacaine 0.25% 20ml on each side Sonar guided TAB|Bupivacaine 0.25% 20ml on each side Sonar guided TAP block. After careful aspiration injection of 20ml of 0.25% bupivacaine will be performed and hypoechoic layer will be detected on ultrasound then the maneuver will be repeated on the other side
75330038|NCT02976597|Drug|Morphine 10mg|Morphine 10mg will be added to bupivacaine in sonar guided- TAP block divided into 5mg on each side.
76079001|NCT05397288|Behavioral|Aerobic exercise (A)|"A 6-month programs led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) (45 mins each) are delivered in a tapering schedule:~1st month: group practice (1 time/week), home visits (2 times/week)~2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~3rd month: group practice (1 time/week), phone calls (2 times/week)~4th month: phone calls (2 times/week)~5th month: phone calls (1 time/week)~6th month: weaning period"
76079002|NCT05397288|Behavioral|Healthy lifestyle education (E)|"A 6-month program led by retired nurses covering topics including nutrition, sleep, medication, cognition, and exercising. During the 6-month program, group talks and individual consultation (45 mins each) are delivered in a tapering schedule:~1st month: group talk (1 time/week), individual consultation (2 times/week)~2nd month: group talk (1 time/week), individual consultation (1 time/week), phone call (1 time/week)~3rd month: group talk (1 time/week), phone calls (2 times/week)~4th month: phone calls (2 times/week)~5th month: phone calls (1 time/week)~6th month: weaning period"
76079003|NCT04453644|Other|Muscle static stretching|On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
76079004|NCT05166174|Procedure|Transvaginal ultrasound in the third trimester pregnancy|Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
76079005|NCT05396976|Behavioral|Yoga and Muscle Relaxation Exercise Practices|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
76079006|NCT01131052|Drug|Insulin Glargine|glargine once a day
76079007|NCT01131052|Drug|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
75330039|NCT02976597|Drug|Morphine 15mg|Morphine 15mg will be added to bupivacaine in sonar guided- TAP block divided into 7.5mg on each side.
75330040|NCT03020329|Drug|Paclitaxel liposome|"Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy.~Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.~Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily."
75637353|NCT01033448|Drug|COPEGUS|COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
75637354|NCT01033448|Drug|peginterferon alfa-2a [Pegasys]|PEGASYS 180 micrograms sc once weekly for 24 weeks
75637355|NCT02843724|Other|Naturopathic Care|Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion
75637356|NCT02843724|Other|Usual (Conventional) Care|2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
75637357|NCT02774655|Device|Pai APP|prescribed 100 PAI weekly
75637358|NCT02774655|Device|FitBit APP|prescribed 10000 steps daily
75651779|NCT05602402|Other|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
75651780|NCT05594693|Other|Questionnaire|Electronic self-report questionnaires before and after integrative interventions, and monthly.
76079008|NCT01131052|Drug|Insulin glulisine|glulisine given as needed before meals
75470007|NCT05410314|Drug|Myo-Inositol and D-Chiro-Inositol (MIC)|Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).
75470008|NCT05410275|Drug|Rivaroxaban|Experimental group Each patient will receive successively over 3 distinct periods the 3 doses of rivaroxaban to be evaluated, i.e., 5 mg, 10 mg, and 15 mg as a single daily dose (once daily over 3 days for each dose).
75637359|NCT04754607|Other|Low-Level Laser Therapy|Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.
75637360|NCT02873390|Biological|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
75637361|NCT02770833|Other|Fish and carbohydrats with low or high GI|
75637362|NCT02770833|Other|Veal and carbohydrats with low or high GI|
75330041|NCT03020329|Drug|Cisplatin|Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.
75330042|NCT03020329|Drug|5-fu|Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.
75330043|NCT03020329|Radiation|Radical radiotherapy|Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.
75330044|NCT05395975|Device|Oxygen Reserve Index|It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg< PaO2 ≤ 200 mmHg).
76079009|NCT03687138|Other|24h urin sample|The samples will analyzed by proteomic techniques
75637363|NCT05335824|Other|The platelet-rich plasma (PRP)|"Twenty ml of venous blood was drawn from each patient with the use of PRP tubes that contain anticoagulant citrate dextrose. The double-spin technique was used to prepare the PRP. The injection areas were anesthetized with lidocaine 2% with epinephrine 1/80000 and left for 10 minutes. 15 units (0. 15 mL) of PRP were injected interaligamentlly in the middle, distobuccal, and distopalatal areas of the distal surface of the upper canines (5 units in each area) together with submucosal injections buccally and palatally (100 units and 50 units~, respectively)."
75330045|NCT00980785|Drug|Ramipril|Ramipril 5 mg/day
75330046|NCT00980785|Drug|Placebo|Matching Placebo
75330047|NCT04772547|Drug|Vigabatrin Only Product|enteral medication administration, serial blood draws, and outcome assessment
75330048|NCT03019861|Behavioral|Ayurvedic nutritional counseling|
75470009|NCT05410119|Behavioral|8-week Resilience Group Psychotherapy|Resilience Group Psychotherapy was intervened by a psychotherapy developed by the researchers. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
75470010|NCT05410119|Other|Usual care|Usual care means treating as usual, such as regular home visit.
75470011|NCT05410093|Drug|Resveratrol|Take Resveratrol (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months
75470012|NCT05410093|Drug|Vitamin E|Take vitamin E at a dose of 100 mg per day for three months
75470013|NCT05410067|Other|Cervicothoracic Junction Mobilization Technique|It is a part of manual therapy technique. Patient would be in prone position with his forehead in the palm of the therapist. Maitland mobilization to the C7- T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions unilateral PA glide) is given. For central PA glide, a central pressure angled towards the participant's head was given with overlapping thumbs of the therapist placed on the spinous process of C7. The therapist's thumbs were placed on the posterior surface of the articular process to be mobilized (C7 on the side of restriction), and anteriorly directed oscillatory pressure was applied for unilateral PA mobilization.
75470014|NCT05410067|Other|Eccentric Muscle Energy Technique|Eccentric muscle energy technique would be applied to the patient's cervical spine. The cervical spine would be brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then patient would be asked to push their heads into the direction opposite that of the barrier.
75651781|NCT05594693|Other|Physical Exam|Physical measures before and after integrative interventions, and monthly. Thoracic kyphosis will be measured with a non-invasive gravity dependent inclinometer (Isomed Inc.).
75651782|NCT05594615|Drug|EDP-235|Subjects will receive EDP-235 once daily on Days 5-15
75330049|NCT03019861|Behavioral|Conventional nutritional counseling|
75330050|NCT00981253|Behavioral|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
75330051|NCT00981253|Behavioral|Standard Cardiac Rehabilitation|Supervised exercise, three times per week, for 12 weeks.
75330052|NCT03019705|Other|Observation|
75330053|NCT05028153|Drug|Azithromycin Oral Liquid Product|10 mg/kg for 3 consecutive days
75330054|NCT05028153|Other|Placebo mixture|Placebo mixture containing no active substance
75330055|NCT03126760|Drug|Acthar Gel|Acthar Gel 1 mL (80U) for subcutaneous injection
75651783|NCT05594615|Drug|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
75470015|NCT05410041|Biological|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/kg (D-5~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/kg (D-5~D-3), determined by tumor burden at baseline.
75470016|NCT05410028|Other|No intervention in clinical treatment|No intervention in clinical treatment
75470017|NCT05410015|Other|Normal clinical treatment without intervention|Normal clinical treatment without intervention
75637364|NCT05335824|Other|The injectable platelet-rich fibrin (I-PRF) group|"Twenty ml of venous blood was drawn from each patient in this experimental group.~I-PRF was prepared with the use of 20 ml of blood drawn from the patient in dry sterile tubes without anticoagulant (quickly before coagulation starts) by following the centrifugation protocol requires one cycle only (700 RPM for 3 minutes) Injection procedures, sites, and time were similar to the PRP group."
75330056|NCT03126760|Drug|Placebo|Placebo for subcutaneous injection
76079010|NCT01132144|Procedure|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
76079011|NCT01132144|Procedure|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
76079012|NCT01379274|Drug|Lenalidomide and azacitidine combination|"lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy."
75330057|NCT00982033|Drug|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
75637365|NCT05335824|Device|The control group|NiTi closed-coil springs (American Orthodontics, Sheboygan, WI) were used to impose 150 g force from the first molar band hook to the bracket of canine on each side on 0.019*0.025-in SS archwire Patients' follow-up appointments were two weeks intervals; at each visit, the force produced by the coil was checked and readjusted when needed in order to keep it at 150-g level and the appliances were examined for any deformation or change in the position because of chewing. Canine retraction continued until achieving Class I canine relationship.
75637366|NCT02873234|Drug|Traditional Chinese Medicine|Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
76079013|NCT05389410|Device|PICO 7|Participant will receive 7 days of NPWT following revision hip or revision knee surgery.
76079014|NCT05389410|Device|PICO 14|Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
75330058|NCT00982033|Drug|placebo|placebo qd for 24 weeks
75470018|NCT05409950|Procedure|Immediate implant placement using socket shield technique|Evaluation of socket shield technique with immediate implant placement at the esthetic zone in comparison with the conventional immediate implant placement
75330059|NCT03127228|Other|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
75330060|NCT03127228|Device|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
75330061|NCT05026905|Drug|Gemcitabine 1000 mg|Gemcitabine 800mg/m2 in N/S 250ml over 30 minutes (or fixed dose rate 10 mg/m2/min) IV infusion on day 1 repeated every 14 days.
75330062|NCT05026905|Drug|Nab paclitaxel|Nab-paclitaxel 125mg/m2 over 30 minutes IV infusion on day 1 repeated every 14 days, followed by Gemcitabine
75330063|NCT05026905|Drug|S1|"S-1 orally 60-100 mg/day day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~BSA < 1.25 m2: 60 mg/day~1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day~BSA ≥ 1.5 m2: 100 mg/day"
75330064|NCT05026905|Drug|leucovorin|leucovorin 30mg BID day 1 to 7 on in a 2-week cycle
75330065|NCT05026905|Drug|Oxaliplatin|Oxaliplatin 75mg/m2 in 250 mL of D5W over 120 minutes IV infusion on day 1 repeated every 14 days
75470019|NCT05409898|Device|smart wearable device|screening masked hypertension with smart wearable devices
75470020|NCT05409820|Procedure|use of different spinal anesthesia techniques|Comparison of spinal anesthesia with 5 mg hypobaric bupivacaine and 5 mg hyperbaric bupivacaine in outpatients
75470021|NCT05409755|Other|Vivacy|Vivacy and minoxidil
75470022|NCT05409742|Diagnostic Test|Modified Hall technique|The standard Hall technique was later modified with several modifications including occasional/rare use of anesthetic and about 1 mm proximal slice that the preformed metal crown fits without separation, and minimal occlusal reduction of the cusps
75637367|NCT02873234|Drug|Antidepressants|Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
75637368|NCT02774811|Drug|Prostaglandin analogue|Topical therapy
75637369|NCT02774811|Procedure|Selective laser trabeculoplasy|Laser therapy into drainage angle
75637370|NCT02774811|Device|laser|
75637371|NCT00817050|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
75637372|NCT00817050|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
75651784|NCT05594615|Drug|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
75786460|NCT01198886|Other|Exercise-Nutrition Program|Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
75470023|NCT05409729|Behavioral|retrospective charts reviewing|
75786461|NCT01293500|Procedure|Goal-directed Therapeutic Protocol|A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.
75922769|NCT03516084|Drug|ZL-2306(nirapairb)|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
75651785|NCT05594615|Drug|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
76079015|NCT01171690|Drug|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
76079016|NCT03153384|Procedure|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
76079017|NCT02522988|Behavioral|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
75651786|NCT05594602|Drug|EDP-235|Subjects will receive EDP-235 on Days 1 and 14
75786462|NCT01198964|Procedure|Low-level cortical stimulation|A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
75330066|NCT00982189|Drug|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
75330067|NCT00982189|Drug|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
75330068|NCT04752735|Other|endovascular treatment|all enrolled patients must receive endovascular treatment.
75330069|NCT03019471|Genetic|Isolation of tumor DNA|
75470024|NCT05409703|Behavioral|reiki therapy|reiki therapy for nurses
75470025|NCT05409677|Other|This was a retrospective study with no intervention other than normal treatment|This was a retrospective study with no intervention other than normal treatment
75470026|NCT05409625|Device|Intraoral Scanner (TRIOS 4, 3Shape TRIOS A/S, Copenhagen, Denmark)|Intraoral scanner which is able to generate a 3D-model of the teeth and is being used for caries detection.
75470027|NCT05409625|Device|Intraoral camera (DIAGNOcam, KaVo, Biberach, Germany, software version 3.0.1/2.9.1)|Intraoral camera used for caries detection in the occlusal and proximal surfaces.
75470028|NCT05409625|Device|X-ray device (X-ray device SOREDEX, MINRAY®; Image plates VistaScan; Image plate scanner VistaScan Mini View, Dürr Dental)|X-ray device used for caries detection. Two radiographs (bitewings) are taken, one in each side.
75470029|NCT05409625|Procedure|Oral cleaning|Removal of tartar and plaque. Tartar removal done at baseline and the fifth visit, but only on selected teeth at the second, third and fourth visit. Regular cleaning with a toothbrush done at all visits.
75651787|NCT05594602|Drug|EDP-235|Subjects will receive EDP-235 on Days 1 and 23
75651788|NCT05594602|Drug|EDP-235|Subjects will receive EDP-235 on Days 1 and 8
75651789|NCT05594602|Drug|Itraconazole|Subjects will receive itraconazole QD Days 5-18
75651790|NCT05594602|Drug|Carbamazepine|Subjects will receive carbamazepine BID Days 5-23 and Days 24-27
75651791|NCT05594602|Drug|Quinidine|Subjects will receive quinidine BID Days 5-12
75786463|NCT01566656|Drug|total lymphoid irradiation and anti-thymocyte globulin|"TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0"
75786464|NCT01566734|Other|Cefazolin irrigation|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
75786465|NCT01566734|Other|Normal Saline Irrigation|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
75922770|NCT03516084|Drug|Placebo|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
76079018|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
76079019|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
76079020|NCT05396664|Behavioral|ATWA|The Adolescent Transition in West Africa (ATWA) program is an in-school (Niger, Mali, Burkina Faso) and out-of-school (Niger and Mali) educational intervention implemented by local staff members at Save the Children, local community members, and teachers. ATWA provides internationally-recognized life skills education (LSE) to adolescents ages 10-19 years, and seeks to improve adolescents' knowledge and behaviors regarding sexual and reproductive health and rights. Outcome indicators to assess knowledge, behavior and attitudes of adolescents will vary by adolescent demographics as well as by country context, as based on the final set of curriculum deemed appropriate by the respective Ministries of Education (MOE).
76079021|NCT05389254|Device|continuous glucose monitoring system|use real-time CGM system to check and adjust blood glucose
76079022|NCT05389254|Device|capillary blood glucose monitoring|monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
75637373|NCT04224831|Combination Product|Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis|"Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment."
75637374|NCT00816972|Drug|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
75786466|NCT00050778|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
75637375|NCT00816972|Drug|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
75637376|NCT00816972|Drug|Placebo for Desloratadine 2.5 mg|Placebo BID
75637377|NCT00816972|Drug|Placebo for Oxybutynin 2.5 mg|Placebo BID
75637378|NCT02770677|Other|Modified Dantien Salee Yoga Training Program|The intervention aims to improve pulmonary function and functional fitness.
75637379|NCT02690688|Device|determination of dynamic preload variables|
75637380|NCT02774577|Other|whole body vibration training in vibrating platform in young|
75637381|NCT02774577|Other|whole body vibration training in vibrating platform in elderly|
75637382|NCT02841150|Drug|IMBRUVICA (Treatment A)|IMBRUVICA (reference treatment), 4*140 milligram (mg), capsules.
75637383|NCT02841150|Drug|Ibrutinib (Treatment B)|Ibrutinib (test treatment), 1*560 mg, tablet.
75786467|NCT00050778|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ [CD4+] T-cell count was >=100*10^6 cells per liter).
75786468|NCT00050778|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was >=100*10^6 cells per liter).
75330073|NCT03128008|Drug|Carboplatin|Single arm non randomized open label study. Subjects will receive standard of care Carboplatin IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
75330074|NCT03128008|Drug|Paclitaxel|Single arm non randomized open label study. Subjects will receive standard of care Paclitaxel IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
75470030|NCT05409586|Procedure|segmental mastectomy|The preferred method in the treatment of some patients diagnosed with IGM
75637384|NCT02774733|Device|spirometer;Intraocular pressure;Color doppler imaging|
75637385|NCT02774499|Drug|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
75786469|NCT05670392|Device|laser and High intensity Tesla magnetic stimulation|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals followed by Eight (8) HITS therapies) Patients will receive two (2) HITS treatments per week for four (4) weeks(.
75637386|NCT02774499|Drug|Placebo|equivalent volume (5mL) of syrup given preoperatively
75637387|NCT02770443|Drug|withdrawal|withdrawal of beta blocker and ACE inhibitors
75637388|NCT02770443|Drug|standard of CARE|STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
75637389|NCT02770053|Procedure|Foraminal enlargement|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
75637390|NCT02770209|Biological|biomimetic cartilage matrix + autologous chondrocytes|
75637391|NCT02770209|Procedure|arthroscopic debridement|
75637392|NCT02770209|Procedure|microfracture surgery|
75637393|NCT02774109|Dietary Supplement|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
75637394|NCT02774109|Dietary Supplement|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
75637395|NCT02774109|Procedure|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
75637396|NCT02774109|Procedure|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
75637397|NCT02774031|Device|Aisys with Et control|
75637398|NCT02774031|Device|Aisys conventional|
75637399|NCT02774031|Device|Flow-i with ACG|
75637400|NCT02774031|Device|Flow-i conventional|
75637401|NCT04224909|Diagnostic Test|Video Head Impulse Test|Diagnosis of dysfunction of the semicircular canals using the vHIT
75637402|NCT02769663|Behavioral|questionnaires and neuropsychological assessments|
75637403|NCT02769819|Device|Flexible fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia~Glottic visualization will be evaluated by direct laryngoscopy.~The endotracheal tube will be loaded onto the scope after silicon spray lubrication~Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
75637404|NCT02774187|Drug|Sorafenib|administration of Sorafenib
75637405|NCT02774187|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
75637406|NCT02774187|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
75637407|NCT02769897|Behavioral|Physical exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
75637408|NCT02773797|Drug|IN-DEX 1.0 mcg/kg, intranasal saline|
75786470|NCT05670392|Device|laser (without HITS treatment)|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals as described above.
75470031|NCT05409560|Other|Swimming participants in the 6-hour cold water swim|The 6-hour cold water swim was the qualifying swim for the English Channel swim during the Channel Swim Camp Dinard 2021 and participants were the swimmers registered for the 6-hour cold water swim who volunteered to participate in this study
75637409|NCT02773797|Drug|IN-DEX 1.5 mcg/kg, intranasal saline|
75470032|NCT05409521|Other|Kinesio taping|Kinesio taping with the mechanical correction technique will be applied on the thoracic region
75470033|NCT05409521|Other|Placebo taping|Placebo taping with no tension and technique will be applied on the arm
75330075|NCT03128008|Radiation|Daily hyperfractionated radiation therapy|All subjects will receive 6 fractions(2Gy per fraction) of radiation therapy weekly. All subjects will complete an interim PET-CT after 48Gy-54Gy of RT . Subjects with a complete response on PET will complete RT at 60 Gy; subjects who have residual disease on interim PET and meet strict planning constraints eligibility will proceed to boost RT for a total RT dose of 72Gy. Interim PET-CT response will be measured using PERCIST criteria.
75330076|NCT04744935|Device|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.
75470034|NCT05409469|Procedure|surgery|surgery on patients with aortic dissection
75470035|NCT05409417|Drug|Experimental drug|Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
75470036|NCT05409339|Drug|Caffeine|150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
75470037|NCT05409339|Drug|Placebo|Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
75637410|NCT02773797|Drug|Placebo - Saline|
75637411|NCT02769741|Other|Cashews followed by Control|Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
75637412|NCT02769741|Other|Control followed by Cashews|Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
75637413|NCT02769429|Device|Ultrasound-guided CISB|This group will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
75637414|NCT02769429|Device|nerve stimulator-guided CCPVB|This group will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
75637415|NCT02769507|Device|DC Stimulator PLUS (NeuroConn)|
75637416|NCT02773953|Device|T4PTelemonitoring|addition of a Telemonitoring unit on the CPAP line to standard care.
75637417|NCT02773953|Device|CPAP|CPAP treatment for treatment of obstructive sleep apnea syndrome
75637418|NCT02769585|Behavioral|Self-hypnosis|Self-hypnosis
75637419|NCT02769585|Behavioral|CDE training|standard CDE training for an obese diabetic
75637420|NCT02773875|Device|Artificial pancreas system (Algorithm + CGM + pump)|The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
75637421|NCT02773719|Other|True Biofield therapy|
75786471|NCT01199510|Other|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
75786472|NCT01199510|Other|Standard of Care|Post Cataract Surgery Standard of Care
75786473|NCT01199588|Drug|Nexagon® Low Dose|Weekly, topical application of Nexagon® low dose used with compression dressings.
75330077|NCT05017311|Drug|Escitalopram|All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).
75470038|NCT05409326|Drug|TQH2722 injection|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
75637422|NCT02773719|Other|Fake Biofield therapy|
75637423|NCT02768961|Drug|sofosbuvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines"
75637424|NCT02768961|Drug|ledipasvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines"
75637425|NCT02769039|Other|No intervention. Observational studies of sleep, movement and brain imaging|Participants will be asked to visit the University for 3 baseline visits which include a screening visit & sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
75637426|NCT02773641|Drug|Botulinum Toxin Type A|
75637427|NCT02773641|Drug|Sterile Saline Solution|
75637428|NCT02773563|Other|EUS with air insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using air insufflation
75637429|NCT02773563|Other|EUS with CO2 insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using CO2 insufflation
75637430|NCT02773329|Other|sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
75637431|NCT02773329|Other|Intervention without game-based exercise|Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
75637432|NCT02768805|Biological|15 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
75470039|NCT05409326|Drug|Placebo to match TQH2722|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
75470040|NCT05409313|Behavioral|EBP training|The EBP training program was modified by the 5A-steps EBP teaching model that which aimed to enhance nurses' EBP competencies and application. A 12-hours EBP training consisted of lectures, hand-on practice, group and individual consulting, group presentations and reflections, and disseminating findings to publish.
75470041|NCT05409313|Behavioral|SDM training|A 10-hour SDM training program included lecture 4 hours and workshops 6 hours, with focused on 3-talk model for SDM skills, 4-habit model for communication skill, and how to use Ottawa personal decision guide. Teaching strategies included lectures, clinical scenarios role play, and post-scenario debriefing. The major contents were SDM concepts and essential steps, SDM tools, strategies for the clinical implementation, the concept and purpose of choosing wisely campaign, and patient-centered communication skills.
75470042|NCT05409261|Biological|Ad26.COV2.S|Recombinant vaccine, contains Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein
75330078|NCT05017311|Drug|Brexpiprazole|Depending on the initial randomization process, patients will either receive blinded brexpiprazole (0.5-2 mg/d) for the entire study duration (12 weeks) or for the last 4 weeks of the study if they received the placebo during the first 8 weeks of the study and were non-responders.
75470043|NCT05409261|Biological|NVX-CoV2373|Recombinant, adjuvanted vaccine, contains SARS-CoV-2 spike protein adjuvanted with Matrix-M
75470044|NCT05409248|Other|Personalized cognitive stimulation|Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser. Performance feedback will be shown after each activity.
75470045|NCT05409248|Other|Sham cognitive stimulation|Non-therapeutic online games based on artistic tasks designed to not train the specific cognitive abilities at test. The time of each session will match that of the experimental group. Performance feedback will be shown after each game.
75470046|NCT05409196|Biological|ShigETEC live, attenuated, oral vaccine|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
75470047|NCT05409196|Drug|Placebo|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
75637433|NCT02768805|Biological|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
75637434|NCT02768805|Biological|15 µg/strain of the licensed quadrivalent vaccine|Single dose of the licensed quadrivalent vaccine
75637435|NCT02773251|Drug|hyaluronic acid-carboxymethylcellulose|
75637436|NCT04224597|Diagnostic Test|ultrasonography|all participants will be determined by ultrasonography.
75637437|NCT02768649|Drug|RBP-7000|Sequential dosing of each cohort
75637438|NCT02768649|Drug|risperidone|All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
75637439|NCT02773173|Procedure|IPP in colorectal laparoscopic surgery|Deep neuromuscular blockade can only be reversed with sugammadex, so in the IPP group, it will be used as neuromuscular blocking agent and its effect will be reversed with sugammadex (4mg / kg) at the end of the surgery. During surgery: deep neuromuscular blockade (PTC 1-5), Protective ventilation strategy, Optimal position and Pre stretching as a tool to decrease intraabdominal pressure maintaining optimal workspace.
75651792|NCT05594056|Procedure|Transorbital ultrasound of the optic nerve sheet|Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
76079023|NCT01132378|Procedure|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
75330079|NCT03128086|Procedure|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
75786474|NCT01199588|Drug|Nexagon® High Dose|Weekly, topical application of Nexagon® high dose used with compression dressings.
75786475|NCT01199588|Drug|Nexagon® Vehicle|Weekly, topical application of Nexagon® Vehicle used with compression dressings.
75786476|NCT04153682|Diagnostic Test|Rapid Diagnostic Testing|Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples
75786477|NCT04153682|Diagnostic Test|Antimicrobial stewardship|After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
75786478|NCT01199120|Dietary Supplement|Omega 3|measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
75786479|NCT00050622|Drug|Methylphenidate 0.15 mg/kg|0.15 m/kg/dose immediate-release methylphenidate
75786480|NCT00050622|Behavioral|Low-Intensity BMOD|Lower-intensity behavioral treatment package.
76079024|NCT05389176|Drug|Esmolol|a continuous esmolol infusion titrated to maintain heart rate between 70/min and 100/min
75330080|NCT05395273|Device|Game Ready cryocompression|Cryotherapy on the coldest tolerable level and intermittend compression on the knee
75330081|NCT00360087|Drug|Bosentan|
75330082|NCT00982423|Drug|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
75330083|NCT03073486|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
75330084|NCT03073486|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
75786481|NCT00050622|Drug|Methylphenidate 0.3 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
75786482|NCT00050622|Drug|Placebo|
75786483|NCT00050622|Drug|Methylphenidate 0.6 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
75786484|NCT00050622|Behavioral|High Intensity BMOD|Comprehensive high-intensity Summer Treatment Program (STP)
75470048|NCT05409170|Procedure|COVID|Each surgical procedure was considered an independent event. Moreover, the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
76079025|NCT05396508|Procedure|interfacial injection|10 ml of bupivacaine and steroid injection was applied between the leaves of the thoracolumbar fascia under the guidance of ultrasonography.
76079026|NCT05396508|Procedure|physical therapy|protocol including hot pack for 20 min/session, therapeutic continuous Ultrasound (frequency, 1 MHz; intensity 1.5 W/cm2) for 6 min/session, therapeutic exercises for low back muscles. Therapeutic exercises included stretching ,posterior pelvic tilt ,hyperextension ,bridge and cat-camel exercises
76079027|NCT01132690|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
75786485|NCT00308087|Drug|Sargramostim (Leukine)|Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
76079028|NCT05380830|Other|Tied deep-Water Running|4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
76079029|NCT05396274|Device|High Flow Nasal Cannula|high flow nasale cannula
75470049|NCT05409144|Procedure|Thoracic epidural infusion|Upon locating the desired site spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle. Once achieving local anesthesia, the epidural needle advanced with its stylet in place and with its bevel point cephalad; this will ultimately contribute to the proper location of the epidural catheter. The epidural needle must be advanced through the skin, subcutaneous tissue, supraspinous, and interspinous ligaments. Once there, the stylet must be removed, and the Loss of Resistance syringe (filled up with saline, air, or both) must be attached to the needle. The needle must be advanced while applying pressure to the plunger. Once the ligamentum flavum is pierced, a loss in resistance will be noted; this is the epidural space, and 5 to 10 cc of saline is injected to expand the epidural space; this may decrease the risk of vascular injury.
75637440|NCT02773173|Procedure|SPP in colorectal laparoscopic surgery|A depolarizing neuromuscular blocking will be used (as routine clinical practice at each center) to maintain moderate neuromuscular blockade and its effect will be reversed with anticholinesterase at the end of the surgery. During surgery: Moderate neuromuscular blockade ( TOF 2-4) , position to surgeon criteria, no prestretching and Protective ventilation. Fixed IAP (12mmHg).
75637441|NCT02768883|Behavioral|Respira Sano|The intervention is all three components: clinic + home + community.
76079030|NCT04454034|Procedure|arthroscopic synovectomy|arthroscopic synovectomy
76079031|NCT01132846|Other|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
75637442|NCT04224675|Drug|Atenolol|Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms
75922771|NCT03368924|Other|SCA patients (SS genotype)|"The clinical data relative to the patients will be collected in each of these stages (CVO, basic state).~Besides, to estimate the severity of the CVO, we shall use an index of severity of the episode ( IS2) adapted from the one who was validated by our group to stratify the severity of vasoocclusifs episodes at the drepanocytic child SS.~Main clinical parameters: taken of analgesic at home (level), temperature in the admission, SaO2 in the admission, number of painful sites, thoracic pain with or without associated cough, score EVA in the entrance, feeling of the patient of bigger gravity of the CVO with regard to its crises previous, heart rate to the admission, … Main biological parameters: rate of leukocytes, of polynucléaires neutrophiles, of réticulocytes, Lactate déshydrogénase, of haemoglobin, C-reactive Protein … The biological data can be studied according to their raw rate or according to their difference with their basic value (in the stable state)."
75922772|NCT05366452|Device|IMPELLA CP|Implantation of the IMPELLA CP will be performed using the femoral route in most patients. Echo guided puncture to gain access for IMPELLA CP will be encouraged and a local angiography will be promoted to check the feasibility of device implantation. The implantation will follow gold standard after obtaining an ACT >250 s. As soon as the device is in place it will be started.
75786486|NCT00308087|Drug|Rituximab|Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
75330089|NCT00983281|Drug|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
75637443|NCT04175145|Other|Posterior spinal instrumentation|A fusion construct consisting of all pedicle screws except at uppermost instrumented vertebra. Contoured dual 6-mm stainless steel rods were used to connect the construct. Pedicle screw location and density was determined by the surgeon based on perceived curve stiffness and fusion length with an even distribution of fixation points along the construct. Pedicle screw instrumentation was performed by the free hand technique with biplanar fluoroscopic and direct screw EMG impedance testing for confirmation of placement. Reduction was via cantilever-segmental-translation maneuver in all cases.
75798683|NCT03859284|Other|self adhering flowable with adhesive|moist bonding self adhering flowable composite with the aid of an adhesive system.
75798684|NCT02525328|Other|blood or saliva specimen|blood or saliva specimen is sampled for DNA extraction in CT family's members
75798685|NCT02525172|Drug|Rituximab|
75798686|NCT02525172|Drug|intravenous immune globulin|
75798687|NCT02525172|Drug|Bortezomib|
76079032|NCT01132846|Drug|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
76079033|NCT01132846|Drug|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
76079034|NCT03130608|Other|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
76079035|NCT05396196|Device|Kinesio® Tape|Manual Fascial Glide Application
75330090|NCT05394961|Procedure|Treatment in an intensive care unit with a diagnosis of sepsis and/or ARDS and/or covid-19|As above
75330091|NCT03129178|Dietary Supplement|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
75330092|NCT03019393|Other|Beef|200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.
75470050|NCT05409144|Device|Erector Spinae Plane Block|The block-level will be at T5. The ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which the following layers will be visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle and T5 transverse process. 3ml lidocaine 1% will be used on skin and subcutaneous fat, Echogenic block needle will be inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process.
75470051|NCT05409144|Device|Serratus Anterior Plane Block|The block is performed with full aseptic precautions. Arm abduction is preferred. The ultrasound probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, then, 3ml lidocaine 1% will be used for skin and subcutaneous fat, using ultrasound guidance, a 38-mm 22-gauge regional block needle is going to be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep into the serratus anterior muscle.
75637444|NCT02768493|Drug|1.0 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
75637445|NCT02768493|Drug|1.5 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
75637446|NCT02768415|Drug|Apatinib|
75786487|NCT04942184|Behavioral|Memory strategies in Arm 1|Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.
75637447|NCT02768415|Drug|Oral Vinorelbine|
75637448|NCT02773095|Other|Novartis Access|Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
75637449|NCT02768337|Drug|Afatinib|
75470052|NCT05409092|Dietary Supplement|Astaxanthin|8 mg/day in one capsule for 4 weeks
75470053|NCT05409092|Dietary Supplement|Placebo|8 mg/day in one capsule for 4 weeks
75637450|NCT02768337|Radiation|2 Gy targeted radiotherapy|
75786488|NCT04942184|Device|Electroencephalogram (EEG) headset in Arm 1|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
75637451|NCT02768337|Radiation|4 Gy targeted radiotherapy|
75637452|NCT02768571|Drug|Cerebrolysin|Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day * 21 days with rehabilitation
75786489|NCT04942184|Other|Tablet in Arm 1|A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
75786490|NCT04942184|Behavioral|Memory strategies in Arm 2|Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.
75798688|NCT02525172|Drug|Methotrexate|
76079036|NCT01173016|Drug|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
76079037|NCT05165784|Procedure|femoral vein identification|Femoral vein identification using V technique
75470054|NCT05409053|Procedure|open reduction|the displaced fractures will be treated with open reduction so as to achieve the near anatomical alignment
75637453|NCT02768571|Drug|Placebo|Placebo- saline 100 ml/day * 21 days with rehabilitation
75637454|NCT02696889|Procedure|ROSE-1 Protocol|A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur.
75637455|NCT02768025|Other|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
75637456|NCT02768025|Other|NRT, counselling|Nicotine Replacement Therapy, counselling
75637457|NCT02767713|Drug|Dexamethasone|Intravenous dexamethasone (0.1 mg/kg) was administered 10 hours before surgery.
76079038|NCT05165784|Procedure|femoral vein identification|Femoral vein identification using palpation technique
75637458|NCT02767713|Other|Placebo|Normal saline (placebo) in the equal volume as active treatment was administered 10 hours before surgery.
75637459|NCT02767245|Drug|Thiamine|Thiamine IV 100 mg/day
75637460|NCT02768181|Behavioral|Nutrition-specific Behaviour change communication (BCC)|Door-to-door counseling on nutrition during pregnancy and exclusive breastfeeding from enrolment into study till birth; exclusive breastfeeding and nutrition of lactating mothers during post-natal 6 months; timely and appropriate complementary feeding with continued breastfeeding until 2 years of child's age, and nutrition of lactating mothers during post-natal 6-24 months; all counseling would be supplemented with associated issues including hygiene and sanitation, mother's sleep and rest, maternal and child healthcare seeking etc.
75786491|NCT04942184|Device|Electroencephalogram (EEG) headset in Arm 2|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
76079039|NCT04215900|Behavioral|High-speed yoga multi-directional yoga|The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
76079040|NCT01133158|Drug|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
75637461|NCT02768181|Dietary Supplement|Nutrient supplement to pregnant women (PNS)|"A lipid-based micronutrient supplement (LNS) is packed in ~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.~Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA ~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
76079041|NCT03109626|Dietary Supplement|DHA|
75651793|NCT05589844|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo standard of care allogeneic hematopoietic stem cell transplant
76079042|NCT01133860|Drug|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
75651794|NCT05589844|Procedure|Biospecimen Collection|Correlative studies
75651795|NCT05589844|Biological|CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine|Given intradermally
75786492|NCT04942184|Other|Tablet in Arm 2|A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
75330093|NCT04741425|Other|REST intervention|"The breastfeeding talk will be conducted by Zoom at the third trimester about breastfeeding benefits and other practical advices. There is also a sharing session by a successful breastfeeding mother and a group discussion with different breastfeeding scenarios.~Once the mothers return home after delivery, individualized breastfeeding coaching will be provided by PI through a daily Zoom videoconference within 24 hours upon hospital discharge till Day 7 after delivery.~During the last breastfeeding videoconference, mothers will be reminded to have weekly telephone follow-ups by PI from week 2 to 2 months postpartum.~Women who are randomised into the intervention group will receive REST in addition to the standard antenatal and postnatal care (described at below) by the Obstetrics Department of their delivery hospitals."
75786493|NCT01090284|Device|Inguinal hernioplasty|A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
75786494|NCT01202006|Other|Training of general practitioners in an uptitration protocol.|The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
75786495|NCT00307931|Biological|Certolizumab pegol|"certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks."
75786496|NCT01097148|Drug|Atracurium, TBW|Dose atracurium 0.5 mg/kg based on total body weight
75786497|NCT05668052|Other|questionnaire|This survey was conducted in Zhejiang Provincial Hospital of Traditional Chinese Medicine from December 2022 to December 2023. The research objects were patients with COVID-19.
76079043|NCT04455516|Procedure|Meniscus repair; partial meniscectomy|69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
76079044|NCT05372406|Other|• no intervention|• no intervention
76079045|NCT01134016|Drug|Antroquinonol|"Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded."
76079046|NCT04819074|Procedure|Microsurgery|Microsurgery for unruptured intracranial aneurysm
76079047|NCT01173874|Drug|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
75330094|NCT03129568|Biological|CDC infusion|Injection of CDCs (0.3 million per kg of body weight).
75330095|NCT04737759|Behavioral|Taking Care of Us|A social-behavioral intervention that is targeted at the couple living with heart failure and delivered via Zoom.
75330096|NCT04737759|Other|SUPPORT|SUPPORT is an educational counseling intervention that is targeted at the couple living with heart failure and delivered by Zoom.
75330097|NCT00983359|Radiation|Radiation Therapy|Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
75330098|NCT04719819|Procedure|Spinal anaesthesia for caesarean section|Descriptive questionnaire with open and closed questions, to be completed during the procedure
75637462|NCT02768181|Dietary Supplement|Nutrienr supplement to children 6m to 2 years|"A lipid-based micronutrient supplement (LNS) is packed in ~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets ~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
75637463|NCT02767401|Device|stenting or balloon expansion|all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
75637464|NCT02767401|Drug|aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
75330099|NCT02981719|Procedure|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment
75786498|NCT01097226|Other|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
75786499|NCT01097226|Other|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
75786500|NCT01097226|Other|Apple granules delivering 70 mg epicatechin|Delivered as a puree
75786501|NCT01097226|Other|Water delivering no epicatechin|Delivered as flavoured water
75786502|NCT05670080|Behavioral|Motor Imagery|Motor imagery is the imagining of action without its physical execution and motor imagery elicits activity in brain regions that are normally activated during actual task performance. The brain perceives real experiences and the visualization process as similar. For this reason, imagery is considered a mental exercise
75786503|NCT05670080|Behavioral|Physical Therapy|Electrotherapy (TENS), cold pack therapy, joint range of motion exercises, and strengthening exercises for the muscles around the shoulder.
75786504|NCT01095432|Procedure|PWS Testing|Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
75786505|NCT03844724|Device|ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
75786506|NCT03844724|Device|Peripheral Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
75922773|NCT05366452|Other|Conventional therapy|The patients will receive up to date management according to the consensus of care regarding inotropes and vasopressors in CS (2,4). A dedicated protocol will ensure that management is similar between centers and in both groups. The shock team will be in charge of all therapeutic decisions.
76079048|NCT04815798|Combination Product|Bacteriophage-loaded Microcapsule Spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
76079049|NCT04815798|Combination Product|Placebo|Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.
76079050|NCT04815798|Procedure|Standard of Care|Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
75330100|NCT02981719|Procedure|irreversible electroporation|percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.
75330101|NCT03073876|Drug|Donepezil Hydrochloride|5mg of Donepezil Hydrochloride by mouth
75330102|NCT03073876|Drug|Placebo|prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
75330103|NCT00954109|Behavioral|Exercise|daily exercise: supervised treadmill walking or cycle ergometry use
75330104|NCT05006625|Other|Collaborative Care Model|Use of the collaborative care model to screen and deliver care for depression in adolescents and young adults aged 15-24 years seeking HIV prevention and treatment services
75330105|NCT02980237|Other|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.
75786507|NCT01199276|Drug|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
75786508|NCT01199276|Drug|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
75922774|NCT03377738|Diagnostic Test|spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
75637465|NCT02767479|Drug|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
75330106|NCT02980237|Other|eHealth_program|The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
75637466|NCT02767479|Drug|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
75922775|NCT02300376|Drug|Dosage of Calcium edetate de sodium|There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
75470055|NCT05409053|Procedure|Closed reduction|the non displaced fractures will be treated with closed reduction and percutaneous pinning
75330107|NCT04718961|Drug|Volixibat|Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
75470056|NCT05409053|Other|Conservative management|the non displaced fractures will be treated with closed reduction and castor slab
75786509|NCT03955380|Drug|Contraloid|Oral administration of capsules, drug substance or placebo without any exipients.
75470057|NCT05407272|Other|Health Education Manual|A health education manual based on a shared model
75470058|NCT05407272|Other|manual|routine care
75470059|NCT05405335|Other|Prone Positioning Maneuver|intermittent prone positioning for eight hours per day for seven days. each cycle should not be less than 30 minutes or more than 3 hours.
75470060|NCT05398952|Diagnostic Test|Laboratory investigations|Laboratory investigations correlated with symptoms and imaging results
75470061|NCT05397054|Behavioral|Education|- Education: Education about risk of high sodium intake, type of sodium, nutrition ingredients
75470062|NCT05397054|Behavioral|Reformulation|- Reformulation: Dietary recommendation in low sodium intake
75470063|NCT05397054|Behavioral|Environmental change|- Environmental change: Encourage about low sodium intake in community
75637467|NCT02767791|Other|Acupuncture|Acupuncture
75637468|NCT02767791|Other|Auriculotherapy|Auriculotherapy
75637469|NCT02767635|Drug|Botox-Epic|injected 20 units of Botox into lateral epicondyle in Botox-Epic group
75786510|NCT01199354|Procedure|Mastectomy, preservation of the skin envelope,followed by immediate reconstruction with autologous latissimus dorsi flap.|Mastectomy, preservation of the skin envelope, removal of the nipple-areolar complex and dissection of the axillary lymph nodes followed by immediate reconstruction with autologous latissimus dorsi flap with or without prosthesis.
75786511|NCT01199666|Other|Text message|text message appointment and immunization reminders
75786512|NCT01202084|Drug|Formoterol/Fluticasone|
76079051|NCT05391282|Other|ultrasound assessment|Transfontanel ultrasound assessment before and after prone positioning
75330108|NCT04718961|Drug|Placebo|Capsules matched to study drug minus active substance.
75330109|NCT03130738|Drug|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
75470064|NCT05397054|Device|Salt meter|- Used salt meter: at least 3 times/wk
75637470|NCT02767635|Drug|Botox-Tend|injected 20 units of Botox into tender point of muscles in Botox-Tend group
75637471|NCT02767635|Drug|triamcinolone acetonide (Steroid)|injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
75637472|NCT04224441|Drug|Chlorpromazine Pill|The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
75922776|NCT02300454|Device|Non-slip element balloon (NSE)|Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)
76079052|NCT05337384|Diagnostic Test|Sonography|Sonographic Venous Doppler Imaging
76079053|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
76079054|NCT01174030|Drug|Vehicle Gel|Vehicle Gel QD
75330110|NCT03130738|Drug|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
75470065|NCT05397054|Behavioral|standard treatment|standard treatment
75470066|NCT05387278|Drug|EV-Pure™ and WJ-Pure™|The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care
75470067|NCT05387278|Drug|Placebo|Cryopreservation media plus standard care
75470068|NCT05357924|Procedure|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
75637473|NCT02767089|Drug|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
75637474|NCT02767089|Drug|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
75637475|NCT02767167|Other|Semi-skimmed cow's milk|430ml of semi-skimmed cow's milk / day for 12 weeks
75786513|NCT01202084|Drug|Foraseq®|
75786514|NCT01202084|Drug|Fluticasone|
75786515|NCT03842072|Device|Cervical collar|cervical collars prescribed will be use immediately following anterior cervical discectomy and fusion surgery.
76079055|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
75637476|NCT04711317|Device|Nasal high flow oxygen|Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen
75786516|NCT03839264|Diagnostic Test|Graft stenosis and thrombosis|
76079056|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
76079057|NCT01174030|Drug|Vehicle Gel|Vehicle Gel BID
76079058|NCT01174576|Other|caffeinated and decaffeinated coffee|3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
75330111|NCT03130738|Drug|14-Day Placebo - Oil Vehicle|14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
75330112|NCT00374920|Drug|MEM 1003|
75637477|NCT02766855|Drug|Cysteamine|Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
75637478|NCT04705701|Procedure|Hemodialysis|Renal replacement therapy is considered standard of care for end stage renal disease patients for clearing the blood and also helping with volume optimization, has different modalities, in our study we are using intermittent hemodialysis.
75637479|NCT02762643|Drug|DP-R213|Investigational product is prescribed to all of randomized subjects
75637480|NCT02762643|Drug|Raloxifene|Investigational product is prescribed to all of randomized subjects
75637481|NCT02762643|Drug|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
75637482|NCT02766699|Drug|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
75786517|NCT04133792|Drug|Simvastatin 40mg|40 mg orally daily for 5 years.
75786518|NCT04133792|Drug|Placebo oral tablet|40 mg orally daily for 5 years.
75786519|NCT01204034|Drug|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
76079059|NCT04641936|Other|No intervention required|No intervention required
76079060|NCT01134328|Drug|AC-150 Combo|1 drop in each eye for up to 14 days
76079061|NCT01134328|Drug|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
75637483|NCT04224363|Procedure|staining from cervical esophagus to esophagogastric junction|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
75786520|NCT01202240|Drug|Tasocitinib (CP-690,55) plus Ketoconazole|Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
75330113|NCT02977377|Other|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
75330114|NCT02977377|Other|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
75330115|NCT02976675|Biological|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
75637484|NCT04224363|Procedure|staining from esophagogastric junction to cervical esophagus|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
75637485|NCT04552041|Drug|Prospecta|Oral administration.
75637486|NCT04552041|Drug|Placebo|Oral administration.
75637487|NCT04222881|Procedure|AVF anastomosis|Type of arteriovenous anastomosis
75786521|NCT01204112|Drug|Tasocitinib (CP-690,550) plus Rifampin|Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
75786522|NCT05670314|Dietary Supplement|Inulin Fibre supplement|20g/ day. Inulin is easily dissolvable in liquid and can be incorporated into the usual diet - by adding to water, juice, smoothies, cereal, yogurt etc.
75786523|NCT05670314|Dietary Supplement|Maltodextrin (Placebo)|10g/ day which can be consumed by adding to breakfast cereal/ smoothie/ yogurt or drink of choice
75922777|NCT02300454|Device|Balloon|Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
75922778|NCT02157363|Procedure|Repositioning|
75922779|NCT02157363|Procedure|Single positioning|
75922780|NCT03368846|Drug|Varlitinib|[14C]-Varlitinib
76079062|NCT01134328|Drug|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
76079063|NCT01134328|Drug|Vehicle|1 drop in each eye once per day for up to 14 days
76079064|NCT04636554|Other|Phage Therapy|Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
76079065|NCT05165004|Behavioral|Kangaroo Mother Care|the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation
76079066|NCT05165004|Behavioral|Hammock Positioning|After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed
76079067|NCT05165004|Behavioral|Routine Care of NICU|; encircling the neonate in a fetal position using rolled towel inside the incubator.
75330116|NCT02976675|Biological|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
75637488|NCT02762409|Other|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
75330117|NCT04988373|Device|Modified aligner appliance|Patients will be treated using a single aligner appliance with NiTi Springs in order to align their crowding teeth.
75330118|NCT04988373|Device|Traditional fixed appliance|Patients will undergo typical orthodontic treatment using an MBT-prescription of metallic brackets.
75330119|NCT00983983|Dietary Supplement|Oxepa|Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
75470069|NCT05357924|Procedure|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
75470070|NCT05356520|Procedure|Endoscopy Ivor-lewis|Endoscopy Ivor-lewis
75470071|NCT05356520|Procedure|Laparoscopic transabdominal enlarged gastrectomy|Laparoscopic transabdominal enlarged gastrectomy
75786524|NCT05670314|Behavioral|Exercise|Joint Academy An app-based exercises platform (Joint Academy®) will be used as an intervention given to the treatment arm. The programme consists of a mixture of open and close chain exercises, a combination of concentric, eccentric and focusing on the global strength of legs including the muscles around the hips and knee joints as well as balance enhancement exercises.
75786525|NCT05670002|Dietary Supplement|Milk supplement|Children will take the milk supplement for a period of 6 months. During the intervention, anthropometry data, Zinc Protoporphyrin levels, dietary intake, any illness will be recorded.
75786526|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
75786527|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
75637489|NCT02762409|Other|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
75637490|NCT04224207|Biological|Wharton's jelly derived mesenchymal stem cell|The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .
75786528|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
75786529|NCT01204268|Procedure|Sev-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
75786530|NCT01204268|Procedure|Sevo continuous inhalation|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
75786531|NCT02965898|Dietary Supplement|Vitamin D 100ug|Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.
75786532|NCT02965898|Dietary Supplement|Vitamin D 10ug|Placebo dose. Minimal recommended dose.
75786533|NCT03843866|Other|4-0 Monocryl|sutures and steri-strips
75786534|NCT03843866|Other|Adhesive Glue|Adhesive Glue
75786535|NCT01204346|Other|MBT|The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
76079068|NCT04622124|Drug|Placebo|
76079069|NCT04622124|Dietary Supplement|fasted vs. high-fat meal|
76079070|NCT04622124|Drug|Placebo|
75330120|NCT00983983|Dietary Supplement|Jevity 1.5|Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
75330121|NCT00983983|Dietary Supplement|Jevity 1.0|Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
75330122|NCT00984139|Biological|Engerix™-B Kinder|Intramuscular, one dose.
75330123|NCT04672395|Biological|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22
75786536|NCT01204346|Other|treatment as usual|less intensive and structured psychotherapeutic program
75470072|NCT05334550|Other|Home Based Early Intervention by Parent|Through a video communication program called ZOOM, the parents of intervention group are educated once every two weeks for three months. Parent education consists of a program developed by our pediatric rehabilitation therapist to help premature infants develop motor skills. Parents provide daily exercise training to their children as educated.
75637491|NCT04223895|Drug|CKD-386 Formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
75330124|NCT04672395|Biological|Placebo; 0.9% saline|Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22
75330125|NCT04672395|Biological|SCB-2019 vaccine|Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant
75786537|NCT01567202|Procedure|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
75786538|NCT01567202|Drug|Chemotherapy|Temozolomide(TMZ), 200mg·m^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
76079071|NCT01134952|Drug|Mycophenolate to sirolimus switch|Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
75470073|NCT05326919|Other|Biobanking|For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.
75470074|NCT05286502|Device|fundus photography|color fundus photography
75470075|NCT05281302|Device|Neck muscle vibration|Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.
75786539|NCT01567202|Radiation|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
75786540|NCT01567202|Biological|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
75922781|NCT05533450|Device|Multi-focal rigid scleral contact lens|True scleral lenses rest on the sclera and do not touch the cornea and limbus, leaving a clear area between the contact lens and the cornea.
75330126|NCT04672395|Biological|SCB-2019 vaccine for Placebo|Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart
75330127|NCT03131206|Drug|Alectinib|"Oral, BID~Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."
75470076|NCT05281302|Device|Neck muscle vibration + sham-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy.. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. The tDCS will be automatically turned off after 20 seconds. This allows the reproduction of the initial mild itching sensation at the beginning of active tDCS, thus ensuring that the patient stays blind to the activation status of the device."
75470077|NCT05281302|Device|Neck muscle vibration + anodal-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. A continuous 2 mA current will be delivered for 20 minutes simultaneously to NMV stimulation. The stimulation will begin 5 minutes before the beginning of occupational therapy."
75470078|NCT05262010|Biological|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
75637492|NCT04223895|Drug|CKD-386 Formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
75330128|NCT03132298|Other|Implicit Theories of Personality Program|This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
75330129|NCT03132298|Other|Control Program|This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
75330130|NCT00985543|Drug|lopinavir/ritonavir|Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
75330131|NCT04978467|Device|Exoskeleton|Participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
75637493|NCT04223895|Drug|D012, D326 and D337|A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
75637494|NCT02762487|Device|The LINX® Reflux Management System|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
75637495|NCT04547283|Other|Usual Care|No clinical team recommendation, patients will remain in their natural choice of position
75470079|NCT05262010|Biological|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
75470080|NCT05189340|Other|Educational Videos|Series of six videos each covering a specific aspect of post-transplant care related to medication use or monitoring
75470081|NCT05155527|Drug|Ivermectin Tablets|6 mg/tablet
75470082|NCT05155527|Other|Placebo|The placebo has same form as Ivermectin.
75470083|NCT05151146|Drug|ANJ900|Metformin hydrochloride delayed-release tablets
75470084|NCT05151146|Drug|Metformin IR|metformin hydrochloride
75470085|NCT05068063|Drug|Bupivacaine Injection|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
75470086|NCT05068063|Drug|normal Saline|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
76079072|NCT03130686|Device|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
75330132|NCT05440305|Procedure|surgery type/exstirpation/debulking|Evaluation of benefit according to surgery
75330133|NCT05394415|Drug|Tislelizumab|The 1st and 2nd doses were administered concurrently with TP regimen chemotherapy, 200 mg each, on D1 and D22 by intravenous infusion. In patients with successful conversion therapy, one dose of 200 mg on D60, was administered sequentially at the time before surgery after radiation therapy, and two doses of immunotherapy, on D150 and 171, were administered 8 weeks after surgery in concurrent with the 3rd and 4th cycles of chemotherapy as adjuvant therapy; in patients with failed conversion, two doses of chemotherapy combined with tislelizumab, on D60 and D81, were administered 2 weeks after the completion of radiation therapy.
75470087|NCT05002452|Other|Search of factors predicting therapeutic effects and prognosis|There factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
75330134|NCT05394415|Drug|Paclitaxel|A TP regimen with paclitaxel 135 mg/m^2 + carboplatin AUC=5 was used, on D1 and D22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150, 171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, on D60, 81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
75330135|NCT05394415|Drug|Carboplatin|A TP regimen with paclitaxel 135 mg/m^2 + carboplatin AUC=5 was used, on D1, 22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150,171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, D60,81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
75330136|NCT05394415|Radiation|Radiotherapy|Radiotherapy was scheduled to be given on D1 of the 2nd cycle of chemotherapy. The primary lesions and/or lymph nodes in the operation area would be radiated in 2 stages. A dose of 30Gy/12F would be given in the first stage. When 12 Fractions were given, our MDT team would evaluate the regression of the lesions according to CT and MR results. If surgery is feasible, radiotherapy would be stopped for the primary lesions and lymph nodes in the operation area; if not resectable, the 2nd stage of radiotherapy would be given with a dose of 15Gy/6F, totaling to 45Gy/18F to the ESCC lesions. Radiotherapy for all lymph nodes outside the operation area was with DT of 45Gy/18F. All radiotherapy in this study was scheduled to be 2.5Gy/F, 1F/d, 5F/w. The preoperative radiotherapy target area was outlined by the consensus of the thoracic surgeon and radiotherapist.
75470088|NCT04967378|Behavioral|HEPPI|10 weekly individual sessions, 90 minutes each, at the participants' homes. The content of sessions includes psychoeducation, cognitive training, psychotherapeutic intervention, and compensatory strategy training.
75470089|NCT04948996|Behavioral|El Buen Consejo Móvil- Group (EBCM-G)|"Psycho-education and Information using a CBT toolbox approach.~Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol.~Additionally, participants in the Group Intervention will be able to communicate with and respond to one another through the group chat rooms within the app."
75470090|NCT04948996|Behavioral|El Buen Consejo Móvil- Individual (EBCM-I)|"Psycho-education and Information using a CBT toolbox approach.~Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol."
75470091|NCT04935437|Other|Supervised rehabilitation program.|The program includes aerobic exercise, strengthening exercises, physiotherapy, psychological support and dietary advice.
75470092|NCT04908657|Drug|Sildenafil 20 MG|oral sildenafil 20 mg three times per day for 3 years
75470093|NCT04896814|Procedure|Transcutaneous tibial nerve stimulation|The participant will be placed in the supine position with the soles of the feet together and the knees flexed and abducted at 90º. Two adhesive electrodes will be used for each leg. First one: 32 mm of diameter that will be placed in the posterior tibial nerve, that is, 4-5 cm cranial to the internal malleolus, between the posterior edge of the medial border of the tibia and the soleus tendon. Second one: 50x50 mm to be placed in the ipsilateral calcaneus. The electrodes will be connected to the NeuroTracTM PelviTone stimulation device. The stimulation range will be selected according to the tolerable pain limit for the patient, between 0.5 and 20 mA (adjustable in 1 mA levels).The intensity elevation will be allowed each time the patient perceives the fading of the previous sensation due to accommodation. Under no circumstances should the stimulation cause a painful feeling.
75637496|NCT04547283|Other|APPS|Clinical team guidance on prone positioning of patients
75637497|NCT04540341|Other|Mulligan mobilization|Mulligan mobilization technique will be apply.
76079073|NCT04590222|Other|blood sample|One blood sample of 60 mL (EDTA)
75330137|NCT03134092|Other|Probabilistic Risk Communication Tool (PRT)|The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
75470094|NCT04896814|Procedure|Placebo|The participant will be placed in the same position. Two 50 x 50 mm adhesive electrodes will be placed on the external face of the thigh, on a single leg. This area is outside the territory of the posterior tibial nerve. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied. This simulated current being considered to be insufficient to achieve therapeutic effects in the body and to be outside of the usual ranges described in electrotherapy manuals regarding pain management. The intensity will be selected according to the paint limit level of the patient, between 0.5 and 60 mA (adjustable in 0.1 mA levels), where a low or moderate sensation of the patient will be sought, without muscle contraction.
75470095|NCT04887389|Drug|Nano Silver Fluoride varnish|Nano Silver Fluoride(5%) is a new experimental formulation containing silver nanoparticles, chitosan and fluoride combines preventive and antimicrobial properties. It is a yellow solution and safe to be used in humans
75470096|NCT04887389|Drug|nano-hydroxyapatite varnish|nano-hydroxyapatite (10%) has antibacterial effect, higher solubility, surface energy and bioactivity and its structure is similar to dental apatite.
75470097|NCT04887389|Drug|sodium Fluoride Varnish|Fluoride varnish (5%) applied every six months is effective in preventing caries in the primary and permanent dentition of children and adolescents
75470098|NCT04836325|Procedure|transcranial static magnetic field stimulation (tSMS)|The intervention group will receive a treatment of tSMS in the primary motor cortex.
75470099|NCT04836325|Procedure|Sham transcranial static magnetic field stimulation|The placebo group will receive a dummy treatment
75470100|NCT04816734|Other|Self-report questionnaires|"Evaluation system of initial therapeutic education program about pediatric home parenteral nutrition.~The assessment takes place after the parents have participated in the therapeutic education program and before their child returns home."
75470101|NCT04747808|Drug|LL-BMT1|Drug-printed contact lens in both eyes
75470102|NCT04725552|Behavioral|'Change' - an e-health intervention|The aim of the e-health intervention is to support the patient's change process and facilitate the doctor's ability to help. We plan for a web-application instead of a native application. A web-application enables use from mobile devices and from computers and is thus not dependent on a specific mode or system. Before including patients (postponed to September 2020 because of the Corona-virus pandemic), about 30 members of the general public have tested the e-health intervention.
75637498|NCT04540341|Other|Core stabilization|Core stabilization technique will be apply.
75637499|NCT04540341|Other|Conventional therapy|Conventional therapy exercise will be apply.
75637500|NCT02762253|Drug|Riboflavin drops|Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
75637501|NCT02762097|Procedure|polypectomy|. During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.
75637502|NCT02762097|Procedure|saline sonography|saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
75637503|NCT02762097|Drug|normal saline|Normal saline would be injected into uterine cavity to delineate defects
75637504|NCT00746941|Drug|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
75637505|NCT02761863|Other|CD 74, VEGF detection|"All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.~The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).~The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade."
75786541|NCT01567202|Drug|blank placebo|Saline that has the same appearance with DC vaccine.
75786542|NCT02796170|Drug|Dapagliflozin|5mg pill taken once daily
75786543|NCT02796170|Drug|Placebo|5mg pill taken once daily- placebo of Dapagliflozin
75470103|NCT04724655|Other|gastric lavage with paraffin oil and bicarbonate|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube
75637506|NCT04532463|Drug|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week|To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
75786544|NCT02725658|Device|DOSI|Breast tissue properties scanning
75786545|NCT03844178|Procedure|The option for compensation of Pupil centroid shift was ON|The option for compensation of Pupil centroid shift was ON
75786546|NCT03844178|Procedure|The option for compensation of Pupil centroid shift was OFF|The option for compensation of Pupil centroid shift was OFF
75786547|NCT03844178|Drug|installation of Tetracaine 1%|installation of Tetracaine 1%
75922782|NCT05533450|Device|Rigid gas permeable contact lens|"RGP contact lens is designed from a special rigid hydrophobic material. Patients wear RGP contact lens to form a contact lens-tear-cornea system to correct irregular astigmatism, reduce aberrations, provide good visual quality, and control the development of the disease through mild shaping effect."
75922783|NCT02153385|Other|Yoga|Yoga program was 60 min per session, twice per week for 8 weeks. Led by an experienced yoga instructor.
75330138|NCT03134092|Other|Narrative Enhanced Risk Tool (NERT)|Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patients sharing their stories - put into a in a structured format of ~ 2-minute length and recorded.
75330139|NCT04352959|Device|mouthrinse with bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
75330140|NCT04352959|Device|mouthrinse without bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
75330141|NCT00360945|Drug|cisplatin|
75330142|NCT00360945|Drug|temozolomide|
75330143|NCT00360945|Genetic|fluorescence in situ hybridization|
75330144|NCT00360945|Genetic|loss of heterozygosity analysis|
75330145|NCT00360945|Other|immunohistochemistry staining method|
75330146|NCT00360945|Other|laboratory biomarker analysis|
75330147|NCT00360945|Radiation|radiation therapy|
75330148|NCT05394181|Other|Notification|Notification of patient and primary care clinician of presence of at least moderate coronary artery calcium on a prior non-gated chest CT
75330149|NCT03019237|Drug|anti-IgE|intranasal anti-IgE
75330150|NCT03019237|Other|intranasal allergen|intranasal allergen
75330151|NCT03019237|Other|intranasal saline|intranasal placebo
75330152|NCT03134248|Device|Dailies Aquacomfort Plus Toric|daily disposable contact lens
76079074|NCT01175434|Other|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
75330153|NCT03134248|Device|1-Day Acuvue Moist for Astigmatism|daily disposable contact lens
75470104|NCT04724655|Other|gastric lavage with coconut oil and bicarbonate|Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube
75330154|NCT03134248|Device|MyDay Toric|daily disposable contact lens
75470105|NCT04724655|Drug|standard treatment|inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
75786548|NCT03844178|Procedure|Photorefractive keratectomy (PRK)|periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)
75922784|NCT04525040|Dietary Supplement|ProbioKid®|Probiokid formulation includes three probiotic strains and fructooligosaccharides.
75922785|NCT04525040|Other|Pragmatic comparator|Standard of care as usual without a preventive intervention
75922786|NCT03377582|Other|Exercise|Both interventions uses exercises
75922787|NCT03377504|Behavioral|mirror therapy|Mirror therapy will include wrist flexion/extension, ulnar/radial deviation, hand finger flexion/extension and abduction/adduction, thumb abduction/adduction/opposition, and forearm supination/pronation movements as well as various object grasping activities according to the status of the patient's hand functions.
76079075|NCT01175902|Drug|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
76079076|NCT01175902|Drug|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
76079077|NCT05384730|Other|Group nutrition and exercise support|Weekly group nutrition and exercise support delivered online through trained volunteers
76079078|NCT01135186|Drug|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
75330155|NCT00361023|Drug|losartan|
75330156|NCT03019159|Device|Teleconsulting|
75330157|NCT00361101|Drug|AMD11070|200 mg PO BID (by mouth two times per day) for 10 days.
75330158|NCT03134326|Device|R1-25 and R2-25 Pulse Oximeter Sensor|
75330159|NCT00374998|Biological|FP9-PP (FP9 polyprotein)|
75330160|NCT00374998|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
75330161|NCT02976831|Drug|AZD0284|Oral solution, concentration: 2 mg/mL and 15 mg/mL
75330162|NCT02976831|Drug|Placebo|Placebo matching AZD0284 in the form of an oral solution with water.
75330163|NCT04959838|Behavioral|Impact of prolonged work|Evaluate the impact of prolonged work (up to 60 consecutive hours) on the surgical capacities evaluated on a simulator, as well as on stress markers (questionnaires, saliva assays, skin conductance, quality of sleep) compared to a standard day.
75330164|NCT04965129|Drug|Placebo|Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo
75470106|NCT04724655|Other|gastric lavage with saline and bicarbonate|Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube
75922788|NCT03377504|Behavioral|Routine physical therapy and exercise program|Routine physical therapy and exercise program including contrast baths, hot pack, TENS, desensitization, exercises and occupational therapy will be applied to all patients
75922789|NCT02157441|Procedure|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
76079079|NCT05379114|Other|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
76079080|NCT05379114|Other|Comparator device|well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
75637507|NCT04092361|Device|optical coherence tomography|It generates cross sectional images by analyzing the time delay and magnitude change of low coherence light as it is backscattered by ocular tissues. An infrared scanning beam is split into a sample arm and a reference arm. As the sample beam returns to the instrument it is correlated with the reference arm in order to determine distance and signal change via photodetector measurement. The resulting change in signal amplitude allows tissue differentiation by analysis of the reflective properties, which are matched to a false color scale. As the scanning beam moves across tissue, the sequential longitudinal signals, or A-scans, can be reassembled into a transverse scan yielding cross-sectional images, or B-scans, of the subject. The scans can then be analyzed in a variety of ways providing both empirical measurements (e.g. RNFL or retinal thickness/volume) and qualitative morphological information.
76079081|NCT05376228|Drug|Oral Vancomycin|As part of standard of care
76079082|NCT05164848|Drug|JMT101|JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.
75786549|NCT03843788|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
76079083|NCT05164848|Drug|Afatinib|Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
76079084|NCT05164770|Drug|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX|"Zanubrutinib+R-CHOP Regimen: Zanubrutinib 160mg bid; R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-DA-EPOCH Regimen: Zanubrutinib 160mg bid; R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-HD MTX Regimen: Zanubrutinib 160mg bid; R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
75330165|NCT04965129|Drug|Fish oil|All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
75637508|NCT02762019|Device|Laser therapy|Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.
75330166|NCT00986401|Drug|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
75786550|NCT04702724|Behavioral|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
75922790|NCT05361460|Other|Cognitive decline|This is an observation study with the aim of explore patients' experiences of their early and late postoperative cognition after major orthopaedic surgery in relation to postoperative cognitive function assessed with validated neuropsychological tests, inflammatory signalling molecules and quality of postoperative recovery as well as to describe the relative's view of early postoperative cognition.
75330167|NCT00986401|Drug|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
75330168|NCT04957498|Behavioral|Guided Self-Help for Family Based Treatment|A online website provided to parents containing information learned in Family Based Treatment and up to 12 coaching sessions with a therapist.
75637509|NCT02762019|Device|Sham therapy|Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
75637510|NCT04092049|Other|lollipop|chewing lollipop for 10 minutes
75637511|NCT02766621|Biological|PF-06823859|Comparison of different dosages of PF-06823859 to placebo
75922791|NCT02296398|Drug|Romidepsin|Received romidepsin per standard of care or through a clinical trial for more than one cycle
75922792|NCT02153463|Behavioral|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
75922793|NCT03377426|Drug|LYS228|LYS228 IV infusion
75922794|NCT03377426|Drug|Standard of care therapy|IV infusion of standard of care antibiotics
75922795|NCT03520062|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Treatment with Liraglutide (3.0mg per day) for ~6 weeks
75922796|NCT02206984|Drug|Tamoxifen|
75330169|NCT04957498|Behavioral|Family Based Treatment|Standard Family Based Treatment provided for up to 15 sessions.
75637512|NCT02766621|Drug|Placebo injection SC/IV|Comparison of Placebo to different doses of PF-06823859
75922797|NCT02206984|Drug|Anastrozole|
75922798|NCT02206984|Drug|Fulvestrant|
75922799|NCT02150655|Biological|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
75922800|NCT02150655|Biological|Placebo|
75637513|NCT02761707|Other|Electrical Brainstem Responses|Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
75786551|NCT02670902|Behavioral|Critical Time Intervention-Residential (CTI-R)|CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
76079085|NCT05164770|Drug|R-CHOP; R-DA-EPOCH; R-HD MTX|"R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
75470107|NCT04722835|Procedure|Bronchoscopy with Bronchoalveolar Lavage (BAL)|"Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage).~Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test.~Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device.~Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity.~Blood draw~Medical Health and Symptom Questionnaires~Physical Exam by study doctor to determine suitability and safety for participation."
75637514|NCT02761707|Other|Olfactory Tests|Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
75637515|NCT02761707|Other|Visual Deprivation|During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
75637516|NCT02761707|Other|Peripheral Nerve Stimulation|Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
75637517|NCT04019977|Other|Nurse Home Visiting Program|Brief nurse home visiting program
75637518|NCT04091815|Other|Type of anaesthesia|Two different types of anesthesia general vs combined (spinal and general)
75637519|NCT02761473|Other|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
75637520|NCT02761473|Other|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
75637521|NCT02599285|Device|Fixation|Fixation of the posterior malleolus with lag-screws or plate-fixation. If syndesmosis is intra-operatively stable, no syndesmotic positioning screws will be placed.
75637522|NCT02599285|Device|NO Fixation|Posterior malleolus will not be fixated. Syndesmotic positioning screws will be placed.
75637523|NCT02766387|Other|Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.|
75637524|NCT00746785|Drug|2.5 mg Olanzapine|2.5 mg
75637525|NCT00746785|Drug|5mg Olanzapine|5 mg
75637526|NCT00746785|Drug|placebo|placebo
75637527|NCT02761551|Behavioral|Reminder notifications via autodialer|
76079086|NCT05374668|Behavioral|Video-based Yoga Exercises|They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
76079087|NCT05164692|Combination Product|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
76079088|NCT05164692|Drug|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
76079089|NCT01922583|Drug|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
76079090|NCT01922661|Drug|REGN1908-1909|
76079091|NCT01922661|Other|placebo|
76079092|NCT05090982|Other|Audio recordings during the consultations|50 patients with audio recordings of the consultation
76079093|NCT05090982|Other|Audio recordings during the consultations and test of the shared medical decision-making tool for modification|50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification
75330170|NCT03018847|Device|COPD Co-Pilot|The COPD Co-Pilot is a system that guides a patient through a software application (web or mobile app) to collect, track, and trend daily symptoms related to Chronic Obstructive Pulmonary Disease (COPD). The system is intended to be used by patients as a support tool to track COPD symptoms as part of their personal disease management plan. The COPD Co-Pilot allows health care providers to view and triage subject symptoms via the provider web-based application. Health care providers also have the ability to send responses to subjects, like medication recommendations, through preset forms in the system.
75637528|NCT04515771|Behavioral|PARTNER-MH|The study intervention consists of a peer navigation program developed by the study team. The navigation program focuses on navigating VA mental health services, as well as patient engagement in mental health services and patient-provider communication. The intervention will last for 6 months, during which the participant will commit to regularly meeting with their peer specialist (interventionist). Peer navigation sessions will be guided by the specific aims of the study program, but in a way that is tailored to the participants' specific needs.
75637529|NCT04090021|Drug|Esomeprazole 40mg|Use in a drug combination for H. pylori eradication
75637530|NCT04090021|Drug|Clarithromycin 500mg|Use in a drug combination for H. pylori eradication
75330171|NCT00375076|Drug|enoxaparin|
75786552|NCT02670902|Behavioral|Enhanced Usual Discharge Services-Residential|The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.
75786553|NCT01204424|Device|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)
75798689|NCT01176396|Other|Caries prevention active intervention|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.~High Caries Risk The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office."
76079094|NCT05090982|Other|Audio recordings during the consultations and test of the shared medical decision-making tool for validation|50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.
75330172|NCT04897594|Drug|TERN-201|Investigational drug
75470108|NCT04669743|Other|Ozone exposure|Exposures will take place at the UCSF Human Exposure Chamber Core Facility. Ozone will be added to the air in the chamber and concentration measured every 30 seconds. Subjects will exercise for two 15-minute intervals of each hour on a cycle ergometer, and will rest for two 15-minute intervals between exercise sessions. The rate of exercise will be individually adjusted to produce a targeted minute ventilation of 15-20 L/min/m2 body surface area. Subjects will be sent home post-exposure and will return to the laboratory on the following day and six days after the exposure for bronchoscopy.
76079095|NCT05370222|Behavioral|Dietary weight loss intervention|Based on an energy assessment from the data collected at T0 (energy intake, physical activity level, and resting metabolism), individualized nutritional advice will be given during an interview in order to propose a dietary rebalancing and a light caloric restriction. Caloric restriction will be generated to decrease body weight by ≈ 0.5 to 1 kg per week, as advised in several publications. As for the dietary rebalancing, it will concern in particular the distribution of macronutrients and their nature (glycemic index, nature of lipids), the fibers intake, or the reduction of consumption of refined and/or energy-dense foods based on the ANSES Recommended Dietary Allowances and on the food consumption guidelines of the National Nutrition and Health Program.
76079096|NCT00634569|Biological|Flebogamma 5% DIF|Intravenous Immune Globulin (Human)
75330173|NCT04897594|Other|Placebo|Matching placebo
75330174|NCT02977143|Procedure|Fluid loading of volulyte 300 ml|Administration of volulyte 300 ml and measurement of increase in cardiac index
75330175|NCT00987415|Drug|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
75330176|NCT00987415|Drug|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
75330177|NCT04807504|Drug|Ropivacaine|All patients receive erector spinae plane blocks with ropivacaine.
75330178|NCT04784884|Device|HSI|diagnostic hyperspectral imaging
75330179|NCT04586751|Other|Pecs block|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed.
75330180|NCT04586751|Other|no Pecs block|no regional block will be performed in this arm
75330181|NCT04945395|Device|FES and Conventional training|The experimental group will be fitted with the Functional electrical stimulation system L300 Go to be used during 4 weeks of inpatient rehabilitation in the subacute phase after hemiplegic stroke. Settings will be adjusted continuously to enhance dorsiflexion of the affected foot during walking and mobility training.
75330182|NCT04945395|Device|AFO and Conventional training|The control group will be fitted with an ankle-foot-orthosis (AFO) according to clinical practice to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions during 4 weeks of inpatient rehabilitation including walking and mobility training in the subacute phase after hemiplegic stroke
75330183|NCT03138382|Device|Vestibular Nerve Stimulator|Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.
75330184|NCT03138382|Device|Sham stimulator|Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
75330185|NCT00955201|Behavioral|Exercise|Structured aerobic exercise (treadmill).
75330186|NCT00955201|Behavioral|Exercise|Structured isokinetic strength exercise (dynameter).
75330187|NCT04926129|Other|Other: Assessments|Administered as specified in the treatment arm.
75470109|NCT04655625|Biological|Group A (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 2-week intervals
75470110|NCT04655625|Biological|Group A (Placebo)|Placebo twice at 2-week intervals
75470111|NCT04655625|Biological|Group B (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 4-week intervals
76079097|NCT04396353|Other|Electronic questionnaire|Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).
76079098|NCT01175980|Other|Laboratory Biomarker Analysis|Correlative studies
76079099|NCT01175980|Drug|Vorinostat|Given PO
76079100|NCT04246554|Drug|Ketorolac|Oral ketorolac for pain control following ACL reconstruction surgery
76079101|NCT04246554|Drug|Oxycodone-Acetaminophen|Oral oxycodone-acetaminophen for post-operative pain control
75330188|NCT04707040|Other|Neurocognitive Exercise Program|Neurocognitive Exercise Program (NEP) is defined as a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercise progression is performed from easy to difficult, and consist of simple and complex tasks. Different sports equipment (such as different sizes of balls, racket, tulle, pilates ball, eye band, rope, etc.) is used in motor coordination exercises where multiple extremities can be used in NEP. These materials are used during different exercises including cross-limb movements, throwing, jumping, walking, involving different cognitive tasks. The cognitive task used and the degree of difficulty of the task are provided by different visual (colored cards, numbered cards, gestures, etc.) or auditory (keywords, ring signal, etc.) signs. For example, showing a red card might indicate throwing a ball with the left hand, while showing a blue card indicates throwing a ball with the right hand and walking forward
75330189|NCT04707274|Other|Survey study|Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire will be applied.
75330190|NCT04343547|Drug|DWP16001|Tablets, Oral, once daily single dose
75470112|NCT04655625|Biological|Group B (Placebo)|Placebo twice at 4-week intervals
75330191|NCT04343547|Drug|DWC202001+DWC202002|Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
75330192|NCT04343547|Drug|DWP16001+DWC202001+DWC202002|Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
76079102|NCT01922817|Drug|Saxagliptin|5mg saxagliptin
76079103|NCT04275765|Behavioral|Arm 2:Behavioral Intervention with nudges & Facebook interaction|Participants will receive nudges and be enrolled to Facebook group for self-learning.
75922801|NCT03373292|Procedure|Venous stenting for internal jugular vein stenosis|"After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg)."
76079104|NCT04275765|Other|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
76079105|NCT05697432|Diagnostic Test|Oral Examination|A complete examination of oral and dental hygiene any health problems will be registered
76079106|NCT05697432|Diagnostic Test|PUFA index|An assessment of the presence of oral conditions resulting from untreated caries. P=Pulpal involvement, U=ulceration, F=fistula, A=abscess index
76079107|NCT05697432|Diagnostic Test|Plaque index|An assessment of the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth. The index varies between 0-4.
75330193|NCT04707118|Drug|cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
76079108|NCT05697432|Diagnostic Test|Streptococcus mutans screening|A strip test for specific bacteria named streptococcus mutans, which plays an important role in caries formation, from patients' collected saliva
76079109|NCT05697432|Behavioral|Education|Education on correct toothbrushing technique, oral hygiene, dietary education on foods detrimental for dental hygiene.
76079110|NCT01176448|Device|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
76079111|NCT01176448|Device|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
76079112|NCT04275609|Other|AI generated report|After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
75330194|NCT04707118|Drug|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
75330195|NCT02977221|Procedure|Piezosurgery|The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
75330196|NCT03086356|Drug|Dabigatran etexilate|Days 1-4 and Day 8-11
75330197|NCT03086356|Drug|Idarucizumab|Day 11
75330198|NCT03140254|Drug|Chlorhexidine gluconate|
75470113|NCT04647734|Behavioral|High intensity interval training|12 weeks of high intensity interval training on exercise bike for 38 minutes 3 times a week
75470114|NCT04647734|Behavioral|Standard care|standard care after discharge from hospital (control group)
75470115|NCT04637893|Other|Colonoscopy|Pt. underwent colonoscopy
75637531|NCT04090021|Drug|Metronidazole 500 mg|Use in a drug combination for H. pylori eradication
75637532|NCT04090021|Drug|Amoxicillin 1000 MG|Use in a drug combination for H. pylori eradication
75637533|NCT04090021|Drug|Levofloxacin 500mg|Use in a drug combination for H. pylori eradication
75637534|NCT04090021|Drug|Rifabutin 150 MG|Use in a drug combination for H. pylori eradication
75637535|NCT04223973|Device|Medtrum A7+ insulin Pump|Use of the Medtrum pump during 3 months in combination with a CGM
75637536|NCT04223973|Biological|Lab A1C|Measure of Lab A1C at baseline and end of study
75637537|NCT00750919|Drug|esmirtazapine|
75637538|NCT02766309|Other|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker & Gandeck, 2002).
76079113|NCT04275609|Other|physicians writing report|After the endoscopic procedure, the physicians writing the report in computer according the procedure.
75330199|NCT03140254|Drug|N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride|
75637539|NCT02761161|Drug|Mianserin|mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.
75637540|NCT02761161|Behavioral|Imagery Rehearsal Therapy|IRT is add-on treatment to treatment as usual.
75330200|NCT03140254|Drug|Placebo|
75637541|NCT04094155|Diagnostic Test|retinal vascular analysis|Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
75637542|NCT02761395|Procedure|Al-hijamah|"Strict sterilization of selected anatomical sites.~Suction using sterile plastic disposable sucking cups~Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions."
75637543|NCT02761395|Drug|Deferasirox|20-40 mg/kg/day orally
75637544|NCT04091737|Biological|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734|"Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion~Plerixafor to mobilize hematopoietic stem cells prior to each apheresis~Single dose melphalan before administration of CSL200"
75786554|NCT01204424|Device|minimal invasive crestal sinus lift with the JEDER Systh.|"The mucous membrane is opened from the toothless part of the maxillary crest up to the bone and the bone is scraped by a cylindrical cutter in the shape of a tunnel up to slightly underneath the maxillary sinus membrane and hydraulic pressure is being built up within the DKK. A centrally placed drill within the DKK slowly moves in the direction of the membrane. At the moment of the first minimal perforation of the remaining bone the pressurized fluid pushes the membrane back and ensures that the membrane is not perforated by the drill.~The SVP is used to generate hydraulic vibrations, which help to further raise the membrane from the bone (principle of the percussion drill). After the maxillary sinus membrane has successfully been elevated, the working fluid is extracted and bone replacement material is introduced via the bore."
75922802|NCT03373292|Procedure|One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis|"Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time."
75922803|NCT03516006|Drug|UCMSC|infusion of aUCMSC at day 0, 7, 14, and 21
75786555|NCT00049842|Biological|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg Weekly QW SC for 36 months
75786556|NCT00307151|Drug|Lamivudine|4 mg/kg twice daily
75786557|NCT00307151|Drug|Lopinavir/ritonavir|16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
75786558|NCT00307151|Drug|Nevirapine|Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m^2/dose to max 200 mg twice daily
75786559|NCT00307151|Drug|Zidovudine|180 mg/m^2 twice daily
75786560|NCT03979157|Device|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
75922804|NCT03516006|Drug|UDCA|oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d
75922805|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
75922806|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
75922807|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
75922808|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
75922809|NCT03512652|Device|Patello|The Patello is a new intervention device which mobilizes the Patella passively and continuously in cranial-caudal direction to increase Patella mobility.
76079114|NCT04275921|Diagnostic Test|MRI scan|MRI analysis using TWIST and HASTE
76079115|NCT04275921|Diagnostic Test|4D MRI|4D MRI alongside 4D CT in lung cancer
76079116|NCT05350644|Other|Primary exposure variable|"Specific activated CD8+ T-cell transcriptome signature in biopsies is associated with better treatment outcome~Specific activated CD8+ T-cell transcriptome signature in blood is associated with better treatment outcome"
76079117|NCT05350644|Other|Other (exploratory) exposure variables|Specific transcriptomic signatures in intestinal biopsies and peripheral blood mononuclear cells (PBMCs) of IBD patients can work as a predictive biomarker for the tumor necrosis factor inhibitors (TNFi) treatment response
75330201|NCT04343391|Behavioral|Brief transdiagnostic cognitive-behavioral therapy|Time-limited transdiagnostic evidence-based psychological treatment
75330202|NCT04343391|Drug|Pharmacological treatment|Treatment as usual in PC
75637545|NCT02599207|Biological|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
75637546|NCT02761317|Drug|standard preparation (2L PEG-ELS)|Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
75330203|NCT03140722|Drug|vadadustat|vadadustat
75330204|NCT03140722|Drug|epoetin alfa|epoetin alfa
75330205|NCT03142438|Device|F&P Seal Improvement Project|Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
76079118|NCT04397289|Drug|Heparin and Rivaroxaban|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
75922810|NCT02157597|Other|NIRS based management|"Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair~Deepen anesthesia with volatile or intravenous agent.~Consider Extra-Corporeal Membrane Oxygenation (ECMO)."
76079119|NCT01135420|Behavioral|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
76079120|NCT01135420|Other|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
76079121|NCT04396275|Other|Food-1|Cooked whole navy beans (300 kcal)
75330206|NCT00982345|Drug|quetiapine (Seroquel XR)|Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
75330207|NCT00375622|Drug|Tamoxifen|
76079122|NCT04396275|Other|Food-2|Cooked whole yellow split peas (300 kcal)
75637547|NCT02761317|Drug|low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)|Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
75786561|NCT03978923|Device|preparation of the implant site with Piezosurgery vs drill|"The surgery was always performed by the same operator (M.M.) to reduce the bias of the study. Loco-regional anesthesia was performed with Mepivacaine hydrochloride with 1:100000 adrenaline.~For the preparation of implant sites using traditional methods, the drills were used following manufacturer's protocol by the implant system in use (WINSIX®- BioSAF IN s.r.l, Trezzano Rosa, Trezzano Rosa, Milano - Italy).~For the preparation of sites was used ultrasonic device, (Surgysonic II, Esacrom S.r.l., Imola, Italy). For the final preparation and insertion of implants, 5-6 ultrasound inserts were used in sequence as follows: tip-shape 1st insert (ES012X) and 2nd insert (ES052XG), crown-shape 3rd insert (ES040), 4th insert (ES041), 5 ° insert (ES043) and 6th insert (ES044).~The implant insertion was performed with a maximum torque of 35 Ncm. Finally, the cap screws were positioned, and the flaps were sutured in Vycril® 3.0."
75330208|NCT03087604|Procedure|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
75786562|NCT03981029|Other|4.0mg Folic Acid received through participation in FACT (NCT01355159)|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid intervention are provided below:~Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid"
75786563|NCT03981029|Other|Placebo received through participation in FACT|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid placebo are provided below:~Placebo x 4 tablets will be taken daily by oral administration."
75786564|NCT02654132|Drug|Elotuzumab|
75786565|NCT02654132|Drug|Pomalidomide|
75786566|NCT02654132|Drug|Dexamethasone|
75922811|NCT02157597|Other|Control|During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
76079123|NCT04396275|Other|Food-3|Cooked rice considered as control (300 kcal)
75330209|NCT03087604|Procedure|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
75330210|NCT03087604|Drug|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
75330211|NCT03090256|Device|AcrySof® IQ PanOptix™ IOL|Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
75330212|NCT00987727|Drug|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
75330213|NCT00987727|Drug|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
75637548|NCT02761317|Drug|high-volume preparation (4L PEG-ELS)|Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
75651798|NCT05584280|Device|Orsiro stent on shelf|Cluster randomization to Orsiro stent on shelf vs. control
75651799|NCT05584280|Device|Promus stent on shelf|Cluster randomization to Promus stent on shelf vs. treatment
75651800|NCT05566951|Other|Psychosocial program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
75922812|NCT02300532|Other|No intervention|
75922813|NCT02021578|Behavioral|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
75922814|NCT02021578|Behavioral|Written information|Reading materials about depression
75922815|NCT03373214|Biological|Na-GST-1|Na-GST-1/Alhydrogel®
75922816|NCT03373214|Biological|CPG 10104|CPG 10104
75922817|NCT02157675|Dietary Supplement|Polyherbal capsule|
75922818|NCT02157675|Dietary Supplement|Placebo capsule|
75922819|NCT03512574|Drug|Pregabalin|One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
76079124|NCT05697354|Procedure|Cognitive rehabilitation using interactive tablet|the cognitive rehabilitation exercises will be administered using the Khymeia VRRS Home Tablet. Patients will be asked to actively carry out exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
76079125|NCT05697354|Procedure|Cognitive rehabilitation using smartphone App Medico Amico|the cognitive rehabilitation exercises will be administered through patients' smartphone using the Medico Amico App. Patients will be asked to observe and concentrate on exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
76079126|NCT00634179|Drug|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
76079127|NCT00634179|Biological|Rituximab|Rituximab 375 mg/m²
76079128|NCT00634179|Drug|Doxorubicin|Doxorubicin 50 mg/m²
75637549|NCT04019899|Dietary Supplement|control group|"2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation."
76079129|NCT00634179|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m²
76079130|NCT00634179|Drug|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
76079131|NCT00634179|Drug|Prednisone|Prednisone 100 mg/day given orally on days 1-5
76079132|NCT01178944|Other|Laboratory Biomarker Analysis|Correlative studies
76079133|NCT01178944|Drug|Oxaliplatin|Given IV
76079134|NCT01178944|Drug|Pralatrexate|Given IV
76079135|NCT03011788|Drug|Golytely Oral Solution|Bowel purge prior to,colonoscopy
75637550|NCT04019899|Dietary Supplement|study group|"2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;~600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation."
75637551|NCT02761239|Device|The NIM 3.0 Nerve Monitoring System|Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
76079136|NCT01179490|Drug|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
76079137|NCT01179490|Drug|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
75637552|NCT02761083|Device|Novosyn® Quick|Eye surgery
75786567|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|0.5 mL, Subcutaneous
76079138|NCT01179568|Drug|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
76079139|NCT01179568|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
76079140|NCT01179568|Other|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
76079141|NCT01180036|Drug|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
76079142|NCT01180036|Drug|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine >30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
75637553|NCT02761083|Device|Vicryl® Rapid|Eye surgery
75637554|NCT00746551|Drug|Ferli-6® (Continental Pharm co., ltd.)|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
75637555|NCT00746551|Drug|Venofer® (Vifor AG, St. Gallen, Switzerland)|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
75651801|NCT05566951|Other|Standart care|Parents and children in the intervention group will be applied standard support approaches to be applied in the center where they receive treatment.
75651802|NCT05541393|Behavioral|Active Intervention Group|The intervention will involve meetings with the church health ministers to discuss COVID-19 vaccines and booster shots.
75786568|NCT01064141|Biological|OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|0.5 mL, Subcutaneous and 0.5 mL, Intravascular
76079143|NCT01180894|Drug|Iron sucrose|100 mg IV TIW
76079144|NCT01180894|Drug|Placebo|
75786569|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
76079145|NCT01181050|Drug|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
76079146|NCT01181050|Drug|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
76079147|NCT03011944|Other|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
75637556|NCT02766075|Behavioral|Supervised TAVR Exercise Program|Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait & Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
75637557|NCT04223817|Device|7.0 T RMI|Single 7.0 Tesla MRI of both hands in the same time
75637558|NCT02761005|Drug|Eradication of H. pylori|For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
75786570|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)|0.5 mL Subcutaneous and 0.5 mL Subcutaneous
75786571|NCT03241342|Drug|GTx 024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
75786572|NCT03241342|Drug|Placebo|Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
75786573|NCT02532803|Other|Novel Pelvic MRI scan assessment|A novel MRI assessment of early rectal cancers will be provided for all patients in MINSTREL
75922820|NCT03512574|Drug|Dexmedetomidine|One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
75922821|NCT03512574|Other|Placebo|One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
75922822|NCT03512574|Drug|Pregabalin and dexmedetomidine|One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
75922823|NCT03373136|Device|Polypectomy|Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
76079148|NCT03877926|Biological|AV7909|AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
75330214|NCT02160535|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
75637559|NCT02696577|Drug|Low dose aspirin|
75637560|NCT02696577|Drug|Omega 3|
75786574|NCT03837470|Drug|0.9% Sodium Chloride|Intravenous infusion of 0.25ml/kg/min of 0.9% sodium chloride intravenously for a total of 60 minutes
75786575|NCT03837470|Drug|Furosemide 40 mg|Bolus intravenous injection of 40 mg furosemide
75922824|NCT01994980|Drug|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
75922825|NCT03368768|Other|Obtain inform consent via questionnaire of Monkey Survey|This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
75922826|NCT02296554|Procedure|SLAP Repair|SLAP repair for SLAP tear
75922827|NCT02296554|Procedure|Biceps Tenodesis|Biceps tenodesis for SLAP tear
76079149|NCT03877926|Biological|BioThrax|BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
75330215|NCT04913337|Drug|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
75330216|NCT04913337|Drug|NGM707 plus pembrolizumab|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab~Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
75330217|NCT04913337|Drug|NGM707|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle."
75330218|NCT04913337|Drug|NGM707|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle."
75637561|NCT00753649|Biological|Infanrix™ hexa|Intramuscular, three doses
75786576|NCT04614844|Behavioral|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
75786577|NCT04614844|Behavioral|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
75922828|NCT02153697|Device|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
75922829|NCT02153697|Drug|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
76079150|NCT01181674|Drug|insulin glargine|sc injection
76079151|NCT01181674|Drug|metformin|oral administration
76079152|NCT01181674|Drug|acarbose|oral administration
75330219|NCT04913337|Drug|NGM707|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle."
75637562|NCT04093609|Genetic|XIST gene deletion|detection of XIST gene deletion by fluorescence in situ hybridization
75637563|NCT04091425|Drug|TAK-925|TAK-925 IV infusion
75922830|NCT03373058|Procedure|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m^2 and cisplatin 75 mg/m^2, respectively, 43°C, 90min.
75922831|NCT03373058|Procedure|cytoreductive surgery|Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.
75637564|NCT04091425|Drug|Placebo|TAK-925 placebo-matching IV infusion
75637565|NCT04223427|Procedure|Directional and single ring STN-DBS on gait|"Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~Surgery for STN-DBS electrodes implantation~Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~Intraoperative electrophysiological recordings~Intraoperative clinical evaluation~Intraoperative identification of the electrodes and final position with X-Ray~Post-operative 3D helical TDM without iode injection~STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~Placement of the neurostimulator (5 days after surgery)~Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)"
75637566|NCT04222491|Drug|Peanut oral immunotherapy|Peanut oral immunotherapy for peanut allergy
75637567|NCT02765685|Device|brace ODRA (PROTEOR company)|Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
75922832|NCT03373058|Drug|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group."
75922833|NCT02292342|Dietary Supplement|Water|Control
75922834|NCT02292342|Dietary Supplement|Epicatechin 0.1 mg/kg|EC 0.1 mg/kg
76079153|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
75651803|NCT05525377|Behavioral|Better living with non-memory led dementia course|Caregivers online training and educational phenotype-specific programme on how to support people with non-memory-led dementia.
75786581|NCT04572646|Other|NRT proposition and exhaled CO measurement|"Nicotine replacement therapy is proposed to every patient included in the study.~Whether the patient accepts the therapy or not, exhaled carbon monoxide is measured at the preoperative consultation (about 15 days before surgery) and the day of surgery by a nurse. These two measures are compared to assess efficacy of nicotine replacement therapy."
75922835|NCT02292342|Dietary Supplement|Epicatechin 0.5 mg/kg|EC 0.5
75922836|NCT02292342|Dietary Supplement|Epicatechin 1.0 mg/kg|EC 1.0
75922837|NCT02151045|Procedure|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
75330220|NCT04913337|Drug|NGM707 plus pembrolizumab|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle.~Drug: pembrolizumab~Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
75922838|NCT02151045|Procedure|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
75922839|NCT02296632|Behavioral|Motion sensors and daily online assessments|Patients will be asked to wear motion sensors during their waking hours and complete daily Patient Reported Outcomes online assessments.
75922840|NCT03377348|Procedure|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
75922841|NCT02157831|Biological|CP-870,893|
75922842|NCT02296710|Procedure|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
76079154|NCT01181674|Drug|insulin glargine|sc injection
76079155|NCT01181674|Drug|metformin|oral administration
76079156|NCT01181674|Drug|acarbose|oral administration
76079157|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
76079158|NCT01181674|Other|Standard glycemic care|as informed by the current clinical practice guidelines
75330221|NCT04913337|Drug|NGM707 plus pembrolizumab|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle.~Drug: pembrolizumab~Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
75330222|NCT05386459|Drug|Interferon Gamma|injection form
76079159|NCT01182376|Drug|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
76079160|NCT01182376|Drug|Placebo|Placebo will be administered by the patient's team according to established guidelines.
76079161|NCT01183312|Drug|Flumazenil|Sublingual flumazenil
76079162|NCT05219136|Other|Modified Fasting Group|a new fasting protocol is applied to subjects.
76079163|NCT05219136|Other|Conventional Fasting Group|a conventional fasting protocol is applied to subjects.
76079164|NCT03188172|Drug|Cyclophosphamide|Chemotherapy
76079165|NCT03188172|Drug|Bortezomib|Chemotherapy
76079166|NCT03188172|Drug|Lenalidomide|Chemotherapy
75330223|NCT02245945|Drug|TFV 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
75330224|NCT02245945|Drug|HEC Placebo Gel|Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
75470116|NCT04624581|Device|Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device|"This intervention measures the response to electrical stimulation of the sural nerve using a pair of percutaneous electrodes placed at the external malleolar retro passage of the nerve (2 cm apart) and connected to the stimulation device (Nicolet Vicking). Reflex muscle responses will be collected using surface electrodes placed on the femoral biceps muscle of the participant and connected to an Electromyogram recording device.~The RIII will be determined twice (rest period between each 10-minute). In order to induce the reflex nociceptive flexion response, repeated cutaneous electrical stimulations (30 to 40) will be applied at the level of the sural nerve following a variable interval of 6 to 10 seconds in order to overcome the phenomena of habituation and predictability. Each stimulus test will consist of a single rectangular pulse of 0.5 ms, of variable intensity (0-100mA) until a reflex nociceptive flexion threshold is detected or a maximum current of 100 mA is reached"
75637568|NCT02765685|Other|Usual care|"The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, …), non-medicinal (physiotherapy, port of an orthosis, …), even surgical, according to the influencers."
75637569|NCT00750139|Drug|NAFT-500|topical cream 1 application every day up to 4 weeks weeks
76079167|NCT03188172|Drug|Daratumumab|Chemotherapy
75330225|NCT04531761|Behavioral|Parent Support Program|The parent support program includes three modules aimed at increasing knowledge, positive attitudes, and supportive behaviors towards trans youth. Each online module includes several activities including writing prompts, videos, interactive quizzes, and other educational activities.
75470117|NCT04520516|Device|Active VAGUSTIM device|20min/day of stimulation at 25 Hz Frequency, 50 microsec pulse width with intensity escalation up to 15 mA or below in case of auricular discomfort
75470118|NCT04520516|Device|Sham VAGUSTIM device|The sham device : no electrical signal for VNS will be delivered.
75786582|NCT03837236|Other|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
75786583|NCT03636880|Behavioral|Brief treatment for Insomnia|This behavioral intervention provides participants with an individualized plan to modify sleep patterns contributing to insomnia, as well as education about sleep hygiene and habits that help and hurt sleep.
75922843|NCT02153775|Behavioral|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
75922844|NCT03368690|Dietary Supplement|Oligopin®|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
75922845|NCT03368690|Other|Placebo|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
76079168|NCT03188172|Drug|Dexamethasone|Chemotherapy
76079169|NCT03188172|Drug|Melphalan|Chemotherapy
76079170|NCT03188172|Drug|Filgrastim|Haematopoietic agent for the stem cell harvest
76079171|NCT05340036|Procedure|Bimaxillary orthognathic surgery using conventional plates|"le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion."
75330226|NCT03018613|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.
75637570|NCT00750139|Drug|Placebo 2-weeks|placebo cream 1 application every day for up to 4 weeks
75637571|NCT00750139|Drug|Naftin 1%|topical allylamine cream applied once a day for up to 4 weeks
75637572|NCT00750139|Drug|Placebo 4-weeks|topical placebo cream applied once a day for up to 4 weeks
75330227|NCT03018613|Other|Normal Saline|Normal saline and the traditional treatments for chronic functional constipation in part 2
75330228|NCT04342845|Behavioral|Experimental: Motivational interviewing Placebo Comparator: Traditional lectures|Patients in the intervention group (n=117) received a four-session patient empowerment program in small groups over one month by trained nurses and doctors. he control group received traditional lectures that consisted solely of conveying healthcare information to patients.
75330229|NCT03018535|Drug|Rituximab|Rituximab,1 g IV, day 1 and day 15
75786584|NCT03636880|Behavioral|Sleep Monitoring|This intervention involves using sleep diaries to track daily aspects of sleep, including bed time, wake time, hours of sleep, nighttime awakenings, daytime naps, and sleep quality.
75470119|NCT04487990|Drug|unfractionated Heparin|Addition of unfractioned heparin to CVVHD system already running under citrate regional anticoagulation.
75470120|NCT04476979|Drug|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3
75470121|NCT04476979|Drug|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
75637573|NCT04192461|Procedure|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the multi-radicular mandibular molars to be extracted as a reference and as an aid to engage the inter-radicular septum
75470122|NCT04411953|Drug|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
75470123|NCT04411953|Drug|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
75637574|NCT02765763|Drug|2-Minute Reveal Masque|
75330230|NCT03018535|Drug|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
75330231|NCT03018535|Drug|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
75330232|NCT02160847|Behavioral|DRIVE Program|The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
75637575|NCT02765763|Drug|24/7 Barrier Repair Cream|
75637576|NCT02765763|Drug|8-in-1 BioSerum|
75637577|NCT02765763|Drug|Null Formula 2-Minute Reveal Masque|
75637578|NCT02765763|Drug|Null Formula 24/7 Barrier Repair Cream|
75637579|NCT02765763|Drug|Null Formula 8-in-1 BioSerum|
75637580|NCT02765919|Radiation|HDR Brachytherapy of 9 Gy in 2 fractions|Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
75637581|NCT02765919|Radiation|HDR Brachytherapy of 7 Gy in 3 fractions|Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
75786585|NCT01199900|Drug|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
75786586|NCT01199900|Drug|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
75786587|NCT01199900|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
75922846|NCT03515928|Other|Ultrasonic noise exposure|Group will be exposed to 40kHz ultrasonic noise at 110-120 dB SPL for 15 minutes.
75786588|NCT01199900|Drug|PF-04171327|3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
75922847|NCT03515928|Diagnostic Test|Pure Tone Audiometry|Participants will undergo 2 (pre and post exposure) hearing tests
75922848|NCT03368612|Other|Electronic evaluation system|spirometry, plethysmography, cardiopulmonary exercise test
75922849|NCT03368612|Other|Electronic evaluation system|AirGo recording
75922850|NCT02255253|Drug|Telmisartan|capsule,40mg per day,2 months
75330233|NCT00360477|Procedure|Floseal|Bioglue that seals the kidney
75330234|NCT00360477|Procedure|Cope Loop|Nephrostomy tube for fluid drainage from the kidney
75330235|NCT00360477|Procedure|Fascial Stitch|Stitch that closes the kidney
75330236|NCT02975739|Device|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
75470124|NCT04411940|Drug|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
75470125|NCT04411940|Drug|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
75637582|NCT02765841|Drug|Lomitapide|
75637583|NCT02760771|Other|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
75637584|NCT02760771|Other|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
75637585|NCT00750061|Drug|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks."
75470126|NCT04309734|Drug|AT-777|Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.
75470127|NCT04309734|Drug|Placebo|Administered orally, as one or two placebo capsules, depending on the arm.
75470128|NCT04309734|Drug|AT-527|Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm.
75637586|NCT00750061|Drug|Placebo|Matching placebo
75922851|NCT02255253|Drug|Hydrochlorothiazide|tablet, 25mg per day, 2 months
75922852|NCT02296788|Behavioral|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
75922853|NCT02300688|Drug|Treatment A|administration of 1 time administration of the test drug (Treatment A)
75922854|NCT02300688|Drug|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
76079172|NCT05340036|Procedure|Bimaxillary orthognathic surgery using patient specific plates|"The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws."
76079173|NCT01184014|Drug|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
76079174|NCT01184014|Drug|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
76079175|NCT03130140|Procedure|Macroscopic on-site evaluation|Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
76079176|NCT03130140|Other|Control|Conventional EUS-FNA
76079177|NCT01185028|Drug|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
76079178|NCT03011866|Drug|Wound topically irrigated with 500mg TXA|
76079179|NCT03011866|Drug|1mg/kg/hr TXA intravenous infusion till the last suture|
76079180|NCT05263596|Diagnostic Test|dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound|"Results from the routine geriatric assessment:~Mini Mental State Exam (MMSE)~Clock-drawing test (CDT)~Geriatric depression scale (GDS)~Functional independence measure (FIM) at admission~Timed up and go Test (TUG)~Gait speed~Hand grip strength (HGS)~Nutritional risk screening (NRS)~Additional measurements:~Chair-stand-test~Clinical frailty scale (CFS)~Calf circumference and mid-arm circumference~Body impedance analysis (BIA)~US~DXA"
76079181|NCT05199168|Procedure|intraoperative nerve monitoring|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
76079182|NCT01143142|Behavioral|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
75786589|NCT01199900|Drug|PF-04171327|10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
75922855|NCT02151201|Behavioral|Influenza vaccination video education|Influenza vaccination video education
76079183|NCT02186938|Device|FloTrac|
76079184|NCT05190822|Other|College student|Our research will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students studying in departments other than Physiotherapy and Rehabilitation at Acibadem Mehmet Ali Aydinlar University.
76079185|NCT02187016|Device|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
76079186|NCT02187016|Device|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
76079187|NCT02187016|Device|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
76079188|NCT02187016|Device|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
75786590|NCT01199900|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
75786591|NCT01199900|Drug|Prednisone|5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
75786592|NCT03841838|Other|Energy drink|Two 12 oz bottles of commercially available energy drink
75786593|NCT03841838|Other|Placebo drink|Two 12 oz bottles placebo drink. Placebo drink will contain carbonated water, lime juice, and cherry flavoring.
75922856|NCT02151201|Behavioral|Hand washing video education|Hand washing video education
76079189|NCT05439798|Drug|Ondansetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
76079190|NCT05439798|Drug|Palonosetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
75922857|NCT03368378|Procedure|Early DVC ligation|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
76079191|NCT05439798|Drug|Dexamethasone|Dexamethasone
76079192|NCT02188576|Drug|high dose TXA|
76079193|NCT02188576|Drug|Low dose TXA|
75786594|NCT03841916|Diagnostic Test|transvaginal ultrasound|transvaginal ultrasound to measure endometrial thickness
75786595|NCT01200056|Drug|Atorvastatin 10mg versus 40mg.|2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
75637587|NCT04223739|Drug|Landiolol|"Landiolol infusion with incremental doses (range from 2,5µg/kg/min to 80 µg/kg/min) with go of heart rate < 90 bpm. Doses are modified every 10 minutes if necessary.~Once heart rate goal is obtained, switch to an oral dose of Bisoprolol."
75470129|NCT04264767|Procedure|Blood collection|Peripheral blood collection via routine venipuncture
75637588|NCT04223739|Drug|Amiodarone|Amiodarone loading dose of 5-7 mg/kg in 1 hour followed by an infusion of 1 g/day until conversion to sinus rhythm. Once sinus rhythm is obtained, switch to an oral dose of 200mg/day
75637589|NCT04091269|Device|automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence|The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
75637590|NCT02765997|Biological|Unmanipulated UCB|Unmanipulated UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen [G-CSF] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
75637591|NCT02765997|Biological|SR-1 UCB|SR-1 UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen [G-CSF] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
75637592|NCT00916981|Procedure|percutaneous autologous preosteoblast cells implantation|percutaneously injection of preosteoblast into the nonunion under radioscopic control
75637593|NCT02765607|Procedure|Heart surgery|
75786596|NCT01204502|Biological|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~dose 1 5x104 cells/kg~dose 2 5x105 cells/kg"
75922858|NCT03896984|Drug|Radium-223 (Xofigo, BAY88-8223)|Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
75922859|NCT03896984|Drug|Abiraterone|Abiraterone is a CYP17 inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2011, and for patients with metastatic high-risk castration-sensitive prostate cancer in 2018.
75922860|NCT03896984|Drug|Enzalutamide|Enzalutamide is an androgen receptor inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2012, with warning and precautions added in 2017 regarding the risk of seizure and encephalopathy.
75922861|NCT02292498|Device|FLIR ONE|
75637594|NCT02765295|Device|medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
75637595|NCT02765295|Device|Medical molecular mesh oxygen generator|"medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation."
75637596|NCT02765529|Procedure|Blood sampling|
75922862|NCT02151279|Other|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
75922863|NCT02151279|Other|Control|
75922864|NCT03519828|Other|No intervention has been conducted|It is an observational study, and no intervention has been conducted
75922865|NCT02157987|Drug|bevacuzimab spray|
75330237|NCT05386069|Drug|NOMO Protocol|Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
75330238|NCT00989911|Drug|Bosentan|Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
75786597|NCT02473874|Device|Skin Spect dermoscope|Skin imaging
75922866|NCT03861728|Device|0.01% Hypochlorous acid|Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
75922867|NCT03861728|Other|Placebo|Placebo to be used four times a day to the affected eye for 2 weeks
75922868|NCT02159313|Drug|Riociguat(Adempas,BAY63-2521)|Single dose of a whole 2.5 mg riociguat tablet
75922869|NCT03377114|Procedure|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
75330239|NCT05343091|Device|cardiac ultrasound|Cardiac ultrasound with Pocket ultrasound by expert and non expert physician
75470130|NCT04264182|Other|ICD programming|Re-programming of the ICD device for VA detection (see above)
75470131|NCT04225962|Other|Intimate quality of life questionnaire|Preparation of an intimate quality of life questionnaire
75470132|NCT04202185|Other|Data collection|Retrospective collection data from diagnostic Data collected following to medical exam as part of care
75470133|NCT04202185|Genetic|Genetic analysis|Research of mutation and identification of genetic panel as part of care
75786598|NCT02473874|Device|Spatially modulated quantitative|Skin imaging
75922870|NCT03377114|Procedure|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
76079194|NCT05439720|Dietary Supplement|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.
76079195|NCT05439720|Dietary Supplement|Placebo|Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.
75922871|NCT03515772|Drug|Co-administration of darunavir with a cardiovascular drug|Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
75637597|NCT02760537|Behavioral|Lay Health Worker Intervention|Lay Health Worker Phone Intervention The second phase addressed phone intervention training, where LHWs who had completed the first phase and were willing to participate in the second phase learned the process for calling participants to remind them to complete a series of HBV vaccinations. The LHWs assigned to the intervention group conducted phone interventions by reminding participants about completing a series of vaccinations at Months 1, 2, and 6, and also provided accompanying resources and support.
76079196|NCT05439720|Behavioral|Exercise|A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
76079197|NCT05439642|Other|Evaluation of health related quality of life|Evaluation of health related quality of life of boys with hemophilia with the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool and the Pediatric Inventory of Quality of Life
75330240|NCT05311891|Diagnostic Test|RT PCR|Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
75330241|NCT04038957|Drug|SEP-363856|SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule
75330242|NCT05189119|Diagnostic Test|non invasive ventilation|invasive mechanical ventilation session in the BIPAP Mode with a pressure support (PS) level of 5cmH2O, a positive end expiratory pressure (PEEP) level of 5 cmH2O and an inspiratory fraction of oxygen (FiO2) allowing a pulse saturation (SpO2) of at least 92% for a one minute and followed by an increase of the PS level to 30cmH2O.The plethysmographic PAR (PAR) was calculated based on the following formula: PARpleth= PP30 / PP5
75330243|NCT02977065|Drug|Atorvastatin 20mg|PO daily for 4weeks
75637598|NCT02760537|Behavioral|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
75330244|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 50 mg|PO daily for 4weeks
75798690|NCT01176396|Other|control treatment|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk Control group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).~High Caries Risk The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding)."
75637599|NCT02765451|Behavioral|interventions of the Cancéropôle Nord-Ouest|"During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,....."
75922872|NCT02158065|Other|Coaching program|The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
75330245|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 100 mg|PO daily for 4weeks
75330246|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 200 mg|PO daily for 4weeks
76079198|NCT02189122|Drug|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
76079199|NCT02189122|Drug|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
76079200|NCT02189122|Drug|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
76079201|NCT02189122|Drug|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
76079202|NCT02189122|Drug|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
75330247|NCT02977065|Drug|Rosuvastatin 10 mg|PO daily for 4weeks
75330248|NCT02977065|Drug|Rosuvastatin 10 mg + CKD-519 100 mg|PO daily for 4weeks
75330249|NCT03018769|Drug|Chinese Herb|
76079203|NCT02189122|Drug|Placebo|Subjects will take matching placebo for five days.
76079204|NCT05309460|Drug|Labetalol Oral Tablet|See Labetalol arm.
76079205|NCT05309460|Drug|NIFEdipine ER|See Nifedipine arm.
75330250|NCT04031547|Device|Transcranial Electrical Stimulation (tES)|In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
75330251|NCT04343937|Procedure|retrolaminar block|local anesthetic injection on the between the lamina of the vertebra and the paraspinous muscle
75330252|NCT04886427|Other|No intervention|Measure the experiences of the current care
76079206|NCT03261804|Behavioral|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
76079207|NCT01093690|Drug|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
75470134|NCT04186377|Other|Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers|Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing
76079208|NCT01093690|Drug|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
76079209|NCT05301426|Other|Stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
76079210|NCT05301426|Other|Neural slippage of the sciatic nerve.|Neurodynamic technique on the sciatic nerve.
76079211|NCT05301426|Other|Passive upper limb mobilisations.|Passive mobilisations performed on the upper limbs used as a placebo.
76079212|NCT04455360|Other|Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol|EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.
76079213|NCT01143610|Procedure|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
76079214|NCT01143610|Other|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
76079215|NCT05439486|Device|hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
76079216|NCT01143688|Drug|albuterol|
76079217|NCT01143688|Drug|placebo inhaler|
75330253|NCT03146806|Drug|Intranasal ketamine|"10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse."
75922873|NCT02296944|Other|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
75470135|NCT04186377|Drug|S26E|Daily application of S26E extract on wound site
75922874|NCT03368300|Other|Clinical and biological exam|"The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma)."
75470136|NCT04068792|Other|RSV Mobile Application|Participants will not receive any intervention in observational phase of this study. Participant's respiratory symptoms will be captured by RSV mobile application installed in participant's caregiver/parent mobile phone.
75637600|NCT02760303|Behavioral|Cognitive Behavioral Therapy|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.
75637601|NCT02760303|Behavioral|Mindfulness Based Stress Reduction|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.
75798691|NCT01287312|Procedure|Endoscopic repair of recurrent TEF by trichloroacetic acid aplications|
75798692|NCT03865134|Diagnostic Test|Snellen Test|Visual acuity measurement
75798693|NCT03865134|Diagnostic Test|Autorefractometer|Refraction measurement
75798694|NCT03865134|Diagnostic Test|Titmus Stereo Fly Test|Stereopsis measurement
75922875|NCT02300844|Drug|NNC0174-0833|"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."
75922876|NCT02300844|Drug|placebo|Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
75922877|NCT03124628|Other|Flywheel resistance exercise|Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.
75798695|NCT03865134|Diagnostic Test|Optical Kohlerans Tomography|Retinal development measurement
75798696|NCT03865134|Behavioral|Investigation of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
75798697|NCT03865134|Behavioral|Peabody Developmental Motor Scales - II|Evaluation of motor development
75798698|NCT03865134|Behavioral|World Health Organization Quality of Life - BREF|Assesment of quality of life
75798699|NCT03865134|Behavioral|State - Trait Anxiety Inventory|Assesment of anxiety
75922878|NCT03124628|Other|Weight-stack resistance exercise|Conventional weight-stack resistance exercise
75922879|NCT03519750|Drug|Melatonin 25 mg|24-48 hour monitoring of plasma melatonin as well as adverse events.
76079218|NCT01143688|Procedure|placebo acupuncture|
76079219|NCT04455594|Drug|Almonertinib|Oral, 110mg QD
76079220|NCT04455594|Drug|Erlotinib|Oral, 150mg QD
76079221|NCT04455594|Drug|Cisplatin|Cisplatin(75mg/m2) be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
76079222|NCT04455594|Drug|Carboplatin|Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
76079223|NCT04455594|Drug|Pemetrexed|Pemetrexed (500mg/m2) to be administered with Cisplatin(75mg/m2) or Carboplatin (AUC=5) on Day 1 of every 3-week cycle for 3 cycles
75330254|NCT03090958|Behavioral|AllyQuest|AllyQuest is a novel, high impact secondary prevention intervention delivered via mobile phones to improve linkage and engagement in care among newly diagnosed HIV+ YMSM. The development of this intervention is both timely and vital given the urgency of the ongoing HIV epidemic among YMSM. The features of the intervention aim to target previously identified barriers to care among newly diagnosed youth, namely, low HIV health literacy, lack of social support, and internalized stigma related to their diagnosis.
75330255|NCT04468516|Device|KKT|Vibroacoustic sound waves applied focally.
75637602|NCT02760303|Behavioral|Diabetes Support and Education|Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
75786599|NCT05668442|Behavioral|Online exercise and group meetings|"The intervention consists of 8 weeks of 30 minutes of online supervised high intensity physical exercise followed by 30 minutes of online group meeting once a week in Microsoft Teams. The program consist of a short warm-up, followed by interval.-based physical activity including bodyweight aerobic and strength training, followed by stretching.~Following the online exercise session, participants will be sent out in smaller break-out rooms in Microsoft Teams. The online group meeting sessions are intended to serve as a platform for group discussion evaluation of weekly physical acitvity.~Each online group will be facilitated by a participant. All participants will be encouraged to set physical activity goals to increase habitual physical activity As a part of the intervention, participants will wear a Garmin Vivofit 4 activity watch or a Garmin 245 watch."
75786600|NCT01200134|Other|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
75786601|NCT01200212|Drug|Taxane, Avastin|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
75786602|NCT01200212|Drug|Taxane, Avastin, Xeloda|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
75637603|NCT02765373|Drug|Exemestane|
75786603|NCT00306995|Biological|SB218352_15|Non-adjuvanted pandemic influenza A formulation 1 vaccine
75786604|NCT00306995|Biological|SB218352_8|Non-adjuvanted pandemic influenza A formulation 2 vaccine
75786605|NCT00306995|Biological|SB218352_4|Non-adjuvanted pandemic influenza A formulation 3 vaccine
75786606|NCT00306995|Biological|SB218352_2|Non-adjuvanted pandemic influenza A formulation 4 vaccine
75922880|NCT02159391|Behavioral|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
75922881|NCT03372668|Other|massage therapy combined with components of mirror therapy|"Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb."
75922882|NCT03512340|Drug|SRF231|SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
75637604|NCT02765373|Drug|Letrozole|
75637605|NCT02765373|Drug|Anastrozole|
75922883|NCT02158143|Dietary Supplement|vitamin D3|
75922884|NCT03372590|Other|NICU-based rehabilitation bundle|Maternal-driven gestational age-appropriate intervention/activity bundle, including the evidence-based elements of vocal soothing, comforting touch, scent exchange, kangaroo care, and infant massage
75922885|NCT03372590|Other|Standard of care|Standard NICU care
75330256|NCT04468516|Device|sham KKT|sham KKT
75637606|NCT02760615|Drug|Caffeine|Caffeine tablets
75637607|NCT02760615|Drug|Losartan|Losartan tablets
75786607|NCT00306995|Biological|SB218352_8AL|Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
75786608|NCT00306995|Biological|SB218352_4AL|Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
75786609|NCT00306995|Biological|SB218352_2AL|Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
75786610|NCT00121108|Biological|Motavizumab|Intramuscular dose of motavizumab 15 mg/kg will be administered every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
75786611|NCT00121108|Other|Placebo|Intramuscular dose of placebo matched to motavizumab will be administered every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
75786612|NCT03978845|Drug|Lidocaine|Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
75637608|NCT02760615|Drug|Omeprazole|Omeprazole capsules
75637609|NCT02760615|Drug|Dextromethorphan|Dextromethorphan capsules
75637610|NCT02760615|Drug|Midazolam|Midazolam syrup
75637611|NCT02760615|Drug|Vedolizumab|Vedolizumab solution for IV infusion
75637612|NCT02760459|Drug|Dexamethasone|
75637613|NCT02760459|Drug|Normal saline solution|
75637614|NCT02765217|Drug|Lactobacillus reuteri DSM 17938|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
75330257|NCT04706806|Dietary Supplement|apple cider vinegar|2 tablespoons diluted in water taken twice daily with meals
75330258|NCT04706806|Dietary Supplement|vinegar pill|one pill taken daily
75470137|NCT04068792|Drug|Placebo|Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.
75470138|NCT04068792|Drug|JNJ-53718678 2.5 mg/kg|JNJ-53718678 will be administered to Age Group 1 twice daily for 7 days.
75637615|NCT02765217|Drug|Placebo|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
75330259|NCT00362349|Drug|IgNextGen 10%|"Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days"
75637616|NCT02765217|Drug|Amoxicillin-Clavulanic Acid|All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
75922886|NCT02158221|Drug|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
75922887|NCT02292576|Other|Cocoa Pure|Cocoa Pure.
76079224|NCT05439408|Drug|Dasatinib ASD 100 mg|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation
76079225|NCT05439408|Drug|Dasatinib 140 MG [Sprycel]|SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
76079226|NCT05261880|Other|Neural mobilization|Neural mobilization and bone are two common physical therapy interventions used for Carpal Tunnel Syndrome. Neural mobilization reinstates the plasticity of the nervous system and restoring the capacity of stretching.
75330260|NCT03997929|Diagnostic Test|1.3 BETA D GLUCAN|dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)
75330261|NCT03438357|Other|Analysis of cerebral MRI with automatic segmentation software|Pixyl.Neuro software versus manual analysis of lesions
75330262|NCT02975427|Other|Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
75330263|NCT02975583|Drug|Vorapaxar|2.08 mg oral tablet daily
75330264|NCT02975583|Drug|Placebos|Placebo oral tablet daily
75330265|NCT03983421|Other|Screening|Screening for Early Psychosis and Clinical High Risk of Psychosis
75330266|NCT03983421|Other|Warm Hand-Off|Among those determined eligible, transfer of care between the student health and counseling center and the coordinated specialty care program outreach coordinator occurring over the phone while the student is in the counselor's office immediately following the results of the screening.
75330267|NCT02974959|Device|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
75637617|NCT02760381|Device|NBI + Acetic Acid (AA)|Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
75637618|NCT02760225|Drug|89Zr-Pembrolizumab|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
75637619|NCT02760225|Device|89Zr-Pembrolizumab PET|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
75637620|NCT02764983|Behavioral|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2
75786613|NCT02387996|Drug|Nivolumab|
75786614|NCT03841370|Procedure|endodontic treatment|Color measurements of endodontically treated teeth (incisors, canines or premolar) will be collected regardless of technique, treatment time and sealer used.
75786615|NCT01204580|Drug|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
75470139|NCT04068792|Drug|JNJ-53718678 3 mg/kg|JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
75470140|NCT04068792|Drug|JNJ-53718678 4.5 mg/kg|JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
75470141|NCT04060134|Other|SimpliDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
75470142|NCT04060134|Other|AlloDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
75786616|NCT01566812|Behavioral|Breast feeding optimization|Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
75786617|NCT01566812|Behavioral|Usual care|Usual care applied in the hospital
75922888|NCT02292576|Other|Placebo|Placebo.
75922889|NCT02158299|Drug|Avitene|
75922890|NCT02158299|Drug|Sapylin|
75922891|NCT02158299|Behavioral|axillary drainage|
75922892|NCT02158299|Other|reexamine|
76079227|NCT05261880|Other|Scaphoid , hamate mobilization|Bone mobilization in Carpal Tunnel Syndrome involves gliding at scaphoid and hamate.
76079228|NCT04453800|Drug|sofadil【Neu2000KW】|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
76079229|NCT04453800|Drug|Sofadil|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
76079230|NCT04453800|Drug|Sofadil|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
75330268|NCT02974959|Device|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
75637621|NCT02764983|Behavioral|Fitness-to-Drive Screening Measure|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
75637622|NCT02764983|Other|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Strength. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
75637623|NCT02764983|Behavioral|Propensity for Angry Driving Scale|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
75922893|NCT03512106|Other|Acupuncture|Chinese traditional acupuncture
75786618|NCT04673708|Diagnostic Test|H - Test|Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
75637624|NCT02764983|Behavioral|Community Integration Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
75330269|NCT03095638|Drug|Conventional dolutegravir 10 mg tablet|Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
75330270|NCT03095638|Drug|Conventional dolutegravir 50 mg tablet|Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
75330271|NCT03095638|Drug|Dispersible dolutegravir 5 mg tablet|Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
75922894|NCT02519816|Other|Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.|
75922895|NCT02297022|Device|Deep Brain Stimulation|Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
75470143|NCT04060134|Other|AlloMax HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
75637625|NCT02764983|Behavioral|Satisfaction with Life Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
75637626|NCT02764983|Procedure|Driving simulator evaluation|The driving simulator evaluation uses a driving simulator with simulated drives engineered to address Veteran driving concerns such as reactions to other drivers and road conditions (e.g., debris). The simulator is used at baseline and post-tests 1 and 2. The intervention sessions (X3) also occur using simulator.
75786619|NCT05181514|Other|20% Intralipid|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of 20% fat emulsion (Intralipid 20%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-[2H2]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of [U-13C] glucose.
75798700|NCT01285674|Drug|Intra-tympanic Cisplatinum|Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
75922896|NCT02519894|Behavioral|Dietary Scanning Calculator|
75922897|NCT03372512|Diagnostic Test|Bioimpedance spectroscopy|Fluid overload will be assessed by bioimpedance spectroscopy
75922898|NCT02301000|Biological|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
75922899|NCT02301000|Drug|Metronidazole|Peroral metronidazole 400 mg t.i.d. for ten days
75922900|NCT02154165|Other|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
75922901|NCT02158455|Procedure|NT SVG grafts|
75922902|NCT02292732|Drug|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter [mm]) to be taken orally and once daily
75922903|NCT02292732|Drug|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
75922904|NCT02292732|Drug|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
75922905|NCT02292732|Drug|Placebo|Each green tablet will contain only inert ingredients: D&C yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
76079231|NCT04453800|Other|placebo|Saline was administered intravenously
76079232|NCT01188460|Behavioral|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
76079233|NCT01188460|Behavioral|Sleep diary|
76079234|NCT03011476|Drug|Donepezil|"Start with 5 mg/day for 4 weeks~Increased to 10 mg/day for 8 weeks"
75637627|NCT02764983|Other|Focus Group Discussion Interview Guide|Focus group discussion will occur once using the interview guide
76079235|NCT03011476|Drug|Placebos|"Start with 5 mg/day for 4 weeks~Increased to 10 mg/day for 8 weeks"
76079236|NCT05438784|Procedure|orbital bone reconstruction with patient specific titanium implant|orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology
76079237|NCT05438784|Procedure|orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model|orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
76079238|NCT02522754|Biological|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
75786620|NCT05181514|Other|Normal Saline|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of normal saline (Sodium Chloride 0.9%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-[2H2]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of [U-13C] glucose.
76079239|NCT02522754|Biological|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
75637628|NCT04685967|Device|Glass ionomer|Equia Forte HT, GC, Tokyo, Japan
75637629|NCT04685967|Device|Bulk-fill composite|SonicFill2, Orange, CA, USA
75637630|NCT00744757|Drug|Decitabine|Decitabine 20 mg per m^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
75786621|NCT04662398|Device|JT Device|Shocker giving electrical shocks on testes
75786622|NCT03841786|Other|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.
75786623|NCT03841786|Other|Control Diet|Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week
75786624|NCT04644614|Device|Magnetic Stimulation - Armchair type|MS and Sham MS will be applied two days a week, 20 minutes a day, for 8 weeks, a total of 16 sessions.
75786625|NCT05181202|Other|Blood sampling|Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.
75637631|NCT02760147|Device|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
76079240|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
75637632|NCT02760147|Device|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
76079241|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
75637633|NCT02760147|Device|PEEP Over Level|PEEP Level upward by 50%, 2 hours
75786626|NCT02016248|Radiation|Stereotactic Ablative Body Radiotherapy as Monotherapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
75786627|NCT02016248|Radiation|Stereotactic Ablative Body Radiotherapy as a Boost|The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
75786628|NCT03212326|Drug|Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]|Perflutren 1.3mL diluted in 50 mL is infused intravenously, and intracardiac echo imaging is recorded to analyze for areas of possible myocardial scar, which is then compared with areas of abnormal electrical signal via direct catheter mapping which is performed during ablation of ventricular tachycardia.
75786629|NCT03833882|Device|MAF1217|The study population will have to self-administer the study treatment in a TID posology.
75786630|NCT03833882|Other|Cationorm|The study population will have to self-administer the study treatment in a TID posology.
76079242|NCT01188694|Drug|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
76079243|NCT01188694|Behavioral|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
76079244|NCT01188694|Behavioral|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
76079245|NCT04453566|Other|Online Survey|Online Survey
76079246|NCT04454112|Device|24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).|24-hour esophageal pH monitoring application
76079247|NCT04454268|Procedure|cyst extirpation|complete removal of the cyst without rupture
76079248|NCT01188928|Drug|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
76079249|NCT01188928|Drug|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
76079250|NCT01188928|Drug|Calcipotriene|Topical suspension once daily for up to 8 weeks.
75637634|NCT02760147|Device|PEEP Under Level|PEEP Level downward by 50%, 2 hours
75651804|NCT05519540|Drug|Xevinapant (Debio 1143)|All participants (Japanese and non-Japanese East Asian) will receive single oral dose of xevinapant (Debio 1143) on Day 1.
75651805|NCT05506124|Device|airbag-type stretchable electrode array (ASEA) device|Propose a novel airbag-type stretchable electrode array (ASEA) device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
75651806|NCT05506124|Device|two-channel hard electrode device|Propose a two-channel hard electrode device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
76079251|NCT01188928|Drug|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
76079252|NCT05438706|Drug|chidamide|Chidamide, an HDAC inhibitor
76079253|NCT05438706|Drug|camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
75786631|NCT03834194|Behavioral|Lottery + Monthly Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
75786632|NCT03834194|Behavioral|Lottery + Overall Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
75786633|NCT03834194|Behavioral|Lottery + Overall Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
75330272|NCT03095638|Drug|Conventional dolutegravir 25 mg tablet|Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
75786634|NCT03834194|Behavioral|Loss + Overall Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
75786635|NCT03834194|Behavioral|Loss + Overall Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
75922906|NCT03376958|Drug|Apatinib|Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
76079254|NCT05438706|Drug|carboplatin|Carboplatin [diammine(1,1-cyclobutanedicarboxylato)platinum(II)] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
76079255|NCT05438706|Drug|capecitabine|Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
75330273|NCT03385629|Behavioral|CSM theory-based didactic education and skills training|Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
75330274|NCT03385629|Other|AAP-based didactic education|American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
75330275|NCT03385629|Other|Practice EMR changes|Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
75330276|NCT03913923|Biological|BCD-217|Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion for first 4 blinded infusions
75330277|NCT03913923|Biological|BCD-100|Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion
75330278|NCT03913923|Other|Placebo|Placebo
75330279|NCT04458688|Other|Observation of Ocrelizumab as Treatment in RRMS Patients|It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.
75637635|NCT02765139|Behavioral|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
75637636|NCT02765139|Other|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
75637637|NCT00917527|Drug|Atorvastatin|Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
75637638|NCT04222179|Device|ultrathın esophagogastroduodenoscope|Place the naso-enteric tube together with the ultrathin esophagogastroduodenoscope from the same nasal cavity
75637639|NCT02597647|Biological|LAIV|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of LAIV.
75637640|NCT02597647|Other|Saline|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of saline nasal spray.
75651807|NCT05494632|Device|Treatment-modifications to CI speech processor program|We will modify the CI speech processor program to reduce interaural loudness and pitch mismatches.
75651808|NCT05485519|Drug|Dexmedetomidine|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
75637641|NCT02764905|Behavioral|intensive cognitive physical rehabilitation program|include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
75637642|NCT00745849|Drug|esomeprazole|40mg by mouth twice daily
75637643|NCT00745849|Drug|placebo|
75637644|NCT02759913|Procedure|Lumbar puncture|Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
75786636|NCT03834194|Behavioral|Lottery + Monthly Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
75786637|NCT03834194|Behavioral|Loss + Monthly Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
75330280|NCT04450108|Diagnostic Test|Vivatmo pro FeNO Test|Breath gas analysis
75330281|NCT03899883|Drug|Pegloticase 8 MG/ML [Krystexxa]|One time dosing of pegloticase will be administered. Participants will receive an infusion of pegloticase over two hours in the outpatient clinical and translational research center (CTRC) at Children's Hospital Colorado, and will be monitored after infusion.
75330282|NCT03891849|Drug|Octreotide Injection|Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
75330283|NCT03884985|Other|Visual stimulation|In the experiments, participants will sit in front of a computer monitor located a less than a meter of distance and will analyze the content of images extracted from collections of natural and computer-generated scenes. Subjects will be asked to report verbally or by pressing keys on a keyboard on image characteristics such as the locations of the objects present in the scenes, their number and/or their identities. Some experiments will involve a search paradigm in which subjects will have to report on the location and/or fine characteristics of a target element among a field of distracting similar elements, and/or visual discrimination tasks. The duration of the interval of time in which the image is maintained on the screen may be varied between few tens of milliseconds to several seconds. In a set of experiments, the eye movements performed by the subjects during the execution of the visual tasks will be recorded as explained below.
75330284|NCT02974569|Device|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
75330285|NCT04341831|Drug|Teicoplanin|We will be used 200mg Teicoplanin powder for each level of instrument.Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site.
75330286|NCT03158038|Biological|Monovalent Influenza Vaccine|A single dose of monovalent influenza vaccine [10^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain] will be administered as intranasal spray on Day 1.
75330287|NCT03158038|Other|Placebo|A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.
75330288|NCT00361959|Drug|Tiotropium bromide 18mcg|
75330289|NCT00361959|Drug|Fluticasone propionate/ salmeterol combination 50/500mcg|
75330290|NCT03158116|Drug|Inhaled Aztreonam|Inhaled antibiotic with anti-pseudomonal properties
75637645|NCT02764827|Biological|Pollen sensitization|Skin prick test with local and imported Bermuda, Johnson and careless weed allergen extracts at concentration of 10,000, 3,000, 1,000 and 300 AU/mL and measure specific IgE levels
75637646|NCT02599051|Device|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
75637647|NCT02599051|Device|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
75637648|NCT02764671|Biological|10μg/0.5ml recombinant hepatitis B vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
75637649|NCT02759991|Drug|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
75637650|NCT02759991|Drug|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
75637651|NCT04112277|Drug|Cumulative morphine consumption|morphine equivalent [mg] 24 hours after the procedure
75637652|NCT00749203|Drug|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
75637653|NCT00749203|Drug|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
75637654|NCT02764515|Drug|Kunxian Capsule|Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
75637655|NCT02764515|Drug|Methotrexate|the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
75330291|NCT03096730|Drug|Normal saline|Normal saline is intravenously administrated before anesthesia induction
75330292|NCT03096730|Drug|Remifentanil|Remifentanil is intravenously administrated
75330293|NCT03096730|Drug|Sufentanil|Sufentanil is intravenously administrated
75651809|NCT05485519|Drug|Midazolam|(1 mcg/kg/minute. up to a maximum of 5 mcg/kg/minute.
75798701|NCT01179126|Procedure|complete multivessel revascularization|After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
75637656|NCT02598115|Other|Collaborative Pharmaceutical Care|The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
75637657|NCT04223271|Diagnostic Test|Indicor|Handheld device with attached PPG sensor that is paired with a tablet to estimate left ventricular end diastolic pressure. Subjects will blow into the device in order to perform a standardized Valsalva maneuver for 10 seconds. The index finger will be resting in the PPG sensor during the test. Each test requires three efforts, with 45 seconds rest between efforts.
75637658|NCT00748969|Drug|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
75637659|NCT02759679|Other|Human breath samples|
75786638|NCT03834194|Behavioral|Loss + Monthly Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
75786639|NCT03229486|Drug|Sugammadex Injection [Bridion]|Return to T2 point (two contractions) on TOF device is replied by iv 2 mg/kg sugammadex administration, contained in a blinded syringe.
75922907|NCT02159625|Device|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
75922908|NCT02297178|Procedure|Cystoscopy only|Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
75922909|NCT02297178|Procedure|Cystoscopy and Urethral dilatation|Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
75922910|NCT03376802|Drug|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
75922911|NCT03376802|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
75922912|NCT03515694|Drug|Sugammadex Injection [Bridion]|Injection of 10mL of translucide solution
75637660|NCT02764749|Dietary Supplement|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
75637661|NCT02764749|Dietary Supplement|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
75637662|NCT02759757|Other|Kinesio Taping|This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.
75637663|NCT02759757|Other|Placebo|A micropore tape will be used as placebo
75637664|NCT02764437|Biological|Whole lung antigen challenge, segmental allergen challenge|Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
75786640|NCT03229486|Drug|Neostigmine+Glycopyrronium|Return to T2 point (two contractions) on TOF device is replied by iv 0.06 mg/kg neostigmine and 0.005 mg/kg glycopyrrolate administration, contained in a blinded syringe.
75786641|NCT03833648|Other|UControl Pain App with Education|The intervention will include educational information on pain management, e.g., using acetaminophen and NSAIDs to manage pain, as well as information on addiction and safe storage of medications.
75922913|NCT03376724|Other|Functional Exercise Protocol|Functional exercise protocol. This protocol started with corporal conscience exercise, breathing, abdominal activation, activities such as sitting, getting up, climbing stairs, reaching with arms, moving forward, bodyweight exercises, bridges and boards. This protocol will be performed during 12 weeks, two sessions per week.
75330294|NCT03096730|Drug|Dexmedetomidine injection|Dexmedetomidine is intravenously administrated before anesthesia induction
75330295|NCT03096730|Drug|Nalmefene|Nalmefene is intravenously administrated before anesthesia induction
75330296|NCT00362037|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
75330297|NCT04342923|Other|No intervention|Blood analysis
75637665|NCT02759601|Drug|Tefinostat|Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
75637666|NCT02764359|Drug|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
75637667|NCT04221867|Procedure|Stricture dilation with CRE balloon|Esophageal stricture is treated by dilation therapy.
75637668|NCT04221867|Procedure|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
75922914|NCT03376724|Other|Minimal|Analgesic use when necessary and a single back scholl class
75922915|NCT03541707|Device|Deep TMS Brainsway's H coil|"During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes."
75922916|NCT03367676|Drug|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
75786642|NCT03833570|Dietary Supplement|Rapid Release Capsules Melatonin, 10 mg|Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.
75922917|NCT03367676|Drug|Docetaxel|Docetaxel 100mg/m2，d1，iv，q3w*4
75922918|NCT03515616|Diagnostic Test|TP us in labour|TP US will be made to pregnant lady in first stage of labour with OS and PC angel measurements
75922919|NCT02158611|Other|Lifestyle counseling|
75637669|NCT02759367|Other|High potassium diet|An increase in consumption of high potassium fruits and vegetables
75637670|NCT04594707|Drug|PRM-151 (Zinpentraxin Alfa)|"Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.~Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo."
75637671|NCT02696655|Behavioral|Behavioural intervention|Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
75637672|NCT04221399|Drug|DWP16001|Tablets, Oral, Once daily, Single dose
75922920|NCT03367598|Genetic|rs662799 (APOA5 -1131T>C)|Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T>C polymorphism.
75637673|NCT04221399|Drug|DWP16001|Tablets, Oral, Once daily, Multiple dose
75637674|NCT02759445|Other|routine treatment|No intervention, only observation and describing
75637675|NCT02764125|Drug|Stalevo|levodopa/carbidopa/entacapone
75786643|NCT03833570|Drug|Miconaz oral gel|Antifungal agent
75786644|NCT03833570|Drug|BBC oral spray|Topical anesthetics and anti-inflammatory agent
76079256|NCT05438472|Other|data collection in healthcare professionals with COVID-19 mRNA vaccine booster|Day 3 (48 - 96h) post COVID-19 mRNA booster: data collection on symptoms (chest pain, dyspnea, myalgia, fever, chills); blood sample for cardiomyocyte injury (hs-cTnT, hs-cTnI). If elevated hs-cTnT concentration, participant has to avoid strenuous exercise. Work-up on Day 4: clinical evaluation, ECG, 2. blood sampling for hs-cTnT. If hs-cTnT > 100 ng/l, cardiac magnetic resonance imaging is done for signs of cardiac inflammation. If hs-cTnT rises above upper limit but doesn't exceed 100 ng/l, clinical exam might be evaluated. In confirmed myocarditis, a clinical assessment (treatment, need for hospitalization, length of rhythm monitoring, rest) is evaluated by a cardiologist. Day 4: EDTA blood from all subjects with elevated troponin at day 3 post-vaccination is collected for pathomechanism of mRNA vaccine associated myocarditis. 1-month follow-up: questionnaire on predefined cardiac endpoints.
75330298|NCT03872271|Procedure|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
75470144|NCT04060134|Other|FlexHD HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
75637676|NCT02764125|Drug|levodopa MR|levodopa MR/carbidopa/ODM-104
75637677|NCT02764281|Drug|MEDA|"Methotrexate, 3.0g/m2/d iv, day 1~Etoposide, 100mg/m2 iv, day 2 to day 4~Dexamethasone, 40mg/d iv, day 1 to day 4~Pegaspargase, 2500IU/m2/d im, day 4~The MEDA chemotherapy will be repeated every 3 weeks."
75637678|NCT02764281|Procedure|Auto-HSCT|Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.
75786645|NCT03833570|Drug|Oracure gel|Topical analgesic gel
75786646|NCT03833570|Other|Alkamisr sachets|Sodium bicarbonate mouthwash
75786647|NCT01779050|Drug|Doxorubicin|
75786648|NCT01779050|Biological|Trastuzumab|
75786649|NCT01779050|Drug|Cyclophosphamide|
75786650|NCT01779050|Drug|Paclitaxel|
75786651|NCT01779050|Drug|Epirubicin|
75786652|NCT01779050|Drug|Docetaxel|
75786653|NCT01779050|Drug|Carboplatin|
75786654|NCT01779050|Drug|Fluorouracil|
75786655|NCT01200446|Dietary Supplement|Docosahexaenoic Acid|8 docosahexaenoic acid (4.0 grams) capsules per day for 3 weeks.
75786656|NCT01200446|Dietary Supplement|Placebo Docosahexaenoic Acid|8 placebo docosahexaenoic acid (corn and soy oil blend) capsules per day for 3 weeks.
75786657|NCT03841136|Drug|anlotinib|anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1~D3
75786658|NCT05669768|Drug|Pamiparib/Tamoxifen|Pamiparib 40mg PO BID, Tamoxifen 20mg PO BID
75786659|NCT03843398|Procedure|Colorectal cancer resection via minilaparotomy|According to the cancer location, a 7 cm incision is made in specific area of the patient's abdomen. The whole procedure of operation will be finished within this incision. If the incision must be lengthen due to the surgical demand, the failure of the minilaparotomy is determined.
75786660|NCT03843398|Procedure|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
75922921|NCT02292810|Device|Inspiratory muscle exercise|For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
75330299|NCT03872271|Procedure|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
75330300|NCT03866031|Other|implant-supported mandibular overdenture|The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
75330301|NCT03834441|Other|Oral HRSN screening|Verbal screening delivered by an RA
75330302|NCT03834441|Other|Written HRSN screening|Patient completes written screen on iPad.
75330303|NCT03161158|Device|CHIARA-System|Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.
75922922|NCT02292810|Device|Inspiratory muscle exercise placebo|For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
75922923|NCT03515538|Drug|RRx-001|RRx-001 for injection
75922924|NCT03515538|Drug|Cisplatin for injection|Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
75922925|NCT03515538|Radiation|Radiation Therapy|Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
75470145|NCT04060134|Other|DermACELL HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
75637679|NCT02764203|Other|Dark Chocolate|50g dark chocolate consumed for a period of 2 weeks
75786661|NCT03843320|Device|SAPIEN 3|Transcatheter aortic valve replacement
75786662|NCT03843320|Device|SAPIEN XT|Transcatheter aortic valve replacement
75786663|NCT03843320|Device|INSPIRIS RESILIA|Surgical aortic valve replacement
76079257|NCT05167344|Behavioral|Healthy Relationships Program-Enhanced|The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
76079258|NCT01189240|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
76079259|NCT01189240|Biological|bevacizumab|Given IV
75330304|NCT03161158|Other|Usual care IV diuretics|Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
75330305|NCT03161938|Drug|Dexamethasone|intravenous
75330306|NCT02975115|Other|RQ-PCR RNA Analysis|Conventional Q-RT-PCR every 3 months
75786664|NCT03843320|Device|EDWARDS INTUITY|Surgical aortic valve replacement
75330307|NCT03321045|Drug|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
75330308|NCT03321045|Diagnostic Test|PET/MRI Imaging|5-6 days post injection the patients will undergo PET/MRI imaging.
75470146|NCT04035109|Drug|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.
75470147|NCT04035109|Drug|Preservative-free 0.9% sodium chloride (Placebo)|A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.
75470148|NCT04035109|Biological|House dust mite allergen|Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
75637680|NCT02764203|Device|Wearable devices|Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
75637681|NCT02763969|Drug|BMS-986202|
75637682|NCT02763969|Drug|Placebo|
75786665|NCT03843320|Device|Carpentier-Edwards PERIMOUNT Magna-Ease|Surgical aortic valve replacement
75637683|NCT02763969|Drug|Interferon alpha-2a recombinant|
75637684|NCT02763969|Drug|Famotidine|
75637685|NCT02763969|Drug|Ustekinumab|
75651810|NCT05462262|Drug|Intensive lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
75786666|NCT00306527|Biological|Cell culture derived influenza vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
76079260|NCT01189240|Other|laboratory biomarker analysis|Correlative studies
76079261|NCT01189240|Other|pharmacological study|Correlative studies
75786667|NCT00306527|Biological|egg-derived influenza subunit vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
75470149|NCT04035109|Biological|Cat hair allergen|Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
75470150|NCT04030429|Drug|Crizotinib 250 MG|bid orally
75786668|NCT05669378|Behavioral|Appetite to Play +|In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
76079262|NCT03467490|Behavioral|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
76079263|NCT03462264|Device|Scoliogold App|The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
76079264|NCT03462264|Other|Pre-Formatted Diary|The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
76079265|NCT03013348|Device|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography [EEG] recordings) that are pathognomonic for PNES activity.
76079266|NCT03467334|Dietary Supplement|B. breve|Bifidobacterium probiotic strain at 1E+08 cfu/day
75637686|NCT02696187|Behavioral|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
76079267|NCT03467334|Dietary Supplement|B. breve plus L. fermentum|Probiotic combination at 2E+08 cfu/day
76079268|NCT03467334|Drug|Simethicone 20 MG|Standard treatment for infant colic
76079269|NCT02880384|Other|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
76079270|NCT03462186|Other|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
75637687|NCT02758977|Procedure|ALPPS|For detailed information please refer to description of experimental arm
75637688|NCT02758977|Procedure|TWO STAGE HEPATECTOMY|For detailed information please refer to description of active comparator arm
75786669|NCT03832166|Other|Fruits and Vegetables|Fruits and vegetables delivery, once/week for 24 weeks
75786670|NCT03832166|Other|Cooking|Nutrition education and cooking instruction class, one class/week for 6 weeks
76079271|NCT02874144|Drug|AZ compound|40 mg three times daily po for 12 weeks
75470151|NCT04014595|Procedure|Rotational atherectomy in combination with cutting balloon|Treatment of severely calcified coronary lesion using rotational atherectomy followed by balloon angioplasty using a cutting balloon and Implantation of the hybrid sirolimus-eluting stent.
75637689|NCT02759211|Other|Backwards Walking|The Backwards Walking Group will perform backwards walking for the entire treatment intervention.
75637690|NCT02759211|Other|Forwards Walking|The Forwards Walking Group will perform forwards walking for the entire treatment intervention.
75637691|NCT04660929|Biological|CT-0508|anti-HER2 CAR macrophages
75637692|NCT04660929|Biological|Pembrolizumab|anti-PD antibody
75637693|NCT04223349|Drug|JNJ-70033093|JNJ-70033093 capsules will be administered orally .
75637694|NCT04223349|Drug|Placebo|Matching placebo in capsule will be administered orally.
75637695|NCT02764047|Dietary Supplement|Probiotic|L. acidophilus 10⁹, B. lactis 10⁹
75637696|NCT02763657|Other|fMRI scanning|All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
75786671|NCT01066247|Drug|Morphine hydrochloride; Midazolam|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
76079272|NCT02874144|Other|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
76079273|NCT02874144|Drug|Intranasal corticosteroid|QD Nasal Spray
76079274|NCT02874144|Drug|Placebo|looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
76079275|NCT03467178|Drug|Decitabine|Nucleic Acid Synthesis Inhibitor
76079276|NCT03467178|Drug|Carboplatin|Chemotherapy medication
76079277|NCT03467178|Drug|Pegylated Liposomal Doxorubicin|Chemotherapy medication
76079278|NCT03467178|Drug|Gemcitabine|Chemotherapy medication
76079279|NCT03467178|Drug|Paclitaxel|Chemotherapy medication
76079280|NCT03462108|Biological|Rotavirus (Bio Farma) Vaccine|Rotavirus (Bio Farma) Vaccine
76079281|NCT03462108|Other|Placebo|Placebo contains 30% sucrose in DMEM
76079282|NCT03467100|Drug|XEN901|Capsule filled with XEN901
76079283|NCT03467100|Drug|Inert Ingredients Oral Product|Placebo capsule
76079284|NCT05434182|Procedure|Intradermal Suture|Skin closure with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
76079285|NCT05434182|Procedure|Metallic Staples|Skin closure with metallic stapling using Visistat® (Weck®) 35W skin stapler.
76079286|NCT02847078|Device|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
76079287|NCT02847078|Device|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
76079288|NCT02835534|Drug|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
76079289|NCT02835534|Drug|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
76079290|NCT02722200|Drug|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
76079291|NCT02722200|Other|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
76079292|NCT04066218|Other|Interviews|"Participation will serve as verbal consent.~Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~REDCap link will be sent for PROMIS SexFS Brief.~PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
75637697|NCT02758821|Other|No CRP will be measured onsite|No CRP will be measured onsite
75637698|NCT02758821|Other|CRP cut-off of 20mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever < 20mg/L.
75922926|NCT02158689|Drug|Letrozole|
75922927|NCT02158689|Drug|human menopausal gonadotropin (hMG)|
75922928|NCT03372200|Drug|FYU-981|Oral daily dosing for 14 weeks
75922929|NCT03372200|Drug|Febuxostat|Oral daily dosing for 14 weeks
75330309|NCT00989989|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
75637699|NCT02758821|Other|CRP cut-off of 40mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever < 40mg/L.
75637700|NCT04221711|Device|Repetitive pulsed magnetic stimulation|"OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility.~The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla.~The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected.~For comfortable transport and application the product is compact and portable."
75922930|NCT02159781|Procedure|periodontal treatment - scaling and root planning|
75922931|NCT03372122|Drug|Chlorhexidine Gluconate|A cloth to cleanse and disinfect the skin
75922932|NCT03372122|Combination Product|HUBS with Hibiclens|A dry cloth to be used in combination with water and antimicrobial soap to cleanse and disinfect the skin
75922933|NCT02292888|Other|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
75922934|NCT02158845|Drug|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
75922935|NCT02158845|Drug|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
75922936|NCT03372044|Drug|PF-06865571 Immediate release suspension|Suspension
75922937|NCT03372044|Drug|PF-06865571 Slow release MR tablets|Modified release tablets
75922938|NCT03372044|Drug|PF-06865571 Fast release MR tablets|Modified release tablets
75922939|NCT03372044|Drug|PF-06865571 Immediate release tablets|Immediate release tablets
75922940|NCT02301078|Procedure|Percutaneous Needle Aponeurotomy|single procedure (day 0)
76079293|NCT04453176|Other|Patient Satisfaction|Patient satisfaction evaluated with EVAN G questionnaire
76079294|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
76079295|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
76079296|NCT01094548|Drug|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
76079297|NCT01094548|Drug|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
76079298|NCT01094704|Drug|sodium chloride (7%)|4mL nebulized 7% sodium chloride
76079299|NCT02611830|Drug|Vedolizumab 300 mg IV|Vedolizumab intravenous infusion
76079300|NCT02611830|Drug|Placebo IV|Vedolizumab intravenous infusion placebo
75637701|NCT04221711|Procedure|Eccentric Calf Muscle Training for Achilles Tendinopathy|"Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day.~The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling."
75637702|NCT04221633|Behavioral|Enhancing Early Engagement (E3) webinar|Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.
75637703|NCT04221633|Behavioral|Consultation for E3 training|10 consultation calls with experts in engagement, child trauma, and mental health screening to support the webinar training
75637704|NCT02758743|Drug|Acetium Lozenge|Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
75786672|NCT01066247|Drug|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
75786673|NCT00306293|Drug|valacyclovir|valacyclovir
75786674|NCT03980951|Procedure|Dural Puncture Epidural Technique|three labor analgesia techniques
75922941|NCT02301078|Drug|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
75922942|NCT04786977|Other|No Intervention, Observational Study|No Intervention
76079301|NCT02611830|Drug|Vedolizumab 108 mg SC|Vedolizumab subcutaneous injection
76079302|NCT02611830|Drug|Placebo SC|Vedolizumab subcutaneous injection placebo
76079303|NCT03461874|Behavioral|Education of patients|"During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night."
75330310|NCT00989989|Procedure|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
75330311|NCT00989989|Drug|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
75330312|NCT00989989|Procedure|Sham laser photocoagulation|Sham laser treatment administered at day 1.
75330313|NCT04331080|Drug|Granexin® gel 100 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
75637705|NCT02758743|Drug|Placebo|Placebo with no active substance will not have the effect on intervention device.
75637706|NCT02758587|Drug|Defactinib|cross reference with arm/group descriptions
75637707|NCT02758587|Drug|Pembrolizumab|cross reference with arm/group descriptions
75651811|NCT05462262|Drug|Moderate-intensity lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
75786675|NCT03980951|Procedure|Combined Spinal Epidural without intrathecal opioids|three labor analgesia techniques
75786676|NCT03980951|Procedure|epidural|three labor analgesia techniques
75786677|NCT03980795|Other|Exercise Program|Participants met with an exercise physiologist at their monthly center appointment over a 3-month period (4 meetings). The consultations took place either together or separate from or with the dietitian's consultation (depending on appointment logistics). In addition the Exercise Physiologists telephone called each intervention participant on a weekly basis.
75786678|NCT03978455|Behavioral|Learn, Connect, and Quit Mobile Application|The Learn, Connect, and Quit (LCQ) Mobile Application is an application for electronic tablets that can: assess smokers' interest in quitting; answer smokers' questions about smoking, quitting, and available treatments; provide information about treatment options; communicate information about patients' smoking status, concerns, and treatment interest to their provider; and connect patients with treatment options including the Wisconsin Tobacco Quitline (WTQL), and other smoking intervention resources provided by their healthcare system.
75798702|NCT01179126|Procedure|stress echocardiography and revascularization if required|after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
75922943|NCT03367520|Behavioral|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
75922944|NCT02292966|Drug|DCV/ASV/BCV|Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
75922945|NCT02159937|Other|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
75922946|NCT03519672|Other|No intervention|This is a non-interventional study.
75798703|NCT01285752|Drug|AK106-001616|
75922947|NCT02519660|Drug|Lidocaine/Tetracaine patch|
75922948|NCT02519660|Drug|Lidocaine/Prilocaine cream|
76079304|NCT03461874|Behavioral|ACT|"ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program.~Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions."
76079305|NCT03461874|Drug|Pharmacological prophylaxis|Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
75470152|NCT03970694|Radiation|Radiotherapy|"Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option.We recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and it was exciting. According to our results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively.Colorectal cancer diagnoses and treatment guidelines written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy."
75637708|NCT02763891|Other|Intervention group (Body body suspension and tilting exercises)|The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises. The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method. During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles. Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation. Each session lasts 30 minutes.
75637709|NCT02763891|Other|Control group (global muscle stretching)|Subjects receiving submitted a global muscle stretching session twice a week for eight weeks. During this period. All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
75637710|NCT04634955|Procedure|tranforaminal epidural injection|tranforaminal epidural injection which is performed by fluoroscopic guidance
75637711|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin|
75637712|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin + Boceprevir|
75637713|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin +Telaprevir|
75637714|NCT02758509|Drug|Ledipasvir/Sofosbuvir|
75786679|NCT01066325|Behavioral|Neuro Emotional Technique|"NET is considered an alternative stress-reduction technique. Its aim is to remove neurological abnormalities which have a specified physiopathological pattern. The goal of NET is to normalize the aberrant patterns through a physical correction.~During the NET procedure, various psychological components of the anxious state are considered: cognitions, emotions, and behaviours. These various components are explored for a physiological reaction in the participant. Once a physiological reaction is found, the practitioner helps the participant identify the specific emotion. The procedure is concluded when the patient no longer feels distress or discomfort. Following the intervention, patients frequently report feeling subjective relief."
75786680|NCT01066325|Other|Stretching Instruction|This arm is the Active Control Arm and will receive two 20-minute sessions of Stretching Instructions. During these instructions, participants will hold stretches for not longer than 5 seconds, which in not likely to have any therapeutic effect.
75786681|NCT02532491|Drug|Aripiprazole|Initial dose: 10 mg.
75786682|NCT02532491|Drug|Risperidone|Initial dose: 2 mg.
76079306|NCT03461718|Drug|Ketamine|Experimental arm for sedation.
75786683|NCT01066403|Drug|Pergolide|"0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group."
76079307|NCT03461718|Drug|Midazolam injection|Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
75798704|NCT01285752|Drug|AK106-001616|
75798705|NCT01285752|Drug|Active comparator|
76079308|NCT03461718|Drug|Fentanyl|Part of standard sedation regimen
76079309|NCT03467022|Drug|Vitamin C|Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
76079310|NCT02522364|Device|BioMonitor device|Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration
76079311|NCT02522364|Other|Standard|Clinical and intermittent electrocardiographic follow-up of patients
76079312|NCT03129594|Diagnostic Test|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
75637715|NCT02758509|Drug|Ombitasvir/paritaprevir/ritonavir+Dasabuvir|
75637716|NCT02758509|Drug|Daclatasvir+Sofosbuvir|
75637717|NCT02758509|Drug|Simeprevir+Sofosbuvir|
75637718|NCT02763813|Device|Herbst (propulsion type oral appliance)|Oral appliance
75330314|NCT04331080|Drug|Granexin® gel 200 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
75330315|NCT04331080|Drug|Vehicle gel|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
75330316|NCT00362193|Behavioral|Telephonic diabetes care|
75637719|NCT02763813|Device|Retention type appliance (ORM)|
75637720|NCT02758353|Drug|Community distribution of SP|SP delivered at both the community and facility level by trained CBHVs in three LGAs.
75786684|NCT01064219|Drug|human chorionic gonadotrophin|intrauterine injection of 100 IU hCG followed by endometrial biopsy .
75786685|NCT03980639|Drug|patient treated with DMARD|Case report of cancer overall
75786686|NCT03978299|Diagnostic Test|Positive Prostate-Specific Antigen test result|Positive PSA test result as part of opportunistic screening or due to the presence of symptoms suggestive of disease.
75786687|NCT03978221|Other|Post-extubation TDI|A diaphragmatic tissue Doppler evaluation will be performed during non-invasive ventilation and spontaneous breathing trial applied in random sequence. Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragmatic examination will be performed to assess the speed of diaphragmatic displacement during inspiration and expiration.
75786688|NCT03978143|Drug|Treatment A|Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
75786689|NCT03978143|Drug|Treatment B|A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
75786690|NCT03978143|Drug|Treatment C|A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
75786691|NCT03978143|Drug|Treatment D|A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
75786692|NCT03978143|Drug|Treatment E|250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.
75922949|NCT03511872|Other|Basic life support training|"A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group."
75637721|NCT00635583|Other|Increased Dairy Consumption|"3 additional servings of dairy (two of which must be milk or yogurt)~8 oz milk~6 oz yogurt~1.5 oz cheese"
75922950|NCT02297334|Device|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
75922951|NCT03376412|Device|Raindrop Near Vision Inlay|A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
75922952|NCT03371966|Dietary Supplement|High Nitrate Beetroot Juice|High nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of low nitrate beetroot juice.
75330317|NCT03802773|Procedure|CB transplantation|Myeloablative conditioning with post-transplant cyclophosphamide in patients receiving a matched CB transplant for hematological malignancies.
75637722|NCT02763423|Procedure|umbilical cord mesenchymal stem cell|allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection
75786693|NCT03978143|Drug|Treatment F|250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.
75786694|NCT03978143|Drug|Treatment G|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
75786695|NCT03978143|Drug|Treatment H|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
75786696|NCT00294671|Drug|diflunisal|given twice daily for 24 months
75786697|NCT00294671|Other|placebo|an inactive substance given twice daily for 24 months
75786698|NCT01064453|Drug|E2/DRSP (Angeliq, BAY86-4891)|Take one tablet daily, continuously
75786699|NCT01064609|Procedure|Biopsy by cryoprobes|Transbronchial lung biopsy with cryoprobes.
75786700|NCT01064609|Procedure|Biopsy with conventional forceps|Transbronchial lung biopsy with conventional forceps.
75786701|NCT03980327|Dietary Supplement|probiotic|Lactobacillus probiotic
75922953|NCT03371966|Dietary Supplement|Low Nitrate Beetroot Juice|Low nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of high nitrate beetroot juice..
75470153|NCT03970694|Drug|oxaliplatin+capecitabine|Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
75470154|NCT03951077|Drug|Elagolix|Capsule administered orally
75637723|NCT02758275|Behavioral|Teaching: Individual (5606)|"Usual care and Teaching: Individual (5606): It consists of 6 educational sessions:~Behavior Modification (4360) Promotion of a behavior change.~Teaching Disease Process (5602) Assisting the patient to understand information related to a specific disease process.~Teaching: Prescribed Medication (5616) Preparing a patient to safely take prescribed medications and monitor for their effects.~Teaching: Prescribed Diet (5614) Preparing a patient to correctly follow a prescribed diet.~Teaching: Prescribed Exercise (5612) Preparing a patient to achieve and/or maintain a prescribed level of activity.~Coping Enhancement (5230) Assisting a patient to adapt to perceived stressors, changes, or threats that interfere with meeting life demands and roles."
76079313|NCT03461640|Other|Community-based doula support for labour|CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.
76079314|NCT03461640|Behavioral|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
76079315|NCT03466788|Other|Self questionnaires of quality of life and living conditions|Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
75922954|NCT03541473|Dietary Supplement|Peptamen® 1.5 Vanilla|Nutritionally complete formula with 10g MCT in 250 mL, commercially available
76079316|NCT03466710|Procedure|Colposcopy|"Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix."
76079317|NCT03466710|Other|Pap test|"Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or >LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is >/=CIN II. Results of </=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization)."
75637724|NCT02758197|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) course directly following medical treatment optimization. The MBSR course consists of eight weekly 2-hour sessions and one 6 hour session midway through the course and involves psychoeducation, relaxation techniques, gentle stretching (very mild form of yoga), and different forms of meditation. Participants will learn ways to better cope with their pain and the disability and distress related to it with a goal of reducing the stress response that is our body's normal reaction to pain. All sessions will be conducted by a psychologist or social worker with a minimum of 2 years of experience in chronic pain management, formal MBSR training and 2 years of experience leading MBSR groups.
75922955|NCT03541473|Dietary Supplement|Boost Plus® Vanilla|Product of same nutritional composition but without MCT
75922956|NCT03371888|Biological|Platelet-Rich Plasma intramuscular injections|A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.
75786702|NCT03980327|Dietary Supplement|medium chain triglyceride oil|
75922957|NCT03371888|Biological|Placebo Comparator: 0,9% NaCl intramuscular injections|A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
75786703|NCT03980249|Drug|Carvedilol|Carvedilol: Start at 6.26 mg PO twice daily for 1-2 weeks and if tolerated, will be increased to 12.5 mg PO twice daily for 6 cycles as tolerated.
75786704|NCT01495598|Drug|Pomalidomide|5 mg by mouth (p.o.) for 21 of 28 days
75637725|NCT02758041|Device|Sebacia Microparticles|
75786705|NCT01204892|Procedure|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
75786706|NCT01204892|Procedure|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
75786707|NCT05668130|Procedure|Sacrospinous ligament fixation|Women with stage II or higher pelvic organ prolapse with apical compartment involvement planned for surgical management will be randomised to either sacrospinous ligament fixation arm or uterosacral ligament suspension arm. those raandomized to sacrospinous ligament fixation arm will undergo unilateral (right) sided sacrospinous ligament fixation of apex as a part of pelvic organ prolapse surgery.
75470155|NCT03951077|Drug|Placebo|Capsule administered orally
75470156|NCT03941132|Drug|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously."
75470157|NCT03941132|Drug|Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously."
75786708|NCT05668130|Procedure|Uterosacral Ligament Suspension|Similarly women randomised to uterosacral ligament suspension arm will undergo modified high uterosacral ligament suspension of apex. Both arms will be followed up in 6 months and 12 months for anatomical and functional outcome.
76079318|NCT03466710|Diagnostic Test|HPV test|Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
76079319|NCT03466632|Drug|Propofol|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.
76079320|NCT03466632|Drug|Dexmedetomidine|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
75637726|NCT02763501|Procedure|closure of mesenteric defects|Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT
75786709|NCT01297166|Drug|LEO 27989 ointment|once daily application, 3weeks
75637727|NCT02763501|Procedure|non-closure of mesenteric defects|Mesenteric defects are left open
75637728|NCT02763267|Other|Oral glucose tolerance test|75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant [4-14 weeks gestation] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)
76079321|NCT03466554|Device|Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes|60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
76079322|NCT03461562|Other|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
75786710|NCT01297166|Drug|Calcipotriol plus LEO 27989 ointment|once daily application, 3weeks
75922958|NCT02154321|Device|Electroencephalogram (EEG)|The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
75922959|NCT02297490|Drug|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
75922960|NCT02297490|Biological|Allergovit 6-grasses|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
76079323|NCT05348928|Device|Continuous glucose monitoring device|Continuous glucose monitoring device
76079324|NCT05348928|Other|Laboratory plasma glucose concentration determination|Laboratory plasma glucose concentration determination
76079325|NCT01144624|Drug|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
76079326|NCT01144624|Drug|Placebo|Intravenous infusion of a saline solution
75637729|NCT02762955|Biological|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
75330318|NCT04282564|Other|Co-OP treatment|"The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke"
75637730|NCT02762955|Biological|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
75637731|NCT02757807|Behavioral|Utilization of Serenita for Relaxation|Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
75637732|NCT04191681|Drug|Sacubitril-Valsartan|Sacubitril-valsartan at low or equivalent dose to be initiated or added to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
75786711|NCT01297166|Drug|Calcipotriol ointment|once daily application, 3weeks
75786712|NCT01297166|Drug|Vehicle ointment|once daily application, 3weeks
75786713|NCT03843476|Device|Patient Specific Rod|Posterior spinal fusion rod
75786714|NCT01202474|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day
75798706|NCT03865056|Device|Optiflow (High-flow Nasal Cannula)|Optiflow will be applied for 20 minutes
76079327|NCT05339334|Drug|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days
76079328|NCT01096810|Drug|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
76079329|NCT03461328|Drug|Magnesium Sulphate|intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
75470158|NCT03873246|Drug|OC-01 0.1% 0.6 mg/ml|OC-01 (varenicline) nasal spray: 0.1 % (0.6 mg/ml)
75470159|NCT03873246|Drug|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
75470160|NCT03873246|Other|placebo comparator|vehicle control
75470161|NCT03849417|Other|ECT|ECT administered as part of normal clinical management
75470162|NCT03769649|Device|CelluTite|CelluTite: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
75470163|NCT03734406|Other|Videoclips|The images contained in the videoclips show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
75637733|NCT04191681|Drug|Usual care (standard-of-care) arm|Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
75330319|NCT03018301|Drug|Ketamine|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
75330320|NCT03018301|Other|Normal saline|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
75637734|NCT02757729|Drug|PAC-14028 cream 0.1%|Topical application
75330321|NCT03100864|Drug|Spesolimab|12 weeks treatment
75786715|NCT01202474|Drug|INSULIN GLARGINE|Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
75330322|NCT00990769|Other|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
75330323|NCT04242550|Behavioral|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT (see description below) with executive function training. EF-BED will focus on teaching compensatory strategies to enhance adherence to the strategies recommended in CBT.
75330324|NCT04242550|Behavioral|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
75330325|NCT03018457|Device|ISQ|Measured by Osstell.
75637735|NCT02757729|Drug|PAC-14028 cream 0.3%|Topical application
75637736|NCT02757729|Drug|PAC-14028 cream 1.0%|Topical application
75330326|NCT00421941|Procedure|Tube feeding|
75637737|NCT02757729|Drug|PAC-14028 cream vehicle|Topical application
75637738|NCT02757651|Drug|Hydrogen Peroxide|Hydrogen Peroxide
75637739|NCT02753049|Behavioral|Peer led mHelath behavioral intervention|A trained peer adherence coach will schedule five, weekly-60 minute, 'ACCESS' sessions, delivered to participants via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
75786716|NCT05667818|Drug|Amlodipine besylate tablets (trade name: Norfloxacin ®）|Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
75922961|NCT03371810|Behavioral|Bright light therapy|Mobile therapeutic light (10.000 LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419). Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.
75330327|NCT03018067|Drug|RDX227675|
75786717|NCT05667818|Drug|Amlodipine besylate controlled-release tablets|Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9% Expiry date: October 24, 2024 Storage conditions: dark, sealed at room temperature. Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
75798707|NCT03865056|Device|Non-invasive Ventilation|non-invasive ventilation will be applied for 20 minutes
75470164|NCT03715439|Device|Dental implant|A single dental implant was inserted 3 months after tooth extraction
75470165|NCT03714880|Drug|Mifepristone 200 MG|Ingestion of study medication vs placebo
75470166|NCT03714880|Drug|Placebo Oral Tablet|Ingestion of study medication vs placebo
75470167|NCT03645941|Behavioral|Facebook Group|The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
75470168|NCT03619850|Drug|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
75470169|NCT03619850|Drug|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
75470170|NCT03559686|Drug|Certolizumab Pegol|The recommended maintenance dose of Cimzia® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .
75470171|NCT03559660|Drug|Certolizumab Pegol|
75470172|NCT03532516|Drug|Brivaracetam|"Patients will start on the individual Brivaracetam (BRV) dose that they had reached at the completion of the previous study. The BRV dose can be adjusted based on the individual patient's seizure control and tolerability; however, the BRV dose may not exceed 200 mg/day in divided (preferably symmetrical) morning and evening doses, taken with or without food.~Up- and down-titration steps should be performed in steps of maximum 50 mg/day on a weekly basis. The full down-titration should include a 1-week step at 20 mg/day."
75637740|NCT02752503|Drug|Nalmefene|
75637741|NCT04479579|Drug|Apixaban 2.5 milligram|apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day
75637742|NCT02752659|Procedure|Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference|
75470173|NCT03530358|Device|Technology-aided rehabilitation|"VRRS involves performing different kinds of motor tasks with the patient holding a real manipulable object in their hands while interacting with a virtual scenario.~Braccio di Ferro task consists in center-out reaching movements and return. The subject is required to start from a central target, reach one of five peripheral targets arranged on a semi-circle with a 20 cm radius and then return to the central target."
75637743|NCT02757495|Drug|Dexmedetomidine|Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
75637744|NCT02757183|Device|"IntelliH"|"IntelliH is a mobile health and a web-based software application that allows patients to enter their blood glucose, weight, medication, diet and other life-style data for review by their providers and monitor their health remotely."
75637745|NCT02752581|Device|Suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
75637746|NCT02752581|Device|No suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
75786718|NCT01205204|Drug|Fentanyl|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
75786719|NCT01205204|Drug|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
75786720|NCT01205204|Drug|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
75786721|NCT01205204|Drug|clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
75786722|NCT01205282|Drug|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
75330328|NCT03018067|Drug|Placebo|
75330329|NCT04744857|Combination Product|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.|Using the grip-loading system, the artificial aortic valve was squeezed and loaded into the sheath of the transporter through the vascular approach.The artificial aortic valve is delivered and positioned at the correct anatomical position for release. For example, the artificial main valve is displayed after partial release If the aortic valve is not in the correct anatomical position, the artificial aortic valve can be recovered and placed into the sheath tube of the transporter for re-positioning and release.
75637747|NCT02752347|Device|Surface EMG device|measuring the muscles activity using surface EMG device
75637748|NCT04220697|Other|electroencephalography (EEG)|recording of resting state EEG using 64 surface electrodes
75637749|NCT04220697|Other|questionnaires|Hospital Anxiety Depression Scale (HADS) Neuropathic Pain questionnaire (DN4) Brief Pain Inventory (BPI) Fatigue Assessment Scale (FAS)
75786723|NCT01205282|Drug|Placebo|There will be a 2 week period of placebo run-in.
75786724|NCT05666414|Procedure|sandwich interpositional bone grafting computer guided|performing the 2 vertical and the 1 horizontal osteotomies using a cutting patient specific guide and fixation of the vertically elevated bony segment after gap calculation using patient specific fixation guides
75786725|NCT05666414|Procedure|conventional interpositional bone grafting|performing the conventional interpositional sandwich osteotomies free-hand and fixation of the mobilized bone segment free-hand
75786726|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
75922962|NCT03371810|Behavioral|Physical exercise|"During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually.~Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity."
75922963|NCT03511716|Device|HRT Mitral Bridge Mitral Valve Repair|Surgical mitral valve implant intended to reduce mitral regurgitation by direct reduction of the septo-lateral mitral annular diameter, promoting early coaptation of the valve leaflets and restraining the leaflets below the intra-annular plane
75922964|NCT02154399|Drug|EF5|Given IV
75922965|NCT02154399|Other|Laboratory Biomarker Analysis|Correlative studies
75922966|NCT02154399|Procedure|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
75922967|NCT02154399|Other|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
76079330|NCT02455284|Device|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
75470174|NCT03530358|Behavioral|Conventional rehabilitation|The patients will be asked to perform a wide range of exercises, including: shoulder flexion-extension, abduction-adduction, internal-external rotation, circumduction, elbow flexion-extension, forearm pronation-supination, hand-digit motion. Standardized instructions and modalities will be followed when providing exercises to the patients in order to control for any variability in leading the therapy session due to the therapist.
75470175|NCT03439774|Device|Topcon CT-800|tonometer
75798708|NCT01179204|Procedure|Preoperative heat stimulation|Preoperative short and long tonic heat stimulation
75922968|NCT02519192|Device|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
75922969|NCT02519192|Procedure|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
75330330|NCT00991081|Behavioral|Counseling|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~One week prior to the target quit date (TQD)~Two weeks post-TQD~Four weeks post-TQD"
75330331|NCT00991081|Behavioral|Self-help guide|A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
75330332|NCT00991081|Drug|Pharmacotherapy|"8-week course of genetically-tailored pharmacotherapy~Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~Participants with the A2 allele (CC) were assigned to receive bupropion"
75786727|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
75786728|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
75786729|NCT01200914|Device|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
75922970|NCT02519192|Procedure|ostomy bag|Non Vac Arm will receive ostomy bag applications.
75922971|NCT02519192|Procedure|wet to dry dressings|Non Vac arm will receive wet to dry dressing changes.
75637750|NCT04220697|Other|high frequency electrical stimulation of the forearm skin (HFS)|HFS consists of transcutaneous electrical stimuli delivered as 42 Hz trains (pulse width: 2 ms) lasting 1 s. The trains are repeated 12 times. Each train is separated by 10 seconds.
75330333|NCT00991081|Behavioral|Genetic feedback, verbal|During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
75922972|NCT02293200|Device|Standard BLS|basic life support without any feedback device
75922973|NCT02293200|Device|TrueCPR|CPR with feedback device
75922974|NCT03542799|Biological|EGFR IL12 CART|EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
75922975|NCT02519972|Device|low dose computed tomography|Participants will receive 3 round of low dose computed tomography screening every year
75330334|NCT00991081|Behavioral|Genetic feedback, printed|After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
75330335|NCT03163342|Biological|Licensed seasonal influenza vaccine|20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
75470176|NCT03439774|Device|Topcon TRK-2P|tonometer, pachymeter
75470177|NCT03426878|Other|Modified genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive modified genetic counseling to help them understand the results.
75470178|NCT03426878|Other|Traditional genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive traditional genetic counseling to help them understand the results.
75637751|NCT04220697|Other|cutaneous mechanical pinprick stimulation|Mechanical pinprick stimuli will be applied manually by the operator on the skin using a mechanical stimulator (maximum weight 128 mN).
75637752|NCT02757261|Device|Laser|Low-level laser therapy administrated to acupoints
75637753|NCT02757261|Device|Occlusal splint|Occlusal splint with expander
75637754|NCT02757261|Device|Placebo laser|Placebo laser (Low-level laser therapy administrated to acupoints)
75637755|NCT02752425|Device|Visual feedback|Use of ultrasound echography for tongue articulatory visual feedback
75637756|NCT02757027|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
75637757|NCT02757027|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
75637758|NCT02756871|Other|online guided self-help intervention for perfectionism|"CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony"
75637759|NCT04220541|Behavioral|Motor learning based exercise|Symptomatic exercise
75637760|NCT02752113|Drug|Empagliflozin and Linagliptin|Empagliflozin and Linagliptin
75637761|NCT02752113|Drug|Metformin and Insulin sc|Metformin and Insulin sc
75637762|NCT02751957|Behavioral|Early Start Denver Model|The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
75637763|NCT00745615|Drug|Laquinimod|Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
75637764|NCT00745615|Drug|Placebo|Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
75637765|NCT02756715|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation.
75637766|NCT02756715|Drug|Desflurane group|Patient will be anesthetized by using desflurane inhalation during operation.
75786730|NCT01200914|Procedure|PTA alone without use of the GORE VIABAHN|Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
75798709|NCT03365596|Other|Conventional therapy|According to the status of a patient, optimized therapy will be applied.
75922976|NCT02297568|Drug|Calciferol|Comparison 25OHD levels between calciferol and placebo
75922977|NCT02297568|Drug|placebo|
75922978|NCT02154555|Procedure|debridement|post-operative debridement at 1 week follow-up visit
75922979|NCT03376334|Other|Mental Motor Imagery|
75922980|NCT03515382|Drug|GLPG1690|A single oral dose of GLPG1690.
75922981|NCT03515382|Drug|Itraconazole|A single oral dose of itraconazole.
75922982|NCT03515382|Drug|Voriconazole|A single oral dose of voriconazole.
75786731|NCT04533308|Behavioral|Relaxation in virtual reality|Natural 360-degrees scenes from different locations in the world with or without interactions with animals in the virtual reality
75786732|NCT01297556|Behavioral|Cognitive Behavior Therapy(CBT)|Cognitive Behavior Therapy(CBT) for 6 weeks.
75922983|NCT02154633|Behavioral|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
75637767|NCT02756325|Device|MRI|Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
75786733|NCT01205516|Drug|Methadone|Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
75786734|NCT01205516|Drug|Controlled Release Morphine|controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
75786735|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
75786736|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
75786737|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
75922984|NCT02154633|Behavioral|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
75922985|NCT02297646|Behavioral|Endurance Training|
75922986|NCT02519426|Procedure|Mandibular third molar surgery|Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
75922987|NCT03738189|Other|Augmented Reality Video|Augmented Reality selfies will place a selection of denture teeth in pictures of the participants in order to enable the selection of their preferred teeth on their new denture.
75922988|NCT03519360|Other|UFR-restricted dialysis|UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.
75922989|NCT03519360|Other|UFR-unrestricted dialysis|UFR's will be unlimited and prescribed according to the standard of care.
76079331|NCT03466398|Behavioral|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
76079332|NCT04453254|Other|Whole Food Meal|Isocaloric/ macronutrient whole food meal
76079333|NCT04453254|Other|Supplement Food Meal|Isocaloric/ macronutrient supplement food meal
75637768|NCT02756091|Other|No study-specific intervention|
75637769|NCT02756169|Other|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
75637770|NCT04221321|Drug|Atorvastatin 40 mg|Atorvastatin 40 mg
75637771|NCT04221321|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
75637772|NCT04221321|Drug|RAPA114|RAPA114 tablet
75637773|NCT04221243|Device|3D printed space maintainer by NextDent Ortho Rigid|Biocompatible 3D printing material
75637774|NCT04221243|Device|Conventional Band and Loop|metal space maintainer
75637775|NCT02755701|Drug|Branched-chain Amino Acid|BCAA (livact) will be administered 3 times a day during 24 weeks
75637776|NCT02755701|Drug|Placebo|Placebo will be administered in the same way
75637777|NCT02751801|Other|no intervention|
75637778|NCT02755857|Drug|Lozanoc|65 mg
75637779|NCT02755545|Drug|Product A|Product A applied topically to the entire face or other affected area of the skin once daily
75637780|NCT02755545|Drug|Product B|Product B applied topically to affected area of the skin 1 to 3 times daily
75637781|NCT02755389|Drug|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
75637782|NCT02755389|Drug|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
75637783|NCT02755389|Drug|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
75637784|NCT02695797|Other|IVIG|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
75637785|NCT02695797|Drug|Prednisolone|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
75786738|NCT01201070|Drug|antithrombin III|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
75637786|NCT02755311|Procedure|liver resection|Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.
75637787|NCT02755311|Procedure|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
75786739|NCT01205594|Device|ITPR|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
75786740|NCT02937454|Drug|ferric carboxymaltose|FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered
75786741|NCT02937454|Other|Normal saline 0.9%|Normal saline will be administered as a bolus injection.
75637788|NCT02755311|Drug|carboplatin|Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
75637789|NCT02755311|Drug|lipiodol|Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
75637790|NCT02755311|Drug|epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.
75786742|NCT01205672|Drug|Metformin|850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
75786743|NCT01205750|Other|Glucose clamp|450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
75922990|NCT02158923|Procedure|Alveolar recruitment maneuver|To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
75922991|NCT02158923|Procedure|Calculation of optimal PEEP|Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .
75922992|NCT02158923|Procedure|Postoperative CPAP|Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
75922993|NCT03690518|Other|Cardiac rehabilitation|Educational/Counseling/Training : Rehabilitation, , cardiovascular rehabilitation in congenital heart disease
75786744|NCT01297712|Device|Latest generation colonoscopy as diagnostic instrument|this endoscope is used as compared to an older generations cope (classic line) currently in use
75786745|NCT01297790|Other|Cough Challenge Tests|Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
75786746|NCT01297790|Other|ambulatory cough recording|Cough recording with a portable device to capture cough sounds
75786747|NCT01297790|Other|Cough questionnaires|Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
75798710|NCT01174602|Behavioral|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
75798711|NCT01174602|Behavioral|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
75922994|NCT02297802|Drug|PD-0325901|
75922995|NCT02159001|Device|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
75922996|NCT03511560|Drug|Tacrolimus Extended Release Oral Tablet|Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
75922997|NCT03511560|Drug|Tacrolimus|Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
75922998|NCT02160171|Device|Algorithm for Neonatal Seizure Recognition|Software system for neonatal seizure detection recognition
75922999|NCT03519126|Other|electrostimulation|Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.
75786748|NCT03843086|Device|Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients using low intensity shockwave therapy. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)"
75786749|NCT03012386|Drug|Sildenafil Citrate in G allele carrier|chronic use of phosphodiesterase 5 inhibitor in G allele carrier
75786750|NCT03012386|Drug|Sildenafil Citrate in non G allele carrier|chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier
75923000|NCT03688802|Drug|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
75470179|NCT03412578|Procedure|Massage Therapy|Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
75470180|NCT03337802|Behavioral|mediterranean diet|The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
75637791|NCT02755311|Other|absorbable gelatin sponge particles|Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
75330336|NCT03165058|Diagnostic Test|mucosal impedance (MI) testing|During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.
75330337|NCT03018145|Device|Wagon|
75330338|NCT03018145|Device|Standard stretcher car|
75637792|NCT04554771|Drug|Tocilizumab 20 Mg/mL Intravenous Solution|tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation
75637793|NCT04554771|Drug|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29
75637794|NCT04554771|Drug|Carboplatin|Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29
75637795|NCT04554771|Radiation|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy
75786751|NCT01202552|Biological|seasonal influenza vaccine|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
75786752|NCT01202552|Biological|seasonal influenza vaccine|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group
75923001|NCT03688802|Drug|Placebo (vehicle control) nasal spray|Placebo
75923002|NCT02159157|Behavioral|Exercise prescription|A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
76079334|NCT01145638|Drug|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
76079335|NCT01145638|Drug|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
75330339|NCT01351623|Drug|Carfilzomib|Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
75330340|NCT03017911|Procedure|Piccline|
75330341|NCT03168022|Drug|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
75330342|NCT03168022|Drug|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
75470181|NCT03333005|Drug|APX001 with Standard of Care anti-fungal agent|safety assessment
75470182|NCT03330496|Other|Pain Measurement|Measurement of infant responses (behavioral and physiological) during a painful procedure.
75470183|NCT03284268|Genetic|VCN-01|VCN-01 intravitreal injection
75470184|NCT03231995|Biological|Collection of nasopharyngeal specimen collected at D0, D1, D2 and D5.|"Analyses will be performed on nasopharyngeal specimen collected at D0, D1, D2 and D5.~Definition and validation of nasopharyngeal microbiome biomarkers (bacterial, viral, transcriptomic signature)"
75637796|NCT02755233|Other|Pulmonary Function|Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
75637797|NCT02751723|Other|validated questionnaires|
75637798|NCT02755155|Drug|Human serum albumin infusion 4%|Continuous infusion of 15mL/kg of bodyweight over 24h/day
75637799|NCT02755155|Drug|Human serum albumin infusion 20%|Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
75786753|NCT01202552|Biological|seasonal influenza vaccine|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
75786754|NCT01205906|Behavioral|Internet-based guided self-help for tinnitus|Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
75786755|NCT01205906|Behavioral|Cognitive-behavior group therapy for tinnitus|Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
75786756|NCT01205906|Other|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
75330343|NCT03272529|Other|Patient-specific simulated rehearsals|Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.
75786757|NCT01202630|Dietary Supplement|Lactobacillus acidophilus CL1285® and Lactobacillus casei|2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
75786758|NCT01202630|Dietary Supplement|Placebo|2 capsules of placebo (no live cells), consumed once daily for 60 days
75786759|NCT01205984|Drug|methylprednisolone|Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
75786760|NCT03842852|Procedure|Inguinal hernia repair|The grupo one underwent open repair and laparoscopic repair
75786761|NCT05282576|Other|NPF Group|Participants allocated to the experimental group completed until discharged, neurophysiological facilitation(NPF) techniques in addition to conventional physiotherapy.
75786762|NCT05282576|Other|Control Group|Critical ill patients was applied their conventional physiotherapy which includes chest physiotherapy and mobilization until discharged
75786763|NCT01297868|Other|exercise|
75786764|NCT01202708|Device|On line hemofiafiltration|hemodiafiltration with the Gambro AK 200 ULTRA
75923003|NCT03511482|Device|myAsthma Application|myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.
75470185|NCT03166813|Procedure|Remote Ischaemic Preconditioning|The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
75470186|NCT03166813|Other|Control|Placement of blood pressure cuff without inflation for 30 minutes.
75637800|NCT02751645|Procedure|Acute Normovolemic hemodilution|ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
75637801|NCT02754843|Device|Phonak's equivalent newly developped power BTE|
75786765|NCT01202708|Device|On line hemodiafiltration|On line hemodiafiltration with the Gambro AK 200 ULTRA System
75786766|NCT01297946|Device|Conventional continuous subcutaneous insulin infusion therapy|
75786767|NCT01297946|Device|Dual-hormone closed-loop|
75637802|NCT02754843|Device|Equivalent competitor device|
75786768|NCT04475978|Device|IVUS-guide DCB PTCA|IVUS-guide DCB PTCA
75637803|NCT02751411|Device|micro-enema with Promelaxin|The intervention has a lubricating, protective action on the anus and rectum and a balanced osmotic action which elicits the evacuation reflex.
75786769|NCT04475978|Device|Angio-guide DCB PTCA|Angio-guide DCB PTCA
75786770|NCT04451798|Device|Impella CP microaxial pump|ramp test
75786771|NCT03829904|Drug|VGH-BPH1|A scientific Chinese granule powder
75786772|NCT03829904|Drug|Placebo (Corn starch pill manufactured to mimic VGH-BPH1)|Corn starch pill manufactured to mimic VGH-BPH1
75786773|NCT03211858|Drug|Insulin aspart|SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG <10 millimoles/liter [mmol/L] [<180 milligram/deciliter {mg/dL}]) while avoiding hypoglycemia.
75786774|NCT03211858|Drug|NovoLog/NovoRapid|NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG <10 mmol/L [<180 mg/dL]) while avoiding hypoglycemia.
76079336|NCT03466320|Biological|NKR-2|This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
75470187|NCT03148366|Drug|Levofloxacin based sequential therapy|D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days
75786775|NCT03211858|Drug|Insulin glargine (HOE901)|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
75786776|NCT01298102|Biological|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
75786777|NCT01206218|Drug|FLOT Regimen|FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
75786778|NCT01206218|Drug|FLO Regimen or FLOT Regimen|FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
75786779|NCT01298180|Drug|Growth hormone (Genotonorm® or Omnitrope®)|drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.
75786780|NCT01298180|Procedure|DEXA, blood tests, H.G.P.O, osseous age.|"SPW, GHD, SPW-B :~blood tests : centralized dosage H.G.P.O : adjusted to children's age."
75786781|NCT01298180|Procedure|biopsy|Biopsy : Cutaneous and fat tissue biopsy.
75786782|NCT03211156|Drug|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
75786783|NCT03211156|Other|Placebo|Placebo
75786784|NCT01298258|Drug|Aliskiren|Aliskiren 150mg
75786785|NCT01298336|Drug|Clarithromycin|500 mg twice a day seven days a week
75786786|NCT01298336|Drug|Moxifloxacin|400 mg per day seven days a week
75786787|NCT01201148|Device|tDCS (Eldith DC-Stimulator (CE certified))|For participants receiving intermittent tDCS or oscillating TES, one electrode will be placed over the left pF3 electrode site (overlying the left dorsolateral prefrontal cortex and identified on the scalp using an EEG cap based on the 10/20 system) and the other over the right temporal area.
75330344|NCT03272529|Other|Idealized simulated rehearsals|Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.
75923004|NCT03511482|Device|Lloyds Pharmacy Online Doctor|"Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare."
75786788|NCT05669456|Device|Halo Alert System|The Halo Alert System consists of an EEG sensor headband and is paired with a data transfer device.
75786789|NCT04472494|Biological|Abatacept|Specified dose on specified days
75786790|NCT04472494|Other|Placebo|Specified dose on specified days
75923005|NCT02160249|Behavioral|Community-based rehabilitation|
75923006|NCT02160249|Other|Facility based care|
75923007|NCT03518970|Other|Nursing intervention|"The intervention was built on the components of the theory of uncertainty in illness and was designed to give in a face to face meeting with the caregiver education about advanced cancer in palliative care through an educational material.~Educational material: The educational booklet has the purpose of giving information to the family caregiver about palliative care. This material aims to be an easily accessible resource to understand the palliative care of the cancer patient. In addition, this booklet will be used to ensure the standardization of the intervention during the face-to-face meeting with the participants and the investigator.~Face-to-face meeting: The nursing intervention has a face-to-face meeting component between the investigator and the participant. This nursing educational session will be supported by the contents of the booklet and will have the purpose of discussing the contents of the booklet and resolving doubts on the part of the family caregivers."
75923008|NCT03511404|Other|physiotherapy rehabilitation|All subjects will receive a course of conventional physiotherapy that incorporating components of pain relief and functional restoration with the use of electrotherapy and exercise therapy for twelve sessions twice weekly in six weeks guided by a registered physiotherapist in Hong Kong.
75637804|NCT02751411|Drug|Macrogol 4000|Stool softener
75470188|NCT03148366|Drug|bismuth quadruple therapy for 10 days (BQ)|D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
75470189|NCT03122496|Drug|durvalumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
75637805|NCT02754921|Procedure|percutaneous dilatational tracheostomy using Ultra-Perc|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc
75637806|NCT02754921|Procedure|Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
75637807|NCT02755077|Procedure|Head rotation during mask ventilation|Patient's head position is axially rotated 45 degrees to the right.
75786791|NCT04568200|Drug|Durvalumab|Durvalumab 1500mg i.v. day 1-22-43-64
75786792|NCT04568200|Drug|Carboplatin|Chemotherapy
75786793|NCT04568200|Drug|Paclitaxel|Chemotherapy
75786794|NCT04568200|Radiation|Radiotherapy 23 x 1.8 Gy|Radiotherapy 23 x 1.8 Gy
75786795|NCT04419506|Drug|BI 1015550|18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
75786796|NCT04419506|Drug|Placebo|placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
75786797|NCT03842774|Dietary Supplement|Exract of Gelidium elegans|Exract of Gelidium elegans will be given to the test group.
75786798|NCT03842774|Dietary Supplement|Placebo|Placebo supplement will be given to the test group.
75786799|NCT03236506|Drug|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet|Drugs will be given to participants to treat hepatitis C infection
75798712|NCT05420428|Device|supraglottic airway device|under general anesthesia, patients received supraglottic airway device
75798713|NCT05420428|Device|endotracheal intubation|under general anesthesia, patients received endotracheal intubation
75330345|NCT03272529|Other|Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
75330346|NCT03017989|Device|NIRF imaging|By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
75786800|NCT03236506|Behavioral|Psychological intervention|"Participants randomised to fortnightly pick-up with psychological intervention will have an interview with the study nurse designed to aid their compliance with the drug regimen. During the intervention participants will be guided by their trial nurse in the completion of a personalised booklet, Hepatitis C and Me. The booklet uses the principles of node-link mapping to structure the intervention."
75330347|NCT04342533|Procedure|Thulium fiber laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
75923009|NCT03656744|Drug|HTD1801|HTD1801 tablets, 250mg
75330348|NCT04342533|Procedure|Holmium laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
75330349|NCT03102190|Drug|Verapamil Hydrochloride Intranasal|Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
75923010|NCT03656744|Drug|Placebo|tablets manufactured to mimic HTD1801 tablets
75470190|NCT03122496|Drug|tremelimumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
75923011|NCT02297880|Other|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
75923012|NCT02297880|Other|Still water|Still water (no flavour)
75923013|NCT02298036|Behavioral|(Remote) Cognitive Behaviour Therapy|Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
75923014|NCT02293356|Drug|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
75923015|NCT03518892|Diagnostic Test|Resting Metabolic Rate|30 minute test to determine daily caloric needs
75330350|NCT04353427|Behavioral|The Seven Pathways to Healing, Health and Wellness curriculum|"The curriculum seeks to increase civic engagement by fostering a sense of community and a sense of social and personal responsibility in community. There will be 7 monthly session that will be approximately 1 hour in duration. Session topics include:~Education and Information (including mental health awareness, and a one-day certificate program in Mental Health First Aid)~Connection with Others~The Body as Temple~Emotional Healing~The Nature of Mind~Life Assessment~The Nature of Spirit"
75651812|NCT05461950|Procedure|Extrauterine placental transfusion and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room, the umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infants is breathing regularly (within 10 minutes after delivery)
75923016|NCT03518892|Diagnostic Test|Body Composition|Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat
75923017|NCT03518892|Behavioral|Dietary Assessment|Self administered dietary logs
75923018|NCT03616418|Drug|antiplatelet drugs;statins;antihypertensive drugs|
76079337|NCT03466242|Drug|Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
75330351|NCT03263949|Other|Diagnostic|For the analysis of myocardial function, conventional 2D echocardiography and tissue doppler will be used. For the evaluation of myocardial mechanics, 2D speckle tracking, strain, strain rate and mechanical dispersion will be obtained.
75330352|NCT04342455|Other|double-low scanning|a CT angiography protocol with low radiation and contrast agent exposure
75330353|NCT02163811|Behavioral|VETPALS|"VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.~VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care."
75330354|NCT02163811|Behavioral|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
75330355|NCT03168334|Drug|IDP-123 Lotion|Tazarotene 0.045% Lotion
75330356|NCT03168334|Drug|IDP-123 Vehicle Lotion|Vehicle Lotion
75330357|NCT03254667|Biological|Brodalumab|Brodalumab
75786801|NCT03236506|Drug|Sofosbuvir 400 MG|Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection
75330358|NCT03254667|Drug|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
75470191|NCT03122496|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab
75786802|NCT01201226|Other|Removal of half an ovary|Removal of half an ovary
75786803|NCT01201304|Behavioral|Standard exposure|Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
76079338|NCT03466242|Drug|Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine
75470192|NCT03107104|Device|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes
75470193|NCT03107104|Device|TRC-50DX retinal camera|The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes
75330359|NCT05108467|Diagnostic Test|Point of care Lactate|"StatStrip Lactate is a handheld, point-of-care (POC) meter that brings lactate testing directly to the bedside. Lactate measured with blood gas analyzers is problematic for bedside care. Blood gas analyzers require arterial samples, large sample volumes (100-200 μL), and long analysis times (up to 2.5 minutes). In addition, blood gas analyzers are complex to use, stationary, and expensive to purchase and run.~StatStrip Lactate testing is as easy as bedside glucose testing. Single-use, pre-calibrated biosensors provide the fastest turnaround time (13 seconds) from the smallest whole blood sample (0.6 μL) with excellent correlation to central laboratory reference methods."
75330360|NCT03102736|Drug|Placebos|Placebo saline
75330361|NCT03102736|Drug|Ketamine|0.5 mg/kg ketamine
75637808|NCT00744523|Device|Mo.Ma cerebral protection device|Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
75330362|NCT03102736|Drug|Nitroprusside|0.5 mcg/kg nitroprusside
75637809|NCT02597569|Behavioral|CO-OP KT Exposure|"Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.~The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support."
75637810|NCT00744991|Drug|Enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
75637811|NCT02754999|Drug|SANGUINATE™|As needed (PRN) infusions of 500 mL of SANGUINATE
75637812|NCT02751489|Other|Bain De Soliel - Solid|0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
75637813|NCT04090801|Drug|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|
75637814|NCT04090801|Drug|Topical minoxidil 5% in pure ethanol alone|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
75637815|NCT04090801|Other|Placebo (Ethanol)|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
75637816|NCT02754609|Other|Gluten micro-challenge|From week 12 to week 24, all participants will start a gluten micro-challenge from 10mg/day for the first 2 weeks escalating over the this period to 50mg/day at the end of week 24.
75637817|NCT02754609|Other|Inadvertent gluten challenge|From week 24 to week 36, all participants will be on gluten 50mg/day and 1g twice weekly.
75637818|NCT02754609|Other|Moderate gluten challenge|From week 36 to week 42, all participants will be on gluten 2g/day.
75923019|NCT03515148|Procedure|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
75923020|NCT03515148|Procedure|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
75923021|NCT03371576|Device|intraocular lenses|
75330363|NCT03743103|Drug|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
75330364|NCT03743103|Drug|Nitroprusside, Sodium|0.5 ug/kg/min every 3 minutes until reaching the pressure target
75330365|NCT04049266|Drug|KSI-301|Intravitreal Injection
75330366|NCT04049266|Drug|Aflibercept|Intravitreal Injection
75330367|NCT04049266|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
75470194|NCT03073694|Drug|Mitomycin c|Mitomycin-c will be given to participants in Treatment Arm 1 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes. 45 minutes into the perfusion, a maintenance dose will be administered.
75637819|NCT02754609|Other|Liberal diet|From week 42, all participants will be unblinded and those who have received hookworm therapy have the option to go on a liberal diet of more than 10g of gluten/day from week 42 to week 94.
75637820|NCT02754609|Other|Necator americanus-hookworm larvae L3-10|A total of 40 participants at week 0 and week 8 will have hookworms L3-10 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
75637821|NCT02754609|Other|Tabasco® Sauce|Arm: Placebo Comparator: Tabasco® Sauce A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing
75637822|NCT02754609|Other|Necator americanus-hookworm larvae L3-20|A total of 40 participants at week 0 and week 8 will have hookworms L3-20 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
75637823|NCT02754609|Other|Gluten free diet|From week 0 to week 12, all participants will be on a gluten free diet.
75637824|NCT04089631|Drug|Capecitabine|6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
75637825|NCT00917059|Drug|Escitalopram|Fixed dose of 10 mg per day
75637826|NCT00917059|Drug|Bupropion XL|Fixed dose of 150 mg per day
75637827|NCT02751333|Procedure|FCSEMS with Endostitch (ES)|The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.
75923022|NCT03511170|Drug|XELIRI|Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle
75786804|NCT01201304|Behavioral|Enhanced exposure|Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
75786805|NCT01201304|Behavioral|Intensive exposure|Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
75786806|NCT01201304|Behavioral|Expressive writing|Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
75637828|NCT02751333|Procedure|FCSEMS with No Suturing (NS)|The insertion of FCSEMS with no suturing.
75637829|NCT02751333|Device|Fully Covered Self-Expanding Metal Stents (FCSEMS)|This is the stent that will be used to treat the esophageal pathology in both groups
75637830|NCT02751333|Device|EndoStitch (ES) with the OverStitchTM system|This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
75637831|NCT02754531|Device|USG|USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.
75637832|NCT02754531|Other|Cole Formula|Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
75330368|NCT00992719|Biological|Inactivated H1N1 Vaccine|H1N1 vaccine [Influenza A (H1N1) 2009 Monovalent Vaccine] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
75330369|NCT03169816|Drug|Lorcaserin|Lorcaserin 10mg, twice daily
75637833|NCT00917137|Procedure|TBNA + transbronchial lung biopsy + bronchial washing|
75637834|NCT03973645|Other|Patient presenting peritonitis managed with fungal research during year 2016|Patient presenting a peritoneal fungal with panfungal PCR and BDG compared to Peritonitis score (PS) and microbiological (ED direct fungal examination)
75637835|NCT02598037|Dietary Supplement|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
75637836|NCT02751567|Other|BAY987516|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
75637837|NCT02751567|Other|Untreated skin|One site is patched without treatment as control
75330370|NCT03169816|Drug|Placebo|Matched placebo for lorcaserin condition dosed twice daily
75330371|NCT03103282|Device|PuraStat®|Synthetic haemostatic material
75637838|NCT00917449|Drug|L-arginine|Oral L-arginine (3.2 gr bid)for 18 months
75637839|NCT00917449|Drug|Placebo|Oral Placebo BID for 18 months
75637840|NCT02754687|Drug|Placebo|Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients
75637841|NCT02754687|Drug|11βmethyl nortestosterone dodecylcarbonate|Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
75637842|NCT02597335|Radiation|Spectro-MRI|Spectro-MRI for D-2HG detection
75637843|NCT02597335|Other|Dosage of free circulating plasmatic DNA|
75637844|NCT02597335|Other|Dosage of D-2HG in the urine|
75637845|NCT02754453|Behavioral|Behavioral lifestyle intervention|20 session lifestyle behavioral intervention with the goal of altering diet and physical activity and decreasing problematic behaviors associated with weight regain and session behavioral intervention addressing increasing physical activity, improving adherence to dietary recommendations and altering problematic eating behaviors.
75637846|NCT04254315|Behavioral|Group based cognitive therapy|"Patients are informed about the Optima program in the inclusion interview, and patients are participating in groups of maximum 4 persons. Each of the 5 session has a duration of 1,5 - 2 hours.~The psychologist have developed the content of each session, with attention to thoughts and feelings regarding the current situation after a heart-condition, and the effects on life conditions. Patients get the tools to overcoming the difficulties, they experience, f.x. anxiety and stress.~When other hospitals are joining the Optima project, the project nurse and psychologist are training the hospital staff as well as supervising."
75786807|NCT04933708|Behavioral|Labor Podcast|"Listening to podcasts.~Topics include:~Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth"
75786808|NCT01201382|Behavioral|IPT-AST|A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
75786809|NCT01201382|Behavioral|Group Counseling|Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
75798714|NCT03300804|Drug|20-herb formulation|Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
75798715|NCT03300804|Drug|Placebo|Placebo herb formulation
75330372|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM
75330373|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 Ml, 4 doses, IM
75637847|NCT04220151|Genetic|DNA methylation|DNA methylation will be measured by real time polymerase chain reaction
75786810|NCT04421404|Biological|COVID-19 Convalescent Plasma (CCP)|COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the purpose of preventing or treating the infectious disease it causes. Convalescent plasma for this trial will be obtained from Vitalant (or American Red Cross if necessary). Patients identified as having recovered from COVID-19 will serve as potential donors. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined.
75786811|NCT04421404|Biological|Placebo|Standard plasma will be obtained from Vitalant (or American Red Cross if necessary) and will be either collected prior to 12/1/2019 or tested and confirmed to be negative for anti-SARS-CoV-2.
75637848|NCT05429775|Drug|Budesonide|single dose of 2 mg oral suspension formulation administered orally under fasting conditions
75330374|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM with concommitant vaccines
75637849|NCT02754219|Drug|Evogliptin|DPP4-inhibitor, Evogliptin
75923023|NCT03511170|Drug|XELOX|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
75923024|NCT03518814|Other|Questionnaires|FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
76079339|NCT03013270|Other|Aerobic-Resistance-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
76079340|NCT03013270|Other|Aerobic-Resistance|"Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)"
76079341|NCT03013270|Other|Aerobic-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
76079342|NCT03013270|Other|Aerobic Training|Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)
75330375|NCT00362505|Drug|Clevudine|
75330376|NCT03103438|Biological|BCD-089|
75330377|NCT00993187|Drug|Sitagliptin/Metformin FDC|Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
75330378|NCT00993187|Drug|Comparator: Glimepiride|Glimepiride tablet orally up to 6 mg daily for 30 Weeks
75923025|NCT02301312|Device|POSS-PCU vascular graft|New vascular access graft
75330379|NCT00993187|Drug|Matching placebo to Sitagliptin/Metformin FDC|Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
75330380|NCT00993187|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet orally daily for 30 weeks
75330381|NCT03106636|Behavioral|KEEP-P|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
75637850|NCT05429619|Device|OnCall mobile health peer support app|"Mobile health platform that provides anonymous access to peer support services that has been co-design by and for Canadian public safety personnel. OnCall is for frontline public safety providers; features include links to mental health self-assessment tools, a wellness toolbox, tips to cope articles and peer wisdom videos, and options to reach out to a peer support provider of their choice via telephone or text. The OnCallSupport app is for the peer support providers which includes a list of resources and an opportunity to create post-action reports following the peer support encounter. Connections are made to peer support via a telephone service that disguises the contact information of both parties. The app platform includes options to complete feedback surveys related to the app and to the peer support encounter."
75637851|NCT04232631|Device|IntraOx Vioptix|Vascular imaging device
75637852|NCT04232631|Device|Hyperview, HyperMed Imaging|Vascular imaging device
75637853|NCT04232631|Device|Snapshot NIH, Kent Imaging|Vascular imaging device
75637854|NCT05429385|Drug|HLX70|Single-dose, intravenous infusion
75786812|NCT01298414|Genetic|RNA analysis|
75786813|NCT01298414|Other|laboratory biomarker analysis|
75923026|NCT03511092|Dietary Supplement|HMB-FA|One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
75923027|NCT03511092|Dietary Supplement|HMB-Ca|One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
75923028|NCT03511092|Dietary Supplement|alfa-HICA|Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.
76079343|NCT03461250|Diagnostic Test|HCV serology|Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
75786814|NCT03227692|Device|Persona Knee System|Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
75786815|NCT03227692|Procedure|Total Knee Arthroplasty|Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
75786816|NCT03227692|Device|iAssist Knee|Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
75786817|NCT01298726|Other|PHARMACEUTICAL CARE|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
75786818|NCT01298726|Other|HEALTH USUAL CARE|Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
75786819|NCT01298804|Behavioral|Problem Solving Education and Activated Referral to Care|"The intervention represents an integrated identification and intervention system based on the evidence-based construct of screening, brief intervention, and referral to treatment (SBIRT). Within the comprehensive case management services of Head Start, eligible women will be randomized to receive either usual care or the Head Start-based intervention. In our intervention, mothers at risk for depression will receive a problem-solving intervention; depression symptom monitoring; and an Activated referral to more definitive services for those who have worsening symptoms over time."
75786820|NCT05180578|Other|Goat milk diet|Elimination of cow milk from diet . Goat milk containing diet.
75786821|NCT01298882|Drug|Diacerein|
75923029|NCT03511092|Other|Placebo comparator|One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
75923030|NCT03376178|Combination Product|lidocaine and ropivacaine injection through catheters|injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
75923031|NCT02298114|Device|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
75923032|NCT02298114|Other|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
75923033|NCT03514836|Biological|DCVac/PCa|"Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy.~DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy."
75330382|NCT03106636|Behavioral|KEEP-P+|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
75330383|NCT03173170|Drug|TAK-954|TAK-954 Infusion
75923034|NCT03514836|Drug|Cyclophosphamide|immunomodulatory medication given around the ONCOS-102 dosing
75637855|NCT05429385|Drug|Placebo|Single-dose, intravenous infusion
75923035|NCT03511014|Device|Microcurrent|Micrucurrent will be apply
75923036|NCT03376100|Procedure|Ultrasound guided nerve blocks|Ultrasound guided nerve blocks of the radial and median nerves
75923037|NCT03376100|Procedure|Hematoma Block|Conventional local anesthetic method using hematoma block
75923038|NCT03376022|Other|Attitudes, knowledge|To investigate attitudes and knowledge to oral Health and oral care
75923039|NCT03518580|Other|real-time assessment of biopsychosocial functioning|the participants were asked to provide biopsychosocial data using the mobile device
75923040|NCT03371342|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
75923041|NCT03371342|Drug|Botox|Botox(Botulinum toxin type A)
75923042|NCT02302326|Drug|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
75330384|NCT03173170|Drug|Itraconazole|Itraconazole Capsule
75330385|NCT03106870|Drug|Insulin Mixtard|"Insulin dose:~0.7 IU/Kg (at the second trimester of pregnancy).~0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration."
75637856|NCT02753829|Procedure|Cardiovascular rehabilitation program using Kinect of Xbox|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
75786822|NCT01298882|Other|Placebo|
75923043|NCT02302326|Dietary Supplement|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
75923044|NCT03367130|Behavioral|Mobile phone reminder|Intervention described already in arm/group descriptions.
75923045|NCT02293590|Drug|Certolizumab Pegol|
75923046|NCT02302404|Drug|GSK2982772 solution|Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
75923047|NCT02302404|Drug|GSK2982772 capsule|Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
75923048|NCT02302404|Drug|Placebo solution|Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
75923049|NCT02302404|Drug|Placebo capsule|Size 00 White Opaque capsule containing Placebo as white to almost white solid
75923050|NCT03124082|Drug|Remifentanil|continuous infusion intraop
75330386|NCT03106870|Drug|Metformin|"Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day."
75330387|NCT00375154|Device|Noninvasive Positive-Pressure Ventilation (NPPV)|
75330388|NCT00375310|Drug|Gemcitabine, Sorafenib|"Gemcitabine is given IV~Sorafenib is given orally of varying doses:~Sorafenib 200 mg po qd ( during combination therapy)~Sorafenib 400 mg po qd ( during combination therapy)~Sorafenib 400 mg po bid ( during combination therapy)"
75330389|NCT00375310|Procedure|Radiotherapy|1.8 Gy CTV daily for 5 weeks
75923051|NCT03124082|Drug|Ketamine|bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
75330390|NCT03687892|Device|continuous Theta Burst Stimulation|Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
75330391|NCT03687892|Device|intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
75923052|NCT03124082|Drug|Lidocaine|lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
75786823|NCT05180266|Other|Therapeutic Touch|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form, PSQI,MRS and MENQOL. After pre-test data collection, women will be given an appointment for therapeutic administration.The therapeutic touch group will be applied to the therapeutic touch group once a week for four weeks in a suitable room in the Faculty of Nursing and on the specified day and time by the researcher.At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
75786824|NCT05180266|Other|Music Listening Group|Each of the women was informed about the purpose and content of the study at the first meeting, and informed consent was obtained from the women who met the conditions for participation and accepted to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. Music stream, music will be uploaded to mobile phones. He will be asked to listen to music (relaxation music in the relaxation exercises CD prepared by the Turkish Psychological Association) for 30 minutes before going to sleep every day for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again
75786825|NCT05180266|Other|Control Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. No action will be taken on the control group for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
75923053|NCT03124082|Drug|Clonidine|clonidine 4 mcg/kg
75923054|NCT03109860|Behavioral|Open-hidden|Administration of a treatment openly (in full view of the patient) vs hidden (without the patient's knowledge).
75923055|NCT02301702|Biological|Tdap|Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
75923056|NCT02301702|Biological|Td|The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
75923057|NCT03552224|Procedure|Recording of auditory nerve activity|near field recording of auditory nerve activity with contact electrode
75923058|NCT03518502|Procedure|transarterial chemoembolization (TACE)|Standard therapy for intermediate HCC, but nor for advanced HCC
75923059|NCT03518502|Drug|Sorafenib|Standard therapy for advanced HCC
75923060|NCT02301780|Drug|Aspirin|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
75923061|NCT02301780|Drug|Placebo|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
75330392|NCT03670953|Drug|IR CD-LD|Active comparator - IR CD-LD
75923062|NCT03124004|Procedure|periodontal debridement|with ultrasonic device supragingival and subgingival full-mouth debridement is provided
75923063|NCT02302482|Other|The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6|
75923064|NCT03124238|Other|Massage|Massage therapy localized to the back of the individuals for a duration of 30 minutes
75330393|NCT03670953|Drug|IPX203 ER CD-LD|Investigational formulation - ER CD-LD
75330394|NCT03670953|Other|Placebo Matching IPX203|Double dummy placebo capsules
75330395|NCT03670953|Other|Placebo Matching IR CD-LD|Double dummy placebo tablets
75470195|NCT03073694|Drug|Melphalan|Melphalan will be given to participants in Treatment Arm 2 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes.
75470196|NCT03069703|Biological|PCV13|one dose of PCV13 at D0 (arm A) or two double doses at D0 and D7 (Arm B) or one quadruple dose at D0 (arm C)
75470197|NCT03069703|Biological|PPV23|one dose of PPV23 at M5
75786826|NCT03828500|Behavioral|Assistant-encouraged fasting up to ASA/CAS guideline limits|Research Assistant encourages patient to drink clear fluids up to 2 hour limit before surgery, in accordance with the latest ASA and CAS guidelines.
75786827|NCT05281250|Other|Supervised physical exercise|A supervised exercise is randomized. Although this intervention is not standard in our setting, it is a recommended practice, since it is known that rehabilitation strategies in hospitalized patients have different benefits.
75786828|NCT01206530|Drug|Hydroxychloroquine|Dose:600 or 800 mg Route:PO daily Treatment Administration: Daily
75786829|NCT01206530|Drug|Oxaliplatin|Dose: 85mg/m2 Route: IV infusion over 2 hours Treatment Administration: Day 1
75786830|NCT01206530|Drug|Leucovorin|Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1
75330396|NCT04736914|Drug|R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAOx (cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~Zanubrutinib, 160mg PO BID, continuously for 2 year or until progressive disease。~Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT"
75330397|NCT00362583|Drug|Fentanyl|
75637857|NCT02753829|Procedure|Cardiovascular rehabilitation program using paper manual|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
75923065|NCT04527068|Drug|Bevacizumab|7.5 mg/kg intravenously every 3week
75923066|NCT04527068|Drug|Tripleitriumab|240mg intravenously every 3week
75637858|NCT02753829|Other|Educational component|It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
75637859|NCT04220073|Biological|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005
75637860|NCT04220073|Drug|placebo|placebo
75637861|NCT02753907|Dietary Supplement|Low LA|Individuals who replaced 10 mL soy oil with one apple
75786831|NCT01206530|Drug|5-fluorouracil|Dose: 400mg/m2 Route: IV bolus immediately following leucovorin Treatment Administration Day 1
75786832|NCT01206530|Drug|5-fluorouracil|"Dose: 2,400mg/m2 Route: IV continuous infusion over 46 hours immediately following bolus injection.~Treatment Administration: Days 1-2"
75923067|NCT02302638|Other|embryo culture in different single-step media|Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
75330398|NCT00657241|Drug|Carvedilol CR|
75330399|NCT00657241|Drug|Valsartan|
75330400|NCT04342065|Drug|Celecoxib capsules|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
75330401|NCT04342065|Drug|Pregabalin 150mg|received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.
75330402|NCT03179410|Drug|Avelumab|10 mg/kg intravenously every 2 weeks
75330403|NCT00478465|Drug|valganciclovir|
75786833|NCT01206530|Drug|Bevacizumab|
75786834|NCT03210220|Procedure|Pecs II block|After identifying the axillary vein and artery, the ultrasound probe was positioned inferio-laterally, between the 3rd and 4th ribs, and then the pectoralis major and minor, and serratus anterior muscles were confirmed. The needle was advanced in a medio-lateral direction in-plane view of the ultrasound. For the Pecs II block, a total 30 mL of 0.5% ropivacaine was injected. First, the needle tip was advanced into the fascia between the pectoralis major and minor muscles and 10 mL of 0.5% ropivacaine was injected. Thereafter, the needle tip was advanced into the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL of 0.5% ropivacaine was injected in a similar manner.
75923068|NCT04526756|Procedure|Mechanical Thrombectomy|Solitaire stent and manual aspiration thrombectomy were performed as the first-line endovascular treatment
75923069|NCT02739360|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
75923070|NCT03510936|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5*10^7CFU for 2 weeks
75923071|NCT03375944|Other|Rehabilitation|"The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population."
75923072|NCT03132870|Other|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions
75923073|NCT03123770|Drug|Pegylated liposomal doxorubicin|a new kind of doxorubicin
75330404|NCT05364892|Other|Blood samples (80 mL)|Blood samples (80 mL) at inclusion, once a year for 5 years, and if relapse or change of treatment
75330405|NCT05364892|Other|Fecal samples|Fecal samples at inclusion
75330406|NCT05364892|Other|Urinary sample (20-40 mL)|Urinary samples at inclusion, once a year for 5 years, and if relapse or change of treatment
75330407|NCT05364892|Other|Questionnaires|Questionnaires at inclusion, once a year for 5 years, and if relapse or change of treatment
75330408|NCT03655587|Device|Solid ankle foot orthotic|
75330409|NCT03655587|Device|Resting night splint|
75637862|NCT02753907|Dietary Supplement|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
75637863|NCT02753985|Other|Survey|
75637864|NCT05429151|Drug|Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd andcandida antigen|"Group 1: will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions~Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions."
75330410|NCT04982887|Other|Exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
75330411|NCT05364736|Dietary Supplement|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks
75923074|NCT03123770|Drug|Cyclophosphamide|traditional chemotherapy drug
75923075|NCT03123770|Drug|Epirubicin|traditional chemotherapy drug used in breast cancer
75923076|NCT03123770|Drug|Docetaxel|traditional chemotherapy drug used in breast cancer
75637865|NCT04219995|Drug|methylprednisolone sodium succinate|Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.
75923077|NCT04464642|Drug|Methotrexate|Methotrexate 25 mg subcutaneous is given in group A
75923078|NCT04464642|Drug|Tofacitinib|tofacitinib 10 mg given in group B
75923079|NCT02293668|Drug|FSH 225IU and hMG 225IU|
75923080|NCT02293668|Drug|FSH 150IU and hMG 150IU|
75330412|NCT05364736|Other|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
75330413|NCT00421785|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.|
75330414|NCT03155295|Other|Physical reality simulation|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.
75470198|NCT03069703|Drug|Rituximab|375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18
75470199|NCT03067675|Device|Topcon DRI OCT Triton (plus)|OCT Machine used for diagnostic purposes
75470200|NCT02982174|Device|3D OCT-1 Maestro|Image acquisition of the posterior surface of the eye
75470201|NCT02982174|Device|DRI OCT Triton|Image acquisition of the posterior surface of the eye
75637866|NCT04219995|Other|Placebo|The placebo used in this study will be simple syrup.
75637867|NCT02753517|Device|Hepatobiliary scintigraphy|hepatobiliary scintigraphy with functional assessment of the future remnant liver before an extended hepatectomy of 4 or more segments
75637868|NCT05428605|Other|Blood sample|10 mL on lithium heparinate tubes, 10 mL on EDTA tubes.
75637869|NCT04191369|Diagnostic Test|Esophagogastroduodenoscopy|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
75923081|NCT02293668|Drug|Letrozole 5mg and hMG 150IU|
75923082|NCT04526678|Dietary Supplement|Iron supplement (27mg)|The participants will be randomized to an intervention group or a control group. The intervention group will ingest 27mg iron daily for three months.
75923083|NCT02302014|Other|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
75923084|NCT03123692|Drug|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
75923085|NCT03123692|Drug|Placebo|14 days treatment with placebo
75923086|NCT03367052|Procedure|Two level Prodisc-C vivo|Two level of Prodisc-C vivo artificial disc replacement will be done in one group of patients.
75923087|NCT03367052|Procedure|Hybrid|The hybrid method will be used in one group of patients.
75923088|NCT03510858|Other|Multilevel training intervention (intervention group)|QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act). The QC will then repeat one PDCA cycle. The control group will receive the same intervention one year later.
75923089|NCT03510858|Other|Multilevel training intervention (control group with crossover)|The control group will undergo a crossover and receive the same intervention one year after the intervention group. QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act).
76079344|NCT03461172|Procedure|Surgery of breast cancer|Surgery of breast cancer
75330415|NCT03155295|Other|Virtual reality simulation|The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
75923090|NCT04465032|Other|Gut microbiome transplantation|Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
75923091|NCT03375632|Drug|FYU-981|Oral daily dosing for 14 weeks
75330416|NCT04333030|Other|questionnaire|Tobacco Use and Risk Questionnaire
75923092|NCT02302170|Biological|H. pylori vaccine|
75923093|NCT02302170|Biological|placebo|
75923094|NCT02302794|Procedure|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
75637870|NCT04191369|Diagnostic Test|Endoscopic ultrasound|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
75637871|NCT02753673|Behavioral|qualitative interviews with patients|
75637872|NCT02753673|Behavioral|questionnaires|
75923095|NCT02302794|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
75923096|NCT03366896|Diagnostic Test|Malay 3D-CAM diagnostic tool 1|Assessor 1 uses Malay 3D-CAM to detect Delirium
75923097|NCT03366896|Diagnostic Test|Malay 3D-CAM Diagnostic tool 2|Assessor 2 uses Malay 3D-CAM to detect Delirium
75330417|NCT03324724|Behavioral|Integrative cognitive-affective therapy for adolescents (ICAT-A)|Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
75330418|NCT03157336|Other|Non Inferiority WTM Interventional Trial|The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be < 10 ppm as per the recommendations of the World Health Organization.
75637873|NCT04506645|Drug|REGN5381|Single dose REGN5381 administered via IV infusion
75637874|NCT04506645|Other|Placebo|Placebo matching single dose REGN 5381 administered via IV infusion
75637875|NCT02753361|Procedure|Ultrasound guidance|In the second arm, ultrasound will be used to guide the regional block
75923098|NCT02302872|Device|ARTO System|
75923099|NCT03363698|Other|Cough variant asthma treatment|Evaluation of the treatment response to inhaled corticosteroids, long-acting beta-agonists, montelukast, prednisone.
75637876|NCT05428371|Diagnostic Test|Multiomic analyses of blood and surgical specimens|"The following items will be evaluated:~cell free dna length and integrity~presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples~qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)"
75637877|NCT04200417|Procedure|Chemoembolization|Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.
75637878|NCT04200417|Drug|Mitomycin C|Mitomycin (5mg/m^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
75637879|NCT04200417|Drug|Lipiodol|Mitomycin (5mg/m^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
75637880|NCT04200417|Drug|Embospheres|Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.
75637881|NCT04219527|Procedure|Dual-target injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid) + 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
75637882|NCT02753439|Drug|Geistlich Bio Oss|Extraction of Impacted 3rd Molars,
75637883|NCT02753205|Drug|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
75923100|NCT03371186|Other|Community Health Worker|The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers
75923101|NCT03371186|Other|Continuous Surveillance|Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.
76079345|NCT03461172|Other|Clinical data collection|The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
75470202|NCT02963415|Behavioral|Exergame|Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
75786835|NCT03842540|Behavioral|SpeakOut|"SpeakOut aims to increase social communication about contraception between adolescent IUD and implant users and their peers. SpeakOut has four components:~Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~Digital materials for recipients to keep and/or share with friends.~Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut."
75786836|NCT03842540|Behavioral|PartyWise|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. Staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
75470203|NCT02862548|Drug|TAF|Tablet administered orally
75786837|NCT03209518|Drug|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
75470204|NCT02862548|Drug|TDF|Tablet administered orally
75470205|NCT02862548|Drug|Other approved antivirals|Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
75637884|NCT02753205|Drug|normal saline|infusion of normal saline
75786838|NCT01201538|Drug|Nilotinib|
75786839|NCT03646214|Device|Midline traction oral appliance|Device positions the mandible forward to open airway; device can be titrated to gradually advance the mandible.
75786840|NCT03725852|Drug|GLPG1205|GLPG1205 will be provided as an oral hard gelatin capsule.
75923102|NCT03371186|Other|CB-Integrated Management of Newborn and Childhood Illness|Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
75923103|NCT03371186|Other|Group Antenatal and Postnatal Care|The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
76079346|NCT03466164|Behavioral|Mindfulness Based Stress Reduction Program|8 week, 10-session course of mindfulness training
75786841|NCT03725852|Drug|Placebo|GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
75786842|NCT01202942|Other|Quest|Participants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.
76079347|NCT02980120|Other|SCID-I|The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig & Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
76079348|NCT02980120|Other|EAT|The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner & Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
75330419|NCT03147885|Drug|Selinexor|Given PO
75330420|NCT05241392|Biological|B7-H3-targeting CAR-T cells|Patients will be treated with anti-B7-H3 autologous CAR-T cells that are delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device.
75330421|NCT00421863|Drug|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
75330422|NCT00421863|Drug|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
75330423|NCT00421863|Drug|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
75470206|NCT02851277|Drug|ASP0892 Intradermal|Intradermal injection
75637885|NCT05358561|Dietary Supplement|Flaxseed and Chia|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes
75637886|NCT04219683|Procedure|Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap|Using Free Fibula Flap for reconstruction of mandibular segemental defect
75637887|NCT04174677|Drug|Inebilizumab|Infusion of Inebilizumab
75637888|NCT04174677|Drug|VIB4920|Infusion of VIB4920
75637889|NCT04174677|Drug|Inebilzumab+VIB4920|Infusion of Inebilizumab and VIB4920
75637890|NCT00635895|Other|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
75637891|NCT05157633|Other|Controls|questionnaire food scale: HME data collection of food survey
75637892|NCT02751021|Other|pacemaker diagnostic algorithm|evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
75786843|NCT03840512|Drug|CBD|"CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin."
75923104|NCT03371186|Other|Balanced Post-Partum Contraceptive Counseling|Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care-antenatal care, labor and delivery, postnatal care, and infant care-are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
76079349|NCT02980120|Other|EDI-2|The Eating Disorder Inventory 2 (Paul & Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
76079350|NCT02980120|Other|SCID-II|The SCID-II interview (German, see Wittchen, Zaudig & Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
75637893|NCT02751021|Other|Attended cardiorespiratory sleep study|sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
75637894|NCT04488003|Drug|Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
75637895|NCT04488003|Drug|Physician's Choice|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
75786844|NCT03842462|Other|nCPAP|infants receive primary non-invasive respiratory support by mean of nCPAP
75786845|NCT03842462|Other|NIPPV|infants receive primary non-invasive respiratory support by mean of NIPPV
75786846|NCT03842462|Other|NHFOV|infants receive primary non-invasive respiratory support by mean of NHFOV
75637896|NCT02751099|Other|transplanted patients|bone biopsy, echocardiogram, blood samples
75637897|NCT02751177|Genetic|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|Mutation in plasma DNA vs tumor tissue
75786847|NCT04284410|Behavioral|CLASP-PE arm|Participants will complete 8-16 weekly or twice weekly individual therapy sessions (with total session number determined by clinical need, as is typical in clinical trials of PE for PTSD), 1 therapy session (session 3) with a supportive significant other (SO), consistent with the CLASP protocol, and 11 brief (30 minute) phone calls as possible, with calls occurring every week in between therapy sessions and on a less frequent basis following treatment termination up to 3 months after the final in-person therapy session. In addition, the supportive SOs will complete 11 brief (30 minute) phone calls with the therapist at the same frequency as participants. Participants will sign a release of information prior to involving the supportive significant other in treatment.
75786848|NCT03840590|Device|CSK AI system|CSK system is equipped with the endoscopic mainframe and alarms the examiners when suspect lesions appear.
75923105|NCT02302248|Behavioral|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
75923106|NCT02302248|Behavioral|Expressive writing intervention|3 week access to a web-based expressive writing platform.
75923107|NCT03366818|Device|thrombectomy|mechanical thrombectomy
75923108|NCT02302950|Drug|raltegravir|HIV therapy component
75637898|NCT02750787|Other|Nutritional Study Product|Two 220 ml servings per day
75637899|NCT02750631|Other|Triple Therapy|The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
75923109|NCT02293746|Device|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
75330424|NCT00421863|Drug|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
75330425|NCT00421863|Drug|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
75470207|NCT02851277|Drug|ASP0892 Intramuscular|Intramuscular injection
75637900|NCT05125731|Behavioral|Parental absence|Parent does not accompany the child during dental treatment
75637901|NCT05125731|Behavioral|Parental visual support|The parent does not accompany the child during the dental treatment but watches behind the glass and is seen by the child.
75637902|NCT05125731|Behavioral|Parental presence|Parent accompanies the child during dental treatment
75637903|NCT02695641|Drug|1.25mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
75330426|NCT00421863|Drug|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
75637904|NCT02695641|Drug|2.50mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
75637905|NCT02695407|Other|3 days cannulation|assessment of artery stenosis after 3 days of artery cannulation
75637906|NCT02695407|Other|5 days cannulation|assessment of artery stenosis after 5 days of artery cannulation
76079351|NCT02980120|Other|LoPF|In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke & Krischer, 2011).
75330427|NCT00421863|Drug|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
75637907|NCT02750553|Drug|SHR0534|
75786849|NCT03840590|Device|Standard Colonoscopy|This is the routine examination in nowadays clinical practice. Both the equipment and the procedure are as usual as clinical routine.
75786850|NCT05282420|Procedure|intravitreal injection of Ranibizumab|intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
75786851|NCT05282420|Procedure|intravitreal injection of Aflipercept|intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
75923110|NCT03366740|Other|GB mixed full strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
75923111|NCT03366740|Other|Full strength rice suji Alone|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
75330428|NCT00421863|Drug|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
75330429|NCT00421863|Drug|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
75330430|NCT02853292|Biological|urine collection|
75330431|NCT05241080|Other|Survey|It is a survey based on questionnaire
75330432|NCT05363956|Drug|salvadora|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
75330433|NCT05363956|Drug|Eucalyptus Oil|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
75470208|NCT02851277|Drug|Placebo Intradermal|Intradermal injection
75470209|NCT02851277|Drug|Placebo Intramuscular|Intramuscular injection
75470210|NCT02851147|Device|SL-D301|Slit Lamp
75470211|NCT02851147|Device|DC-4|Digital Camera Attachment
75470212|NCT02851147|Device|SL-3G|Slit Lamp
75470213|NCT02818738|Drug|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
75470214|NCT02818738|Other|Placebo|matching verum
75470215|NCT02782442|Behavioral|Structured Cognitive Training & PRIME|The treatment condition-- 30-35 hours of CT over 16 weeks (~2 hours per week) is a structured program of 20 hours of auditory processing exercises followed by 10 hours of social cognition exercises, combined with the personalized PRIME coaching application
75637908|NCT02750553|Drug|Placebo|
75786852|NCT05282420|Drug|Ranibizumab|Ranibizumab
75786853|NCT05282420|Drug|Aflibercept|Aflipercept
75786854|NCT01566968|Other|Cough challenge test|Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
75786855|NCT01566968|Other|24 hour ambulatory cough recording|Cough recording by using an ambulatory sound recording device.
75786856|NCT01566968|Other|Cough quality of life questionnaire|questionnaire designed to assess impact of cough on a person's life
75786857|NCT04241510|Device|Kinesio Taping|Kinesio Taping is a special taping method developed by Dr. Kenzo Kase in 1973. This technique triggers natural healing responses of human body by activating nervous and circulatory systems. The tapes are thin, latex-free, cotton, porous and anti-allergenic, with equal thickness of epidermis. It has elastic properites which allows the tape to elongate to %55-60 of its original lenght. Tape can be used up to 1 week even after sweating or cleaning with water. There are different application techniques for different purposes. Facilitation technique facilitates muscle contractions and supports muscle function. Mechancial correction technique is used for joint positioning and correcting motion of muscle-joint dynamics.
75786858|NCT01298960|Drug|Somatropin|0.1 IU/Kg/day from day one of stimulation until rHCG triggering
75786859|NCT01206686|Behavioral|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
75786860|NCT01206686|Behavioral|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
76079352|NCT02980120|Other|HAWIK-IV|The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann & Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
75637909|NCT02750475|Drug|Sunscreen Sport Lotion (BAY987516)|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)
75637910|NCT02750475|Other|Untreated Skin|This site is patched without treatment as irradiated control
75637911|NCT02750241|Behavioral|Active video game-based intervention|"Attend 12 weekly group session at the UTMB Breast Health Clinic to play the active video games using Wii Fit U or Xbox 360.~Participate in self-paced home sessions~Monitor daily, weekly, and monthly steps using Wii Fit Meter~Feedback on physical activity and physical function"
75637912|NCT02750241|Behavioral|Pedometer|"Attend 3 monthly UTMB Breast Cancer Support Group Sessions~Monitor daily, weekly, and monthly steps using a pedometer (Digi-walker CW-700/701)~Feedback on physical activity and physical function"
75923112|NCT03366740|Other|3/4th strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
75637913|NCT02749851|Device|MRI|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
75637914|NCT02749851|Device|MRI - IUGR|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
75923113|NCT03510780|Procedure|Periodontal surgery with Enamel Matrix Derivative|Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft
75637915|NCT04217265|Drug|Letrozole then misoprostol|total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
75470216|NCT02782442|Behavioral|Computer Games Control & PRIME|Computer games control condition which comes in the official PositScience wrapper. 30-35 hours of games over 16 weeks (~2 hours per week), combined with the personalized PRIME coaching application.
75330434|NCT00636818|Drug|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
75637916|NCT04217265|Drug|placebo then misoprostol|placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
75637917|NCT00635973|Drug|Gefitinib (Iressa)|Iressa
75786861|NCT01206686|Behavioral|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
75786862|NCT00304031|Drug|Concurrent temozolomide|Daily oral temozolomide (75 mg/m2) up to 49 doses.
75330435|NCT05363722|Drug|IBI310（0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W
75470217|NCT02742090|Drug|TGR-1202|
75330436|NCT05363722|Drug|IBI310（0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W
75330437|NCT05363722|Drug|sintilimab|sintilimab 200 mg IV d1 Q3W
75786863|NCT00304031|Radiation|Concurrent radiation therapy|60 Gy in 2 Gy fractions
75786864|NCT00304031|Drug|100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
75330438|NCT05363722|Drug|bevacizumab|bevacizumab 15 mg/kg IV d1，Q3W
75330439|NCT05363566|Device|airway divice|inserted airway device
75470218|NCT02723747|Other|myocardial perfusion with magnetic resonance imaging|
75470219|NCT02710682|Procedure|Mini-open surgery|"This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.~Skin disinfection; Local anesthesia (lidocaine 1%).~Skin incision, slightly anterior to lateral epicondyle.~Exposure of the plane between the tendon and fascia.~Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.~Excision of diseased tissue of the ECRB tendon.~ECRL tendon is sutured back to the fascia. The skin is closed.~Patient is monitored for 30 minutes after procedure."
75470220|NCT02710682|Device|Ultrasound-guided Tendon fenestration|"This treatment will be administered by a fellowship-trained MSK radiologist.~Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.~Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.~Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.~Patient monitored for 30 minutes, before being discharged."
75470221|NCT02432898|Device|3D OCT-1|Spectral Domain OCT Device
75923114|NCT03510780|Procedure|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
76079353|NCT02980120|Device|fMRI|To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
76079354|NCT03466008|Behavioral|Whole-Body Cryotherapy|10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
76079355|NCT05324280|Procedure|Acupuncture|Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture.
76079356|NCT02522052|Other|Blue mussel diet|5 meals a week containing blue mussels
76079357|NCT02522052|Other|Meat/Control diet|5 meals a week containing meat
76079358|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed QD
76079359|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed BID
76079360|NCT01190878|Drug|DuraSite Vehicle|Vehicle dosed BID
75637918|NCT02749929|Other|Low level laser therapy|The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser
75637919|NCT02749929|Other|Placebo Low Level Laser Therapy|The placebo laser is an identical device to the active laser, made by Irradia Midlaser
75637920|NCT02752971|Drug|Bupivacaine|
75786865|NCT00304031|Drug|75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle|Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
75923115|NCT03363620|Device|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
75923116|NCT03363620|Device|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
75923117|NCT02293824|Drug|Caffeine|Given per standard of care.
76079361|NCT01190878|Drug|Xibrom™|0.09% bromfenac dosed BID
76079362|NCT03465930|Procedure|Supermicrosurgical lymphatico-venous anastomoses|Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
75637921|NCT02752971|Drug|Sodium diclofenac|
75637922|NCT02750007|Drug|HS-20004|
75637923|NCT02750163|Drug|paracetamol|Paracetamol will be given to febrile septic patients
75637924|NCT04217421|Drug|Allopurinol|Allopurinol powder for solution for infusion (PFI) 20 mg/kg body weight per administration will be administered early postnatally (within 45 minutes and 12 hours after the first dose), preoperatively (12 hours before surgery), intraoperatively (during surgery) and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Allopurinol PFI will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
75786866|NCT01567046|Other|laboratory biomarker analysis|Correlative studies
75786867|NCT01206842|Other|Training in Affect Recognition|A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
75786868|NCT01201616|Other|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
75786869|NCT01201616|Other|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
75923118|NCT03366662|Device|Monitoring of frontal electrical muscle activity|Continuous monitoring of frontal electrical muscle activity during general anesthesia simultaneous to burst suppression electroencephalogram
75923119|NCT03510702|Diagnostic Test|Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.|"Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers."
76079363|NCT01146496|Device|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
76079364|NCT03461094|Device|Preload assessment and volume expansion|Fluid therapy perform
76079365|NCT01146808|Drug|Adefovir dipivoxil and hepatitis B vaccination|Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
76079366|NCT02522130|Drug|Lidocaine|intracervical injection
76079367|NCT02522130|Drug|oral misoprostol|oral treatment
76079368|NCT02522130|Drug|naproxen|oral treatment
76079369|NCT02522130|Other|placebo|oral treatment
76079370|NCT03461016|Behavioral|Exposure Therapy|"Exposure therapy is a form of behavior therapy that is widely used to treat anxiety disorders, including specific phobia. It involves systematic and repeated confrontation with a feared stimulus. It works by (a) implosive therapy, habituation, in which repeated exposure reduces anxiety over time by a process of extinction; (b) disconfirming fearful predictions; and (c) increasing feelings of self-efficacy and mastery. In vivo exposure [is] a type of exposure therapy, generally used for treating individuals with phobias, obsessive compulsive disorder, and other anxiety disorders, in which the client directly experiences anxiety-provoking situations or stimuli in real-world conditions. (VandenBos, 2015)"
76079371|NCT01148524|Biological|No Vaccine|
76079372|NCT01148524|Biological|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
75330440|NCT03127995|Radiation|HYPOFRACTIONATED|40 Gy/ 15 fractions / 3 weeks
75637925|NCT04217421|Drug|Mannitol|Mannitol powder for solution (PFI) placebo will be administered early postnatally (within 45 minutes and 12 hours after birth), preoperatively (12 hours before surgery), intraoperatively (during surgery), and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Mannitol PFI-placebo will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
75637926|NCT02749695|Drug|Melsmon|Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
75637927|NCT02749695|Other|Placebo|2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
75786870|NCT01567124|Drug|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
75786871|NCT01567124|Drug|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
75786872|NCT01567124|Drug|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
75330441|NCT03127995|Radiation|NORMOFRACTIONATED|50 Gy/ 25 fractions / 5 weeks
75330442|NCT01922492|Procedure|Autologous islet transplantation|"Islet was isolated from the normal part of resected pancreas with modified Ricordi method.~After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization."
75330443|NCT01922492|Drug|Oral anti-diabetic drugs|"Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose."
75330444|NCT03127137|Drug|Experimental Group 1 triamcinolone and lidocaine|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
75330445|NCT03127137|Drug|Experimental Group 2 triamcinolone and saline|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
75330446|NCT05356780|Device|Aligner|A method of straightening teeth without fixed braces
75330447|NCT03122847|Drug|Methylprednisolone|Intravenous methylprednisolone
75330448|NCT05355142|Behavioral|PM+|"1 Brief introduction to PM+ & NDA (5 min) Assessment-based review with PSYCHOLOPS (psychopomps psychology ) assessment (10 min) What is PM+ (20 minutes) Understanding Adversity (30 minutes) Stress Management (20 minutes) Closing the meeting (5 minutes)~2 General Review (5 min) Issue management (70 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~3 General Review (5 minutes) Problem Management (35 minutes) Take action and be consistent (35 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~4 General Review (5 minutes) Issue Management (20 minutes) Take action and be persistent (20 minutes) Strengthening Social Support (30 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~5 General Review (20 minutes) Staying Healthy (30 minutes) Imagining how to help someone (20 minutes) Looking ahead (15 minutes) Closing the de-briefing (5 minutes)"
75330449|NCT00636506|Device|AMS 700 IPP with MS Pump|AMS 700 Series Inflatable Penile Prosthesis with MS Pump
75330450|NCT04745091|Procedure|total mesorectal excision|excision of the rectum with complete excision of the mesorectum
75330451|NCT04342221|Drug|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
75786873|NCT01567124|Drug|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
75330452|NCT04342221|Drug|Placebo|Placebo capsules
75786874|NCT01299194|Drug|ATORVASTATIN|80mg once daily for 3 months
75637928|NCT04217187|Device|Neuromuscular Electrical Stimulation|Upper extremity neuromuscular electrical stimulation
75637929|NCT04217187|Device|Sham Electrical Stimulation|Sensory only upper extremity electrical stimulation
75637930|NCT02749773|Device|Oocyte Aspiration needle|Oocyte aspiration in women go through an IVF procedure,.
75637931|NCT04219137|Genetic|Molecular Profiling|This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.
75637932|NCT02749539|Device|Kinesio tape|Standard 2 -inches ( 5-m) Kinesio TexR tape was used for application in the experimental group
75637933|NCT02749539|Procedure|physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
75786875|NCT03827408|Drug|Midazolam group (MDZ)|IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland
75786876|NCT03827408|Drug|Dexmedetomidine group (DEX)|IV Ampules of Precedex 4mcg/ml, Hospira. Inc., Lake Forest,IL USA.
75786877|NCT03827408|Drug|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Combination of Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.(
75786878|NCT03556904|Radiation|Ablative Radiation Therapy|Radiotherapy will typically be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions.
75786879|NCT03556904|Drug|Hormone therapy or chemotherapy|Current standard of care dosing with standard agents; hormone therapy or chemotherapy.
76079373|NCT03460938|Procedure|Remote ischemic preconditioning|RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
75786880|NCT00332189|Drug|sapropterin dihydrochloride|5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
75786881|NCT01206998|Drug|Vaginal progesterone gel|Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
75786882|NCT01206998|Drug|Placebo vaginal gel|Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
75923120|NCT03363542|Dietary Supplement|fruits, vegetables and/or whole grain high fiber rich diet|Dietary education to Increase fruits, vegetables and/or high fiber intake
76079374|NCT03460860|Dietary Supplement|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|The intervention is to be taken once daily, for 12 weeks.
75923121|NCT04464330|Other|no intervention|This is an observation study, with no intervention
75330453|NCT03632889|Behavioral|GoToSleep Program|For the control group only the sleep hygiene handout will be given in this arm. For the computerized group a sleep hygiene handout along with assess to the GoToSleep online program.
75637934|NCT04219371|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
75923122|NCT03370796|Other|Reminiscence Therapy Program|The Reminiscence Therapy program is composed of: (i) main strand lasting 7 weeks, with sessions twice a week (total of 14 sessions); (ii) maintenance strand, which runs for 7 weeks, once a week (total of 7 sessions). The duration for each session will be 60 minutes.
75923123|NCT03510624|Drug|Rebaudioside A|Rebaudioside A 3g
76079375|NCT03460860|Dietary Supplement|Placebo|The intervention is to be taken once daily, for 12 weeks.
76079376|NCT01191736|Behavioral|No training, assessed within 60 mins|Subjects receive no training in resuscitation
76079377|NCT01191736|Behavioral|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
75330454|NCT03525028|Drug|Metformin|The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.
75637935|NCT04217031|Other|No intervention|No intervention
75637936|NCT02749461|Procedure|heel stick|Consecutive routine blood sampling heel sticks
75637937|NCT04583241|Other|Constitution of serum bank at D0|Blood samples at Day 0 (day of surgery)
75637938|NCT04583241|Other|Constitution of serum bank during follow-up|Blood samples are obtained at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years.
76079378|NCT01191736|Behavioral|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
76079379|NCT01191736|Behavioral|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
76079380|NCT01191736|Behavioral|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
75330455|NCT03525028|Drug|Placebo|The investigators use placebo in the control group.
75330456|NCT00636194|Device|Bausch & Lomb Multipurpose Solution|daily care of contact lenses
75637939|NCT04583241|Other|ELISA assays of serum markers of bone remodeling at D0|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at Day 0 (day of surgery)
75637940|NCT04583241|Other|ELISA assays of serum markers of bone remodeling during follow-up|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years
75637941|NCT04583241|Other|Analysis of bacterial gene expression at D0|Assessement of bacterial gene expression on surgery residual tissue (bone tissue, joint fluid, fragment of prostheses) collected at Day 0 (day of the surgery)
75786883|NCT00331799|Drug|Duloxetine|Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
75786884|NCT01207076|Biological|90Y-AHN-12|"The intervention consists of two parts.~The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~Dose escalation of nonradiolabeled AHN-12:~Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy."
75923124|NCT03510624|Drug|Placebo|Empty capsules
75923125|NCT03366584|Dietary Supplement|Beta carotene|Beta carotene 25,000 IU
75923126|NCT03366584|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 IU
75923127|NCT03366584|Dietary Supplement|Zinc|Zinc 50 mg
75923128|NCT03366584|Drug|Dexamethasone|Dexamethasone 6 mg
75923129|NCT03507972|Radiation|ankle ultrasound|Ankle ultrasound performed during emergencies visit.
75923130|NCT03507972|Radiation|Member MRI|Member MRI (without injection of contrast product) performed within 7 days following the trauma
76079381|NCT01191736|Behavioral|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
76079382|NCT01191736|Behavioral|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
76079383|NCT03460782|Biological|Ipilimumab|"Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).~Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.~This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor."
75637942|NCT00636129|Behavioral|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
75923131|NCT03366506|Other|Observation|
75923132|NCT02293278|Behavioral|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
75923133|NCT03363386|Procedure|Proprioceptive Exercises|Patients trained for proprioceptive exercises
75923134|NCT03363386|Procedure|Resistive Exercises|Patients trained for resistive exercises
75923135|NCT03363386|Procedure|Aerobic Exercise|Patients were educated with treadmill walking for 30 minutes of each exercise session
75637943|NCT04572789|Dietary Supplement|Omega-3 polyunsaturated fatty acids|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA, 1.8 g/day) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
75923136|NCT03518346|Behavioral|Virtual Reality|Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
75923137|NCT03518346|Behavioral|Standard of Care|Books, movies, TV
75923138|NCT03363308|Behavioral|training for health care workers supplmented by QI teams|Jhpiego will deliver maternal and newborn health and family planning (MNH+FP) training using evidence-based low-dose, high-frequency (LDHF) learning approaches and support hospital staff-led quality improvement efforts to increase the coverage of facility-based high-impact interventions, including care of the mother and newborn on the day of birth and through the first week postpartum and post abortion services.
75637944|NCT04572789|Dietary Supplement|omega-6 PUFAs|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
75637945|NCT02749383|Drug|PAC-14028 cream 0.3%|Topical application
75923139|NCT03518268|Drug|Vivomixx|The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
75923140|NCT03518268|Drug|Placebo|The intervention consists of 2 sachets a day of placebo, for 6 months
75923141|NCT03366350|Procedure|Allogeneic hematological stem cell transplantation|Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
75923142|NCT03363230|Behavioral|Mindfulness skills training|Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
75330457|NCT00636194|Device|Alcon OptiFree Replenish Multipurpose Solution|daily care for contact lenses
75330458|NCT03631797|Procedure|Microvascular reactivity evaluation|Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
75330459|NCT00754312|Drug|SNDX-275|
75637946|NCT02749383|Drug|PAC-14028 cream 1.0%|Topical application
75637947|NCT02749383|Drug|PAC-14028 cream vehicle|Topical application
75637948|NCT02748993|Drug|PAC-14028 Cream 0.1%|Topical application
75637949|NCT02748993|Drug|PAC-14028 Cream 0.3%|Topical application
75637950|NCT02748993|Drug|PAC-14028 Cream 1.0%|Topical application
75637951|NCT02748993|Drug|PAC-14028 Cream Vehicle|Topical application
75637952|NCT04036929|Drug|Estrogen-bazedoxifene|Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
75637953|NCT04036929|Drug|Placebo oral tablet|Placebo oral tablet
75786885|NCT01299350|Other|Nt-proBNP guided discharge|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
75786886|NCT03826940|Drug|Lovastatin 60 MG|60 MG Lovastatin per day for 3 consecutive days
75786887|NCT03826940|Drug|Placebos|60 MG Placebo per day for 3 consecutive days
75786888|NCT04177238|Dietary Supplement|Fruit concentrate - either cherry or blueberry|Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).
75786889|NCT01201694|Drug|Surface-Controlled Water Soluble Curcumin|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
75786890|NCT01201694|Drug|Surface-Controlled Water Soluble Curcumin MTD|Dose will be maximum tolerated dose (MTD) from Arm 1.
75923143|NCT03363230|Behavioral|Interpersonal Effectiveness skills training|Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
75923144|NCT02519114|Procedure|Donor Bone Marrow stem cell transplantation|KIR-mismatched haploidentical Bone Marrow stem cell transplantation
75923145|NCT03370562|Drug|Dexmedetomidine|Administration of 10 mcg intravenous dexmedetomidine
75923146|NCT03370562|Drug|Placebo|Administration of normal saline
75923147|NCT03370484|Dietary Supplement|Control|Water with 80 mg sucralose
75923148|NCT03370484|Dietary Supplement|Milk mineral supplement|Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
75637954|NCT04219293|Device|Microneedling w/ and w/o PRP|i. Split face comparison. Vertical line drawn midline nose extending upwards to hairline and downwards to jawline separating face into two equal treatment areas. The patients determined side of face will be treated with SkinPen Microneedling and PRP the other (nondetermined from randomization) will be treated with SkinPen Microneedling and glide. The patient side of face that will not use PRP will be treated first. The following settings will be used as treatment protocol. Topical anesthetic Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% will be applied covering entire treatment area. The anesthetic will remain on skin for 30 minutes.
75786891|NCT01201928|Drug|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
75786892|NCT01201928|Drug|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
75923149|NCT03507738|Biological|MT-5625 low dose|Intramuscular injection
75637955|NCT04281147|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow clinical administration
75637956|NCT02749071|Procedure|Laparoscopic implantation surgery|Laparoscopic surgery to implant the pulse generator and bipolar lead.
75637957|NCT02749071|Device|EndoStim stimulation for first six months of study|Lower esophageal stimulation
75637958|NCT02749071|Device|EndoStim stimulation from Month 6 thru end of study|Lower esophageal stimulation
75637959|NCT02749071|Device|Sham EndoStim stimulation for first six months of study|"EndoStim device remains off (no stimulation delivered)"
75637960|NCT02748915|Other|Electrophysiological and psychoacoustic tests|
75637961|NCT04218981|Drug|Antipsychotic drugs|Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group
75637962|NCT04218981|Drug|Mood stabilizer|Choose lithium or valproate for bipolar disorder group
75637963|NCT04218981|Drug|Paroxetine|Patients with major depressive disorder are treated with paroxetine
75637964|NCT04218513|Drug|Compound Edaravone Injection|30 min intravenous infusion
75923150|NCT03507738|Biological|MT-5625 middle dose|Intramuscular injection
75923151|NCT03507738|Biological|MT-5625 high dose|Intramuscular injection
75923152|NCT03507738|Biological|Rotarix|Oral administration
75330460|NCT04736368|Other|EDIP Diet Suggestions|CD participants will receive EDIP diet suggestions after random allocation.
75330461|NCT04736368|Other|diet guidance|Control group will be given diet guidance according to routine experience under the participant's request.
75330462|NCT03623373|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
75330463|NCT03623373|Drug|Rituximab|In Cycle 1, rituximab will be administered at a dose of 375 mg/m^2 IV on Day 1 or 2 at the investigator's discretion in order to reduce the risk of a first infusion reaction. Rituximab will be given on Day 1 of Cycles 1 through 6.
75470222|NCT02432898|Device|3D OCT-2000|Spectral Domain OCT Device
75637965|NCT04218513|Drug|Edaravone Injection|30 min intravenous infusion
75637966|NCT04218513|Drug|2-Aminoethanesulfonic Acid Injection|30 min intravenous infusion
75637967|NCT02748759|Device|CPM|15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)
75637968|NCT02748759|Other|Manual mobilization|Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
75637969|NCT04218435|Drug|Sacubitril / Valsartan Oral Tablet|"Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB."
75637970|NCT02748837|Drug|ERY974|
75637971|NCT02695485|Procedure|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
75637972|NCT02748681|Device|Auto CPAP AirSense™ 10(Resmed)|AutoSet CPAP without telemedicine monitoring
75637973|NCT04158765|Other|DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).|DNA will be extracted from sperm using the DNeasy Tissue Kit and Telomerase activity in samples will be measured using a PCR- based assay.
75923153|NCT03507738|Biological|Placebo|Intramuscular injection
75637974|NCT04218669|Procedure|Roux-en-Y Hepaticojejunostomy|The common hepatic duct was cut and the duodenal side is closed by suture. The small intestine was cut off 15 cm below the ligament of Treitz. The distal end was lifted, and a 1-2 cm incision was made at the jejunal wall 4-5 cm from the jejunal stump. The anastomosis is used a 5-0 PSD Ⅱ suture, with double needles, inside-out in the jejunum and outside-in in the hepatic duct. One side of needles was used to continuely penetrate and suture the whole layer of the posterior-lateral wall of the jejunum, the posterior-lateral wall of the biliary duct, and the other side of needles was used to continuely stuere the anterior part of the anastomosis. Mucosa-to-mucosa contact should be ensured with every stitch.The anastomotic stomas were then checked for leakage. Enteric-enteric anastomosis was performed 60 cm below the site of the hepatojejunal anastomosis.
75637975|NCT04218669|Procedure|T-tube drainage|The T-tube was placed for biliary drainage and the common bile duct was intermittently sutured with 4-0 vicryl sutures.
75637976|NCT04452045|Device|SweetDreams|SweetDreams is a mHealth adaptation of existing evidence-based sleep interventions. It is a user friendly and developmentally appropriate modularized 4-week web-based intervention available on computer, tablet or mobile phones.
75786893|NCT01299428|Device|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
75923154|NCT04524806|Other|stabilization splint|Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles
75923155|NCT03507660|Other|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
75330464|NCT03623373|Drug|Acalabrutinib|The capsules should be swallowed intact with water and with or without food.
75637977|NCT04138875|Drug|Rituximab|Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a >10% change in weight dosing will be readjusted.
75637978|NCT04138875|Drug|Brentuximab Vedotin|Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
75637979|NCT04138875|Drug|Bendamustine|Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
75637980|NCT04124445|Procedure|Pulsed Radiofrequency Ablation|"Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain."
75637981|NCT04218747|Behavioral|VA 365 Demonstration Benefits|Reducing hunger 365 days a year in households with school children by transforming schools into food hubs ( free breakfast, lunch, supper, and food backpacks for the weekend) and providing nutrition education to parents.
75786894|NCT01203176|Procedure|Hysteroscopic polypectomy|Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
75786895|NCT00303719|Biological|anti-thymocyte globulin|"ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG."
75330465|NCT03623373|Drug|Cytarabine|On Days 1 and 2 of Cycles 4-6, following rituximab dosing, cytarabine will be administered IV every 12 hours for a total of 4 doses.
75330466|NCT03623373|Procedure|Leukapheresis|Until collection of ≥ 2 x 106 CD34+ stem cells / kg
75330467|NCT03623373|Procedure|Peripheral blood|-Baseline, end of Cycle 3, 4-6 weeks after Cycle 6 Day 1, and if the patient discontinues protocol therapy prior to completion of Cycle 6
75330468|NCT03623373|Procedure|Oral rinse|-Baseline
75330469|NCT03623373|Procedure|Bone marrow collection|-Bone marrow will be collected at baseline if the patient requires a marrow for staging purposes and at end of treatment if the patient requires a marrow for restaging.
75330470|NCT04744779|Behavioral|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
75923156|NCT03370328|Other|Peppermint oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
76079384|NCT01192282|Procedure|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
75330471|NCT03622359|Diagnostic Test|SPECT/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
75330472|NCT03622359|Diagnostic Test|PET/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
75637982|NCT02748447|Device|Automated FiO2 adjustment|AVEA ventilator according to SpO2 target range delivers an automated FiO2
75637983|NCT02748135|Drug|TB-403 20mg/kg|bi-weekly intravenous doses of TB-403 20mg/kg
75786896|NCT00303719|Drug|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
76079385|NCT04607382|Drug|LEP|LEP dosage up to the discretion of the treating gynecologists.
76079386|NCT04607382|Drug|NSAIDs and/or Chinese medicine (CM)|Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
76079387|NCT01192828|Drug|taurine|Take Taurine for 4 1/2 days, two doses per day
75330473|NCT04736524|Other|Rapid antibody test|Serial serology tests on day 21, 90, 180 and 365 following the first dose of the COVID-19 vaccine to detect the temporal trend of the IgM and IgG production in response to the vaccination.
75470223|NCT02432898|Device|DRI OCT-1|Swept Source OCT Device
75637984|NCT02748135|Drug|TB-403 50mg/kg|bi-weekly intravenous doses of TB-403 50mg/kg
75637985|NCT02748135|Drug|TB-403 100mg/kg|bi-weekly intravenous doses of TB-403 100mg/kg
75637986|NCT02748135|Drug|TB-403 175mg/kg|bi-weekly intravenous doses of TB-403 175mg/kg
75637987|NCT02747979|Other|hemodialysis only|hemodialysis treatment only
75637988|NCT02747979|Other|hemodialysis plus hemoperfusion(HA330)|combination of hemodialysis and hemoperfusion (HA330) treatment
75637989|NCT02747979|Other|hemodialysis plus hemoperfusion(HA130)|combination of hemodialysis and hemoperfusion (HA130) treatment
75637990|NCT02695563|Drug|Lactoferrin|
75637991|NCT04218045|Procedure|Laparoscopic single anastomosis sleeve ileal bypass|a simple loop gastro-ileal bypass is added to the sleeve procedure.
75637992|NCT04218045|Procedure|Laparoscopic sleeve gastrectomy|Conventional sleeve gastrectomy using endoscopic stapler
75637993|NCT03838965|Device|biobeat sensor|biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
75923157|NCT03370328|Other|Ginger oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
75923158|NCT03507582|Other|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
75923159|NCT03507582|Other|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
75330474|NCT03097107|Drug|Saroglitazar Magnesium 1 mg|Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
75637994|NCT02747901|Other|KINESIOTAPING|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
75470224|NCT02432898|Device|NW-300|Fundus Camera
75637995|NCT02747901|Other|COLD THERAPY|Cold therapy group received cold packs immediately after operation and following postoperative days
75637996|NCT02747823|Biological|CBT124|1 mg/kg IV infusion
75786897|NCT00303719|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of >200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
75923160|NCT02303106|Drug|Lamotrigine|
75923161|NCT04525664|Drug|Clarithromycin 500mg|500 mg per os twice daily for 14 consecutive days.
75330475|NCT03097107|Drug|Saroglitazar Magnesium 2 mg|Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
75330476|NCT03097107|Drug|Saroglitazar Magnesium 4 mg|Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
75330477|NCT03097107|Drug|Placebo|Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
75330478|NCT00362661|Drug|Cortisol|Cortisol 10 mg/d for 3 months
75637997|NCT02747823|Biological|EU Sourced Avastin®|1 mg/kg IV infusion
75637998|NCT02747823|Biological|US Sourced Avastin®|1 mg/kg IV infusion
75637999|NCT02747745|Behavioral|Four risk areas reflecting the great needs of FCGs of PWDs|The intervention involves home visits & phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
75638000|NCT04217889|Other|Questionnaire|Short questionnaire that can be completed during the usual consultation.
75638001|NCT02747511|Drug|Haloperidol|
75638002|NCT02747511|Drug|Placebo|
75638003|NCT04217733|Drug|pentoxyifylline|Pentoxyifylline two times daily for 3 months
75638004|NCT04217733|Drug|Mebeverine|Mebeverine 3 times for 3 months
75638005|NCT04217733|Drug|ethosuximide|ethosuximide 3 times for 3 months
75786898|NCT00303719|Drug|fludarabine|Fludarabine 30 mg/m^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m^2 for 5 days.
75786899|NCT00303719|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if < 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) > 0.5 x 109 /L).
75786900|NCT00303719|Procedure|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
75330479|NCT04767646|Procedure|Intensive rehabilitation program with CPNB|"The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB.~The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program"
75330480|NCT03621345|Procedure|Erector spinae plane block|Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.
75330481|NCT03621345|Other|sham block|A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
75330482|NCT05232136|Biological|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
75786901|NCT00303719|Radiation|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
75330483|NCT03410446|Drug|Ketamine Hydrochloride|Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
75330484|NCT00375388|Drug|Metformin on top of intensive insulin therapy|
75470225|NCT02432898|Device|CT-1P|Tonometry
75470226|NCT02432898|Device|TRK-2P|Tonometry, Corneal Topography
75330485|NCT00375778|Drug|memantine (drug)|
75923162|NCT04525664|Drug|Amoxicillin 1000 MG|1000 mg per os twice daily for 14 consecutive days.
76079388|NCT01099618|Drug|metformin|The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
75330486|NCT04663594|Other|WofB|Online experience designed to reduce anxiety and depression and support mental health and wellbeing
75330487|NCT04663594|Other|Ashmolean Website|A generic museum website owned by the Ashmolean Museum of Art and Archaeology at the University of Oxford.
75330488|NCT05222386|Other|Parkinson Disease Standard Care|Under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. After one year of baseline data collection, eight practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. Per the stepped-wedge design an additional eight practices will be randomized 18 months into the data collection period, and the final eight will enter the intervention 24 months into the data collection period to allow for 12 months intervention recruitment for all practices.
75470227|NCT02432898|Device|SP-1P|Specular Microscopy
75470228|NCT02432898|Device|SL-D701|Slit Lamp Imaging
75638006|NCT04216875|Procedure|Best Practice Diabetes Management in Primary Care|Practice adherence to best practice guidelines treating diabetes patients in different primary care practices is shown in this before- and after observational study
75638007|NCT03363087|Device|Mapping and ablation|Ultra high density scar mapping Collection of impedance data during ablation
75470229|NCT02432898|Device|MC-4S|Visual Acuity Testing
75470230|NCT02427256|Device|Topcon Specular Microscope SP-1P|
75470231|NCT02427256|Device|Konan Specular Microscope CELLCHEK XL|
75470232|NCT02426671|Device|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
75470233|NCT02377089|Device|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
75470234|NCT02377089|Device|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
75638008|NCT03363087|Device|Mapping|Omnipolar mapping of left atrial scar and pulmonary vein isolation lines
75638009|NCT03889353|Device|BCI sessions|up to 3 test sessions (D-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (D1-D5 and D8-D12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
75638010|NCT04171869|Other|no intervention|observational study, no intervention
75638011|NCT03961737|Procedure|prostate biopsies|"Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment.~Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients."
75638012|NCT02747199|Device|SYNERGY stent|
75638013|NCT02747199|Device|BVS ABSORB scaffold|
75638014|NCT02746887|Other|Preterm/term cohort|
75638015|NCT02414607|Biological|Elderberry Juice|
75786902|NCT00303719|Drug|filgrastim|Patients with white blood cell (WBC) counts < 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) > 2500 for 2 consecutive days.
75786903|NCT01207232|Behavioral|Planning Prompt|A prompt to write down a planned date (or date and time) for getting a flu shot
75786904|NCT01207232|Behavioral|Control Condition|A basic reminder mailing prompted each subject to get their flu shot.
75786905|NCT01207310|Behavioral|smoking cessation counseling|two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
75786906|NCT01207310|Drug|Nicotine patch|8 weeks' worth of nicotine patches
75786907|NCT01207310|Device|alphanumeric pager|therapeutic messages to be delivered for three months
75786908|NCT00331409|Drug|Everolimus|2.5 mg by mouth daily
75786909|NCT00331409|Drug|imatinib mesylate|600 mg by mouth daily
76079389|NCT01099618|Drug|placebo|The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
75638016|NCT02414607|Other|Placebo|
75786910|NCT03820778|Diagnostic Test|Whole Body MRI|WBMRI with axial and coronal STIR (short inversion time inversion recovery) images + DWI (diffuse weighted imaging) will be performed and compared to regional MRI to assess value of this diagnostic test for the identification of suspicious looking lesions (i.e. diffuse nodular lesions or atypical plexiform neurofibroma)
75786911|NCT01203254|Drug|Colesevelam|Colesevelam 625 mg tablet; 3 times daily 2 tablets
75786912|NCT01203254|Drug|Placebo|Placebo tablet: 3 times daily 2 tablets
75786913|NCT01064843|Device|Imtec MDI|4 Imtec MDI
75923163|NCT04525664|Drug|Omeprazole 40 MG|40 mg per os twice daily for 14 consecutive days.
75923164|NCT04525664|Drug|Omeprazole 20 MG Oral Tablet|20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
75923165|NCT03510546|Drug|Pyridostigmine|Study dose as per protocol.
75923166|NCT03510546|Drug|Placebo oral capsule|Study dose as per protocol.
75923167|NCT03505008|Drug|Methotrexate|Route of Administration: Oral
75923168|NCT03505008|Drug|Adalimumab|Route of Administration: Subcutaneous
75786914|NCT03826394|Behavioral|Exercise Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be exercise specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
75638017|NCT02746731|Other|Cardiorespiratory and resistance training.|"A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.~Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training."
75786915|NCT03826394|Behavioral|Dietary Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be diet specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
75786916|NCT01064921|Drug|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
75786917|NCT01064921|Drug|cisplatin|Given IV
75786918|NCT01064921|Radiation|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
75786919|NCT01064921|Procedure|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
75786920|NCT05623826|Other|Cognitive- behavioral imagery-based training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
75786921|NCT01299662|Drug|Poly ICLC|One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
76079390|NCT01099618|Drug|Sitagliptin|The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
75330489|NCT05222386|Other|Online Community-Supported Palliative Care|"Neurologist Teleconferences: Training and coaching in palliative care will be provided using the Extension for Community Healthcare Outcomes (ECHO) model augmented by a Community of Inquiry Framework to address a desire for greater peer connection, enhance self-efficacy, and to address potential weaknesses in the ECHO model for more complex interventions such as palliative care.~Additional support services provided to carepartners and patients will be through the Family Caregiver Alliance's CareNav platform, including tailored educational materials, support groups and social support."
75330490|NCT00994123|Drug|MM-121|MM-121 (SAR256212) = intravenous solution
75638018|NCT02746731|Other|Reference|No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
75638019|NCT04403139|Drug|Shingrix|All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
75638020|NCT02746653|Device|TroClose1200(TM)|Creation of access port and closure it by the same device, TroClose1200(TM)
75638021|NCT02746497|Procedure|Acupuncture|"Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally."
75638022|NCT02746419|Device|Vessix|Renal denervation using radio-ablation
75786922|NCT00303485|Drug|Placebo|po monthly for 6 months
75786923|NCT00303485|Drug|Vitamin D and calcium supplementation|As prescribed
76079391|NCT01099774|Drug|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
75330491|NCT00994123|Drug|Erlotinib|erlotinib = daily oral tablet
75470235|NCT02376868|Device|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
75470236|NCT02376868|Device|iVue|OCT machines used for diagnostic purposes
75638023|NCT00636285|Drug|Placebo|Placebo
75638024|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
75638025|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
75638026|NCT02746185|Drug|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
75638027|NCT02746185|Drug|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
75638028|NCT04216485|Behavioral|Intensive Lifestyle Intervention|Dietary intervention combined with healthy lifestyle counseling
75786924|NCT00303485|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
75786925|NCT01299740|Behavioral|Participation in DBT Skills Group|Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
75786926|NCT01299740|Other|Control Group|Treatment as usual
76079392|NCT01099774|Drug|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
76079393|NCT03013192|Other|Text message reminder|Patients will receive automated text message reminders regarding their physical therapy
76079394|NCT01328574|Drug|TRC105|15 mg/kg intravenously
75923169|NCT03363074|Device|Orthotic Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole,and 3mm,15 Shore A hardness ethyl vinyl acetate was used for covering.Orthotic insoles have been emplemented in a pair of sports shoes.
75923170|NCT03363074|Device|Low-Level Laser|A low density laser with a power density of 0.05-0.10 (w / cm2), a therapeutic dose of 0.7-7 (j / cm 2) of gallium-arsenic 904 nm will be applied. It will be 3 administered times a week for 5 weeks. Laser treatment will be applied along the tibialis posterior tendon. 3 different point (proximal tibial tendon, distally tibial tendon and posterior medial malleol) applications will be done.
75923171|NCT03362996|Dietary Supplement|Freshly-Pressed Extra Virgin Olive Oil|Dietary Supplement: Freshly-pressed extra virgin olive oil Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
75638029|NCT04216485|Behavioral|Standard Care|Standard prenatal care on diet, nutrition and physical activity
76079395|NCT03460626|Drug|Lavender Oil|The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.
76079396|NCT03460626|Other|Placebo|an odorless oil without any therapeutic effect
75330492|NCT03001726|Procedure|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
75638030|NCT05630391|Device|High-Fidelity Simulation Manikin|A high-fidelity simulator was developed to teach skills in nursing education, and it is sized to represent an adult male patient. The mannequin can be controlled using a computer program, it can breathe, and its vital signs can be monitored using a bedside monitor.
75638031|NCT05630391|Other|Education|Training for 26 nursing students who constituted the control group performed personnel protective equipment (PPE) wearing-removal practice
75638032|NCT05630157|Behavioral|Unplugged plus gambling component|12 units/lessons of the Unplugged prevention curriculum plus a gambling component including specific gambling contents in units 3-4-5-7-9 and a 13th unit based on probability and mathematical concepts taught through an online simulator
75638033|NCT02745951|Other|Heliox|Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.
75638034|NCT02745951|Other|Standard of care|The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
75638035|NCT02742051|Drug|Everolimus|Neoadjuvant endocrine therapy
75638036|NCT02742051|Drug|Letrozole|Neoadjuvant endocrine therapy
75923172|NCT03362996|Combination Product|extra virgin olive oil|Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
75923173|NCT03362996|Other|mediterranean diet|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
75923174|NCT03507504|Other|SCU-B|"SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home."
75330493|NCT03001726|Drug|oxaliplatin|oxaliplatin 100 mg/m2
75330494|NCT03001726|Drug|S1|S1 40mg/m2
75638037|NCT02742051|Drug|Fluorouracil|Neoadjuvant chemotherapy
75638038|NCT02742051|Drug|Epirubicin|Neoadjuvant chemotherapy
75638039|NCT02742051|Drug|Cyclophosphamide|Neoadjuvant chemotherapy
75786927|NCT03818906|Procedure|Molar extraction - Control Group|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
75330495|NCT03001726|Drug|Docetaxel|docetaxel 40 mg/m2
75330496|NCT03595527|Diagnostic Test|HIV and HCV screening|HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott
75330497|NCT04697329|Drug|Preincisional infiltration with levobupivacaine|Local, preincisional infiltration of port sites with levobupivacaine 5 mg/ml 20 ml
75470237|NCT02335099|Drug|ticagrelor|ticagrelor 90 mg twice a day for 6 months
75470238|NCT02335099|Drug|Placebo|1 pill twice a day for 6 months
75638040|NCT02741973|Other|Yoga|
75638041|NCT02741973|Other|School sport|
75638042|NCT02741895|Behavioral|Fitbit monitoring|Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
75786928|NCT03818906|Procedure|aPDT + Molar Extraction - Test Group 1|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.
75638043|NCT02741817|Drug|Aspirin|The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
75638044|NCT02745873|Drug|Ascorbic Acid|Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
76079397|NCT04453488|Biological|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.
76079398|NCT04453488|Biological|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
76079399|NCT01100242|Drug|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
76079400|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
76079401|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
76079402|NCT03460548|Device|Remogen|instil 1 drop of the product in each eye, 4 times per day
75330498|NCT02974413|Behavioral|self-care supported|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
75330499|NCT00995215|Procedure|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
75638045|NCT02745639|Radiation|VMAT-SIB|Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.
75638046|NCT02745639|Drug|XELOX|The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
75638047|NCT02741739|Drug|REGN1033|
75638048|NCT02745717|Drug|Thymoglobulin|administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
75638049|NCT02745717|Procedure|Cord blood|transfusion of one unit of at least 4/6 HLA loci matched cord blood.
75638050|NCT02745717|Drug|Cyclosporine Oral Product|administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
75638051|NCT02745561|Drug|Endostatins|Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
75638052|NCT02745561|Drug|Oxaliplatin|Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
75638053|NCT02745561|Radiation|Radiotherapy|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.
75638054|NCT02745795|Behavioral|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
75638055|NCT02745795|Behavioral|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
75786929|NCT03818906|Procedure|Infrared + Molar Extraction - Test Group 2|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion
75786930|NCT03818906|Procedure|aPDT + Infrared + Molar Extraction - Test Group 3|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
75923175|NCT03366038|Procedure|Shark Mouth Modified Pancreaticojejunostomy|"The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis."
75923176|NCT02311452|Device|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
76079403|NCT03460548|Device|Cationorm|instil 1 drop of the product in each eye, 4 times per day
75638056|NCT02745483|Device|Separable clustered electrodes|patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
75638057|NCT02741583|Other|altitude rehabilitation program|altitude exposure
75786931|NCT03983915|Drug|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
75786932|NCT03983915|Drug|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
75786933|NCT03983915|Device|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
76079404|NCT01149616|Drug|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
76079405|NCT01149616|Drug|placebo|2 ml normal saline IV x1
76079406|NCT03465462|Dietary Supplement|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
76079407|NCT03465462|Dietary Supplement|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
75330500|NCT00995215|Device|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
75786934|NCT01300754|Procedure|Dextrose Injection|12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
75786935|NCT01300754|Procedure|Lidocaine Injection|1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
75786936|NCT01300754|Other|Usual Care|Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
75923177|NCT03507426|Procedure|Retrobulbar block|Patients will receive a single retrobulbar injection with 3-4ml of an equal mixture of Lidocaine 2% & Bupivacaine 0.5% + Hyaluronidase (10 IU/ml), after induction of general anesthesia.
75923178|NCT03507426|Procedure|Ketamine|Patients will receive a 0.5 mg/kg bolus followed by an infusion of 0.25 mg/kg/h of intravenous Ketamine, after induction of general anesthesia.
75923179|NCT03362918|Behavioral|High Intensity Interval Training|"The exercise prescription is as follows:~Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.~Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles~High intensity for most individuals will occur at approximately 90% of maximum heart rate. Using the rating of perceived exertion scale, participants should be exercising at a 9/10, which is very difficult to maintain the intensity and results in only being able to speak a few words at a time.~Low intensity is defined as light activity and rated as 2-3/10 on the rating of perceived exertion scale. Participants should be able to carry on a conversation and maintain the pace for hours.~Duration: 30 minutes Frequency: 3 times per week"
75923180|NCT03362918|Behavioral|Continuous Aerobic Exercise Training|"The exercise prescription for the continuous aerobic exercise group is as follows:~Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.~Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.~Duration: 50 minutes Frequency: 3 times per week"
76079408|NCT03465462|Dietary Supplement|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
75330501|NCT04581031|Device|Continuous vital sign monitoring - Isansys Patient Status Engine|CE marked wearable continuous vital signs monitors
75330502|NCT04581031|Other|Machine Learning/AI Algorithm|Patient data will be subjected to machine learning/AI algorithms to determine whether algorithms may be beneficial as an early indication of patient's condition worsening.
75470239|NCT02330562|Drug|MRZ|"MRZ dosing in Phase 1 to range from 0.55 to 0.8 mg/m2. Dose Escalation: MRZ dose-escalation will occur using a standard 3+3 study design.~The RP2D of MRZ (0.8.mg/m2) will be used in a two stage design, with fifteen response-evaluable patients entered in the first stage. If 1 or more responses are observed at the MRZ RP2D, then the second stage will be implemented with an additional 15 response-evaluable patients treated."
75470240|NCT02330562|Drug|BEV|BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
75638058|NCT02741583|Other|rehabilitation program|Rehabilitation at low altitude
75638059|NCT02741661|Other|No intervention. Observational study|No intervention
75330503|NCT03078543|Device|ANTHEM™ PS Total Knee System implant|"The ANTHEM™ PS Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ PS Total Knee System consists of the following components:~Cobalt-Chrome (Co-Cr) femoral components - Posterior stabilised~Titanium primary tibial components~Posterior-stabilised ultra-high molecular weight polyethylene (UHMWPE)~Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications."
75330504|NCT04646746|Dietary Supplement|100% wheat|100 g of bread backed with 100% wheat
75330505|NCT04646746|Dietary Supplement|50% nude barley and 50% wheat|100 g of bread backed with 50% nude barley and 50% wheat
75330506|NCT04646746|Dietary Supplement|75% nude barley and 25% wheat|100 g of bread backed with 75% of nude barley and 25% wheat
75470241|NCT02293174|Device|Topcon TRC-NW400|Retinal Fundus Camera
75470242|NCT02293174|Device|TRC-NW8|Retinal Fundus Camera
75470243|NCT02293174|Device|TRC-NW400|Retinal Fundus Camera
75638060|NCT02695251|Other|low AGE meal|Patients will receive a low AGE (eggs) meal
75786937|NCT01203332|Behavioral|Effectiveness of different strategies in HIV testing and linkage to care|HIV testing Linkage to Care
75786938|NCT03825848|Procedure|trans jugular intrahepatic portal systemic shunt|Shunting left or right PV branch in the TIPS procedure
75330507|NCT04646746|Dietary Supplement|50% gene-modified high-amylose barley and 50% wheat|100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
75786939|NCT03825614|Behavioral|training|plates and therapeutic exercises applied on young adults
76079409|NCT03460470|Drug|Sildenafil|PDE5 Inhibitor
76079410|NCT03460470|Drug|Placebo oral capsule|Placebo for Sildenafil
75330508|NCT04444843|Drug|Mycophenolate Mofetil Capsules|Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first choice post transplantation
75470244|NCT02293174|Device|Canon-CR2|Retinal Fundus Camera
75470245|NCT02293174|Device|Zeiss Visucam PRO|Retinal Fundus Camera
75470246|NCT02138266|Device|Topcon Specular Microscope SP-1P|
75470247|NCT02138266|Device|Konan Specular Microscope CELLCHEK XL|
75638061|NCT02695251|Other|High AGE meal|Patients will receive a high (mixed nuggets) AGE (eggs) meal
75638062|NCT04347603|Procedure|TAVR|Femoral percutaneous aortic prosthesis (TAVR)
75638063|NCT02745015|Procedure|non-surgical periodontal treatment|full-mouth scaling and root planing
75638064|NCT02741427|Other|Conventional toothpaste|The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
76079411|NCT03465306|Behavioral|Cognitive Behavioral Therapy|Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
75638065|NCT02741427|Other|Whitening toothpaste|The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
75470248|NCT02053363|Drug|Tranexamic Acid (Cyklokapron)|
75638066|NCT02741427|Other|10% carbamide peroxide|"The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen"
75638067|NCT02745093|Drug|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
75638068|NCT02745093|Drug|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
75638069|NCT02741505|Device|Actigraph|Participants will be asked to wear an actigraph
75786940|NCT03825770|Behavioral|"The PEP (Personal Energy Planning) Program"|The PEP program is designed to teach people on dialysis with fatigue how to conserve energy during day-to-day tasks, and how to use energy conservation to accomplish their goals. The program is delivered over 7-9 weekly sessions. It consists of 2 educational web modules about energy conservation, and 5-7 goal-focused training sessions with a study clinician that utilize a problem-solving training approach known as the Cognitive Orientation to Occupational Performance (CO-OP) approach. Each program session lasts ~20-30 mins. Sessions are completed either in person during hemodialysis, or via telephone (based on patient preference). The program is administered by a trained study clinician (occupational therapist or nurse).
75786941|NCT03825770|Behavioral|General Education about Kidney Disease|"General education about kidney disease involves a review of information from the Kidney Foundation of Canada's patient handbooks Living with Reduced Kidney Function and Living with Kidney Failure (www.kidney.ca/manual) during 6-8 brief individual sessions with a trained study clinician (occupational therapist or nurse).The handbooks contains general information about managing kidney disease, addressing topics such as medication management, diet, and emotional well-being on dialysis. Sessions will take place either in person during hemodialysis, or via telephone (based on patient preference)."
75786942|NCT03235726|Drug|CCI15106|One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
75923181|NCT02311530|Drug|Felodipine|Extended Release Tablets, 10mg
76079412|NCT03465306|Device|Self-guided|Self-guided refers to any contact between the participants and a therapist or coach.
75638070|NCT02745171|Other|physical therapy|Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
75923182|NCT02311530|Drug|Felodipine (Plendil®)|
76079413|NCT01101100|Drug|AMG 827|210 mg SC or 140 mg SC
76079414|NCT03460392|Drug|Antibiotic therapy|To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
76079415|NCT01149772|Behavioral|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
76079416|NCT05201118|Drug|Selinexor|Selinexor, 20 mg/tablet, is a first-in-class, oral Selective-Inhibitor-of-Nuclear-Export (SINE) compound that impedes XPO-1which is a major nuclear export protein of macromolecular cargo frequently overexpressed in MM.
75470249|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.
76079417|NCT05201118|Drug|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
75638071|NCT02745249|Behavioral|Maternal Nutrition Behavior change|
76079418|NCT05012436|Drug|YHD1119 75mg|A single oral dose
76079419|NCT01101880|Biological|filgrastim|Given SC
76079420|NCT01101880|Drug|clofarabine|Given IV
76079421|NCT01101880|Drug|cytarabine|Given IV
75470250|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.
75470251|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.
75470252|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.
75470253|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.
75923183|NCT04522466|Drug|Hydroxychloroquine (HCQ)|"Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ)."
75923184|NCT02306772|Drug|TP05 Coating A|One radio-labelled tablet given to subjects
75923185|NCT02306772|Drug|TP05 Coating B|One radio-labelled tablet given to subjects
76079422|NCT03460080|Diagnostic Test|AFP-L3 and PIVKA-II in HCC|"Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI"
76079423|NCT04989972|Drug|PSIL428|1 mg of psilocybin
76079424|NCT04989972|Dietary Supplement|Oyster mushroom|1 mg of oyster mushroom
76079425|NCT04989972|Drug|PSIL428|1 mg psilocybin
75786943|NCT03235726|Drug|Placebo|One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
75786944|NCT00303953|Drug|belinostat|Given IV
75330509|NCT04341987|Behavioral|brief Imagery Rehearsal Therapy|Two-sessions of behaviorally-based imagery rehearsal therapy.
75470254|NCT04176250|Drug|HRZE|Participants will receive Isoniazid [H] / rifampicin [R] / pyrazinamide [Z] / ethambutol [E] (HRZE), a fixed dose combination (H: 75 mg / R: 150 mg / Z: 400 mg / E: 275 mg) tablet QD for 14 days.
75923186|NCT03358394|Behavioral|A human-interventional study|"The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone"
75923187|NCT03132558|Drug|Radiopaque Media|
75638072|NCT04326075|Device|CPAP treatment|CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
75923188|NCT04463472|Biological|AG0301-COVID19|1.0 mg of AG0301-COVID19 twice at 2-week intervals
75923189|NCT04463472|Biological|AG0301-COVID19|2.0 mg of AG0301-COVID19 twice at 2-week intervals
75330510|NCT04341987|Other|Treatment As Usual|may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
75638073|NCT03797391|Drug|EMB-01|"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."
75638074|NCT02740881|Other|Counselor Training Methods|
75330511|NCT04395937|Other|exercises|One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises
75330512|NCT01022359|Device|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
75330513|NCT01022359|Device|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
75330514|NCT00635804|Drug|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
75786945|NCT03823820|Other|Bioimpedance Analyser|Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.
75786946|NCT03840122|Other|ACB + IPACK block with injection of local anesthetic|"ACB + IPACK block with injection of local anesthetic which is comprised of the following agents and amounts:~Ropivacaine 5mg/ml (49.25ml)~Epinephrine 1mg/ml (0.5ml)~Ketorolac 30mg/ml (1ml)~Clonidine 0.1mg/ml (0.8ml)~Saline 48.45ml"
75786947|NCT03840122|Other|ACB + IPACK block without injection|ACB + IPACK block without an injection of local anesthetic
75786948|NCT04385758|Other|Diabetes-REM Program|A comprehensive community paramedicine management program designed to support adults with uncontrolled diabetes and a recent emergency department visit or hospitalization
75786949|NCT04375462|Device|AspireAssist device|"Allows for aspiration of gastric contents into a receptacle or the toilet to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically in an identical fashion to a standard PEG tube G 1-2 days after enrollment"
75786950|NCT04375462|Device|Standard decompressive PEG tube|"Allows for gastric drainage to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically 1-2 days after enrollment"
75923190|NCT04524650|Diagnostic Test|the level of vWF|the peripheral level of vWF
75923191|NCT03507348|Drug|visits of tocilizumab injection (every 4 weeks, up to 5 visits)|every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).
75923192|NCT03507348|Drug|Rituximab 375 mg/m2 at Day-30|Rituximab 375 mg/m2 at Day-30
75923193|NCT03507348|Drug|Rituximab 375 mg/m2 at Day-15 (only for donors living)|Rituximab 375 mg/m2 at Day-15
75923194|NCT03507348|Other|Transplant Day-0|TRANSPLANTATION
75470255|NCT02044276|Drug|lipegfilgrastim|6 mg
75923195|NCT03362840|Behavioral|Early Start Denver Model|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system
75470256|NCT02044276|Drug|pegfilgrastim|6 mg
75470257|NCT01975571|Device|Cochlear® Nucleus™ Hybrid L24|The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.
75786951|NCT04375462|Other|gastric outlet obstruction scoring system (GOOSS) questionnaire|"Gastric outlet obstruction scoring system (GOOSS) questionnaire~Both groups will receive the questionnaires via a phone call"
75786952|NCT04375462|Other|Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire|"Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire~Both groups will receive the questionnaires via a phone call"
75786953|NCT04375462|Other|Patient satisfaction and ease of use survey|"Patient satisfaction and ease of use survey~Both groups will receive the questionnaires via a phone call"
75786954|NCT04343872|Behavioral|Receive lifestyle modification alone|Participants will receive a 12-month lifestyle intervention program (telehealth + peer coach). The intervention comprises of the Center for Disease Control and Prevention (CDC)-adapted DPP Prevent Type 2 (PreventT2) lifestyle intervention program consisting of 26 classes delivered by trained health educators via telehealth. Additionally, the peer coach provides ongoing support over 12-months with tapered calls mirroring ongoing classes. Participants are randomized at the practice level. Two clinics will be randomized to receive the lifestyle intervention program alone.
75638075|NCT00839254|Biological|Pneumococcal conjugate vaccine Synflorix (GSK1024850A)|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
75638076|NCT00839254|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children < 12 months of age at the time of first study vaccination.
75638077|NCT00839254|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children >= 12 months of age at the time of first study vaccination.
75638078|NCT02740959|Drug|Astragalus Polysaccharides 500 mg|PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
75638079|NCT02740959|Drug|Astragalus Polysaccharides 250 mg|PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
75638080|NCT02745405|Other|Fat Suit|Participants wear a fat suit.
75638081|NCT02745405|Other|Control Condition|Participants wear same clothing as intervention, but in their own size.
75786955|NCT04343872|Behavioral|Metformin therapy|The two other clinics will be randomized to receive the lifestyle intervention program (described above) with METFORMIN therapy recommendations. Participants are randomized at the practice level. The primary care provider at the clinic will prescribe metformin and participants would be encouraged to take it if the primary care provider consider prescribing.
75786956|NCT01314274|Drug|Bevacizumab|100mg intranasal submucosal bevacizumab in 10ml
75786957|NCT01314274|Drug|NaCl|10ml of 0.9% NaCl intranasal submucosal
75786958|NCT03818984|Behavioral|Safer Conception for Men with At Risk Partners|CBT based safer conception counseling with longitudinal follow-up and booster sessions. The primary outcome will be HIV RNA suppression at 6 months. Secondary outcomes include early ART uptake, adherence, serostatus disclosure, couples HIV counseling and testing uptake, and limiting unprotected sex to peak fertility.
75923196|NCT03362840|Behavioral|Eclectic preschool intervention|"The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria."
75923197|NCT03450252|Device|Active pacing|Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.
75638082|NCT02741115|Drug|Udenafil|Active drug
75330515|NCT00635804|Drug|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
75638083|NCT02741115|Drug|Placebo|Matching Placebo
75330516|NCT04353193|Drug|Terlipressin|Terlipressin 1mg IV bolus
75330517|NCT04353193|Drug|Terlipressin|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
75330518|NCT04353193|Drug|Octreotide|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
75330519|NCT01023841|Drug|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
75638084|NCT02740803|Other|Sodium fluoride toothpaste 1,450 ppmF|
75638085|NCT02740803|Other|sodium monofluorophosphate toothpaste 1,450 ppmF|
75638086|NCT02740803|Other|stannous fluoride combined with sodium fluoride toothpaste 1,450 ppmF|
75638087|NCT02740803|Other|sodium fluoride combined sodium monofluorophosphate toothpaste 1,450 ppmF|
75638088|NCT02740803|Other|Amine fluoride toothpaste 1,400 ppmF|
75638089|NCT02740803|Other|Non-fluoridated toothpaste 0 ppmF|
75638090|NCT02695017|Device|Iso inertial|
75638091|NCT02695017|Device|Conventional machine|
75638092|NCT02744859|Other|Label Condition|Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
75638093|NCT02740647|Drug|Amoxicillin Clavulanate|getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
75638094|NCT02740647|Drug|Placebo|50 ml of 0.9% sodium chloride three times a day
75638095|NCT02744781|Device|Lumbar disc degeneration; LDD|All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
75330520|NCT01023841|Drug|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
75330521|NCT00635648|Drug|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
75330522|NCT05240768|Diagnostic Test|Fractional flow reserve, instantaneous wave-free Ratio|Clinical outcomes observed for patients with moderate coronary lesions in whom coronary revascularization was deferred due to a negative physiologic study.
75330523|NCT05240690|Biological|Umbilical Cord Blood Derived MAK Immune Cells|Intravenous drip
75470258|NCT01975571|Device|Cochlear® Nucleus™ Hybrid S12|The Nucleus Hybrid S12 cochlear implant incorporates an electrode array designed to stimulate the high-frequency, basal region of the cochlea while maintaining useful acoustic hearing in the low-frequency, apical region. This has been accomplished by employing a short, thin, straight intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The electrode array incorporates a collar to prevent over-insertion, or further migration, into the cochlea beyond the point where the basal turn curves into the ascending segment. Thus, the electrode array is placed within the straight segment of the basal turn of the scala tympani via a cochleostomy.
75470259|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
75470260|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
75786959|NCT03840044|Other|Cold air exercise test|Subjects will perform a submaximal 90 minutes exercise test in a controlled cold air environment (-5°C, 60% relative humidity) in a climate chamber with evaluation pre§/during*/post§ of heart rate (HR)§* and blood pressure (BP)§*, spirometry§*, PNIF§, FeNO§, electrocardiogram (ECG)§*, body & exhaled air temperature§*, capsaicin cough threshold test§, histamine bronchial challenge test§, and sampling of nasal fluid§, induced sputum§, and venous blood§.
75470261|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
75470262|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
75470263|NCT01157091|Drug|pazopanib hydrochloride|Given orally
75638096|NCT02740725|Other|Patching Therapy|Occlusion of a dominant eye with better best corrected visual acuity
75638097|NCT02740725|Device|Interactive Binocular Treatment System|Dissociation of two eyes with more foveal stimulation to the amblyopic eye
75638098|NCT05628909|Procedure|PPV with SO tamponade|Patients randomized into silicone oil group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
75786960|NCT05620550|Procedure|ozonated oil|Post operative scar treatment with ozonated oil
75786961|NCT05620550|Procedure|non ozonated oil|Post operative scar treatment with non ozonated oil
75923198|NCT03450252|Device|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
75923199|NCT03365960|Dietary Supplement|Watermelon Rind|watermelon rind
75923200|NCT03365960|Dietary Supplement|Watermelon Flesh|watermelon flesh
75330524|NCT00995449|Biological|KB003|KB003 IV x5 doses
75330525|NCT00995449|Other|Placebo Comparator|Placebo IV x5 doses
75923201|NCT03365960|Dietary Supplement|Watermelon Seeds|watermelon seeds
75923202|NCT03365960|Dietary Supplement|Placebo|Control Comparator
75923203|NCT02518802|Drug|Gefitinib|Gefitinib 250mg per day for 2 years.
75923204|NCT02518802|Drug|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
75330526|NCT05240456|Drug|Beta3-Agonists, Adrenergic|The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
75330527|NCT05240456|Drug|Anticholinergic drug, Solifenacin|Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
75330528|NCT03574779|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
75470264|NCT01157091|Other|laboratory biomarker analysis|Correlative studies
75470265|NCT01157091|Other|immunologic technique|Correlative studies
75470266|NCT01100775|Drug|Galantamine|A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
75470267|NCT01100775|Drug|Placebo|Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
75470268|NCT00578123|Behavioral|Quality of Life Questionnaires|Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
75470269|NCT00504712|Drug|Testosterone|Sustanon- 200mg- Intramuscular testosterone every 2 weeks
75470270|NCT00504712|Drug|saline|Saline injection every two weeks
75470271|NCT05413226|Dietary Supplement|Celastrol|Four increasing doses of Celastrol to each of five men.
75923205|NCT02303340|Radiation|Dual Energy X-ray Absorptiometry|
76079426|NCT01101958|Device|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
75470272|NCT05413213|Procedure|Ambulatory rehabilitation program|Experimental group: Ambulatory rehabilitation program based on mobilization and muscular solicitation.
75330529|NCT03574779|Biological|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to Programmed cell death protein 1 (PD-1) resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
75330530|NCT03574779|Biological|Bevacizumab|Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
75638099|NCT05628909|Procedure|PPV with fovea-sparing ILMP and gas tamponade|Patients randomized into gas group 1 were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
75638100|NCT05628909|Procedure|PPV with gas tamponade|Patients randomized into gas group 2 were received pars plana vitrectomy surgery without internal limiting membrane peeling and gas tamponade.
75923206|NCT04524026|Drug|Letrozole 5 mg|recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
75638101|NCT05629455|Device|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
75638102|NCT00586339|Biological|Cervarix|Intramuscular injection, 3 doses
75330531|NCT03574779|Drug|Carboplatin|Carboplatin will be infused intravenously over 60 minutes at the prescribed dose of area under the concentration versus time curve of 5 to 6 mg/milliliters (mL) per minute on Day 1 of every 21-day cycle
75330532|NCT03574779|Drug|Paclitaxel|Paclitaxel will be administered intravenously over 180 minutes at the prescribed dose of 175 mg/meter square (m^2) on Day 1 of every 21-day cycle
75330533|NCT01922570|Dietary Supplement|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
75470273|NCT05413200|Drug|Isotretinoin|oral isotretinoin with a standard dose regime for 90 days
75470274|NCT05413187|Drug|Medical Grade Cannabis oil|MGC, 30% CBD and 1.5% Δ9-THC
75638103|NCT00586339|Biological|Placebo Control|Intramuscular injection, 3 doses
75638104|NCT02740491|Other|Remission Consultation|"At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient."
75638105|NCT04190667|Diagnostic Test|Genomic testing|A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status.
75638106|NCT02744547|Dietary Supplement|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
75638107|NCT03737253|Drug|Follitropin alpha|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
75638108|NCT03737253|Drug|Menotropin|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
75638109|NCT02740569|Other|No intervention|Observational study. Intervention according to the clinical routines (not included in this part)
75638110|NCT00812968|Drug|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
75638111|NCT02744703|Drug|total-etch adhesive|comparator use of total-etch adhesive
75638112|NCT02744703|Drug|CAPE-T|experimental group
75786962|NCT01299974|Other|Parents and Residents in Session|Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
75923207|NCT04523948|Behavioral|Behavioral and pharmacological support to reduce combustible tobacco use.|Behavioral and pharmacological support to reduce combustible tobacco use.
75923208|NCT02311608|Drug|Terlipressin|administered as a first-line medicine or as salvage
75923209|NCT02311608|Drug|Usual Dose Somatostatin/Octreotide|administered as a first-line medicine or as salvage
75923210|NCT02311608|Drug|High Dose Somatostatin/Octreotide|administered as salvage
75923211|NCT02307006|Drug|Ceftaroline|Surgical prophylaxis
75923212|NCT02307006|Drug|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
76079427|NCT01101958|Device|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
76079428|NCT04978038|Drug|mRNA- COVID-19|Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
76079429|NCT04978038|Drug|Prevnar13|Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
76079430|NCT01194466|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
75470275|NCT05413187|Drug|Placebos|Olive oil and Chlorophyl
75786963|NCT02935894|Drug|Ibuprofen|400 mg ibuprofen given to inhibit cyclooxygenase metabolism
75330534|NCT04341883|Drug|anti-PD-1+Albumin-Bound Paclitaxel|"anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody"
75638113|NCT02744703|Drug|self-etch adhesive|comparator use of total-etch adhesive
75786964|NCT02935894|Other|Physiological induction of sweating|15 minutes exercise at 60-80% oxygen consumption to induce sweating
75786965|NCT02935894|Drug|Pilocarpine|Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
75786966|NCT03818750|Device|MRI|"Subjects review alcohol ads in different contexts (neutral context vs positive context such as parties and sport) and answer with buttons lever while being in the MRI to express their desire to consume alcohol or not.~Subjects will be exposed to 288 ads set up."
75786967|NCT03818750|Behavioral|Alcohol Use Disorders Identification Test|Questionnaire
75330535|NCT05240300|Biological|BX005-A|phage gel
75470276|NCT05413109|Radiation|Coronary CT angiography|"A coronary CT angiography will be used to study the relationship between the PA and the LMCA and 4 radiological patterns will be considered:~Normal: minimum distance between the two vessels> 1 mm;~Proximity: distance between the two vessels ≤1 mm without displacement or stenosis of the LMCA;~Dislocation: dislocation of the LMCA by the main branch of the PA with a take-off angle <60 ° (the take-off angle is defined by the angle formed by the perpendicular to the aortic valve ring and the longitudinal axis of the LMCA);~Compression: stenosis of the LMCA ≥50% due to extrinsic compression by the PA."
75638114|NCT02744703|Drug|CAPE-S|experimental group
75786968|NCT01300130|Dietary Supplement|low docosahexaenoic acid formula|
75786969|NCT01300130|Dietary Supplement|medium docosahexaenoic acid formula|
75786970|NCT01300130|Dietary Supplement|high docosahexaenoic acid formula|
76079431|NCT03011632|Drug|Mometasone Nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
75330536|NCT05240300|Other|Placebo|vehicle gel
75330537|NCT00995761|Drug|Docetaxel and Cisplatin|splitted administration of docetaxel and cisplatin.
75330538|NCT00375700|Dietary Supplement|Nutritional Supplement|
75330539|NCT00362271|Drug|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
75330540|NCT00635102|Drug|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
75470277|NCT05412849|Radiation|Radiotherapy|Radiotherapy site, time perspective and dose
75638115|NCT02744937|Drug|Aspirin|aspirin is continued by its regular dosing
75638116|NCT02744625|Drug|Higher doses of vasopressor therapy for a MAP of 75 mmHg|
76079432|NCT03011632|Drug|placebo mometasone|a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
76079433|NCT01102270|Drug|Eszopiclone|3mg tablet once prior to sleep
75330541|NCT00635102|Drug|Placebo D-Cycloserine PO and placebo Glycine IV|Placebo
75638117|NCT02744625|Drug|Lower doses of vasopressor therapy for a MAP of 65 mmHg|
75638118|NCT02744625|Drug|Propofol for light sedation|Propofol for light sedation
75638119|NCT00839098|Other|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
76079434|NCT01102270|Drug|Placebo|1 placebo capsule prior to sleep
76079435|NCT01102894|Device|SmartPill|SmartPill
75330542|NCT00635102|Drug|Placebo D-Cycloserine PO and Glycine IV|
75330543|NCT00635102|Drug|D-Cycloserine PO and placebo Glycine IV|
75330544|NCT04736212|Device|Bed sensor monitoring system|Respiratory patterns in the post-anesthesia care unit will be assessed using a validated, modified under bed weighing scale placed under the patient's bed in the PACU.
75330545|NCT00996775|Behavioral|brief alcohol intervention|this intervention consists of brief assessment and feedback
75330546|NCT00996775|Behavioral|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
75651813|NCT05461950|Procedure|Extrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room and necessary respiratory support is initiated (CPAP or PPV) by a neonatal team. The umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infant is breathing regularly with or without support (at maximum 10 minutes after delivery)
75786971|NCT01300130|Dietary Supplement|breast milk|a non randomized group of breast milk fed infants was included
75786972|NCT04548076|Other|Block group|Control group
75786973|NCT05669300|Procedure|Yilmaz Suturation|uterine closure with Yilmaz Technique and single layer continue locked suturation
75786974|NCT03224182|Drug|Qapzola|Qapzola administered by the intravesical route.
75786975|NCT03224182|Drug|Placebo|Qapzole-matching placebo administered by the intravesical route.
75786976|NCT03821480|Drug|Test drug|Fluconazole capsule 50 mg Manufacturer: West Ryde
75786977|NCT03821480|Drug|Reference drug|Fluconazole capsule 50 mg Manufacturer: Amboise
75786978|NCT05623436|Behavioral|Nursing students will be trained through virtual reality.|Nursing students will be trained through virtual reality.
75786979|NCT01203488|Drug|Vitamin A|5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
76079436|NCT01103440|Drug|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
76079437|NCT01103440|Drug|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
75638120|NCT00839098|Other|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction & Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
75330547|NCT03041883|Procedure|Crosslinking with riboflavin of the corneal graft-support|Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
75638121|NCT02598973|Behavioral|Exercise|Aerobic walking
75638122|NCT02744469|Other|No intervention (observational study)|
75330548|NCT03041883|Procedure|De-epithelisation of the corneal graft support with instillation of riboflavin|Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
75786980|NCT01203488|Other|Sham Procedure|Control infants received a sham procedure rather than placebo injections.
75786981|NCT02935192|Biological|Vaccine|Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection
75786982|NCT02935192|Other|Placebo|Phosphate buffered saline, 0.5 mL by IM injection
75786983|NCT03819998|Diagnostic Test|measurement of Fetuin-A level in serum|Fetuin A level will be measured in blood of the PCOS women
75923213|NCT03362762|Other|Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:|The physician or the endocrinologist will see the patient during his consultation. The pharmacist will see the patient when he goes to the pharmacy for an insulin treatment. In each case, the patient will be informed about the study, about the medical data that will be collected anonymously. The date will be strictly confidential and under medical secrecy. Then the patient will meet the physician during another consultation at the University Hospital Center of Guadeloupe, in order to collect information's on a questionnaire. Otherwise, the physician can meet the patient at his home, in case he can't move to the University Hospital Center of Guadeloupe.
75923214|NCT02307084|Procedure|Ultrasound imaging of the long saphenous vein|Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
75923215|NCT03362684|Drug|Cetuximab|Cetuximab every 2 weeks
75923216|NCT03362684|Drug|FOLFOX|FOLFOX-4 every 2 weeks
75923217|NCT02311686|Dietary Supplement|10 g ethanol|Alcohol single oral dose
75786984|NCT03819920|Behavioral|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
75923218|NCT02311686|Dietary Supplement|20 g ethanol|Alcohol single oral dose
75330549|NCT04332718|Device|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
75638123|NCT02610556|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
75638124|NCT02610556|Drug|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
75786985|NCT03819920|Behavioral|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
75786986|NCT01314352|Drug|Desloratadine|Desloratadine Tablets, 5 mg
75786987|NCT03636802|Other|Questionnaire BPI|Brief Pain Inventory (BPI) This is a scale of self-assessment, the Concise Pain Questionnaire in French. For all adult patients For any type of pain This is to ask the patient to answer questions in order to learn about us characteristics of his pain (its intensity and its repercussions on the plane biopsychosocial).
75786988|NCT03818282|Drug|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.
75786989|NCT05281640|Behavioral|Affect Dysregulation intervention|See relevant study arm for description
75786990|NCT05281640|Behavioral|Negative Self Concept intervention|See relevant study arm for description
75923219|NCT02311686|Dietary Supplement|40 g ethanol|Alcohol single oral dose
75638125|NCT02610556|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
75638126|NCT02610556|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
75786991|NCT05281640|Behavioral|Disturbed Relationships intervention|See relevant study arm for description
75923220|NCT02311686|Dietary Supplement|60 g ethanol|Alcohol single oral dose
75923221|NCT02311686|Dietary Supplement|80 g ethanol|Alcohol single oral dose
75923222|NCT03362606|Biological|OC-CTLs|2 to 4 infusions, once a week, for 1x10^5~4x10^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
75923223|NCT02311764|Drug|Carboplatin|Carboplatin will be administered weekly
75923224|NCT03365726|Diagnostic Test|Dobutamine stress test with trans-esophageal echocardiography|"Dobutamine stress echocardiography will be performed: before skin incision and at the end of surgery.~After a TEE evaluation at rest to assess myocardial structure, function and potential regional wall motion abnormalities, dobutamine infusion will be started~If no regional wall motion abnormalities will be detected, a dobutamine stress echocardiography will be started at the range infusion of 50 γ/kg/min (ADST: Accelerated Dobutamine Stress Test). The Test will be continued up to the 85% of maximum heart rate adjusted for the patient age and echo images will be stored.~If regional wall motion abnormalities are present, a gradual dobutamine stress test will be started at the initial dose of 10 mcg/kg/min (GDST: Gradual Dobutamine Stress Test) and it will be increased every 3 minutes until the 85% of maximum heart rate, adjusted for patient's age (maximal dose: 40 mcg/kg/min) and echo images will be stored."
75470278|NCT05412797|Behavioral|Cycling/Using a DeskCycle|The intervention was conducted in two phases. In phase 1, the intervention group were given the DeskCycles to use for 8 weeks. In phase, the control group from phase 1 were given the DeskCycles to use. Intervention group from phase 1 became controls in phase 2
75638127|NCT02740101|Drug|oxytocin treatment|intranasal administration of oxytocin (40 IU)
75638128|NCT02740101|Drug|placebo treatment|intranasal administration of placebo (40 IU)
75786992|NCT03818126|Drug|del Nido cardioplegia|"The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml). This solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 4:1 ratio (crystalloid:blood).~The dosage is 20ml/kg. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius. Additional dose of the cardioplegia is given only if the cross-clamp time exceeds 90 minutes. Due to high volume given in a single delivery, 40 milligrams of furosemide are injected into cardiopulmonary circuit."
75638129|NCT02612116|Drug|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
75638130|NCT02612116|Drug|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
75786993|NCT03818126|Drug|cold blood cardioplegia|"The cold blood cardioplegia components are: Plasma-Lyte A (435ml), Mannitol 15% (20ml), NaHCO3 8.4% (20ml), KCl 2mEq/mL (25ml). The solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 1:4 ratio (crystalloid:blood).~The initial dose is 15ml/kg and a dose of 5ml/kg is added every 20-30 minutes or whenever cardiac activity is observed. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius."
75786994|NCT01300910|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
75786995|NCT01300910|Procedure|Male circumcision|A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
75786996|NCT03722264|Device|OpalSeal|OpalSeal is a fluoride releasing orthodontic primer that is FDA approved for use during bonding of orthodontic brackets
75638131|NCT02612116|Drug|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
75786997|NCT03722264|Device|TransbondXT|Transbond is a primer used to bond orthodontic brackets that does not contain fluoride
75330550|NCT03554265|Drug|Somatropin|Genotropin given by injection
75330551|NCT03034005|Drug|Budesonide|1600 ug inhaled daily for 6 weeks
75923225|NCT02307162|Drug|RPL554|Phosphodiesterase 3 and 4 Inhibitor
75330552|NCT04296916|Drug|IOP lowering eye drops|"Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops."
75470279|NCT05412797|Behavioral|Regular activities|The active comparator performed normal daily activities
75470280|NCT05412771|Procedure|Hysteroscopy|Samples will be collected from consenting patients undergoing a surgical hysteroscopy for medical purposes
75470281|NCT05412732|Other|prospective biomedical research study|A prospective biomedical study, in which a comparison will be made of the outcome of a specific disease (in this case, AMI).
75470282|NCT05412719|Behavioral|THE EFFECT OF FINGER PUPPET MANIPULATION ON PAİN AND PHYSİOLOGıCAL PARAMETERS DURING URINARY CULTURE WITH URINARY CATHETERIZATION IN INFANTS|the effect of finger puppet manipulation on pain and physiological parameters during urinary culture with urinary catheterization
75638132|NCT02744235|Device|Polysomnography Data|
75638133|NCT02744235|Device|Jawbone UP®|
75638134|NCT02744235|Device|Fitbit Charge ®|
75638135|NCT02744079|Behavioral|Low carbohydrate diet|45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal
75638136|NCT02744079|Behavioral|Low fat diet|20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
75638137|NCT02744157|Behavioral|Longterm effects after a structured lifestyle program|present study was to describe a structured intervention to reduce cardiovascular risk in a clinical setting and to study the effects of the program on lifestyle habits and quality of life in individuals at risk after six months and one year.
75786998|NCT05623202|Behavioral|Multi-level behavior-change intervention to strengthen food- and diet-related capital to promote food security and diet quality among low-income Hispanic/Latino adults|The behavior-change intervention with low-income Hispanic/Latino adults will mobilize existing sources of human, material, social, and cultural capital at the individual, household, social, and community level, and will include a nutrition education component and a food access component.
75923226|NCT02307162|Drug|Placebo|Dummy solution
75923227|NCT03358160|Behavioral|Action discrimination tasks.|The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
75923228|NCT02303418|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
75923229|NCT02303418|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
76079438|NCT03011554|Device|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
76079439|NCT01152112|Device|Myomectomy|Removal of fibroids and / or polyps
75330553|NCT00635024|Biological|anti-thymocyte globulin|2.5 mg/kg
75638138|NCT02740023|Device|Hearing Aid (Phonak Audéo V90-13)|Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
75786999|NCT01300364|Drug|Reboxetine|8mg/day.
75923230|NCT03365648|Dietary Supplement|Lertal® + standard therapy|"Lertal® is a novel food supplement. Each tablet contains the following active ingredients:~Quercetin 150 mg: a natural flavonoid that inhibits the release of histamine, leukotrienes, PGD2, IL (IL-6, IL-8, TNF-alpha).~Perilla frutescens 80 mg: A dry extract of the seeds containing rosmarinic acid, luteolin, apigenin and crysoeriol that inhibits the release of histamine and expression of interleukins (IL-6, TNF-alpha).~Vitamin D3 5 mcg (200 IU), which contributes to the normal function of the immune system.~Standard therapy: antihistamine."
75923231|NCT03365648|Other|Placebo + standard therapy|"Placebo tablet identical in appearance, size and taste to Lertal® tablets. Standard therapy: antihistamine.~Standard therapy: antihistamine"
75923232|NCT03362528|Device|WM3.4NR|Investigational Medical Device collecting spectral raman data from tissue.
76079440|NCT04352374|Other|Aerobic exercise|a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.
75330554|NCT00635024|Drug|melphalan|16 mg/m^2
75330555|NCT03544359|Device|Transcranial electrical stimulation (tES)|"In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS."
75330556|NCT01922648|Procedure|Blood sample|An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
75330557|NCT02975193|Behavioral|Computer task assessing cognition|Participants will complete a short computer game to assess cognition.
75330558|NCT02975193|Behavioral|Impulsive-Compulsive Disorders in Parkinson's Disease|Standard clinical questionnaire
75330559|NCT02975193|Procedure|Deep Brain Stimulation Surgery|DBS surgery for the implantation of electrodes for the treatment of motor disorders.
75330560|NCT04865458|Drug|HEC89736|HEC89736 tablets QD every 28 days for each cycle
75330561|NCT03005379|Drug|Fecal Microbiota Therapy (FMT)|Oral capsule-delivered FMT
75638139|NCT02740023|Device|Hearing Aid (Successor of Phonak Audéo V90-13)|The successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
75638140|NCT02739945|Procedure|Cubital tunnel release|The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
75330562|NCT03005379|Drug|Placebo|Oral capsule-delivered placebo
75638141|NCT00813748|Drug|Xolair|
75638142|NCT02743767|Procedure|Introducing five different treating adaptations|Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
75330563|NCT03182920|Drug|Lasmiditan|Oral administration
75638143|NCT05629299|Biological|Samples|Men will give semen, saliva, skin, urine and blood specimens
75638144|NCT02610400|Combination Product|RACD|"Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) > 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop"
75787000|NCT01300364|Drug|citalopram (SSRI)|30mg/day
75787001|NCT03722030|Other|Baseline Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
75787002|NCT03722030|Behavioral|Strength-Training|2 sessions per week (20-40 min), home-based resistance training
75787003|NCT03722030|Other|Mid-point Measures|Accelerometer (steps)
76079441|NCT04352374|Device|Device guided breathing|The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
76079442|NCT01105312|Drug|letrozole|
76079443|NCT01105312|Drug|panobinostat|
76079444|NCT01105312|Genetic|RNA analysis|
75330564|NCT03182920|Drug|Placebo|Oral administration
75330565|NCT03514173|Device|Remote Patient Monitoring|Use of remote patient monitoring
75330566|NCT03485547|Drug|Venetoclax|VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
75330567|NCT03185182|Drug|Ioflupane I123|"185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution."
75330568|NCT02992275|Other|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
75330569|NCT02992275|Other|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
75470283|NCT05412680|Procedure|TOETVA|TRANSORAL ENDOSCOPIC THYROIDECTOMY BY VESTIBULAR APPROACH
75470284|NCT05412680|Procedure|conventional thyroidectomy|conventional open thyroidectomy by cervical approach
76079445|NCT01105312|Genetic|microarray analysis|
75787004|NCT03722030|Other|Post-Study Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
75787005|NCT05617352|Diagnostic Test|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
75787006|NCT05623124|Other|No intervention|No intervention
75787007|NCT03221842|Drug|C1-esterase inhibitor|C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
76079446|NCT01105312|Genetic|reverse transcriptase-polymerase chain reaction|
76079447|NCT01105312|Other|enzyme-linked immunosorbent assay|
75330570|NCT04089280|Dietary Supplement|Sanprobi Barrier-multispecies probiotic|"Multi-strain probiotic Sanprobi Barrier (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus lactis W19, Lactobacillus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24) or placebo. Patients will be randomized to one of the two products (A or B) each containing probiotic/placebo and administered for 12 weeks. After 12 weeks of supplementation, the probiotic/placebo product A or B will be discontinued and reintroduced again after next 4 weeks - patients will be switched to the other A or B group of probiotic/placebo arm. Patients will be administered with 4 capsules per day for 24 weeks (12 weeks for group A probiotic/placebo and 12 weeks for group B probiotic/placebo allowing 4 weeks washout between the group assignment)."
75330571|NCT04089280|Other|Placebo Comparator|Carrier material of Sanprobi Barrier-multispecies probiotic product, not containing bacterial strains,similar appearance as the probiotic
75470285|NCT05412641|Other|Intervention - Responsible Fatherhood Programming|Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management.
75470286|NCT05412589|Drug|mFOLFOX7+Camrelizumab+Apatinib|"Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Drug: Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle. Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Drug: Camrelizumab 200mg infusion on D1 for every 21 days Drug: Apatinib 250mg，po，qd for every 21 days"
75470287|NCT05412576|Drug|Lidocaine Hydrochloride 2% Injection Solution|Injectable
75470288|NCT05412576|Drug|0.9% NaCl|Injectable
75470289|NCT05412537|Other|MI|How to motivate people
75470290|NCT05412537|Other|CAU|consult as usual
75638145|NCT02610400|Combination Product|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
75638146|NCT02610400|Combination Product|rfMDA|"Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) > 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop"
75638147|NCT02743299|Device|Handivent Ventilator|CPR with use of a turbine-driven ventilator (Handivent)
75651814|NCT05461950|Procedure|Delayed umbilical cord clamping|Umbilical cord is clamped and cut minimum 60 seconds after delivery to facilitate placental transfusion. Placenta is delivered after cord clamping. Infants needing respiratory support or other stabilisation are transferred to a warmer in the adjacent room where a neonatal team is waiting.
75651815|NCT05429788|Drug|Low dose RLS103|3 mg CBD inhaled powder administered before public speaking challenge
75787008|NCT03221842|Drug|Placebo|Excipients of C1-INH plus albumin
75787009|NCT01203566|Procedure|LESS appendectomy|See under arms description
75787010|NCT01203566|Procedure|Conventional 3-port laparoscopic appendectomy|See under arms description
75787011|NCT01300442|Other|TEDS in COPD patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
75787012|NCT01300442|Other|TEDS in healthy patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
76079448|NCT01105312|Other|immunohistochemistry staining method|
76079449|NCT01105312|Other|laboratory biomarker analysis|
75470291|NCT05412485|Other|Robotic assisted gait training|Robotic assisted gait training is advanced technology used in the rehabilitation of neurological injuries and conditions like spinal cord injury, brain injury, stroke, multiple sclerosis, Parkinson's, cerebral palsy. It provides a repetitive task-specific motor training and modulates afferent input to spinal cord to generate rhythmic gait patterns that may be transformed to overground walking. The intensive repetitions of the rhythmic stepping movement during the training stimulates dependent plasticity and it may lead to brain reorganization. It facilitates cortical neural activities associated with motor control of walking.
75787013|NCT01300520|Device|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
75470292|NCT05412472|Drug|GC4419|45 mg IV infusion of GC4419 over 60 minutes.
75470293|NCT05412303|Other|data collection|age, gender, body weight, height, personal medical history, ASA score, EuroSCORE2, type of cardiac surgery, the preoperative left ventricular ejection fraction, the duration of CPB, the duration of aortic clamping, the need for intraoperative blood transfusion, norepinephrine, dobutamine, creatinine value, time to extubation (hours), any occurrence of complications during the stay in the ICU or in the hospital, and the LOS in the ICU and hospital
75787014|NCT05369000|Biological|LAVA-1207|In part 1 & part 2 LAVA-1207 will be administered via intravenous infusion.
75638148|NCT00813592|Drug|SOM230B|SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
75923233|NCT03510000|Drug|Empagliflozin 25mg|Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.
76079450|NCT01328496|Drug|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
76079451|NCT04488978|Drug|Irbesartan/Amlodipine|QID
75470294|NCT05412238|Dietary Supplement|micro-and macro-nutrients fortified sachets|Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months
75638149|NCT02743143|Behavioral|Exercise therapy|
75638150|NCT02743143|Other|Follow-up care as usual|
75638151|NCT02739633|Drug|Genexol-PM|125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
75638152|NCT02739633|Drug|Gemcitabine|1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
75638153|NCT02739477|Drug|Favipiravir|"Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results."
75638154|NCT02739399|Drug|Phenylephrine|Intravenous administration
75787015|NCT03819608|Device|real iTBS|Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
75787016|NCT03819608|Behavioral|real APT|APT-III is an attention processing training program
75787017|NCT03819608|Behavioral|placebo APT|computerized cognitive training
75787018|NCT03819608|Device|placebo iTBS|delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
75787019|NCT03364738|Biological|rhPTH(1-84)|Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.
75470295|NCT05412147|Dietary Supplement|RECO-18|4 pills daily, oral
75470296|NCT05412147|Dietary Supplement|Multi-vitamins|one tablet daily, oral
75470297|NCT05412043|Behavioral|Dance therapy|The dance group will attend choreo-based dance therapy which includes both cognitive training to remember the choreo's and motor training to execute them (with and without music). Each session will consist of a ten-minute warm up, dance training and a ten-minute cool down. The participants will be taught three choreographies, which will increase in difficulty level. 1) floor work on a slow rhythm with focus on proprioception, abdominal muscle strength, coordination and working memory. 2) slow paced with a group part and a canon part with focus on working memory, static and dynamic balance and strength. Furthermore, it will require dynamic balance, walking and cognition. 3) higher rhythm and will be danced with a cane which will require more speed, coordination and dual tasking.
75787020|NCT05622890|Drug|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
75787021|NCT00303329|Drug|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
75787022|NCT01300988|Drug|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
75330572|NCT04744701|Diagnostic Test|Hemochron Signature Elite Whole Blood Microcoagulation System|Bedside test of Activated Partial Thromboplastin Time
75923234|NCT03510000|Device|Single hormone artificial pancreas|Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.
75923235|NCT03510000|Behavioral|Meal strategies|Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.
75330573|NCT03187678|Drug|i.v. selexipag|Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
75330574|NCT03187678|Drug|oral selexipag (Uptravi)|Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
75330575|NCT03192826|Drug|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
75638155|NCT02742831|Behavioral|Intervention|"The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:~Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.~Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.~Problem solving techniques.~Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.~Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.~Reflection, repeat behavioral chain analysis. Update crisis plan."
75330576|NCT03192826|Drug|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
75330577|NCT03192826|Drug|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
75330578|NCT03285724|Device|Harpoon Artificial ePTFE Chords|The Harpoon Medical Transapical device is intended to be used to reduce the degree of degenerative mitral regurgitation by delivering and anchoring one or more ePTFE cords to the affected mitral valve leaflet(s) via a small left thoracotomy on the beating heart in patients with anterior, bi-leaflet or posterior prolapse.
75470298|NCT05412043|Other|Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability|The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests
75638156|NCT02742831|Other|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
75787023|NCT01300988|Drug|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
75787024|NCT01064999|Drug|Oxaliplatin|CRT:50mg/m2,IV,weekly*5 cycle CT: 130mg/m2,IV,d1,q 21 day
75923236|NCT03504930|Other|Impact of biotherapy on postoperative morbidity in ulcerative colitis|Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
75923237|NCT03362450|Other|Fetal ultrasound during the second or third trimester/ Postnatal surgery / Post mortem examination|Fetal ultrasound during the second or third trimester Postnatal surgery Post mortem examination
75923238|NCT03365492|Device|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
75923239|NCT03507270|Diagnostic Test|FABP|Assessment of changes in FABP concentrations
75470299|NCT05412017|Diagnostic Test|Hepatitis C Point of Care Testing and Treatment|Pharmacy led hepatitis C point of care testing
75330579|NCT03287674|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
75330580|NCT03287674|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
75330581|NCT03287674|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
75330582|NCT03287674|Drug|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
75787025|NCT01064999|Drug|Capecitabine|CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
75787026|NCT01064999|Radiation|Radiotherapy|High intensity group:55Gy Low intensity group:50Gy
75787027|NCT01064999|Procedure|Surgery|Lower anterior resection or abdominoperineal resection
75787028|NCT03818048|Drug|Propofol|after inicial bolus of propofol, remained sedated with propofol infusion (1-2 mg/kg/min)
75787029|NCT03818048|Drug|Sevoflurane|after inicial bolus of propofol, remained sedated by inhalation with sevoflurane at a concentration of 2 vol% through a nasal cannula with an oxygen flow.
75787030|NCT01325519|Other|video decision aid|video
75787031|NCT05614388|Diagnostic Test|COVID-19 Self testing and related messaging|Provisioning of voluntary, free self-testing for COVID-19 (approved and validated in the country) and related Information, Education and Communication (IEC) messages
75470300|NCT05411952|Other|Medical nutrition therapy and carbohydrate counting education|Children and their mothers have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
75787032|NCT01301924|Drug|Meglumine antimoniate|"Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine."
75638157|NCT02743065|Device|HepaSphere with 50-75mg Doxorubicin|HepaSphere with 50-75mg Doxorubicin
75638158|NCT06179459|Procedure|Endoscopic management of pancreatic fluid collections|Patients with pancreatic fluid collections will be undergoing EUS-guided drainage and/or endoscopic necrosectomy
75638159|NCT06179433|Procedure|Root canal treatment|Two-visit root canal treatment will be performed.
75638160|NCT06179433|Procedure|Regenerative endodontic procedure|Regenerative endodontic procedure with i-PRF and blood clot induction will be performed.
75638161|NCT06179420|Other|total cumulative gonadotrophin usage|total dosage in IU
75787033|NCT00329849|Biological|Meningococcal ACWY-CRM conjugate vaccine|MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
75787034|NCT00329849|Biological|Meningococcal ACWY-PS polysaccharide vaccine|MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
75787035|NCT05655806|Drug|Aminophylline bolus then infusion|half an hour before discontinuation of isoflurane
75787036|NCT05655806|Drug|aminophylline bolus|after discontinuation of isoflurane
75787037|NCT05655806|Drug|normal saline|given as placebo
75787038|NCT02934178|Biological|Shigella sonnei Strain WRSS1 Vaccine|Live attenuated, oral Shigella WRSS1 vaccine
75787039|NCT02934178|Biological|Placebo|Sterile saline solution
75787040|NCT03983759|Drug|sintilimab maintenance|the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
75787041|NCT01300598|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
75787042|NCT01300676|Drug|Tualang honey|"This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia."
75923240|NCT03358082|Drug|Tacrolimus 0.03% Ointment|topical tacrolimus 0.03% twice daily for 6 months
75923241|NCT03358082|Drug|Hydrocortisone Acetate 1% Ointment|hydrocortisone acetate 1% ointment twice daily for 6 months
75470301|NCT05411952|Other|Medical nutrition therapy and carbohydrate counting education|Only children have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
75470302|NCT05411952|Other|No intervention|Control group didn't receive any intervention by trained dietitian. Furthermore they continued their routine health controls.
75470303|NCT05411913|Drug|GoodFOR Pain|GoodFOR Pain is a FDA registered topical analgesic.
75470304|NCT05411913|Drug|Icy Hot|a FDA OTC registered topical analgesic.
75638162|NCT06179407|Drug|MK-6552|Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
75638163|NCT06179407|Drug|Placebo|In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
75638164|NCT06179355|Procedure|manual astigmatic keratotomy|manual astigmatic keratotomy using a diamond knife
75638165|NCT06179355|Procedure|femtosecond laser astigmatic keratotomy|astigmatic keratotomy using femtosecond lase
75638166|NCT06179342|Diagnostic Test|Multiple-Breath-Washout|One additional diagnostic test is performed using the Multiple-Breath-Washout technology
75787043|NCT03814694|Dietary Supplement|CRHP Diet|Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat
75787044|NCT03814694|Dietary Supplement|CD Diet|Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
75787045|NCT00329303|Drug|Certolizumab Pegol (Cimzia®)|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Dose and Administration details :~2 x 1 mL Certolizumab Pegol at Week 0, followed by~1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10~2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10"
75923242|NCT03358004|Drug|Vinorelbine Tartrate|Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A
75923243|NCT03358004|Drug|Capecitabine 500 MG|Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
75470305|NCT05411913|Drug|Tiger Balm|a FDA OTC registered topical analgesic
75470306|NCT05411913|Drug|Bengay|a FDA OTC registered topical analgesic.
75470307|NCT05411913|Drug|CBD Clinic Muscle and Joint Pain Relief Ointment|a non FDA registered topical analgesic.
75470308|NCT05411913|Drug|CBD FX CBD Muscle and Joint Cream: Cooling Formula|a non FDA registered topical analgesic.
75638167|NCT06179329|Procedure|Coronary artery bypass graft|Randomization will be performed for stratification according to the target coronary arteries and the randomly determined block size from 4 to 6. The randomization result will be delivered in a sealed envelope in the operating room (before the time out) for one of the two drawn strategies.
75638168|NCT06179316|Procedure|Robot Assisted Radical Prostatectomy|Performing radical prostatectomy operation using robotic equipment while preserving bilateral nerve bundles
75787046|NCT03806816|Dietary Supplement|Melatonin|5 daily enteral doses of melatonin 10 mg/kg. (=2 ml/kg)
75923244|NCT03507192|Device|Muscle relaxation using full body massage machine|Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
75923245|NCT03509922|Drug|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
75638169|NCT06179277|Device|PrefGel® + Emdogain®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
75638170|NCT06179277|Device|PrefGel®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
75638171|NCT06179199|Device|SOOMA™ tDCS™|The SOOMA™ tDCS™ device is designed to treat chronic pain, with a stimulation current of 2milliampere and a duration of 20 minutes
75638172|NCT06179173|Other|HIIT-RCE|High-intensity interval training on semi-recumbent cycle ergometer
75638173|NCT06179173|Other|Conventional physiotherapy|Conventional physiotherapy
75638174|NCT06179147|Other|cervical traction|Traction of the uterine cervix applied in the study; It is the process of pulling the anterior and posterior lips of the cervix towards the intraoitus, downwards and backwards for approximately 90 seconds using overpens. Traction is applied until the cervix reaches the level of vaginal introitus. It is a cost-effective, new, simple intervention with no reported adverse effects.
75638175|NCT06179134|Behavioral|Goal Management Training|"The main objective of GMT intervention are to train individuals to periodically STOP what they are doing, attend to task goals, evaluate their performance and monitor or check outcomes as they proceed (Levine & Stamenova, 2017)."
75923246|NCT03509922|Drug|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
75923247|NCT03365336|Drug|polyherbal formulation|Each Flu Care consist of 350 mg of polyherbal component
75330583|NCT03287674|Drug|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
75330584|NCT03287674|Drug|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
75470309|NCT05411913|Drug|Essential Wholesale Muscle Gel|a non FDA registered topical analgesic.
75651816|NCT05429788|Drug|High dose RLS103|6 mg CBD inhaled powder administered before public speaking challenge
75787047|NCT03806816|Other|PLACEBO group|5 daily enteral doses of placebo 2 ml/kg
75787048|NCT01301222|Drug|Inj. Octreotide|100 mcg subcutaneously for 5 days
75923248|NCT03365336|Drug|Oseltamivir 75mg|All the participant has to take 75 mg of oseltamivir for five days.
75651817|NCT05429788|Drug|placebo inhaled dry powder|placebo inhaled powder administered before public speaking challenge
75923249|NCT03509844|Behavioral|Psychotherapy|Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
75923250|NCT03362216|Drug|Compound Methyl Salicylate Liniment|Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
75923251|NCT03362216|Drug|Diclofenac Sodium Liniment|Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
75923252|NCT03365258|Dietary Supplement|Trophic feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0->Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
75923253|NCT03365258|Dietary Supplement|volume-based feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0->Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
75923254|NCT02303496|Biological|Platelet Rich Plasma Cream|Cream Containing Platelet Rich Plasma and Oleaginous Base
75330585|NCT00634244|Drug|alvocidib|Given IV
75330586|NCT00634244|Drug|mitoxantrone hydrochloride|Given IV
75330587|NCT00634244|Drug|carboplatin|Given IV
75330588|NCT00634244|Drug|cytarabine|Given IV
75330589|NCT00634244|Drug|sirolimus|Given PO
75330590|NCT00634244|Drug|etoposide|Given IV
75330591|NCT00634244|Drug|topotecan hydrochloride|Given IV
75470310|NCT05411913|Drug|Extract Labs Muscle Cream|a non FDA registered topical analgesic.
75651818|NCT05411744|Drug|1 month Rifapentine, Isoniazid and Vitamin B6|Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.
75787049|NCT03817658|Drug|SHR-1210|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight <50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
75787050|NCT03817658|Drug|Placebo|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight <50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
75923255|NCT02303496|Biological|Placebo - Sterile Water Cream|Cream Containing Sterile Water and Oleaginous Base
75923256|NCT03362138|Device|dermoscopy|Solely after the dermatologist has decided to biopsy a lesion and sent the patient to biopsy, a dermoscopic image is captured by a camera attached to a dermoscope.
75923257|NCT03507114|Behavioral|Rumination-Focused CBT (RFCBT)|RFCBT consists of six online modules that include psycho-education, mood diaries, on-line experiential exercises using audio-recordings & vignettes of participants experiences of the therapy.
75923258|NCT03123536|Device|Point-of-care Ultrasound|Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
75923259|NCT03504696|Other|Non-interventional|Non-interventional
75330592|NCT03194698|Device|Intense Pulsed Light Treatment (IPL)|IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.
75787051|NCT01301300|Device|Disinfecting Cap|Replace standard practice with using the disinfecting cap
75787052|NCT02532569|Biological|Japanese encephalitis vaccine|Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
75638176|NCT06179121|Other|DNA test for screening HLA-DQ2 and DQ8 from dried blood spots to early detect Celiac Disease|Phase 1 and 2: After blood collection (in combination with regular care) and informed consent, a blood droplet obtained by an additional fingerprick (Phase 1 and just an extra droplet from an existing finger prick for Phase 2) will be deposited on filter paper S&S 903™ (Schleicher and Schuell). DNA will be isolated using the QIAamp method designated for this purpose from dried blood spots (Qiagen). The results of the HLA-DQ2 and DQ8-typing using the dried blood spots will be compared with the results of the traditional HLA-typing. Factors that may influence the quality of the material will be taken into account in the validation process.
75638177|NCT06179095|Other|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI just before the intrauterine device insertion procedure, and again with STAI after the procedure.
75638178|NCT06179069|Drug|ZL-1310|Drug: ZL-1310
75638179|NCT06179056|Diagnostic Test|assess the possible role of Salicylic acid, Isotretinoin, and N-acetylcysteine in improving the susceptibility of C. acne for Azithromycin and Doxycycline.|"Microbiological samples were collected from all patients for:~Isolation of C. acnes~Antibiotic susceptibility testing for C. acnes isolates against the most commonly used antibiotics in the treatment of acne(Azithromycin and Doxycycline) in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine~Testing biofilm forming ability of C. acnes isolates in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine"
75638180|NCT06179017|Other|Experimental group:Intervention Group|Intervention Group:Interventionist choose the optimal endovascular treatment (EVT) strategy and device based on the patient's condition and local guidelines. The patient will receive the best medical treatment according to the local guidelines.
75638181|NCT06179017|Other|Control group:best medical treatment|Best medical treatment:Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.
75787053|NCT03817424|Drug|VIB7734|Participants will receive VIB7734 via injection.
75787054|NCT03817424|Drug|Placebo|Participants will receive placebo matching to VIB7734 via injection.
75787055|NCT04535596|Other|Exercise|12 week long strength training exercises for knee
75638182|NCT06179004|Drug|Liposomal bupivacaine|The medication liposomal bupivacaine of the dose of 133 mg in the form of a supraclavicular single shot injection perineural as a one-time administration
75638183|NCT06179004|Drug|Bupivacaine Hydrochloride|The medication plain bupivacaine of the concentration of 0.25% will be administered as a perineural injection in the form of a one-time supraclavicular single shot injection.
75787056|NCT01302002|Drug|Metformin Pre-Surgery|500 mg tablet, taken twice a day for 3 weeks
75787057|NCT03817346|Drug|GT-002|Single ascending dose
75787058|NCT03817346|Drug|Placebo oral capsule|Comparator single ascending dose
75787059|NCT03216850|Device|Sublingual microcirculation assessment|Non-invasive investigation of the endothelial glycocalyx in the sublingual microcirculation.
75330593|NCT03194698|Procedure|Meibomian Gland Expression|Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
75330594|NCT01922804|Dietary Supplement|K2 vitamin|K2 vitamin tablet
75787060|NCT03814772|Procedure|Liver transplant|blood transfusion
75787061|NCT01303250|Drug|balanced 6% hydroxyethylstarch 130/0.4|Fluid administration and optimization based on cardiac output findings during surgery.
75787062|NCT01303250|Drug|balanced crystalloid|Fluid administration and optimization based on cardiac output findings during surgery.
75330595|NCT01922804|Dietary Supplement|Placebo|Placebo tablets
75787063|NCT01303328|Drug|C1|Local application of the experimental gel or placebo gel.
75787064|NCT03817034|Drug|Multimodal analgesia|Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
75787065|NCT03814616|Drug|Pyronaridine tetraphosphate 180mg:artesunate 60mg|ACT
75787066|NCT03814460|Diagnostic Test|Assessment of Tone, Pain and Thickness|Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles
75787067|NCT01303484|Dietary Supplement|Bi2muno® GOS|5.5g/day for 10 weeks
75787068|NCT01303484|Dietary Supplement|Maltodextrin|5.5g daily for 10 weeks
75787069|NCT00302159|Procedure|adjuvant therapy|
75787070|NCT00302159|Drug|Temozolomide|Orally 75mg/m^2 first day of radiation until completion. Restart 4 weeks post radiation.
75787071|NCT00302159|Drug|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
75923260|NCT03357770|Drug|mesenchymal stem cells|we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature [5]. The low-dose is 1 × 10^7cells / 3mL, the medium-dose is 5 × 10^7cells / 3mL and the high dose is 1 × 10^8cells / 3mL
75330596|NCT03289858|Drug|Exparel|Subcutaneous injection at conclusion of surgical fixation of hip fracture
75330597|NCT03289858|Drug|Sodium Chloride|Saline Injection
75787072|NCT00302159|Radiation|Radiation therapy|External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
75787073|NCT03814226|Other|Evaluation of headache inducing capabilities of PACAP38|We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
75787074|NCT03804320|Other|Active Surveillance|
75787075|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 24 weeks
75330598|NCT04396418|Behavioral|Education|Randomization between two groups at site level. One cluster with education and one without.
75638184|NCT06178978|Device|KalEYEdoscope|"KalEYEdoscope is a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration. In the future, developing such a device for home monitoring of macular degeneration may increase access to timely treatment to prevent vision loss.~This study was conducted at the Kellogg Eye Center in Ann Arbor. Participants in the outpatient setting who agreed to enroll in the study tested the device and provided user feedback via a questionnaire as well as completed questionnaires about their visual function. This study assessed the usability, comfort, duration, ergonomics, and ease of use of the device among AMD patients in a single session."
75638185|NCT06178965|Procedure|Incisional Hernia Repair by Abdominal Wall Component Release with Contemporary Onlay Mesh Fixation|patients with incisional hernia will be operated by hernia reduction and sac closure followed by placement of onlay mesh after creating suitable flaps.
75330599|NCT00375856|Device|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
75330600|NCT03418714|Drug|Salvinorin A|Salvinorin A, blinded doses
75787076|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.0 mcg/kg QW SC for 24 weeks
75787077|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 16 weeks
75330601|NCT01922960|Other|micro-imaging|micro-imaging
75330602|NCT03153488|Radiation|MRI|All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
75330603|NCT03194776|Drug|LLG783|LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
75330604|NCT03194776|Drug|Placebo|Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
75787078|NCT00302081|Drug|ribavirin (SCH 18908)|800-1200 mg daily for 24 weeks
75787079|NCT00302081|Drug|ribavirin (SCH 18908)|800-1200 mg daily for 16 weeks
75787080|NCT00302003|Radiation|radiation therapy|Undergo radiation therapy
75787081|NCT00302003|Drug|doxorubicin hydrochloride|Given IV
75330605|NCT03421210|Drug|Nicotine patch|Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.
75330606|NCT01025791|Drug|MK-8266 0.1 mg|Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
75787082|NCT00302003|Drug|vincristine sulfate|Given IV
75787083|NCT00302003|Drug|prednisone|Given orally
75787084|NCT00302003|Drug|cyclophosphamide|Given IV
75787085|NCT00302003|Drug|ifosfamide|Given IV
75787086|NCT00302003|Drug|vinorelbine tartrate|Given IV
75787087|NCT00302003|Drug|dexamethasone|Given IV
75787088|NCT00302003|Drug|etoposide phosphate|Given IV
75787089|NCT00302003|Drug|cisplatin|Given IV
75330607|NCT01025791|Drug|MK-8266 1.0 mg|MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
75330608|NCT01025791|Drug|Placebo|Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
75330609|NCT03195010|Biological|Platelet Transfusion|Undergo lower dose platelet transfusion
75330610|NCT03195010|Biological|Platelet Transfusion|Undergo higher dose platelet transfusion
75787090|NCT00302003|Drug|cytarabine|Given IV
75787091|NCT00302003|Biological|filgrastim|Given IV or subcutaneously
75787092|NCT00036270|Drug|exemestane (Aromasin)|exemestane, orally, 25 mg, for 5 years
75787093|NCT00036270|Drug|tamoxifen + exemestane|tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
75787094|NCT03951324|Other|Interobserver agreement or Interrater agreement|Interobserver agreement or Interrater agreement using 9 visual criteria for diagnosing VLE clips that feature indeterminate biliary or pancreatic duct strictures
75787095|NCT01097382|Drug|ZOLPIDEM|Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
75787096|NCT00301067|Dietary Supplement|Calcitriol|The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle
75787097|NCT00301067|Drug|Temozolomide|The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
75923261|NCT02307240|Drug|CUDC-907|CUDC-907 oral with meals.
75923262|NCT03365180|Device|Starter Kit Algorithm|Long acting insulin titration to target
75923263|NCT02307396|Drug|Olanzapine|
75923264|NCT02307396|Drug|Amisulpride|
75923265|NCT02307396|Drug|Risperidone|
75787098|NCT01325285|Device|RespirAct|"Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each:~Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)~10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)~20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)~Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)~250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)~500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)~Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)"
75638186|NCT06178939|Procedure|control group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.
75638187|NCT06178939|Procedure|intervention group|For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
75638188|NCT06178926|Drug|Propofol|Propofol was IV infused 1.0-1.5mg/Kg and then maintenance at 1.0-2.0mg/Kg/h
75330611|NCT03423082|Drug|18F fluciclovine|Each subject will receive one IV dose of 18F fluciclovine for PET scanning
75330612|NCT03423082|Device|18F fluciclovine PET|Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
75787099|NCT02530086|Procedure|Nasogastric tube placement|Placement of a Nasogastric tube
75638189|NCT06178926|Drug|Ciprofol|Ciprofol was IV infused 0.2- 0.3mg/Kg and then maintenance at 0.2-0.3mg/Kg/h
75787100|NCT02530086|Procedure|No Nasogastric tube use|No placement of a Nasogastric tube
75787101|NCT03979859|Drug|WCK 4873|
75787102|NCT03979859|Drug|Placebo Oral Tablet|
75787103|NCT03955458|Drug|EXPAREL|FICB with EXPAREL + Bupivacaine HCL (single dose)
75923266|NCT02307396|Drug|Haloperidol|
75923267|NCT02307396|Drug|Quetiapine|
75330613|NCT04736290|Other|NLR|Calculation of NLR
75330614|NCT04736290|Other|PLR|Calculation of PLR
75330615|NCT03294850|Procedure|Bariatric surgery|Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied
75330616|NCT03294850|Device|HepQuant SHUNT Dual Cholate Liver Diagnostic Kit|For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.
75330617|NCT00996931|Drug|lenalidomide|2.5 mgs per day orally for 12 weeks
75330618|NCT03295630|Device|Accelerometer|Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count.
75330619|NCT01026805|Device|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
75330620|NCT00997555|Procedure|bronchoscopy|Scheduled bronchoscopy.
75330621|NCT03197038|Behavioral|Partially supervised home-based walking exercise|Participants will be asked to exercise at home by walking at a moderate intensity. Each participant will receive an exercise prescription. Participants will receive a heart rate monitor. The heart rate monitors will be used to achieve a desired exercise intensity and to monitor adherence levels. The participants will receive biweekly to weekly phone calls, and monthly in person meetings will be used to address any barriers, provide encouragement, and progress the exercise.
75638190|NCT06178913|Other|Exercise intervention|The exercise intervention method is a circuit training method that combines strength training and aerobic exercise forms and consists of a total of 12 movements. Performing movements 1 to 12 in order is 1 set. After completing the set, when the heart rate returns to the plateau (less than 59% of maximum heart rate), proceed to the next set, for a total of 3 sets.
75638191|NCT06178887|Diagnostic Test|imaging|cardiac angioRMN
75638192|NCT06178874|Drug|Insulin Glargine|hyperglycemic control
75638193|NCT06178874|Drug|Insulin Degludec|hyperglycemic control
75787104|NCT03955458|Drug|Ropivacaine|FICB with continuous infusion of ropivacaine
75787105|NCT03955458|Drug|Bupivacaine Hydrochloride|FICB with EXPAREL + Bupivacaine HCL (Single dose)
75923268|NCT02307396|Drug|Perphenazine|
75923269|NCT02307396|Drug|Sulpiride|
75638194|NCT06178874|Drug|Insulin regular|hyperglycemic control
75638195|NCT06178861|Device|Group wearing a radiotherapy bra|Group wearing a radiotherapy bra
75787106|NCT03983681|Behavioral|Strategy-Based Training to Enhance Memory (STEM)|Protocol designed to improve memory functioning in individuals with neurological injuries administered for 4 weeks (8 training sessions).
75787107|NCT03983681|Behavioral|Placebo control exercises|Placebo control memory exercises will be administered for 4 weeks (8 training sessions).
75787108|NCT00007020|Drug|Cholic Acids|10-15 mg/kg body weight/day taken orally.
75923270|NCT02307396|Drug|bromperidol|
75923271|NCT02307396|Drug|Zuclopenthixol|
75923272|NCT02307396|Drug|Thioridazine|
75923273|NCT02307396|Drug|Paliperidone|
75923274|NCT02307396|Drug|Ziprasidone|
75923275|NCT02307396|Drug|Benperidol|
75923276|NCT02307396|Drug|Fluspirilene|
75923277|NCT02307396|Drug|Pimozide|
75923278|NCT02307396|Drug|Perazine|
75923279|NCT02307396|Drug|Fluphenazine|
75923280|NCT02307396|Drug|Flupentixole|
75923281|NCT02307396|Drug|Sertindole|
75923282|NCT03357692|Procedure|all on four implant rehabilitation|implant insertion after piezoelectric site preparation for trans-sinusal implants
75923283|NCT04523636|Device|Splinting|Pre-fabricated or custom resting hand splints
75638196|NCT06178848|Drug|propofol group|During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
75923284|NCT03509688|Drug|entecavir+resveratrol|entecavir+resveratrol
75923285|NCT03509688|Drug|Entecavir|Entecavir
75923286|NCT03509688|Drug|entecavir+thymosin α1|entecavir+thymosin α1
75638197|NCT06178848|Drug|remimazolam group|The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
75638198|NCT06178835|Drug|Erythropoietin|500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
75638199|NCT06178835|Drug|normal saline|The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
75638200|NCT06178822|Other|No intervention|There is no intervention
75638201|NCT06178796|Device|Dental implant|Dental implant placement
75787109|NCT03955536|Other|Group A: Group routine cardiac rehabilitation program (RCRP)|"Patient education, Chest Physiotherapy, Abdominal and chest breathing, Bronchial hygiene techniques, Segmental breathing exercises, Triflow, exercise and mobilization,graduated exercise, positioning, active joint movement, moving inside bed, sitting at the edge of the bed, transfer from bed to chair, standing walking program, up and down stairs.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
75923287|NCT03365024|Behavioral|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
75923288|NCT03365024|Behavioral|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform
75923289|NCT03132402|Diagnostic Test|ELISA validation|ELISA validation of hypersensitive rapid diagnostic test results for detection of P. falciparum
75923290|NCT03361904|Procedure|Colonoscopy|Total colonoscopy : All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were: patients scheduled for partial colonoscopy, interventional colonoscopy (for stent insertion, stenosis dilation).
75923291|NCT02307474|Radiation|Stereotactic Radiosurgery|3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
75923292|NCT02307474|Drug|Pazopanib Hydrochloride|Given PO starting at 800mg to be systematically altered following drug related toxicities.
75923293|NCT02518880|Other|Parabolic flight|
75923294|NCT02518880|Other|plasma volume measurements|
75923295|NCT03504618|Drug|FOLFOXIRI|"Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day"
75330622|NCT03197038|Behavioral|Control|Participants will be asked to exercise at home by walking at a moderate intensity. The participants will receive biweekly phone calls, but will not receive a heart rate monitor, individual exercise prescription, or meet with the investigators monthly.
75330623|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
75330624|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
75923296|NCT02518412|Other|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
75923297|NCT02518412|Other|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
75638202|NCT06178731|Device|rTMS|3 min rTMS delivery with iTBS to the left DLPFC
75638203|NCT06178731|Other|Virtual Reality|2-15 min VR viewing, 15 min descriptive and imaginal recounting
75638204|NCT06178718|Drug|TNP-2092|The drug will be administered once in each group.
75638205|NCT06178718|Drug|Placebo|The Placebo will be administered once in each group.
75638206|NCT06178705|Behavioral|Helpful Parenting Program Intervention|8-10 sessions with 60 minutes duration once in a week will be conducted with the parents in group and one-on-one setting. Helpful parenting program would be based on social learning theory, behavior modification and couple counseling. The program will be used as an intervention strategy with parents to built insight about their child's emotional & behavioral issues. Different strategies to teach parenting skills will also be used as an intervention. Further more, this program will target parents' psychological distress and couples' problematic conflicts regarding parenting
75638207|NCT06178692|Diagnostic Test|Validation of miRNA-serum signatures associated with IDH1 status|Validation of miRNA-serum signatures associated with IDH1 status and prognosis, as reliable, specific and sensitive circulating diagnostic biomarkers also useful to improve prognostic stratification of patients.
75638208|NCT06178666|Biological|BCG|Three dose levels of intradermal BCG
75330625|NCT00634088|Drug|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
75787110|NCT03955536|Other|Group B: Group RCRP and inspiratory muscle training|"use of additional virtual reality goggles in the routine cardiac rehabilitation program Virtual reality glasses installed in the patient will feel the best way to feel an environment.~Virtual reality glasses are planned to be used 15 minutes by increasing the usage period.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
75638209|NCT06178653|Other|Pulmonary Rehabilitation|Pulmonary rehabilitation consists of diaphragmatic, pursed-lip, and segmental breathing techniques, and also included inspiratory muscle training (will adjust 30% of maximal inspiratory pressure value)
75923298|NCT02303652|Procedure|Radiofrequency maze procedure|RF energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In all patients a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System®, Medtronic Inc, Minneapolis, MN, USA).
75923299|NCT02303652|Procedure|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography (Philips ultrasound system (iE33®, Andover, MA, USA)) at 3,6,12,24 months in order to specifically monitor the evolution of cardiac chambers dimensions and systolic performance and to record left and right atrial contractility presence.
75638210|NCT06178653|Other|Trunk Control Training|Trunk Control Exercises will be based on the neurodevelopmental process. Exercises will progressively include activities such as stretching, turning, etc. while sitting on different surfaces (firm/soft).
75638211|NCT06178627|Drug|Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.|Different amphotericin B dosage
75638212|NCT06178627|Drug|Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.|Different amphotericin B dosage
75638213|NCT06178601|Drug|RC48-ADC|RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, combined with cadonilimab（AK104）
75638214|NCT06178601|Drug|AK104|AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）combined with RC48-ADC
75638215|NCT06178588|Procedure|Biopsy|Undergo tumor biopsy
75787111|NCT03955536|Other|Group C: Group RCRP and virtual reality application|"nspiratory muscle training with Threshold for routine cardiac rehabilitation Training intensity~- 30% of the maximum measured inspiratory pressure per week (15 min.). Every 10 breaths after rest.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
75787112|NCT03952884|Behavioral|Resistance Exercise|Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
75638216|NCT06178588|Procedure|Biospecimen Collection|Undergo blood sample collection
75638217|NCT06178588|Procedure|Computed Tomography|Undergo PET/CT scan
75638218|NCT06178588|Procedure|Magnetic Resonance Imaging|Undergo MRI
75923300|NCT03357458|Behavioral|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
75923301|NCT02303730|Drug|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose<2.9 mmol/l or < 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
75923302|NCT02303730|Drug|insulin glargine|"The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c <8% use 0.1 -0.2 U/kg per day;HbA1c >8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) > 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose <70mg/dl（3.9mmol/l）: 10%-20%; blood glucose <40mg/dl（2.2mmol/l）: 20%-40%."
75923303|NCT04524728|Drug|Palbociclib|tablets
75923304|NCT04524728|Drug|Letrozole 2.5mg|tablets
75923305|NCT04524728|Drug|Fulvestrant|intramuscolar injections
75923306|NCT04523792|Drug|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
75330626|NCT00634088|Drug|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
75638219|NCT06178588|Procedure|Positron Emission Tomography|Undergo PET/CT
75638220|NCT06178588|Biological|Sacituzumab Govitecan|Given IV
75651819|NCT05392556|Dietary Supplement|Probiotic|Cerebiome (Lallemand Health Solutions): probiotic supplement containing Bifidobacterium longum R0175, Lactobacillus helveticus R0052, and maltodextrin. Dosing: Oral, 3.6 g/d containing 3x10^9 CFU/d (powder form)
75651820|NCT05392556|Dietary Supplement|Prebiotic|Bimuno-GOS (Clasado Biosciences): Dosing: Oral; 3.6 g/d containing 2.75 g active GOS/d (powder form)
75651821|NCT05392556|Other|Placebo|Maltodextrin 3.6 g/d (powder form)
75787113|NCT03952884|Behavioral|No Resistance Exercise|Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
75330627|NCT01027195|Device|Bipolar Radiofrequency (Aquamantys 6.0)|
75787114|NCT03952884|Dietary Supplement|Leucine|Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
75638224|NCT06178536|Procedure|Bone Consumption|The surgery will be done using a bone consumption protocol
75638225|NCT06178536|Procedure|Bone expansion|implants will be placed after a bone expansion protocol
75638226|NCT06178523|Drug|Clomiphene Citrate.|Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).
75638227|NCT06178523|Drug|Sildenafil Citrate|Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle (Group-A).
75638228|NCT06178523|Procedure|Intrauterine Insemination|IUI (Group-B).
75638229|NCT06178510|Device|INTELLiVENT-ASV.|INTELLiVENT-ASV® is a closed-loop ventilation mode that automatically adjusts respiratory rate and tidal volume according to the oxygen and ventilatory patient needs
75638230|NCT06178471|Diagnostic Test|Transesophageal Echocardiography|The use of transesophageal echocardiography to diagnose cardiopulmonary failure in ICU patients with suboptimal or inadequate transthoracic echocardiography examinations.
75787115|NCT03952884|Dietary Supplement|Dileucine|Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
75787116|NCT01097538|Other|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
75787117|NCT01097538|Other|Total body recumbent stepper training|Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
75787118|NCT03955224|Device|Basic Oral Care + active LLLT|"Compliance with the Basic Oral Care Associated with~Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
75787119|NCT03955224|Other|Basic oral Care + inactive LLLT|"Compliance with the Basic Oral Care Associated with~Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
75787120|NCT03955224|Other|Basic Oral Care|Compliance with the Basic Oral Care only
75787121|NCT00300755|Drug|pantoprazole sodium enteric-coated spheroid|pediatric spheroids taken daily x 8 weeks
75330628|NCT01027195|Device|Standard Bovie Electrocautery|
75330629|NCT00998023|Device|Mynx Vascular Closure Device|Comparison of two different vascular closure devices.
75330630|NCT00998023|Device|AngioSeal Vascular Closure Device|Comparison of two different vascular closure devices.
75330631|NCT03428230|Drug|30 mg Paracetamol 3% (1 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
75787122|NCT00033540|Drug|capecitabine|650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
75787123|NCT00033540|Drug|gemcitabine hydrochloride|1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
75787124|NCT00300365|Drug|Pioglitazone|Pioglitazone, initially 30 mg, then titrated to 45 mg/day
76079452|NCT04464486|Other|SCH Intervention|In addition to receiving usual care from their oncologist and staff, the SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants in the intervention receive automated self-management support messages for symptoms reported. In addition, COVID-19 symptoms and poorly controlled or worsening cancer symptoms will generate alerts. Based on preset thresholds, alerts automatically generate immediately from the patient's daily call data. The study nurse practitioners (NPs) monitor alerts. The NPs provide follow-up care using the guideline based SCH symptom clinical decision support system. The NPs log into the SCH Alert and Call Data website which displays all of the patients who have called that day and met an alert threshold. The NP calls the patient, delivers symptom management care by phone, and documents care in the patients' electronic health records.
75470311|NCT05411900|Drug|BoNT-A|"A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
75923307|NCT02303808|Device|INHALATION WITH PEP DEVICE (Acapella Duet)|Intervention will be performed during 5 consecutive days. The performance order of both arms will be randomized.
75923308|NCT03364946|Other|No intervention|No intervention, observational study
75923309|NCT02312232|Drug|levodopa, carbidopa, ODM-104|
75923310|NCT04524884|Drug|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
75923311|NCT04524884|Drug|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
75330632|NCT03428230|Drug|60 mg Paracetamol 3% (2 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
75330633|NCT03428230|Drug|90 mg Paracetamol 3% (3 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
75638231|NCT06178458|Other|No intervention|To collect data of pain score and opioid consumption of index and previous cesarean delivery
75638232|NCT06178445|Drug|SOC plus trastuzumab and pembrolizumab|SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab
75638233|NCT06178432|Genetic|CRG003 injection|The dose of CRG003 will be calculated according to the participant's weight with single intravenous infusion.
75638234|NCT06178419|Device|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
75638235|NCT06178419|Device|sham-RIC|Sham-RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The sham RIC protocol includes five cycles of 5-min inflation to 60mmHg and 5-min deflation.
75470312|NCT05411900|Drug|Placebo|"Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
75470313|NCT05411874|Drug|Chidamide|5mg po biw for 24 weeks
75923312|NCT03509610|Other|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
75638236|NCT06178406|Behavioral|dysmenorrhea|Dysmenorrhea, defined as painful menstrual cramps of uterine origin, is the most common gynecological condition among women of reproductive age.
75787125|NCT00300365|Other|Placebo|Pioglitazone placebo
75787126|NCT00300365|Drug|Niacin ER|Niacin ER 2.0 g/day
75787127|NCT00300365|Drug|Aspirin|asprin 325 mg/day
75787128|NCT03980015|Other|antibiotic treatment|Patients were treated with: ceftriaxone intravenously 2 g OD for 14 days or doxycycline orally 100 mg bid for 10 to 14 days or cefuroxime axetil orally 500 mg bid for 14 days or amoxicillin orally 500 mg tid for 14 days
75787129|NCT01101048|Drug|Placebo|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
75787130|NCT01101048|Drug|AMG 167|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
75787131|NCT01095588|Drug|200 mg Avanafil|2 X 100mg tablets avanafil
75638237|NCT06178354|Procedure|Cryosurgery|Undergo focal cryotherapy ablation
75923313|NCT02307708|Device|8° incline shoe|"Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).~The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
75923314|NCT02307708|Other|kinesitherapy|Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
75330634|NCT03428230|Drug|Placebo, 0.9% saline solution|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
75330635|NCT03428230|Drug|NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection|Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
75330636|NCT01027819|Device|Mobile bearing|Mobile bearing in total knee arthroplasty
75330637|NCT01027819|Device|Fixed bearing|Fixed bearing in total knee arthroplasty
75330638|NCT02163967|Device|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
75330639|NCT03296800|Drug|Bexagliflozin|Bexagliflozin 20 mg, tablet; qd
75470314|NCT05411874|Drug|HD-DXM|40mg po qd for 4days
75787132|NCT01095588|Drug|Placebo|2 tablets
75787133|NCT03951246|Other|Cognitive and Motor Training|"In the first phase of the trial, all participants (patients and healthy children) will complete cognitive and motor functions assessment.~Then the sample of patients who have cognitive/motor impairment will be randomized to an either Intervention or Control group.~In the second phase of the trial, survivors in the Intervention Group will receive 6 sessions of cognitive and motor training during two weeks, and survivors in Control Group will undergo …..~After this treatment phase, motor and cognitive functions assessment will be conducted in all patients once again.~In the third phase, the Control Group will be provided the active intervention (i.e. 6 sessions of cognitive and motor training during two weeks), while the Intervention Group engages in passive reading.~After this, motor and cognitive functions assessment will be carried out in all patients once again."
75470315|NCT05411809|Drug|drug adjuvant therapy|The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
75470316|NCT05411796|Device|Tampax menstrual cup|regular flow size
75470317|NCT05411796|Device|Other menstrual cup|size 1
75470318|NCT05411783|Procedure|Low tie of IMV|The IMV will be tie under the left colic vein
75923315|NCT04521530|Other|immediate functional implant loading|Patients will undergo implant placement and a minimum of 35 Ncm reading with the graded torque wrench. Temporary crowns in functional occlusion were cemented.
75923316|NCT04521530|Other|immediate non functional implant loading|implant will be placed into the site following the manufacturer's protocol making sure to have a minimum of 35 Newton centimeter reading with the degraded torque wrench. Non-functional temporary crowns were cemented.
75923317|NCT03506958|Procedure|Standard trauma care|In both groups, all procedures and management will be done according to the hospital's standard of care.
75923318|NCT04521452|Drug|Evogliptin|Subjects will receive evogliptin 5 mg daily
75923319|NCT03504540|Procedure|Blood test|Blood test for complement factors and genetic polymorphisms of AMD analysis
75470319|NCT05411770|Device|Thoracic kyphosis and lumbar lordosis angle assessment|Thoracic kyphosis and lumbar lordosis angle assessment was performed with the reliable Baseline Bubble Inclinometer®.
75638238|NCT06178354|Procedure|High-Intensity Focused Ultrasound Ablation|Undergo high intensity frequency ultrasound ablation
75638239|NCT06178354|Other|Survey Administration|Ancillary studies
75638240|NCT06178328|Behavioral|Things You Do Course|Participants receiving the brief psychological intervention ('Things You Do' Course) will have access to a single online lesson that includes course materials and printable materials (i.e., an activity guide and planner) that can be retained for longer-term use. The course materials include an introduction to the purpose and content of the course, education about factors that impact mental health, and information about the 'Big Five' things participants can do to improve their mental health. Participants will also receive automated no-reply emails (5 days/week) through the intervention platform to remind them to practice the skills from the course.
75923320|NCT03361670|Other|Observational Study|
75923321|NCT03509532|Device|PCI|PCI
75923322|NCT03364790|Procedure|PLIF|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
75923323|NCT03364790|Procedure|TKA|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
75923324|NCT03504462|Procedure|Specific block of medial and lateral plantar nerves|"Specific injection of long duration local anesthetic in contact with medial and lateral plantar nerves.~Local anesthetic : Ropivacaine : 0,375% - 5 ml per nerve."
75923325|NCT02303886|Drug|Methylene blue|In NaCL0.9% 100 ml
75923326|NCT02303886|Drug|Methylene blue|in NaCl 0.9% 100 ml
75923327|NCT02518958|Drug|RRx-001|
75923328|NCT02518958|Drug|Nivolumab|
75923329|NCT03506802|Radiation|18F-FHBG|Given IV
75923330|NCT03506802|Biological|Aldesleukin|Given SC
75923331|NCT03506802|Biological|Cellular Therapy|LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV
75330640|NCT03296800|Drug|Probenecid|Probenecid tablets, 500 mg; bid
75470320|NCT05411770|Device|Temporomandibular range of motion|TMJ range of motion, maximum mouth opening amount (MAAM), right and left lateral movements of the mandible (laterotrusion), anterior movement of the mandible (protrusion), and backward movement of the mandible (retrusion) were measured with a millimetric ruler, while the adolescent was seated on a chair.
75638241|NCT06178315|Procedure|EUS-guided celiac plexus block|Under EUS-guidance, celiac plexus block will be performed with injection of bupivacaine and triamcinolone into the area of celiac plexus.
75638242|NCT06178315|Procedure|Sham procedure|Celiac plexus will not be performed in this arm.
75787134|NCT01097772|Device|Implant of Ovation Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
75330641|NCT03296800|Drug|Rifampin|Rifampin, 600 mg (2 x 300 mg capsules); qd
75330642|NCT03296800|Drug|Verapamil|Verapamil hydrochloride tablet, 120 mg; qd
75470321|NCT05411770|Device|Measuring the cervical joint range of motion|Cervical joint flexion, extension, lateral flexion and rotation ranges of motion were measured with a universal goniometer while the adolescent was sitting in a chair.
75470322|NCT05411770|Device|Craniovertebral angle measurement|Head posture of the adolescent was evaluated by craniovertebral angle (CVA) method. Adolescents sat on a chair with back support in an upright position and turned sideways to the worker. The pivot point was accepted as the seventh cervical vertebra, and the angle between the head (tragus) and the horizontal plane was measured with a goniometer and recorded in degrees.
75638243|NCT06174272|Behavioral|Transitional Care Program|Intensive monitoring post discharge for cirrhosis and fluid overload
75638244|NCT06174207|Other|Oxygen|Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula.
75638245|NCT06173804|Other|Adapted Look Ahead Lifestyle Intervention|Participants will be educated about improving healthy lifestyles involving physical activity and healthy eating to improve physical function and improve glycemic control.
75638246|NCT06173492|Procedure|Dental extraction|After local anesthesia (mepivacaine 2%), the tooth is extracted atraumatically with levers and forceps taking care to preserve the cortex. The roots of multi-rooted teeth are separated before extraction. The pocket epithelium and granulation tissue inside the socket are removed.
75787135|NCT03951168|Behavioral|Routine Management|Routine Management Model of Health Education for diabetes Patient will receive the Routine Management Model of Health Education for Diabetes. After the patient was admitted to hospital, the responsible nurse carried on the diabetes health education for the patient. There are no regulations on the path and time of education. Interspersed with diabetes health education at work. Follow up 2 weeks with phone call after discharge. This is the current clinical model in hospital.
75787136|NCT03951168|Behavioral|Standardized Management|Standardized Management Model of Health Education for Diabetes The patients were educated by full-time diabetic education nurses according to diabetes education path. Including diabetes diet, exercise, drugs, hypoglycemia, diabetic foot, and so on. Telephone follow-up was performed at 2 weeks and 4 weeks after discharge and 12 and 24 weeks follow-up in diabetes education clinic. Develop telephone follow-up standardized content and implement telephone follow-up according to standardized content.Full-time education nurses carry on education according to diabetes mellitus health education path table.
75787137|NCT00048048|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
75787138|NCT01327170|Procedure|Subthreshold diode micropulse laser|
75787139|NCT03953118|Drug|Azithromycin Oral Product|Oral azithromycin dosed at 1 gram per week for 3 weeks
75787140|NCT03953118|Drug|Placebo Oral|Oral placebo tablet
75923332|NCT03506802|Procedure|Computed Tomography|Undergo PET/CT
75330643|NCT00634010|Drug|Morphine|15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
75330644|NCT00634010|Drug|Methadone|5 mg orally every 12 hours; additional capsules every 2 hours as needed.
75330645|NCT04053751|Procedure|closed suctioning system|a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
75330646|NCT03202264|Other|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
75330647|NCT00633932|Drug|Esomeprazole|20mg once daily
75923333|NCT03506802|Biological|Filgrastim|Given SC
75923334|NCT03506802|Other|Laboratory Biomarker Analysis|Correlative studies
75330648|NCT00633932|Drug|Esomeprazole|40 mg once daily
75330649|NCT00633932|Drug|Omeprazole|20mg once daily
75330650|NCT01028131|Behavioral|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
75470323|NCT05411770|Device|Tragus-to-wall distance measurement|Tragus-to-wall distance was measured using a tape measure and recorded in cm.
75470324|NCT05411770|Device|Scoliosis angle assessment|Scoliosis angle assessment was done with a scoliometer.
75470325|NCT05411757|Combination Product|IBR900 combined with Lenvatinib|IBR900 cell injection: 4.0×10^9 cells, D1,D3 of each cycle. Lenvatinib: body weight ≥ 60kg, 12mg/qd; body weight < 60kg, 8mg/qd; administered continuously from D5 of the first cycle
75470326|NCT05411757|Combination Product|IBR900 combined with Bevacizumab|IBR900 cell injection: 4.0×10^9 cells, D1,D3 of each cycle. Bevacizumab:15mg/kg, D1 of each cycle.
75470327|NCT05411666|Procedure|Saline solution maintenance of the CVC|"Saline solution maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B|Braun, according to local standard procedures."
75923335|NCT03506802|Drug|Lenalidomide|Given PO
75923336|NCT03506802|Procedure|Leukapheresis|Undergo leukapheresis
75923337|NCT03506802|Drug|Melphalan|Given IV
75923338|NCT03506802|Drug|Plerixafor|Given SC
75923339|NCT03506802|Procedure|Positron Emission Tomography|Undergo PET/CT
75330651|NCT01028131|Behavioral|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
75330652|NCT03297112|Drug|Perflutren Lipid Microspheres|Given IV
75638247|NCT06173492|Device|Platelet Rich Fibrin|The clot obtained by centrifugation is made into PRF cylinders and inserted into the socket and compacted.
75787141|NCT01101126|Other|Pulmonary disease management|Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations
75787142|NCT01101126|Other|Usual care|Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
75923340|NCT02518724|Procedure|RIPC intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
75923341|NCT02518724|Procedure|placebo intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
75923342|NCT03364712|Other|routine medical care, venipuncture|
75330653|NCT03297112|Procedure|Contrast-Enhanced Subharmonic Ultrasound Imaging|Undergo contrast-enhanced subharmonic ultrasound imaging
75330654|NCT03831542|Behavioral|direct follicular aspiration|direct follicular aspiration
75330655|NCT03831542|Behavioral|follicular flushing|follicular flushing
75330656|NCT01028677|Drug|intranasal spray with oxytocin|6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
75330657|NCT01028677|Other|nasal spray without oxytocin|6 insufflations of nasal spray without oxytocin (0.1 metered dose/insufflation) twice daily for 6 weeks
75470328|NCT05411666|Procedure|No maintenance of the CVC|"No maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B|Braun. Just visual inspection to local site of CVC insertion."
75638248|NCT06173466|Drug|Liposomal bupivacaine|Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
75638249|NCT06173466|Drug|Bupivacaine Hydrochloride combined with dexamethasone|Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
75638250|NCT06173375|Diagnostic Test|Cologuard|Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.
75638251|NCT06173375|Diagnostic Test|Fecal Immunochemical Test|Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.
75787143|NCT01097850|Drug|henna paste|Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
75330658|NCT03298048|Biological|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
75787144|NCT01101204|Drug|Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg|Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
75787145|NCT01095822|Drug|Aliskiren + Valsartan|Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
75330659|NCT03298048|Biological|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
75330660|NCT03298048|Biological|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
75330661|NCT01923038|Procedure|First arm: patients ventilated with zero end expiratory pressure|
75330662|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure|
75330663|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
75330664|NCT01923116|Drug|HPV-16 vaccine|Vaccination with SLP-HPV-01® with or without interferon-a injections.
75330665|NCT04735276|Device|HFNO for 5 min|1st basic MRI then HFNO for 5 min with mouth closed breathing and 2nd MRI. Analysis of the surface of the gastric antrum.
75330666|NCT01028911|Drug|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
75330667|NCT01028911|Drug|Placebo|"Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator."
75330668|NCT04706884|Device|Near infrared spectroscopy|The rSO2 (cerebral oxygen satutation) was continuously monitored by NIRS (Near infrared spectroscopy) with a sensor positioned on the forehead of the patient
75330669|NCT03204526|Device|deep brain stimulation|
75787146|NCT01095900|Procedure|conservative lateral internal sphincterotomy|
75787147|NCT01095900|Procedure|Intra-sphincteric Botulinum-toxin injection|
75787148|NCT03954912|Procedure|MAKO assisted unicondylar knee arthroplasty|MAKO assisted
75787149|NCT03954912|Procedure|NAVIO assisted unicondylar knee arthroplasty|NAVIO assisted
75923343|NCT03364634|Diagnostic Test|Intracranial pressure monitoring|Weekly ICP monitoring sessions beginning at discharge from the neuro-intensive care unit and carried out until 1 month after cranioplasty.
75923344|NCT03361592|Procedure|Spinal Manipulative Therapy|Lumbar (SMT) was performed using Diversified techniques, aiming to correct vertebral dysfunctional lumbar segments. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
75787150|NCT03954600|Drug|NPT520-34 (125 mg)|NPT520-34, 125 mg oral capsules (size 1)
75638252|NCT06173323|Behavioral|ImPart - Improving Chronic Kidney Disease Decisional Partnerships|ImPart is a decision support intervention developed and refined in partnership with a advisory group of patients with and caregivers of people living with Chronic Kidney Disease. The program is designed to support decision-making throughout the illness experience.
75638253|NCT06172556|Procedure|Endovascular coiling, Surgical clipping, Mix|Endovascular coiling, Surgical clipping, Mix
75638254|NCT06172374|Genetic|Sano Genetics Testing Kit|Genetic testing spit collection tubes for DNA testing
75638255|NCT06171841|Other|low-intensity resistance training|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions performed twice a week for 6 weeks.
75638256|NCT06171841|Other|high-intensity resistance training|4 sets of 10 repetitions of leg press exercise at 70-80% one-repetition maximum (weeks 1-3: 70%, weeks 4-6: 80%) in normoxic conditions performed twice a week for 6 weeks.
75638257|NCT06171841|Other|low-intensity resistance training combined with blood flow restriction|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
75923345|NCT03361592|Procedure|SHAM|"The SHAM (pre-load positioning SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
75923346|NCT03504384|Other|questionnaire|All patients will be interviewed using a semi-structured questionnaire detailing patients' demographic characteristics (age, sex, education, occupation, residence), and the factors that could affect their quality of life such as pain and neurological symptoms, orthopedic disorder in another part of the body and history of spinal surgery.
75923347|NCT03361514|Behavioral|Supported Protocolized Discontinuation (SPD)|Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.
75330670|NCT03302416|Drug|Hydrocortisone|
75330671|NCT03302416|Radiation|[C-11]NOP-1A|
75330672|NCT03435562|Other|JUUL electronic cigarette|Effects of JUUL electronic cigarette use.
75638258|NCT06171841|Other|low-intensity resistance training in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in hypoxia conditions (3500 meters above sea) performed twice a week for 6 weeks.
75638259|NCT06171841|Other|low-intensity resistance training combined with blood flow restriction in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normobaric hypoxia conditions (3500 meters above sea) with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
75787151|NCT03954600|Drug|Placebos (125 mg)|Placebo, 125 mg oral capsules
75787152|NCT00300053|Biological|CLBS14 (low-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 1 x 10^5 (=100000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
75330673|NCT03435562|Other|IQOS electronic cigarette|Effects of IQOS electronic cigarette use.
75330674|NCT03435562|Other|Own Brand cigarette|Effects of own brand cigarette use.
75330675|NCT01000285|Drug|Bortezomib|
75330676|NCT01000285|Drug|Etoposide|
75330677|NCT01000285|Drug|Vincristine|
75330678|NCT01000285|Drug|Doxorubicin|
75330679|NCT01000285|Drug|Prednisone|
75330680|NCT01000285|Drug|Cyclophosphamide|
75330681|NCT01000285|Drug|Raltegravir|
75330682|NCT03207022|Procedure|axillary brachial plexus block|ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
75330683|NCT03208192|Procedure|liver transection during laparoscopic liver resection|liver transection during laparoscopic liver resection
75330684|NCT01000987|Drug|varenicline|1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
75330685|NCT01000987|Drug|placebo|placebo
75330686|NCT00633464|Drug|ixabepilone|"injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.~Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria."
75470329|NCT05411640|Other|Aerobic exercise with Blood flow restriction|Experimental group will be given aerobic exercises with blood flow restriction training. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. . Arterial occlusion of 60% will be achieved by Blood Flow Restriction apparatus. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
75330687|NCT00633464|Drug|ixabepilone + cetuximab|"Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.~Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Cetuximab 400 mg/m^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria."
75330688|NCT03436810|Procedure|Motor imagery|Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.
75330689|NCT03436810|Procedure|Health education|Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.
75330690|NCT03436810|Procedure|Task-Oriented Circuit Class Training|Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
75330691|NCT03129776|Drug|Hyperpolarized 13C-Pyruvate|The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
75330692|NCT03129776|Drug|18F-FDG|18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
75330693|NCT03437044|Drug|Ticagrelor|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
75330694|NCT03437044|Drug|Clopidogrel|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
75470330|NCT05411640|Other|Aerobic exercise without Blood flow restriction|Active Comparator group will be given aerobic exercises. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
75470331|NCT05411640|Other|Patient Education and dietary modification|Participants will individually instruct to reduce total energy intake and increase physical activity, aiming at a 5% reduction in body weight. The participants will be given pamphlets providing general information on pre diabetes and dietary modifications. Total intervention protocol for the group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
75470332|NCT05411601|Other|Methodology of attachment of external foot prothesis|establishing the methodology of specific measurements of attachment of external foot prothesis
75787153|NCT00300053|Biological|CLBS14 (high-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 5 x 10^5 (=500000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
75787154|NCT00300053|Biological|placebo injection|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Placebo will be delivered in 10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma into the target areas of myocardial ischemia.
75787155|NCT01098084|Drug|Decitabine|20mg/m2/day, one hour intravenous infusion, every day during 5 days
75787156|NCT01101282|Device|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
75787157|NCT01101360|Device|Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
75787158|NCT01101360|Device|Matrix RF followed by Pulse Dye Laser|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
75787159|NCT01101360|Device|Pulse Dye Laser followed by Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
75470333|NCT05411510|Procedure|Densah bur|Surgical treatment
75787160|NCT03952572|Drug|Cyclophosphamide|750mg/m² ivgtt on day 1
75787161|NCT03952572|Drug|pegylated liposomal doxorubicin|40mg/m² ivgtt on day 1
75470334|NCT05411432|Drug|68Ga labeled HER2 Affibody|inject the tracer to subjects and perform PET/CT scans
75470335|NCT05411328|Device|virtual reality|All children in the two groups received physical therapy protocol for 30 minutes in addition to virtual reality game traditional physical therapy group traditional physical therapy group
75330695|NCT03148106|Device|Somatosensory Electrical Stimulation|We will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
75330696|NCT01923194|Drug|Highly Purified Urofollitropin|for Injection
75330697|NCT01923194|Drug|Recombinant Human Follitropin Alfa|for Injection
75330698|NCT03303196|Device|Bihormonal Bionic Pancreas|A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
75330699|NCT04759508|Dietary Supplement|Flax Oil Capsule|Flaxseed with brand name Flax Oil Capsule will be administered to subjects receiving antihypertensives.
75787162|NCT03952572|Drug|Vincristine|1.4mg/m²(Maximum 2 mg) ivgtt on day 1
75787163|NCT03952572|Drug|Prednisone|Prednisone100mg/m² po on day1-5
75923348|NCT03361514|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|In addition to the SPD patients are offered Mindfulness Based Cognitive Therapy (MBCT) in homogeneous groups of patients willing to withdraw from their medication. MBCT will be offered according to the treatment protocol developed for recurrent depression, adaptated to the specific needs of patients discontinuing their antidepressant medication. The mindfulness courses will be provided by teachers qualifying the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders. All teachers will receive additional training in using the specific study protocol at the start of the project.
75330700|NCT04759508|Dietary Supplement|Placebo Soya Oil Capsule|Placebo capsule filled with soya oil and inert(inactive) substances will be administered to subjects remaining anti hypertensives.
75470336|NCT05411276|Drug|Pyrotinib maleate|Pyrotinib maleate tablets 400 mg/day, oral within 30 minutes after breakfast, every 4 weeks is a cycle
75787164|NCT03952572|Drug|Doxorubicin|50mg/m² ivgtt on day 1
75787165|NCT00299975|Drug|MaZiRenWan (MZRW) Low dose|Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
75787166|NCT00299975|Drug|MaZiRenWan (MZRW) Median dose|Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
75923349|NCT02307864|Drug|Tramadol HCl|Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
75923350|NCT02307864|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg tablet administered orally.
75923351|NCT02307864|Drug|Tramadol HCl Placebo|Placebo matched to tramadol HCl IR tablet administered orally.
75651822|NCT05381610|Device|Peristeen|The Peristeen system will be handled by Coloplast trained personnel. The investigator and a trained nurse will participate in all the investigation related procedures. The nurse is trained in the handling of the investi-gational product as well as this is described in detail in the Instruction for Use (IFU). Subjects (and their caregivers, if appropriate) will also be trained on the use of Peristeen prior to independent use at home.
75651823|NCT05366296|Biological|A Lyophilized COVID-19 mRNA Vaccine|Active substance: NTD-RBD derived from S protein of Omicron variant Excipient: ALC-0315 (4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2- hexyldecanoate), ALC-0159 (2-[(polyethylene glycol)-2000]-N, N-ditetradecylacetamide), DSPC [1,2- distearoyl-sn-glycero-3-phosphocholine], Cholesterol, Trometamol and Sucrose
75787167|NCT00299975|Drug|MaZiRenWan (MZRW) High dose|Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
75787168|NCT03951090|Other|Results of the brief geriatric assessment|Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
75923352|NCT02307864|Drug|Moxifloxacin Placebo|Placebo matched to Moxifloxacin 400 mg tablet administered orally.
75923353|NCT03504306|Other|Ventriject validation|comparing measurements from echocardiography, echoseismography to measurements of maximal oxygen uptake
75923354|NCT03364556|Other|No intervention|
75923355|NCT03509376|Procedure|Suture repair|The diastasis is repaired with continous nylon suture
75923356|NCT03509376|Procedure|Rolled mesh repair|Continuous nylon suture is done over a narrow strip of self gripping Rolled mesh to repair the diastasis
75923357|NCT04444778|Device|CPAP|Continuous positive airway pressure
75923358|NCT03504150|Behavioral|SPHERE|Comprehensive Internet-based CBT program with no human support
75923359|NCT03504150|Behavioral|PRISM|Brief Internet-based CBT program with no human support
75923360|NCT03364478|Procedure|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach.
75923361|NCT03364478|Procedure|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach.
75923362|NCT02303964|Biological|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
75923363|NCT02303964|Drug|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
75330701|NCT01923272|Device|AlphaCore Device|Active stimulation to the vagal nerve
75330702|NCT01923272|Device|AlphaCore|Active AlphaCore treatment
75330703|NCT03082664|Device|PICO Single Use Negative Pressure Wound Therapy|The PICO device will be placed over the closed cesarean section incision.
75330704|NCT00633152|Drug|ceftaroline|600 mg injected every 12 hours for at least 5 but not more than 14 days
75330705|NCT00633152|Drug|linezolid|600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
75470337|NCT05411224|Other|Custom made orthosis|In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.While the treadmil is in a static state, pressure distribution measurement will be taken by baropedography, and personalized insoles will be produced according to the baropedographic pressure map. Patients will be delivered to the patient for indoor and outdoor use for 4 weeks. After a 4-week usage period, measurements related to pressure and walking parameters will be repeated.
75470338|NCT05411172|Behavioral|Mastery Learning Model for Chemical, Biological, Radiological, and Nuclear threats and hazards (MLM-CBRN Education Program) on student nurses|"The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks. . The data were collected before and right after the intervention and in the 1st and 3rd months after the intervention using the Personal Information Form, Nursing Student CBRN Knowledge Test, Nursing Student CBRN Attitude Scale, and Nursing Student CBRN Self-Efficacy Scale. Moreover, only the knowledge scores of the students in the experimental group were collected using the unit follow-up tests, which enabled us to check whether the Learning Objective related to the unit taught was achieved. During the skill training, the START Triage and JumpSTART Triage Skill Check List, Gas Mask Wearing-Removing Skill Check List, and Level C Clothes Wearing-Removing Skill Check List were scored for each student in the experimental group after observing the students twice."
75787169|NCT03951090|Other|No results of brief geriatric assessments|Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
75787170|NCT03954522|Other|interview|"Child = A clinical interview (recorded, duration approximately 30 min) and a scale of acute stress (IES child) will be performed at 2 times (during the 7 days following the first visit of hospitalized kin and 1 month after the kin was discharged from ICU)~Accompanying parent/kin = Semi-directive interviews (recorded - duration approximately 30 min) will be performed at the same time as those of the child and will be recorded. The parent/kin will also complete a socio-demographic questionnaire of the family group and a depression anxiety scale (HADS)~Nursing staff = A semi-directive interview (recorded - duration approximately 30 min) will be performed only once (during the 7 days following the first visit to the hospitalized kin). The caregiver will also complete a socio-demographic questionnaire and a Moral Distress Scale (MDS-R)~Hospitalized parent = One month after ICU discharge, a depression anxiety scale (HADS) and an acute stress scale (IES) will be performed"
75923364|NCT04520984|Other|Integrated ambulatory palliative and nephrology care|"Monthly ambulatory care visits with the kidney palliative care team in the intervention group for three months.~The intervention in this study is addition of a palliative care team to the care team of the subject. This intervention will not change or impact their regular nephrology care. The subjects in the intervention arm will be seen by the palliative care team three times over the 12-week study period (once per month).The intervention will be delivered by a physician trained in both palliative care and nephrology, the PI of the study."
75330706|NCT00633152|Drug|Aztreonam|1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
75470339|NCT05407259|Behavioral|Resistance exercise|There will be four conditions (three exercises and one control) on visits 3-6. For the three exercise conditions, all training parameters except intensity will be the same. The sets in high, moderate, and low intensity correspond to the rate of perceived exertion (0-10 scale) 7-9, 5-6, and 3-4, respectively. Therefore, the participants will perform 5 repetitions barbell squat, barbell press, and barbell deadlift with 8RM (78% 1RM), 11RM (72% 1RM), and 16RM (65% 1RM) for 3 sets
75330707|NCT01030783|Drug|tivozanib (AV-951)|Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
75638260|NCT06170229|Behavioral|eHIIT|"Education and High intensity Interval Training (Aerobic Exercise)~The focus of the one educational session is rationale for aerobic exercise, expected physiological effects of aerobic exercise, diet when performing an exercise program, how the knee accommodates to exercise (including potential experience of muscle soreness and how that is different from joint pain), and management of potential knee OA symptom flares.~HIIT is an aerobic exercise form. The eHITT protocol consist of eight 2-minute intervals of high intensity training (with the goal to train at a heart rate of at least 80% of HRmax) followed by 2 minutes of moderate training intensity (with the goal to train at a heart rate of at least 60% of HRmax).~There will be several types of exercise modalities for aerobic exercise available (treadmills, cross-trainers, row- and cycle ergometers) and participants may choose whichever they prefer."
75651824|NCT05366296|Biological|Placebo|Normal saline (0.9% sodium chloride solution
75787171|NCT00004980|Device|repetitive transcranial magnetic stimulation (rTMS)|a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
75470340|NCT05406843|Other|Preoperative cognitive functions of participants undergoing open heart surgery|Surgery times and cross-clamping times of the participants who will undergo open heart surgery were recorded.
75651825|NCT05363839|Drug|ACH-000029|ACH-000029 will be administered orally via a capsule.
75651826|NCT05363839|Drug|Placebo|Placebo will be administered orally via a capsule.
75787172|NCT00004980|Device|sham stimulation|"132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site"
75787173|NCT03954756|Drug|Apatinib and PD1|"Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks."
75923365|NCT04520984|Other|Standard nephrology care|Standard nephrology care
75923366|NCT02304042|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
75923367|NCT02304042|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
75330708|NCT01030783|Drug|Sorafenib|Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
76079453|NCT03465228|Device|Training and LED group|The LED application will be performed before GTL training sessions and will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
75330709|NCT00633074|Biological|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
75330710|NCT00633074|Biological|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
75787174|NCT00326963|Drug|Background ARVs|As prescribed
75787175|NCT00326963|Drug|PI|As prescribed
75787176|NCT00326963|Drug|enfuvirtide [Fuzeon]|90mg sc bid
75787177|NCT03983525|Dietary Supplement|Goji berry|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take 28 grams of goji berry once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
75787178|NCT03983525|Dietary Supplement|Lutein + zeaxanthin supplementation|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take one capsule of lutein + zeaxanthin supplementation once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
75330711|NCT03304054|Drug|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
75923368|NCT04521218|Other|Thrust Joint Manipulation|"Experimental group included TJM, Cervical hot pack, strengthening exercises and home plan; 3 sessions of manipulation per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold."
75923369|NCT04521218|Other|Reverse Sustained Natural apophyseal glides|"Control group included Moist Hot Pack (Cervical contour- 8.25 x 10 x 2) for 10 Mins, Reverse SNAGS (10 Repetitions holding for 10 sec in each glide with a rest time of 30 seconds in between), Strengthening exercise and home plan. 3 sessions of mobilization per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold"
75923370|NCT02307942|Procedure|Gastric banding|The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
75923371|NCT03364322|Other|Observation|Observation
75923372|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
75923373|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
75638261|NCT06170229|Behavioral|NEMEX-e|"Education and Neuromuscular Exercise~The focus of the two educational sessions is on providing knowledge of OA and treatment options to the participants, with a special focus on knee OA, diet, and exercise and its benefits. Furthermore, advice about self-management is given.~The exercises are based on neuromuscular principles to improve sensorimotor control and achieve compensatory functional stability. Sensorimotor control is the ability to coordinate muscle activity and maintain functional stability during movement allowing for joint stability during physical activity. Various positions (sitting, lying, standing) are used to achieve the desired postural activity. The overall goal is to obtain muscle control and stability in situations resembling daily life and/or more strenuous activities. The focus is on achieving good quality of the performance in each exercise with appropriate postural orientation (e.g., joint positioned appropriately in relation to each other)."
75470341|NCT05406843|Other|Postoperative cognitive functions of particiants undergoing open heart surgery|Changes in mini mental test scores were recorded in the postoperative period.
75923374|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
75923375|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 1inh|
75923376|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
75330712|NCT03304054|Drug|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
75330713|NCT01929278|Drug|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
75470342|NCT05405699|Behavioral|digitalized group psychoeducation|"Problem Solving Approach based problem solving skills psychoeducation's session topics of eight weeks are as follows:~Introduction and warm-up,~Problem orientation-identifying the problem,~Identifying prior problems-Which do I want to start from?~Recognizing the losses caused by problems and complaints,~Setting reachable and realistic goals,~Generating alternatives -What can I do?~Regulating emotions,~Experimenting and exploring. The main outcomes of each session were determined, and sessions were completed in approximately one hour as a semi-structured interactive group training according to group dynamics.~Three days a week for eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. Participants were connected to the live broadcast of the research team and interacted via text messages."
75470343|NCT05398939|Diagnostic Test|Blood test and skin evaluation|The patients received blood tests for serum 25-hydroxyvitamin D level and skin evaluation for severity of acne vulgaris and lesion counts.
75787179|NCT01065233|Genetic|DNA extraction|DNA extraction of blood sample for DNAship analysis
75330714|NCT01929278|Other|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
75638262|NCT06169397|Drug|XTMAB-16|XTMAB-16 infusion
75330715|NCT01929278|Other|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril [approximately 2 cm x 2 cm]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
75330716|NCT01929356|Procedure|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
75330717|NCT01923350|Behavioral|Weight Reduction Intervention|"The weight trial intervention components were:~Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).~Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.~Print mailings/emailings~3 Get Ready e-messages in the four weeks before the weight intervention began~Pedometers and program guides. (IVR users received printed activity logs with their program guides.)~Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals."
75638263|NCT06169267|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration/biopsy
75638264|NCT06169267|Procedure|Bone Marrow Biopsy|Undergo bone marrow aspiration/biopsy
75638265|NCT06169267|Procedure|Music Therapy|Listen to music
75923377|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
75330718|NCT01923350|Behavioral|Weight Reduction Control Arm|Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
75330719|NCT01923350|Behavioral|Tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
75330720|NCT01923350|Behavioral|Not tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
75330721|NCT03210376|Drug|Deep Neuromuscular Blockade (NMB)|Deep Neuromuscular Blockade (NMB) given during surgery.
75330722|NCT03210376|Drug|Moderate Neuromuscular Blockade (NMB)|Moderate Neuromuscular Blockade (NMB) given during surgery.
75638266|NCT06169267|Other|Questionnaire Administration|Ancillary studies
75638267|NCT06169046|Drug|Clenbuterol|tablets
75638268|NCT06169046|Drug|Placebo|tablets
75638269|NCT06168786|Drug|Fruquintinib|Fruquintinib:5mg ,qd,po, d1-d14, q3w
75638270|NCT06168786|Drug|Cadonilimab|Cadonilimab:10mg/kg, ivgtt, d1, q3w
75638271|NCT06168786|Radiation|SBRT|SBRT:8-10Gy×5F，qod， in 10 days
75638272|NCT06167226|Drug|Personalized Ayurveda treatment protocol|The treating physician decided and advised personalized Ayurveda treatment protocol based on disease and patient's condition
75638273|NCT06166498|Drug|SP (Macleods Pharmaceuticals Ltd)|Children who weigh <10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh >10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
75638274|NCT06166498|Drug|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
75638275|NCT06166446|Device|subtractive technique|The milled denture teeth are then bonded into the milled recesses using a special PMMA bonding system.
75638276|NCT06166446|Device|additive technique|The denture teeth were printed as one unit using the same method with tooth resin (DENTCA Denture Tooth, Shade A2).
75638277|NCT06165367|Drug|EmbryoGlue Medium|Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
75638278|NCT06164496|Device|standart manual toothbrush|Device on plaque removal efficacy
75638279|NCT06164496|Device|360 degree toothbrush|Device on plaque removal efficacy
75638280|NCT06163742|Device|Product X|The investigational device is a polyethylene glycol-based biomaterial. It can be applied to donor sites on the arms, torso, and legs.
75638281|NCT06163742|Device|Standard-of-Care|The active comparator includes the current standard-of-care treatment: hydrocellular polyurethane dressing covered with TegadermTM film for 48 hours, followed by an occlusive gauze impregnated with 3% Bismuth Tribromorphenate in petrolatum.
75638282|NCT06163352|Drug|Norepinephrine|The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
75923378|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
75923379|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|
75923380|NCT02308176|Behavioral|APP + health advice|health advice and reinforcement to it
75923381|NCT02308176|Behavioral|health advice|health advice
76079454|NCT03465228|Device|Training group|The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.
75787180|NCT00326885|Drug|catumaxomab|Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
75330723|NCT03210376|Drug|Sugammadex|4 mg/Kg, intravenously as a single bolus injection after surgery.
75923382|NCT03364166|Procedure|surgical excision|"Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~A neck dissection will be done in all cases of negative or positive neck lymph node.~Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery."
75638283|NCT06160817|Procedure|Conservative sharp debridement|The debridement method for all patients, regardless of the assigned sequence, will involve the removal of non-viable tissue from the ulcer bed, edges, and perilesional skin using a scalpel (No. 3) with a No. 10 and/or No. 15 blade, along with Adson forceps and straight dissecting forceps.
75923383|NCT03504072|Drug|Tofacitinib 5 mg,|tofacitinib 5 mg 12 hourly daily for 9 months
75923384|NCT03504072|Drug|Etanercept|Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
75923385|NCT03361280|Drug|Beta blocker|Beta blockers are administered as described in arms.
75330724|NCT03210376|Drug|Neostigmine|70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
75330725|NCT03210376|Behavioral|Pain Assessment|Pain assessment done at about 15, 45, and 90 minutes after surgery.
75330726|NCT04396028|Other|data collection|retrospective data collection
75638284|NCT06159777|Drug|Polyethylene Glycol 3350|*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
75330727|NCT01929434|Other|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
75923386|NCT02308254|Drug|Lixisenatide|Abdominal administration
75923387|NCT02308254|Drug|Placebo|Abdominal administration
75330728|NCT01929434|Biological|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
75330729|NCT01929512|Drug|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
75330730|NCT01929512|Drug|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
75330731|NCT01929512|Drug|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
75330732|NCT03127904|Procedure|Vein Fitness|Vein fitness is a combination of whole-limb exercises, manual lymphatic drainage, and usual care (wound care and compressive therapy).
75330733|NCT03127904|Procedure|Compressive therapy and wound care|"Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.~As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it."
75330734|NCT04447898|Drug|PPV-06 10 μg|Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
75638285|NCT06157086|Other|ofatumumab|There is no treatment allocation. Participants with MS that initiated treatment with ofatumumabas per neurologist practice and regardless of the study protocol
75787181|NCT01065311|Behavioral|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
75787182|NCT01065311|Behavioral|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
75787183|NCT01065311|Biological|Standard psychiatric care|"Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
75787184|NCT03979703|Other|12 week yoga class|Intervention is a 12 week yoga class with classes twice a week. Each yoga class will last about 1 hour. Furthermore, focus group interviews will be conducted after the first and last yoga class.
75923388|NCT03361202|Other|blood sampling|"atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~control group:before coronary angiography and at hospital discharge."
75923389|NCT03357146|Device|Optical coherence tomography angiography|OCTA scans per built-in device protocol
75923390|NCT02304120|Other|Proprioceptive postural training|
75923391|NCT02304120|Other|Treadmill training|
75330735|NCT04447898|Drug|PPV-06 50 μg|High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
75923392|NCT02304120|Other|Conventional physiotherapy|All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
75923393|NCT03361124|Drug|Oxytocin|Administration of additional 20 mU Oxytocin
75787185|NCT00326495|Drug|Cetuximab|Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
75787186|NCT00326495|Drug|BAY 43-9006|Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
75638286|NCT06155266|Diagnostic Test|2 additional whole blood samples of 6mL each will be taken|"As part of the initial blood work-up, 2 additional samples of 6mL each of whole blood will be taken, to which 1mL of Cytodelics® Stabiliser will be added. The tubes will be mixed by inverting 10 to 15 times, incubated at +20°C for 10 minutes, then transported within 1 to 2 hours at 4°C by courier to the CRB at Pitié-Salpêtrière for aliquoting and freezing at -80°C . The expression level of cell surface markers will then be measured in series on an Aurora spectral cytometer, after frozen samples (1 to 2 aliquots) have been sent from the CRB-PSL to CIMI (INSERM U1135) at -80°C approximately once a month.~Any remaining samples sent to CIMI will be destroyed once the analyses have been completed."
75638287|NCT06154356|Other|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
75638288|NCT06154356|Other|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
75787187|NCT03983447|Behavioral|School-based intervention to promote PA and reduce ST|"This intervention was realized with all the children (1st grade-5th grade) and involved :~Physical (Environmental) adaptation of playgrounds~Time adaptation of lunch breaks~Curriculum-based program for children~Workshops and newsletters for parents~Meetings for teachers"
75787188|NCT00326417|Drug|Fludarabine|Doses of 30 mg/m^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
75923394|NCT02312388|Other|catheter-over-the-needle technique|using a 22 G Angiocath Plus™ catheter
75330736|NCT04447898|Drug|Placebo|Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
75330737|NCT03211234|Drug|2.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
75330738|NCT03211234|Drug|4.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.
75638289|NCT06153355|Drug|LY3839840|Administered orally.
75638290|NCT06153355|Drug|Placebo|Administered orally.
75638291|NCT06151847|Procedure|Biospecimen Collection|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2
75638292|NCT06151847|Drug|Cyclophosphamide|Given IV
75638293|NCT06151847|Procedure|Echocardiography|Undergo echocardiography
75638294|NCT06151847|Drug|Fludarabine|Given IV
75638295|NCT06151847|Biological|Interleukin-2|Given IV
75923395|NCT02312388|Other|Thin-wall needle technique|using 18 - 21 G introducer needle
75923396|NCT03364088|Procedure|Spinal anesthesia with tourniquet|Operation is done under spinal anesthesia and surgical tourniquet is used.
75923397|NCT03364088|Procedure|Spinal anesthesia without tourniquet|Operation is done under spinal anesthesia and without the use of surgical tourniquet.
75923398|NCT03364088|Procedure|General anesthesia with tourniquet|Operation is done under general anesthesia and surgical tourniquet is used.
75923399|NCT03364088|Procedure|General anesthesia without tourniquet|Operation is done under general anesthesia and without the use of surgical tourniquet.
75923400|NCT03364088|Drug|Oxycodone by patient-controlled analgesia (PCA)|PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
75923401|NCT02304198|Drug|Udenafil|Udenafil 50mg tablet
75330739|NCT03211234|Drug|Lucentis|Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
75330740|NCT01030861|Drug|Teplizumab|intravenous infusions
75330741|NCT01030861|Drug|Placebo infusion|Placebo for Teplizumab
75330742|NCT03105518|Drug|Fentanyl|0.5, 1 mcg/kg
75330743|NCT03105518|Drug|Acetaminophen|Single + Oxycodone
75330744|NCT03105518|Drug|Oxycodone|With Acetaminophen
75330745|NCT01929668|Drug|polyethylene glycol|
75330746|NCT01929668|Drug|Ascorbic Acid|
75330747|NCT01031095|Other|coronary intervention|elective coronary intervention
75330748|NCT01929746|Biological|BIIB019 subcutaneous injection|participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
75787189|NCT00326417|Drug|Cyclophosphamide 150mg|A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
75923402|NCT02304276|Radiation|18F-Fluoride PET-CT|Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
75923403|NCT02304276|Radiation|CT calcium score of aortic valve|CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
75923404|NCT04524260|Behavioral|perioperative painting art therapy (LOM® solution centered art therapy)|We plan to apply painting art therapy as a health-related intervention to patients coming to our department for elective major surgery of the pancreatic and lower gastrointestinal tract for malignant pathologies. Patients will have 3 patient art therapy sessions: one before surgery, one on day 3-5 after surgery during the hospital stay and one during the follow-up 6 weeks postoperative
76079455|NCT03465228|Other|LED group|This group will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
75787190|NCT00326417|Drug|Cyclophosphamide 100mg|A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
75330749|NCT03212638|Drug|Baricitinib suspension|Administered orally
75330750|NCT03212638|Drug|Baricitinib tablet|Administered orally
75330751|NCT03506048|Drug|Lenvatinib|Given orally once daily continuously
75330752|NCT02161705|Drug|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
75638296|NCT06151847|Biological|Lifileucel|Given IV
75638297|NCT06151847|Procedure|Magnetic Resonance Imaging|Undergo MRI
75638298|NCT06151847|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
75787191|NCT00326417|Drug|Cyclophosphamide 50mg|A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
75787192|NCT01060787|Procedure|Fluocinolone Acetonide 0.59 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
76079456|NCT03460002|Biological|Measles vaccine|A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.
75638299|NCT06151847|Procedure|Tumor Resection|Undergo tumor resection
75638300|NCT06151314|Procedure|Dental implants.|5 conventional implants measuring from 4 to 5 mm in width and 7 to 10mm in length according to the bone width were inserted in the mandible from right premolar area to left premolar area
76079457|NCT03460002|Biological|Oral polio vaccine|A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.
75330753|NCT02161705|Drug|Saline|Up to 0.8 mL/kg of normal saline administered
75638301|NCT06150014|Drug|Placebo|TQA3605 placebo tablets were orally administered under fast condition (at least 2 hours before or after meals) with warm water for a total of 24 weeks.
76079458|NCT01105702|Drug|Temozolomide|
76079459|NCT01105702|Drug|Bevacizumab|
75330754|NCT01929824|Other|Oral Nitric Oxide testing|o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.
75330755|NCT03216382|Behavioral|Attention Training Technique|The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
75330756|NCT03216382|Behavioral|Control Condition|In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
75330757|NCT01031953|Drug|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
75330758|NCT01031953|Drug|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
75638302|NCT06150014|Drug|TQA3605 tablets|TQA3605 inhibits viral replication.
75638303|NCT06150014|Drug|Entecavir dispersible tablets|Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
75638304|NCT06150014|Drug|Tenofovir disoproxil fumarate tablet|Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
75638305|NCT06150014|Drug|Tenofovir alafenamide fumarate tablet|Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
75638306|NCT06149520|Drug|BAY3018250|Dose 1 or dose 2 of BAY3018250
75787193|NCT01060787|Procedure|Fluocinolone Acetonide 2.1 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
75787194|NCT01065389|Behavioral|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
75787195|NCT01065389|Behavioral|Unstructured Nonprogressive resistance exercise|Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
75787196|NCT01065467|Drug|LBH589|Taken orally three times per week.
75787197|NCT01065545|Drug|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
76079460|NCT01105702|Drug|Lithium Carbonate|
76079461|NCT01105702|Radiation|Radiation|
76079462|NCT03465150|Other|acne|Patient with acne
76079463|NCT01197898|Biological|Collagenase Santyl Ointment|Topical daily application
76079464|NCT01197898|Other|Placebo Comparator|Topical daily application
76079465|NCT03129750|Device|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
76079466|NCT03468582|Combination Product|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
76079467|NCT04453332|Drug|Oral hormone therapy (estradiol and micronized natural progesterone)|Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month
76079468|NCT04453332|Drug|Non-oral hormone therapy (estradiol and micronized natural progesterone)|Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
75638307|NCT06149520|Drug|Placebo to BAY3018250|Matching placebo to BAY3018250
76079469|NCT03464994|Diagnostic Test|ophthalmological examination|"Refraction~Best corrected visual acuity~Intraocular pressure~Slit lamp examination with vital dye (Oxford grading)~Tear break-up time (TBUT)~Schirmer I testing~Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch & Lomb) corneal videotopographies~Pachymetry~Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~questionnaire about ichthyosis severity~questionnaire about life quality specifically for patient presenting ichthyosis"
75638308|NCT06147076|Behavioral|Social Support Network Counseling Intervention|Social support counseling intervention for kidney transplant candidates along with their social support networks.
75330759|NCT01031953|Other|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
75330760|NCT01031953|Procedure|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
75330761|NCT03310450|Other|140kms cycling|Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)
75330762|NCT01923584|Drug|EPI-743 400mg|
75330763|NCT01923584|Drug|EPI-743 200mg|
75330764|NCT04305626|Device|Endovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms with flow diversion.
75330765|NCT01032733|Behavioral|Lifestyle Counseling|In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
75638309|NCT06145607|Drug|ABBV-CLS-7262|ABBV-CLS-7262
75638310|NCT06140810|Other|Lung Recruitment|Lung Recruitment will be performed during general anesthesia to reduce areas of atelectasis
75330766|NCT01032733|Other|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
75330767|NCT01928420|Drug|Drug: NIC5-15|A natural product, found in many foods and plants with mild insulin sensitizing effects
75330768|NCT01928420|Drug|Placebo|Subjects with Alzheimer's Disease placebo comparator
75330769|NCT03441178|Device|ENSEAL X1|ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
75330770|NCT01004107|Device|Radiesse Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
75330771|NCT03218566|Device|Indigo Aspiration System|use of mechanical thrombectomy to treat pulmonary embolism
75330772|NCT00630344|Drug|RAD001|
75330773|NCT00630344|Drug|Bicalutamide|
75330774|NCT02167867|Device|Lay End Users|Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
75330775|NCT02167867|Device|Treatment Subject Group|Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
75330776|NCT01923818|Drug|rivaroxaban|orally active direct factor Xa inhibitor
75330777|NCT01923818|Drug|Aspirin|non-steroidal anti-inflammatory drugs
75638311|NCT06140615|Device|Ultrasound|Ultrasound of lungs
75638312|NCT06138860|Other|strain counter strain technique|It will be done in accordance with the technique principles in which the therapist will locate trigger point, and then find a position of comfort or mobile point (at least a 70% decrease in tenderness),monitored the tender point, holding the position o f comfort for 90 seconds, It will be conducted three times per session, for twelve sessions three times per week every other day over the course of a month.
75638313|NCT06138860|Other|physical therapy exercises|"Physical therapy exercises for twelve sessions, three times a week, over the course of a month.~Exercises will include:~stretching exercises for the hamstring, calf muscles, and back muscles.~strengthening exercises for back muscles and abdominal muscles."
75638314|NCT06135103|Drug|talfirastide|TXA127, a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II) is a sterile solution containing angiotensin (1-7) [A(1-7)], supplied in a 3 mL, single-use, stoppered vial.
75638315|NCT06135103|Drug|Placebo|Placebo is a sterile solution containing supplied in a 3 mL, single-use, stoppered vial.
75638316|NCT06134154|Other|Endoscopic insufflation gas|Carbon dioxide gas versus air for endoscopic insufflation
75787198|NCT01065623|Drug|BAY79-4620|1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
75787199|NCT03979469|Drug|Ketamine, dexmedetomidine|Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively
75330778|NCT01923818|Drug|placebo|
75330779|NCT03442036|Device|Suture-Method Technique|Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve
75330780|NCT03442036|Device|Through-the-Needle Technique|Perineural catheters are inserted through a straight hollow-bore needle
75330781|NCT02913261|Drug|Ruxolitinib (RUX)|Ruxolitinib was provided as 5 mg tablets for oral use.
75787200|NCT03979469|Drug|fentanyl, remifentanil|Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
75787201|NCT01060865|Drug|Aliskiren|150 mg during the first two weeks , 300 mg for another 10 weeks
75787202|NCT01065701|Drug|Dexmedetomidine|Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
75787203|NCT03825341|Drug|Hydroxyurea|Drug: Hydroxyurea oral liquid dose administered will be 20mg/kg/day or infants's usual daily dose.
75787204|NCT03825341|Drug|Hydroxyurea Oral Capsule|Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
75923405|NCT04524260|Behavioral|perioperative painting art therapy (LOM® solution centered art therapy) - control|"usual care, no particular intervention during the perioperative setting. There will be 2-3 painting art therapy sessions after the follow-up 6 weeks postoperative. Therefore this group is called usual care- or delayed intervention group."
75923406|NCT02308332|Drug|Eviplera|switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
75787205|NCT01060943|Device|KOKEN|"atelocollagen filler~1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year."
76079470|NCT03458286|Device|BRH-A2 wound healing device|Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
75330782|NCT02913261|Drug|Best Available Therapy (BAT)|BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
75330783|NCT02169115|Drug|Omalizumab|150mg, s.c., every 4 weeks
75638317|NCT06133452|Procedure|skin reducing mastectomy|"The goal of mastectomy skin reducing is to create a breast reconstruction that appears natural and aesthetically harmonious by minimizing excess skin. Excess skin can be removed in two main ways: as a conventional ellipse around the nipple-areola complex or, preferably, as part of an inverted T-shaped incision, commonly used in reduction mammoplasty. This procedure adheres to oncological principles of skin-conserving mastectomy and also incorporates a lower dermal flap, used to create a dermo-muscular pocket that reinforces the coverage of the prosthetic implant.~This technique allows complete detachment of the pectoral muscle at the bottom while ensuring full coverage of the prosthetic implant with a dermo-muscular layer. By increasing the implant pocket and providing an additional tissue layer at the bottom of the breast, this technique can reduce the risk of complications and improve aesthetic outcomes."
75787206|NCT01060943|Device|Atelocollagen Filler|1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
75923407|NCT03361046|Device|Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)|Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses
75638318|NCT06123338|Drug|Pembrolizumab|Pembrolizumab will be administered on an every 3-week dosing schedule
75638319|NCT06123338|Drug|Trastuzumab|Trastuzumab will be administered on an every 3-week dosing schedule
75638320|NCT06122831|Drug|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor.
75923408|NCT02308410|Procedure|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
75923409|NCT03360968|Procedure|Variable-PS|Variable-PS mode switched on for 1 hour
75923410|NCT03360968|Procedure|SPN-CPAP/PS|SPN-CPAP/PS mode switched on for 1 hour
75923411|NCT03360968|Procedure|Variable-PS|Variable-PS mode switched on for 1 hour
75330784|NCT02169115|Drug|Omalizumab|300mg, s.c., every 4 weeks
75638321|NCT06122831|Drug|TQB3617 Capsules|TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor
75638322|NCT06121258|Other|Educational video series|The intervention is a web-based educational video series that was developed using a patient-centered approach that discusses breast cancer treatment, sexual health side effects, and provides treatment and mitigation strategies for these side effects.
75787207|NCT01065857|Drug|Sodium picosulphate, light magnesium oxide and anhydride citric acid.|2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).
75787208|NCT01065857|Drug|Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.|4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).
75787209|NCT01061021|Behavioral|In The Mix|Five small group + 2 individual counseling intervention designed to addresses HIV transmission risk behavior and HIV treatment adherence in men and women living with HIV/AIDS.
75923412|NCT01822522|Drug|Cabozantinib S-malate|Given PO
75923413|NCT01822522|Other|Laboratory Biomarker Analysis|Correlative studies
75923414|NCT01822522|Other|Pharmacological Study|Correlative studies
75923415|NCT03509298|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
75923416|NCT03509298|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
75923417|NCT03360812|Other|Online training resource|Please see information included in the description of the intervention group.
75923418|NCT03503994|Drug|Inhaled Beclomethasone Dipropionate Monohydrate|"Beclomethasone Dipropionate (HFA-BDP, QVAR*) in the following doses will be evaluated:~200 mcg bid~400 mcg bid~600 mcg bid~800 mcg bid"
76079471|NCT03468504|Device|Mirror Therapy|Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.
75923419|NCT04520828|Other|postural repositioning|The 10-min transdisciplinary intervention aimed (1) to facilitate and activate axial extension during standing and then during sitting; (2) to actively mobilize the trunk, cervical spine, and pelvic and shoulder girdles during standing and then during sitting; and (3) to adjust the seated position, as needed, with supports to ensure its maintenance throughout the experiment. Cushion, balls, boxes, or rolls were used to stabilize the final seated position.
75923420|NCT03509220|Drug|PBK-1701TC|The subject will receive PBK-1701TC for colonoscopy.
75470344|NCT05397366|Diagnostic Test|Task Specific Training|"Group A will be given Task Specific protocol with routine physical therapy treatment for 45 mins on the upper limb for 3 days a week for a period of 12 weeks.~This Task Specific protocol will include different exercises like, do the polishing of the table top , can perform arm cradling, can supinate and pronate the cylindrical object with arm , while pushing the cylindrical object can extend the wrist , can reach forward to touch or to pick an object , can bend side ways to pick the object and place it on the table in front , can pour the 1/2cup of water to the wide jar that is held by the patient in other hand , patient can comb his hair , patient can drink and eat independently , can lift the jar and bring it close to lips , can pick up pen by using thumb and two fingers , can do the stacking checkers , can throw a ball into the basket , can push the ball on wall from front and side."
75638323|NCT06118346|Behavioral|Female-Specific Cognitive Behavioral Therapy (FS-CBT)|FS-CBT is a unique 12-session weekly group CBT treatment designed for women Veterans with AUD and/or risky drinking, and provides (1) AUD interventions, (2) general female-specific content, (3) female-Veteran content, (4) wellness and self-care, and (5) a novel 24/7 social support for abstinence discussion mobile app.
75923421|NCT03509220|Drug|Standard oral preparation|The subject will receive the standard oral preparation for colonoscopy
75638324|NCT06118346|Behavioral|Usual Care|Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.
75638325|NCT06114407|Drug|Baricitinib 2mg|Participants of arm 'A' will be treated with tablet baricitinib 2 mg twice daily for 12 weeks
75923422|NCT04524494|Other|biopsy of intestinal tissue|4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)
75638326|NCT06114407|Drug|Tofacitinib 5 mg|Participants of arm 'B' getting tablet tofacitinib 5 mg twice daily for 12 weeks will be taken as historical control arm from another study on the efficacy of tofacitinib in refractory axial spondyloarthritis
75638327|NCT06112990|Dietary Supplement|creatine monohydrate|Creatine is part of the phosphagen system and plays a critical role in energy metabolism. Creatine monohydrate supplementation increases availability of creatine and phosphocreatine in the skeletal muscle. Increased phosphocreatine enables greater buffering of adenosine triphosphate, an organic compound providing energy to cells, enhancing training volume (e.g., an individual can work-out harder and longer).This augmentation in exercise capacity amplifies training adaptations. Additionally, creatine monohydrate supplementation reduces levels of inflammatory markers, which are associated with severe muscle loss.
75638328|NCT06112990|Other|Placebo|Placebo supplementation consists of a flavorless, colorless, dextrose powder and will be supplied in concealed, unlabeled packaging.
75787210|NCT01061021|Behavioral|Information Support Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
75923423|NCT04524494|Other|blood draw|40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)
75330785|NCT02169115|Drug|Placebo|Placebo, s.c., every 4 weeks
75330786|NCT03219892|Device|High-frequency rTMS|It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
75923424|NCT04524494|Other|urine collection|Midstream Urine collection
75923425|NCT01796002|Drug|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
75923426|NCT01796002|Drug|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
75923427|NCT04524338|Device|Transcranial Direct Current Stimulation|Brain Stimulation Devices attached to scalp
75923428|NCT03509142|Device|Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
76079472|NCT03468504|Device|Placebo Mirror Therapy|"Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
75330787|NCT03219892|Device|Sham rTMS|The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
75330788|NCT03656107|Behavioral|Cognitive Training|Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
75330789|NCT00376792|Drug|docetaxel|
75330790|NCT00376792|Other|active surveillance|
75330791|NCT00376792|Procedure|adjuvant therapy|
75787211|NCT00297479|Behavioral|MBAT Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence
75787212|NCT00297479|Drug|Nicotine|6 weeks of nicotine patch therapy
75787213|NCT00297479|Behavioral|Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
75638329|NCT06112990|Behavioral|Home-based, telehealth|Home-based, individualized, whole-body RT program, supervised via the telehealth platform within the electronic medical record system. The RT program consists of 12 resistance exercises, focusing on all major muscle groups including upper and lower body, core, and whole-body. Exercises within each participant's individualized RT program progress with a periodization model as recommended by the American College of Sports Medicine. In addition, the cancer exercise trainer will inquire about space availability in the home for completing resistance prior to developing the personalized prescription. This logistical information is key to ensure feasibility of completing the exercises prescribed. Participants will be provided with beginner and advanced sets of elastic resistance bands to enable progression throughout the 52-week study.
75787214|NCT00297479|Behavioral|Individual Therapy|In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
75923429|NCT04520360|Drug|Carisbamate|Carisbamate is currently under investigation as an adjuvant antiepileptic therapy in Lennox-Gastaut patients. Lennox-Gastaut syndrome (LGS) is a rare and highly debilitating form of childhood epilepsy that typically is diagnosed between 2 and 8 years of age, with peak onset at 3 to 5 years of age, and frequently persists into adulthood. Treatment options are limited and complicated by the multiple seizure types associated with LGS. Given the breadth of physical and cognitive disabilities associated with LGS, the development of antiseizure medications with appropriate oral dosing forms is needed to ensure administration feasibility and compliance in the target population.
75923430|NCT03132480|Other|fluid resuscitation|when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
75330792|NCT03015415|Procedure|Elbow Open Arthrolyses|Elbow arthrolysis by posterior access
75330793|NCT03015415|Procedure|Non-surgical intervention|Rehabilitation with splinting protocols
75330794|NCT03220048|Drug|PrEP-001|
75470345|NCT05397366|Diagnostic Test|Neurodevelopmental Training|"Group B will receive the Neurodevelopmental protocol with the routine physical therapy for 45 mins on the upper limb 3 times a week for period of 12 weeks. The intervention will be performed by the trained physical therapist.~This Neurodevelopmental protocol will include different exercises like , patient should sit while bearing weight , patient can do self-overhead movements with hand clasped , while holding the gymnastic ball reach forward and overhead position while sitting , weight bearing while plantigrade or quadruped position , while sitting or standing can move the ball in forward , backward and sideways."
75470346|NCT05396781|Drug|Proflavine|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
75470347|NCT05396781|Device|Mobile, Augmented High Resolution Microendoscope|The marHRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
75787215|NCT01069367|Biological|Emulsion, Cell Culture-based, influenza HA vaccine H1N1|Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
75787216|NCT01069445|Dietary Supplement|VSL#3® probiotic blend|Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
75787217|NCT01069445|Dietary Supplement|AISA-5203-L fruit extracted terpene|Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
75923431|NCT03356912|Drug|Cabazitaxel|"Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route"
75330795|NCT03220048|Other|Placebo Comparator|
75330796|NCT00635882|Drug|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
75330797|NCT00635882|Drug|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
75330798|NCT00635882|Drug|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
75330799|NCT00635882|Drug|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
75330800|NCT00635882|Drug|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
75330801|NCT00635882|Drug|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
75638333|NCT06111443|Drug|Dapagliflozin 10 mg [Farxiga]|Dapagliflozin 10 mg [Farxiga] for 3 months after catheter ablation of atrial fibrillation
75638334|NCT06107192|Other|Dietary intervention - apple catechin diet|The intervention will provide a catechin-containing apple juice, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.
75787218|NCT01069445|Dietary Supplement|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
75923432|NCT03356912|Drug|Prednisone|Prednisone should be administred by oral route
75923433|NCT02308566|Procedure|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
75923434|NCT02308566|Procedure|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
75923435|NCT00102687|Drug|azacitidine|"Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation."
75330802|NCT03148015|Other|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
75470348|NCT05386420|Drug|Hymecromone tablets|Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.
75470349|NCT05386420|Other|Placebo|Conventional treatment combined with Placebo.
75923436|NCT04509440|Drug|isotonic dextrose 5% in water (D5W) solution|Neurol prolotherapy (NP) is the subcutaneous perineural injection of isotonic dextrose 5% in water (D5W) solution.
75330803|NCT03445156|Behavioral|Video game|Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
75470350|NCT05378308|Other|Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)|Patients with AF or VTE; OAC treatment patterns according to patient demographics, clinical factors, risk stratification, geographic regions, local NOAC medical insurance policy and NOACs availability
75470351|NCT05303038|Combination Product|Cryoablation Combined with Tirelizumab and Bevacizumab|"Cryoablation of 1-2 typical metastatic lesions will be performed on D1 under general anesthesia and ultrasound guidance for two cycles.~200mg Tirelizumab ( IV Q3W) + Bevacizumab 7.5mg/kg ( IV Q3W) will be administered at D14 after cryoablation."
75470352|NCT05290818|Device|MAKO™ Partial Knee Arthroplasty|The robotic-arm will be used to position a partial knee arthroplasty.
75470353|NCT05290818|Device|Triathlon (Stryker) Total Knee Arthroplasty|Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert.
75638335|NCT06107192|Other|Dietary intervention - low catechin diet|The intervention will provide a nutritionally-matched beverage without catechins, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.
75638336|NCT06106256|Device|Galvanic Vestibular Stimulation (GVS)|Four electrodes, forehead, behind both ears, and back of your neck, provide bidirectional electrical stimulation and receive information about the amplitude delivered accounting for skin impedance
75330804|NCT03445156|Behavioral|Controller|Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.
75638337|NCT06106256|Other|Flight simulations in virtual reality (VR)|Highly immersive, 3D virtual flight simulation environment
75638338|NCT06106256|Other|3-DOF Bertec Portable Essential's dual-balance force plate system|Firm surface/plate to stand on while being presented disorienting visual patters of moving vertical and/or horizontal bars of alternating black and white.
75787219|NCT01069445|Behavioral|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
75787220|NCT00688870|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
75787221|NCT00688870|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
75787222|NCT00297167|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
75787223|NCT00297167|Drug|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
75923437|NCT04509440|Drug|corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
75330805|NCT03082495|Behavioral|Exercise|Supervised high-intensity interval training (HIIT) during NACRT followed by unsupervised moderate-to-vigorous intensity continuous exercise training after the completion of NACRT and before surgery
75330806|NCT03001063|Other|Supported Self-Management|This Supported Self-Management intervention consists of bibliotherapy (the Antidepressant Skills Workshop) that is provided to a patient by a health or social worker. The patient is supported in the use of the skills found in the workbook over the course of two months. The skills in the workbook are based on the principles of Cognitive Behavioural Therapy.
75330807|NCT03001063|Other|Enhanced treatment as usual|Participants in the control arm will received enhanced treatment as usual in the form of usual care at primary care centres and a leaflet providing information about depression.
75330808|NCT03316378|Drug|Ropivacaine injection|single dose, subcutaneous injection
75330809|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0008%|
75330810|NCT00637130|Drug|Travoprost ophthalmic solution, 0.001%|
75330811|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0012%|
75470354|NCT05280925|Behavioral|Episodic Future Thinking|Participants will be prompted three times daily to think vividly about personally meaningful future events.
75470355|NCT05280925|Behavioral|Healthy Information Thinking|Participants will be prompted three times daily to think about their responses to informational health vignettes.
75638339|NCT06104670|Dietary Supplement|Synaquell(TM)|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
75638340|NCT06104670|Dietary Supplement|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
75638341|NCT06104566|Drug|lisaftoclax +BTK inhibitor|lisaftolax + BTK inhibitor
75638342|NCT06104566|Drug|BTK inhibitor|BTK inhibitor
75638343|NCT06104124|Drug|Dazodalibep|IV infusion
75638344|NCT06104124|Drug|Placebo|IV infusion
75330812|NCT00637130|Drug|TRAVATAN|
75330813|NCT00637130|Other|Vehicle|
75330814|NCT02847559|Biological|Bevacizumab|Given IV
75330815|NCT02847559|Procedure|Electric Field Therapy|Undergo electric field therapy using Optune device
75470356|NCT05275504|Drug|TT-01488|TT-01488 tablet will be administered orally once daily per protocol defined schedule.
75787224|NCT00297167|Drug|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
75330816|NCT02847559|Device|NovoTTF-200A Device|Undergo electric field therapy using Optune device
75923438|NCT02312544|Drug|OTX-TP|OTX-TP and placebo drops
75638345|NCT06101797|Other|Remote supervised exercise group|The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised by video call. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.
75787225|NCT00297167|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
75787226|NCT02532335|Drug|Obeticholic acid|active drug
75787227|NCT02532335|Drug|Obeticholic acid placebo|matching placebo
75787228|NCT03216226|Drug|dasiglucagon|Glucagon Analog
75787229|NCT03216226|Drug|GlucaGen|Native Glucagon
75923439|NCT02312544|Drug|Timolol|Timolol drops and placebo punctum plug
75330817|NCT02847559|Procedure|Quality-of-Life Assessment|Ancillary studies
75638346|NCT06101797|Other|In-person supervised exercise group|The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised at a physiotherapy clinic. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.
75638347|NCT06095505|Drug|Alisertib|Alisertib enteric-coated tablets
75638348|NCT06090721|Drug|DMT310|Topical Powder
75638349|NCT06090721|Drug|Placebo|Placebo Topical Powder
75787230|NCT03215758|Drug|QAW039|QAW039 once daily
75787231|NCT03215758|Drug|Placebo|Placebo once daily
75787232|NCT00290771|Drug|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
75787233|NCT00290771|Drug|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
75787234|NCT01069601|Biological|Focetria (2x H1N1 vaccine with MF59 adjuvants)|7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
76079473|NCT03468504|Device|Treadmill|Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
75330818|NCT00637052|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
75330819|NCT01921868|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine, 2 g/day, up to 24 months.
75330820|NCT02150785|Drug|Streptokinase|
75787235|NCT00274625|Device|Surgisis Gold Graft|Surgisis Gold Graft is placed as an underlay following open bariatric surgery.
75787236|NCT00274625|Procedure|Control|Incision is closed without the placement of a graft material (standard of care control)
75923440|NCT03360734|Drug|First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)|Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR
75923441|NCT02308644|Drug|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
75923442|NCT04510636|Drug|Pembrolizumab|Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
76079474|NCT04906434|Drug|60mg ABSK-011capsule|Three 20mg capsules,QD for oral administration
76079475|NCT04906434|Drug|120mg ABSK-011capsule|One 20mg capsule and one 100mg capsule,QD for oral administration
76079476|NCT04906434|Drug|180mg ABSK-011capsule|One 100mg capsule and four 20mg capsules,QD for oral administration
76079477|NCT04906434|Drug|240mg ABSK-011capsule|Two 100mg capsules and two 20mg capsules,QD for oral administration
76079478|NCT04906434|Drug|320 mg ABSK-011capsule|Three 100mg capsule and one 20mg capsule,QD for oral administration
76079479|NCT04906434|Drug|400mg ABSK-011capsule|Four 100mg capsules,QD for oral administration
75330821|NCT03220204|Behavioral|PP-based health behavior intervention|The positive psychology exercises include 3 modules: gratitude-based activities, strength-based activities, and meaning-based activities. The goal-setting portion of the program focuses primarily on physical activity (8 weeks) but also includes 4 weeks focusing on diet and medication adherence.
75330822|NCT03220204|Behavioral|MI-based educational control condition|The MI-based educational program includes information on five topics: (1) information about heart disease and risk factors for worsening heart disease, (2) physical activity, (3) a heart-healthy diet, (4) medication adherence, and (5) stress management.
75330823|NCT01925534|Device|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
75330824|NCT01925534|Device|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
75923443|NCT04510636|Drug|Bendamustine Hydrochloride|Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.
75923444|NCT05618626|Other|Physical exercise and dietary intervention for NAFLD|Investigators will assess the efficiency of the intervention by measuring adherence to physical exercise and nutritional diet.
75330825|NCT02165605|Drug|HylaCare|cream
75330826|NCT02165605|Drug|Placebo|placebo
75923445|NCT02308722|Radiation|5-fraction stereotactic body radiation therapy|"The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV_R) 10Gy/# (total dose 50Gy)"
75923446|NCT03540849|Drug|Brentuximab Vedotin (Bv)|HL patients who are eligible for the study, will receive maintenance Bv. The first Bv dosage will be administered three months after allo-SCT (day 90) at the dosage of 1.8 mg/kg every 21 days for 12 cycles. post allo-SCT maintenance Bv for Hodgkin lymphoma
75470357|NCT05274555|Other|Assessment|"The Upper Limb Short Questionnaire was administered by the researcher in face-to-face sessions with the children and their caregivers.~The lower extremity functions and ambulation levels of the children were evaluated by the researcher using the Vignos Scale.~The Brooke Upper Extremity Functional Rating Scale and ABILHAND-Kids were used to evaluate children's upper extremity functions."
75638350|NCT06088173|Other|exercises|Patients in both group will use Kleinert splint. Sessions will start with ice application if there is edema and continue with scar tissue massage. After general hand massage, passive flexion, active extension exercises; tenodesis exercise and passive punch will be performed for the postoperative (postop) first two weeks. In postop 3-4 weeks, four finger sliding exercises, active half fist and NMES (Neuromuscular electrical stimulation) will be performed. In postop 5-6 weeks, blocking exercises, full punch, grappling hooks and small on-digits holding and releasing exercises will be performed additionally.
75330827|NCT01926158|Drug|Denosumb|Prefilled syringe of 1 mL denosumab solution
75330828|NCT01926158|Drug|Placebo (for denosumab)|
75330829|NCT03445390|Drug|Acetaminophen|Acetaminophen 1 g intravenous given at the beginning and end of surgery.
75330830|NCT03445390|Drug|Placebo|Placebo to match acetaminophen given at the beginning and end of surgery.
75470358|NCT05273840|Dietary Supplement|Ivital Control|Patients in the intervention group will take 2 sachets of nutritional supplements(Ivital Control) once a day in lieu of one meal, besides receiving lifestyle interventions.
75470359|NCT05273840|Behavioral|lifestyle intervention|Patients will receive lifestyle interventions.
75638351|NCT06088173|Other|Exercises and Education|In addition to the same treatment as the patients in the first group, in the first postoperative (postop) two weeks, the gmi will be explained to the patients and lateralization will be started. lateralization refers to right-left discrimination and the patients will be presented with visuals with the help of the noi recognise app and they will have to decide whether the visual is right or left hand. In the postop 3-4th weeks, the motor imagery stage will be started and imagery will be practiced with the help of the same app. In postop 5-6 weeks, mirror therapy will be practiced with the help of a mirror box.
75638352|NCT06082167|Drug|Zanzalintinib|Specified doses on specified days
75638353|NCT06082167|Drug|Zanzalintinib-matched Placebo|Specified doses on specified days
75638354|NCT06082167|Biological|Pembrolizumab|Specified doses on specified days
75330831|NCT00981890|Drug|Sunitinib|Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
75638355|NCT06077877|Drug|GSK4524101|GSK452101 will be administered.
75923447|NCT04509362|Device|Advanced Hybrid Closed Loop System|Evaluation of the use of an 8-day structured protocol to initiate patients from MDI to the AHCL system, in achieving safe glycemic control
75923448|NCT02160405|Dietary Supplement|native potato|
75923449|NCT03509064|Other|Collection sheet|Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet
76079480|NCT04904250|Device|Emboshield|a distall occlusion Emboshield NAV6 will be used as the embolism protection device during CAS
76079481|NCT04904250|Device|Spider|a distal SpiderFX will be used as the embolism protection device during CAS
76079482|NCT04348422|Diagnostic Test|COVID-19 RT-PCR|Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
76079483|NCT04348422|Diagnostic Test|COVID-19 Serology|Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
76079484|NCT04348422|Other|Symptoms questionnare|Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
76079485|NCT04453098|Behavioral|3-week residential program based on a tryptic (diet,|"3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education)."
76079486|NCT03456570|Drug|Dydrogesterone 10 mg|Dydrogesterone 10 mg twice daily
75330832|NCT02165761|Device|GORE® Hybrid Vascular Graft|
75330833|NCT02165761|Device|Non-heparin bonded synthetic graft|
75638356|NCT06077877|Drug|Niraparib|Niraparib will be administered.
75923450|NCT03356678|Drug|Pralatrexate|"Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed.~Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed."
75923451|NCT02160483|Other|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
76079487|NCT03456570|Drug|Placebo Oral Tablet|oral tablets twice daily
75638359|NCT06073535|Procedure|Extraction of mandibular third molar|"After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle.~An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary."
75638360|NCT06073535|Device|i-PRF|20 ml of venous blood will be drawn from the ante-cubital vein of all patients and collected in 2 plastic tubes (Vacutainer, Becton& Dickinson, Rutherford, NJ) containing no anticoagulant or gelling agent. The tubes will be placed in a centrifuge (DUO Centrifuge, Nice, France) at 700 round per minute for 3 min, at the end of which time the blood will be separated into 2 fractions: the layer of injectable liquid i-PRF, which is more superficial, and the layer of red blood cells, in the deep part. From each tube, i-PRF will be withdrawn using a sterile syringe and it will be infiltrated into the lesion.
75638361|NCT06071624|Biological|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
76079488|NCT05203224|Drug|Dornase Alfa|Intravenous Dornase alfa
75330834|NCT03221764|Drug|Amiodarone with CoSeal|CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients [8]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
75330835|NCT03221764|Device|CO2 driver|The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
75787237|NCT01325597|Other|Combined training|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.
75787238|NCT01325597|Other|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
75787239|NCT01325597|Other|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
75787240|NCT01325597|Other|Control group|No intervention
75330836|NCT03122444|Drug|Imipramine|Imipramine will be given daily for 21-30 days.
75330837|NCT05593783|Procedure|lithotripsy|lithotripsy
75330838|NCT01924130|Other|Classroom feeding|Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.
75787241|NCT00290693|Drug|Capecitabine|Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
75787242|NCT00290693|Drug|Docetaxel|30 mg/m2, IV, days 1 and 8 every 3 weeks
75787243|NCT03214666|Drug|GTB-3550 TriKE® Phase I|"The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~Dose Level 1 - 5 μg/kg/day~Dose Level 2 - 10 μg/kg/day~Dose Level 3 - 25 μg/kg/day~Dose Level 4 - 50 μg/kg/day~Dose Level 5 - 100 μg/kg/day~Dose Level 6 - 150 μg/kg/day~Dose Level 7 - 200 μg/kg/day"
75787244|NCT03214666|Drug|GTB-3550 TriKE® Phase II|Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
75787245|NCT00274469|Drug|fulvestrant|500 mg intramuscular injection
75787246|NCT00274469|Drug|anastrozole|1 mg oral tablet
75787247|NCT03214588|Drug|TAK-831|TAK-831 tablets
75787248|NCT03214588|Drug|TAK-831 Placebo|TAK-831 placebo matching tablets
75923452|NCT03503760|Device|LIMFA Therapy®|It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
75923453|NCT04509206|Behavioral|Nutritional education|The curriculum for the four classes include understanding MyPlate guidelines, learn basic knife skills, meal prep, and plan, home farming and no-cook cooking.
76079489|NCT03464838|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
76079490|NCT03464838|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
76079491|NCT04870554|Behavioral|Enteric feeding|All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
76079492|NCT03456180|Device|Haemoadsorption with Cytosorb cartridge|microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
75923454|NCT05532826|Other|donor EBV-specific T lymphocytes|"EBV-DNA reactive after transplantation, or did not turn negative after +30 days, peripheral blood lymphocytes of the donor were collected to prepare EBV-CTL, and the first transfusion of EBV-CTL 6.0x105 was given at 48h to rapidly culture EBV-CTL, then EBV-CTL 6.0x105/kg was injected once a week untile EBV-DNA negative for 2 consecutive times or GVHD happened. After the second infusion, EBV-DNA did not decrease and there was no aGVHD patients, EBV-CTL infusion volume was increased to 1.2x106/kg, once a week. After 2 cycle infusion, EBV-DNA still did not decrease, and the reinfusion was terminated.~Peripheral blood lymphocytes were collected from donors of high-risk patients at +14 days after allogeneic hematopoietic stem cell transplantation to prepare EBV-CTL, and EBV-CTL 6.0x105/kg was infused at +21d, +28d, +35d and + 42D for prevention. During treatment, if the patient develops GVHD, the infusion should be stopped."
75923455|NCT02160561|Other|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
75923456|NCT02304354|Drug|Rituximab|For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
75923457|NCT05615350|Other|Meals served during breakfast with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during breakfast at the eating behaviour lab
75330839|NCT01924130|Behavioral|Nutrition education lessons|Students receive breakfast specific nutrition education lessons.
75470360|NCT05263960|Drug|CM350_group 1|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 5ug of CM350 on the first day of first cycle (C1D1), 5ug on C1D8, 5ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75923458|NCT05615350|Other|Meals served during lunch with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during lunch at the eating behaviour lab
75330840|NCT01924130|Behavioral|Social Marketing|A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.
75638362|NCT06069869|Dietary Supplement|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily for one month.
75330841|NCT01924130|Behavioral|Parent outreach|A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
75330842|NCT02848989|Other|Qigong Mind-Body Exercise|An exercise program that involves gentle movements combined with breathing/relaxation techniques
75470361|NCT05263960|Drug|CM350_group 2|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 15ug of CM350 on the first day of first cycle (C1D1), 15ug on C1D8, 15ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75330843|NCT03317002|Drug|AZD5718|Oral dose of AZD5718 (tablet)
75638363|NCT06069869|Dietary Supplement|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
75638364|NCT06069869|Dietary Supplement|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
75638365|NCT06069206|Other|T2Bacteria® Panel (direct-from-blood testing)|Providers will be prompted to order the T2Bacteria® Panel (direct-from-blood testing) and accompanying communications regarding panel results will be delivered.
76079493|NCT03468348|Drug|Duloxetine|patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
76079494|NCT03464682|Drug|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
76079495|NCT03464682|Drug|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
76079496|NCT03464682|Drug|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
76079497|NCT03464682|Drug|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
75330844|NCT03317002|Drug|AZD5718|Oral dose of AZD5718 (tablet)
75330845|NCT03317002|Drug|Placebo|Matching placebo (tablet)
75470362|NCT05263960|Drug|CM350_group 3|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 45ug on C1D8, 45ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75638366|NCT06069206|Other|Usual Care|Standard blood cultures.
75638367|NCT06063135|Other|Physical Exercise Intervention|Two strength training session per week and one endurance training session per week
75638368|NCT06062069|Drug|CT-868|CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
75330846|NCT02390505|Drug|Vitamin C|
75330847|NCT02390505|Drug|Placebo|
75330848|NCT05593081|Genetic|HLA|Distinguish based on clinical features
75330849|NCT05592925|Diagnostic Test|coagulation-related factors|We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
75330850|NCT03223246|Other|Additional teaching|A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
75638369|NCT06062069|Device|CT-868 Pen Injector|The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
75638370|NCT06062069|Drug|: CT-868 Pen Injector, Placebo|The placebo pen injector is identical and contains the same ingredients except for CT-868.
75638371|NCT06055842|Other|over-denture|implant retained overdenture prosthesis.
75470363|NCT05263960|Drug|CM350_group 4|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75470364|NCT05263960|Drug|CM350_group 5a|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75470365|NCT05263960|Drug|CM350_group 5b|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75330851|NCT02169427|Drug|OPC|The drug substance of 100 mg OPC was administered as 1 capsule.
75330852|NCT02795247|Procedure|Anterior Cruciate Ligament Reconstruction|
75330853|NCT03452176|Device|Scrambler|Scrambler is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of nociceptive fibers with the intent of re-organizing maladaptive signaling pathways which has been investigated for treatment of peripheral neuropathy.
75470366|NCT05263960|Drug|CM350_group 6a|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75470367|NCT05263960|Drug|CM350_group 6b|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 270ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75470368|NCT05263960|Drug|CM350_group 7|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75638372|NCT06052553|Device|TopSpin360|Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.
75638373|NCT06051318|Other|Standardized breakfast A|Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
75638374|NCT06051318|Other|Standardized breakfast B|Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
75638375|NCT06050798|Diagnostic Test|Von willebrand antigen|Von willebrand antigen change and hematological disorder in patients with angiodysplasia
75638376|NCT06049329|Drug|NNC0487-0111|Participants will get one tablet to swallow at the same time of the day.
75787249|NCT01556776|Drug|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
75923459|NCT03356600|Combination Product|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy"
75923460|NCT04464018|Other|working grup|After each student received theoretical training, they performed an intravenous injection on the model. In the study group performed hybrid simulation. After finishing the simulation application. the students went to the analysis room and watched their own application videos. The analysis session was held immediately after all the students in the group completed their applications.The IM injection success Test and Student Satisfaction and self-confidence scale were applied to the study and control groups after the laboratory application was completed.
75923461|NCT00102531|Drug|Cisplatin liposomal|
75923462|NCT05347654|Other|Local treatment with silver sulphadiazine only|Local treatment with silver sulphadiazine and tulle from day 0 to day 8 (included). From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
75923463|NCT05347654|Other|Local treatment with silver sulphadiazine followed by URGOCLEAN® dressing|Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
75923464|NCT03360266|Combination Product|Sodium Fluoride with CPP-ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
75923465|NCT03360266|Combination Product|sodium fluoride with ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
75923466|NCT03360266|Drug|5% Sodium Fluoride Varnish|ffor children with ECC, this varnish effectively remineralizes the white spot lesion
75923467|NCT02154789|Drug|polidocanol|
75923468|NCT02154789|Procedure|infra-red coagulation|
75923469|NCT02154789|Procedure|cryotherapy|
76079498|NCT03464682|Drug|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
75330854|NCT03452176|Device|Scrambler Sham Control|Sham control should be indistinguishable to the participants from experimental Scrambler therapy.
75330855|NCT03454048|Drug|Piperaquine (low dose)|subcurative regimen (480 mg)
75330856|NCT03454048|Drug|Piperaquine (high dose)|Curative regimen (960mg)
75330857|NCT03454048|Drug|Sulfadoxine pyrimethamine|Curative regimen (1000mg/50mg)
76079499|NCT03464682|Drug|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
76079500|NCT03464526|Drug|Orvepitant|Tablet, once daily, oral
76079501|NCT03464526|Drug|Placebo|Tablet, once daily, oral
75330858|NCT03454048|Drug|Atovaquone Proguanil|Curative regimen (1000/400 mg, for 3 days)
75330859|NCT03454048|Other|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
75330860|NCT03454048|Other|Blood stage malaria challenge infection, P. falciparum 3D7|P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
75330861|NCT02165839|Behavioral|Brief Behavioral Therapy for Insomnia (BBT-I)|
75330862|NCT02165839|Behavioral|Healthy Eating Education Learning (HEAL)|
75330863|NCT04396184|Procedure|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
75330864|NCT03226366|Other|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
75330865|NCT04395872|Behavioral|Psychiatric counseling|Patients who are admitted to the COVID-19 care unit of the Catholic University of Daegu Hospital are subject to consultation with the psychiatrist. By retrospectively reviewing the medical records of the request and the results of the subjects, We collected Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R) This study evaluates whether there is a difference in psychological scale according to differences in socio-demographic status and medical severity, and compares psychological psychological measures before and after referral to mental health medicine to evaluate the effectiveness of psychiatric counseling.
75470369|NCT05263960|Drug|CM350_group 8|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 405ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
75923470|NCT05532748|Device|Respiratory exercise protocol with the modified Pachon's incentive|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a slow, deep breath, fully stretching the condom, and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe for 3 minutes at a gentle intensity through your nose without extra effort.~All these instructions will be explained through a video."
75330866|NCT03015337|Behavioral|New physical education instructions|
75330867|NCT04395092|Biological|K-NK002|"K-NK002 will be administered intravenous (IV) on Day -2, Day +7 and Day +28.~Part One (Safety run-in):~An initial safety run-in to confirm the starting dose, and safety and tolerability of K-NK002;~Dose cohort 1 will include 3 patients who will receive a dose of K-NK002 at 1 x 10E7 NK cells per kg.~Dose cohort 2 will include 3 patients who will receive K-NK002 at 1 x 10E8 NK cells per kg.~Part Two (Open Enrollment):~Enrollment into the second part of the study (Open Enrollment) can begin following Part One, confirmation of dose and safety."
75470370|NCT05263960|Drug|CM350_MTD level|CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
75470371|NCT05263960|Drug|CM350_MTD-1 level|CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
75638377|NCT06049329|Drug|Placebo (NNC0487-0111)|Participants will get one tablet to swallow at the same time of the day.
75638378|NCT06046794|Other|Analyze of GemCore status|Genomic analyze of GemCore status
75923471|NCT05532748|Device|"Respiratory exercise protocol with Branded respiratory incentive, Triflo II®"|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a smooth deep breath lifting as many spheres as you can and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe gently through your nose for 3 minutes without extra effort.~All these instructions will be explained through a video."
75923472|NCT03506490|Other|Aerobic exercises|The training session lasted 45 minutes and was composed of running exercises.
75923473|NCT03503682|Radiation|standard treatment|3000 cGy in 10 daily fractions
75923474|NCT03503682|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
75923475|NCT05532592|Other|Perceptions and attitudes towards COVID-19 and COVID-19 vaccine|Attitude towards COVID-19; Knowledge about COVID-19 vaccine
76079502|NCT04336878|Behavioral|Healthy Habits in Pregnancy and Beyond|Habit-based intervention to support the development of 10 healthy dietary and activity behaviours for pregnant women with overweight or obesity.
76079503|NCT03468192|Other|Non-precaution group|Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed
76079504|NCT02522598|Drug|VVZ-149 injections|Colorless, transparent liquid in water for injection
75638379|NCT06045416|Procedure|venous blood puncture|"Venous blood puncture performed at first hospital contact, and at 28 days, 3 month, and 6 months after hospital admission.~Lumbar puncture and joint puncture for the study will be performed if it is indicated due to diagnostic or therapeutic reasons."
75638380|NCT06043154|Other|Patients with severe to extreme anorexia nervosa admitted to hospital for refeeding|Clinical and biological measurements, blood and stool sample collection
75923476|NCT02771145|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
75330868|NCT04395092|Procedure|Conditioning Regimen|"From Day -7 to Day -3:~Melphalan: 140 mg/m2 (100mg/m2 in patients ≥ 60) on Day -7.~Fludarabine: 40 mg/m2 daily for 4 doses starting on days -7.~TBI: 2 Gy on Day -3."
75330869|NCT04395092|Procedure|HaploBMT|Bone marrow is the only allowed graft source for patients enrolled in this clinical trial
75330870|NCT03015571|Device|Esophagus inspection in Narrow Band imaging.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.
75330871|NCT03015571|Device|Standard High definition endoscopy.|Whole procedure will be performed in standard High definition endoscopy.
75330872|NCT03015571|Device|Esophagus inspection in Narrow Band imaging and increased care.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.
75638381|NCT06042608|Procedure|intercostobrachial nerve block|injection of local anesthetic to target the intercostobrachial nerve in the axilla
75638382|NCT06040619|Behavioral|Therapy Together|8-week caregiver-led pediatric constraint-induced movement therapy program
75787250|NCT01556776|Drug|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
75787251|NCT05425810|Device|Apply ENABLE sensing pad|The developed ENABLE system is integrated into the standard prosthetic liner and measures the pressure distribution during locomotion. Using the ENABLE system may lead temporary increase in the temperature inside the prosthetic socket and it is expected that the total exposition during the experimental procedure will be less than 10 min.
75787252|NCT05425810|Device|Insert small pads at pressure tolerant locations|To change the pressure distribution inside the socket, four fitting conditions are introduced by adding small pads at patella tendon (PT), lateral tibial crest (LTC), medial tibial crest (MTC), and popliteal fossa (PF) respectively. Including the no pads scenario, totally of five fitting conditions are simulated.
75787253|NCT03166618|Device|Juvéderm® VOLUMA XC|Juvéderm® VOLUMA XC hyaluronic acid injectable gel
75787254|NCT02810236|Procedure|Ultrasound|Ultrasound will be performed.
75330873|NCT03015571|Device|Standard High definition endoscopy and increased care.|Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
75787255|NCT02810236|Behavioral|Discussion|Radiologist will discuss with the patient the findings on mammogram.
75923477|NCT02771145|Device|Soft contact lenses (SCL)|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.
75330874|NCT01924286|Drug|Prednisone|
75330875|NCT01924286|Drug|Placebo|
75330876|NCT04443439|Device|GE Discovery MR750 3.0t superconducting MRI|T2WI, FLAIR, DWI, 3D BRAVO, 3D-ASL, rs-fMRI, DKI sequences to exclude other organic lesions
75330877|NCT03455218|Drug|Nitric Oxide|20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
75330878|NCT03455218|Drug|Placebo|INOmax device connected to oxygenator, but no gas is delivered
75638383|NCT06040619|Behavioral|Usual Care|8 weeks of usual care received in an early intervention therapy program
75638384|NCT06037421|Other|Human breast milk sampling|Human breast milk sampling
75638385|NCT06037421|Other|Saddle sampling|Saddle sampling
75638386|NCT06037421|Other|Skin sampling|Skin sampling
75787256|NCT05353036|Other|Survey|Survey assessing incidence, frequency, and type of illicit substance use
75923478|NCT02771145|Device|SCL preservative solution|Commercially available solution for rinsing soft contact lenses
75923479|NCT02308800|Device|Quantum™ Therapy - NPWT with Prontosan|Negative pressure wound therapy with Prontosan irrigation.
75923480|NCT02308800|Device|Quantum™ Therapy|Negative pressure wound therapy without irrigation.
76079505|NCT02522598|Drug|Placebo|water for injection
76079506|NCT03464370|Other|Measure of emotional stressors|"For the Epileptic Group~Rapid interrogation, completing the clinical data~A scale of impact of the precipitating factors of crises~An emotional Stroop~A task of detecting emotional targets against threatening information~A measure of the perception of emotions using film clips~A scale of measurement of perceived stress~The transfer of psychiatric scales~For the healthy volunteers group :~A rapid interrogation, gathering the possible medical history, the level of studies, the manual laterality~An emotional Stroop~A task of detecting emotional targets against threatening information~A scale of measurement of perceived stress~A measure of the perception of emotions using film clips~A rapid neuropsychological assessment"
75330879|NCT03455218|Device|INOmax|All patients will have the INOmax device connected to the oxygenator
75638387|NCT06037421|Other|Saliva sampling|Saliva sampling
75638388|NCT06037421|Other|blood sampling|blood sampling
75638389|NCT06031402|Procedure|Endoscopy|Endoscopy
75638390|NCT06026046|Other|Adapted sport program based on fencing|"This adapted sport program includes 3 to 5 sessions per week of adapted fencing (excluding weekends and public holidays), carried out either by a fencing master trained in adapted sport, or by an APA teacher trained in adapted fencing by the fencing master.~Sessions can last from 10 to 30 minutes. The course of the session is validated by the fencing master and adapted to each patient. The limiting factors are taken into account, in order to direct towards a specific practice.~The sessions are progressive with very short and varied sequences calling on the imagination and experience of the fencing masters."
75638391|NCT06019078|Device|SedLine|Continuous 4 channel processed neurological monitor
75638392|NCT06017557|Diagnostic Test|Artificial Intelligence|With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, it would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumors can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.
75638393|NCT06017479|Drug|Fosfomycin 3000 MG|Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
75638394|NCT06017479|Drug|Levofloxacin 500mg|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
75638395|NCT06016920|Biological|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
75638396|NCT06016920|Drug|Pembrolizumab|"Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes."
75787257|NCT05294614|Behavioral|"Sonreír es diveritdo - Smiling is fun"|Smiling is Fun is an online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules. The modules and their aims are: 1) Motivation for change; advantages and disadvantages of changing and importance of motivation; 2) Understanding emotional problems; psychoeducational information, maintaining factors and management of medication and sleep hygiene; 3) Learning to get going; behavioural activation strategies; 4) Learning to be flexible; how interpret negative thoughts and situations in a more flexible way; 5) Learning to enjoy; importance of positive emotions and strategies to promote them; 6) Learning to live; how to identify the psychological strengths and importance of doing activities based on values and vital goals; 7) Living and learning; putting into practice the strengths identified in previous module; 8) From now on… what?; a relapse prevention module.
75923481|NCT05260840|Other|Evaluation study - provision of an online questionnaire|Evaluation study - provision of an online questionnaire
75638397|NCT06012851|Behavioral|Mobile behavioral parent training (mBPT) and prompts|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access. In-the-moment feedback will include parenting feedback and parenting strategies.
75787258|NCT05225818|Behavioral|PLAN - Home|home-based intervention program for dementia evaluation, education, and care planning
75923482|NCT04444414|Other|Manual therapy|bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
75923483|NCT04444414|Other|Control group|The control group received no treatment, they only attended the evaluations.
75923484|NCT03506256|Drug|Norfloxacin 400 MG|Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
75923485|NCT04508660|Drug|CGB-400|BID application
75638398|NCT06011109|Drug|APG-157|The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.
76079507|NCT04862052|Procedure|Intravascular management of prior implanted coronary drug eluting stent restenosis|Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
75638401|NCT06005350|Dietary Supplement|Niagen|Nicotinamide-Riboside-Chloride Preparation 1000mg/day
75638402|NCT06005350|Other|Placebo|Placebo Preperation
75787259|NCT02599558|Device|Cytosponge|A capsule with a string attached with a sponge inside is swallowed. The string is held without any tension to allow the capsule to move into the stomach. The string will be held for five minutes to allow the capsule to dissolve in the stomach; a round mesh sponge about the size of a quarter is released.
75923486|NCT02308956|Behavioral|Integrated mental health in primary care|A task-shared model of collaborative mental health care integrated into the primary care setting.
75923487|NCT02308956|Behavioral|Psychiatric nurse-led specialist care|A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
75923488|NCT03356444|Drug|Abiraterone Acetate|Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
75923489|NCT03356444|Drug|Docetaxel|"Docetaxel: intravenously, 75 mg/m^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment"
75923490|NCT05597176|Other|Spinal Cord Injury Exercise Group|Participants will have an initial accommodation period of 4 weeks, during which four 10-minute exercise bouts/day will be interspersed with 5 minutes of rest. The bouts will gradually increase until at least continuous 40-minute sessions. The remaining 12-week intervention will be set at 70% max heart rate for a total of 16 weeks.
75923491|NCT04520438|Procedure|Leukocyte and platelet rich fibrin|L-PRF membrane and irrigation with L-PRF exudate in the same treatment session of NSPT
75923492|NCT04520438|Procedure|Non-Surgical Periodontal treatment|The control group only received NSPT (scaling and root planing) in one treatment session.
75470372|NCT05260398|Behavioral|Mightier Online Gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
75470373|NCT05227157|Other|swab with iron sulfate solution|measurement of the intensity of perception of metallic taste by affixing a swab iron sulfate solution 10g/l at 4 places on the tongue depending on the glossopharyngeal nerve: tip of the tongue (right and left); base of the tongue (right and left). Visual analogic Scale (0 to 5)
75470374|NCT05218291|Other|Yoga Practice|In this study, the yoga initiative to be made for the caregivers in the experimental group consists of breathing, meditation and yoga poses.
75638403|NCT05998460|Behavioral|Glucose-Guided Eating with CGM|The GGE intervention consist of up to four weeks of training to learn to eat when glucose levels are at or below their usual fasting level. Specifically, participants following GGE will self-monitor their glucose levels with an unblinded CGM while using a mobile app (GGE app) that will provide feedback on whether or not to eat. At desired mealtimes participants will enter their current glucose level, rate their perceived hunger, and label the type of hunger they are experiencing (physical, emotional, sensory and practical). Participants following GGE will be instructed by the app to eat when two conditions are met: (a) the desire to eat arises and (b) their glucose levels are at or below a personalized threshold. During the training period, participants are meant to associate feelings of perceived hunger with fasting glucose levels (i.e., physical hunger). After the training period, participants continue to follow GGE without CGM or use of the app.
75638404|NCT05998460|Other|CGM only|Comparator participants will use unblinded CGM for up to 4 weeks without the use of the GGE app or any other dietary recommendations.
75638405|NCT05995444|Drug|Epetraborole and matching placebo|Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)
75638406|NCT05995444|Drug|Epetraborole|Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)
75638407|NCT05995444|Drug|Placebo|Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)
75638408|NCT05995444|Drug|Moxifloxacin|Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)
75638409|NCT05995106|Other|Heart4U|Mobile app.
75638410|NCT05993481|Diagnostic Test|Blood Pressure Measurement|"NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program."
75638411|NCT05992935|Biological|mRNA-1403|Sterile liquid for injection
75638412|NCT05992935|Biological|mRNA-1405|Sterile liquid for injection
75638413|NCT05992935|Biological|Placebo|0.9% sodium chloride (normal saline) injection
75638414|NCT05991102|Device|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
75638415|NCT05989373|Diagnostic Test|Scratch collapse test|Scratch test performed by the surgeon but with a dynamometer
75638416|NCT05987254|Procedure|suprainguinal fascia iliaca block|ultrasound guided suprainguinal fascia iliaca block
75638417|NCT05987254|Procedure|pericapsular nerve group block|ultrasound guided pericapsular nerve group block
75638418|NCT05985694|Drug|AD17002|"The investigational intranasal pharmaceutical product named AD17002 contains a detoxified Escherichia coli heat-labile enterotoxin, LTh(αK).~Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32."
75470375|NCT05218291|Other|Ongoing caregivers|Caregivers included in the control group, who did not apply any yoga intervention, will be observed as caregivers.
75787260|NCT02422498|Radiation|external beam radiation therapy|Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.
75787261|NCT02422498|Drug|cisplatin|Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 mg/m^2 ivpb once a week (+ 3 days) for 1-2 weeks prior to radiation. The length of one cycle of Cisplatin is 21 days.
75470376|NCT05213052|Other|Topical cream|Topical cream applied to painful joint or muscle
75470377|NCT05197218|Dietary Supplement|Prebiotic|Combination of a polyphenol rich extract of chokeberry (Aronia melanocarpa) and a polyphenol rich extract of cranberry (Vaccinium macrocarpon Aiton) will be administered for 18 days.
75638419|NCT05985694|Drug|Placebo|Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.
75638420|NCT05975268|Biological|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005/placebo
75638421|NCT05975099|Biological|mRNA-1975|Dispersion delivered IM
75638422|NCT05975099|Biological|mRNA-1982|Dispersion delivered IM
75470378|NCT05195255|Dietary Supplement|Prebiotic|Guar gum (8 g/d) will be administered for 18 days
75638423|NCT05975099|Biological|Placebo|Solution delivered IM
76079508|NCT03453918|Dietary Supplement|polyphenols|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~Starter: duck gizzard salad.~Main course: black pudding and pasta.~French cheese.~Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
76079509|NCT03453918|Other|Placebo|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~Starter: duck gizzard salad.~Main course: black pudding and pasta.~French cheese.~Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
76079510|NCT03468114|Behavioral|Safe Start|Participant households will receive four visits over a 10 week period from health extension workers promoting safe food preparation, storage and feeding, and will be provided with products to support these practices (a bowl, spoon, cup, hand washing station, liquid soap dispenser).
76079511|NCT03468114|Behavioral|Active Control|Participant households will receive 4 visits by health extension workers delivering standard care
76079512|NCT03452982|Other|sentinel node technique|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
75330880|NCT01920230|Behavioral|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams & Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
75330881|NCT01920230|Behavioral|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
75330882|NCT01050907|Drug|Miltefosine|2.5 mg/kg/day for 28 days
75638424|NCT05974202|Device|Active H7-coil repetitive transcranial magnetic stimulation (rTMS)|A magnetic current created by the device creates an electrical current in the brain to stimulate the medial prefrontal cortex and dorsal anterior cingulate cortex.
75330883|NCT03120650|Other|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
75330884|NCT03120650|Other|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
75330885|NCT01924520|Drug|FK949E|Oral
75638425|NCT05974202|Device|Sham H7-coil repetitive transcranial magnetic stimulation (rTMS)|A sham coil is in the same helmet as the active coil. The sham coil mimics the sound, scalp sensations, and facial muscle activation caused by the active coil, but does not create an electrical current in the brain.
75787262|NCT02422498|Procedure|Biopsy of Target Tumor|Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
75787263|NCT01314976|Drug|Metronidazole|"Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents."
75787264|NCT01314976|Drug|Placebo|"Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis."
75787265|NCT04615000|Diagnostic Test|SARS-CoV-2 serological assessment (IgG)|Periodic assessment of the serology status (SARS-CoV-2 specific IgG) with a 3 to 6 month interval
76079513|NCT03468036|Other|none, does not apply|none: does not apply
76079514|NCT04803786|Drug|Transition from Xyrem to Xywav|This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
76079515|NCT03464214|Device|Neck Muscle Vibration|Local vibration device applied on neck muscles for 8 weeks
75330886|NCT04433845|Drug|Psilocybin|Open-label
75330887|NCT01920308|Device|5 mm Bard LifeStent Vascular Stent|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
75638426|NCT05967351|Genetic|delandistrogene moxeparvovec|No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
75638427|NCT05964179|Behavioral|time extended feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 14 hours per day.
75638428|NCT05964179|Behavioral|time restricted feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 8 hours per day.
75787266|NCT01973452|Drug|Dexmedetomidine|
75787267|NCT01973452|Drug|Placebo|
75787268|NCT04504942|Drug|Leronlimab|Drug: Leronlimab 525mg
75923493|NCT03737487|Procedure|Multidisciplinary fall risk and geriatric comprehensive assessment|"Complete blood count, serum electrolytes, C-Reactive Protein, transaminases and gamma-glutamyl transferase, thyroid-stimulating hormone, and 25OH vitamin D.~Calculation of BMI~A 40-min assessment of balance, walking speed, muscle strength, activity, and functional status by a physiotherapist~A 40-min assessment by an occupational therapist, including a detailed questionnaire on social support, living situation and home environment, fear of falling, and cognitive function~A 20-min assessment by a podiatrist including an examination of the patient's feet and footwear.~A 60-min assessment by a geriatrician including assessment of circumstances of the previous fall(s), review of current medications and medical history, and an in-depth examination of the patient to detect possible contributors or risk factors for falling~A 20-min review meeting with the 4 healthcare professionals in order to prioritize recommendations to be provided."
75638429|NCT05956860|Procedure|abdominopelvic vascular intervention through the radial artery access|"According to the pathological changes and needs of the subjects (any abdominal and pelvic arterial intervention that can be performed through the radial artery access, including but not limited to:~hepatic intervention, such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), etc.;~Other visceral intervention, such as spleen, kidney, mesentery, etc.;~Pelvic intervention, such as uterine artery embolism, prostatic artery embolism, etc.;~Others, such as preoperative embolization of bone tumors (lumbar, sacral vertebra), etc."
75923494|NCT03503604|Biological|hPV19 mAb|Intravenous (IV) infusions, 4 and 6 milligrams per kilogram (mg/kg) every 2 weeks
75923495|NCT03503604|Biological|hPV19 mAb|Intravenous (IV) infusions, 6 milligrams per kilogram (mg/kg) every 3 weeks
75638430|NCT05953935|Device|OKTO|Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz
75923496|NCT03503604|Drug|5-Fluorouracil|400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks
75923497|NCT03503604|Drug|Oxaliplatin|IV Infusion, 85 milligrams per square meter (mg/m2) every 2 weeks
75923498|NCT03503604|Drug|Leucovorin|IV infusion, 400 mg/m2 every 2 weeks
75923499|NCT03503604|Drug|Paclitaxel|IV infusion, 175 mg/m2 every 3 weeks
75330888|NCT04431973|Device|Medacta Shoulder System|Surgical placement of the Medacta Shoulder System prothesis on patients with pathologies requiring the insertion of a total reverse shoulder prothesis for primary omarthrosis, cuff tear arthropathy, massive cuff rupture or post instability arthropathy
76079516|NCT03464214|Behavioral|Cervical Stabilization Exercises|Cervical stabilization exercises performed by healty individuals for 8 weeks
76079517|NCT03464058|Drug|BOS172767 tablets|Oral tablets
75923500|NCT03503604|Drug|Carboplatin|IV infusion, AUC=6 every 3 weeks
75330889|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
75330890|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
75638431|NCT05953935|Device|Standard clinical procedures|standard clinical procedures
75638432|NCT05948605|Device|Empower Neuromodulation System|The Empower Neuromodulation System is designed to provide transcutaneous stimulation to the branches of a spinal nerve. The system comprised of three key components: (A) The Stimulator, (B) the Empower smartphone app, and (C) the Gel Patch. The smartphone application is used to coordinate treatment and record participant responses.
75923501|NCT03503604|Drug|Gemcitabine|IV infusion, 1000 mg/m2 at day1 and day 8 every 3 weeks
75923502|NCT03503604|Drug|Carboplatin|IV infusion, AUC=4 every 3 weeks
76079518|NCT03464058|Drug|BOS172767 liquid capsules|Oral capsules
75638433|NCT05948475|Drug|Tinengotinib 8 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.
76079519|NCT03464058|Drug|BOS172767 micronized capsules|Oral capsules
76079520|NCT03464058|Drug|BOS172767 immediate release capsules|Oral capsules
75638434|NCT05948475|Drug|Tinengotinib 10 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either10 mg QD., self-administered orally QD in 28-day cycles.
75787269|NCT04466800|Other|Intervention group_rehabilitation program|"Regular physical activity, supervised by a physical education educator, a systematic malnutrition screening and a nutritional follow-up performed by a dietetician.~Patients will follow a 4-week rehabilitation program, comprising 3 physical activity sessions per week for 4 weeks. First sessions will be supervised by a physical activity educator and patients will perform the following sessions at home, using physical training software. The physical activity educator will call patients once a week to ensure the sessions are correctly performed and adapt the program if necessary. Patients will also undergo a nutritional assessment carried out by a dietitian at the beginning of the program. A dietitian will call patients once a week to ensure their nutritional status is appropriate."
75787270|NCT01882816|Radiation|IMRT|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC
75787271|NCT01882816|Device|DWI MRI|The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.
75923503|NCT03503604|Drug|Irinotecan|IV Infusion,180 milligrams per square meter (mg/m2) every 2 weeks
76079521|NCT03464058|Drug|BOS172767 matching placebo capsules|Oral capsules
76079522|NCT03464058|Drug|BOS172767 matching placebo tablets|Oral tablets
76079523|NCT03464058|Drug|Rabeprazole|Oral tablets
76079524|NCT03463902|Device|left IFG anodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
75638435|NCT05948475|Drug|Physician's Choice|For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.
75638436|NCT05932667|Drug|Milademetan|The study treatment, including a combination of milademetan and fulvestrant, is administered into two successive parts: a safety run-in part followed by a phase II part. Once GATA3 mutational status confirmed, patients will continue to receive study drug treatment until progression of disease, unacceptable toxicity, patient withdrawal of consent, Investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.
75923504|NCT05334706|Biological|Nonavalent HPV vaccine (9vHPV/Gardasil-9™).|"Sterile suspension, 0.5 ml dose, intramuscular administration in a 3 dose-regimen (Day 1, Month 2, Month 6), prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from 9 HPV types: 6/11/16/18/31/33/45/52/58.~9vHPV is currently indicated in the EU in individuals from 9 years of age for the prevention of diseases caused by vaccine's 9 HPV types: genital warts (HPV6 and 11) and premalignant lesions and cancers affecting the cervix, vulva, vagina and anus (HPV16, 18, 31, 22, 45, 52 and 58). It was authorized for marketing in the EU on June 9th, 2015."
75923505|NCT02154867|Biological|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
75330891|NCT04408027|Behavioral|Virtual-Care Cognitive Behavioural Therapy|The feasibility, participation barriers, and acceptability of the intervention, virtual-care cognitive behavioural therapy (VC-CBT), will be evaluated for children with anxiety. The VC-CBT protocol will involve 12 sessions (of one hour in duration) delivered by a CBT therapist using PHIPA (Personal Health Information Protection Act) compliant Zoom. An initial session will review therapy goals and psychoeducation about anxiety. Sessions 2 and 3 will focus on feeling identification and will introduce relaxation strategies. Sessions 4 and 5 will introduce cognitive distortions and restructuring strategies. Sessions 6 and 7 will introduce exposure tasks. Sessions 8 to 11 will involve practicing cognitive restructuring skills and completing exposures. The final session will review relapse prevention. Parents will participate in the first and last sessions, as well as join at the end of each session for a brief review of the skills learned during the session.
75330892|NCT03460990|Drug|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
75330893|NCT03460990|Drug|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
75330894|NCT03460990|Drug|IVA|Participants received IVA orally once daily in the evening.
75330895|NCT03460990|Drug|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
75638437|NCT05932667|Behavioral|Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)|Measure of interest is the mean difference in the change from baseline to different specific visit (each disease radiological assessment, disease progression and/or treatment discontinuation) in total/subscale scores of the 5 Dimension 5 Level (EQ-5D-5L) scale and the EORTC-QLQ-C30 questionnaire
75638438|NCT05932628|Other|This study will observe participants who receive a supported self management approach for thumb base osteoarthritis but it is not an interventional study.|Participants will receive an occupational or physiotherapist led supported self-management programme, which equates to normal NHS care, having been adopted by the sites involved. This involves education, progressive exercises and hand splints if required. The educational materials used, and a minimum number of appointments will be consistent across the study sites. Additional treatments for coexisting conditions will be provided, additional stepped care for thumb base osteoarthritis will also be recorded.
75638439|NCT05930938|Drug|Xevinapant|Xevinapant is a multi-IAP antagonist that blocks the activity of several IAPs including X-linked IAP (XIAP), cellular inhibitor of apoptosis proteins (cIAP) 1, cIAP2 and ML-IAP
75638440|NCT05930938|Drug|Placebo|Xevinapant without active substance
75923506|NCT02154867|Other|Placebo fecal transplant|Fecal transplantation with own feces
75923507|NCT04508816|Drug|cetuximab (CTX) or nimotuzumab (NTZ)|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.
75923508|NCT03503526|Behavioral|Receptive music therapy|12 weekly trauma-focused Group therapy sessions of a length of 2.5 hours. The core element is receptive music psychotherapy with music listening, art making, and other art based methods.
75923509|NCT03356210|Behavioral|Neurofeedback|The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
75923510|NCT02304588|Biological|Mesenchymal stem cells|10-20 x 10^6 cells/20mL
75923511|NCT02160639|Other|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
75923512|NCT03359876|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily
75923513|NCT03359876|Drug|Warfarin sodium|Individually adjusted dose
75923514|NCT02309034|Behavioral|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
75923515|NCT02309034|Behavioral|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
75923516|NCT02309034|Other|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
75923517|NCT03541395|Drug|GnRH antagonist|
75330896|NCT03460990|Drug|Placebo|Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
75330897|NCT01924598|Device|DBS to nucleus accumbens/anterior limb of internal capsule|deep brain stimulation followed by 12 month post switch on followup
75330898|NCT01052545|Behavioral|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
75330899|NCT01924832|Drug|dimethyl fumarate|tablet
75330900|NCT04332562|Other|dietary restriction (salt restriction)|salt restriction for one week after being diagnosed with hypertension
75638441|NCT05930938|Drug|cetuximab|cetuximab
75638442|NCT05930938|Radiation|IMRT|IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction)
75638443|NCT05924464|Other|Group Preconception Care|Groups of 6-10 patients to initiate biweekly virtual group care sessions on a rolling basis, with completion of enrollment and the virtual curriculum within a year.
75638444|NCT05917340|Drug|High dose rifampicin (25mg/kg)|Given for 2 months
75638445|NCT05917340|Drug|Moxifloxacin 400mg|Given for 2 months
75638446|NCT05917340|Drug|Aspirin 150 mg|Given for 2 months
75638447|NCT05917340|Drug|Isoniazid|Given for 6 months
75638448|NCT05917340|Drug|Pyrazinamide|Given for 6 months
75638449|NCT05917340|Drug|Steroid|Tapering dose of dexamethasone or prednisolone upto 8 weeks
75330901|NCT01920542|Drug|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
75638450|NCT05917340|Drug|Rifampicin|Standard dose for 4 months after the initial treatment with high dose
75787272|NCT01882816|Drug|Doxorubicin|Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
75330902|NCT01920542|Drug|no dexmedetomidine|no administration of dexmedetomidine on control group
75638451|NCT05917340|Drug|HRZE|2 months
75638452|NCT05917340|Drug|HRE|7-10 months as per TB program guidelines
75638453|NCT05902819|Behavioral|Imagery|Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.
75787273|NCT01882816|Other|Modified Barium Swallow Impairment Profile (MBSImP)|The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.
75787274|NCT03162796|Drug|Guselkumab|Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
75787275|NCT03162796|Drug|Placebo|Participants will receive matching placebo as SC injection.
75787276|NCT03162328|Device|PowerSleep Stim|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
75787277|NCT03162328|Device|PowerSleep Sham|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
75787278|NCT00272987|Drug|lapatinib|(GW572016) 1000 mg QD
75787279|NCT00272987|Drug|paclitaxel|80 mg/m2 IV weekly for three weeks
75923518|NCT03503448|Procedure|Osteotomy between the maxillary central incisors|Surgically Assisted Rapid Maxillary Expansion with osteotomy between the central incisors.
75330903|NCT03319810|Biological|Octagam 10%|FDA approved human normal immunoglobulin solution ready for intravenous administration
75330904|NCT01052701|Drug|Ribavirin|"Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight >75 kg)"
75638454|NCT05902819|Drug|Minocycline|Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
75638455|NCT05902819|Drug|Placebo|Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
75330905|NCT01052701|Drug|Ribavirin plus Abacavir (ABC)|"Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight >75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours"
75330906|NCT01920620|Behavioral|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
75638456|NCT05901051|Drug|vonoprazan|Potassium competitive acid blocker
75638457|NCT05901051|Drug|Amoxicillin|Antibiotics for H. pylori eradication
75638458|NCT05900271|Device|rTMS|10 Hz repetitive-transcranial-magnetic-stimulation
75638459|NCT05900271|Device|iTBS|neuronavigated intermittent theta burst transcranial-magnetic-stimulation
75638460|NCT05898776|Device|Lung transplantation after 10°C donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.
75638461|NCT05898776|Device|Lung transplantation after standard ice cooler donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
75638462|NCT05890469|Combination Product|Zirconia surface implant and guided bone regeneration|"The Straumann® PURE Ceramic Implant System is made from 100 % yttria-stabilized zirconia. Its surface features a topography characterized by macro- and micro-roughness to offer a structure for cell attachment and the osseointegration of this surface has been successfully proven. Owing to the increasing aesthetic standards in the field of implant dentistry and the concerns on sensitivity to titanium, there has been a growing interest towards metal-free implant rehabilitation.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
75787280|NCT00272987|Drug|trastuzumab|4 mg/kg loading dose and 2 mg/kg weekly IV
75787281|NCT01069757|Drug|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
75787282|NCT01070927|Drug|RO4929097|80mg po daily, 3 days on 4 days off schedule
75330907|NCT01920620|Behavioral|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
75330908|NCT01920776|Other|ultrasound examination|
75787283|NCT01070927|Drug|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
75787284|NCT03976271|Procedure|hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp|For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia. This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
75923519|NCT03503448|Procedure|Osteotomy between the maxillary lateral incisors and canines|Surgically Assisted Rapid Maxillary Expansion with bilateral osteotomy between the lateral incisors and canines
75638463|NCT05890469|Combination Product|Hydrophilic titanium surface implant and guided bone regeneration|"The Straumann® Standard Plus (SP) Implant is a Soft Tissue Level Implant with a smooth neck section of 1.8 mm. It has a fundamentally improved hydrophilic surface chemistry (SLActive®) which accelerates the osseointegration process in the early healing phase.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
75787285|NCT01069913|Drug|BG00012|"Sequence 1: Oral 240 mg BG00012 Standard Formulation & Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API & Following 7 day washout period, 240 mg BG00012 Standard Formulation."
75638464|NCT05881408|Genetic|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
75638465|NCT05881408|Genetic|placebo|Single IV infusion of matching placebo
75638466|NCT05870488|Device|Use of iFuse TORQ|Use of iFuse TORQ for the treatment of SI Joint dysfunction
75638467|NCT05868382|Biological|mRNA-1010|Sterile liquid for injection
75638468|NCT05868382|Biological|mRNA-1010.4|Sterile liquid for injection
75638469|NCT05868382|Biological|mRNA-1010.6|Sterile liquid for injection
75638470|NCT05865106|Device|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
75638471|NCT05865106|Other|Traditional speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
75638472|NCT05840510|Drug|Adagrasib|KRAS G12C inhibitor
75638473|NCT05840510|Drug|nab-Sirolimus|mTOR inhibitor
75638474|NCT05832567|Device|Active rTMS|Subjects will undergo repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
75638475|NCT05832567|Device|Sham rTMS|Subjects will undergo sham repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
75787286|NCT01730950|Biological|bevacizumab|Staring within 14 days of randomization, IV 10mg/kg every two weeks until disease progression.
75787287|NCT01730950|Radiation|radiation therapy|Starting with second dose of bevacizumab, 35 Gy in 10 fractions of 3.5 Gy each delivered on consecutive treatment days (typically 5 fractions per week).
75787288|NCT01069991|Behavioral|Patient education group|Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
75787289|NCT01069991|Behavioral|Wait list control group|No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
75787290|NCT00271505|Drug|Bevacizumab (Avastin)|15 mg/kg intravenously (IV) every 3 weeks
75923520|NCT05236582|Drug|Herombopag|The subjects will initiate treatment with 7.5 mg/d Herombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 7.5 mg daily. Subjects whose platelet count ≤100×109/L，the Herombopag dose will maintain. If platelet count >100×109/L for 2 weeks, the subjects need to reduce the dose of Herombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Herombopag to 2.5mg once every other day or lower frequency during the treatment period, Herombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Herombopag if the platelet is greater than 50×109/L.
75923521|NCT03354650|Diagnostic Test|blood culture|blood culture to determine causative organisms of neonatal sepsis
75923522|NCT02160951|Drug|LGH447|LGH447, QD
75923523|NCT02304666|Procedure|Colonoscopy for biopsies samples|
75923524|NCT05226832|Procedure|40mg Triamcinolone Injections in the Bladder|Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic. Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy. Injections will be performed using a 17fr flexible cystoscope in the outpatient setting. There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline. The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip. The patient may experience discomfort with cystoscopy and injections. Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section. This is estimated to take 30 minutes.
75923525|NCT03354572|Drug|Acetyl cysteine|acetyl cysteine 150 mg/kg prior to surgery
75923526|NCT03354572|Drug|Placebos|saline 0.9% prior to surgery
75923527|NCT03508674|Device|Levita Magnetic Surgical System|use of surgical tool
75923528|NCT02161029|Device|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
75638476|NCT05832567|Dietary Supplement|Open Placebo|The open placebo will consist of an inactive substance pill commonly used in clinical trials and given to the subject in a regular pill dispenser.
75638477|NCT05830201|Behavioral|No Dog Present|Dog is not present during pin removal
75638478|NCT05830201|Behavioral|Dog is Present|Dog is present during pin removal
75638479|NCT05827978|Biological|mRNA-1010|Sterile liquid for injection
75638480|NCT05827978|Biological|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Sterile suspension for injection
75923529|NCT02161029|Device|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
75923530|NCT03359798|Behavioral|Narcotic counseling script|Script regarding post-cesarean section narcotic use
75638481|NCT05827055|Drug|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)
75638482|NCT05827055|Drug|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)
75638483|NCT05827055|Drug|Proglumide|Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) in vegan capsules
75638484|NCT05827055|Drug|Placebo|Placebo given in vegan. capsules orally three times a day
75638485|NCT05820191|Drug|Amyvid, Intravenous Solution|Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
75638486|NCT05808309|Other|Salivary sampling|Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)
75923531|NCT03359798|Behavioral|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
75923532|NCT02309346|Drug|Clindamycin|Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
75923533|NCT03541239|Device|Single Cuff Tourniquet 8000|If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
75638487|NCT05801809|Device|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
75638488|NCT05798156|Drug|Glofitamab|Glofitamab is a fully humanized, engineered monoclonal bivalent antibody of the IgG1 isotype.
75638489|NCT05798156|Drug|Rituximab|Rituximab is a genetically engineered chimeric mouse/human anti-CD20 monoclonal antibody
75923534|NCT03356054|Combination Product|R-DHAP|3 cycles q 3 weeks
75787291|NCT00271505|Drug|Carboplatin|AUC 6 IV every 3 weeks
75787292|NCT00271505|Drug|Docetaxel|75 mg/m2 IV every 3 weeks
75923535|NCT03356054|Drug|Brentuximab Vedotin|3 cycles q 3 weeks added to R-DHAP
75923536|NCT05531032|Other|Phone Interview|Phone interview questionnaire
75923537|NCT02161107|Biological|Grass-SPIRE|Intradermal injection
75923538|NCT02161107|Biological|Placebo|Intradermal injection
75923539|NCT03508596|Other|educational intervention for the supervisors|The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
75787293|NCT01642186|Drug|everolimus|
75787294|NCT01642186|Drug|letrozole plus leuprolide|
75923540|NCT03354494|Drug|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa|
75923541|NCT03727581|Diagnostic Test|Ultrasound guidance|Jugular vein is punctured with ultrasound guidance and guidewire is advanced. Right atrium and inferior vena cava junction is visualized by ultrasound using substernal view. Presence of guidewire in inferior vena cava or right atrium is confirmed. The procedure of catheter insertion is continued.
75923542|NCT02312700|Behavioral|Interactive empowerment tool|
75923543|NCT02518568|Drug|V0355|Oral administration (2 tablets)
75923544|NCT03359720|Other|no intervention survey|survey
75923545|NCT02304744|Other|Observational study, no intervention.|Observational study, no intervention.
75923546|NCT05532514|Other|MICRONUCLEI COUNT|MICRONUCLEI COUNT IN PRECBCT and POSTCBCT EXPOSURE
75923547|NCT03354338|Drug|Amoxicillin|Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
75923548|NCT03354338|Other|Placebo|Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
75923549|NCT02304822|Drug|Multiple-dose of Ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
75923550|NCT02304822|Drug|Single-dose of Ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
75923551|NCT02304822|Drug|Zero-dose of Ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
75923552|NCT05532436|Other|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
75923553|NCT03359564|Procedure|micro endoscopic discectomy|the patients receive micro endoscopic discectomy surgery therapy
75923554|NCT04688164|Drug|REL-1017|REL-1017 tablet
75923555|NCT04688164|Drug|Placebo|Placebo tablet
75923556|NCT02309424|Dietary Supplement|Vinegar|0,50mmol vinegar (6% acetic acid)
75923557|NCT02309424|Other|Placebo|50 ml water
75923558|NCT03359486|Behavioral|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
75638490|NCT05798156|Drug|Obinutuzumab|Obinutuzumab is a fully humanized, glycoengineered type II monoclonal antibody of the IgG1 isotype that binds to an epitope on CD20
75638491|NCT05798156|Drug|Polatuzumab vedotin|Polatuzumab vedotin is an antibody-drug-conjugate that contains a humanized IgG1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent (MMAE) linked through a protease-cleavable linker.
75638492|NCT05783063|Device|Active iTBS|MagPro X100
75638493|NCT05783063|Device|Sham iTBS|MagPro X100
75638494|NCT05778825|Drug|Oral Minoxidil|minoxidil at a dose of 0.01 (<40kg) and 0.02 (≥40kg) mg/kg/day
75638495|NCT05778825|Other|Placebo|placebo for 4 months
75787295|NCT01642186|Drug|combination of everolimus, letrozole and leuprolide|
75787296|NCT03953352|Other|Helical intensity-modulated radiotherapy (IMRT)|Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.
75787297|NCT03546322|Other|Registry|Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients. All head and neck cancer patients monitored by the clinic will be included.
75787298|NCT01413802|Procedure|Continuous nerve monitoring|Continuous nerve monitoring is performed during thyroid surgery.
75787299|NCT01264510|Other|audiological test battery|routine audiological measurements.
75787300|NCT01315054|Behavioral|MMT provider dosage training|Training on methadone dosing provided to health care providers working in methadone maintenance clinics
75787301|NCT01315054|Behavioral|targeted counseling|targeted counseling provided to methadone maintenance clinic attendees
75923559|NCT03359486|Behavioral|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
75638496|NCT05775510|Device|Commercially available neurostimulation systems|Spinal cord stimulation therapy delivered during trialing and following implant of commercially available neurostimulation systems
75638497|NCT05774899|Drug|CB-103|First-in-class pan-NOTCH inhibitor, capsule taken orally.
75638498|NCT05774899|Drug|Abemaciclib|CDK4/6 inhibitor, tablet taken orally.
75638499|NCT05774899|Drug|Lenvatinib|Per standard care, capsule taken orally.
75638500|NCT05767047|Drug|Apremilast|Oral tablets or liquid suspension
75787302|NCT01315054|Other|national guidelines|Provided a hard copy of the existing national guidelines for methadone dosing
75787303|NCT00423514|Biological|filgrastim|
75923560|NCT03506178|Drug|Oxymetazoline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
75923561|NCT03506178|Drug|Menthol Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
75923562|NCT03506178|Drug|Normal saline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
75923563|NCT03506178|Device|Nasal mask with partly blocked|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
75923564|NCT04519034|Other|no intervention|There will be no intervention
75923565|NCT02312778|Other|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
75923566|NCT03354260|Other|Personalized adapted oral diet and nutritional education|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
75923567|NCT02304900|Other|white implant|"st intervention (in the month following the inclusion): Randomization of the color of the implant~nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
75330909|NCT01920776|Other|Ultrasound group|Ultrasound group will receive ultrasound examination at least once a day, the results will be noted to the attending who is in charge of the treatment.
75330910|NCT03322930|Diagnostic Test|Rod sensitivity|diagnostic test for rod loss in central retina
75330911|NCT05528809|Other|Blood sampling|A blood sampling will be performed during the inclusion visit (day 0).
75330912|NCT01921010|Drug|Niaspan|See Arm Description
75330913|NCT01921010|Drug|Placebo|See Arm Description
75330914|NCT02246491|Other|A-T iPS cell line|Reprogramming A-T patients iPS cell line
75638501|NCT05766202|Other|An group intervention for multiparas with fear of childbirth|The intervention consists of 4 group meetings, three during pregnancy and once after giving birth. It also includes a phone call.
75638502|NCT05759988|Device|Outpatient Foley catheter|Outpatient Foley catheter placement for induction of labor
76079525|NCT03463902|Device|left IFG cathodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
75787304|NCT00423514|Drug|clofarabine|
75787305|NCT00423514|Drug|melphalan|
75787306|NCT00423514|Drug|mycophenolate mofetil|
75787307|NCT00423514|Drug|tacrolimus|
75787308|NCT00423514|Drug|thiotepa|
75923568|NCT02304900|Other|yellow implant|"st intervention (in the month following the inclusion): Randomization of the color of the implant~nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
75330915|NCT02246491|Other|Carrier patients iPS cell line|Reprogramming iPS cell line from carrier patients
75638505|NCT05737485|Drug|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
75638506|NCT05735041|Behavioral|Multi-domain cognitive digital therapy|Patients in the cognitive digital therapy group received multi-dimensional targeted cognitive function training electronically, involving attention, memory, executive function, thinking, processing speed and perception. The system will adjust the training difficulty and training plan adaptively according to the patient's current training time and performance, and train the patient's weak cognitive ability as far as possible. The patients had the same total amount of training each day.
75787309|NCT00423514|Procedure|allogeneic bone marrow transplantation|
75787310|NCT00423514|Procedure|allogeneic hematopoietic stem cell transplantation|
75787311|NCT00423514|Procedure|peripheral blood stem cell transplantation|
75787312|NCT00120952|Device|Bi-Metric femoral implant (titanium versus cobalt-chromium)|
75787313|NCT01329874|Procedure|Type of block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
75787314|NCT00289991|Drug|Itraconazole|Prophylaxis
75923569|NCT04517006|Behavioral|Self-focused acts|Completion of daily acts for personal enjoyment.
75923570|NCT04517006|Behavioral|Prosocial acts|Completion of daily acts for the benefit of others.
75638507|NCT05735041|Behavioral|Basic cognitive therapy|The training content of the positive control group was cognitive training tasks with weak difficulty or no difficulty change. The patients underwent cognitive function training with fixed programs, including 15 training items, and the internal difficulty of the training items remained constant without change. The system presents the training content randomly according to the training scheme. The patients had the same total amount of training each day.
75787315|NCT00289991|Drug|Vfend - voriconazole|Prophylaxis
75787316|NCT00289913|Biological|Comparator: VAQTA™|"VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age."
75923571|NCT03503214|Diagnostic Test|In vitro determination of non-carbonic buffer power|In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
75638508|NCT05733455|Drug|Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)|Participants will ingest two overencapsulated tablets of alpelisib at 23:00, along with a saltine cracker.
75923572|NCT03503214|Diagnostic Test|Classic description of acid-base status|Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
75923573|NCT02578186|Drug|Diphenhydramine Hydrochloride|30 mL at bedtime
75638509|NCT05733455|Drug|Placebo (microcrystalline cellulose), 2 capsules|Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
75638510|NCT05733455|Device|FreeStyle Libre Pro|Continuous glucose monitoring for 24 hours (double blinded)
75638511|NCT05733455|Diagnostic Test|Oral glucose tolerance test (OGTT) with Trutol glucose beverage|Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
75787317|NCT00289913|Biological|Comparator: Infanrix™|"Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit."
75787318|NCT00289913|Biological|Comparator: PedvaxHIB™|"PedvaxHIB™ (Haemophilus B Conjugate Vaccine [Meningococcal Protein Conjugate]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit."
75923574|NCT02578186|Drug|Placebo|30 mL at bedtime
75923575|NCT02304978|Biological|Group CRC|blood samples
75923576|NCT02304978|Biological|Group control|Blood samples
76079526|NCT03463902|Device|left IPL anodal|Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
76079527|NCT03463902|Device|left IPL cathodal|Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
76079528|NCT03463902|Device|Placebo|Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
75330916|NCT01921088|Other|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
75330917|NCT01921088|Behavioral|Ambulatory Training|Subjects are provided with an ambulatory training.
75330918|NCT01921244|Other|Decision Aid|"Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters."
75638512|NCT05733455|Dietary Supplement|BOOST Plus nutritional beverage|Participants will consume a quantity of BOOST Plus calculated to match their daily caloric needs, divided over three liquid meals.
75638513|NCT05733312|Device|InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system|Focused ultrasound which targets energy to a specific area in the brain based on imaging and disrupts the blood brain barrier which keeps certain drugs and other molecules out of the brain.
75638514|NCT05729399|Biological|GT201|Autologous tumor infiltrating lymphocyte injection
75638515|NCT05727891|Drug|Tonabersat|Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
75787319|NCT01325675|Behavioral|Interval training|Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
75787320|NCT01325753|Procedure|cryotherapy|Undergo CT-guided CA
75787321|NCT01325753|Procedure|quality-of-life assessment|Ancillary studies
75923577|NCT03123458|Biological|clonal fetal MSCs|
75923578|NCT05530876|Other|Telerehabilitation with virtual game|It will be applied 10 sessions of remote rehabilitation in women with and without breast cancer, in order to promote physical activity.
76079529|NCT05163444|Device|Gait analysis with rolling cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
76079530|NCT05163444|Device|Gait analysis with quadripod cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
76079531|NCT03451734|Drug|antipsychotic medications|olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
76079532|NCT03451734|Drug|adjunctive group|antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
76079533|NCT03451734|Drug|metformin and lifestyle intervention|different dose metformin combines lifestyle intervention
75638516|NCT05727891|Other|Placebo|Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
75787322|NCT00270413|Drug|SU11248|sutent 50 mg daily 4w on 2w off
76079534|NCT03129984|Device|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
75787323|NCT01325831|Device|repetitive transcranial magnetic stimulation(rTMS)|10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
75787324|NCT01325831|Device|Sham repetitive transcranial magnetic stimulation(rTMS)|Sham repetitive transcranial magnetic stimulation(rTMS)
75787325|NCT00289289|Device|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
75787326|NCT00270257|Drug|Buprenorphine/Naloxone|Oral tablet
75787327|NCT00269633|Device|Blue Light Box 467 nm|467 nm Blue LED Light
75787328|NCT00269633|Device|Red Light Box 657 nm|657 nm Red LED Light
75787329|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75787330|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75787331|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75787332|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
75787333|NCT00269399|Drug|Rifaximin (Xifaxan)|
75787334|NCT00269399|Drug|Vancomycin|
75787335|NCT00269087|Drug|fluticasone propionate/salmeterol combination DISKUS|
75330919|NCT03325816|Drug|Nivolumab|Nivolumab is administered intravenously
75638517|NCT05727787|Radiation|Stereotactic Body Radiation Treatment|Single fraction SBRT 27 Gy
75638518|NCT05718024|Drug|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
75638519|NCT05718024|Drug|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
75638520|NCT05714085|Drug|Vericiguat tablet|2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
75638521|NCT05714085|Drug|Vericiguat suspension|0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
75638522|NCT05714085|Drug|Placebo tablet|Placebo for vericiguat administered orally once daily in tablet form
75638523|NCT05714085|Drug|Placebo suspension|Placebo for vericiguat administered orally once daily in suspension form
75638524|NCT05710718|Device|PureWick™ System|The PureWick™ FEC is intended for non-invasive urine output management in female patients. The PureWick™ FEC is a flexible, contoured external catheter that is positioned against the area where urine exits the female body. The PureWick™ FEC will be connected to the PureWick™ Urine Collection System (PUCS) via connector tubing. The PUCS uses suction (not felt by the user) to pull voided urine through the device, regardless of the urine flow rate. Urine continues through vinyl tubing until it reaches a collection canister, away from the body.
75638525|NCT05710718|Device|Hollister® Female Urinary Pouch External Collection Device|It is designed to be emptied and should be attached to a drainage bag. The FUP is made with hydrocolloid skin adhesive and polymer/copolymer plastics.
75638526|NCT05708482|Other|Sling-Swing Position|The device is hammock which look likes a rope
75787336|NCT00289133|Device|total knee arthroplasty|Gamma Vacuum Foil polyethylene tibial insert
75787337|NCT00289133|Device|total knee arthroplasty|cross-linked polyethylene tibial insert
75787338|NCT00288587|Drug|IV loop diuretic|Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
76079535|NCT03467880|Other|Clinical Observation|No treatment given but observation with IOS
75638527|NCT05704244|Drug|FE 999326|75 mL FE 999326 (3 x 10^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter
75638528|NCT05700266|Drug|Rivaroxaban|Rivaroxaban (2.5mg orally twice a day for 90 days)
75787339|NCT00288587|Device|NxStage System One|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
75787340|NCT00268463|Drug|capecitabine|"Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2"
75787341|NCT00268463|Drug|floxuridine|Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles
75787342|NCT00268463|Drug|oxaliplatin|"Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1~Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2"
75787343|NCT00288509|Biological|Botulinum toxin type A|In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety & efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
75787344|NCT03975023|Device|NeuroCatch Platform (NCP)|The NCP plays a proprietary 6-minute auditory stimulus sequence of tones and words that elicit involuntary evoked responses in the brain. Tone stimuli elicit N100 and P300 responses, and spoken word pairs elicit N400 responses. The NCP proprietary software identifies the latency and amplitude (timing and size) of three selected ERPs. Latency and amplitude values are reported as empirical (measured) values.
75787345|NCT03741803|Procedure|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds after birth
75787346|NCT03741803|Procedure|Early cord clamping|The umbilical cord will be clamped as soon as feasible after birth, usually within the initial 15 seconds after birth.
75470379|NCT05191108|Behavioral|mindfulness stres reduction programe|Complaints about PMS and sharing information about these complaints, Practice of breathing focused meditation, mplementation of mindful eating exercises,Raising awareness in daily activities,Teaching the body scanning exercise and repeating this practice during the week with the audio recordings given.Ensuring environmental awareness Ensuring that you live by being aware of the moments experienced during the week, 20 minutes of sitting breathing focused sitting meditation Coping with stress Sharing the experiences of the previous week Implementation of mindful vision practices Explaining the relationship between stress and experienced events.Eating exercises Mindful breathing Ensuring environmental awareness Explaining the importance of thinking about the relationship between stress and their reactions and accepting them without judgment, and sharing the experiences at the end of the day of silence.
75787347|NCT01070147|Other|Computerized Asthma Management System|The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
75638529|NCT05700266|Drug|Clopidogrel|Clopidogrel (300mg loading dose, then 75mg once daily for 90 days)
75470380|NCT05176678|Dietary Supplement|1 gram of a protein hydrolysate|After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
75470381|NCT05176678|Dietary Supplement|2 grams of a protein hydrolysate|After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
75787348|NCT01071005|Drug|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
75638530|NCT05700266|Drug|Aspirin|Aspirin (100mg once a day for 1 year)
75638531|NCT05700266|Other|Risk Factor Management in both arms|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed
75787349|NCT01071005|Drug|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
75787350|NCT00266825|Drug|DHA|600 mg DHA
75787351|NCT00266825|Other|Placebo capsule|Placebo capsule
75787352|NCT03976037|Drug|Misoprostol|"Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
75923579|NCT03123224|Behavioral|Combined Aerobic and Resistance Exercise + Caregiver Skills Training|The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
75638532|NCT05699226|Device|Soterix Medical Incorporated 4x1 adapter|Device permits individualized amplitudes
75787353|NCT00265889|Biological|filgrastim|480 mcg beginning day +5
75787354|NCT00265889|Drug|busulfan|11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
75787355|NCT00265889|Drug|cyclophosphamide|60 mg/kg IV over 2 hours x 2 days
76079536|NCT03451344|Other|Integrated rehabilitation group|Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
76079537|NCT03451344|Other|Community-based rehabilitation group|Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
75787356|NCT00265889|Drug|etoposide|60 mg/kg, IV
75787357|NCT00265889|Drug|melphalan|150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
75787358|NCT00265889|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|autologous-autologous tandem hematopoietic stem cell transplantation
75787359|NCT00265889|Radiation|radiation therapy|radiation therapy
75470382|NCT05176678|Dietary Supplement|4 grams of a protein hydrolysate|After 4 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
75470383|NCT05176678|Dietary Supplement|8 grams of a protein hydrolysate|After 8 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
75470384|NCT05161039|Device|Serranator|Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular
75470385|NCT05161039|Device|POBA|Plain balloon angioplasty device
75638533|NCT05699226|Device|Traditional ECT device|FDA approved ECT device with fixed amplitude.
75638534|NCT05694169|Biological|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
75638535|NCT05693129|Drug|Leniolisib|The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).
75638536|NCT05690113|Procedure|CATS scale|During the inclusion visit (J0), enrolled children will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire).
76079538|NCT03467802|Biological|enamel matrix derivative|Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.
76079539|NCT03467802|Device|Porcine collagen matrix|Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.
76079540|NCT01198366|Biological|AERAS-402 1.5 x 10^10 vp|
76079541|NCT01198366|Biological|AERAS-402 3.0 x 10^10 vp|
76079542|NCT01198366|Biological|AERAS-402 1.0 x 10^11 vp|
76079543|NCT01198366|Biological|Placebo|
76079544|NCT03130218|Other|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
75787360|NCT01333696|Drug|Pemetrexed|Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
75330920|NCT03325816|Radiation|177Lu-DOTA0-Tyr3-Octreotate|"177Lu-DOTA0-Tyr3-Octreotate will be administered every 8 weeks. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Each dose is infused over 30 minutes. On the day of 177Lu-DOTA0-Tyr3-Octreotate infusion, an intravenous bolus of anti-emetics will be given (suggested options: ondansetron (8 mg), granisetron (3 mg), or tropisetron (5 mg)). Administration of 177Lu-DOTA0-Tyr3-Octreotate may be given one day earlier or delayed up to 1 week due to holidays, inclement weather, conflicts, or similar reasons.~Concurrent amino acids are given with each dose of 177Lu-DOTA0-Tyr3-Octreotate since co-infusion of amino acids leads to a significant reduction (47%) in the mean radiation dose to the kidneys. The amino acid solution and 177Lu-DOTA0-Tyr3-Octreotate are administered in parallel by peripheral vein infusion"
75330921|NCT00986570|Biological|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
75787361|NCT01333774|Drug|Glucobay (Acarbose, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
75470386|NCT05097157|Device|Potenza|Subjects are treated with the Potenza™ device if they present with conditions such as, but not limited to: wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, or loose skin on the face, neck and/or body.
75470387|NCT05082103|Other|Enzyme lozenge 1|Participants are instructed to take one enzyme containing lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
75470388|NCT05082103|Other|Enzyme lozenge 2|Participants are instructed to take one lozenge with 3x higher enzyme concentration three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
75470389|NCT05082103|Other|Placebo lozenge|Participants are instructed to take one placebo lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
76079545|NCT03129906|Dietary Supplement|Gluten|
76079546|NCT03129906|Dietary Supplement|Rice protein|
75638541|NCT05685173|Drug|Odronextamab|Odronextamab will be administered by IV infusion
75638542|NCT05685173|Drug|REGN5837|REGN5837 will be administered by IV infusion
75638543|NCT05680116|Device|MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device|Patients will wear Myovolt shoulder device twice a week and each session will continue 30minutes. This therapy will apply during the radiotherapy process. The device will be applied on the bare skin of the shoulder area. The first 10 minutes of the 30 minutes will be intermittent vibration, the other 20 minutes will be done in the sinusoidal vibration program. Both programs will be in the range of 20-100 Hz.
75638544|NCT05680116|Other|Home based exercise|Patients will do home based exercise during the radiotherapy process. 5 days a week. 2 sessions a day, each exercise will be 10x2 repetitions
75787362|NCT01333852|Drug|metformin up to 2500mg/d|metformin up to 2500mg/d
75787363|NCT01333852|Drug|paclitaxel 175mg/m² q21d|paclitaxel 175mg/m² q21d
75787364|NCT01333852|Drug|placebo|placebo
75923580|NCT03123224|Behavioral|Stretching Balance and Flexibility + Caregiver Skills Training|The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
75923581|NCT02305056|Drug|C13 N15 Valine|C13 N15 Valine administration
76079547|NCT03011320|Drug|EC1456|intravenous (IV) bolus dose
76079548|NCT03011320|Drug|99mTc-Etarfolatide|Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
76079549|NCT03463746|Device|LYRA® gait trainer|The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.
76079550|NCT03463746|Device|Standard individual physical therapy|The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
76079551|NCT03451266|Drug|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
76079552|NCT03451266|Drug|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
76079553|NCT05322486|Procedure|surgery of the primary tumour|Surgical resection of the colon tumour, R0. No surgical intervention on metastasis.
75638545|NCT05674617|Behavioral|Written Exposure Therapy|WET will be conducted in accordance with the Written Exposure Therapy for PTSD: A Brief Treatment Approach for Mental Health Professionals Manual and the VA evidence-based practice (EBP) rollout training.
76079554|NCT05322486|Drug|chemotherapy|Chemotherapy with or without biological drugs.
75638546|NCT05674617|Behavioral|PTSD Education|"The 5-session PTSD psychoeducation and skills protocol we will be utilizing for our PTSD education control condition was developed by PTSD clinical team (PCT) clinicians at the Washington DC VA Medical Center as a group protocol for Veterans admitted to the PCT and who were on the waitlist for individual therapy with an EBP for PTSD. The PTSD 101 protocol consists of psychoeducation on topics related to PTSD symptoms and an introduction to PTSD-related coping skills. Its duration and structure will be similar to WET (5 weekly individual 50-minute sessions). To parallel the time an attention given in individual WET sessions more closely, participants will quietly review any written materials or videos that are a part of the manualized curriculum for 30 minutes of the session, bookended by a 10-minute check-in with their provider on symptoms and introduction to new materials at the start of session and another 10-minute debrief of reviewed materials at the end of session."
75638547|NCT05671757|Biological|Daratumumab|Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
75787365|NCT01333930|Other|Active O2|oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)
75787366|NCT01333930|Other|Adelholzener Mineralwasser|natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
75787367|NCT01334008|Biological|Blood sampling|30ml of patient peripherical blood will be collected
75787368|NCT01334164|Behavioral|Recovery Management Checkups|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
75787369|NCT01334164|Other|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own
75787370|NCT01334242|Drug|Schedule A|Dosing 1 hour before breakfast
76079555|NCT03463668|Device|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
76079556|NCT03467646|Procedure|Sleeve Gastrectomy|The patients undergo a Sleeve Gastrectomy as bariatric procedure
76079557|NCT03467646|Procedure|Roux-en-Y gastric bypass|The patients undergo a Roux-en-Y gastric bypass as bariatric procedure
75330922|NCT00986258|Drug|Tapentadol Prolonged Release|"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."
75638548|NCT05671757|Biological|Daratumumab|Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
75638549|NCT05671757|Biological|Daratumumab|Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
75787371|NCT01334242|Drug|Schedule B|Dosing 0.5 hour before breakfast
75787372|NCT01334242|Drug|Schedule C|Dosing immediately before breakfast
75787373|NCT01334242|Drug|Schedule D|Dosing immediately before lunch
76079558|NCT03467646|Procedure|One-Anastomosis Gastric Bypass|The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure
76079559|NCT01199146|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg by mouth per day
76079560|NCT01199848|Dietary Supplement|Placebo|whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
76079561|NCT01199848|Dietary Supplement|10G|whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
76079562|NCT01199848|Dietary Supplement|20G|whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
76079563|NCT01199848|Dietary Supplement|40G|whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
76079564|NCT01199848|Dietary Supplement|Placebonofiber|Placebo without Fiber
76079565|NCT03467568|Dietary Supplement|Sodium Chloride|300mg sodium chloride will be provided in a capsule
76079566|NCT03467568|Other|Placebo capsule|A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
76079567|NCT03467568|Dietary Supplement|Water|Twice during the morning a drink of 150ml of water will be consumed
75787374|NCT01334242|Drug|Schedule E|Split dose, dosing 1 hour before breakfast and dinner
75330923|NCT00986180|Drug|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
75923582|NCT03506100|Other|Water Walking|Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
75923583|NCT03123146|Behavioral|Functional Behavior-Based Cognitive Behavioral Therapy|Fb-CBT involved nine 2-hour weekly sessions with three to four children in each group and two therapists. Therapy consisted of group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
75787375|NCT01334320|Procedure|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
75787376|NCT01334398|Behavioral|Health & Wellness|"The specific content of the intervention was adapted from four existing evidence-based interventions: (1) Healthy Lifestyles for People with Disabilities, (2) Promoting Wellness for Women with MS, (3) Living Well with Disability, and (4) Social Skills and TBI: A Workbook for Group Treatment."
76079568|NCT03467568|Biological|No water consumed|No water will be consumed during the monring
75638550|NCT05661149|Device|Hybrid closed loop insulin delivery systems|Tandem Control-IQ ; DBLG1 system ; MiniMed 780G system
75330924|NCT00986180|Drug|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
75638551|NCT05651945|Other|Cardiac rehabilitation program|The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.
76079569|NCT01199926|Dietary Supplement|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
75330925|NCT01053013|Biological|RENCA macrobeads|
75330926|NCT03015493|Other|Neural mobilization combined with traction|Neural mobilization techniques combined with cervical traction for the cervical nerve roots
75330927|NCT03015493|Other|Traction|Traction techniques for the cervical spine
75330928|NCT01054183|Device|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
75330929|NCT01054183|Device|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
75330930|NCT01054339|Drug|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
75330931|NCT04247971|Procedure|Blood draw|23 ml of blood collected
75330932|NCT04247971|Procedure|Sputum collection|Induced sputum sample collected
75330933|NCT04247971|Procedure|Pulmonary function test|Pulmonary function testing
75638552|NCT05646381|Drug|Pelacarsen (TQJ230) 80mg|Pelacarsen (TQJ230) 80mg
75638553|NCT05646381|Drug|Matching placebo|Matching placebo
75330934|NCT01056601|Drug|Bortezomib|1.3 mg/m^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
75330935|NCT01056601|Drug|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
75330936|NCT01056913|Device|Compression Anastomosis Device|Restoring intestinal continuity using the NITI CAR27 device
75330937|NCT01056913|Other|follow-up colonoscopy|endoscopic exploration of anastomosis after complete healing
75330938|NCT05429203|Device|Duodenoscope with single-use distal cover|Newer duodenoscope with a single-use distal cover
75330939|NCT05429203|Device|Conventional duodenoscope|Conventional duodenoscope with standard methods of reprocessing
75330940|NCT03014947|Drug|MSB11022|Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
75330941|NCT03014947|Drug|US-licensed Humira|Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
75330942|NCT03014947|Drug|EU-approved Humira|Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
75330943|NCT01057225|Drug|carfilzomib|Given IV
75638554|NCT05630014|Behavioral|Aliviado DSD Caregiving Mastery Program|Family caregiver intervention consisting of mHealth-app based educational videos and articles; caregiver-administered assessment tools and care plans; and motivational push notification reminders and encouragements.
75787377|NCT03209362|Combination Product|SI-613|SI-613 will be repeated intra-articularly administered.
75787378|NCT03209362|Combination Product|Placebo|Placebo will be repeated intra-articularly administered.
75787379|NCT05151406|Other|educational program|The needed knowledge about hematopoietic stem cell transplantation in a trial to correct their myths and misconceptions about this type of treatment. The educational pamphlet included three theoretical parts: bone marrow transplantation, bone marrow donation, and stem cells banking
75787380|NCT02932462|Drug|DSXS|topical product
75330944|NCT01057225|Drug|cyclophosphamide|Given orally
75330945|NCT01057225|Drug|thalidomide|Given orally
75330946|NCT01057225|Drug|dexamethasone|Given orally
75330947|NCT01057381|Drug|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
75330948|NCT01057381|Drug|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
75787381|NCT02932462|Drug|Placebo|topical product
75330949|NCT01057381|Drug|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
75638555|NCT05617300|Behavioral|Mindfulness-Based Dementia Caregiving|Mindfulness Based Stress Reduction (MBSR) is a standardized program that is both psychoeducation and skills-based, which uses mindfulness meditation practices to help people better cope with their emotions. This study uses a version of MBSR designed specifically for care partners of people living with dementia (PLWD) called Mindfulness Based Dementia Caregiving. Mindfulness Based Dementia Caregiving (MBDC) is a program with 8 weekly 2 hour sessions (plus one extended practice 4 hour retreat) including both formal and informal mindfulness practices, role play, and lectures combined with some dementia-specific education. Participants learn how to incorporate mindfulness practices into day-to-day life to help cope with the challenges and stresses of dementia care.
75638556|NCT05616312|Behavioral|Educational Teach Back|Patients will receive teach-back education while they fill out questionnaires.
75638557|NCT05613387|Drug|ZP8396|"Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used."
75638558|NCT05613387|Drug|Drug: Placebo (ZP8396)|"Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin)."
75787382|NCT03365362|Drug|Long-Term Varenicline|Varenicline tablet x 24 weeks
75787383|NCT03365362|Drug|Short-Term Varenicline|varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg tablet
75923584|NCT02309502|Device|Green Pascal|"Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
75923585|NCT02309502|Device|Yellow Pascal|": Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
75923586|NCT04128436|Other|Taking blood samples for analyzing progesterone levels|As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
75330950|NCT01057381|Drug|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
75330951|NCT00986102|Drug|doripenem|500mg vial by injection every 8 hours for 5 to 14 days
75330952|NCT01058239|Drug|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
75330953|NCT01058239|Drug|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
75330954|NCT01058941|Drug|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
75330955|NCT01058941|Drug|Placebo|Placebo LA and placebo oil capsules for 18 months
75330956|NCT04150549|Biological|Fecal Microbial Transplants|Healthy donor stool will be processed and placed into capsules.
75638559|NCT05607862|Other|Home Physiotherapy Group|The intervention group will receive 2 sessions per week for 8 weeks supervised and assisted by a physiotherapist at the patient's home. Muscle strengthening exercises of the lower and upper limbs, stretching, coordination and balance exercises, gait re-education with the relevant technical aids, a pattern of exercises to be performed daily by the patient and health education guidelines will be carried out.
75638560|NCT05607862|Other|Control Group|The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment. All patients included in this study will receive physiotherapy treatment, and those in the control group will be treated once the intervention and the post-intervention assessment have been completed.
75787384|NCT03365362|Behavioral|Directly Observed Therapy|Varenicline doses are administered by opioid treatment program nurses
75787385|NCT03365362|Behavioral|Self Administered Therapy|Varenicline doses are self-administered
75923587|NCT03354182|Procedure|Open flap surgery|Elevation of a flap in order to access the treated furcation
76079570|NCT01199926|Drug|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
75787386|NCT03206788|Drug|Losartan|25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
75787387|NCT03206788|Drug|placebo|Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
75787388|NCT03356392|Other|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
76079571|NCT03463590|Device|Bilateral surgical implantation of DBS system to habenula|The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.
75330957|NCT04150549|Biological|Fecal Microbial Transplants|Participants stool will be processed and placed into capsules.
75330958|NCT00985946|Drug|panobinostat (LBH589)|Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
75330959|NCT01059877|Device|1072nm infrared Photobiomodulation|1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
75470390|NCT05080647|Behavioral|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
75330960|NCT01059877|Device|Photobiomodulation SIMULATED|Device mounted and procedure followed but with no stimulation.
75330961|NCT05351983|Procedure|Surgical biopsy of tumoral tissue for organoid generation|In surgically-resectable lesions, tumoral samples will be collected from the main surgical specimens, before sending it for final pathological examination. Patients with metastatic disease, will be offered to undergo port-a-cath implantation for chemotherapy delivery and concomitant laparoscopic surgical excisional biopsy of suspicious metastatic lesions. Intraoperative frozen section will confirm the presence of malignant cells in the sample. Part of the specimen will be sent for assessment of contamination by bacterial and/or fungal flora by the Microbiology Laboratory. The remaining tumour sample will be sent for patient-derived organoid (PDO) formation. Two patients' blood samples will be retrieved in ethylenediaminetetraacetic acid (EDTA) tubes and will be sent with the surgical specimen. All patients will then receive the standard of care (SOC) treatment according to the clinical judgement of the oncologist in charge, always within the framework of the international guidelines.
75470391|NCT05077800|Drug|FOLFIRNINOX|Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion
75470392|NCT05077800|Drug|Losartan|Taken Orally
75470393|NCT05077800|Drug|9-ING-41|Administered by intravenous infusion
75470394|NCT05042674|Dietary Supplement|Placebo|after a blood draw placebo will be consumed followed by 2 additional blood draws
75470395|NCT05042674|Dietary Supplement|Ergothioneine, 25 miligrams|after a blood draw 25 miligrams of ergothioneine will be consumed followed be 2 additional blood draws
75470396|NCT05042674|Dietary Supplement|Ergothioneine, 25 miligrams, daily for 1 week|a blood draw will be administered after a week of consuming 25mg ergothioneine daily
75470397|NCT05015062|Behavioral|Mobile-based HIV-related educational message delivery|HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.
75470398|NCT05015062|Behavioral|Incentive policies evaluation|village doctors in Intervention A and B will receive different types of monetary compensation. Doctors in Intervention A will receive standardized compensation for completing their assigned tasks. Doctors in Intervention B will receive performance-based compensation whose amount depends on how well the participants perform on the follow-up questionnaires.
75470399|NCT05013021|Other|Sprint Interval Training|"The Sprint Interval Training (SIT) training consists of 3 successive blocks of 5 training sessions each. The sessions are 24 to 48 hours apart.~. One block lasts two weeks. After the end of one block, the following block begins the day after.~The Sprint Interval Training lasts 6 weeks.~Each session consists of a series of sprints, the number of which varies from 8 to 14. Thus a session will last from 30 to 45 min approximately~So, the time frame of this study is Baseline, Block 1, Block 2 and Block 3 (Not in day or week or month)"
75470400|NCT04961320|Behavioral|Occupational Therapy|Participate in OT session
75638561|NCT05599711|Behavioral|Transitioning Together (TT) / Juntos en la Transicion (JET)|"One individual family joining session when each family dyad meets with group therapists to establish rapport and share their own unique family's background, goals, and supports.~A series of four 2.5-hour multi-family group psychoeducation intervention sessions focused on problem-solving education and psychoeducational autism transition-to-adulthood content which can include independence in adulthood, community involvement, guardianship and legal issues, employment and education, health and well-being."
75787389|NCT04989478|Other|Fasting|After the standardized breakfast meal, all participants will only consume water for 24 hours
75787390|NCT03205150|Drug|LIK066|Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
75787391|NCT03205150|Drug|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
75787392|NCT02932306|Drug|IDP-121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
75787393|NCT02932306|Drug|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
75787394|NCT04936984|Combination Product|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
75787395|NCT04936984|Combination Product|abaloparatide-sMTS (Kindeva)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
75923588|NCT03354182|Device|Bio-oss collagen|Biomaterial for periodontal surgery
75923589|NCT03354182|Device|Bio-gide|Biomaterial for periodontal surgery
75470401|NCT04961320|Other|Questionnaire Administration|Complete questionnaires
75470402|NCT04957238|Other|ARBORea decision-making tool|Online ARBORea decision-making tool will guide the use of physical restraints in ICU patients based on objective information on neurological status, level of equipment related to critical illness, and patient's family presence and involvement in patient's surveillance.
75470403|NCT04934397|Other|Study Infant Formula|Powdered partially hydrolyzed whey (WPH) based infant formula with oligosaccharides
75470404|NCT04927585|Biological|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid
75470405|NCT04927585|Biological|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid
75470406|NCT04927585|Biological|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
75470407|NCT04927585|Biological|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
75787396|NCT04936984|Combination Product|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes
76079572|NCT01106326|Behavioral|Intervention|"Teens participating in this study will have:~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
76079573|NCT03463434|Device|Air Fluidized Therapy|AFT bed used for pressure injury treatment
76079574|NCT03463434|Device|Continuous Low Pressure-LAL|Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
75330962|NCT05592457|Diagnostic Test|MSCT|multislice computed tomography
75330963|NCT00985790|Biological|Influenza vaccine GSK2321138A|Intramuscular injection
75470408|NCT04922411|Device|STN DBS|PD patients with DBS STN will be scanned and tested with DBS ON and OFF
75638562|NCT05599711|Behavioral|Usual autism transition care|An expedited referral will be made for participants to establish care with a BMC Autism Program Transition/Resource Specialist. Data will be abstracted from the electronic medical record on how many visits each family completes with a BMC Autism Program Transition/Resource Specialist or other BMC Developmental and Behavioral Pediatrics provider throughout the study period.
75638563|NCT05584670|Drug|SAR445877|Concentrate for solution for infusion
75787397|NCT04936984|Combination Product|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes
75923590|NCT02313012|Drug|CC-90003|CC-90003 PO once daily
75923591|NCT03359330|Other|Degradable Conduit Small Gap Tublization|Degradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
75923592|NCT03506022|Other|standard polysomnography|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters : electroencephalogram, electro-oculogram, electromyogram [chin], continuous nasal airflow body position, thoracic and abdominal strain gauges, haemoglobin oxygen saturation (SaO2) with an oximeter (Medatec) attached to finger. Blood pressure was measured in the evening during the physical examines, and then the CGMS recording startedpressure was measured in the evening during the physical examines, and then the CGMS recording started
76079575|NCT03463356|Behavioral|Shame Intervention|In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
75787398|NCT04901416|Biological|DVX201|"Based upon the occurrence of DLT (does limiting toxicity), the MTD will be estimated as the highest dose at which the toxicity probability is the closest to the target probability (denoted pT=0.30) following up to 2 doses of DVX201. The corresponding dose allocation methodology is a modified toxicity interval design based upon (Ji et al., 2010; Ji et al., 2013).~All patients who have at least one dose initiated will be included in the safety analysis. Patients who are enrolled but never exposed to investigational product will be replaced for all analyses. Patients who get exposed to lymphodepleting chemotherapy will be followed and reported for outcomes overall, but for determination of safety and efficacy, only those subjects who have been exposed to the investigational agent will be included."
75787399|NCT04886050|Drug|LC350189 Tablet|Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5
76079576|NCT03463278|Diagnostic Test|Pregnancy Rate|The pregnancy and live birth rate according to number of blastocysts formed in our three groups
76079577|NCT03463200|Other|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
76079578|NCT03463200|Other|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
75330964|NCT00985790|Biological|Fluarix™|Intramuscular injection
75330965|NCT03016273|Procedure|creation of bladder flap|Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
75330966|NCT01060345|Drug|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
75330967|NCT02170519|Drug|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
75330968|NCT05288257|Behavioral|Learning Module|Safe Cholecystectomy Learning Module
75330969|NCT04072705|Drug|General principles of care and judgement of researcher|Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
75470409|NCT04912557|Other|postoperative pain assess|numerical pain scale and Metameric levels of cold insensitivity
75470410|NCT04911478|Genetic|ADI-001|No study drug is administered in this study. Patients who have received Adicet allogeneic γδ CAR T cell therapy will be evaluated in this trial for long-term safety and efficacy
75470411|NCT04898478|Behavioral|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|The investigators will design a culturally grounded treatment seeking intervention for Pacific Islanders with OUDs
75470412|NCT04885946|Other|Fecal microbiota transplantion (FMT)|Single donor, fecal microbiota transplantion (FMT) from healthy human donors.
75470413|NCT04885946|Other|Placebo|Food coloring, water, glycerol
75470414|NCT04787315|Device|Conventional intensive functional rehabilitation + Workstations|Equipment will be provided to participants where they can do exercises to increase their motor abilities at the lower limbs, trunk and upper limbs, in addition to conventional intensive functional rehabilitation
75470415|NCT04787315|Behavioral|Conventional intensive functional rehabilitation|Includes rehabilitation interventions provided by professionnals (OT, PT, speech language therapy, neuropsychologists...)
75638564|NCT05584241|Behavioral|Diagnostic Disclosure Protocol|Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.
75787400|NCT04886050|Drug|LC350189 Capsule|Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5
75923593|NCT02309658|Drug|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
75638565|NCT05584241|Behavioral|Biomarker Disclosure Protocol|Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
75787401|NCT02932228|Other|ImPACT|"The ImPACT team offers the following services:~An intensive intake process, including a home visit if deemed appropriate~Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs~After-hours access to on-call team member in order to avoid unnecessary emergency care~Optimization of chronic condition management using evidence-based protocols~Navigation of transitions between hospital and home~Coordination of specialty care, including contact with specialists when indicated~Rapid response to signs of health status deterioration or other stressful events~Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment"
75787402|NCT02931838|Drug|BMS-986165|
75787403|NCT02931838|Drug|Placebo for BMS-986165|
75787404|NCT03201562|Drug|Aceclidine+tropicamide combination|Ophthalmic Solution
75787405|NCT03201562|Drug|Aceclidine|Ophthalmic Solution
75787406|NCT03201562|Drug|Vehicle|Ophthalmic Solution
75787407|NCT03321916|Device|577-nm PASCAL laser|The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
75787408|NCT04693390|Procedure|Acupuncture|Application of acupuncture
75787409|NCT04596982|Other|Placement of IMPELLA®|ultrasound and hemodynamic parameters of patients in order to establish a predictive score for right-sided dysfunction after placement of IMPELLA®
75787410|NCT03200860|Drug|Empagliflozin 10 MG|10 mg daily, oral, 30 days
75787411|NCT03200860|Drug|Placebo Oral Tablet|Matching Placebo, 10 mg daily, oral, 30 days
75787412|NCT03636646|Device|X.ray|Surgical treatement of posterior acetabular wall fractures
75330970|NCT05239117|Device|Plenhyage|"Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter."
75470416|NCT04783597|Diagnostic Test|Arterial Stiffness and Wave Reflection|Arterial stiffness and wave refection, a non-invasive test, will be collected and combined with standard clinical markers (blood biomarkers, ultrasound imaging) as well as medical and psychosocial questionnaires in order to test a comprehensive, multi-marker approach for pre-eclampsia prediction in high risk pregnant women.
75638566|NCT05580601|Drug|CIML-NK Cells|"The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~Human Serum Albumin~Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested."
75787413|NCT04520932|Procedure|Radiofrequency ablation|RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.
75330971|NCT00985712|Drug|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
75330972|NCT00985712|Drug|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
75787414|NCT04501432|Other|No intervention|This study does not include an intervention
75787415|NCT03198754|Device|PEI Experimental Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
75787416|NCT03198754|Device|Comparison Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
75787417|NCT03198520|Device|Solvay Dental 360™|polymer Removable Partial Denture (RPD)
75787418|NCT01314508|Drug|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
75923594|NCT02309658|Drug|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
75330973|NCT00985712|Device|HumaPen Memoir|subcutaneously, daily for 24 weeks
75787419|NCT03194464|Other|submaximal exercise (grip)|participants perform repeated gripping with visual feedback to task failure
75330974|NCT00985712|Device|HumaPen Luxura|subcutaneously, daily for 24 weeks
75330975|NCT04275284|Biological|PCV10|0.5 ml injection
75330976|NCT04275284|Biological|PCV13|0.5 ml injection
75470417|NCT04766476|Drug|BMS-963272|Specified dose on specified days
75787420|NCT04040920|Device|Ozone|One minute of pretreatment with ozone by using the OzoneDTA device
75787421|NCT04040920|Other|Pits and fissure sealants|cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';
75470418|NCT04766476|Other|Placebo matching BMS-963272|Specified dose on specified days
75787422|NCT03192904|Device|Energy Instruments|Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.
75923595|NCT02309658|Radiation|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
76079579|NCT03463200|Other|Rigid Tape|Application of Micropore tape in the erector spine muscles.
75923596|NCT04508738|Other|ERP|"The ERP intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~ERP: 1) neck cooling with an iced gel pad, 2) drinking a ∼ 6% CHO solution, 3) mouth-rinsing with a ∼10% CHO, ∼6 mg ･ kg -1 caffeine solution, 4) performing submaximal squats and 5) hyperventilating a hyperoxic mixture"
75330977|NCT02984150|Dietary Supplement|dodecanoic acid|
75923597|NCT04508738|Other|Placebo|"The control intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~1) neck cooling with room temperature gel pack, 2) drinking an artificially sweetened solution, 3) mouth-rinsing with artificially sweetened solution (containing no caffeine), 4) performing unloaded squat manoeuvres, 5) deep breaths with room air"
75923598|NCT02309736|Device|ReSure Sealant|
75923599|NCT05532280|Drug|Etoricoxib 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
75923600|NCT05532280|Drug|Arcoxia 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
75923601|NCT04508426|Drug|[14C]AR882|Single dose of [14C]AR882
75923602|NCT04463706|Other|Predictors adverse evolution|Predictors adverse evolution in all hospital participant admitted patients
75923603|NCT04463706|Other|Predictors of health care provide|Predictors of death, unequity, variability in process of care, cost in all COVID positive patients form the Basque Country
75923604|NCT04508114|Behavioral|Technology-assisted Index|The participant will be informed the ATP testing result and explanation in pretest.
75923605|NCT02305134|Drug|Tipepidine Hibenzate|
75923606|NCT02305134|Drug|Placebo|
75923607|NCT05532202|Behavioral|NICU Mom and Baby Net|See arm descriptions.
75923608|NCT05532202|Other|NICU Developmental Awareness System|See arm description.
75330978|NCT02984150|Dietary Supplement|saline|
75330979|NCT04347746|Behavioral|stretching physiotherapy|"A booklet with images and a description of all movements to be performed during therapy will be offered to patients. The booklet illustrates the movements for stretching the upper limbs divided as follows: three movements for the neck, three movements for the arms and forearms and four movements for the hands.~The therapy will be carried out twice a week at the Unopar research center, under the guidance of a physiotherapist trained in technique and supervision by a senior therapist. At the end of each movement, the individual is instructed to maintain the position for 40 seconds.~Patients will be instructed to appear in comfortable clothes and the environment will have favorable conditions."
75330980|NCT04347746|Behavioral|Myofascial therapy|Myofascial therapy will be performed on the upper limbs, pectoral and dorsal regions with the aid of hooks (instrument assisted soft-tissue mobilization). In the supine position, the pectoral muscles will be manipulated (infracromial, external, axillary-claviculopectoral fossa), biceps brachii (short head, long and forearm insertion), round pronator, anterior forearm musculature (compartment of the radial extensor of the long carpus and brevis, finger extensor and ulnar carpal extensor). In lateral decubitus the deltoid muscle in the anterior, middle and posterior portions. In the prone position, the trapezius muscle (in its cervical, scapular and nuchal insertions), scapular levator muscle, great dorsal muscle (in its lateral insertions) and triceps brachii muscle. The hook manipulation time is two minutes of execution for each muscle mentioned above, making a total time of each section of forty minutes. There will be two weekly sessions with an interval between forty-eight hours.
75638567|NCT05572957|Drug|Guideline-Directed Medical Therapy(GDMT)|"Quadruple anti-heart failure drug therapy: BB, ACEI/ARB/ARNI, MRA, and SGLT2i. If the initial dose according to guidelines is tolerated, the protocol would then direct the uptitration of medication dose over time to a specified target dose, unless not well tolerated.~*Criteria for <3 months of optimized (complete) GDMT: 1) according to the latest management of HF, any of the new quadruple therapy is not used if the condition allowed; Or 2) the dose of any drug dose not reach the maximum tolerated target; Or 3) under the maximum tolerated dose of BB, ivabradine is not added with a heart rate still ≥70 bpm at rest."
75638568|NCT05572957|Combination Product|left bundle branch pacing combined with Guideline-Directed Medical Therapy(LBBP+GDMT)|"GDMT is the same as Drug intervention. LBBP is confirmed when: 1) the LBBB morphology disappeared and the paced RBBB pattern (typical or atypical) is observed in V1; and 2) LVAT is ≤100 ms at low output(≤3 V/0.5 ms); and at least 1 of the following is achieved: a) abrupt shortening of LVAT by >10 ms during mid/deep septal lead placement with a RBBB pattern in V1 at high output, which then remains short and constant at high and low output with further advancement of the lead to the final position; b) transition from nonselective to selective LBBP (QRS morphology transition from atypical RBBB to typical rsR' pattern in V1 and wide/large S-wave in V6 , with the appearance of an isoelectric segment and no LVAT change at high and low outputs); and c) transition from nonselective LBBP to LV septal pacing (lengthening of LVAT by at least 10 ms with or without obvious QRS morphology transition during threshold testing).~HBP or BiVP is attempted using the standard-of-care technique."
75787423|NCT03192904|Device|Stapling Device|Stapling Device, including linear stapler and curved stapler.
75787424|NCT03912532|Biological|NGM282|NGM282
75787425|NCT03912532|Other|Placebo|Placebo for NGM282
75787426|NCT01314586|Dietary Supplement|secoisolariciresinol diglucoside-containing extract of flaxseed|0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
75787427|NCT03188536|Other|No Intervention|As it was an observational study, no intervention was administered in this study.
75787428|NCT03187756|Drug|Cyclophosphamide|Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
75923609|NCT00103311|Drug|ispinesib|Given IV
75923610|NCT00103311|Other|laboratory biomarker analysis|Correlative studies
75923611|NCT04517162|Drug|Collagen-Polyvinylpyrrolidone|1.5 mL of polymerized-type I collagen or placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
75923612|NCT02305212|Behavioral|Cogmed|
75923613|NCT02155023|Drug|Insulin dosing|
75923614|NCT02155023|Device|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
75923615|NCT04444232|Other|Media Intervention|View an educational video
75470419|NCT04725864|Drug|Progesterone vaginal tablet|The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
75638569|NCT05561829|Behavioral|Sleep Optimization|Automated digital administration of a sleep optimization module via mobile or web application, lasting approximately six weeks. Based on the participant's situation and needs, sleep restriction, sleep compression, or circadian-rhythm normalization is advised and conducted. The aim is to optimise the participant's sleep efficiency.
75923616|NCT04444232|Other|Survey Administration|Complete survey
75638570|NCT05561829|Behavioral|Stimulus Control Therapy|Automated digital administration of a stimulus control therapy module via mobile or web application, lasting approximately six weeks. The aim is to strengthen associations between sleep and the sleep environment and to eliminate conditioning of non-sleep behavior and the sleep environment.
75638571|NCT05561829|Behavioral|Relaxation Training|Automated digital administration of a relaxation training module via mobile or web application, lasting approximately six weeks. The aim is to reduce somatic tension and limit intrusive thought processes that interfere with sleep.
75638572|NCT05561829|Behavioral|Cognitive Therapy|Automated digital administration of a cognitive therapy module via mobile or web application, lasting approximately six weeks. The aim is to identify, challenge, and modify dysfunctional beliefs about sleep.
75923617|NCT03542721|Drug|DA-5515|Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)
75638573|NCT05561829|Behavioral|Sleep Hygiene Education|Automated digital administration of a sleep hygiene education module via mobile or web application, lasting approximately six weeks. The aim is to identify and modify environmental and lifestyle factors that may interfere with sleep.
75638574|NCT05557734|Procedure|caudal block|injection of local anesthestic through the scral hiatus into the sacral canal to reach caudal epidural space
75923618|NCT03542721|Drug|Placebo of DA-5515|Placebo (three times a day)
75923619|NCT02305368|Other|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
75923620|NCT05530564|Procedure|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
76079580|NCT04212780|Device|Medtronic Summit Rechargable (RC)+S|Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO
75787429|NCT03248674|Diagnostic Test|CT FFR|CT FFR calculated the fractional flow reserve based on the data derived for a regular coronary CT angiography. Computation is based on development of an anatomic model of the epicardial coronary arteries for each case and calculating the maximum coronary flow during maximal hyperaemia based on a mathematical model incorporating fluid dynamics. These post-processing steps require quantification of the patient-specific myocardial mass as this allows for an estimation of the baseline coronary blood flow.
75787430|NCT03022708|Device|Xeltis Bioabsorbable Pulmonary Valved Conduit|Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit
75787431|NCT02926924|Device|Wound Vac|a therapeutic technique using a vacuum dressing to promote healing in acute or chronic wounds and enhance healing of first and second degree burns.
75787432|NCT02926924|Other|Standard Dressing|standard dressing with drain tube and bandage
75923621|NCT05530564|Procedure|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
76079581|NCT04212780|Procedure|ipsilateral thalamic (VIM+VO) DBS|Implantation of two new ipsilateral thalamic (VIM+VO) DBS
75470420|NCT04721821|Drug|Tofacitinib|Patients who received Tofacitinib for RA
75923622|NCT04507958|Diagnostic Test|auscultation by using conventional stethoscope without PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
75923623|NCT04507958|Diagnostic Test|auscultation by using electronic stethoscope in full PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
75923624|NCT05530486|Device|CC|Application of placebo LASER
75923625|NCT05530486|Device|LG1|Application of LASER GasAs 660nm 4 J/cm².
75923626|NCT05530486|Device|LG2|Application of LASER GasAs 660nm 8 J/cm².
76079582|NCT04212780|Procedure|standard ET DBS|Single Lead VIM
76079583|NCT04212780|Procedure|ipsilateral VO|second lead in the ipsilateral VO
76079584|NCT01106950|Biological|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is < or = 8 x 10^7 nucleated cells/kilogram.
76079585|NCT01106950|Drug|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
75470421|NCT04700059|Behavioral|Virtual perinatal home visiting|10 perinatal home visits
75470422|NCT04688333|Other|Internet-Based Intervention - Complete iConquerFear program|Online adaptation of a highly effective face-to-face treatment for fear of recurrence.
75470423|NCT04688333|Other|Quality-of-Life Assessment|Ancillary studies
75470424|NCT04688333|Other|Questionnaire Administration|Complete questionnaires
75638575|NCT05557734|Procedure|perianal block|local anesthestic infiltration in the perianal area to block terminal branches of the nerves supplying the anal canal
75638576|NCT05546515|Drug|Suvorexant (dual orexin receptor antagonist)|Participants will be prescribed up to 30 days of SUVO.
75638577|NCT05546515|Drug|Placebo|Participants will be prescribed up to 30 days of placebo medication.
75787433|NCT03187132|Device|Digital Pain Reduction Kit|A two-component intervention consisting of (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain and to teach skills related to chronic pain; (2) TENS unit, used to reduce acute localized pain.
75787434|NCT03187132|Device|Active Control|An active control TENS unit used to reduce acute localized pain.
75470425|NCT04655391|Drug|Bosutinib Monohydrate|Given PO
75470426|NCT04655391|Drug|Decitabine|Given IV
75923627|NCT05530486|Device|LG3|Application of LASER GasAs 660nm 12 J/cm².
75470427|NCT04655391|Drug|Enasidenib Mesylate|Given IV
75638578|NCT05537610|Behavioral|CDT|In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.
75638579|NCT05537610|Behavioral|Control|This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
75638580|NCT05502341|Drug|Bictegravir|Tablets administered orally without regard to food
75330981|NCT01921556|Behavioral|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
75638581|NCT05502341|Drug|Lenacapavir|Tablets administered orally without regard to food
75638582|NCT05502341|Drug|BIC/LEN FDC|Tablets administered orally without regard to food
75787435|NCT03184558|Drug|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor.
75787436|NCT03183778|Drug|Patiromer|Patiromer dosing will be determined based on fasting potassium concentrations measured at the end of each week, factoring in both the absolute concentration, as well as the rate of change. The baseline dose of patiromer will correspond to the study by Weir et al. (2015); 8.4-g once per day for participants with a baseline serum potassium of greater than or equal to 5.1 mEq/L.
75787437|NCT03183778|Dietary Supplement|Research Diet Menu|During the study, participants will be asked to consume only the foods provided in the research diet
75923628|NCT05530486|Procedure|Dressing|Application of Helianthus annuus oil dressing.
75330982|NCT01924910|Dietary Supplement|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
75330983|NCT01924910|Dietary Supplement|Placebo|
75470428|NCT04655391|Drug|Gilteritinib Fumarate|Given PO
75470429|NCT04655391|Drug|Glasdegib Maleate|Given PO
75470430|NCT04655391|Drug|Ivosidenib|Given PO
75330984|NCT04395638|Dietary Supplement|3200IU Vitamin D3 per day for 8 weeks|3200IU Vitamin D3 per day for 8 weeks
75470431|NCT04655391|Drug|Venetoclax|Given PO
75470432|NCT04647994|Diagnostic Test|SARS-CoV-2 serology|Serology test of SARS-CoV-2 for pregnant women
75470433|NCT04644861|Other|Program of adapted physical activity|3 workouts of one hour every week during 4 months. Program will be conducted by adapted physical activity teachers and sports doctor.
75787438|NCT03182686|Biological|4 mL injection of Ampion|4 mL injection of Ampion
75787439|NCT03182686|Drug|4 mL Injection of Placebo|4 mL Injection of Placebo
75787440|NCT03181594|Device|ClariFix Device|Cryoablation in the nasal passageway using the ClariFix Device
75787441|NCT03180736|Drug|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
75470434|NCT04635878|Other|Blood collection|Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes
75470435|NCT04619368|Other|Follow up calls|The follow-up will consist in phone call with an intensive care doctor. These visits would be the opportunity to screen the complications after intensive-care with, find solutions to cure them or decrease their impact on patient's life to improve quality of life and prevent the post-traumatic syndrome disorder PTSD. A review would be sent to the patients' General Practitioners at the end of each visit.
75470436|NCT04609098|Drug|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.
75923629|NCT04444388|Dietary Supplement|cocoa|Sachets of 5 grams of cocoa daily supplementation
75923630|NCT04444388|Dietary Supplement|Placebo|Sachets of 5 grams of maltodextrin daily supplementation
75923631|NCT02163213|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
75923632|NCT02305602|Biological|VentriGel|VentriGel will be injected via MyoStar catheter after NOGA mapping
75923633|NCT04443920|Drug|Tranexamic acid (TXA)|Randomly assigned [1:1 ratio] using a computer generated table of random numbers to 1 of the 2 intervention groups
75330985|NCT04395638|Dietary Supplement|20,000IU Vitamin D3 per week for 8 weeks|20,000IU Vitamin D3 per week for 8 weeks
75470437|NCT04609098|Drug|Tafenoquine 100mg [Arakoda]|Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
75470438|NCT04605614|Radiation|Copper Cu 64-DOTA-pembrolizumab|Given IV
75470439|NCT04605614|Biological|Pembrolizumab|Given IV
75470440|NCT04605614|Procedure|Positron Emission Tomography|Undergo PET
75470441|NCT04560439|Dietary Supplement|Dietary Intervention|Undergo METFIT program
75638583|NCT05502341|Drug|Stable Baseline Regimen|"SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~Nucleos(t)ide Reverse Transcriptase Inhibitors:~Abacavir~Emtricitabine~Lamivudine~Tenofovir alafenamide~Tenofovir disoproxil fumarate~Zidovudine~Non-Nucleosite Reverse Transcriptase Inhibitors:~Delavirdine~Efavirenz~Nevirapine~Rilpivirine~Doravirine~Integrase Inhibitors:~Bictegravir~Cabotegravir~Dolutegravir~Elvitegravir~Raltegravir~Protease Inhibitors:~Atazanavir~Darunavir~Fosamprenavir~Indinavir~Lopinavir~Nelfinavir~Saquinavir~Tipranavir~Chemokine Co-receptor 5 (CCR5) Antagonist:~Maraviroc~Fusion Inhibitors:~Enfuvirtide~gp120 Attachment Inhibitor:~Fostemsavir~Anti-CD4 Monoclonal Antibodies:~Ibalizumab-uiyk"
75638584|NCT05501990|Behavioral|Health intervention based on intelligent applet|Patients are jointly managed by a MDT team based on the applet. The supportive intervention based on the applet mainly includes three parts: Nutrition, psychology, and patient management which includes four main parts: Cancer patient education, self-management, patient community, and real-time communication.
75330986|NCT01921712|Drug|PUR0200|Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
75330987|NCT01921712|Drug|PUR0200 Placebo|Randomized, single dose of inhaled placebo matched to PUR0200
75638585|NCT05499975|Other|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
75638586|NCT05494736|Drug|MK-8527|MK-8527 capsule taken by mouth.
75787442|NCT03180736|Drug|Pomalidomide|Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.
75330988|NCT01921712|Drug|Active comparator|Randomized single dose of inhaled active comparator product
75787443|NCT03180736|Drug|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
75923634|NCT04443920|Drug|Placebo Normal Saline (NS)|Randomly assigned [1:1 ratio] using a computer generated table of random numbers to 1 of the 2 intervention groups
75330989|NCT04395404|Diagnostic Test|MRI|Patients with unilateral ASS, with and without the prosthesis in situ, are analysed by 3D- magnetic resonance imaging (MRI) with 64 channel head coil using T1 and T2 weighted, DIXON/ IDEAL, and T2 inversion recovery sequences.
75330990|NCT04395716|Biological|ResCure™|Patients will be treated with nebulized ResCure™
75330991|NCT04347980|Drug|Dexamethasone and Hydroxychloroquine|"Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before."
75923635|NCT02309814|Device|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
75330992|NCT04347980|Drug|Hydroxychloroquine|Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
75330993|NCT01925300|Drug|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
75330994|NCT01925300|Drug|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
75330995|NCT01925300|Drug|Concor 5mg 2T and Crestor 20 mg 1Tab|
75330996|NCT04395794|Diagnostic Test|SARS-CoV-2-test|Nasopharyngeal and oropharyngeal testing for SARS-CoV-2
75923636|NCT03542643|Dietary Supplement|n-3 Polyunsaturated fatty acid|1g of Eicosapentaenoic acid (EPA)
75923637|NCT03542643|Dietary Supplement|Placebo|Olive oil ethyl esters
76079586|NCT01106950|Drug|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
75330997|NCT04395794|Other|SARS-CoV-2 questionnaire survey|Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients
75330998|NCT03326986|Drug|MK-7252|1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
75330999|NCT03326986|Drug|Placebo|Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
75331000|NCT04275596|Drug|2QR complex|Application of topical gel containing 2QR complex on the anal wound until complete wound healing
75331001|NCT04275596|Drug|Placebo|Application of topical placebo on the anal wound until complete wound healing
75331002|NCT01921946|Drug|Fimasartan|
75331003|NCT01921946|Drug|Rosuvastatin|
75331004|NCT01925378|Drug|Nelfinavir|"All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration."
75331005|NCT03328624|Device|Deep Vein Thrombosis (DVT) Cuff|Recovery Force's DVT II Cuff
75638587|NCT05477524|Biological|VLA15|Shot in the deltoid muscle (preferable in the nondominant arm)
75638588|NCT05477524|Other|Saline|Shot in the deltoid muscle (preferable in the nondominant arm)
75638589|NCT05473442|Drug|EQU-001|20 mg pills of EQU-001
75638590|NCT05473442|Other|Matching Placebo|20 mg matching placebo pills
75787444|NCT05240092|Behavioral|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
75787445|NCT03178942|Drug|Permethrin Cream, 5%|Permethrin Cream 5%
75787446|NCT03178942|Drug|Elimite™ Cream (permethrin) 5%|Permethrin Cream 5%
75923638|NCT02313090|Other|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
76079587|NCT01106950|Drug|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
76079588|NCT01106950|Procedure|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
76079589|NCT01106950|Drug|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m^2 every other day for 6 doses).
76079590|NCT01107730|Drug|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
75331006|NCT03095300|Procedure|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
75638591|NCT05467657|Device|repetitive Transcranial Magnetic Stimulation|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
75638592|NCT05465590|Drug|MB1707|"MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.~MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism."
75638593|NCT05462704|Drug|Ferric derisomaltose|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.
75638594|NCT05462704|Drug|Ferrous sulfate|325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.
75638595|NCT05455346|Diagnostic Test|Ultrasound imaging|"Ultrasound B-mode images will be unilaterally collected from the biceps femoris muscle of the dominant limb for each participant using a commercial ultrasound system and linear array transducer. Standardized image locations will correspond to 33%, 50%, and 67% of the thigh length from the ischial tuberosity.~Three repeat longitudinal extended-field-of-view images of the entire biceps femoris muscle will be collected for offline analysis for fascicle length, muscle thickness, and pennation angle. Transverse extended-field-of-view images will be captured at the proximal, mid-belly, and distal locations to determine regional anatomical cross-sectional area of the biceps femoris long head muscle.~To determine changes in tissue stiffness via ultrasound shear wave speed, the same transducer will be placed in the same locations in a longitudinal view. Shear wave maps will be generated by the ultrasound system and shear wave speed measures extracted from the middle of the map."
75787447|NCT05239702|Biological|CD7 CAR T-cells|Each subject receive CD7 CAR T-cells by intravenous infusion
75787448|NCT03175198|Drug|Prazaxa® Capsules|Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg [as 2 capsules of 75 mg] twice a day (b.i.d)) or 220 mg (110 mg [as 1 capsule of 110 mg] b.i.d) for a treatment duration of 52 weeks.
75923639|NCT03359018|Drug|Apatinib|Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
75923640|NCT03359018|Drug|SHR-1210|Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
75331007|NCT01925456|Drug|Toviaz|Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
75331008|NCT04395950|Drug|PF-05221304|PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)
75787449|NCT03087448|Drug|Ceritinib|"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~Ceritinib 300mg~Ceritinib 450mg~Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study"
76079591|NCT01107730|Drug|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
75787450|NCT03087448|Drug|Trametinib|"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~Trametinib 1.5mg~Trametinib 1.5mg~Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study"
76079592|NCT01107730|Drug|Placebo|Placebo
76079593|NCT03463122|Device|field of regard-focused visual exploration therapy|field of regard-focused visual exploration therapy in addition to conventional therapy
76079594|NCT03463122|Other|conventional therapy|conventional therapy for stroke rehabilitation
76079595|NCT03011164|Procedure|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
76079596|NCT03463044|Drug|nangibotide|Continous i.v. infusion
76079597|NCT03463044|Drug|Placebo|Placebo
76079598|NCT02522208|Drug|BiDil XR|fixed combination capsule
76079599|NCT02522208|Drug|BiDil Immediate Release (IR)|fixed combination tablet
76079600|NCT01107964|Drug|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
76079601|NCT01107964|Drug|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
76079602|NCT05684172|Drug|Tenecteplase|If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the pontine arteries.
76079603|NCT05684172|Other|endovascular thrombectomy alone|Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
76079604|NCT01200160|Drug|Niacin|
76079605|NCT04452786|Procedure|Endoscopic sleeve gastroplasty|Four-hour solid mixed meal test
75331009|NCT04395950|Drug|Placebo|Placebo two tablets daily in the morning for 6 weeks
75923641|NCT05530252|Drug|Oral biological antimicrobial gel|The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
75787451|NCT03175120|Drug|Insulin degludec/liraglutide|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
75923642|NCT05530252|Drug|minocycline hydrochloride ointment|The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
76079606|NCT04452786|Procedure|Laparoscopic sleeve gastrectomy|Four-hour solid mixed meal test
76079607|NCT01153672|Drug|vorinostat|Given PO
76079608|NCT01153672|Other|laboratory biomarker analysis|Correlative studies
76079609|NCT01153672|Procedure|biopsy|Optional correlative studies
76079610|NCT01153672|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
76079611|NCT01153672|Procedure|positron emission tomography|Correlative studies
76079612|NCT01153672|Drug|anastrozole|Given PO
76079613|NCT01153672|Drug|letrozole|Given PO
76079614|NCT01153672|Drug|exemestane|Given PO
75331010|NCT01925690|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
75638596|NCT05455346|Other|Hamstring Eccentric Strength Testing|"Prior to each test, participants will perform a standardized 5-minute general warm-up followed by a task-specific warm-up including 3 sets of submaximal trials. Load increases (5-20%) will be added for each RDL 3-repetition maximum trial attempt until the participant cannot complete 3 repetitions through the full range of motion using proper technique. A 3-minute rest will be administered between all warm-up and testing sets to allow for full recovery.~Participants will kneel on a commercial device used to assess maximum eccentric knee flexor strength via uniaxial load cells with their ankles secured into fixed hooks. Participants will slowly lower their torso to the ground with arms crossed across their chest and without bending at the hips or spine. The maximal test will consist of 1 set of 3 maximal repetitions. If participants can control lower themselves to the ground, then they will hold barbell plates (5-10 lb increments) across their chest while performing the NHE."
75638597|NCT05455346|Other|Maximal 60 m Sprint|Following a standardized warm-up, inertial measurement units (IMUs) will be placed on the sternum, sacrum, and bilaterally on the thighs, legs, and foot. Each participant will perform a total of 3 maximal 60 m sprints from a standing position with 1.5-3 min rest in between each trial to minimize the effects of fatigue.
75331011|NCT01925690|Behavioral|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
75331012|NCT03229252|Drug|Placebo Inhalation Solution|Normal Saline Inhalation Solution
75331013|NCT03229252|Drug|SPX-101|SPX-101 Inhalation Solution
75470442|NCT04475016|Drug|Albumin-Bound Paclitaxel|260 mg/m² IV over 30 minutes on Day 1
75638598|NCT05455346|Other|Romanian Deadlift|The RDL intervention will be performed twice per week for 6 weeks. Participants will hinge at the hips lowering the bar to just below their patella before reversing the movement. The RDL will be performed with a 6 second eccentric component and returning to the start position with a maximal concentric hip extension.
75787452|NCT03175120|Drug|Insulin degludec|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
75787453|NCT03172702|Drug|Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
76079615|NCT01153672|Genetic|gene expression analysis|Correlative studies
76079616|NCT05321628|Behavioral|Internet-based Cognitive Behavioural Therapy (iCBT) with Decision Support Tool|Cognitive Behavioural Therapy för depression, panic disorder and social anxiety delivered thru texts and home works assignments via an internet platform with therapist weekly support through text messages. Therapist use a traditional, detailed therapist manual with the additions of a Clinical Decision Support Tool (DST) that identifies patients at risk of treatment failure and give suggestions to the therapist on how to act in relation to the specific patient.
76079617|NCT05321628|Behavioral|Internet-based Cognitive Behavioural Therapy (iCBT)|iCBT, as described above, using only the traditional, detailed therapist manual.
75470443|NCT04475016|Drug|Ifosfamide|1200 mg/m² IV over 2 hours on Days 1-3
75470444|NCT04475016|Drug|Cisplatin|25 mg/m² IV over 2 hours on Days 1-3
76079618|NCT03010072|Drug|low-dose sucroferric oxyhydroxide|250 mg suroferric oxyhydroxide
76079619|NCT03010072|Drug|high-dose sucroferric oxyhydroxide|2000 mg suroferric oxyhydroxide
76079620|NCT02734212|Behavioral|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
76079621|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
76079622|NCT01202578|Device|tympanostomy tube|tympanostomy tube delivery system
76079623|NCT03462810|Drug|cabotegravir, CAB|open label investigational product
76079624|NCT01202656|Drug|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
76079625|NCT01202656|Drug|Saline|intrauterine saline infusion 1 cc
75923643|NCT05530252|Other|SRP|only scaling and root planning was performed on the patient
76079626|NCT03462732|Device|Endotracheal tube|Nasotracheal intubation will be done with endotracheal tube
75638599|NCT05455346|Other|Nordic hamstring exercise|The NHE will be performed twice per week for 6 weeks. Participants will be instructed to maintain their ankles in a dorsiflexed position, lower themselves as close to the ground as possible at a constant and controlled speed while maintaining a neutral position of the hips and trunk, and to cross their arms in front of their chest.
76079627|NCT03462732|Device|Nelaton catheter|plus nelaton catheter
76079628|NCT01219738|Drug|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
76079629|NCT01219738|Drug|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
76079630|NCT01219738|Drug|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
75470445|NCT04475016|Drug|Nimotuzumab|400 mg IV on Day 1
75470446|NCT04475016|Drug|Triprilimab|240 mg IV on Day 1
76079631|NCT01219738|Drug|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
76079632|NCT01219738|Drug|Placebo|A single inhaled dose of placebo from a DPI.
75638600|NCT05451849|Biological|TC-510|TC-510
75787454|NCT02795182|Drug|Zanubrutinib|
75787455|NCT02795182|Drug|Tislelizumab|
75787456|NCT05213182|Behavioral|Young Women of Today|Adolescent mothers engaged in the development and implementation of the intervention which also involved key community stakeholders to address stigma related to mental illness and adolescent motherhood. Community health workers and peer educators in the intervention arm were recruited and trained on co-facilitating peer support groups. The intervention arm (n=104 adolescent mothers) participated in the peer support groups and completed sociodemographic, base-, mid-, and end-line surveys. The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys. Peer support groups (12 groups with 6-12 participants in each group) met in-person twice a month and completed 12 peer-group sessions from May-August 2019 addressing participant identified topics such as depression. WhatsApp Messenger was used for training and implementation support. Key community stakeholders met to discuss project progress and recommendations to improve adolescent mothers' health.
75638601|NCT05451849|Drug|Fludarabine|Fludarabine
75638602|NCT05451849|Drug|Cyclophosphamide|Cyclophosphamide
75787457|NCT05206162|Device|theta burst stimulation|TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.
75787458|NCT03054766|Procedure|Ranibizumab combined macular laser|subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
75787459|NCT03054766|Drug|Ranibizumab|all subjections received 3+PRN ranibizumab injections by BCVA stabilization
75787460|NCT05068570|Other|ARMEROMTERY|ARMERGOMTERY TRAINING FOR UPPERLIMB
75923644|NCT03505866|Behavioral|Community home-based care intervention|HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
75638603|NCT05441982|Other|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
75638604|NCT05438329|Drug|DB-1305|Administered I.V.
75638605|NCT05438329|Combination Product|Pembrolizumab|Administered I.V.
75923645|NCT02305524|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
75923646|NCT02305524|Device|Macintosh laryngoscope|intubation with macintosh laryngoscope with conventional tube
76079633|NCT04639752|Behavioral|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
75638606|NCT05434767|Device|Mobile application|Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.
75638607|NCT05434767|Other|Standard rehabilitation program|All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
76079634|NCT04639752|Behavioral|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
76079635|NCT03848754|Drug|Gemtuzumab Ozogamicin 3 mg/m^2|"GO 3 mg/m^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle."
76079636|NCT03848754|Drug|Gemtuzumab Ozogamicin 2 mg/m^2|GO 2 mg/m^2 on Day 1 of a 28-day cycle.
76079637|NCT03848754|Drug|Pracinostat - 45 mg|Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.
76079638|NCT03848754|Drug|Pracinostat - 60 mg|Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
76079639|NCT01155154|Drug|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
76079640|NCT01155154|Drug|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
76079641|NCT01155154|Drug|placebo|Two placebo capsules every 6 hours for 7 days
76079642|NCT02521896|Device|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
76079643|NCT03786432|Device|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
76079644|NCT04614714|Drug|Nicotinamide riboside chloride|Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)
76079645|NCT04614714|Drug|Placebo|Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)
76079646|NCT01221298|Drug|ABT-450|tablets
76079647|NCT01221298|Drug|ABT-072|tablets
76079648|NCT01221298|Drug|Ribavirin|tablets
75923647|NCT02163291|Drug|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
75470447|NCT04409743|Behavioral|Remote Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
75470448|NCT04392180|Other|Qualitative Interview|There is no intervention as part of this study. Caregivers will participate in a qualitative interview over the phone or by video.
75470449|NCT04372680|Diagnostic Test|CTUS examination|fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
75470450|NCT04359056|Other|Clinical pharmacy activities along the care pathways|"PICC line implantation: Optimize the logistics circuit of the PICC line by rationalizing orders through the evaluation of potential losses.~Ensure the due traceability of the implanted medical device. Discharge order : Analysis, optimization and pharmaceutical interventions if necessary Discharge Pharmaceutical Interview : Discussion with the patient, Information about the PICC line maintenance and associated therapies, Information about the prescribed drugs.~Call to the community pharmacist to transfer the patient's prescription. Follow-up calls for 3 months after discharge~Patients: Two calls the first week after implantation, then one call per month for a maximum of 3 months, Clinical data collection :Pharmaceutical advices if necessary~Liberal nurses: same frequency, Clinical data collection, Pharmaceutical advices if necessary~Community pharmacist: one call per month, information relevant to the patient's follow-up will be collected."
75470451|NCT04331795|Drug|Tocilizumab|"Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~CRP decrease is < 25% at 24 hours following tocilizumab administration and CRP > 40mg/L"
75638608|NCT05433467|Procedure|CT-guided localization for micro hepatocellular carcinoma before surgical resection|After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
75638609|NCT05430854|Biological|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
75638610|NCT05430360|Biological|GT201|Autologous tumor infiltrating lymphocyte injection
75787461|NCT03036748|Dietary Supplement|Standardized sodium diet|Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
76079649|NCT01221298|Drug|Ritonavir|capsules
75787462|NCT03036748|Drug|Tbl amiloride|Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
75787463|NCT04933786|Behavioral|Digital Health Nudging|Short daily text messages with information and motivation concerning physical activity.
75638611|NCT05416125|Drug|Lisdexamfetamine Dimesylate|Vyvanse treatment
75638612|NCT05416125|Behavioral|Lifestyle therapy|Lifestyle treatment
75638613|NCT05404711|Device|CGM|Participants will wear blinded Dexcom G6 Pro continuously for 10 days in their home environment. Two challenges will be completed at home: 1) glucose, using 1.75 g/kg (max 75g) glucose beverage provided by study team, and 2) mixed food, containing 50g carb as well as protein and fat content of participant's choice.
75787464|NCT04935736|Device|root canal sealer : CORTISOMOL SP|The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.
75787465|NCT04935736|Device|root canal sealer : SEALITE REGULAR|The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.
75787466|NCT03167242|Drug|KAF156|KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
75787467|NCT03167242|Drug|Coartem|Coartem comes as 20/120 mg dispersible tablets or 80/480 mg tablets for oral administration. Coartem was administered twice daily for 3 days as active comparator.
75787468|NCT03167242|Drug|Lumefantrine Solid Dispersion Formulation|LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.
75923648|NCT03358940|Other|urine collection|For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
75923649|NCT05532124|Biological|LAENNEC (Human Placenta Hydrolysate)|Intravenous Injection
76079650|NCT05321004|Other|Semi-structured interviews will be conducted - there will be no intervention.|The use of semi structured interviews and questionnaires
76079651|NCT01222234|Drug|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
76079652|NCT01222234|Device|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
76079653|NCT01222234|Drug|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
76079654|NCT01203046|Drug|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
76079655|NCT04604184|Drug|BI 764198|BI 764198
76079656|NCT04604184|Drug|Placebo|Placebo
75923650|NCT05532124|Other|normal saline|Intravenous Injection
75923651|NCT03358862|Device|NaturalVue Multifocal Contact Lens|NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
75923652|NCT02313168|Other|observation, inspection|
75923653|NCT03354104|Device|The tunnel technique for root coverage with Emdogain|The tunnel technique for root coverage with Emdogain
75638614|NCT05401045|Behavioral|Met exercises|Exercise plan: Each session of the self-designed MET exercise program was divided into 8 components: stretching exercises, chest expansion exercises, kicking exercises, lateral movement exercises, body rotation exercises, whole-body exercises, jumping exercises, and a cool down. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening. For patients with moderate fatigue and an RPFS score of 4 to 6 points, low-intensity exercise was recommended, i.e., patients could choose 1 to 4 metabolic equivalent exercises and repeat them twice; for patients with mild fatigue and an RPFS score of 1 to 3 points, moderate-intensity exercise was recommended, i.e., patients could choose to complete the entire set of metabolic equivalent exercises or 5 to 8 of the exercises and repeat them twice. The exercise frequency was 5 times per week.
76079657|NCT04604106|Diagnostic Test|Eyetracker|Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
76079658|NCT04604106|Diagnostic Test|Ages & Stages questionnaire|The Ages & Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.
76079659|NCT04604106|Diagnostic Test|Bayley Scale of Infant Development|The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
75638615|NCT05390723|Behavioral|Communciation intervention|The investigators cannot reveal the manipulated communication as this might influence participant outcomes.
75787469|NCT02964052|Other|Brain CT imaging|Investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. Investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.
75787470|NCT05438056|Other|education with mobile application|providing training to mothers of premature babies with a mobile application
75787471|NCT03636334|Behavioral|Computer-based decision support system|At intervention sites, physicians will receive training and support on use of the DSS, which will be installed on their local IT system. Individuals eligible for DSS at Intervention sites will be randomized or assigned to different drug sequence protocols for BP-lowering therapy using their current antihypertensive medications, co-morbidities, and intolerance to medications and according to the assignment plan in the Algorithm. If the protocol is not suitable for the patient because of new co-morbidities, medication intolerance or contraindication, the DSS will recommend switching to a new protocol.
75787472|NCT03636178|Procedure|Classic alar base suture technique|An index finger will be used to apply extraoral pressure on the alar base region, and a dentate forceps will grasp this tissue through the intraoral incision. A suture bite will be taken at this point through the tissue previously held by the forceps. The same procedure will be applied on the opposite side. After passing the suture on both sides, it will be tightened with attention to the alar base response. If the alar base suture will be judged to be adequate, the vestibular incision will then be closed in a routine fashion, with or without performing a V-Y lip closure
75787473|NCT03636178|Procedure|Modified alar base suture technique|The alar base will be marked with 3 landmarks: left alar base (point LAB), columella (point C), and right alar base (point RAB). A needle will be inserted through the skin at the nasofacial skin fold and exited through the fibroareolar tissue. A nonabsorbable suture without a needle will be inserted through the needle from the oral cavity to the outside. The needle will be retracted through point RAB without leaving the skin point, then returned to the oral cavity in a medial position. Finally the needle will be retracted from point RAB, leaving the suture through the soft tissue. The same procedure will be repeated on the other side. The 2 free ends of the sutures will be then tied together after passing through a hole made in the nasal spine.
75787474|NCT05432050|Device|Bispectral index and Patient state index monitoring|The depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
75787475|NCT01330186|Other|FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)|This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
75923654|NCT03354104|Device|The tunnel technique for root coverage without Emdogain|The tunnel technique for root coverage without Emdogain
75923655|NCT05531968|Biological|BMI2006|IM
75923656|NCT05531968|Biological|BOTOX®|IM
75923657|NCT03354026|Drug|AICH-PXZY|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
76079660|NCT04549272|Other|No interventions|No interventions - observational study
76079661|NCT04542720|Procedure|Randomized: Decompression|Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
76079662|NCT04542720|Procedure|Randomized: Extension Fusion|Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
76079663|NCT04542720|Procedure|Observational: Decompression|This intervention is identical to the Randomized: Decompression intervention. Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
75331014|NCT01922180|Radiation|Chest CT scans|CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
75331015|NCT03330262|Device|BALCAP prosthesis|The noninvasive BALCAP prosthesis offers uses six degrees-of-freedom (6-DOF) sensing to detect postural imbalance and actuate low-amplitude vibrotactile cues directly to the head to provide the wearer with feedback concerning head tilt in the pitch and roll plane.
75787476|NCT02026414|Dietary Supplement|PrimaVie|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
75787477|NCT02026414|Other|Exercise|
75787478|NCT01330654|Drug|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
75787479|NCT01330810|Drug|curcumin|standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
75923658|NCT03354026|Drug|AICH-without PXZY|AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
75923659|NCT03354026|Drug|AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin
75923660|NCT05524792|Other|no interventional study|no interventional study
75923661|NCT02309892|Drug|L-DOS47|A treatment cycle will be 21 days, with patients receiving L DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
75923662|NCT02163369|Drug|Peppermint and Lavender Essential Oils|
75923663|NCT03505788|Drug|Acetazolamide|In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
75923664|NCT03505788|Drug|Placebo|In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
75923665|NCT03358784|Procedure|Hemi-shoulder Arthroplasty|Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus
76079664|NCT04542720|Procedure|Observational: Extension Fusion|This intervention is identical to the Randomized: Extension Fusion intervention. Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
75638616|NCT05382403|Device|Jada® System|This is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted. The device is made of medical grade silicone. The distal end, which is placed in the uterus, is an elliptical loop. The circular cervical seal, just outside the external cervical os, is filled with 60 - 120 mL sterile water. Low-level vacuum (80 ± 10 mm Hg) is applied and pooled blood is evacuated from the uterus as it collapses. Once there is no bleeding, the device remains in the uterus for at least 1 hour. The suction is then disconnected, the seal emptied of water, the device left in place, and the patient monitored for an additional 30 minutes. If bleeding remains controlled, the device is removed. If bleeding is uncontrolled with the Jada® System patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
75638617|NCT05382403|Other|Standard care|Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
75923666|NCT03358784|Procedure|PHILOS Plate|PHILOS plate treating three or four-part fractures of proximal humerus
75923667|NCT04967313|Behavioral|Behavioral Change Techniques|"Four behavioral changes techniques (BCTs) will be administered to participants in random order. The BCTs are defined as follows:~Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~Action planning: prompt detailed planning of performance of behavior (must include a setting [walking to the mailbox], frequency, duration, and intensity. Example: Develop a plan to walk today.~Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today. This is 1,000 steps above your baseline."
75923668|NCT02309970|Drug|acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran|subject in this group will receive oral treatment with anti platelet drug
76079665|NCT04504266|Behavioral|POWER|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
76079666|NCT03462420|Other|Physical Therapy program|The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
75331016|NCT03235180|Drug|Sulfur Hexafluoride|Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
76079667|NCT03449394|Other|Metacognitive Training|4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases
76079668|NCT05320848|Behavioral|cardiac rehabilitation|Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.
75331017|NCT03235180|Device|Ultrasound Elastography|Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
75923669|NCT02309970|Drug|alteplase|subject in this group will receive intravenous tPA
75923670|NCT02309970|Procedure|endovascular|
76079669|NCT03449316|Behavioral|Inhaler technique education|Teaching of inhalers use with placebo devices in real training
75638618|NCT05369182|Diagnostic Test|Invasive physiologic assessment|"All coronary physiologic parameters are measured following diagnostic angiography. Resting pd/pa, FFR, CFR and IMR will be calculated using coronary physiologic parameters.~In patients treated by PCI, post-PCI physiologic assessment including CFR, IMR, and FFR will be performed."
75638619|NCT05369182|Diagnostic Test|Intravascular imaging|By the operator's discretion, stent-optimization will be performed under intravascular imaging devices (IVUS [Boston Scientific, Natick, Massachusetts, USA] or OCT [Abbott Vascular], St. Paul, MN, USA]).
75787480|NCT01331044|Dietary Supplement|Plumpy Nut|to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered ~ 125 kcal/kg in 1st 24 hours, ~ 150 kcal/kg in 2nd 24 hours, then~200k cal/kg by the third day).
75923671|NCT03353948|Drug|MET|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
75923672|NCT03353948|Drug|COMBI|In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
75923673|NCT02161653|Drug|Prednisone plus Metadoxine|
75923674|NCT02161653|Drug|Pentoxifylline plus Metadoxine|
75331018|NCT03235180|Device|Ultrasound Vascularity|Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
75331019|NCT03235180|Device|Magnetic Resonance Enterography (MRE)|Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
75331020|NCT03470740|Behavioral|rheumatoid arthritis self-management program|The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
75331021|NCT03471832|Device|stenfilcon A lens|contact lens
75331022|NCT03471832|Device|narafilcon A lens|contact lens
75331023|NCT00985166|Biological|ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)|A Single 0.5 mL subcutaneous injection at Day 1
75923675|NCT03386526|Drug|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
75331024|NCT00985166|Biological|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 1
75331025|NCT00985166|Biological|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 1
75331026|NCT00985166|Biological|Comparator: Placebo|A Single 0.5 mL subcutaneous placebo injection at Day 1
75331027|NCT04735120|Device|iLASE DIODE LASERS|940nm diode laser with 1.5 watts activated in a continuous mode and applied on to the canal orifices during root canal treatment to reduce intraoperative pain and further its effect on post operative pain is assessed
75638620|NCT05362344|Procedure|Stool tests|Non-invasive, stool-based tests for colorectal cancer screening.
75638621|NCT05339269|Procedure|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
75638622|NCT05338294|Procedure|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection is performed by the same surgical team.
75638623|NCT05337735|Drug|XmAb20717|Given by vein (IV)
75638624|NCT05325437|Procedure|Laparoscopic splenectomy and azygoportal disconnection|The laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
75638625|NCT05325424|Procedure|Laparoscopic splenectomy|The laparoscopic splenectomy was performed by the same surgical team.
75923676|NCT02576938|Drug|Baricitinib|Administered orally
75923677|NCT02576938|Drug|Placebo|Administered orally
75923678|NCT02576938|Drug|Triamcinolone (Optional)|Administered topically
75923679|NCT03358628|Other|Molecular Profiling & In Vivo drug testing in PDX|Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
75923680|NCT02163603|Procedure|Pelvic osteotomy|
76079670|NCT05320536|Drug|Guilingji Capsule|This medicine is capsule medicine, take method is oral.
76079671|NCT05320536|Drug|Placebo|This medicine is capsule medicine（Placebo）, take method is oral.
76079672|NCT02460588|Drug|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
76079673|NCT02460588|Drug|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
76079674|NCT02460588|Drug|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
76079675|NCT03641430|Other|Supportive care with OCT product|Participants will apply over-the-counter product for a certain period with or without light challenge. We will perform clinical assessments of the skin associated with product application as well as assess these changes with and without light challenge. Skin biopsies will be obtained following standard medical practice and will be used to analyze skin markers related to photoaging, pigmentation, oxidative stress, and other dermatologic conditions.
75331028|NCT03235414|Device|MRI|Will receive a one time research MRI (MR elastography)
75331029|NCT03235414|Diagnostic Test|Blood draw|Will receive a one time blood draw to confirm healthy liver status
75331030|NCT04735900|Procedure|Liquid biopsy sampling|Biweekly liquid biopsy sampling to measure circulating tumor DNA (ctDNA) level up to and including 9 months after start first-line therapy.
75331031|NCT03474172|Device|Cloak Shape Device for Sham Tuina|The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
75787481|NCT01331044|Dietary Supplement|Khichuri and Halwa|"Day 1: Milk suji, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day 125kcal/kg.day~Day 2: Milk suji, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day & khichuri 10gm/kg; 2 feed per day 150kcal/kg.day~Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day & khichuri 10gm/kg; 2 feed per day 175kcal/kg.day~Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 3 feed per day & khichuri 10gm/kg; 3 feed per day 200kcal/kg.day~Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) & halwa 20gm/kg; 3 feed per day & khichuri 20gm/kg; 3 feed per day 200kcal/kg.day"
75331032|NCT03474172|Device|Cloak Shape Device for Genuine Tuina|The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
75638626|NCT05316623|Device|TENS|TENS (strong and comfortable intensity) applied during exercises in a telerehabilitation setting.
75923681|NCT03505632|Device|Recruitment with low PEEP|Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .
76079676|NCT04369638|Device|3D NAM|"After consent and birth of the child, a face MRI will be taken of the newborn before discharge from the hospital utilizing the feed and swaddle technique. The MRI will be sent to the dental team to convert into a format compatible with 3D software. With the image, a NAM appliance will be digitally fabricated and 3D printed. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment."
76079677|NCT04369638|Device|Traditional NAM|The patient will be seen for visit at the clinic for traditional intraoral impression and a dental stone model will be poured. An acrylic NAM will be fabricated on the stone model. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment.
76079678|NCT05320458|Other|Pulmonary Rehabilitation|1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
75331033|NCT03474406|Other|follow up system and multimodality approach|To provide a new service system for cancer pain in pain clinic by early detecting red flag sign to consult other departments, early alleviating severe pain, following patients intensively by telephone call and giving pain education
75331034|NCT03474874|Device|NeoMatriX Collagen Dressing|Collagen wound dressing
75331035|NCT03476278|Other|Questionnaire|Postoperative questionnaire, and records of complications in the peri-operative period
75331036|NCT02264379|Radiation|normal fractionated irradiation|25*2 Gy (once a day, 5 days a week)
75331037|NCT02264379|Radiation|hypo fractionated irradiation|3*10 Gy (once a day, 2-3 days a week)
75787482|NCT01331122|Drug|droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
75331038|NCT03335254|Drug|TSX-011|TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
75638627|NCT05315648|Procedure|anesthesia approach (general anesthesia or non-general anesthesia)|patients in group GA received general anesthesia followed with FNB. patients in group NGA received CSEA followed with FNB
75638628|NCT05313165|Device|LimFlow Stent Graft System|Creation of an arteriovenous fistula in the desired limb location
75638629|NCT05304455|Drug|Apixaban 2.5 MG|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
75787483|NCT01320280|Drug|BIBW 2992 (Afatinib)|50 mg BIBW 2992 (Afatinib) tablets daily continuously
75787484|NCT01331278|Procedure|Total Knee Arthroplasty with Custom Cutting Blocks|Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
75331039|NCT02226159|Drug|Lidocaine|
75331040|NCT02226159|Drug|Lidocaine with Dexamethasone|
75331041|NCT03335800|Device|Apple Heart Study App|The Apple Heart Study app is a mobile medical app that analyzes pulse rate data. The app identifies episodes of irregular heart rhythms consistent with atrial fibrillation and other arrhythmias.
75331042|NCT02202369|Other|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
76079679|NCT05320224|Other|Patient-Oriented Music Intervention (POMI)|The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
76079680|NCT03449160|Device|UPRIGHT|A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day
76079681|NCT03449160|Other|physical therapy|routine physical therapy
76079682|NCT03449082|Biological|High concentration of Allo-ASC|10 million cells of Allo-ASC 0.5cc
76079683|NCT03449082|Biological|Low concentration of Allo-ASC|1 million cells of Allo-ASC 0.5cc
75638630|NCT05304455|Drug|Dipyridamole 25Mg Tab|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
75787485|NCT01331278|Procedure|Total Knee Arthroplasty via Computer Assisted Surgery|Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
75923682|NCT03505632|Device|High PEEP without RM|Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)-152.4} for men and 45.5 + 0.91 × {height (cm) - 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
75923683|NCT03355586|Combination Product|Electromagnetic navigation|Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
76079684|NCT03449082|Drug|Fibrin glue|Fibrin glue 0.5cc
76079685|NCT03449082|Drug|Normal saline|Normal saline 0.5cc
76079686|NCT05308134|Other|Standard fortification|Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
76079687|NCT05308134|Other|Target fortification|Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
76079688|NCT05308134|Other|BUN adjustable fortification|BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
75331043|NCT02202369|Other|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
75331044|NCT03338686|Procedure|Free Gingival Graft (FGG)|Free Gingival Graft (FGG) was performed on all study sites in this arm.
75638631|NCT05304455|Drug|subcutaneous Low Molecular Weight Heparin|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
75787486|NCT01331356|Drug|Botox|One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
75787487|NCT01331434|Drug|exemestane|25 mg tablet
75787488|NCT01331590|Drug|G-CSF|
75787489|NCT01331590|Drug|Ifosfamide|
75787490|NCT01331590|Drug|Etoposide|
76079689|NCT03449004|Other|Validation of the OPSI questionnaire|A questionnaire to measure satisfaction with online information for patients with low back pain
76079690|NCT03129672|Procedure|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
75331045|NCT03338686|Procedure|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
75331046|NCT03241030|Drug|Sucralfate|Will receive 20mg/kg/dose up to 1 gram.
75331047|NCT03241030|Other|Placebo|Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
75331048|NCT03241030|Drug|Acetaminophen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
75787491|NCT01331590|Drug|Dexamethasone|
75787492|NCT01331590|Drug|Mesna|
75787493|NCT01331746|Drug|APD515|20 mg oromucosal-oral administration qds for 7 days
75787494|NCT01331746|Drug|Placebo|qds for 7 days
75787495|NCT03635866|Diagnostic Test|Fluciclovine PET/MRI|It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.
75787496|NCT01331902|Other|Maximal Hyperemia with Adenosine Followed by Nicorandil|Firstly FFR was measured with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
76079691|NCT03130062|Other|Exercise|The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
76079692|NCT03413202|Drug|butylphthalide(NBP)|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
76079693|NCT03413202|Drug|placebo|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
75787497|NCT01331902|Other|Maximal Hyperemia with Nicorandil Followed by Adenosine|Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
75923684|NCT03542487|Behavioral|Practice Orientation|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. This will allow diabetic patients at these practices to enter any self-monitored glucose measurements. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose.
75923685|NCT03542487|Behavioral|Standard Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets
75923686|NCT03542487|Behavioral|Gift Card Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets. In these reminders, they will also be notified that that they will be entered to win a $50 gift card for each day entering data.
75923687|NCT03542487|Behavioral|Physician Reminders|Patients receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT)
76079694|NCT02521818|Other|Modified Atkins Diet|
76079695|NCT02521818|Other|NIA Diet for Seniors|
75470452|NCT04331795|Drug|Tocilizumab|"Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~CRP decrease is < 25% at 24 hours following tocilizumab administration and CRP > 40mg/L"
75638632|NCT05300516|Procedure|vagus nerve-guided group|The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
76079696|NCT04169100|Drug|Prednisone|We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
75331049|NCT03241030|Drug|Ibuprofen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
75331050|NCT03479944|Procedure|FLACS|Femtosecond laser assisted cataract surgery consisting of LenSx® and Centurion® combination
75638633|NCT05292391|Biological|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
75638634|NCT05292391|Biological|Sm-p80|The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.
75787498|NCT01331980|Device|Peripheral quantitative computed tomography (pQCT)|A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
75787499|NCT01331980|Device|Dual X-ray absorptiometry (DXA)|A total body DXA scan will be conducted at a single study visit
75787500|NCT01332058|Behavioral|Motivational Interviewing|8 possible weeks of motivational interviewing sessions
75331051|NCT03479944|Procedure|Manual conventional surgery|Removal of cataractous lens by phacoemulsification
75331052|NCT03479944|Device|CENTURION® Vision System|Phacoemulsification aspiration platform for use during cataract surgery
75331053|NCT03479944|Device|LenSx®|Femtosecond laser system used for continuous curvilinear capsulorhexis (CCC) and lens fragmentation during cataract surgery
75331054|NCT03241810|Drug|Seribantumab|Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling
75331055|NCT03241810|Drug|Fulvestrant|Fulvestrant is an estrogen receptor antagonist with no agonist effects
75331056|NCT03241810|Drug|Placebo|Placebo
75331057|NCT02129751|Drug|bupropion hydrobromide|study drug
75331058|NCT02129751|Drug|Placebo|placebo arm
75331059|NCT03242590|Drug|LPCN 1021|Oral testosterone undecanoate
75787501|NCT04261972|Genetic|Next generation sequencing (NGS)|NGS
75787502|NCT01332214|Drug|AZD2820|Subcutaneous Injection in abdomen or Thigh
76079697|NCT03698448|Drug|OligoG Dry powder for inhalation|10 capsules Dry Powder for Inhalation, BID
75470453|NCT04321551|Drug|Testosterone Cyp 200Mg/Ml Inj (in Oil)|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.
76079698|NCT04155996|Device|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
75331060|NCT03481270|Behavioral|Concordant|We will be randomizing across providers - we are particularly interested in racial concordance.
75331061|NCT03247738|Drug|Cangrelor|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
75331062|NCT03247738|Other|Placebo|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
75331063|NCT02660385|Behavioral|Cognitive Behavioral Therapy for Insomnia|This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
75331064|NCT02660385|Behavioral|Self-Management Education for Heart Failure|This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
75331065|NCT03341728|Behavioral|Optical flow perturbations|Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
75331066|NCT03341728|Behavioral|Normal walking|Usual treadmill walking without optical flow perturbations
75331067|NCT03345160|Drug|Peanut Flour|open label oral immunotherapy
75331068|NCT01874067|Device|Arthritis glove|Isotoner three-quarter finger arthritis glove
75331069|NCT03345394|Behavioral|Contingency Management|Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples
75638635|NCT05287685|Behavioral|Screen media adapted School Readiness Parenting Program|For the screen time adapted parenting intervention, screen time intervention components will be infused into the SRPP (described below) to address three primary areas shown in research to play an important role in healthy screen media use: (1) reducing and managing screen time use; (2) maximizing benefits of screen time content; and (3) promoting positive parent-child interactions during co-use of screen media. Psychoeducation and practice of these strategies will be incorporated into sessions of the SRPP in which relevant behavioral concepts are addressed.The screen time adapted parenting intervention will utilize the same format (large group, 8 weekly 1.5 hour sessions) as the SRPP.
75638636|NCT05287685|Behavioral|School Readiness Parenting Program|The SRPP is an 8-week parenting program for parents of preschool aged children with externalizing behavior problems. The SRPP targets child externalizing behavior problems specifically, as well as to help parents promote children's school readiness skills. The SRPP follows a group Parent-Child Interaction Therapy (PCIT) model and also uses motivational interviewing and modelling problem solving approaches. The SRPP utilizes a large group format (10-15 parents) with weekly sessions lasting 1.5 hours. The SRPP curriculum contains traditional aspects of behavioral management strategies (e.g., improving parenting skills and the parent-child relationship; discipline strategies such as time out). Specific sessions of the SRPP also directly target parental interactions during children's learning activities and setting up homework and household structure and routines. In its original form, SRPP does not address children's screen time.
75638637|NCT05284227|Other|Electronic Clinical Decision Support Application|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application, that calculates perioperative risks for the patient and informs the anaesthesiologist on indicated diagnostics and procedures according to clinical guidelines in real-time.
75331070|NCT03345394|Behavioral|Standard treatment|Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program
75331071|NCT01567605|Drug|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
75638638|NCT05284227|Other|Standard procedures of the hospital and Sham Clinical Decision Support Application|Preoperative anaesthesiological assessment using standard procedures of the hospital. In addition a sham clinical decision support application will be used. Information on perioperative risks and indicated diagnostic procedures according to clinical guidelines is not given to the physician.
75331072|NCT01567605|Other|Placebo lubricant|Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
75638639|NCT05282264|Other|device|closed-loop insulin
75638640|NCT05282173|Behavioral|Siyakhana CHW Training|Please see arm description.
75787503|NCT01332214|Drug|Placebo|Subcutaneous Injection in abdomen or Thigh
75787504|NCT01332370|Drug|Rosiglitazone + Metformin|At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
75787505|NCT01332370|Drug|Sitagliptin + Metformin|At least 180 days of continuous therapy with STG+MET after the first Rx for STG
75787506|NCT01332448|Drug|Orlistat 120|Orlistat 120mg tid
75787507|NCT01332448|Drug|Orlistat 60|Orlistat 60mg tid
75787508|NCT03552094|Other|Blood donations of hemochromatosis or polycythemia patients|Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
75787509|NCT03552094|Other|Blood donations of healthy donors|Blood samples are from blood donations of healthy donors.
75787510|NCT04484428|Drug|K-285|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
76079699|NCT05239806|Biological|SCTV01C|Day 0; intramuscular injection
76079700|NCT05239806|Biological|SCTV01E|Day 0; intramuscular injection
76079701|NCT05239806|Biological|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
76079702|NCT05239806|Biological|Comirnaty|Day 0; intramuscular injection
75331073|NCT01545999|Other|Brain Stimulation via Transcranial Magnetic Stimulation|"PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task."
75638641|NCT05281263|Biological|CPI-RSV-F Vaccine (BLB-201)|see arm/group description
75331074|NCT02604537|Drug|betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone
75638642|NCT05279937|Drug|Dextrose 50% Intravenous Solution|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
76079703|NCT05239806|Biological|SCTV01E|Day 180; intramuscular injection
76079704|NCT01155778|Biological|Recombinant human heparan N-sulfatase (rhHNS)|
76079705|NCT04155840|Drug|Copanlisib|Given IV
75331075|NCT02604537|Drug|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
76079706|NCT04155840|Biological|Rituximab|Given IV
75470454|NCT04321551|Drug|Letrozole|Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1- ylmethylene)dibenzonitrile. Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C. Letrozole is available as 2.5 mg tablets for oral administration.
75638643|NCT05279937|Drug|Lidocaine 1% Injectable Solution|10mL of 1% Lidocaine (Control)
76079707|NCT04155840|Drug|Bendamustine|Given IV
75638644|NCT05258422|Radiation|stereotactic body radiotherapy, 20 Gy in 1 fraction|A single dose of focused radiation therapy of 20 Gy in 1 fraction to the PTV of the arrhythmogenic substrate
75638645|NCT05257603|Behavioral|RPCW|Psychosocial intervention that includes two in-person group sessions two weeks apart and two on-line units during the intervening two weeks. Behavioral training, educational materials, discussions and videos, as well as interactive online materials are included to increase awareness of sexual assault cues, dating and drinking protective behavioral strategies, barriers to defending oneself, and saying no to hazardous drinking and sexual advances.
75638646|NCT05257603|Behavioral|HEC|Health Education time and attention control that includes two in-person sessions two weeks apart and two on-line units during the intervening two weeks. The in-person sessions cover stress management and sleep, while the online units cover nutrition and physical activity. The in-person and online sessions are designed to foster discussion and be interactive.
75638647|NCT05255380|Behavioral|Mindfulness and compassion-based practices; approximately 5-10 minutes two times/day|The app-based (audio-guided) interventions consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3-minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
75638648|NCT05255380|Behavioral|Mindful awareness and reporting of current thoughts and feelings, 2 times/day|Participants are instructed to be mindful (pay attention) to their current thoughts and feelings and complete ecological momentary assessments of their current psychological stress states (e.g., stress appraisals, affect, perseverative cognitions, self-criticism, social connection)
75638649|NCT05247242|Behavioral|Lakeshore Online Fitness (Online)|Online physical activity program delivered to residents of Tarrant, AL via teleconferencing technology to a local community center. Instructors from Lakeshore will lead the physical activity program. This intervention will last six weeks.
75638650|NCT05247242|Behavioral|Get Active with Virtual Reality (VR)|Participants will utilize the Oculus Quest 2 virtual reality headset, which is a head-mounted display system where users can interact with a virtual environment in a gaming setting. The Oculus Quest 2 incorporates social features where participants can interact with other users. This VR intervention will include periods of gameplay where participants can play games in either competitive or cooperative settings. This intervention will last six weeks.
75923688|NCT03355508|Device|pucture in the arteriovenous fistula|"The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw."
76079708|NCT03448848|Drug|BCAA preparation Intravenous infusion|BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug
76079709|NCT03448848|Drug|sterile normal saline|sterile normal saline in a volume equal to the study drug
76079710|NCT05086770|Device|Gelatin microsphere (Nexsphere™)|Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
76079711|NCT05086770|Device|Embosphere|Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
76079712|NCT03448770|Drug|PEG- 17 gm sachet|PEG- 17 gm sachet 3-4 times per day
76079713|NCT03448770|Drug|Lactulose : 20-30gm|Lactulose : 20-30gm
75638651|NCT05238883|Drug|HFB200301|Participants will be administered HFB200301 as described in the experimental arm.
75923689|NCT02313246|Behavioral|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
75331076|NCT02603133|Behavioral|Three Good Things|"In this tool participants reflect on good things that happened that day during evenings across 10 days. Participants are also able to voluntarily share their good things and read other participants' good things through the nightly anonymous log. By savoring good moments from earlier that day, participants are thought to shift from the natural focus on what went poorly due to negativity bias1 to an appreciation for what went well. This shift in focus is thought to reduce rumination and depression symptoms. In prior research, 3GTs was found to increase happiness and decrease depression in internet participants.2 In prior cohorts of 3GTs, we saw improvements in burnout, depression symptoms, work-life balance, and happiness. Participants also report benefiting from viewing nightly Three Good Things logs of others."
75470455|NCT04295824|Diagnostic Test|Skin imaging and Skin biopsy|"Imaging includes:~Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~Angiographic OCT- Vessel depth/morphology.~Polarisation-sensitive OCT - Tissue birefringence / collagen index.~Skin biopsies will be taken from the same volar forearm site as the imaging is performed."
75470456|NCT04293679|Drug|STP705|Investigational Product
75470457|NCT04252560|Procedure|Colectomy, CRS+HIPEC|No special interventions are going to be performed. Fecal samples are going to be taken and analysed
75470458|NCT04247269|Other|Enteral Tube Feeding|Enteral tube feeding
75470459|NCT04224792|Other|Center-based exercise program|A routine individualized exercise prescription and supervised exercise sessions at a minimum of once per week for 11 weeks with an exercise prescription updated monthly.
75470460|NCT04224792|Other|Home-based exercise program|A one-time supervised exercise session with Cardiac Rehabilitation staff and a routine individualized exercise prescription for exercises to do at home. Additionally, weekly telephone followup calls by a clinical exercise physiologist for 11 weeks consisting of an exercise tip.
75470461|NCT04175730|Device|Ultrasound and MRI|A single subsequent ultrasound guided prostate biopsy with MRI fusion
75787511|NCT04484428|Drug|Menthol|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
75787512|NCT01332604|Drug|GDC-0980|Oral escalating dose
75787513|NCT01332604|Drug|bevacizumab|Intravenous repeating dose
75923690|NCT05524636|Device|Exercise with peripheral magnetic stimulation of the abdominal wall muscles|8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
75923691|NCT05524636|Other|Exercise of the abdominal wall muscles|8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
75923692|NCT02310048|Drug|MT-1303-FormA|
75923693|NCT02310048|Drug|MT-1303-FormB|
75923694|NCT03355430|Procedure|combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
75470462|NCT04175730|Device|Ultrasound|A single subsequent ultrasound guided prostate biopsy
75470463|NCT04174781|Drug|Sintilimab|Sintilimab: 200mg iv Q3W D1
75470464|NCT04174781|Drug|DEB-TACE|DEB-TACE(epirubicin 60mg) D1; Additional DEB-TACE procedures were carried out every 4-6 weeks based on tumor response. A treatment cycle was defined as one DEB-TACE procedure plus two doses of sintilimab. The combination of DEB-TACE and sintilimab was continued for a maximum of 3 cycles until surgical resection, radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first.
75638652|NCT05238883|Drug|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
75923695|NCT03355430|Procedure|accelerated corneal collagen cross-linking (CXL)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
75470465|NCT04156516|Behavioral|HEART|sexual health intervention
75638653|NCT05238493|Drug|VEL-101|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
75638654|NCT05238493|Drug|Placebo|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
75638655|NCT05228470|Drug|Elranatamab|BCMA-CD3 bispecific antibody
75638656|NCT05210257|Other|Conventional physiotherapy|Group 1 was given conventinal physiotherapy Physiotherapy agents; 5 min ultrasound 1.5 watts/cm2 20 min conventional TENS 20 min heat agent application (hot pack) Exercise program; Stretching and relaxation exercises, Neck strengthening exercises that include concentric and isometric contractions Posture exercises 3 sets per day, 1 in the hospital with 10 repetitions
75787514|NCT01332604|Drug|capecitabine|Oral repeating dose
75787515|NCT01332604|Drug|mFOLFOX6|Intravenous repeating dose
76079714|NCT03443778|Drug|Bupivacaine 0.5%|Marcaine 0.5% Injectable Solution
76079715|NCT03443778|Drug|Bupivacaine 0.5% , Dexamethasone|Bupivacaine 0.5% , Dexamethasone
76079716|NCT03443778|Drug|Nacl 0,9 %|Injectable Solution
75787516|NCT01332760|Other|narrow diameter heavy dental tool|8mm diameter, heavy periodontal tool made from steel
75787517|NCT01332760|Other|large diameter light weight tool|Periodontal tools (4-8) provided to dental practitioners to use for all dental scaling or cleaning. This tool handle diameter is 11 mm diameter and it is made from lightweight Delrin.
75787518|NCT01332838|Procedure|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
75787519|NCT01332838|Device|compression stockings (Sigvaris )|Specialized monoleg compression
76079717|NCT03443622|Drug|SC-43 Oral Solution|SC-43 Oral Solution has drug substance of 1-[4-chloro-3(trifluoromethyl)phenyl-3-[3-(4-cyanophenoxy)] urea, or SC-43. SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings. As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells. The anti-tumor activity of SC-43 was also investigated in a variety of xenograft tumor models. Administration of SC-43 provides the tumor-bearing animals survival benefits, including the reduction of tumor volume and prolonged lifespan. SC-43 has been proposed to be evaluated as an anticancer therapeutic in in subjects with refractory solid tumors in the phase I trial.
75923696|NCT02305836|Procedure|acupuncture|"For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand."
76079718|NCT01872312|Device|treatment with valves (The Spiration® IBV Valve System)|treat BPF
76079719|NCT03443544|Procedure|Aggressive debridement|Aggressive debridement of the tissues undergoing fascitis
76079720|NCT02948712|Behavioral|Distress Screening Thermometer|Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
76079721|NCT02948712|Behavioral|NCCN Guidelines: Distress management|Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
76079722|NCT03129516|Behavioral|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
75331077|NCT02603133|Behavioral|Gratitude|In this tool participants are offered the opportunity to cultivate gratitude toward others through a guided gratitude letter writing exercise.2 Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways. Previous research has found that gratitude interventions increase well-being in a number of ways, particularly in boosting positive affect.
75638657|NCT05210257|Other|Neuroscience education|"Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.~In sessions ; neurons and nerve conduction in the session, the formation process of pain, peripheral neuropathic pain, pain spread during the session, neuroplasticity, peripheral and central sensitization, hyperalgesia and allodynia, acute-chronic pain, The effects of stress, fear, anxiety, false thoughts and beliefs about pain and other psychosocial factors on the pain process and determining possible psychosocial factors in the patient during the session, Strategies for controlling the pain process and coping with psychosocial factors in the session will be completed by explaining the effect mechanisms of exercise on pain."
75923697|NCT02305836|Drug|donepezil|cholinesterase inhibitors (ChE-Is)
75787520|NCT01332916|Procedure|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
75787521|NCT01332916|Procedure|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
75787522|NCT03286426|Diagnostic Test|Pictor|The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
75787523|NCT03127696|Procedure|Fecal Microbiota Transplantation|FMT
75787524|NCT03127696|Behavioral|Lifestyle Modification Program|Lifestyle
75923698|NCT04522934|Behavioral|Pain Neuroscience Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of pain neuroscience education. The latter was focused on the influence of psychosocial factors in the experience of pain, differences between acute and chronic pain and central-peripheral awareness.
75331078|NCT02603133|Behavioral|Random Acts of Kindess|In this tool, participants report kind acts that they have committed, received, and/or witnessed, each day. By committing random acts of kindness participants experience a boost of positive emotions, and report lower negative affect. Recipients of acts of kindness benefit as well.
75470466|NCT04156516|Behavioral|HealthyMinds|Growth mindsets of personality and mental health
75787525|NCT03127696|Procedure|Sham|Sham
75787526|NCT01333150|Drug|Propranololhydrochlorid|One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions
75787527|NCT01333150|Drug|Placebo|One single dose of placebo
75787528|NCT01333228|Other|Autologous bone marrow-derived endothelial progenitor cells|Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
75787529|NCT01333306|Procedure|Transcranial direct current stimulation (tDCS)|
75787530|NCT02913664|Drug|Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)|"Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)"
75923699|NCT04522934|Behavioral|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of biomedical education. The latter was focused on the anatomy and pathomechanics of the shoulder.
76079723|NCT03443466|Device|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
76079724|NCT03443466|Device|Loss of resistance (LOR)|Using loss of resistance technique only
76079725|NCT03448380|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
75923700|NCT02161809|Behavioral|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
75923701|NCT03353714|Other|Pudendal block|Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)
75923702|NCT02576860|Drug|CLS001 (Omiganan)|Topical gel
75923703|NCT02576860|Drug|Vehicle|Vehicle gel
75923704|NCT03503136|Drug|docetaxel, nedaplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
75470467|NCT04132453|Device|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
76079726|NCT03443388|Device|Hövding inflatable helmet|The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
75331079|NCT02603133|Behavioral|Awe|This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
75331080|NCT02603133|Behavioral|1 Good Chat|This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
75470468|NCT04132453|Device|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
75470469|NCT04132453|Device|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
75470470|NCT04109963|Device|Remote ischemic conditioning|Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
75470471|NCT04094779|Other|Usual relation care|When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.
75470472|NCT04094779|Other|"Flash activity breath of fresh air"|When a patient begins to agitate , he will be isolated from the group and the patient leave from the unit to walk outside with the caregiver.
75638658|NCT05206565|Procedure|Neurotization - Autologous Reconstruction with DIEP/TRAM|"Transverse Rectus Abdominis Muscle/Deep Inferior Epigastric Artery Flap Harvest - Prior to elevation of flaps in the suprafascial plane from using loupe magnification to identify medial and lateral row of perforators bilaterally, sensory nerves T10-12 are identified and dissected into the muscle bilaterally to prepare for nerve coaptation, nerves are divided at the level of the fascia where they are pure sensory nerves.~Chest Intercostal Nerve Harvest - During standard of care chest vessel dissection, intercostal nerves T3-4 are identified. After completion of vein coupling it will be determined whether neurotization can be performed or if autograft. Primary nerve coaptation will be performed if there is adequate length for direct end to end apposition.~Coaptation of nerve or nerve graft endings will be performed using 9-0 nylon suture in an interrupted fashion."
75638659|NCT05205005|Drug|Endocalyx|3,712mg (six capsules) of DSGP for eight weeks.
75638660|NCT05205005|Drug|Placebo|Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
75787531|NCT02913664|Behavioral|Aerobic Exercise Training|Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.
75787532|NCT02913664|Other|Usual Care|Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
75787533|NCT02913664|Behavioral|Stretching Exercise|Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
75787534|NCT02911402|Other|sea sickness questionnaires|
75787535|NCT01333462|Biological|NB-1008|NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
75787536|NCT01333462|Other|Control|The controls include PBS placebo control as well as Fluzone IN and IM active controls.
75787537|NCT02818582|Drug|GS-5734|Daily GS-5734 delivered intravenously (IV) for 5 days
75787538|NCT02818582|Other|Placebo Comparator|Placebo delivered intravenously (IV) for 5 days.
75787539|NCT02728258|Drug|Copanlisib|Given IV
75787540|NCT02728258|Other|Laboratory Biomarker Analysis|Correlative studies
75923705|NCT03503136|Drug|nedaplatin|Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
75923706|NCT03503136|Drug|docetaxel, cisplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
75923707|NCT03503136|Drug|cisplatin|Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
75331081|NCT01384773|Other|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
75470473|NCT04083690|Device|Reprogramming of CRT Device Settings to Optimal Electrical Synchrony|Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.
75470474|NCT04074460|Drug|Propofol|General Anaesthesia
75470475|NCT04074460|Drug|isoflurane, sevoflurane or desflurane|General Anaesthesia
75470476|NCT04069000|Behavioral|Mindfulness-based social-emotional learning program|Grade 3 teachers implement MindUP in their classrooms over the academic year. MindUP is a manualized program informed by cognitive-developmental neuroscience, contemplative science, positive psychology, and social-emotional learning. The curriculum consists of 15 sequential lessons taught in 10-15 minute chunks and cross-curricular extension activities. There are four lesson units: Getting Focused (introduction to brain structure and function, the core practice, and how focused awareness affects brains and feelings), Sharpening Your Senses (focus on internal experiences such as mindful smelling and tasting), It's All About Attitude (focus on cognitive experiences such as positive mindset, perspective-taking, and practicing gratitude), and Taking Action Mindfully (performing acts of kindness to others and building positive relationships). An essential component is the core practice, a focused breathing exercise and mindfulness practice that is implemented three times daily.
75638661|NCT05193942|Behavioral|Intervention Our Plan|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the intervention arm will be granted access and instructed to use the Our Plan program as directed. The Our Plan program includes modules covering topics of communication, decision-making, HIV/STI prevention, and stigma and discrimination. Each module contains content, questions, and activities for the participant and couple to complete. One goal of OurPlan is to help both partners of the couple create and use a risk- reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own confidence, intention, and perceived ability to use these strategies.
75923708|NCT03503136|Drug|docetaxel, cisplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
75470477|NCT04069000|Behavioral|Regular grade 3 program|Grade 3 teachers are expected to implement activities to achieve a number of pre-specified social-emotional learning outcomes that are identified by the Ministry of Education. Educators have leeway over how they achieve these curriculum expectations and they will report on a weekly basis regarding their implementation of social-emotional learning activities.
75923709|NCT03503136|Drug|docetaxel, nedaplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
75638662|NCT05193942|Behavioral|Internation Informational Control|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the informational control condition will receive a webpage that contains information about HIV/STI prevention options and resources. This control condition represents the current equivalent of a standard of care for online HIV resources.
75638663|NCT05179499|Drug|Norepinephrine|Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
75638664|NCT05179499|Other|Balanced Crystalloid|IV fluids administered as per standard care
75923710|NCT04445168|Behavioral|Telephone-based motivational interviews|2-year telephone-based motivational interviews to increase physical activity.
75923711|NCT02305992|Procedure|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
75923712|NCT02305992|Procedure|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
75923713|NCT02305992|Procedure|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
75923714|NCT03355352|Drug|Sufentanil|Sufentail sublingual 15ug nanopills
75923715|NCT05529940|Drug|Folfirinox|The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
75923716|NCT02313324|Device|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
76079727|NCT03448302|Radiation|Computed tomography perfusion|Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time & permeability surface measurements will be obtained.
75331082|NCT01384773|Device|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
75331083|NCT02539329|Other|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
75331084|NCT01352403|Procedure|Roux-en-Y gastric bypass|
75331085|NCT01352403|Behavioral|Psychotherapy-enhanced lifestyle intervention|
75331086|NCT01063075|Drug|Cetuximab|Administered Intravenously
75331087|NCT01063075|Drug|Carboplatin|Administered Intravenously
76079728|NCT03443310|Procedure|Ultrasound assessment of DVT|Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
76079729|NCT03955614|Other|pedal-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
76079730|NCT03955614|Other|ML-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
76079731|NCT03955614|Other|NoGo|The operating theatre environment is recorded to observe baseline teamwork.
76079732|NCT01203826|Biological|Asfotase Alfa|
75638665|NCT05165069|Drug|Mecobalamin 5 MG Disintegrating Oral Tablet|Mecobalamin 0.5mg / time, 3 times / day,was taken continuously for 6 months
75638666|NCT05165069|Drug|placebo|placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
75638667|NCT05157880|Behavioral|Recovering Together|In the skills-based intervention group, sessions focus on developing skills to cope and manage ANI related stressors. The intervention will be tailored consistent with AHA recommendations for ANI skills-based interventions and will include 2 general and 4 specific modules. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered, in person if possible, within the NICU, or through live video using Zoom if patients leave the hospital before sessions occur, and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom.
75638668|NCT05157880|Behavioral|Recovering Together|Those in the educational program will receive general health information that mimics the skills-based intervention, but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. There will also be 6 sessions, 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits following discharge. The educational program group will not have the opportunity to specify which modules they would like to take; the modules will be predetermined. All participants will receive medical care as determined by their medical team.
75638669|NCT05157126|Drug|Gentamicin|Liquid gentamicin administered at the open fracture site
75787541|NCT01333618|Device|curving introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
75923717|NCT02313324|Device|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
75923718|NCT03353636|Dietary Supplement|Magnesium|150mg elemental magnesium
75923719|NCT03353636|Dietary Supplement|Placebo|Rice flour
75923720|NCT05524558|Device|Pulmonary artery catheter|PAC already in place
75923721|NCT05524558|Device|Esophagal pressure|Esophagal pressure already in place
75923722|NCT04463160|Other|"prevention program for prediabetes Say No to Diabetes"|10 therapeutic education sessions
75923723|NCT04523402|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy with GEMOX regimen before liver resection
75923724|NCT04463784|Drug|Efavirenz 400Mg Oral Tablet|The experimental arm will receive 400mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
76079733|NCT03943836|Behavioral|Music|Patients in the music group will listen to classical music during their dental procedure.
76079734|NCT03448146|Drug|Para-Toluenesulfonamide|
76079735|NCT03011008|Drug|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
76079736|NCT03011008|Drug|Insulin|Receive insulin following clinician's instruction.
76079737|NCT03443232|Procedure|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
76079738|NCT03443232|Procedure|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
76079739|NCT04983732|Drug|FL-101-Intravenous|150 mg administered via the IV route
75638670|NCT05157126|Drug|normal Saline|Normal saline administered at the open fracture site
75787542|NCT01333618|Device|straight introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
75787543|NCT05186506|Drug|Ensatinib|225 mg administered once daily orally for two years.
76079740|NCT04983732|Drug|FL-101-Subcutaneous|150 mg administered via the SC route
76079741|NCT04452552|Other|healthy diet|balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks
76079742|NCT01157416|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
76079743|NCT01157416|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
76079744|NCT01157416|Behavioral|CBT|12-session CBT protocol, called Youth PTSD Treatment.
75470478|NCT04041063|Device|Upper limb robotic training|"Subjects will remain seated in their own wheelchair in front of the InMotion Hand™ Robot (Interactive Motion Technologies, Massachusetts, MA, Figure 6) facing a video screen.~The arm of the participants will be abducted, forearm supported, and hand grasping a cone shaped handle. Velcro straps will lightly hold the forearm and fingers secure. The InMotion Hand™ robot attaches to the InMotion Arm™ robots to provide 'assisted-as-needed'™ gross grasp and release motion and support for functional reach. In each session, patients perform a total of 1024 movement repetitions (Cortes et al., 2013). Patients will receive a total of 18 sessions (3x/week, 6 weeks) comprising one hour of interactive hand robotic training. The interactive robotic features involve visuomotor task, moving the robotic manipulandum according to targets on a computer screen mounted at eye level."
75923725|NCT04463784|Drug|Efavirenz 600Mg Oral Tablet|The active comparator arm will receive 600mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
75923726|NCT04507880|Device|Reverse Total Shoulder Arthroplasty|The RTSA (GLOBAL UNITE Reverse Fracture System) from DePuy Synthes.
75923727|NCT04507880|Device|Hemiarthroplasty|The shoulder hemiarthroplasty
75787544|NCT05186506|Drug|chemotherapy|"Pemetrexed : Participants will receive 500 mg/m^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Cisplatin :Participants will receive 75 mg/m^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Paclitaxel: Participants will receive 175 mg/ m^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ，until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
75923728|NCT02310282|Device|Telemedicine|In-hospital telemedicine
75923729|NCT03355196|Drug|LRX712|Ascending single dose on Day 1
75638671|NCT05154019|Behavioral|Managing Minds at Work Online Training|"The intervention will be an online, interactive training course which will include evidence-based material, guidance, and practical exercises. The training will cover the following topics, presented as a series of independent, stand-alone modules:~Module one: Looking after your own mental health Module two: Designing and managing work to promote mental well-being Module three: Management Competencies that Prevent Work-related Stress Module four: Developing a Psychologically Safe Workplace Module five: Having conversations about mental health at work Each module will be designed to take between 20 and 30 minutes to complete. Participants will be permitted by their employer to complete the training within their work time. The training is self-led, so each participant can progress through each module at their own pace and at a time that suits them."
75923730|NCT03355196|Drug|Placebo|Ascending single dose on Day 1
75923731|NCT03502902|Drug|HEC 68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
75331088|NCT01063075|Drug|5 - FU|Administered Intravenously
75331089|NCT01341405|Drug|CG100649|once daily for 28 days
75638672|NCT05153668|Drug|Everolimus Oral Tablet|Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
75638673|NCT05145491|Procedure|Immediate Vitrectomy|Surgery to remove epiretinal membrane (ERM). Vitrectomy will be performed on eyes within 1 month of randomization
75787545|NCT01337440|Drug|UDCA|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
75923732|NCT03502902|Drug|Placebo|Placebo
75923733|NCT04507802|Device|Non invasive ventilation via helmet|Patients requiring long hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet
75923734|NCT02310360|Radiation|Fallypride|
75923735|NCT03353558|Device|Actigraph|The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.
75923736|NCT02310438|Other|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
76079745|NCT03443154|Diagnostic Test|VF-Test|A vaginal fluid test of interleukin-6 (IL-6) and alphafetoprotein (AFP).
75331090|NCT01341405|Drug|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
75923737|NCT05524324|Device|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|Patients randomized to the CRT ON / CRT OFF arm will undergo a first intervention to activate their device and then a second intervention for 3 months to inactivate their device.
75331091|NCT02981485|Device|Fat Grafting|Treatment of breast cancer related lymphedema by fat grafting
75331092|NCT03015103|Device|Intimate Lubrificant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
75331093|NCT01113567|Dietary Supplement|Lactose-free milk|3.5 g of lactose
75923738|NCT05524324|Device|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|Patients randomized to the CRT OFF / CRT ON arm will undergo a first intervention to inactivate their device and then a second intervention for 3 months to activate their device.
76079746|NCT01206478|Drug|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
76079747|NCT01206478|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
75331094|NCT01113567|Dietary Supplement|Whole milk|Whole milk with 24 g lactose
75331095|NCT01064323|Device|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
75923739|NCT02310516|Device|preoperative adequate explanations about awake surgery|
75923740|NCT02310516|Other|no preoperative explanation|
75923741|NCT03353480|Drug|Azithromycin Tablet manufactured in China|250 mg Azithromycin Tablet manufactured in China
75923742|NCT03353480|Drug|Azithromycin Tablet manufactured in US|250 mg Azithromycin Tablet manufactured in US
75470479|NCT04041063|Procedure|Nerve transfer surgery|C5 injury; Teres minor branch of axillary nerve transferred to long head of triceps branch of radial nerve (RN); Brachialis branch of musculocutaneous nerve to anterior interosseous nerve (AIN); Supinator branch of RN to posterior interosseous nerve (PIN). C6 injury; Teres minor branch of axillary nerve to long head of triceps branch of RN; Extensor carpi radialis brevis (ECRB) branch of RN to AIN; Supinator branch of RN to PIN. C7 injury with preserved triceps, loss of grasp/release; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN; Supinator branch of RN transferred to PIN. C7 injury with preserved triceps/finger extension, loss of grasp; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN.
75923743|NCT02306070|Drug|Metformin|metformin treatment + standard of care dietary and exercise advice
76079748|NCT01206478|Drug|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
75638674|NCT05145491|Procedure|Deferred Vitrectomy|"Vitrectomy may be performed only if at least one of the following criteria is met:~Decrease in visual acuity ≥10 letters from baseline at a single visit presumed to be from ERM~Decrease in visual acuity ≥5 letters from baseline at two consecutive visits presumed to be from ERM~a. Visits must be at least one month apart~Participant actively requests surgery due to worsening symptoms~Complication requires prompt surgical intervention (e.g., macular hole, retinal detachment, non-clearing vitreous hemorrhage)"
76079749|NCT04963530|Procedure|Treatment with monolithic zirconia restorations|Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
76079750|NCT04963530|Procedure|Treatment with lithium disilicate restorations|Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
76079751|NCT04963530|Procedure|Treatment with metal ceramic restorations|Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
76079752|NCT04963530|Procedure|No intervention|No intervention.
76079753|NCT01158820|Drug|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
76079754|NCT01158820|Drug|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
76079755|NCT01158820|Drug|Midazolam load|2 mg bolus prior to bronchoscopy
76079756|NCT01158820|Drug|Fentanyl load|50 µg bolus prior to bronchoscopy
75638675|NCT05139368|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75638676|NCT05122754|Drug|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.
75638677|NCT05122754|Drug|TDF-based triple ART regimen switching to B/F/TAF|Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.
75470480|NCT04033406|Drug|VIR-2482|VIR-2482 given by intramuscular injection
75638678|NCT05119855|Biological|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular (IM) injection
75923744|NCT02306070|Drug|No metformin treatment|no metformin treatment + standard of care dietary and exercise advice
75923745|NCT04513886|Procedure|Subepithelial connective tissue graft (SCTG) using the single incision technique, with and without suturing the palate|A SCTG was harvested using the single incision technique described by Hürzeler & Weng. The palatal incisions were standardized to extend between the area between mesial of the canine and mesial of the first molar.In the Suture Group sites a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate. In the no Suture Group sites, no suture was performed. In both groups, a CHS was placed after removing the graft to achieve the haemostasis of the palate and subsequent compressed with gauze soaked in saline for 5 minutes.
75923746|NCT05304130|Biological|Otilimab|Otilimab will be administered via pre-filled syringe.
76079757|NCT01158820|Drug|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
76079758|NCT01158820|Drug|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
75638679|NCT05119855|Biological|mRNA-1273 Vaccine|mRNA-1273 50 mcg dose administered as a 0.25-mL IM injection
75638680|NCT05099770|Biological|Renal Autologous Cell Therapy (REACT)|Participants will receive either 2 REACT injections or 2 Sham REACT injections into biopsied and non-biopsied contralateral kidneys 3 months apart.
76079759|NCT01158820|Drug|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
76079760|NCT01158820|Drug|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
76079761|NCT01158820|Drug|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
76079762|NCT03707028|Drug|Rivoceranib|Film-coated tablet
76079763|NCT03707028|Drug|Paclitaxel|Solution administered intravenously
76079764|NCT03447756|Drug|ABX-1431|Capsules of either 2mg, 10mg, or 50mg
76079765|NCT03447756|Drug|Placebo oral capsule|placebo to match
76079766|NCT01207570|Procedure|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
76079767|NCT01207570|Procedure|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
75470481|NCT04033406|Drug|Placebo|Sterile normal saline (0.9% NaCl) given by intramuscular injection
76079768|NCT03447678|Drug|Pembrolizumab|humanized antibody used in cancer immunotherapy
76079769|NCT01207648|Drug|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
75923747|NCT02306148|Other|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
75923748|NCT04512326|Procedure|Total or Subtotal colectomy|Total or subtotal colectomy (emergent or elective) with primary anastomosis (ileorectal or ileosigmoid)
75923749|NCT03502824|Device|PuraPly® Antimicrobial Wound Matrix|PuraPly® AM is a class II medical device, that has been 510(k) cleared by US Food and Drug Administration (FDA) (K051647) and is intended for the management of acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.
75638681|NCT05078450|Behavioral|Mood Lifters|Participants will need to attend 12 hour long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
75638682|NCT05078385|Drug|AGLE-102|AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
76079770|NCT04945278|Other|Double mirror device ALTER-EGO|"The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?"
75638684|NCT05067647|Device|ENSEAL X1 Curved Jaw Tissue Sealer|ENSEAL X1 curved jaw tissue sealer is used for transecting and sealing vessels during thoracic, urologic, or ENT procedures according to instructions for use.
75923750|NCT03502824|Other|SOC for Pressure Ulcers|SOC group will receive institutional standard of care which includes, but is not limited to, debridement, negative pressure wound therapy (i.e. VAC), ensuring perfusion and oxygenation, evaluating nutritional status and addressing deficits, offloading, keeping the ulcer bed moist with appropriate cleansing at the time of each dressing change. Standard dressings may include hydrocolloids, alginates, transparent film, foam, moist gauze dressings. In addition, a non-toxic topical antiseptic, may be used per NPUAP Clinical Practice Guidelines (2014) for SOC group only, if colonization is suspected.
75923751|NCT05524090|Other|Implementation - International best-practice care|The PREOPANC-4 project aims to safely implement the international standard of excellence for LAPC management and surgery using a multidisciplinary best-practice training program, based on the experiences of four leading international expert centers (i.e. NYU Langone Health, University of Colorado, Heidelberg University, and MD Anderson Cancer Center). We hypothesize that the PREOPANC-4 implementation project will result in the improvement in multidisciplinary patient management and selection in line with current international best-practice.
75923752|NCT03358550|Diagnostic Test|Accommodation Measurement|Accommodation was measured for different distances and light conditions.
76079771|NCT04945278|Other|EASE test|The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
76079772|NCT01225354|Drug|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
75638685|NCT05067491|Behavioral|Augmented reality exposure therapy|Virtual objects will be placed in the patient's visual field, superimposed on their real environment for exposure therapy.
75638686|NCT05058872|Drug|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg
75787546|NCT01337440|Drug|Sitagliptin|"UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
75787547|NCT01337518|Drug|EZN-4176|EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
75787548|NCT03635710|Device|The patient will undergo no intervention|Night coughs will be monitored using smartphone a app and interpreted using machine learning algorithm.
75787549|NCT05186194|Drug|Vitamin D, Calcium|Vitamin D, calcium are available in tablets. During the 8 weeks of training, subjects were asked to take supplement tablets per day after dinner.
75787550|NCT05186194|Drug|Placebo|Placebo
75787551|NCT01337830|Other|Ariva® Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
75331096|NCT01064713|Drug|Tesetaxel|"Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days."
75331097|NCT01065571|Dietary Supplement|carrageenan|The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
75331098|NCT01065571|Other|dietary intervention with no-carrageenan diet|The intervention will consist of the no-carrageenan diet.
75331099|NCT05136157|Drug|Rapid-Acting Insulin|50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS
75331100|NCT05136001|Device|polysomnography|Duration of sleep was collected with polysomnography on second postoperative night. (from 20:00pm to 06:00am).
75923753|NCT04445324|Behavioral|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
75923754|NCT04445324|Other|Control Group (pharmacotherapy and/or psychotherapy, n=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
76079773|NCT04937790|Behavioral|Core stabilization group(CSG)|Exercises training of this group occurs from 3 stages. In the stage 1 covering the first two weeks, core stabilization exercises are going to be applied 3 sets of 10 repetitions except side plank. Side plank is going to be performed 3 sets of 10 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, exercises are going to be performed 3 sets of 12 repetitions except bride dog, plank and side plank. These exercises are going to be applied 3 sets of 15 seconds. Patients are going to perform exercises of stage 3 from 6 to 8 weeks. Exercises of stage 3 are going to be practiced 3 sets of 15 repetitions except bride dog, side plank and plank exercises which are going to be applied 3 set of 20 second. All stages include the same exercises except modified push-up exercise includes instead of plank exercise in stage 1. All of the exercises are going to practiced 3 days a week for 8 weeks. One of the sessions is estimated to take approximately 45-60 minutes.
75638687|NCT05058872|Drug|Placebo|Placebo comparator
75331101|NCT03936127|Procedure|Ultrasound (US) Targeted Fusion Biopsy|Ultrasound (US) Targeted Fusion Biopsy
75638688|NCT05049057|Drug|Erenumab 140 Mg/mL Subcutaneous Solution|Active erenumab delivered via subcutaneous injection.
75638689|NCT05049057|Drug|Placebo|Placebo delivered via subcutaneous injection.
75331102|NCT01921790|Biological|Avastin|Avastin 7.5mg/Kg, intravenous drip D1
75331103|NCT01921790|Drug|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
75638690|NCT05042128|Drug|CEND-1|CEND-1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
75638691|NCT05042128|Drug|Gemcitabine Injection|Chemotherapy drug provided as solution to be administered via IV infusion.
75638692|NCT05042128|Drug|Nab paclitaxel|Chemotherapy drug provided as solution to be administered via IV infusion.
75331104|NCT01921790|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 intravenous drip D1
75331105|NCT01921790|Drug|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
75331106|NCT01921790|Drug|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
75331107|NCT02153541|Drug|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
75638693|NCT05040568|Drug|Cetuximab|Given IV
75638694|NCT05040568|Drug|CB-NK-TGF-Î²R2-/NR3C1|Given IV
75638695|NCT05040568|Drug|Fludarabine phosphate|Given IV
75638696|NCT05040568|Drug|Cyclophosphamide|Given IV
75638697|NCT05033080|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
75787552|NCT01337830|Other|Silver Wintergreen|Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
75787553|NCT04446676|Device|stabilization with stem|In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.
75470482|NCT03957928|Other|Low fat cookie|to determine the effects of low fat cookie consumption on satiety and metabolic parameters in overweight/obese adults
75638698|NCT05033080|Drug|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
75638699|NCT05033080|Drug|IVA|Tablet for oral administration.
75638700|NCT05033080|Drug|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
75638701|NCT05033080|Drug|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
75638702|NCT05033080|Drug|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
75787554|NCT04446676|Device|stabilization with sleeve|In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.
75787555|NCT01338142|Other|CCC|"600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.~1.5 mg of 42Ca labeled CaCl2 through IV injection"
75787556|NCT01338142|Other|ACC|600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
75638703|NCT05022901|Combination Product|Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)|Melphalan administered directly to the liver via the Hepatic Delivery System (HDS) infused over a 30 minute period, followed by a 30 minute washout period
75787557|NCT01338376|Behavioral|Structured Education|"All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.~Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS~Physician Activity: frequent insulin titration"
75331108|NCT02153541|Other|Glycerin with Oxyquinoline Sulfate|50% of participants will receive the glycerin with oxyquinoline sulfate. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
75638704|NCT05010122|Drug|Decitabine and Cedazuridine|Given PO
75638705|NCT05010122|Drug|Gilteritinib|Given PO
75470483|NCT03957928|Other|Mango fruit|to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults
75470484|NCT03936452|Drug|Sintilimab|Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy
75638706|NCT05010122|Drug|Venetoclax|Given PO
75638707|NCT04999462|Other|Full-fat fermented dairy|Subjects assigned to the full-fat fermented dairy condition will consume 1 serving/d each of full-fat yogurt (plain or reduced sugar varieties) and full-fat fermented cheese.
75638708|NCT04999462|Other|Low-fat fermented dairy|Subjects assigned to the low-fat fermented dairy condition will consume 1 serving/d each of low-fat yogurt (plain or reduced sugar varieties) and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
75638709|NCT04999462|Other|Non-dairy, non-fermented foods|Subjects assigned to the control condition will consume 2 servings/d of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
75638710|NCT04997356|Behavioral|Hostile Bias Modification Training|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They will refrain from making words that can only form aggressive words.
75638711|NCT04997356|Behavioral|Other training|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words.
75638712|NCT04994457|Device|Virtual Reality Visual Field|A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses
75787558|NCT01338376|Behavioral|Conventional Diabetes Education|"The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.~Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia~Physician Activity: less frequent insulin titration"
75638713|NCT04994457|Diagnostic Test|Standard Automated Perimetry|Standard of care perimeter
75638714|NCT04989946|Drug|Degarelix|standard Gonadotropin-releasing hormone (GnRH) antagonist
75638715|NCT04989946|Biological|pTVG-AR|DNA vaccine encoding androgen receptor ligand-binding domain
75787559|NCT01338376|Drug|Scilin®M30|Subjects will be treated with Scilin®M30 twice daily
75787560|NCT05186038|Diagnostic Test|iVYCHECK GIP Urine|To determine the presence of Gluten Immunogenic Peptides (GIP) in urine samples using the immunochromatographic test iVYCHECK GIP Urine (Biomedal S.L).
75787561|NCT05186038|Diagnostic Test|CeliacDetect|To determine the presence of IgA anti-tTG antibodies in blood samples using the immunochromatographic test CeliacDetect (Biomedal S.L).
75923755|NCT02306304|Other|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
75923756|NCT04299802|Drug|Leukocyte-Rich Platelet-Rich Plasma|LR-PRP will be a concentration of PRP with the addition of leukocytes. Studies have shown that LR-PRP is more effective in treating tendinopathy than leukocyte-poor platelet-rich plasma.
75923757|NCT04299802|Procedure|Percutaneous Ultrasonic Tenotomy|Discussed in Percutaneous Ultrasonic Tenotomy Arm section
75331109|NCT03248440|Drug|SUN-131 1.5% TDS|SUN-131 1.5% TDS will be worn for 14 days
75331110|NCT03248440|Drug|Placebo TDS|No active substance; Placebo TDS will be worn each day for 14 days
75331111|NCT03487276|Drug|IFX-1|Single IV infusions of IFX-1 diluted in sodium chloride.
75331112|NCT03487276|Drug|Placebo|Placebo
75331113|NCT04352803|Biological|Autologous Adipose MSC's|Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV
75331114|NCT03487588|Drug|A-101 Topical Solution|A-101 Topical Solution applied Day 1, Day 15 and Day 29
75470485|NCT03884231|Device|Infinity DBS System with MR Conditional labelling (Leads-only configuration)|Patients will undergo MRI procedures using Leads-only configuration
75470486|NCT03884231|Device|Infinity DBS System with MR Conditional labelling (Full system configuration)|Patients will undergo MRI procedures using Full system configuration
75470487|NCT03881579|Behavioral|nurse-led supportive care assessment|Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
75470488|NCT03817125|Drug|Placebo for antibiotic|Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.
76079774|NCT04937790|Behavioral|Wobble board group (WBG)|Patients in this group are going to perform exercise on computerized wobble board. This device is going to provide unstable surface to patient and offer visual feedback about their movement qualities. The 8 weeks program consists of 3 stages and each stage includes six exercises. In the first stage covering the first two weeks, repetitive exercises are going to be practiced 3 sets of 10 repetitions; time controlled exercises are going to be practiced 3 sets of 20 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, repetitive exercises are going to be performed 3 sets of 12 repetition and time controlled exercises are going to be performed 3 sets of 25 seconds. Stage 3 is going to last from 6 to 8 weeks. In this stage, repetitive exercises are going to be practiced 3 sets of 15 repetitions and time controlled exercises are going to be practiced 3 sets of 30 seconds. One of the sessions is estimated to take approximately 45-60 minutes.
75331115|NCT03250234|Other|Adequate Carbohydrate|During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
75638716|NCT04989946|Drug|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
75331116|NCT03250234|Other|Low Carbohydrate|"During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage.~For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion"
75331117|NCT03489850|Drug|Ibudilast|Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
75331118|NCT03489850|Other|Placebo|Placebo is matched to ibudilast active medication.
75470489|NCT03817125|Drug|Vancomycin pretreatment|Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.
75638717|NCT04989946|Drug|Cemiplimab|Cemiplimab is a human PD-1 blocking antibody approved for the treatment of patients with non-small cell lung cancer, cutaneous squamous cell carcinoma, and locally advanced basal cell carcinoma.
75638718|NCT04989946|Drug|Fianlimab|Lymphocyte activation gene-3 (LAG-3) is a protein that is upregulated on activated CD4+ and CD8+ T cells following T-cell receptor engagement. Binding of LAG-3 to MHC II on professional antigen-presenting cells suppresses the proliferation, activation, and cytokine secretion of T cells. Fianlimab is a human IgG4 antibody to lymphocyte activation gene-3 (LAG-3) that blocks LAG-3/MHC II-mediated T-cell inhibition.
75787562|NCT04442152|Behavioral|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
75787563|NCT01338454|Drug|transamin|TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
75787564|NCT01338532|Other|A 12 week supervised exercise program and patient education|"The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.~All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time."
76079775|NCT02521662|Drug|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
76079776|NCT02521662|Device|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
75331119|NCT03490942|Drug|Glucagon|CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.
75331120|NCT03490942|Drug|Placebo|The placebo solution is a non-active formulation containing excipients only.
75331121|NCT01069003|Drug|Placebo Arm|Placebo and ASA (75 mg - 325 mg)
75331122|NCT01069003|Drug|Thienopyridine Therapy|Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
75331123|NCT01069003|Device|Surveillance Arm|Non randomized arm to understand clinical outcomes in a commercial setting
75331124|NCT00376870|Drug|Pioglitazone|pioglitazone 30 mg/d
75331125|NCT00376870|Drug|Placebo|Placebo 30 mg/d
75331126|NCT03015025|Genetic|Acenocoumarol|A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
75331127|NCT01069315|Procedure|Type of fluid lavage solution|Comparison of castile soap solution vs. normal saline solution.
75331128|NCT01069315|Procedure|Type of fluid lavage pressure|Comparison of low pressure vs. high pressure.
75331129|NCT03350542|Device|SYNERGY 48 mm|A drug eluting coronary stent system
75470490|NCT03817125|Drug|Nivolumab|Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.
75470491|NCT03817125|Drug|Matching Placebo for SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
75470492|NCT03817125|Drug|SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
75638719|NCT04989946|Drug|FLT PET/CT|Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43
75638720|NCT04983745|Drug|Combination drug|niraparib and dostarlimab combination
75638721|NCT04966702|Drug|Albendazole Pill|Using a MDA approach, fieldworkers will admister albendazole using directly observed treatment methodology to participants
75638722|NCT04966702|Drug|Ivermectin Pill|Using a MDA approach, fieldworkers will admister ivermectin using directly observed treatment methodology to participants
76079777|NCT02521662|Drug|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
75331130|NCT03014869|Device|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
75331131|NCT03252964|Device|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
75331132|NCT03252964|Device|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
75470493|NCT03703102|Drug|KHK4083|Anti-OX40 Monoclonal Antibody KHK4083
75470494|NCT03703102|Drug|Placebo|Matching placebo
75470495|NCT03699397|Diagnostic Test|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
75470496|NCT03676582|Diagnostic Test|Acoustic analysis plus pulse oximetry|Acoustic analysis plus pulse oximetry
75470497|NCT03661294|Diagnostic Test|GE Healthcare Metabolic Oxygenator|
75470498|NCT03647085|Device|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
75470499|NCT03581370|Drug|1 hour infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.
75470500|NCT03581370|Drug|4 hours infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours
75470501|NCT03568604|Drug|Prasterone|6.5 vaginal insert prasterone (dehydroepiandrosterone)
75470502|NCT03566381|Device|Application of a soft patch composed of medical-grade silicone that collects sweat during a subject's natural behaviors.|This device contains sweat sensors embedded in an elastomer and is applied to the skin with a medical grade adhesive.
75470503|NCT03539055|Drug|Dabigatran Etexilate Oral Capsule|Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.
75470504|NCT03512132|Biological|Blood samples|5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
75470505|NCT03512132|Biological|Urine sample|Urine sample on an empty stomach
75470506|NCT03485534|Drug|Tenofovir Disoproxil Fumarate|Viread 300mg
75638723|NCT04966702|Drug|Ivermectin Injectable Product|Veterinary ivermectin injectable will be given to livestock in the relevant cluster
75787565|NCT01338532|Other|Patient education|All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
75787566|NCT02882152|Procedure|femoral nerve blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery"
75787567|NCT02882152|Procedure|morphine|Intrathecal morphine injection
75787568|NCT05185804|Drug|Dimolegin|60 mg orally, 1 time per day
75470507|NCT03485534|Drug|Tenofovir Disoproxil|Virehepa 245mg
75470508|NCT03466255|Other|Ultrasound|Contrast-enhanced ultrasound (CEUS)
75638724|NCT04965090|Drug|Amivantamab|Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.
75638725|NCT04965090|Drug|Lazertinib|Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh <80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
75787569|NCT05185804|Drug|Clexane|40 mg subcutaneously, 1 time per day
75787570|NCT01338766|Procedure|Decompression using the iO-Flex® system|Decompression using the iO-Flex® system
76079778|NCT02521662|Behavioral|Behavioural support|Withdrawal-oriented behavioural support
76079779|NCT01226914|Drug|EVICEL|EVICEL
76079780|NCT01158976|Dietary Supplement|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
75638726|NCT04962412|Other|"Standard care bundle"|"The management for AKI patients were performed by implementing a standard care bundle suggested by the Kidney Disease Improving Global Outcome (KDIGO) guideline."
75470509|NCT03461549|Device|Pressure and Temperature Sensor|This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
75470510|NCT03395704|Drug|LJPC-401|LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
75787571|NCT05185648|Behavioral|standard trauma care taining|trauma care training
75787572|NCT01338844|Dietary Supplement|Myo-inositol|
75787573|NCT01338844|Dietary Supplement|D-chito-Inositol|
75787574|NCT01338922|Device|Continuous subcutaneous insulin infusion therapy|Insulin is given continuously using an insulin pump. Devices are allowed having marketing approval. Insulins are permitted with marketing approval.
76079781|NCT01158976|Other|Placebo|soybean oils with strawberry flavoring
76079782|NCT04937556|Dietary Supplement|Probiotic: Lactobacillus salivarius + Vit D + Zinc|A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.
76079783|NCT04937556|Dietary Supplement|Placebo|Placebo in 1 capsule will be daily administrated during 28 days.
75331133|NCT03252964|Behavioral|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
75470511|NCT03395704|Drug|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
75470512|NCT03335813|Device|Endoesophageal Brachytherapy|Balloon repositioning, multichannel brachytherapy applicator which has 6 channels instead of 3-tubes which will be used to deliver localized radiation
75331134|NCT01070095|Other|Electronic Asthma Action Plan System|The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
75331135|NCT03491800|Behavioral|Question/Topic Prompt List|A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
75787575|NCT01338922|Device|Multiple daily injection therapy|Multiple daily injection therapy with different devices and insulin types. Devices and insulin types have to have marketing approval.
75923758|NCT03353402|Procedure|Fecal Microbiota Transplant (FMT)|Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
75638729|NCT04940468|Other|Diet Intervention|The dietary fiber intake target will be 19 g/d for ages 9-18 and females age 19 and older and 23g/d for males age 19 and older.
75638730|NCT04938128|Device|CPAP|Gold standard treatment for obstructive sleep apnea. In this group, patients will be prescribed CPAP treatment according to local policy.
75638731|NCT04933084|Behavioral|Pre-operative Opioid Education|"The pre-operative education in the text handout and pre-recorded video will include the topics of:~Description of expected postoperative pain after robotic prostatectomy and typical opioid consumption after RARP.~Efficacy of non-opioid multimodal analgesia and recommendation to take nonopioid alternatives prior to prescribed opioids.~Adverse short- and long-term effects of opioids including nausea, vomiting, sedation, hypoventilation, hypotension, dizziness, constipation, depression, and addiction."
75923759|NCT03508362|Device|Functional Magnetic Resonance Imaging (fRMI)|Acquisition of a functional MRI on the sub thalamic nucleus
75638732|NCT04932109|Other|No intervention|No intervention in this group
75638733|NCT04927065|Biological|mRNA-1273.211|Sterile liquid for injection
75638734|NCT04927065|Biological|mRNA-1273|Sterile liquid for injection
75638735|NCT04927065|Biological|mRNA-1273.617.2|Sterile liquid for injection
75787576|NCT05185414|Diagnostic Test|Venipuncture and skin biopsy for RNA extraction|"Blood sampling (standard venipuncture)~Skin biopsy (fibroblasts)"
75787577|NCT05185336|Diagnostic Test|ultrasound assessment|gastric volume assessment by ultrasound
75787578|NCT01315522|Device|ComVi stent|Endoscopic insertion of ComVi stent
75923760|NCT04444934|Other|histological examination|Patients were classified in two groups based on the surgeon's visual examination of the right diaphragmatic peritoneum. The accuracy of visual examination has been assessed comparing surgeon's opinions to histological examination
75923761|NCT02310828|Drug|Acetium|Capsule for oral administration contains L-cysteine 100mg
75923762|NCT02310828|Drug|Placebo|A placebo capsule matching Acetium for oral administration.
75923763|NCT03353324|Drug|intravitreal injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness, if in month four or more the CMT is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeatet and follow up in this manner is continued until 9 months.
76079784|NCT01227382|Procedure|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
76079785|NCT05183880|Dietary Supplement|Phosphatidylcholine-lipid encapsulated vitamin C|Ingesting 1000 mg of vitamin C in phosphatidylcholine-lipid encapsulated form
75331136|NCT02246725|Other|Contact with palliative care unit.|
75331137|NCT05017207|Procedure|Pancreaticoduodenectomy|Pancreaticoduodenectomy with one of 2 types of pancreaticojejunal anastomosis: Blumgart and conventional duct-to-mucosa
75331138|NCT03256162|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.
75331139|NCT03256162|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
75638736|NCT04927065|Biological|mRNA-1273.213|Sterile liquid for injection
75638737|NCT04927065|Biological|mRNA-1273.529|Sterile liquid for injection
75638738|NCT04927065|Biological|mRNA-1273.214|Sterile liquid for injection
75638739|NCT04927065|Biological|mRNA-1273.222|Sterile liquid for injection
75638740|NCT04927065|Biological|mRNA-1273.815|Sterile liquid for injection
75638741|NCT04927065|Biological|mRNA-1273.231|Sterile liquid for injection
75787579|NCT01315522|Device|Uncovered SEMS|Endoscopic insertion of uncovered SEMS
75470513|NCT03311152|Diagnostic Test|"Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)"|The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
75470514|NCT03296007|Behavioral|Mindfulness Meditation|A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
75470515|NCT03253354|Device|repetitive magnetic stimulation|Neurostimulation
75787580|NCT01339156|Drug|P3914|"Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
75923764|NCT03353324|Radiation|intravitreal injection of bevacizumab+ targeted laser|"patients in this group undergone laser photocoagulation of retinal non perfused areas based on FAG wide field imaging .~After 9 month follow up the outcomes such as Vusal acuity, Central macular thickness, intraocular pressure, neovascular formation are compared"
75923765|NCT02313402|Device|EOL (Eye On Line)|the intervention consists in training program allowing a gradual acquisition of the eye-writing
75923766|NCT04298944|Diagnostic Test|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
75923767|NCT04298944|Diagnostic Test|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep
75923768|NCT04298944|Diagnostic Test|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
75923769|NCT04298944|Behavioral|Emotional/ Behavioural assessments|Emotional /Behavioral well being will be determined by questionnaires: Pediatrics Adverse Childhood Experiences Questionnaire (ACEs Q), Childrens Emotion Management Scale Questionnaire (CEMS) and Behavior Assessment System for Children (BASC)
75331140|NCT03493828|Procedure|TAP block using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
75331141|NCT03493828|Procedure|TAP block using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
75331142|NCT03493828|Procedure|TAP block using Normal Saline|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
75331143|NCT03014557|Device|left atrial appendage closure device implantation|to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
75638745|NCT04914689|Other|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
75638746|NCT04914689|Other|Visual internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
75638747|NCT04914689|Other|Auditory external focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving auditory feedback. Participants will be instructed to perform each functional task in a manner that does not cause the auditory tool to elicit a noise.
75638748|NCT04909450|Biological|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
75638749|NCT04909450|Biological|Vehicle Control|Matching vehicle control without the drug substance
75923770|NCT04444856|Drug|Eptacog alfa (activated)|The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
75923771|NCT04444856|Other|Standard of care|The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.
75923772|NCT03355040|Other|induction of labour|induction of labour
75923773|NCT03508206|Dietary Supplement|SBRP|SBRP capsules
75923774|NCT03508206|Dietary Supplement|PLACEBO|Placebo capsules
75923775|NCT03354962|Combination Product|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab alone (standard dosage regimen)
75923776|NCT03354962|Combination Product|Combined treatment schema|SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
75923777|NCT03502590|Device|IGEL Laryngeal mask|Insertion of an IGEL device in anaesthetised patients
75923778|NCT04463550|Other|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
75923779|NCT05531500|Drug|Injection|Injection of local anesthetic + steroids
75923780|NCT05531500|Device|Radiofrequency|Application of radiofrequency on the diseased nerve
75923781|NCT04511468|Dietary Supplement|Zinc, Chromium, Vitamin C, and Copper Supplementation|Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper
76079786|NCT05183880|Dietary Supplement|Crystalline vitamin C|Ingesting 1000 mg of vitamin C in crystalline form
75331144|NCT04936633|Other|Intervention by medical staff based on a cloud system|"Remote intervention by medical staff (between Visit 1 and Visit 2; Week 2, 4, 6, 8, 10) : analyzing continuous glucose monitoring data for last two weeks in the cloud system~- Intervention contents~Diet, exercise pattern~Causes of hypoglycemia~Causes of hyperglycemia~Causes of glycemic variability~Counseling for improvement plans for the cause~Counseling to strengthen lifestyle modification~Counseling for insulin administration~Counseling for Insulin dose adjustment (adjusted dose)~Counseling for how to use a FSGM"
75331145|NCT03495856|Behavioral|Mindfulness Training For Chronic Pain|4-week group Mindfulness training program for adults with chronic pain
75638750|NCT04906759|Behavioral|Meals plus exercise|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. Participants will also will receive an exercise kit from the MOW driver with their first meal delivery which will contain 2 tennis balls, 2 1-pound hand weights, and one towel. Every week, the driver will give the participants a handout containing 3 exercises from the NIA Go4Life Workout-to-Go book that are designed to help with strength/endurance, balance, and flexibility20. The participants will be asked to do the 3 exercises every day, if possible, on their own. Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
75787581|NCT01339156|Drug|Placebo|"Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
75638751|NCT04906759|Behavioral|Meals only|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. they will be asked to continue their usual level of activity.Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
75787582|NCT01339234|Other|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
75331146|NCT03496324|Drug|Nurofen for Children®|Nurofen for Children® 400 mg/10 ml
75638752|NCT04903119|Drug|Nilotinib 100mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
75638753|NCT04903119|Drug|Nilotinib 200mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
75638754|NCT04903119|Drug|Nilotinib 300mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 300mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
75787583|NCT01339312|Biological|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
75787584|NCT01339312|Biological|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
75331147|NCT03496324|Drug|Algifor® Junior|Algifor® Junior 400 mg/20 ml
75331148|NCT03354598|Drug|Sulopenem-Etzadroxil/Probenecid|Treatment of uncomplicated urinary tract infection
75331149|NCT03354598|Drug|Ciprofloxacin|Treatment of uncomplicated urinary tract infection
75331150|NCT02169895|Drug|BIA 9-1067|
75638755|NCT04903119|Drug|Nilotinib 400mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 400mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
75638756|NCT04903119|Drug|Dabrafenib|All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.
75638757|NCT04903119|Drug|Trametinib|All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.
75638758|NCT04894240|Drug|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
75787585|NCT01339312|Biological|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
75331151|NCT02169895|Drug|Placebo|
75331152|NCT02169895|Drug|Prolopa®|levodopa/benserazide 100/25 mg
75331153|NCT01072669|Drug|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily[if the lower dose is tolerated] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
75331154|NCT03014713|Drug|Dezocine|Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
75331155|NCT03014713|Drug|Flubiprofen|Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
75787586|NCT01339312|Biological|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
75331156|NCT03014713|Drug|Dexmedetomidine|Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
75470516|NCT03246503|Device|BiliCam estimated bilirubin (BCB)|Images will be obtained using the BiliCam app installed on a commercial smartphone and used to calculated a BCB level. The BCB levels will be used for study purposes only and not used for clinical care
75331157|NCT03354754|Drug|LYS228|LYS228 IV infusion every 6 hours
75470517|NCT03228602|Other|Recording of GEP (Gustatory Evoked Potentials)|record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
75638759|NCT04889755|Behavioral|SibACCESS|The primary goal of the SibACCESS program is to increase siblings' exposure to and opportunity to process cancer-related cues to decrease onset or intensification of posttraumatic stress. The program is focused on siblings, with a brief parent education component. Parents will receive psychoeducation and brief skills training to support siblings enrolled in the program. Siblings will participate in 7 group sessions and one individual session in which they will learn skills and strategies to confront information about cancer and tolerate uncomfortable thoughts and feelings related to cancer, and thereby reduce avoidance of cancer-related emotions.
75638760|NCT04885621|Dietary Supplement|nutrisystem-D|Nutrisystem meal replacements and Glytec glucomander-outpatient algorithm for insulin management decisions
75638761|NCT04854616|Behavioral|CoSTED Intervention|Brief smoking cessation advice, the provision of an e-cigarette starter kit and training in its use, and referral to stop smoking services.
75638762|NCT04848779|Drug|Alglucosidase alfa GZ419829|"Pharmaceutical form: Lyophilized powder for solution~Route of administration: intravenous"
75331158|NCT03354754|Drug|Standard of care therapy|IV infusion of standard of care antibiotics
75638763|NCT04843371|Diagnostic Test|Photoplethysmography|Photoplethysmography (PPG) is a non-invasive technique that can detect volumetric changes in the peripheral blood. It only requires skin contact and relies on light absorption. PPG is a good indicator of the cardiovascular dynamics in the human body. PPG has been incorporated into various new smartphones and wearable devices such as, smartwatches and fitness wristbands making it readily available to all consumers. This sensor can record biometrics such as, heart rate, blood pressure, oxygen saturation, etc.
75638764|NCT04836494|Drug|BBP-671|BBP-671, oral suspension
75638765|NCT04836494|Drug|Placebo|Placebo matching BBP-671
75638766|NCT04836494|Drug|BBP-671|BBP-671, tablet
75638767|NCT04836026|Device|HF20™|HF20™ will be used for CRRT
75787587|NCT01339468|Drug|Advagraf|oral
75787588|NCT01339468|Drug|Prograf|oral
75331159|NCT01073449|Procedure|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
75331160|NCT03270436|Behavioral|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|Faith based diabetes curriculum that teaches participants to connect faith and health.
75331161|NCT03270436|Behavioral|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|Family and community based diabetes prevention curriculum that teaches participants to engage their social support to have a healthy weight.
75331162|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
75331163|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
75470518|NCT03195868|Device|Realief Therapy|Patients will be treated using class IV laser using a proprietary algorithm developed by REALief neuropathy centers
75470519|NCT03170908|Behavioral|Interpersonal Psychotherapy|Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
75470520|NCT03091881|Drug|Granisetron 0.1 MG/ML|Granisetron 0.1 MG/ML Will be given 10 min before spinal block
75470521|NCT03091881|Drug|Placebos|Placebos will be given 10 min before spinal block
75470522|NCT03053765|Other|training in IPT|Follow-up training in IPT to determine which best enhances fidelity
75470523|NCT03039595|Other|Ploidy and tumour:stromal ratio measurements|Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)
75470524|NCT03016754|Device|Wearable Cardioverter Defibrillator|LifeVest Wearable Cardioverter Defibrillator
75470525|NCT02864368|Drug|5-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m^2/day on days 1-5 of each 28 day cycle
75638768|NCT04833907|Drug|rAAV-Olig001-ASPA|Intracerebroventricular administration of a single dose
75638769|NCT04833907|Drug|Levetiracetam|Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
75638770|NCT04833907|Drug|Prednisone|Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.
75787589|NCT01339468|Drug|Prograf|intravenous
75787590|NCT01339624|Drug|FENTANYL|FENTANYL CITRATE, NASAL, 3 GAMMA/KG
75787591|NCT01339624|Drug|Ketorolac Tromethamine AND morphine|morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
75787592|NCT05184946|Drug|Camrelizumab Combined with SOX|Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma
75923782|NCT04511468|Behavioral|Standard healthy lifestyle intervention|Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
75923783|NCT04511468|Other|Placebo|Placebo with inactive ingredients
75331164|NCT01075087|Drug|Placebo|Bilateral TAP block using sterile normal saline.
75331165|NCT01075087|Drug|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
75638771|NCT04814420|Device|Delayed enhancement magnetic resonance imaging (DE-MRI)|The patient will be injected with late gadolinium enhancement (0.01 mmol/kg standard dosage), which is a contrast agent used in clinical practice in MRI imaging studies. The contrast agent is used to enhance specific regions/tissues on MRI and, in this study, will allow the investigators to identify fibrotic tissue within the heart. The patient then undergoes the MRI sequence, which lasts approximately 20-25 minutes. Images will be reviewed for quality by trained technicians. This will be repeated after 6 months.
75638772|NCT04810013|Procedure|non-invasive measurement of cerebral autoregulation|Non-invasive measurement of the cerebral autoregulation in the postoperative period in 80 neonates and infants with complex congenital heart disease undergoing cardiopulmonary bypass surgery. A continuous, moving Pearson's correlation coefficient will be calculated between the arterial pressure and near-infrared spectroscopy signals and displayed continuously during surgery using a laptop computer and the ICM+ software (Cambridge Enterprise).
75638773|NCT04809259|Device|Isothermal pouch|The study will verify it the use of an isothermal pouch to maintain the content of an elastomeric pump at 10° to 15°C avoids unacceptable meropenem degradation over the 24 hour infusion period.
75638774|NCT04803825|Other|Heavy Slow Exercises|"Load magnitude: A dumbbell as heavy as possible within the given repetitions and sets.~Number of repetitions: week 1: 15 reps, Week 2-3: 12 reps, Week 4-5: 10 reps, Week 6-8: 8 reps, Week 9-12: 6 reps~Number of sets: 3~Rest between sets: 2 - 3 min.~Number of exercise interventions: 2~Duration of experimental period: 12 weeks~Fractional and temporal distribution of the contraction modes per repetition and duration of one repetition: 3s concentric, 2s isometric: while change concentric/eccentric phase, 3s eccentric.~Rest in-between repetitions: No~Range of motion: Full range of motion~Intervention frequency: 3 times a week, with minimum 48 h recovery time in-between."
75787593|NCT01339702|Other|The National Prehospital TBI Management Guidelines|"In the post-implementation (after) cohort, implementation of the entire bundle of the TBI treatment guidelines with special emphasis on prevention and treatment of hypotension (IV crystalloids), prevention and treatment of hypoxia (pre-oxygenation with high-flow O2 via non-rebreather mask, bag-valve-mask, extraglottic airways/intubation when basic maneuvers have failed), and prevention of hyperventilation (in intubated patients) and prevention/treatment of hypoventilation (in all patients)."
75787594|NCT01339780|Radiation|BS, SPECT/CT, PET/CT, MRI|Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
75787595|NCT01340092|Other|Family Navigator|"Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:~Help family identify key issues they need to address to get their child autism-specific services~Help family address barriers to obtaining these services and strategize approaches to overcome them."
75787596|NCT01340170|Device|OsseoSpeed TX|OsseoSpeed TX dental implants, 6-17 mm
75787597|NCT01340248|Drug|Dilatrend 64mg capsule|"Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
75787598|NCT01340326|Drug|high dose of valsartan|comparison of different dosages of drug
75638775|NCT04803825|Device|Extracorporeal Shock wave therapy|Two thousand impulses of shock waves are applied to the painful tendon, with a pressure between 1.5 and 3.0 bar (depending on what the patient tolerates). We use a power hand piece that provides energy of 0.01-0.35 mJ/mm2
75787599|NCT01340326|Drug|usual dose of valsartan|comparison of different dosages of drug
75331166|NCT01075399|Drug|[F 18]HX4|Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with [F 18]HX4
75638776|NCT04803825|Other|Information and advice|Information and advice are based on assessment and will comprise the standardized oral and written information. Participants will be educated regarding pain during and after activities and encouraged to be physically active. With only one session, there is great reliance on self-management. Thus, information and advice are made available through a handout.
75638777|NCT04803123|Drug|Copanlisib|Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.
75787600|NCT05184322|Drug|XW004|2, 7, 15, 30mg tablets once daily for 15 days.
75787601|NCT05184322|Drug|T2026|Once daily for 15 days.
75787602|NCT05184322|Drug|Placebo|Once daily for 15 days.
75787603|NCT01340404|Procedure|Stem cell transplantation|Stem cell transplantation
75787604|NCT01340404|Procedure|Transfusion program|Transfusion program
75787605|NCT05184010|Device|ulnar nerve mini open release|the ulnar nerve mini open release was performed before arthroscopic release for elbow
75787606|NCT05184010|Device|without ulnar nerve mini open release|arthroscopic release for elbow stiffness alone without ulnar nerve mini open release
75787607|NCT01340638|Device|cookgas mask|This group will be assigned to use cookgas mask
75787608|NCT01340638|Device|LMA mask|LMA mask
75787609|NCT01340716|Other|Tai Chi Chuan exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
75787610|NCT01340716|Other|stretching exercise|patients in this group held weekly classes of two stretching for 12 weeks.
75923784|NCT02313480|Other|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
75923785|NCT05531422|Drug|Fentanyl|Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
75923786|NCT03354884|Drug|cabozantinib|cabozantinib 60 mg orally once daily
75923787|NCT03354806|Procedure|Continuous peripheral nerve blocks|6 weeks-ropivacaine treatment delivered by continuous peripheral nerve blocks Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
75787611|NCT00286091|Biological|Denosumab|Administered by subcutaneous injection
75787612|NCT00286091|Biological|Placebo|Same volume subcutaneous injection
75787613|NCT01340950|Drug|zidovudine-lamivudine-nevirapine|96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily
75787614|NCT01340950|Drug|tenofovir-lamivudine-efavirenz|96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily
75923788|NCT03354806|Procedure|Analgesic treatment|6 weeks-analgesic treatment according to WHO's pain relief ladder Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
75331167|NCT03358576|Drug|Ertapenem|Antibiotic for complicated intra-abdominal infection
75470526|NCT02864368|Drug|21-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)
75638778|NCT04795323|Device|TARA v3.1, only non-pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
75787615|NCT01341028|Procedure|Roux-en-Y gastric bypass (LRYGBP)|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
75787616|NCT01341028|Procedure|LRYGBP+gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
75787617|NCT01341106|Drug|Treatment with entecavir(Baraclude®)|Patient will be daily treated with 1 tablet of entecavir per oral
75787618|NCT01341184|Drug|Rifabutin|Rifabutin 300 mg orally on days 20-41
75787619|NCT01341184|Drug|Rifampin|Rifampin 600 mg orally on days 20-41
75787620|NCT01341184|Drug|TMC207|TMC207 400 mg orally on days 1 and 29
75787621|NCT00285857|Drug|Lovastatin|"Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent."
75923789|NCT03508128|Other|surgical procedure|Surgical procedure
75923790|NCT04443998|Device|Bone reducion forceps|Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction
75331168|NCT03358576|Drug|Sulopenem-Etzadroxil/Probenecid|Antibiotic for complicated intra-abdominal infection
75787622|NCT05183386|Procedure|dental socket regeneration|after a dental extraction the fresh socket is filled with graft materials and compared with the spontaneous healing (control)
75787623|NCT03975101|Biological|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
75787624|NCT01341262|Drug|Thalidomide|"INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200~AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200"
75787625|NCT01341262|Drug|Dexamethasone|"INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)~AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)~AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
75787626|NCT01341262|Drug|Zoledronic acid|"INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)~AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)~AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
75787627|NCT01341262|Drug|Cyclophosphamide|Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
75787628|NCT01341262|Drug|Melphalan|Melphalan 200 mg/sqm on day -1 for first and second ASCT
75787629|NCT01341340|Device|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
75923791|NCT03122912|Dietary Supplement|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
75923792|NCT03122912|Dietary Supplement|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
75331169|NCT03358576|Drug|Ciprofloxacin|Antibiotic for complicated intra-abdominal infection
75331170|NCT03358576|Drug|Metronidazole|Antibiotic for complicated intra-abdominal infection
75470527|NCT02864368|Biological|PEP-CMV: Component A|500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered
75470528|NCT02864368|Drug|Tetanus-Diphtheria booster|At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
75923793|NCT02313714|Device|stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),|All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
75923794|NCT02313714|Device|Sham|very low electric muscular stimulation
75331171|NCT03358576|Drug|Amoxicillin-Clavulanate|Antibiotic for complicated intra-abdominal infection
75331172|NCT03358576|Drug|Sulopenem|Antibiotic for complicated intra-abdominal infection
75331173|NCT03016117|Procedure|Pecs II block and parasternal block|The Pecs II block will be performed under ultrasound guidance, at fourth rib level, on the axillary line, into the fascial plane between pectoralis minor muscle and serratus muscle. The parasternal block will be performed under ultrasound guidance, at the second and fourth intercostal space, between the pectoralis major muscle and the intercostal muscles, near to the external intercostal membrane.
75787630|NCT01341418|Procedure|Suprapatellar approach|Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
75787631|NCT01341418|Procedure|Infrapatellar approach|The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
75923795|NCT04504058|Other|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
75470529|NCT02864368|Drug|Tetanus Pre-Conditioning|All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
75331174|NCT03822013|Drug|Miglustat|Treatment with Zavesca regimen based on body surface area as follows: SQRT [Height (cm) × Weight (kg)] / 3600 <1.25 : 200mg TDS 0.88- 1.25: 200mg BID 0.73- 0.88: 100 mg TDS 0.47- 0.73: 100 mg BID <0.47: 100 mg Daily
75923796|NCT05529082|Other|Opioid Attitudes|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
75923797|NCT05529082|Other|Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
75331175|NCT00376324|Drug|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
75787632|NCT01341496|Biological|Epigenetically Modified Autologous Tumor|5x 10^7 autologous tumor cells emulsified in 0.5 mL ISCOMATRIX adjuvant will be administered IM every 4 weeks for 6 months
75787633|NCT01341496|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
75787634|NCT01341496|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
75787635|NCT05183074|Device|MR-linac|1.5-Tesla MR-linac based SBRT
75787636|NCT05182996|Behavioral|smoking education|Educate on the relationship between inflammatory bowel disease and smoking and the necessity and importance of quitting smoking.
75787637|NCT00284141|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
75923798|NCT03505398|Procedure|microperimetry|define the retinal fixation point and the differential sensitivity threshold of the retina.
75923799|NCT03505398|Procedure|visual acuity|using ETDRS scales
75923800|NCT03505398|Procedure|automated visual field|recording visual attention based on central or peripheral visual information
75331176|NCT03800563|Device|LipoLife system|Abdominal/ Outer thighs Laser Assisted Liposuction. Five to twenty subjects out of the study group will also undergo facial fat grafting.
75331177|NCT00376402|Biological|H5N1 Pandemic Influenza Vaccine|
75331178|NCT00376480|Biological|anti-thymocyte globulin|
75331179|NCT00376480|Biological|peripheral blood lymphocyte therapy|
75331180|NCT00376480|Drug|fludarabine phosphate|
75331181|NCT00376480|Drug|methylprednisolone|
75470530|NCT02864368|Biological|PEP-CMV: Component B|500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered
75470531|NCT02856698|Drug|Midazolam|Dose use according to the product technical sheet
75470532|NCT02856698|Drug|Morphine|Dose use according to the product technical sheet
75470533|NCT02812225|Device|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
75470534|NCT02688751|Radiation|time-resolved CT Angiography|A multi-phase contrast CT
75787638|NCT05182684|Device|Vital Patch(TriBell Lab)|"Electrocardiograms were recorded using VP-100 for more than six hours and transmitted to a central data server located in Seoul National University Hospital.~The data on a central server was confirmed and evaluated."
75787639|NCT05182138|Other|Unfortified potato plus placebo|Volunteers will be given 300g of zinc unfortified cooked potato as well as a placebo every day.
75787640|NCT05182138|Other|Zinc Biofortified potato plus placebo|Volunteers will be given 300g of cooked potato biofortified with zinc and a placebo every day.
75787641|NCT05182138|Other|Unfortified potato plus zinc supplement|Volunteers will be given 300g of zinc unfortified cooked potato and a zinc supplement containing 18mg of zinc, every day.
75787642|NCT03975257|Device|Medical Device: Ectoin Lozenge|Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use
75787643|NCT02531945|Device|Use of Biomod device|
75787644|NCT01341808|Biological|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
75787645|NCT03975725|Device|the use of the WitCard|electrocardiogram (ECG)
75787646|NCT03975725|Other|the use of WitDisplayer|a software to visualize, measure, annotate, comment, archive, and share the different ECGs acquired with the WitCard (ECGW) of different patients.
75331182|NCT00376480|Drug|thiotepa|
75331183|NCT00376480|Procedure|allogeneic hematopoietic stem cell transplantation|
75331184|NCT00376480|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75331185|NCT00376480|Radiation|total-body irradiation|
75787647|NCT04597528|Other|Elective Induction|"All patients admitted to the labour room would be approached to be enrolled in the study.~Those satisfying the inclusion and exclusion criteria would be prospectively enrolled to the study after procuring an informed consent. If a patient appears to meet the criteria for the study, she will be told about the study and asked for written informed consent to participate. Consent may be obtained anytime from 34 weeks 0 days to 38 weeks 6 days of gestation. Data would be procured on a pre set proforma, entered in real time and safely stored.~The data would later be abstracted to an excel sheet."
75923801|NCT03505398|Procedure|eye movements recording|recording of explicit visual attention based on central or peripheral visual information
75638779|NCT04795323|Device|TARA v3.2, both non-pharmacological and pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
75638780|NCT04784091|Drug|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
75331186|NCT03016039|Dietary Supplement|Curcumin supplementation|use of curcumin supplementation as an additive treatment to the conventional treatment
75331187|NCT03362944|Behavioral|Active Music Therapy|The intervention consists of a standardized series of Music Therapy tasks, all based at a constant rhythmic pulse.
75787648|NCT01314196|Other|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers using bat without charge, training and isometric exercises commuting to the cuff muscles, without producing subacromial impaction.
75331188|NCT03362944|Behavioral|Passive Music Therapy|The intervention consists of a series of recorded listening tracks, matched in style to the active intervention, all based at a constant rhythmic pulse.
75331189|NCT03497026|Device|Robotic Bronchoscopy Platform|Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
75331190|NCT02175979|Dietary Supplement|enriched enteral nutrition|enriched enteral tube feeding perioperative
75638781|NCT04784091|Drug|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
75787649|NCT01314196|Other|biceps resistance training and therapeutic exercises|The biceps resistance training based on calculations of maximum resistance (MR), being conduct in three series 10 reps with 50% of MR in the first series of training and 75% of MR in the second series, with 2 minutes between each and therapeutic exercises for the shoulder and scapula stabilizers.
75787650|NCT01315990|Drug|FOLFIRI + Cetuximab|"Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~Irinotecan 180 mg/m² iv , 90 min on day 1~Folic acid (racemic) 400 mg/m², 120 min on day 1~5-FU 400 mg/m² bolus on day 1~5-FU 2400 mg/m² iv over 46 h on day 1 to 2"
75787651|NCT00265343|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
75787652|NCT00265343|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
75787653|NCT01341886|Drug|Metformin|in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
75787654|NCT03975881|Other|application on smartphone|The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
75787655|NCT05162950|Diagnostic Test|physical exercise as a standardized high intensity exercise test|High intensity exercise test, cycling, performed at the Karolinska University Hospital
75787656|NCT05162950|Behavioral|Stress vulnerability|Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire
75787657|NCT03637114|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
75923802|NCT03350360|Behavioral|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
75923803|NCT03350360|Behavioral|Comparison Task|Neutral- neutral stimuli prior to response task
75331191|NCT02175979|Dietary Supplement|standard|standard of care
75331192|NCT03498196|Drug|Avelumab|avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
75331193|NCT03613519|Behavioral|SHUTi|A woman assigned to SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
75470535|NCT02688751|Procedure|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
75923804|NCT05529004|Drug|Oral Capsule pregapalin|oral cap of pregapalin has been administration to patient before surgery to prvent PONV
75923805|NCT05529004|Device|laparoscope device|general anesthesia with complete relaxation under laparoscopic cholecystectomy
75923806|NCT03350282|Dietary Supplement|GAA-creatine|
75923807|NCT03350282|Dietary Supplement|Creatine|
75923808|NCT02316210|Device|electrical stimulation|
75331194|NCT03613519|Behavioral|modified SHUTi (i.e., SHUTi-BWHS)|A woman assigned to modified SHUTi (i.e., to SHUTi-BWHS) receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the modified SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
75787658|NCT03637114|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
75787659|NCT00283595|Drug|Recombinant Human Growth Hormone|Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
75331195|NCT03613519|Behavioral|Patient education|A woman assigned to patient education receives access to a website that provides detailed information on habits and environments that may help or hinder sleep. The site can be visited as often as desired. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health, as well as sleep diaries to gather information about her daily sleep pattern. Time 1 is just before first logging into the sleep information website. Time 2 is about 9 weeks later and Time 3 is six months after that. The questionnaires will be used to assess the effect of the sleep information program on the participant's sleep and health.
75787660|NCT00283595|Drug|Placebo for Recombinant Human Growth Hormone|Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
75787661|NCT01342042|Biological|rExenatide-4|This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 [glucagon-like peptide-1] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
75787662|NCT00265109|Drug|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
75638782|NCT04777643|Drug|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
75638783|NCT04777643|Other|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
75638784|NCT04769310|Device|Cardiac and Brain MRI|"A CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner will be used. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
75787663|NCT03637036|Other|Communication intervention|The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
75923809|NCT03350204|Procedure|Meniscectomy|This will be to see what occurs in both kinetics and kinematics after you have a surgery and how this links on to osteoarthritis
75331196|NCT03500302|Drug|Evolocumab|Evolocumab sq once a month for a total of two doses
75331197|NCT02176837|Drug|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
75470536|NCT02660164|Device|Nautilus BrainPulse Recording|Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
75470537|NCT02625610|Drug|Avelumab|Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
75638785|NCT04766866|Diagnostic Test|sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation|A ratio cutoff of >p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
75923810|NCT03350204|Other|Helathy control comparison|This group will be used to get a baseline for normal and natural walking, running and other several tasks which will be used as a comparison for the meniscus injury group.
75923811|NCT02316288|Behavioral|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
75638786|NCT04766723|Drug|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
75638787|NCT04766723|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
75923812|NCT02316288|Behavioral|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
75923813|NCT02313792|Drug|Palifermin|
75923814|NCT05285878|Drug|Fingolimod|0.5 mg daily
75923815|NCT05285878|Drug|Placebo|0.5 mg daily
75787664|NCT01342198|Drug|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
75787665|NCT01342198|Drug|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
75787666|NCT01342198|Drug|erythromycin|A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
75787667|NCT01342276|Behavioral|vHFC|Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
75787668|NCT01342354|Radiation|Stereotactic Radiation|Escalating Doses of SBRT in periods of three doses over 10 days
75787669|NCT04806022|Other|Fatigability assessment|Each participant will do both types of fatigue over 2 appointments spaced by 7 days so that the subject can recover from induced fatigue. The sequence of fatigue tasks will be randomized.
75787670|NCT03235024|Biological|B244|B244 suspension
75923816|NCT02314182|Procedure|Primary tumor resection + chemotherapy|"Step 1: Primary Tumor (PT) resection~Within 3 weeks after randomization~Immunonutrition given 7 days prior to PT resection~Mechanical bowel preparation performed before surgery according to the local practices~Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)~Step 2: postoperative CT-scan~Must be performed within 4 weeks after surgery~CT-scan/MRI with the same criteria as pre-treatment evaluation~Step 3: Chemotherapy +/- target therapy~Within 4 weeks after the surgery~Chemotherapy administered according to the usual scheme for the chosen protocol~All validated and/or registered perioperative rectal cancer treatments authorized~The duration of one treatment cycle depending on the type of treatment administered~Radiotherapy is allowed after randomization if indicated"
75923817|NCT02314182|Drug|Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|"Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.~If complications occur, emergency surgery can be performed according to the local practices of each investigator center.~Radiotherapy is allowed after randomization if indicated (MDOC)."
75331198|NCT03501550|Drug|CDI-31244|investigational drug
75638788|NCT04763356|Other|Symptom Care at Home with NP follow up|In the SCH-NP group all participants will report their CIPN related symptoms daily via the app, website or phone tree. Any concerning symptoms will trigger a call back from a nurse practitioner who will use a consensus and evidence based algorithm to prescribe therapies for the CIPN symptoms.
75638791|NCT04746235|Drug|Decitabine and Cedazuridine|Given PO
75638792|NCT04746235|Drug|Venetoclax|Given PO
75638793|NCT04733027|Combination Product|Dose escalation, first-in-human phase I clinical trial with an Expansion phase|PEP-010 will be administered on days 1, 2 and 3 every week, as a 3-hour intravenous infusion. Treatment will be administered until disease progression, unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Each cycle will be of 21 days duration.
75638794|NCT04732871|Biological|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
75638795|NCT04718779|Other|Digital Engagement Application (GD App)|This is a chart review (prospective) data analysis study to describe the effect of the treatment change on the clinical parameters and patient reported outcomes (PROs) with the use of a digital engagement application (GD app) (to evaluate participants clinical engagement, shared decision making, emotional wellbeing, activities of daily living, goal attainment and Gaucher Disease specific measures).
75787671|NCT03235024|Biological|Vehicle|Vehicle suspension
75787672|NCT01342432|Other|General exercise only|exercises for stretch and strength of paraspinal and abdominal muscles
75787673|NCT01342432|Other|Balance reeducation plus general exercise|patients perform balance reeducation exercises in addition to general exercises for stretch and strength of back and abdominal muscles
75787674|NCT05155774|Device|Twin block|Twin Block orthodontic appliance for treating patients with Angle class II molar relationship and a large horizontal overjet, often in combination with an incomplete lip closure
75787675|NCT03635476|Other|Qualitative interview study|The group in question is part of a research program aimed at developing and evaluating the LIFANA Nutrition Solution, a meal planning recommended system, which suggests meals based on the user's personal profile. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists.
75331199|NCT03501550|Drug|SOF/VEL|sofosbuvir and velpatasvir fixed dose combination
75331200|NCT03503578|Drug|Sevoflurane|Subjects will received sevoflurane for approximately 60 minutes.
75331201|NCT03503578|Drug|Ketamine|Subjects will received sevoflurane and ketamine for approximately 60 minutes.
75331202|NCT03506386|Other|No Intervention|As it was an observational study, no intervention was administered.
75331203|NCT03270514|Drug|Exparel Injectable Product|Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
75638796|NCT04718779|Other|No Intervention|This is a chart review (retrospective) data analysis study to describe the effect of the treatment change on the clinical parameters.
75638797|NCT04715451|Other|Novel Swaddle|A novel swaddling method.
75638798|NCT04714190|Drug|RC48-ADC|2.5 mg/kg IV every 2 weeks
75787676|NCT01342588|Procedure|Electric pulse train stimulation|Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
75638799|NCT04714190|Drug|Paclitaxel injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
75787677|NCT01342744|Drug|Metformin|Metformin(850 mg) 1tab oral twice aday
75923818|NCT04503980|Biological|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10^5 CAR+ T cells/kg will be infused on day 0.
75923819|NCT02316444|Biological|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
75923820|NCT05267860|Device|Prophylactic Drain|We want to put a prophylactic drain after cholecystectomy.
75923821|NCT02316600|Device|smart insole|smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
75923822|NCT03350048|Diagnostic Test|Trans-Dot point-of-care test|"Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.~Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response."
75923823|NCT05531344|Device|Composite Steep-pulse Treatment Device|Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia
75923824|NCT05531344|Drug|Tamsulosin Hydrochloride Capsules|Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
75923825|NCT02311140|Other|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
75923826|NCT04504292|Drug|SUPREP Bowel Prep Kit|Bowel prep prior to colonoscopy
75923827|NCT04504292|Drug|Golytely Oral Product|Bowel prep prior to colonoscopy
75923828|NCT03505242|Device|bronchial blocker for BB group|Using bronchial blocker to block right middle lower lobe during surgery.
75923829|NCT03505242|Device|double lumen tube for DLT group|Using double lumen tube to achieve single lung ventilation during surgery.
75331204|NCT03270514|Drug|Bupivacaine Hydrochloride|Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
75638800|NCT04714190|Drug|Irinotecan Hydrochloride Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
75923830|NCT02311218|Dietary Supplement|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
75923831|NCT02311218|Dietary Supplement|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
75787678|NCT01342744|Drug|Placebo|Placebo 1 tab oral twice a day
75923832|NCT05531266|Other|hUC-MSCs|Participants will be treated with hUC-MSCs at a dose of 1×10^6 /kilogram (kg) actual body weight at Screening for twice per week in 1-2 weeks and once a week in 3-4 weeks after being rolled into this study. At the same time, patients will be treated with glucocorticoids according to patients' condition.
75923833|NCT05531266|Other|glucocorticoids|Participants were treated with glucocorticoids only.
75923834|NCT04504214|Other|Upper limb repeated multi-site tendon vibrations|Upper limb tendon vibration protocol will be added to the usual rehabilitation protocol performed during hospitalization
75923835|NCT03502512|Other|Questionnaire Administration|Ancillary studies
75923836|NCT03502512|Procedure|Reconstructive Surgery|Undergo reconstructive surgery with REVOLVE technique
75923837|NCT03502512|Procedure|Reconstructive Surgery|Undergo reconstructive surgery with PureGraft technique
75787679|NCT01342822|Device|Angioplasty (PROMUS Element™, and Xience™ Prime stent)|Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
75787680|NCT05150782|Dietary Supplement|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin (2%), boswellia serrata (1.5%) and ascorbic acid (6%).
75787681|NCT01342900|Device|connected to the InSpectra Monitor|
75787682|NCT01340560|Procedure|Endometrial biopsy|Endometrial biopsy was performed with biopsy catheter
75331205|NCT03277378|Device|lead placement followed by BurstDR stimulation|lead placement followed by BurstDR stimulation
75331206|NCT02178241|Drug|Eribulin Mesylate|Given IV
75638801|NCT04714190|Drug|Apatinib Mesylate Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
75638802|NCT04703166|Device|Samsung Galaxy Watch Active2|The Samsung wearable device will collect data; photoplethysmography (PPG) waveforms, heart rate, heart rate variability, step counts, oxygen saturation levels, sleep pattern and quality.
75787683|NCT05251246|Behavioral|recovery management program|The recovery management program consists in training the nurses and physicians during a 15-day training course to optimize their recovery abilities : sleep management according to the schedules by anticipation and recovery, and stress management through cardio-feedback techniques (cardiac coherence) also called controlled breathing techniques and mental imagery.
75787684|NCT03760120|Device|PEP-MASK|
75787685|NCT01316068|Drug|intravenous use of sulodexide followed by oral use|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.
75638803|NCT04702542|Drug|Enteral oxygen therapy|Enteral oxygen therapy during the rehabilitation period of patients with CGDP.
75331207|NCT02178241|Drug|Gemcitabine Hydrochloride|Given IV
75331208|NCT03509974|Device|Osseointegrated Steady State Implant|Bone anchored, bone conduction hearing system
75331209|NCT03015727|Drug|Docetaxel|3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.
75331210|NCT03015727|Drug|Cisplatin|3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.
75331211|NCT03015727|Radiation|IMRT/TOMO|intensity modulated radiation therapy or tomotherapy
75923838|NCT05523544|Behavioral|schematherapy|psychotherapy
75331212|NCT03015727|Drug|Chemotherapy|2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
75923839|NCT05523466|Other|Acupuncture Active|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Active acupuncture using specific Traditional Chinese Acupuncture points: E36, BP6, F3, IG4, for 20 minutes.
75787686|NCT01316068|Drug|use of sulodexide orally only|Patients receive 1000 LSU per day orally for 52 weeks
75923840|NCT05523466|Other|Acupuncture Sham|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Sham acupuncture using sham points (points not recognized as Acupuncture points), with the duration of 20 minutes
75331213|NCT03584659|Device|Electronic patient-reported outcomes|Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
75923841|NCT04507490|Device|Whole body vibration|315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
75923842|NCT03501810|Device|Distractor use for vertebrae separation|Distractor use where separation of vertebrae is required, including corpectomy, insertion of disc prosthesis, insertion of an anterior lumbar interbody fusion (ALIF) cage, and tumor surgery
75923843|NCT03501732|Behavioral|Values Affirmation|Experimental Group selects two values and describes why they are important
75331214|NCT03015883|Radiation|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
75923844|NCT03501732|Behavioral|Risk Feedback|Experimental and comparator conditions both receive normative feedback in domains of risk
75331215|NCT01077973|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
75331216|NCT01077973|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg) plus placebo
75331217|NCT01077973|Drug|Placebo|Single-dose of placebo
75331218|NCT03514420|Drug|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx solution for SC injection.
75638804|NCT04682964|Drug|Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.|Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
75638805|NCT04670549|Other|Implementation of treatment guidelines|To improve knowledge of OA treatment recommendations among people with hip and knee OA, a lay language summary will be emailed all OA patient participants. A second summary of the treatment recommendations, targeting general practitioners (GPs) will also be emailed the OA patient participants. The patients will be encouraged to print and bring this summary to their GP at the next visit (user-initiated implementation). Barriers and facilitators for providing evidence-based OA care among primary care physiotherapists will be mapped through interviews. Thereafter, a tool-kit of strategies and practical aids intended to help overcome these barriers will be developed and made available for the physiotherapists.
75787687|NCT03233308|Drug|Netarsudil Ophthalmic Solution 0.02%|1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
75787688|NCT03233308|Other|Placebo Comparator|1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
75923845|NCT03349814|Procedure|Diagnostic laparoscopy without appendectomy|A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.
75923846|NCT03349814|Procedure|Diagnostic laparoscopy with appendectomy|A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed
75331219|NCT02973646|Drug|Entecavir or Tenofovir|Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
75331220|NCT02973646|Drug|Peginterferon Alfa-2B|
75331221|NCT03296059|Other|conventional treatment with RBC transfusion|Besides conventional treatment, neonates is given RBC transfusion.
75331222|NCT03296059|Other|conventional treatment|neonates is treated with conventional treatment.
75331223|NCT03369340|Other|P3P 1|2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
75331224|NCT03369340|Other|P3P 2|2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
75331225|NCT03369340|Other|P3P 3|1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
75331226|NCT03369340|Other|P3P 4|2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
75331227|NCT01078363|Drug|ramipril|Use of a ACE ( angiotension converting enzyme) inhibitors post heart Transplant for Blood pressure control.
75331228|NCT01078363|Drug|Placebo|Use of a placebo post heart Transplant for Blood pressure control.
75331229|NCT03370042|Procedure|semilunar coronally positioned flap with free gingival graft|
75331230|NCT03370042|Procedure|semilunar coronally positioned flap alone|
75638806|NCT04667169|Procedure|Haemorrhoidal Artery Ligation|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
75638807|NCT04667169|Procedure|Laser Haemorrhoidoplasty|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
75638808|NCT04664972|Drug|Docetaxel +doxorubicin+ cyclophosphamide|The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
75638809|NCT04664972|Drug|Docetaxel +Cisplatin|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
75787689|NCT05250934|Device|Robotic rehabilitation|The upper limb rehabilitation will be carried out with the planar rehabilitation robot Icone (a CE Class IIA medical device manufactured by Heaxel). The proposed exercises require the patient to move a cursor on the screen using the end-effector of the robot to reach specific points (planar reaching exercises). When the patient is able to perform these exercises independently, the robot assists the movement by minimizing the interaction force applied to the hand and limiting itself to acquiring the kinematic and dynamic parameters of the exercise, which are useful in determining the state of motor skills. Icone assist the subject by applying a force to his hand that helps him complete the task in the phases where the patient plans the movement correctly but is unable to complete it. As a result, the system will enable you to perform planar elbow and shoulder movements in active, passive, or active-assisted modes, with visual and acoustic feedback.
75923847|NCT05528536|Behavioral|Acceptance and Commitment Therapy (ACT)|A two-hour ACT will focus on enhancing participant's psychological flexibility towards pain. All sessions will be delivered face-to-face within their local community centre.
75923848|NCT05528536|Other|Art|To be comparable with the experimental group, the Art session will be a two-hour long session which aims to share different art techniques, without any active components. All sessions will be delivered face-to-face within their local community centre.
75923849|NCT05528536|Other|Exercise|An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.
75923850|NCT05528536|Other|Treatment as usual|treatment as usual within their community centres
75923851|NCT03501654|Device|TecnisSymfony®|Patients received implantation of unilateral or bilateral TecnisSymfony® IOL after phacoemulsification by a single surgeon (MK Kim).
75923852|NCT03349736|Other|Pelvic Floor Muscle Training|All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
75638810|NCT04658238|Other|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
75638811|NCT04658238|Other|Ocular immune system|Functional characterization of the tear fluid proteome, histology of conjunctival tissue and molecular assays
75787690|NCT04391686|Diagnostic Test|indirect calorimetry|to determine and compare the resting energy expenditure of each group
75923853|NCT05531110|Device|Cataract surgery with insertion of Eyhance ICB00|Cataract surgery with insertion of Eyhance ICB00
75923854|NCT05531110|Device|Cataract surgery with insertion of Alcon SN60WF|Cataract surgery with insertion of Alcon SN60WF
75923855|NCT02314338|Other|Pulmonary rehabilitation|In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
75923856|NCT03349658|Other|general anesthesia|effect of general anesthesia on transcranial regional cerebral oxygen saturation
75638812|NCT04657679|Drug|Ribociclib|Patients will receive ribociclib 600 mg oral (PO) daily for 21 consecutive days of 28-day cycles and endocrine therapy with either letrozole or fulvestrant. Fulvestrant 500 mg intramuscular (IM) will be administered on days 1, 15, 29 of cycle one, and then monthly. Letrozole 2.5 mg oral daily continuously. If premenopausal women have not undergone bilateral salpingo- oophorectomy, they will receive a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., goserelin leuprolide) for ovarian suppression in combination with fulvestrant or letrozole and ribociclib.
75638813|NCT04655755|Drug|Decitabine and Cedazuridine|Given PO
75638814|NCT04655755|Drug|Venetoclax|Given PO
75638815|NCT04647136|Diagnostic Test|Fertility Health Screening|Basic fertility health screening comprising an anti-Mullerian hormone (AMH) test and semen analysis, a doctor's consultation to explain the results, and standardised reproductive counselling by a trained nurse comprising a discussion of reproductive plans (including addressing barriers the couple face), education on age-related fertility decline and limitations of artificial reproductive technologies, advice on the optimal reproductive timing and when to seek further help. An educational brochure will be handed to the couple during the counselling session.
75923857|NCT03349658|Other|spinal anesthesia|effect of spinal anesthesia on transcranial regional cerebral oxygen saturation
75923858|NCT05523388|Other|Collection of health-related data|A multimodal set of data including experimental, clinical, functional, radiological and biomechanical data is compiled before and after routine surgical intervention at baseline and at one-year follow-up.
75923859|NCT02314416|Biological|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
75923860|NCT03353012|Drug|Etonogestrel Drug Implant|Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
75638816|NCT04647136|Behavioral|Fertility Awareness Tools|Online intervention consisting of 1) video targeting fertility education and specific attitudes, social norms and perceived control for having children, 2) a fertility awareness tool (FERTISTAT) and 3) an educational brochure on fertility. This intervention can be self-administered and is therefore easily scalable.
75787691|NCT05117320|Device|AI support|Images were allocated to participants. In randomized allocation, one half of the images for each participant are viewed with AI support and the other half is viewed without AI support on the first trial day. On the second trial day the same images are viewed without versus with AI, respectively. This ensures that all images are read twice by the same participant both with and without AI support.
75923861|NCT03353012|Drug|Levonorgestrel Drug Implant|Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
75638817|NCT04645654|Behavioral|Hypnosis|Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
75638818|NCT04645550|Drug|Apixaban|From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
75923862|NCT02316756|Drug|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
75923863|NCT02316756|Drug|Placebo|Placebo which will be given as oral suspension
75923864|NCT03352856|Other|Barley starch|Highly purified barley starch
75923865|NCT03352856|Other|Maize starch|Maize starch
75923866|NCT05523232|Other|Vibration training with 42 Hz|Vibration exposure was given using a handheld vibration device.
75923867|NCT05523232|Other|Vibration training with 63 Hz|Vibration exposure was given using a handheld vibration device.
75923868|NCT04462614|Drug|Decrease per-dialytic heparin therapy|Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.
75923869|NCT03349580|Behavioral|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
76079787|NCT01159054|Drug|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
76079788|NCT04451694|Other|nutritional intervention|nutritional evaluation and intervention and orientation towards adapted care establishment
76079789|NCT01209442|Drug|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
75331231|NCT03371836|Drug|Clobazam|Clobazam is used as an adjunct medicine for all participants.
75787692|NCT00283439|Biological|AMG 531|"Planned Cohorts:~100 mcg,~300 mcg,~700 mcg,~1000 mcg;~Optional Cohorts:~cohort expansion,~schedule change,~new dose"
75923870|NCT05518552|Other|Manual lumbar traction|Patient in the group were treated with manual traction
75923871|NCT05518552|Other|Prone traction|Patient in the group were placed on prone traction
75923872|NCT02314494|Behavioral|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
75923873|NCT02316912|Drug|ATX2417|Randomised double blind parallel group ascending dose assessment
75638819|NCT04645550|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
75638820|NCT04645550|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
75638821|NCT04645550|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
75638822|NCT04645550|Drug|Low molecular weight heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
75638823|NCT04614233|Dietary Supplement|RiduZone (90% OEA)|Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA ) daily for 16 months
75638824|NCT04614233|Drug|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
75787693|NCT05114824|Behavioral|Mindfulness-Based Cognitive Therapy|The intervention is based on a mixed MBCT program with training in mindfulness strategies for 8 weeks. The adapted MBCT intervention will consist of eight weekly group sessions of 1 hour and 30 minutes, led by a certified instructor, to address the symptoms in the university population. In addition, complemented with the inclusion of audiovisual material, aimed at guiding self-applied daily exercises.
75923874|NCT02316912|Drug|Placebo|Randomised double blind parallel group ascending dose assessment
75923875|NCT03349424|Drug|Somatostatin|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
76079790|NCT01209442|Drug|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
76079791|NCT01209442|Radiation|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
76079792|NCT04451928|Diagnostic Test|Serum sample analysis|Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
76079793|NCT04452006|Drug|ACT-541478 10 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
75923876|NCT02314572|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
75638825|NCT04611802|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
75638826|NCT04611802|Other|Placebo (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
75787694|NCT03233230|Drug|M2591 25 mg QD|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
75923877|NCT04506710|Behavioral|Audio recording of the counseling conversation|The patient will have an audio-recorded counseling conversation. Audio recording will be carried out using a portable recorder ZOOM H2n. The audio recordings of the counseling conversations will be performed by the health workers selected to participate in the study.
75923878|NCT02572570|Device|Filtek Bulk Fill Posterior|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Bulk Fill Posterior). Procedures done using local anesthesia and following ordinary restorative techniques.
76079794|NCT04452006|Drug|ACT-541478 30 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
75923879|NCT02572570|Device|Filtek Supreme Ultra|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Supreme Ultra). Procedures done using local anesthesia and following ordinary restorative techniques.
75331232|NCT01078753|Drug|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
75638827|NCT04611802|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21
75638828|NCT04611802|Other|Placebo (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21
75787695|NCT03233230|Drug|M2951 75 mg QD|Participants received 75 mg of M2951 orally QD for 12 weeks.
75787696|NCT03233230|Drug|M2951 50 mg BID|Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
75787697|NCT03233230|Drug|Placebo|Participants received placebo matched to M2951 orally for 12 weeks.
75787698|NCT00283049|Drug|Insulin Glargine|Insulin glargine administered subcutaneously once daily.
75923880|NCT03122990|Procedure|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
75923881|NCT03122990|Procedure|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.Performed in 3 weeks time frame."
75923882|NCT03349346|Drug|Idelalisib|Tablet (s) or dispersible tablets for suspension administered orally twice daily
75923883|NCT03349346|Drug|Rituximab|375 mg/m^2 administered intravenously
75923884|NCT03349346|Drug|Ifosfamide|3 mg/m^2 administered intravenously
75923885|NCT03349346|Drug|Carboplatin|635 mg/m^2 administered intravenously
75923886|NCT03349346|Drug|Etoposide|100 mg/m^2 administered intravenously
75923887|NCT03502434|Drug|SM04755|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
75923888|NCT03502434|Other|Vehicle|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
75331233|NCT01078753|Drug|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
75331234|NCT03372382|Drug|Ibuprofen|NSAID
75923889|NCT03502434|Other|White Petrolatum|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
75923890|NCT03502434|Other|Sodium lauryl sulfate|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
76079795|NCT04452006|Drug|ACT-541478 100 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 50 mg.
75331235|NCT03372382|Drug|Acetaminophen|analgesic
75331236|NCT03372382|Drug|Norco|acetaminophen plus opioid
75331237|NCT03372928|Dietary Supplement|Standard EAA|EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation
75331238|NCT03372928|Dietary Supplement|High EAA|EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation
75331239|NCT03373162|Drug|onabotulinumtoxinA|This study is a pre- and post-design. One scan will be collected prior to BOTOX injection and the second will be collected 14-21 days post-injection. BOTOX injections will be limited to 20 units in the glabellar area, as approved by the FDA .
75638829|NCT04611802|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
75787699|NCT00283049|Drug|Insulin Glulisine|Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
76079796|NCT04452006|Drug|ACT-541478 300 mg|ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 50 mg and 250 mg.
76079797|NCT04452006|Drug|ACT-541478 1000 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 250 mg.
76079798|NCT04452006|Drug|ACT-541478 high or low dose (or placebo)|Cross-over design: ACT-541478 will be provided in HPMC capsules for oral administration at high or low dose strengths (to be defined after completion of Part A).
75331240|NCT03373240|Behavioral|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on cognitive-affective self-regulatory processes.
75470538|NCT02625610|Drug|Oxaliplatin|"Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
75331241|NCT03373240|Behavioral|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
75331242|NCT03374176|Drug|Amoxicillin 500 mg / Metronidazole 250 mg|Subjects were instructed to take a capsule three times a day for 7 days
75470539|NCT02625610|Drug|5-Fluorouracil|Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m^2 IV push on Day 1 and 2400 mg/m^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
75470540|NCT02625610|Drug|Leucovorin|"Induction Phase: Leucovorin was administered at a dose of 200 mg/m^2 IV (or) Leucovorin 400 mg/m^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
75470541|NCT02625610|Drug|Capecitabine|"Induction Phase: Capecitabine was administered at a dose of 1000 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
75638830|NCT04611802|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)|In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
75638831|NCT04601480|Behavioral|Choice Architecture Nudge|During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.
75787700|NCT04645108|Behavioral|Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
75787701|NCT04645108|Behavioral|Noom Healthy Weight; mobile behavior change program for weight loss|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity. During the first week of the study, participants will be introduced to the program, and the Noom app.
75787702|NCT00264875|Drug|pregabalin|75mg BID, titrated up to 300mg according to individual response and tolerability
75787703|NCT04897672|Other|Observational study|Observational study
75787704|NCT05069662|Other|Directive Interview|One directive interview conducted by telephone
75923891|NCT04302142|Device|ventilation with critical intracuff pressure (Pcr)|Once the intra-cuff pressure is measured and recorded, the cuff will be deflated by drawing the air 0.5ml per step with each step lasting 3 breaths until a leak, in which a 10% reduction in expiratory volume over the inspiratory tidal volume, is detected.Cuff will then be reinflated until the expiratory tidal volume reaches the inspiratory tidal volume and the discrepancy between the inspiratory and expiratory tidal volume is less than 10 percent. If the intra-cuff pressure applied by the anesthesia care team is inadequate and the discrepancy between the inspiratory and expiratory tidal volume is 10% or greater, the cuff will be further inflated with air 0.5ml per step with each step lasting 3 breaths until it reaches Pcr. This Pcr will be maintained during the entire anesthesia time until extubation.During the course of surgery, if any leak is detected, the cuff will be re-inflated by 0.5ml of air until the leak is not detectable.
75923892|NCT04302142|Device|ventilation with critical intracuff pressure (Pcr)|Pcr is obtained just as it is done in the intervention group. The cuff will then be reinsufflated to the actual cuff pressure the care team initially chose. The care team will be blinded to the measured critical cuff pressures and hence will maintain the usual level of intracuff pressure in the control group during the entire anesthesia time.
76079799|NCT04452006|Drug|ACT-541478 dose E1|E1 is a dose level that has been investigated and well tolerated in the adult dose level groups C1 to C3. ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 10, 50, and 250 mg.
75331243|NCT03374176|Drug|Clindamycin 300 mg|Subjects were instructed to take a capsule three times a day for 7 days
75331244|NCT03281200|Drug|L - Antineoplastic and immunomodulating agents|L - Antineoplastic and immunomodulating agents
75331245|NCT03281200|Drug|L01 - Antineoplastic agents|L01 - Antineoplastic agents
75331246|NCT03281200|Drug|L01X - Other antineoplastic agents|L01X - Other antineoplastic agents
75331247|NCT03281200|Drug|L01XE - Protein kinase inhibitors|L01XE - Protein kinase inhibitors
75331248|NCT03281200|Drug|L01XE31 - Nintedanib|L01XE31 - Nintedanib
75331249|NCT03514966|Behavioral|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
75638832|NCT04601480|Behavioral|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration & nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
75331250|NCT03520348|Drug|PRO-167|"Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic"
75787705|NCT03152110|Other|HIIT|"A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.~Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.~Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO."
75787706|NCT03635398|Device|Sipnose device|SipNose's intranasal drug delivery platform uses an innovative mechanism that is suposed to improves efficacy, patient compliance and safety
75787707|NCT03635398|Device|MAD (Mucosal Atomization Device)|MAD (Mucosal Atomization Device)
75787708|NCT03635398|Drug|midazolam|oral administration of midazolam
75787709|NCT04832074|Other|Dry Needling|Real Dry Needling in the most active Myofascial Trigger Point
75787710|NCT04832074|Other|Sham Dry Needling|Sham Dry Needling in the same location, but not piercing the skin
75331251|NCT03520348|Drug|Corneregel|Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
75331252|NCT03282682|Procedure|Strength training|The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
75331253|NCT03380026|Drug|Triamcinolone|Apply up to three times daily on select lesions.
75331254|NCT03380026|Drug|Valchlor 0.016 % Topical Gel|Apply valchlor nightly on select lesions.
75331255|NCT03380572|Device|Senhance Assisted Cholecystectomy|Cholecystectomy performed using Senhance surgical robotic system
75331256|NCT03380572|Procedure|Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy
75470542|NCT02625610|Other|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
75470543|NCT02625610|Drug|Oxaliplatin|Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
75787711|NCT04812652|Behavioral|Digitally distributed yoga|Yoga distributed through internet.
75787712|NCT03151408|Drug|Pracinostat|60 mg capsule
75787713|NCT03151408|Drug|Placebos|capsule
75787714|NCT03151408|Drug|Azacitidine|SC or IV injection
75787715|NCT05250232|Other|onlays conservative|Partial coverage of cusps with shoulder finish line
75787716|NCT05250232|Other|onlays conventional|all coverage of cusps as overlay with shoulder finish line
75923893|NCT02317068|Device|HBR|
75923894|NCT02317068|Device|DD|
75923895|NCT03352700|Drug|3L PEG|Group A patients (n = 300) used only 3L PEG before colonoscopy.
75923896|NCT03352700|Drug|3L PEG+Dyclonine Hydrochloride Mucilage|Patients in group B (n = 300) were additionally advised to Dyclonine Hydrochloride Mucilage plus 3 L PEG
75331257|NCT01079143|Drug|Certican®|Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
75638833|NCT04601428|Biological|IA therapy of HCC with CSR02-Fab-TF|Intra-Arterial Infusion of CSR02-Fab-TF
75638834|NCT04601233|Drug|XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector|Self injection testosterone treatment
75638835|NCT04592744|Drug|Angiotensin II|Angiotensin II infusion for Intraoperative management during liver transplantation
75638836|NCT04592744|Drug|Norepinephrine|Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
75638837|NCT04592237|Drug|Cabazitaxel|Given IV
75638838|NCT04592237|Drug|Carboplatin|Given IV
75923897|NCT05522998|Drug|Ciprofol|Ciprofol (0.4-0.5mg/kg) for anesthesia induction
75923898|NCT05522998|Drug|Propofol|propofol(2-2.5mg/kg) for anesthesia induction
75331258|NCT01079143|Drug|Neoral|Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
75470544|NCT02625610|Drug|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m^2 IV push on Day 1 and 2400 mg/m^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
75787717|NCT05226442|Drug|Argatroban|Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects
75787718|NCT05226442|Drug|Unfractionated heparin|Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism.
75638839|NCT04592237|Biological|Cetrelimab|Given IV
75638840|NCT04592237|Drug|Niraparib|Given PO
75638841|NCT04588285|Drug|Ambroxol|Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
75923899|NCT03349190|Drug|ULIPRISTAL ACETATE|Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)
75923900|NCT05528224|Other|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"OCD patients will take part in four structured online lessons for 6 weeks. Lesson one: Psychological Health Education, including the knowledge about OCD, SUDs and other related information.~Lesson two: Exposure and Response Prevention (ERP), including the knowledge about ERP, exposure item list and other related information.~Lesson three: Practice of Exposure and Response Prevention. Patients are asked to perform ERP practice based on what they have learned previously: practice at least once a day, a day about one hour all together. On this basis, in the main study, patients with severe obsessive and compulsive symptoms(Y-BOCS≥24) will be provided with extra therapist-guided ICBT: twice a week, about an hour one time. While in the pilot study, non-responders at week 3(YBOCS score reduction rate<25%) will be provided with extra therapist-guided ICBT.~Lesson four: Practice retrospection and relapse prevention."
75923901|NCT05528224|Other|Cognitive Behavioral Group Therapy (CBGT)|OCD patients will be asked to come to Shanghai Mental Health Center to take part in the offline CBT group. Each group will be treated for 6 weeks, twice a week for 2 hours each time. The treatment was supervised by an experienced CBGT therapist. The structure of the course basically corresponds with the SC-ICBT group.
75923902|NCT05528224|Drug|conventional medical treatment (TAU)|"In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual."
75923903|NCT03498534|Drug|Isoniazid 300Mg Tab|-TST tests will receive isoniazid 300Mg Tab for 6 months
75923904|NCT03498534|Drug|Isoniazid 300 MG|+ TST test will receive isoniazid 300MG Tab for 6 months
76079800|NCT04452006|Drug|Matching placebo|Matching placebo will be provided in HPMC capsules for oral administration.
75470545|NCT02625610|Drug|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m^2 IV (or) Leucovorin 400 mg/m^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
75470546|NCT02625610|Drug|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
75638842|NCT04588285|Drug|Placebo|Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
75638843|NCT04583826|Device|CAVA|CAVA is a medical device containing 5 face-mounted ECG electrodes which are used to record the movement of the eyes.
75923905|NCT03498534|Drug|Isoniazid 300 MG|HIV positive patient will receive isoniazid 300MGTab for 6 months
76079801|NCT01160380|Drug|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
76079802|NCT01160380|Drug|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
75638844|NCT04567160|Drug|Propofol|"In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.~After tracheal intubation, TCI of remifentanil is paused."
75638845|NCT04567160|Drug|Sevoflurane|In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.
75787719|NCT01316458|Drug|STI571 (Glivec®)|
75787720|NCT04391452|Dietary Supplement|Stress Resist® (oral dietary supplement)|Stress Resist® (dietary supplement) is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg). Oral supplementation. All subjects in the MAGRITTE study will receive either a dietary supplement or a placebo for 28 days (morning intake). The effects on stress will be studied both with questionnaires, biological samples (blood, urine and stool), with a Heart Rate Variability test. 40 subjects (20 subjects per group) will have an fMRI exam.
75787721|NCT01316536|Other|provide headphones with music playing|Participants will be provided with music through headphones
75787722|NCT01316536|Other|Sounds|recorded ICU sounds will be provided to participants through headphones
75787723|NCT05198128|Drug|Calcium intravenous infsuion|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
75787724|NCT05198128|Drug|0.9 % saline|0.9 % saline
75787725|NCT01316848|Drug|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
75331259|NCT01079143|Drug|Myfortic|"Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days."
75331260|NCT01079143|Drug|Simulect®|The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
75638846|NCT04564911|Combination Product|Flash Glucose Monitoring and Education|Participants will wear the flash glucose monitoring system, and receive an education package on how to self-manage their glucose levels. They will use the flash glucose monitoring system continuously for 6 weeks. From week 6 to week 24, the frequency of use of flash glucose monitoring will be reduced to one sensor every 4 weeks. They will receive education at weeks 0, 2, 8 and 16. They will also wear a blinded sensor for the last 2 weeks of the intervention period (week 25 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
75638847|NCT04564911|Combination Product|Capillary glucose monitoring and Education|Participants will use a capillary glucose meter and receive an education package on how to self-manage their glucose levels. Participants will be encouraged to test their blood glucose levels at least twice a day, but preferably 4 times daily: pre-meal and bedtime blood glucose levels. They will receive education at weeks 0, 2, 8 and 16. They will wear a blinded sensor again after the last 2 weeks of the intervention period (week 24 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
75923906|NCT02518178|Device|NFC Necklace|
75638848|NCT04549571|Other|Decision Aid iCanDecide - ESE website|Utilize the iCanDecide - ESE website
75787726|NCT02121184|Drug|Routine oxytocin|per regular oxytocin protocols
75923907|NCT02518178|Device|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
75923908|NCT02518178|Device|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
75923909|NCT03502356|Drug|Azithromycin|In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
75923910|NCT05518318|Drug|GLS-010|Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W
75470547|NCT02545660|Other|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
75638849|NCT04549571|Other|Decision Aid iCanDecide - S website|Utilize the iCanDecide - S website
75638850|NCT04549571|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75638851|NCT04549571|Other|Interview|Participate in interview
75638852|NCT04549571|Other|Training|Receive training
75638853|NCT04549571|Other|Media Intervention|Utilize the CDB
75638854|NCT04549571|Other|Best Practice|Utilize usual care
75787727|NCT02121184|Drug|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
75787728|NCT01485874|Drug|Doxil (Pegylated Liposomal Doxorubicin)|Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
75787729|NCT01485874|Drug|BIBF 1120|"Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle"
75787730|NCT05159128|Drug|JNJ-75105186|JNJ-75105186 will be administered orally in Part 1 and 2.
75638855|NCT04549571|Other|Survey Administration|Ancillary studies
75638856|NCT04549571|Other|Quality-of-Life Assessment|Ancillary studies
75638857|NCT04535011|Behavioral|PPKAY (brief intervention)|PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.
75787731|NCT05159128|Other|Placebo|Matching placebo to JNJ-75105186 will be administered orally in Parts 1 and 2.
75787732|NCT04786756|Drug|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
75787733|NCT00546754|Drug|losartan potassium (+) hydrochlorothiazide|losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
75923911|NCT05518318|Drug|Chemotherapy of Investigator's choice|Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
75923912|NCT04509518|Other|Exercise therapy program plus TENS therapy|All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
75470548|NCT02545660|Other|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
75331261|NCT01079143|Drug|Corticosteroids|An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
75470549|NCT02515591|Other|Bronchoalveolar Lavage validation study|Bronchoalveolar lavage involved the washing out of the right middle lobe of the lung of a healthy volunteer with 200mls of warmed normal saline with or without sedation.
75470550|NCT02514447|Drug|Trilaciclib|
75638858|NCT04535011|Behavioral|Standard Booster|After discharge from the hospital, a standard motivational text message will be sent to their cell phone twice monthly for the duration of the study. In a rotating fashion, one of four standard motivational texts translated into Swahili will be sent to their cell phones.
75638859|NCT04535011|Behavioral|Personalized Booster|After discharge from the hospital, a personalized motivational text message will be sent to participant cell phones twice monthly for the duration of the study. In a rotating fashion, one of four personalized motivational texts will be sent to their cell phones. Personalized texts will be created with the content obtained from the motivational interview sessions. At each session, the research nurse conducting the intervention will record four messages based on the content of the session to be sent as the Personalized Booster.
75470551|NCT02514447|Drug|Placebo|
75470552|NCT02514447|Drug|Topotecan|
75470553|NCT02257346|Drug|Lidocaine|Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.
75470554|NCT02257346|Drug|Normal Saline|Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
75923913|NCT05522920|Other|Therapy with and without spinal cord stimulation|Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.
75923914|NCT03498456|Drug|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
75923915|NCT03498456|Drug|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
75923916|NCT03352622|Other|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
75923917|NCT03352622|Other|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
75470555|NCT02167477|Device|Macintosh laryngoscopy|Tracheal intubation
75470556|NCT02167477|Device|Storz C-MAC, standard blade|Tracheal intubation
75470557|NCT02167477|Device|Storz C-MAC, D-BLADE|Tracheal intubation
75923918|NCT05518240|Device|Stent Retrievers|Procedure: Embotrap device
75470558|NCT02096393|Device|Zimmer Patient specific instruments|A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
75923919|NCT05518240|Device|Stent Retriever|Procedure: Solitaire device
75923920|NCT02317146|Drug|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
75923921|NCT04463238|Combination Product|Guided cartilage regeneration membrane|On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.
75923922|NCT04463238|Procedure|Microfracture|Operate in accordance with the clinical microfracture surgery method.
75923923|NCT04509830|Other|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator
75470559|NCT02096393|Device|Standard instrumentation|Standard instrumentation will be used during total knee replacement surgery.
75470560|NCT01785563|Device|Nasal NIV-NAVA|Infants will be placed on nasal NIV-NAVA. Patients initial NAVA level will be set to generate a peak inspiratory pressure that is 8 cm of water greater than their current peak end expiratory pressure. If the infants are on nasal NIV-NAVA at the time of study entry their NAVA level will be increased by 50% rounded up to the nearest 0.1 cm of water per microvolt.
75638860|NCT04530058|Drug|Metformin|Metformin 500 mg twice a day, administered orally or via gastric tube.
75923924|NCT04509830|Other|quadriceps strengthening, stretch hamstring,cuff muscles|multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch
76079803|NCT03071328|Drug|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
76079804|NCT03447600|Behavioral|Alternate Day Fasting|25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
75331262|NCT03381742|Drug|Ticagrelor|ticagrelor 45 mg twice daily for 5 consecutive days at least.
75638861|NCT04530058|Drug|Placebos|Placebo twice a day, administered orally or via gastric tube.
75638862|NCT04526236|Drug|Methadone Injectable Product|Perioperative use of placebo for pain management and remifentanil during the surgery.
75331263|NCT03381742|Drug|ticagrelor|ticagrelor 90 mg once daily for 5 consecutive days at least.
75331264|NCT03381742|Drug|ticagrelor|ticagrelor 90 mg twice daily for 5 consecutive days at least.
75331265|NCT03381742|Drug|clopidogrel|clopidogrel 75 mg once daily for 5 consecutive days at least.
76079805|NCT03447600|Behavioral|Continuous dietary restriction|25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
76079806|NCT03447444|Other|music and physical activity|This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
76079807|NCT04956042|Drug|Fosciclopirox|Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle
76079808|NCT04956042|Drug|Fosciclopirox + Cytarabine|"Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle"
76079809|NCT03442998|Other|Suburban walk|Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
75331266|NCT01079299|Device|Intermittent, gradient, pneumatic compression device|lymphedema pump provides external compression in a segmental,gradient fashion
75331267|NCT04735042|Drug|Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill|association between SGLT2-inhibitor and DPP4-inhibitor
75331268|NCT04735042|Drug|Empagliflozin or Dapagliflozin Pill|SGLT2-inhibitor: diabetic oral drug with diuretic properties.
75331269|NCT04734964|Behavioral|exercise training|Exercise training session for 45 minutes.
75331270|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
75331271|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
75331272|NCT04564807|Behavioral|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
75470561|NCT01595802|Device|Nautilus NeuroWave|"The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.~In this intervention, patients are recorded using the Nautilus Neurowave device."
75470562|NCT01595802|Device|Transcranial Doppler (TCD)|Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
75470563|NCT01480401|Other|low-sodium diet (1500 mg daily)|
75638864|NCT04521348|Drug|multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody|Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
75638865|NCT04505397|Drug|SKL24741|An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.
75638866|NCT04505397|Drug|Placebo|Sugar pill manufactured to mimic SKL24741
75638867|NCT04498377|Biological|F-652|IL-22 fusion protein administered intravenously
75638868|NCT04498377|Biological|Placebo|Placebo administered intravenously
75923925|NCT05528146|Dietary Supplement|Psyllium huks|psyllium in 250ml of water
75923926|NCT02317224|Procedure|"3-Hole subxiphorid and subcostal approach"|"3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection"
75923927|NCT02317224|Procedure|Trans sternal approach|Trans sternal approach anterior mediastinum tumor resection
75923928|NCT02317224|Procedure|VATS approach|Video-assisted thoracoscope anterior mediastinum tumor resection
75923929|NCT05528068|Behavioral|supervised lifestyle intervention|Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
75923930|NCT05528068|Behavioral|healthy lifestyle education|Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
75923931|NCT02518334|Other|Alcohol consumption|28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
75923932|NCT02317302|Device|FDG-PET/MR|
75923933|NCT02317302|Device|FDG-PET/CT|
75638869|NCT04497389|Biological|Human Amniotic Fluid|Patients will receive 10ml intravenous hAF each day for 5 consecutive days.
75638870|NCT04477486|Drug|Ibrutinib|Capsule; Oral
75638871|NCT04477486|Drug|Venetoclax|Tablet; Oral
75638872|NCT04475432|Drug|TP-03, 0.25%|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
75638873|NCT04475432|Drug|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
75638874|NCT04457596|Biological|Trastuzumab Emtansine|Given IV
75638875|NCT04457596|Drug|Placebo Administration|Given PO
75638876|NCT04457596|Drug|Tucatinib|Given PO
75787734|NCT00546754|Drug|Comparator: Valsartan (+) Hydrochlorothiazide|Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
75331273|NCT04564807|Behavioral|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
75331274|NCT00376090|Biological|MVA-CMDR|10^7 PFU IM, 1.0 mL
75470564|NCT01434290|Radiation|36.25 Gy IMRT|36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.
75923934|NCT05518084|Other|Liponovo tissue product|Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
75923935|NCT04503824|Diagnostic Test|saliva samples|Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.
75331275|NCT00376090|Biological|Placebo|1.0 mL IM
75331276|NCT00376090|Biological|MVA-CMDR|10^6 PFU ID, 0.1 mL
75331277|NCT00376090|Biological|Placebo|0.1 mL ID
75331278|NCT00376090|Biological|MVA-CMDR|10^8 PFU IM, 1.0 mL
75470565|NCT01434290|Radiation|51.6 Gy IMRT|51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.
75470566|NCT00788502|Behavioral|Healing Touch|
75638877|NCT04457596|Other|Questionnaire Administration|Ancillary studies
75923936|NCT05522686|Other|Patients in the Brochure Education Group|Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
75923937|NCT05522686|Other|Patients in the Video Education Group|Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
75923938|NCT05522686|Other|Patients in the Brochure-Supported Video Education Group|Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
76079810|NCT03442998|Other|Nature walk|Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
76079811|NCT01228084|Drug|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
75331279|NCT00376090|Biological|MVA-CMDR|10^7 PFD ID, 0.1 mL
75331280|NCT04521439|Diagnostic Test|18F-florbetapir PET+MRSI|PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.
75331281|NCT03530098|Device|BoneAgeModel|BoneAgeModel is an Artificial Intelligence tool that takes in a hand radiograph and gender, and outputs the skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
75470567|NCT00788502|Behavioral|Desensitization Therapy|
75470568|NCT00765791|Procedure|Selective Neck Dissection Excluding Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is not dissected.
75470569|NCT00765791|Procedure|Selective Neck Dissection Including Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is also dissected.
75470570|NCT00750269|Radiation|SBRT 40.0 Gy|SBRT delivered in 5 fractions of 8.0 Gy/fraction over 1.5 to 2 weeks for a total of 40.0 Gy
75470571|NCT00750269|Radiation|SBRT 42.5 Gy|SBRT delivered in 5 fractions of 8.5 Gy/fraction over 1.5 to 2 weeks for a total of 42.5 Gy
75638878|NCT04457596|Other|Quality-of-Life Assessment|Ancillary studies
75638879|NCT04455841|Drug|INCB000928|INCB000928 Dose Escalation
75638880|NCT04455841|Drug|ruxolitinib|INCB000928 +ruxolitinib Dose Expansion
75638881|NCT04425629|Drug|casirivimab+imdevimab combination therapy|Administered intravenously (IV) single dose
75638882|NCT04421261|Device|Air-Q Self Pressurized Airway Device with Blocker|used in low risk adult females undergoing elective surgeries
75638883|NCT04421261|Device|Proseal Laryngeal Mask Airway|used in low risk adult female patients undergoing elective surgeries
75787735|NCT04768426|Drug|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.
75787736|NCT04473508|Drug|Local administration of ropivacaine|Erector nerve block with local ropivacaine injection in addition with conventional anesthesia for spine surgery
75787737|NCT04473508|Drug|Local administration of placebo (saline solution)|injection of saline solution in addition with conventional anesthesia for spine surgery
75787738|NCT04471402|Drug|Precedex|Intranasal Precedex 3mcg/kg
75787739|NCT00282347|Drug|Rituximab|Rituximab was provided as a sterile solution for injection.
75787740|NCT00282347|Drug|Placebo|Placebo was provided as a sterile solution for injection.
75787741|NCT00282347|Drug|Mycophenolate mofetil|
75787742|NCT00282347|Drug|Methylprednisolone|
75638884|NCT04417959|Procedure|Phaco-DSAEK|The intervention will be performed as a DSAEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DSAEK.
75470572|NCT00750269|Radiation|SBRT 45.0 Gy|SBRT delivered in 5 fractions of 9.0 Gy/fraction over 1.5 to 2 weeks for a total of 45.0 Gy
75638885|NCT04417959|Procedure|Phaco-DMEK|The intervention will be performed as a DMEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DMEK.
75787743|NCT00282347|Drug|Diphenhydramine|
75923939|NCT05522686|Other|Control Group|Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
75638886|NCT04417218|Dietary Supplement|Lysine|Lysine is an essential amino acid which is acquired from dietary sources.
75331284|NCT03386110|Behavioral|Couples Health Project (CHP)|The CHP intervention focuses on addresses drug use and HIV transmission risk by enhancing dyadic communication skills and motivation to work towards shared health goals. The last session of the CHP intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
75331285|NCT03386110|Behavioral|Education|The Education intervention consists of a 3-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format with a male couple. Additionally, the last session of the education intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
75923940|NCT03352544|Behavioral|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week)
75331286|NCT01082575|Device|Oxygen Monitoring|No intervention
75470573|NCT00750269|Radiation|SBRT 47.5 Gy|SBRT delivered in 5 fractions of 9.5 Gy/fraction over 1.5 to 2 weeks for a total of 47.5 Gy
75470574|NCT00750269|Radiation|SBRT 50.0 Gy|SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
75638887|NCT04417218|Dietary Supplement|Controlled Diet|Individuals will be instructed to consume specific foods, to adhere to a controlled lysine diet.
75638888|NCT04388891|Device|Minimally supervised therapy with the ReHapticKnob|The therapy with the ReHapticKnob is performed in the clinic in addition to the conventional therapy. During the supervised and semi-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes. During the minimally supervised phase (third and fourth week), the duration of the ReHapticKnob therapy is not specified, since the patient can decide by him/herself when to use the device, e.g. during freetime or during the weekend.
75923941|NCT02317458|Biological|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
75331287|NCT03578926|Device|fanfilcon A toric lens|contact lens
75923942|NCT02317458|Biological|Sham comparator|One arm with standard of care undergoing a sham procedure
75923943|NCT05518006|Dietary Supplement|PreMama Balance|Premama Balance is a blend of the following: Vitex (Chasteberry Extract), commonly used to help regulate hormones; Antioxidants, Selenium, and Magnesium, also help support the cleansing of hormonal birth control from the liver and help strengthen the uterine lining.
75787744|NCT00282347|Drug|Acetaminophen|
75923944|NCT05518006|Dietary Supplement|Placebo Drink|Blended Placebo drink
75331288|NCT03578926|Device|senofilcon A toric lens|contact lens
75787745|NCT00282347|Drug|Prednisone|
75923945|NCT03349112|Behavioral|4% Lidocaine Spray|2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.
75923946|NCT03349112|Behavioral|2% Viscous Lidocaine|2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
75923947|NCT03501420|Other|Interview|A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
75923948|NCT03501420|Other|PSC questionnaire|All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
75923949|NCT03501420|Other|PRFs|PRFs will be completed by the physicians for seven of their consulting pSS subjects.
75331289|NCT03172273|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
75470575|NCT00750269|Radiation|SBRT 52.5 Gy|SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
75470576|NCT00750269|Radiation|SBRT 55.0 Gy|SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
75470577|NCT00750269|Radiation|SBRT 57.5 Gy|SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
76079812|NCT01228084|Other|Laboratory biomarker analysis|Correlative studies
75470578|NCT00750269|Radiation|SBRT 60.0 Gy|SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
75470579|NCT00712322|Drug|Darifenacin|Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.
75787746|NCT01334632|Procedure|Continuous interscalene block|The continuous interscalene block will be performed with ultrasound 30 minutes before the intervention.
75787747|NCT01334632|Procedure|PCA morphine|Postoperative with iv self-administration of morphine
75787748|NCT00405964|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
75787749|NCT00405964|Drug|Placebo tablet|Placebo tablet, once daily for 12 weeks
75787750|NCT04379206|Diagnostic Test|HIV self-test kit|fingerprick and oral fluid HIV self-tests with optional on-site or hotline staff assistance
75787751|NCT04379206|Other|Graphical User Interface|Gamification or neumorphism user interface
75787752|NCT00264797|Drug|Methylphenidate (OROS-MPH)|Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
75787753|NCT00264797|Drug|Methylphenidate (OROS-MPH) - Placebo|Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
75923950|NCT02320890|Device|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
75923951|NCT02320890|Device|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
75331290|NCT03172273|Procedure|paracentesis|paracentasis plus albumine invision
75638889|NCT04342000|Other|Movement education workshop|"30 minutes total:~10 minutes sedentary activity (LE injury risk factor and anatomy instruction)~10 minutes moderate activity (guided discovery of body segment alignment and stability with squat, lunge, plank, jump, and hop technique assessment and corrective feedback)~10 minutes vigorous activity (practical application of body segment alignment and stability including hopping, jumping, and running activities with technique assessment and corrective feedback)~For the month following the athlete workshop, prior to the final assessment, subjects will receive periodic text message instructions. These messages will include key facts and takeaways from the workshop, and reminders about correct form."
75787754|NCT03148756|Drug|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
75923952|NCT03352466|Biological|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine.
75331291|NCT01083199|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
76079813|NCT01228084|Other|Pharmacological study|Correlative studies
75331292|NCT03388294|Behavioral|Parents and Infants Engaged|A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
75331293|NCT02171611|Drug|Dabigatran etexilate pellets|
75331294|NCT02171611|Drug|Dabigatran etexilate powder|
75331295|NCT02171611|Drug|Dabigatran etexilate capsule|
75331296|NCT03389854|Device|RestoreX PTT - randomized and open label|Penile traction therapy in the straight and bent positions
75787755|NCT03148756|Drug|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
75787756|NCT00282113|Dietary Supplement|ProBioPlus|ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.
75923953|NCT03352466|Biological|BioThrax|Commercially available anthrax vaccine
75923954|NCT03352466|Other|Placebo|Normal saline
75923955|NCT02320968|Other|MedclineTM Sleep Assist Pillow|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
76079814|NCT03009994|Procedure|Repair of uterine incision|
76079815|NCT03009994|Procedure|Exteriorization of the uterus|
76079816|NCT03009994|Procedure|Non exteriorization of the uterus|
76079817|NCT03442920|Other|Exercise|This group made exercise for 12 week/3 times a week.
76079818|NCT03010696|Other|No interventions, questionnaire, collect specimen|
76079819|NCT04923984|Procedure|Embolization of the middle meningeal artery|embolization of the middle meningeal artery with an embolic agent.
75331297|NCT03389854|Device|RestoreX PTT - open label phase only|Penile traction therapy in the straight and bent positions
75331298|NCT01083667|Drug|Pyrimethamine|Open Label, dose escalating,
75331299|NCT01083901|Behavioral|Resistance training|high intensity progressive resistance exercise training
75331300|NCT03533374|Diagnostic Test|Electroencephalogram (EEG) and visual evaluation|Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).
75331301|NCT01083979|Drug|Liposomes|Intravesical instillation
75331302|NCT03585790|Device|Contact lens with Multifocal Optics|This contact lens has optics to aid the accommodative and convergence systems
75331303|NCT03585790|Device|Contact lens with Single Vision Optics|This contact lens has standard single vision optics
75331304|NCT00942305|Drug|Brincidofovir|Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.
75331305|NCT00942305|Drug|Placebo|"Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort."
75787757|NCT00282113|Dietary Supplement|Culturelle|Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.
75787758|NCT00282113|Other|Placebo|A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
76079820|NCT03447366|Diagnostic Test|mitral doppler|Mitral doppler before and after vascular filling
76079821|NCT01229410|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
76079822|NCT01229410|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
76079823|NCT02521740|Other|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
76079824|NCT01212172|Device|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
76079825|NCT01212172|Device|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
75923956|NCT05522608|Procedure|transabdominal preperitoneal hernia repair|It is made through 3 holes, 10 mm optical port from the umbilicus, and 5 mm ports each from the right and left lower quadrants. The peritoneum is opened a few cm above the defect in the form of an arc. Dissection of the peritoneum, first lateral and then medial to the defect, is performed. It is continued until the pubic bone is found medially and the periphery of the bone is released. The dissection of the cord elements and the sac is completed. Posterior dissection is a very important step to avoid recurrence. Here, the peritoneum is thoroughly dissected posteriorly, the ductus deferens and vessels are removed from the peritoneum so that no recurrence occurs under the patch. 1-2 to the pubic tubercle, 3-5 to the upper edge of the patch, to the upper edge. Staples at the upper edge should remain above the iliopubic tract, no staples should be placed below. The patch is closed by overlapping the peritoneal leaves so that the patch is not visible.
75638890|NCT04342000|Other|Sham Education Workshop|"30 minutes total:~10 minute sedentary activity (sleep, nutrition, and hydration instruction)~10 minutes moderate activity (performance of squat, lunge, plank, jump, and hop activities - no technique assessment or corrective feedback)~10 minutes vigorous activity (hopping, jumping, and running activities - no technique assessment and corrective feedback)"
75638891|NCT04317066|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
75331306|NCT01084759|Drug|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. > 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
75331307|NCT01084759|Drug|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
75923957|NCT05511350|Drug|TJ210001|
75923958|NCT03498222|Drug|Atezolizumab|Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).
75923959|NCT03498222|Drug|Pemetrexed|Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.
75923960|NCT03498222|Drug|Carboplatin|Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.
75923961|NCT03498222|Drug|ADI PEG20|Administered by intramuscular (IM) injection to patients once weekly.
75923962|NCT05522530|Other|Assessment scale|Evaluation scale to carry out its cross-cultural adaptation and study its validity
75331308|NCT03012997|Other|Fraction of inspired oxygen 40%|
75331309|NCT03012997|Other|Fraction of inspired oxygen 100%|
75331310|NCT01110187|Drug|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
75331311|NCT01110187|Drug|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
75331312|NCT04357223|Drug|extract from Angelica archangelica leaf|A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily
75331313|NCT04357223|Drug|Placebo|Placebo
75638892|NCT04314544|Drug|TILD|one 1 mL injection of study medication
75638893|NCT04314544|Drug|matching placebo injections|one 1 mL injection of placebo
75638894|NCT04314531|Drug|TILD|one 1 mL injection of study medication
75638895|NCT04314531|Drug|matching placebo injections|one 1 mL injection of placebo
75787759|NCT01343680|Drug|Heparin|5ml 10 units/ml IV heparin 3 times per week
75787760|NCT01343680|Drug|Normal saline|10ml normal saline IV weekly
75787761|NCT04502836|Behavioral|Preliminary psychological intervention|psychological intervention including providing knowledge and tools for problems solving according to the Choice - Agenda - Resilience - Emotional support (CARE) model . After intervention session patients and their parents will be asked to complete questionnaires
75638896|NCT04312932|Drug|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
75638897|NCT04312932|Dietary Supplement|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
75638898|NCT04292743|Biological|Eryaspase|intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg
75787762|NCT01343758|Other|5% dextrose in normal saline|Subjects will be randomized to receive a intravenous fluid bolus of 5% dextrose in normal saline or normal saline
75787763|NCT01343836|Other|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
75787764|NCT01343836|Other|Saline|Intratendinous saline injection with eccentric exercises
75787765|NCT00281957|Drug|sorafenib tosylate|Given orally
75470580|NCT00370604|Device|19g Tuohy-type epidural needle, 23g catheter|Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
76079826|NCT03442686|Behavioral|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
76079827|NCT03447054|Behavioral|Combined TDCS active and ICT active|Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
76079828|NCT03447054|Behavioral|Combined TDCS sham and ICT active|Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
75331314|NCT04357301|Device|Closed-loop vasopressor|The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients
75787766|NCT00281957|Drug|tipifarnib|Given orally
75923963|NCT02518022|Drug|Insulin|Insulin for beer
76079829|NCT03447054|Behavioral|Combined TDCS active and ICT inactive|Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
75331315|NCT03013231|Behavioral|Brief Resilience Scale|6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
76079830|NCT03447054|Behavioral|Combined Sham TDCS and inactive ICT|Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
76079831|NCT01160458|Drug|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
75331316|NCT04358939|Other|Prone decubitus|According to the tolerance, the objective is to spend as much time as possible, up to 16 hours and beyond in prone position every 24 hours. At least two sessions of at least 30 minutes each must be performed daily.
75331317|NCT04357145|Other|High Dosage Home Exercise Training|"By giving more exercise to the experimental group, exercise adherence, pain and functionality will be compared with the standard exercise group.~3 times more reputation than control~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~Hamstring stretching exercise~Terminal knee extension exercise~Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~Stepping exercise~Sit up and stand up without support~Active knee flexion exercise~Moving forward exercise"
75331318|NCT04357145|Other|Standard Dosage Home Exercise Training|"5-6 standard reputations for all exercises~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~Hamstring stretching exercise~Terminal knee extension exercise~Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~Stepping exercise~Sit up and stand up without support~Active knee flexion exercise~Moving forward exercise"
75470581|NCT00370604|Device|=> 18g Tuohy-type needle|Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
75638899|NCT04292743|Drug|FOLFIRINOX|intravenous administration of FOLFIRINOX
75638900|NCT04286555|Other|DASH4D diet|"DASH stands for Dietary Approaches to Stop Hypertension. The DASH diet is a healthy dieter that lowers blood pressure. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages. The DASH4D dietary pattern is a version of the DASH diet that is lower in carbohydrate."
75638901|NCT04286555|Other|comparison diet|The comparison dietary pattern is based on a typical American diet, with macronutrient distributions generally at the average of typical US intake, and micronutrient targets generally near the 25th percentile of usual US intake (with the exception of sodium).
75923964|NCT03352388|Dietary Supplement|Dairy- and berry-based snacks|High-protein dairy-based products and energy-enriched berry products for three months
75638902|NCT04286555|Other|higher sodium|3700 mg/day sodium
75638903|NCT04286555|Other|lower sodium|1500 mg/day sodium
75787767|NCT00281957|Drug|temsirolimus|Given IV
75787768|NCT01071161|Drug|azithromycin|azithromycin, tablets, during 12 weeks, three times a week, 250mg
75787769|NCT01071161|Drug|placebo|placebo
75923965|NCT03498144|Device|Anterior segment OCT|lower punctum examination by AS-OCT
75331319|NCT01110421|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
75470582|NCT00323856|Drug|Alphanate SD/HT|Plasma-derived preparation of Factor VIII
75470583|NCT05415150|Drug|Thrombolytic Agent|Subjects may receive one or more of the treatment options
75787770|NCT03975335|Behavioral|Health education|In this health education intervention, emphasis is given on evoking adolescents' internal desire to change, supporting self-efficacy to be changed, guiding self-regulatory ways along with facilitating desired changing process by empowering them with choices and skills.
75787771|NCT03975335|Other|Carrier Guidance|Carrier opportunities and counselling
75923968|NCT03497988|Drug|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
75923969|NCT03497988|Drug|Placebo|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
75923970|NCT04610476|Drug|Prednisolone|Prednisolone oral 1-5 mg/day
75923971|NCT04610476|Drug|Sulfasalazine|Sulfasalazine oral 2 x 1000 mg/day
75923972|NCT04610476|Drug|Leflunomide|Leflunomide oral 20 mg/day
75923973|NCT04610476|Drug|Methotrexate|Methotrexate oral > 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week
76079832|NCT03109704|Procedure|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
76079833|NCT03109704|Procedure|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
76079834|NCT03109704|Procedure|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
76079835|NCT01212484|Drug|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
75331320|NCT01110421|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
75331321|NCT01110421|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
75331322|NCT01110421|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
75331323|NCT01110421|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
75470584|NCT05414942|Behavioral|Opioid Reduction Program|Subjects will engage in a brief, educational session which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
75470585|NCT05414929|Diagnostic Test|HPV self-sampling|HPV self-sampling (Cobas Uniswab)
75638904|NCT04267939|Drug|Elimusertib (BAY1895344)|Elimusertib will be administered in 28-day cycles.
75638905|NCT04267939|Drug|Niraparib|Niraparib will be administered in 28-day cycles.
75638906|NCT04264403|Device|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
75638907|NCT04263285|Device|rTMS|The study team will deliver rTMS five days a week for four weeks, according to a specific and approved protocol for participant positioning, motor threshold determination, and dosing.
75638908|NCT04251819|Drug|Placebos|Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
75638909|NCT04251819|Drug|Baclofen 5 mg|Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
75638910|NCT04251819|Drug|Baclofen 10mg|Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
75923974|NCT04610476|Drug|Tofacitinib|Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day
75923975|NCT04610476|Drug|Apremilast|Apremilast oral 2 x 30 mg/day/1 x 30 mg/day
75638911|NCT04241341|Procedure|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
75638912|NCT04241341|Procedure|Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|Current standard treatment at Memorial Sloan Kettering [MSK]).
75923976|NCT04610476|Drug|Etanercept|Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week
75923977|NCT04610476|Drug|Adalimumab|Adalimumab s.c. 40 mg every 2 weeks
75923978|NCT04610476|Drug|Infliximab|Infliximab i.v. 5 mg/kg BW every 8 weeks
75923979|NCT04610476|Drug|Certolizumab pegol|Certolizumab pegol s.c. 1x 200 mg every 2 weeks/1x400 mg every 4 weeks
75923980|NCT04610476|Drug|Golimumab|Golimumab s.c. 1x 50 mg every 4 weeks
75923981|NCT04610476|Drug|Abatacept|Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks
75923982|NCT04610476|Drug|Secukinumab|Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks
75470586|NCT05414890|Diagnostic Test|CBA-TSA|Compare the specificity, sensitivity, and clinical correlation between CBA and CBA-TSA, in detecting AQP4, MOG, and NMDAR IgG
75923983|NCT04610476|Drug|Ixekizumab|Ixekizumab s.c. 1x 80 mg every 4 weeks
75923984|NCT04610476|Drug|Ustekinumab|Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks
75923985|NCT03348800|Procedure|Dental anesthesia|A tooth extraction will be performed
76079836|NCT01212484|Drug|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
76079837|NCT03446976|Biological|CT-P13 SC Auto-injector|Each subject may receive single dose by subcutaneous administration using Auto-Injector
76079838|NCT03446976|Biological|CT-P13 SC Pre-filled Syringe|Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
75923986|NCT03501342|Other|Virtual reality group|"Immersive virtual reality training protocol consisted of Football and Guillotine games."
75923987|NCT03501342|Other|Dynamic Balance Training|Dynamic balance training protocol consisted of holding the ball and running away from the ball with a physiotherapist.
75923988|NCT03352310|Biological|autologous umbilical cord blood (UCB)|autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth
75923989|NCT03352310|Procedure|standard care|standard care procedure to the newborn infants presence of HIE and/or anemia
75331324|NCT04356911|Other|PLACEBO (Negative Control)|"The group received in-office bleaching. A 45-minute application of 35% hydrogen peroxide gel (Whiteness HP, FGM, Joinville, SC) was carried. After whitening therapy, a water-soluble placebo gel (KY®, Johnson & Johnson, SP, Brazil) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the placebo gel for 20 seconds in each tooth surface. After washing the placebo gel, the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of low-level laser therapy (LLLT).~This protocol was performed in 3 sessions, with an interval of seven days between them."
75638913|NCT04241341|Other|quality-of-life questionnaires|Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
76079839|NCT03109548|Other|Standard care initiated by the general practitioner|Patients are treated based on their symptoms and the research group does not interfere with this.
76079840|NCT01212874|Drug|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
76079841|NCT01212874|Drug|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
75470587|NCT05414799|Other|figure eight vision exercise|figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.
75638914|NCT04241341|Other|measured by arm volume|Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
75787772|NCT03975413|Other|Fecal Microbiota Transplantation (FMT)|Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
75787773|NCT03974633|Combination Product|Injection|All information is included in the Arm/group descriptions
75787774|NCT01070225|Drug|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
75787775|NCT00281099|Device|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
75787776|NCT01070459|Behavioral|Aerobic exercise group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
75923990|NCT02314806|Drug|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
75923991|NCT02314806|Drug|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
75923992|NCT02314806|Drug|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
76079842|NCT03446898|Other|Chronic hypoxic environment|Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
76079843|NCT03442608|Procedure|Zoll 2000 and/or CureWrap 3500 cooling system|Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
76079844|NCT03446820|Other|hygro cotton sheets|hygro cotton sheets will be utilized to impact microclimate
76079845|NCT03446742|Other|Cardiovascular rehabilitation|The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
76079846|NCT03129438|Diagnostic Test|continuous EEG (cEEG)|differential use of continuous versus routine EEG
76079847|NCT03129438|Diagnostic Test|routine EEG (rEEG)|differential use of continuous versus routine EEG
76079848|NCT03442530|Behavioral|ToPIC|Expanded tobacco cessation counseling for pregnant women.
76079849|NCT03442530|Behavioral|Tobacco Treatment As Usual (TTAU)|Standard of care tobacco cessation counseling for pregnant women
75638915|NCT04237727|Device|Fluxmed GrH will be used to measure the ventilation parameters|The study will be a prospective descriptive multicenter study where measurement of ventilation data will be sampled during CPR by EMS treating patients with OHCA.
75923993|NCT04502654|Device|Actiwatch 2 (Philips Respironics, Murrysville, USA)|Actiwatch 2 is an unobtrusive, waterproof, light sensor and wrist-worn device (weight 16.0g, size 4.3 cm* 2.3 cm* 1.0 cm), containing a tri-axial accelerometer able to records a digitally integrated measure of gross motor activity (a piezoelectric sensor to detect vertical accelerations at the wrist between 0.5 and 2.0 g with a frequency response range between 0.35-7.5 Hz). Activity counts from the device reflect the peak acceleration detected over each epoch and are used in determining sleep and wake intervals, which can be used to rest-activity patterns, quality of physical activity and sleep for 15-60 seconds/ epoch, 24 hours/ day, 2 weeks.
75923994|NCT03501186|Other|Backward walking on sand|the patient will be walking backwards on sand with therapist standing close to support in case of fall.
75923995|NCT04506476|Device|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
75923996|NCT03497754|Device|Probefix|A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.
75923997|NCT02321124|Other|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
75923998|NCT02321124|Behavioral|life style advice|We will apply life style advice for four weeks.
75923999|NCT05522218|Device|Eluvia drug eluting stent|Eluvia drug eluting stent for peripheral arterial disease
75924000|NCT02321202|Drug|Omega-3 Fatty Acid-Based Parenteral Nutrition|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid [FA] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
75470588|NCT05414799|Other|chin nodding|chin nodding performed in sitting for keeping head placed straight over spine, place finger on chin and tuck-in the chin while head straight back until a stretch is felt at base of head.
75470589|NCT05414799|Other|neck stretching|"trapezius : neck flexion with opposite side bending and same side rotation for both sides.~sternocleidomastoid : neck extension with opposite side bending and same side rotation for both sides."
75638916|NCT04232969|Drug|Exenatide extended release 2mg (Bydureon)|Subcutaneous Injection
75924001|NCT02321202|Drug|Structolipid|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
75924002|NCT00709202|Drug|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..
75638917|NCT04232267|Device|MEB-001|Software medical device used to aid in the screening of patients with potential depressive burden symptoms.
75924003|NCT00709202|Drug|Placebo Oral Tablet|
75924004|NCT02314884|Drug|Cafusertib Hydrochloride|
75924005|NCT05517538|Device|Electromyography-Needle Intramuscular Drug guidance|EMG-guided needle neurotoxin injection
75924006|NCT05517538|Drug|Botulinum toxin type A|Botulinum toxin type A injection into the Corrugator Supercilii muscle
75924007|NCT02321280|Drug|Denosumab|Single dose subcutaneous administration
76079850|NCT03442452|Other|Electronic Decision Aid Tool|The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
75787777|NCT01070459|Behavioral|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
75787778|NCT01070459|Behavioral|Follow-up first aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
75638918|NCT04230148|Drug|Egaten (Triclabendazole) 250 mg tablets|Egaten 250 mg scored tablets for oral use.
75638919|NCT04228627|Drug|Parentral Iron|Correction of Iron stores without anaemia
76079851|NCT04900584|Other|Checklist|Checklist of guideline-based treatment before discharge
76079852|NCT04900584|Other|Education|Heart failure education before discharge
75787779|NCT01070459|Behavioral|Follow-up control group|No intervention will be offered in a period of 9 months after the passive mobilisation programme
75638920|NCT04209842|Device|gastric balloon|non surgical weight loss via placement of gastric balloon
75638921|NCT04197336|Device|Bariatric Embolization of Arteries with imaging visible Embolics|The BEATLES study is an investigator-initiated, prospective, doubleblind, randomized, sham-controlled study that will assess the impact of bariatric embolization on the systemic levels of obesity related hormones and, as a consequence, on weight loss. The goal of this study is to help treat obesity combining a lifestyle program and a minimally invasive, angiographic (i.e., through blood vessels) approach.
75638922|NCT04197336|Other|Control Arm|Participants randomized to the control arm will follow the same screening and pre-procedure assessment, and will also take the same pre-procedure medications. The procedural team instead will follow a prescribed simulated protocol that will mimic an actual embolization procedure.
75638923|NCT04153149|Drug|Vutrisiran|Vutrisiran 25 mg will be administered by SC injection q3M.
75638924|NCT04153149|Drug|Sterile Normal Saline (0.9% NaCl)|Sterile normal saline (0.9% NaCl) will be administered by SC injection q3M.
75924008|NCT03501108|Other|STOPPFrail deprescribing criteria|STOPPFrail is a recently validated set of explicit deprescribing criteria devised specifically for use in older patients with advanced physical and /or mental morbidity such that the 1-year survival prognosis is likely to be poor. STOPPFrail-defined medications that appear on the patient's medication list are highlighted to the attending physician for his/her consideration for deprescribing i.e. removal from the medication list immediately or gradually as appropriate.
75924009|NCT03348644|Dietary Supplement|Phosphate tablets.|
75924010|NCT03348644|Dietary Supplement|High cheese intake.|
75638925|NCT04150718|Behavioral|slow-wave disruption|A tone will be played through a speaker mounted over the bed that disrupts subjects while they are in slow-wave sleep. The tone will not be loud enough to wake up.
75924011|NCT03348644|Dietary Supplement|High milk intake.|
75924012|NCT03501030|Behavioral|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
75924013|NCT02317536|Dietary Supplement|Carnipure Product 1|
75924014|NCT02317536|Dietary Supplement|Carnipure Product 2|
75638926|NCT04134767|Behavioral|Health Linkage|Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.
75924015|NCT02317536|Other|Placebo|Placebo
76079853|NCT04900584|Other|Telephone monitoring|Telephone monitoring after discharge
76079854|NCT03442218|Drug|Clorhexidine|Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
76079855|NCT03442218|Drug|Saline solution|Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
76079856|NCT01859741|Drug|OMP-59R5|OMP-59R5 administered intravenously
75924016|NCT03352154|Diagnostic Test|P300 - Auditory long latency potential|Perform the P300 exams.
75924017|NCT02321358|Behavioral|Two-time implementation intention|Will be given intervention and booster at six weeks
75924018|NCT02321358|Behavioral|One-time implementation intention|Will only be given the intervention once
75924019|NCT02321358|Behavioral|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
75924020|NCT02321358|Behavioral|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
76079857|NCT01859741|Drug|Etoposide|administered intravenously
76079858|NCT01859741|Drug|Placebo|administered IV
76079859|NCT01859741|Drug|Cisplatin or Carboplatin|administered intravenously
76079860|NCT01212952|Drug|pomalidomide|Given orally
75924021|NCT05527366|Other|Vagus stimulation|The Vagus Stimulation Group received auricular vagus stimulation for a total of 15 sessions of 25 minutes 5 days a week. The patients were applied with vagustim device consisting of TENS device with electrodes placed bilaterally in the outer ear with headphones that can be selected according to ear size. During the application, the gel was used to avoid causing any damage and to ensure conductivity. It is placed so that tragus and konkaya are facing. The pulse duration of the TENS device is less than 500 microseconds, the frequency is 10 Herzt, the module was applied in TENS mode and in the form of a biphasic asymmetric wave.
75924022|NCT05527366|Other|Consevative treatment|A total of 15 sessions 5 days a week, 20 minutes of hotpack, 20 minutes of TENS, 5 minutes of 1,3 watt/cm2 ultrasound consisting of a total of 25 minutes of treatment was applied to the neck area.
76079861|NCT01212952|Drug|bortezomib|Given IV
75924023|NCT04502342|Combination Product|Hydroxycloroquine and Azythromycine|dual treatment with Hydroxycloroquine and Azythromycine
76079862|NCT01212952|Drug|dexamethasone|Given orally
75638927|NCT04134767|Behavioral|Overdose Education|Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
75638928|NCT04132050|Drug|R788|Oral administration
75638929|NCT04132050|Drug|Placebo|Oral administration
75924024|NCT04502342|Combination Product|Cospherunate/Azythromycine|dual treatment with Cospherunate and Azythromycine
75924025|NCT04502342|Combination Product|Cospherunate/Phytomedicine/Azythromycien|triple treatment with Cospherunate, Asen and Azythromycine
75924026|NCT02315040|Device|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
75924027|NCT02315040|Other|Standard Intrauterine Insemination|standard intrauterine insemination procedure
75924028|NCT04462848|Biological|anti-SARS-CoV-2 human convalescent plasma|Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.
76079863|NCT01212952|Other|laboratory biomarker analysis|Optional correlative studies
76079864|NCT01212952|Other|gene expression analysis|Optional correlative studies
76079865|NCT05161182|Other|High fat, low carbohydrate diet|Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
76079866|NCT05161182|Other|Low fat, high carbohydrate diet|Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
76079867|NCT04609865|Drug|Lidocaine 2%|the lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours, and then 0.6mg/kg/h for 14 days or until extubation.
75924029|NCT00709124|Device|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
76079868|NCT04609865|Drug|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
76079869|NCT04608695|Procedure|Ovarian puncture|One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.
75924030|NCT00709124|Device|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
76079870|NCT01229722|Device|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
76079871|NCT01229722|Device|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
75331325|NCT04356911|Other|FBM|This group received photobimodulation with low level laser therapy (LLLT) of infrared spectrum with a wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), at two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. The laser was applied in 3 sessions with a time interval of seven days between them.
75470590|NCT05414721|Drug|Low flow desflurane anesthesia (Group D)|When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air). Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
75470591|NCT05414695|Device|real acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud & Dragon Medical Device Co, Ltd, China. Needle penetrates the skin 4 mm
75470592|NCT05414695|Device|Placebo acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud & Dragon Medical Device Co, Ltd, China. Needle does not touch the skin.
75470593|NCT05414669|Drug|Allopurinol Tablet 300 mg|Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
75470594|NCT05414669|Drug|Control Group|Placebo was given orally for a total of 3 days, beginning a day before ESWL.
75470595|NCT05414656|Device|Saddle contoured metal matrix, Pre-contoured self-adhesive matrix|Saddle contoured metal matrix placed with the small clipper. The -contoured self-adhesive matrix has self adhesive ability.
75638930|NCT04115345|Biological|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
75924031|NCT05522062|Procedure|surgical treatment for humerus shaft fracture|surgical treatment for humerus shaft fracture
75787780|NCT01070459|Behavioral|Follow-up second aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
75924032|NCT03500952|Other|Birth Control After Pregnancy|A 27-page patient decision aid in portable document format (and an accompanying 3-page supporting document in portable document format) hosted online.
75924033|NCT03500952|Other|Postpartum Birth Control|A 4-page patient information leaflet in portable document format and text format hosted online.
75924034|NCT02315118|Drug|T-cell therapy + Rituximab + IL-2|"T cells collection~T cells expansion and modification in the laboratory~T cells infusion back to the patients"
75924035|NCT03500796|Procedure|Platelet rich plasma clot implantation|Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane
75470596|NCT05414643|Other|Standard care|No interventions were used, as this is an observational study.
75470597|NCT05414630|Drug|Envafolimab|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. The duration of treatment with Envafolimab should not exceed 2 years.
75470598|NCT05414539|Other|OptiCogs Online|A multicomponent intervention to rehabilitate cognitive deficits in people post-stroke
75470599|NCT05414279|Diagnostic Test|Sodium determination|Through a single finger prick 10 drops of capillary blood will be drawn. The venous blood sample will be taken through a standard venipuncture. Both samples will be send to the lab for indirect sodium determination
75638931|NCT04101565|Behavioral|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
75638932|NCT04096716|Drug|Tc-99m tilmanocept|Tc-99m tilmanocept is a radioactive diagnostic agent.
75638933|NCT04093427|Other|softSTOPP|Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end
75787781|NCT01070537|Device|Bonfils fiberscope intubation|
75787782|NCT01070615|Drug|Prucalopride|
75787783|NCT00262925|Biological|alemtuzumab|Given subcutaneously
75787784|NCT00262925|Drug|asparaginase|Given IM
75787785|NCT00262925|Drug|methotrexate|Given IV or orally
75787786|NCT00262925|Drug|dexamethasone|Given orally
75787787|NCT00262925|Drug|leucovorin calcium|Given IV
75787788|NCT00262925|Drug|mercaptopurine|Given orally
75787789|NCT00262925|Drug|vincristine|Given IV
75924036|NCT03500796|Procedure|Wound closure with amniotic membrane|Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
75924037|NCT05527288|Drug|Drug: [18F]florbetaben|All eligible patients will receive a single administration of the imaging agent [18F]florbetaben at a radioactive dose of 300 MBq.
75924038|NCT03497598|Drug|Mannose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
75924039|NCT03497598|Drug|Lactose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
75638934|NCT04092010|Behavioral|Problem-solving education (PSE)|PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
75924040|NCT05521750|Procedure|Transforaminal Percutaneous Endoscopic Lumbar Decompression|TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting
75638935|NCT04092010|Behavioral|Engagement sessions|Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
75638936|NCT04092010|Behavioral|Usual care|Normal services provided children and their mothers in Head Start
75638937|NCT04091022|Drug|Solaraze and Vaniqa|Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months
75924041|NCT03122756|Drug|Dexamethasone|Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.
75924042|NCT03122756|Other|Normal Saline|Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
76079872|NCT01859507|Drug|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
76079873|NCT01140594|Procedure|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
76079874|NCT01140594|Procedure|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
76079875|NCT03442140|Other|Harmonica playing|Patients will play the harmonica for up to 6 months
75638938|NCT04088799|Other|No intervention|No intervention
75638939|NCT04070287|Combination Product|SMART Pack|The SMART pack is a re-branded and repackaged box for HIV self-testing kits. The intervention aims to promote distribution of HIVST kits through in institutions, vocational centers, and social media platforms. The intervention would also include a referral systems, where participants provided with the HIV self-testing kits are provided with information with youth-friendly health facilities for uptake of testing for sexually transmitted infections. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the SMART pack and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Yaba local government area in Lagos state.
75787790|NCT01581515|Device|Promus Element everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
75787791|NCT01581515|Device|Xience Prime everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
75787792|NCT03720470|Drug|PF-04965842 100 mg|"PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows:~In the arm PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~In the arm Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 subjects take PF-04965842 100 mg from Week 16 to Week 20."
75924043|NCT03500718|Device|Cochlear implant|After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).
75924044|NCT03122678|Drug|Thiamine|
75924045|NCT03122678|Drug|Placebos|
75924046|NCT05521594|Procedure|Fine Needle Aspiration Cytology|Comparison between FNAC and post operative specimen after thyroid surgery
75924047|NCT04506398|Procedure|liver transplant|Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.
75924048|NCT04506398|Diagnostic Test|ctDNA|Circulating Tumor DNA Correlates With Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma
75924049|NCT04506398|Diagnostic Test|whole exome sequencing|xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.
75924050|NCT03348488|Procedure|Ultrafiltration dose|Fixed high volume of ultrafiltration over an hour during dialysis
75924051|NCT03502122|Other|VR rehabilitation for motor function|rehabilitation for motor function
75924052|NCT04503512|Procedure|removal of fat pad|Removal removal of fat pad
75924053|NCT04503512|Procedure|non removal of fat pad|non removal of fat pad
75924054|NCT02315274|Other|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
75924055|NCT02317770|Drug|Lidocaine Spray|5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
75924056|NCT02317770|Drug|Nebulized Lidocaine|The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
75924057|NCT03348410|Behavioral|Motivational interviewing|Motivational interviewing with insurance officer
75924058|NCT02317848|Other|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
75924059|NCT04506242|Drug|SHR-1210|PD-1
75924060|NCT04506242|Drug|Apatinib|VEGFR2
76079876|NCT04608227|Device|Clearsight monitoring|Non invasive hemodynamic monitoring using a finger cuff Cardiac ultrasound performed to calculate Velocity - Time - integral (VTI) Both intervention are performed before and after a passive leg raising challenge.
76079877|NCT03442062|Other|Assessment Feedback Incentives and eXchange|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
76079878|NCT03442062|Other|Physician-to-physician engagement|Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
76079879|NCT03442062|Other|Active Intervention Control|Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
75638940|NCT04070287|Combination Product|Luv Box|"The Luv box is packaged in two colors: blue and pink. The LUVBox would be made available in supermarkets, on-line stores, mini-marts, pharmacies, neighborhood stores and markets, for easy accessibility in hard to reach areas. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the Luv Box and the location where the pack can be obtained for individuals who are interested.For this pilot study, the intervention will be implemented in Yaba in Lagos state."
75638941|NCT04070287|Combination Product|Bili Vibes|The HIV self-testing kits will be available for interested individuals at the community youth events. These events and information the HIV self-testing kits will be on flyers that would be promoted at community centers and schools. For this pilot study, the intervention will be implemented in Ngenevu/Bunker communities in Enugu state.
75787793|NCT03720470|Drug|PF-04965842 200 mg|"PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows:~In the arm PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~In the arm Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842 subjects take PF-04965842 200 mg from Week 16 to Week 20."
75787794|NCT03720470|Drug|Dupilumab|Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.
75787795|NCT03720470|Drug|Oral Placebo|"Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16."
75787796|NCT03720470|Drug|Injectable Placebo|Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
75787797|NCT00262847|Biological|Bevacizumab|Given IV
75787798|NCT00262847|Drug|Carboplatin|Given IV
75787799|NCT00262847|Other|Laboratory Biomarker Analysis|Correlative studies
75924061|NCT05526898|Device|SyntrFuge System|Microsized Adipose Tissue
75924062|NCT05526898|Drug|Triamcinolone Injection|Corticosteroid
75924063|NCT02317926|Drug|Levothyroxine|
75331326|NCT04356911|Other|ESTRÔNCIO|After whitening therapy, a toothpaste with 10% strontium chloride (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. The desensitizer therapy was realized in 3 sessions with a time interval of seven days between them.
75331327|NCT04356911|Other|FBM+ESTRÔNCIO|After whitening therapy, a 10% strontium chloride toothpaste (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of whitened teeth with the help of a Microbrush applicator applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. After washing the desensitizer, the photobimodulation was realized with Low Level Laser Therapy (LLLT) of infrared spectrum with wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), in two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. This protocol was performed in 3 sessions, with an interval of seven days between them.
75331328|NCT04357067|Device|Lingual brackets|A type of bracket that applied lingual surface of teeth.
75331329|NCT04357067|Device|Labial brackets|A type of bracket that applied labial surface of teeth.
75924064|NCT02317926|Drug|Levothyroxine Plus Liothyronine|
75331330|NCT04358627|Drug|Dexmedetomidine Injectable Product|continuous intravenous infusion of dexmedetomidine
75787800|NCT00262847|Drug|Paclitaxel|Given IV
75787801|NCT00262847|Other|Placebo|Given IV
75787802|NCT00262847|Other|Quality-of-Life Assessment|Ancillary studies
75787803|NCT03803930|Device|Using 22G FNB, the first pass is SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
75787804|NCT03803930|Device|Using 22G FNB, the first pass is MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
75924065|NCT02317926|Drug|Desiccated Thyroid Extract|
76079880|NCT01876043|Drug|plitidepsin|"Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~Stage 1(17 participants): if <=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~Stage 2 (37 participants): if >= 11 non-progressions, Aplidin was considered promising."
76079881|NCT01875731|Behavioral|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
75787805|NCT03803930|Device|Using 20G FNB, the first pass is SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
75787806|NCT03803930|Device|Using 20G FNB, the first pass is MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.
76079882|NCT01875731|Behavioral|Guideline|Strategy based on enforced guideline guided antibiotic use
75638942|NCT04070287|Combination Product|BeterDoc|"The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the BeterDoc Safety Kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Ibadan, Dugbe and Agbowo in Oyo state."
75787807|NCT05329532|Biological|Modi-1/Modi-1v|Modi-1/Modi-1v administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
75787808|NCT05329532|Biological|Pembrolizumab|Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
75787809|NCT05329532|Device|MicronJet600™ microneedle device (NanoPass)|Intradermal injection device
75787810|NCT01303562|Other|Whole grain oats and barley|One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
75787811|NCT03803462|Other|Behçet's disease Overall Damage Index (BODI)|BODI is a tool to document any organ damage that has occurred in patients since the onset of BD. It includes a form and an associated glossary with the definition of the items.
75638943|NCT04070287|Combination Product|IUNGO|The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the HIV self-testing kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Akure South, Orita-Obele, Ipinsa, Ilara Mokin and Ijare in Ondo state.
75787812|NCT03814070|Procedure|Fiber-reinforced framework|Glass fiber- reinforced framework is to be picked up over the implant abutments to strengthen the full arch acrylic restorations
75787813|NCT03814070|Procedure|No framework|Non-reinforced acrylic full arch prosthesis is to be picked up directly over the implant abutments.
75787814|NCT01303640|Device|Biolimus-eluting stent|Biolimus-eluting stent
75787815|NCT01303640|Device|Everolimus-eluting stent|Everolimus-eluting stent
75924066|NCT05526820|Biological|The live attenuated varicella vaccine and the inactivated hepatitis A vaccine|"The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd,the inactivated hepatitis A vaccine was manufactured by Sinovac Biotech Co., Ltd.~The live attenuated varicella vaccine:live varicella-zoster virus in 0.5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection.~The inactivated hepatitis A vaccine:250 U inactivated virus in 0.5mL of aluminium hydroxide solution per injection.~All subjects received hepatitis A vaccine in the upper left arm and varicella vaccine in the upper right arm."
75924067|NCT02321592|Drug|AFM13|
75924068|NCT03352076|Drug|Vaginal Danazol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
75787816|NCT03817268|Drug|Capecitabine monotherapy|Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
75787817|NCT00280397|Drug|E7080|E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.
75787818|NCT03817112|Drug|Dexmedetomidine Hydrochloride 0.1 MG/ML|Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min
75787819|NCT03817112|Drug|Propofol 10 MG/ML|Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
75787820|NCT03816722|Device|Airvo2|Treatment with HighFlow through the Airvo2 device, 8 hours per day
75787821|NCT03816722|Other|Usual care|"High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients"
75924069|NCT03352076|Drug|Oral Danatrol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
75924070|NCT02321670|Procedure|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
75924071|NCT02321670|Procedure|Graft|Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
75924072|NCT05521282|Drug|Treatment group|Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
76079883|NCT03129204|Behavioral|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
75924073|NCT05311124|Device|Integra Dermal Regeneration template (IDRT)|Integra Dermal Regeneration Template is a two-layer skin regeneration system. The outer layer is made of a thin silicone film that acts as your skin's epidermis. It protects the wound from infection and controls both heat and moisture loss. The inner layer is constructed of a complex matrix of cross-linked fibers. This porous material acts as a scaffold for regenerating dermal skin cells, which enables the re-growth of a functional dermal layer of skin. Once dermal skin has regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
75787822|NCT05302934|Device|Pheno4U|Total Knee Arthroplasty represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or other indications resulting in joint destruction. In general, Implantation of a total knee prosthesis improves the quality of life through pain alleviation, deformity correction, joint stabilization, and/or functional range of motion (ROM) through restoration of normal knee kinematics and functionality
75924074|NCT03502044|Device|Inactive Kinetic Oscillation Stimulation (KOS)|10 minutes inactive KOS treatment in each nasal cavity.
75924075|NCT03502044|Device|Active Kinetic Oscillation Stimulation (KOS)|10 minutes active KOS treatment in each nasal cavity.
75924076|NCT03497442|Drug|Brimonidine Tartrate|Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.
75924077|NCT03497442|Drug|Placebo Vehicle Gel|Vehicle Gel
75924078|NCT05516602|Other|Peer Support|"Peer-led support groups over the weekend will include the following activities:~Peer leader counselling on oral PrEP and HIV risk reduction~Peer leader discussion to dispel myths and misconceptions around oral PrEP~Peer leader sharing of experiences of daily pill taking~Participants sharing experiences of influencers and barriers to oral PrEP uptake and adherence followed by a discussion by group members.~1-2 role plays per support group session."
75924079|NCT04503122|Procedure|pulmonary vein isolation|pulmonary vein isolation : cryoablation or radiofrequency
75924080|NCT02738580|Drug|COS with GnRH antagonists and rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
75924081|NCT02738580|Drug|COS with GnRH antagonists and HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
75924082|NCT03348332|Behavioral|Exercise pregnant women|A supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 10 to 39) was conducted. Each session consisted of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training. Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor during the training sessions to control the intensity.
76079884|NCT03441828|Procedure|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
76079885|NCT03441828|Drug|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
75638944|NCT04062552|Behavioral|Virtual Learning Collaborative|"Patients undergo a palliative care assessment, participate in up to 6 ENABLE telehealth sessions with an ENABLE coach (20-45 minutes each), and complete up to 6 monthly follow-up calls over a 26-week period.~The practice sites participate in a VLC consisting of group-based learning sessions, coaching, and applied quality improvement data collection, analysis and feedback opportunities monthly for up to 15 months."
75787823|NCT00262301|Drug|recombinant human C1 inhibitor|IV
75787824|NCT00262301|Drug|Placebo|IV
75787825|NCT03814148|Drug|LENINGRADO 5 association|1 coated sustained-release tablet, oral, once a day.
75787826|NCT03814148|Drug|Natrilix® SR|1 coated sustained-release tablet, oral, once a day.
76079886|NCT03441828|Drug|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
76079887|NCT03446430|Device|PWV measurement by LDV|PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
75638945|NCT04062552|Behavioral|Technical Assistance|"Patients undergo a palliative care assessment, participate in up to 6 ENABLE telehealth sessions with an ENABLE coach (20-45 minutes each), and complete up to 6 monthly follow-up calls over a 26-week period.~The practice sites undergo practice-based consultation calls with an ENABLE/TA expert monthly for up to 15 months."
75638946|NCT04031001|Device|No-React Non-valved Conduit|Operative replacement of infected graft or implantation in infected area.
75787827|NCT03814148|Other|Natrilix SR Placebo|1 coated sustained-release tablet, oral, once a day.
75787828|NCT03814148|Other|Leningrado 5 association Placebo|1 coated sustained-release tablet, oral, once a day.
75924083|NCT02318004|Other|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
75924084|NCT04505696|Other|Speech-Language Pathology Presentation|45 minutes presentation on Speech-Language Pathology introduction and scope Introduction to speech and language Introduction to a range of disorders The scope of practice
75924085|NCT05521204|Drug|Olverembatinib|Given PO
75924086|NCT03497364|Drug|bupivacaine|0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173~174cm, 1.65 ml for 170~172cm, 1.6 ml for 168~169cm, 1.55 ml for 165~167cm, 1.5 ml for 163~164cm, 1.45 ml for 160~162cm, 1.4 ml for 158~159cm, 1.35 ml for 155~157cm, 1.3 ml for 153~154cm, 1.25 ml for 150~152cm, 1.2 ml for 148~149cm)，1.15 ml for 145~147cm).
75924087|NCT03497364|Drug|ropivacaine|0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173~174cm, 2.225 ml for 170~172cm, 2.15 0ml for 168~169cm, 2.075 ml for 165~167cm, 2.000 ml for 163~164cm, 1.925 ml for 160~162cm, 1.850 ml for 158~159cm, 1.775 ml for 155~157cm, 1.700 ml for 153~154cm, 1.625 ml for 150~152cm, 1.55 0ml for 148~149cm, 1.475 ml for 145~147cm)
75924088|NCT03348254|Drug|Single shot antibiotic prophylaxis|single shot preoperative antibiotic prophylaxis
75924089|NCT03348254|Drug|Multiple shot antibiotic prophylaxis|Multiple shot perioperative antibiotic prophylaxis
75924090|NCT03348176|Other|Vegetable exposure|Repeated exposure to variety of vegetables
75924091|NCT03348176|Behavioral|VIPP-Feeding Infants|Promoting responsive feeding practices
75924092|NCT03348176|Other|Control|Phone calls with mother about development of child, no advice on complementary feeding
75924093|NCT02315508|Drug|AUT00063|800 mg orally, once a day, for 4 weeks
76079888|NCT04891614|Device|PRISM|Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
76079889|NCT01873859|Drug|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
75787829|NCT03816566|Device|patch|A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.
76079890|NCT03446274|Drug|Evenamide|This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.
76079891|NCT00493896|Drug|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
76079892|NCT00493896|Drug|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
76079893|NCT00388908|Behavioral|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
76079894|NCT00388908|Other|Usual Care|
75787830|NCT03801824|Other|Standard Nutrition Therapy|Subjects will be advised on standard diet appropriate for the management of Gestational Diabetes Mellitus (GDM) designed to be high in fiber and have moderate to high dietary glycemic index
75331331|NCT04356677|Drug|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
75787831|NCT03801824|Other|Low Glycemic Index|Subjects will be advised to eat low glycemic index foods
76079895|NCT04288674|Other|Retrospective data collection of demographics|Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.
75331332|NCT04356677|Drug|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
75638947|NCT04028063|Drug|doxorubicin with AGEN1884 and AGEN2034|The first cycle of treatment will consist of AGEN2034 and AGEN1884 alone. Beginning with Cycle 2, doxorubicin will be administered every 21 days for a maximum of 6 cycles (Cycles 2-7) with appropriate premedications and pegfilgrastim growth factor support. Doxorubicin will be administered as bolus infusion on day 1 with dexrazoxane cardioprotection. Patients must have central line access for this protocol, including pheresis or trifusion catheter, PICC line, or port. AGEN2034 will be administered every cycle (every 21 days) up to two years. AGEN1884 will be administered every other cycle (Cycle 1, 3, 5, and 7) with maximum of 4 infusions.
75638948|NCT04024462|Drug|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.
76079896|NCT04288674|Other|Retrospective data collection of underlying diseases|Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.
76079897|NCT04288674|Other|Retrospective data collection of duration of hospitalization|Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.
75331333|NCT04356833|Drug|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1|Patients in the cohort 1 rt-PA group will receive the first dose as soon as possible after registration. 10mg rt-PA in 5mL diluent will be administered by nebulisation every 6 hours for 14 days, resulting in a total daily dose of 40mg.
75787832|NCT03813914|Dietary Supplement|Sineos|glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
75787833|NCT01303718|Device|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
75787834|NCT01303718|Other|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
75787835|NCT03800888|Other|Daily SMS reminders for TB patients|Daily SMS Medication reminders will be sent to TB patients to remind them take their medications.
75787836|NCT03800888|Other|SMS Notifications for social supporters|SMS Notifications will be sent to social supporters to assit TB patients take their medication
75787837|NCT03800888|Other|Weekly SMS remiders|Weekly SMS reminders sent to TB patients to remind them take medication
75787838|NCT00279305|Drug|Anti-CD20 (rituximab)|
75924094|NCT02315508|Drug|Placebo|orally, once a day, for 4 weeks
75924095|NCT05516446|Device|DEB for de Novo Lesions|The surface of the SeQuent® Please NEO balloon is coated with Paclitaxel at a concentration of 3 μg Paclitaxel per mm² of balloon surface. The matrix composed of Paclitaxel and Iopromide (Paccocath technology) allows homogeneous release of the active ingredient through the vessel surface.
75924096|NCT05516446|Device|DES for de Novo Lesions|The latest generation DES : everolimus-eluting platinum-chromium alloy coronary stent system (Promus Premier, Promus Elite)
75924097|NCT02318082|Drug|Interleukin-2|
76079898|NCT04884438|Behavioral|Psychological intervention for the promotion of gratitude|"A brief intervention protocol has been developed for the promotion of gratitude. The protocol is manualized and the content will be explained to each participant in the videoconference sessions, and a copy of the manual will be given (or sent) to the patients at the end of the therapy sessions.~The structure and contents of the intervention are summarized below:~Psychoeducation about gratitude and its effects on health (both physical and psychological).~Gratitude towards life:~Gratitude walk~Three positive things~Sharing gratitude~Social gratitude:~Daily thanks to others~Gratitude letter~Proof of gratitude~Self-gratitude: this part includes an exercise aimed at fostering self-gratitude in three different areas:~Gratitude for the things I do to take care of my physical health.~Gratitude for what I do to take care of my mental health, my self-esteem and my personal development.~Gratitude for what I do to take care of others."
75331334|NCT04356833|Drug|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV|Patients on IMV will receive 60mg daily over three doses for 14 days
75787839|NCT00279305|Drug|Placebo Comparator|Placebo intravenous infusion
75787840|NCT03800810|Drug|Hyaluronic Acid|
75787841|NCT03800810|Biological|Umbilical Cord Mesenchymal Stem Cell|
76079899|NCT03450486|Other|exercise|one 30 minute bout of mild exercise
76079900|NCT03441672|Behavioral|Meaning of Screening|Interactive technology game providing education about prenatal screening and what the results may mean.
75638949|NCT04024462|Drug|Trastuzumab IV|Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
75924098|NCT04994470|Behavioral|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
75924099|NCT04994470|Behavioral|Two-week web-based text messages containing fun facts|"The web-based sham comparator consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham comparator, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
75470600|NCT05414266|Drug|Placebo|Placebo is acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
75638950|NCT04024462|Drug|Pertuzumab and Trastuzumab FDC SC|The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
75638951|NCT04024462|Drug|Doxorubicin|Doxorubicin 60 milligrams per meter squared of body surface area (mg/m^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
75638952|NCT04024462|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
75638953|NCT04024462|Drug|Docetaxel|Docetaxel 75 mg/m^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
75787842|NCT03800810|Biological|Recombinant Human Somatropin|
75787843|NCT01325909|Behavioral|Exercise programme|
76079901|NCT03449940|Procedure|Immediate repair|
76079902|NCT03449940|Procedure|Delayed repair|
76079903|NCT03449940|Drug|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
76079904|NCT03449940|Drug|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
76079905|NCT03449940|Drug|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
76079906|NCT03449862|Other|Simulation-based clinical decision on brain CT ordering|Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.
75638954|NCT04024462|Procedure|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
75638955|NCT04024462|Radiation|Post-Operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
75638956|NCT04024462|Drug|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
75638957|NCT03987581|Behavioral|Cognitive Behavioral Therapy (CBT)|Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
75638958|NCT03987581|Behavioral|Mobile Contingency Management (mCM)|Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
75787844|NCT03799796|Behavioral|Flash Glucose Monitoring with Online Peer Support|Hispanic Adults who are Spanish-Speaking with type 2 diabetes who are not using insulin will be asked to use flash glucose monitoring and to sign up for an moderated online peer support group where they can ask questions and share progress.
75638959|NCT03987581|Behavioral|Long-term incentive|This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
75787845|NCT01301378|Procedure|Molteno 3 glaucoma drainage shunt|Patients needing glaucoma drainage surgery
75787846|NCT05030402|Procedure|Maitland|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
75787847|NCT05030402|Procedure|Tens, exercise, SW|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
75787848|NCT05030402|Procedure|Conventional physiotherapy|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
75638960|NCT03978936|Behavioral|Medication Therapy Management (MTM) Video Telehealthcare|"MTM is an individualized approach to optimize medication use for improved patient outcomes and is designed to empower patients to take an active role in managing patients' medications thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up"
75638961|NCT03978936|Behavioral|Electronic Adherence Self-Management (EAM)|Participants will have a sensor which monitors their adherence to medication use
76079907|NCT04452240|Device|thoracic endovascular repair|Repair of thoracic aorta lesions with the application of a dedicatet stent-graft by endovascular way.
75331335|NCT04356833|Drug|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV|NIV patients will receive 60mg daily for over 3 doses for two days, followed by 12 days receiving 40mg daily over two doses.
75331336|NCT04664387|Diagnostic Test|coronary angiography|A coronary angiography is a test to find out if there is stenosis in coronary artery.
75638962|NCT03976349|Drug|BIIB094|Administered as specified in the treatment arm.
75638963|NCT03976349|Drug|Placebo|Administered as specified in the treatment arm.
75638964|NCT03964532|Drug|Talazoparib|Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
75638965|NCT03964532|Drug|Avelumab|Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
75787849|NCT03799640|Other|Standard Yoga|Yoga using standard poses and linear movements
75787850|NCT03799640|Other|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses.
75787851|NCT03799640|Other|Educational Control|Lectures on health and fitness
75787852|NCT00278993|Drug|E7389|Intravenous 1.4 mg/m2 on a 3-week course.
75787853|NCT03816800|Dietary Supplement|ImmunoBon|The dietary agent contains vitamin A, Zn, chelated iron and whey proteins.
75787854|NCT03816800|Dietary Supplement|Placebo|the dietary agent does not contain vitamin A, Zn, chelated iron and whey proteins
75924100|NCT02318160|Other|measurement of oxidant status in AIT|measurement of thyroid-stimulating hormone (TSH) and free thyroxin (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers
75924101|NCT02518100|Device|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
75331337|NCT04358783|Biological|Plasma|The plasma unit will be fractionated in 200 mL aliquots for storage at -80°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.
75638966|NCT03960580|Drug|OPN-375|OPN-375, BID
75638967|NCT03942783|Other|WORKWELL|Individualised, tailored work advice and work/vocational rehabilitation, including self-management and job modifications.
75638968|NCT03942783|Other|Control|Published arthritis work booklets;written guidance on work problem identification; potential actions
75638969|NCT03939169|Other|Installation of a naso-gastric feeding tube|Insertion of the feeding tube with skin-to-skin contact or whilst being held in the mother's arms, or by using the four hands technique or by performing positional support with appropriate equipment
75638970|NCT03934372|Drug|Ponatinib|Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
75787855|NCT03974867|Drug|Prednisone 5Mg Tab|"Glucocorticoids:~d1-d7: Oral Pred. 1mg/kg/d a (maximum daily dosage is no more than 60mg); d8-d9: Oral Pred. 10mg less than d7; d10-d11: Oral Pred. 10mg less than d9; d12: Oral Pred. 10mg less than d11; d13: Oral Pred. 10mg less than d12; d14: Oral Pred. 10mg less than d13;"
75787856|NCT03974867|Drug|Methylprednisolone 40 mg|"Glucocorticoids:~7 intratympanic injections of 40mg/ml Met. in 14 days, one injection every other day;"
75787857|NCT03816410|Procedure|LAA amputation|complete surgical amputation of the left atrial appendage
75787858|NCT03799406|Drug|Cholecalciferol|Therapeutic trial of vitamin D supplementation during acute episode of bronchiolitis
75787859|NCT03799406|Other|Placebo|Placebo supplementation during acute episode of bronchiolitis
75787860|NCT05270876|Device|Cochlear Implant and sound processor device fitting paradigm or diagnostic/measurement technique|Experimental: The investigational device will be a new device fitting paradigm or diagnostic/measurement technique implemented for use with the commercially available sound processor and implant.
75787861|NCT05270876|Device|Standard of care fitting or diagnostic measurement of Cochlear Implant and sound processor|The comparator will be the standard of care fitting or diagnostic or measurement approach.
75787862|NCT03799172|Drug|Echinocandin treatment|Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
75924102|NCT02518100|Device|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
75924103|NCT04301674|Device|Breath Biopsy|ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)
75924104|NCT03501888|Behavioral|Cognitive Behavior Therapy|18 sessions of individual treatment, no manual.
76079908|NCT03446196|Device|Fluid replacement based on MOSTCARE up|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
76079909|NCT03441516|Drug|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
75638971|NCT03929601|Drug|Rituximab-pvvr|All participants will receive Rituximab-pvvr dosing from Week 1 to Week 4 of the trial. Rituximab-pvvr will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart.
76079910|NCT03441516|Drug|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
75638972|NCT03929601|Drug|Abatacept|Participants in the active drug arm will receive initial Abatacept dosing at Week 16 of trial. Abatacept will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing be will determined according to weight: Up to 25 kg: 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL).
75638973|NCT03929601|Drug|Sterile Sodium Chloride|Participants in the placebo arm will receive initial placebo injection at Week 16 of trial. Saline Placebo will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing volume be will determined according to weight to match active comparator: Up to 25 kg: 0.4 mL; 25 to <50 kg receive 0.7 mL and > 50 kg receive 1.0 mL.
75787863|NCT03799172|Drug|Triazole treatment|"Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida."
75787864|NCT03799094|Drug|Vitamin C|Participants will receive intravenous vitamin C therapy at the indicated dose.
75787865|NCT03799094|Drug|Tyrosine kinase inhibitor|Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
75787866|NCT00277355|Drug|minocycline|Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (~ 8 hours apart)
75924105|NCT03501888|Behavioral|Acceptance and Commitment Therapy|18 sessions of group treatment, manual based.
75924106|NCT03347006|Dietary Supplement|SPM Active|"Supplement or placebo will be administered orally between 9 am to 9:30 am.~Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups [this will be on a 1:1:1:1:1:1:1:1 ratio]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval."
75787867|NCT00277355|Drug|Matching placebo|Matching placebo 1 capsule twice daily, 18 months treatment duration.
76079911|NCT03445962|Diagnostic Test|Assessment of OSAS predictive factors|"All subjects of the two groups realized the same assessment:~Anthropometric evaluation~biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~rest electrocardiogram~motor assessment (strenght, flexibility and balance)~actigraphy~Autonomic nervous system assessment during sleep~Autonomic nervous system assessment during head up tilt test before and after physical exercise~maximal treadmill test (VO2 max measure)~polysomnography~seismocardiography~questionnaires :sleep and physical activity"
75787868|NCT03799250|Drug|Ringer lactate|Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU
75787869|NCT03799250|Other|standard care|standard care
75787870|NCT03974399|Dietary Supplement|Bacopa Monnieri|subjects will take Bacopa Monnieri daily for 3 months
75787871|NCT00262223|Behavioral|Seeking Safety|Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
75924107|NCT03497286|Behavioral|Text-based mentorship|The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.
75924108|NCT03497286|Behavioral|Control text messaging|Control participants will receive periodic texts from NurturePA with information about child safety and health.
76079912|NCT03445884|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV.
76079913|NCT03449550|Other|Home Respiratory Polygraphy (HRP)|Randomizing to start with home respiratory polygraphy
76079914|NCT03449550|Other|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
76079915|NCT03449550|Other|Home Respiratory Polygraphy (HRP)|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
76079916|NCT03449550|Other|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
76079917|NCT03441438|Dietary Supplement|Water|Serum and urine markers will be obtained after drinking 5 oz of water
75331338|NCT04358783|Other|Best Available Therapy|It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.
75638974|NCT03896581|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
75638975|NCT03896581|Other|Placebo|Subjects will receive placebo at pre-specified time-points.
75638976|NCT03877497|Behavioral|Adapted SBIRT-T for transgender women|Transgender women will be screened for substance use. Those at moderate risk or less will be randomized into the study into either the intervention arm (SBIRT-A) or the control arm (CONTROL-C). Those at higher risk will be ineligible for the study and referred for substance use treatment services
75787872|NCT00262223|Drug|Sertraline|An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
75787873|NCT00262223|Drug|Pill placebo|
75787874|NCT05575700|Drug|Ibuprofen|400 mg tablet three times daily
75787875|NCT05575700|Drug|Placebo|tablet three times daily
75787876|NCT00276419|Drug|Diclofenac|Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
75787877|NCT00276419|Drug|Placebo|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
76079918|NCT03441438|Dietary Supplement|Red wine|Serum and urine markers will be obtained after drinking 5 oz of water
76079919|NCT03441438|Dietary Supplement|Polyphenolic Compounds|Serum and urine markers will be obtained after consuming 100 mg of provinols powder
76079920|NCT01857869|Biological|GSK257049 Dosage 1|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
75638977|NCT03868592|Procedure|Gastric sleeve/bariatric surgery|weight loss
75638978|NCT03855449|Behavioral|eDECIDE Web-based Intervention Group|"Will conduct 9 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention"
76079921|NCT01857869|Biological|GSK257049 Dosage 2|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
75638979|NCT03854903|Drug|Palbociclib|Palbociclib is taken orally.
75638980|NCT03854903|Drug|Bosutinib|Bosutinib is taken orally.
75787878|NCT03975569|Other|Probiotic vaginal gel|Total daily administration of 2.5 ml of probiotic gel, containing three lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus pentosus KCA1 and Lactobacillus plantarum WCFS1). Final dosage per gram of gel: 10^9-10^10 colony forming units of lactobacilli.
76079922|NCT01857869|Procedure|Sporozoite-infected mosquitoes challenge|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21)."
76079923|NCT01230424|Drug|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
75787879|NCT05569070|Other|Guided Young United Parents! Website Intervention|Participants assigned to Guided YUP! will receive two months of structured use of the YUP! website intervention, which involves weekly review of written and video content, meetings with near-peer mentors, use of the goal tool, interaction with the online community, and receipt of tips and affirmations.
75787880|NCT05569070|Other|Nutrition Website|Participants assigned to the Nutrition Website will be provided with the link to the MyPlate website, which is maintained by the U.S. Department of Agriculture. At the enrollment session, participants will be given brief instruction during the enrollment session about features available on the website that may be interesting to them and encouraged to engage in any of the website or app features at whatever level they are comfortable with. No further direction will be provided to them after the enrollment session.
75924109|NCT03348098|Drug|Apatinib|500 mg, po, qd. 12weeks
75924110|NCT03348098|Drug|Paclitaxel|drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
75924111|NCT02315742|Behavioral|Let's Move Program|Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
75924112|NCT02321826|Behavioral|Music|Participants choice among 4 genres of music matched on music characteristics
75470601|NCT05414266|Drug|SADBE 5%|SADBE 5% is a solution of 5% Squaric Acid Dibutyl Ester (SADBE) in acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
75638981|NCT03854903|Drug|Fulvestrant|Fulvestrant is given as an intramuscular injection.
75924113|NCT02321826|Behavioral|Audiobook|Participants choice among 4 types of audiobooks
75924114|NCT05526274|Diagnostic Test|Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)|VCTE with associated CAP is an effective, non-invasive and safe diagnostic method to estimate the degree of fibrosis and steatosis in the liver.
75924115|NCT03351920|Other|mechanical ventilation|All patients who need an invasive or non invasive mechanical ventilation, initiated in Prehospital or IntraHospital Emergency Department by an emergency Physician
75924116|NCT02318238|Other|6 minutes walking test|
75924117|NCT02318238|Other|6 minutes step test|
75924118|NCT02318238|Other|4 meters gait speed|
75924119|NCT04503356|Procedure|OMNI as a standalone procedure|It uses a single, self-sealing clear corneal incision with ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System as a standalone procedure.
76079924|NCT01230424|Drug|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
75638982|NCT03849443|Drug|Tranexamic Acid Injectable Product (1000 mg intravenous bolus)|Intravenous methods to decrease blood loss
75638983|NCT03849443|Drug|Vitamin C 250 MG Oral Tablet|Oral method of placebo
75638984|NCT03849443|Drug|Tranexamic Acid 650Mg Tablet|Oral method of treatment group
75638985|NCT03843359|Drug|GSK3745417|GSK3745417 will be administered.
75638986|NCT03843359|Drug|Dostarlimab|Dostarlimab will be administered.
75638987|NCT03827798|Drug|CFZ533|s.c.
75638988|NCT03827798|Drug|Placebo to CFZ533|s.c.
75638989|NCT03827798|Drug|LYS006|p.o.
75638990|NCT03827798|Drug|Placebo to LYS006|p.o.
75638991|NCT03827798|Drug|MAS825|s.c.
75638992|NCT03827798|Drug|Placebo to MAS825|s.c.
75638993|NCT03827798|Drug|LOU064 25mg|p.o.
75638994|NCT03827798|Drug|LOU064 100mg|p.o.
75638995|NCT03827798|Drug|Placebo to LOU064|p.o.
75638996|NCT03827798|Drug|VAY736|s.c.
75638997|NCT03827798|Drug|Placebo to VAY736|s.c.
75924120|NCT04503356|Procedure|OMNI combined with cataract surgery|Phacoemulsification with intraocular lens implantation is performed. Then, ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System.
75924121|NCT02318316|Other|Exhaled breath condensate|Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
75331339|NCT04358861|Procedure|Nonsurgical Root canal therapy|After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.
75638998|NCT03812653|Device|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
75638999|NCT03804996|Drug|TG-1801|Intravenous infusion over 1 hour every 4 weeks
75639000|NCT03804996|Biological|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks"
75639001|NCT03803202|Biological|ASP3772|Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly
75639002|NCT03803202|Biological|PCV13|Participants received a single dose of PCV13 intramuscularly.
75787881|NCT03813680|Other|Passive Vertebral Mobilization|Posteroanterior glides was given to cervical spine using Maitland method along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
75787882|NCT03813680|Other|PNF exercise|The subjects was given PNF exercises comprising PNF diagonal patterns for neck along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
75787883|NCT03813680|Other|Routine Physiotherapy|Thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
75787884|NCT03798548|Behavioral|Brief Bedside CBT|4 sessions of CBT including psychoeducation about TAVR and how mood can impact recovery in cardiac patients, discussion of patients' expectations and any concerns. Teaching and practice of cognitive restructuring and behavioral goal setting techniques for a healthy recovery.
75787885|NCT03798470|Behavioral|Peer Addiction Counseling|After identification, a 24/7 on-call FRC was paged and met with the patient in the ED. The patients were offered recovery services at the bedside by the FRC. The research team members offered voluntary participation and obtained informed consent to enrolling a longitudinal study looking into the success of his intervention. Patients did not need to participate to be eligible for counseling and resources from AVOR. The FRCs counselled and engaged the patient along with the family to offer a variety of services including active recovery coaching, group treatment modalities, family support services and transportation. After he initial encounter in the ED, the FAVOR team re-engaged the participant by phone or in person the next day and gradually increasing intervals thereafter.
75924122|NCT03346928|Procedure|Head and neck reconstruction|Head and neck free flap reconstruction
75787886|NCT03798392|Device|Self-pressurizing Air Q blocker mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
75787887|NCT03798392|Device|Baska mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
75787888|NCT03816020|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside capsules 250mg x 2 BID
75787889|NCT03816020|Other|Placebo|Placebo capsules BID
75787890|NCT03813758|Diagnostic Test|wrinkle test|soaking in 40 deg water for 40 min. every 10 min the hand will be photo
75470602|NCT05414253|Device|Parallel Assignment|Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
75639003|NCT03803202|Biological|PPSV23|Participants received a single dose of PPSV23 intramuscularly.
75639004|NCT03801720|Other|Ultrasound|Using ultrasound stimulation to induce micturition.
75639005|NCT03786224|Behavioral|Contingency Management|Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
75639006|NCT03737812|Drug|elezanumab|solution for infusion
75639007|NCT03737812|Drug|placebo|solution for infusion
75639008|NCT03727360|Other|Exercise Training|Supervised exercise conducted four days per week for six months.
75639009|NCT03727360|Other|Flexibility Control|Supervised exercise conducted four days per week for six months.
75639010|NCT03719859|Other|Physical Therapy|"Subjects who will participate in the physical therapy intervention group will attend therapy 4-6 days after discharge from the hospital, and continue in therapy approximately once a week for three months. The physical therapy progression will follow the standard of care developed at Duke Sports Medicine Physical Therapy for rehabilitation following RSA. Some of the patients in the PT intervention cohort may have physical therapy at an institution outside of Midwest Orthopaedics at Rush. All patients, whether in the Rush system or outside, will be given a prescription with the identical instructions for physical therapy, status post (R/L) reverse total shoulder arthroplasty, 1-2 x per week x 12 weeks."
75470603|NCT05414188|Behavioral|Pulmonary rehabilitation|Pulmonary rehabilitation runs for 60 minutes per session. The pulmonary rehabilitation program is based on a comprehensive approach, not simply providing regular exercise. And it includes patient education, active encouragement, and psychological support by investigators. Exercise is performed more than twice a week. Each session is performed for 60 minutes and includes breathing exercises, low to medium-intensity aerobic exercises, and muscle exercises under the guidance of a investigator. After radiation therapy is completed, investigators will recommend that patients perform pulmonary rehabilitation at home more than twice a week and for 60 minutes or more. The patients will record whether and when exercise is performed every day in the diary for pulmonary rehabilitation.
76079925|NCT02521428|Other|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
76079926|NCT01230502|Drug|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
75331340|NCT04358861|Device|Dental operating microscope|Dental operating microscope; a high magnification and illumination device was used in experimental group for performing nonsurgical root canal therapy.
75639011|NCT03719859|Other|Home Therapy|The surgeon/Nurse Practitioner/Physician Assistant will advance rehabilitation exercises and activity guidelines at customary scheduled postoperative appointments for this surgical procedure: 2 weeks (+/- 5 days), 6 weeks (+/- 1 week), 3 months and 6 months (+/- 1 month), and 1 and 2 years (+/- 2 months).
75787891|NCT03815864|Diagnostic Test|Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation|Anti-AT1R antibodies were tested on pre-transplantation sera using ELISA kit (Lot #30, One Lambda, Canoga Park, CA)
75331341|NCT04356521|Procedure|Lateral Sagittal Approach|The US probe will be located medial to the coracoid process in the sagittal plane in the infraclavicular region, and then three cords of the brachial plexus will be viewed. Using the in-plane technique, bupivacaine 0.5% will be administered around the posterior cord (7ml), lateral cord (7ml), and medial cord (6ml).
75470604|NCT05414149|Procedure|preoperative intravitreal injections of ranibizumab or conbercept|IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.
75639012|NCT03692325|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
75639013|NCT03673722|Other|Foods consistent with a MDP|We aim to increase MDP by 3 points, according to a 14-point MEDAS score
76079927|NCT01230502|Other|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
75639014|NCT03673722|Other|Physical Activity|We aim to increase PA to 150 minutes moderate activity per week.
75639015|NCT03673722|Other|Control|Participants will be given generic healthy eating advice based
75639016|NCT03662659|Biological|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
75787892|NCT03798236|Drug|PBF-1650 oral capsules|Adenosine A3 receptor (AA3R) antagonist
75787893|NCT03798236|Drug|Placebo oral capsule|solid microcrystalline cellulose
75787894|NCT03815942|Biological|ChAdOx1-MVA 5T4 vaccine|ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10^8 plaque forming units
75639017|NCT03662659|Biological|Nivolumab|Specified dose on specified days
75787895|NCT03815942|Drug|Nivolumab Infusion [Opdivo]|Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
75639018|NCT03662659|Drug|XELOX|Oxaliplatin + capecitabine
75639019|NCT03662659|Drug|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
75639020|NCT03662659|Drug|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
75639021|NCT03646123|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion
75787896|NCT03813602|Drug|Cannabis Sativa|750 mg cannabis cigarette with 12.5% THC
75924123|NCT02318394|Biological|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
75924124|NCT05516368|Behavioral|TF-CBT|Modular TF-CBT therapy programme of 16 weekly individual sessions, each lasting 60-90 minutes.
75924125|NCT03351842|Drug|cis Platinum/Carboplatin, Pemetrexed Disodium|Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours
75924126|NCT03351842|Procedure|Undergo surgery|Therapeutic conventional surgery, R0 resection
75331342|NCT04356521|Procedure|Costoclavicular Approach|The US probe will be placed parallel to the clavicle in the midclavicular area and tilted toward the cephalad and the axillary artery, and three cords will be viewed. A needle will be forwarded from lateral to medial with the in-plane technique, and 20 ml of bupivacaine 0.5% will be administered at the center of the three cords.
75639022|NCT03646123|Drug|doxorubicin|25 mg/m^2 by IV infusion
75639023|NCT03646123|Drug|vinblastine|6 mg/m^2 by IV infusion
75787897|NCT01303874|Drug|Etanercept (ETN)|ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
75924127|NCT02321904|Procedure|Corneal Confocal Microscopy|Close-up pictures of the front part of the eye (the cornea)
75787898|NCT01303874|Drug|Placebo|ETN-matching placebo SC injections once weekly and MTX orally once weekly.
76079928|NCT01230502|Other|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
75331343|NCT04356443|Device|AirGo Respiratory Monitor|AirGo™ is composed of a wearable, miniaturized recorder unit and a medical grade Holter worn over the floating ribs of patients both at rest and during normal activity. The recorder measures live circumference changes.
75639024|NCT03646123|Drug|dacarbazine|375 mg/m^2 by IV infusion
76079929|NCT03438240|Drug|Bupivacaine|patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%
75639025|NCT03646123|Drug|G-CSF|Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
75787899|NCT03798158|Other|Multidisciplinary Dyspnea Profile questionnaire|Multidisciplinary Dyspnea Profile questionnaire at the beginning and the end of an hospitalization
75787900|NCT03813056|Drug|Glanatec|Rho kinase Inhibitor
75787901|NCT03813056|Drug|Optive, Ophthalmic Solution|artificial tears (placebo)
75787902|NCT03813056|Procedure|Descemet Membrane Endothelial Keratoplasty|Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
75787903|NCT04093076|Drug|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
75787904|NCT04093076|Device|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.
75787905|NCT04093076|Drug|Placebo|Placebo will be administered ID on Day 0 and Week 4.
75787906|NCT01560494|Other|STAC curriculum|The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
75787907|NCT01301612|Drug|Nimotuzumab|Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
75331344|NCT05620277|Diagnostic Test|Mobile Dental Photography|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography
75331345|NCT05620277|Diagnostic Test|Mobile Dental Photography with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter
75331346|NCT05620277|Diagnostic Test|Mobile Dental Photography with gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a gray reference card
75639026|NCT03646123|Drug|nivolumab|240 mg by IV infusion
75787908|NCT01301612|Drug|Cisplatin|Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
75639027|NCT03642509|Device|Left atrial appendage occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
75639028|NCT03642509|Drug|NOAC|Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
75639029|NCT03641560|Drug|Enzalutamide|Enzalutamide will be administered orally
75639030|NCT03641560|Drug|Androgen deprivation therapy (ADT)|All participants will be required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
75787909|NCT01301612|Radiation|Brachytherapy|"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."
75787910|NCT01301612|Drug|Cisplatin|Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
75924128|NCT02321904|Procedure|Nerve Conduction Studies|The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
75924129|NCT02321904|Procedure|Quantitative sensory testing|Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
75924130|NCT02321904|Procedure|Neuropathy Symptom Score|A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
75639031|NCT03640481|Drug|Belumosudil (KD025)|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
75639032|NCT03635424|Device|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
75787911|NCT01301612|Radiation|Radiation Therapy|"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"
75787912|NCT03815630|Drug|pd-1 and dc-cik cells|Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
75787913|NCT03815786|Dietary Supplement|Symbiotic|2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout
75787914|NCT03815786|Dietary Supplement|Placebo|2-months oral administration of the placebo (2 bags/day) + 1 month washout
76079930|NCT03438240|Drug|Fentanyl|Plus 50 µg fentanyl
76079931|NCT03438240|Drug|Dexmedetomidine|Plus 50 µg dexmedetomidine
76079932|NCT01160848|Drug|Area cleaned with saline water and occluded with Tegaderm|
76079933|NCT01160848|Drug|Area cleaned with saline water|
76079934|NCT01160848|Drug|Area cleaned with Ethyl alcohol solution|
76079935|NCT01160848|Drug|Visonac left on the skin for 24 hours in facial area one|
76079936|NCT01160848|Drug|Visonac wiped off after one hour|
76079937|NCT01160848|Drug|Visonac left on the skin 24 hours in facial area two|
75331347|NCT05620277|Diagnostic Test|Mobile Dental Photography with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter and gray reference card
75470605|NCT05414045|Procedure|Autologous testicular tissue transplantation of prepubertal frozen testicular tissue|"Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells (SSCs).~If patient has a childwish on adult age and in case no spermatozoa are found in the ejaculate or after performing a testicular biopsy (TESE), we will perform autologous testicular tissue transplantation with the primary objective being to restore spermatogenesis and fertility."
75787915|NCT03813134|Procedure|Percutaneous coronary intervention (PCI)|Primary PCI or early/immediate PCI for NSTEMI will be undertaken according to recommended Guideline standards of care. This will include appropriate pre-loading with dual anti-platelet therapy, a preferred radial approach, intra-procedural anti-coagulation (with measure of ACT if considered appropriate every 30 minutes) and the use of drug eluting stents. Treatment will be delivered essentially to the culprit vessel only. A successful procedure will be one considered to have achieved TIMI 2-3 flow and residual stenosis < 50%. PCI failure will not be an exclusion itself from the trial.
75924131|NCT02321904|Procedure|Clinical nerve examination|Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
75470606|NCT05413993|Radiation|photobiomodulation|Laser application intraorals and extraoral points in the region of the salivary glands bilaterally
75470607|NCT05413967|Other|Mills manipulation in addition to myofasical release therapy|Group A will receive Mills manipulation in addition to myofasical release therapy as baselin
75924132|NCT05520970|Biological|AdCLD-CoV19-1|All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region
75924133|NCT02315820|Procedure|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
75924134|NCT04505306|Procedure|Macular Laser|All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.
76079938|NCT03445572|Other|Best Practice|Receive standard supportive care
76079939|NCT03445572|Procedure|Meditation Therapy|Perform MSB
75924135|NCT02571244|Behavioral|Motivational Interview plus text message|After discharge the experimental group has received extended care including a counseling session and text messages. The session provided basic information about smoking and successful quitting. The counselor has used motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The focus was to increase motivation to make quit attempt, including confidence building, medication use, and cessation planning. The session lasted approximately 30 minutes. Participants in the experimental arm were offered up to 30 text messages to help them to implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or those that had already quit have received 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages followed the self efficacy theory.
75639033|NCT03632356|Behavioral|Stepped Care Intervention (STEP)|A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
75639034|NCT03632356|Diagnostic Test|Screening only|Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
76079940|NCT03445572|Procedure|Meditation Therapy|Perform IK meditation
76079941|NCT03445572|Other|Questionnaire Administration|Ancillary studies
75470608|NCT05413967|Other|Nirschl exercises in addition to myofascial release therapy|Group B will receive Nirschl exercises in addition to myofascial release therapy as baseline
75470609|NCT05413954|Other|Control|Control group ate snacks composed of dried vegetables, one classical egg yolk and 2.3g of sunflower oil during 10 weeks
75639035|NCT03603808|Device|Electroporation|Undergo electroporation
75639036|NCT03603808|Biological|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|Given IM
75639037|NCT03603808|Other|Laboratory Biomarker Analysis|Correlative studies
76079942|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
76079943|NCT01213576|Drug|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
76079944|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
76079945|NCT01213576|Drug|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
76079946|NCT03445416|Behavioral|POL arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
75331348|NCT05620277|Diagnostic Test|Digital Camera|Tooth color changes of 30 patients will be evaluated using a Digital Camera
75331349|NCT05620277|Diagnostic Test|Digital Camera with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using a Digital Camera with cross-polarization filter
75639038|NCT03598790|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
75639039|NCT03581942|Drug|Ibrutinib|(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
75639040|NCT03581942|Drug|Copanlisib|(MTD) Copanlisib 60 mg weekly (3w on/1w off)
75639041|NCT03565367|Other|Gadolinium|gadolinium enhanced MRI
75639042|NCT03565367|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
75639043|NCT03565367|Procedure|Magnetic Resonance Imaging|Undergo MRI
75639044|NCT03565367|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
75639045|NCT03564691|Drug|MK-4830|MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
75787916|NCT03813134|Other|Pharmacological Support|Use of pharmacological agents (Norepinephrine, Dobutamine, Levosimendan) according to ESC Guidelines to maintain mean arterial pressure >75 mmHg in accordance with recognised standards of care. Changes in pharmacotherapy will NOT be regarded as escalation therapy. However the number of and dose of inotropes will be documented in the CRF.
75924136|NCT03497208|Procedure|Microneedling|The technique is about applying a dermaroller equipped with 0.25 mm needles over the vitiligo area.
76079947|NCT03445416|Behavioral|Comparison arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
76079948|NCT05088408|Dietary Supplement|Resource® Energy Apricot|"Bowel preparation as usual plus two bottles of Resource® Energy Apricot (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), with ingestion of one bottle of 200 mL of the dietary supplement at 08:00 and the other at 12:00, and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
76079949|NCT05088408|Other|Bowel preparation as usual.|"Bowel preparation as usual (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
75470610|NCT05413954|Other|Test|Tes group ate snacks composed of dried vegetables, one test egg yolk naturally enriched in rumenic acid, docosahexaenoic acid and punicic acid, 0.34g of pomegranate seed oil and 2.26g of olive oil during 10 weeks
75470611|NCT05413902|Drug|Toradol|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
75787917|NCT03813134|Device|VA-ECMO|"Following PCI of the culprit lesion, patients will have ECMO initiated as soon as echocardiography (to exclude mechanical causes) has been completed, once they have been assessed as having failed to improve (with the aim to start ECMO as early as possible from 30 mins after completed P-PCI procedure ad fully established within 6 hours after randomisation).~Peripheral Veno-arterial ECMO will be employed with a flow rate according to individual patient needs. Other methods of LV unloading, distal limb perfusion, maintenance of ejection/aortic valve opening and anti-coagulation will be instituted as per sites' usual care.~A minimum 24 hours be allocated to the randomised therapy in order that strategy failure is demonstrated but this will be at the physicians' discretion."
75787918|NCT03798002|Other|Neuro-muscular exercise training Group|"Training takes place 3 days a week for 8 weeks follow up, under the supervision of physical therapist A training session lasts for 40 minutes, and consists of three parts.~PART 1:Warming up:~warm-up period consists of ergometer cycling for 10 minutes~PART 2: Circuit program:~comprises four exercises, core stability/postural function; postural orientation; lower extremity muscle strength; and functional exercises. Each exercise is performed 2-3 sets 10-15 repetitions.~PART 3:Cooling down:~The cooling down part consists of walking exercises forward and backwards, about 10 meters in each direction, in front of mirror (mobility exercises for the lower extremity muscles for a total of about 10 minutes. Changes in patient's symptom assessed by structural questionnaire"
75924137|NCT03497208|Procedure|Cell suspension|The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.
75924138|NCT03497208|Radiation|Phototherapy|The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.
75470612|NCT05413902|Drug|Morphine|Provide the standard postoperative morphine dose for pain management as part of the traditional opioid-based pain management regime.
75639046|NCT03564691|Drug|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV Q3W.
75639047|NCT03564691|Drug|Carboplatin|Carboplatin will be administered IV Q3W.
75924139|NCT02447406|Drug|AZD6094|
75639048|NCT03564691|Drug|Pemetrexed|Pemetrexed will be administered IV Q3W.
75639049|NCT03564691|Drug|Lenvatinib|Lenvatinib will be administered orally once daily.
75639050|NCT03564691|Drug|Paclitaxel|Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).
75639051|NCT03564691|Drug|Cisplatin|Cisplatin will be administered IV Q3W.
75639052|NCT03564691|Biological|MK-4830A|MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.
75639053|NCT03561896|Radiation|IGRT|Image-Guided Radiation Therapy
75639054|NCT03561896|Radiation|SRS|stereotactic radiation therapy
75639055|NCT03554317|Drug|Testosterone cypionate|Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
75924140|NCT02447406|Drug|docetaxel|
75924141|NCT05584982|Device|AtbFinder|In the present study, we provided a prospective evaluation of the effectiveness of antibiotics selected with AtbFinder compared to a retrospective analysis of antibiotic efficacy selected with conventional culture-based antibiotic susceptibility tets in patients with cystic fibrosis
75639056|NCT03554317|Drug|Nivolumab|Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
76079950|NCT03010774|Behavioral|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
75787919|NCT03798002|Other|quadriceps training program|"Apply Tens (10min+ hot pack 7-10min) Before excercise ROM,Quadriceps and hamstring stretching exercise's and strengthening exercises.~4th-6th week (in addition): Straight leg raise, Quads over a roll, Hamstring curls. 7th and 8th week (in addition): Elastic band exercise, Hamstring curls, Quads chair, isometric strengthening All exercises are performed in set of 10 repetitions. 1 set of all exercises was twice a day for first 3 week, and 2 sets twice a day until 6th week and then 3 sets twice a day until 8th week"
75470613|NCT05413902|Drug|Orphenadrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
76079951|NCT03010774|Behavioral|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
76079952|NCT04452630|Other|Infectious Disease and Cardiology Clinical Consultations|Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
76079953|NCT04452318|Drug|REGN10933 + REGN10987|Subcutaneous (SC) or Intramuscular (IM) injections
75787920|NCT03813212|Device|MRI|Magnetic resonance imaging. Trans-abdominal sonography (TAS) and transvaginal sonography (TVS) will be performed using a 3.5 or 5 MHz transabdominal convex transducer and a 7 MHz trans-vaginal transducer.
76079954|NCT04452318|Drug|Placebo|SC or IM injections
76079955|NCT01161160|Biological|GSK Biologicals' GSK2340274A (two different formulations)|Intramuscular injection
76079956|NCT01161160|Biological|GSK Biologicals' - GSK2340272A|Intramuscular injection
76079957|NCT04621578|Device|HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)|"Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point."
76079958|NCT04573764|Dietary Supplement|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|"The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded."
76079959|NCT04573764|Dietary Supplement|Placebo|Taste-matched water
76079960|NCT04571190|Behavioral|Prenatal MBSR|Prenatal MBSR is an adaptation to the original MBSR program. The essential program elements characterizing MBSR is maintained and integrated with the particular context and specific needs of this group of pregnant women. Adaptations to the MBSR program draw upon both empirical data as well as existing research and theory.
76079961|NCT03010618|Other|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
76079962|NCT03438162|Behavioral|Education|Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
76079963|NCT03010852|Behavioral|Focused incentive spirometer education and monitoring|
76079964|NCT03438084|Dietary Supplement|Interesterified fat|50 g fat provided as commercially available interesterified fat.
75331350|NCT05620277|Diagnostic Test|Digital Camera with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a cross-polarization filter and gray reference card
75331351|NCT05620277|Diagnostic Test|Digital Camera with gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a gray reference card
75331352|NCT05620277|Diagnostic Test|Rayplicker|Tooth color changes of 30 patients will be evaluated using Rayplicker
75331353|NCT05620277|Diagnostic Test|Rayplicker with gray reference card|Tooth color changes of 30 patients will be evaluated using Rayplicker with gray reference card
75787921|NCT03812978|Other|Smart phone application|Smart phone application including exercise videos, push notifications for exercise, questions and answers, exercise diary.
75924142|NCT02315976|Drug|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
75924143|NCT03122210|Device|Automated oxygen administration|In the control group, usual oxygen administration and titration is planned
75924144|NCT02321982|Other|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
75331354|NCT05620277|Diagnostic Test|Vita Easyshade|Tooth color changes of 30 patients will be evaluated using Vita Easyshade
76079965|NCT03438084|Dietary Supplement|Non- interesterified fat|50 g fat provided as commercially available non-interesterified fat.
75639057|NCT03553095|Procedure|Periodontal Surgery|Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
75639058|NCT03529513|Diagnostic Test|Medibio Depression Diagnostic Aid|The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.
75787922|NCT01303952|Drug|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
75924145|NCT04505150|Behavioral|Lifestyle changes, e.g., take part in regular exercise, quitting smoking, and reduce salt consumption|Intervention participants will receive ongoing counselling with evidence-based information with pictures, fact sheets, published literature about the harmful effect of smoking on hypertension and other cardiovascular diseases for the cessation of smoking and to take part in regular exercise.
75924146|NCT02322060|Procedure|Ovariotomy|Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
75924147|NCT02322060|Procedure|Activate dormant follicles|Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
75924148|NCT02322060|Procedure|Ovary tissue transplantation|After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
75924149|NCT02322060|Procedure|Ovarian superficial cut|Superficial cut of the ovarian cortex by laparoscopy or laparotomy
75639059|NCT03529513|Diagnostic Test|Mini International Neuropsychiatric Interview|The Mini International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview that was developed as a simple tool to assist clinicians to conduct psychiatric diagnoses according to the DSM-IV and International Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10) criteria.
75639060|NCT03529513|Diagnostic Test|Hamilton Rating Scale for Depression - 17 Item|The clinician-administered Hamilton Depression Rating Scale (also known as the HAM-D) is the most widely used depression assessment scale . The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. There are numerous versions with varying lengths that include the HDRS21, HDRS24, and HDRS29. This study will utilize the HDRS17 (HAMD-17) version.
75787923|NCT04952714|Device|Oxiris|Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.
75924150|NCT04505228|Drug|Safflower (Carthamus Tinctorius) IgG4 &#X7C; Serum &#X7C; Allergy|The designed Chinese herb formulas
75924151|NCT04505228|Drug|Atropine Sulfate|The basic treatment for heart disease
76079966|NCT03438084|Dietary Supplement|Rapeseed oil|50 g fat provided as commercially available rapeseed oil.
76079967|NCT03438084|Dietary Supplement|Butter|50g fat provided as commercially available spreadable butter
76079968|NCT04807764|Combination Product|Standing transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation during standing followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
76079969|NCT04807764|Combination Product|Lying transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation while lying supine on a therapy table followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
76079970|NCT04807764|Other|Standing sham transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of sham transspinal stimulation during standing at an intensity where sensation is absent followed by 30 minutes of robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
75331355|NCT05620277|Diagnostic Test|Vita Easyshade with gray reference card|Tooth color changes of 30 patients will be evaluated using Vita Easyshade with a gray reference card
75787924|NCT03970616|Drug|Tivozanib|Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day
75639061|NCT03521596|Other|MRD and clonal evolution|Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques
75639062|NCT03513510|Behavioral|iChoose|
75787925|NCT03970616|Drug|Durvalumab|1500mg every 28 days
75924152|NCT02316054|Device|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
75924153|NCT02322138|Other|Experimental 1 Infant Formula|Ready to feed infant formula to be fed ad-libitum
76079971|NCT01161862|Device|Bi-hormonal (insulin and glucagon) artificial pancreas|Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
76079972|NCT01214356|Dietary Supplement|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
76079973|NCT01214356|Dietary Supplement|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
76079974|NCT01214824|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
76079975|NCT03437850|Other|Usual care|Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
75331356|NCT01110499|Drug|AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye once daily for 7 days.
75639063|NCT03505086|Diagnostic Test|Blood withdrawal|"Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure.~Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time.~Urine sampling will be for a maximum of 5 times per admission.~Urine can be sampled from a catheter when present, or collected regular."
75924154|NCT02322138|Other|Experimental 2 Infant Formula|Ready to feed infant formula to be fed ad-libitum
75639064|NCT03505086|Other|Questionnaire for former bleeding events|Questionnaire to investigate a bleeding tendency before diagnosis.
75787926|NCT01304030|Behavioral|Empathy Training Modules|The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.
75787927|NCT01304030|Behavioral|Residency Training as usual|Residents will receive their typical didactic and clinical education
75787928|NCT03815552|Device|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with diabetes for the operating life of the sensor.The System comprises a sensor and a transmitter. The small sensor will be subcutaneously inserted in the arm.The transmitter reads glucose data from the subcutaneous sensor.
75787929|NCT01301768|Other|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
75470614|NCT05413902|Drug|Gabapentin|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
75639065|NCT03454451|Drug|CPI-006|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.
75639066|NCT03454451|Drug|CPI-006 + ciforadenant|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.
75639067|NCT03454451|Drug|CPI-006 + pembrolizumab|Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.
75787930|NCT03812900|Drug|Echinacea purpurea alcoholic extract|Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
75924155|NCT02322138|Other|Reference Group|Breast fed ad libitum
75924156|NCT05584826|Drug|MDMA|On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (~84 mg MDMA) + 40 mg MDMA HCl (~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
75924157|NCT02318628|Device|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|"CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.~CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability."
76079976|NCT03437772|Behavioral|Mindfulness Cognitive Behavioral Therapy program|16 simultaneous-but-separate therapy sessions for parents and children.
76079977|NCT01214980|Device|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
76079978|NCT01214980|Other|Standard of care|Standard of care provided per site-specific protocol
75470615|NCT05413902|Drug|Acetaminophen|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
75639068|NCT03454451|Drug|CPI-006|Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.
75639069|NCT03454451|Drug|CPI-006 + ciforadenant|Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.
75639070|NCT03454451|Drug|CPI-006 + pembrolizumab|Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.
75639071|NCT03445481|Device|Medacta femoral prosthesis|patients' treatment with a new implant prosthesis
75639072|NCT03443687|Behavioral|Pelvic Floor Physical Therapy|Pelvic floor exercises for 3 months under instruction of physical therapist
75470616|NCT05413902|Drug|Bupivacaine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
75470617|NCT05413902|Drug|Epinephrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
75470618|NCT05413902|Drug|Xylocaine Injectable Solution|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
75639073|NCT03443687|Device|Home Biofeedback|Pelvic floor exercises for 3 months using biofeedback device
75639074|NCT03384654|Drug|Daratumumab|Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
75639075|NCT03384654|Drug|Vincristine|Participant will receive vincristine 1.5 milligram per meter square (mg/m^2) in cohort 1 and cohort 2.
75639076|NCT03384654|Drug|Prednisone|Participant will receive prednisone 40 mg/m^2 in cohort 1 and cohort 2.
75639077|NCT03384654|Drug|Doxorubicin|Participant will receive doxorubicin 60 mg/m^2 in cohort 2.
75639078|NCT03384654|Biological|Peg-asparaginase|Participant will receive peg-asparaginase 2500 units per meter square (U/m^2) in cohort 2.
75639079|NCT03384654|Drug|Cyclophosphamide|Participant will receive cyclophosphamide 1 gram per meter square (g/m^2) once in cohort 2.
75639080|NCT03384654|Drug|Cytarabine|Participant will receive cytarabine 75 mg/m^2 in cohort 2.
75639081|NCT03384654|Drug|6-mercaptopurine|Participant will receive 6-mercaptopurine 60 mg/m^2 orally daily in cohort 2.
75787931|NCT03815474|Drug|anlotinib|Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
75787932|NCT03797846|Procedure|combined glaucoma surgery|combined procedure with trabeculectomy and cataract removal
75787933|NCT01304108|Other|VTE-P Tollgate|Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
75787934|NCT01304108|Other|BLAZE Pop up|Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
75787935|NCT01304108|Other|Usual Care|No addition to the baseline system for care
75924158|NCT02324400|Device|RenaSense Stimulation|RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall
75924159|NCT02324400|Device|RenaSense Sham Control|RenaSense Catheter,no delivery of stimulation
75639082|NCT03384654|Drug|Methotrexate|Participant will receive methotrexate 5 g/m^2 intravenously (IV) in cohort 2.
75639083|NCT03379168|Device|Microfragmented Adipose Tissue (Lipogems)|Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.
75639084|NCT03379168|Drug|Corticosteroid injection|Cortisone is a standard of care injection to reduce joint inflammation.
75924160|NCT02573350|Drug|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
75924161|NCT02573350|Drug|OBR|Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
75639085|NCT03379168|Drug|Saline|Sterile saline injection will act as a placebo group.
75639086|NCT03375489|Other|Telehealth|"Teleconference meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
76079979|NCT03445338|Drug|K0706|Study
75639087|NCT03375489|Other|In-person PC|"In person meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
75639088|NCT03372057|Drug|Duvelisib|Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
75639089|NCT03372057|Drug|Duvelisib|Duvelisib PO 75 mg BID in 28-day cycles.
75787936|NCT01304186|Behavioral|Tailored Information|The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
75787937|NCT05644730|Device|Fusion closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
75787938|NCT03797768|Behavioral|Behavioural-FCHV Visit|Female Community Health Volunteer will visit selected households on average 3 times a year for providing health promotion messages on improving lung health status and avoiding risk factors to COPD.
75787939|NCT01302158|Drug|ASP1941|oral
75639090|NCT03372057|Drug|Duvelisib|Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase)
75639091|NCT03319940|Drug|Tarlatamab|Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
75787940|NCT01302158|Drug|Glimepiride|oral
75787941|NCT03812822|Device|Insole|Custom-made insoles which support the foot at subtalar neutral position
75924162|NCT02322294|Dietary Supplement|Glucodia™|
75924163|NCT02322294|Other|Placebo|
75924164|NCT02322372|Drug|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
75924165|NCT02322372|Drug|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
75639092|NCT03319940|Drug|Pembrolizumab|Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
75639093|NCT03319940|Drug|CRS Mitigation Strategies|Participants will be treated with one of the CRS mitigation strategies.
75639094|NCT03245320|Device|Integra TITAN™ Total Shoulder Generation 1.0|Total Shoulder Arthroplasty or Hemiarthroplasty
75787942|NCT03797612|Drug|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
75787943|NCT03797612|Drug|Placebo 6 mL|Single preoperative intrathecal injection
75787944|NCT03880292|Procedure|Document intraoperative Maneuvers|Monitoring procedure during surgery
75787945|NCT01302236|Drug|Eplerenone|50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
75787946|NCT03861806|Behavioral|PAS true|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
75787947|NCT03861806|Behavioral|PAS sham|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
75924166|NCT01376804|Drug|valganciclovir [Valcyte]|Oral, daily for up to 200 days.
75924167|NCT02322450|Drug|QGC001|
75924168|NCT02322450|Drug|Placebo|
76079980|NCT03445338|Drug|K0706|Study
76079981|NCT03445338|Drug|K0706|Study
76079982|NCT03445260|Other|Nutritional Supplements|PreCovery is a carbohydrate loading nutritional supplement, INergy FLD is an immunonutrition formulated liquid diet, and ISOlution is a protein supplement.
76079983|NCT03445260|Other|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
75787948|NCT03797534|Other|dose regime|The initial dose of the experimental group will be calculated by the Bayesian model.
75787949|NCT01304264|Device|Color Doppler Imaging|Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
76079984|NCT01232920|Drug|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
75331357|NCT01110499|Drug|AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye once daily for 7 days.
75787950|NCT03797300|Device|Spry Loop Band|Loop band measures pulse oximetry and respiration rate
75924169|NCT03500250|Other|Post-Stroke Depression toolkit|The Post-Stroke Depression toolkit consists of three components: (1) two screening instruments, (2) seven evidence-based nursing interventions, and (3) an instruction manual.
75924170|NCT05526118|Drug|Bictegravir/emtricitabine/tenofovir alafenamide|Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
75924171|NCT02324478|Procedure|autonomic nervous system analysis|electrocardiographic and pulse-photoplethysmographic waves of patients under general anesthesia for laparoscopic cholecystectomy will be recorded on a laptop pc for offline analysis of autonomic nervous system modulation a three main time point: 1) at baseline, before general anesthesia induction, 2) five min after tracheal tube placement, 3) five min after pneumoperitoneum insufflation.
75924172|NCT03122132|Drug|ombitasvir/paritaprevir/ritonavir 8 weeks|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks
75924173|NCT03122132|Drug|dasabuvir 8 weeks|Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
75924174|NCT04461912|Device|Eye Scan Ultrasound System (ESUS)|"• For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved."
75924175|NCT03351686|Drug|Tranexamic Acid|Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
75787951|NCT01304342|Drug|Remifentanil|1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
75924176|NCT03347942|Behavioral|Intervention group|Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.
75924177|NCT03347942|Other|Control group|The control group will also serve the dish of the form, but can serve additional portion without waiting.
76079985|NCT01232920|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
76079986|NCT03445182|Procedure|Local anaesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anaesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
75331358|NCT01110499|Drug|AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye once daily for 7 days.
75331359|NCT01110499|Drug|AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye once daily for 7 days.
75924178|NCT04461990|Procedure|Multidisciplinary cooperative comprehensive treatment|Local surgery, radiation therapy, and systemic therapy such as chemotherapy, endocrine and molecular targeting.
75924179|NCT02318862|Procedure|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
75924180|NCT03347864|Drug|68Ga-NOTA-RM26|1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
75787952|NCT01304342|Drug|Fentanyl|Intranasal fentanyl 200 micrograms 5 min before the ERCP
75924181|NCT03494400|Other|Aerobic Training Presential|The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days, more follow-up.
75331360|NCT01110499|Drug|AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye once daily for 7 days.
75787953|NCT01304342|Drug|Normal saline|Normal saline intravenously and intranasally
75787954|NCT01560026|Procedure|surgery|endometrial cancer with or without oophorectomy
75924182|NCT03494400|Other|Aerobic Training Home-based|The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities, more follow-up.
75924183|NCT04503200|Procedure|Double guidewire|After the 3rd passage of the guidewire into the pancreatic duct, the catheter will be removed leaving the guidewire in place. The catheter will be re-inserted and a second guidewire will be used and directed above the pancreatic wire in the 11-12 o'clock direction to attempt cannulation of the common bile duct.
75639095|NCT03231306|Drug|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
75787955|NCT03815318|Drug|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
75924184|NCT04503200|Procedure|Transpancreatic precut|After the 3rd passage of the guidewire unintentionally into the pancreatic duct, the guidewire will be left in the pancreatic duct, a sphincterotome will be used to cut in the direction of 11-12 o'clock attempting to deroof the pancreatic duct and gain access into the common bile duct. The wire will then be retracted and reinserted in the direction of the cut to attempt cannulation of the common bile duct.
75639096|NCT03219268|Biological|tebotelimab 1 mg|1 mg IV every other week
75639097|NCT03219268|Biological|tebotelimab 3 mg|3 mg IV every other week
75639098|NCT03219268|Biological|tebotelimab 10 mg|10 mg IV every other week
75639099|NCT03219268|Biological|tebotelimab 30 mg|30 mg IV every other week
75639100|NCT03219268|Biological|tebotelimab 120 mg|120 mg IV every other week
75639101|NCT03219268|Biological|tebotelimab 300 mg|300 mg IV every other wee
75639102|NCT03219268|Biological|tebotelimab 400 mg|400 mg IV every other wee
75639103|NCT03219268|Biological|tebotelimab 600 mg|600 mg IV every other week
75639104|NCT03219268|Biological|tebotelimab 800 mg|800 mg IV every other week
75639105|NCT03219268|Biological|tebotelimab 1200 mg|1200 mg IV every other week
75924185|NCT02319018|Drug|Alisertib|Given PO
75924186|NCT02319018|Drug|Fluorouracil|Given IV
75331361|NCT01110499|Drug|AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye once daily for 7 days.
75331362|NCT01110499|Drug|AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
75331363|NCT01110499|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
75331364|NCT04358471|Biological|Intravitreal AAVCAGsCD59|AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye
75787956|NCT03815084|Drug|pd-1 and DC-NK cells|total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
75787957|NCT03812744|Drug|Whole coffee cherry extract (WCCE)|100mg WCCE
75787958|NCT03812744|Drug|Placebo Oral Capsule [CEBOCAP]|Silica Oxide
75787959|NCT03653546|Drug|AZD3759|AZD3759 200mg PO BID.
75787960|NCT03653546|Drug|Erlotinib|SoC EGFRTKI Erlotinib 150 mg PO Q.D
75787961|NCT03653546|Drug|Gefitinib|SoC EGFRTKI Gefitinib 250 mg PO Q.D
75924187|NCT02319018|Other|Laboratory Biomarker Analysis|Correlative studies
75331365|NCT04358471|Other|Intravitreal Sham Injection|Sham injection mimics a real injection in the enrolled eye
75470619|NCT05413902|Drug|Methylprednisolone|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
75639106|NCT03219268|Biological|margetuximab|15 mg/kg IV every 3 weeks
75639107|NCT03153202|Drug|Ibrutinib|once daily oral intake ibrutinib
75639108|NCT03153202|Drug|Pembrolizumab|200mg IV pembrolizumab on Day 1 of each cycle
75639109|NCT03146754|Other|Methodology|No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
75639110|NCT03108131|Drug|Atezolizumab|Given IV
75639111|NCT03108131|Drug|Cobimetinib|Given PO
75639112|NCT03088878|Drug|Cirmtuzumab (2-16 kg/mg) plus Ibrutinib|Participants will receive escalating doses of cirmtuzumab (2-16 mg/kg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily, starting at week 4.
75639113|NCT03088878|Drug|Cirmtuzumab (300mg) plus Ibrutinib|Participants will receive cirmtuzumab (300 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
75639114|NCT03088878|Drug|Cirmtuzumab (600 mg) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
75787962|NCT05143190|Drug|PTR-01|Intravenous recombinant collagen 7
75787963|NCT01304420|Device|Ultrasonography|Scanning 5 joints bilaterally with an ultrasound scanner
75787964|NCT03812432|Device|Near-infrared fluorescence cholecystocholangiography|Device: Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
75787965|NCT01302314|Behavioral|Goal management training (GMT)|Fourteen hours of GMT during a time period of three months.
75924188|NCT02319018|Drug|Leucovorin Calcium|Given IV
75924189|NCT02319018|Drug|Oxaliplatin|Given IV
75924190|NCT05584748|Device|transcranial direct current stimulation|tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).
75924191|NCT02574520|Drug|SABER-Bupivacaine (Part 1)|5 ml once at end of surgery
75924192|NCT02574520|Drug|SABER-Bupivacaine (Part 2)|5 ml once at end of surgery
75924193|NCT02574520|Drug|Saline Placebo|5 ml once at end of surgery
75924194|NCT02574520|Drug|Bupivacaine HCl|0.5%, 15 ml, once at end of surgery
75924195|NCT04425226|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
75787966|NCT03812354|Other|THRIVE 4L/kg/min|High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
75924196|NCT04425226|Drug|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
75924197|NCT03497052|Other|In vitro culture in medium 1|Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
75924198|NCT03497052|Other|In vitro culture in medium 2|Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
75787967|NCT03812354|Other|THRIVE 2L/kg/min|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
75924199|NCT03351452|Device|real anodal transcranial direct current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
75787968|NCT05108948|Behavioral|Quality of life questionnaires|Oswestry Disability Index Scoliosis Research Society-22R Short Form 36 Health Survey Questionnaire Tobacco, Alcohol, Prescription medication, and other Substance use Core Outcome Measures Index : back and neck
75924200|NCT03351452|Device|real transcranial alternating current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
75924201|NCT03351452|Device|sham transcranial electric current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
75924202|NCT05520658|Drug|combined digoxin and furosemide|one session every 2 weeks for maximum 6 sessions
75924203|NCT05520658|Drug|5 fluorouracil|5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
75924204|NCT02324634|Device|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
75924205|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
75924206|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
75924207|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
75924208|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
75787969|NCT05108948|Procedure|Radiography|Spinal radiography : full, face, profile
75787970|NCT03812120|Procedure|Dural closure with L-PRF|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair
75787971|NCT03812120|Procedure|Dural closure with classical fibrin sealants|Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair
76079987|NCT03445182|Device|Local anaesthesia with conventional syringe + Dentalvibe|"Buccal infiltration in posterior maxillary region. The tip of the DentalVibe device is placed in the mucobuccal fold above the tooth to be anesthetized. The device is activated for 5 s. A 27 gauge short needle is inserted as close as possible to the inner side of the prong while the vibration is still on.~Local anaesthetic infiltration speed 1ml/min. After injection the needle is withdrawn and vibration continues for another 5 s.~Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
76079988|NCT03010540|Drug|MORPHINE PLUS FENTANYL|Effect Of Morphine Plus Fentanyl On Emergence Delirium
75331366|NCT04356131|Other|progressive relaxation exercises and massage|Progressive relaxation exercises included 30 minute rhythmic breathing and muscle relaxation exercises were demonstrated in the second part of the CD with river sounds and verbal instructions. Massage techniques were performed on the site between upper symphysis pubis and umbilicus with 15 minute effleurage demonstrated in the third part of the CD with nature sound.
75787972|NCT03796910|Drug|SPR720 for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
75331367|NCT04347083|Diagnostic Test|Electrodiagnostic test|Muscle spindle- based reflex latency will be measured
75787973|NCT03796910|Drug|Placebo for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
75787974|NCT03796910|Drug|SPR720 for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
75787975|NCT03796910|Drug|Placebo for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
75787976|NCT01302470|Procedure|Primary epicardial placement of left ventricular lead|Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
75924209|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
75924210|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
75924211|NCT05526040|Dietary Supplement|Immunonutrient-enriched oral nutrition supplementation|"Individualized dietary assessment and counselling with additional high energy, high protein, immunonutrient-enriched oral nutrition supplement; taken 3 servings per day, from 1 week prior to cancer treatment and continued throughout the cancer treatment.~Oral Impact® is an oral nutrition supplement product enriched with arginine (3.3g/sachet), omega-3 fatty acids (0.8g/sachet) and nucleotides (0.3g/sachet). The immunonutrient-enriched formula is also a complete and balanced formula, and is gluten free. The osmolality of the formula is 620 mOsm/kg water."
75639115|NCT03088878|Drug|Cirmtuzumab (RDR) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily
75787977|NCT01302470|Procedure|Transvenous placement of left ventricular lead|Conventional placement of left ventricular leads performed in the electrophysiology department.
75924212|NCT05526040|Dietary Supplement|Standard medical nutrition therapy|Individualized dietary assessment and counselling and standard nutrition supplementation via oral nutrition supplementation or enteral nutrition as necessary.
76079989|NCT03010540|Drug|Fentanyl|Effect Of Fentanyl Only On Emergence Delirium
75639116|NCT03088878|Drug|Cirmtuzumab plus ibrutinib|Arm A: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
75639117|NCT03088878|Drug|Ibrutinib alone|Arm B: Participants will receive ibrutinib (420 mg) orally once daily
76079990|NCT03445104|Other|Huperzine A|During one of the two experimental sessions, participants will be given huperzine A.
75787978|NCT03796520|Diagnostic Test|EpiPick simplified seizure classification algorithm|"EpiPick simplified seizure classification algorithm input:~Grey matter brain lesion Exclusively nocturnal seizures First seizure at age > 20 years Lip smacking or chewing during seizures Staring with impaired awareness, lasting less than 20s without postictal confusion Sudden irregular jerks, in isolation or brief series, if none of the following applies: Are the jerks consistently in the same limb? When resting in bed when falling asleep? Bilateral tonic-clonic seizures within 1h of awakening or immediately preceded by irregular jerks Any of the following is present: Skin turning pale pre-ictally; Loss of consciousness immediately after urination or defecation; Sudden slump with loss of awareness, lasting less than 10 seconds; Seizure lasting longer than 10 minutes, with eyes closed throughout the seizure; Severe pre-ictal headache; Episodes consisting of falls that occur always after change in posture to the upright position, or coughing or feeling pain."
75639118|NCT03087071|Other|Laboratory Biomarker Analysis|Correlative studies
75787979|NCT03812042|Diagnostic Test|Enzyme assay and molecular sequencing|Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
75924213|NCT03351374|Other|Software|multi-module system of web software tools
75924214|NCT05520580|Procedure|Mother's push during CS|after uterotomy, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary
75924215|NCT04462926|Diagnostic Test|[68Ga]Ga-PSMA-11 PET/CT|1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
75331368|NCT01112293|Drug|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
75331369|NCT02174419|Drug|nalbuphine HCl ER tablets 90 mg BID|nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
75924216|NCT02319096|Other|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
75924217|NCT05525962|Behavioral|questionnaries, scales, cognitive tests|"A first interview is planned with a psycholgist in the weeks following the minor arrival in the structure (M0)~M0: cognitive test, psychiatric classification and psychologic assessments~M12 and M24: psychiatric classification and psychologic assessments"
75924218|NCT03494244|Procedure|Direct-to-implant breast reconstruction|Terminal prosthetic implanted at the time of mastectomy.
76079991|NCT03445104|Other|Placebo|During one of the two experimental sessions, participants will be given a placebo.
76079992|NCT03445026|Diagnostic Test|dental panorama|radiographic examination
75331370|NCT02174419|Drug|nalbuphine HCl ER tablets 180 mg BID|nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
75331371|NCT02174419|Drug|Placebo tablets BID|Placebo tablets BID administered for 10 weeks
75331372|NCT00942851|Drug|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
75331373|NCT00942851|Drug|placebo|topical treatment NOT containing AH-8
75331374|NCT05620589|Drug|Amoxicillin + Tetracycline + Bismuth + Esomeprazole|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
75331375|NCT05620589|Drug|Amoxicillin + Tetracycline + Bismuth + Vonoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
75639119|NCT03087071|Biological|Panitumumab|Given IV
75639120|NCT03087071|Drug|Trametinib|Given PO
75639121|NCT03085485|Drug|Ivacaftor 150 MG|Ivacaftor is a CFTR potentiator
75639122|NCT03085485|Drug|Placebo|placebo pills
75639123|NCT03071861|Drug|Darbepoetin Alfa|Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age
75639124|NCT03071861|Drug|Normal Saline|Single dose of normal saline, IV, given at less than 24 hours of age
75639125|NCT03043872|Drug|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
75639126|NCT03043872|Drug|Tremelimumab|IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
75639127|NCT03043872|Drug|Carboplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
75639128|NCT03043872|Drug|Cisplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
75639129|NCT03043872|Drug|Etoposide|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
75639130|NCT03015610|Drug|commercially available lansoprazole|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily lansoprazole for 24 weeks
75639131|NCT03015610|Drug|matched placebo|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
75924219|NCT03494244|Device|Acellular dermal matrix|Banked tissue used to support the directly implanted breast prosthesis.
76079993|NCT01234714|Other|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
76079994|NCT01234714|Procedure|Major liver resection|Hepatectomy of >= 3 liver segments
76079995|NCT03440580|Device|BOOSTH|BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
75924220|NCT05584592|Other|Intergrate early palliatuve care + Conventional chemotherapy|Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
75924221|NCT05584592|Other|Conventional chemotherapy|patients to receive routine palliative care when they want it or when it is needed by health care providers. In other words, if a patient assigned to the control group desires palliative care, they can receive conventional palliative care.
75924222|NCT02322684|Device|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
75924223|NCT05516056|Other|ERAS clinical pathway|Prospective evaluation of the clinical results of ERAS implementation in the first 50 patients undergoing ERAS for cholecystectomy in CHUK, Rwanda
75924224|NCT02324712|Device|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
75924225|NCT02324712|Device|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
75924226|NCT04503044|Other|Retrospective observational study|No intervention to occur
75639132|NCT03012529|Drug|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
75787980|NCT03796364|Drug|Endostar|Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
75924227|NCT02322918|Genetic|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
75924228|NCT03351140|Other|Qualitative Interviews|Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
75470620|NCT05413746|Device|Reoxcare antioxidant dressing|After wound cleaning activities, wound bed debridement if necessary and elimination of hyperkeratotic edges, wounds are treated with Reoxcare as primary dressing and the approppriate secondary dressing for adequate exudates management
75470621|NCT05413694|Other|telephone interview 24 months after hospitalization for Covid-19|telephone interview 24 months after hospitalization for Covid-19
75639133|NCT03012529|Drug|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
75639134|NCT03005860|Drug|2,6-Diisopropylphenol|In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.
75924229|NCT03351140|Other|PROMIS Physical Function Items|PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
75924230|NCT02319252|Device|Gastric tube (Nutricia Flocare® Pur Tube Enlock)|Nutricia Flocare® Pur Tube Enlock, Ch. 12
75924231|NCT02319252|Device|Jejunal tube (Nutricia Flocare® Bengmark®)|Nutricia Flocare® Bengmark®, Ch. 10
75924232|NCT03499938|Device|Structured Light Plethysmography|Non-invasive non-contact measurement of tidal breathing during hospital admission
75924233|NCT05520424|Dietary Supplement|The Daily Supplement|"The ingredient list of the product includes the following:~400mg of curcumin (Longvida) 300mg of lemon balm extract (Cyracos) 200mg of American ginseng (Cereboost) 50mg of epigallocatechin gallate derived from green tea Organic oat milk powder Phosphatidylserine (SerinAid) (active) B6 (in the form of P5P) Folate (Quatrefolic) B12 Silica (non-active)"
75924234|NCT02319330|Behavioral|Nurse-delivered mobile phone counseling intervention|Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
75924235|NCT02319330|Behavioral|Treatment as Usual|Routine HIV clinic-based counseling
75924236|NCT05081362|Other|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity during ten minutes in rest and ten minutes in orthostatic position
75787981|NCT03796364|Drug|standard SRILI treatment|Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
75787982|NCT03795974|Biological|MNC|Hematopoietic stem cells derived from allogenic umbilical cord
75787983|NCT03795974|Biological|MSC|Mesenchymal cells derived from allogenic umbilical cord
75924237|NCT02324790|Device|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
75924238|NCT03351062|Drug|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day.
75924239|NCT03351062|Drug|Toremifene|Patients will be given 60mg Toremifene once a day.
75924240|NCT02324868|Device|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
75331376|NCT05620589|Drug|Amoxicillin + Tetracycline + Bismuth + Tegoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
75331377|NCT05620511|Behavioral|Mindfulness based stress reduction|Mindfulness based stress reduction v.s.Relaxation
75470622|NCT05413512|Other|Acute psychological stress|Participants will undergo an acute psychological stress task that has been shown to elicit neural, cardiovascular, and psychological (feelings of stressfulness) responses.
75470623|NCT05413382|Dietary Supplement|Biofresh® 4plus|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
75470624|NCT05413382|Dietary Supplement|Placebo|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
75639135|NCT03005860|Drug|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.
75639136|NCT03005860|Drug|Fentanyl Citrate|Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.
75639137|NCT03005860|Drug|Atracurium Besylate|Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
75639138|NCT02978521|Other|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
75787984|NCT03795974|Procedure|Control|control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .
75787985|NCT03812198|Drug|LEO 32731 modified release tablet|At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
75924241|NCT02324868|Device|Conventional IV catheter protection|No Shower patch will be provided during study period
75924242|NCT05515900|Dietary Supplement|Sodium|Daily sodium supplementation of 2000 mg.
75924243|NCT05515900|Dietary Supplement|HMB|Daily HMB supplementation of 3 g.
75924244|NCT05515900|Other|Placebo|Placebo pills that will be identical to sodium or HMB supplementations
75924245|NCT03496740|Procedure|Penile Block|Ultrasound guided dorsal penile nerve block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
75924246|NCT03496740|Procedure|Pudendal Block|Nerve stimulation guided bilateral pudendal block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
75924247|NCT03496740|Drug|Bupivacaine (Block Drug)|Block drug
75924248|NCT04888676|Procedure|Class II Restoration|A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
75924249|NCT03499860|Diagnostic Test|Passive Leg Raising Test|A passive leg raising test is performed in all patients included in the study
75331378|NCT01086475|Drug|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
75331379|NCT01086475|Drug|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
75331380|NCT01112683|Drug|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
75331381|NCT01112683|Drug|Placebo|These are identically-looking pills to those in the Memantine Arm.
75331382|NCT02245373|Drug|Antidepressants|
75331383|NCT02245373|Other|Active Monitoring|
75331384|NCT02906839|Other|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
75470625|NCT05411042|Device|Dance somatosensory game|dance somatosensory game (DSG), DANZ BASE developed by International Games System Company
75470626|NCT05410899|Other|exercise|Women with urinary incontinence will done exercise including pelvic floor muscle and will taught pelvic floor muscle anatomy, physiology, disorders, treatment of disease
75470627|NCT05410886|Other|Questionnaire|A questionnaire including up to 20 questions will be distributed to study participants. This questionnaire will be used to identify women with FHA.
75470628|NCT05409365|Other|Immunohistochemical staining monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody)|Immunohistochemical staining
75924250|NCT04504760|Drug|ONO-2910|Single ascending dose of ONO-2910 will be administered orally.
75924251|NCT04504760|Drug|Placebo|Single dose of placebo will be administered orally.
75331385|NCT04355741|Other|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
75639139|NCT02950337|Radiation|Group 1: Peripherally Located Tumors|Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
75639140|NCT02950337|Radiation|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
75639141|NCT02950337|Radiation|Group 3: Centrally Located Tumors|Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
75639142|NCT02928224|Drug|Encorafenib|Orally, once daily.
75639143|NCT02928224|Drug|Binimetinib|Orally, twice daily.
75787986|NCT03812198|Drug|LEO 32731 blend, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
75787987|NCT03812198|Drug|LEO 32731 API, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
75924252|NCT04504760|Drug|ONO-2910|Multiple ascending dose of ONO-2910 will be administered orally.
75924253|NCT04504760|Drug|Placebo|Multiple dose of placebo will be administered orally.
75924254|NCT05525884|Other|non-invasive method, Fibroscan|Liver Ultrasound and transient elastography (FibroScan®)
75924255|NCT02324946|Other|Mass Screening|Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
75924256|NCT05520268|Behavioral|Conventional music therapy (CMT)|CMT comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and led by a professional music therapist. For PWDs living in a care home, the CMT sessions are implemented as inpatient rehabilitation held at the care home. For PWDs living at home, the CMT sessions are implemented as outpatient rehabilitation held at a local day activity centre.
75639144|NCT02928224|Drug|Cetuximab|Standard of care.
75639145|NCT02928224|Drug|Irinotecan|Standard of care.
75639146|NCT02928224|Drug|Folinic Acid|Standard of care.
75639147|NCT02928224|Drug|5-Fluorouracil|Standard of care.
75639148|NCT02842086|Drug|F/TAF|200/25 mg tablet administered orally once daily
75639149|NCT02842086|Drug|F/TDF|200/300 mg tablet administered orally once daily
75639150|NCT02842086|Drug|F/TAF Placebo|Tablet administered orally once daily
75639151|NCT02842086|Drug|F/TDF Placebo|Tablet administered orally once daily
75639152|NCT02800070|Biological|Lentivirus Alpha-gal A transduced stem cells|
75639153|NCT02788474|Drug|nintedanib|
75639154|NCT02788474|Drug|placebo|
75787988|NCT03812198|Drug|LEO 32731 soft capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
75787989|NCT03812198|Drug|LEO 32731 gastro-resistant capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
75787990|NCT03812198|Drug|LEO 32731|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
75787991|NCT03812198|Other|Placebo|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
75787992|NCT03796052|Other|Avena Sativa Skincare Regimen|Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)
76079996|NCT03440502|Procedure|spinal anaesthesia|Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine
76079997|NCT01162096|Device|Haploidentical Allogeneic Transplantation|Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
76079998|NCT03437538|Device|MCO-HD|Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
76079999|NCT03437538|Device|High-flux HDF|Measurements will be done during a single hemodiafiltration session with standard high-flux filter
75331386|NCT03032549|Dietary Supplement|RTD|Ready to Drink Supplement
75331387|NCT03032549|Dietary Supplement|Placebo|Placebo
75331388|NCT01113385|Drug|D-Galactose|Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
75331389|NCT04355351|Other|blood sampling|blood sampling done on hospital staff without sars-coV-2 symptoms
75331390|NCT04355351|Other|additional blood tubes|Additionnal blood tube taken during the classical blood sampling in hospital
75331391|NCT04355507|Diagnostic Test|Chest computed tomography (CT)|Chest computed tomography (CT) examination
75331392|NCT04355507|Diagnostic Test|Reverse-transcription polymerase chain reaction (RT-PCR)|Identification of viral RNA by reverse-transcription polymerase chain reaction
75331393|NCT01087801|Drug|ChiRhoStim|Human Secretin for Injection
75331394|NCT01087801|Drug|Placebo|Saline for Injection
75331395|NCT04355273|Drug|Heparin|heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
75331396|NCT04355273|Drug|Heparin|heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
75787993|NCT03796130|Procedure|Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (1): myomectomy will be performed before ART~In group (2):women will have their trial of ART without myomectomy~In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
75787994|NCT03796286|Other|Medium-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
75639155|NCT02720445|Drug|Nicotine Transdermal Patch|21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.
75787995|NCT03796286|Other|High-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
75787996|NCT03796286|Other|Control bar (0 g fiber)|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
75787997|NCT03795896|Diagnostic Test|Optic nerve sheath diameter|The intracranial pressure will be measured by the optic nerve sheath diameter and after giving the mannitol osmotherapy the intracranial pressure will be monitored by the optic nerve sheath diameter
75787998|NCT03793322|Drug|Indocyanine-Green(ICG)|ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
75787999|NCT03793244|Dietary Supplement|TARGET protocol EN 1.5 kcal/mL|Enteral nutrition
75788000|NCT03811730|Diagnostic Test|Transesophageal echocardiography|Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
75788001|NCT03795584|Procedure|sterile repositionable hemostasis clipping device close the large duodenal papilla incision|After the bile duct stent was placed, the investigators can use sterile repositionable hemostasis clipping device to close large duodenal papilla incision at 11 o'clock on the duodenal papilla.
75924257|NCT05520268|Behavioral|Digital music rehabilitation (DMR)|DMR comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and implemented using a novel digital music content service called HILDA. In HILDA, there are a number of stand-alone musical programs hosted by a virtual presenter which the PWDs can follow and through which they can interact. The DMR sessions are moderated by an instructor (care home staff member or research assistant). For PWDs living in a care home, the DMR is implemented as live sessions held at the care home using a HILDA box connected to a TV screen and operated via a remote controller by the instructor. For PWDs living at home, the DMR is implemented as virtual sessions using a video communication platform that allows the instructor to stream and control the HILDA service and the participants to see and hear each other and interact.
75924258|NCT02443896|Procedure|Pit and Fissure Sealant of permanent molars|The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
75924259|NCT02443896|Procedure|No sealant of permanent molars|No sealant applied to permanent molars.
75924260|NCT05515822|Drug|Oxycodone Hydrochloride|The doses were calculated according to the ideal body weight. Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
75924261|NCT05515822|Drug|Dezocine|Dezocine was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
75470629|NCT05406258|Device|Modified Self-Catheterization Mirror|Following training, participants will have a modified mirror available for self-catheterization, as well as a standard, hospital-provided mirror. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
75470630|NCT05404074|Drug|Cobitolimod 500mg|Rectal administration
75470631|NCT05397587|Biological|Experimental Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
75470632|NCT05397587|Biological|Control Vaccine|The EV71 vaccine was manufactured by Institute of Medical Biology,Chinese Academy of Medical Sciences ,and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
75470633|NCT05387785|Drug|ANG-3070|Orally administered tyrosine kinase inhibitor capsule.
75470634|NCT05387785|Drug|Placebo|Orally administered placebo capsule
75470635|NCT05379244|Behavioral|CBT-i|Behavioral intervention based on Cognitive Behavioral Therapy for insomnia, adjusted for psychiatric patients with anxiety disorders, affective disorders and trauma
75639156|NCT02720445|Drug|Placebo Patch|Matching placebo patches worn during waking hours.
75639157|NCT02693223|Other|GWTG Stroke program|Evidence based recommended therapies and counseling prior to hospital discharge.
75639158|NCT02678572|Combination Product|Melphalan/HDS|Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
75639159|NCT02665195|Other|saliva specimen|
75639160|NCT02665195|Behavioral|questionnaire|
75639161|NCT02631746|Other|Laboratory Biomarker Analysis|Correlative studies
75639162|NCT02631746|Biological|Nivolumab|Given IV
75639163|NCT02631746|Other|Pharmacogenomic Study|Correlative studies
75639164|NCT02529319|Procedure|MRI-Guided Ablation|Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.
75639165|NCT02529319|Procedure|Conventional Ablation|Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
76080000|NCT04801290|Procedure|TIPS insertion|Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
76080001|NCT01234870|Drug|Gadolinium|
75924262|NCT05515822|Drug|Esketamine and Oxycodone|Esketamine was administered 5min before skin incision, and Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
76080002|NCT01234870|Drug|Adenosine|
76080003|NCT05665686|Device|Relaxation training with device|Relaxation training will be applied with the device.
75639166|NCT02484950|Biological|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
75639167|NCT02484950|Procedure|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
75639168|NCT02394964|Other|Sample Collection|Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
75924263|NCT05520112|Biological|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
75639169|NCT02381886|Drug|IDH305|
75639170|NCT02322840|Device|Twelve TMVR Implant|Implantation of the Twelve TMVR System -Apical
75788002|NCT05078918|Other|Comprehensive care program|Comprehensive care program includes education and re-evaluation process. Education using video-materials to help patients adapt to the new normal before and after surgery. And re-evaluation patient's needs 1 month after surgery and arrangement resources.
75788003|NCT05078918|Other|Usual care|Usual care includes encouraging deep breathing and exercise using inspirometer, postoperative early ambulation, giving information at discharge and follow up 1 month after surgery.
75788004|NCT01304576|Behavioral|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
75788005|NCT01304576|Other|MRI|Cerebral MRI
76080004|NCT05665686|Other|Home Exercise|An exercise application including home exercise programs will be performed for six weeks.
76080005|NCT03437460|Drug|Ibuprofen 600 mg|The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
76080006|NCT03437460|Dietary Supplement|Prenatal vitamins|The investigators administer one single prenatal multivitamin immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
75639171|NCT02322840|Device|Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System|Implant of Intrepid valve -Transfemoral
75639172|NCT02293655|Drug|OROS-Methylphenidate (MPH)|OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
75639173|NCT02166463|Biological|Bleomycin Sulfate|Given IV or SC
75788006|NCT03795662|Other|No intervention|Obervational
75788007|NCT03792776|Other|cuff inflation with air|Endotracheal tube cuff inflation with air
75788008|NCT03792776|Drug|cuff inflation with lidocaine 1%|Endotracheal tube cuff inflation with lidocaine 1%
75788009|NCT03792776|Drug|cuff inflation with lidocaine 2%|Endotracheal tube cuff inflation with lidocaine 2%
76080007|NCT03444792|Procedure|mechanical dilatation of the cervix|"the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure.~- If failed the surgeon will use artery forceps to dilate cervix"
76080008|NCT03444636|Drug|Ropivacaine/Fentanyl|Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
76080009|NCT03444636|Drug|Bupivacaine/Fentanyl|Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
75639174|NCT02166463|Drug|Brentuximab Vedotin|Given IV
75639175|NCT02166463|Drug|Cyclophosphamide|Given IV
75639176|NCT02166463|Drug|Doxorubicin Hydrochloride|Given IV
75639177|NCT02166463|Drug|Etoposide|Given IV
75639178|NCT02166463|Other|Laboratory Biomarker Analysis|Correlative studies
75639179|NCT02166463|Drug|Methylprednisolone|Given IV
75639180|NCT02166463|Other|Pharmacological Study|Correlative studies
75639181|NCT02166463|Drug|Prednisone|Given PO
75639182|NCT02166463|Other|Quality-of-Life Assessment|Ancillary studies
75639183|NCT02166463|Other|Questionnaire Administration|Ancillary studies
75924264|NCT05520112|Other|Standard treatment according to the clinical protocols|Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
76080010|NCT01215292|Drug|Acyline|300 mcg/kg on Day 1
76080011|NCT01215292|Drug|Testosterone gel|5 gm of 1% T Gel applied transdermally for 10 days
76080012|NCT01215292|Drug|ketoconazole 400|400 mg PO daily, Days 3-10
76080013|NCT01215292|Drug|Ketoconazole 800|800 mg PO daily, Day 3-10
76080014|NCT01215292|Drug|Dutasteride|2.5 mg PO daily, Day 3-10
76080015|NCT01215292|Drug|Anastrozole|1 mg PO daily, Day 3-10
76080016|NCT01215292|Drug|Placebo ketoconazole|placebo to mimic ketoconazole
76080017|NCT04796454|Drug|Cisplatin|Cisplatin IV 25 mg/m² on d1 and d8 - always combined with Gemcitabine; maximum treatment 2 years
76080018|NCT04796454|Drug|Gemcitabine|Gemcitabine IV 1000 mg/m² on d1 and d8 if in combination with Cisplatin; Gemcitabine IV 1000 mg/m² on d1 and d15 if in combination with Oxaliplatin; maximum treatment 2 years
76080019|NCT04796454|Drug|Oxaliplatin|Oxaliplatin IV 100 mg/m² on d1 and d15 - always combined with Gemcitabine; maximum treatment 2 years
76080020|NCT04796454|Drug|Pamiparib|Pamiparib 60 mg PO twice a day from d1 to day28 in a 4-week cycle - always combined with Temozolomide; until progression or maximum treatment 2 years
75788010|NCT03792776|Other|Induction of anesthesia|The induction of anesthesia will be made following a preoxygenation with a facial mask with 100% Oxygen. It consists on the intravenous injection of Sufentanil 5 mcg or Fentanyl 50mcg, Lidocaine 1mg/Kg, Propofol 2.5mg/kg, Rocuronium 0.6mg/kg or Cisatracurium 0.15mg/kg.
75788011|NCT03792776|Other|Maintenance of anesthesia|Maintenance of anesthesia will be done by sevoflurane + nitrous oxide, and reinjections of morphinomimetics and curare will be made as needed (the total doses will be noted at the end of the intervention).
75639184|NCT02166463|Drug|Vincristine Sulfate|Given IV
75639185|NCT02118467|Drug|Norepinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
75788012|NCT03792776|Other|Endotracheal intubation|The intubation is made by a N° 7.5 tube in men and a N° 7 tube in women. Cuff inflation will be done upon placement of the endotracheal tube. The cuff's pressure will be monitored at several intervals of the intervention and kept < or = 20 centimeter of water (cmH2O).
75788013|NCT03792776|Other|Systematic post-operative analgesia|All patients will receive Paracetamol every 6 hours for the first 24 hours after the end of surgery.
75788014|NCT03795740|Diagnostic Test|3-D CT scanning|For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
75788015|NCT03795272|Drug|Rucaparib|2:1 randomization to receive rucaparib/placebo twice daily for 24 month
75788016|NCT03795272|Drug|Placebo|placebo
75788017|NCT03794960|Biological|TOL-3021|A plasmid expression vector containing the coding sequences for full-length human proinsulin.
76080021|NCT04796454|Drug|Temozolomide|Temozolomide 60 mg PO once a day from d1 to d7 in a 4-week cycle - always combined with Pamiparib; until progression or maximum treatment 2 years
75639186|NCT02118467|Drug|Epinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
75788018|NCT03794960|Other|TOL-3021 Placebo|TOL-3021 Placebo
75639187|NCT02118467|Drug|Phenylephrine|Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
75639188|NCT02118467|Drug|Vasopressin|Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
75639189|NCT02101034|Biological|Cetuximab|
75788019|NCT00956930|Radiation|yttrium Y 90 glass microspheres|Patients undergo radioembolization.
75788020|NCT00956930|Drug|Doxorubicin|75mg fixed dose
75788021|NCT03792698|Other|Aidcube digital app-based platform|Use of customizable, patient-specific mHealth home rehabilitation plan
75788022|NCT05625386|Device|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
75924265|NCT03496584|Other|Pomegranate Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of pomegranate juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
75924266|NCT03496584|Other|Placebo Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of placebo juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
75924267|NCT02322996|Other|questionnaires|The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
75924268|NCT04294654|Drug|Vortioxetine|Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.
75924269|NCT02325102|Other|No intervention|As this is an observational study, no intervention was conducted.
76080022|NCT03437382|Device|Quirem Medical Holmium-166 radioembolization microspheres|radioembolisation as adjuvant treatment to RFA
75639190|NCT02101034|Drug|PD 0332991|
75639191|NCT02016599|Other|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
75788023|NCT03794804|Device|ColdZyme|"ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (<1 %), calcium chloride, trometamol and menthol.~ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap."
75788024|NCT03794804|Device|ColdZyme Placebo|The placebo mouth spray solution has the following composition: ethanol (<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
75924270|NCT04772144|Behavioral|behavioural and cessation aids|information, motivational interview, refferal to healty life-centers, free cessation aids
75639192|NCT02000622|Drug|Olaparib|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
75639193|NCT02000622|Drug|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days~Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days~Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days"
75788025|NCT03811652|Drug|MEDI7247|Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
75788026|NCT03792854|Other|EORTC QLQ C30|standardized questionaire
75788027|NCT03792854|Other|EORTC QLQ CR29|standardized questionaire
75788028|NCT03181412|Diagnostic Test|Questionnaire|"Tests from Cincinnati prehospital stroke severity scale (CPSSS) will be carried out by the physician at emergency medical services on telephone call with firemen, paramedics or the emergency medical services team for any stroke suspicion that meets the criteria for inclusion. Emergency department physician will have to follow a standardized questionnaire to complete the different items of the score. The score will not be calculated by emergency department physician and will not influence the orientation and management of patients.~The final diagnosis will be the presence or absence of a large vessel occlusion. This diagnosis will be done on cerebral imaging by a neurologist."
75639194|NCT01817192|Drug|Adjuvant Chemotherapy|Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
75639195|NCT01817192|Other|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.
75331397|NCT04355273|Drug|normal saline|normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
76080023|NCT05113680|Behavioral|compassion focused group|Based on compassion focused therapy (CFT) principles practices : soothing breathing rythm, compassionate-self, compassion for shame and self-criticism 12 sessions of 2h each
75639196|NCT01817192|Other|14-Gene Prognostic Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
75639197|NCT01016340|Drug|MCS|MCS-5 Softgel 5 mg
75331398|NCT04352725|Procedure|End-expiratory lung volume measurement and incremental PEEP titration|"End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat<28cmH2o~incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
75639198|NCT00965991|Drug|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
75639199|NCT00965991|Drug|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
75924271|NCT05525728|Other|Neurosensory|Physiological and neurophysiological investigations
75924272|NCT03496506|Drug|Selexipag|Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
75924273|NCT03496506|Drug|Clopidogrel|Each film-coated tablet containing 75 mg of clopidogrel (oral use)
75924274|NCT02325024|Drug|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
76080024|NCT05113680|Behavioral|emotional competencies|Emotional competencies group focused on identification, comprehension, expression, regulation, utilization. practices : TCC, cognitive restructuring, and mindfulness 12 sessions of 2h each
75788029|NCT03794648|Behavioral|Mobile Interactive Supervised Therapy (MIST)|MIST system will send a reminder notification (via push or SMS) to participants 10 to 15 minutes before the scheduled time for taking their medication. Participants will then activate the recording function of the MIST app on their phone, and record themselves taking their medication.Participants will be asked to go through a series of steps for recording the video.
75788030|NCT03792620|Combination Product|Cyclo Thal Dex Daratumumab|Cyclo Thal Dex Daratumumab
75924275|NCT05525650|Drug|House Dust Mite Extract, Dermatophagoides Farinae|"[Group 1] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~[Group 2] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~[Group 3] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E."
75924276|NCT03132324|Drug|INCB059872|INCB059872 tablets
75924277|NCT05519956|Radiation|level Ib-covering IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
75924278|NCT05519956|Radiation|level Ib-sparing IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
75924279|NCT03346616|Other|Texting Group|See above in arm/group description
75924280|NCT03346616|Other|Non Texting Group|See above in arm/group description
75924281|NCT02319564|Drug|Beclomethasone|
75924282|NCT02319564|Drug|Beclomethasone and Salbutamol|
75924283|NCT02319564|Drug|Placebo|
75924284|NCT02319564|Device|Aerochamber Max®|
76080025|NCT02521506|Device|Verio Pattern Alert® activated|
76080026|NCT02521506|Device|Verio Pattern Alert® deactivated|
76080027|NCT02189668|Drug|Antibiotics only (Zosyn then Augmentin)|Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
75331399|NCT04355429|Drug|captopril 25mg|Drug administration
75331400|NCT01114555|Drug|Bevacizumab, Irinotecan and Temozolomide|Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
75331401|NCT01114945|Device|McGrath|Intubation with the McGrath device
75331402|NCT01114945|Device|GlideScope|Intubation with the GlideScope device
75924285|NCT05515666|Diagnostic Test|Wearable electrocardiogram|All participants will have their ECG monitored at home using a wearable ECG, and then be hospitalized for coronary angiography and quantitative flow fraction to confirm the presence of coronary artery disease.
75924286|NCT03122054|Procedure|laparoscopic cholecystectomy|First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.
75788031|NCT05027594|Drug|NMS-03597812|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 in repeated 4-week cycles.
75924287|NCT05515510|Other|FU-APP|"FU-APP is a web-based application using the guidelines and oral health recommendations provided by the current German Ratgeber 2020. It provides information related to oral health care for the parents of children between 6 to 72 months of age. An account was made on a certified online web-development platform and an application was developed on it.~This application serves as a practical guide for the parents of children under 6 years of age. It provides all the essential German guidelines related to first dental visits, expected dental findings, practical brushing technique steps, plaque disclosing activity, motivational brushing video, nutritional facts and behavioral habits to be avoided. It is a complete package of essential information and with high quality content that promotes prevention of ECC at an early age."
75924288|NCT05515510|Other|Oral health recommendations|"Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020"
75924289|NCT02325180|Drug|Dihydroartemisinin-Piperaquine|
75639200|NCT00959140|Device|CD3+ T cell depletion|"The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.~Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis."
75639201|NCT00811668|Device|CPAP before SOMNOVentCR|4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
75639202|NCT00811668|Device|SOMNOventCR before CPAP|4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
75639203|NCT00798135|Drug|itraconazole|oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
75639204|NCT00782574|Drug|AZD2281|Tablets Oral BID
75639205|NCT00782574|Drug|Cisplatin|IV every 3 weeks
75639206|NCT00643955|Other|muscle strength|muscle strength
75639207|NCT00579969|Drug|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
75924290|NCT02325180|Drug|Artemether-lumefantrine|
75924291|NCT05052658|Procedure|Neuraxial block placement|The time and ease of administering neuraxial blocks in high BMI patients,for the management of labor and delivery pain, will be assessed.
76080028|NCT03437304|Biological|Immunose™ FLU 1%|Quadrivalent influenza vaccine with 30 μg HA/strain and 1% Endocine™, dosing volume 200 μl, intranasal administration x 2
76080029|NCT03437304|Biological|Immunose™ FLU 2%, 200 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 200 μl, intranasal administration x 2
76080030|NCT03437304|Biological|Immunose™ FLU 2%, 300 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 300 μl, intranasal administration x 2
76080031|NCT03437304|Biological|Influenza antigen|Quadrivalent influenza vaccine with 30 μg HA/strain, dosing volume 200 μl, intranasal administration x 2
75639208|NCT00579969|Drug|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
75639209|NCT00579371|Drug|Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
75639210|NCT00270933|Device|Registry|
75639211|NCT00135226|Drug|Aspirin|
76080032|NCT03437304|Drug|Placebo|NaCl dosing volume 200 μl, intranasal administration x 2
75639212|NCT00135226|Drug|Omega-3 Ethyl Esters|
75639213|NCT00135226|Drug|Placebo Aspirin|
75788032|NCT05027594|Drug|NMS-03597812 + dexamethasone|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 and Dexamethasone administered orally once a week on Days 1, 8, 15 and 22 in repeated 4-week cycles.
75331403|NCT01114945|Device|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
75331404|NCT01114945|Device|Video-Mac|Intubation with the Video-Mac device
75639214|NCT00135226|Drug|Placebo Omega-3 Ethyl Esters|
75639215|NCT02742909|Drug|rhBNP|rhBNP was administered as a continuous infusion for 24 hours before or after placebo
75639216|NCT02742909|Drug|placebo|normal saline as a placebo was administered as a continuous infusion for 24 hours
75639217|NCT02742675|Drug|Bicalutamide|Given orally
75639218|NCT02742675|Drug|goserelin acetate|Given subcutaneously or as an injection
75639219|NCT02742675|Drug|flutamide|Given orally
75639220|NCT02742675|Drug|leuprolide acetate|Given subcutaneously or as an injection
75639221|NCT02742675|Drug|triptorelin|Given subcutaneously or as an injection
75639222|NCT02742675|Procedure|Definitive Treatment|surgery to remove prostate or radiation therapy to the prostate.
75788033|NCT03792542|Drug|Anlotinib|Anlotinib Hydrochloride ( 12mg, quaque die（QD）, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from adverse events(AEs), they can get declined dosage.
75924292|NCT03499626|Drug|ASLAN001|"Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD"
75788034|NCT03811418|Drug|Trastuzumab|"administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
75788035|NCT03811418|Drug|Pertuzumab|"administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
76080033|NCT03437304|Biological|i.m comparator|Quadrivalent influenza vaccine containing 15 μg HA/strain, 500 µl for intramuscular administration x 1
75924293|NCT00709592|Biological|Thymoglobulin|Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
75924294|NCT00709592|Radiation|Total-Body Irradiation|Undergo TBI
75331405|NCT01115101|Drug|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
75924295|NCT00709592|Procedure|Allogeneic PBSCT or BMT|Undergo allogeneic PBSCT or BMT
75331406|NCT01115101|Drug|Piritramid|"Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded."
75331407|NCT00943631|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
75639223|NCT02742753|Other|Data collection|Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
75639224|NCT02742597|Behavioral|TIP / IMPACT Plus Care Coordination|The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
75924296|NCT00709592|Drug|Tacrolimus|Given PO
75470636|NCT05371795|Device|Comfort Marker 2.0|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
75639225|NCT00813358|Device|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
75639226|NCT05628753|Diagnostic Test|Lung Ultrasound (LUS)|LUS performed 30 mins prior to and 120 minutes after planned extubation with a linear high frequency probe longitudinal approach was used in all three zones Repeated third scan will be done prior to re-intubation (if required) The ultrasound total execution cut-off time expected to be less than 5 minutes
75639227|NCT02742207|Other|Electrical atrial fibrillation Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
75788036|NCT03811418|Drug|Vinorelbine|"administered as combined therapy with Kanjinti® and pertuzumab.~Vinorelbine will be administered as an IV dose of 25 milligrams per kilogram (mg/kg) on days 1 and 8 of cycle 1 (1 cycle length = 21 days), and 25mg/kg up to 30 mg/kg (as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
75788037|NCT03811418|Drug|Docetaxel|"administered as combined therapy with Kanjinti® and pertuzumab.~Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m^2 (up to 100 mg/m^2 as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
75924297|NCT00709592|Drug|Mycophenolate Mofetil|Given PO
75924298|NCT02325258|Other|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
75924299|NCT05515354|Other|Timing of nicotine replacement therapy start date|Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.
75924300|NCT05515354|Drug|Nicotine Replacement Therapy Agent|Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
75924301|NCT03499548|Other|INSPiRe Programme|Intensive CBT for suicide
76080034|NCT02981290|Drug|Renodapt|Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
76080035|NCT02981290|Drug|Mycept|Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
75331408|NCT02245529|Drug|Tamsulosin|
75924302|NCT05052190|Behavioral|Text Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
75924303|NCT05052190|Behavioral|Text Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
76080036|NCT02981290|Drug|Cellmune|Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
75924304|NCT05052190|Behavioral|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period advising them to get the flu vaccine at their upcoming appointment.
75924305|NCT05052190|Behavioral|Portal Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
75924306|NCT05052190|Behavioral|Portal Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
75924307|NCT05052190|Behavioral|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via the portal advising them to ask their doctor for the flu vaccine at their upcoming appointment via text when they schedule a visit during the study period.
75924308|NCT03496350|Behavioral|Internet-delivered CBT|Culturally adapted transdiagnostic internet-delivered CBT in Arabic
75924309|NCT05525182|Drug|ES16001 40 mg|Composition: Elaeocarpus extract 40mg tablet
75639228|NCT02742207|Other|Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
75470637|NCT05371795|Device|Lancets|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
75924310|NCT05525182|Drug|ES16001 80 mg|Elaeocarpus extract 80 mg tablet
75639229|NCT00812812|Drug|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
75788038|NCT03794570|Device|Blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure
75788039|NCT03794570|Device|Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure
75788040|NCT03014336|Device|memsorb|memsorb is a CO2 filter replacing current chemical CO2 absorbers
75924311|NCT05525182|Drug|ES16001 160 mg|Elaeocarpus extract 160 mg tablet
75788041|NCT03794492|Drug|Mycophenolate mofetil 500mg Tab. or 250mg Cap.|- Orally, up to 1g BID(total 2g daily)
75788042|NCT03794492|Drug|Tacrolimus|- Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml
75924312|NCT05525182|Drug|Placebo|Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
75924313|NCT02325336|Device|BCMA (bar-code-assisted medication administration)|"Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.~In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification."
75924314|NCT03499470|Other|Protocol for structured discharge and follow-up|
75924315|NCT05051878|Device|T-scan|occlusal analysis T-scan
75924316|NCT05051878|Other|articulating paper|articulating paper occlusal analysis
75788043|NCT03794492|Drug|Methylprednisolone/prednisolone|- Methyprednisolone 500mg / Prednisolone 5mg
75788044|NCT03794492|Drug|Basiliximab|- IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)
75788045|NCT01304810|Biological|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
76080037|NCT02981290|Drug|CellCept|CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
75639230|NCT00812812|Drug|paroxetine 20mg tablet|1 tablet once a day
75788046|NCT01304810|Biological|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
75470638|NCT05352178|Other|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
75639231|NCT00812812|Drug|matched placebo to paroxetine 10mg|2 tablets once a day
75639232|NCT00812812|Drug|matched placebo to paroxetine 20mg|1 tablet once a day
75639233|NCT02739165|Drug|ART-123|380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
75639234|NCT02739165|Drug|Placebo|Placebo by intravenous drip infusion in addition to standard of care steroid therapy
75639235|NCT02739243|Behavioral|Tailored group intervention (PREPARE)|
75639236|NCT02739243|Behavioral|Individual treatment as usual|
75924317|NCT05519722|Behavioral|Expectation-focused online intervention|Patients receive an expectation-focused online intervention (around 30 minutes) consisting of a video with general information about psychotherapy, a video with reports of patients' therapy experiences, questions on the content of the videos as well as open questions on personal strengths, fears and expectations in the context of therapy. This intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the psychotherapeutic process.
75924318|NCT02325492|Drug|Aramchol|
75924319|NCT02325492|Drug|Placebo|
75924320|NCT02325492|Device|Ultrasound|
76080038|NCT03437226|Drug|Levosimendan 2.5 MG/ML|Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
75924321|NCT04745468|Device|CRP apheresis|Selective CRP apheresis by use of the PentraSorb-CRP adsorber
75788047|NCT05625074|Procedure|Conventional surgery for great saphenous vein insufficiency|Arch ligation and stripping of great saphenous vein. Prophilatic anticoagulation - Low molecular weight heparin vs DOACs Antibiotics Non-steoridal anti-inflamatory drugs
76080039|NCT03437226|Drug|Placebos|Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
76080040|NCT03444558|Dietary Supplement|Natural supplement containing chlorogenic acid and luteolin|50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
76080041|NCT03444558|Other|Placebo (without any active ingredients)|50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
75788048|NCT03792230|Behavioral|Video|Video group receive body mechanic education via CD material,
75788049|NCT03792230|Behavioral|Brochure|Brochure group receive body mechanic education via written material (brochure)
76080042|NCT01236196|Behavioral|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
75788050|NCT03811106|Device|NeuromuscularElectricalStimulation+ConventionalPhysiotherapy|Sırt ekstansör kaslarına nöromusküler elektrik stimülasyonu uygulanacaktır
76080043|NCT01236196|Behavioral|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
75639237|NCT02742285|Drug|Artemether + lumefantrine|A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
75639238|NCT05297344|Procedure|direct pulp capping|direct pulp capping
75788051|NCT03811106|Other|Conventional physiotherapy and rehabilitation|Konvansiyonel fizyoterapi ve rehabilitasyon uygulamaları yapılacaktır.
75788052|NCT03792152|Drug|Rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).
75788053|NCT03792152|Drug|Warfarin|After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
75788054|NCT03792386|Procedure|Ultrasound guidance with fluoroscopic confirmation|the cervical spine will be sonographically examined to determine the C7 transverse process then after lidocaine skin infiltration, a 22G spinal needle is directed towards the hypoechoic shadow of the nerve root using the in-plane technique. then 1ml of non-ionic contrast will be injected and AP and the oblique foraminal fluoroscopic view will be obtained. After confirmation of correct placement of the needle,(2ml, 8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
76080044|NCT03444480|Drug|Remimazolam Tosylate|Initial dose plus supplemental doses
76080045|NCT04793412|Device|Cochlear Implant|Cochlear implantation of a device from one of the three manufacturers available in the US.
76080046|NCT01236742|Device|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
76080047|NCT01236742|Device|single-vision glasses|daily wear of spectacle glasses to correct vision
76080048|NCT04788420|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
75639239|NCT05297344|Procedure|pulpotomy|pulpotomy
75639240|NCT04190199|Other|Observational|Cross-sectional only
75639241|NCT05756608|Diagnostic Test|68Ga-FAPI and 18F-AlF-FAPI PET-MR|Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer
75639242|NCT03673527|Drug|topical formulation of tacrolimus|Topical application of tacrolimus twice daily for 14 days (one dose on Day 14).
75639243|NCT04030546|Drug|Ivabradine|Ivabradine capsule
75788055|NCT03792386|Procedure|Fluoroscopic guidance with ultrasonographic confirmation.|After AP view, alignment or squaring of the target lower end plate, an oblique foraminal view is obtained. Following lidocaine 1% skin infiltration, a 22G spinal needle is directed towards the target foramen then, the superficial ultrasound probe will be applied to delineate the foramen. The needle will be advanced ~3mm towards the dorsal root ganglia under fluoroscopic guidance. After contrast confirmation of needle placement, 2ml,8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
75924322|NCT03499392|Other|psychological tests|psychological tests psychological interviews
75924323|NCT02437370|Drug|Pembrolizumab|Given IV
75924324|NCT02437370|Drug|Docetaxel|Given IV
75924325|NCT02437370|Drug|Gemcitabine Hydrochloride|Given IV
75924326|NCT05515120|Drug|Rivaroxaban 20 MG [Xarelto]|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
75924327|NCT05515120|Drug|Aspirin 300mg|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
75924328|NCT05515120|Drug|Acenocoumarol Oral Tablet|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
75924329|NCT02323074|Procedure|Brain Computer Interface|
76080049|NCT01282138|Drug|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
76080050|NCT01282138|Other|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
76080051|NCT01922973|Other|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
75924330|NCT03496116|Other|ECIG Session|Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
75924331|NCT05515042|Drug|Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)|As included in arm/group descriptions
75924332|NCT04664270|Behavioral|e-CBT|e-CBT + Mindfulness + Problem Solving
75788056|NCT00262067|Drug|Bevacizumab|Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
75924333|NCT02323152|Behavioral|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
75788057|NCT00262067|Drug|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody.
75331410|NCT00947765|Biological|Autologous blood injection|Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
75331411|NCT00947765|Drug|Local corticosteroid injection|Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
75331412|NCT01089517|Drug|E10030 plus Lucentis|once a month intravitreal injection
75331413|NCT01089517|Drug|Lucentis|10 mg/mL intravitreal injection monthly
75331414|NCT04311515|Radiation|Tau Positron emission tomography (PET)|Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
75639244|NCT05756530|Other|Affective touch paradigm|"Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm.~After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness.~As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch in close relationships."
75331415|NCT04311515|Radiation|Fluorodeoxyglucose (FDG) Positron emission tomography (PET)|Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
75639245|NCT04030390|Behavioral|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
75639246|NCT04030390|Behavioral|Control|time-matched task (sitting on the bike without pedalling)
75639247|NCT02739009|Drug|MOR106 single ascending doses, intravenous|
75639248|NCT02739009|Drug|Placebo single ascending doses, intravenous|
75639249|NCT02739009|Drug|MOR106 multiple ascending doses, intravenous|
75788058|NCT00262067|Drug|Chemotherapy|"The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~Docetaxel 75-100 mg/m^2 IV~Paclitaxel protein-bound particles (Abraxane®) 260 mg/m^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~5-fluorouracil 500 mg/m^2 IV + epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV~5-fluorouracil 500 mg/m^2 IV + doxorubicin 50 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV~Doxorubicin 50-60 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV~Epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV~Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle"
75639250|NCT02739009|Drug|Placebo multiple intravenous administrations|
75639251|NCT05210296|Behavioral|Exercises|Therapeutic exercise will be applied to the elderly
75639252|NCT02738931|Drug|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
75788059|NCT05624762|Device|Low-Intensity Focused Ultrasound (LIFU)|LIFU device (LCA200; Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China).
75788060|NCT05624762|Device|Sham Low-Intensity Focused Ultrasound|Sham Low-Intensity Focused Ultrasound
75788061|NCT01304888|Other|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
75924334|NCT02323152|Other|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
75924335|NCT04502108|Behavioral|Covid19|Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.
75924336|NCT02323230|Biological|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
75924337|NCT02323230|Drug|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
75639253|NCT02738931|Drug|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
75639254|NCT02738931|Drug|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
75788062|NCT01304888|Other|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
75788063|NCT01304888|Other|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
75788064|NCT01304888|Other|Control|No benefits were provided
75639255|NCT02738931|Drug|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
75639256|NCT00810082|Device|ActiveStep|ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
75639257|NCT00810082|Other|Standard Physical Therapy for Fall Prevention|Standard physical therapy for fall prevention
75639258|NCT02738697|Drug|Adjuvant chemotherapy|8~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
75639259|NCT02738697|Procedure|Follow-up|Patients received just follow-up instead of adjuvant chemotherapy
75639260|NCT02736747|Other|Cryotherapy|
75639261|NCT02736747|Other|Placebo|
75639262|NCT02738619|Drug|Vitamin D3|1600 UI
75639263|NCT02738619|Drug|placebo|placebo
75639264|NCT04016116|Drug|Pembrolizumab|Pembrolizumab IV every 3 weeks
75639265|NCT04016116|Drug|Ruxolitinib|Ruxolitinib po days 1-21
75639266|NCT02736591|Drug|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.
75639267|NCT02736591|Drug|Growth Hormone-Releasing Hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
75639268|NCT02736591|Drug|Placebo 1|Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
75639269|NCT02736591|Drug|Placebo 2|Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
75788065|NCT03794102|Other|Water|Sterile water irrigation from standard sterile water bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
75788066|NCT03794102|Other|Saline|0.9% saline irrigation from standard saline bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
75788067|NCT03974165|Other|Cereal-legume product 1|The intervention examines the effect of cereal based product fortified with legumes-1 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
75788068|NCT03974165|Other|Cereal-legume product 2|The intervention examines the effect of cereal based product fortified with legumes-2 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
75788069|NCT03974165|Other|Cereal product|The intervention examines the effect of cereal product in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
75924338|NCT02323308|Other|blood sampling|
75639270|NCT02736513|Drug|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
75639271|NCT02610322|Behavioral|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
75639272|NCT02610322|Behavioral|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and <30% of energy as total fat.
75639273|NCT05756452|Diagnostic Test|Anamnesis and clinical evaluation|All partecipants will undergo a global echocardiographic evaluation, a 24-hour ECG Holter recording to assess HRV and blood samples collection for neurotransmitter measurements, platelet activation and reactivity evaluation and inflammatory profile assessment by proteomics analysis, inflammasome activity evaluation, NLRP3, pro-IL-18 and pro-IL-1β expression level by qPCR and epigenetic analysis.
75639274|NCT02738385|Behavioral|High Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
75639275|NCT02738385|Behavioral|Moderate Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
75788070|NCT03974165|Other|Reference food|The intervention examines the effect of reference food in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
75924339|NCT03121898|Device|Platelet function test|Measurement of P2Y12 and PAR-dependent platelet function activity before and after cardiac surgery by ADPtest and TRAPtest
75470639|NCT05352178|Drug|Androgen deprivation therapy|Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
75639276|NCT04853290|Device|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
75639277|NCT04853290|Device|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by the registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture protocol instituted in the hospital where the study will be conducted
75639278|NCT02736435|Device|Magnetic Resonance Guided High Intensity Focused Ultrasound|Direct treatment of uterine fibroids with MR-HIFU
75639279|NCT02736435|Drug|leuprolide acetate for depot suspension|Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
75639280|NCT02738541|Drug|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
75639281|NCT02738541|Drug|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
75924340|NCT02319720|Biological|Bone Marrow Aspirate|Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
75924341|NCT02319720|Biological|Cultured Bone Marrow Cells|The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
75924342|NCT02319720|Procedure|Control|The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
75924343|NCT04610060|Behavioral|Power walking|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~It is a form of exercise where active upper body movement is performed along with usual walking. It is a fast walking exercise done at a speed of 6 to 8 km/h. During power walking the back is kept straight with the centre of gravity moving from heal, sole, and to hallux. There is active swing back and forth movement of elbow joint with 90 degrees of flexion while walking.~Weekly protocol for power walking~Week 1 60-65 % of the target heart rate (THR) 5,000 to 7,499 steps/day~Week 2 65-70 % of the target heart rate (THR) 7,500 to 9,999 steps/day~Week 3 70-75 % of the target heart rate (THR) >=10,000 steps/day~Week 4 75-80 % of the target heart rate (THR) >12,500 steps per day"
75924344|NCT04610060|Behavioral|Standardised outpatient cardiac rehabilitation|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines the intervention group received the following four weeks of intense training program
75924345|NCT02319798|Other|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
75924346|NCT02319798|Other|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
75639282|NCT02610244|Other|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
75639283|NCT02736279|Drug|Dimethyl fumarate|Observation of impact of dimethyl fumarate treatment initiation on mood and gut microbiome over the first 6 months of therapy
75639284|NCT04851262|Behavioral|Exercise|The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted.
75639285|NCT00748189|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
75788071|NCT00275561|Drug|Fluticasone|Aerosolized swallowed fluticasone 880 mg twice a day
75788072|NCT00275561|Drug|Placebo|Placebo inhaler swallowed twice a day for 6 weeks
75788073|NCT02802020|Device|Pancreatic fully-covered self-expanding metal stent (FCSEMS)|The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent.
75788074|NCT01071473|Other|12 Week Exercise Intervention|Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
75470640|NCT05352178|Drug|Androgen receptor targeted therapy|Enzalutamide
75470641|NCT05328141|Other|Bread and butter|A bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)
75470642|NCT05328141|Other|X.gideon|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)
75470643|NCT05328141|Other|X.gideon with ascorbic acid|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid
75788075|NCT01070849|Other|educational booklet|"Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell."
75924347|NCT05512468|Drug|carbon dye|Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
75924348|NCT05583734|Device|Portomar(TM) Device|Portomar(TM) access device for bone marrow biopsy
75924349|NCT04461756|Drug|PPP001|inhalation (vape)
75924350|NCT04297306|Behavioral|Exercise Prescription|Standardised Exercise Prescription.
75924351|NCT04297306|Device|Exercise Prescription and Virtual Reality Exercise Gaming support|Standardised Exercise Prescription with the additional support of Virtual Reality Promoted Exercise Games.
75924352|NCT05583656|Procedure|Pulmonary valve replacement|Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.
75331416|NCT04311515|Diagnostic Test|Cerebrospinal fluid (CSF) Biomarkers|A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
75470644|NCT05310916|Drug|Dapagliflozin 10mg Tab plus another oral hypoglycemic agent|Dapagliflozin is a member of Sodium-glucose co-transporter 2 inhibitors class which in addition to its glucose control effect, has reno-protective and cardioprotective effects, controls blood pressure and causes weight loss.
75470645|NCT05310916|Drug|Two oral hypoglycemic agents other than dapagliflozin|Two oral anti-diabetic agents not including sodium-glucose co-transporter 2 inhibitors
75639286|NCT00748189|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
75788076|NCT01070849|Other|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
75470646|NCT05278481|Behavioral|Reward Message with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
75470647|NCT05278481|Behavioral|Reward Message with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
75470648|NCT05278481|Behavioral|Threat/Self-efficacy with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
75639287|NCT02610166|Behavioral|Game|"In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to lose the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom."
75639288|NCT02610166|Other|Usual Care|Children in usual care group receive standard medical care.
75924353|NCT02325570|Device|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
75924354|NCT02325570|Procedure|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
75924355|NCT01977638|Drug|CXD101|Capsules, administered orally
75924356|NCT03495804|Drug|polyethylene glycol|Experimental group was given polyethylene glycol as oral contrast agent.
75924357|NCT03495804|Drug|mannitol|Active comparator group was given mannitol as oral contrast agent.
75331417|NCT04311515|Diagnostic Test|Blood Biomarkers|Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
75331418|NCT04311515|Behavioral|Rating Scales|Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
75331419|NCT04311515|Drug|PU-AD|PU-AD 30mg daily for 6mos
75331420|NCT04311515|Drug|Placebo|Placebo 30mg daily for 6mos
75331421|NCT01089595|Drug|Nilotinib|Nilotinib 400 mg po bid
75924358|NCT05580926|Behavioral|Watch your Weight During Holidays|"Participants in this group will have an individual face-to-face session (with a maximum duration of half an hour) and a face-to-face group session. This intervention will include strategies for self-monitoring (body weight, diet and physical activity), information on healthy lifestyles, as well as information about the energy contained in local festive foods and their equivalent in minutes of physical activity or steps per day.~Participants will be asked to weight themselves at least twice a week, as a form of self-monitoring of weight, from the start of the intervention. They will have access to weekly forms with boxes, where they can fill in the data obtained for each day of weight self-monitoring, energy intake restriction report and minutes of physical activity performed."
76080052|NCT03440346|Other|Few-foods diet|The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
76080053|NCT03444402|Drug|CKD-381(formulation I)|1 tablet administered before the breakfast during 7 days
75639289|NCT02736201|Device|Capacitive diathermy (T-CaRe®)|The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.
76080054|NCT03444402|Drug|CKD-381(formulation II)|1 tablet administered before the breakfast during 7 days
75331422|NCT01089595|Drug|Nilotinib with Imatinib|Nilotinib 400 mg po BID Imatinib 400 mg po daily
75788077|NCT01070849|Other|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
75331423|NCT04268693|Other|urine collection|Collect three urine samples either in the clinic or at home. This will occur prior to starting neoadjuvant chemotherapy, and again at the end of the scheduled course of neoadjuvant chemotherapy.
75788078|NCT03792308|Drug|SPR206|"SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13."
76080055|NCT03444402|Drug|D026(Nexium 40mg)|1 tablet administered before the breakfast during 7 days
76080056|NCT01238536|Procedure|Epidural steroid with local anesthetic injection|Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
76080057|NCT01238536|Procedure|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
75470649|NCT05278481|Behavioral|Threat/Self-efficacy with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
75470650|NCT05278481|Behavioral|Social norms message with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
75470651|NCT05278481|Behavioral|Social norms message with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
75470652|NCT05272475|Dietary Supplement|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
75639290|NCT02736201|Other|Instrumental manual therapy|Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)
75639291|NCT02609230|Drug|ONC-201|
75639292|NCT02738307|Other|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
75639293|NCT04028908|Diagnostic Test|radiographs in two views of the tibia|The anterior tilt angle of the tibia will be measured by two specialized radiologists according to a specific radiological angle measurement tool (PACS Sectra IDS7TM, Linköping, Sweden).
75639294|NCT00913822|Drug|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
75331424|NCT03032159|Behavioral|Text2Breathe Study Group|
75331425|NCT01089751|Drug|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
75331426|NCT01089751|Drug|placebo|Placebo once daily on an empty stomach for 14 weeks.
75331427|NCT03032315|Drug|TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
75331428|NCT03032315|Drug|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
75331429|NCT03032315|Drug|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
75924359|NCT05580926|Other|Control Group (minimal intervention)|Participants in this group will receive a printed information, as well as a PDF file, brochure during a face-to-face session at the beginning of the 8-week period. This information will be about having a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
75924360|NCT03499158|Other|nerve conduction study|nerve conduction study
75924361|NCT04968496|Other|Food Secure Group|Weekly meals (five breakfast and five lunch meals) will be provided to all children randomized to this group to prevent the onset of summertime food insecurity
75924362|NCT05580848|Procedure|Wrist arthroscopy|"Wrist arthroscopy is a minimally invasive endoscopic method that enables the diagnosis and treatment of certain diseases and injuries of the radiocarpal, mediocarpal and distal radioulnar joints.~Wrist arthroscopy enables a direct view of the articular surface of the wrist and the assessment and adequate treatment of articular fractures The wrist arthroscopy procedure also enables the detection and necessary treatment of associated soft tissue injuries (scapho-lunate and/or luno-triquetral ligament, i.e. triangular fibrocartilaginous complex) and/or cartilage lesions in extra-articular and articular fractures."
75924363|NCT02325648|Drug|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
75924364|NCT05519410|Drug|Sintilimab and Lenvatinib|Tislelizumab, 200mg, ivd,q3w; Lenvatinib,8mg/kg,po,qd.
75924365|NCT05519410|Drug|HAIC-FOLFOX|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
75924366|NCT05578586|Drug|Meropenem 1000 mg|given as 6 or 3 infusions in 15 minues or 3 hours.
76080058|NCT01238536|Drug|Epidural steroid injection|Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
75331430|NCT01090921|Drug|Bortezomib|"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."
75470653|NCT05272475|Dietary Supplement|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
75639295|NCT00913822|Drug|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
76080059|NCT01238536|Drug|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
75924367|NCT05514886|Device|Gene Expert molecular Point-of-Care (POC) (Xpert® Xpress SARS-CoV-2/Flu/RSV test|POC viral load (VL) assay in improving the availability of SARS-CoV-2 detection for COVID-19 patient management in decentralized healthcare facilities of resource-constrained settings in Tanzania, DR Congo and Burkina Faso.
75331431|NCT03537274|Biological|PEG-Intron|PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
75331432|NCT03537274|Biological|Interferon Alfa-2B|Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
75331433|NCT01091155|Device|ColonRing (Colorectal anastomosis)|Creation of a colorectal compression anastomosis
75924368|NCT03121976|Device|Ultrasound|Femoral catheter inserted using ultrasound only
75639296|NCT05603091|Procedure|cryoablation of pulmonary veins|Procedures are guided by pressure waveforms analysis, which are obtained by connecting the internal lumen of the catheter through the lateral port of the hemostatic valve attached to the catheter, to a pressure transducer connected in turn to a heparinized saline serum bag and to the cryoablation console.
75639297|NCT02736123|Drug|Nivolumab - Arm A|Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
75924369|NCT03121976|Device|Ultrasound + Nerve Stimulation|Femoral catheter inserted using ultrasound and nerve stimulation
75924370|NCT02570152|Procedure|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever [body temperature ≥ 38°C/≥ 100.4°F] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
75924371|NCT03495726|Behavioral|Headspace app|Headspace is a Contemplative Application (App) for Well-being (CAW). Participants will be provided initial instructions for downloading and using the Headspace app. The Headspace app includes guided meditations, articles and videos. Participants will be asked to engage in meditation practice for an average of 10 minutes a day during the 6-week training period.
76080060|NCT03437070|Drug|Trabectedin|Administered intravenously per protocol on Day 1 for 21-day cycles.
76080061|NCT03437070|Drug|Doxorubicin|Administered intravenously per protocol on Day 1 for 21-day cycles.
76080062|NCT03437070|Drug|Olaratumab|Administered intravenously per protocol
76080063|NCT04346446|Drug|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion
76080064|NCT04346446|Other|Supportive Care|Supportive Care
76080065|NCT04346446|Drug|Random Donor Plasma|Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement
76080066|NCT00634101|Device|nelfilcon A|contact lens
76080067|NCT00634101|Device|narafilcon A|contact lens
76080068|NCT04478058|Behavioral|Live CBT|Weekly in-person Cognitive Behavioural Therapy
76080069|NCT04478058|Behavioral|e-CBT|Weekly online Cognitive Behavioural Therapy
75788079|NCT03792308|Drug|Placebo|0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
75788080|NCT03810872|Drug|Afatinib|Open label
75924372|NCT02323386|Device|Primary Total Knee Arthroplasty (ATTUNE Knee System)|"The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected."
75924373|NCT02325726|Procedure|Renal Resistive Index compared with NephroCheckTM|
75924374|NCT03495570|Diagnostic Test|blood draw|single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count
76080070|NCT01284244|Device|Uresta pessary|Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
76080071|NCT01284244|Device|Silastic ring|The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
75639298|NCT02736123|Drug|Nivolumab + Ipilimumab - Arm B|Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
75639299|NCT02735967|Other|manual therapy|the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
75788081|NCT03810872|Drug|Paclitaxel|Paclitaxel
75924375|NCT03494010|Other|Observation|There is no intervention. Patients will receive the HCL system as part of their clinical care.
75924376|NCT03495492|Device|Dermal Chelation|Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.
75788082|NCT03810950|Behavioral|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
75924377|NCT03495492|Dietary Supplement|Nutritional Therapy|Vitamins and minerals that will be taken one or more times a day.
75924378|NCT03495336|Other|coffee abstention phase|no coffee consumption for 2 weeks
75924379|NCT03495336|Other|LR Coffee consumption|for 4 weeks participants consumed only LR Turkish coffee
75924380|NCT03495336|Other|DR Coffee consumption|for 4 weeks participants consumed only DR Turkish coffee
75924381|NCT02570074|Drug|Fosfomycin|Broad spectrum antibiotic
75924382|NCT03499002|Other|Simulated Learning Environment|Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
75470654|NCT05263466|Diagnostic Test|PET-MRI|For the diagnostic imaging aspect included in this pilot study, [68Ga]PSMA-11 will be used. This is a peptidomimetic agent with a covalently bound chelator (HBED-CC) that is FDA-approved in prostate cancer imaging. We will use PET-MRI to visualise a) the concentration and b) the distribution of this tracer to establish a functional map of primary brain tumour activity
75470655|NCT05263466|Procedure|Brain tumour biopsy|All patients included in our study will undergo stereotactic surgery for biopsy/resection of the tumour as part of the standard of care at KCH. During this study we will not vary from the surgical standard of care for primary brain tumours and will only extend the surgery time due to additional stereotactic biopsies (an additional 3 biopsies increasing the time of the operation by ~30 minutes). Professor Ashkan (KCH) has defined the additional surgical risk of performing these biopsies to be ~0%, since targeted biopsies will only be taken within the tumour just before resection. The stereotactic biopsy may be targeted to areas of high [68Ga]PSMA SUV within the tumour as defined by the PET MRI scan.
75470656|NCT05252559|Procedure|ultrafiltration|In cardiac surgery patients, ultrafiltration is usually applied to reduce free water and concentrate all blood components before weaning from cardiopulmonary bypass
75470657|NCT05252559|Diagnostic Test|maximal clot firmness in EXTEM assay of ROTEM test|before and after applying ultrafiltration, arterial blood sample underwent EXTEM and FIBTEM assays of rotational thromboelastometry
75788083|NCT03810950|Behavioral|Reading Newspaper|Participants read newspaper
75788084|NCT03810950|Behavioral|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
75924383|NCT03498924|Diagnostic Test|Measure of biomarkers in serum and endometrial tissue|Blood sample and endometrial sample
75788085|NCT03794180|Drug|TJ003234|Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
75788086|NCT03794180|Drug|Placebo|Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
75788087|NCT05669144|Biological|mitochondria and MSC-derived exosomes|autologous mitochondria and MSC-derived exosomes
75788088|NCT00274937|Drug|Amifostine|Given subcutaneously
75924384|NCT02569996|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
75924385|NCT03498846|Procedure|Modified EA and AMLK|Two pieces of corneal epithelial tissue with 2mmx3mm will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
75924386|NCT03498846|Procedure|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
75924387|NCT02325882|Drug|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
75924388|NCT02325882|Drug|Fentanyl 1|conventional fentanyl-based epidural PCA
75924389|NCT02325882|Drug|Fentanyl 2|conventional fentanyl based intravenous PCA
75788089|NCT00274937|Drug|Cisplatin|Given IV
75788090|NCT00274937|Drug|Fluorouracil|Given IV
75924390|NCT05519332|Procedure|percutaneous vertebral-disc plasty|percutaneous vertebroplasty combined percutaneous cement discoplasty
75924391|NCT03498768|Other|Questionnaire Administration|Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
76080072|NCT04469088|Other|Dry needling|Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.
75331434|NCT00939653|Drug|Clofarabine|40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
75470658|NCT05233709|Dietary Supplement|FeSO4 + OTf|OTf (apo ovotransferrin) + FeSO4
75470659|NCT05233709|Dietary Supplement|FeSO4 + Lf|Lf (lactoferrin) + FeSO4
75924392|NCT03498690|Behavioral|Integrative|Stakeholder groups: a-b
75924393|NCT03498690|Behavioral|Role specific|Stakeholder groups: a or b
75924394|NCT03498690|Behavioral|Consecutive|Stakeholder groups: a=> b
75924395|NCT04424836|Device|high flow nasal cannula device|device is supplying oxygen with heated and humidified air in a high flow rate
75331435|NCT00939653|Drug|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
75470660|NCT05233709|Dietary Supplement|FeSO4|Ferrous sulfate
75470661|NCT05414461|Drug|Combinations|PD-1 inhibitor-based combinaiton treatment
75924396|NCT02323542|Other|Nutrition intervention with cereal products|acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
75924397|NCT04424758|Other|Video information about mammography screening|A video informing about mammography screening
75331436|NCT00939653|Drug|Cyclophosphamide|440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
75331437|NCT00939653|Drug|Filgrastim|Administered in Courses 1 and 2 only. 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000 x 2 days.
75331438|NCT00939653|Drug|Cytarabine|"Given intrathecally on day 1 at the dose defined by age below:~30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients >3 years of age"
75331439|NCT02527291|Other|Blood test|Blood test for CMV PCR and IL28
75331440|NCT04355039|Drug|Pomalidomide|4 mg Days 1-21
75331441|NCT04355039|Drug|Dexamethasone|40 mg Days 1, 8, 15 and 22
75470662|NCT05173896|Drug|Tadalafil 20 MG|Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
75470663|NCT05173896|Drug|Placebo|Daily dose of oral over-encapsulated placebo tablets for three months.
75470664|NCT05173701|Dietary Supplement|Probiotics|Selected probiotics mixture, in powder form, will be administered once daily for three months in the morning.
75470665|NCT05173701|Dietary Supplement|Placebo|A placebo (2,7g maltodextrin) will be administered once daily for three months in the morning.
75639300|NCT02735967|Device|diadynamic current|Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
75639301|NCT00744055|Drug|Prazosin|prazosin (16mg/day) 2 times a day
75639302|NCT00744055|Drug|Placebo|Placebo
75639303|NCT02735811|Device|Assesment of long-term outcome of ICD patients|Evaluation during follow-up of the occurrence of complications related to ICD implantation and of death
75639304|NCT00748033|Device|Reference catheter: LoFric PVC, Nelaton 40 cm, CH 12|The subjects were first catheterized with this reference catheter.
75639305|NCT00748033|Device|LoFric POBE Hydro-Kit II, 5 seconds|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 5 seconds
75788091|NCT00274937|Other|Laboratory Biomarker Analysis|Correlative studies
75788092|NCT00274937|Radiation|Radiation Therapy|Undergo radiotherapy
75788093|NCT03791996|Procedure|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
75470666|NCT05165537|Device|NIMM_MRS|evaluation of new MRS methods
75788094|NCT04914728|Procedure|mini-invasive lumbar arthrodesis|"The mini-invasive posterior approach is performed using a trans-muscular Wiltse approach. Pedicle screws, neurological decompression and intersomatic cage placement are performed.~The mini-invasive anterior approach is performed via a left retroperitoneal pararectal approach. After complete discectomy, an intersomatic cage stabilised by a screwed plate will be placed."
75788095|NCT01305122|Behavioral|neurocognitive tests|"inclusion~1 year~3 years~5 years"
75788096|NCT03811184|Diagnostic Test|MemScreen|Neuropsychological test on smartphone or digital tablet, on self assesment.
75788097|NCT03794414|Procedure|PEEP challenge|apply PEEP 10 mmHg in one-lung ventilating patients.
75788098|NCT01582295|Drug|Cabozantinib|Starting dose 40 mg daily
75924398|NCT04424758|Other|Video information about smart energy systems|A video informing about smart energy systems
75924399|NCT05144646|Other|MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL|The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.
75924400|NCT05144646|Other|MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL|In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
75924401|NCT02323620|Procedure|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
75924402|NCT02572882|Dietary Supplement|p-inulin|12 week self-administered treatment phase
75924403|NCT02319954|Procedure|Direct compression|Direct compression by the surgeon with their hands on the nasal sidewall
75639306|NCT00748033|Device|LoFric POBE Hydro-Kit II, 24 hours|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 24 hours
75924404|NCT00708500|Drug|Boceprevir (SCH 503034)|Boceprevir, 200 mg capsules, 800 mg TID PO
75924405|NCT00708500|Biological|Pegylated interferon alfa-2b (SCH 54031)|PEG2b 1.5 μg/kg/week subcutaneously (SC)
75924406|NCT00708500|Drug|Ribavirin (SCH 18908)|Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
76080073|NCT04469088|Other|Manual Therapy Treatment|Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
76080074|NCT03129048|Behavioral|MedDiet|"Research subjects will be randomly assigned to one of three intervention groups.~The MedDiet-A group will learn about and how to adhere to the Mediterranean Diet. Over the course of 8 months, they will receive twenty-two classes 60-minute in length.~The MedDiet-WL group will learn about the Mediterranean Diet, how to adhere to is and engage in lifestyle choices like exercising and eating fewer calories so that they will loose weight. Over the course of 8 months they will receive 22 classes, each 90 minutes in length.~The Typical Diet Control group will be asked to maintain current eating and activity patterns over the course of the 14 month study."
76080075|NCT04450290|Device|CIDEXEL implant|The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
75331442|NCT04355039|Drug|INCB053914 50 mg bis in die (BID)|Dose level 0: 50 mg BID
75639307|NCT03545763|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
75639308|NCT02736903|Behavioral|PennFit mobile individual intervention|PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
75788099|NCT03793946|Other|AB-assistant|The AB-assistant is an antimicrobial stewardship smartphone application that offers local antimicrobial guidelines to physicians currently assessed per website or paper/digital booklet.
75788100|NCT01071551|Behavioral|Life-style intervention|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
75924407|NCT00708500|Drug|Boceprevir placebo|Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
75924408|NCT05144100|Procedure|Surgery with or without Neck Dissection|An appropriate surgery as open, endoscopic, TLM, TORS or a combination with or without neck dissection e.g. levels dissected, sparing or sacrifice of the SCM, accessory nerve, etc as per patient disease and status will be performed
75331443|NCT04355039|Drug|INCB053914 65 mg BID|Dose level 1: 65 mg BID
75331444|NCT04355039|Drug|INCB053914 80 mg BID|Dose level 2: 80 mg BID
75788101|NCT01071551|Behavioral|Physical activity only|Children allocated to this group will attend 20 physical activity classes.
75470667|NCT05150951|Behavioral|Novel Exploration|Exploration of a novel 3D-environment in virtual reality.
75639309|NCT02736903|Behavioral|PennFit mobile online network intervention|PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
75639310|NCT02737995|Drug|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
75639311|NCT02738073|Drug|Control: Saline|
75924409|NCT05144100|Radiation|Radiation|Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of upto 7 weekly doses, administered during the course of IMRT.
75639312|NCT02738073|Drug|Tranexamic Acid|
75639313|NCT02737761|Behavioral|Qualitative Interview and Adherence Measurements|Subjects will undergo an open-ended, semi-structured interview within two weeks of enrollment. The interview will be approximately 1 hour in length, performed by study staff who have been trained in qualitative research methods. This interview will be completed again 12 weeks later. Subjects will complete the MOS SAS, Automated Self-Administered 24-hour recall (ASA24), Life Orientation Test-Revised (LOT-R), Positive and Negative Affect Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Medical Outcomes Study Short Form-12 (SF-12) at baseline and again at 12 weeks.
75639314|NCT03967483|Drug|Indometacin|patient who are taken indomatacin for headaches and migraine
75639315|NCT00735553|Drug|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
75639316|NCT00735553|Drug|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
75639317|NCT00735553|Drug|Placebo|Two placebo capsules orally daily for up to four months
75639318|NCT02595775|Other|Individualized A/F report|Individualized A/F report containing 9 colonoscopy quality measures.
75639319|NCT02595775|Other|A/F report plus a high intensity intervention|E.g. Master class in colonoscopy
75639320|NCT02595775|Other|A/F report plus a low intensity intervention|E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.
75639321|NCT02595775|Other|A/F report alone|
75639322|NCT00740779|Drug|Silodosin 8 mg|Silodosin 8 mg daily
75639323|NCT00740779|Drug|Placebo|Placebo
75639324|NCT00740779|Drug|Silodosin 4 mg|Silodosin 4 mg daily
75639325|NCT00735475|Biological|CSL Limited Influenza Virus Vaccine (Afluria®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
75639326|NCT00735475|Biological|US Licensed Influenza Virus Vaccine (Fluzone®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
75639327|NCT01026818|Drug|Tadalafil|Administered by mouth for 9 months
75924410|NCT05144100|Drug|Cisplatin based chemotherpay|Cisplatin (dose-40 mg/m2weekly,upto6-7cycles) cycle 1 will be administered within first 2 # of radiation. The rest of the cycles will be given weekly.
76080076|NCT00633477|Drug|Resatorvid|Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
76080077|NCT00633477|Drug|Placebo|Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
76080078|NCT03128970|Other|synchronizing blastocysts|transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.
76080079|NCT03128736|Drug|Esomeprazole group|Esomeprazole 40mg qd
75331445|NCT03537664|Procedure|Root canal preparation|First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
75331446|NCT03537664|Procedure|Intracanal medication|The second endodontic treatment includes the intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation
75331447|NCT01116037|Device|ATS 3f Aortic Bioprosthesis|Equine Pericardial Bioprosthesis for replacement of diseased valve
75331448|NCT02524405|Other|Pittsburgh Compound B [11C]-PIB|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B [11C]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
75331449|NCT03538678|Other|Kwit smartphone app|Kwit smarphone app
75331450|NCT03032081|Other|High intensity exercise|High intensity exercise, defined as an exercise intensity of > 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
75639328|NCT01026818|Drug|Placebo|Administered by mouth, daily or on demand for 9 months
75639329|NCT00735397|Drug|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
75639330|NCT03967405|Device|MolecuLight PID|Hand-held, real-time fluorescence imaging device
75639331|NCT02593747|Drug|Loratadine oral solution|Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
75639332|NCT02593747|Drug|Loratadine (Claritin peach syrup)|Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
75639333|NCT00735007|Drug|Rebif® New Formulation (RNF) using RebiSmartTM|RNF 44 mg, 3 times a week by subcutaneous injection.
75639334|NCT04089397|Device|Light Therapy|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis
75639335|NCT00743509|Drug|Cyclophosphamide and Sirolimus|"The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously"
75639336|NCT04089319|Other|Music recording|Participants will listen to music for 45 minutes while they rest with acupuncture needles in place.
75788102|NCT03793790|Behavioral|Conditioning with partial reinforcement|Conditioning with partial reinforcement (PRF) provides an uncertain pairing of unconditioned high pain stimuli and conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device). During PRF only 70 percent of unconditioned stimuli are paired to conditioned stimuli. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device and are also used in the 30 percent of unreinforced trials.
75788103|NCT03793790|Behavioral|Conditioning with continuous reinforcement|During conditioning with continuous reinforcement (CRF) unconditioned high pain stimuli are paired to conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) in 100 percent of conditioning trials. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device.
75788104|NCT03793790|Behavioral|Counterconditioning|During counterconditioning, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) to thermal pain stimuli of low intensity.
75788105|NCT03793790|Behavioral|Extinction|During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) only to control stimuli of moderate intensity (previously paired to the deactivation of the mock device).
75924411|NCT04552340|Other|Patient with SAR-CoV-2 infection|Study population The study cohort will be enrolled among patients referred to our the Humanitas Research Hospital, the Hospital Cliniche Gavazzeni (Bergamo) hospitals for SARS-CoV-2 screening who will/will not be hospitalized in wards dedicated to COVID-19 patients or admitted to intensive care unit.
75924412|NCT02320032|Drug|Aripiprazole Lauroxil|Gluteal IM injection, given once every 4 to 8 weeks
75924413|NCT05514652|Drug|Low opioid anesthesia|Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
75924414|NCT05573282|Other|Regorafenib combine with ICIs|Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W
75924415|NCT03495258|Procedure|Clarion Evolve Laser Vaporization System|
75639337|NCT04089319|Other|Mindfulness recording|Participants will listen to a recording of mindfulness for 15 minutes and then listen to music for 30 minutes while they rest with acupuncture needles in place.
75331451|NCT03032081|Other|Moderate intensity exercise|Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
75924416|NCT03495258|Procedure|Olympus TURis Plasma Vaporization|
75924417|NCT05143398|Dietary Supplement|Diet + protein|Comparison of the efficacy
75639338|NCT02595697|Behavioral|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
75639339|NCT00917605|Other|Robot-assisted therapy|Patients will receive an intervention for 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The Robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany), will be used in this project. The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension (Hesse et al., 2003; Hesse et al., 2005). Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. Mode 3 is an active mode as in 2, but the paretic arm had to overcome an individually set, initially isometric resistance to allow the bilateral movement. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually.
75639340|NCT00734929|Drug|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
75639341|NCT00734929|Drug|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
75924418|NCT05143398|Dietary Supplement|Diet + EAA|Comparison of the efficacy
75331452|NCT03014323|Drug|Galantamine|Galantamine 4 mg twice a day for 4 weeks
75331453|NCT03014323|Drug|Placebo|Placebo 1 capsule twice a day for 4 weeks
75639342|NCT00734851|Drug|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
75788106|NCT03793790|Behavioral|Sham Conditioning|In the sham group, participants receive different instructions (namely, that the activation of the device is not expected to affect their pain sensitivity). Additionally, during sham conditioning unconditioned stimuli are not consistently paired to conditioned stimuli, thereby preventing the formation of an association between high pain stimuli and the activation of the mock medical device. In the attenuation phase participants undergo an extinction procedure.
75788107|NCT03794258|Drug|SOF+DCV+CDI-31244|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg administered orally once daily.
75788108|NCT03794258|Drug|SOF+DCV+CDI-31244+ASV|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
75788109|NCT03792074|Drug|SCT510|SCT510 Injection
75788110|NCT03792074|Drug|Bevacizumab|Bevacizumab Injection
75788111|NCT03792074|Drug|Paclitaxel|Paclitaxel Injection
75788112|NCT03792074|Drug|Carboplatin|Carboplatin injection
75924419|NCT05143398|Dietary Supplement|Diet + EAA and TCA|Comparison of the efficacy
75924420|NCT05143398|Other|Diet|Comparison of the efficacy
75924421|NCT00673244|Drug|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
75924422|NCT05568992|Device|AI system of optical detection of advanced adenomas|AI system of optical detection of advanced adenomas
75331454|NCT04352413|Drug|PLM60|Administration: Intravenous infusion
75639343|NCT00734851|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
75639344|NCT00734851|Radiation|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
75639345|NCT02597413|Procedure|Catheterization|Women in this group will be systematically catheterized before leaving the delivery room.
75924423|NCT04424680|Behavioral|Advanced Care Planning program of health decisions|Application of an Advanced Care Planning program program for decision-making in patients with advanced Heart Failure, in comparison to usual follow up and care.
75639346|NCT00734617|Drug|Nicotine Patch|"Groups 1 & 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 & 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day"
75924424|NCT04501016|Behavioral|Tailored behavioral counseling|Participants will initially receive a six-session telephone intervention. Standard cognitive behavioral treatment strategies will be included. Participants will be screened for elevated depressive symptoms, risky alcohol use, and concerns about weight and and offered supplemental behavioral counseling related to these issues as appropriate. Those that are unable to quit tobacco initially will receive an enhanced, four-session counseling module focused on reduced scheduled smoking. Those who do quit tobacco use initially will receive four sessions of extended counseling based on positive psychology intervention strategies.
75924425|NCT04501016|Drug|Tobacco cessation pharmacotherapy|Pharmacotherapy will be selected based on medical and psychiatric history and potential interactions with other current medications combined with shared decision making. Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily). Monotherapy and combination therapy options will be provided.
76080080|NCT03128736|Drug|Dexlansoprazole group|Dexlansoprazole 60mg qd
75331455|NCT02448823|Other|Mass media and Stylish Events|"Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses."
75331456|NCT02448823|Other|Mass Media|1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
75788113|NCT01305590|Other|Survey to Understand Medication Adherence among HIV Patients|"We want to better understand how this particular population would react to commitment devices designed to increase medication adherence. We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
75639347|NCT00743431|Drug|Caelyx (Pegylated Lyposomal Doxorubicin)|Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
76080081|NCT01923207|Drug|DX-2930|
75331457|NCT03393208|Drug|Test GIR|Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
75331458|NCT03393208|Drug|Reference GIR|Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
75639348|NCT02737839|Other|Stepping On Education Program|
75639349|NCT02737839|Other|Home visit|
75639350|NCT02737839|Other|Patient Questionnaire|-Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy
75639351|NCT02737839|Other|Mini-Balance Evaluation Systems Test|"The Mini-BESTest includes 14-items that assess balance across four domains: 1) anticipatory postural adjustments, 2) reactive postural responses, 3) sensory orientation, and 4) stability in gait. Each item is rated on a 0-2 scale with 0 indicating poor balance and 2 indicating no impairment. The total possible score on the Mini-BESTest is 28 points~Balance testing will take approximately 15 minutes."
75639352|NCT02737839|Other|GAITRite|"Gait will be assessed using the 4.87-m GAITRite~The GAITRite is a computerized mat that allows for measurement of spatiotemporal measures (e.g., gait velocity, stride length) of gait. We will measure gait in the following conditions: 1) comfortable forward, 2) fast-as-possible, and 3) dual-task. For comfortable forward, participants will be asked to walk at their self-perceived normal pace. For fast-as-possible, participants will be asked to walk as quickly and safely as possible. For dual-task, participants will be asked to walk at their comfortable pace forward while saying as many words that begin with a letter given to them just prior to the start of the trial. Participants will complete five trials of each condition. Gait testing will take approximately 15 minutes."
75639353|NCT02737839|Other|Precise measure of movement testing|We will conduct additional movement-based testing with participants wearing small, portable sensors (APDM, Inc., Portland, OR). These sensors allow for precise measurement of movement characteristics. The sensors will be worn on the outside of clothing and will be placed on the following body locations: 1) sternum, 2) low back, 3) right wrist, 4) left wrist, 5) right ankle, and 6) left ankle. The participants will wear these sensors during the following movement tasks: 1) Two Minute Walk Test, 2) Timed Up & Go, 3) Dual Timed Up & Go, 4) Stand and Walk (SAW), and 5) 360 Degree Turn test. These sensors will allow for capture of precise measures postural sway, arm swing, gait variability, and many other variables the proposed movement tasks.
75639354|NCT02737605|Drug|Intranasal Esketamine|Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.
75639355|NCT02737605|Drug|Intravenous Esketamine|Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.
75639356|NCT02737605|Drug|Moxifloxacin|Participants will receive 400 mg Moxifloxacin orally.
75788114|NCT00251693|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
75788115|NCT00251693|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
75331459|NCT04352491|Other|No intervention|No intervention
75331460|NCT01092559|Drug|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
75331461|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
75788116|NCT00251693|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
75331462|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
75788117|NCT03791918|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75788118|NCT03791918|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
75788119|NCT03791918|Procedure|TACE|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.
75331463|NCT01116661|Drug|5-Aminolevuline Acid (ALA)|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
75331464|NCT00944021|Drug|PA-824|50mg
75331465|NCT00944021|Drug|PA-824|100mg
75331466|NCT00944021|Drug|PA-824|150 mg
75331467|NCT00944021|Drug|Rifafour e-275 mg|275 mg
75331468|NCT00944021|Drug|PA-824|200 mg
75639357|NCT02737605|Drug|Oral Placebo|Participants will receive matching placebo orally.
75639358|NCT02737605|Drug|Intravenous Placebo|Participants will receive placebo 40 minutes, intravenous infusion.
75639359|NCT02737605|Drug|Intranasal Placebo|Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
75639360|NCT02737371|Drug|F901318 Dose level A oral|Adverse events days 1-10
75639361|NCT02737371|Drug|Placebo dose level A oral|Placebo adverse events days 1-10
75788120|NCT03791918|Drug|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
75788121|NCT03793712|Drug|Lu AF11167 (1-2 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
75788122|NCT03793712|Drug|Lu AF11167 (3-4 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
75788123|NCT03793712|Drug|Placebo|Placebo oral dose, tablets. Once daily. 12 weeks.
75788124|NCT01305278|Other|Use of Nintendo Wii Balance Gaming system|Use of Nintendo Wii Balance Gaming system
75788125|NCT03793868|Drug|Perampanel|Oral tablet
75788126|NCT03793868|Other|Placebo|Placebo (not drug)
75788127|NCT01303016|Dietary Supplement|Chispuditos|Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
75788128|NCT03974477|Device|SALT CONTROL H equipment to control and monitor salt during cooking process|Participants will use SALT CONTROL H at home during 8 weeks to cook meals with adequate salt content.
75788129|NCT01305434|Dietary Supplement|Mulberry leaf extract effect on post prandial blood glucose|"Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications."
75331469|NCT04354883|Procedure|External Chest Compressions on Manikin in Underwater Setting|Two different methods of CPR in an analogue model of mircogravity
75331470|NCT03393754|Biological|Hepatitis B Vaccination|Prophylactic Hepatitis B Vaccination
75331471|NCT03394768|Other|No additional intervention|Patients will be treated as per department protocols and no additional intervention will be performed
75331472|NCT03587428|Drug|Zinc-A toothpaste|Participants received 6.0 grams (g) [± 0.3g] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 [generally 7] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
75331473|NCT03587428|Drug|Zinc-B toothpaste|Participants received 6.0 grams (g) [± 0.3g] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 [generally 7] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
75331474|NCT03587428|Other|Mineral water|Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 [generally 7] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
75331475|NCT03593200|Drug|Pegcetacoplan|Complement (C3) Inhibitor
75639362|NCT02737371|Drug|F901318 Dose level B oral|F901318 adverse events days 1-10
75639363|NCT02737371|Drug|Placebo dose level B oral|Placebo adverse events days 1-10
75639364|NCT02737371|Drug|F901318 Dose level C oral|F901318 adverse events days 1-10
75639365|NCT02737371|Drug|Placebo Dose level C oral|Placebo adverse events days 1-10
75639366|NCT02737527|Procedure|24G intravenous route for Lumbar Sympathetic Block (LSB):|Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
75639367|NCT02737527|Device|15-cm Chiba needle for Lumbar Sympathetic Block (LSB)|The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
75788130|NCT01305512|Drug|SPARC1028|SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
75788131|NCT03793634|Drug|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
76080082|NCT01923207|Drug|Placebo|placebo, subcutaneous administration
76080083|NCT01218958|Drug|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
75331476|NCT03398278|Drug|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fast state
75639368|NCT02737527|Device|Ultrasound for Lumbar Sympathetic Block (LSB)|Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
76080084|NCT01218958|Drug|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
76080085|NCT01218958|Drug|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
75639369|NCT02737527|Device|Fluoroscope for Lumbar Sympathetic Block (LSB)|Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
75788132|NCT00250835|Other|Chemotherapy, Celecoxib, and Radiation|Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
75788133|NCT01817504|Procedure|Systematic transplantectomy|Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
76080086|NCT01218958|Drug|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
75788134|NCT01817504|Procedure|Progressive reduction of immunosuppression|"Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.~In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group."
75788135|NCT05624216|Device|BTL-084|Radiofrequency and targeted pressure energy devices for the treatment of cellulite
75788136|NCT03810716|Device|Interactive Platform|The participants will see the interactive platform.
75924426|NCT02320188|Other|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
75924427|NCT02320188|Other|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
75924428|NCT05143242|Procedure|Hard tissue augmentation at the buccal aspect of single implants.|One or two releasing incisions are made. The periosteum is released and multiple bone perforations are made in the buccal bone prior to the application of deproteinized bovine derived xenograft. A Creos® membrane (Nobel Biocare, Gothenburg, Sweden) is used to cover the occlusal part of the alveolar crest and the xenograft particles. Finally, multiple single monofilament sutures are used for primary tension-free wound closure.
75924429|NCT05143242|Procedure|Soft tissue augmentation at the buccal aspect of single implants.|A CTG is taken from the palate and transplanted to the buccal side between the alveolar bone and the buccal flap. The CTG is secured with single monofilament sutures.
75924430|NCT05561348|Device|Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time. In the sham stimulation group, the electrodes were fixed at the same position without releasing current.
76080087|NCT03444246|Dietary Supplement|Iodine free diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
75331477|NCT03398278|Drug|OXYCONTIN®|Orally taking OXYCONTIN® 40mg in fast state
75331478|NCT03593902|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
75331479|NCT03593902|Drug|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
75331480|NCT03593902|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
75331481|NCT03593902|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
75331482|NCT03593902|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
75331483|NCT03593902|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
75331484|NCT03593902|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
75331485|NCT03593902|Biological|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
75331486|NCT03593902|Biological|Autologous Stem Cells|Infusion of patient's own stem cells
75331487|NCT00948935|Drug|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
75639370|NCT02737527|Drug|10 ml of 0.25% levobupivacaine injection for LSB|After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
75788137|NCT01303094|Drug|Trabectedin|Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.
75788138|NCT01303094|Other|Drug: holiday|A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.
75788139|NCT04869644|Behavioral|Goal setting|Goal setting: set or agree on a goal defined in terms of behavior to be achieved.
75788140|NCT04869644|Behavioral|Action Planning|Action planning: prompt detailed planning of performance of behavior (must include a setting [walking to the mailbox], frequency, duration, and intensity.
75924431|NCT05512078|Procedure|bone positioning surgical guide|patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
75924432|NCT02517788|Drug|Interferon beta-1a HSA-free biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
76080088|NCT03444246|Dietary Supplement|Normal iodine diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
75331488|NCT04354805|Drug|Chlorpromazine|(Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)
75639371|NCT02737527|Procedure|Temperature measurement for Lumbar Sympathetic Block (LSB)|Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
75788141|NCT04869644|Behavioral|Self-monitoring of behavior|Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit.
75924433|NCT02517788|Drug|Interferon beta-1a HSA+ biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
75924434|NCT02517788|Drug|Interferon beta-1a original|6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
75924435|NCT02323776|Other|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
76080089|NCT01240330|Device|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
75788142|NCT04869644|Behavioral|Behavioral Practice/Rehearsal|Behavioral rehearsal: prompt practice or rehearsal of walking one or more times in a context when the performance may not be necessary, in order to increase habit and skill.
75924436|NCT05143086|Other|Mouthwash 100% Nano-F|Use 10 ml of mouthwash 100% Nanoencapsulated Fluoride after brushing for one week, twice a day.
75924437|NCT05143086|Other|Mouthwash 50% Nano-F|Use 10 ml of mouthwash 50% Nanoencapsulated Fluoride after brushing for one week, twice a day.
75924438|NCT05143086|Other|Mouthwash standard|Use 10 ml of mothwash after brushing for one week, twice a day. It's for the positive control of fluoride.
75924439|NCT05143086|Other|Placebo|Use 10 ml of mouthwash without fluoride
75924440|NCT03347630|Diagnostic Test|MRI|Thoraco-abominal MRI
75924441|NCT04293406|Other|Decision Navigation Intervention (DNI)|This study will develop and test the acceptability and feasibility of a decision navigation intervention (DNI) for AA or H/L men with prostate cancer through consideration of the role of partners and family members in the decision-making process. In the decision navigation intervention (DNI), participants will meet with the navigator in person or via phone, prior to their specialist treatment consultation. At the end of the DNI visit, participants will receive a personalized list of prioritized questions. At the end of the decision navigation appointment, all navigated patients will complete a five-item navigation rating scale evaluating the intervention and its impact on their preparation for the consultation visit.
76080090|NCT04377360|Radiation|Diffusing Alpha-emitter Radiation Therapy|Diffusing Alpha-emitter Radiation Therapy (DaRT) is a method of delivering interstitial brachytherapy, based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life). These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. As the radioisotope has a short half-life, the majority of radiation absorption happens in the tumor.
76080091|NCT04752228|Other|Philadelphia ACE Survey|The Philadelphia ACE survey assesses the three major domains featured within the original ACE Study Questionnaire developed by Felitti et al. (abuse, neglect, and family dysfunction), in addition to five community-level stressors.
76080092|NCT04752228|Other|Lifestyle Assessment|The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.
76080093|NCT03440268|Drug|N Acetyl Cysteine|Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
75639372|NCT02737527|Procedure|Postprocedure care for LSB|Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
75639373|NCT00734539|Drug|fluconazole|6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
75639374|NCT00734539|Drug|placebo|normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
75639375|NCT02737137|Procedure|Manual measurement|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic
75639376|NCT02737137|Procedure|Measurement with a gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
75788143|NCT04869644|Behavioral|Habit Formation|Prompt rehearsal & repetition of walking 2,000 steps or more in the same context repeatedly so that the context elicits the behavior.
75924442|NCT02320344|Behavioral|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
75924443|NCT03347552|Behavioral|HOME|"Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care."
75924444|NCT05128266|Procedure|Endodontical Retreatment|"Linear canal Removal of the coronal dentine in order to create the space useful to an extractor to catch and remove the instrument. The preferred instrument to reach this aim is a .15 or .20 ultrasonic tip.~Curve canal When the instrument is broken inside a curve canal, it is not possible to create a circumferential space around the separated instrument without the risk of root perforation. Thus, the first step is the removal of the dentine of the external wall of the root canal. The second step is the removal of the dentine of the internal wall of the root canal. This selective removal of dentinal tissue unlocks thee separated instrument and determines its mobilization. Thus, the irrigation itself makes the instrument available for the removal.~After the removal of the broken instrument, root canal preparation was completed Canal filling was performed based on Schilder's technique."
76080094|NCT03440268|Drug|Placebos|These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
75639377|NCT02737059|Drug|Naloxegol|25mg daily
76080095|NCT04369014|Drug|etomidate anesthesia|etomidate is used for induction and maintenance of general anesthesia
76080096|NCT04369014|Drug|propofol anesthesia|propofol is used for induction and maintenance of general anesthesia
75639378|NCT02737059|Drug|Codeine|30mg 4 times daily
76080097|NCT03436914|Drug|PPI|After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
76080098|NCT03436836|Drug|Nalbuphine|"Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery"
75331489|NCT04354571|Procedure|Erector spinae plane block|An ultrasound-guided Erector spinae plane block was performed with the patient lying on the his side and the surgical side on the top. After skin disinfection, sterile draping was be placed and the ultrasound probe was sheathed. The level of the block was the transverse process of L2. The block was performed using a 9-12 MHz linear probe (LOGIQe, GE Healthcare, USA), which was placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) was identified, and a 22 G, 50 mm insulated needle (Sonoplex Stim, Pajunk, Germany) was inserted cranio-caudally in plane between the transverse process and the fascia of the ESM. After negative aspiration, 0.3 ml/kg of 0.25% bupivacaine was injected to confirm the correct position by visualizing the solution lifting the ESM off the transverse process.
75788144|NCT03791684|Device|Cross linking|Cross linking strategy either standard or accelerated
75331490|NCT04354571|Procedure|caudal block|caudal block was performed using anatomical landmarks and ultrasound guided and confirmed with a concentration of bupivacaine of 0.25%.
75331491|NCT03944681|Drug|Droperidol Injectable Solution|An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
75331492|NCT03032003|Other|Cysticlean|2 BID for 15 days
75331493|NCT03032003|Other|Placebo|2 BID for 15 days
75639379|NCT02737059|Drug|codeine placebo|4 times daily (placebo will be made to match the codeine)
75639380|NCT02737059|Drug|naloxegol placebo|placebo will match naloxegol, given daily
75639381|NCT00743275|Biological|Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)|0.5 mL, intramuscular
75639382|NCT02735889|Other|No Carbonation|500 ml of beverage consisting of water + 10% glucose and no carbonation
75639383|NCT02735889|Other|Low carbonation|500 ml of beverage consisting of water + 10% glucose and low carbonation
75639384|NCT02735889|Other|High carbonation|500 ml of beverage consisting of water + 10% glucose and high carbonation
75639385|NCT02731911|Drug|dexamethasone intravitreal implant|Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
75788145|NCT03791762|Procedure|WaveOne Gold|"WaveOne Gold was operated by an endomotor (VDW Gold, Munich, Germany) at WaveOne ALL setting."
75788146|NCT03791762|Procedure|Reciproc Blue|"Reciproc Blue was operated by an endomotor (VDW Gold, Munich, Germany) at Reciproc ALL setting."
76080099|NCT03436836|Drug|lidocaine, bupivacaine, hyaluronidase , saline|lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
76080100|NCT03436836|Drug|lidocaine, bupivacaine , hyaluronidase|2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)
76080101|NCT03444012|Drug|ticagrelor 90 mg|persistence and adherence on ticagrelor in ACS patients
76080102|NCT04729452|Other|blood test|blood test to test immune response to SARS-CoV-2
75639386|NCT02731677|Other|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
75639387|NCT02731599|Procedure|treadmill training with cues|20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
75639388|NCT05461677|Device|SAIRE smart walker|Participants will walk along the 10-meter walkway 5 times using the SAIRE smart walker
75639389|NCT05461677|Device|Standard 4-wheeled walker|Participants will walk along the 10-meter walkway 5 times using a standard 4-wheeled walker
75639390|NCT05461677|Other|No walking aid|Participants will walk along the 10-meter walkway 5 times without using a walking aid
75639391|NCT02731365|Device|Activa PC+S|The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
75924445|NCT05514262|Other|The stress ball|Covid-19 vaccination procedure with individuals in the stress ball group: With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.
75924446|NCT05514262|Device|The Buzzy® device|Covid-19 vaccination procedure with individuals in the Buzzy® group: Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
75788147|NCT03791762|Procedure|ProTaper Next|ProTaper Next was operated by an endomotor (VDW Gold, Munich, Germany) with 16:1 contra angle at the settings suggested by the manufacturer (350 rpm, 3 Ncm).
76080103|NCT00331773|Radiation|Conventional 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy
76080104|NCT00331773|Radiation|Hypofractionated 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
75639392|NCT04089163|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
75639393|NCT04089163|Drug|Toca FC (extended-release formulation of flucytosine)|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
75639394|NCT02731443|Procedure|Epilepsy surgery|Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
75788148|NCT03791372|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
76080105|NCT03440034|Drug|Pioglitazone|Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
76080106|NCT04708938|Other|High voltage electrical stimulation+exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
76080107|NCT04708938|Other|Exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
76080108|NCT03433326|Drug|Elbasvir/Grazoprevir|Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks
75331494|NCT01116895|Drug|LEO 22811|Oral solution
75331495|NCT01116895|Drug|Placebo|Placebo
75331496|NCT03935555|Drug|PU-H71|PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
75331497|NCT03031691|Drug|brontictuzumab|starting dose of 1.5mg/kg administered intravenously (IV)
75331498|NCT03031691|Drug|trifluridine/tipiracil|
75788149|NCT03791372|Biological|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Cerebral Palsy for safety and effect evaluation.
76080109|NCT03436446|Other|Interview|Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
76080110|NCT03439956|Procedure|Transvaginal specimen extraction|Previous transvaginal specimen extraction through posterior colpotomy.
75331499|NCT03031613|Procedure|PEEP group|Application of 5cmH20 positive end expiratory pressure
75331500|NCT03031613|Procedure|ZEEP group|No application of positive end expiratory pressure
75331501|NCT02430103|Drug|Goserelin 3.6 MG|In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
75331502|NCT03031535|Drug|Intranasal octreotide acetate|Intranasal spray of octreotide acetate
75924447|NCT02320422|Behavioral|Behavioral Telehealth|The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
75639395|NCT02731443|Procedure|Depth electrodes insertion|Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
75639396|NCT00743197|Drug|Aspirin|Aspirin 81 mg daily
75639397|NCT00743197|Drug|Lisinopril|Lisinopril 10 mg every night
75788150|NCT03788954|Other|Kinesiotaping|Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
75924448|NCT03493776|Biological|VZV subunit vaccine|VZV subunit vaccine
75924449|NCT04599790|Drug|TACE combined with lenvatinib and sintilimab|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
76080111|NCT03439878|Dietary Supplement|Galactose|Co-ingestion of d-galactose with a high-fat meal
75639398|NCT00743197|Drug|Simvastatin|Simvastatin 20 mg every night
75639399|NCT00743197|Drug|Lovaza|Lovaza 1 gram daily
75924450|NCT02517632|Behavioral|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
75924451|NCT02517632|Behavioral|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
76080112|NCT03439878|Dietary Supplement|Glucose|Co-ingestion of d-glucose with a high-fat meal
76080113|NCT04327518|Device|TECNIS® Toric II|Toric Intraocular Lens
76080114|NCT03439800|Other|Mental and Physical Practice|"Subjects will see a video of the typical gait and will attempt to analyze the sequence of the gait cycle.~They will imagine themselves walking in the first-person perspective (kinesthetic) using the gait of the non-pathological pattern during 2 minutes.~From the 1st to 4th session, the subjects will perform gait with corrections identified in previously in the video for 2 minutes.~From 5th to 8th session: the subjects will do the protocol already described, however, the imagined gait will be in an environment with obstacles, also for 2 minutes. They will continue with the physical practice of the gait with obstacles.~From 9th to final training session: both mental and physical practice of the dual task gait."
75331503|NCT03031535|Drug|Subcutaneous octreotide acetate|Subcutaneous injectable solution of octreotide acetate
75470668|NCT05150951|Behavioral|Threat conditioning|Session 1. Threat conditioning to two different (CS+, CS-) virtual reality contexts (i.e rooms). One of these is paired with a mild electric shock. The context paired with the electric shock (CS+) is counterbalanced across participants. Participants are instructed that they may receive electrical shocks during the procedure.
76080115|NCT03439800|Other|Physical Practice|"Subjects will see a video about PD which does not mention physiotherapy treatments related to gait and they will explain their understanding about the theme.~Then, the patients will make the physical gait protocol. Patients will be invited to perform the gait, in flat and firm ground with a length of 60 meters. The execution will be carried out for 10 minutes.~From the 5th to 8th session, the subjects will do the physical practice of the gait with obstacles (which will be: going through 2 cones zigzag, going up and down 1 step, going through a narrow door, going up and down 1 ramp, going over 1 box of shoes, climbing a ramp, going down 1 step) for 2 minutes.~From the 9th to the final training session, the subjects will do physical practice of the dual task gait."
76080116|NCT04760223|Behavioral|Video intervention|a 100-second video, presenting a personal story of a boy/girl dealing with depression
76080117|NCT03439722|Other|Polysomnography|Participants will be admitted for 1 night at the Danish Center of Sleep Medicine for polysomnography.
75331504|NCT03031535|Diagnostic Test|Growth hormone-releasing hormone|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
75331505|NCT03031535|Diagnostic Test|Arginine hydrochloride|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
75470669|NCT05150951|Behavioral|Extinction|Session 2. Participants are repeatedly exposed to the both contexts from session 1 (CS+, CS-), but no shocks are delivered.
75639400|NCT00743197|Behavioral|Therapeutic Lifestyle Changes|Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
75788151|NCT04663568|Device|Levonorgestrel-releasing intrauterine system|Levonorgestrel-releasing intrauterine system will be inserted during the menstrual cycle
75788152|NCT03810326|Device|CTR device (tradename named Xtend)|Non invasive active splint
75788153|NCT05669066|Behavioral|Mindful meditation|Adding mindful meditation to pre- and post-operative care for patients who are having a TKA
76080118|NCT00244101|Drug|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
75331506|NCT03031925|Other|ANXA2|serum and urinary concentration
75331507|NCT01118221|Behavioral|pulmonary rehabilitation|structured exercise program
75331508|NCT04353947|Diagnostic Test|Mini Cognitive Examination (MCE)|This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.
75331509|NCT04353947|Diagnostic Test|Beck Depression Inventory-II (BDI-II)|This test evaluates the absence or presence of depressive symptoms.
75639401|NCT02731287|Drug|Timolol|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
75924452|NCT03132168|Behavioral|Assessments|These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.
75924453|NCT03132168|Procedure|Blood Draw|Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.
75788154|NCT03788876|Other|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge.
75924454|NCT03132168|Other|Standardized Anesthetic Care|Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
75924455|NCT04937062|Drug|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|"Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf)."
75639402|NCT02731287|Drug|Placebo|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
75639403|NCT02595385|Device|Cell Salvage|Reinfusion of shed blood during the operation
76080119|NCT00244101|Device|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
76080120|NCT00244101|Drug|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
75639404|NCT02595385|Procedure|Retrograde Autologous Prime|Removal of fluid from the bypass circuit
75639405|NCT02731209|Device|urinary catheter|
75639406|NCT02735499|Drug|onabotulinum toxin A|Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
75639407|NCT02735733|Device|Cold Bakri Balloon|In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
75331510|NCT04353947|Diagnostic Test|Global Deterioration Scale (GDS)|This scale measures the level of deterioration of the subject.
75331511|NCT04353947|Diagnostic Test|Memory alteration test (M@T)|In this test different memory subtypes are evaluated.
75331512|NCT04353947|Diagnostic Test|Spanish-Complutense Verbal Learning Test (TAVEC)|This test is used to assess immediate memory, deferred memory and learning ability.
75639408|NCT02735655|Other|Physician's opinion|To get physician's opinion about the current global state of gastrointestinal endoscopy training programs and to identify the unmet needs and how to improve it through a web based questionnaire.
75331513|NCT04353947|Diagnostic Test|Barcelona test (BT)|"This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category animals in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter p in 3 minutes."
75470670|NCT05150951|Behavioral|Reinstatement|Session 3. Participants are again repeatedly exposed to both contexts from session 1 (CS+, CS-), after a few shocks delivered in a neutral context.
75639409|NCT02735343|Drug|Compazine|Compazine 10mg with diphenhydramine 25 mg IV
75470671|NCT05150951|Behavioral|Visual attention control task|Session 2. A visual attention task used as a control task instead of novel exploration.
75470672|NCT05121896|Device|MRI Scan|7.0 tesla functional MRI scan
75470673|NCT05111821|Procedure|Magnetic Resonance Imaging (MRI)|Quantification of iron will be performed through Magnetic Resonance Imaging
75470674|NCT05111821|Drug|Deferiprone treatment|Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
75470675|NCT05105282|Procedure|Two different blocks with same local anesthetic volume|Deep serratus anterior block and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
75639410|NCT02735343|Drug|Ketamine|Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
75639411|NCT02730975|Drug|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
75788155|NCT03788876|Other|Conventional care|Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
75788156|NCT03789032|Drug|Vadadustat|Vadadustat 300 mg
75788157|NCT03789032|Drug|Rabeprazole|Oral Rabeprazole
75924456|NCT04256408|Device|Bronchoscopic transparenchymal interlobar fissure closure using Aeriseal|Transbronchial or transparenchymal injection of AeriSeal into the interlobar collateral ventilation channels region to convert CV-positive lobes into CV-negative lobes.
75924457|NCT02320500|Behavioral|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
76080121|NCT04959708|Other|Insula treatment|he intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
76080122|NCT03436212|Device|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device
76080123|NCT02337465|Device|Cone-Beam Computed Tomography|Undergo kilo-voltage cone beam computed tomography
76080124|NCT02337465|Radiation|3-Dimensional Ultrasound-Guided Radiation Therapy|Undergo ultrasound-guided radiation therapy
75924458|NCT02320500|Other|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
75924459|NCT00708734|Behavioral|functional exercise training|twice weekly group sessions for 5 weeks
75924460|NCT02320578|Procedure|3D Laparoscopy|3D Laparoscopy approach
75639412|NCT02730975|Drug|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
75924461|NCT02320578|Procedure|Standard Laparoscopy|Standard laparoscopy approach
75924462|NCT04923724|Device|tourniquet|tourniquet is a device used during total knee surgery.
75470676|NCT05086835|Other|Working Memory Task|A smartphone-based visual-spatial working memory task that will be optimized in the Stage 1A phase of this study.
75331514|NCT04353947|Diagnostic Test|Rey-Osterrieth Complex Figure Test (ROCFT)|In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated.
75331515|NCT04353947|Diagnostic Test|Frontal assessment battery (FAB)|This test is a composite tool for assessing executive functions related to the frontal lobe.
75639413|NCT02730975|Drug|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
75639414|NCT00734071|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
76080125|NCT03436134|Other|Sessions of conventional apheresis|"Patient receiving sessions of Plasma exchange as treatment of chronic antibody mediated rejection.~The plasma exchange uses a single filter to remove whole plasma and the volume is replaced with a matched volume of blood products +/- saline.) 8 sessions plasma exchange.Patients will have one session per day, 4 consecutive days and then three days without, then one session per day for 4 consecutive days. That's 11 days of treatment at all. The fourth and eighth sessions will be followed by an infusion of Rituximab 375 mg / m2.~At the beginning and at the end of each session, the patients will have a blood test to measure the parameters of the routine care and the analyzes, collection of biological samples planned for the study."
75639415|NCT00734071|Drug|Placebo|Vortioxetine placebo-matching capsules
75639416|NCT02735265|Behavioral|Virtual reality|12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.
75639417|NCT02735265|Behavioral|Standard treatment|CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
75639418|NCT02730897|Procedure|Central/Peripheral|Central versus peripheral location of the primary tumor
75788158|NCT03788798|Device|Patient infotainment system|The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
75788159|NCT03788720|Procedure|Suture of the ovarian cortex|Suture of the ovarian cortex after laparoscopic enucleation of endometriomas, using one single monofilament suture material, continuous suture technique with maximum 5 transfixion of the ovarian cortex and intracorporeal knots only (no extracorporeal knots).
75788160|NCT03788720|Procedure|No suture of the ovarian cortex|Laparoscopic enucleation of endometriomas without suture of the ovarian cortex
75924463|NCT04923724|Device|No tourniquet|tourniquet is a device used during total knee surgery, this group does not get one
75924464|NCT03347474|Procedure|Bilateral surgical implantation of DBS system to NAc|The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.
75924465|NCT02323932|Behavioral|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
75924466|NCT04502498|Diagnostic Test|Lower limb duplex & doppler|Lower limb duplex and doppler one week before radical cystectomy
75924467|NCT02324010|Drug|Sitagliptin|100mg mane for 2 days
75924468|NCT02324010|Drug|Placebo|Inactive drug (Placebo)
75924469|NCT05513794|Device|MRI Imaging|Neuromelanin sequence imaging
75924470|NCT02517710|Procedure|Stratafix synthetic barbed suture|hysterotomy closure in Cesarian section
75924471|NCT02517476|Dietary Supplement|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
75470677|NCT05086835|Other|Visual Search Task|A smartphone-based visual search task that will be optimized in the Stage 1A phase of this study.
75639419|NCT04109469|Device|Shark Screw® transplant|Application of a Shark Screw® transplant for osteosynthesis or arthrodesis in hand- or foot surgery
75639420|NCT02731053|Behavioral|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
75639421|NCT02730741|Drug|Lcr restituo® sachet|symptomatic treatment of diarrhoea
75639422|NCT02730741|Drug|Placebo|
75639423|NCT04188951|Drug|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
75639424|NCT02730585|Biological|C-reactive protein measurement|All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.
75924472|NCT02320656|Other|Blood sampling|Longitudinal (3 stages of the disease)
75924473|NCT02320656|Other|Bone marrow aspirate|Longitudinal (3 stages of the disease)
75924474|NCT02320656|Other|Skin biopsy|Single biopsy (optional)
75924475|NCT02320656|Other|Buccal swab|Single sampling.
75924476|NCT03346304|Other|Photodynamic Therapy (PDT)|Photodynamic Therapy (PDT) using photosensitiser drug Fotolon
75924477|NCT03493308|Other|Pain neuroscience education|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
75331516|NCT04353947|Diagnostic Test|Positive and Negative Affect Scale (PANAS)|It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale).
75331517|NCT04353947|Diagnostic Test|Auto-Assessment Manikins (SAM)|It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
75331518|NCT01093417|Drug|Vitamin D|Vitamin D 4000 IU will be administered to enrollees on the active comparator arm
75331519|NCT01093417|Other|Placebo|Placebo pills will be administered to enrollees in this arm
75331520|NCT04354415|Procedure|Carpal tunnel or trigger finger release|Carpal tunnel or trigger finger release with and without the use of tourniquet
75788161|NCT03788486|Device|2-3 Joule LED blue light device|application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
75788162|NCT01306370|Drug|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
75331521|NCT01586455|Drug|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
75331522|NCT04354337|Behavioral|Sleep Innovations for Preschoolers with Arthritis (SIPA)|The SIPA intervention is interactive and personalized. Every week, parent will receive an email sent automatically through the system with instructions for this week's activity, designed to take about 30 minutes to complete. The SIPA weekly modules will begin with a learning module, then direct participants through goal setting, anticipated barriers, and problem solving. The intervention site will include fillable responses to queries, instructions, and assignments. Tasks for parents and their young children will use multimedia elements to enhance delivery of information, such as links to videos and pictures targeting self-efficacy, motivation, and patient activation. Submissions and progress will be monitored by the study team, who will send email, call or text with reminders (whichever the family prefers) and answer questions as needed, review progress, and help problem solve any technology issues or barriers to implementing skills.
75788163|NCT01306370|Drug|Fibrin glue|Topical administration, before to close the surgical wound. Dosage: 2 mL.
75639425|NCT00739297|Drug|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
75788164|NCT01306370|Biological|Fibrin glue|Topical administration, before to close the surgical wound.
75639426|NCT00739297|Drug|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
75788165|NCT01306370|Other|Habitual haemostasis|The surgical habitual haemostasis.
75788166|NCT03791528|Other|Kinesio-taping treatment group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the SIJ, and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire.
75331523|NCT03031379|Other|shortened fast|fast of 45 minutes prior to surgery as opposed to standard 6 hour fast
75331524|NCT01093651|Drug|Sitagliptin|100 mg sitagliptin daily for 4-6 months
75331525|NCT01093651|Drug|Placebo|Daily placebo for 4-6 months
75639427|NCT05430243|Drug|Empagliflozin 10 MG|once daily empagliflozin 10mg+/- diuretics
75639428|NCT05430243|Drug|Diuretics|diuretics as clinically indicated
75639429|NCT02730117|Device|Dialysis with continuous renal replacement therapy|Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
75639430|NCT02730117|Device|Mechanical ventilator|Invasive or noninvasive form of respiratory support
75639431|NCT02730117|Drug|Anti-Bacterial Agents|Antibacterial agents deemed appropriate by physicians in the ICU
75639432|NCT02730117|Drug|Vasopressors|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
75331526|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
75331527|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
75331528|NCT03031301|Device|Vibrant capsule|One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.
75639433|NCT05423223|Device|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
75639434|NCT05423223|Device|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
75788167|NCT03716024|Drug|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
75788168|NCT03716024|Drug|Linezolid|Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
75788169|NCT01305746|Drug|A-623|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
75788170|NCT01305746|Drug|A-623|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
75788171|NCT01305746|Drug|A-623|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
75788172|NCT00250679|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 ųg BID by nebulization
75788173|NCT00250679|Drug|Arformoterol 25 ųg BID|Arformoterol 25 ųg BID by nebulization
75331529|NCT03031301|Device|Sham capsule|One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
75788174|NCT00250679|Drug|Formoterol 12 ųg BID|Formoterol fumarate 12 ųg BID via aerolizer/DPI
75788175|NCT00250679|Drug|Placebo|Placebo nebule or placebo aerolizer
75788176|NCT05620706|Biological|GPC3 CAR-T cells|patients treated with GPC3 CAR-T cells
75924478|NCT03493308|Other|Exercise|Exercise will be provided in different formats including general exercise, strengthening, dance.
76080126|NCT03436134|Other|Sessions of news apheresis with double filtration|"Patient receiving DFPP as treatment of chronic antibody mediated rejection. 8 sessions~A Double filtration plasmapheresis (DFPP) is a variation of plasma exchange. The circuit contains two plasma filters : the first is a standard plasma filter and the second is a high molecular weight filter that primarily removes immunoglobulins. The depleted plasma is returned to the blood circuit and then to the patient."
76080127|NCT03439644|Other|Measurement of the upper eyelid laxity|Measurement using a soft slider of the distance between our 2 marks The difference obtained between the measurement and the initial 10 millimeters corresponds to the tarsal laxity.
75788177|NCT03791294|Drug|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
76080128|NCT00633243|Procedure|Modified Directly Observed Therapy (mDOT)|
76080129|NCT00633243|Procedure|Self-Administered Therapy (SAT)|
76080130|NCT04759677|Other|Exercise with active video games|45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.
76080131|NCT04451382|Biological|OnabotulinumtoxinA (BoNTA)|
76080132|NCT04451382|Procedure|Percutaneous tibial nerve stimulation (PTNS)|
75788178|NCT01567358|Biological|Infliximab|100mg/vial
76080133|NCT04276389|Device|OCT-guided paclitaxel drug-coated balloon angioplasty|OCT-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
75331530|NCT03013465|Other|Control Diet|Participants will receive a controlled diet with 0 g/d of broccoli. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
75470678|NCT05066815|Other|Vita Enamic (Hybrid dental ceramic)|Vita Enamic (Hybrid dental ceramic) is provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology.
75470679|NCT05036772|Device|Virtual reality|The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
75470680|NCT05005455|Drug|bevacizumab with new manufacturing process.|3mg/kg,I.V.,single dose
75788179|NCT01567358|Biological|Infliximab|100mg/vial
75788180|NCT04603430|Other|Participation in a community wellness program|Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.
75788181|NCT03790982|Drug|Placebo of AD-35 60mg /AD-35 30mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
75788182|NCT03790982|Drug|Placebo of AD-35 60mg /AD-35 60mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
75924479|NCT02320734|Drug|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
75924480|NCT03346226|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg，adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery
75924481|NCT03346226|Drug|Propofol|Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts，adjust the propofol's dose to keep BIS between 70-80 before the end of surgery
75924482|NCT03347240|Procedure|Brain Lesioning|Stereotactic radiofrequency lesioning of the pallidum or thalamus
75924483|NCT03347240|Procedure|Combined anterior and posterior lumbosacral rhizotomy|Combined anterior and posterior lumbosacral rhizotomy
76080134|NCT04276389|Device|Angiography-guided paclitaxel drug-coated balloon angioplasty|Angiography-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
76080135|NCT03128658|Diagnostic Test|Thromboelastography|Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
75331531|NCT03013465|Other|Base Diet with Broccoli|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
75331532|NCT04744623|Drug|large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP|10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
75788183|NCT03790982|Drug|AD-35 30 mg + Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
75788184|NCT03790982|Drug|AD-35 60 mg|AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
75788185|NCT03790826|Device|cystoscopy|Comparison of bladder mucosa via cystoscopy.
75924484|NCT03347240|Device|Deep brain stimulation|Bilateral DBS
75924485|NCT03347240|Device|Intra-thecal baclofen infusion|Intra-thecal Baclofen infusion
75924486|NCT02324088|Drug|Docetaxel|
75924487|NCT02324088|Drug|Cyclophosphamide|
75924488|NCT02324088|Drug|Epirubicin|
75924489|NCT04597294|Combination Product|FLOT + HIPEC + Surgery|HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy
75924490|NCT04597294|Combination Product|FLOT + Surgery|Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery
75924491|NCT02324166|Drug|Cefazolin|cephalosporin antibiotic
75924492|NCT02324166|Drug|Lidocaine|local anesthetic
76080136|NCT03128658|Diagnostic Test|Computational model|The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
75639435|NCT02595619|Device|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
75639436|NCT02595463|Drug|Lidocaine|Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
75639437|NCT02595463|Drug|Saline|Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
75639438|NCT02730273|Device|Trial Nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
75639439|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation
75639440|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.
75639441|NCT02593669|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
75639442|NCT02593669|Drug|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells.
75639443|NCT02729961|Drug|Brentuximab Vedotin|Given IV
75639444|NCT02729961|Drug|Ceritinib|Given PO
75639445|NCT02729961|Other|Laboratory Biomarker Analysis|Correlative studies
75639446|NCT02729961|Other|Pharmacological Study|Correlative studies
75639447|NCT02735031|Drug|Exenatide|6 weeks treatment with exenatide on top of insulin treatment
75924493|NCT05518942|Behavioral|sensorimotor rhythm neurofeedback training|In this study, baseline brain waves will be recorded for 5 minutes before each treatment, and the average value of SMR waves was used as the basis for setting the treatment threshold for the week. During the treatment, the subjects are arranged to sit in front of a computer screen with a game or animation playing. The individual focuses on the games or animations on the screen. The software will analyze the brain wave signals from the brain and convert them into visual and auditory feedback on the computer screen. Clients can learn to control brain activity and give visual and auditory feedback when a set threshold is reached
75331533|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
75331534|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
75331535|NCT03031223|Radiation|low-level laser therapy|low-level laser therapy
75470681|NCT05005455|Drug|bevacizumab with old manufacturing process.|3mg/kg,I.V.,single dose
75470682|NCT05003622|Drug|Encorafenib|oral capsule
75639448|NCT02735031|Drug|Placebo|6 weeks treatment with placebo on top of insulin treatment
75639449|NCT02595541|Drug|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
75639450|NCT02595541|Drug|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
75639451|NCT03433911|Device|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
75639452|NCT03433911|Procedure|Laparoscopic bilateral tubal sterilization|Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)
75639453|NCT00739063|Drug|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
75639454|NCT01026194|Drug|Placebo / Teneli (Teneligliptin) + pio (pioglitazone)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
75639455|NCT01026194|Drug|Teneli / Teneli + pio|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
75639456|NCT03374553|Device|MINI DO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
75331536|NCT05620199|Procedure|Upfront resection|Resection of the primary tumor
75331537|NCT00633945|Drug|Lenalidomide|
75470683|NCT04983017|Dietary Supplement|Dietary supplement|iron bisglycinate manganese chloride vitamin D2 guar gum indole-3-carbinol L-methionine piceatannol biotin caffeine beta-carotene lutein zinc sulfate
75470684|NCT04983017|Other|Placebo|Matched Placebo to Intervention
75470685|NCT04969406|Other|Brillouin Spectroscopy via BOSS System|Biomechanical Imaging of the Cornea and Lens
75639457|NCT03374553|Device|MINI SO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
75639458|NCT02593513|Device|Daifert|
75331538|NCT03729713|Other|Computerized cognitive rehabilitation|6 week course of cognitive rehabilitation focused on attention, learning, and memory
75331539|NCT03729713|Other|Sham placebo|an alternative home-based computer program not designed for cognitive remediation but of the same duration
75331540|NCT02980445|Behavioral|Outdoor activity 1|40-minute outdoor activity
75331541|NCT02980445|Behavioral|Outdoor activity 2|Dose 1 plus an additional 40-minute outdoor activities during recesses
75331542|NCT03031067|Device|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
75331543|NCT01118845|Drug|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
75639459|NCT02593513|Procedure|Control Group|Control - Morphological Assessment
75639460|NCT02734875|Other|Intervention|The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
75639461|NCT04300712|Behavioral|Questionnaires at the start and end of the school year|Interventions will be proposed to children identified in a worrisome situation. The Strengths and Difficulties. Questionnaire will be used by teachers to score these situations. The recognition process of mental health problem and need continue with responses. Responses are supporting a graduated response process in school and facilitating external support when needed (mental health services, community supports). Early intervention is one of all responses, which involve caregivers. Responses to worrisome situations aim to improve schooling conditions, to acknowledge mental health problems or condition and the health services need for children. To evaluate the intervention, the impact supplement of SDQ and the follow-up questions will be used by the teachers and the parents of children who benefit of the intervention. The interventions will be experimented during year 2020-21. Children might benefit of them from several weeks to one year, according to their need.
75788186|NCT04550156|Procedure|Colorectal Bundle|"Preoperative optimization of the nutritional status: Perform nutritional risk screening (NRS), measure albumin or prealbumin preoperatively and initiate nutritional support~Preoperative showering with an antiseptic agent~Administer preoperative antibiotic prophylaxis~Hair removal in the operative field with clippers~Peri-, intra-, and postoperative warming to maintain body temperature~Peri- and intraoperative glucose control~Usage of a wound protection device~Change of gloves and instruments after anastomosis~Anastomosis only with experienced senior surgeon present in theatre for any elective and emergency procedures"
75788187|NCT01306448|Device|Vibrant capsule|vibrating capsule
75788188|NCT03790904|Other|Co.|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
75331544|NCT01118845|Drug|Rituximab|The administration of rituximab at 375 mg/m^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
75788189|NCT03790904|Other|Kin|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
75788190|NCT03790904|Other|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
75788191|NCT03790748|Procedure|Standard Lumbar Epidural Technique|Standard Lumbar Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
75788192|NCT03790748|Procedure|25G Dural Puncture Epidural Technique|25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
75331545|NCT03031457|Diagnostic Test|Duplex ultrasound|Duplex ultrasound of lower extremity venous system
75639462|NCT05416593|Behavioral|General exercise prescription (FITT)|The (1) control group (FITT) will receive a preexercise evaluation and 3 individualized training sessions based on the ACSM and FITT principles (ACSM, 2021). These are the procedures commonly used for apparently healthy individuals that start to exercise in health clubs.
75788193|NCT03790748|Procedure|27G Dural Puncture Epidural Technique|27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
75788194|NCT03788408|Behavioral|Intensive Psychotherapy and case management for refugee trauma|CVT's approach emphasized active interdisciplinary coordination and a relational focus anchored in cultural humilityX to address survivors' priorities, empower survivors as the primary architects of their healing, and work alongside each survivor to co-construct meaning and behavioral change.
75788195|NCT03809858|Other|Klue App|The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
75788196|NCT05566652|Device|Neural Pressure Support|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
75788197|NCT05566652|Drug|Pressure Support Ventilation|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
75788198|NCT05693870|Device|Fixed space maintainer|Appliance bonded with composite resin or/banded and cemented with glass ionomer cement
75788199|NCT03788330|Device|Fresh air system with filtration|Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms
75788200|NCT03790592|Device|trifocal IOL|intraocular lens
75788201|NCT00261833|Biological|Alpha1-proteinase inhibitor|60 mg/kg body weight/week intravenous
75788202|NCT00261833|Other|Placebo|Lyophilized preparation: 60 mg/kg body weight/week intravenous
75788203|NCT01308242|Drug|Sevelamer Carbonate|Sevelamer 800 mg by mouth three times daily with meals for 3 months
75924494|NCT03346538|Drug|Continuous infusion high-dose MCI-186|intravenous injection
75924495|NCT03346538|Drug|Continuous infusion low-dose MCI-186|intravenous injection
75924496|NCT03346538|Drug|Continuous infusion placebo|intravenous injection
75924497|NCT03346538|Drug|Approved dosing regimen MCI-186|intravenous injection
75924498|NCT03346538|Drug|Approved dosing regimen placebo|intravenous injection
76080137|NCT03128619|Procedure|Biopsy of Breast|Undergo biopsy
75470686|NCT04959149|Device|AirTraq videolaryngoscope|intubation of morbidly obese patient using Airtraq videolaryngoscope
75470687|NCT04904107|Diagnostic Test|modified HEART score (including POC hs cTnI analysis)|"The modified HEART score was developed in 2007 and has been validated to stratify the risk of short-term adverse cardiac events in patients with chest pain at the ED. Negative predictive value (NPV) of the modified HEART score for ACS as well as positive predictive value (PPV) for major adverse cardiac events (MACE) within 6 weeks after presentation is high.~The modified HEART score is an acronym for history, ECG, age, risk factors and troponin at arrival.The components can be rated 0,1 or 2 points each and result in a total score between 0 and 10."
75924499|NCT05513170|Procedure|Use of Densah Burs in closed sinus lift|Closed sinus will be performed using Densah Burs. Densah Burs enhance bone quality through osseodensification; a process through which bone is compacted and auto-graphted in the marrow spaces and apically to elevate the sinus floor and enhance bone density.
75470688|NCT04904107|Other|Standard care and triage according to the local (EMT)protocol.|Standard care and triage of chest pain patients according to the local (EMT)protocol.
76080138|NCT03128619|Drug|Copanlisib|Given IV
75470689|NCT04890977|Behavioral|Talking Story|A culturally grounded modular intervention to increase mental health treatment-seeking among Pacific Islanders.
75470690|NCT04880486|Other|Education|Usual pulmonary rehabilitation education and pharmacological therapies, and taught them some limbs exercise, using social application to contact and suggestion giving as supervision.
75470691|NCT04880486|Other|Supervision upper limb weight training exercise with VR|Participant is supervised by physical therapist to conduct upper limb weight training exercise with VR.
75470692|NCT04875260|Other|Critical Care|Critical care in the intensive care units
75639463|NCT05416593|Behavioral|Affective regulation (AFFECT)|As for the (2) experimental group (AFFECT), the focus will be given to exercise intensity assessment and manipulation. The same preexercise evaluation, number of individualized sessions, and methodological approach (i.e., FITT) will be made. However, individual preferences and experiences regarding exercise intensity will be assessed in the preexercise evaluation. These will be used to select the exercise sessions' initial intensity. Moreover, intensity self-selection guidance and affective response assessments will be made throughout the session for continuous intensity adjustments (aiming for pleasurable feelings).
75639464|NCT02595307|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
75639465|NCT02595229|Procedure|Pronator quadratus repair|Suturing of the pronator quadratus muscle
75639466|NCT05411289|Procedure|acupressure|"Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6).~pressure was applied gradually for 30 seconds on the above mentioned points. Then this pressure was slowly intensified to the extent that the patient felt tingling, numbness, heaviness, and strain in the surrounding area."
75470693|NCT04870632|Other|Education|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.
75639467|NCT05411289|Procedure|sham acupressure|Pressures were applied on sham points consecutively
75639468|NCT04088461|Drug|Linagliptin / Metformin Oral Tablet|Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
75639469|NCT04088461|Drug|Metformin|Metformin 850 mg twice daily plus lifestyle modifications program
75639470|NCT01033136|Behavioral|Multiple Channel Exposure Therapy - Veterans|MCET-V offers individual therapy that provides psychoeducation about panic attacks and trauma and involves behavioral and cognitive exposure exercises.
75639471|NCT01033136|Behavioral|Cognitive Processing Therapy|CPT offers individual therapy that targets trauma and PTSD symptoms via cognitive restructuring.
75639472|NCT04246983|Diagnostic Test|Opportunistic infection Ultrasound (OpUS) screening|this point-of-care ultrasound protocol will include lung ultrasound, assessment of pericardial and pleural effusions, ascites, abdominal lymphadenopathy and splenic micro abscesses, as well as a focused ultrasound of liver and kidneys.
75639473|NCT02595151|Device|CLE|The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
75639474|NCT02729883|Other|Quality-of-Life Assessment|Ancillary studies
75788204|NCT01306682|Biological|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
75788205|NCT01306682|Biological|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
75788206|NCT03973463|Behavioral|Elastic knee joint movement|Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.
75788207|NCT01308320|Drug|fentanyl citrate|According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
75788208|NCT01308320|Drug|saline|According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
75788209|NCT01072253|Procedure|eye amputation|
75788210|NCT01306760|Drug|Ketamine|Ketamine used as the anaesthetic during ECT.
76080139|NCT03128619|Other|Laboratory Biomarker Analysis|Correlative studies
75470694|NCT04870632|Other|Video-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by watching Youtube videos which were made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
75470695|NCT04870632|Other|Booklet-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
75470696|NCT04858399|Diagnostic Test|Evaluation|To examine the differences in respiratory functions, orofacial muscle tone changes, anxiety/ depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
75470697|NCT04798144|Device|Distilled water irrigation kept at 2.5°C degree|The use of cold distilled water for final irrigation of root canal system during root canal treatment
75639475|NCT02729883|Other|Questionnaire Administration|Complete interviews
75788211|NCT01306760|Drug|Propofol|The standard anaesthetic used for ECT.
76080140|NCT03128619|Drug|Letrozole|Given PO
75331546|NCT03240887|Behavioral|Peer Group Connection|Faculty advisors at each participating high school are trained to run the program and teach a daily leadership course to peer leaders. Eleventh and twelfth-grade peer leaders who participate in the daily leadership development class facilitate outreach sessions with their assigned group of ninth graders. PGC can be offered in either a half-year (semester) or full-year format. In either format, a minimum of 18, 45-minute outreach sessions are expected to be offered to PGC participants during the course of their ninth-grade year. Outreaches are created to facilitate the transition to high school and encourage students to attend school, set goals for themselves, and make healthy decisions.
75924500|NCT05513170|Procedure|Closed sinus lift using osteotomes|Closed sinus lift will be performed using osteotomes. Osteotomes elevate the sinus floor and enhance the bone quality.
75788212|NCT01567436|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.
75788213|NCT05693714|Diagnostic Test|Pcr|Polymerase chain reaction
75788214|NCT03788252|Drug|Renamezin|7 capsules once, three times a day, for 48 weeks
75788215|NCT03788096|Behavioral|Peer Support with Motivational Interviewing|Mentors will trained in motivational interviewing and will conduct weekly telephone calls with participants randomized to the PS-PICS peer support intervention arm.
75924501|NCT02513342|Biological|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
75924502|NCT02513342|Drug|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
75331547|NCT03162731|Biological|Nivolumab|Given IV
75331548|NCT03162731|Biological|Ipilimumab|Given IV
75470698|NCT04798144|Device|Distilled water irrigation kept at room temperature|The use of distilled water kept at room temperature for final irrigation of root canal system during root canal treatment
75639476|NCT02729883|Procedure|Supportive Care|Receive patient navigation via the Take the Fight strategists
75639477|NCT00738673|Drug|degarelix|Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
75639478|NCT02694627|Behavioral|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
75639479|NCT02594995|Drug|NBP|
75639480|NCT00811954|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
75788216|NCT03788096|Behavioral|Usual Care Group|Usual care.
75788217|NCT03787940|Drug|Isoniazid|standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
75788218|NCT01306838|Dietary Supplement|MicroLipid and fish oil|Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
75788219|NCT01306838|Other|Routine care|Routine care
75788220|NCT03788018|Drug|lidocaine and dexmedetomidine IV|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
75788221|NCT03788018|Drug|saline IV|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
75788222|NCT03790202|Device|VistaCare®|Controlled atmosphere wound healing device
75788223|NCT05585060|Diagnostic Test|the changes of end expiratory lung impedence|the changes of end expiratory lung impedence measured by EIT
75788224|NCT05585060|Diagnostic Test|the changes of end expiratory lung volume|the changes of end expiratory lung volume measured by apnea method
75924503|NCT02513342|Drug|Cisplatin|d4，cisplatin，75（mg/m2），iv；
75924504|NCT05513092|Diagnostic Test|placenta accreta index score|role of placenta accreta index score in prediction of conservative surgery for placenta placenta accreta spectrum
75470699|NCT04759872|Other|Hyperinsulinemic-euglycemic Clamp|Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).
75924505|NCT02517320|Drug|MT-3995 Low|
75924506|NCT02517320|Drug|MT-3995 Middle|
75331549|NCT03162731|Radiation|Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Undergo simultaneous integrated boost integrated modulated radiation therapy
75331550|NCT03162731|Radiation|Volume Modulated Arc Therapy|Undergo volumetric modulated arc therapy
75331551|NCT03030911|Drug|Dexmedetomidine|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
75470700|NCT04751825|Behavioral|I-EAET|See information in arm description.
75924507|NCT02517320|Drug|MT-3995 High|
75924508|NCT02517320|Drug|Placebo|
75924509|NCT03491826|Biological|rupture of membrane|
75924510|NCT04589962|Other|access axillary or brachial artery|access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting
75788225|NCT01305902|Behavioral|contingency management|Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
75788226|NCT01307072|Procedure|Vitrectomy|Vitrectomy. Diabetic retinopathy
75331552|NCT03030911|Drug|Midazolam|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
75788227|NCT03785990|Other|adipose tissue|taking a sample of the adipose tissue during operation
75331553|NCT03030911|Drug|Fentanyl|The drug will be administered in both groups
75331554|NCT03030911|Device|Indirect calorimetry|The device will be used for measurement of basal metabolic rate
75788228|NCT03785990|Other|blood|taking a blood sample when a peripheral venous catheter is inserted before operation
75788229|NCT03785990|Diagnostic Test|PEAPOD|Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)
75788230|NCT05693636|Procedure|Total wrist arthroplasty|Two different surgical interventions for treatment of end-stage arthritis are compared
75788231|NCT03785756|Drug|Ibuprofen 300 mg Oral Tablet|2 x 300 mg tablets twice in 24 hours
75788232|NCT03785756|Drug|Ibuprofen 200 mg Oral Tablet|2 x 200 mg tablets three times in 24 hours
75331555|NCT01120405|Drug|Xenon|
75639481|NCT00811954|Drug|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
75639482|NCT00811954|Drug|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
75639483|NCT00811954|Drug|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
75639484|NCT00811954|Drug|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
75639485|NCT00917839|Drug|lamotrigine|100 mg, once daily, 12 months
75639486|NCT02694705|Device|Continuous Positive Airway Pressure (CPAP)|CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
75639487|NCT02694705|Device|Bag-Valve-Mask (BVM)|Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
75639488|NCT02694705|Device|Non-rebreather Mask (NRM)|Preoxygenation provided by NRM, oxygen flow rate 15 l/min
75788233|NCT03785756|Other|Placebo of PR tablet|Up to 2 tablets four times in 24 hours
75788234|NCT03785756|Other|Placebo of IR tablet|Up to 2 tablets four times in 24 hours
75788235|NCT01307228|Other|Health Systems Evidence|Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
75788236|NCT03788174|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
75788237|NCT03788174|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
75788238|NCT03787550|Drug|The Sedatives, analgesics and antibiotics|The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
75788239|NCT03787784|Other|AI presentation|Automatic diagnosis information of AI is visible to endoscopist
75788240|NCT05694806|Other|analysis of thoracic scans|analysis of thoracic scans realised in standard care
75788241|NCT03787394|Other|adding taste enhancer|Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
75788242|NCT03790514|Other|Heat Wrap|Commercially heat tapes ( without drugs) will be applied to patients.
75788243|NCT03789890|Drug|BAY1902607|BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
75924511|NCT02512952|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
76080141|NCT03128619|Drug|Palbociclib|Given PO
75331556|NCT01120405|Drug|Sevoflurane|
76080142|NCT03128619|Other|Pharmacological Study|Correlative studies
75331557|NCT03030833|Device|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
75331558|NCT03399370|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
75331559|NCT03399370|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
75331560|NCT02859779|Behavioral|education programs|Four audio-recorded discussion groups will be organized in each of the 10 clinical settings
75331561|NCT03013387|Radiation|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
75331562|NCT03013387|Procedure|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
75470701|NCT04742322|Dietary Supplement|Bifidobacterium Lactis CCT7858|Probiotic B Lactis
75639489|NCT01032200|Drug|Armodafinil|Given orally
75639490|NCT01032200|Other|placebo|Given orally
75639491|NCT05539599|Diagnostic Test|Comprehensive evaluation|Non-ultrasound parameters: Central venous pressure, hand-grip strength evaluation, P0.1, Maximal inspiratory pressure, Blood gas analysis ultrasound parameters: Diaphragmatic displacement, thickening fraction, TFmax, E/e', Triscuspidal annular Plane Systolic Excursion, Lung score
76080143|NCT04451616|Diagnostic Test|Blood sample collection|Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.
75924512|NCT02512952|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
76080144|NCT04451616|Diagnostic Test|Hair sample collection|Hair sample collection will be performed. Hair mineral analysis will be performed.
75639492|NCT02694471|Behavioral|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
75788244|NCT03789890|Drug|Itraconazole|Itraconazole is administered at a dose of 200 mg once a day (oral solution of 10 mg mL-1) on Day 1 to Day 14 of study period 2.
76080145|NCT04451616|Diagnostic Test|Urine sample collection|Urine sample collection will be performed. Urine mineral analysis will be performed.
76080146|NCT04451616|Diagnostic Test|Body composition analysis|Body composition analysis with the use of electric bioimpedance will be performed.
76080147|NCT04451616|Diagnostic Test|Questionnaires|Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.
76080148|NCT04451616|Diagnostic Test|Blood pressure, pulse and blood oxygen saturation measurement|Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.
76080149|NCT04395573|Device|Accuro|ultrasound device (Accuro, Rivanna Medical, Charlottesville, VA) with automated pattern recognition software programmed (SpineNav3DTM technology) to calculate the depth to epidural space and identify bony landmarks
76080150|NCT04395573|Device|standard ultrasound device|standard ultrasound device (o calculate the depth to epidural space and identify bony landmarks
76080151|NCT03433092|Other|serum carotenoids|In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography
75331563|NCT03013387|Drug|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
75331564|NCT00950729|Procedure|Driving with running shoes|Participant was asked to do all the experiments with their own running shoes
75331565|NCT00950729|Procedure|Plaster cast|The participant was ask to do all the experiments with a plaster cast molded on his right leg
75331566|NCT00950729|Procedure|Driving with Aircast|The participant was ask to do all the experiments with a aircast on his right leg
75639493|NCT02734563|Other|Collagen turnover|Type IV and V collagen synthesis and breakdown
75788245|NCT01305980|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months
75788246|NCT03787706|Other|Dry Needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
76080152|NCT04451538|Dietary Supplement|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g (12 spoons, 500 kcal)/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g [12 spoons, 440 kcal]/day, twice a day).
76080153|NCT04451538|Dietary Supplement|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
76080154|NCT03433014|Procedure|0.5% Levobupivacaine|The infiltration group will receive local infiltration with 0.5% Levobupivacaine. The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision (2 ml for the 5-mm trocar and 3 ml for the 10-mm trocars, and 10 mL for specimen retrieval incision). The specimen retrieval incision will be performed in one of two techniques, depending on the surgeon's preference, a 4-6 cm length midline incision (extending from the Hasson trocar incision) or a 4-6 cm length Pfanensteil incision.
75788247|NCT03787706|Other|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
75788248|NCT01308554|Drug|Placebo: sterile normal saline|Bilateral TAP block using 20 ml of normal sterile saline per block.
75788249|NCT01308554|Drug|Marcaine|Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
75788250|NCT03787238|Device|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation using the gammaCore Sapphire device
75924513|NCT02512952|Procedure|OFD with Titanium Platelet rich fibrin (TPRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
75924514|NCT03493230|Biological|quantification of BRAF and NRAS mutation|Quantification of cell-free BRAF and NRAS mutations with digital PCR
75924515|NCT02513108|Procedure|same day discharge|same day discharge after PCI for stable CAD
75924516|NCT03495024|Drug|Varenicline|Oral medication approved to facilitate smoking cessation
75788251|NCT05693402|Procedure|opioid anesthesia|opioid-free general anesthesia vs non opioid-free general anesthesia
75788252|NCT05694728|Biological|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|"For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6.~For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6."
75788253|NCT05694728|Biological|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)|A 3-dose regimen administered at months 0, 2 and 6.
75788254|NCT01307540|Device|phototherapy|low level light therapy, broad band light wavelengths.
75788255|NCT05694572|Device|Implantation of a CIED|Implantation of a CIED
75924517|NCT02513030|Procedure|Defibrillation testing during ICD replacement|
76080155|NCT03433014|Other|Control|No infiltration
75639494|NCT05756374|Behavioral|OUT to IN|OUT to IN comprises 20 body-oriented biweekly 40-minute sessions facilitated by a psychomotor therapist in a pedagogical partnership with the preschool teacher. Sessions are implemented outdoors. All sessions are framed in a context of freedom and self and mutual bodily resonance, according to the following structure: First, children are invited to engage in exercise play activities. Second, children engage in ludic relaxation proposals. Finally, children are asked to reflect on their bodily experiences and express themselves through different expressive mediators. Preschool teachers also participate in a 25-hour training focused on the underlying principles of OUT to In and participate in 20 body-oriented biweekly 20-minute relaxation sessions, facilitated by a psychomotor therapist.
75788256|NCT03787316|Device|Study group|4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
75331567|NCT02784353|Behavioral|Perioperative rehabilitation program|"Perioperative rehabilitation program~preoperative rehabilitation : 2 weeks prior to operation~postoperative rehabilitation : 3 months after operation"
75331568|NCT02784353|Behavioral|Conventional|conventional perioperative management without rehabilitation program
75788257|NCT01306136|Behavioral|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
75788258|NCT01306136|Behavioral|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
75788259|NCT03789734|Biological|BLS-M22|BLS-M22 250mg/capsule
75788260|NCT03789734|Other|Placebo|BLS-M22 placebo 250mg/capsule
75788261|NCT01308632|Drug|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
75788262|NCT03789812|Device|Manual toothbrush|Soft manual toothbrush (Oral B) will be used to brush occlusal, buccal and lingual teeth surfaces.
75788263|NCT03789812|Device|Electric Toothbrush|Electric toothbrush (Jetpik JP210) will be used to brush occlusal, buccal and lingual teeth surfaces.
75788264|NCT03789812|Device|Superfloss|Superfloss (Oral B) will be used to clean interproximal teeth surfaces.
75788265|NCT03789812|Device|Dental Water Jet|Dental water jet (Jetpik JP210) will be used to clean interproximal teeth surfaces.
75788266|NCT03789578|Drug|NNC0148-0287sema|Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
76080156|NCT01872689|Drug|Lebrikizumab|Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
75331569|NCT03597178|Device|senofilcon A|ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
76080157|NCT01872689|Drug|Pirfenidone|Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
76080158|NCT01872689|Drug|Placebo|Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
76080159|NCT04678908|Drug|HB0025|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
75331570|NCT01782989|Drug|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
75331571|NCT01782989|Drug|Placebo|Placebo capsule daily for 24 months
75331572|NCT03544216|Device|Multifocal Contact Lens|The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks
75331573|NCT03544216|Device|Single Vision Contact Lens|The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
75331574|NCT02245607|Behavioral|Compensatory Cognitive Training|
75639495|NCT03345771|Combination Product|Antimicrobial Barrier Dressing|Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.
75788267|NCT03789578|Drug|Semaglutide|Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
75788268|NCT03789578|Drug|NNC0148-0287|Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
75788269|NCT03713684|Drug|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
75788270|NCT03713684|Drug|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
75331575|NCT02245607|Behavioral|Recreational Therapy|
75331576|NCT01120639|Drug|Temozolomide|75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
75331577|NCT01120639|Procedure|Stereotactic Radiosurgery (SRS)|Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)
75470702|NCT04742322|Dietary Supplement|Maltodextrin|Maltodextrin
75788271|NCT03713684|Drug|Background therapy|Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
75788272|NCT03785522|Drug|Insulin degludec|Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter.
75788273|NCT05694416|Drug|Etoposide Plus Cisplatin|Etoposide Plus Cisplatin ivdrip d1-5
76080160|NCT03999606|Behavioral|Music Training - Choir participation|"Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform."
76080161|NCT03435978|Behavioral|MetS+|
76080162|NCT03435978|Other|MetS-|Data processing from Patient Medical Files
75924518|NCT02512796|Drug|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
75331578|NCT00951821|Behavioral|Concurrent treatment|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
75331579|NCT00951821|Behavioral|Adolescent treatment only|Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
75639496|NCT03345771|Device|Negative Pressure Wound Therapy (NPWT)|PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing
75639497|NCT00586105|Drug|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
75639498|NCT02729571|Biological|MTBVAC|Live-attenuated tuberculosis vaccine
75639499|NCT02729571|Biological|BCG|Commercially available live-attenuated tuberculosis vaccine
75639500|NCT00743119|Drug|Placebo capsules|Placebo capsules
75639501|NCT00743119|Drug|Inactive marijuana (0% THC)|Inactive marijuana cigarettes (0% THC) provided by NIDA
75788274|NCT01308710|Dietary Supplement|Omega-3 fatty acid (Eicosapentaenoic acid)|1.0 grams daily for 6 weeks
75788275|NCT03787160|Diagnostic Test|initial VOC|Difference in VOC profile between patients with CDH and healthy controls (2 samples per patient will be obtained after obtaining informed consent).
75788276|NCT03787160|Diagnostic Test|initial fecal microbiome|Difference of alpha and beta diversity and relative fecal bacterial abundance between patients with CDH and healthy controls (1 stool sample will be taken per patient after obtaining informed consent)
75924519|NCT05040048|Other|Clinical, biological and imaging assessment|
75924520|NCT04188314|Drug|Desflurane|The intervention group will receive desflurane for maintenance of anaesthesia, and the quality of recovery score will be compared post-operatively with the control group who received isoflurane.
75924521|NCT04188314|Drug|Isoflurane|The control group will receive Isoflurane for maintenance of anesthesia. The quality of recovery score will be compared post-operatively with patients in the intervention group who received desflurane.
75924522|NCT05512780|Drug|Dalpiciclib|"An exploratory study of a single-arm, open design~All subjects enrolled will receive the following treatment:~Dalpiciclib combined with Letrozole, 28 days as one cycle."
75924523|NCT04501172|Behavioral|Questionnaire completion|"Participants are contacted through social networks (Facebook) which provide a link to website that contains the questionnaire. Then, they complete the questionnaire which consists of the following 2 parts:~participant's demographic characteristics with questions regarding age, visual acuity - refractive error, spectacles and contact lenses use, and compliance to mask-wearing directives.~20 items that construct 5 subscales: a) near vision (5 items), b) distance vision (3 items), c) ocular discomfort (3 items), d) driving (2 items), e) limitations (3 items), need for help (2 items), work collaboration (1 item), and emotional impact (1 item).~The impact of spectacles on the compliance of Greek people to mask-wearing directives will be assessed via this questionnaire."
75331580|NCT00676351|Procedure|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
75639502|NCT00743119|Drug|Low dose Dronabinol|Dronabinol 10mg
75639503|NCT00743119|Drug|High dose Dronabinol|Dronabinol 20mg
75639504|NCT00743119|Drug|Low THC marijuana|marijuana cigarettes (1.98% THC) provided by NIDA
75639505|NCT00743119|Drug|High THC marijuana|Marijuana cigarettes (3.56% THC) provided by NIDA
75639506|NCT02729493|Biological|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
75639507|NCT02734251|Dietary Supplement|Relora|750 mg/day
75639508|NCT02734251|Dietary Supplement|Placebo|
75639509|NCT04089241|Other|Contrast 3D Ultrasound|an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
75639510|NCT02610010|Drug|Cisplatin|Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.
75639511|NCT02610010|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
75639512|NCT02734329|Procedure|conventional laparoscopic partial nephrectomy|renal artery will be clamped during surgery.
75639513|NCT02734329|Procedure|zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)|
75639514|NCT02597023|Drug|MitoQ|Mitoquinone pill, 20 mg/day
75639515|NCT02597023|Drug|Placebo|Placebo pill with inert excipient, 1 time/day
75639516|NCT02610088|Drug|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by > 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.
75639517|NCT02610088|Drug|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by > 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
75788277|NCT03787160|Diagnostic Test|initial pulmonary microbiome|Difference of alpha and beta diversity and relative pulmonary bacterial abundance between patients with CDH and healthy controls (1 deep induced sputum sample will be taken per patient after obtaining informed consent)
75788278|NCT03787160|Diagnostic Test|Maximum oxygen uptake|Comparison of the maximum oxygen uptake (corrected for body weight and gender) as determined by bicycle spiroergometry between patients with CDH and healthy controls
75788279|NCT03787160|Diagnostic Test|Functional residual capacity|FRC will be determined by spirometry, bodyplethysmography and N2-breath wash out method. FRC will be compared between patients after CDH and healthy controls.
75788280|NCT03787160|Dietary Supplement|Probiotic treatment|CDH patients will receive OmniBiotic 6(R) (Allergosan, Graz, Austria) probiotic supplementation 1 sachet daily for 3 months.
75788281|NCT03787160|Diagnostic Test|VOC probiotic|Determination of the VOC profile 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
75788282|NCT03787160|Diagnostic Test|Fecal microbiome probiotic|Determination of the fecal microbiome from 1 sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
75924524|NCT02324322|Device|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
75639518|NCT02734407|Procedure|Assigned Intervention|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
75639519|NCT02734407|Drug|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
75788283|NCT03787160|Diagnostic Test|Pulmonary microbiome probiotic|Determination of the fecal microbiome from 1 deep induced sputum sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
75788284|NCT01560650|Device|CRRT|Difference dose of CRRT
75788285|NCT03785444|Other|WHODAS 2.0|WHO Disability Score
75788286|NCT03785444|Other|EQ5D|Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level
75788287|NCT03785444|Other|IADL|The Lawton Instrumental Activities of Daily Living
75788288|NCT03785444|Other|Barthel-Score|Barthel Score of the patient
75788289|NCT03785444|Other|SF-36|Short Form Health 36
75788290|NCT03785444|Other|MoCA Blind|Montreal Cognitive Assessment
75924525|NCT02324322|Other|Muscle Biopsies|"Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking."
75331581|NCT02422043|Other|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
75331582|NCT01095757|Drug|Plerixafor|240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is > 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
75788291|NCT03789344|Other|acupuncture|Acupuncturists apply the seven-days' electro-acupuncture treatment on the acupoints of Neiguan points and Daling points for 30min per day.
75788292|NCT03789344|Other|Psychotherapy|Subjects in psychotherapy group would be accepted 20mins- psychotherapy per day.
75788293|NCT03789344|Other|blank control|Blank control subjects would be observed only during this investigation.
75924526|NCT02324322|Other|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
75924527|NCT02517242|Device|Pens Device|
75924528|NCT02517242|Device|Syringe|
75924529|NCT02517242|Other|Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)|
75924530|NCT03494712|Drug|S 95010|Single administration of S 95010 in healthy volunteers
75924531|NCT03494712|Other|Placebo|Single administration of placebo in healthy volunteers
75331583|NCT03549598|Drug|68Ga-DOTATATE PET/CT|5.4 mCi of 68Ga-DOTATATE will be administered by intravenous route.
75331584|NCT03549598|Drug|18FDG PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 18FDG will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
75639520|NCT02596789|Device|"TMS Magpro®, Magventure Inc device"|
75639521|NCT02734173|Drug|ABT450r-ABT267-ABT333 +/- Ribavirin|12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
75639522|NCT05757154|Other|Diet|All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
75639523|NCT02729337|Behavioral|ITG (In This Together)|Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
75639524|NCT05297422|Procedure|Forearm surgey|Microsurgery Clinic , KAT Hospital Athens
75639525|NCT05297422|Drug|Ropivacaine|Ropivacaine
75639526|NCT05297422|Drug|Ketamine|Ketamine
75639527|NCT02734095|Device|Ultrasound|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
75639528|NCT02609074|Procedure|Minimally invasive internal fixation surgeries|
75639529|NCT02609074|Device|CPC/rhBMP-2 micro-scaffolds|
75788294|NCT03789422|Drug|association of levocetirizine and tranexamic acid|levocetirizine 10 mg/day + tranexamic acid 2 g/day
75788295|NCT03789422|Drug|Levocetirizine only|levocetirizine 20 mg/day
75788296|NCT03789266|Procedure|drain ablation|drain ablation will be done in Aspiration mode or in non Aspiration mode
75924532|NCT02517164|Other|Measurement of serum 25-hydroxyvitamin D|
75924533|NCT02517164|Other|"Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA)."|
75470703|NCT04742010|Drug|Zoledronic Acid|"A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted)~Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)~Administration: slow intravenous infusion with a duration of at least 15 minutes"
75788297|NCT03786848|Other|MiniPDX Group|Mini patient derived xenograft (MiniPDX) is a drug sensitivity test model established by transplanting primary human tumor cells into immunodeficient mice by special methods. This test can provide sensitivities of single drug or drug combination within 7 days to screen out the optimal individualized regimens for each patient.
75788298|NCT03787004|Drug|CNTX-6970|Oral dose CNTX-6970
75788299|NCT03787004|Other|Placebo|Oral dose placebo
75924534|NCT05511376|Device|AURICULAR VAGUS NERVE STIMULATION|For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.
75924535|NCT05511376|Behavioral|DIET|For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)
75924536|NCT05511376|Behavioral|EXERCISE|Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
75924537|NCT03346460|Other|Tongue Scraping|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
75924538|NCT03346460|Radiation|aPDT|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
76080163|NCT03435900|Drug|Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.
75639530|NCT02609074|Device|CPC paste|
75788300|NCT03785132|Procedure|Cardiac surgery|The relationship between performance measurement of blood pressure during cardiac surgery (before, during and after cardiopulmonary bypass) and postoperative mortality
75788301|NCT04751084|Drug|Buscopan 20 milligrams/ML Injectable Solution|cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
75924539|NCT03346460|Radiation|Tongue scraper and aPDT|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
76080164|NCT03435900|Drug|Standard antibiotics intravenously|4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
76080165|NCT00632931|Drug|vorinostat|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
76080166|NCT00632931|Drug|Comparator: placebo (unspecified)|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
76080167|NCT04666974|Behavioral|iCBT|Online CBT modules will be completed weekly with content mirroring in-person CBT for their diagnosis. Homework will be submitted weekly through the OPTT platform which will be reviewed by a trained professional who will provide personalized feedback.
75470704|NCT04742010|Drug|Placebo|as above
75470705|NCT04733911|Other|75 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 5 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
75470706|NCT04733911|Other|150 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 10 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
75639531|NCT00733369|Device|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
75639532|NCT00733369|Device|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
75639533|NCT02729415|Procedure|Stromal Vascular Fraction Cells (SVF Cells) Injection|The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
75788302|NCT03785054|Drug|HTL0014242|HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)
75788303|NCT03785054|Drug|Placebo oral capsule|Placebo treatment
75639534|NCT02729415|Procedure|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
75788304|NCT04703348|Diagnostic Test|Motor imagery Questionnaire - Revised Second (MIQ-RS)|"Patients fulfill a questionnaire measuring individuals capacities to realize mental imagery. For more facilities and less risk of bias, the MIQ-RS was written on an online version with questions recorded in audio format. No official cut-off exists but studies seem to prove that people with :~a score less than 48/98 are unable to do motor imagery~a score between 49 and 73/98 have disturbed motor imagery capacities~a score more than 74/98 have normal motor imagery capacities."
75788305|NCT01307852|Device|Plastic Scintillation Detectors|Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
75788306|NCT03784976|Other|Iyengar Yoga Therapy|2 weekly yoga class (1.25 hours each)
75788307|NCT03782012|Behavioral|Supported|Visual organization of knowledge base items plus discourse-based discussion supporting knowledge availability and accessibility
76080168|NCT04666974|Behavioral|In-Person CBT|Participants will be assigned to in-person CBT that will mirror the content and homework covered in the iCBT group. It will be delivered by professionals and attended weekly.
76080169|NCT01857323|Drug|Albuterol Spiromax®|Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
75331585|NCT03549598|Drug|13NH3 PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
75639535|NCT02729415|Other|Hair Measurements|Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
75639536|NCT00813124|Drug|Fludarabine|40 mg/m^2 by vein over 60 minutes on Day -5 through Day -2.
75788308|NCT05690048|Drug|Fecal microbiota transfer|FMT via capsule (50 g of fecal matter) on day 0 and day 21.
75788309|NCT05690048|Drug|Vancomycin Oral Capsule|Vancomycin orally (125 mg 4xd, day -3 to 0).
76080170|NCT03439488|Drug|JNJ-440|JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.
76080171|NCT03439488|Drug|Placebo|Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
76080172|NCT03435822|Other|asthma action plan management group|Patients will follow the directions in asthma action plan when their asthma get worse.
75331586|NCT05497817|Behavioral|Algorithm|Current and/or former Care Partners of persons with dementia will be matched using an algorithm to other Care Partners who might provide emotional support.
75331587|NCT05497817|Behavioral|Random Match|Current and/or former Care Partners of persons with dementia will be randomly matched to other Care Partners who might provide emotional support.
75331588|NCT01034527|Other|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
75331589|NCT03031145|Biological|Felis Domesticus|Nasal Administration of Felis Domesticus
75331590|NCT00376636|Drug|SPP635 (drug)|
75639537|NCT00813124|Drug|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
75639538|NCT00813124|Drug|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
75788310|NCT05690048|Drug|Atezolizumab + Bevacizumab|Atezolizumab 1200mg i.v. & Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).
75788311|NCT05690048|Drug|Placebo Vancomycin Oral Capsule|Placebo Vancomycin orally (125 mg 4xd, day -3 to 0).
75788312|NCT05690048|Drug|Placebo Fecal microbiota transfer|Placebo Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21.
75639539|NCT00813124|Drug|Azacitidine|Start cycles of 32 mg/m^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
76080173|NCT03435822|Other|conventional management group|Patients will follow the directions in conventional strategy when their asthma get worse.
76080174|NCT03104439|Drug|Nivolumab|The antibodies in nivolumab work by causing programmed cell death of the cancer cells
76080175|NCT03104439|Drug|Ipilimumab|The antibodies in ipilimumab work by not allowing cancer cell growth
76080176|NCT03104439|Radiation|Radiation Therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
75331591|NCT03830125|Drug|BBT-877, Single dose|Single dose of BBT-877, 5 dose levels, oral capsule
75331592|NCT03830125|Drug|Placebo group|Placebo matched to BBT-877, oral capsule
75331593|NCT03830125|Drug|BBT-877, Multiple doses|Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule
75331594|NCT02245451|Drug|Tipranavir|
75331595|NCT02245451|Drug|Ritonavir|
75331596|NCT02245451|Drug|Methadone|
75331597|NCT01096771|Drug|ClinOleic 20%|96 hour continuous infusion.
75331598|NCT01096771|Drug|Intralipid 20%|96 hour continuous infusion.
75639540|NCT00813124|Procedure|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
75788313|NCT01560806|Other|Commune Hypertension Management|"People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI"
75788314|NCT05694104|Other|Malnutrition|For the diagnosis of malnutrition, we adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
75788315|NCT01308866|Behavioral|Share decision tool|
75331599|NCT00951899|Drug|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
75331600|NCT00951899|Other|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
75788316|NCT01308086|Drug|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 12 cycles
75924540|NCT04834362|Drug|Analog Insulin|"For a patient who is known to have diabetes but were not getting insulin previously (or previous insulin dosage is not known), insulin therapy will be started at a total daily dose of 0.3-0.4 units/kg/day for an admission BG between 10-15 mmol/L or 0.5-0.6 units/kg/day for a BG >15 mmol/L. In previously insulin treated patients, ongoing total daily dose of insulin will be started. If there is history of poor glycemic control with ongoing insulin dose, then 10-20% increase of daily dose of insulin will be considered.~For a patient who is not known to have diabetes, insulin therapy will be started if admission BG is >10 mmol/L in two or more occasions. A total daily dose of 0.3-0.4 units/kg/day will be started if admission BG is 10-15 mmol/L and 0.5-0.6 units/kg/day for a BG >15 mmol/L."
75331601|NCT00951899|Behavioral|Diet|Subjects were instructed to follow a weight maintenance diet (~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
75924541|NCT04834362|Drug|Human insulin|Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm.
75331602|NCT00951899|Drug|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
75331603|NCT01035151|Behavioral|Experimental|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
75331604|NCT01035151|Behavioral|Control|Written Cessation Materials
75331605|NCT01097395|Drug|ribavirin|Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
75331606|NCT03030521|Diagnostic Test|the aortic delamination test|The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.
75639541|NCT02733939|Device|Home monitoring kit|"The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~leaves the home without notice, since this might occur in a moment of disorientation;~leaves a water tap open;~forgets something on the stove;~gets out of bed during the night and doesn't come back within a certain time interval;~never goes to the bathroom in 24 hours;~never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~automatically turn on a light to help avoid a fall during the night;~alert the caregiver when the temperature in the house falls or rises excessively;~act as burglar alarm in some areas of the home."
75788317|NCT01308086|Drug|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 12 cycles
75788318|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
75788319|NCT01308086|Drug|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
75788320|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
75788321|NCT01308086|Drug|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 6 cycles
75788322|NCT01308086|Drug|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 6 cycles
75788323|NCT01308086|Drug|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
75788324|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
75331607|NCT01036009|Other|Withdrawal of immunosuppression and donor lymphocyte infusion|Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
75331608|NCT00467987|Drug|androgel|androgel 1%
75639542|NCT02729259|Behavioral|Virtual Reality Snowworld|The subjects will receive Virtual Reality Snowworld during their wound care procedure. The nurse will be doing their wound care.
75788325|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
75788326|NCT03786458|Behavioral|web-based decision aid|The decision aid is then developed further process of evidence synthesis and multidisciplinary external review.
75788327|NCT05694026|Device|Intense pulsed light|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
75788328|NCT05694026|Drug|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
75924542|NCT05507710|Diagnostic Test|Near-infrared fluorescence imaging of perfusion|Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
75924543|NCT03121274|Procedure|vaginal delivery|vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
75924544|NCT03493074|Diagnostic Test|Noninvasive pulse wave analysis sensor, ECG-sensor|The sensors are noninvasively attached
75924545|NCT05512702|Drug|Tissue Plasminogen Activator, Alteplase|Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
76080177|NCT03432780|Drug|Docetaxel|
75331609|NCT00467987|Drug|placebo|placebo
75331610|NCT00433589|Drug|anthracycline-based|
75331611|NCT00433589|Drug|docetaxel and capecitabine|
75331612|NCT00433589|Drug|tamoxifen|
75331613|NCT00433589|Drug|Letrozole|
75331614|NCT03013075|Procedure|Spinal anesthesia with Bupivacaine heavy and Morphine|Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery
75331615|NCT03013075|Drug|Bupivacaine heavy and Morphine|
75331616|NCT03013075|Drug|General Anesthetics|
75331617|NCT02180893|Other|Paravertebral Block|Paravertebral nerve block injection
75331618|NCT02180893|Other|Placebo Comparator|"No block~Patients who did not receive PVB"
75331619|NCT03014089|Biological|mRNA-1325|Escalating dose levels
75331620|NCT03014089|Other|Placebo|
75639543|NCT02729259|Behavioral|Virtual Reality slides of nature|The subjects will receive Virtual Reality Slides of Nature during their wound care procedure. The nurse will be doing their wound care.
75639544|NCT02729259|Behavioral|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
75639545|NCT05133700|Other|Interview or focus group discussion|There is no intervention. This is a qualitative piece of work only
75639546|NCT05133700|Other|Review of submitted medicines audit tools|There is no intervention. This is a qualitative piece of work only
75788329|NCT03786302|Drug|TAMP bioglass|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
75788330|NCT03786302|Drug|Biodentine|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
75788331|NCT03782090|Device|Endobronchial intubation|"In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated."
75924546|NCT05512702|Drug|Low-molecular weight heparin|Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
75924547|NCT02516930|Behavioral|crowdsourced video|video promoting condom use
75639547|NCT00733291|Device|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
75924548|NCT02516930|Behavioral|social marketing video|
76080178|NCT03432780|Biological|Hormone and radiation therapy|
75331621|NCT03030677|Procedure|Pectoralis II block & catheter without Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
75639548|NCT00733291|Device|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
75639549|NCT00733291|Device|FID 107027 solution|Commercially marketed solution for contact lens disinfection
75639550|NCT02729181|Device|DRX9000|
75639551|NCT03964597|Diagnostic Test|Measurement of lens opacification|Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.
75639552|NCT02733783|Device|Cold dry air machine|Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
75788332|NCT05443802|Drug|Insulin 0.05 IU/kg/h|In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
75788333|NCT05443802|Drug|Insulin 0.10 IU/kg/h|In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
75788334|NCT01311284|Device|Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope|Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
75788335|NCT01311284|Device|Macintosh laryngoscope|intubate with the macintosh laryngoscope
75788336|NCT01311284|Device|McGrath|Intubate with McGrath device
75788337|NCT01311284|Device|Airtraq Nasotracheal|intubate with Airtraq Nasotracheal
75788338|NCT01308164|Device|MD Logic Pump Advisor|Insulin pump setting (i.e basal plan, correction factor, carbohydrate ratio and insulin activity time)will be adjusted using the MD-LOgic Pump Advisor
75924549|NCT03494634|Drug|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
75924550|NCT05507632|Combination Product|Donafenib plus Sintilimab in combination with transarterial chemoembolisation|Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)
75924551|NCT05512546|Drug|Aspir-Low Pill|patients were prescribed 75 mg/day of either aspirin
75924552|NCT02517086|Other|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
75924553|NCT02517086|Other|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
75788339|NCT01308944|Drug|Propranolol|
76080179|NCT03432780|Radiation|Radiation therapy|
76080180|NCT00055731|Drug|bicalutamide|
75788340|NCT01311596|Other|Icons|Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
76080181|NCT00055731|Drug|Goserelin Acetate|
76080182|NCT00055731|Drug|docetaxel|
76080183|NCT00055731|Drug|Estramustine phosphate sodium|
75788341|NCT03784664|Diagnostic Test|Arterial blood gas|arterial blood sample with puncture of the radial artery
75788342|NCT03784664|Diagnostic Test|Veinous blood gas|veinous blood sample using peripheral venepuncture
76080184|NCT00055731|Drug|acetylsalicylic acid|
76080185|NCT00055731|Procedure|conventional surgery|
76080186|NCT00055731|Radiation|radiation therapy|
76080187|NCT03432702|Procedure|Horizontal ridge augmentation|Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
75788343|NCT03781856|Behavioral|La Vida Buena Program|The intervention is series of interactive one hour weekly classes over the course of 8 weeks related to child healthy weight, exercise and nutrition. Facilitated by community health workers, the classes are interactive and play-based and designed to engage both the child and accompanying parent or guardian in activities.
75788344|NCT03781856|Behavioral|Brief Educational Session|A one hour session about nutrition and physical activity to address obesity facilitated by a community health worker
75788345|NCT03781622|Device|WOLF Thrombectomy Device|Mechanical thrombectomy for the neurovasculature
75788346|NCT03777488|Drug|Tranexamic Acid 1 gram intravenously|Intravenous tranexamic acid crossover to oral and intramuscular arms
75924554|NCT02517086|Other|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
75924555|NCT04879498|Drug|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia fixed partial dentures
75639553|NCT00732199|Other|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
75924556|NCT04879498|Other|Veneered zirconia|To assess the clinical performance and survival of posterior veneered zirconia fixed partial dentures
75924557|NCT04879498|Other|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic fixed partial dentures
75924558|NCT05511220|Behavioral|PRIMeR|Virtual PRIMeR intervention consists of coaching parents to use strategies derived from Social Routines (to boost positive affect) and Reciprocal Imitation Training (to boost toy play)
75924559|NCT05511220|Behavioral|PRT|Virtual PRT intervention consists of coaching parents to use key PRT strategies to enhance children's communication skills
75924560|NCT03345134|Drug|MK-3475 and BCG|combination treatment with MK-3475 and BCG after endoscopic ablation
76080188|NCT03435744|Drug|Simvastatin 20 mg|Simvastatin 20 mg added to TAU for 3 months.
75639554|NCT02733549|Other|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
76080189|NCT03435744|Other|Placebo Oral Tablet|Matched placebo added to TAU for 3 months
75639555|NCT02728869|Biological|Heat Stable Rotavirus (HSRV) Vaccine|It is a lyophilized live attenuated pentavalent (G1-G4 and P1[8]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection
75639556|NCT02728869|Biological|Placebo for Heatstable Rotavirus vaccine|It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
75639557|NCT02728869|Biological|RotaTeq®|It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7[5]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A[8]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
75639558|NCT02594761|Biological|Hercules|Powder Concentrate for Intravenous Infusion, 150 mg/vial
75639559|NCT02594761|Biological|Herceptin EU|Powder for Concentrate for Solution for Infusion, 150 mg/vial
75639560|NCT02594761|Biological|Herceptin US|Intravenous Infusion, 440 mg/vial
75639561|NCT02728947|Drug|ROTIGOTINE|1 week at each dose
75788347|NCT03777488|Drug|Tranexamic acid 2 grams oral solution|Oral tranexamic acid crossover to intravenous and intramuscular arms
75788348|NCT03777488|Drug|Tranexamic acid 1 gram intramuscular|Intramuscular tranexamic acid crossover to oral and intravenous arms
75788349|NCT03777566|Diagnostic Test|sonohysterography|sonohysterography with measuring the uterine cavity volume
75788350|NCT03784742|Other|Nitrate rich beetroot juice|James White Drinks Limited beetroot juice (0.4-0.45 g nitrate/70 ml drink).
75788351|NCT03784742|Other|Placebo beetroot juice|James White Drinks Limited Placebo beetroot juice (0 nitrate/70 ml drink).
75788352|NCT03777254|Biological|RC28-E|RC28-E intravitreous injection 50ul
75788353|NCT03711266|Behavioral|PE-PC|PE-PC treatment will follow the PE-PC manual and patient workbook. Treatment content for PE-PC is drawn from the PE model and condensed so as to deliver the most efficacious components of PE. PE-PC consists of four, 30-minute appointments scheduled approximately once a week over 4-6 weeks
75924561|NCT05605496|Drug|NP137|IV infusion, 14mg/kg, Q3W
75924562|NCT05605496|Drug|anti-PD-1/PD-L1|IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.
75924563|NCT02512562|Drug|AL-335|AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
75924564|NCT02512562|Drug|ACH-3102|ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
75924565|NCT02512562|Drug|Simeprevir|Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
76080190|NCT03975504|Device|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
76080191|NCT03975504|Device|artificial intelligence (AI)|AI was performed in high-risk individuals recruitment and lung nodules management
76080192|NCT03975504|Diagnostic Test|autofluorescence imaging (AFI)|AFI applied in screening of centrally located SCC.
76080193|NCT03439410|Other|Clinical Complexity Index|Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.
76080194|NCT03435666|Drug|Capecitabine|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
76080195|NCT03435666|Drug|XELODA|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
76080196|NCT00632541|Drug|Sorafenib|Sorafenib 200mg po daily
75639562|NCT02594605|Device|Platelet Rich Fibrin|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
75788354|NCT01561352|Drug|activated recombinant human factor VII|If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
75788355|NCT01312298|Procedure|General anesthesia|Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml
75639563|NCT02594605|Device|Conventional Flap Surgery|Only Conventional Flap Surgery treatment the bone loss limitedly.
75924566|NCT03489096|Device|Cryoballoon Ablation: PVI + substrate modification|Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
75924567|NCT05511142|Other|Classic Peyton's Four-Step Approach|Instructor demonstrated endotracheal intubation and mask ventilation procedural skills directly to the preclinical students, followed by direct hands-on practice using manequin, ended with giving feedback to the students
75331622|NCT03030677|Procedure|Pectoralis II block & catheter with Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
75331623|NCT03030677|Other|catheter insertion|catheter insertion after Lidocaine dissection
75331624|NCT03035513|Other|Continuous spikes and waves during slow sleep (CSWS)|
75331625|NCT03030365|Device|"Siemens Biograph mMR PET-MR (3T)"|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
75331626|NCT01122901|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
75639564|NCT02594839|Drug|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
75788356|NCT01312298|Procedure|Regional anesthesia|Patients will receive intrathecal anesthesia
75788357|NCT01560884|Drug|Renazorb 1500 mg/day|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
75788358|NCT01560884|Drug|Renazorb 3000 mg/day|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
75788359|NCT01560884|Drug|Renazorb 4500 mg/day|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
75788360|NCT01560884|Drug|Renazorb 6000 mg/day|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
75788361|NCT01309022|Drug|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
75788362|NCT01309022|Drug|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
75788363|NCT01309022|Drug|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
75788364|NCT01309022|Drug|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
75924568|NCT05511142|Other|Modified Peyton's Four-Step Approach|Video tutorial of endotracheal intubation and mask ventilation were given to the students without explanation, followed by video tutorial making using manequin (without instructor) by the students which will be uploaded to Youtube
75924569|NCT02516774|Drug|Adalimumab|
75924570|NCT05510986|Drug|Fentanyl group|Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
75924571|NCT05510986|Drug|Oxycodone Hydrochloride group|"Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes."
75924572|NCT04856358|Drug|GLPG3121|GLPG3121 modified-release tablet
75924573|NCT04856358|Drug|Placebo|Matching placebo
76080197|NCT00632541|Drug|Bevacizumab|"Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks"
76080198|NCT00632541|Other|Imaging|Imaging every third cycle
75331627|NCT01122901|Procedure|therapeutic conventional surgery|Undergo surgery
75331628|NCT01122901|Other|pharmacological study|Correlative studies
75331629|NCT01122901|Other|laboratory biomarker analysis|Correlative studies
75331630|NCT03035435|Other|fast-track rehabilitation|
75331631|NCT03035435|Other|standard care rehabilitation|
75331632|NCT01097785|Drug|Simvastatin|40 mg, P.O.,daily for 30 days
75639565|NCT02594839|Drug|Placebo|intravenous infusion of 400 mL saline
75639566|NCT02729103|Drug|Xofigo (Radium 223 dichloride,BAY88-8223)|Retrospective claims analysis. Descriptive analyses of treatment patterns.
75639567|NCT02594527|Other|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
75639568|NCT02733705|Other|Control|normal saline IV
75639569|NCT02733705|Drug|Fentanyl|fentanyl 0.5 mcg/kg ideal BW
75639570|NCT02733705|Drug|propofol|propofol infusion
75788365|NCT05111132|Diagnostic Test|Fluid challenge (cristalloïd, NaCl 0,9%)|A fluid challenge according to group will be administrated by infusion pump
75788366|NCT01318226|Drug|ATx08-001|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
75788367|NCT01318226|Drug|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
76080199|NCT01872611|Drug|Nepafenac Ophthalmic Suspension, 0.3%|
76080200|NCT01872611|Other|Vehicle|Inactive ingredients used as placebo comparator
76080201|NCT01872611|Drug|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
75924574|NCT02512640|Procedure|Volume-controlled ventilation|a tidal volume of 8 ml/kg
75788368|NCT03776708|Other|Spinal manipulation|Spinal manipulation is defined as a quick, passive and forced manoeuvre applied to spinal joints, and sometimes followed by a characteristic cracking sound. It can be compared to a mobilisation, which is a passive manual therapy as well, but is applied slower and repetitively on the joints. Spinal manipulation has been shown to have a significant clinical impact in the treatment of musculoskeletal pain
75331633|NCT01097785|Drug|Placebo|1 capsule daily for 30 days
75331634|NCT03030287|Drug|OMP-305B83|intravenous (in the vein) infusion
75331635|NCT03030287|Drug|Paclitaxel|administered intravenously
75331636|NCT01098253|Behavioral|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
75639571|NCT00917917|Behavioral|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.~Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
75639572|NCT00917917|Behavioral|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
75639573|NCT02694939|Behavioral|STAND (Behavior Therapy + Motivational Interviewing)|Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
75331637|NCT03030209|Procedure|Distal pancreatectomy|Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
75331638|NCT03035279|Drug|SC-006|Intravenous
75331639|NCT03035279|Drug|ABBV-181|Intravenous
75924575|NCT02512640|Procedure|Pressure-controlled ventilation|a peak airway pressure to maintain a tidal volume of 8 ml/kg
75924576|NCT04872400|Drug|Vancomycin|1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
75924577|NCT04872400|Drug|Tobramycin|1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
75924578|NCT02512406|Other|The Sensory Profile|60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
75924579|NCT02512406|Other|The Adult/Adolescent Sensory Profile|60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
75924580|NCT02512406|Other|Children's Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
75331640|NCT03035357|Drug|Daratumumab|16 mg/kg by vein once weekly for a total of 4 doses.
75331641|NCT00940589|Drug|Circadin|Prolonged Release melatonin (Circadin) 2mg tablets
75331642|NCT00940589|Drug|Placebo|Matched placebo tablets, with identical features to the Circadin tablets
75331643|NCT03603106|Drug|P03277|"Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s."
75639574|NCT02694939|Behavioral|Usual Care|Community Therapists free to deliver any therapy they feel is indicated.
75639575|NCT02597257|Drug|Lidocaine HCl|lidocaine continuous infusion
75639576|NCT02597257|Drug|Normal saline|Normal saline continuous infusion
75639577|NCT02596477|Drug|Vepoloxamer|
75639578|NCT02596477|Other|5% dextrose in water|
75639579|NCT02690337|Drug|DS-1123|starting intravenous (IV) dose of 0.1 mg/kg.
75639580|NCT04089007|Device|SOmNI app|In addition to allowing users to track sleep behaviours across the four-week intervention period, the SOmNI app will also provide messaging via alerts and tips to outline the importance of sleep to health, suggest optimal sleep timing/duration, and suggest sleep promotion strategies. Daily review questions in the app will help the participants link changes in sleep behaviours to changes in health outcomes. As well, when goals related to sleep extension are met, the SOmNI rewards program awards points to the participant and these points can then be redeemed in $5 increments to a maximum of $40 for gift certificates.
75639581|NCT04089007|Other|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
76080202|NCT04451148|Other|Obese with or without metabolic syndromesubjects|Children with obesity and with or without metabolic syndrome
76080203|NCT03432624|Diagnostic Test|Serum MicroRNA-25 detection|The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.*all arms are given the same intervention.
76080204|NCT04607681|Behavioral|EDUCATION|WEB BASED EDUCATION
75331644|NCT03603106|Drug|Placebo|"Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s."
75331645|NCT02574078|Drug|Nivolumab|
75331646|NCT02574078|Drug|Bevacizumab|
75331647|NCT02574078|Drug|Pemetrexed|
75924581|NCT02512406|Other|Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
75331648|NCT02574078|Other|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
75788369|NCT03776708|Other|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires"
75788370|NCT03776786|Biological|TY014|TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)
75924582|NCT02512406|Other|Yale Global Tic Severity Scale|Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
75924583|NCT02512406|Other|Demographic Data|Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
75924584|NCT00101907|Drug|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
75924585|NCT00101907|Biological|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
75924586|NCT00101907|Drug|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m^2.
75470707|NCT04733911|Other|300 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 20 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
75331649|NCT02574078|Drug|nab-Paclitaxel|
75924587|NCT00101907|Drug|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m^2.
75331650|NCT02574078|Drug|Paclitaxel|
75924588|NCT02512484|Procedure|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
75924589|NCT03491748|Drug|ETX0282|Oral Gelatin capsules
75924590|NCT03491748|Drug|Cefpodoxime proxetil|Oral tablets
75331651|NCT02574078|Drug|Docetaxel|
75331652|NCT02574078|Drug|Gemcitabine|
75331653|NCT02574078|Drug|Erlotinib|
75470708|NCT04697095|Other|Blood samples|: The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.
75470709|NCT04646681|Behavioral|ConnectCare|increased monitoring between clinical mental health visits
75331654|NCT02574078|Drug|Crizotinib|
75639582|NCT02596633|Behavioral|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
75639583|NCT04178811|Device|Holmium Laser Enucleation of Prostate|Use of Holmium Laser Enucleation of Prostate in management of Benign Prostatic Hyperplasia patients
75639584|NCT02596555|Drug|Dabigatran|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
75924591|NCT03491748|Drug|Placebo|Oral Gelatin capsules
75924592|NCT04769206|Drug|Galantamine|4mg daily titrating up to 8mg twice a day
75924593|NCT04769206|Drug|Placebo|1 pill a day for 4 weeks, 2 pills a day for 8 weeks
75331655|NCT02574078|Drug|Carboplatin|
75331656|NCT03029897|Other|My eReport France|"patients are educated to the use of My eReport France application"
75331657|NCT03030053|Dietary Supplement|Cocoa-Flavanol Supplements|3 capsules each containing 300mg cocoa flavanols (total daily dose of 900mg cocoa-flavanols).
75331658|NCT03030053|Dietary Supplement|Control Supplements|3 capsules each containing 0mg cocoa-flavanols
75331659|NCT03605914|Drug|diclofenac|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
75331660|NCT03605914|Drug|Norco|The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
75331661|NCT00376714|Drug|GSK233705|
75470710|NCT04641234|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
75470711|NCT04636034|Procedure|Sphenopalatine Ganglion Block with Local Anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL
75470712|NCT04636034|Procedure|Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|Block performed with bilaterally inserted q-tips with isotone NaCl
75639585|NCT03328065|Other|Interviews|Semi-directed interviews, recorded and transcribed for analysis
75639586|NCT03328065|Other|Questionnaires|economic and psycho-social questionnaires
75788371|NCT03776786|Other|0.9% Saline|Placebo
75788372|NCT01560962|Drug|povidone iodine|over the counter (OTC) 5% povidone iodine (PI)
75788373|NCT01560962|Other|No Intervention|
75788374|NCT01560962|Drug|Azithromycin|
75788375|NCT01560962|Drug|tobramycin-dexmethasone|
75788376|NCT01560962|Other|warm soaked eyelid wash|
75924594|NCT03791840|Diagnostic Test|Ultrasound evaluation|High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
75331662|NCT04353479|Drug|Camrelizumab(SHR-1210)|A humanized monoclonal immunoglobulin
75924595|NCT04598932|Device|Brillouin microscopy|The Brillouin clinical instrument is comprised of three parts: a human interface, a laser-scanning confocal microscope, and an etalon-based spectrometer. The human interface is a modified ophthalmic slit-lamp instrument with chin support and headrest. The light source is a single longitudinal mode CW laser at 780 nm. A polarizing beam splitter and quarter-wave plate assembly sends the laser beam to the human interface. To focus light into the eye, a long-working distance microscope objective is used. Brillouin scattered light from the eye is collected with a single-mode optical fiber. For spectral analysis, a two-stage VIPA-etalon spectrometer configured with the cross-axis cascade principle and the spectrum is measured on a EM-CCD camera.
75331663|NCT04353479|Drug|Decitabine|A DNA methyltransferase inhibitor
75331664|NCT03027791|Behavioral|Virtual Reality|Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
75331665|NCT03027791|Behavioral|Group Sessions|12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
75331666|NCT03554746|Other|GC group|"core stability training: hold 5s/rep, 20 reps/times~supine, pelvic posterior tilt with TrA contraction.~supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~All four position with leg raise~Stretching ex. : hold 15 s/reps, 5 reps/times~Hamstring~Quadriceps~Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~clam ex. without resistance~single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~maintain 3rd to 4th ex.~single leg standing on rock board to maintain balance 6th:~maintain 5th ex.~lunge ex. without hip internal rotation"
75331667|NCT03554746|Other|CG group|"core stability training: hold 5s/rep, 20 reps/times~supine, pelvic posterior tilt with TrA contraction.~supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~All four position with leg raise~Stretching ex. : hold 15 s/reps, 5 reps/times~Hamstring~Quadriceps"
75331668|NCT05260307|Other|hearing aid condition|The intervention will be a hearing aid or a modification to the sound stimulus that simulates a hearing aid configuration, style, or processing strategy.
75470713|NCT04636034|Procedure|"Sham-block with Placebo (Isotone NaCl)"|Block performed with bilaterally inserted q-tips with isotone NaCl. The q-tips are inserted a maximum of 3 cm into the nasopharynx thus not reaching the mucus above the ganglion.
75470714|NCT04594941|Drug|Flurpiridaz (18F) Injection|All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein at rest.
75470715|NCT04524663|Drug|Camostat Mesilate|Camostat Mesilate administered as oral tablets
75639587|NCT00807040|Procedure|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
75639588|NCT00807040|Procedure|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
75788377|NCT05401058|Drug|Droperidol Injection|About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.
75788378|NCT05401058|Drug|Saline|About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.
75788379|NCT03781466|Procedure|Cervical cerclage|Cervical cerclage indicated by short cervix ≤25mm
75331669|NCT05252507|Behavioral|Paint Night|There will be 8 Sessions (4 paint nights and 4 educational sessions alternating weeks). For the painting sessions, participants will paint for 45 minutes and then participate in a combined presentation/discussion session (45 minutes). For the educational sessions, they will attend a 30-minute presentation presented by a researcher on heart health and then have the opportunity to discuss with the researcher and other members of the group (60 minutes).
75470716|NCT04524663|Drug|Placebo|Placebo to match camostat mesilate
75639589|NCT02728713|Procedure|Cranial Manipulation|Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
75639590|NCT02728713|Procedure|Sham/Placebo|A laying on of hands with no actual treatment being performed.
75639591|NCT02733471|Drug|Lidocaine|
75331670|NCT03608488|Dietary Supplement|Vitamin D|Vitamin D3 50.000 IU/per week, for 8 weeks
75331671|NCT03608488|Other|Exercise|Core stability, balance exercises
75331672|NCT03035045|Drug|Paracetamol|
75331673|NCT03035045|Drug|Placebo Oral Tablet|
75470717|NCT04524663|Other|Standard of Care Treatment|Standard of Care Treatment for COVID-19 Infection
75470718|NCT04475744|Drug|G-CSF treatment for Bone marrow derived stem cell Mobilization|Mobilization treatment. On the fifth day, collection will be started.
75639592|NCT02733471|Drug|Placebo|Placebo
75639593|NCT05756218|Other|nursing diagnoses - taboo game|Playing 7 weeks nursing diagnoses taboo cards
75788380|NCT03781466|Drug|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
75788381|NCT03781310|Drug|Tocilizumab|IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
75924596|NCT04419480|Device|CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization|Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.
75924597|NCT02517008|Other|Mama kit|A low-cost non-monetary incentive (mama kit) was provided to all women who delivered at the facility between June 1, 2013 - Aug 31, 2013. Women were told about the intervention during ANC, and safe motherhood groups in the community promoted the intervention in the catchment areas of the treatment facilities.
75924598|NCT03492996|Drug|LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose|To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose to healthy subjects
76080205|NCT03089853|Device|Neuromuscular electrical stimulation (NMES)|Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
76080206|NCT03439176|Other|Standard adhesive 1|This strip contains a standard hydrocolloid adhesive found in ostomy devices
76080207|NCT03439176|Other|Standard adhesive 2|This strip contains a standard hydrocolloid adhesive found in ostomy devices
76080208|NCT03439176|Other|PL4|This strip contains a new adhesive
76080209|NCT03439176|Other|PL16-L|This strip contains a new adhesive
76080210|NCT03432468|Drug|Valsartan 1|the high dose of valsartan
75639594|NCT04189887|Behavioral|aerobic exercise (cycling)|People who perform aerobic exercise will ride on a stationary bike for 20 minutes after motor skill learning
75639595|NCT04189887|Behavioral|Implicit sequence learning|All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.
75788382|NCT03781076|Behavioral|Sleep Intervention|The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
75924599|NCT02161965|Drug|Rivaroxaban|20mg or 15mg
76080211|NCT03432468|Drug|Valsartan 80 mg|a single dose of valsartan
75470719|NCT04475744|Procedure|Platelet Rich Plasma ovarian injection|Mobilized peripheral blood will be obtained to prepare the PRP for injection. Both ovaries will be injected when proper anatomical access can be assessed.
75639596|NCT02733237|Drug|oxytocin treatment|intranasal administration of oxytocin (40 IU)
76080212|NCT03086967|Device|Double-lumen balloon catheter|introduction of catheter into cervix for ripening prior to induction of labor following standard of care practices
76080213|NCT03435588|Procedure|EUS|Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.
76080214|NCT03435588|Procedure|FNA with ROSE|Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.
75331674|NCT03557086|Behavioral|Advance Care Planning Video Decision Support Tool|Advance care planning video intervention as previously described
75331675|NCT03557086|Other|Verbal Narrative|Verbal description of end of life care options
75331676|NCT03034733|Drug|Dexamethasone|intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
75331677|NCT03034733|Drug|Sodium Chloride, (24)NaCl 0,9%|intravenous placebo
75331678|NCT05512416|Drug|dalpiciclib plus letrozole|Six 4-week cycles of dalpiciclib orally, 150mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28
75331679|NCT03034499|Procedure|Single-port sacrocolpopexy|Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
75470720|NCT04462198|Drug|PIPE-505|Intratympanic injection
75470721|NCT04462198|Drug|Placebo|Intratympanic injection
75470722|NCT04458155|Device|Siemens® Point-of-care high sensitive troponin I analyzer|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Siemens® device.
75639597|NCT02733237|Drug|placebo treatment|intranasal administration of placebo (40 IU)
75639598|NCT02728323|Drug|Levobupivacaine|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
75639599|NCT02728323|Drug|Saline|20 ml of saline saline by intramuscular injection, at the end of surgery
75788383|NCT03150862|Drug|Pamiparib|Administered as specified in the treatment arm
75924600|NCT02161965|Drug|Fluindione|
75924601|NCT02161965|Drug|Warfarin|
75924602|NCT02565784|Device|Restylane|Facial tissue augmentation
75924603|NCT02565784|Device|Perlane|Facial tissue augmentation
76080215|NCT03435588|Procedure|FNB alone|Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).
76080216|NCT01856543|Other|Eucerin|
76080217|NCT01856543|Other|Mometasone Furoate 0.1%|
76080218|NCT03435432|Dietary Supplement|Glucose|Glucose drink
76080219|NCT03435432|Dietary Supplement|Water|Control
76080220|NCT03439098|Dietary Supplement|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg daily for 8 weeks
76080221|NCT03439098|Dietary Supplement|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg daily for 8 weeks
76080222|NCT03439098|Dietary Supplement|Placebo|Placebo daily for 8 weeks
75639600|NCT03311451|Device|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
75639601|NCT00811720|Drug|Placebo|as-needed use, tablets, orally, 6 months
75639602|NCT00811720|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
75639603|NCT04030156|Procedure|tonsillectomy|Tonsillectomy was performed under general anesthesia using cold dissection method.
75331680|NCT03034499|Procedure|Multi-port sacrocolpopexy|Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
75331681|NCT03557476|Dietary Supplement|Octacosanol|One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
75639604|NCT04202679|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
75924604|NCT02050308|Other|Internet-All Nations Breath of Life (I-ANBL)|"Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~Weekly procedures will follow the same format as for the first session"
75788384|NCT03150862|Drug|TMZ|Administered as specified in the treatment arm
75331682|NCT03557476|Dietary Supplement|Placebo|A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
75331683|NCT05512338|Other|Treatment|ACT-informed interventions combined with standard physiotherapy methods.
75331684|NCT05512338|Other|Active control group|Standard physiotherapy methods.
75639605|NCT04202679|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
75639606|NCT04202679|Drug|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
75639607|NCT04202679|Drug|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
75639608|NCT04202679|Drug|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
75639609|NCT00811642|Drug|Posaconazole|400mg BID oral suspension for 12 weeks
75788385|NCT03150862|Radiation|Radiation|Up to 60 Gy (total) over 6 - 7 weeks
75788386|NCT01318928|Drug|Metronidazol|metronidazol. 400mg x 3 per day for 10 days
75331685|NCT03027011|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
75331686|NCT03027011|Procedure|Control|Control group without remote ischemic preconditioning
75331687|NCT04734496|Other|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
75331688|NCT04353635|Device|dolphin 3d|software
75639610|NCT05756062|Dietary Supplement|Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)|Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
75639611|NCT02609152|Drug|Continuous perfusion of esmolol|In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
75788387|NCT03784352|Device|Virtual Reality|A calming virtual reality game will be played
75788388|NCT03781232|Device|Prototype 0.3|Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
75924605|NCT02050308|Other|Honoring the Gift of Heart Health|"These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities."
76080223|NCT03439020|Procedure|Plastic stent anchoring|Insert an additional plastic stent to anchor the fully covered self expandable metal stent.
76080224|NCT03439020|Procedure|FCSEMS|Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
76080225|NCT03432312|Drug|Nicotine lozenge|Nicotine mint lozenge, 4 mg
76080226|NCT03432312|Drug|Nicotine lozenge|NiQuitin mint lozenge, 4 mg
76080227|NCT03438942|Dietary Supplement|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
75331689|NCT03403504|Drug|Oxycodone Tamper Resistant|Orally administered Oxycodone Tamper Resistant 10mg
75331690|NCT03403504|Drug|OXYCONTIN®|Orally administered OXYCONTIN® Tablet 10 mg
75331691|NCT04598802|Device|covered stent|atherosclerotic aorto-iliac aneurysm
75470723|NCT04438668|Device|Centaflow and Standard Care|The intervention is screening methods
75788389|NCT01309178|Drug|Amitriptyline|2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.
75788390|NCT01309178|Drug|Mannite|Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
75924606|NCT02050308|Drug|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
75924607|NCT02164071|Other|Geriatric Assessment of Health Status Scale administration|Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
75331692|NCT05512728|Device|VR|"The IVR environment was provided by Shinecon VR (Shinecon, china). Shinecon VR features, have a large field of view and high-quality display; with aspheric lens , lens diameter 40MM, view angle 108 , sharpness 99%, visibility 100%, color .38MM and pupillary distance adjustment 65 MM.~The shinecon VR setup was powered by a HUAWEI Y7 prime phone running the freely available IVR software.~Shinecon VR provides videos for nature, forest, wind, desert and animals. That included noise-cancelling headphones playing background sound from the IVR simulation."
75639612|NCT02609152|Drug|Continuous perfusion of saline|In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
75639613|NCT02733393|Procedure|Sphenopalatine Ganglion (SPG) Block|Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.
75639614|NCT02733393|Drug|lidocaine|
75924608|NCT03345056|Procedure|vitrectomy with planned foveal detachment|23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula
75924609|NCT05502718|Other|Stretching and Strengthening Exercises|The patients in the study group will be given exercise videos. These exercise videos will be selected in accordance with the patient's cervical dystonia type (Torticollis, laterocollis, retrocollis, anterocollis). During the exercises, stretching exercises will be applied to the muscle groups that cause dystonia, and isometric strengthening exercises will be applied to the contralateral muscle groups. Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week. Patients will be asked to mark after each exercise on the exercise chart prepared to determine continuity and compliance with exercise. Patients will be called and followed up on a weekly basis with the exercise chart given to the patients and by telephone.
75639615|NCT02733315|Behavioral|Diabetes Conversation Map Program|"The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants."
75639616|NCT02728011|Other|Scientific Brain Training (SBT)|Cognitive training
75639617|NCT02728011|Other|Tetris|
75331693|NCT05512728|Drug|Midazolam|• (titration of 0.05 mg/kg per dose) according to Modified Wilson sedation scale Score to achieve grade 1 (Oriented, eyes may be closed but can respond to 'Can you tell me your name?' 'Can you tell me where you are right now?'
75470724|NCT04438668|Diagnostic Test|Standard Care|The intervention is screening methods
75639618|NCT02728167|Device|Pre-coagulation of the liver parenchyma with HIFU|6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
75639619|NCT00809926|Drug|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
75639620|NCT00809926|Drug|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
75639621|NCT05344131|Other|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Biopsychosocial approach
75639622|NCT02728245|Drug|Dienogest|Dienogest 2mg po qd
75639623|NCT02728245|Drug|Placebo drug|Placebo 1 table po qd
75639624|NCT02728245|Procedure|Surgery|conservative surgery without intent to oophorectomy
75788391|NCT05382260|Other|Listening to music|After 5 minutes baseline, participants would listen to three kinds of music with 3 minutes washout and another 5 minutes baseline in the end, while EEG would record their cortical activity. And the order of the three kinds of music is random.
75798716|NCT05598892|Device|Training with Robotic Hand Exoskeleton|The intervention consists in Robotic Hand training sessions. Each subject received 16 sessions lasting 60 minutes each and a frequency of 2 sessions per week. The sessions will be applied by an Ocupational Therapist with experience in Robotic training. Robhand exoskeleton (ITAP, Valladolid, Spain) is an exoskeleton-type electromechanical device, which is attached to the patient's hand and provides assistance for performing different types of finger movement rehabilitation therapies. The exoskeleton is composed of five independent subassemblies that are placed on a platform which is located on the back of the hand, with the exception of the thumb subassembly that is mounted on a separated module connected to the hand support platform through a linkage device.
76080228|NCT03438942|Dietary Supplement|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
76080229|NCT03438864|Device|Electrotherapy, interferential current|Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
76080230|NCT03438864|Other|Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
76080231|NCT03432234|Other|Biomarkers|This is an observational study, there is no intervention
75639625|NCT02732925|Device|Arm 2 Balloon Kyphoplasty|"Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~Bisphosphonates~Pain relief~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy"
75788392|NCT05346068|Device|OPN™ NCB Super High Pressure PCI Balloon|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
75470725|NCT04435795|Drug|Normal Saline intranasal and placebo inhaler|Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
75788393|NCT05346068|Device|Shockwave™ C2 IVL Catheter|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
75788394|NCT03780998|Drug|Life7|Life7 will used on the perianal skin with finger tips
75331694|NCT03609658|Behavioral|Nurse Navigator Pathway|In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.
75331695|NCT03609658|Behavioral|Usual Care|In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
75788395|NCT01343992|Behavioral|Bed rest|Patients will rest in bed ten minutes after the embryo transfer.
75788396|NCT01343992|Behavioral|No bedrest|Patients will not rest in bed after the embryo transfer.
75924610|NCT05502718|Other|Breathing and Rhythmic Coordination Exercises|The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.
75924611|NCT02164149|Other|Patients with primary colon cancer|CT scan two days after surgery
75924612|NCT04790916|Drug|RO7049665|RO7049665, subcutaneous injection, Q2W.
75924613|NCT04790916|Other|Placebo|RO7049665-matching placebo, subcutaneous injection, Q2W.
75331696|NCT02565810|Drug|Adalimumab PFS and Pen|
75924614|NCT02516852|Other|Egg production|Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
76080232|NCT03432156|Biological|Autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro.
75331697|NCT00940901|Drug|sildenafil|sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
75331698|NCT00940901|Other|placebo|placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)
75331699|NCT05512650|Device|Virtual Reality Meditation|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
75470726|NCT04435795|Drug|Ciclesonide|Ciclesonide 600mcg BID inhaled with aero chamber
75639626|NCT02732925|Procedure|Conservative Management|"Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~Concomitant treatment with bisphosphonates~Pain relief as required~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy"
75639627|NCT02732769|Device|GammaKnifePerfexion®|neurosurgery
75639628|NCT02732769|Device|GammaKnifeIcon®|neurosurgery
75639629|NCT02732769|Device|Efficast®|Thermoformed mask
75639630|NCT02732769|Device|MRI|
76080233|NCT04451070|Other|Clinic First curriculum|"The Clinic First model was designed by the Association of Family Medicine Residency Directors (AFMRD) in collaboration with the University of California San Francisco's (UCSF) Center for Excellence in Primary Care. The components of the Clinic First model are summarized in the Association of American Medical Colleges' (AAMC) publication titled High-Functioning Primary Care Residency Clinics: Building Blocks for Providing Excellent Care and Training. Using the principles of Clinic First, the authors of this study drafted a Family Medicine residency curriculum to be implemented at David Grant Medical Center at the beginning of the 2020-2021 academic year."
76080234|NCT04450680|Other|Beta-lactam Therapeutic Drug Monitoring|Monitoring serum beta-lactam levels to individualise beta-lactam doses and ensure therapeutic target attainment
75639631|NCT02690415|Procedure|Antibiotics Given|Patients who's treating physician prescribed antibiotics
75639632|NCT02690415|Procedure|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
75639633|NCT02727855|Biological|Shanchol|Oral Cholera Vaccine
75639634|NCT05753722|Biological|PRTH-101|PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody
75924615|NCT05510830|Procedure|diagnostic cervical conization|For the patients who met the inclusion criteria, the gynecologists perform cervical conization and pathological examinations. Then the patients will be followed-up for at least two years with the tests of cervical TCT & HPV, and colposcopy if necessary. The data will be analyzed and see if the patients with high risk factors benefit from the surgery or not.
75924616|NCT02516618|Drug|Fasinumab|
75924617|NCT02516618|Drug|Placebo|
75639635|NCT05753722|Biological|Pembrolizumab|PRTH-101 in combination with Pembrolizumab
75788397|NCT05330702|Device|Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft No Intervention: No Soft Tissue Augmentation|Fibro-gide is the VCMX
75788398|NCT05330702|Procedure|Tuberosity Connective Tissue Graft (CTG)|CTG will be taken from the patient's own mouth
75924618|NCT05507554|Drug|Opioid|"Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
75924619|NCT05507554|Drug|Non-Opioid Analgesic|"Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later."
75924620|NCT05507554|Drug|Non-Opioid|"Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Diclofenac Sodium 50 mg) will be given to the patients on discharge. For Pain control oral Diclofenac Sodium 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
75924621|NCT02512328|Device|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
75924622|NCT05502640|Other|Education model|Chicken legs will be used for each student in the study. Intermittent and continuous suture techniques will be studied on the incision made on the chicken leg.
75331700|NCT05512650|Device|Non-VR Meditation|Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
75639636|NCT02732613|Device|Laryngeal Mask Airway|If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.
75639637|NCT04736992|Other|No intervention involved|No intervention involved
75639638|NCT02727621|Drug|Dexmedetomidine|Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
75639639|NCT02727621|Drug|propofol|Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
75639640|NCT02608606|Drug|Tacrolimus|compared oral administration versus sublingual administration of tacrolimus.
75639641|NCT02732535|Procedure|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
75639642|NCT02727465|Other|Meningitis cases|None - blood draw only
75639643|NCT05755828|Biological|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was > 2*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
75639644|NCT02727543|Other|Medisafe|"Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements"
75639645|NCT02608918|Drug|BMS-955176|
75639646|NCT02732223|Dietary Supplement|Functional treatment|Omega 3 fatty acids, plant sterols and polyphenols
75788399|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational innovator formulation
75788400|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation a
75788401|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation b
75788402|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation c
75788403|NCT01319162|Other|Weight reduction regimen|The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
75924623|NCT05502640|Other|Routine Education model|In the study, 15 cm x 20 cm sponge will be used for each student. Intermittent and continuous suture techniques will be practiced on the sponge.
75924624|NCT02516384|Biological|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (>18 year old) patients with active ulcerative colitis (UC).
76080235|NCT03438786|Procedure|Trans-inguinal Pre-peritoneal Hernioplasty|"patients were catheterised pre-operatively, to prevent any injury to the bladder and aid in preperitoneal dissection. The catheter was removed after 48 hours post-operatively.~Incision of TIPP is same as that of Lichtenstein technique . After dissection of the sac, the transversalis is fascia is incised to enter the preperitoneal space. The preperitoneal space is developed by dissection with index finger. The space extends from rectus muscle medially, arcuate line cranially, a little beyond the anterior superior iliac spine over the psoas muscle laterally and the lilipubic tract caudally. A 15 cm x 15 cm polypropylene mesh, cut into dimension 15 cm x 12 cm, the inferior medial angle of the mesh is trimmed in a semicircular fashion to prevent trauma to the bladder neck. The mesh is placed in the preperitoneal space and anchored to the Cooper's ligament with a single 2-0 interrupted prolene suture"
75331701|NCT04353713|Dietary Supplement|40% Dextrose Gel|Prophylactic administration of 40% dextrose gel via buccal mucosa to prevent newborn hypoglycemia
75639647|NCT02732223|Dietary Supplement|Control treatment|placebo supplements
75331702|NCT04353713|Dietary Supplement|2% carboxymethylcellulose gel|placebo
75639648|NCT02727309|Drug|Apatinib|Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
75639649|NCT02732379|Procedure|Lavender Aromatherapy|the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
75788404|NCT01317082|Device|Acupressure|P 6 Pressure Point
75788405|NCT01317238|Drug|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
75924625|NCT04110366|Biological|Live attenuated influenza vaccine|Vaccination with live attenuated influenza vaccine (LAIV)
75924626|NCT04110366|Other|Vehicle control|Vehicle control nasal challenge
75924627|NCT05507320|Behavioral|Mechanisms of action perception and execution|Study the mechanisms of action perception and execution
75924628|NCT02512016|Other|Study Procedures|"Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)~Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.~Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.~Measures of strength and body habitus:~8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index~1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod~Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings."
75924629|NCT00995202|Procedure|Standard Monitoring CEA|No specific follow-up of CEA
75924630|NCT00995202|Procedure|Intensive Monitoring CEA|CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
75639650|NCT02732379|Procedure|Rose Aromatherapy|the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
75639651|NCT02732379|Procedure|Ginger Aromatherapy|the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
75639652|NCT02732379|Procedure|Placebo Aromatherapy|the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
75639653|NCT05755750|Drug|Genipin|Intratendinous genipin injection
75639654|NCT02732067|Other|anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital
75639655|NCT05093062|Other|Tian Jiu Therapy|
75788406|NCT01319474|Other|Whole-leg compression ultrasound|Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
75788407|NCT01344148|Drug|INH RIF Rifb PZA EMB AZT 3TC D4T EFV|The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
75788408|NCT03784196|Other|Conservative rehabilitation|WAD participants underwent 2-weeks rehabilitation.
75788409|NCT01335178|Behavioral|Intervention|The intervention consisted of the following elements: (a) Three motivational interviews, scheduled for baseline, one month, and three months; (b) Feedback on air quality in the home (PM2.5 was measured using a Sidepak and/or a Dylos monitoring device, and air nicotine was measured using passive air nicotine dosimeters); (c) Feedback on child's exposure via hair nicotine; (d) a website designed especially for the project [parents.org.il];and (e) various self-help materials, including a booklet, a magnet about TSE, and air fresheners.
75788410|NCT04942964|Drug|Bocidelpar|Oral
75788411|NCT04231942|Device|Graduated Compression Stocking: continuous using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
75331703|NCT03611062|Behavioral|VR Executive Functions Training|"The Windows 10-based VICT program invites children to rescue an animated character named Lubdub from a castle. The program consists of three challenging and child-friendly tasks that correspond to the three core EFs."
75331704|NCT03611062|Behavioral|VR Placebo Game|In this game, children in the control group will use the VR hand controller to cast different types of spells (bees, bouncy balls, sparkler spells) to objects in the virtual world. Objects in the VR world will all react differently to a spell being cast so as to provide children a relaxing and EF-free gaming experience.
75331705|NCT05507502|Biological|Influenza vaccination administration|There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.
76080236|NCT03438786|Procedure|Lichtnestein's hernioplasty|incision 1 cm above and parallel to inguinal ligament,Opening subcutaneous fat ,Opening Scarpa fascia to external oblique aponeurosis ,visualization of external ring and lower border of the inguinal ligament,Opening deep fascia of the thigh,checking for a femoral hernia ,Division of external oblique aponeurosis from external ring laterally for 5 cm, safeguarding ilioinguinal nerve ,Mobilization of superior and inferior flaps of external oblique aponeurosis exposing underlying structures ,Mobilization of spermatic cord along with the cremaster, including (ilioinguinal ,genitofemoral) nerves, and spermatic vessels; all of these structures may be encircled in a tape ,Opening of the coverings of spermatic cord, identification and isolation of the hernia sac ,Inversion, division, resection, or ligation of the sac ,Placement and fixation of mesh to edges of the defect or weakness in the posterior wall of inguinal canal creating artificial internal ring,Closure
76080237|NCT03438708|Drug|Axitinib Oral Tablet [Inlyta]|Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
76080238|NCT00632463|Biological|RI-001|Dose 1
76080239|NCT00632463|Biological|RI-001|Dose 2
76080240|NCT00632463|Biological|RI-001|Placebo
76080241|NCT03435276|Drug|AZD9977|Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
76080242|NCT03435276|Other|Placebo|Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
76080243|NCT01923597|Drug|Green tea extract|200mg/capsule Administered orally 4 capsules per day For 3 months
75331706|NCT02981771|Behavioral|Balance activity program|Participants will take part in a biweekly, 12 week physical activity program that will include balance and coordination exercises
75331707|NCT02981771|Behavioral|Strength activity program|Participants will take part in a biweekly, 12 week physical activity program that will include traditional strength exercises
75788412|NCT04231942|Device|Graduated Compression Stocking: intermittent using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
75331708|NCT05512572|Device|IPL|intense pulsed light
75924631|NCT00995202|Procedure|Standard Monitoring Imagery|Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years
75924632|NCT00995202|Procedure|Intensive Monitoring Imagery|Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
75331709|NCT05512572|Procedure|Conservative treatment or excision with curettage|conservative treatment or excision with curettage but without IPL-MGX treatment as a control
75331710|NCT03034655|Device|CDP|Vestibular rehabilitation using CDP
75788413|NCT01561118|Other|Bicycle-Ergometer Training|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis."
75924633|NCT02516462|Device|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
75924634|NCT02516462|Drug|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
75924635|NCT02516072|Other|RIPC|IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
75788414|NCT01335256|Drug|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
75798717|NCT01287390|Procedure|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
75331711|NCT03034655|Device|Mobile posturography|Vestibular rehabilitation using mobile posturography
75331712|NCT03034655|Other|10 sessions|Vestibular rehabilitation, ten sessions
75331713|NCT03034655|Other|5 sessions|Vestibular rehabilitation, five sessions
75331714|NCT03560128|Device|Endocuff Vision device|Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.
75924636|NCT04650204|Drug|Anticonvulsant Agent|Given ASD
75331715|NCT03560128|Device|AmplifEYE device|Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
75331716|NCT02981927|Other|Physical inactivity|
75331717|NCT05512104|Procedure|bone marrow aspirate and biopsy|fiow cytometry of bone marrow aspirate
75331718|NCT05107739|Biological|Drug Product De-TIL-0255|Autologous tumor-infiltrating lymphocytes
75331719|NCT03614416|Device|EOXY device|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
75924637|NCT04650204|Drug|Perampanel|Given PO
75331720|NCT03614416|Device|Gold standard oximeter|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
75924638|NCT04650204|Other|Quality-of-Life Assessment|Ancillary studies
75924639|NCT04650204|Other|Questionnaire Administration|Ancillary studies
76080244|NCT03435198|Diagnostic Test|Collect exhaled breath during low and normal blood sugar|Collect exhaled breath during low and normal blood sugar to determine if there are any differences between the two in people with type 1 diabetes.
76080245|NCT00632229|Drug|Paliperidone|Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
76080246|NCT00632229|Drug|Placebo|Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
76080247|NCT03435120|Other|No intervention|No intervention
76080248|NCT01923675|Other|Spectacles with red-blocking tint|Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
76080249|NCT01923675|Other|Spectacles with holographic diffuser and color neutral tint|Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
75470727|NCT04435795|Drug|Ciclesonide nasal|intranasal ciclesonide 200 mcg DIE
75788415|NCT03784274|Behavioral|Stakeholder analysis|"• INCLUSION CRITERIA FOR NET MAPPING ACTIVITIES: Those respondents who are directly involved or knowledgeable about pneumonia related policy environment in the country/province.~Respondents who consent to participate in the study.~Respondents belonging to Sindh, Punjab, Baluchistan, KPK and Islamabad.~EXCLUSION CRITERIA:~• Respondents belonging to Gilgit-Baltistan (GB), Azad Jammu and Kashmir (AJK) and Federally Administered Tribal Area (FATA). Reasons of their exclusion are newly developed governance system (GB), separate governance (AJK) and security threat (FATA)."
75924640|NCT04501250|Drug|Rinsulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
75331721|NCT03614416|Procedure|SaO2 sampling|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
75331722|NCT05507268|Other|no intervention|no intervention
75924641|NCT04501250|Drug|Humulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
76080250|NCT01923675|Other|Spectacles with holographic diffuser and red-blocking tint|Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
76080251|NCT01923675|Other|Spectacles with color neutral tint|Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
76080252|NCT03434964|Diagnostic Test|the intraoperative effectiveness of the AIFIB software in real time in the detection of atrial fibrillation drivers during an ablation procedure.|Real-time validation by an expert operator of the correct detection of atrial fibrillation driver
76080253|NCT03431922|Device|endovascular denervation|multi-electrode catheter-based endovascular denervation
76080254|NCT01923753|Device|Aerosure at 15 Hz|Active Aerosure HFAO device operating at lower frequency
76080255|NCT01923753|Device|Aerosure at 25 Hz|Active Aerosure HFAO device operating at higher frequency
75331723|NCT02981693|Procedure|Root canal sealer|Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
75331724|NCT03026465|Device|Polymer-free stent|PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
75331725|NCT03026465|Device|Biodegradable-polymer stent|PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
75331726|NCT03564886|Drug|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
75639656|NCT02609932|Drug|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
75639657|NCT02727231|Device|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
75639658|NCT02727231|Device|CSII with CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
75639659|NCT02726919|Drug|Clobazam|Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
75639660|NCT02727153|Other|"Ultra E.R.A.S."|
75639661|NCT02727153|Other|Classic E.R.A.S.|
75639662|NCT05753566|Drug|Rezvilutamide|Specifications of 80 mg; orally, once a day
75639663|NCT05753566|Drug|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
75639664|NCT05753566|Radiation|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,~50.4 grays to the pelvis if needed)
75924642|NCT02761629|Drug|Peg-Interferon Alpha-2A|Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
75924643|NCT02761629|Drug|Ribavirin|Ribavirin will be administered as either 1000 milligrams (mg) (2*200 mg tablets in morning and 3*200 mg tablets in evening) for participants weighing less than (<) 75 kilograms (kg) or as 1200 mg (3*200 mg tablets in morning and 3*200 mg tablets in evening) for participants weighing greater than or equal to (>/=) 75 kg.
75924644|NCT03345992|Drug|Clarithromycin|Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
75924645|NCT03345992|Drug|Water for injection|Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days
76080256|NCT01923753|Device|Sham Aerosure|Deactivated but identical Aerosure HFAO device
76080257|NCT00631137|Drug|testosterone gel applied to skin|Application of testosterone gel
76080258|NCT00631137|Dietary Supplement|whey powder protein|
76080259|NCT03428880|Drug|Morphine|spinal morphine is done before cesarean section
76080260|NCT03428880|Drug|Quadratus lumborum block|a US Block QLB is done after surgery
76080261|NCT01923831|Drug|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
75788416|NCT01335334|Drug|bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole|Pylera capsule contains bismuth subcitrate potassium, 140 mg (q.i.d.), metronidazole, 125mg (q.i.d.), tetracycline hydrochloride, 125mg (q.i.d.). Generic omeprazole (20mg, b.i.d) tablets
75639665|NCT02726841|Procedure|Open thoracoabdominal aortic repair + abdominal stenting|Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
75788417|NCT01071629|Other|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
75788418|NCT01071629|Other|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
75788419|NCT01335412|Biological|Japanese Encephalitis Virus vaccine, inactivated, adsorbed|2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
75639666|NCT02726841|Procedure|Classic thoracoabdominal aortic repair|Thoracoabdominal aortic dissection (TAAD) repair
75924646|NCT03488940|Device|24-hours group|"Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
76080262|NCT01923831|Drug|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
75331727|NCT03564886|Drug|Normal saline|Lactate Ringer's (LR, 273mOsm/L)
75331728|NCT05086133|Device|transcranial magnetic stimulation|transcranial magnetic stimulation with continuous theta burst pattern, 90% RMT, 50Hz within train and 5Hz train for 200 train and 40 second in total.
75639667|NCT05753488|Diagnostic Test|graft function|renal transplantation
75331729|NCT05086133|Device|sham stimulation|TMS coil vertical to the brain surface, with same protocol as cTBS
75331730|NCT05512026|Device|Feasibility Assessment|To validate the performance of the Poseidon System™ for fluid management during water-aided endoscopic procedures in the colon.
75331731|NCT03034109|Device|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
75331732|NCT03565666|Device|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
75331733|NCT03565666|Drug|iLet Bionic Pancreas insulin-only configuration with Fiasp|iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
75639668|NCT05187741|Device|mobile health (mHealth)|"A message will be sent on Monday and Friday at 9:00 am for 3 months, the first day they will receive a message focused on adherence and the second day a message focused on motivation. Subsequently, a message will be sent on Mondays for 3 more months.~Reminders for appointments with your treating physician will be sent during the entire intervention period (6 months)."
75639669|NCT02721615|Procedure|Insertion of intra spinal sub dural pressure monitor|
75639670|NCT02721615|Procedure|Insertion of sub dural microdialysis probe|
75639671|NCT03060213|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
75639672|NCT02726529|Behavioral|Brighter Bites|
75788420|NCT03776084|Device|Continuous Positive Airway Pressure|CPAP indication
75788421|NCT01072487|Procedure|Capnography|Monitoring of the capnography curve for early detection of apnea
75788422|NCT01344304|Drug|Aprepitant / Fosaprepitant|"Aprepitant:~125 mg PO on day 1 80 mg PO on days 2 to 3~Fosaprepitant:~150 mg IV on day 1"
75788423|NCT01309334|Procedure|PET scan|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
75788424|NCT01309334|Procedure|MRI|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
75788425|NCT02532101|Dietary Supplement|Oil Palm Phenolics|Palm fruit derived phenolics compound
75788426|NCT01072565|Other|SMBG to guide clinical decisions|The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
75788427|NCT01072565|Other|SMBG and CGM|The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
75788428|NCT03776006|Procedure|Transperineal Laser Ablation|Transperineal Laser Ablation of the Prostate
75331734|NCT03565666|Other|Usual care|Usual care
75331735|NCT03034343|Behavioral|Mindfulness|
75331736|NCT05502822|Device|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
75331737|NCT05502822|Device|sham high definition transcranial alternating current stimulation|. In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention.
75639673|NCT02726529|Behavioral|CATCH|The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
75639674|NCT02721303|Dietary Supplement|3-day diet Run-in|Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.
75639675|NCT02721303|Procedure|fMRI|After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
75788429|NCT03775616|Other|Educational Intervention|Receive financial navigation program intervention
75924647|NCT03488940|Device|16-hours group|"Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
76080263|NCT01923909|Drug|Intra-articular platelet-rich plasma|Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
76080264|NCT01923909|Drug|Intra-articular corticosteroid injections|Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
76080265|NCT03434886|Other|CFView|Registry patient portal
76080266|NCT03434886|Other|CF educational videos|CF educational videos
76080267|NCT03434808|Other|Whole Blood Donation|Study subjects will provide 250ml whole blood donation for the manufacture and banking of iPS cells.
76080268|NCT03428724|Drug|Standard Preparation|standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
75788430|NCT03775616|Other|Questionnaire Administration|Ancillary studies
75788431|NCT03775616|Other|Quality-of-Life Assessment|Ancillary studies
75924648|NCT03488940|Device|intermittent group|"Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
76080269|NCT03428724|Drug|Individualized Preparation|individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age>65, neurologic comorbidities)
76080270|NCT04450602|Dietary Supplement|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
76080271|NCT04450602|Other|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
75331738|NCT05502744|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis due to the advantages of small wounds, less use of abdominal drains , less need for antibiotics and analgesics and less postoperative hospital stay time.Laparoscopic cholecystectomy in acute cholecystitis may be performed as soon as begging of the symptoms called emergency or urgent and maybe scheduled in advance after controlling acute attack after 6-8weeks called elective.
75331739|NCT03026153|Behavioral|Control Group Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
75331740|NCT03026153|Behavioral|Intervention Group Oral Survey 2|Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
75639676|NCT02721303|Procedure|Intravenous catheter placed for blood draws|On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
75639677|NCT02721225|Dietary Supplement|Fructooligosaccharide|"A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
75639678|NCT02721225|Dietary Supplement|Pocari-Sweat|Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
75788432|NCT01320020|Drug|catumaxomab|Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
75788433|NCT00260429|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
75788434|NCT01313468|Behavioral|1 x 4 minute interval|1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
76080272|NCT04450602|Other|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
76080273|NCT04450602|Other|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
75788435|NCT01313468|Behavioral|4 x 4 minutes Intervals|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
75788436|NCT01313468|Behavioral|Moderate continuous Training|47 minutes of Moderate continuous Training
75924649|NCT02511860|Dietary Supplement|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
75924650|NCT02511860|Dietary Supplement|Placebo|Methylcellulose (inert) tablet taken as placebo
75924651|NCT02162121|Procedure|Continuous lumbar plexus: stimulating catheter|"Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia."
75924652|NCT02162121|Procedure|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
75924653|NCT02162121|Procedure|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
76080274|NCT04450602|Dietary Supplement|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
75924654|NCT02162121|Procedure|Intravenous analgesia|Ketorolac 30mg 3 times a day
75924655|NCT02162121|Procedure|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS>4
75924656|NCT02162121|Drug|Mepivacaine 1%|
75924657|NCT02162121|Drug|Levobupivacaine 0,5%|
75924658|NCT02162121|Drug|Ropivacaine 0,2%|
75924659|NCT02162121|Drug|Ketorolac 30mg|
75924660|NCT02162121|Drug|Buprenorphine 0,2mg|
75924661|NCT02162121|Device|Stimulong, Pajunk, Germany.|
75331741|NCT05502666|Behavioral|¡Salud! Por la Vida|Lay health worker (LHW) delivered educational intervention for colorectal cancer screening (CRCS). The intervention consisted in having the participant complete a tailored interactive multimedia intervention (TIMI). TIMI consisted of a series of educational videos that addressed common barriers to colorectal cancer screening as well as provided information about colorectal cancer (CRC) and CRCS tests. Participants were able to tailor the TIMI for sex (male/female) and CRC family history. After TIMI completion, the LHW provided participant with a copy of the SPLV newsletter and printed infographics on CRC, CRCS, and an action plan tailored by type of CRCS (FOBT/FIT or colonoscopy). The Intervention Group subject participation took approx. up to 2 hours and Control Group up to 1 hour (half hour for each: baseline and follow-up interview). Follow-up data was collected 6 months post education session (intervention group) or post-baseline survey (control group).
75924662|NCT02162121|Procedure|Continuous lumbar plexus: non-stimulating catheter|
75924663|NCT02511938|Other|Menu Only|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants.
75924664|NCT02511938|Other|Menu Plus intervention|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants. In addition, project will provide promotional materials and brief restaurant staff trainings to promote the new menu.
75924665|NCT02164227|Other|Respiratory pattern|
75924666|NCT02511548|Other|Financial incentive|Financial incentive will be proposed to participant of the intervention arm
75924667|NCT02164305|Other|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
75924668|NCT02164305|Other|Neuromuscular group|Closed-chain exercise for shoulder muscles
75924669|NCT02164305|Other|Control|No exercise training
75924670|NCT03345758|Other|outcome|telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
75331742|NCT03620890|Drug|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
75788437|NCT00379288|Drug|mometasone furoate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
75924671|NCT03730467|Behavioral|Phone call to the patient|Phone call to the patient
75788438|NCT00379288|Drug|mometasone furoate combination MDI 400/10 mcg BID|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
75788439|NCT00379288|Drug|Fluticasone/Salmeterol 250/50 mcg BID|F/SC 250/50 twice daily for 1 year
75924672|NCT02507492|Drug|RM-493|
75788440|NCT00379288|Drug|Fluticasone/Salmeterol 500/50 mcg BID|F/SC 500/50 twice daily for 1 year
75331743|NCT03620890|Drug|Detemir insulin|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
75788441|NCT03784040|Drug|OTSGC-A24|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
75788442|NCT03784040|Drug|Nivolumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
75788443|NCT03784040|Drug|Ipilimumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
75788444|NCT00243503|Drug|SU011248/Trastuzumab|SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
75788445|NCT03780686|Drug|Norepinephrine, dopamine|drugs to decrease bleeding
75788446|NCT04725136|Biological|FURESTEM-AD inj|Repeated administration group: 3 times high or low dose at 4 week intervals. Single administration group: 1 time high or low dose, 2 times placebo injection at 4 week intervals Placebo: 3 times placebo injection at 4 week intervals.
75924673|NCT02162199|Drug|Debio 1450|Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
75924674|NCT02162199|Drug|Placebo|Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
75924675|NCT02507414|Other|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
75924676|NCT02507414|Other|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
75331744|NCT05507112|Drug|PD-1 inhibitor|Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy
75331745|NCT05507112|Drug|Capecitabine|Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.
75331746|NCT05507112|Radiation|Long-course radiation therapy|45-50 Gy/day, 5 days a week for a total of 5 weeks.
75331747|NCT03024983|Other|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
75788447|NCT03780764|Other|"A Pre-adjusted edgewise brackets: 3M Gemini Unitek, 0.022 Roth prescription brackets"|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and tied with elastomers (figure of 8)."
75331748|NCT03024983|Other|Semolina soup|Semolina soup (322 g) eaten with 500 mL of water
75924677|NCT02507414|Other|Head down tilt|"At three different time points the participants will be head down tilted in 20 degrees.~End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)"
75924678|NCT03540693|Procedure|RYGB|RYGB-weight loss surgery
75924679|NCT03540693|Procedure|SG|SG- weight loss surgery
75331749|NCT03024983|Other|Bread|Bread (122 g) eaten with 500 mL of water
75331750|NCT03024983|Other|Penne (fresh)|Cooked penne (132 g) eaten with 500 mL of water
75331751|NCT03024983|Other|Penne (dry)|Cooked penne (142 g) eaten with 500 mL of water
75331752|NCT03024983|Other|Spaghetti (dry)|Cooked spaghetti (142 g) eaten with 500 mL of water
75639679|NCT02726607|Behavioral|HIV Infant Tracking System (HITSystem) 2.0|The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
75639680|NCT02726607|Behavioral|Standard of PMTCT care|Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
75639681|NCT02726685|Other|respiratory training.|breathing exercise.
75924680|NCT03540693|Procedure|LAGB|LAGB- weight loss surgery
75331753|NCT03569020|Other|Subsidy for food purchases and dietitian education|$105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
75331754|NCT03833609|Behavioral|Online yoga training (Group A)|The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
75924681|NCT02511470|Other|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
75331755|NCT03833609|Behavioral|Online aerobic dance training (Group B)|The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
75331756|NCT05502510|Behavioral|MyHealthyPregnancy|MyHealthyPregnancy is a mobile application prescribed to expectant mothers in conjunction with normal prenatal care. The application uses behavioral decision science principles to identify risks of preterm birth and alert the mother and care team of these risks.
75924682|NCT02511470|Other|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
75924683|NCT02760927|Device|Endotracheal Tube Fastener|The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
75924684|NCT04500782|Other|Observation at home.|An appointment will be made at home, first one of the parents will be interviewed using the 'Social Functioning' subdomain of the PEDI-NL (Ostensjo, Bjorbaekmo, Brogren Carlberg, & Vollestad, 2006) to determine the validity of the CFCS-NL and the VSS NL . This section contains some aspects that question the communication skills. The PEDI-NL was chosen as there is no gold standard to investigate functional communication in people with CP. Most standardized test and observational instruments only investigate language comprehension and / or language production and are furthermore developed for normally developing children. On the other hand, a video recording will be made in which the child interacts with a relative and an unknown person (the researcher) so that the CFCS-NL and VSS-score can be determined by the student and the speech therapists of the CP reference center.
75924685|NCT02511704|Drug|Nicotine|Multiple dose nicotine
76080275|NCT04450602|Other|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
75331757|NCT00952133|Drug|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
75331758|NCT00952133|Drug|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
75639682|NCT02726685|Other|sham training.|range of motion (ROM) exercise, stretching exercise or positioning exercise.
75639683|NCT00590824|Drug|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
75639684|NCT00590824|Drug|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
75639685|NCT02841969|Other|Electrolysed water|Irrigation of wound using electrolysed water
75639686|NCT02841969|Other|Prontosan|Irrigation of wound using Prontosan
75639687|NCT02720913|Device|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
75788448|NCT03780764|Other|"Self- ligating brackets: Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets"|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and held in place by bracket's gate in the self-ligating brackets side."
75788449|NCT00338260|Drug|MK0954, /Duration of Treatment : 5 Years|
75639688|NCT02720913|Procedure|Standard Suture Tying|Standard Suture Tying
75639689|NCT05753410|Behavioral|Mindful Courage|Self-guided online intervention
75788450|NCT00338260|Drug|Comparator : atenolol /Duration of Treatment : 5 Years|
75788451|NCT01561196|Procedure|arterial catheterisation|arterial catheterisation in Arterial Radialis
75788452|NCT03775772|Procedure|Oral Health|"test group will receive an dental hygiene program for one year~control group will remain with dental hygiene regime like done before study participation (maximum of two dental hygiene Treatments per year)"
75788453|NCT03775772|Procedure|Bite Force|"test group will receive physiotherapy with the aim of increasing muscle strength in chewing muscles for 3 months~control group will remain without such training"
75924686|NCT02511704|Drug|Nicotine|Multiple dose nicotine
75924687|NCT02164461|Biological|ADXS11-001|
75924688|NCT02511392|Procedure|rTMS-1Hz|
75924689|NCT02511392|Procedure|rTMS-10 Hz|
75924690|NCT02511392|Procedure|Sham rTMS|
76080276|NCT04450602|Other|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
76080277|NCT04450602|Other|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
76080278|NCT04892940|Device|Virtual Reality (VR) technique|"The PICO G2 4k helmet from the Chinese manufacturer Pico which is an autonomous virtual reality helmet will be used.~The sessions proposed last 20 minutes with a child pain protocol. The teenager will be able to choose his universe (forest, beach, mountain, aquatic, space), the voice that accompanies him (man, woman, none), the sound environment of music therapy (6 to choose from).~Each patient in the experimental group benefits from a virtual reality program including two daily sessions during their stay in the continuing care unit from the first post-operative day until the third post-operative day. Each session is proposed by a nurse anesthetist from the pain team and trained in the proper use of the equipment.This virtual reality program will be added to the standard analgesic protocol for the experimental group."
75924691|NCT02162277|Device|diagnostic osteoporotic kit ( including 7 genes and 4 life styles)|Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
75924692|NCT04500704|Drug|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
75924693|NCT04500704|Drug|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
75924694|NCT02164617|Other|Wheelchair-bound Senior Elastic Band exercise program (WSEB)|Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
76080279|NCT04892940|Drug|Analgesic protocol|"Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively."
76080280|NCT04885218|Drug|SHR-1209 ;placebo|SHR-1209/placebo high dose
75639690|NCT02726217|Behavioral|CareSmarts Mobile Health Diabetes Program|Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.
76080281|NCT04885218|Drug|SHR-1209 ;placebo|SHR-1209/placebo medium dose
76080282|NCT04885218|Drug|SHR-1209 ;placebo|SHR-1209/placebo low dose
76080283|NCT03305250|Device|Implantable Loop Recorder|An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
75924695|NCT02507180|Other|LEFt clinical decision rule|"The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: > 1 point"
75924696|NCT02166567|Procedure|Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS|
75639691|NCT02726217|Behavioral|Standard of Care Reminders and Self Assessments|
75639692|NCT02720991|Drug|Mifepristone|200 mg of oral mifepristone
75639693|NCT02720991|Drug|Sublingual misoprostol|400 ug of misoprostol sublingually following mifepristone
75788454|NCT00239837|Behavioral|Middle School Success Intervention (MSS)|This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
75788455|NCT03775928|Drug|Apatinib|apatinib 425mg qd po
75788456|NCT03775928|Drug|capecitabine|capecitabine 1000mg/m2 bid d1-d14
75788457|NCT03775538|Drug|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
75788458|NCT03775538|Device|Renishaw Drug Delivery System|Stereotactically implanted device
75788459|NCT00259649|Drug|eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
75788460|NCT03884920|Dietary Supplement|Polyherbal formulation|Test candidate will be administered per oral before / with meal in two divided doses
75798718|NCT01287390|Procedure|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
75788461|NCT01320098|Behavioral|Home-Based Parenting Program|"The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.~Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.~Increasing the quality and quantity of positive interactions between you and your child~Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.~Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week."
75639694|NCT04687228|Behavioral|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
75788462|NCT01320098|Behavioral|Clinic-Based Parenting Program|"The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.~The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.~Parents learn techniques and skills to promote positive interactions with their child, including:~Increasing the positive attention you give to your child.~Reducing the inappropriate use of commands, questions and criticisms.~Appropriate use of praise and physical attention (e.g., hugs) as rewards.~Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors."
75639695|NCT04687228|Behavioral|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
75639696|NCT02726373|Other|type of walking|Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
75639697|NCT02720601|Drug|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
75924697|NCT02166567|Procedure|Swim-up|Semen processing will be carried out with the conventional swim-up method.
75788463|NCT01320098|Behavioral|Wait-List Control Group|If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
75788464|NCT01335490|Other|Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel|The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
75798719|NCT01287390|Other|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
75924698|NCT04500314|Device|whole body vibration device|20 patients will receive vibration training on vibration platform (Power Plate International, Irvine, California, USA) at a frequency of 25-30 Hz and amplitude of 3-5mm, plus traditional physical therapy program 3 sessions per week for total period of 8 weeks. The total duration of the WBV training stimulus will 10 min in first week and progress gradually to 25 min in the 8th week with regular increase by 5 minutes after each 2 successive weeks
76080284|NCT03085563|Drug|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
76080285|NCT03085563|Drug|Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
76080286|NCT03431766|Device|placebo gel|On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
75639698|NCT02725983|Behavioral|SPT consultation|
75639699|NCT02725983|Device|SOPROCARE®|
75639700|NCT00590590|Drug|Lidocaine/Diphenhydramine|semi solid, twice weekly, 4 months
75639701|NCT00590590|Drug|lidocaine|semi solid, twice weekly for 4 months
75639702|NCT00590590|Drug|placebo|semi solid, twice weekly for 4 months
75788465|NCT01335568|Procedure|Hepatocyte Matrix Implant|Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
75788466|NCT01315444|Drug|Stop PPI gradually|
75639703|NCT02720367|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
75924699|NCT04500314|Other|routine physical therapy treatment|The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
75639704|NCT02693769|Drug|fluticasone propionate/formoterol fumarate breath actuated inhaler|
75639705|NCT02693769|Drug|Indacaterol maleate / glycopyrronium bromide capsules|
75639706|NCT02726295|Drug|E. coli Nissle 1917(Mutaflor®)|
75331759|NCT05511636|Other|Oxygen therapy|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
75331760|NCT03033953|Dietary Supplement|Native whey|
75331761|NCT03033953|Dietary Supplement|Milk|
75331762|NCT03033953|Other|Strength training|
75331763|NCT05506644|Other|HRV-Biofeedback/Mind-Body Therapy|A 7-week protocol using real-time feedback on heart rate variability
75331764|NCT03033797|Device|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
75788467|NCT01315444|Drug|Stop PPI gradually|
75924700|NCT02166645|Other|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
75924701|NCT02166645|Other|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
75924702|NCT02507258|Device|PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell|PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
75924703|NCT02164773|Drug|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
75331765|NCT03033797|Device|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
75639707|NCT02726295|Drug|Placebo|
75788468|NCT01320176|Biological|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
75788469|NCT01320176|Biological|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
75788470|NCT01335646|Procedure|Lumbar Microdiscectomy|lumbar discectomy within 1 month of randomization
75331766|NCT04293978|Behavioral|CalmPlace|Self-contained VR application allowing the user to build and custom a relaxation session, with options to vary session length (9-20 minutes), music/sound, relaxation exercises, and specific nature environment (three available) including time of day and events (e.g. rain). Delivered using an Oculus Go devices in kiosk-mode.
75331767|NCT03570658|Drug|RO7049389|RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
75331768|NCT03570658|Drug|Placebo|Placebo will be administered orally at a dose and frequency matched to RO7049389.
75788471|NCT01335646|Other|Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories|Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
75788472|NCT01309412|Drug|Siltuximab|5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
75788473|NCT00307060|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks|
75788474|NCT00307060|Drug|losartan / Duration of Treatment: 6 weeks|
75788475|NCT01320254|Drug|Cisplatin, Gemcitabine, Panitumumab|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
75788476|NCT01320254|Drug|Cisplatin, Gemcitabine|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
75788477|NCT00092638|Drug|MK0653, ezetimibe|
75788478|NCT00092638|Drug|Comparator: ezetimibe, placebo|
75788479|NCT01335802|Genetic||Genetic counseling
75331769|NCT00941681|Drug|CK-1827452|50 mg MR CK-1827452 BID for 10 days
75331770|NCT00941681|Drug|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
75331771|NCT00941681|Drug|CK-1827452|100 mg MR CK-1827452 BID for 10 days
75924704|NCT02164773|Drug|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
75924705|NCT03540459|Diagnostic Test|sleep polygraphy|sleep polygraphy (one night) in all included patients
75924706|NCT02507024|Other|Online questionnaire|
75331772|NCT05042375|Drug|camrelizumab + famitinib|Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
75331773|NCT05042375|Drug|pembrolizumab|pembrolizumab 200 mg.
75331774|NCT05042375|Drug|camrelizumab|Camrelizumab for injection, 200 mg.
75639708|NCT04044820|Drug|Standardized Prescription|"Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~0-5 pills for simple surgeries such as a trigger finger release~10 pills for carpal tunnel or Dupuytren's contracture releases~15 pills for a ganglion cyst excision or simple tendon transfer~20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion."
75639709|NCT02725749|Radiation|Laser|Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
75788480|NCT03780218|Other|Respiratory function|Respiratory function test evaluates the participants' pulmonary function and respiratory muscle strength
75788481|NCT01344694|Other|patient with liver fat|30 patient with liver fat
75788482|NCT01344694|Other|pts. with excess of visceral fat|pts. with excess of visceral fat
75788483|NCT01344694|Other|control|30 control subjects
76080287|NCT03431766|Device|0.20% chlorhexidine gel|On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
76080288|NCT04450446|Drug|Low molecular weight heparin|Anticoagulation therapy
75331775|NCT03571672|Drug|DEFINITY|All subjects will receive a single dose of DEFINITY®
75639710|NCT02725749|Other|EXE|"Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
75639711|NCT02725749|Radiation|Laser + EXE|"Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
75331776|NCT05502120|Device|Laryngoscopy with Vie-Scope laryngoscope|Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications
75331777|NCT05502120|Device|Laryngoscopy with Macintosh blade laryngoscope|Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
75331778|NCT04592172|Behavioral|Bedtime Routine Education|The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
75331779|NCT00952211|Device|CPAP|CPAP at therapeutic pressure during nighttime
75331780|NCT00952211|Device|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
75639712|NCT05071924|Behavioral|PLH Teens Original: In-person PLH programme for parents and teens by community-based workers|This in-person intervention is delivered over 14 sessions (10 joint parent and teen sessions and 4 separate parent and teen sessions).
75639713|NCT05071924|Behavioral|PLH Teens Hybrid: Hybrid delivery for parents and teens by facilitators|The hybrid intervention delivered over 12 sessions (8 sessions delivered via WhatsApp groups to parents only and 4 sessions delivered in-person to parents and teens together).
75788484|NCT01344772|Procedure|Internal fixation|Two cannulated screws are placed under x-ray guidance
75788485|NCT01344772|Procedure|Total hip arthroplasty|A total hip arthroplasty is performed through a standard posterior approach
75788486|NCT03783728|Drug|Rifapentine 600 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
75788487|NCT03783728|Drug|Isoniazid 900 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
75788488|NCT03783728|Drug|Pyridoxine 50 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
75788489|NCT03620422|Other|Mannitol|Mannitol-Induced Cough Challenge
76080289|NCT03274752|Drug|Paroxetine|Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.
76080290|NCT03274752|Drug|Placebo oral capsule|Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
75331781|NCT03023189|Drug|Tranexamic acid|"At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA"
75788490|NCT03620422|Drug|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
75788491|NCT03620422|Other|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
75788492|NCT03775226|Device|ChampioNIR® SFA Stent|The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.
75788493|NCT04228354|Drug|Semaglutide|Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks
75788494|NCT03780374|Device|Phonak Audéo L2M with Sound Processing Principle 1|Compensation of a hearing loss with Sound Processing Principle 1.
75788495|NCT03780374|Device|Phonak Audéo L2M with Sound Processing Principle 2|Compensation of a hearing loss with Sound Processing Principle 2.
75470728|NCT04356248|Behavioral|Endurance Training|Treatment in both arms consists of specific endurance exercise modalities (HIIT or ST). Treatments differ in the applied training intensities. Participants in both arms will exercise 3 times per week over a period of 3 weeks on a bicycle ergometer. Exercise sessions will be supervised by a trained physical therapist. Exercise intensity will be heart rate monitored based on the maximum heart rate (HRmax) assessed during the initial cardiopulmonary exercise test. Exercise sessions in both arms will include a warm-up and a cool-down period at low intensity (50% HRmax) for 3 min each.
75470729|NCT04356248|Behavioral|Education|Treatment in both arms consists of specific energy management education interventions (IEME or PMR). Treatments differ in the applied education approaches. Participants in both arms will exercise 2 times per week over a period of 3 weeks.
75470730|NCT04350593|Drug|Dapagliflozin 10 milligram (mg)|Active Comparator: Dapagliflozin 10 mg
75331782|NCT03023189|Drug|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
75470731|NCT04350593|Drug|Placebo|Placebo Comparator
75331783|NCT04590534|Drug|Chromax|Treatment of BPH by Chromax for 3 Months
75331784|NCT04590534|Drug|Sildosin Group|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
75331785|NCT04590534|Other|Placebo Group|patients will receive placebo 3 times daily for 12 weeks
75639714|NCT02720289|Other|Video-based social learning class|Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.
75788496|NCT03780374|Device|Phonak Audéo L2M with Sound Processing Principle 3|Compensation of a hearing loss with Sound Processing Principle 3.
75331786|NCT03033719|Procedure|Laparotomy|Open surgery
75788497|NCT01344928|Behavioral|HIT exercise intervention|
75470732|NCT04342754|Device|Deep Brain Stimulation (DBS)|The device will be ON
75470733|NCT04342754|Device|Sham Stimulation|The device will be OFF
75470734|NCT04320836|Procedure|Cervical epidural steroid injection|Interlaminar cervical epidural steroid injection with steroid and normal saline at C6-7 and C7-T1 (standard of care).
75470735|NCT04302857|Other|routine MRI|MRI with routine DTI sequence
75470736|NCT04298112|Diagnostic Test|PSMA PET/CT|Whole-body PET/CT (contrast enhanced CT or low-dose CT); from vertex to thighs.
75639715|NCT02720289|Other|Traditional didactic class|Child passenger safety lecture by a child passenger safety technician.
75639716|NCT02725827|Other|EmbryoGlue (Vitrolife)|A hyaluronan-enriched embryo transfer medium
75639717|NCT02725827|Other|Control medium|The usual embryo transfer medium used in the study centres.
75639718|NCT05755126|Behavioral|Iatrosedation|Alleviating the anxiety of patients by iatrosedative interview and clinical encounter
75639719|NCT05755126|Behavioral|Musical Therapy|Patients were provided with headphones and a playlist to listen to the music of their choice for 10 minutes
75639720|NCT02720133|Biological|biochemical parameters|"patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison."
75639721|NCT02725437|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection
75639722|NCT02725437|Biological|Placebo|0.5 mL intramuscular injection
75639723|NCT02720055|Other|Psychological workbook|
75788498|NCT01344928|Behavioral|Aerobic exercise intervention|
75788499|NCT03775148|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
75924707|NCT02166723|Device|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
76080291|NCT03256734|Other|Policy intervention|Incentive payment for physicians
76080292|NCT03902418|Drug|emtricitabine/tenofovir|Women recruited at ante-natal clinics, counseled about PrEP, and provided medication and follow up if desired
75639724|NCT02720055|Other|Basic information workbook|Basic rehabilitation information that represents current practice.
76080293|NCT03428568|Other|Herbal Melanin|Herbal melanin extracted from Nigella sativa seeds
75331787|NCT03033719|Procedure|Laparoscopy|Minimally invasive surgery
75331788|NCT03033485|Radiation|18F-P3BZA|18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
75331789|NCT03033641|Device|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
75470737|NCT04298112|Diagnostic Test|PSMA PET/MR|Pelvic PET/MR in addition to targeted PET/MR according to other findings from the PET/CT (e.g. columna)
75470738|NCT04233645|Other|5-minute educational video|The 5-minute educational video depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
75470739|NCT04233645|Other|Usual Care|The groups will be given a standard scripted verbal and identical written instructions as per usual care.
75470740|NCT04222283|Drug|BIKTARVY 50Mg-200Mg-25Mg Tablet|At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
75331790|NCT00941993|Device|Iontophoresis System (Acclarent)|Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
75331791|NCT02561832|Drug|Olaparib|tablets taken orally twice daily
75639725|NCT02725359|Drug|Placebo|Group Placebo: will receive a placebo pill 1 hour before surgery
75788500|NCT04667416|Biological|PalinGen Flow Amniotic Tissue Allograft|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
75788501|NCT01309490|Drug|Ribavirin|Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
75331792|NCT02561832|Drug|Carboplatin|intravenous injections on day one of each cycle
75331793|NCT02561832|Drug|Anthracycline|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
75331794|NCT02561832|Drug|Cyclophosphamide|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
75788502|NCT04082104|Diagnostic Test|Stuttering Severity Instument version 3|Riley's Stuttering Severity Instrument is used for the objective assessment of severity and in other examinations of stuttered speech. Current versions of the instrument measures three parameters: 1) stuttering frequency; 2) duration of selected stutters; 3) observed physical concomitants.
75788503|NCT04883840|Drug|Rosuvastatin 10mg|Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).
75924708|NCT02166723|Device|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
75924709|NCT02511158|Procedure|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
75924710|NCT02511314|Device|TENA Identifi|TENA Identifi
75924711|NCT00101439|Drug|ezetimibe|
75924712|NCT00101439|Drug|Comparator: placebo|
75924713|NCT02507102|Device|Voyager|Non-invasive RFE therapy
76080294|NCT03428568|Drug|Nexium|omeprazole
76080295|NCT03428568|Drug|Amoxil|Antibiotic
75470741|NCT04153006|Device|POC troponin analysis.|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Minicare® device.
75470742|NCT04137367|Behavioral|Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the active condition, the probe appears at the location of the most positive stimuli of each pair in 87 % of trials (encouraging a positive affective bias). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
75639726|NCT02725359|Drug|Tizanidine|Group T: 6 mg tizanidine1 hour before surgery
75639727|NCT02725359|Drug|Bupivacaine|Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
75639728|NCT02725359|Drug|Saline|USG guided SCPB with saline bilaterally 10 ml each side
75788504|NCT01345084|Radiation|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
75788505|NCT01345084|Drug|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
75788506|NCT01345084|Drug|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
76080296|NCT03428568|Drug|Clarithromycin|Antibiotic
76080297|NCT03431688|Drug|PAM|treatment with PPI, metonidazole, amoxicillin
76080298|NCT03431688|Drug|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
75331795|NCT02982161|Drug|MR308|Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
75331796|NCT02982161|Drug|Tramadol|Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
75331797|NCT02982161|Drug|Placebo|Capsule, Dosing frequency: four times daily, Mode of administration: oral
75639729|NCT00809614|Biological|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
75639730|NCT00809614|Biological|Placebo|Matching placebo to AIN457
76080299|NCT00630825|Drug|LY2189265|
76080300|NCT00630825|Drug|Placebo|
76080301|NCT03431610|Drug|SB414 2%|Twice daily
76080302|NCT03431610|Drug|SB414 6%|Twice daily
76080303|NCT03431610|Drug|Vehicle|Placebo comparator
75331798|NCT05506488|Drug|Dasatinib 100 MG + Quercetin (1000 MG)|The intervention group will receive intermittent orally administered dasatinib (100 mg/day) plus quercetin (1000 mg/day) on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
76080304|NCT04257474|Behavioral|Self-Report Survey|The self-report survey will be created using the Health Services Utilization Model (HSUM)
76080305|NCT04257474|Behavioral|Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi structured qualitive interviews exploring factors impacting utilization of screening breast MRI
76080306|NCT03434574|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
75788507|NCT01320332|Drug|ASP3291|Oral tablets
75639731|NCT04150419|Other|Group 1|Attentional training to avoid threatening, negative or pain-related information.
75639732|NCT04150419|Other|Group 2|Attention training for vigilance for positive emotional information.
75788508|NCT01320332|Drug|Placebo|Oral tablets
75788509|NCT03780530|Procedure|subcuticular suturing|Those undergoing Subcuticular suturing of perineal skin using 910 polyglactin vicryl No 2/0 (EGYCRYL®).
75788510|NCT03780530|Procedure|Surgical glue|Those undergoing perineal skin closure using adhesive glue n-butyl-2-cyanoacrylate (Histoacryl®).
75639733|NCT04150419|Other|Group 3 (control group)|Neutral attentional training (control group).
75788511|NCT03780530|Procedure|adhesive steri-strip tape|Those undergoing closure of perineal skin via Adhesive surgical water-resistant tape application. (3M® Transpore™ Surgical Tapes).
75788512|NCT03780140|Drug|Cefiderocol|Cefiderocol for intravenous infusion
75788513|NCT03774836|Drug|Tramadol|IV Tramadol 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
75924714|NCT02166801|Behavioral|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand & Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
76080307|NCT03434574|Dietary Supplement|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa).
76080308|NCT03434496|Device|Gait Trainer 3|With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
75331799|NCT05506488|Other|Placebo|The placebo group will receive intermittent orally administered placebo tablets on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
75470743|NCT04137367|Behavioral|Sham Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the sham condition, the probe appears at the location of the most positive stimuli of each pair in 50 % of trials (no contingency between facial expressions shown and the probe location). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
75470744|NCT04103424|Behavioral|Short-term Exercise Training|Participants will perform 2-weeks of supervised exercise training on a stationary bike.
75639734|NCT02725281|Other|Stress ball|The patients in this group were given stress ball into their both palms 5 min before the lithotripsy and told to squeeze the ball whenever they would like until end of the process. This ball was medium hard and has been made of high quality silicon.
75639735|NCT02725281|Other|Music|The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
75331800|NCT00942149|Drug|Daptomycin|single dose of 6 mg/kg of daptomycin
75331801|NCT03033563|Procedure|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
75331802|NCT03023111|Drug|Sbv|Standard treatment for CL, parenteral drug used during 20 days.
75331803|NCT03023111|Drug|Miltefosine plus placebo|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
75470745|NCT04074486|Device|BrainScope Ahead 300iP-O|BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.
75470746|NCT04074486|Diagnostic Test|SCAT5|Sports Concussion Assessment Tool 5
75639736|NCT02725203|Behavioral|Activate|The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
75331804|NCT03023111|Drug|Miltefosine plus GM-CSF|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
75639737|NCT04674592|Other|Blood samples and biopsies|Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.
75639738|NCT02719821|Behavioral|Behavioral techniques|"Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.~Device: Actiwatch-2 (Philips Respironics)"
75639739|NCT00731731|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
75639740|NCT00731731|Procedure|Cognitive Assessment|Ancillary studies
75639741|NCT00731731|Other|Laboratory Biomarker Analysis|Correlative studies
75788514|NCT03774836|Drug|Morphine|Morphine 4 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
75788515|NCT03774836|Other|Placebo|Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
75788516|NCT03774680|Drug|Cetuximab nanoparticles|The active group will receive cetuximab in nanoparticles as an anti-microbial drug.
75639742|NCT00731731|Drug|Temozolomide|Given PO
75788517|NCT03774680|Drug|Oral approved anticancer drug|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
75788518|NCT03783650|Behavioral|Control condition|Practices will submit control data and not receive centralized data feedback. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic.
75639743|NCT00731731|Drug|Vorinostat|Given PO
75924715|NCT02166801|Behavioral|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
76080309|NCT03434340|Biological|Peppermint essential oil|2 drops applied on a nasal strip
76080310|NCT03434340|Drug|Granisetron|1mg intravenous injection
75639744|NCT02719665|Dietary Supplement|SPM Emulsion, Dose-modality|"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"
75331805|NCT03022253|Biological|Liberal platelet transfusion|"Liberal platelet transfusion: In Intervention group the investigators will transfuse platelet concentrates to maintain a platelet count above 1,00,000 per microliter until one of the following endpoints is met, whichever is applicable:~PDA closes or~A maximum of 120 hours after the point of randomisation"
75788519|NCT03783650|Behavioral|QIC with PCP and without subspecialist|During this phase, practice will begin working on improving HTN practices within their clinic via a QIC, while the other cohort will act as a control (usual care) with data collection. They will attend an initial 1-day interactive video webinar learning session where they will learn QI methodology, enhance and practice QI skills, identify local 30-60 day aims to improve local HTN practices and increase their understanding of pediatric HTN. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic. They will participate in QI coaching, monthly video conferences, and monthly mini-root cause analyses (Mini-RCAs).
75788520|NCT03783650|Behavioral|QIC with Subspecialist|Practices will integrate their HTN subspecialist into the QIC and focus on issues at the boundary of PCP and subspecialty care (e.g. pre-referral work-up, communication across providers, and time for next available appointment).
75331806|NCT03022253|Biological|Restrictive platelet transfusion|"The investigators will transfuse platelets only if:~(i) Platelet count is < 20,000 per microliter or (ii) Subject has a clinical bleed or (iii) Subject has platelet count < 50000 per microliter and requires a major non-neurosurgical interventional procedure as per the current standard of care, or (iv) Subject has a platelet count < 1, 00,000 per microliter and requires a neurosurgical procedure"
75331807|NCT03022253|Drug|Paracetamol|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
75331808|NCT03022253|Drug|Ibuprofen|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral"
75331809|NCT03033407|Other|Tailored mobile coaching messages|Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
75331810|NCT01037881|Drug|LEO 29102|comparison of different dosages of drug
75639745|NCT02719665|Dietary Supplement|SPM Softgel, Dose-Modality|Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
75639746|NCT02719665|Dietary Supplement|Placebo Softgel|Days 43-47: 4 Placebo softgel; Day 48-64 Washout
75639747|NCT02719587|Procedure|Placebo|placebo drug identical except for the fish oil supplement, were only performed at baseline.
75639748|NCT02719587|Procedure|Omega-3|omega-3 PUFAs supplement, were only performed at baseline.
75788521|NCT03783650|Behavioral|Hub and Spoke co-management|Practices will continue QIC components and implement a hub and spoke model, where the PCP diagnoses and provides definitive management for pediatric HTN with subspecialist support.
75788522|NCT03783650|Behavioral|Sustainability of changes|Practices will sustain their changes, illustrating the durability of these system changes even after QIC completion and without central feedback and regular meetings.
75788523|NCT03774602|Behavioral|Health promotion and provision of RMNCH services|Implementation of quality, high-impact interventions at institutional and community levels to increase access to and utilization of RMNCH services
76080311|NCT03434340|Drug|Dexamethasone|4mg intravenous injection
76080312|NCT03088605|Drug|TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
76080313|NCT03088605|Drug|Placebo to TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
76080314|NCT03431454|Procedure|trained to do the pencil push-ups procedure|15 minutes per day, five days a week
76080315|NCT03431454|Procedure|using a major amblyoscope twice weekly with additional home orthoptic therapy|60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
75331811|NCT01037881|Drug|Elidel®|comparison
75331812|NCT03017651|Dietary Supplement|OM3-supplement 1|1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
75331813|NCT03017651|Dietary Supplement|OM3-supplement 2|1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
75331814|NCT03021863|Behavioral|Group A Reminder|Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
75331815|NCT03021863|Behavioral|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
75331816|NCT03021863|Behavioral|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
75788524|NCT03783806|Diagnostic Test|Posturography measurements|Determination of functional status, Posturography measurements, postural tests
75924716|NCT03345680|Other|Referred to a specific hospital for treatment|To King Saud University Dental College, treatment will be provided free of charge to the referred participants.
75788525|NCT03783338|Combination Product|Aerobic exercises and Vitamin D supplementation|"Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks."
75788526|NCT03774524|Drug|Misoprostol|400 μg of sublingual misoprostol
75788527|NCT03774524|Drug|TA|1 gm of tranexamic acid in 100 ml saline iv
75788528|NCT03774524|Drug|placebo to misoprostol|placebo tablets to misoprostol subligual
75924717|NCT02166879|Behavioral|Questionnaire|Participants complete anesthesia questionnaire before elective surgical procedure.
75924718|NCT03344822|Diagnostic Test|68Ga-PSMA-11|radioactive tracer for PET-CT (68Ga-PSMA-11)
75924719|NCT03344822|Diagnostic Test|18F-Choline PET-CT|radioactive tracer for PET-CT (18F-Choline PET-CT)
75924720|NCT02166957|Procedure|Recanalization|"All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.~The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.~The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance."
75924721|NCT02506712|Device|SmartDrive assisting device|oxygen consumption
75924722|NCT02506712|Device|Standard manuel wheelchair|oxygen consumption
75331817|NCT03021863|Behavioral|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
75788529|NCT03774524|Drug|placebo to TA|110 ml saline iv
75788530|NCT03774290|Drug|PBF-680|PBF-680 is an adenosine A1 receptor antagonist
75331818|NCT03021863|Behavioral|Group E Reminder|Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
75788531|NCT03774290|Drug|Placebo oral capsule|Oral gelatine capsule
75788532|NCT03774212|Device|Active noise cancelling headphones|The white noise will play from an 'iPod touch' (Apple), through the active noise cancelling headphones.
75788533|NCT04775420|Diagnostic Test|Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)|MPV and NLR are easily accessible and inexpensive tests
75788534|NCT03780296|Device|Real-time action observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
75788535|NCT01314560|Other|Blood sample|Blood sample
75788536|NCT03779750|Diagnostic Test|s.creatinine|All ESRD patients on regular hemodialysis in dialysis unit of Assiut university Hospital duing one year. will be subjected to 3- Routine investigations including complete blood picture ,blood urea , s.creatinine,urine analysis , calcium, phosphorus, and parathyroid hormone.
75331819|NCT03021863|Behavioral|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
75331820|NCT03021863|Behavioral|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
75331821|NCT03021863|Behavioral|Group H Reminder|Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
75331822|NCT03021863|Behavioral|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
75331823|NCT03017807|Biological|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
75331824|NCT00947219|Device|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
75924723|NCT02162355|Drug|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
75924724|NCT02162355|Drug|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
75331825|NCT00947219|Device|Control device|Device is used 3 times a week on non-consecutive days
75331826|NCT01124305|Device|Customized Patient Instrumentation|Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
75331827|NCT01124305|Device|Traditional Instrumentation|Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
75924725|NCT02162355|Drug|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
75924726|NCT02162355|Drug|Placebo|1 or 2 matching placebo tablets once daily for 10 days
75924727|NCT03345602|Diagnostic Test|serum S100B protein assay measurement|serum S100B protein assay measurement within the 3 hours after head trauma
76080316|NCT03431454|Procedure|using three diopter over-minus lenses and a base out prism|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
76080317|NCT01923987|Radiation|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
75639749|NCT02719587|Procedure|SRP|Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
75639750|NCT04022044|Behavioral|Observational group|
76080318|NCT01923987|Drug|Chemotherapy|"Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~Bevacizumab 5 mg/kg IV over 90 mins on Day 1~Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)"
75639751|NCT02719509|Procedure|Cardiac Ultrasound|
75639752|NCT02719197|Drug|AC-083|Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
75639753|NCT02719197|Drug|Placebo|Placebo capsules matching AC-083 capsules
75639754|NCT02719431|Drug|Warfarin|
75639755|NCT02719431|Drug|K-877|
75788537|NCT03774368|Other|Emergency contraception website|Existing website with factual information about emergency contraception
75924728|NCT02515838|Drug|Sevuparin|The Drug Product sevuparin solution for IV infusion
76080319|NCT01923987|Procedure|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
76080320|NCT03101163|Biological|Autologous peripheral blood stem cells and hyaluronic acid|Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy
76080321|NCT03101163|Other|Hyaluronic acid|Regimen of intra-articular HA injections and postoperative physiotherapy
75639756|NCT00806494|Drug|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
75639757|NCT02725125|Biological|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
75639758|NCT02719275|Behavioral|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
75639759|NCT02725047|Other|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
75788538|NCT03774368|Other|Emergency contraception video|Existing video with factual information about emergency contraception
75788539|NCT03773900|Dietary Supplement|Kiotransine (chitin-glucan from aspergillus niger)|The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.
75331828|NCT03408730|Biological|Hepatitis B Vaccination|Hepatitis B Vaccination
75639760|NCT02725047|Other|Placebo - Sand|Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
75639761|NCT02719119|Procedure|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
75639762|NCT02719119|Procedure|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
75639763|NCT02948361|Other|QT Ultrasound Breast Scan|Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
75639764|NCT02719041|Other|Immunohistochemistry staining method|
75639765|NCT02718885|Dietary Supplement|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
75639766|NCT02718885|Dietary Supplement|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
75639767|NCT02724813|Behavioral|Cognitive Orientation to Occupational Preformance (COOP)|
75788540|NCT03773900|Dietary Supplement|Placebo|The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
75924729|NCT02515838|Other|Placebo|Placebo for IV infusion
75924730|NCT04033068|Biological|Two MV-ZIKA-RSP vaccinations (high dose)|"In this arm of the study, 14 participants will receive:~V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
75639768|NCT00806416|Drug|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
75639769|NCT00806416|Drug|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
76080322|NCT02521194|Behavioral|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
76080323|NCT01924065|Procedure|Cardioversion|Electrical cardioversion
75639770|NCT00806416|Dietary Supplement|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
76080324|NCT01924065|Drug|Oral Anticoagulant|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
75924731|NCT04033068|Biological|Two MV-ZIKA-RSP vaccination (low dose)|"In this arm of the study, 14 participants will receive:~V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
76080325|NCT03428412|Drug|TCM and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
75788541|NCT03783260|Other|Mediterranean diet|During both Mediterranean diet periods, participants will be provided with meals and snacks representative of the Mediterranean nutritional habits. Participants will be required to eat only the meals provided.
75331829|NCT03033251|Device|Non Invasive Ventilation|Patients will receive non invasive ventilation as a standard of care.
75331830|NCT03033251|Device|High Flow Oxygen Cannula 50|Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
75331831|NCT03033251|Device|High Flow Oxygen Cannula 30|Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
75639771|NCT02724969|Behavioral|MILK or Text4Baby text message intervention|MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
75639772|NCT02724735|Drug|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
75639773|NCT02724657|Other|Buteyko Method|Intervention will be held twice a week during 3 weeks.
75639774|NCT02724891|Other|paper form|questionnaires in paper form
75639775|NCT02724891|Other|web/smartphone form|questionnaires in web/smartphone
75788542|NCT03774056|Drug|HC-1119|oral
75331832|NCT03017729|Biological|Botulinum toxin type A|This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
75639776|NCT00811252|Drug|Placebo|capsules; daily; orally
75639777|NCT00811252|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
75639778|NCT00811252|Drug|Duloxetine|encapsulated tablets; daily; orally
75639779|NCT02724501|Behavioral|questionnaire|Using questionnaire to obtain patient's medical and family history of cancer.
75788543|NCT03783104|Dietary Supplement|B12 Supplement|Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
75788544|NCT01309724|Other|USCOM-guided fluid administration|Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
75788545|NCT03773744|Drug|Ad-MAGEA3|Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
75788546|NCT03773744|Drug|MG1-MAGEA3|MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
75788547|NCT03773744|Drug|Pembrolizumab|monoclonal antibody; checkpoint inhibitor of PD1
76080326|NCT03428412|Drug|TCM placebo and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
75639780|NCT02724501|Procedure|Blood sample-DNA testing / Tumour-genetic markers|Using Samples obtained to produce summary statistics on the tumour markers
75639781|NCT02718729|Procedure|Laparoscopic resection for rectal cancer|Formal curative radical laparoscopic rectal resection.
75639782|NCT02609854|Device|Sustained Acoustic Medicine (SAM)|Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
75639783|NCT02609854|Device|Sham Device|Inactive ultrasound device
75639784|NCT05755594|Procedure|Robot-assisted Pancreaticoduodenectomy|By performing pancreaticoduodenectomy on the subject using the latest generation Da Vinci robotic surgical system and assisted by another surgeon for the entire procedure
75788548|NCT03773744|Drug|Cyclophosphamide|low-dose chemotherapy
75788549|NCT03779516|Other|Saline|Effect of saline on postoperative sore throat
75788550|NCT03779516|Other|Lidocaine|Effect of nebulized lidocaine on postoperative sore throat
75798720|NCT01287390|Other|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
75924732|NCT04033068|Biological|One MV-ZIKA-RSP vaccination (high dose) and one placebo|"In this arm of the study, 12 participants will receive:~V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
76080327|NCT03431298|Behavioral|Aerobic exercise & movement control|"The aerobic exercise content is no different between the experimental group and the active comparator group.~The movement control is individual training which divided into fourths progressing sessions.~First, lumbo-pelvic and hip dynamic direction control.~Second, trunk muscle groups, hip muscle groups and thigh muscle groups extensibility control.~Third, trunk muscle groups and hip muscle groups through range control.~Fourth, functional movement control training"
76080328|NCT03431298|Behavioral|Aerobic exercise|"The aerobic exercise will organized in groups. Each group has 6-8 persons. The exercise form is fixed at each time.~The description of exercise form is as below:~10 min Warm up~40 min Aerobic exercise (which focus on lower extremity muscle strengthening and increasing muscle endurance)~10 min Cool down"
75639785|NCT04114617|Other|Starch-thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
76080329|NCT00638703|Biological|Oxalobacter formigenes|NLT (not less than) 10^7 CFU Oxalobacter formigenes twice daily for 24 weeks
76080330|NCT00638703|Drug|Placebo|placebo
76080331|NCT03431220|Device|RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device|NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
76080332|NCT01924143|Drug|TD-9855|radiolabeled (100 µCi [14C]-Labeled) TD-9855 (20 mg)
76080333|NCT03434106|Drug|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
76080334|NCT03434106|Drug|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
75639786|NCT04114617|Other|Xanthan-gum thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
76080335|NCT01924377|Procedure|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance >5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
75788551|NCT03779594|Drug|Acetazolamide|Patients will be assign and treated by acetazolamide from time of allocation until surgery (2-6 weeks after treatment initiation). The maximal dose of acetazolamide will be the same dose used to treat glaucoma, considering similarity of patients' characteristics, such as age and polypharmacy. We will start at a low dose of 250 mg once a day, and increase it slowly to a maximal dose of 500 mg twice a day. Dose will be individualized according to side-effects and tolerability. Renal and liver function tests will be performed before initiation of treatment, and will be examined again two weeks after treatment had begun.
75788552|NCT04503590|Device|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
75331833|NCT03408808|Procedure|Platelet rich plasma|Aspiration of ganglion and injection with platelet rich plasma.
75331834|NCT03408808|Procedure|Aspiration alone|Aspiration of the ganglion
75639787|NCT04114617|Combination Product|Barium concentration|Commercially available barium products diluted to different concentrations (i.e., 20% w/v, 40% w/v) through the addition of water
75639788|NCT04029532|Device|Respiratory exchange ratio|Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.
75639789|NCT04029532|Device|Heart rate variability|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.
75639790|NCT04029532|Device|Body composition|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.
75639791|NCT04029532|Behavioral|Eating behavior|Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
75639792|NCT04029532|Behavioral|Physical activity recall|Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).
75639793|NCT04029532|Behavioral|Depression|Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).
75639794|NCT04029532|Behavioral|Body image|Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
75788553|NCT03779672|Drug|Memantine Hydrochloride 10 mg|"Week #1: 5 mg id (am), 1 caps~Week #2: 5 mg bid (am and pm), 2 caps~Weeks #3-6: 5 mg am & 2x 5 mg pm, 3 caps~Weeks #7-8: Washout~Placebo~Week #9: id (am), 1 caps~Week #10: bid (am and pm), 2 caps~Weeks #11-14: 1 caps am & 2 caps pm, 3 caps~OR Placebo~Week #1: id (am), 1 caps~Week #2: bid (am and pm), 2 caps~Weeks #3-6: 1 caps am & 2 caps pm, 3 caps~Weeks #7-8: Washout~Memantine~Week #9: 5 mg id (am), 1 caps~Week #10: 5 mg bid (am and pm), 2 caps~Weeks #11-14: 5 mg am & 2x 5 mg pm, 3 caps"
75788554|NCT03779282|Drug|Dexmedetomidine|see descriptions
75788555|NCT01320566|Device|AeriSeal System|Not applicable. Follow-Up study only.
75331835|NCT03021941|Drug|Elelyso 60 units/kg|All patients receive Elelyso 60 units/kg.
75331836|NCT03410914|Device|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery.
75331837|NCT03017495|Drug|Midazolam|2 mg/mL oral solution
75331838|NCT03017495|Drug|ACT-541468|Hard gelatin capsules for oral use at a strength of 25 mg
75639795|NCT02608996|Drug|Nesiritide|This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
75639796|NCT02608996|Drug|Placebo|For comparison to elucidate the true effect of nesiritide
75788556|NCT03782870|Diagnostic Test|echocardiography, lab tests|
75331839|NCT03021161|Drug|Probiotic Formula|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
75331840|NCT03021161|Other|Placebo Oral Capsule|Capsule containing no probiotic
75331841|NCT01039207|Other|Laboratory Biomarker Analysis|Correlative studies
76080336|NCT01924377|Procedure|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
76080337|NCT03428334|Drug|Oral roflumilast|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
76080338|NCT01924611|Procedure|Atraumatic Restorative Technique using cotton rolls|Atraumatic Restorative Technique using cotton rolls.
76080339|NCT01924611|Procedure|Atraumatic Restorative Technique|"Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.~This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.~This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier."
76080340|NCT01241344|Drug|Brincidofovir|"Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
76080341|NCT01241344|Other|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
76080342|NCT01925001|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
76080343|NCT01925001|Drug|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
75331842|NCT01039207|Biological|Rilotumumab|Given IV
75331843|NCT03417466|Device|Enlite 1 connected to iPro2 recorder|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
75639797|NCT00736957|Drug|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
75788557|NCT03773588|Device|Closed-Loop propofol Target controlled infusion by Entropy and SPI|Closed loop target infusion of propofol using BD TCI pumps guided by entropy and Surgical pleth index
75788558|NCT03773588|Device|Open-loop propofol target controlled infusion|Propofol target controlled infusion using Schnider algorithm to determine effect site concentration
75788559|NCT03773510|Drug|Trabectedin discontinuation|"Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
75788560|NCT03773510|Drug|Trabectedin continuation|Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
75788561|NCT03773432|Other|Probe meal|The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).
75798721|NCT01287390|Other|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H&N 35).
76080344|NCT03009682|Drug|Olaparib|"Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack."
75331844|NCT03830047|Device|nd yag laser|nd yag laser will be applied on the vulval warts
75331845|NCT02981537|Device|two-staged endobronchial blocker insertion|positioning endobronchial blockers in two-staged method
75331846|NCT02981537|Device|single-staged endobronchial blocker insertion|positioning endobronchial blockers in traditional single-staged method
75331847|NCT03621202|Device|Saranas Early Bird Bleed Monitoring System (EBBMS)|Participants will undergo their planned endovascular procedure with monitoring for internal bleeding using the Saranas EBBMS.
75331848|NCT01125163|Dietary Supplement|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.
75331849|NCT01125163|Dietary Supplement|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
75331850|NCT03033329|Drug|Single intravenous doses of MRX-4|Intravenous single escalating doses of MRX-4
75331851|NCT03033329|Drug|Single intravenous doses of placebo|Intravenous single doses of placebo to match MRX-4
75924733|NCT04033068|Other|Two placebo injection|"In this arm of the study, 8 participants will receive:~V1= day 0; placebo treatment~V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
75331852|NCT03033329|Drug|Multiple intravenous doses of MRX-4|Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
75331853|NCT03033329|Drug|Multiple intravenous doses of placebo|Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
75331854|NCT03033329|Drug|Single dose of intravenous and oral MRX-4|Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
75924734|NCT02162589|Procedure|POEM|Per oral endoscopic myotomy
75924735|NCT02162745|Drug|Isotonic solution (NaCl 0.9%)|
75924736|NCT02162745|Drug|Hypertonic solution (NaCl 3%)|
75924737|NCT02506790|Drug|metformin|
75924738|NCT02506790|Drug|Melatonin|
75924739|NCT02506790|Drug|Toremifene|
75788562|NCT01314950|Behavioral|Home based occupational therapy|"An occupational therapist (OT) will deliver the home-based intervention. There are three cycles of intervention over two years, with each cycle delivering eight 60-90 minute home sessions. Cycle one takes place over 16 weeks, cycle two over 32 weeks, and cycle three over one year. Telephone calls take place in intervening weeks, with additional phone calls allowed to assist with problem solving and interval problems. At minimum, the OT will perform an assessment at the beginning of each cycle in order to tailor the home based component for individual dyads at each cycle. The OT will collaborate with the patients and caregivers to develop client centered goals with homework each week in order to encourage carryover of strategies, home environmental modifications, or home exercise programs."
75788563|NCT01314950|Behavioral|Best practices primary care|Collaborative care is provided by an advanced practice nurse working in collaborations with a family caregiver, the primary care physician, and geriatric medicine specialists. Caregivers complete a formal assessment of problematic behaviors to assess current symptoms and stressors, and the care manager makes recommendations based on these results and using standardized protocols. Protocols focus first on non-pharmacologic interventions. If these interventions fail, the care manager collaborates with the primary care physician and/or specialists to institute protocol-based drug therapy or other strategies. Patients and caregivers are also offered access to support groups.
75788564|NCT03779360|Drug|Erythromycin 4% topical gel formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
75788565|NCT03779360|Drug|Clindamycin 1% lotion formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
75788566|NCT03779360|Drug|Prednisolone tablet (0.5mg/kg; parallel comparison):|2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
75788567|NCT03779360|Drug|Clobetasol propionate 0.05% topical formulation (crossover comparison):|"2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2."
75924740|NCT02162901|Behavioral|Choice-Class with IVR Calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
75924741|NCT02162901|Behavioral|Random-Class with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
76080345|NCT03431142|Drug|Clopidogrel|Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
76080346|NCT03431142|Drug|Clopidogrel+aspirin|Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
76080347|NCT02521272|Other|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
76080348|NCT02521272|Device|air pocket|Zero air pocket or one-liter air pocket in the snow.
75639798|NCT02608294|Device|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
76080349|NCT03831321|Drug|Diclofenac Sodium|50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
76080350|NCT03831321|Device|Cystoscopy|Diagnostic cystoscopy
76080351|NCT03831321|Drug|Lubricant Gel|To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
75331855|NCT03020693|Procedure|Invasive electrostimulation combined with exercises|Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
75331856|NCT03020693|Procedure|Placebo electrostimulation and exercises|First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
75331857|NCT01099969|Device|Glidescope videolaryngoscope|
75331858|NCT01099969|Device|McGrath videolaryngoscope|
75331859|NCT01099969|Device|Non-styletted Endotrol endotracheal tube (ETT)|
75788568|NCT03779360|Other|Lipopolysaccharide|As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
75924742|NCT02162901|Behavioral|Random-Class only|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
75924743|NCT02162901|Behavioral|Choice-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
75924744|NCT02162901|Behavioral|Random-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
75924745|NCT02511080|Device|Spot-On|use of active hot measures
75924746|NCT04649736|Other|Respiratory and psychological rehabilitation|"Respiratory rehabilitation consists of 12 sessions of respiratory and physical exercises that patients perform at home with the help of a physiotherapist. Sessions have 1 hour of duration and are performing twice a week. Exercises include (1) Training of the respiratory muscles through pursed-lip breaths. (2) Effective cough exercises. (3) Diaphragmatic contractions in a supine position with a lightweight placed on the anterior abdominal wall. (4) Stretching exercise of extremities and the back.~The psychological support consists of 1 session to make the psychological history of the participant, and 6 sessions of emotion-centered problem-solving therapy, with cognitive-behavioral components and psychological management of emergencies and crises. These sessions have a 1-hour duration and are telephone-provided once a week by psychologists following the guidelines of the Inter-Agency Standing Committee on Mental Health and Psychosocial Support in Humanitarian and Disaster Emergencies."
75924747|NCT03540615|Drug|BAY1830839|Dose escalation in healthy male subjects
75924748|NCT03540615|Drug|Placebo|Matching placebo
75924749|NCT04500002|Drug|Isonicotinic Acid Hydrazide|total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
75924750|NCT04500002|Drug|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
76080352|NCT01285024|Device|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
75788569|NCT03782948|Device|Standard gait training on BART without pelvic perturbations|The Balance Assisted Robot on Treadmill (BART) enables various types of gait training on treadmill with visual feedback. It interfaces to the pelvis of the walking subject in an actuated and admittance-controlled manner, thus providing transparent haptic interaction with negligible power transfer.
75924751|NCT05149716|Dietary Supplement|Taurine|Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
75924752|NCT05149716|Dietary Supplement|Placebo|Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day
75924753|NCT03345524|Other|Peer-Buddy System|"2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed"
75924754|NCT03345524|Other|Usual Care|"Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)"
75924755|NCT02444130|Device|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
75924756|NCT02515682|Dietary Supplement|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
75788570|NCT03782948|Device|Robotised gait training with BART with pelvic perturbations|In addition to the standard gait training, the BART will deliver perturbations in the forward/backward and left/right direction.
75788571|NCT01560728|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Individual psychotherapeutic approach occurring once per week for 12 to 20 weeks
75331860|NCT01099969|Device|Regular endotracheal tube (ETT) with Gliderite stylet|
75331861|NCT03017339|Other|Functional Exercise|
75331862|NCT03017339|Radiation|Low Level Laser Therapy|
75331863|NCT03017339|Radiation|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
75331864|NCT03417778|Drug|Filgotinib|100 mg tablet administered orally
75331865|NCT03013855|Device|FIT-SOC|Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
75331866|NCT03013855|Device|FIT-DRE|Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
75331867|NCT03032939|Procedure|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
75788572|NCT05271734|Device|Lid retractor placement|Insertion of a lid retractor to find out if the corneal limbus is exposed in 360 degress
75924757|NCT02515682|Dietary Supplement|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
76080353|NCT03430908|Other|Blind Gastric Tube Placement|The provider will be blinded to the ultrasound imaging throughout the entire insertion. This blind insertion process is the standard of care currently practiced at MSKCC. After the provider verbalizes that they have completed the insertion the investigators will stop the ultrasound imaging and complete the data form. No information will be given to the provider about the location of the gastric tube as to not deviate from the standard of care. The only time that information will be provided to the practitioner inserting the tube will be if the tube is positioned in any of the following positions that are thought to be potentially injurious if unrecognized. These positions include intrapulmonary, cranial, nasal or oral pharyngeal placements and diverticular or hiatal hernia sac coiling and remain unrecognized by the practitioner. These are considered positions that have the potential for injury and therefore will be divulged to prevent ensuing injury.
76080354|NCT01925079|Behavioral|Intensive Education|"Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~Routine education at discharge.~4 education brochures will be delivered to patients.~Calendar with healthy tips will be delivered to patients before discharge.~A follow-up brochure with medical expert letter.~A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up."
76080355|NCT01925079|Other|Control|"Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~Routine education at discharge.~A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up."
76080356|NCT03156582|Other|Data collecting|
76080357|NCT04450134|Other|Lactose|Placebo: Lactose capsules
75470747|NCT04074486|Diagnostic Test|Near Point Convergence|Manual ocular function measurement conducted only if electronic version on device fails
75788573|NCT01320800|Behavioral|Skills for Academic and Social Success|12-week cognitive-behavioral, school-based group intervention
75788574|NCT01320800|Behavioral|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors.
75788575|NCT01320878|Drug|iloprost nebuliser solution|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
75788576|NCT01320878|Drug|iloprost nebuliser solution|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
75788577|NCT01320878|Drug|distilled water|distilled water 2 ml per session
75788578|NCT01321034|Drug|Niacin/Laropiprant|1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.
75788579|NCT03779438|Drug|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
75788580|NCT03779438|Drug|placebo to 17-OHPC|patients received weekly placebo to17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
75924758|NCT02515682|Dietary Supplement|Placebo|Participants will be give placebo for 24 weeks.
76080358|NCT04450134|Drug|Fexofenadine Hydrochloride|H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
76080359|NCT04450134|Drug|Famotidine|H2 receptor antagonist: 40 mg Famotidine
76080360|NCT04450134|Other|High-intensity interval training (HIIT)|6 weeks HIIT
76080361|NCT01286818|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
75331868|NCT04734808|Diagnostic Test|Electroencephalography|Electroencephalography is an electrophysiological monitoring method to record electrical activity of the brain.
75331869|NCT04734808|Diagnostic Test|Electromyography|Electromyography is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles. We will use the hdEMG version.
75331870|NCT03013153|Procedure|Low ligation with apical lymph node dissection|Low ligation with apical lymph node dissection (LAND). Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta.
75470748|NCT04070352|Drug|Fidaxomicin|patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI
75470749|NCT04065152|Drug|Talimogene laherparepvec|Talimogene laherparepvec
75788581|NCT03778814|Biological|TCR-T cells|Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
75788582|NCT03773354|Behavioral|Cognitive-behavioural therapy group for individuals with somatic symptom disorders|The intervention is a cognitive-behavioural therapy group for designed for individuals with a formal diagnosis of a somatic symptom disorder (i.e., Somatic Symptom and Related Disorders from the DSM-5) who are interested in learning self-management skills to cope with somatic symptoms and reduce emotional dysregulation, increasing their understanding of factors that contribute to somatic symptoms, and learning relaxation skills to help reduce stress.
75470750|NCT03962998|Drug|Lactulose/Rhamnose solution|Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine
75788583|NCT03782714|Device|Low-level laser therapy|It is a diode laser device that has laser set at low level, used for pain relief and inflammation reduction to induce healing
75924759|NCT03492684|Procedure|total hip arthroplasty|total hip arthroplasty and EMG
75924760|NCT02510924|Device|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
75924761|NCT02510846|Behavioral|Intensive educative management|5 hours a week
75924762|NCT02510768|Device|ELAPR002f|Intradermal implant
75924763|NCT02510768|Device|ELAPR002g|Intradermal implant
75924764|NCT02510768|Device|Saline|Intradermal implant
75924765|NCT02515604|Drug|Misoprostol|
75924766|NCT02510534|Drug|Menopur 150 international units|Menopur 150 international units given x 1 dose
75639799|NCT02608294|Device|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
75639800|NCT04189185|Procedure|Suture fixation|The fracture is reduced. A 2.5 mm hole is drilled in the dorsal olecranon 15mm from the fracture. A suture is passed through the hole and is fixed to the triceps muscle. A second suture is fixed to the triceps muscle in a figure 8 configuration.
75470751|NCT03962998|Drug|MB-102|MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
75788584|NCT01321112|Drug|conversion from CNI to MMF|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
75788585|NCT03773042|Drug|HSK3486|For induction and maintenance of sedation.
75788586|NCT03773042|Drug|Propofol|For induction and maintenance of sedation.
75788587|NCT03778892|Behavioral|'Project Raincoat' Mobile Phone Application|Mobile phone application with weekly input channels for PrEP use, condom use, number of sex partners and sex acts and a calculation of self-HIV risk feedback scoring. Scoring system for attendance of visits, normal blood tests and use of application. Points redeemable for cash. Optional alarm system to remind to take medications and attend visits.
75924767|NCT02510534|Drug|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
75924768|NCT03799146|Behavioral|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
75924769|NCT03799146|Other|Waiting List|Waiting List control group
75924770|NCT02510612|Drug|Dexmedetomidine|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
75924771|NCT02510612|Drug|placebo|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
75788588|NCT01310348|Device|whole-body vibration (WBV)|The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
75788589|NCT01310348|Device|WBV (Sham stimulation)|Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
75470752|NCT03947450|Biological|Autologous Skin Fibroblasts|The site or whole stump will be injected with autologous fibroblasts
75924772|NCT03749616|Drug|Ibuprofen|NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
75924773|NCT03749616|Drug|Acetaminophen|Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
75924774|NCT03491514|Other|Test Granola|51 g Test Granola
75788590|NCT03782480|Drug|Intrarosa|Prasterone intravaginal inserts
75788591|NCT03782480|Drug|Placebos|Placebo intravaginal inserts
75788592|NCT03778970|Other|Pain Neuroscience Education|Pain neuroscience education (2 sessions during 40 minutes) administered by an interactive workshop
75788593|NCT03778970|Other|Self-Management Education|A self-management education (2 sessions during 40 minutes) administered by an interactive workshop
75924775|NCT03491514|Other|Control Granola|54.1 Control Granola
76080362|NCT01286818|Drug|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
76080363|NCT01286818|Drug|levofolinate|IV infusion, 200 mg/m² every 2 weeks
76080364|NCT01286818|Drug|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
75470753|NCT03947450|Biological|Placebo|The site or whole stump will be injected medium only without autologous skin fibroblasts
75639801|NCT05754970|Procedure|laser treated|"The second surgical stage was done after a healing period 12 ± 4 weeks (T1) where all the healing abutments were placed. Each healing abutment had repeated the two surfaces as twice follows: laser-treated/machined/ laser-treated/machined. Experimental healing abutment was removed after 30 ± 7 days, the same time as the soft tissue biopsy.~After the healing period (30 ± 7 days), before starting with the prosthetic restoration of the fixtures, an impression was taken of the small-diameter Has, and circular sections (diameter 5 mm) soft tissues around them were retrieved for analysis."
75924776|NCT04499222|Device|Portex|nasotracheal intubation with PORTEX POLAR [Smiths Medical International, Hythe, United Kingdom] nasotracheal tube.
75639802|NCT02724267|Biological|131I-chTNT-1/B|29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment
75639803|NCT02718495|Drug|PTI-428|
75639804|NCT02718495|Drug|Placebo|
75639805|NCT04659226|Genetic|Blood sampling for microRNA testing|Blood samples will be collected and analyzed for the microRNA profile by means of microfluidic cards
75639806|NCT02724189|Device|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
75924777|NCT04499222|Device|Mallinckrodt|nasotracheal intubation with Mallinckrodt TaperGuard [Covidien, Ireland] nasotracheal tube.
75924778|NCT04532502|Drug|Anesthetics, Inhalation|Work environmental exposure
76080365|NCT03113292|Other|Pilates|"The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.~."
76080366|NCT03113292|Other|Home Exercises|The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
75639807|NCT02724189|Other|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
75639808|NCT04021654|Procedure|Data collection|Data collection of growth, neuromotor, sensorial, behavioral, and cognitive development.
75639809|NCT05294523|Procedure|Rocuronium priming dose|Add the priming dose of rocuronium after the first supramaximal stimulation data measured
75639810|NCT04640662|Biological|Platelet-Rich Plasma|Single-injection of 2 ml PRP into the lesion under ultrasound-guided
75639811|NCT04640662|Biological|Prolotherapy|Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
75639812|NCT02723877|Drug|PQR309|Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
75639813|NCT02723877|Drug|Eribulin|non.taxane microtubule dynamics inhibitor
75639814|NCT00736879|Drug|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
75639815|NCT00736879|Drug|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
75639816|NCT02608372|Other|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
75639817|NCT02608372|Other|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
75639818|NCT02608372|Other|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
75639819|NCT02718339|Behavioral|Intensive counseling|
75639820|NCT02718261|Drug|Pantoprazole|
75639821|NCT02718261|Drug|Saline 0.9% (matching placebo)|
75788594|NCT03778970|Other|Movement Control Exercises|Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.
75788595|NCT03712280|Drug|MNK6106|1 gram tablet of MNK6106 for oral administration
75639822|NCT00806260|Drug|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
75788596|NCT03712280|Drug|Rifaximin|550 mg tablet of rifaximin for oral administration
75639823|NCT00806260|Drug|Placebo|Placebo daily for 4 weeks
75639824|NCT00806260|Other|Alcohol|
75788597|NCT01561508|Drug|gamma-amino-butyric acid|gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
75788598|NCT01561508|Dietary Supplement|Xylitol|The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
75788599|NCT03772886|Device|Peanut Ball|A peanut shaped exercise ball.
75788600|NCT03772808|Dietary Supplement|Lycocomfort|Evaluate of the perceived efficacy of LycoComfort™ supplements in alleviating symptoms associated with lower urinary tract symptoms (LUTS) and general prostate discomfort over the duration of 12 weeks intervention
75788601|NCT01320410|Drug|ISM®|
76080367|NCT04450056|Other|No intervention|No intervention
75639825|NCT00806260|Other|alcohol placebo|fruit juice
75639826|NCT05283213|Diagnostic Test|Early biomarkers of acute kidney injury|"The biomarkers tested will be:~creatinine levels [pre-, post-CC, H6],~urinary TIMP2*IGFBP7 [H6],~Plasma NGAL [Pre-, Post-CC, H6].~Urinary NGAL [H6]~Plasma cystatin C [Pre-CC, Post-CEC & H6],~plasma HI [pre-, post-CC, H6],~plasma IL-6 [post-CC, H6],~uremia [pre-, post-CC, H6],~urinary DKK3 [pre-CC], These biomarkers will, if necessary, be corrected for hemodilution or dilution of urine, if any, using [pre-, post-CC, H6] protein and [pre-, post-CC, H6] creatinine, respectively."
75639827|NCT05753020|Behavioral|CKM Jumpstart Tool|The CKM JumpStart Tool is a 1-page handout that describes the values of a patient and words that a providers can try with the patient to explore the patient' values more and to provide a values-based introduction to CKM. The values described in the CKM JumpStart Tool is based on a patient's response to a single validated question that we will ask the patient at T1, if they had to choose, do they value care directed at longevity or comfort. Using the patient's answer to the values question, study staff will generate a CKM JumpStart Tool prior to their upcoming clinic visit with their nephrologist. Study staff will inform the patient that their response to the values question will be shared with their provider prior to their next clinic visit and that their providers might bring up their values and treatment options for kidney disease, if the situation permits. We will share the CKM Jumpstart Tool with their provider and provide instruction on how to use the Tool.
75788602|NCT01561664|Other|muscle and fat biopsy|muscle and fat biopsy
75788603|NCT03772496|Diagnostic Test|circulating tumor cells test|10 ml Peripheral blood are drawn from patients enrolled before surgery/FNAB and centrifuged to collect the peripheral blood mononuclear cells. Then, negative and positive immunomagnetic selections are used to exclude white blood cells and enrich tumor cells. After isolating mRNA, RT-PCR array is used to measure expression of target genes.
75924779|NCT02506478|Other|Beverage procurement|All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
75924780|NCT02506166|Device|Positive Airway Pressure Therapy|Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
75924781|NCT03491436|Device|iHealth Align|remote monitor glucometer
75924782|NCT02762565|Device|PEFS system (Product Name: Intelligent Breast Exam™ or iBE™|
75924783|NCT03488550|Biological|ANX007|Single ascending dose
75924784|NCT02506322|Behavioral|SEKT - Cognitive-Behavioral-Emotional|"This Bipolar Disorder specific psychotherapy has 4 modules:~psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~behavior changes, (social, problem solving) skill training, communication skills, crisis management"
75788604|NCT03772496|Diagnostic Test|Fine needle aspiration biopsy|patients with potential malignant thyroid nodules are performed fine needle aspiration biopsy with the aid of ultrasound. The result of FNAB were classified by Bethesda rating system.
75788605|NCT03769610|Other|Inpatient Foley catheter|
75788606|NCT03769610|Other|Outpatient Foley catheter|
75924785|NCT02506322|Behavioral|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
75788607|NCT03772418|Drug|Cream Base|The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
75788608|NCT03772418|Drug|Pomegrante and Ginkgo biloba group|The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
75788609|NCT03772262|Dietary Supplement|goldenseal|Oral 500 mg capsules
75470754|NCT03917667|Diagnostic Test|EWGSOP2|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia, considered as a dichotomous variable -yes/no- in presence of low grip strength + low muscle mass + low gait speed.
75470755|NCT03859635|Drug|Liposomal Bupivacaine|20 ml
75470756|NCT03859635|Drug|Bupivacaine, 0.25%|10 ml
75639828|NCT02718183|Other|Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)|bleaching teeth gel to intracameral use.
75788610|NCT03772262|Drug|Metformin|Oral solution
75788611|NCT03772262|Drug|Furosemide|Oral solution
75788612|NCT03772262|Drug|Midazolam oral solution|Oral syrup
75788613|NCT03772262|Drug|Rosuvastatin Oral Tablet|Oral tablet
75788614|NCT03772340|Drug|Tradipitant|Oral capsule
75788615|NCT03772340|Drug|Placebo|Oral capsule
75788616|NCT03772106|Drug|Propofol Fresenius|Propolipid 1% : IV
75788617|NCT03772106|Drug|sevorane|sevorane Quick fill (sevoflurane) : inhalation
75788618|NCT03778736|Other|Cumulase denudation|Testing the effect of cumulase for women with poor oocyte yield due to poor ovarian reserve
75924786|NCT03488394|Genetic|Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.|"The drug product target dose is more or equal to 8x10^6 CD34+ cells/Kg, with a minimum dose of 4x10^6 CD34+ cells/Kg and a maximum dose of 35x10^6 CD34+ cells/Kg.~The product will be injected intravenously."
75924787|NCT02515526|Drug|caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Reference period
75924788|NCT02515526|Drug|ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Test period
75470757|NCT03859635|Drug|Bupivacaine, 0.5%|30 ml
75470758|NCT03847090|Drug|Reloxaliase|Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day
75470759|NCT03847090|Drug|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
75470760|NCT03796026|Drug|Seltorexant 40 mg|Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
75470761|NCT03796026|Drug|Placebo|Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
75470762|NCT03783013|Other|High Lycopene Tomato Juice With Soy Germ Extract|Tomato juice made from high lycopene tomatoes with soy germ extract added
75470763|NCT03783013|Other|Low Lycopene Tomato Juice|Tomato juice made from low lycopene tomatoes with no soy germ extract added
75639829|NCT02718183|Other|carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).|bleaching teeth gel to intracameral use.
75639830|NCT00742885|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
75639831|NCT00811174|Drug|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
75639832|NCT02723487|Drug|Bupivacaine 0.125%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
75470764|NCT03738423|Drug|REGN3500|Administered subcutaneous (SC)
75470765|NCT03738423|Drug|REGN3500-Matching Placebo|Administered subcutaneous (SC)
75470766|NCT03726229|Device|Cholate assay|Labeled oral and IV cholate will be administered once to the Fontan cohort and blood specimens will be collected at baseline and timepoints thereafter.
75639833|NCT02723487|Drug|Bupivacaine 0.25%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
75788619|NCT03778346|Biological|CAR-T therapy in Relapsed/Refractory multiple myeloma|Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells to treat Relapsed/Refractory multiple myeloma
76080368|NCT01925157|Biological|LY3090106 - SQ|Administered SQ.
76080369|NCT01925157|Biological|LY3090106 - IV|Administered IV.
76080370|NCT01925157|Biological|Placebo - SQ|Administered SQ.
76080371|NCT01243294|Device|SS|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
76080372|NCT01243294|Device|SenSura|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
75788620|NCT03771950|Behavioral|Early team based neuro-rehabilitation|A structured interview will be made by OT about activity level, and an examination of the patients bodily and neurological symptoms will be made by PT. Based on this result a rehabilitation plan is established consisting of the patient's goals, and the purpose that the patient shall be as active as possible without triggering symptoms. An individual exercise program is prescribed. Between each appointment the patient will have personal tasks to accomplish with the purpose of being active based on symptoms and the adaptation to the current level of energy. The perceived symptoms will be logged. A week-schedule will be created in the purpose of helping the patient to a balanced activity level in relation to their current capacity. The PT assesses physical activity level and reactions to physical strain. Adaptations are made to the exercise program and advice is given on physical activity and exercises. When appropriate OT advices about returning to work and adaptations concerning work.
75788621|NCT03771794|Device|ReguRate neurostimulation|"Device: ReguRate neurostimulation Device:~Sham : ReguRate neurostimulation - mock sham stimulation mode"
75788622|NCT03771872|Device|Virtual Prism Adaptation Therapy|Hand trajectory will deviate to the right side in the virtual reality.
75788623|NCT03771872|Device|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
75788624|NCT01316588|Other|Plastic adesive drape|Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg
75788625|NCT01316588|Other|Microbial Sealant|Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
75788626|NCT04141592|Procedure|Bariatric Surgery|Already clinically indicated surgical procedures
75788627|NCT03778268|Procedure|sentinel lymph node biopsy|"Injecting carbon nanoparticles (CNP)[Not Equipped with near-infrared fluorescent vascular imager] or CNP combining Indocyanine Green(ICG)[Equipped with near-infrared fluorescent vascular imager].~Identifying and removing sentinel lymph nodes.~Staining all nodes using hematoxylin-eosin staining."
75788628|NCT01345240|Biological|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
75788629|NCT01345240|Biological|Engerix-B™ vaccine|Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
75788630|NCT01345240|Biological|Infanrix/Hib™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
75788631|NCT01345240|Biological|Polio Sabin™ vaccine|Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
75788632|NCT01345240|Biological|Rotarix™ vaccine|Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
76080373|NCT03428256|Device|Optiflow and THRIVE technique|Nasal high flow humidified oxygen
75788633|NCT01345240|Biological|Synflorix™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
75788634|NCT01345240|Biological|Measles vaccine|Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
76080374|NCT03428256|Device|Standard anaesthetic face mask|Oxygen delivery via an anaesthetic facemask
76080375|NCT00635505|Drug|albuterol HFA (Armstrong's)|180 mcg QID 12 weeks
75639834|NCT02717871|Device|PACK-CXL|"Local anesthesia~- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~Homatropin or Scopolamin, if anterior chamber reaction~Systemic NSAID/NSAR, if substantial pain~Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching"
75639835|NCT02717871|Drug|Cefazolin in combination with either tobramycin or gentamicin|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml)."
75639836|NCT02717871|Drug|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
75788635|NCT01345240|Biological|Yellow fever vaccine|Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
75788636|NCT03771638|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
75788637|NCT03771638|Other|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
76080376|NCT00635505|Drug|albuterol HFA (Proventil HFA)|180 mcg QID 12 weeks
76080377|NCT00635505|Drug|HFA placebo|2 actuations QID 12 weeks or until use of rescue drug
76080378|NCT03428178|Drug|rAAV2-ND4|rAAV2-ND4 of vitreous cavity injection
76080379|NCT01243450|Drug|Tretinoin|Treatment of acne
76080380|NCT01243450|Drug|placebo|treatment of acne
76080381|NCT01925313|Drug|CJ-30044|20.51mg a day,PO,QD
76080382|NCT01925313|Drug|TALION TAB. 10mg|10mg a day,PO,BID
75470767|NCT03712228|Biological|Factor XIIa antagonist monoclonal antibody|Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use
75470768|NCT03712228|Drug|Placebo|Buffer without active ingredient
75470769|NCT03626922|Drug|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
75331871|NCT03013153|Procedure|High ligation|High ligation (HL) Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
75331872|NCT03032861|Other|Orange juice|Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
75331873|NCT03033017|Other|Blood Testing|
75470770|NCT03626922|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
75788638|NCT03771404|Other|blood sampling|Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
76080383|NCT03433872|Other|We Grow Together: The Q-CCIIT Professional Development System|We Grow Together is designed to strengthen high quality caregiver interactions with infants and toddlers. The starting point for the We Grow Together study is assessment of a caregiver's interactions with infants and toddlers in the caregiver's ECE setting, using the Q-CCIIT observational measure. Data from the Q CCIIT observations highlight areas for growth in the caregiver's practices and will inform a PD goal-setting process, with the help of a PD Provider. An array of We Grow Together materials targeting practices assessed by the Q-CCIIT measure and informed by professional development and behavior change research are organized into modules, and delivered on an interactive website. Over the course of a program year, each caregiver in the study will work with a PD provider who is trained in guiding caregivers through the use of We Grow Together materials.
76080384|NCT05249751|Diagnostic Test|Assessement of serum copeptin by ELISA technique|Assessement of serum copeptin by ELISA technique
76080385|NCT03430830|Drug|Ravidasvir 50mg|50mg, Tablet
76080386|NCT03430830|Drug|Ravidasvir 200mg|200mg, Tablet
75331874|NCT05308147|Dietary Supplement|First Reference product|Dextrose (containing 25 grams of carbohydrates)
75331875|NCT05308147|Dietary Supplement|Second Reference product|Dextrose (containing 25 grams of carbohydrates)
75331876|NCT05308147|Dietary Supplement|Third Reference product|Dextrose (containing 25 grams of carbohydrates)
75639837|NCT02717871|Drug|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
75639838|NCT02717871|Drug|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
75639839|NCT02593435|Genetic|NGS test|"To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2."
75331877|NCT05308147|Dietary Supplement|First Concept product|Infant Formula (containing 25 grams of carbohydrates)
75639840|NCT04030078|Other|Survey|Questionnaire-based survey
75788639|NCT03771482|Behavioral|Quiztime modules|Text Messaging or Email system
75331878|NCT05308147|Dietary Supplement|Second Concept product|Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
75470771|NCT03626922|Drug|Oxaliplatin|"Oxaliplatin-Dose level1: 85 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~Dose level 2: 120 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~The MTD dose of oxaliplatin in the study combination of Cohort 2 will be the recommended Phase II dose (RP2D) for the cohort expansion."
75788640|NCT03771248|Device|peek telescopic partial denture|removable partial denture
75470772|NCT03626922|Drug|Dexamethasone|Dexamethasone-4 mg by mouth twice daily on: the day before, the day of, and the day after each dose of pemetrexed.
75788641|NCT03778112|Radiation|SBRT to whole prostate|Those patients with negative mpMRI prostate scan (PI-RADS 0-2) will receive SBRT (36.25 Gy/5 fractions) to the whole prostate
76080387|NCT00635193|Drug|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
76080388|NCT00635193|Drug|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
76080389|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
76080390|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
76080391|NCT01925391|Drug|Tono-pen XL Applanation tonometer + Ocu-film +|
75331879|NCT05308147|Dietary Supplement|Third Concept product|Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
75331880|NCT03575962|Drug|GSK3640254 bis-hydrochloride salt capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
75470773|NCT03626922|Dietary Supplement|Folic Acid|Folic Acid-400 micrograms by mouth daily starting 5 days prior to first dose of pemetrexed and continue daily to include 21 days after the last dose of pemetrexed.
75470774|NCT03626922|Dietary Supplement|Vitamin B-12|1000 micrograms administered intramuscularly 7 days prior to the first dose of pemetrexed, every 9 weeks, and should continue until 3 weeks after the last dose of pemetrexed.
75639841|NCT02717715|Behavioral|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
75639842|NCT02608528|Radiation|[18F]fluoroglucose(FDG)|
75924789|NCT03492450|Other|Treadmill training|Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.
75788642|NCT03778112|Radiation|IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions|Patients with positive or equivocal mpMRI prostate scan (PI-RADS 3-5) will receive IMRT (45 Gy/25 fractions) to the prostate + seminal vesicles +/- lymph nodes followed by SBRT boost (18 Gy/3 fractions) to the whole prostate with simultaneous integrated boost (21 Gy/3 fractions) to MRI defined intraprostatic lesions
75788643|NCT01335880|Behavioral|Coupons for use within the next week|Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.
75788644|NCT01335880|Behavioral|Coupons for use within the next 3 months|Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.
75470775|NCT03600818|Drug|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75639843|NCT04088929|Drug|CBD|A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
75788645|NCT00092560|Drug|MK0653, ezetimibe|
75788646|NCT00092560|Drug|Comparator: fenofibrate monotherapy|
75788647|NCT03771170|Drug|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
75788648|NCT03771170|Drug|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
75924790|NCT04497662|Drug|KPL-404|humanized IgG4 monoclonal antibody
75639844|NCT02723253|Radiation|Radiotherapy|Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement > 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
75639845|NCT02723253|Drug|Tom-OX|The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
75639846|NCT04616794|Behavioral|Cognitive Engagement Group|Participants in this group will be encouraged to lead a cognitively stimulating lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase cognitively stimulating activities and by assisting participants outlining goals to progressively adopt a more cognitively active lifestyle.
75924791|NCT04497662|Other|Matching Placebo|Placebo
75924792|NCT05135130|Drug|ON101 Cream|Not applicable in this retrospective study
75924793|NCT02505932|Procedure|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
75924794|NCT02505932|Procedure|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
75470776|NCT03600818|Drug|Sarilumab-matching placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75788649|NCT03280732|Device|Lung Ultrasound|A Mindray-DC-T6 ultrasound machine equipped with a linear probe with frequencies ranging from 7.5 to 12 MHz will be use. LUS examination will consist of both longitudinal and transversal sections according to the methodology described by Copetti and colleagues.
75924795|NCT04460976|Behavioral|Psychoeducation for Adults With Autism and Their Significant Others/Family members (Prisma)|Psychoeducation in groups
75924796|NCT04460976|Behavioral|Treatment as usual/standard care|Standard care at disability/habilitation services.
75924797|NCT02167191|Behavioral|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
75924798|NCT02515448|Drug|gentamicin|
75924799|NCT04223622|Biological|ASC secretome|The osteochondral explants isolated from arthroplasty patients will be induced to an OA phenotype and treated with ASC secretome (either complete conditioned medium or extracellular vesicles) in order to investigate its therapeutic potential.
75924800|NCT02506088|Behavioral|Your Voice Your View|Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
75924801|NCT02170857|Drug|Hyaluronic Acid|This material will be used in conjunction with the ordinary surgical procedure
75924802|NCT04460820|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2,IV on Day 1 of each cycle
76080392|NCT00633789|Drug|brivanib|Tablets, Oral, 800 mg, once daily, until progression
76080393|NCT00633789|Drug|Placebo|Tablets, Oral, 0 mg, once daily, until progression
75470777|NCT03600818|Drug|Prednisone|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
75470778|NCT03600818|Drug|Prednisone-matching placebo|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
75470779|NCT03600818|Drug|Prednisone|Pharmaceutical form:tablets Route of administration: oral administration
75470780|NCT03578276|Drug|Pred-Gati-Brom|The combination drop therapy containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075%
75924803|NCT02510378|Radiation|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
75470781|NCT03578276|Drug|Prednisolone acetate 1% ophthalmic suspension|Steroidal anti-inflammatory
75470782|NCT03578276|Drug|Gatifloxacin Ophthalmic|Antibiotic
75639847|NCT04616794|Behavioral|Physical Activity Group|Participants in this group will be encouraged to lead a physically active lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase physical activities and by assisting participants outlining goals to progressively adopt a more physically active lifestyle.
75924804|NCT02170935|Drug|BIBR 1048 capsule|
75924805|NCT03345368|Device|rTMS|Patients will be stimulated in the dorso lateral frontal cortex. First, the motor threshold will be determined for each patient. To induce currents to the left primary sensory-motor cortex hand area (M1/S1) the coil will be placed over the scalp oriented at 45 ° from the mid-sagittal plane while subjects will sit comfortably on a chair. The coil will be systematically moved in this area until a contraction of the abductor will be identified. Motor evoked potentials (MEPs). MEPs will be registered with surface electrodes on the left hand abductor pollicis muscle using the same Magstim equipment. Then the parameters will be adjusted for the stimulation as was described before.
75924806|NCT03345368|Device|sham rTMS|As well as the rTMS group, the motor threshold of each patient will be determined. They will experience a similar rTMS session with the difference that they not will be stimulated.
75924807|NCT03345368|Other|Diet|This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
75924808|NCT03488316|Procedure|Carie removal|Carie removal with a low speed handpiece
75924809|NCT03488316|Procedure|Absolute isolation|Absolute isolation with rubber dam
75924810|NCT03488316|Drug|Manipulation of the temporary filling material based on Calcium Hydroxide|Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
75331881|NCT03575962|Drug|GSK3640254 Mesylate Salt Capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
75639848|NCT04616794|Behavioral|Diet Group|Participants in this group will be encouraged to adopt a healthy diet, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to change their diet and by assisting participants outlining goals to progressively adopt a Mediterranean-like diet.
75331882|NCT03019991|Drug|Danoprevir|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
75639849|NCT04616794|Behavioral|Multimodal group|Participants assigned to this group will select which domain they wish to tackle first. Interventions are as described for the single-domain interventions.
75924811|NCT03488316|Drug|Manipulation of the temporary filling material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.
75924812|NCT03488316|Procedure|Material insertion on the root canal|Material insertion on the root canal according to the manufacturer's recommendations
75470783|NCT03578276|Drug|Bromfenac 0.075% Oph Solution|Non-steroidal anti-inflammatory
75470784|NCT03514784|Drug|BB-12 with LGG (Higher Dose)|BB-12 with LGG - Higher Dose (10 billion CFUs)
75639850|NCT05752942|Behavioral|Student Intervention Matching System (SIMS)|"The Student Intervention Matching System (SIMS) is a pre-intervention matching assessment following the behavioral consultation model. The SIMS entails three steps to sequentially assess and then match students' individual characteristics to precise acquisition- or performance-based interventions. The 1st step corresponds to the problem identification stage in behavioral consultation. The 2nd step corresponds to the problem analysis stage of behavioral consultation.The 3rd step of SIMS corresponds to the implementation planning and evaluation stages of behavioral consultation."
75924813|NCT03488316|Procedure|Material re-insertion on the root canal accordging to the infection needs.|Material re-insertion on the root canal according to the manufacturer's recommendations
75924814|NCT03488316|Procedure|Definiteve canal root obturation|Definiteve canal root obturation with gutta-percha and definitive cement.
75924815|NCT03488316|Procedure|Definitve restoration|Definitve restoration confecction.
75924816|NCT03540537|Other|Patient-controlled intravenous analgesia|PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
76080394|NCT01287208|Device|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
76080395|NCT01287208|Device|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
75331883|NCT03019991|Drug|Ritonavir|Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
75331884|NCT03019991|Drug|Placebo|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
75331885|NCT05307835|Biological|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;
75331886|NCT05307835|Biological|GM-CSF|4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses
75331887|NCT00947297|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
75331888|NCT03576118|Drug|Deep neuromuscular block|Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum
75470785|NCT03514784|Drug|Placebo|Maltodextrin
75470786|NCT03514784|Drug|BB-12 with LGG (Lower Dose)|BB-12 with LGG - Lower Dose (1 billion CFUs)
75639851|NCT05752942|Behavioral|group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based intervention (group-based social skills training). We selected group-based social skills training for four reasons: (a) participating schools had already been delivering it as their treatment-as-usual, (b) it is a common intervention in US schools, (c) it is only effective for students with acquisition needs, and (d) it represents a counterfactual contrast to the treatment condition because externalizing behaviors driven by performance needs will be reduced more by performance-based interventions than acquisition-based ones.
75639852|NCT02717481|Device|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
75924817|NCT03540537|Other|Quadratus Lumborum Block|Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
75924818|NCT03540537|Other|Thoracic Paravertebral Block|Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
75924819|NCT02510222|Dietary Supplement|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
75639853|NCT05264727|Drug|Dextrose|Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes
75639854|NCT05264727|Drug|Clinisol 15%|Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
75924820|NCT02510222|Other|Placebo|
75639855|NCT02723097|Behavioral|3 RP|
75924821|NCT02444910|Drug|KDT501|600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
75639856|NCT02722785|Behavioral|Aerobic and Resistance Exercise Training|Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum [1-RM] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
75639857|NCT02722473|Biological|"NSE dosage hypothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
75788650|NCT03769064|Drug|Placebo|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
75788651|NCT03769064|Drug|Methylphenidate 60 mg|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
75924822|NCT04497818|Other|Cross Sectional study using scientifically validated psychometric Scales|Cross Sectional study using scientifically validated psychometric Scales (FEAR OF COVID-19, a 5 item Likert Scale & Modified Dental Anxiety 5 item Likert Scale).
75924823|NCT02167269|Device|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
76080396|NCT00630201|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
75331889|NCT03576118|Drug|Moderate neuromuscular block|Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
75639858|NCT02722473|Biological|"NSE dosage normothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
75788652|NCT03769064|Drug|Treatment Phase Sequence 4213|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
75788653|NCT03769064|Drug|Treatment Phase Sequence 2134|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
75331890|NCT03017417|Other|Exercise Intervention|Various exercise tests
75331891|NCT03017417|Other|standard of care|standard treatment
75331892|NCT03623698|Drug|Nebulised hypertonic saline|Nebulised hypertonic saline used for a period of at least 12 months
75331893|NCT03017183|Procedure|EBUS-TBNA|Endobronchial ultrasound guided transbronchial needle aspiration
75331894|NCT03017183|Procedure|Endobronchial forceps biopsy|Conventional endobronchial forceps biopsy
75331895|NCT03019913|Other|Observational cohort|Evaluation of bedside methods to measure muscularity in critically ill patients
75331896|NCT03019835|Drug|Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery|
75924824|NCT05100264|Other|Vaginal washing with 5% acetic acid|Induction of labor (vaginal tablet dinoprostone and vaginal washing with 5% acetic acid)
75924825|NCT05100264|Other|Vaginal washing with 0.9% NS|Induction of labor (vaginal tablet dinoprostone and vaginal washing 0.9% NS)
75924826|NCT03491358|Device|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
75924827|NCT03491358|Device|Aerogen Solo|Aerogen Ltd., Galway, Ireland
75924828|NCT02167347|Behavioral|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
75924829|NCT02505776|Drug|Bimatoprost cutaneous solution 0.03%|Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
75788654|NCT03769064|Drug|Treatment Phase Sequence 1342|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
75788655|NCT03769064|Drug|Treatment Phase Sequence 3421|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
75924830|NCT03540381|Other|neoatherosclerosis|
75924831|NCT03491124|Other|Auricular Acupuncture|Up to five small ASP needles placed in each ear until pain is reduced to 1/10.
75788656|NCT04129658|Behavioral|Educational outreach visit|Two-four hours of discussion between a cardiologist and the primary care physicians at the PHCC encompassing evidence-based treatment guidelines and counseling upon specific patient cases and their diagnose and treatment for congestive heart failure.
75924832|NCT03491124|Other|Sham Treatment|Laser pointer pointed at the ear, but not turned on.
75924833|NCT02505854|Dietary Supplement|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
75924834|NCT02505854|Dietary Supplement|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
75924835|NCT02505854|Dietary Supplement|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
75924836|NCT02171013|Drug|Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)|
75470787|NCT03506893|Device|Alphapump|"Alfapump® device: a completely internalized medical device, implanted under the skin, which mobilizes ascites from the peritoneal cavity to the bladder where they are eliminated by the urinary tract.~Medical device marked CE, used in the indication provided for marking"
75924837|NCT02171013|Drug|Dabigatran polymorph I|
75470788|NCT03506893|Procedure|Ascites puncture|Hospitalizations for evacuating ascites are performed at least twice a month and can be up to 2 times a week. A clinical and biological examination is carried out at each visit.
75470789|NCT03491267|Drug|Retinoic acid|The study team will treat skin with topical retinoic acid
75470790|NCT03491267|Device|Laser|The study team treat skin with a surface laser.
75788657|NCT00090298|Drug|MK0653A, ezetimibe (+) simvastatin|
75924838|NCT03490890|Other|Microwave ablaton|Patients with pathology verified GGO were treated with MWA.
75924839|NCT02261181|Device|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
75924840|NCT02509832|Device|Cooling + PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
75331897|NCT03019835|Other|Spontaneous recovery|just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
75331898|NCT03628456|Device|International Biophysics AffloVest|High-frequency chest wall oscillation vest
75331899|NCT03628456|Device|Hill-Rom Monarch|High-frequency chest wall oscillation vest
75331900|NCT00955877|Drug|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
75331901|NCT00955877|Drug|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
75470791|NCT03491267|Drug|Sham treatment|No drug will be given
75470792|NCT03491267|Device|Sham treatment|No laser treatment will be given
75470793|NCT03439982|Biological|FMT|FMT processed from routinely screened donors
75639859|NCT02722551|Device|Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve|Replacement of the mitral valve through a transcatheter approach
75639860|NCT02722629|Procedure|FEESST|Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
75639861|NCT00730405|Drug|Albaconazole 100mg|Albaconazole for 36 weeks
75639862|NCT00730405|Drug|Albaconazole 200mg|Albaconazole for 36 weeks
75470794|NCT03384602|Other|Dalcroze Eurhythmics Program|music-based multi-task exercise in group setting
75470795|NCT03384602|Other|home exercise strength program|simple strength exercise program to perform individually at home
75639863|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 36 weeks
75639864|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
75639865|NCT00730405|Drug|Placebo 400 mg|Placebo for 36 weeks
75788658|NCT00090298|Drug|Comparator: Rosuvastatin|
75788659|NCT03771092|Dietary Supplement|SunActive®Fe|SunActive® Fe is a colorless, odorless, tasteless iron fortifier in a powder form. This product is most commonly used to increase the amount of iron in food, beverage, and dietary supplement applications.
75924841|NCT02509832|Device|PCI only|Standard of Care for PCI
76080397|NCT04396197|Other|Physiotherapy|Daily physiotherapy to include respiratory care and rehabilitation based on the individual therapists clinical reasoning
76080398|NCT05241483|Diagnostic Test|mesure valition|Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems
75639866|NCT02722707|Device|magnetic anal sphincter augmentation for fecal incontinence|Surgical placement of HUD called FENIX for female patients that have failed conservative therapy and less invasive therapies or who are not candidates for such therapies
75639867|NCT04129359|Behavioral|FamilieTrivsel|FamilieTrivsel is a modular internet-based low-cost and brief psychoeducation intervention based on the Robusthed (Resilience) programme (RP). Mentalisation approaches are used to increase resilience and ability to handle the challenges of life. The programme is licence free and can be used with low or high intensity and it can be combined with any other interventions. RP provides simple explanations and tools that can be used to discover, understand and regulate one's own thoughts and feelings by activating mental and physical resources and it provides examples and exercises that may promote communication about mental states between parents and the child. The content has been developed to include video-based training sessions based on different stages of pregnancy and early childrearing. RP appears suitable for use in general practice, where the GP sees young parents regularly and thus can direct patients towards components of the programme when need appears greatest.
75470796|NCT03365063|Other|Active Knowledge Translation|"Integration of the KFRE in the CPCSSN DPT - The DPT will report the output from the KFRE for all patients with CKD Stages G3-G5 from the clinic sites. The risk output will include interpretation and automated categorized risk of progression to kidney failure, and will recommend actions based on the KFRE risk based care pathway.~Audit and Feedback - Providers at CPCSSN clinics receive sentinel feedback reports on a panel of chronic conditions and quality improvement targets. The investigators will add CKD to the feedback report for the intervention sites, and provide detailed feedback on the practices' risk profile.~Medical Detailing - The intervention CPCSSN clinics will receive a standardized presentation to clinic staff by the principal investigator, who will provide the evidence for the accuracy of the KFRE and guidance on implementation of a risk based treatment pathway, as well as describe the supporting visual aids."
75639868|NCT04129359|Other|enhanced care as usual|Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice
75639869|NCT02596399|Drug|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
76080399|NCT01288534|Radiation|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
76080400|NCT01925547|Dietary Supplement|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
75639870|NCT02596399|Drug|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
75639871|NCT02722317|Behavioral|psychological support|psychological support was given to men by the service, the researcher didn't interfered in the intervention, just ask questions about it.
75788660|NCT03771092|Dietary Supplement|Lipofer®|Lipofer® is a micronized and microencapsulated source of iron, enhances the bioavailability of iron and does not taste metallic or oxidize unsaturated fats.
75788661|NCT03771092|Dietary Supplement|Intravenous ferric gluconate|Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 - 440,000 daltons on gel chromatography. It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate.
75639872|NCT04088695|Other|Video through a web page|Participants will see a video about blood donation.
75788662|NCT03771326|Biological|Kisspeptin-10|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
75788663|NCT03778034|Other|female with Forward head posture|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
75788664|NCT03778034|Other|healthy female without (FHP)|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
75639873|NCT04088695|Other|Informative text|Participants will see a brief text about blood donation.
75639874|NCT02722161|Drug|[14C]BI 1482694|
75639875|NCT02694237|Behavioral|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
75788665|NCT04026646|Procedure|Proprioceptive Neuromuscular Facilitation stretching exercise|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.It will be applied 3 days in a week for 8 week.
75788666|NCT04026646|Procedure|Static stretching exercise|Static stretching exercises will be applied 2 repetition. Totally 30 seconds stretching for hamstring muscle group will be performed. It will be applied 3 days in a week for 8 week.
75788667|NCT03768908|Drug|Artemether-lumefantrine|Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation
75788668|NCT03768908|Drug|Artesunate + Amodiaquine|Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation
75788669|NCT03777878|Drug|Carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
76080401|NCT01925547|Dietary Supplement|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
76080402|NCT04395807|Device|Helmet CPAP|Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
76080403|NCT04395807|Device|HFNC|Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
76080404|NCT03122301|Drug|Stellate Ganglion Block injection with bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
75924842|NCT02165163|Other|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
75924843|NCT04166214|Other|Imaging using intraoral cameras|The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.
75924844|NCT02510066|Device|Acupuncture|Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.
75924845|NCT02510066|Device|Placebo acupuncture|Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
75924846|NCT02757963|Other|Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool|The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score >=3) and meet all other eligibility requirements will be enrolled in Part I of the study.
75924847|NCT02757963|Other|International Prostate Symptom Score (IPSS) screening tool|The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score >=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
75924848|NCT02509754|Procedure|Atrial fibrillation catheter ablation|
75924849|NCT02509754|Procedure|Rate control|Composite of optimal medical therapy and device implantation
76080405|NCT03122301|Drug|Saline|sham injection with saline
76080406|NCT01920087|Drug|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
75639876|NCT02694237|Behavioral|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
75639877|NCT02694237|Behavioral|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
76080407|NCT01920087|Drug|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
75639878|NCT02594449|Drug|Benzalkonium Chloride Solution|To compare pharmacodynamics among the different concentrations of BCS and NS
75639879|NCT02722083|Drug|Chlorpheniramine maleate (BAY X002134)|4 mg tablet, single dose, orally
75639880|NCT02722083|Drug|Placebo|placebo tablet, single dose, orally
75788670|NCT03777878|Drug|oxytocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
75788671|NCT03777878|Drug|TA|2 ampoules of TA in 100 ml saline by slow infusion
75788672|NCT03777878|Drug|placebo to carbetocin|placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
75788673|NCT03777878|Drug|placebo to TA|2 placebo ampoules to TA in 100 ml saline by slow infusion
75788674|NCT03777878|Drug|placebo to oxytocin|two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
75639881|NCT05257135|Biological|Biological collection|- Blood samples collected at different times: at inclusion and during treatment ( every 6 month)
75639882|NCT02694081|Procedure|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
75639883|NCT02694081|Procedure|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
75639884|NCT02722005|Behavioral|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
75639885|NCT02722005|Behavioral|Access to referral to social services|Access to referral to a host of social services.
75639886|NCT02721927|Other|Syrian Refugees|Adult Syrian patients who visited the Emergency Department
75639887|NCT02721849|Behavioral|Yoga for adolescents|12 week hatha yoga course for adolescents
75639888|NCT02721849|Behavioral|Yoga for parents|12 week hatha yoga course
75639889|NCT02721693|Device|Treadmill exercise test|Patients are subjected to an incremental exercise test to exhaustion on a treadmill
75639890|NCT02721771|Procedure|Ultrasound examination|echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.
75639891|NCT00736645|Dietary Supplement|selenomethionine|Given orally
75639892|NCT00736645|Drug|finasteride|Given orally
75639893|NCT00736645|Other|placebo|Given orally
75331902|NCT00955877|Drug|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
75924850|NCT02167425|Other|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
75924851|NCT02509676|Other|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
75924852|NCT03111732|Biological|Pembrolizumab (MK-3475)|200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle
75924853|NCT03111732|Drug|Oxaliplatin|130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
75331903|NCT03951610|Device|Test lens|contact lens
75639894|NCT02716467|Other|intercessory prayer|Intercessory prayer will be offered by a group of six Christian people.
75639895|NCT02716467|Radiation|Radiotherapy|All participants will receive treatment by radiotherapy
75331904|NCT03951610|Device|Control lens|contact lens
75639896|NCT02716701|Behavioral|Exercise Group|
75639897|NCT02716701|Other|Control Group|
75639898|NCT02716701|Other|wristband activity tracker|
75639899|NCT02716389|Other|Zebris CMS 70|
75788675|NCT01345396|Behavioral|Health education about asthma|Three face-to-face appointments (<20, 36 weeks of gestation and 12 weeks after the baby birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
75924854|NCT03111732|Drug|Capecitabine|750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
75924855|NCT01663714|Biological|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
75331905|NCT04332328|Dietary Supplement|Diet|Group of diet types
75331906|NCT03960658|Drug|ketamine-enhanced prolonged exposure|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
75331907|NCT00422890|Drug|5-Azacytidin|in case of decreasing CD34 chimerism
75331908|NCT04580290|Device|JewelACL|The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction
75331909|NCT04617574|Device|AEON Endostapler|Surgery with AEON Endostapler
75331910|NCT04617574|Device|Endo GIA Reloads with Tri-Staple Technology|Surgery with Endo GIA Reloads with Tri-Staple Technology
75639900|NCT02716389|Other|3-D Bulls Eye Spirit Meter|
75639901|NCT00736489|Drug|AZD3199|Dry powder for inhalation, single dose
75639902|NCT00736489|Drug|Formoterol|Dry powder for inhalation, single dose
75639903|NCT00736489|Drug|Placebo|Dry powder for inhalation, single dose
75639904|NCT02318355|Other|normal saline|Crystalloid intravenous solution
75639905|NCT02318355|Other|lactated ringers|Crystalloid intravenous solution
75639906|NCT04964973|Device|Control|Post-surgical physiotherapeutic activity.
75639907|NCT04964973|Device|Experimental|Post-surgical physiotherapeutic activity with the application of the technique
75639908|NCT04964973|Device|Placebo|Post-surgical physiotherapeutic activity with the application of the non-activated technique
75639909|NCT02288637|Other|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
75639910|NCT02288637|Other|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
75639911|NCT02288637|Other|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
75788676|NCT04008004|Drug|EDP-514|Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
75788677|NCT04008004|Drug|Placebo|Placebo to match EDP-514
75788678|NCT03620344|Other|ADH-Me Book and ADHD Informational Brochure|"Understanding ADHD information brochure published by American Academy of Pediatrics and a children's book about ADHD condition"
75788679|NCT03620344|Other|ADHD Informational Brochure Only|"Understanding ADHD information brochure published by American Academy of Pediatrics"
75788680|NCT03707912|Drug|Anaferon|Oral administration.
75788681|NCT03707912|Drug|Placebo|Oral administration.
75788682|NCT03246958|Drug|Nivolumab|Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
75924856|NCT02165319|Device|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
75924857|NCT02165319|Device|Tapered|Tapered-shaped tube will be used during general anesthesia.
75788683|NCT03246958|Drug|Ipilimumab|Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
75788684|NCT03157960|Other|Blueberry drink|Participant receive blueberry drink
75788685|NCT03157960|Other|Blueberry and pizza|Participant receive blueberry drink and a slice of pizza
75788686|NCT03157960|Other|Soft beverage|Participant receive a soft beverage drink
75788687|NCT03157960|Other|Soft beverage and pizza|Participant receive a soft beverage drink and a slice of pizza
75788688|NCT03157960|Other|Fructose|Participant receive a drink containing fructose
75924858|NCT02505308|Other|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
75924859|NCT02941146|Device|The ZELTIQ System|The CoolSculpting System will be used to perform the treatments with the CoolAdvantage family of applicators.
75924860|NCT02515136|Behavioral|Stimulus-response|See summary
75924861|NCT02514902|Device|Lateral Flow Device|A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
75639912|NCT02069925|Behavioral|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
75639913|NCT02069925|Behavioral|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
75639914|NCT02716233|Drug|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
75639915|NCT02716233|Drug|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
75639916|NCT02047929|Other|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
75639917|NCT00730327|Device|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
75788689|NCT03157960|Other|Fructose and pizza|Participant receive a fructose drink and a slice of pizza
75924862|NCT05510752|Behavioral|Cognitive Behavioural Group Therapy|CBGT is a 6-week group that meets weekly for 2-hours per week, where participants learn cognitive and behavioural techniques to enhance coping skills for their everyday anxieties.
75924863|NCT05510752|Behavioral|Psychoeducation|Psychoeducation is the most common non-pharmacological treatment for perinatal distress, where participants learn about healthy infant milestones and how to implement self-care in their daily lives, which in turn reduces distress during the perinatal period.
76080408|NCT01920243|Behavioral|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
76080409|NCT01925859|Drug|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
75788690|NCT01321268|Dietary Supplement|dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)|oral, twice daily in morning and evening for 6 months
75788691|NCT01321268|Dietary Supplement|Viatmin E|oral, twice daily in morning and evening for 6 months
75924864|NCT03490578|Device|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.
75924865|NCT03490578|Device|Intensive treadmill training|Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
75788692|NCT03768830|Behavioral|Exercise training|Exercise program includes breathing and upper and lower limbs exercise.
75788693|NCT03988270|Other|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
75788694|NCT02883244|Device|Soft-Picks Advanced|Soft-picks Advanced will be used once a day to clean interdental sites at home.
75788695|NCT02883244|Device|Floss|Floss will be used once a day to clean interdental sites at home.
75788696|NCT05162066|Drug|BCX9930|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
75788697|NCT01335958|Drug|DMUC5754A|Escalating intravenous dose
75924866|NCT02255487|Device|IrriSept System|"The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.~Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation."
75639918|NCT00730327|Other|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
76080410|NCT04347837|Device|Titan SGS stapler|Stapler for the longitudinal resection of the stomach
76080411|NCT01920321|Procedure|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
76080412|NCT03435627|Drug|Somatropin|Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.
76080413|NCT01920399|Drug|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
76080414|NCT01920399|Drug|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
76080415|NCT01926171|Drug|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
76080416|NCT01926327|Biological|PRP injection|Injection of PRP in patients with knee osteoarthritis.
76080417|NCT01926327|Biological|Placebo|
75639919|NCT01999569|Drug|Letrozole|Letrozole administered daily through the time of ovulation.
75639920|NCT02716077|Radiation|FDG PET/CT imaging|
75788698|NCT03768674|Other|Assessment of diagnoses, functioning and health services|Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services
75788699|NCT01561274|Drug|2 ml bupivacaine|2 ml bupivacaine
75788700|NCT01561274|Drug|1.5 ml bupivicaine.|1.5 ml bupivicaine.
76080418|NCT03092037|Procedure|Blood draw|The Investigators will collect serum and whole blood from participants.
75788701|NCT02882854|Drug|Guanfacine|Patients will receive 1 mg of guanfacine to take orally.
75639921|NCT04087915|Drug|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
75639922|NCT04078035|Behavioral|Socio-evaluative speech task|5-minute speech task designed to induce physiological arousal in a laboratory setting.
75639923|NCT04078035|Behavioral|Control, Quiet Rest|5-minute quiet rest period.
75639924|NCT02715843|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
75639925|NCT02715921|Other|Tele-exercise|
75788702|NCT02882854|Drug|Placebo|Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
75788703|NCT04469348|Diagnostic Test|nasal swab|nasal swab will be performed to analysis biological markers at every visit.
75924867|NCT02255487|Other|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) as surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
75924868|NCT02505386|Drug|Ertapenem|
75788704|NCT03707522|Behavioral|Growth mindset|10 minute interactive article describing neuroplasticity
75788705|NCT03707522|Behavioral|Modifiable risk factor (MRF) information|10 minute interactive article describing modifiable risk factors for depression and anxiety
75788706|NCT03707522|Behavioral|Control|10 minute interactive article describing activity scheduling
75788707|NCT03770936|Drug|Candesartan|Candesartan 8 mg/day
75788708|NCT03770936|Drug|Ramipril|ramipril 1.25 mg/day
75924869|NCT03488160|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
76080419|NCT05247723|Device|Standard IV Cannula for aspiration of testicular sperm|After local anesthesia, a wide bore 14-G standard IV cannula was introduced near the lower pole of the testis. The needle was withdrawn and the catheter introduced into the testicular tissue. A 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. Back and forth motions were performed covering as many areas of the testis as possible.
76080420|NCT05247723|Procedure|Micro-TESE|Conventional Microscopic Testicular Sperm Extraction (Micro-TESE), Open Testicular Biopsy using surgical Microscope
76080421|NCT01926405|Procedure|saliva collection|collection of saliva
76080422|NCT01920945|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
76080423|NCT01926483|Other|Neoadjuvant Chemoradiotherapy|Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
76080424|NCT01926639|Biological|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
76080425|NCT01921413|Device|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
76080426|NCT01926795|Procedure|Short leg cast|
76080427|NCT01926795|Procedure|No Immobilization|
75639926|NCT02715687|Drug|Amiodarone|Will receive 30 days treatment with oral amniodarone of 200mg
75639927|NCT02715687|Drug|Placebo|Will receive 30 days treatment with oral placebo of 200mg
75639928|NCT00742417|Biological|Albutein 5%|"18 Plasma Exchanges using Albutein 5%:~three weeks of intensive treatment with two plasma exchanges per week~six weeks of maintenance treatment with one weekly plasma exchange~three months of maintenance treatment with one plasma exchange every two weeks"
76080428|NCT02199496|Biological|Stelara (ustekinumab)|"In the single-phase part of the study, subjects receive a single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit.~In the multi-phase part of the study, subjects receive single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit with follow up dose of Stelara (ustekinumab) 90 mg subcutaneously at Week 8, Week 16, Week 24, Week 32 and Week 40"
76080429|NCT04395417|Drug|Hyaluronic Acid|Patients were infiltrated with injection single dose 30 mg/2 ml 1500 kilodalton high molecular weight hyaluronic acid at the lateral epicondyle according to the standard technique.
75639929|NCT00742417|Other|Control|Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
75639930|NCT00917995|Device|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
75639931|NCT04859517|Drug|ADG20|Single dose of ADG20
75639932|NCT04859517|Drug|Placebo|Single dose of placebo
75639933|NCT02715999|Procedure|Quadratus Lumborum Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
75639934|NCT02715999|Procedure|Transversus Abdominis Plane Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
75639935|NCT01798173|Biological|Serum, plasma and DNA samples|
75639936|NCT01798173|Procedure|Radiological exploration by CT scan or MRI|
75788709|NCT03150082|Drug|GR37547 tablet|"A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side."
75788710|NCT03150082|Drug|Ciprofloxacin reference tablet|"A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side."
75788711|NCT01321346|Drug|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
75788712|NCT01321346|Drug|Cytarabine|"All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.~All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation."
75788713|NCT01321346|Drug|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
75788714|NCT02600182|Device|Bilevel Positive Airway Pressure|Bilevel positive airway pressure twice per day during the hospital stay.
75788715|NCT02118610|Drug|L-tetrahydropalmatine (30mg)|Active comparator
75788716|NCT02118610|Drug|Sugar pill|Placebo
75788717|NCT01561742|Drug|Minocycline|Minocycline will be given orally at 200 mg a day for 4 months
75788718|NCT01561742|Drug|Placebo|EquivalentPlacebo will be given
75924870|NCT02509364|Other|No intervention|
75924871|NCT05507086|Other|Antimicrobial therapy|Antimicrobial therapy
75924872|NCT04984668|Drug|GT90001+KN046|GT90001 7.0mg/Kg， KN046 5mg/Kg
75331911|NCT01005407|Biological|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
75639937|NCT02715531|Drug|5-FU|5-FU (400 mg/m^2) will be administered as an IV bolus, followed by 2400 mg/m^2 by continuous IV infusion over 46 (± 1) hours, q2w.
75639938|NCT02715531|Drug|Atezolizumab|Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group E2, and Arm F) or 840 mg q2w (Arm B, Arm C, and Groups E1 and E3).
75639939|NCT02715531|Drug|Bevacizumab|Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group F1) or 10 mg/kg q2w (Arm B).
75788719|NCT03770702|Drug|Angiotensin receptor blockers|Candesartan
75788720|NCT03770702|Drug|Statins|Atorvastatin
75788721|NCT03768596|Behavioral|Nudge|Influenza Vaccine Prescription Form accompanied on the back of telephone numbers of occupational health centers of different hospitals where interns are likely to be on probation.
75788722|NCT03768596|Other|vaccination form|a form about vaccination
75924873|NCT04984668|Drug|GT90001+KN046|GT90001 7.0mg/Kg ， KN046 3mg/Kg
75924874|NCT04984668|Drug|GT90001/KN046|GT90001 4.5mg/Kg / KN046 5mg/Kg
75924875|NCT04984668|Drug|GT90001+KN046|GT90001 4.5mg/Kg， KN046 3mg/Kg
75924876|NCT04984668|Drug|GT90001+KN046|GT90001 3mg/Kg ， KN046 3mg/Kg
75924877|NCT02514980|Drug|Bupivacaine|Infraorbital nerve block using bupivacaine 0.25% on each side.
75924878|NCT02514980|Drug|Ketamine|Infraorbital nerve block using 0.5mg/kg ketamine on each side.
75924879|NCT03344588|Procedure|artery preserving varicocelectomy|During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
76080430|NCT04395417|Biological|Prolotherapy|Patients were infiltrated with 5cc of dextrose 15% at the lateral epicondyle according to the standard technique. For solution, 1 cc 2% lidocaine, 5 cc 30% hypertonic dextrose and 4 cc 0.9 % isotonic were used.
75924880|NCT03344588|Procedure|artery ligation varicocelectomy|During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
75639940|NCT02715531|Drug|Gemcitabine|Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
75639941|NCT02715531|Drug|Leucovorin|Leucovorin 200 mg/m^2 L-isomer form or 400 mg/m^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
75639942|NCT02715531|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
75639943|NCT02715531|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 will be administered IV over 120 (± 5) minutes q2w.
75639944|NCT02715531|Drug|Capecitabine|Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m^2) twice daily on Days 1-4 of a 21-day cycle.
75924881|NCT04412044|Drug|Mepolizumab Injection [Nucala]|Patients receive monthly injection with 100 mg mepolizumab
75924882|NCT02165475|Behavioral|Biofeedback|
75924883|NCT02165475|Drug|Loperamide|
76080431|NCT02199574|Drug|EXPAREL|133 mg EXPAREL in 10 mL.
75331912|NCT01005407|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
75639945|NCT02715531|Drug|Cisplatin|Cisplatin will be administered as 80 mg/m^2 IV over 120 minutes q3w (Group E2).
75639946|NCT02715453|Other|Intervention on frailty|"Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):~Nutritional evaluation and intervention after randomization and regularly during follow-up~Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year~Psychiatrist or psychologist assistance for 1 year after discharge"
75924884|NCT02165475|Drug|Stool bulking agent (stericulia or isphagula husk)|
75924885|NCT02165475|Other|Combination of biofeedback and medical treatment|
75924886|NCT03345212|Other|Exercise training|The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
75639947|NCT00811018|Drug|Sitaxsentan|Sitaxsentan 100 mg tablets once daily
75639948|NCT02715297|Radiation|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
75639949|NCT02715063|Behavioral|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
75924887|NCT04862338|Dietary Supplement|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
76080432|NCT03088527|Drug|RAD140|RAD140 will be supplied as formulated drug-in-capsules for oral administration.
75331913|NCT03633448|Drug|Children's Mucinex® Grape Flavor|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
75331914|NCT03633448|Drug|Children's Mucinex® Grape Flavor|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
75331915|NCT05313958|Drug|Cladribine|5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
75331916|NCT05313958|Drug|G-CSF|5ug/kg/day d0-5,if Peripheral blood leukocytes<20,000/ul
75331917|NCT05313958|Drug|Cytarabine|2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
75639950|NCT02715063|Behavioral|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
75639951|NCT02715063|Behavioral|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
75639952|NCT02715063|Other|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
75639953|NCT04037085|Drug|Ketamine|Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
75639954|NCT00914056|Drug|lactulose|withdrawal of lactulose
75788723|NCT01345708|Drug|prednisone, low dose rituximab|"Patients with warm AIHA will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)~Patients with CHD will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)"
75788724|NCT04332224|Device|Blanketrol cooling device and water-perfused blankets|Blanketrol and water-perfused blankets
75788725|NCT04332224|Device|Blanketrol and Kool Kit|Blanketrol cooling device with water-perfused vest, hood and lower body blanket
75788726|NCT04332224|Device|Arctic Sun|Arctic Sun cooling device with gel cooling pads
75788727|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
75924888|NCT02171325|Drug|irinotecan|60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
76080433|NCT01926951|Device|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
76080434|NCT02199652|Drug|Prazosin|
76080435|NCT02199652|Drug|Placebo|
75639955|NCT02715219|Other|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
75639956|NCT02714907|Device|Cortrium C3 device|Data is read from Cortrium C3 monitor
75639957|NCT02714907|Device|Holter device|Date is read from Holter device
75639958|NCT02714673|Drug|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
75639959|NCT00730171|Drug|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
75639960|NCT04787835|Procedure|Forearm nerve block|Local anesthesia will be used to perform a forearm block of the median, radial, and ulnar nerves.
75639961|NCT04787835|Procedure|Local anesthetic infiltration|Local anesthesia will be infiltrated at the site of injury
75788728|NCT01345864|Drug|Scopolamine + Donepezil 5 mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 5 mg tablet orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
75788729|NCT01345864|Drug|Scopolamine + Donepezil 10mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 10 mg (2 x 5 mg tablets) orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
75788730|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 0.25 mg oral liquid x 1 dose on Day 1
75788731|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 15 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 15 mg oral liquid x 1 dose on day 1
75788732|NCT04320602|Biological|Eculizumab|Participants must have been prescribed and be receiving a stable dose of eculizumab 1200 milligrams (mg) every 2 weeks (q2w) for at least 3 months prior to the Screening Period. During the Screening Period, participants will continue to receive eculizumab 1200 mg q2w.
75788733|NCT04320602|Biological|Ravulizumab|During the Treatment Period, participants will receive a loading dose of ravulizumab on Day 1, followed by maintenance doses on Day 15 and every 8 weeks, administered by intravenous infusion. Ravulizumab loading and maintenance doses will be based on participants' body weight per approved dose regimen.
75788734|NCT03948022|Drug|Dydrogesterone 10Mg Tablet (duphaston)|40 mg daily oral tablets
75788735|NCT03948022|Drug|Progesterone 50Mg/mL Oil|100 mg daily intramuscular injections
75788736|NCT03948022|Drug|Crinone 8% Vaginal Gel|180 mg daily vaginal gels
75788737|NCT03777644|Procedure|Continuous Paravertebral block with ropivacaine|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose ropivacaine 0.5%ropivacaine with 1:200,000 adrenaline, 25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of ropivacaine 0.2% ropivacaine, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg"
75788738|NCT03777644|Procedure|Continuous Paravertebral Block with Saline|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose saline,25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of saline 0.9% saline, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose"
75788739|NCT03777644|Drug|Patient-controlled analgesia with morphine|Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg
75788740|NCT04345666|Drug|Testosterone cypionate|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
76080436|NCT05241561|Drug|Cabozantinib|"Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety.~At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile."
76080437|NCT05241561|Biological|Blood sample|biomonitoring and pharmacokinetics
75639962|NCT02714751|Behavioral|Daily asynchronies information|
75639963|NCT02714829|Device|Inject BMP|Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.
75639964|NCT02714829|Device|ExcelOS-inject|Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
75639965|NCT02593981|Dietary Supplement|Fruit/Honey drink|2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
75331918|NCT05313958|Drug|Idarubicin|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
75639966|NCT02593981|Dietary Supplement|Placebo|2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
75639967|NCT00730015|Drug|Matching Placebo|Oral, once daily
75639968|NCT00730015|Drug|Linaclotide|Oral, once daily
76080438|NCT05241561|Other|Questionnaires of quality of life|FKSI-19 and FKSI-DRS and EUROQOL EQ-5D-5L
76080439|NCT03009916|Drug|"cholestagel® (Colesevelam)"|3750mg
76080440|NCT03009916|Drug|Placebos|3750mg
75331919|NCT05313958|Drug|Mitoxantrone|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
75331920|NCT05313958|Drug|Sorafenib|200mg/m2/day was taken orally until molecular biology remission for 2 years
75639969|NCT00806026|Drug|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
75331921|NCT01006655|Drug|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
75639970|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
75639971|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
75924889|NCT03344432|Diagnostic Test|with intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
76080441|NCT01921491|Procedure|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
75639972|NCT00806026|Drug|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
75639973|NCT00806026|Drug|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
75639974|NCT00806026|Drug|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
75639975|NCT04026165|Drug|SEL|Tablet administered orally once daily
75639976|NCT04026165|Drug|Placebo|Tablet administered orally once daily
75788741|NCT04345666|Drug|Placebos|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
75788742|NCT03770624|Drug|QL-007 tablet|QL-007 will be administered orally daily over the 28 days under fasted state.
75788743|NCT03770624|Drug|TDF|TDF will be administered orally daily over the 28 days e.
75788744|NCT01336192|Drug|Gemcitabine|Gemcitabine 1250mg/m^2 Day 1 and 8, 28 days per cycle until PD
75788745|NCT01336192|Drug|Best supportive care|Best supportive care
75788746|NCT01567592|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
75788747|NCT01909570|Procedure|Elective single embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.
75788748|NCT01909570|Procedure|Double embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
75788749|NCT04607200|Drug|AGEN2034|Anti-PD-1 Monoclonal Antibody
75788750|NCT04607200|Drug|AGEN1884|Anti-CTLA-4 Monoclonal Antibody
75788751|NCT03770156|Behavioral|Questionnaires|Overall Impression of the current state and evolution since the attacks
75924890|NCT03344432|Diagnostic Test|without intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
75924891|NCT01663636|Behavioral|SMS message reminding mothers to come for their scheduled vaccines|Reminder
75924892|NCT02509286|Drug|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
75331922|NCT01006655|Drug|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
75331923|NCT01006967|Device|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
75331924|NCT01006967|Other|Physical Therapy|Standard program of physical therapy for gait and balance
75331925|NCT03633526|Drug|VX-659/TEZ/IVA|VX-659/TEZ/IVA FDC tablet.
75331926|NCT03633526|Drug|IVA|IVA mono tablet.
75639977|NCT04227093|Drug|Acetazolamide|Oral acetazolamide tablets of 250 mg taken twice daily.
75639978|NCT04227093|Drug|Placebo|Matching placebo tablets taken twice daily.
75639979|NCT02714517|Other|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
75639980|NCT02714517|Other|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
75639981|NCT00805792|Drug|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
75639982|NCT02714127|Other|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
75639983|NCT02714127|Other|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
75639984|NCT04020250|Device|Echocardiography|"Echocardiographic parameters:~Tricuspid annulus plane systolic excursion (TAPSE) Tricuspid regurgitation peak gradient (TRPG)"
75639985|NCT04777929|Other|test Phthalates, estrogen and progesterone|test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
75639986|NCT04764591|Other|Lateral sagittal approach|Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block
75788752|NCT03770234|Drug|Transtec 35 µg/hour transdermal patch|Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
75788753|NCT01336270|Other|biological collection|to collect some human cell samples in melanoma
76080442|NCT01921491|Device|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
76080443|NCT01921569|Behavioral|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
76080444|NCT01921569|Other|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
76080445|NCT01921569|Other|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
75924893|NCT02509286|Drug|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
75924894|NCT02509286|Drug|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
76080446|NCT01289080|Drug|OPC-34712|administered orally
76080447|NCT01927029|Drug|Progesterone|Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
76080448|NCT01927029|Drug|Placebo|
76080449|NCT01921647|Drug|YH4808|
76080450|NCT01921647|Drug|Nexium|
75331927|NCT03017027|Behavioral|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
75331928|NCT03017027|Behavioral|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
75331929|NCT03016949|Biological|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
75788754|NCT01336348|Drug|Prasugrel|60 mg loading dose given orally at presentation
75788755|NCT01336348|Drug|Tirofiban|Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
75788756|NCT01345942|Drug|RO5428029|Single oral dose
75639987|NCT04764591|Other|Costoclavicular approach|Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
75639988|NCT00590044|Drug|insulin glargine+ glulisine|Daily insulin glargine + glulisine before meals
75639989|NCT00590044|Drug|NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
75639990|NCT04227015|Drug|CTA101|CTA101 UCAR-T cell injection by intravenous infusion
75639991|NCT02714361|Dietary Supplement|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
75639992|NCT02714361|Other|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
75639993|NCT04741581|Dietary Supplement|ThickenUp® Gel Express|Thickening gel
75788757|NCT01346098|Procedure|Pancreaticoduodenectomy with pancreatic anastomosis|Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia
75788758|NCT01346098|Procedure|Total pancreatectomy with islet autotransplantation|If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
75788759|NCT04328818|Diagnostic Test|indwelling device biofilm identification|performance of the NGS-based identification technique in comparison with the conventional culture-based one, for the same indwelling device biofilm sample
75924895|NCT02509286|Drug|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
75924896|NCT02509286|Drug|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
75924897|NCT02509286|Drug|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
75924898|NCT02509286|Radiation|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
75924899|NCT02165553|Dietary Supplement|Hibiscus sabdariffa calyces extract as a cold drink|
75924900|NCT03065244|Drug|IVIG|Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
75924901|NCT03065244|Drug|Infliximab|Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
76080451|NCT01921647|Drug|Amoxicillin|
76080452|NCT01921647|Drug|clarithromycin|
76080453|NCT01246258|Other|Vestibular evoked myogenic potentials (VEMPs)|Standard test of balance function
76080454|NCT01246258|Other|Utricular centrifugation test|Standard test of balance function
76080455|NCT01927107|Dietary Supplement|Probiotics mixture|Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
76080456|NCT03087591|Other|Laboratory Biomarker Analysis|Correlative studies
76080457|NCT03087591|Biological|siRNA-transfected Peripheral Blood Mononuclear Cells APN401|Given IV
76080458|NCT03087357|Other|SmartNIPT|A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
75639994|NCT02778321|Device|Uses of SpiderFlash monitor|"Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~The data collected :~Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)~Data on the CI:~Monitoring Results scope ICU Neurovascular.~Presence palpitations~Treatment influencing the rate (beta-blockers or antiarrhythmic)~Data on cardiac monitoring:~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist"
75924902|NCT05502484|Behavioral|Integrative Dialectical Behavioural Therapy (DBT)|8 weeks outpatient pre-treatment DBT followed by integrative, inpatient DBT of 40 weeks, using standard DBT, augmented with an experience-oriented, body-oriented skills training based on DBT-principles by trained DBT-therapists, and a follow-up phase of 12 weeks outpatient aftercare (maximal 8 sessions individual DBT and 4 booster sessions) and 12 weeks no DBT. The inpatient treatment takes place in a living environment that is based on the principles of DBT and takes into account several aspects of autism.
75639995|NCT05069649|Drug|Ergoferon|Tablet for oral use.
75639996|NCT05069649|Drug|Placebo|Tablet for oral use.
75639997|NCT02778087|Behavioral|Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.
75639998|NCT02778087|Behavioral|Sham Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
75639999|NCT02778243|Biological|steroids concentrations determination|
75640000|NCT02713971|Device|Gamepad system|Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
76080459|NCT01339858|Drug|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
75788760|NCT01346254|Drug|Vildagliptin|50mg tablets once daily 20 min before breakfast for 3 months
75924903|NCT02171481|Drug|Dabigatran etexilate polymorph II|
75331930|NCT03016949|Biological|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
75331931|NCT04502056|Behavioral|Acknowledgement Racial Injustice AMA|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
75331932|NCT04502056|Behavioral|African American Sender Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
75331933|NCT04502056|Behavioral|African American Sender in Informational Videos.|Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
75331934|NCT04502056|Behavioral|Racial Inequality Highlighted|Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
75788761|NCT01346254|Drug|Pioglitazone|30mg tablets once daily 20 min before breakfast for 3 months
75788762|NCT01346254|Behavioral|Life-Style Modification|All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
75788763|NCT03142750|Device|Gastrostomy tube dressing|Two types of dressings to secure gastrostomy tube in children
75788764|NCT04592536|Drug|CVL-865 High dose|High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)
75924904|NCT02171481|Drug|Dabigatran etexilate polymorph I|
75924905|NCT02171559|Drug|Enoxaparin prefilled syringes|
75924906|NCT02171559|Drug|Dabigatran etexilate capsules|
75924907|NCT02165709|Procedure|Salpingectomy|
75924908|NCT02165709|Procedure|Traditional sterilization|
76080460|NCT01339858|Other|sugar pill|matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
75924909|NCT02964780|Procedure|Gastric bypass surgery|
75924910|NCT02964780|Behavioral|Conservative weight loss program|
75924911|NCT03343808|Procedure|cooled radiofrequency ablation of genicular nerves|Cooled RF consists of creating an injury in the nerve trough a high frequency flow. Unlike conventional RF, in cooled RF through a closed circuit where intravenous flows, we can create an injury for a longer period of time, at a lower temperature (standard RFA 90º C, cooled RFA 60º C) and within an area 8 times larger. As the lesion is spherical, and larger (about 10-12 mm in diameter), the chances of neurolysis of the nerve increase.
75924912|NCT04901754|Drug|Camrelizumab Plus Apatinib|"-Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.~Other Name: SHR-1210~-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD."
75788765|NCT04592536|Drug|Alprazolam 1mg XR|Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)
75924913|NCT03343730|Diagnostic Test|Non-mydriatic color fundus photography with the RetinaVue camera|This hand-held device allows the primary care physician to capture an image of the patient's retina and transmit the image to a board-certified ophthalmologist for interpretation.
75788766|NCT04592536|Drug|Placebo|Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
75924914|NCT03343730|Diagnostic Test|Referral for dilated eye exam with an eye care professional|All patients will be given a referral to an eye care professional for a routine, dilated, diabetic eye exam.
75640001|NCT02713971|Other|Conventional physiotherapy|A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
75788767|NCT04592536|Drug|CVL-865 low dose|Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)
76080461|NCT03831555|Behavioral|PREP-C|"The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:~Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment~Information: knowledge about HCV treatment and one's own HCV disease status~Medication Adherence: current prescribed medications and adherence to them in the prior month~Self-efficacy: self-confidence about adhering to HCV treatment~Social Support and Stability: stability of financial, housing, and social support resources~Alcohol and substance use: alcohol and substance use behaviors and current treatment~Psychiatric Stability: current psychiatric status, previous and current treatment~Energy Level: sleep and fatigue~Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory."
76080462|NCT03087123|Behavioral|P-Mobile App|The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
76080463|NCT04275453|Drug|FDG|FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.
76080464|NCT04275453|Dietary Supplement|Ketone Drink|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants
76080465|NCT04275453|Other|Ketogenetic Diet|Subjects needs to be on Ketogenetic diet
75640002|NCT02778009|Radiation|iDEXA Scan|Subjects will receive pre study and post study scans to assess body mass composition
75640003|NCT02778009|Other|Wellness Lectures|Subjects in the Fit Physician Arm will be required to attend monthly wellness lectures
76080466|NCT01339936|Device|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
75788768|NCT01346332|Device|Iontophoresis System with Headset|Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
75924915|NCT04499378|Diagnostic Test|Lung CT|Computed tomography of the thorax
75924916|NCT02514590|Device|Freedom SCS System|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 Hz therapy.
75924917|NCT02509208|Device|SurgiClot haemostatic dressing|haemostatic dressing
76080467|NCT05248425|Other|Nurse Monitoring|Questionnaire responses that indicate new or worsening symptoms will be monitored by a study nurse who will contact the participant for clinical assessment and develop a management plan following irAEs management guidelines.
75640004|NCT02778009|Other|Exercise intervention|Subjects in the Fit Physician Arm will be required to attend weekly exercise interventions
75924918|NCT02505620|Procedure|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
75924919|NCT02505620|Procedure|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
75788769|NCT04544488|Procedure|Recording of expulsive efforts by connection of a pressure sensor to the women's bladder probe|"Using a pressure probe connected to a Foley Catheter, intra bladder pressure wille be registered during the whole duration of expulsive phase.~The device will be inserted into women's bladder using usual guidelines for insertion of Foley catheter"
75788770|NCT01336582|Drug|taxotere|70 mg/m2 for age of ≥ 65
75788771|NCT01346566|Device|Cionni Modified Capsule Tension Ring|Cionni ring was used to fixate the capsular bag to the sclera and IOL was implanted in-the-bag
75924920|NCT02505152|Procedure|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
75640005|NCT02778009|Other|Activity monitor|Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
75640006|NCT00248703|Drug|Docetaxel|Docetaxel 100 mg/m2 3 qw x 6
75640007|NCT02713893|Drug|Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream|
75924921|NCT02514356|Behavioral|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
76080468|NCT05246865|Drug|oral androgen challenge with dehydroepiandrosterone (DHEA)|The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.
76080469|NCT01289392|Device|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
76080470|NCT01289392|Device|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
76080471|NCT01289392|Behavioral|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
76080472|NCT01921725|Device|hydrophilic-based dressing (KoCarbonTM)|"BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes."
76080473|NCT03111537|Other|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
76080474|NCT03111537|Other|E-Cigarette|Use of E-cigarette: multiple flavors offered.
76080475|NCT03111537|Other|Nicotine Gum or Lozenge|Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
75640008|NCT02713893|Drug|Placebo plus Econazole nitrate 1% intravaginal cream|
75640009|NCT02713893|Drug|Placebo plus Benzydamine HCl 0.12% intravaginal cream|
75640010|NCT02713893|Drug|Placebo intravaginal cream|
75640011|NCT02713737|Device|heated humidified high-flow nasal cannula|HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) > 92%.
75640012|NCT02713737|Device|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 > 92%.
75640013|NCT00805480|Drug|AIN457|AIN457 was administered intravenously.
75470797|NCT03338504|Diagnostic Test|Invasive coronary angiography|Where patients are fit, coronary angiography will be performed via the femoral or radial artery with 6F arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, Minnesota) will be used to determine distal coronary pressure and the fractional flow reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) hyperaemia. Optical coherence tomography (OCT) will be performed in all three coronary vessels using a Dragonfly® coronary imaging catheter (Abbott Diagnostics, Abbott Park, Illinois) with pullback at 20 mm/s to identify features consistent with vulnerable plaque or recent plaque rupture.(16) If there is evidence of inducible myocardial ischaemia due to coronary artery stenosis, revascularisation with percutaneous coronary intervention may be considered if in the patients best interests.
75640014|NCT00805480|Drug|Placebo|Matching placebo to AIN457 was administered intravenously.
75640015|NCT02713815|Radiation|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
75640016|NCT02713815|Radiation|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
75640017|NCT02777853|Dietary Supplement|Green tea|The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
75640018|NCT02777853|Dietary Supplement|Placebo tea|A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
75640019|NCT02713581|Biological|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
75640020|NCT05030103|Device|Reading glasses, +2.0 diopters|The participants in the glasses-group are asked to wear the reading glasses during near-work.
75788772|NCT03149848|Drug|Cabotegravir|It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
75788773|NCT03149848|Drug|Rifabutin|It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
75788774|NCT01346644|Other|Infant formula|Powder infant formula
75788775|NCT01346644|Other|Infant formula|Powder infant formula
75924922|NCT02514356|Behavioral|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
75924923|NCT02504996|Drug|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
75924924|NCT02504996|Drug|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
75924925|NCT02504996|Drug|Placebo|Intravenous 100 ml normal saline
75924926|NCT02508818|Other|Parabolic flight|
75640021|NCT02777775|Procedure|Skin Biopsy|"The procedure to sample the cutaneous neurofibroma involves a skin incision and will take approximately 10 to 15 minutes. The tissue will be taken in the following way:~The skin area will be cleaned~The skin area will be numbed (by either a numbing cream or a tiny numbing shot)~Cutaneous (skin) Neurofibroma: will be taken via a small incision and removal of the neurofibroma whenever possible.~A small piece of normal (skin) tissue will be numbed as above and taken using a special skin biopsy device.~Afterward, the area will be cleaned and the skin put back together with medical super glue or 1 to 2 dissolvable stitches that will dissolve as the incision heals, they do not require removal. The purpose of taking this piece of skin is to compare normal skin with the skin of a cutaneous neurofibroma."
75924927|NCT02508818|Other|Cardiovascular measurements|
75470798|NCT03338504|Radiation|CT coronary angiography|CT coronary angiography will be performed using a 128 multidetector row CT. Patients with a heart rate exceeding 65 beats/min will receive oral beta-blockade 1 hour before computed tomography. Additional intravenous beta blockers will be given depending on heart rate at the time of imaging. All patients will receive sublingual glyceryl trinitrate (300 μg) immediately prior to dual cardiac and respiratory-gated computed tomography imaging of the coronary arteries. The investigators will quantify total plaque burden using CT calcium scoring. A bolus of 80-100 mL of contrast will be injected intravenously at 5 mL/s. An assessment of the functional consequences of coronary artery stenosis will be made using the computed tomography fractional flow reserve (CT-FFR) technique, using the HeartFlow platform.
75640022|NCT00729937|Drug|Cephalexin|500 mg, four times per day.
76080476|NCT01289548|Device|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
75331935|NCT04502056|Behavioral|AMA Acknowledgement Drug Pricing|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
75331936|NCT04502056|Behavioral|White Sender in Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
75640023|NCT00729937|Drug|Clindamycin|300 mg, four times per day.
75640024|NCT00729937|Other|Placebo|Placebo tablet administered orally.
75924928|NCT02508896|Biological|AFFITOPE® AT04A+adjuvant|subcutaneous injection
75924929|NCT02508896|Biological|AFFITOPE® AT06A+adjuvant|subcutaneous injection
76080477|NCT01927263|Biological|NI-071|100mg/vial
75788776|NCT01346800|Drug|Prasugrel|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
75788777|NCT01346800|Drug|Ritonavir|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
76080478|NCT01927263|Biological|Infliximab|100mg/vial
75331937|NCT04502056|Behavioral|White Sender in Informational Videos|Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
75331938|NCT04502056|Behavioral|No Racial Inequality Highlighting|In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
75331939|NCT04502056|Behavioral|Placebo videos|Videos not related to covid-19 will be shown
75331940|NCT05502432|Device|Active repetitive transcranial magnetic stimulation|Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation
75788778|NCT03902314|Drug|Lidocaine Iv|Intravenous infusion
75788779|NCT03902314|Drug|Saline Solution|Intravenous infusion
76080479|NCT01921881|Other|St John's wort|
76080480|NCT01341730|Drug|Atorvastatin 20mg|20 mg QD for 3 months
76080481|NCT01341730|Drug|Atorvastatin 20 mg + Pioglitazone 30 mg|atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
75640025|NCT00729937|Drug|Trimethoprim-sulfamethoxazole|4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
75788780|NCT01336660|Biological|Equine F(ab')2 antivenom|A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute
75788781|NCT01336660|Other|Intensive care support plus placebo|Intensive care support as needed plus placebo
75788782|NCT03706040|Biological|Placebo|subcutaneous (SC) injection
75788783|NCT03706040|Biological|Risankizumab|subcutaneous (SC) injection
75788784|NCT03768518|Diagnostic Test|68Ga-exendin-4 PET/CT|68Ga-exendin-4 PET/CT
75924930|NCT02508896|Biological|Adjuvant without active component|subcutaneous injection
76080482|NCT01921959|Behavioral|Intervention|Postpartum women are randomized to intervention or control group
76080483|NCT01247272|Drug|Fluoxetine Hydrochloride|90 mg Capsules
75924931|NCT02514434|Radiation|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
75924932|NCT02514434|Radiation|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
75924933|NCT02504606|Drug|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
75924934|NCT02504606|Drug|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
75924935|NCT00100815|Biological|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
75924936|NCT00100815|Drug|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
76080484|NCT01247272|Drug|PROZAC WEEKLY®|90 mg Capsules
75788785|NCT01321970|Procedure|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
75924937|NCT00100815|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
75788786|NCT01321970|Procedure|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
75924938|NCT00708422|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
75924939|NCT00708422|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
75924940|NCT02165865|Procedure|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
75331941|NCT05502432|Device|Sham repetitive transcranial magnetic stimulation|Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation
75470799|NCT03338504|Diagnostic Test|Cardiac MRI|Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner. The MRI scan will consist of localisers, axial and coronal HASTE images, standard breath-held and ECG-gated cine sequences. Short-axis cine images will be obtained for the assessment of left ventricle function and volumes. Left ventricle volumes, mass and ejection fraction will be assessed using dedicated software and values indexed to body surface area. Breath-held, ECG-gated T2 mapping sequences of the myocardium will be performed in the short-axis as a marker of myocardial inflammation. T1-weighted imaging of the coronary arteries will be performed to look for evidence of recent intraplaque thrombus or haemorrhage. The late gadolinium enhancement and T2 mapping techniques will identify regions of new or old myocardial infarction as well as other patterns of injury. Where there are no contraindications, stress MRI will be performed using intravenous Regadenoson.
75788787|NCT01321970|Procedure|Coronary angiography|"Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:~Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)~Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)~Circumflex (proximal, middle and distal) and collateral (first and second marginal)"
75788788|NCT04276376|Drug|Atezolizumab|Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w
75788789|NCT04276376|Drug|Rucaparib|Inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) 600mg BID
75788790|NCT03770000|Drug|Tenalisib|Tenalisib, BID orally daily
75788791|NCT03770000|Drug|Romidepsin|Romidepsin IV
75924941|NCT02514200|Procedure|Topography-based CXL (KXL2)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
75924942|NCT02514200|Procedure|Conventional pulsed CXL (pCXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
75924943|NCT02514200|Drug|Riboflavin|Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
75924944|NCT02514200|Device|Avedro KXL II|The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
75331942|NCT05314894|Behavioral|Education|Giving training to the students in the initiative group to quit smoking in three sessions, sending messages via whatsapp program and telephone counseling
75331943|NCT01007591|Drug|LEO 80190|Applied once daily
75331944|NCT01007591|Drug|Hydrocortisone|Applied once daily
75331945|NCT03019601|Behavioral|Group Education|Structured group education on family planning facilitated by Peer Champions
75331946|NCT03019523|Dietary Supplement|Caffeine Blend|Taken orally in capsule form
75331947|NCT03019523|Other|Sugar Pill|Taken orally in capsule form
75331948|NCT01008059|Drug|Alfentanil|No drug treatment before alfentanil
75470800|NCT03257696|Diagnostic Test|Close-ended questionnaire|"Yes/no questionnaire used in order to identify reliable respondent and unreliable respondent"
75788792|NCT03770312|Drug|Low intensity statin|Use of low intensity statin for primary prevention of cardiovascular disease.
75788793|NCT03770312|Drug|Moderate intensity statin|Use of moderate intensity statin for primary prevention of cardiovascular disease.
75788794|NCT03770078|Device|Test Product A|The test product is a newly developed ostomy product
75924945|NCT04645797|Drug|APR003|This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.
75924946|NCT02165943|Device|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
75924947|NCT02508740|Drug|bevenopran|Single oral dose
75924948|NCT02167659|Device|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and <10% above pre-surgical baseline.
76080485|NCT03430089|Biological|Shz QIV 0.25 mL, 2 doses|Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
76080486|NCT03430089|Biological|Shz QIV 0.5 mL, 2 doses|Administered intramuscularly into the deltoid muscle, 28 days apart
76080487|NCT03430089|Biological|Shz QIV 0.5 mL, single dose|Administered intramuscularly into the deltoid muscle.
75640026|NCT02713347|Behavioral|ADAPT Intervention|"The intervention includes 3 components:~nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone."
75640027|NCT04981366|Dietary Supplement|Protein supplement|40g of whey protein in the breakfast;
76080488|NCT01290484|Drug|Sildenafil|Sildenafil oral tablet three times daily
75640028|NCT04981366|Dietary Supplement|isocaloric supplement|42g of isocaloric supplement in the breakfast;
76080489|NCT01247428|Device|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
75331949|NCT03634306|Device|Ultravision System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.
75331950|NCT03634306|Procedure|Laparoscopic Hysterectomy|Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System
75924949|NCT02504684|Device|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
75924950|NCT02504684|Device|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
76080490|NCT04397055|Dietary Supplement|Cottonseed Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil
75331951|NCT01008605|Other|delivery system|syringe
75331952|NCT00377026|Behavioral|lifestyle intervention|Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
75640029|NCT02609620|Device|Peristaltic Feeding Tube|
75331953|NCT01009619|Drug|Azithromycin|Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
75331954|NCT01009619|Drug|Placebo|Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
75788795|NCT01561820|Behavioral|5-month aerobic exercise intervention|The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5[HRmax-HRrest]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
75788796|NCT03158272|Biological|Cabiralizumab|Specified dose on specified days
76080491|NCT04397055|Dietary Supplement|Olive Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil
75788797|NCT03158272|Biological|Nivolumab|Specified dose on specified days
75924951|NCT03540303|Drug|CAR19 T cells carrying cytoplasmic activated PD-1|"step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
76080492|NCT04396743|Procedure|Periapical surgery with use of prf-high clot and membrane|Periapical surgery will be done followed by placement of prf-high clot into the defect and membrane over the defect before closure of the flap.
76080493|NCT04396743|Procedure|Periapical surgery with use of prf-medium clot and membrane|Periapical surgery will be done followed by placement of prf-medium clot in the defect and membrane over the defect before closure of the flap.
76080494|NCT03518619|Behavioral|PFIcope+EMI|The intervention will be comprised of (1) an initial orientation session where the intervention is introduced, receipt of personalized normative information, motives feedback, and the development of an individual's personalized relapse prevention coping skills messages to be utilized through the course of the intervention; (2) EMA for monitoring of affect, drinking intention, alcohol use, and coping skills use; (3) EMI-tailored text messages sent based on EMA responses: individualized, self-chosen relapse prevention coping skills messages when participants report negative affect and intent to drink.
76080495|NCT01928043|Drug|Curcumin|
76080496|NCT01342666|Dietary Supplement|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
75331955|NCT02973568|Other|Observational Study|
75640030|NCT02609620|Device|ConvaTec Levin Duodenal Tube|
75640031|NCT02713503|Other|Driving Observation|Driving observation using the DriveSafety CDS-250 Driving Simulator.
75640032|NCT02713503|Other|VisionCoach|Visual field evaluation using VisionCoach
75640033|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
75924952|NCT05142579|Other|ENDOTRAKEAL TUBE HOLDER|During this process, the tube detection of endotracheal tube holder was changed every 24 hours, and the tubes were repositioned every 4 hours. On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale. In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
75924953|NCT05142579|Other|BANDAGE|On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale.In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
75331956|NCT01010009|Dietary Supplement|Trans- resveratrol|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
75924954|NCT02504450|Drug|Adasuve|Inhaled medication to treat acute agitation in the emergency department
75924955|NCT02504450|Drug|Alternative medications|Medication given to treat acute agitation in the emergency department
75924956|NCT02504762|Procedure|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
76080497|NCT01342666|Dietary Supplement|Cucumber consumption|Daily consumption of 300g of cucumber.
76080498|NCT02979886|Drug|GnRH-a|the hormone reaction to the down regulation of the patients
76080499|NCT02979886|Drug|Human Menopausal Gonadotropins|the effects on the serum LH level of day of HCG
75331957|NCT01010009|Other|Placebo (silica)|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
75331958|NCT04467424|Drug|ketamine, propofol|anesthesia with ketofol in pediatric surgery
75331959|NCT04467424|Drug|ketamine, propofol, lidocaine|anesthesia with ketofol plus lidocaine in pediatric surgery
75331960|NCT03016715|Drug|Sirolimus 2%|
75640034|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
75640035|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
75788798|NCT03763292|Behavioral|Specific information brochure|A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
75788799|NCT03705494|Other|Home-based peer counselling (web-based) intervention|The intervention consists of 5-6 home based visits (web-based) over 6 months by trained peer counsellors who will focus on breastfeeding among mothers who have already decided to breastfeed and are interested in this programme.
75788800|NCT01336816|Other|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
75788801|NCT01336816|Other|Placebo Wintergreen|Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
75788802|NCT03768362|Procedure|Plication strabismus surgery|The technique was the same as resection up to muscle suturing, in the next step, the sutures were passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures. At the end, conjunctiva was repaired by vicryl 8/0.
75788803|NCT03768362|Procedure|Resection strabismus surgery|resection strabismus surgery
75924957|NCT02504762|Procedure|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
75640036|NCT05755516|Device|Self-expanding Intracranial Stent (Tonbridge)|Stent assisted coiling with Self-expanding Intracranial Stent (Tonbridge).
75640037|NCT05755516|Device|LVIS and LVIS Jr. (MicroVention)|Stent assisted coiling with LVIS and LVIS Jr. (MicroVention).
75640038|NCT00913900|Biological|autologous CD133+ cells|Intramuscular injection
75640039|NCT00729859|Drug|Acyline|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
75924958|NCT02171637|Drug|BIBW 2992|escalating doses
76080500|NCT01928121|Other|Care provided by AF expert program|
76080501|NCT01290640|Device|DePuy fixed-bearing Total Condylar III (TC3) TKA|
76080502|NCT01290640|Device|DePuy PFC Rotating Platform TC3 TKA|
76080503|NCT01928511|Drug|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
76080504|NCT01928511|Drug|Nucleos(t)ide analogue therapy|
76080505|NCT05241327|Dietary Supplement|Beetroot Juice|Inorganic Nitrate
76080506|NCT05241249|Drug|Bethanechol|Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at our research pharmacy.
76080507|NCT05241249|Drug|Gemcitabine|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2
76080508|NCT05241249|Drug|nab-paclitaxel|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2
75924959|NCT02166021|Biological|Mesenchymal stem cells|A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
75924960|NCT02504528|Other|house dust mites|house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
75924961|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
75924962|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
75924963|NCT02171715|Drug|BIBW 2992 MA2|powder for oral solution
75924964|NCT02760069|Drug|Inhaled isopropyl alcohol|Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
75924965|NCT02760069|Drug|Oral ondansetron|Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
75924966|NCT02760069|Drug|Inhaled normal saline|Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
75924967|NCT02760069|Drug|Oral placebo|Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
75924968|NCT02504138|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
75924969|NCT02504138|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
75924970|NCT04499144|Procedure|modified buccal flap and subepithelial connective palatal flap|The connective flap was harvested from the deeper area of the palatal mucosa. Pedicle flap dimensions were reported using the periodontal probe. The flap was then rotated to cover the oro antral communication (OAC) area. The rotation could be in mesial or distal direction, related to OAC position and for the convenience of the donor site. The connective palatal flap was sutured to the buccal periostium using mattress sutures.
75924971|NCT02166099|Procedure|Choledochoscopy using Digital Spyglass|Choledochoscopy using Digital Spyglass during Endoscopy
75924972|NCT02508584|Biological|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
75924973|NCT02166177|Drug|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
75924974|NCT02508662|Other|Review of Screening Tests and Molecular Test Results|Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
75331961|NCT03016715|Drug|Vehicle|
75640040|NCT00729859|Drug|Acyline + Testosterone gel|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
75924975|NCT02171793|Drug|BI 1744 CL|
75924976|NCT02171793|Drug|Placebo|
75331962|NCT03637348|Device|TrueTear|Ues of TrueTear neurostimulator
75331963|NCT00377104|Drug|alvocidib|Given IV
75331964|NCT00377104|Other|pharmacological study|Correlative studies
75331965|NCT00377104|Other|laboratory biomarker analysis|Correlative studies
75640041|NCT00729859|Drug|Acyline + testosterone gel + anastrozole|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
75924977|NCT02508506|Drug|ALKS 5461|Single dose, given orally
75924978|NCT02171871|Other|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
75924979|NCT02513810|Device|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
75924980|NCT02513810|Device|BioMatrix or Ultimaster with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
76080509|NCT05241171|Device|Fitbit|The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.
76080510|NCT03430752|Other|questionnaires|Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
76080511|NCT01928667|Other|Whole saliva sample|Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
76080512|NCT03433716|Other|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
75331966|NCT03016793|Drug|Puerarin|purabone (puerarin) is a bone graft used for surgical repair of bony defects.
75331967|NCT03016793|Drug|β- tricalcium phosphate|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
75331968|NCT03016793|Drug|β- tricalcium phosphate alone|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
75331969|NCT03016637|Device|SharkCore (TM) FNB Exchange System|
75331970|NCT03928522|Drug|hand mixed vancomycin|hand mixed vancomycin powder into cement
76080513|NCT01928823|Behavioral|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
75470801|NCT03245268|Procedure|Balloon pulmonary angioplasty|BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
76080514|NCT01928823|Drug|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
75640042|NCT00810394|Drug|Sorafenib|Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
75331971|NCT03928522|Drug|hand mixed tobramycin|hand mixed tobramycin into cement
75331972|NCT03928522|Device|pre-mixed tobramycin|this cement is already pre-mixed with tobramycin
75331973|NCT01010399|Dietary Supplement|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
75331974|NCT01010399|Drug|fosamprenavir/ritonavir|Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
75331975|NCT03638908|Drug|Fluoxetine|
75331976|NCT01041781|Drug|carboplatin|Given IV
75640043|NCT00736333|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m^2, given for up to 6 cycles
75640044|NCT02608840|Other|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
75640045|NCT02608840|Other|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
75640046|NCT03929302|Device|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used only in Phase-2 of the study. Phase-1 doesn't include any intervention.
75331977|NCT01041781|Drug|celecoxib|Given orally
75640047|NCT00736255|Drug|Transdermal Nicotine Patch|All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
75640048|NCT00736255|Drug|Lis-dexamphetamine (Vyvanse)|Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week.
75640049|NCT00736255|Drug|Placebo|Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
75640050|NCT03920254|Drug|TD-1473 Dose A|See Arm description
75640051|NCT03920254|Drug|TD-1473 Dose B|See Arm description
75640052|NCT03920254|Drug|TD-1473 Dose C|See Arm description
75788804|NCT03763214|Device|Stenting with PTFE-coated stent (HILZO)|Placing a metal stent in the biliary tract by duodenoscopy
75788805|NCT01431508|Drug|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
75788806|NCT03769922|Procedure|Extensive mesenteric resection|The mesentery is resected avoiding the root region.
75924981|NCT02167737|Behavioral|Bedside Decision Aid|"This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.~Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
76080515|NCT01290874|Drug|Tiotropium|Tiotropium bromide 18 mcg once daily for one year of treatment.
75640053|NCT04087993|Drug|Polyglucoferron|intravenous administration
75640054|NCT04087993|Drug|Ferric carboxymaltose|intravenous administration
75640055|NCT04087993|Drug|Ferrous Sulfate|oral administration
75640056|NCT02593357|Device|COPD patients|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)
76080516|NCT01290874|Drug|Salmeterol|Salmeterol 50 mcg twice daily for one year of treatment.
76080517|NCT01290874|Drug|Formoterol|Formoterol 12 mcg twice daily for one year
76080518|NCT02977494|Drug|Daratumumab|Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
76080519|NCT02977494|Drug|Bortezomib|
75331978|NCT01041781|Drug|gemcitabine hydrochloride|Given IV
75470802|NCT03196206|Drug|BMS-986177|Oral Suspension
75640057|NCT05754814|Other|Malignant lymph nodes|Patients with a condition; either lymphoma on the neck or head and neck cancer with lymph node metastases on the neck.
75640058|NCT00729469|Drug|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
75640059|NCT00729469|Drug|Placebo|oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
75788807|NCT03769922|Procedure|Limited mesenteric excision|The mesentery is retained.
75788808|NCT01347190|Biological|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
75788809|NCT01347190|Biological|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
76080520|NCT02977494|Drug|Dexamethasone|
76080521|NCT01929603|Procedure|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
76080522|NCT01929603|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
76080523|NCT01929603|Drug|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
75924982|NCT02167737|Behavioral|Control Arm|"This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.~Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
75788810|NCT03847402|Behavioral|The early integrated intervention for GDD|The early integrated intervention for GDD integrates developmental approaches with strategies of applied behavior analysis.
75640060|NCT00742183|Device|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
75640061|NCT00742183|Device|Silvadene|Silvadene - dressing changes every day, more frequently if needed
75640062|NCT00808444|Biological|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
75640063|NCT00808444|Biological|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
75924983|NCT03121742|Behavioral|Ecological Momentary Intervention|Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
75788811|NCT03847402|Behavioral|The early integrated intervention for ASD|The theoretical underpinnings of the early integrated intervention for ASD originate from Early Start Denver Model.
75788812|NCT03847402|Behavioral|The early integrated intervention for ADHD|The methods of the early integrated intervention for ADHD includes behavior training, sensory integration training and psychological counseling
75788813|NCT03847402|Behavioral|community intervention for ASD|TEACCH (Treatment and Education of Autistic and related Communication- handicapped Children) intervention or ABA(applied behavior analysis) intervention
75924984|NCT03121742|Behavioral|Treatment as Usual|Standard care as part of inpatient hospitalization.
75924985|NCT02166255|Biological|siRNA-transfected peripheral blood mononuclear cells APN401|Given IV
75924986|NCT02166255|Other|laboratory biomarker analysis|Correlative studies
75924987|NCT02166411|Procedure|myomectomy using barbed sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).
75640064|NCT00808444|Biological|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
75924988|NCT02166411|Procedure|myomectomy using conventional sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
75924989|NCT02508350|Drug|Daptomycin|Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days
75331979|NCT01041781|Drug|pemetrexed disodium|Given IV
75331980|NCT01041781|Other|placebo|Given orally
75640065|NCT00808444|Biological|Rotarix|Oral, 2 doses
75788814|NCT03847402|Behavioral|Community intervention for GDD|community intervention based on developmental approaches
75788815|NCT03847402|Behavioral|community intervention for ADHD|School and family education
75331981|NCT01010477|Drug|Nicotine Nasal Spray|minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day
75331982|NCT01010477|Behavioral|Behavioral counseling|Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
75331983|NCT03921190|Procedure|Local anesthesia|Patients scheduled for a dental procedure that requires local anesthesia will be given the injection using two 2 techniques; an open-mouth and closed-mouth techniques
75331984|NCT00953849|Drug|Celecoxib|Celecoxib (400 mg twice daily)
75470803|NCT03174184|Drug|Rifampin|Oral administration of rifampin at a dosage of 20 mg/kg daily
75640066|NCT05752396|Other|Conditioned Pain Modulation|Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
75640067|NCT05752396|Other|Offset Analgesia|Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
75640068|NCT05752396|Other|Spatial Summation|Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.
75788816|NCT03825172|Diagnostic Test|Caudal Epidural Ultrasonography|Ultrasonographic Measurement
75788817|NCT03788512|Other|observational only- no intervention|observational only- no intervention
75788818|NCT01321502|Drug|famciclovir|500 mg tablet
75788819|NCT01347268|Procedure|GnRH antagonist|GnRH antagonist administration and continued low dose r-FSH 75 IU
75788820|NCT01347268|Procedure|withdrawing GnRH agonists|withdrawing GnRH agonists and continued low dose r-FSH 75 IU
75788821|NCT02402504|Other|Control|Non pulse extruded snack
75788822|NCT02402504|Other|Small particle size pea flour|Pulse extruded snack
75788823|NCT02402504|Other|Large particle size pea flour|Pulse extruded snack
75788824|NCT02402504|Other|Lentil flour|Pulse extruded snack
75788825|NCT02402504|Other|Navy bean flour|Pulse extruded snack
75924990|NCT02508350|Other|determination of plasma concentration|A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
75924991|NCT02171949|Biological|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
75924992|NCT02503826|Drug|Sufentanil|low dose
75788826|NCT02402504|Other|Pinto bean flour|Pulse extruded snack
75788827|NCT01347346|Genetic|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
75788828|NCT05187052|Other|Tracheal intubation|Video-assisted intubation technique
75924993|NCT02503826|Drug|Sufentanil|moderate dose
75924994|NCT02503826|Drug|Sufentanil|high dose
75788829|NCT02385890|Other|Control|Non pulse ingredient bagel
75924995|NCT02503826|Drug|Midazolam|Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
75924996|NCT02503826|Drug|propofol|
75924997|NCT02503826|Drug|cisatracurium|
75924998|NCT02172027|Device|Immunomagnetic Detection|Analysis of pleural effusion through immunomagnetic detection device.
75924999|NCT02166489|Biological|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
75925000|NCT03121664|Drug|PF06649751, Itraconazole|PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
75331985|NCT00953849|Drug|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
75331986|NCT00953849|Drug|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
75925001|NCT02174679|Drug|68Ga DOTATATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
75925002|NCT02503904|Procedure|Concomitant Tumescent Antibiotic Delivery & IV Delivery|Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.
75925003|NCT02503904|Device|Subcutaneous Tumescent Infiltration|Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump
75925004|NCT02503904|Drug|cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)|
76080524|NCT04217850|Other|250 kcal Dietary Energy Restriction|The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
75331987|NCT03911752|Other|Semi-structured interviews|Semi-structured interviews were used to obtain the main data in this study.
75331988|NCT03911752|Other|Canadian Occupational Performance Measure|The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
75331989|NCT01010555|Device|lotrafilcon B|Commercially marketed, silicone hydrogel, spherical contact lens
75331990|NCT01010555|Device|balafilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
75470804|NCT03174184|Drug|MEROPENEM 2 grams TID|Intravenous administration at a dosage of 2 grams thrice daily
75470805|NCT03174184|Drug|MEROPENEM 1 gram TID|Intravenous administration at a dosage of 1 gram thrice daily
75470806|NCT03174184|Drug|MEROPENEM 3 grams QD|Intravenous administration at a dosage of 3 grams once daily
75788830|NCT02385890|Other|Pea flour|Pulse ingredient bagel
75788831|NCT02385890|Other|Pea fibre|Pulse ingredient bagel
75788832|NCT02385890|Other|Pea protein|Pulse ingredient bagel
75788833|NCT02385890|Other|Pea flour + pea protein|Pulse ingredient bagel
75788834|NCT02385890|Other|Pea fibre + pea protein|Pulse ingredient bagel
75788835|NCT04538560|Procedure|polar body biopsy|Undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
75788836|NCT01337206|Device|Stenting with ELLA Biodegradable stent|Treating benign esophageal lesions with the placement of a degradable stent
75788837|NCT01337206|Procedure|Standard Dilations|Treating benign esophageal lesions with standard dilation therapy
75925005|NCT02172105|Drug|BI 1744 CL|
75470807|NCT03174184|Drug|Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily
75470808|NCT03174184|Drug|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily
75640069|NCT05752396|Other|Temporal Summation|Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
75640070|NCT00914134|Drug|Levodopa infusion|Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
75925006|NCT02172105|Drug|Placebo|
75925007|NCT05142423|Drug|AK109+AK104|It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.
75640071|NCT04952896|Diagnostic Test|Synovitis diagnosis|
75925008|NCT04498676|Other|CB-0002B|CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
75925009|NCT02261259|Procedure|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
75925010|NCT02513654|Drug|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
75925011|NCT02504060|Drug|Starch Placebo|
75925012|NCT02504060|Drug|N-acetyl-D-glucosamine|
75925013|NCT03538977|Procedure|Hydrotherapy|A re-sterilizable stainless steel bucket with an upper diameter of 30 cm, a depth of 32 cm, with water at a temperature between 37 and 38º Celsius will be used. The amount of water used will be sufficient to keep the baby submerged up to shoulder height. The baby will be immersed in the heated water of the bucket and will be suspended by occipital support performed by the physiotherapist, who alternates lateral-lateral and anteroposterior movements with only static suspension. The therapy will last from eight to ten minutes and will be discontinued if there is agitation, cyanosis, worsening respiratory distress or major evacuation. If the baby is using any type of ventilatory support or oxygen therapy, the same will be maintained during the procedure of hydrotherapy.
75925014|NCT03538977|Procedure|Conventional Physiotherapy|Conventional physiotherapy consists of manipulations of Thoracoabdominal Rebalancing, a registered technique which uses simultaneous passive stretching of inspiratory muscles and stimulation of the diaphragm. The manipulation used to improve the dynamic diaphragm included the thoracic-abdominal and lower abdominal support maneuvers. Back repositioning was used to minimize posteriorization of the ribs and costal kyphosis due to thoracic distortion.
75925015|NCT02503748|Other|Online tutorial|website informing about treatment options in localized prostate cancer
75925016|NCT02167971|Other|Active Coil|The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
75331991|NCT01010555|Device|senofilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
75331992|NCT01010555|Device|enfilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
75925017|NCT02167971|Other|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
75331993|NCT03019211|Other|Exercise|
75331994|NCT04425850|Combination Product|Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)|Topical application in the nose and oral cavity
75331995|NCT01011179|Behavioral|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
75331996|NCT01011179|Behavioral|Self-Management|"Adolescents' own best efforts at managing their JIA"
75331997|NCT03639766|Drug|AbobotulinumtoxinA|AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
75331998|NCT03639766|Other|Saline solution|Non-bacteriostatic saline solution
75331999|NCT03016559|Other|releasing muscle|At baseline, hip and knee angles were measured. The quadratus lumborum muscle was released. After that, the hip and knee angles were re-measured.
75332000|NCT03641716|Behavioral|Mealtime PREP Intervention|Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
75332001|NCT05307445|Device|Photobiomodulation with Bioptron Hyperlight Therapy|The Bioptron® Device provides polarized visible polychromatic noncoherent light with 90 W; light wavelength = 480-3400 nm; degree of polarization = 95%; specific power = 40 mW/cm2; energy density = 2.4 J/cm2. The duration of each treatment session was 10 min. Bioptron light was positioned 10 cm from the oral mucosa and a mouth opener was positioned for the entire duration of the session. Two weekly sessions during the first 4 weeks of treatment were applied.
75640072|NCT05754736|Drug|Ametinib combined with bevacizumab|Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w
75925018|NCT02513888|Dietary Supplement|vitamin D + diet and lifestyle|subjects will be given vitamin D along with diet and lifestyle modification counselling
75925019|NCT02513888|Dietary Supplement|Placebo + diet and lifestyle|placebo along with diet and lifestyle modification counselling
75925020|NCT00101595|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
75332002|NCT01042795|Drug|Sunitinib|Sunitinib 37.5 mg daily X 16 weeks
75332003|NCT03644212|Drug|Vitamin D3|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
75332004|NCT03906448|Combination Product|TTFields with adjuvant temozolomide|Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.
75640073|NCT04029376|Drug|Iberogast®|The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
75640074|NCT04946812|Other|Split-belt treadmill training|18 sessions of SB-TM training, where the velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%.
75640075|NCT00742027|Drug|Panobinostat|Panobinostat hard gelatin capsules.
75925021|NCT02513576|Other|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
75925022|NCT02503592|Other|Vestibular testing|Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
75640076|NCT03996369|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
76080525|NCT04217850|Other|Aerobic Exercise|Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
75788838|NCT03758846|Behavioral|Cognitive-motor exergaming|Participants undergo 6 weeks of cognitive-motor exergaming using Wii-fit Nintendo. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
75788839|NCT03758846|Behavioral|Conventional balance Training|Participants undergo 6 weeks of conventional exercise training. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
75788840|NCT03758846|Behavioral|Dance Therapy for Stroke|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
76080526|NCT04178460|Drug|Niraparib combined with MGD013|"The dose escalation part will enroll about 9 - 24 Gastric cancer (including gastroesophageal junction cancer) subjects, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level.~For the dose expansion part, patients with advanced or metastatic Gastric cancer (including gastroesophageal junction cancer), Triple negative breast cancer, Biliary tract carcinoma, Endometrial carcinoma will be enrolled, about 35 subjects for each expansion cohort during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation)."
76080527|NCT01344616|Behavioral|lifestyle support|computer-based lifestyle improvement support and clinician support
75925023|NCT02174757|Drug|Inersan|Probiotic
75640077|NCT03996369|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
75925024|NCT02174757|Drug|Doxycycline|Antibiotic
75640078|NCT03844282|Diagnostic Test|Clinical assessment (SCAT5)|The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
75925025|NCT03121196|Other|Epices score|Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression
75925026|NCT02168049|Device|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
75640079|NCT03844282|Diagnostic Test|ImPACT|ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
76080528|NCT01929837|Device|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
76080529|NCT01929837|Device|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
76080530|NCT01929837|Device|sham E-field navigated rTMS|
76080531|NCT01929837|Device|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
76080532|NCT01928901|Drug|administration of Sinupret|
76080533|NCT01928901|Drug|administration of Bronchipret|
76080534|NCT01928901|Drug|administration of Sinupret Placebo|
76080535|NCT01928901|Drug|administration of Bronchipret Placebo|
76080536|NCT01290952|Procedure|Off-pump bypass surgery|is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
76080537|NCT01290952|Procedure|On-pump bypass surgery|is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
76080538|NCT03008902|Procedure|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
76080539|NCT01928979|Other|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
75925027|NCT02168049|Device|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
75332005|NCT03012919|Other|active decision support system|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
75332006|NCT03897634|Device|Remote Microphone|Experienced hearing aid users will be trained on and use a remote microphone for 30 days. Pre- and Post- measures will be taken to determine benefit. Participant characteristics will also be assessed (such as self-efficacy) to explore personality factors that may contribute to benefit from devices.
75332007|NCT01011413|Drug|Efavirenz 600mg|3 x EFV 200 milligram (mg) tablets once daily
75640080|NCT03844282|Behavioral|CANTAB|"Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test."
75640081|NCT03844282|Diagnostic Test|I-PAS/Dx100|I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
75332008|NCT01011413|Drug|Efavirenz 400mg|2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily
75332009|NCT03889444|Drug|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
75332010|NCT04352647|Behavioral|female athletes|The type of incontinence is assessed, whether there are risk factors and quality of life and psychological performance
75332011|NCT00956657|Behavioral|Psychological Intervention Session|One-off session aimed at changing participants beliefs around illness control and consequences, applied using a motivational interviewing style.
75332012|NCT00377650|Device|Percutaneous thrombectomy|
75332013|NCT01104025|Drug|ATG, rabbit|ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
75788841|NCT03758846|Behavioral|Dance Therapy for Older adults|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two therapists."
75788842|NCT03758846|Behavioral|Home education for Older adults|Participants will receive a one-hour education on conventional physical exercises.
75788843|NCT01347424|Drug|Paclitaxel , carboplatin, endostatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3-4h， d1～15，q3w
75788844|NCT01347424|Drug|Paclitaxel and Carboplatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
75332014|NCT01104025|Drug|Etoposide|Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
75332015|NCT01104025|Drug|Methotrexate|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
75332016|NCT01104025|Drug|hydrocortisone|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
75332017|NCT01104025|Drug|Dexamethasone|will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
75332018|NCT03649750|Drug|Mucinex®|Mucinex® 600 mg ER bi-layer tablets
75332019|NCT01104103|Device|BOA(R)-Constricting IV Band|Device applied in accordance with manufacturer's instructions
75332020|NCT01104103|Device|Standard elastic constricting band|Standard therapy
75332021|NCT04343092|Drug|Ivermectin (IVM)|Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
75332022|NCT01105117|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
75925028|NCT02168049|Device|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
75925029|NCT03121508|Behavioral|Taking on Diabetes to Advance You (TODAY) Project|This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
75925030|NCT02168127|Drug|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
75925031|NCT02168127|Drug|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
75925032|NCT02513420|Behavioral|Perineal muscle training|It is a combination of perineal massage and Kegel exercises.
75788845|NCT02288702|Device|monitoring BIS in both groups|We will be monitoring BIS in both groups. A BIS monitor may be placed prior to induction or immmeditaely afterwards for monitoring BIS. All patients will receive general anesthesia. A standard inhalation induction agent such as sevoflurane and oxygen will be administered via face mask with or without an oral airway. An inhalation agent will be administered for the duration of the procedure. The MAC goal for inhalation agents will be 1. If the patient moves, the MAC goal will be increased to 1.5 and this change will be recorded.
75788846|NCT01322438|Drug|Regorafenib (BAY73-4506) + rifampin|Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
75788847|NCT01347658|Dietary Supplement|Echinacea purpurea|Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
75788848|NCT03762980|Other|Bilateral training (BAT)|Each group received bilateral training) for upper extremities for 3 days per week for 01 hour/day for up to 6 weeks. Tasks included functional tasks such as stacking cones and cups, positioning the cup upright, throw a ball into basket, carrying a wooden block and buttoning and unbuttoning of shirt with counting. Each task was performed for 10 minutes and had a rest break of 1 minute.
75798722|NCT03336112|Behavioral|Internet-delivered cognitive behavioral therapy (I-CBT)|The intervention (I-CBT) will consist of 5 weeks of Internet-delivered cognitive behavioral therapy using three main parts. The first is psychoeducation that aims to educate the patients about chest pain and other causes than the cardiac ones. The other part concerns avoidance and exposure. This includes exposing the patients to physical activities that patients perceive as a threat to the heart. The third part contains awareness (mindfulness) training to teach the patients to have contact with the present moment despite chest pain and not trying to avoid it.
75798723|NCT03336112|Other|Information program|Information program delivered by the Internet during 5 weeks.
75640082|NCT03844282|Biological|Saliva sample|Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
75640083|NCT03844282|Other|fMRI|RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
75925033|NCT02172183|Drug|Psychopharmacological treatment|methylphenidate or atomoxetine
75925034|NCT02172183|Behavioral|CBT group|
75925035|NCT02174835|Drug|AVP-786|
75925036|NCT02174835|Drug|AVP-923|
75925037|NCT02255877|Device|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
75925038|NCT02255877|Device|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
75332023|NCT01105117|Drug|Flolan®|per Prescribing Information
75332024|NCT03888274|Device|ClearUP Sinus Pain Relief|Microcurrent Device Treatment
75332025|NCT03650842|Device|Near infrared spectroscopy (NIRS)|One monitor will be placed on the forehead to measure cerebral oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation.
75640084|NCT03967951|Other|CT radiomic feature evaluation|"Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated.~In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be.~Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated."
75925039|NCT02174991|Drug|Rho-Kinase Inhibitor (AR-12286)|
75925040|NCT02255955|Drug|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
75925041|NCT02255955|Drug|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
75925042|NCT02255955|Drug|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
75640085|NCT03790852|Drug|KSI-301|Intravitreal injection
75640086|NCT02609698|Device|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
75925043|NCT02172261|Drug|BI 10773|
75925044|NCT02172261|Drug|Glimepiride|
75332026|NCT01044589|Device|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft reinforcement
75640087|NCT02609698|Drug|3 months DAPT|
75640088|NCT02609698|Drug|6 months DAPT|
75925045|NCT02501564|Drug|Naproxen Sodium Codeine|One tablet twice a day
75925046|NCT02501564|Drug|Placebo|One tablet twice a day
75925047|NCT02172339|Drug|Tiotropium, solution ampoules|
75925048|NCT02503670|Behavioral|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
75925049|NCT02503670|Other|Control Group|Continue with standard care.
75925050|NCT02172417|Drug|Cimetidine + Tiotropium|
75332027|NCT01044589|Other|Overlapping Sphincter Repair|Overlapping Sphincter Repair Alone
75332028|NCT03885154|Drug|Valproic Acid (VPA)|IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
75925051|NCT02172417|Drug|Ranitidine + Tiotropium|
75640089|NCT05750134|Other|OBPLUS Clinical Database : data analysis|The data processed relates to patients cared for in the Hepato-gastroenterology and nutrition department of the Antoine Béclère Hospital at the Assistance Publique - Hôpitaux de Paris (AP-HP. All of the clinical and paraclinical data are collected during the visits and entered into the OBPLUS database (database registered in the AP-HP register). These data will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
75640090|NCT05750134|Other|"Biological collection Liver, bile ducts and pancreas: sample analysis"|"The samples (plasma, serum, saliva, stool) collected during the samples taken as part of the patient's care were the subject of a biological collection Liver, bile ducts and pancreas. These samples will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication."
76080540|NCT04075734|Behavioral|Managing Your Health: Self-Management + Peer Mentoring|"The online educational component consists of 5 self-management educational modules:~(1) Understanding Your Survivorship Care Plan; (2) Managing Your Healthcare; (3) Family and Significant Other Involvement in Your Healthcare; (4) Emotions about Your Health and Follow-Up Care; (5) Staying Healthy.~Participants will be matched with a peer mentor and complete a total of six calls. The first call is to build a rapport and identify the participant's self-management strengths, weaknesses, and goals. The next five calls align with the topic of each module, which the mentee is expected to complete prior to their scheduled call."
75925052|NCT02172417|Drug|Tiotropium|
75640091|NCT02713113|Drug|sugammadex reversal of neuromuscular blockade|
75640092|NCT05749822|Drug|Fenofibrate 200mg|Fenofibrate 200mg/day
76080541|NCT05240859|Drug|Geleli|Adalimumab Biosimilar
75925053|NCT02501486|Other|ACTH stimulation test|An ACTH stimulation test will be done
75925054|NCT02255643|Device|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
76080542|NCT04395105|Drug|High-Dose Dexamethasone|IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10
76080543|NCT04072770|Dietary Supplement|Pea|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
76080544|NCT04072770|Dietary Supplement|Casein|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
76080545|NCT01291108|Drug|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
75925055|NCT03343340|Other|Early CRRT|Continous Renal Replacement Therapy
76080546|NCT01291108|Drug|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
76080547|NCT01291108|Drug|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
76080548|NCT01920789|Radiation|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
75332029|NCT03885154|Drug|Dihydroergotamine (DHE)|0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
75332030|NCT01106833|Drug|Sirolimus + calcineurin inhibitor + prednisone|"The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
75332031|NCT01106833|Drug|Sirolimus + prednisone|"The target serum level for sirolimus is 3-12 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
75640093|NCT05749822|Drug|Placebo|1 tablet/ day
75640094|NCT05749822|Drug|UDCA|UDCA 13-15mg/kg/day
75640095|NCT04226781|Diagnostic Test|Hyperspectral-Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
75640096|NCT04226781|Diagnostic Test|Indocyaningreen-Fluorescence imaging|Photos were taken with the Fluorescence camera after injection of the indocyaningreen-dye of the gastrointestinal anastomosis
75332032|NCT00957047|Drug|eslicarbazepine acetate|oral tablets
75332033|NCT00957047|Drug|placebo|once daily placebo comparator
75332034|NCT00957047|Drug|ESL - Part II|Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
75640097|NCT05749744|Other|cardiac telerehabilitation program by videoconference|"A video conference interview with an Adapted Physical Activity (APA) teacher before starting physical training~Exercise training for 3 weeks via distance coaching~Therapeutic patient education (TPE) workshops conducted remotely with 1 workshop per week.~Medical follow-up via teleconsultation~Psychological and/or dietetic follow-up if necessary.~Final assessment at 1 month with evaluation of aerobic metabolism, functional evaluation and final shared educational assessment (BEP).~Appointment with an association Cœur et Santé and Sport-Santé 42 or setting up of an individual physical activity"
75925056|NCT03343340|Other|Late CRRT|Continous Renal Replacement Therapy
75925057|NCT03343340|Other|Standard Medical Therapy|Standard Medical Therapy
75925058|NCT02168205|Drug|Pomalidomide|Capsules
75925059|NCT02168205|Other|Caffeine|Capsules
75925060|NCT02168205|Other|Tobacco|Cigarettes
75925061|NCT04496570|Procedure|periodontal therapy|Non surgical periodontal therapy was performed to patients with peridontitis
75925062|NCT02168283|Combination Product|treatment arm|Hypertonic peritoneal dialysis cycles
75925063|NCT02168283|Behavioral|Control arm|Dietary counseling
75925064|NCT03343652|Drug|Nivolumab|3 mg/kg IV infusion on day 1,14 up to 3 cycles
75925065|NCT03343652|Drug|Bendamustine Hydrochloride|90 mg/kg IV infusion on day 1 up to 3 cycles
75925066|NCT02175069|Procedure|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
75332035|NCT00957359|Drug|Psilocybin|Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
75332036|NCT00957359|Drug|Niacin|Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg
75640098|NCT02713191|Drug|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
75925067|NCT02175069|Drug|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
75925068|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
75925069|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
75925070|NCT02175069|Drug|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
75925071|NCT02175069|Procedure|Shoulder Surgery|As per individual requirement (patient-dependent)
75925072|NCT02503280|Drug|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs.
75925073|NCT02503280|Drug|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
75925074|NCT02503280|Drug|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).
75925075|NCT02503280|Device|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
75925076|NCT02503046|Other|Estimation of Pentraxin3|5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
75925077|NCT02503046|Genetic|Estimation of P.Gingivalis levels|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
75925078|NCT04498520|Drug|Abexinostat Tosylate|Given PO
75925079|NCT04498520|Drug|Fulvestrant|Given IM
75925080|NCT04498520|Drug|Palbociclib|Given PO
75925081|NCT02168595|Drug|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
75640099|NCT02713191|Drug|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
75640100|NCT02713191|Other|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
75925082|NCT02168595|Drug|Placebo|
75332037|NCT03013777|Behavioral|8-week CBT Program|
75332038|NCT03013699|Behavioral|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
75332039|NCT03013699|Behavioral|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
75640101|NCT02713191|Drug|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
75640102|NCT02713191|Drug|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
75640103|NCT00611169|Drug|tirofiban|tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
75640104|NCT02608138|Other|Iodine status among portuguese school children|
75640105|NCT02777697|Other|chronic pain|
75640106|NCT05749120|Procedure|Recipient vessel selected for microanastomosis|Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
75798724|NCT01179282|Biological|dust mite extract or placebo|intervention will be to stop study drug or placebo
75798725|NCT03859362|Drug|Ertapenem Injection|1 g of ertapenem q24h, 30 min infusion
75798726|NCT01287546|Drug|LY2875358|Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
75798727|NCT01287546|Drug|LY2875358 + erlotinib|Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
75925083|NCT03344276|Diagnostic Test|Neurocognitive Assessments|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. Prior to surgery patients will undergo a battery of neurocogntive assessments 1 month and 2 months prior to surgery.
75925084|NCT03344276|Diagnostic Test|Measurements of inflammatory biomarkers|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. After surgery, patients will undergo blood draws to measure for inflammatory biomarkers.
75925085|NCT03344276|Procedure|Carotid Artery Stenting|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis.
75925086|NCT02172495|Drug|Tiotropium bromide|Tiotropium bromide 18 micrograms
75925087|NCT02172573|Drug|Pramipexole|
75925088|NCT02172573|Drug|Bromocriptine|
75332040|NCT03880474|Biological|MVA-NP+M1|Trial Vaccine
75332041|NCT03880474|Drug|Saline|Sodium Chloride Placebo
75332042|NCT01045057|Device|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
75332043|NCT00957593|Drug|Oxytocin|Continuation of oxytocin once in active labor
75332044|NCT00957593|Drug|Oxytocin discontinuation|Oxytocin will be stopped once in active labor
75925089|NCT02172573|Drug|Placebo pramipexole|
75925090|NCT02172573|Drug|Placebo bromocriptine|
75925091|NCT02175303|Biological|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals.
75925092|NCT03344120|Other|Administration of USSQ Symptoms questionnaire after stent positioning|Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy
76080549|NCT01920789|Radiation|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
75640107|NCT04226703|Diagnostic Test|Ultrasonographic upper airway measurements|"Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge root.~Indirect Laryngoscopy: Grading of laryngoscopic view (I=Visible anterior commissure and vocal cords, II= visible posterior part of vocal cords and posterior commissure, III= Visible posterior commissure and epiglottis, IV= Visible only epiglottis tip and posterior pharyngeal wall)"
75925093|NCT02507882|Biological|IL28B Polymorphism|SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
76080550|NCT01929213|Drug|Udenafil|Udenafil is administered
76080551|NCT01929213|Drug|Bosentan|Bosentan is administered
75925094|NCT02507882|Biological|miRNA quantification|"RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen)."
76080552|NCT01929213|Drug|Udenafil/Bosentan|Udenafil and Bosentan are administered
76080553|NCT01291498|Device|High Intensity Focused Ultrasound|One or two HIFU sessions
76080554|NCT02984085|Drug|Genetically corrected cultured epidermal autograft (ATMP)|"Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.~By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery."
76080555|NCT03726060|Other|control group|In the control group the patient will undergo gnathologic therapy for 6 months with neuromuscural splint every night for 3 months
75640108|NCT04897048|Procedure|Incremental exercise test (IET)|Incremental cardio pulmonary exercise test until exhaustion
75332045|NCT00957671|Drug|Recombinant human growth hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
75332046|NCT04322968|Drug|A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.|Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
75640109|NCT04897048|Procedure|Constant work rate exercise test (CWRET)|constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
75640110|NCT02713035|Behavioral|Self help intervention|For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
75798728|NCT01287546|Drug|LY2875358 at Part A highest dose|Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
75925095|NCT02175381|Drug|Carboplatin|Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
75925096|NCT02175381|Drug|Gemcitabine|Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
75925097|NCT03540225|Drug|Progesterone|Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
75332047|NCT01108003|Drug|broccoli sprout extract|Given orally
75332048|NCT01108003|Other|laboratory biomarker analysis|Correlative studies
75332049|NCT01108003|Other|Mango Juice|given orally
75640111|NCT05754502|Drug|Trastuzumab emtansine|observational study. After the signature of the Informed Consent Form, all their data reported in the medical charts up to then (as detailed in section 12 of the protocol) will be extracted retrospectively and inserted in the study database. From the end of the washout period following the last treatment with T-DM1, each subject will enter in an observation phase for a maximum of 3 years, or until death whichever happens first. This phase will be prospective after the signature of the Informed Consent Form.
75640112|NCT02712957|Drug|NEO6860|TRPV1 antagonist
75640113|NCT02712957|Drug|NEO6860 placebo|Inactive substance
75640114|NCT02712957|Drug|Naproxen|NSAID
75640115|NCT02712957|Drug|Naproxen placebo|inactive substance
75798729|NCT01287546|Drug|LY2875358 at Part A highest dose + trametinib|Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
75798730|NCT05598268|Biological|T3011|T3011 will be administered through IV drip
75798731|NCT03182166|Drug|Golimumab (Optimization)|"Increase dose of golimumab.~For patients treated at 50 mg will be performed, dose will be intensified at 100 mg every four weeks.~For patients treated at 100 mg will be performed, dose will be intensified at 100 mg every two weeks while four weeks."
75798732|NCT03182166|Diagnostic Test|Rectosigmoidoscopy|Rectosigmoidoscopy will be realized for calculated Mayo score
75798733|NCT03182166|Biological|Blood samples|Blood samples will be collected for analysis the concentration of golimumab and antibodies to golimumab (ADAb) in the blood
75925098|NCT02501252|Procedure|trained midwives and nurses working in the community to provide skilled SBA services|After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
76080556|NCT03726060|Other|test group|In the test group the patient will undergo gnathologic therapy with neuromuscural splint every night for 3 months in association with physical therapy
76080557|NCT05604651|Other|no intervention|no intervention
76080558|NCT05240625|Device|"aetherAI Computer-aided Polyp Detection (CADe) Systems for Colonoscopy"|"The investigational medical device is intended to automatically detect potential polyps via colonoscopy in real-time during colonoscopy examinations.~The subject device contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic mucosal lesions and the detected polyps will be highlighted to the endoscopists during the real-time colonoscopy procedures."
76080559|NCT05240625|Procedure|Standard colonoscopy|Standard colonoscopy procedure.
76080560|NCT03430518|Drug|Durvalumab|1.12g given IV on day 1 every 21 day cycle
75332050|NCT03018899|Procedure|paravertebral block|Ultrasound guided two-segment paravertebral block
75788849|NCT03768050|Other|Advanced care for frail elderly|"Home-based case management group receives advanced nursing care meeting the health and social needs of patient and/or carer. It is carried out through a process of evaluation, planning&coordination, facilitating the provision, monitoring and evaluation of the options and resources necessary for the resolution of the case. It is person-centred. The service also provides palliative care.~Home hospitalisation/early discharge dispenses medical and nursing care at home on a transient basis after hospitalisation when patients still need surveillance and assistance. It is done in the acute, subacute or post-acute phase. In the last phase the focus is on functional recovery.~The geriatric residences group is assisted by health care teams with expertise in geriatrics. They coordinate with primary care and health professionals of the residences to improve the attention. They are highly accessible, have high-resolutive capacity and can activate the resources of the healthcare network."
75788850|NCT00654628|Drug|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
76080561|NCT03430518|Drug|Eribulin|1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.
76080562|NCT02938806|Other|No intervention|No intervention
76080563|NCT05240157|Drug|Corticosteroid Derivatives|observational
75332051|NCT03018899|Procedure|epidural anesthesia|thoracic epidural anesthesia
75332052|NCT01108081|Behavioral|Physical activity|Moderate-intensity physical activity
75470809|NCT03052933|Drug|Copanlisib|"For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level+0), or 60 mg/dose (level+1) of copanlisib. Maximal tolerated dose will be determined by modified 3+3 design including level-1 dose de-escalation.~For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.~Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study."
75470810|NCT03052933|Drug|Gemcitabine|For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,000 mg/m2 on Days 1 and 8 of each 28-day treatment cycle until maximum 6 cycles.
75470811|NCT02959697|Drug|Subcut. + Subconj. Xylocaine|Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
75640116|NCT05023083|Other|Functional Status Questionnaire Urdu version|The FSQ instrument translated into Urdu consists of only 34 items, main sections addressed physical function in the activities of daily living, psychological function, role function, social function and variety of performance measures.(8) Scores range from a 0 - 4, 1 - 4, and 1 - 6 scale per question depending on section. It increases reliability and patients ease and comfort. Total score range from 0 to 100 higher score represents the more severe condition.
75788851|NCT03767972|Device|Energy-based device|Patients will receive one treatment for rejuvenation using one or multiple energy-based devices based on investigator discretion.
75788852|NCT00536380|Drug|5-mg Desloratadine|5-mg desloratadine tablets, once daily for four weeks.
75788853|NCT00536380|Drug|10-mg Desloratadine|10-mg desloratadine tablets, once daily for four weeks.
75788854|NCT00536380|Drug|20-mg Desloratadine|20-mg desloratadine tablets, once daily for four weeks.
75788855|NCT05186896|Other|Risk perception questionnaire|A questionnaire for risk perception will be developed and administered
75788856|NCT01337362|Procedure|Insulin clamp|Patients will be exposed to low bloodsugar
75788857|NCT03758768|Other|Blue light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
75925099|NCT02507648|Drug|Oseltamivir|1 tablet contains 75 mg oseltamivir
75925100|NCT02507648|Drug|Tamiflu®|1 tablet contains 75 mg oseltamivir
75925101|NCT02172729|Drug|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
75925102|NCT02503124|Behavioral|Single night's wake therapy|Eligible patients are assisted in maintaining total sleep deprivation during one night
76080564|NCT03430440|Device|Apply CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.
75925103|NCT02503124|Device|Bright light|Bright light according to patients´ own circadian rhythm each morning for a week.
75925104|NCT02503124|Other|Treatment as usual - inpatient care|All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
75925105|NCT02503124|Other|Informative meeting|A short sleep hygiene consultation.
75332053|NCT01108081|Behavioral|Diet|Dietary weight loss
75332054|NCT01108081|Behavioral|Health education|Attention control intervention
75332055|NCT00958919|Drug|naloxone|10 mg naloxone in 25 ml total volume
75332056|NCT00958919|Drug|normal saline|25 ml
75332057|NCT04323592|Drug|Methylprednisolone|Usual standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 > 350 mmHg or a CRP < 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to < 20% of normal range and/or PaO2:FiO2 > 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient.
75640117|NCT05023083|Other|Original Functional Status Questionnaire|FSQ was developed to allow the comprehensive and efficient assessment of physical, psychosocial, social, and role functioning in ambulatory patients. It is a self-administered survey that takes approximately 15 min to complete. The results can be scored to produce a one-page report for clinicians to use in their practices. The responses to items within a scale are averaged and transformed to a scale with a potential range of 0 to 100.Higher score represents the more severe condition.
75788858|NCT03758768|Other|Full spectrum light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
75788859|NCT03762824|Biological|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccination during antirheumatic treatment
75788860|NCT03762824|Biological|23-valent pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccination during antirheumatic treatment
75788861|NCT03762746|Device|Transcranial Magnetic Stimulation|A custom TMS stimulator (MagStim) is used to generate repetitive biphasic magnetic pulses. Magnetic pulses are delivered with a figure-8-coil (Magnetic Coil Transducer). During the experiment, rTMS pulse intensity is adjusted to 90% of the motor threshold. Patients will be randomly assigned to receive a 1 Hz. The target area is stimulated for 10 consecutive days. Stimulation at 1 Hz was applied once a day for 10-days
75788862|NCT03762746|Drug|Control|The control group is receiving treatment as usual. EEG recording and psychopathological ratings are performed one day before the start and on the last day of the study
75925106|NCT02503124|Drug|Treatment as usual - medicine|Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
76080565|NCT03430440|Device|Conventional mode|PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
76080566|NCT01920867|Procedure|RB (Retrobulbar)|Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
75470812|NCT02959697|Drug|Subcut. + Sham Subconj. Injection|Patient will receive the standard subcutaneous local anesthetic as well as a subconjunctival sham injection of Normal Saline.
75925107|NCT02172807|Drug|Tiotropium low|Tiotropium 18 µg inhalation capsule
75640118|NCT05748652|Device|digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for anxiety.
75640119|NCT05748652|Other|Psychoeducation|Participants will be provided with psychoeducation which will be delivered digitally upon allocation to the psychoeducation arm.
76080567|NCT01920867|Procedure|ST (Subtenon)|Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
76080568|NCT01920867|Procedure|IV (Intravenous)|Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
75788863|NCT03767816|Drug|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml around umbilicus
75788864|NCT03767816|Drug|Ultrasound erector spinae plane block|Ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml at T7 level
75788865|NCT03762434|Other|mobile application|"Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management."
75925108|NCT02172807|Drug|Tiotropium high|Tiotropium 36 µg inhalation capsule
75925109|NCT02172807|Drug|Placebo MDI|Placebo metered dose inhaler (MDI)
75925110|NCT02172807|Drug|Placebo inhalation capsule|
75925111|NCT02172807|Drug|Oxitropium|Oxitropium MDI (100 µg/puff)
75925112|NCT03343262|Device|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
75925113|NCT03343262|Other|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
76080569|NCT01920867|Procedure|IVIT (Intravitreal)|Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
76080570|NCT01920867|Procedure|IO (Intraocular)|Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
75332058|NCT04323592|Other|standard care|"usual standard of care:~oxygen therapy (regular or high-flow) and monitoring~empiric antibiotic therapy~mechanical ventilation (invasive or noninvasive)~ECMO when needed and available~pronation when possible~other treatment which can be used are: antivirals, chloroquine, vitamins"
75470813|NCT02959697|Procedure|Blepharoptosis Repair|Patients will undergo blepharoptosis repair using an anterior approach.
75470814|NCT02953652|Drug|HBI-8000|Orally twice weekly
75470815|NCT02924935|Dietary Supplement|L-Histidine|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
75470816|NCT02900560|Drug|CC-486|CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
75470817|NCT02900560|Biological|Pembrolizumab|Pembrolizumab 200 mg IV every 21 days
75470818|NCT02877550|Drug|Obinutuzumab|Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
75470819|NCT02877550|Drug|Venetoclax|p.o. once daily according to dose level (DL) or MTD
75470820|NCT02792205|Other|Non interventional study|no intervention
75925114|NCT04568421|Drug|Immunosuppressive Agents|Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
75925115|NCT02502968|Drug|Cytarabine|
76080571|NCT03128424|Device|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
76080572|NCT01925937|Drug|Atorvastatin|
76080573|NCT01925937|Drug|Coenzyme Q10|
75788866|NCT05260346|Dietary Supplement|Cranberry juice|composition: Water, cranberry juice concentrate
76080574|NCT01925937|Drug|placebo for coenzyme Q10|
75332059|NCT04353245|Other|BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM|Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.
75470821|NCT02775812|Drug|Cisplatin|Given IV
75640120|NCT02777463|Other|diffusion-weighted MRI|Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
75640121|NCT04226625|Drug|Propofol|Intravenous administration
75640122|NCT04226625|Drug|Desflurane|Volatile administration
75788867|NCT05260346|Dietary Supplement|Placebo|composition: Water, dextrose, citric acid, malic acid, fumaric acid, colorants, xanthan gum, natural flavor, emulsion
75788868|NCT03758690|Device|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
75788869|NCT00496834|Drug|losartan potassium|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
76080575|NCT03430362|Drug|Hyoscine N Butylbromide|7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
75798734|NCT05598190|Device|Pro-Yellow laser 577|4 session for cases with digtal photo before and after sessions
75925116|NCT02502968|Drug|BL-8040|
76080576|NCT03430362|Drug|Normal Saline 0.9%|Group B, will receive 2 ml of normal saline single intravenous dose
75925117|NCT02502968|Drug|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
75332060|NCT01047241|Drug|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
75332061|NCT03651856|Drug|ATM FOG in PD|open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
76080577|NCT05240079|Device|Heart rate measurement with Caducy system (twice). SpO2 measurement with Caducy system (Twice).|Heart rate and SpO2 measurement with Caducy (the visage of the subject is filmed 30 seconds and 1 minute with a camera) and heart rate and SpO2 measurement with gold standard (heart rate monitor and oximeter pod linked to an acquisition station). The procedure is repeated twice.
76080578|NCT03430284|Behavioral|Lifestyle therapy|The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.
75332062|NCT01012661|Device|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
75332063|NCT01012661|Device|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
75332064|NCT05298943|Other|walking in 4 situations|Recording of cerebral hemodynamic with fNIRS during gait in exoskeleton with Four strength levels of aid : total aid (A100%), partial aid (A50%), no aid (A0%) and resistance of 25 % (R25%) to walking from the exoskeleton. Each subject are recorded during 8 trials for each level (32 trials). The order is counterbalanced among the subjects
75332065|NCT04325542|Diagnostic Test|HBSAg (sure screen test)|Diagnostic test for Hepatitis B
75470822|NCT02775812|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75470823|NCT02775812|Other|Laboratory Biomarker Analysis|Correlative studies
75470824|NCT02775812|Biological|Pembrolizumab|Given IV
75470825|NCT02679170|Drug|Crizotinib|Treatment with crizotinib following routine clinical practice
75925118|NCT04496648|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
75925119|NCT04496648|Procedure|Sham-percutaneous coronary intervention|Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
75470826|NCT02518009|Other|Genetic men treated with estrogen|Observational during estrogen treatment
75470827|NCT02518009|Other|Genetic women treated with androgen|Observational during androgen treatment
75470828|NCT02505022|Drug|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
75470829|NCT02505022|Behavioral|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
76080579|NCT03430284|Drug|Pharmacotherapy|"Pharmacological therapy is individualized. 1.Glucose-lowering agents:~Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~GLP-1 receptor agonist~Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels."
75640123|NCT02777541|Dietary Supplement|Resumption of feeding 3 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
76080580|NCT03430284|Other|Monitoring and management|Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.
75332066|NCT04353323|Other|Blood sampling|3 blood samples (D0, D15 and D30) will be taken from each participant
75470830|NCT02357082|Radiation|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
75470831|NCT02238496|Procedure|Cytoreductive surgery|Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
75470832|NCT02238496|Drug|Perifosine|Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
75470833|NCT02238496|Drug|Temsirolimus|Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
75925120|NCT02172963|Biological|Decidual Stromal Cell therapy|Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10^6 cells/kg.
75640124|NCT02777541|Dietary Supplement|Resumption of feeding 8 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
75640125|NCT02777619|Drug|0.0ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0ng/ml
76080581|NCT03430284|Other|General treatment|General treatment is carried out based on the device from the general practitioners at present.
76080582|NCT03057639|Other|Quality-of-Life Assessment|Ancillary studies
76080583|NCT03057639|Other|Questionnaire Administration|Ancillary studies
76080584|NCT03428022|Drug|Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
76080585|NCT05076396|Drug|PM14|PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
76080586|NCT00986661|Drug|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
75640126|NCT02777619|Drug|0.4ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4ng/ml
75640127|NCT02777619|Drug|0.6ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6ng/ml
75332067|NCT05289583|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
75470834|NCT02234531|Device|EVER TEACHER|"The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment."
75640128|NCT02777619|Drug|0.8ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8ng/ml
75640129|NCT02777619|Drug|Propofol|
75640130|NCT05754424|Drug|AT278|Concentrated rapid acting insulin aspart
75640131|NCT05754424|Drug|NovoRapid|Rapid-acting insulin aspart
75925121|NCT02502578|Drug|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
75925122|NCT02502812|Drug|Clop F1|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
75925123|NCT02502812|Drug|Clop F2|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
76080587|NCT03128112|Other|Exam room with poster|This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
75925124|NCT02502812|Drug|Innovator|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
76080588|NCT00989781|Radiation|3-D Ultrasound|One time pelvic ultrasound
75332068|NCT03016481|Behavioral|Active Comparator: the Community Health Worker -Personalized Support for Progress|Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.
75332069|NCT03016481|Behavioral|Care as Usual- Social Worker|Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
75470835|NCT02234531|Device|NEVER TEACHER|The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
75470836|NCT02034110|Drug|Dabrafenib|A 150 mg twice daily capsule administered orally on a continuous basis.
75470837|NCT02034110|Drug|Trametinib|A 2 mg once daily tablet administered orally on a continuous basis.
75640132|NCT05754424|Drug|Humulin R 500 UNT/ML Injectable Solution|Regular human insulin
75640133|NCT05747560|Dietary Supplement|Buckwheat|Take buckwheat at a dose of 500 mg twice a day for 6 months.
76080589|NCT00989781|Drug|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
76080590|NCT00989781|Drug|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
76080591|NCT00989781|Drug|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
76080592|NCT00989781|Drug|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
75470838|NCT01968213|Drug|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
75640134|NCT05747560|Dietary Supplement|Astragalus extract|Take astragalus extract at a dose of 450 mg twice a day for 6 months.
75640135|NCT05747560|Dietary Supplement|Wolfiporia extract|Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.
75640136|NCT02777307|Other|Hemopatch Sealing Hemostat|Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
75640137|NCT04867473|Behavioral|Teleyoga|12 weekly 75 minute therapist-led teleyoga sessions
75640138|NCT00636831|Drug|Antibiotic: cefazolin Sodium|1g continuous IV at 30 minutes before starting operation
75640139|NCT02712567|Drug|Th-302|300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
75640140|NCT04226859|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
75788870|NCT00496834|Drug|Comparator: carvedilol|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
75788871|NCT00496834|Drug|Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
75925125|NCT02175537|Behavioral|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
75925126|NCT02168751|Drug|propofol|
75925127|NCT02168751|Drug|Sevoflurane|
75925128|NCT02507726|Device|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
75925129|NCT02173041|Other|Prevention Awareness Groups (PAG)|
75925130|NCT02173041|Other|Standard Care|
75925131|NCT02507570|Drug|Enzalutamide|used concomitantly
75925132|NCT02507570|Radiation|Radium ra 223 dichloride|
75925133|NCT03344042|Drug|Fentanyl|100mcg Fentanyl
75925134|NCT03344042|Drug|Sufentanil|10mcg sufentanil
75925135|NCT02173119|Other|MRI post-TACE|Perform lipiodol delivery measurements with MRI post-TACE.
76080593|NCT00989781|Drug|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
76080594|NCT01292746|Device|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
76080595|NCT03430128|Dietary Supplement|IMPACT immunotherapy|Powdered formula that is pre-packaged in individual packets which the patients will be instructed to mix with water before consumption.
76080596|NCT03430128|Dietary Supplement|ENSURE|Liquid milk formula available over the counter
75332070|NCT02246803|Procedure|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
75470839|NCT01968213|Drug|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
75470840|NCT01711333|Drug|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
75925136|NCT03343964|Diagnostic Test|Amplitude-integrated electroencephalography|Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
75332071|NCT02246803|Procedure|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
75332072|NCT02245919|Other|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
75332073|NCT03655444|Drug|Abemaciclib|Abemaciclib is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
75332074|NCT03655444|Drug|Nivolumab|Nivolumab is commercially available
75470841|NCT01656486|Radiation|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
75470842|NCT01631318|Procedure|Dynamic contrast-enhanced ultrasound imaging|Ultrasound imaging procedure
75470843|NCT01631318|Device|Optical Tracking Device|Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.
75640141|NCT04193631|Drug|Cannabidiol (CBD)|A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.
75640142|NCT04856631|Drug|Toripalimab Injection|240mg once per 3 weeks
75788872|NCT00496834|Drug|Comparator: carvedilol (+) hydrochlorothiazide|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
75332075|NCT03655444|Procedure|Tumor biopsy|"Phase II patients only~If the patient consents, fresh tumor tissue will be collected at baseline and then during Cycle 2 (between days 8-22) of abemaciclib and nivolumab."
75332076|NCT03655444|Procedure|Peripheral blood|"Phase II patients only~Peripheral blood will be collected at baseline, at the end of the Lead In (cycle 1 day 1 prior to treatment), during cycle 2 (between days 8-22), and during cycle 3 (between days 21-28). If patient does not have progression after cycle 3, patient will also have peripheral blood collected at time of progression."
75332077|NCT03655444|Other|EORTC QLQ-30|"Phase II patients only~Screening , Cycle 2 D1, Cycle 4 D1, and End of treatment (EOT)"
75332078|NCT03018977|Other|The sedative weaning protocol group|After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.
75470844|NCT01631318|Device|Electromagnetic Tracking Device|Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.
75470845|NCT01631318|Drug|Perflutren|Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.
75470846|NCT01627574|Behavioral|Motivational Intervention|There are two, 45-60 minutes sessions of tailored MI that occur at the enrollment of the study, and at 3 month follow-up.
75640143|NCT04856631|Drug|Cetuximab Solution for infusion|First infusion 400mg/m2，Subsequent infusions 250mg/m2。once per week
75640144|NCT00611481|Behavioral|Tai Chi|a set of pre-designed Tai Chi Movements
75640145|NCT00611481|Behavioral|Strength training|Lower-extremity strength training exercises
75640146|NCT00611481|Behavioral|Low-Impact Exercise Control|a set of chair-based low-impact exercises
75640147|NCT00808210|Drug|Infliximab|Intravenous repeating dose
75640148|NCT00808210|Drug|Methotrexate|Oral or parenteral repeating dose
75640149|NCT00808210|Drug|Methylprednisolone|Intravenous repeating dose
75640150|NCT00808210|Drug|Ocrelizumab|Intravenous repeating dose
75640151|NCT00808210|Drug|Placebo|Intravenous repeating dose
75640152|NCT02712411|Drug|HCP1303|
75640153|NCT02712411|Drug|HGP1201|
75640154|NCT02712411|Drug|HIP1402|
75640155|NCT02777229|Drug|Dolutegravir 50 mg|1 tablet once a day
75640156|NCT02777229|Drug|Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg|Fixed dose combination, 1 tablet once a day
75640157|NCT02777229|Drug|Efavirenz 400 mg|1 tablets once a day
75640158|NCT02712489|Other|No intervention|
75788873|NCT05244122|Behavioral|Feedback|presence or absence of trial by trial feedback
75788874|NCT05244122|Behavioral|Prevalence|"In some blocks, skin cancer target images were present on 50% of trials (high prevalence). In other blocks, disease prevalence was 20%."
75788875|NCT03758612|Drug|TBI-223 50mg|TBI-223 50 mg supplied for oral administration.
75788876|NCT03758612|Drug|Placebo for TBI-223 50mg|Matching placebo for TBI-223 50mg supplied for oral administration.
75788877|NCT03758612|Drug|TBI-223 100, 300, 600, 1200, 2000, 2600 mg|TBI-223 100, 300, 600, 1200, 2000, 2600 mg supplied for oral administration.
75925137|NCT03538509|Other|PCI and implantation drug eluting stent or bare metal stent|Percutaneous Coronary Angioplasty
75925138|NCT04495322|Drug|TG-1000|Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
75925139|NCT04495322|Drug|Placebo|Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
75925140|NCT02175927|Drug|Lansoprazole|antisecretory drug of each quadruple therapy
75925141|NCT02175927|Drug|Bismuth Potassium Citrate|one component of each quadruple therapy
75925142|NCT02175927|Drug|Metronidazole|antibiotic of each quadruple therapy
75925143|NCT02175927|Drug|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
75332079|NCT03018977|Other|The usual group|After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
75640159|NCT02606812|Dietary Supplement|Traditional-food|Intake of ethnic local food
75925144|NCT02175927|Drug|Tetracycline|antibiotic of classical quadruple therapy
75332080|NCT03018821|Drug|Standard - Yinchengao Decoction plus Ganlu Detoxification Pill|Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.
75332081|NCT03018821|Drug|Entecavir or Tenofovir|Western drug for anti-HBV such as Entecavir and Tenofovir
75332082|NCT03018821|Drug|Standard - Ge Xia Zhu Yu Decoction|Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
75332083|NCT03018821|Drug|Advanced - Supplemented Taohong Huazhuo Decoction|Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
75332084|NCT03018821|Drug|Standard - Chaihu Shugan San|Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
75470847|NCT01627574|Behavioral|Didactic Educational Intervention|There are two, 45-60 minute didactic sessions designed to provide information and awareness for sexual health involving contraception and STI prevention. The first session occurs after enrollment in the study, the second at 3 month follow-up.
75640160|NCT02712177|Biological|4CMenb|
75640161|NCT02712177|Biological|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
75640162|NCT02712177|Biological|conjugated pneumococcal vaccine|
75788878|NCT03758612|Drug|Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg|Matching placebo for 100, 300, 600, 1200, 2000, 2600 mg TBI-223 supplied for oral administration.
75640163|NCT02712177|Biological|MMRV|
75640164|NCT00635037|Drug|bupivacaine and acupuncture|"trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~acupuncture twice a week"
75788879|NCT03758612|Drug|TBI-223 300 mg capsule|TBI-223 300 mg capsule supplied for oral administration
75788880|NCT03758612|Drug|Placebo for TBI-223 300 mg capsule|Placebo for TBI-223 300 mg capsule supplied for oral administration
75788881|NCT03758612|Drug|TBI-223 Prototype 1 SR Tablet|Prototype 1 TBI-223 600 mg sustained-release (SR) tablet
75640165|NCT02777151|Drug|REGN3470-3471-3479|
75640166|NCT02777151|Drug|Placebo|
75788882|NCT03758612|Drug|TBI-223 Prototype 2 SR Tablet|Prototype 2 TBI-223 600 mg SR tablet
75788883|NCT03758612|Drug|TBI-223 Prototype 3 SR Tablet|Prototype 3 TBI-223 900 mg SR tablet
75788884|NCT03758612|Drug|TBI-223 IR Tablet|TBI-223 1000 mg immediate release (IR) tablet
75788885|NCT00189280|Drug|Imiquimod|cream 5%, 5 days out of seven, for 6 weeks
75788886|NCT01352494|Drug|docetaxel|docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
75640167|NCT02776995|Other|Thermography imaging|Thermography imaging of the treated - irradiated body area.
75640168|NCT02777073|Drug|Farxiga|Single dose of dapagliflozin
75640169|NCT02777073|Drug|Victoza|Single dose of Liraglutide
75640170|NCT02777073|Drug|Placebo|Single dose of generic placebo
75640171|NCT02711865|Biological|IGF1R antibody MK0646|
75640172|NCT02711865|Other|Saline solution|
75640173|NCT02712021|Other|Lycra suit and physiotherapy treatment|Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
75640174|NCT02712021|Other|physiotherapy treatment|All the children will be involved in regular physiotherapy treatment (2-3/week).
75640175|NCT02711943|Drug|Levofloxacin 500|Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
75640176|NCT02711787|Device|Experimental group|Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
75640177|NCT02711787|Device|Control group|Physiotherapy and occupational therapy.
75640178|NCT02711787|Device|traditional rehabilitation|Assisted stretching, shoulder and arm exercises, and functional reaching tasks
75640179|NCT02776761|Biological|Hantaan Vaccine:|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
75640180|NCT02776761|Biological|Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
75640181|NCT02776761|Biological|Hantaan/Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
75640182|NCT00736099|Drug|linagliptine 5 mg|safety and efficacy of linagliptine 5 mg open label
75788887|NCT01352494|Drug|gemcitabine|gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
75788888|NCT03758534|Other|No intervention|This is a retrospective chart review study.
75788889|NCT05217602|Behavioral|AC+ARwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+ARwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+ARwdC group will be offered incentives for using their anchoring plan during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
75925145|NCT00707486|Device|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
75925146|NCT00707486|Device|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
75925147|NCT03539991|Other|Internet-Based Intervention|Complete online courses
75925148|NCT03539991|Other|Meeting|Participate in virtual meetings
75925149|NCT03539991|Other|Survey Administration|Ancillary studies
75925150|NCT05460884|Dietary Supplement|Seaweed extract LD and white bread|109g of white bread with 0.5g of seaweed extract
75925151|NCT05460884|Dietary Supplement|Seaweed extract HD and white bread|109g of white bread with 1g of seaweed extract
75925152|NCT05460884|Dietary Supplement|White bread|109g of white bread
75332085|NCT03018821|Drug|Advanced - Soothe the liver and regulate qi Decoction|Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
75788890|NCT05217602|Behavioral|AC+RwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+RwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+RwdC group will be offered incentives for meditating during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
75332086|NCT03018821|Drug|Standard - Xiaoyao powder|Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
75640183|NCT00736099|Drug|linagliptine 5 mg and pioglitazone 30 mg|efficacy and safety of the combination linagliptine and pioglitazone
75788891|NCT05217602|Behavioral|Usual Calm Control (UC)|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the UC group will watch a video with information about the study and how to create an anchoring plan for their meditation habit. Participants in the UC group will be offered incentives for completing the baseline, post-intervention, and follow-up surveys.
75332087|NCT03018821|Drug|Advanced - Supplemented Ganbi Decoction|Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
75640184|NCT00611637|Biological|CMV pp65 Specific T Cells|Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
75640185|NCT04188795|Procedure|Delirium Preventive Care Protocol|"Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
75788892|NCT03198598|Behavioral|Iyengar Yoga|The patients are going to practice Yoga two times per week during 60 minutes each composed by: 40 minutes of postures, 10 minutes of breathing exercises and 10 minutes of meditation. The proposed Yoga postures will depend on disease severity and will be adapted according to each patient.
75640186|NCT02711397|Other|Observational study|Comparison excretion levels of gluten immunogenic peptides
75640187|NCT02711631|Behavioral|MedBIKE|MedBIKE is an exercise cardiac rehabilitation system that allows participants to perform clinical cardiac rehabilitation at home or at a local center, instead of having to travel to the hospital. It provides a high level of physiological monitoring to allow patient safety to be continually monitored while exercising.
75788893|NCT03198598|Behavioral|Yoga app|The patients showing EDSS scores above 6.0 will be divided in two groups of 20. Due to their movements limitations it is not possible to perform a regular Yoga class. In this case they will receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips.
75788894|NCT01347736|Other|scrambler therapy|Undergo scrambler therapy
75788895|NCT01347736|Other|questionnaire administration|Ancillary studies
75788896|NCT01347736|Procedure|dermatologic complications management/prevention|Undergo scrambler therapy
75788897|NCT01347814|Drug|Domperidone 10mg|10mg domperidone tablet 30 minutes before a test-meal.
75788898|NCT01347814|Drug|Placebo|Homeopathic (Sugar) pill-Placebo
75788899|NCT03758456|Biological|HAL-MRE1|HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
75788900|NCT01347892|Other|DeNovo NT Natural Tissue Graft|DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
75788901|NCT01348048|Other|Specialised palliative care (SPC)|The interventions given by the SPC centres follow the the WHO and the EAPC guidelines for palliative care. It is not possible in advance to describe the interventions more specifically as these will be adjusted to each particular patient. As part of the study the medical records of all patients in the intervention group will be reviewed with the purpose of describing the interventions given for the different symptoms and problems.
75788902|NCT01348126|Drug|Docetaxel|75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion
75788903|NCT01348126|Drug|Combination of ganetespib and docetaxel|Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
75788904|NCT01348204|Other|quercetin|health food supplement
76080597|NCT03427944|Drug|Calcium Dobesilate group|Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
75332088|NCT03018821|Drug|Standard - Yiguan Decoction|Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
75332089|NCT03018821|Drug|Advanced - Supplemented Zimu Dan|Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
75640188|NCT02711085|Other|No intervention|No intervention - observational study
75640189|NCT02711319|Device|rTMS|For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
75640190|NCT02711319|Device|sham rTMS|"Sham Comparator: sham rTMS (SHAM GROUP)~For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2)."
75640191|NCT00735943|Other|No intervention|No intervention
76080598|NCT03427944|Drug|Conventional Treatment group|Conventional treatment were used to treat patients with chronic renal failure.
75640192|NCT02693613|Drug|ASP1517|Oral
75640193|NCT02693613|Drug|Kremezin®|Oral
75788905|NCT00166504|Drug|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
76080599|NCT03050463|Procedure|Biospecimen Collection|Undergo blood and saliva sample collection
75332090|NCT03018821|Drug|Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus|Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
75788906|NCT00166504|Drug|atorvastatin|atorvastatin 10 mg
75788907|NCT01348282|Drug|Lithium|lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
75788908|NCT01348282|Drug|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
75925153|NCT05452460|Behavioral|Mindfulness intervention|"The mindfulness program called Mindfulness-based peak performance (MBPP) will be used in this study. MBPP is a program that consists of eight 60-min training, and a 60-min session weekly for 8-weeks. The MBPP program will include (1) 5 minutes of will start with a brief recap of the preceding session and homework discussion, (2) after which the 5 minutes of a brief story about performance aimed at inducing the learning motivation of the participants; (3) Followed by 20 minutes of a theoretical lecture introducing a new topic and then (4) 25 minutes of mindfulness exercise. (5) Finally, how to apply the mindfulness skills to sports context will be discussed at the end of each session for 5 minutes."
75925154|NCT02759055|Other|Clinical Decision Support|an EHR-linked, Web-based clinical decision support (CDS) system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke
75925155|NCT03343106|Behavioral|ACT plus ERP|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Acceptance and Commitment Therapy plus Exposure and Response Prevention (ACT plus ERP).
75925156|NCT03343106|Behavioral|ERP alone|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Exposure and Response Prevention (ERP alone) monotherapy.
75925157|NCT02496182|Drug|Placebo|Placebo tablet only with the excipients of the Pirfenidone tablet
76080600|NCT03050463|Procedure|Functional Magnetic Resonance Imaging|Undergo fMRI related tasks
76080601|NCT03050463|Other|Questionnaire Administration|Ancillary studies
75332091|NCT03018821|Drug|Advanced - Guifu Erxian Decoction|Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
76080602|NCT01922193|Drug|Highly Purified Urofollitropin|for injection
76080603|NCT01922193|Drug|Recombinant Human Follitropin Alfa|for injection
75332092|NCT03018821|Drug|Advanced - Supplemented Ganji Decoction|Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
75332093|NCT04322500|Dietary Supplement|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
75332094|NCT04322500|Other|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
75332095|NCT01014455|Behavioral|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
75640194|NCT04087837|Device|bougie|The endotracheal tube is used in the bougie mode under the direct view of the electronic imaging laryngoscope.
75640195|NCT04087837|Device|Nasogastric(NG) tube|The endotracheal tube is used in the NG tube mode under the direct view of the electronic imaging laryngoscope.
75640196|NCT02711241|Drug|Dipyrone|1 gram by slow IV infusion
75640197|NCT02711241|Drug|Papaverine|80 mg by slow intravenous infusion
75640198|NCT02594059|Other|endothelial function|measure of reactive hyperemia-peripheral artery tone index
75640199|NCT02711163|Dietary Supplement|Extensively Hydrolyzed formula|
75640200|NCT02711163|Dietary Supplement|Amino acid formula|
75640201|NCT02711007|Drug|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
75640202|NCT04226235|Behavioral|Yoga session|a 1-hour yoga session was completed by all participants following a DVD.
75640203|NCT02776839|Device|Mobile sensing|
75788909|NCT03137992|Drug|Placebo|Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
75788910|NCT03137992|Drug|Test Product (tiotropium bromide inhalation powder)|Double-Blind: Single dose of test product 18 mcg of test product Open-Label: once daily administration of test product (tiotropium bromide inhalation powder) 18 mcg administered by test dry powder inhaler.
75788911|NCT03137992|Drug|Reference Product (Spiriva®)|Reference product (Spiriva®) 18 mcg.
75788912|NCT04501588|Behavioral|Responsive training with no video feedback|Parents will receive responsive training, but will not watch themselves on video to reflect on their strategy use.
75788913|NCT04501588|Behavioral|Responsive training with video feedback|Parents will receive responsive training and watch themselves on video to reflect on their strategy use.
75788914|NCT04470778|Drug|BMS-986256|Specified dose on specified days
75788915|NCT04470778|Drug|Famotidine|Specified dose on specified days
75788916|NCT01352572|Drug|antidepressant response|Antidepressants administration for 6 weeks under therapeutic dose responders
75788917|NCT01352572|Drug|antidepressant non-response|Antidepressants administration for 6 weeks under therapeutic dose nonresponders
76080604|NCT03427788|Drug|BAY2328065|Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets
76080605|NCT03427788|Drug|Placebo|Matching placebo, once daily in an escalating manner as LSF or tablets
76080606|NCT03429972|Device|Elasto-Gel™|Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.
76080607|NCT03429972|Drug|Paclitaxel|80mg/m^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
75925158|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg
76080608|NCT05601999|Biological|GNR-060|GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus
76080609|NCT05601999|Biological|Metalyse|Metalyse will be administered in an individual dose depending on body weight as a single intravenous bolus
76080610|NCT03423576|Behavioral|comprehensive patient-centered outpatient health service with multiple components|Individualized multi-component education and counselling program coordinated by a case Manager.
75640204|NCT04193241|Procedure|Closure of chest tube wound|At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
75640205|NCT02710773|Other|Backward Walking Treadmill Training|The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
75640206|NCT02710773|Other|Treadmill Training|The intervention will consist of 20 minutes of forward walking on a treadmill device.
75640207|NCT04226469|Procedure|Tooth movement|The subject's canines will be retracted distally and crevicular fluid is collected
75925159|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
76080611|NCT01347034|Procedure|External Beam Radiation Therapy (RT)|"Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival."
75925160|NCT02496026|Device|tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched on
75925161|NCT02496026|Device|Sham tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
75925162|NCT02168907|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
76080612|NCT01347034|Biological|Autologous Dendritic Cells|"Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.~Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities."
75332096|NCT01014455|Behavioral|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
75332097|NCT01047475|Drug|MB-6|6# TID with meal
75640208|NCT02710695|Behavioral|Control|This group will receive a standardized 10 minute discussion.
75925163|NCT02168907|Drug|bendamustine hydrochloride|Given IV
75640209|NCT02710695|Behavioral|Intervention|This group will receive a standardized 10 minute discussion
75640210|NCT02710539|Drug|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
75925164|NCT02168907|Biological|rituximab|Given IV
75925165|NCT02168907|Other|laboratory biomarker analysis|Correlative studies
75925166|NCT03343028|Other|Psychotherapy|
76080613|NCT03423498|Other|toe-spread-out exercise|The therapeutic intervention lasted 14 days and focused on doing the TSO exercise. This exercise was performed unilaterally under the supervision of a qualified physiotherapist. The starting position of the TSO exercise was the sitting position with the knee joint and hip bent at 90 degrees. The exercise consisted of 3 consecutive phases: dorsiflexion of the toes keeping the metatarsal heads and the heel on the ground, moving the fifth toe down and in a lateral direction, moving the big toe down and abduction. The final position needs to be maintained for 5 seconds. The whole sequence was repeated 200 times a day.
76080614|NCT04351282|Radiation|SBRT|SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
75640211|NCT02710539|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
75925167|NCT02500784|Drug|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
75332098|NCT01047475|Drug|Placebo|6# TID with meal
75640212|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test
75640213|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test right after taking the mixture of grape and pomegranate polyphenols
75640214|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test ten hours after taking the mixture of grape and pomegranate polyphenols
75640215|NCT02710617|Device|Blood glucose monitoring systems for point-of-care-testing|
75640216|NCT00735709|Drug|Vortioxetine|Encapsulated immediate-release vortioxetine tablets
75925168|NCT02500784|Other|Formoterol B (placebo)|2mL, BID inhaler for 12 months
75925169|NCT02176317|Biological|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
75925170|NCT03538353|Other|pain education video|The video was made for the DOD and VHA to educate their soldiers and veterans about chronic pain.
75925171|NCT02495870|Other|Pork|
75925172|NCT02168985|Behavioral|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
75925173|NCT02495792|Device|Biofeedback Sensor|Tibia accelerometer strapped to distal tibia to detect tibial shock
75925174|NCT02176395|Drug|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
75925175|NCT02176395|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
76080615|NCT03427710|Drug|CiVi007|cholesterol lowering drug
75640217|NCT00735709|Drug|Placebo|Vortioxetine placebo-matching capsules
75640218|NCT00635115|Device|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
75788918|NCT01352650|Drug|plerixafor|Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
75925176|NCT02176395|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
75925177|NCT02500940|Drug|Cisplatin|Neoadjuvant chemotherapy regimen with cisplatin
75925178|NCT02500940|Drug|Fluorouracil|Neoadjuvant chemotherapy regimen with Fluorouracil
75925179|NCT02500940|Radiation|Radiation therapy|Intensity-Modulated Radiation Therapy
76080616|NCT03427710|Other|Placebo|matching placebo to CiVi007
76080617|NCT01349140|Drug|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
76080618|NCT05248113|Device|Electrical stimulation of cochlear nerve|Intraoperative electrical stimulation of the cochlear nerve in patients undergoing surgery for resection of vestibular schwannoma. Activation of the auditory system monitored with scalp recording of auditory brainstem response.
76080619|NCT03079167|Drug|Epoetin Alfa|
76080620|NCT03079167|Drug|Normal saline|
76080621|NCT04449900|Other|This is observational study with the examination of OCTA|This is observational study with the examination of OCTA
76080622|NCT03427632|Drug|Bone Cements|patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
75332099|NCT03877432|Device|Dermatome stimulation|Dermatome (S2-S4) stimulation is aimed at improving the function of bladder storage and bladder capacity. A total of 8 serial cystometrograms will be performed: 2 control fills, followed by 4 fills with stimulation, followed by 2 control fills. The minimum (or threshold) stimulation amplitude (T) necessary to elicit the genito-anal reflex was first determined for each subject. Subsequently, each subject received a randomized sequence of cystometric fill trials with and without continuous dermatome stimulation. The dermatome stimulation was randomly stimulated at stimulation amplitudes of 1, 2, 3, and 4 T.
75640219|NCT00635115|Device|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
75640220|NCT02776527|Drug|Apatinib Mesylate Tablets|taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
75640221|NCT02596165|Device|Pulse wave analysis measurement with Schiller BR-102 Plus PWA device|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
75925180|NCT02500940|Drug|Leucovorin|Neoadjuvant chemotherapy regimen with Leucovorin
76080623|NCT03427554|Drug|Tretinoin cream 0.1%|Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
76080624|NCT03427554|Drug|RETIN-A® Cream|RETIN-A® (Tretinoin) Cream (Valeant)
75640222|NCT04088617|Dietary Supplement|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
75640223|NCT04088617|Dietary Supplement|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
75640224|NCT02708589|Dietary Supplement|probiotic|
75640225|NCT02708589|Other|Placebo|
75640226|NCT02708823|Other|CogCheck application|The application is administered once to all study participants.
75640227|NCT02611089|Procedure|Tissue biopsy|Sampling of tissue as described.
75788919|NCT01352650|Drug|decitabine|decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
75788920|NCT03762278|Dietary Supplement|Leucine|Participants will ingest 15g of leucine supplementation/day during the immobilisation period. Leucine supplementation will be administered in powdered form (Infinit Nutrition, Canada) and participants will be required to consume 5g of leucine mixed with 250-300 ml of water during each meal. Leucine is a dietary supplement according to the US FDA. This supplementation protocol has been demonstrated in humans (Murphy et al., 2016, AJCN) with no reported side effects. The quantity of leucine supplementation falls well within the safe limits outlined by Rasmussen et al. (2016). Infinit Nutrition Leucine is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Infinit Nutrition Leucine is not a medicinal product.
75788921|NCT03762278|Dietary Supplement|Placebo|"Participants will ingest 15g of placebo supplementation/day during the immobilisation period. Placebo supplementation will be administered in powdered form and participants will be required to consume 5g of placebo supplementation mixed with 250-300 ml of water during each meal (3x/day).~Placebo supplementation will contain 5g of non-essential amino acids (Infinit Nutrition, Canada) and will be calorically matched to the leucine supplementation.This supplementation protocol has been demonstrated previously in humans, with no reported side effects (Murphy et al., 2016, AJCN)."
76080625|NCT03427554|Drug|Vehicle of the test product|Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
76080626|NCT03128190|Other|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
76080627|NCT01349920|Drug|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
76080628|NCT03128346|Procedure|Transthoracic Transversus Plane Block|The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
76080629|NCT03128346|Drug|Hydromorphone Hydrochloride|IV, Hydromorphone
76080630|NCT03128346|Drug|Aspirin|Oral Aspirin
76080631|NCT03128346|Drug|Acetaminophen|Oral acetaminophen
76080632|NCT03128346|Drug|Fentanyl|IV, fentanyl
76080633|NCT03423108|Behavioral|G150|This group will receive 150 min/week of combined exercise training, structured and supervised.
76080634|NCT03423108|Behavioral|G300|This group will receive 300 min/week of combined exercise training, structured and supervised.
76080635|NCT02521116|Other|Dynamic Vessel Analyzer|
75640228|NCT00729157|Radiation|Fludeoxyglucose F-18|Correlative studies
75640229|NCT00729157|Other|Laboratory Biomarker Analysis|Correlative studies
75640230|NCT00729157|Other|Pharmacological Study|Correlative studies
76080636|NCT02521116|Other|Oxymap T1|
75925181|NCT02176473|Behavioral|Computerized Cognitive Behavioral Therapy|"The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/."
76080637|NCT03427476|Drug|CTT1057|"Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging."
76080638|NCT03423030|Drug|PBTZ169 Formulation|PBTZ169 Formulation supplied as powder for oral solution
76080639|NCT03423030|Drug|Placebo|matching placebo supplied as powder for oral solution
76080640|NCT03423030|Drug|PBTZ169 NCP|PBTZ169 NCP supplied as powder for oral solution
76080641|NCT03427242|Drug|Apatinib|oral apatinib 750mg qd
76080642|NCT01252732|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
76080643|NCT01252732|Drug|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
76080644|NCT02854644|Other|additional blood sample|
76080645|NCT00989235|Drug|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
76080646|NCT00989235|Drug|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
76080647|NCT06154122|Device|Virtual Reality Upper Limb Rehabilitation Games|"A VR upper limb rehabilitation programme prescribed by the therapist with games chosen depending on the exercise task required and the level of difficulty adapted to the ability of the individual. The participant will use the VR system's user interface to navigate through menus to set their gameplay preferences and select which games to play.~The games of the intervention will involve facilitating and replicating upper limb movements including gross movements of the shoulder, such as rotation, abduction and addiction, movements of the upper and lower arms, such as flexion and extension of the elbow, and hand, wrist and finger movements, including wrist pronation supination, and finger flexion and extension, as well as tenodesis movements, grasping, and pinching."
76080648|NCT06154122|Other|Upper Limb Rehabilitation|Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
76080649|NCT06154109|Drug|Xiaopi granules|Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
76080650|NCT06154109|Drug|Xiaopi decoction|Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
76080651|NCT06154109|Drug|Placebo|The placebo does not contain any active pharmaceutical ingredients .
75640231|NCT00729157|Procedure|Positron Emission Tomography|Correlative studies
75640232|NCT00729157|Biological|Ziv-Aflibercept|Given IV
75640233|NCT02710305|Drug|oral hyoscine butyl bromide tablets plus lidocaine cream|patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
75640234|NCT02710305|Drug|oral placebo tablets plus placebo cream|patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
75640235|NCT02708511|Diagnostic Test|Computed Tomography|Undergo PET/CT
75640236|NCT02708511|Drug|Copper Cu 64-DOTA B-Fab|Given IV
75640237|NCT02708511|Other|Laboratory Biomarker Analysis|Correlative studies
75640238|NCT02708511|Other|Pharmacological Study|Correlative studies
75640239|NCT02708511|Diagnostic Test|Positron Emission Tomography|Undergo PET/CT
75640240|NCT00728689|Drug|ST-246 Days 1 - 3|First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
75640241|NCT00728689|Drug|ST-246 Days 11 - 13|Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
76080652|NCT06154096|Other|Acute glucagon infusion|All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
75640242|NCT02596243|Biological|GX-188E|1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
75788922|NCT01352728|Drug|Axitinib|5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
75788923|NCT03704636|Device|INVSENSOR00028|Noninvasive pulse oximeter sensor
75788924|NCT01348438|Device|Medtronic Engager Transcatheter Aortic Valve Implantation System|Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
75788925|NCT01348516|Drug|KM-023|-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
75332100|NCT03012451|Behavioral|Advancing Adolescents|"The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities."
75925182|NCT02500472|Dietary Supplement|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
76080653|NCT06154070|Drug|DaxibotulinumtoxinA|"Patients enrolled who meet eligibility will receive a total of 344 units of DAXI Injections in divided doses over 19 landmarks, including the face, head and shoulders, as identified per the EEG paradigm, at visit 2.~Follow-up visits via combination of phone and in office will occur at V3, week 8 thru V9, week 24."
75640243|NCT02596243|Biological|Placebo|0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
75640244|NCT02717793|Other|Strength testing|"isometric muscle strength~1RM measurement of muscle strength"
75788926|NCT01348516|Drug|Placebo for KM-023|-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
75788927|NCT03761966|Other|Pregnant women|
75788928|NCT01352806|Procedure|identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation|Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
75925183|NCT02495636|Drug|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
75925184|NCT02495636|Drug|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
75925185|NCT02176551|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days.
75925186|NCT02176551|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
76080654|NCT06154044|Biological|CD34+ stem cell therapy|After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
75332101|NCT01047709|Device|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
75332102|NCT03866434|Drug|SPD422|Participants will receive 1 mg of SPD422 (2*0.5 mg) capsule orally on Day 1 and 8 in fasted state.
75640245|NCT02710227|Other|(PSQI), (STQ).|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
75640246|NCT02594137|Procedure|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
75640247|NCT02710149|Biological|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
75640248|NCT02592811|Procedure|ERCP|Common bile duct cannulation with a cannulation catheter
75640249|NCT02592811|Procedure|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
75640250|NCT02592811|Device|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
75640251|NCT02592811|Procedure|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
75640252|NCT02717091|Drug|FOLFIRINOX|
75640253|NCT02717091|Drug|gemcitabine + nab-paclitaxel|
75640254|NCT02592733|Device|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
75788929|NCT03761888|Diagnostic Test|optic nerve sheath measurement and transcranial doppler|evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
75788930|NCT04470388|Drug|EDP-514|Oral Capsule
75788931|NCT04470388|Drug|Placebo|Placebo to match EDP-514
75788932|NCT03997448|Drug|Pembrolizumab|Pembrolizumab 200mg IV
75788933|NCT03997448|Drug|Abemaciclib|Abemiciclib 150mg PO
75788934|NCT01343134|Device|Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)|Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
75925187|NCT02495714|Behavioral|Active learning|Physical activity one hour a day as part of academic learning
75925188|NCT02495714|Behavioral|Dietary councelling|Teaching children and parents about a healthy diet
75925189|NCT02169063|Radiation|carbon-11 acetate|Given IV
75925190|NCT02169063|Radiation|fluorine F 18 sodium fluoride|Given IV
75925191|NCT02169063|Procedure|positron emission tomography|Undergo 11C-acetate and 18F-fluoride PET
76080655|NCT06154031|Behavioral|Dyad learning|All participants will perform a gamified exercise using a dyad learning protocol. This means that all participants will practice the gamified exercise in pairs (dyads), for 60 minutes on two consecutive days.
75332103|NCT03866434|Drug|Omeprazole|Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
75470848|NCT01498458|Drug|Pazopanib plus capecitabine|"Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~dose level I: 400 mg~dose level II: 600 mg~dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level."
75470849|NCT01427712|Drug|Pancrelipase|
75470850|NCT01369147|Drug|Parenteral Nutrition|The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
75925192|NCT02169063|Other|laboratory biomarker analysis|Correlative studies
75470851|NCT01369147|Drug|Propofol|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL).
75470852|NCT01369147|Drug|Clevidipine|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in clevidipine (2 kcal/mL).
75470853|NCT01369147|Drug|Dextrose-containing IV Fluids|The PN dose will be written for each 24-hr period taking into account calories provided from dextrose-containing IV fluid orders exceeding 500 mL/day.
75640255|NCT02593279|Genetic|asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
76080656|NCT06154018|Drug|Protamin|ACT and Clot- Pro test will be ran after initial and possible next protamine administrations
76080657|NCT06153992|Device|Intelligent portable isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using intelligent portable isokinetic muscle strength test training system
75640256|NCT02593279|Genetic|asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
75640257|NCT02592889|Device|MITRACLIP|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
75640258|NCT00727909|Device|Hearing Aid Treatments|"Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)"
75788935|NCT03982160|Drug|L-Arginine|Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.
76080658|NCT06153992|Device|isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using isokinetic muscle strength test training system
75640259|NCT02708043|Other|Flexible-Laryngeal Mask Airway|
75640260|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
75925193|NCT02495558|Other|Reflex Cough Test|Peak of Cough Expiratory Flow of the reflex cough
75640261|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
75640262|NCT02593201|Drug|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
75640263|NCT02593201|Drug|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
75640264|NCT02707809|Drug|Dexmedetomidine|Dexmedetomidine infusion
75640265|NCT00585325|Drug|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
75788936|NCT03982160|Other|Placebo|Saline
75925194|NCT04496882|Drug|Vemlidy|25mg Tenofovir Alafenamide
75925195|NCT02176629|Other|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
75925196|NCT02176629|Other|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
75788937|NCT03689920|Device|Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
75332104|NCT00962039|Drug|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
75925197|NCT02502500|Drug|Celecoxib|
75925198|NCT02502500|Drug|AKB-6548|
75925199|NCT02500394|Procedure|Ionosteril|biomarker guided volume substitution with Ionosteril
75332105|NCT00962039|Drug|Placebo|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
75332106|NCT03375385|Drug|dexmedetomidine/ propofol|The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
75470854|NCT01369147|Drug|Enteral feeding|Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
76080659|NCT06153992|Other|without test training|Treatment was performed without using any isokinetic muscle strength test training system
76080660|NCT06153979|Biological|Verorab|Participants in each group will receive rabies vaccination (standard 3-dose series given as PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment.
75640266|NCT00585325|Other|Placebo (0.9% Normal Saline)|.9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
76080661|NCT06153953|Device|vacuum device|use of vacuum device in dressing of diabetic wounds
76080662|NCT06153953|Other|conventional dressing therapy|us of conventional dressing with betadine and iruxol in diabetic wounds
76080663|NCT06153940|Device|Treatment|"The Everglade™ Stem, is a second generation cementless blade style hip stem Forged in Titanium and proximally Antero-Posterior (AP) flared with Titanium Plasma Spray + Hydroxyapatite (TPS + HA) coated for bone on-growth.~The stem has distal geometry and a polished anodized surface finish to minimize the stem hanging in Dorr A femurs.~The World Acetabular Cup is a porous coated and mated with the Cross-linked polyethylene World Liner"
76080664|NCT06153927|Diagnostic Test|CT-FFR|CT-FFR was calculated using HeartMedi+ 1.0 according to the manufacturer's instructions
75332107|NCT03012373|Procedure|Ear acupressure alone|The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
75332108|NCT03012373|Procedure|Electroacupuncture plus ear acupressure|Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
75332109|NCT03867838|Device|compliant support|Participants will be given compliant arm support and their reachable workspace measured
75332110|NCT03018665|Drug|Exenatide|subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
75332111|NCT03018665|Drug|BIAsp30|subcutaneous injection，fit dosage twice a day in three months
75332112|NCT03018665|Drug|Metformin|oral，0.85g，twice a day in three months
75332113|NCT03012763|Drug|Paracetamol|Oral administration of 250 mg paracetamol
75332114|NCT03012763|Drug|Sulfasalazine|Oral administration of 50 mg sulfasalazine
75332115|NCT03012763|Drug|Fexofenadine|Oral administration of 120 mg fexofenadine
75640267|NCT02717325|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation- SR16-08)
75640268|NCT02717169|Device|Biometrical tracker|35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
75640269|NCT02717247|Device|Active tRNS|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).~100Hz-650Hz, 2mA, 30min, twice daily, 5 days"
75788938|NCT01321580|Device|Masimo Pronto 7|non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
75788939|NCT01343212|Other|stiffness measurement using ARFI|Stiffness measurement will be performed for HCC using ARFI technique.
75788940|NCT03767660|Drug|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
75788941|NCT03689608|Other|Intermittent Fasting (IF)|Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
75788942|NCT03689608|Other|Daily Restriction (DR)|Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
75788943|NCT03689608|Other|standard care (SC)|Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.
75788944|NCT03761654|Diagnostic Test|Global Longitudinal Strain measure|Global Longitudinal Strain measure on day 1 of hospitalization
75788945|NCT03767504|Dietary Supplement|Thymol|Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
75788946|NCT01352884|Drug|AMP-224|Escalating doses of AMP-224
76080665|NCT06153914|Procedure|Sequential Adult Left Lateral Liver Transplantation|Hemihepatectomy combined with orthotopic left lateral lobe liver transplantation is performed first, and residual liver resection is performed after the graft has grown to a sufficient functional liver volume. After the two-stage surgery, we will follow up on all subjects for one year.
75332116|NCT03012763|Drug|Valsartan|Oral administration of 40 mg valsartan
75332117|NCT03012763|Device|non-caloric water|Oral administration of 240 ml non-caloric water
75332118|NCT03012763|Device|caloric drink|Oral administration of 240 ml caloric drink
75332119|NCT03012763|Device|grapefruit juice|Oral administration of 240 ml grapefruit juice
75470855|NCT01197066|Drug|Certolizumab Pegol|Certolizumab Pegol 200mg
75470856|NCT01945827|Device|DeltaMaxx Microcoil System|
75470857|NCT01945840|Procedure|Roux en Y Gastric Bypass Surgery|
75470858|NCT01945840|Other|Gut hormone infusion|
75470859|NCT01945840|Other|Placebo infusion|
75788947|NCT01352884|Drug|AMP-224|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
75640270|NCT02717247|Device|Sham tRNS|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
75640271|NCT02514525|Device|CryoBalloon Ablation System|CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
75925200|NCT02502422|Device|Classic laryngeal mask airway|"measurement of head and neck~Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip~sternal notch), modified mallampati classification under sitting position, thyromental distance.~laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~# 4.0 for female, #5.0 for male~initial cuff volume(air) : maximum volume recommended by the manufacturer~check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured."
75925201|NCT02173587|Dietary Supplement|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
75925202|NCT02173587|Dietary Supplement|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
75925203|NCT02495480|Device|A novel disposable sheath|a new sheath will be placed on the endoscope in sheathed group
75332120|NCT01015781|Procedure|Progressive Tinnitus Management|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support"
75332121|NCT01015781|Procedure|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
75925204|NCT02173665|Drug|BI 1356 BS - Powder in bottle (PIB)|
75925205|NCT02173665|Drug|BI 1356 BS - Tablet|
75925206|NCT02173665|Drug|Placebo|
75925207|NCT02495324|Drug|Placebo|2 weeks of placebo PO daily
75332122|NCT03661762|Device|CAVA|prototype device for monitoring dizziness
75332123|NCT03012607|Drug|Truvada|Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
75332124|NCT03018509|Drug|JTE-451|Active drug tablets containing JTE-451
75332125|NCT03018509|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
75332126|NCT04316260|Behavioral|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
75640272|NCT02717013|Dietary Supplement|Placebo|Placebo capsules containing calcium lactate similar to the HMB capsules.
75640273|NCT02717013|Dietary Supplement|HMB|HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
75640274|NCT02716857|Drug|Oxycodone extended-release|
75640275|NCT02716857|Drug|Placebo of oxycodone extended-release|
75788948|NCT03767270|Biological|MRT5201|Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid with lipid-based nanoparticles
75788949|NCT03767270|Other|Placebo|5% dextrose in water
75332127|NCT04316260|Behavioral|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
75332128|NCT01048879|Procedure|pharmacokinetic blood sampling|blood samples collected to assess oseltamivir concentrations
75640276|NCT04164303|Other|Physical Therapist management|Physical Therapist management included joint manipulation, mobilization with movement, strengthening exercises, and grip proprioception training.
75470860|NCT01945840|Other|Very low calorie diet|
75470861|NCT01945853|Device|7 Tesla MRI|
75788950|NCT01343290|Drug|Canagliflozin|Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
75788951|NCT03761342|Behavioral|Multiple Traffic Light Label|The United Kingdom's Multiple Traffic Light label has repeatedly demonstrated effectiveness and has been widely implemented in Europe. The label shows how much calories, fats, saturated fats, sugar and salt are present in a product, with associated traffic light signals for high (red), medium (amber) and low (green) percentages for each attribute.
75925208|NCT02495324|Drug|Fimasartan|60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
75925209|NCT02495324|Drug|Valsartan|80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
75925210|NCT02495324|Drug|Olmesartan medoxomil|10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
75925211|NCT02173743|Other|PRP|platelet enriched autologous blood plasma
75925212|NCT02173743|Other|Control|Regular barbotage/care as usual
75925213|NCT02500238|Other|Saliva sample|All participants will provide a saliva sample.
75470862|NCT01945879|Drug|Enoxaparine|al patients received additional low molecular heparin, if the safety cohort of three patients received at least 4 weeks of combined treatment without severe side effects, recruitment were continued until a minimum of 15 patients completed at least 3 months of treatment.
75925214|NCT02500238|Other|Urine Sample|All participants will provide a urine sample.
75332129|NCT01048879|Procedure|pharmacokinetic blood and dialysate sampling|blood and dialysate samples collected and assayed for oseltamivir concentrations
75332130|NCT05272657|Other|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
75925215|NCT02500238|Other|Toe nail clippings|All participants will provide toe nail clippings.
75332131|NCT05272657|Other|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
75470863|NCT01945892|Drug|Ozurdex|"- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior."
75332132|NCT04296448|Device|Cellscope|Cellphone otoscope (Cellscope) to evaluate pediatric patient ears.
75332133|NCT05230771|Combination Product|Palliative surgery after translational therapy|"A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy .~location."
75470864|NCT01945905|Other|Intramural|Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free
75470865|NCT01945905|Other|Extramural|In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
75332134|NCT05230771|Drug|Chemotheraoy along|Patients receive only the prescribed chemotherapy.
75470866|NCT01945918|Behavioral|Self-management support education|Same as Arm Description
75470867|NCT01945918|Behavioral|Connection to Health Interactive Behavior Change Technology|Same as Arm Description
75470868|NCT01945918|Behavioral|Connection to Health plus Coaching (CTH+C)|Same as Arm Description
75640277|NCT02716935|Dietary Supplement|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
75640278|NCT02716935|Dietary Supplement|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
75640279|NCT02716623|Other|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.
75640280|NCT02716623|Behavioral|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
75925216|NCT02500238|Other|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
75470869|NCT01945931|Other|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
75640281|NCT02709993|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
75925217|NCT02173821|Procedure|Blood sampling|Blood sample will be collected at a single visit
75925218|NCT02495246|Biological|ChAd3-EBO-Z|
75925219|NCT02495246|Biological|Ad26.ZEBOV|
75925220|NCT02495402|Behavioral|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
75925221|NCT02256033|Drug|Istradefylline|One 40 mg-tablet administered on Day 1
75925222|NCT02502110|Drug|rosuvastatin|All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
75925223|NCT02173899|Biological|varicella-1|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
75332135|NCT05314738|Combination Product|NXL Energy 1|Riboflavin drops + NXL System to Total Energy Level 1
75925224|NCT02173899|Biological|varicella-3|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
75925225|NCT02173899|Biological|varicella-5|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
75925226|NCT02173977|Other|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
75925227|NCT02173977|Other|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
75332136|NCT05314738|Combination Product|NXL Energy 2|Riboflavin drops + NXL System to Total Energy Level 2
75332137|NCT05314738|Combination Product|NXL Energy 3|Riboflavin drops + NXL System to Total Energy Level 3
75332138|NCT05314738|Combination Product|Sham Treatment|Sham Drops and No exposure to NXL system
75788952|NCT03761342|Behavioral|Nutri-Score Label|In late 2017, France began voluntary implementation of one FOP label, termed Nutri-Score, adapted from its predecessor, the 5-colour Nutrition Label. Consumer acceptability and understanding of the NS label has been demonstrated in several studies. It provides a letter score as a composite grade of a product's nutrition quality from A (best) to E (worst).
75788953|NCT03761264|Drug|Odontopaste®|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
75470870|NCT01945957|Drug|Oxytocin|"For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin."
75640282|NCT02709915|Other|Breakfast Diet (Bdiet)|The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%. In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system. The investigators will assess also the Clock Genes mRNA expression in white blood cells. at baseline and after 12 weeks of diet intervention
75640283|NCT02709915|Other|6Meal Diet (6Mdiet|The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks. In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
75332139|NCT03010345|Device|Osmed self inflating tissue expanders|Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
75332140|NCT03010345|Other|Iliac bone graft|Bone grafting the cleft without the use of osmed self inflating tissue expander
75332141|NCT04290676|Drug|DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
75640284|NCT02716545|Device|balloon assisted enteroscopy|Patients with recurrent bleeding (>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
75640285|NCT02709837|Other|Nutritional|
75640286|NCT02709759|Behavioral|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
75640287|NCT02709759|Behavioral|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
75640288|NCT02709759|Behavioral|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
75640289|NCT02709681|Other|Physician standard-of-care in SCD patients|
75788954|NCT03761264|Drug|Pulpdent|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Pulpdent paste will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
75788955|NCT03761264|Drug|Amoxicillin|Teeth with abscess will be opened from the crown to allow cleaning of the canals . A sterile cotton pellet will be placed in the pulp chamber and cavity sealed with capsulated Glass ionomer cement. The patient will be prescribed oral amoxicillin at 15mg/kg body weight tds for 5 days
75788956|NCT05096312|Dietary Supplement|Zinc gluconate|oral zinc gluconate 200mg
75332142|NCT03112993|Drug|sugammadex|once at the end of the surgery
75332143|NCT03112993|Drug|Neostigmine|once at the end of the surgery
75788957|NCT05096312|Drug|Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]|Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening
75788958|NCT05096312|Other|Placebo|contains cornstarch
75788959|NCT03758378|Other|Dietary intervention|Limiting dietary exposure to high intensity sweeteners and sugar alcohols; limiting eating out to a maximum of 2 days per week.
75788960|NCT03758300|Other|Radiofrequency|See previous page
75925228|NCT02502344|Behavioral|healthy lifestyle|food control and intensive exercise to lose weight
75925229|NCT02502344|Drug|Metformin|use metformin to reduce insulin resistance
75925230|NCT04496180|Device|Closed incision negative pressure therapy versus standard dressing after emergency abdominal laparotomies|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply the PREVENA just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
75925231|NCT02174211|Drug|Ranibizumab|Intravitreal injection of ranibizumab
75925232|NCT02174211|Drug|Aflibercept|Intravitreal injection of aflibercept
75925233|NCT02500160|Device|Patient specific instrumentation (MRI)|
75925234|NCT02500160|Device|Patient specific instrumentation (CT)|
75470871|NCT01945983|Drug|Early norepinephrine|Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
75640290|NCT00917761|Drug|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
75640291|NCT00917761|Drug|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
76080666|NCT06153901|Procedure|endoloop mediated cardioplication (ECLC) procedure|The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
75788961|NCT05088668|Other|Augmented reality|"The subjects will perform scapular repositioning exercise using glasses of augmented reality to see their scapular movement simultaneously. Furthermore, they will also see at the same time a video record of an ideal scapular movement, and will me encouraged to simulate that ideal scapular movement."
75788962|NCT05088668|Other|Scapular repositioning exercise|Subjects will perform scapular repositioning exercises for improving scapular movement.
76080667|NCT06153862|Diagnostic Test|Immuno analytical assay|The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.
76080668|NCT06153849|Diagnostic Test|urine sample collection|Urine samples from patients receiving BCG instillation was collected for LC-WGS to evaluate CIN and urinary microbiome.
76080669|NCT06153823|Other|virtual reality glasses|child behavior management will be done by using VR glasses distraction
76080670|NCT06153823|Other|Tell Show and Do|child behavior management will be done by using tell show and do technique
76080671|NCT06153784|Drug|Hydroxyurea and Thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
76080672|NCT06153771|Other|Collection of brain and kidney NIRS measurements|(recorded continuously) by a person not involved in the study 30 minutes before echocardiography was performed
76080673|NCT06153771|Other|echocardiography|on day 2, day 4 and day 7 of life
76080674|NCT06153745|Device|Tecnis Eyhance ICB00 intraocular lens (Johnson&Johnson Vision, Santa Ana, CA USA)|pediatric cataract surgery
75332144|NCT03670030|Drug|ABI-009|rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
76080675|NCT06153706|Drug|Subgingival application of L-PRF loaded with metronidazole|After phase I therapy, L-PRF loaded medical grade metronidazole was applied sub gingivally into the pockets using blunt gauge needle and Perio-pack was placed (two applications with one week apart were applied subgingivally.
76080676|NCT06153706|Other|Subgingival application of L-PRF|The L-PRF alone was applied subgingivally into the pockets and Perio-pack was placed (two applications with one week apart.
75332145|NCT04271020|Device|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
76080677|NCT06153680|Device|Insoles|"Device : Insoles~At Day 0, the patient received the insoles and adapted them to his shoes.~The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.~The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14."
76080678|NCT06153667|Device|Bearing nsPVA|Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Bearing nsPVA Embolization Particles are used for the embolization of symptomatic (leiomyoma uteri) uterine fibroids.
75640292|NCT00917761|Drug|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
75640293|NCT02709603|Drug|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
75640294|NCT02709603|Drug|placebo|oral placebo; 2 tablets 30 minutes before the procedure
75332146|NCT02924155|Drug|SJP002|"Period 1 (single dose)~Day1: Placebo, Topical administered one drop to each eye (Once a day)~Day2: SJP002, Topical administered one drops to each eye (Once a day)~Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day [0h, 4h, 8h, 12h])~Period 2 (multiple dose) - Day10~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day [0h, 4h, 8h, 12h])"
75470872|NCT01945983|Drug|Placebo|5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
75640295|NCT05162469|Drug|SHR-1909 injection|SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
75640296|NCT02593045|Biological|IPH4102|
75640297|NCT05156775|Other|Serratus Plane Block (SPB)|While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.
75788963|NCT03767192|Device|Active Stimulation|SPG stimulation and standard of care
75788964|NCT03767192|Device|Sham Stimulation|Sham SPG stimulation and standard of care
75788965|NCT03767114|Diagnostic Test|RT-PCR for ERAP1 detection|Reverse transcriptase -Polymerase Chain Reaction for ERAP1 detection
76080679|NCT06153641|Other|N/A-Observational Study|N/A-Observational Study
75470873|NCT01946009|Drug|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.|
76080680|NCT06153628|Other|Virtual reality glasses|Videos consisting of nature and undersea images will be played through virtual reality glasses, which the woman wants to watch and can change whenever she wants.
76080681|NCT06153615|Other|EEG (64 electrodes)|EEG recording while awake, at rest then during an attentional cognitive test
75332147|NCT02924155|Drug|Placebo|"Period 1 (single dose)~Day1: Placebo, Topical administered one drop to each eye (Once a day)~Day2: Placebo, Topical administered one drops to each eye (Once a day)~Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day [0h, 4h, 8h, 12h])~Period 2 (multiple dose) - Day10~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day [0h, 4h, 8h, 12h])"
75332148|NCT03859960|Diagnostic Test|body composition|fat mass % (FM%) and fat-free mass (FFM%)% of arms, legs, trunk, android, gynoid and total body
75332149|NCT03859960|Diagnostic Test|glucose, insulin, glycohemoglobin|In the morning after 12 hours overnight fast, all individuals underwent a 75 gram (g) oral glucose tolerance test (OGTT). Blood samples were taken before loading glucose and then 30, 60, 90 and 120 minutes after taking glucose solution in order to measure serum glucose and insulin levels. Glycohemoglobin (HbA1c) was measured in blood samples taken before the OGTT. We calculated the Matsuda index and Homeostasis model assessment index (HOMA-IR) using glucose and insulin levels.
75332150|NCT01163461|Behavioral|speech therapy|individuals will receive 60 hours of behavioral speech therapy
75332151|NCT03857230|Drug|Follitropin alfa (Primapur)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
75332152|NCT03857230|Drug|Follitropin alfa (Gonal-F)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
75332153|NCT02864485|Procedure|live donor liver transplantation|live donor liver transplantation
75788966|NCT03767036|Drug|Tramadol hydrochloride 25 mg capsule|Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.
75788967|NCT03767036|Drug|Ketorolac Tromethamine 10 mg tablet|Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
75788968|NCT03758144|Drug|Rifaximin 200 MG|patients with type 2 diabetes and gut dysbiosis will be given rifaximin
75788969|NCT01322126|Device|ultrasound probe|we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
76080682|NCT06153615|Other|Cognitive task (SART)|Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)
76080683|NCT06153615|Other|Pupillometry and eye tracking|Study of pupil size and gaze path during the cognitive test (correlated with alertness)
76080684|NCT06153615|Other|Thoracoabdominal belts|Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)
76080685|NCT06153602|Drug|Nalbuphine Hydrochloride 10 MG/ML|Nalbuphine(10mg/ml) 0.08 ml intrathecal
76080686|NCT06153602|Drug|Sodium Chloride 0.9 % in 5 ML Injection|0.9% Sodium Chloride 0.08 ml intrathecal
75332154|NCT02181127|Device|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
75470874|NCT01946022|Drug|randomization between the two GnRH analogues (agonist and antagonist)|
75470875|NCT01946035|Drug|Doxazosin XL|
75470876|NCT01946035|Other|Placebo|
75470877|NCT01946048|Biological|mesenchymal stem cells|"Procedure: Selected patients were randomly divided into a cell therapy group and a control group.~Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million."
75470878|NCT01946061|Drug|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
75470879|NCT01946087|Procedure|Remote ischemic preconditioning at left upper arm|Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) & 5 min reperfusion (deflation)
75788970|NCT03766880|Procedure|Transjugular HVPG measurement|By means of catheterization of a hepatic vein with a balloon catheter.
75788971|NCT03766880|Procedure|MR imaging|MR images for the post-processing analysis
75788972|NCT04908488|Device|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
75788973|NCT04908488|Device|Etafilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
75788974|NCT03766802|Behavioral|Wearable watch training group.|3 orientation session Watch notifies 3/week for exercise
75788975|NCT03766802|Behavioral|Mobile application training group.|"3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise."
75470880|NCT01946087|Procedure|Control group|keeping the cuff deflated
76080687|NCT06153589|Other|Musicotherapy|"Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.~Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.~The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.~The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement."
75332155|NCT03670264|Behavioral|Quitline Incentive|The incentive structure emphasizes engaging with the quitline, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the quitline, for maintaining involvement in the quitline program (compensation per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
75332156|NCT03670264|Behavioral|Tobacco Cessation Incentive|The incentive payment structure emphasizes quitting regardless of engagement with the quitline (though the quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
76080688|NCT06153524|Behavioral|Physical activity|12x weekly advice sessions and autonomous physical activity to gradually build up moderate-vigorous exercise.
75332157|NCT03670264|Behavioral|Way to Health (WTH) Platform|The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
75470881|NCT01946217|Other|questionnaire administration|Ancillary studies
75640298|NCT05156775|Other|Rhomboid intercostal nerve block (RIB)|In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
75640299|NCT00611793|Drug|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
75332158|NCT03670264|Behavioral|Quitline Delivered Treatment|The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
75332159|NCT04241146|Device|Enteric Tube|A post pyloric feeding tube used in patients requiring enteral nutrition
75640300|NCT02709213|Diagnostic Test|Diagnostic|Determination of pathogens and faecal calprotectin in the stools
75788976|NCT03766802|Behavioral|Supervised exercise training group|3/week training supervised by a physical therapist
75788977|NCT04876274|Behavioral|TMU-LOVE|Patients in intervention group could attend diabetes-related health educational video through the TMU-LOVE platform. Researcher would also send 2-3 videos per week with care massage every 2 weeks to the patients.
75788978|NCT03766724|Drug|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD
75788979|NCT03766724|Drug|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin|Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD
75788980|NCT03766724|Drug|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD
75788981|NCT03766724|Drug|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin|Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD
75788982|NCT04865354|Device|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
75332160|NCT04241146|Device|CORTRAK enteral access system|Electromagnetic guidance system for enteric feeding tube placement
75470882|NCT01946256|Drug|Amoxicillin|
75470883|NCT01946256|Drug|Erythromycin|
75788983|NCT04865354|Device|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
75788984|NCT04860518|Drug|IFN beta-1a|Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised
75788985|NCT04860518|Drug|Dexamethasone|Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised
75788986|NCT03110380|Drug|B/F/TAF|50/200/25 mg FDC tablet(s) administered orally once daily
75788987|NCT03110380|Drug|F/TAF|200/25 mg FDC tablet(s) administered orally once daily
75788988|NCT03110380|Drug|DTG|50 mg tablet(s) administered orally once daily
75788989|NCT03110380|Drug|DTG Placebo|Tablet(s) administered orally once daily
75640301|NCT03821337|Device|repetitive Trans Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that is able to alter cortical excitability and is FDA-approved to treat Major Depressive Disorder. Magnetic fields pass unimpeded through the scalp, skull and meninges, and can directly excite cortical areas.
75640302|NCT03821337|Device|Sham TMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real rTMS. This type of sham has been demonstrated to be indistinguishable from real rTMS, has been well tolerated (George et al., 2010; George et al., 2014) and successfully used in other clinical trials (Borckardt et al., 2008; Arana et al., 2008). During each session of rTMS the investigators will present a series of opioid related images, including those utilized in previous studies (Garland et al., 2015; Garland & Howard, 2014).
76080689|NCT06153524|Behavioral|Smartphone time|12x weekly advice sessions and autonomous use of replacement activities and strategies to gradually reduce daily smartphone use.
75332161|NCT01166347|Device|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
75640303|NCT00611871|Drug|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
75640304|NCT00611871|Drug|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
75640305|NCT02709447|Behavioral|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
75640306|NCT02709447|Behavioral|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
75640307|NCT02709291|Behavioral|behavioral parent training|Parents receive up to 6 sessions of the Family Check-Up program
75640308|NCT02709291|Behavioral|interventionist training|Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
75640309|NCT02693301|Other|Exercise program|
75640310|NCT02709525|Drug|hyaluronic acid|
75640311|NCT02709525|Other|Placebo|
75640312|NCT05087589|Drug|Tofacitinib|Tofacitinib 5mg was taken orally twice a day for 6 months
75640313|NCT00741091|Device|Carotid WALLSTENT Monorail Endoprosthesis|A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
75640314|NCT00741091|Device|FilterWire EZ™ System™|Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
75640315|NCT02708979|Other|University exam-period|This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
75788990|NCT03110380|Drug|F/TAF Placebo|Tablet(s) administered orally once daily
75788991|NCT03110380|Drug|B/F/TAF Placebo|Tablet(s) administered orally once daily
75332162|NCT01166347|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
75788992|NCT03757910|Drug|18F-MK-6240|This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
75332163|NCT04240678|Other|Electronic HBV Alert|Electronic HBV Alert deployed in electronic medical charts of at risk patients
75332164|NCT04332094|Drug|Tocilizumab|162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)
75470884|NCT01946269|Other|Goal-directed Resuscitation Therapy (GDT)|"A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.~The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.~When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~The final step will be red blood transfusion to reach a hematocrit higher than 28%.~If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg."
75332165|NCT04332094|Drug|Hydroxychloroquine|400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
75332166|NCT04332094|Drug|Azithromycin|500 mg / day v.o. for 3 days
75470885|NCT01946269|Other|Standard protocol|The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
75470886|NCT01946295|Drug|Famotidine|100mg x 2 p.o.
75640316|NCT02708979|Other|University non-exam-period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
75640317|NCT00611949|Other|Geranium oil|2 applications of topical oil per week for 2 weeks
75640318|NCT05066451|Other|%5 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
75470887|NCT01946295|Drug|Placebo|
75470888|NCT01946308|Other|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
75788993|NCT03757910|Drug|11C-PIB|This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
75788994|NCT03473366|Device|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
75788995|NCT03473366|Device|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
75640319|NCT05066451|Other|%15 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
75640320|NCT05043051|Device|Vagal stimulation|Vagal stimulation
76080690|NCT06153511|Procedure|Robot assisted spinal transpedicular fixation|Surgical technique which joins two or more vetebrae with screws and rods to prevent any relative movement between them. It is a major surgery that usually lasts several hours and in which the patient is subjected to general anesthesia. The screws to be placed go through a narrow area of the vertebra known as the pedicle. Each patient will undergo a singular intervention.
75640321|NCT05043051|Device|Sham stimulation|Sham vagal stimulation
75788996|NCT01322204|Drug|Codeine|One single oral dose of 1 mg/kg of codeine
75788997|NCT01353040|Drug|AVI-6003|Single intravenous administration
75925235|NCT02169141|Other|Pharmacokinetics|multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
75925236|NCT02495012|Drug|placebo|Freeze-dried powder without snake venom will be dissovled in saline
76080691|NCT06153472|Device|VR-based intervention|The Virtual Reality-based sensory stimulation intervention will last for up to fourteen days, with all interventions administered by a research team. The primary outcomes will include delirium incidence, duration, and severity. The secondary outcomes will encompass patients' psychological well-being (post-traumatic stress disorder, sleep quality, and ICU memory), patients' clinical outcomes, and other outcomes (quality of life, independence, and cognitive function).
75332167|NCT05122585|Procedure|MagSeed and MagTrace in breast cancer patiënts|Combining MagSeed and Magtracer to perform a wide local excision breast conserving surgery and sentinel node biopsy.
75332168|NCT04234672|Drug|TAK-831 Oral Tablet|TAK-831 tablet.
75332169|NCT04234672|Drug|[14C]TAK-831 IV Infusion|[14C]TAK-831 IV infusion.
75332170|NCT04234672|Drug|[14C]TAK-831 Oral Suspension|[14C]TAK-831 oral suspension.
75332171|NCT05070715|Other|Analyzing of microplastic level|Blood samples will be taken from the vein of the umbilical cord. Placental tissues will be taken from the maternal side of the placenta. Placental tissues and serum samples will be stored in the temperature set to -80 °C until analysis. Extraction methods involving chemical reactions will be used to separate and purify microplastics in placenta and cord blood samples. After the extraction process, analysis of microplastic levels in tissues and serum will be done by µ-Raman spectroscopy.
75332172|NCT02752243|Drug|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
75640322|NCT02709057|Behavioral|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
75788998|NCT01353040|Drug|Placebo|Single intravenous administration
75332173|NCT03676270|Other|Phase I|Chemotherapy, ITK, Hormotherapy, Immunotherapy
75332174|NCT02980081|Other|abdominal plain x-ray|Abdominal plain x-ray as prescribed by the emergency physician
75332175|NCT05314270|Diagnostic Test|Diagnostic tests|Diaagnostic tests for all pt diagnosed as Non-B Non-C Liver Cirrhosis
75332176|NCT03676972|Device|LithoVue Ureteroscope System|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes.
75332177|NCT02335957|Radiation|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
75332178|NCT03681808|Device|Control|Contact Lens
75332179|NCT03681808|Device|Test|Soft Contact Lens
75332180|NCT01166971|Device|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction
75788999|NCT03766568|Device|JGG endoscope(R)|The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.
75789000|NCT01348750|Other|Healing Touch & Guided Imagery|"Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and the energy centers which control the flow of energy to the physical body.~HT complements traditional health care and is used together with other approaches to health and healing.~Guided Imagery (GI) is a form of focused relaxation used to create harmony between the mind and body. Positive mental imagery can promote relaxation, reduce stress and improve mood as well as alter heart rate, blood pressure and breathing."
75925237|NCT02495012|Drug|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
75925238|NCT02169297|Procedure|Ultrasound-guided Sub-Paraspinal Block|Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter [maximum pump infusion rate]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
75332181|NCT01166971|Device|Tecnis MF|Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
76080692|NCT06153433|Drug|Rosuvastatin Immediate-Release Tablet (IRT) 10mg|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
76080693|NCT06153433|Drug|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
76080694|NCT06153420|Drug|CIN-103|CIN-103 BID
76080695|NCT06153420|Drug|Placebo|Placebo for CIN-103 BID
76080696|NCT06153342|Drug|TL-925|TL-925 is an eye drop.
76080697|NCT06153342|Drug|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
76080698|NCT06153329|Drug|THDB0206 injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
76080699|NCT06153329|Drug|Humalog®|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
76080700|NCT06153329|Drug|BC222insulin lispro injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
76080701|NCT06153316|Other|School shooting incident|The school has experienced a gun shooting incident within the past 2 years of the study (for 3 case schools) and prior to 2 years (for 3 case schools). Incidents where a gun was displayed but no shot was fired, or where a shot was fired by police or security officer will not be included.
75640323|NCT04999371|Behavioral|Brief Alcohol Intervention|"The participants in the treatment group received free three-time counsel and constant multi-media messages about the topic of alcohol consumption for three months. One-to-one counseling services will be provided via a telephone call, which is based on World Health Organization (WHO) recommendations. A total of three counsels are conducted, which are set on the second week, sixth and tenth week after the baseline survey.~Brief intervention counselors are from the team of this study and trained by Hongkong University. All counselors are required to attend a full-day workshop before participant recruitment. The contents of the workshop include (1) knowledge of excessive drinking harms and benefits of controlling drinking; (2) overview of AUDIT; (3) alcohol reduction advice; (4) a standard procedure of brief intervention."
75640324|NCT04999371|Behavioral|Financial Incentive Intervention|The participants in financial Incentive intervention group were conducted by deducting money. Firstly, a certain amount of vouchers were given to the participants, which was equivalent to the reward for passing seven tests. Then, the voucher would be deducted according to every test result. Finally, the participants will receive cash according to the vouchers.
75640325|NCT04087447|Procedure|Thyroidectomy|Thyroidectomy
75640326|NCT02708901|Dietary Supplement|Vivomixx®|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
75789001|NCT04851314|Device|ICU certified ventilator|Examine anesthetic consumption rates
75925239|NCT02169297|Procedure|PCA only|Patients received intravenous PCA post-operatively
76080702|NCT06153238|Drug|GME751|400 mg Q6W, i.v. infusion, over 24 weeks period
76080703|NCT06153238|Drug|Keytruda - EU|400 mg Q6W, i.v. infusion, over 24 weeks period
75332182|NCT04208698|Drug|CIN-102 Dose 1|Deuterated domperidone (deudomperidone)
75332183|NCT04208698|Drug|CIN-102 Dose 2|Deuterated domperidone (deudomperidone)
75640327|NCT02708901|Dietary Supplement|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
75640328|NCT04087525|Drug|HIP1701|Vildagliptin
75640329|NCT04087525|Drug|HGP1809|Vildagliptin
75925240|NCT02494934|Behavioral|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
75925241|NCT02494934|Behavioral|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
76080704|NCT06153238|Drug|Keytruda - US|400 mg Q6W, i.v. infusion, over 24 weeks period
76080705|NCT06153199|Behavioral|Video training - Self-management|Short video modules on self-management of back pain without medication
76080706|NCT06153199|Behavioral|Video training - Ergonomics|Short video module on ergonomic adjustment for limiting back pain in nursery and landscape work
76080707|NCT06153199|Behavioral|Supervisor training|In person discussion of work processes and support for workers to implement self-management and ergonomic modifications
75332184|NCT04208698|Drug|Placebo for CIN-102|Placebo
75470889|NCT01946321|Other|Post-amputation functional rehabilitation (normal clinical practice)|
75470890|NCT01946334|Device|anorectal manometry and high-resolution three-dimensional|
75789002|NCT04851314|Device|Non-ICU certified ventilator|Examine anesthetic consumption rates
75789003|NCT01348906|Procedure|intermittent normoxia|3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
75789004|NCT03757754|Drug|HPPH 2.5 mg/m2|HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
75789005|NCT03757754|Drug|HPPH 3 mg/m2|HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
75789006|NCT03757754|Drug|HPPH 3.5 mg/m2|HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
75925242|NCT02169375|Other|Brain computer Interface Mu (SMR) rhythm|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
75640330|NCT00612651|Drug|Temodar and SCH 66336|2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated & escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle & escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning & evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 & 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
75332185|NCT01167595|Other|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
76080708|NCT06153199|Behavioral|Guided choice of ergonomic options matched to most difficult tasks|Survey based guidance on ergonomic choices appropriate for work tasks that are the most difficult due to back pain
75332186|NCT03835078|Device|methafilcon A contact lenses|Bilateral daily wear of methafilcon A contact lenses
75332187|NCT03835078|Device|fanfilcon A contact lenses|Bilateral daily wear of fanfilcon A contact lenses
75332188|NCT02184169|Device|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
75332189|NCT02184169|Device|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
75332190|NCT03681886|Device|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
75640331|NCT02592577|Biological|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
75925243|NCT04496492|Drug|Tocotrienol|Tocotrienol 200 mg orally twice a day
75925244|NCT02500004|Radiation|18F-FDG PET-MRI-imaging|BAT activity: 18F-FDG PET-MRI-imaging.
75332191|NCT03681886|Procedure|Optic Exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
75925245|NCT02500004|Radiation|DXA scanning|Body composition: DXA scanning, D2O and MRI.
76080709|NCT06153199|Behavioral|Prioritized lists of self management options|Survey based guidance for prioritized choices of self-management
76080710|NCT06153199|Behavioral|Text reminders|Reminders to implement choices
76080711|NCT06153186|Drug|Flunarizine Hydrochloride|Flunarizine tablet
76080712|NCT06153160|Device|HemaShock device|The HemaShock is a tight silicone ring attached to a pressure stocking. It comes wrapped into a doughnut and has a set of handles. The operator simply puts the doughnut over the foot or hand, and pulls on the handles to unravel the HemaShock while applying pressure throughout the appendage. The device displace blood from limbs to central blood system, thus improving preload and cardiac output.
75332192|NCT01167829|Drug|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
75332193|NCT01167829|Drug|Acyline|300 ug/kg injection on Day 0
75332194|NCT03820258|Drug|SOF/VEL/VOX|Administered once daily with food.
75332195|NCT02066623|Device|ABSORB Scaffold|Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
75332196|NCT04974151|Drug|Amlodipine besylate tablets|The amlodipine used in this study is a listed product. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
75332197|NCT04974151|Drug|Amlodipine besylate And Folic Acid Tablets|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
75925246|NCT02500004|Procedure|Abdominal subcutaneous adipose tissue biopsy|Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
75925247|NCT02500004|Procedure|Blood sampling|Systemic inflammatory profile: blood sampling.
75925248|NCT02500004|Other|Indirect calorimetry|Resting metabolic rate: indirect calorimetry.
75925249|NCT02500004|Device|Accelerometry|Physical activity level: accelerometry.
75925250|NCT02500004|Other|Double-labeled water|Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
75925251|NCT02500082|Drug|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
75925252|NCT02499848|Drug|PRX302|Single prostate cancer lesion injected with PRX302.
75925253|NCT02502188|Drug|CC-90005|
75925254|NCT02502188|Drug|Placebo|
76080713|NCT06153134|Drug|10% Curcuma xanthorriza Roxb.|Patients in experimental arms will receive 10% Curcuma xanthorriza Roxb. cream for 2 months
76080714|NCT06153134|Drug|2% Kojic Acid|Patients in experimental arms will receive 2% Kojic Acid cream for 2 months
76080715|NCT06153108|Device|PAMSys pendant PAMSys wrist sensors|The PAMSysTM sensor consists of a 3-axis accelerometer, battery, and built-in memory for recording long-term data. Accelerometer data is recorded at a sampling frequency of 50 Hz
75789007|NCT03757754|Drug|HPPH 4 mg/m2|HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
75640332|NCT03961321|Radiation|stereotactic mr guided adaptive radiotherapy|Study patients will be treated with an online MR-guided hypofractionated course of radiotherapy in 5 fractions of 7.25 Gy per fraction delivered on the prostate with a simultaneous integrated sparing (SIS) of the urethra with a dose of 32.5 Gy in 5 fractions (6.5 Gy per fraction).
75925255|NCT02502032|Drug|Cisatracurium|Different groups received different pretreatments of cisatracurium.
75925256|NCT04495244|Diagnostic Test|Syantra DX Breast Cancer|Blood test for detecting the presence of breast cancer.
75925257|NCT03343496|Procedure|Awake fiberoptic intubation (AFOI)|With forty patients (ASA I~II, aged 18~75, simulating cervical instability injury) recruited to be operated on under general anesthesia, two experienced anesthesiologists performed the whole procedures within the study. Pre anesthetic interview was taken to illustrate the procedures of tracheal intubation to the patients. The simplified method consisted of three parts: conscious sedation, regional anesthesia and intubation. The time of AFOI, rate of one-time intubation success, hemodynamic parameters, pulse oxygen saturation (SpO2), rate of amnesia of the intubation, patients' satisfaction, and relative complications were recorded accordingly.
75925258|NCT02494856|Drug|Surgery with Naproxen|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
75925259|NCT02494856|Drug|Surgery with Naproxen and Esomeprazole|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
75332198|NCT04974151|Drug|5-methyltetrahydrofolate (5-MTHF)|The 5-MTHF used in this study is a listed product. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (0.2mg/tablet, 200 tablets/bottle).
75332199|NCT04195594|Other|Nic's Keto Diet|Participants will be instructed to follow Nic's keto diet plan for 140 days. They will be asked to not exceed 20 g of carbohydrates (up to 5% caloric intake) and to consume the remaining 70% of calories from fat sources and 25% from protein sources.
75640333|NCT00918307|Drug|Varenicline|Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily
75640334|NCT00918307|Drug|Placebo|Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
75640335|NCT00741013|Drug|placebo pill and placebo IV|"Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
75640336|NCT00741013|Drug|Lovastatin pill and placebo IV|"lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
75640337|NCT00741013|Drug|placebo pill and recombinant human activated protein C IV|"placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
75640338|NCT00741013|Biological|Endotoxin|Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
75789008|NCT03757754|Drug|HPPH 5 mg/m2|HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
75789009|NCT03757754|Drug|HPPH 6 mg/m2|HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
75789010|NCT03675724|Dietary Supplement|Fisetin|Flavonoid Family
75925260|NCT04495010|Biological|Nivolumab|Specified dose on specified days
75470891|NCT01946347|Other|mixed meal|"Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g."
75470892|NCT01946347|Other|Acute in vivo induced hyperinsulinemia|Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
75925261|NCT04495010|Biological|Ipilimumab|Specified dose on specified days
75925262|NCT02169531|Drug|ex vivo Activated Immune Cells|The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
76080716|NCT06153095|Biological|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
75470893|NCT01946360|Device|Methacetin Breath Test in ACLF and ALF patients|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
75470894|NCT01946386|Drug|LEO 90100 Aerosol, foam|The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
75470895|NCT01946386|Drug|Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle|
75470896|NCT01946386|Drug|LEO 90100 Aerosol, foam, vehicle|
75789011|NCT03675724|Drug|Placebo oral capsule|Placebo
75925263|NCT03539913|Biological|Probiotic : Saccharomyces boulardii|Treatment for 5 days
75925264|NCT03539913|Biological|Probiotic : Bacillus clausii|Treatment for 5 days
75925265|NCT03539835|Other|Resistance training (RT)|Resistance training (RT) will include 15 repetitions for two sets and to exhaustion on the third set for seven major muscle groups: the leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl. Resistance is gradually increased to account for strength gains when subjects are able to complete 20 repetitions on the third set.
75470897|NCT01946386|Drug|Daivobet® ointment|
75470898|NCT01946386|Drug|Dermovate® cream|
75470899|NCT01946386|Drug|Synalar® ointment|
75470900|NCT01946399|Drug|Ozurdex implant|Intravitreal injection of Dexamethasone implant
75470901|NCT01946555|Drug|Morphine|
75470902|NCT01946555|Drug|Fentanyl|
75925266|NCT03539835|Behavioral|Cognitively-based compassion training control (CBCT)|Cognitively-based compassion training control (CBCT) classes will be performed in a group setting for 1.5-2 hours per week, and consist of didactics, class discussion, and guided meditation practice. Each class will begin with a period of meditation to calm and focus the mind, followed by analytical practices designed to challenge unexamined assumptions regarding feelings, and actions toward others with a focus on generating spontaneous empathy and compassion for themselves and others.
75640339|NCT05375851|Other|Digital Interventions|"The digital interventions will consist of two parts:~A) Psychoeducation videos: Five psychoeducation videos on mental health and GAD will be produced especially for the research to be watched by the patient between consultations. These videos will last approximately 3 minutes, will use animations and educational content. They will be available on +PSI app. The topics of the videos will be as follows: Normal Anxiety versus Pathological Anxiety; Sleep Hygiene; Healthy Eating and Mental Health; Physical Exercise and Mental Health; Excessive Consumption of Alcohol and Drugs.~B) GAD-7 Scale: The patient will be instructed to respond to the GAD-7 self-administered scale the day before their next scheduled appointment. This instrument will also be available free of charge on +PSI mobile app and will be used to guide clinical management."
75640340|NCT05375851|Drug|Treatment as Usual|"The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil."
75640341|NCT05373745|Behavioral|Active Brains 1|Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
76080717|NCT06153095|Biological|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
76080718|NCT06153095|Biological|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
76080719|NCT06153082|Diagnostic Test|ROTEM|In ROTEM group if CT EXTEM >80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM <35 and MCF FIBTEM <8 CRYO or Fibrinogen concentrate, if MCF EXTEM<35 and MCF FIBTEM >8 Platelet, CL LY>50 Trenaxemic acid
75470903|NCT01946555|Drug|Methadone|
75470904|NCT01946555|Drug|Buprenorphine|
75470905|NCT01946555|Drug|Oxycodone|
75925267|NCT03343418|Drug|Desmopressin|Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
75470906|NCT01946555|Drug|Hydromorphone|
76080720|NCT06153082|Diagnostic Test|Thromboelastography|Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.
76080721|NCT06153056|Diagnostic Test|Bloed-, ontlasting- en speekselmonsters|"In addition, the blood collected (24 mL) will be used for the following analyses:~GLP-1, PYY, branched-chain amino acids, Adipokines, leptin, adiponectin Blood bile acid levels: total and detailed analyzed by HPLC MS/MS Serum microbiome profile Genome-wide association study.~The stool sample will be used to establish the :~Intestinal bile acid profile Intestinal microbiota profile Saliva sampling for oral microbiota profiling."
75470907|NCT01946555|Drug|Tapentadol|
75470908|NCT01946568|Drug|Dalbavancin|Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients <5 years of age.
75470909|NCT01946581|Procedure|Cataract Surgery|
75925268|NCT03343418|Drug|Placebo|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
75925269|NCT03539757|Device|Non-Contrast Magnetic Resonance Imaging|The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
75332200|NCT04918693|Device|Ultrasound scanning|All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
75470910|NCT01946594|Other|Acetaminophen|
75470911|NCT01946594|Other|Placebo|
75470912|NCT01946607|Drug|Citalopram|
75470913|NCT01946607|Drug|Placebo|
75470914|NCT01946620|Drug|Flutiform|
75470915|NCT01946620|Drug|Formoterol|
75470916|NCT01946633|Device|magnetic-controlled capsule endoscopy(Navicam)|
75470917|NCT01946646|Drug|S-1-CCRT|
75470918|NCT01946659|Behavioral|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
75470919|NCT01946659|Other|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
75470920|NCT01946737|Radiation|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)|
75470921|NCT01946737|Radiation|Active Comparator: Invasive coronary angiography (ICA)|
76080722|NCT06153043|Other|Women patients with classical congenital adrenal hyperplasia|The Easily and Médifirst medical files of these patients will be studied in order to collect the desired variables. If the files are incomplete, and if data concerning fertility, pregnancy, and the characteristics of the newborn are missing, patients will be contacted to ask them to answer the questionnaire to obtain this information.
76080723|NCT06153030|Other|no intervention|No intervention
75640342|NCT05373745|Behavioral|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight and Medical appointments. The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity."
75640343|NCT04087603|Behavioral|Weekend Morning Bright Light & Early Bedtime|
75640344|NCT02592967|Biological|JNJ-64041757 (Cohort 1A and 1B)|JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU] ) and at a higher dose in Cohort 1B (1x10^9 CFU)
75640345|NCT02592967|Biological|JNJ-64041757 (Cohort 2A and 2B)|JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
75789012|NCT03757676|Behavioral|No Play|Participants in this group were asked not to download or play Pokémon Go during the study period and were asked to simply continue with their normal daily activities. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
76080724|NCT06152991|Drug|GODEX|"The amount of active ingredient per dose (1 capsule)~Carnitine Orotate 150mg~liver extract antitoxic fraction 12.5㎎~Adenine Hydrochloride 2.5mg~Pyridoxine Hydrochloride 25mg~Riboflavin 0.5mg~Cyanocobalamin 0.125mg~Biphenyl Dimethyl Dicarboxylate 25mg"
76080725|NCT06152991|Drug|Placebo|"Anhydrous lactose 50mg.~Colloidal silicon dioxide 12mg.~Amorphous cellulose 50mg.~Lactose monohydrate 215.625mg.~Magnesium stearate 7mg.~Upper and lower brown opaque capsules 77mg."
75470922|NCT01946750|Biological|Serum|
75470923|NCT01946750|Biological|Stools|
75925270|NCT02499926|Dietary Supplement|Arginine|"Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals."
76080726|NCT06152978|Drug|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
75470924|NCT01946750|Biological|Saliva|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
76080727|NCT06152978|Drug|Chemotherapy|Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
76080728|NCT06152939|Other|Primary percutaneous coronary intervention or thrombolytic therapy|Primary percutaneous coronary intervention or thrombolytic therapy
75470925|NCT01946750|Biological|Whole blood|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
75640346|NCT04087759|Drug|Bedaquiline (Test formulation)|Participants will receive bedaquiline orally.
75640347|NCT04087759|Drug|Bedaquiline (Reference formulation)|Participants will receive bedaquiline orally.
75640348|NCT00740857|Drug|placebo|2 placebo gels capsules delivered as a single dose.
75640349|NCT00740857|Drug|ibuprofen Formulation 1|2 marketed ibuprofen gels
75640350|NCT00740857|Drug|ibuprofen Formulation 2|2 marketed ibuprofen gels
75640351|NCT02595853|Other|Non interventional study|All upper gastro-intestinal bleeding need endoscopic hemostasis. Endoscopic hemostasis conventional methods are injection of saline with epinephrine, placement of hemoclips and thermic or plasma coagulation. Hemospray™ will be sprayed onto bleeding lesions seen in endoscopy after failure of conventional methods or in salvage therapy at the discretion of endoscopists. Retrospective analysis of prospectively cellected data.
75640352|NCT05239663|Drug|Ganglioside-Monosialic Acid|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
75640353|NCT05239663|Drug|250ml normal saline (NS)|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus 250ml normal saline (NS)
75640354|NCT00808132|Drug|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
75789013|NCT03757676|Behavioral|At Will Play|Participants in this group were asked to download Pokémon Go and play for at least 30 minutes initially, then play as much or as little as desired during the 4 week intervention period, with no specific instruction or goals for play. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
75925271|NCT03539679|Other|Encouraging physical activity.|Encouraging physical activity with motion sensor's feedback.
76080729|NCT06152926|Other|Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions|"People diagnosed with a urological cancer receiving Immune checkpoint inhibitor treatment at a single centre trust will be invited to either face to face or online video-conference individual interviews (Microsoft teams) according to participant preference.~Consenting participants will be interviewed via semi-structured interview methods round a topic guide and audio-recorded. Inductive thematic analysis will be conducted to explore participant experiences and perceptions of physical activity and exercise."
75332201|NCT01924819|Drug|Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel|"Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)"
75640355|NCT00808132|Drug|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
75332202|NCT01924819|Radiation|Preoperative chemoradiotherapy|"Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
75470926|NCT01946763|Behavioral|pre operative education|Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.
75470927|NCT01946763|Behavioral|pre operative education|
75640356|NCT00808132|Drug|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
75640357|NCT00808132|Drug|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
75640358|NCT00808132|Drug|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
75640359|NCT00727441|Biological|GVAX pancreatic cancer vaccine|Given intradermally
75640360|NCT00727441|Drug|cyclophosphamide|Given IV (Arm B), given orally (Arm C)
75640361|NCT02983279|Dietary Supplement|Dietary Intervention|Undergo caloric restriction diet
75640362|NCT02983279|Other|Counseling|Undergo counselor-led dietary counseling
75640363|NCT02983279|Procedure|Therapeutic|Undergo standard of care surgery
75640364|NCT00717769|Drug|SUN13834|Low dose, orally 3 times a day (tid) for 28 days of SUN13834
75640365|NCT00717769|Drug|Placebo|Placebo, orally (tid) for 28 days of SUN13834
75640366|NCT04153929|Drug|BI 456906|Solution for Injection
75640367|NCT04153929|Drug|Placebo|Solution for Injection
75640368|NCT04153929|Drug|Semaglutide|Solution for Injection
75640369|NCT02606890|Other|MRI|Stroke patients routinely undergo MRI at Charite Campus Benjamin Franklin. Type of MRI stroke pattern is evaluated with regard to presence or detection of (new) atrial fibrillation.
75925272|NCT03341780|Procedure|amblyopia therapy|Any of the following amblyopia training activities may be employed during patching: board games, card games, coloring in O's, comic books, craft projects, crossword puzzles, dot-to-dot patterns, drawing, hammering nails, jacks, jigsaw puzzles, lego and other blocks, marbles, mazes, peg-board activities, perceptual materials, pickup sticks, reading, sewing, shooting games, stringing beads, throwing or hitting games, tracing, and video or computer games.
75925273|NCT05504096|Device|Actxa BGM Tracker (GLO2)|Wrist-worn wearable
75925274|NCT05504096|Device|SVT In-Ear Prototype (IEP)|In-Ear wearable
75925275|NCT03341702|Other|penintetiary's incident reports collection|collection of clinical and penitentiary 's data
75925276|NCT02174289|Device|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
75925277|NCT03341624|Procedure|cataract surgery cataract extraction and intraocular implantation|
75640370|NCT00591214|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
75640371|NCT00612729|Procedure|Polylens Y30 intraocular lens|cataract surgery
75640372|NCT00612729|Procedure|Orange Series Model PC 440 Y intraocular lens|cataract surgery
75640373|NCT05754268|Procedure|Chinese version of the surgical risk assessment system|There is no need to interfere with the patient. Investigators can observe the outcome after using the system for evaluation.
75640374|NCT05715346|Drug|LEV102 1.0%|Oxymetazoline ophthalmic gel
75640375|NCT05715346|Drug|LEV102 2.0%|Oxymetazoline ophthalmic gel
75640376|NCT05715346|Drug|Vehicle|Vehicle ophthalmic gel
75925278|NCT02176785|Device|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
75470928|NCT01946776|Device|implantable heart rate monitor|Implantation of Reveal XT
75470929|NCT01946789|Biological|ALT-803|Intravenous infusion for dose level 1-5; subcutaneous injection for dose level 5a-8; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
75470930|NCT01946828|Device|FIM|Field Induced Mydriasis device
75470931|NCT01946841|Dietary Supplement|RealDiet®Renal|
75640377|NCT00613431|Drug|CS8080|CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
75640378|NCT00613431|Drug|Placebo|Some subjects will receive matching placebo instead of CS-8080.
75640379|NCT00914368|Drug|Clopidogrel|Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
75925279|NCT02501798|Drug|Methylphenidate|Drug: Methylphenidate
75925280|NCT02501798|Drug|Placebo|Drug: Placebo
75640380|NCT04168983|Other|sophrology|Sophrology session provided by a nurse sophrologist in addition to the usual care during BMAB
75640381|NCT00725725|Behavioral|Cognitive-behavioral therapy|Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
75640382|NCT00725725|Drug|Org 25935|4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
75640383|NCT00725725|Drug|Org 25935|12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
75640384|NCT00725725|Drug|Placebo|Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
75925281|NCT02501720|Procedure|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
75925282|NCT02501720|Procedure|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
75332203|NCT01924819|Procedure|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers [Siewert Type II and Siewert Type III] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
75640385|NCT02607982|Drug|Paclitaxel|PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
75640386|NCT02607982|Drug|Oxaliplatin|oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.
75640387|NCT02607982|Radiation|Radiotherapy|Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
75640388|NCT02692989|Procedure|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
75640389|NCT04886115|Other|Neuromuscular evaluation|"Before and after training.~Muscle function:~voluntary maximal isometric force of the knee extensors~evoked force in the knee extensors by double percutaneous electrical stimulation at 100 and 10 Hz~level of voluntary activation~voluntary maximum force in concentric and eccentric mode at an angular speed of 60°.s-1~squat jump and counter-movement jump"
75640390|NCT04886115|Other|Assessment of aerobic capacity, muscle architecture and habituation to the eccentric pedaling task|"Before and after training.~Cardiovascular-respiratory function:~Oxygen consumption during the incremental concentric pedaling test conducted to high effort perception.~heart rate during pedaling tasks~Muscle architecture:~- Pennation angle and thickness of vastus lateralis, rectus femoris, gastrocnemius medialis and lateralis muscles, before and after training.~Familiarization with eccentric pedaling"
75640391|NCT04886115|Other|Pedaling at 15 rpm|3 training sessions per week for 6 weeks
75640392|NCT04886115|Other|No pedaling, usual activity|Maintain usual physical activity and diet for a period of 6 weeks.
75640393|NCT04886115|Other|Pedaling at 60rpm|3 sessions per week of training for 6 weeks
75640394|NCT00725101|Drug|Treatment for Fibromyalgia|FM participants starting any new pharmacologic FM agent.
75640395|NCT04882293|Drug|Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose|1 tablet once a day, 20 mg /160 mg, Orally
75789014|NCT03757676|Behavioral|Goal Oriented Play|Participants in this group were asked to download and play Pokémon Go and achieve a minimum player level of 20 within the game during the study period. They were given materials that described game features and functions to show them how to play the game. There were no restrictions on which features to pursue within the game to achieve this goal nor on how long or how frequent their play sessions should be. Upon reaching their goal (Level 20), participants were encouraged to continue to play as much or as little as they desired. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
75789015|NCT03766490|Drug|Anlotinib Hydrochloride|Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle
75789016|NCT03766490|Drug|Gefitinib|Tablet, P.O. 250mg qd
75789017|NCT03766490|Drug|Icotinib|Tablet, P.O. 125mg tid
75789018|NCT03645070|Device|multipolar and self expandable thermometer|Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.
75789019|NCT03645070|Device|Single probe thermometer|Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury
75789020|NCT01348984|Drug|transdermal fentanyl patch|TFP = transdermal fentanyl patch (50 microgram/hour)
75789021|NCT01348984|Drug|placebo patch|group 2 = placebo patch
75925283|NCT02501720|Procedure|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
75925284|NCT02174367|Device|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
75925285|NCT05503004|Behavioral|Prehabilitation|10 min exercise, 5 min respiratory mindfulness, and preoperative nutrition assessment.
75925286|NCT05503004|Behavioral|Standard care|Standard care before surgery
75789022|NCT01567670|Drug|Naloxone|2 mg x 1-2
75789023|NCT01567670|Drug|naloxone placebo|h2o placebo spray
75798735|NCT01285830|Dietary Supplement|Lactobacillus reuteri|The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
75925287|NCT02169609|Drug|Dinutuximab. Immunotherapy|"Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy."
75925288|NCT02499614|Drug|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
75925289|NCT02169687|Device|HIFU|High Intensity focalized Ultrasounds
75925290|NCT02501876|Other|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
75925291|NCT02169765|Other|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
75640396|NCT04882293|Drug|Atorvastatin (Lipitor ®)|1 tablet once a day, 20 mg, Orally
75332204|NCT01168687|Drug|Levetiracetam (Keppra)|"Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days."
75470932|NCT01946893|Behavioral|Mindfulness Meditation|A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.
75640397|NCT04866693|Other|None - this is an exploratory qualitative study to understand patient safety problems in community-based mental healthcare.|Qualitative study
75332205|NCT01168687|Drug|Placebo|
75640398|NCT04862715|Drug|Ferinject|"Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited"
75640399|NCT04862715|Other|Placebo: NaCl (sodium chloride 0.9%)|Medication name: NaCl (sodium chloride 0.9%) Active ingredient: NaCl (sodium chloride 0.9%) Dosage form: 0.9% w/v NaCl as sterile solution in water for injection Excipients: Water Strength/Packaging: 100 ml container with 100 ml normal saline Manufacturer: As per local hospital supplier
75640400|NCT04856475|Drug|Neratinib|"As per investigator's choice, eligible subjects in all cohort will receive:~Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)"
75640401|NCT04106739|Device|Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)|"This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary."
75640402|NCT03954691|Other|brain tumor-immune cells communication|tumoral and immune cell isolation from biopsis
75640403|NCT03755895|Other|formal hypnosis|patients will have brachytherapy detachment under Kalinox and formal hypnosis
75640404|NCT03755895|Drug|Kalinox|patients will have brachytherapy detachment under Kalinox
75332206|NCT03685396|Biological|Platelet rich fibrin ( PRF)|"Venous blood was collected with a butterfly needle in two 10 mL tubes without anticoagulants or other chemicals. The tubes were immediately centrifuged at 3000 rpm for 10 minutes.~At the end of centrifugation a fibrin clot (PRF) was obtained in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. The PRF clot was taken from the tube and the red cells portion at the base of the clot was eliminated with sterile scissors Then the PRF was enveloped in sterile gauzes and positioned between two glass plates: the compression drove out the serum from the clot obtaining PRF membranes that were ready to be used in the surgical site."
75332207|NCT03685396|Drug|hemostatic agents with oxidized and regenerated cellulosa|In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
75332208|NCT04214080|Other|Neurodevelopmental treatment (NDT)|NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.
75640405|NCT04824885|Device|Chlorhydric acid based acid concentrate for bicarbonate hemodialysis (medical device)|usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months
75640406|NCT02608060|Drug|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
75640407|NCT03504579|Other|rt-fMRI neurofeedback|use of real time fMRI neurofeedback to achieve targeted brain changes
75640408|NCT02607826|Procedure|Starvation|Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
75640409|NCT02607670|Drug|TAT4 Gel|
75640410|NCT02607670|Drug|Matching placebo|
75798736|NCT01285830|Dietary Supplement|Placebo|The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
75798737|NCT03091738|Drug|Ramelteon Pill|Patients with compensated cirrhosis and insomnia will be provided ramelteon
75798738|NCT01179360|Other|Integrated FDG PET/CT|Optimized PET/CT imaging with dedicated head-and-neck protocol
75332209|NCT04214080|Other|Feeding and oral-motor intervention strategies|Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.
75332210|NCT04214080|Other|Neck and trunk stabilization exercises|Trunk control affects head control. After gaining head control, it causes jaw stability and oral motor control (tongue control and lip closure). All of these affect communication and quality of life.
75640411|NCT05357599|Diagnostic Test|EUS|The decision to start a beta-blocker will be made at the conclusion of the EGD based on the endoscopic findings (presence of esophageal varices)
75640412|NCT04905381|Behavioral|Usual care|This arm receives usual care (control group)
75640413|NCT04905381|Behavioral|LENA Star Program sessions|LENA Start is an evidence-based community program designed to engage families and help them learn how to increase conversation with their children during the first few years of life.
75789024|NCT01349062|Drug|"Kallunk oxide (Immunotherapy) "|"The study is assigned Arm 1 above 450 cu/mm^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
75789025|NCT03100240|Procedure|Modified Supper Long Protocol|In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
75789026|NCT04848662|Drug|BDA MDI (PT027) 160/180 μg|Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.
75789027|NCT04848662|Drug|Pulmicort Respules 0.5 MG/ML Inhalation Suspension|Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.
75789028|NCT03766412|Other|High School start time|The time that the school starts
75789029|NCT03757598|Other|ePartogram use|Electronic partograph based on WHO standard paper partograph is given in Android tablet used by provider monitoring clients in labor. Providers had received training in using the ePartogram and ongoing trouble shooting.
75925292|NCT02169765|Other|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
75925293|NCT03341468|Device|Urethral catheter immobilization|"Subjects assigned to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial.~Subjects will be asked to fill out a symptom-based questionnaire prior to leaving the office. This will conclude their participation in the study."
75925294|NCT02169843|Drug|Sevoflurane|inhale Sevoflurane
75925295|NCT02169843|Drug|Dexmedetomidine|intravenous pumping Dexmedetomidine 0.2µg/kg/h
75925296|NCT02169843|Drug|Placebo(for Dexmedetomidine)|normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
75925297|NCT03341390|Drug|Aspirin|1 x 325 mg tablet of aspirin administered once daily
75925298|NCT03341390|Drug|BMS-986177|200 mg of BMS-986177 administered twice daily
75789030|NCT03757520|Diagnostic Test|Pain Pressure Threshold|The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.
75798739|NCT03631888|Diagnostic Test|preoperative abdominal ultrasound examination|Performing preoperative abdominal ultrasound examination in patients that will be scheduled for elective laparoscopic surgery for any gynecologic indication
75925299|NCT03341390|Drug|Placebo|200 mg of Placebo administered twice daily
75332211|NCT01169311|Device|Hemorrhoidopexy|
75332212|NCT03688282|Device|Wearable vibration belt|The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
75332213|NCT03688282|Device|Sham, wearing belt|The device is worn, for a specified time. It will not be turned on during this period. It is only sham.
75332214|NCT01126255|Drug|Clobetasol propionate 0.05%|Topical application, once daily about 2 g, during 12 weeks
75332215|NCT01126255|Drug|Progesterone 8%|Topical application, once daily about 2 g, during 12 weeks
75640414|NCT04085575|Drug|Acide Tranexamique|Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007. They were assigned in two groups: 1 g of intra-articular tranexamic acid (TXA) and 2 g of intra-articular tranexamic acid.
75640415|NCT04796883|Device|Hanita Glaucoma shunt Ver.3.2|The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.
75640416|NCT04071015|Device|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line.
75640417|NCT00585169|Drug|Memantine Hydrochloride|10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
75640418|NCT00807742|Drug|Nicotine Replacement Treatment (NRT)|Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.
75925300|NCT02169921|Device|Atherectomy Catheter|"Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm."
75925301|NCT02499536|Device|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
75925302|NCT02174445|Drug|Imatinib|Imatinib, 400 to 800 mg p.o., daily
75925303|NCT02174445|Drug|Nilotinib|300mg p.o., twice-daily
75925304|NCT02501408|Device|propriofoot prosthesis|Adaptation of the device and evaluation after 1 month at home using the studied device
75925305|NCT02499458|Other|None- observational study|
75925306|NCT00708032|Device|spectacles|habitual spectacles
75925307|NCT00708032|Device|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
76080730|NCT06152900|Device|Accufit|"Magnet-based and Direct muscle stimulation devices are commonly used to generate current flow through the muscles in order to activate the muscle. The Accufit Electrical Muscle Stimulation device is an FDA cleared device having a two-channel stimulator that provides up to 8 electrodes with waveforms of interferential and biphasic for muscle stimulation. The Accufit system is indicated for relaxation of muscles, muscle re-education, reduction of pain and increased local blood circulation.~Muscle stimulation technology has been around for many decades and has been shown to be safe and effective for a variety of clinical applications. The foundational basis for the technology revolves around electrical current flowing through the muscle can be used to activate the muscle."
75332216|NCT04198948|Drug|Omeprazole|Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.
75332217|NCT04198948|Drug|Placebo oral tablet|Placebo will be administered orally once daily for 5 days in one of the two treatment periods.
75332218|NCT04198948|Drug|Gliclazide|Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.
75640419|NCT00807742|Behavioral|Brief Advice|Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
75332219|NCT01169467|Drug|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
75332220|NCT01169467|Other|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
75470933|NCT01946893|Behavioral|Education|The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
75640420|NCT00807742|Behavioral|Contingency Management|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
75640421|NCT00807742|Behavioral|Non-Contingent Reinforcement|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
75640422|NCT04085497|Other|Treatment|KT application: KT application includes 2 stages. The banding in the first step is directed to the patellar tendon in order to absorb the load of the knee. The second step is directed directly on the medial plica to benefit from its analgesic effect. For the first step, an I-band is measured from the top of the patella to the tuberositas tibia. I-band is 6 cm wide and 5 mm thick. This I-band is cut into Y-band. First, the part of the band above the patella is pasted with 10% tension. Then the patient's knee is flexed to maximum flexion and the tails of the band are pasted around the patella with 0% tension. The tails of the band are combined together on the tuberositas and completed. For the second step, 4 I-bands 8 cm long and 1.5 cm wide are prepared. The middle of the I-bands is attached to the medial plica with a 0% tension, giving a star shape.
75789031|NCT03757520|Diagnostic Test|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected."
75789032|NCT03766334|Dietary Supplement|Highland Barley Diet|Highland Barley Diet(20g, thrice-daily)
75925308|NCT02178267|Dietary Supplement|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
75789033|NCT03701516|Device|etafilcon A with novel molding process|TEST Lens
75789034|NCT03701516|Device|etafilcon A with current molding process|CONTROL Lens
75925309|NCT00707174|Drug|Imiquimod Cream|Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve
75332221|NCT04186780|Other|Shiitake cereal bar|patients with borderline cholesterol exposed to bars with Shiitake
75332222|NCT04822363|Drug|Aspirin|Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B
75332223|NCT04822363|Drug|Clopidogrel|Arms C and E
75332224|NCT01170247|Drug|Ketamine|Intranasal Ketamine (100 mg/mL)
75332225|NCT01170247|Drug|Ketamine|Intramuscular Ketamine
75470934|NCT01946906|Drug|Rifaximin|
75470935|NCT01946945|Genetic|Next Generation Sequencing after Blastocyst biopsy|PGD using blastocyst biopsy and testing of the biopsy by NGS
75470936|NCT01946958|Behavioral|Training in PC Triple P|PC Triple P is a brief parenting intervention combining specific advice from provider with parent rehearsal and self-evaluation.
75789035|NCT04351256|Drug|Durvalumab Injection [Imfinzi]|Durvalumab fixed dose of 1,500 mg
75789036|NCT04351256|Radiation|Thoracic Radiotherapy (TRT) conventionally|Conventionally fractionated TRT consisting of 30 x 2 Gy (60 Gy) within 6 weeks
75925310|NCT00707174|Drug|Tazarotene Cream 0.1%|Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
75925311|NCT02177019|Other|Personalized health plan|
75925312|NCT03341234|Drug|Bupivacaine|30 ml %0,25 bupivacaine
76080731|NCT06152887|Device|Sooma Oy (tDCS), Helsinki, Finland|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1)
75925313|NCT03341234|Drug|Saline|2 ml saline subcutaneously
75925314|NCT03341234|Device|Ultrasound|Ultrasound guided block
75640423|NCT04741815|Device|Forced Air Warming|It consists of the WarmAir® unit and FilteredFlo® blankets. FilteredFlo® blankets are a cover designed to cover the entire body and extremities with air channels that provide the appropriate distribution of patient warm. The WarmAir® warming device connected to the shroud via a pipe; it has three temperature settings, 32.2 C, 37.8 C, and 43.3 C.
75640424|NCT04741815|Device|Peripheral Carbon Fiber Warming|It was developed by the researcher. Designed as gloves and socks, these warming materials have three layers. The first layer in contact with the patient and the third layer in contact with the external environment is a thermal material to maintain body temperature. The second floor consists of a USB-connected carbon fiber warmer and foil.
75640425|NCT03413163|Drug|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
75640426|NCT03413163|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
75640427|NCT00724945|Device|balafilcon A|multifocal contact lens
75640428|NCT00724945|Device|senofilcon A|multifocal contact lens
75640429|NCT05754112|Other|B lymphocyte profiling|All individuals will undergo peripheral venous blood sampling and ultrasound-guided synovial tissue biopsy following a standardized procedure. B-lymphocytes will be sorted from PBMCs isolated by Ficoll gradient method using magnetic CD19-microbeads whereas tissue B-lymphocytes will be isolated from synovial tissue biopsies digested with Liberase. CD19 positive cells from PBMC will be incubated with pro-inflammatory molecules in presence or absence of Ubadacitinib. After stimulation, CD19 positive cells will be collected and processed for single cell RNA sequencing. Moreover, the impact of JAK-1 selective inhibition on B-lymphocyte cultures stimulation will be tested using ELISA method for the assessment of cytokines/chemokines production. Synovial tissue and synovial tissue B-lymphocyte subpopulations will be assessed through FACS analysis using IgD/CD27 classification. Finally, we will compare the transcriptomic profile of synovial tissue B lymphocytes from 5 subject groups.
75640430|NCT00612963|Drug|Frio Oral Rinse|Prescription Mouth Rinse
75640431|NCT05738434|Drug|Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib|camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investigator' choice： paclitaxel 135~150 mg/m2, i.v. d1,q3w; paclitaxel-albumin 150~180 mg/m2, i.v. d1,q3w. up to 4 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w
75332226|NCT04765423|Device|[F-18] NaF PET/CT|Radiotracer F-18 NaF used on the PET/CT imaging
75789037|NCT04351256|Radiation|Thoracic Radiotherapy (TRT) hypofractionated|Hypofractionated TRT consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks
75789038|NCT03700892|Other|Cinnamaldehyde e-liquid|Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
75925315|NCT02178423|Procedure|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
75925316|NCT02499224|Drug|YYB101|"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"
75925317|NCT02169999|Other|Personalized Diabetes Care Website|Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
75925318|NCT03120416|Behavioral|Resistance exercise training|12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
75789039|NCT03700892|Other|PG/VG e-liquid|Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
75789040|NCT03700736|Behavioral|Healthy Moms|The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.
75332227|NCT04765423|Device|[F-18] fluciclovine PET/CT|F-18 fluciclovine (Axumin ®) used on the PET/CT camera
75332228|NCT03700372|Device|IOWA Approach Cardiac Ablation System|Epicardial ablation using the IOWA Approach Cardiac Ablation System
75332229|NCT04352257|Radiation|pelvic Ultrasound|pelvic and transrectal ultrasound
75470937|NCT01946958|Other|Care As Usual|Pediatric residents not exposed to PC Triple P provide their standard care to parents struggling with parenting issues or child behavior concerns.
75470938|NCT01946971|Drug|Lansoprazole|
75470939|NCT01946971|Drug|Placebo|
75640432|NCT05738434|Drug|Camrelizumab+Chemotherapy→Camrelizumab|camrelizumab 200 mg, i.v. d1,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investgator' choice： paclitaxel 175 mg/m2, i.v. d1,q3w; paclitaxel-albumin 200 mg/m2, i.v. d1,q3w up to 6 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w;
75640433|NCT03925935|Biological|AB-205|Engineered human umbilical vein endothelial cells
75640434|NCT02954224|Other|CPAP treatment|Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3
75640435|NCT00803452|Drug|doxycycline|Oral doxycycline 100mg bid
75640436|NCT00803452|Drug|azithromycin|topical 1% azithromycin daily to eye
75640437|NCT02949076|Behavioral|Exercise|Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
75789041|NCT03766256|Behavioral|Shared decision-making with pharmacists|Pharmacist will engage patient with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
75789042|NCT03760094|Device|Colour Doppler|evaluation of lymph nodes by Doppler
75789043|NCT01322282|Drug|Cetirizine|A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
75789044|NCT01322282|Drug|Cetirizine|A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
75789045|NCT03757364|Drug|Methotrexate|Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
75789046|NCT03757286|Procedure|FSF with CAD\CAM customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla and scapula. The CT scan will be sent to the modeling company that produce 3D autoclavable models and cutting guides to be used during resection and scapular harvesting as well as a model of the final reconstructed maxilla.~surgery will performed by two surgical teams one for tumor resection and the other harvesting the flap.~access to the maxilla was obtained and the cutting guides were secured in the planned position; the cuts were completed. The scapular guides were secured to the harvested scapula to replicate the cuts that were planned previously.~The scapula and plate will be fixed and pedicle anastomosis is performed. the operation then completed with soft tissue reconstruction."
75925319|NCT02177097|Biological|Blood samples|4 x 10 ml blood samples.
75925320|NCT02178501|Dietary Supplement|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
75925321|NCT04496102|Device|Triathlon|Modern TKA design (Triathlon) with patellar resurfacing
75925322|NCT02499068|Device|Telehealth|Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
75925323|NCT03337022|Drug|CC-90006|CC-90006
75925324|NCT03337022|Other|Placebo|Placebo
75925325|NCT02178735|Procedure|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
75925326|NCT02178735|Procedure|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
75640438|NCT00613197|Drug|Epanova|4g/day in divided doses
75640439|NCT03957759|Diagnostic Test|Structured self-monitoring during an altitude ascent and stay at high altitude|Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).
75789047|NCT03757286|Procedure|FSF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla .~The C.T scan will be sent to the modeling company for planning three-dimensional model of the maxilla. autoclavable model will be prepared to be used during the workflow for plate reshaping to conforme the prices position of the maxilla.~surgery will performed in a single step by two surgical teams, one for cervicofacial resection and the other for harvesting the flap.~Resection-reconstruction then performed in aconventional surgical manner with microvascular anastomosis. finally the operation will be completed with soft tissue reconstruction as needed."
75798740|NCT01174680|Procedure|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
75925327|NCT03120494|Drug|Emtricitabine and Tenofovir|All subjects will be provided study drug for use daily for one year.
76080732|NCT06152887|Device|Sooma Oy (Sham), Helsinki, Finland|For the sham treatment, an electrical current will also be increased from 0 mA to 2 mA over the first 30 seconds, however, the current will be ramped back down to 0 mA after the initial ramp-up phase and no stimulation is delivered for the rest of the treatment.
76080733|NCT06152848|Other|Data and samples collection|Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples
75470940|NCT01946984|Procedure|ERCP|endoscopy, retrograde cholangio-pancreaticography.
75470941|NCT01946984|Drug|Diclofenac hydroxyethylpyrrolidine|
75470942|NCT01946984|Drug|Normal Saline|
75470943|NCT01946997|Other|OCT Imaging both Normal and diabetic groups|Images taken to determine thickness values in the retina
75470944|NCT01947010|Biological|Prevenar 13|
75470945|NCT01947010|Biological|Pneumovax|
75470946|NCT01947049|Other|Rapid Influenza Testing with Xpert Flu|Participants with recieve rapid influenza testing with Xpert Flu
75470947|NCT01947062|Drug|Intravenous Cisplatin & etoposide|Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 & 2. The dose of etoposide will be 100mg/m2 on days 1, 2 & 3.
75332230|NCT04182958|Drug|(14C)-OPC-61815|On the morning of Day 1, all subjects will receive a single IV infusion of (14C) OPC-61815
75640440|NCT05738278|Behavioral|HR-informed change in routine|"The intervention is given for a situation occuring at least ten times and accompanied by an increase in HR at least 80% of the time, during the two-week registration period. Change in care (intervention) is introduced from week 3.~The intervention is in one of four forms:~changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~revised personal hygiene procedure."
75789048|NCT03766178|Drug|Nimotuzumab + SHR-1210|"SHR-1210: 200 mg/time, intravenous injection, q2W continuous medication, a course of treatment needs 28 days. The cumulative longest medication period is 2 years.~Nimotuzumab: 200 mg/time, intravenous injection, administered on the 1st and 8th days of each cycle, every 2 weeks is one cycle."
75789049|NCT04737278|Drug|Cunermuspir|"Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:~Organic evaporated cane juice powder, hypromellose, titanium dioxide"
75789050|NCT04737278|Other|Placebo|same non-medical ingredients and encapsulation as Intervention 1
75925328|NCT03537573|Behavioral|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
75925329|NCT03537573|Behavioral|Opioid Justification|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
75925330|NCT03537573|Behavioral|Provider Comparison|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
75925331|NCT03120962|Drug|Oxycodone|Oxycodone 20mg/day, for 4 weeks
75925332|NCT03120962|Drug|Gabapentin|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
75332231|NCT01126099|Drug|Prazosin|4 mg capsules twice daily for 12 weeks
75332232|NCT01126099|Drug|Placebo|Placebo capsules twice daily for 12 weeks
75332233|NCT04176406|Device|rTMS|excitatory 5Hz rTMS will be used
75332234|NCT04176406|Device|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
75332235|NCT04171102|Device|ProFlor Hernia implant|Inguinal hernia repair
75789051|NCT03759860|Combination Product|R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy|Lucentis (ranibizumab) injection into the vitreous cavity after R:GEN laser treatment (Selective Retina Therapy)
75798741|NCT03859050|Other|bronchoscopy with intrabronchial administration of lipopolysaccharide|The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
75798742|NCT03193216|Drug|Alginates|Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
75925333|NCT03120962|Drug|Famciclovir|Famciclovir 500mg three-times daily for 7 days
75332236|NCT03807544|Device|TENS|Transcutaneous electrical nerve stimulation
75332237|NCT01170715|Drug|Etanercept|self-administered for 52 weeks
75332238|NCT03809182|Drug|Dexmedetomidine|A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.
75332239|NCT03809182|Drug|0.9% Sodium-chloride|The same infusion rate used in the dexmedetomidine group.
75332240|NCT03809182|Drug|Fentanyl|Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
75332241|NCT03809182|Drug|Morphine Sulfate|Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
75332242|NCT01170949|Drug|Miltefosine|50 or 100 or 150mg per day
75332243|NCT01170949|Drug|Placebo|Placebo
75332244|NCT03805672|Drug|Low Dose Enoxaparin|
75332245|NCT03805672|Drug|High Dose Enoxaparin|
75332246|NCT04555135|Device|EndoVigilant Software|While using this device, colonoscopy will continue to be performed in the standard manner as is done without the use of this device. The video signal from the colonoscope will be fed into a computer running the EndoVigilant software in addition to the standard video output to the procedure monitor. The gastroenterologist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the augmented video on the second monitor. The gastroenterologist may rely on the second monitor (with augmented video generated from EndoVigilant software) for polyp detection, but the standard procedure monitor with the original feed will always be operational and available for maneuvers such as fast insertion, polypectomy etc.
75332247|NCT04158466|Device|Kalifilcon A Daily Disposable Contact Lenses|Contact lens
75640441|NCT05738278|Behavioral|Delayed HR-informed specific change in routine|"The intervention is given for a situation occuring at least twenty times and accompanied by an increase in HR at least 80% of the time, during the four-week registration period. Change in care (intervention) is introduced from week 5.~The intervention is in one of four forms:~changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~revised personal hygiene procedure."
75789052|NCT03766100|Behavioral|Cognitive behavioural therapy (CBT-i)|CBT-i aims to alter behaviours that sustain or add to insomnia and correct cognitions that drive these behaviours. The behavioural components of CBT-i are stimulus control (SC) and Sleep Restriction Therapy (SRT). SC works through the extinction of a conditioned arousal that emerges when bed and bedroom have become associated with wakefulness. With SRT time in bed is reduced to build up sleep pressure. When wakefulness is decreased, time in bed is gradually increased until optimal sleep is attained. With the cognitive component, insomnia is treated by identifying and changing unhelpful or inaccurate thinking regarding sleep and distressing emotional responses to insomnia. The last component of CBT-i aims to reduce hyperarousal with relaxation techniques, scheduled worry time, creating a time to unwind, and employing cognitive therapy strategies.
75640442|NCT04546113|Procedure|Ultrasound-guided Bilateral Paravertebral Block performed with a 20 ml injection of ropivacapine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaïne 3,75 mg/ml/side
75640443|NCT04546113|Procedure|Ultrasound-guided Bilateral Erector Spinae plane Block performed with a 20 ml injection ropivacaine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaïne 3,75 mg/ml/side
75789053|NCT03759782|Drug|Ribavirin|Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.
75789054|NCT03759782|Drug|Tenofovir|Tenofovir as per standard of care
75789055|NCT03757208|Dietary Supplement|carbohydrate rich drink|The carbohydrate rich drink (CHD) group received oral carbohydrate (200 ml) 2-3 h before surgery,
75789056|NCT04725500|Device|Auto-Titrating EPAP|In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
75789057|NCT03757052|Diagnostic Test|Penicillin Skin Testing|Skin test protocol: prick skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 100 mg/mL, amoxicillin 71 mg/mL, histamine/positive control, diluent/negative control), then intradermal skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 1 mg/mL, diluent/negative control), administered as an intradermal injection of a standardized volume of 0.02 mL. Graded oral challenge with amoxicillin : a first dose of 50 mg of amoxicillin; 20-minute observation period; in the absence of any objective symptom of an allergic reaction, a second dose of amoxicillin of 450 mg; final observation period of 60 minutes, under nurse and medical supervision.
75789058|NCT03759704|Drug|Hyperpolarized 13CPyruvate|Bolus injection of study drug during MRSI.
75789059|NCT03176108|Behavioral|Cognitive Behavorial Therapy (CBT)|Cognitive Behaviorial Therapy (CBT)
75789060|NCT03176108|Behavioral|Body mediation|Body mediation (theatre)
75789061|NCT03765944|Drug|sirolimus|SIngle administration under fasted condition
75925334|NCT02178813|Drug|Administration of minocycline|"Administration of minocycline with the following schedule:~Day prior to procedure: 800mg p.o., 700mg p.o.~Day of procedure: 600mg i.v., 500mg p.o.~Day after procedure: 400mg p.o., 400mg p.o."
76080734|NCT06152822|Drug|pyrotinib+capecitabine+bevacizumab|pyrotinib: ≥160mg qd capecitabine: 1000mg/m2,bid,q1-14,q3w bevacizumab:7.5mg/kg,iv,q3w
76080735|NCT06152796|Drug|Paracetamol|Anti_inflammatory drug
75332248|NCT04158466|Device|Biotrue ONEday Daily Disposable Contact Lenses|Contact lens
75925335|NCT03341000|Device|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system.
75925336|NCT03340922|Device|Automatic annotation of LAT (WF-method)|Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
75332249|NCT03802864|Drug|Liposomal Bupivacaine|After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.
75470948|NCT01947062|Drug|Intravenous Cisplatin & etoposide along with oral cyclophosphamide|Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 & 2. The dose of etoposide will be 100mg/m2 on days 1, 2 & 3.
75789062|NCT03756974|Drug|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
75789063|NCT03756974|Drug|Placebo|Placebo of BX-1, oral solution
75332250|NCT03802864|Drug|Standard Bupivacaine|After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
75925337|NCT03340922|Device|Manual annotation of LAT (M-method)|Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
75925338|NCT02170311|Drug|Z-213|
76080736|NCT06152796|Drug|Ibuprofen|Non steroidal anti_inflammatory drug
76080737|NCT06152757|Biological|First dose|1.0×10^8cells,Intravenous infusion，1 subject is planned to be enrolled
75332251|NCT03797872|Drug|Methotrexate|Methotrexate up to 25mg/week as tolerated po or sc
75332252|NCT03797872|Drug|Sulfasalazine|Sulfasalazine up to 3g daily po
76080738|NCT06152757|Biological|Second dose|3.0×10^8cells,Intravenous infusion，3 subject is planned to be enrolled
76080739|NCT06152757|Biological|The third dose|1.0×10^9cells,Intravenous infusion，3 subject is planned to be enrolled
76080740|NCT06152757|Biological|The fourth dose|3.0×10^9cells,Intravenous infusion，3 subject is planned to be enrolled
76080741|NCT06152731|Genetic|tests to determine HRD status|"Test Giscar AND test myChoice will be performed.~If one or two tests identifies a HRD status :~a PARP inhibitor treatment may be initiated according to current recommendations"
76080742|NCT06152705|Device|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
76080743|NCT06152692|Device|SHAM Continuous positive airway pressure|Placebo treatment
76080744|NCT06152692|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group
76080745|NCT06152679|Other|None - qualitative interviews|Qualitative interviews with patients asking about their experience of day-case endourology.
76080746|NCT06152666|Other|None - qualitative interviews|These are qualitative interviews and involve no intervention
76080747|NCT06152653|Drug|n-acetylcystine (NAC)+ albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
76080748|NCT06152653|Device|Hillrom-Volara System|The Hillrom Volara System combine continuous positive expiratory pressure and nebulizer in one system.
76080749|NCT06152640|Device|Deep transcranial magnetic stimulation|"Neuronavigation: The coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC. The Brainways H7 coil with fluid cooling was used to obtain a greater depth of stimulation, up to about 6 cm below the cortex.~dTMS intervention: the intervention targets were at the left and right ACC, 5 times per week (Monday through Friday), for 6 weeks, a total of 30 treatments were given. Stimulation mode: stimulation frequency 1Hz, stimulation intensity 100% RMT, number of pulses 150, sequence interval 20s, total 6 trials, 900 pulses."
76080750|NCT06152640|Device|Sham deep transcranial magnetic stimulation|"Neuronavigation: The sham coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC.~Sham dTMS intervention: The intervention targets were at the left and right ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field), 5 times per week (Monday through Friday), for 6 weeks, a total of 30 treatments were given."
76080751|NCT06152640|Other|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
75640444|NCT05737342|Dietary Supplement|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
75640445|NCT05737342|Dietary Supplement|Placebo Capsules|Maltodextrin was used as a placebo
75640446|NCT00914212|Drug|Placebo|Single dose placebo to sibutramine in two of three treatment periods.
75640447|NCT00914212|Drug|Comparator: sibutramine|Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
75789064|NCT03765866|Procedure|Thromboelastometry guided transfusion|Comparing resuscitation strategies with standard MTP v.s. ROTEM guided MTP
75789065|NCT04694066|Behavioral|Qigong|Qigong Baduanjin, comprising eight standardized movements, will be adopted in the study. It is practiced as a combination of body movements, breath control, and mindful meditation.
75789066|NCT04694066|Behavioral|Light flexibility exercise|The supervised sessions will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
75789067|NCT04684394|Biological|GEM103|GEM103 500 mcg/50 mcL intravitreal injection
75925339|NCT03121040|Dietary Supplement|Vespa amino acid mixture|17 kinds of amino acids mixture in specific proportion
75640448|NCT05736328|Procedure|Traction|Postoperative lower extremity traction
75640449|NCT04480203|Other|Stressproffen cognitive based stress management|The participants will download an app (Stressproffen 2A) with cognitive based stress management.
75640450|NCT04480203|Other|Stressproffen mindfulness based intervention|The participants will download an app (Stressproffen 2B) with mindfulness based intervention.
75640451|NCT04480203|Other|Control|The participants will receive no app. (They will be able to download it after the end of the 3 year study).
75640452|NCT03889665|Other|Suspension training|Nine sessions of suspension training The suspension device will be TRX (R) The intervention will be administered in work:rest intervals (2:1) A global training approach will seek to train lower limbs, upper body and core musculature
75789068|NCT04684394|Drug|Aflibercept|"Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection"
75925340|NCT02177253|Drug|Ipratropium bromide / Salbutamol|
75925341|NCT02177253|Drug|Placebo Inhalation solution|
75789069|NCT04684394|Drug|Sham|Sham intravitreal injection
75332253|NCT03797872|Drug|Leflunomide|Leflunomide 10-20mg daily po
75332254|NCT03797872|Drug|Methylprednisolone|For IA or IM injection 20-120mg
75332255|NCT03797872|Drug|Triamcinolone|For IA or IM injection 20-120mg
75332256|NCT03782272|Dietary Supplement|Enterade|enterade® (an amino acid-based oral rehydration solution [AA-ORS]) is a medical food product that consists of oral rehydration salts, natural flavor, steviol (sweetener), purified water, and a blend of amino acids that drive the uptake of water and electrolytes.
75798743|NCT03864822|Device|High-Definition Transcranial Direct Current Stimulation|Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.
75925342|NCT02177253|Drug|Ipratropium bromide|
75925343|NCT02177253|Drug|COMBIVENT Inhalation Aerosol|
75925344|NCT02177253|Drug|Placebo Inhalation Aerosol|
75925345|NCT03121118|Other|Scan Opportunity|Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
75925346|NCT02170467|Other|assessment of the intestinal permeability|
75332257|NCT03782272|Dietary Supplement|Placebo|a placebo solution containing natural flavor, steviol (sweetener), and purified water.
75789070|NCT03759626|Behavioral|Impulsive intervention|"As part of the IMAJe project, a 20 min TV series pilot for teenagers was developed by C. Russel of Washington University : Tom in the making. The results of the study show that the mere diffusion of this pilot mobilizes the individual's impulsive system described in the theoretical model developed by Strack and Deutsch. 2 different versions have been developed. Both have the same basic story in three acts with the same main characters. Only the last acts vary according to the consequences of alcohol consumption. The first version shows a positive representation of alcoholization, the other highlights the negative consequences generated by this behaviour. Our tool will be the so-called negative version of the episode where alcohol consumption causes harmful consequences in the young person's life. Following this 20 min episode, a 25 min debate focusing on the characters in the series will be conducted using a questionnaire grid with 8 questions."
76080752|NCT06150794|Device|Excimer laser|Excimer laser will be started at a dose of 300 mj/cm2 and increases 50-100 mj/cm2 each session. The aim of treatment is to deliver a dose that induces visible redness in the psoriatic lesion (supra-erythematous dose), but not induce a blister.
75640453|NCT00589108|Device|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
76080753|NCT06150794|Drug|Methotrexate Injection|A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit, followed by a 2.5-mg intramatrical methotrexate injection into each side of the nail at a point 2.5 mm proximal and lateral to the junction of proximal and lateral nail folds.
75470949|NCT01947088|Behavioral|Music Therapy|Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
75470950|NCT01947101|Biological|Fecal Microbiota Transplant|Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
75332258|NCT01127581|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
75470951|NCT01947114|Drug|Propofol|
75470952|NCT01947114|Drug|Ketamine|
75640454|NCT00589108|Device|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
75640455|NCT00589108|Device|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
75798744|NCT03864978|Drug|Rifaximin delayed release 400 mg tablet|Rifaximin delayed release
75798745|NCT03864978|Drug|Placebo|Placebo
75470953|NCT01947114|Drug|Remifentanil|
75470954|NCT01947166|Dietary Supplement|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
75470955|NCT01947179|Behavioral|Anxiety Risk Reduction|Involves psychoeducation and interoceptive exposure exercises
75470956|NCT01947192|Procedure|Treatment with chlorhexidine|Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.
75640456|NCT04456023|Biological|Tisagenlecleucel|A single intravenous (i.v.) infusion of 0.6 - 6.0×10^8 CAR positive viable T cells.
75640457|NCT04188483|Dietary Supplement|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days.
75640458|NCT04188483|Biological|Influenza vaccination|Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
75640459|NCT05732194|Drug|ITI-333|ITI-333 oral solution
75640460|NCT05732194|Other|Placebo|Matching placebo
75925347|NCT02178891|Device|extra short implant|
75925348|NCT03120884|Procedure|ICSI|A technique that involves microinjection of spermatozoa into mature oocytes.
75925349|NCT03120884|Procedure|IVF|A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
75925350|NCT02498990|Behavioral|Low calorie diet followed by life style intervention|"Low calorie diet of 800 kcal/day for 7 weeks.~Life style intervention for the remaining study period"
75925351|NCT02177331|Drug|Lacidipine|
75925352|NCT03336788|Device|Transcranial Magnetic Stimulation (TMS - ) MagPro®|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
75332259|NCT01127581|Drug|Dinoprostone Vaginal Insert (DVI)|Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
75470957|NCT01947192|Procedure|Water pre-treatment|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
75470958|NCT01947205|Drug|paracetamol|
75470959|NCT01947205|Drug|dexketoprofen trometamol|
75470960|NCT01947205|Drug|suction curettage|
75470961|NCT01947205|Drug|suction curettage|
75925353|NCT03336788|Device|virtual reality for displaying interactive virtual environments|20 sessions navigated with virtual reality
75925354|NCT02170545|Other|Dual Energy Computed Tomography|A Dual Energy Computed Tomography scan will be performed on both upper arms.
75332260|NCT03794752|Device|Head-Mounted Visual Enhancement Device|Evergaze has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It is powered by a battery pack connected to the device. The electronic display will be affixed over only one of the participant's eye. The vision through the unobstructed eye will aid with the participant's balance and spatial orientation. The prototype display and camera will be connected to a battery pack/control box that will allow the user to quickly select one of 3 modes. Each mode will represent a combination of parameters (brightness of the display, focus lock, color/black & white, contrast, magnification) designed to optimize the image for different activities (e.g. reading, walking, computer use).
75332261|NCT04124536|Behavioral|HIV self-testing with partner notification.|HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.
75925355|NCT05233046|Behavioral|Nutrition and Mental health counseling|Nutrition and Mental health counseling with a standardized format included in each session
75470962|NCT01947205|Other|without drug|
75470963|NCT01947231|Other|Global Postural Re-education|Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
75470964|NCT01947231|Other|Standard manual physical therapy|Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
75470965|NCT01947244|Behavioral|Doula Home Visiting|The intervention is a doula enhancement to evidence-based home visiting services. Doulas provide home visits during pregnancy and for the first six weeks postpartum, which focus on prenatal health, preparation for childbirth, bonding with the baby, and breastfeeding education. Family support workers provide longer term home visiting services. These home visits focus on sensitive and responsive parenting, early infant care, bonding with the baby, child health and development, and maternal mental health.
75640461|NCT02693145|Other|Anti-Retroviral Treatment and Access to Services (ARTAS)|Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result. ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology. SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
75925356|NCT05233046|Behavioral|Nutrition and Mental health counseling with Nourish Carolina|Nutrition and Mental health counseling with a standardized format included in each session combined with the intervention of a 12 week immersion of mindfulness based program ,Nourish Carolina, on CMS , school district employees. Nourish Carolina inlcudes, detailed lessons and descriptions with a caledar that includes mindful eating tips, activities, meditations recipes and videos. The program has monthly themes of mindfulness,gratitude and giving
75925357|NCT02179125|Device|RePneu Lung Volume Reduction Coil System|Bronchoscopic lung volume reduction treatment with Coils.
75332262|NCT00377728|Drug|GSK256066|
75332263|NCT01127737|Behavioral|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
75470966|NCT01947244|Behavioral|Case management|Mothers are offered two prenatal and two postpartum case management meetings to assess whether mothers' basic needs (housing, nutrition, health care, mental health) are being met and make appropriate referrals.
75332264|NCT01127737|Behavioral|Placebo|Completed surveys
75332265|NCT03709810|Combination Product|Marketed Denture Adhesive (Super Poligrip Max Seal)|The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
75470967|NCT01947257|Other|the measure TRVMAX|by transthoracic echocardiography
75470968|NCT01947257|Other|the measure of the pulmonary artery|by transesophageal ultrasound
75470969|NCT01947257|Other|the direct measure of the pulmonary pressures|by right catheterization
75640462|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
75640463|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet twice daily x 7 days
75640464|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
75789071|NCT03759626|Behavioral|Reflective Intervention|"This intervention uses modules of the KOTTABOS ® system produced by the National Association for the Prevention of Alcohol and Addiction 59 (ANPAA) and validated by the Interministerial Mission to Combat Drugs and Drug Addiction (MILT). For young people, this educational tool aims to develop an understanding of the mechanisms of blood alcohol levels, the effects and immediate risks associated with alcohol consumption.~It encourages individual and collective reflection on the effects of alcohol on physical, cognitive and intellectual abilities in order to increase individual skills in making risk-appropriate behavioural choices. This pedagogical tool is based on a participatory and experimental approach. 5 devices of the KOTTABOS ® tool were selected and tested with 2 test groups of adolescents of the same school level as the students in the study."
75789072|NCT03759548|Other|Assessment of nutritional status|Observational study. Assessment of nutritional status.
75925358|NCT03340688|Procedure|Cervical cerclage|Cervical cerclage indicated by short cervix ≤15mm
75640465|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
75640466|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet once daily x 7 days
75925359|NCT02177409|Drug|Telmisartan|
75925360|NCT02177409|Device|Amlodipine|
75925361|NCT02177409|Drug|Placebo|
76080754|NCT06150222|Other|Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)|The aim is to include all patients with (induced) oligo metastatic and oligo recurrent settings, irrespective of whether treated with concurrent chemoradiation, systemic chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.)
75925362|NCT02494388|Procedure|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
75925363|NCT02170623|Drug|BIBR 1048 MS Capsule I|25 mg BIBR 1048 MS
75332266|NCT03709810|Other|No Adhesive|No adhesive will be applied.
75332267|NCT01128049|Behavioral|Subjective Questionnaire|The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
75332268|NCT01128049|Procedure|Measurement with wavefront sensor (right eye, then left eye)|The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
75332269|NCT01128049|Drug|Instill Saline Drop|One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
75798746|NCT05597956|Procedure|white defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
75925364|NCT02170623|Drug|BIBR 1048 MS Capsule K|50 mg BIBR 1048 MS
75925365|NCT02170623|Drug|Pantoprazole|40 mg pantoprazole
75925366|NCT02170623|Drug|BIBR 1048 MS drinking solution|50 mg BIBR 1048 MS powder plus solution
75925367|NCT02494544|Device|Off the Shelf Total Knee Replacement|A knee replacement system by DePuy, Zimmer, Biomet, Smith & Nephew, or Stryker
75925368|NCT02494544|Device|ConforMIS iTotal Knee Replacement|A knee replacement performed with patient specific implant and surgical jigs.
76080755|NCT06150040|Drug|NP137|IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
75332270|NCT04498351|Drug|Control Test|"Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side."
75332271|NCT04498351|Drug|Dexmedetomidine|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
75332272|NCT04498351|Drug|Dexmedetomidine and magnesium sulphate|"Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side."
75332273|NCT04498351|Drug|magnesium sulphate|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
75332274|NCT03784300|Drug|50 mg PTI-125|PTI-125 50 mg Oral Solution
75332275|NCT03784300|Drug|100 mg PTI-125|PTI-125 100 mg Oral Solution
75332276|NCT03784300|Drug|200 mg PTI-125|PTI-125 200 mg Oral Solution
75332277|NCT02186665|Drug|calcitriol ointment|
75332278|NCT02186665|Drug|placebo comparator|
75470970|NCT01947270|Other|" Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)"|"The multidisciplinary intervention program include:~Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.~Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis"
75470971|NCT01947309|Drug|Revlimid (lenalidomide)|Revlimid (lenalidomide) as prescribed in usual clinical practice
75470972|NCT01947322|Drug|Allogenic NK cells infusion|HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
75925369|NCT02170701|Drug|BIBR 1048|Ascending doses (in mg) given twice daily
75470973|NCT01947348|Procedure|treatment with A3 SVF|Treatment interarticular and IV with A3 SVF
75925370|NCT02498756|Biological|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
75925371|NCT02498756|Drug|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
75925372|NCT02255721|Behavioral|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
75925373|NCT02255721|Behavioral|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
75925374|NCT03336632|Drug|Chidamide|20 mg orally, twice weekly from D-7 to D+14
75925375|NCT03336632|Drug|Cyclophosphamide|50 mg/Kg intravenously D+3, +4
75925376|NCT03336632|Drug|cyclosporine A|3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
75925377|NCT02498288|Drug|Isotretinoin: Reference Medication 1|Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
75925378|NCT02498288|Drug|Isotretinoin: Reference Medication 2|Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
76080756|NCT06150040|Drug|Azacitidine Injection|Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
75470974|NCT01947374|Procedure|Matrix encapsulated chondrocyte implantation|Each implant contains 6,000,000 autologous chondrocytes.
75470975|NCT01947374|Procedure|Microfracture awl|Is an awl that allow perforation of the subchondral bone.
75470976|NCT01947400|Other|Hospitalists|AIDET Training
75640467|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
75640468|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
75925379|NCT02498288|Drug|Isotretinoin: Test Medication|Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
75640469|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet once every 48 hours x 7 days
75332279|NCT03713398|Behavioral|T4C-SMI|T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
75332280|NCT05313646|Biological|batch 1 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001. It contains 5×10^10 viral particles per 0.5 mL in a vial.
75640470|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
75640471|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
75640472|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
75640473|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
75789073|NCT03759470|Diagnostic Test|CSF examination|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperature. Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with ~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit."
75789074|NCT01322828|Procedure|Distal bicep tendon reconstruction|Randomized to either a single incision technique or a double incision technique.
75640474|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
75640475|NCT04393311|Drug|Ulinastatin|Ulinastatin administered via IV infusion (200,000/infusion)
75789075|NCT03765554|Drug|PF-06700841 Immediate release tablets|Small molecule tablets in immediate release form
75789076|NCT03765554|Drug|PF-06700841 Modified release tablets|Small molecule tablets in modified release form
75925380|NCT02756403|Drug|Azithromycin|500 mg
75925381|NCT02756403|Drug|Doxycycline|200 mg
75332281|NCT05313646|Biological|batch 2 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002. It contains 5×10^10 viral particles per 0.5 mL in a vial.
75470977|NCT01947413|Other|intermittent theta burst stimulation|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)
75470978|NCT01947413|Other|continuous theta burst stimulation|In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
75640476|NCT04393311|Drug|Placebo|Placebo to match ulinastatin administered via IV infusion
75640477|NCT02607436|Drug|Sarpogrelate|Sarpogrelate
75640478|NCT02607436|Drug|Aspirin|Aspirin
75640479|NCT04362579|Device|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing or in the home setting
75640480|NCT02607592|Drug|cisplatin and pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
75789077|NCT04675346|Other|Questionnaire|Questionnaire
75789078|NCT04674644|Behavioral|The psychosocial effects of COVID-19 pandemic on dental professionals|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals using the Turkish version of the Fear of COVID-19 and Coronavirus Anxiety Scales
75789079|NCT04668950|Drug|Fluvoxamine|Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days
75789080|NCT04668950|Drug|Placebo|Will take 2 capsules per day as tolerated for approximately 15 days
75925382|NCT02756403|Drug|Metronidazole|500 mg
75925383|NCT02756403|Drug|Placebo|Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
75925384|NCT03336476|Device|Videolaryngoscopy|Patients will be intubated with the video laryngoscope
75789081|NCT03078478|Drug|Insulin degludec|For subcutaneous (s.c., under the skin) injection once daily
75789082|NCT03078478|Drug|Insulin glargine|For subcutaneous (s.c., under the skin) injection once daily
75789083|NCT01353352|Other|Clinical decision rule - clearing the c-spine|The goal of phase IV of the Canadian C-Spine Rule project is to evaluate the safety and potential impact of an active strategy to empower ED triage nurses to evaluate and clear the c-spine of very low-risk trauma patients.
75925385|NCT03336476|Device|Direct laryngoscopy|Patients will be intubated with the direct laryngoscope
75925386|NCT03539289|Behavioral|MUFA Diet|Control of patient MUFA Diet
75640481|NCT02607592|Drug|nedaplatin+pemetrexed|nedaplatin 90mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
75925387|NCT03539289|Behavioral|SFA Diet|Control of patient SFA Diet
75640482|NCT02607514|Behavioral|hyperthermic yoga|heated yoga, 90-minutes
75640483|NCT04356339|Drug|Interferon-beta-1b (BETASERON, BAY 86-5046)|Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician
75925388|NCT02493296|Other|This observational study will not entail an intervention.|This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
76080757|NCT06150040|Drug|Venetoclax|Orally, 70 mg, every day on Days 1-28
76080758|NCT06149208|Behavioral|Interview|Families will complete interviews about their experiences with the new treatment standard and managing pain at home
75925389|NCT02179281|Device|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
75640484|NCT04334187|Behavioral|Mindfulness Based addition treatment|The intervention is comprised of 8 weekly group MBAT sessions. Two weekly groups of about 10 participants each will be conducted. All participants will also have the option to receive nicotine patches, gum, or lozenges for four weeks as part of their time in the study. Participants will complete surveys at enrollment (baseline), immediately after their last MBAT session (around 2 months after enrollment) and one month after completing treatment (3 months post-enrollment). Surveys will assess primary and secondary outcomes and satisfaction with the intervention.
75640485|NCT03484936|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
75332282|NCT05313646|Biological|batch 3 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003. It contains 5×10^10 viral particles per 0.5 mL in a vial.
75640486|NCT03484936|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.
75640487|NCT04331145|Drug|Ticagrelor 60mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24hrs before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."
75640488|NCT03460522|Drug|Inotuzumab ozogamicin|Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
75640489|NCT00613275|Other|patient Navigation|Assigning a patient navigator to patients with abnormal breast and cervical cancer screening results at one of 6 affiliated community health centers
75789084|NCT04423822|Other|stress test|endurance capacity
75789085|NCT01349218|Other|Blood sample drawn from a vein|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis.
75789086|NCT01349218|Other|Blood sample drawn from a heel stick|A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
75789087|NCT01349296|Drug|Everolimus + BIBF 1120|Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
75789088|NCT04422964|Device|3D Obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
75925390|NCT03336320|Device|ICT Multidomain Intervention Training|Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.
76080759|NCT06145776|Other|tDCS + tredmill training (Standart trehab training)|Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.
76080760|NCT06145776|Other|Cognitite-motor Dual Task Training (DT training)|The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)
76080761|NCT06145594|Other|EMA Monitoring|Weekly prompts to participants' smart phones for collection of PHQ-9 data
76080762|NCT06145594|Other|Scheduling Maintenance TMS sessions|When threshold score is reached, the participants is offered TMS maintenance treatments
75332283|NCT01172197|Drug|Levobupivacaine|Femoral bolus 150μM followed by femoral infusion 400μM
75332284|NCT01172197|Drug|Ropivacaine|Bolus and infusion
75332285|NCT03771274|Device|Tecnis ZLB00 & Symfony IOL|The Symfony IOL will be implanted in the dominant eye while the Tecnis ZLB00 will be implanted in the non-dominant eye.
75332286|NCT04420663|Diagnostic Test|Pleural Manometry|Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
75332287|NCT04141930|Drug|Baloxavir Marboxil|Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset
75332288|NCT04374565|Drug|High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma|Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; ~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.
75640490|NCT00613353|Other|Behavioral|Participants will be asked to wear an accelerometer
75640491|NCT00802438|Biological|mepolizumab|up to three monthly doses of 750mg i.v. mepolizumab
75798747|NCT05597956|Procedure|yellow defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
75640492|NCT04330131|Behavioral|3Ts - Newborn|A video shared with parents/caregivers during a universal screening in hospital mother-baby units. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
75640493|NCT04330131|Behavioral|3Ts - Well Baby|Four videos shared during well child immunization visits at 1-, 2-, 4-, and 6-months in pediatrician offices. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
75640494|NCT04330131|Behavioral|3Ts - Let's Talk!|A series of eight group classes involving education, feedback, and goal setting for parents/caregivers of children age one through three, delivered in a community-based organization. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
75640495|NCT03440086|Device|abdominal Jackson-Pratt drain|One-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
75789089|NCT01343602|Behavioral|mod. Constraint-Induced Movement Therapy|"Therapists of the intervention group are trained in CIMT at home. During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training."
75640496|NCT04009720|Device|Lotus Edge Device|The LOTUS Edge Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] <1.0 cm2 or AVA index <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
75640497|NCT04283253|Device|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
75640498|NCT02605720|Drug|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
75789090|NCT01343602|Other|Therapy as usual|Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
75925391|NCT02494310|Device|High-Resolution Microendoscopy Imaging|Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
75925392|NCT03537417|Procedure|for thoracoscopic ablation of cervical sympathetic chain|bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
75925393|NCT02494466|Drug|montelukast sodium|4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
75925394|NCT02179593|Other|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
75925395|NCT02179593|Other|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
75925396|NCT03537339|Other|Record general information|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
75925397|NCT02177487|Drug|Telmisartan/hydrochlorothiazide|
76080763|NCT06144606|Drug|Tecartus|Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
75798748|NCT05597956|Procedure|brown defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
75798749|NCT03862092|Diagnostic Test|Salivary VZV-DNA PCR|VZV-DNA PCR of saliva samples
75925398|NCT02177565|Biological|carrier plus in vitro expanded autologous BMSCs|The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
75925399|NCT03342872|Behavioral|Core Training: FBS System Mapping and MTFS-I Installation|Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.
76080764|NCT06143371|Biological|CAN10|Single dose intravenous or Multiple doses subcutaneously
76080765|NCT06143371|Biological|CAN10 - Placebo|Single dose intravenous or Multiple doses subcutaneously
76080766|NCT06141317|Biological|PASC transplantation (25 million PASCs/patient)|3 doses of 25 million PASCs implantation via peripheral vein (Day 0, 3 months, 6 months)
76080767|NCT06141317|Biological|Control|0.9% saline solution via peripheral vein (Day 0, 3 months, 6 months)
75332289|NCT01128829|Other|Water|60 ml of water were drank 10 min before doing a OGTT
75789091|NCT03522844|Other|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.
75789092|NCT03522844|Drug|Escitalopram|Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
75925400|NCT03342872|Behavioral|Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings|Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
75925401|NCT02177643|Drug|Diacerein|Diacerein oral capsules
75925402|NCT02177643|Drug|Placebo|Placebo oral capsules
75925403|NCT03340376|Drug|Atezolizumab|atezolizumab
75925404|NCT03340376|Drug|Doxorubicin|Doxorubicin
75925405|NCT02030223|Procedure|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
75925406|NCT03340298|Dietary Supplement|fiber|the intervention of different sources of dietary fibers
75925407|NCT03537105|Procedure|Skin biopsies|Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
75925408|NCT02182167|Drug|IV N-acetylcysteine (NAC)|
75925409|NCT02182167|Drug|Water|
75925410|NCT03537885|Diagnostic Test|Transcranial Direct Current Stimulation|Electrodes are placed on that head to deliver a non-invasive brain stimulation to the target area.
75332290|NCT01128829|Other|Sucralose|60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
75640499|NCT04188561|Drug|Intra articular injection Group|"Patients included in the study had been received 2 ml high molecular weight (1.476 x 106 average Daltons) hyaluronic acid with concentration of 22mg/ml (OPTIVISC UK hyaluronic acid for intra articular injection). Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval. 3 distinct layers are produced by the end of the centrifugation: plasma, buffy coat (platelet) and RBCs, about 3 - 3.5 ml of PRP is produced~at the end with platelet concentration of 1.4 - 1.6 million/μl on average."
75789093|NCT02879578|Drug|Valbenazine|
75925411|NCT03537885|Diagnostic Test|Transcranial Magnetic Stimulation|A coil is held tangential to the head in order to deliver a non-invasive brain stimulation to the target area.
75925412|NCT03537885|Diagnostic Test|Electroencephalography (EEG)|A cap is placed on the head with sensors to detect brain activity during the intervention.
75925413|NCT03336086|Combination Product|weight loss program|A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
75925414|NCT02030145|Procedure|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
75925415|NCT02030145|Procedure|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
75925416|NCT02498366|Other|physical tests|"each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3."
75925417|NCT02182245|Drug|BIBF 1120|
75925418|NCT02182245|Drug|Paclitaxel|
75925419|NCT02182245|Drug|Carboplatin|
75332291|NCT01129141|Procedure|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
75332292|NCT01129141|Procedure|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
75925420|NCT05233124|Drug|Rivaroxaban 15 MG|Rivaroxaban 15mg
75925421|NCT05233124|Drug|Acetylsalicylic acid 100mg|Acetylsalicylic acid 100mg
75925422|NCT05233124|Drug|Clopidogrel 75 Mg Oral Tablet|Clopidogrel 75mg
75332293|NCT04138498|Drug|Dexmethylphenidate 5 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
75332294|NCT04138498|Drug|Dexmethylphenidate 6.25 mg Tablet|Experimental drug for comparative BA evaluation
75332295|NCT04138498|Drug|Dexmethylphenidate 40 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
75789094|NCT01317628|Behavioral|Tobacco smoke reduction trial intervention program|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
75789095|NCT01349374|Other|skin biopsy|Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.
75789096|NCT02982538|Behavioral|Extended Training in Prolonged Exposure Therapy for PTSD|Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).
75789097|NCT02982538|Behavioral|Standard Training in Prolonged Exposure Therapy for PTSD|Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
75789098|NCT00045942|Drug|Itraconazole|Itraconazole was commercially available.
75789099|NCT00045942|Drug|PKC412|PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
75789100|NCT04386616|Drug|MSTT1041A|Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
75332296|NCT04138498|Drug|Dexmethylphenidate 50 mg Tablet|Experimental drug for comparative BA evaluation
75470979|NCT01947413|Other|sham theta burst stimulation|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
75470980|NCT01947426|Dietary Supplement|DHA Supplementation|mothers consuming 400 mg of DHA/day and their neonates
75640500|NCT04188561|Device|Radiofrequency Group|Thermal radiation is done by Neurotherm 2000 (Neurotherm NT 2000 Radiofrequency (RF) Generator is a four electrode pain management (RF) generator for interventional pain management procedures. Neurotherm's newest system offers accurate independent controls of each electrode through the touch screen interface and output control knobs.), Patients from the radiofrequency (RF) group had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
75640501|NCT00588952|Drug|Ketamine and Placebo|Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
75789101|NCT04386616|Drug|MSTT1041A-matched Placebo|Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
75789102|NCT04386616|Drug|UTTR1147A|Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
75789103|NCT04386616|Drug|UTTR1147A-matched Placebo|Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
75925423|NCT04494620|Diagnostic Test|Visual Inspection of Oral Cavity for Precancers and Cancer|Participants were invited for 3 rounds of oral cavity cancer screening, conducted 3-years apart. Screening was conducted by health workers trained to perform visual inspection of the oral mucosa and identify potential precancerous lesions or oral cancer. Lesions found were referred to a weekly clinic for further evaluation by dentists and oncologists with experience in the diagnosis of oral lesions. Oral precancerous lesions were surgically excised whenever possible and those with confirmed oral cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
75925424|NCT03342794|Procedure|cataract surgery|To diagnose the preexisting posterior capsule defects in congenital cataracts after the cataracts are removed by surgery and observe the characteristics
75332297|NCT03714256|Device|Device, patient mobility, powered|Pediatric mobility device
75925425|NCT03335930|Behavioral|a 12-week moderate-intensity exercise training|a 12-week, aerobic, moderate-intensity exercise training
75640502|NCT02606344|Other|Mico-finance based intervention|
75640503|NCT05298267|Device|Do Not Disturb While Driving|Participants will be asked to turn on Do Not Disturb While Driving on their smartphones.
75640504|NCT01021748|Drug|MK-2206|Oral tablets
75640505|NCT01021748|Drug|AZD6244|Oral capsules
75332298|NCT03715426|Behavioral|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
75640506|NCT05283993|Other|No intervention|No intervention
75640507|NCT00614133|Other|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
75332299|NCT05314192|Diagnostic Test|salivary test|saliva was assessed for MIP-1 alpha
75332300|NCT05314192|Diagnostic Test|salivary test|saliva was assessed for IL-6
75332301|NCT01129531|Drug|AGN-214868|AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
75332302|NCT01129531|Drug|Placebo to AGN-214868|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
75470981|NCT01947426|Dietary Supplement|Control (milk without DHA)|mothers consuming placebo product and their neonates
75789104|NCT00045708|Drug|ixabepilone|Given IV
75789105|NCT00045708|Other|pharmacological study|Correlative studies
75789106|NCT00045708|Drug|Anticonvulsant|Drugs that induce hepatic Metabolic enzymes
75925426|NCT02493218|Behavioral|Mindfulness Instruction|Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
75925427|NCT02493218|Behavioral|Health Education|Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
75925428|NCT03340142|Device|VIVO™|Diagnose the area of a PVC or VT onset
75925429|NCT03339986|Behavioral|Reduction or Replacement|
75925430|NCT02498054|Behavioral|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
75640508|NCT00614133|Other|Intravenous nutrition with glucose and amino acids.|Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
75640509|NCT02872610|Behavioral|Self-help Online|"The internet-based self-help program consist of 6 modules that each take a week to complete. Every module consists of a theoretical section, a compulsory exercise, and several optional exercises: Participants are encouraged to spend a minimum of 30 minutes every day with the self-help program. On the website, the participants in the intervention condition may also access an Acute Help page where information on help options are listed and a My Profile page where changes to login and contact details may be made, also, the informed consent form is found here. Participants may furthermore access a message system where they can write questions to the trial manager."
76080768|NCT06140901|Diagnostic Test|Study morphological and functional of respiratory epithelium|The working's investigators hypothesis is that the morphology and functional of the epithelium of children with ADV or RV respiratory infection is different between those who progress to PIBO and those who do not.
75640510|NCT02690493|Procedure|Acupuncture|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
75640511|NCT02690493|Other|Functional Taping|Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
76080769|NCT06139874|Behavioral|THRIVE|Early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
76080770|NCT06139874|Behavioral|Parenting Wisely|Online asynchronous parenting program.
76080771|NCT06137911|Drug|JYP0061|JYP0061 orally administered
75640512|NCT02690493|Other|Acupuncture and Functional Taping|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
75640513|NCT04885257|Drug|Methylphenidate|Methylphenidate oral pill. Dosing instructions given to
75640514|NCT04885257|Drug|Placebo|Placebo arm
75640515|NCT02692677|Drug|JNJ-42756493|Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.
75640516|NCT04982991|Drug|RIPK1 inhibitor|Capsule Oral
75640517|NCT02690259|Procedure|Sentinel node procedure|Patients with Endometrial cancer undergo Sentinel node procedure using Indocyanine green
75640518|NCT00802360|Drug|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
75640519|NCT00802360|Drug|Progestrone vaginal insert|100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
75640520|NCT00802360|Drug|follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
75640521|NCT00802360|Drug|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
76080772|NCT06137911|Drug|placebo|Placebo orally administered
76080773|NCT06137261|Diagnostic Test|Screening for heart failure|"• Anamnesis and Physical examination: Focus on signs of HF; will be performed by a trained employee.~• ECG: A standard 12-lead ECG will be recorded by a trained employee and will be interpreted by an experienced cardiologist.~• Echocardiography: A standard full echocardiogram will be acquired by a trained employee.~• Blood biomarkers: Venous blood samples will be taken and circulating levels of a broad range of markers related to obesity and/or heart failure will be determined. Also, an extra 10 mL blood sample will be drawn during the same venepuncture to be stored to determine additional biomarkers at a later stage.~• EQ-5D-5L questionnaire: EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which are divided into five degrees of severity, ranging from 'no problems' to 'extreme problems'."
75640522|NCT00802360|Drug|Ganirelix|Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
75925431|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m^2 or 1.1 mg/m^2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle
75925432|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m^2 or 1.1 mg/m^2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle
75925433|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m^2 as IV infusion on Day 1 and 8 of 21-day cycle
75925434|NCT02753595|Other|Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg as IV infusion on Day -1 and 7 of 21-day cycle
75925435|NCT02753595|Other|Biologic: PEGylated recombinant human hyaluronidase|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
75925436|NCT03335852|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
75789107|NCT01349452|Drug|Ganciclovir|Ganciclovir 0.15% Ophthalmic gel
76080774|NCT06136819|Combination Product|RT-310|Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)
76080775|NCT06129019|Behavioral|Reiki|Reiki application will be done
76080776|NCT06128291|Procedure|posterior colporrhaphy|posterior colporrhaphy for rectocele.
76080777|NCT06122610|Device|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after first cycle of Lutathera® treatment
76080778|NCT06122610|Device|Photon Emission Tomography / CT (PET/CT)|PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
75640523|NCT04896411|Other|Alternative phrasing for no code|This intervention will use the alternative phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
75640524|NCT04896411|Other|Standard of care for no code|This intervention will use the standard of care phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
75640525|NCT04824729|Procedure|Lower limb revascularization|French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.
75640526|NCT04824729|Procedure|Lower limb revascularization|French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
75640527|NCT04820517|Other|Roy Adaptation Model Based Strengthening Program|"Applications included in the strengthening program sessions:~Awareness study on social media addiction and its effects~Awareness work on the correct and effective use of leisure time~As a result of social media addiction, within the scope of Roy Adaptation Model, scenario sharing and problem solving process related to the problems arising in the fields of physical, group identity - self, role and interdependence~Awareness work on recognizing and managing emotions~Relaxation and Breathing Exercise in Emotion Management"
75789108|NCT01349452|Drug|Artificial tear|Artificial tear 5 times per day
75925437|NCT02177721|Biological|Collection of samples|"Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to Sponsor for determination of raxibacumab concentrations.~Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to Sponsor for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for TNA or ADA."
75789109|NCT03488524|Drug|AMX0035|A combination therapeutic of TUDCA and Sodium Phenylbutyrate
75789110|NCT01349530|Other|Evaluating of usual care|RESEARCH IN CURRENT CARE
75789111|NCT01349530|Other|Evaluation of CREATIF|RESEARCH IN CURRENT CARE
75925438|NCT03335618|Other|Activity Monitoring and Symptom Coaching|Triggered check-ins by study personnel to keep participants on track to meet fitness goals
75925439|NCT03335618|Other|Passive Activity Monitoring|Passive step tracking without check-ins
75789112|NCT00045630|Drug|carboplatin|
75789113|NCT00045630|Drug|gemcitabine|
75789114|NCT00045630|Drug|paclitaxel|
75789115|NCT00045630|Procedure|surgery|
75789116|NCT01357252|Drug|vildagliptin|
75789117|NCT01357252|Drug|Placebo|
75789118|NCT01349608|Behavioral|Telephonic health coaching|Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
75789119|NCT01349686|Procedure|Diet|Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
75789120|NCT01349686|Procedure|Fasting|No intake of fluids during labour.
75789121|NCT03465280|Procedure|Microdebrider|Removal of lesions via microdebrider
75925440|NCT04494464|Other|No intervention|
75925441|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of supervised exercise and education (pulmonary rehabilitation)
76080779|NCT06122610|Drug|64Cu-Dotatate|Standard of care administration of radioactive drug for PET/CT
76080780|NCT06122610|Drug|177Lu-Dotatate|Standard of care administration of radioactive drug for PET/CT and SPECT/CT
76080781|NCT06122103|Device|Clareon Monofocal|Clareon Monofocal Intraocular Lens (toric and non-toric)
76080782|NCT06122103|Device|Light-Adjustable Lens|Light-Adjustable Lens (Intraocular Lens)
76080783|NCT06121024|Procedure|Interventional Bronchoscopy|Bronchoscopy offers vital information when evaluating patients suffering from tracheal stenosis. It enables direct visualisation which identifies the lesion, determines its location and extent of airway involvement, highlights vascularity and fragility, allows for tissue diagnosis and enables the operator to assess the extent of mucosal infiltration and airway compression caused by the tumour. The technique facilitates assessment of stenosis diameter for suitable stent selection. In addition to enabling diagnostic bronchoscopy, rigid bronchoscopy offers therapeutic options such as dilatation, cryotherapy and stenting for tracheal stenosis patients. Our clinical setting employs rigid bronchoscopy for interventional procedures with both diagnostic and therapeutic aspects.
76080784|NCT06119854|Behavioral|Attitudinal inoculation|A brief video focused on bolstering resistance to mis/disinformation about the COVID vaccine. Participants will receive two text messages (1 and 3 days after the inoculation intervention). These text messages will include reminders to get vaccinated.
76080785|NCT06119854|Behavioral|Cognitive-behavioral therapy-informed intervention|A brief video using a CBT-informed approach and focused on addressing barriers to COVID-19 vaccination. Participants will receive two text messages (1 and 3 days after the inoculation intervention). These text messages will include reminders to get vaccinated.
76080786|NCT06119854|Behavioral|Conventional public health messaging|A brief video conveying conventional public health messaging adapted from a review of public health public service announcements with no inoculation messaging. Participants will receive two text messages (1 and 3 days after the inoculation intervention). These text messages will include reminders to get vaccinated.
75789122|NCT03465280|Procedure|Cold-steel surgery (forceps)|Removal of lesions via forceps
75789123|NCT03465280|Procedure|Carbon dioxide laser|Removal of lesions via carbon dioxide laser
75925442|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
75925443|NCT03342482|Other|Low-glutamate diet|The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
76080787|NCT06115525|Other|mNUTRIC score|The mNUTRIC score is a useful means of gauging the nutritional risk of patients in intensive care. Originally designed for IC unit patients, the score is calculated even when patient cooperation is unfeasible, making it applicable for intubated patients. Information necessary for calculation can be obtained from the patient's kin. The mNUTRIC score (without IL-6) classifies patients according to predefined metrics. The following information is necessary: (1) the patient's age, (2) their APACHE II score, (3) their SOFA score, (4) their comorbidities, and (5) the number of days they were hospitalized before being admitted to ICU.
76080788|NCT06115525|Other|NRS-2002|The NRS-2002 score is a tool utilised to measure the nutritional risk of patients in intensive care units. This tool was specifically developed for the purpose of evaluating intensive care unit patients and can be calculated without requiring the patient's active involvement. Additionally, it can be applied to patients who have been intubated and the required information can be sourced from their family members or relatives. The Nutritional Risk Screening (NRS)-2002 assesses a patient's nutritional risk based on five variables: (1) recent unexplained weight loss, (2) appetite, (3) BMI, (4) disease-related stress factors (comorbidities), and (5) age over 70 years which is an additional risk factor.
76080789|NCT06110637|Other|"hard shoes runners evaluation"|"The hard shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
75332303|NCT03746002|Drug|Metolazone 60 minutes prior to furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
75332304|NCT03746002|Drug|Metolazone concurrently with furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
75332305|NCT01172353|Drug|sodium bicarbonate|hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
75470982|NCT01947439|Procedure|Percutaneous Coronary Intervention|Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
75470983|NCT01947452|Behavioral|Employment|Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.
75640528|NCT04811625|Drug|PL-ASA|Pharmacologic profile of different aspirin formulations
75640529|NCT00914446|Procedure|hepatic biopsies|hepatic biopsies
75640530|NCT05722444|Other|Nighttime Feminine Product|"During nights while menstruating:~Standardized nighttime feminine product + typical nighttime behaviors to prevent leak~Standardized nighttime feminine product + refraining from nighttime behaviors to prevent leak"
75640531|NCT00614289|Device|Epikeia Coatings|Topical skin coating
75640532|NCT02607358|Other|blood sampling for HOTPR-testing|All subjects are tested for responderstatus using the VerifyNow System
75640533|NCT02764593|Drug|Nivolumab|Anti-PD-1 targeted immunotherapy
75640534|NCT02764593|Drug|Cisplatin|Anti-cancer alkylating agent
75640535|NCT02764593|Drug|Cetuximab|Epidermal Growth Factor Receptor (EGFR) antagonist
75640536|NCT02764593|Radiation|IMRT|High-precision radiotherapy
75640537|NCT03362476|Behavioral|Computer-based alcohol reduction intervention|Brief computer-based version of motivation enhancement therapy (MET) used in conjunction with clinician-delivered MET and standard clinical care for current substance users. Modules and follow up assignments focus on key concepts in substance use, including cravings, problem solving and decision making skills. The multimedia presentation, based on elementary level computer learning games, requires no previous experience with computers.The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
75789124|NCT03465280|Procedure|Potassium titanyl phosphate (KTP) laser|Removal of lesions via KTP laser
75789125|NCT03465280|Procedure|Pulsed dye laser|Removal of lesions via pulsed dye laser
75789126|NCT03465280|Procedure|Radiofrequency ablation|Removal of lesions via radiofrequency ablation
75925444|NCT02180139|Device|transcranial direct current stimulation|tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.
75925445|NCT02493140|Dietary Supplement|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
75925446|NCT02493140|Dietary Supplement|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
75925447|NCT03339674|Behavioral|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
75925448|NCT03339674|Behavioral|Cognitive Training|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
75925449|NCT00707954|Drug|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
75332306|NCT01172353|Drug|saline|hydration with saline 1ml/Kg/h for 6 hours
75789127|NCT03465280|Procedure|Monopolar suction diathermy|Removal of lesions via monopolar suction diathermy
75925450|NCT00707954|Drug|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
75925451|NCT03339518|Behavioral|BRIM3 educational intervention|Breast Cancer risk education and counseling
75925452|NCT03339518|Behavioral|Wait List|Booklet at the end of study
75925453|NCT03339362|Procedure|Active Procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Active: 4 X-ray guided intra-articular lumbar facet-joint injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml bupivacaine + 20mg methylprednisolone per joint"
75640538|NCT03362476|Behavioral|Brief clinician-delivered MET|Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
75925454|NCT03339362|Procedure|Sham procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Sham: 4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 0.9% sodium chloride per joint."
75925455|NCT03339050|Behavioral|Health for Hearts United|The intervention was framed around three conceptual components (awareness building, clinical learning, and efficacy development), and four types of programming (church-initiated, joint programming, standard programming (culturally tailored post cards and newsletters), and data collection health promotion (generic materials, clinical sessions with an Registered Dietitian). Key messages were identified for the intervention including eating better, moving around more, reducing stress, and taking charge of your health.
75925456|NCT03335462|Other|Paravertebral injections|Paravertebral injections will be performed in the thoraco-lumbar plexus area under CT guidance
75925457|NCT03335462|Other|CT scan|CT scan will be performed as the needles are kept in their position after injecting the contrast
75925458|NCT03335384|Diagnostic Test|Esophageal Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose
75925459|NCT03335384|Diagnostic Test|Gastric Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose
75332307|NCT01129609|Device|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
75470984|NCT01947452|Behavioral|Social-Emotional Learning|Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
75640539|NCT03362476|Behavioral|Standard of care|Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.
75925460|NCT03335384|Diagnostic Test|Nasal Pressure Transducer|Pressure transducer inserted into nasal plug
75925461|NCT02497898|Biological|Cytokine-induced killer cells (CIK)|Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
75925462|NCT03120338|Diagnostic Test|The Development and Wellbeing Assessment|The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
75925463|NCT02494154|Device|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
75925464|NCT02494154|Device|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
75925465|NCT02498210|Other|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
76080790|NCT06110637|Other|"Soft shoes runners evaluation"|"The soft shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
75332308|NCT04089982|Drug|Varenicline|Chantix
75332309|NCT04089982|Drug|Placebo oral tablet|Placebo
75470985|NCT01947465|Biological|Hepatitis A vaccine and tetanus vaccine|Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
75470986|NCT01947478|Device|MDT-2113 Drug-Eluting Balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
75470987|NCT01947478|Device|Standard angioplasty balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
75470988|NCT01947504|Behavioral|education and support intervention|
75470989|NCT01947530|Procedure|Navigational Bronchoscopy|
76080791|NCT06108375|Other|music therapy|music played live by a music therapist
75332310|NCT00985088|Biological|GSK2340274A|one or two intramuscular injections
75332311|NCT00985088|Biological|GSK2340273A|one or two intramuscular injections
75332312|NCT00985088|Biological|Saline placebo|One injection
75640540|NCT02692599|Biological|investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
75925466|NCT02497820|Drug|Aspirin|"Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place."
75332313|NCT03783130|Biological|VRC-HIVRGP096-00-VP|Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.
75332314|NCT03783130|Other|Alum Adjuvant|Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.
75332315|NCT00984542|Drug|bendamustine hydrochloride|Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
75640541|NCT02692599|Biological|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
75640542|NCT01026038|Biological|13-valent pneumococcal conjugate vaccine|All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
75640543|NCT02606266|Drug|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
75925467|NCT02493920|Other|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm).
75925468|NCT02493920|Device|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
75925469|NCT02492906|Other|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
75925470|NCT02492906|Other|Healthy|Healthy and non-symptomatic volunteers.
75925471|NCT02497664|Other|Active Breathing Control|
75925472|NCT03120260|Other|Diet|Intervention 'Diet+ short sleep versus normal sleep
75925473|NCT03338738|Diagnostic Test|Stool culture ans swab|"Patients with ESBL enterobacteria, antibiotic pressure are patients with ESBL positive result diagnosed by stool culture and a rectal swab.~The intervention correspond to addition of 4 stool samples (or 4 rectal swabs in the absence of stool emission) and a blood sample."
75925474|NCT03338660|Biological|Infusion of Platelets|Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).
75925475|NCT03338660|Biological|Infusion of Platelets|Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.
75925476|NCT03338660|Biological|Placebo|Subjects will receive infusion placebo (saline).
75925477|NCT02497742|Other|Basic metabolic panel|Patients blood is collected in routine fashion for basic blood chemistries
75332316|NCT04395014|Diagnostic Test|2D Echocardiography|In this echocardiographic imaging acquisition protocol, the pregnancy patients, are colocated in the left lateral decubitus position on a clinical bed with the left arm flex and the hand behind the head. All the echocardiographic measurements are taken by the examiner in this position.
75332317|NCT00983918|Drug|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
75925478|NCT02497586|Radiation|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
75332318|NCT00983918|Drug|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
75332319|NCT00983918|Drug|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
75332320|NCT00983918|Drug|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
75332321|NCT03057782|Device|Waveguard (TM) EEG cap|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
75332322|NCT03057782|Device|Micro Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
75470990|NCT01947530|Procedure|Standard Bronchoscopy|
75470991|NCT01947556|Drug|insulin aspart|After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
75470992|NCT01947569|Biological|Biological|
75640544|NCT04115020|Drug|Naltrexone|Naltrexone 4.5 mg oral suspension
75925479|NCT02497508|Drug|nivolumab|
75640545|NCT04115020|Drug|Placebo|Placebo oral suspension
75640546|NCT02720211|Device|Gray tinted spectacle lenses|A neutral gray optical tint designed to block all wavelengths in the visible spectrum
75640547|NCT02720211|Device|Thin-Film spectacle lenses|A thin film optical notch filter designed to block 480-nm light in the visible spectrum
75640548|NCT02801266|Behavioral|Evidence informed birth control counseling|Counselors underwent training on the use of 10 best practices for contraceptive counseling.
75925480|NCT02493842|Device|Transverse Intrafasicular Multichannel electrode (TIME)|Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
75925481|NCT03334994|Procedure|Intervention group:(Group B) connective tissue graft combined with immediate implant.|Patients will be treated with connective tissue graft combined with immediate implant.
75925482|NCT02497352|Dietary Supplement|flaxseed|
75925483|NCT02497352|Behavioral|lifestyle modification|
75925484|NCT03338426|Drug|Fimasartan 120mg|Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
76080792|NCT06108375|Other|recording|a recording of the same music played by the music therapist
76080793|NCT06105996|Behavioral|Interoceptive training|There will be 6 interoceptive training sessions carried out over two months. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy and the accuracy of their subjective confidence rating, relative to their objective accuracy.
75640549|NCT02606188|Device|Modified High-flow nasal cannula|Modified High-flow nasal cannula
75640550|NCT02606188|Device|nasal cannula|Conventional oxygen therap
75640551|NCT04160169|Other|Counseling messages on injectable use and HIV acquisition risk|Counseling messages based on 2017 World Health Organization guidance, a review of the Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-related Risks, and the Family Planning Global Handbook were provided to clients expressing interest in injectables during regular family planning appointments.
75640552|NCT02707731|Procedure|Hydrokinesiotherapy|physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.
75640553|NCT03292666|Drug|Oral Anticoagulant|Oral anticoagulants used to treat or prevent venous thromboembolism
75925485|NCT03338426|Drug|Atorvastatin 40mg|Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
75925486|NCT03338426|Drug|Placebo for Fimasartan 120mg|Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
75925487|NCT03338426|Drug|Placebo for Atorvastatin 40mg|Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
76080794|NCT06105788|Other|Exercise|"Arm exercise will be an arm ergometer for 20 minutes, preceded by a 5-minute warm-up.~Leg exercise will be a cycling ergometer for 20 minutes, preceded by a 5-minute warm-up.~The exercise intensity will be set at 70% of the heart rate reserve (HRR) for each type of exercise."
76080795|NCT06100120|Procedure|Implant placement|Placement of osteointegrated implants
75332323|NCT03057782|Device|Pico Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
75332324|NCT03057782|Device|QS Piezostimulator|This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
75640554|NCT02707653|Drug|Misoprostol|400 mcg sublingual misoprostol
75640555|NCT00801892|Device|Continuous Positive Airway Pressure (CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
75640556|NCT00801892|Device|Sham- Continuous Positive Airway Pressure (Sham-CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
75925488|NCT03338348|Drug|Vosaroxin|Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
76080796|NCT06090344|Other|Traditional video format|6 x 3 minute videos designed in the same format as traditionally found on the internet
76080797|NCT06090344|Other|Evidence-informed video format|6 x 3 minute videos designed in the format recommended by advice in the literature
75332325|NCT03057782|Device|tactileTM sensory evaluator|This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
75332326|NCT01925924|Other|Resin-modified glass ionomer cement|This material contains fluoride
75332327|NCT01925924|Other|Composite resin|This material does not include fluoride
75640557|NCT03901131|Drug|Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)|Follow clinical administration
75640558|NCT02707419|Device|Experimental group|Video of the exercises
75640559|NCT02707419|Device|Control group|video of nature scenes
75640560|NCT02707419|Device|Conventional physiotherapy|Mobilization, exercises and transfer practice.
75925489|NCT03338348|Drug|Azacitidine|"Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;~Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
75925490|NCT02497274|Other|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
75925491|NCT03334916|Drug|YMC026|YMC026 20mL TID
75925492|NCT03334916|Drug|Placebo|Placebo 20mL TID
75925493|NCT02497196|Device|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
75925494|NCT02497196|Device|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
75640561|NCT02773264|Device|Ultrasound|Ultrasound Elastography of soft tissue and organ lesions
75925495|NCT02497196|Device|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
75925496|NCT02497196|Device|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
75925497|NCT03334838|Drug|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
75925498|NCT02497118|Drug|Endostatin|Endostatin,7.5mg/m^2,intravenous, d1-14;
75925499|NCT02497118|Drug|Vinorelbine|vinorelbine,25mg/m^2,intravenous, d1, d8;
75925500|NCT02497118|Drug|Cisplatin|Cisplatin，75mg/m^2 intravenous,divide into d1-3
75925501|NCT03334760|Other|Danish National Birth Cohort|DNBC is a nationwide cohort study of pregnant women and their offspring. The women were enrolled early during pregnancy between 1996 and 2002. They provided information on exposures during and after pregnancy by means of four computer-assisted telephone interviews in gestational weeks 12 and 30 and post-partum when the child was 6 and 18 months old.
75332328|NCT01926002|Drug|Low-Dose MK-8351|Single administration of low-dose MK-8351.
75332329|NCT01926002|Drug|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
75332330|NCT01926002|Drug|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
75332331|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
75332332|NCT01926236|Other|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
75332333|NCT01926236|Drug|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
75332334|NCT01926236|Drug|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
75332335|NCT01926236|Drug|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
75332336|NCT03049826|Other|Nutritional status|Body composition and nutrient status
75332337|NCT00983528|Biological|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
75332338|NCT00983528|Drug|Clofarabine|"Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5"
75332339|NCT01926314|Device|PHENIX Neuromuscular Stimulation Therapy System device|
75332340|NCT01926314|Other|usual home care without device|
75470993|NCT01947595|Behavioral|intensified lifestyle intervention|"physical activity 6 hours per week, 50% guided activity~recorded by an accelerometer (Aipermotion 440)~16 sessions per year with a lifestyle advisor~nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
75640562|NCT04371393|Biological|Remestemcel-L|administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
75640563|NCT04371393|Drug|Placebo|administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
75640564|NCT00923182|Drug|alemtuzumab|
75640565|NCT03868839|Drug|Telmisartan Pill|telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
75640566|NCT02605564|Other|Gluten Free Diet|Gluten Free Diet
75640567|NCT02605564|Other|Placebo|Placebo No intervention, standard T1DM diet
75640568|NCT03844659|Other|"Song Weightless by Marconi Union"|"Patients will be randomized to the intervention group (the song Weightless by Marconi Union will be playing) during subjects labor epidural placement. The intervention in this study is solely the addition of music."
75332341|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
75332342|NCT00983372|Drug|Diltiazem ER|One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
75332343|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
75470994|NCT01947595|Behavioral|normal lifestyle intervention|"physical activity 3 hours per week~recorded by an accelerometer (Aipermotion 440)~8 sessions per year with a lifestyle advisor~nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
75470995|NCT01947595|Behavioral|Single lifestyle advice|"- Single Health care advice and lifestyle advice (30 minutes) at the beginning~recommend the individual target weight (5% less, if BMI 25> kg/m²)"
75470996|NCT01947608|Drug|LDK378|750 mg. orally
75470997|NCT01947621|Other||
75789128|NCT03465280|Procedure|Plasma coagulation|Removal of lesions via plasma coagulation
75925502|NCT02496962|Drug|Atorvastatin|atorvastatin were taken daily for 5 days
75470998|NCT01947634|Other|ResMed Apnea Link plus|Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
75640569|NCT03844659|Other|No Song|No song will be played during subjects labor epidural placement.
75640570|NCT03054376|Other|Immobilization|Full length cast of one leg R/L randomized
75640571|NCT03054376|Other|Training with non immobilized leg|Exercise training will be conducted with the non-immobilized leg during the immobilization period of two weeks
75640572|NCT03054376|Other|Exercise training with both legs|Exercise training will be conducted regularly on a cycle ergometer during a four week period
75789129|NCT03465280|Procedure|Other|Removal of lesions via other methods
75789130|NCT03465280|Other|Adjuvant therapies|All adjuvant therapies
75789131|NCT01098630|Other|Medical Chart Review|Patients' medical record information is collected and staff complete the treatment review form
75789132|NCT01098630|Other|Questionnaire Administration|Ancillary studies
75789133|NCT01349764|Drug|Vitamin D3|
75925503|NCT02496962|Drug|placebo|placebo were taken daily for 5 days
75925504|NCT03334604|Dietary Supplement|Multispecies probiotic|Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10^9 Colony Forming Units (CFU), twice daily, orally.
75925505|NCT03334604|Other|Placebo|Placebo identical in taste, smell and color to the multispecies probiotic.
75925506|NCT02492594|Other|Peripheral blood sampling|"Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~at the start of neutropenic fever~after 24 hours~after 48 hours~before the start of antimycotic therapy, if pertinent~at the end of antimycotic therapy, if pertinent"
75925507|NCT03338270|Diagnostic Test|MRI|MRI sequence without intravenous contrast
75925508|NCT02493686|Diagnostic Test|audiogram|hearing test
75925509|NCT02496728|Behavioral|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
75470999|NCT01947660|Drug|Systemic analgesia + Continuous regional anesthesia|Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
75471000|NCT01947660|Drug|Systemic analgesia|Systemic analgesia as usual
75640573|NCT04015960|Other|no intervention|qualitative research and patient reported outcome measure (PROm) development
75640574|NCT02680587|Radiation|SBRT|SBRT (1-5 fractions) will be administered.
75640575|NCT00589420|Drug|docetaxel|
75640576|NCT00589420|Drug|sorafenib tosylate|
75640577|NCT01025336|Other|Blood draw|Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
75640578|NCT01025336|Other|Blood draw|Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
75640579|NCT04114630|Drug|erenumab 70mg/mL|Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors
75640580|NCT03810573|Device|NB1|rhNELL-1/DBX
75640581|NCT00914524|Drug|olmesartan medoxomil|olmesartan medoxomil tablets, once daily
75640582|NCT02605408|Device|LenSx® laser system|Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
75640583|NCT02605408|Procedure|Phacoemulsification|Removal of the cataractous lens
75925510|NCT02496728|Behavioral|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
75925511|NCT02496728|Behavioral|Social Support|Participants may interact with each other through a private Facebook group.
75471001|NCT01947673|Other|Mindfulness Meditation|
75471002|NCT01947673|Other|Health Education|
75471003|NCT01947686|Device|Robotically guided patellofemoral UKA isolated patellofemoral implants|A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
75471004|NCT01947699|Drug|Glyburide|
75789134|NCT02924272|Drug|Ixazomib|Ixazomib Capsules
75789135|NCT01353742|Drug|Lamivudine|100mg tablet
75789136|NCT01353742|Drug|Adefovir dipivoxil|10mg tablet
75789137|NCT01353742|Drug|Fixed dose combination (Lamivudine and Adefovir dipivoxil)|100mg/10mg capsule
75789138|NCT01357330|Drug|SAR245408 (XL147)|Pharmaceutical form:capsule and tablet Route of administration: oral
75789139|NCT01357330|Drug|MSC1936369B|Pharmaceutical form:capsule Route of administration: oral
75789140|NCT01317862|Device|Transcervical foley catheter, Prostaglandins|16 French foley catheter 10mg dinoprostone vaginal insert
75789141|NCT01349842|Biological|Blood sampling|20ml of patient peripherical blood will be collected
75789142|NCT01349842|Other|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
75789143|NCT00003702|Biological|Dactinomycin|Given IV
75789144|NCT00003702|Drug|Methotrexate|Given intramuscularly
75789145|NCT01318720|Other|Manual Therapy|Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
75789146|NCT01350076|Drug|conventional liberal fluid regimen|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
75798750|NCT01568788|Biological|Inactivated Influenza Vaccine|200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
75471005|NCT01947699|Device|Continuous glucose monitor|
75332344|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
75332345|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
75789147|NCT01350076|Drug|restricted fluid regimen|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
75640584|NCT03787095|Biological|Cemiplimab|Administered as an intravenous (IV) infusion
75925512|NCT02496728|Behavioral|Educational Materials|Educational materials regarding healthy behaviors.
75640585|NCT03787095|Biological|Placebo|Diluent for REGN2810, administered as an IV infusion
75925513|NCT02496806|Dietary Supplement|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
75925514|NCT03342326|Other|Exposure to familiar songs|3 conditions : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
75925515|NCT03342326|Other|Music Experience Questionnaire|questions about the past music training
75925516|NCT03342326|Other|Implicit tasks memory|"2 tests : a) Completion of trigrams : freely complete the first 3 letters of a word.~b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
75925517|NCT03342326|Other|Questionnaires|Mini Mental State Examination, 5 words by Dubois and fluence verbal test
75925518|NCT04494230|Behavioral|Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities|to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.
75925519|NCT03338114|Drug|FLX-787-ODT (orally disintigrating tablet)|Oral Disintegrating Tablet
75925520|NCT03334136|Drug|25-Hydroxyvitamin D|Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)
75925521|NCT03334136|Drug|Placebo oral capsule|Five capsules the first day and thereafter one capsule every week for 4 months.
75925522|NCT03342248|Other|access to the social network|The development of a social network via a digital platform for carers of patients suffering from severe mental illness and study of the impact of its use on the health status of caregivers
75925523|NCT03120728|Drug|Etonogestrel/ethinyl estradiol contraceptive vaginal ring|"Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section."
75471006|NCT01947712|Dietary Supplement|dark chocolate with crossover to milk chocolate|40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks
75471007|NCT01947712|Dietary Supplement|milk chocolate with crossover to dark chocolate|40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
75640586|NCT04103385|Behavioral|RISE (Reconnecting to Internal Sensations and Experiences)|The overarching goal of RISE is to increase interoception by reconnecting people with their internal sensations
75640587|NCT04103385|Behavioral|RISE (Reconnecting to Individual Strength and Energy)|Aims to reduce life stressors and improve physical health
75640588|NCT00796978|Biological|trastuzumab|Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
75640589|NCT00796978|Other|laboratory biomarker analysis|Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).
75640590|NCT00796978|Procedure|adjuvant therapy|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
75925524|NCT02496650|Drug|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
75332346|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
75471008|NCT01947738|Drug|VBY-891|Cathepsin S inhibitor
75471009|NCT01947738|Drug|Placebo|
75789148|NCT01098786|Biological|Cell-derived A/H1N1 influenza HA vaccine|Single group vaccinated
75789149|NCT01350154|Drug|Sildenafil|20 mg in gelatine capsules, oral, three times daily
75789150|NCT01350154|Drug|Placebo|Lactose monohydrate oral in gelatine capsules, 3 times daily
75789151|NCT00031590|Drug|Cisplatin|Given at a dose of 70mg/m2 by intravenous (IV) infusion over 8 hours on day 0 of each cycle (Regimen A only).
75925525|NCT03334058|Drug|ARGX-113|human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
75925526|NCT03333902|Procedure|QLB|QLB, quadratus lumborum block.
75925527|NCT03333902|Procedure|Intravenous patient controlled analgesia (PCA)|Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
75925528|NCT02492438|Biological|PPV23 vaccination or PCV13 vaccination|
75789152|NCT00031590|Drug|Cyclophosphamide|Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).
75789153|NCT00031590|Drug|Etoposide|Given at a dose of 150mg/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Given orally at a dose of 50mg/m2 as a single daily dose for 21 days beginning on day 14 of a cycle (Regimen B only).
75789154|NCT00031590|Drug|Lomustine|Given at a dose of 75mg/m2 taken orally on days 0 of each 6-week cycle with vincristine and cisplatin (Regimen A only).
75471010|NCT01947751|Procedure|CVC exchange|CVC exchange when related infection is suspected
75789155|NCT00031590|Drug|Vincristine|Given at a dose of 1.5mg/m2 given by IV infusion once a week for the first six weeks of treatment during radiation therapy. During maintenance therapy, it will be given as an IV push on days 0, 7 and 14 of each 6-week cycle (Regimen A only).
75789156|NCT00031590|Radiation|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (vincristine).
75789157|NCT01350310|Procedure|Intramyocardial injection|Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
75640591|NCT00796978|Procedure|quality-of-life assessment|Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
75640592|NCT03779295|Device|Pulse laser dye therapy (Device name: Candela Family of Pulsed Dye Laser Systems. 501k Number: K050673.)|The face will be split and randomized, one half will receive pulsed laser dye therapy.
75640593|NCT03779295|Drug|Clindamycin|The entire face (both halves) will receive clindamycin.
75640594|NCT00613665|Biological|helicobacter pylori vaccine|Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
75789158|NCT01350310|Procedure|Intracoronary injection|Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.
75789159|NCT01350310|Procedure|Intramyocardial injection|Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
75789160|NCT03412786|Biological|Bcl-Xl_42-CAF09b vaccine|The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion
75798751|NCT01568788|Biological|Inactivated Influenza Vaccine of Pasteur|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
75925529|NCT03337958|Device|Ventilatory re-education|The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
75925530|NCT03337880|Other|instrumental delivery|the birth was assisted with an extractor.
75925531|NCT02496572|Drug|Short course MDR-TB treatment regimen|"Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration."
75925532|NCT03342170|Genetic|G20210A prothrombin gene mutation and Factor 5 Leiden mutation|blood sample
75332347|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
75332348|NCT00983294|Drug|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
75332349|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
75471011|NCT01947751|Drug|CVC maintenance|CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
75640595|NCT00613665|Biological|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
75798752|NCT01568788|Biological|Inactivated Influenza Vaccine of GSK|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
75925533|NCT03333824|Drug|CYP1A2 (caffeine)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
75332350|NCT01926392|Drug|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
75471012|NCT01947764|Behavioral|HADITHI Intervention|"The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.~In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:~Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.~Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.~Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure."
75332351|NCT01926392|Drug|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
75332352|NCT01129765|Device|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
75471013|NCT01947777|Drug|IPI-145|25 mg oral capsule
75471014|NCT01947777|Drug|Rifampin|2x 300 mg oral capsule
75332353|NCT05601830|Drug|QN-030a|NK cell therapy
75332354|NCT05601830|Drug|Cyclophosphamid|Lympho-conditioning Agent
75640596|NCT00613665|Biological|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
75332355|NCT05601830|Drug|Fludarabine|Lympho-conditioning Agent
75640597|NCT00613665|Biological|helicobacter pylori vaccine|Eight subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
75789161|NCT01098864|Device|transcranial magnetic stimulation|low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.
75789162|NCT01318096|Drug|raltegravir and tenofovir and lamivudine|raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
75789163|NCT01318096|Drug|efavirenz+tenofovir+lamivudine|efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
75789164|NCT02530320|Drug|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
75789165|NCT01353820|Dietary Supplement|1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL|1- Intervention with test product ( >10E8 to <5.10E9 cfu/ml of L. delbruckii lactis )
75789166|NCT01353820|Dietary Supplement|2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus|2- Intervention with control product
75332356|NCT05601830|Drug|Cytarabine|Lympho-conditioning Agent
75332357|NCT00982280|Drug|Tapentadol PR|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
75332358|NCT01175317|Procedure|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
75471015|NCT01947790|Drug|pioglitazone group|
75471016|NCT01947790|Drug|Metformin group|
75640598|NCT00613665|Biological|Placebo|Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly
75798753|NCT01287624|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
75798754|NCT01287624|Drug|Gemcitabine, Paclitaxel|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
75925534|NCT03333824|Drug|CYP2C19 (omeprazole)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
75332359|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
75332360|NCT01926470|Procedure|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
75471017|NCT01947803|Drug|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
75471018|NCT01947920|Drug|Tramadol HCl, 50 mg|50-mg overencapsulated tablet for oral administration
75471019|NCT01947920|Drug|Placebo|Size-matching capsules containing an appropriate inactive excipient
75332361|NCT01926470|Procedure|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
75332362|NCT01175395|Drug|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
75332363|NCT03011905|Drug|Dexamethasone|4 ml DexaGalen 4 mg/ml
75332364|NCT03011905|Drug|NaCl (Control)|4 ml NaCl 9 mg/ml
75471020|NCT01947933|Biological|Mirikizumab- IV|Administered IV
75471021|NCT01947933|Biological|Mirikizumab - SC|Administered SC
76080798|NCT06084429|Other|pre and post test (health educational intervention)|"The health education will be provided the following sessions.~Introduction to Global and Bangladesh Health, Health Information access (Validity), Critical Values (Vital signs, BMI, RBS etc.), Emergency Management (burn, chocking, knife cut, fainting etc.), Food (classification, healthy food, unhealthy, food label, salt intake) (NCDs from unhealthy diet), Smoking and Alcohol (NCD related, substance abuse, secondhand smoking), Physical activity (Benefits, sedentary lifestyle, NCD related), Women's health (menstruation, menstrual cycle, hygiene, STD, contraception), Hygiene (water, food, brushing, bath, toileting, healthy habits), Environmental Sanitation and Communicable disease (clean, effects on health), and Women's health and societal contribution"
76080799|NCT06082882|Behavioral|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include a ~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).
76080800|NCT06082882|Behavioral|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
75640599|NCT00613665|Biological|helicobacter pylori vaccine|Nine subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
75789167|NCT03954054|Behavioral|"Choizitaconso - therapeutic patient education programme"|"Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms.~It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment:~Understand the mechanisms that trigger and/or maintain alcohol-related difficulties~Plan and evaluate personalized controlled drinking strategies~Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations~Identify alcohol effects and alcohol-related expectations (by developing self-observation skills)~Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings)~Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons."
75789168|NCT00239681|Drug|Rosuvastatin|Oral
75789169|NCT00239681|Other|Placebo|Oral
75789170|NCT02878330|Drug|MEDI8897|A single IM dose of 50 mg on Day 1 of the study.
75789171|NCT02878330|Drug|Placebo|A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
75925535|NCT03333824|Drug|CYP3A (midazolam)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
75925536|NCT03333824|Drug|Kytril (granisetron)|Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.
75925537|NCT03333824|Drug|Wee-1 kinase inhibitor AZD1775|Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
76080801|NCT06082505|Behavioral|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).
75640600|NCT00613665|Biological|helicobacter pylori vaccine|Ten subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
75332365|NCT03011905|Drug|Paracetamol|Premedication and as needed after operation
75332366|NCT03011905|Drug|EtoriCoxib|Premedication and first 2 postoperative days.
75332367|NCT03011905|Drug|Oxycodone|Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
75332368|NCT03011905|Drug|Ropivacaine|In brachial plexus block
75332369|NCT01926548|Drug|CJ Imatinib mesylate tablet|
75471022|NCT01947933|Biological|Placebo - IV|Administered IV
75640601|NCT04112056|Dietary Supplement|Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)|It is same as that stated in arm description.
75640602|NCT02607501|Device|Implant eCLIPs|Implant eCLIPs at target bifurcation aneurysm
75332370|NCT01926548|Drug|Gleevec film-coated tablet 2 x 100mg|
75332371|NCT03011983|Device|MEG|MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.
75332372|NCT03011983|Device|MRI|MRI is a non-invasive imaging modality that provides measures of brain structure.
75332373|NCT03011983|Behavioral|Neuropsychology assessment|A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
75332374|NCT00981578|Device|ExAblate 2100|Conformal Bone System
75640603|NCT00923572|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
75789172|NCT01354054|Procedure|High Frequency TENS|100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
75789173|NCT01354054|Procedure|Low frequency TENS|100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
75332375|NCT01176877|Behavioral|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
75332376|NCT01176955|Behavioral|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
75640604|NCT02692833|Other|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
75640605|NCT03746769|Biological|Allogenic Human Islet Cells|islet cells transplanted into the portal vein in the liver
75640606|NCT03746769|Drug|Gastrin 17|"Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets."
75640607|NCT00796822|Drug|Pentoxifylline|400 mg three times a day for 8 weeks
75640608|NCT00796822|Drug|Placebo|One pill three times a day for 8 weeks
75789174|NCT01354054|Procedure|Placebo TENS|100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
75640609|NCT03884829|Drug|CYC140|CYC140 single agent
75640610|NCT03622983|Other|collection of sample and data|Recovery of surgical waste during surgery planned in the current care and clinical data collection
75640611|NCT02873156|Drug|E2027|Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.
75640612|NCT02873156|Drug|E2027 matched placebo|Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
75789175|NCT01354288|Other|Educational tool|Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
75789176|NCT01354366|Other|Infant formula|
75789177|NCT00238433|Biological|filgrastim|5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC> 1500 for 2 consecutive days.
75789178|NCT00238433|Drug|busulfan|3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
75789179|NCT00238433|Drug|melphalan|50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
75789180|NCT00238433|Drug|thiotepa|250 mg/m2/day/iv on days -3 and -2
75789181|NCT00238433|Procedure|bone marrow ablation with stem cell support|The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
75925538|NCT03121430|Device|Drug eluting peripheral vascular stent system|Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
75925539|NCT03121430|Device|Nitinol Stent System|Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
75925540|NCT02492516|Biological|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
75925541|NCT03342092|Other|Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
75925542|NCT04494152|Diagnostic Test|Transthoracic echocardiography|Standard Point-of-Care echocardiographic examination in the intensive care unit.
75640613|NCT03822507|Drug|KHK7580|oral administration
75640614|NCT03822507|Drug|Cinacalcet Hydrochloride|oral administration
75640615|NCT04300166|Device|Telemedicine & Humidification|Wireless control of CPAP usage, adherence, leakage and humidifier usage
75640616|NCT04301570|Device|Ultrasound device|"The measurement of bone age is performed via ultrasound with the Ultrasound System for Bone Age Assessment (BAUS) from Sonic Bone (SonicBone Medical Ltd., Rishon Lezion, Israel)."
75640617|NCT04301570|Radiation|XR|The measurement of bone age is performed via imaging procedure via X-ray (Röntgengerät, Stadler SE 4600, Littau, CH) of the left hand.
75789182|NCT00238433|Procedure|peripheral blood stem cell transplantation|Performed 36-48 hours following last chemotherapy dose.
75789183|NCT02532023|Dietary Supplement|omega 3 fatty acid|omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
75332377|NCT01176955|Drug|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
75332378|NCT00980798|Drug|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
75332379|NCT00980798|Drug|Placebo|placebo tablet once daily for 16 weeks
75332380|NCT01177189|Dietary Supplement|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
75332381|NCT01926860|Biological|Prevenar13|
75789184|NCT02532023|Dietary Supplement|curcumin|curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
75332382|NCT01926860|Biological|Hepatitis A vaccine|
75789185|NCT02532023|Dietary Supplement|omega 3 fatty acid placebo|omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
75789186|NCT02532023|Dietary Supplement|curcumin placebo|curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
75789187|NCT01354522|Drug|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
75789188|NCT01354522|Drug|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
75789189|NCT01072721|Other|Elastometry|Fibrosis detection with FIBROSCANN
75789190|NCT00045162|Drug|cisplatin|"Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles"
75789191|NCT00045162|Drug|etoposide|100 mg/m2 IV (over 30-60 min) on Days 1 , 2 & 3. Q 3 weeks x 4 Cycles
75332383|NCT01177735|Drug|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
75471023|NCT01947959|Drug|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
75640618|NCT02872922|Other|Low intensity therapeutic ultrasound|The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
75640619|NCT02692287|Device|The PPH Butterfly|The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
75789192|NCT00045162|Drug|irinotecan hydrochloride|60 mg/m2 IV (over 90 min)on Days 1, 8 & 15. Q 4 weeks x 4 Cycles
75789193|NCT04289038|Other|Autogenic Relaxation|Autogenic relaxation
75789194|NCT04289038|Other|virtual reality game application|virtual reality game application,
75789195|NCT04289038|Other|kidney function narration|kidney function narration
75332384|NCT01135069|Drug|Tretinoin microsphere 0.1%|Treatment of acne vulgaris
75789196|NCT01072799|Biological|Placebo|Two doses (Day 1 and Day 22); 0.5mL
75789197|NCT01072799|Biological|A/H1N1 2009 Influenza VLP Vaccine|Two doses (Day 1 & Day 22); 0.5mL
75332385|NCT01135069|Drug|Brand Retin-A Micro tretinoin microsphere gel 0.1%|Treatment of acne vulgaris
75332386|NCT01135069|Drug|placebo microsphere gel|treatment of acne vulgaris
75471024|NCT01947959|Drug|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
75471025|NCT01947972|Dietary Supplement|Tailored protein fortification|4-4.5g of protein/kg/d
75640620|NCT04301726|Drug|Deutetrabenazine Oral Tablet [Austedo]|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
75640621|NCT04301726|Drug|Placebo oral tablet|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
75789198|NCT02748616|Drug|Ursodiol|Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
75789199|NCT01582373|Behavioral|Cognitive-behavioral couple therapy|The treatment package will include the following: information about the nature of CBCT; education about PVD and how it impacts on sexuality; education concerning a multifactorial view of pain; relaxation techniques; vaginal dilatation exercises; cognitive restructuring exercises (replacing distorted or irrational beliefs about pain and sexuality by more realistic ones); distraction techniques focusing on sexual imagery; expansion of the sexual repertoire; and exercises to improve pain and sexuality-relevant couple interactions (e.g., communication skills training, modification of maladaptive partner responses to pain, emotional disclosure and validation exercises).
75789200|NCT01354600|Other|Exercise or Sedentary|Daily cycling exercise at 50% maximal aerobic fitness for a total of ~120 minutes/day or no daily exercise (sedentary)
75789201|NCT01354678|Procedure|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection of bone marrow mononuclear cells
75789202|NCT01354678|Procedure|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection with placebo
75789203|NCT00238121|Drug|sorafenib tosylate|Given orally
75789204|NCT03386968|Behavioral|Active video gaming|"Children will visit Blythedale for 8 sessions, one 45-session visit per week, in place of one of the child's typical physical therapy sessions. During each session, children will play a video game on the X-Box Kinect system, using the games Kinect Adventures and Kinect Sports. The child will first play a Kinect Adventures game, which requires ambulating, ducking, and dodging one's way through an obstacle course."
75789205|NCT03386968|Behavioral|Usual care physical therapy|Children will attend their usual care physical therapy appointments at Blythedale.
75925543|NCT03337568|Procedure|allogeneic hematopoietic cell transplantation|perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin
75332387|NCT01178281|Drug|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
75332388|NCT01178281|Drug|Placebo|Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
75332389|NCT01178281|Drug|Pomalidomide|Pomalidomide 0.5 mg capsule taken by mouth once daily.
75789206|NCT03635242|Other|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
75789207|NCT03635242|Other|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
75789208|NCT03139552|Other|Apple Crisp|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of apple crisp in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
75789209|NCT03139552|Other|Tea|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of tea in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
75789210|NCT03139552|Other|Oatmeal|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe of oatmeal in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
75789211|NCT01096134|Biological|HPV Vaccine (Gardasil)|"HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.~FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:~20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection"
75925544|NCT02496338|Other|Training program about menopausal health isues|A three sessions raining program about health issues during menopause for spouses of 45-60 years old
75640622|NCT00614679|Drug|catheter lock solution consisting of N-acetylcystein, tigecycline and heparin|N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
75640623|NCT02873000|Behavioral|Incentive Spirometry|Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
75640624|NCT03760965|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
75640625|NCT03760965|Drug|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
75925545|NCT02496494|Drug|Tacrolimus|Tacrolimus for maintenance immunosupression in kidney transplant recipients
75925546|NCT03337412|Other|Adapted physical activity|"Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire"
75640626|NCT01020812|Procedure|TACE|Standard of Care
75640627|NCT01020812|Procedure|SBRT|Standard of Care
75640628|NCT03703869|Drug|Insulin glargine (U300)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
75640629|NCT02872688|Other|GanedenBC30|
75640630|NCT02872454|Behavioral|Text Messaging|Each week, enrolled participants will receive daily text messages from one of three randomly assigned psychotherapeutic modalities-cognitive restructuring, behavioral activation, and techniques based on Acceptance and Commitment Therapy (ACT)-for a total of 12 weeks. The messages were developed, reviewed, and refined by a multidisciplinary team of experienced therapists, including social workers, psychologists, and psychiatrists.
75640631|NCT01032044|Device|Standard endoscopic evaluation|Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy
75640632|NCT01032044|Device|pCLE guided evaluation|Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
75640633|NCT01024946|Drug|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
75640634|NCT00627614|Other|breast imaging study|"1. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.~2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure."
75640635|NCT00724867|Biological|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV over one hour every 28 days
75640636|NCT00724867|Biological|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days
75640637|NCT02692521|Dietary Supplement|Human Milk|
75471026|NCT01947985|Drug|Rivaroxoban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
75789212|NCT03954288|Diagnostic Test|serum for sclerostin ELISA test|Blood sample to measure serum sclerostin level
75789213|NCT01350622|Drug|PENNSAID|active treatment with PENNSAID and oral placebo. Subjects will apply 40 drops of Pennsaid to the affected ankle joint once, and will take a single placebo pill.
75789214|NCT01350622|Drug|Diclofenac hydroxyethylpyrrolidine|active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
75332390|NCT01135381|Behavioral|IVR-Enhanced Care|Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
75471027|NCT01947985|Drug|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
75925547|NCT03337334|Device|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
75925548|NCT03337256|Diagnostic Test|GI bleeding score|"Risk factor Score component value Age (years) 15-29 -2 30-44 -1.5 45-59 0 60-74 1.5~75 2.5 Haemoglobin(g/L)~10.0 0 <9.9 2 Systolic blood pressure (mmHg)~110 0 90-109 1.5 <90 2.5 Pulse (beats per min) <100 0~100 1.5 Creatinine (mmol/L) <200 0~200 3.5 Number of blood transfusion 0 0~1 1.5~2 2 Presenting symptom Melaena -1.5 Drug treatment Acid blcoking drug 1.5 anticoagulant 3 Endoscopy findings Clean-based ulcer -2 SRH or blood in stomach 4 Varices 5"
75925549|NCT03337178|Behavioral|Blinded Fitbit|Fitbit is worn for 3 months post-operatively with no activity feedback or step goals
76080802|NCT06082505|Behavioral|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
75640638|NCT02873078|Behavioral|Internet-delivered Cognitive behavior therapy|The treatment is delivered via an online platform and is based on interventions for adults, adolescents and children tested in previous trials. Therapists are CBT-psychologists och students in clinical psychology under supervision.
75640639|NCT00627536|Drug|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
75640640|NCT00627536|Drug|Placebo|Matched to avotermin dosage strength
75640641|NCT00724711|Drug|emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|FTC 200 mg/TDF 300 mg tablet, once a day
75640642|NCT00724711|Drug|abacavir (ABC)/lamivudine (3TC)|ABC 600 mg/3TC 300 mg tablet, once a day
75789215|NCT01096212|Drug|original sevoflurane|Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
75640643|NCT04019743|Drug|CKD-330 16/10mg Tab. 1T and D086 Tab. 1T|single oral administration under fasting condition
75640644|NCT04019743|Drug|CKD-333 16/10/40mg formulation 1 Tab. 1T|single oral administration under fasting condition
75925550|NCT03337178|Behavioral|Fitbit|Fitbit is worn for 3 months post-operatively with feedback and step goals
75640645|NCT04019743|Drug|CKD-333 16/10/40mg formulation 2 Tab. 1T|single oral administration under fasting condition
75332391|NCT03012295|Other||
75332392|NCT03994159|Device|"Use of the PARO emotional robot"|PARO is an advanced interactive therapeutic robot designed to stimulate patients with Dementia, Alzheimer's, and other cognition disorders.
75640646|NCT04019509|Diagnostic Test|blood test|blood test for thyroid antibodies and thyroid function (TSH, FT4)
75640647|NCT04019509|Other|follow up treatment outcome|questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery
75789216|NCT01096212|Drug|generic sevoflurane|Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
75789217|NCT03804918|Other|VitalTips mobile application|VitalTips is a mobile learning application with learning on breaking bad news. Participants were expected to spend at least three hours using the mobile learning resource, ensuring that the time did not impact on their clinical and academic commitments.
75789218|NCT03139240|Drug|Oxycodone 10mg oral|Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
75925551|NCT03333512|Behavioral|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
75925552|NCT03333434|Device|Carbon Ankle Seven spring (A7 - Otto Bock, Germany)|
75925553|NCT03333434|Device|Hinged AFO|
75925554|NCT03333278|Drug|Vitamin C|Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days
75925555|NCT03333278|Drug|Thiamine|Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days
75925556|NCT03333278|Drug|Hydrocortisone,|Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
75925557|NCT04494308|Other|biomarker identification|flow cytometric analysis of eosinophils membrane molecules
75925558|NCT02561962|Drug|AMG 224|Administered as an IV infusion.
76080803|NCT06082154|Device|ultrasound|Patient will undergo multiorgan ultrasonography
75332393|NCT01178827|Drug|trospium chloride|trospium chloride (60mg) once daily for 10 days
75332394|NCT01178827|Drug|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
75332395|NCT01178827|Drug|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
75332396|NCT03012217|Other|Observational Study|
75332397|NCT01135537|Biological|Thymoglobulin (rATG)|"Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.~Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy."
75332398|NCT03011749|Other|FLT PET/CT|FLT PET/CT before first series of Radium-223 and after 2 series
75332399|NCT02181517|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
75332400|NCT02181517|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
75789219|NCT03139240|Other|Placebo|Placebo given in addition to standard of care medications in women undergoing medical abortion
75789220|NCT01350700|Other|Scars assessment & QOL|Scar assessment and quality of life questionnaires
75789221|NCT01584180|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
75789222|NCT01584180|Device|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad
75332401|NCT02181517|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
75332402|NCT01179217|Drug|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
75640648|NCT02591797|Procedure|inferior alveolar and lingual nerve block procedure|"The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.~The application of anesthesia shall be in accordance with the following guidelines:~Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).~Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)~anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).~Syringe: carpule syringe-conventional harpoon with suction system."
75640649|NCT01024244|Drug|Placebo|Administered po BID, prior to morning and evening meals for 12 weeks.
75789223|NCT00237809|Drug|D-serine|D-serine (30 mg/kg)
75332403|NCT01179217|Drug|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
75332404|NCT02181829|Radiation|Whole Lung IMRT|External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
75640650|NCT01024244|Drug|LY2599506|Administered po for 12 weeks
75789224|NCT00237809|Behavioral|Cognitive Retraining (CRT)|Cognitive retraining therapy (CRT)
75789225|NCT00237809|Drug|Placebo|Placebo D-serine Drug
75332405|NCT03010267|Drug|DP-R213|Investigational product is prescribed to all of randomized subjects
75640651|NCT00721279|Drug|Sifrol® (pramipexole dihydrochloride)|
75789226|NCT00237809|Behavioral|Cognitive Retraining Placebo|Cognitive retraining therapy (CRT) control
75789227|NCT01350856|Drug|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
75789228|NCT01350856|Drug|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
75332406|NCT03010267|Drug|Raloxifene|Investigational product is prescribed to all of randomized subjects
75332407|NCT03010267|Drug|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
75332408|NCT03977311|Device|Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)|-To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients
75332409|NCT03977311|Radiation|Radiation therapy|-Standard of Care
75789229|NCT02530398|Drug|Cinobufacini Injection|Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
75789230|NCT01351012|Other|Corn and safflower oil|The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks
75789231|NCT01351012|Other|Canola oil|The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks
75332410|NCT01181323|Other|Placebo|0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
75332411|NCT01181323|Biological|Cold-adapted live attenuated influenza virus vaccine, trivalent|Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
75789232|NCT01351012|Other|High oleic acid canola oil|The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks
75640652|NCT01030952|Drug|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
75640653|NCT01030952|Drug|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
75640654|NCT02872298|Device|Targeted Lung Denervation (TLD)|The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.
75640655|NCT04299074|Other|addiction|questionnaire
75640656|NCT04299152|Combination Product|Stem Cell Educator-Treated Mononuclear Cells Apheresis|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
75640657|NCT04299932|Procedure|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
75640658|NCT04299932|Procedure|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
75640659|NCT01030874|Other|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
75789233|NCT01351012|Other|DHA enriched high oleic acid canola oil|The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks
75789234|NCT01351012|Other|Flax and safflower oil|The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
75789235|NCT03973775|Drug|Permethrin Cream 5%|Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
75789236|NCT01351168|Drug|Levodopa|CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
75789237|NCT01351168|Drug|Zolpidem first dose|Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg
75789238|NCT01351168|Drug|Zolpidem second dose|Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.
75789239|NCT01351168|Drug|sugar pill|a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
75789240|NCT00003498|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75789241|NCT01351246|Behavioral|CBT Based Self-help Workbook + Counseling Telephone|"Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual Therapy program for children with hyperactive and oppositional problem behavior THOP (Döpfner, Schürmann, & Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, & Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet."
75789242|NCT01096524|Other|Standard Physiotherapy|The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
75332412|NCT01181323|Other|Placebo|0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
75332413|NCT01181323|Biological|Trivalent inactivated influenza vaccine|Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
75789243|NCT01096524|Device|Kneehab|"NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.~Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes."
75925559|NCT04847596|Other|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
76080804|NCT06080217|Device|study group|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, where high frequency electricity was released to the bladder for 20 minutes with a frequency of 1.0 MHz and energy to maximum 410 C. Initialy, maximum energy of 75% and a frequency of 0.8 MHz was applied, which was reduced depending on the heat that was pleasant for the patient. Then, the power was reduced to 50% and increased the frequency to 1.0 MHz, which also meant moderate energy absorption. The procedure with this energy was continued until the end, and the patients absorbed 18-19 kJ of energy in average."
75789244|NCT01351324|Dietary Supplement|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
75789245|NCT03952026|Procedure|osteosynthesis of the pelvis|Osteosynthetic Fixation of the pelvic fracture
75332414|NCT03855943|Behavioral|Personalized Computer Program|Training with a personalized computerized inhibitory training program
75471028|NCT01947998|Drug|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
75471029|NCT01947998|Drug|Warfarin|For VTE prevention, DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, warfarin.
75640660|NCT01030874|Other|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
75789246|NCT01351402|Procedure|Massage or Rest|Participants either received 15 minutes of moderate pressure Swedish massage on the upper back, or rested quietly sitting in a chair for 15 minutes.
75471030|NCT01947998|Drug|Antiplatelet drugs|For the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor
75471031|NCT01948011|Drug|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
75925560|NCT04847596|Other|Covid-19 vaccine|Prospective observational cohort study. There is no treatment allocation. Participants will obtain the COVID-19 FDA approved Emergency Use mRNA vaccine through their HCP (private insurance) or appropriate federal, state or local program.
75471032|NCT01948011|Drug|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
75925561|NCT02565706|Behavioral|WIC Fresh Start Program|The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
75925562|NCT02565706|Behavioral|Existing Online Health Education|Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
75332415|NCT03855943|Behavioral|CBT|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
75332416|NCT02246881|Biological|Optivate® (Human Coagulation Factor VIII)|
75471033|NCT01946932|Other|Temperature treatment|
75640661|NCT01030874|Other|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
75332417|NCT00980330|Drug|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
75332418|NCT00980330|Drug|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
75332419|NCT00980330|Drug|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
75332420|NCT00980330|Drug|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
75471034|NCT01948024|Drug|SAPHRIS|10 mg BID sublingual tablet
75332421|NCT01138735|Drug|adapalene/benzoyl peroxide|daily topical application for 12 weeks
75332422|NCT01138735|Drug|Topical Gel Vehicle|daily topical application for 12 weeks
75332423|NCT01181479|Drug|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel
75332424|NCT01181479|Drug|Lessina crossover to AG200-15|Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen for 6 cycles followed by AG200-15 for 6 cycles.
75332425|NCT00980174|Drug|60 mg denosumab|60 mg denosumab (SC injection every 6 months)
75640662|NCT01030874|Other|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
75640663|NCT01030874|Other|Drug Recommendations|The protocol permits the study physician to recommend medications for orthostatic hypotension. The patient's clinical team can implement, ignore, or modify these recommendations and only the clinical team can write orders for them. Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily [Mukai 2002; Grubb 2003]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily [Low, 1997]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
75640664|NCT03611751|Drug|BMS-986165|Specified dose on specified days
75640665|NCT03611751|Other|Placebo|Specified dose on specified days
75640666|NCT03611751|Drug|Apremilast|Specified dose on specified days
75640667|NCT00613743|Drug|mouth wash with morphine|morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
75640668|NCT00613743|Drug|placebo|placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
75640669|NCT00614757|Drug|N-acetylcysteine 20% 4ml|N-acetylcysteine 20% 4ml
75640670|NCT00614757|Drug|N-acetylcysteine 20% in 4 ml|N-acetylcysteine 20% in 4 ml
75640671|NCT02692365|Procedure|Magnetic Resonance + hemodynamic + infusion of gadolinium|
75640672|NCT03492099|Drug|buprenorphine|Patients in this study will receive dosages to be determined by a physician that are specific to each patient.
75640673|NCT03481959|Drug|Methylphenidate|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
75925563|NCT05510518|Diagnostic Test|oral glucose tolerance test (OGTT)|• The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.
75332426|NCT00980174|Other|Placebo|Placebo for denosumab (SC injection every 6 months)
75332427|NCT01138969|Drug|esomeprazole|esomeprazole 20 mg qd for 6 months
75332428|NCT01139515|Drug|Eletriptan commercial tablet|20 mg tablet, single dose
75332429|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
75332430|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
75471035|NCT01948024|Drug|Asenapine|10 mg BID sublingual tablet
75640674|NCT03481959|Other|Matching Placebo|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
75640675|NCT03245229|Drug|Aprocitentan|Capsule for oral administration
75640676|NCT03245229|Drug|Rosuvastatin|Tablet for oral administration
75925564|NCT03339752|Drug|Rosuvastatin|10 mg tablet
75925565|NCT03339752|Drug|ACT-541468|25 mg hard capsule
75925566|NCT00706628|Drug|BIBF 1120|
75332431|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
75332432|NCT00980018|Drug|Nilotinib|Participants received two 150 [a total of 300 mg at each dosing] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules [a total of 400 mg at each dosing] for patients enrolled prior to Protocol Amendment 1).
75332433|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
75332434|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
75332435|NCT00987272|Drug|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
75332436|NCT00987272|Drug|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
75332437|NCT03010033|Other|pulmonary rehabilitation|"pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).~pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations)."
75471036|NCT01948037|Other|hydrotherapy|30-minutes/per day,for 4weeks
75471037|NCT01948037|Other|hydrotherapy|30-minutes/per day;4weeks
75640677|NCT03327597|Other|Clinical follow-up 1|Participants receive routine care outside the bounds of the trial. No further work-up.
75789247|NCT03952104|Other|Strength training|Strength training
75789248|NCT01351558|Other|Knee muscle strengthening exercises|Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
76080805|NCT06080217|Device|placebo (sham control)|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, but without any energy transferred through the probe,"
76080806|NCT06077461|Behavioral|mandala painting|Patients in this group will be subjected to mandala painting.
75640678|NCT03327597|Other|Mental Health and Quality of Life questionnaire|Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
75789249|NCT01351558|Other|Upper extremity strengthening exercises|Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
75332438|NCT00986882|Drug|SAF312A|
75332439|NCT00986882|Drug|Placebo|
75789250|NCT01351558|Other|Cardiovascular fitness exercises|Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
75789251|NCT01351636|Drug|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months
75789252|NCT01351636|Drug|Non arotinolol group|Antihypertensive medications without arotinolol for 18 months
75789253|NCT00003492|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75789254|NCT01351714|Procedure|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
75789255|NCT01101672|Procedure|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
75789256|NCT01101672|Procedure|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
75925567|NCT00706628|Drug|BIBW 2992|
75332440|NCT00986882|Drug|Ibuprofen|
75332441|NCT01927094|Dietary Supplement|Probiotic|Comparison of probiotics vs. ORS
75332442|NCT01927094|Dietary Supplement|ORS|ORS ad libitum
75640679|NCT03327597|Other|Standard follow-up or treatment.|Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
75925568|NCT00706628|Drug|Sequential BIBF 1120 + BIBW 2992|
75640680|NCT03327597|Other|Clinical follow-up 2|Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
75789257|NCT01351792|Drug|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
75789258|NCT01351792|Drug|Symbicort® Turbohaler® 200/6 μg/actuation|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
75925569|NCT05502406|Procedure|Instrument Assisted Soft tissue Mobilization|Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
75332443|NCT00983060|Drug|NIM811|BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
75332444|NCT00983060|Drug|Placebo BID + SOC|Placebo BID + SOC (PEG IFN and RBV)
75332445|NCT05600816|Device|Pounce Venous Thrombectomy System|The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
75332446|NCT05607914|Procedure|percussion massage|percussion massage to the dominant leg hamstring muscle for 5 minutes
75925570|NCT05502406|Procedure|Manual Myofascial Release|"Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand"
76080807|NCT06058936|Other|exercises using virtual reality technology|this is a one-dimensional therapy game using (Handle/ or Multiball) five games are available for the Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Applehunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week
75332447|NCT05607914|Procedure|static stretching|Static stretching to the dominant hamstring muscle for 5 minutes
75332448|NCT04759352|Other|Post-test genetic counseling delivered by telephone|Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.
75789259|NCT03952260|Other|Fasting time for clear fluid prior to anaesthesia|"This study is to evaluate the latest fasting protocol that is currently adopted and recommended by United Kingdom, France and Royal Children Hospital Melbourne.~The research question is should we change our fasting protocol for paediatric patients prior to operation The anaesthesia service is being studied. Prior to induction, the amount of abdominal contents was examined using ultrasound scan. In addition, parents will complete a questionnaire after the surgery to assess anxiety level of patients before and after the surgery."
75332449|NCT01927172|Device|AirSonea|
75332450|NCT04759430|Other|Supervised Group|Individuals will apply ten different stabilization exercises in company with a physiotherapist.
75332451|NCT04759430|Other|Telerehabilitation group|Same stabilization exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone.
75789260|NCT01351870|Radiation|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
75789261|NCT01351870|Radiation|Hyperfractionated Radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
75925571|NCT03332966|Diagnostic Test|Psychiatric questionnaires|"Participants will fill in the following questionnaires as part of routine intake assessments:~Generalised Anxiety Disorder Assessment (GAD-7); Mini-Social Phobia Inventory; Beck Depression Inventory 21A; Pittsburgh Sleep Quality Index; Insomnia Severity Index; Youth Experiences and Health Questionnaire; Adolescent Dissociative Experiences Scale (abbr.); Adolescent Peer Relations Instrument (APRI-B + cyberbullying, abbr.); Adolescent Trauma and Dissociation Scale (abbr.); Alcohol Use Disorders Identification Test; Alcohol, Smoking and Substance Involvement Screening Test - Lite (extended); Nicotine Questionnaire incl. Heavy Smoking Index; Internet Addiction Test (abbr.); European School Survey Project on Alcohol and Other Drugs 2015 Social Media Use and Computer Gaming; McMaster Family Assessment Device - General Functioning positive items; Multidimensional Scale of Perceived Social Support; Brief Resilience Scale; The Short Warwick-Edinburgh Mental Well-Being Scale"
75925572|NCT03332966|Diagnostic Test|Semi-structured psychiatric interview|Kiddie Schedule for Affective Disorders and Schizophrenia, version K-SADS-PL 2013.
75332452|NCT00988052|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
75332453|NCT04557800|Drug|DNL151|oral dose(s)
75640681|NCT03327597|Other|Clinical follow-up 3|Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
75332454|NCT04557800|Drug|Placebo|oral dose(s)
75332455|NCT05607836|Device|IntuBrite intubation|Use of new laryngoscope IntuBrite for intubation in patients with cardiopulmonary arrest and during resuscitation
75332456|NCT05607836|Device|Macintosh laryngoscope|Use of standard Macintosh blade laryngoscope for intubation in patients with cardiac arrest and requiring cardiopulmonary resuscitation
75332457|NCT04395170|Biological|COVID-19 convalescent plasma|Plasma from convalescent patients with COVID-19 and at the same time receiving supportive therapy, with inactivation / reduction of pathogens, in the scheme of two doses of 200 - 250 mL administered on days 1 and 3 of the intervention.
75471038|NCT01948089|Behavioral|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
75471039|NCT01948089|Behavioral|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
75640682|NCT03327597|Other|Clinical follow-up control|Control clinical visit
75640683|NCT03462069|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
75640684|NCT03462069|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
75332458|NCT04395170|Biological|Anti-COVID-19 human immunoglobulin|"Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S, intravenously at a dose of immunoglobulin 10% IgG solution (10% mL vial) for:~Patient of 50 Kg or more, a dose of 50 mL, administered on days 1 and 3 of treatment.~Patient under 50 Kg, the dose will be 1 mL / Kg, administered on days 1 and 3 of treatment.~The supply of anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S included once it has been authorized by INVIMA and/or the regulatory requirements in force for the production of drugs are met."
75332459|NCT04395170|Drug|Standard (specific) therapy for COVID-19|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
75332460|NCT04394936|Drug|Guselkumab|100 mg guselkumab administered subcutaneously
75332461|NCT04394936|Drug|Placebos|Sodiumchloride 0,9% solution for injection
75640685|NCT03462069|Drug|Empagliflozin|"Pharmaceutical form: capsule~Route of administration: oral"
75640686|NCT03462069|Drug|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
75640687|NCT03414723|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
75640688|NCT03414723|Drug|Ramipril|"Pharmaceutical form: tablets~Route of administration: oral"
75640689|NCT03387657|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
75789262|NCT01351948|Biological|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
75789263|NCT01351948|Biological|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections
75640690|NCT03387657|Drug|Hydrochlorothiazide|"Pharmaceutical form: Tablet~Route of administration: Oral"
75640691|NCT00721123|Drug|Tocilizumab|Tocilizumab (myeloma receptor antibody [MRA]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
75789264|NCT01351948|Biological|AdCh63 AMA1 + AMA1-C1/Alhydrogel®|5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections
75925573|NCT05465252|Dietary Supplement|Krill Oil 500 MG|Qualified subjects start to take supplementation from Day 1 in the trial. Specifically, subjects from Intervention group take 3 capsules of krill oil per day.
76080808|NCT06054061|Behavioral|Experimental: experimental wellbeing promotion group (Think and Cope Positively)|"Session 1: Welcome. 2: Identifying and amplifying positive emotions. 3: Experiencing positive emotions. 4: Identifying my negative trap thoughts. 5: Transforming my automatic thoughts into positive ones. Session 6: Experiencing my positive thoughts I. 7: Experiencing my positive thoughts II. 8: Learning to be kinder to myself. 9: Identifying a life project (Individual appointment).10: Identifying coping strategies I. 11: Identifying coping strategies II. 12: Identifying adaptive coping strategies linked to well-being. 13: Building my life purpose with my environment. 14: Helping me to build my life purpose? 15: Multi-family session, farewell and closing."
76080809|NCT06054061|Behavioral|TAU|The usual treatment in the intervention of people affected by severe mental disorder in the network of public and subsidized centers in Spain consists of improving psychosocial functioning. To this end, and depending on the characteristics of the user, work is done in groups and individually on social skills, psychoeducation about the disease, adherence to pharmacological treatment, improvement of daily living activities, promotion of independent leisure, support to families in the process of relapse prevention, and training for labor market insertion.
76080810|NCT06051188|Device|Flow-controlled ventilation|Flow-controlled ventilation (FCV)
75789265|NCT01351948|Biological|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
75925574|NCT05465252|Dietary Supplement|Olive Oil 500MG|Qualified subjects start to take placebo from Day 1 in the trial. Specifically, subjects from placebo group take 3 capsules of olive oil , which has the same color and smell as the krill oil.
76080811|NCT06045793|Drug|TNX-1300 (Injection)|Patients will receive a single IV injection of TNX-1300.
76080812|NCT06045793|Drug|Placebo (Injection)|Patients will receive a single IV injection of placebo with usual care (UC).
76080813|NCT06039579|Drug|VH4004280|VH4004280 will be administered.
76080814|NCT06039579|Drug|VH4011499|VH4011499 will be administered.
76080815|NCT06039579|Drug|VH4004280 Matching Placebo|VH4004280 matching placebo will be administered.
76080816|NCT06039579|Drug|VH4011499 Matching Placebo|VH4011499 matching placebo will be administered.
76080817|NCT06036446|Procedure|Cervical cerclage|Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.
76080818|NCT06036446|Drug|Vaginal Suppository Progesterone|Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
76080819|NCT06031623|Device|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.
76080820|NCT06029049|Drug|Modified Time Principle Induction (MTPI) with rocuronium|Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the discretion of the care team, administered within 10 seconds of rocuronium and the intubation will be performed with a C-MAC
76080821|NCT06029049|Drug|RSI succinylcholine|Participants will be induced as per routine care using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, propofol 1-2 mg/kg IV, and succinylcholine 1mg/kg IV, and the intubation will be performed with a C-MAC
76080822|NCT06028620|Behavioral|Trauma Focused-Cognitive Behavior Therapy|TF-CBT consisted of 8 units in which different issues realted to trauma are reviewed. Units are: psychoeducation and parenting skills, relaxation techniques, affective expression and regulation, cognitive coping and processing, trauma narrative and processing, in vivo exposure, co-joint sessions and enhancing safety and future growth.
75471040|NCT01948115|Drug|equimolar mixture of oxygen and nitrous oxide or medical air|"We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention."
75471041|NCT01948128|Drug|Vitamin D3|Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
75471042|NCT01948128|Other|Placebo|Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
75789266|NCT01351948|Biological|AdCh63 AMA1 + MVA AMA1|5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 112. IM injections
75789267|NCT01099176|Drug|To compare monotherapies and combined therapy with each other|"Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets"
75789268|NCT01317706|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
75925575|NCT03331172|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
75332462|NCT04394702|Other|One Shape Single-file rotary system|rotational single file system used for mechanical debridement of root canals
75640692|NCT02694003|Behavioral|BNBD-NDD Intervention|The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
75640693|NCT02590549|Procedure|Corneal Collagen Crosslinking|"Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes.~After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,"
75925576|NCT05463614|Drug|Propafenone and Propranolol|Propafenone Hydrochloride Tablets, 100-200mg, 1 or 2 times per day; Propranolol Hydrochloride Sustained-Release Capsules, 40mg, 1 times per day
75332463|NCT04394702|Other|manual stainless steel K-file|sequential manual filing with stainless steel K-files
75332464|NCT04559516|Behavioral|Exercise Intervention|"The Ethica mobile app will provide a daily alert accompanied by a short educational statement about PAH, disease self-management tips, dietary and nutritional advice, goal setting, and a motivational statement to encourage patients.~Participation with each session will be assessed by a mobile app-embedded survey administered at the end of the day. Patients will be presented with weekly alerts to complete validated patient-reported quality of life questionnaires using the EmPHasis-10 and the Living with Pulmonary Hypertension Questionnaire, as well as the PRAISE self-efficacy score for pulmonary rehabilitation. The app will also ask patients to report their WHO/NYHA functional class every week. Using in-app buttons, participants can log adverse events associated with each exercise session."
75332465|NCT04559516|Behavioral|Standard Care|Participants will be provided usual care administered at the PH clinic at the University of Calgary and no supervised exercise session will be performed.
75332466|NCT01927328|Drug|Iron isomaltoside 1000|
75640694|NCT02590549|Device|Ufalink|UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation
75332467|NCT04552808|Drug|Yimitasvir Phosphate|Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
75640695|NCT00720499|Drug|BI 1744 CL plus tiotropium bromide|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
75332468|NCT04552808|Drug|Yimitasvir Phosphate|Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
75640696|NCT00720499|Device|Respimat® Inhaler|
75640697|NCT02592187|Behavioral|ReMemory-MCI training|
75789269|NCT01352026|Drug|Metformin|
75789270|NCT03136198|Other|LUS-guided strategy-of-care|"For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.~Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)~Reassessment every 2 hours"
75789271|NCT03136198|Other|Usual Care|Patients will receive usual AHF care
75925577|NCT02491658|Biological|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
75925578|NCT05232968|Other|Long-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
75925579|NCT05232968|Other|Short-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
75925580|NCT03332888|Drug|Rituximab|Rituximab will be studied in patients with HFrEF, and verify the patients safety.
76080823|NCT06023290|Diagnostic Test|Heart rhythm measurements with Preventicus®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
75640698|NCT02592187|Behavioral|Control intervention|
75789272|NCT03136198|Drug|Intravenous Loop Diuretic|IV loop diuretic
75789273|NCT03136198|Drug|Vasodilator|IV, topical, or SL Vasodilator
75789274|NCT03136198|Device|Non invasive Ventilation (NIV)|Face, mouth, or nasal mask applied to provide positive pressure ventilation
75332469|NCT04552808|Drug|Yimitasvir Phosphate|Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
75789275|NCT00042666|Drug|LY317615|500 mg, oral, QD, up to six 28 day cycles
75789276|NCT01357486|Drug|sorafenib|patients receiving sorafenib 400 mg - twice a day
75789277|NCT01357486|Drug|Pravastatin|patients receiving pravastatin 40 mg - once a day
76080824|NCT06023290|Diagnostic Test|Heart rhythm measurements with FibriCheck®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
75789278|NCT01357486|Drug|Sorafenib + Pravastatin|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
75332470|NCT04552808|Drug|Yimitasvir Phosphate|Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
75332471|NCT04557566|Behavioral|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
75332472|NCT05607602|Other|Comparison of blood samples between the two groups|In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation[18]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
75332473|NCT01927406|Drug|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
75332474|NCT01927406|Drug|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
75640699|NCT04087369|Other|Bundled NCD WHO PEN Intervention|In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population. In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.
75789279|NCT01357486|Other|patients receiving best supportive care|palliative management
75332475|NCT05607524|Dietary Supplement|probiotics|Eat a capsule for once, and twice a day
75332476|NCT05607524|Dietary Supplement|placebo|Eat a capsule for once, and twice a day
75332477|NCT01182493|Device|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
75332478|NCT01927484|Drug|25 mg/week oral methotrexate tablets|active oral methotrexate drug
75332479|NCT01927484|Drug|25mg/week oral placebo tablets|placebo comparator oral drug
75332480|NCT01140295|Drug|polyethylene glycol, senna|"Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age >12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.~Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days."
75471043|NCT01948167|Behavioral|Interpersonal Psychotherapy- Adolescent Skills Training|A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
75640700|NCT04086979|Behavioral|Parental Friendship Coaching|In this condition, therapists instructed parents in ways to coach their children to display better friendship behaviors using skills teaching, role play, active practice, and homework. This is a 10 week group intervention.
75789280|NCT01318564|Drug|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
76080825|NCT06023290|Diagnostic Test|Heart rhythm measurements with Apple Watch®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
75789281|NCT01318564|Behavioral|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
75798755|NCT05597800|Drug|Nivolumab and Ipilimumab|"Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles)."
75332481|NCT04551404|Other|transcranial Random Noise Stimulation (tRNS) with acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions, parallel to the application of AS with WN 15 dB above the individual MML in one study arm. TRNS will be applied using two electrodes (35 qcm, 0,9% saline -soaked). Stimulus intensity will be below individual sensation threshold, but max. 2 mA. AS will never surpass 85 dB SPL at the ears.
75471044|NCT01948167|Behavioral|Coping with Stress|A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
75471045|NCT01948180|Biological|baltaleucel-T|Autologous EBV-specific T-cells
75471046|NCT01948219|Device|ENTegral Artificial Larynx implant|
75471047|NCT01948232|Drug|Perindopril|Angiotensin converting enzyme inhibitor
75332482|NCT04551404|Other|transcranial Random Noise Stimulation (tRNS) without acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions
75640701|NCT04086979|Behavioral|Coping with ADHD through Relationships and Education|In this condition, the therapist provided parents with psychoeducation about ADHD and friendship difficulties, and encouraged them to apply this information to their child and to support one another with tips about how to address these problems. This is a 10 week group intervention.
75640702|NCT02592109|Behavioral|Enhanced Counseling using CFR based on Linear Programming|
75640703|NCT04087135|Other|direct laryngoscopy|Participants will intubate the hemoptysis cadaver model in simulation with direct laryngoscopy MacIntosh blade.
75640704|NCT04087135|Other|videolaryngoscopy McGrath|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade)
75640705|NCT04087135|Other|videolaryngoscopy McGrath with suction|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade) and a suction they will advanced directly before the optic of the camera.
75925581|NCT03332810|Behavioral|SME family based physical activity|"One train-the-trainer workshop: to train the service providers from 8-15 NGO service units on the concept of SME, ways of conducting mental well-being activities and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder).~Two SME family-based physical activities held by each NGO service unit: to organize enjoyable activities according to the needs of individual district as well as to promote positive psychology under the theme of SME. All these activities are organized by the NGO service providers in collaboration with District Healthy City Committee."
75640706|NCT00724243|Drug|Infliximab|Infliximab given in accordance with the local summary of product characteristics
75640707|NCT02590705|Drug|Lidocaine|surface anesthesia with lidocaine
75789282|NCT01352104|Behavioral|PEP-TE|"PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses."
75925582|NCT03332810|Behavioral|Gathering activity|- Gathering activities will be held for control groups. However, SME concept or techniques will not be introduced during the activity. Physical activity will not be used as the intervention method.
75640708|NCT04085107|Behavioral|Face-to-face interviews|243 PwMCI will receive two face-to-face interviews to complete two sets of questionnaires, of which 30 participants will be recruited attend a 1-hour semi-structured interview.
75925583|NCT03332732|Drug|VNRX-5133|β-lactamase inhibitor
75640709|NCT00720343|Drug|Choline|Oral Choline 20 grams before surgery
75925584|NCT03332732|Drug|VNRX-5022|Approved β-lactam antibiotic
75925585|NCT03332732|Drug|Metronidazole|Approved antibiotic and antiprotozoal medication
75925586|NCT03332732|Drug|Placebo|Placebo (matching VNRX-5133 + VNRX-5022)
75925587|NCT03324854|Procedure|Rives technique|Open ventral hernia repair followed by the placement of the mesh.
75925588|NCT03324854|Procedure|Drainage|Placement of active-close drainage in surgical site.
75925589|NCT03324854|Drug|Prophylactic|Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
75925590|NCT02492360|Procedure|Blood sample collection|Six tubes of blood will be collected during one blood draw.
75925591|NCT02492360|Behavioral|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
75925592|NCT02492282|Device|Closed-Loop propofol and remifentanil system by Bispectral Index|
75925593|NCT02492282|Device|Open-Loop propofol and remifentanil by Target Controlled Infusion|
75640710|NCT00720343|Drug|Placebo|Gelatin Capsule
75332483|NCT01182805|Device|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
75332484|NCT01182805|Device|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
75471048|NCT01948271|Drug|Trichuris Suis Ova|During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
75471049|NCT01948284|Procedure|half-maximal pressure|the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
75471050|NCT01948284|Procedure|maximal pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
75471051|NCT01948284|Device|Suction Unit|
75925594|NCT02492282|Drug|propofol|
75925595|NCT02492126|Other|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
75925596|NCT03331016|Behavioral|Heart to Heart Training|Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
75471052|NCT01948297|Drug|Debio1347 (CH5183284)|Debio1347 (CH5183284) tablets for oral administration
75640711|NCT00720109|Drug|Asparaginase|Given IT
75640712|NCT00720109|Drug|Cyclophosphamide|Given IV
75640713|NCT00720109|Drug|Cytarabine|Given IT or IV
75640714|NCT00720109|Drug|Dasatinib|Given PO
75640715|NCT00720109|Drug|Daunorubicin Hydrochloride|Given IV
75640716|NCT00720109|Drug|Dexamethasone|Given IV or PO
75925597|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
75789283|NCT00042432|Drug|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
76080826|NCT06023290|Diagnostic Test|Heart rhythm measurements with 6L Kardia Mobile®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
75640717|NCT00720109|Drug|Etoposide|Given IV
76080827|NCT06020937|Diagnostic Test|TDI|Sniffin' Sticks Threshold and Identification Test
76080828|NCT06020937|Diagnostic Test|Trigeminal Test|Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response
75789284|NCT01352338|Drug|Lenalidomide, endoxan, prednisone|dose-finding
75789285|NCT01352338|Drug|lenalidomide, endoxan, prednisone|oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
75925598|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
75925599|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
75925600|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
76080829|NCT06020937|Diagnostic Test|Cognitive Evaluation by Montreal Cognitive Assessment|Montreal Cognitive assessment
76080830|NCT06020937|Diagnostic Test|Anxiety and Depression questionnaire|Specific test to evaluate patient's mood
76080831|NCT06020937|Diagnostic Test|Visual Analogue Scale Ratings|"Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)"
76080832|NCT06020937|Diagnostic Test|Quality of smell Questionnaire|Patients will answer to a validated questionnaire
76080833|NCT06018493|Device|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
76080834|NCT06018493|Device|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
76080835|NCT06013995|Drug|BMS-986326|Specified dose on specified days
76080836|NCT06013995|Other|Placebo for BMS-986326|Specified dose on specified days
76080837|NCT06003543|Behavioral|Virtual Reality|Virtual Reality
75332485|NCT01182805|Device|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
75332486|NCT04552730|Drug|Cenegermin-Bkbj|Topical Cenegermin-bkbj 6 times per day for 8 weeks.
75332487|NCT01184755|Behavioral|Relaxation|Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
75640718|NCT00720109|Biological|Filgrastim|Given IV or SC
75798756|NCT01176552|Drug|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
75798757|NCT05597644|Procedure|Trans-arterial uterine artery embolization|transarterial angioembolization of uterine artery
75925601|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
75925602|NCT03324776|Drug|Afrezza Inhalant Product|Mealtime Ultra-Rapid Acting Insulin
75925603|NCT03332654|Other|Determine prevalence of stress urinary incontinence|
75925604|NCT02561806|Drug|Ixekizumab|Administered SC
75925605|NCT02561806|Drug|Ustekinumab|Administered SC
75925606|NCT02561806|Drug|Placebo|Administered SC
76080838|NCT06002191|Behavioral|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
76080839|NCT06002191|Behavioral|Questionnaires of Online Experiences|Adolescents will receive brief questionnaires related to their online experiences and the impact those experiences have had on their stress level.
76080840|NCT06001853|Drug|BM-MSC injection|BM-MSCs at the dose 10 x 106 in 1 ml per facet joint for a total of 2 joints
76080841|NCT06001853|Drug|DSMO Injection|After 12 months, patients randomized to Arm B: DMSO will be unblinded and re-assigned to Arm A: treatment then be followed for 12 months.
75332488|NCT01184755|Device|RESPeRate|
75640719|NCT00720109|Drug|Hydrocortisone Sodium Succinate|Given IT
75640720|NCT00720109|Drug|Ifosfamide|Given IV
75640721|NCT00720109|Other|Laboratory Biomarker Analysis|Correlative studies
75640722|NCT00720109|Drug|Leucovorin Calcium|Given IV or PO
75640723|NCT00720109|Drug|Mercaptopurine|Given PO
75640724|NCT00720109|Drug|Methotrexate|Given IT, PO, or IV
75640725|NCT00720109|Drug|Methylprednisolone|Given IV
75640726|NCT00720109|Drug|Pegaspargase|Given IM
75640727|NCT00720109|Drug|Prednisone|Given PO or IV
75640728|NCT00720109|Radiation|Radiation Therapy|Some patients undergo cranial RT
75640729|NCT00720109|Drug|Vincristine Sulfate|Given IV
75789286|NCT01599520|Behavioral|Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)|"Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled Cómo tratar el estrés durante la quimioterapia. Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques."
75789287|NCT01599520|Behavioral|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
75789288|NCT00003474|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75789289|NCT01099332|Other|Gastro-retentive zinc cysteine tablet|Oral, one tablet, once daily with water for 6 months.
75789290|NCT01099332|Other|Tablet identical physically to active comparator containing some lactose|Oral, once daily, with water, 6 months.
75789291|NCT01354834|Drug|hMG|Patients with a condition
75789292|NCT01099410|Procedure|Fiberoptic bronchoscopy|"which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours."
75925607|NCT03324620|Other|Specific program functional and respiratory rehabilitation|It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
75789293|NCT01099410|Procedure|blood draw|Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
75789294|NCT01099410|Procedure|intravenous catheter|An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
75789295|NCT01099488|Procedure|Blood withdrawal|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
75789296|NCT01542736|Drug|Carboplatin|Administered concurrently with craniospinal radiation.
75640730|NCT02590627|Drug|Artemether-lumefantrine|Artemether-lumefantrine
75789297|NCT01542736|Drug|Vincristine|Administered concurrently with craniospinal radiation.
75789298|NCT01542736|Radiation|24 Gy|Craniospinal radiation.
75640731|NCT02590627|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
75640732|NCT01015118|Drug|Placebo|comparator to BIBF 1120
75640733|NCT01015118|Drug|Paclitaxel|Paclitaxel (standard chemo-therapy)
75789299|NCT01099566|Drug|Prasugrel|Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
75789300|NCT01099566|Drug|Placebo|A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
75789301|NCT05105230|Diagnostic Test|soluble programmed death 1biomarker|soluble programmed death 1biomarker
75640734|NCT01015118|Drug|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
75925608|NCT03332576|Biological|DPX-Survivac|SubQ injection
75925609|NCT03332576|Biological|DPX-Survivac(Aqueous)|SubQ injection
75925610|NCT03332576|Drug|Cyclophosphamide|PO BID
75925611|NCT03330938|Behavioral|CBI and Resilience|A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).
75640735|NCT01015118|Drug|Carboplatin|Carboplatin (standard chemo-therapy)
75640736|NCT01015118|Drug|Paclitaxel|Paclitaxel (standard chemo-therapy)
75640737|NCT01015118|Drug|Carboplatin|Carboplatin (standard chemo-therapy)
75640738|NCT00800176|Drug|Placebo|po daily for 12 weeks
75640739|NCT00800176|Drug|RO4998452|2.5mg po daily for 12 weeks
75640740|NCT00800176|Drug|RO4998452|5mg po daily for 12 weeks
75640741|NCT00800176|Drug|RO4998452|10mg po daily for 12 weeks
75640742|NCT00800176|Drug|RO4998452|20mg po daily for 12 weeks
75640743|NCT00800176|Drug|RO4998452|40mg po daily for 12 weeks
75640744|NCT04086355|Other|oromotor exercises and neuromuscular electrical stimulations|treatment study group with occupational exercises and electrical stimulation
75640745|NCT04086667|Other|Spinal manipulation|Spinal manipulation: The patient is placed in the side-position and a standard manipulation lumbar-roll technique will be applied at the indicated segment dependent on the subgroup indication.
75640746|NCT04086901|Radiation|Radiotherapy dose escalation|Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG-PET) scans will be used to identify and delineate the tumour sub-volumes with the highest tracer uptake to guide the dose-escalation. The dose to the Gross tumor volume (GTV) will be escalated to a high dose while clinical target volume (CTV) and planning target volume (PTV) will be treated with standard dose.
75640747|NCT03943381|Device|Duplex US|Duplex US (Caliper, wave forms...)in evaluation of Pelvic Veins (namely left ovarian vein). in pelvic congestion syndrome
75640748|NCT02502903|Drug|BIV009|
75640749|NCT02502903|Other|Placebo|
75640750|NCT04112446|Drug|Saroglitazar magnesium|On Day 1, subjects will receive a single oral dose of [14C]-saroglitazar magnesium
75640751|NCT02415153|Other|Laboratory Biomarker Analysis|Optional correlative studies
75640752|NCT02415153|Other|Pharmacological Study|Correlative studies
75640753|NCT02415153|Drug|Pomalidomide|Given PO
75640754|NCT04111744|Other|Preoperative Exercise Training|Patients undergoing CABG and randomized to the Training Group complete six sessions of aerobic endurance training prior CABG surgery
75640755|NCT04111744|Other|Optimal medical therapy|Standard medication for stable CAD
75640756|NCT02337621|Other|No intervention|
75640757|NCT00628160|Drug|Terlipressin|Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.
75640758|NCT00628160|Drug|alpha adrenergic drugs|Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
75640759|NCT02590471|Procedure|Angioplasty with stenting of the femoral artery|"A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
75640760|NCT02590471|Procedure|Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel|"Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
75640761|NCT04298996|Diagnostic Test|taking saliva samples to determine oxidative stress markers TAS and TOS|
75640762|NCT02274285|Biological|DTaP-IPV/Hib Combined vaccine|0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart
75640763|NCT02274285|Biological|DTaP-IPV vaccine and Hib vaccine|0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart
75789302|NCT01099722|Drug|Flutiform|inhaler 2 puffs bd daily
75789303|NCT01099722|Drug|Symbicort Turbohaler|2 puffs bd daily
75789304|NCT01346410|Radiation|Stereotactic Body Radiotherapy|Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)
75925612|NCT03330938|Behavioral|Cognitive-behavioral Intervention|Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
75925613|NCT03330860|Other|Twelve clips regarding maternal and neonatal health topics|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
75640764|NCT02274285|Biological|DTaP-IPV/Hib Combined vaccine|0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
75640765|NCT00614835|Drug|Docetaxel plus Gemcitabine|Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
75640766|NCT00715429|Drug|vitamin d|After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
75640767|NCT00715429|Drug|placebo|After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
75640768|NCT02606032|Drug|Metronidazole|active comparator
75640769|NCT02606032|Drug|Doxycycline|active comparator
75640770|NCT02606032|Drug|Terbinafine|active comparator
75640771|NCT02606032|Drug|Placebo|identical placebos to all antibiotics
75640772|NCT02145507|Drug|SOLX (Investigational)|SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
75640773|NCT02145507|Drug|AS-3 (Control)|AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
75640774|NCT02043405|Behavioral|Weight loss and exercise training intervention|Combined weight loss and exercise training intervention
75640775|NCT02043405|Behavioral|Weight loss Only Intervention|Weight loss Only Intervention
75640776|NCT02590159|Device|BONGO NASAL EPAP|The BONGO NASAL EPAP device consists of two nasal inserts (a connected pair), each containing an actuated valve, with a patient attachment mechanism. The device works by providing an inhalation port that offers minimal inhale resistance during inhalation, but is closed by the actuated valve so that exhalation occurs against a fixed orifice. This mechanism provides increased EPAP upon exhalation.
75789305|NCT03953586|Diagnostic Test|Bubble suction test and tubal peristalsis|Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)
75798758|NCT01287702|Dietary Supplement|Delayed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
75640777|NCT02590237|Device|Ambu KingVision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
75789306|NCT01361542|Drug|anti TNF alpha agent|Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study Etanercept at 50mg weekly for the duration of the study
75789307|NCT01361542|Drug|Anti TNF alpha therapy|Infliximab 3-5 mg/kg as per recommended protocol or Etanercept 50mg/week for 1 year
75640778|NCT02590237|Device|Miller Direct Laryngoscopy|At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
75640779|NCT01743651|Drug|arbaclofen|40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day
75640780|NCT01743651|Drug|baclofen|80 mg/day as 20 mg baclofen administered orally 4 times per day
75640781|NCT01743651|Drug|Placebo|arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
75640782|NCT00715117|Drug|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
75640783|NCT00715117|Other|Placebo, sugar pill|Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
75640784|NCT04086277|Procedure|Continuous Intrapartum Support|Received the usual obstetric care plus continuous intrapartum support that was provided by a Bachelor of Nursing and Obstetrics who received prior training by a professional doula.
75640785|NCT00855855|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
75640786|NCT00723229|Drug|acyclovir|Acyclovir 400 mg PO BID for 28 days
75640787|NCT02590081|Drug|Dextrose 5%|
75789308|NCT00003456|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75789309|NCT03950778|Drug|Human albumin|Patients are divided into 2 groups by envelope randomization. In the treated group, albumin supplementation occurs up to a target of 30 g / l at the end of the test period at a maximum dose of 3 x 100 ml, and no albumin is added above the control value of 20 g / l. Patients with albumin below 20 g / l in the control group are excluded from the study and albumin supplemented. Blood samples are taken directly at the intensive care class, and at the same time on the following days. Urine was collected for 24 hours. The kinetics of the parameters are examined for five days.
75789310|NCT03953664|Other|Experimental-Exercise training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.
75789311|NCT03950700|Drug|Bupivacaine-epinephrine|BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S
75640788|NCT02590081|Drug|normal saline|
75640789|NCT01093521|Drug|100 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
75789312|NCT03950700|Drug|Saline Solution|Saline solution 0.9% (Baxter laboratories).
75925614|NCT03330860|Other|Control Clip|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
75925615|NCT03324542|Drug|Aflibercept [Eylea]|Anti-vascular endothelial growth factor (VEGF)
75332489|NCT04275440|Behavioral|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
75640790|NCT01093521|Drug|200 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
75640791|NCT04084639|Dietary Supplement|Mycoprotein Ingestion|Ingestion of various doses of mycoprotein compared to placebo control
75640792|NCT01030718|Drug|dasatinib|Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
75789313|NCT02719522|Device|Pipeline™ Flex Embolization Device with Shield Technology™|"Pipeline™ Flex Embolization Device with Shield Technology™ utilizes a phosphorylcholine (PC) surface treatment to the implant combined with the PFED delivery system. The Shield Technology™ surface treatment applied to the implant is an inert polymer material created to mimic the outer membrane of a human red blood cell.~The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular embolization of cerebral aneurysms and is designed to be placed across the opening (or 'neck') of a brain aneurysm and redirect blood flow away from the aneurysm, causing the blood within the aneurysm to clot."
75798759|NCT01287702|Dietary Supplement|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
75925616|NCT03324386|Behavioral|Experimental: Individual Orientation|This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.
75332490|NCT04275440|Behavioral|Caloric restriction|"In the first two weeks, participants would reduce their daily energy intake to 100% -110% of his or her basal metabolic energy under instruction, and stick to it till the end of the intervention.~According to the dietary recommendation proposed by Chinese government, participants are required to take in cereals, vegetables, fruits, meat and eggs, while minimize the consumption of sugar-sweeten beverages.~Participants are instructed to arrange their three meals according to the recommended energy distribution (3:4:3)."
75332491|NCT04275050|Drug|TQB3303|TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
75332492|NCT05607446|Drug|TQC3564 tablets|TQC3564 tablets are CRTH2 antagonists.
75789314|NCT00237185|Drug|Imatinib mesylate|Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
75789315|NCT01357798|Drug|Botulinum toxin type A|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
76080842|NCT05999812|Drug|all trans Retinoic Acid|ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days
75332493|NCT05607446|Drug|Placebo tablets|The intervention drug is placebo.
75640793|NCT00722761|Drug|drospirenone and ethinyl estradiol|Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
75789316|NCT01357798|Drug|0,9% saline|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
75789317|NCT00003222|Biological|aldesleukin|Systemic subcutaneous delivery of low-dose IL-2.
75789318|NCT00003222|Biological|gp100 antigen|
75789319|NCT00003222|Biological|incomplete Freund's adjuvant|
75789320|NCT00003222|Biological|sargramostim|
75789321|NCT00003222|Biological|tetanus peptide melanoma vaccine|
75640794|NCT00722761|Drug|Placebo tablet|Placebo tablet (no active drug) given once daily for 24 weeks
75789322|NCT00003222|Biological|tyrosinase peptide|
75789323|NCT01361698|Behavioral|Illness Management and Recovery (IMR)|In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
75789324|NCT01357876|Other|Metformin|withdrawral
75925617|NCT03324386|Behavioral|Experimental: VLE for Distance Learning|Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
75925618|NCT03324386|Behavioral|Experimental: E-blended Lerarning|This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
75332494|NCT05607446|Drug|TQC3564 tablets, montelukast sodium tablets|The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
75332495|NCT05607446|Drug|Placebo tablets, montelukast sodium tablets|The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.
75332496|NCT01141075|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
75332497|NCT01927952|Procedure|Kirschner wire|Surgical fixation utiliziing Kirschner wire
75640795|NCT02692053|Biological|blood sampling|additional blood sampling (volume: 18 mL)
75640796|NCT00331227|Drug|Isotonix OPC-3 (flavonoid supplement)|
75640797|NCT00628238|Drug|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
75640798|NCT00628238|Drug|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
75640799|NCT00719953|Dietary Supplement|Cognitex|Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks
75789325|NCT03973307|Diagnostic Test|UroX bladder cancer biomarker test|Urine test using novel UroX biomarker test for bladder malignancy
75789326|NCT05626062|Device|Toilet alarm|A Malem toilet alarm (wristworn, discretely in underwear, or bed mat) will be used to promote prompred voiding in a toilet
75925619|NCT03324386|Other|Conventional Therapy - Control Group|This approach may be individual orientation with conventional therapy may be making 2 nursing visits at baseline and 1 after 120 days,
76080843|NCT05999812|Drug|Atezolizumab|Atezolizumab IV D1, 840 mg every 14 days
76080844|NCT05999812|Drug|Bevacizumab|Bevacizumab IV D1, 10 mg/kg every 14 days
76080845|NCT05999396|Drug|Administration of CC-3|Accelerated titration phase, Standard 3+3 titration phase, expansion phase
75332498|NCT01927952|Procedure|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
75332499|NCT01927952|Procedure|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
75789327|NCT01581983|Behavioral|Internet Mindfulness Meditation|one hour session each week for six weeks
75925620|NCT02561572|Other|Acupuncture|Yintang point acupuncture
75925621|NCT03330782|Drug|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
75925622|NCT03330782|Drug|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
76080846|NCT05998837|Drug|Dapagliflozin 10mg Tab|"Dapagliflozin will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
75332500|NCT02185105|Device|comfilcon A MTO|Randomized to a test lens in one eye and control lens in the other as a matched pair.
75640800|NCT03207087|Device|WEB Aneurysm Embolization|Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
75332501|NCT02185105|Device|comfilcon A|Randomized to a test lens in one eye and control lens in the other as a matched pair.
75925623|NCT03332342|Other|Eye wash|Research subjects will perform a wash of their ocular surface with phosphate buffered saline
75332502|NCT01928264|Behavioral|Physical activity|
75471053|NCT01948323|Behavioral|HEDUAfrica IT package+ standard care|"The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
75640801|NCT05132179|Drug|Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution|Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
75789328|NCT01581983|Behavioral|Individual Mindfulness Meditation|one hour session each week for six weeks
75332503|NCT05606900|Behavioral|addiction-focused eye movements desensitization and reprocessing (AF-EMDR)|AF-EMDR includes desensitization and functional reprocessing of the targeted memory or the moment with lateral eye movements. In each session of the psychotherapy, which will be applied as 3 sessions, a memory or a moment that causes alcohol craving will be practised. The processing will continue until the patient becomes desensitized to the memory or the moment that cause the craving. In the first session, a memory of craving will be discussed, in the second session a current trigger that causes craving, and in the third session, a moment that is thought to cause craving in the future will be focused.
75471054|NCT01948336|Drug|Dexmedetomidine|a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
75471055|NCT01948336|Drug|Ketamine|ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.
75789329|NCT02877082|Biological|Thymoglobulin|Given IV
75789330|NCT02877082|Drug|Bortezomib|Given IV
75789331|NCT02877082|Drug|Tacrolimus|Given IV and PO
75789332|NCT03951558|Other|Diet for calciuria prevention|Dietary recommendations for water, salt, calcium and proteins according to age and DIR
75789333|NCT03951558|Drug|Hydrochlorothiazide|Hydroclorothiazide recommendations for hypercalciuria
75332504|NCT02185183|Drug|Alequel|Alequel
75471056|NCT01948336|Drug|Propofol|propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
75471057|NCT01948349|Other|Tongue scraping|Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
75471058|NCT01948349|Other|Bracket design|Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
75471059|NCT01948362|Drug|Sulforadex|Active compound
75789334|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
75789335|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
75925624|NCT02492048|Device|Cellutome Epidermal Harvesting System|Cellutome Epidermal Harvesting System
75925625|NCT02492048|Procedure|Split Thickness Skin Graft|Split Thickness Skin Graft
75640802|NCT02871830|Behavioral|Physical Activity|15 mins physical activity per day within the school setting.
75789336|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal
75332505|NCT05606822|Other|Observational|Collection of data from electronic health record
75789337|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
75789338|NCT01361776|Biological|FSME-immune|0.5 ml im as scheduled in the 4 arms
75789339|NCT04847128|Behavioral|Chronic aerobic exercise|Participants in the experimental group will exercise more than 30 minutes each time and 3 times weekly for 8 weeks. The chronic aerobic exercise in the present trial is running. The heart rate is required to 60% -85% of the maximum heart rate during exercise. Maximum heart rate = 220 - age.
75789340|NCT01361932|Other|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
75789341|NCT01362010|Drug|Topical Minocycline Foam FXFM244|Topically applied once a day.
75789342|NCT02875834|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
75332506|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.
75789343|NCT02875834|Drug|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
75789344|NCT02875834|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
75789345|NCT02875834|Drug|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
75925626|NCT05506540|Drug|ENN0403 1mg|ENN0403 capsules for oral use
75925627|NCT05506540|Drug|ENN0403 4mg|ENN0403 capsules for oral use
75925628|NCT05506540|Drug|ENN0403 10mg|ENN0403 capsules for oral use
75925629|NCT05506540|Drug|ENN0403 20mg|ENN0403 capsules for oral use
75925630|NCT05506540|Drug|ENN0403 30mg|ENN0403 capsules for oral use
75925631|NCT05506540|Drug|ENN0403 20mg (Fed)|ENN0403 capsules for oral use
76080847|NCT05998837|Drug|Placebo|"Placebo will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
76080848|NCT05992571|Other|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 90 minutes of rest.
76080849|NCT05992571|Dietary Supplement|β-OHB|Ingestion of a high dose [R]-3-hydroxybutyl [R]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 90 minutes of rest.
76080850|NCT05989100|Behavioral|Favourate taste stimulation|The taste stimulaiton for swallowing is completed with long swab. Taste solution will be prepared with sugar, salt, citric acid, or paprika mixed with water. And the swab will be immersed in the solution and freezed in -18℃ circumstances. Bilateral buccal mucosa，palate and tounge will be brushed. Four swabs will be used in a training session.
75471060|NCT01948362|Drug|Alpha cyclodextrin|Placebo control
76080851|NCT05989100|Behavioral|Sour taste stimulation|Using sour swab to brush oral cavity and tounge.
76080852|NCT05989100|Behavioral|Thermal stimulation group|Only ice-water swab to brush oral cavity and tounge.
76080853|NCT05985395|Behavioral|HEART Camp Connect|Once eligible and enrolled, participants will complete 150 minutes of moderate-intensity exercise a week with help of a virtual exercise coach.
75789346|NCT01099878|Device|Cycling Exercise with Functional Electrical Stimulation|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
75789347|NCT01099878|Device|cycling exercise|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
75332507|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.
75471061|NCT01948401|Drug|LABA|long-acting beta-agonist treatment
75789348|NCT02875366|Drug|LUM/IVA|
75789349|NCT02875366|Drug|Placebo|
75925632|NCT05506540|Drug|ENN0403 6mg QD X 14 Days|ENN0403 capsules for oral use
75925633|NCT05506540|Drug|ENN0403 12mg QD X 14 Days|ENN0403 capsules for oral use
75925634|NCT05506540|Drug|ENN0403 20mg QD X 14 Days|ENN0403 capsules for oral use
75471062|NCT01948401|Drug|corticosteroids|chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
75925635|NCT05506540|Drug|Placebo|Placebo capsules for oral use
75925636|NCT03332186|Drug|BMS-986231|Intravenous infusion administration
75925637|NCT05506462|Drug|Ketamine Hydrochloride|Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride
75471063|NCT01948401|Drug|prednisolone|additional 0.5 mg/kg orally for 7 days
75471064|NCT01948414|Procedure|electroencephalography|
75925638|NCT03330704|Drug|3% Sodium Chloride|3% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
75925639|NCT03330704|Drug|23.4% Sodium Chloride|23.4% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
75925640|NCT03330704|Drug|8.4% Sodium Bicarbonate|8.4% sodium bicarbonate will be infused into patients for the treatment or prevention of raised intracranial pressure
75925641|NCT05506306|Other|Assessment|Clinical, biological and imagery before and after 6 weeks of using AtalanteTM exoskeleton
75925642|NCT03330626|Device|InBody group|As one of representative BIVA, it provides the patients' fluid status with more objective data such as TBW, ECW, ICW, etc.
75925643|NCT03330626|Other|IO group|Fluid removal are guided by intake-output balance.
75640803|NCT02591641|Device|Anti-shear mattress overlay|A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.
75925644|NCT03330548|Behavioral|TeleMOVE!|Active comparator- telehealth treatment program for weight management and health promotion
75925645|NCT03330548|Behavioral|Culinary Rx|Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
75925646|NCT05501938|Procedure|Physical Exam Indicated Cerclage|Transvaginal cervical cerclage
76080854|NCT05982665|Other|Molecular hydrogen|Hydrogen gas, purity >99.9%, flow rate 300 ml/min.
76080855|NCT05982665|Other|Placebo|Ambient air, flow rate 300 ml/min.
76080856|NCT05977530|Behavioral|self-rescue training|children will receive training for self-rescue if they are alone in water
75332508|NCT05606744|Device|Eccentric exercise / Eccentric exercise with blood flow restriction|Individuals will be randomized to receive eccentric exercise only, or eccentric exercise with blood flow restriction.
75332509|NCT05606666|Other|reliability of the NPQ|The aim of this study is to study the validity and reliability of the Modified Pain Neurophysiology Questionnaire in patients with neck pain.
75332510|NCT02980159|Other|Triage liaison physician|A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
75471065|NCT01948414|Biological|Blood sampling|
75471066|NCT01948414|Behavioral|Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)|
75640804|NCT02591641|Other|Standard of Care|Standard ambulance stretcher mattress
75640805|NCT04084873|Behavioral|PBrE|PbRE is a word reading task implementing through an App developed for smartphones. The patient will choose emotional positive and negative words related to personal and clinical characteristics.
75640806|NCT04084873|Behavioral|PBrE-Control|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
75640807|NCT04084873|Behavioral|Control|Participants do not receive the intervention.
75925647|NCT03330470|Behavioral|exercise|participants will be subjected to 3 months supervised exercise intervention
75789350|NCT01362400|Drug|IPI 504 plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 & 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
75332511|NCT01186705|Drug|MK-2206|Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.
75332512|NCT01928342|Drug|Coenzyme A|Coenzyme A 400mg per day
75332513|NCT01928342|Drug|Placebo|Capsule without coenzyme A.
75332514|NCT01928498|Device|Paclitaxel Eluting Balloon Angioplasty|
75640808|NCT01019486|Drug|Regadenoson myocardial perfusion imaging|Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
75925648|NCT03330470|Dietary Supplement|carnosine supplementation|participants will be instructed to take carnosine 2 times daily
75925649|NCT03330470|Behavioral|stretching|participants will be subjected to 3 months supervised stretching program
75640809|NCT01019486|Drug|Regadenoson MRI myocardial blood flow|CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
75925650|NCT03330470|Dietary Supplement|supplementation with placebo|participants will be instructed to take placebo 2 times daily
75925651|NCT03332108|Other|EpxBreastfeeding|"We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past [x] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories."
75332515|NCT01928498|Device|Percutaneous Transluminal Angioplasty (PTA)|
75640810|NCT02891265|Behavioral|Smoking cessation patch|To compare the smoking cessation outcome in patients with fractures with or without the help of smoking cessation patches.
75789351|NCT01362400|Drug|Placebo plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 & 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
75789352|NCT00002850|Drug|ciprofloxacin|Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
75925652|NCT03332108|Other|Baby book survey|"We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe"
75925653|NCT03324152|Other|High-intensity interval training (HIIT) - myositis|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
75925654|NCT03324152|Other|Standard low-intensity home exercise|12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
76080857|NCT05972265|Behavioral|Moderate Intensity Exercise (one day)|Participants will engage in 40 minutes of cycling at 70-75% maximum heart rate (MHR).
75332516|NCT04558502|Drug|Minocycline hydrochloride capsule|Antibiotic for H. pylori eradication
75332517|NCT04558502|Drug|Clarithromycin|Antibiotic for H. pylori eradication
75332518|NCT04558502|Drug|Amoxicillin|Antibiotic for H. pylori eradication
75640811|NCT02803203|Drug|osimertinib|
75640812|NCT02803203|Drug|Bevacizumab|
75640813|NCT00714493|Biological|Infliximab|3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
75640814|NCT02873624|Procedure|Laparoscopic cholecystectomy|
75640815|NCT03277131|Device|DURAFIBER Ag|DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing
75798760|NCT01287702|Dietary Supplement|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
75332519|NCT04558502|Drug|colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
75332520|NCT04558502|Drug|esomeprazole|Proton pump inhibitor
75332521|NCT01218997|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
75332522|NCT01218997|Drug|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
75332523|NCT01928654|Device|Micropulse laser treatment|Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
75332524|NCT01928654|Device|Laser modified ETDRS|Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
75332525|NCT01219777|Drug|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
75332526|NCT01219777|Drug|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
75332527|NCT01219777|Drug|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 & 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
75640816|NCT01019252|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
76080858|NCT05972265|Behavioral|Placebo - Light Intensity Exercise (one day)|Control participants will engage in 40 minutes cycling at 40-50% maximum heart rate (MHR).
76080859|NCT05972265|Behavioral|Moderate Intensity Exercise (9 wks)|Participants will be asked to engage in moderate-intensity activity four days each week, 40 minutes each time, and will wear an activity monitoring device to assess their fidelity to the intervention.
76080860|NCT05972265|Other|Day 1 Assessments|Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), Life Events Checklist (LEC-5), and neuropsychological testing: approximately 1.50 hours
75332528|NCT05603156|Drug|the usage of Olverembatinib combined with Inotuzumab Ozogamicin|patients in this arm will accept a 28 days treatment regimen: Olverembatinib 40mg QOD (d1 to d28 )and Inotuzumab Ozogamicin 1.2mg/m2 (divided into 2 days, d1 and d8, 0.6mg/m2, respectively).
75640817|NCT04216407|Procedure|Remote ischemic preconditioning|An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.
75640818|NCT01013870|Drug|Atorvastatin|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
75640819|NCT01013870|Drug|Placebo|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
75640820|NCT01013792|Device|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs)
75640821|NCT01013792|Device|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
75640822|NCT05020184|Drug|Cimetidine|Oral Cimetidine 800mg twice daily.
75640823|NCT05020184|Drug|Placebo|Placebo twice daily
75789353|NCT00002850|Drug|ofloxacin|Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
75925655|NCT03324152|Other|High-intensity interval training (HIIT) - healthy|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
75640824|NCT00628316|Dietary Supplement|caffeine|caffeine daily intake will be reduced form 150 ml per day
75640825|NCT01018862|Drug|Azelastine hydrochloride nasal spray 0.15%|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
75640826|NCT01018862|Drug|Azelastine hydrochloride nasal spray 0.10%|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
75640827|NCT01018862|Drug|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
75789354|NCT00002850|Drug|160 mg trimethoprim and 800 mg sulfamethoxazole|Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet [TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole] every 12 hours for two months..
75789355|NCT01362556|Drug|Sodium bicarbonate|"Administration of a calculated amount of sodium bicarbonate 8% [SB] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].~Formula: SB [ml] = -BE * kg * 0.1"
75925656|NCT03331952|Other|Prospective study|To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
75925657|NCT03331952|Other|Prospective study|To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015
75925658|NCT03331952|Other|Cross-sectional surveys|Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
75925659|NCT05506228|Other|No intervention|
75925660|NCT03330392|Dietary Supplement|AGP|take two tablets per day (500 mg/day) for 8 weeks
75925661|NCT03330392|Dietary Supplement|Placebo|take two tablets per day (500 mg/day) for 8 weeks
75925662|NCT04820218|Device|With Try-on glasses|Subjects will be asked to measure their visual acuity with their try-on glasses
75789356|NCT01362556|Drug|Sodium Chloride|"Administration of a calculated amount of sodium chloride 0.9% [SC] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].~Formula: SC [ml] = -BE * kg * 0.1"
75925663|NCT02491346|Procedure|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
76080861|NCT05972265|Other|Symptom Measures and Neuropsychological Tests|Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), and neuropsychological testing: approximately 1.25 hours
75471067|NCT01948440|Behavioral|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
75640828|NCT01018394|Drug|nicotine lozenges|4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.
75640829|NCT01018394|Drug|tobacco-free snuff|Tobacco-free snuff used ad lib for a maximum of 12 weeks
75925664|NCT02491346|Procedure|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
75925665|NCT05506072|Other|Blood flow restriction therapy|Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
75925666|NCT05506072|Other|Standard Physical Thearapy|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
75640830|NCT04299698|Behavioral|lifestyle|Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.
75925667|NCT03330314|Biological|HM12460A|HM12460A is a long-acting insulin
75640831|NCT04567394|Behavioral|Peer Network Counseling-txt|4-week text counseling program
75640832|NCT04301336|Drug|Omega 3|Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months
75640833|NCT04301336|Drug|Vit D|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
75640834|NCT04301336|Drug|Zinc sulfate|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
76080862|NCT05972265|Other|Day 36 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
75640835|NCT04301336|Drug|Statins (Cardiovascular Agents)|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
75640836|NCT04301336|Drug|Hydroxy Urea|50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
75640837|NCT04301336|Drug|Folic Acid Supplementation|Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
75640838|NCT04301336|Drug|Morphine Sulfate|Morphine medication as a pain killer is administered, if Patient weight <50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
75640839|NCT04301336|Procedure|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
76080863|NCT05972265|Other|Day 57 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
76080864|NCT05972265|Other|Day 78 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
75332529|NCT05603078|Radiation|Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5)|Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.
75332530|NCT04759742|Drug|ropivacaine|According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).
75471068|NCT01948453|Dietary Supplement|Garlic|Garlic tablet in adjunct to medical treatment
76080865|NCT05970406|Other|high intensity dysphagia therapy|Intensive swallowing interventions with Speech Language Pathologists to begin within 24 hours of video swallow study results. Daily treatment will include two 30-minute sessions, 5-6 days a week which will include the evidence-based dysphagia exercises focusing on tongue resistance, head lift/chin tuck against resistance and expiratory muscle strength training tasks
75471069|NCT01948466|Behavioral|Commercials|These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
75640840|NCT02873546|Device|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
75640841|NCT00627848|Drug|rivastigmine|Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
75640842|NCT04298060|Drug|DAS181|SD (4.5mg/day), HD (9mg/day)
75640843|NCT04298060|Drug|Placebo|Placebo 0mg/day
75640844|NCT04299854|Drug|Dinoprostone 10mg|Vaginal delivery system containing 10mg of dinoprostone placed at the bottom of the vagina
75640845|NCT04299854|Device|single balloon Foley catheter|A single balloon Foley catheter is being inserted on transcervical and inflated above the internal cervical os
76080866|NCT05970224|Drug|Ir-CPI|Participants receive a single intravenous dose of Ir-CPI during 48 hours
76080867|NCT05968170|Device|CliniMACS® device|CliniMACS TCR αβ+/CD19+ cell depletion for related or unrelated haploidentical/mismatched/matched hematopoietic stem cell transplant patients and/or high risk GVHD patients.
75640846|NCT02872220|Drug|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
75640847|NCT02872220|Drug|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
75640848|NCT02872220|Drug|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
75640849|NCT02872220|Drug|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride [NaCl]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
75640850|NCT01017146|Drug|Tazarotene foam|Tazarotene foam once a day application to the face
75640851|NCT01017146|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
75640852|NCT02872064|Drug|Verteporfin|Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
76080868|NCT05961215|Device|Penguin Cold Cap|Penguin cold cap: administered 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
76080869|NCT05954741|Other|Motor rehabilitation alone|Participants will undergo motor training consisting of a walking session (20 minutes), balance exercises, postural control exercises, proprioceptive exercises, joint mobilization exercises, and muscle strengthening exercises for a total of 25 minutes. A muscle relaxation session will follow (45 minutes).
76080870|NCT05954741|Other|Motor rehabilitation and Cognitive rehabilitation (paper-based)|Group 2 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a standard cognitive intervention, with the execution of cognitive exercises in the domains of attention, memory, executive function, visuo-spatial abilities, space-time orientation, by paper-pencil support (45 minutes per day).
76080871|NCT05954741|Other|Motor rehabilitation and cognitive rehabilitation (digital-based)|Group 3 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a digital cognitive intervention, with the execution of cognitive exercises on attention, memory, executive functions, visual-spatial ability, space-time orientation, employing device support (tablet) with interactive exercises presented by specific software (VRRS Home tablet Khymeia Srl) (45 minutes).
75471070|NCT01948479|Device|Optimised instant offloading insole|
75640853|NCT02871908|Drug|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 twice daily 2 x 10^8
75640854|NCT02871908|Drug|Placebo|Placebo
75640855|NCT02871596|Other|Placebo|A combination of maltodextrins and red and blue food colors.
75640856|NCT02871596|Dietary Supplement|Flavonoids|A combination of blueberry extract, black current extract, and black rice extract.
75640857|NCT02871596|Dietary Supplement|Flavonoids+Prebiotics|A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
75640858|NCT01010750|Drug|Lisdexamfetamine Dimesylate (LDX)|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
75640859|NCT01010750|Drug|Immediate Release Mixed Amphetamine Salts (MAS-IR)|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
75640860|NCT01010750|Drug|LDX Placebo + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
75471071|NCT01948492|Dietary Supplement|Protein intake|On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
75471072|NCT01948531|Drug|Gynomunal® gel|A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
75640861|NCT01012622|Drug|Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride|OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
75640862|NCT00722371|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
76080872|NCT05941416|Diagnostic Test|Nordic Orofacial test- screening arabic modified version|Nordic Orofacial Test- screening is an instrument that can be used for the identification of orofacial myofunctional disorders in children aged three years or older, in youths and in adults. It is divided into two sections, interview and examination. The screening can be directed by dental or health care professional personnel.
76080873|NCT05934994|Other|Bone scan|the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
75471073|NCT01948557|Behavioral|Infant feeding counselling and support|"Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.~Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice."
75471074|NCT01948583|Drug|Hyaluronic Acid|Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
75471075|NCT01948596|Dietary Supplement|Omega-3 polyunsaturated fatty acids|
75471076|NCT01948622|Drug|Mulungu|500 mg/single dose/1 hour before dental surgery
75640863|NCT00722371|Drug|Pioglitazone hydrochloride|Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
75471077|NCT01948622|Drug|Placebo|500 mg/single dose/1 hour before dental surgery
75789357|NCT01102920|Behavioral|Behavioural strategies to promote physical activity and weight loss|"8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.~Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.~Treatments are provided by a physical therapist and a dietician."
75789358|NCT01102920|Device|CPAP|CPAP-treatment as usual (during nights)
75789359|NCT01362634|Behavioral|Trans-theoretical Process of Change Model-self|self-administered, computer-based intervention
75789360|NCT01362634|Behavioral|Trans-theoretical Process of Change Model - interviewer|interviewer-administered intervention
75471078|NCT01948635|Device|tapered PVC-cuffed tracheal tubes|Patients will be intubated with tapered-shape tracheal tubes
75471079|NCT01948635|Device|Standard PVC-cuffed tracheal tube|Patients will be intubated with standard PVC cuffed tracheal tubes
75640864|NCT00722371|Drug|Matching placebo to sitagliptin|Matching placebo to sitagliptin orally once daily for 54 weeks.
75640865|NCT00722371|Drug|Matching placebo to pioglitazone|Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
75640866|NCT00722371|Drug|Metformin|Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
75789361|NCT01362712|Radiation|[F18]CP-18 Injection|Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.
75789362|NCT04234906|Drug|Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
75332531|NCT04556162|Diagnostic Test|fractional sodium excretion|fractional sodium excretion will be compared to urinary sodium/creatinin, sodium/potassium ratio's and sodium concentration.
75332532|NCT04556162|Other|risk subgroups|subgroup analysis will be performed to identify the patient groups at risk for sodium depletion
75332533|NCT05602922|Combination Product|Liu-Zi-Jue Exercise|Combined with the actual situation of stroke patients, this Liu-Zi-Jue Exercise adopts the sitting position.
75332534|NCT05602922|Other|Basic treatment +Swallowing rehabilitation training|Basic treatment +Swallowing rehabilitation training
75471080|NCT01948648|Drug|Colesevelam|Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.
75471081|NCT01948648|Dietary Supplement|Fish Oil|In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.
75471082|NCT01948648|Drug|Combination of fish oil and colesevelam|combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
75471083|NCT01948661|Dietary Supplement|Mirtoselect® + Meriva®|
75471084|NCT01948661|Dietary Supplement|Placebo|
75471085|NCT01948674|Behavioral|Computerized tasks|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
75471086|NCT01948713|Other|Strengthening of pelvic floor muscles.|Kegel exercises kinesiotherapy
75471087|NCT01948713|Other|Strengthening of hip muscles.|Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
75471088|NCT01948726|Radiation|Hypofractionation with simultaneous integrated boost|
75471089|NCT01948752|Other|Nutrition information on menus|
76080874|NCT05930756|Procedure|Radiofrequency ablation|Genicular radiofrequency ablation uses thermal energy to percutaneously create lesions in neural tissues of the genicular nerves that innervate the anterior knee capsule and disrupt the conduction of pain signals.
76080875|NCT05925868|Behavioral|mindfulness app|Parents will use the mindfulness app, Headspace, for at least 10 minutes on 4 days/week.
76080876|NCT05925634|Behavioral|RPE (usual care)|Patients in the active comparator group will follow standard exercise prescription protocols in cardiac rehabilitation.
75471090|NCT01948765|Drug|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
75471091|NCT01948765|Drug|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
75471092|NCT01948778|Device|oXiris™ filter|
75471093|NCT01948778|Device|Toraymyxin Filter|
75640868|NCT04298762|Other|No peer comparison email|The comparison group received no email communication on their cancer stage documentation activity.
75640869|NCT04298762|Other|Peer comparison email|The intervention group received three separate emails with individualized data on their cancer stage documentation activity in the previous 1-3 months. The email described the number and percent of attributed patients for whom cancer stage was documented, and included a figure showing their staging documentation rate compared to their peers.
75640870|NCT02871986|Drug|Routine transdermal oestrogen patch|Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
75640871|NCT04298840|Dietary Supplement|Creatine Monohydrate Supplementation|Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.
75640872|NCT04298840|Dietary Supplement|Placebo Supplementation|Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.
75640873|NCT00722137|Drug|Rituximab 375 mg/m^2|Intravenous rituximab 375 mg/m^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.
75640874|NCT00722137|Drug|Cyclophosphamide 750 mg/m^2|Intravenous cyclophosphamide 750 mg/m^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
75640875|NCT00722137|Drug|Doxorubicin 50 mg/m^2|Intravenous doxorubicin 50 mg/m^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
75789363|NCT04234906|Drug|Magnesium Sulfate|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
75789364|NCT04234906|Drug|Amiodarone|I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
76080877|NCT05925634|Behavioral|GXT+THHR (intervention)|Patients in the personalized care group will perform a graded exercise test and the peak heart rate from the test will allow the researcher to calculate a target heart rate range (THRR). Then, the patients will receive psychoeducational feedback (PF) about their test results and exercise performance. After PF, their THRR will be reviewed and how it will be used to guide exercise intensity in CR will be discussed.
75789365|NCT04234906|Drug|Procainamide|IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
75789366|NCT04470232|Other|Self-assessment questionnaires|"120 patients with coxofemoral pathologies will pass the SUSHI-score and the HOOS-12 score questionnaires.~The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
75789367|NCT01362868|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
76080878|NCT05918952|Diagnostic Test|Covid-19 Antibody Test|"The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap."
75789368|NCT01363024|Drug|MFGR1877S|Intravenous escalating dose
76080879|NCT05918952|Other|Short Clip videos|Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
75332535|NCT03361826|Device|MagPro MST with Cool TwinCoil|MST treatments will be administered using the MagPro MST with Cool TwinCoil. The investigators will evaluate the effectiveness of MST for reducing suicidality and depressive symptoms in an open-label clinical trial of up to 15 treatment sessions. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
75332536|NCT03361826|Behavioral|DBT|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
75471094|NCT01948778|Device|Standard of Care|
75471095|NCT01948804|Drug|GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)|
75471096|NCT01948804|Drug|microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)|
75471097|NCT01948804|Drug|Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)|
75471098|NCT01948804|Drug|GnRH antagonist protocol (Cetrotide, Serono)|
75471099|NCT01948817|Drug|Deferasirox|Deferasirox 20mg/kg taken BID
75471100|NCT01948843|Drug|ADI-PEG 20|
75640876|NCT00722137|Drug|VELCADE 1.3 mg/m^2|Intravenous VELCADE 1.3 mg/m^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles
75640877|NCT00722137|Drug|Prednisone 100 mg/m^2|Oral prednisone 100 mg/m^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
75640878|NCT00722137|Drug|Vincristine 1.4 mg/m^2|Intravenous vincristine 1.4 mg/m^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
75640879|NCT02591329|Behavioral|Mail-out hard copy materials (education plus self-regulatory strategies examples)|
76080880|NCT05917626|Behavioral|Digital SPA|A psychological digital intervention for chronic pain in adolescents, based on evidence-based cognitive-behavioral and Acceptance and Commitment Therapy techniques. The intervention will be co-created with patients in a previous phase of the study, so the exact number or format of sessions and content has not been determined yet.
76080881|NCT05916235|Device|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
76080882|NCT05909553|Drug|Venetoclax|Oral; Tablet
76080883|NCT05896436|Behavioral|Emotion Focused Therapy|12 sessions of Emotion Focused Therapy (EFT). The focus in EFT is to promote the individual's experiencing and facilitate participants' self-disclosure and openness to their own experience, rather than the therapist's agenda or techniques. Key processes within EFT include helping people overcome their avoidance of emotion, maintaining a collaborative focus on emotions, and exploring emotions in therapy.
76080884|NCT05891158|Drug|Fazirsiran|Fazirsiran SC injection.
76080885|NCT05890794|Biological|Ilofotase Alfa, 0.8 mg/kg|Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
76080886|NCT05890794|Biological|Ilofotase Alfa, 3.2 mg/kg|Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
75640880|NCT02591329|Behavioral|Standard Care|
75640881|NCT02590315|Other|Invitation for breast screening and random allocation|Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.
75640882|NCT02590315|Device|DBT|Combo-mode DBT. DBT participants will have an additional radiation exposure for breast tomosynthesis.
75640883|NCT02590315|Device|Conventional digital mammography.|Conventional digital mammography.
75640884|NCT04086043|Device|Endovascular Denervation|multi-electrode catheter-based endovascular denervation
75640885|NCT01775722|Device|Pulsed Dye Laser|port wine stain
75640886|NCT01775722|Device|Combined Bipolar Radiofrequency&Pulsed Dye Laser|Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment
75640887|NCT02604862|Other|FIB ONE|FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
75789369|NCT01363102|Procedure|SOMS|Apply a number to mobilization goal for patient
75789370|NCT00002766|Biological|dactinomycin|
75789371|NCT00002766|Biological|sargramostim|
75925668|NCT05501782|Other|questionnaire|A questionnaire consisting of seven parts was applied to the participants. In the first part, 20; demographic data and general health status of the participants; There were 11 questions including nutritional habits and anthropometric measurements (body weight and height). The other parts of the questionnaire were the Intuitive Eating Scale (IES-2), Power of Food Scale (PFS-Tr), Food Craving Questionnaire (FCQ-T), the Pittsburg Sleep Quality Scale (PUKI), Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) and Palatable Eating Motive Scale (PEMS), respectively contains. Consent from the participants was also obtained with the questionnaire form.
76080887|NCT05889221|Other|Drug and medical device|Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
75332537|NCT01928810|Behavioral|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
75640888|NCT02604862|Other|AZD1236|AZD1236 will be delivered at microdose concentrations and is thus considered to be unable to exert any pharmacologic effect outside the area of administration and unlikely to cause an adverse reaction.
75640889|NCT04114396|Drug|Anti-IL5 Antibody|Asthma group: Anti-IL5 treatment Control group: No biologic.
75640890|NCT04114396|Procedure|Bronchoscopy|Optional for both arms
75640891|NCT00796666|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day
75640892|NCT00796666|Drug|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
75640893|NCT00799708|Drug|Comparator: placebo|placebo capsule once daily for 7 days.
75640894|NCT00799708|Drug|Comparator: Estrace|Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
75640895|NCT00796510|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
75789372|NCT00002766|Drug|carmustine|
75789373|NCT00002766|Drug|cyclophosphamide|
75789374|NCT00002766|Drug|cytarabine|
75789375|NCT00002766|Drug|daunorubicin hydrochloride|
75789376|NCT00002766|Drug|doxorubicin hydrochloride|
75789377|NCT00002766|Drug|etoposide|
75789378|NCT00002766|Drug|mercaptopurine|
75789379|NCT00002766|Drug|methotrexate|
75789380|NCT00002766|Drug|mitoxantrone hydrochloride|
75789381|NCT00002766|Drug|pegaspargase|
75789382|NCT00002766|Drug|prednisone|
75789383|NCT00002766|Drug|vincristine sulfate|
75789384|NCT00002766|Radiation|radiation therapy|
75789385|NCT02636530|Behavioral|Ground Reaction Forces|6 month exercise program that loads the body via gravitational forces.
75789386|NCT02636530|Behavioral|Joint Reaction Forces|6 month exercise program that loads the body via loading the joints.
75332538|NCT01928888|Drug|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
75332539|NCT01928888|Drug|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
75332540|NCT01928888|Drug|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
75332541|NCT04557722|Procedure|0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.
76080888|NCT05886816|Drug|Mitoquinone/mitoquinol mesylate|Mitochondrial antioxidant
75925669|NCT03331874|Diagnostic Test|Reflectance Confocal Microscopy|In-vivo microscope
75332542|NCT04557722|Procedure|New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
75332543|NCT01928966|Other|Pumpkin Seeds|Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
75332544|NCT04556084|Drug|Blinatumomab|"Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day"
75640896|NCT00796510|Drug|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
75640897|NCT04111432|Biological|Concomitant administration of EV71vaccine with EPI vaccines|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
75640898|NCT04111432|Biological|Single injection of EPI vaccine|The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
75640899|NCT04111432|Biological|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
75640900|NCT00915070|Drug|BQ-123|60 mcg/min, infusion period: 60 min
75640901|NCT00915070|Drug|Physiological saline solution|infusion period 60 minutes
75640902|NCT00915070|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
75640903|NCT00915070|Device|Goldmann Applanation Tonometer|intraocular pressure measurements
75640904|NCT00915070|Other|squatting|subjects will perform squatting for 6 minutes while blood flow measurements
75640905|NCT00588640|Drug|d-Methadone|8 subjects to receive 40 mg d-Methadone twice a day
75640906|NCT00588640|Drug|D-methadone|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
75640907|NCT00588640|Drug|placebo|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
75640908|NCT04111198|Radiation|Cardiac MRI|Cardiac MRI
75640909|NCT01016912|Drug|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
75789387|NCT01355380|Drug|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
75789388|NCT01103076|Device|Polyamide HD membrane|Single use polyamide membrane
75789389|NCT01355614|Drug|QAX576|
75789390|NCT01355614|Drug|Infliximab|
75789391|NCT01355692|Device|Nd: YLF laser treatment|grid selective retinal treatment
75925670|NCT05501626|Device|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
75925671|NCT05501626|Device|Sham Theta Burst Stimulation (TBS)|Each session will be comprised of SHAM TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
75925672|NCT03323996|Other|Semi-Structured interviews|individual semi-structured interviews
75925673|NCT05505994|Drug|DWP16001|DWP16001 A mg tablet
75925674|NCT05505994|Drug|Dapagliflozin|Dapagliflozin tablet
75925675|NCT05505994|Drug|DWP16001 Placebo|DWP16001 Placebo tablet
75925676|NCT05505994|Drug|Dapagliflozin Placebo|Dapagliflozin Placebo tablet
75925677|NCT03323918|Other|ImPACT|Teaching parents to train social communicative skills as outlined in arm description.
75925678|NCT03323918|Other|TAU|TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
75925679|NCT05501392|Behavioral|STEPS-PreK|Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).
75925680|NCT02180217|Drug|osilodrostat|Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
76080889|NCT05886816|Other|Placebo|Placebo pills
75640910|NCT01016912|Drug|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
75640911|NCT01016912|Drug|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
75640912|NCT01016912|Drug|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
75640913|NCT01016912|Drug|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
75640914|NCT04114318|Other|Dual-task cognitive-cycling training|Cognitive and cycling training simultaneously for dual-task cognitive-cycling training; stationary bicycle exercise training for single-task cycling training
75789392|NCT01584492|Drug|beclomethasone+formoterol 50/6 (1 inhalation)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
75789393|NCT01584492|Drug|CHF 1535 50/6 (2 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
76080890|NCT05873556|Behavioral|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|This is an online personalized feedback intervention that contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
75925681|NCT02180217|Drug|LCI699 matching placebo|Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
75640915|NCT04111120|Diagnostic Test|SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI|Coagulation assessment using heparinase treated SONOCLOT
75789394|NCT01584492|Drug|CHF 1535 50/6 (4 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
75925682|NCT03323840|Other|Incentivized Care|Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
75332545|NCT04394780|Procedure|cooling|First, patients underwent peritoneal dialysis (PD) at 37 C (standard temperature) and then patients underwent PD cooling. After each PD session, the patient had a CT scan for the study team to study myocardial perfusion at rest and after introduction of a pharmacological stressor.
75640916|NCT04299308|Behavioral|Aerobic Exercise|Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload
75789395|NCT01584492|Drug|Formoterol + Beclomethasone dipropionate|"Formoterol HFA pMDI 6 µg / actuation~Extrafine BDP HFA pMDI 50 µg/actuation"
75332546|NCT01929122|Dietary Supplement|Placebo-Control Meals and Snacks|
75332547|NCT01929122|Dietary Supplement|Cooked Navy Bean Powder Meals and Snacks|
75789396|NCT01584492|Drug|Placebo (6 inhalations)|Matched placebo via pMDI
75789397|NCT01355848|Behavioral|Brief Intervention for Suicidality|Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
75925683|NCT05501314|Other|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. During home monitoring, heartrate, respiratory rate, posture and movement are monitored every 5 minutes for at least 4 days, using a wearable sensor. Core temperature is monitored using an ear thermometer. Patients are contacted once per day by a nurse from the Virtual Monitoring Centre (VMC) to assess pancreatitis related complaints, intake of fluids and food, pain and the use of analgesics. Patients are asked to provide information to the hospital using a smartphone app.
75925684|NCT03323762|Device|Remote Ischaemic Conditioning (RIC)|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
75332548|NCT01929122|Dietary Supplement|Rice Bran Meals and Snacks|
75332549|NCT04394234|Drug|Direct oral anticoagulant (DOACs)|Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
75925685|NCT02491424|Device|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
75925686|NCT04723810|Drug|Indocyanine Green|The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
75925687|NCT02491268|Drug|Cilostazol|
75925688|NCT02491268|Drug|Placebo|
75332550|NCT04394234|Drug|Warfarin|Data of participants newly exposed to warfarin from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
75640917|NCT04110964|Drug|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
75640918|NCT02605798|Drug|Elbanovir|1 tablet contains 400 mg sofosbuvir
75640919|NCT02605798|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
75925689|NCT05509504|Other|Low-intensity online intervention|The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills. Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for ~45 minutes. Participants will attend these sessions once a week.
75925690|NCT02182323|Drug|BI 201335 NA|
75925691|NCT02182323|Drug|Placebo solution|
75925692|NCT03323684|Other|Quadratus lumborum block Group (QL)|20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
75471101|NCT01948856|Drug|J022X ST|"Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~First month: 4 consecutive days per week during 3 consecutive weeks~5 next months: 4 consecutive days per month at monthly intervals"
75640920|NCT02605798|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
75332551|NCT05602844|Procedure|PSI Lapidus|Design of PSI: DICOM files will be imported into the Model Intestinal Microflora in Computer Simulation (MIMICS 21.0) 3D image processing software (Materialize, Belgium) for 3D rendering. The segmented bone images will be used for design of the computer-aided modelling (CAM) surgical jigs. 3D printing of PSI jig. PSI-assisted Lapidus Surgery.
75640921|NCT04114240|Drug|Xybilun|Erectil dysfunction, Viagra generic (sildénafil)
75640922|NCT04113850|Device|Mobile Acoustic startle Reflex monitoring System (MARS)|Acoustic startle testing
75640923|NCT00802672|Drug|Ciclopirox Olamine Cream|topical cream
75640924|NCT00802672|Drug|Loprox Cream 0.77%|topical cream
75640925|NCT00802672|Drug|Placebo|topical cream
75640926|NCT04113772|Drug|Nitisinone|Measure bio equivalency/efficacy of nitinosine and orfadin
75640927|NCT04113772|Drug|Orfadin|Orfadin
75640928|NCT04113928|Dietary Supplement|Broccoli & mustard seed soup|200ml acute feed
75640929|NCT04113928|Dietary Supplement|Broccoli soup|200ml acute feed
75640930|NCT00914680|Procedure|magnetic seizure therapy|antidepressant treatment with MST
76080891|NCT05872789|Drug|Diazepam 1% oral gel|Diazepam 1% used with topic oral gel on tongue and palate twice daily.
76080892|NCT05872789|Drug|Placebo|Placebo oral gel used on tongue and palate twice daily.
75332552|NCT05602844|Procedure|Conventional Lapidus|exposure of the 1TMTJ via a 3-5cm medial longitudinal skin incision and capsulotomy. Freehand creation of the fusion surface with fluoroscopic assistance. Fixation of the Lapidus arthrodesis will be performed with two 3.5mm headless compression screws
75332553|NCT04552652|Behavioral|High-Intensity Interval Training|Remotely monitored exercises will be performed at home. The high-intensity interval group warms-up for 5 minutes at moderate intensity (65-75% of maximal heart rate). After warm-up exercise, will continue in 4 minutes intervals at high-intensity to reach the target zone (85-95% of maximal heart rate) Each interval will be separated by 3 minutes of active recoveries (at 65-75% of maximal heart rate). The session ends with a 3-minute cool-down phase. Overall training exercise time will be 33 minutes - isocaloric compared to moderate-intensity continous training group. All participants will train using a heart rate monitor during each workout.
75332554|NCT04552652|Behavioral|Moderate-intensity continuous training|Remotely monitored exercises will be performed at home. Patients in the moderate-intensity continuous training group will perform a 41-minute constant workout with an intensity of 65-75% of maximum heart rate, representing the same total training load as the high-intensity aerobic exercise group. All participants will train using a heart rate monitor during each workout.
76080893|NCT05870033|Device|Electromyography (EMG) measurement|Electromyography (EMG) measurement of m. quadriceps femoris and semitendinosus muscle during static functional tasks
75332555|NCT02569710|Drug|AL-335|AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
76080894|NCT05865886|Drug|BI 1291583|BI 1291583
75789398|NCT01355926|Other|Flexible Fiber-based CO2 Laser, Quality of Life forms|. Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
75789399|NCT01355926|Other|electrocautery resection and quality of life forms|Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
75789400|NCT02306122|Behavioral|Pharmacist calls patient unless physician cancels call|
76080895|NCT05865886|Drug|Placebo|Placebo matching BI 1291583
76080896|NCT05856513|Drug|ZSP1273|Participants receive ZSP1273 orally.
76080897|NCT05856513|Drug|ZSP1273|Participants receive ZSP1273 orally.
76080898|NCT05856513|Drug|ZSP1273|Participants receive ZSP1273 orally.
75332556|NCT02569710|Drug|Odalasvir (ODV)|ODV capsules will be administered in a dose range of 25 to 50 mg.
75332557|NCT02569710|Drug|Simeprevir (SMV)|SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
75332558|NCT04550624|Drug|Pembrolizumab Injection [Keytruda]|200mg IV on day 1 of each cycle
75332559|NCT04550624|Drug|Lenvatinib Mesylate|20mg PO daily days 1-21 of each cycle
75332560|NCT03379064|Behavioral|Culturally adapted Cognitive Behavior Therapy for IBS|Culturally adapted Cognitive Behavior Therapy for IBS
75332561|NCT04550546|Drug|Nystatin|600,000 U/mL of nystatin in a rinse suspension
75332562|NCT01929200|Drug|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
75332563|NCT01929200|Drug|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
75471102|NCT01948856|Drug|Placebo|"Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~First month: 4 consecutive days per week during 3 consecutive weeks~5 next months: 4 consecutive days per month at monthly intervals"
75471103|NCT01948869|Device|Phoenix II (BAY81-2996)|
75471104|NCT01948869|Device|Phoenix I (BAY81-2996)|
75471105|NCT01948895|Drug|Desvenlafaxine|Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
75471106|NCT01948921|Drug|placebo|
75471107|NCT01948921|Drug|Meperidine|
75471108|NCT01948934|Procedure|Amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
75471109|NCT01948960|Drug|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
75471110|NCT01948973|Device|Subsensory|The stimulation is here set to 90% of the sensory threshold
76080899|NCT05852717|Procedure|AutoSCT OR CAR T-cell Therapy|Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP
76080900|NCT05852717|Drug|GDP|Gemcitabine Cisplatin Dexamethasone
76080901|NCT05852717|Drug|Epcoritamab|Epcoritamab
76080902|NCT05849142|Device|MRIdian Linac|Radiation therapy (RT) will be delivered with an integrated MRI-RT delivery system (MRIdian Linac). Participants will then receive standard-of-care RT with a dose prescription of 70 Gy in 35 fractions on the MRIdian Linac. Adaptive RT (ART) planning will occur every 5th fraction of RT.
75471111|NCT01948973|Device|OFF|The stimulation is here turned OFF
75471112|NCT01948973|Drug|Suprasensory|The stimulation is here set suprasensory
75471113|NCT01948999|Procedure|ECT|Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis
75471114|NCT01948999|Procedure|SHAM ECT|Anesthesia and concomitant muscular paralysis
75789401|NCT02306122|Behavioral|Patient nonadherence information sent to physician|
75789402|NCT02306122|Behavioral|Pharmacist calls patient if physician requests call|
75789403|NCT02306122|Behavioral|Doctor receives information and may be allowed certain actions|
75925693|NCT03323684|Other|Transversus abdominis plane Group (TAP)|20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
75925694|NCT03323684|Other|Control group (C)|No intervention will be done
75925695|NCT03323684|Drug|Paracetamol infusion|Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
75925696|NCT03323684|Drug|Ketorolac analgesia|In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
75925697|NCT03323684|Drug|fentanyl|With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
75332564|NCT04394312|Other|Parent PLAYSHOP|"The Parent PLAYSHOP includes:~Educational Training- the 75 min workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities. Parents will be provided with modifications to perform activities 'at home'.~Distribution Education and Activity Resources- At the workshop conclusion parents are given education Resources (e.g. Canada's 24-hour movement guidelines for the early years, activity idea booklet, and a physical literacy handout) and inexpensive activity resources (ball, bean bag, scarves, balloons etc.).~Provide Follow-up Support- Research staff will send parents a follow-up email with key workshop messages (e.g., rationale and importance of physical literacy); support and encouragement for parents to engage in purposeful play with their child; and an opportunity for parents to provide feedback and/or seek further support."
75471115|NCT01948999|Drug|Anesthesia|Temporary induced state of analgesia
75471116|NCT01949012|Other|Capnography|Capnography waveform and capnometry readings
75789404|NCT00001962|Drug|Daclizumab|Daclizumab, 1mg/kg, every 2 weeks for a total of 5 infusions.
75471117|NCT01949025|Other|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
75789405|NCT01356004|Drug|live attenuated chicken pox vaccine|Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).
75789406|NCT01356004|Drug|saline, efficacy|4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
75789407|NCT03951714|Behavioral|Marketed experience application on adherence|To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
75789408|NCT01356082|Device|CNAP|Non-invasive blood pressure monitor
75789409|NCT01584570|Drug|0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min|ECG monitoring for evaluation of QTc interval
75925698|NCT02182401|Drug|BI 207127 NA|Days 3-8 and days 25-30
76080903|NCT05849077|Other|Sat75|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
75640931|NCT04115800|Drug|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
75925699|NCT02182401|Drug|BI 201335 NA|Days 15-30
75925700|NCT02182401|Drug|Midazolam|Days 1, 7, 23 and 29
75640932|NCT04011046|Device|Stent|
75640933|NCT04115410|Drug|PD-1 inhibitor|PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.
75789410|NCT01101984|Drug|diquafosol ophthalmic solution|DE-089 topical ocular application, 6 times daily for 4 weeks.
75789411|NCT01101984|Drug|0.1% sodium hyaluronate ophthalmic solution.|0.1% HA topical ocular application, 6 times daily for 4 weeks.
75925701|NCT02182401|Drug|Tolbutamide|Days 1, 7, 23 and 29
75925702|NCT04292080|Drug|Dimethyl Fumarate (TECFIDERA™)|Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
75925703|NCT04292080|Other|No active : no treatment|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
75925704|NCT03323606|Behavioral|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
75471118|NCT01949038|Drug|Oral alprazolam|
75471119|NCT01949038|Drug|Sublingual alprazolam|
75471120|NCT01949038|Drug|Oral placebo|
75471121|NCT01949038|Drug|Sublingual placebo|
75471122|NCT01949064|Device|Grindcare|
75471123|NCT01949064|Device|Michigan-type occlusal splint|
75332565|NCT04394078|Other|Online survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
75789412|NCT01103154|Drug|carvedilol|6.25mg per day, increase to 6.25mg bid
75925705|NCT03323606|Behavioral|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
75332566|NCT01219855|Drug|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
75640934|NCT04115410|Drug|Chemotherapy Drugs, Cancer|Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
76080904|NCT05849077|Other|Sat50|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
75640935|NCT04010812|Other|Questionnaire|RHDS- Readiness For Hospital Discharge Scale, Patient Self-Assessment Form
75640936|NCT04027036|Biological|Inactivated poliovirus vaccine in reduced doses|"contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age"
75789413|NCT01103154|Drug|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
75789414|NCT01103310|Drug|BAY94-9392|
75789415|NCT05625828|Behavioral|Cognitive-motor Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of cognitive-motor exercises where participants have to perform two tasks consequently (for example, walking while answering math questions or throwing a ball while reverse walking) and 5 minutes of stretching exercises.
75789416|NCT05625828|Behavioral|Multifactorial Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of multifactorial exercises that consists of high speed walking, resistance training and balance training in single task condition and 5 minutes of stretching exercises.
75789417|NCT01100190|Device|NUVANCE Facial Rejuvenation System|The NUVANCE™ Facial Rejuvenation System is a partially absorbable porous mesh device implant with applicator.
75789418|NCT01100346|Drug|Gonal-f (Follitropin alpha)|A starting dose of 75 IU/day subcutaneously is maintained for a period of 7 to 14 days. The follitropin alpha dose would be subsequently increased by 37.5 IU/day at weekly intervals based on the ovarian response.
75925706|NCT02177955|Drug|7.5 mg Midazolam|7.5 mg midazolam 45 minutes before surgery
75925707|NCT02177955|Drug|10 mg diazepam|10 mg midazolam 45 minutes before surgery
75332567|NCT01219855|Drug|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
75640937|NCT05668780|Behavioral|NIATx Coaching|"The intervention will consist of:~a Nominal Group Technique session to identify priorities in integrating HIV/HCV/MOUD~rapid cycle improvement coaching sessions from a NIATx coach, using data dashboards and screening alerts to improve identification and treatment for HIV/HCV/OUD~training for primary care providers"
75640938|NCT04115332|Biological|bio-feedback training|The aim of this study was to explore the abused PW nurses who receiving bio-feedback training as an intervention improve, and change of physiological indicators before and after intervention (3 months later), which included Respiratory Rate (RR), skin conduction (SC), heart rate variability (HRV), and resilience.
75640939|NCT02604706|Device|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
75925708|NCT04290988|Device|EEG Neurofeedback|Active EEG neurofeedback
75925709|NCT04290988|Device|Sham Feedback|Sham EEG feedback sessions identical to active sessions except that the feedback given to the participant will not be based on the individual's live EEG activity.
75332568|NCT01219855|Drug|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
75332569|NCT01219855|Drug|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
75332570|NCT01219855|Drug|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
75332571|NCT02984072|Drug|Menthol|Topical menthol in aqueous cream
75332572|NCT02984072|Drug|Aqueous Cream|placebo
75925710|NCT03323528|Drug|Benzalkonium Chloride-Benzocaine Topical|Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
75332573|NCT05506410|Drug|Rituximab|Young patients (< 65 years of age) were treated with R-BAP for 6 cycles (efficacy was assessed every 2 cycles, and adverse events were recorded), together with oral ibrutinib, followed by oral ibrutinib for 1 year after chemotherapy (efficacy was assessed every 3 months). Elderly patients (≥65 years of age) received 4 cycles of R-BAP (efficacy assessed every 2 cycles, and adverse reactions recorded), followed by 4 cycles of rituximab consolidation (efficacy assessed every 2 cycles) and 1 year of oral zanubrutinib (efficacy assessed every 3 months).
75332574|NCT05506332|Drug|Venetoclax|Venetoclax and 6-mercaptopurine
75640940|NCT02604706|Device|LP acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
75640941|NCT02604706|Behavioral|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
75640942|NCT02604628|Behavioral|Antibiotic Stewardship Intervention|The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
75640943|NCT02604784|Drug|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²) The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
75640944|NCT02604784|Drug|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Escalating dosage of drugs for PIPAC: Cisplatin + Doxorubicin (from 15 mg/m² + 3 mg/m² to 100 mg/m² + 30 mg/m²) or Oxaliplatin (from 92 mg/m² to 300mg/m²).The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters.
75789419|NCT03950388|Behavioral|Intervention|Wards randomly assigned to receive the intervention will have a Band 8a Psychologist based on the ward for 0.5FTE for 7 months. During this time, all patients will be involved with the proposed stepped model of care intervention at one of three levels. The level the patient receives will be decided by the multidisciplinary ward team. At Step one, all patients will have a psychological formulation developed by the psychologist in conjunction with the patient or members of the ward team. At Step 2, all qualified nurses will be trained and supervised to deliver guided self-help material of psychological interventions targeting key problem areas for patients. At Step 3, patients will be offered up to 16, one-to-one therapy sessions with the psychologist.
75789420|NCT01103388|Drug|Rituximab|375 mg/m^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
75789421|NCT01102062|Dietary Supplement|orange juice|
75789422|NCT01327326|Drug|Naltrexone|Oral, 50 mg, 1 Time Dose
75789423|NCT01327326|Drug|Placebo|Oral, 1 Time Dose
75789424|NCT03950544|Drug|Fosfomycin|Fosfomycin and meropenem
75789425|NCT03950544|Drug|Tigecycline|Tigecycline and meropenem
75789426|NCT03950544|Drug|Polymyxin B|Polymyxin B and meropenem
75789427|NCT05625672|Other|Training|Hemovigilance module training
75789428|NCT00028002|Procedure|Conventional Surgery|Undergo surgical resection
75925711|NCT03323528|Drug|Placebo Oral Tablet|"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
75925712|NCT02180295|Biological|V212 Lot 1|Inactivated Varicella Zoster Virus vaccine
75925713|NCT02180295|Biological|V212 Lot 2|Inactivated Varicella Zoster Virus vaccine
75332575|NCT05506332|Drug|6-mercaptopurine|Venetoclax and 6-mercaptopurine
75471124|NCT01949103|Drug|TD-1607|
75471125|NCT01949103|Drug|Placebo|
75471126|NCT01949168|Drug|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)|
75789429|NCT00028002|Drug|Imatinib Mesylate|Given orally
75789430|NCT03949998|Device|Dry Needling|Comparison between dry needling and/or manual therapy of the cervical region.
75789431|NCT03949998|Other|Manual Therapy|soft tissue release, cervical traction and/or cervical mobilization
75789432|NCT00256997|Drug|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
75925714|NCT02180295|Biological|V212 Lot 3|Inactivated Varicella Zoster Virus vaccine
75925715|NCT05501158|Drug|Tamoxifen|Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
75925716|NCT03329534|Other|Gluten free diet|A month long gluten free diet
75925717|NCT03537807|Drug|Riluzole|For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).
75925718|NCT03323450|Behavioral|CogMed®|"It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~Baseline before the participant is introduced to the CogMed® training program~Within 2 weeks of completion of the CogMed® program~At 3 months of completion of the CogMed® program to establish maintenance of gains~At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains"
75332576|NCT01220869|Drug|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
75332577|NCT04124666|Biological|Granulocytes|Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
75332578|NCT05604872|Procedure|Small Incision Lenticule Extraction|A 500 kHzVisumax (Carl Zeiss Meditec AG) femtosecond laser was used with cap thickness ranging from 100 to 130μm, cap diameter from 7.3 to 7.9 mm. The lenticule was dissected with a blunt spatula through a 30 to 60-degree incision at the 10 o'clock position and removed using forceps afterward. Treatment targets of both eyes were set to emmetropia, the refraction corrections were based on manifest refractions
75332579|NCT05511402|Other|Exercise training|People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.
75789433|NCT00256997|Drug|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
75789434|NCT00027846|Biological|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC >1500/μl given subcutaneously or intravenously.
75789435|NCT00027846|Drug|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA <0.45m2 the dose is 12.5 mg/kg/day.
75789436|NCT00027846|Drug|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
75789437|NCT00027846|Drug|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA < 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
75789438|NCT00027846|Drug|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA<0.45m2 the dose is 0.05mg/kg.
75925719|NCT02182479|Drug|Berodual® via Respimat®, high dose|
75925720|NCT02182479|Drug|Berodual® via Respimat®, low dose|
75925721|NCT02182479|Drug|Berodual® via MDI, high dose|
75925722|NCT02182479|Drug|Placebo Respimat®|
75925723|NCT02182479|Drug|Placebo MDI|
75925724|NCT02560558|Drug|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
75332580|NCT04124354|Behavioral|Physical Activity|Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)-exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
75332581|NCT05600192|Other|Aerobic or anaerobic exercise|Aerobic or anaerobic exercise in the morning or in the afternoon
75332582|NCT01927874|Procedure|Infiltration|injection of local anesthetic, associated with general anesthesia
75332583|NCT01927874|Procedure|Spinal block|injection of anesthetic
75332584|NCT01927874|Drug|Bupivacaine|10ml 0.5% bupivacaine.
75925725|NCT03329456|Drug|Ropivacaine|Minimum effective volume
75332585|NCT01927874|Drug|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
75332586|NCT05604716|Other|observational study|observational study
75789439|NCT00027846|Radiation|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
75925726|NCT02178033|Drug|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
75925727|NCT02491736|Drug|Ketoprofen|2.5% ketoprofen gel
75925728|NCT02491736|Other|Placebo|Placebo gel
75332587|NCT04124276|Dietary Supplement|Lycium barbarum polysaccharide|Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks
75332588|NCT04124276|Dietary Supplement|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks.
75332589|NCT04124510|Drug|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
75640945|NCT04110808|Drug|hypotensive anaesthesia using Nitroglycerine|"effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure."
75789440|NCT00027846|Drug|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
75925729|NCT05501080|Other|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
75471127|NCT01949168|Drug|Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection|
75925730|NCT05501080|Drug|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
75925731|NCT02256657|Behavioral|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
75640946|NCT04110652|Other|pulmonary rehabilitation program|"The pulmonary rehabilitation program consisting of inspiratory muscle training, manual hyperinflation. chest wall mobilization, rib-cage compression, cough function training, postural drainage and secretion removal will be applied to patient group.~The program will be conducted by physical therapists for 30-45 minutes daily during ICU stay.~The exercise intensity will be increased gradually over the course. Each patient's performance during the exercise sessions will be recorded and reported regularly."
75925732|NCT03331406|Other|Physical Activity Program|12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
75925733|NCT04721938|Behavioral|Systematic weight loss intervention|"Weight reduction through life style changes in diet and exercise by the following means:~Counselling with a Nutritionist Nurse on diet and exercise~Online Smartphone coaching program (Life-sum App)~Motivational and adjustment dialogue and counselling with Nutritionist Nurse including anthropometric measures every month"
75925734|NCT02491970|Drug|Fluticasone/Formoterol|
75925735|NCT02491970|Drug|Fluticasone/Salmeterol|
75925736|NCT02491814|Other|1% M.F. Milk|
75925737|NCT02491814|Other|Yogurt Beverage|
75925738|NCT02491814|Other|Soy Beverage|
75925739|NCT02491814|Other|Almond Beverage|
75925740|NCT02491814|Other|Water|
75925741|NCT02491814|Other|Breakfast cereal|
75925742|NCT02182557|Drug|WAL 801 CL Dry Syrup|
75925743|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup|
75925744|NCT02182557|Drug|WAL 801 CL Dry Syrup placebo|
75925745|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup placebo|
76080905|NCT05847322|Biological|Bordetella pertussis B1917|The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Pertactin (PRN), Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.
76080906|NCT05847322|Drug|Azithromycin Pill|A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
75640947|NCT04110886|Drug|HSK21542|Single dose, injection, starting dose of 0.2ug escalating up to 20ug
75640948|NCT04110886|Drug|Placebo|Single dose, injection matching placebo
75789441|NCT00027846|Procedure|therapeutic conventional surgery|
75789442|NCT00027378|Drug|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
75789443|NCT00027378|Drug|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
76080907|NCT05844280|Procedure|BFR+NMES at therapeutic level|This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.
75471128|NCT01949168|Drug|Rebetol® (ribavirin), 1000/1200mg by mouth daily|
75640949|NCT00714415|Drug|BeneFIX|Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
75640950|NCT00714259|Drug|Fludarabine|Fludarabine 30 mg/m2/day x 3 days
75640951|NCT00714259|Radiation|Total Body Irradiation|TBI 200cGy x1 dose on transplant day
75789444|NCT03949062|Drug|Ibrutinib|Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles
75789445|NCT03949062|Drug|Lenalidomide|Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles
75640952|NCT00714259|Other|Infusion of Stem Cells|On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.
75789446|NCT03949062|Drug|Rituximab|Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles
75789447|NCT00235391|Drug|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
75789448|NCT01103622|Drug|AZD1656|Oral tablet bd, step-wise increased dosage
75789449|NCT01103622|Drug|Digoxin|Oral tablet od on Day 4
75789450|NCT01103622|Drug|Placebo|Oral tablet bd, step-wise increased dosage
75925746|NCT02182635|Drug|Ba253BINEB|
75925747|NCT02182713|Drug|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
75925748|NCT02182713|Drug|Salbutamol|Salbutamol 100 mcg per puff
75925749|NCT02490644|Procedure|Blood sampling|Blood sampling 5ml
75925750|NCT03331328|Device|MonaLisa Touch|MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
75925751|NCT03323372|Drug|3% potassium nitrate and 0.25% sodium fluoride|
75925752|NCT03323372|Drug|5% potassium nitrate and 2% sodium fluoride|
75925753|NCT02178111|Other|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
75925754|NCT02178111|Procedure|episiotomy|
75925755|NCT03329222|Other|Specific hydrolysed proteins|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
75925756|NCT03329222|Other|Standard cow's milk with prebiotics mixture|Standard cow's milk with prebiotics mixture
75332590|NCT05604638|Drug|Tenecteplase plus Tirofiban|Patients will receive a continuous intravenous infusion of tirofiban at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
75332591|NCT05604638|Drug|Tenecteplase plus Placebo|Patients will receive a continuous intravenous infusion of Placebo at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
75332592|NCT04123808|Device|IpsiHand Treatment|The IpsiHand system utilizes a Brain-Computer Interface (BCI) as a control for a robotic hand orthosis donned on the affected upper extremity as participants are guided through a rehabilitation program on a tablet. Participants will complete 16-32 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 3 months post no-device use, to track progress.
75332593|NCT03033758|Other|Budesonide/Formoterol treated patients|patients who are eligible to start their treatment with budesonide/formoterol therapy
75471129|NCT01949181|Procedure|Lung surgery|
75471130|NCT01949194|Drug|Regorafenib|"The dose of regorafenib given will be 160 mg once a day (od) oral (po), using a 21 days on / 7 days off treatment schedule. This equates to four (4) tablets once a day for three (3) weeks. The patient should take the dose at the same time each day, with a full glass of water, and following a light meal. A light mealconsists of less than 30% fat and around 300-550 calories."
75471131|NCT01949207|Procedure|EVLA|Endovenous laser ablation of great saphenous vein
75471132|NCT01949207|Procedure|phlebectomies|removal of incompetent veins
75640953|NCT02591485|Behavioral|Attention Control Training|In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
75640954|NCT00918619|Device|Sangustop|Application of Sangustop haemostatic agent on resection area
75640955|NCT00918619|Drug|Tachosil|Application of Tachosil fibrin sealant on resection area
75789451|NCT01100424|Device|Opti-Free RepleniSH|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
75789452|NCT01100424|Device|ReNu MultiPlus|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
75789453|NCT01100424|Device|Balafilcon A|Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.
76080908|NCT05844280|Procedure|BFR+NMES at sub therapeutic level|This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
76080909|NCT05838131|Drug|Experimental: CAR-T cells Infusion|"Biological:~chimeric antigen receptor T cells"
75332594|NCT05604092|Diagnostic Test|VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)|VolBrain, a fully automated platform that uses anonymized compressed NIFTI files to generate the volumetric data. Volbrain is increasingly recognized and compared to other volumetric tools. LesionBrain is a pipeline to automatically segment WM-L from T1 and FLAIR data. Number of lesions, absolute total lesion volume (in cubic cm), normalized lesion volume (percentage of total lesion volume to whole brain volume), lesion burden (percentage of total WM lesion volume to WM volume), and location (Periventricular, Juxtacortical, and Infratentorial) were obtained.
75471133|NCT01949207|Procedure|TRansluminal Occlusion of Perforators (TRLOP)|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
75471134|NCT01949233|Drug|Irbesartan 150-300mg capsules daily for 6 months|
75471135|NCT01949233|Drug|Doxycycline 100-200mg capsules daily for 6 months|
75471136|NCT01949233|Drug|Doxycycline placebo capsules daily for 6 months|
75471137|NCT01949233|Drug|Irbesartan placebo capsules daily for 6 months|
75471138|NCT01949272|Device|esophageal pressure mesurement|"EXPRESS study ventilatory setting the optimization of PEEP with esophageal pressure mesurement"
75471139|NCT01949285|Device|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
75471140|NCT01949298|Procedure|dental implant placement|
75640956|NCT00796120|Drug|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
75640957|NCT00796120|Drug|Doxorubicin|Doxorubicin 60 or 75 mg/m^2 will be given intravenously every 3 weeks until disease progression.
75640958|NCT00796120|Drug|Ifosfamide|Ifosfamide 6 to 9 g/m^2 will be given intravenously every 3 weeks until disease progression.
75640959|NCT05685121|Device|Apollo Neuro|The device is a wearable nerve stimulator.
75640960|NCT00795886|Drug|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
75789454|NCT01100424|Other|Unisol 4|Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
75789455|NCT01102296|Biological|Hepatitis A vaccine|2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.
76080910|NCT05833880|Behavioral|Self-administered questionnaire|Self-administered questionnaire regarding complementary and alternative medicine use
75471141|NCT01949350|Dietary Supplement|Carbohydrate|Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
75640961|NCT04110418|Drug|Methylene Blue|"Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h"
75789456|NCT01072955|Biological|Bovine Heparin|5.000UI/mL bottle with 5mL
75789457|NCT01072955|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
75789458|NCT01102452|Dietary Supplement|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
75789459|NCT01102452|Dietary Supplement|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
75789460|NCT01326143|Device|ORM Narval MRD|
75789461|NCT02981108|Drug|HS-10296|HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.
75789462|NCT00234533|Drug|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
75789463|NCT03759236|Behavioral|Health Messaging via SMS|This intervention aims to provide health education on topics including HPV Vaccination, Cervical Cancer screening, contraceptive methods, menstrual problems, diet and exercise geared towards women with children of vaccination age.
76080911|NCT05829031|Behavioral|Targeted music listening|Participants listen to self-selected relaxing music. They can choose between a duration of either 10 minutes or 20 minutes.
76080912|NCT05826951|Drug|Alcohol|Alcohol (0.8g/kg)
75789464|NCT03759236|Behavioral|CDC Health Pamphlets|This intervention aims to provide health education on the HPV Vaccination to women with children of vaccination age.
75789465|NCT00026208|Drug|Vincristine|1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
75789466|NCT00026208|Drug|Cyclophosphamide|650 mg/m², on week 1 and 5
75789467|NCT00026208|Drug|Doxorubicin|25 mg/m², on week 1, 3, 5, 7
75789468|NCT00026208|Drug|Prednisone|40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy
75789469|NCT00026208|Drug|Bleomycin|5 u/m² intravenously (IV) on week 2, 4, 6, 8
75789470|NCT00026208|Drug|Etoposide|60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
75789471|NCT00026208|Radiation|Low-dose radiotherapy (RT)|20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.
75789472|NCT03765476|Behavioral|SALIENCE|"3 computer-based training sessions with program SALIENCE per week over 3 weeks (see study description)"
76080913|NCT05826951|Drug|Placebo|Placebo
75640962|NCT02604472|Other|CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
75640963|NCT02604472|Other|IC+CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
75789473|NCT03765476|Behavioral|TAU|treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.
75789474|NCT00025662|Drug|RFT5-SMPT-dgA|A specific anti-interleukin-2 receptor immunotoxin
75789475|NCT00025662|Drug|Isolex system|CD34 selection/ T cell depletion used this system
75789476|NCT03765398|Behavioral|VR Cognitive-motor-balance training|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
76080914|NCT05807399|Drug|Sutezolid|"STZ belongs to the oxazolidinone class of antibiotics and is currently under development for the indication treatment of TB.~Sutezolid is not licensed yet and will be dosed at 1200 mg once daily in arm 4"
76080915|NCT05807399|Drug|Rifampicin|Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.
76080916|NCT05807399|Drug|Isoniazid|Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.
76080917|NCT05807399|Drug|Pyrazinamide|Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.
75640964|NCT04004962|Device|Infrared spectroscopy|Infrared spectroscopy
75640965|NCT00719563|Drug|American ginseng|Given orally
75640966|NCT00719563|Other|placebo|Given orally
76080918|NCT05807399|Drug|Moxifloxacin|Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2, and 400 mg orally once daily in arm 4.
76080919|NCT05807399|Drug|Bedaquiline|Bedaquiline will be dosed as 200 mg orally once daily for the first 8 weeks, thereafter 100 mg once daily in arm 4.
76080920|NCT05807399|Drug|Delamanid|Delamanid will be dosed as 200 mg orally once daily in arm 4.
76080921|NCT05806177|Drug|AD16 30mg、40mg|AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
76080922|NCT05806177|Drug|AD16 Placebo 30mg、40mg|AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
76080923|NCT05802056|Biological|Aldesleukin|Given IP
76080924|NCT05802056|Procedure|Biopsy|Undergo biopsy
76080925|NCT05802056|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
75789477|NCT02935478|Device|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
75789478|NCT03759158|Drug|N-Acetyl Cysteine|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
75925757|NCT05509426|Behavioral|Cognitive Rehabilitation|This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
75332595|NCT05604092|Other|Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|It includes the Symbol Digit Modalities Test (SDMT) for evaluating the information processing speed, the California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory, and the Brief Visual Memory Test (BVMT) for evaluating visual learning and memory. Cut off values were calculated as 1.5 SD below mean according to a group of healthy individuals who are matched in age, sex and education as following: 22 for SDMT, 38 for CVLT, and 10 for BVMTR
75332596|NCT02999438|Device|Actigraph to check activity levels at home|
75332597|NCT01016483|Drug|Pimasertib|
75332598|NCT01016483|Drug|Gemcitabine|
75332599|NCT01016483|Drug|Placebo|
75332600|NCT05603936|Other|Questionnaire|"The original QOLISSY questionnaire was first developed in 2011, it is available as a patient reported and a parent reported instrument. It includes:~QoLISSY questionnaire for children and adolescents (8-12, 13-18 yrs)~QoLISSY questionnaire for parents of children with short stature (4-7, 8-12 and 13-18 yrs) The QoLISSY instrument can be used to assess the health-related quality of life in short stature youth regardless of its cause; however it was specifically developed for patients with GHD and ISS and their parents.The aim of the current study is the adaption, implementation and validation of the instrument for the investigation of the short stature specific quality of life (QoLISSY) for children (age 0-4 years) with achondroplasia (ACH), Small for Gestational Age (SGA) and Growth Hormone Deficiency (GHD) from a parental perspective."
75332601|NCT04123730|Other|Fixed-dose compared to variable oxygen flow supplementation during walking|"At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT"
75332602|NCT05603780|Behavioral|exploratory protocol|physiological and cognitive evaluations
75640967|NCT04110184|Other|Systemic lupus erythematosus disease activity index (SLEDAI)|The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease
75640968|NCT02604316|Other|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.
75640969|NCT02604316|Other|Beta- Glucan|10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
76080926|NCT05802056|Procedure|Computed Tomography|Undergo PET/CT
76080927|NCT05802056|Procedure|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
75332603|NCT02569476|Drug|Zanubrutinib|
75332604|NCT02569476|Drug|Obinutuzumab|
75789479|NCT03759158|Drug|Placebo Oral Tablet|Placebo Oral Tablet twice daily.
75789480|NCT03756584|Device|Theta-burst stimulation|iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)
75789481|NCT03765086|Procedure|Karydakis procedure|Pilonidal sinus will be excised by Karydakis procedure
75789482|NCT03765086|Procedure|Limberg Flap|Pilonidal sinus will be excised by Limberg Flap
76080928|NCT05802056|Drug|Fluorouracil|Given IV
76080929|NCT05802056|Drug|Leucovorin Calcium|Given IV
75789483|NCT00025506|Other|Laboratory Biomarker Analysis|Correlative studies
75789484|NCT00025506|Drug|Thalidomide|Given orally
76080930|NCT05802056|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
76080931|NCT05802056|Biological|Nivolumab|Given IV
76080932|NCT05802056|Drug|Oxaliplatin|Given IV
75332605|NCT04123028|Other|observatory|observation for 1 year period
75471142|NCT01949350|Dietary Supplement|Carbohydrate protein|Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
75471143|NCT01949350|Dietary Supplement|Starved|Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
75925758|NCT02180529|Drug|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.
76080933|NCT05802056|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MRI
76080934|NCT05797831|Drug|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
76080935|NCT05797831|Drug|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
76080936|NCT05795842|Device|wearable wristband model|MOTO 360 smartwatch: is a specific consumer wearable wristband model (Motorola: MOTO 360), fitted with proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting. The device is not a medical or diagnostic device, but rather a photoplethysmography (PPG) data collection device. PPG is a non-invasive technology that uses light to measure the change in the volume of blood beneath the skin that occurs as the heart beats. LifeQ has developed software that enables the collection of vital signs data from PPG technology.
75332606|NCT00963677|Procedure|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
75332607|NCT05603234|Behavioral|Symptom Monitoring|Reporting symptoms each day via a symptom questionnaire
75640970|NCT00795184|Device|Imaging procedures (NBI)|"Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites."
75789485|NCT03756428|Procedure|Deep dry needling in tibialis posterior|The inspector, with gloves, disinfects the area to be treated with 70º alcohol. Once the alcohol is applied, the intervenor locates and takes the myofascial trigger point and places the needle with the guide tube resting on the skin of the patient. The inspector holds the guide tube between the index and middle fingers lightly touch the needle with the index finger of the other hand to insert the needle perpendicularly into the skin, directing it towards the inspector's thumb. Once the needle is inserted subcutaneously, the guide tube is removed. The controller deepens the needle to myofascial trigger point, and makes fast inputs and outputs into it. The rapid exit is made to the subcutaneous cellular tissue, outside the muscle, but not outside the skin. Next, hemostasis is performed in the area. Once this hemostasis is completed, the patient is incorporated and dressed.
75789486|NCT03756428|Procedure|Sham technique in tibialis posterior|The patient lies on the stretcher without the trousers. The interventor, with the guide tube, simulates the technique of puncture in the right twin of the subject. The comptroller cleans the area with 70º alcohol. Once the alcohol is applied, he performs the simulated dry needling technique in a plane with his index and middle fingers with the guide tube. It is important that the subject has his head stuck in the hollow of the head of the stretcher throughout the technique to make a correct masking.
75789487|NCT05461040|Procedure|optic capture|optic capture of Intraocular lens without anterior vitrectomy
75789488|NCT05461040|Procedure|In-the-bag implantation of Intraocular lens|in-the-bag implantation of Intraocular lens with anterior vitrectomy
75789489|NCT00024258|Drug|arsenic trioxide|
75789490|NCT03756272|Procedure|Bupivacaine block|stellate ganglion bupivacaine injection
75789491|NCT03756272|Procedure|Placebo ganglion block|stellate ganglion sodium chloride injection
75925759|NCT02180529|Drug|Placebo|
75332608|NCT04393064|Device|fiberoptic endoscopic evaluation of swallowing|"intreventions name :-Fiberoptic endoscopic evaluation of swallowing(FEES) will be performed on all infants enrolled in this study.~interventions type: flexible nasopharyngeal laryngoscope 3,5 mm in size with portable camera & light source & video recording system will be used. Procedure will be done without anesthesia~."
75925760|NCT04412122|Other|Kinesio Taping|In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
75332609|NCT00955253|Drug|Guanfacine|2mg oral guanfacine (encapsulated)
75332610|NCT00955253|Drug|Placebo|placebo
75471144|NCT01949363|Drug|Cefixime|Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
75471145|NCT01949402|Other|Computed Tomography|"The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.~Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study visit."
75471146|NCT01949402|Other|Thoracic ultrasound|The ultrasound will be performed by a single operator. The patient's position will ideally be with the patient sitting up at 45°. Ultrasound images and clips will be recorded at 10 points over each hemithorax - the 2nd, 4th and 6th intercostal spaces (ICS) in the mid-clavicular line; the 2nd, 4th and 6th ICS in the mid-axillary line; and the 2nd, 5th, 7th and 9th ICS posteriorly. Ultrasound estimation of the height of the right internal jugular vein will be undertaken. Central venous pressure will be calculated by adding 5cm. Inferior vena cava diameter will also be measured at end-inspiration and expiration. The time taken to perform each ultrasound will be recorded. Control, COPD and ILD groups will be scanned on a single occasion. Haemodialysis group will have 4 scans.
75640971|NCT00795184|Device|HDWLE|
75640972|NCT00795184|Device|pCLE|
76080937|NCT05795842|Device|Standard of care extended ECG monitoring|Participants enrolled in the study are prescribed ambulatory ECG monitoring (Mobile Cardiac Outpatient Telemetry, Biotel e-Patch, or LINQ insertable cardiac monitor). If the patient is negative for Afib during their time wearing an ECG monitoring patch, then patients may proceed with LINQ insertable cardiac monitor, as part of their standard of care. These are standard-of-care FDA-approved devices and detection software. Researchers will rely on the final ECG report to identify arrhythmic events to use as a golden standard to evaluate the algorithm findings. Specifically, the raw data will be used for establishing and getting an accurate ground truth for the algorithm.
76080938|NCT05792787|Diagnostic Test|Echo-color-doppler|"To perform the initial screening patients will undergo panoramic radiography and clinical examination followed by periapical radiographs of the teeth suspected of AP using the long cone paralleling technique with a film holder. The following parameters will be recorded:~The number of decayed, missing and filled teeth (DMFT index)~The number of teeth with AP~Periapical Index Score All individuals will undergo a cardiovascular examination in the Unit of Vascular Surgery, University of Siena (Siena, Italy). The cardiovascular assessment included physical examination, blood pressure measurement, past medical history and echo-color-doppler for the assessment of carotid intima-media thickness (cIMT), presence of abdominal aortic aneurysm and presence of peripheral pulses."
76080939|NCT05792319|Diagnostic Test|24 hour copper in urine and liver function test|sampling 24 hour copper in urine and liver function test
75332611|NCT04392986|Other|Sunlight exposure|The weather was sunny and found suitable for outside activity and sunlight exposure program, with a mean temperature of 27.0-28.5 °C, the humidity of 64-80%, and global solar exposure of 1.28 to 2.99 MJ/m2 during treatment.[15] Participants were asked to lie on the beach for 45 minutes per day between 2 to 3 pm to avoid extreme skin irritation and sunburn from direct sunlight exposure.
75925761|NCT04412122|Other|Breathing Exercise|Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
75925762|NCT04412122|Other|Kinesio Taping+Breathing Exercise|In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
75640973|NCT00915226|Procedure|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
76080940|NCT05791695|Other|Non Applicable|No study-specific interventions for this observational study.
75640974|NCT00915226|Procedure|Squatting|Squatting
75789492|NCT01321658|Other|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
75789493|NCT03756194|Device|Socially-assistive Pepper robot with a CARESSES cultural competence solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. The robot will be culturally aware i.e., it will be aware of the participants' cultural background prior to the testing commencing. As such, it will pre-load the appropriate CKB and apply this during its time with the participants. During the next two sessions, the robot will interact and provide culturally-competent assistance, however, it will not learn and adjust to the participants' individual cultural values and preferences.~Week 2. The participants will again utilize the robot for three days, but it now will learn from the responses it receives from them, consequently interacting in a culture-specific personalised way."
75798761|NCT05597566|Procedure|modified electroconvulsive therapy|The patient underwent MECT therapy. The treatment instrument is Xingmaitong IV ECT multifunctional treatment instrument (USA, SOMATICS THYMATRON company), fasting for 6 hours before surgery, emptying urine. Routine preoperative preparations were made, followed by intravenous injection of atropine, propofol, and succinylcholine chloride injection, artificial respiration, placement of dental pads, and electroconvulsive therapy. The whole process is completed by an anesthesiologist and a therapist in cooperation with each other. The first 3 times are once a day, and the next 5 times are once every other day. A total of 8 courses of treatment.
75640975|NCT02589925|Device|Vercise deep brain stimulation|implantation of a Vercise neurostimulation system
75925763|NCT04412122|Other|Control Group|No intervention was performed to reduce pain in the control group.
75640976|NCT02589925|Procedure|subthalamic nucleus (STN) stimulation|bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
75640977|NCT02589925|Procedure|NBM stimulation|bilateral low-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
75640978|NCT02589925|Procedure|sham stimulation|ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
75332612|NCT00963911|Other|Geriatric screening tests|"The G-8 consists of eight items: patient age (>85, 80-85, <80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with lower scores indicating a higher risk of impairments. The cut-off value for an 'impaired' reference test score was <=14 and the time taken to complete the test was recorded.~VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For three pre-identified centers, patients also filled in the questionnaire at the following geriatric visit. VES-13 consisted of four groups of questions: age, self-perceived health, difficulties to perform six specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score >=3 was considered to show impairment."
75640979|NCT02589769|Other|unsaturated fat for saturated fat|Substituting unsaturated fat for saturated fat
75640980|NCT02589769|Other|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
75925764|NCT02178189|Other|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
75925765|NCT02178189|Other|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
75925766|NCT03323216|Diagnostic Test|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the CRT implantation and 6 months after the CRT implantation."
75925767|NCT03323216|Diagnostic Test|Study specific questionnaire|"Study specific questionnaire~The questionnaire is performed prior the CRT implantation and 6 months after the CRT implantation."
75925768|NCT03323216|Procedure|Blood collection|"Blood collection during surgery:~coronary sinus~arterial~peripheral venous~Blood collection 6 months after surgery:~- peripheral venous"
76080941|NCT05787743|Other|Facial cream with 2% palm tocotrienols extract|Apply on the face twice a day
76080942|NCT05787743|Other|Base cream|Apply on the face twice a day
75640981|NCT05292859|Biological|Neoantigen specific TCR-T cell drug product|No study drug is administered in this study. Patients who have received Neoantigen specific TCR-T cell drug product will be evaluated in this trial for long-term safety and efficacy
75640982|NCT02589457|Drug|CKD-390|Tenofovir Disoproxil Aspartate 1T PO
75640983|NCT02589457|Drug|Viread® tablet|Tenofovir Disoproxil Fumarate 1T PO
75640984|NCT03941353|Other|Usual care|Benchmark study with retrospective patient analysis evaluating the actual care patients with a fragile hip fracture receive
75640985|NCT00718861|Drug|Placebo|
75640986|NCT00718861|Drug|Zoledronic acid|
75789494|NCT03756194|Device|Socially-assistive control Pepper robot with an alternative CARESSES solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. During the next two sessions, the CARESSES control robot will not be culturally aware: it will pre-load a generic and more limited CKB that is not tailored for anyone's cultural profile. It will also not learn and adjust to the participants' values and preferences.~Week 2. Participants will again utilize the robot for three days, but the CARESSES control robot will now be configured to be able to learn and adapt to the individual's particular profile. This robot's learning will not include propagation: improving its cultural knowledge base in one area will not also automatically lead to knowledge improvements in other related areas. This robot will possess the same full suite of functions as the CARESSES robot although will be less likely to offer these in a culturally appropriate way."
75789495|NCT03759080|Procedure|mental practice|training of mental practice to do the pattern of proprioceptive neuromuscular facilitation
75789496|NCT03759080|Procedure|proprioceptive neuromuscular facilitation|upper limb Pattern: Flexion -Abduction- External rotation
75925769|NCT02182791|Drug|Nevirapine|
75925770|NCT02182791|Drug|EE/NET|
75925771|NCT03329144|Behavioral|Cognitive Behavioural Therapy|The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
76080943|NCT05787041|Other|high-fat diet group（AD16 20mg）|AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
76080944|NCT05787041|Other|fasted group（AD16 20mg）|Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
76080945|NCT05787028|Drug|AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Take one AD16 tablet in the morning
75640987|NCT02589613|Dietary Supplement|tap water|300ml tap water via nasogastric tube
75640988|NCT02589613|Dietary Supplement|Glucose|300ml tap water with 75g Glucose via nasogastric tube
75640989|NCT02589613|Dietary Supplement|Fructose|300ml tap water with 25g Fructose via nasogastric tube
75640990|NCT05310643|Drug|Nivolumab|"Induction therapy with nivolumab 240 mg; 4 infusions, every 3 weeks.~Maintenance therapy with nivolumab 480 mg; 21 infusions, every 4 weeks."
75640991|NCT05310643|Drug|Ipilimumab|Induction therapy with ipilimumab 1 mg/kg; 4 infusions, every 3 weeks.
75640992|NCT05257213|Drug|Heparin solution|3 ml saline solution containing 5000 IU heparin.
75640993|NCT05257213|Drug|Anti-adhesion barrier gel|2 ml biodegradable barrier gel containing sodium hyaluronate (10 mg/ml), sodium chloride (8.5 mg/ml), disodium hydrogen phosphate (0.34mg/ml), sodium dihydrogen phosphate (0.14 mg/ml) and water for injection (QS to weight).
75640994|NCT04086199|Procedure|Lumbar discectomy|Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.
75640995|NCT00918697|Procedure|Mechanical debridement|For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
75789497|NCT03765008|Other|Water intake manipulation|for 5 days prior to each experiment subjects will undergo manipulation of their water intake.
75789498|NCT03756116|Procedure|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
75925772|NCT03329066|Behavioral|MAST - Managing Asthma & Sleep in Teens|This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
75925773|NCT03329066|Behavioral|ASMA - Asthma Self-Management for Adol|This behavioral intervention focuses only on asthma care.
75925774|NCT03329066|Behavioral|Information & Referral Control Group|Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
75925775|NCT03536325|Drug|Guselkumab Dose 1|Participants will receive Dose 1 of guselkumab on Day 1.
75925776|NCT03536325|Drug|Guselkumab Dose 2|Participants will receive Dose 2 of guselkumab on Day 1.
76080946|NCT05787028|Drug|AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Participants will take a placebo pill matching AD16 once in the morning
76080947|NCT05785806|Behavioral|Skin to skin contact and co-parenting theory course|On the day before delivery, pregnant women and their husbands attend a course on the theory of skin contact and co-parenting to explain the role and importance of skin contact ; to understand the knowledge of co-parenting and parenting care ; to learn the communication method and future parenting plan based on the theory of co-parenting, and to learn the operation of skin contact with newborns after delivery.
75640996|NCT00918697|Procedure|Alcohol-assisted debridement|For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
75789499|NCT03756116|Procedure|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
75640997|NCT05325697|Combination Product|Intervention consisting of a multicomponent exercise program combined with an oral nutritional supplement|The multicomponent exercise program to prevent frailty and risk of falls (Vivifrail) was developed by a European expert group co-funded by the ERASMUS+ programm of the European Union. The program consists of a screening and a subsequent 12-week exercise program. The screening classifies individuals into four categories: disabled, frail, pre-frail, or robust and the difficulty of the program's exercises is adapted to the categories and it includes endurance, balance, and resistance training as well as stretching exercises. This exercise program will be combined with an oral nutritional supplement (Moltein®Plus), which was specifically designed to promote muscle health in elderly people. Moltein®Plus is completely balanced oral nutrition supplement made from whey protein fortified with leucine. Enriching dietary protein with leucine allows to maximize muscle protein synthesis rates without calling for very high protein doses, which are difficult to ingest for older individuals.
75640998|NCT00918853|Procedure|resection of adenocarcinoma of the head of the pancreas|quality standard for the resection of adenocarcinoma of the head of the pancreas
75789500|NCT00023712|Drug|bortezomib|Given IV
75640999|NCT02589223|Other|Multisensory Stimulation|Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
75789501|NCT00023712|Other|laboratory biomarker analysis|Correlative studies
75641000|NCT02589223|Other|Control|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
75789502|NCT00023712|Other|pharmacological study|Correlative studies
75789503|NCT00023322|Drug|Peginterferon Alpha-2a|Treatment
75789504|NCT04640168|Drug|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name [1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
75789505|NCT04640168|Drug|Dexamethasone|Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.
75925777|NCT03536325|Drug|Guselkumab Dose 3|Participants will receive Dose 3 of guselkumab on Day 1.
76080948|NCT05785806|Behavioral|Skin to skin contact instruction manual and co-parenting theory brochure|According to reading and analyzing the literature on skin contact, summarize the content of skin contact operation guidance ; read and analyze the relevant literature of co-parenting theory, and summarize the theoretical knowledge and practical operation methods of co-parenting. Pregnant women and their spouses can check in time.
75789506|NCT04640168|Other|Placebo|Placebo matching oral baricitinib or intravenous dexamethasone.
75789507|NCT04640168|Drug|Remdesivir|Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
75789508|NCT00022698|Drug|Capecitabine|
75789509|NCT00022698|Drug|Irinotecan|
75789510|NCT03951402|Drug|100 mg CG5503 (tapentadol hydrochloride) PR tablet|100 mg CG5503 (tapentadol hydrochloride) PR tablet.
75789511|NCT03951402|Drug|Placebo matching CG5503 PR tablet|Matching placebo tablet to CG5503 PR tablet.
75789512|NCT03951402|Drug|Placebo matching moxifloxacin capsule|Matching placebo capsule to moxifloxacin capsule.
75789513|NCT03951402|Drug|400 mg Moxifloxacin tablet (overencapsulated)|Overencapsulated 400 mg Moxifloxacin tablet.
75789514|NCT03948828|Biological|Autologous NK cell therapy|After conventional treatment, the patients were treated with autologous NK cells.
75925778|NCT03536325|Drug|Placebo|Participants will receive matching placebo on Day 1.
75925779|NCT03536637|Drug|DMT310|Topical Powder
75925780|NCT03536637|Drug|Hydrogen Peroxide|Liquid Diluent
75925781|NCT03536637|Drug|Placebo|Placebo Topical Powder
75925782|NCT02488538|Drug|Combined oral contraceptives|Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation
75925783|NCT02488538|Drug|Fluoxetine|women will receive oral fluoxetine 20 mg daily
75925784|NCT02488538|Drug|Combined oral contraceptives placebo|women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
75925785|NCT02488538|Drug|Fluoxetine placebo|women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
76080949|NCT05785806|Behavioral|Daily face-to-face skin to skin contact guidance during hospitalization|After delivery, face-to-face skin-to-skin contact guidance and co-parenting communication and practice were given to the parturient and her husband on a daily basis during hospitalization. Establish a daily fixed skin contact duration target, and the specific operation is freely allocated by both parents.
75471147|NCT01949402|Other|Spirometry|All participants in the study will undergo basic spirometry as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
75789515|NCT03948828|Drug|GnRHa combained with reverse addition therapy|Postoperative patients were treated with GnRHa combined with reverse addition treatment.
75471148|NCT01949402|Other|Blood tests|All participants in the study will undergo blood tests as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
75641001|NCT05253391|Other|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
75925786|NCT02488538|Procedure|Daily record of severity of problems|Women will record their symptoms daily using the daily record of severity of symptoms.
75641002|NCT05684731|Biological|KM1|Administer via intraperitoneal infusion for 3 or 6 doses Q3D.
75925787|NCT02180685|Other|Anchor fixation|
75641003|NCT05684731|Drug|Chemotherapy|"Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6."
75641004|NCT05184907|Behavioral|Remote Motivational Enhancement (RME) Intervention Arm|Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing within 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
75641005|NCT05184907|Other|Information Only|Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
75789516|NCT03764852|Procedure|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.
75789517|NCT03764852|Procedure|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy without robotic assistance.
75789518|NCT03948750|Procedure|Aqueous humour sampling|Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting
75789519|NCT03755960|Procedure|acupuncture|semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
75789520|NCT03755960|Drug|routine care|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
75925788|NCT04492826|Procedure|Postoperative infections rate|Assess the postoperative infection rate after otolaryngology bone flap surgery.
75925789|NCT02568046|Drug|Sym004|Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
76080950|NCT05785806|Behavioral|Online punching skin to skin contact|Share common parenting related knowledge, daily skin contact reminders, emphasize mutual recognition and mutual support of parents, and conduct WeChat follow-up every two weeks to understand the physical and mental status of both parties and the growth of infants.
76080951|NCT05785806|Behavioral|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
75789521|NCT03948594|Dietary Supplement|resource|1 packet resource(237ml), 1.05kcal/ml, 53.6g carbohydrate and 9g protein
75789522|NCT03948594|Other|plain water|250ml plain water
75789523|NCT03759002|Diagnostic Test|Imaging|Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
75789524|NCT03759002|Other|Blood sampling|Blood sampling will performed on all participants for measuring hematological parameters including MPV.
75925790|NCT02568046|Drug|FOLFIRI|The standard FOLFIRI regimen consists of Irinotecan (180 mg/m^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m^2 IV bolus, then 2400 mg/m^2 infused over 46 hours).
75925791|NCT02180763|Biological|Gammanorm|Sub-Q IgG
75925792|NCT02488460|Behavioral|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
75925793|NCT03536481|Drug|ensartinib capsules (test product)|Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
75925794|NCT03536481|Drug|ensartinib capsules (reference product)|Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
76080952|NCT05782244|Drug|Sildenafil Citrate low dose|Sildenafil citrate 20 mg, oral, TID
75471149|NCT01949441|Biological|ToleroMune HDM|Intradermal injection 1 x 4 administrations 4 weeks apart
75471150|NCT01949441|Biological|Placebo|Intradermal injection 1 x 4 administrations 4 weeks apart
75471151|NCT01949454|Drug|Fluorometholone 0.1% ophthalmic solution|
75471152|NCT01949454|Other|Artificial tears (Placebo)|Artificial tears (Placebo)
75925795|NCT02488616|Other|5-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days."
75332613|NCT00963911|Other|Multidimensional geriatric assessment|Patients underwent a geriatric evaluation in the month following the completion of G8 and VES-13 (+/- seven days) before treatment began. The nurse completed six of the seven instruments of the MGA (MNA, Timed Get up and Go (TUG), Activities of Daily Living (ADL), Instrumental ADL (IADL), Mini Mental State Examination (MMSE), and Geriatric Depression Scale (GDS-15)), and the geriatrician rated comorbidity on the Cumulative Illness Rating Scale (CIRS-G), recorded the time required for the consultation, identified patients who needed personalized geriatric interventions, and, if necessary, proposed further geriatric evaluation (outside of the scope of this study).
75332614|NCT04123106|Procedure|ESP block|ESP block bilaterally performed at the level of the surgical site prior to surgery.
75332615|NCT04123106|Procedure|Wound infiltration|Wound infiltration performed at the surgical site at the end of surgery.
75332616|NCT04079504|Procedure|Ligation of indirect hernia sac|Indirect inguinal hernia sac will be separated from the spermatic cord and contents of the sac will be reduced before ligating it at the deep inguinal ring.
75471153|NCT01949467|Drug|iron fumarate|All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
75641006|NCT02591407|Procedure|TAP Block|This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
75641007|NCT02591407|Procedure|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion
75641008|NCT04085965|Behavioral|Boys and Girls Club summer day camp|Daily camp activities included sports, games, obstacle courses, swimming and boating, summer learning and arts and crafts. Lunch was served daily via the USDA's Summer Food Service Program.
75641009|NCT02589301|Biological|Pegfilgrastim|
75641010|NCT01016600|Drug|Lenalidomide|
75641011|NCT01016600|Drug|Azacitidine|
75641012|NCT04084405|Other|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
75641013|NCT05175235|Device|CURATE.AI|Efficacy and toxicity measurements at the end of each two-/three- week dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of nivolumab/pembrolizumab for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
75641014|NCT05175235|Drug|Nivolumab, Pembrolizumab|Treatment with the selected regimen will take up to a maximum duration of 12 months, in two-/three- week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; Maximum total cumulative dose per cycle of nNivolumab/pembrolizumab in the predetermined safety range is set at 100% of standard starting dose (i.e. , 240 mg/m2 once every 2 weeks for single agent Nivolumab and 200 mg/m2 once every 3 weeks for single agent Pembrolizumab). Minimum total cumulative dose per cycle of nivolumab/pembrolizumab in the predetermined safety range is set at 30% of the standard starting dose (i.e. 8072 mg/m2 once every 2 weeks for single agent Nivolumab and 60 mg/m2 once every 3 weeks for single agent Pembrolizumab). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
75641015|NCT01016132|Device|lotrafilcon A contact lens|Investigational silicone hydrogel, single-vision, soft contact lens worn for four weeks at least as often as and on the same basis as participant's habitual lenses, as prescribed by participant's eye care practitioner -- ie., on a daily wear, flex wear, or extended wear basis.
75789525|NCT01100580|Dietary Supplement|low salt diet|Daily salt intake less than 4 g/day
75789526|NCT01100580|Dietary Supplement|water therapy|abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
75789527|NCT03948360|Device|Low-Irradiance Monochromatic Biostimulation (LIMB) Device|The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.
75789528|NCT03948360|Other|Standard of Care|Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.
75925796|NCT02488616|Other|5-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.~Participants will have been previously shown how to use the study insulin pump."
75471154|NCT01949493|Device|mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
75925797|NCT02488616|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
75925798|NCT02488616|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
75925799|NCT02488616|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
75925800|NCT05094219|Other|No intervention will be offered|No intervention will be offered
75925801|NCT03323138|Procedure|Ex-PRESS and phacoemulsification|
75925802|NCT03323060|Device|Transanal endoscopic surgical procedure|Resection of tumors or lesions
76080953|NCT05782244|Drug|Placebo|Placebo, oral, TID
75332617|NCT04079504|Procedure|Non-ligation of Indirect Inguinal hernia sac|the indirect inguinal hernia sac will be separated from the spermatic cord and reduced/inverted in to the peritoneal cavity through the deep inguinal ring along with its contents.
75332618|NCT00963989|Device|Penumbra System|The Penumbra System is used to revascularize clotted cerebral blood vessels.
75641016|NCT01015820|Procedure|EGD with EUS|EUS was performed in order to measure blood flow in duodenum.
75641017|NCT01015820|Device|4D-ELF|During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
75332619|NCT05609006|Dietary Supplement|High-Energy, Low-Volume ONS|2 bottles/day of a High-Energy, Low-Volume ONS
75641018|NCT04297670|Other|Measurement of HPV types prevalence|Self collected genital samples to be tested for the presence of different HPV types.
75471155|NCT01949493|Other|Care as usual|Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
75641019|NCT00628004|Device|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
75641020|NCT00628004|Device|Local best practice|"N/A - since intervention is local best practice"
75641021|NCT04298684|Drug|METFORMIN|"After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control. In case of intolerance, the tolerated and effective dose will be taken back provided an effective glycemic control.~A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced."
75641022|NCT04298684|Drug|Sitagliptin|"After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced."
75641023|NCT04298294|Other|injectable platelet rich fibrin|biologic activator
75641024|NCT02871674|Behavioral|Good Night Project|The behavioural interventions have been designed on the basis of three sources. Firstly, a systematic review conducted by the research team that examined the best evidence in the field in different countries. Secondly, a Delphi study, which aimed to identify behavioural interventions that can be used to manage sleep difficulties in Saudi Arabia in accordance with professionals' views and primary caregivers' needs, and which was also conducted by the research team. Thirdly, evidence-based practice resources that help in understanding and managing sleep difficulties will be translated into Arabic.
75789529|NCT03949608|Other|E-learning|"The intervention consists of the presentation and installation of an internet tool to educate the patient about his heart condition and about his medications in addition to usual care. The tool is an interactive web-hosting video called Mon Coeur, mon BASIC adaptable to smartphones and tablets. The total length of the video is around 15 minutes. The e-learning is interactive because of the possibility to click in the video to have more details about a particular point. The tool includes a part about the heart and particularly about the ACS (physiopathology, diagnosis, coronarography, angioplasty). A second part includes an education about the medications prescribed. The patient will select the medication being prescribed and receive information about it."
75641025|NCT00628472|Drug|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
75789530|NCT01100736|Drug|Bosentan|Bosentan 125mg tablets, orally, twice daily for 7 days
75641026|NCT04298372|Drug|Lenalidomide 25mg|"As single arm study, patients will be treated as follows:~Lenalidomide : D1~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg.~Dexamethasone : D1~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted."
75641027|NCT04424888|Other|WB-011|WB-011 medical food product.
75789531|NCT01100736|Drug|Sitaxsentan|Sitaxsentan 100mg tablets, orally, once daily for 7 days
75925803|NCT03328910|Device|SPI monitor (GE Healthcare, Helsinki, Finland)|The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
75925804|NCT02256423|Drug|REFERENCE 1: Nurofen® 200 mg tablet|
75925805|NCT02256423|Drug|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|
75925806|NCT02256423|Drug|ibuprofen 200 mg soft gel capsule|
75925807|NCT03322982|Behavioral|Low-fat diet|less than 20% calories from fat daily
76080954|NCT05782244|Drug|Sildenafil medium dose|Sildenafil 40 mg, oral, TID
75641028|NCT04424888|Other|Placebo|Placebo Capsules identical to those containing WB-011.
75641029|NCT04424888|Device|Continuous Glucose Monitor|Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
75789532|NCT01100736|Drug|Placebo|Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
75925808|NCT05141097|Other|Integrative medicine approach|By treated by integrative medicine approaches instead of conventional medicine
75925809|NCT02185677|Other|Clinical evaluation|
75332620|NCT05609006|Dietary Supplement|High-Energy Standard ONS|2 bottles/day of a High-Energy Standard ONS
75332621|NCT04394390|Dietary Supplement|vitamin d|vitamin D levels
75471156|NCT01949519|Drug|Lycopene and Docetaxel|During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
75471157|NCT01949558|Behavioral|Dietary Intervention|
75789533|NCT01100736|Biological|Endothelin-3|5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
75789534|NCT03947268|Radiation|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.
75789535|NCT01584726|Drug|Magnesium Sulfate|single dose of magnesium sulfate nebulization
75925810|NCT02185677|Other|neuropsychological battery test|
76080955|NCT05782244|Drug|Sildenafil high dose|Sildenafil 80 mg, oral, TID
76080956|NCT05778994|Device|INTORUS|Exercise protocol with intorus
76080957|NCT05777174|Drug|MB-102|130 mg administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30-60 seconds.
76080958|NCT05777174|Device|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements will be collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements will continue until the sensor no longer detects MB-102 in the body.
76080959|NCT05777031|Drug|Collagenase Clostridium Histolyticum (CCH)|Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
76080960|NCT05768841|Behavioral|mental health issues|survey on mental health issues in endurance athletes
76080961|NCT05768087|Radiation|Escalated proton therapy|According to allocated dose level: level 1-8, 69-90 Gy in 30 fractions of 2.3-3.0 Gy, to a subvolume of the radiation target
76080962|NCT05761860|Drug|OxyCODONE 5 mg Oral Tablet|Oxycodone 5mg oral administration
75332622|NCT05608928|Dietary Supplement|VSL#3|VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.
76080963|NCT05761860|Drug|OxyCODONE 2.5 mg Oral Tablet|Oxycodone 2.5mg oral administration
76080964|NCT05761860|Other|Placebo oxyCODONE Oral Tablet|Oxycodone 0mg (placebo) oral administration
76080965|NCT05761860|Drug|Oxytocin Nasal Spray (48 IU)|Intranasal oxytocin administration (48 IU)
76080966|NCT05761860|Other|Placebo Oxytocin Nasal Spray|Intranasal oxytocin placebo administration
75641030|NCT01010204|Drug|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
75332623|NCT05608928|Device|Capscan device|"The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body."
75332624|NCT05608928|Combination Product|Placebo|microcrystalline cellulose
75332625|NCT05608850|Other|Exercise Then Stretch|This arm (sequence) will perform an anti-gravity kinetic chain intervention and then a passive, partner-assisted stretching intervention, separated by a one-week washout period.
75332626|NCT05608850|Other|Stretch Then Exercise|This arm (sequence) will perform a passive, partner-assisted stretching intervention and then an anti-gravity kinetic chain intervention , separated by a one-week washout period.
75332627|NCT01016873|Device|IRay|Low voltage stereotactic radiotherapy system
75332628|NCT04120454|Biological|Pembrolizumab|Given IV
75332629|NCT04120454|Biological|Ramucirumab|Given IV
75789536|NCT01584804|Drug|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
75789537|NCT01584804|Drug|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
75789538|NCT01105494|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
75789539|NCT06159582|Behavioral|eSTEP|eSTEP (Electronic Support to Engage with PrEP) is an mHealth intervention to promote engagement on the full PrEP care continuum and is tailored to the unique needs of GBMSM and TW. eSTEP is a mobile app (eSTEP) intervention with interactive components delivered before in-person HIV testing and PrEP initiation visit and interactive components delivered after PrEP is initiated.
75789540|NCT06159582|Behavioral|Usual Care|Usual HIV testing and PrEP clinical care
75789541|NCT06159530|Procedure|dental implants|4 dental implants placed in the mandible according to all-on 4 concept
75789542|NCT06159530|Procedure|peek framework|peek framework screwed to multi-unit abutments of 4-implants
75789543|NCT06159530|Procedure|visio-lign nano composite|peek framework veneered with nano composite (visio-lign) as an occlusal material
75789544|NCT06159530|Procedure|zirconia crowns|peek framework covered with zirconia crowns as an occlusal material
75789545|NCT06159504|Drug|sofosbuvir/velpatasvir (SOF/VEL)|400mg of SOF and 100mg of VEL self administered daily as a tablet.
75789546|NCT06159504|Diagnostic Test|Shortened read time of rapid diagnostic test for hepatitis C virus.|Administered once during hepatitis C testing. Test is read after 5 minutes rather than its usual time of 20 minutes.
75925811|NCT02185677|Other|MRI|
75925812|NCT02185677|Other|Actigraphy|Actigraphy recording will be performed during 7 days after inclusion.
75925813|NCT05464472|Device|Transcatheter Aortic Valve Implantation (TAVI)|Guideline/ FDA approved implantation of a Transcatheter Aortic Valve Implantation (TAVI)
75925814|NCT03320486|Drug|Dapaconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
75925815|NCT03320486|Drug|Ketoconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
75925816|NCT02180919|Device|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
76080967|NCT05759299|Procedure|Tracheal intubation|Advanced airway management with tracheal intubation performed after induction with hypnotic and/or opioid drugs and laryngoscopy
75332630|NCT03018431|Other|CT Scan|patients undergoing chest CT scan at admission and repeated lung ultrasonography
75641031|NCT01010204|Drug|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
75641032|NCT04296188|Procedure|serratus anterior plane block|ultrasound guided serratus anterior plane block will be done with % 0.25 bupivacaine.
75641033|NCT04296188|Procedure|erector spina plane block|ultrasound guided erector spina plane block will be done with % 0.25 bupivacaine.
75789547|NCT06159491|Drug|Pacritinib|Participants will take Pacritinib 100 mg - 200mg BID for each 28 day cycle
76080968|NCT05759052|Behavioral|self-administered questionnaire|Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
76080969|NCT05753800|Device|INTORUS|Motor intervention protocol with Intorus consisting of a series of exercises of progressive difficulty
76080970|NCT05744323|Other|Functional training|Physical and motor function training for children,may use BOSU balls, medicine balls, balance mats, fitness steps, and other training equipment to improve gradually
76080971|NCT05743582|Procedure|Bronchoscopy for sample collection|Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.
76080972|NCT05743582|Procedure|Blood donation|Participants will donate a single blood sample for isolation of immune cells from peripheral blood.
76080973|NCT05741034|Device|JUVÉDERM® VOLITE™|Injection, subdermal and/or intradermal
76080974|NCT05741034|Other|Control|No-treatment control
76080975|NCT05740046|Device|INTORUS|INTERVENTION PROTOCOL WITH INTORUS
76080976|NCT05733377|Diagnostic Test|Arrow Test|It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.
76080977|NCT05733377|Diagnostic Test|Angle measurement by imaging device|First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
76080978|NCT05726539|Behavioral|Group-based peer support|Receipt of semi-structured curriculum based group peer support that addresses common concerns of military spouses
75332631|NCT04122404|Diagnostic Test|LF-LAM|Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
75332632|NCT01017497|Radiation|Stereotactic Radiosurgery|PTV Diameter < 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
75332633|NCT01017653|Drug|Irinotecan|Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
75332634|NCT01017653|Drug|Panitumumab|Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
75332635|NCT00965237|Device|lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
75332636|NCT00965237|Device|lotrafilcon B single vision contact lens|Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use
75332637|NCT00965237|Other|Over-reader spectacles|Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
75641034|NCT00718549|Drug|Cladribine|Cladribine will be adminiatered at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4 of each 28-day cycle during induction phase.
75641035|NCT00718549|Drug|Cyclophosphamide|Cyclophosphamide will be administred at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.
75332638|NCT00966641|Drug|Naproxen|Single orally administered dose of 500 mg naproxen
75789548|NCT06159491|Drug|Azacitidine|Azacitidine 75mg/m^2 will be administered IV or SQ QD D1-7 of each 28 day cycle
75789549|NCT06159452|Drug|SAR153191-P3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
75789550|NCT06159452|Drug|SAR153191-P2 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
75789551|NCT06159452|Drug|SAR153191-C1F3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
75789552|NCT06159439|Diagnostic Test|Contrast enhanced ultrasound scan|Contrast enhanced ultrasound using Sonovue microbubble contrast
76080979|NCT05724784|Behavioral|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
76080980|NCT05714527|Device|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
75789553|NCT06159439|Diagnostic Test|MRI scan|Arterial-spin labelling magnetic resonance imaging
75641036|NCT00718549|Drug|Rituximab|Rituximab will be administered at a dose of 375 mg/m^2 as IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m^2 as IV infusion on Day 1 of Cycles 2-6 during induction phase. Rituximab will be administered at a dose of 375 mg/m^2 as IV infusion on Day 1 of each 12-week cycle during maintenance phase.
75641037|NCT00793624|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
75641038|NCT00793624|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
75641039|NCT00793624|Drug|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
75789554|NCT06159413|Device|VIRTUAL REALITY|LUMBAR MULTIFIDUS MUSCLES FUNCTION AMONG PATIENTS WITH LOW BACK PAIN: VIRTUAL REALITY VERSUS STABILIZATION EXERCISES.
75789555|NCT06159348|Diagnostic Test|Anemia Diagnostic Assistant (ADA)|The Anemia Diagnostic Assistant is non-invasive and simultaneously detects two markers of anemia, blood hemoglobin and the End-Tidal carbon monoxide levels. The device comprises an optical sensor module and ETCO breath sampling module.
75789556|NCT06159348|Diagnostic Test|Serum hemoglobin|Venous blood will be drawn on the same day as the ADA was applied and sent to the hospital lab for hemoglobin analysis.
75789557|NCT06159322|Drug|Olanzapine|Antipsychotic medication
75789558|NCT06159322|Drug|Clozapine|Antipsychotic medication
75641040|NCT00793624|Drug|Placebo|Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
75641041|NCT00793624|Drug|Placebo|Placebo for comparison Formoterolon safety and efficacy in COPD patients
75641042|NCT00919243|Drug|prednisone|1 mg/kg/day with a maximum dose of 60 mg/day given orally
75641043|NCT00919243|Drug|allopurinol|allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
75789559|NCT06159296|Device|Hydroxy gas|Hydroxy gas is a combination of hydrogen and oxygen together.
75789560|NCT06159283|Drug|Immunoglobulins|Dosage is Immunoglobulin 1,000mg/kg IV. It administer over 2~3 days.
75641044|NCT05236387|Drug|99m Tc-TM|Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.
75641045|NCT05160571|Device|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
75789561|NCT06159270|Other|Blood sample|Venuous blood sampling
75789562|NCT06159257|Diagnostic Test|Blood test|"Whenever possible, samples will be collected by the nurse in the patient's home, according to the study visit schedule. However, if this is not possible, patients will be asked to come in for sample collection at another mutually convenient time at the CERBA ALLIANCE LABORATORY closest to the patient's address.~Venous blood will be drawn on each visit."
75789563|NCT06159244|Other|stool withdrawal|stool withdrawal at day 0 and day 7
75789564|NCT06159218|Device|CEST - coiled oesophageal string test|All patients will swallow a small string (CEST) which will be removed and then analysed for biomarkers and microbiome.
76080981|NCT05714527|Device|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
75641046|NCT05225857|Drug|AGA2118|"Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC."
75641047|NCT05225857|Drug|Placebo|"Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC."
75789565|NCT06159205|Other|standard exercises|Standard exercises for TKA patients.
75789566|NCT06159205|Other|core stability exercises|Core stability exercises for TKA patients.
75789567|NCT06159166|Drug|Mirdametinib|This study is designed to assess Mirdametinib safety and efficacy in two phases: phase 1 tests the safety of up to four dose regimens of Mirdametinib, administered continuously or intermittently (3 weeks on/1 week off) to identify up to two recommended phase 2 doses. Phase 2a of the study will test the safety and efficacy of the recommended phase 2 dose(s) in adults with NF1 and cNF. The following dosing strategy will be assessed in participants ≥ 18 years old with NF1 and a minimum of 12 measurable cNF who desire systemic treatment of their cNF due to disfigurement, pain or itching. Each treatment cycle in this study is 28 days.treatment cycle in this study is 28 days.
75641048|NCT02589379|Procedure|Pancreatic Resection|Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
75641049|NCT04007068|Diagnostic Test|FDG PET/CT|FDG PET/CT baseline, month 1, month 4, month 10, than every 6 months
75789569|NCT06159140|Device|MRI|In vivo MRI
75789570|NCT06159127|Behavioral|SMART@Home|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
75789571|NCT06159114|Drug|Ningmitai capsule|Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
75789572|NCT06159114|Drug|Celecoxib capsule|Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.
75789573|NCT06159114|Drug|Ningmitai placebo|Ningmitai placebo, a look-alike substance that contains no active drug, similar to Ningmitai capsule in color, smell, taste, shape, texture and other characteristics, 0.38g/ capsule.
75789574|NCT06159114|Drug|Celecoxib placebo|Celecoxib placebo, a look-alike substance that contains no active drug, similar to Celecoxib capsule in color, smell, taste, shape, texture and other characteristics, 0.2g/ capsule.
75332639|NCT00966641|Drug|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
75332640|NCT02565576|Drug|Placebo|
75332641|NCT02565576|Drug|CFZ533|
75641050|NCT05612386|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
75641051|NCT00794950|Drug|Sunitinib|"Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.~Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy."
75789575|NCT06159101|Drug|HLX13|A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.
76080982|NCT05713123|Other|A SPECT-CT whole body is added in VERITON-CT camera|A SPECT-CT whole body in VERITON-CT camera is added after the conventional procedure recorded in Anger camera
75471158|NCT01949571|Drug|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
75641052|NCT02591173|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
75641053|NCT02591173|Drug|Saline|Normal saline will be used as the placebo comparator.
75641054|NCT02605330|Procedure|Fibrinogen plasma level|At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
75641055|NCT02590861|Procedure|Dental implant|All participants will receive the same intervention, this is a single group study.
75641056|NCT02604394|Procedure|Rheolytic Thrombectomy|"RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:~The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.~The disposable pump connects to a bag of heparinized saline.~The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,"
75641057|NCT02604394|Procedure|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
75641058|NCT00793546|Drug|Bosutinib|300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
75641059|NCT00793546|Drug|exemestane|25 mg tablet once daily
75789576|NCT06159101|Drug|CN-sourced ipilimumab|A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.
75789577|NCT06159101|Drug|EU-sourced ipilimumab group|A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.
75789578|NCT06159101|Drug|US-sourced ipilimumab group|A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.
75789579|NCT06159062|Drug|162|The investigational product 162 is a novel monoclonal antibody targeting HBsAg.
75789580|NCT06159062|Drug|Placebo|Placebo do not consist any active ingredients.
76080983|NCT05709002|Behavioral|MASP+|mHealth (mobile app) for smoking cessation
75471159|NCT01949584|Device|nasal continuous positive airway pressure less than or equal to 6 cm H2O|Low level continuous positive airway pressure delivered during sleep.
75471160|NCT01949597|Procedure|laparoscopic surgery for deep endometriosis|
75641060|NCT00793546|Drug|Exemestane|25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
75641061|NCT05607082|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
75641062|NCT04113460|Other|Yoga|Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
75641063|NCT02604238|Drug|Alteplase|Enoxaparin (1mg) 100UI aXa/kg/sc [LMWH], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing <50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
75641064|NCT04109092|Drug|E7766|E7766, solution, intravesically.
75641065|NCT00798694|Drug|Xalatan|one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
75471161|NCT01949610|Drug|14C-JNJ26489112|Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
75471162|NCT01949623|Other|Anterior Chamber (AC) tap|Aqueous Samples will be collected for measurement of biomarkers
75641066|NCT00798694|Drug|Travatan Z|one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
75641067|NCT00718315|Drug|erlotinib [Tarceva]|150mg po daily
75641068|NCT00718315|Drug|fusidic acid [Verutex]|topical, daily for 30 days.
75789581|NCT06159049|Diagnostic Test|68Ga-FAPI dimer(68Ga-LNC1013)|68Ga-LNC1013 was evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer.
75789582|NCT06159036|Device|Inertial Strength training|Low speed strength training with classic movements, derived from Olympic lifting and jumping
75789583|NCT06159023|Device|bronchial washing using a thin bronchoscope|For intervention, we plan to perform bronchial washing using a thin bronchoscope instead of bronchoalveolar lavage with the conventional thick bronchoscope to diagnose pulmonary TB.
75798762|NCT01179438|Drug|Dexmedetomidine|The loading does of 0.5 mcg/kg dexmedetomidine is infused over 10 minutes. The following maintenance does of dexmedetomidine is 0.5 mcg/kg/hour.
76080984|NCT05709002|Behavioral|Control|A mobile app designed to assist the general population with smoking cessation.
76080985|NCT05698940|Procedure|Infundibultomy|Infundibultomy on one side of patient
76080986|NCT05694312|Drug|Ibrutinib 420 mg|Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
75471163|NCT01949636|Other|Functional Magnetic Resonance Imaging|
75789584|NCT06158997|Device|EyePeace|EyePeace a commercially available for enhancing meibum expression. The flexible, handheld device is made of silicone and provides regulated vertical pressure on closed eyelids (https://www.eyepeace.de). EyePeace will be used to assess its usefulness in improving evaporative dry eye signs and symptoms.
75789585|NCT06158997|Device|Heated Eye Mask|Heated Eye Mask will be used once a day to assess its usefulness in improving evaporative dry eye signs and symptoms.
75641069|NCT00718315|Drug|erythromycin [Eritex]|topical, daily for 30 days.
76080987|NCT05693545|Drug|phenoxymethyl penicillin|Prophylaxis
75641070|NCT00718315|Drug|Fisiogel|topical, daily for 30 days
75641071|NCT00798304|Biological|meningococcal B rLP2086 vaccine|vaccination
76080988|NCT05693545|Drug|intramuscular benzathine penicillin G (BPG) prophylaxis|Prophylaxis
76080989|NCT05687305|Other|White Noise|White noise is produced by digitally combining sounds of equal frequency in the laboratory. Then, all of the frequencies in this sound are calibrated to generate noise at each frequency. If the contribution of each region to the noise level is the same, the noise is referred to as white noise. Waterfalls, ocean waves, and wind blowing through trees all produce similar to white noise. Patients in the intervention group are observed by the investigator on the 1st and 2nd postoperative days.Before going to sleep, a bluetooth headset will be used to listen to white noise for 30 minutes and vital signs will be measured before and after the procedure.
75789587|NCT06158958|Drug|ABBV-303|Intravenous (IV) Infusion
75789588|NCT06158958|Drug|Budigalimab|IV Infusion
76080990|NCT05685316|Device|COPLA® cartilage implant|In the investigation, the subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery of the knee with bone marrow stimulation.
75471164|NCT01949649|Behavioral|Peer-Led Group Intervention|
75471165|NCT01949649|Behavioral|Internet-Based Intervention|
75471166|NCT01949649|Behavioral|Clinician-Led Group Intervention|
75471167|NCT01949649|Behavioral|Education Video|
75789589|NCT06158945|Diagnostic Test|urinary endothelin 1|assesment of endothelin 1 in urinary sample
75789590|NCT06158932|Dietary Supplement|Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement|This product contains Myo-Inositol, D-Chiro-Inositol, Folate and Vitamin D.
75789591|NCT06158919|Drug|Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine|"Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w SOX : Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable."
75789592|NCT06158893|Drug|Salbutamol|inhalation anaesthesia
75789593|NCT06158893|Drug|Budesonide|inhalation anaesthesia
75789594|NCT06158893|Other|Saline|saline
75789595|NCT06158854|Drug|ABBV-383|Intravenous Infusion
75789596|NCT06158828|Drug|Rabbit Anti thymocyte globulin|rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.
75471168|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
75641072|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
75641073|NCT00798304|Biological|meningococcal B rLP2086 vaccine|vaccination
75641074|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
75641075|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
75641076|NCT04109872|Drug|Lenalidomide|Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
75641077|NCT00718237|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)|Rotateq orally administered 3 times
75789597|NCT06158828|Drug|Busulfan|Busulfan is administered intravenously either Q6H or Q24H, with a recommended target Busulfan AUC of 70-90 mg*h/L.
76080991|NCT05682339|Other|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
76080992|NCT05682339|Other|L-isoleucine|L-isoleucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
75641078|NCT00718237|Biological|Comparator: Comparator: Placebo (unspecified)|Placebo orally administered 3 times
75641079|NCT04109794|Procedure|E-CTG|Envelope connective tissue graft
75641080|NCT00793780|Drug|Naltrexone 25mg|Naltrexone 25mg caplets taken orally once a day for 8 weeks
75641081|NCT00793780|Other|Placebo|Placebo caplet (inactive substance) taken orally once a day for 8 weeks
75641082|NCT04109326|Other|APAD|"8 PA sessions supervised at the hospital centers and 44 unsupervised home sessions, to be performed twice a week.~6 consultations for nutrition education to teach the principles of well balanced diet, to foster weigh control during treatment, and to induce appropriate feeding behaviors after treatment."
75789598|NCT06158828|Drug|Fludarabine|Fludarabine is administered intravenously at a dose of 40 mg/m^2/dose once daily for 4 days.
75471169|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
75471170|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
75471171|NCT01949688|Biological|HLA-A*2402 or A*0201 restricted peptides|"Open Label, Non-Randomized, Safety/Efficacy study:~HLA-A*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.~HLA-A*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant."
75471172|NCT01949701|Biological|HLA-A*0201restricted URLC10 peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A*0201restricted URLC10 peptides with adjuvant.
75789599|NCT06158828|Drug|Thiotepa|Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.
75925817|NCT03322904|Diagnostic Test|iris photography|"The LF (0.04-0.15 Hz) and HF (0.16-0.4 Hz) ratings were recorded for 24 hours (day and night average) by Holter recording system~Photographs of both irises of the healthy volunteers were taken . An image software program was used to draw circular limits over the iris exterior circle (IEC), coloretta circle (CC), and pupil circle (PC) on digital photographs. The areas between the circles were measured. The likelihood that the IRIS ratio was equal to the LF/HF ratio was calculated using the formula [IEC-PC¬] - [CC-PC] / [CC-PC]."
75925818|NCT02567656|Drug|RP6530|Tablet starting at 200 mg
75925819|NCT02182869|Drug|Combivent® HFA inhalation aerosol|
75925820|NCT02182869|Drug|Combivent® CFC inhalation aerosol|
75641083|NCT05605210|Device|Electric stimulation|Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.
75925821|NCT03109106|Device|PCT Arm|PCT-guided antibiotic therapy per study protocol
75925822|NCT02185833|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
76080993|NCT05682339|Other|Combination of quinine and L-isoleucine|In this condition, both quinine and L-isoleucine will be administered as 'active'.
75471173|NCT01949727|Other|AIM 2: Pulmonary Rehabilitation|Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
75471174|NCT01949740|Other|questionnaire administration|Ancillary studies
75925823|NCT02185833|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
75332642|NCT03018743|Drug|Dapoxetine|Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
75471175|NCT01949740|Procedure|quality-of-life assessment|Ancillary studies
76080994|NCT05682339|Other|Control|"In the condition, where quinine is 'active', control for L-isoleucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-isoleucine will be 'active', control for quinine (10 ml distilled water) will be administered.~Whereas, in a control condition, both for quinine and L-isoleucine, a control solution will be administered."
75641084|NCT04107220|Drug|Sacubitril/Valsartan|Effect of Sacubitril/Valsartan on BNP and NT-proBNP
75641085|NCT04107142|Biological|Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell|Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
75925824|NCT02488382|Drug|Lonquek|Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
75925825|NCT05505682|Biological|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
75641086|NCT02591017|Drug|Morphine|
75641087|NCT02591017|Drug|Ketamine|
75789600|NCT06158828|Drug|Melphalan|Melphalan is administered intravenously at a dose of 70 mg/m^2/dose once daily for 2 days.
75789601|NCT06158828|Biological|TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft|The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.
75925826|NCT02180997|Drug|Tamsulosin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily
75925827|NCT02180997|Drug|Solifenacin|Tamsulosin and solifenacin: Solifenacin 10 mg, once daily
75925828|NCT02180997|Drug|Tamsulosin and solifenacin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
75925829|NCT03328754|Device|Powerscope placed bilaterally for class II correction|Powerscope placed bilaterally for class II correction
75925830|NCT03328754|Device|Group 2 Forsus|Forsus placed bilaterally for class II correction
75925831|NCT03322826|Procedure|systematic sampling of the lymph-node|Systematic Sampling of lymph nodes
75925832|NCT03322826|Procedure|lymphadenectomy|Routine lymph nodes dissection in lung cancer
75925833|NCT02491502|Device|Echopulse|HIFU Under ultrasound guidance
76080995|NCT05676502|Device|AIRVO 2|Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.
76080996|NCT05676463|Procedure|MRI-guided Intensity-Modulated Radiation Therapy|Undergo MRI-guided IMRT
76080997|NCT05676463|Drug|Antiandrogen Therapy|Receive SOC ADT
76080998|NCT05676463|Procedure|PSMA PET Scan|Undergo PSMA PET scan
76080999|NCT05676463|Procedure|Computed Tomography|Undergo CT
75332643|NCT03018119|Other|Survey|
75332644|NCT05511324|Behavioral|Questionnaires|Participants will be asked to complete this assessment on your own time, and it should take about 40 minutes.
75332645|NCT05511324|Behavioral|Caregiver Assessment|These sessions will involve simulation-based, caregiving skill training, and your caregiver will be taught skills to help support you (such as feeding, hygiene, mobility, medication administration, and care coordination).
75332646|NCT05395949|Drug|conservative treatment|Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
75925834|NCT03328520|Behavioral|WILD 5 Wellness Intervention|"Behaviors in 6 areas of wellness: Sleep, Social Connectedness, Exercise, Nutrition, Mindfulness and HERO (Happiness, Enthusiasm, Resilience, Optimism)"
76081000|NCT05676463|Procedure|Magnetic Resonance Imaging|Undergo MRI
76081001|NCT05676463|Procedure|Bone Scan|Undergo bone scan
75471176|NCT01949753|Behavioral|Exposure therapy with pharmacological facilitation|Exposure with response prevention and pharmacological facilitation
75332647|NCT03018197|Other|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
75332648|NCT03018275|Biological|Roseomonas mucosa|R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.
75471177|NCT01949753|Behavioral|Exposure therapy|Exposure with response prevention without pharmacological facilitation
75789602|NCT06158828|Biological|memory-like natural killer cells|The ML NK cells (dose: max capped at 20 x 10^6/kg recipient weight, minimum dose allowed is 0.5 x 10^6/kg recipient weight) will be infused on Day +7.
75641088|NCT02591017|Drug|Placebo|
75641089|NCT02591017|Drug|Chitosan|
75641090|NCT04113148|Other|Physiological measurements from heel|Measurements of blood flow, tissue oxygen saturation, temperature, pressure
75641091|NCT02591095|Drug|ABT-263|
75641092|NCT02588755|Procedure|TACE+Tegafur|Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
75641093|NCT02588755|Procedure|TACE|TACE alone
75641094|NCT00919321|Biological|Pneumococcal polysaccharide vaccine (PPV)|One intramuscular injection
75925835|NCT05505526|Other|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
76081002|NCT05676463|Procedure|Biospecimen Collection|Undergo blood sample collection
76081003|NCT05676463|Other|Quality-of-Life Assessment|Ancillary studies
76081004|NCT05665491|Behavioral|HabitWorks|Smartphone app-delivered interpretation bias intervention
75332649|NCT05395403|Device|Blood pressure measurement device|The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).
75471178|NCT01949766|Drug|Glycerol phenylbutyrate|
75641095|NCT00919009|Procedure|TACE (Transcatheter Arterial Chemoembolization )|"TACE will be performed according to National Cancer Center protocol:~Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions"
75641096|NCT05684263|Other|Weight Science Educational Video|Educational videos on the topic of weight science created by a registered clinical psychologist.
75471179|NCT01949792|Drug|eptacog alfa (activated)|Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
75641097|NCT05684263|Other|Healthy Eating Educational Video|Educational videos on the topic of healthy eating created by a registered clinical psychologist.
75641098|NCT05684263|Other|Healthy Sleep Educational Video|Educational videos on the topic of healthy sleep created by a registered clinical psychologist.
75641099|NCT05684497|Behavioral|Low Back Pain Prevention and Coping Support Program Training in Pregnancy|Preventing low back pain and developing coping strategies with the Pregnancy Low Back Pain Prevention and Coping Support Program based on Pender's Health Promotion Model
75641100|NCT02643303|Drug|Durvalumab|
75641101|NCT02643303|Drug|Tremelimumab|
75789603|NCT06158828|Biological|IL-2|IL-2 is administered subcutaneously at a dose of 1 million units/m^2 on Days +7, +9, +11, +13, +15, +17, and +19 (7 doses total).
75789604|NCT06158828|Drug|Plerixafor|If suboptimal collection of stem cells is predicted, plerixafor may be administered at a dose of 0.24 mg/kg subcutaneous injection once (maximum 40mg/dose). For patients with renal impairment, plerixafor will be administered at a dose of 0.16 mg/kg subcutaneous injection (maximum 27 mg/day).
75789605|NCT06158828|Biological|Granulocyte Colony-Stimulating Factor|G-CSF will be administered at a dose of 10 mcg/kg/day for 5 days, or 6 days if two days of collection are needed.
76081005|NCT05665491|Behavioral|Self-Assessment|Self-assessment of parenting behaviors and anxiety symptoms
76081006|NCT05662592|Device|Broadband Light|Broadband Light device will be used for treatment of pigmented skin lesions
76081007|NCT05660109|Drug|TPM502|TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
76081008|NCT05660109|Other|Placebo|Placebo
75641102|NCT02643303|Drug|Poly-ICLC|
75641103|NCT02555397|Biological|Ad5-yCD/mutTKSR39rep-hIL12|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
75641104|NCT02475759|Dietary Supplement|Nutritional perioperative prehabilitation program for two weeks|nutritional intervention received two weeks before surgical intervention
75789606|NCT06158828|Device|CliniMACS|After stem cells are collected by leukapheresis, in order to create the HPC product, the stem cells will be washed to remove platelets and the cell concentration will be adjusted per laboratory and CliniMACS technology recommendations. The cells are then labeled using the CliniMACS TCRαβ Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product.
75641105|NCT02475759|Dietary Supplement|Nutritional perioperative prehabilitation program for one week|nutritional intervention received one weeks before surgical intervention
75641106|NCT04216173|Other|Acupuncture|Acupuncture weekly for 12 consecutive weeks. Acupuncture protocol consists of both scalp and body acupuncture points.
75925836|NCT05505526|Other|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
75925837|NCT02488226|Other|Gaze-contingent eye-tracking technology|When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
75925838|NCT05509114|Device|Virtual Reality Glasses|The intervention group of patients watched a video with virtual reality glasses during the transrectal biopsy process.
75925839|NCT02488304|Radiation|HRCT scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.~An upper airway (UA) scan will be taken on visit 2."
75925840|NCT03322748|Other|Usual physical therapy+ strengthening of lower limbs muscles|Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
75641107|NCT02345655|Procedure|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
75641108|NCT02345655|Other|no test|normal procedure decided by the general practitioner
75641109|NCT04216095|Device|Electroconvulsive Therapy (n=30)|Right unilateral (RUL) ECT (n=15) or bitemporal (BT) ECT (n=15) using a Thymatron IV device (Somatics LLC, USA) twice weekly.
75641110|NCT04216095|Device|Magnetic Seizure Therapy (n=30)|High-dose magnetic seizure therapy (HD-MST) over the vertex using Magstim Theta device (Magstim Company Limited, Whitfield, Wales, UK) at 100% maximal output of the device (constant), with pulse frequency 100Hz and train duration 10 seconds twice weekly.
75641111|NCT00615147|Procedure|CT pulmonary angiogram and d-dimer draw|A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
75641112|NCT01029717|Device|Standard polyurethane Central Venous Catheter|Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
75641113|NCT01029717|Device|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
75641114|NCT01029717|Device|Heparin bonded polyurethane CVC|Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
75925841|NCT03322748|Other|Usual physical therapy|Usual physical therapy
75925842|NCT03322670|Other|Signs of CAP and a positive chest X-Ray|"collection of clinical examination data~biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~self-reported questionnaires on duration of symptoms and restriction of activity~telephone contact on day 28 and day 90 if hospitalized before day 28"
75925843|NCT03322670|Other|Patients directly hospitalized|"collection of clinical examination data~telephone contact on day 28 and retrieval of hospitalization report~telephone contact on day 90"
75925844|NCT03322670|Diagnostic Test|Control patients|- bacteriological examinations (urine)
75925845|NCT03322670|Other|Patients with partial participation|- collection of clinical examination data
75925846|NCT03322670|Other|Signs of CAP and a negative chest X-Ray|"collection of clinical examination data~telephone contact on day 28"
75925847|NCT02560012|Drug|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
75332650|NCT05395247|Other|Geriatric assessment|Geriatric assessment by a trained nurse and a geriatrician for older kidney transplantation candidates in Caen University Hospital. The geriatric assessment includes a evaluation of cognitive functions, depressive symptoms, risk of fall, nutrition, frailty, and functional status.
75332651|NCT05395169|Other|dietary supplement ,electronic treadmill ,DASH diet.|Control group Will be receive medical treatment for 12 weeks. Study group Will be receive the same medication as in control group in addition to DASH diet and aerobic exercise for 12 weeks.
75332652|NCT05394857|Drug|SHR-1314|SHR-1314 subcutaneously
75471180|NCT01949792|Drug|eptacog alfa (activated)|Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
75471181|NCT01948245|Device|TaurolockTMHep100|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
75641115|NCT00790036|Drug|Everolimus|Everolimus was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
75641116|NCT00790036|Drug|Everolimus Placebo|Everolimus placebo was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
75925848|NCT02560012|Drug|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
75332653|NCT00970073|Biological|Thymoglobulin 3mg total|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
75332654|NCT00970073|Biological|Thymoglobulin 4.5mg total|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
75332655|NCT00970073|Drug|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
75332656|NCT00970073|Drug|tacrolimus 3-8|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
75641117|NCT05563168|Drug|DILTIAZEM TEVA 60 mg or placebo|DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
75925849|NCT02560012|Drug|Sorafenib|400 mg (2 tablets) orally twice daily without food
75925850|NCT02560012|Drug|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
75925851|NCT02560012|Drug|Everolimus|10 mg orally once daily with or without food
75925852|NCT02560012|Drug|Axitinib|5 mg orally twice daily
75925853|NCT03320174|Drug|Tafenoquine|Tafenoquine 200mg
75925854|NCT03320174|Other|Placebo|Placebo
75925855|NCT05500768|Procedure|hypothermic compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants, a frozen prosthesis is added
75925856|NCT05500768|Procedure|Conventional compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants
75332657|NCT00970073|Drug|tacrolimus 8-12|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
75471182|NCT01948245|Device|Heparin 100 IE/ml|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
75332658|NCT00970853|Behavioral|MOM Program home visiting|Mixed professional home visiting program.
75471183|NCT01949805|Drug|Peg-P-IFN-alpha-2b (AOP2014)|Pegylated interferon alpha 2b given Q2W as SC injection
75641118|NCT00789958|Drug|capecitabine|"Adjuvant chemotherapy: 1500 mg/m^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT"
75641119|NCT00789958|Drug|gemcitabine hydrochloride|1000 mg/m^2, IV, Days 1 & 8 of each cycle
75641120|NCT00789958|Radiation|3-dimensional conformal radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
75641121|NCT00789958|Radiation|intensity-modulated radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
75641122|NCT00789880|Drug|Vitamin D3|Administration of oral vitamin D3 at 4000IU
75641123|NCT00789880|Drug|Placebo|Administration of oral Vitamin D3 placebo
75641124|NCT04001686|Other|incidence aplastic anemia|Ambispective chart review
75641125|NCT00915304|Behavioral|The EBMeDS reminders|"Phase I: EBMeDS reminders specific to the visiting or caring patient and his/her clinical problem are generated when the practitioner uses the electronic patient record. During visits of intervention group patients the EBMeDS reminders will be shown on screen to the practitioner.~Phase II: As phase I and in addition, results of the Virtual Health Check (VHC) of all the intervention group patients will be shown to the practitioners.Phase II will be fulfilled in Autumn 2010 and follow-up time will be about 3 months."
75641126|NCT04108780|Device|T-tube|T shaped tube used as stent after CBD exploration
75641127|NCT00915616|Drug|Melatonin|
75925857|NCT03328442|Procedure|VISTA Technique|VISTA with PRF membrane includes Treatment of recession class I and II using autologous PRF membrane
75925858|NCT03328442|Procedure|modified coronally advanced flap|modified coronally advanced flap with PRF membrane for Treatment of recession class I and II
75925859|NCT03328364|Drug|enzalutamide|oral
75332659|NCT00970853|Other|Control|Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
75332660|NCT02569398|Drug|Atabecestat, 5 mg|One atabecestat, 5 mg tablet orally once daily up to 54 months.
75332661|NCT02569398|Drug|Atabecestat, 25 mg|One atabecestat, 25 mg tablet orally once daily up to 54 months.
75641128|NCT00914836|Drug|Betamethasone Sodium Phosphate|1cc:2cc
75925860|NCT03328364|Drug|docetaxel|intravenous infusion
75471184|NCT01949805|Drug|Hydroxyurea|Hydroyurea capsules taken daily po
75471185|NCT01949818|Drug|Yangzhengxiaoji capsule combined with CHOP regimen|Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
75641129|NCT00914836|Drug|1 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
75641130|NCT00914836|Drug|2 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
75641131|NCT04106752|Dietary Supplement|Caffeine|Provide caffeine supplements with or without meal before exercise
75641132|NCT04113070|Device|Anthropometric measuring|To divide participants into overweight and obesity and non-overweight group according to their weight status, height (H), weight (W) and waist circumference (WC) will be measured with a uniform tool, which has been calibrated. When measuring the height, the subjects are required to take off their shoes and stand in an upright position. To measuring weight, the subjects are required to wear close-fitting clothes and bare feet. Subjects are required to take the standing position to measure waist circumference horizontally at the mid-point of line between the lower margin of the ribs and the upper margin of the ilium. All those data will be kept one decimal place. Anthropometric measuring will be taken at baseline and follow-up periods.
75925861|NCT05505370|Device|Colonoscopy|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
75925862|NCT03328286|Behavioral|Weekly group meeting w/psychotherapist|Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
75925863|NCT03322592|Diagnostic Test|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
75925864|NCT03322592|Diagnostic Test|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
75925865|NCT03322436|Diagnostic Test|HeartLinc kit|Samples are collected and analyzed afterwards
75641133|NCT04113070|Other|Growth environment evaluation|The information of children' growth environment, including family environment, physical activities, dietary and sleep habits, will be collected by parent-report questionnaire at baseline and follow-up periods.
75641134|NCT02603692|Other|PROMIS-QOL|PROMIS questionnaires completed every 3 months for up to 2 years.
75471186|NCT01949818|Drug|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
75641135|NCT04106440|Behavioral|Application Use|Use applications after initial diagnosis to share information with study team.
75641136|NCT00792298|Drug|Suvorexant|oral tablet taken before bedtime
75641137|NCT00792298|Drug|Dose-matched Placebo to Suvorexant|Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
75641138|NCT04108390|Other|Dry needling|For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.
75641139|NCT02605096|Procedure|MRI|Magnetic Resonance Imaging Scan
75641140|NCT02605096|Procedure|X-ray|X-ray exam (conventional radiography)
75641141|NCT02603458|Drug|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
75641142|NCT02603458|Drug|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
75641143|NCT02603380|Other|No intervention|This is an observational study. No intervention will be given.
75641144|NCT00718159|Drug|LY573636-sodium|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for acute myeloid leukemia (AML) and Day 1 of a 28-day cycle for essential thrombocythemia (ET) for at least one cycle. A participant may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
75641145|NCT02603302|Radiation|Dose Escalation Radiotherapy|RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
75641146|NCT02603302|Procedure|Delayed surgery|Surgery after 8 weeks with TME (total mesorectal excision)
75641147|NCT04112680|Behavioral|Debunking Misinformation through Audio Dramas|The audio dramas (one drama of 4 episodes per intervention group), aim to debunk misinformation about an infectious disease. The content of the two dramas differ in the two groups; in intervention group 1, the drama will state the misinformation and provide a plausible alternative, delivered through a trusted source, in line with world views. In intervention group 2, the audio drama will avoid mentioning the misinformation and instead only state the correct information about the infectious disease
75789607|NCT06158815|Other|proprioceptive neuromuscular facilitation exercise|The basic principle of Proprioceptive Neuromuscular Facilitation exercises, which is defined as facilitating the responses of the neuromuscular mechanism by stimulating the proprioceptors, is that the movements in the human body have a rotational and oblique character and that a greater response can be obtained with movement against maximum resistance. It is aimed to achieve improvement in strength and movement ability through hand contacts, visual and verbal stimuli.
76081009|NCT05659160|Procedure|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
76081010|NCT05652270|Behavioral|Goal Attainment|Development of an attainable goal
75471187|NCT01949831|Other|Assessment of functional ability in combination with follow-up at home|
75471188|NCT01949896|Other|NPO|Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
75641148|NCT04112680|Behavioral|Control group audio jingles|The control group will receive audio jingles about exclusive breastfeeding
75641149|NCT05136313|Behavioral|Time-restricted eating|16 weeks of TRE consisting of an 8-hour eating window.
75641150|NCT02603068|Drug|Oral treprostinil|Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
75641151|NCT05684185|Biological|Intramuscular (IM) rabies post-exposure prophylaxis|one-site, 0.5 mL at Day 0, D3, D7 and D14
75641152|NCT05684185|Biological|Intradermal (ID) rabies post-exposure prophylaxis|two-site, 0.1 mL at Day 0, D3 and D7
75641153|NCT05325931|Device|kalifilcon A Daily Disposable Multifocal|kalifilcon A Daily Disposable Multifocal low add and high
75641154|NCT05325931|Device|samfilcon A for Presbyopia|Ultra for Presbyopia Low and High Add Contact Lenses
75641155|NCT00718081|Drug|Oral sufentanil|Oral dosage of sufentanil
75641156|NCT00718081|Drug|Placebo|Oral dosage of placebo
75641157|NCT00788710|Drug|etoricoxib (MK0663) 120 mg|120 mg of etoricoxib (MK0663) for a total of 5 days
75641158|NCT00788710|Drug|Comparator: Placebo|Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
75641159|NCT00788710|Drug|etoricoxib (MK0663) 90 mg|90 mg of etoricoxib (MK0663) for a total of 5 days
75641160|NCT04084093|Device|Surfactant Gel|This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.
75641161|NCT05684107|Procedure|IPACK block|the probe is applied to the popliteal fossa for identification of the popliteal artery and femur. Then, the probe is slid distally for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared. a spinal needle 22G x 3.5 inches is advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reached the medial edge of the femur, nearly at the level of the popliteal artery, negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
75789608|NCT06158802|Other|Questionnaire|"Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient."
75789609|NCT06158789|Procedure|MR guided low intensity focused ultrasound|Low intensity focused ultrasound opens the blood brain barrier
75332662|NCT02569398|Drug|Placebo|One matching placebo tablet orally once daily up to 54 months.
75332663|NCT00971633|Drug|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
75332664|NCT00971633|Drug|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
75332665|NCT00971633|Drug|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
75332666|NCT05506176|Drug|SIM0417|dose of 750 mg SIM0417 with 100 mg ritonavir.
75332667|NCT05506176|Drug|Placebo|Placebo (tablet)
75789610|NCT06158763|Behavioral|Web-based CBT guided self-help Interventions|An existing CBT-based transdiagnostic self-help manual (Naeem et al., 2014) that has been used successfully in RCTs (Amin et al., 2020; Naeem et al., 2014) and has been used as an online intervention (http://khushiorkhatoon.com/) will be further adapted. The intervention consists of seven modules, including cognitive restructuring, problem-solving and behavioural activation.
75789611|NCT06158750|Device|p64/p48 MW HPC Flow Modulation Device|Endovascular intervention with p64/p48 MW HPC Flow Modulation Device was performed in patients diagnosed with intracranial aneurysms
75925866|NCT03328052|Device|MYnd Analytics PEER Online directed antidepressant therapy|"PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm."
75925867|NCT03328052|Other|Conventional antidepressant therapy|Anti-depressant therapy chosen based on physician best judgement.
75925868|NCT04514302|Drug|Placebo|Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
75925869|NCT04514302|Drug|Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)|INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.
75925870|NCT05508958|Procedure|Anterior approach|Anterior approach
75925871|NCT05508958|Procedure|Posterolateral approach|Posterolateral approach
76081011|NCT05652270|Behavioral|Goal Development|"A Systematic process to help patients create SMaRT  goals"
75332668|NCT05511168|Procedure|Craniostnostosis surgery|Surgery of craniosynostosis
75332669|NCT00971789|Radiation|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
75332670|NCT00971789|Drug|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
75332671|NCT00971789|Other|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
75332672|NCT05510934|Behavioral|Shared-care model|A Shared care follow-up strategy involving patients, PCPs and specialists that uses an automated reminder system (TCARS).
75332673|NCT05510778|Dietary Supplement|Charcocaps|250 mg capsules containing Activated charcoal, Gelatin, Titanium Dioxide, and Carmine
75332674|NCT05510778|Other|Placebo|capsules containing ~250 mg cellulose
75332675|NCT05510622|Other|Vaginal swab and endometrial biopsy|A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
75332676|NCT00972335|Drug|Everolimus|This drug will be dosed at 10 mg orally DAILY for the duration of the study.
75332677|NCT00972335|Drug|Bevacizumab|This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
75332678|NCT02337530|Drug|Selumetinib|
75332679|NCT02337530|Drug|Pemetrexed|
75332680|NCT02337530|Drug|Cisplatin|
75332681|NCT02337530|Drug|Carboplatin|
75332682|NCT03831230|Genetic|collection of blood, urine, tumor and ascite samples|collection of blood, urine, tumor and ascite samples during ovarian surgery
75471189|NCT01949896|Other|Control group: continue feedings|Feedings will be continued in this group.
75641162|NCT05684107|Procedure|adductor canal block|"the transducer is placed anteromedially, approximately at the junction between the middle and distal third of the thigh or somewhat lower.~The saphenous nerve block should be performed at the most distal level where the artery still lies immediately deep to the sartorius muscle, thus minimizing the amount of motor nerve block of the vastus medialis; an adductor canal nerve block is typically performed more proximally, around the mid-thigh level. The needle is inserted in-plane in a lateral-to-medial orientation and advanced toward the femoral artery. Once the needle tip is visualized anterior to the artery and after careful aspiration, 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn"
76081012|NCT05652270|Behavioral|Goal Tracking|Setting milestones to allow patients to track their progress towards their developed goal
75471190|NCT01949909|Biological|CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
75471191|NCT01949909|Biological|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
75471192|NCT01949909|Biological|TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
75471193|NCT01949909|Biological|TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
75789612|NCT06158737|Drug|JS010 injection|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
75641163|NCT05684107|Procedure|sciatic nerve block|patient in a supine position with the hip and knee on the operated side flexed and the leg externally rotated at approximately 45 degrees. The ultrasound transducer is first positioned perpendicular to the skin approximately 8 cm distal to the inguinal crease. The location is then scanned by sliding and tilting the transducer until a clear transverse image of the hyperechoic sciatic nerve located posterior and medial to the lesser trochanter is obtained. a spinal needle 22G x 3.5 inches is advanced parallel and in line with the ultrasound transducer while the sciatic nerve is kept in the middle of the screen. The needle is advanced slowly under real-time ultrasound guidance until it is near the nerve then negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
75925872|NCT03327974|Other|DEPASSE Apllication|"Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.~Depasse is available for all on the App store and on Googleplay.~This application has several interests:~- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.~There is the possibility to generate a graph representing the evolution of these parameters.~Tips adapted to the actual mood are provided related to the dysfunctional parameters."
76081013|NCT05636397|Dietary Supplement|L-Citrulline|Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
75641164|NCT04106206|Drug|LY3372689|Administered orally
75789613|NCT06158737|Drug|Placebo|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
75925873|NCT03327896|Other|Charlson score and Community Social Deprivation|This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
75925874|NCT03319862|Procedure|Inferior pédicule gynaecomastia|Inferior pédicule gynaecomastia
75925875|NCT04796038|Device|Balloon dilatation|Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation.
75925876|NCT03319784|Drug|Ketorolac|Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
76081014|NCT05635344|Drug|Pembrolizumab|Single dose 200mg dose of Pembrolizumab given intravenously
76081015|NCT05630521|Behavioral|Medication Adherence Problem Solving for Hypertension|The MASH program is a 12-week intervention containing two components: (1) four education modules on HTN causes, risks, treatment, and barriers to treatment; and (2) telehealth visits every 2 weeks with a registered nurse to deliver evidence-based managed problem solving strategies tailored on patients' responses to assessments of HTN beliefs, medication beliefs, and barriers impacting their medication adherence.
75641165|NCT04106206|Drug|Placebo|Administered orally
75641166|NCT04083625|Drug|carbetocin 100 mcg|a 10 cm syringe containing 100 mcg carbetocin just before skin incision of myomectomy.
75641167|NCT04083625|Drug|placebo|a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
75789614|NCT06158724|Other|Personal Protective Equipment|Simplified PPE for use in COVID-19 departments.
75798763|NCT03859206|Other|Medical thoracoscopy|• With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken & If no lesion, biopsy from parietal pleura was obtained from any sites.
76081016|NCT05630183|Drug|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
76081017|NCT05630183|Drug|Gemcitabine|Standard-of-care chemotherapy administered intravenously.
76081018|NCT05630183|Drug|Nab-paclitaxel|Standard-of-care chemotherapy administered intravenously.
76081019|NCT05624918|Drug|Nab paclitaxel|125 mg/m^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
75641168|NCT03938935|Procedure|Absorbable polydioxanone suture (PDS)|PDS is a Polydioxanone synthetic monofilament which is absorbable.
75641169|NCT00787930|Drug|Valproic Acid|Tablets, 250mg-3000mg
76081020|NCT05624918|Drug|Gemcitabine|1000 mg/m^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
75641170|NCT02588911|Procedure|Conventional Surgery|Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
75641171|NCT02588911|Procedure|Radiofrequency Ablation|Catheter-based ablation of the great saphenous vein
75641172|NCT04083547|Diagnostic Test|iCellate|New method of circulating tumour cell detection and capture.
75641173|NCT00914914|Drug|p28|p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
75641174|NCT04083703|Procedure|Interbody cage insertion in lumbar disc prolapse|Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
75641175|NCT04106050|Drug|BIIB095|Administered as specified in the treatment arm.
75641176|NCT04106050|Drug|BIIB074|Administered as specified in the treatment arm.
75641177|NCT04106050|Drug|Placebo|Administered as specified in the treatment arm.
76081021|NCT05624918|Device|NovoTTF-200T(P)|Worn > 18 hr /day starting C1D1 until completion of cycle 3
75789615|NCT06158685|Other|Study Group|"Treatment: Hyperextension exercises as described by McKenzie (in addition to the conventional physiotherapy program)~McKenzie Hyperextension Exercises:~Exercises:~Prone position, arms by the side, deep breath, relax back muscles, holding for 2-3 minutes.~Prone position, raise trunk by raising head above forearms, elbows at shoulder level, maintaining for 2-3 minutes (10 repetitions).~Prone position, hands at elbow level, straighten elbows, raise the upper body from the floor and backwards as far as pain permits, holding for 2-3 seconds (10 repetitions).~Standing with feet shoulder-width apart, hands on waist, leaning backwards as far as possible from the lumbar region without bending knees, holding for 2-3 seconds (10 repetitions).~Additional Information:~Researcher Consistency: All treatments and evaluations were performed by the same researcher.~Frequency: 5 days a week Duration: 3 consecutive weeks"
75789616|NCT06158685|Other|Control Group|"Treatment: Conventional physiotherapy program~Components:~Hot pack was applied to the lumbar region for 20 minutes~Ultrasound (ITO device) at 1 MHz and 1.5 W/cm2 for 5 minutes~Transcutaneous Electrical Nerve Stimulation (TENS) at 50-100 Hz for 20 minutes~Researcher Consistency: All treatments and evaluations for both groups were performed by the same researcher.~Session Duration: An average of 45 minutes per session~Frequency: 5 days a week~Duration: 3 consecutive weeks~Total Sessions: 15"
76081022|NCT05619458|Behavioral|Mindfulness Intervention|6-week mindfulness intervention
75332683|NCT03038750|Other|Eligibility and lifestyle restrictions check.|Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
75332684|NCT03038750|Other|Medical history, demographic and lifestyle factors|Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
75641178|NCT04106050|Drug|Lidocaine|Administered as specified in the treatment arm.
75641179|NCT05052697|Biological|mIRV|Intramuscular injection
75471194|NCT01949909|Biological|TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
75471195|NCT01949909|Biological|TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
75789617|NCT06158672|Behavioral|Emotional freedom technique group|Menopausal women in the emotional freedom technique group will be administered the emotional freedom technique by the researcher a total of 4 times at one week intervals.
75925877|NCT03319784|Drug|Triamcinolone Acetonide|Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
76081023|NCT05606276|Other|Eccentric Exercise|Individuals will do a randomized crossover intervention involving maximal eccentric contractions (2 sets of 6 per leg; experimental condition)
76081024|NCT05606276|Other|Cycle ergometer|Individuals will do a randomized crossover intervention involving cycling (active control) exercise
76081025|NCT05599750|Procedure|Incisional hernia repair|Participants will undergo incisional hernia repair
76081026|NCT05595694|Other|No intervention|This is a retrospective review of 1320 patients in our database who underwent elective primary and revision TJA in Queen Mary Hospital, Hong Kong from from January 2018 to December 2021. No intervention was involved.
75641180|NCT05052697|Biological|bIRV AB|Intramuscular injection
75641181|NCT05052697|Biological|qIRV|Intramuscular injection
75925878|NCT03319706|Drug|Torrent's Olmesartan Medoxomil Tablets 40 mg|
75925879|NCT03319706|Drug|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
75641182|NCT05052697|Biological|QIV|Intramuscular injection
75641183|NCT05052697|Biological|bIRV AA|Intramuscular injection
76081027|NCT05587361|Drug|Propranolol|Propranolol Capsule; 40 mg IR
76081028|NCT05587361|Drug|Nicotine Patch|Nicotine Patch; 14 mg
76081029|NCT05587361|Drug|Placebo Propranolol|Placebo Capsule, no active ingredients
76081030|NCT05587361|Drug|Placebo Patch|Placebo Patch, no active ingredients
75332685|NCT03038750|Other|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
75332686|NCT03038750|Other|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
75332687|NCT03038750|Other|Forearm blood flow: Visit 1 (EDNRA)|Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
75471196|NCT01949909|Biological|TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
75471197|NCT01949922|Procedure|Injection of autologous muscle fibers into the anal sphincter.|
75471198|NCT01949922|Procedure|Pelvic floor muscle training|Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
75471199|NCT01949922|Behavioral|Dietary intervention|Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
75471200|NCT01949922|Drug|Analgesia|Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
75471201|NCT01949935|Drug|Mupirocin|
75641184|NCT05052697|Biological|bIRV BB|Intramuscular injection
75641185|NCT02588365|Behavioral|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving
75641186|NCT02588365|Behavioral|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving
75641187|NCT02588365|Behavioral|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem solving
76081031|NCT05586360|Drug|Simvastatin 40mg|Simvastatin 40mg taken orally daily for 8 weeks
76081032|NCT05584397|Procedure|Venipuncture|Draw of peripheral blood (about 20 ml and 40 ml, during the screening and procedure visits, respectively).
75641188|NCT00588094|Drug|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|"ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.~Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.~For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is > 100kg. Leukapheresis will continue."
75641189|NCT05684029|Device|Near-infrared devices|This device can emit and collect near-infrared light of a specific wavelength. The parathyroid glands in the specimen appear as a high-brightness image in the device, to find the parathyroid gland that may be accidentally removed from the specimen.
75789618|NCT06158672|Behavioral|Sham emotional freedom technique group|Menopausal women in the sham emotional freedom technique group will be administered sham emotional freedom technique by the researcher a total of 4 times with one week intervals.
75925880|NCT05045170|Drug|Influence of propofol sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
75641190|NCT05684029|Diagnostic Test|PTH test strip|The PTH test strip is to detect the PTH in the specimen by immunocolloidal gold technology to determine whether it is parathyroid.
75641191|NCT04107922|Dietary Supplement|Glicoset|Patients will take a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
75641192|NCT04107922|Other|Placebo|Patients will take placebo
75641193|NCT05193175|Behavioral|Prolonged sitting|Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping
75641194|NCT05684419|Other|Fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers|Evaluation of the fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers.
75641195|NCT02603224|Drug|MRG-201|Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
75641196|NCT02603224|Drug|Placebo|Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
75641197|NCT02602990|Device|SQUID™|
75641198|NCT04006600|Procedure|Sphincter saving proctectomy|"After rectal resection, when colorectal anastomosis is subperitoneal, it is currently recommended to perform a protective stoma to reduce the potential consequences of a fistula. This stoma, which is intended to be temporary, appears to be permanent in 6 to 32% of cases in the literature.~The objective of the study is therefore to look for a statistical link between the persistence of a permanent stoma and the intraoperative difficulty represented by pelvic anatomical stress."
75641199|NCT02605252|Drug|Peginterferon alfa-2b|peginterferon alfa-2b 80 micrograms/week for 48 weeks
75641200|NCT05047627|Behavioral|Smartphone-Based Digital Intervention|The digital intervention will be a prototype, and the current trial will be used to continue to both develop and refine the intervention. The current intervention will be based on a combination of cognitive-behavioral principles. As with prior research, the mobile platform will be delivered via Qualtrics, a HIPAA compliant and mobile-friendly platform. The cognitive-behavioral therapy will be primarily based on components with strongest support in digital interventions. The app will continuously collect passive sensing data on patterns in 1) sleep duration and quality;(2) light (3) location; (4) movement (5) social contact including duration and frequency of incoming and outcoming calls and text messages; (6) screen time; and (7) heart rate variability; (8) sound levels captured through passively collected smartphone The platform will deliver interactive interventions where participants will view texts and images, and it will also allow user interaction.
75641201|NCT00914992|Procedure|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
75641202|NCT00914992|Other|Squatting|Squatting
75641203|NCT04107844|Diagnostic Test|Novel facilitating agility dual-task test combined with already known tests|We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.
75789619|NCT06158646|Device|kinematic knee prosthesis|Patients with a kinematically aligned total knee prosthesis and having a post-operative follow-up consultation within at least 1 year after their surgery are consecutively pre-selected according to the eligibility criteria.
76081033|NCT05584397|Procedure|Targeted physical medical exam|"Study participants will be undergoing a physical exam where vitals will be recorded (e.g. temperature, blood pressure, heart rate). The registered nurse (RN) will also perform auscultation of heart and lungs.~Study participants will be also asked to fill out a survey with questions related to his/her medical history, current use of medications, sexual history and substance abuse."
75641204|NCT00482157|Drug|Vitamin D (Calcitriol)|
75789620|NCT06158646|Device|biomechanic knee prosthesis|A group of patients with a mechanically aligned TKA and scheduled for a follow-up consultation 1 year after surgery will be identified to be matched on the aforementioned criteria (sex, age, BMI).
75798764|NCT01285986|Procedure|Vein collar at the distal anastomosis|Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
75641205|NCT04215939|Behavioral|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
75332688|NCT03038750|Other|Forearm blood flow: Visit 2 (EDNRA)|Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
75641206|NCT04215939|Behavioral|Thermoneutral environment participants with spinal cord injury|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
75789621|NCT06158633|Drug|Prevora|"Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant.~All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months."
75471202|NCT01949948|Drug|Tenecteplase|0.4 mg/kg single bolus intravenously
75925881|NCT05045170|Drug|Influence of dexmedetomidine sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
75925882|NCT05045170|Drug|Influence of spinal anesthesia on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
75789622|NCT06158607|Behavioral|Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders|Provision of PrEP information through 4 counseling sessions, prevention navigation, and nurse practitioner prescribed PrEP in an addiction treatment setting.
75789623|NCT06158607|Other|Standard of care treatment|Participants in substance use treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
75789624|NCT06158529|Device|spinal cord stimulator|A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain.
75789625|NCT06158529|Device|high frequency spinal cord stimulation|A spinal cord stimulator is an implanted device that sends low levels and high frequency of electricity directly into the spinal cord to relieve pain.
75789626|NCT06158516|Drug|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
75789627|NCT06158516|Drug|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
76081034|NCT05584397|Procedure|Urine pregnancy test|Women of childbearing potential will be asked to run an urine pregnancy test during the second (procedure) visit. Pregnant women will not be allowed to participate in the study.
76081035|NCT05584397|Procedure|Anoscopy|The anoscopy is an examination using a small, rigid, tubular instrument called anoscope (also called an anal speculum). This is inserted a few inches into the rectum in order to collect some small samples of mucosal tissue. We will collect 5 rectum biopsy samples and one cytobrush.
75332689|NCT03038750|Other|Blood biochemistry (PNPLA3)|25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
75471203|NCT01949948|Drug|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
75471204|NCT01949961|Other|Ultrasound|SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for ~30 minutes, using a Bracco infusion pump.
75471205|NCT01949961|Other|Sham ultrasound|Mounting the ultrasound headframe but connecting this to a non-operative channel
75332690|NCT03038750|Other|Blood EPCR function (PROCR)|Blood sample taken will be analysed via ELISA and FACS.
75471206|NCT01949974|Drug|Standard Palliative Chemotherapy|Standard Palliative Chemotherapy, depending on type cancer.
75471207|NCT01949974|Other|Integral Attention Program (PAI)|The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
75332691|NCT03038750|Other|Blood platelet coagulation and function (PROCR)|Blood sample taken will be analysed using a Platelet coagulation and function assay.
75332692|NCT03038750|Other|Blood endothelial permeability (PROCR)|Blood sample will be analysed in vitro using a permeability assay kit.
75332693|NCT03038750|Other|Blood leukocyte-endothelium adhesion (PROCR)|Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
75332694|NCT03038750|Other|Baseline Venepuncture (PNPLA3, Visit 1)|Up to 25ml Blood will be taken.
75332695|NCT03038750|Other|Deuterium water - Loading dose 1 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
75332696|NCT03038750|Other|Deuterium water - Loading dose 2 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
75332697|NCT03038750|Other|Energy-balanced dinner (PNPLA3, Visit 1)|Provided following baseline bloods and loading dose 1.
75332698|NCT03038750|Other|Fasting venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
75471208|NCT01949987|Other|two hours|
75641207|NCT04215939|Behavioral|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
75789629|NCT06158438|Device|BTL-754-4 Treatment|Treatment with the BTL-754 device with the BTL-754-4 applicator for reduction of facial wrinkles.
75789630|NCT06158425|Radiation|long-leg radiograph|A flat-panel digital radiography(DR) equipment (Siemens DR AXIOM Aristos AX/VX) was used to capture full-length bipedal lower extremities in a standing position. The technician moved the detector from top to bottom, capturing four parts: the bilateral hip joints, femur, tibia and fibula and ankle joint. The exposure parameters for each part were as follows: 1st exposure - 85kV, 75mAs; 2nd exposure - 80kV, 50mAs; 3rd exposure - 75kV, 40mAs; 4th exposure - 68kV, 20mAs. The distance from the source (kv-kg) was 300cm, and the field of view was 43.18cm x 43.18cm. All 4 X-rays were stitched using the Siemens DR Station.
75789631|NCT06158373|Other|infant massage practice|infant massage practice
75925883|NCT03322202|Behavioral|Motivational Interviewing|Motivational Interviewing is a communication style that is intended to give patients the tools to reach goals through their own desires and actions.
75925884|NCT05505058|Behavioral|Audio-visual material|Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
75925885|NCT02488148|Behavioral|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
75332699|NCT03038750|Other|Deuterium water - Maintenance dose (PNPLA3, Visit 2)|every hour, maintenance dose 0.04 g/kg body water
75332700|NCT03038750|Other|Consumption of high carbohydrate meal (PNPLA3, Visit 2)|Provided following fasting blood sample.
75332701|NCT03038750|Other|Postprandial Venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
75332702|NCT03038750|Other|Venepuncture (PROCR)|Up to 50ml Blood will be taken.
75332703|NCT03341156|Drug|Kcentra|Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)
75332704|NCT03341156|Drug|Frozen Plasma Product, Human|If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.
75332705|NCT02983994|Device|TURBUHALER®|
75332706|NCT02983994|Device|SPIROMAX®|
75332707|NCT04122560|Drug|Fluconazole 200mg tab|PO dose of 400mg
75332708|NCT04122560|Drug|Fluconazole 2 MG/ML|IV dose of 400mg
75332709|NCT04122326|Behavioral|Workstation Modification|Participants are asked to work in a sequence of workstation setups for ten minutes each. The sequence include 1. sitting with workstation adjusted by the participant, 2. sitting with workstation adjusted to promote proper posture, 3. sitting with workstation adjusted to promote unnatural posture, 4. standing with workstation adjusted by the participant, 5. standing with workstation adjusted to promote proper posture, and 6. standing with workstation adjusted to promote unnatural posture. After the sequence of setups, the participant allowed to adjust the workstation in either sitting/standing to work in 60 minutes in their own desired position.
75332710|NCT02569242|Drug|Nivolumab|
75332711|NCT02569242|Drug|Docetaxel/Paclitaxel|
75332712|NCT04122014|Other|Progressive balance training|Progressive balance training program
75332713|NCT04122014|Other|Normal daily activities|Usual daily activities
75332714|NCT05608382|Other|sterile Phosphate Buffer Saline|control group
75332715|NCT05608382|Other|SGW13|active comparator
75332716|NCT05501808|Procedure|cerasmart|the patient received a crown made of cerasmart ceramic
75332717|NCT05501808|Procedure|enamic|the patient received a crown made of enamic ceramic
75332718|NCT04122248|Other|standard radiographic imaging|standard radiographic imaging
75332719|NCT05501730|Diagnostic Test|Quantra QPlus System|Coagulation monitoring system
75471209|NCT01949987|Other|one hour|
75471210|NCT01950000|Drug|Fentanyl|
75471211|NCT01950000|Other|Placebo|
75471212|NCT01950026|Procedure|cryotherapy application|"Height, weight and BMI verification~subjects in supine position after 20 minutes of resting~cryotherapy application by cold thermal bag (thermoGel brand) size P~15-20 cm above the ASIS~temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil"
75471213|NCT01950052|Dietary Supplement|Diet group 800 Kcal diet|Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
75925886|NCT02488148|Behavioral|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
75925887|NCT02487992|Biological|Cytokine-Induced Killer Cells|CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.
75925888|NCT05500534|Device|Laser lithotripsy with stone recognition|Application of Revolix HTL+ which features automatic real-time stone recognition
75925889|NCT05500534|Other|Laser lithortripsy|Standard laser lithotripsy
75925890|NCT03327818|Procedure|hysterectomy|
75641208|NCT04215939|Behavioral|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
75332720|NCT04124588|Device|Nexpowder (Hemostatic powder)|Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.
75789632|NCT06158373|Other|Safe Swaddling|Safe Swaddling
75789633|NCT06158373|Other|Control|Control
75789634|NCT06158347|Device|hyperbaric oxygen chamber|Hyperbaric oxygen therapy allows patients to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied by gradually increasing the barometric pressure from normal pressure to 1.5 atmospheres absolute (ATA).
75789635|NCT06158334|Drug|Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures|All surgical data will be collected: surgery, biology, administration of Elocta®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding
75789636|NCT06158334|Drug|Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures|All surgical data will be collected: surgery, biology, administration of Alprolix®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding…
75789637|NCT06158321|Device|M1 or DLPFC sham stimulation|Participants receiving M1 or DLPFC sham stimulations will complete the same procedures as those in the active groups. The sham coil, with the same stimulation parameters, will provide auditory and sensory effects similar to the active coil without delivering active stimulation.
75789638|NCT06158321|Device|M1 rTMS|The stimulation parameter of the active M1-rTMS is a 10 Hz stimulation frequency with a total of 1500 stimulation pulses.
75925891|NCT03327818|Procedure|uterine conservative study|
75925892|NCT05508802|Other|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
75925893|NCT05508802|Other|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
75925894|NCT03327740|Drug|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
75332721|NCT04124588|Device|Conventional Technique|Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).
75332722|NCT05501496|Procedure|intramedullary nailing|Flexible intramedullary nailing using 2 nails
75332723|NCT05501496|Procedure|casting|casting with long leg cast
75332724|NCT05501418|Biological|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion with 12 months of follow up after treatment.
75471214|NCT01950091|Behavioral|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
75471215|NCT01950091|Other|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
75471216|NCT01950104|Other|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development.
75471217|NCT01950104|Other|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development
75925895|NCT03327740|Drug|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
75925896|NCT03327740|Drug|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
75925897|NCT03327740|Drug|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
75925898|NCT03327740|Drug|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
75332725|NCT05501418|Biological|Controlled normal saline|Normal saline will be IV infusion with 12 months of follow up after treatment.
75471218|NCT01950117|Procedure|Endoscopic mucosal resection|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.
75641209|NCT04215939|Behavioral|Thermoneutral environment healthy male participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
75789639|NCT06158321|Device|DLPFC rTMS|The stimulation parameter of the active DLPFC-rTMS is a 1 Hz stimulation frequency with a total of 1500 stimulation pulses.
75789640|NCT06158308|Procedure|Laproscopic Appendicectomy|A type of surgery done without a large incision. Instead, from 1 to 3 tiny cuts are made. A long, thin tube called a laparoscope is put into one of the incisions. It has a tiny video camera and surgical tools.
75789641|NCT06158308|Procedure|Open Appendicectomy|A cut or incision about 2 to 4 inches long is made in the lower right-hand side of your belly or abdomen. The appendix is taken out through the incision.
75789642|NCT06158269|Drug|DVRd|The patients will receive 4 cycles of DVRd induction therapy. After achieving PR or better response, they will receive stem cell mobilization, collection and the following ASCT. Then, the patients will accept 4 cycles of DVRd consolidation and DVR maintenance therapy. Once they sustain MRD negative condition for at least 12 months, the patients will enter the maintenance stage of lenalidomide monotherapy. Otherwise, the triple drug maintenance therapy will be continued for a total of 24 cycles or until disease progression, death, intolerance, withdrawal due to other reasons, or termination/end of the study.
75332726|NCT05501340|Drug|Serplulimab|PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
75471219|NCT01950117|Procedure|Conventional polypectomy|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
75789643|NCT06158243|Other|Sono-anatomical Study|The arm is abducted (90°), externally rotated, with the forearm flexed over the arm (90°). A linear ultrasound probe (8-15 MHz) is placed in front of the humeral head, in a sagittal plane. Location begins at axillary level, vessels, nerves and humerus are identified, and the probe is moved medially to reach and identify the humeral head.
75471220|NCT01950143|Dietary Supplement|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
75641210|NCT04215939|Behavioral|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
75789644|NCT06158230|Drug|Pizotifen|Pizotifen will be given only at night time to avoid daytime somnolence. Starting dose will be 0.5mg then gradually increased to 1.5 mg
75789645|NCT06158230|Drug|Amitriptyline-propranolol|"Amitriptyline will be given at bedtime only, starting at 10 mg daily and gradually increasing to 25 mg daily.~Propranolol will be started in 40 mg daily in divided doses, which gradually increases to 80 mg daily in divided doses"
75789646|NCT06158217|Procedure|ultrasound combined with microbubbles|IBC tumors were treated with microbubbles (MBs) stimulated by ultrasound
75789647|NCT06158191|Behavioral|Lifestyle modification program|Participants will take part in a lifestyle modification program focused on physical activity and diet.
75789648|NCT06158178|Diagnostic Test|Diagnostic accuracy|The PET CT study with choline, being part of the normal standard diagnostic work-up of the patients, was performed following the normal clinical protocol. By analyzing the data retrospectively, the time elapsed following the prostatectomy operation and the follow up time after the choline PETCT study will be evaluated.
75789649|NCT06158152|Dietary Supplement|AM3 + Probiotic|Two capsules daily in the morning during 12 weeks. The capsule contains the mixture of AM3 Technology and probiotic SynBalance Metsyn.
75789650|NCT06158152|Dietary Supplement|Placebo|Two capsules daily in the morning during 12 weeks. The capsule contains starch.
75789651|NCT06158152|Dietary Supplement|AM3|Two capsules daily in the morning during 12 weeks. The capsule contains AM3 Technology.
75925899|NCT03327662|Other|Active CTC Assessment|CTC Counts used to guide treatment switch
75925900|NCT03322124|Drug|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
75925901|NCT03322124|Other|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
75925902|NCT02567266|Behavioral|Unified Protocol for Adolescents (UP-A)|The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
75332727|NCT05501340|Drug|Molgramostim|200ug qd subcutaneous injection for 7 days
75332728|NCT05501340|Radiation|Hypofractionated radiotherapy/Sterotactic body radiotherapy|8Gy*3f
75471221|NCT01950143|Dietary Supplement|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
75471222|NCT01950143|Dietary Supplement|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
75332729|NCT00972725|Biological|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
75332730|NCT00972725|Drug|Chloroquine|One dose of 300 mg
75925903|NCT02567266|Behavioral|Youth Outcomes Questionnaire|"The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision."
75925904|NCT02567266|Behavioral|Treatment as Usual|Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
75332731|NCT05501262|Device|Cryoablation|Image (ultrasound and fluoroscopic guided) cryoablation will be performed of the Morton's neuroma after nerve block.
75641211|NCT04215939|Behavioral|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
75789652|NCT06158139|Biological|iC9-CAR.B7-H3 T cell infusion|iC9-CAR.B7-H3 T cell product will be administered via intravenous injection over 5 - 10 minutes.
75332732|NCT05501262|Procedure|Nerve block|Ultrasound and fluoroscopic guided nerve block.
75332733|NCT04274660|Behavioral|DWELL (Diabetes and WELLbeing) Programme|12-week psychoeducational programme
75641212|NCT04215939|Behavioral|Thermoneutral environment healthy female participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
75641213|NCT04215939|Behavioral|Warm environment healthy female participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
75641214|NCT02706015|Drug|Cefaliv® & Placebo|02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
75641215|NCT02706015|Drug|Neosaldina® & Placebo|02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
75641216|NCT00615225|Procedure|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
75641217|NCT02705937|Other|Dairy product|Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days
75641218|NCT02705937|Device|Aequasyal mouth spray|The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
75641219|NCT04215705|Procedure|Quadratus block versus peritubal local infiltration|Quadratus lumborum block III versus peritubal local infiltration in patients undergoing Percutaneous Nephrolithotomy operation
75641220|NCT02705781|Device|smARTrack Feeding Tube System|
75641221|NCT04083313|Device|Technique used for closing the appendiceal stump|In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
75789653|NCT06158126|Drug|Initiating daily oral PrEP during pregnancy|Group 1a, will include pregnant women who initiate oral PrEP at enrollment into the study.
75641222|NCT04083469|Behavioral|Peer-Led Peer-Elected Intervention|The intervention will be given to students by a peer opinion leader that the students in the audience elected. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
75789654|NCT06158126|Drug|Already using daily oral PrEP at the time of pregnancy diagnosis|Group 1b will include women already using daily oral PrEP at the time of pregnancy diagnosis and enrollment in the study.
75789655|NCT06158126|Drug|Initiating injectable PrEP during pregnancy|Group 2a will include pregnant women who initiate injectable PrEP (CAB-LA) at enrollment into the study.
75789656|NCT06158126|Drug|Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis|Group 2b will include women using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis.
75789657|NCT06158113|Drug|Baricitinib 4 milligram Oral Tablet|4 milligrams once daily
75789658|NCT06158100|Drug|Venetoclax|Venetoclax will be given orally (PO) at the assigned doses of 50 or 100 mg once daily for 7, 14 or 21 days starting at day 1 of each 28-day cycle, for up to 12 cycles.
75798765|NCT03864666|Drug|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
75925905|NCT03327584|Procedure|Arthrocentesis|Athrocentesis
75925906|NCT04442984|Drug|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
75925907|NCT04442984|Drug|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
75332734|NCT04394000|Other|thromboprofylaxis protocol|This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
75332735|NCT04394000|Other|standard protocol|This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
75332736|NCT05600660|Drug|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6 cycles during induction treatment.~Daily Orelabrutinb will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
75925908|NCT04442984|Drug|5-FU|d1-2 5-FU 2200 mg/m² every two weeks
75925909|NCT04442984|Drug|5-FU|d1 5-FU 250 mg/m² every two weeks
75925910|NCT04442984|Drug|Leucovorin|d1 Leucovorin 400 mg every two weeks
76081036|NCT05584397|Procedure|Esophagogastroduodenoscopy (EGD)|The EGD involves looking at the esophagus, stomach, and first and second portion of the duodenum. This procedure involves the use of an endoscope to remove small tissue samples. This procedure uses conscious sedation drugs given by a vein in the arm. The procedure takes about 1½-2 hours, including time for recovery. We will collect 5 duodenal biopsies and one cytobrush.
76081037|NCT05573178|Procedure|cardiac ganglion plexus ablation(cardioneuroablation)|Under the guidance of three-dimensional system, the located ganglion plexus was ablated with saline irrigating electrode. The upper limit of power was 40W, the upper limit of temperature was 43 ℃, and the washing rate of saline was 17ml/min. The site of vagal reaction during ablation was defined as the effective ablation site. The surgical end point of denervated interventional therapy is defined as the disappearance of vagal response at the effective ablation site or the ablation of each effective point discharge for at least 30 seconds.
75641223|NCT04083469|Behavioral|Adult-Led Intervention|The intervention will be given to students by an adult. The intervention is a version of CATCH My Breath curriculum that has been modified to match the Peer-Led Intervention curriculum but is able to be administered by an adult.
75641224|NCT04083469|Behavioral|Peer-Led Non-Elected Intervention|The intervention will be given to students by a peer opinion leader that was elected by other students. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
75641225|NCT02707575|Drug|Ranibizumab|Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
75641226|NCT00919399|Drug|Exemestane|25mg a day during 4 months
75641227|NCT00919399|Drug|tamoxifen|One 20 mg tablet a day started 1 week after the first Aromasine intake
75641228|NCT00784654|Drug|Lisdexamfetamine dimesylate (LDX)|LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
75789659|NCT06158100|Drug|Azacitidine|Azacitidine will be administered at a dose of 20mg/m^2 once daily subcutaneously (SC) or intravenously (IV) for five days (Days 1-5) of each 28-day cycle.
75789660|NCT06158100|Biological|Donor Lymphocyte Infusion|"Donor lymphocyte infusions (DLI) may be administered at the discretion of the treating physician, if certain criteria are met. Participants may receive up to three (3) infusions of donor lymphocytes (a type of white blood cell) at the following dose levels and study timepoints:~DLI 1: 1x10^6 cluster of differentiation 3+ (CD3+) cells/kg, after cycle 3~DLI 2: 5x10^6 CD3+ cells/kg, after cycle 5, if there is persistent MRD~DLI 3: 1x10^7 CD3+ cells/kg, after cycle 7, if there is persistent MRD."
75789661|NCT06158087|Device|pEGASUS Stent System|Endovascular intervention with p64/p48 MW HPC pEGASUS Stent System was performed in patients diagnosed with intracranial aneurysms
75789662|NCT06158074|Procedure|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25~35 mA) for 60 minutes targeted the pudendal nerve, thrice weekly for a total of 4 weeks.
75789663|NCT06158074|Procedure|sacral neuromodulation|In the prone position, patients undergo sacral nerve root localization through MRI and CT fusion analysis. A 3D-printed sacral foramen puncture template is crafted for precision. Using local anesthesia, a 20G needle at a 60° angle enters the S3 sacral foramen along the template. A temporary stimulator, delivering square waves (14-35 Hz, 210-360 μs), tests motor and sensory responses to confirm accuracy. Self-fixating electrodes are then implanted, validated, and tunneled subcutaneously. External connection to a temporary stimulator provides a 4-week therapeutic experiential stimulation.
75925911|NCT04442984|Drug|5-FU|d1 5-FU 400 mg/m² every two weeks
75925912|NCT04442984|Drug|5-FU|d1-2 5-FU 2400 mg/m² every two weeks
75925913|NCT03327506|Drug|Alprazolam 0.5 mg|alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
75925914|NCT02567188|Other|MIRCERA|
75925915|NCT02487914|Device|iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)|drug delivery through interferential current.
75332737|NCT05600660|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy.
75641229|NCT00784654|Drug|Placebo|Placebo capsule once per day (double-blind period)
75641230|NCT02707185|Behavioral|Simulation-Based Training|An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.
75641231|NCT02588287|Other|Blood draws for tenofovir PK, renal function|
75641232|NCT02707107|Drug|Intravenous infusions of WCK 5222|
75641233|NCT02707107|Drug|Placebo|
75641234|NCT02707263|Drug|intravenous continuous infusion of heparin (IV UFH)|
75641235|NCT02707263|Drug|Subcutaneous Heparin|
75641236|NCT04105348|Diagnostic Test|HbA1c|patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
75641237|NCT00919087|Device|Avivo System|Non invasive external monitoring deive
75641238|NCT03997084|Other|phone interviews|phone interviews
75641239|NCT02705547|Drug|Rosuvastatin|Daily oral administration of Rosuvastatin (10 mg) for 3 months
75925916|NCT02487914|Drug|Lidocaine 10% was sprayed at the identified region|
75925917|NCT02487914|Device|interferential current|
75925918|NCT02487680|Dietary Supplement|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
75925919|NCT02487680|Dietary Supplement|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
75925920|NCT04411888|Other|observation|observation
75925921|NCT03319550|Dietary Supplement|Casein|see experimental description
75925922|NCT03319550|Dietary Supplement|Whey|see experimental description
75789664|NCT06158061|Diagnostic Test|tryptase enzyme level|"In serum:~Three ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into redtop plain glass tubes. Blood samples will be allowed to coagulate during 30-60 minutes. Serum will be obtained by centrifugation at t 1262 g for 10 minutes, aliquoted, and immediately frozen at -20°C until analyzed to determine serum tryptase level. Serum tryptase concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.~In tissue:~Punch skin biopsies of 3mm depth will be taken under local anesthesia from back of Acne vulgaris patients and from matched sites of control subjects. Skin biopsies will be fixed in 10% formalin solution, and submitted to Pathology department in our institute for routine tissue processing by special stain for assessment of tissue tryptase level and number of mast cells tissue biopsy."
75925923|NCT03319550|Dietary Supplement|Leucine-enriched whey|see experimental description
76081038|NCT05572879|Biological|EuCorVac-19|COVID-19 vaccine
76081039|NCT05572879|Biological|ChAdOx1 nCoV-19|COVID-19 vaccine
75471223|NCT01950156|Biological|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
75332738|NCT05600660|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
75332739|NCT03830762|Drug|Xanamem|Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
75332740|NCT03830762|Drug|Matching Placebo|Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
75332741|NCT04759118|Behavioral|modified childbirth education program|The participants in the intervention group are pregnant women and their husbands. The instructors employed teaching methods such as a group discussion, watching videos, and brainstorming, as well as questions and answer periods, demonstrations, childbirth simulation, and practice. The primary investigator (PI) will teach particular sessions, including maternal-fetal attachment skills, parenting skills, comfort measures, childbirth positions, as well as knowledge about anatomy and physiology during pregnancy and birth Classes consisted of 120-minute sessions held once a week for four weeks.
75332742|NCT04121702|Procedure|Cardiac Rehabilitation|Implementation of a physical exercise program (PEP) with tele-monitoring
75798766|NCT03864666|Drug|PMR 200 mg|Two PMR 200 mg at 08:00, single oral dose (total daily dose of 400 mg)
75332743|NCT00972959|Drug|Bortezomib|1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
75471224|NCT01950182|Drug|Endocrine therapy combined with trastuzumab|Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab
75471225|NCT01950182|Drug|Chemotherapy combined with trastuzumab|Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab
75641240|NCT05345379|Other|Single intervention|Single intervention at the day of fixed orthodontic appliance bonding
75332744|NCT00972959|Drug|Zoledronic Acid|4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
75471226|NCT01950195|Procedure|Stereotactic Radiosurgery (SRS)|
75471227|NCT01950195|Biological|Ipilimumab|
75641241|NCT02587507|Other|Orange juice|Individuals will consume the HFHC meal with 500mL of orange juice.
75798767|NCT03858972|Drug|Tesetaxel|Tesetaxel plus reduced dose of capecitabine
75641242|NCT02587507|Other|Water|Individuals will consume the HFHC meal with 500mL of water.
75641243|NCT02587507|Other|Water with glucose|Individuals will consume the HFHC meal with 500mL of water with glucose.
75641244|NCT00615303|Drug|Simethicone|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded
75641245|NCT00615303|Drug|Placebo|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
75641246|NCT04082845|Other|Education|Web-based patient education
75641247|NCT04831281|Drug|ATH-1017|Daily subcutaneous injection of ATH-1017 in a pre-filled syringe
75925924|NCT05508490|Diagnostic Test|renal chemistry, serum electrolyte,|detection of renal chemistry affection and electrolyte disturbance in diabetic ketoacidosis
75925925|NCT04442906|Drug|Dexmedetomidine|Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
76081040|NCT05570812|Drug|Placebo|(4-week ramp, 4-week steady dosing)
76081041|NCT05570812|Drug|Pregnenolone|(4-week ramp, 4-week steady dosing)
75332745|NCT00972959|Drug|Dexamethasone|12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
75471228|NCT01950221|Dietary Supplement|POMx|"POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract."
75471229|NCT01950221|Other|Placebo|
75471230|NCT01950247|Drug|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
75471231|NCT01950247|Drug|SOC|
75471232|NCT01950312|Drug|gevokizumab|
75471233|NCT01950325|Biological|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
75471234|NCT01950338|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
75471235|NCT01950416|Drug|Ticagrelor 180mg loading dose and 90mg bid maintenance dose|
75471236|NCT01950416|Drug|Clopidogrel 600mg loading dose and 150mg maintenance dose|
75471237|NCT01950442|Device|Balloon dilation|
75471238|NCT01950455|Drug|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
75471239|NCT01950468|Drug|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
75471240|NCT01950468|Drug|DaTscan|A single intravenous dose of 3 to 5 mCi
75471241|NCT01950481|Drug|LDK378|Oral LDK378 750 mg once
75471242|NCT01950494|Other|fiteBac Hand Sanitizer|Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
75471243|NCT01950507|Drug|Budesonide|Entocort EC 3 mg given orally three times daily for at least 14 days
75471244|NCT01950507|Drug|Fluconazole|400 mg orally once daily for CrCl greater than or equal to 50 ml/min
75471245|NCT01950507|Drug|Voriconazole|Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours
75471246|NCT01950507|Drug|Micafungin|Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
75471247|NCT01950533|Procedure|Oral food challenge|Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
75332746|NCT00973739|Drug|Lapatinib|"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response."
75471248|NCT01950546|Drug|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
75471249|NCT01950559|Other|Oral food challenge|Oral food challenge to determine allergy to soy
75471250|NCT01950585|Drug|Hydroxyurea|
75641248|NCT04831281|Drug|Placebo|Daily subcutaneous injection of Placebo in a pre-filled syringe
75789665|NCT06158048|Drug|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75789666|NCT06158048|Drug|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
75789667|NCT06158035|Drug|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75798768|NCT03858972|Drug|Capecitabine|Reduced dose of capecitabine
75798769|NCT03091348|Drug|Testosterone|Testosterone cypionate injection
75798770|NCT02525016|Biological|Blood sampling|
75798771|NCT02525016|Drug|Lidocaine|
75925926|NCT04442906|Drug|Fentanyl|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)
75925927|NCT04442906|Drug|Bupivacain|Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.
75471251|NCT01950598|Procedure|Boston KPro type I - fresh graft|Boston KPro mounted on fresh corneal carrier graft for implantation
75471252|NCT01950598|Procedure|Boston KPro type I surgery - frozen graft|Boston KPro mounted on frozen corneal carrier graft for implantation
75641249|NCT00787150|Drug|Apixaban|Apixaban 5 mg tablet BID for 12 weeks
75641250|NCT00787150|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 12 weeks
75641251|NCT00787150|Drug|Warfarin sodium|At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
75641252|NCT02705469|Drug|ZEN003694|
75332747|NCT05608148|Biological|Biological|Intravenous injection of GAIA-102 alone
75332748|NCT05608148|Biological|Biological|Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination
75332749|NCT00974051|Drug|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
75332750|NCT00974051|Other|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
75471253|NCT01950611|Drug|Bortezomib|Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute promyelocytic leukemia
75471254|NCT01950637|Behavioral|No treatment given|Completion of 90-item online questionnaire.
75471255|NCT01950637|Behavioral|survey|Completion of 58-item online questionnarie.
75925928|NCT05500456|Device|Clear aligners|Each aligner will be worn for about two weeks, and then replaced by the next in the series until the final position is achieved.
75471256|NCT01950650|Behavioral|No treatment given|Survey conducted through computer-assisted telephone interviewing.
75471257|NCT01950650|Behavioral|survey|Survey conducted via the Internet.
75471258|NCT01950676|Device|Smart phone application|The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
75471259|NCT01950689|Drug|Nimorazole|
75471260|NCT01950689|Radiation|Radiotherapy|
75925929|NCT05500456|Device|Fixed appliances|Conventional wires and brackets will be used.
76081042|NCT05568056|Behavioral|Visualizing and Verbalizing for Language comprehension and Thinking|The V/V intervention program is a language remediation program designed by Dr. Nanci Bell, and developed by the Lindamood-Bell Learning Processes (LBLP) (Bell, 1991b). It has been widely used among children with reading disorders, but not with children with ASD. This intervention is based on the use of nonverbal sensory input, in the form of imaged gestalts, in order to develop oral and written language comprehension, establish vocabulary, and develop higher order thinking skills (Bell, 1991a,b).
75332751|NCT00974051|Other|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
75641253|NCT02705703|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
75641254|NCT03606837|Drug|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
75641255|NCT03606837|Drug|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
75641256|NCT03173703|Device|Implant the XenoSure patch|The LeMaitre XenoSure patch will be used when close the repaired vessel
75332752|NCT04129814|Procedure|Non surgical periodontal therapy|single session full-mouth scaling and root planing
75332753|NCT00974363|Procedure|Blood Sampling|A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
75332754|NCT04129892|Behavioral|"In Favor of My Resilient Self Academic course"|Assessing the effect of an academic course on student's emotional resilience.
75332755|NCT05604248|Other|Intervention|Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil
75332756|NCT03017963|Drug|Sodium Thiosulfate Pentahydrate|Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min
75332757|NCT04121390|Behavioral|Newborn Parenting Class|Newborn Parenting Class designed by Mount Sinai Parenting Center. The class is 1-hour long and taught be pediatric attending and residents to all families who deliver well babies at Mount Sinai.
75332758|NCT03018353|Drug|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
75641257|NCT03173703|Procedure|Repair/reconstruction of the diseased vessel|The diseased vessel is surgically repaired such as removing the clots.
75641258|NCT03173703|Device|Implant the Vascular-Patch|The B. Braun Vascular-Patch will be used when close the repaired vessel
75641259|NCT02587585|Behavioral|Feedback against tailored target|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. In the active group, the watch will summate activity movement in two hour epochs and the target for the day for that epoch is the activity in the same epoch 24 hours earlier, plus 5%. During an epoch the patient is shown progress towards the target at at the end of an epoch, they will see their final process towards target for that epoch.
75641260|NCT02587585|Behavioral|No feedback|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. However the watch face will simply show which epoch a person is in. The watch will collect the activity in exactly the same way over the day.
75789668|NCT06158035|Drug|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
75789669|NCT06158022|Drug|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75789670|NCT06158022|Drug|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
75789671|NCT06158009|Drug|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
75925930|NCT03322046|Behavioral|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
75925931|NCT02487602|Device|Gelesis100|Gelesis100 capsules
76081043|NCT05555173|Device|Buzzy|Buzzy is a small vibrating bee with ice-pack wings.
75332759|NCT04120844|Behavioral|Motivational interviewing (MI)-based patient empowerment program (PEP)|Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
75641261|NCT03016065|Dietary Supplement|Pea Fiber|Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls
75641262|NCT03016065|Dietary Supplement|Control|Baked goods (2 snacks) without added fiber
76081044|NCT05555056|Device|MxN-9 HD-tES Stimulator (Soterix Inc.)|Patients will be stimulated with high definition transcranial direct current stimulation (HD-tDCS) for 5 weeks (every weekdays; one session per day). In each session, a constant current at 2mA will be passed on the target brain areas for 20 minutes.
76081045|NCT05555056|Device|Sham Stimulation|The same stimulation protocol will be used as in Active stimulation except that a sham mode will be selected in the stimulator machine.
75332760|NCT04120844|Behavioral|Traditional lecture style health education|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
75641263|NCT02587663|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo bilateral breast contrast enhanced MRI
75641264|NCT02587663|Procedure|Mammography|Undergo bilateral mammography
75641265|NCT02587663|Procedure|Therapeutic Conventional Surgery|Undergo breast conserving surgery
75332761|NCT00977171|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
75641266|NCT02587663|Procedure|Ultrasonography|Undergo bilateral whole-breast ultrasound
75641267|NCT02587663|Procedure|Ultrasonography|Undergo targeted breast ultrasound
75332762|NCT04121000|Procedure|VIDEO ASSISTED THOTACOSOPIC SURGERY|VATS
75641268|NCT02587663|Other|Gadolinium|Contrast agent used in MRI
75641269|NCT02705313|Drug|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
75641270|NCT00786838|Drug|Trabectedin|Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
75641271|NCT00786838|Drug|Placebo|Participants will receive 3-hour placebo intravenous infusion on Day 1.
75789672|NCT06158009|Drug|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
75789673|NCT06157996|Drug|lenvatinib and tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
75789674|NCT06157996|Drug|tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
75798772|NCT01179594|Drug|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
75925932|NCT02487602|Other|Placebo|Sucrose (sugar) capsules
75925933|NCT04696744|Biological|CTC detection|"The collection and analysis of CTCs will be carried out in the following 6 steps: A blood sample will be taken: a maximum volume of 30 ml on 3 x 10 ml BD Vacutainer® EDTA tubes is required for the study.~CTCs will be enumerated and characterized by immunofluorescence after immunostaining with the following antibodies: anticytokeratin, anti-CD44, anti-N-cadherin and anti-PD-L1.~• - Secondary criterion(s) : Different tumor and clinical parameters will be analysed to find a correlation with CTC detection Gene expression profiles will be analyzed using the RNAseq single-cell at different times: before treatment, at interim times, and in case of relapse in order to establish correlations between patients at high risk of relapse and their molecular profiles"
75925934|NCT05504980|Procedure|Repositioning|Patients in the intervention group will be given 30 degrees right lateral, supine, and 30 degrees left lateral positions, 1 hour apart, respectively.
75925935|NCT02487836|Device|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
76081046|NCT05552716|Other|School safety tactics and policies|A list of school safety tactics and policies (such as metal detectors, armed security guards, active shooter drills) that were in place at the school at the time of shooting.
76081047|NCT05551936|Drug|Bendamustine|90 mg/m^2 IV Days 1-2, Cycles 1-3
75641272|NCT05683951|Drug|DWKH|Administration of DWKH three times daily
75641273|NCT05683951|Drug|DWKH-R|Administration of DWKH-R three times daily
75641274|NCT05683951|Drug|Placebo|Administration of Placebo three times daily
75641275|NCT02705079|Other|EEG Monitoring|Value of EEG monitoring as adjunct to standard monitoring
75641276|NCT02604004|Drug|Epivir ® tablet 150-mg single dose (drug reference)|Bioequivalence lamivudine 150 mg tablets fasting condition
75641277|NCT02604004|Drug|Lamivudine 150-mg tablet single dose (drug test)|Bioequivalence lamivudine 150 mg tablets fasting condition
75641278|NCT02588521|Drug|AL-794|
75641279|NCT02588521|Other|Placebo/Vehicle|Suspension vehicle without active drug
76081048|NCT05551936|Drug|Rituximab|375 mg/m^2 IV Day 1 Cycles 1-6
75641280|NCT02705157|Procedure|Stabilisation of (impending) pathological fracture|Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
75641281|NCT02705157|Radiation|Radiotherapy of bone metastasis|Radiotherapy of bone metastasis, single or multi-fractionated
75641282|NCT04104880|Device|Continuous positive airway pressure (CPAP)|Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
75641283|NCT02705001|Other|all admissions except accident and emergency|No additional intervention, retrospective study
76081049|NCT05551936|Drug|Tazemetostat|RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
75332763|NCT04129424|Device|Insulin pump (Microtech, Equil®)|Those patients of different types of diabetes mellitus were assigned to different groups, those groups were classified by the time to reach target blood glucose .
75641284|NCT05095207|Drug|Abemaciclib|100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
75925936|NCT05500300|Device|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
75641285|NCT05095207|Drug|Bicalutamide|150 mg orally daily, day 1 to 28.
75641286|NCT02604082|Other|Vibrocompression (VB)|Vibrocompression is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation (MV)
75925937|NCT05500300|Device|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
75641287|NCT02604082|Other|Hyperinflation (HMV)|Hyperinflation technique with mechanical ventilator which aims to clear the airways of patients on mechanical ventilation
75641288|NCT02604082|Other|HMV+VB|Association between Vibrocompression and Hyperinflation with mechanical ventilator
75789675|NCT06157983|Other|measurement of lipoprotein(a)|Plasma lipoprotein(a) will be measured in the biological relatives group as part of a clinical health care development project
75789676|NCT06157970|Procedure|Sphenopalatine Ganglion Block|For SPGB, the plastic part of the 16G angiogram is advanced transnasally into both nostrils, with the patient in the supine position and the head in 15-20° extension, until it contacts the posterior mucosa, and after contact, it is withdrawn 1 mm and 2 ml of 0.5% bupivacaine is dripped into the postnasal space within 1 minute. is applied.
75789677|NCT06157918|Drug|SYHA1813 oral solution (2.0g:25mg)|SYHA1813 oral solution, 25mg, oral
75789678|NCT06157918|Drug|SYHA1813 oral solution (20ml:200mg)|SYHA1813 oral solution, 25mg, oral
75789679|NCT06157905|Drug|Oral Tofacitinib citrate|oral tofacitinib citrate was initiated at 5 mg twice daily after ruling out contraindications
75789680|NCT06157892|Drug|disitamab vedotin|Given into the vein (IV; intravenous)
75789681|NCT06157892|Drug|tucatinib|300mg given twice daily by mouth (orally)
75925938|NCT05500300|Device|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
75925939|NCT05500300|Device|RBS-IPI|"Subjects will receive RBS-IPI electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
75925940|NCT05500300|Device|HIFEM|"Subjects will receive HIFEM electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
76081050|NCT05550675|Other|Questionnaires|Disease specific questionnaires
76081051|NCT05540613|Behavioral|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
75332764|NCT00955487|Drug|Inhaled Nitric Oxide (iNO)|iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
75332765|NCT00955487|Drug|Nitrogen (placebo)|Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
75641289|NCT04148079|Other|physical therapy|low frequency currents (galvanic or TENS), medium frequency currents (interferential) and high frequency currents (short wave diathermy), all combined with an individualized exercise program and massage therapy
75641290|NCT02602912|Device|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
75641291|NCT03354039|Drug|Tamoxifen|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
75641292|NCT03354039|Drug|Matching placebo|Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
75641293|NCT04105426|Dietary Supplement|Antioxidants|one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
75789682|NCT06157879|Device|WVI-MIS-01-2022|Microwave scans
75641294|NCT04105426|Dietary Supplement|Placebo|one placebo tablet three times per day for 3 months.
75798773|NCT01179594|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
75798774|NCT01179594|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
75798775|NCT01179594|Drug|placebo|orally daily, 24 weeks (weeks 12-36)
75641295|NCT02704923|Drug|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
75332766|NCT04120922|Other|calcium carbonate|See arm description
75641296|NCT02704923|Drug|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
75641297|NCT05548192|Device|SmartPICC-1 System|The SmartPICC system is indicated for use as an alternative method to chest x-ray or fluoroscopy confirmation of PICC tip placement in adult patients when proper ECG detection is available. The SmartPICC system provides a supplemental intravascular ionic dilution feature that provides qualitative blood flow information to the user to aid catheter navigation during PICC placement.
75641298|NCT04215627|Device|non-invasive monitoring|Comparing the PiCCO monitor to the non-invasive BB-613PW device in hemodynamically unstable critically ill patients in the ICU
75641299|NCT04105504|Drug|Glutathione|Oral glutathione capsule (500 mg), were taken once daily by the subjects.
75789683|NCT06157853|Procedure|Radiofrequency Microneedling|A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.
76081052|NCT05540613|Behavioral|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
76081053|NCT05540613|Behavioral|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
75789684|NCT06157853|Other|Facial Cleanser|Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).
76081054|NCT05537389|Device|In-line filter|"All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.~In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.~In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed."
76081055|NCT05535075|Device|Vancomycin model-informed precision dosing|A dosing calculator is used for a posteriori calculation of vancomycin dose using a target AUC/MIC between 400-600 mg*h/L
76081056|NCT05535075|Drug|Vancomycin|Vancomycin treatment
75332767|NCT04120922|Other|sevelamer carbonate|See arm description
75332768|NCT01663740|Drug|Valganciclovir|Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
75332769|NCT04758884|Other|Telemedicine|Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
75332770|NCT04129190|Biological|Glucose|Oral Intake of Glucose
75332771|NCT02984228|Biological|PRP|
75332772|NCT02984228|Drug|Hyaluronic Acid|
75641300|NCT04105504|Drug|Placebo oral tablet|Placebo oral capsule were taken once daily by the subjects.
75641301|NCT02704611|Device|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
75641302|NCT02704611|Device|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
75641303|NCT04815967|Drug|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
76081057|NCT05534984|Drug|Tecovirimat Oral Capsule|"Drug: Tecovirimat Oral capsules~Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
75332773|NCT02984228|Device|Ultrasound|
75332774|NCT03828266|Other|No intervention|Patients will undergo routine clinical practice. There is no additional intervention.
75332775|NCT05501184|Other|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
75332776|NCT05501184|Other|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
75332777|NCT00979121|Drug|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
75332778|NCT00979121|Drug|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
75332779|NCT03828032|Procedure|Mannitol injection|Standard mannitol injection to decrease intracranial pressure of patients
75641304|NCT04815967|Drug|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
75641305|NCT04815967|Drug|Phase 2; Placebo|Intramuscular injections on Day 1
76081058|NCT05534984|Drug|Placebo|"Drug: Placebo Oral capsules~Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days"
75641306|NCT04815967|Drug|Phase 3; MYOBLOC|Intramuscular injections on Day 1
75641307|NCT04815967|Drug|Phase 3; Placebo|Intramuscular injections on Day 1
75789685|NCT06157853|Other|Facial Moisturizer|Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.
75332780|NCT03828032|Procedure|Hypertonic saline injection|Standard Hypertonic saline injection to decrease intracranial pressure of patients
75332781|NCT03827876|Drug|Enstilar 0.005%-0.064% Topical Foam|Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
75332782|NCT02960282|Procedure|Biospecimen Collection|Undergo collection of fecal specimens
75471261|NCT01950702|Procedure|Laryngoscope assisted lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~The Macintosh laryngoscope (female: 3rd blade, male: 4th blade) was inserted into the oral cavity to provide direct view of the epiglottis and then the tip of the lightwand was placed below the epiglottis."
75641308|NCT02704767|Drug|Apatinib|a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
75641309|NCT02704767|Drug|Tarceva|
75641310|NCT02704767|Drug|Placebo|
75641311|NCT02587273|Drug|Fentanyl|In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
75641312|NCT02704533|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54
75641313|NCT02704533|Biological|PfSPZ Challenge (NF54)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
75641314|NCT02704533|Biological|PfSPZ Challenge (7G8)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
75641315|NCT02704533|Other|Normal saline|0.9% sodium chloride
75789686|NCT06157853|Other|Sunscreen|Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
75332783|NCT02960282|Other|Laboratory Biomarker Analysis|Correlative studies
75332784|NCT01960127|Behavioral|Aerobic Exercise|Aerobic exercise
75332785|NCT01960127|Behavioral|No Intervention|No Intervention
75332786|NCT03898934|Drug|Vitamin D|receive 6000iu daily for 8 weeks
75332787|NCT03898934|Drug|Placebo Oral Tablet|placebo for the same period
75641316|NCT04104724|Other|Self-help|self-help materials - cognitive behavioural and compassion-focused; psychoeducation, practical help re. attending cervical cancer screening
75641317|NCT04107454|Device|Active microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Active application of laser radiation on the vulvar skin. The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
75641318|NCT04107454|Device|Sham microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Sham application of laser radiation on the vulvar skin. Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
75641319|NCT02704221|Behavioral|Fitbit activity tracker|Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
75641320|NCT02704221|Behavioral|Monetary rewards|Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
75641321|NCT02704221|Behavioral|BPT training sessions|Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
75332788|NCT00979199|Other|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
75798776|NCT03751098|Drug|Tropicamide/Phenylephrine ophthalmic solution (TR/PE)|Tropicamide 1%/phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
75925941|NCT02487758|Procedure|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
75925942|NCT04696354|Diagnostic Test|IVUS|Those who are randomized to the interrogation arm will have diagnostic imaging performed by IVUS to determine their treatment plan.
75925943|NCT04696354|Other|Continued Compression Therapy/Stockings|Those who are randomized to the deferred interrogation arm while continue compression therapy as prescribed.
75925944|NCT02491034|Behavioral|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
75332789|NCT04128800|Drug|Apatinib S-1|apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
75789687|NCT06157840|Device|mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity
75789688|NCT06157840|Device|Simplified mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will receive a simplified version of the app with sleep hygiene instructions and will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.
75789689|NCT06157814|Other|STOMA Care web-based application|The STOMA Care App, with program software developed in collaboration with the Information Technology Department at Mount Sinai, is organized in a web-based app accessible on any smart-phone (e.g., Android and iOS), tablet, or computer device and consist of: 1) provision of information through text, and graphics; 2) videos of physicians and nurses answering questions; and 3) videos of patients describing their experiences and modelling competencies 4) mental health, support group, and ostomy supplier resources.
75925945|NCT04510012|Other|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
75925946|NCT03327350|Device|WATCHMAN transplantation|WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
75925947|NCT03327350|Drug|Oral anticoagulant drugs|This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
75332790|NCT04129112|Drug|We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening|Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening
75332791|NCT01608893|Drug|Carvedilol|6.25 po bid titrated to 25 mg bid as tolerated over a 1 month period
75332792|NCT01608893|Drug|Metoprolol|titrated to 50 mg po bid as tolerated over a 1 month period
75332793|NCT04128878|Drug|Sotalol|The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
75332794|NCT04128878|Drug|Dofetilide|Same as described above with sotalol.
75332795|NCT00979745|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
75925948|NCT03327272|Drug|Methylprednisolone|Injection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
75925949|NCT03327272|Drug|Saline|Administration of saline at surgical site prior to incision closure
75332796|NCT00979745|Drug|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
75332797|NCT04120532|Behavioral|Perioperative Rehabilitation|Physical therapist will be consulted one day before and after the operation (OP) day. On the day before the OP day, they focus on education, including how to get up from bed and stand up from a chair. Five rehabilitation exercises are also demonstrated: 1) ankle flexion and extension, 2) knee flexion and extension, 3) hip joint abduction and adduction, 4) hip joint flexion and extension, and 5) drawing-in maneuver. The participants will be required to repeat each component to confirm that they can do it correctly. Each exercise is suggested to be done 10 times per day following MI-TLIF, and the number will be recorded 3 days (pre-OP day, post-OP day, and post-OP day 2).
75332798|NCT00042341|Drug|clofarabine (IV formulation)|
75641322|NCT02602834|Other|interval training|4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
75641323|NCT02602834|Other|moderate exercise|30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
75471262|NCT01950702|Procedure|Lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~After 2min from administration of rocuronium, the clinician holds the wand similar to a pencil, stands directly behind the patient's head, inserts the device into the side of the mouth and sweeps the tip to the midline. After confirmation of precise location via clear light source on anterior neck, endotracheal tube was inserted and withdrawn lightwand."
75641324|NCT02587975|Drug|Evogliptin|10 mg
75471263|NCT01950715|Device|sacral nerve stimulation|Sacral nerve stimulation
75641325|NCT02704299|Biological|Autologous T cells-Based Immunotherapy|TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
75641326|NCT02703831|Procedure|Dual attending|Two attending spine surgeons perform surgery
75641327|NCT02703831|Procedure|Single Attending|One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
75789690|NCT06157814|Other|Usual Care|Patients and caregivers NOT given access to the web-based application.
75332799|NCT03828110|Device|Robotic Assisted Gait Training (Lokomat)|The RAGT treatment consisted of sessions lasting 45 minutes each performed with the commercially available Lokomat device. The same exercises were offered to the children with preset duration, speed, and difficulty. For all patients, the initial body-weight support was set at 50%, and was then gradually decreased according to the individual functional capacity. The guidance force was initially set to 100% for all children, and then gradually reduced.
75641328|NCT04104568|Behavioral|iSupport for dementia - European-Portuguese version|iSupport for dementia, European-Portuguese version consists in an online self-help training and support program developed by the World Health Organization to to provide education, skills training and support to informal caregivers of people with dementia and culturally adapted to Portugal by the Institute of Biomedical Sciences Abel Salazar and CINTESIS. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques. The program comprises 23 lessons on dementia and caregiver support distributed by 5 modules: 'Introduction to dementia'; 'Being a carer'; 'Caring for me'; 'Providing everyday care' and 'Dealing with behavior changes'. The education plan can be personalized by the caregiver and each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed.
75789691|NCT06157775|Diagnostic Test|Shear-wave elastography|Shear-wave elastography using a manual ultrasound with a 9L-Probe in B-mode.
75789692|NCT06157762|Procedure|Erector spinae plane block|ultrasound guided lumbar erector spinae plane block
75789693|NCT06157762|Procedure|Erector spinae plane block performed by surgeon|Erector spinae plane block performed by surgeon
75925950|NCT00706238|Biological|GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A|IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.
75925951|NCT03321968|Biological|Quadrivalent VLP Influenza Vaccine|Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine
75925952|NCT04493450|Other|Documentation of cancer treatment side effects|Standardized documentation of occurred side effects
75925953|NCT05508178|Biological|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
75925954|NCT05508178|Biological|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant
76081059|NCT05534984|Drug|Tecovirimat Oral Capsule (Open Label)|"Participants weighing 4 to <6kg and >7 days old - Tecovirimat 50mg every 12 hours for 14 days~Participants weighing 2.5 to <4kg and >7 days to <4 weeks old - Tecovirimat 20 mg every 12 hours for 14 days~Participants weighing 4 to <6kg and ≤7 days old - Tecovirimat 50mg every 24 hours for 14 days~Participants weighing 2.5 to <4 kg and ≤7 days old - Tecovirimat 20mg every 24 hours for 14 days~Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
76081060|NCT05532891|Other|COVID-19 pandemic|Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
76081061|NCT05524493|Diagnostic Test|Structural MRI|We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2*-weighted sequences
76081062|NCT05524493|Diagnostic Test|Quantitative MRI|We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
76081063|NCT05524493|Diagnostic Test|Diffusion MRI|We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
75332800|NCT03828110|Procedure|Physiotherapy|The physiotherapic sessions aimed at strengthening the gluteus and quadriceps muscles, stretching the hip flexor and hamstrings muscles, increasing static balance, increasing dynamic balance, increasing functional abilities, improving ground gait and climbing stairs.
75332801|NCT03827954|Other|HeartMapp+CT|HeartMapp+CT is a mobile system that includes physiological modules that support self-monitoring and exercises that promote heart health, and computerized plasticity-based adaptive cognitive training modules that train participants to enhance cognitive functions and ultimately heart failure outcomes.
75332802|NCT00980681|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
75925955|NCT05508178|Drug|Placebo|Norovirus vaccine (rNV-2v) vehicle without antigen
75925956|NCT03327194|Device|ADHEAR Audio Processor|"ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark."
76081064|NCT05524493|Diagnostic Test|fMRI|We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
76081065|NCT05524493|Diagnostic Test|MR Spectroscopy|We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
75332803|NCT00980681|Other|Time of Flight|Each subject will undergo a TOF MRA
75332804|NCT03828188|Dietary Supplement|Red Ginseng Concentrated Powder|Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.
75332805|NCT03828188|Dietary Supplement|Placebo|Placebo for 12 weeks.
75798777|NCT03751098|Drug|Placebo|Eyewash administered with the Optejet microdose dispenser
75925957|NCT03327116|Drug|Methotrexate|oral, 15 mg per week, 24 weeks
75789694|NCT06157723|Other|None (Observational study)|"Data related to the knee osteoarthritis will be extracted from patients' medical records:~The sociodemographic and clinical participants' characteristics: age, weight, height, duration of the condition, and occupational activity.~The healthcare costs: the number of visits in primary and specialized care, diagnostic tests, surgical interventions, and emergencies at both health centers and hospitals, physical rehabilitation and number of sessions.~Charlson Comorbidity Index (CCI). Pharmacotherapy (type of drug and dose). Work absences (temporary and permanent)."
75332806|NCT04759040|Dietary Supplement|Migraineguard|2 Capsules per day for 7 Months
75641329|NCT04104568|Other|e-book (comparator)|The e-book contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
76081066|NCT05524480|Behavioral|Salud en Mis Manos - Dissemination and Implementation Assistance|The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).
75641330|NCT04082065|Other|conventional physical therapy|hot pack for 15 minutes Myofacial release (10 minutes) and Stretching of hamstrings and Piriformis (5 reps each with 2 second hold)
75789695|NCT06157710|Behavioral|Digital intervention through modules|"Introduction~Goal Setting Techniques~Motivation~Barriers to Action~Managing Maladaptive Thoughts and Beliefs~Value Clarification~Moving Forward"
75789696|NCT06157684|Behavioral|Postprandial ambulation|See arm description
75789697|NCT06157645|Device|Prolene mesh|Application of mesh onlay post stoma closure
75789698|NCT06157632|Procedure|Thyriodectomy|Thyroidectomy
75789699|NCT06157619|Procedure|Oocyte Vitrification /Warming|In Vitro matured oocytes will be randomly assigned to any of the two Vitrification protocols
75789700|NCT06157593|Procedure|NAVA|weaning from mechanical ventilator using neurally adjusted ventilatory assist
75789701|NCT06157580|Drug|Compound 21|differences in vasodilation to compound 21 in the skin between groups
75789702|NCT06157580|Drug|Angiotensin II|differences in vasoconstriction to angiotensin II in the skin between groups
75925958|NCT04678960|Behavioral|Trust-based Relational Intervention Training|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI Group Training is comprised of three components: TBRI Youth Group Training (youth only), Caregiver Training (caregivers only), and Nurture Groups (youth-caregiver joint roleplay activities), which is conducted prior to youth's release."
76081067|NCT05524480|Behavioral|Salud en Mis Manos- Usual Implementation Practice|The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
75789703|NCT06157554|Other|Breathing Exercises|During the exercise sessions, participants will be seated in a chair. In the first five and last five minutes of the session, they will be instructed to focus on their breathing and the sensations produced in the body while sitting comfortably in a relaxed position with all joints in the chairs with their eyes closed. After the initial 5 minutes of relaxed breathing, participants will be instructed to perform diaphragmatic and costal breathing for 10 minutes. After 5 minutes of diaphragmatic breathing, the patient will be rested for 1 minute and then 5 minutes of costal breathing will be performed. While doing coastal breathing, patients will be asked to place their hands on their costas, take a deep breath and inflate the bottom of their hands; then they will be asked to exhale the breath they take in a longer (1:2) time.
75789704|NCT06157554|Other|Conventional treatment|Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
76081068|NCT05523609|Drug|Letrozole 2.5mg|20 patients will receive Letrozole only for 12 weeks
75789705|NCT06157528|Diagnostic Test|Magnetic resonance imaging|Patients were treated with abarelix prior to the examination
75789706|NCT06152861|Drug|Travoprost Ophthalmic Topical Cream low-dose|travoprost ophthalmic topical cream low-dose once daily in the evening to both eyes
76081069|NCT05523609|Drug|Letrozole + vitamin D3 and calcium|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
76081070|NCT05518435|Other|None, observational study|The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
76081071|NCT05509751|Behavioral|GAM, exercise, health education|geriatric assessment, exercise and health education
76081072|NCT05505344|Device|VentriJect Seismofit validation|All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
75332807|NCT04759196|Drug|Topamax|TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.
75641331|NCT04082065|Other|cyriax lumber manipulation group|Hot Pack, Myofacial Release, stretching of hamstrings and Piriformis (five reps each with 2 seconds hold) and Cyriax Lumbar Manipulation Techniques
75641332|NCT05683795|Other|Consensus study|Modified-Delphi study and consensus meetings
75641333|NCT02703753|Behavioral|Lifestyle intervention|The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
75332808|NCT04759196|Drug|Levetiracetam|LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.
75332809|NCT05506020|Procedure|indocyanine green (ICG) fluorescence cholangiography|indocyanine green (ICG) fluorescence cholangiography during operation
75332810|NCT04128332|Radiation|Pre-operative stereotactic ablative body radiotherapy|Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
75641334|NCT02587741|Drug|Metformin|start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose
75789707|NCT06152861|Drug|Travoprost Ophthalmic Topical Cream mid-dose|travoprost ophthalmic topical cream mid-dose once daily in the evening to both eyes
75925959|NCT04678960|Behavioral|Trust-based Relational Intervention In-Home Structured Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Structured Training includes four structured in-home coaching sessions."
75925960|NCT04678960|Behavioral|Trust-based Relational Intervention In-Home Responsive Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Responsive Training includes at least 2 structured in-home coaching sessions plus additional sessions indefinitely as needed."
75641335|NCT02587741|Drug|Lantus|started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）
75641336|NCT02587741|Drug|Novomix30|started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
75641337|NCT04105192|Dietary Supplement|dietary supplement consumption|Consumption of the product under study for 84 days, plecebo or experimental product
75789708|NCT06152861|Drug|Travoprost Ophthalmic Topical Cream high-dose|travoprost ophthalmic topical cream high-dose once daily in the evening to both eyes
75925961|NCT06036420|Device|Flashed Light Therapy|Light flashes will be presented over 60 minutes as 3-millilisecond flashes of white light at 4,000 lux every 20 seconds
76081073|NCT05493033|Procedure|Intracorporeal anastomotic after LRC|Complete laparoscopic dissection of the mesocolon is mandatory. D2 or D3/CME is optional. And the extent of colon resection is based on the location of the tumor while the ileocecal resection is excluded. After fully mobilization of the colon and mesentery, the terminal ileum and transverse colon will be transected by a laparoscopic linear stapler. The side-to-side anastomosis is performed laparoscopically. The enterotomy is closed by a double-layer suture. All the anastomotic procedures are completed laparoscopically. The specimen is then removed through a Pfannenstiel incision within a specimen bag.
76081074|NCT05493033|Procedure|Extracorporeal anastomotic after LRC|The procedures of the mobilization and vessel ligation are similar. After that, the mobilized colon and terminal ileum are brought out through the upper mid-line incision with the wound protector. The colon and terminal ileum are similarly dissected distally to the specimen with a stapling device. The side-to-side anastomosis is completed and the anastomotic site is reinforced. The anastomotic bowel is returned to the abdominal cavity.
76081075|NCT05489237|Drug|IDRX-42|IDRX-42 will be administered at assigned doses and schedules once daily in continuous cycles of 28 days each.
76081076|NCT05489237|Drug|IDRX-42|IDRX-42 will be administered at RP2DS once daily in continuous cycles of 28 days each.
76081077|NCT05487846|Behavioral|Patient Navigation|Receive peer navigation services
76081078|NCT05487846|Other|Genetic Counseling|Receive genetic counseling
76081079|NCT05487846|Other|Survey Administration|Ancillary studies
76081080|NCT05487846|Other|Best Practice|Receive standard care
76081081|NCT05487846|Other|Genetic Counseling|Receive genetic counseling
76081082|NCT05487846|Other|Survey Administration|Ancillary studies
76081083|NCT05482646|Behavioral|Tai Chi|The Tai Chi intervention will be prescribed as a 3-month program with two 1.5-h sessions weekly instructed by qualified Tai Chi instructors.
76081084|NCT05482646|Behavioral|Conventional exercise|The conventional exercise intervention will be prescribed as a 3-month program with two 1.5-h sessions of generic fitness training weekly instructed by qualified instructors.
76081085|NCT05482646|Behavioral|Health Education Control|Participants in the control group will participate in a health education program delivered by research personnel.
76081086|NCT05481437|Drug|Brentuximab Vedotin|Brentuximab Vedotin injection, 50 mg, once every 2 weeks
75641338|NCT02703519|Procedure|resection of uterine scar tissue|resection of uterine scar tissue of a previous cesarean section during a second cesarean section
75641339|NCT04024618|Procedure|Parenteral Nutrition/Enteral Nutrition|Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
75641340|NCT02703363|Drug|Minocycline|
75641341|NCT02703363|Drug|Celecoxib|
75641342|NCT02703363|Drug|Placebo|
75641343|NCT00615381|Drug|Insulin|insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
75789709|NCT06152861|Drug|Timolol maleate ophthalmic solution, 0.5%|timolol maleate ophthalmic solution, 0.5% twice daily (morning & evening) to both eyes
75789710|NCT06152861|Drug|Travoprost Ophthalmic Solution, 0.004%|travoprost ophthalmic solution, 0.004% once daily in the evening to both eyes
75471264|NCT01950728|Device|Interferential current|Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 100 Hz.
75471265|NCT01950728|Device|Aussie Current|Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 100 Hz.
75641344|NCT00785980|Drug|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) administered on the morning of Day 1 after an overnight fast of at least 10 hours.
75332811|NCT05501106|Other|Integrated Improvement strategies|"Integrated improvement strategies include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases.~A checklist (named as Risk Assessment and Preparedness for Postpartum Hemorrhage (Traffic Light in Delivery Room)) will be used in each virginal delivery to help obstetric staff and teams identify risk factors after admission, before and during labor, and improve the adherence to all known best practices.~The Postpartum Hemorrhage Rescue Format will be asked to be used in each postpartum hemorrhage rescue to record the rescue process.~Each case of postpartum hemorrhage exceeding 1000 ml will be reviewed. We will convene a QI Panel and a Task Force to assist the hospitals in postpartum hemorrhage case review and quality improvement strategy development."
75332812|NCT04274114|Drug|L Glutamine|Powder
75332813|NCT04274114|Drug|Placebos|Powder
75332814|NCT04737642|Procedure|Papillary ballon dilatation|Trans cystic papillary ballon dilatation during cholecystectomy
75332815|NCT04286334|Device|Bone augmentation with cad-cam laser-sintered mesh|Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.
75332816|NCT04128254|Drug|Apixaban Oral Tablet|Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism
75641345|NCT00785980|Drug|Ciprofloxacin 500 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
75641346|NCT00785980|Drug|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
75789711|NCT06152406|Procedure|Ablation and Pacemaker Implantation|All patients will be implanted with a pacemaker device with one lead positioned in right ventricle (control arm only) and an additional lead will be positioned on the distal (ventricular) HIS bundle if in intervention arm. All patients will undergo ablation.
75789712|NCT06152250|Other|Liver Fine-Needle Aspiration|"At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy."
75789713|NCT06152211|Behavioral|Choir|A choir for older adults is a musical/singing ensemble composed of individuals aged 65 and above. The choir rehearsals are weekly, 2 hours each and the length of the intervention is 16 weeks total.
75789714|NCT06152211|Behavioral|Group Music Listening|A weekly collective music listening, 2 hours each for 16 weeks.
75789715|NCT06151782|Dietary Supplement|Wheat gluten 1000 mg|Nothing to add here
76081087|NCT05481359|Device|Ablamap Software|Subjects will receive cardiac ablation guided by the Ablamap software. The software will identify atrial fibrillation sources to help guide ablation therapy in patients with persistent atrial fibrillation.
76081088|NCT05475678|Drug|（Carrelizumab + TCb） regimen|Carrelizumab +docetaxel + carboplatin regimen
76081089|NCT05475678|Drug|TCb regimen|docetaxel + carboplatin regimen
76081090|NCT05470036|Behavioral|Educational intervention.|Educational intervention with trained educator on overview, rationale, implications, and risks and benefits of germline testing in prostate cancer.
76081091|NCT05468203|Drug|Dapagliflozin 10mg Tab|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
76081092|NCT05468203|Drug|Placebo|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
76081093|NCT05466331|Other|Mobile Tele-HCV Care|Study participants receive HCV care via telemedicine. Telemedicine appointments are performed on a mobile van.
76081094|NCT05466331|Other|Enhanced Usual Care|Study participants are referred to a clinician in their area for HCV care.
75332817|NCT04128020|Drug|Nivolumab|Nivolumab
75332818|NCT04128020|Drug|Azacitidine|Azacitidine
75641347|NCT04805073|Drug|Promethazine|1cc 25mg/ml Promethazine (study medication)
75641348|NCT04805073|Drug|Placebo|1cc 0.9% Sodium Chloride (placebo)
75641349|NCT05683561|Biological|CoronaVac|D0; intramuscular injection
75641350|NCT05683561|Biological|SCTV01E|D0; intramuscular injection
75789716|NCT06151782|Dietary Supplement|Barley gluten 1000 mg|Nothing to add here
75789717|NCT06151782|Dietary Supplement|Barley gluten 50 mg|Nothing to add here
75789718|NCT06151782|Dietary Supplement|Barley hydrolyzed gluten 50 mg|Nothing to add here
75789719|NCT06150976|Behavioral|MAAT-YS|MAAT is an evidence-based cognitive-behavioral therapy composed of eight 45-minute telehealth appointments and an accompanying workbook.
75789720|NCT06150807|Device|ultrasound and doppler|Ultrasound examinations of the liver and spleen including color Doppler imaging of the portal veins, hepatic veins, splenic vein, and superior mesenteric vein will done in the Department of Pediatric
76081095|NCT05458934|Other|No intervention|no intervention
76081096|NCT05450770|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
76081097|NCT05446324|Drug|Gallium-68-tilmanocept|All participants receive a cervical injection with 10 MBq 68Ga-tilmanocept in an outpatient setting (at least one week) before surgery. Within 30-90 minutes post-injection a PET with contrast enhanced CT is performed (PET/CT). Data (i.e. detection rate) from the imaging modalities are collected.
76081098|NCT05442437|Biological|hUCMSCs|Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells
76081099|NCT05440890|Other|Best current rehabilitation protocol|Inflamation control and edema with physical agents, recover full pasive and active range of motion, normalize gait pattern, lower limb strengthening (specially quadriceps and hamstrings), neuromuscular control training, cycling, landings and running.
75641351|NCT00915694|Drug|nelfinavir mesylate|
75641352|NCT00915694|Drug|temozolomide|
75641353|NCT00915694|Procedure|adjuvant therapy|
75641354|NCT00915694|Radiation|radiation therapy|
76081100|NCT05440890|Other|Cross-training protocol|Beginning on 2º week after ACLR, 3 times per week during 8 weeks, based on isotonic exercise at least to 80% of 1RM in leg extension. 5 sets o 6 repetions with 1,5 - 2 minutes between series.
75789721|NCT06150430|Device|APO|"Subjects will take part in 14 experimental sessions: two baseline sessions (T1-T2), three familiarization sessions (F1-F3), six training sessions (E1-E6), two assessment sessions (one pre-training T3 and one post training T4) and one 2-month follow-up session (T5). Depending on the session, the subject will walk with and/or without the APO. During the assessment sessions (T3-T4), the subject will be evaluated through different standard tests (such as 10MWTs and 2mWTs) and instrumented gait analysis, with and without the APO.~The goal of each training session (E1-E6) will be to achieve a minimum of 30 minutes of overground walking assisted by the APO, leaving up to 15 minutes to rest if needed. Training sessions will occur 2-3 times a week for 2-3 weeks to complete the training protocol."
75789722|NCT06150105|Other|Exercise training|Intense endurance training
75789723|NCT06149819|Other|Diagnostic and safety of a nursing pathway for the management of non-traumatic chest pain|trained nurses will take in charge non-traumatic chest pain patient according to the standardized algorithm based on the recommendations .
75471266|NCT01950728|Device|TENS|TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 100 Hz.
75471267|NCT01950754|Behavioral|standing with both feet|
75471268|NCT01950754|Behavioral|descent of the platform|
75925962|NCT06036420|Behavioral|Videoconference-delivered Cognitive Behavioral Therapy|Treatment will involve psychoeducation on sleep, circadian rhythms and light exposure, motivational interviewing, advancing of bedtime schedule, time management and coping with poor sleep, sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring for worry.
75641355|NCT02703675|Device|Excel Cryo Cooling Collar|Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.
75641356|NCT04802629|Device|Near-infrared spectroscopy|For NIRS measurements the t-NIRS 1 and NIRO 200 NX (Hamamatsu, Japan) will be used. A cerebral sensor will be placed and fixed with a CPAP (Continuous Positive Airway Pressure) cap on the left forehead and a peripheral sensor on the right forearm. Duration of measurement will be two hours.
75641357|NCT04107610|Device|I-PAS|I-PAS is a portable, head-mounted display goggle system with integrated eye tracking technology. I-PAS records eye movements in response to visual and auditory stimuli.
75641358|NCT02703441|Other|Tablet computer|Patients randomized to the intervention group will receive a tablet computer with an app-like software solution supporting nutrition and physical activity. The patients operate the computer and order their meals from the hospital menu; register dietary intake, and receive feedback informing about their current status for protein and energy intake. Likewise, the patients use small series of brief videos instructing in daily life activities for strengthening their muscles. After this, they register their performed activities and will receive informing and motivating feedback. Nudging and prompting is part of the solution.
75641359|NCT02703285|Other|Sound|task of the participants in the study to determine the chest sound based on specific sounds: Vesicular - Diminished; Expiratory Wheeze; Bronchovesicular; pneumonia; pulmonary Oedema; Stridor; Agonal respiration
75641360|NCT00791518|Drug|No intervention|No intervention
75641361|NCT02703129|Other|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
75641362|NCT03293901|Behavioral|Exercise|Treadmill exercise for 60 minutes with load carriage (weighted vest, 30% body weight) completed three times during the 6 day kinetic period.
75789724|NCT06147986|Biological|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.
75641363|NCT04787419|Other|placebo|saccharum lactis
75789725|NCT06147986|Other|Control group|Standard-of-care for STEMI
75925963|NCT06036407|Diagnostic Test|Hearing test|Participants visit a local hearing aid shop to assess their hearing function
75471269|NCT01950754|Behavioral|standing on the platform, feet together and always with simultaneous performance of a task of mental count|
75925964|NCT06036394|Diagnostic Test|The images (CT, MRI, PET) used for RT planning, mid-treatment imaging as part of IGRT or disease evaluation, and response assessment/ surveillance post-RT|The radiation plans and dose-volume histogram will be obtained from TPS. All the images and radiation-related data will be downloaded from the PACS and TPS, applying anonymization filters. Clinical features (patient, disease, treatment-related characteristics, and outcomes) will be extracted by review of electronic medical records. Imaging pre-processing will be done, which will include skull stripping and registration across different modalities (e.g., MRI and CT) or different sequences(e.g., T1C, T2W, ADC) will be done using rigid or deformable algorithms as suited best for the modality
75925965|NCT06036381|Diagnostic Test|Radiomic analysis of imaging - MRI, PET, CT|Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.
75925966|NCT06036368|Device|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve
75471270|NCT01950793|Drug|triamcinolone acetonide|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid"
75471271|NCT01950793|Drug|Hyaluronic Acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
75471272|NCT01950806|Other|Pecan-containing diet|
75641364|NCT04787419|Combination Product|probiotics|Lactobacillus acidophilus, Bifidobacterium longum, Strepococcus thermophilus
75641365|NCT02703051|Drug|GMI-1271|
75641366|NCT02703051|Drug|Filgrastim|
75641367|NCT02703051|Drug|Placebo Injection|
75641368|NCT02703051|Drug|Placebo Infusion|
75641369|NCT04107688|Other|Control|Subjects will use plain water as an oral rinse twice a day for 3 days.
75641370|NCT04107688|Other|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
76081101|NCT05429268|Drug|Tafasitamab|Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
75471273|NCT01950806|Other|Nut-free diet|
75789726|NCT06147167|Device|individualized intermittent theta burst sitmulation (iTBS)|Participants undergo daily sessions of individualized intermittent theta-burst stimulation (iTBS) administered with the MagStim stimulator (Rapid2, MagStim, Whiteland, United States). The intervention spans five days a week and extends over a three-week period. In this group, participants receive a personalized iTBS protocol comprising three pulses of stimulation delivered at 50 Hz, repeated every 200 ms. The stimulation frequency is tailored based on the electroencephalogram (EEG) results and is administered every 10 seconds, with a total duration of 190 seconds. The treatment is administered once a day for five days a week and continues for three weeks, with an immediate cessation in case of any discomfort. This study design ensures a meticulous and tailored approach to iTBS administration.
75471274|NCT01950832|Other|Investigating clinically normal patients with optic coherence tomography|
75471275|NCT01950845|Device|Closed loop automated System (LIR®: learning intravenous resuscitator)|Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
75471276|NCT01950845|Device|manual current practice by anesthesiologist team|The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
75471277|NCT01950858|Biological|Weight reduction|
75641371|NCT02691975|Drug|SHR3680|SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
75789727|NCT06147167|Device|standard iTBS|The MagStim stimulator (Rapid2, MagStim, Whiteland, United States) was employed in the current study. The intermittent theta-burst stimulation (iTBS) protocol utilized three pulses of stimulation delivered at a frequency of 50 Hz, with a repetition rate of every 200 ms. These pulses were organized into 2-second trains, repeated every 10 seconds, resulting in a cumulative duration of 190 seconds (equivalent to a total of 600 pulses). Notably, the administration of the treatment ceased promptly in the event of any participant discomfort.
75925967|NCT06036355|Drug|Oral NMN combined with DC cell vaccine|The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
75789728|NCT06147167|Device|sham stimulation|The device and protocol are identical to the standard iTBS, with the only difference being the orientation of the coil, which is perpendicular to the scalp.
75789729|NCT06144164|Procedure|Immediate Lymphatic Reconstruction|Immediate Lymphatic Reconstruction will happen at the time of Axillary Lymph Node Dissection
75789730|NCT06144164|Diagnostic Test|Volumetric arm measurements|Volumetric arm measurements will occur at each in-person postoperative visit time points.
75925968|NCT06036342|Diagnostic Test|MobiCARE test|7-days continuous electrocardiography monitoring using MobiCARE device
75925969|NCT06036329|Device|Group A : provided with 1 Whitsundays Nasal mask without a spare mask cushion|Group A will be provided with 1 Whitsundays Nasal mask without a spare mask cushion (replacement cushions will only be provided when requested)
75471278|NCT01950871|Device|Prostate HistoScanning|In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
75471279|NCT01950884|Drug|Ezetimibe|Ezetimibe tablets
75471280|NCT01950884|Behavioral|Lifestyle|lifestyle
75471281|NCT01950923|Drug|sildenafil citrate|Given PO
75471282|NCT01950923|Other|placebo|Given PO
75471283|NCT01950923|Procedure|therapeutic conventional surgery|Undergo standard robotic partial nephrectomy
75641372|NCT02702973|Other|Observe the fundus characteristics after therapy.|
75925970|NCT06036329|Device|Group B : provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|Group B will be provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
75471284|NCT01950936|Other|Discontinuation of Antibiotcs|Discontinuation of Antibiotcs against lower respiratory tract infections
75471285|NCT01950949|Other|300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation|
75641373|NCT00785512|Drug|Nebivolol|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
76081102|NCT05429268|Drug|Lenalidomide|Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
76081103|NCT05415488|Other|Online dietary group treatment|Dietary advice will be given during one 90 minute online group session
75471286|NCT01950962|Other|Sampling of blood|
75471287|NCT01950975|Biological|Peripheral blood samples in EDTA tubes|
75471288|NCT01950975|Procedure|Skin biopsies|
75471289|NCT01950988|Device|Manual toothbrush reference|
75641374|NCT00785512|Drug|Placebo|Matching placebo tablets, oral administration
75641375|NCT02702817|Drug|Naproxen|pale blue oval tablets
75789731|NCT06144164|Other|Lymphatic massage|Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
76081104|NCT05406635|Diagnostic Test|Biomarkers: Troponins and natriuretic peptides|Biomarker monitored treatment with measurement of NT-proBNP and cTNT / TNI in weeks 0, 9, 18, 30 and 48 of the treatment period.
76081105|NCT05405881|Other|Proprioception measurement tool|No intervention, as it is a psychometric properties study
75789732|NCT06144164|Other|Range of motion exercises|Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
75925971|NCT06036316|Behavioral|Language assessment|"The proposed speech and language therapy assessment will consist of a battery of standardized tests that speech and language therapists can use to assess the language skills in reception and expression of adult patients.~Concerning the assessment of the interactions between working memory and semantic abilities, a complete protocol has been developed."
75925972|NCT06036316|Behavioral|TLC - Scale for the Assessment of Thought, Language, and Communication|This scale is frequently used in psychiatry and is used to measure formal thought disorders in patients suffering from psychosis. As part of this study, it will be intended for patients suffering from schizophrenia
75925973|NCT06036316|Behavioral|MINI - Mini International Neuropsychiatric Interview|This scale corresponds to a rapid assessment of the psychiatric and psychological state of patients. It helps detect any psychiatric disorders. Here, it will be offered to volunteers who are part of the control group.
76081106|NCT05405166|Drug|Isatuximab IV|Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
76081107|NCT05405166|Drug|Isatuximab SC|Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
76081108|NCT05405166|Drug|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
75641376|NCT02702817|Drug|Placebo|pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
75641377|NCT04083079|Drug|PEG-rhG-CSF|Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
75789733|NCT06144164|Other|Compression garment use|Participants will use compression garments 24 to 48 h after surgery and will continue daily use for at least 8 h a day for 3 months or until 3 months after any adjuvant treatments are completed
76081109|NCT05405166|Drug|Pomalyst or equivalent|Pharmaceutical form: hard capsules; Route of administration: Oral
75789734|NCT06143657|Diagnostic Test|Automated Gram Staining Machine analysis|Measure urine and sputum specimens using this device.
75789735|NCT06132880|Drug|Human Urinary Kallidinogenase|Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.
76081110|NCT05403359|Drug|Steroids|"Description of the intervention in each of the work packages:~WP1A admission: Steroid dose >6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~WP2 ICU admission: High-dose steroids (dexamethasone >6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone >6 mg daily or equivalent corticosteroids) or no steroids up to day 28."
75789736|NCT06132880|Other|Clinical Routine Treatment|Conventional therapy of acute ischemic stroke after based on Chinese guidelines
75789737|NCT06127043|Drug|Rosnilimab|PD-1 agonist antibody
75789738|NCT06127043|Drug|Placebo|Administered via SC
75925974|NCT06036316|Combination Product|CAST - Cannabis Abuse Screening Test|The purpose of this questionnaire is to approximate participants' cannabis consumption and to assess any disorders associated with cannabis consumption. It will be offered to all participants, patients and healthy controls
75925975|NCT06036277|Other|General data|General data will be collected to ensure that both groups are comparable : maternal age, maternal BMI, gestational age, parity, number of children in current pregnancy, history of caesarian section, newborn child weight
76081111|NCT05402566|Diagnostic Test|Deuterium metabolic imaging|MRI after oral administration of 75g of [6,6'-2H2]glucose.
75471290|NCT01950988|Procedure|Measure of the dental plaque|
75471291|NCT01950988|Device|Manual toothbrush Broscyl®|
75471292|NCT01951001|Drug|Prasugrel|For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.
75471293|NCT01951014|Other|Social Media Education|Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
75471294|NCT01951027|Drug|GX-G3 12.5 μg/kg or Placebo|Single SC injection
75641378|NCT04083079|Drug|rhG-CSF|Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
75641379|NCT02702739|Drug|Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks|Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
75641380|NCT02602444|Drug|ticagrelor|180 mg loading dose
75641381|NCT02602678|Procedure|Supine then Prone position|One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)
75471295|NCT01951027|Drug|GX-G3 25 μg/kg or Placebo|Single SC injection
75471296|NCT01951027|Drug|GX-G3 50 μg/kg or Placebo|Single SC injection
75471297|NCT01951027|Drug|GX-G3 100 μg/kg or Placebo|Single SC injection
75641382|NCT02602678|Procedure|Prone then supine position|One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
75641383|NCT02702661|Procedure|Fascia Iliaca Compartment Block (FICB)|Fascia Iliaca Compartment Block
75789739|NCT06126276|Procedure|Biopsy|Undergo tumor biopsy
75789740|NCT06126276|Procedure|Biospecimen Collection|Undergo collection of blood samples
75789741|NCT06126276|Procedure|Computed Tomography|Undergo CT scan
75789742|NCT06126276|Procedure|Echocardiography|Undergo ECHO
75789743|NCT06126276|Procedure|Magnetic Resonance Imaging|Undergo MRI
75789744|NCT06126276|Procedure|Multigated Acquisition Scan|Undergo MUGA
75789745|NCT06126276|Drug|Neratinib Maleate|Given PO
75789746|NCT06126276|Drug|Palbociclib|Given PO
75798778|NCT05595226|Procedure|RT3D-TEE-guided mitral valve repair|RT3D-TEE forms a surgical plan before surgery and 3 to 4 senior doctors with more than 50 cases of mitral valve repair perform the procedure.
75798779|NCT05576428|Behavioral|Diet and exercise|diet and exercise in patients of NAFLD
75789747|NCT06125535|Diagnostic Test|Sub-phenotyping by biomarkers concentration|Plasma will be collected at ICU admission (i.e., < 6 hours from graft reperfusion), centrifuged (1500G for 15 min), frozen at -80°c, and then centralized at the Institutional laboratory. The following biomarkers will be assessed: sRAGE, SP-D, P-selectin (for alveolar damage); ICAM-1, IL6, IL8, IL10, TNF-alfa, IFN-gamma, CCL2, GM-CSF, TNFR1 (inflammation); angiopoietin-1, angiopoietin-2, TIMP-1 (endothelial damage). Analyses will be carried out on a Luminex platform (BioRad, Hercules, California, USA) - available at our Institution.
75789748|NCT06114875|Behavioral|Peer support intervention|"Flags will appear beside posts that the risk algorithm has identified as containing descriptions of distress or mental health concerns (these flags will not be visible to the original poster). Next to these flags, users will also see a brief blurb such as: This person might be going through something difficult. To learn more about what to say to peers who may be experiencing distress, click this banner. RallyPoint users will then have the option of clicking on these flags, where they will be directed to a psychoeducational information page on how to provide support to peers who may be experiencing distress."
75789749|NCT06114862|Behavioral|Stigma-reduction intervention|"Participants will be presented with a list of common reasons why people report not wanting to tell other people about their mental health concerns, drawing from research in this area. Participants will be asked to click on any reason that resonates with them or about which they are interested in learning more. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns. For example, if a participant replies that they wouldn't reach out to peers because others don't understand what I'm going through, we might present context showing that many of their peers have had similar challenges with mental health and have found peer support helpful. Participants will be able to click on as many reasons on this list that they would like to."
75925976|NCT06036277|Other|Other data|Other data collected will be used to estimate primary and secondary outcomes : request for an epidural anesthesia by the parturient, medical indication for peridural anesthesia, duration of childbirth, delivery methods, occurrence of maternal or neonatal complications.
75789750|NCT06114849|Behavioral|Treatment as usual|Treatment-as-usual will follow the existing RallyPoint procedures for concerning posts on the site. In the current procedures, a RallyPoint staff member sends a supportive message to the member containing resource information on the Veteran's Crisis line, 911, and connecting with a therapist. This information is typically sent within 24 hrs of seeing a concerning post. Participants in both the control and intervention conditions will receive treatment-as-usual.
75925977|NCT06036264|Other|Collected of Datas|age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)
75641384|NCT02702661|Procedure|Local Anaesthetic Infiltration (LAI)|Local Anaesthetic Infiltration (LAI) of the portal tracts
75641385|NCT02702661|Drug|Levobupivacaine|Levobupivacaine 0.125% - 40ml
75789751|NCT06114849|Behavioral|Barrier Reduction Intervention|"After a post is identified in real-time by the risk algorithm, participants will be shown a pop-up message offering information on mental health resources (e.g., crisis line). Participants will be asked about their likelihood of using these resources. For participants who indicate they are not likely to use these resources, they will then be presented with a list of common barriers to help-seeking, drawing from research in this area (e.g., Treatment is too expensive or I'm concerned about the police or paramedics getting involved.). Participants will be asked to click on any reason that resonates with them. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns and encourage professional help-seeking."
75789752|NCT06113016|Procedure|Biospecimen Collection|Undergo collection of blood samples
75789753|NCT06113016|Other|Educational Intervention|Receive handout on physical activity
75925978|NCT06036264|Other|semi-structured interview|Semi-structured interviews will be realized. The goal is to establish a qualitative analysis of the relevance and organization of pre-transplant assessments, of the reactivity in the adjustment of requests and assessments, and to identify the strong points or areas for improvement.
75925979|NCT06036199|Device|Focused Ultrasound Pallidotomy|Use of ExAblate Transcranial MR guided Focused Ultrasound as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
75925981|NCT06036095|Drug|Sevoflurane|Inhalational maintenance of anesthesia group using sevoflurane
75925982|NCT06036095|Drug|Propofol|Intravenous maintenance of anesthesia group using propofol
76081112|NCT05398354|Behavioral|Active retirement|"During the intervention, the sensorimotor training program will have a progressive increase in load, the exercises will be divided into 3 levels of intensity: easy (without external load, during the first 8 weeks), intermediate (application of external load: elastic bands, shin guards and free weights, from the 9th to the 16th week) and advanced (increased external load compared to the previous level, from the 17th to the 24th week).~During the sessions we will still assess the intensity through the subjective perception of effort (RPE) scale. In addition, adherence and control of the level of control through the Physical Activity Enjoyment (PACES) survey applied to participants."
76081113|NCT05397600|Drug|Bimatoprost Ophthalmic|Eyedrops
75641386|NCT04107532|Other|Virtual Reality Therapy and Imagination Exposure Therapy|Virtual Reality Therapy and Imagination Exposure Therapy
75641387|NCT04215549|Other|No intervention|cross sectional study，no intervention
75641388|NCT02702505|Biological|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted
75641389|NCT02702505|Other|ProRoot MTA|Control group
75641390|NCT02702349|Other|penicillin test|children are tested for penicillin allergy and then challenged with penicillin P.O.
75641391|NCT00785356|Drug|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
75641392|NCT00785356|Drug|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
75641393|NCT00785356|Drug|Placebo|Placebo, 2 capsules daily for 3 months
75641394|NCT02702427|Biological|virus-specific T-Cells|infusion
75789754|NCT06113016|Other|Exercise Intervention|Receive individually tailored exercise intervention
75925983|NCT06036043|Drug|Botulinum toxin type A|"The treatment will be administered either as a) subcutaneous infiltration with BoNT, covering the painful area, identified as allodynia during sensory examination, or b) perineural injection corresponding to the peripheral nerve(s) innervating the area where the pain is localized.~100 IU Xeomin is mixed with 4 ml NaCl. Injections are performed with a 1.5 cm spacing. Maximum of 40 injections (200 IU).~100 IU of botulinum toxin is mixed with 10 ml NaCl. For administration around multiple nerves, 50-100 IU per nerve (maximum 300 IU).~The treatment will primarily be provided by the principal investigator, or an anesthesiologist specializing in nerve blocks.~The specific method will be determined on an individual basis.~If there is no effect after one to two treatments, the treatment will be considered ineffective and discontinued. A treatment interval of 3 months has been established in accordance with a previous larger study."
75641395|NCT04104334|Drug|Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively|NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
75641396|NCT04104334|Drug|Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices|Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
75789755|NCT06113016|Drug|Fisetin|Given PO
75789756|NCT06113016|Other|Physical Performance Testing|Ancillary studies
75789757|NCT06113016|Drug|Placebo Administration|Given PO
75789758|NCT06113016|Other|Quality-of-Life Assessment|Ancillary studies
75925984|NCT06036030|Drug|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
75925985|NCT06036030|Drug|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
76081114|NCT05390567|Behavioral|Participant Choice of HPV Self-Test|Opportunity for participants to complete the HPV self-test in a non-clinical setting to be returned via a mailer or courier servie.
76081115|NCT05390567|Behavioral|Survey: Participant cancer history and cervical cancer prevention/screening knowledge|Asking women to respond to questions about their cancer history and knowledge of cervical cancer prevention and screening.
76081116|NCT05390567|Behavioral|Participant Choice of Standard of Care in-clinic Pap-test|Participant choice of cervical cancer screening method with either a SOC in-clinic pap test or HPV self-test
76081117|NCT05366166|Biological|Pembrolizumab|In the induction phase, participants will receive a single intravenous infusion of pembrolizumab 400 mg prior to chemoradiotherapy. In the Maintenance Phase, participants will receive pembrolizumab 400 mg every 42 days for 8 cycles.
76081118|NCT05366166|Drug|Olaparib|In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.
75641397|NCT02701959|Dietary Supplement|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (~530 mg nitrate derived).
75925986|NCT06036030|Drug|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
76081119|NCT05366166|Drug|Cisplatin|"In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly."
75641398|NCT02701959|Dietary Supplement|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (~3 mg nitrate derived).
75789759|NCT06113016|Other|Questionnaire Administration|Ancillary studies
75789760|NCT06111651|Behavioral|Parenting Intervention|parent training program with an added emphasis on ethnic-racial socialization and healthy lifestyle behaviors
75789761|NCT06111131|Device|Enteroscopy|A procedure that uses a specially equipped endoscope to examine the small intestine lining. An enteroscopy uses an endoscope, a tube with a light and camera on the end and the endoscope, in the case of this study, is equipped with a single balloon overtube to advance the scope deeper into the small intestine, to reach the middle third of the small bowel.
75789762|NCT06110754|Behavioral|I-STRONG for SCD|I-STRONG for SCD is a group-based, multi-component intervention that includes mind-body, cognitive-behavioral, and neuromuscular movement training. The intervention includes 16 sessions that occur over 8 weeks. Adolescents attend every session and parents attend 6 of the 16 sessions.
75789763|NCT06108011|Other|Lollipop|sucking of lollipop after operation
75789764|NCT06107582|Other|data collection|The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
75798780|NCT05576428|Drug|NAC with diet and exercise|NAC with diet and exercise in patients of NAFLD
75925987|NCT06036030|Other|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
75925988|NCT06035991|Procedure|Heart transplantation|Heart transplantation in patients who have obtained a favourable and motivated opinion from the Multidisciplinary Consultation Meeting (RCP) of the cardiac surgery department of the Hospital Pitié-Salpêtrière
75925989|NCT06035978|Drug|Nebivolol|Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
75925990|NCT06035978|Drug|Valsartan and Sacubitril|Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
75641399|NCT05055427|Drug|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|"Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. In additional, patients also receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.~Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.~Daily dose: 1 bag per time, 2 times per day"
75641400|NCT00785044|Drug|I-123 mIBG|This was an observational study. Participants were previously dosed in separate study.
75641401|NCT04215393|Drug|Conbercept eye drop|In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.
75925991|NCT06035978|Drug|Carvedilol|Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
75641402|NCT04215393|Drug|Placebo|In the second stage, subjects will be receive Conbercept eys drop or a placebo.
75332819|NCT05510388|Device|High-flow nasal cannula oxygenation|The patients receive oxygen flow of 6L/min for preoxygenation with an high-flow canular oxygenation device before losing of conscious. Then, the oxygen flow is adjusted to 60L/min with the oxygen concentration of 100% and the temperature of 37℃ until the end of procedure.
75641403|NCT02702037|Dietary Supplement|oral protein-rich supplement|The older person will be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week).
75471298|NCT01951053|Drug|JNJ-40411813|Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
75332820|NCT05510388|Device|Regular nasal cannula oxygenation|The patients receive an oxygen flow of 6L/min for preoxygenation with a disposal regular nasal cannula until the end of procedure.
75471299|NCT01951053|Drug|Placebo|Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
75471300|NCT01951053|Drug|Citalopram|Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
75471301|NCT01951079|Drug|Intra-amniotic injection of DIGOXIN|
75641404|NCT02702037|Other|Exercise|The older person will get up from a chair to stand and then sit down again repeatedly at least four times per day, 7 days during 12 weeks
75641405|NCT02602600|Drug|Liraglutide|"Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~Weight maintenance diet for 2 weeks"
75789765|NCT06106204|Other|ROAD Home Intervention|Hospitals randomized to receive the ROAD Home Intervention will undergo (1) a baseline needs assessment to create a customized suite of stewardship strategies, (2) supported decision-making in selecting ROAD Home strategies to implement, and (3) external facilitation following an implementation blueprint.
75789766|NCT06096844|Drug|Carboplatin|Given IV
75789767|NCT06096844|Procedure|Computed Tomography|Undergo CT scan
75789768|NCT06096844|Procedure|Magnetic Resonance Imaging|Undergo MRI
75789769|NCT06096844|Drug|Nab-paclitaxel|Given IV
75471302|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
75471303|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
75471304|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
75471305|NCT01951144|Drug|PF-06372865 or Placebo or Lorazepam|Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
75471306|NCT01951183|Drug|Placebo|RO681135 placebo subcutaneously daily
75471307|NCT01951183|Drug|RO6811135|Subcutaneously daily
75471308|NCT01951209|Drug|Rifaximin|550mg orally twice daily for 12 weeks
75471309|NCT01951209|Drug|Placebo|Matched placebo
75789770|NCT06096844|Drug|Paclitaxel|Given IV
75789771|NCT06096844|Biological|Pembrolizumab|Given IV
75789772|NCT06096844|Drug|Pemetrexed|Given IV
75789773|NCT06096844|Procedure|Positron Emission Tomography|Undergo PET
75789774|NCT06096844|Other|Quality-of-Life Assessment|Ancillary studies
75925992|NCT06035978|Drug|Bisoprolol|Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
75925993|NCT06035978|Drug|Metoprolol|Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
75925994|NCT06035978|Drug|Spironolactone|Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
75332821|NCT03827642|Drug|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
75332822|NCT03827642|Drug|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
75332823|NCT03827642|Drug|Treatment C: Naloxone HCl Intravenous (IV) Injection|Participants received naloxone HCl IV injection following a 10 hour fast.
75332824|NCT03827642|Drug|Treatment D: Naloxone HCl Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
75471310|NCT01951222|Drug|V0162|
75471311|NCT01951222|Other|Placebo|
75471312|NCT01951248|Device|CPAP - continuous airway pressure|3 months of treatment with CPAP treatment
75471313|NCT01951287|Other|Acute beverage (water) consumption|Acute beverage consumption includes water.
75471314|NCT01951287|Other|Acute beverage (Black Coffee) consumption|Acute beverage consumption includes black coffee.
75789775|NCT06096844|Other|Questionnaire Administration|Ancillary studies
75789776|NCT06094881|Drug|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 60 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
75925995|NCT06035952|Diagnostic Test|3D topographical scan|Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.
76081120|NCT05366166|Radiation|IMRT (intensity modulated radiation therapy)|In the chemoradiation phase, participants will receive 70 Gray external beam radiotherapy, at 2 Gray/fraction dose, 35 fractions, delivered once a day, on weekdays, using Intensity Modulated Radiotherapy Treatments or proton radiotherapy techniques, over 7 weeks.
75332825|NCT03827720|Device|SENSE Device|Non-invasive radiofrequency (RF) sensor
75641406|NCT00615537|Procedure|Laser Ablation of Thyroid Nodule|Laser ablation using a laser generator, disposable fiberoptic laser fiber, cooling catheter and pump, will be performed under conscious sedation. Ultrasound will be used to localize masses. Local anesthesia will be administered both intradermally and subcutaneously. The laser applicator will be placed into the mass and laser energy will be delivered at 15W for 30-120 seconds. Real-time ultrasound monitoring of the ablation front will be used to ensure complete treatment of the target lesion. In larger masses applicators may be placed of the applicator into multiple locations. The number of locations will be determined by the treatment team, and based on lesion morphology, size, location, and accessibility.
75641407|NCT04104958|Genetic|qRTPCR (mRNA level).|RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay
75641408|NCT00615615|Drug|Levetiracetam|"high total tablet weight (HTTW) formulation in tablet strengths of 166.5 mg, 250 mg, and 500 mg was used for patients weighing at least 40.1 kg~low total tablet weight (LTTW) formulation in tablet strengths of 166 mg and 250 mg was used for patients weighing 40 kg or less"
75641409|NCT00615615|Drug|Placebo|Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy
75641410|NCT02602366|Other|HEC Placebo Gel|
75641411|NCT02602366|Other|Placebo Vaginal Insert|
75789777|NCT06085573|Drug|Dexmedetomidine Hydrochloride|"<Sedation of non-invasive procedures and tests without intubation in pediatrics> For children aged 2 years or older, the usual dosage of dexmedetomidine is 12 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~For children aged 1 month to < 2 years old, the usual dosage of dexmedetomidine is 9 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~The infusion rate should be reduced according to patient's condition."
75789778|NCT06085313|Behavioral|CAI|Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality
75925996|NCT06035926|Other|questionnaire|questionnaire
75925997|NCT06035913|Drug|Dihydroergot mesylate|take medicine
75925998|NCT06035900|Drug|Psilocin|single 4mg dose of psilocin mucate was administered to healthy 10 volunteers
75641412|NCT02602366|Other|Placebo Vaginal Film|
75925999|NCT06035887|Diagnostic Test|Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated)|RETEval Complete hand-held electroretinogram
75926000|NCT06035887|Diagnostic Test|Trolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated)|UTAS multifocal electroretinogram
75926001|NCT06035887|Diagnostic Test|Spectral-Domain Optical Coherence Tomography (Standard of Care test)|Heidelberg Engineering Spectralis Spectral-Domain Optical Coherence Tomography (macular structural scan)
75926002|NCT06035887|Diagnostic Test|Macular Autofluorescence (Standard of Care test)|Heidelberg Engineering Spectralis Autofluorescence imaging (macular structural image)
75926003|NCT06035861|Drug|XBD173|Participants will be treated with XBD173 90mg, once or twice daily, for 8 weeks
76081121|NCT05362968|Drug|Freeze-dried strawberry powder|Whole strawberries are freeze-dried to form a powder with improved shelf life that will be used in this research study. Strawberry powder will be provided by the California Strawberry Commission (Watsonville, CA)
76081122|NCT05359185|Behavioral|Family Wellness|https://familywellness.com/
75641413|NCT02602366|Other|Placebo Intravaginal ring (IVR)|
75641414|NCT00784810|Drug|Oxycodone/Naloxone|5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
76081123|NCT05359185|Behavioral|Career Coaching|Individualized career coaching and employment services.
76081124|NCT05359185|Behavioral|Financial Planning|Individualized financial planning services.
76081125|NCT05352958|Procedure|Diaphragmatic ultrasound|duration 15 minutes, performed at M0, M3, M6 and M9
76081126|NCT05352958|Other|Electro-physiological exploration of the diaphragm|duration between 30 and 60 minutes performed at M0
75332826|NCT05505786|Behavioral|Normal stance width|Normal self-selected stance width when performing squat exercises.
75332827|NCT05505786|Behavioral|Wide stance width|Increased stance with (by 20% over their own self-selected stance width) when performing squat exercises.
75332828|NCT03827486|Other|Standard of care (exercise)|Exercise program according to the standard of care
75332829|NCT03827486|Other|Domicilary exercise program|Domicilary exercise program according to protocol (evidence based medicine)
75332830|NCT05510310|Procedure|Breast stimulation|By breast pump
75332831|NCT05510310|Biological|Oxytocin|Oxytocin will be administered intravenously and titrated
75332832|NCT04129034|Device|Neurolyser XR|Non-Invasive Thermal Ablation of the Medial Branch Nerves
75471315|NCT01951287|Other|Acute beverage (Orange Juice) consumption|Acute beverage consumption includes Orange Juice..
75641415|NCT00784810|Drug|Codeine/Paracetamol|15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
75641416|NCT02701803|Device|Parkinson's KinetiGraph™ logger|Logger is recording device which records the movement and acceleration of upper extremity
75641417|NCT02603770|Drug|XueZhiKang|
75789779|NCT06085313|Behavioral|CAPA|Web App-based information and coaching/support program for cancer pain management
75926004|NCT06035848|Procedure|Association of the components of metabolic derangement and paracentesis.|"In the intervention group were determined:~Components of metabolic derangement~Paracentesis. Determination of surgery: 3 positive points of the components of the metabolic derangement and a positive paracentesis.~The components of the metabolic derangement are the 7 parameters described by Tepas: positive blood culture, metabolic acidosis, neutropenia, bandemia, thrombocytopenia, hyponatremia and hypotension, being considered positive when 3 or more parameters are present.~Paracentesis was considered positive according to Kosloske's criteria: obtaining more than 0.5ml of serohematic fluid, Gram-positive fluid and obtaining fecal material.~Both groups had the same pre, trans and postoperative care."
75926005|NCT06035848|Procedure|Bell's criteria: pneumoperitoneum|In the control group, the surgery was determined according to Bell's criteria, in the presence of radiographic pneumoperitoneum as an absolute indication for surgery.
75789780|NCT06079372|Drug|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
75789781|NCT06079372|Drug|asfotase alfa|Asfotase alfa will be administered via SC injection.
75789782|NCT06079281|Drug|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
75789783|NCT06079281|Drug|Placebo|Placebo will be administered via SC injection.
75926006|NCT06035835|Combination Product|Lacticaseibacillus rhamnosus|Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day)
75926007|NCT06035835|Combination Product|Lactobacillus acidophilus + Bifidobacterium bifidum|Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h)
75789784|NCT06078475|Other|Postoperative analgesia management|Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
75789785|NCT06077331|Drug|HS-10374 tablets 1mg|Administered orally QD for 12 weeks
75926008|NCT06035796|Device|tNGS|By means of super-multiple PCR amplification or probe hybridization capture, tNGS can enrich dozens to hundreds of known pathogenic microorganisms and their virulence and drug resistance genes in the samples to be tested, and then conduct high-throughput sequencing.
76081127|NCT05350462|Behavioral|Community pilot L-PZQ distribution - intervention is NOT part of this observational study|Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.
76081128|NCT05330780|Other|Breathing Room|8 total group classes performed twice a week over the course of 4 weeks, with IMTs utilized during the classes as well as 3 days outside of the class days at 5 sets of 5 breaths completed 5 times a day
76081129|NCT05313516|Device|OKKO Health app|Use of OKKO Health app for home monitoring.
76081130|NCT05304052|Behavioral|Mindfulness Meditation classes|The mindful awareness practices (MAPS) intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA, but takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life (as compared to the focus on stress and stress reduction in mindfulness-based stress reduction). Key components of the intervention include development of bodily awareness, managing pain, working with difficult thoughts and feelings, cultivating positive emotions and loving kindness, and relational mindfulness practices. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for group discussion and sharing. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes.
76081131|NCT05289076|Drug|Chemotherapy drug|Different combinations of chemotherapies will be tested in combination with monoclonal antibodies in zebrafish embryos against inplanted patients livermetastatic tissues.
76081132|NCT05282485|Dietary Supplement|Synbiotic|Synbiotic (2'-FL HMO + B. infantis probiotics)
76081133|NCT05282485|Dietary Supplement|Maltodextrin|Maltodextrin
75641418|NCT02603770|Drug|Lovastatin|
75641419|NCT04081909|Drug|Fentanyl，Remifentanil|Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.
75789786|NCT06077331|Drug|HS-10374 tablets 5mg|Administered orally QD for 12 weeks
75789787|NCT06077331|Drug|HS-10374-matched placebo tablets|Administered orally QD for 12 weeks
75789788|NCT06074237|Other|Immersive resident education|Using the AIMS framework (Announce, Inquire, Mirror, Secure), residents will complete online modules designed to improve vaccine education, promote vaccine confidence and improve vaccine counseling in general. There will also be modules dispelling myths and controversies specific to HPV, MMR, Covid and influenza vaccines that often limit or prevent vaccination uptake.
75471316|NCT01951287|Other|Acute beverage (Whole Milk) consumption|Acute beverage consumption includes whole milk
75471317|NCT01951287|Other|Acute beverage (2% Milk) consumption|Acute beverage consumption includes 2% milk
75471318|NCT01951287|Other|Acute beverage (Skim Milk) consumption|Acute beverage consumption includes skim milk
75641420|NCT04081909|Drug|Ketamine,Dexmedetomidine|Patients in OFA,anesthesia induction will receive ketamine 1 mg/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , dexmedetomidine of 0.4-0.8ug/ kg/ hr.
75641421|NCT03272217|Drug|Atezolizumab|Atezolizumab 1200 mg (flat dose) IV every 21 days
75641422|NCT03272217|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
75798781|NCT03751020|Behavioral|Expressive Writing (EW) Intervention|The EW intervention will utilize the procedures piloted earlier with gay and bisexual male college students in urban and rural regions of the US. In this condition, participants will be instructed to write for 20 minutes across three consecutive days in a free-form manner about the most stressful or traumatic LGB-related event that they have encountered.
75332833|NCT05510232|Device|A treatment group that will watch a non-VR video via an iPad|"The iPad is a tablet computer first offered by Apple in 2010.The device resembles a much larger version of Apple's iPhone or its iPod Touch, and is about the same size as a magazine.The iPad uses the same operating system as the Apple iPhone, and uses very similar hardware. iPad will be used to deliver non VR video to patients.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups."
75641423|NCT02586571|Behavioral|Breastfeeding|Breastfeeding at 5.5 months of age (exclusive or partial)
75641424|NCT02701725|Device|CRI status|Measurement of CRI
75332834|NCT05510232|Device|A treatment group that will have headset on and will watch a non-VR video|"Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver non VR video to patients. Headset will be administered before intervention and removed at the completion of the intervention unless patient requests otherwise. Patients visual field will not change with head motion and will remain static throughout cast removal or pin/suture removal.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups."
75471319|NCT01951300|Other|Gallium-68 citrate|Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
75641425|NCT00919945|Other|Continuous feeding at time 1 and NPO at time 2|Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
75789789|NCT06074237|Other|Standardized patient (SP) encounter|"After completion of the Immersive Resident Education modules, residents will participate in a telemedicine standardized patient encounter. They will interview a vaccine-hesitant patient and this encounter will be video recorded. At the end of the encounter, the SP will provide the resident with patient-centered feedback on their communication skills. The SP will also complete a communication checklist regarding each resident encounter and the research team will review the recorded encounters for accuracy of medical content conveyed during each encounter."
75789790|NCT06071884|Device|Bridge Percutaneous Nerve Field Stimulator|The Bridge device is an FDA-cleared, drug-free, non-surgical device that uses neuro-modulation to aid in the reduction of symptoms associated with opioid withdrawal through application to branches of the Cranial Nerves V, VII, IX, X, and the occipital nerves. This study is investigating its effectiveness treating post-surgical pain.
75641426|NCT00919945|Other|NPO at time 1 and continuous feeding at time 2|NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
75926009|NCT06035783|Device|Orbital Atherectomy|The Diamondback 360° Coronary orbital atherectomy system (OAS) is a device dedicated to debulk severely calcified coronary lesions to facilitate stent delivery and enable stent expansion with optimal results. The OAS's main mechanism is the synergistic rotation of the crown around its axis and simultaneously its endoluminal orbital motion. This effect allows blood to flow continuously and it facilitates heat dispersion which results in reduced heat damage to the arterial walls and subsequently to less myocardial damage, at the same time it softens the plaques tissue. It also appears that the microparticles created from sanding the artery plaques do not create any agglomeration to the branching arteries
76081134|NCT05280535|Behavioral|Cue Reactivity Task|In the cue-reactivity task, participants will be exposed to either a combustible cigarette or e-cigarette cue (within-subjects randomized order across laboratory sessions) and a neutral water bottle cue. Participants will report their craving for cigarettes and e-cigarettes.
75641427|NCT00613899|Other|telesurveillance|A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).
75471320|NCT01951313|Other|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (< 2g) and low carotenoid (< 2000µg) meal as the 2nd meal.
75471321|NCT01951404|Drug|Allopurinol|
75641428|NCT00791128|Device|GI Liner|Medical device placed endoscopically in the duodenum, nutritional counseling
75641429|NCT04081597|Drug|Star-101|Administered orally
75641430|NCT04081597|Drug|Placebo|Administered orally
75471322|NCT01951404|Drug|Placebo (for allopurinol)|
75641431|NCT04107376|Diagnostic Test|Retroviewing endoscopy|The colon is inspected with a new retroviewing endoscope
75641432|NCT02587039|Procedure|Remote ischemic pre-conditioning|Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
75789791|NCT06070194|Behavioral|Time restricted eating (TRE)|Subjects randomized to this arm will be asked to follow an 8h eating duration/day for 4 weeks. Participants will be asked to continue habitual sleep patterns.
75641433|NCT02587039|Behavioral|Delirium Assessment|The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
75641434|NCT03262701|Drug|Hydrogen Peroxide Gel, 13 weeks|13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
75641435|NCT03262701|Drug|Hydrogen Peroxide Gel, 26 weeks|26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
75641436|NCT03262701|Other|Scaling and Root planing group|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without custom tray application of 1.7% peroxide gel
76081135|NCT05280535|Behavioral|Computerized Visual Dot Probe|In the computerized visual dot probe task, participants will view a series of substance (cigarette or e-cigarette by trial block) versus neutral (water bottle) image trials and then respond to a subsequent image presented behind either the neutral or substance image. Order of block presentation within the task is randomized within-subjects across study sessions (i.e., cigarette OR e-cigarette block first).
75332835|NCT05510232|Device|A treatment group that will be immersed in the VR game (Bear Blast) via the headset.|VR using the Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver VR images and sound. Patients will watch a 15-minute VR experience called Bear Blast. Bear Blast is an immersive, 360-degree, game experience that takes place in a fantasy world where the user attempts to shoot balls at a wide range of moving objects by gently maneuvering his or her head toward the targets. Bear Blast is a nonviolent and noncompetitive game that incorporates motivational music and features positively reinforcing sounds, animation, and direct messages to patients. Bear Blast will be used as the standardized game for all patients in the VR group of both study arms. The VR reality Samsung Oculus headset can be controlled entirely via head motion and does not involve the use of patients extremities. iPad will be set up and held for patients in the iPad group.
75332836|NCT04123574|Drug|Talabostat Mesylate|"BXCL701 tablets dosage strengths include 0.2mg and 0.05mg tablets for oral administration.~Patients are to self-administer the prescribed number of BXCL701 tablets for a total daily dose of 0.6 mg. BXCL701 should not be taken on an empty stomach.~Daily blood pressure monitoring will be performed during the dosing period. Administration of at least 1L of intravenous (IV) fluids is required on Day 1.~On days when pharmacokinetic (PK) assessments are being performed, BXCL701 should be administered at the study center and should be administered at (approximately) the same time of day on each treatment day."
75332837|NCT05500950|Other|CDU and CT-DCG or CT examination|patients with space occupying lesions in the lacrimal sac area completed CDU and CT-DCG or CT examination before surgery
75471323|NCT01951430|Drug|Antibiotic and antifungal drugs|
75471324|NCT01951443|Dietary Supplement|Ginseng|400mg of encapsulated Rg3-KRG
75641437|NCT00915382|Drug|S-1 and cisplatin|"S-1: 80 mg/m2/day po on Days 1-14~cisplatin: 60 mg/m2 iv on Day 1"
75641438|NCT00915382|Drug|S-1 and cisplatin|"S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and~cisplatin: 60 mg/m2 iv on Day 1 or 8"
75641439|NCT04103866|Device|Juvederm Voluma|Juvederm will be used in various parts of the foot to increase collagen volume and decrease high pressures of stress typically seen as people age. It will serve to promote the following: foot cushioning due to tissue atrophy, increase comfort when walking, decrease gait peak pressures which will decrease stress on bones and soft tissue and heal calluses, skin lesions, etc. It will also decrease the patient need for balancing and offloading by the use of an in-shoe orthotic device that requires a closed shoe system. Many people complain of pain walking barefoot, in high heels and sandals where orthotics are not effective.
75641440|NCT02701881|Device|Long stenting using drug-eluting stent (Zilver PTX)|Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty
75641441|NCT02701881|Device|Spot stenting using drug-eluting stent (Zilver PTX)|Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion
75641442|NCT02602522|Drug|Shandong Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
75641443|NCT02602522|Drug|Sichuan Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
75789792|NCT06066996|Drug|Transdermal Nicotine Patch|Blinded Nicotine Patch
75789793|NCT06066996|Drug|Placebo Nicotine Patch|Blinded Patch with No Nicotine
75926010|NCT06035770|Other|Mental Health First Aid (educational training program)|"The MHFA program is a 12-hour face-to-face training program delivered in four sessions of three hours each across four consecutive weeks by two accredited MHFA instructors. The class was administered in small groups with a maximum of 10-15 students.The program included didactic lectures and role playing to teach students how to recognize and react to the signs and symptoms of mental health illness. Participants enrolled in the intervention group received an accompanying manual with content that covered helping people in mental health crises and/or the early stages of mental health problems.~The mental health problems addressed during the training session included depressive symptoms, anxiety, psychotic disorders, and substance use disorders. The mental health crisis situations included suicidal thoughts/attempts and behaviors, acute stress reactions,panic attacks, and acute psychotic behaviors."
75471325|NCT01951443|Dietary Supplement|Wheat Bran|400mg of encapsulated wheat bran
75471326|NCT01951456|Behavioral|Resistance training|
75471327|NCT01951456|Behavioral|Health and Wellness|
75471328|NCT01951482|Drug|Pemetrexed/cisplatin|receive Pemetrexed/cisplatin every 21 days
75789794|NCT06066684|Other|n/a, observational|n/a, observational study
75798782|NCT03751020|Behavioral|Self-Affirmation (SA) Intervention|The SA intervention will ask participants to read a brief description, over the course of 3 consecutive days, of a (hypothetical) LGB youth who is facing minority stress. Each day's description will contain a different LGB youth facing a different stigma-related stressor derived from Phase 1 and 2 interviews. Participants will then be asked to write a letter for 20 minutes to advise the LGB youth how best to cope with minority stress drawing on their personal experiences.
75926011|NCT06035757|Drug|Bridion 200 MG in 2 ML Injection|Sugammadex and neostigmine are administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each revesal agent is determined with response to TOF or PTC.
76081136|NCT05280535|Behavioral|Choice Task|In the choice task, participants will choose between smoking their usual brand cigarette or their own e-cigarette over ten sequential ad-libbed trials.
76081137|NCT05280275|Drug|Belantamab Mafodotin-Blmf|"Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes."
75332838|NCT04128098|Other|Evaluation|"Functional tests: 400-meter walking test, 200-meter brisk walking test, Sorensen test, Shirado test, measurement of maximum isometric force of extensors/back flexors.~3D analysis of locomotion and posture~Test of the flexion-relaxation phenomenon of the lumbar erector muscles"
75641444|NCT02701569|Other|Rebound exercise|Repeated jumping on a mini trampoline was administered
75641445|NCT04152135|Procedure|vena cava inferior diameter measurement|Ultrasound equipment with convex probe will be used to measure IVC diameters of the patients in supine position.The IVC sagittal section is described with the probe in the area of subxiphoid. IVC diameters at the junction point of the IVC and right atrium (2cm caudal) are standardized measurement.
75926012|NCT06035757|Drug|Neostigmine Methylsulfate|Sugammadex and neostigmine are administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each revesal agent is determined with response to TOF or PTC.
75926013|NCT06035705|Other|Patient acuity tool|A tool for measuring patient acuity as a part of daily management will be implemented in four somatic in-patient care units.
75926014|NCT06035679|Drug|Pyrotinib and Trastuzumab|Small and large molecules combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer
75926015|NCT06035666|Other|Your World|Your World consists of a vitality session and use of the Your World app
75926016|NCT06035666|Other|Control app|Control app, no effect on stress/vitality
75926017|NCT06035640|Other|Interview|Participants will be engaged in a semi-structured interview.
75926018|NCT06035627|Other|Prevention hypothermia|Hypothermia was prevented by warming the case group. control group remained stable. As a result, the presence of surgical site infection was followed.
75471329|NCT01951482|Drug|Bevacizumab and Pemetrexed/cisplatin|receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days
75471330|NCT01951508|Drug|Methylphenidate|60mg per os, single dose
75471331|NCT01951508|Drug|Modafinil|600mg per os, single dose
75641446|NCT05344443|Drug|Lemborexant|A dual orexin antagonist
75641447|NCT05344443|Drug|Placebo|A placebo that looks and tastes like Lemborexant tablets
75641448|NCT02701335|Device|Neural mobilization|The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.
75641449|NCT02701335|Device|Gloreha device|Robotic assisted passive mobilization.
75926019|NCT06035614|Device|exciplex|exciplex, excimer lamp 308nm produced by clarteis
75926020|NCT06035614|Drug|Tacrolimus ointment|tacrolimus monohydrate ointment 0.1% TACRUS
75926021|NCT06035588|Other|Daily whitening|Daily application of a 16% carbamide peroxide bleaching gel in volunteers without sensitivity.
75332839|NCT04128098|Other|Questionnaires|Self-questionnaires: Oswestry, Québec, SF-12, VAS pain, HAD, pain dramatization questionnaire, physical activity questionnaires, VAS and GPE satisfaction, FABQ, GPE functional status and EPICES score.
75332840|NCT04128098|Other|Rehabilitation care program|"Personalized global exercises (aerobics) on ergometers~Muscle strengthening with resistance~Balneotherapy~Learning health skills related to their condition (therapeutic education)~Personal and group motivational interviews~Nutritional advice~Relaxation session"
75471332|NCT01951508|Drug|MDMA|125mg per os, single dose
75471333|NCT01951508|Drug|Placebo|per os
75471334|NCT01951521|Radiation|Boost|External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
75471335|NCT01951534|Behavioral|Breast Reconstruction Decisional Aid (BRDA)|
75471336|NCT01951534|Behavioral|Usual Care|
75471337|NCT01951547|Procedure|Nonsurgical periodontal therapy|Periodontal intervention All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
75471338|NCT01951547|Procedure|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
75471339|NCT01951560|Drug|Valproic Acid|By infusion over 1 hour
75471340|NCT01951560|Drug|Isotonic saline solution|By infusion over 1 hour
75471341|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
75641450|NCT02701335|Device|Standardized exercise|9 exercises: active range of motion, strengthen grip and pinch
75641451|NCT02701491|Dietary Supplement|Ginger|ginger
75641452|NCT02701491|Other|Placebo|Placebo
75926022|NCT06035588|Other|Alternate whitening|Volunteers will apply the whitening gel at 16% carbamide peroxide, alternating a rest day with an application day. Patients should not be sensitive before starting the study.
75926023|NCT06035562|Behavioral|PVSET|6, one-hour sessions of individual therapy, consisting of Positive Valence System Enhancement Treatment for Anxiety and Depression (PVSET), which will consist of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
75926024|NCT06035549|Behavioral|Culturally Tailored Digital Resilience-Building|The Culturally Tailored Digital Resilience-Building intervention consists of 6 modules, including an introduction of advance care planning and resilience skills that specifically address cultural beliefs and barriers.
75926025|NCT06035510|Dietary Supplement|whey protein supplement|Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative care on postoperative outcomes after gynecological cancer surgery
75641453|NCT00919555|Drug|Pioglitazone and Tretinoin|Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)
75789795|NCT06064110|Behavioral|Pictou County Person Empowerment Program|The 6 month home-based program focuses on aerobic and strength training, meditation/relaxation techniques, social connection, and overall healthy lifestyle practices supported with daily email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily, the meditation/relaxation practice is 10 minutes daily, the intimacy and connection component consists of engaging in at least one form of intimacy practice prescribed, per day. Optional social connection components will be offered, such as pairing participants up with peers from the study, monthly Zoom videoconferences, and monthly in-person events in Pictou County to further promote healthy lifestyle habits.
75789796|NCT06056505|Procedure|partial kidney nephrectomy|surgery for partial nephrectomy
75926026|NCT06035484|Other|Seat height|Seat height of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
75926027|NCT06035484|Other|Seat inclination|Seat inclination of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
76081138|NCT05280275|Drug|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
75926028|NCT06035471|Diagnostic Test|MeD-seq|MeD-seq analyse: DNA treatment bisulfite --> unmethylated C-nucleotide trabsformed in uracil.--> PCR --> next generation sequencing (NGS) --> localization methylated nucleotides (enzym LpnPI).
76081139|NCT05280275|Drug|Lenalidomide|Lenalidomide will be administered per os.
75471342|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).
75471343|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).
75471344|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.
75471345|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.
75471346|NCT01951612|Behavioral|Executive Function Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
75471347|NCT01951612|Behavioral|Psychoeducational Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
75471348|NCT01951664|Other|Baseline Study Measures|Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
75471349|NCT01951664|Behavioral|Yoga Evaluation|The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
75641454|NCT00919555|Drug|Tretinoin and Pioglitazone HCL|Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day
75641455|NCT00919555|Drug|Placebo|Placebo
75641456|NCT02979093|Drug|Oxytocin|All women will receive a nasal spray containing oxytocin.
75641457|NCT02979093|Drug|Placebos|All women will receive a nasal spray containing a placebo solution.
75641458|NCT02979093|Procedure|Functional MRI scanning|Study participants undergo two functional MRI scans.
75641459|NCT02588131|Drug|tremelimumab plus MEDI4736|tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
75641460|NCT04767139|Behavioral|counseling for family planning|all mothers presented to infant immunization units of the selected health centers will be counseled for family planning service and referred to the family planning unit if they decided to use.
75789797|NCT06056505|Device|DaVinci Robot|device to perform the surgery for partial nephrectomy (not the intervention of interest)
75789798|NCT06056505|Device|Innersight 3D software|investigational product to generate the 3D model
75789799|NCT06052098|Device|The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system|Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.
75926029|NCT06035432|Other|Bluesky software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Bluesky software.
76081140|NCT05280275|Drug|Dexamethasone|Dexamethasone will be administered intravenously or per os.
76081141|NCT05278065|Other|Nicotine|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at weekly assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose commercially available e-liquid flavors (tobacco) at each weekly assessment.
76081142|NCT05244226|Drug|Fentanyl/Hydromorphone|Per routine care
76081143|NCT05244226|Drug|Methadone|Initial dosing 0.1mg/kg, potential to escalate to 0.15mg/kg following interim analysis
76081144|NCT05242874|Drug|Fosaprepitant , Tropisetron and Olanzapine|fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. tropisetron 5mg i.v. on day 1 before undergoing chemotherapy. olanzapine 5mg p.o. on day 1-4
76081145|NCT05242874|Drug|Fosaprepitant , Tropisetron, Dexamethasone and Olanzapine|"On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.~fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. tropisetron 5mg i.v. on day 1 before undergoing chemotherapy. olanzapine 5mg p.o. on day 1-4"
76081146|NCT05237869|Device|Blood Flow Restriction Device|Occlusion training involves the application of a cuff to the upper arm that is designed to restrict only the low-pressure blood flow in veins. It does not prevent blood flowing from the heart to the arm.
75789800|NCT06052098|Device|The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system|Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.
75789801|NCT06042413|Other|Personalized CPC Prehabilitation|Patients for elective surgery randomized to the intervention group will be scheduled for a preoperative evaluation (3-6 weeks prior to the surgical date) and will receive standardized and personalized assessment and prehabilitation according to UPMC's established disease-specific algorithms.
75332841|NCT05500872|Other|Cross-education and blood flow restriction training|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. During this training, a cuff will be worn from the upper part of the thigh muscles, as in the blood pressure devices, which will slow down the blood flow in the leg. The participant will be cross-educated with the cuff inflated to a safe pressure range that will not cause discomfort. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
75471350|NCT01951664|Behavioral|Yoga Program|The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
76081147|NCT05237869|Other|Standard Physical Therapy|Standard physical therapy protocol for lateral epicondylitis rehab without blood flow restriction.
75641461|NCT04766983|Diagnostic Test|bronchoalveolar lavage|BAL and ETA are performed as per clinical practice on clinical suspicion of VAP (Johanson score)
75641462|NCT04766437|Drug|Prasugrel 10mg|Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
75641463|NCT04766437|Drug|Ticagrelor 90mg|Twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
75641464|NCT00776230|Biological|IC51|6 mcg im. at day 0 and day 28
75641465|NCT02586259|Drug|budesonide MMX®|
75641466|NCT00775606|Drug|Lopinavir 400 mg/ritonavir 100 mg|Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
75641467|NCT00775606|Drug|Efavirenz|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
76081148|NCT05224986|Behavioral|Fixed Schedule|Participants will be asked to maintain a fixed schedule for 12 weeks.
76081149|NCT05213273|Behavioral|nutritional guidelines to promote healthy diet and increase fish intake|"Nutritional guidelines based on the Mediterranean diet will be provided to both groups (gropu A and group B) through infographic material, recipes and menus.~Both groups will be guided to increase their fish consumption to 3 servings per week. Group A will do that through the consumption of fresh or frozen fish and group B through fresh, frozen and canned fish."
75641468|NCT04761601|Drug|UCT-01-097|Orally available kinase inhibitor
75641469|NCT04761601|Drug|Gemcitabine|Gemcitabine injection for intravenous use.
75641470|NCT04761601|Drug|Paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound).
75641471|NCT02960763|Drug|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
75641472|NCT02960763|Drug|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
75641473|NCT02960763|Drug|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
75641474|NCT02960763|Drug|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
75641475|NCT02960763|Drug|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
76081150|NCT05194124|Drug|Setmelanotide 20mg weekly|1:1 randomization in the double blind period, followed by open label
76081151|NCT05194124|Drug|Placebo daily|1:1 randomization in the double blind period
76081152|NCT05194124|Drug|Setmelanotide 30mg weekly|1:1 randomization in the double blind period, followed by open label
76081153|NCT05194124|Drug|Setmelanotide 2mg daily|1:1 randomization in the double blind period
76081154|NCT05194124|Drug|Setmelanotide 3mg daily|1:1 randomization in the double blind period
76081155|NCT05194124|Drug|Placebo weekly|1:1 randomization in the double blind period
76081156|NCT05175469|Diagnostic Test|Flow cytometric analysis of neutrophil myeloperoxidase expression|"Performance of flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed on the same day of collection.~Blood samples will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8/12-color flow cytometer and analyzed using flow cytometry software. Myeloperoxidase expression in the peripheral blood neutrophil population within an individual subject will be expressed as intra-individual robust coefficient of variation (RCV)."
75641476|NCT00775528|Drug|Pancrelipase Delayed Release|3,000, 6,000 and 12,000 unit Lipase Capsules
75641477|NCT04760665|Biological|Fecal microbiota transplantation|Patients will receive four fecal microbiota transplantation (FMT) capsules. Microbiota is obtained from healthy patients.
75641478|NCT04760665|Other|Placebo|Patients will receive four oral capsules containing placebo. These capsules will have the same shape, weight and colour as capsules containing FMT.
75641479|NCT02700867|Device|NIO|Intraosseous access device NIO (Defibtech)
75789802|NCT06042413|Behavioral|Cognitive Training|Participants will be provided with access to the Lumosity (Lumos Labs) software for installation on a home device. They will be trained to navigate the touchscreen tablet and guided through an introductory series of brain exercise games focused on 5 main categories: memory, speed, attention, flexibility, and problem-solving. Patients will be asked to complete a cognitive exercise dosage of a minimum of 20 minutes a day for ≥5 days prior to their date of surgery. Research coordinators and volunteers from UPMC's Hospital Elder Life Program (HELP) will reach out to participants daily for a quick social check-in and to remind them to perform their training. Compliance data will be retrieved from the Lumosity app.
75789803|NCT06042413|Behavioral|Meditation|A single guided meditation session with instructions will be provided using a smart device. The meditation session will last for at least 10 minutes daily starting at least 1-week prior to surgery. If the subject does not own a smart device, one will be provided or meditation will be completed in-person or over the phone.
75798783|NCT03751020|Other|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days. This control matches the time and activity of the EW and SA arms and has been implemented across dozens of EW and SA studies.
75926030|NCT06035432|Other|3D slicer software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by 3D slicer software.
76081157|NCT05157464|Drug|Losartan|Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
75798784|NCT01176708|Drug|dipeptidyl peptidase 4 (DPP4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
75926031|NCT06035432|Other|OnDemand software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by OnDemand software.
76081158|NCT05155605|Device|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
76081159|NCT05154318|Procedure|Pericapsular Nerve Group Block|Nerve block targeting major hip joint sensory nerves.
76081160|NCT05154318|Procedure|Fascia iliaca compartment block|Routine nerve block for hip fracture surgery.
76081161|NCT05153863|Device|C Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
75798785|NCT01176708|Other|oral glucose|50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
75926032|NCT06035432|Other|Mimics software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Mimics software.
75471351|NCT01951664|Behavioral|Yoga Practice Plan|To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
75641480|NCT04977271|Drug|Venlafaxine|The Immediate Release generic formulation of this drug will be used due to its ability to be crushed for those patients who rely on parenteral administration of medications.
75641481|NCT05343897|Behavioral|Low intensity exercise - Ping-Shuai Gong (PSG)|Participants were asked to conduct and record 30 minutes of PSG in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
75641482|NCT05343897|Behavioral|Low intensity exercise - Arm-Swing Exercise (ASE)|Participants were asked to conduct and record 30 minutes of ASE in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
75641483|NCT02701179|Drug|Lignocaine 1% concentration solution|
76081162|NCT05133245|Other|Diagnostic study only|Diagnostic study only
76081163|NCT05132842|Other|Survey Administration|Complete a Survey
76081164|NCT05130229|Behavioral|Sleep Well Bee Well|Sleep program to help toddlers sleep better
76081165|NCT05126862|Behavioral|MindTrails|MindTrails is a web-based cognitive bias modification intervention. Training sessions are designed to encourage cognitive flexibility through repeated practice assigning benign resolutions to ambiguous, anxiety-provoking situations.
76081166|NCT05117632|Drug|ALTO-100 PO tablet|one tablet twice daily
75641484|NCT02701179|Drug|Lignocaine 2% concentration solution|
75641485|NCT05343663|Behavioral|Education|Self-Management Program Conducted with Tele-Nursing will increase Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients.
75926033|NCT06035419|Other|education|breastfeeding education for migrant mothers
75926034|NCT06035406|Drug|Retagliptin Phosphate Tablet|Retagliptin Phosphate Tablet;100mg
76081167|NCT05116241|Biological|BPZE1 pertussis vaccine and placebo|Live attenuated pertussis vaccine and placebo
76081168|NCT05116241|Biological|BPZE1 pertussis vaccine and Boostrix|Live attenuated pertussis vaccine and tetanus, diphtheria, and aP vaccine
76081169|NCT05116241|Biological|Placebo and Boostrix|Tetanus, diphtheria, and aP vaccine and placebo
76081170|NCT05116046|Biological|Recifercept|Recifercept
75789804|NCT06042413|Behavioral|Daily Exercise|Participants in the intervention group will meet with an occupational or physical therapist approximately 1-6 weeks before surgery who will discuss the potential benefits of exercise and give directions for an easy strength training exercise. Participants will then be provided with a video link for a guided exercise and encouraged to walk or perform a seated strength exercise for ≥ 5 minutes each day for at least 1 week before surgery and after surgery. Patient reported frequency, fitness app compliance and exercise duration with REDCap email or mobile link or over telephone will be collected before and after surgery. Patients will be cleared by an occupational or physical therapist to perform the upper-extremity exercises and will confirm the exercises are not contraindicated after surgery. An occupational or physical therapist will see subject again post-surgery to mitigate risk of injury.
75789805|NCT06042413|Behavioral|Enhanced Social Support|"Research coordinators and volunteers from HELP will reach out to patients daily prior to their surgery to discuss concerns they may have, provide daily social touchpoints, and remind them to perform their cognitive exercises. In addition, the importance of social support will be discussed with family members and other caregivers and they will be encouraged to participate.~e. Proactive depression treatment: All patients will receive preoperative interventions to manage their depression under their CPC prehabilitation program."
75798786|NCT01176708|Other|intravenous glucose|1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
75641486|NCT02701023|Drug|MitoGel|The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
75641487|NCT02586961|Drug|0.9% saline solution|"Placebo:~Nebulized 0.9% saline solution"
75641488|NCT02586961|Drug|oral betamethasone placebo|placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
75641489|NCT02586961|Drug|adrenaline|Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
75641490|NCT02586961|Drug|oral betamethasone|Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
75926039|NCT06035380|Other|placebo group|aromatherapy
75926040|NCT06035380|Other|mint oil group|aromatherapy
75926041|NCT06035380|Other|rose oil group|aromatherapy
75926042|NCT06035367|Device|Non-invasive continuous monitoring device to record photoacoustic signal|"Neogly is in two parts, the measurement head, to be worn on the wrist and the power box, to be worn on the forearm or upper arm. The ribbon cable makes the connection between the two parts.~A handset is used to start/stop the device. The medical device record a continuous photoacoustic signal."
75926043|NCT06035354|Drug|AK120|subcutaneous injection once a week
75926044|NCT06035354|Drug|AK120|subcutaneous injection once a week
75332842|NCT05500872|Other|Cross-education|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
75332843|NCT04127552|Procedure|Adrenalectomy|Adrenalectomy accordint to 2016 ESE guidelines
75471352|NCT01951664|Other|Study Assessments|Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
75641491|NCT02586337|Drug|Anlotinib|Anlotinib p.o. qd
75641492|NCT02586337|Drug|Placebo|Placebo p.o. qd
75641493|NCT04781595|Dietary Supplement|Watermelon|A single dose of watermelon powder containing 3g of L-citrulline
75641494|NCT04781595|Dietary Supplement|Beetroot|A single dose of beetroot powder containing 8 mmol of nitrate
75641495|NCT04781595|Dietary Supplement|Watermelon + beetroot|A single dose of watermelon and beetroot powder containing 3g of L-citrulline and 8 mmol of nitrate
75641496|NCT04781595|Dietary Supplement|Placebo|A single dose of maltodextrin
75641497|NCT02700711|Drug|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
75926045|NCT06035354|Drug|Placebo|subcutaneous injection once a week.
75641498|NCT02700711|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
75926046|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
75926047|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
75926048|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
75471353|NCT01951677|Drug|HBsAg|Standard hepatitis B vaccine antigen
75471354|NCT01951677|Biological|PreS HBsAg|preS hepatitis B surface antigen
75471355|NCT01951677|Biological|Advax-1(TM)|Adjuvant formulated with vaccine antigen
75926049|NCT06035354|Drug|Placebo|subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.
75471356|NCT01951677|Biological|Advax-2(TM)|Adjuvant formulated with vaccine antigen
75926050|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks
75926051|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
75471357|NCT01951677|Biological|Advax-3(TM)|Adjuvant formulated with vaccine antigen
75789806|NCT06042413|Other|Proactive Bundle Interventions|Participants randomized to the proactive bundled intervention group (Group D) will receive a routine intraoperative SSEP and EEG monitoring as well as optimization of intraoperative physiology by maintaining normal blood pressure, oxygen levels, opioid sparing analgesia, avoiding deep anesthesia and benzodiazepines. For example, increasing mean arterial pressure can stabilize SSEP (Fig. 6). If persistent focal changes in SSEP and EEG, (i.e., changes in one hemisphere) occur efforts will be made to increase brain perfusion by ensuring and maintaining hematocrit >30, MAP >70, and anesthetic BIS >50-60; soon after surgery, patients will get stroke management and thrombectomy if indicated.
75789807|NCT06042413|Procedure|Pre-operative Standard of Care|Patients in the control group will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC.
75641499|NCT02700711|Drug|Duloxetine|The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
75926052|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
75641500|NCT04215159|Drug|Trastuzumab biosimilar|1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
75641501|NCT04215159|Drug|Gemcitabine Hydrochloride|1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
75926053|NCT06035341|Other|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
75926054|NCT06035328|Other|Wheat (Four times per week)|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
75926055|NCT06035315|Dietary Supplement|Multiple Micronutrients during pregnancy|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given additional micronutrients (Complete multi micronutrients-Calcium-Vitamin D-DHA); and perform ultrasound examinations each trimester and additional laboratory examination (Vitamin D level-Lipid profile-Zinc)
75926056|NCT06035276|Other|Exposure to clean air|"Subjects will be exposed to filtered indoor air (clean air) for 4 hours in the Fraunhofer Environmental Exposure Chamber. The chamber can accommodate up to 18 subjects, is ventilated by HEPA-filtered and conditioned air, ensuring a constant humidity (40 ± 10%), temperature (22 ± 2°C), and airflow (1500 ± 100 m3/hr). During exposure they will perform an intermittent bicycle ergometer activity at 50 W for 10 minutes alternating with 20 minutes rest."
75926057|NCT06035276|Other|Exposure to urban air|"Subjects will be brought to a traffic dense urban region (urban air) with high traffic density and increased levels of particulate matter and vehicle emissions. Subjects will stay in this area for 4 hours. During exposure, all subjects will walk together with study staff. Rest periods are only allowed outside. Intervals of activity and rest will be similar to the clean air regimen."
75926058|NCT06035224|Drug|AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally|AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(<60kg，8 mg qd；≥60kg，12mg qd, orally.
75641502|NCT04215159|Drug|Irinotecan Hydrochloride|100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
76081171|NCT05113641|Dietary Supplement|Alkalizing Fruit and Vegetables|The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life. All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation. Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values < 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day. If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.
76081172|NCT05113641|Drug|Sodium bicarbonate|Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the Seven Oaks Hospital pharmacy.
75641504|NCT02700633|Device|Pacemaker|
75798787|NCT01288794|Drug|Diuretics plus human albumin|The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
75798788|NCT01288794|Drug|Diuretics (standard medical treatment)|The patients will receive standard medical treatment (diuretics)
75471358|NCT01951677|Biological|Alum|Adjuvant formulated with vaccine antigen
75641505|NCT02586883|Other|bronchial ddp test|bronchial ddp test during endoscopy, nasal smear, bronchial smear
75641506|NCT02700789|Procedure|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
75641507|NCT03937063|Other|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
75641508|NCT05342961|Procedure|spinous balloon dilatation catheter (Plastic-Blade)|To treat Coronary artery disease
75641509|NCT05342961|Procedure|spinous balloon dilatation catheter(lacrosse NSE)|To treat Coronary artery disease
75641510|NCT00920257|Drug|GSK2141795|GSK2141795 is an oral AKT inhibitor.
75641511|NCT02699541|Behavioral|Diabetes Self-Management Education|"This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.~Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight."
75641512|NCT02700243|Behavioral|Fitbit|Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
75641513|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
75789808|NCT06042413|Procedure|Intra-operative Standard of Care|This includes routine intraoperative SSEP and EEG monitoring. Physician oversight and interpretation of real-time neuromonitoring data will be performed using a combined on-site and remote model at UPMC. In the event that changes in EEG or SSEP are considered significant by the oversight neurophysiologists, the surgical team will be immediately informed so that immediate appropriate action can be taken to reverse the change.
75926059|NCT06035185|Procedure|apical shaping size|24 patients will randomly be assigned to two groups according to the apical shaping size during root canal treatment: 25/.04 and 35/.04. Microbiological sampling of the teeth will be done with paper cones in three steps during the root canal treatment: 1. Sterility control samples (SR1) from the tooth surface after cavity preparation, 2. The first microbiological sample (S1) from the root canal after the initial file reaches the working length. 3. The second microbiological sample (S2) from the root canal after the shaping and irrigation of the root canal is finished. 4. The third microbiological sample (S3) from the root canal after the irrigation activation in the root canal is finished.The samples will be sent to the genetic analysis laboratory for further analysis in the cold chain using a Droplet Digital PCR.
75926060|NCT06035172|Behavioral|guided imagery|The guided imagery technique, which is one of these methods, is used in the method of pain by establishing a connection between mind and body. In the technique, a peaceful scene is depicted in which positive energy is reflected in the person to ensure complete relaxation and relaxation.
75789809|NCT06038240|Behavioral|Savoring Meditation|Participants will learn about pain neuroscience and will learn/practice a positive emotion generative practice (Savoring Meditation).
75332844|NCT05500794|Other|MBSR (Mindfulness-Based Stress Reduction)|"MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.~In each weekly session, the instructor creates a supportive environment in which:~Guided meditation practices;~Mindfulness stretching and yoga;~Reflection and group discussion periods aimed at promoting mindfulness in daily life;~Practice instructions and opportunity to ask questions;~Instructions for home practice. Audio recordings and a manual are provided to support personal practice.~Audio recordings and a manual are provided to support personal practice"
75332845|NCT00981227|Drug|Eslicarbazepine acetate|Scored tablets
75789810|NCT06038240|Behavioral|Pain Self-Management and Education|Participants will learn about the biopsychosocial drivers of chronic pain.
75332846|NCT00981227|Drug|Placebo|oral route
75641514|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
75332847|NCT05505708|Drug|hydroxyethyl starch in sodium chloride injection Brand Name: Voluven|"(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5."
75332848|NCT05505708|Drug|saline solution|Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
75332849|NCT00981305|Drug|Lactate-containing vaginal lubricant|vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
75471359|NCT01951716|Drug|Graded Glucose Infusion with Placebo|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
75471360|NCT01951716|Drug|Graded Glucose Infusion with GIP Alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
75471361|NCT01951716|Drug|Graded Glucose Infusion with xenin-25 alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
75641515|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
75641516|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
75641517|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
75641518|NCT02700477|Dietary Supplement|Fenugreek seeds extract|Fenugreek seed extract 500mg, BD
75641519|NCT02700477|Other|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
75641520|NCT02700321|Device|OPTIFLOW/ AIRVO|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
75641521|NCT02700321|Procedure|STANDARD Face Mask|"Patients randomized in STANDARD Face Mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
75332850|NCT00981305|Drug|Placebo vaginal lubricant|vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
75641522|NCT00615849|Procedure|thoracoscopic surgery|stapled wedge resection of the lung mechanical pleural abrasion
75641523|NCT02691819|Device|single stent and embedded balloon angioplasty|
75641524|NCT04103944|Procedure|Core Decompression|10 patients will be randomized chosen in this group
75641525|NCT04103944|Procedure|Osteonecrotic Repair Device|10 patients will be randomized chosen in this group
75641526|NCT02699385|Other|Oral Rehydration Therapy|Each participants will initiate ORT in the physician's office on Day 1.
75641527|NCT02699385|Drug|Domperidone|Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
75789811|NCT06035081|Drug|Prednisolone|see arm description
75926061|NCT06035172|Behavioral|music recital|It is stated that the acemasiran tune (instrumental music) has a reducing effect on the duration of labor, as well as having labor pain and muscle relaxant properties.
75471362|NCT01951716|Drug|Graded Glucose Infusion with GIP plus xenin-25|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
75641528|NCT02699385|Drug|Placebo|Each participants will receive placebo oral suspension thrice daily for up to 7 days.
75641529|NCT02586103|Device|MRI simulation|It is not a working MRI machine but sounds and feels just like the real machine.
75641530|NCT02700399|Device|Erigo® Hocoma|Robotics assisted tilt table, without functional electrical stimulation
75641531|NCT02700399|Device|Traditional tilt table from Rehab-Care|Traditional tilt table
75641532|NCT04082923|Other|Liquid meal|Four-hour liquid mixed meal test
75789812|NCT06035081|Other|Placebo|Placebo similar to prednisolone
76081173|NCT05107349|Procedure|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
75332851|NCT04525404|Diagnostic Test|MRI (heart, brain, lungs, liver)|MRI (heart, brain, lungs, liver)
75332852|NCT04525404|Diagnostic Test|Bloodwork|Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
75332853|NCT04525404|Other|Cognitive testing|NIH toolbox Cognitive Measures
75641533|NCT04082923|Other|Solid meal|Four-hour solid mixed meal test
75471363|NCT01951716|Drug|Meal Tolerance Test with Placebo|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
75471364|NCT01951716|Drug|Meal Tolerance Test with xenin-25|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
75641534|NCT02700087|Drug|ranitidine or famotidine|Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
75641535|NCT02700087|Drug|Placebo|Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
75641536|NCT00615771|Procedure|Day 3 embryo transfer|Standard of care
75926063|NCT06035146|Procedure|Mechanical energy monitoring|Monitoring of the mechanical energy acting on the lung parenchyma during mechanical ventilation.
75926064|NCT06035146|Procedure|Conventional mechanical ventilation|The conventional procedure of mechanical ventilation controlled according to the physician's decision.
75926065|NCT06035133|Drug|CapeOX + cetuximab|CapeOX + cetuximab for RAS wild-type patients and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
75641537|NCT00615771|Procedure|Day 2 embryo transfer|Embryos are transferred 1 day prior to standard of care
75641538|NCT02586181|Dietary Supplement|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
75641539|NCT02586181|Dietary Supplement|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
75641540|NCT02699307|Behavioral|Counseling|OT led counseling
75641541|NCT03181035|Radiation|(18)F-Fluoroazomycin arabinoside|FAZA PET diagnostic testing
75641542|NCT03181035|Drug|Pimonidazole|oral pimonidazole hypoxia labeling
75641543|NCT05626465|Other|Blood test|Proteomic analyses on serum
75641544|NCT02698917|Other|Low normal PaCO2|4.5-4.7 kPa
75926066|NCT06035133|Drug|CapeOX + bevacizumab|CapeOX + bevacizumab for RAS mutant patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
75926067|NCT06035133|Radiation|radiotherapy|radiotherapy
75926068|NCT06035107|Diagnostic Test|Radar blood pressure device|The radar blood pressure device will be compared with other traditional blood pressure measurement methods.
75332854|NCT04525404|Other|Olfaction testing|Brief Smell Identification Test (BSIT)
75332855|NCT04525404|Diagnostic Test|Spirometry|Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
75332856|NCT04525404|Other|Walk Test|Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
75332857|NCT04127708|Biological|acupuncture|acupuncture group and control group
75332858|NCT02246231|Device|MR imaging|
75641545|NCT02698917|Other|High normal PaCO2|5.8-6.0 kPa
75641546|NCT02698917|Other|Low normal PaO2|10-15 kPa
75641547|NCT02698917|Other|High normal PaO2|20-25 kPa
75641548|NCT02698917|Other|Low normal MAP|65-75 mmHg
75789813|NCT06034925|Drug|Maribavir|maribavir 400mg twice daily
75789814|NCT06034925|Drug|Valganciclovir|valganciclovir 900mg once daily
76081174|NCT05098444|Behavioral|Cognitive behavioral psychotherapy|Internet-based Cognitive Behavioural Therapy aims to reduce the impairment due to endometriosis by using cognitive behavioural intervention techniques. Furthermore, therapy should enable the patients in coping with symptoms in the future.
75789815|NCT06034301|Device|Medication Reminder App|"If the participant is randomized to the intervention group, they will:~receive a brief education session and be handed a flyer about the importance of medication adherence.~get training on how to use the medication reminder app and participant will be given a user guide on how to use the app~demonstrate their understanding on an iPad using the teach back method~install and set up the medication reminder app on their phone~receive a MEMS cap and be given instructions on how to use it with their blood pressure medication. Study team members will use a participant ID to log into the MEMS cap application; no identifiable information will be entered."
75641549|NCT02698917|Other|High normal MAP|80-100 mmHg
76081175|NCT05098444|Other|Waiting list|Participants of the waiting list receive no treatment for 5 months. Afterwards they receive the same treatment as the experimental group.
75789816|NCT06031454|Drug|Midazolam|oral
75789817|NCT06031454|Drug|Omeprazole|oral
75789818|NCT06031454|Drug|Rosuvastatin|oral
75789819|NCT06031454|Drug|Verapamil|oral
75926069|NCT06035068|Drug|Indocyanine green|Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.
75926070|NCT06035055|Drug|Ceftolozane/tazobactam|9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
75926071|NCT06035016|Drug|pyrotinib combined with Capecitabine|Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
75926072|NCT06035016|Drug|treatment of physician's choice|Treatment of physician's choice
75926073|NCT06034990|Other|10-min online survey|This is a cross-sectional study. The data are collected by a 10-min online survey administered to included physicians which will be distributed via online channels such as such as official website or Facebook pages of Society of intensive care or Society of nephrology of corresponding countries.
76081176|NCT05090865|Dietary Supplement|Liberalized dietary potassium via fruits and vegetables|On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
75789820|NCT06031454|Drug|Rifampin|oral
75789821|NCT06031454|Drug|Leritrelvir|oral
75926074|NCT06034977|Drug|ADI-PEG20|Lenvatinib + ADI-PEG20 combination treatment.
75926075|NCT06034964|Drug|Tislelizumab|Tislelizumab：200mg, iv, d1, 21 days per cycle, until disease progression or intolerable toxicity
75926076|NCT06034951|Dietary Supplement|Compleat 1.5 HP|Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
76081177|NCT05090865|Dietary Supplement|Standard dietary potassium restriction|Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake < 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
75332859|NCT04125368|Behavioral|Health Facility Interventions|"Intensified counselling on dietary diversity and increased meal frequency during pregnancy.~Strengthened government distribution of IFA supplies with counseling about its importance, managing side effects, and reminder about subsequent supplies.~Weight-gain monitoring with messaging to mothers about healthy diet and adequate rest; excess weight gain as a danger sign.~Intensified counseling on importance, benefits, and how-tos of early initiation of breastfeeding and exclusive breastfeeding."
75926077|NCT06034938|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Switch previous therapy with DOR/TDF/3TC
75926078|NCT06034886|Drug|Troriluzole|
75926079|NCT06034860|Drug|MT-8421|Experimental treatment with MT-8421
75471365|NCT01951729|Drug|Control|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes."
75641550|NCT02699853|Other|Questionnaire Administration|Ancillary studies
75926080|NCT06034860|Drug|Nivolumab|480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
75641551|NCT02699853|Procedure|Radical Cystectomy|Undergo RRC
75641552|NCT02699853|Procedure|Radical Cystectomy|Undergo ORC
75641553|NCT04080973|Diagnostic Test|CT scan|non contrast spiral CT of the urinary tract including the bony structures of the spine and pelvis
75641554|NCT04080973|Diagnostic Test|24 hour urine collection|24 hours collection of urine and measurement of the concentration of calcium, phosphorous, uric acid, oxalate and citrate
75641555|NCT02699931|Device|Electric3D|Oral-B 3D with orthodontic head
75789822|NCT06029517|Other|Education Intervention|Receive Indigneous SIPin intervention
75789823|NCT06029517|Other|Interview|Complete interviews
75789824|NCT06029517|Procedure|Discussion|Attend focus groups
75789825|NCT06029075|Device|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
75789826|NCT06029075|Device|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
75789827|NCT06029075|Device|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
75926081|NCT06034847|Device|Mechanical thrombectomy in proximal large vessels|mechanical thrombectomy with retrievable stents to remove clots in proximal large vessels, combined or not with distal aspiration, combined or not with IV thrombolytics
75926082|NCT06034847|Device|Rescue mechanical thrombectomy in distal vessels|In addition to mechanical thrombectomy in proximal large vessels, mechanical thrombectomy in distal vessels with small stent retrievers combined or not with contact aspiration, or intra-arterial perfusion of thrombolytics such as tPA or uPA or tenecpeplase
75789828|NCT06029062|Device|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
75789829|NCT06029062|Device|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
75789830|NCT06029062|Device|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
75641556|NCT02699931|Device|Manual|Oral-B orthodontic
75641557|NCT02699619|Device|Pinloc|3 hook pins interlocked in plate.
75789831|NCT06028698|Other|Inducing positive emotion music|listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.
75789832|NCT06024928|Device|Control-IQ use in Type 2 Diabetes under basal insulin injections|Testing the safety and feasibility of using Automated Insulin Delivery (AID) in people with Type 2 Diabetes under basal insulin injections to achieve safe and fast basal insulin titration.
76081178|NCT05079620|Drug|Ceftriaxone|If there is low risk for P. aeruginosa and/or methicillin-resistant staphylococcus aureus (MRSA), as deemed by the treating team: Ceftriaxone 2 g IV, every 24 hours for 5 days
76081179|NCT05079620|Drug|Amoxicillin clavulanic acid|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on ceftriaxone to the oral agent Amoxicillin + clavulanate (Augmentin) 875 mg PO or per feeding tube, twice daily for the remainder of 5 days
76081180|NCT05079620|Drug|Cefepime|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Cefepime 2 g IV, every 8 hours for 5 days, plus vancomycin
76081181|NCT05079620|Drug|Vancomycin|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Vancomycin IV, dosed by trough or AUC/MIC (area under the curve/minimum inhibitory concentration) monitoring for 5 days, plus cefepime. Order nasal MRSA swab and consider discontinuing vancomycin if MRSA swab is negative.
75471366|NCT01951729|Drug|Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes."
75641558|NCT02699619|Device|2 Hansson pins|2 isolated hook pins.(Without plate)
75641559|NCT00775138|Drug|280 mg Arikayce™|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
75641560|NCT00775138|Drug|Matching Placebo for Cohort 1|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
76081182|NCT05079620|Drug|Levofloxacin|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on cefepime to levofloxacin PO or per feeding tube, 750 mg every 24 hours for the remainder of 5 days
76081183|NCT05079321|Device|Hydra-PEG|Zen™ RC scleral lenses (Hydra-PEG coated)
75641561|NCT00775138|Drug|560 mg Arikayce™|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
75789833|NCT06018883|Drug|Ascorbate|Vitamin C 900 mg/day, three times a day, orally.
76081184|NCT05079321|Device|Uncoated|Zen™ RC scleral lenses (non-coated)
76081185|NCT05068869|Other|Dignio Digital Remote Care intervention group|"The intervention consists of Dignio Prevent (for healthcare professionals) and MyDignio (for patients). The system is CE marked and the system satisfies all regulatory requirements for privacy and information security. Various components can be added for an individualized follow-up of the patients.~Elements of the digital outpatient service in Dignio include patient reported outcomes and other questionnaires, tasks, objective measures, reminders and information, in addition to a chat function for asynchronous contact with healthcare personnel and video consultations for real-time consultations."
75641562|NCT00775138|Drug|Matching Placebo for Cohort 2|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
75641563|NCT02699073|Drug|regorafenib|"160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity."
75641564|NCT04081987|Device|non-invasive monitoring|Comparing blood pressure (diastolic & systolic), heart and respiration rates, blood oxygen level and body temperature measurement using the BiPS non-invasive monitor to an arterial line.
76081186|NCT05068869|Other|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
75641565|NCT04748601|Drug|Qudexy XR|Extended-Release Capsule
76081187|NCT05049850|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.
76081188|NCT05037461|Radiation|High-dose-high precision MR-guided radiotherapy|MR-guided radiotherapy as described in the group information
76081189|NCT05036655|Procedure|Perioperative glycemic management pathway|The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
75641566|NCT04748601|Drug|Placebo|Qudexy XR Matching capsules
75641567|NCT04081519|Device|active rTMS over DLPFC|15 sessions of active rTMS over DLPFC
75641568|NCT04081519|Device|Add-on active rTMS over DLPFC|15 additional sessions of active rTMS over DLPFC
75641569|NCT04081519|Device|Add-on active rTMS over LPC|15 additional sessions of active rTMS over LPC
75641570|NCT04081519|Device|Add-on sham rTMS|15 additional sessions of sham rTMS over DLPFC or LPC
75641571|NCT02699775|Other|Motion Analysis|Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
75789834|NCT06018883|Drug|Nab paclitaxel|Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks
75789835|NCT06018883|Drug|Gemcitabine|Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
75789836|NCT06017388|Behavioral|Hypnosis|We will propose a hypnotic induction followed by a suggestion of mystical experience (based on Lynn & Evans, 2017).
75789837|NCT06017388|Behavioral|Control|We will propose the neutral reading of a mystical expetience suggestion (based on Lynn & Evans, 2017).
76081190|NCT05033002|Behavioral|Labda Siku Moja stigma reduction intervention|The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.
76081191|NCT05026827|Other|Iyengar Yoga|Participation in Iyengar Yoga classes
76081192|NCT05026827|Other|Socialization Control|Participation in socialization control group sessions
76081193|NCT05019170|Behavioral|Smartphone-based Financial Incentives|Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples < 6 ppm will be considered negative and those > 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.
75471367|NCT01951729|Drug|GIP without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes."
75471368|NCT01951729|Drug|Placebo with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
75471369|NCT01951729|Drug|Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
75641572|NCT03236805|Drug|Ketamine|Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
75641573|NCT03236805|Drug|Morphine|Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
75641574|NCT02698995|Drug|Dexamethasone|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
75641575|NCT02698995|Drug|Ropivacaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
76081194|NCT05019170|Behavioral|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
75332860|NCT04125368|Behavioral|Community Interventions|"Home visits to pregnant women by HEWs to discuss maternal nutrition (dietary diversity, adequate food intake, IFA supplementation, and weight gain), early breastfeeding practices, provide ANC and Pregnant Women Conference referrals, and engage husbands.~HEWs use A&T intervention tools (e.g. posters and maternal nutrition follow-up card) at Pregnant Women Conferences/ Mother Support Groups to reinforce maternal nutrition messages, encourage ANC attendance, distribute IFA tablets, measure and track weight gain, promote early breastfeeding practices, and encourage husband participation.~HEWs and community volunteers (Women's Development Army (WDA), imams, etc.) deliver maternal nutrition messages and encourage ANC visits at kebele and community meetings."
75471370|NCT01951729|Drug|GIP with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
75641576|NCT02698995|Drug|Paracetamol|After the block regression, at the first analgetic request the patients received the same analgesia protocol
75641577|NCT02698995|Drug|Morphine|After the block regression, at the first analgetic request the patients received the same analgesia protocol
75641578|NCT02698995|Drug|Lidocaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
75641579|NCT00920101|Drug|Atorvastatin|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
75641580|NCT00920101|Behavioral|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
75641581|NCT02698839|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
75789838|NCT06015308|Drug|Amlitelimab|Subcutaneous injection in abdomen, outer thigh, or upper arm
75789839|NCT06015308|Drug|Placebo|Subcutaneous injection in abdomen, outer thigh, or upper arm
75789840|NCT06015308|Biological|Tdap vaccine|Intramuscular (IM) injection into the deltoid muscle of the upper arm
75789841|NCT06015308|Biological|PPS vaccine|Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm
75789842|NCT06008795|Drug|Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone|Each PPF-active nerve block will consist of 20mg (4ml) ropivacaine plus 4mg (1ml) dexamethasone
75789843|NCT06008795|Procedure|Placebo Pteryogpalatine Fossa Injection|Each placebo PPF-injection will consist of 5ml normal saline
75789844|NCT06006884|Procedure|Bronchoscopies and Bronchoalveolar Lavages (BALs)|Bronchoscopies use a thin, lighted tube, which enters through the mouth or nose and moves down the throat to the airways to look at the lungs. BALs are done during bronchoscopies to collect samples from the lungs for testing. During this procedure, a saline solution is put through the tube to wash the airways and collect a fluid sample.
75641582|NCT02698839|Device|BuMA™|Stent platform: stainless steel
75789845|NCT06006884|Diagnostic Test|Chest Tomography (CT)|X-ray to create images of the bones and internal organs of the body
75926083|NCT06034834|Diagnostic Test|Near-infrared fluorescence imaging of perfusion|Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
75926084|NCT06034782|Diagnostic Test|Fine Needle Aspiration|Fine Needle Aspiration of a salivary gland tumor
75926085|NCT06034782|Procedure|Histologic Examination|Histologic examination of resected salivary tumor
76081195|NCT05017662|Other|Data collection|Participants will have surveillance visits every 3 months up to 5 years after their first dose of 177Lu-IPN01072 in Study OPS-C-001.
76081196|NCT05010369|Diagnostic Test|spectroscopic measurement|measurement of the tissue with spectroscopy
75641583|NCT00616785|Drug|cisplatin|
75641584|NCT00616785|Drug|etoposide|
75789846|NCT06006884|Diagnostic Test|Electrocardiogram (ECG)|Measures the electrical activity of the heart by using sticky pads that are placed on your chest and limbs.
75789847|NCT06006884|Diagnostic Test|Pulmonary function tests (PFTs)|Testing to measure how well lungs are working
76081197|NCT05010369|Diagnostic Test|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
75471371|NCT01951729|Drug|GIP plus Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes."
75641585|NCT00616785|Drug|irinotecan hydrochloride|
75641586|NCT00616785|Radiation|radiation therapy|
75641587|NCT00616005|Drug|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle & every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, & 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
75641588|NCT04081675|Device|Ankle Foot Orthosis (AFO)|Thermoplastic orthotic device spanning the calf, ankle and foot.
76081198|NCT05010369|Diagnostic Test|histopathology and cytology|Histopathology and cytology will be performed on the samples
75641589|NCT02698527|Drug|Non-Buffered Lidocaine|Active comparator
75641590|NCT02698527|Drug|Buffered Lidocaine|Experimental, additIon of Sodium Bicarbonate to Lidocaine
75641591|NCT04215237|Drug|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg oral once a day
75641592|NCT05593315|Other|Mindfulness and Buteyko techniques|Joint implementation of a general relaxation program and a respiratory rehabilitation program in patients with poorly controlled asthma.
75641593|NCT02917083|Genetic|CAR T Cells|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10^7 cells/m2. Dose Level Two: 1x10^8 cells/m2. Dose Level Three: 2x10^8 cells/m2."
75641594|NCT02586649|Drug|Tiotropium Bromide|Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
75641595|NCT02586649|Drug|Placebo|Placebo is a non-active inhalation capsule .
75641596|NCT04213833|Drug|Propofol Injection [Diprivan]|patients will be sedated with 50 mg propofol(10 mg/ml) given slowly intravenously over 1 min
75789848|NCT06006884|Diagnostic Test|6 minute walk test (6MWT)|Walking test to see how well the lungs function with exercise over 6 minutes
75789849|NCT06005545|Device|Passive Ultrasonic Irrigation (PUI) group|Passive ultrasonic irrigation is the current golden standard in root canal cleaning and irrigation devices. It is used after root canal shaping using manual or rotary instruments. It uses sodium hypochlorite which is mobilized in the canal using ultrasonic non-cutting tips to clean, debride, disinfect, and prepare the root canal for obturation.
75789850|NCT06005545|Device|Endoclean (EC) group|Endoclean is a novel device that uses hydraulic inertial cavitation with the help of pressure and saline solution to debride the root canal after minimal shaping using manual or rotary shaping instruments. It is used to effectively clean, debride and prepare the root canal before obturation in the root canal treatment procedure.
75789851|NCT06005545|Device|Conventional group|Conventional root canal preparation uses manual or rotary files along with manual irrigation using syringes and irrigant solutions like sodium hypochlorite or EDTA to clean, debride and prepare the root canal for obturation.
75789852|NCT06005272|Other|Questionnaire|Interviewer assisted completion of questionnaire.
76081199|NCT05003518|Behavioral|ParentText|ParentText delivers content, aligning with children's developmental stages (0-23 months, 2-9 years, 10-17 years). ParentText content is delivered through text messages, images, audio and video for parents/ caregivers and their children. Parents receive parenting content surrounding three themes: 1) relationship building by spending time together, 2) positive reinforcement, 3) stress reduction for parents and caregivers. Further supportive content is available for parents of children living with disabilities, child development, online child safety, talking about COVID-19 with children, family budgeting, family harmony, helping with schoolwork and sexual violence prevention.
76081200|NCT05001282|Drug|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
76081201|NCT04986241|Drug|Statin|Chronic use of statin prescribed previously by the assistant physician.
76081202|NCT04986241|Other|Physical activity|Physically active participants
76081203|NCT04986241|Other|Sedentary|Physically inactive or sedentary participants.
75641597|NCT04213833|Drug|Dexmedetomidine [Precedex]|patients will received 0.5 mcg/ kg dexmedetomidine intravenously followed by syringe containing 50 mg propofol(10 mg/ml).
75641598|NCT04213833|Drug|Palatable Lidocaine Topical Gel|15 g of palatable lidocaine gel will be gradually applied 3-5 min before the endoscopy at three consecutive 30-s intervals to the base of the tongue, the palate and the peritonsillar areas and the patients will be informed to spread it within their mouth with their tongue and swallow it later to cover the oropharynx and esophagus. Patients will be asked to register the onset of numbness, then patient will receive syringe containing 50 mg propofol (10 mg/ml) intravenously as a sedation.
76081204|NCT04982497|Behavioral|Video game based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker & Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
76081205|NCT04982497|Other|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
75332861|NCT04125368|Behavioral|Health System Interventions|"Trainings on the maternal nutrition interventions for health center heads, nurse-midwives, HEWs, community volunteers (WDA, imams, etc.), woreda health officers, and other key actors.~Supportive supervision of maternal nutrition activities conducted by woreda nutrition officers, woreda health officers, TDA or A&T."
75641599|NCT04605991|Drug|LY900014|Administered SC
75789853|NCT06004219|Behavioral|Peer counseling group|A community advisory board (CAB) will be set up for need assessment and to design the peer support program. Virtual meetings will be held quarterly for year 1 and 2. The group will consist of (up to 12 members) and will include at least 2 patient partners (patients with a recently diagnosed ulcer), 2 peer pals (patients with a healed DFU), family members or caregivers (limited to only 1 person per family represented on the CAB), healthcare workers (podiatrist, nurse, or case manager), medical equipment company representatives, and others. We will ask them about potential barriers at the first meeting, have flexible meeting times, and intentionally limit the number of healthcare providers. At the last meeting, we will seek feedback and input from the CAB. In addition, this group will have the opportunity to participate in a focus group which will be moderated with a trained, bilingual assistant and will last 40-60 minutes.
75332862|NCT01022567|Procedure|Appendicectomy|Standard appendicectomy
75332863|NCT01022567|Drug|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
75641600|NCT04605991|Drug|Insulin Glargine|Administered SC
75641601|NCT00783796|Device|2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System|Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
75641602|NCT02698605|Device|Usability test study of the MirrorPath|"The study was conducted by research assistants. Each subject received one assessment that last lasted 30 minutes. The subjects were not paid for participation. In that, no randomization or masking were performed. Prior to the experiment part of the study, the subjects provided basic biographical information. We then explained the experimental process and demonstrated the operation of the device.~A novel rehabilitation device, the MirrorPath, designed for the upper limb rehabilitation of patients with hemiplegic stroke. The MirrorPath that was 1180x440x300mm in size and had a shell was constructed of acrylonitrile butadiene styrene (ABS). The control module featured an on/off switch, a knob for adjusting the speed, and an emergency cutoff switch."
76081206|NCT04977999|Other|Exercise|Both arms/conditions use varying forms of exercise as the intervention.
76081207|NCT04969198|Drug|Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)|Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
75332864|NCT03831308|Diagnostic Test|clinical and physical assessment|information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
75332865|NCT03827096|Drug|Suspension of human autologous MSC 3P in 1.5 ml|During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
75641603|NCT04951921|Drug|Hyperpolarized 13C Pyruvate|Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection
75641604|NCT00637065|Drug|Bosentan|Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.
75641605|NCT00637065|Drug|Placebo|Placebo tables - identical to active drug but without the active ingredient -
75641606|NCT02698683|Other|lymphocyte count|lymphocyte count
75641607|NCT00616863|Drug|Oxcarbazepine|
76081208|NCT04968847|Device|FemaSeed Localized Directional Insemination|Subjects undergoing FemaSeed Artificial Insemination
75332866|NCT04411524|Drug|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody After neo-CRT: 3 cycles of PD-1 antibody
75332867|NCT04411524|Drug|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
75332868|NCT04411524|Drug|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1*28 6/6) or 65mg/m2 qw (UGT1A1*28 6/7)
75332869|NCT04411524|Radiation|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
76081209|NCT04968405|Device|Catalyst CSR Total Shoulder System|The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
75789854|NCT06003946|Behavioral|BreLax: Antenatal education class|An antenatal education class over 9 hours with information regarding pregnancy, labour and birth, pain management as well as the postpartum period with an integrated breathing and relaxation technique (prolonged exhalation in the individual rhythm) and 4 accompanying positions (standing upright, sitting supported, four-footed, supported lying on the side). In addition, participants receive a manual for independent practice at home.
76081210|NCT04965012|Behavioral|Online CBT with MET treatment|The CBT with MET treatment condition will begin with an MET-therapist guided introduction to the program and first module. After this guided introduction, they will have access to the remaining 7 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
75332870|NCT02983916|Procedure|Adhesiolysis|Diagnostic laparoscopy or laparotomy with lysis of adhesions.
75332871|NCT05500638|Behavioral|Virtual Reality|At this stage, trainings were given for epileptic seizures. Parents were asked to wear SG glasses and they were trained on the correct approach to seizures over the Focal to bilateral tonic-clonic seizure scenario integrated into the SG glasses. The clinic and process of focal to bilateral tonic-clonic seizure and the training of what to do and not to do during the seizure were given again through SG glasses. Parents interfered with the patient scenario many times during their free work time and had the chance to interfere with the seizure again and again by restarting the seizure.
75332872|NCT04127396|Drug|Lenvatinib Pill|Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW)>60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW<60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)
75471372|NCT01951729|Drug|GIP plus Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
75471373|NCT01951781|Other|blood sample|"blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)~When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood."
75641608|NCT02698761|Other|Comprehensive Care Plan|"Care Plan~Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.~Other Medications. All medications will be given during daytime hours, if possible.~Pain Psychology.~Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.~Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.~Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).~Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily."
75471374|NCT01951807|Behavioral|Psychotherapy|
75641609|NCT02603536|Other|WelTel|An evidence-based, text messaging solution for improving patient adherence.
75471375|NCT01951833|Device|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
75641610|NCT04213443|Other|Analysis of a patient registry|Analysis of a patient registry.
75641611|NCT04102306|Other|reliability and validity construct of the TMIQ|comparison of the TMIQ to the gold-standard questionnaire (KVIQ) and test-retest
75471376|NCT01951846|Drug|BIBF 1120|
75471377|NCT01951859|Other|Neuropathy/Ulcer Homeopathic topical cream|This is a GRAS topical agent containing homeopathic ingredients
75471378|NCT01951872|Behavioral|Manual-based treatment for caffeine dependence|Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
75471379|NCT01951898|Drug|Montelukast|10mg/day, once a daily after dinner, for 28dyas
75471380|NCT01951911|Drug|Ketamine|Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
75641612|NCT04936477|Other|Calculation of ventilation-perfusion ratio|"Three to five paired measurements of fraction of inspired oxygen and peripheral oxygen saturations.~Insertion of mainstream capnograph with combined pressure and flow sensor to perform end-tidal capnography measurement.~Echocardiogram to assess intra-cardiac shunting."
75789855|NCT06003946|Behavioral|Standard care (control)|An antenatal education class over 9 hours, with information regarding pregnancy, labour and birth, pain management and the postpartum period as well as some relaxation exercises.
76081211|NCT04965012|Behavioral|CBT without MET treatment|The CBT without MET treatment condition will begin with a brief non-MET trained research assistant welcome to the program, and will not include working through the first module together. After this welcome, they will have access to the 8 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
76081212|NCT04960605|Procedure|Dental implants|Treatment of the toothless regions with dental implants
75471381|NCT01951911|Drug|Placebo|
75789856|NCT06003166|Drug|4-Aminopyridine|Study drug will be a one time dose of 5mg immediate release 4 aminopyridine
75789857|NCT06003166|Other|Placebo|Matched placebo
75641613|NCT04214847|Procedure|Ahmed Glaucoma Valve surgery|The surgical procedure was identical for both implant types and was performed as described previously.9,14 All surgical procedures were performed under local anesthesia except for children, general anesthesia was used. The valve plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
75641614|NCT04935697|Device|nVNS|3x daily treatment of nVNS + SOC
75789858|NCT06002685|Behavioral|Attachment and Biobehavioral Catch-Up|The ABC program consists of 10 one-hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic. Principal intervention activities include a discussion of basic attachment principles, guided practice of new parenting behaviors, and a review of video clips from previous sessions to help reinforce parenting targets. The parent coach promotes (a) nurturance, especially in response to distress; (b) following the child's lead with delight; and (c) avoiding frightening caregiving behavior. As specified by the ABC protocol, any/all other family members will be invited to observe or participate in each ABC session Each full-time ABC parent coach will serve 8 to 10 families at a time (i.e., complete 8-10 hourly ABC visits per week).
76081213|NCT04948853|Behavioral|Individual Placement Support - Supported Employment|Individual, person-centered intervention designed to help individuals living with mental illnesses obtain and sustain meaningful employment. This is an evidence-based practice for individuals with severe mental illnesses.
76081214|NCT04943900|Drug|BMS-986416|Specified dose on specified days
76081215|NCT04943900|Drug|Nivolumab|Specified dose on specified days
75641615|NCT04935697|Other|SOC|Standard of care patient management.
75641616|NCT00616161|Drug|Istaroxime|0.5 microgram/kg/min IV for 6 hours
76081216|NCT04943861|Behavioral|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
76081217|NCT04943861|Other|Usual Care|There is no peer navigation within usual care.
76081218|NCT04941300|Other|Mailed FIT Outreach|We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.
76081219|NCT04941300|Other|Standardized navigation|"The standardized navigation includes, but is not limited to, the following key components:~Identification of individuals with abnormal FIT~Results review and colonoscopy order by provider~Results reporting to patient~Insurance approval for colonoscopy~Colonoscopy scheduling~Bowel preparation & colonoscopy completion~Colonoscopy results provided to patient and CHC~Referral-to-Care for patients with CRC (if necessary)"
76081220|NCT04939402|Diagnostic Test|Serological testing|Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity
76081221|NCT04939220|Procedure|TEE with SGA|SGA Placement and maintenance with inhalational anesthetic or propofol
76081222|NCT04939220|Procedure|TEE with Deep Sedation|Deep sedation with propofol and natural airway
76081223|NCT04935138|Genetic|cfDNA analysis|sequencing data from cfDNA analysis
75332873|NCT04127396|Procedure|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
75332874|NCT04127396|Drug|Sorafenib|Sorafenib capsules will be administered orally, 400 mg twice daily (BID) oral dosing.
75641617|NCT00616161|Drug|Istaroxime|1.0 microgram/kg/min IV for 6 hours
76081224|NCT04935034|Dietary Supplement|Vitamin D supplement|This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.
76081225|NCT04928664|Drug|Liposomal bupivacaine|Single shot injection of 10ml 1.33% LB; Due to the milky colour of LB, syringe containing the LB will be covered; Followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml NS; The default fixed rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
76081226|NCT04928664|Drug|Standard bupivacaine|Single shot injection of 10 ml 0.25% SB in ISB; In order to have blinding to the drug injected, syringe containing SB will be covered; followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml 0.2% SB; The default fixed-rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
76081227|NCT04928261|Drug|Trastuzumab|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
75332875|NCT04127396|Procedure|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
75332876|NCT04120064|Drug|Cholecalciferol|Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
75332877|NCT04127630|Procedure|mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
75332878|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
75332879|NCT00982007|Drug|Ferrous Sulfate Tablets|325 mg Ferrous Sulfate tablets taken orally three times a day
75641618|NCT00616161|Drug|Istaroxime|1.5 microgram/kg/min IV for 6 hours
75641619|NCT00616161|Drug|Placebo|Placebo
75641620|NCT02584387|Behavioral|3D Video Virtual Reality Exposure Therapy|The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
75789859|NCT06002685|Other|Home-Based Book-of-the-Week|The HBOW program is an active control condition developed by PI Berlin. It consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. During each of the 10 weeks, a trained RA will visit each HBOW mother to drop off the book and to ask briefly about the mother's and child's well-being (using a standard set of questions). Thus, this condition will parallel the intervention condition in duration (number of weeks) and structure, although it will be less intensive in terms of participant contact time per visit.
75789860|NCT05996900|Device|Intracranial electrodes|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
75926086|NCT06034730|Device|Portable GC device for brath analysis|Patients were asked to orally exhale 1-2 L breath into a 5 L Tedlar bag via a one-way mouthpiece and Nafion filter for moisture removal, as shown in Figure 1B. The process usually takes about a few minutes. The breath analysis took place either in-situ immediately after the breath sample collection or within 24 h of breath collection. The Tedlar bags were stored under ambient condition until analyzed. During the breath analysis, the Tedlar bag was connected to the sampling port of the portable GC (Figure 1C). Approximately 350 mL of breath was pulled from the Tedlar bag into the GC for analysis. The GC operation was controlled using LabView via a laptop. The total assay time was 30 min, including 5 min of breath sampling time from the Tedlar bag at a flow rate of 70 mL/min (see the blue path in Figure 1A), 5 min of desorption/transfer time, 10 min of chromatographic separation time (see the orange path in Figure 1A), and 10 min of GC system cleaning time.
75641621|NCT04079647|Drug|Immunotherapy|Patients receive immunotherapy for cancer treatment
75641622|NCT02697981|Behavioral|nutrition counseling|nutrition counseling and guidance.
76081228|NCT04916392|Drug|Liposomal bupivacaine|5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
76081229|NCT04908384|Behavioral|Improving Asthma Care Together (IMPACT)|IMPACT is a novel health application and wearable device
76081230|NCT04902352|Procedure|No Periadventitial dissection of the SMA|lymphoneural tissue around SMA left intact
76081231|NCT04902352|Procedure|Periadventitial dissection of the SMA|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well."
76081232|NCT04897568|Other|Patient decision aid|Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
75471382|NCT01951924|Drug|Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
76081233|NCT04887454|Behavioral|Once-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT once weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Participants will repeat the 25-minute HIIT bout three times with 30-60 minutes break in between each 25-minute HIIT bout. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
76081234|NCT04887454|Behavioral|Thrice-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT thrice weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
75471383|NCT01951924|Drug|Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
75789861|NCT05996900|Device|TMS|TMS will be used for the delivery of noninvasive brain stimulation both before and after implantation electrode surgery.
75471384|NCT01951976|Other|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
75789862|NCT05993572|Diagnostic Test|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessments include functional status, fraility comorbidity, cognition, mental health, social support, nutrition, and geriatric syndromes
75789863|NCT05993234|Drug|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC."
76081235|NCT04887454|Other|Usual Care|Participants in the usual care control group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to obesity including causes, prevalence, epidemiology, associated diseases, healthy diet, caloric restriction advice, physical activity, stress management, adequate sleep, as well as lifestyle counseling/consultation and goal-setting/record-keeping strategies for behavioral changes.
76081236|NCT04884334|Device|VAC-Stent®|treatment with the VAC-Stent®
75471385|NCT01951976|Other|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
76081237|NCT04879706|Other|None planned|No intervention planned
75332880|NCT00982007|Drug|IV Iron (standard of care)|IV standard of care (other IV iron) per the Investigator's discretion
75926087|NCT06034704|Other|Plantar fascia self massage with a magnetic fascia ball|Participants were asked to roll the magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
75641623|NCT04081207|Behavioral|AAC for Language Recovery (AAC-LaRc)|iPads will be programmed with a personalized communication application (app) and a structured 4-step intervention will be employed to instruct patients how to cue themselves during anomic events via pictures, text, or speak buttons.
75926088|NCT06034704|Other|Plantar fascia self massage with a non-magnetic fascia ball|Participants were asked to roll the non-magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
75332881|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
75332882|NCT04274582|Dietary Supplement|chokeberry extract|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
75332883|NCT04274348|Other|Skin biopsies and blood samples|Two skin biopsies and 30 ml of blood will be collected.
75332884|NCT04825548|Other|No intervention|Examination of patients with previous DVT
75332885|NCT03826862|Radiation|CT three-dimensional reconstruction|All patients will receive CT three dimensional reconstruction before surgery
75641624|NCT04213599|Diagnostic Test|Coronary intervention|Patients with STEMI undergo coronary intervention
75641625|NCT04213521|Other|Multisensory balance exercise|Multisensory balance training describes a balance exercise incorporating individual sensory manipulation of vision, vestibular, proprioception and sensory integration.
75641626|NCT04213521|Other|Conventional balance exercise|such as static and dynamic standing balance without altered sensory inputs.
75926089|NCT06034691|Biological|pcsk9 inhibitor|The treatment group received postoperative use of 140 mg of Ribavirin, administered every two weeks, with 140 mg administered subcutaneously for a total of 48 weeks. There was no additional intervention with lipid-lowering drugs in the control group.
75332886|NCT04818294|Device|Pain treatment by electrostatic charge to the whole body|"Study Type is Observational as participants in the study receive therapeutic interventions in the therapy cabin as part of routine medical care and a researcher studies the effect of the intervention.~The study includes all persons who are already receiving therapy in the mentioned facilities, no external, specifically selected persons, but existing patients suffering from chronic pain who meet the specified conditions.~The therapy aims to alleviate chronic pain by applying an electrostatic charge of 50'000 Volt to the whole body in the special, electrically insulated cabin. The treatment is done upon the instructions of a physician. It is done with the patient standing up in the treatment cabin. The person is charged and discharged several times over the course of 2x 4 minutes. The charge can be felt on the skin and it can be seen through bristling of the hairs on the body. This treatment is repeated once a week."
75332887|NCT04346732|Other|Vapocoolant spray|Vapocoolant spray
75471386|NCT01951989|Drug|Imiglucérase (drug) pharmacokinetics|
75471387|NCT01952002|Other|Inspiratory Muscle Training|Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
75471388|NCT01952093|Behavioral|Home-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the home.
75641627|NCT04214769|Diagnostic Test|Audiometry and tympanometry, vHIT, VEMP, ENG|Diagnostic tests
75641628|NCT04214925|Other|Tai Chi|Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.
75926090|NCT06034678|Behavioral|Food Allergy Mastery Program|Food Allergy Mastery Program sessions will be delivered by masters-level counselors as 6 45-minute biweekly telehealth or in-person sessions over a period of 3 months. Session 1 will include both youth and caregiver, Session 2 will be a group session with 5-6 youth, Session 3 will include both youth and caregiver, Sessions 4-5 will be individual youth sessions, and Session 6 will include both youth and caregiver. Sessions will incorporate a variety of formats, each based on the needs of the session content.
75471389|NCT01952093|Behavioral|Clinic-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the clinic.
75471390|NCT01950065|Device|iovera|
75471391|NCT01952106|Other|play computer game|
76081238|NCT04868695|Procedure|1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3|1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
75332888|NCT04814940|Other|MENOPUR Cohort|"Non-interventional~All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study take place."
75332889|NCT03826784|Combination Product|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
75332890|NCT05042934|Procedure|Fine-Needle Aspiration|Undergo fine-needle aspiration
75332891|NCT05042934|Drug|Irinotecan|Given IV
75332892|NCT05042934|Drug|Irinotecan Hydrochloride|Given IV
75332893|NCT05042934|Drug|Lurbinectedin|Given IV
75332894|NCT02983526|Device|Total hip replacement (2 different designs)|Patients will randomly receive either CFP or Corail stem
75332895|NCT05505006|Drug|Ferric Carboxymaltose Injection|Anemic patients with ID will receive i.v. iron. Dosage will be based on Hb level and patient body weight.
75641629|NCT02698059|Device|iNAP® Sleep Therapy System (iNAP)|The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
76081239|NCT04866251|Diagnostic Test|Gag reflex test; assessment of Mallampati Score|Testing of gag reflex Assessment of Mallampati Score
76081240|NCT04859725|Device|Hyperspectral Imaging with Snapscan camera|Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).
76081241|NCT04854668|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
75789864|NCT05992831|Device|Accelerated iTBS|The investigators will treat participants with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro TMS System with a Cool-B65 coil, targeting to direct the stimulation to the left dorsolateral prefrontal cortex (l-dlPFC). The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. Total treatment time will be controlled; all participants will perceive receiving active treatment for 10 3-min sessions with 10-15 min inter-session intervals, resulting in a 3-hour treatment day. At pre-treatment, a focal electrical sham will be individually titrated to participant tolerability. Participants then receive an individualized level of sham stimulation throughout treatment, to bolster the blind. Participants will be told that they will be receiving different doses throughout the treatment day, again to maintain the integrity of the blind.
75641630|NCT02697903|Dietary Supplement|Natural Pomegranate Juice|Supplements (1500ml) of pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Experimental: 9 elite weightlifter
75789865|NCT05992831|Device|Sham Comparator|To achieve adequate blinding, participants will go through the same number of sessions per day irrespective of the active and/or sham dose-step combination to which they are assigned. Sham sessions will be assigned in random order over the 10 sessions. The sequence of active and/or sham sessions for each treatment day is assigned a random code that is entered into the TMS system by the coordinator to maintain the integrity of the blind.
75789866|NCT05986552|Behavioral|Individual Schema Therapy (IST)|IST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in individual sessions by trained therapists.
75789867|NCT05986552|Behavioral|Individual-Group Schema Therapy (IGST)|IGST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in the combination of individual sessions and group therapy sessions by trained therapists.
75789868|NCT05983432|Drug|BL-B01D1|The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.
75789869|NCT05981469|Device|Cervical Stiffness Assessmenr|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
75789870|NCT05981469|Other|Bishop's Score Assessment|Sterile digital vaginal examination to illicit the Bishop's score (0-12).
75789871|NCT05980117|Drug|Remimazolam|Remimazolam (1.0mg IV) titrated to modified observer's assessment of sedation score of 3 -4 during cataract surgery.
75789872|NCT05980117|Drug|Midazolam|Midazolam (0.5-2mg IV) titrated to modified observer's assessment of sedation score of 3 - 4 during cataract surgery.
76081242|NCT04854668|Drug|Bevacizumab|Bevacizumab 7.5mg/kg, intravenous drip, on Day 1
75641631|NCT02697903|Dietary Supplement|Placebo Juice|Supplements (1500ml) of Placebo juice (PLA) were taken three times daily in the 48h which proceed the second tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Placebo Comparator: 9 elite weightlifter
75789873|NCT05976763|Drug|Zanubrutinib|Given PO
76081243|NCT04854668|Drug|Oxaliplatin|Oxaliplatin 130mg/m2, intravenous drip, on Day 1；
76081244|NCT04854668|Drug|Capecitabine|Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
76081245|NCT04842084|Biological|Blood samples|sampling of 10 S-Monovette tubes (Sarstedt) 4.3 ml of blood specifically for the study representing a total blood volume of 43 ml
75789874|NCT05976763|Biological|Rituximab|Given IV
76081246|NCT04837521|Behavioral|Unified Protocol|Five session psychotherapy
75789875|NCT05976763|Other|Patient Observation|Undergo observation
75789876|NCT05976763|Procedure|Bone Marrow Biopsy|undergo bone marrow biopsy
75789877|NCT05976763|Other|Fludeoxyglucose F-18|Given IV
75789878|NCT05976763|Procedure|Positron Emission Tomography|Undergo PET
75789879|NCT05976763|Procedure|Computed Tomography|Undergo CT
75789880|NCT05976763|Procedure|Magnetic Resonance Imaging|Undergo MRI
75641632|NCT00617253|Drug|recombinant interleukin-21|3 mcg/kg, s.c. injection
75926091|NCT06034626|Procedure|Intense pulsed light|Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
75789881|NCT05976763|Procedure|Esophagogastroduodenoscopy|Undergo EGD
75789882|NCT05976763|Procedure|Colonoscopy|Undergo colonoscopy
75641633|NCT00617253|Drug|sunitinib|Hard gelatine capsules, 12.5 mg
75789883|NCT05976763|Procedure|Biospecimen Collection|Undergo blood sample collection
75789884|NCT05976763|Other|Questionnaire Administration|Ancillary studies
75789885|NCT05971407|Device|Remote Ischaemic Preconditioning|RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
75926092|NCT06034626|Drug|0.3% hyaluronic acid eye drops|0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
75926093|NCT06034613|Behavioral|internet-based mindfulness intervention for emotional distress(iMIED）|The iMIED program integrates the rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from MBIs. In addition, the iMIED program selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks. In total, it took about 30 min per day to finish all the tasks. The program lasted for 49 days.
75926094|NCT06034587|Diagnostic Test|multimodal ultrasound|An Aixplorer ultrasound machine (SuperSonic Imaging, Ltd, Aixen-Provence, France), equipped with AngioPLUS(AP) and shear wave elastography(SWE) functions, was used for all examinations using a 4-15MHz linear probe.AP function can detect microvessels of lesions,SWE can evaluate the stiffness of lesions and high frequency ultrasound can measure the thickness and volume of keloid.
75926095|NCT06034587|Radiation|radioisotope applicator therapy|The radioisotope applicator therapy utilized 90Sr-90Y(0094SR814975) isotope, customized by the China Atomic Energy Research Institute. The element therapy instrument used had overall dimensions of 2.8cm x 2.8cm, with an effective treatment area of 2.0cm x 2.0cm. It delivered a radiation dose of 5.0Gy/h. Each patient received superficial radiation therapy through a single 90Sr source, administered in repeated doses. The isotope therapy instrument was customized to fit the exact size of the keloid, ensuring coverage the irradiation range extending 0.5cm beyond the keloid's edge. During treatment, the surface of the applicator was aligned with the irradiated area and directly contact the surface of the keloid tissue. The treatment was carried out low-dose irradiation method, over 5 sessions, with each session delivering a dose of 2Gy. Each irradiation lasted for 25min.
75926096|NCT06034574|Device|Continuous glucose monitoring|Assessment of accuracy of two different continuous glucose monitoring devices during exercise
75926097|NCT06034561|Drug|Bortezomib|Patients should receive one or two courses of this regimen, aiming to achieve complete remission as a bridge to proceed with allogeneic HSCT.
75926098|NCT06034548|Behavioral|diabetes and hypertension self-management|12-weeks of 75 minutes of educational sessions
75641634|NCT00617253|Drug|recombinant interleukin-21|10 mcg/kg, s.c. injection
75641635|NCT00617253|Drug|recombinant interleukin-21|30 mcg/kg, s.c. injection
75641636|NCT00617253|Drug|recombinant interleukin-21|100 mcg/kg, s.c. injection
75789886|NCT05971407|Device|Sham Remote Ischaemic Preconditioning|Sham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
75641637|NCT02585947|Drug|Tenofovir|Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).
75641638|NCT04079569|Behavioral|Tobacco|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
75641639|NCT04079569|Behavioral|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
75641640|NCT02697825|Procedure|Schiotz tonometer for Intraocular Pressure|Both Values will be corelated
75641641|NCT04081051|Other|diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)|Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers
75641642|NCT02697513|Behavioral|simple infection management protocol|Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
75789892|NCT05952180|Device|Virtual reality and Cycloergometer|The session performed uses a standard cycloergometer, with the participant pedaling in a seated position with the lower limbs. A 43 inches TV screen is placed in front of the cycloergometer where the participant will watch a video of a walk through a natural environment on. The speed of the walk is linked to the pedaling speed so that the faster the participant pedals, the faster the video goes too. The session last 30 minutes in the participant's room.
76081247|NCT04836312|Behavioral|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
76081248|NCT04830488|Behavioral|e-learning didactic module|Participants utilize e-learning
75789893|NCT05952180|Other|Standard cycloergometer|the session uses usual cycloergometer with the participant pedaling in a seated position with the lower limbs. The session lats 30 minutes in the participant's room.
75789894|NCT05952076|Dietary Supplement|B. infantis Bi-26|A once-daily oral dose of Bi-26 will be provided to infants for 28 days.
76081249|NCT04830488|Behavioral|Personal reflection activities|Participants complete questionnaires
75789895|NCT05952076|Dietary Supplement|Placebo|A once-daily oral dose of placebo maltodextrin will be provided to infants for 28 days
75926099|NCT06034522|Device|Adipearl|Injection of the investigational device in the face.
76081250|NCT04830410|Dietary Supplement|Fructan reintroduction|Patients will reintroduce fructan powder after 14-day of a low FODMAP diet
75641643|NCT04649671|Behavioral|Mobile health|"Perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening).~Mobile application: Hepatocellular carcinoma by Second Doctor Wearable device: Dofit"
75641644|NCT02607891|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
75641645|NCT02607891|Drug|Placebo|Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
75641646|NCT02585869|Drug|Gemcabene 150 mg|Blinded capsules and tablets, 150 mg, once daily, 84 days
75926100|NCT06034483|Other|Pelvic floor exercise training|"Pelvic floor muscle contraction will be verified with vaginal palpation and a progressive pelvic floor muscle training program will be given.~In the pelvic floor muscle training program:~Fast and slow pelvic floor muscle contractions will be taught,~Training will begin with 3 sets of exercises per day, exercise compliance of individuals will be monitored in the controls to be made every 2 weeks, and the number of exercise sets will be increased by one set.~1 set of exercises: It will include 10 fast + 10 continuous (frequent-(3-10 sec) hold-release) contractions.~Individuals will be tracked with exercise diaries.~At the end of the 8th week, post-intervention evaluations will be made again.~The exercise program will be completed with a total of 6 sets of exercises per day (60 fast and 60 slow per day)."
75926101|NCT06034483|Other|Patient/individual education|"In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~Explaining menopause and menopausal symptoms~Defining the Genitourinary Syndrome of Menopause (MGS)~The effect of MGS on sexual function cycle and sexual function,~Conservative recommendations on MGS management~Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month."
75926102|NCT06034444|Other|interRAI LTCF|Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.
75926103|NCT06034418|Device|Pulse radiofrequency treatment|In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, pulse radiofrequency will be applied to each nerve in 2 cycles of 120 seconds for the patients in this group. The pulse radiofrequency current will be 20 milliseconds wide and 45 volts in size. The tip temperature shall not be more than 42℃.
76081251|NCT04830410|Dietary Supplement|Placebo reintroduction|Patients will reintroduce placebo powder after 14-day of a low FODMAP diet
76081252|NCT04820933|Drug|Doravirine 100 Mg|Doravirine 100 Mg orally dail
76081253|NCT04804605|Drug|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream
75641647|NCT02585869|Drug|Gemcabene 300 mg|Blinded capsules and tablets, 300 mg, once daily, 84 days
75641648|NCT02585869|Drug|Gemcabene 600 mg|Blinded capsules and tablets, 600 mg, once daily, 84 days
75789896|NCT05951023|Drug|Eszopiclone 2 mg|Eszopiclone tablet (encapsulated)
76081254|NCT04788264|Other|Medical Device Usage and Evaluation|Receive Fitbit
76081255|NCT04788264|Other|Consultation|Receive consultation from a physical therapist
76081256|NCT04788264|Other|Exercise Intervention|Attend exercise training sessions
76081257|NCT04788264|Behavioral|Behavioral Intervention|Attend sessions with a behavioral therapist
76081258|NCT04788264|Other|Questionnaire Administration|Ancillary studies
76081259|NCT04788264|Other|Quality of Life Assessment|Ancillary studies
75641649|NCT02585869|Drug|Gemcabene 900 mg|Blinded capsules and tablets, 900 mg, once daily, 84 days
75789897|NCT05951023|Drug|Placebo|Sugar capsule manufactured to match encapsulated Eszopiclone
75789898|NCT05949203|Drug|Cabotegravir Injection|Administration of HIV pre-exposure prophylaxis with cabotegravir 600 mg/3mL extended release injectable suspension every other month.
75789899|NCT05948748|Procedure|foot surgery|minimally invasive osteoarticular foot surgery
75789900|NCT05947838|Procedure|Circulating tumoral DNA directed neoadjuvant therapy arm|Given by IV (vein)
75641650|NCT02585869|Drug|Placebo|Blinded capsule and tablets, once daily, 84 days
75641651|NCT02607813|Drug|LXH254|pan-RAF inhibitor
75641652|NCT02607813|Drug|PDR001|Biological: PDR001 anti-PD1 antibody
75641653|NCT04079725|Procedure|Combined trabeculotomy-trabeculectomy with mitomycin c|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease
75789901|NCT05945784|Other|Use of Rare Beauty makeup products|Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.
76081260|NCT04786093|Radiation|Stereotactic radiation therapy|Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.
75789902|NCT05945732|Drug|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~Trastuzumab (T-DXd) to be administered according to the SmPC.~Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC."
75926104|NCT06034418|Drug|Nerve block with 1 cc betamethasone and 1 cc 1% lidocaine|In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, patients will be injected with 1 cc betamethasone and 1 cc 1% lidocaine for each nerve. A total of 2 cc volume will be injected for each nerve.
75926105|NCT06033638|Other|Score assessment|PBS Score
76081261|NCT04786093|Drug|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
76081262|NCT04785976|Procedure|Surgical clipping and endovascular coiling|Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
76081263|NCT04779684|Other|Advance care planning by proxy for health care proxies of people without medical decision making capacity|Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.
76081264|NCT04778709|Device|Puros allograft|"Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone."
76081265|NCT04778059|Drug|USB002|USB002 is pharmaceutically formulated Angiotensin 1-7 [A(1-7)], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
76081266|NCT04778059|Drug|Placebo|The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
75332896|NCT05505006|Drug|Folic acid|Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
75641654|NCT02697747|Other|Education|Educational intervention in the use of ultrasound to identify landmarks
75641655|NCT00783718|Drug|vedolizumab|Vedolizumab for intravenous infusion
75641656|NCT00783718|Other|Placebo|Placebo intravenous infusion
75641657|NCT04213287|Drug|Dexketoprofen Trometamol|Drug: Dexketoprofen Trometamol oral tablet
75789903|NCT05942365|Drug|ZSP1273|Drug Warfarin oral Drug midazolam oral
75789904|NCT05938712|Drug|Dapagliflozin 10 MG|Semaglutide subcutaneous once weekly for 12 weeks.
75789905|NCT05938712|Drug|Semaglutide, 1.0 mg/mL|Dapagliflozin oral once daily for 12 weeks.
76081267|NCT04773470|Diagnostic Test|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
75332897|NCT05505006|Drug|B12|Anemic patients with B12 deficiency will receive B vitamin complex 1 tablet per day for 1 month
75332898|NCT03826706|Device|C-MAC Videolaryngoscope D blade|C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
75332899|NCT03826706|Device|McGrath MAC Videolaryngoscope X3 blade|McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
75641658|NCT04213287|Other|spinal anesthesia|Drug: heavy bupivacaine 2,5 ml 0,5%
75641659|NCT04213287|Other|IPACK|Drug: bupivacaine 20 ml 0,025%
75641660|NCT04213287|Other|PAI|Drug: bupivacaine 30 ml 0,025%
75641661|NCT04213287|Other|Adductor canal block|Drug: bupivacaine 20 ml 0,025%
75641662|NCT04917601|Behavioral|Evira Care treatment|The intervention aim to examine the effectiveness of using a digital support system (Evira) in treatment of childhood obesity. Through daily weighings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored. Participants can be randomized to either the intervention group or the control group. The control group will receive local standard treatment.
75641663|NCT04917601|Behavioral|Standard Lifestyle Care|The control group will receive the local standard care of treatment addressing lifestyles for childhood obesity without any restriction in visits or clinical support. This is the current standard care of treatment for childhood obesity.
75641664|NCT02585791|Other|Propylene Glycol|inhaled Propylene Glycol (PG) by vaporing
75641665|NCT02585791|Other|vegetable glycerin|inhaled vegetable glycerin (VG) by vaporing
75789906|NCT05937854|Drug|Tadalafil|one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
75789907|NCT05937854|Drug|Placebo|one or two encapsulated tablets of placebo po QD
76081268|NCT04765033|Drug|Nebulized 5% Hypertonic saline|nebulized 0.9% saline
75789908|NCT05927363|Other|Therapeutic educational consolidation program in Phase 3 of cardiac rehabilitation associating a patient & caregiver partnership|"In the experimental group, patients benefit from the usual management as part of the phase 2 post-CR follow-up, with the provision of an information booklet on the benefits of physical activity, and a telephone contact in the event of any questions. In addition, they benefit from the Consolidation therapeutic education program in phase 3 of CR associating a patient & caregiver partnership, which consists of two teleconsultation sessions at 2 and 4 months, followed by a remote group education workshop co-facilitated by the patient and caregiver partnership at 5 months.~Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions."
75789909|NCT05927363|Other|Teleconsultation at 2 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
75926106|NCT06033417|Other|Increased lifestyle walking (intervention)|Participants will increase their baseline steps by a minimum of 3,000 extra steps/day, 5-days/week, for 8-weeks. Baseline steps will be assessed using a pedometer over a 7-day period before the intervention, after which a new (higher) daily step target will be assigned. The intervention will take place in the free-living setting, with participants reaching their step goals by engaging in more activities of daily living or via purposeful physical activity. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants will be supported in their efforts to meet their daily step targets by engaging in once-weekly walking groups (30-mins/session) led by research staff. They will also receive 20-minute phone calls once every two weeks to set goals and create action plans for reaching their step targets.
75926107|NCT06033417|Other|Health education only (control)|Those randomized to the delayed participation group will be instructed to maintain their 'normal' lifestyle activities, thereby avoiding any significant increase in daily step counts beyond their 'baseline' values. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants in this group will attend once-weekly group health education sessions (30-minutes/session), in addition to 5-minute, 'touch base' phone calls once every 2-weeks, but these phone calls will not involve goal-setting or action planning. After completing the initial 8-week period, these individuals can then opt to undertake the 'increased lifestyle walking' intervention of 3,000 extra steps/day over 5-days for 8-weeks if desired.
76081269|NCT04726150|Other|ILR implantation|If LGE is present on CMR, ILR implantation will be proposed
76081270|NCT04724421|Drug|Voxelotor|synthetic small molecule
76081271|NCT04723784|Other|Initial Assessment|In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.
76081272|NCT04723784|Other|Implementation of assistive technology in the daily life of participants|The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.
76081273|NCT04723784|Other|Application of outcome measures|After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
76081274|NCT04708808|Behavioral|music therapy|cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
76081275|NCT04699838|Drug|Cisplatin|Cisplatin
76081276|NCT04699838|Drug|Carboplatin|Carboplatin
76081277|NCT04699838|Drug|Etoposide|Etoposide
76081278|NCT04699838|Drug|Durvalumab|Durvalumab
76081279|NCT04699838|Drug|Ceralasertib|Ceralasertib
75641666|NCT02585791|Other|PG+VG|inhaled PG+VG by vaporing
75641667|NCT04913389|Drug|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
75641668|NCT04913389|Drug|Placebo|Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses 1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.
75641669|NCT04080817|Device|Neolexon|Application (Neolexon) on Tablet. Same frequency & intensity as in the other interventions
75641670|NCT04080817|Other|Speech therapy|standard logopedic speech therapy. Same frequency & intensity as in the other interventions
75641671|NCT04080817|Other|Self training|Same frequency & intensity as in the other interventions
75641672|NCT02528721|Device|Dual Mode BreathID Hp System|The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
75641673|NCT04904965|Drug|Propofol Group 1|Propofol 2.0 mg/kg/hr per 10 min
75641674|NCT04904965|Drug|Propofol Group 2|Propofol 4.0 mg/kg/hr per 10 min
76081280|NCT04690049|Other|Neuromuscular resistance exercise program|This neuromuscular resistance exercise program will be organized in 5 stages, distributing the different phases in 2, 4, 4, 2 and 2 weeks respectively, with a frequency of 3 sessions/week. In addition, 2 weekly sessions of aerobic work with cycloergometer will be developed. The duration of each session will last 30 minutes. The parameters of load and execution speed will be modified as the exercise program progresses along the phases, with the goal of have an impact on the different aspects of the neuromuscular system.
76081281|NCT04690049|Other|Control exercise program with elastic band|"This program is based on previous literature so that it remains comparable to the experimental program.~The parameters will consist in 3 sets of 10 repetitions, 2 times/day, 3 times/week, for a total of 6 weeks."
76081282|NCT04626583|Biological|Allogeneic MSC|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells
76081283|NCT04621266|Behavioral|Online Home-based peer support|Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
76081284|NCT04621227|Drug|PF-06882961|120 mg and 200 mg BID
76081285|NCT04621227|Drug|Rosuvastatin|10 mg single dose
76081286|NCT04621227|Drug|Midazolam|2mg single dose
76081287|NCT04597918|Drug|Faricimab|A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
75332900|NCT05509920|Other|S-PRG barrier coat|S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
75641675|NCT04904965|Drug|Propofol Group 3|Propofol 6.0 mg/kg/hr per 10 min
75641676|NCT04904965|Drug|Propofol Group 4|Propofol 8.0 mg/kg/hr per 10 min
75641677|NCT02602132|Procedure|Clamping|To clamp before the removal of short-term indwelling urethral catheters
75641678|NCT05324865|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
75926108|NCT06032351|Other|Innovation-integrated curriculum for dementia care and care management|The curriculum integration group will receive two intervention phases, including an innovation-integrated curriculum for dementia care and an innovation-integrated curriculum for care management with Entrustable Professional Activities (EPAs), lectures, Situated Simulation Learning, Team-based learning, and Objective Structured Clinical Examination(OSCE).
75641679|NCT00617565|Drug|biphasic insulin aspart|
75641680|NCT00617565|Drug|biphasic human insulin|
75641681|NCT00774748|Device|Insuflon|Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
75641682|NCT05324787|Device|Grency venous stent system|Venous stent implantation during the index procedure
75641683|NCT04079413|Drug|GP40071|GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
75641684|NCT04079413|Drug|NovoRapid® Penfill®|NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
75641685|NCT00915460|Drug|Interferon beta-1a (Avonex)|dosage and frequency as per Biogen Idec protocol
76081288|NCT04592549|Drug|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
76081289|NCT04592549|Other|Placebo|Placebo
76081290|NCT04591990|Drug|Administration of AVP|Administration of AVP
76081291|NCT04591990|Drug|Administration of placebo AVP|Administration of placebo AVP
76081292|NCT04591990|Drug|Administration of placebo hydrocortisone|Administration of placebo hydrocortisone
76081293|NCT04591990|Drug|Administration of hydrocortisone|Administration of hydrocortisone
76081294|NCT04586023|Drug|Fenebrutinib|Participants will receive fenebrutinib.
75332901|NCT04392518|Other|exercise|Breathing, posture, dynamic core stabilization, upper and lower extremity strengthening exercises.
75332902|NCT05509764|Diagnostic Test|lung ultrasound score|determination of atelectasis by lung ultrasound score
75332903|NCT05509686|Device|Intermittent theta burst stimulation (iTBS)|A single-session standard 600-pulse intermittent theta burst stimulation (iTBS) is applied to the ipsilesional primary motor cortex.
75332904|NCT05509686|Device|Sham intermittent theta burst stimulation (iTBS)|The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp. Electrical field simulation shows that the setups for sham stimulation would not induce any valid cortical activation.
75471392|NCT01952119|Other|Secure message reminder|Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
75471393|NCT01952184|Device|CBSvit HS device|closed vitrification with closed storage
75641686|NCT02434107|Procedure|Completion Lymphadenectomy|
75641687|NCT02434107|Procedure|Clinical Monitoring (Palpation and node ultrasound)|
75641688|NCT00587860|Drug|St. John's wort|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
75641689|NCT00587860|Drug|Placebo|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
75641690|NCT00617643|Drug|Nevirapine without dose escalation|Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
75926109|NCT06032351|Other|Traditional classroom teaching course programs|The conventional teaching group will receive only traditional classroom teaching course programs.
76081295|NCT04586023|Drug|Teriflunomide|Participants will receive teriflunomide.
76081296|NCT04586023|Drug|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
76081297|NCT04583033|Behavioral|Cognitive Behavioral Therapy (CBT)|Treatment components include stimulus control, sleep restriction therapy, relaxation, and cognitive therapy. Each session will last approximately one hour and will be provided on line.
76081298|NCT04562870|Drug|Selinexor|Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
75471394|NCT01952184|Device|Cryotop SC device|open vitrification with closed storage
76081299|NCT04562870|Other|Physician's Choice Treatment|Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
75471395|NCT01952197|Other|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
75641691|NCT00617643|Drug|Nevirapine initiation with dose escalation|Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
75641692|NCT04106908|Biological|Eqwilate|Eqwilate® is a new generation, albumin-free, high-purity, double virus-inactivated, freezedried concentrate of VWF and FVIII
76081300|NCT04553185|Other|Study procedure|All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
75641693|NCT03147807|Device|betaLACTA® rapid diagnostic test|Since ≥1 bacteriological sample(s) from ICU patients empirically treated with carbapenems (i.e. respiratory sample such as quantitative tracheobronchial aspirate with available volume ≥1 mL; urinary sample such as single catheter urine specimen; or blood culture) is positive for ≥2 GNB/field on direct examination, empirical carbapenem will be adapted: 1) early, since the second dose, according to the results of the betaLACTA® rapid diagnostic test (BLT) in the intervention arm (i.e. de-escalation to cefepim or to ceftazidim+amikacin in case of negativity, and carbapenem continuation in case of positivity); or 2) after 48-72h according to the results of the antibiotic susceptibility test in the control arm.
75641694|NCT02585557|Other|Primary Care Practice Support|The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
75641695|NCT00617721|Other|Blood withdrawal|Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
75789910|NCT05927363|Other|Teleconsultation at 4 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
75789911|NCT05927363|Other|Remote group education workshop|This remote workshop will be co-facilitated by the patient and caregiver partnership at 5 months
75789912|NCT05927363|Other|Administration of self-questionnaires: IPAQ, EMAPS, the Exercise Confidence Survey, EQ-5D-5L and the Mediterranean diet adherence score.|Patients are then randomly assigned to either the control group (usual management) or the experimental group (management with Patient and Caregiver partnership).
76081301|NCT04547634|Other|Therapeutic Exercise and Education|The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
76081302|NCT04546126|Drug|Dexamethasone (Group 2)|Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
76081303|NCT04546126|Drug|Cosyntropin (Group 3)|Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
75789913|NCT05927363|Diagnostic Test|6-minute walk test and administers the modified Borg scale at its conclusion.|What is a modified Borg scale? The Modified Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered following a six-minute walking test, one of the most common and frequently used measures to assess disease severity in patients with pulmonary arterial hypertension. Upon conclusion of the 6-minute walking test, the modified Borg scale will be recorded.
75789914|NCT05927363|Diagnostic Test|Biological check-up|This check-up includes total cholesterol, LDL, HDL, triglycerides, HbA1c.
75926110|NCT06032273|Behavioral|Investigator-designed lung transplant education website|Caregiver participants assigned to the intervention will access the investigator-designed educational resource via their login to a secure website.
75926111|NCT06032260|Other|Enriched panettone|Volunteers consumed 100 grams of panettone enriched with fiber (JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
76081304|NCT04546126|Combination Product|PET/CT Scan with FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
75926112|NCT06032260|Other|Panettone standard|Volunteers consumed 100 grams of panettone standard
75926113|NCT06032221|Device|Thermidas Vista Telehealth App|Thermal camera with telemedicine app
75926114|NCT06030713|Drug|Cefazolin|Cord clamping before or after antibiotic (cefazolin) prophylaxis
75926115|NCT06027632|Other|Cognitive exercises with supervision|"The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the PRESCO program of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
76081305|NCT04543617|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
75471396|NCT01952210|Behavioral|nutritional consultation and exercise program|The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
75926116|NCT06027632|Other|Cognitive exercises without supervision|"Patient will have access to the program named PRESCO of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
75926117|NCT06023108|Device|Orthokeratology|OK lenses will be used to evaluate the condition that causes dry eye in the treatment of myopia.
75641696|NCT02791503|Procedure|Irreversible electroporation (IRE)|IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
75926118|NCT06023108|Device|Spectacles|Spectacles will be used to evaluate the condition that causes dry eye in the treatment of myopia.
75926119|NCT06022393|Behavioral|Cognitive Reappraisal|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to cognitively reappraise fear or anger inducing situations and are encouraged to implement this strategy into their daily lifes.
75926120|NCT06022393|Behavioral|Reflection|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to reflect on certain topics of their day.
75789915|NCT05927363|Device|Accelerometer|"An accelerometer is given to the patient, with instructions to wear it for 7 days following the visit (it will then be returned by post).Pre-stamped bubble envelopes are given to the patient to return their accelerometer to the measurement points specified in the follow-up."
75926121|NCT06021418|Device|DKB-119|Experimental and Acitve Comparator are applied 4 times to each of crow's feet on both sides of the subject.
75926122|NCT06021379|Drug|Trastuzumab|AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
75926123|NCT06020417|Device|O-ARM (Medtronic, Inc, Louisville, CO)|scanner that allows imaging of screws intraoperatively
76081306|NCT04543617|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
76081307|NCT04543617|Drug|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
75641697|NCT02791503|Procedure|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
75641698|NCT02584075|Drug|Byetta (Exenatide)|Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
75641699|NCT02584075|Drug|Glucophage ( Metformin Hydrochloride)|Metformin 500mg Tid
75641700|NCT02585479|Drug|Pirarubicin|"Pirarubicin 30mg/m2 intravenously~Pirarubicin17mg/m2 are infused through the right and left hepatic arteries"
75641701|NCT02585479|Drug|Oxaliplatin|"Oxaliplatin 100 mg/m2 intravenously~Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries"
75641702|NCT02585479|Drug|Lipiodol|Lipiodol 5-10ml infused through the right and left hepatic arteries
75789916|NCT05927363|Other|Administration of a logbook|The patient is given a logbook for daily monitoring of non-measurable physical activities, treatments and medical procedures carried out, as well as any intercurrent events.
75926124|NCT06020417|Procedure|Conventional corrective surgery for arthrodesis|Conventional procedure without neuronavigation guide
75926125|NCT06020404|Procedure|supine position|At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate < 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.
75926126|NCT06020404|Procedure|prone position|"After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position."
75926127|NCT06019871|Procedure|Dialysis|Patients who have decided for dialysis either center haemo-dialysis or peritoneal dialysis
75926128|NCT06011070|Behavioral|Gambling Personalised Feedback|The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
75926129|NCT06008834|Procedure|First-day discharge protocol|Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
75926130|NCT06007014|Drug|Chiglitazar sodium|tablets 48mg/ day administered for 18 weeks
75926131|NCT06007014|Drug|Chiglitazar placebo|tablets 48mg/ day administered for 18 weeks
75926132|NCT06003933|Drug|Bupivacaine Hydrochloride|10 ml of 0.25% bupivacaine on each side of cervical region at C5
76081308|NCT04543617|Drug|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
76081309|NCT04540211|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
76081310|NCT04540211|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.
76081311|NCT04540211|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
76081312|NCT04540211|Drug|Cisplatin|Cisplatin 60-80 mg/m^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
75471397|NCT01952210|Behavioral|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
75789917|NCT05925985|Other|NA-Observational Registry|NA Observational Registry
75789918|NCT05925972|Procedure|Plane block|Plane block application in laparoscopic hysterectomies
75471398|NCT01952236|Behavioral|Web+Mobile|We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 1,271 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.
75789919|NCT05923229|Behavioral|Mindfulness Based Walking Therapy (MBWT)|MBWT is a modified version of the Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking mediations and is acceptable for people with Parkinson disease and freezing of gait.
75789920|NCT05923229|Other|Freezing of Gait (FOG) Education|Participants will receive materials to read weekly about FOG and track their usual care regimens.
75789921|NCT05923060|Drug|Topical Aminolevulinate|Topical Levulan Kerastick is applied to actinic keratoses.
75789922|NCT05923060|Procedure|Photodynamic therapy (PDT)|PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.
75471399|NCT01952236|Behavioral|Web Only|A Web-based PC-delivered best practices smoking cessation intervention.
75471400|NCT01952249|Drug|Demcizumab|administered intravenously
75641703|NCT02585479|Device|Gelfoam|Hepatic artery embolization with Gelfoam.
75789923|NCT05923060|Procedure|Red light illumination|To occur post-PTD; used for activation of ALA during photodynamic therapy.
75789924|NCT05907174|Behavioral|Siyakhana - P|A trained peer recovery coach (PRC) will be integrated onto the healthcare worker team randomized to Siyakhana - P. The PRC on this team will work with eligible and consenting patients who are seen by members of this healthcare team.
75471401|NCT01952249|Drug|Taxol|administered intravenously
75471402|NCT01952275|Procedure|Collection of biological samples|
75471403|NCT01952314|Drug|Naftopidil 75mg|naftopidil 75mg 1T qd hs
75789925|NCT05906368|Diagnostic Test|ClearSight HPI Monitoring system|Continuous blood pressure monitoring for precision hypotensive event response
75789926|NCT05906368|Diagnostic Test|Standard of Care Blood Pressure Monitoring|Blood pressure (BP) monitoring using a conventional arm cuff and inflation after epidural anesthesia as standard procedure. Standard of care blood pressure monitoring includes measurement of blood pressure at the time of epidural test dose delivery, 3-minute cycles of BP monitoring for 30 minutes after epidural placement, and then BP monitoring every 15 minutes per existing clinical standards for at least 4-hours, or until delivery.
75789927|NCT05896579|Behavioral|Exercise training|Exercise training will include supervised high-intensity interval training for ~35 minutes 3x/week on an upright stationary bicycle and unsupervised continuous aerobic exercise for ~30 minutes 2x/week.
75471404|NCT01952314|Drug|Placebo for Naftopidil|Placebo 1T qd hs
75471405|NCT01952314|Drug|Standard treatment|Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
75471406|NCT01952327|Device|The pleurapump system|Implantation of the pleurapump system
75471407|NCT01952353|Procedure|Preoprative TACE|
75471408|NCT01952353|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
75641704|NCT00583453|Drug|Celecoxib|"Celecoxib 200 mg capsule~capsule the night before surgery~capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
75641705|NCT00583453|Drug|Placebo|"Placebo capsule~capsule the night before surgery~capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
75641706|NCT03931603|Other|MRI|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
75471409|NCT01952405|Behavioral|Dialectical behavior therapy (DBT)|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
75471410|NCT01952431|Device|Total Lung Capacity (TLC) testing|Comparison of TLC results
75471411|NCT01952457|Device|Zilver PTX|
75471412|NCT01952457|Device|prosthetic bypass|
75471413|NCT01952496|Other|Assisted Standing Treatment Program|"Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months.~Arm: Force-measuring platform"
75641707|NCT02584231|Drug|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: >6 months and < 2years: 60µg; ≥2 years and <4 years: 120µg PO and ≥4 years and <8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
75789928|NCT05893459|Behavioral|Debrief|Post-Stressor Discussion with a Friend
75471414|NCT01952535|Drug|HMS5552|
75471415|NCT01952535|Drug|Placebo|
75471416|NCT01952548|Drug|K-312|
75471417|NCT01952548|Drug|Placebo|
75471418|NCT01952561|Drug|dapivirine ring|
75471419|NCT01952587|Biological|A peripheral blood sample|A peripheral blood sample will be collected from HIV-infected subjects and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
75789929|NCT05872399|Other|Attitudes Towards Psychiatry - 30|The participants will answer their beliefs in 30 statements about psychiatry and mental health.
75789930|NCT05872243|Device|active rTMS|Each participant will receive two 1800 pulse active rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
75789931|NCT05872243|Device|sham rTMS|Each participant will receive two 1800 pulse sham rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
75789932|NCT05872230|Device|Massage Percussion Therapy device|Using massage percussion postoperatively.
75789933|NCT05872191|Other|No intervention|There is no intervention to be administered, only collection of data through various tests and questionnaires.
75789934|NCT05870761|Procedure|Biospecimen Collection|Undergo collection of blood samples
75789935|NCT05870761|Procedure|Computed Tomography|Undergo MRI/CT
75789936|NCT05870761|Biological|Dostarlimab|Given IV
75789937|NCT05870761|Procedure|Magnetic Resonance Imaging|Undergo MRI/CT
75789938|NCT05870761|Drug|Niraparib|Given PO
75926133|NCT06003933|Drug|Lidocaine Hydrochloride|10ml xylocaine on each side of cervical region at C5
75332905|NCT04392752|Other|Dieting intervention|This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.
75789939|NCT05862844|Behavioral|Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )|The Intervention Arm involves a 90-minute educational session tailored to Muslim women. They will learn about HPV infection risks, cervical cancer risks, and benefits of early screening and HPV vaccination. Discussions cover transmission, consequences, risk factors (behaviors, infections, family history), and importance of early detection. The session provides information on screening methods, check-ups, and HPV vaccine safety. Participants actively engage in discussions, ask questions, and share thoughts. The session empowers women with knowledge to make informed decisions about their health, promoting cervical cancer prevention.
75789940|NCT05854836|Behavioral|CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances)|CHOICES-PLEAS includes four manual-guided motivational interviewing sessions delivered by a trained counselor and one family planning counseling session delivered by a family planning clinician. The intervention is based on the Transtheoretical Model (TTM) of behavior change and motivational interviewing that includes a decisional balance exercise, goal self-selection, self-monitoring, self-generated plans, and importance and confidence scales. By using a patient-centered approach based on the TTM that meets patients where they are, counselors can have a more effective impact on patient behaviors. This adaptation from the original CHOICES intervention contains unique features focused on the incarcerated setting, illicit polysubstance use, and risky sexual behaviors most common among women with illicit polysubstance use.
75789941|NCT05850715|Diagnostic Test|Disability Assessment for Dementia (DAD)|The scale consists of 40 items and assesses patients' independence in basic and instrumental activities. The scale is completed by the patient's caregiver with the assistance of the assessor-therapist.
75789942|NCT05850455|Drug|Dexmedetomidine Hydrochloride 'Precedex' combined with|Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist
75789943|NCT05850455|Procedure|Lumbar epidural analgesia with Bupivacaine 0.25% 'Sunnypivacaine'|The epidural insertion point will be 2 segments upper than the surgical procedure level, 10 ml of Bupivacaine 0.25% will be injected in the epidural space to adjust the sensory level
75789944|NCT05850455|Procedure|General anesthesia|Propofol 2-3 mg/kg'Diprivan 1%', Fentanyl 'Fentanyl' 2 μg/kg, and Cisatracurium 'Cisatracure' 0.2 mg/kg will be administered to facilitate endotracheal intubation, and ventilation will be controlled to maintain the end-tidal carbon dioxide (CO2) between 32-38 mmHg, to maintain anesthesia, 2-3% Sevoflurane 'Sevoflurane', and 0.05 mg/kg of the muscle relaxant Cisatracurium will be added at 40-minute intervals according to the conditions of the operation. No other medication will be administered
75789945|NCT05850455|Drug|Local infiltration with Lidocaine HCL 1%'Debocaine'|Lidocaine 1% which is a local analgesic as local infiltration
75789946|NCT05849727|Drug|TQH3821 tablets 200 mg|TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
75789947|NCT05849727|Drug|TQH3821 tablets matching placebo|TQH3821 tablets matching placebo without active substance.
75789948|NCT05849168|Behavioral|Exercise training|Participants will complete a 12-week exercise training program. The program consists of 3x/week HIIT sessions on an upright stationary bicycle (~40 minutes each) and 3x/week home aerobic sessions (any type of aerobic exercise; 45 minutes each).
75926134|NCT06003933|Device|Ultrasound|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block.The five-layered posterior cervical muscles were identified at the level of C5 with a 6-15-MHz linear probe oriented in the transverse plane (SonoSite Edge, Bothell, Washington). The fifth cervical spine was counted from the C7 spinous process with the probe sliding cranially.
75471420|NCT01952613|Device|FES|In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
75926135|NCT06003933|Device|Needle|the needle (22- G, 50-mm block needle (Visioplex, Vygon) was introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of bupivacaine 0.25% was injected5.
75926136|NCT06002256|Procedure|Mostafa Maged maneuver|While the patient is on the lithotomy position , The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)
75471421|NCT01952626|Drug|Ondansetron|intravenous injection
75471422|NCT01952626|Drug|Palonosetron|intravenous injection
75471423|NCT01952639|Dietary Supplement|protein type and amount|Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
75471424|NCT01952652|Drug|Group N:Naproxen sodium|drug will be given 60 minutes before surgery
75471425|NCT01952652|Drug|Group NC :naproxen sodium codeine phosphate|drug will be given 60 minutes before surgery
75471426|NCT01952704|Behavioral|Aerobic exercise|
75641708|NCT04080193|Behavioral|Smartphone-based interventional trial|According to the SIRs the 12-week intervention will contain exercises from three out of six different key modules (e.g. self-efficacy, impulsivity). The remaining modules will be implemented as mini-modules during the end of the intervention phase. The study will be designed gender-sensitive instead of gender-dichotomous. This means that treatment contents will be individualized based on gender-related SIRs and not biological sex. Participants choose between two different styles of presentation for each module and the contents can be deepened within specific exercises.
75798789|NCT03861546|Behavioral|Healthy lifestyle Shared Medical Appointment (SMA) program|Social network-based, culturally-tailored healthy lifestyle SMA program for high risk SAs will be piloted to collect pre-post data on diet and exercise habits, and to determine feasibility and acceptability. Patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight. Biometric measurements (weight, height, blood pressure) will be collected, point of care glucose and lipid testing will be done.
75926137|NCT06002256|Procedure|Bimanual uterine compression|the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands.
75926138|NCT06001398|Behavioral|Parent Acceptance and Commitment Therapy (PACT)|PACT is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature
75926139|NCT06001398|Behavioral|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate
75926140|NCT06000267|Procedure|Intubation|All the patients will be ventilated with face mask and intubated before elective surgery
75332906|NCT03018392|Device|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
75926141|NCT05999513|Drug|AB521|Administered as specified in the treatment arm
75641709|NCT00920335|Other|tumoral sample|Ependymoma tumoral sample
75332907|NCT02979548|Drug|Aprepitant|Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
75926142|NCT05994807|Drug|DC-806|Oral tablets
76081313|NCT04540211|Drug|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
75641710|NCT04630873|Drug|Botulinum toxin|The triceps surae along with the posterior tibialis muscle will be injected. The units that will be injected are the average being injected in our University Clinic. I.e. 50 units for each head of the gastrocnemius muscle- single injection site, 100 units for the soleus muscle- two injection sites and 50 units for the posterior tibialis muscle- single injection site.
75641711|NCT04630873|Diagnostic Test|gait analysis|The gait analysis will be performed with two systems. A foot pressure sensitivity walkway (medicapteurs Win-Track), and an IMU network system (RehaGait Pro) using seven IMU's placed in specific anatomical positions. In combination those two systems can provide a wide range of spatiotemporal analytics of gait:
75641712|NCT02584153|Drug|Fibrin Sealant|TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
75641713|NCT02584153|Drug|Silver Microparticles|Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
75641714|NCT02585401|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
75641715|NCT04876729|Behavioral|Otago Exercise Program|Otago Exercise program implemented including education on fall risk reduction, instruction on strength and balance exercises and walking program. Perform a home safety assessment and provide recommendations to reduce trip hazards. CHRs will engage local housing authority services to complete the modifications (such as grab bar installation). CHRs will complete approximately 10 home visits during 12 months with reassessment at 3, 6, and 12 months.
75641716|NCT04115605|Device|Altis Single Incision Sling|Minimally invasive system including permanently implantable synthetic suburethral sling for the surgical treatment of female Stress Urinary Incontinence
75798790|NCT01176786|Other|Culture Swabs, Rodac Plate Cultures|Culture swab is taken when breast tissue expander is removed and when breast implant is placed in breast pocket. Rodac Plate cultures are taken after the surgical procedure of the surgeons dominant palm, forearm of gown and subject's drape closest to the breast.
75926143|NCT05994807|Drug|Itraconazole|Oral capsules
75926144|NCT05994807|Drug|Carbamazepine|Oral tablets
75332908|NCT02979548|Drug|Ondansetron|Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
75332909|NCT02979548|Drug|Metoclopramide|Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
75798791|NCT01174836|Other|Educational session|Physicians will have a brief education session provided in powerpoint about the risks of CT
75798792|NCT01288872|Drug|Praziquantel|Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
75926145|NCT05993117|Device|G114R VNS system|All patients treated with Rechargeable Implantable Vagus Nerve Stimulation System (G114R)
75926146|NCT05991687|Other|In-home drug disposal pouch|Will receive a drug disposal pouch to inactivate leftover prescription opioids for disposal after surgery.
75926147|NCT05991687|Other|Mail-in prepaid envelope|Will receive a prepaid envelope to mail leftover prescription opioids for disposal after surgery
75926148|NCT05983913|Behavioral|cognitive-motor training|The cognitive-motor training program consists of five cognitive tasks related to concentration, reaction time, and executive function, combined with physical exercises using an interactive system. The five tasks include: (1) number sequence, (2) number-word sequence, (3) card matching games, (4) memorizing numbers, and (5) route-finding games.
76081314|NCT04540211|Drug|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
76081315|NCT04534413|Device|composite optical fiberscope (COF)|Fiber Technology
76081316|NCT04533672|Diagnostic Test|MRI Sequences|New multiparametric MRI techniques
75641717|NCT04080349|Drug|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
75641718|NCT04080349|Drug|Misoprostol 200Mcg Tab|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
75641719|NCT04080349|Drug|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
76081317|NCT04531917|Other|Pain Neuroscience Education|Pain Neuroscience Education (PNE) teaches patients about complex pain mechanisms known to be of importance in pain following breast cancer such as malfunctioning of the endogenous analgesic system and pain memories.
76081318|NCT04531917|Other|Behavioural Graded Activity|"Patients in the experimental group will receive a behavioural treatment integrated within the concepts of operant conditioning. The purpose of Behavioural Graded Activity (BGA) is to increase the level of physical activity in the patient's daily lives in a time-contingent manner. On top of that, a healthy behaviour will be positively reinforced to consequently create a withdrawal of the attention towards pain behaviour, which is seen as an unreliable alarm sign in chronic pain patients. The implementation of BGA after PNE is described in the guideline reported by the International Association for the Study of Pain."
76081319|NCT04531917|Other|Usual care|The content of the leaflet has a biomedical approach in explaining pain and providing information on the different pain medication classes. This leaflet is mostly available in waiting rooms of oncology centres and units of the Flemish part of Belgium.
75926149|NCT05983913|Behavioral|cognition training|The intervention consists of five cognitive tasks (memory, attention, spatial and temporal perception) with difficulty levels adapted to the individual's cognitive abilities.
75926150|NCT05976139|Device|subthreshold treatment with micropulsed laser|"The laser instrument used is the Q 577® Laser System, Iridex, wavelength 577 yellow. The standard pattern used is:~Power: 5% Duty Cycle~Power 250 mw~Pulse duration 200 ms~Spot size 100 micron~Pattern spacing 0.0 confluente, griglie 7x7"
75926151|NCT05975216|Other|Contact the patient|Phone call, email or letter to contact the patient to relink them.
75471427|NCT01952704|Behavioral|Placebo control|Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
75641720|NCT02587429|Behavioral|Patient education|
75641721|NCT02585323|Behavioral|Education session, Fitbit/FitViz, PT counselling|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
75641722|NCT02585323|Behavioral|Same intervention with a 3 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 3 month delay.
75641723|NCT02585167|Procedure|operation|the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
75641724|NCT02585167|Device|VAAFT|Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
75641725|NCT02585089|Other|Spanish cured-pork ham|"Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day."
75926152|NCT05964296|Other|The MAURISSE application use|"Exchanges with the care team via the messaging system,~Postponement of consumption,~Monitoring of consumption,~Access to information on the To Do List,~Access to personal content to help with management (Socio-professional situation, type of life, personal history..).~Postponement of a feeling of boredom,~Access to proposals to fight against this feeling."
75926153|NCT05964296|Other|Usual care|The usual care within the center will consist of appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation.
75926154|NCT05961865|Diagnostic Test|Markers of inflammation and fibrosis|"Will be analyzed the following inflammation markers:~Interleukin 6, N-terminal propeptide of type 1 procollagen (P1NP), chitinase-3-like protein 1 (YKL-40), tumor necrosis factor (TNF-alpha), GlycA, proprotein convertase subtilisin/kexin type 9 and omega-3 fatty acids."
75641726|NCT02585089|Other|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
75641727|NCT02585011|Drug|Ropivacaine|
75641728|NCT02585011|Drug|Epinephrine|
76081320|NCT04513925|Drug|Atezolizumab|Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.
76081321|NCT04513925|Drug|Tiragolumab|Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.
75332910|NCT03012776|Device|Total Posterior Spine System (TOPS)|Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis
75332911|NCT03012776|Procedure|Transforaminal Lumbar Interbody Fusion (TLIF)|Fusion with placement of interbody cage and posterolateral instrumentation
75332912|NCT05504928|Other|School nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
75332913|NCT02568384|Device|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
75332914|NCT03821558|Other|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
75789949|NCT05848752|Behavioral|psychophysics|Subjects will be shown a pair of jars each filled with the same absolute number but different ratios of red/blue balls. Three blocks of trials exist, short-term inference (subjects must identify which of the equally likely jars is currently in use), long-term inference (subjects must predict the subsequent jar in use on the next trial, where jar switches are correlated across trials), or multi-timescale inference (subjects must both report the current jar and predict the subsequent jar, combining the short and longterm inferences). Subjects will draw balls as many balls as they wish with replacement (free response) during the short-term and multi-timescale blocks but will know the current jar in use for long-term inference.
75926156|NCT05957926|Procedure|hyaluronic acid added to hydroxyapetite|"The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~The whole pathological tissues will be enucleated and sent for histopathological examination.~The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~hydroxyapetite with hyaluronic acid will be inserted in the bony cavity to initiate healing .~The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
75926157|NCT05957926|Procedure|Hydroxyapatite alone|"The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~The whole pathological tissues will be enucleated and sent for histopathological examination.~The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~hydroxyapetite will be inserted in the bony cavity to initiate healing .~The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
75926158|NCT05955872|Drug|VX-147|Tablets for oral administration.
75926159|NCT05954676|Other|CareOrbit|CareOrbit is a third-party organization that provides a HIPAA-compliant, patient-centered digital engagement platform that helps create, organize, and update content to educate and serve the patient and caregivers through their entire treatment journey.
75332915|NCT05509530|Other|anti-BCMA/GPRC5D CAR-T CELL|anti-BCMA/GPRC5D autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy
75332916|NCT03826472|Other|Almond Butter|Natural almond butter
75926160|NCT05947695|Behavioral|Palliative and Survivorship Care Model|The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
75926161|NCT05946902|Drug|tolterodine|tolterodine 4 mg per day
75926162|NCT05946902|Drug|mirabegron|mirabegron 25 mg per day
75926163|NCT05946902|Drug|tolterodine , mirabegron|tolterodine 4 mg and mirabegron 25 mg per day
76081322|NCT04513925|Drug|Durvalumab|Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight >/= 30 kg) on Day 1 of each 28-day cycle.
76081323|NCT04484142|Drug|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
75641729|NCT02585011|Drug|Saline|
75332917|NCT05499936|Drug|68Ga-FAPI|68Ga-FAPI were injected into the patients before the PET/CT scans
75332918|NCT03826316|Drug|Nalbuphine|Pharmacokinetic study under fasting conditions
75641730|NCT00920413|Dietary Supplement|Vitamin C|vitamin C 500mg orally once a day
75641731|NCT00920413|Dietary Supplement|placebo|
75641732|NCT02583997|Procedure|Suturing of lower alveoli|After extraction of wisdom teeth, the lower alveoli are sutured closed.
75641733|NCT02583997|Procedure|Non suturing of lower alveoli|After extraction of wisdom teeth, no alveoli are sutured closed.
75641734|NCT02584777|Biological|Pacritinib|QD (Once a day)
75641735|NCT02583529|Device|Back Tibial Nerve Electrostimulation|The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
75641736|NCT02583529|Device|Placebo Electrostimulation|The BTNPE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
75641737|NCT00920725|Drug|Insulin (Aspart Insulin [Novolog], Regular Insulin)|"Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous"
75641738|NCT00920491|Biological|biomarker-enhanced disposition decision with proADM|To compare the outcome of standard of care with an approach combining the standardized course and biomarker levels (biomarker-enhanced disposition decision with proADM) for the disposition of patients with non-specific complaints presenting to the emergency department (ED), in order to evaluate safety.
75641739|NCT05449249|Procedure|Long-term fasting|The participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision.
75641740|NCT02583451|Drug|Placebo tablet matching lemborexant|Tablet form taken orally at bedtime.
75641741|NCT02583451|Drug|Placebo tablet matching zopiclone|Tablet form taken orally at bedtime.
75641742|NCT02583451|Drug|Zopiclone 7.5 mg|7.5 mg tablet taken orally at bedtime.
75641743|NCT02583451|Drug|Lemborexant 2.5 mg|2.5 tablet taken orally at bedtime.
75641744|NCT02583451|Drug|Lemborexant 5 mg|5 mg tablet taken orally at bedtime.
75332919|NCT04393610|Drug|Lidocaine|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group).
75332920|NCT04393610|Drug|Magnesium Sulphate|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
76081324|NCT04467567|Other|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after Lutathera® treatment (at 24h, 96h and 168h after the infusion of Lutathera®) on the conventional camera and on the VERITON-CT camera
76081325|NCT04466683|Radiation|Low dose radiation 35 cGy|A dose of 35 cGy of whole thorax irradiation will be delivered at a single timepoint
76081326|NCT04466683|Radiation|High dose radiation 100 cGy|A dose of 100 cGy of whole thorax irradiation will be delivered at a single timepoint
75789950|NCT05848089|Behavioral|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
75789951|NCT05848089|Behavioral|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
76081327|NCT04459806|Procedure|intracranial pressure monitoring|Invasive monitoring of intracranial pressure by using CereLink monitor.
76081328|NCT04451863|Drug|Low THC|Vaporized THC (5 mg)
75332921|NCT04393610|Drug|Fentanyl|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
75789952|NCT05848089|Behavioral|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
76081329|NCT04451863|Drug|High THC|Vaporized THC (15 mg)
76081330|NCT04451863|Drug|Low Myrcene|Vaporized Myrcene (0.5 mg)
76081331|NCT04451863|Drug|High Myrcene|Vaporized Myrcene (12.0 mg)
76081332|NCT04451863|Drug|Low Beta-Caryophyllene|Vaporized Beta-Caryophyllene (0.5 mg)
76081333|NCT04451863|Drug|High Beta-Caryophyllene|Vaporized Beta-Caryophyllene (7.5 mg)
76081334|NCT04451863|Drug|Placebo|Vaporized Placebo
76081335|NCT04398706|Biological|Pneumococcal Conjugate Vaccine formulation 1|Pharmaceutical form:liquid Route of administration: intramuscular
75332922|NCT04502316|Device|Barostim™ System|Implantation of the Barostim™ System
75332923|NCT03826238|Diagnostic Test|Validation Gate task|"The task is to observe several moving unfilled white circles on a dark background. The circles move in straight paths. Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a jump. The subjects' task is to press the space bar every time they detect a displacement (e.g. jump). A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions. During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting. Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls. Task-dependent EEG data will be recorded during the Validation Gate task."
75641745|NCT02583451|Drug|Lemborexant 10 mg|10 mg tablet taken orally at bedtime.
75641746|NCT05435911|Drug|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|Remimazolam Besylate is used as an intervention drug for general anesthesia, followed by flumazenil administration at the end of anesthesia, compared to propofol-based total intravenous anesthesia during breast cancer surgery under general anesthesia
75641747|NCT05435911|Drug|Flumazenil|Flumazenil is used as an additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
75641748|NCT05435911|Drug|Propofol|Propofol is used as an active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during breast cancer surgery under general anesthesia.
75641749|NCT02583607|Device|Brava|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
75789953|NCT05842382|Drug|Active Ingredient|IV Vitamin C (12g/day)
75789954|NCT05842382|Drug|Placebo|IV dextrose 5%
75789955|NCT05837819|Device|Active Lighting Intervention|Lighting intervention using high light levels designed to effect the circadian system
75789956|NCT05837819|Device|Control Lighting Intervention|Lighting intervention using low light levels designed to not effect the circadian system
75789957|NCT05834881|Behavioral|Contingency Management (CM) combined with vocational/educational coaching|Two evidence based practices, CM and vocational/educational coaching, will be combined and delivered by paraprofessional coaches in an intervention named PEERS (Peers Education Empowering Recovery Supports). CM uses positive reinforcement (e.g., chances to win prizes) for clients who abstain from substance use. A standardized and well-validated CM protocol will be used in the proposed study. Vocational/educational coaching assists individuals in completing educational and vocational goals. A workbook developed specifically for vocational/educational coaching in emerging adults will be used in the study.
76081336|NCT04398706|Biological|Pneumococcal Conjugate Vaccine formulation 2|Pharmaceutical form:liquid Route of administration: intramuscular
76081337|NCT04398706|Biological|Pneumococcal Conjugate Vaccine formulation 3|Pharmaceutical form:liquid Route of administration: intramuscular
76081338|NCT04398706|Biological|Varicella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
76081339|NCT04398706|Biological|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
76081340|NCT04398706|Biological|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Pharmaceutical form:liquid Route of administration: intramuscular
76081341|NCT04398706|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)|Pharmaceutical form:liquid Route of administration: intramuscular
76081342|NCT04398706|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:liquid Route of administration: oral
75332924|NCT03820466|Drug|Aspirin|Once daily application of platelet inhibiting medication
75332925|NCT03820466|Drug|Atorvastatin|Once daily application of lipid lowering medication
75641750|NCT04479631|Drug|BRII-196|BRII-196 given intravenously
75332926|NCT03820466|Drug|Placebo Aspirin|Once daily application of placebo
75641751|NCT04479631|Drug|Placebo|Placebo given intravenously
75926164|NCT05929183|Device|Repetitive Transcranial magnetic stimulation|"Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of depressive symptom was dorsolateral prefrontal cortex (DLPFC). In this study, we use high frequency rTMS in the occipital lobe are precisely targeted by navigation, by stimulating the primary visual cortex（V1), can affect the orbitofrontal cortex (OFC), which is functionally connected to V1, and thus affect the entire nerve ring pathway excitability, thereby rapidly, effectively and safely improving mood symptoms in the acute phase of bipolar depressive episode.~After the target was determined by fMRI navigation and positioning, the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000."
76081343|NCT04398706|Biological|Hepatitis B Vaccine* [Recombinant] *as applicable|Pharmaceutical form:liquid Route of administration: intramuscular
76081344|NCT04381260|Other|No intervention|There is no intervention for patients included in this group as this is a retrospective data registry only.
76081345|NCT04381260|Other|Interview|Key Informant Interview
76081346|NCT04381260|Other|Survey|Stakeholder survey
76081347|NCT04353739|Behavioral|Self-Management for HIV-positive Asian Pacific Americans|Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.
76081348|NCT04351906|Device|ECCO2R|ECCO2R integrated into the multiFiltrate device
75332927|NCT03820466|Drug|Placebo Atorvastatin|Once daily application of placebo
75332928|NCT03826004|Drug|Clemastine|Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
75332929|NCT03826004|Drug|Saline Solution|Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
75471428|NCT01952743|Procedure|AF ablation with Renal Denervation|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
75471429|NCT01952743|Procedure|AF ablation alone|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
75471430|NCT01952756|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
75641752|NCT02584699|Radiation|Stereotactic Ablative Radiotherapy (SABR)|Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
75471431|NCT01952756|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
75332930|NCT04127240|Other|DASH diet containing daily intakes of red meat|Each participant was randomized to consume 3 or 6 ounces of red meat as a part of the DASH dietary pattern for 12-weeks.
75471432|NCT01952769|Biological|MDV9300|"The study will be done in the following manner:~Evaluation of MDV9300 and radiation-~Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.~Cohort B -3 patiens: if no toxicity >grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given~Evaluation of MDV9300 and cyclophosphamide~After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:~Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2"
75641753|NCT02584621|Behavioral|Check Yourself App with Feedback|
75641754|NCT04080037|Other|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, with a specific focus on the CDC opioid guidelines.~Cases will cover typical primary care patients presenting with acute and chronic pain, who may or may not be already taking opioid medication."
76081349|NCT04344717|Drug|Apixaban single dose|A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured
76081350|NCT04344717|Drug|Apixaban steady-state|Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
76081351|NCT04334759|Drug|Durvalumab|Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks
76081352|NCT04334759|Drug|Standard Chemotherapy|Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation
76081353|NCT04334759|Drug|Ipilimumab and Nivolumab|Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years
76081354|NCT04324437|Other|eRAPID online symptom monitoring in lung cancer|The eRAPID in lung cancer intervention is an online symptom monitoring system which provides tailored advice depending on the severity of symptoms reported. The system is integrated into the electronic medical record and results can be viewed by the medical team.
75332931|NCT03097094|Diagnostic Test|Male dog|Male dog extract
75332932|NCT03097094|Diagnostic Test|Female dog|Female dog extract
75926165|NCT05929183|Device|Sham Repetitive Transcranial magnetic stimulation|The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters were the same as the Active Comparator arm.
75332933|NCT02338076|Drug|Petrolatum application under occlusion|"Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)~1 well will be empty and the other well will contain petrolatum~Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch~1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)"
75926166|NCT05919277|Diagnostic Test|Dengue Immunoglobulin G antibodies performed with ELISA|All participants who agree to participate by signing an informed consent form will undergo a finger prick for the determination of Immunoglobulin G antibodies measured by ELISA. In a subgroup of persons who test positive, they will be invited to have blood drawn for neutralization determination in order to study serotypes and the presence of other flaviviruses.
75926167|NCT05907369|Other|Active EC training|The active EC includes pairing contamination-related pictures (CSs) with pleasant pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels.
76081355|NCT04317586|Device|Trident II Tritanium Acetabular Shell for Revision|A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
75332934|NCT03829670|Diagnostic Test|Cytochrome P450 test|Blood samples will be drawn for cytochrome P450 testing.
75641755|NCT02583685|Drug|PR4 + LDV/SOF + ASV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
75332935|NCT03829826|Biological|HyQvia|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
75332936|NCT04126694|Behavioral|CBT with smartphone application SenseSupport|SenseSupport intervention system used as an augment to a 12 week in-person CBT treatment for transdiagnostic binge eating pathology
75471433|NCT05876793|Drug|Remimazolam tosilate|The fixed dose of propofol in this study was 0.5mg/kg, with an injection time of 30 seconds. Subsequently, remimazolam was administered at an initial dose of 0.1mg/kg. After 1 minute of administration, sedation was evaluated using MOAA/S. When the MOAA/S score was ≤ 1, endoscopic examination could begin. If the patient did not show physical activity or coughing, sedation was considered successful, and the next patient's medication dose was reduced by 0.02mg/kg; On the contrary, if sedation fails, the next patient will receive an additional 0.02mg/kg of medication.Successful sedation results in a positive reaction, while failure results in a negative reaction. This study ends when 7 positive and negative reactions intersect
75641756|NCT02583685|Drug|PR4 + LDV/SOF + SMV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
75789958|NCT05832359|Radiation|Panoramic rad.|In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.
75789959|NCT05829733|Device|SYNOLIS VA 80/160|SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
75789960|NCT05822362|Drug|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.
75789961|NCT05822362|Other|Placebo|Placebo arm.
75789962|NCT05820906|Drug|Cadonilimab+Regorafenib+GC|Cadonilimab:10mg/kg, iv,q3w,D1 Regorafenib: 80mg, po, orally once daily Gemcitabine:1000 mg/m2, iv, Q3W，D1,D8 Cisplatin:25 mg/m2, iv, Q3W, D1,D8
75926168|NCT05907369|Other|Sham EC training|The active EC includes pairing contamination-related pictures (CSs) with neutral pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels, the same as active EC training.
75926169|NCT05907369|Other|Active tDCS|For the active tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum. The brain stimulation is delivered with a 2mA current intensity for 20 minutes in 10 sessions (5 days a week).
76081356|NCT04270123|Other|EORTC QLQ-BR45 questionnaire|The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
76081357|NCT04267874|Procedure|Biospecimen Collection|Undergo collection of nasal swabs, blood, urine, and stool
75332937|NCT02978534|Drug|Quetiapine|Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
75789963|NCT05819476|Procedure|OLP-injection|Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.
75789964|NCT05819476|Other|Scripted Evidence-based treatment rationale|As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
75789965|NCT05819476|Other|Experimental model of acute pain|Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).
75789966|NCT05816265|Drug|IV Iron Infusion Group|Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
75641757|NCT02583685|Drug|PR4 + LDV/SOF + ASV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
75641758|NCT02583685|Drug|PR4 + LDV/SOF + SMV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
75789967|NCT05812118|Behavioral|Physical active learning|The intervention will last for 8-10 weeks. The ALPHYL intervention will be conducted in physical education (PE) and non-PE lessons by teachers. In addition to the PE lessons, at least three physically active activities in subjects other than PE will be conducted every day (5 days per week), with a total duration of approximately 30 minutes of light and moderate-to-vigorous physical activity per day. The weekly dose of physically active learning will thus be 100-150 minutes, so that a volume of 800-1200 minutes is foreseen during the 8-10 weeks. The PE classes will also be conducted in a mix of cooperative learning, non-linear pedagogy and health-based PE.
75641759|NCT02583685|Drug|PR4 + LDV/SOF + ASV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
75789968|NCT05799638|Other|Guideline-Directed Medication Treatment (GDMT)|GDMT contains ACEIs/ARBs/ARNI, β blockers, SGLT2is, MRAs. ACEI/ARB/ARNI and β blocker will gradually be titrated up to the maximum tolerable dose
75789969|NCT05798390|Drug|Bempedoic acid and/or its fixed dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided as part of this protocol to the patients. Medications will be as prescribed by the treating physician in line with clinical practice.
75789970|NCT05796388|Device|Virtual Reality|Both groups will receive standard of care linaclotide 290 mcg.
75789971|NCT05786404|Drug|PRIM-DJ2727 - FROZEN|Patients with active UC will receive induction dose of 100 grams of stool via frozen retention enema, Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-FROZEN administered in clinic. This consists of microbiota suspension from well-screened donors. Twice filtered fecal microbiota product diluted in saline to 500 mL containing 100g of study drug will be administered as frozen enema induction dose
75789972|NCT05786404|Drug|PRIM-DJ2727 - CAPSULES|Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
75789973|NCT05776836|Device|Dermal filler|Subjects will be consecutively included to receive FASY F in nasolabial folds and cheeks and FASY P in periorbital areas.
75789974|NCT05760300|Drug|Bulevirtide (BLV)|Administered via subcutaneous (SC) injections
75789975|NCT05755997|Drug|Cerebrolysin|40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year
75789976|NCT05755997|Drug|0.9 % NaCl|100 ml 0.9% NaCl per day for 4 days every month for 1 year
75926170|NCT05907369|Other|Sham tDCS|For the sham tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum, the same as active tDCS. The device is on for 20 minutes, but the current intensity is under the threshold of affecting cortical activity modulation. The participants receive the sham tDCS in 10 sessions (5 days a week).
76081358|NCT04267874|Dietary Supplement|Nutritional Supplementation|Given black raspberry nectar PO
75789977|NCT05755074|Procedure|Ablation through left arm|Ablation through left arm
76081359|NCT04267874|Drug|Placebo Administration|Given PO
75332938|NCT03829982|Behavioral|Exposure to bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
75332939|NCT03829982|Behavioral|Exposure to dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
75789978|NCT05755074|Procedure|Ablation through femoral vein|Ablation through femoral vein
75789979|NCT05754593|Biological|Anti-Mullerian hormone (AMH) level|Measure of Anti-Mullerian hormone (AMH) level by blood sample
75789980|NCT05754593|Other|Antral follicle count (AFC)|Measure of Antral follicle count (AFC) by ultrasound imaging
75332940|NCT02983760|Device|Planar V/Q-based strategy|Strategy based on planar pulmonary scintigraphy
75789981|NCT05754593|Other|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
76081360|NCT04267874|Other|Questionnaire Administration|Ancillary studies
75332941|NCT02983760|Device|CTPA-based strategy|Strategy based on pulmonary angiography
75332942|NCT02983760|Device|V/Q SPECT-based strategy|Strategy based on pulmonary tomoscintigraphy
75332943|NCT01222117|Biological|Plasmin|Plasmin prepared in 0.9% saline for injection
75332944|NCT01222117|Biological|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
75332945|NCT01222117|Other|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
75789982|NCT05752305|Drug|Dexamethasone 4 Mg/mL Injectable Solution|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
75789983|NCT05752305|Drug|MethylPREDNISolone 40 Mg/mL Injectable Suspension|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
76081361|NCT04219020|Other|Co-created intervention|
76081362|NCT04214184|Behavioral|Increased sleep duration|Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
76081363|NCT04210713|Drug|Minocycline|200 mg/day
76081364|NCT04210713|Drug|Sugar pill|Matched placebo
75926171|NCT05906979|Other|PAHOLA (digital health assistant)|Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.
76081365|NCT04198779|Device|APPLI|The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
75332946|NCT04392830|Drug|ALZ002 DS|Administered orally
75641760|NCT02583685|Drug|PR4 + LDV/SOF + SMV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
75641761|NCT02583685|Drug|PR4 + LDV/SOF + ASV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
75641762|NCT02583685|Drug|PR4 + LDV/SOF + SMV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
75641763|NCT04506151|Behavioral|Sleep-Opt|12-week behavioral intervention
75641764|NCT04506151|Behavioral|Healthy Living|Healthy Living
76081366|NCT04192071|Other|virtual technology - high interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer and dietary intake. Interactive nutrition risk feedback will be customized based on user input.
75332947|NCT04392830|Drug|Placebo|Administered orally
75332948|NCT02976428|Procedure|Sensor Guided Soft Tissue Balancing|Primary TKR with soft tissue balancing with a sensor guided device.
75332949|NCT02976428|Procedure|Standard Soft Tissue Balancing|Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
75332950|NCT01222195|Drug|Lenalidomide|10 mg/day by mouth on days 1-21 of every 28 day cycle.
75332951|NCT01222195|Drug|Darbepoetin alfa|200 mcg subcutaneously every 2 weeks of a 28 cycle.
75332952|NCT04126616|Diagnostic Test|chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent|chest MRI will be performed at rest and after moderate exercise
75641765|NCT04079959|Procedure|endometrial biopsy|. Endometrial samples are obtained using a biopsy catheter as follows: the Pipette is inserted through the cervical os and advanced gently until resistance is felt. The inner piton of the device is then withdrawn to create suction, and the endometrial sample is obtained by moving the pipette up and down approximately 2-3 cm within the uterine cavity. The device is rotated 360° to ensure adequate coverage of the area.
75641766|NCT04079101|Drug|BIIB104|Administered as specified in the treatment arm.
75641767|NCT04079101|Drug|Placebo|Administered as specified in the treatment arm.
75641768|NCT04606771|Drug|Osimertinib + Savolitinib|"Osimertinib 80 mg oral QD~Savolitinib 300mg oral QD"
75789984|NCT05752110|Drug|Ketamine|0,5mg/kg single dose Ketamine (0.05ml/kg) intravenously administered
75789985|NCT05752110|Other|Saline|0.09% Saline (0.05ml/kg) intravenously administered
75789986|NCT05746455|Behavioral|Motivation Skills Training (MST)|MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation, so that one can better initiate and sustain goal-directed behavior.
76081367|NCT04192071|Other|virtual technology - low interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer. Minimally interactive risk feedback will be delivered.
75332953|NCT01222273|Dietary Supplement|cholecalciferol (Vitamin D3)|4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
75332954|NCT04126460|Drug|Toripalimab|Toripalimab is a type of PD-1 antibody
75332955|NCT03161912|Drug|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion.
75641769|NCT04606771|Drug|Savolitinib + Placebo|"Savolitinib 300mg Oral QD~Placebo to Osimertinib 80mg oral QD"
75641770|NCT04079023|Procedure|Sleeve Gastrectomy|Subtotal vertical gastrectomy
75641771|NCT04504123|Drug|Doxycycline Hyclate|Doxycycline Hyclate capsules, USP 50 mg
75641772|NCT04504123|Drug|Placebo|Placebo
75641773|NCT04078633|Behavioral|Hand hygiene interventions|Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.
75641774|NCT04465669|Device|Orsiro stents|"Percutaneous coronary intervention with implantation of either:~a Orsiro® biolimus a9 eluting coronary stent"
75789987|NCT05741892|Device|Fracture reposition with 3D printed patient specific repositions guides|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
75926172|NCT05906979|Other|Standard information on alcohol use and health|A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.
75926173|NCT05905081|Other|aerobic exercise|30-minutes aerobic exercise intervention on the bicycle ergometer. The exercise protocol includes 5 minutes of warm-up, 20 minutes of loading and 5 minutes of cool-down. The intensity of the exercise will be adjusted to be between 46% and 63% of the VO2max calculated according to the exercise programming guide published by the American College of Sports Medicine (ACSM), and the perceived effort level on the Borg scale will be 12-13. Warm-up and cool-down periods will be set to 46% of VO2max and Borg perceived exertion level below 9.
75789988|NCT05727644|Drug|NNC0194-0499|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
75926174|NCT05901987|Genetic|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
75926175|NCT05901259|Device|Exopulse Mollii Suit|The registry is designed to demonstrate the impact of Exopulse Mollii Suit on improvement of muscle relaxation, muscle activation, local blood circulation and/or chronic pain relief. The subjects included use the suit for 60 minutes every other day, unless other is specified by the Investigator, in their home environment for up to a maximum of 12 consecutive weeks. Qualitative and quantitative measures will be collected at baseline (T0), after 60 minutes stimulation (T1), after 4 weeks (T4) and at the end of the 12-week intervention period (T12).
75641775|NCT04465669|Device|Resolute Integrity® stents|"Percutaneous coronary intervention with implantation of either:~a Resolute Integrity® zotarolimus eluting coronary stent"
75641776|NCT02584543|Biological|HEV vaccine|
75926176|NCT05898763|Drug|TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)|Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in an alternating limb. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).These patients will receive three rounds of combination treatment with TEIPP24 vaccination and pembrolizumab every three weeks. Pembrolizumab will be administered as per standard of care.
75641777|NCT02584543|Biological|HBV vaccine|
75789989|NCT05709678|Other|Standard Education|Sport nutrition education
75789990|NCT05709678|Other|Enhanced Education|Sport nutrition education with peer testimonials on negative effects of REDs
75789991|NCT05709639|Other|Individualized counselling in nutrition|Individualized counselling in nutrition - collaborate on a nutrition plan
75789992|NCT05703607|Biological|Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
75789993|NCT05703607|Biological|Candidate 1: PF-07915234: VZV modRNA Suspension for Injection|Intramuscular injection
75789994|NCT05703607|Biological|Candidate 2: PF-07921188: VZV modRNA Suspension for Injection|Intramuscular injection
75789995|NCT05703607|Biological|Candidate 3: PF-07921186: VZV modRNA Suspension for Injection|Intramuscular injection
75789996|NCT05703607|Biological|Shingrix|Intramuscular injection
75789997|NCT05703607|Biological|Selected Vaccine Candidate group (Dose level, Schedule)|Intramuscular injection
75641778|NCT04078165|Device|Zero-Gravity|Free-floating, suspended personal radiation protection
75641779|NCT04078165|Device|Conventional radiation protection|Standard lead shields and aprons
75641780|NCT02583763|Other|Echocardiography|During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
75789998|NCT05703607|Biological|Shingrix - SSB|Intramuscular injection
75789999|NCT05702879|Drug|Ozanimod|Start of standard therapy
75790000|NCT05702879|Drug|TNF Inhibitor|Start of standard therapy
75926177|NCT05898737|Device|NOL-Index|NOL Index monitoring with the PMD100™ (Medasense Biometrics Ltd.)
75790001|NCT05702879|Drug|Steroids|Start of standard therapy
75790002|NCT05702879|Drug|Vedolizumab|Start of standard therapy
75790003|NCT05702879|Drug|Ustekinumab|Start of standard therapy
75790004|NCT05699551|Behavioral|Exercise regimen|Exercise will take place Monday, Wednesday, and Friday from 12:00-1:00 pm for 6 weeks. Aerobic exercise will consist of walking, beginning with a 10-minute duration, with gradual progression to 20 minutes. Muscle strength, endurance and range-of-motion exercise will then be performed. Muscle strength and endurance training will begin using no weight and performing one set of 6 repetitions. Progression using added resistance in the form of dumbbell weights (1-6 lbs.) and increased sets and repetitions will be applied as Subjects become increasingly fit. For static range of motion exercise, positions will be held for 10-15 seconds in the beginning and increased over time. Exercise will be kept at a moderate level of intensity. Each session will then end with relaxation training.
75790005|NCT05699239|Drug|TS-172 10mg bid|oral administration of TS-172 10 mg bid
75790006|NCT05699239|Drug|TS-172 30mg bid|oral administration of TS-172 30 mg bid
75790007|NCT05699239|Drug|TS-172 60mg bid|oral administration of TS-172 60 mg bid
75790008|NCT05699239|Drug|TS-172 20mg tid|oral administration of TS-172 20 mg tid
75790009|NCT05699239|Drug|Placebo|oral administration of placebo
75790010|NCT05696418|Procedure|Total knee arthroplasty with a Mobile Bearing system.|The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Mobile Bearing system without resurfacing the patella.
75790011|NCT05696418|Procedure|Total knee arthroplasty with a Fixed Bearing system.|The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Fixed Bearing system without resurfacing the patella.
75641781|NCT02583763|Procedure|Blood sample|The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age.
75641782|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Higher Dairy|12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
75641783|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Lower Dairy|12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
75790012|NCT05695911|Behavioral|Limb Load Biofeedback Training Intervention|Loadsol data will be used to inform the EXP telehealth sessions, as the interventionist guides the participant to self-monitor their movement, problem solve movement patterns that promote asymmetrical limb loading, and create weekly action plans for improving limb load symmetry. Weekly goals will be made in the context of functional task progression over the 40-week intervention.
75641784|NCT02583841|Procedure|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
75641785|NCT04077853|Drug|17 Hydroxyprogesterone Capronate|Intramuscular injection 250 mg
75641786|NCT00583219|Drug|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
75641787|NCT00583219|Drug|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
75790013|NCT05695911|Other|Attention Control|The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group. The CTL group sessions will include a review of the standard of care home-exercises, a summary of healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use, home safety).
75790014|NCT05691504|Procedure|Biopsy|Undergo biopsy
76081368|NCT04192071|Other|non-colorectal cancer related module|Participants engage with web-based content not related to colorectal cancer or nutrition.
76081369|NCT04185415|Drug|bepranemab|"bepranemab will be administered in a predefined dosage.~Pharmaceutical Form: Solution for infusion~Route of Administration: Intravenous"
76081370|NCT04185415|Drug|Placebo|"Pharmaceutical Form: Solution for infusion~Concentration: 0.9% w/v sodium chloride aqueous solution~Route of Administration: Intravenous"
75926178|NCT05891509|Procedure|Minimally Invasive Hematoma Evacuation|Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
75926179|NCT05891509|Other|Best Medical Therapy|Best medical therapy
75926180|NCT05886023|Dietary Supplement|High nitrate vegetables|Vegetable burger containing high nitrate vegetables
75926181|NCT05886023|Dietary Supplement|Low nitrate vegetables|Vegetable burger containing to low nitrate vegetables
75926182|NCT05884242|Drug|Adalimumab|Adalimumab will be administered subcutaneously.
75926183|NCT05884242|Drug|Lipopolysaccharide (LPS)|LPS will be administered intravenously.
76081371|NCT04180488|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
76081372|NCT04180488|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
75332956|NCT01222585|Drug|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with >=14 postnatal days and every 24 hours for infants <14 postnatal days.
75641788|NCT04490785|Procedure|MRI|1 MRI 5 days after surgery (-1; +4 days), with intravenous administration of gadolinium
75641789|NCT04490785|Biological|Postoperative dosage of released troponin|Dosage of troponin I Hs H4, H8, H12, H24, H48, and H72 after the aortic cross-unclamping.
76081373|NCT04180488|Drug|non sedating H1-antihistamine|Pharmaceutical form:Tablet Route of administration: oral administration
76081374|NCT04151264|Device|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
75641790|NCT05674669|Drug|Lysergic Acid Diethylamide (LSD) 50µg|
76081375|NCT04149314|Other|HPI based hemodynamic optimization algorithm|Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
76081376|NCT04141839|Behavioral|Safer Bars|Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
75641791|NCT05674669|Drug|Lysergic Acid Diethylamide (LSD) 75µg|
75641792|NCT05674669|Drug|Lysergic Acid Diethylamide (LSD) 100µg|
75790015|NCT05691504|Procedure|Biospecimen Collection|Undergo collection of blood
75790016|NCT05691504|Drug|Cobimetinib|Given PO
75790017|NCT05691504|Procedure|Computed Tomography|Undergo CT
75790018|NCT05691504|Procedure|Echocardiography|Undergo ECHO
75790019|NCT05691504|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790020|NCT05691504|Procedure|Multigated Acquisition Scan|Undergo MUGA
75332957|NCT04126382|Procedure|Intubate-Surfactant-Extubate(INSURE)|Infants are given an endotracheal intubation, with manual lung inflation in order to keep the oxygen supply，and the surfactant(kelisu,China Resources Shuanghe Pharmaceutical) was slowly instilled into the airway through the tracheal tube, and the tracheal tube was removed for non-invasive NCPAP(nasal continuous positive airway pressure)-assisted breathing.
75641793|NCT05674669|Drug|Placebo/Lysergic Acid Diethylamide (LSD) 75µg|
75641794|NCT05674669|Drug|Lysergic Acid Diethylamide (LSD) 50µg/75µg|
75641795|NCT02583373|Drug|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
75641796|NCT02583373|Drug|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
75641797|NCT02583373|Drug|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
75790021|NCT05691504|Drug|Pelcitoclax|Given IV
75790022|NCT05691491|Procedure|Biopsy|Undergo biopsy
75926184|NCT05868837|Drug|Rituximab|Rituximab 1000 mg IV on RCP days 1 and 15
75926185|NCT05868837|Other|Placebo|Placebo 1000 mg IV on RCP days 1 and 15
75926186|NCT05866627|Drug|Famotidine|Specified dose on specified days
75926187|NCT05866627|Drug|Afimetoran|Specified dose on specified days
75926188|NCT05864703|Procedure|Adjustment|Instrument-assisted, high velocity, low amplitude adjustment
75926189|NCT05864703|Procedure|Sham|Instrument-assisted light touch to neck
75926190|NCT05860049|Device|istrument assisted soft tissue mobilization|"Each subject in group (A) will receive 12 sessions of physical therapy 3 sessions per week for 4 weeks).~Each subject in group (B) will receive 8 sessions of physical therapy(two sessions per week for four weeks)."
76081377|NCT04133376|Other|Electronic hookah vaping with nicotine|Participants will be invited to vape a 30-minute session of e-hookah containing nicotine
76081378|NCT04133376|Other|Electronic hookah vaping without nicotine|Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine
76081379|NCT04127214|Other|ITA Integrated Treatment|The ITA Model combines outpatient intervention (mainly psychotherapy), day hospital care and hospitalization as a function of patients' characteristics. Case conceptualization of the psychological processes of patients is formulated and revised within a team including psychologists, psychotherapists, psychiatrists, nutritionists, physicians, nurses, and social workers. The major emphasis of the ITA model is on psychological interventions which include individual psychotherapy, family therapy and/or guidance, and group therapy of various formats and contents (e.g., drug abuse, mindfulness, emotion work) tailored to the needs of each patient. However, when required, drugs are prescribed adjusting type of medication and dosage to the need of the patient.
75926191|NCT05858580|Behavioral|Bennett Kids PowerUP Project|Information targeting dietary and activity behaviors while also identifying and addressing barriers to permanent lifestyle change. The foundation of the curriculum is the Diabetes Prevention Program Lifestyle Balance and its subsequent adaptations for non-Native adult, Native adult, and Native child populations.
75926192|NCT05850078|Other|FB101|Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo
75926193|NCT05847504|Behavioral|mSTARS|mSTARS combines inpatient cognitive-behavioral skills training and outpatient use of a mobile app encouraging application of acquired skills to real life situations.
75926194|NCT05841667|Drug|Remimazolam besylate|"This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam."
75926195|NCT05835453|Other|Whitening|Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each tray, completing a total of 4 weeks of whitening procedure.
76081380|NCT04121221|Drug|GA Depot|Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
76081381|NCT04121221|Other|Placebo|IM injection once every 4 weeks
75641798|NCT04122313|Other|Evaluation of Dupuytren's Disease Treatment|There are no study interventions. The study interaction will be asking the patients to complete an additional outcome questionnaire and allow a medical record review.
75641799|NCT02583295|Behavioral|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
75790023|NCT05691491|Procedure|Biospecimen Collection|Undergo collection of blood samples
75790024|NCT05691491|Procedure|Computed Tomography|Undergo CT scan
75790025|NCT05691491|Procedure|Magnetic Resonance Imaging|Undergo MRI
75332958|NCT04126382|Procedure|less invasive surfactant administration(LISA)|Infants are spontaneously breathing with nasal CPAP(continuous positive airway pressure) support without manual lung inflation and surfactant(kelisu,China Resources Shuanghe Pharmaceutical) is administered through vocal cords via a smaller catheter.
75790026|NCT05691491|Drug|Temozolomide|Given orally (PO)
75641800|NCT02583295|Behavioral|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
75790027|NCT05691491|Drug|Tuvusertib|Given PO
75790028|NCT05687136|Procedure|Biopsy|Undergo tissue biopsy
75790029|NCT05687136|Procedure|Biospecimen Collection|Undergo blood sample collection
76081382|NCT04117334|Other|Bracing|
76081383|NCT04116658|Biological|Multiple dose of EO2401|Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase
76081384|NCT04102098|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
76081385|NCT04102098|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
76081386|NCT04092257|Procedure|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
76081387|NCT04083170|Drug|Fludarabine|Given IV
75332959|NCT03829592|Drug|misoprostol in a neutral media|giving misoprostol in a neutral media
75332960|NCT03829592|Drug|misoprostol in an acidic media|giving misoprostol in an acidic media
75332961|NCT03829592|Drug|misoprostol in an alkaline media|giving misoprostol in an alkaline media
75332962|NCT01142323|Drug|fenofibrate|160 mg po daily
75332963|NCT04126226|Other|Speech-language guidance|Speech-language guidance for speech enhancement and on food management in terms of consistency, volumes, utensils and temperature, beyond the care for safe and efficient swallowing.
75641801|NCT04307407|Behavioral|Aerobic Exercise|Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm
75641802|NCT04449211|Device|Implantation|Reconstructing the long bone defect with 3D-printed customised Titanium alloy implant
75790030|NCT05687136|Procedure|Computed Tomography|Undergo CT
75790031|NCT05687136|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790032|NCT05687136|Drug|Peposertib|Given PO
75790033|NCT05687136|Procedure|Positron Emission Tomography|Undergo PET
75790034|NCT05687136|Drug|Tuvusertib|Given PO
75790035|NCT05686447|Other|Observational studies, no intervention|Observational studies, no intervention
75790036|NCT05683756|Behavioral|Brief Parent Behavioral Intervention|PBI administered in pediatric primary care by an embedded therapist.
75790037|NCT05683756|Behavioral|Sleep-Focused Parent Behavioral Intervention|SF-PBI administered in pediatric primary care by an embedded therapist.
76081388|NCT04083170|Drug|Cyclophosphamide|Given IV
76081389|NCT04083170|Drug|Thiotepa|Given IV
76081390|NCT04083170|Radiation|Total-Body Irradiation|Undergo TBI
76081391|NCT04083170|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
76081392|NCT04083170|Biological|Dilanubicel|Given IV
76081393|NCT04056910|Drug|ivosidenib and nivolumab|"Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events.~Nivolumab will be administered at 480 mg IV every 28 days."
76081394|NCT04054557|Other|Telemedicine|Participate in virtual visits with oncologist
76081395|NCT04054557|Other|Best Practice|Receive 4 in-office visits with oncologist
76081396|NCT04054557|Other|Questionnaire Administration|Ancillary studies
75332964|NCT04126226|Other|Speech therapy exercises for swallowing|Use of lip exercises and facial muscles, laryngeal elevation maneuver and airway protection technique, 5 repetitions 3 times a day for a month.
75641803|NCT04296877|Device|Daily Disposable Contact Lens|Soft, daily disposable spherical contact lens used to correct distance vision.
75641804|NCT02581501|Drug|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
76081397|NCT04054557|Other|Quality-of-Life Assessment|Ancillary studies
75641805|NCT05292079|Device|CAPTURER|Patients in whom treatment with (CAPTURER) has been attempted
75641806|NCT01072175|Drug|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
75790038|NCT05682365|Behavioral|prevANS intervention|prevANS intervention will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP). The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants will be classified as moderate-high or low risk of anxiety. Both groups of risk will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically; also, they will work towards manage stressors and enhance protective factors. However, participants with moderate-high risk of anxiety will also receive a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills).
75790039|NCT05680012|Dietary Supplement|Gluten containing snack bar|Ingest snack bars containing 3 grams of gluten every day for 7 weeks.
75790040|NCT05677763|Drug|OM-85|Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)
75790041|NCT05677763|Drug|Placebo|Subjects will be administered Placebo once daily. (10 days per month)
75641807|NCT01072175|Drug|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
75790042|NCT05662384|Other|No intervention is planned|Observational study, no intervention
75926196|NCT05835284|Device|Investigational Edge-on Silicon Photon Counting CT device|Administration of IV contrast material, if applicable, shall be done according to the hospital's SOC. Administration of oral contrast material, if applicable, shall also be done according to the hospital's SOC. Images will then be compared with the previously acquired CT conducted as standard of care. The investigational scan will take approximately 60-120 minutes.
75926197|NCT05833711|Drug|Froniglutide|SC Weekly Injection
75926198|NCT05833711|Drug|Placebo|SC Weekly Injection
76081398|NCT04054557|Other|Survey Administration|Complete electronic survey
75332965|NCT04126226|Other|Speech therapy exercises for speech|Use of over-articulation technique and glottal firmness exercise, 5 repetitions 3 times a day for a month.
75332966|NCT01142947|Drug|beclomethasone dipropionate|160 mcg twice a day (320 mcg per day total)
75332967|NCT02972294|Drug|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
75332968|NCT02972294|Drug|Tranexamic Acid|Tranexamic acid will be use.
75332969|NCT02972294|Drug|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
75641808|NCT04078711|Drug|Losartan 100Mg Tab|100Mg Tab, qd, po, 6 months
75641809|NCT04078711|Drug|Qianyangyuyin 20g Granule|20g, Granule, bid, po, 6 months
75641810|NCT04078711|Drug|placebo|Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
75790043|NCT05657548|Radiation|spine and pelvis radiography|X-ray of the spine and pelvis from the front and the side will be performed under the standardized conditions that we put in place: in a sitting position on a specific modular chair.
75790044|NCT05648097|Device|Baldachin|"Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing room ventilation and hospital policy infection prevention and control measures."
76081399|NCT04054557|Behavioral|Behavioral Intervention|Use smart pill bottle
76081400|NCT04054557|Other|Educational Intervention|Receives time-specific reminders and messages
76081401|NCT04048278|Drug|Lidocaine Hydrochloride|IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
76081402|NCT04048278|Drug|Saline Solution for Injection|IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
76081403|NCT04047368|Procedure|Rotablation|Percutaneous Coronary Intervention using Rotablation
76081404|NCT04047368|Procedure|Coronary Lithoplasty|Percutaneous Coronary Intervention using Lithoplasty
76081405|NCT04045717|Radiation|Hypo-FLAME 2.0 study|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
76081406|NCT04024020|Other|lumbar puncture|Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
76081407|NCT04008121|Combination Product|Fluorescein sodium and Zeiss FF450 fundus camera|Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
75641811|NCT04078009|Diagnostic Test|Aquagen|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
75790045|NCT05631236|Device|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a more intense therapeutic blue light.
75790046|NCT05631236|Device|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a non-therapeutic blue light.
75926199|NCT05828953|Drug|Anlotinib|"Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up."
75641812|NCT04078009|Diagnostic Test|Grazax|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
75790047|NCT05625204|Behavioral|Center based attention control|Center based attention control
75790048|NCT05625204|Behavioral|Center based HIIT|Center based HIIT
75790049|NCT05625204|Behavioral|Home based HIIT|Home based HIIT
75926200|NCT05828953|Drug|Placebo|Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
75926201|NCT05825534|Other|EIT monitoring|EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
75926202|NCT05824975|Drug|GI-102|"Dose escalation phase:~GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles)."
75926203|NCT05824975|Drug|GI-102|"Dose expansion phase:~GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles)."
75926204|NCT05809713|Other|Technology-enabled Team Care|Patients randomized to the TTC arm will receive telehealth-enabled team-based care. The team will include a physician and/or advanced practice provider, a pharmacist with Certified Pharmacist Practitioner (CPP) status or similar skills in NC, and will incorporate brief nutritionist-directed lifestyle behaviors counseling (DASH diet; exercise) initially delivered every other week by phone for two months, followed by monthly calls (once SBP values achieve individualized goal and remain stable for 14 days) over 12 months supported by cellular enabled home BP monitoring.
76081408|NCT04008121|Combination Product|MB-102 and Zeiss FF450 fundus camera|MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
76081409|NCT04008121|Combination Product|Fluorescein sodium and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
76081410|NCT04008121|Combination Product|MB-102 and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
75641813|NCT04283851|Diagnostic Test|testing functional haemodynamic parameters for preload assessment|dynamic testing of preload responsivity plus echocardiography
75790050|NCT05618431|Other|NIPT|This research aims to develop and validate a new method for non-invasive prenatal testing
76081411|NCT04004065|Drug|Vesleteplirsen|Vesleteplirsen injection, for IV use
75641814|NCT04304573|Diagnostic Test|Total serum calcium blood test|Total serum calcium measurements will be done on the first postoperative day. Also ionized calcium, corrected total serum calcium for serum albumin with Payne's formula and PTH will be monitored.
75641815|NCT02581735|Other|Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
75790051|NCT05602883|Behavioral|music therapy|Music is played for 30 minutes to the pregnant woman who is hospitalized due to the threat of premature birth.
75790052|NCT05602779|Device|tVns Program|Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.
75790053|NCT05602779|Other|Phone App Program|Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.
75790054|NCT05602779|Combination Product|tVNS and Phone App Program|Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.
75790055|NCT05602779|Other|Enhanced Treatment as Usual|Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.
75790056|NCT05600452|Other|Heat acclimation|Repeated heat exposures with light exercise sufficient to elevate deep body temperature to ~ 38.5C
75790057|NCT05577702|Drug|Tislelizumab|Administered as an intravenous infusion
75790058|NCT05577702|Drug|Ociperlimab|Administered as an intravenous infusion
75790059|NCT05577702|Drug|LBL-007|Administered as an intravenous infusion
75926205|NCT05809713|Other|Enhanced Usual Care|Patients randomized to the enhanced usual care (EUC) arm will receive telehealth enabled home BP monitoring equipment including set-up and instruction and basic hypertension-specific lifestyle (diet, exercise) instruction and materials at baseline, but will not receive telehealth-enabled team-based care, active home BP monitoring by a pharmacist, or detailed DASH intensive lifestyle counseling.
75926206|NCT05792917|Drug|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
75926207|NCT05792917|Drug|tafolecimab (a original manufacturing process)|450mg，SC，single dose
75926208|NCT05786066|Drug|Perampanel 6 MG|Perampanel will be administered 2.5 hours before Ketamine infusion
76081412|NCT04003506|Drug|Liposomal bupivacaine|LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine
76081413|NCT04003506|Drug|Bupivacaine Injection|LIA with ACB will be given using 20ml 0.5% standard bupivacaine
75332970|NCT02972294|Drug|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
75332971|NCT02983214|Drug|Clopidogrel|
75641816|NCT04426669|Drug|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
75641817|NCT04426669|Drug|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
75641818|NCT04426669|Biological|Tumor-Infiltrating Lymphocytes (TIL)|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
75641819|NCT04426669|Drug|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
75790060|NCT05577702|Drug|Cisplatin|Administered as an intravenous infusion
75790061|NCT05577702|Drug|Carboplatin|Administered as an intravenous infusion
75790062|NCT05577702|Drug|Pemetrexed|Administered as an intravenous infusion
75790063|NCT05577702|Drug|Paclitaxel|Administered as an intravenous infusion
75641820|NCT00627107|Device|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device.
75790064|NCT05576194|Device|TauroPace|All the hardware (leads, suture sleeves, pulse generator) is washed and the device pocket irrigated with an adjunct antimicrobial solution containing Taurolidine (TauroPace™, Tauropharm, Bavaria, Germany), during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system since January 2019
75790065|NCT05576194|Device|Hydrogen Peroxide|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing 3% hydrogen peroxide (H2O2) during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2020
75790066|NCT05576194|Drug|Taurolidine|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing taurolidine in a galenic formulation during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2019
75790067|NCT05574413|Other|Moderate intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 70% of the power output at lactate threshold until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
75641821|NCT02874989|Drug|Dasatinib + Quercetin|
75790068|NCT05574413|Other|High intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
75790069|NCT05574413|Other|High intensity interval exercise|Participants will perform an acute bout of interval cycling at at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
75790070|NCT05574413|Other|Resting (no exercise) control|Participants will remain in a rested state (i.e., no exercise) for the entire session. Blood samples will be obtained at the same time-points as the exercise sessions.
75790071|NCT05568914|Device|Indirect Calorimetry|Indirect Calorimetry (Q-NRG Metabolic Monitor, COSMED) is performed to determine the Resting Energy Expenditure before hemodialysis.
75926209|NCT05786066|Drug|Ketamine|Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.
75926210|NCT05786066|Drug|Placebo|Placebo will be administered 2.5 hours before Ketamine infusion
76081414|NCT03998501|Behavioral|Cognitive Behavioral Therapy with Mindfulness Class|The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
76081415|NCT03980457|Device|Indego Exoskeleton|Powered generated orthosis
76081416|NCT03980457|Other|Standard Rehabilitation|Standard Rehabilitation
75332972|NCT02983214|Drug|Cilostazol|
75332973|NCT03825068|Procedure|ESP Block|20 ml of lacal anaesthetics will be placed below the erector spinae muscle under ultrasound guide
75332974|NCT03825068|Drug|general anesthetic|patient receive general anaesthetic only
75641822|NCT02874989|Drug|Placebo|
75641823|NCT01071317|Drug|Naproxen|Naproxen 500mg PO bid prn headache
75641824|NCT01071317|Drug|Sumatriptan|100mg po q day prn headache
75641825|NCT01071317|Behavioral|Migraine education|Educational program available through NIH/ national library of medicine/ X-plain
75641826|NCT01071317|Behavioral|Reenforcement of diagnosis|Patient advised has migraine headache and how the headache meets migraine criteria
75641827|NCT01071317|Other|Typical care|Care to be determined by attending physician
75790072|NCT05568914|Device|Bio-electrical Impedance Analysis (BIA)|Bio-electrical Impedance Analysis (BIA101/BIVA, Akern) is used to analyse the body composition (Fat Mass, Fat Free Mass, Phase Angle).
76081417|NCT03974711|Other|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
76081418|NCT03965299|Device|VERUM TTNS|"Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
76081419|NCT03965299|Device|SHAM TTNS|"Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
76081420|NCT03964493|Drug|TNP-2092|TNP-2092 100mg/vial
76081421|NCT03964493|Drug|Vancomycin|Vancomycin 1g/vial
76081422|NCT03951909|Behavioral|Physiotherapy activity and awareness intervention: PAAI|10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
75641828|NCT04283149|Device|EVO/EVO+ Visian ICL|The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
75790073|NCT05568914|Other|Nutritional assessments|The Nutritional assessments consist of a dietary anamnesis and a 3-day nutritional diary to determine the nutritional (caloric and protein) intake of the participants.
75641829|NCT00783094|Drug|Tadalafil 2.5 mg|oral, daily
75926211|NCT05782101|Diagnostic Test|Integrated proteomic HPLC-ESI-MS analysis of salivary peptides|A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
75926212|NCT05781087|Diagnostic Test|Optical coherence tomography and pressure wire assessment|Non-culprit coronary arteries
75641830|NCT00783094|Drug|Tadalafil 5 mg|oral, daily
75641831|NCT00783094|Drug|Placebo|oral, daily
75641832|NCT02874599|Procedure|Dental restoration|
75641833|NCT02581579|Dietary Supplement|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14
75641834|NCT02581579|Other|Placebo|Placebo, 1 capsule per day during 14
75641835|NCT04303637|Behavioral|Phone use|Objective and subjective reports of smartphone use (e.g., number of hours, number of pick-ups, how phones are used)
75790074|NCT05563766|Drug|Itraconazole|Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
75790075|NCT05563298|Device|Neuro RX Gamma device|The Neuro RX Gamma device is a portable, wearable, low level light therapy (LLLT) delivery device. The Vielight Neuro RX Gamma delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
75790076|NCT05563298|Device|Sham Neuro RX Gamma device|The Sham device is indistinguishable from the active device. The sham device will not deliver light for the 20 minutes session duration.
75926213|NCT05781087|Diagnostic Test|Cardiac magnetic resonance angiogram|1.5T
75926214|NCT05779930|Biological|CD19 specific Chimeric Antigen Receptor T Cell|Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy
75926215|NCT05776888|Other|Ofatumumab|There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
75926216|NCT05776641|Device|GENUS|Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
75926217|NCT05774587|Behavioral|mHealth control group|Cardiac rehab control group
75641836|NCT02874833|Other|Exercise|After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
75641837|NCT04303247|Biological|CD19 and CD22 targeted CAR-T cells|The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
75641838|NCT02875925|Other|MTM|Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
75641839|NCT02874755|Other|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
75641840|NCT00790582|Drug|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
75790077|NCT05558371|Other|No intervention.|No intervention administered as part of this study; observational only.
75926218|NCT05774587|Behavioral|mHealth technology assisted exercise counselling (mHealth)|Exercise and counselling through mHealth technology
75926219|NCT05769244|Other|near-infrared spectroscopy (NIRS)|NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
75790078|NCT05555355|Device|Prevena Plus 125 Therapy Unit|"The investigators will utilize the KCI USA, Inc Prevena Plus 125 vacuum-assisted closure device in patients undergoing spine surgery as a method to prevent surgical site infections and wound dehiscence after surgery. The device has been approved by the FDA under the name Prevena 125 and Prevena Plus 125 Therapy Units and regulation number 21CFR 878.4783."
75332975|NCT04393688|Combination Product|Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter|"Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
75332976|NCT03824678|Drug|CC-220|CC-220
75641841|NCT04078087|Drug|Non obese|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
75790079|NCT05555355|Procedure|Spine surgery|Patients will receive spine surgery
75790080|NCT05554549|Other|Dietary pattern observed|Dietary pattern: regular meat-eater, occasional meat-eater, pescatarian, and vegetarian. There are no interventions in this observational cohort.
75790081|NCT05551780|Device|SoundBite Crossing System|Use of the SoundBite Crossing System to cross calcified chronic total occlusions
75926220|NCT05767372|Other|Coherent Breathing Exercise|"Step 1: Focus on your natural breathing and count the time of your inhale and exhale.~Step 2: Sit in a comfortable position to practice the coherent breathing technique. Gently place one hand on your stomach.~Step 3: Inhale for four seconds and then exhale for four seconds. Repeat this for one minute.~Step 4: Repeat the above step but lengthen your inhales and exhale for five seconds.~Step 5: Repeat the above step but extend the breaths to six seconds. Once you're able to do this for five minutes, gradually work your way up to 20 minutes.~During this breathing exercise, keep your hand on your stomach. Using diaphragmatic breathing can help you feel your breaths."
75332977|NCT02085356|Behavioral|Protect your family|"Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)"
75790082|NCT05541211|Other|Coeliac plexus neurolysis|Coeliac plexus neurolysis (CPN) will be performed bilaterally. Neurolytic solution will be injected around the coeliac plexus (a network of nerves located in the abdomen).
75790083|NCT05541211|Other|Splanchnic nerve neurolysis|Splanchnic nerve neurolysis (SNN) will be performed bilaterally. Neurolytic solution will be injected around the splanchnic nerves (a nerve located at thoracic trunk).
75926221|NCT05767372|Device|Inspiratory muscle training|"The patient was in the comfortable sitting position and then put the nose clip on the patient's nose~After setting the maximum training; the user recognized the load at which they could effectively execute ten breaths at greatest resistance relying upon the patient's pace of apparent effort.~Training was begun with a load at low intensity 20-30% of the patient maximum 10 repetition method using inspiratory muscle training (IMT) device.~Progress slowly and monitor carefully.~As the inspiratory muscle became stronger the inspiratory load was progressed to 50% of maximum effort over 3 weeks as tolerated.~Patient took full breath in (maximal and deep inspiration) then longer and slow expiration. Continue this breathing pattern for 10-20 breath.~Repeated step (5), 4-6 times or about 10-15minutes with rest in between 30 seconds.~The session was repeated three times per week for 12 weeks."
76081423|NCT03951909|Behavioral|Psychological intervention: Teaching recovery techniques (TRT)|TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
76081424|NCT03942653|Drug|Goserelin Acetate|Goserelin Acetate, SQ, Q4W
76081425|NCT03942653|Drug|Pembrolizumab|Pembrolizumab, IV, Q3W
75641842|NCT04078087|Drug|Obese.|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
76081426|NCT03939026|Genetic|ALLO-501|ALLO-501 is an allogeneic CAR T cell therapy targeting CD19
75641843|NCT01048541|Device|Test Catheter - SpeediCath Compact Male|Compact catheter for intermittent catheterisation
75641844|NCT01048541|Device|SpeediCath|Catheter for intermittent catheterisation
75641845|NCT04077931|Other|exercises|Walking on treadmill with fixed 0% grade inclination
75641846|NCT00916240|Behavioral|Multisystemic Therapy|Treatment will consist of a home- and community-based intensive intervention. Psychological treatment sessions will be provided in participants' homes, at a time designated by the participant and will last about 1 hour.
75790084|NCT05539534|Behavioral|Training on suicide prevention|Suicide prevention training in Flanders is organised by the Centre for the Prevention of Suicide and the suicide prevention workers of the Centra for Mental Health Care. These trainings are announced via the website zelfmoord1813.be/vormingen or are organized on demand. When a participant registers, they will be invited to participate in the study one week before the training.
76081427|NCT03939026|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
76081428|NCT03939026|Drug|Fludarabine|Chemotherapy for lymphodepletion
76081429|NCT03939026|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
75790085|NCT05537948|Drug|Pitavastatin|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~pitavastatin monotherapy~monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of Pitavastatin: Pitavastatin at visit 0 will be prescribed at a dose of 2 mg, after 1 month in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg.~The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with pitavastatin, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). There will be visits on the 7th, 9th and 12th months."
75926222|NCT05750550|Other|Instrument Assisted Soft Tissue Mobilization|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
75790086|NCT05537948|Drug|PCSK9 inhibitor|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~pitavastatin monotherapy~monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months."
75790087|NCT05532943|Biological|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment.
75790088|NCT05532943|Biological|Control group|Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.
75790089|NCT05532722|Drug|ABC008|Given subcutaneous injection
75790090|NCT05530499|Other|Almond supplementation|Daily consumption of 57g of whole almonds
75790091|NCT05530499|Other|Cookie supplementation|Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
75790092|NCT05522803|Device|TMS followed by sham TMS|Transcranial Magnetic Stimulation followed by sham TMS
75790093|NCT05522803|Device|Sham TMS followed by TMS|Sham Transcranial Magnetic Stimulation followed by TMS
75790094|NCT05521529|Other|no intervention, as this is an observational study|no intervention
75790095|NCT05520567|Drug|Gilteritinib|Oral
75790096|NCT05520567|Drug|Venetoclax|Oral
75790097|NCT05520567|Drug|Azacitidine|Subcutaneous injection or intravenous infusion
75641847|NCT00916240|Behavioral|Home-based, Non-Directive Family Support|Treatment will consist of Rogerian, client-centered, non-directive counseling. Participants will receive weekly home-based, supportive family counseling, with sessions lasting about 45 minutes.
75790098|NCT05515718|Other|Standard pain management|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician, under strict aseptic conditions After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
75790099|NCT05515718|Other|Femoral nerve block|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician under strict aseptic conditions, immediately after oral informed consent is obtained. After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
75790100|NCT05513274|Behavioral|Pain Psychology Neuroscience + Written Emotional Disclosure|A 15 to 20-minute exercise which they examine variables in themselves that suggest that their pain is driven by central nervous system processes. Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
75926223|NCT05749627|Drug|Neoantigen peptide vaccine|Personalized tumor neoantigen peptide vaccine
75926224|NCT05749627|Drug|Neoantigen-based DC immune preparation|Personalized tumor neoantigen DC therapeutic immune preparation
75926225|NCT05745207|Drug|E2086|E2086 tablets.
75926226|NCT05745207|Drug|Placebo|E2086 matched placebo tablets.
75641848|NCT02583217|Drug|Ketamine|To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
75641849|NCT02583217|Drug|remifentanyl|
75641850|NCT02583217|Drug|propofol|
75790101|NCT05513274|Behavioral|Pain Psychology Neuroscience + Healthy Habits Disclosure|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes in their brains. Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
75926227|NCT05744843|Behavioral|exercise|cardiovascular and lower limb strengthening exercise programme
75926228|NCT05744843|Procedure|Deep venous stenting|Planned surgical intervention
75926229|NCT05744648|Procedure|Composite resin restoration using Titania nanoparticle reinforced bonding agent|Each group will receive Composite resin restoration for Class-I and Class-II carious lesion. In group A, titania nanoparticle reinforced bonding agent will be used
75926230|NCT05744648|Procedure|Composite resin restoration without Titania nanoparticle incorporated bonding agent|Composite resin restoration without Titania nanoparticle incorporated bonding agent
75641851|NCT02583217|Device|laryngeal mask|
75641852|NCT00774046|Drug|Ara-C|"Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)"
75641853|NCT00774046|Drug|Mitoxantrone|Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
75790102|NCT05513274|Behavioral|Health Behavior Control + Written Emotional Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
75926231|NCT05738954|Other|Ultrasound|"Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.~The DL/SL algorithms will work in a competitive/collaborative way. Following the 'no-free-lunch' theorem, we shall use the competitive phase to establish the most suitable DL/SL technique for the identification and anomaly detection of each organ, and the collaborative phase to make all the algorithms work together in providing a 'second' opinion."
75926232|NCT05726409|Other|Mobile application|Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
75926233|NCT05718674|Procedure|Extracorporeal Photopheresis|ECP is performed by collecting leucocytes from the patient through leukopheresis and incubating them with 8-MOP and UVA in extracorporeal circulation. The treatment steps are the collection of leucocytes, photoactivation and subsequent reinfusion of the treated cells.
75471434|NCT05876741|Diagnostic Test|history taking , vital signs and labaratory investigations|"Complete history taking:~With stress on age, sex, epigastric pain, comorbidities (ischemic heart disease, diabetes, liver cirrhosis, renal failure, malignancy), syncope, disturbed conscious level, blood transfusion, drug history .~Clinical examination:~Pulse, blood pressure, calculating the shock index, pallor, jaundice, cachexia, purpura, ecchymosis, conscious level, abdominal examination.~Laboratory investigations:~Complete blood count (CBC).~Creatinine and blood urea nitrogen (BUN).~liver function tests (serum bilirubin, serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), prothrombin concentration (PC), and international normalized ratio (INR)).~Serum electrolytes and arterial blood gases.~Fasting blood sugar.~Assessment of risk and predicting outcomes by:~Pre-endoscopic Rockall score (pRS).~Glasgow-Blatchford score (GBS).~AIMS65 score.~ABC score.~Horibe score."
75471435|NCT05876728|Genetic|Genotyping|Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.
75471436|NCT05876702|Device|endoscopy|use of upper endoscopy with i-scan specially , in diagnosis of esophageal lesions and comparison of results with histopathology.
75471437|NCT05876624|Other|Blood Pressure measurement|Blood Pressure measurement
75641854|NCT00774046|Drug|Etoposide|Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
75641855|NCT01046903|Drug|Fragmin® (Dalteparin Sodium)|Administered per prescribing physician
75926234|NCT05718063|Behavioral|MAP for Coaches - Complete Course|The MAP for Coaches is an eLearning (web-based) knowledge translation training course aimed at providing youth sport coaches with the evidence-based education and motivation they need to reduce the risk of musculoskeletal injuries in young athletes. Course modules include a description of: (1) musculoskeletal injuries in youth sport; (2) the importance of injury prevention, and instructions on: (1) applying best practices for musculoskeletal athletic injury prevention, including neuromuscular training programs; (2) using behavioral strategies to successfully implement neuromuscular training warm-up programs in coaching sessions.
75926235|NCT05718063|Behavioral|Map for Coaches - Overview|This is a summarized version of the MAP for Coaches. It comprises a 2-page sport-specific injury prevention e-book (reading) containing an overview of the MAP for Coaches training and an infographic summary.
75926236|NCT05710341|Dietary Supplement|Water with added nitrate|Water with added nitrate
75926237|NCT05710341|Dietary Supplement|Water without added nitrate|Water without added nitrate
75926238|NCT05708365|Other|Standard-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~Plateau Pressure ≤ 30 cm of water~PEEP and FiO2 set according to ARDSnet table~Driving Pressure ≤ 15 cm of water~Respiratory rate between 8 and 30 breaths per minute"
75926239|NCT05708365|Other|Ultra-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~Plateau Pressure ≤ 30 cm of water~PEEP and FiO2 set according to ARDSnet table~Driving Pressure ≤ 15 cm of water~Respiratory rate between 8 and 30 breaths per minute"
75926240|NCT05708053|Drug|Metformin|Metformin 500 mg twice
75926241|NCT05701020|Other|questionnary|If agreeing to the protocol, ; patients will answered questions about sexual health during the gynecologic consultation
75471438|NCT05876598|Drug|antibiotic treatments|The outcome of the study will be to implement Prediction Models to support clinicians for the assessment of risk of having a bloodstream infection.
75471439|NCT05876585|Drug|Ondansetron 8 mg ampoule|Study drug
75471440|NCT05876585|Drug|Metoclopramide 10 mg ampoule|Comparator drug
75641856|NCT02581423|Drug|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
75641857|NCT04102072|Diagnostic Test|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
75641858|NCT04102072|Diagnostic Test|dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
75641859|NCT02875457|Drug|apatinib;etoposide and cisplatin|
75641860|NCT02875457|Drug|placebo;etoposide and cisplatin|
75641861|NCT00773968|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
75641862|NCT05527210|Dietary Supplement|Prebiotic|Prebiotin® is a fine, white to slightly yellow powder, which is mixed into water and has a slightly sweet taste.
75641863|NCT05527210|Dietary Supplement|Placebo Prebiotic|Placebo prebiotic mixed into water
75471441|NCT05876559|Other|Joyuus Self-care Mobile App|Joyuus is an innovative self-care mobile tool designed to address the needs of underserved women who are at greater risk for adverse postpartum outcomes. It provides the appropriate information, knowledge, and skills to improve postpartum health through self-care, and identifies when it is appropriate to seek care.
75471442|NCT05876559|Other|Standard Care|Standard care is access to typical resources women have access to during postpartum and does not include the Joyuus intervention.
75471443|NCT05876520|Procedure|Total pulpotomy with I-prf mixed with Nano-bioactive glass|Total pulpotomy is done in mature permanent molars followed by I-prf mixed with Nano-Bioactive glass application. Topped with BC putty for coronal seal, RMGI and restored with composite as final restoration
75471444|NCT05876507|Behavioral|Progressive relaxation exercise|Progressive relaxation exercises will take 25-30 minutes of patients daily.
75471445|NCT05876481|Drug|Psilocybin|Product name: Psilocybin Pharmaceutical form: capsule, hard Dose number and units: 25 mg per day (8-hour dosing session) x 2 Route of administration: oral
75471446|NCT05876468|Device|Continuous anterior chest compression|"Patients with severe to moderate ARDS who were placed in prone position by the attending physician :~First CACC : the applied pressure is equal to the one observed in the prone position~Second CACC : The applied pressure is set at 60 - 80 cmH20"
75471447|NCT05876455|Procedure|Conventional Subgingival Instrumentation|On the conventional non-surgical periodontal therapy side, a power-driven piezo-electric ultrasonic scaling device with scaling tips will be used the majority of the time to debride subgingival biofilm and calculus, and manual standard Gracey curette instruments (Gracey curettes Hu-Friedy, Chicago, IL, USA) will be used to remove residual deposits from the root surface.
75471448|NCT05876455|Procedure|minimally invasive non-surgical periodontal therapy|minimally invasive non-surgical periodontal therapy will undergo careful scaling and root planing under magnification (use of 3.5 X magnification loupes) with mini curettes and using an ultrasonic device with specific thin and delicate tips. These instruments will be carefully inserted through the periodontal pocket of the affected tooth to reach the root surface for debridement. Caution will be taken to preserve the stability of soft tissues.
75471449|NCT05876429|Other|New Standardized Accept Note|A standardized accept note for transfer patients will be implemented, after stakeholder engagement and subsequent finalization.
75471450|NCT05876429|Other|Existing Transfer Patient Admission Process|Maintain existing transfer patient admission processes, across GMS, Cardiology, and Oncology services.
75641864|NCT04078867|Procedure|tricuspid valve repair|Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
75641865|NCT04077385|Behavioral|Retrieval-extinction (R-E) Training|The retrieval-extinction (R-E) training intervention will occur on two consecutive days and consist of (a) retrieval of high calorie food cue-reward associative memories and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 high calorie food images (e.g., cakes, cookies, muffins, hamburgers, french fries, potato chips, pizza). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M&M or potato chip.
75790103|NCT05513274|Behavioral|Health Behavior Control + Healthy Habits Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
75790104|NCT05489406|Drug|DTG DT (6 x 5 mg)|DTG 5mg dispersible tablet
75790105|NCT05489406|Drug|F/TAF TOS (3 x 60/7.5 mg)|60/7.5 mg TOS emtricitabine/TAF
75790106|NCT05488509|Drug|Cannabis|Participants will inhale vapor from cannabis containing either 20mg THC or 40mg THC.
75790107|NCT05488509|Drug|Placebo|Participants will inhale vapor from a placebo product.
75926242|NCT05699122|Other|Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day."
75926243|NCT05699122|Other|Gentle intimate hygiene and skin protective barrier application - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution."
75926244|NCT05699122|Other|Low Level Laser Therapy - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
75926245|NCT05699122|Other|Low Level Laser Therapy - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
75926246|NCT05674292|Device|Erchonia Violet Zerona Z6|405nm violet diode low level laser device
75926247|NCT05671861|Device|Trismus Device Prototype|Device is noninvasive and will be inserted between patient's upper and lower teeth
75471451|NCT05876364|Biological|QTP104 1ug|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
76081430|NCT03926767|Other|Pain Neuroscience Education (PNE)|A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
76081431|NCT03926767|Other|Orofacial Manual Therapy|A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
76081432|NCT03926767|Other|Orofacial Exercises|Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
76081433|NCT03926767|Other|Neck Motor Control Exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
75332978|NCT03824834|Drug|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions (three times per week for five weeks) on an electronically braked bike, supervised by a trained exercise specialist. Exercise sessions will be individualized based on participants' peak power output (60% PPO) determined from incremental exercise testing, and progressed to ensure the participant is exercising at a breathlessness intensity rating of between 3-5 Borg CR10 scale units and can complete at least 20-min of continuous cycling. Exercise duration will be increased in 5-min intervals up to 40-min. Thereafter, exercise intensity will be increased by 5-15% of baseline PPO.
75471452|NCT05876364|Biological|QTP104 5ug|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
75926248|NCT05671861|Other|Questionnaires|Surveys will be administered to participants
75471453|NCT05876364|Biological|QTP104 25ug|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
75471454|NCT05876325|Other|FINassist|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
75471455|NCT05876325|Other|FINassist|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
75790108|NCT05486689|Other|Pulmonary Rehabilitation|"The enrolled subjects will receivePR program. The 3 weeks inpatient PR will include education, exercise training, nutritional and psychological counselling.~Education: individualized session of 20 minutes each and group session of 45 minutes each. Endurance training: at least twelve 30-minute daily sessions of supervised incremental exercise training according to Maltais, continuous cycling at 50-70% of the maximal load calculated on the basis of the baseline 6MWT according to Hill. Strength training: twelve 30-minute daily sessions of peripheral limb muscle strength training: 2 set of 8 repetitions during the first week, increased at 12 from the second. The initial load will be set at 30/50% of maximal voluntary isometric strength (MVS). Psychological intervention: individual tailored intervention will be offered when the Hospital Anxiety and Depression Scale (HADS) score is >10 or judged necessary by clinicians, after verifying the subject's motivation."
75790109|NCT05480930|Other|paper-based clinical decision support (dCDS) tool|The paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
75790110|NCT05480930|Other|digital clinical decision support (dCDS) tool|The intervention is a digitized version of the paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
75926249|NCT05671861|Other|Mobile Application|A study-specific, accompanying secure mobile application for users to track progress will be created.
75790111|NCT05478902|Procedure|Exercise Therapy|Exercise protocol for rotator cuff related shoulder pain
75790112|NCT05478902|Procedure|Extracorporeal Shockwave Therapy|High Energy Extracorporeal Shockwave Therapy
75926250|NCT05671523|Procedure|Dry needling|Firstly the skin is cleaned with a piece of cotton immersed in alcohol. Then sterilized disposable thin, stainless steel needles (25 × 0.30 mm) will be inserted into the skin over the nodule in A1 pulley anatomic location. The duration of needling will be 1 minute. The needle will be inserted deeply at 45° to the level of metacarpophalangeal level to the nodule. The needle may be inserted into the tendon. This is confirmed by needle movement when the patient ﬂexes and extends the distal phalanx. The needle is withdrawn slowly until this motion ceases, and the needle tip is in the A1 pulley. This will be repeated 2 times per week for 5 weeks.
75471456|NCT05876208|Other|BAND Connect's VirtuaCare™ platform|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
75790113|NCT05478902|Procedure|Ultrasound-Guided Percutaneous Irrigation|Two sessions of Ultrasound-Guided Percutaneous Irrigation
76081434|NCT03925389|Procedure|External septorhinoplasty|A surgical procedure to repair defects or deformities of both the nasal septum and the external nasal pyramid through an external incision at the columella.
76081435|NCT03915574|Device|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
75471457|NCT05876208|Other|Standard of Care Physical Therapy|Standard of care physical therapy without the use of the BAND CVCP
75332979|NCT03824834|Other|Exercise training with placebo|Diluted simple syrup prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions as per the experimental group.
75332980|NCT03829124|Drug|Propofol|Propofol 10mg/ml IV push slowly 0.5-2mg/kg
75790114|NCT05470881|Drug|Atropine Sulfate|Administration of one drop QD on both eyes for 14 days.
75332981|NCT03829124|Drug|Ketamine|Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
75332982|NCT03828890|Other|Screening eye exam using Optos technology|Retinal imaging using Optos technology to identify Diabetic Retinopathy
75790115|NCT05467774|Behavioral|Operant RF H-reflex conditioning|Operant down-conditioning of rectus femoris H-reflex
75790116|NCT05463250|Device|Smartwatch|Wearing a smartwatch and having access to its data
75926251|NCT05671523|Other|conventional treatment|"Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing."
75926252|NCT05667142|Drug|XEN1101|XEN1101 capsules
75471458|NCT05876195|Biological|Keyhole-Limpet Hemocyanin|Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)
75926253|NCT05667142|Drug|Placebo|Placebo capsules
75926254|NCT05661188|Drug|Atezolizumab plus Tiraglolumab|All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
75471459|NCT05876195|Drug|Saline|Placebo intervention.
75471460|NCT05876195|Drug|Montanide ISA 51 VG|Montanide ISA-51 (Seppic, France) is a water-in-oil vaccine adjuvant
75641866|NCT04077385|Behavioral|Extinction Training|The extinction control group will engage in two consecutive days of intervention consisting of (a) retrieval of memories not associated with high calorie foods and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 non-food-related neutral images (e.g., office supplies, tools). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M&M or potato chip. The 60-min extinction training is the same as the extinction training received by participants in the R-E training intervention.
75332983|NCT03829202|Device|Own mechanical knee|Daily use of own mechanical knee
75332984|NCT03829202|Device|RheoKnee microprocessor prosthetic knee|Daily use of RheoKnee microprocessor prosthetic knee
75332985|NCT03011216|Behavioral|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
75332986|NCT03011216|Behavioral|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
75332987|NCT03828578|Procedure|High flow oxygen therapy|High flow oxygen therapy delivered via Airvo2
75332988|NCT02965976|Biological|Botulinum Toxin Type A|Given IM
75332989|NCT02965976|Procedure|Esophagectomy|Undergo esophagectomy
75471461|NCT05876195|Drug|Alhydrogel|Alhydrogel is a vaccine adjuvant
75471462|NCT05876169|Procedure|Orthognathic surgery|Surgical corrections of the maxilla and/or the mandible. Integrated jaw-neck movement patterns, muscle activity, bite force and occlusal contact area will be registered and mapped with quantitative objective functional variables. The state-of-the-art core equipment to evaluate jaw-neck motor function in detail is located in the Movement Lab (Department of Odontology, Umeå University).
75641867|NCT04101994|Device|Virtual cycling training|Virtual cycling training is a convenient and easy approach for muscle strengthening.
75641868|NCT04101994|Device|Repetitive transcranial magnetic stimulation|Intermittent theta burst stimulation produces short TBS trains intermittently to facilitate cortical excitability.
75790117|NCT05441384|Behavioral|Family Caregiver - Fear Of Recurrence Therapy (FC-FORT)|7 weekly sessions of 90-120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
75790118|NCT05440188|Diagnostic Test|Breath Detect Platform|Use of the Breath Detect platform for respiratory health monitoring.
75790119|NCT05439330|Device|MRI of teeth and surrounding structures|included above
75790120|NCT05429658|Device|Thrombectomy|The Route 92 Medical Reperfusion System is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within the internal carotid, middle cerebral, basilar and vertebral arteries.
75790121|NCT05423444|Behavioral|TF-CBT|evidence-based psychotherapy for trauma in youth
75926255|NCT05656469|Other|Personalised medication advice based on pharmacogenetic testing|Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
75926256|NCT05653518|Device|Tandem t:slim X2 with Control-IQ Technology|FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
75926257|NCT05653518|Device|Sensor augmented pump (SAP) therapy|Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump
75926258|NCT05649787|Behavioral|Supervised aerobic training|Supervised moderate to high-intensity interval aerobic training
75926259|NCT05649787|Behavioral|Supervised aerobic plus low to moderate-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
75926260|NCT05649787|Behavioral|Supervised aerobic plus moderate to high-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
75790122|NCT05423444|Behavioral|TAU|treatment as usual
75790123|NCT05422144|Device|Antimicrobial Skin & Wound Cleanser (AWC)|BIAKŌS™ Antimicrobial Skin & Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKŌS™ Antimicrobial Skin and Wound Cleanser is a pure, colorless, isotonic cleanser that is safe. The preservative, polyhexamethylene biguanide (PHMB), at a concentration of 0.1% w/w is added to the product to inhibit the growth of microorganisms such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA). and fungus Candida albicans within the product.
75790124|NCT05422144|Device|Antimicrobial Wound Gel (AWG)|"BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial polyhexamethylene biguanide (PHMB).~BIAKŌS Antimicrobial Wound Gel:~Resists microbial colonization within the gel during shelf storage.~Provides an amorphous gel covering.~Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
75332990|NCT02965976|Other|Quality-of-Life Assessment|Ancillary studies
75332991|NCT03824288|Diagnostic Test|Intraoral ultrasound|The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.
75641869|NCT04101994|Device|Transcranial electric stimulation|TES is a constant current with low intensity delivered to the skull through surface electrodes.
75926261|NCT05640674|Drug|Ibuprofen|Non-opioid
75926262|NCT05640674|Drug|Hydrocodone/acetaminophen|Opioid
75641870|NCT04060381|Drug|Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine|Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
75332992|NCT03824288|Procedure|The landmark technique|A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
75332993|NCT00982397|Device|Protecta VR-ICD|Protecta single-chamber implantable cardioverter defibrillators.
75790125|NCT05421676|Device|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
75790126|NCT05419830|Behavioral|BBTI|Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
75790127|NCT05419830|Other|PM antihypertensive dosing or Chronotherapy|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
75926263|NCT05640674|Drug|Acetaminophen|Non-opioid
75926264|NCT05629689|Drug|GEH200520 Injection / GEH200521 (18F) Injection - Part A|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
75926265|NCT05629689|Diagnostic Test|Dynamic and Static - PET/CT scan|Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
75926266|NCT05629689|Drug|GEH200520 Injection / GEH200521 (18F) Injection - Part B|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
75926267|NCT05629689|Diagnostic Test|Static - PET/CT scan|Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.
75332994|NCT00982397|Device|Protecta DR-ICD or CRT-D|Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
75332995|NCT03828656|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
75471463|NCT05876143|Device|Unicompartmental knee arthroplasty|"Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state."
75471464|NCT05876130|Radiation|POHIM_EM|hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)
75641871|NCT04032379|Other|Standard treatment|No intervention, some patients have additional neuro-psychological testing.
75641872|NCT00782626|Drug|everolimus|
75641873|NCT04076371|Drug|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
75641874|NCT04076371|Drug|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
75641875|NCT04076371|Drug|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
75641876|NCT04076371|Drug|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
75641877|NCT04076371|Drug|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
75641878|NCT04076371|Drug|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
75926268|NCT05620784|Drug|Furosemide|20mg of IV furosemide injection during the morcellation phase of HoLEP
75926269|NCT05619471|Device|VIO|Skin conditions that are candidates for skin biopsies
75926270|NCT05608694|Other|Prostate MRI|Group placement is determined by GRS score, Family history, and germline testing
76081436|NCT03915574|Device|Standard Epidural|Control group - standard epidural (no dural puncture)
76081437|NCT03914196|Diagnostic Test|Liver Stiffness Ultrasound|Research imaging will include liver assessments of stiffness (ultrasound shear wave elastography), tissue attenuation (if available), and blood flow (gray-scale and Doppler imaging).
76081438|NCT03912272|Behavioral|High-intensity Interval Training|In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.
75641879|NCT04076371|Drug|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
75641880|NCT04076371|Drug|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
75641881|NCT02583139|Behavioral|Designed Music Narratives|"Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.~The narrative and music reflect and support each other."
75790128|NCT05419830|Other|AM antihypertensive dosing|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
75790129|NCT05416905|Device|STN-DBS|"The patients will be treated with deep brain electrode placement of STN target under local and general anesthesia. Switching the system on: the stimulator will be switched on 3 weeks after surgery to allow time for the brain edema and stun effect to wear off. Postoperative medication: The subject taking medication in the past will continue the medication. If the subject with no medication before, will be required not to take medication related to dystonia."
75790130|NCT05416905|Device|GPi-DBS|The patients will be treated with deep brain electrode implantation of GPi target under local and general anesthesia. Except that the surgical target was GPi, the operation process, stimulator switch-on time, and postoperative medication were the same as those in the STN-DBS group.
75790131|NCT05412602|Procedure|full spine corrective protocol|36 chiropractic adjustments over 12 weeks (3 visits per week) with in office spinal traction on the 3D Denneroll Traction Table, as well as supplemental home exercises
75790132|NCT05409287|Procedure|Immediate Implant Loading|A single implant crown will be mounted on the implant immediately after implant placement
75790133|NCT05409287|Procedure|Early Implant Loading|A single implant crown will be mounted on the implant 4 weeks after implant placement.
75926271|NCT05596760|Behavioral|Jumpstart Guide|The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families in the outpatient setting. The intervention's goal is to prompt clinicians to provide, during a scheduled (non-urgent) clinic visit, standard of care which includes a discussion with patients (and/or their LNOKs) about their goals of care. It is designed to promote and guide these discussions for older adults with memory problems through suggestions and tips on the Jumpstart Guide.
75926272|NCT05595629|Behavioral|App-based remote blood pressure monitoring|Fully synched bluetooth-enabled remote blood pressure monitoring using a smartphone application. The digital health company, Twistle, has modified an existing postpartum hypertension pathway in their app according to our hospital's management algorithm.
75926273|NCT05595629|Behavioral|text-message based remote blood pressure monitoring|Participants will receive automatic blood pressure cuffs and instructions as to how to upload their measurements to the Electronic Medical Record.
75926274|NCT05586477|Drug|Placebo|A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
75926275|NCT05586477|Drug|Diphenhydramine|Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention
75790134|NCT05404373|Other|Normobaric Hyperoxia (NBO)|NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups
75926276|NCT05578651|Device|SternaLock XP|Plating system with cable cerclage bands that is used in the stabilization and fixation of fractures of the anterior chest wall, including sternal fixation following sternotomy
75926277|NCT05577858|Other|Meat based|Omnivorous diet following dietary guidelines
75926278|NCT05577858|Other|Pulse based|Vegetarian pulse-based diet following dietary guidelines
75926279|NCT05577338|Behavioral|Theory of Mind psychotherapy|a semi-structured, multidomain, tailored group psychotherapy
75926280|NCT05577338|Behavioral|health education|disease-related health knowledge
75926281|NCT05573763|Device|F&P Toffee|Nasal pillows mask
75926282|NCT05572450|Other|Infectious Titre 1|Approximately 10^5.5 TCID50/mL (titre may be adjusted based on stock titre)
75641882|NCT05400733|Dietary Supplement|Total Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartate, Cystine, Glutamine, Glutamate, Glycine, Proline, Serine, Tyrosine. All supplements are commercially available.
75790135|NCT05404373|Other|Low flow oxygen|immediately given oxygen inhalation at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
75790136|NCT05394493|Drug|avelumab|as provided in real world setting
75790137|NCT05394493|Drug|axitinib|as provided in real world settings
75926283|NCT05572450|Other|Infectious Titre 2|Approximately 10^4.5 TCID50/mL (titre may be adjusted based on stock titre)
75926284|NCT05572450|Other|Infectious Titre 3|To be determined (TBD), depending on outcome of Part A
75926285|NCT05572450|Other|Infectious Titre 4|TBD, depending on outcome of Part A
75926286|NCT05570266|Diagnostic Test|Breast Cancer Risk Prediction Software|Genotyping of known breast cancer-related markers (313 variants) will be conducted using a microarray genotyping chip (Genetic Risk). Survey answers will determine Gail Model scores and thus Clinical Risk Score.
75926287|NCT05568706|Drug|EDP-938|Subjects will take EDP-938 once daily for 5 days
75926288|NCT05568706|Drug|Placebo|Subjects will take matching placebo, once daily for 5 days
76081439|NCT03912272|Behavioral|Usual Care Control|In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
76081440|NCT03902912|Drug|Prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
75926289|NCT05564598|Biological|CMV Cytotoxic T-Lymphocytes|Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.
75926290|NCT05564598|Drug|Anti-viral Therapy|"All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~Reduce dose by 50% for ANC less than 500 cells/mm3~Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~Treatment will continue for 6 months"
76081441|NCT03887481|Device|"High-definition active tDCS (HD-tDCS) + Repeat After Me (RAM) Treatment"|"Device: Active HD-tDCS & Repeat After Me (RAM) Treatment~Stimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
76081442|NCT03887481|Device|"Sham + Repeat After Me (RAM) Treatment"|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
75926291|NCT05549219|Drug|GLM101|GLM101 IV Infusion
75471465|NCT05876052|Device|Hypothermic oxygenated Perfusion - HOPE|HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers.
75471466|NCT05876039|Drug|Initial remifentanil effect-site concentration|Different initial remifentanil effect-site concentration
75641883|NCT05400733|Dietary Supplement|Essential Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
75790138|NCT05393232|Behavioral|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
75790139|NCT05393232|Behavioral|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
75790140|NCT05390580|Device|transcutaneous auricular vagal nerve stimulation|Stimulus of the auricular branch of the vagal nerve with the transcutaneous auricular vagal nerve stimulation.
75926292|NCT05547919|Radiation|18F-PSMA PET/CT|Patients with metastasized gastrointestinal tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
75926293|NCT05542628|Other|No intervention included|No intervention included
75926294|NCT05540990|Device|Robot assisted gait training|15 sessions of robot-assisted gait training (two times per week with a maximum of 45 minute each).
75926295|NCT05540990|Other|Conventional physiotherapy|individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
75926296|NCT05538871|Diagnostic Test|Survey + Physical exam|"Survey:~Demographic data Pain Oswestry disability index International Physical Activity Questionnaire Scoliosis Research Society (SRS-22r) Spinal appearance questionnaire Fear Avoidance and Beliefs Questionnaire Short Orebro musculoskeletal pain questionnaire Work Ability Index~Physical exam:~Repeated movements (MDT) Posture ROM Neuro Updated treatment based classification tests Pathoanatomical classification tests"
75926297|NCT05537792|Device|Robotic Knee/Ankle Prosthesis|The intervention is an experimental robotic knee/ankle prosthesis that has been previously developed by the team. It is used to improve walking gait performance.
75926298|NCT05536739|Device|Robotic hip exoskeleton|The intervention is an experimental robotic hip exoskeleton that has been previously developed by the team. It is used to improve walking gait performance.
75471467|NCT05876013|Procedure|ACL reconstruction|Randomized between hamstring and patellar tendon graft
75471468|NCT05875935|Procedure|ECoG : electrocorticography|"The skull and the dura are opened under general anesthesia and the two grids of 64 cortical electrodes will be applied to the cortex, one facing the glial lesion, and the other at a distance from the glial lesion in the so-called area. Healthy (non-tumor), before the patient wakes up. They consist of 8 recording slides each comprising 8 electrodes of 2 mm in diameter each spaced 0.5 mm (DispoMed®, USA)."
75641884|NCT05400733|Dietary Supplement|Essential Amino Acids + Hydroxy-methylbutyric acid (HMB)|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, HMB. All supplements are commercially available.
75641885|NCT05400733|Dietary Supplement|Essential Amino Acids + Leucine|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Extra leucine. All supplements are commercially available.
75641886|NCT05400733|Dietary Supplement|Essential Amino Acids High|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
75641887|NCT05400733|Dietary Supplement|Placebo Water|Water
75641888|NCT04077697|Diagnostic Test|RT-PCR for influenza|influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.
76081443|NCT03879096|Other|Therapeutic Exercise and Education|Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
75790141|NCT05390580|Device|Sham transcutaneous vagal nerve stimulation|Patients assigned to the controls arm will have no electricity applied to the Auricular Branch of the Vagus Nerve. Stimulus will be provided to the lobule of the ear, which is not innervated by the Auricular Branch of the Vagus Nerve.
75790142|NCT05385913|Other|Multivitamin-no intervention|No intervention. All participants will be given a multi-vitamin to take for the duration of the study
75641889|NCT01071083|Drug|natalizumab|300 mg intravenous every 4 weeks
75790143|NCT05379634|Drug|Nipocalimab|Nipocalimab will be administered intravenously in double-blind period and LTE period.
75790144|NCT05379634|Other|Placebo|Nipocalimab matching placebo will be administered intravenously in double-blind period.
75926299|NCT05535855|Drug|CD19 Directed CAR T Cell|The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
75926300|NCT05535023|Drug|SAR444245|Given by vein (IV)
75926301|NCT05535023|Drug|Cemiplimab|Given by vein (IV)
75926302|NCT05507333|Device|Gedea pessary|Daily administration of the Gedea pessary during 6 days
76081444|NCT03877744|Behavioral|interactive virtual presence|parents will install car seat through remote guidance via interactive virtual presence
75641890|NCT01071083|Drug|interferon beta 1-a|30 ug intramuscular once per week
75790145|NCT05379634|Drug|Glucocorticoids|Prednisone or equivalent will be administered orally as Glucocorticoid.
76081445|NCT03877744|Behavioral|live technician|parents will install car seat through guidance from a live certified technician who is present
76081446|NCT03864406|Drug|Cobicistat|Each tablet of Tybost contains 150 mg of cobicistat.
75790146|NCT05373784|Biological|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of another individual. This is currently an accepted method of treatment for recurrent colitis secondary to Clostridium difficile infection refractory to antibiotics/medical management. FMT can be delivered via capsule endoscopy or via colonoscopy. In this study, it will be administered via colonoscopy.
75790147|NCT05364099|Drug|Lidocaine 1% Injectable Solution|2.5 ml of 1% Lidocaine will be administered via injection in suprascapular nerve in the suprascapular notch
75790148|NCT05364099|Drug|Triamcinolone Injection|0.5 ml 40mg/ml Triamcinolone will be administered via injection in suprascapular nerve in the suprascapular notch
75926303|NCT05506891|Behavioral|Physical therapy group|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
75926304|NCT05506891|Drug|Astragalus|After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
75926305|NCT05505500|Behavioral|Interview|Concept Elicitation Interviews are used to create tools followed by Cognitive Debrief Interviews that are used to review created tools.
76081447|NCT03864406|Drug|Darunavir/Cobicistat|Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
76081448|NCT03864406|Drug|Rivaroxaban|Each tablet of Xarelto contains 10 mg of rivaroxaban.
75641891|NCT01071083|Drug|methylprednisolone|1000 mg intravenous every 4 weeks
75641892|NCT01071083|Other|IV placebo|placebo intravenous every 4 weeks
75641893|NCT01071083|Drug|glatiramer acetate|20 mg subcutaneous once daily
75641894|NCT04302935|Other|Global pain-assessment|Global pain-assessment, based on the ICF framework
75641895|NCT04077307|Drug|Karonudib|Dose escalation of administration with Karonudib. Three different dose cohorts are planned.
75641896|NCT01070771|Device|Radi pressure wire (pressure wire assessment)|Intracoronary insertion of pressure wire at the time of diagnostic angiography.
75641897|NCT02581033|Drug|Nucleoside Analogue therapy|Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
75641898|NCT03968341|Other|Pharmacokinetic and pharmacodynamic study of antibiotics used in severe endophthalmitis from samples taken from treated patients|"A 5mL dry tube will be taken by puncture of the humeral vein like a conventional blood test. This tube is not usually collected unless specifically requested by the ophthalmologist. This sample will be sent quickly (within two hours) to the CHNO Medical Biology Laboratory for centrifugation, serum separation and storage at -80°C.~Samples stored at -80°C will be sent weekly to the Microbiology and Anti-infectives Laboratory at Hospital Paris Saint-Joseph, with the dosage request form duly completed with the usual information."
75790149|NCT05364099|Procedure|Suprascapular Nerve Block|This procedure involves injection of a lidocaine and triamcinolone mixture into the suprascapular nerve in the suprascapular notch using ultrasound guidance for proper placement of drugs.
75790150|NCT05358821|Drug|SAGE-718|SAGE-718 oral softgel lipid capsules
75790151|NCT05358821|Drug|Placebo|SAGE-718-matching oral capsules
75790152|NCT05355025|Behavioral|WiserAD|"See Arms"
75790153|NCT05355025|Behavioral|Attention control|"See Arms"
75926306|NCT05503849|Behavioral|Lifestyle modification|This lifestyle modification aiming to provide proactive health management during pregnancy, which contains the following: 1) balanced dietary intake based on the Chinese Dietary Guideline; 2) sufficient physical activity; 3) changes in lifestyles (e.g. sleep, sun exposure etc.)
75926307|NCT05503316|Other|Dynamic balance training|Participants will receive dynamic balance training while walking on the GRAIL device.
75926308|NCT05503316|Other|Traditional gait rehabilitation|Participants will receive traditional gait rehabilitation that also includes balance training while walking but not on the GRAIL device.
75926309|NCT05500976|Other|Semi-controlled dietary intervention - Western|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Western diet foods (eg, beef, potatoes, bread, sour cream) provided during each intervention and will be repeated twice.
75926310|NCT05500976|Other|Semi-controlled dietary intervention - MiniMed|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Mediterranean foods (eg, oatmeal, salmon, nuts, basil, olive oil, fruits) provided during each intervention and will be repeated twice.
76081449|NCT03853122|Other|Best current practice exercise programme|"Therapeutic Physical Exercise programme based on the protocol of Afredson (for Achilles and patellar tendinopathies) and LEAP (for gluteal tendinopathy).~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetitions of two eccentric exercises~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetions of one eccentric exercise~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL: an exercise programme divided into stages with progression in different exercises, volumes and loads"
76081450|NCT03853122|Other|Experimental exercise programme|Therapeutic Physical Exercise programme structured in five stages oriented to specific neuromuscular adaptations based on the characteristics of the neuromuscular system, once daily, three times/week, sets, repetitions and load based on individually performed tests.
76081451|NCT03850782|Drug|Bimatoprost (SR)|"Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR."
75332996|NCT04125680|Behavioral|ESL Health Literacy Classes|The intervention will last 8-weeks, and the first and last classes will be devoted to survey assessments. Participants will be asked to reflect on their health knowledge and behaviors, and how they have changed since starting the program. The curriculum administered during the classes will use pedagogies for health literacy as a practice. It will focus on skills needed to learn about lead exposure in the ESL classroom: (1) vocabulary; (2) grammar; and (3) identifying risk factors, symptoms and preventive strategies. A focus on health literacy as practice will include personal engagement using language in context: (1) role-play interactions about lead exposure prevention; (2) discussing views about risk, and how to talk about it with peers and family members; (3) identifying sources of reliable health information; and (4) learning to ask for support and resources.
75641899|NCT02875379|Procedure|Measurements|Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
75790154|NCT05347485|Drug|Cilta-cel|Cilta-cel will be administered as an IV infusion.
75790155|NCT05347485|Drug|Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)|Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
75790156|NCT05346835|Drug|Cilta-cel OOS Therapy|Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
75790157|NCT05345197|Drug|emicizumab|This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
75790158|NCT05344326|Other|Cognitive Analytic Therapy - Guided Self Help (CAT-GSH)|CAT-GSH is a novel intervention designed to help those with depression by focusing on the relationships within their life. GSH is used in step two of IAPT services and is typically six fortnightly sessions where the PWP helps the service user complete the self help manual.
75926311|NCT05487183|Behavioral|Medoc cutaneous probe|A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH
75926312|NCT05487183|Behavioral|Quantitative sensory testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
75790159|NCT05340478|Behavioral|Intensive Transdiagnostic Cognitive Behavioral Therapy|cognitive behavioral treatment that addresses multiple anxiety problems simultaneously and delivered in a massed format over one weekend
75790160|NCT05334901|Device|High intensity light cure|Bulk fill resin composite restoration cured with high intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
75926313|NCT05487183|Behavioral|Computer tasks|QST and computer tasks are used to measure changes in pain intensity
75926314|NCT05485974|Drug|HBI-2438|KRAS G12C Inhibitor
75926315|NCT05484076|Other|breastfeeding counseling|"A breastfeeding booklet will be created by the researchers by taking expert opinion. This booklet will explain everything about breastfeeding in five sessions.~At 34-38 weeks of pregnancy, the first interviews will be done face-to-face at the hospital. The second interview will be made face-to-face or online, depending on the conditions, in the first 1-5 days after the birth. Subsequent interviews (postpartum 1-4 weeks, postpartum 5-12 weeks, postpartum 13-24 weeks) will be held online. The scales used in the research will be applied twice, before and after the training."
75926316|NCT05457907|Device|Ultrasound device|Low energy ultrasound therapy will be administered to the spleen
75926317|NCT05455658|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given IV
75926318|NCT05455658|Biological|Sargramostim|Given ID
75926319|NCT05450679|Procedure|Cervical Radiofrequency Ablation (RFA)|"During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.~During the motor stimulation testing step, the pain physicians performing the procedure will assess the presence or absence of cervical paraspinal muscle twitching by using a standardized grading scale (per radiofrequency electrode: 0 = no twitches observed or palpated; 1 = twitches palpated but not observed; 2 = twitches observed and palpated at 1-2 levels; 3 = twitches observed at > 2 levels). A total score and a weighted score (total score divided by the number of radiofrequency lesion sites), will be recorded for each patient, and the RFA procedure will be completed per usual practice.~RFAs will be performed in the usual manner and as per standard of care. Providers will not use any new or experimental devices to perform the RFA."
75926320|NCT05449366|Drug|Intraperitoneal Paclitaxel Solution (Ml)|Weekly cycles of intraperitoneal paclitaxel monotherapy
75926321|NCT05447806|Device|Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support|This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
75790161|NCT05332145|Behavioral|MAP to Health|In Phase 1, participants will complete the web-based interview and Aim 1 measures, assessing acceptability and usability of the intervention. The investigators will review whether the intervention appropriately gathers information needed to program theory-based, personalized text messages. After completing the measures, a list of text messages for that participant will be generated and sent to the participant for review. Participants will review the text messages and rate the extent to which the messages are personalized. In Phase 2, the investigators will conduct a proof-of-concept pilot trial in which participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 weeks.
75790162|NCT05331456|Device|Unilateral alveolar cleft repair|Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty
75790163|NCT05318287|Behavioral|Walk with Me|Walk with Me is a perinatal grief mobile application to provide supportive care to bereaved parents. The application includes modules to guide bereaved parents through strategies to help support them through their grieving.
76081452|NCT03846804|Diagnostic Test|Karius Test|Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
76081453|NCT03832686|Other|Virtual Coach|The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.
75471469|NCT05875909|Procedure|corneal flap transplantation|Patients with macular holes underwent a 25-gauge, 3-port pars plana vitrectomy . Fluid-air exchange was performed in patients with pathologic myopia suffering from macular holes with retinal detachment. We used a flute needle to drain the subretinal fluid. A corneal flap was obtained by small incision lenticule extraction (SMILE). Stripping pliers were applied to spread corneal flap over the macular hole. A drop of fresh autologous whole blood was dripped over the corneal flap to immobilise it. The vitreous cavity was filled with 14% perfluoropropane (C3F8) for macular holes with retinal detachment . The surgical incision was self-closed or sutured with a 6-0 polyglactin 910 suture . The patients were instructed to maintain a prone position for 2 weeks postoperatively.
75471470|NCT05875883|Procedure|Neck ultrasound|The investigators will scan patients' necks with an ultrasound and look for anatomical landmarks to identify the phrenic nerve
75471471|NCT05875844|Diagnostic Test|Wrist Splint|Wrist Splint to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
75471472|NCT05875844|Diagnostic Test|Occupational Therapy|Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
75471473|NCT05875831|Behavioral|Active Cycle of Breathing|Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients
75471474|NCT05875831|Diagnostic Test|Coughing|Coughing to Improve Pulmonary Functions in Post-Surgical Patients
75641900|NCT05674591|Behavioral|Cognitive Processing Therapy (CPT)|The CPT therapist will teach the patient about PTSD, depression, and anxiety, and outline the treatment regimen and rationale for its effectiveness. In the initial sessions, women will be asked to express their impact statements on the intimate partner violence to which they had been subjected. Women will be taught how to differentiate between events, thoughts, and emotions, as well as their interrelationships. Thoughts of self-blame and other misconceptions of the situation will be addressed using Socratic questioning. Women will be instructed on how to detect and counteract negative thoughts, as well as how to communicate more effectively. Women will be encouraged to evaluate negative thinking relating to five themes: safety, trust, power/control, self-esteem, and intimacy. During the final sessions, their impact statements on the violence to which they had been subjected will be altered to include emotional and cognitive insights obtained during the CPT.
75641901|NCT01070381|Device|nelfilcon A contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
75790164|NCT05316922|Drug|Levothyroxine|Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.
75790165|NCT05310799|Other|Shared Decision Making (SDM)|The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smart phone.
75790166|NCT05297838|Other|Stationary Bike|Stationary Bike while hand is submerged in ice bath
75790167|NCT05297838|Other|Virtual Reality (VR) Headset|VR headset containing gameplay
75471475|NCT05875818|Diagnostic Test|In-clinic Rehabilitation|Effects of In-clinic Rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
75641902|NCT01070381|Device|ocufilcon D contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
75471476|NCT05875818|Diagnostic Test|Tele-rehabilitation|Effects of Tele-rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
76081454|NCT03826199|Drug|TDF-FTC|We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
76081455|NCT03826199|Behavioral|Counselling on PrEP in antenatal and postnatal care|Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.
76081456|NCT03823534|Drug|Ketorolac|IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.
75641903|NCT04302779|Behavioral|Solid Model|Cupcakes will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating drying and discrimination tests 'which is the stronger in drying'). Measuring mucoadhesion via protein content remaining in saliva samples following consumption of cupcakes.
75471477|NCT05875792|Device|EvolvRehab - MoveWell|The Intervention has been developed and has a CE mark and has medical device level 1 approvals in the UK. It will be developed with patients in Phase 1 and will consist of initial staff training [training package]. Exercise prescription will be encouraged, in line with usual care, for the either one week (stage 1, phase 2) or six weeks (stage 2, phase 2). Individuals will be able to continue using the EvolvRehab - MoveWell system beyond 6 weeks from stage 2, phase 2, and technical support will continue until the end of the study completion, participants will not be limited in the additional activity that can be performed during this time, and encouraged to do as much as they wish, except if needed for clinical reasons. The intervention will be supported by the clinical team in keeping with routine care. The research therapist will attend clinical visits and support as required. The number of visits will be recorded, and will hopefully reduce to zero over the study.
75332997|NCT04392596|Device|Bone Mineral Density and Trabecular Bone score|"structural damage in the cervical and lumbar spine was scored according to the modified Stoke AS Spinal Score (mSASSS) which yielded a final summation score ranging from zero to 72.~BMD was measured using DXA (Lunar Prodigy densitometer, GE Healthcare, Madison, WI, USA).~BMD was measured at the lumbar spine (L1-L4) and the left hip (femoral neck and total proximal femur).~TBS was analyzed using DXA images over exactly the same region as the lumbar BMD assessment (L1-L4). Lumbar spine DXA images were reanalyzed using TBS iNight software version 2.1 (Med-I maps, Merignac, France). Patients were divided in 3 TBS groups according to guidelines for fracture risk [22]: any TBS >1.31 was considered as normal; TBS values between 1.23 and 1.31 were consistent as partially degraded structure; and any TBS <1.23 was considered as degraded structure."
75332998|NCT05394389|Other|sensory stimulating therapy|therapy session in the snoozlen room accompanied by social support.
75332999|NCT05394389|Other|social support|ten minutes of conversing.
75641904|NCT04302779|Behavioral|Liquid Model|To study the perception of whey protein beverages using repeated consumption sensory methods (e.g. rating mouthdrying over repeated sips of the drink).
75641905|NCT00627185|Behavioral|Internet-delivered continuing professional development|Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
75333000|NCT02963948|Behavioral|Meetings with implementation leader(s)|The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.
75471478|NCT05875766|Other|Osteopathy|4 sessions of osteopathy after DIDT surgery
75641906|NCT00627185|Other|No intervention arm|
75641907|NCT02580955|Device|LEGFLOW DCB|
75641908|NCT04078399|Drug|Azacitidine combined with interferon preemptive treatment|Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system
75790168|NCT05297838|Other|Ice Bath|Pain was elicited via a cold pressor test, which is an established method of producing controlled and repeatable painful stimuli in an experimental setting
75471479|NCT05875766|Other|Physiotherapy|Physiotherapy after DIDT surgery (reference treatment)
75641909|NCT04077151|Behavioral|PrEP Demonstration Project|In phase 2, a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth will be developed by incorporates the PK data from phase 1 and data gathered from focus groups and in-depth interviews with young transgender women and transgender men. During phase 3, this intervention will be given to the experimental arm and tested versus a standard-of-care control group.
76081457|NCT03823534|Drug|Normal saline|An IV normal saline placebo prepared by the hospital pharmacy.
75641910|NCT04076995|Other|Water Intake|Increased water intake during the 11 h protocol
75641911|NCT04077229|Behavioral|Intervention arm: Text Message Intervention|Participants will receive a combination of messages promoting both psychological well-being and education /support around health behavior adherence, such as physical activity or diet. In the first part of the study, participants will receive 28 fixed text messages that alternate between physical activity and PP (Positive Psychology) messages. In the second part of the study, participants will first receive a set of 14 pre-selected daily messages that contain a broad range of attributes to allow sufficient participant feedback to clearly identify preferences. After the first 14 messages, new messages will be selected based on the prior preferences of participants.
75641912|NCT02582827|Drug|ABI-011|ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
75641913|NCT05189509|Drug|TNK-Tissue Plasminogen Activator|0.25 mg TNK thrombolysis
76081458|NCT03823534|Drug|Acetaminophen|acetaminophen 500 mg PO Q4 hours PRN for mild pain
76081459|NCT03823534|Drug|Oxycodone Acetaminophen|oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
75471480|NCT05875753|Diagnostic Test|68Ga-FAPI-FS PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-FAPI-FS. The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-FAPI-FS administration."
75333001|NCT02963948|Behavioral|the SAAS survey|Medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS) to gather information about attitudes from medical staff who do not participate in the focus groups, or may be uncomfortable sharing negative attitudes in a group of their peers. The SAAS is a validated multidimensional instrument that evaluates physician attitudes toward substance-using patients. It includes specific measures of attitudes toward permissiveness, treatment intervention, stereotypes, treatment optimism, and moralism, and has been used in prior studies of primary care physicians. Collecting information on staff attitudes toward substance users and substance use interventions will be helpful to inform about any sources for low adoption of the tools, and any needs for additional provider education and training.
75471481|NCT05875714|Drug|Apremilast|Apremilast (Otezla), oral medication Day 1: 10 mg in the morning. Day 2: 10 mg in the morning and 10 mg in the evening. Day 3: 10 mg in the morning and 20 mg in the evening. Day 4: 20 mg in the morning and 20 mg in the evening. Day 5: 20 mg in the morning and 30 mg in the evening Day 6: 30 mg twice daily Maintenance dosing: 30 mg twice daily
75641914|NCT03909061|Behavioral|Wheelchair Maintenance Training|Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.
75798793|NCT01286064|Device|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
76081460|NCT03823534|Drug|Morphine|morphine IV PRN (or other opioid) for severe breakthrough pain
76081461|NCT03823534|Drug|Hydrocodone/Acetaminophen|At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
76081462|NCT03823534|Drug|Oxycodone|Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
76081463|NCT03807440|Drug|Empagliflozin|Empagliflozin
76081464|NCT03807440|Drug|Sodium Glucose Transporter 2 inhibitor|Sodium Glucose Transporter 2 inhibitor
75333002|NCT02963948|Behavioral|Patient surveys|Patient surveys regarding attitudes toward substance use screening and interventions in the primary care clinic will be distributed to patients presenting for care, regardless of whether they completed screening, at regular time periods throughout this study phase. The survey will be conducted for 1 week at the following approximate intervals following successful implementation: 1 month, 4 months, 7 months, and 10 months
76081465|NCT03807440|Drug|Dipeptidyl-peptidase 4 inhibitor|Dipeptidyl-peptidase 4 inhibitor
76081466|NCT03807440|Drug|Glucagon-like peptide 1 agonist|Glucagon-like peptide 1 agonist
76081467|NCT03799874|Drug|Inhaled Carbon Monoxide at 200 ppm|Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
76081468|NCT03799874|Other|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
75333003|NCT03828812|Behavioral|Breakfast promotion|Recommendation of having breakfast daily
75471482|NCT05875688|Other|Cementation Technique A|"Use of adequate amount of cement.~Prevention of wastage of cement.~Retention of crowns for longer duration."
75641915|NCT05182879|Diagnostic Test|Assessement with GERONTOPOLE scale|"The practitionner assesses the frailty of the elderly outpatient with the GERONTOPOLE scale and compares it with the évaluation gériatrique standardisée (GDS)"
75471483|NCT05875688|Other|Cementation Technique B|"Use of Sufficient Cement Quantity.~Keeping cement from going to waste.~Increased time that crowns remain in place."
75641916|NCT04076293|Drug|HM15912|The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
75641917|NCT04076293|Drug|Placebo|The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
76081469|NCT03796884|Drug|Linaclotide|Given PO
76081470|NCT03796884|Other|Placebo|Given PO
76081471|NCT03783403|Drug|CC-95251|Specified dose on specified days
76081472|NCT03783403|Drug|Rituximab|Specified dose on specified days
76081473|NCT03783403|Drug|Cetuximab|Specified dose on specified days
76081474|NCT03774849|Device|PicoWay™ 532nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
76081475|NCT03774849|Device|PicoWay™ 730nm wavelength|PicoWay™ Laser System is picosecond 532/1064/785 laser
76081476|NCT03774849|Device|PicoWay™ 1064nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
75333004|NCT03828812|Behavioral|Nighttime snack reduction|Recommendation of reducing frequency of nighttime snacking
75333005|NCT04393220|Drug|Bevacizumab Injection|15mg/kg (Q3W)
75333006|NCT04393220|Drug|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
75333007|NCT01025453|Drug|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
75333008|NCT04125602|Other|High fat low carbohydrate diet|Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
75641918|NCT03897751|Device|ABT12 Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
75641919|NCT03897751|Device|COMPLETE Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
75641920|NCT03897751|Device|Sensitive Eyes® Rewetting Drops|For use as needed during the study.
75641921|NCT01010126|Biological|Bevacizumab|Given IV
75641922|NCT01010126|Drug|Temsirolimus|Given IV
75641923|NCT04076839|Behavioral|Goal Management Training|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.
75641924|NCT02580487|Procedure|appendicectomy|Appendix was removed either laparoscopically or open surgery
75641925|NCT03892603|Other|Strengthening exercises program|Participants from this group will be given a progressive shoulder strengthening exercises program based on 1 RM that will involve isometric, concentric and eccentric contractions. The exercises will target shoulder internal/external rotators and abductors and the scapular muscles. They will have to exercise every other day for 12 weeks. At each session with the therapist (6 over a 12 week period), strength will be reassessed and the program will be progressed accordingly. Any questions or concerns will also be addressed and participants will be requested to complete a paper based or digital record of their exercise participation.
75641926|NCT03892603|Other|Motor control exercises program|Each session will start with a series of clinical tests that will look at the influence of different corrections to alleviate symptoms during upper limb movements.The tests will be performed in a sequential format through four key areas: thoracic repositioning, scapula facilitation, humeral head procedures and neuromodulatory techniques. If a correction reduces pain, that technique will then be performed as exercises and incorporated into the participant's functional movement. In addition, motor control exercises during arm elevation, progressed through a standardized 6-phase retraining sequence, will be executed. Retraining phases will be graded according to: 1) resistance applied on the shoulder; and 2) use or non-use of feedback. Once participants reach pain free execution, the program will be progressed into re-education exercises according to the participants' work, sport and activities of daily living and will incorporate activities involving the upper and lower limbs.
75798794|NCT01286064|Device|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
75926322|NCT05444855|Other|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liaison via text messages throughout the study.
75926323|NCT05440214|Behavioral|Dialectical Behavior Therapy Skills Training|Dialectical Behavior Therapy Skills Training (DBT-ST) is a group-based intervention focused on teaching skills for improving emotion regulation. The sessions will be offered in-person or via approved telehealth services.
75926324|NCT05423262|Biological|TRK-950|Intravenously over 60 minutes
75926325|NCT05422248|Device|Series Topical Oxygen Therapy|Standard care provided to the whole wound followed by intervention device care to the whole wound.
75926326|NCT05422248|Device|Paired Topical Oxygen Therapy|Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
75926327|NCT05415462|Biological|mRNA-1010|Sterile liquid for injection
75926328|NCT05415462|Biological|Licensed quadrivalent inactivated seasonal influenza vaccine|Sterile suspension for injection
75926329|NCT05413135|Drug|ARO-APOC3|ARO-APOC3 Injection
75926330|NCT05411523|Other|Quality-of-Life Assessment|Complete quality of life assessment
75926331|NCT05411523|Other|Questionnaire Administration|Complete questionnaires
75926332|NCT05411523|Procedure|Spinal Cord Stimulation|Receive spinal cord stimulation therapy
76081477|NCT03770338|Drug|Teriparatide|20ug dosage daily injection, 1-month preoperative
75333009|NCT04125602|Other|Low fat high carbohydrate diet|Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
75333010|NCT05394311|Other|sports based mental health promotion program|sports related programs
75333011|NCT03824054|Procedure|colorectal resection|Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
75471484|NCT05875688|Other|Cementation Technique C|"The utilisation of an appropriate quantity of cement.~The mitigation of cement waste.~Prolonged retention of dental crowns."
75471485|NCT05875675|Drug|Drug: Pioglitazone Oral Tablet|Dietary Supplement: Pioglitazone 30 mg by mouth daily
75471486|NCT05875675|Dietary Supplement|Placebo|Dietary: Supplement: Placebo
75471487|NCT05875610|Drug|Venlafaxine 75 MG|Venlafaxine 75 mg extended release capsules for a 7-days duration
75333012|NCT05394233|Drug|Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed|Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks, Pemetrexed, 500 mg/m2, intravenously every 3 weeks, Tislelizumab, 200 mg IV every 3 weeks
75641927|NCT03892603|Other|Education and advice|Each participant will be given written information about the shoulder (anatomy and function), basic pain science and will be directed to the Internet to watch a series of carefully selected educational videos. Comprehensive written advice will include: Information about the shoulder and the condition; Pain neuroscience; Activity modification (when to increase and decrease); Pain management (night and day); A series of educational videos to watch with 2 questions to answer per video: a) what was the most important message? and b) was there anything you didn't understand in the video?
75333013|NCT03824210|Other|App|Mobile phone app
75641928|NCT05380141|Behavioral|Individual patient interviews|"Two individual interviews, of one hour duration, will take place for each patient before the beginning of participating to the workshops and in the month following the end of the workshops.~They will be led by a psychologist and a nurse from the functional pain and palliative medicine unit of Necker Hospital and 3 questionnaires will be completed during each interview."
75641929|NCT04137835|Device|Showmotion|Each healthy volunteers will wear sensors at the interested joint and do the measurement.
75641930|NCT04381195|Diagnostic Test|REALS Development|Complete drafting of an item pool (adults with ASD, parents, adult service providers); Assign items to all parts of our conceptual framework to ensure sufficient construct coverage across employment, social, and independent living domains; and Conduct cognitive interviews with 25 caregivers of adults with ASD and 25 self-reporting adults with ASD.
75641931|NCT04381195|Diagnostic Test|REALS Testing|A national sample of proxy reporters (e.g., parents, clinicians, group home staff) for 1000 autistic adults and self-reporting autistic adults and adults with other IDD will complete the REALS draft items and a co-calibration battery to establish psychometrics, generate short-forms, and ensure applicability across adults with ASD.
75641932|NCT04076137|Other|Targeted T-cell armed with bispecific antibody (Decitabine)|In this study, 10 patients eligible for the study were clinically screened for intravenous infusion of targeted activated T cells,every participant has a unique identification number and emergency letter which have the information of group.
75641933|NCT03879577|Drug|Docetaxel|Administered to all patients for a minimum of 4 cycles for 12 weeks.
75333014|NCT03823976|Other|Types of the dental procedures in general anaesthesia|Analysis of the mean number of preventive, prophylactic, therapeutic and rehabilitation procedures
75641934|NCT03879577|Drug|Herceptin|Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.
75790169|NCT05286983|Behavioral|Family Centred Care (FCC) interventions as potentially better practices (PBPs)|"After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness"
75333015|NCT00982553|Drug|Ribavirin|800mg once daily
75333016|NCT00982553|Drug|Raltegravir|400mg twice daily
75333017|NCT03823898|Behavioral|Supervised exercise|Two supervised exercise sessions per week from months 4 to 16
75333018|NCT03823898|Behavioral|Lifestyle intervention from baseline to 4 months|Lifestyle intervention from baseline to 4 months
75641935|NCT03879577|Drug|FEC|Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
75333019|NCT03823898|Behavioral|Monthly behavioral sessions|Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study
75333020|NCT02945384|Behavioral|Creating Connections: Strong Families, Strong Brains|Dual-generation intervention
75641936|NCT03879577|Drug|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
75333021|NCT02939300|Drug|Nivolumab|"Melanoma:~- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.~Non-small Cell Lung Cancer / Head and Neck Cancer:~- Combination therapy with Nivolumab 3 mg/kg~Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 240 mg per cycle.~Renal Cell Carcinoma / Other Solid Tumors (not listed above):~Combination therapy with Nivolumab 3 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle."
75471488|NCT05875610|Drug|Gabapentin 400 mg|Gabapentin 400 mg capsules
75333022|NCT02939300|Drug|Ipilimumab|"Non-small Cell Lung Cancer / Head and Neck Cancer:~- Combination therapy with Ipilimumab 1 mg/kg~Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~- Combination therapy with Ipilimumab 3 mg/kg for 4 doses~Renal Cell Carcinoma / Other Solid Tumors (not listed above):~Combination therapy with Ipilimumab 3 mg/kg for 4 doses"
75333023|NCT03823664|Diagnostic Test|Cardiorespiratory Fitness|Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
75333024|NCT03823508|Device|anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.
75641937|NCT03879577|Drug|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
75926333|NCT05400161|Behavioral|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. Investigators will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
75641938|NCT03879577|Drug|LHRH agonist|Administered to all premenopausal patients.
75641939|NCT03875209|Biological|10E8.4/iMab|bispecific monoclonal antibody
75790170|NCT05275023|Drug|JNJ-73763989|JNJ-73763989 will be administered subcutaneously.
76081478|NCT03767231|Diagnostic Test|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|The investigators will randomly assign eligible and consented patients to either to HCV POC VL Group or Reference Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the HCV POC VL Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 1 to 1½ hours of the testing.
76081479|NCT03761706|Behavioral|Engagement in Physical Activity|Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.
75333025|NCT03823508|Device|sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
75641940|NCT03869515|Other|No intervention|It's an observational study, so no intervention will be carried out.
75641941|NCT05325541|Device|Visual Biofeedback Therapy|Visual Biofeedback intervention will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
75641942|NCT05325541|Behavioral|Conventional Balance exercise|Conventional Balance exercises will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
75333026|NCT02910986|Behavioral|Written educational brochure|Written educational brochure about breast density
75333027|NCT02910986|Behavioral|Promotora interaction|Promotora education about breast density
75333028|NCT03822260|Diagnostic Test|Bezmialem VAkif Unv. Ethical board|If ıs any trials not convenient to Helsinki Agrement about Human research rules
75333029|NCT04392128|Drug|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine is an anti-malarial drug also used as anti-inflammatory treatment for systemic lupus erythematosus and rheumatic disorders. HCQ also inhibits pH-dependant replication stages of diverse types of viruses including flavivirus, retrovirus and coronaviruses.
75641943|NCT03837379|Behavioral|Treatment as Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
75790171|NCT05275023|Drug|PD-1 inhibitor|PD-1 inhibitor will be administered as IV infusion.
76081480|NCT03761706|Other|Questionnaires|Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
76081481|NCT03746522|Drug|Setmelanotide|SC injection of setmelanotide
76081482|NCT03746522|Drug|Placebo|SC injection of placebo
75641944|NCT03837379|Combination Product|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
75641945|NCT00617877|Drug|losartan potassium|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
75790172|NCT05275023|Drug|Tenofovir Disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
75333030|NCT04392128|Drug|Azithromycin 250 MG Oral Capsule|Azithromycin is amacrolide antibiotic.
75333031|NCT04392128|Drug|Placebo oral tablet|Placebo of Hydroxychloroquine Sulfate 200 MG [Plaquenil].
75333032|NCT04392128|Drug|Placebo oral capsule|Placebo of Azithromycin capsules.
75790173|NCT05275023|Drug|Tenofovir Alafenamide|TAF film-coated tablets will be administered orally.
75790174|NCT05275023|Drug|Entecavir|ETV film-coated tablets will be administered orally.
75790175|NCT05273151|Device|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
75790176|NCT05267132|Behavioral|Other-Focused Acts of Kindness Intervention with Reflection|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine. Participants will then reflect on their kind acts after each week.
75333033|NCT03822026|Other|Hyperventilation test|Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
75333034|NCT04125056|Drug|Hydronidone Capsule(Specification: 30 mg / grain）|Test group
75641946|NCT00617877|Drug|Comparator: Hydrochlorothiazide|Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
76081483|NCT03715712|Other|standardized blood pressure management|Standardized blood pressure management of a mean blood pressure > 65mmHg and a systolic blood pressure of < 160mmHg using norepinephrine continuous infusion
75790177|NCT05267132|Behavioral|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
75926334|NCT05400161|Behavioral|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. Investigators will organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily and provides feedback to participants. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed and counts of sessions viewed and comments posted. Participants randomized to the intervention will also have the option to take part in a preliminary virtual session through a secure video platform (e.g. BlueJeans) and will receive weekly engagement text messages. Women in the intervention group will be enrolled in the online depression treatment program, MoodGym.
76081484|NCT03715712|Other|Individualized blood pressure management|Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
75926335|NCT05395494|Drug|D-Cycloserine|"Daily oral D-cycloserine 100mg during TMS treatments (20 days).~Other Names:~Seromycin"
76081485|NCT03710161|Drug|Vitamin D|Vitamin D taken in two different dosages daily for six months.
75333035|NCT04125056|Drug|Hydronidone Capsule(Specification: 15 mg / grain）|Control group
75641947|NCT04076215|Behavioral|Stressogenic stimulus|Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting
75641948|NCT04076215|Device|Biobeat smart watch and adhesive biosensor patches.|Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.
75641949|NCT00617955|Drug|Aprotinin|compare outcomes of Aprotinin versus Amicar
75641950|NCT00617955|Drug|Amicar|compare outcomes of Aprotinin versus Amicar
75926336|NCT05395494|Drug|Placebo oral tablet|Daily oral placebo during the TMS treatments (20 days).
75641951|NCT05324007|Other|Basic Science|This is a basic science experiment to test whether infants' looking time to video stimuli differ according to the race of the individuals shown.
75641952|NCT02582437|Other|History for opioid use|
75790178|NCT05267132|Behavioral|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
75926337|NCT05395494|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
75333036|NCT02565186|Drug|Lasmiditan|oral tablet
75641953|NCT00618033|Procedure|Hemodialysis|varying concentration of glucose in dialysate
75790179|NCT05265039|Behavioral|Cognitive Processing Therapy|An evidence-based treatment for posttraumatic stress disorder (PTSD)
75790180|NCT05265039|Behavioral|Relaxation Training|Guided relaxation
75926338|NCT05394064|Genetic|SBT101|SBT101 Treatment
75641954|NCT04213131|Other|Stem cell transplantation|The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.
75641955|NCT05674201|Combination Product|Propofol-Dexmedetomidine|Propofol-Dexmedetomidine AND Propofol-Remifentanil
75641956|NCT01070303|Biological|Adalimumab 40 mg eow or ew|Adalimumab 40 mg by subcutaneous injection every other week or every week
75641957|NCT00618111|Drug|Granisetron|
75790181|NCT05262517|Drug|Rimegepant|75 mg ODT
75790182|NCT05262517|Drug|Placebo|matching placebo
75926339|NCT05394064|Procedure|Imitation Procedure|Procedure that mimics SBT101 infusion, but contains no drug administered
75926340|NCT05393297|Diagnostic Test|Imaging: Intra-treatment FDG-PET-CT and MRI|FDG-PET-CT and MRI scan will be used during radiotherapy to assess early treatment response and identify tumours eligible for dose-escalation.
76081486|NCT03709667|Behavioral|EX|An individualized aerobic and resistance-exercise program will be developed for each participant on the basis of a maximal incremental exercise test and strength assessments performed at baseline. This test will measure aerobic capacity (VO2 max) and the metabolic or lactate threshold (VO2θ) (i.e., the level of O2 uptake that defines one's ability to perform prolonged work), using indirect calorimetry with an automated metabolic-measurement system. The intervention will comprise 24 sessions over 8 wk (3x/wk), supervised by a credentialed exercise specialist. Each session will consist of a 5-min warm-up, 30-40 min of aerobic activity on a treadmill, 15-20 min of resistance training, and a 5-min cool-down.
75333037|NCT03823352|Drug|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
75641958|NCT01009814|Drug|BMS-663068|BMS-663068 will be administered as a tablet formulation
75641959|NCT01009814|Drug|Ritonavir|Ritonavir will be administered as a capsule.
75790183|NCT05261126|Drug|MK-0616|MK-0616 administered orally
75790184|NCT05261126|Drug|Placebo|Placebo matching MK-0616 administered orally
75790185|NCT05258448|Other|Chemoradiotherapy|Cardiac Magnetic Resonance scan and ECG
75790186|NCT05247203|Biological|Telitacicept|subcutaneous injection
75641960|NCT04212819|Other|Before Erythrocyte Suspension (ES)|ES transfusion needs of the patients were determined according to clinical signs and symptoms. Vital signs were closely monitored and recorded before, during and after transfusion. Infusion was performed slowly for the first 15 minutes in terms of allergic reaction, and then the transfusion rate was adjusted according to the patient's clinic.
75333038|NCT03823586|Diagnostic Test|Questionnaire AQUA©, pediatric version|A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
76081487|NCT03709667|Behavioral|CON|Participants attend 50-min sessions 3x/wk matched to EX for staff contact. A counselor will facilitate integrative group discussions, and will conduct a multimedia program addressing various health, wellness and lifestyle topics, such as nutrition, dental care, stress relief, sleep hygiene, relationships, immunizations, health screening, smoking, environmental health, and time management.
76081488|NCT03709277|Behavioral|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
75333039|NCT04124978|Device|mandibular advancement device|use of prefabricated adjustable mandibular advancement device to improve OSA
75333040|NCT04758494|Other|Questionnaire|"In the present study a questionnaire was designed by combining three separate questionnaires, which were weighted for use in Greek population and which are often being used to investigate quality of life of young populations diagnosed with stroke or multiple sclerosis, according to international literature. Those were the following questionnaires: Bathrel (Mahoney et al), Patient Health Questionairre (PHQ-9) (Thomson K et al), Health Survey SF-12 (Kontodinopoulos et al 2007). A draft questionnaire was then created with the addition of questions deemed necessary to provide necessary research information. Overall the questionnaire consisted of 42 questions.~Part A The first part of the questionnaire included demographics of participants. Part B. The second part of the questionnaire included an assessment of the functionality and independence, an evaluation of experienced depression and an assessment of the quality of life of the target population."
75333041|NCT04274504|Diagnostic Test|Osteopontin|Serum osteopontin (OPN) was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.
75641961|NCT04212819|Other|After Erythrocyte Suspension (ES)|Venous blood samples were obtained from patients who needed ES transfusion before transfusion. Control venous blood samples were obtained from the patients who did not develop any complications for 24 hours after starting of the transfusion and became hemodynamically stable.
75641962|NCT04212741|Dietary Supplement|A+ HA(tm)|oral solution of hyaluronic acid mixture
75790187|NCT05247203|Drug|standard therapy|A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
75641963|NCT04212741|Dietary Supplement|Placebo|oral solution with no-active ingredients
75641964|NCT03824587|Drug|Tenapanor|Active Drug
75641965|NCT03824587|Drug|Placebo|Inactive Drug
75641966|NCT03824587|Drug|Phosphate Binder Agents|standard of care phosphate binder use at study entry was maintained throughout the entire study
75926341|NCT05393297|Radiation|Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation|Tumours eligible for dose-escalation (boost), as seen on intra-treatment FDG-PET-CT and MRI scan, will receive 76.9 Gy to the residual gross primary tumour. The radiotherapy plan will be replanned to incorporate the simultaneous-integrated-boost to the GTVp which will be delivered over the last 3 weeks of treatment
75641967|NCT00773734|Drug|Apremilast 10mg|
75641968|NCT00773734|Drug|Apremilast 20mg|
75641969|NCT00773734|Drug|Apremilast 30 mg|
75641970|NCT00773734|Drug|Placebo|
75641971|NCT00773734|Drug|Apremilast 30mg|
75641972|NCT00773734|Drug|Apremilast 20mg|
75790188|NCT05245006|Drug|89Zr-DFO-YS5|3 mCi will be administered intravenously
75790189|NCT05245006|Biological|YS5 antibody|20 or 50 mg administered intravenously
75790190|NCT05245006|Procedure|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging which combines a CT scan and a PET scan
75790191|NCT05245006|Procedure|Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)|Imaging which combines an MRI scan and a PET scan
75790192|NCT05242640|Other|Mindful attention|Participants will listen to mindful attention audio recordings via headphones
75926342|NCT05389995|Drug|Potassium citrate|7 days potassium citrate followed by 24 hour urine collection
75790193|NCT05242640|Other|Exercise|Participants will complete a moderate-intensity walking program
75926343|NCT05389995|Drug|Crystal light|7 days crystal light followed by 24 hour urine collection
75790194|NCT05242640|Other|Exercise with mindful attention|Participants will complete a moderate-intensity walking program while listening to mindful attention audio recordings via headphones
75926344|NCT05389995|Drug|Potassium citrate + crystal light|7 days potassium citrate + crystal light followed by 24 hour urine collection
75926345|NCT05389787|Device|Transcranial Magnetic Stimulation|The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is ~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.
75926346|NCT05386238|Behavioral|Standard behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts. The intervention will focus on changes to eating, physical activity, and self-monitoring.
76081489|NCT03692494|Other|Standard of care voice therapy|Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
75333042|NCT04274816|Drug|Tremelimumab|Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
75641973|NCT04502888|Drug|Drug: SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
75641974|NCT02871206|Biological|Fluad|
75790195|NCT05235659|Behavioral|Basic modules|Caregivers will only have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child.
75790196|NCT05235659|Behavioral|"Basic modules and experimental condition My coach"|Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Professional support of the caregiver will be provided. Caregivers will receive one phone call (50 minutes) to support processing of information from module 1 and 2. Finally, they will receive text messages or emails with the core message of the modules.
75790197|NCT05235659|Behavioral|"Basic modules and experimental module Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
75926347|NCT05386238|Behavioral|Tailored behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts or videos tailored to men working in blue-collar occupations. The intervention will focus on changes to eating, physical activity, and self-monitoring.
75926348|NCT05374304|Other|Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool|The BC/WC framework guides clinicians to present a choice between two options and uses scenario planning (narrative descriptions of plausible outcomes that acknowledge uncertainty) to describe the best, worst, and most likely case for each option. Scenarios are informed by clinical judgement and knowledge of patient risk factors. These scenarios plus an accompanying graphic aid help patients formulate and express preferences and concerns about treatment burdens and outcomes. The clinician then provides a goal-concordant recommendation.
75641975|NCT02871206|Biological|Fluzone|
75926349|NCT05371873|Procedure|Liver resection method|undergo anatomical or non-anatomical resection of liver cancer
75926350|NCT05351580|Device|DiSCERN|Smart watch Monitoring
75926351|NCT05341310|Behavioral|ADHDCoach|ADHDCoach is an individually-tailored intervention to reduce parents' of children diagnosed with ADHD distress.
75333043|NCT05509374|Drug|Carfilzomib 56 MG [Kyprolis]|Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)
75333044|NCT05509374|Drug|Pomalidomide|Pomalidomide 4 mg per os (Day1-21)
75333045|NCT05509374|Drug|Dexamethasone|Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
75333046|NCT04675554|Other|Follow up of physical activity|participants will fill in the non-opposition form via the application and will complete, with their smartphone, a series of psychometric questionnaires. Participants will then use the mobile application for a period of 12 weeks during which time, physical activity data provided from participants smartphone will be gathered After 12 weeks, participants will complete again the same series of psychometric questionnaires.
75333047|NCT04124744|Other|Health Champions intervention|Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week
75641976|NCT04297202|Drug|Apatinib Combined With SHR-1210 Injection|"3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle: D1、D15、D31 : SHR-1210 200mg, I.V, q2w； D1-D20 : Apatinib 250 mg, orally, qd; D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation; After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. Three weeks is a treatment cycle with a total of 8 cycles~In each cycle:~D1: SHR-1210 200mg, I.V, q3w; D1-D21: Apatinib 250mg, orally, qd;"
75641977|NCT02582281|Device|intrauterine device TCu 380A|
75641978|NCT02237469|Radiation|Prone and supine simulation|Treatment planning in the two positions.
75641979|NCT04297982|Other|Mandala Activity|Mandala is a method of expressing one's feelings and thoughts. The person draws and paints the paper in a round shape.
75641980|NCT04297982|Other|Routine nursing care|Interventions routinely implemented by nurses in the clinic
75641981|NCT02691897|Drug|Melatonin|Melatonin 3mg once daily at bedtime
75641982|NCT02691897|Drug|Placebo|Placebo 1 tablet once daily at bedtime
75641983|NCT04373473|Drug|PRIM-DJ2727|Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
75641984|NCT04373473|Drug|Placebos|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
75641985|NCT03067155|Genetic|CMV-specific T cells|
75641986|NCT03067155|Drug|Standard anti-viral therapy|Continue with the anti-viral treatment as per standard of care.
75333048|NCT04124744|Other|Control group-treatment as usual|Participants will receive treatment as usual from their Community Mental Health Team
75641987|NCT03498001|Drug|GLP-1 agonists|Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg
75926352|NCT05341310|Other|Treatment as usual|Treatment as usual in the outpatient clinic
75641988|NCT03498001|Procedure|Cardiac MRI|T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides ([TG] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).
75641989|NCT03498001|Other|Follow up by phone|at 2 and 4 mois
76081490|NCT03692494|Other|Expiratory muscle strength training (EMST)|EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
76081491|NCT03689049|Procedure|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
76081492|NCT03689049|Procedure|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
75333049|NCT04124822|Drug|Piroxicam 20 mg|Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels
75790198|NCT05235659|Behavioral|"Basic modules and experimental modules Who am I and where do I belong? and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 5. Finally, they will receive text messages or emails with the core message of the modules."
75333050|NCT04124822|Drug|prednisolone 20 mg|prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
75333051|NCT01453790|Behavioral|Parent-Specific Depression Education and Motivation|Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
75641990|NCT04075669|Diagnostic Test|Multiplex Strip PCR|Corneal scraping from patients will have its DNA extracted and eluted in the buffer. The DNA than mixed with the primer strips tube and be analyzed in Real-Time PCR machine. According to the record information from the hospital, the pathogen that usually found from endophthalmitis, keratitis, corneal ulcer diseases in our hospital is Pseudomonas sp., Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter sp., Pseudomonas aeruginosa, Acanthamoeba sp., Aspergillus fumigatus, Aspergillus flavus, Fusarium sp., and Candida albicans. And based on the report from Zhao et al (2014) Herpes Simplex Virus may be detected from patients with keratitis. Therefore in this study, we are trying to detect all of the pathogens simultaneously using the real-time PCR assay from patients corneal scraping who experience eye infections as mention above.
75926353|NCT05341297|Behavioral|ParentKIT|The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
75333052|NCT01453790|Behavioral|General Depression Education-Motivation|General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
75926354|NCT05338333|Device|Lehfilcon A multifocal contact lenses|Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia
75333053|NCT04802226|Other|self exclusion procedure|self exclusion procedure( responsible gambling tool)
75641991|NCT04214223|Other|Pre-Anesthesic Consultation|Classical Pre-Anesthesic Consultation with an anesthesist of the maternity hospital of Nancy (France)
75790199|NCT05235659|Behavioral|"Basic modules and experimental module You are safe here"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
75926355|NCT05338333|Device|Lotrafilcon B multifocal contact lenses|Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia
75926356|NCT05338333|Device|CLEAR CARE®|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
75926357|NCT05338268|Behavioral|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth.
75926358|NCT05338268|Behavioral|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
75926359|NCT05337618|Diagnostic Test|Full-band Electrocorticography|Diagnosis of spreading depolarizations in continuous electrocorticography
75926360|NCT05337618|Combination Product|Treatment Algorithm|Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations
75926361|NCT05336864|Other|Non-invasive cerebral oximetry monitoring|"Main study (all patients): Continuous bilateral frontal cerebral near-infrared spectroscopy (NIRS) monitoring will be performed in all patients for the duration of general anesthesia. Intraoperative parameters including NIRS and invasive blood pressure will be collected and recorded in real-time using the software ICM+.~Postoperative hemodynamics substudy (facultative): Cerebral NIRS monitoring will be continued postoperatively in a subset of patients being admitted to the ICU."
76081493|NCT03682536|Drug|Luspatercept|Specified dose on specified days
76081494|NCT03682536|Drug|Epoetin alfa|Specified dose on specified days
75790200|NCT05235659|Behavioral|"Basic modules and experimental modules You are safe here and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 4. Finally, they will receive text messages or emails with the core message of the modules."
76081495|NCT03670316|Drug|Algorithm Treatment|Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
76081496|NCT03670316|Other|Quitline only|eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
76081497|NCT03596801|Biological|RSV 6120/∆NS1|Delivered as nose drops
76081498|NCT03596801|Biological|RSV 6120/F1/G2/∆NS1|Delivered as nose drops
76081499|NCT03596801|Biological|Placebo|Delivered as nose drops
76081500|NCT03570892|Drug|Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
75926362|NCT05336864|Other|additional perioperative blood sampling|"Main study (all patients): Creatinine, high-sensitivity troponin (T hs-cTnT), Growth/Differentiation Factor-15 (GDF-15), Hemoglobin~Neurological injury substudy (facultative): Neurofilament Light Chain (NFL)"
75926363|NCT05336864|Other|clinical & telephone assessments|Main study (all patients): Telephone follow-up (1-year MACE).
75926364|NCT05336864|Other|Non-invasive somatic oximetry monitoring|Tissue perfusion substudy (facultative): Continuous somatic NIRS monitoring of an extremity (i.e. on skin of leg or arm) will be performed intraoperatively and postoperatively in a subset of patients being admitted postoperatively to the ICU.
76081501|NCT03570892|Drug|Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)|"Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.~*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy"
75641992|NCT04214223|Other|Pre-Anesthesic Numerical Evaluation|Home-based Pre-Anesthesic Numerical Evaluation with the aid of a questionnaire, achieved with a computer, digital tablet or smartphone, on a secured platform.
76081502|NCT03498378|Drug|Avelumab|Avelumab (IV on days 1 and 15 of 28 day cycle)
76081503|NCT03498378|Drug|Palbociclib|"Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day."
76081504|NCT03498378|Drug|Cetuximab|"Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min."
75333054|NCT05504694|Drug|Ofatumumab|"The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion."
75333055|NCT02854670|Drug|Capsaicin patch|After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
75333056|NCT05509296|Device|SINOMED CBC|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
75641993|NCT01009580|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
75641994|NCT01009580|Drug|biphasic insulin aspart 30|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
75926365|NCT05335668|Procedure|Clinical Testing|Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
75471489|NCT05875597|Other|Physical therapy exercise programme|Carrying out a programme of therapeutic physical exercise for 12 weeks, twice a week for 45 minutes.
75926366|NCT05334433|Procedure|Local anesthesia injection|Local anesthesia administration
76081505|NCT03493165|Drug|Everolimus|mTOR inhibitor
76081506|NCT03478956|Drug|Etrolizumab|Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
75641995|NCT04101604|Other|Collection of blood samples|Collection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.
75641996|NCT05268393|Behavioral|BREATHE-T1D|BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.
76081507|NCT03477110|Drug|Temozolomide|Given PO
76081508|NCT03477110|Radiation|Radiation Therapy|Undergo radiation therapy
75471490|NCT05875571|Drug|Ketorolac|Patients will get IV ketorolac during IUD placement under sedation
75471491|NCT05875571|Drug|Placebo|Patients will get IV placebo during IUD placement under sedation
75471492|NCT05875558|Procedure|M-TACE|Lipiodol combined with microspheres
75641997|NCT04212897|Other|Music Therapy|"Participants in the intervention arm will be asked to practice a rhythmic auditory synchronous finger tapping intervention task at home for a total of 25 minutes split between two ten-minute sets with a five-minute break between the sets every day for 8-weeks. During training sessions participants must listen to the instrumental of a pre-selected well-known Chinese melody, Moonlight over the Lotus Pond by Phoenix Legend, whose melody duration is 259s. This song was selected for its strong beat and familiarity to the participants. Participants must follow the beats of the melody and tap their right index finger simultaneously to the beats. A visual cue will be displayed to indicate the beats, identical to the one in the assessment. The training session will be conducted once daily after patients have taken their medication. Participants' primary caretaker will be asked to monitor and record completion of sessions."
75641998|NCT04103242|Other|16s rRNA gene sequencing|High-throughput sequencing of the microbial 16s rRNA subunit to define the abundance of microbial phyla and genera
75790201|NCT05235659|Behavioral|"Basic modules and experimental modules You are safe here and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
75926367|NCT05332769|Genetic|FLIM parameters|Cumulus samples (CCs) will be collected following the protocol on the day of oocyte pick up (OPU). CCs are frozen by the cryo-tech method, then stored in liquid nitrogen at -196oC. Information of CC samples and processed date/time is recorded. After all, samples are collected, they will be transferred to The Needleman Lab, Northwest Lab Building 359,52 Oxford Street Cambridge MA 02138 to measure mitochondria metabolism using FLIM.
75926368|NCT05327309|Drug|Bleomycin|
76081509|NCT03477110|Device|NovoTTF-200A Device|Undergo tumor treatment fields therapy using NovoTTF-200A device
76081510|NCT03477110|Procedure|Tumor Treating Fields Therapy|Undergo tumor treatment fields therapy using NovoTTF-200A device
76081511|NCT03475043|Behavioral|Auditory training: temporal cues|Behavioral training for 6-9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.
76081512|NCT03467113|Drug|ZX008 0.2 to 0.8 mg/kg/day|ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
75471493|NCT05875545|Other|Breathing Exercises|Diaphragmatic breathing exercises with a physiotherapist for 8 weeks, two days a week
75471494|NCT05875545|Other|Pelvic Floor Exercises|Pelvic floor exercises with a physiotherapist for 8 weeks, two days a week
75471495|NCT05875519|Drug|Local anaesthesia with vasocontrictor (Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg)|Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg
75471496|NCT05875480|Procedure|synchronized telerehabilitation|In the synchronized telerehabilitation group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. after 2 weeks, they were treated 2 days a week until the 6th week by meeting with the physiotherapist in real time via the Albert Health Assistant application. In the remaining days, they were asked to follow the exercise videos uploaded to the Albert system, it will be checked whether they have done the daily exercises, and a daily reminder message will be sent through the system.
75641999|NCT01009346|Drug|RAD001|"Dose Level -1 2.5mg/day~Dose Level 1 5mg/day*~Dose Level 2 10mg/day~MTD RAD001"
75926369|NCT05318794|Drug|Doxorubicin and Cisplatin|Pressurised intraperitoneal aerosol chemotherapy
76081513|NCT03467113|Drug|Cannabidiol|Cannabidiol
76081514|NCT03465098|Other|Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT|The patients will receive 2 PET/CT , first exam with standard diet preceded by 12h fasting and second exam preceded by 3 meals strict low diet and 12h fasting
76081515|NCT03415828|Device|Ethanol gel|Intradiscal injection of ethanol gel
75471497|NCT05875480|Procedure|asynchronized telerehabilitation|The exercise program for the asynchronized telerehabilitation group will be uploaded to the Albert Health Assistant in the form of 2-week programs in video form from the first Day. Whether the patients apply these videos on a daily basis will be checked through the system, a message reminding the daily routine exercise program will be sent through the system.
75642000|NCT01009346|Drug|Cetuximab|250mg/m2/week
75642001|NCT01009346|Drug|Cisplatin|40mg/m2 Day 1, 8 every 28 days
75926370|NCT05315752|Procedure|Bariatric surgery|"Bariatric surgery includes (but is not limited to)~Gastric bypass: surgical bypass of the entire stomach, duodenum and approximately 1 m of the proximal small intestine~Sleeve: a large part of the stomach is removed laparoscopically, the open vertical edges are put back in place to leave a sleeve-like tube.~Bariatric surgery is considered a treatment option~for patients with a BMI >40 kg/m 2 , assuming the patient has previously participated successfully in a group weight management programme (weight loss >7%) or~for patients with a BMI of 35-40 kg/m 2 when the obesity is associated with type 2 diabetes or hypertension, or OAS (with CPAP therapy) or severe musculoskeletal disease"
76081516|NCT03415828|Drug|Prednisolone acetate|Intradiscal infiltration of steroids
76081517|NCT03356886|Procedure|Spinal Manipulative Technique|1) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
76081518|NCT03356886|Behavioral|Pain Neuroscience Education|All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
76081519|NCT03347760|Drug|DOTATOC-68Ga PET initial|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
76081520|NCT03347760|Drug|DOTATOC-68Ga PET at 6 months|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
76081521|NCT03347760|Biological|blood sample|blood tests will be carried out during the control visit to ensure that biological parameters are normalized
76081522|NCT03347110|Drug|Bimekizumab|Bimekizumab at a prespecified dose.
76081523|NCT03345576|Device|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
76081524|NCT03345576|Drug|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
76081525|NCT03343236|Radiation|Radiotherapy|All patients will undergo radiotherapy or surgery, or combined modality treatment
76081526|NCT03332303|Drug|Estrace® Cream|Estrace® Cream
75333057|NCT05509296|Device|NSE Coronary Dilatation Catheter|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
75333058|NCT01453868|Other|Non Impact Aerobics|a 12 week, twice a week class in non impact aerobics
75333059|NCT01453868|Other|Passive : lecture series|a 12 week, once a week for one hour lecture series with no exercise. Topics will cover symptom management in Multiple Sclerosis
75333060|NCT05509140|Other|observation|investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis
75642002|NCT01009346|Drug|Carboplatin|"Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance."
75798795|NCT03864354|Procedure|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a cost-effective, noninvasive treatment that is used to optimize the body's structure and function. By improving the biomechanical, autonomic, and circulatory mechanisms involved in the disease process of asthma, OMT can help maximize respiratory function. The specific OMT protocol used in this study included the following: supine OA joint myofascial release (MFR), supine cervical spine Still technique, supine thoracic inlet MFR, supine rib raising soft tissue, supine rib MFR, supine abdominal diaphragm MFR, seated thoracic spine Still technique, and seated posterior rib Still technique. Treatments were performed by Predoctoral Osteopathic Manipulative Medicine (OMM) Fellows at Des Moines University (DMU) and supervised and checked by one of two board-certified OMM/NMM physicians from the OMM Department at DMU. The treatment lasted an average of 21 minutes and repeated three times, spaced one week apart.
75926371|NCT05312593|Other|Aftoral Oral Gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
76081527|NCT03332303|Drug|Estradiol Vaginal Cream|Estradiol Vaginal Cream
75926372|NCT05312593|Other|Unidea Chlorhexidine mouthwash|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
76081528|NCT03332303|Drug|Vehicle Cream|Vehicle Cream
76081529|NCT03306615|Drug|Hyaluronidase|HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
76081530|NCT03306615|Drug|Placebo|0.9% Sodium Chloride Injection
76081531|NCT03283878|Drug|Cefazolin|"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."
75333061|NCT03519308|Drug|Nivolumab|Before Surgery Wks 1 &3, After Surgery Wks 1 &3
75333062|NCT03519308|Drug|Nab-Paclitaxel|Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
75333063|NCT03519308|Drug|Gemcitabine|Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
75333064|NCT03519308|Drug|Paricalcitol|Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
75642003|NCT05323305|Procedure|ultrasound guided regional block|Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.
75642004|NCT04103164|Device|Cutera excel V™ Laser|The Cutera® excel V laser is manufactured by Cutera, Inc. This laser with 532 nm KTP and 1064 nm Nd:YAG wavelengths has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the device for use in surgical and aesthetic applications requiring selective photothermolysis of target chromophores in soft tissue 510(k) number 022226. The 532 nm wavelength is indicated for the coagulation and hemostasis of benign vascular and cutaneous lesions in dermatology including, but not limited to, benign vascular lesions like angiomas, hemangiomas, port wine stains, venous anomalies and telangiectasia; benign pigmented lesions like nevi, lentigines, chloasma, café-au-lait; verrucae; skin tags; keratoses; plaques. The Cutera® excel V laser has also obtained the European CE Mark. The system was tested to ensure compliance with federal laser performance standards as applicable.
75642005|NCT04212975|Other|joint lavage with dextrose|joint lavage with dextrose
75642006|NCT03999346|Other|retrospective analysis of the Swiss Trauma Registry data|retrospective analysis of protectively documented registry data based on data completeness, patient outcomes, patient characteristics
76081532|NCT03278730|Drug|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
76081533|NCT03278730|Drug|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
76081534|NCT03277729|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD20 CAR T cell IV
76081535|NCT03277729|Drug|Cyclophosphamide|Given IV
76081536|NCT03277729|Other|Laboratory Biomarker Analysis|Correlative studies
76081537|NCT03277729|Procedure|Leukapheresis|Undergo leukapheresis
75790202|NCT05235659|Behavioral|"Basic modules and experimental modules You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 4, and 5. Finally, they will receive text messages or emails with the core message of the modules."
75790203|NCT05235659|Behavioral|"Basic modules and experimental module Watch out!"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior."
75926373|NCT05296538|Other|Broad-Minded Affective Coping Intervention|The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.
75926374|NCT05296538|Other|Risk Assessment and Signposting|A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
76081538|NCT03277729|Drug|Fludarabine Phosphate|Given IV
76081539|NCT03261505|Device|Acupuncture|Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
76081540|NCT03240965|Diagnostic Test|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
75333065|NCT02843282|Behavioral|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
75798796|NCT03864588|Drug|Ropivacaine|For primary TKA, Ropivacaine is used in both arms, either performed intra-operatively by surgeon or post-operatively (ultrasound guided) by anesthesiologist.
75926375|NCT05266937|Combination Product|Atezolizumab,Paclitaxel, Carboplatin|"Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle + Carboplatin area under the curve 2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle + nab-Paclitaxel at a dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle.~In the absence of disease progression or unacceptable toxicity, study treatments will continue until the end of the study (2 years from last patient enrolled or study termination by the Sponsor)."
75926376|NCT05263830|Other|Quantitative assay of GlypicanPC-3|Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein
75333066|NCT01454024|Device|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
75333067|NCT01454024|Device|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
75333068|NCT02565108|Drug|GWP42003-P 20 mg/kg/Day Dose|GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
75333069|NCT02565108|Drug|Placebo|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
75926377|NCT05256901|Drug|Sugammadex|Participants will receive 4mg/kg for a TOF 0-1 and 2mg/kg for a train of four (TOF) 2 or greater.
76081541|NCT03240965|Other|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
76081542|NCT03240965|Diagnostic Test|Taste-/smell-test|Taste-/smell-test
76081543|NCT03240965|Diagnostic Test|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
76081544|NCT03206801|Procedure|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
76081545|NCT03093909|Drug|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
76081546|NCT03089320|Behavioral|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
76081547|NCT03089320|Behavioral|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
75333070|NCT02565108|Drug|Clobazam|Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
75333071|NCT03821168|Drug|injection of bevacizumab and erythropoietin|injection of bevacizumab and erythropoietin
75642007|NCT05323227|Diagnostic Test|Coronary CTA|Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.
75642008|NCT04101682|Drug|Bupivacaine|Administered by an anesthesiologist or certified nurse anesthetist, under ultrasound guidance a catheter placed overlying the nerve sheath. This catheter is then connected to a device with a reservoir that administers local anesthetic at a set rate.
75790204|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out! and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 3. Finally, they will receive text messages or emails with the core message of the modules."
75333072|NCT03821168|Drug|injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
75790205|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out! and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
75798797|NCT03861312|Behavioral|Neck Laterality|"Patients who belonged to the neck group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
75798798|NCT03861312|Behavioral|Foot Laterality|"Patients who belonged to the foot group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
75798799|NCT01176864|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy
75471498|NCT05875480|Procedure|supervised (face to face) rehabilitation|In the supervised physiotherapy group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. After 2 weeks, they attended the rehabilitation program in the physical therapy department of the hospital accompanied by a physiotherapist, starting from the 14th postoperative day, 2 days a week until the 6th week. The ROM, pain, functional and general health evaluations of the patients in this group were carried out on the online platform. In addition, on the days when they did not come to treatment, their daily routine exercises were followed through the Albert system.
75471499|NCT05875428|Drug|Mitoxantrone Hydrochloride Liposome Injection|Be given intravenously at 20 mg/m^2 on days 1 of each treatment cycle.
75471500|NCT05875402|Drug|Chimeric antigen receptor T cell preparation targeting GCC|Chimeric antigen receptor T cell preparation targeting GCC
75471501|NCT05875389|Other|Virtual assessment|virtual assessment with a stroke neurologist/advanced practice nurse, with interdisciplinary support, to facilitate the care of patients admitted to primary stroke centres using existing tools for remote evaluation and review.
75471502|NCT05875376|Behavioral|Couple group therapy|"Introduction of I statements~Focus of each conversation~Emotion acknowledgement~Self-assurance and positive feedback~teamwork and cooperation~Reflection"
75642009|NCT01001702|Drug|Aripiprazole|Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
75642010|NCT05322915|Other|line dancing|The intervention included 60-minute sessions, two days a week for four weeks for a total of eight sessions. All sessions were administered by the physiotherapist who has 26 years of experience in dance therapy. The dance was performed on a one to one basis with minimal support from the therapist. The line dancing sequence, which was specially created for this training program, was designed as a structured goal-oriented dance. Line dancing movements/steps are comprised of moving forward and backward, or sideways and turns and scuff. In addition, the fact that one foot is always in contact with the ground makes it ideal for patients with multiple sclerosis, who may have balance problems.
75333073|NCT01454180|Drug|gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.|"Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
75798800|NCT01176864|Procedure|Single-balloon enteroscopy|Single-balloon enteroscopy
75798801|NCT03858660|Other|No intervention|No intervention
76081548|NCT03089320|Behavioral|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
75642011|NCT02602210|Drug|Hydrocortisone|IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
75926378|NCT05256901|Drug|Neostigmine/Glycopyrrolate|Participants will receive 0.07mg/kg of Neostigmine and 0.01mg/kg of Glycopyrrolate, administered by anesthesia once at least two twitches are present.
76081549|NCT03083431|Drug|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
76081550|NCT03083431|Drug|Placebo|Oral solution containing the same excipients as propranolol solution
76081551|NCT03077399|Device|SCALA|All items of SCALA are applied
76081552|NCT03050931|Device|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
76081553|NCT03025334|Device|High-definition transcranial direct current stimulation|brain stimulation to increase neuronal excitability in the targeted regions
76081554|NCT02974881|Device|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
76081555|NCT02972788|Drug|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
76081556|NCT02972788|Other|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
76081557|NCT02951052|Drug|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
76081558|NCT02951052|Drug|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"
76081559|NCT02951052|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
76081560|NCT02951052|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
76081561|NCT02951052|Drug|2 NRTIs plus an INI, NNRTI, or PI|"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~NNRTI (either the initial or second cART regimen)~Boosted PI (or atazanavir [ATV] unboosted) (either the initial or second PI-based cART regimen)"
76081562|NCT02927769|Biological|Nivolumab|Specified Dose on Specified Days
76081563|NCT02927769|Biological|brentuximab vedotin|Specified Dose on Specified Days
76081564|NCT02927769|Biological|bendamustine|Specified Dose on Specified Days
76081565|NCT02878174|Procedure|internal jugular vein catheterization|internal jugular vein catheterization using ultrasound (US) or US-based prelocation techniques
76081566|NCT02874040|Procedure|Endoresection|Endoresection of the tumor scar
76081567|NCT02874040|Procedure|Laser diode|Transpupillary thermotherapy by laser diode on the tumor scar
75798802|NCT01176942|Dietary Supplement|Probiotic bacterium Bifidobacterium lactis|Probiotic placebo controlled intervention
75798803|NCT03090100|Drug|Guselkumab|Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
75798804|NCT03090100|Drug|Placebo|Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
75798805|NCT03090100|Drug|Secukinumab|Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
75642012|NCT02602210|Drug|NaCL 0.9%|IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
75642013|NCT04294394|Other|rhomboid block|Rhombid block, on the other hand, is a method which make up analgesia by providing lokal anestethetic enjection between intercostal muscles and rhomboid muscles and blocks between t3- t9 levels
75642014|NCT04294394|Other|erector spinae block|The Erector spinae plan block is a recently developed regional block method .Adminestering of lokal anesthetic between the transver proces and erector spinae muscles provides the dorsal and ventral branch blokades of regional spinal nerve and make up the analgesia.İt have a wide range usage such as surgery of thoracal and abdominal area
75798806|NCT03864432|Drug|Gemigliptin 25mg|Gemigliptin 50mg 1/2T
76081568|NCT02864563|Procedure|Blood sampling|"Blood sample at diagnosis to evaluate MYCN amplification in plasma.~In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up."
76081569|NCT02851992|Device|GTS cementless stem|Total Hip Arthroplasty
75333074|NCT01454180|Drug|Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI|"Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
75333075|NCT03820934|Diagnostic Test|Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
75333076|NCT02564952|Drug|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
75642015|NCT04294394|Other|control|For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
75642016|NCT00618345|Drug|everolimus|
75798807|NCT03864432|Drug|Gemigliptin 50mg|Gemigliptin 50mg 1T
75798808|NCT03864432|Drug|Gemigliptin 100mg|Gemigliptin 50mg 2T
75333077|NCT02564952|Drug|Clobazam|Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
75333078|NCT01454336|Biological|Cell injection|MSCs introduced into portal vein
75333079|NCT03820856|Procedure|acupuncture plus fire needle therapy|The protocol used in this group was the same as that used in the acupuncture alone group except that fire needle therapy was added. The treatments were administered twice weekly for 6 weeks. Fire needle therapy was performed as follows: an acupuncture needle made of tungsten was heated until red-hot over a lighter and then inserted into the two Ah shi points (the tender points on the common extensor tendon, specifically extensor carpi radialis). The red-hot needle was inserted rapidly into the Ah shi point (approximately 5-8 fen deep, 1 cun = 10 fen) for approximately half a second and then removed. Pressure was then applied to the needle hole using a sterilized dry cotton ball.
75471503|NCT05875363|Other|collect data|"The Juvenile Affairs Division provided the records without person-identifiable data (i.e., name, ID) to the researchers. The researchers coded the above data (i.e., the offenders' sociodemographic data, medical history, and criminal history).~Demographic characteristics were collected, which are the offenders' age, gender, occupation, education level, and residence (district). We recorded the offenders' household members (without the name or age), main caregivers (e.g., father, or mother), and the parents' socioeconomic and marital status. We also tracked whether the offenders live with family members with mental illness, whether they are from at-risk families, and whether had been victims of domestic violence. The medical history and deviant (or criminal) behaviors will be collected in the attached measure."
75642017|NCT00618345|Genetic|DNA analysis|
75642018|NCT00618345|Genetic|protein analysis|
75642019|NCT00618345|Genetic|western blotting|
75642020|NCT00618345|Other|flow cytometry|
76081570|NCT02827435|Drug|Rocuronium bromide|Pharmacokinetic-pharmacodynamic modeling blood sampling and Rocuronium bromide concentration measure muscle relaxation evaluation
76081571|NCT02824991|Procedure|detection of local twitch response intensities during dry needling|
75642021|NCT00618345|Other|laboratory biomarker analysis|
75642022|NCT00618345|Procedure|biopsy|
75642023|NCT02601898|Device|Lipoic acid|Vaginal capsules (medical device) containing 10 mg of lipoic acid (1 per day)
75642024|NCT02601898|Drug|Progesterone|Vaginal capsules (drug) containing 200 mg of progesterone (2 per day)
75798809|NCT03864432|Drug|Gemiglptin 50mg multiple dose|Gemigliptin 50mg 1T * 10days
76081572|NCT02802969|Procedure|Surgery|"The operative approach and operating time will be performed according to neurosurgical practices (for head and neck) or surgical orthopaedic team (for sacrum) depending on the location, the extension and the relationship of the lesion to critical structures.~The surgery can be macroscopically complete or incomplete."
76081573|NCT02802969|Radiation|Protontherapy|Radiotherapy will be done with the Cyclotron, for a total dose of 78 Gray Relative Biological Effective (Gy RBE) - 70 Gy RBE to the tumor bed and macroscopic volume and 8 Gy RBE to the the hypoxic component volume, delivered in 39 fractions spread over 67 days.
75642025|NCT01070069|Device|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
75798810|NCT01288950|Dietary Supplement|Vitamin D3 (cholecalciferol)|A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
75798811|NCT01174914|Other|ARV's + Placebo|Patients continued ARV's plus a placebo nightly for 9 months
75798812|NCT01174914|Drug|Naltrexone|Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
75798813|NCT01174914|Drug|Naltrexone + ARV's|Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
75798814|NCT03858738|Device|Thermographic breast examination performed by Braster device|Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
75798815|NCT01177020|Other|Biological specimen|Biological specimen taken from placenta
75333080|NCT03820856|Procedure|acupuncture|We selected acupoints that have often been recommended for the treatment of lateral epicondylitis. Triple needling was performed at the Ah shi point, i.e., the 1-2-cm area encompassing the most painful spot on the humeral epicondyle. We also manipulated acupuncture needles in the following areas: LI10 (Shousanli), LI11 (Quchi), LI12 (Zhouliao) and LU5 (Chize). The treatments were administered twice weekly for 6 weeks.
75333081|NCT05504538|Procedure|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope
75333082|NCT05504538|Device|Tight rope|Adjustable button device from Arthrex Naples USA
75333083|NCT05564286|Drug|Fosaprepitant|In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
75333084|NCT05564286|Drug|tropisetron|All patients received tropisetron 5mg on day 1.
75333085|NCT05564286|Drug|Dexamethasone|.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
75642026|NCT01070069|Device|SEVAR (IntuiTrak)|Standard vascular exposure for access prior to EVAR
75642027|NCT01070069|Device|PEVAR (Prostar XL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
75642028|NCT00618423|Drug|Placebo|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
75790206|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out!, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 5. Finally, they will receive text messages or emails with the core message of the modules."
76081574|NCT02802969|Drug|18F FAZA|FAZA PET/CT, in order to target the hypoxic zones
75333086|NCT03820700|Behavioral|Hypnosis (Hypn)|The hypnosis session will consist of a 20-minute hypnosis recording created by Marie-Elisabeth Faymonville and recorded by Anne-Sophie Nyssen, both professionals in hypnosis from University of Liège. The recording includes suggestions about relaxation, corporal sensations, respiratory techniques and visual imaginative stimuli about a beautiful landscape. With this tool, the hypnosis session is standardized for all patients and there is no need of a psychotherapist to deliver hypnosis.
75333087|NCT03820700|Behavioral|Virtual reality (VR)|VR sessions. This session will consist in using a head-mounted 3D graphical display with goggles. With this tool, participants will be able to visualize a 3D immersive landscape for 20 minutes consisting of a shed near a lake at sunrise followed by a relaxing moment in the clouds. The session ends on the lake's edge.
75333088|NCT03820700|Behavioral|Virtual reality hypnosis (VRH)|The combined tool sessions. Participants will be simultaneously subjected to the same hypnosis recording and 3D visual stimuli used in the Hypn and VR conditions.
75333089|NCT05504460|Device|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Treatments in the test group will lasts for 12 months, and symptomatic treatment will be provided based on the actual symptoms of the subjects. Subjects in the test group will be required to receive inhalation for at least 4 days every 7 days with at least 3780L inhaled every 7 days (It is recommended to inhale at least 540L per day; If the flow rate is 3L/min, it is recommended that the cumulative inhalation time should be at least 3 hours per day. If the flow rate is 1.5L/min, it is recommended that the cumulative inhalation time should be at least 6 hours per day).
75471504|NCT05875324|Device|virtual reality application|VR was used for 10 minutes a day in the sitting position for three weeks, twice a week, by watching a walking video before beginning the exercises. Patients were instructed to imagine themselves walking while concentrating on walking and watching the video. The patients were asked to stop watching video by removing their VR glass if they experienced discomfort such as dizziness and nausea during the VR application. They were told to continue watching the video when the discomfort was gone. In cases where similar discomforts recurred, the treatment was terminated.
75790207|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out! and You are safe here"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
75471505|NCT05875324|Other|exercise|activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were provided an exercise program for at-home practice.
76081575|NCT02794571|Drug|Atezolizumab|Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.
76081576|NCT02794571|Drug|Tiragolumab|Several dose levels will be evaluated for tiragolumab administered as a single agent and in combination with atezolizumab and/or other anti-cancer therapies. Tiragolumab will be given via IV infusion on Day 1 of each cycle (21-day or 28-day depending on study cohort and phase) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent tiragolumab may receive combination treatment with tiragolumab and atezolizumab and/or other anti-cancer therapies. Combination treatment may continue until disease progression or loss of clinical benefit.
76081577|NCT02794571|Drug|Carboplatin|Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab IV infusion.
76081578|NCT02794571|Drug|Cisplatin|Cisplatin 75 milligram per square meter (mg/m^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
76081579|NCT02794571|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and tiragolumab.
76081580|NCT02794571|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.
76081581|NCT02794571|Drug|Etoposide|Etoposide 100 mg/m^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.
76081582|NCT02794571|Drug|Capecitabine|Capecitabine 1250 mg/m^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.
76081583|NCT02794571|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
76081584|NCT02794571|Drug|Pembrolizumab|Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.
76081585|NCT02788773|Drug|Durvalumab|
76081586|NCT02788773|Drug|Tremelimumab|
75642029|NCT00618423|Drug|Ketamine|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
75642030|NCT04296032|Behavioral|virtual reality game traning|The controllers were attached to upper extremity to control the game. The game could train the shoulder, elbow, and wrist control.
75790208|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out!, You are safe here, and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 4. Finally, they will receive text messages or emails with the core message of the modules."
75798816|NCT01179750|Device|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
75798817|NCT03102892|Procedure|Scaling root planing|Treatment by scaling and root planing alone.
75798818|NCT03102892|Procedure|Antimicrobial photodynamic therapy|Treatment with methylene blue dye and red laser
76081587|NCT02768792|Drug|pembrolizumab,|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
76081588|NCT02754544|Procedure|Direct Electrocortical Stimulation|Undergo direct electrocortical stimulation
76081589|NCT02754544|Other|Electrocorticography|Undergo electrocorticography
75333090|NCT05504460|Other|basic treatment|supportive treatment determined by the investigator based on the condition of the patients
75333091|NCT01454804|Drug|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
75642031|NCT04296032|Behavioral|standard treatment|The program included bilateral hand, grasp/release, and pinch activities.
75642032|NCT04101760|Drug|Long-acting granulocyte colony stimulating factor|Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
75642033|NCT04101760|Drug|Short-acting granulocyte colony stimulating factor|Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns
75642034|NCT00616551|Drug|C2L-OCT-01 PR, 30 mg|Administered by deep IM injection (gluteus) on days 1 and 42
76081590|NCT02688400|Drug|Diacerein|
76081591|NCT02688400|Drug|Celecoxib|
76081592|NCT02688400|Drug|Placebo|
76081593|NCT02637583|Drug|PCV13|Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
76081594|NCT02637583|Drug|PPV23|Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
75333092|NCT01454804|Drug|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
75333093|NCT01454804|Drug|Trastuzumab (Herceptin®)|"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"
75333094|NCT01454804|Drug|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
75333095|NCT03820622|Device|Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)|patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
75642035|NCT00616551|Drug|Octreotide acetate prolonged release, 30 mg|Administered by deep IM (gluteus) on Days 1, 28 and 56
75333096|NCT03820622|Device|Paclitaxel-Eluting Balloon (Bingo)|patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)
75926379|NCT05245955|Device|Assessments of the hand sensory function with the ReHapticKnob|During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).
75333097|NCT05504382|Device|naproxen phonophoresis|transmission of naproxen molecule by therapeutic ultrasound
75333098|NCT04391972|Device|SAV|SAV multifocal intraocular lens is a implantable IOL which offers multifocal vision.
75642036|NCT04214145|Drug|Phenylephrine|"Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg * 5@ + D5W 200 mL) if mean BP < 60mmHg.~Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr)~Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP < 60mmHg after 5 minutes~Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)"
75642037|NCT04214145|Drug|Norepinephrine|"Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg * 1@ + D5W 200 mL) if mean BP < 60mmHg.~Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)~Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP < 60mmHg after 5 minutes~Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)"
75642038|NCT04214145|Drug|Vasopressin|"Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u * 1@ + D5W 200 mL) if mean BP < 60mmHg.~Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr)~Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP < 60mmHg after 5 minutes~Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)"
75798819|NCT01177176|Other|Extended Care Management|Telephone-based care management of tobacco cessation for 3 months after hospital discharge that features 2 innovations: (1) to increase medication use, smokers receive a free refillable 30-day sample of their choice of FDA-approved smoking cessation medication (nicotine replacement, bupropion, or varenicline) at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers seeking or most likely to benefit from continued counseling after hospital discharge.
75926380|NCT05243524|Other|Maveropepimut-S|SC injection on days 7, 28, then q8w
75926381|NCT05243524|Drug|Cyclophosphamide 50mg|PO BID, one week on, one week off
75926382|NCT05226455|Drug|venetoclax + azacitidine +/- donor lymphocyte infusion|Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
75926383|NCT05223205|Procedure|Air|Test if air is sufficient for macular hole closure.
75926384|NCT05223205|Procedure|10% SF6 and 90% air|Test if 10% SF6 and 90% air is sufficient for macular hole closure.
76081595|NCT02626455|Drug|Copanlisib (BAY80-6946)|"Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days."
75642039|NCT04103008|Diagnostic Test|Speckle tracking echocardiography|assess left ventricular function on admission and after 40 days
75642040|NCT04295954|Other|Yoga Intervention|"It is an intervention based on Hatha yoga designed specifically to improve dysmenorrhea. This intervention consists of physical postures, also called asanas; meditation and breathing. It begins with a progression of various asanas until reaching the three central postures: cat, cobra and fish. The compensation asanas of these central postures are then performed, and it is closed with a relaxation. The program and Yoga Intervention have been triangulated by experts and piloted afterwards."
75642041|NCT04212429|Drug|Levofloxacin Ophthalmic Product|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
75642042|NCT04212429|Drug|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
75642043|NCT01068665|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
75642044|NCT01068665|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
75798820|NCT01177176|Other|Standard Care|Usual care provided to hospitalized smokers during their inpatient stay, with no post-discharge care management plan
75798821|NCT03089944|Drug|Glecaprevir/Pibrentasvir|Tablet
75926385|NCT05215418|Drug|VI-0521|Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
75926386|NCT05215418|Drug|Phentermine|Phentermine 30 mg capsule
75926387|NCT05215418|Drug|Placebo|Inactive oral capsule
75333099|NCT05047146|Other|Morphological classifications of HCC|Morphological classifications of Hepatocellular carcinoma
75333100|NCT03823040|Drug|Oxiconazole Nitrate Cream 1%|Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
75333101|NCT03823040|Drug|Oxiconazole nitrate SLNs loaded gel.|Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
75333102|NCT04282980|Drug|DCC-2618|Oral kinase inhibitor
75333103|NCT03823196|Dietary Supplement|Verum900|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks
76081596|NCT02626455|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
76081597|NCT02626455|Drug|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
76081598|NCT02626455|Drug|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
75790209|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out!, You are safe here, and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
76081599|NCT02626455|Drug|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
75642045|NCT01001390|Device|AFO Device|Ankle Foot Orthoses impact on net oxygen consumption.
75642046|NCT00618501|Drug|cytarabine|
75642047|NCT00618501|Drug|daunorubicin hydrochloride|
75798822|NCT03864198|Dietary Supplement|Genante|A dietary supplement for male infertility
75798823|NCT01174992|Biological|Evicel|EVICEL is a human plasma derived fibrin sealant
75798824|NCT01174992|Other|Sutures only|Standard of care
75798825|NCT01287780|Device|Collagen-gentamicin sponge|A 10 by 10 cm sponge consisting of 280 mg collagen and 130 mg gentamicin.Two sponges are inserted during hemiarthroplasty surgery, one in the joint and one underneath the fascia at the time of surgical closure.
75926388|NCT05211388|Procedure|RFA controlled using echo decorrelation imaging|"The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion.~The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume.~To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points."
76081600|NCT02626455|Drug|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
76081601|NCT02626455|Drug|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
76081602|NCT02626455|Drug|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
76081603|NCT02492932|Device|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
75926389|NCT05211388|Procedure|RFA controlled using standard manufacturer-specified algorithms|The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.
76081604|NCT02433197|Device|Aerobic program|"The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
76081605|NCT02352896|Drug|EPI-743|EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.
76081606|NCT02320136|Behavioral|cognitive testing|patients perform simple tasks like watching a video or memorizing items
76081607|NCT02242266|Drug|Tiotropium low dose|inhalation powder, hard PE capsule
76081608|NCT02242266|Drug|Tiotropium medium dose|inhalation powder, hard PE capsule
75642048|NCT00618501|Drug|etoposide|
75642049|NCT00618501|Drug|imatinib mesylate|
75642050|NCT00618501|Drug|leucovorin calcium|
75642051|NCT00618501|Drug|methotrexate|
75642052|NCT00618501|Drug|prednisolone|
75642053|NCT00618501|Drug|therapeutic hydrocortisone|
75642054|NCT00618501|Drug|vincristine sulfate|
75642055|NCT00618501|Procedure|allogeneic hematopoietic stem cell transplantation|
75642056|NCT05322759|Other|aquatic exercises|aquatic polymetric exercises for 30 min including hip abduction/adduction, knee flexion/extension, hip flexion/extension, holding pool from sides, bending forward and picking up objects, shoulder flexion/extension kangroo jumpes, jumping to sides.
75642057|NCT05322759|Other|halliwick exercise programme|Halliwick exercise programme for 30 min include sagittal rotations, transversal rotations, longitudnal rotations and combined rotations.
75642058|NCT04294316|Diagnostic Test|Sonovue|Twice dose of 2.4ml of Sulphur hexafluoride microbubbles contrast Sonovue administration to evaluate brain microcirculation
76081609|NCT02242266|Drug|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
76081610|NCT02242266|Drug|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
76081611|NCT02242266|Drug|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
75642059|NCT04212507|Diagnostic Test|The serum level of Claudin-3 and intestinal Fatty acid binding protein|The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.
75642060|NCT02870426|Procedure|Frontal Craniotomy and retrieval of OBs|For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique. For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
76081612|NCT02193347|Biological|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
75642061|NCT02870426|Procedure|OB Retrieval During Anterior Cranial Surgery|Group 2: The patients routine anterior cranial surgery would proceed as planned without change to the surgical procedure. In the event that the ON had to be sacrificed for the purposes of surgery the OB of the concomitant nerve would be retrieved.
75790210|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out!, You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation. They will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Further access will be provided to module 4 You are safe here on improving children´s relationship-related safety and facilitating solid relationships. Access to module 5 Who am I and where do I belong? will support caregivers in helping their child develop an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support will be provided. They will receive four phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, 4, and 5. Text messages or emails with the core message of the modules will be provided."
76081613|NCT02193347|Biological|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
76081614|NCT02193347|Drug|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
76081615|NCT02176434|Procedure|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
76081616|NCT02176434|Biological|hematopoietic stem cell|
75333104|NCT03823196|Dietary Supplement|Verum1800|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
75642062|NCT00772954|Biological|Vaccine diluent buffer|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
75642063|NCT00772954|Biological|Clostridium difficile toxoid vaccine (50 μg)|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
75790211|NCT05234632|Device|PICO 14 single-use Negative Pressure Wound Therapy System|The PICO14 device delivers negative pressure across the wound bed or closed incision and surrounding area, and exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film.
75790212|NCT05231265|Other|Walking task|Treadmill walking task with study of fractal variability (complexity) for 10 minutes.
75926390|NCT05210387|Other|Duration of therapy|"In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1)."
75926391|NCT05209425|Dietary Supplement|Vitamin D3|Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
75926392|NCT05201040|Device|JETKNEE Synovial Fluid Supplement|2mL of JETKNEE Synovial Fluid Supplement
75926393|NCT05201040|Device|Normal saline|2mL of normal saline
75926394|NCT05198557|Drug|Inebilizumab|Participants will receive IV inebilizumab.
75926395|NCT05198557|Drug|Placebo|Participants will receive IV placebo matched to inebilizumab.
76081617|NCT02045381|Procedure|MRI Group|A single research MRI
76081618|NCT02039843|Other|Emotional Support Dogs|Emotional Support Dogs were required to pass the American Kennel Club Canine Good Citizen and the American Kennel Club Community Canine tests and be well-behaved and well-socialized.
76081619|NCT02039843|Other|Service Dogs|Service Dogs were required to pass the American Kennel Club Canine Good Citizen and the Assistance Dogs International Public Access tests and trained to complete five PTSD-specific tasks (lights, sweep, bring, block, & behind).
76081620|NCT02004275|Drug|pomalidomide|given PO
75333105|NCT05504226|Drug|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
75642064|NCT00772954|Biological|Clostridium difficile toxoid vaccine (100 μg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
75642065|NCT05322681|Drug|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
75333106|NCT05504226|Drug|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
75642066|NCT04295876|Behavioral|The BRIDGES Project Intervention|The BRIDGES Project will use Peer Navigators, who are other women living with HIV who have had similar experiences and have been successful in accessing care, to help other women living with HIV to access HIV care and stay in HIV care. The BRIDGES Project will also provide support to women through group sessions co-facilitated by a licensed clinical therapist and Peer Navigator. Through participation in BRIDGES, women will: (1) build skills to cope with HIV care and treatment barriers (e.g., violence, trauma, adverse mental health, substance use); (2) be connected to HIV treatment and other support services (e.g., domestic violence, mental health, substance use); and (3) learn interpersonal skills to connect with support (e.g., service providers, peers, friends, family) when faced with new or ongoing barriers.
75642067|NCT05322603|Drug|Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)|A decrease in the pain severity (VAS);opioid-sparing effect
75642068|NCT05322603|Drug|Analgesics|A decrease in the pain severity (VAS)
75790213|NCT05225688|Behavioral|Bike exertion test|maximal exercise test
75790214|NCT05224063|Device|Individualized CEN-targeted rTMS|Delivers patterned magnetic stimulation based on individualized CEN targeting
75926396|NCT05177601|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.
75926397|NCT05177601|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
75926398|NCT05177601|Drug|D-cycloserine|Daily oral D-cycloserine 100mg during TMS treatments (20 days).
76081621|NCT02004275|Drug|ixazomib|given PO
76081622|NCT02004275|Drug|dexamethasone|given PO
76081623|NCT01935713|Drug|Nicotine polacrilex|Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.
76081624|NCT01935713|Drug|Electronic Cigarette|Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.
76081625|NCT01935713|Drug|Dissolvable Tobacco Lozenge|Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, >2 packs per day).
76081626|NCT01911013|Procedure|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
76081627|NCT01911013|Device|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
76081628|NCT01911013|Device|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
76081629|NCT01731444|Drug|Phenylephrine|
75926399|NCT05177601|Drug|Placebo oral capsule|Daily oral placebo during the TMS treatments (20 days).
76081630|NCT01630785|Device|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
76081631|NCT01559129|Drug|Pomalidomide (CC-4047)|1 mg orally every day for 52 weeks
75333107|NCT04282044|Biological|CRX100 suspension for infusion|A fixed dose of CIK cells combined with the specified dose of CDSR.
75333108|NCT03822806|Other|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
75471506|NCT05875311|Device|telemonitoring|"The system consists of the following elements:~Professional website at the ambulatory centre, which allows:~To set up an individualised care plan To establish the patient's risk profile and targets for improvement. Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred Advise the patient on self-management strategies.~Mobile application software with the following functions:~Scheduled exercise sessions Medication reminder Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.) Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~Training monitor: guides the patient in the performance of their exercise. Access to certified health information for patients"
75471507|NCT05875311|Other|control follow-up|Patients are instructed to perform 150 minutes per week of moderate physical activity and follow healthy lifestyles
75642069|NCT05508256|Device|CE-marked Catheter Ablation|Once patients have been randomized to the catheter ablation (CA) group, the ablation procedure must be performed within 4 weeks. CA will initially aim at pulmonary vein isolation.
75642070|NCT04214301|Drug|BLI800|BLI800 Bowel Preparation
75790215|NCT05224063|Device|Neuronavigated rTMS|Delivers patterned magnetic stimulation based on MRI images
75790216|NCT05224063|Device|Scalp-targeted rTMS|Delivers patterned magnetic stimulation based on BEAM F3 targeting
75790217|NCT05224063|Device|Sham rTMS|Delivers placebo magnetic stimulation
75790218|NCT05217680|Biological|Bevacizumab|Administration of monthly intravitreal bevacizumab (4-12 injections)
75790219|NCT05217680|Biological|Lucentis®|Administration of monthly intravitreal ranibizumab (4-12 injections)
76081632|NCT01559129|Drug|Placebo|Matching placebo capsules taken orally once a day
76081633|NCT01488240|Procedure|pulsed dye laser|laser energy
76081634|NCT01210781|Procedure|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
76081635|NCT01005303|Drug|Placebo|1 Tablet Daily
76081636|NCT01005303|Drug|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
76081637|NCT01003028|Drug|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
76081638|NCT01003028|Drug|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
76081639|NCT00388882|Drug|tiotropium|
76081640|NCT00388882|Drug|ipratropium bromide / albuterol|
76081641|NCT00355238|Drug|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
76081642|NCT00303303|Biological|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
76081643|NCT00303303|Biological|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
75642071|NCT00618579|Drug|LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects|Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
75642072|NCT04101448|Other|prevalence|percentage of bronchectasis in COPD and its effect as prognostic measure
75642073|NCT04214457|Procedure|Biopsy and peripheral blood collection|"After obtaining informed consent, the samples (tumor tissue and peripheral blood) will be collected at the time of surgery, which the patient had already planned by medical indication according to the usual clinical practice. Part of the sample will be sent to histopathology for gold standard diagnosis while the rest of the sample will be sent to Igenomix for molecular analysis.~If samples are available from patients who underwent surgery prior to the study, after they sign the Informed Consent, the samples will be sent to Igenomix for molecular analysis and the results obtained by histopathology will be collected from the patient's medical record."
75642074|NCT00781768|Drug|Standard PO (Zofran + Dexamethason)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
76081644|NCT00303303|Biological|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
76081645|NCT00275444|Drug|Tipranavir|
75790221|NCT05210374|Drug|Disulfiram|"To be taken orally (PO) daily in the AM, rounded for pill size (max 480mg/day).~To be administered day 1-7 of lead-in week and day 1-28 cycles~Cycle length: 28 days,~maximum 12 cycles Level -1 (150mg/m^2/day) Level~0 (225mg/m^2/day) Level 1 (300mg/m^2/day), max~480mg/day"
75790222|NCT05210374|Drug|Copper Gluconate|"To be taken orally (PO), 5.2mg/m2/day daily in the PM, rounded~for pill size (max 9mg/day) To be administered day 1-7~Lead-in week and day 1-28 cycles Cycle length: 28~days, maximum 12 cycles"
75790223|NCT05210374|Drug|Liposomal Doxorubicin (Doxil)|"To be given IV, 30mg/m2/dose~To be administered day 1 of cycles~Cycle length: 28 days, maximum 12 cycles"
75790224|NCT05206539|Drug|Self-assembling peptide (P11-4)|"Prior to application, teeth are isolated by cotton rolls and gently air dried. The surface of the lesion is conditioned with a 2% sodium hypochlorite solution for 20 s and then rinse with water. Application of 35% phosphoric acid etching gel for 20 sec followed by rinsing with water-air spray for 30 sec. Drying the surface with compressed oil-free air for 60 sec. Curodont Repair is dissolve in 0.05 ml of distilled water and applied to the surface and allowed to work for about 5 min.~Participants will receive oral hygiene instructions."
75790225|NCT05206539|Drug|CPP-ACFP|"Prior to application, teeth are isolated by cotton rolls and gently air dried. Application of fluoride varnish with a brush applicator on the surface of the teeth for 5 minutes. Patients is advising not to brush their teeth or chew food for at least 4 h after treatment.~Participants will receive oral hygiene instructions"
75798826|NCT05546632|Diagnostic Test|Blood sampling|Patients will have one blood sampling using one EDTA tube and one Cyto-Chex BCT tube, one after the other
76081646|NCT00274560|Drug|Tiotropium|
76081647|NCT00274560|Drug|Salmeterol|
75471508|NCT05875298|Other|physical therapy protocol|the patients will receive physical therapy protocol in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus.
75798827|NCT01179828|Drug|Oxycodone 15mg|15mg single administration p.o.
75798828|NCT01179828|Drug|Clobazam|20mg single administration p.o.
75798829|NCT01179828|Drug|Imipramine|75mg single administration p.o.
75798830|NCT01179828|Drug|Tolterodine|1 mg single administration p.o.
75798831|NCT01179906|Behavioral|Exercise training|Subjects exercise trained for 48 weeks with personal trainers at a college wellness center
75926400|NCT05172479|Diagnostic Test|Measurement of qSOFA score|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.
75926401|NCT05172479|Diagnostic Test|Measurement of SIRS criteria|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.
75926402|NCT05172479|Diagnostic Test|Measurement of NEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.
75926403|NCT05172479|Diagnostic Test|Measurement of NEWS2|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.
76081648|NCT00274508|Drug|tiotropium bromide|
76081649|NCT00239447|Drug|Tiotropium|
76081650|NCT00239447|Device|HandiHaler|
76081651|NCT00239447|Device|Respimat SMI|
76081652|NCT00144248|Drug|nevirapine|
76081653|NCT00056641|Drug|tipranavir|
76081654|NCT00056641|Drug|ritonavir|
76081655|NCT00056641|Drug|saquinavir|
76081656|NCT00056641|Drug|amprenavir|
76081657|NCT00056641|Drug|lopinavir|
76081658|NCT03422874|Drug|MLN9708|MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
75333109|NCT05508828|Procedure|Percutaneous Continuous Irrigation assisted Vacuum Drainage Combined With Transgastric Necrosectomy|All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.
75642075|NCT00781768|Drug|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO [blinded] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO [blinded] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
75790226|NCT05206539|Drug|Resin infiltration|The validated ICON Vestibular (DMG) infiltration lesion infiltration protocol is applied. Icon Etch (DMG) etching gel containing 15% hydrochloric acid is applied for 120 seconds using an applicator. It is then removed by rinsing thoroughly with water-air spray for 30 seconds. Then follows application of pure alcohol - Icon Dry (DMG) for 30 seconds for complete drying of the lesion and additional drying compressed oil-free air for 40 sec. Application of Icon Infiltrant (DMG) using a microapplicator allows it to penetrate for 3 minutes, during which, if necessary, it is reapplied several times. Excess material is removed with dry microbrushes and followed by light curing for 40 seconds. Re-applying of the infiltrate for 1 minute, removal of excess material, light curing for 40 seconds. Participants will receive oral hygiene instructions
75926404|NCT05172479|Diagnostic Test|Measurement of MEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.
75926405|NCT05164991|Behavioral|Visuo-tactile stimulations of the right hand|Participants lay down in the magnetic resonance (MR) scanner are presented with visual stimuli (videos of the virtual rubber hand - visual stroking) simultaneously in real time with tactile stimuli (robotic stroking of the participant's hand - tactile stroking). An MR-compatible robot systematically provides the tactile stroking on the participant's hand. MR-compatible goggles show the visual stroking. Patterns of long and short robotic movements will be provided.
75926406|NCT05163665|Procedure|Closure type|Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
75926407|NCT05163028|Drug|HBI-2376|SHP2 Inhibitor
75926408|NCT05155709|Drug|siremadlin|Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
75926409|NCT05155709|Drug|venetoclax|Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
75926410|NCT05155709|Drug|azacitidine|Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
75926411|NCT05152914|Drug|Cerliponase Alfa|Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
75926412|NCT05150639|Other|IVF|Women planning to undergo frozen embryo transfer IVF procedure will be included. Samples will be obtained, but no study intervention will be applied. Pregnancy outcome data will be obtained, following frozen embryo transfer, to correlate against other data from samples (vaginal microbiome etc).
75926413|NCT05149781|Procedure|Standardized diagnosis and treatment|Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.
75926414|NCT05136807|Other|Quality-of-Life Assessment|Complete questionnaires
75926415|NCT05136807|Other|Questionnaire Administration|Complete questionnaires
75926416|NCT05134545|Device|Genoss® DCB|Peripheral Drug Coated Balloon
75642076|NCT01005680|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
75642077|NCT01005680|Drug|Gemcitabine|1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
75642078|NCT01005680|Drug|Cisplatin|75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
75798832|NCT01179906|Behavioral|Diet modification|Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
75798833|NCT05437588|Genetic|Genetic testing|Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action
75926417|NCT05134545|Device|IN.PACT Admiral® DCB|Peripheral Drug Coated Balloon
75926418|NCT05132504|Drug|Pembrolizumab|Pembrolizumab will be initiated starting with the Cycle 2 Day 1 and will be administered every 6 weeks with a max amount of 9 cycles throughout the study.
75926419|NCT05132504|Drug|Folfirinox|Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil) chemotherapy treatment. Each cycle is 14 days; a total of six cycles will be administered. Patients will receive growth factor support at the discretion of treating physician.
75926420|NCT05114018|Dietary Supplement|Pasteurized A. muciniphila|Daily oral dose
75926421|NCT05114018|Dietary Supplement|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
75926422|NCT05108519|Other|Electronic Health Record Review|Medical records are reviewed
75642079|NCT04214379|Procedure|Ptosis surgery|Frontalis sling surgery using pose-up and Wright's fascia-lata needle
75926423|NCT05072795|Behavioral|Trier Social Stress Task (TSST)|The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
75642080|NCT04101370|Drug|Bosentan 125 mg|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
75642081|NCT04101370|Drug|Tracleer 125Mg Tablet|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
75926424|NCT05067621|Drug|Semaglutide Pen Injector|Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
75926425|NCT05067621|Drug|Placebo|Injection pen contains excipients.
76081659|NCT03422874|Drug|Nelfinavir|Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
76081660|NCT01253824|Drug|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
76081661|NCT01253824|Drug|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
76081662|NCT03422796|Drug|Cilostazol 200mg|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
76081663|NCT03422796|Drug|SUMAtriptan 6 MG/ML|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
76081664|NCT03422796|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
76081665|NCT04396977|Procedure|Histamine 10 mg/ml skin prick|Skin prick through 5 µL histamine diHCl (10 mg/ml)
76081666|NCT04396977|Procedure|Placebo (saline) skin prick|Skin prick through 5 µL saline (0.9% NaCl)
76081667|NCT03429738|Drug|Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets|Experimental drug
76081668|NCT03429738|Drug|RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets|Active Comparator
76081669|NCT05242185|Other|Observational study|- Baseline data of prognostic importance, including demographic, social information, lifestyle factors, medical history, underlying comorbidities, anthropometric measurements, clinical, laboratory, imaging and treatment records will be collected using a standard case report form. A detailed clinical examination including measurement of vital signs, blood pressure, pulse oximetry, anthropometric measurements, neurological, pulmonary, cardiovascular system examination, mental and fuctional status assessment. routine laboratory assays including complete blood count (CBC), serum alanine transaminase (ALT), serum creatinine, fasting capillary blood glucose using glucometer and urine routine examination, ECG, echocardiography, chest X-ray and pulmonary function test. Additional tests when required such as fasting blood sugar, glycated haemoglobin, MRI/CT scan of brain, Thyroid function tests such as FT4, FT3 and TSH and C peptide etc
76081670|NCT03429660|Other|Medical information|"The information collected are about :~Introduction or non-introduction of treatment~Cumulative dose of treatment~Drug dispensation and withdrawal~Hospitalization reason~Safety information~Demographic data (date of death)"
76081671|NCT01253902|Drug|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
76081672|NCT01253902|Drug|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
76081673|NCT01253902|Drug|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
76081674|NCT02843100|Other|Modified Exclusive Enteral Nutrition|Two weeks of Exclusive Enteral Nutrition with Modulen
76081675|NCT02843100|Other|Crohn's Disease Exclusion Diet|a limited whole food diet
75642082|NCT04101214|Other|Dry needling|Dry needling into spastic muscle
75642083|NCT04101214|Other|Sham dry Needling|Sham dry needling into spastic muscle
75926426|NCT05058690|Diagnostic Test|Oral Glucose Tolerance Test|"Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~Collect a further blood sample at 120 minutes.~Send samples all together to laboratory for glucose measurement."
76081676|NCT02843100|Other|Partial Enteral Nutrition|25-50% of Energy from formula
75333110|NCT01454882|Behavioral|Effects of Clothing|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
75333111|NCT01454882|Behavioral|Effects of Temperature|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
75642084|NCT04188249|Drug|Golimumab|This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.
75798834|NCT01177332|Other|exercise|2 hours cycling exercise at 50 % of maximal power output
75798835|NCT01286220|Other|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
75798836|NCT01286220|Other|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
76081677|NCT02843100|Other|Standard Exclusive Enteral Nutrition|8 weeks of Exclusive Enteral Nutrition
76081678|NCT01253980|Drug|Amoxicillin|Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
76081679|NCT01253980|Drug|Placebo|"Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days"
75790227|NCT05206539|Other|Control Group, No Treatment|Everyday oral hygiene instructions Subjects will receive non-prescription fluoride toothpaste (1400 ppm Fluoride, Elmex junior) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate and rinse.
75471509|NCT05875298|Other|physical therapy protocol and medical drugs|the patients will receive physical therapy protocol and medical drugs in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus. The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
76081680|NCT04449354|Device|HidraWear Ax|An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. The perforated section of the garment sits on the outer surface of the dressing providing provisional fixation. Next, an outer patch is placed on the outside of the garment on the footprint of the dressing. Through a hook and loop mechanism the dressing is now fully secured in place.
75642085|NCT01005602|Other|Digoxin Dosing per Nomogram|Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
75642086|NCT01005602|Drug|Digoxin|All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
76081681|NCT00988533|Drug|0.5% Ivermectin Cream|Topical 0.5% ivermectin cream applied to scalp and hair on day 1
76081682|NCT01254214|Behavioral|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
76081683|NCT01254214|Behavioral|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
76081684|NCT03048669|Other|Continuous quality improvement|A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
76081685|NCT01254760|Device|Nelfilcon A multifocal contact lens, investigational|Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
75471510|NCT05875298|Other|medical drugs|The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
75642087|NCT00916318|Behavioral|Obesity-Children|"(A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group."
75642088|NCT02601742|Other|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
75642089|NCT02601742|Other|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
75642090|NCT01068509|Biological|Cvac|Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.
75790228|NCT05189769|Behavioral|CP no REACT|Coping Power no REACT
75790229|NCT05189769|Behavioral|CP+/No REACT|CP+ and no REACT
75790230|NCT05189769|Behavioral|CP and REACT|Coping Power traditional and REACT
75790231|NCT05189769|Behavioral|CP+ and REACT|CP+ and REACT
75790232|NCT05188287|Behavioral|HealthyCells|Smoking cessation smartphone app
75926427|NCT05053750|Drug|Paclitaxel/Bev (control)|Given by PO
75926428|NCT05053750|Drug|Paclitaxel/Bev + ZA (experimental)|Given by PO
75926429|NCT05051774|Behavioral|1. Education|Three monthly face-to-face group education with 8 to10 participants using a validated educational booklet will be provided by the researcher at the study hospital.
75926430|NCT05051774|Behavioral|2. Exercise|"The exercise intervention comprised of two elements as follows:~Three monthly hospital-based supervised group exercise consists of 8 to 10 participants. First two sessions: warm-up exercise-5 minutes, brisk walking-20 minutes at low intensity with music, and cool-down exercise-5 minutes. Third session: brisk walking for 30 minutes at moderate intensity with music.~Twelve-weeks home-based exercise: The participants will be asked to continue the exercise performed in the previous week at the hospital with music at least five times per week."
75926431|NCT05051774|Behavioral|3. Telephone follow-up|A 20-minutes telephone follow-up at weeks 3, 7, and 11 for strengthening the volition of the participant to perform the exercise and follow the healthy diet at home.
75926432|NCT05051579|Drug|LY3502970|Administered orally
75926433|NCT05051579|Drug|Placebo|Administered orally
76081686|NCT01254760|Device|Nelfilcon A multifocal contact lens, commercial|Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
76081687|NCT05601375|Other|Echocardiography|Fetal echocardiography (ultrasound)
76081688|NCT02984007|Behavioral|Motivational Interviewing|"Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a research assistant (RA). The RA will have first received a standardized training session on the content and techniques of MI.~The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes."
75642091|NCT01009034|Other|Measuring semen samples|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
75790233|NCT05180591|Biological|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
75790234|NCT05180591|Biological|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
75790235|NCT05179083|Other|High-Impact Aerobic Exercise|Participants will be submitted to a 12-week high-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (80% of maximum) is reached, followed by 10 minutes of cool down.
75926434|NCT05045404|Drug|Poziotinib Hydrochloride|"1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO"
75926435|NCT05045404|Biological|1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE|"Biological/Vaccine Ramucirumab 947687-13-0, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, ramucirumab, RAMUCIRUMAB~Given IV"
75790236|NCT05179083|Other|Low-Impact Aerobic Exercise|Participants will be submitted to a 12-week low-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (40% of maximum) is reached, followed by 10 minutes of cool down.
75333112|NCT01454882|Behavioral|Low Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
75790237|NCT05172934|Drug|intra-arterial tenecteplase|intra-arterial drug administered after mechanical thrombectomy
75642092|NCT04212663|Procedure|The tendon release of musculi tibialis posterior|To release the tendon of musculi tibialis posterior.
75642093|NCT04212663|Procedure|Anterior tibial tendon transfer(TATT)|To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.
75790238|NCT05166811|Drug|Magnesium Sulfate, Heptahydrate|A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.
75790239|NCT05166811|Drug|0.9% saline|A single dose of intravenous 0.9% sodium chloride given over 20 minutes through a peripheral intravenous line as the placebo arm of the study.
75790240|NCT05165940|Behavioral|Treatment As Usual|Care Coordination Treatment as usual with a VA mental health treatment coordinator
75926436|NCT05044676|Other|patients with hepatocellular carcinoma|The response of the hepatocellular carcinoma to treatment will be evaluated as part of the care
75333113|NCT01454882|Behavioral|High Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
75333114|NCT01454882|Behavioral|Direct calorimetry and doubly labeled water|TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
75333115|NCT02929160|Procedure|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
75642094|NCT04212663|Procedure|Achilles tendon lengthing|To lengthen the achilles tendon by using two incisions.
75926437|NCT05044546|Behavioral|Behavioral Activation Therapy|Participate in BA counseling
75926438|NCT05044546|Procedure|Discussion|Participate in focus group
75926439|NCT05044546|Behavioral|Health Education|Participate in health and wellness education counseling
75926440|NCT05044546|Other|Questionnaire Administration|Ancillary studies
75926441|NCT05044546|Other|Tobacco Cessation Counseling|Participate in smoking cessation counseling
75926442|NCT05041998|Device|Trans-femoral prosthetic socket|"Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~Soft socket (Socket made from softer material than unmodified original)~Stiff socket (Socket made from stiffer material than unmodified original)~moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~Oversized socket (The socket volume is 6% larger than the unmodified original)~Undersized socket (The socket volume is 6% smaller than the unmodified original)~CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)"
75333116|NCT02929160|Procedure|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
75333117|NCT05504148|Drug|crocin|Take saffron total glucosides tablets for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day.
75333118|NCT05504148|Drug|Placebo|Take placebo piece during for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day
75333119|NCT02566902|Device|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
75642095|NCT04212663|Procedure|Fascial release|To cut off the metatarsal fascia in the middle part.
75333120|NCT02566902|Device|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
76081689|NCT02984007|Other|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the research assistant.
75790241|NCT05165940|Behavioral|New Health Services Intervention|The experimental care coordination intervention begins with a 60-minute in-person session and continues with regular, brief contacts between the Veteran and clinician. During the first session, the clinician and Veteran will (1) discuss the Veteran's beliefs about their presenting problem; (2) collaboratively identify SMART goals; (3) discuss treatment options; (4) use shared decision-making to match treatment to SMART goals; (5) develop criteria to evaluate treatment progress; and (6) manage treatment expectations. During follow-up sessions, the clinician and Veteran will reflect on treatment progress, make appropriate updates to SMART goals, and re-evaluate barriers to CPT or PE.
75790242|NCT05165472|Other|Quadri-pulse theta burst stimulation|High frequency transcranial quadri-pulse theta burst stimulation prior to hand motor function training
75790243|NCT05162755|Drug|S095029|S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
75790244|NCT05162755|Drug|S95029 and Sym021|Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
75790245|NCT05162755|Drug|S095029 and Sym021 and anti-HER2 therapy|Patients will be administered with S095029, Sym021 and anti-HER2 therapy.
75790246|NCT05162755|Drug|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|Patients will be administered with S095029, Sym021 and futuximab/modotuximab.
75790247|NCT05147584|Device|Dual fetal oxygen sensors|Placement of both internal and external fetal oxygen sensors
75926443|NCT05039281|Biological|Atezolizumab|Given IV
75926444|NCT05039281|Drug|Cabozantinib|Given PO
75926445|NCT05031494|Drug|YH003|YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
75926446|NCT05031494|Drug|Toripalimab|Toripalimab will be administered at a dose of 240 mg every 3 weeks.
75926447|NCT05031494|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
76081690|NCT01350388|Drug|Febuxostat|80 mg/day of febuxostat for 24 weeks
75790248|NCT05143138|Device|GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent
75790249|NCT05142189|Biological|BNT116|intravenous injection
75790250|NCT05142189|Biological|Cemiplimab|intravenous infusion
75790251|NCT05142189|Drug|Docetaxel|intravenous infusion
75790252|NCT05142189|Drug|Carboplatin|intravenous infusion
75790253|NCT05142189|Drug|Paclitaxel|intravenous infusion
75790254|NCT05141487|Device|UroMonitor|The UroMonitor is small wireless sensor that is temporarily inserted into the bladder. While in the bladder it transmits bladder pressure measurements to an external radio. After a short period of use it is removed using an extraction string and discarded.
75926448|NCT05031494|Drug|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
75926449|NCT05024955|Procedure|Discussion|Attend a focus group
75926450|NCT05024955|Other|Interview|Attend interview
75926451|NCT05023889|Drug|patisiran|"Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days)."
75926452|NCT05022368|Device|LabraGuard|Protection of the lips and the oral commissure during transoral procedures
75926453|NCT05019703|Biological|Atezolizumab|Given IV
76081691|NCT01350388|Drug|Placebo|1 placebo tablet per day for 24 weeks
76081692|NCT03154749|Drug|DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)|All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
76081693|NCT03633396|Biological|Imsidolimab|Administered by subcutaneous injection once a month
76081694|NCT03633396|Drug|Placebo|Administered by subcutaneous injection once a month
75333121|NCT02566902|Drug|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
75333122|NCT02566902|Procedure|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
75333123|NCT02566902|Procedure|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
75926454|NCT05019703|Drug|Cabozantinib|Given PO
75926455|NCT05019651|Device|Apollo Wearable System|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
76081695|NCT03422718|Behavioral|Healthy Behavior Texts|Participants receive motivational health behavior texts
76081696|NCT03422718|Behavioral|No healthy behavior texts|Participants do not receive healthy behavior texts
75790255|NCT05141487|Device|ASCU|The ASCU is a wearable nerve stimulator containing a radio and computer processor. It receives pressure information from the bladder and determines when to turn on sacral nerve stimulation. It is only used temporarily during research visits.
76081697|NCT03422718|Behavioral|BP Monitoring Daily Via Text Messaging|Daily text messages will prompt participants for BP by home cuff
75926456|NCT05014074|Other|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
75926457|NCT05010681|Drug|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
75926458|NCT05010681|Drug|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
76081698|NCT03422718|Behavioral|BP Monitoring Weekly Via Text Messaging|Weekly text messages will prompt participants for BP by home cuff
76081699|NCT03422718|Behavioral|Physician appointment and transportation scheduling|Participants receive assistance scheduling physician appointment and transportation to those appointments
76081700|NCT03422718|Behavioral|No physician appointment and transportation scheduling|Participants do not receive assistance scheduling physician appointment or transportation
76081701|NCT00988065|Drug|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
76081702|NCT00988065|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
75333124|NCT01454960|Behavioral|Clinical Decision Support: Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
76081703|NCT00988065|Drug|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
76081704|NCT00988065|Drug|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
76081705|NCT03422640|Drug|Apremilast|Open label treatment with apremilast
76081706|NCT03427164|Procedure|Transjugular Intrahepatic Portosystemic Shunt|The TIPS procedures creates an artificial shunt from the portal vein to the hepatic vein. TIPS allows blood from the congested portal circulation to bypass the fibrotic liver and directly enter the systemic circulation.
76081707|NCT05601297|Other|questationair|acceptability of women to partner violance
76081708|NCT01351090|Drug|Ketorolac tromethamine|10 mg Intranasal (2 x 100 uL of a 5% solution)
76081709|NCT01351090|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution)
76081710|NCT01351090|Drug|Placebo|Intranasal
76081711|NCT01918644|Radiation|stereotactic body radiation therapy|Undergo SBRT
76081712|NCT01918644|Drug|capecitabine|Given PO
76081713|NCT01918644|Procedure|therapeutic conventional surgery|Undergo definitive surgery
75333125|NCT01454960|Behavioral|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
75333126|NCT01454960|Behavioral|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
75333127|NCT03820154|Diagnostic Test|Skin Prick Test|Skin Prick Testing with inhalant allergens
75790256|NCT05140954|Drug|co-formulated 25mg TAF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
75790257|NCT05140382|Drug|AZD4573|AZD4573 will be given intravenously
75790258|NCT05138848|Behavioral|Time in Bed Restriction|Participants will undergo a 4-week sleep intervention that includes specified in- and out-of-bed times as well as a restriction to their habitual time in bed (average sleep opportunity including naps). This will be truncated equally at the beginning and end of the night.
75790259|NCT05138848|Behavioral|Sleep Schedule|Participants will maintain their typical sleep schedule for 4-weeks.
75926459|NCT05010668|Drug|cryoablation|Cryoablation treatment starts at day 0.
75926460|NCT05010668|Drug|Sintilimab|Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
75926461|NCT05010668|Drug|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
75926462|NCT05008874|Other|Natural History Observation|Data collection on progression of disease
76081714|NCT01918644|Procedure|magnetic resonance imaging|Optional correlative studies
76081715|NCT01918644|Other|laboratory biomarker analysis|Optional correlative studies
76081716|NCT00987831|Other|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
76081717|NCT00987831|Other|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
76081718|NCT00987831|Drug|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
76081719|NCT03608358|Drug|Dapagliflozin 10 mg|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
76081720|NCT03608358|Drug|Dapagliflozin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
76081721|NCT03608358|Drug|Dapagliflozin 10 mg placebo to match|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
75790260|NCT05136859|Procedure|preserve|preserve the perivascular fat of the target cephalic vein
75926463|NCT04996940|Device|E-cigarette product|"Participants will be randomized 1:1 to e-cigarette flavor order either:~tobacco e-cigarette~menthol e-cigarette"
75926464|NCT04979377|Other|Clinical hyperandrogenism assessment|Modified Ferriman-Gallwey scale
76081722|NCT03608358|Drug|Dapagliflozin 5 mg placebo to match|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
75642096|NCT05490940|Drug|Tisseel®|"The investigational medical product (IMP) in this study is Tisseel®, which is a tissue sealer consisting of two components:~Sealer protein: Human fibrinogen as glue component and synthetic Aprotinin, which delays fibrinolysis.~Human thrombin: Thrombin is an unique molecule that functions both as a procoagulant and anticoagulant. It activates platelets through its receptor on the platelets and regulates its own. generation by activating coagulation factors V, VIII and even XI resulting in a burst of thrombin formation.~Its indications are a better hemostasis, enforcement of vessel/gastrointestinal sutures and tissue sutures (mesh grafts, flaps etc)."
75642097|NCT04304261|Drug|Dapagliflozin|Near infrared detection of brain function in diabetic patient at baseline and after 12 weeks of Dapagliflozin(10mg/day) treatment
75642098|NCT04304261|Drug|Metformin|Near infrared detection of brain function in diabetic patient at baseline and after 12 weeks of Metformin (1500-2000mg/day) treatment
75790261|NCT05121337|Behavioral|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
75926465|NCT04979377|Diagnostic Test|Total testosterone (ng/dL)|Circulating total testosterone (LC-MS/MS or IQL-CDC method) at follicular phase
75926466|NCT04979377|Diagnostic Test|A1c (%)|High Performance Liquid Chromatography (HPLC)
75926467|NCT04979377|Diagnostic Test|Total cholesterol|Determined by enzymatic methods
75926468|NCT04979377|Other|Body mass index (BMI) (kg/m2)|Defined as body weight divided by the square of body height, and expressed in kg/m2
75926469|NCT04979377|Diagnostic Test|Frequency of chronic vascular complications [n (%)]|Retinopathy, nephropathy, neuropathy, and macrovascular disease.
76081723|NCT03608358|Drug|Saxagliptin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
76081724|NCT03608358|Drug|Metformin|Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
76081725|NCT04274907|Drug|Venetoclax|Tablet: Oral
76081726|NCT04274907|Drug|Pembrolizumab|Intravenous (IV) Infusion
75471511|NCT05875285|Other|Iontophoresis with methotrexate|"The methotrexate iontophoresis group the patient's hands are placed in direct contact with the conductive electrodes.~The patient will receive full explanation to the purpose of the treatment, the therapeutic and physiological benefits of this method of treatment. Before starting the treatment, all the previous measurements of each patient in this group is taken for a comparison.~Every patient will receive 12 sessions 3times/week every session consist of 30 minutes application of methotrexate iontophoresis using continuous direct current, the patient should feel mild tingling sensation (not painful), the polarity should be reversed halftime of treatment session, as the anodal current is more effective."
75926470|NCT04979377|Diagnostic Test|Polycystic ovary morphology|Sonographic assessment
76081727|NCT01256164|Device|Fibrocaps (fibrin sealant)|Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
75471512|NCT05875285|Other|Iontophoresis with coal tar ointement|For coal tar ointement group the ointement is putted direct on the skin after describing the instruction and method of application and time of application and do alarm instead not to forget.
75471513|NCT05875194|Device|active transcranial direct current stimulation (tDCS)|2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
75926471|NCT04979377|Diagnostic Test|Cardiovascular autonomic reflex tests (CARTs)|Cardioautonomic function assessement by Vital scan HW7-HW6T:
75926472|NCT04979377|Diagnostic Test|Sex hormone-binding globulin (SHBG) (nmol/L)|Circulating SHBG (IQL) at follicular phase
75926473|NCT04979377|Diagnostic Test|Dehydroepiandrosterone-sulphate (IQL) (ng/mL)|Circulating DHEAS (IQL) at follicular phase
75926474|NCT04979377|Other|Waist circumference (cm)|Waist circumference measurement made at the top of the iliac crest
75926475|NCT04979377|Other|Waist-to-hip ratio|Waist circumference divided by hip circumference (measurement should be taken around the widest portion of the buttocks)
75926476|NCT04979377|Other|Body composition|Vital Scan HW7-HW6T
75926477|NCT04979377|Diagnostic Test|Mean glucose (mg/dL)|Continuous glucose monitoring (GCM) records
75926478|NCT04979377|Diagnostic Test|Time in target range (hours)|Continuous glucose monitoring (GCM) records
75926479|NCT04979377|Diagnostic Test|Time in hyperglycemia (hours)|Continuous glucose monitoring (GCM) records
75926480|NCT04979377|Other|Insulin dose (UI/Kg)|Daily insulin dose divided by body weight
75926481|NCT04979377|Other|Insulin sensitivity|Equation that relies on routine clinical measures: A1c, presence of hypertension, and waist circumference
75926482|NCT04979377|Diagnostic Test|High-density lipoprotein (HDL) (mg/dL)|Enzymatic methods after precipitation of serum with phosphotungstic acid and Mg2+
75926483|NCT04979377|Diagnostic Test|Low-density lipoprotein (LDL) (mg/dL)|Estimated by the Friedewald's equation.
75926484|NCT04979377|Diagnostic Test|Triglycerides (mg/dL)|Determined by enzymatic methods
75926485|NCT04965181|Behavioral|Mindfulness-Based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly virtual 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation.
75790262|NCT05121337|Behavioral|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
75790263|NCT05116683|Drug|ATX-101|Patients will be given ATX-101 at 60 mg/m2 IV weekly in continuous 21 day cycles.
75790264|NCT05113069|Drug|SHR-A1912|SHR-A1912, dose escalation and expansion.
75642099|NCT04212585|Diagnostic Test|Serology test|"Serology for Helicobacter pylori (immunoglobulin G for all sites, immunoglobulin M optional, immunoglobulin A optional) will be collected from all participants. 90 samples (immunoglobulin G, immunoglobulin M and immunoglobulin A) at least needed from each site.~Stool antigen for Helicobacter pylori"
75926486|NCT04965181|Drug|Nicotine Replacement Therapy|"Patch therapy (beginning quit day) for participants who smoke >10 cigarettes/day will consist of 4 weeks of 21 mg patches, 2 week of 14 mg patches, and 2 week of 7 mg patches. Patch therapy for participants who smoke less than 10 cigarettes/day will consist of 4 weeks of 14 mg patches and 4 weeks of 7 mg patches.~Lozenge therapy (beginning quit day) for participants who smoke first cigarette within 30 minutes of waking up will consist of 8 weeks of 4mg lozenges. Lozenge therapy (beginning quit day) for participants who smoke first cigarette 30 minutes of more after they wake up will consist of 8 weeks of 2mg lozenges."
75926487|NCT04965181|Behavioral|Self-help materials|"Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al., 2008) and include the Clearing the Air booklet developed by the National Cancer Institute (NCI) and a referral to the Tobacco Cessation Quitline (1-800-QUIT-NOW)."
75798837|NCT01180062|Drug|Latanoprost|"Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost."
75798838|NCT01180062|Drug|Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
75798839|NCT01180062|Drug|Latanoprost SR insert|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
75926488|NCT04965181|Behavioral|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
75926489|NCT04964167|Combination Product|Plant extract|Natural plant extract
75926490|NCT04964128|Device|MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)|The AHCL system with Meal Gesture Dosing evaluated in this study includes a commercial/CE-Marked insulin pump with investigational software, and the Klue Health mobile app with investigational software (installed on Apple Watch) for meal gesture detection and micro dosing.
75926491|NCT04954794|Drug|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
76081728|NCT01256164|Device|Gelfoam|An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
76081729|NCT03422484|Other|Detection and correction of medication error at hospital admission|Detection and correction of medication error at hospital admission
76081730|NCT03427086|Drug|Biotin|High dose biotin
76081731|NCT03427086|Drug|Placebo Oral Tablet|Placebo tablet similar in shape and size to the biotin tablet
76081732|NCT03148665|Device|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
76081733|NCT03427008|Other|mHealth Intervention|The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
75333128|NCT03820154|Diagnostic Test|Skin Prick Test TAPE|Skin Prick Testing with a Tape, integrating the allergens and needles
75333129|NCT05508516|Drug|Shugan Dingtong decoction|Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
75333130|NCT05508516|Drug|Duloxetine Hydrochloride|Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
75333131|NCT03820076|Other|AZT-04|Staphylococcus epidermidis
75471514|NCT05875155|Diagnostic Test|Infectious Disease Labwork|Infectious disease labs will be drawn and resulted.
75471515|NCT05875155|Diagnostic Test|Fertility-Based Labwork|Other labwork to understand fertility may be drawn.
75471516|NCT05875064|Combination Product|Restoration with resin composite and polyvinyl crown|Restorative treatment of anterior primary teeth with monochromatic composite resin in single insertion through polyvinyl crowns, after selective removal of carious tissue compared to the effectiveness of conventional restoration.
75471517|NCT05875064|Procedure|Restoration with conventional resin composite|Restorative treatment of anterior primary teeth with conventional composite resin, after selective removal of carious tissue
75333132|NCT05563740|Other|Psychosocial|Daily telephone calls with two sessions of Brief Interventions for alcohol
75333133|NCT05503914|Radiation|low-dose radiotherapy|On the first and second days of induction chemotherapy, local tumor were irradiated with 0.5Gy bid for 4 times.
75642100|NCT02874911|Other|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
75642101|NCT00618735|Drug|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
75642102|NCT00618735|Drug|BIIB021|Twice daily dosing
75642103|NCT02874677|Other|Effort reeducation program|personalized reeducation program at a load level preceding hyperventilation
76081734|NCT00986973|Drug|Sapropterin|All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
76081735|NCT01887522|Drug|Vinblastine + Nilotinib|"Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28"
75642104|NCT02580721|Device|Dentsply Astra Tech Implant System EV|Dentsply Astra Tech Implant System EV will be placed
76081736|NCT01887522|Drug|Vinblastine|· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
76081737|NCT03422406|Other|Dietary iodine intake restriction|All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
76081738|NCT03426930|Other|self-evaluation of the Body Mass Index|Evaluation of the Body Mass Index before and after the treatment
76081739|NCT03426930|Other|Cognitive-behavioral psychotherapies|Cognitive-behavioral psychotherapies before and after the treatment
76081740|NCT00986427|Drug|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
76081741|NCT00986427|Drug|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
76081742|NCT05245461|Other|Assessments|Muscle Strength, Proprioception, Kinesiophobia
75642105|NCT02037945|Procedure|18F-FCH PET Scan|
76081743|NCT03426852|Other|No intervention|No intervention
76081744|NCT05601063|Behavioral|Winterlight Speech Assessment|Digital assessment of speech and language abilities
75333134|NCT01455506|Drug|Decitabine plus Fludarabine and Busulfan|"Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient >20% above ideal body weight~Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.~Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.~Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.~Hematopoietic cells will be infused on day 0."
75333135|NCT05563428|Procedure|Free gingival graft|A free gingival graft will be carried out for recession treatment.
75333136|NCT05563428|Procedure|Connective tissue graft|The pouch technique with a connective tissue graft will be carried out for recession treatment.
75333137|NCT03821012|Other|in-hospital process optimization|
75333138|NCT03821012|Other|PPCI hospital-based regional STEMI transfer network construction|
75642106|NCT00768430|Drug|Ketamine|Single dose .5 mg/kg IV (in the vein) infused over 40 minutes
75642107|NCT00768430|Drug|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
75642108|NCT04211883|Behavioral|ACTIVE intervention|The Project ACTIVE intervention was adapted to suit workflow demands of our busy inner-city clinic: (1) identify patients who could most benefit from improvements in adherence to evidence-based preventive care, (2) use a validated mathematical model to quantify and rank the estimated amount of health benefit that would arise from improved adherence to each USPSTF preventive care guideline, (3) communicate this information in a manner informed by risk communication studies relevant to patients from disparate cultural groups and with low literacy and numeracy, (4) engage the patient in a shared decision making process in which the patient identified which preventive health goals aimed to achieve, and (5) set particular action steps for the next visit that were congruent with these goals .
75642109|NCT04212195|Genetic|Next generation sequencing|Saliva samples
75790265|NCT05111925|Other|PREPARE Initial Clinical Assessment - Pilot (two iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~Two-Minute Walk~Gait~Double Leg Squat~Single Leg Squat~Jump-Landing~Single Leg Triple Hop~Closed Kinetic Chain Upper Extremity Stability Test~Functional Movement Screen Shoulder Clearing Test~Prone Plank~Active Hip Abduction~Joint range of motion assessments:~Knee Extension~Hip Abduction~Hip Internal Rotation~Hip External Rotation~Ankle Dorsiflexion~Psychosocial assessments:~NIH PROMIS Physical Function, Pain Interference, Depression, & Anxiety~Tampa Scale of Kinesiophobia"
75790266|NCT05111925|Other|PREPARE Initial Clinical Assessment - Pre-Injury (one iteration)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~Two-Minute Walk~Gait~Double Leg Squat~Single Leg Squat~Jump-Landing~Single Leg Triple Hop~Closed Kinetic Chain Upper Extremity Stability Test~Functional Movement Screening Shoulder Clearing Test~Prone Plank~Active Hip Abduction~Joint range of motion assessments:~Knee Extension~Hip Abduction~Hip Internal Rotation~Hip External Rotation~Ankle Dorsiflexion~Psychosocial assessments:~NIH PROMIS Physical Function, Pain Interference, Depression, & Anxiety~Tampa Scale of Kinesiophobia"
76081745|NCT03426774|Device|Gentle Jogger|Passive Simulated Jogging device (Gentle Jogger)
76081746|NCT03426774|Device|Gentle Jumper|Passive Simulated Jumping Device ( Gentle Jumper)
76081747|NCT02842320|Other|biological samples|bone marrow and blood
76081748|NCT00986349|Device|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
75333139|NCT03821012|Other|the whole-city STEMI care network construction|
75642110|NCT04212195|Diagnostic Test|Imaging and fluid biomarkers|Magnetic resonance imaging of the brain and urine, blood and cerebrospinal fluid sampling
76081749|NCT03426696|Behavioral|psychological condition|Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
76081750|NCT03426618|Other|Non-interventional|Non-interventional
76081751|NCT03429192|Procedure|Surgery|Surgeries plus dissection of lymph nodes
75926492|NCT04954794|Combination Product|TACE|TACE is performed by using drug-eluting beads or using microspheres combined with Lipiodol-pirarubicin emulsion per Investigator's decision. TACE treatment starts at day 0. Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after TACE.
75642111|NCT04101136|Drug|Atorvastatin - placebo controlled clinical trial|The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
75642112|NCT00618969|Other|haploidentical allogeneic PBSC transp|"Days -5 and -4: IV busulfan 3.2 mg/kg/dose daily for 2 days~Day -3: IV melphalan 100 mg/m2 as a single dose~Days -2 and -1: IV alemtuzumab 30 mg/dose daily for 2 days~Day 0: Transplantation of haploidentical related allogeneic peripheral blood stem cells (PBSCs)- target cell dose 10 x 106 donor CD34+ cells per kilogram of recipient weight"
75642113|NCT01064297|Drug|Lamotrigine monotherapy|Lamotrigine monotherapy
75642114|NCT01064297|Drug|Lamotrigine polytherapy including valproate|Lamotrigine polytherapy including valproate
76081752|NCT03426540|Drug|Conbercept|Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
76081753|NCT03426462|Drug|Propofol|Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
76081754|NCT03421938|Other|Walking Exercise|Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..
75926493|NCT04943341|Procedure|Eco-guided Triamcinolone-Acetonide injection|"The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with in plane technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed."
76081755|NCT03421860|Drug|"cardiac output changes with ephedrine"|measure cardiac output after giving a bolus of ephedrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
76081756|NCT03421860|Drug|"cardiac output changes with phenylephrine"|measure cardiac output after giving a bolus of phenylephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
75642115|NCT01064297|Drug|Lamotrigine polytherapy without valproate|Lamotrigine polytherapy without valproate
76081757|NCT03421860|Drug|"cardiac output changes with ondansetron"|measure cardiac output after giving a bolus of ondansetron intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
75471518|NCT05875051|Other|Reduced-exertion high intensity training|The intervention of the REHIT group will consist of three parts: i) 3 minutes of warm-up part at 50% of HRmax obtained in the effort test; ii) 3 min 20 sec to 3 min 40 sec of REHIT; and iii) 3 minutes of cool-down at 50% of HRmax obtained in the effort test. The REHIT part will consist of maximum cycling sprints of all-out exercise at 100% of the HRmax, increasing for up to 10 seconds, 15 seconds on week two and 20 seconds on week three. Then, 3 minutes of active rest at 50% of HRmax. Finally, 10 seconds of all-out exercise at 100% of the HRmax, rising to 15 seconds on week two and 20 seconds on week three.
75926494|NCT04931056|Device|Titanium Facial Plates|The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.
75926495|NCT04931056|Device|Titanium Mandibular Plates|"The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length."
76081758|NCT03421860|Drug|"cardiac output changes with nor-epinephrine"|measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
75642116|NCT00619125|Other|palm pilot recording responses to questionnaires|Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
75642117|NCT01939665|Device|"NanoKnife Irreversible electroporation (IRE)"|Tumor ablation with irreversible electroporation with the NanoKnife
75642118|NCT00781456|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
75642119|NCT00781456|Drug|Placebo|1 tablet daily to match experimental arm
75642120|NCT04984447|Device|TNIB Catheter|Subjects will be asked to fast for 8 hours prior to study procedure and no liquids 2 hours prior to study procedure. Lidocaine jelly will may be used to help insert the TNIB Catheter through the Nares. Once inserted past the pharynx, imaging will begin. We will attempt to image the duodenum within 3 hours of study procedure starting.
75642121|NCT00627263|Behavioral|Stress reduction treatment (SRT) program|The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
76081759|NCT03426384|Behavioral|Mymee Program|A combination of digital therapeutics and telephonic health coaching is used to identify and test dietary, lifestyle, and environmental triggers in order to reduce symptoms of auto-immune disease.
75333140|NCT05508438|Device|Transfemoral mitral-valve repair|Transfemoral mitral-valve repair
75333141|NCT03822104|Dietary Supplement|Bovine Colostrum|Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.
75790267|NCT05111925|Other|PREPARE Initial Clinical Assessment - Post-Injury (up to three iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report thee most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~Two-Minute Walk~Gait~Double Leg Squat~Single Leg Squat~Jump-Landing~Single Leg Triple Hop~Closed Kinetic Chain Upper Extremity Stability Test~Functional Movement Screening Shoulder Clearing Test~Prone Plank~Active Hip Abduction~Joint range of motion assessments:~Knee Extension~Hip Abduction~Hip Internal Rotation~Hip External Rotation~Ankle Dorsiflexion~Psychosocial assessments:~NIH PROMIS Physical Function, Pain Interference, Depression, & Anxiety~Tampa Scale of Kinesiophobia"
75642122|NCT02580175|Procedure|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.
76081760|NCT04448730|Diagnostic Test|serum marker levels|two groups comparisons
76081761|NCT03421626|Device|Xpert BCR-ABL Ultra|Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML
76081762|NCT04449120|Behavioral|Mediterranean diet-based culinary intervention|The culinary intervention was developed integrating four culinary workshops that were given every week, once per week, during one-month intervention. The duration of each culinary workshop was 3,5 h, thus, the program provided a total of 14h of practice in cooking activities. The courses took place in a well-equipped kitchen from the Basque Culinary Center. Each culinary workshop was divided in two differentiated parts in order to work on the specific objectives established for each day. All cooking classes began with a theoretical introductory part that aimed to explain the main take-home messages from the workshop. Subsequently, every class was characterized by a hands-on part that included the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients. At the end of the session, participants were encouraged to taste the prepared meals, to share their preferences and their view about the cooking experience.
76081763|NCT04449120|Behavioral|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
75642123|NCT02580175|Procedure|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
76081764|NCT03421548|Device|EyeMate|Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.
76081765|NCT04448652|Drug|NSAID|no other intervention than described in the groups.
75642124|NCT02874521|Other|Intra-dialytic LF-EMS|Electrical muscle stimulation during haemodialysis
75642125|NCT02874521|Other|Intra-dialytic cycle training|Cycle training during haemodialysis
75798840|NCT03857958|Procedure|endoscopic retrograde cholangio-pancreatography|In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
75926496|NCT04931056|Device|Add-on Condyle|The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.
76081766|NCT03483324|Biological|Unmanipulated Umbilical Cord Blood (UCB)|Human leukocyte antigen (HLA) matched umbilical cord blood
76081767|NCT03483324|Biological|AB-110|Expanded cord blood stem cells and engineered human endothelial cells
75471519|NCT05875051|Other|Short moderate intensity training|The SMIT group will receive a short moderate-intensity training with the same warm-up and cool-down exercises as the REHIT group. In addition, the main part of the session consisted of 6 minutes of moderate intensity exercise at 60-70% HRmax obtained in the effort test. In addition, the main part of the session increases 3 min every week as 6 min for the first 2 weeks, 9 min for the 3rd and 4th weeks, and 12 min for the last two weeks.
75642126|NCT03798223|Procedure|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
75798841|NCT01289106|Biological|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
75926497|NCT04931056|Device|HTR-PEKK|The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
75926498|NCT04901156|Device|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
75333142|NCT03822104|Dietary Supplement|FM85|Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
76081768|NCT03426150|Drug|CPP-ACP|The surfaces of specimens were pretreated with CPP-ACP for 3 min
76081769|NCT03426150|Drug|Placebos|The surfaces of specimens were pretreated with deionized water for 3 min
76081770|NCT02053584|Device|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
76081771|NCT02053584|Device|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
76081772|NCT03127878|Other|Exercise|
75926499|NCT04901156|Behavioral|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
76081773|NCT03421314|Dietary Supplement|Zinc gluconate and/or Selenium yeast|30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast
76081774|NCT03421236|Biological|Ty21a|intravesical administration of Ty21a
76081775|NCT03425994|Drug|Elvitegravir/Cobicistat/Emtricitabine|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya) film coated tablet
76081776|NCT03421158|Behavioral|breastfeeding|Newborns were breastfed during the procedure
76081777|NCT03421158|Dietary Supplement|oral sucrose|Newborns were given oral sucrose during the procedure
75790268|NCT05111925|Other|PREPARE Optimized Clinical Assessment|"Participants will complete an optimized set of clinical assessments that may include semi-automated field-expedient functional movement quality, joint ranges of motion, and/or psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~Two-Minute Walk~Gait~Double Leg Squat~Single Leg Squat~Jump-Landing~Single Leg Triple Hop~Closed Kinetic Chain Upper Extremity Stability Test~Functional Movement Screening Shoulder Clearing Test~Prone Plank~Active Hip Abduction~Joint range of motion assessments:~Knee Extension~Hip Abduction~Hip Internal Rotation~Hip External Rotation~Ankle Dorsiflexion~Psychosocial assessments:~NIH PROMIS Physical Function, Pain Interference, Depression, & Anxiety~Tampa Scale of Kinesiophobia"
75926500|NCT04901156|Device|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
75926501|NCT04890067|Other|Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
75471520|NCT05875038|Other|video system|The video surveillance system will analyze the position of subjects in real time using algorithms based on artificial intelligence. The system works continuously without video capture and sends an alert with a photo if a person is lying down after a fall. The alert is confirmed after an operator has checked the photo capture on a dedicated platform.
76081778|NCT03421158|Behavioral|Skin-to-Skin contact|Newborns were placed in direct contact with their mothers during the procedure
76081779|NCT03421158|Behavioral|Non-nutritive sucking|newborns were given a pacifier to suck on during the procedure
75471521|NCT05875038|Other|Tele-alarm|Tele-alarm
75471522|NCT05875012|Other|action observation physical training|Action observation training 3 sessions per week for 3 successive months
75790269|NCT05111561|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
76081780|NCT03421080|Behavioral|MoodGYM|The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.
76081781|NCT03421080|Behavioral|Check Your Drinking|Internet intervention designed to assess and provide feedback on hazardous alcohol use. The CYD has been subjected to seven randomized trials from two independent research groups, all of which displayed a significant impact of the CYD to reduce hazardous alcohol consumption compared to controls.
76081782|NCT03416712|Other|Screening survey and accompanying handout for resources|Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
76081783|NCT03425916|Other|Physical therapy intervention|Primiparous women start a physical therapy intervention in week 6 after normal one-child delivery, based on abdominal and pelvic floor exercises, education and behavior advices. Abdominal muscle condition and activation are measured by transabdominal ultrasound and surface electromiography. This group is going to be examined after treatment and 6 and 12 months after treatment.
75471523|NCT05875012|Other|Traditional physical therapy training|Traditional physical therapy training 3 sessions per week for 3 successive months
75471524|NCT05874986|Other|Resistance training|12-week resistance training intervention
75471525|NCT05874934|Device|Intrahepatic biliary stent with retrieval string|Plastic biliary stent with 3-0 nylon (ethilon) thread tied to the distal end of the stent through the existing sidehole.
75642127|NCT04205825|Other|The New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
75642128|NCT04028089|Behavioral|Diet Modification Group|The diet modification group will receive diet counselling by an experienced dietician at least every four weeks throughout pregnancy starting in the first trimester. The dietary counselling will be guided by the individual glucose profiles obtained through flash glucose monitoring.
75642129|NCT04028089|Other|Regular Diet Group|"Participants of the standard diet will receive general diet counselling on one occasion at the onset of the study."
75642130|NCT05674123|Procedure|Colonoscopy|Undergo colonoscopy
75642131|NCT05674123|Procedure|Endoscopic Ultrasound|Undergo rectal endoscopic ultrasound
75642132|NCT05674123|Other|Medical Chart Review|Ancillary studies
75642133|NCT05674123|Other|Medical Device Usage and Evaluation|Undergo resection with the Flex Robotic System
75642134|NCT05674123|Procedure|Resection|Undergo resection with the Flex Robotic System
75333143|NCT02564796|Drug|Epoetin Alfa and Iron|Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
75926502|NCT04887987|Radiation|strengthening training and LED PBMT|Participants will be submitted to a supervised 8-wk training program (3 d/week) involving a specific lumbar extension exercise on the Roman bench and four complementary exercises to improve core strength and spine stabilization. Participants will receive LED PBMT 30 minutes before each training session, through a device containing 264 LEDs, which will be placed on the lumbar region (between L1 and L5).
75926503|NCT04887987|Radiation|strengthening training and placebo PBMT|Participants will be submitted to a supervised 8-wk training program (3 d/week) involving a specific lumbar extension exercise on the Roman bench and four complementary exercises to improve core strength and spine stabilization. Participants will receive placebo PBMT 30 minutes before each training session, through a off-line device (turned off) containing 264 LEDs, which will be placed on the lumbar region (between L1 and L5).
75926504|NCT04881760|Drug|LY3437943|Administered SC
75926505|NCT04881760|Drug|Placebo|Administered SC
76081784|NCT03416634|Behavioral|App|The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
75333144|NCT02564796|Drug|Iron|Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
75333145|NCT05563350|Diagnostic Test|Blood samples|p-chlordiazepoxide and metabolites, p-omeprazole and metabolites, p-midazolam and metabolites, CYP3A4 and CYP2C19 genotyping
75333146|NCT05503836|Procedure|abdominal surgeries|abdominal surgeries
75333147|NCT01455584|Drug|HM781-36B tablets|Q1X28D/4W for HM781-36B tablets
75333148|NCT04273100|Combination Product|PD-1 mAb combined with TACE and lenvatinib|the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib)
75471526|NCT05874882|Other|resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
75471527|NCT05874882|Other|chlorhexidine mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
75642135|NCT00626873|Drug|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
75642136|NCT00626873|Other|medical chart review|
75642137|NCT02579941|Procedure|Blood sampling (pregnant)|"5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
75642138|NCT02579941|Procedure|Blood sampling (non pregnant)|"5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
75642139|NCT02874209|Other|sodium MRI|
75642140|NCT04205591|Procedure|split bone block technique|A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants
75790270|NCT05111561|Drug|Binimetinib|Given PO
75790271|NCT05111561|Procedure|Biopsy|Undergo biopsy
75790272|NCT05111561|Procedure|Biospecimen Collection|Undergo collection of blood samples
75790273|NCT05111561|Procedure|Computed Tomography|Undergo CT
75790274|NCT05111561|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790275|NCT05105633|Drug|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
75790276|NCT05105633|Drug|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
75790277|NCT05102929|Device|active intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with patients with schizophrenia. This research study is using iTBS off label in SCZ patients to examine research questions.
75790278|NCT05102929|Device|sham intermittent Theta Burst Stimulation (iTBS)|"Sham TBS over the left DLPFC will be performed using a Cool-B65 A/P TMS coil, designed to support blinded clinical trials. Specifically, when the coil is placed in the P position (i.e. the placebo position), only a very small amount of current is induced in tissue, thus preventing the activation of cortical neurons."
75642141|NCT04302701|Other|Dichoptic treatment using virtual reality|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
76081785|NCT03416634|Behavioral|Wearable Device|A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
76081786|NCT03416634|Behavioral|Automated Motivational Message|An automated behavioral intervention will be delivered once weekly via an in-app motivational message, over the 12-week intervention period.
76081787|NCT03416634|Behavioral|Personalized Motivational Message|A behavioral intervention will be delivered once weekly via an in-app motivational message adapted to each patient's personalized PA goal progression based on the previous week data from the smartphone activity app (Microsoft band) or the Garmin wearable device over a 12-week intervention period.
76081788|NCT03421002|Drug|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
75333151|NCT01457222|Behavioral|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
75926506|NCT04879797|Other|Implementation of Maternal Safety Bundles|In the second phase, implementation of the bundles will take place. During this phase investigators will conduct quarterly surveys with the health facilities to measure implementation progress, including an index of evidence-based practices. Investigators will conduct surveys with postpartum women to measure their patient experience. Surveys will be conducted using RedCap software. Participants will be given the opportunity to complete the survey online or if they prefer, a research assistant can call them to conduct the survey over the phone. Data on SMM will be collected through PELL
76081789|NCT03420924|Device|Thermal suit|Forced-air warming device will be connected to the trouser legs of the thermal suit.
75642142|NCT04302701|Other|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near.
75790279|NCT05102578|Behavioral|Digital Decision Aid Tool|The digital DAT will ask people about their current pain levels, medications and physical activity. Following this, it will include a Discrete Choice Experiment (DCE)-like component with a series of questions that ask users to choose between different pain management packages. Similar to a standard DCE, packages (or plans) are described by attributes and levels, which include broad categories of guideline-based pain management strategies routinely available in clinical practice. The descriptors used for the attributes and levels were informed by a previous qualitative research study and based on therapeutic options that are helpful and important to people with persistent pain .
75926507|NCT04879797|Other|Doula Services|Investigators are evaluating doula services that are offered by two doula organizations at three hospitals.
75926508|NCT04857645|Drug|ASTX727|Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
75926509|NCT04857645|Other|Donor Lymphocyte Infusions|In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
75926510|NCT04848974|Drug|Cladribine|Given IV
76081790|NCT03420924|Device|Conventional hospital clothes|The warming mattress and a forced-air warming blanket for the lower body will be used intraoperatively.
76081791|NCT03420846|Other|OCT Mapped|Presurgical mapping of Basal Cell Carcinoma margins
76081792|NCT02521038|Drug|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
75333152|NCT01457222|Behavioral|Music relaxation|Music relaxation 10 minutes daily
75790280|NCT05102383|Device|Comfilcon A Toric contact lenses|Monthly replacement contact lenses
75790281|NCT05102383|Device|Verofilcon A for Astigmatism Daily Disposable contact lenses|Daily disposable contact lenses
75798842|NCT01289106|Biological|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
75926511|NCT04848974|Drug|Cytarabine|Given SC
75926512|NCT04848974|Drug|Uproleselan|Given IV
75926513|NCT04845893|Other|Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
75926514|NCT04844099|Drug|Dihydroartemisinin Piperaquine|Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
75333153|NCT02564718|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
75333154|NCT01453946|Drug|Entocort|Entocort capsules, taken orally, 6 mg daily.
75333155|NCT05503758|Device|Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|The MyotoPRO device is a portable objective device for measuring the contractile (tone), and biomechanical (stiffness) properties of lumbar paravertebral muscles (LPVMs).
75333156|NCT05508126|Diagnostic Test|DECT examination|DECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).
76081793|NCT03416556|Procedure|Mobilization to the glenohumeral joint|The treatment condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder. In particular, a Grade III AP glide to the humeral head with the arm positioned in 90º of glenohumeral abduction and full internal rotation was used. The posterior gliding force to the humeral head was applied maintaining the glide at right angles to the plane of movement and at a frequency of 2 Hz which was controlled by means of a metronome. The arm was returned to its original position between each set.
76081794|NCT03416556|Procedure|The manual contact condition|During the manual contact condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition. However, a simulated posterior glide was performed but with minimal pressure actually applied. The number of repetitions and sets were as per the treatment condition.
76081795|NCT03416556|Other|No-contact condition|During the no-contact condition, the subject remained in the initial starting position thorough the entire session but there was no manual contact between the therapist and the participant. The total treatment time was the same as per the other conditions.
75471528|NCT05874882|Other|placebo mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
75471529|NCT05874856|Diagnostic Test|Heart rate variability, blood pressure and pulse wave velocity|Resting HRV in supine and standing position, blood pressure and pulse wave velocity in supine position at first and last week of inpatient treatment
75471530|NCT05874856|Diagnostic Test|Assessment of cognitive function, balance, strength and cardiorespiratory fitness|"THINC-it test for cognitive function; One-leg Standing test for balance assessment; 10-time chair rise test and hand grip test for strength assessment; Åstrand-Ryhming Test for cardiorespiratory fitness.~All assessments will be performed at first and last week of inpatient treatment."
75642143|NCT00587158|Drug|Paricalcitol|Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.
75642144|NCT00587158|Other|Corticosteroid Avoidance Immune Suppression Protocol|Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
75642145|NCT04303091|Behavioral|Physical Activity for Advanced Cancer Treatment (PAACT)|12-week physical activity intervention. 60 minute group-based exercise classes held once per week. Home-based exercise recommendations provided weekly along with basic take-home exercise equipment. Optional palliative care consultations offered.
75926515|NCT04837014|Other|prescription for regular acetaminophen and naproxen|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
75926516|NCT04837014|Other|prescription for regular acetaminophen , naproxen and dilaudid|prescription for regular acetaminophen , naproxen and dilaudid
76081796|NCT03416478|Diagnostic Test|ctDNA test|ctDNA test to find some possible mutation.
75333157|NCT05508126|Diagnostic Test|mpMRI examination|The examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).
75471531|NCT05874856|Behavioral|Monitoring of physical activity and sleep|GENEActiv accelerometer will be worn on the wrist daily during 8-week inpatient treatment.
75642146|NCT00582907|Drug|Rilonacept|2.2 mg/kg/wk by subcutaneous injection, for 3 months
75790282|NCT05099393|Dietary Supplement|Non Nutritive Sweeteners|"The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo.~The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period."
75790283|NCT05099367|Diagnostic Test|Microdialysis, current induced vasodilation|"CIV will be applied over all microdialysis fibers: one perfused with saline, one perfused with a preferential COX-1 blocker; and one perfused with a preferential COX-2 blocker.~CIV will be applied over all fibers in the following conditions: one perfused with saline, one perfused with fluconazole and L-NMMA, and the last one perfused with lidocaine.Dialysate collection will be performed after each CIV: dermal PGI2 metabolite (6-ketoPGF1α) and other COX-dependent prostanoids or metabolite (e.g. 11-dehydroTXB2) will be collected in the dialysate fluid and quantified. One hour after the last condition, treprostinil will be perfused over all fibers."
75333158|NCT01455896|Drug|ITCA 650|ITCA 650
75333159|NCT01455896|Other|ITCA placebo|ITCA placebo
75333160|NCT05503602|Other|Classical Physiotherapy|Only classical physiotherapy application, 5 sessions per week for 4 weeks.
75790284|NCT05099367|Diagnostic Test|Skin biopsy|Skin biopsy will be proposed. It will be performed on the internal superior calf (medial gastrocnemius), at a reasonable distance from the foot
75926517|NCT04834349|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
75926518|NCT04834349|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
75926519|NCT04834349|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75926520|NCT04834349|Biological|Pembrolizumab|Given IV
75926521|NCT04834349|Other|Quality-of-Life Assessment|Ancillary studies
75926522|NCT04834349|Other|Questionnaire Administration|Ancillary studies
75926523|NCT04834349|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75333161|NCT05503602|Other|IASTM Technique Application|Instrument-assisted soft tissue mobilization application 2 sessions per week together with 3 sessions of classical physiotherapy per week for 4 weeks. IASTM application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
76081797|NCT03416400|Other|Oocyte vitrification|Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
76081798|NCT00985959|Drug|JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
75926524|NCT04815668|Other|Acupuncture group|Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
76081799|NCT00985959|Drug|JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
76081800|NCT00985959|Drug|JNJ-26866138 1.3 mg/m2|Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
76081801|NCT00985959|Drug|Melphalan|Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
76081802|NCT00985959|Drug|Prednisolone|Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
75642147|NCT00582907|Drug|Placebo|placebo by subcutaneous injection weekly for 3 months
75642148|NCT01062113|Drug|Celecoxib|"Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS"
76081803|NCT05607849|Other|"Leaflet decidons ensemble (making a decision together)"|"At the beginning of the intervention, material i) informing women of the existence of the DA for participation or not in breast cancer screening and (ii) aiming to promote the implementation of shared medical decision will be sent or not sent to women and their GPs according to their allocation arm. This material will be sent at the same time as the breast cancer screening invitation letter.~For the secondary outcomes, questionnaires will be sent to a sample of women in each arm."
76081804|NCT00985725|Drug|SPD489 (Lisdexamfetamine dimesylate)|Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
76081805|NCT00985725|Drug|Matching placebo|oral, once daily
76081806|NCT01294306|Drug|Akt Inhibitor MK2206|Given PO
76081807|NCT01294306|Drug|Erlotinib Hydrochloride|Given PO
76081808|NCT01294306|Other|Laboratory Biomarker Analysis|Correlative studies
76081809|NCT01294306|Other|Pharmacological Study|Correlative studies
76081810|NCT00985491|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
75333162|NCT05503602|Other|Foam Roller Technique Application|2 sessions of foam roller technique per week along with 3 sessions of classical physiotherapy per week for 4 weeks. Foam roller application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
75471532|NCT05874856|Behavioral|Monitoring of self-rated exhaustion, mood and tension|Using the customized PsyMate app.
75471533|NCT05874830|Other|Fecal microbiota transplant or plasebo through endoscopy|Colonoscopy and gastroscopy
75642149|NCT01062113|Drug|Celecoxib|Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
75642150|NCT01062113|Drug|Placebo|Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
75642151|NCT02875145|Procedure|Cataract surgery|
75642152|NCT00916396|Drug|Dehydroepiandrosterone|100 mg of DHEA a day (50 mg twice a day) for six weeks
75642153|NCT00916396|Drug|placebo|100 mg of Placebo a day (50 mg twice a day) for six weeks
75790285|NCT05099367|Diagnostic Test|peri-ulcerated skin biopsy|Non-ulcerated skin from the peri-wound area will be collected. These patient will not undergo all the procedures included in this protocol.
75790286|NCT05090033|Other|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
75790287|NCT05085002|Drug|Lerociclib + Letrozole or Fulvestrant|All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
75790288|NCT05084053|Drug|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
75790289|NCT05075993|Drug|LVGN3616 + LVGN6051 + Nab-Paclitaxel|Given by IV, Given by PO
76081811|NCT05602701|Other|Preoperative assessment|Preoperative assessment of physical fitness
76081812|NCT01351480|Biological|abatacept|Abatacept administered SC weekly at 125 mg dose
75790290|NCT05075993|Drug|LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
76081813|NCT03416829|Behavioral|Ambulatory voice biofeedback|Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
76081814|NCT04348149|Dietary Supplement|Lindera obtusiloba extract|One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
76081815|NCT05607693|Drug|SHR3680 tablets|Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
76081816|NCT01352182|Drug|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
76081817|NCT00984867|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 48 weeks
76081818|NCT00984867|Drug|Placebo|Matching placebo tablet
76081819|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
75333163|NCT05508048|Behavioral|The existential approach and logotherapy-based psychosocial support program|Existential Approach and Logotherapy Based Support Program, which raises awareness about the meaning and purpose of the individual's life, enables them to produce solutions to the sense of meaninglessness, anxiety, feeling of emptiness, and many other problems, and develops different perspectives.The content of the program is base on existential analysis and logotherapy. The program lasted for eight weeks, with the first and last session of the scale applications. Additional sessions were set for each session where the aims and objectives of the session could not achieve. A session lasting at least 50 minutes were held each week.
75471534|NCT05874778|Drug|6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy|All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.
75471535|NCT05874778|Radiation|Radiotherapy beyond standard R-CHOP Chemotherapy|Radiotherapy: after completion of the standard R-CHOP treatment, enrolled patients will be divided into radiotherapy group and non-radiotherapy group. In radiotherapy group, further consolidation radiotherapy targeting patients' pre-treatment large masses or extranodal affected areas will be given, with routine segmentation of 30-36Gy/15-18f.
75790291|NCT05075993|Drug|LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|Given by IV, Given by PO
75790292|NCT05075993|Drug|LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
75926525|NCT04815668|Other|Placebo acupuncture group|The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.
75926526|NCT04815668|Other|Rescue medication group|Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
75790293|NCT05072613|Other|Malaria screening|Participants are screened for malaria and a dried blood spot is collected from malaria positive cases
75790294|NCT05070260|Drug|Intravenous glenzocimab (ACT017) 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
75790295|NCT05070260|Drug|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
75790296|NCT05066984|Other|structured, multidisciplinary and personalized post-ICU care|Structured, personalized and multidisciplinary post-ICU care tailored to patients' health problems initiated by ICU clinicians and coordinated by GPs.
76025360|NCT05279963|Procedure|electroacupuncture|"The prespecified acupoints applied here will include bilateral Sanyinjiao(SP6), Shenshu(BL23), Ciliao(BL32), Zhongliao(BL33), Zhibian(BL54) .~Acupuncture treatment is carried out by acupuncturists who have been well trained. Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China). Electroacupuncture procedures will be performed with electronic instruments (Hans-100A, Nanjing Jisheng Medical TechnologyCo., Ltd, China). Two paired of acupoints (i.e., two Shenshu(BL23) and two Ciliao(BL32), respectively) are connected to the EA apparatus. Alternating-frequency mode is selected and frequency is 2/100 Hz. EA intensity is determined in accordance with patients' endurance. EA will last for 30 min for each treatment. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks."
76081820|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
76081821|NCT01294384|Drug|carboxymethylcellulose sodium based Eye Drops|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
76081822|NCT01257802|Drug|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
76081823|NCT01257802|Drug|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
76081824|NCT05607303|Other|Clinical estrogen therapy|No research interventions will be used as a part of the study since the research is observational. Estrogen treatment will be prescribed and followed by participant's clinical physician.
76081825|NCT02979964|Behavioral|Audit and Feedback|
75333164|NCT01455740|Behavioral|Provider Visit Incentive (PVI)|"All participants received the standard of care (SOC), which included not only medical care but also a wide range of social services. In addition, participants in the PVI arm received financial incentives designed to motivate health-improving behaviors. After the initial study enrollment visit, participants in the PVI arm received a $30 payment each time they showed up as scheduled for one of their next four HIV primary care visits.~Participants in the PVI arm were also asked to return for a sixth, unanticipated study visit approximately three months after the last of the four study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the fifth and sixth study visits."
75926527|NCT04813042|Behavioral|Working Out Dads|"The WOD is a manualised group intervention underpinned by solution-focused therapy and social cognitive theories. Psychoeducation about the transition to fatherhood and its potential impacts on wellbeing and family relationships is provided. Fathers are encouraged to share practical ideas for managing stress, revisit previous strategies, validate what they are doing well, and explore solutions.~The group discussion is followed by a structured group fitness session provided by a personal trainer. This session focuses on body weight exercises, cardio-based activities, stretching, mobility and incidental activity.~Fathers in the WOD study arm receive 10 weeks of encouraging text messages - one each week during the intervention, and four in the weeks after. These will be sent via the WhatsApp group created for each WOD group. These text messages and the WhatsApp group are designed to facilitate fathers' active engagement with the intervention, and to maintain contact with each other."
75790297|NCT05048459|Other|Standard surveillance|Participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
75790298|NCT05048459|Other|Telemedicine surveillance (tele-surveillance)|The tele-surveillance visit occurs annually after completion of therapy and consists of a phone call with or without video conferencing between the patient and the treatment team (physician, nurse, and/ or nurse practitioner). The use of video conferencing is strongly encouraged. Clinic visits, endoscopies, and imaging studies can be performed at the discretion of the treatment team for concerning patient symptoms.
75471536|NCT05874765|Diagnostic Test|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5)|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5) , will be used to diagnose and classify the Tics among all included patients
75471537|NCT05874752|Diagnostic Test|Transthoracic echocardiography|noninvasive myocardial work
75642154|NCT04369807|Diagnostic Test|Outpatient MRI|"Participation in the study includes up to 3 visits to a partnering imaging facility - this will include measurement of height and weight (to calculate BMI), blood pressure measurement, 3 sets of blood tests, 3 Questionnaires and 3 MRI tests.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications."
75642155|NCT04303871|Diagnostic Test|Invasive blood pressure assessment by radial artery canulation|radial artery canula used to measure central blood pressure compared to non invasive automated device to measure BP in pregnant females
75471538|NCT05874700|Drug|Sivelestat sodium was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
75471539|NCT05874700|Drug|Placebo was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
75471540|NCT05874687|Drug|hypotension + treat|Heart Rate and Mean Arterial Pressure (MAP) will be recorded throughout the procedure (every 2 minutes for the first 15 minutes). Ephedrine (in 6 mg increments) will be used as well as the isotonic balanced crystalloid solution to treat hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg (250 mL bolus). The Ephedrine dose will be recorded. Bradycardia, which is defined as a heart rate less than 50 beats per minute, will be treated with intravenous Atropine (0.5 mg).
75471541|NCT05874674|Drug|Nafamostat Mesylate|Comparison effect of nafamostat and cnoxan
75790299|NCT05048459|Other|Questionnaires|EORTC QLQ-C30 and EORTC QLQ-HN43 at 12 and 24 months, FACE-Questionnaire Module, Telehealth Usability Questionnaire, Telehealth Usability Questionnaire, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction -Patient Satisfaction inventory
75790300|NCT05047913|Drug|18F-FTX|Given By IV
75790301|NCT05042388|Behavioral|Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)|Integrates evidenced-based practices to decrease the probability and severity of relapse for those in addiction recovery. MBRP incorporates components from CBT relapse prevention and includes training in meditation practices as a means to foster increased awareness of emotional and cognitive experiences. MBRP also includes training in brief informal meditations aimed at increasing awareness and adaptive response to drug cues and negative affect.
75333165|NCT01455740|Behavioral|Incentive Choice (IC)|"All participants received the SOC. In addition, participants in the IC arm received financial incentives designed to motivate health-improving behaviors. At the initial study enrollment visit, participants in the IC arm chose between either the incentive scheme assigned to the PVI arm or an incentive scheme that tied payments to clinic attendance and ART medication adherence. Participants who selected the 2nd option received a $30 payment at each of their next 4 HIV primary care visits if the (i) showed up as scheduled and (ii) presented a dose-recording pill bottle cap indicating that they correctly took at least 90% of doses of a sentinal medication since the previous study visit.~Participants in the IC arm were also asked to return for a 6th, unanticipated study visit approximately three months after the last of the 4 study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the 5th and 6th study visits."
75333166|NCT03829748|Procedure|Intermittent aspiration|Endoscopic ultrasound is done for the localization of the lesion and to localize the site of puncture.Prior to the puncture of the lesion the stylet is removed and a vacuum syringe is prepared with 10 cc of vacuum allowing the generation of continous pressure inside and connected to the end of the needle. Once the lesion is punctured 15 movements in and out of the lesions will be made while the syringe is opened and closed on and off for a total of 3 times each pass. A total of 4 passes will be done in each lesion.
75471542|NCT05874661|Other|External Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an external focus being thinking about a target or outcome in the environment.
75471543|NCT05874661|Other|Internal Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an internal focus being thinking about what one's body is doing.
75471544|NCT05874648|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
75471545|NCT05874609|Other|Teaching with VR spine simulator|The participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session. The learning objective with the VR simulator is to review the 3D lumbar spine anatomic model，learn the sonoanatomy presented by a dynamic ultrasound scan of the sagittal and transverse plane, and practice a preprocedural ultrasound scan.
75471546|NCT05874609|Other|Traditional didactic teaching|A 30-min traditional didactic teaching session of spine ultrasonography. This session was consisted of general spine anatomy, sonographic technique and sonoanatomy, description of five key spine ultrasonographic views (transverse spinous process view, transverse interlaminar view, parasagittal oblique interlaminar view, parasagittal articular process view, parasagittal transverse process view), and a stepwise technique of preprocedural lumbar spine scan
75642156|NCT00626951|Device|LMA Supreme|Extraglottic airway devices
75642157|NCT00626951|Device|LMA ProSeal|
75642158|NCT04302389|Behavioral|myWW App, Virtual Workshops, and Private Facebook Group|The 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and a private online community. Participants are given a personalized food plan based on expert healthy eating guidelines and the latest nutritional science, an activity plan designed to promote regular physical activity and techniques to help shift members towards a helpful mindset for lasting change all within the WW app. Participants will attend weekly virtual workshops led by an expert WW Coach. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals each week. Participants will be encouraged to participate in a private Facebook group that gives participants an opportunity to receive motivational support from each other. Participants can post about their journey through photos, videos, and comments.
75790302|NCT05042388|Behavioral|Treatment-As-Usual|Standard treatment programming procedures for all individuals residing within the residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on general issues related to mental health and SUDs; and medication counseling.
75790303|NCT05038592|Drug|Decitabine|Given IV
75790304|NCT05038592|Biological|Tagraxofusp-erzs|Given IV
75790305|NCT05025657|Behavioral|ALLY|ALLY is a universal, school-based prevention program that takes place during the school day with individual students over 6 weeks.
75790306|NCT05014165|Other|Cord blood Sample Collection|Obtain banked cord blood samples from consecutive childhood leukemia patients
75790307|NCT05014165|Other|Case identification and recruitment|Cases meeting eligibility and who have given consent through APEC14B1 for future contact for non-therapeutic studies
75790308|NCT05014165|Other|Questionnaire Administration|The family will be given an option to complete questionnaire on paper, online, or over the telephone.
76025361|NCT05279963|Drug|Amitriptyline|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of individual participants will be recorded on diary cards.
75790309|NCT05012865|Drug|avelumab|as provided in real world practice
75790310|NCT05012865|Drug|axitinib|as provided in real world practice
75790311|NCT05011903|Behavioral|Cross-tailored Dynamic Feedback|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.
75790312|NCT05011903|Behavioral|Personalized Feedback Intervention|Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.
75790313|NCT05011903|Behavioral|Dynamic Feedback on General Health Behaviors|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
75790314|NCT04987528|Diagnostic Test|Aminoterminal type III peptide of procollagen|Serial Measurement of PIIINP in serum and/or BAL
75790315|NCT04987528|Diagnostic Test|Lung computed tomography|Screening for the presence of reticulation or bronchiectasia within lung parenchyma
75790316|NCT04986293|Device|CPAP|Different settings of CPAP and BiPAP will be tested using a home mechanical ventilator
75790317|NCT04972565|Behavioral|Usual Care plus Inspiratory Muscle Training (IMT)|Participants will receive usual care and will also be provided with a personalized prescription for an IMT program for 8 weeks. Participants will perform two daily IMT sessions of 30 breaths (< 5 minutes/session), 5 days per week in their home environment. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is < 7.
76081826|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
76081827|NCT00984009|Other|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
76081828|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
76081829|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.
76081830|NCT00983931|Drug|Cyclosporine|A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
76081831|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
75790318|NCT04970771|Behavioral|Solving Wellness platform|Interactive wellness resources available include a wide range of curated content and resources including fitness and yoga classes, cooking classes, webinars on sleep and various mental health topics including resilience, stress management, relationships and mindfulness, and resources including e-books, videos and guided meditations. Online discussion groups will foster awareness for specific issues and allow casual discussion. A curated collection of links to additional resources including the Solving Healthcare podcast will also be provided.
75471547|NCT05874583|Drug|Combined route administration of Tranexamic acid|tranexamic acid in topical route administration
76081832|NCT05606211|Other|No intervention|Observational, no intervention
76081833|NCT03075111|Diagnostic Test|ImmunoXpert|Host based immune response test distinguishing viral versus bacterial infection
76081834|NCT05604573|Diagnostic Test|cell free DNA in blood, genetic mutation in tissue|Diagnostic test for cell free DNA in blood, genetic mutation in tissue
75642159|NCT00772330|Device|Glaucoma Drainage Device|Insertion of MIDI Arrow subconjunctivally with a fornix-based incision after pretreatment of scleral surface with 0.4 mg/mL MMC and insertion of MIDI Arrow tube through sclera into anterior chamber of eye
75642160|NCT04019587|Diagnostic Test|Fear of Falling Avoidance Behavior Questionnaire administration|The Questionnaire includes 14 items dealing with avoidance behavior. All items will be asked by face to face technique.
75642161|NCT04694885|Behavioral|Structured Hypnotherapy|"The Intervention includes 10 structured hypnotherapy sessions lasting 45 to 60 minutes. During hypnosis, patients reach a trance-like state comparable to a deep relaxation. The therapist guides the patient verbally and also communicates with the patient.~Patients will be supported to use their own imagination without suggesting any imagery. By repeatedly asking what the patient is perceiving, and by verbally repeating what the patient is saying, the therapist can help the patient to go deeper into trance. In these trance states the patient learns to reduce negative side effects of the chemotherapy and increase the quality of life by activating both physical and mental resources using imagination and focusing on positive memories and feelings."
76081835|NCT02984319|Dietary Supplement|Cherry versus placebo concentrate|Acute cherry concentrate
75642162|NCT04075201|Biological|One dose of investigational vaccine|One dose of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research & Development Co., Ltd.
75642163|NCT04075201|Biological|One dose of control vaccine|One dose of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
75642164|NCT04075201|Biological|Three doses of investigational vaccine|Three doses of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research & Development Co., Ltd. on the schedule of month 0,1,2
75790319|NCT04968912|Other|Placebo|Placebo infusion will be administered intravenously.
75471548|NCT05874583|Drug|Intravenous route Tranexamic acid injection|Intra venous route administration
75642165|NCT04075201|Biological|Three doses of control vaccine|Three doses of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
75642166|NCT04304027|Other|Tailored exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at target heart rate reserve followed by 2 minutes working rest (target heart rate reserve may vary between sessions depending on the level of self-reported fatigue)
75642167|NCT04304027|Other|Standard exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at >70% heart rate reserve followed by 2 minutes working rest
75790320|NCT04968912|Drug|Nipocalimab|Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
75471549|NCT05874518|Other|warm needling combined with electroacupuncture|Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation.
75798843|NCT01289106|Biological|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
75926528|NCT04813042|Behavioral|Usual care|The Usual Care arm, also known as 'Talking about being dad' comprises a telephone consultation with a qualified mental health professional. Topics including in this consultation include: (a) discuss family and fathering; (b) health and wellbeing; (c) mental health symptoms and conduct a risk assessment for suicidal ideation; (d) current supports and support needs; (e) provide referral options to telephone support services (PANDA; MensLine); and (f) encourage a general practitioner visit to discuss a mental health care plan.
75926529|NCT04794634|Diagnostic Test|Optical coherence tomography (OCT)|to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects
75926530|NCT04794634|Diagnostic Test|Optical coherence tomograpohy angiography (OCTA)|to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects
75926531|NCT04779918|Device|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
75926532|NCT04776213|Drug|Mavenclad®|This low interventional extension study involves the follow up of participants in the parent study. The participants will be followed up for an additional 2 year period (until 4 years after initial administration of Mavenclad® tablets), during which the participants are not treated with Mavenclad®, as per European Medicines Agency (EMA) label of Mavenclad®.
76081836|NCT05604495|Diagnostic Test|Sweat Test|In people with cystic fibrosis (CF), there is a problem in the transport of chloride across cell membranes. This results in higher concentrations of chloride (as salt) in sweat compared to those who do not have cystic fibrosis. So, if there is a family history or a possibility of CF, the sweat test is part of the special tests to help make, or exclude, a diagnosis of cystic fibrosis.
76081837|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg, q8h, 12 weeks
76081838|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
76081839|NCT00983853|Biological|peginterferon alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks
76081840|NCT00983853|Drug|ribavirin (fixed dose)|Tablet, Oral, 800 mg, b.i.d., 48 weeks
76081841|NCT00983853|Drug|ribavirin (weight-based dose)|Tablet, Oral, 1000 mg for subjects weighing <75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
76081842|NCT05604261|Drug|Anaprazole sodium 40 mg|Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
76081843|NCT05604261|Drug|Anaprazole sodium 60 mg|Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
76081844|NCT05604261|Drug|Rabeprazole sodium 20 mg|Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
76081845|NCT03032601|Dietary Supplement|N-acetyl Cysteine|The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
76081846|NCT05604105|Other|Questionnaire|The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.
75642168|NCT01038869|Drug|Azelaic acid|Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
75790321|NCT04968912|Drug|Standard of Care Treatment|Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
75790322|NCT04946409|Other|no intervention|no intervention
75642169|NCT01038713|Device|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
75642170|NCT00768040|Drug|Aliskiren|300 mg once daily
75471550|NCT05874518|Drug|The treatment with letrozole tablets was started on the fifth day of the menstrual cycle|Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
75471551|NCT05874505|Drug|Adalimumab|Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
75471552|NCT05874505|Drug|Tocilizumab|Tocilizumab 162 mg subcutaneous each week for 15 weeks
75471553|NCT05872412|Drug|Doxorubicin|60 mg/m2 IV bolus on day 1 every three weeks for four cycles.
75642171|NCT00768040|Drug|Placebo|Matching placebo once daily
75642172|NCT03771937|Other|Education and telephone follow-up intervention|A telephone follow up and a pre-discharge education
75790323|NCT04935125|Procedure|Standard Program + Endurance and Strength training|Sessions of strength training added to a standard inpatient multidisciplinary programme
75790324|NCT04935125|Procedure|Standard Program|Standard inpatient multidisciplinary programme (including endurance training)
75642173|NCT04364191|Behavioral|Multicomponent Behavioral Sleep Intervention for Insomnia|The MBSI-I will include a meaningful activity protocol during the day and ART therapy at night.
75790325|NCT04905212|Drug|Telitacicept 160mg|Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.
75790326|NCT04905212|Drug|Telitacicept 240mg|Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.
75790327|NCT04905212|Drug|Placebo|Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
75790328|NCT04904588|Drug|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
75926533|NCT04774393|Drug|Decitabine and Cedazuridine|Given PO
75926534|NCT04774393|Drug|Enasidenib|Given PO
75926535|NCT04774393|Drug|Ivosidenib|Given PO
75926536|NCT04774393|Drug|Venetoclax|Given PO
75926537|NCT04762069|Drug|Berubicin|Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
75926538|NCT04762069|Drug|Lomustine|"Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent."
75926539|NCT04749797|Drug|Liposomal bupivacaine|Used as cranial block for craniotomy surgery
75926540|NCT04749797|Drug|Bupivacaine Injection|Used as cranial block for craniotomy surgery
76081847|NCT04759287|Device|C-MAC VS|The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS
75333167|NCT03829358|Drug|Lactobacillus plantarum IS-10506|Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.
75333168|NCT03829358|Drug|Placebo|Fermented milk containing placebo to be consumed once daily for three weeks.
75333169|NCT01452308|Biological|Simtuzumab|
75333170|NCT05562882|Drug|Daratumumab Injection|intravenous daratumumab administration
75642174|NCT04364191|Behavioral|Active Control|The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education.
75471554|NCT05872412|Drug|Cyclophosphamide|600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.
75471555|NCT05872412|Drug|Paclitaxel|80 mg/m2 IV over 1 hour weekly for 12 weeks
75642175|NCT05056051|Device|WATS-3D tissue sampling prior to forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells.
76081848|NCT04759287|Device|flexible fibreoptic bronchoscope|The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
76081849|NCT05603013|Drug|Vinorelbine|Vinorelbine Tartrate Oral
75471556|NCT05872412|Drug|Carboplatin|Area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles
75471557|NCT05871476|Behavioral|Hospital Cohort Care Intervention at the hospital|There will be 3 different cohort groups for the patients: 1) Unknown CRE colonisation status with increased barrier precautions (all patients until screening results arrive will belong to this group unless there are available screening results from referral hospital), 2) CREpos, and 3) CREneg. CREpos patients (2) will be treated in one area of the ICUs by specially assigned nurses/personnel.
75790329|NCT04904588|Drug|Busulfan|Given IV pre-transplant as part of conditioning regimen
76081850|NCT05603013|Radiation|Radiotherapy|hypofractionated radiotherapy
75790330|NCT04904588|Drug|Fludarabine|Given IV pre-transplant as part of conditioning regimen
75790331|NCT04904588|Radiation|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
75790332|NCT04904588|Drug|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
75790333|NCT04904588|Drug|Melphalan|Given IV pre-transplant as part of conditioning regimen
75790334|NCT04904588|Procedure|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.
76081851|NCT05603013|Drug|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
75333171|NCT03825146|Biological|Autologous Multi-lineage Potential Cells (AMPC)|"Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10^8 (0.5 to 5.0 x 10^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0."
75333172|NCT05561634|Radiation|Radiotherapy|Irradiation of the tumoral bed.
75333173|NCT05561634|Other|Observation|Patients will be followed up in consultation every 3 months.
75333174|NCT05561634|Drug|Vismodegib|Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,
75333175|NCT02579174|Device|Medacta GMK Sphere|
75333176|NCT05560542|Drug|Atropine and Dexamethasone|Intrathecal dexamethasone, atropine or their combination.
75790335|NCT04904588|Procedure|Bone Marrow Hematopoietic Stem Cell Transplantation|Bone marrow graft is infused from a mismatched unrelated donor on Day 0.
75333177|NCT01455974|Other|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
75333178|NCT05560308|Drug|Trastuzumab Emtansine for Injection|3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle;
75333179|NCT05560308|Drug|Pyrotinib Maleate Tablets|The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle;
75790336|NCT04904588|Drug|Post-transplant Cyclophosphamide|Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.
75790337|NCT04904588|Drug|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.
75790338|NCT04904588|Drug|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.
75926541|NCT04749797|Drug|Saline|Used as cranial block for craniotomy surgery
75926542|NCT04748861|Other|Indoor Cycling (IC)|Participants will ride a Peloton bike 3x/week for 18 months.
75926543|NCT04747275|Drug|Liquid stable levothyroxine (L-T4) Tirosint-SOL|Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
75926544|NCT04747275|Drug|Oral tablet levothyroxine (L-T4)|Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
76081852|NCT05603013|Drug|GM-CSF|GM-CSF subcutaneous injection
76081853|NCT05603013|Drug|IL-2|IL-2 subcutaneous injection
76081854|NCT00983073|Drug|Tapentadol|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
75790339|NCT04904588|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
75790340|NCT04904588|Other|Patient-Reported Outcomes|Survey assessments will be administered to study participants pre- and post-transplant.
75790341|NCT04903106|Device|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the meniscus is repaired using FAST-FIX FLEX device.
75790342|NCT04903106|Device|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the FASTFIX FLEX device is used during the meniscal allograft transplantation procedure.
75926545|NCT04728724|Drug|Sintilimab|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
75926546|NCT04728724|Drug|Chemotherapy|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
75926547|NCT04722575|Drug|Cobimetinib 20 MG Oral Tablet|Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
75790343|NCT04892797|Other|Covid-19+ observational|This is observational--there is no intervention
75790344|NCT04884165|Device|Remote monitoring of home mechanical ventilation (NIV) using SRETT|Patients will use the SRETT device attached to their home ventilator.
75790345|NCT04884165|Other|Home mechanical ventilation (NIV) without remote monitoring|Usual care
75790346|NCT04881903|Behavioral|Mobile Intervention for Suicidal Thoughts (MIST)|This is an interpretation bias modification intervention that is designed to target cognitive factors that contribute to suicide risk. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
75790347|NCT04881903|Behavioral|Mobile Intervention for Reducing Anger (MIRA)|This is an interpretation bias modification intervention that is designed to target hostile interpretation bias. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
75926548|NCT04722575|Drug|Vemurafenib 240 Mg Oral Capsule|960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
75926549|NCT04722575|Drug|Atezolizumab 1200 MG in 20 ML Injection|840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
75926550|NCT04721886|Procedure|Ultrasonsgraphy|Undergo ultrasonography
75926551|NCT04721886|Drug|Perflutren Lipid Microcpheres|Given IV
75926552|NCT04721886|Procedure|Contrast - Enhanced Ultrasound|Undergo CEUS
75926553|NCT04699981|Other|Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)|"For patients included in the Control group on discharge from hospitalization and 60 days after inclusion of patients, data will be collected either from the patient's medical file (T1Control) or during '' a telephone call from the patient (T2Control). The data collected concerns the occurrence of an infectious episode. They will also benefit from a stool sample at T1 control in order to assess the evolution kinetics of the relative fecal abundance of ESBL-producing enterobacteria in these patients who are not subjected to antibiotic pressure but subjected to other drug pressures (PPI, corticosteroids, etc.)."
75926554|NCT04699981|Other|Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)|"A stool culture is performed on the first stool emitted after the start of antibiotic therapy. 72 hours after the start of antibiotic therapy, a blood sample (5 ml) and a stool sample will be taken. A stool sample will be taken at the end of the antibiotic therapy and 60 days after the end of the antibiotic therapy. In the event of normal transit (daily bowel movements), the stool emitted 48 hours after the start of antibiotic therapy will be analyzed. If the patient does not pass stool, an eswab rectal swab will be taken. In the event of discharge from the hospital before the end of the antibiotic therapy and / or the D60 after the end of the antibiotic therapy, the patient will be given a prescription and an appointment at the collection center of the center concerned for the sample stool."
75926555|NCT04696289|Diagnostic Test|Standardized catheterization assessment|"There are four components to the pulmonary vein assessment.~Angiography: pulmonary artery wedge injection and/or selective pulmonary vein injection.~Intravascular ultrasound: manual pullback of IVUS catheter from lobar segment to left atrium.~Pressure assessment: pulmonary vein pressure (mmHg) measured before and after (if applicable) intervention.~Compliance testing: the compliance of the vein will be measured using a compliant conventional balloon."
75926556|NCT04695600|Drug|Botulinum Toxin Type A Injection [Botox]|100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
75926557|NCT04685577|Drug|Nefopam|Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
75926558|NCT04685577|Other|Placebo (Vehicle)|Participants will receive vehicle with out the investigational product
75926559|NCT04671810|Biological|Elizaria®|Elizaria® will be prescribed by the Physician according to the actual SMPC.
75926560|NCT04667039|Biological|GNR-067|GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
75926561|NCT04667039|Biological|Lucentis®|Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
76081855|NCT05602857|Other|Balance Training|"The BT program has multiple difficulty levels, and each child will progress at an individual pace tailored to their balance skills. Training sessions will emphasize top-down control of balance and contain a combination of dynamic and static balance exercises. Children and their parents will receive written step-by-step instructions, with photos, verbal and/or video instructions on their private OneDrive folder.~To monitor compliance, whether the exercises were done properly, and evaluate a child's progress, the parent/guardian will film the sessions, and upload the video to OneDrive, so we can score the child's performance and provide them with a progress tracking chart.~Every child will be given the equipment needed to do the balance exercises: two wooden beams that will make a 12-foot balance beam, four small wooden cubes that will raise the balance beam 5 inches off the ground, a wobble board, a hopscotch mat, one roll of painter's tape, one measuring tape, a bell, a small book."
76081856|NCT05602857|Other|Music Training|"Children assigned to MT will be asked what kind of music and what performers they like best, and what songs they like most. After those open-ended questions, they will be asked about specific songs, guided somewhat by the child's previous answers, and will watch short excerpts from music videos to see which the child would like to listen to and watch during Week 1 of the MT program. This is all to guide the selection of music videos the child will enjoy and might give some thought to.~They will receive 10 music videos per week, through the child's private OneDrive folder, from which they can choose 4 to watch every session. Children will be instructed to not do anything else, but simply watch the videos or listen with their eyes closed.~To monitor compliance, and to check if the child was paying attention to the music videos or just having them play in the background while doing something else, the parent/guardian will film the MT sessions, and upload the video to OneDrive."
76081857|NCT05604027|Diagnostic Test|Visual Analogue Scale|Clinical criteria and rating system for nociplastic pain affecting the musculoskeletal system and PainDETECT scale to determine pain type SF-36 Quality of Life Scale, Roland Morris Disability Questionnaire, Pain Catastrophizing Scale, and Visual Analog Scale to determine the effects
76081858|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
75642176|NCT05056051|Device|WATS-3D tissue sampling following forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells. This will be done after forceps biopsies in this arm.
75790348|NCT04877275|Drug|Selinexor (80mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;"
75926562|NCT04666584|Device|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon
75333180|NCT04782726|Other|Software Solution for Radiation Therapy Treatment|Software has been developed for individualized pre optimization evaluation of the patient anatomy and prescribed dose of radiation therapy.
75333181|NCT04782726|Other|Radiation therapy|Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer
75333182|NCT03822494|Radiation|CyberKnife SBRT|Radiation Therapy
75333183|NCT04779528|Procedure|Fiberoptic intubation in supine position.|"Patients will be placed in supine position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
75333184|NCT04779528|Procedure|Fiberoptic intubation in lateral position.|"Patients will be placed in lateral position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
75333185|NCT04273568|Other|Scapular PNF|Rhythmic initiation and repetitive stretching techniques in scapula anterior elevation-posterior depression and anterior depression-posterior elevation patterns were applied twice a week for 6 weeks.
75642177|NCT02580565|Other|telephone interview|Clinical assessment for screening and a phone call for questionnaire administration
75642180|NCT03445663|Drug|AMG 424|Subjects will receive IV infusions of AMG 424
75642181|NCT02580643|Biological|APS|intra-articular injection
75642182|NCT02580331|Drug|SRP and placebo|Placement of placebo gel into classII furcation defects after scaling and root planing
75642183|NCT02580331|Drug|SRP and 1% metformin|Placement of 1% metformin gel into classII furcation defects after scaling and root planing
75926563|NCT04666584|Device|Device: standard non-compliant balloon|Pre-dilatation with a standard non-compliant balloon
75926564|NCT04643899|Device|Muscle Electrostimulation|"Scheduled sessions of 20 minutes per day; 5 days a week~In physiotherapy or in their room for the most dependent patients~Installation and monitoring by a physiotherapist or by the trained clinical research nurse~Modalities:~Device program n ° 1: 20mn (2mn of warm-up, 15mn of work at 75hz, then 3mn of recovery)~4 electrodes (2 per thigh): large model (5 * 10 cm) for better comfort - Dura-Stick Plus model (reference 42200)~Gradual auto-increase of the intensity to the highest possible value tolerated, nevertheless allowing a contraction"
75926565|NCT04641871|Drug|Sym021|IV infusion over 30 minutes on day 1 and 15 of each cycle.
75926566|NCT04641871|Drug|Sym022|IV infusion over 30 minutes on day 1 and 15 of each cycle.
75926567|NCT04641871|Drug|Sym023|IV infusion over 30 minutes on day 1 and 15 of each cycle.
76081859|NCT00982137|Biological|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
75790349|NCT04877275|Drug|Selinexor (100mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;"
75333186|NCT04273568|Other|Exercise program|An exercise program consisting of exercises used in the conservative treatment of shoulder impingement syndrome for both groups was applied twice a week for 6 weeks.
75333187|NCT01456208|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
75642184|NCT04075357|Other|Amniotic membrane transplantation|Amniotic membrane was located over median nerve during surgery of CTS, prior of closing.
75790350|NCT04877275|Drug|Pegylated liposomal doxorubicin|25 mg/m^2 intravenously on day 1 , QW
75790351|NCT04877275|Drug|Dexamethasone|Dexamethasone 40mg/d QW
75790352|NCT04877275|Drug|Cyclophosphamide|Cyclophosphamide：300mg/m2, d1 QW，
75926568|NCT04641871|Drug|Irinotecan Hydrochloride|IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
75926569|NCT04633187|Drug|EDP-938|"EDP-938 800mg~Dose adjustments will be made for subjects taking azole antifungals."
75642185|NCT05042167|Other|Resistance exercise|4 total resistance exercises that target all major muscle groups.
75642186|NCT00767806|Drug|Duloxetine|60 mg orally once daily for 12 weeks
75790353|NCT04873830|Biological|volume stable collagen matrix placement|volume stable collagen matrix placement to augment the buccal defect.in class I siebert at the same time of implant placement
75790354|NCT04873830|Procedure|connective tissue grafting|connective tissue placement to augment the buccal defect.in class I siebert at the same time of implant placement
75790355|NCT04873453|Drug|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
75790356|NCT04873453|Drug|Placebo|Placebo arm
75790357|NCT04825483|Other|Weight loss|"Participants will receive resources to support the weight loss program including a recipe book, activities book and how-to guide. The diet program comprises two phases: 1) intensive weight loss through a ketogenic Very Low Calorie Diet (VLCD), including meal replacements for two meals/day, and 2) transition from ketogenic VLCD onto a longer-term eating plan for weight maintenance. Meal replacements will be provided free of charge for up to 6 months. Participants will be encouraged to lose at least 10% body weight."
75790358|NCT04825483|Other|Exercise|"Participants will receive resources to facilitate the physiotherapy management plan, including information about the video-conference platform, osteoarthritis information, an exercise plan/log book and a booklet of possible exercises. The physiotherapist consultations include a structured, progressive exercise and physical activity plan. Participants will be given exercise resistance bands and a ankle weight for home exercises.~Physiotherapists will choose from a list of exercises, aiming to prescribe 5-6 at once. Intensity is determined using a modified Rating of Perceived Exertion (RPE) scale, where it should feel hard to very hard to perform a full set of each exercises. Participants are encouraged to complete exercises three times per week. Physiotherapists encourage the participant to increase their general and incidental levels of physical/aerobic activity based on their individual needs and goals, as well as their current level of activity."
75790359|NCT04809987|Other|Virtual Gait|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.
75790360|NCT04809987|Other|Physical Exercise|Specific gait exercise was conducted.
75926570|NCT04633187|Drug|Placebo|Subjects will take EDP-938 matching placebo tablets once a day orally for 21 days
75926571|NCT04628988|Drug|CC-90011|Capsule
75926572|NCT04628988|Drug|Abiraterone|Tablet
75926573|NCT04628988|Drug|Prednisone|Tablet
75926574|NCT04621435|Drug|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
75926575|NCT04621435|Procedure|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes
75926576|NCT04621435|Drug|Copper-64 labeled (64Cu-) FAP-2286|The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
75926577|NCT04598009|Drug|Binimetinib|Taken orally (PO) twice a day (BID)
75926578|NCT04598009|Drug|Imatinib|Taken orally (PO) once a day (QD)
76081860|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
76081861|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
76081862|NCT05603715|Drug|Pyridostigmine Bromide|Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks
76081863|NCT04394793|Radiation|Low dose radiation therapy|Patient will be treated with a dose of 70 cGy in one fraction radiation therapy in addition to standard therapy
76081864|NCT00981747|Drug|Sildenafil|Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
75333188|NCT01456208|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
75333189|NCT01456208|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
75642187|NCT00767806|Drug|Placebo|Placebo once daily orally for 12 weeks
76081865|NCT00981747|Drug|Losartan|Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
76081866|NCT00981747|Drug|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
76081867|NCT00981747|Drug|Placebo Oral Tablet|Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
76081868|NCT05602545|Other|food consumption in periodontal health and disease|To determine individuals' daily energy and nutrient intakes and the consumption amounts of food groups, food consumption records were kept by the nutritionist for three consecutive days, with one of them was weekend, using the 24-hour recall method. Data on individuals' frequency and amount of consumption of some fermented products were recorded, considering the foods available in our culture and the market.
76081869|NCT04394403|Behavioral|Internet-based guided self-help based on CBT principles|Individuals are provided basic rationale of CBT to deal with stress, worry, anxiety, dysphoria, sleep difficulties, emotion dysregulation, and memories all related to COVID-19
76081870|NCT03046251|Drug|Natalizumab|
76081871|NCT03030183|Drug|Zilucoplan (RA101495)|0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
76081872|NCT03029169|Drug|Propafenone i.v.|Treatment
75642188|NCT02580409|Behavioral|Exercise Intervention|Investigators are proposing an innovative rehabilitative care program for older primary care patients at risk for mobility decline. The program targets newly identified risk factors for mobility decline and utilizes mobile health technology to deliver patient centered care more efficiently. Study participants will receive exercise instruction with a licensed physical therapist for an average of 8-10 training sessions, with the possibility of up to 16 sessions. some at home and some in the clinic. The exercise training sessions will focus on improving mobility, balance and ability to get up from a chair with the use of an exercise application (Wellpepper) being used on a study issued iPad.
75642189|NCT04074889|Dietary Supplement|(Microbial cell preparation) Probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
75790361|NCT04809987|Other|Documental projection|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
75790362|NCT04802317|Diagnostic Test|Identification of the composition of the intestinal microbiota|Identification of the composition of the intestinal microbiota
75790363|NCT04787679|Procedure|Hip replacement surgery|After hip replacement surgery the sponsor obtains femoral head samples for the study
75790364|NCT04765384|Biological|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
75790365|NCT04765111|Drug|Acalabrutinib|Given PO
75790366|NCT04765111|Biological|Rituximab|Given IV
75926579|NCT04596852|Device|Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch|"Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability."
75926580|NCT04595188|Other|Sulphur amino acids|"For the total sulphur amino acid requirement, there are 7 different methionine test levels (without dietary cysteine) ranging from 5 to 40 mg of methionine per kilogram body weight per day.~For the minimum methionine requirement, there are 7 different methionine test levels (with excess dietary cysteine)."
75926581|NCT04583072|Diagnostic Test|The Stockholm3 test|Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.
75926582|NCT04569903|Device|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
75926583|NCT04558593|Procedure|Active surveillance|Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)
75926584|NCT04558593|Procedure|Surgery|Per standard of care: partial or full resection of the kidney, imaging annually
76081873|NCT03029169|Drug|Amiodarone i.v.|Treatment
76081874|NCT04759209|Diagnostic Test|Biopsies|
76081875|NCT04275219|Drug|Tongfu capsules|Tongfu capsules include 5 herbals
76081876|NCT04275219|Drug|The Placebo of Tongfu capsules|The Placebo of Tongfu capsules are made from dextrin, starch and so on.
76081877|NCT05609955|Drug|MgSO4|The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
76081878|NCT04129905|Biological|BNP blood sample test|Performed during normal recommended follow-up of the HCM patients.
75642190|NCT04074889|Other|Placebo|Placebo sachet with no microbial cell preparation
76081879|NCT04129905|Diagnostic Test|Electrocardiogram|Performed during normal recommended follow-up of the HCM patients.
76081880|NCT04129905|Diagnostic Test|Holter ECG|Performed during normal recommended follow-up of the HCM patients.
76081881|NCT04129905|Diagnostic Test|Echocardiography|Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
75642191|NCT05674045|Drug|EG017 3mg|EG017 3mg/day Oral administration for 12 weeks, once daily
75642192|NCT05674045|Drug|EG017 6mg|EG017 6mg/day Oral administration for 12 weeks, once daily
75642193|NCT02580253|Drug|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
75642194|NCT02580253|Drug|mFOLFOX6|Oxaliplatin,Fluorouracil
75642195|NCT00780910|Drug|MP-424|750 mg every 8 hours for 12 weeks
76081882|NCT04129905|Diagnostic Test|Air venous plethysmography|Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
76081883|NCT04129905|Diagnostic Test|Upper member arterial Doppler echography with analysis of FMD|Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
76081884|NCT04129905|Biological|Endothelial function biomarkers|Performed specifically for the research. Blood sample test, 5 minutes.
75642196|NCT00780910|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
75642197|NCT00780910|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
75790367|NCT04764253|Behavioral|Modified Sodium Watcher Program + Digital Self-Monitoring|Participants randomized to the experimental group will be asked to follow the modified Sodium Watchers Program intervention along with goal setting for low salt foods. Each participant will be registered to assign a unique ID in the Connected Health Platform developed by the Center on Smart and Connected Health Technologies at UT Health Science Center San Antonio and each account from the individuals' wireless and wearable devices (Fitbit and BP monitor) will be connected to his or her unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor. Through the Connected Health Platform, the Fitbit app and BP monitor will transmit the data of the intervention group to the research team.
75926585|NCT04556552|Device|Non invasive VN stimulation (nVNS)|"Stimulation of vagus nerve with active device. Participants will be administered nVNS using the electroCore GammaCore-S non-invasive VNS device. The intensity of the stimulus will be adjusted by the user, to the maximum tolerable level to ensure nVNS without causing excessive pain, the burst frequency to 5 kHz, and the envelope frequency to 25 Hz.~The duration of delivery will be 2 minutes, and the beginning will coincide with initiation of acquisition of the HR-PET scan which will be 90 seconds in duration; following an additional 8 minutes, a second VNS delivery will be administered, in conjunction with which another scan will be obtained."
76081885|NCT01295710|Biological|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
75926586|NCT04556552|Drug|Oxygen (15-O) Water|Injection of radiolabelled water. H2[15-O] is a radioactive material. Each patient will have eight H2[15-O] blood flow scans. For each O-15 water scan 20 mCi of H2[15O] will be injected as an intravenous bolus.
75926587|NCT04556552|Device|Sham Stimulation|"Sham stimulation of vagus during opioid cue exposure. Each subject in the SHAM group will undergo the action of administering the intervention, but the device will be programmed such that the stimulation will not activate the vagus nerve."
75642198|NCT04099576|Other|physiotherapy and education|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program. In addition to physiotherapy, therapeutic neuroscience education were applied to experimental group. One-to-one speech sessions focusing on pain neurophysiology were organized twice a week for three weeks. Each session lasted 40 minutes. The Therapeutic neuroscience education program included nociception, ion channel neurophysiology, central and peripheral sensitization, methods to help reduce sensitization, neuroplasticity, psychosocial factors involved in the transition from acute pain to chronic pain and behavioral, cognitive responses to pain.
75926588|NCT04553718|Other|experimental group|provide mHealth program, which has pregnant women using wearable device and app
76081886|NCT01295710|Biological|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
76081887|NCT01258504|Drug|St. Johns Wort|"Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
76081888|NCT01258582|Procedure|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
76081889|NCT01258582|Procedure|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
76081890|NCT04351828|Procedure|Blood draw once a time|Investigation of intestinal permeability by measuring serum zonulin levels in blood sample
76081891|NCT01259128|Drug|SER120 Nasal Spray 500 ng/day|SER120 Level 1
76081892|NCT01259128|Drug|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
76081893|NCT01353976|Drug|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
75642199|NCT04099576|Other|Physiotherapy alone|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program.
75642200|NCT02582203|Drug|Ceftaroline|
75642201|NCT02582203|Drug|Vancomycin|
75642202|NCT03395275|Behavioral|Quantitative Sensory Tests|"Three testing modalities will be utilized for this study:~Hot threshold test: The hot threshold method we will be utilizing has been described in the literature with good reproducibility and reliability. We will be using a similar system and have reproduced the program using a non-invasive device.~Cold threshold test: the same non-invasive device will be used to test cold detection and pain threshold levels. This method is previously described.~Pressure threshold: Mechanical testing (pressure pain threshold) will be assessed utilizing an algometer. We have used this method in a previous study and published results."
75642203|NCT03395275|Behavioral|surveys|surveys including anxiety, depression, pain behavior, fatigue, pain interference, physical function, sleep disturbance, self-efficacy, satisfaction roles
75642204|NCT00767104|Other|Silk like Pillowcase|sleep on silk-like pillowcase each night
75642205|NCT00767104|Other|Cotton Pillowcase|Sleep on placebo cotton pillowcase each night
75642206|NCT03691987|Biological|Preprocessed thawed donor FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
76081894|NCT01353976|Other|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
76081895|NCT01354444|Drug|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
76081896|NCT01354444|Drug|Placebo|a pill that will look like the active drug but will not contain any carvedilol
76081897|NCT01259440|Behavioral|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
76081898|NCT01259440|Behavioral|Usual Care|Consists of one week telephone call and one month clinic visit
76081899|NCT03009526|Drug|Sulfadoxine-pyrimethamine|500 mg sulfadoxine and 25 mg pyrimethamine
76081900|NCT03009526|Drug|dihydroartemisinin-piperaquine|40 mg dihydroartemisinin and 320 mg piperaquine
76081901|NCT01259596|Behavioral|cognitive behavioral therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
76081902|NCT01259596|Behavioral|nondirective supportive therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
76081903|NCT03831243|Radiation|Stereotactic body radiotherapy|Treatment will be prescribed to the periphery of the target, i.e. 80% of the dose should cover 95% of the PTV. The organ at risk (OAR) dose constraints will be in accordance with the recommendations from the report of the American Association of Physicists in Medicine (AAPM) task group 101. Image-guidance will consist of cone-beam CT in combination with 6 degrees of freedom corrections using robotic couch.
76081904|NCT03831243|Radiation|3D-conformal radiotherapy|In the standard setting, 95% of the PTV should receive 95% of the prescribed dose while near maximum dose (Dnear-max) in the PTV should not exceed 107%. Image-guidance will consist of portal images showing the relevant bony anatomy.
76081905|NCT01354990|Drug|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
76081906|NCT01355224|Genetic|Genetic|Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
75642207|NCT03691987|Biological|Preprocessed thawed autologous FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
75642208|NCT04100980|Other|No Intervention|There is no intervention for this study
75790368|NCT04764253|Behavioral|Usual care + Digital Self-Monitoring|Participants randomized to the control group will be asked to follow usual care which is based on their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium-restricted diet and take medications as prescribed. The participants will receive wireless and wearable devices (Fitbit wristband, BP monitor). Each participant will be registered to assign a unique ID in the Connected Health Platform at the baseline and each account from the individual's wireless and wearable devices (Fitbit and BP monitor) will be connected to their unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
75926589|NCT04546958|Dietary Supplement|Whey protein supplements|Nutritional counseling and whey protein supplements for 3 months
76081907|NCT01355224|Behavioral|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
76081908|NCT01260454|Drug|Qutenza (8% capsaicin)|We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
76081909|NCT01296646|Drug|Naltrexone|50 mg oral naltrexone once/day
76081910|NCT01296646|Behavioral|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
76081911|NCT01296646|Drug|Placebo|An inactive pill to control for non-pharmacological responses.
76081912|NCT01297348|Drug|90ug levonorgestrel / 20 ug ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
75642209|NCT05035927|Drug|TRYP-0082|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
75642210|NCT05035927|Behavioral|Psychotherapy|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
75790369|NCT04763421|Device|ENSEAL X1 Curved Jaw|ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
75926590|NCT04546958|Other|Nutritional counseling|Nutritional counseling by dietitians for 3 months
75926591|NCT04540107|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
75926592|NCT04540107|Procedure|Magnetic Resonance Imaging|Undergo MRI
75926593|NCT04540107|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
75926594|NCT04534556|Device|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation. VNS stimulation as described in the current study consists of 0.5 second trains of 0.8 mA; 100 µsec biphasic pulses at 30 Hz. Stimulation trains are delivered only during rehabilitation.
76081913|NCT01297348|Drug|Oral Contraceptives containing 20 ug of ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
75790370|NCT04752319|Device|BreEStim|BreEStim will be applied for 10 to 20 minutes per session for multiple sessions
76081914|NCT01856309|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
76081915|NCT01856309|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
75790371|NCT04752319|Device|EStim|EStim will be applied for 10 to 20 minutes per session for multiple sessions
75926595|NCT04534556|Device|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
75926596|NCT04529889|Other||
75926597|NCT04529252|Other|Specimen collection|Blood, urine, stool, cerebrospinal fluid, and skin biopsy may be collected
75926598|NCT04523493|Combination Product|Toripalimab combined with Lenvatinib|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
76081916|NCT01856309|Drug|Placebo|Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
76081917|NCT01260688|Drug|cediranib maleate|Given orally
76081918|NCT01260688|Drug|dasatinib|Given orally
76081919|NCT01355458|Drug|CD07805/47 gel|applied topically once daily
76081920|NCT01355458|Drug|Placebo|applied topically once daily
75333190|NCT05507736|Other|Acupuncture|13 Indwelling, sterile and disposable needles (SEIRIN NEW PYONEX® from 0.9 mm in length and 0.22 mm in diameter) on day 1 and 5 of the second cycle of irinotecan leaving them inserted for 4 days.
75333191|NCT04847726|Diagnostic Test|contrast enhanced ultrasound|contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride
75333192|NCT04847726|Diagnostic Test|Dynamic CT|Participants underwent dynamic CT for hepatic lesion
75926599|NCT04523493|Combination Product|Placebo combined with Lenvatinib|"Control group:~Placebo, one unit, IV infusion, once every 3 weeks, combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
75642211|NCT04075045|Behavioral|Wellth Smartphone App|Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).
75926600|NCT04507919|Drug|Dabrafenib|150 mg
75926601|NCT04507919|Drug|Trametininb|2.0 mg
75926602|NCT04503551|Drug|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
75333193|NCT04847726|Diagnostic Test|Liver MRI|Participants underwent liver MRI for hepatic lesion
75926603|NCT04503551|Drug|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
76081921|NCT01298128|Drug|NuvaRing|NuvaRIng 21 days for IVF pre-treatment.
76081922|NCT01298128|Drug|marvelon|marvelon 21 daily
75642212|NCT04075045|Behavioral|Targeted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at pharmacies.
75642213|NCT04075045|Behavioral|Non-Restricted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at most stores, except for prohibited purchases such as alcohol, tobacco, or firearms, and is not redeemable for cash.
75642214|NCT03363373|Biological|GM-CSF + Naxitamab|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody
75642215|NCT00771472|Drug|vorinostat|Parts I & II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
75333194|NCT05475834|Drug|SIM0417|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
75333195|NCT04273646|Biological|UC-MSCs|4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).
75333196|NCT04273646|Drug|Placebo|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
75333197|NCT05436522|Drug|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
75333198|NCT05436522|Drug|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
75333199|NCT04273334|Drug|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
75333200|NCT01456286|Drug|sapropterin|two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
75333201|NCT05349240|Device|C2 CryoBalloonTM Ablation System.|Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
75333202|NCT03780010|Drug|TRC105|Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
75333203|NCT03826550|Drug|Diclofenac Sodium Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
75333204|NCT03826550|Drug|Solaraze 3% Topical Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
75333205|NCT03826550|Other|Placebo|Twice daily for 60 days. Each patient is expected to receive 120 doses
75642216|NCT00771316|Drug|MK0826 (ertapenem)|A single dose of 1.0g IV infused over a 30 minute interval at hour 0
75642217|NCT00771316|Drug|Comparator: meropenem|500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
75642218|NCT03995290|Other|3D Hip Model from Pre-operative CT scan|A printed 3D model will be created based off of the patient's standard of care preoperative CT scan.
75790372|NCT04751526|Device|BreEStim 240|240 BreEStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
75790373|NCT04751526|Device|EStim 240|240 EStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
75790374|NCT04750954|Procedure|Biospecimen Collection|Undergo collection of blood samples
75790375|NCT04750954|Procedure|Computed Tomography|Undergo CT
75790376|NCT04750954|Drug|Lutetium Lu 177 Dotatate|Given IV
75790377|NCT04750954|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790378|NCT04750954|Drug|Peposertib|Given PO
75790379|NCT04750564|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
75790380|NCT04750564|Device|EStim|EStim will applied for 10 to 20 minutes.
75790381|NCT04750551|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
75790382|NCT04750551|Device|EStim|EStim will applied for 10 to 20 minutes.
75790383|NCT04750538|Device|BreEStim 120|120 BreEStim stimuli will applied for about 10 minutes.
75790384|NCT04750538|Device|BreEStim 240|240 BreEStim stimuli will applied for about 20 minutes.
75790385|NCT04750525|Device|BreEStim|120 BreEStim stimuli will applied for about 10 minutes.
75790386|NCT04750525|Device|EStim|120 EStim stimuli will applied for about 10 minutes.
75790387|NCT04742803|Device|Straberi Epistamp Microneedling Treatment|"The patient's entire face will be treated with the Straberi Epistamp needling device.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
75790388|NCT04740268|Device|Straberi|"The patient's entire face will be treated with the Straberi microneedling devise.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
75926604|NCT04497909|Behavioral|Mindfulness|Mindfulness online training
75926605|NCT04496167|Drug|EN3835|Collagenase clostridium histolyticum
75926606|NCT04496167|Drug|Placebo|Placebo comparator
75642219|NCT02601664|Procedure|Combined Intervention|pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
76081923|NCT01298752|Drug|Mapracorat|Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
76081924|NCT01298752|Drug|Vehicle|Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
75926607|NCT04485195|Drug|Vernakalant|an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
76081925|NCT02199964|Drug|Cyclosporin 0.05% emulsion|Topical therapy for dry eye
76081926|NCT02199964|Drug|Endura, Refresh artificial tears|Over the counter therapy for dry eye, used 4 times a day
75333206|NCT05325762|Drug|Propofol|At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
75333207|NCT05325762|Drug|Dexmedetomidine|Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
75333208|NCT05325762|Drug|Saline|At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
75790389|NCT04740255|Device|Straberi Epistamp|The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
75790390|NCT04706390|Biological|covid-19 vaccine|vaccination
75790391|NCT04706000|Genetic|Beclin 1 gene|The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.
75926608|NCT04485195|Drug|Procainamide|15 mg/kg in 500 mL of normal saline given over 60 minutes
75926609|NCT04485130|Drug|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
75333209|NCT04391738|Other|Patients admitted to Intensive Care Unit with SARS-CoV2|Patients admitted to Intensive Care Unit with SARS-CoV2
75642220|NCT02601664|Procedure|Conventional PCI|Conventional PCI
75642221|NCT04074577|Diagnostic Test|Standard technique First|colonoscopy without automated polyp detection software
75642222|NCT04074577|Diagnostic Test|combination technique First|automated polyp detection software
75642223|NCT03347227|Procedure|Catheter ablation|Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
75642224|NCT02582047|Biological|Influenza vaccination with PPV23|GCflu and Pneumovax-23
75642225|NCT02582047|Biological|Influenza vaccination with PCV13|GCflu and Prevenar-13
75642226|NCT06184880|Behavioral|behavioral|International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,
75642227|NCT06184880|Other|Sedentary|Actimetry (cumulative time without movement over 24h, prolonged sedentary periods >30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
75642228|NCT06184854|Other|3D Training Models|3D Jenga polo model for task 1 and 3D suturing model for task 2
75642229|NCT06184854|Other|2D LapPass Training Models|2D LapPass polo model for task 1 and 2D LapPass model for task 2
76081927|NCT01299454|Drug|OPC-34712|All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
76081928|NCT02323048|Drug|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
76081929|NCT02323048|Drug|placebo|Placebo (sugar pill)
76081930|NCT01265446|Drug|Lidocaine 8mg + CPC 2mg|one single dose
76081931|NCT01265446|Drug|Lidocaine 1mg + CPC 2mg|one single dose
76081932|NCT01265524|Drug|CLP|Oral administration
76081933|NCT01265524|Drug|Placebo|Oral administration
76081934|NCT01299610|Drug|GW870086 2.0%|White to slightly colored opaque cream
76081935|NCT01299610|Drug|GW870086 0.2%|White to slightly colored opaque cream
76081936|NCT01299610|Drug|FP 0.05%|White cream
76081937|NCT01299610|Drug|Placebo|White to slightly colored opaque cream
76081938|NCT01300624|Behavioral|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
75642230|NCT06184841|Drug|HAIC combined with intravenous PD-1|Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
75642231|NCT06184828|Biological|Whole blood transfusion|The transfusion of whole blood units
75790392|NCT04704518|Drug|Sodium Hyaluronate Ophthalmic 0.4%|Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.
75790393|NCT04704518|Drug|Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%|Topical ophthalmic administration of one drop of Thealoz® Duo QID.
75790394|NCT04678232|Behavioral|Positive Processes and Transition to Health (PATH)|See arm/group description for details regarding this intervention
75790395|NCT04671381|Behavioral|Hearing Evaluation|Behavioral thresholds for pure tones will be conducted along with speech perception measures.
75926610|NCT04485130|Drug|Placebo|This study will provide placebo. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days
76081939|NCT04352062|Drug|Melatonin|
76081940|NCT04352062|Other|placebo|
76081941|NCT04352062|Drug|Pantoprazole 40mg|pantoprazole 2 x 40mg
76081942|NCT04352062|Drug|Amoxicillin|Amoxicillin 2 x 1000mg
75790396|NCT04671381|Device|Personal Sound Amplification Product (PSAP) Fitting and Orientation|Study participants will be fitted with binaural PSAPs in addition to receiving information on how to use and care for their devices.
75790397|NCT04671381|Behavioral|Four Weeks of Aural Rehabilitation|Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.
75642232|NCT06184828|Biological|Blood components transfusion|The transfusion of blood components units rather than whole blood
75926611|NCT04469491|Drug|inhaled type I interferon|The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
75333210|NCT05313568|Other|static stretching|The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
75642233|NCT06184815|Behavioral|Educational programme 12|Consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months and multidisciplinary treatment
75642234|NCT06184815|Behavioral|Standard education and treatment|Outpatient management and education in the office and consultation referral to nutrition and psychology
75642235|NCT06184802|Behavioral|TAU+Multisensory room|Multisensory room session included exercises in different interaction areas that allow to make up a multisensory experience where the patient can freely perform in different directions experimenting combinations of play
75642236|NCT06184802|Behavioral|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
75642237|NCT06184789|Diagnostic Test|Echocardiographic assessment|Echocardiographic and hemodynamics assessment of Mitraclip results
75642238|NCT06184776|Other|Lumbar Stiffness Disability Index|The development and evaluation of the Turkish version of the Lumbar Stiffness Disability Index (LSDI) are planned. After ensuring the eligibility of adult participants included in the study, language validity will be established for the Turkish version of LSDI, and internal consistency will be assessed using Cronbach's alpha coefficient. Additionally, the test-retest reliability of the index will be evaluated by reapplying it to participants with a one-week interval. For external structure validity, LSDI scores will be correlated with Oswestry Disability Index, Functional Reach Test, and goniometric measurements. The study will include demographic data and measurements to examine the eligibility of individuals with specific medical conditions for the intervention.
75642239|NCT06184763|Other|6-minute walk test|"6-minute walk test in a 40-metre corridor. Included patients are used to performing this test, which is part of the standard care performed during patient follow-up, at least once a year.~Parameters collected during the test: distance walked, minimum SpO2, average SpO2, maximum heart rate, average heart rate, average heart rate over the last 2 minutes, dyspnea scale."
75790398|NCT04671381|Device|Provision of Personal Sound Amplification Products (PSAPs)|Study participants will receive binaural PSAPs. Participants will fit their PSAPs based on manufacturer guidelines without the help of an audiologist.
75926612|NCT04469491|Drug|WFI water nebulization|The interventional arm includes a WFI water nebulization comparator.
76081943|NCT04352062|Drug|Levofloxacin 500mg|Levofloxacin 2 x 500mg
76081944|NCT01302808|Combination Product|Erlotinib plus Romidepsin (8 mg/m^2)|
76081945|NCT01302808|Combination Product|Erlotinib plus Romidepsin (10 mg/m^2)|
76081946|NCT01302808|Combination Product|Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis|
76081947|NCT01302808|Combination Product|(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis|
76081948|NCT01267240|Drug|Capecitabine|Given PO
76081949|NCT01267240|Drug|Vorinostat|Given PO
75333211|NCT05313568|Other|self massage|In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.
75790399|NCT04668833|Procedure|Autologous lymphocyte infusion (ALI)|On the day after completing the last dose of radiation therapy, the patient will have an appointment scheduled in the Apheresis Unit for the infusion of unmunipulated cryopreserved cells. Patients will be pre medicated with acetaminophen (325-650 mg PO) and diphenhydramine (12.5-25 mg PO or IV) prior to infusion. Cells will be infused without a leukoreduction filter at a rate determined by cell volume.
75790400|NCT04667468|Biological|Cold Stored Platelets (CSP)|early infusion of urgent release CSP
75926613|NCT04460924|Drug|Integrase strand transfer inhibitors|Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
75926614|NCT04458948|Drug|Hydroxychloroquine|Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.
75926615|NCT04458948|Drug|Azithromycin|Azithromycin 500 mg, IV or po for 5 days
75926616|NCT04432857|Drug|AN0025|oral administration
75926617|NCT04432857|Drug|Pembrolizumab|Infusion
76081950|NCT01357564|Other|Tailored Activity Program|The interventionist, an occupational therapist, meets with the caregiver and introduces the intervention goals. The OT provides and reviews written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed is The 36 Hour Day. The OT interviews the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT also observes interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale.
76081951|NCT01357564|Other|Attention Control|Caregivers in this group received bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers were provided information about dementia and strategies for disease management. Each telephone contact began with a brief overview the session purpose, followed by a description of key facts, and concluded with a question and answer period. The attention control group intervention was delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
76081952|NCT01855919|Drug|Duloxetine|Administered orally
75790401|NCT04667468|Biological|Standard Care|standard care including blood and blood component therapy
76081953|NCT01855919|Drug|Placebo|Administered orally
75642240|NCT06184737|Behavioral|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
75642241|NCT06184737|Behavioral|Patient Education (PE)|The PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
76081954|NCT01357720|Biological|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
76081955|NCT01357720|Biological|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), inactive pertussis bacteria (>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
75790402|NCT04655963|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
75790403|NCT04633369|Dietary Supplement|dietary fibers|during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
75790404|NCT04633239|Drug|Abemaciclib|Given PO
75790405|NCT04633239|Procedure|Biopsy|Undergo tumor biopsy
75790406|NCT04633239|Procedure|Biospecimen Collection|Undergo collection of blood
76081956|NCT01871519|Device|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
75790407|NCT04633239|Drug|Olaparib|Given PO
75790408|NCT04617015|Drug|Ipratropium Bromide|All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
75790409|NCT04616547|Other|Questionnaire Administration|Ancillary studies
75790410|NCT04616547|Radiation|Tin Sn 117m Pentetate|Given IV
75790411|NCT04616248|Biological|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IT
76081957|NCT01871285|Drug|Buprenorphine|
76081958|NCT01871285|Drug|Placebo film|Matching placebo buccal film
75790412|NCT04616248|Drug|Poly ICLC|Given IT
75790413|NCT04616248|Radiation|Radiation Therapy|Undergo radiation therapy
75790414|NCT04616248|Biological|Recombinant Flt3 Ligand|Given IT
75790415|NCT04613076|Behavioral|"Me cuido y me siento mejor"|A multicomponent, collaborative, computer-assisted, psycho-educational intervention for the management of depressive symptoms in primary care patients with diabetes and/or hypertension.
75790416|NCT04613076|Behavioral|Enhanced Usual Treatment|Enhanced Usual Treatment
75790417|NCT04611022|Behavioral|HPV Educational Intervention|The videos are 8-minute narrative films created using an entertainment-education (E-E) approach that embeds an educational narrative message into an entertainment format such as media. E-E narratives have demonstrated a significant effect (r = .12, p < .001) on health behavior change. Evidence-based small media interventions that Dr. Borrayo has produced include videos that are highly verbal, visual, and entertaining (e.g., acted fictional stories). The aims of the video will be to model uptake of the HPV vaccine, but also to reinforce self-efficacy, subjective norms, and behavioral intentions, all significant precursors to behavior change.
75790418|NCT04607616|Behavioral|Baseline sessions TAU|TAU consists of sessions lasting around one/one and a half hour ; the consultant is practicing as usual. The interventions focus on child's behavior, parent infant relationship, with moments of play with the child, advices, informations about child development and Autism.
75926618|NCT04386746|Drug|Gemcitabine|1g gemcitabine in 50ml sterile water; instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
75926619|NCT04386746|Drug|Docetaxel|37.5mg docetaxel in 50ml normal saline solution (NSS); instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
75926620|NCT04383119|Drug|Trabectedin|Trabectedin in monotherapy
75926621|NCT04383119|Drug|Gemcitabine|Gemcitabine, control arm
75926622|NCT04383119|Drug|No Intervention: Observational Cohort|Treatment according clinical practice
75926623|NCT04381650|Drug|TAK-981|TAK-981 IV infusion.
75926624|NCT04381650|Drug|Pembrolizumab|Pembrolizumab IV infusion.
75926625|NCT04357756|Drug|YH001|YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
75926626|NCT04357756|Drug|Toripalimab|Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
75790419|NCT04607616|Behavioral|Interactive guidance therapy|"The objective is to reinforce the identification, deciphering, interpretation, and answer to child's signals by the parent, in order to to promote a synchronous and attuned response to the child's needs.~Sessions last around one/one and a half hour. Parent plays 7-10 minutes with the child, in the presence of the therapist, with toys chosen according to the child's developmental stage. Then therapist proposes an immediate viewing of the play session. The therapist selects short moments of positive interaction. He has determined a  focus , depending on the play, previous sessions, the child's difficulties and parent's interventions. He accompanies, guides and supports the parent to describe the interaction, the alternance in play, joint attention, shared affect, in a co-construction: the parent discovers the child's and his own skills."
75790420|NCT04607616|Diagnostic Test|Developmental and diagnostic assessments|MSEL, CARS, ECAR, CIM10, DMS5, ADOS, ADIR
75926627|NCT04350502|Procedure|chest tube drainage|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day).
76081959|NCT01871285|Drug|Oxycodone|Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
76081960|NCT01871285|Drug|Morphine sulfate|Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
76081961|NCT01871285|Drug|Placebo capsule|Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
76081962|NCT01358266|Drug|DE-109 44 ug|Low dose
75642242|NCT06184724|Other|Implementation Package for CGA|The Implementation Package will include a set of implementation strategies to improve the use of CGA before surgery. These strategies will be applied at the clinic-level to help increase the reach and adoption of the CGA.
75642243|NCT06184724|Other|Routine Clinical Care|Routine care may or may not include the use of the CGA before surgery. The use of CGA in clinical care is up to the medical and surgical healthcare providers.
75926628|NCT04350502|Biological|antibiotic concentration in pleural fluid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
75926629|NCT04350502|Drug|Amoxicillin + clavulanic acid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
75642244|NCT06184711|Device|Transcranial Magnetic Stimulation+McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with Transcranial Magnetic Stimulation (TMS) will be applied to the first experimental group.
75926630|NCT04339101|Drug|Fludarabine|Given via infusion
76081963|NCT01358266|Drug|DE-109 440 ug|Medium dose
76081964|NCT01358266|Drug|DE-109 880 ug|High dose
76081965|NCT01870973|Procedure|root canal treatment, anesthesia, pain medications, and antibiotic|Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.
76081966|NCT01870973|Procedure|no root canal treatment, anesthesia, pain medications, and antibiotic|
76081967|NCT01267864|Drug|Metoclopramide|10mg IVSS
75642245|NCT06184711|Device|Sham Transcranial Magnetic Stimulation +McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with sham Transcranial Magnetic Stimulation (TMS) will be applied to the sham comparator group.
75642246|NCT06184711|Device|Transcranial Magnetic Stimulation|Only Transcranial Magnetic Stimulation (TMS) will be applied to the second experimental group.
75642247|NCT06184698|Drug|liposomal irinotecan|liposomal irinotecan 70 mg/m²
75642248|NCT06184698|Drug|5-FU|5-FU 2400 mg/m²
75642249|NCT06184698|Drug|LV|5-FU 2400 mg/m²
75642250|NCT06184698|Drug|Bevacizumab|bevacizumab 5 mg/kg
75642251|NCT06184685|Drug|Sahasthara Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
75790421|NCT04607616|Behavioral|Developmental assessment -Parental scales|Vineland II, IFDC, IDE
75790422|NCT04607616|Behavioral|Qualitative analysis|Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).
75926631|NCT04339101|Drug|Itacitinib Adipate|Given PO
75926632|NCT04339101|Drug|Melphalan|Given IV
75926633|NCT04339101|Other|Quality-of-Life Assessment|Ancillary studies
75926634|NCT04339101|Other|Questionnaire Administration|Ancillary studies
75926635|NCT04339101|Drug|Sirolimus|Given PO
75926636|NCT04339101|Drug|Tacrolimus|Given IV or PO
75790423|NCT04602572|Behavioral|Lifestyle course.|Pharmacotherapy
75790424|NCT04602572|Procedure|Bariatric surgery.|Sleeve gastrectomy or gastric bypass.
75926637|NCT04333745|Other|Controlled Diet|Participant will consume a controlled low oxalate diet for five days
76081968|NCT01267864|Drug|Ketorolac|30g IVSS
76081969|NCT01267864|Drug|Valproate|1gm IVSS
76081970|NCT01854827|Drug|Intravenous immunoglobulin (IVIG)|All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
75642252|NCT06184685|Drug|Diclofenac Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
75790425|NCT04601779|Behavioral|VIPP-PUF|The VIPP-PUF Intervention is developed as an add-on to the existing PUF-program to address infants with major cognitive and regulatory vulnerabilities identified at age 9-10 months and adapted to the settings of community health nurses. The intervention (VIPP-PUF) will be created from an evidence-based method, the Video-based Intervention to Promote Positive Parenting (VIPP), to comprise six therapeutic sessions delivered by the community health nurse during home visits over a three months period. The VIPP -PUF builds on teaching the health nurses to promote parents' sensitivity to meet infants' cognitive and regulatory vulnerabilities, while taking in account the particular needs of families of psycho-social disadvantage.
75926638|NCT04333745|Dietary Supplement|Carbon-13 Oxalate and Sucralose Ingestion|Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.
75926639|NCT04305548|Drug|Trabectedin|Treatment with trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
75926640|NCT04294134|Behavioral|MIO-CPP|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) Studies have revealed that CPP caregivers' outcomes include decreased depression, PTSD and other symptoms, increased empathy towards children and an increase in the quality of parent-child interactions. CPP focuses on working with families offering weekly sessions for nine-12 months."
75926641|NCT04294134|Behavioral|MIO-CPP-CRS|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) CPP focuses on working with families offering weekly sessions for nine-12 months.~Certified Recovery Specialists (CRS) provide peer support services are an evidence-based…model of care which consists of a qualified peer support provider who assists individuals with their recovery from mental illness and substance use disorders."
76081971|NCT04415255|Other|EABPI plus IABPI|If the patient was assigned to EPABI plus IABPI, while the extrapleural space was reached, ~ 15 ml of autologous blood was injected at the extrapleural space through the coaxial needle. Then the central stylet was reinserted and the coaxial needle was advanced into the lung parenchyma with a single puncture. The needle was stopped inside the proximal part of the target and the center needle was removed. A 20-G/16 cm fully-automated biopsy needle was introduced through the 19-G/13.8 cm coaxial needle and specimens were identically obtained. After specimens were collected, the biopsy needle was removed, and immediately the remaining autologous blood (~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
76081972|NCT04415255|Other|IABPI-alone|If the patient was assigned to IABPI-alone, after collecting the biopsy specimens, immediately the autologous blood (~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
76081973|NCT04414709|Other|Double short implant|Patients receives 2 short implants to restore missing posterior teeth, loaded with splinted screw retained crowns.
75790426|NCT04599556|Biological|anti-CD7 CAR-T|Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion
76081974|NCT04414709|Other|Single short implant|Patients receives single short implants, loaded with single screw retained crowns.
76081975|NCT02196688|Drug|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
76081976|NCT02196688|Drug|placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
76081977|NCT01359748|Device|Reference sphygmomanometer|* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
76081978|NCT01359748|Device|Sphygmomanometer under test|Electronic Oscillometric method.
76081979|NCT03009448|Other|Interview|Each subject will be interviewed using a semi constructed interview.
76081980|NCT01360450|Drug|Clonidine HCL|At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between < 9.
76081981|NCT01360450|Drug|saline|Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
76081982|NCT03009214|Drug|AMC303|AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
76081983|NCT01268644|Drug|Leptin|weight based sub-cutaneous injection twice daily of Leptin
75642253|NCT06184646|Dietary Supplement|Prune|30 g of prune/day
76081984|NCT01303744|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
75790427|NCT04597372|Drug|Tamsulosin|Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.
75790428|NCT04597372|Drug|Placebo|Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.
75790429|NCT04595747|Procedure|Biopsy|Undergo biopsy
75790430|NCT04595747|Procedure|Biospecimen Collection|Undergo blood sample collection
75642254|NCT06184607|Other|Distance from contact point to attachment level|A periodontal probe will be used to measure distance between contact point to attachment level in maxillary central incisors
76081985|NCT01303744|Drug|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
76081986|NCT01303744|Drug|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
75333212|NCT05313568|Other|Manual Stimulation|"In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each)."
75333213|NCT04391582|Other|Tilapia skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
75333214|NCT04391582|Drug|silver sulfadiazine cream 1%|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
75333215|NCT03768856|Radiation|Temporally Feathered Radiation Therapy (TFRT)|Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
75471558|NCT05871476|Behavioral|, Household Education Communication Hygiene Intervention, Livestock Antibiotic Intervention|The intervention will focus on two main measurable outcomes: 1) Decrease feco-oral-animal transmission route to prevent in-HH and community spread of CRE +/- CoRE. 2) Decrease unindicated community use of ABs for humans and animals. This WP focuses on a one health intervention in collaboration with local health authorities, developing and implementing an HH Education Communication Hygiene Intervention (HECHI) to improve HH hygiene and health management and reduce the risk of transmission between humans and animals, a Provider Engagement Intervention (PEI) to improve case management of common infection and decrease unindicated AB, and and a Livestock AB Intervention (LAI) to reduce the use of AB in livestock through improved biosecurity conditions and animal husbandry.
76081987|NCT01303744|Drug|Placebo|oral tablet, once a day in the morning for 12 weeks
75642257|NCT06184568|Drug|IBI362|Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC)
75642258|NCT06184568|Drug|Semaglutide|Once-weekly injections of gradually increased doses of Semaglutide, subcutaneously (SC)
75642259|NCT06184529|Behavioral|Virtual Reality|The virtual reality simulation includes a one time viewing of a brief video tutorial and then trying out a one time virtual reality simulation with a child avatar that takes 10-20 minutes to complete in-person.
75642260|NCT06184516|Procedure|Reproductive organ sparing radical cystectomy|"Participants on this arm will undergo a reproductive organ sparing radical cystectomy if they are classified as favorable based on the decision tool."
75926642|NCT04293224|Other|DGA Mediterranean diet pattern, energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations.
75926643|NCT04293224|Other|DGA Mediterranean diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations
76081988|NCT01361620|Drug|aspirin|aspirin 81mg, 7-10 days
76081989|NCT01361854|Device|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
75333216|NCT05498064|Drug|Ensartinib|Ensartinib 225 mg administered once daily orally
75333217|NCT04845386|Device|TOF Cuff on arm|The TOF Cuff will be installed on one arm in opposite of TOF Scan. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
75333218|NCT04845386|Device|TOF Cuff on lower leg|The TOF Cuff will be installed on one lower leg. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
75333219|NCT04845386|Device|TOF Scan on toe|The TOF Scan will be installed on hallux . After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
75333220|NCT04845386|Device|TOF Scan on adductor pollicis|The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
75333221|NCT04845386|Device|TOF Scan on corrugator supercilii|The TOF Scan will be installed on corrugator supercilii. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
75333222|NCT03767062|Drug|Topamax|An antiepileptic agent used for migraine prophylaxis.
75333223|NCT03767062|Procedure|Greater Occipital Nerve Block + Supratrochlear Nerve Block|An injection to paralyze the occipital and supratrochlear nerves.
75333224|NCT01456364|Drug|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
75333225|NCT01456364|Drug|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
75333226|NCT05497986|Device|High flow nasal cannula|HFNC with the maximum tolerated flow (up to 60 L/min). Titration of supplemental oxygen to a SpO2 between 88 - 92%.
75642261|NCT06184516|Procedure|Radical cystectomy|"Participants on this arm will undergo a radical cystectomy if they are classified as unfavorable based on the decision tool."
75642262|NCT06184503|Drug|Velmanase Alfa|Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.
75333227|NCT05497986|Device|Conventional low flow oxygenation|Conventional oxygenation through nasal prongs or a facemask, with supplemental oxygen titrated to a SpO2 between 88 - 92%.
75790431|NCT04595747|Procedure|Computed Tomography|Undergo CT scan and PET/CT scan
75926644|NCT04293224|Other|TAD diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends.
75926645|NCT04288245|Device|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper extremity rehabilitation. VNS stimulation as described in the current study consists of 0.5 s trains of 0.8 mA 100 µs biphasic pulses delivered at 30 Hz. Stimulation trains are delivered only during rehabilitation.
75926646|NCT04288245|Device|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
75926647|NCT04286607|Drug|Topical roflumilast|Active treatment
75926648|NCT04270136|Procedure|total mastectomy|breast cancer non conserving surgery
75926649|NCT04246177|Drug|Lenvatinib|Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) via oral capsules once a day during each 21-day cycle.
75926650|NCT04246177|Biological|Pembrolizumab|Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
75926651|NCT04246177|Drug|Oral Placebo|Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
75926652|NCT04246177|Drug|IV Placebo|Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
75926653|NCT04246177|Procedure|TACE|Conducted as a background procedure of chemotherapeutic and embolic agent(s).
75926654|NCT04238481|Drug|Pudexacianinium chloride|Intravenous
75926655|NCT04234386|Radiation|GammaPod Radiation|The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
75926656|NCT04227054|Device|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
75926657|NCT04222010|Drug|loco-regional anesthesia serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia
75926658|NCT04222010|Drug|Loco-regional anesthesia : paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
76081990|NCT01269736|Behavioral|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
75333228|NCT02901314|Other|on-demand audio messages of heart failure education themes|
75333229|NCT04281420|Drug|ATG-019|ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
75333230|NCT04281420|Combination Product|ATG-019 + Niacin ER|ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
75333231|NCT03765502|Device|Nasal Glucagon Device (NG)|NG devices will be provided empty of drug product
75333232|NCT03765502|Device|GEK|Used to administer glucagon intramuscularly (IM)
75333233|NCT03765502|Drug|IM Glucagon|Administered IM via GEK
75642263|NCT06184490|Procedure|Prone position with thoraco-abdominal cushion|Prone position with cushions positioned laterally on the chest, abdomen, and pelvis
75642264|NCT06184464|Other|ACETATE LEUPRELINE|USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
75642265|NCT06184438|Drug|Micronized purified flavonoid fraction(Daflon 1000mg)|Received Micronized purified flavonoid fraction(Daflon 1000mg) BID after surgery from day to day 7
75926659|NCT04222010|Drug|Loco-regional anesthesia : serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
75926660|NCT04205409|Biological|Nivolumab|Given IV
75642266|NCT06184438|Drug|Placebo|Received placebo after surgery.
75790432|NCT04595747|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790433|NCT04595747|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75926661|NCT04179526|Behavioral|Transdiagnostic Internet-delivered REBT|The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
76081991|NCT01305772|Drug|Panitumumab|Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 & 4 of RT alone or weeks 1 & 4 of cisplatin/RT if they tolerated first dose of panitumumab.
75790434|NCT04595747|Drug|Rogaratinib|Given PO
75790435|NCT04587674|Device|Spinal Cord Stimulation|Lead(s) and Implant Pulse Generator
75790436|NCT04587427|Drug|Radium 223 dichloride (Xofigo, BAY88-8223)|Prescribed by physicians.
76081992|NCT01305772|Procedure|Surgery|Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).
76081993|NCT01305772|Procedure|Radiation Therapy|Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
75790437|NCT04585815|Drug|Sasanlimab Prefilled syringe|prefilled syringe
75790438|NCT04585815|Drug|Encorafenib|capsules
75790439|NCT04585815|Drug|Binimetinib|tablets
75790440|NCT04585815|Drug|Sasanlimab|solution supplied in vials
75790441|NCT04585815|Drug|Axitinib|tablets
75790442|NCT04585815|Drug|SEA-TGT|solution in vials
75926662|NCT04179500|Drug|Pretomanid|pretomanid 200 mg (once daily) for 26 weeks (with meal)
75333234|NCT04845230|Behavioral|FreshRx Nourishing Healthy Starts|This is a field experiment study that incorporates referrals to public programs, food supplementation and nutrition education, or integrative care services provided by a Licensed Masters Social Worker.
75642267|NCT06184425|Procedure|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 25-gauge pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
75926663|NCT04179500|Drug|Bedaquiline|bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
75926664|NCT04179500|Drug|moxifloxacin|moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
76081994|NCT01270126|Device|Repetitive transorbital alternating current stimulation|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
75642268|NCT06184425|Procedure|Dural Puncture Epidural technique using pencil-point 27G Whitacre needle|- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 27-gauage pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
75790443|NCT04570436|Drug|gabapentin 600 mg|participants will receive an oral dose of gabapentin 600 mg
75790444|NCT04570436|Drug|gabapentin 1200 mg|participants will receive an oral dose of gabapentin 1200 mg
75926665|NCT04179500|Drug|pyrazinamide|pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
75926666|NCT04166643|Behavioral|WHHIP PLUS|Worksite health promotion and occupational health and safety (total worker health)
76081995|NCT01270516|Drug|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
75926667|NCT04166643|Behavioral|Education only control|Education at the start of the project
75642269|NCT06184386|Other|NIDCAPARENTALIM|PARENTALIM practice that strengthens the NIDCAP. It is proposed in a routine way in the NICU since 2019. PARENTALIM supports and monitors parental implication in nursing care. It is led by a speach language therapist specialized in early feeding development who proposes 5 individualized interviews and uses an educational booklet on eating development care with a lot of illustrations and few words.
75790445|NCT04570436|Drug|gabapentin 1800 mg|participants will receive an oral dose of gabapentin 1800 mg
75333235|NCT04455828|Device|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.
75333236|NCT04587492|Drug|Nusinersen|Treatment with nusinersen
75471559|NCT05870826|Other|Multiwave locked system laser therapy|High intensity laser therapy
75471560|NCT05870826|Other|Sham laser therapy|Sham laser therapy
75790446|NCT04570436|Drug|diazepam 20 mg|participants will receive an oral dose of 20 mg dose of diazepam
75790447|NCT04570436|Other|placebo|participants will receive an oral dose of placebo
75790448|NCT04563845|Drug|GSK3640254|GSK3640254 will be administered.
75790449|NCT04563845|Drug|Placebo|Placebo will be administered.
75790450|NCT04563845|Drug|Moxifloxacin|Moxifloxacin will be administered.
75926668|NCT04145700|Drug|Ramucirumab|Ramucirumab given IV
75926669|NCT04145700|Drug|Gemcitabine|Gemcitabine given IV
75926670|NCT04145700|Drug|Docetaxel|Docetaxel given IV
75926671|NCT04140110|Other|Intensive BP lowering|The aim is to achieve a systolic BP level of <120mmHg within 1 hour after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
75926672|NCT04128683|Drug|amisulpride|Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
75333237|NCT03761368|Procedure|Remote Ischemic Preconditioning|four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff
75333238|NCT03761368|Procedure|Sham Remote Ischemic Preconditioning|deflated cuff placed on the left arm for 40 min
75471561|NCT05870124|Device|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
75471562|NCT05870124|Other|Conventional Medical Management|Conventional Medical Management is the best standard of care treatment for the patient
75471563|NCT05869006|Behavioral|Designed SIA Instrument Supported Interpersonal Relations-Based Group Practice|Group Practice
75471564|NCT05869006|Behavioral|Placebo group practice|The placebo control group application was carried out simultaneously with the intervention group application, and the group application without active curative content was applied.
75471565|NCT05864807|Device|UCon|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
75471566|NCT05860166|Other|Test Scale|Developing an Neurodevelopment Test for evaluating infants in their neonatal period.
75471567|NCT05856461|Procedure|Pulmonary vein isolation|Circumferential pulmonary vein isolation procedure using 3D navigation systems with entrance and exit block verification
75471568|NCT05856461|Procedure|Sham pulmonary artery denervation|Sham pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries with creation of the false ablation points. No true ablation lesions will be performed in the pulmonary artery
75926673|NCT04128683|Drug|bromocriptine|Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
76081996|NCT01270516|Drug|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
76081997|NCT01270516|Drug|Saline|Control
75926674|NCT04125537|Behavioral|IHI Breakthrough Collaborative Model|Staff teams at participating dialysis centers take part in a quality improvement/collaborative learning model that was initially planned to include three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement kidney supportive care best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project. Patients at the sites then receive care that has been improved via this staff education and quality improvement activities.
76081998|NCT01271452|Biological|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
75926675|NCT04117126|Behavioral|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
75926676|NCT04111497|Drug|Glasdegib|Given PO
76081999|NCT01271452|Biological|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
76082000|NCT01271686|Drug|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
75926677|NCT04108156|Drug|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
76082001|NCT01362946|Behavioral|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
76082002|NCT01362946|Behavioral|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
75926678|NCT04108156|Drug|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
76082003|NCT01854047|Drug|Dupilumab|Solution for injection, Subcutaneous injection
75471569|NCT05856461|Procedure|Pulmonary artery denervation|Pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries and 3 circles of ablation lesions (bifurcation of the main pulmonary artery, left and right pulmonary arteries)
75642270|NCT06184386|Behavioral|SOFS|SOFS is a behavioral practice of orofacial stimulations. Il has been mainly carried out by nurses or a speach language therapist specialized in early feeding development. SOFS has been applied through routine protocol in the NICU until 2018.
75642271|NCT06184373|Device|Dexcom G7 CGM|CGMs will be worn intermittently for a maximum of 10 days per period for a total of 5 periods
75642272|NCT06184373|Diagnostic Test|Oral Glucose Tolerance Test|At 12 weeks postpartum, participants will complete an oral glucose tolerance test, which involves drinking a glucose substance and having glucose levels measured a maximum of 3 times.
75926679|NCT04085653|Drug|alpelisib|"Alpelisib will be provided as 50 mg, 125mg and 200 mg film coated tablets as individual patient supply, and will be dosed on a flat scale of mg/day not to be adjusted to body weight or surface area.~In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.~In Pediatric patients, alpelisib will be administered at a maximum starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed."
75926680|NCT04079738|Drug|TAK-659|TAK-659
75926681|NCT04079738|Drug|Ixazomib|Ixazomib
75926682|NCT04066504|Drug|sonidegib|Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
75926683|NCT04063085|Device|PROTAHERE Absorbable Adhesion Barrier|40 mg/ml (4%) cross-linked hyaluronan
75926684|NCT04063085|Device|Hyalobarrier Gel|Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan
76082004|NCT01854047|Drug|placebo|Solution for injection, Subcutaneous injection
76082005|NCT01854047|Drug|ICS/LABA therapy|Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
76082006|NCT01854047|Drug|Salbutamol/albuterol|Oral inhalation as needed
76082007|NCT01854047|Drug|Levosalbutamol/levalbuterol|Oral inhalation as needed
76082008|NCT01363258|Behavioral|Care-resistant mouth care (MOUTh)|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
76082009|NCT01363258|Procedure|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
75471570|NCT05845398|Drug|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
75926685|NCT04063085|Other|No treatment|No anti-adhesion agent applied
75926686|NCT04063085|Device|Seprafilm Adhesion Barrier|a hyaluronate carboxymethylcellulose-based bioresorbable membrane
76082010|NCT01363492|Biological|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
76082011|NCT01307098|Drug|Sebelipase alfa 0.35 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
76082012|NCT01307098|Drug|Sebelipase alfa 1 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
76082013|NCT01307098|Drug|Sebelipase alfa 3 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
76082014|NCT01870739|Drug|sacubitril/valsartan (LCZ696)|200 mg tablets
76082015|NCT01870739|Drug|olmesartan|
76082016|NCT01870739|Other|placebo to sacubitril/valsartan (LCZ696)|placebo
76082017|NCT01870739|Other|placebo to olmesartan|placebo
75642273|NCT06184373|Diagnostic Test|Hemoglobin A1c|At 11-14 months postpartum, participants will be asked to have their blood drawn to check their hemoglobin A1c to look for signs of developed insulin resistance
76082018|NCT01870739|Drug|Amlodipine (Optional)|If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
76082019|NCT01272388|Drug|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
75471571|NCT05845398|Drug|Placebo|0.9% saline for injection.
75642274|NCT06184334|Drug|Solfenacin|pills taken once day
75790451|NCT04555161|Device|Aria CV Pulmonary Hypertension System|The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
76082020|NCT01272388|Drug|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
75790452|NCT04551040|Drug|Terazosin|Terazosin 1 mg oral capsule
76082021|NCT01613417|Drug|gadoteridol|ProHance 0.1 mmol/kg
76082022|NCT01613417|Drug|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
76082023|NCT01364740|Device|PMP-300E|Data collected from Level 3 device
76082024|NCT01364740|Device|In-lab PSG|Data collected from Type I In-Lab Polysomnography
76082025|NCT04414865|Device|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
75471572|NCT05823675|Drug|Itolizumab|Subjects will receive Itolizumab concomitant within 72 hours of systematic Corticosteroids.
75471573|NCT05823675|Drug|Methylprednisolone|Methylprednisolone will be taperred as required
75471574|NCT05874869|Drug|Dihydroartemisinin-piperaquine|The drug will be administered once a day for three consecutive days for three months (March, April, and May)
75642275|NCT06184334|Drug|Mirabegron|pills taken once day
75642276|NCT06184334|Drug|Tadalafil 5mg|pills taken once day
75642277|NCT06184321|Biological|Alteplase|Instilled into IPC
75642278|NCT06184321|Drug|Placebo Administration|Instilled into IPC
75642279|NCT06184308|Behavioral|Home-based Physical Rehabilitation|Six out of seven days a week, gentle flexibility practice (upper arm and shoulder movements) that can be done seated or standing and two slow walking sessions focused on balance. In addition, complete a breathing practice focused on breathing in through the nose and exhaling through the mouth.
75642280|NCT06184308|Behavioral|Health Coaching|Study-trained nurse whom utilizes participant data to guide interactions in weekly calls.
75790453|NCT04550494|Procedure|Biopsy|Undergo biopsy
75790454|NCT04550494|Procedure|Biospecimen Collection|Undergo blood sample collection
75790455|NCT04550494|Procedure|Computed Tomography|Undergo CT scan
76082026|NCT01364896|Procedure|Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples|"Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:~Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)~High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria~Anal cytology testing"
76082027|NCT01870583|Drug|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
76082028|NCT01870583|Drug|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
76082029|NCT01870583|Drug|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
76082030|NCT04351594|Drug|Biofreeze 4 % Topical Gel|Biofreeze gel with active manufactured ingredient (Menthol 4%)
76082031|NCT04351594|Other|Biofreeze placebo gel|Biofreeze gel with no active manufactured to have the same look, feel and odour as Biofreeze topical gel.
76082032|NCT04603469|Other|Non invasive blood pressure|measurement of blood pressure during induction of general anesthesia
76082033|NCT01308814|Drug|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
75642281|NCT06184243|Behavioral|Parent Training|Parent training will cover the topic of creating social skills, goal setting, creating a video model, how to implement the video model intervention, and the parent-child interaction procedures during play. Parents will learn the steps in the fidelity checklist and demonstrate the steps at 90% proficiency by the end of the training. Parent coaching will continue before and after child intervention sessions.
75790456|NCT04550494|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790457|NCT04550494|Drug|Talazoparib|Given PO
75790458|NCT04543539|Combination Product|IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort|For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
75471575|NCT05816603|Device|Real Soterix Mini-CT tDCS stimulator|Real transcranial electrical stimulation at 2mA intensity will be delivered to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration.
75790459|NCT04543539|Combination Product|IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort|For treatment of stenosis in the AV circuit
75790460|NCT04537650|Diagnostic Test|Videofluoroscopic Swallowing Study (VFSS)|A standardized dynamic radiographic examination of oropharyngeal swallowing
75790461|NCT04536077|Drug|CDX-301|The drug will be supplied free of charge by Celldex
75790462|NCT04536077|Drug|CDX-1140|The drug will be supplied free of charge by Celldex
75642282|NCT06184243|Behavioral|Video Modeling|The child will be recorded for a video model engaging in play at their home. The videos will be created with the parent and researcher in the home. A video using the same materials in the same location will be created depicting the child in a play scenario. The video will be two-to-three minutes in length. Each child will receive at least three sessions of intervention and no more than five sessions of intervention per week.
76082034|NCT01308814|Drug|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
76082035|NCT03009760|Drug|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
76082036|NCT03009760|Drug|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
76082037|NCT03009760|Drug|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
76082038|NCT03009760|Drug|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
76082039|NCT03009604|Drug|Simethicone|Simethicone 40mg oral tablets
76082040|NCT03009604|Drug|Enema|sodium dihydrogen phosphate dihydrate 19.2 gram & disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
76082041|NCT01275586|Drug|Tasigna|Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
76082042|NCT01275664|Procedure|Adjuvant Therapy|Ancillary studies
75642283|NCT06184230|Biological|Hepatitis A Vaccine|Hepatitis A Vaccine
75642284|NCT06184191|Other|Robotic hand rehabilitation|Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.
76082043|NCT01275664|Drug|Aprepitant|Given IV and PO
75333239|NCT04841642|Other|MANUAL THERAPY|The investigators will apply manual therapy for ten minutes a week, for 8 weeks, based on cervical mobilizations and suboccipital inhibitions.
75790463|NCT04536077|Procedure|Research blood draw|At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery
75471576|NCT05816603|Device|Sham Soterix Mini-CT tDCS stimulator|Sham stimulation to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration. The device will ramp up and ramp down current delivery from 0 mA -2 mA - 0 mA over 30 seconds at the start of the 20-minute protocol with no active stimulation until the end of the 20 minutes, at which time the 30-second ramp up/ramp down will be repeated.
75790464|NCT04531644|Procedure|double stimulation|the patients will be treated with two consecutive ovarian stimulations in one cycle
75790465|NCT04531644|Procedure|conventional ovarian stimulation|the patients will be treated with one conventional ovarian stimulation in one cycle
75790466|NCT04517253|Drug|Baricitinib|Administered orally
75790467|NCT04514484|Procedure|Biospecimen Collection|Undergo blood sample collection
75790468|NCT04514484|Drug|Cabozantinib S-malate|Given PO
75790469|NCT04514484|Procedure|Computed Tomography|Undergo CT
76082044|NCT01275664|Drug|Carboplatin|Given IP
76082045|NCT01275664|Drug|Cisplatin|Given IP
76082046|NCT01275664|Drug|Dexamethasone|Given PO
75333240|NCT04841642|Other|THERAPEUTIC EXERCISE|"The exercises recommendations will be based on a simulation of the exercises in the same session of the manual therapy of each week, helped by the physiotherapist.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need."
75333241|NCT03774134|Procedure|Complete mesocolic excision|Based on the principles of CME. The inferior mesenteric artery (IMA) was divided at its origin from the aorta to perform central lymph nodes dissection along the IMA between the aorta and the branching of the left colic artery. Sigmoid resection included the complete sigmoid colon and resection of the upper part of the rectum to ensure sufficient perfusion of the colo-rectal anastomosis. To achieve sufficient distance at the proximal bowel resection margin, parts of the descending colon or even left hemicolectomy were performed at the surgeon's discretion.
75471577|NCT05814757|Drug|OTX-DED|0.3mg dexamethasone ophthalmic insert
75471578|NCT05814757|Drug|Controlled Insertion|Collagen Punctal Plug 0.2mm (Controlled Insertion)
75471579|NCT05814757|Drug|Collagen Punctal Plug|Collagen Punctal Plug 0.2mm (Full Insertion)
75471580|NCT05799820|Drug|QL1706|5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
75471581|NCT05799820|Drug|Bevacizumab|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
75333242|NCT03774134|Procedure|Conventional colon resection|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
75471582|NCT05799820|Drug|Oxaliplatin injection|130mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
75471583|NCT05799820|Drug|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
76082047|NCT01275664|Drug|Granisetron Transdermal Patch|Apply one patch to upper arm
76082048|NCT01275664|Procedure|Management of Therapy Complications|Ancillary studies
76082049|NCT01275664|Other|Questionnaire Administration|Ancillary studies
76082050|NCT02193490|Drug|DNase|DNase 0.1% eye drops four times a day for 8 weeks
76082051|NCT02193490|Drug|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
76082052|NCT01367080|Drug|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
76082053|NCT01367080|Drug|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
76082054|NCT01367860|Procedure|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
76082055|NCT01367860|Procedure|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
76082056|NCT01869959|Drug|LY2405319|Administered SC
76082057|NCT01869959|Drug|Placebo|Administered SC
76082058|NCT01368874|Device|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
75642285|NCT06184178|Other|Socio-health care|Socio-health care under TEC-MED model and an integral assessment
75642286|NCT06184165|Procedure|Personalized rTMS|"5 personalized targets accessible to TMS (at less than 3.5 cm distance from the scalp or the coil's hot spot) are placed in the hyper-perfused premotor regions.~The patient is installed on the robotic device. The technician puts a neuro-navigation tracker on the subject's forehead and proceeds to the co-registration. The motor threshold is defined, and stimulator output's intensity is adjusted accordingly (120%) The robotic system ensures that the actual stimulation is performed according to the personalized protocol. This adequacy will be evaluated secondarily based on the recordings of the coil positions during each"
75333243|NCT03758716|Drug|FB825, FB825-15D11, Anti-CemX|Pharmaceutical form: 20mg/ml solution Route of administration: IV
75333244|NCT05285124|Drug|Melatonin|Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
75333245|NCT05285124|Other|Placebo|Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS
75471584|NCT05796882|Behavioral|Whole Food Plant-Based Diet Ad Libitum|"Participants will follow a Low Fat Whole Food Plant-Based Diet Ad Libitum for 8 weeks. It consists of increasing the daily consumption of fruits and vegetables, including sources of vegetable protein such as legumes (beans, lentils, chickpeas, peas, etc), soybeans and their derivatives (tofu, textured soybeans, soymilk), and whole grains. (oats, wheat, rice, quinoa, corn), nuts and seeds high in omega-3 fatty acids (chia, flaxseed, hemp), and minimize processed foods, and foods high in saturated fat. Avoiding animal-sourced foods.~There will be no caloric restriction, however, visual support will be provided, in the form of a traffic light, to distinguish the frequency with which each type of food can be consumed"
75471585|NCT05796882|Behavioral|Nutritional Standard Care|Nutritional Consultation every month for 2 months. Recommendations on healthy eating and lifestyle will be given. Duration 8 weeks
75471586|NCT05790928|Device|Lotrafilcon A spherical contact lenses|CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity
75642287|NCT06184139|Drug|Misoprostol|Oral misoprostol for induction of labor in late term pregnancies
75790470|NCT04514484|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790471|NCT04514484|Biological|Nivolumab|Given IV
75790472|NCT04484272|Behavioral|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).
75790473|NCT04484272|Behavioral|Self-monitoring of pain, stress, and opioid use + alerts/reminders.|Self-monitoring of pain, stress, and opioid use + alerts/reminders.
75798844|NCT02637492|Other|Collection of clinical signs and symptoms|Collection of clinical signs and symptoms used for developing a Clinical prediction rule of critical lower limb ischaemia (diagnosed by haemodynamic methods: ankle pressure, toe pressure-laser Doppler or photo-plethysmography, transcutaneous oxygen pressure) in patients with peripheral occlusive arterial disease
75926687|NCT04063085|Device|Gynecare Interceed (TC7) Absorbable Adhesion Barrier|an oxidized regenerated cellulose absorbable membrane
75798845|NCT01177488|Behavioral|Behavioral Activation Therapeutic Exposure (BATE)|This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
75926688|NCT04054635|Device|Silver diamine fluoride|Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
76082059|NCT01369030|Other|Deplin®|Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
76082060|NCT01613027|Biological|Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
76082061|NCT01369108|Device|Flowable composite|Restoration of small Class V and I cavities in molar and premolar teeth
76082062|NCT01369108|Device|Conventional composite restorative|Restoration of small Class V and I cavities in molar and premolar teeth
75471587|NCT05790161|Drug|Caffeine|2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)
75642288|NCT06184100|Other|Virtual Self-Management Program (SMP)|Four sessions, 60-90 minutes each, will be conducted over eight weeks with a group size of 4-6 participants via videoconferencing platforms such as Zoom or Microsoft Teams. Each session will include Power Point delivered presentations, interactive activities, and group discussions. This is a multifaceted program that includes JIA disease education, self-management strategies, and peer support.
75642289|NCT06184100|Other|No Intervention|No intervention. Participant only receives standard of care.
75926689|NCT04048239|Procedure|cochlear implantation|cochlear implantation is a system developed to restore hearing in people with profound sensorineural hearing loss, whose classical hearing aids are ineffective. Surgery is necessary to insert the internal part into the cochlea and requires milling the mastoid to access the round window. This approach is technically difficult, and is performed under a microscope by an experienced surgeon.
75926690|NCT04048239|Other|computerized tomography (CT) scan|computerized tomography (CT) scan of the facial nerve
76082063|NCT04595045|Drug|Botulinum toxin type A infiltrations|Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice
75333246|NCT05285124|Other|HD-tDCS|Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes
75642290|NCT06184087|Other|Educational/Instructional|ICAP constructive-interactive engagement mode
75798846|NCT03860766|Other|Photobiomodulation|An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
75926691|NCT04048239|Other|electromyograph|electromyographic verification of the facial nerve
75926692|NCT04033510|Other|Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm|Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
75926693|NCT04017247|Drug|Oxytocin|Intermittent oxytocin Infusion
75926694|NCT04017247|Drug|Oxytocin|Continous oxytocin Infusion for 16 hours
75333247|NCT01450046|Drug|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
75333248|NCT03757312|Diagnostic Test|Ultrasound|Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
75642291|NCT06184048|Procedure|Intra-Articular knee injection of LC-PRP|Blood Collection 45mL, Processed Neutrophil-Poor PRP, 2 Injections at day 0 and 3 weeks.
75642292|NCT06184035|Drug|[177Lu]Lu-SN201|Intravenous infusion
75642293|NCT06184022|Combination Product|Augmented reality serious game design for promoting children's science education cognition:|"The experimental group utilized the three game lesson modules of the AR science education app designed for this study, including Animals vision,  Light transmission, and Color-Light mixing.~The experimental group's total learning time was limited to 20 minutes, the testing process was completed under the supervision of the instructor and the experimenter, and the children's behavioral characteristics were recorded. During the experiment, the participants were not disturbed in any way; researchers only intervened when they faced difficulties or requested assistance. The participants were given a 15-minute respite at the conclusion of the trial to take another POE test. Before and after the intervention, each participant's performance on the game was recorded."
75926695|NCT03953235|Biological|GRT-C903|a shared neoantigen cancer vaccine prime
75926696|NCT03953235|Biological|GRT-R904|a shared neoantigen cancer vaccine boost
75926697|NCT03953235|Biological|nivolumab|anti-PD-1 monoclonal antibody
75642294|NCT06184009|Drug|ALL, High risk|"Intervention Description :~Clinical and genetic factors consistent with High risk : Induction → Consolidation~BM MRD &lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~BM MRD ≥ 0.01% after Induction, &lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~BM MRD ≥ 0.01% after Consolidation~T cell ALL : Change to very high risk regimen~Pre-B ALL : IM #1 → Intensification~BM MRD &lt; 0.01% after IM #1 : Continue with &#39;No. 2&#39; of High risk regimen starting with DI #1~BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported."
75642295|NCT06183970|Device|AssistI patients|The AsistI software package rehabilitation involves tailored upper limb exercises under an individual program. The regimen consists of 10-12 sessions, each lasting 30 minutes. Patients execute 10 exercises sequentially with their unaffected and affected limbs, involving tasks like touching mouth, forehead, and trunk parts with hand's brush, and amplitude movements in upper limb joints. AsistI assesses exercise accuracy, prevents unfavorable patterns, and logs target achievement, considering speed, accuracy, and repetitions.
75798847|NCT03858582|Drug|pembrolizumab|pembrolizumab 200mg
75798848|NCT03858582|Radiation|Radiation|52.8Gy/24Fx or 59.4Gy/27Fx
75798849|NCT01287858|Drug|AC430|Healthy volunteers will either receive AC430 or placebo.
75798850|NCT05269836|Device|Surgify Safety Burr|Use of Surgify Safety Burr in hard tissue cutting, head and spine area
75926698|NCT03953235|Biological|ipilimumab|anti-CTLA-4 monoclonal antibody
75926699|NCT03935997|Other|Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program|"Our team will work with long-term care homes in the study to implement the Strengthening a Palliative Approach in Long Term Care (SPA-LTC) which consists of the following core, evidence-informed components:~Palliative Champion Teams (to provide leadership and support implementation); Palliative Care Education (including illness trajectory pamphlets); Comfort Care Rounds with staff (for capacity building and reflection); Prognostic Tools to trigger end-of-life discussions; Palliative Care Conferences with families and residents; Bereavement Pamphlets; and Post-Bereavement Follow-Up for families, and staff."
75926700|NCT03933696|Device|Tailored Lighting Intervention|Lighting Intervention either Active or Placebo
75926701|NCT03904875|Other|collection of data about each acute exacerbation of COPD|COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.
75926702|NCT03897998|Drug|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
76082064|NCT01369732|Drug|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
75333249|NCT01450124|Drug|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
75333250|NCT05587166|Other|ultrasound guided adductor canal block|ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
75333251|NCT05587088|Drug|Petiveria Alliacea Preparation|Petiveria Alliacea Preparation in pill
75926703|NCT03897998|Other|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
76082065|NCT01369732|Drug|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
76082066|NCT01869725|Drug|gallium Ga 68-edotreotide|Given IV
75642296|NCT06183970|Device|Habilect patients|The Habilect rehab program involves 10-12 sessions using software and hardware. Patients perform upper limb exercises for 30 minutes individually, focusing on specific movements. They repeat 10 exercises, first with the healthy limb, then the affected one. Tasks include touching mouth, forehead, and trunk, along with joint movements like shoulder flexion. Habilect assesses exercise accuracy, preventing wrong moves, and tracks progress, considering speed, accuracy, repetitions.
75790474|NCT04473430|Device|Dexcom real-time G6 Continuous Glucose Monitoring System (CGM)|"Dexcom G6, a factory-calibrated CGM system, is innovative in many aspects: 1) it does not require finger stick POC BG for calibration, 2) the sensor is small, compact, light-weight, 3) has no interference with several substance and drugs, and 4) protective urgent low soon alarm, with proven prediction of hypoglycemia within 20 minutes in advance. The sensor uses a novel semi-permeable membrane that blocks interference with most clinically relevant substances, including high levels of urea and creatinine, and commonly used medications. Dexcom G6 CGM is a commercially-available, minimally invasive sensor, with a flexible and thin wire that is inserted into the abdominal subcutaneous tissue. Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia < 55 mg/dL within the preceding 20 minutes)."
75790475|NCT04473430|Diagnostic Test|POC BG|POC BG (standard of care) uses commercially-available glucose meters for blood glucose monitoring. It is approved to be used in dialysis populations.
75790476|NCT04452864|Device|Computerized Cognitive Training|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.
75926704|NCT03891706|Drug|tumor-specific TCR-T cells|On day 0 and day 14, 0.5-5x10^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
75926705|NCT03891706|Drug|Interleukin-2|Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
75642298|NCT06183944|Other|Hierarchical clustering methods|Hierarchical clustering methods will be used to form homogeneous groups of patients based on their data at diagnosis: presence or absence of symptoms, clinical and biological data, and presence or absence of favouring factors. Patient evolution at 6 months can fall into categories: stable, aggravation or progress, which are determined by events such as recurrence, hemorrhage, functional sequelae or death.
75926706|NCT03885401|Behavioral|Enhanced care planning|The intervention includes (1) screening for unhealthy behaviors, mental health needs, and social needs, (2) creation of a care plan, (3) quarterly updates to the plan, (4) a clinical navigator and community health worker to support accomplishing the care plan, (5) registry of community resources and programs, and (6) messaging and video-visit system for team members.
75926707|NCT03862417|Other|Schroth exercises|An exercise program begun individually and then continued in groups.
75926708|NCT03852992|Drug|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
76082067|NCT01869725|Procedure|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
76082068|NCT01869725|Radiation|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
76082069|NCT01869725|Procedure|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
75926709|NCT03852992|Drug|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
75926710|NCT03852992|Device|Laser|Fractional ablative, deep mode, 5% fractional coverage
76082070|NCT01869725|Procedure|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
76082071|NCT01309360|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
75642299|NCT06183931|Drug|ALXN2220|Participants will receive ALXN2220 via IV infusion.
76082072|NCT01309360|Drug|prilocaine 1%|40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block
76082073|NCT01309360|Drug|prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
75642300|NCT06183931|Drug|Placebo|Participants will receive placebo via IV infusion.
75926711|NCT03852992|Drug|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
76082074|NCT01309360|Drug|prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
75926712|NCT03852992|Drug|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
75926713|NCT03852992|Drug|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
76082075|NCT01851863|Drug|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
76082076|NCT01851863|Drug|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
76082077|NCT01851863|Drug|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
76082078|NCT01851863|Drug|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
76082079|NCT01369888|Drug|Cyclophosphamide|60 mg/m^2, intravenous (IV) (in the vein) x 2 days
76082080|NCT01369888|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
76082081|NCT01369888|Biological|Tumor Infiltrating Lymphocytes|IV over 30 minutes on day 0
76082082|NCT01369888|Drug|IL-15|IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
75790477|NCT04452864|Device|Documentaries with delayed Computerized Cognitive Training|The active control group watches documentaries for three months before starting with the CCT.
75790478|NCT04439370|Diagnostic Test|Microneurography to measure muscle sympathetic nerve activity (MSNA)|Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves
75790479|NCT04439370|Diagnostic Test|Baroreflex sensitivity testing|Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.
75790480|NCT04439370|Diagnostic Test|Sympathoexcitatory Maneuvers|Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed
75926714|NCT03832569|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
75642301|NCT06183918|Drug|Tranexamic acid|"Group: Gauze soaked with 1000 mg TXA-topical~Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration."
76082083|NCT01850615|Drug|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
76082084|NCT01850615|Drug|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
76082085|NCT02196766|Other|Bioclean First Care EX / comfilcon A|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
76082086|NCT02196766|Other|Aosept Clearcare / comfilcon A|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
76082087|NCT04602221|Drug|Lamotrigine|Tablet
76082088|NCT04602221|Drug|BI 409306|Film-coated tablet
76082089|NCT04602221|Drug|Placebo|Tablet, Film-coated tablet
76082090|NCT04602221|Drug|BI 425809|Film-coated tablet
76082091|NCT01309906|Device|Investigational lens|Bausch & Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.
75333252|NCT05587088|Drug|Placebo|Placebo in pill
75333253|NCT01450202|Other|bowel insufflation gas|air insufflation, during colonoscopy and esophagogastroduodenoscopy
75642302|NCT06183918|Other|Saline|3. Group: Gauze soaked with 10 cc of saline-topical. The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.
75790481|NCT04439370|Diagnostic Test|Blood tests|Serum FSH, estrogen, progesterone, and testosterone will be measured
75790482|NCT04433767|Drug|Transdermal Nicotine patch|"Participants will begin a 12- week open label trial of transdermal nicotine patch during the day and remove it at night (16 hours). Dose titration starting at 3.5 mg patch/daily to maximum of 21mg patch/daily.~After week 12 , dose will be slowly tapered over 3 weeks."
75790483|NCT04427592|Diagnostic Test|ultrasound|trans-vaginal and trans-abdominal ultrasound using different modalities such as grey-scale, Doppler, multi-planer mode
75798851|NCT01180140|Device|Seamguard|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
75333254|NCT01450202|Other|bowel insufflation gas|CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
75926715|NCT03826342|Behavioral|Health Check-up for Expectant Moms|A brief intervention (one session plus two booster sessions)
75926716|NCT03826342|Behavioral|Time, attention, and information-matched control|We will include facts about alcohol/drug use and risky sex during pregnancy, along with informational brochures that provide face validity.
75926717|NCT03820726|Drug|Nintedanib|Bid
75333255|NCT03748264|Other|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant but will continuously be available to site staff personnel.
75926718|NCT03774446|Drug|Seliciclib|Drug: Seliciclib
76082092|NCT01309906|Device|Air Optix Aqua lens|Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
76082093|NCT04415099|Other|Muscle fatigue protocol|"Tibialis posterior was fatigued using 2 exercises:~Unilateral heel raise exercise~Close chain resisted foot adduction exercise"
76082094|NCT01372462|Device|NIOV - Room Air|Noninvasive ventilation with device powered by compressed room air.
76082095|NCT01372462|Device|NIOV - Oxygen|Noninvasive ventilation with device powered by compressed medical (100%) oxygen.
75642303|NCT06183905|Diagnostic Test|Prostate imaging|"Multiparametric ultrasound (mpUS) The mpUS examinations are performed in the order of greyscale imaging, elastography and contrast-enhanced ultrasound (CEUS), with the patients in the left lateral decubitus position.Greyscale imaging and elastography are evaluated by one radiologist. After standard step-sectional greyscale imaging, transverse elastic images are obtained from the base to the apex by manual compression. The amplitude and frequency of compression are adjusted according to the visual compression indicator on the screen to minimize interoperator variability. CEUS is performed using a bolus of 2.4 mL contrast agents (SonoVue, Bracco) using Contrast mode.~Multiparametric MRI (mpMRI) Prostate mpMRI images were acquired using a 3-T scanner with an external phased-array coil."
75926719|NCT03754634|Drug|Eltrombopag and Diacerein|The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
75333256|NCT03748264|Device|DreamMapper Application|The DreamMapper application condition will receive the site's therapy initiation standard of care and will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously.
75471588|NCT05786040|Procedure|Biopsy|Undergo biopsy
75471589|NCT05786040|Procedure|Biospecimen Collection|Undergo collection of blood samples
75798852|NCT01180218|Procedure|complete revascularization|-Complete revascularization : one time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions in patient with ST elevateion myocardial infarction (STEMI) and multivessle disease
75798853|NCT01180218|Procedure|Culprit revasularization|Culprit revascularization : PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
75798854|NCT01177566|Drug|pimecrolimus|pimecrolimus 1% cream twice daily
75798855|NCT01177566|Device|topical medical device|Eletone cream three times daily
75926720|NCT03751618|Procedure|Hip arthroscopy|"Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure."
75926721|NCT03745404|Drug|Lidocaine 5% medicated Plaster|
76082096|NCT01372462|Device|Nasal Cannula Oxygen|Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
76082097|NCT01373242|Drug|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
76082098|NCT01279564|Device|ETview TVT endotracheal tube|intubation
75333257|NCT03748264|Device|DreamMapper Application with Therapist Assist|The DreamMapper with Therapist Assist will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, their Philips Respironics mask and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously.
75333258|NCT03751124|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
75471590|NCT05786040|Procedure|Computed Tomography|Undergo CT
75333259|NCT03751124|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
75333260|NCT03751124|Drug|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
75333261|NCT03751124|Drug|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
75471591|NCT05786040|Procedure|Positron Emission Tomography|Undergo PET
75471592|NCT05786040|Biological|Rituximab|Given IV or SC
75471593|NCT05786040|Biological|Tafasitamab|Given IV
75471594|NCT05770882|Drug|Chidamide|Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.
75471595|NCT05770882|Drug|Regorafenib|Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.
75471596|NCT05763368|Diagnostic Test|Clinical tests and proprioception evaluation|Each patient will be evaluated using clinical scales (BBS, HHS, HOOS, SF12) and ''Delos Proprioceptive System'' to assess postural stability and proprioception.
75471597|NCT05761249|Other|HeartInsight activation|HeartInsight is activated at enrollment. The attending physicians are free on how to integrate HeartInsight in the patient care. Any treatment is based on routine care according to guidleines. Only documentation occurs on how the physicians use HeartInsight and actions taken in response to HeartInsight alerts
75471598|NCT05733650|Biological|Epcoritamab|Eligible patients will receive epcoritamab (28-day cycle) that will be administered as subcutaneous (SC) injections until disease progression, or one or more of the treatment discontinuation criteria are met.
75471599|NCT05718362|Behavioral|Ayres Sensory Integration Therapy|It is an intervention method whose effectiveness is questioned. It is a therapy program applied according to Ayres Sensory Integration Fidelity Measure.
75471600|NCT05718362|Behavioral|Home Program|These are the activities created for the participants (both intervention and control groups) and to be done in the home environment.
75798856|NCT01181154|Drug|rituximab (Mabthera®)|1000 mg at day 1 and day 15
75798857|NCT01181154|Drug|Placebo|equivalent volume total
75798858|NCT03101566|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV
75798859|NCT03101566|Drug|Cisplatin|Cisplatin 25 mg/m2 IV
75798860|NCT03101566|Drug|Ipilimumab|Ipilimumab 1 mg/kg IV
75798861|NCT03101566|Drug|Nivolumab|Nivolumab 360 mg or 240 mg IV
75926722|NCT03745404|Drug|Placebo Plaster|
75926723|NCT03744312|Drug|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
76082099|NCT01279564|Device|Endotracheal tube|Intubation
75642304|NCT06183905|Procedure|Prostate biopsy|All patients will undergo standard 12-core systematic biopsy (SB) within 1 week following the imaging protocol in conjunction with targeted biopsy (TB) for suspicious lesions on mpUS and/or mpMRI. First, 12-core SB is performed, followed by cognitive mpUS-TB with 2-3 cores for each suspicious lesion. The suspicious lesions on mpUS include hypoechoic lesion(s) on greyscale imaging, reproducible stiff lesion(s) on elastography, and hypoperfused area(s) with ill-defined boundaries or increased focal/asymmetric contrast enhancement on CEUS. Thereafter, MRI/US fusion TB is performed sampling 2-3 cores for each lesion with a Prostate Imaging Reporting and Data System (PI-RADS) version 2 score of 3 or above.Each biopsy sample is placed in the micro-cassette and labelled to identify the biopsy technique and location.
75790484|NCT04427592|Procedure|closure of uterine wall defect|uterine incision above placental bulge by at least 5 mm then complete separation of the placenta starting from areas of least resistance to areas of high resistance leaving a clear defect which will be closed by non locked running sutures from inside the uterus starting from one edge, hitch the bed to the other edge of the defect and controlling placental bed hemorrhage then closing the uterine incision via running sutures in 2 layers with compressing the bed from outwards in the first layer. hemostasis of the abnormal pelvic vasculature if excessive bleeding internal iliac artery may be ligated then insertion of intra-peritoneal drain followed by closing the abdomen.
75333262|NCT01456442|Device|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
75333263|NCT01456442|Device|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
75333264|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0
75333265|NCT01450280|Biological|ChAd63 CS, MVA CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
75471601|NCT05693857|Other|Cardiovascular prevention guidelines|Cardiovascular prevention guidelines use estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk to guide treatment decisions and engage patients in shared decision-making
75642305|NCT06183892|Drug|Tacrolimus Sustained-release Capsules|"Immediate-release tacrolimus for at least 3 months after liver transplantation, and then convert to tacrolimus sustained-release capsules at a ratio of 1:1 to 1:1.2; Take the medicine once a day on an empty stomach in the morning.~(The specific medication plan is decided by the clinician according to the actual situation)"
75642306|NCT06183879|Device|cryoballoon pulmonary vein isolation (Medtronic 4th gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Medtronic 4th gen balloon
75642307|NCT06183879|Device|cryoballoon pulmonary vein isolation (Boston 2nd gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Boston 2nd gen balloon
75642308|NCT06183840|Device|Glutack|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Glutack
75926724|NCT03744312|Drug|Florbetaben|Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
75926725|NCT03737123|Drug|Carboplatin|Carboplatin AUC 4 IV Day 1 of each 21 day cycle
75790485|NCT04425148|Device|Transcranial Alternating Current Stimulation (tACS)|tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.
75790486|NCT04425148|Device|Sham Transcranial Alternating Current Stimulation (sham tACS)|Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.
75926726|NCT03737123|Drug|Gemcitabine|Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
75926727|NCT03737123|Drug|Atezolizumab|Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
75926728|NCT03737123|Drug|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
75926729|NCT03712813|Device|Macrodyne LivMD plate|Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
75926730|NCT03668327|Other||
75926731|NCT03651687|Other||
75926732|NCT03650374|Other|Standard of Care Rehabilitation|Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
75926733|NCT03650374|Other|Experimental Strength Training|Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
76082100|NCT01280110|Drug|Hydroxypropylmethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month
76082101|NCT01280110|Drug|Carboxymethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month.
75471602|NCT05686096|Drug|MYK-224|Specified dose on specified days
75471603|NCT05679700|Other|Rigid Taping|Rigid taping was applied to stroke patients with knee hyperextension.
75471604|NCT05677412|Behavioral|suggestive relaxation|suggestive story before sleep onset
75471605|NCT05677412|Behavioral|Neutral story|neutral story before sleep
75471606|NCT05676801|Drug|Photodynamic Therapy|PDT with methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
76082102|NCT03009136|Drug|SCRT|composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
75333266|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0
75333267|NCT01450280|Biological|ChAd63, MVA CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
75333268|NCT01456598|Procedure|Laparoscopic gastrectomy|"After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
75333269|NCT01456598|Procedure|Open gastrectomy|"After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
75333270|NCT02859116|Procedure|Collection of digestive tissues|The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
75642309|NCT06183840|Device|Conventional|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Traumatic fixation
75642310|NCT06183827|Procedure|Emergency Medical Service intervention|"Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control."
75642311|NCT06183801|Dietary Supplement|Probiotics 1|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.
75642312|NCT06183801|Dietary Supplement|Probiotics 2|Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.
75642313|NCT06183801|Dietary Supplement|Probiotics 3|Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.
75642314|NCT06183801|Dietary Supplement|Probiotics 4|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.
75790487|NCT04419467|Biological|CSL346|VEGF-B antagonist monoclonal antibody
75790488|NCT04419467|Drug|Placebo|Normal saline
75926734|NCT03639714|Biological|GRT-C901|a patient-specific neoantigen cancer vaccine prime
75926735|NCT03639714|Biological|GRT-R902|a patient-specific neoantigen cancer vaccine boost
75926736|NCT03639714|Biological|nivolumab|anti-PD-1 monoclonal antibody
75926737|NCT03639714|Biological|ipilimumab|anti-CTLA-4 monoclonal antibody
75926738|NCT03634267|Radiation|Internal Radiation Therapy|Undergo brachytherapy
75642315|NCT06183801|Dietary Supplement|Probiotics 5|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.
75642316|NCT06183801|Dietary Supplement|Placebo 1|Subjects take capsule three times a day before meal.
75642317|NCT06183801|Dietary Supplement|Probiotics 6|After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
75642318|NCT06183801|Dietary Supplement|Probiotics 7|After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
75642319|NCT06183801|Dietary Supplement|Placebo 2|After 1 month wash out, subjects take capsule three times a day before meal.
75790489|NCT04416581|Drug|PPI|rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.
75926739|NCT03634267|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
75926740|NCT03633162|Other||
75926741|NCT03631056|Biological|Human Acellular Vessel (HAV)|
75790490|NCT04416581|Drug|P-CAB 50|tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.
75798862|NCT01289496|Drug|Peg-interferon alpha-2a, Ribavirin|"4 weeks RBV priming;~24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);~24 weeks Follow-Up~Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.~Ribavirin 200 mg tablets"
75926742|NCT03625102|Drug|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
75926743|NCT03625102|Other|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
75926744|NCT03567876|Drug|Venetoclax|Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
75926745|NCT03518801|Behavioral|Prolonged Exposure|psychotherapy
75926746|NCT03518801|Drug|Cannabidiol|active medication
75926747|NCT03518801|Drug|placebo|non-active medication
75926748|NCT03502707|Biological|Placebo|Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
75926749|NCT03502707|Biological|RSV preF Protein 50 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
76082103|NCT03009136|Drug|Placebos|is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
76082104|NCT01403584|Device|AutoVPAP with addition of AutoEPAP|Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.
75926750|NCT03502707|Biological|RSV preF Protein 150 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
75333271|NCT02563548|Drug|PEGPH20|PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
75333272|NCT02563548|Drug|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
75642320|NCT06183762|Other|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
75642321|NCT06183749|Other|hospitalisation for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit|diagnosed as traumatic brain injury by neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and receivied appropriate necessary treatment
75642322|NCT06182592|Drug|Liposomal cytarabine-daunorubicin for injection|First induction: 100 units/m^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m^2 by 90-minute IV infusion on Days 1 and 3.
75790491|NCT04397172|Procedure|Study Arm|"First inpatient examination (within 24 hours after admission to ICU):~Clinical examination~Laboratory tests, Biobanking, Mitochondrial function testing~Neurophysiological examination (MVRC recording)~Follow-up inpatient examinations (day 2, 5 and 10 after admission):~Clinical examination~Laboratory tests, Biobanking, Mitochondrial functions testing~Neurophysiological examination (MVRC recording)~Day 10 only: Extended neurophysiological examination according to diagnostic criteria~Day 10 only: Grading of muscle strength (Medical Research Council (MRC) system)~Follow-up outpatient examination (after discharge from intensive care):~Clinical examination~Grading of muscle strength (MRC)~Modified Rankin Scale (mRS)~Barthel Scale~Questionnaires (Short Form (36) Health Survey, Essener Questionnaire for Coping with a Disease and Beck's Depression Inventory II)"
75926751|NCT03502707|Biological|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1*10^11 vp.
75926752|NCT03502707|Biological|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
75926753|NCT03502707|Biological|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
75333273|NCT01450358|Other|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
75333274|NCT04081324|Drug|Lasmiditan|Administered orally
76082105|NCT01403584|Device|AutoVPAP with EPAP manually selected|Conventionally applied Expiratory Positive Airway Pressure (EPAP)
76082106|NCT01374490|Drug|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
76082107|NCT01374802|Drug|Darunavir|400 mg tablet for oral administration
76082108|NCT01374802|Drug|Ritonavir|tablet for oral administration
76082109|NCT01374802|Drug|BI 201335|
76082110|NCT01375660|Drug|Placebo|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
76082111|NCT01375660|Drug|50K vitamin D2|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
75790492|NCT04382326|Biological|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
75790493|NCT04382326|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
75790494|NCT04379739|Drug|Camrelizumab|camrelizumab 200mg, q3w, i.v., 2-4 cycles;
75926754|NCT03502707|Biological|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
75926755|NCT03502707|Biological|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
76082112|NCT01868477|Drug|Deferasirox DFX, DT|provided as dispersible tablets for oral use in 125 and 250, 500 mg
76082113|NCT01868477|Drug|Erythropoietin alpha|
76082114|NCT01868477|Drug|Deferasirox DFX, FCT|provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
75333275|NCT04081324|Drug|Placebo|Administered orally
75333276|NCT01456676|Drug|Nilotinib + LDE225|Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
75333277|NCT01456754|Dietary Supplement|low feeding frequency (3x)|3 meals a day
75333278|NCT01456754|Dietary Supplement|High feeding frequency (14x)|14 meals a day
75333279|NCT04424706|Diagnostic Test|diagnosed as type 2 diabetes without atherosclerosis|patients diagnosed as type 2 diabetes without atherosclerosis
75333280|NCT04424706|Diagnostic Test|diagnosed as type 2 diabetes with atherosclerosis|patients diagnosed as type 2 diabetes with atherosclerosis
75333281|NCT04424706|Diagnostic Test|people without type 2 diabetes or atherosclerosis|normal people without type 2 diabetes or atherosclerosis
75790495|NCT04372797|Device|Diagnostic test|A battery of oculomotor tests
75926756|NCT03502707|Biological|Selected Regimen|A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
76082115|NCT01849289|Drug|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
76082116|NCT01849289|Drug|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
76082117|NCT01868243|Drug|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
76082118|NCT01868243|Drug|Warfarin|Warfarin adjusted-dose
75333282|NCT04042324|Drug|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
75790496|NCT04369911|Procedure|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
75926757|NCT03480334|Other|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
75926758|NCT03473535|Combination Product|BEACON + Problem Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.
75642323|NCT06182592|Drug|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 will be administered as: cytarabine at a dose of 100 mg/m^2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m^2/day on Days 1, 2, and 3.~Second induction: 5+2 will be administered as: cytarabine at a dose of 100 mg/m^2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m^2/day on Days 1 and 2.~Consolidation therapy: 5+2 will be administered as: cytarabine at a dose of 100 mg/m^2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m^2/day on Days 1 and 2."
75642324|NCT06180174|Biological|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion
75790497|NCT04362488|Procedure|Preoperative evaluation|"Preoperative evaluation using differents clinical evaluation tests, questionnaires, and instrument:~Delos system (computerized oscillating platform)~Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
75790498|NCT04362488|Procedure|Postoperative evaluation|"Postoperative evaluation at 4 months of follow up after surgery using differents clinical evaluation tests, questionnaires, and instrument:~Delos system (computerized oscillating platform)~Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
75790499|NCT04359901|Biological|SARILUMAB|Single dose of 400 mg subcutaneous sarilumab
75926759|NCT03473535|Behavioral|Problem-Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist.
75926760|NCT03467750|Drug|Ketorolac|Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
75926761|NCT03467750|Drug|Standard of Care|"All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered."
76082119|NCT01611935|Drug|Vasopressin|After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
76082120|NCT02201056|Drug|TAK-935|TAK-935 oral solution
76082121|NCT02201056|Drug|Placebo|TAK-935 placebo-matching oral solution
76082122|NCT01868009|Device|ELLIPTA|Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
75333283|NCT04042324|Drug|Heparin|Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
75333284|NCT04391660|Drug|0.5% sodium hypochlorite solution|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.
75333285|NCT04391660|Drug|0.5% sodium hypochlorite solution and 70% ethanol|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
76082123|NCT01868009|Device|DISKUS|Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
76082124|NCT02201212|Drug|Everolimus|
75642325|NCT06180096|Drug|Riociguat film coated tablets|1 tablet of 2.5 mg Riociguat
76082125|NCT01376050|Device|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
76082126|NCT01376050|Device|Placebo Laser|Placebo Laser has no therapeutic output emitted.
76082127|NCT01376362|Drug|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
75642326|NCT06180096|Drug|Adempas Filmtabletten|1 tablet of 2.5 mg Riociguat
75642327|NCT06180083|Drug|Azelastine Hydrochloride/ Fluticasone propionate nasal spray|A single dose [four sprays (two sprays in each nostril)] of Azelastine HCL/ Fluticasone Propionate 137 mcg/50 mcg Nasal Spray
75642328|NCT06180083|Drug|'DYMISTA' NASAL SPRAY|A single dose [four sprays (two sprays in each nostril)] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
75333286|NCT05497440|Device|All'InCath CBC 035M Balloon Dilatation Catheter|All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
75333287|NCT04842422|Drug|Imiquimod 3.75% Cream|Imiquimod 3.75% Cream
75333288|NCT05497362|Device|Real tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 15 minutes. Speech therapy was delivered simultaneously.
75926762|NCT03447951|Drug|Para-Toluenesulfonamide|A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
75926763|NCT03445559|Behavioral|Clinical Order Check|A Clinical Order Check is an evidence-based, systems-level method to affect significant behavior change. It addresses the intervention functions of education, enablement and incentivization which are effective methods to change behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. All VA facilities currently use locally adapted clinical reminders. This strategy is technologically simple, straightforward, and is considered to be a best practice within the VA IT community. The reminder will be self-explanatory and non-intrusive to workflow.
75333289|NCT05497362|Device|Sham tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 30 sec. Speech therapy was delivered simultaneously.
75471607|NCT05671315|Drug|Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue|"1.Peginterferon alfa-2b injection: 180μg, subcutaneously inject, once a week, from week 1 to Week 48.~2, NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
75926764|NCT03445559|Behavioral|Academic Detailing|Academic detailing is an individual and facility-level intervention consistently shown to improve provider behavior. This strategy addresses the intervention functions of persuasion, coercion, modeling, and education which are effective methods for affecting behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. During the meeting, the detailer will follow a script explaining that the visit is part of an experimental program to provide physicians with up-to-date, unbiased information about imaging to stage prostate cancer.
75926765|NCT03445559|Behavioral|Audit and Feedback|Audit and feedback is an effective, individual-level intervention for changing healthcare provider behavior, resulting in small but potentially clinically important benefits. Audit and feedback addresses the intervention functions of education, persuasion and incentivization, all of which are important for addressing beliefs about capabilities and consequences, knowledge, and social influence.
75926766|NCT03432741|Drug|Belinostat|Given intralesionally
76082128|NCT03009292|Drug|lenvatinib|once daily continuous dosing
76082129|NCT01312948|Device|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
76082130|NCT04346680|Procedure|ADSC administration|The treated nerve will be identified and released. Scar tissue will be removed, and nerve fibers will be exposed. Prepared solutions of ADSC will be administered via microinjection with a 30-G needle along the released nerve fascicles, above and below the reconstructed area and around the adjacent tissue, which stayed in contact with the nerves.
75333290|NCT04066426|Drug|naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol|NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
75333291|NCT04232982|Procedure|Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).|Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.
75333292|NCT04232982|Procedure|G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)|"Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas."
75333293|NCT01450514|Drug|Pipamperone|15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
75333294|NCT01450514|Drug|Placebo|matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
75471608|NCT05671315|Drug|Nucleos(t)ide analogue|"NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
75926767|NCT03432741|Drug|Carfilzomib|Given intralesionally
75926768|NCT03432741|Drug|Copanlisib Hydrochloride|Given intralesionally
75926769|NCT03432741|Biological|Daratumumab|Given intralesionally
76082131|NCT01962792|Drug|Ibrutinib|
76082132|NCT01962792|Drug|Carfilzomib|
76082133|NCT01962792|Drug|Dexamethasone|
76082134|NCT01849055|Drug|Placebo|Administered orally
76082135|NCT01849055|Drug|LY3023703|Administered orally
76082136|NCT01849055|Drug|Celecoxib|Administered orally
75926770|NCT03432741|Drug|Fludeoxyglucose F-18|Undergo FDG-PET
75642329|NCT06180057|Drug|Chenodeoxycholic acid|Two capsules were administered orally
75333295|NCT04279314|Drug|Trofinetide|Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
75642330|NCT06180057|Drug|Chenodeoxycholic acid leadiant|Two capsules were administered orally
75926771|NCT03432741|Drug|Gemcitabine Hydrochloride|Given intralesionally
75926772|NCT03432741|Other|Laboratory Biomarker Analysis|Correlative studies
75926773|NCT03432741|Biological|Nivolumab|Given intralesionally
76082137|NCT01404832|Drug|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
76082138|NCT03420690|Other|satisfaction questionnaire after art therapy session|After the administration of art therapy sessions (>1) and the death of patients (> 1 month), the intervention consists in submitting to families of patients a satisfaction questionnaire intended to evaluate the impact of art therapy session and in particular about their relationships.
76082139|NCT01848353|Behavioral|Exercise training|All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
76082140|NCT02418390|Procedure|prophylactic central lymph node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
76082141|NCT03420534|Drug|Iloperidone 1 MG|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
76082142|NCT03420534|Drug|Placebo|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
75471609|NCT05662215|Drug|CK-3828136|CK-3828136
75471610|NCT05662215|Drug|Placebo for CK-3828136|Placebo for CK-3828136
75471611|NCT05654545|Behavioral|Lapse prevention dialog: Boost motivation and self-efficacy|"In the boost motivation and self-efficacy dialog, the conversational agent will tell the participant that they can successfully resist smoking, try to take away their self-doubts and assert that the participant can and will succeed. For example, the conversational agent will send text messages such as: Even though the temptation can be high, I have no doubts that you can resist smoking in this situation. If you want something, you can do it. Believe in yourself!."
75642333|NCT06179472|Device|BALT GOLDBAL2 Balloon|Placement and retrieval of the GOLDBALLOON Detachable Balloon for severe CDH
75642334|NCT06178055|Drug|KUS121 high dose|Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
75642335|NCT06178055|Drug|KUS121 low dose|Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
75642336|NCT06178055|Drug|Sham procedure|Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
75642337|NCT06177483|Dietary Supplement|95% curcumin extract powder|95% curcumin extract powder
75642338|NCT06177483|Dietary Supplement|curQ+ curcumin formulation|curQ+ curcumin formulation
75926774|NCT03432741|Biological|Obinutuzumab|Given intralesionally
75926775|NCT03432741|Biological|Pembrolizumab|Given intralesionally
75926776|NCT03432741|Procedure|Positron Emission Tomography|Undergo FDG-PET
75926777|NCT03432741|Biological|Rituximab|Given intralesionally
75926778|NCT03432741|Drug|Romidepsin|Given intralesionally
75926779|NCT03432741|Other|Saline|Given intralesionally
76082143|NCT03420534|Dietary Supplement|fasting|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
76082144|NCT03420534|Dietary Supplement|postprandial|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
76082145|NCT03416322|Other|Water exchange|Infusion and remove water during inertion and withdrawal of colonoscope
76082146|NCT01313494|Drug|Roflumilast|Roflumilast tablets
76082147|NCT01313494|Drug|Placebo|Placebo tablets
76082148|NCT01313494|Drug|Salbutamol|Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
75333296|NCT04059250|Device|Nobio composite|Nobio has developed a bactericidal composite, which does not leak out the bactericidal nano fillers
75926780|NCT03432741|Biological|Trastuzumab|Given intralesionally
75333297|NCT04059250|Device|traditional composite|traditional composite which has no bactericidal activities
75333298|NCT01456910|Behavioral|Resistance Training Program|Frequency, volume, repetitions, load, interval
75333299|NCT01450592|Other|No drug|Diabetic Population
75333300|NCT01450592|Other|No drug|Non-Diabetic Population
75333301|NCT04840706|Device|HFNC Airvo|HFNC device (Airvo) long-term use in in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation of COPD
75333302|NCT04840706|Other|Standard care|No HFNC treatment
75926781|NCT03425006|Drug|Itacitinib|a JAK 1 selective small molecule inhibitor
75926782|NCT03425006|Biological|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
75642339|NCT06176820|Drug|Vaginal Gel|Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
76082149|NCT01847885|Device|Smartpatch Peripheral Nerve Stimulation (PNS) System|"The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator)."
76082150|NCT01314742|Drug|Biotene OralBalance® gel|Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
76082151|NCT01314742|Other|Sterile Water moisten cotton tipped applicator|One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
76082152|NCT01407094|Drug|Sertraline|50-200mg/day
76082153|NCT01407094|Drug|Placebo|1-4 pills per day
75642340|NCT06176820|Drug|Vaginal lubricant|Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
75642341|NCT06176651|Drug|Miebo|Subjects will be instructed to use the Miebo eye drop four times per day in both eyes during their participation in clinical trial. The subjects will be required to remove their contact lenses prior to instillation of the Miebo eye drop and must wait 30 minutes before reinserting their contact lenses.
75642342|NCT06176547|Diagnostic Test|HbA1c|Blood glucose in last 3 months
75642343|NCT06176170|Device|VividWhite Glaucoma Implant (VW-51)|Subconjunctival surgical implantation of the VW-51 implant in the study eye.
75642344|NCT06175364|Other|Health Professionals in the Field of Orthotics Prosthetics|Three data collection tools will be used as data collection methods for the research. These data collection tools; demographic information form, Health Sciences Evidence-Based Practice Survey and Information Literacy Self-Efficacy Scale.
75642345|NCT06174363|Drug|Maxigesic|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
75790500|NCT04358289|Other|Basic antimicrobial stewardship education|Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines
75926783|NCT03407157|Dietary Supplement|Probiotic supplementation|Participants will take two capsules daily of Urex Plus VCap-5 (each containing 2.5 billion CFUs of L. rhamnosus and L. reuteri) and one lozenge of Blis K12 (1 billion CFUs of streptococcus Salivarius)
75926784|NCT03407157|Other|Placebo|Participants will be asked to take 2 placebo capsules and 1 placebo lozenge daily from 25 weeks pregnancy
75642346|NCT06174363|Drug|0.9% saline solution|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
75926785|NCT03401073|Drug|Intravenous immunoglobulin|Gamunex-C [immune globulin injection (human) 10% caprylate/chromatography purified] is a sterile solution of human immune globulin protein.
75926786|NCT03401073|Drug|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
75926787|NCT03359954|Radiation|Radiation Therapy|Undergo radiation therapy
75642347|NCT06173869|Drug|FE 999049|FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.
75790501|NCT04358289|Other|Participatory action research group in commune health center and community|"Establish a participatory action research group~Engagement with the group through participatory action research involving problem identification, planning change strategies, implementing strategies, and evaluation"
75798863|NCT01383772|Procedure|Pan retinal Photocoagulation|All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
75926788|NCT03359954|Procedure|Therapeutic Conventional Surgery|Undergo breast surgery
75926789|NCT03331133|Other|No intervention|
76082154|NCT01407094|Drug|BupropionXL|150-450 mg/day
75926790|NCT03310632|Drug|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
76082155|NCT01867307|Drug|Empagliflozin|
76082156|NCT01867307|Drug|BI 10773|open label
75926791|NCT03285581|Device|truSculpt RF|Subjects will receive RF treatments
76082157|NCT01845077|Drug|2x500 mg Metformin (Glumetza)|2 tablets
76082158|NCT01845077|Drug|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
76082159|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
76082160|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
76082161|NCT01845077|Drug|3x500 mg Metformin (Glumetza)|3 tablets
76082162|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
76082163|NCT01845077|Drug|2 x 500 mg Metformin (Glumetza)|2 tablets
76082164|NCT01845077|Drug|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
75333303|NCT04424472|Diagnostic Test|Ultrasonography|Abdominal Ultrasonography
76082165|NCT01845077|Drug|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
76082166|NCT01866917|Drug|Ropivacaine 0.5% 20cc injectate bilaterally|
76082167|NCT01866917|Drug|Placebo|
76082168|NCT01407952|Device|HydroCoil Embolic System|HydroCoil Embolic System
76082169|NCT01407952|Device|Control (bare platinum coils)|bare platinum coils
76082170|NCT01316302|Drug|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
75642348|NCT06173869|Drug|GONAL-F|"GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days.~Coasting was not allowed."
75926792|NCT03273374|Device|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
76082171|NCT01316302|Drug|Placebo|Matching placebo, taken QD for 12 weeks.
76082172|NCT01410058|Dietary Supplement|Moringa oleifera|leaf powder, 1.85g once daily, hard gelatin capsules
76082173|NCT01410058|Drug|Efavirenz 600mg|Efavirenz 600mg based regimen
76082174|NCT01410058|Drug|Nevirapine 200Mg Oral Tablet|Nevirapine 200mg based regimen
76082175|NCT01380106|Drug|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
76082176|NCT01380106|Drug|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
76082177|NCT01381120|Drug|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
76082178|NCT01381120|Drug|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
75926793|NCT03269422|Radiation|MR-based image-guided, intensity-modulated radiotherapy|Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
75926794|NCT03227419|Drug|Tocilizumab Prefilled Syringe|"Treatment arm: tocilizumab (RoActemra®):~162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below)."
75926795|NCT03227419|Drug|Abatacept Prefilled Syringe|"Treatment arm: abatacept (Orencia®)~125 mg weekly after an initial dose of 500 mg (body weight <60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight >100 mg) 24 hours before the first subcutaneous injection."
75926796|NCT03213730|Other|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
76082179|NCT01316770|Drug|Dexamethasone Parotid Irrigation|Irrigation of the parotid gland from one side of the mouth with dexamethasone.
76082180|NCT01316770|Drug|Placebo Parotid Irrigation|Irrigation of the parotid gland on the opposite side of the mouth with placebo saline.
76082181|NCT01316926|Drug|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
75642349|NCT06172933|Behavioral|Move with Meaning|Participants will engage in twice weekly text message sessions, will listen to a weekly audio session, and will work towards a physical activity goal each week, for a total of eight weeks.
75642350|NCT06171191|Behavioral|Move-ARound And Get Active|The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.
75642351|NCT06169306|Procedure|throat pack|Following endotracheal intubation, one saline soaked, throat pack will inserted into the hypopharynx under direct vision. The packs will record in writting on the anaesthesia safety form.
75642352|NCT06167785|Drug|Tislelizumab|Tislelizumab 200mg intravenously every 3 weeks
75642353|NCT06167785|Drug|Zanubrutinib|Zanubrutinib 160 mg oral twice daily
76082182|NCT01316926|Drug|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
76082183|NCT01318408|Drug|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
76082184|NCT01319110|Drug|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
76082185|NCT01319110|Dietary Supplement|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
76082186|NCT01383616|Device|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
76082187|NCT03008512|Drug|Genexol-PM|
76082188|NCT04351516|Drug|Hydroxychloroquine|dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days
76082189|NCT04351516|Other|Placebo|Placebo: Film Coated Tablette
76082190|NCT01411696|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
76082191|NCT01412086|Drug|No Intervention|No Intervention.
76082192|NCT01844765|Drug|nilotinib|Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
76082193|NCT01412164|Device|FIREHAWK biodegradable polymer rapamycin-eluting stent|DES PCI for CAD
76082194|NCT04346758|Procedure|lumbar plexus block|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
76082195|NCT01866293|Drug|Cabozantinib (XL184)|
75642354|NCT06167785|Drug|Tislelizumab + Zanubrutinib|Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks + Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle
75642355|NCT06167486|Drug|SG2918|The SG2918 will be administrated by intravenous infusion every 3 weeks
75642356|NCT06166628|Procedure|Geniculate artery embolization|Femoral arterial access will be obtained under ultrasound guidance. An angiographic catheter will then be advanced to the distal superficial femoral artery. Angiography will be performed to identify the appropriate genicular branches supplying the regions of hyperemia. A microcatheter (1.7-2.4-French) will then be advanced super-selectively into the genicular arteries and 100-300 um EmboSpheres (Merit Medical) will be injected under fluoroscopic guidance. Multiple geniculate arteries may be embolized until neovascularity is no longer seen and pathologic hyperemia is resolved. A repeat lower extremity angiogram will be performed to evaluate for success of embolization and to exclude complication. The catheter and sheath will then be removed, and hemostasis will be achieved using an AngioSeal (Terumo Vascular Interventions) vascular closure device.
76025362|NCT05279963|Procedure|sham electroacupuncture|"In the trunk region, the points are 5 cm away from respective acupoints. In the lower limb region, the point is 3 cm away from Sanyinjiao(SP6). All points will only receive shallow insertion.~Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China).The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the electric needle group."
75642357|NCT06166628|Procedure|Genicular nerve phenol nerve ablation|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 2 cc of 6% phenol will be injected at each location with an end target of fascial expansion under the relevant fascial plane.
75642358|NCT06166628|Procedure|Skin infiltration of 2cc of 0.25% bupivacaine at the knee|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis will be identified. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 1.5 cc of sterile saline will then be injected at each location.
75790502|NCT04358289|Other|Antimicrobial stewardship program in hospitals|"The intervention activities in hospitals will include: training a health-worker in each of the participating hospitals to act as a facilitator or activator; forming an antibiotic stewardship group; meeting regularly and following an action-research cycle that includes problem identification, planning change strategies, implementing strategies, and evaluating strategies"
75790503|NCT04358289|Other|Community education|Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels
75790504|NCT04349826|Drug|Azithromycin|Azithromycin 20 mg/kg/day for 7 days
75790505|NCT04349826|Drug|Cefixime|cefixime 20-30 mg/kg/day for 7 days
75790506|NCT04349826|Drug|Placebo|cefixime-matched placebo for 7 days
76082196|NCT01844687|Drug|CBD|Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
76082197|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
76082198|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
76082199|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
76082200|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
76082201|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
76082202|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
76082203|NCT01844375|Dietary Supplement|Carbohydrate group|The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
76082204|NCT01844375|Other|Control group|The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
76082205|NCT02367456|Drug|PF-04449913 (Glasdegib)|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
76082206|NCT02367456|Drug|Azacitidine|75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
76082207|NCT03416166|Device|Transcatheter Tricuspid Intervention|Any available transcatheter tricuspid valve intervention
76082208|NCT03420456|Device|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
76082209|NCT03420378|Dietary Supplement|vitamin D|Vitamin D replacement
76082210|NCT03425682|Other|ViBone|Viable Bone Allograft
76082211|NCT03415932|Behavioral|health education|Health information by a multimodal team
76082212|NCT03425604|Procedure|Intrauterine insemination|
76082213|NCT03425448|Drug|Heparin|Heparin hemodialysis catheter lock solution
76082214|NCT03425448|Device|Neutrolin|Neutrolin hemodialysis catheter lock
76082215|NCT03419988|Behavioral|Exercise Intervention|24 sessions of aerobic exercise
76082216|NCT03425370|Procedure|Closure of surgical wounds using buried sutures or tissue adhesive on aesthetic outcome.|Effect of replacing buried sutures with tissue adhesive on aesthetic outcome of surgical wounds will be measured using the POSAS.
76082217|NCT03415698|Drug|G-CSF|G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
76082218|NCT03415698|Drug|Standard Medical Therapy|Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
75642359|NCT06156449|Other|Thyme oil|The composition of NV-2016 Coded Thyme Essential oil (Origanum vulgare) (GC-201900528) was obtained with Nature&Nurture (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751). Content of origanum vulgare oil used: 1.3% y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2 borneol, 1.2% β-Bisabolene Contains 3.2% tymol and 75.7% carvacrol.
75790507|NCT04339738|Procedure|Biospecimen Collection|Undergo collection of blood
75926797|NCT03213730|Other|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
76082219|NCT03425214|Other|fMRI|"Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is themonetary incentive delay task."
76082220|NCT03425214|Other|Videopolysomnography|Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.
76082221|NCT03425214|Other|NC (narcolepsy-cataplexy)|The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.
76082222|NCT03419910|Drug|BMS-986165|Specified dose on specified days
76082223|NCT03419910|Drug|Cyclosporine|Specified dose on specified days
76082224|NCT03419754|Dietary Supplement|Glucose|Glucose
76082225|NCT03419754|Behavioral|Fidgetting|low intensity physical activity (fidgetting)
76082226|NCT03415542|Behavioral|Exercise Promotion|Evidence-based techniques (goal-setting, reduced barriers) for increasing exercise behavior
75471612|NCT05654545|Behavioral|Lapse prevention dialog: Future-selves and implementation intentions|"In the future-selves and implementation intentions dialog, the conversational agent will first tell the participant to imagine themselves in a future in which they successfully quit smoking (i.e., desired future self). The conversational agent can send text messages such as: Please think about yourself in the future. Imagine that you have quit smoking successfully. Think about the person you will be. What do you look like? What does your life look like? Consider this future image as well as you can.. This procedure will be repeated for a future in which the participant continued smoking (i.e., the undesired future self). Finally, the conversational agent will explain to the participant that it is important to think about how to resist smoking in HRSs (i.e., implementation intentions) to ensure that the participant comes closer to becoming their desired future self as non-smoker and to avoid their undesired future self as a smoker."
75642360|NCT06155643|Device|Eko Sensora|The exam involves placing the stethoscope in the aortic, pulmonic, tricuspid, and mitral areas for 15-30 seconds until a green light is displayed indicating that useful sound has been recorded. The recording is then uploaded by the device using wi-fi to the AI program for analysis. It does not carry patient identifiers. The device then indicates whether a clinically significant heart murmur was heard, and if so in which recording.
75642361|NCT06154447|Drug|VX-828|Suspension for Oral Administration
75642362|NCT06154447|Drug|Placebo|Suspension for Oral Administration
75642363|NCT06154447|Drug|Itraconazole|Solution for Oral Administration
75790508|NCT04339738|Drug|Cabozantinib S-malate|Given PO
75790509|NCT04339738|Procedure|Computed Tomography|Undergo CT, spiral CT
76082227|NCT04801602|Diagnostic Test|Rapid diagnostic tests|To evaluate different RDTs that are commercially available internationally for detecting antigens or antibodies to Salmonella Typhi and use blood culture as standard for comparison.
76082228|NCT03425136|Other|Systems Analysis and Improvement Approach (SAIA)|Five-step systems analysis and iterative improvement cycles applied by district maternal and child health supervisors to subordinate health facilities providing prevention of mother-to-child HIV transmission services at the facility level.
75790510|NCT04339738|Procedure|FDG-Positron Emission Tomography|Undergo FDG-PET
75790511|NCT04339738|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790512|NCT04339738|Biological|Nivolumab|Given IV
75790513|NCT04339738|Drug|Paclitaxel|Given IV
75790514|NCT04339738|Other|Quality-of-Life Assessment|Ancillary studies
76082229|NCT01319812|Device|Astron Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
76082230|NCT01319812|Device|Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
76082231|NCT03415386|Drug|Combination of antiplatelet drugs and anticoagulants for at least one month|Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
76082232|NCT03415230|Other|Therapeutic massage|Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.
76082233|NCT03415230|Other|Sham massage|Sham massage involves only light touch massage in a non systematic way
76082234|NCT01865747|Drug|Cabozantinib tablets|
76082235|NCT01865747|Drug|Everolimus (Afinitor) tablets|
76082236|NCT03424980|Combination Product|Tyrosine kinase inhibitors|Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
75642364|NCT06154447|Drug|Midazolam|Syrup for Oral Administration
75642365|NCT06153459|Procedure|Umbilical Cord Clamping at ~30 seconds|Care team will wait to clamp the umbilical between 1-<60 seconds after birth. 30 seconds is the ideal time of clamping.
75790515|NCT04339738|Other|Questionnaire Administration|Ancillary studies
75926798|NCT03198325|Other|Stop of ART|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
75926799|NCT03187925|Procedure|open, transcervical versus rigid endoscopic treatment|The goal of the project is to perform the first prospective, multi-institutional long-term (5 year) study comparing the outcomes of open, transcervical versus rigid endoscopic treatment of cervical esophageal diverticulum and cricopharyngeal dysfunction in resolving associated symptoms, complications, and recurrence rates of dysphagia surgery. This study will also include cricopharyngeal bar as it pertains to an early Zenker's diverticulum.
75926800|NCT03183245|Biological|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
76082237|NCT03424902|Diagnostic Test|cardiac computed tomography and cardiac catheterization|assesment of certain predictors with CT and fluroscopy for paravalvular leakage
76082238|NCT03415074|Behavioral|Protein restriction|In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
76082239|NCT01385644|Other|Placental MSC|MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
76082240|NCT03424746|Drug|disodium EDTA|Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
76082241|NCT03414918|Drug|Clarithromycin|Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
76082242|NCT04448496|Drug|Dexamethasone implant|Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
76082243|NCT01387672|Drug|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
75642366|NCT06153459|Procedure|Umbilical Cord Clamping at ~120 seconds|Care team will wait to clamp the umbilical cord between 60-180 seconds after birth.120 seconds is the ideal time of clamping
75642367|NCT06153459|Procedure|Umbilical Cord Milking|For infants who need their cord clamped before the target in the DCC-120 group. Care team may milk the umbilical cord towards the infant four times.
75642368|NCT06149559|Drug|rozanolixizumab|rozanolixizumab solution for injection
75642369|NCT06149507|Drug|Acetaminophen|Prescribe the drug to the child
75642370|NCT06149507|Drug|Ibuprofen|Prescribe the drug to the child
75790516|NCT04338685|Drug|RO7119929|RO7119929 will be administered orally as a capsule
75790517|NCT04338685|Drug|Tocilizumab|"Tocilizumab will be administered in case of severe steroid-refractory cytokine release syndrome.~Tocilizumab will be administered as concentrate for solution for IV infusion at a dose: for participants > 30 kg: 8 mg/kg, for participants < 30 kg: 12mg/kg IV"
75790518|NCT04324619|Other|Online interactive learning activities|"3-hour video-storyline-based interactive learning program~Micro-learning activities that can be completed on mobile devices (eg, smartphones)"
75790519|NCT04324229|Drug|Liraglutide 6 MG/ML [Victoza]|Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.
75790520|NCT04324229|Drug|Placebos|Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
75926801|NCT03183245|Procedure|Arteriovenous fistula (AVF)|Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
75651827|NCT05359627|Drug|Polymyxin B|Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.
75471613|NCT05654545|Behavioral|Lapse prevention dialog: Identity-related positive self-talk|"In the identity-related positive self-talk dialog, the conversational agent will tell the participant to use positive self-talk focused on their identity to motivate themselves to successfully resist smoking. For example, the conversational agent will send text messages such as: When you feel tempted to smoke, it can help to say positive things to yourself and motivate yourself to resist the temptation. What positive things can you say about yourself to motivate yourself to resist smoking? For instance, 'I am a strong person who can resist smoking' or 'I am a person who is persistent and has control over the urge to smoke'. Now say the sentence(s) you find motivating or your own motivating words to yourself, by thinking it, and repeating it in your head or out loud.."
75471614|NCT05654545|Behavioral|Attention control dialog: neutral topic|"The neutral dialog will act as an attention control condition. In this dialog, the conversational agent will not provide support using relapse prevention strategies. Instead, the conversational agent will start with a short introduction (e.g., Hi, how are you doing?), ask questions to show interest (e.g., How are you feeling today?) and will talk about a neutral topic (e.g., animals; What is your favorite animal?), and then closes the conversation (e.g., It was nice speaking with you. I hope you have a good rest of the day!)."
75651828|NCT05357625|Behavioral|Feedback Informed Treatment|FIT is based on two simple questionnaires and aims to assess and improve the effectiveness of therapeutic treatment. Treatment outcomes are assessed with the Outcome Rating Scale (ORS), a four-item self-report instrument measuring client functioning in the area of quality of life. Therapeutic alliance is assessed using the four-item Session Rating Scale (SRS). In FIT the feedback from the client is used to continuous adjustment and improvement of therapy
75790521|NCT04259983|Other|Maximal exercise test|The maximal exercise test will be performed on an electronically braked bicycle ergometer.
75651829|NCT05316584|Behavioral|Remote monitoring|See prior description of the intervention.
75790522|NCT04259983|Other|Endothelial dysfunction assessment|Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.
75926802|NCT03181971|Behavioral|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
75926803|NCT03173560|Drug|lenvatinib|lenvatinib capsules.
75790523|NCT04259983|Other|Arterial stiffness assessment|Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.
75790524|NCT04251585|Drug|Regular Novolin R|Intranasal insulin
75790525|NCT04251585|Drug|Placebo|Intranasal placebo (0.9% saline)
75790526|NCT04250025|Procedure|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
75790527|NCT04247334|Device|Transcranial direct current stimulation|20 minutes of 2 milliamp transcranial direct current stimulation
75790528|NCT04241978|Other|Patient Decision Aid (PtDA)|Patient Decision Aid (PtDA) are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
75790529|NCT04241978|Other|Brochure with general information about osteoarthritis|Participants of the control group will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
75471615|NCT05648968|Biological|Ianalumab|i.v. infusion, prepared from concentrate solution
75471616|NCT05648968|Drug|Placebo|i.v. infusion, prepared from matching placebo
75926804|NCT03173560|Drug|everolimus|everolimus tablets.
75926805|NCT03164265|Biological|Regulatory Donor-Derived Dendritic Cell infusion|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to surgery
75926806|NCT03127774|Drug|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
75926807|NCT03127774|Drug|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
75926808|NCT03127774|Procedure|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
75926809|NCT03120325|Device|Vagal Nerve Stimulation|Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
76025363|NCT03161197|Behavioral|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
76025364|NCT03160963|Other|Power Testing|Chair stand, vertical jump, computerized squat
75651830|NCT05298774|Device|G-tech WPS|G-tech WPS patches applied and activated within 4 hours of surgery
75651831|NCT05264337|Other|Self-reported lymphedema|Lymphedema as reported by LymQOL questionnaire.
75790530|NCT04234568|Procedure|Biospecimen Collection|Correlative studies
75790531|NCT04234568|Procedure|Computed Tomography|Undergo CT
75790532|NCT04234568|Drug|Lutetium Lu 177 Dotatate|Given IV
75790533|NCT04234568|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790534|NCT04234568|Drug|Triapine|Given PO
75790535|NCT04225520|Device|Cardiac resynchronization therapy ON|Implantation of a CRT device. Bi-ventricular pacing will be turned ON.
76025365|NCT05158543|Other|conventional therapy|The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.
75333306|NCT04758728|Procedure|Great saphenous vein stripping and varicectomies|Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.
75642371|NCT06149013|Device|MindAhead Active|MindAhead's Active app focuses on increasing meaningful and enjoyable cognitive, physical, and social activities specifically adapted to patients with early cognitive decline (MCI or mild dementia). These techniques include psychoeducation (explaining the rationale, the components of behavioral activation, and protective activities), action planning (selecting activities, goal setting, activity scheduling, graded task assignment, written schedules, and step-by-step sequencing) and action/self-monitoring (assessing execution of and enjoyment in activities, monitor mood and cognitive problems), as well as value-based activation (understanding most important values, selecting activities according to these values). This process aims to enable the users to understand which activities are enjoyable and meaningful to them and how to implement these activities into their daily lives. MindAhead's Active app consists of one to five sessions per week.
75790536|NCT04225520|Device|Cardiac resynchronization therapy OFF|Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.
75926810|NCT03116529|Combination Product|Combination Radiation, Immunotherapy, Surgery|"Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as >10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease."
75926811|NCT03104504|Behavioral|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
75926812|NCT03104504|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
75926813|NCT03104504|Behavioral|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
75926814|NCT03104504|Behavioral|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
75926815|NCT03099681|Other|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
75926816|NCT03080948|Behavioral|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
75926817|NCT03080948|Other|Saliva samples|Germline DNA analysis
75926818|NCT03025698|Drug|Eltrombopag|Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily
75926819|NCT03025698|Drug|hATG|Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)
76082244|NCT01387672|Other|Placebo|Placebo ointment
75333307|NCT04758728|Drug|Epinephrine Topical|Use of epinephrine/adrenaline solution 1:1000 topically
75333308|NCT04758728|Drug|normal saline|Use of normal saline solution NaCl 0,9% topically
75333309|NCT01450670|Dietary Supplement|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
75333310|NCT01450748|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
75333311|NCT01450748|Drug|Placebo|matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
75790537|NCT04224272|Drug|ZW25 (Zanidatamab)|Administered intravenously
75926820|NCT03025698|Drug|CsA|Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day
75333312|NCT01457066|Behavioral|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
75642372|NCT06149013|Other|Treatment-as-usual|Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.
75790538|NCT04224272|Drug|Palbociclib|Administered orally
75790539|NCT04224272|Drug|Fulvestrant|Administered as an intramuscular injection
75790540|NCT04223856|Drug|Enfortumab vedotin|Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
75790541|NCT04223856|Drug|Pembrolizumab|IV infusion on Day 1 of every 3-week cycle
75790542|NCT04223856|Drug|Cisplatin|administered as IV infusion on Day 1 of each 3-week cycle
75790543|NCT04223856|Drug|Carboplatin|Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
75926821|NCT03023124|Drug|Trabectedin|Treatment with trabectedin repeated every 21 days for 6 cycles
76082245|NCT03419520|Behavioral|Nutritional counseling|Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
76082246|NCT01843673|Procedure|computed tomography|Undergo FBCT
76082247|NCT01843673|Procedure|cone-beam computed tomography|Undergo dual CBCT
76082248|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian kV OBI
76082249|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
76082250|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian MV OBI
76082251|NCT01843673|Procedure|electronic portal imaging|Undergo EPID imaging
76082252|NCT01843673|Radiation|image-guided adaptive radiation therapy|Undergo IGART
76082253|NCT03419442|Drug|Xofigo|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
76082254|NCT03419442|Drug|Taxotere|Docetaxel injection 75mg/m2 every 3 weeks
76082255|NCT03419442|Drug|Jevtana|Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
75926822|NCT03023124|Drug|Adriamycin|Treatment with Adriamycin at day 1 every 21 days for 6 cycles
75333313|NCT03808948|Device|VFI|The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
75333314|NCT02559570|Drug|Placebo|Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
75333315|NCT02559570|Drug|LIN Dose A|Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
75642373|NCT06148948|Drug|BI 1584862|BI 1584862
75642374|NCT06148948|Drug|Placebo|Placebo matching BI 1584862
75790544|NCT04223856|Drug|Gemcitabine|IV infusion on Days 1 and 8 of every 3 week cycle
75790545|NCT04223284|Other|D-Limonene|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes
75642375|NCT06139302|Drug|BI 1015550|BI 1015550
75333316|NCT02559570|Drug|LIN Dose B|Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
75642376|NCT06124456|Other|Usual Care Control Group|Subjects in the usual care control group will receive health education as the attention control. The program will consist of eight 150-minute bi-weekly sessions covering major health issues relating to general health and NAFLD, to be obtained from publicly accessible resources from the Hong Kong Department of Health. Health education information on non-communicable diseases (e.g., cancers, diabetes, coronary heart diseases, obesity, and mental illness), infectious diseases (e.g., COVID-19), and a healthy lifestyle (e.g., balanced diet, physical activity, good sleep, tobacco use, alcohol cessation, and stress management) will also be distributed to the subjects in the exercise groups through recorded presentation videos and leaflets/pamphlets during the first 16 weeks.
75642377|NCT06124456|Other|Moderate-intensity Exercise Intervention|The walking time in each session will be 50 minutes for the moderate-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
75790546|NCT04223284|Other|SLVO|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes
75333317|NCT02559570|Drug|LIN Dose C|Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
75333318|NCT02559570|Drug|LIN 145 µg|Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
75790547|NCT04218864|Behavioral|Strength for U in Relationship Empowerment (SURE)|A brief computer-based intervention (one session plus one booster session) based on motivational interviewing.
75790548|NCT04218864|Behavioral|Attention, time, and information matched control|A brief computer based intervention (one session plus booster session) that involves viewing of popular television shows
75926823|NCT03023124|Drug|Dacarbazine|Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
75926824|NCT03004833|Drug|Nivolumab|Infusion of Nivolumab
75926825|NCT03004833|Drug|Adriamycin|Infusion of Adriamycin
75926826|NCT03004833|Drug|Vinblastine|Infusion of Vinblastine
75926827|NCT03004833|Drug|Dacarbazine|Infusion of Dacarbazine
75926828|NCT02957981|Behavioral|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
75926829|NCT02957981|Behavioral|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
75926830|NCT02932111|Procedure|osteopathic session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
76082256|NCT01412710|Drug|Cholecalciferol|4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
76082257|NCT03424668|Behavioral|diet|lifestyle factors
76082258|NCT01843205|Drug|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
76082259|NCT01843205|Drug|Placebo|The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
76082260|NCT01412866|Behavioral|EDSS with CO feedback and health checklist|Web-based electronic decision support system with CO feedback and health-checklist
76082261|NCT01412866|Behavioral|EDSS with health checklist feedback alon|Web-based electronic decision support system (EDSS) with health-checklist feedback alone (without CO feedback)
76082262|NCT03419208|Other|SPIN-HAND Program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
76082263|NCT03419130|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
76082264|NCT03419130|Other|Laboratory Biomarker Analysis|Correlative studies
76082265|NCT03419130|Biological|Pembrolizumab|Given IV
76082266|NCT03419130|Radiation|Radiation Therapy|Undergo conventionally fractionated RT
75926831|NCT02932111|Procedure|Placebo manipulative session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
75642378|NCT06124456|Other|Vigorous-intensity Exercise Intervention|The walking time in each session will be 25 minutes for the vigorous-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
75642379|NCT06122961|Other|No treatment given|No treatment given
75790549|NCT04216290|Procedure|Biopsy of Bladder|Undergo bladder biopsy
75790550|NCT04216290|Procedure|Biospecimen Collection|Undergo tumor tissue and blood sample collection
75642380|NCT06120790|Other|3 Oz water screen|Patient will consume 3 oz of water continuously without stopping and then will be monitored for one minute post completion. Patient will complete this twice in the same session.
75642381|NCT06118099|Drug|Amlitelimab|Injection solution SC injection
75926832|NCT02915263|Drug|IGIV-C|Gamunex-C [immune globulin injection (human) 10% caprylate/chromatography purified] is a sterile solution of human immune globulin protein.
75926833|NCT02915263|Drug|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
75642382|NCT06118099|Drug|Placebo|Injection solution SC injection
75642383|NCT06117930|Other|Non-Interventional Study|Non-interventional study
75790551|NCT04216290|Drug|Cisplatin|Given IV
75926834|NCT02845947|Behavioral|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
75642384|NCT06108492|Drug|SHR-2005|"In dose Escalation: Five dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period.~In indication Expansion: Indications will be selected to evaluate preliminary efficacy."
75926835|NCT02825160|Drug|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
75642385|NCT06104657|Other|Non-Interventional Study|Non-interventional study
75651832|NCT05264337|Other|Dielectric constant ratio|Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
75926836|NCT02807597|Drug|LS301|-LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.
75926837|NCT02807597|Device|Cancer Vision Goggles and standard fluorescence imaging systems|-Member of the operating team will wear the CVG during surgery
75926838|NCT02807597|Procedure|Surgery|-Standard of care
75651833|NCT05264337|Other|Limb volume|Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
75651834|NCT05262374|Procedure|Procedure/Surgery: Laparoscopic|Surgeon
75926839|NCT02777892|Other|Sapien S3|Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
75651835|NCT05262374|Procedure|Robotic|Versius system.
75651836|NCT05259163|Device|LFR-260 portable phoropter|Portable unit to evaluate visual refractive state of the patient
75790552|NCT04216290|Procedure|Computed Tomography|Undergo CT
76025366|NCT05158543|Other|Task oriented training (moderate intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.
75790553|NCT04216290|Procedure|Cystoscopy|Undergo cystoscopy
75790554|NCT04216290|Biological|Durvalumab|Given IV
75333319|NCT01457144|Drug|RiBVD|"Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"
75333320|NCT01450904|Procedure|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
75333321|NCT01450904|Procedure|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
75333322|NCT01450904|Procedure|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
75333323|NCT04051684|Procedure|Transverse abdominal plane block|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
75790555|NCT04216290|Drug|Fluorouracil|Given IV
75790556|NCT04216290|Drug|Gemcitabine Hydrochloride|Given IV
75790557|NCT04216290|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790558|NCT04216290|Drug|Mitomycin|Given IV
75790559|NCT04216290|Other|Patient Observation|Undergo observation
75790560|NCT04216290|Radiation|Radiation Therapy|Undergo radiation therapy
75790561|NCT04207307|Behavioral|Multimodal exercise program|Multimodal exercise intervention (machine-based resistance, coordination and endurance training).
75790562|NCT04207307|Behavioral|Usual Care|General recommendations for healthy ageing, no machine-based strength training intervention.
75790563|NCT04205708|Diagnostic Test|Tuberculosis test|Tuberculosis (TB) test: A blood sample is collected for lab testing to determine if you have tuberculosis (QuantiFeron test). Alternatively, the test is done by injecting a small amount of fluid (called tuberculin) into the skin on the lower part of the arm. A person given the tuberculin skin test must return within 48 to 72 hours to have a trained health care worker look for a reaction on the arm.
75790564|NCT04205708|Diagnostic Test|Chest X-ray|Chest X ray: non-invasive medical test that helps physicians diagnose and treat medical conditions of the lungs and chest. The Chest X-ray will be done to check for abnormalities on the lungs. The test is non-invasive.
75926840|NCT02777606|Drug|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
75926841|NCT02777476|Device|B-Lite- Light Weight Breast Implants|
75642386|NCT06094413|Behavioral|Multicomponent Training Intervention|The intervention will be implemented and supervised by a well-trained, highly experienced professional with post-graduate education in the fields of exercise science and health promotion. Each session will consist of three phases: warm-up/initiation, conditioning, and cooldown. The intervention will be composed of aerobic, resistance, balance, and flexibility exercises. At each session subjects will be informed of the program goals and the methods used to document exercise tolerance of the session's training loads. The quality of the intervention will be measured by patient compliance, adherence, and feedback such as rates of perceived exertion (RPE) which will be documented during the session to measure immediate effect of the intervention. Progressions will be guided by individual responsiveness and measured by RPE. Progressions will be based on the training principles of specificity, adaptability, and overload.
75642387|NCT06088693|Other|Electroacupuncture and Standard Therapy|Acupuncture Needle Insertion with Electroacupuncture machine.
75790565|NCT04205708|Diagnostic Test|Pulmonary Function Test|A pulmonary function test (PFT, spirometry) is a breathing test that measures how much air your lungs can hold as well as how hard and fast you can blow air out of your lungs. The test is not invasive and involves blowing into a machine.
75926842|NCT02737462|Drug|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
75790566|NCT04203017|Biological|allogeneic fecal microbiota|All patients receive autoHSCT with RIC (Cyclophosphamide, Antithymocyte globulin, Rituximab). After immune system reconstitution (approximately starting D+60 up to D+120), patients will receive FMT from healthy donor via po capsules.
75926843|NCT02735083|Biological|UCART19 follow-up|UCART19 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19. The roll-over occurs at the end of the parent study, or at any time after UCART19 administration, in case of premature discontinuation from the parent study.
75926844|NCT02730923|Drug|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
75333324|NCT04051684|Drug|Ropivacaine|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
75333325|NCT02854124|Procedure|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
75333326|NCT04057768|Device|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.
75333327|NCT01457300|Other|Rehabilitation|Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
75333328|NCT04052542|Behavioral|Traditional online continuing education|30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV
75790567|NCT04193956|Other|Standard-of-care procedures|Patients receive standard of care anti-PD-1 treatment as monotherapy or in combination with other checkpoint inhibitors. Related assessments, as laboratory assessments, CT-thorax-abdomen and FDG-PET will be performed according to clinical routine procedures.
76082267|NCT01320826|Procedure|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
75333329|NCT04052542|Behavioral|Interprofessional education|One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session
75790568|NCT04193956|Other|Study procedures|Patients will undergo tumor biopsies, venous blood sampling and feces sampling in combination with a food questionnaire before, during and at the end of standard of care anti-PD-1 treatment.
75790569|NCT04190394|Other|Intermittent retraining program.|Patient benefits from an intermittent retraining program for 8 weeks, with three 45-minute sessions per week.
75790570|NCT04185558|Device|ActiGraft|Whole Blood Clot (WBC) gel
75790571|NCT04185558|Device|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
75798864|NCT03739866|Drug|Lenacapavir|Administered subcutaneously in the abdomen
76082268|NCT03414840|Drug|Atorvastatin|Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
76082269|NCT01414036|Other|Enhanced Traditional Care control|Educational brochure, list of hospital and community resources
75926845|NCT02730923|Drug|Anastrozole|"Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
75926846|NCT02631447|Drug|LGX818|LGX818 450 mg p.o. od
75926847|NCT02631447|Drug|MEK162|MEK162 45 mg p.o. bid
75926848|NCT02631447|Drug|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
75926849|NCT02631447|Drug|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
75926850|NCT02630615|Other|Blood draw|Whole blood will be collected using standard phlebotomy procedures
76082270|NCT01414036|Behavioral|Patient navigation|Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
76082271|NCT03414762|Device|PICO Negative Pressure Wound Therapy|The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.The dressing is applied to the wound and extra strips are placed over the outside edge to help hold the dressing in place. When the pump is turned on, air is pulled out of the dressing and excess fluid from the wound will start to enter the dressing.
75642393|NCT06075147|Drug|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.
75642394|NCT06073119|Drug|SAR441566|Tablet
75642395|NCT06073119|Drug|Placebo|Tablet
75333330|NCT04052542|Behavioral|Just-in-time education|"Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV"
75333331|NCT04840238|Drug|Cholecalciferol|30,000IU cholecalciferol
75642396|NCT06072339|Other|Lung Ultrasound for PEEP setting|NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.
75642397|NCT06072339|Procedure|Non invasive ventilation session|"The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above."
75926851|NCT02542852|Drug|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
75926852|NCT02526901|Other|No intervention|
75926853|NCT02483312|Biological|IL-12|
75333332|NCT04840238|Drug|Placebo|Placebo tablets
75333333|NCT01450982|Drug|JNJ-38518168 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
75333334|NCT05015010|Drug|Alectinib|600 mg p.o. (four 150 mg capsules) twice daily with food (within 30 minutes after a meal, in the morning and evening).
75333335|NCT03829618|Drug|Topical lidocaine|1% lidocaine topically applied in 4 mL aliquots
75333336|NCT03829618|Drug|Nebuliser solution|2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer
75333337|NCT03829618|Drug|Nebuliser Suspension|2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer
75642398|NCT06072339|Biological|Arterial blood gas|Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.
75642399|NCT06072339|Other|Interview on pain and comfort|The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).
75642400|NCT06070610|Drug|BI 1015550|BI 1015550
75926854|NCT02463266|Behavioral|SUSTAIN Monitoring and Care Management|Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
75926855|NCT02424656|Procedure|MRI|EEG-functional MRI, structural MRI, diffusion MRI
75926856|NCT02424656|Procedure|TMS-EEG|Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
75926857|NCT02424656|Procedure|FDG-PET|
76082272|NCT03414762|Device|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing
76082273|NCT03424590|Device|Clearblue Connected Ovulation Test System|Urinary LH test to predict ovulation
76082274|NCT04351672|Behavioral|Early Time-Restricted Feeding|Eat between 8 am and 4 pm for two weeks
75790572|NCT04149457|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.
75790573|NCT04149457|Other|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
75926858|NCT02424656|Other|Clinical scales|Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
75642401|NCT06070610|Drug|Nintedanib|Soft capsules
75642402|NCT06070610|Drug|Pirfenidone|Film-coated tablets
75790574|NCT04142320|Device|closed-loop rTMS|Delivers patterned magnetic stimulation in closed-loop fashion
75790575|NCT04142320|Device|open-loop rTMS|Delivers patterned magnetic stimulation in open-loop fashion
75790576|NCT04142320|Device|sham rTMS|Delivers placebo magnetic stimulation
75642403|NCT06068764|Drug|Etomidate|The type of general anesthesia induction agent for CABG surgery
75926859|NCT02415933|Behavioral|Trickle Up|"Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~Provision of seed grants to assist in business start-ups through microfinance loans;~One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~Trainings on financial planning and household livelihoods."
76082275|NCT04351672|Behavioral|Late Time-Restricted Feeding|Eat between 1 pm and 9 pm for two weeks
76082276|NCT03424434|Other|Survey diffusion|The study consists in a survey diffusion during several weeks by emailing each practitioner and resident and inviting them to participate to a questionnaire about occupational blood exposure. This survey is strictly anonymous. No identity data is required, only age, gender, function, surgical or medical specialty, work quota and hospital group they belong. This survey is diffused in four UHC (Lyon, Grenoble, Clermont-Ferrand and Saint-Etienne) in France.
76082277|NCT01414426|Drug|vandetanib|Given PO
76082278|NCT01414426|Other|placebo|Given PO
76082279|NCT01414426|Other|immunohistochemistry staining method|Correlative studies
76082280|NCT01414426|Other|laboratory biomarker analysis|Correlative studies
75642404|NCT06068764|Drug|Propofol|The type of general anesthesia induction agent for CABG surgery
75790577|NCT04127578|Biological|LY3884961|Participants will receive a single dose of LY3884961, administered intra-cisterna magna
76082281|NCT01414426|Procedure|biopsy|Correlative studies
76082282|NCT01414426|Other|pharmacological study|Correlative studies
76082283|NCT03418974|Drug|Pitavastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
76082284|NCT03418974|Drug|Atorvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
76082285|NCT03418974|Drug|Rosuvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
76082286|NCT03424356|Drug|Rocuronium Bromide|0.15 mg/kg rocuronium bromide
75642405|NCT06067919|Other|decision tree for the choice of intraoperative antibiotic prophylaxis|Presentation of a decision tree to anaesthetists to guide the choice of intraoperative antibiotic prophylaxis
75642406|NCT06061627|Procedure|LOT-CRT group|"In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads~LBBAP includes LBBP and LVSP.~LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms:~Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and QRS onset;~When reducing the output voltage, the LVAT undergoes a sudden change of>10ms;~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
75642407|NCT06061627|Procedure|BiVP group|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
75642408|NCT06060756|Other|questionnaires completion|"Patients will complete the following questionnaires at 3, 6 and 12 months after start of the treatment for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS):~Pain-related questionnaire~Endometriosis-specific questionnaire~Hospital Anxiety and Depression scale~Questionnaire McGill on Quality Of Life~Insomnia-related questionnaire"
75790578|NCT04127578|Drug|Methylprednisolone|6 IV pulses administered as concomitant medication over 3 months
75790579|NCT04127578|Drug|Sirolimus|Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
75790580|NCT04120298|Behavioral|Supervised exercise|An individualised exercise programme supervised by a trained instructor
75790581|NCT04109586|Behavioral|Personalized nutritional therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
75790582|NCT04100408|Other|Biospecimen Collection|Undergo saliva or buccal mucosa collection
75790583|NCT04100408|Other|Laboratory Biomarker Analysis|Correlative studies
75790584|NCT04100408|Other|Questionnaire Administration|Ancillary studies
75790585|NCT04096274|Behavioral|Leadership for Organization Change and Implementation (LOCI)|LOCI is a multicomponent implementation strategy that engages organizational executives and first-level leaders (i.e., those who administratively supervise clinicians) to build an organizational climate to support the implementation of a focal evidence-based practice (EBP) with fidelity. In this study, the focal EBP is the OQ-A system. LOCI includes two overarching components: (1) monthly organizational strategy meetings between executives and LOCI consultants/trainers to develop and embed policies, procedures, and practices that support implementation of a focal EBP, and (2) training and coaching for first-level leaders, to develop their skills in leading implementation. The aim of these components is to develop an organizational implementation climate in which clinicians' perceive that use of the OQ-A with high fidelity is expected, supported, and rewarded.
75798865|NCT03739866|Drug|Placebo|Administered subcutaneously in the abdomen
75798866|NCT03739866|Drug|B/F/TAF|50/200/25 mg tablets administered orally once daily
75798867|NCT03739866|Drug|TAF|Tablets administered orally
76082287|NCT03424356|Drug|Saline Solution|1-2 ml saline solution
76082288|NCT03424356|Drug|Fentanyl|1mcg/kg for induction
75642409|NCT06053372|Device|Apple Watch|Wearable monitor for heart rate and arrhythmia detection
75642410|NCT06052566|Drug|Efinopegdutide|Subcutaneous injection administered at a dose of 7 mg
75642411|NCT06049095|Drug|LTG-001|Oral doses
75790586|NCT04096274|Behavioral|Training and Technical Assistance Only|"All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback."
75790587|NCT04092270|Procedure|Biospecimen Collection|Undergo blood sample collection
76082289|NCT03424356|Drug|Propofol|2-3mg/kg for anaesthetic induction
75926860|NCT02415933|Behavioral|Trickle Up Plus|"In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage)."
76082290|NCT03424356|Procedure|cystoscopy|patients will treated with this surgical procedure
76082291|NCT03127410|Other|Lumbar traction|Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
76082292|NCT03414528|Diagnostic Test|Diagnostic Test|Analysis of DNA samples of patients with molecularly undetermined PID by whole exome/genome sequencing Transcriptome analysis of patients with molecularly undetermined PID
75333338|NCT04272788|Drug|Infliximab|The CD patients at initial active stage without treatment of glucocorticoids, immunosuppressants and biological agents are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
75333339|NCT01457690|Drug|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
75333340|NCT01457690|Drug|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
75333341|NCT01457690|Drug|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
75471617|NCT05641467|Other|virtual reality glasses|OculusQuest 2 128GB brand virtual reality glasses will be used in our research. OculusQuest 2 128GB is the original all-in-one gaming system for virtual reality. It can only be used as desired with the VR headset and controllers. It adapts to its environment. In this way, it can be played standing and sitting in small and large areas. When glasses will be used on another pregnant women within the scope of COVID-19 measures, disinfection will be provided with 'DiverseyOxivir Plus (hydrogen peroxide)' surface disinfectant. Before the episiotomy repair, the video glasses will be opened, the video will be adjusted to suit the woman. In order for the repair method to be the same for all women, It will be planned to use absorbable, synthetic, braided, sterile surgical thread produced from 1-0 polyglactin.
75642412|NCT06049095|Drug|Placebo|Oral doses
75642413|NCT06043674|Drug|Glofitamab|"2:1 T-cell bispecific humanized monoclonal antibody, 2.5 mL or 10 mL single-use vial, via intravenous infusion per protocol."
75642414|NCT06043674|Drug|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, 50 mL single-use vial, via intravenous infusion per protocol.
75926861|NCT02390869|Drug|R2-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
75926862|NCT02390869|Drug|R-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
75926863|NCT02343952|Drug|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
75926864|NCT02281513|Other|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
75926865|NCT02281513|Other|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
76082293|NCT03414450|Drug|ETC-1907206|ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.
76082294|NCT03414450|Drug|dasatinib|dasatinib tablets at 140 mg will be dosed every day
75333342|NCT05497206|Device|One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System|Total Hip Arthroplasty
75642415|NCT06043674|Drug|Polatuzumab Vedotin|Antibody-drug conjugate, 30 mg or 140 mg vial, via intravenous infusion per protocol.
75642416|NCT06043674|Drug|Atezolizumab|Humanized immunoglobulin monoclonal antibody, 840 mg/14 mL or 1200 mg/20 mL single-use vial, via intravenous infusion per protocol.
75642417|NCT06043674|Drug|Tocilizumab|For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, 20 mg/mL single-dose vials, via intravenous infusion per protocol.
75642418|NCT06033066|Behavioral|Financial Incentives|Small financial incentive or prize incentive
75642419|NCT06033066|Behavioral|Message|Message inviting participant to enroll
75642420|NCT06027463|Procedure|Head and neck vascular recanalization|Head and neck vascular recanalization
75642421|NCT06026462|Diagnostic Test|Observation of clinical indicators related to asthma|Observe the severity of asthma, drug compliance, comorbidities, asthma control, pulmonary function, FeNO, and the number of acute episodes of asthma
75642422|NCT06020118|Biological|Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)|Influenza vaccination and mRNA COVID-19 booster will be given at Visit 1.
75642423|NCT06020118|Biological|Sequential Vaccination (Influenza vaccine then mRNA COVID booster)|Influenza vaccine will be given at Visit 1 and mRNA COVID booster will be given at Visit 2.
75642424|NCT06020118|Biological|Sequential Vaccination (mRNA COVID booster then Influenza vaccine)|mRNA COVID booster will be given at Visit 1 and Influenza vaccine will be given at Visit 2.
75642425|NCT06019845|Device|MAGiC™|Robotic magnetic radiofrequency (RF) ablation catheter
75642426|NCT06009757|Device|GUIDEX® guiding catheter|"The main steps of the procedure Percutaneous Coronary Intervention are :~The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~The catheter should should address the selected vascular site~The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI."
75651837|NCT05259163|Device|Traditional phoropter (Standard of Care)|Standard unit for evaluating visual refractive state of the patient
75790588|NCT04092270|Procedure|Computed Tomography|Undergo CT scan
75790589|NCT04092270|Procedure|Echocardiography|Undergo ECHO
75790590|NCT04092270|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790591|NCT04092270|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
75790592|NCT04092270|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75790593|NCT04092270|Drug|Peposertib|Given PO
76082295|NCT03414294|Drug|K-755 Part A (SAD)|Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
75790594|NCT04084080|Biological|Red Blood Cell|Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of <20% and a pre-transfusion hemoglobin S of <30%.
75790595|NCT04084080|Other|Standard of care|NHLBI/ASH/ATS Expert Panel recommended guidelines
75790596|NCT04080739|Drug|ropivicaine 0.2%|2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
75790597|NCT04075903|Behavioral|Storytelling|"A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
75790598|NCT04074954|Procedure|Cataract surgery|Patients will receive cataract surgery
75790599|NCT04074096|Radiation|Stereotaxic radiosurgery (SRS)|For patients randomised to arm B only: Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases >5 mm).
76082296|NCT03414294|Drug|Placebo Part A (SAD)|Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
75790600|NCT04074096|Drug|Binimetinib Oral Tablet|All patients: binimetinib 45 mg PO BID.
75790601|NCT04074096|Drug|Encorafenib Oral Capsule|All patients: encorafenib 450 mg PO QD
75790602|NCT04074096|Drug|Pembrolizumab|All patients: pembrolizumab 200 mg IV Q3W
75790603|NCT04063982|Other|none, only assessment at different time points|assessment at different time points
75790604|NCT04046575|Radiation|Intensity Modulated Radiation Therapy|-15 fractions of treatment
75790605|NCT04046575|Drug|Carboplatin|Begins on day 1 of radiotherapy
75790606|NCT04046575|Other|MD Anderson Symptom Inventory (MDASI)-Plus module|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
76082297|NCT03414294|Drug|K-755 Part B (MAD)|Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
75651838|NCT05246293|Drug|Tofacitinib|"Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.~Patients who met the inclusion criteria of the study protocol will received tofacitinib 5 mg BID for 12 months"
75651839|NCT05246267|Biological|Dupilumab|Standard of care treatment with dupilumab
75651840|NCT05243147|Device|nasal stents|using nasal stents after septoplasty
75651841|NCT05243147|Device|merocel|using merocel after septoplasty
75790607|NCT04046575|Other|EuroQol (EQ-5D)|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
75790608|NCT04046575|Other|SF-12|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
75790609|NCT04046575|Other|MOS Social Support Measure|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
76082298|NCT03414294|Drug|Placebo Part B (MAD)|Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
76082299|NCT03414294|Drug|K-755 Part C (FE)|Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
76082300|NCT03414294|Drug|K-755 Part D (FE)|Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
76082301|NCT03414294|Drug|K-755 Part E (MAD)|Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
75790610|NCT04046575|Other|CES-D|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
75790611|NCT04046575|Procedure|Blood for ctDNA (optional)|-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
75926866|NCT02281513|Other|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
75926867|NCT02250937|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
75333343|NCT04390880|Drug|18F-DCFPyL|Study participants will receive intravenous administration of 18F-DCFPyL and undergo a PET/CT imaging study. Patients may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
75642427|NCT06009757|Device|Launcher™ coronary guide catheter|"The main steps of the procedure Percutaneous Coronary Intervention are :~The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~The catheter should should address the selected vascular site~The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI."
75642428|NCT06007586|Drug|Aprepitant Injection|Two antiemetic groups use placebo,Dexamethasone and Ondansetron, Three antiemetic groups use Aprepitant,Dexamethasone and Ondansetron.
75642429|NCT06005740|Drug|TORL-4-500|antibody drug conjugate
75642430|NCT06003283|Drug|Rituximab|IV rituximab
75642431|NCT06000813|Behavioral|REACH-Es|REACH-Español is a mobile health platform adapted from the original REACH intervention to a Latino population with type 2 diabetes. The goal of REACH-Español is to improve diabetes medication adherence and glycemic management in this population.
75642432|NCT06000813|Behavioral|ETAU|Participants will maintain care as usual (medication treatment and physician monitoring) in addition to a welcome SMS following enrollment, a SMS each time an HbA1c is collected with a link to a secure website that displays the result, and bi-monthly information on diabetes self-care education.
75642433|NCT05998785|Device|TAPESTRY Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
75642434|NCT05995899|Drug|Tenapanor|IBS-C patients will ingest one capsule of tenapanor (50 mg per dose), twice daily, before breakfast and dinner for a total of 8 weeks
75926868|NCT02250937|Drug|Busulfan|Given IV
75642435|NCT05985148|Radiation|Single-fraction stereotactic radiosurgery (SRS)|"Patients will be treated with single-fraction radiation therapy at three dose levels:~70 Gy, 80 Gy, and 90 Gy using image-guided SRS techniques."
76082302|NCT03414294|Drug|Placebo Part E (MAD)|Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
75642436|NCT05984589|Behavioral|RISE Personalized Self-Managament Training (PSMT)|Along with patient education and internalization of self-determination, the RISE intervention focuses on replacing unhealthy habits with health-promoting habits. Ongoing practice and guidance in generating and enacting SMART (specific, measurable, achievable, realistic, and time-bound) health goals is the centerpiece of the RISE intervention. Working one-on-one with the PI, participants will set goals and develop practical strategies to establish sustainable healthy behavior (HB) change. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create lasting change. The 6-week intervention includes 2 in-person visits and 4 videoconference sessions.
75790612|NCT04046575|Procedure|Blood for SCCA|-Collected at pre-treatment, completion of therapy, and 6 month follow-up
75926869|NCT02250937|Drug|Cladribine|Given IV
76082303|NCT01389076|Drug|Bexxar|"Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body."
75926870|NCT02250937|Drug|Fludarabine Phosphate|Given IV
75926871|NCT02250937|Other|Laboratory Biomarker Analysis|Correlative studies
75790613|NCT04046575|Drug|Paclitaxel|Begins on day 1 of radiotherapy
75798868|NCT03857724|Procedure|prolapse surgery|prolapse surgery
75926872|NCT02250937|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
75926873|NCT02250937|Other|Pharmacological Study|Correlative studies
75926874|NCT02250937|Drug|Venetoclax|Given PO
76025367|NCT05158543|Other|Task oriented training (high intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
75333344|NCT02913092|Behavioral|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
75333345|NCT03741088|Device|VORTX Rx treatment|Cavitation-based cellular destruction using focused ultrasound
75926875|NCT02223208|Drug|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~14mg/ms day +1 and +8~10mg/ms day +1 and +8~8mg/ms day +1 and +8~CHOEP-21~Doxorubicin 50 mg/ms iv day +1 or +2,~Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~Cyclophosphamide 750 mg/ms iv day +1 or +2~Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
75790614|NCT04026581|Behavioral|Speech generating device (SGD) evaluation including BCI access|At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.
75926876|NCT02223208|Drug|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~Romidepsin dose according to phase I iv day +1 and +8~Doxorubicin 50 mg/ms iv day +1 or +2,~Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~Cyclophosphamide 750 mg/ms iv day +1 or +2~Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
75790615|NCT04026581|Behavioral|Training and treatment|Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.
75926877|NCT02043964|Procedure|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
75333346|NCT01451060|Drug|Metaraminol|It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
75790616|NCT04024943|Device|Quadripolar LV Lead|The Attain Stability Quad MRI SureScan LV Lead (Model 4798) is an active fixation quadripolar LV lead based on the Attain Performa lead family models (4298, 4398, and 4598). The lead incorporates an active fixation helix similar to the OUS commercialized Attain Stability bipolar LV lead (Model 20066/4796) which is designed to allow an implanter more options in lead location.
75790617|NCT04022915|Drug|64Cu-FBP8|Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.
75790618|NCT04022915|Diagnostic Test|PET-CT imaging|All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.
75333347|NCT01451060|Drug|Ephedrine|It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
75471618|NCT05576090|Behavioral|Mindfulness Meditation|The mindful awareness practices (MAPS) for Sleep intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA. This intervention includes educational and behavioral content related to sleep, including the importance of regularity of sleep schedules, minimizing noise and light, and reducing caffeine use later in the day. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for questions and group discussion. Home practice is a key component of MAPs and is particularly important for addressing sleep disturbance. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes, with practice prior to bedtime, and to practice at night if they awake and cannot return to sleep.
75471619|NCT05576090|Behavioral|Sleep Education|The Sleep Education intervention provides education and behavioral content based on the National Institutes of Health and National Sleep Foundation tips for better sleep (e.g., changing poor sleep habits and establishing a bedtime routine). Each session provides didactic instruction, review of behavioral techniques, and opportunity for questions. Homework includes practicing sleep hygiene and weekly reading. Key components of the intervention include information about sleep biology, characteristics of healthy and unhealthy sleep, sleep problems, stress biology and stress reduction, self-monitoring of sleep behavior, relaxation methods for improving sleep, and weekly behavioral sleep hygiene strategies.
75926878|NCT01891422|Other|Non-interventional.|
76082304|NCT01389076|Drug|Low Dose Methotrexate|Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
75333348|NCT05497128|Device|Ultrahigh-speed cut rate 27-gauge system|The ultrahigh-speed cut rate 27-gauge system (27+®GA HYPERVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
75333349|NCT05497128|Device|Standard cut rate 27-gauge system|The current standard cut rate 27-gauge vitrectomy system (27+®GA Advanced ULTRAVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
75333350|NCT01451138|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
75333351|NCT01143181|Drug|Brincidofovir|Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
75471620|NCT05574712|Drug|Neoadjuvant treatment|Each drug will be dosed at its respective FDA-approved dose. These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily. All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects
76082305|NCT02948478|Other|Exposed|Precarious patients
76082306|NCT02948478|Other|Non exposed|Non precarious patients
76082307|NCT02813226|Other|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
76082308|NCT03414216|Procedure|Group 1 early offloading surgery|As above.
76082309|NCT03414216|Procedure|Group 2 - off-loading in fiberglass cast|As above.
76082310|NCT03127800|Drug|Morphine sulphate|5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
75642437|NCT05984589|Behavioral|Standardized Self-Managament Training (SSMT)|Participants randomized to the control condition will receive 6 standardized sessions from one of the OT interveners, matched to the PSMT for setting. At these visits, participants will be presented with slides containing pre-specified, standardized didactic content about the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) healthy behavior recommendations (HBRs). We hypothesize that these visits will control for the effect of research participation and increased knowledge about HBRs, and that simply providing standardized didactic content as an intervention modality without any personalization will have negligible effects on participants' healthy behaviors (HBs), self-efficacy, or quality of life. Content will follow the WCRF/AICR HBRs. Weeks 1-2 will focus on physical activity; weeks 3-4 will focus on diet and alcohol, and weeks 5-6 will focus on weight management and generalized strategies for HB change.
75926879|NCT01872208|Biological|HAV implantation|Patients will be implanted with a Human Acellular Vessel (HAV) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques.
76082311|NCT01389856|Drug|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
76082312|NCT01389856|Drug|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
76082313|NCT04448964|Drug|JNJ-70033093|JNJ-70033093 will be administered orally as per assigned treatment sequence.
76082314|NCT03423966|Device|Smartphone Pedometer App|Installation of the free pedometer app and explanation to participants to target 10000 steps per day. The intent is not the accuracy of the pedometer but the motivation especially to a community yet to harness the full potentials of the mobile phone technology
76082315|NCT03418896|Drug|human chorionic gonadotropin|a single injection of a standard dose
76082316|NCT03414138|Behavioral|Mindfulness Training|A well-validated brief mindfulness-based mental training regimen [four sessions; 20 min/session] will be used to teach patients to independently practice mindfulness meditation.
75471621|NCT05547724|Other|Virtual reality|Virtual reality visit of the birth room, cesarean and pediatric hospitalization department: neonatology and neonatal intensive care
75926880|NCT01798407|Device|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
76082317|NCT03414138|Behavioral|Book Listening Control|Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
76082318|NCT01323010|Drug|Albuterol - Experimental|The Experimental group will receive higher doses of albuterol in the first hour: 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
76082319|NCT01323010|Drug|Albuterol - Control|The Control group will receive the following doses of albuterol in the first hour 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg)
75333352|NCT04199676|Diagnostic Test|Glucose tolerance test|Oral administration of a 75g glucose tolerance test during the postpartum hospitalization
76082320|NCT03127176|Other|Genome sequencing of fecal samples|Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
75471622|NCT05537727|Device|robotic-assisted surgery|Gynecology: robot-assisted and laparoscopic hysterectomy for benign or low risk malignant disease
76082321|NCT03423810|Drug|Hydralazine|Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.
76082322|NCT01835015|Drug|CLG561|Administered by intravitreal injection, Day 1
76082323|NCT03414060|Device|Menstrual Cup|
76082324|NCT03413904|Procedure|transanal TME|transanal approach to TME in rectal cancer
75333353|NCT03740152|Device|Transcranial Light Therapy|Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
75333354|NCT03739684|Drug|18F-DCFPyL|A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
75333355|NCT03739684|Diagnostic Test|PET/CT Imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
76082325|NCT03413904|Procedure|laparoscopic TME|laparoscopic approach to TME in rectal cancer
76082326|NCT01390246|Drug|Bupropion SR|Bupropion SR 150 mg tablet
76082327|NCT01390246|Behavioral|Smoking Cessation Counseling|35-min counseling by trained research nurse
75333356|NCT04819620|Drug|PN-232|Active Drug
75333357|NCT04819620|Drug|Placebo|Matching Placebo
75333358|NCT01143649|Device|transcranial direct current stimulation (tDCS)|Subjects will be stimulated at 1 mA for 40 minutes.
76082328|NCT01390246|Drug|Placebo|Matching Bupropion SR placebo tablet
76082329|NCT03418584|Device|HybridAPC|HybridAPC is a device which combines submucosal fluid injection with APC
76082330|NCT01390870|Drug|5ARI or AB or Combination Therapy (5ARI + AB)|5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
76082331|NCT03127254|Behavioral|Video narrative|create a 10-15 minute video intervention about teen experiences after being diagnosed with cancer
75790619|NCT03995238|Behavioral|Error-augmentation gait training|Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.
75926881|NCT01798407|Other|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
75926882|NCT01793493|Other|Cognitive stimulation|"Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.~Meetings (each lasting about 2 hours) have a common structure:~body awakening (10 minutes)~cognitive stimulation (1 hour and a half) scheduled as follow:~temporospatial orientation~attentional abilities~one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)"
75926883|NCT01793493|Other|Sanitary education|Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
75926884|NCT01744418|Device|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
76082332|NCT03127254|Behavioral|PedsQL|A generic 23-item Health Related Quality of Life measure initially developed using pediatric cancer patients
75471623|NCT05537727|Device|robotic-assisted surgery|Urology: robot-assisted and laparoscopic partial nephrectomy
75471624|NCT05537727|Device|robotic-assisted surgery|General surgery: robot-assisted and laparoscopic right colectomy
75642438|NCT05967117|Drug|Iohexol (320mgI/mL) with 120kVp|Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
75642439|NCT05967117|Drug|Iohexol (320mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
75642440|NCT05967117|Drug|Iohexol (270mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
75642441|NCT05967117|Drug|Iohexol (240mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
75642442|NCT05965856|Drug|BL-B01D1|Administration by intravenous infusion
75642443|NCT05965856|Drug|SI-B003|Administration by intravenous infusion
75642444|NCT05957289|Behavioral|multidimensional rehabilitation|Multidimensional lifestyle interventions
75790620|NCT03995238|Behavioral|Error-correction gait training|Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.
75926885|NCT01710176|Drug|epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)|
75926886|NCT01710176|Drug|gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)|
75926887|NCT01710176|Drug|trabectedin 1.3 mg/m2|
75926888|NCT01710176|Drug|high-dose ifosfamide 14 g/m2, given in in 14 days|
75926889|NCT01710176|Drug|etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)|
75926890|NCT01710176|Drug|gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)|
76082333|NCT03127254|Behavioral|Ten Item Personality Inventory|The TIPI consists of ten items and measures personality based the subject's agreement of descriptions of themselves taken from the Big-5 model of personality
76082334|NCT03127254|Behavioral|Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test|The D-KEFS Verbal Fluency Test consists of three subtests, which take approximately 6 minutes to complete
76082335|NCT03127254|Behavioral|The Cognitive Log|The Cog-Log is a 5-10 minute assessment designed to measure basic cognitive functioning and orientation
75642445|NCT05956990|Behavioral|multidimensional rehabilitation|Multidimensional lifestyle interventions
75651842|NCT05229224|Other|Osteo fluidic Sensitive méthod|Manual therapy, without manipulative treatment, based on rebalancing of the body with manual pressures on specific body areas.
75333359|NCT01143649|Procedure|constraint induced movement therapy (CIMT)|
75333360|NCT01143649|Device|transcranial alternating current stimulation (tACS)|Subjects will be stimulated at 15Hz for 20 minutes.
75333361|NCT03937570|Device|echo-optimization|LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.
75333362|NCT01143727|Drug|Santyl|Apply one 24-hr period sufficient to cover the wound.
75333363|NCT01143727|Drug|Tegaderm Hydrogel|Apply once 24-hr period sufficient to cover the wound.
76082336|NCT03008668|Other|acupuncture|a stimulation of the body or auricular points
76082337|NCT03423732|Drug|CardioCell|"Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion."
76082338|NCT03423732|Drug|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
75790621|NCT03995238|Behavioral|Supervised walking|An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
75790622|NCT03984422|Other|Smartphone application|use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
75926891|NCT01660971|Drug|Dasatinib|Given PO
75790623|NCT03973931|Behavioral|Nudge|Interventions will include a variety of text messages aimed at improving medication adherence.
76082339|NCT04631952|Behavioral|Online exercise|SMS messeages on encouraging active lifestyle and online exercise video will be sent to the participant weekly for 8 weeks.
76082340|NCT04631952|Behavioral|SMS message|SMS messeages on encouraging active lifestyle will be sent to the participant weekly for 8 weeks.
76082341|NCT02231814|Dietary Supplement|Crohns Disease Exclusion Diet + PEN|"Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase."
75471625|NCT05532657|Other|Hearing intervention|The hearing intervention is best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist for 3 years and will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
75642446|NCT05954377|Other|Quarterly remote motivational interviews|Remote motivational interview will be in the form of quarterly telephone call (at 3, 6 and 9 months after the start of annual follow up; the patient is seen again at 12 months as part of the annual follow-up) and this for 4 years. It will be performed by medical staff trained in motivational interviewing and who have completed at least 40 hours training in therapeutic education
75642447|NCT05948943|Drug|Alpelisib|"In Stage 1: adult participants (≥18 years of age) will receive dose 1 or dose 2 of alpelisib; pediatric participants (6-17 years of age) will recieve dose 2 or dose 3 of alpelisib.~In Stage 2: Adult participants will receive alpelisib at the dose selected for confirmatory phase in adult participants; pediatric participants (6-17 years of age) will will receive alpelisib at the dose selected for confirmatory phase in pediatric participants; and pediatric participants of 2-5 years of age will receive dose 3 of alpelisib"
75642448|NCT05948943|Drug|Placebo|In Stage 2, participants will receive matching placebo for 24 weeks of the study
75642449|NCT05938621|Behavioral|behavioral therapy and education|Sessions that focus on developing self-awareness and strategies to improve well-being will be the focus of the interventions.
75651843|NCT05229224|Other|Placebo method|Soft Manual pressures at specific points that are defined as non-effective and non-deleterious for patients.
75790624|NCT03959163|Diagnostic Test|Quick MRI|"A quick MRI scan takes about 15 mins or less. No IV or sedation will be necessary. The participant will be required to lie flat and still during the test. A parent will be allowed to be with the participant while they are in the scanner. The machine will produce loud intermittent sounds of banging or knocking so they will have to wear protective headphones. They can listen to music if they would like. If they are less than 1 year old, they will be swaddled and can be held during the test. If a child needs to have a parent in the scanner, it is ideal if the parent can have their head near the participant's legs and arms stretched out to hold the child's hands. If the parent needs to be by the patient's head, it can be accomplished by the parent lying head to head with the child or the parent lying on the child. Ideally they are lying head to head, or just outside of the scanner reaching in."
75926892|NCT01660971|Drug|Erlotinib Hydrochloride|Given PO
75926893|NCT01660971|Drug|Gemcitabine Hydrochloride|Given IV
76082342|NCT02231814|Other|Crohns Disease Exclusion Diet|Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
76082343|NCT03413826|Behavioral|Exercise|The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
76082344|NCT03413748|Procedure|Elective Cesarean Section|lower segment cesarean section
76082345|NCT03413748|Other|Peritoneal irrigation|Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
75790625|NCT03957954|Biological|cLSC|Transplantation of cLSC
75926894|NCT01644357|Other|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
75790626|NCT03957954|Device|Scleral contact lens (SCL)|Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
75333364|NCT05496816|Diagnostic Test|CAC in septic patients|"Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge."
75926895|NCT01639573|Drug|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
75926896|NCT01592370|Biological|Nivolumab|Administered by intravenous (IV) infusion
75333365|NCT03738826|Behavioral|Behavioral Intervention|Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
75926897|NCT01592370|Biological|Ipilimumab|Administered by IV infusion
75333366|NCT03011827|Other|Fibrinogen and/or platelets administration|Fibrinogen and/or platelets administration to maintain clot amplitude at 10 minutes of the thromboelastometry between 35-40 mm along liver transplant procedure
75471626|NCT05532657|Other|Successful aging/delayed hearing intervention|The successful aging health education program follows the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator, with initial sessions spaced over the 2-3 months post-randomization and semi-annual sessions for 3 years. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
75642450|NCT05934487|Device|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP)"
75642451|NCT05934474|Biological|Peripheral venipuncture blood sampling, as part of standard care procedures|Collection of 36 mL of blood
75642452|NCT05934474|Other|Interview with a psychiatrist|Research project data collection
75790627|NCT03953898|Procedure|Biospecimen Collection|Undergo collection of blood
75926898|NCT01592370|Biological|Lirilumab|Administered by IV infusion
75926899|NCT01592370|Biological|Daratumumab|Administered by IV infusion
75926900|NCT01592370|Drug|Pomalidomide|Administered PO
75926901|NCT01592370|Drug|Dexamethasone|Administered PO and by IV infusion
75333367|NCT05496660|Other|NHE+KT|the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
75790628|NCT03953898|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
75333368|NCT05496660|Other|NHE|the Nodic hamstring exercise plus the kinesio taping without tension during 4-week consisting 12 sessions
75333369|NCT05496582|Diagnostic Test|No intervention|No intervention
75333370|NCT03735862|Biological|Hepatic derived surgical matrix|Hiatal hernia repair with MIROMESH
75333371|NCT01143883|Other|Silverlon|Silverlon dressings are gauze impregnated with silver ions
75333372|NCT01143883|Other|Standard of Care Dressing|Standard dry gauze dressing
75333373|NCT01451294|Drug|Administration of phenylephrine|Phenylephrine: 50-100µg
75333374|NCT01451294|Drug|Administration of ephedrine|Ephedrine: 5- 10 mg
75790629|NCT03953898|Drug|Olaparib|Given PO
75333375|NCT01187017|Drug|Cyclophosphamide|60 mg/kg
75333376|NCT01187017|Drug|Fludarabine|125 mg/m squared
75333377|NCT00378118|Other|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
75333378|NCT00378118|Other|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
75471627|NCT05531721|Other|Observation|Observation and retrospective data collection
75790630|NCT03945591|Drug|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.
75790631|NCT03945591|Drug|Cyclophosphamide|50 mg/kg IV over 2 hours on Day +3 and +4
75790632|NCT03937921|Drug|Gadavist 15Ml Solution for Injection|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
75790633|NCT03890484|Behavioral|Peer Type - New Peer|Participants drink with 2 unfamiliar confederate peers
75926902|NCT01552356|Other|Laboratory Biomarker Analysis|Correlative studies
75926903|NCT01552356|Drug|Pazopanib Hydrochloride|Given PO
75926904|NCT01552356|Other|Pharmacological Study|Correlative studies
75926905|NCT01495637|Drug|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
76082346|NCT03418506|Behavioral|SMOKELESS TOBACCO AWARENESS PROGRAM|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
76082347|NCT01842581|Drug|Rifaximin|Rifaximin will be administered per the dose and schedule specified in the arms.
76082348|NCT01842581|Drug|Lactulose|Laculose will be administered per the schedule specified in the respective arm.
76082349|NCT04448028|Drug|Placebo|Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.
76082350|NCT04448028|Drug|Esomeprazole 20mg|Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
76082351|NCT04447950|Procedure|Type 2/posterior Quadratus Lumborum block|Injection of local anaesthetic into posterior boundry of Quadratus Lumborum muscle.
76082352|NCT04447950|Procedure|Placebo block with Saline|Injection of saline into posterior boundary of Quadratus Lumborum muscle.
76082353|NCT04414553|Behavioral|Community Active and Healthy Families|"Community-AHF will consist of eight, semimonthly 2-hour group appointments. Community-AHF sessions will target two areas: 1) Practical information regarding importance of healthy behaviors, and 2) Problem-solving skills to overcome barriers to improving diet and increasing physical activity and other related healthy behaviors. Each session covers specific objectives, includes a number of complementary activities and provides participants with take-home materials to facilitate behavior change.~Community-AHF will be delivered by a nurse and a Community Health Worker (CHW) trained by a consultant nutritionist and study investigators. The CHW will contact families between group sessions to discuss challenges and successes regarding lifestyle changes."
76082354|NCT05169996|Other|Real Food|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Food condition, the tangram pieces were tempting food products (i.e., pieces of chocolate). Players had to physically move the chocolate pieces with their hands and puzzle them together.
75333379|NCT02896088|Other|decayed tooth surfaces|The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
75642453|NCT05930171|Procedure|Ultrasound guided L-ESPB and PENG block using Bupivacaine|Combined Lumbar Erector Spinae Plane Block and Pericapsular Nerve Group Block in Patients Undergoing Hip Surgeries
76082355|NCT05169996|Other|Real Nonfood|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of wood). Players had to physically move the wooden pieces with their hands and puzzle them together.
76082356|NCT05169996|Other|Virtual reality Food|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together.
75471628|NCT05527301|Drug|Lactobacillus Fermentum|Lactobacillus Fermentum
75471629|NCT05527301|Drug|Placebo|Placebo
75471630|NCT05523336|Other|observation|observation and prospective data collection
75471631|NCT05519735|Diagnostic Test|Multimodality Imaging|Patients receive CXCR4-targeted PET/CT, CMR and Echo
75642454|NCT05930171|Drug|Postoperative conventional analgesia in form of Acetaminophen|Postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
75642455|NCT05921994|Other|secukinumab|Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.
75642456|NCT05921747|Other|Standard core stability exercise program|The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.
75642457|NCT05921747|Device|Off-the-shelf virtual reality system|HTC Vive (HTC Corporation, Bellevue, WA) VR Head-Mounted Display (110º field of view, 1080 × 1200 pixels/eye, 90 Hz refresh) along with the Vive hand controllers and trackers to provide an immersive VR experience. The Vive Tracker can be used to track limb and trunk position and motion while in a VR experience. This setup will be paired with a gaming computer with the power to run a VR experience at a high frame rate to mitigate the risk of motion sickness. KVET™( Karuna Virtual Embodiment Training) consists of 10-30 minute sessions of exercises in an embodied VR experience.
75642458|NCT05916313|Drug|BI 764532|BI 764532
75790634|NCT03890484|Behavioral|Peer Type - Close Friends|Participants drink with 2 close friends
75790635|NCT03885349|Behavioral|SBIP+ ADAPs-IMP|Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
75333380|NCT05496504|Other|Holter ECG|
75333381|NCT04553094|Other|Endurance training|Aerobic circuit training
75471632|NCT05515653|Genetic|Exposure to genetics (polygenic)|The polygenic risk score (PRS) aggregates the effects of genetic variants into a single number that predicts the genetic predisposition to a phenotype. PRS are typically composed of hundreds to millions of genetic variants, usually Single Nucleotide Polymorphisms (SNPs). For each individual, the number of risk alleles computed in each variant is summed and weighted by the estimated value of the obtained effects (log odds ratio for traits with binary values or Beta coefficients for traits with continuous value) obtained from large-scale genomic studies ( GWAS)
75642459|NCT05912244|Drug|IO102/IO103|IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.
75471633|NCT05510063|Drug|Humira (Adalimumab)|Subcutaneous (SC) injection
75642460|NCT05912244|Drug|Nivolumab-Relatlimab|Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.
75790636|NCT03885349|Behavioral|SBIP+IMP|Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
75790637|NCT03880240|Device|Transcranial Alternating Current Stimulation (tACS)|tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
75926906|NCT01437709|Biological|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
75333382|NCT04553094|Other|Muscle building training|Muscle strengthening circuit training
75333383|NCT01145833|Other|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
75471634|NCT05510063|Drug|SB5 (Adalimumab Biosimilar)|Subcutaneous (SC) injection
75471635|NCT05509998|Behavioral|Screening Method (SM)|All consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate.
75642461|NCT05900388|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain
75642462|NCT05900388|Drug|Standard of care (SOC)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
75642463|NCT05871606|Drug|iNO|Inhaled Nitrous Oxide
75642464|NCT05857878|Drug|BI 1815368|BI 1815368
75642465|NCT05857878|Drug|Matching placebo|Matching placebo
75926907|NCT01437709|Other|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 & 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
75926908|NCT01093183|Drug|lenalidomide|Given PO
75926909|NCT01093183|Drug|cyclophosphamide|Given PO
75926910|NCT01093183|Other|laboratory biomarker analysis|Correlative studies
75926911|NCT01093183|Other|questionnaire administration|Ancillary studies
75926912|NCT01093183|Other|quality-of-life assessment|Ancillary studies
75333384|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
75333385|NCT04035694|Other|Media Aware Sexual Health - High School|Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
75790638|NCT03880240|Other|Sham Transcranial Alternating Current Stimulation|Placebo Control, simulation of transcranial alternating current stimulation without receiving any stimulation
75790639|NCT03878095|Procedure|Biopsy|Undergo tumor biopsies
75790640|NCT03878095|Procedure|Biospecimen Collection|Undergo collection of blood
75926913|NCT00848315|Behavioral|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
75333386|NCT04391192|Behavioral|Virtual Overdose Response|All participants will be provided the phone number and encouraged to call when they use alone.
75471636|NCT05509998|Behavioral|Screening and Communication Method (SCM)|Clinicians will be trained to discuss findings and provide referrals using the ComPsych model. ComPsych prepares clinicians to effectively communicate diagnostic, prognostic and treatment information about FEP and CHR with patients and families, using a model that instils realistic hope and provides information effectively to encourage shared decision making about treatment. All consecutive patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Following the evaluation, the clinician will schedule a session with the patient, their family, and their treatment team (as applicable) and use the ComPsych model to discuss the findings of the evaluation, provide psychoeducation, and make referrals to specialty services, as appropriate.
75790641|NCT03878095|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
75471637|NCT05508815|Drug|Modified Zhiwang Decoction Combined with methotrexate|Modified Zhiwang Decoction 100 ml (twice, per day) and methotrexate (7.5-15mg, once a week) for 12 weeks.
75471638|NCT05508815|Drug|Methotrexate|Methotrexate(7.5-15mg, once a week) for 12 weeks.
75471639|NCT05501912|Drug|ABM-1310|"Dose escalation starting dose will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials.~Dose expansion will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level."
75642466|NCT05853458|Drug|Hydroxyurea|Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment
75790642|NCT03878095|Procedure|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
75790643|NCT03878095|Drug|Ceralasertib|Given PO
75790644|NCT03878095|Procedure|Computed Tomography|Undergo CT scans
75790645|NCT03878095|Procedure|Magnetic Resonance Imaging|Undergo MRI scans
75790646|NCT03878095|Drug|Olaparib|Given PO
75790647|NCT03872427|Procedure|Biospecimen Collection|Undergo collection of blood
75926914|NCT00777036|Drug|Dasatinib|
75926915|NCT00720720|Dietary Supplement|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
75926916|NCT00720720|Dietary Supplement|placebo margarine|
75926917|NCT00641225|Drug|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
75471640|NCT05471726|Behavioral|Prospective audit-and-feedback|The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge.
75642467|NCT05850520|Drug|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose|Intravitreally (IVT) injection.
75642468|NCT05850520|Drug|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg|Intravitreally (IVT) injection.
75790648|NCT03872427|Procedure|Computed Tomography|Undergo CT or PET/CT
75926918|NCT00365157|Drug|Eribulin Mesylate|Given IV
75926919|NCT00365157|Other|Laboratory Biomarker Analysis|Correlative studies
75333387|NCT01451450|Drug|QGE031|QGE031 liquid for subcutaneous injection.
75642469|NCT05850520|Drug|Sham|Sham procedure will be given on visits when an active injection is not planned.
75926920|NCT00365157|Other|Pharmacological Study|Correlative studies
75926921|NCT00176644|Drug|Transdermal Estradiol|"application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
75333388|NCT01451450|Drug|Placebo|Placebo liquid for subcutaneous injection.
75471641|NCT05463861|Drug|Lemborexant|Lemborexant tablet administered orally once daily.
75642470|NCT05850520|Diagnostic Test|Fluorescein|Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
75642471|NCT05844332|Other|LUTATHERA|There is no treatment allocation. Patients administered LUTATHERA by prescription can be enrolled.
75790649|NCT03872427|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790650|NCT03872427|Other|Pharmacodynamic Study|Correlative studies
75790651|NCT03872427|Procedure|Positron Emission Tomography|Undergo PET/CT
75790652|NCT03872427|Drug|Telaglenastat Hydrochloride|Given PO
75790653|NCT03839706|Device|PET MRI|18F-Fluorodeoxyglucose Positron Emission Tomography combined with Primovist MRI
75790654|NCT03799835|Drug|BCG|Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
75790655|NCT03799835|Drug|Atezolizumab|IV perfusion
75790656|NCT03778554|Drug|Metoprolol Succinate|Eligible patients randomized to receive long-term therapy with oral beta-blockade
75790657|NCT03778554|Drug|Bisoprolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
75790658|NCT03778554|Drug|Carvedilol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
75926922|NCT00106171|Drug|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
75926923|NCT00045201|Drug|Erlotinib Hydrochloride|Given orally
75926924|NCT00045201|Drug|Irinotecan Hydrochloride|Given IV
75926925|NCT03327038|Behavioral|Web-Based Cognitive Behavioral Therapy|Patients will receive access to a 5-week web-based CBT program entitled 'Mood Gym'. The program is derived from traditional, therapist-directed cognitive behavioral therapy. The program consists of 5 modules, and patients will asked to complete 1 module per week over, during weeks 2-6 over their intervention period.
75926926|NCT03327038|Other|Short Questionnaires|Patients will receive emails to complete bi-weekly, web-based questionnaires at weeks 2, 4, and 6 of their intervention period. The short questionnaires will ask to patients to self-report their Depression (PHQ-9) and Anxiety (GAD-7) symptoms; along with their Crohn's Disease activity (PRO-2) or Ulcerative Colitis Disease Activity (MAYO-6).
75471642|NCT05463861|Drug|Placebo|Placebo to match Lemborexant tablet administered orally once daily.
75642472|NCT05839600|Drug|BI 1821736|Solution for infusion
75642473|NCT05827926|Biological|Fluarix|quadrivalent seasonal influenza vaccine
75926927|NCT03327038|Behavioral|Nurse Monitoring|Patient responses to the short questionnaires will be monitored by an IBD advanced practice nurse. The IBD nurse will determine if there are elevations in anxiety, depression, and disease activity over the intervention period. Based on patient responses to the short questionnaires, the nurse will follow-up with patients via email or telephone to address patient symptoms. If there are clinically important changes in the patients' disease activity the nurse may also arrange for the patients to receive expedited outpatient follow-up with their gastroenterologist.
75926928|NCT03327038|Other|Detailed Questionnaires|Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CACHE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GAD-7) symptoms.Quality of Life will be measured using the 10 item Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which has a total score range of 10 to 70, with higher scores indicating better quality of life. Patient Satisfaction with Health Care in IBD will be measured using the 32 item CACHE Questionnaire, which scores from 0 -least satisfaction to 100-highest satisfaction.
76082357|NCT05169996|Other|Virtual reality Nonfood|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of virtual wood). Players had to physically move the virtual wood pieces with the grab button on the controller and puzzle them together.
75642474|NCT05827926|Biological|mRNA-1083.1|Sterile liquid for injection
75642475|NCT05827926|Biological|mRNA-1083.2|Sterile liquid for injection
75642476|NCT05827926|Biological|mRNA-1083.3|Sterile liquid for injection
75790659|NCT03778554|Drug|Nebivolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
75790660|NCT03768128|Device|Journey™ II UNI Unicompartmental Knee System|"Journey™ II UNI UKS is a CE Marked medical device. The device has been designed to treat both medial and lateral unicompartmental disease.~It is a comprehensive system designed to allow surgeons to perform UKA. It is comprised of the following anatomic components: Oxidized zirconium femoral components Titanium tibial components with a grit-blasted surface Polyethylene tibial insert components The device is asymmetric and is available in oxidized zirconium to reduce wear and increase implant longevity."
75790661|NCT03752333|Drug|Pembrolizumab|"Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies.~The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection."
76082358|NCT05169996|Other|Virtual reality Food Branded|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together. In the background of the puzzle, a chocolate brand ('Milka') is shown
75642477|NCT05827926|Biological|mRNA-1010.4|Sterile liquid for injection
75642478|NCT05827926|Biological|mRNA-1283.222|Sterile liquid for injection
75642479|NCT05827926|Biological|mRNA-1273.222|Sterile liquid for injection
75642480|NCT05827926|Biological|mRNA-1010|Sterile liquid for injection
75642481|NCT05827926|Biological|Fluzone HD|quadrivalent seasonal influenza vaccine
75642482|NCT05795465|Drug|GEn-1124|Intravenous infusion
75642483|NCT05795465|Drug|Placebo|Intravenous infusion
75642484|NCT05781100|Behavioral|Technology Use during Feeding Conditions|At 1 month and 4 months, mother-infant dyads will be observed during 3 different feeding conditions counterbalanced across 3 days, with a 1-day wash-out period between conditions: TV Use condition: mothers will be asked to watch a 22-minute long TV show on a large tablet while they feed their infants. Mothers will choose from four preselected episodes of popular sitcoms. Mobile Device Use condition: mothers will be asked to use their mobile device in a way they find relaxing and pleasurable. Control condition: mothers will be asked to feed their infant in a room free of all potential technological distractions. During all conditions, mothers will feed their infants their typical milk (breast milk or formula) from their typical mode (breast or bottle).
75642485|NCT05777304|Device|wearable device|IMU sensors and EMG sensors
75790662|NCT03744676|Biological|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
75642486|NCT05776914|Biological|Donor Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
75642487|NCT05776914|Biological|Autologous Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
75642488|NCT05772871|Drug|Huaiqihuang granule|Huaiqihuang Granule, oral administration, recommended daily dose: for body weight <10 kg, 5g, twice a day; for 10 kg ≤ body weight <20 kg, 10g, twice a day; for 20 kg≤body weight <30 kg, 15g, twice a day; for 30 kg≤body weight <50 kg, 20g, twice a day; for body weight>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
75790663|NCT03742921|Drug|Istodax|Istodax
75790664|NCT03738553|Device|MRI|Diffusion Weighted Imaging and Dynamic Contrast enhanced MRI
75790665|NCT03738553|Drug|Trastuzumab|Single dose of Trastuzumab prior to surgery
75790666|NCT03736538|Drug|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
75790667|NCT03736538|Drug|Placebo gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen.
75926929|NCT03327038|Other|Screening Form|Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms. Their depression symptoms will be reported on the 9-item Patient Health Questionnaire (PHQ-9), which has a total score ranging from 0 to 27, with scores of 5, 10, 15 and 20 representing cut points for mild, moderate, moderately severe, and severe depression. Their generalized anxiety symptoms will be reported on the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), which has a total score ranging from 0 to 21, with scores of 5, 10, and 15 representing cut points for mild, moderate, and severe anxiety. Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
76082359|NCT03418194|Procedure|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation(TAES) is a kind of noninvasive therapy similar to acupuncture and moxibustion. Its physiological effect is similar to that of electroacupuncture and hand acupuncture which is a Chinese traditonal therapy using acupuncture.
76082360|NCT03418194|Procedure|sham transcutaneous acupoint electrical stimulation|Sham transcutaneous acupoint electrical stimulation is the same procedure as transcutaneous acupoint electrical stimulation at points without electronic stimulation.
76082361|NCT03413514|Drug|NACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0<n<8)
76082362|NCT03413514|Procedure|SDM|Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making
76082363|NCT03413514|Procedure|Surgery|Radical surgery with D2 lymph node dissection
76082364|NCT03413514|Drug|ACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0<n<8)
76082365|NCT03413514|Other|Questionnaire|MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy
76082366|NCT01833533|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
76082367|NCT01833533|Drug|Ribavirin|Capsule
76082368|NCT01833533|Drug|Placebo for Ribavirin|Capsule
75471643|NCT05462210|Other|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos Simulated clinical immersion videos created for the mobilization protocol for patients in the intervention group will be sent to their smartphones once they are admitted to the clinic. The videos prepared within the scope of the mobilization protocol will be watched by patients in company with the researcher the day before the operation, their questions will be answered, and the correct mobilization techniques will be shown practically. It is expected that patients watch the videos at least four times, as twice with the researcher and twice by themselves.
75651844|NCT05221606|Behavioral|Nurse AMIE|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, mindfulness, CBT, DBT, soothing music.
75790668|NCT03736343|Drug|Alcohol|Participants will complete two drinking sessions.
75790669|NCT03734653|Drug|Transdermal Testosterone|Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
76082369|NCT03413436|Drug|Lobaplatin|at least one cycle adjuvant chemotherapy after esophagectomy
76082370|NCT03413436|Drug|Cisplatin|at least one cycle adjuvant chemotherapy after esophagectomy
76082371|NCT01833455|Drug|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
76082372|NCT01833455|Drug|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
75790670|NCT03734653|Drug|Standard of Care, Enzalutamide|Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
75790671|NCT03732820|Drug|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
75790672|NCT03732820|Drug|abiraterone acetate|1000 milligrams (mg) once daily
75790673|NCT03701282|Procedure|Biospecimen Collection|Undergo collection of blood
75790674|NCT03701282|Procedure|Bone Marrow Biopsy|Undergo biopsy
75790675|NCT03701282|Procedure|Computed Tomography|Undergo CT
75790676|NCT03701282|Drug|Ibrutinib|Given PO
75790677|NCT03701282|Biological|Obinutuzumab|Given IV
75790678|NCT03701282|Other|Quality-of-Life Assessment|Ancillary studies
75790679|NCT03701282|Drug|Venetoclax|Given PO
76082373|NCT03418116|Device|Argus II Retinal Prosthesis|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
75926930|NCT03326960|Drug|Sevoflurane|Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
76082374|NCT03413358|Drug|Sheng Bai oral liquid|"Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy.~Subjects will be treated for 2 courses"
75790680|NCT03678753|Drug|Cenobamate|12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. The adolescent subjects will follow the same regimen in an oral suspension adolescent equivalent dose based on weight.
75926931|NCT03326960|Drug|Propofol|Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
75471644|NCT05458947|Procedure|pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing
75642489|NCT05772871|Drug|Prednisone|Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again [2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
76082375|NCT03413358|Drug|Platinum-based two medicine (carboplatin / cisplatin) .|Using Platinum-based two medicine (carboplatin / cisplatin)
76082376|NCT01833143|Drug|Bortezomib|
76082377|NCT01833143|Drug|Acyclovir|
76082378|NCT03127332|Other|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
75333389|NCT05491122|Behavioral|Increasing or decreasing daily total fluid intake|1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI. The diurnal saliva cortisol response at rest will be examined at the end of both experimental periods and the saliva cortisol response to an acute psychological stress will be examined at the end of the habitual experimental period only.
75333390|NCT01451528|Biological|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
75471645|NCT05458947|Procedure|electrical stimulation (ES)|high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
75642490|NCT05772871|Drug|Levamisole placebo|Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
75642491|NCT05772871|Drug|Levamisole|Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
75471646|NCT05458947|Procedure|electrical stimulation (ES) and pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing and high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
75471647|NCT05442021|Device|Neubie Direct Current Electrical Stimulation Device|Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
75651845|NCT05221606|Behavioral|Usual Care|Binder of written supportive care materials
75926932|NCT03326960|Drug|Desflurane|Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
75926933|NCT03319394|Behavioral|The First Twenty|The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
75333391|NCT01224145|Drug|5x5cm bupivacaine collagen sponges|
75333392|NCT05496426|Drug|KL130008/Placebo|Drug: KL130008 Drug: Placebo
75651846|NCT05215652|Other|adherence monitoring package (AMoPac)|"AMoPac is a tool that consists of~an electronic monitoring device,~data management and data analysis,~feedback on patient's performance,~clinical-pharmaceutical evaluation of medication adherence,~transmission of an adherence report."
75790681|NCT03678753|Drug|Placebo|Matching Placebo
75790682|NCT03660826|Procedure|Biospecimen Collection|Undergo blood sample collection
75790683|NCT03660826|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspiration and biopsy
75790684|NCT03660826|Procedure|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
75790685|NCT03660826|Drug|Capivasertib|Given PO
75790686|NCT03660826|Drug|Cediranib|Given PO
75790687|NCT03660826|Drug|Cediranib Maleate|Given PO
75471648|NCT05442021|Device|TENS|Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
75471649|NCT05375032|Other|Cycling combined with cognitive tasks|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM). The cognitive task will be a PowerPoint presentation structured in a way that is consistent with the phases of the cycling program. The passive phases (6 minutes of warm-up and 4 minutes of passive cycling back to cool down), images of the nearby environment will be played. For the active phase (20 minutes of assisted active cycling) the PowerPoint presentation will be structured with tasks related to: orientation, memory, calculation, language, similarities.
75642492|NCT05772871|Drug|Huaiqihuang Granule placebo|Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight <10 kg, 5g, twice a day; for 10 kg ≤ body weight <20 kg, 10g, twice a day; for 20 kg≤body weight <30 kg, 15g, twice a day; for 30 kg≤body weight <50 kg, 20g, twice a day; for body weight>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
75642493|NCT05768165|Behavioral|High intensity exercise|"Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets.~Exercise guidance follows principles of self-efficacy and person-centeredness."
75471650|NCT05375032|Other|Cycling|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM).
75642494|NCT05754177|Dietary Supplement|Probiotic|Participants in this arm will receive a daily dose of 1x10^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days
75471651|NCT05365516|Other|Implementing medical safety huddles|These short, virtual huddles are led by a huddle leader and occur on a weekly or once every two week basis. Each site will be adapting the Medical Safety Huddles for their context and workflow to specifically engage physicians.
75790688|NCT03660826|Procedure|Computed Tomography|Undergo CT scan
75790689|NCT03660826|Biological|Durvalumab|Given IV
75471652|NCT05333263|Device|Treadmetrix|Programmable treadmill that delivers controlled postural disturbances
75926934|NCT03319394|Behavioral|Comparison|Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
75926935|NCT04669444|Device|Ventilator|The patient starts at a ventilator driving pressure of 10-15 cm of H2O as per guidelines for patients on ECMO with ARDS. The driving pressure is then decreased as tolerated for two hours to evaluate the effects on pulmonary, cardiac, and inflammatory biomarkers.
75926936|NCT03319238|Other|ketamine|The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
75642495|NCT05754177|Other|Placebo|Participants in this arm will receive an equivalent placebo for 84 days.
75642496|NCT05739643|Biological|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
75642497|NCT05738291|Drug|BI 1839100|BI 1839100
75642498|NCT05738291|Drug|Placebo matching BI 1839100|Placebo matching BI 1839100
75790690|NCT03660826|Procedure|Echocardiography|Undergo Echo
75790691|NCT03660826|Procedure|Multigated Acquisition Scan|Undergo MUGA
75790692|NCT03660826|Drug|Olaparib|Given PO
75790693|NCT03656081|Drug|inhaled Ambisome®|inhaled liposomal amphotericin B = inhaled LAmB
75790694|NCT03656081|Drug|inhaled placebo|inhaled isotonic saline
75790695|NCT03656081|Drug|Itraconazole|Itraconazole tablet
75790696|NCT03620032|Drug|Nimotuzumab|humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)
75333393|NCT01458002|Other|Tailored Internet Communication with Relational Agent|"The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site."
75333394|NCT01458002|Other|Tailored Internet Communications|Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
75333395|NCT01187095|Behavioral|Expressive writing|3 consecutive days of writing
75333396|NCT01187095|Behavioral|Active ctrl|Control
75333397|NCT01451840|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
75333398|NCT01451840|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
75333399|NCT05496270|Procedure|total mesorectal excision|
75471653|NCT05323708|Biological|Bmab 1000|60mg/ml Prefilled syringe single dose
75471654|NCT05323708|Biological|Prolia®|60mg/ml Prefilled syringe single dose
75471655|NCT05312515|Other|Warm Application to Feet|Warm Application to Feet after Cesarean Section
75790697|NCT03620032|Drug|Vinorelbine|Chemotherapy
75790698|NCT03620032|Other|Radiotherapy|RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS
75926937|NCT04664608|Device|wearable EEG sensor|Wireless wearable EEG devices offer a new, non-invasive, and easy way of performing EEG monitoring.
75790699|NCT03615495|Device|Flourish Pediatric Esphogeal Atresia device|The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.
75790700|NCT03605667|Drug|troriluzole|Oral BHV-4157 will be given daily for up to 48 weeks
75926938|NCT03321890|Drug|Chidamide|Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
75926939|NCT03321890|Drug|prednisone|oral, 20mg / day,after breakfast
75642499|NCT05738291|Drug|midazolam|midazolam
75926940|NCT03321890|Drug|Cyclophosphamide|oral, 50mg / day,after lunch
75926941|NCT03321890|Drug|etoposide|oral, 50mg / day,after dinner
75926942|NCT03321890|Drug|Methotrexate|oral, 10mg / times, once a week,after breakfast
75642500|NCT05738291|Drug|digoxin|digoxin
75790701|NCT03605667|Drug|Placebo oral capsule|Oral matching placebo will be given daily for up to 48 weeks
75790702|NCT03600701|Drug|Atezolizumab|Given IV
75926943|NCT02487368|Device|Needle stimulation pad|
75926944|NCT05499910|Behavioral|NSBAA|The Neuro Strengths-Based Approach to Autism is an approach that teaches people how the autistic brain works and the best practices for providing intervention.
75926945|NCT03319160|Device|Defibrillation|Wearable Cardioverter Defibrillator
75926946|NCT05504824|Other|Case-based education|"The education phase This stage included the explanation of the CR process, the analysis of CR cases, the drafting of new cases suitable for the CR process by students, and the analysis process.~The education program was carried out on a web platform (Zoom) consistent with the changes in the COVID-19 pandemic process. The CR cases to be used in case-based education were sent to the students via e-mail before the group interview to make sure students came prepared for the group discussion. In case-based education, after the students read the case, they were asked some questions to determine their decisions and reasoning."
75333400|NCT01451918|Drug|Resveratrol|500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
75471656|NCT05312502|Other|Birth Ball|During labour, the pregnant woman was positioned using a birth ball.
75790703|NCT03600701|Procedure|Biopsy|Undergo biopsy
75790704|NCT03600701|Procedure|Biospecimen Collection|Undergo collection of blood
75790705|NCT03600701|Drug|Cobimetinib|Given PO
75926947|NCT04492748|Combination Product|Collagen and platelet rich plasma (PRP)|Ultrasound guided injections
75926948|NCT04492748|Combination Product|Collagen|Ultrasound guided injections
75926949|NCT04492748|Combination Product|Platelet rich plasma (PRP)|Ultrasound guided injections
75926950|NCT05504668|Dietary Supplement|Turmeric Brainwave|A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
75926951|NCT03326882|Device|Endotracheal intubation|
75926952|NCT05464394|Drug|Tranexamic Acid Injection [Cyklokapron]|A set dose of 1500 mg will be used, based on the study population with morbid obesity. It will be administered intravenous dissolved in 100 ml sodium chloride 0.9% in a time frame of 15-30 minutes, with a maximum of 100 mg/min.
75926953|NCT05464394|Drug|Sodium chloride 0.9%|100 ml sodium chloride 0.9% will be administered in a time frame of 15-30 minutes
76082379|NCT05169528|Other|Colorectal Cancer Prehabilitation Programme|Assessment and Interventions involving the Prehabilitative domains of medical optimisation, exercise prescription, nutrition and mental health optimisation
75333401|NCT01187329|Other|hyperinsulinemic normoglycemic clamp (HNC)|Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is <110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose > 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
75642501|NCT05738291|Drug|rosuvastatin|rosuvastatin
75642502|NCT05718882|Drug|Lenvatinib Oral Product Plus VIC1911|"Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN."
75642503|NCT05714839|Drug|Bela|Bela will be administered.
75642504|NCT05714839|Drug|Belamaf|Belamaf will be administered.
75642505|NCT05714839|Drug|Lenalidomide|Lenalidomide will be administered.
75642506|NCT05714839|Drug|Dexamethasone|Dexamethasone will be administered.
75642507|NCT05714839|Drug|Standard of Care|Either standard of care (SoC) or an emerging treatment for Multiple Myeloma will be administered
75642508|NCT05712278|Drug|SAR445419|Cell suspension, by intraveneous (IV) injection
75642509|NCT05712278|Drug|fludarabine|Solution for injection , by IV injection
75642510|NCT05712278|Drug|cytarabine|Solution for injection, by IV injection
75790706|NCT03600701|Procedure|Computed Tomography|Undergo CT scan
75790707|NCT03600701|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790708|NCT03600350|Biological|pTVG-HP|Plasmid DNA vaccine encoding Prostatic Acid Phosphatase (PAP)
75790709|NCT03600350|Drug|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
75790710|NCT03600350|Drug|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
76082380|NCT01841567|Device|Mepilex border post. op|
75926954|NCT05464316|Device|Adjustable Transobturator Male System|The ATOMS sling was developed in 2008 by Agency for Medical Innovations GmbH in Austria. It is a self-anchoring adjustable system which supports the bulbar urethra dorsally and uses the trans obturator approach. This device gained its fame in the male sling scene by being adjustable, which theoretically makes it more efficacious than its competitors.
75790711|NCT03597165|Other|Incidental Genomic Sequencing Results|"Patient will receive GS results related to their primary indication (cancer), as well as the option to learn incidental GS results. Incidental results will be categorized into five bins based on Berg et al.'s framework (medically actionable and pharmacogenetic, common disease SNPs, Mendelian conditions, early-onset brain diseases, and carrier status). In pre-test counseling, patients will have the option to select which bins of incidental results they would like to learn, if any."
75642511|NCT05707351|Biological|Adynovate|Adynovate will be injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (<=) 5 minutes (maximum infusion rate, 10 milliliters per minute [mL/min]).
75790712|NCT03597165|Other|GS Results for Primary Indications only|Patients will receive GS results related to the primary indication (cancer) only.
75790713|NCT03582033|Drug|SEA-BCMA|Given into the vein (IV; intravenously)
75790714|NCT03582033|Drug|dexamethasone|Given by mouth (orally) or by IV
75926955|NCT05464316|Device|Artificial Urinary Sphincter|"The AMS800™, which is by far the most frequently implanted AUS, was first marketed in 1983 and was developed by America Medical Holdings in Minnesota. Today, the AUS has been given the title gold standard for surgical treatment for PPI. This device is an inflatable cuff which wraps around the urethra to supply circumferential pressure. It has a control pump, which is found in the scrotum and is operated by the patient. The patient can void simply by squeezing the pump, which brings the fluid from the cuff to a reservoir and release the pressure around the urethra. The cuff is then automatically refilled with fluid within a couple of minutes to close back the sphincter."
75926956|NCT05499754|Other|pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL|a SAD was inserted by all anaesthetists participating in the study had at least 3 years experience of airway management and were experienced with both the pLMA, sLMA and I-jel. Inadequate ventilation after two attempts was considered a failed placement, and these patients were excluded, while the practitioner was freed to use an alternative airway device.
75926957|NCT03321812|Procedure|decalcification bone scaffold|Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
75926958|NCT03321812|Procedure|microfracture|Microfracture is the surgical option for conventional treatment of cartilage defects.
75926959|NCT05499598|Procedure|Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
75926960|NCT05499598|Procedure|Modified minimally invasive surgical technique with PRF|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. The resultant PRF clot will be placed into the intra-osseous defect.
75926961|NCT04476082|Other|No intervention - observational study only|No intervention - observational study only
75926962|NCT05232656|Behavioral|Pre-Discharge Checklist and Patient Safety Dashboard|Pre-discharge preparation checklist for patients to assess discharge readiness. Patient safety dashboard for clinicians to proactively identify at-risk patients.
75926963|NCT04442750|Procedure|Erector spinae plane block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will be then rotated into a longitudinal orientation 2-3 cm lateral to vertebral column. The lumbar skin region will be sterilized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex A'; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a cranial-to-caudal direction until contact will made with the L4 transverse process. Local anesthetic solution will be injected and its type will be selected according to the studied group and patients were placed in a supine position and general anesthesia will be started.
75926964|NCT04442750|Procedure|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 1-1.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium o.1 m\kg will be provided every 30 minutes.~Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of baseline levels.~At the end of surgery, residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and will extubation be performed after complete recovery of the airway reflexes."
75926965|NCT04442750|Drug|Bupivacaine 0.5%|The patient will receive 30ml bupivacain 0.5% in erector spinae block
75926966|NCT04442750|Drug|Bupivacaine 0.375%|The patient will receive 30ml bupivacain 0.375% in erector spinae block
75333402|NCT01187329|Other|control group|Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose >150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose < 180 mg/dL.
75790715|NCT03582033|Drug|pomalidomide|Given orally
75642512|NCT05705531|Procedure|Biospecimen Collection|Undergo blood specimen collection
75642513|NCT05705531|Other|Electronic Health Record Review|Undergo medical record abstraction
75642514|NCT05705531|Procedure|Magnetic Resonance Imaging|Undergo MRI
75642515|NCT05705531|Other|Survey Administration|Complete surveys
75642516|NCT05702645|Procedure|Biospecimen Collection|Patients undergo saliva/buccal and blood sample collection
75642517|NCT05702645|Other|Clinical Evaluation|Undergo a clinical assessment
76082381|NCT01841567|Device|Mepilex border post op|
75333403|NCT04758182|Device|High intensity laser therapy|Device: HIRO 3.0 device high peak power (3kW), a wavelength of 1064 nm
75333404|NCT04758182|Device|Ultrasound therapy|Device: Chattanooga intellect mobile ultrasound device frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100%
75333405|NCT01146379|Other|Intensive task-specific upper extremity rehabilitation|The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
75333406|NCT05490966|Other|isometric trunk extensor muscles fatigue|Participants will perform three sets of intermittent isometric efforts between 50 and 60 percents of their maximal isometric strength. A padded force sensor will be placed approximately at the level of the 7th thoracic vertebrae. The first two sets will last six minutes each, while the third set will last three minutes. Between each set participants will rest for two minutes.
75333407|NCT00378196|Drug|Ranibizumab|0.3 mg/0.05 ml dose
75333408|NCT00378196|Drug|Ranibizumab|0.5 mg/0.05 ml dose
75333409|NCT00378274|Behavioral|Observation|
75333410|NCT01188109|Drug|Gemcitabine|"Standard of care chemotherapy and dosage~Dose - 1000 mg/m²~Schedule - Days 1 and 15; Q 28 days"
75333411|NCT01188109|Drug|Cisplatin|"Dose - 50 mg/m²~Schedule - Days 1 and 15; Q 28 days"
75333412|NCT01458080|Drug|eltrombopag|eltrombopag
75471657|NCT05310773|Behavioral|Community stigma reduction training|Key aspects of the training include community stigma awareness training of people living with HIV, use of antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP) for prevention of HIV and attitudes towards people who use alcohol and drugs. Selected modules will be modified from the existing clinic-based training to fit community stigma awareness and attitudes, as needed, to focus on aspects of stigma specific only to young women and men who engage in syndemic-related behaviours who live in their communities. This intervention has been adapted from implementation in clinics in Pretoria for use in a community setting in Cape Town. The stigma reduction training workshops will be delivered in communities randomized to receive this training (N=12 communities; estimated N=1164 participants).
75642518|NCT05702645|Other|Questionnaire Administration|Ancillary studies
75642519|NCT05702645|Other|Survey Administration|Ancillary studies
75642520|NCT05690386|Biological|Lonapegsomatropin|Once-weekly subcutaneous injection of Lonapegsomatropin
75642521|NCT05690386|Drug|Somatropin|Once-daily subcutaneous injection of Somatropin
75642522|NCT05690061|Dietary Supplement|Grain-Fed Beef Hamburger|Bowl of grain-fed beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
75642523|NCT05690061|Dietary Supplement|Grass-Fed Beef Hamburger|Bowl of grass-fed, grass-finished beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
75642524|NCT05690061|Dietary Supplement|Impossible BurgerTM|Bowl of plant-based Impossible burger cooked without seasonings. 250 grams of uncooked Impossible burger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
75926967|NCT04442750|Drug|Bupivacaine 0.25%|The patient will receive 30ml bupivacain 0.25% in erector spinae block
75926968|NCT05499364|Behavioral|TinCat|7-10 minute personalized video sessions based in tobacco cessation modules.
75926969|NCT05499364|Behavioral|Quit.gov program|7-10 minute generic videos directing participants through quit.gov program
75926970|NCT03319004|Device|apply phase lag entropy sensor|apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
75926971|NCT03318848|Other|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
75926972|NCT05333224|Other|Telerehabilitation|Family-centered, goal-oriented early physiotherapy approaches will be applied.
75926973|NCT05333224|Other|Control|Family-centered, goal-oriented early physiotherapy approaches will be applied.
75642525|NCT05682378|Drug|Inclisiran|Inclisiran sodium 300mg (equivalent to 284mg inclisiran*) in 1.5mL solution administered subcutaneously in pre-filled syringe
75642526|NCT05676372|Procedure|CRC+HIPEC|Sample prelevation of cytoreductive surgery
75642527|NCT05675930|Device|Photobiomodulation Therapy|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation/PBM (via Thor LX2.3 system device) for 28 days
75926974|NCT02490566|Other|Telehealth|Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
75926975|NCT05504200|Other|Bladder and Pelvic Floor Muscle Training|The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
75926976|NCT02487290|Device|Aneufix ACP-T5|The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.
75926977|NCT05294458|Drug|cotadutide solution for injection|cotadutide solution for injection
75926978|NCT02491190|Behavioral|EMPOWER Educational Module|Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
76082382|NCT03413280|Drug|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
76082383|NCT03413280|Drug|Intercostal nerve block|Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
76082384|NCT05169450|Drug|Diterpene ginkgolides meglumine injection|Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.
76082385|NCT05169450|Drug|Ginaton|Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
76082386|NCT03411174|Radiation|hypofractionated partial breast irradiation|deliver 40Gy/15Fx to tumor bed areas
76082387|NCT04448340|Diagnostic Test|machine learning model|Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.
76082388|NCT03417648|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
76082389|NCT03417648|Other|Supplement|unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
76082390|NCT03411018|Other|Mechanical ventilation exposure|
76082391|NCT01833065|Drug|Elobixibat 10 mg/day|Elobixibat 10 mg/day
76082392|NCT01833065|Drug|Elobixibat 5 mg/day|Elobixibat 5 mg/day
75642528|NCT05675930|Other|Placebo sham device|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days
75642529|NCT05665972|Other|Mandala coloring|Each participant will be given 12 colored felt-tip pen paint sets and 12 mandala coloring pages by the researchers. Participants will be asked to dye for 3 menstrual cycles, 14 days before the start of menstruation, 1 day a week, at any time of the day and for an average of 20-30 minutes each time.
75642530|NCT05662033|Drug|AZD6793|AZD6793 will be administered orally
75926979|NCT05564572|Other|Routine Health Status Assessment|Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
75926980|NCT02490410|Dietary Supplement|protein supplement|
75926981|NCT03326648|Other|Strength training|Heavy load strength training performed twice a week for 10 weeks.
75926982|NCT03326648|Dietary Supplement|Protein supplementation|Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
76082393|NCT01833065|Drug|Placebo|Placebo
76082394|NCT03413124|Drug|MGL-3196 Tablet|MGL-3196 in Tablet form
76082395|NCT03413124|Drug|MGL-3196 Capsule|MGL-3196 in Capsule form
75471658|NCT05310773|Behavioral|Couples Health CoOp Plus (CHC+)|The Couples Health CoOp Plus (CHC+) was adapted from the initial Couples Health CoOp (CHC)-an empowerment-based intervention developed for South African couples that addresses the syndemic of alcohol and other drug (AOD) use, gender-based violence (GBV), and HIV risk. It is grounded in Social Cognitive Theory and promotes prevention strategies that address the relational context of equality in which sexual risk takes place. The adapted Couples Health CoOp Plus (CHC+) incorporates antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) for a biobehavioral approach with an emphasis on uptake and good adherence (N=12 communities; estimated N=240 couples).
75471659|NCT05285566|Drug|Exparel|106mg (8 mL) subcutaneous injection injected after costal cartilage harvest
75471660|NCT05285566|Drug|Xylocaine|8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site
75471661|NCT05204576|Behavioral|CBT4CBT COPES|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily IVR assessment calls
75642531|NCT05662033|Drug|Placebo|Placebo will be administered orally
75642532|NCT05659914|Drug|olaparib+durvalumab|olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
75642533|NCT05655299|Drug|VTX958|Dose A
76082396|NCT03410940|Device|CLS Brevius stem with Kinectiv technology|
76082397|NCT04860102|Procedure|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
76082398|NCT03413046|Diagnostic Test|Peripheral and bone marrow sampling|We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.
76082399|NCT02520804|Drug|sterofundin|sterofundin for shock patients in the first 72 hours
76082400|NCT02520804|Drug|normal saline|Normal saline for shock patients in the first 72 hours
75642534|NCT05655299|Drug|VTX958|Dose B
75642535|NCT05655299|Drug|VTX958|Dose C
75642536|NCT05655299|Drug|VTX958|Dose D
75642537|NCT05655299|Drug|Placebo|Placebo
75790716|NCT03580083|Genetic|RGX-111|Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette
75790717|NCT03569657|Behavioral|A positive psychology workshop|Group workshop
75790718|NCT03539497|Diagnostic Test|Biomarker|Plasma mitochondrial DNA, plasma Cytochrome C
75790719|NCT03533595|Device|Barbed|Barbed Suture
75790720|NCT03521804|Device|SoundBite™ Crossing System Active Wire 14|Successful crossing of the CTO into the true arterial lumen distal to the occlusion, following use of the SoundBite™ Crossing Wire during the procedure and using antegrade only approach. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (i.e. Stingray). The absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.
75790721|NCT03513952|Drug|Atezolizumab|Given IV
75790722|NCT03513952|Procedure|Biopsy|Undergo biopsy of tumor
75790723|NCT03513952|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
75790724|NCT03513952|Procedure|Computed Tomography|Undergo CT
75790725|NCT03513952|Biological|Glycosylated Recombinant Human Interleukin-7|Given IM
75790726|NCT03513952|Other|Laboratory Biomarker Analysis|Correlative studies
75790727|NCT03513952|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790728|NCT03513952|Procedure|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT
75790729|NCT03498066|Drug|Beta-blockers withdrawal|withdrawal of all type of betablockers
75790730|NCT03498066|Drug|Continuation of the Betablockers (βB) treatment|Use Betablockers treatment
75790731|NCT03495011|Diagnostic Test|Breast MRI|Quantitative, multiparametric breast MRI
75790732|NCT03495011|Other|Laboratory Biomarker Analysis|Only patients with pure DCIS on surgical excision will have advanced pathologic markers and Oncotype Dx DCIS Score testing.
76082401|NCT03412968|Procedure|Polysulfone Filter|The intervention for this group consisted using a Polysulfone filter in order to hemofiltration in the procedure involving Cardiopulmonary Bypass (CPB).The perfusionist's role is essential during the procedure, as they control both Cardiac Output (CO) and gas exchange, depending on their action, will affect blood lactate levels.
75471662|NCT05196698|Other|High Flow Oxygen Therapy|"HFOT will be delivered validated medical devices and established as follow:~Patient will be acclimatized to HFOT which will aim to achieve a flow of air of 30L/min at a temperature of 34°C using dedicated nasal canula.~Once patient acclimatized, oxygen will be entrained in the HFOT device at a flow that will aim to achieve a saturation > 90%. An arterial blood gas will be performed with such oxygen delivery, flowrate and temperature to ensure a PaO2 ≥ 8kPa"
75471663|NCT05196698|Other|Long-term oxygen therapy|LTOT delivery will be performed according to French guidelines
76082402|NCT03412968|Procedure|Procedure/ Surgery: without Polysulfone Filter|In this group, no intervention is performed during the procedure involving Cardiopulmonary Bypass (CPB)
76082403|NCT02520882|Drug|68Ga-NOTA-Aca-BBN|68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
75926983|NCT04649164|Behavioral|Peer mentor support and caregiver intervention|Sixteen-week modular curriculum with printed/online workbook, additional resources, and weekly phone discussion with Lewy Body Dementia peer mentor.
76082404|NCT02520882|Device|PET/CT|
76082405|NCT01831817|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
76082406|NCT01831817|Drug|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
75642538|NCT05648279|Other|Personalized hemodynamic management|Personalized hemodynamic management: Intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index. Preoperative baseline cardiac index will be determined one day before surgery with the patient being awake and resting in the supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2). Intraoperative cardiac index will be measured using the Baxter Starling Fluid Management System.
75642539|NCT05646680|Procedure|two step adnexectomy|instead of standard resection of salpinx and ovary, they are now separately excised
76082407|NCT01831817|Drug|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
76082408|NCT01831817|Drug|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
76082409|NCT04839744|Drug|TG103 produced by the modified manufacturing process|Drug: TG103 (a modified manufacturing process), 15mg, SC
76082410|NCT04839744|Drug|TG103 produced by the original manufacturing process|Drug: TG103 (the original manufacturing process), 15mg, SC
76082411|NCT03397836|Other|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers who will collect information electronically using a tablet computer. The volunteers will collect information about the client's health goals, health risks, and needs using a specifically designed application (TAP-App). Once the data is gathered, it is summarized into a report (TAP-report) which is securely and electronically sent to the health care clinic (TAP huddle). The team can leverage clinic supports and/or community supports as they deem appropriate to help clients reach their health goals and address any needs and risks which were reported during the volunteer visits.
76082412|NCT03397836|Other|Usual Care|Usual care while waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
76082413|NCT03397758|Device|Study population|First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
75333413|NCT03980470|Device|TrueFidelity|"TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms."
75333414|NCT01458236|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
75642540|NCT05612035|Drug|MK-5475|MK-5475 380 µg administered as dry powder inhalation once daily.
75642541|NCT05612035|Drug|Placebo|Placebo administered as dry powder inhalation once daily.
75642542|NCT05603910|Drug|Lenvatinib|Lenvatinib capsules taken daily by mouth
75642543|NCT05603910|Drug|Pembrolizumab|200 mg Pembrolizumab administered intravenously (IV) once on Days 1, 22 and 43.
75926984|NCT04649164|Other|Focus group to provide feedback on educational materials and mentoring program|Participation in a 2-3 hour focus group to review pilot and revised materials and provide feedback
75926985|NCT02490956|Biological|Verorab® (PVRV; Purified Vero Cell Vaccine)|"Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
75926986|NCT03326570|Behavioral|Medical Data Collection|Medical information collected after bronchoscopy for up to 2 years.
75926987|NCT03326414|Procedure|Constant PEEP - low tidal volume|The respirator is set according to study protocol
75926988|NCT03326414|Procedure|Constant PEEP - high tidal volume|The respirator is set according to study protocol
75333415|NCT01458236|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
75926989|NCT03326414|Procedure|constant tidal volume - low PEEP|The respirator is set according to study protocol
75790733|NCT03469609|Other|mucous fistula refeeding|Transfer of infants' own stool
75642544|NCT05603910|Radiation|Hypofractionated External Beam Radiation Therapy|HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks.
75642545|NCT05595213|Device|Wrist cooling device with cooling plate|This device is worn like a watch and pressing the button activates the cooling function to begin to col the wrist skin temperature to 47 degrees. Pushing the device button again cools the skin to 60 degrees and a third time to 77degrees.
75642546|NCT05595213|Device|Wrist fan activating device without cooling plate|This device is worn like a watch and pressing the button activates the cooling fan for 5 minutes.
75642547|NCT05595213|Other|Hot Flash Diary|Participants will be instructed to daily document each hot flash experience and indicate if it was mild, moderate, or severe and whether they activated the wrist cooling device.
75642548|NCT05594875|Drug|SHR-1921|Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
75642549|NCT05591625|Behavioral|Eye Movement Desensitisation and Reprocessing|"EMDR is a trauma-focussed, psychological talking therapy whereby the participant verbally relates a narrative of an emotionally disturbing memory, in brief sequential doses, while simultaneously focusing on an external stimulus, most commonly side-to-side finger movements of the psychological therapist. EMDR aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR is widely practiced, so is scalable. It is also protocolised, so can be taught and tested, and allows for fidelity assessment in controlled studies.~The number of sessions will depend on ongoing presence of disturbing memories. This will be determined by the psychological therapist and participant."
75790734|NCT03428477|Drug|Icosapent Ethyl|Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
75790735|NCT03428477|Other|Placebo|"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
75790736|NCT03417960|Device|iTBS|The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method.
75790737|NCT03413501|Behavioral|MUD-PI|
75790738|NCT03385226|Drug|Pembrolizumab|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
75790739|NCT03385226|Radiation|Radiotherapy|12Gy in 3 fractions
75926990|NCT03326414|Procedure|constant tidal volume - high PEEP|The respirator is set according to study protocol
75926991|NCT03326258|Drug|Glembatumumab Vedotin|Given IV
75926992|NCT03326258|Biological|Ipilimumab|Given IV
75926993|NCT03326258|Other|Laboratory Biomarker Analysis|Correlative studies
75926994|NCT03326258|Biological|Nivolumab|Given IV
75926995|NCT03326258|Other|Pharmacological Study|Correlative studies
75333416|NCT01146457|Drug|Morphine|Active dosage
75333417|NCT01146457|Drug|Saline|Saline Control
75790740|NCT03382561|Drug|Carboplatin|Given IV
75790741|NCT03382561|Drug|Cisplatin|Given IV
75790742|NCT03382561|Drug|Etoposide|Given IV
75790743|NCT03382561|Biological|Nivolumab|Given IV
75926996|NCT05564260|Behavioral|Kaleidescope|watching kaleidescope
75926997|NCT05564260|Behavioral|Virtual Reality|wearing virtual reality glasses
75926998|NCT03326102|Drug|DHP107|DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
75926999|NCT03326102|Drug|IV Paclitaxel|IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
75927000|NCT05564182|Device|High intensity laser therapy|HILT will be applied to the patients five times a week for a period of three weeks and one session per day for a total of 15 sessions by a physical therapy technician who is experienced in using a laser device (BTL-6000 high intensity laser 12 W, Stevenage, Hertfordshire, England). It will be used in the rotator cuff muscles area in two stages, Phase I and Phase II. For analgesic effect in phase I. Phase II will also be applied for the biostimulation effect.
75927001|NCT05564182|Other|Therapeutic Exercise|Therapeutic Exercise As therapeutic exercise program; A multidisciplinary stroke rehabilitation program will be implemented in the presence of a specialist physiotherapist. In addition, a therapeutic exercise program including passive, actively supported and active ROM exercises, stretching, strengthening and mobilization exercises will be applied to all patients by physiotherapists according to the level of pain and limitation.It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes.
75927002|NCT02487212|Drug|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
75927003|NCT02487212|Drug|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
75333418|NCT04018924|Device|Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)|Debridement and Dressing or compressive dressing if needed
75790744|NCT03321643|Drug|Atezolizumab|Given IV
75333419|NCT05026346|Diagnostic Test|Pathologic Exercise|"In the first phase of the project, a series of 5 active shoulder mobilization exercises characterized by an adequate range of motion will be tested to verify the set up for the video recording.~In the second phase shoulder movements will be recorder by a smartphone.~A questionnaire will be used and adapted on the basis of which to evaluate the correctness of the exercises performed by each healthy subject / patient. This questionnaire will provide a Clinical Score (CS) which assigns a numerical value to the patient's overall performance for each repetition.~The videos of each repetition of exercises performed by the healthy subjects / patients will then be evaluated by two different clinicians, blinded, using the questionnaire.~The Artificial Intelligence learning algorithm will be able to output an evaluation score that will be compared with that produced by clinicians."
75642550|NCT05590949|Other|Physical Evaluation|Participants will be assessed at Timepoint 0 (last dose of denosumab injection) and then at 9,12,18 and 24 months following discontinuation of denosumab. The evaluation will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work for bone turnover markers (including serum carboxy-terminal collagen crosslinks (CTX) in serum and bone specific alkaline phosphatase). Bone turn-over markers should be drawn in the morning, after at least 8 hours of fasting (water, black coffee and plain tea allowed).
75333420|NCT05496114|Device|Checklist|A checklist is an aid that outlines assessments or actions systematically. In this study, the checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
75642551|NCT05590949|Diagnostic Test|Dual-energy X-ray absorptiometry scans|Dual-energy X-ray absorptiometry (DEXA) scans will be performed at the 12 months timepoint , and then at the 24 month timepoint.
75642552|NCT05590949|Diagnostic Test|Trabecular Bone Score|TBS is an innovative gray-level texture measurement that utilizes lumbar spine DEXA images to discriminate changes in bone microarchitecture. Specifically, TBS measures bone quality through tridimensional bone areas with different trabecular and microstructural characteristics. The combination of TBS microstructure evaluation with bone density measured by DEXA has been shown to be superior to either measurement alone in the assessment of fracture risk.
75333421|NCT01452230|Behavioral|Supervised physical activity|Supervised physical activity
75333422|NCT04011436|Other|Strengthening program|"Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises"
75333423|NCT04272866|Other|Clinpro sealant|Resin based sealant
75333424|NCT04272866|Other|Embrace wetbond sealant|Moisture tolerant hydrophilic resin based sealant
75333425|NCT04272866|Other|Triage sealant|Glass ionomer sealant
75333426|NCT04346498|Other|Chest-to-back|
75333427|NCT02892890|Procedure|Muscle Magnetic Resonance Imaging (RMI) evaluation|
75333428|NCT02892890|Device|MRI|
75333429|NCT05495958|Drug|Topical Vitamin D eye drop|25 Microgram/cc or 1000 IU
75642553|NCT05581667|Other|post isometric relaxation|PIR is performed by first passively lengthening the muscle, then having the patient lightly contract (10-20% of maximum) against resistance for 5 seconds passively before exhaling and relaxing the muscle and repeated. The clinician then takes up the slack within the muscle and repeats the technique 3 to 5 times
75333430|NCT05495958|Drug|Topical placebo eye drop|The same-shape packed drop without vitamin D
75333431|NCT04011592|Drug|Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg)
75333432|NCT04011592|Drug|Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg)
75642554|NCT05581667|Other|Swedish Massage|classic Swedish massage for the cervical and upper thoracic region. Massage is a method that is applied to superficial soft tissues such as muscles, skin, ligaments and fascia and structures located under the superficial tissues and aims to relax.
75790745|NCT03321643|Procedure|Biopsy|Undergo biopsy
75790746|NCT03321643|Procedure|Biospecimen Collection|Undergo collection of blood samples
75790747|NCT03321643|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75790748|NCT03321643|Procedure|Computed Tomography|Undergo CT or PET-CT
75790749|NCT03321643|Drug|Gemcitabine|Given IV
75790750|NCT03321643|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790751|NCT03321643|Drug|Oxaliplatin|Given IV
75790752|NCT03321643|Procedure|Positron Emission Tomography|Undergo PET-CT
75333433|NCT04416828|Device|Portable wireless ultrasonography devices|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging
75790753|NCT03321643|Biological|Rituximab|Given IV
75333434|NCT04416828|Device|Cart-based ultrasonography device|Patients with suspected ganglion cyst of the wrist or hand receive conventional cart-based ultrasound imaging
75790754|NCT03314584|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
75790755|NCT03314584|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
75333435|NCT05024162|Diagnostic Test|MRT Accuracy|Predicted Grade Group (GG) by the MRI-based Radiomics Tool (MRT) at each Magnetic Resonance Imaging of the Prostate (MRI-P)
75790756|NCT03301792|Behavioral|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
75790757|NCT03299179|Device|MRI scan|Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).
75790758|NCT03299179|Device|Physiological monitoring|During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance
75790759|NCT03299179|Biological|Blood sample|Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.
75642555|NCT05573646|Other|Dual-task training|Participants will receive a one-hour online group-based dual-task training session twice a week for 12 weeks, giving a total intervention time of 24 hours. A co-design approach will be adopted to develop the training components in the dual-tasks. For the cognitive training component, arithmetic operation, verbal fluency, and upper limb/ finger movements are included. For the physical training component, we select chair-based exercises are included. A group-based training mode led by a facilitator will be adopted. During the session, participants will be asked to turn on their camera so that they can see and interact with each other. They will also have their audio on as they will have to participate in the cognitive tasks by voicing out their answers.
75642556|NCT05573646|Other|Attention Control|Participants will receive eight one-hour online group-based interactive education on health topics other than exercise and cognitive health.
75471664|NCT05187130|Other|Mindfulness|60 patients in the mindfulness-based breathing and music therapy group were divided into subgroups of 5 participants each. Each 6-person group started by having participants complete the pretest State Anxiety Inventory, Beck Depression Inventory, and Psychological Well-Being Scale via Survey Monkey. Mindfulness-based breathing and music therapy was applied to each patient group in approximately 45-minute sessions per day. At the end of the session, participants re-filled the posttest State Anxiety Inventory, Work-Related Tension Scale, and Psychological Well-Being Scale. A total of 3 sessions were completed with an interval of two days.
75790760|NCT03299179|Device|Blood pressure measurement|Measuring blood pressure before and after MRI-scan
75642557|NCT05566301|Drug|Clopidogrel|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
75333436|NCT05024162|Diagnostic Test|MRT Stability|MRT's predicted GG at second MRI-P.
75333437|NCT04098172|Device|Pressure Guidewire|Fractional Flow Reserve measurement
75333438|NCT01458470|Drug|Memantine|oral tablet, 1 BID, 24 weeks
75333439|NCT01458470|Other|Placebo|oral tablet, 1 BID, 24 weeks
75642558|NCT05566301|Drug|Ticagrelor|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
75333440|NCT05025488|Drug|Peptide-based vaccine|ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.
75790761|NCT03299179|Device|Body temperature|Measuring body temperature before and after MRI-scan
75927004|NCT02487212|Device|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
75927005|NCT03318614|Dietary Supplement|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
75927006|NCT03318614|Other|Control group|No probiotic intervention was given to the control group for three months.
75333441|NCT05025488|Drug|Poly ICLC|ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.
75333442|NCT04019626|Other|Continue-smoking|Ad-libitum use of subjects' usual brand combustible cigarette
75333443|NCT04019626|Other|myblu Tobacco 2.5%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine
75333444|NCT04019626|Other|myblu Tobacco 4.0%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine
75642559|NCT05566080|Procedure|Carotid endarterectomy|Patients who have a significant carotid stenosis and who undergo surgical carotid endarterectomy
75642560|NCT05563090|Other|Questionnaires+Tongue diagnosis+Pulse diagnosis|Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools
75642561|NCT05553704|Drug|Metformin|metformin group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily
75642562|NCT05548764|Procedure|Prevention Bundles for SSIs|10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.
75790762|NCT03299179|Other|Questionnaires|Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)
75790763|NCT03299179|Diagnostic Test|Pregnancy test|Test for pregnancy using a pregnancy dipstick test
75333445|NCT04019626|Other|myblu Honeymoon 2.5%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
75333446|NCT04019626|Other|myblu Honeymoon 4.0%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
75333447|NCT04019626|Other|JUUL 5%|Ad-libitum use of JUUL 5% e-cigarette
75333448|NCT01452464|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
75333449|NCT05490732|Biological|Blood sampling|"Patient will be subjected to 3 blood sampling over 24hours. At H0, H4 and H12-24.~For each one, one microsampling and one venipuncture"
75471665|NCT05179278|Other|Post-surgical nurse follow-up|Follow-up face-to-face consultation or follow-up telephone consultation a month after the intervention and telephone consultation at one year
75642565|NCT05545280|Drug|Neostigmine with glycopyrrolate|Administration by intravenous infusion
75927007|NCT03318536|Drug|Granisetron Hydrochloride|Patients received Granisetron.
75927008|NCT03318536|Drug|No Granisetron|Patients who did not receive Granisetron.
75927009|NCT05504122|Procedure|inguinal hernia repair|Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
76082414|NCT05169294|Other|Telerehabilitation Program|Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.
76082415|NCT05169294|Other|Written Home Program|Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
76082416|NCT02520648|Other|Neuro-lymphatic treatment|The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
76082417|NCT02520648|Other|Articulatory spinal manual therapy|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
76082418|NCT02520648|Other|Articulatory costal Manual therapy|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
76082419|NCT03410550|Device|Exoskeleton Training|Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
75642566|NCT05545280|Drug|Sugammadex|Administration by intravenous infusion
76082420|NCT03412656|Device|SoftHand Pro with CUFF force feedback device|Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
76082421|NCT03412500|Drug|Vancomycin equation-based method|Vancomycin dosage will be adjusted according to the equation-based method
75333450|NCT01452542|Drug|Eliglustat, common blend proposed commercial formulation|All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.
75471666|NCT05145439|Device|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf.
75642567|NCT05544032|Drug|INCA34176|Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks
75333451|NCT01452542|Drug|Eliglustat, Phase 3 capsule formulation|All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
75642568|NCT05526157|Drug|Finerenone (Kerendia, BAY 948862)|Retrospective analysis using secondary data collection from various sources
75642569|NCT05526157|Drug|Sodium-glucose cotransporter 2 inhibitors (SGLT2i)|Retrospective analysis using secondary data collection from various sources
75642570|NCT05526157|Drug|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Retrospective analysis using secondary data collection from various sources
75642571|NCT05526157|Drug|Steroidal mineral corticoid receptor antagonists (sMRA)|Retrospective analysis using secondary data collection from various sources
75333452|NCT01458548|Drug|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
75333453|NCT01458548|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
75333454|NCT04022668|Radiation|Coronary angiogram|Routine coronary angiogram, if indicated
75333455|NCT05027204|Drug|Docetaxel|Docetaxel for Injection (Albumin-bound), Q3W, i.v. 60 min
75333456|NCT05027204|Drug|Nivolumab|Nivolumab, Q3W, i.v. 30 min
75333457|NCT01458626|Drug|mirtazapine|mirtazapine 30mg QD
75642572|NCT05526157|Drug|Non-steroidal mineral corticoid receptor antagonists (nsMRA)|Retrospective analysis using secondary data collection from various sources
75642573|NCT05525572|Device|Shockwave Therapy (SWT)|"Shockwave Therapy (SWT):~720 shocks will be administered administered in every session to each treated region (left and right corpora cavernosa and crura). Each session will last approximately 20 minutes. A total of 3600 shocks will be administered over 5 weekly sessions."
75642574|NCT05525572|Drug|Autologous Platelet-Rich Plasma (PRP)|"Autologous Platelet Rich Plasma (PRP):~5 mL PRP will be administered via intra-cavernous penile injection with a 30 ± 7 day treatment interval."
75790773|NCT03254381|Behavioral|Resistance Training|Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
75790774|NCT03254381|Behavioral|Balance and Tone Training|Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
75790775|NCT03252808|Biological|TBI-1401(HF10)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
75790776|NCT03252808|Drug|Gemcitabine|1000 mg/m^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
75333458|NCT01458626|Drug|paroxetine 20mg QD|paroxetine 20mg QD
75642575|NCT05509621|Other|The Effect of Supine Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
75790777|NCT03252808|Drug|Nab-paclitaxel|125 mg/m^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
75642576|NCT05509621|Other|The Effect of Prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
75790778|NCT03252808|Drug|TS-1|TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
75790779|NCT03250325|Biological|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.
75927010|NCT02181153|Other|sample blood and fecal collection|Blood and fecal samples will be collected at the day of enrolment
76082422|NCT03412500|Drug|Vancomycin trough concentration method|Vancomycin dosage will be adjusted according to the trough concentration method
75790780|NCT03250325|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
75790781|NCT03246230|Biological|Hepatitis B vaccine (HBV)|Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
76082423|NCT01417780|Drug|AB103|AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion
75333459|NCT00377806|Drug|Diclofenac gel|
75333460|NCT03725098|Device|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
75790782|NCT03246230|Biological|Bacillus Calmette-Guérin (BCG)|Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
75790783|NCT03229278|Drug|Enzyme Inhibitor Therapy|Given trigriluzole PO
75790784|NCT03229278|Other|Laboratory Biomarker Analysis|Correlative studies
75790785|NCT03229278|Biological|Nivolumab|Given IV
75790786|NCT03229278|Biological|Pembrolizumab|Given IV
75927011|NCT04283812|Device|DBS Electrode Implantation using D1 Sterotactic System|Treatment intervention will consist of subjects undergoing Mayo Clinic standard deep brain stimulation surgery specific to their diagnosed neurological disorder consisting of implantation of stimulating electrodes using the D1 stereotactic system.
75927012|NCT03318458|Other|Pilates|The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
75927013|NCT03537027|Dietary Supplement|Vitamin D3|In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
75333461|NCT03725098|Device|FLOSEAL|The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
75927014|NCT04396041|Device|Microvascular Plug (MVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Microvascular Plugs.
75927015|NCT04396041|Device|Amplatzer Vascular Plug (AVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Amplatzer Vascular Plugs.
75927016|NCT04396041|Device|Detachable coils|Patient's Pulmonary AVM(s) treated via transcatheter embolization with detachable coils.
75927017|NCT04282876|Drug|Degarelix|Patients receiving Degarelix
75927018|NCT02183025|Drug|Meloxicam 7.5 mg|
75927019|NCT02183025|Drug|Meloxicam 15 mg|
75927020|NCT02183025|Drug|Mefenamic acid 500 mg|
75927021|NCT02183025|Drug|Placebo matching 7.5 mg meloxicam|
76082424|NCT01417780|Drug|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
76082425|NCT01840943|Drug|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
76082426|NCT01840943|Drug|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
76082427|NCT03397524|Other|optima4BP|optima4BP will provide the treating physician with a treatment action recommendation for consideration.
76082428|NCT03127020|Drug|PQR309|taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
75927022|NCT02183025|Drug|Placebo matching 15 mg meloxicam|
75333462|NCT04281030|Behavioral|PMR (Progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
75790787|NCT03217058|Behavioral|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
75333463|NCT04281030|Behavioral|Monitored Usual Care (MUC)|General Education Session consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
75333464|NCT04179708|Other|Pain Neuroscience Education|"Intervention description Patients participate in a back school program including initial and final assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hours of educative initial assessment and ½ hour of educative final assessment.~The content of Pain Neuroscience Education (experimental group) focuses on deconstruction of patho-anatomical and biomechanical believes, and the explanation of pain from the biology. This framework allows the introduction of coping strategies (eg gradual exposure to exercise, activity and physical activity) and regulation strategy (eg fragmentation of activity, stress management, and so on)."
75333465|NCT04179708|Other|Conventional education|"assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it)."
75651847|NCT05212610|Biological|Pfizer-BioNTech mRNA COVID-19 vaccine|Participants will receive an initial or additional dose of a highly protective COVID-19 mRNA vaccine for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in an environment where the investigators and staff are experienced in the care of patients with allergic reactions.
75927023|NCT02183025|Drug|Placebo matching 500 mg mefenamic acid|
75927024|NCT05464004|Other|Nintendo Wii balance board|"Experimental group was given Nintendo Wii balance board therapy in combination with conventional physical therapy for 16 sessions/8 weeks~Control group was conventional physical therapy which include stretching of the hamstrings, quadriceps and calf muscles. strengthening of the lower limb. Balance exercises include walk in parallel bar"
75333466|NCT04111276|Device|Breg Osteoarthritis Brace gait fluoroscopy|Gait under fluoroscopy surveillance with brace
75790794|NCT03201445|Drug|Filgotinib|200 mg tablet administered orally once daily
75790795|NCT03201445|Drug|Placebo|Placebo to match filgotinib tablet administered orally once daily
75790796|NCT03201445|Drug|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
75790797|NCT03199885|Drug|Atezolizumab|Given IV
75790798|NCT03199885|Procedure|Biopsy|Undergo biopsy
75790799|NCT03199885|Procedure|Bone Scan|Undergo bone scan
75790800|NCT03199885|Procedure|Computed Tomography|Undergo CT scan
75790801|NCT03199885|Drug|Docetaxel|Given IV
75790802|NCT03199885|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790803|NCT03199885|Drug|Paclitaxel|Given IV
75790804|NCT03199885|Biological|Pertuzumab|Given IV
75790805|NCT03199885|Other|Placebo Administration|Given IV
75927025|NCT04282174|Device|CliniMACS|allogeneic Human leukocyte antigen-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system
75927026|NCT04282174|Procedure|Bone Marrow Transplant|Bone Marrow Transplant will come from either an HLA matched related sibling or HLA un-related donor
75927027|NCT04282174|Drug|Hyperfractionated Total Body Irradiation|Hyperfractionated Total Body Irradiation is administered at a dose rate of < 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).
75927028|NCT04282174|Drug|Thiotepa|Thiotepa: 5mg/kg/day IV over approximately 4 hr. daily x 2 (Day -5 and Day -4). If scheduling of transplant harvests requires, the dose of Thiotepa may be administered as a single dose of 10mg/kg/day x 1.
75333467|NCT04111276|Other|Gait fluoroscopy without brace|Gait under fluoroscopy surveillance without brace
75790806|NCT03199885|Other|Quality-of-Life Assessment|Ancillary studies
75651848|NCT05212610|Biological|Moderna mRNA COVID-19 vaccine|Participants will receive an initial or additional dose of a highly protective COVID-19 mRNA vaccine for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in an environment where the investigators and staff are experienced in the care of patients with allergic reactions.
75790807|NCT03199885|Biological|Trastuzumab|Given IV
75790808|NCT03193333|Drug|PRO-122|Posology: 1 drop every 12 hours for 90 days
75790809|NCT03193333|Drug|Timolol eye drops|1 drop every 12 hours for 90 days
75790810|NCT03193333|Drug|Dorzolamide-Timolol Ophthalmic|1 drop every 12 hours for 90 days
75790811|NCT03193333|Drug|Brimonidine Ophthalmic Solution|1 drop every 12 hours for 90 days
75790812|NCT03193333|Other|Placebo1|1 drop of each dropper bottle every 12 hours for 90 days
75790813|NCT03193333|Other|Placebo 2|1 drop of each dropper bottle every 12 hours for 90 days
75790814|NCT03193333|Drug|Krytantek|Posology: 1 drop every 12 hours for 90 days
75790815|NCT03189914|Drug|RX-3117|RX-3117 will be administered orally in combination with Abraxane.
75790816|NCT03160794|Diagnostic Test|[18F]DCFPyL PET/MRI scan|PET/MRI imaging using the radiotracer, [18F]DCFPyL
75927029|NCT04282174|Drug|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is > 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.
75927030|NCT04282174|Drug|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified
75927031|NCT04282174|Drug|Melphalan|Melphalan 70mg/m2/day x 2 days IV over 30 minutes. Dose should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight per MCI standard of care guidelines. Melphalan will be administered on Days - 7 and -6 for multiple myeloma patients.
75642577|NCT05509621|Other|The Effect of left lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
75642578|NCT05509621|Other|The Effect of right lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
75333468|NCT04111276|Diagnostic Test|JointVue ultrasound|JointVue ultrasound procedure to reconstruct 3D femoral and tibial bones
75651849|NCT05207501|Behavioral|Exercise|Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.
75790817|NCT03160794|Radiation|Stereotactic Ablative Radiotherapy|SABR as treatment for lesions identified using [18F]DCFPyL PET/MRI
75790818|NCT03155191|Biological|TBI-1501|"Phase-I portion:~Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10^5 cells/kg, cohort 1: 1×10^6 cells/kg, cohort 2: 3×10^6 cells/kg).~Phase-II portion:~Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501."
75790819|NCT03142802|Diagnostic Test|Low-dose computed tomography (LDCT)|"In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance:~Normal LDCT:~- Patient continues on the study (i.e. continued surveillance)~Suspicious LDCT:~- Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study~Elevated serum tumour markers or other evidence of metastatic disease:~Patient goes off study"
75927032|NCT04282174|Drug|Fludarabine|"Fludarabine 25mg/m2/days x 5 days IV over 30 minutes. Fludarabine may be adjusted in the case of renal toxicity.~In select cases in which the peripheral blood stem cells must be harvested a day later than requested due to a scheduling issue with the donor or Stem Cell Processing Laboratory."
75927033|NCT03321500|Other|Versacryl soft liner|Versacryl has been used to construct different parts of complete and partial dentures . It can be used as thermo-elastic liner which consistency can be controlled to tailor the reline to each individual case, by adding or subtracting drops of liquid B, as explained in the directions for use. The reline can be re-adapted repeatedly, even by the patient if necessary.
75927034|NCT03321500|Other|Silicone-based soft liner|gold standard for denture relining material
75927035|NCT02185989|Other|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
75927036|NCT03321422|Other|No intervention Observational study|follow up of the function of the hip after lateral shelf acetabuloplasty by harris hip score and WOMAC score
75333469|NCT04111276|Diagnostic Test|Computer Tomography|Computer Tomography scan limited to the study knee and will image 6 inches distal on the tibia and 6 inches proximal on the femur
75333470|NCT05495724|Drug|Disitamab Vedotin Tislelizumab|Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
75333471|NCT05495724|Drug|Disitamab Vedotin|Disitamab Vedotin
75333472|NCT02559414|Drug|Aspirin|
75333473|NCT02559414|Drug|Clopidogrel|
75333474|NCT03527264|Drug|Nivolumab induction|2 doses Nivolumab 240mg IV
75333475|NCT03527264|Drug|Cisplatin|40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.
75333476|NCT03527264|Radiation|Radiation|"Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field"
75333477|NCT03527264|Drug|Nivolumab with chemoradiation|Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.
75790820|NCT03112044|Drug|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
75790821|NCT03112044|Device|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
75790822|NCT03066297|Procedure|Extent of pulmonary resection|Extent of pulmonary resection selected based on the institutional decision-making algorithm
75790823|NCT03030378|Procedure|Biopsy|Undergo a tumor biopsy
75927037|NCT02186067|Other|Referral System|"Primary Level:~Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)~Secondary Level:~Community health center at Aga Khan University will serve as the secondary care center.~Family physician will manage patients with CVD, CKD or more than 3 drugs.~Tertiary care:~Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.~Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months"
75927038|NCT05503888|Drug|Almonertinib combined with SHR-1701|"Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral"
75790824|NCT03030378|Procedure|Biospecimen Collection|Undergo collection of blood
75790825|NCT03030378|Procedure|Computed Tomography|Undergo a CT scan
75927039|NCT05503888|Drug|Almonertinib|"Phase Ⅱ:~Almonertinib: tablets, oral"
75927040|NCT02490332|Device|Ventilation tube treatment|Tympanostomy
75927041|NCT02181309|Drug|Meloxicam, low dose|
75927042|NCT02181309|Drug|Meloxicam, medium dose|
75333478|NCT03527264|Drug|Nivolumab maintenance|Nivolumab 480 mg IV every 4 weeks for 2 years
75333479|NCT04160260|Drug|Omadacycline|Omadacycline: PO Tablets
75790826|NCT03030378|Biological|Edodekin alfa|Given SC
75790827|NCT03030378|Procedure|Magnetic Resonance Imaging|Undergo a MRI
75790828|NCT03030378|Biological|Pembrolizumab|Given IV
75790829|NCT03030378|Procedure|Positron Emission Tomography|Undergo a PET scan
75790830|NCT03018041|Drug|Omacor|"As described in Arms."
75471667|NCT05138172|Device|"Forced Air Heating Temperature control Twinwarm II"|"For this purpose, we will use a device that is already routinely used in all operation rommss at MHH, the so-called warm air device Twinwarm, Generation III. This device has a valid CE mark and will be used according to its purpose pre-, intra- and postoperative maintenance of the normothermic body temperature of the patient. The device will be used strictly according to the existing in-house SOP Heat Management of 04/2021 of the Department of Anesthesiology and Intensive Care Medicine of the MHH.~Convective air heating has been shown to be effective in many studies and can be used flexibly with a variety of different ceiling models."
75790831|NCT03018041|Drug|Placebo Oral Capsule|"As described in Arms."
75790832|NCT03015974|Drug|Corticosteroid|
75790833|NCT03015974|Drug|Cyclophosphamide|
75790834|NCT03015974|Drug|Mycophenolate mofetil|
75927043|NCT02181309|Drug|Meloxicam, high dose|
75333480|NCT04713904|Drug|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets|Investigational Medicinal Product
75333481|NCT04713904|Drug|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets|Evafem 20 (Trademark)
75333482|NCT04081818|Other|Nutritious Mushrooms|The Intervention group will consume antioxidant rich and Vitamin D2-enhanced mushrooms as a snack daily for 3 months.
75333483|NCT01458704|Other|next generation sequencing|next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
75790835|NCT03015974|Drug|Dipyridamole|
75790836|NCT03015974|Drug|ACE Inhibitor or Angiotensin receptor antagonist|
75790837|NCT03011372|Drug|Pemigatinib|"Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing."
75790838|NCT03008408|Drug|Everolimus|Given PO
75927044|NCT02186145|Drug|Association of metronidazole; nystatin and dexamethasone|
75927045|NCT02186145|Drug|Flagyl|Vaginal cream of metronidazole and nystatin
75927046|NCT03325868|Drug|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
75927047|NCT02183103|Drug|meloxicam rapid release tablet, 12mg, UH AC62MU|
75927048|NCT03325790|Drug|200mg SPI-1005 BID|Active: low dose
75927049|NCT03325790|Drug|400mg SPI-1005 BID|Active: high dose
75333484|NCT03995680|Drug|Mebendazole|Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
75333485|NCT01452698|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
75471668|NCT05133986|Other|Onion Feeding|The intervention includes feeding individuals a 120g portion of onions (experimental condition).
75790839|NCT03008408|Drug|Letrozole|Given PO
75790840|NCT03008408|Drug|Ribociclib|Given PO
75790841|NCT03006354|Device|nHFOV|Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
75790842|NCT03006354|Device|nCPAP|Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
75927050|NCT03325790|Other|Placebo|Placebo Comparator
75927051|NCT02181465|Biological|G17DT|
75927052|NCT02490020|Biological|mesenchymal stem cell|
76082429|NCT03412422|Diagnostic Test|fluid responsiveness assessment|During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
76082430|NCT01840163|Other|Static version of CanSORT tool|
76082431|NCT01840163|Other|CanSORT Online Tool|
76082432|NCT05171400|Procedure|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
76082433|NCT05171400|Device|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
76082434|NCT05171400|Device|Palatal Wound treated with Insulin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
75642579|NCT05509621|Other|The Effect of Quarter prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
75927053|NCT02186379|Behavioral|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
76082435|NCT02203630|Drug|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
76082436|NCT02203630|Drug|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
75333486|NCT01452698|Drug|Placebo|"Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
75333487|NCT01452698|Drug|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
75333488|NCT01452698|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
75333489|NCT05490576|Radiation|[18F] PI-2620 Tau Ligand|Tau binding ligand
75333490|NCT04005586|Device|Light Delivery Device (LDD)|Study eye will undergo Light delivery Device treatments
75333491|NCT01452776|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
75333492|NCT01452776|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
75333493|NCT03990298|Diagnostic Test|Awake endoscopy|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.
75333494|NCT05029856|Biological|SII B.1.351|"Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
75471669|NCT05133986|Other|Couscous Feeding|The intervention includes feeding individuals a 120g portion of couscous (control condition).
75471670|NCT05133986|Other|Onion Supplementation Period|Three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised.
75471671|NCT05129722|Drug|Low dose combination polydiuretic therapy|"Low dose combination polydiuretic therapy treatment consists of:~Loop diuretic bumetanide 0.5 mg Mineralocorticoid receptor antagonist eplerenone 25 mg Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg"
75790843|NCT02984566|Device|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
75790844|NCT02960230|Biological|K27M peptide|K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently
75790845|NCT02960230|Drug|Nivolumab|anti-PD1 monoclonal antibody
75790846|NCT02942368|Device|tDCS|Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
75790847|NCT02935686|Biological|Ad26.Mos4.HIV|Ad26.Mos4.HIV at a dose of 5*10^10 viral particles (vp), administered intramuscularly.
75927054|NCT02186379|Behavioral|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
75642580|NCT05498766|Drug|Huaier granule|Huaier granule, oral administration, 20g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgment, participants will no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule 10 days after surgery.
76082437|NCT05169138|Other|Aromatherapy application /massage with lavender oil|The application was applied to 37 pregnant women in total, and the effect of massage with lavender oil on labor pain was investigated.
76082438|NCT05169138|Other|Aromatherapy application / inhalation with lavender oil|The application was applied to 41 pregnant women in total, and the effect of inhalation with lavender oil on labor pain was investigated.
75333495|NCT05029856|Biological|SII B.1.351|"Intramuscular (deltoid) injections of 5 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
75642581|NCT05498766|Drug|Oxaliplatin|Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.
75642582|NCT05498766|Drug|Tegafur, Gimeracil and Oteracil Potassium|Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
75642583|NCT05498766|Drug|Capecitabine|Participants will receive oral Capecitabine (1000 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
75927055|NCT04493918|Combination Product|Mesenchymal Stem cell + Nacl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit
75927056|NCT04493918|Combination Product|NaCl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml
75927057|NCT02181543|Drug|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
76082439|NCT03397446|Drug|Lisdexamfetamine dimesylate|50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
76082440|NCT04447482|Device|ENB with image-guided lung biopsy|Electromagnetic navigational bronchoscopy system with tip tracked instruments.
76082441|NCT04447482|Procedure|Conventional Bronchoscopy guided by Fluoroscopy|Bronchoscopic lung biopsy with fluoroscopy.
76082442|NCT02196922|Device|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
76082443|NCT02196922|Other|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
76082444|NCT05168904|Drug|fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
75333496|NCT05029856|Biological|SII Bivalent|Intramuscular (deltoid) injections of 6 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
75333497|NCT05029856|Biological|SII Bivalent|Intramuscular (deltoid) injections of 10 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
75333498|NCT05029856|Biological|SII B.1.617.2|"Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
75333499|NCT05490498|Other|Collection of breast milk|Collection of breast milk through a sterilized breastfeeding device. Once the collection is completed, the milk will be transferred to a sterile jar provided in a dedicated survey package for transport to the laboratory.
75333500|NCT03505372|Device|Contrast enhanced mammography|Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
75471672|NCT05129722|Drug|Comparator monotherapy empagliflozin|Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg
75471673|NCT05100745|Device|Therapeutic Device|This device delivers ultrasound energy to the targeted area of the lower limb.
75471674|NCT05061108|Behavioral|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education
75471675|NCT05060510|Diagnostic Test|Take home saliva kit|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
75642584|NCT05460169|Device|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
75642585|NCT05456191|Drug|Asciminib|Asciminib 80 mg QD administered under fasting conditions.
75642586|NCT05456191|Drug|Nilotinib|Nilotinib 300 mg BID administered under fasting conditions.
75927058|NCT02181621|Device|Iodosorb|Cadexomer iodine gel
75927059|NCT02181621|Device|Solosite gel|Hydrogel
75927060|NCT02490176|Drug|liraglutide|Liraglutide were taken daily for 7 days
75927061|NCT02490176|Drug|placebo|Placebo were taken daily for 7 days
75927062|NCT02181699|Drug|KHK2823|single agent KHK2823
75927063|NCT03318302|Other|Survey|Survey of the adult population in Israel
76082445|NCT03127098|Biological|ETBX-011|ETBX-011 immunization will be administered by subcutaneous (SC) injection.
76082446|NCT03127098|Biological|ALT-803|ALT-803 will be administered by SC injection.
75927064|NCT02181777|Behavioral|GRASP|GRoup trAining for Social skills in Psychosis
75927065|NCT02181777|Behavioral|Standard care|Treatment as usual
75927066|NCT03321344|Device|Focused Ultrasound Thermal ablation|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
75927067|NCT02181855|Procedure|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
76082447|NCT03410472|Behavioral|Web based diet application|This group will be asked to record their diets for 8 weeks after being told an approximate calorie goal. This group will receive weekly emails with tips on how to eat healthy
76082448|NCT03397368|Diagnostic Test|Transperineal Ultrasound -|Every women with stress incontinence witll be subjected to urodynamics to confirm genuine stress incontinence then will be subjected Transperineal US
75333501|NCT02883140|Other|Three-dimensional sialography CBCT and MRI sialography|"MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo).~3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections"
75333502|NCT05495412|Other|Rebound therapy|Exercise therapy delivered twice weekly for 6 weeks, during Phase B of an ABA single case study design.
75333503|NCT03429712|Device|Dual-source multi-detector computed tomography (DSSE)|Dose split technique in a cohort of pediatric patients to determine, without increase in patient radiation dose, the optimal patient-specific and task-specific radiation dose levels for pediatric cardiothoracic and abdominal CT applications.
75642587|NCT05454852|Other|Survey|Interviewer-administered survey
75790848|NCT02935686|Biological|Clade C gp140 plus adjuvant|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.
75790849|NCT02935686|Biological|Clade C gp140/Mosaic gp140 plus adjuvant|Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.
75790850|NCT02935686|Other|Placebo|Placebo Containing 0.9 percent normal saline, administered intramuscularly.
75927068|NCT03325478|Other|"Over the phone interviews on the BCI Stay in Contact"|"This study used phone call interviews on a BCI Stay in Contact, 6 months after suicide attempt behavior.The questionnaire used for the interview of included suicide attempters was pilot tested to assess acceptability and feasibility of the study. It included 24 questions, which were based on literature's data.They covered seeking care and help items and assess the subjective quality appreciation of medical care in the PED and on the BCI.Closed-ended and multiple-choice questions were mixed. Included patients were informed that the questionnaire was anonymous and that seeking their views and feedbacks would help adjusting the implementation of follow-up interventions closer to their needs.The baseline interviews were conducted on the phone, on weekdays, during a mean time of 10 to 15minutes by a trained resident in psychiatry as the only interviewer."
75927069|NCT02183181|Drug|Meloxicam capsule|
75927070|NCT02183181|Drug|Meloxicam tablet|
75333504|NCT02881970|Drug|autologous cord blood stem cell|Injection of 5.107 / kg autologous mononuclear cells from umbilical cord blood
75471676|NCT05056376|Behavioral|Digital Diabetes Prevention Program (dDPP)|"The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes.~The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc."
75471677|NCT05056376|Behavioral|Human Coach-based Diabetes Prevention Program (hDPP)|The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
75471678|NCT05055505|Diagnostic Test|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
75471679|NCT05055492|Diagnostic Test|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
75642588|NCT05454852|Other|Focus group|Focus group for selected participants
75642589|NCT05454839|Other|Survey|Interviewer-administered survey
75642590|NCT05454839|Other|Focus group|Focus group for selected participants
75642591|NCT05446545|Other|ND-EOC or platinum-sensitive rEOC|platinum-based combined chemotherapy or bevacizumab will be used for adjuvant treatment, followed by maintenance therapy with poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, or bevacizumab, or other anti-tumor angiogenesis drugs or immune checkpoint inhibitors
75642592|NCT05445843|Drug|JDQ443|JDQ443 orally administered
75642593|NCT05430555|Biological|Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR|Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy
75927071|NCT02490098|Other|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
76082449|NCT04681794|Other|exercise-based intervention|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, jumping/hopping, and movement-based mindfulness.
76082450|NCT04667442|Diagnostic Test|Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)|COVID-19 Rapid Antigen Diagnostic Test
76082451|NCT03410316|Other|No intervention|
76082452|NCT03397290|Device|Ultrasound (US) Imaging|Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
75333505|NCT03950310|Device|Excimer laser catheter|The excimer laser catheter is equipped with multiple optical fibers on the periphery of the guide wire lumen corresponding to 0.014 inch, which is used for the purpose of reperfusion of barrier site of coronary artery. The connector on the front side is connected with the CVX-300 laser generator, and the tip at the top contact directly with the lesion. The laser catheter consisting of multiple optical fibers transmits the energy in the ultraviolet region from the CVX300 laser generator to the blockage in the blood vessel. The ultraviolet energy is transmitted from the tip of laser catheter, transpires the fibrous, calcified and arteriosclerotic lesion by light, and enables reperfusion in the lesion. The laser catheter has appropriate hydrophilic coating and easily follows the inside of coronary artery.
76082453|NCT03410238|Behavioral|Saferteens Brief Intervention|A 30 minute private one-on-one brief motivational interviewing intervention administered by clinic staff. The goal of the intervention is to reduce and prevent youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on-one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior. In the 2 months following the intervention, participants will receive booster text messages tailored to their responses during the intervention.
75471680|NCT05044962|Drug|Cabotegravir/ Rilpivirine|"For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709"
76082454|NCT04656522|Behavioral|Participatory Comic Intervention|This participatory comic intervention promotes sexual violence prevention and post-rape care with refugee youth and health care providers. In 4-hour workshops, a customized comic book featuring eight sexual violence scenarios will be distributed. Each 1-page scenario speaks to a unique theme of sexual violence experiences among youth or post-rape care preferences. During the workshop participants will explore social, sexual, and psychological needs of youth in Bidi Bidi and practice ways of developing and maintaining healthy relationships (youth) as well as discuss post-rape care responses that attend to the needs and priorities of young refugees in Bidi Bidi who have experienced sexual violence (health care providers). Each workshop will include 20 participants and will be facilitated by trained staff from Real Medicine, Uganda. Further, each workshop will have at least 2 facilitators who are trained in the bystander model.
75642595|NCT05420662|Procedure|Manipulation of vagina during abdominal hysterectomy operation|The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point.
75642596|NCT05420662|Procedure|Classical conventional abdominal hysterectomy operation|Classical conventional abdominal hysterectomy operation without any manipulation from the vagina.
75651850|NCT05207280|Combination Product|Noradrenaline plus Terlipressin|Comparison Norepinephrine plus placebo versus Terlipressin plus Norepinephrine for the Treatment of Septic Shock
76082455|NCT03397212|Other|NADA acupuncture|Ear acupuncture protocol described by National Acupuncture Detoxification Association
76082456|NCT03397212|Other|Sham acupuncture|Ear acupuncture using inactive sham points
76082457|NCT01417936|Drug|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
76082458|NCT05171010|Other|no study-based therapeutic interventions|no study-based therapeutic interventions
76082459|NCT05170932|Procedure|CHX gel 2 % + 24% EDTA|The local drug delivery gel (24% of EDTA gel on root and bone surface and then application of 2% of chlorhexidine gel on root surface) were placed for group 2 in the periodontal pockets Filter paper were inserted into the orifice of the pocket for 1 minute. This was done in the day of surgery then after 3 days, 7 days, 14 days and 21 days after the local drug delivery to measure the gel release profile.
76082460|NCT01418482|Device|Mepilex Border Ag|a silver dressing
76082461|NCT05168358|Procedure|Overnight Bladder Drainage|Parents or caregivers of the patients will be taught to place an indwelling catheter in the bladder at bedtime for about 8-12 h under a clean technique every night for one year. The catheter will then be allowed to drain freely into a gravity drainage collecting bag or in the diapers. On the next morning, the catheter will be removed and the timed voiding regimen will be resumed.
76082462|NCT03410160|Diagnostic Test|Clinical and biochemical examination.|Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
76082463|NCT01393132|Drug|Thymosin Beta 4 eye drops|Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
76082464|NCT01393132|Drug|Vehicle Control|Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
76082465|NCT03412110|Other|active surveillance: electronic platform|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
75471681|NCT05044962|Drug|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm
75471682|NCT05044962|Drug|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
75471683|NCT05044962|Drug|Levonorgestrel|Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm
75471684|NCT05044962|Drug|NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens|ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
75471685|NCT05027919|Drug|Morphine|30mg subcutaneous injections of morphine 4 times daily on days 1 through 5.
75651851|NCT05203835|Drug|Acebilustat|By mouth, once a day, 100 mg capsule
75651852|NCT05203835|Drug|Placebo|Placebo to match acebilustat by mouth, once a day
75790851|NCT02935686|Biological|gp140 HIV Bivalent Vaccine|gp140 HIV Bivalent Vaccine is adjuvanted protein co-formulation with a dosage strength of 80 mcg Clade C protein, 75 mcg Mosaic protein and 425 mcg aluminum (as aluminum phosphate adjuvant).
75790852|NCT02923206|Device|TheraSorb sFlt-1 adsorber|Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
75927072|NCT02490098|Other|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
75927073|NCT02490098|Other|6-day intervention with dual-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
75927074|NCT02490098|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
76082466|NCT05170620|Procedure|laser ablation|Laser ablation will be done for the squamous intraepithelial lesions of the lower anogenital tracts.
76082467|NCT01324882|Device|Colonoscopy with Olympus Technically Improved Colonoscope|The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
76082468|NCT01324882|Device|Control with standard colonoscope Olympus CF-H180|Standard colonoscopy using the adult scope, Olympus CF-H180.
76082469|NCT03397056|Other|Questionnaire|The Questionnaire is provided in the links at the end of the declaration.
76082470|NCT02520570|Drug|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
76082471|NCT03396978|Other|GnRHag|Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
75471686|NCT05027919|Drug|Naloxone + lofexidine pretreatment|0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)
75471687|NCT05027919|Drug|Naloxone + placebo pretreatment|0.4mg naloxone injection during the Naloxone challenge
75471688|NCT05027919|Drug|Lofexidine|Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.
75642597|NCT05411705|Drug|rhTPO|rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10^9/L or when the platelet count rises to ≥250×10^9/L.
75642598|NCT05411705|Drug|Control|Non-rhTPO treatment
75642602|NCT05393713|Biological|Anti-PD-L1 Monoclonal Antibody IMC-001|Given intra-lymphatically via DoseConnect device
75642603|NCT05393713|Procedure|Punch Biopsy|Undergo punch biopsy
75651853|NCT05196854|Other|Group 1. Standard Home Blood Pressure Measurement|Measurement of Blood Pressure using Home blood pressure monitor
75790853|NCT02918253|Radiation|targeted focal HDR brachytherapy|
76082472|NCT04632966|Biological|Biological: PTP-001|allogeneic placental tissue particulate
76082473|NCT03396900|Drug|RhBMP-2 Protein, Recombinant|Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
76082474|NCT03396900|Other|Conventional Corticotomy|A conventional PAOO Surgical procedure will be performed for individuals in this arm
76082475|NCT03412032|Other|assessment|different assessments in both arms
75471689|NCT05027529|Device|CytoSorb|An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit
75471690|NCT05027529|Other|VA-ECMO only|only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added
75471691|NCT05014568|Drug|tapinarof cream, 1%|applied topically once daily
75471692|NCT05014568|Drug|Vehicle cream|applied topically once daily
75471693|NCT04994431|Drug|Tamsulosin Hydrochloride|0.4mg orally nightly for the two days immediately prior to surgery and the morning of surgery.
75471694|NCT04993872|Drug|Biktarvy Tab|Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
75471695|NCT04986787|Device|tACS|a non-invasive brain stimulation technique that allows interaction with endogenous cortical oscillatory rhythms
75471696|NCT04986787|Device|TMS|a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain, it will be specifically cerebellar stimulation
75790854|NCT02918253|Radiation|Whole-gland HDR Brachytherapy|Control/Standard of Care
76082476|NCT03410082|Device|Titration under the guidance of BIS|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if BIS is greater than 80; The infusion rate is decreased by 0.1mcg/kg/h if BIS is less than 60.
75333506|NCT05314348|Device|High-density surface EMG|High-density surface EMG for fasciculation detection
75333507|NCT05314348|Device|Ultrasound|Ultrasound for fasciculation detection
75333508|NCT04424628|Radiation|Low dose radiotherapy A|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
75333509|NCT04424628|Radiation|Low dose radiotherapy B|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
75333510|NCT01452932|Other|Physiotherapy|"The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.~The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.~Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.~The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them."
75927075|NCT02490098|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
75642604|NCT05373342|Device|iCount system assembled with swabs|Designed as single use. Intended purpose - To be used to count swabs and tampons after childbirth in an objective manner. This is intended to be used in women during and after childbirth.
75642605|NCT05344066|Other|Best NHS Care|Personalised advice and support from a diabetes dietician to follow NICE healthy eating diet and physical activity recommendations for GDM.
75927076|NCT02490098|Device|Continuous Glucose Monitoring System Enlite sensor®, Medtronic|Enlite sensor®, Medtronic
75927077|NCT02490098|Device|Insulin pump MiniMed® Paradigm® Veo™, Medtronic|MiniMed® Paradigm® Veo™, Medtronic
75927078|NCT02183259|Drug|ESR 1150 CL, Capsule, oral|
75927079|NCT02183259|Drug|ESR 1150 CL, solution, intravenous|
75927080|NCT02486822|Procedure|Amniotomy|Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
75927081|NCT02486822|Drug|Oxytocin|Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
75471697|NCT04986787|Device|TIS|temporal interference stimulation targeted to striatum, a non-invasive brain stimulation technique that allows interaction with endogenous cortical oscillatory rhythms deep in the brain
75927082|NCT02486822|Procedure|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
75927083|NCT02186457|Drug|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
75927084|NCT02186457|Other|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
75471698|NCT04966546|Drug|Memantine Hydrochloride|Active drug arm
75471699|NCT04966546|Drug|Placebo|Simple syrup with peppermint oil added to match the commercial solution and make it indistinguishable
75471700|NCT04966416|Dietary Supplement|Pyrophosphate|50 mg/kg bwt once daily in gelatine capsules.
75471701|NCT04966416|Dietary Supplement|Placebo|Glucose in gelatine capsules.
75642606|NCT05344066|Other|Intermittent Low Energy Diet|Two non-consecutive days of a food based 1000 kcal diet and five days of the NICE healthy eating diet and physical activity recommendations for the best NHS care group.
75651854|NCT05196854|Other|Group 2. Hypnosis script prior to home blood pressure measurement|Pre-recorded clinical hypnosis script (approx 5 mins long) used prior to standard home blood pressure measurement. Clinical Hypnosis is used as a non-pharmacological technique for reducing procedural anxiety, distress and discomfort with patients.
75651855|NCT05177679|Dietary Supplement|Active supplement|Carotenoid supplement comprised of 10mg lutein and 2mg zeaxanthin.
75927085|NCT03321266|Device|Cook Biodesign® Fistula Plug|The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
75927086|NCT02256501|Biological|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
75927087|NCT02486900|Device|fMRI-based neurofeedback|During scanning patients will be exposed to picture stimuli (showing alcoholic drinks and life goals) projected on a screen behind the scanner and viewed through a mirror attached on the MRI head coil. In each session patients will be trained to down-regulate/up-regulate activation levels in brain areas that show reliable responses to the alcohol/life goals pictures in a 'localiser' scan. Self-regulation of these brain responses will then be guided by real-time feedback of alcohol/life goals-cue elicited activation, consisting of changes in the visible alcohol/life goals picture (decreasing size = successful down-regulation; increasing size = successful upregulation). Functional MRI data will be acquired in short blocks having a duration of 5-8 minutes.
75651856|NCT05177679|Dietary Supplement|Placebo control|Placebo control supplement
75927088|NCT02486978|Other|Control (109 g white bread)|Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
76082477|NCT03410082|Diagnostic Test|Titration under the guidance of OAA/S|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if OAA/S is greater than 3; The infusion rate is decreased by 0.1mcg/kg/h if OAA/S is less than 3.
76082478|NCT03411876|Device|Oxymizer® pendant nasal cannula|Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
76082479|NCT03411876|Device|conventional nasal cannula|Supplemental oxygen is provided by a conventional nasal cannula.
76082480|NCT03410004|Drug|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
76082481|NCT03396744|Device|Light|Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
75471702|NCT04912063|Drug|Lemzoparlimab|Intravenous (IV) Infusion
75471703|NCT04912063|Drug|Azacitidine|Subcutaneous Injection or Intravenous (IV) Injection/Infusion
75471704|NCT04912063|Drug|Venetoclax|Oral Tablet
76082482|NCT03411798|Drug|Yisaipu®|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR & CRP reduce to normal and BASDAI<4) maintenance.
76082483|NCT03409536|Device|SSEP monitoring|Participants will be monitored using the SSEP device both before and after induction of a brachial plexus block.
76082484|NCT03408756|Drug|methotrexate|Participants will receive methotrexate through oral or subcutaneous route of administration
76082485|NCT03406806|Other|Gaitbox|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System [6] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
75333511|NCT01452932|Other|Yoga|"The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.~The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.~No instruments were needed for this intervention."
75642607|NCT05339412|Behavioral|Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
75790855|NCT02907866|Device|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
75790856|NCT02862275|Drug|Atezolizumab|Given IV
75333512|NCT00377416|Genetic|rAAV2-CB-hAAT Gene Vector|Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
75333513|NCT01458938|Other|treatment plan|Data Collection Study
75333514|NCT05490342|Diagnostic Test|Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.|Blood test to value the antibody response to vaccination
75333515|NCT03352882|Diagnostic Test|Ultrasound|Hepatic ultrasound using gray scale, color Doppler, and spectral Doppler imaging to evaluate hepatic vein and portal vein patency, direction and velocity of flow respectively. ARFI will be performed in the right hepatic lobe. Three measurements of stiffness (m/s) will be performed and the mean value recorded.
75790857|NCT02862275|Procedure|Biopsy|Undergo tissue biopsy
75790858|NCT02862275|Procedure|Biospecimen Collection|Undergo blood specimen collection
75333516|NCT01459094|Drug|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
75333517|NCT01459094|Drug|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
75333518|NCT05495100|Drug|Mitoxantrone liposome、Chidamide、Azacitidine|Mitoxantrone liposome 20mg/m2, d1; Chidamide 20mg, biw; Azacitidine 100mg, d1~7; Every 4 weeks is a cycle, with a maximum of 4 cycles of treatment.
75333519|NCT03325114|Drug|Chlorthalidone|Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
75790859|NCT02862275|Procedure|Computed Tomography|Undergo CT scan
75790860|NCT02862275|Other|Laboratory Biomarker Analysis|Correlative studies
75927089|NCT02486978|Dietary Supplement|Dose 1|The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
75927090|NCT02486978|Dietary Supplement|Dose 2|The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
75790861|NCT02862275|Procedure|Magnetic Resonance Imaging|Undergo MRI
75927091|NCT02186535|Dietary Supplement|Vitamin D and Calcium|
76082486|NCT03406806|Other|SprintSystem device|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System [6] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
75333520|NCT05495022|Behavioral|Mindfulness-based stress reduction (MBSR) program|Mindfulness-based stress reduction (MBSR) program will be applied by the researcher to the midwives in the experimental group. Conscious Awareness-Based Stress Reduction will be applied by the researcher (S.Ö.C.) who has received training (16 hours) and has a certificate in this field. Stress reduction program based on mindfulness is planned as 2 sessions per week for 4 weeks, a total of 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individual and group sessions by determining the days when midwives are available online.
75333521|NCT05494944|Procedure|ThuLEP|Minimal invasive prostate intervention
75333522|NCT01453400|Drug|Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
75333523|NCT01453400|Drug|Acetaminophen + placebo|Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
75333524|NCT01453400|Drug|Placebo|Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
75333525|NCT05490186|Procedure|Total Knee Replacement|Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.
75471705|NCT04853446|Drug|Dexamethasone 12 mg|Two identically appearing, opaque capsules will be administered: one capsule containing 12 mg of dexamethasone and one capsule containing placebo.
75927092|NCT03325400|Other|Toothpaste non-fluoride and fluoride|"Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation."
75333526|NCT05023850|Procedure|TLIPB|Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
75471706|NCT04853446|Drug|Placebo|Two identically appearing, opaque capsules will be administered: two capsules containing placebo.
75471707|NCT04853446|Drug|Dexamethasone 24 mg|Two identically appearing, opaque capsules will be administered: two capsules each containing 12mg dexamethasone.
75471708|NCT04846231|Dietary Supplement|Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
75471709|NCT04846231|Drug|Rosuvastatin|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
75642608|NCT05337540|Device|EVI-01|Single intra-articular injection of high molecular weight hyaluronic acid
75642609|NCT05337540|Device|Active comparator Synvisc-One|Single intra-articular injection of active comparator Synvisc-One
75642610|NCT05336123|Behavioral|Hatha Yoga|Weekly hatha yoga classes lasting 10 weeks.
75642611|NCT05336123|Behavioral|Health Education|Weekly health education classes lasting 10 weeks.
75642612|NCT05323149|Other|Saline|Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
75642613|NCT05323149|Drug|Tranexamic acid|Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
75642614|NCT05322577|Drug|Bemarituzumab|Intravenous (IV) infusion
75471710|NCT04846231|Other|Placebo|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
75642615|NCT05322577|Drug|CAPOX|CAPOX administered as a combination of oxaliplatin as an IV infusion and capecitabine orally as tablets.
75471711|NCT04811651|Biological|Umbilical Cord-derived Mesenchymal Stem Cells|umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million.
75642616|NCT05322577|Drug|SOX|SOX administered as a combination of oxaliplatin as an IV infusion and S-1 orally.
75790874|NCT02839720|Other|Laboratory Biomarker Analysis|Correlative studies
75790875|NCT02839720|Drug|Selumetinib Sulfate|Given PO
75790876|NCT02834637|Drug|bivalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
75471712|NCT04811651|Drug|Placebo|intravenous placebo solution with the same appearance as the treatment group.
75471714|NCT04784689|Biological|COVID-19 Vaccine|COVID-19 Vaccine
75471715|NCT04778189|Drug|Placebo|while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia
75471716|NCT04778189|Drug|i.v dexmethasone|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia
75927093|NCT02186613|Behavioral|Telephone support|Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
75927094|NCT03325244|Other|EEG monitor|sleep patterns will be monitored using EEG monitor
75471717|NCT04761146|Radiation|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT is a brachytherapy treatment comprising stainless-steel 316LVM wires coated with radium-224 (Alpha DaRT seeds). The radioactive seeds are inserted directly into the tumour on the perineum and will be removed after 14 days.
75471718|NCT04710615|Device|Synapse platform|"The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.~The Synapse platform offers a panel of functions to help the doctor to prescribe medication."
75642617|NCT05322577|Drug|Nivolumab|IV infusion.
75790877|NCT02834637|Drug|nonavalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
75790878|NCT02773407|Drug|Azithromycin|
75790879|NCT02773407|Drug|Co-trimoxazole|
75927095|NCT03325244|Other|FitBit|activity levels will be monitored
75927096|NCT02181933|Drug|Nevirapine|
75927097|NCT02181933|Drug|Zidovudine (ZDV)|
75333527|NCT05023850|Procedure|ESPB|Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
75333528|NCT03992014|Drug|Linerixibat tablet|Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.
75642618|NCT05316532|Device|Prismalung + treatment|Low-flow extracorporeal CO2 removal with or without concurrent continuous renal replacement therapy
75651857|NCT05153252|Behavioral|Morning Exercise|Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
75790880|NCT02763683|Radiation|PiB and VAT|There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
75790881|NCT02709343|Drug|Bone-marrow derived MSCs|Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells
75790882|NCT02709343|Drug|Placebo|Placebo product visually very similar to mesenchymal stromal cells
75790883|NCT02708914|Biological|UB-851|UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
75790884|NCT02708914|Biological|Eprex|Eprex® is chosen as the comparator.
75790885|NCT02696239|Device|V-lock suture|
75927098|NCT02181933|Drug|Lamivudine (3TC)|
75927099|NCT02183337|Drug|BI 1356|
75927100|NCT02183337|Drug|BI 1356 + Pioglitazone|
75333529|NCT03992014|Drug|[14C]-linerixibat intravenous infusion|[14C]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.
75790886|NCT02696239|Device|Vicryl Suture|
75790887|NCT02696239|Device|Lapra-Ty II|
75790888|NCT02649647|Procedure|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
75790889|NCT02649647|Procedure|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
75790890|NCT02643095|Device|scleral contact lens|Scleral contact lens
75790891|NCT02642042|Drug|Docetaxel|Given IV
75927101|NCT02183337|Drug|Pioglitazone|
75927102|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except friday|
75927103|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except thursday and friday|
75790892|NCT02642042|Other|Laboratory Biomarker Analysis|Correlative studies
75790893|NCT02642042|Drug|Trametinib|Given PO
75642619|NCT05306418|Drug|Mim8|"For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin"
75790894|NCT02631733|Drug|Ferumoxytol|Given IV
75790895|NCT02631733|Drug|Irinotecan Sucrosofate|Given IV
75790896|NCT02631733|Other|Laboratory Biomarker Analysis|Correlative studies
75790897|NCT02631733|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790898|NCT02631733|Drug|Veliparib|Given PO
75790899|NCT02608268|Drug|MBG453|Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
75790900|NCT02608268|Drug|PDR001|Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
75927104|NCT02489786|Drug|patients take 0.125 mg of digoxin daily|
75790901|NCT02608268|Drug|Decitabine|commercially available chemotherapy
75333530|NCT03992014|Drug|Linerixibat oral solution|Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
75642620|NCT05294991|Behavioral|Calm Meditation|This is the active intervention group.
75790902|NCT02596802|Device|FETO therapy|Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
75790903|NCT02595879|Procedure|Biospecimen Collection|Undergo collection of blood samples
75790904|NCT02595879|Radiation|Brachytherapy|Undergo LDR brachytherapy
75790905|NCT02595879|Drug|Cisplatin|Given IV
75790906|NCT02595879|Procedure|Computed Tomography|Undergo FDG-PET/CT
75790907|NCT02595879|Radiation|External Beam Radiation Therapy|Undergo pelvic EBRT
75790908|NCT02595879|Other|Fludeoxyglucose F-18|Undergo FDG-PET/CT
75333531|NCT05490108|Biological|ZR202-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype)
75333532|NCT05490108|Biological|ZR202a-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (variant)
75642621|NCT05294991|Behavioral|Health Education Podcast|This is the active comparator/control group.
75642622|NCT05293080|Other|Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)|Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.
75642623|NCT05293080|Other|Usual care for atrial fibrillation|Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.
75642624|NCT05276804|Drug|Sugammadex|The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
75642625|NCT05273762|Device|FlowTriever|Mechanical thrombectomy for pulmonary embolism
75790909|NCT02595879|Radiation|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
75790910|NCT02595879|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75790911|NCT02595879|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790912|NCT02595879|Other|Pharmacological Study|Correlative studies
75790913|NCT02595879|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
75790914|NCT02595879|Drug|Triapine|Given IV and PO
75790915|NCT02523716|Other|Hypoxia|Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
75790916|NCT02523716|Other|Normoxia|Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
75790917|NCT02510261|Drug|Patisiran|Patisiran was administered IV.
75790918|NCT02506192|Drug|Modified-Release Prednisone|Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
75790919|NCT02506192|Drug|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
75790920|NCT02476825|Drug|Fluticasone propionate|Flixotide Accuhaler 500 micrograms b.i.d.
75790921|NCT02476825|Device|Accuhaler|Flixotide Accuhaler 500 micrograms b.i.d.
75790922|NCT02453984|Other|89Zr-MPDL-3280A-PET scans|89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
75333533|NCT05490108|Biological|Comirnaty®|Comirnaty® (Pfizer-BioNTech)
75333534|NCT05025644|Drug|Pre and post-CPB Drug: Dobutamine Hydrochloride|"Pre-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) until a PG ≥ 50mmHg is achieved (DBT peak dose). The DBT peak dose (DBT-pd) will be recorded.~Post-CPB provocation test at the DBT-pd achieved preoperatively."
75333535|NCT05025644|Drug|Post-CPB Drug: Dobutamine Hydrochloride|"Pre-CPB no intervention will be required.~Post-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) or until postoperative provocable PG is >16 mmHg."
75790923|NCT02421718|Radiation|Radiotherapy|
75927105|NCT02489786|Drug|digoxin dose is calculated using Jusko-Koup method and given daily|
75927106|NCT02489864|Drug|Terlipressin|
75927107|NCT02182011|Drug|Tenecteplase|
75927108|NCT02182011|Drug|Alteplase|
75927109|NCT02182011|Drug|Streptokinase|
75927110|NCT02486744|Drug|Acthar Gel|Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
75927111|NCT02186769|Drug|Risperdal® Consta®|
75927112|NCT02186769|Drug|LY03004|
75642626|NCT05270759|Diagnostic Test|Estimated absolute blood volume|Baseline absolute blood volume will be inferred based on the change in relative blood volume (RBV) after a single 240mL replacement fluid infusion and then monitored throughout the session via the RBV value.
75927113|NCT02486432|Drug|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
75642627|NCT05270759|Diagnostic Test|Modified VExUS evaluation|The presence of at least 2/3 abnormal venous Doppler waveforms at the following sites: Portal vein, hepatic vein, and femoral vein.
75790924|NCT02413606|Other|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
75790925|NCT02408757|Procedure|Sonographic monitoring|Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
75471719|NCT04705428|Other|FLUORINE VARNISH|"Participants in all groups will receive written oral hygiene and oral prophylaxis instructions. All groups will receive the application of fluorine varnish every 3 months.~The application of fluoride in the three groups will be done as follows:~-Drying of the teeth, placement of the fluorine varnish on the teeth by quadrants. The varnish will be left to dry for a few seconds according to the manufacturer's instructions. Children in all groups will be asked to avoid brushing and flossing for one day after applying fluoride. They will be instructed to avoid hard food and hot drinks for 4 hours. Children and parents will be instructed on how to care for their teeth at home: brush teeth with conventional toothpaste containing 1000 ppm sodium fluoride, for 3 minutes without rinsing.~In the following reviews (3 and 6 months) the effectiveness of the treatments will be evaluated by visual examination, tactile examination, fluorescence and photography."
75471720|NCT04671225|Behavioral|Groups Psychoeducation|Manual-structured group psychoeducation with 8 sessions of 90 minutes over the course of 8 weeks (at one session per week). The manual is centred on behavioural principles from social education and self-regulation philosophies. All groups will have 6-8 participants and two health professionals to conduct the sessions; a psychiatric nurse and either a psychologist or a psychiatric resident. Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives.
75642628|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
75642629|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
75642630|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
75642631|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
75790926|NCT02395666|Drug|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
75790927|NCT02339220|Behavioral|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
75927114|NCT05182047|Drug|Butamirate citrate|Butamirate citrate syrup will be administered orally.
75790928|NCT02339220|Behavioral|Lakeshore Enriched Fitness Training (LEFT)|This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
75927115|NCT05182047|Drug|Sinecod|Sinecod syrup will be administered orally.
75927116|NCT02489240|Drug|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 days
75927117|NCT02489240|Drug|placebo|2000 IU placebo tablets were taken daily for 6 days
75927118|NCT02183415|Drug|BI 1356 BS, low dose|
75927119|NCT02183415|Drug|BI 1356 BS, medium dose|
75927120|NCT02183415|Drug|BI 1356 BS, high dose|
75927121|NCT02183415|Drug|Placebo|
75927122|NCT02486510|Drug|Maraviroc|"Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours"
75927123|NCT02190123|Drug|ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
75927124|NCT04493840|Drug|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
75333536|NCT02558790|Drug|L-Threonic Acid Magnesium Salt (L-TAMS)|
75333537|NCT01459172|Other|limonene containing massage oil|daily massage application to the breast for 4 weeks
75333538|NCT05494710|Other|Bleomycin electrosclerotherapy treatment|The combination of Bleomycin and electroporation of the treated area which is called electrochemotherapy (ECT).
75333539|NCT03810066|Drug|Osimertinib|All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
75333540|NCT03992482|Drug|Intravenous Immune Globulin (IVIG)|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
75471721|NCT04671225|Behavioral|Waiting-list|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
76082487|NCT03406806|Other|NIH toolbox 4 meter walk|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System [6] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
75333541|NCT03992482|Drug|Placebo|Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
75471722|NCT04664933|Drug|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
75471723|NCT04662554|Device|1-mm Resolution Clinical PET camera|1-Millimeter Resolution Clinical PET System in Head and Neck Cancer (HNC) Imaging
75471724|NCT04660760|Drug|Paclitaxel|Given IV
75642632|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
75642633|NCT05262400|Drug|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
75927125|NCT04493840|Drug|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
75927126|NCT04493528|Combination Product|Meso-Jet, 2% lidocaine(xylocaine)|Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.
75927127|NCT04493528|Combination Product|Needle,2% lidocaine(xylocaine)|Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.
75790929|NCT02339220|Behavioral|standard Transfer Package (sTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
75927128|NCT02190201|Device|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
75471725|NCT04660760|Other|Quality-of-Life Assessment|Complete questionnaires
75471726|NCT04660760|Biological|Ramucirumab|Given IV
75927129|NCT02190201|Device|Direct laryngoscope|A kind of traditional laryngoscopes
75927130|NCT02183493|Drug|BI 1356|
75927131|NCT02187081|Procedure|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
75927132|NCT02187081|Procedure|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
75471727|NCT04660760|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
75642634|NCT05262400|Drug|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
76082488|NCT03411720|Other|FES Row Training|Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
75333542|NCT04390490|Device|Graphene quantum dots combined with Si nanowire photoelectrochemical immunosensor|Graphene quantum dots combined with Si nanowire is a new method of photoelectrochemical immunosensor
75333543|NCT03793920|Other|Facial Emotion Test|All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
75333544|NCT01453478|Drug|GSK1325756|CXCR2 antagonist
75333545|NCT00377494|Biological|MVA-CSO Vaccine|
75333546|NCT00377494|Biological|PfCSP DNA (VCL-2510) Vaccine|
75333547|NCT01459250|Drug|AGO178C|
75333548|NCT03747588|Procedure|Minimally-invasive pancreaticoduodenectomy|Minimally-invasive pancreaticoduodenectomy for resection of pancreatic tumor
75333549|NCT03747588|Other|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy for resection of pancreatic tumor
75333550|NCT03269968|Device|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
75471728|NCT04651569|Other|Observational study|none, Observational study
75471729|NCT04650698|Drug|Tranexamic acid|IV, Total Dosage: 2 grams (1 gram before surgical incision + 1 gram, 3 hours after first dose)
75471730|NCT04642222|Behavioral|APOLO-Teens web-based intervention|The APOLO-Teens web-based intervention is a 6-month cognitive-behavioral lifestyle program developed to optimize treatment as usual for pediatric obesity in public portuguese hospitals.
75642635|NCT05262400|Drug|PF-07104091 + PF-07220060 + letrozole dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with letrozole
75642636|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
75642637|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
75642638|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
75642639|NCT05253677|Device|CT-guided PCI|CT-guided PCI with standardized pre-procedural planning and online guidance.
75642640|NCT05253677|Device|IVUS-guided PCI|use of IVUS during PCI procedure (standard of care)
75927133|NCT02485106|Drug|Rifaximin|400mg three times per day for 28 days
76082489|NCT03411564|Other|Filming Together to See Ourselves in a New 'Present'|"PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process."
75927134|NCT02485106|Drug|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
75927135|NCT02187237|Device|YOLO TOUCH Low Level Laser|
75927136|NCT02485028|Drug|Dapoxetine 30mg tablet|
75333551|NCT03269968|Device|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
75333552|NCT01453556|Procedure|Laparoscopic right colectomy|Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
75927137|NCT02485028|Drug|Mirodenafil 50mg tablet|
75927138|NCT02183571|Drug|Merck Glucophage® high dose|Part I: Treatment A
75927139|NCT02183571|Drug|BMS Glucophage® high dose|Part I: Treatment B
75471731|NCT04642222|Other|Treatment as Usual for Pediatric Obesity|Treatment as Usual for pediatric obesity in portuguese public hospitals.
75471732|NCT04633655|Other|outcome measures for CIPN testing|questionnaires administration, physician based scales for CIPN data collection
75642641|NCT05233930|Procedure|TKR with augmented reality-based navigation system|Surgery
75642642|NCT05233930|Procedure|TKR with traditional mechanically aligned technique|As per local practice and standard guidelines.
75927140|NCT02183571|Drug|Merck Glucophage® low dose|Part II: Treatment C
75642643|NCT05230914|Other|Simplified imaging strategy|NCCT and CTA will be used to screen patients for endovascular treatment
75333553|NCT04390412|Radiation|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA treatment plan
75642644|NCT05230914|Other|Standard imaging strategy|NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
75642645|NCT05229900|Drug|SGN-ALPV|Given into the vein (IV; intravenously)
75642646|NCT05220956|Behavioral|Intermittent fasting|One arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
75927141|NCT02183571|Drug|BMS Glucophage® low dose|Part II: Treatment D
75927142|NCT03318146|Device|drug delivery system|The EXP-LP sustained released formula inserted into a small punctual plug. The plug is designed to release the drug over a period of up to 6 months in a slow release profile.
75927143|NCT03318146|Drug|XALATAN®|one drop in the affected eye(s) once daily in the evening
75927144|NCT03536091|Diagnostic Test|Magnification endoscopy|All IBD patients will undergo magnification endoscopy with 136-fold optical magnification in conjunction with optical chromoendoscopy
75927145|NCT02183649|Drug|pentoxyverine citrate|
75790930|NCT02339220|Behavioral|enhanced Transfer Package (eTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
75790931|NCT02323464|Procedure|Open surgery for colorectal cancer|
75790932|NCT02323464|Procedure|Laparoscopic or robotic surgery|
75790933|NCT02257528|Other|Laboratory Biomarker Analysis|Correlative studies
75333554|NCT04166032|Device|Alertgy non-invasive continuous glucose monitoring device (ANICGM)|Alertgy non-invasive continuous glucose monitoring device (ANICGM)
75333555|NCT02556138|Device|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
75333556|NCT04303156|Drug|Islatravir|Single oral dose of 60 mg Islatravir administered in capsule form
75333557|NCT04390334|Drug|Daridorexant|Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.
75333558|NCT04390334|Drug|Famotidine|Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.
75471733|NCT04631211|Biological|Thrombosomes|Human platelet derived lyophilized hemostatic
75471734|NCT04631211|Biological|Liquid Stored Platelets (LSP)|Leukocyte reduced apheresis platelets or whole blood derived pooled platelet concentrate equivalent (4-6 units)
75471735|NCT04572750|Behavioral|EMPOWER-ED|An electronic app that runs on a variety of platforms and provides education and tools designed to promote self-driven reduction of benzodiazepines.
75642647|NCT05220956|Behavioral|DGE diet|The control arm is not a subject to any time restrictions concerning eating while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
75790934|NCT02257528|Biological|Nivolumab|Given IV
75790935|NCT02245321|Dietary Supplement|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
75790936|NCT02245321|Dietary Supplement|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
75927146|NCT02183649|Drug|Placebo|
75927147|NCT03318068|Other|Yoga Intervention|The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
75927148|NCT02187315|Device|Chrono-chemotherapy pump:Melodie|
75927149|NCT02187315|Device|Routine intravenous drip|
75927150|NCT02187315|Drug|induction chemotherapy|
75927151|NCT02187315|Drug|cisplatin chrono-chemotherapy|
76082490|NCT01394614|Biological|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
75642648|NCT05218499|Drug|Brigimadlin (BI 907828)|Brigimadlin (BI 907828)
76082491|NCT04588818|Drug|Adalimumab plus Methotrexate|"Adalimumab 40 mg (≥30kg weight) or 20mg (<30kg weight) subcutaneously every other week without loading dose.~Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) ."
75927152|NCT02187315|Radiation|intensity-modulated radiation therapy|
75927153|NCT02187315|Drug|cisplatin routine-chemotherapy|
76082492|NCT03406494|Other|Early multicomponent physical therapy program|"Positioning (upright bed standing; turning, moving on bed).~Peripheral muscle strength training (active or passive full range of motion, lower extremities ergometer cycling).~Respiratory muscle training (supine abdominal breathing training).~Neuromuscular electrical stimulation (NMES) on target muscles (bilateral bicipital muscles, quadriceps femoris muscles and rectus femoris).~Gut rehabilitation (midfrequency NMES; abdominal manual or vibration massage)."
76082493|NCT01394692|Procedure|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
76082494|NCT01394692|Procedure|standard microsurgery|microsurgical tumor resection
76082495|NCT01422226|Drug|Misoprostol|Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
76082496|NCT01422226|Other|Placebo|Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
76082497|NCT01423162|Other|Dietary Intervention (with Vit C then without Vit C)|Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
76082498|NCT01423162|Other|Dietary Intervention (without Vit C followed by with Vit C)|Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
76082499|NCT05170542|Drug|Camrelizumab+S-1|Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.
76082500|NCT01328782|Drug|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
76082501|NCT01328782|Drug|Bupivacaine 0.25%|"Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
75333559|NCT04390334|Drug|Efavirenz|Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
75333560|NCT02880020|Biological|Ipilimumab|Given IV
75642649|NCT05218499|Drug|Doxorubicin|doxorubicin
75642650|NCT05213936|Device|Scalp cooling with hairstyle|Hair will be prepared accordingly for the cooling cap fitting based on which approach the patient prefers: braids/cornrows/twists
75927154|NCT02489396|Behavioral|Nutrition facts automatically or not automatically displayed|"For two months nutrition information on the Rosie site will be displayed in a tab that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen healthiest, and fifteen least healthy items in six grocery categories; chips, cookies, cereal & breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items."
75927155|NCT02489396|Behavioral|Nutrition facts in color|For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.
76082502|NCT01328782|Drug|Ropivacaine 0.20%|"Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
76082503|NCT04447326|Drug|Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy|Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles
76082504|NCT04447326|Drug|IC＋CCRT|IC＋CCRT
75333561|NCT02880020|Other|Laboratory Biomarker Analysis|Correlative studies
75333562|NCT02880020|Biological|Nivolumab|Given IV
75333563|NCT05494554|Device|Changing mechanical ventilation mode|On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio). Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. MP values were calculated from the minute respiratory parameters of all patients with the MP formulas defined in the software.
75333564|NCT01453634|Drug|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
75333565|NCT01453634|Drug|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
75642651|NCT05213936|Device|Scalp cooling with conditioner and water emulsion|Hair will be prepared accordingly for the fitting based on which approach the patient prefers: or conditioner and water emulsion to coat the hair.
75642652|NCT05209867|Drug|CBD oil|"Each participant will be provided two 30mL(Milliliters) bottles (2000mg CBD per bottle) with a syringe dropper during their initial (baseline) visit with instructions to administer the solution under the tongue (0.5 cc ~1/2 dropper) twice per day (BID) 8-12 hours apart (morning and evening) at the prescribed daily dosage (63mg/day).~The investigators plan to collect samples from five patients over three time points: baseline (no CBD), and after one and two months of CBD-administration"
76082505|NCT01426360|Other|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
76082506|NCT01426360|Other|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
75790937|NCT02245321|Other|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
76082507|NCT03411330|Drug|Hyaluronidase|Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
75642653|NCT05201547|Drug|Carboplatin-Paclitaxel|Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles
76082508|NCT03411330|Drug|Lidocaine|lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)
75333566|NCT05494476|Procedure|implant insertion|after flap detachment, implant bed will be prepared with twist-drill, implant will be inserted according to randomization (1 or 2 mm under bone)
75333567|NCT03150160|Drug|brinzolamide 1%/brimonidine 0.2% fixed combination|One drop applied topically to the affected eye(s) in the morning and evening
75333568|NCT03150160|Drug|Placebo|One drop applied topically to the affected eye(s) in the morning and evening
75642654|NCT05201547|Drug|Dostarlimab|Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years.
75642655|NCT05196815|Other|Ultrasound|Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
75927156|NCT02489396|Behavioral|Nutrition Facts Label in Larger Font|For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.
76082509|NCT03411330|Drug|Bupivacaine|bupivacaine (0.5%)
75642656|NCT05196815|Procedure|Catheters|During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
75642657|NCT05196815|Procedure|Soft study wire|Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
75790938|NCT02245321|Other|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
76082510|NCT05167890|Dietary Supplement|Coffee|Coffee 3 times per day
76082511|NCT05167890|Dietary Supplement|Orange juice|Orange juice 3 times per day
76082512|NCT03411252|Drug|Mirabegron 50 MG|Myrbetriq (Mirabegron) tablet
76082513|NCT03411252|Drug|Placebo|Sugar pill manufactured to mimic Mirabegron
76082514|NCT03394170|Other|Collection of specimens prior to and during surgery|Collection of specimens prior to and during surgery
75333569|NCT03150160|Drug|travoprost 0.004% ophthalmic solution|One drop applied topically to the affected eye(s) in the evening
75333570|NCT01459406|Dietary Supplement|Glucose|500 ml water drink containing 40g glucose
75333571|NCT01459406|Dietary Supplement|Fructose|500 ml water drink containing 40g fructose
75642658|NCT05196815|Radiation|X-ray|Participants will have chests x-ray when the soft study wire is inserted.
75642659|NCT05196815|Drug|Dobutamine|Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
75651858|NCT05153252|Behavioral|Evening Exercise|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
75790939|NCT02245321|Dietary Supplement|Placebo|Receive pills to take daily that contain 0 mg iron.
75790940|NCT02223819|Drug|Crizotinib|"An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.~Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration."
75790941|NCT02160015|Procedure|Biospecimen Collection|Undergo blood sample collection
75790942|NCT02160015|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
75790943|NCT02160015|Procedure|Computed Tomography|Undergo CT
75790944|NCT02160015|Procedure|Electrocardiogram|Undergo ECG
75790945|NCT02160015|Drug|Ibrutinib|Given PO
75790946|NCT02160015|Drug|Lenalidomide|Given PO
76082515|NCT03396354|Procedure|Integrated robotic surgery|Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.
76082516|NCT03396354|Procedure|Conventional laparoscopic surgery|conventional laparoscopic gastrectomy will be performed.
76082517|NCT05167812|Other|Observation of pregnancies after intake|Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss
76082518|NCT04390620|Device|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
76082519|NCT01831427|Drug|Andecaliximab|Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
76082520|NCT01831427|Drug|Placebo to match Andecaliximab|Placebo to match andecaliximab administered by IV infusion
76082521|NCT01426828|Biological|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
75333572|NCT01459406|Dietary Supplement|Fructan|500 ml water drink containing 40g fructan
75333573|NCT01459406|Dietary Supplement|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
75333574|NCT01453712|Radiation|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
76082522|NCT03396120|Diagnostic Test|Pulmonary function test|forced vital capacity and diffusing capacity
76082523|NCT01830881|Drug|Midazolam|5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
75927157|NCT02489396|Behavioral|Healthier Items First|For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
76082524|NCT01830881|Drug|Ibuprofen|800 mg oral ibuprofen 30-60 minutes prior to procedure
76082525|NCT01830881|Other|Placebo-Cherry syrup|5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
76082526|NCT01830881|Drug|Lidocaine|injection of 20 mL 1% lidocaine without epinephrine
76082527|NCT03404700|Behavioral|Egg breakfast|"Containing:2 Scrambled Eggs, 120 mL Skim Milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 30g Margarine, 18g Smuckers Strawberry Jam~10 g of Margarine, 18 g of Smuckers® Strawberry Jam"
76082528|NCT03404700|Behavioral|Egg breakfast with high saturated fat|Containing:2 Scrambled Eggs, 120 mL 2% milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 15 g Butter, 15g Smuckers Strawberry Jam
75927158|NCT02489162|Device|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
75333575|NCT01453712|Radiation|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
75333576|NCT05494320|Drug|Folfox Protocol|Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
75333577|NCT03988426|Biological|Octanorm|Octanorm
75471736|NCT04533594|Behavioral|NOVELA|The family caregivers that consent to participate will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the telenovela video (one of four episodes, each 3-6 mins) over the course of 4 hospice visits (one episode per visit). All four visits will be in person using telehealth via video-conferencing. The number of visits is based on the number of videos which content is prioritized based on previous work. The interventionist will introduce the purpose and topic of the video, facilitate video viewing and then elicit clarifying questions and reinforce main message.
75471737|NCT04522726|Drug|Weiyang Yuping Fang|Weiyang Yuping fang is a combination of the classic ancient Yuping dispersion used to prevent qi deficiency and susceptibility and Bushen Naqi granules optimized formated by Professor Shao Changrong's experience in treating chronic cough and asthma.
75642660|NCT05177484|Drug|oral ferric maltol|The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.
75790947|NCT02160015|Procedure|Magnetic Resonance Imaging|Undergo MRI
75790948|NCT02160015|Biological|Rituximab|Given IV
75790949|NCT02078648|Drug|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated)."
75790950|NCT02078648|Drug|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
75927159|NCT02489162|Device|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
76082529|NCT03404700|Behavioral|Cereal breakfast|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1 Slice Mrs. Bairds Extra Thin Bread, 35g Margarine, 10 g Smuckers Sugar Free Strawberry Jam
76082530|NCT03404700|Behavioral|Cereal breakfast with high saturated fat|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1/2 Slice Arnold Double Protein Whole Grain Bread, 15 g Butter
76082531|NCT01396486|Drug|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
75927160|NCT02256735|Drug|Treatment A|Ritobegron Cl (KUC 7483 CL) tablets low dose
76082532|NCT01396486|Drug|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
75333578|NCT01890356|Device|Transcranial electrical stimulation|
75333579|NCT05489952|Drug|iron sucrose and ferrous lactate|The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
75642661|NCT05164458|Drug|IBI 308 injection|IBI308 IV 200mg Q3W Day1
75927161|NCT02256735|Drug|Treatment B|
75927162|NCT02256735|Drug|Treatment C|
75333580|NCT03123328|Device|Radical-7 Pulse CO-Oximeter and sensor|Noninvasive device that measures hemoglobin.
75333581|NCT04272398|Other|dynamic elastomeric fabric orthoses|Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
75471738|NCT04507217|Drug|Tislelizumab, Carboplatin, Pemetrexed|"Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle"
75333582|NCT01459640|Drug|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
76082533|NCT05215002|Other|Telephone Call|Patient will be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
75333583|NCT01459640|Biological|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
75333584|NCT04257396|Device|Carbon-Fibre Adjustable Reuseable Accessory (CARA)|Breast support device having a carbon-fibre breast cradle for supine patient positioning.
75471739|NCT04447846|Drug|Cannabidiol|Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.
75790951|NCT02078648|Drug|SL-701 + GM-CSF|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~150 μg GM-CSF should be administered as a SC injection immediately after SL-701 emulsion administration and within 1 cm from the center of the SL-701 emulsion injection site."
75790952|NCT02078648|Drug|Imiquimod|Within 5 minutes following the administration of the SL-701 emulsion, approximately 125 mg of imiquimod cream will be applied topically on the injection site. The imiquimod cream should be rubbed in until the cream is no longer visible.
76082534|NCT05215002|Other|No telephone call|Patient will not be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
75471740|NCT04415424|Biological|4CMenB vaccine|A four-component meningococcal B vaccine
75471741|NCT04415424|Other|Placebo|0.5 ml of 150 mmol sodium chloride (0.9% saline solution)
75471742|NCT04406467|Device|Xen Gel Stent|Ab-interno or Ab-Externa Xen with closed or open conjunctiva.
75471743|NCT04405245|Drug|Latanoprost ophthalmic solution|Latanoprost opthalmic solution to be dosed once daily
75642662|NCT05164458|Drug|IBI 389 Injection|IBI 389 IV Q2~Q3W Day 1
75927163|NCT02256735|Drug|Treatment D|
75333585|NCT01500772|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
75333586|NCT01500772|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
75642663|NCT05161195|Drug|Ribociclib|Participants continue ribociclib as was administered in their parent study
75642664|NCT05161195|Drug|Letrozole|Participants continue ribociclib in combination with letrozole as was administered in their parent study
75333587|NCT01500772|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
75642665|NCT05161195|Drug|Anastrozole|Participants continue ribociclib in combination with anastrozole as was administered in their parent study
75927164|NCT02256735|Drug|Placebo|
75927165|NCT02256735|Drug|Moxifloxacin|
75927166|NCT02484794|Behavioral|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
75927167|NCT02484794|Behavioral|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
75927168|NCT02183805|Drug|Abraxane,Cyclophosphamide,Carboplatin|High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
75927169|NCT03316352|Procedure|Ultrasound-assisted paramedian technique spinal anesthesia|Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
75333588|NCT02840630|Other|Tinned mackerel fish|Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
75333589|NCT04257162|Other|Tumor and Blood sample collection|"This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.~Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.~Tumor sample and blood sample will be collected within the framework of HER2-Predict Study"
75333590|NCT04272476|Other|acupuncture and moxibustion|
75927170|NCT03316352|Procedure|Landmark-guided paramedian technique spinal anesthesia|Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.
75333591|NCT04272476|Drug|Fluoxetine|
75471744|NCT04405245|Drug|AKB-9778 4%|Razuprotafib opthalmic solution
75471745|NCT04405245|Drug|Placebo|placebo for razuprotafib opthalmic solution
75642666|NCT05161195|Drug|Goserelin|Participants continue ribociclib in combination with goserelin as was administered in their parent study
75790953|NCT02048813|Drug|Cyclophosphamide|Given IV
75790954|NCT02048813|Drug|Fludarabine Phosphate|Given IV
75790955|NCT02048813|Drug|Ibrutinib|Given PO
75790956|NCT02048813|Other|Laboratory Biomarker Analysis|Correlative studies
75790957|NCT02048813|Other|Pharmacogenomic Study|Correlative studies
75790958|NCT02048813|Other|Quality-of-Life Assessment|Ancillary studies
75333592|NCT03276390|Behavioral|Hispanic Kidney Transplant Program (HKTP)|The HKTP entails culturally targeted education in Spanish about transplantation, outreach to dialysis patients by bicultural health care providers.
75790959|NCT02048813|Biological|Rituximab|Given IV
76082535|NCT03395964|Procedure|Hybrid Dyna-CT guided localization|We will perform intraoperative lung tumor localization in CGMH hybrid operation room(Room 51) equipped with the Siemens Artis Zeego system with DynaCT imaging capabilities. The system provides images equivalent to a 16-slice spiral CT scanner in a single 6-s sweep.
75333593|NCT03984838|Drug|JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet|JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
75471746|NCT04369599|Device|V/Q System|With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.
75333594|NCT03136692|Behavioral|Lose It! commercial weight loss app|Lose It! is a commercial weight loss smart phone app designed for easy caloric tracking. It provides a free mobile and web interface for users to construct an individualized weight loss plan by entering their goal weight and desired weekly weight loss. Using the user's height, current weight, gender and age, the app generates a daily caloric budget designed for the user to reach their goal. Users can then log their caloric intake, exercise, and weight to track progress toward their goal.
75333595|NCT01890668|Other|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility…) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
75471747|NCT04356391|Procedure|Connective Tissue Graft Technique|For the sites receiving the control technique (Connective Tissue Graft), the technique described by Langer B. and Langer L. will be started with a sulcular incision followed by a partial thickness flap. A CTG is then harvested according to the technique described by Bruno, the first incision is perpendicular to the 2nd premolar and 1st molar and is 2-3mm apical to their gingival margin as wide as the recipient site, followed by a second incision parallel to the for mentioned teeth, 1-2mm apical to the first incision, then the CTG is raised by periosteal elevator and released from apical and lateral attachments by sharp incision when needed. The graft is then prepared to have a homogenous thickness of 1.5-2mm. The donor CTG is stabilized to the underlying connective tissue interproximally using 4-0 Vicryl sutures. The recipient flap is repositioned coronally, to cover as much as possible of the graft with no tension, 2mm coronal to the CEJ, then sutured with 4-0 Vicryl sutures.
75642667|NCT05161195|Drug|Tamoxifen|Participants continue ribociclib in combination with tamoxifen as was administered in their parent study
75642668|NCT05161195|Drug|Fulvestrant|All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
75642669|NCT05155865|Device|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement
75642670|NCT05155865|Device|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement
75642671|NCT05149638|Diagnostic Test|Cosyntropin stimulation test|In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.
75642672|NCT05136170|Drug|Oxervate|One drop of the test product will be instilled in both eyes TID
75790960|NCT02030067|Drug|RX-3117|
75790961|NCT02027935|Biological|Aldesleukin|Given SC
75790962|NCT02027935|Biological|Autologous CD8+ Melanoma Specific T Cells|Given IV
75790963|NCT02027935|Drug|Cyclophosphamide|Given IV
75790964|NCT02027935|Biological|Ipilimumab|Given IV
75790965|NCT02027935|Other|Laboratory Biomarker Analysis|Correlative studies
75790966|NCT02017366|Other|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
75790967|NCT02003209|Drug|Aromatase Inhibition Therapy|Given at the investigator's discretion
75790968|NCT02003209|Drug|Carboplatin|Given IV
75790969|NCT02003209|Other|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
75790970|NCT02003209|Drug|Docetaxel|Given IV
75790971|NCT02003209|Drug|Goserelin Acetate|Given SC
75790972|NCT02003209|Other|Laboratory Biomarker Analysis|Correlative studies
75790973|NCT02003209|Biological|Pertuzumab|Given IV
75790974|NCT02003209|Other|Quality-of-Life Assessment|Ancillary studies
75790975|NCT02003209|Procedure|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
75790976|NCT02003209|Biological|Trastuzumab|Given IV
75790977|NCT02003209|Radiation|Whole Breast Irradiation|Undergo whole breast irradiation
75790978|NCT01866540|Drug|FLUENZ|live attenuated influenza vaccine
75927171|NCT03316352|Device|Ultrasound|A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).
75333596|NCT01890668|Other|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
75642673|NCT05136170|Other|Vehicle|One drop of the placebo will be instilled in both eyes TID
75927172|NCT03316352|Drug|0.5% heavy bupivacaine|During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
75927173|NCT02187549|Device|HYMOVIS|Intra-articular injection
75333597|NCT01890902|Drug|Ketoprofen 10% Cream|
75333598|NCT01890902|Drug|Placebo|
75927174|NCT02187549|Device|Placebo|Intra-Articular Injection
75927175|NCT02484560|Drug|Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell|
75927176|NCT02030301|Biological|VCL-HB01|Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
75333599|NCT04423926|Drug|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1~d10# 21days a cycle
75927177|NCT02030301|Biological|VCL-HM01|Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
75927178|NCT02030301|Biological|PBS|Phosphate-buffered saline
75927179|NCT02484482|Drug|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
75333600|NCT04423926|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
75333601|NCT04423926|Drug|Doxorubicin|Doxorubicin 50 mg/m2 d1
75333602|NCT04423926|Drug|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
75333603|NCT04423926|Drug|Prednisolone|Prednisolone 60mg/m2 d1-5
75333604|NCT03979066|Drug|Atezolizumab|840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
75333605|NCT03979066|Drug|PEGPH20|PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
75333606|NCT05021432|Other|Virtual reality training group|This group will receive video based games
75333607|NCT05021432|Other|Circuit Training group|They will receive Task-oriented Circuit training exercise program
75333608|NCT03968848|Drug|acalabrutinib|A 50-mg single oral dose of acalabrutinib will be administered.
75333609|NCT05494086|Procedure|DPLDG|Dual-port laparoscopic distal gastrectomy
75333610|NCT05494086|Procedure|LDG|Laparoscopic distal gastrectomy
75333611|NCT02829242|Device|NIRS Monitoring (SenSmart Monitor)|
75333612|NCT01484314|Drug|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
75642674|NCT05118724|Drug|Atezolizumab|Atezolizumab 840mg i.v., on Day 1 and Day 15 (q2w) of every 28-day treatment cycle for a total of 12 cycles (24 doses)
76082536|NCT03395964|Procedure|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
75642678|NCT05097820|Device|Placement of testicular prosthesis|The surgical implantation of one or two testicular prostheses on request of the patient
75790979|NCT01811394|Radiation|protons|Treatment is performed using 16 x 4 GyE protons
75790980|NCT01811394|Radiation|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
75790981|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide|
75642679|NCT05093868|Device|Electrographic Flow Mapping|Electrographic Flow Mapping will be collected
75642680|NCT05066165|Genetic|Arm 1: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
75642681|NCT05066165|Genetic|Arm 2: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
75642682|NCT05044286|Other|no intervention|no intervention
75642685|NCT05028751|Drug|Lanraplenib|Orally via tablets
75642686|NCT05028751|Drug|Gilteritinib|Orally via tablets
75642687|NCT05018507|Other|Data collection only|No intervention, just data collection from system machines
75790982|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib|
75790983|NCT01708941|Biological|Ipilimumab|Given IV
75790984|NCT01708941|Other|Laboratory Biomarker Analysis|Correlative studies
75790985|NCT01708941|Biological|Recombinant Interferon Alfa-2b|Given IV or SC
75927180|NCT02187627|Drug|[11C]RO6924963|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6924963 injected will be </=10 micrograms (mcg), injection volume </=20 milliliters (mL). Target injected activity for [11C]RO6924963 will be 370-740 megabecquerel (MBq) [10-20 millicurie (mCi)].
76082537|NCT03397680|Diagnostic Test|13C Urea Breath Test|After the H.pylori eradication treatment course completed, participants then was tested with 13C Urea Breath Test to confirm treatment effectiveness at least after ceasing PPI and antibiotics for 4 weeks.
76082538|NCT01397656|Procedure|CPR using 30:2 ratio|Participants will begin performing CPR using a ratio of 30 compressions to 2 ventilations. Participants will then cross over to the other intervention and use continuous compressions.
75333613|NCT05023148|Procedure|Electroacupuncture|Stimulating acupoints using electric stimulator
75333614|NCT05023148|Procedure|Thread embedded acupuncture|Stimulating acupoints using thread embedded
75642688|NCT04994613|Other|Sensory adaptive environment|A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
75642689|NCT04991935|Drug|CC-93538|CC-93538
75642690|NCT04991480|Drug|ART4215|Participants will receive ART4215 by mouth daily in 21-day cycles.
75790986|NCT01652235|Device|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
75790987|NCT01580826|Other|pasteurization of mother's own milk|mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
75790988|NCT01495676|Other|Radiation + cisplatin|"RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.~A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.~In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.~In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study."
75927181|NCT02187627|Drug|[11C]RO6931643|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6931643 injected will be </=10 mcg, injection volume </=20 mL. Target injected activity for [11C]RO6931643 will be 370-740 MBq (10-20 mCi).
75927182|NCT02187627|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [18F]RO6958948 injected will be </=10 mcg, injection volume </=20 mL. Target injected activity for [18F]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of [18F] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection.
75927183|NCT02484638|Drug|CSL689|Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
75927184|NCT02484638|Drug|Eptacog alfa (activated)|Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
75642691|NCT04991480|Drug|Talazoparib|Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
75927185|NCT02187705|Drug|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
75927186|NCT03317912|Drug|Lidocaïne 2%|Continuous infusion during per and postoperative periods
75927187|NCT03317912|Drug|Placebo (for Lidocaïne)|Continuous infusion during per and postoperative periods
76082539|NCT01397656|Procedure|CPR using continuous compressions|Participants will begin performing CPR using continuous chest compressions. Participants will then cross-over to the other intervention arm and perform CPR using a ratio of 30 compressions to 2 ventilations.
75333615|NCT05493930|Other|The hospital where the treatment is performed|
75333616|NCT03020446|Device|Sorbion Dressing|Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
75333617|NCT01459952|Dietary Supplement|Rose hip Liquid|Rose hip Liquid, 20 ml BID
75642692|NCT04991480|Drug|Niraparib|Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
75642693|NCT04991467|Behavioral|CARE Program and Valera Application with care manager functionality|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.
75927188|NCT02183961|Other|Restech|
75927189|NCT02183961|Other|Peptest|
75927190|NCT02183961|Other|Detection of pepsin in adenoid specimen|
75333618|NCT01479010|Drug|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
75333619|NCT01452074|Other|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
75642694|NCT04991467|Behavioral|Valera Application with care manager functionality|Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.
75642695|NCT04991467|Behavioral|CARE Program|Participant will take part in 12 week CARE program.
75642696|NCT04991467|Behavioral|Valera Application|Participant will receive the Valera health application which will provide parent education materials.
75927191|NCT03321110|Other|Placebo|Placebo (dextrin)
75642697|NCT04991467|Behavioral|CARE Program and Valera Application|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials.
75927192|NCT03321110|Dietary Supplement|Coenzyme Q10|150 mg or 300 mg
75927193|NCT02187939|Other|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
75790989|NCT01495676|Other|Radiation + cisplatin + gemcitabine|"Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.~Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection."
76082540|NCT01330420|Behavioral|Relaxation Response Resiliency Program for Depression|"The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~Examination and reversal of negative thought patterns.~Physical movement, including stretching and yoga.~Healthy eating and other positive lifestyle behaviors.~Goal setting."
76082541|NCT03126942|Device|Novaloc|Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
76082542|NCT03126942|Device|Locator|Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
76082543|NCT01838681|Drug|Placebo|Once daily, tablets, orally
75790990|NCT00915122|Radiation|Dose Escalated IMRT|Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
75790991|NCT00890006|Procedure|Advanced imaging for radiotherapy planning and guidance|Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
75790992|NCT00791115|Procedure|whole-mount sectioning of the prostate|A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
75790993|NCT00762645|Drug|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
75790994|NCT00762645|Drug|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
75790995|NCT00630617|Behavioral|Diet, Physical activity, Physical inactivity|Community based participatory research design
75790996|NCT00274599|Drug|Telmisartan|
75790997|NCT00274599|Drug|Ramipril|
75927194|NCT03317756|Other|Patient Educational Intervention|Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
75790998|NCT00165256|Other|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
75790999|NCT03949686|Drug|Saline Solution|0.5 ml/kg saline
75927195|NCT03317756|Other|Patient Control|Patients will receive an attention control
75927196|NCT03321032|Device|Polymer-free amphilimus-eluting stents|Cre8 Evo coronary stent system (CID, Saluggia, Italy)
75927197|NCT03321032|Device|Biolinx Polymer-based zotarolimus-eluting stents|Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
76082544|NCT01838681|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
76082545|NCT01838681|Drug|ADT|Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
76082546|NCT03404544|Drug|Carbetocin bolus|Carbetocin 100 mcg intravenous as a bolus (less than 2 sec)
75333620|NCT01452074|Other|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
75333621|NCT01472692|Drug|Febuxostat|80mg PO daily for 8 weeks
75333622|NCT05028764|Diagnostic Test|Buccal Swabs, Blood Draws and Skin Punch Biopsy|Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers
75333623|NCT00378820|Behavioral|Whey without milk minerals|
75333624|NCT00378820|Behavioral|Whey with milk minerals|
75791000|NCT03949686|Drug|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
75791001|NCT03946956|Behavioral|Prebooking|Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
76082547|NCT03404544|Drug|Carbetocin infusion|Carbetocin 100 mcg intravenous as a 10 minutes infusion
75791002|NCT03946956|Behavioral|Pictured invitation|Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
75791003|NCT01105572|Device|Intel Health Guide|An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
76082548|NCT01398280|Drug|Topical aminocaproic acid (ACA) mixed with Vanicream|25% Aminocaproic acid cream twice daily for up to 12 weeks.
76082549|NCT01398280|Drug|Vehicle cream|Vehicle cream moisturizer twice daily for up to 12 weeks
76082550|NCT03403842|Device|Sublingual sufentanil tablet system|Administration of sublingual sufentanil with a PCA
76082551|NCT03403842|Device|Peridural catheter|Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
76082552|NCT03403842|Drug|PCA Morphine|Administration of endovenous morphine with a PCA
76082553|NCT01398982|Drug|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
76082554|NCT01398982|Drug|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
75791004|NCT01105572|Other|Case Management|Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
75927198|NCT04335279|Other|SPIN-CHAT Program|Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
76082555|NCT03394092|Diagnostic Test|Quantitative measurements the changes of IgG glycosylation|Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
75333625|NCT00378820|Behavioral|Casein without milk minerals|
75471748|NCT04356391|Procedure|Pinhole Surgical Technique|For the sites receiving the test technique (Chao Pinhole Surgical Technique) the surgery starts with a small pinhole opening in the alveolar mucosa apical to the mucogingival junction of the affected tooth, the flap is then undermined using special instruments to create a full thickness pouch, followed by extending the pouch horizontally and coronally to undermined the adjacent papilla without incising it and free the flap for its coronal displacement. Then multiple 2x12mm strips of collagen resorbable membrane material (Bio-Gide, Geistlich Pharma AG) are packed under the papilla to secure the flap in a coronal direction. Gentle pressure is applied for 5 minutes to minimize the thickness of the blood clot after each of the procedures. The patients are advised to brush all teeth and sites except the buccal surfaces of the operated-on teeth, which are to be cleaned with 0.12% Chlorhexidine mouth rinse.
75927199|NCT03320954|Behavioral|Anomia treatment|Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
75927200|NCT02488850|Procedure|Surgery|
75927201|NCT02488850|Radiation|SABR|
75927202|NCT02188017|Drug|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
75927203|NCT03317600|Device|Lidocaine|Intervention is a nerve block with Lidocaine 2% with Adrenaline.
75927204|NCT03317600|Drug|Placebo|"Intervention is a placebo nerve block with isotonic saline"
75927205|NCT02184117|Drug|Adenosine|Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
75927206|NCT02184117|Drug|Contrast Media|"Intracoronary injection of contrast medium to induce hyperemia for contrast FFR"
75927207|NCT02184117|Drug|Resting conditions|Baseline measurement of aortic and coronary pressures
75927208|NCT02486354|Drug|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
75927209|NCT02184273|Drug|Magnesium metamizol|
75927210|NCT02184273|Drug|Placebo|
75333626|NCT00378820|Behavioral|Casein with milk minerals|
75471749|NCT04335968|Drug|Melatonin 4 mg|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery.
75927211|NCT02486198|Drug|placebo|"For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
75471750|NCT04335968|Drug|Placebo oral tablet|placebo of this drug with the same schedule, during the same period of time.
75471751|NCT04332796|Drug|Chorhexidine scrub|Chorhexidine scrub was given to patients for 4 weeks
75471752|NCT04332796|Device|ZnO-NPs socks|ZnO-NPs socks was given to patients for 4 weeks
75333627|NCT01891136|Drug|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
75333628|NCT01891214|Other|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)|
75333629|NCT05020808|Dietary Supplement|NEAA|Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
75333630|NCT05020808|Dietary Supplement|PPI|Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
75333631|NCT02558400|Drug|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
76082556|NCT02203162|Device|electronic cigarette exposure|30 puffs of a disposable electronic cigarette, 30 seconds apart.
76082557|NCT04589897|Device|Manuka honey sinus rinse|Will follow a modified NHS nasal rinse protocol with the addition of manuka honey
76082558|NCT04589897|Device|Standard sinus rinse|will follow the standard NHS nasal rinse protocol
76082559|NCT04290000|Other|additional biological samples during CAR-T CELL treatment|"Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~Apheresis sampling~CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure."
75791005|NCT04061382|Procedure|Venepuncture|"One study visit will be conducted by research study staff and blood sampling will be carried out.~Up to three follow-up visits will be conducted for a percentage of participants, where additional blood samples will be collected. The blood sample will initially focus on looking at population immunity to diphtheria, group C invasive meningococcal disease and SARS-CoV-2."
75791006|NCT04061382|Procedure|Oral fluid swab|Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.
75791007|NCT03949842|Drug|Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists|A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
75791008|NCT03949842|Drug|Fluticasone furoate/umeclidinium/vilanterol|The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
75791009|NCT01584960|Behavioral|endurance training|2 years of home-based endurance training
75927212|NCT02486198|Drug|GM|"For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
75927213|NCT02486198|Drug|oxaliplatin-based chemotherapy|chemotherapy contains oxaliplatin
75927214|NCT03536013|Other|Other: Full-thickness placental allograft|A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.
75333632|NCT02558400|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
75333633|NCT02558400|Drug|Latanoprost Ophthalmic Solution 0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
75333634|NCT02825264|Device|STARflo Implant|All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
75471753|NCT04332796|Combination Product|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks was given to patients for 4 weeks
75927215|NCT03316040|Behavioral|JIC|"The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older."
75927216|NCT02188173|Drug|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
75927217|NCT03535935|Drug|Astragalus Powder|"3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.~Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week."
75471754|NCT04328181|Device|Spectral Photon Counting Computed Tomography (SPCCT)|"For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:~Tube potential 120 kVp;~Tube current time product of 150 mAs;~Gantry revolution time 0.33 s;~Automatic exposure control (angular and longitudinal) combined xyz-axis;~Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;"
75471755|NCT04328181|Device|DECT (Dual Energy CT)|"The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:~Base platform : iCT scanner~Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp~Tube current (mA) : 10 - 300~Spatial Resolution : > 30 lp/cm, ≤ 250 µm~Z-coverage isocenter (mm) : 20 mm~FOV (mm) : 500~Minimum rotation time : 0.33 s/rotation~Acquisition modes : Axial, Helical, Step & Shoot"
75333635|NCT05493696|Device|Antigravity treadmill|Alter G training for 30-minute, 3 times/week, 75% body weight
75333636|NCT05493696|Other|Traditional physical therapy program|applied 3 times/week for 12 weeks
75333637|NCT02352818|Other|no study intervention|
75333638|NCT04359732|Other|hybrid PET/MRI|An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
75333639|NCT04758260|Dietary Supplement|Antioxidant|Oral antioxidant oral intake in the 3 months prior to inclusion in the study
75333640|NCT01446250|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
75333641|NCT01446250|Drug|Boceprevir|BOC 800 mg (4 x 200 mg soft gel capsules) administered orally
75927218|NCT03535935|Other|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
76082560|NCT05167188|Other|no intervention|no intervention
76082561|NCT04447560|Procedure|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol and two researchers will measure the radius and area of those vessels separately. Researchers who are measuring the radius and area of vessels won't know whether those images belong to pre or post- ESP block. The results two researchers measure will be compared statistically and if there are no statistically significant differences, the mean value of their separate recordings will be taken into account for the statistical analysis.
76082562|NCT03394014|Procedure|sciatic nerve block|blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
76082563|NCT03401970|Behavioral|Acellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
76082564|NCT03401970|Behavioral|Cellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
75333642|NCT01446250|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
75642698|NCT04975698|Biological|HST-NEETs|HST-NEETs are manufactured from an autologous peripheral blood or MNCs via apheresis collection and will be administered as a single intravenous (IV) infusion of 2x10^7/m^2 cells between 3 Days and 7 Days post-ASCT.
75333643|NCT01446250|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
75642699|NCT04975698|Biological|Bone Marrow Transplant|Day 0 is the day of bone marrow transplantation.
75642700|NCT04972123|Drug|CPC - Capsaicin, Phenylephrine, Caffeine|CPC is a combination of Capsaicin, Phenylephrine and Caffeine
75642701|NCT04972123|Diagnostic Test|Tilt Table Test|Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).
75642702|NCT04972123|Drug|Placebo|Placebo for CPC
75642703|NCT04965909|Other|Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.|Online group therapeutic program (small groups), applied for 3 months.
75642704|NCT04958239|Drug|BI 765179|BI 765179
75642705|NCT04958239|Drug|Ezabenlimab|Ezabenlimab
75791010|NCT01103856|Behavioral|Patient Mentor Intervention|The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
75333644|NCT05493618|Drug|Pembrolizumab|Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
75333645|NCT05493618|Drug|Belantamab mafodotin|Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
75333646|NCT05493618|Drug|Dexamethasone|Dexamethasone 40 mg IV q3 weeks (20 mg if patient >75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
75333647|NCT00379600|Drug|rosiglitazone XR|
75333648|NCT02936206|Drug|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
75642706|NCT04935359|Drug|NIS793|Concentrate for solution infusion (Liquid in Vial)
75642707|NCT04935359|Drug|Nab-paclitaxel|Per locally approved formulation
75642708|NCT04935359|Drug|Gemcitabine|Per locally approved formulation
75642709|NCT04935359|Drug|Placebo|Dextrose 5% in water (D5W) solution for infusion
75642710|NCT04925752|Drug|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
75642711|NCT04925752|Drug|F/TDF|Tablets administered orally
75642712|NCT04925752|Drug|Sub-cutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
75642713|NCT04925752|Drug|Placebo SC LEN|Administered via SC injections
75642714|NCT04925752|Drug|PTM F/TDF|Tablets administered orally
75642715|NCT04925752|Drug|PTM Oral LEN|Tablets administered orally
75642716|NCT04925752|Drug|F/TAF (for US participants only)|F/TAF tablets administered orally once daily
75642717|NCT04917796|Device|Electroacupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
75651859|NCT05149378|Drug|Venetoclax combined with azacitidine regimen|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
75791011|NCT01103856|Behavioral|HIV transmission risk reduction|The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
75642718|NCT04917796|Device|Sham Acupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
76082565|NCT03401970|Behavioral|Low-carbohydrate high-fat diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
76082566|NCT01427296|Drug|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
76082567|NCT01427296|Drug|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
75791012|NCT01102608|Drug|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
76082568|NCT03126162|Procedure|InstilIing normal saline into bladder|Backfilling the bladder with 200 mL of normal saline immediately postoperatively, prior to foley catheter removal, after same-day total laparoscopic hysterectomy can potentially increase time to first spontaneous void and time to discharge.
75791013|NCT01105728|Procedure|Endoscopic resection|Endoscopic resection of the gastric subepithelial mass
76082569|NCT03126162|Procedure|Removal of foley catheter|Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
75791014|NCT01321736|Dietary Supplement|dietary fiber|mixture of fiber sources added to liquid nutrition product
75791015|NCT01105806|Behavioral|(CPR) video and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
76082570|NCT03401736|Device|Mechanical Ventilation|Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
76082571|NCT03401736|Drug|Midazolam|The impact of Midazolam on the diversity of intestinal microbiota.
76082572|NCT03401736|Drug|Dexmedetomidine|The impact of dexmedetomidine on the diversity of intestinal microbiota.
76082573|NCT02203786|Drug|Haloperidol|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol."
76082574|NCT02203786|Drug|Fluphenazine|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine."
76082575|NCT02203786|Drug|Dexedrine|"Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine."
76082576|NCT02203786|Drug|Placebo|"Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1."
75333649|NCT02936206|Drug|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
75333650|NCT01891526|Drug|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
75642719|NCT04896008|Drug|Sotatercept|Sotatercept is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
75333651|NCT01426516|Device|Genecept Assay|Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
75642720|NCT04896008|Other|Placebo|Placebo
76082577|NCT02203786|Behavioral|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
75642721|NCT04895709|Drug|BMS-986340|Specified dose on specified days
76082578|NCT03009058|Biological|IMM-101|A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
76082579|NCT03009058|Drug|Gemcitabine|Standard of Care chemotherapy
76082580|NCT03009058|Drug|Nabpaclitaxel|Standard of Care chemotherapy
75642722|NCT04895709|Drug|BMS-936558-01|Specified dose on specified days
75333652|NCT01891604|Dietary Supplement|breast milk with Bifidobacterium Longum subp. Infantis R0033|
75333653|NCT01891604|Dietary Supplement|breast milk|
75642723|NCT04895709|Drug|Docetaxel|Specified dose on specified days
75333654|NCT05493462|Drug|Human FGF-1|Intranasal administration of human FGF-1
75642724|NCT04884035|Drug|CC-220|CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
75642725|NCT04884035|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
75642726|NCT04884035|Drug|Cyclophosphamide|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
75471756|NCT04277507|Device|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
75791016|NCT01105806|Behavioral|cardiopulmonary resuscitation (CPR) narrative script and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
75927219|NCT03315884|Procedure|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)|"Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used."
75791017|NCT01102686|Drug|Pyrimethamine|Pyrimethamine will be taken orally as a single daily dose of 25 mg/day for 4 weeks, then increasing by 25 mg per dose in three four-week steps, to a final dose of 100 mg/day
75642727|NCT04884035|Drug|Doxorubicin|Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
75927220|NCT03315884|Procedure|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch|Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
75642728|NCT04884035|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
75791018|NCT01102686|Drug|Leucovorin|To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
75791019|NCT03949296|Behavioral|Mindfulness Intervention|"10-session program~Introduction to mindfulness and its potential benefits~Introduction to mindful practices and yoga poses~Conditioned reactions to stress; integrating mindfulness into everyday life~Challenges and insights gained in practicing mindfulness~Using mindfulness to observe and reduce negative means of reacting to stress, and find more effective responses~Reacting vs. responding to stressors~Self-regulation and coping with stressors and communication challenges~Fostering continuity of moment-to-moment awareness while practicing different forms of mindfulness~Choosing and creating one's own blend of mindfulness practices~Maintaining momentum to practice mindfulness once the program ends"
75791020|NCT03949296|Behavioral|Sleep Hygiene|"Session includes a handout with15 sleep hygiene tips:~Maintain a regular sleep pattern~Only try to sleep when feeling tired or sleepy~If unable to sleep, do something calm until feeling tired and returning to bed~Avoid caffeine & nicotine for 4-6 hours before going to bed~Avoid alcohol for 4-6 hours before going to bed~Use the bed only for sleeping and sex~Avoid naps during the day~Develop rituals to get relaxed and ready to sleep~Try a hot bath prior to bedtime~Avoid checking the clock during the night~Use a sleep diary for a few weeks to track progress~Avoid strenuous exercise before bedtime~Avoid a heavy meal before bedtime~Create a sleep environment that is quiet, comfortable, and dark~Maintain a regular daytime routine"
75927221|NCT02184351|Drug|Roxanes's clotrimazole troches|
75927222|NCT02184351|Drug|Mycelex® troches|
75927223|NCT02188251|Dietary Supplement|Activamp|
75927224|NCT02188251|Other|Placebo|
75927225|NCT03320798|Other|Data record|
76082581|NCT03009058|Drug|Capecitabine|Standard of Care chemotherapy
75471757|NCT04262024|Drug|cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education|Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)
75642729|NCT04884035|Drug|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
75642730|NCT04884035|Drug|CC-99282|CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
75642731|NCT04884035|Drug|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
75642732|NCT04884035|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
75791021|NCT05500404|Diagnostic Test|Ultrasound measurment of placental thickness|The maximum placental thickness in the lower uterine segment will obtained using trans-abdominal ultrasound scan. For the image to be deemed suitable, a midline sagittal section of the lower uterine segment (with the implanted placenta) and the cervical canal, with the intervening urinary bladder will be required (Bhide et al., 2019). The measurement will be performed by a researcher who will be blinded to the final diagnosis.
75927226|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
75927227|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
76082582|NCT03009058|Drug|Folinic Acid|Standard of Care chemotherapy
76082583|NCT03009058|Drug|Fluorouracil|Standard of Care chemotherapy
76082584|NCT03009058|Drug|Irinotecan|Standard of Care chemotherapy
75642733|NCT04872738|Other|Survey|Patients in all groups will complete surveys about their decision to receive or not to receive the COVID-19 vaccine. For those who did receive the vaccine, they will indicate their experience with the vaccination and any side effects they may have experienced.
76082585|NCT03009058|Drug|Oxaliplatin|Standard of Care chemotherapy
76082586|NCT03009058|Biological|cetuximab|Standard of Care immunotherapy
75791022|NCT05499468|Other|Popular-Opinion Leader-led encouragement during training meetings and informal conversation|Investigators adapted evidence-based principles from the Popular Opinion Leader framework to increase utilizations of existing one-on-one emotional support resources for physicians-in-training at Stanford (an effective HIV prevention intervention developed by the CDC for changing social norms and reducing behavioral risk factors led by influential members of a community, trained to promote behavior change). All intervention activities designed to encourage utilization were delivered as part of health promotion during pre-existing clinical training meetings and no data was collected during these workshops. Identified POLs were recruited and trained to encourage their colleagues to use existing support resources and engage in two 30-60 minute workshops scheduled to occur during training meetings.
75927228|NCT02184429|Drug|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
75927229|NCT02184429|Drug|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
75927230|NCT02184429|Drug|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
75927231|NCT02184429|Drug|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
76082587|NCT03009058|Biological|Anti-PD1|Standard of Care immunotherapy
76082588|NCT03009058|Biological|Ipilimumab|Standard of Care immunotherapy
76082589|NCT03009058|Drug|Cyclophosphamide|Standard of Care chemotherapy
75333655|NCT02983136|Behavioral|Dialogue and inter-professional learning|"The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice."
75791023|NCT03949374|Drug|CRESTOR, reference formulation of rosuvastatin|Use of ROVASRO for hypercholesterolemia
75791024|NCT03949374|Drug|ROVASRO, generic formulation of rosuvastatin|Use of CRESTOR for hypercholesterolemia
75471758|NCT04262024|Drug|cabergoline 1.5-2 mg/week).orally daily for 1 month without health education|Women with hyperprolactiemia scheduled for cabergoline 1.5-2 mg/week).for one month will not be offered health education (group B)
75791025|NCT05626374|Behavioral|Basic Case Management|Usual case management support during 12-week training program
75791026|NCT05626374|Behavioral|Basic Case Management plus Distress Tool|Usual case management support during 12-week training program plus daily self-reports of distress using Distress Thermometer tool
75791027|NCT05626374|Behavioral|Basic Case Management plus rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus rapid access referral process for healthcare crisis services
75791028|NCT05626374|Behavioral|Basic Case Management plus Distress Tool and rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus daily distress self-reports plus rapid access referral process for healthcare crisis services
75791029|NCT01104012|Biological|"Classification as asthmatic or rhinitis only via proteomic analysis"|Proteomic profiles are established for each patient using plasma and serum samples
75791030|NCT01104012|Biological|"Classification as asthmatic or rhinitis only according to a metacholine test"|A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
75927232|NCT02184429|Drug|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
75927233|NCT03315806|Other|Beetroot juice|140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
75791031|NCT03949530|Drug|IDL-2965 Oral Capsule|Investigational drug
75791032|NCT03949530|Drug|Placebos|Placebo
75791033|NCT05626140|Drug|Lacosamide 50 MG Oral Tablet [Vimpat]|Oral tablet lacosamide is a 3rd generation anti convulsant drug. it is given in a dose of 50 mg 12 hourly for 15 days. It has a longer half life than the other two drugs in comparison and fewer drug interactions as it doesnot interact with the hepatic cytochrome enzymes.hence it is seen to have better pharmacokinetics and pharmacodynamics than the other drugs in study
75927234|NCT03315806|Other|Placebo|140 mL of beetroot juice isent of nitrate
75927235|NCT03317366|Drug|ARQ 092|Open-label expanded access for ARQ 092 capsules
75927236|NCT02030379|Behavioral|QPL-CT|Use the QPL-CT to prioritize questions
75927237|NCT03320720|Other|Home Treatment|Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
76082590|NCT01611857|Drug|Tivantinib|Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
76082591|NCT01611857|Drug|FOLFOX|The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m^2, 5-FU continuous IV 2400 mg/m^2 over 46 hours, leucovorin 400 mg/m^2 IV, and oxaliplatin 85 mg/m^2.
76082592|NCT03393858|Drug|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
76082593|NCT03393858|Biological|DC-CIK Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured DC-CIK cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
76082594|NCT03393858|Device|Thermotron RF-8EX|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week since the 1st week of pembrolizumab for a total of 10 times.
75642734|NCT04857476|Diagnostic Test|Ultrasound scan|"Psoriasis epidemiology screening tool (PEST) score for completion Brief questionnaire about current psoriasis symptoms, current treatment and if any features associated with psoriatic arthritis.~One-off musculo-skeletal ultrasound Questionnaire at 2 years"
75791034|NCT05626140|Drug|Codeine Phosphate|Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
75791035|NCT05626140|Drug|Diclofenac Sodium|Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
75791036|NCT03949452|Other|Subcostal Transversus Abdominis Plane catheter|"Prior to surgery, an ultrasound guided unilateral Subcostal Transversus abdominis plane bolus dose (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) will be given on the same side of the surgical incision.~At the end of surgery, A Transversus abdominis plane catheter will be inserted unilaterally by surgeon during wound closure. Then postoperatively, Transversus abdominis plane infusion of a solution mixture prepared in multiple 50 cm syringes each syringe contain 20 ml bupivacaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivacaine is 0.2%). This solution mixture will be infused through Transversus abdominis plane catheter at a rate of 6 ml/hour for 72 hours postoperatively."
75791037|NCT03949452|Other|Epidural catheter|"Prior to surgery, we will site an epidural catheter in the thoracic T7-T9 region, and inject an epidural bolus dose same as described above (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) for intra operative analgesia.~Postoperatively, patients will receive epidural infusion of the solution mixture (same as described above) prepared in multiple 50 cm syringes each syringe contain 20 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivaccaine is 0.2%). This solution mixture will be infused epidurally at a rate of 6 ml/hour for 72 hours (3 days) postoperatively."
75791038|NCT03764774|Drug|LY3463251|Administered SC
76082595|NCT03393702|Drug|Gabapentin|"Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin.~Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day."
76082596|NCT03393702|Drug|Placebo|"Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.~Patients after surgery receive identical placebo capsules 2 times per day."
76082597|NCT02204176|Other|Exercise info|"Discussion:~benefits of exercise~types of exercise~exercise guidelines~components of an exercise session~how to reduce risk of injuries"
76082598|NCT02204176|Other|Implementation intentions|"Discussion of:~barriers to exercise and how to address/overcome barriers~how to create detailed exercise plans"
76082599|NCT02204176|Other|Industriousness|"Discussion of:~realistic monitoring of efforts related to exercise~reaching and pushing past thresholds for sustained effort for exercise"
76082600|NCT02204176|Device|pedometer|
76082601|NCT03399864|Behavioral|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
76082602|NCT03399864|Other|usual care|The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
76082603|NCT01829477|Drug|TAK-875|TAK-875 50 mg tablets
76082604|NCT01829477|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
76082605|NCT01829477|Drug|Glimepiride|Glimepiride tablet.
76082606|NCT02204566|Device|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
76082607|NCT03126864|Procedure|Leukapheresis|After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10^9 (expected range 5 x 10^8 - 5 x 10^10), for up to two days.
76082608|NCT03126864|Drug|Fludarabine|25 mg/m2 administered by vein on Days -5 to -3.
76082609|NCT03126864|Drug|Cyclophosphamide|900 mg/m2 administered by vein on Day -3.
76082610|NCT03126864|Biological|CD33-CAR-T Cell Infusion|CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is > 1.5 x 105/kg but ≤ 4.5 x 105/kg.
76082611|NCT03399708|Drug|Apremilast 30mg|Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.
76082612|NCT03399630|Other|Injection of Autologous Adipose Tissue|Injection of Autologous Adipose Tissue to study the safety and efficacy of treating osteoarthritis
76082613|NCT03399630|Other|Injection of lactated ringers|Injection of placebo lactated ringers to compare against the injection of autologous adipose tissue.
76082614|NCT03395730|Drug|Intraumbilical vein injection oxytocin|intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
76082615|NCT03395730|Procedure|placental cord drainage|placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
76082616|NCT03395730|Procedure|Expectant managment of 3rd stage of labour|Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
75642735|NCT04846400|Device|ssNPA|The ssNPA is a self-supporting nasopharyngeal airway, a stent that is a non-surgical alternative to treat severe OSA
75642736|NCT04839497|Combination Product|Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees|Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.
75791039|NCT03764774|Drug|Placebo|Administered SC
75927238|NCT03320720|Other|Treatment-as-usual|Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
76082617|NCT01334086|Drug|Aprepitant|Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
75927239|NCT02484170|Drug|Mannitol cream|Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
75927240|NCT02484170|Drug|Placebo|Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
76082618|NCT03399474|Drug|Lidocaine Hydrochloride 2%|Lidocaine Hydrochloride 2%
76082619|NCT03399474|Drug|Dexmedetomidine 0.5 ug/kg|pecedex
76082620|NCT03399474|Drug|Dexmedetomidine Injection 0.25 ug/kg|pecedex
76082621|NCT01611155|Drug|venlafaxine|Given PO
75927241|NCT02188407|Drug|Sevoflurane|MAC 3-5 V% during surgery
76082622|NCT01611155|Drug|placebo|Given PO
76082623|NCT01611155|Other|questionnaire administration|Ancillary studies
76082624|NCT01611155|Other|quality-of-life assessment|Ancillary studies
76082625|NCT01430182|Drug|Methadone|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
76082626|NCT01430182|Drug|Morphine|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
76082627|NCT05166408|Procedure|Buccinator myomucosal flap|Buccinator myomucosal flap for primary cleft palate palatoplasty
76082628|NCT05166408|Procedure|Bardach two flap palatoplasty|Bardach two flap palatoplasty
75791040|NCT03944850|Behavioral|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions. A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body. Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal. Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
75791041|NCT04878042|Device|Hydrogen peroxide|Mouth wash and nasal spray 3 times a day for 3 days
75927242|NCT02188407|Drug|Propofol|Propofol group (P group)- The group anaesthesied with propofol
75927243|NCT02484326|Other|Grouping by different risk stratification|A simple risk score system based on 7 baseline clinical variables divided patients into four groups
75927244|NCT02188563|Other|Comprehensive smoking cessation intervention|
75927245|NCT02188563|Behavioral|Enhanced usual care|
75927246|NCT02184507|Dietary Supplement|Supplement pre CABG|One sachet of the supplement was consumed daily for 7 days before surgery.
75927247|NCT02184507|Dietary Supplement|Supplement post CABG|One sachet of the supplement was consumed daily for 30 days after surgery
76082629|NCT05097768|Drug|Dexamethasone 0.5mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
75927248|NCT02184507|Dietary Supplement|Supplement pre and post CABG|One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
75927249|NCT02184507|Drug|Placebo|One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
76082630|NCT05097768|Drug|Ketorolac 10 Mg Oral Tablet|The patients will be randomly given the medication by mouth 60 min before administering IANB.
76082631|NCT05097768|Drug|Meloxicam 7.5 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
76082632|NCT05097768|Drug|Ibuprofen 600 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
76082633|NCT05097768|Drug|Placebo|The patients will be randomly given the medication by mouth 60 min before administering IANB.
76082634|NCT01829243|Drug|Milnacipran|
75791042|NCT04878042|Device|Placebo|Mouth wash and nasal spray 3 times a day for 3 days
75791043|NCT04813614|Device|STYLAGE M Lidocaine|Injection in the lips
75927250|NCT03317210|Drug|iron sucrose (200 mg VENOFER®)|According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.
75927251|NCT03317210|Drug|recombinant human erythropoietin (10,000 U EPREX®)|According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.
75927252|NCT02184585|Drug|Treatment sequence A|FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
75927253|NCT02184585|Drug|Treatment sequence B|FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
75927254|NCT02184585|Drug|Treatment sequence C|Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
75927255|NCT03317132|Behavioral|IPS|One year of IPS Support
76082635|NCT01829243|Drug|Placebo|
76082636|NCT03393312|Device|Transcranial direct current stimulation (tDCS)|Electric current
76082637|NCT01838447|Dietary Supplement|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
76082638|NCT03395574|Drug|Terlipressin|drug will be given after 30 minutes of induction of anesthesia
76082639|NCT03395574|Drug|Normal saline|drug will be given after 30 minutes as placebo in control group
76082640|NCT03395496|Drug|Biodentine|Biodentine pulpotomy agent
76082641|NCT03395496|Drug|ProRoot (Aggregate)|ProRoot MTA pulpotomy agent
76082642|NCT03399240|Device|Vitasitiq device|Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
75471759|NCT04255849|Biological|9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|Gardasil-9 HPV vaccine
75791044|NCT04813614|Device|Active control group|Injection in the lips
75642737|NCT04835233|Drug|Methyldopa 250 MG|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
75642738|NCT04827953|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
75642739|NCT04827953|Drug|Nab paclitaxel|Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
75642740|NCT04827953|Drug|NLM-001|NLM-001 will be administered three cycles consecutively followed by two rest cycles.
75642741|NCT04827953|Drug|Zalifrelimab|Zalifrelimab administration each 6 weeks.
75927256|NCT02188641|Other|Diet|
75642742|NCT04772079|Drug|Deucravacitinib|Specified dose on specified days
75642743|NCT04772079|Other|Placebo matching deucravacitinib|Specified dose on specified days
75642744|NCT04758533|Biological|AloCELYVIR|Mesenchymal allogenic cells + ICOVIR-5: 500.000 cells/kg
75642745|NCT04756232|Drug|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
75791045|NCT01106118|Drug|Vardenafil (Levitra, BAY38-9456)|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
75791046|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
75927257|NCT02188641|Other|Exercise|
76082643|NCT01829165|Device|rTMS Treatment|MRI-compatible TMS stimulator
76082644|NCT01829165|Device|Sham rTMS Treatment|
76082645|NCT04982172|Drug|Infliximab|Infliximab (Inflectra® [Pfizer]), dosage determined using model-informed precision dosing, intravenously administered
76082646|NCT04982172|Drug|Infliximab|Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
76082647|NCT04592471|Device|kneeMID500-STRONG700|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (2 device types: Knee MID 500 and Knee STRONG 700) totalling 60 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
75333656|NCT04325568|Behavioral|PsyGist and Clinician Manual|This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
75333657|NCT02819908|Drug|Imprimis Dropless|Tri-Moxi-Vanc transzonular intravitreal injection
75791047|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
75791048|NCT01327872|Drug|E5501 40mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
75927258|NCT02188641|Other|Diet and Exercise|
75927259|NCT02188641|Other|Healthy Lifestyle (Control) Group|
75927260|NCT02488772|Device|Sleep mask|
75333658|NCT02819908|Drug|Imprimis Less Drops|Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
75471760|NCT04255849|Other|Saline Placebo|Saline Placebo
75471761|NCT04237103|Drug|Methotrexate|oral capsules taken once a week
75471762|NCT04237103|Drug|Placebos|Administered identically to the experimental group
75471763|NCT04234724|Other|Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.|Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
75471764|NCT04212325|Procedure|Group C (Continuous sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
75471765|NCT04212325|Procedure|Group S (sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After single injection sciatic nerve block, outcome measures will be assessed.
75642746|NCT04756232|Other|Placebo Comparator Challenge|Matching placebo oral pill administered once
75642747|NCT04755127|Procedure|Arthroscopic synovectomy of the wrist|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
75642748|NCT04755127|Drug|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
75642749|NCT04738942|Drug|Vedolizumab|Vedolizumab 300 mg, IV infusion
75651860|NCT05134857|Drug|Zonisamide|The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
75927261|NCT02488772|Other|Standard of care|Standard of care as decided by treating emergency physician
75927262|NCT02488772|Device|Ear Plugs|
75927263|NCT02188797|Behavioral|Group MI risk reduction program|
75927264|NCT02483780|Behavioral|Storytelling|The intervention will center on stories about living with hypertension, with patients speaking in their own words.
75927265|NCT03536403|Radiation|EOS X-rays|EOS X-rays is done with et without a kyphosis induced corset
75333659|NCT01453010|Other|Self-directed Upper Limb SaeboFlex Training|"Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.~Participants are closely monitored at least once a week by a saebo-trained therapist."
75333660|NCT02678858|Behavioral|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
75333661|NCT02678858|Behavioral|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
75333662|NCT04078230|Procedure|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
75333663|NCT01891682|Other|Observational|Observational, Translational non-treatment study
75333664|NCT01406860|Drug|Droperidol|Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
75333665|NCT01406860|Drug|Metoclopramide + diphenhydramine|Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
75642750|NCT04731298|Drug|Emapalumab|"Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first."
75642751|NCT04722991|Drug|Runcaciguat (BAY1101042)|Oral dose of runcaciguat
75642752|NCT04722991|Other|Placebo|Oral dose of matching placebo
75333666|NCT04138212|Drug|Paclitaxel, Cisplatin|Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
75333667|NCT04138212|Radiation|neoadjuvant chemoradiation therapy|Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d*23
75471766|NCT04210557|Device|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.
75791049|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
75791050|NCT03944694|Diagnostic Test|Delirium assessment.|Full blood count analysis.
75791051|NCT01108692|Other|Telecardiology|"Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups."
75927266|NCT03536403|Other|8-meters walk test|8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
75927267|NCT02488694|Drug|Afatinib|40 mg/d
75471767|NCT04201964|Drug|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
75471768|NCT04198805|Dietary Supplement|Vitamin E [(all-rac)-α-tocopheryl acetate]|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months
75927268|NCT02488694|Drug|Pemetrexed|500 mg/m² i.v. on d1 of each 21-day cycle
75333668|NCT02813954|Device|Blood Gas Sampling|analyzing amniotic fluid by blood gas device
75642753|NCT04676412|Biological|Pembrolizumab|IV infusion
75927269|NCT02188875|Behavioral|SMS Text Messages & Fitbit One|The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
75642754|NCT04676412|Drug|Lenvatinib|oral capsule
75642755|NCT04676412|Drug|Placebo for lenvatinib|oral capsule
75791052|NCT00234065|Drug|Cilostazol|oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
75791053|NCT00234065|Drug|Aspirin|oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
75927270|NCT02188875|Behavioral|Fitbit One Only|Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
75927271|NCT02480192|Other|CBT for Menopausal Symptoms (CBT-Meno)|This 12-week CBT-based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
75333669|NCT05493384|Other|Telerehabilitation Group|The program will include stretching, strengthening, breathing, posture, proprioceptive, relaxation exercises and segmental extremity movements. Each exercise will be performed 10 times in a session for the first 4 weeks and 15 times for the last 4 weeks. Exercises will be performed progressively on the patients.
75471769|NCT04198805|Dietary Supplement|Omega-3 fatty acid (DHA EE)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months)
76082648|NCT04944186|Other|Structured Pressure Injury Patient Education (mySPIPE)|It consists of PI education topics which include four main topics; 1) Pressure Injury: Why Me, which will be covering the basic information that patient need to know about PI; 2) Look After Your Skin, in this topics, patient will be thought about how skin checking was done and why it need to be done; 3) Preventing pressure injury, in this topic, patient will be emphasized on the suitable repositioning for them and the benefit of support surfaces and preventive wound dressing; 4) Help your PI heal, in this topic patient will be guided on what are condition that help PI healing and dietary needs to support wound healing
76082649|NCT04944186|Other|Standard Patient Education|No fixed content/ duration of patient education. Basically, patient repositioning emphasized verbally after wound dressing completed.
75927272|NCT02483858|Drug|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
75927273|NCT03316898|Drug|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
76082650|NCT03393234|Radiation|Interoperative radiation by INTRABEAM using low energy X-ray|Intrabeam is a mobile Platform for Intraoperative Radiotherapy (IORT) produced by the ZEISS company in Germany.Interoperative radiation by INTRABEAM using low energy X-ray.The Intrabeam PRS appears to be a safe technique for delivering IORT in rectal cancer patients.
75791054|NCT04730076|Procedure|Standard Balloon Dilation|The standard approach involves a gradual balloon dilation where the balloon is inflated then held at each balloon size for 30-60 seconds then inflated to the next largest balloon diameter size and repeated to the maximum diameter size of that catheter. The dilation session will be repeated as frequently and as many times as needed to achieve the balloon diameter size of 18mm at the discretion of the endoscopist.
75791055|NCT04730076|Procedure|Progressive Balloon Dilation|In the progressive approach, the balloon is continuously inflated over the course of 3-5 minutes starting at the smallest to the largest balloon diameter depending of the balloon catheter used. The dilation will be repeated every 2-3 weeks (total of 2-3 sessions). At the next endoscopic procedure, the balloon diameter used will be the next size up based on previous session.
75791056|NCT03948126|Other|Questionnaire about geophagia (knowledge about soil/clay consumption and knowledge of the health effects of geophagy)|
75791057|NCT02531711|Other|Diet A|Experimental analgesic dietary intervention
75791058|NCT02531711|Other|Diet B|Healthy comparator diet
75791059|NCT01108848|Biological|Berinert® (C1 Esterase Inhibitor)|Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
75791060|NCT04696458|Dietary Supplement|Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483)|Probiotic Capsules in blister packets of capsules containing the probiotic intervention contain a combination of three strains of lactic acid bacteria: two Lactobacillus plantarum (CECT7484 and CECT7485) and one Pediococcus acidilactici (CECT7483).
75791061|NCT04696458|Other|Placebo Comparator: Placebo|Placebo Capsules in blister packets of capsules containing the inert (controlled) non-interventional treatment.
76082651|NCT01837823|Drug|rosuvastatin|All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
76082652|NCT03393156|Behavioral|Internet-based metacognitive therapy|Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
75333670|NCT02773576|Drug|Risperidone implant|
75791062|NCT04660188|Other|Multidisciplinary collaborative care arm|Study participants will be cared for by a team of healthcare professionals; an oncologist, a PCP and a pharmacist navigator.
75791063|NCT00233987|Drug|carmustine|150 mg/m^2 IV over 2 hours 4, 5, and 6 days before transplant.
75333671|NCT01891058|Device|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
75333672|NCT01891838|Procedure|Volume controlled ventilation|
75333673|NCT01891838|Procedure|Pressure-controlled ventilation|
75333674|NCT05489094|Combination Product|Nutrition Education and Growing Up Milk for 1 - 3 years old|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories. while Intervention product is formulated to deliver macro- and micronutrients as part of the dietary intake for children at 1-3 years old with Iron-C formula
75333675|NCT05489094|Behavioral|Nutrition Education|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories.
75927274|NCT03316898|Drug|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
75927275|NCT03316898|Drug|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
75927276|NCT03316898|Drug|Memantine|Memantine as prescribed by the physician as per standard of care.
75927277|NCT02188953|Drug|ACCS100|ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
75927278|NCT02188953|Drug|Calcium carbonate placebo|
75927279|NCT02030613|Genetic|Blood test|
75927280|NCT03316820|Drug|K0706|Study treatment with water after an overnight fast
76082653|NCT03395262|Dietary Supplement|Active with caffeine|Novel formula with caffeine
76082654|NCT03395262|Dietary Supplement|Active without caffeine|Novel formula without caffeine
75471770|NCT04198805|Combination Product|Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months
75927281|NCT03316820|Drug|K0706|Study treatment with water after food
75927282|NCT02483702|Other|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
76082655|NCT03395262|Dietary Supplement|Placebo|Dextrose placebo
75471771|NCT04198805|Other|Placebo|Matching soybean placebo (3 capsules) of all arms daily for 6 months.
75471772|NCT04179890|Drug|Afatinib (Gi(l)otrif®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
75471773|NCT04179890|Drug|Erlotinib (Tarceva®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
75471774|NCT04179890|Drug|Gefitinib (IRESSA®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
76082656|NCT03852888|Biological|Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level|Each patient will have to complete a total of 8 urine samples after treatment with methotrexate. The 8 samples will be taken over one week (just before taking, then 2 hours after taking treatment and then on D3, D4, D5, D6, D7, D8 before the new dose of methotrexate).
75471775|NCT04179890|Drug|Osimertinib (Tagrisso®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
75333676|NCT01394926|Drug|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
75927283|NCT02483702|Other|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
75927284|NCT02184819|Drug|levosimendan|24 hour continuous infusion at the rate of 0,1 µg/kg/min
75927285|NCT02184819|Drug|Placebo|24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
75927286|NCT02189109|Drug|NVX-108|0.2% emulsion administered i.v.
75927287|NCT02189187|Behavioral|Mindfulness|
75927288|NCT02189187|Behavioral|Psychoeducation|
76082657|NCT03399162|Behavioral|PREHAB Workshop|PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
75333677|NCT05489016|Drug|Yuekang Huoxin Pills (concentrated pills)|Huoxin Pill (concentrated pill) is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Ganoderma, Flos Carthami, artificial Moschus, cultured calculus bovis in vitro, Fel Ursi, Margarita, Venenum Bufonis, and Borneolum Syntheticum. It has the effect of invigorating qi and promoting blood circulation. It has been marketed in China for more than 30 years. Clinical studies have shown that Huoxin Pill (concentrated pill) has significant clinical efficacy in improving the symptoms and prognosis of coronary heart disease and angina pectoris. Basic studies have also confirmed that Huoxin Pill (concentrated pill) can play a role in myocardial protection by dilating coronary arteries and promoting angiogenesis. It produced by Guangzhou yuekang biopharmaceuticals co., ltd.
75333678|NCT05489016|Drug|Yuekang Huoxin Pills (concentrated pills)simulant|Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
75471776|NCT04179890|Drug|Afatinib (Gi(l)otrif®)|As first line therapy.
75471777|NCT04179890|Drug|Osimertinib (Tagrisso®)|In the case the T790M resistance mutation was developed (second line therapy).
75471778|NCT04178668|Other|Oral mucosa and saliva samples|one oral mucosa sample and one saliva sample
75927289|NCT02484014|Other|Tarang Adolescence Education programme|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
75927290|NCT02484014|Other|SEHER Intervention|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~Awareness generation activities for all stakeholders in school~Wall-magazine~Speak-out box~Competitions~School Health Promotion Committee~School health policies~Peer groups of students of standard IX~Workshops and talks for all the students from standard IX, and for teachers~Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year."
75927291|NCT02483546|Device|Laerdal®|simulation- based educational intervention
76082658|NCT03399162|Behavioral|PREHAB Exercise Program|An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
76082659|NCT04755972|Other|Inhalation of N-acetylcysteine|Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.
76082660|NCT04755972|Other|Inhalation of 5% sodium chloride|Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.
76082661|NCT04755972|Other|Inhalation of 8,4% sodium bicarbonate|Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.
75651861|NCT05134857|Drug|Placebo|The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
75651862|NCT05116254|Combination Product|AZD1390 + radiotherapy|AZD1390 combined with preoperative radiotherapy
76082662|NCT01828073|Drug|Raltegravir|No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.
76082663|NCT04697693|Drug|Escitalopram|The participant will be begun on either escitalopram 10mg or duloxetine 30mg. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the HRSD >7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study.
76082664|NCT04697693|Drug|Duloxetine|Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study.
75651863|NCT05114590|Drug|Insulin glargine/Lixisenatide|Solution for injection in a pre-filled pen by subcutaneous injection
75791064|NCT00233987|Drug|cyclophosphamide|100 mg/kg IV 2 days before transplant.
75791065|NCT00233987|Drug|etoposide|60 mg/kg IV over 4 hours 4 days before transplant.
75791066|NCT00233987|Drug|melphalan|150 mg/m^2 IV 1 day before transplant.
75791067|NCT00233987|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|2.0 x 10^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
75927292|NCT02483546|Behavioral|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
76082665|NCT03819114|Drug|Levonorgestrel (LNG)|LNG tablet(s) were administered by mouth in a directly observed manner.
76082666|NCT01827839|Biological|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
75791068|NCT00233987|Radiation|radiation therapy|150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
75791069|NCT01108926|Drug|Atripla®|All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
75791070|NCT01106274|Radiation|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
76082667|NCT03399084|Drug|Ferric carboxymaltose|750 mg/15 mL
76082668|NCT05239416|Procedure|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
76082669|NCT04722120|Radiation|Low radiation dose CT|Underwent liver CT with 30% lower radiation dose
76082670|NCT04722120|Radiation|Conventional CT (radiation)|Underwent liver CT without change of radiation.
76082671|NCT04722120|Drug|Low contrast dose CT|Underwent liver CT 20% lower dose contrast media.
76082672|NCT04722120|Drug|Conventional CT (contrast agent)|Underwent liver CT without change of contrast media doses.
76082673|NCT04722120|Other|Deep-learning based contrast boosting algorithms|Applied deep-learning based contrast boosting algorithms on acquired CT images
76082674|NCT04709250|Procedure|interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine will be injected
76082675|NCT04709250|Procedure|selective nerve block|"the patient will be put in the sitting position, linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to view of the suprascapular nerve. 5-8 mL of 0.25% bupivacaine is injected to block the SSN.~The ultrasound probe put on the posterior aspect of the shoulder to view the circumflex artery, 10 mL of 0.25% bupivacaine this will lead to loss of sensation over the deltoid.lateral pectoral nerve block (LPNB) will be done by injecting a volume of 8 ml of a 0.25% bupivacaine The probe will be moved towards the biceps muscle until the musculocutaneous nerve is seen and 8 ml of 0.25% bupivacaine will be injected."
76082676|NCT04709250|Drug|bupivacaine|bupivacaine
76082677|NCT01827371|Biological|MVA Smallpox Vaccine|Subjects receive two dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
76082678|NCT05239260|Diagnostic Test|CMR|CMR
75333679|NCT05021978|Drug|Part A: 20 and 40 mg PRAX-944|Once daily oral treatment
75651864|NCT05109325|Behavioral|IntERact|The IntERact intervention includes: (1) three remotely delivered Health Coach therapist sessions that integrate behavioral therapy (motivational interviewing [MI] + cognitive behavioral therapy [CBT] and strengths-based care management (CM); as well as, (2) an APP supporting and enhancing the therapist intervention by: (a) conducting automated daily assessments; (b) delivering daily MI/CBT messages tailored by the daily surveys; (c) delivering GPS-enabled alert notifications and immediate one-touch pro-social support; (d) providing access to reminders regarding goals/strengths from the ED session, CBT tools/skills (e.g., infographics, coping strategies, harm reduction strategies), and other psychoeducation (e.g., safe storage); (e) facilitating one-touch contact with pro-social support, including the health coach and others; (f) providing easy linkage to care management resources (web links, phone numbers, contact information).
75791071|NCT03946644|Device|EVLA with keeping of securuty distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
75791072|NCT03946644|Device|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
75791073|NCT03947970|Drug|[14C] CR845|Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries [14C] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
75791074|NCT01104480|Drug|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
76082679|NCT03399006|Device|2D ultrasound|Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position & carried out for measurement of fetal CRL and diagnosis of any major fetal defects
75333680|NCT05021978|Drug|Part B: 120 mg PRAX-944|Once daily oral treatment with titration
75333681|NCT05021978|Drug|Part B: 120 mg PRAX-944 and Placebo|Once daily oral treatment with titration followed by placebo
75471779|NCT04173663|Behavioral|ASSIST|The ASSIST program is a 12-week advocacy training to educate parents of youth with autism about the adult service system (note that an optional 13th session on secondary transition planning can be offered if ASSIST is being delivered to families of youth who are in high school). It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.
75471780|NCT04096417|Drug|Pemigatinib|Given PO
75791075|NCT03947892|Diagnostic Test|PET-CT|A PET-CT scan will be performed systematically for all patients included with the SUVmax, SUV peak, MTV of the lesion, and up to 3 suspicious ganglia during the visual analysis.
75333682|NCT04280406|Drug|Azithromycin|azithromycin 500mg one hour before implant placement
75471781|NCT04096417|Other|Quality-of-Life Assessment|Ancillary studies
75927293|NCT02483546|Behavioral|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
75927294|NCT02256813|Drug|BIRT 2584 XX|
75927295|NCT02256813|Drug|Warfarin sodium|
75927296|NCT02256813|Drug|Omeprazole|
75927297|NCT02256813|Drug|Dextromethorphan hydrobromide|
75927298|NCT02256813|Drug|Caffeine|
75927299|NCT02256813|Drug|Midazolam hydrochloride|
75471782|NCT04084210|Device|Juul Electronic cigarette|The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
75791076|NCT01106508|Drug|LEQ506|
75791077|NCT04623242|Drug|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
75791078|NCT04623242|Drug|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
75791079|NCT04623242|Drug|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
75927300|NCT02256813|Drug|Vitamin K1|
76082680|NCT03399006|Device|Doppler Ultrasound|"measurement of UtA-PI & UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated."
76082681|NCT03399006|Device|3D ultrasound|"3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters."
76082682|NCT03392922|Device|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
76082683|NCT03392922|Device|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
76082684|NCT05056116|Drug|Surufatinib Toripalimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
76082685|NCT03126318|Drug|COR-001|Anti-inflammatory therapy
76082686|NCT03126318|Drug|Placebo|Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
76082687|NCT02520258|Other|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
76082688|NCT02520258|Other|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
76082689|NCT03392844|Other|Beds for Kids program|"The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes."
75791080|NCT04623242|Drug|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
75791081|NCT03568266|Procedure|Biospecimen Collection|Undergo collection of saliva
75791082|NCT00233363|Drug|Rebamipide|
75333683|NCT04280406|Drug|Placebo oral tablet|identical placebo one hour before implant placement
75333684|NCT05599828|Drug|AMG 510|Oral Tablet
75333685|NCT05599828|Drug|Omeprazole|Capsule
75333686|NCT05599828|Drug|Famotidine|Tablet
75333687|NCT02675270|Behavioral|Phonological|This treatment involves picture viewing and word repetition.
75333688|NCT02675270|Behavioral|Orthographic|This treatment involves picture viewing, reading, and writing.
75333689|NCT02675270|Behavioral|Semantic|This treatment involves learning about the semantic features (meaning) of each trained word.
75927301|NCT02479958|Procedure|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
75927302|NCT02479958|Procedure|Tooth drying|The tooth was dried with air jet.
75333690|NCT02675270|Behavioral|Lexical|This treatment involves learning about the lexical features (letters and sounds) of each trained word.
75642756|NCT04657120|Procedure|YEARS algorithm|Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, haemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level <1.0 μg/mL (<1000ng/mL), and in patients with ≥1 items and a D-dimer level <0.5 μg/mL (<500 ng/mL) a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.
75333691|NCT02675270|Behavioral|Untrained|These words are not trained during the treatment phase.
75642757|NCT04657120|Procedure|CTPA|Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.
75791083|NCT03946722|Drug|GnRH analogue downregulation|"Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Participants will be exposed to one week of downregulation using a GnRH analogue in the standard downregulation arm and 6 weeks of downregulation using a GnRH analogue in the modified downregulation arm."
75333692|NCT01350232|Drug|Fludarabine|Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
75791084|NCT03946722|Other|Participant questionnaire|Participant will be offered the opportunity to complete an adenomyosis symptom assessment questionnaire at the start of their treatment, and again two months after completion of treatment.
75333693|NCT01350232|Drug|Cytarabine|Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
75791085|NCT03947658|Procedure|Surgical crown lengthening|Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation
75333694|NCT01350232|Device|Cellular Infusions|"Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
75791086|NCT01073033|Dietary Supplement|milk supplement 1|milk supplement with probiotics
75791087|NCT01073033|Dietary Supplement|milk supplement 2|milk supplement without probiotics
75791088|NCT03973073|Combination Product|CapulinTM|camouflage
75791089|NCT03973073|Other|topical applications and NB-UVB|combination therapy of vitiligo
75791090|NCT03972761|Device|Magnetic Resonance Imaging (MRI) 3 tesla|Functional neuroimaging objectifies the activation of specific areas of the brain
75791091|NCT01147666|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arms.
75791092|NCT01147666|Drug|Epoetin Alfa|Epoetin Alfa will be administered per dose and schedule specified in the arms.
75927303|NCT02479958|Procedure|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
76082690|NCT01401166|Drug|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
75333695|NCT01350232|Radiation|Total Body Irradiation|All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
75333696|NCT01350232|Drug|Cyclophosphamide|All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
75791093|NCT01147666|Other|Placebo|Placebo matching to roxadustat will be administered per schedule specified in the arm.
75791094|NCT01073111|Device|zotarolimus-eluting stent (ENDEAVOR®)|zotarolimus-eluting stent
75333697|NCT01350232|Drug|Bortezomib|Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
75333698|NCT01350232|Drug|Rituximab|Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
75333699|NCT01350232|Procedure|Plasmapheresis|Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
75333700|NCT01895660|Behavioral|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
75791095|NCT01073111|Device|sirolimus-eluting stents (CYPHER SELECT® PLUS)|sirolimus-eluting stents
75791096|NCT01073111|Device|everolimus-eluting stents (PROMUS®)|everolimus-eluting stents
75791097|NCT01325987|Dietary Supplement|Vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
75642758|NCT04646473|Behavioral|SweetGoals app|App offers goal setting and feedback
75642759|NCT04646473|Behavioral|Coaching|Web health coaching
75642760|NCT04646473|Behavioral|Incentives|Financial incentives for meeting goals
75642761|NCT04641975|Drug|Mirabegron|Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight < 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
75642762|NCT04641975|Drug|Placebo|Oral/ Oral Suspension
75642763|NCT04633200|Other|DOT mobile app|DOT is a mobile phone app that has daily pill reminders and supportive texts, as well as various features designed to support PrEP medication adherence.
75471783|NCT04084210|Other|Very Low Nicotine Cigarettes|These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).
75642764|NCT04625153|Biological|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
75642765|NCT04625153|Biological|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
75642766|NCT04624204|Biological|Pembrolizumab 200 mg|Pembrolizumab 200 mg Q3W
75791098|NCT01325987|Other|Sugar pill|"group: vitamin D2 50000 IU weekly once for 8 weeks~nd group: placebo weekly once for 8 weeks"
75791099|NCT03464604|Diagnostic Test|active|Pre-screening for melanoma by qualified nurse
75791100|NCT03947502|Behavioral|Educational intervention in neurobiology of pain|The educational intervention will intend to make the individual aware that in the processes of learning, sensitization, habituation and acquisition of beliefs about pain there are automatic unconscious mechanisms, which can be modulated through conscious behaviors. Based on this the investigators propose the active participation of patients in the process of desensitization of their central nervous system. The investigators will try to encourage attention and weaken the neuronal connections that make up the pain neuromatrix to establish new connections thanks to neuroplasticity.
75791101|NCT00256295|Drug|Gemcitabine|1000 mg/m2 IV over 100 minutes Every 21 days
75791102|NCT00256295|Drug|Oxaliplatin|65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
75791103|NCT03944460|Drug|Contraloid|Oral administration of capsules, drug substance or placebo without any excipients.
75927304|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
75927305|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
75927306|NCT02189265|Other|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
75927307|NCT02483624|Drug|BR-DIM|DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
75927308|NCT02483624|Drug|Placebo|Placebo
76082691|NCT01401166|Drug|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
76082692|NCT01401166|Device|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
76082693|NCT01401166|Device|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 mL.
76082694|NCT05238402|Drug|Statin|Statin on COVID 19 patienst
75642767|NCT04624204|Biological|Pembrolizumab 400 mg|Pembrolizumab 400 mg Q6W
75642768|NCT04624204|Drug|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q3W
76082695|NCT03395106|Behavioral|Parent source|Having a parent feature prominently in a news story
76082696|NCT03395106|Behavioral|Doctor source|Having a doctor feature prominently in a news story
75333701|NCT05493228|Drug|Precedex Injectable Product|Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
75333702|NCT05493228|Drug|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
75333703|NCT02758132|Biological|Denosumab|One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
75471784|NCT04084210|Drug|Active Nicotine Patch|Active nicotine patches, with dosing based on the package insert (>10 cigs/day = 21 mg patch and <11 cigs/day = 14 mg patches).
75642769|NCT04624204|Drug|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q6W
75642770|NCT04624204|Drug|Olaparib 300 mg BID|Olaparib 300 mg twice daily (BID)
75642771|NCT04624204|Drug|Olaparib matching placebo|Olaparib matching placebo BID
75642772|NCT04624204|Drug|Etoposide 100 mg/m^2|Etoposide 100 mg/m^2 intravenous (IV) Q3W, Day 1-3
75642773|NCT04624204|Drug|Platinum, investigator's choice|Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m^2 IV Q3W on Day 1 of each cycle
75642774|NCT04624204|Radiation|Standard Thoracic Radiotherapy|Standard Thoracic Radiotherapy
76082697|NCT03395106|Behavioral|Deliberative content|News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.
75333704|NCT02758132|Drug|Enzalutamide|160 mg enzalutamide by mouth daily
75333705|NCT02758132|Drug|Abiraterone|1000 mg abiraterone by mouth daily
75642775|NCT04624204|Radiation|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
75642776|NCT04617002|Drug|ONC201 (dordaviprone)|ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist.
76082698|NCT03395106|Behavioral|Intuitive content|News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.
75642777|NCT04616365|Procedure|Semi-Elective Lung Transplantation|When suitable donor lungs become available for a consented recipient, the transplant procedure (anesthesia starting time) will be allowed to begin earliest at 6am with the lungs being preserved at 10°C cold static preservation upon organ arrival to our hospital using a specific incubator, regardless of when donor cross clamp occurs. The maximum time allowed between donor cross clamp and recipient anesthesia initiation will be 12h.
75791104|NCT01356238|Other|MRC media|Culture media
75791105|NCT01356238|Other|Sydney IVF media|Culture media
76082699|NCT03395028|Drug|Granulocyte Colony-Stimulating Factor|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
75642778|NCT04603560|Behavioral|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
75642779|NCT04603560|Behavioral|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
75642780|NCT04578041|Device|TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|"TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~Modality: Excitatory stimulation~Frequency: 5 Hz~Interval between stimulus: 100 ms~Duration of each stimulus: 25 ms~Duration of stimulation: 40 minutes~Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2"
75642781|NCT04578041|Other|Aerobic Exercise Program|Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
75651865|NCT05108935|Drug|Suboxone|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
75791106|NCT01106664|Drug|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
75791107|NCT01106664|Drug|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
75791108|NCT02877004|Device|3 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatment - at a frequency of 3 times per week for 4 weeks
75791109|NCT02877004|Device|2 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatments - at a frequency of 2 times per week for 6 weeks
75791110|NCT02877004|Device|1 Low-Level Laser Therapy Treatment Weekly|Receive 12 LLLT treatments - at a frequency of once per week for 12 weeks
75791111|NCT04602156|Procedure|Trocar percutaneous cholecystostomy|Percutaneous cholecystostomy using the one-step Trocar technique under US guidance. An 8Fr Trocar catheter will be inserted percutaneously within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
75791112|NCT04602156|Procedure|Seldinger percutaneous cholecystostomy|Percutaneous cholecystostomy using the Seldinger technique under US guidance. Following percutaneous puncture of the gallbladder with an 18G needle under real-time US guidance, an 8Fr catheter will be inserted percutaneously over the wire within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
75791113|NCT04587882|Behavioral|Telehealth|Participants will receive weekly activity summaries and tailored notifications about their activity and goal setting behaviors.
75791114|NCT04587882|Behavioral|Control|Participants will get usual care and wear a smartwatch.
75791115|NCT01356316|Biological|AdimFlu-S Vaccine 2010-2011|Per ml contains following strains 30μg, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
75791116|NCT01363180|Behavioral|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
75791117|NCT01363180|Other|No stress condition|
75927309|NCT02184897|Drug|lenograstim 10 microgram/kg/day|
75927310|NCT02483390|Other|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
75927311|NCT03535779|Biological|Hepatitis B|The Hepatitis B virus, is a double stranded DNA virus that prevents Hepatitis B in the population
75927312|NCT03535779|Biological|Tetanus Toxoid|The Tetanus vaccine, also known as tetanus toxoid (Td/IVP), is an inactive vaccine used to prevent tetanus in the population
75927313|NCT02184975|Procedure|Cold Knife Conization with stitches|In the research arm patients who underwent cold-knife conization of the cervix underwent hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. These sutures were held prior to the onset of cold conization of the cervix.
76082700|NCT03394950|Drug|Butyphthalide combined with rtPA|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
75927314|NCT02184975|Procedure|Cold knife Conization without stitches|In the research arm patients who underwent cold-knife conization of the cervix have not undergone hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. After patient anesthesia and routine antisepsis was performed, cold knife conization of the cervix was performed.
75333706|NCT02758132|Drug|Prednisone|5 mg prednisone by mouth twice daily
75642782|NCT04578041|Other|Computerized CT (Cognitive Training)|"Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session."
75642783|NCT04558840|Procedure|Macromastia|Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
75791118|NCT03946566|Procedure|Acupuncture|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
75642784|NCT04557462|Drug|LNP023|Capsule 200 mg (b.i.d.) taken orally twice a day
75642785|NCT04550260|Drug|Durvalumab|Durvalumab intravenous infusion
75642786|NCT04550260|Drug|Placebo|Durvalumab matching placebo for intravenous infusion
75642787|NCT04550260|Drug|cisplatin + fluorouracil|cisplatin + fluorouracil, as per Standard of Care
75791119|NCT01104948|Drug|DA-8031|
75791120|NCT01104948|Drug|Placebo|
75927315|NCT02189343|Drug|ACY-1215 in combination with pomalidomide and dexamethasone|Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
75927316|NCT03535701|Dietary Supplement|Dietary Intervention|Undergo ketogenic diet
75927317|NCT03535701|Other|Laboratory Biomarker Analysis|Correlative studies
75791121|NCT04410562|Drug|Hydroxychloroquine|Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
75791122|NCT04410562|Drug|Placebo|Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
75791123|NCT01109160|Drug|Azithromycin Dihydrate|"Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.~Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment)."
75791124|NCT01363336|Drug|Nifedipine (Adalat CR, BAYA1040)|patients who are administrated with Adalat CR for hypertension
75927318|NCT03535701|Drug|Paclitaxel|Given standard of care therapy with paclitaxel
75927319|NCT03535701|Other|Quality-of-Life Assessment|Ancillary studies
76082701|NCT03394950|Drug|rtPA|Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
76082702|NCT01473160|Device|delefilcon A contact lens|CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear
76082703|NCT01473160|Device|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
75927320|NCT03535701|Other|Questionnaire Administration|Ancillary studies
75927321|NCT02486276|Drug|Cilostazol|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
75927322|NCT02486276|Drug|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
76082704|NCT03394872|Procedure|Drainage of the pleural effusion|
76082705|NCT03392766|Device|single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.
75333707|NCT04107636|Procedure|Vacuum assisted biopsy|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location.
75333708|NCT04107636|Procedure|conventional lumpectomy|After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
75333709|NCT01891916|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
75642788|NCT04550260|Drug|cisplatin + capecitabine|cisplatin + capecitabine, as per Standard of Care
75642789|NCT04550260|Radiation|Radiation|50-64Gy in total
75642790|NCT04542031|Other|Questionnaire|Questionnaire to be completed at 6 and 12 months
75642791|NCT04527432|Other|Survey|Survey at baseline, 6 and 12 months
75642792|NCT04527432|Diagnostic Test|SARS-CoV-2 antibody test|SARS-CoV-2 antibody test results and testing again at 6 and 12 months
75642793|NCT04522895|Drug|Enasidenib|Participants receive up to 12 cycles of Enasidenib.
75642794|NCT04512131|Procedure|dialysis mode|intermittent hemodialysis or continuous renal replacement therapy
75642795|NCT04509427|Behavioral|Instructional handouts|Handouts will include written instructions for each aspect of the multifaceted exercise/posture training program
75642796|NCT04509427|Behavioral|Physical therapist instruction and monitoring via teleconferencing|The intervention physical therapist (PT) meets with them via Zoom for 60 minutes to help them start the program in the first week. This PT will meet with them again in week 2 to complete initial instructions. The PT will meet with them week 3 and then every other week for 15-minutes to help individuals safely progress the program.
75927323|NCT02486276|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
75927324|NCT02189421|Device|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
76082706|NCT03392766|Device|double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube.
76082707|NCT03392688|Other|kujala patellofemoral pain scale|Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.
75927325|NCT02485886|Drug|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
75927326|NCT02480036|Radiation|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
75927327|NCT02480036|Device|Intrabeam®|
75642797|NCT04509427|Behavioral|Web-based instructional videos|Instructional videos that will lead participants through every part of the intervention - like a commercial exercise video.
75791125|NCT01105026|Device|Alveolar Bone Defect Regeneration Following Tooth Extraction|"Patients underwent surgery under local anesthesia and minimally invasive periotomy was carried out with a surgical blade. Atraumatic extraction with forceps was performed. The extraction socket was carefully curetted to remove the granulation tissue and was rinsed with a physiologic solution. To evaluate the eligibility of the surgical site, the alveolar walls integrity was checked clinically and by means of extemporaneous peri-apical radiography.~Then, the socket was filled to the bone margin with Inion BioRestore™ (granules size 1 to 2 millimetres). Finally, single interrupted (5-0) sutures were tightened to promote the stability of grafted particles. Ten days after the surgery, sutures were removed."
76082708|NCT03392688|Diagnostic Test|Surface EMG|The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
76082709|NCT03392688|Other|Q angle measurement|Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
75791126|NCT01363414|Drug|0.18% sodium hyaluronate|one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
75791127|NCT01363414|Drug|0.9% sodium chloride solution|one drop of sterile 0.9% sodium chloride solution in the other eye
75791128|NCT03946410|Diagnostic Test|Invitation to screening|Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
75791129|NCT01105104|Device|MedMinder System|Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.
75791130|NCT01105104|Device|MedMinder System - deactivated|Participants will receive a one-way reminder unit that will remotely transit information on medication adherence
75791131|NCT02223520|Drug|Mupirocin and Chlorhexidine|
75791132|NCT02223520|Drug|Placebo ointment and placebo cloths|
75791133|NCT01356394|Other|dietary intervention|12-week calorie-restricted diet consisting of 50% carbohydrate, 20-25% protein, and 25-30% fat
75791134|NCT01357954|Other|Regular physiotherapy|The child's regular physiotherapy
75791135|NCT01357954|Other|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
76082710|NCT04586634|Device|Peristeen cone catheter|The active intervention is the Peristeen cone catheter device. The comparator in this investigation is current standard of care for patients with LARS which is conservative bowel management.
75333710|NCT01892072|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
75642798|NCT04509427|Behavioral|Posture training|Participants will learn how to hold a neutral spine posture during sitting, forward leaning in sitting, sit-to-stand-to-sit, standing, forward leaning in standing, supine-to-sit-to-supine, supine-to-prone-to-supine, and lifting. Principles learned with these functional movement patterns will then be put to practice in common tasks like sweeping, washing dishes, dusting, and gardening. This will be taught over two sessions in the first two weeks of the program. To reinforce holding neutral spine with all activities, participants will perform a 5-minute posture warm-up routine prior to exercising.
75791136|NCT01356472|Drug|Imipenem/cilastatin|the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
75927328|NCT02189499|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
75642799|NCT04509427|Behavioral|Marching in place|Participants will perform marching in place five times a week. Participants will be instructed to slowly progress to a goal of performing 30 minutes of marching in place per session. They will be instructed to lift their knees to a height that is between their waist and knee when marching. They will be instructed to march between a rating of 10 -14 on the 20-point Borg scale for rate of perceived exertion
75651866|NCT05108935|Drug|Truvada|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
75791137|NCT01105182|Procedure|Radiofrequency Ablation|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
75791138|NCT01106742|Dietary Supplement|AndoSan|AndoSan, 20mlx3, 12 days
75791139|NCT02122198|Drug|Leuprolide acetate|Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
75791140|NCT02122198|Drug|Estradiol|Climara transdermal patch 0.075mg/day applied weekly months 6-9
75927329|NCT05714228|Procedure|Surgical Mitral Valve Repair|Mitral valve is repaired using open surgical approach
75927330|NCT05714228|Procedure|Transcatheter Mitral Valve Repair|Mitral valve is repaired using Mitraclip transcatheter device
75927331|NCT02189577|Drug|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
76082711|NCT04567992|Procedure|superficial cervical plexus block|ultrasound guided injection of local anaesthesia in the superficial cervical plexus
75333711|NCT01313416|Biological|CT-011|3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
75333712|NCT01313416|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
75333713|NCT05599360|Drug|Vyxeos|Vyxeos (daunorubicin and cytarabine) liposome for injection
75333714|NCT05599360|Drug|Mylotarg|Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin [Ig] G4, kappa antibody produced by mammalian cell culture in non-secreting 0 (NS0) cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab.
75333715|NCT05499234|Drug|Dolantin|If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
75333716|NCT05499234|Drug|Paracetamol|If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
75642800|NCT04494958|Drug|Combination, Palbociclib + Binimetinib|"Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily."
75642801|NCT04492033|Drug|CTX-009 (ABL001)|CTX-009 (ABL001) will be administered biweekly.
75642802|NCT04492033|Drug|Paclitaxel|Paclitaxel will be administered weekly.
75642803|NCT04492033|Drug|Irinotecan|Irinotecan will be administered biweekly.
75642804|NCT04483505|Drug|Combination, Rogaratinib + palbociclib + fulvestrant|"Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.~Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:~Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).~Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).~Treatment will continue until disease progression."
75791141|NCT02122198|Drug|Medroxyprogesterone|Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
75791142|NCT02122198|Drug|Placebo|placebo
75791143|NCT04617860|Drug|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide. It is administered monthly via intrathecal injection.
75791144|NCT03944226|Dietary Supplement|Beetroot juice|The patient will follow a 5 day dietary nitrate intervention programme, taking 3 doses of 7cl (0.4 g nitrate per dose) concentrated beetroot juice (SPORT shot, James White Drinks, Suffolk, U.K.) a day.
75791145|NCT01106820|Other|Supervised progressive resistance training|Supervised progressive resistance training
75791146|NCT01106820|Other|Supervised progressive muscle relaxation training (Jacobsen method)|Supervised progressive muscle relaxation training (Jacobsen method)
75791147|NCT01363570|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
75791148|NCT04608500|Drug|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
75791149|NCT04608500|Drug|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
75333717|NCT01269034|Drug|Exenatide|1.25 mcg before the boost sub-cutaneously.
75333718|NCT01269034|Drug|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
75333719|NCT01269034|Drug|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
75642805|NCT04463771|Drug|retifanlimab|INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
75642806|NCT04463771|Drug|epacadostat|epacadostat will be administered orally BID.
75791150|NCT01109082|Procedure|posterior spine fusion|vertebrae are fused to straighten a spinal curve
75791151|NCT01363648|Drug|choline alfoscerate|Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
75791152|NCT01363648|Drug|placebo (for choline alphoscerate)|Pill manufactured to mimic choline alfoscerate 400mg tablet
75791153|NCT01107054|Drug|PF-00610355|An orally inhaled dose of PF-00610355 450 µg on days 1 to 4
75791154|NCT01107054|Drug|PF-00610355|An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4
75333720|NCT05499156|Other|placenal MSC derived exosomes|placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of PlacentaMSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial
75333721|NCT02670512|Device|Telehome Monitoring|
75791155|NCT01107054|Drug|moxifloxacin|A single oral dose of moxifloxacin 400 mg on Day 4.
75333722|NCT05599126|Drug|Mianserin|Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
75333723|NCT05599126|Drug|Lorazepam|Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
75333724|NCT02669498|Procedure|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
75333725|NCT05313178|Dietary Supplement|Bacillus Coagulans GBI-30, 6086|In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
75333726|NCT01892150|Other|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
75333727|NCT02663752|Procedure|Bone marrow aspirate|Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
75927332|NCT02189577|Drug|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
75791156|NCT01107054|Drug|placebo|A single oral dose of non-matched placebo on Day 4.
75333728|NCT02663752|Drug|Deferasirox|Patients are already on commercial deferasirox before entering the study.
75333729|NCT04389944|Other|convalescent plasma application to SARS-CoV-2 infected patients|In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.
75333730|NCT02654782|Drug|Lactated Ringer's|Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
75333731|NCT02654782|Drug|5% Human Albumin|Colloid given for hemodynamic resuscitation based off of individual patient needs.
75642807|NCT04463771|Drug|pemigatinib|pemigatinib will be administered orally QD.
75642808|NCT04463771|Drug|INCAGN02385|INCAGN2385 will be administered every 2 weeks
75642809|NCT04463771|Drug|INCAGN02390|INCAGN2390 will be administered every 2 weeks
75791157|NCT03944070|Drug|Ranibizumab|Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.
75927333|NCT02189655|Procedure|bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
75333732|NCT02821364|Other|Advanced Life Support|IV FLUIDS, INTUBATION
75642810|NCT04456920|Other|phone consultation|At D1, D2 and D3, patients in the experimental group 1 will receive a call from a neuro-psychologist during which pain, anxiety and esthetical biopsy impact will be assessed using numeric or visual analog scales during a semi-direct interview. During this call, any adverse events related to the breast biopsy will also be noted, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken linked to the biopsy. If detected, pain or significative distress would be specifically managed.
75791158|NCT01363804|Drug|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
76082712|NCT01335724|Drug|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
76082713|NCT01335724|Drug|Placebo gel|Placebo gel
76082714|NCT01476202|Drug|nicotine|nicotine in the form of a mouth strip, lozenge and gum
75333733|NCT02820194|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
75333734|NCT02820194|Procedure|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
75333735|NCT01253668|Drug|Brivanib alaninate|Brivanib by mouth daily at a dose of 800mg.
75333736|NCT01253668|Genetic|Polymerase chain reaction|Undergo 1241-cG250 PET/CT imaging (correlative studies)
75333737|NCT01253668|Other|Iodine I 124 chimeric monoclonal antibody G250|Undergo 124I-cG250 PET/CT imaging (correlative studies)
75333738|NCT01253668|Procedure|Positron emission tomography/computed tomography|Undergo 1241-cG250 PET/CT imaging (correlative studies)
75333739|NCT01253668|Genetic|Protein expression analysis|Correlative studies
75642811|NCT04456920|Other|e-PRO self-completed via connected objects (tablet/phone)|Patients in the experimental group 2 will be asked by SMS or notification to connect to the application in order to complete online the numeric and visual anog scales of pain, anxiety and esthetical impact. Any adverse events related to the breast biopsy will also be noted online, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy. If detected, pain or significative distress would be specifically managed
75642812|NCT04456920|Other|phone consultation|At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.
75791159|NCT02534168|Device|Skin conductance monitor for measuring skin conductance|"The Skin conductance monitor for measuring skin conductance on the palm of the hand or sole of the foot in microSiemens (µS); it then calculates the number of skin conductance responses per second and the area under the registration curve.~The device records sympathetic autonomous nervous system through its effect on skin.~The device (Med-Storm Innovation AS, Gimle Terrasse 4, NO-0264 Oslo, Norway, support@med-storm.com) includes cables, skin electrodes, a measurement unit and a monitor."
75927334|NCT02485652|Drug|HM61713|"800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
75791160|NCT01363882|Other|Sleep study-guided adjustment of NIV|Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
75333740|NCT01253668|Other|Immunohistochemistry|correlative studies
75333741|NCT01890200|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
75333742|NCT01890200|Drug|Ribavirin|conventional treatment of Hepatitis C
75333743|NCT01890200|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
75642813|NCT04456920|Other|visit|And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.
75642814|NCT04447768|Drug|Obinutuzumab|"Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg"
75791161|NCT01363882|Other|Standard initiation of NIV|NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
75791162|NCT03764462|Drug|AD-101 45mg|Raloxifene 45mg tablet
75791163|NCT03764462|Drug|Raloxifene 60mg|Raloxifene 60mg tablet
75791164|NCT03758924|Drug|ANAVEX2-73|Liquid oral solution
75791165|NCT03758924|Drug|Placebo|Liquid oral solution
75791166|NCT05460728|Other|Dry needling|A three-weekly session of DNT was administered with an acupuncture needle (0.30 × 50 mm; Huan Qiu, Suzhou, China). For each session, DNT was applied in the deltoid, biceps brachialis, wrist extensors and flexors, thenar muscles, vastus medialis, gastrocnemius medialis, and tibialis anterior (Hong, 1994). Following focal twitch responses (maximum three), the dry needle was left inserted for 15 minutes in each muscle.
75791167|NCT04585646|Device|Orion daily disposable contact lens|Subjects will be randomized to wear Orion lens for 2 weeks.
75791168|NCT04585646|Device|Gemini daily disposable contact lens|Subjects will be randomized to wear Gemini lens for 2 weeks.
75791169|NCT04074928|Biological|QIVc|Previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1; not previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1 and Day 29.
75791170|NCT04074928|Biological|Comparator QIV|Previously vaccinated subjects received a dose of Comparator QIV on Day 1; not previously vaccinated subjects received a dose of Comparator QIV on Day 1 and Day 29. Subjects 6 months through 35 months of age received a 0.25 mL intramuscular dose of Comparator QIV; subjects 36 months through 47 months of age received a 0.5 mL intramuscular dose of Comparator QIV.
75791171|NCT04584788|Device|Masimo O3 Regional Oximeter|Study sensors will be placed on somatic tissues. Readings will be taken from the tissues underneath the O3 sensors.
75791172|NCT05460572|Dietary Supplement|Peripheral Parental Nutrition|Peripheral parenteral nutrition (PPN) through an intravenous (iv) line
75791173|NCT03764306|Procedure|Carotid Artery Stenting|Carotid artery stenting was considered successful if there was no residual stenosis greater than 20%, and there was no dissection of target artery following the procedure.
75927335|NCT02189733|Biological|Caplacizumab|Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
75927336|NCT02185365|Radiation|Magnetic Resonance Imaging (MRI)|Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.
75927337|NCT02485808|Other|None-observational|For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
75927338|NCT02485808|Procedure|Magnetic Resonance Imaging (MRI)|One time MRI scanning session examining brain structure and function in a resting state and after water consumption.
75927339|NCT02485808|Other|Multimodal Automated Sensory Testing System|Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.
75927340|NCT02485808|Other|Auditory Sensitivity Test|Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
75927341|NCT02189811|Biological|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
75927342|NCT02189811|Biological|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
75927343|NCT02189811|Biological|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
75927344|NCT02189811|Biological|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
75927345|NCT02189811|Biological|tOPV|tOPV till 22 weeks of age
75333744|NCT01890200|Drug|Placebo|Placebo, without acting ingredient.
75333745|NCT01662648|Drug|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
75333746|NCT00378586|Procedure|Rectal biopsy|Rectal biopsy.
75333747|NCT00378586|Procedure|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
75333748|NCT00378586|Procedure|Measurement of rectal lactic acid|Equilibrium dialysis.
75333749|NCT05586620|Procedure|3-snip punctoplasty|punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.
75333750|NCT05586620|Procedure|3-snip punctoplasty and Mitomycin C|"punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.~Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis"
75471785|NCT04084210|Other|Placebo Patch|Placebo patch containing no nicotine.
75642815|NCT04447768|Drug|Venetoclax|"Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily"
75642816|NCT04435366|Drug|Avacincaptad Pegol|Avacincaptad Pegol Intravitreal Injection
75791174|NCT03764306|Procedure|Endarterectomy carotid artery|Surgical endarterectomy was considered successful if there was no residual stenosis after procedure, without symptoms.
75791175|NCT03949504|Procedure|New Find-risk questionnaire software|FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
75791176|NCT05460416|Drug|Acetylsalicylic acid|160mg once a day
75791177|NCT01364194|Drug|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
75471786|NCT04047264|Procedure|Microdialysis|Undergo microdialysis
75471787|NCT04046497|Other|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
75471788|NCT04046497|Other|Usual Care|Usual Care provided by CSC clinic
75471789|NCT04030026|Drug|NAL ER|Participants will receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period.
75471790|NCT04030026|Drug|Placebo|Participants will receive Placebo tablet (matching NAL ER BID) over a 3 week period.
75471791|NCT03968900|Behavioral|Sleep restriction condition|On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep restriction condition (4 hours, TIB [Time in Bed]; 1:00 a.m. to 5:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham (UAB) Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
75642817|NCT04435366|Drug|Sham|Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
75642818|NCT04368845|Device|Telerehabilitation|The treatment arm will be given up to 1-hour breathing exercises, aerobic and resistive training exercises administered by a physiotherapist via a telerehabilitation device every 10 days for a six-month period.
75642819|NCT04356989|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The adminstration dose is decided by the attending physician in advance based on the patients' CrCl and in compliance with local market authorization of rivaroxaban.
75642820|NCT04326673|Other|Testosterone Measurements in healthy volunteers after fasting|salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken
75642821|NCT04326673|Other|Testosterone Measurements after glucose loading|salivary tstosterone and blood testosterone measurements
75642822|NCT04300309|Drug|artemether:lumefantrine (2.5 mg:30 mg)|artemether:lumefantrine (2.5 mg:30 mg)
75642823|NCT04261712|Drug|Paltusotine|Paltusotine, once daily by mouth
75642824|NCT04234022|Drug|Zn-DDC|Zn-DDC added to myeloma samples for culturing
75642825|NCT04234022|Drug|Lanalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
75642826|NCT04234022|Drug|Pomalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
75642827|NCT04233866|Drug|Fluorouracil|Given IV
75642828|NCT04233866|Drug|Gemcitabine|Given IV
75642829|NCT04233866|Drug|Gemcitabine Hydrochloride|Given IV
75642830|NCT04233866|Drug|Leucovorin|Given IV
75642831|NCT04233866|Drug|Leucovorin Calcium|Given IV
75791178|NCT01364194|Drug|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
75791179|NCT03755648|Other|Treadmill training|The motorized treadmill treatment parameters considered will be 50 Hertz, 10 Ampere and 220 Volts. The speed of treadmill will be controlled with a single finger tip allowing an individual to exercise in safe environment with sufficient space.The treadmill training will be provided by giving instructions first and then warm up will be given for 5 minutes prior to the training. The children will be upright with the feet flat on treadmill platform. The height of handrails will be adjustable according to every child thus keeping their gaze forward. The training will be ended at cool down period of 5 minutes.The treatment session will be thirty minutes for each group, six times a week for three months.
75791180|NCT03755648|Other|traditional physical therapy|Traditional therapy includes hot pack for 15 minutes and stretching for 20 minutes
75791181|NCT03755648|Other|Delorme resistance exercise|Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
75791182|NCT03753464|Procedure|Gingival biopsy and blood sample collection|Gingival and blood samples will be collected.
75791183|NCT01321814|Behavioral|Cognitive behavioural therapy|6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
75791184|NCT03906994|Other|Video game Mario Kart Wii|Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior
75927346|NCT04492592|Behavioral|Workshop|Workshop
75927347|NCT04492592|Behavioral|SMS/Texting|SMS/Texting
75927348|NCT02189967|Radiation|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
75927349|NCT02189967|Radiation|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
76082715|NCT01539694|Device|LD118033 contact lens|Multifocal contact lens worn on a daily wear basis for 1 week
75791185|NCT03753386|Other|Oxygen therapy simulation|"The intervention consists of reproducing oxygen therapy situations in healthy individuals by replacing oxygen bottles with bottles of air. A TeleOx® device will be placed on the circuit between the source and the nasal cannula for respiratory signals recording.~The intervention will last 30 minutes, containing the following activities in the given order:~rest (9 minutes);~drinking water (1 minute);~rest (1 minute);~coughing (1 minute);~rest (1 minute);~reading aloud (1 minute);~rest (1 minute);~breathing by the mouth (1 minute);~rest (1 minute);~exercising (running) (3 minutes) and~rest (10 minutes)~Recordings will be retrieved after each test."
76082716|NCT01539694|Device|PureVision multifocal contact lens|PureVision multifocal contact lens worn on a daily wear basis for 1 week.
75642832|NCT04233866|Drug|Liposomal Irinotecan|Given IV
75642833|NCT04233866|Drug|Nab-paclitaxel|Given IV
75642834|NCT04233866|Other|Quality-of-Life Assessment|Ancillary studies
75791186|NCT01364350|Other|standard of care in general clinical practice|Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
75791187|NCT03753308|Biological|Blood Sampling|5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).
75791188|NCT03753308|Biological|Liver biopsy|"The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen"
75927350|NCT03316664|Behavioral|Integrated Neurocognitive Therapy (INT)|Information already included in arm/group description.
75927351|NCT03316664|Behavioral|Integrated Psychological Therapy (IPT)|Information already included in arm/group description.
75927352|NCT03316664|Other|COGPACK|Information already included in arm/group description.
75927353|NCT04633863|Device|Artificial tear MDI - 101|Medical device CE marked - artificial tears containing arabinogalactan, trehalose and hyaluronic acid - 10 weeks treatment
75927354|NCT03315494|Drug|SKI-O-703 capsule|SKI-O-703 200 mg capsule with no inactive excipients.
76082717|NCT01476748|Device|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
76082718|NCT01477450|Device|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
76082719|NCT01477450|Device|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
76082720|NCT01477762|Drug|Dexamethasone|One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.
75642835|NCT04233866|Other|Questionnaire Administration|Ancillary studies
75642836|NCT04228042|Drug|Infigratinib|Given PO
75642837|NCT04228042|Other|Quality-of-Life Assessment|Ancillary studies
75642838|NCT04228042|Other|Questionnaire Administration|Ancillary studies
75642839|NCT04228042|Procedure|Surgical Procedure|Undergo surgery
75642840|NCT04223492|Diagnostic Test|Liquid biopsy|A blood sample containing circulating tumor DNA and circulating tumor cells.
75642841|NCT04223492|Diagnostic Test|Multi-parametric MRI|Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.
75642842|NCT04212013|Drug|Ibrutinib|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.
75642843|NCT04212013|Drug|Rituximab|Will receive rituximab: 375 mg/m^2 on days 1, 8, 15 and 22 of cycle 1
75642844|NCT04212013|Other|Placebo|Placebo capsules will be similarly dosed at 4 capsules daily.
75642845|NCT04207060|Drug|Indomethacin|50 mg twice a day by mouth.
75642846|NCT04207060|Drug|Placebos|Lactose capsules not containing active study drug will be taken twice a day.
75642847|NCT04196010|Drug|Cladribine|Given IV
75642848|NCT04196010|Drug|Cytarabine|Given IV
75642849|NCT04196010|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
75642850|NCT04196010|Drug|Mitoxantrone|Given IV
76082721|NCT01477762|Drug|Placebo|One placebo tablet will be taken ten hours prior to completing study assessments.
76082722|NCT01478854|Radiation|Radiation|Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
75642851|NCT04195451|Other|Live-Video-Supervised Exercise Intervention|The live-video-supervised exercise intervention includes exercise sessions x3/week for 3 months, and then maintenance regimen for 6 months. Maintenance includes live-video-supervised exercise sessions, only x1/week, and self-exercise x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
75333753|NCT01893788|Drug|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
75927355|NCT03315494|Drug|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose.
75927356|NCT03315416|Other|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
75927357|NCT02193633|Drug|AZD2014 3 on/4 off & weekly paclitaxel|AZD2014 3 days on, 4 days off + weekly paclitaxel
75927358|NCT02193633|Drug|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 2 days on, 5 Days off + weekly paclitaxel
76082723|NCT01478854|Drug|Chemotherapy|Temozolomide
76082724|NCT01434472|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
76082725|NCT01434472|Drug|Cyclosporine|Given PO
75333754|NCT01893788|Drug|Eplerenone|50 to 100 mg daily for 48 weeks
75471792|NCT03968900|Behavioral|Sleep extension condition|sleep extension On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep extension condition (10 hours, (TIB); 10:00 p.m. to 8:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
75471793|NCT03963947|Biological|Beltavac® Polymerized with house dust mites|Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice
75927359|NCT03315338|Drug|CORT118335, 25 mg|CORT118335 is supplied as capsules for oral dosing
75927360|NCT03315338|Drug|Prednisone Oral Tablet|"Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered."
75927361|NCT03315338|Drug|Glucose|75 g in 300 mL solution, orally administered
75927362|NCT03315338|Drug|Placebo oral suspension|"Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered."
76082726|NCT01434472|Drug|Fludarabine Phosphate|Given IV
76082727|NCT01434472|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
76082728|NCT01434472|Drug|Mycophenolate Mofetil|Given PO
76082729|NCT01434472|Other|Pharmacological Study|Correlative studies
76082730|NCT01434472|Biological|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
76082731|NCT01434472|Radiation|Total-Body Irradiation|Undergo TBI
76082732|NCT01434472|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
76082733|NCT01434472|Drug|Fludarabine|Given IV
76082734|NCT01435174|Drug|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
75642852|NCT04195451|Other|Usual Care then Live-Video Supervised Exercise Intervention|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the live-video-supervised exercise intervention that includes exercise sessions x3/week for 3 months.
75642853|NCT04192981|Drug|GDC-0084|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily
75642854|NCT04192981|Radiation|whole brain radiation therapy radiation|30Gy in 10 fractions
75927363|NCT03315338|Drug|CORT118335, 75mg|CORT118335 is supplied as capsules for oral dosing
76082735|NCT01435174|Procedure|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
75927364|NCT03315338|Drug|CORT118335, 225mg|CORT118335 is supplied as capsules for oral dosing
75927365|NCT03315338|Drug|CORT118335, 675mg|CORT118335 is supplied as capsules for oral dosing
75927366|NCT03315338|Drug|CORT118335, 600mg|CORT118335 is supplied as capsules for oral dosing
76082736|NCT01435174|Procedure|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
76082737|NCT01436266|Drug|Misoprostol|400 mcg buccally 2 hours prior to procedure
76082738|NCT01436266|Other|Folic acid|2mg buccally 2 hours prior to procedure
76082739|NCT01542502|Drug|Anakinra|Anakinra 100 mg daily subcutaneous injection
76082740|NCT01542502|Drug|Placebo|Placebo daily subcutaneous injection
76082741|NCT01439620|Device|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
76082742|NCT01439854|Drug|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
76082743|NCT01439854|Drug|Placebo|Patients are treated with placebo
76082744|NCT01479478|Drug|Placebo|One placebo capsule daily.
76082745|NCT01479478|Dietary Supplement|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
76082746|NCT04409262|Drug|Remdesivir|Participants will receive intravenous (IV) RDV
76082747|NCT04409262|Drug|Tocilizumab|Participants will receive IV TCZ
75927367|NCT03315338|Drug|CORT118335, 630mg|CORT118335 is supplied as capsules for oral dosing
75927368|NCT03315338|Drug|CORT118335, 375mg|CORT118335 is supplied as capsules for oral dosing
75927369|NCT03315338|Drug|CORT118335, 100mg|CORT118335 is supplied as a suspension for oral dosing
75927370|NCT03315338|Drug|CORT118335, 300mg|CORT118335 is supplied as a suspension for oral dosing
75927371|NCT03315338|Drug|CORT118335, 900mg|CORT118335 is supplied as a suspension for oral dosing
75927372|NCT03315338|Drug|CORT118335, 150mg|CORT118335 is supplied as a suspension for oral dosing
75927373|NCT03315338|Drug|CORT118335, 1500mg|CORT118335 is supplied as a suspension for oral dosing
75927374|NCT03315338|Drug|Placebo oral capsule|Placebo capsules, orally administered
75927375|NCT03315338|Drug|CORT118335, dose to be determined|CORT118335 is supplied as suspension for oral dosing
75333755|NCT05488938|Other|Rehabilitative Intervention|Each program will require the daily performance of different postures and therapeutic activities at the girls' educational facilities and homes, based on the availability of families, for 10 months. Specific strategies that will be implemented will include maintaining asymmetrical postures that oppose the scoliosis curve during activities and exercises in sitting, standing, and walking positions (according to each participant's functional abilities). These strategies refer to a hypercorrective postural positioning of scoliosis. In addition, activities involving weight bearing on the lower limbs, such as walking and standing for at least two hours a day, will be encouraged, and passive stretching and spinal mobilization exercises will be conducted.
75471794|NCT03932097|Behavioral|REAL Parenting|REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
75471795|NCT03932097|Other|Active Control Materials|NIAAA materials on underage drinking for parents
75642855|NCT04190368|Other|Team Clinic Care|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient.~Selected providers will be trained in the Team Clinic Care protocol for completing medical appointments. Team Clinic Care key components:~(1) Shared decision making: Providers, AYA, parent/caregiver will mutually agree on priorities for each medical visit using a shared decision making tool (2) Autonomy supportive care: Providers will be trained in skills building, patient centered key elements, intervention bites, reviewing plans, designed to support AYA autonomy and intrinsic motivation. AYA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach AYA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate. (4) Fidelity Review and process for self-assessment"
75642856|NCT04190368|Other|Standard Care|Participants attend quarterly visits (1 visit every 3 months) and see their diabetes care provider. They do not participate in Team Clinic group visits but if they need diabetes education or supportive services they will be referred for necessary care per usual methods.
75642857|NCT04173104|Diagnostic Test|PET/MR with [18F]PARPi|One PET/MR study (with up to 3 scan times) with [18F]PARPi
75642858|NCT04173104|Drug|[18F]PARPi|Injection of <100ug of [18F]PARPi prior to 1 PET/MR
75642859|NCT04160546|Drug|Ponatinib 15 MG|"Patients will receive ponatinib 15 mg/day for 104 weeks orally. Ponatinib will be self-administered by the patient on a daily schedule.~Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib."
75927376|NCT02185599|Device|DySIS|Colposcopy performed with the DySIS digital colposcope
75927377|NCT02479724|Device|continuous non-invasive blood pressure monitor|continuous blood pressure monitoring using device in parallel with Gold Standard (A-line)
75927378|NCT02193711|Other|Topical Arthritis Cream|
75471796|NCT03927274|Drug|Topotecan|Intratumorally-administered topotecan using convection-enhanced delivery (CED) in patients with suspected recurrent/progressive High Grade Glioma (HGG) requiring stereotactic biopsy and is focused on investigating topotecan brain tissue distribution and determining the safety, toxicity, and tolerability of intratumorally-administered topotecan.
75927379|NCT02193789|Procedure|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
75927380|NCT02193789|Device|Covered Self-expandable Metallic Stents|
75927381|NCT02483156|Drug|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
75927382|NCT02483156|Drug|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
75927383|NCT02483156|Drug|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
75927384|NCT02194413|Procedure|therapeutic touch|receiving healing touch
75927385|NCT02194413|Other|quality-of-life assessment|Ancillary studies
75927386|NCT02194413|Other|questionnaire administration|Ancillary studies
75927387|NCT02483234|Drug|secukinumab|
75927388|NCT00706004|Drug|lubiprostone|lubiprostone 24 microgram capsule taken twice daily for 4 weeks
75927389|NCT02485340|Drug|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
75927390|NCT02485340|Drug|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
75927391|NCT02485340|Drug|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
75927392|NCT05459870|Biological|4SCAR T cells|Infusion of 4SCAR T cells at 10^6 cells/kg body weight via IV
76082748|NCT04409262|Drug|Placebo|Participants will receive IV placebo matched to TCZ
76082749|NCT01481740|Drug|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
76082750|NCT01481740|Drug|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
75927393|NCT05451368|Other|Coronary artery calcification lesions|Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.
75927394|NCT04492514|Drug|Mavrilimumab|treatment infusion
75642860|NCT04160546|Drug|Acetylsalicylic acid 100 MG|Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
75927395|NCT04492514|Drug|Placebo|Placebo infusion
75927396|NCT02485262|Drug|Sofosbuvir and simeprevir|Hepatitis C treatment using Direct Acting Agents
75927397|NCT05432726|Other|calculating CARG score|"Before the initiation of chemotherapy, study participants will complete the GA questions included in the CARG toxicity score.~Total risk score will be calculated ranging from 0 (lowest toxicity risk) to 19 (highest toxicity risk), incorporates measures of functional status such as fall history, hearing problems, physical capabilities, performance status as well as objective measures including age, gender, height, weight, cancer type, type and dose of chemotherapy, hemoglobin, and creatinine clearance.~CARG score will be stratified as low (score 0-5), intermediate (score 6-9) and high risk (score 10-19).~Chemotherapy-related toxicities will be assessed and graded as per the NCI-CTCAE, version 5.0.~Hospitalizations due to AEs during first-line chemotherapy will be collected.~Subsequent changes in chemotherapy dosage, treatment delays, and treatment discontinuation due to adverse effects as well as mortality rate after treatment will also be monitored."
75333756|NCT01231750|Drug|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
75642861|NCT04151940|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75642862|NCT04151940|Procedure|Computed Tomography|Undergo PET/CT scan
75927398|NCT02479490|Drug|Prednisone + Everolimus|"Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.~A treatment cycle consists of 28 days."
76082751|NCT01544062|Drug|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
75333757|NCT01231750|Other|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
75642863|NCT04151940|Drug|Chemotherapy|Receive standard of care chemotherapy
75642864|NCT04151940|Biological|Immunotherapy|Receive standard of care immunotherapy
75642865|NCT04151940|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
76082752|NCT01544062|Drug|Placebo|Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
76082753|NCT04331964|Procedure|partial pulpotomy|Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.
76082754|NCT03392454|Procedure|T+LRTI|T+LRTI is the most commonly used procedure, it removes the entire trapezium
76082755|NCT03392454|Procedure|PT+TI|The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
76082756|NCT03126084|Drug|Acetaminophen|1000 mg of intravenous acetaminophen will be administered twice a day
76082757|NCT03126084|Drug|0.25% Bupivacaine|20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
76082758|NCT03126084|Drug|0.5% Bupivacaine+Glucose|15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
76082759|NCT03126084|Drug|Tramadol HCl|50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
75333758|NCT05488860|Drug|Triamcinolone acetonide(scar)/5-ALA(others)|For scar, the drug is triamcinolone acetonide.
75333759|NCT05488860|Procedure|Piezoelectric drived microneedling|Piezoelectric drived microneedling
75333760|NCT05488860|Drug|5-ALA (a photosensitizer for photodynamic therapy).|For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
75333761|NCT02549716|Drug|IV acetaminophen|Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
75642866|NCT04142437|Drug|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
76082760|NCT03126084|Procedure|Inguinal Hernia Repair|Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
75333762|NCT02549716|Drug|Oral acetaminophen|Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
75333763|NCT02549716|Drug|Oral placebo|Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
75333764|NCT02549716|Drug|IV placebo|Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
75471797|NCT03923699|Device|Anesthesia Control Tower monitoring|Real time data will be monitored through the AlertWatch® system as well as the patient's EHR.
75651867|NCT05108935|Drug|Mavyret|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
75791189|NCT03438448|Other|High sensitive Troponin T monitoring|Three determinations of Roche high-sensitive troponin T (99th percentile (14 ng/L) for each patient: preoperative (during the preoperative visit or just before surgery), 48h, and 72h after surgery. If a rise and/or fall of hs-cTnT with at least one value above the 99th percentile upper reference is detected, a clinical evaluation and a 12-lead ECG will be performed. If no ECG changes, ischemic symptoms, or pulmonary edema to fulfill the diagnostic for PMI the patients will undergo an echocardiographic study.
75642867|NCT04134000|Drug|Atezolizumab|1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
75333765|NCT04081350|Drug|LY3471851|Administered SC
75927399|NCT02479256|Drug|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
75927400|NCT02479256|Drug|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
76082761|NCT03126084|Drug|0.25% Bupivacaine|10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
76082762|NCT03126396|Device|Urgo 310 3166 dressing|Experimental: Urgo 310 3166 dressing
75333766|NCT04081350|Drug|Placebo|Administered SC
75333767|NCT02540434|Device|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
75642868|NCT04134000|Drug|BCG|1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
75333768|NCT02540434|Other|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
75333769|NCT02540434|Drug|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
75333770|NCT05492760|Device|cryoballoon ablation|Patients with AF will accept cryoballoon ablation.
75333771|NCT05498922|Procedure|Peak pressure when mechanical ventilation was switched around a reasonable range|The research protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and written informed consents were obtained from all patients. After induction of anesthesia, Rb patients were transorally intubated and mechanically ventilated. The inspiratory time, ventilation rate, positive end-expiratory pressure, and oxygen concentration were set consistently among patients. When anesthesiologist switch the peak pressure around a reasonable range, indices including tidal volume, lung compliance, mean airway pressure on ventilator screen changed and were recorded when stable. All the ventilator setting parameters followed the guidance of mechanical ventilation in neonates and children (https://doi.org/10.1007/978-3-030-83738-9_8). All the anesthesia and ventilation performance were conducted by a fully qualified senior anesthesiologist to assure standardized and safe anesthesia, ventilation and operation procedure.
75471798|NCT03919344|Other|Critical airway closure pressure (Pcrit) measurment|Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
75642869|NCT04091386|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice
75471799|NCT03919344|Other|Acoustic pharyngometry|Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.
75471800|NCT03919344|Other|High density surface electroencephalogram neural mapping|Mapping of the respiratory neural network will allow us to study the areas of the brain activated during breathing
75927401|NCT02479256|Drug|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
75927402|NCT02479256|Drug|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
75927403|NCT02482844|Other|pacemaker implantation|
75927404|NCT02482844|Other|holter implantation|
75927405|NCT02482766|Drug|Poractant alfa, 200 mg/kg|Endotracheal Surfactant administration
75927406|NCT02482766|Device|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
75927407|NCT02482766|Device|Nasal Continuous Positive Airway Pressure (nCPAP)|After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
76082763|NCT03126006|Procedure|NSPT plus oral hygiene|Non-surgical periodontal therapy under local anesthesia to remove plaque and calculus
76082764|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
76082765|NCT01483378|Other|Choosing to receive the vaccine|
75791190|NCT01364506|Other|Water aerobic exercise|"The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11."
75791191|NCT04575038|Drug|Brequinar|Dihydroorotate dehydrogenase inhibitor (DHODHi)
75791192|NCT04575038|Drug|Placebo|Placebo capsules
75791193|NCT03066622|Drug|Standard of Care as per attending physician|Patients are randomized to standard of care medication (as determined by attending physician)
75927408|NCT04492280|Drug|Hydrocortisone|After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone & fludrocortisone), group H (hydrocortisone) and group C (control group).
75927409|NCT02724644|Biological|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Injectable intervention
75471801|NCT03883880|Other|Epigallocatechin gallate|Colored solution prepared with epigallocatechin gallate to be consumed daily for two weeks during the epigallocatechin gallate intervention.
75471802|NCT03883880|Other|Epigallocatechin gallate control|Colored control solution to be consumed daily for two weeks during the epigallocatechin gallate intervention.
75791194|NCT03066622|Drug|5mg rapidly dissolving olanzapine|5mg rapidly dissolving olanzapine
75927410|NCT02724644|Biological|Placebo Comparator|
75927411|NCT02479178|Drug|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
75927412|NCT02479334|Other|Fat challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
75927413|NCT02479334|Other|Fat challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
75927414|NCT02479334|Other|Carbohydrate challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
75927415|NCT02479334|Other|Carbohydrate challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
75927416|NCT02482922|Other|Exercise & Dietary Supplement|
75927417|NCT02482688|Behavioral|A New Rehabilitation Treatment following Stroke|A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
75927418|NCT04492202|Other|Survey|The survey will be sent to health professionals via online link.
75927419|NCT03314870|Genetic|Genetic signature|To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.
76082766|NCT03392298|Drug|Colla corii asini|15g Colla corii asini granule, once daily for 4 weeks
75333772|NCT05488704|Diagnostic Test|Stress Parameters Measurement|"Pre-Test (0-2 minutes before NST starts) - Measurement of vital parameters (Pre-Test)~Glucose measurement~Taking Salivary Cortisol and Saliva ACTH samples~Filling the Spielberger State Anxiety Inventory~• Starting NST by controlling the noise level Interim Test-(NST 10th minute) - Measurement of vital parameters (Intermediate Test)~Taking Salivary Cortisol and Saliva ACTH samples~Filling the Spielberger State Anxiety Inventory~• Termination of NST after 20 minutes Final Test(within 0-2 minutes after NST is over)~Measurement of vital parameters~Glucose measurement~Taking Salivary Cortisol and Saliva ACTH samples~Filling the Spielberger State Anxiety Inventory After Data Collection - Recording of data~Centrifugation and analysis of saliva samples taken"
75333773|NCT01207726|Drug|Azacitidine|Given SC
75333774|NCT01207726|Drug|Entinostat|Given PO
75471803|NCT03883880|Other|Linoleic acid|Colored emulsion prepared with linoleic acid to be consumed daily for two weeks during the linoleic acid intervention.
75471804|NCT03883880|Other|Linoleic acid control|Colored control solution to be consumed daily for two weeks during the linoleic acid intervention.
75471805|NCT03883880|Other|Capsaicin solution|Colored solution prepared with capsaicin to be consumed daily for two weeks during the capsaicin intervention.
75471806|NCT03883880|Other|Capsaicin control|Colored control solution to be consumed daily for two weeks during the capsaicin intervention.
75642870|NCT04082429|Drug|Concizumab|When patients are randomised/allocated to concizumab prophylaxis, they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week (Wk) 0) (arm 2, 3 and 4) or visit 9a (Wk 24) (arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (Wk 6) or 9a.3 (Wk 30) and will be based on the concizumab exposure level measured at the previous visit 4a (Wk 6) or 9a.2 (Wk 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual replacement therapy until visit 9a (week 24; end of main part). In the extension part, patients in arm 1 will receive daily concizumab subcutaneous injections.
75642871|NCT04074044|Behavioral|BHmApp|Use of BHmApp for bladder education and training in pregnancy
75642872|NCT04066400|Other|Nutritional Intervention|Dietary Counselling
75791195|NCT03764228|Biological|hAECs|Human amniotic epithelial cells（hAECs）
76082767|NCT01440634|Other|Supervised exercise Program|Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
75471807|NCT03832946|Drug|GB0139|GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
75471808|NCT03832946|Drug|Placebo|Placebo is administered as inhalation once a day
75471809|NCT03801369|Procedure|Biopsy|Undergo biopsy
75927420|NCT03314792|Drug|Tapentadol|"Palexia depot 50 mg® (tapentadol depot 50 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. Palexia depot is repeated once after 12 hours.~Palexia 50 mg® (tapentadol 50 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 tablets/24-hour study period. Minimum 1 hour 15 minutes between tablets. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
75927421|NCT03314792|Drug|Oxycodone|"OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. OxyContin is repeated once after 12 hours.~OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 capsules/24-hour study period. Minimum 1 hour 15 minutes between capsules. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
75927422|NCT02476604|Behavioral|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
75471810|NCT03801369|Drug|Capivasertib|Given PO (orally)
75471811|NCT03801369|Drug|Ceralasertib|Given PO (orally)
75471812|NCT03801369|Biological|Durvalumab|Given IV (infusion)
75471813|NCT03801369|Drug|Olaparib|Given PO (orally)
75471814|NCT03801369|Other|Quality-of-Life Assessment|Ancillary studies
75927423|NCT02476526|Drug|Low Volume iso-osmolar non-ionic radio contrast medium|Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
76082768|NCT03392220|Procedure|Unilateral Neck Dissection|patient undergo unilateral (affected side) neck dissection, along with the excision of the laryngeal primary tumor
76082769|NCT03392220|Procedure|Bilateral Neck Dissection|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
75471815|NCT03801369|Drug|Selumetinib|Given PO (orally)
75471816|NCT03764618|Drug|Fostamatinib disodium|"Fostamatinib (100mg PO bid or 150 mg PO bid)~The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed."
75471817|NCT03764618|Drug|Placebo|Placebo
75471818|NCT03744715|Drug|Poziotinib|Poziotinib will be taken by the patient orally, once daily with food and a glass of water at approximately the same time. The dose will be the last dose received or at the standard starting dose of 16 mg poziotinib. If a dose is missed, it may be taken any time during the day preferably with food, but at least 8 hours prior to the next scheduled dose.
75642873|NCT04050228|Device|Quantitative ultrasound to guide adaptive chemotherapy|Quantitative ultrasound results will be used to measure chemotherapy response and guide an adaptive chemotherapy strategy for patients who are found to be nonresponders to their chemotherapy.
75642874|NCT04032704|Drug|ladiratuzumab vedotin|Intravenous (into the vein; IV) infusion
75642875|NCT04032704|Drug|pembrolizumab|200mg given by IV on Day 1 of each 21-day cycle
75642876|NCT04031677|Procedure|Surgery|Large en-bloc curative-intent surgery
75642877|NCT04031677|Drug|Preoperative chemotherapy|"- High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~Note: the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimum threshold must be 7.5 g/m2 per cycle.~- LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks"
75642878|NCT04019288|Drug|Batiraxcept|Given IV
75642879|NCT04019288|Biological|Durvalumab|Given IV
75642880|NCT03984188|Drug|Theophylline ER|200 mg extended release (ER) low-dose theophylline taken orally daily
76082770|NCT03008356|Dietary Supplement|L-carnitine 1000 mg twice daily|Oral L-carnitine to be taken twice daily for 8 weeks
76082771|NCT03008356|Behavioral|Weekly health coaching calls|Weekly health coaching calls lasting 10-15 minutes
76082772|NCT03008356|Dietary Supplement|Placebo capsules|
76082773|NCT04305912|Device|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses.
75642881|NCT03984188|Drug|Placebo oral tablet|Manufactured methylcellulose placebo tablet taken orally daily
75642882|NCT03984188|Other|Standard of Care Treatment|Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment
75642883|NCT03975829|Drug|dabrafenib|dabrafenib oral, twice daily
75333775|NCT01207726|Other|Laboratory Biomarker Analysis|Correlative studies
75333776|NCT05498844|Behavioral|Medical Nutrition Therapy (counselling)|Participants will receive nutrition counseling to enhance adherence to the principles of the Mediterranean diet and support the achievement of adequate levels of lipid control, blood pressure and weight.
75333777|NCT05498688|Dietary Supplement|Low carbohydrate|Participants will have a low carbohydrate meal
75333778|NCT02534038|Drug|AVP-786|d6-DM/Q
75333779|NCT02534038|Drug|Placebo|matching placebo
75333780|NCT01202110|Drug|Propranolol|
75333781|NCT02556918|Drug|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
75333782|NCT02556918|Drug|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
75333783|NCT02556918|Drug|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
75927424|NCT02476526|Drug|Acetylcysteine Inhalation|Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
75642884|NCT03975829|Drug|trametinib|trametinib oral, once daily
75791196|NCT05372120|Drug|ICP-192|ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression
75333784|NCT02556918|Drug|Insulin glargine|"Patients that required continuous insulin infusion (CII) at a rate >1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between >180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG >241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG <100 mg/dl: stop basal"
75927425|NCT02476526|Drug|Sodium Bicarbonate Solution|Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
76082774|NCT04305912|Device|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses.
76082775|NCT01544998|Drug|Nesiritide|10 ug/kg
76082776|NCT01544998|Drug|Tadalafil|5 mg
75927426|NCT02476526|Procedure|64-MDCT Scanning|Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
76082777|NCT01544998|Drug|Placebo|The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
76082778|NCT01544998|Drug|Saline load|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
75333785|NCT02556918|Drug|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG greater than 400 mg/dL; 7-9 units of insulin lispro"
75471819|NCT03721016|Drug|MT10109L|MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
75642885|NCT03957252|Diagnostic Test|Blood test: ClarityDX Prostate|PSA on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
75642886|NCT03948048|Device|ECMO|ECMO is used to intervene septic shock and refractory septic shock
75642887|NCT03898362|Other|pneumatically powered wheelchair or scooter|a wheelchair or scooter powered by compressed air will be used for 6 months. Compressed air is a novel power source and no batteries are used in these devices.
75642888|NCT03898362|Device|battery powered wheelchair or scooter|a wheelchair or scooter powered by a battery will be used for 6 months. These are conventional mobility devices that the participants are using or in the process of obtaining
75642889|NCT03841058|Drug|Abaloparatide|80 mcg delivered SC by a pen
75642890|NCT03841058|Drug|Placebo|A pen to deliver a SC dose of placebo
75642891|NCT03824106|Other|Control|Participants randomized to the control arm will not receive any of the Frailty Management Interventions.
75791197|NCT03029104|Combination Product|CXLO Corneal Strengthening Solution and UVA Illumination Device|CXLO Corneal Strengthening Solution
75791198|NCT03753230|Device|Electroencephalography|Cerebral measurements from electroencephalography devices while music is presented to the participant
75791199|NCT03763916|Procedure|Ureteric dissection|clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
75927427|NCT04491812|Other|Kinesio Tape|Elastic Kinesiology Tape
75927428|NCT04491812|Other|Physical therapy program|designed physical therapy program
75927429|NCT02478944|Device|Manometry|Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
75927430|NCT02479022|Drug|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
76082779|NCT03391830|Drug|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
76082780|NCT03391830|Drug|Placebo|Placebo
76082781|NCT04033770|Other|Urodynamic investigation|Urodynamic investigation using an air-charged measurement system
76082782|NCT04033770|Other|Urodynamic investigation|Urodynamic investigation using a water-perfused measurement system
76082783|NCT01441492|Procedure|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
76082784|NCT01441492|Procedure|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
76082785|NCT01441570|Drug|Nebivolol|Subject will take nebivolol daily for 12 weeks.
76082786|NCT01441570|Drug|Metoprolol succinate|Subject will take metoprolol succinate daily for 12 weeks.
75927431|NCT02479022|Drug|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
75927432|NCT02479022|Drug|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
75927433|NCT02478866|Drug|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
75333786|NCT02556918|Drug|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin aspart~BG between 221-260 mg/dL; 3-5 units of insulin aspart~BG between 261-300 mg/dL; 4-6 units of insulin aspart~BG between 301-350 mg/dL; 5-7 units of insulin aspart~BG between 351-400 mg/dL; 6-8 units of insulin aspart~BG greater than 400 mg/dL; 7-9 units of insulin aspart"
75642892|NCT03824106|Behavioral|Group Exercise|A recent meta-analysis suggests 180 min/week of exercise (with a high challenge to balance) is most effective for fall prevention. Combined strength and endurance training performed at a moderate weekly frequency (i.e., two times per week) may promote marked gains on muscle hypertrophy, strength and power gains in frail older adults. Balance training is a key component of successful exercise programs for vulnerable older adults.
75642893|NCT03824106|Combination Product|Nutrition and Medication review|"Nutrition review: Conduct nutritional screening flow and review any questions, provide some additional counseling/coaching. Protein supplements will be provided to all participants unless contraindicated.~Medication review: Review/update current medication list and forward the list and medical history to the consultant study pharmacist."
75791200|NCT03763916|Procedure|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy [Karl storz] is done to identify the ureteric orifices. ureteric catheters [Roche] are inserted followed by the insertion of Foley's urethral catheter
75471820|NCT03721016|Drug|Placebo|Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
75642894|NCT03824106|Dietary Supplement|Protein Supplement|Protein supplementation will be provided.
75927434|NCT02482454|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
75927435|NCT02482454|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
75927436|NCT02476760|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
75333787|NCT00379756|Drug|LEVITRA (vardenafil)|active comparator
75333788|NCT00379756|Drug|placebo|placebo comparator
75333789|NCT05492292|Diagnostic Test|Perfusion brain scintigraphy imaging|The cerebral perfusion scintigraphy via a SPECT examination aims to analyze the cerebral blood flow and detect possible lesions or inflammations.
75333790|NCT02518750|Drug|Dexamethasone|Given orally (PO).
75333791|NCT02518750|Drug|Panobinostat|Given PO.
75333792|NCT02518750|Drug|Liposomal vincristine|For intravenous (IV) use only.
75642895|NCT03824106|Dietary Supplement|Vitamin D|1000 IU of oral vitamin D
75791201|NCT03763916|Procedure|Cesarean hysterectomy|lateral dissection of the uterus is completed from the pelvic side wall, followed by very CAREFUL BLADDER DISSECTION. Finally clamping of the uterine vessels is done below the level of the placenta with or without complete removal of the cervix. Closure of the uterine stump is performed followed by CAREFUL HEMOSTASIS then closure of the abdomen is performed after leaving two wide bore drains
75791202|NCT01364974|Drug|ASP015K|oral
75791203|NCT01364974|Drug|Placebo|oral
75791204|NCT05323214|Drug|Control Analgesic regimen|testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia
75927437|NCT02476760|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
75927438|NCT02476760|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
75927439|NCT02476760|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
75927440|NCT02476760|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
75927441|NCT02476760|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
75927442|NCT02476760|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
75927443|NCT02476760|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
75333793|NCT02518750|Drug|Mitoxantrone|Given IV.
75333794|NCT02518750|Drug|Peg-asparaginase|"Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection."
75471821|NCT03707340|Drug|Flibanserin Pill|Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.
75471822|NCT03649659|Drug|Silver Diamine Fluoride|SDF will be applied twice during the study
75927444|NCT02476292|Other|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
76082787|NCT03394794|Device|Pelvic floor rehabilitation|The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
76082788|NCT05238012|Drug|Xuezhikang Capsule|Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
75471823|NCT03649659|Drug|Placebo|This is being compared to the SDF and will also be applied twice
75642896|NCT03822468|Drug|Ribociclib|Ribociclib will be supplied as 200 mg tablets as individual patient supply packaged bottles taken by mouth.
75927445|NCT02478554|Other|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
75927446|NCT05460338|Drug|Cholecalciferol|native form of Vitamin D.
76082789|NCT05238012|Drug|Atorvastatin Calcium Tablets|Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
75333795|NCT02518750|Drug|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
75333796|NCT02518750|Drug|Intrathecal Triples|Given IT as ITMHA.
75333797|NCT02518750|Drug|High-dose methotrexate|Given intrathecally (IT) or IV.
75642897|NCT03822468|Drug|Letrozole or Anastrozole|Letrozole 2.5 mg by mouth QD continuously or anastrozole 1 mg by mouth QD continuously (investigator choice)
75642898|NCT03822468|Drug|Goserelin|Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
75642899|NCT03816839|Drug|Amcenestrant (SAR439859)|"Pharmaceutical form: Capsules~Route of administration: Oral"
75642900|NCT03816319|Drug|UAE Inhibitor TAK-243|Given IV
75642901|NCT03798626|Drug|Gevokizumab|60 mg/mL concentration; administered intravenously (IV)
75642902|NCT03798626|Drug|Bevacizumab|25 mg/mL concentration; administered IV
75642903|NCT03798626|Drug|Modified FOLFOX6|Oxaliplatin [5 mg/mL concentration; administered IV], leucovorin [10 mg/mL concentration; administered IV] (or levoleucovorin [10 mg/mL concentration; administered IV]), and 5-fluorouracil [50 mg/mL concentration; administered IV]
75927447|NCT02482220|Behavioral|Physical activity intervention|
75927448|NCT02482142|Dietary Supplement|Effect of phosphorus|Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
75927449|NCT02482064|Other|Flexible resin|This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
76082790|NCT01441882|Drug|Dasatinib|Given PO
76082791|NCT01441882|Other|Laboratory Biomarker Analysis|Correlative studies
76082792|NCT01441882|Other|Pharmacological Study|Correlative studies
76082793|NCT03394716|Radiation|Radiotherapy|standard radiotherapy treatment with 1-3 extra MRIs
76082794|NCT05237856|Device|Capnometry Monitorization|After spinal anesthesia, a non-invasive nasal cannula will be applied to the patient, ETCO2 and IPI values will be continuously measured and recorded from this cannula with a capnometry device.
76082795|NCT01484626|Drug|Bendamustine|The first group of three patients to enter the study will receive a 25 mg/m^2 dose of bendamustine. If this dose is found to be safe, the next three patients will receive 50 mg/m^2. Using a modified Fibonacci dose-escalation design, the dose will continue to increase at a rate of 25 mg/m^2 until the highest safe dose of bendamustine is found. The maximum dose will be 125 mg/m^2. Bendamustine and bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
76082796|NCT04446936|Procedure|Flap covering for pressure ulcer|Flap covering for pressure ulcer
76082797|NCT03394638|Other|Access to online eLearning module|Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.
75333798|NCT02518750|Drug|6-Mercaptopurine|Given PO at consistent time each day.
75333799|NCT02518750|Drug|High-dose cytarabine|Given IT or IV.
75333800|NCT02518750|Drug|Nelarabine|Given IV
75333801|NCT02518750|Drug|Cyclophosphamide|Given IV.
75471824|NCT03620981|Drug|Brexpiprazole|Drug: 1 tablet /day Once daily for 10 weeks
75642904|NCT03798626|Drug|FOLFIRI|Irinotecan [20 mg/mL concentration; administered IV], leucovorin [10 mg/mL concentration; administered IV] (or levoleucovorin [10 mg/mL concentration; administered IV]), and 5-fluorouracil [50 mg/mL concentration; administered IV]
75642905|NCT03798626|Drug|Ramucirumab|10 mg/mL concentration; administered IV
75927450|NCT02476136|Drug|paroxetine, duloxetine, fluoxetine or venlafaxine|
75927451|NCT02476370|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week programm, one introductory session and daily home practice"
75927452|NCT02476370|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
75333802|NCT02518750|Drug|Etoposide|"Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used."
75333803|NCT02518750|Drug|Clofarabine|"Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II."
75333804|NCT05592964|Dietary Supplement|Fasting|Standard fasting
75333805|NCT05592964|Dietary Supplement|Water|In Group S, water was given 1 hour before the operation.
75333806|NCT05592964|Dietary Supplement|Carbohydrate fluid|In Group K, carbohydrate fluid was given 1 hour before the operation.
75471825|NCT03620981|Drug|Placebo|Placebo: 1 tablet /day Once daily for 10 weeks
75471826|NCT03501238|Other|Chocolate Milk|Chocolate bovine milk will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
75471827|NCT03501238|Other|Chocolate milk substitute|Chocolate milk substitute will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
75927453|NCT02476214|Behavioral|group prenatal care|"Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.~There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse."
75927454|NCT05437094|Drug|CRD-740|CRD-740
75927455|NCT05437094|Drug|Itraconazole|Itraconazole
75927456|NCT05413772|Other|Temocillin|To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections
75927457|NCT03314402|Drug|Jaktinib Dihydrochloride Monohydrate|Active Substance
75927458|NCT03314402|Drug|placebo|Placebo
75927459|NCT05713292|Drug|Pirfenidone Oral Product|Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
75927460|NCT05713292|Drug|Pirfenidone placebo|Pirfenidone placebo
76082798|NCT03394638|Other|Access to measurement devices|Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.
76082799|NCT03394638|Procedure|Conventional group|All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
76082800|NCT03394560|Device|High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
76082801|NCT03394560|Device|Sham High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
76082802|NCT03394482|Drug|Lu AF35700 5 mg clinical formulation|Lu AF35700 tablets 5 mg oral single dose
76082803|NCT03394482|Drug|Lu AF35700 5 mg commercial formulation|Lu AF35700 tablets 5 mg oral single dose
76082804|NCT03394482|Drug|Lu AF35700 10 mg clinical formulation|Lu AF35700 tablets 10 mg oral single dose
76082805|NCT03394482|Drug|Lu AF35700 10 mg commercial formulation|Lu AF35700 tablets 10 mg oral single dose
76082806|NCT03394482|Drug|Lu AF35700 20 mg clinical formulation|Lu AF35700 tablets 20 mg oral single dose
76082807|NCT03394482|Drug|Lu AF35700 20 mg commercial formulation|Lu AF35700 tablets 20 mg oral single dose
76082808|NCT01545232|Biological|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
75333807|NCT05492058|Other|tactile stimulation group|The tactile stimulation group will be asked to touch their own abdomen during the NST procedure.
75927461|NCT03314324|Drug|ODM-201|ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
75927462|NCT03314324|Drug|Enzalutamide|Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
75927463|NCT02475902|Behavioral|Computer guided home exercise program|Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.
75927464|NCT02475902|Behavioral|Paper guided home exercise program|Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
75333808|NCT05492058|Other|listen music|Pregnant women in the music group will listen to a song they want with headphones during the NST procedure.
75333809|NCT05492058|Other|virtual reality group|Pregnant women in the virtual reality group will be shown a nature walk video with nature sounds (stream, bird, etc.) during the NST procedure.
75333810|NCT05498532|Diagnostic Test|Functional MRI|Anatomical MRI : T2 fiesta, SSFE, HASTE ; 3D T2 ; T1 FAT SAT ; LAVA Functional MRI : T1 FAT SAT with gadolinium
75333811|NCT01194856|Drug|Atazanavir/ritonavir|300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
75927465|NCT02481752|Other|Approach Avoidance Training|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
75927466|NCT02481752|Other|SHAM Training|
75791205|NCT05323214|Drug|Fentanyl Analgesic regimen|testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia
75927467|NCT02475824|Drug|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
75927468|NCT02475824|Drug|"Meperidine (pethidine®)"|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
75927469|NCT02475824|Drug|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
75927470|NCT02475824|Drug|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
75927471|NCT02478242|Drug|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
75927472|NCT02478242|Drug|Normal saline|
75927473|NCT02475746|Drug|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
76082809|NCT01545232|Biological|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
75333812|NCT01194856|Drug|Efavirenz|Maintain dosage - 600 mg orally QHS for 96 weeks
75333813|NCT05488392|Procedure|Hypothermia with intrajugular cooling|Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.
75333814|NCT05488236|Other|Nuclear magnetic resonance analysis of embryo culture medium|Analysis of culture medium from euploid and aneuploid embryos by magnetic nuclear resonance.
75333815|NCT01182610|Drug|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
75333816|NCT01182610|Drug|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
75471828|NCT03501238|Other|Chocolate milk substitute with gelatin|Chocolate milk substitute with gelatin added will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
75471829|NCT03491722|Other|risk factors and revascularization procedures|arterial revascularizations needed since index procedure
75471830|NCT03486106|Other|Music|Music will be provided via Spotify, which is an Internet streaming music service, and will be played through headphones; this way, no other individual in the operating room will be distracted or influenced by the patient's music selection.
75927474|NCT02475746|Drug|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
75927475|NCT02475590|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
75927476|NCT02475590|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
75927477|NCT02481908|Device|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
75927478|NCT04492046|Other|Manual Lymph Drainage|Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.
75927479|NCT04492046|Other|Bandaging|Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
75927480|NCT02481362|Other|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
75471831|NCT03486106|Other|Headphones|All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
75471832|NCT03486106|Drug|Propofol|All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
75471833|NCT03441659|Procedure|ACL reconstruction|Surgical ACL reconstruction
75642906|NCT03798626|Drug|Paclitaxel|6 mg/mL concentration; administered IV
75791206|NCT05323214|Drug|Dexmedetomidine Analgesic regimen|testing the efficiency of Dexmedetomidine as an adjuvant drug to bupivacaine in epidural analgesia
75927481|NCT02481362|Other|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
75927482|NCT03314246|Other|FAST|Fasting Algorithm for Singaporeans with Type 2 Diabetes
75791207|NCT02369536|Dietary Supplement|nutraceutical mixture|Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
75927483|NCT03314246|Other|Standard of care|Standard of care
76082810|NCT03394404|Device|ECG-I mapping and PVI|ECG-I mapping and PVI
76082811|NCT05237778|Behavioral|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.
75471834|NCT03434275|Drug|N1539|Once Daily
75471835|NCT03434275|Drug|Placebo|Once Daily
75471836|NCT03400371|Other|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
75471837|NCT03400371|Other|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
75642907|NCT03798626|Drug|Cabozantinib|60 mg tablet; administered orally
75642908|NCT03796598|Drug|Fecal Microbial transplant Capsules|Oral capsules of FMT
75927484|NCT05354180|Other|navicular mobilization|Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week
75927485|NCT05354180|Other|rigid tapping|"A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
75927486|NCT05354180|Other|Navicular Mobilization and Rigid Taping|"Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week.~A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
75927487|NCT02475512|Other|Wash wipes (3M)|
75927488|NCT02475512|Other|water and pH neutral soap|
75642909|NCT03796598|Drug|Fecal Microbial Transplant Enema|FMT enema
75642910|NCT03796598|Other|Placebo|Placebo
75642911|NCT03746470|Procedure|ACL reconstruction preserving insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis, preserving their insertion at the level of the hamstring.
75642912|NCT03746470|Procedure|ACL reconstruction detaching insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis tendons completely detached from their insertion at the hamstring.
75791208|NCT02369536|Dietary Supplement|placebo|Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
76082812|NCT05237778|Behavioral|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.
75791209|NCT03753152|Device|experimental|Neuramis® Deep Lidocaine
75791210|NCT03753152|Device|comparator|YVOIRE® Volume Plus
76082813|NCT05237700|Other|Patient positioning on operating table|The patients are either positioned in Trendelenburg with lithotomy positioning or in Trendelenburg without lithotomy positioning on the operating table when undergoing robotic assisted laparoscopic surgery or laparoscopic surgery.
75642913|NCT03731234|Drug|Ibrutinib|Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance
76082814|NCT01545700|Drug|Control-saline|Patients are randomized to receive saline 2 cc
76082815|NCT01545700|Drug|Dexamethasone 4 mg|Patients randomized to receive dexamethasone 4mg and 1 cc saline
76082816|NCT01545700|Drug|Dexamethasone 8 mg|Patients randomized to receive dexamethasone 8mg
76082817|NCT01545700|Drug|Control saline|Patients are randomized to receive saline 2 cc
76082818|NCT01545700|Drug|Dexamethasone 4 mg|Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
76082819|NCT01545700|Drug|Dexamethasone 8 mg|Patients are randomized to receive dexamethasone 8 mg
76082820|NCT02520336|Behavioral|Reminder|
76082821|NCT04006002|Other|Metabolic and Hormonal profile|To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention
75471838|NCT03354013|Procedure|AOA|100% ICSI-AOA will be performed.
75642914|NCT03720197|Other|Online questionnaire - Phase 1|Draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.
75642915|NCT03720197|Other|Online questionnaire - Phase 2|Characterize the causes, experience and consequences of hypoglycemia.
75642916|NCT03720197|Other|Online questionnaire - Phase 3|Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.
75791211|NCT05283746|Drug|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
75791212|NCT01936480|Drug|Moxifloxacin 400mg once time|
75333817|NCT01182610|Drug|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
75333818|NCT01182610|Drug|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
75333819|NCT05491902|Diagnostic Test|[C11] Leucine PET scan|Each participant will receive an i.v. bolus of the PET radioligand, [11C]-Leucine (<100 μg), for each scan. [11C]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (<100 μg) with no adverse effects.
75333820|NCT05491902|Diagnostic Test|[18F] Flutemetamol PET scan|Each participant will receive an i.v. bolus of the PET radioligand, [18F]-Flutemetamol (< 10 μg), for each scan.
75333821|NCT05491902|Diagnostic Test|MRI scan|Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.
75791213|NCT05460260|Device|Cascade CGM|21-days of CGM wear
75791214|NCT03755258|Drug|GCK 100 mg + Placebo 200 mg|GCK 100 mg + Placebo 200 mg, oral, 12 weeks
75791215|NCT03755258|Drug|GCK 200 mg + Placebo 100 mg|GCK 200 mg + Placebo 100 mg, oral, 12 weeks
75791216|NCT03755258|Drug|GCK 300 mg|GCK 300 mg, oral, 12 weeks
75791217|NCT03755258|Drug|Placebo 300mg|Placebo 300mg, oral, 12 weeks
75791218|NCT01575886|Other|Teachable Moment Communication Process|The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
75471839|NCT03354013|Diagnostic Test|Genetic screening|Patients will donate a saliva sample. Genetic screening will take place for PLCzeta (male) and Dux4 (male and female). Also other possible genes involved in embryo development could be tested.
75642917|NCT03720197|Other|Food questionnaire|24-hour food recall questionnaire
75927489|NCT05712980|Device|Implanted pulse generator for SCS with different programming modalities|"Surgical technique~Patients recruited will be scheduled for the implantation of the SCS system in two phases. The implant procedure will be performed following our standardized clinical practice under local anesthesia and moderate sedation.~Clinical parameters~Clinical evaluation of study subjects shall include, in addition to demographic parameters, the assessment of parameters related to pain experience, disability, quality of life, as well as other psychological variables. All these parameters will be evaluated at different times of the study.~Sample processing~10 ml of peripheral blood will be obtained per venopuncture at different moments, always at the same time of day and in the same anatomical location.~Expression arrays~After a manual removal of RNA the expression arrays and the scanning of the crystals will be carried out after hybridization"
75642918|NCT03720197|Other|Pedometer|Participants will wear a podometer for 14 consecutives days
75642919|NCT03720197|Other|Waist circumference|Participants will be asked to measure their waist circumference
75642920|NCT03720197|Other|Blood and urine tests|Participants will be invited to send us their latests blood and urine test results.
75642921|NCT03720197|Other|List of medications|Participants will be invited to send us their list of medications
75642922|NCT03720197|Other|Continuous glucose monitor|Participants will be invited to send us the latest report of their continuous glucose monitor
75642923|NCT03674593|Procedure|Mitral valve chordae prosthesis|"The method consists of five stages:~Measure the required length of the chords~Forming loops~Fixation of the loop group to the papillary muscles~Fixation of chordal loops to the free edge of the valve~Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse"
75642924|NCT03674593|Procedure|Mitral valve chordae translocation|"The method consists essentially of three stages:~Selection of the secondary chord.~Fixation of secondary chords to the free edge of the valve.~Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
75642925|NCT03635021|Drug|FOLFOX regimen|oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
75927490|NCT02475668|Device|Pulse oximeter|Hypoxia
75927491|NCT02481518|Drug|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
75927492|NCT02481518|Other|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
75927493|NCT05712902|Drug|DZD9008|Daily dose of DZD9008
75642926|NCT03635021|Drug|Panitumumab|6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
75642927|NCT03635021|Drug|Bevacizumab|5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
75927494|NCT05715164|Device|E-cigarettes device plus liquid|The four basic care counseling sessions will be held over the course of 48 weeks with the supply of e-cigarettes and liquid. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using e-cigarettes.
76082822|NCT01486810|Drug|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
76082823|NCT01486810|Behavioral|medication management|All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
76082824|NCT04446780|Procedure|Mediolateral episiotomy|Cutting of the perineum during vaginal delivery in order to avoid obstetric anal sphincter injury
76082825|NCT04446546|Procedure|Vascular access by pass using a cold stored venous allograft|Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft
76082826|NCT01487668|Behavioral|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
75791219|NCT03755180|Other|Exercise Training|In exercise training, aerobic exercise and strengthening exercises, especially for gastrocnemius and tibialis anterior muscles, will be applied to the patients. In addition the exercise training, Compression Therapy is applied to patients.
75791220|NCT03755180|Other|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
75791221|NCT01356550|Drug|RO4917838|single oral dose
75791222|NCT03755024|Device|ultrasound|"The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~Biparietal diameter~Head circumference~Abdominal circumference~Femur length~Humerus length"
75791223|NCT01356784|Other|Tailored Physical Activity|Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
75791224|NCT01356784|Behavioral|"Chronic Pain Self-management Programme"|Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
75791225|NCT01356784|Behavioral|Health counselling|Health guidance (1,5h)
75471840|NCT03354013|Diagnostic Test|Calcium pattern analysis|Male patients will donate a sperm sample. Calcium pattern analysis will take place by injecting the patients' sperm into mouse and/or human (in vitro matured) oocytes (research-donated control oocytes). This will estimate the sperm capability to induce calcium oscillations in the oocyte.
75471841|NCT03348423|Drug|DEX-IN|IN Dexmedetomidine + IV placebo
75471842|NCT03348423|Drug|Fentanyl|IN Placebo + IV Fentanyl
75791226|NCT01356862|Drug|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
75642928|NCT03635021|Drug|FOLFIRI regimen|irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
75642929|NCT03631628|Device|Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)|The stimulator is a 120z Dual-Channel TENS Unit (ITO Physiotherapy & Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching, to provide sensory stimulation to both paretic and intact arms. Two pairs of disposable surface electrodes will be applied over the median nerve from the carpal tunnel to the flexor digitorum superficialis and the superficial radial nerve from the extensor pollicis longus to the extensor digitorum communis, with the cathode on the proximal site, and the anode on the distal site.
75791227|NCT01356862|Drug|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
75791228|NCT03763760|Drug|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
75791229|NCT03763682|Device|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Six (6) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4, 5 and 6 month(s) after implantation
75791230|NCT01357096|Behavioral|Integrated health care team|CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring
75791231|NCT01357096|Other|Traditional group|CAD education fryers
75642930|NCT03631628|Behavioral|Mirror Therapy (MT)|"A customised angle-adjustable frame with a mirror board will be used. All subjects are instructed to perform~Elbow flexion and extension exercise~Forearm pronation and supination exercise~Wrist flexion and extension exercise~Wrist radial and ulnar deviation exercise~Fingers opposition exercise~Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of mirror, and paretic arm will be placed behind the mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively.~Participants will be encouraged to focus on the image of intact arm when performing upper limb exercises bilaterally."
75791232|NCT04501952|Drug|RDV|Administered as an intravenous infusion
75791233|NCT04501952|Drug|Placebo to Match RDV|Administered as an intravenous infusion
75927495|NCT05715164|Drug|Nicotine Pouches|The four basic care counseling sessions will be held over the course of 48 weeks with a supply of nicotine pouches. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches.
75927496|NCT05715164|Other|Basic care counseling about smoking cessation|The four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health.
76082827|NCT03398772|Behavioral|Comprehensive Health Coaching Program|Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
75791234|NCT00321100|Drug|bevacizumab|Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
75791235|NCT00321100|Drug|cetuximab|Cetuximab 400mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly each 21 day cycle
75791236|NCT00321100|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 IV day 1 every 21 days
75791237|NCT00321100|Drug|Capecitabine|Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
75791238|NCT01365520|Drug|turoctocog alfa|A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
76082828|NCT04446624|Other|Music therapy intervention|Group psychotherapy with music intervention
76082829|NCT01443442|Drug|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
75927497|NCT02481284|Device|Laser Doppler perfusion imaging|LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
75927498|NCT02475356|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|The treatment of Mirena should comply with the local product information.
76082830|NCT01443442|Drug|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
75791239|NCT05191732|Combination Product|Platelet-Rich Plasma; Bone marrow concentrate|Platelet-rich plasma (PRP) (Dosage form: APA-15) Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
75791240|NCT05191654|Diagnostic Test|evaluation of cardiopulmonary parameters, gross motor development and hand grip strength|Gross motor development was evaluated with Gross Motor Function Measure (GMFM-88). Hand grip strength was measured with the Baseline Pneumatic Bulb Dynamometer. Cardiopulmonary parameters values was evaluated with echocardiography.
75791241|NCT02930122|Drug|anakinra (150mg)|intraarticular administration
75791242|NCT02930122|Other|Saline intraarticularly|intraarticular administration
75791243|NCT01365598|Drug|Primaquine|Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
75791244|NCT01365676|Drug|GAMALINE® + HIPERICIN®|GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
75791245|NCT01365676|Drug|GAMALINE®|GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
75791246|NCT01365208|Drug|Chemotherapy|platinum-based chemotherapy
76082831|NCT03389646|Device|CERAMENT G V|"During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU)."
76082832|NCT01444924|Drug|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
75642931|NCT03631628|Behavioral|sham-Mirror Therapy (sham-MT)|"A customised angle-adjustable frame with a mirror board will be used while the reflecting surface of the mirror was covered with paper. All subjects are instructed to perform~Elbow flexion and extension exercise~Forearm pronation and supination exercise~Wrist flexion and extension exercise~Wrist radial and ulnar deviation exercise~Fingers opposition exercise~Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of covered mirror, and paretic arm will be placed behind the covered mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively."
75642932|NCT03631628|Behavioral|Conventional Rehabilitation Program|Standardized upper limb training
76082833|NCT01444924|Drug|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
76082834|NCT03389568|Behavioral|singing-based music therapy program|A single 1-hour singing-based intervention is conducted with each primary caregiver of an ICU patient. The intervention is composed of three steps: 1) listening to a participant's preferred music and identifying his and her emotional states (15 minutes), (2) singing for emotional changes (30 minutes), and (3) discussing what he or she experiences during singing and identifying how they apply such experience to their personal use of music for emotional changes in his or her everyday life (15 minutes).
76082835|NCT01546402|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
76082836|NCT01546402|Procedure|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
76082837|NCT03389490|Drug|Insulin Glargine 300 UNT/ML|Self titration of insulin glargine U300
76082838|NCT03389490|Drug|Neutral protamine hagedorn insulin|Self titration of NPH insulin
76082839|NCT01546636|Other|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
76082840|NCT01546636|Other|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
76082841|NCT03391752|Combination Product|Integrated Nutrition Pathway for Acute Care|algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement
76082842|NCT03391674|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation through oral capsules after omeprazole pre-treatment
76082843|NCT01547806|Drug|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
75927499|NCT05710562|Other|Name not applicable|In this study, we do not provide any type of intervention but only require the fulfillment of self-report tools by patients during their routine outpatients visit.
75642933|NCT03631199|Drug|canakinumab|canakinumab every 3 weeks (squamous and non-squamous)
75642934|NCT03631199|Drug|canakinumab matching placebo|canakinumab placebo every 3 weeks (squamous and non-squamous)
75642935|NCT03631199|Drug|pembrolizumab|200 mg every 3 weeks (squamous and non-squamous)
75642936|NCT03631199|Drug|carboplatin|Area Under the Curve (AUC) 5 mg/mL*min every 3 weeks (non-squamous) or AUC 6 mg/mL*min (squamous)
75642937|NCT03631199|Drug|cisplatin|75 mg/m2 every 3 weeks (non-squamous)
75927500|NCT05708768|Other|Receiving physician manned rapid response car services|All patients receiving services from the physician manned rapid response car will be included
75642938|NCT03631199|Drug|paclitaxel|200 mg/m2 every 3 weeks (squamous)
75927501|NCT02481128|Procedure|without preoperative access to lymphoscintigraphy findings|axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
75927502|NCT02475200|Device|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
76082844|NCT01547806|Drug|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
76082845|NCT01547806|Procedure|Apheresis|The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
76082846|NCT03391596|Behavioral|Internet-based ACT intervention|The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.
75642939|NCT03631199|Drug|nab-paclitaxel|100 mg/m2 every 3 weeks (squamous)
75642940|NCT03631199|Drug|pemetrexed|500 mg/m2 every 3 weeks (non-squamous)
76082847|NCT03391596|Behavioral|Standardized rehabilitation|Standardized institutional rehabilitation in a rehabilitation center
76082848|NCT03391596|Behavioral|Support by voluntary caregiver associations|Support given by voluntary caregiver associations
76082849|NCT01445626|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
76082850|NCT03398460|Diagnostic Test|Survey|Burnout rates before and after the introduction of a bereavement card Burnout rates before and after an ICU rotation for physicians
75471843|NCT03348423|Drug|Placebo|IN Placebo + IV Placebo
75642941|NCT03610256|Procedure|SADI-S|Laparoscopic SADI-S, recently described as an evolution of the BPD-DS, combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction, associating a sleeve gastrectomy and a duodeno-ileal bypass at 2.5 meters from the ileo-caecal valve if BMI ≥ 50 kg/m² or at 3 meters if BMI < 50
75927503|NCT02474966|Device|Deep Transcranial Magnetic Stimulation (dTMS)|Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
76082851|NCT02744742|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
76082852|NCT02744742|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
76082853|NCT02744742|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
76082854|NCT02744742|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
76082855|NCT01548040|Device|Kneehab XP|NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively
75333822|NCT05574946|Procedure|Anterior Cruciate Ligament Reconstruction|Anterior Cruciate Ligament Reconstruction with four strand semitendinosus graft
75333823|NCT05488158|Other|Osteopathic manipulation|Pain and somatic disfunction were treated with osteopathic manipulations as deemed appropriate by a trained DO.
75333824|NCT01165450|Drug|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
75333825|NCT01165450|Drug|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
75333826|NCT05485896|Drug|Pembrolizumab plus Lenvatinib|Pembrolizumab plus Lenvatinib
75333827|NCT01148056|Radiation|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
75642942|NCT03610256|Procedure|RYGB|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~a small gastric pouch (about 30cc)~an antecolic alimentary limb~a gastro-jejunal anastomosis using a linear stapler~a 150cm long alimentary limb~a 50cm biliary limb~a latero-lateral jejuno-jejunal anastomosis~closure of the mesenteric defects"
75791247|NCT01358032|Behavioral|an in-home cognitive behavioral program|The in-home cognitive behavioral program aims to learn older persons, living in the community, how to deal with concerns about falling and to increase physical, social and functional activity. The principles of cognitive restructuring are used for shifting maladaptive in adaptive attitudes with respect to falling as well as increasing self efficacy beliefs and feelings of control. The following themes are discussed during the program: concerns about falling, thoughts about falling, physical exercise, assert oneself, overcome personal barriers, recognizing fall-ty habits and managing concerns about falling. Duration of the program is 10 weeks with 7 individual sessions (3 home visits (60, 60 and 75 minutes, respectively) & 4 telephone contacts (35 minutes each). The program is facilitated by trained nurses qualified in the field of geriatrics and working for home care agencies.
75791248|NCT01365286|Drug|Ivabradine (Procoralan)|Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)
75791249|NCT01365286|Drug|Placebo|Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
75791250|NCT01365364|Behavioral|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
75791251|NCT01365364|Behavioral|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
75927504|NCT02475122|Other|azygos blood flow measurements by MRI|
75927505|NCT02475044|Behavioral|Cognitive-Behavioral Therapy|16 Sessions of CBT.
75927506|NCT05715008|Other|Kefir|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
75927507|NCT05715008|Other|Placebo|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
75927508|NCT02480894|Drug|BMS-663068|BMS-663068
75927509|NCT02480894|Drug|Maraviroc|Maraviroc
75927510|NCT05356364|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|cognitive and behavioral treatment for perinatal insomnia.
75927511|NCT05356364|Behavioral|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|Mindfulness and behavioral based therapy for perinatal insomnia.
76082856|NCT01548040|Device|Quadriceps TENS|on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
75333828|NCT05488002|Behavioral|Pharmaceutical intervention|Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
76082857|NCT03389334|Other|massage|The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
76082858|NCT01548742|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
76082859|NCT01548742|Behavioral|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
75927512|NCT02478086|Dietary Supplement|use amine acids parenteral 3.5g|"Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
75927513|NCT02478086|Dietary Supplement|use amine acids parenteral 4g|"Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
75927514|NCT02480816|Dietary Supplement|Mineral water|Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
75927515|NCT02480660|Behavioral|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
75927516|NCT02474888|Other|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
75927517|NCT02474732|Device|Beactive(r) Brace|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
75927518|NCT02474654|Drug|Bupivicaine|15mg
75927519|NCT02474654|Drug|Fentanyl|15mcg
75927520|NCT02474654|Drug|Epimorphine|150mcg
75642943|NCT03587532|Diagnostic Test|Indocyanine green angiography|ICGA will be performed twice during standard esophagectomy: 30 minutes after the stomach graft creation and immediately before the esophagogastric anastomosis. stock dose of 25 mg ICG (Pulsion Medical Systems, Germany) will be diluted to 5 mg/mL with sterile water. An IV bolus of 0.5 mg/kg of ICG will be injected via a central venous catheter. Video data will be obtained with a charge-coupled device (CCD) camera fitted with a light-emitting diode emitting at a wavelength of 760mm (Visera® elite II, Olympus medical system corp, Tokyo, Japan). Images will be recorded starting immediately prior to injection until 3 minutes afterwards.
75927521|NCT02474654|Drug|Normal Saline|0.3 ml
75333829|NCT05485818|Drug|Low Dose|12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
75642944|NCT03587532|Diagnostic Test|Hemodynamic evaluation|Advanced continuous hemodynamic monitoring during surgery will be performed using a PiCCO® (Pulse index Continuous Cardiac Output, Pulsion Medical Systems, Germany) catheter.
75791252|NCT03697460|Drug|INCB018424|INCB018424 PHOSPHATE CREAM 1.5%, topical application, twice daily on lesions of cutaneous LP.
75791253|NCT05191498|Device|QuiremSpheres®|Intratumoral injection of QuiremSpheres®
75791254|NCT03754712|Dietary Supplement|Vitamin D3|Dietary supplement : Vitamin D3 one tablet of vitamin D3 (2000IU) per day for 8 weeks
75791255|NCT01318954|Biological|Allergen immunotherapy|
75791256|NCT03752606|Biological|TACHOSIL GROUP|
75927522|NCT02474654|Drug|Normal Saline|30ml
75927523|NCT02474654|Drug|Normal Saline|100 ml
75927524|NCT02474654|Drug|Ropivicaine|100 ml
75927525|NCT02474654|Drug|Epinephrine|600 mcg
75927526|NCT02474654|Drug|Ketorolac|30 mg
75927527|NCT02474654|Drug|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
75927528|NCT05284604|Drug|Mesenchymal Stem Cells (MSCs)|The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
75927529|NCT05272514|Other|Hypoxia|Individuals will be exposed to varying levels of hypoxia according to the protocol detailed above.
75927530|NCT05260268|Behavioral|TEST Intervention|The TEST intervention will include standard post-transplant care and include additional touchpoints utilizing the Way to Health system. Details on this intervention are included in the study arm description.
75791257|NCT05191342|Diagnostic Test|Enzyme-linked immunosorbent assay for PCSK9|Enzyme-linked immunosorbent assay for plasma PCSK9
75791258|NCT01365754|Procedure|standard|fusion
75927531|NCT02478008|Device|CardiAQ TMVI System (Transapical DS)|
75333830|NCT05485818|Drug|Middle Dose|12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
75791259|NCT01365754|Procedure|new|dynamic stabilization
75791260|NCT01370044|Drug|Carbogen|3 minutes administration of carbogen
75791261|NCT01370044|Drug|Placebo|3 minutes administration of oxygen
75791262|NCT00070018|Biological|rituximab|250 mg/m^2, as part of Zevalin regimen
75791263|NCT00070018|Drug|Cyclophosphamide|750 mg/m^2
75791264|NCT00070018|Drug|doxorubicin hydrochloride|50 mg/m^2
75791265|NCT00070018|Drug|prednisone|100 mg
75791266|NCT00070018|Drug|vincristine sulfate|1.4 mg/m^2
75791267|NCT00070018|Radiation|radiation therapy|4000-5000 cGy total
75791268|NCT00070018|Biological|Yttrium-90 ibritumomab tiuxetan|0.4 mCi/kg
75791269|NCT00070018|Biological|Indium-111 ibritumomab tiuxetan|5 mCi
75791270|NCT03750812|Behavioral|Aerobic Exercise|Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes
75927532|NCT02477930|Other|No interventions are done|No intervention is done. This is a registry study.
75471844|NCT03299322|Drug|Jia Wei Yang He granule|This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
75471845|NCT03299322|Drug|Jia Wei Yang He granule Placebo|Made from 1/20 doses which has certain taste, but no therapeutic effect
75471846|NCT03262142|Drug|Piperacillin/tazobactam|Intravenous Piperacillin/tazobactam four times daily
75791271|NCT03750812|Behavioral|Watching television|Sitting and watching television for 30 minutes
75333831|NCT05485818|Drug|High Dose|12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
75333832|NCT05485818|Other|Placebo|15 subjects will be randomly assigned to the placebo for 7 days
75333833|NCT05507398|Drug|Placebo, metformin and atorvastatin|comparing the anti-tumor effects of metformin and atorvastatin
75333834|NCT05487612|Device|Minimal Invasive Extracorporeal Circulation|Cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC).
75791272|NCT03750734|Diagnostic Test|Bronchoscopy|Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
75791273|NCT03750734|Diagnostic Test|Blood test|Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
75791274|NCT00231413|Biological|HPV 16/18 L1 AS04|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
75927533|NCT02477852|Drug|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
76082860|NCT03125772|Device|TAXUS Element™ Paclitaxel-Eluting Stent System|Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
75333835|NCT05487612|Device|Conventional cardiopulmonary bypass|Cardiac surgery with conventional cardiopulmonary bypass (cCPB).
75471847|NCT03262142|Drug|Ciprofloxacin|Oral Ciprofloxacin twice daily
75471848|NCT03228134|Drug|Ke Chuan Liu Wei Granule|Traditional Chinese Medicine
75471849|NCT03228134|Drug|Yang He Ping Chuan Granule|Traditional Chinese Medicine
75471850|NCT03228134|Other|Ke Chuan Liu Wei Granule placebo|Placebo
75471851|NCT03228134|Other|Yang He Ping Chuan Granule placebo|Placebo
75471852|NCT03150810|Drug|Pamiparib|60 mg (20 mg capsules) administered orally twice a day
75471853|NCT03150810|Drug|Temozolomide|Doses of up to 120 mg (as 20 mg capsules) administered orally once daily (QD) as specified in the treatment arm
75471854|NCT03133273|Other|Oncogramme®|Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.
75471855|NCT03117998|Biological|REMD-477|Administered as repeated SC doses in subjects with Type 1 Diabetes
75791275|NCT00231413|Biological|HPV-16/18/31/45 L1 AS04 Formulation 1|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
75791276|NCT00231413|Biological|HPV-16/18/31/45 L1 AS04 Formulation 2|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
75791277|NCT00231413|Biological|HPV-16/18/31/45 L1 AS04 Formulation 3|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
75791278|NCT00231413|Biological|HPV-16/18/31/45 L1 AS04 Formulation 4|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
75791279|NCT00231413|Biological|HPV-16/18/31/45 L1 AS04 Formulation 5|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
75333836|NCT02414698|Procedure|Percutaneous Hydrodiscectomy|The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
75333837|NCT02414698|Drug|TESI|Transforaminal epidural steroid injections given in the lumbar spine.
75471856|NCT03117998|Biological|Placebo Comparator|Administered as a repeated SC doses in subjects with Type 1 Diabetes
75471857|NCT03114865|Drug|Blinatumomab 9ug|Cycle 1 - Days 1-7: 9 ug/day IV daily
75471858|NCT03114865|Drug|Blinatumomab 28 ug|Cycle 1 - Days 8-28: 28 ug/day IV daily
75471859|NCT03114865|Drug|Blinatumomab|Cycle 2 - Days 1-28: 28 ug/day IV daily
75471860|NCT03114865|Drug|Dexamethasone|Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
75471861|NCT03100370|Device|tsDCS-Anodal Stimulation|2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
75471862|NCT03100370|Device|tsDCS-Cathodal Stimulation|2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
75471863|NCT03100370|Device|tsDCS-Sham Stimulation|2.5mA sham tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
75471864|NCT03100370|Device|Robotic-assisted training of arm and hand functions|70 minutes of robotic-assisted training (RAT) of arm and hand functions will follow each of the tsDCS sessions, five days a week, for two weeks. Robotic-assisted training will be provided by using the MAHI Exo-II device.
75471865|NCT02920008|Drug|guadecitabine|In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.
75927534|NCT02477852|Drug|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
75927535|NCT02477852|Drug|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
75927536|NCT02477852|Drug|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
75333838|NCT05485506|Other|Multimodal exercise program|"Running technical drills: pogo, askip, dribble, scissor, etc. Exercises for lumbopelvic stabilization: mobility exercises, hip thrust, dead lift, lunge to skip.~Resisted sprints by using a sled: resistance leading to a 60% and 30% of optimal load (previously calculated)"
75471866|NCT02920008|Drug|Treatment Choice (TC)|"High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).~Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.~Best Supportive Care (BSC)."
75471867|NCT02868671|Other|acupuncture|
75471868|NCT02868671|Other|sham acupuncture|
75642945|NCT03587532|Diagnostic Test|Biological and pathological markers of ischemia|"Systemic and local capillary lactate on blood samples~Mitochondrial Respiratory activity analyses on biopsies at 3 region of interest (ROI)~Pathological analyses of the biopsies at 3 ROI"
75927537|NCT02480738|Behavioral|Computerized Cognitive Training Apparatus|"CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process."
76082861|NCT03125772|Device|Xience PRIME Everolimus-Eluting Stent System|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
76082862|NCT03391518|Procedure|Water drinking test|Ingestion of 800 ml water in less than 5 minutes.
76082863|NCT03391440|Drug|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
76082864|NCT01447888|Drug|150% Oral Morphine Equivalent (OME)|Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
75471869|NCT02866747|Radiation|Hypofractionated stereotactic radiation therapy|
75471870|NCT02866747|Drug|Durvalumab|
75471871|NCT02777528|Device|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
75471872|NCT02777528|Procedure|Revascularization Procedure|Revascularization procedure of the great vessel
75642946|NCT03562637|Biological|adagloxad simolenin combined with OBI-821|In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.
75791280|NCT00231413|Biological|HPV-16/18/31/45 L1 AS04 Formulation 6|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
75791281|NCT03991988|Drug|Montelukast|"Participants in this arm will take a pill of Montelukast daily on escalating doses: 10, 20 to 40 mg.~All participants will be initiated on 10 mg. The dose will be increased in 2-week increments to 20 mg and 40 mg as long as participants report no intolerable symptoms or adverse events."
75791282|NCT03991988|Drug|Placebo oral tablet|Participants in this arm will take a matched placebo pill daily
75791283|NCT01370122|Other|Survey|
76082865|NCT01447888|Other|Clinical Judgment|This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
76082866|NCT03398382|Dietary Supplement|Magnesium tablet group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-artikain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected, the patient will receive magnesium citrate tablets. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
75333839|NCT02415166|Biological|INFLUENZA VACCINE|THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
75333840|NCT02415166|Other|NaCl-saline placebo|placebo
75333841|NCT02403154|Procedure|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
75471873|NCT02766335|Drug|Docetaxel|Given IV
75471874|NCT02766335|Biological|Durvalumab|Given IV
75471875|NCT02766335|Other|Laboratory Biomarker Analysis|Correlative studies
75471876|NCT02745847|Radiation|Re-irradiation with SBRT|Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
75791284|NCT03752372|Procedure|hematopoietic stem cell transplantation|"Reduced intensity conditioning(RIC) chemotherapy regimen before transplantation~All patients were cared for in single rooms ventilated with a highly effective particulate air filtration system. All patients received intravenous immunoglobulin and antimicrobial prophylaxis, which included antiviral, antifungal, and Pneumocystis jirovecii prophylaxis with ganciclovir and micafungin, as per routine clinical practice before transplantation.~Umbilical cord blood transplantation"
75927538|NCT02474810|Drug|Alteplase|Alteplase for CVC dysfunction.
75927539|NCT02480504|Other|dietary intervention intermittent energy restriction|Randomized clinical trial
75642947|NCT03562637|Device|Globo H IHC Assay|The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.
75642948|NCT03562637|Other|Standard of care treatment|Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.
75791285|NCT04494646|Drug|Bardoxolone Methyl|Once-daily administration of bardoxolone methyl (20mg)
75791286|NCT04494646|Drug|Placebo|Once-daily administration of matching placebo
75791287|NCT03634774|Other|CHOICE+ Training Program|CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
75927540|NCT02480504|Other|continuous energy restriction|
76082867|NCT03398382|Dietary Supplement|Placebo tablets group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected , the patient will receive placebo tablets which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
76082868|NCT03398382|Dietary Supplement|Magnesium lozenge group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX..) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive magnesium citrate lozenge.The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate lozenges. 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
76082869|NCT03398382|Dietary Supplement|Placebo lozenges group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive placebo lozenges which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo lozenges 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
75471877|NCT02739711|Drug|Glycoprotein IIb/IIIa inhibitors|Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
75927541|NCT02725268|Drug|Paclitaxel|Paclitaxel intravenous solution.
75927542|NCT02725268|Drug|Sapanisertib|Sapanisertib capsules.
75927543|NCT02725268|Drug|MLN1117|MLN1117 capsules.
75642949|NCT03513939|Combination Product|Sernova Cell Pouch|"The Sernova Cell Pouch will be implanted against the rectus abdominis. The patient will receive either an 8-plug or 10-plug Cell Pouch configuration depending on Cohort assignment. A minimum of three weeks after Cell Pouch implantation, immunosuppression will be initiated and optimized for another 3 weeks. This will allow for proper vascularization of the Cell Pouch chambers and the patient to be stabilized on immunosuppression prior to islet transplantation. A mass, >3,000 islet equivalent (IEQ) numbers per kg of patient body weight (IEQ/kg), of highly purified islets will be transplanted in the Cell Pouch.~Patients who elect to retain the Cell Pouch after completion of the study will be asked to consent to long term safety follow-up, with data collected beyond the study scheduled visits every 3 months for up to 3 years until the last Cell Pouch explant (and then for a minimum of 3 months thereafter)."
75651868|NCT05104307|Device|Cardiac Performance System (CPS) Device|CPS is a passive measurement system that acquires signals from multiple sensor sources that monitor cardiac heart sounds. The passive sensor systems measure sound only and do not produce energy. The CPS system also includes a Patient Monitor device that acquires data from the sensors as well as from three standard ECG electrodes. The CPS system does not acquire or store any protected health information or any subject characteristics. The CPS system has received FDA clearance K173156. Note that the CPS system was previously named Integrated CardioRespiratory (ICR) system. The CPS is FDA cleared for the ejection fraction (EF) assessment which will be its intended use for this study.
75791288|NCT01073189|Drug|Intra-Renal Fenoldopam|Placement of an intra-renal catheter for infusion of fenoldopam mesylate
75927544|NCT02480426|Device|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
76082870|NCT03391206|Diagnostic Test|Inbody 720|We investigated the diagnostic accuracy of breast cancer related lymphedema diagnosed by bioimpedance analysis (Inbody 720) and arm circumference measurement..
76082871|NCT03389256|Drug|Apatinib|Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
76082872|NCT03389256|Drug|EGFR-TKI|Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po
76082873|NCT01490788|Drug|Treatment A|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
76082874|NCT01490788|Drug|Treatment B|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
76082875|NCT01490788|Drug|Treatment C|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
75471878|NCT02607423|Drug|Cisplatin|Given IV
75471879|NCT02607423|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
75791289|NCT01073189|Drug|Furosemide|Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
75791290|NCT05191186|Drug|Grass pollen extract - Alutard Phleum pratense, ALK|injection in lymph node
75927545|NCT02480426|Drug|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
75471880|NCT02607423|Drug|Docetaxel|Given IV
75471881|NCT02607423|Radiation|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
75471882|NCT02607423|Drug|Gemcitabine Hydrochloride|Given IV
75471883|NCT02607423|Drug|Pemetrexed Disodium|Given IV
75471884|NCT02607423|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT
75927546|NCT05212142|Behavioral|verbal education|Participants will receive oral health anticipatory guidance in the form of verbal and written education alongside the same preventive follow up and recall appointment schedule.
75927547|NCT05212142|Behavioral|verbal education, visual aids, and motivational interviewing|Participants will receive oral health anticipatory guidance through a combination preventive strategy using motivational interviewing, individualized goal setting, visual aids, and verbal education alongside a preventive follow up and recall appointment schedule
75927548|NCT02480348|Device|Polymer-free DES (Drug Eluting Stent)|
75471885|NCT02577523|Drug|ND0612 (Levodopa/Carbidopa solution)|The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.
75642950|NCT03496181|Behavioral|Multilingual Aphasia Examination|"For patients only prior to MRI scans.~The MAE contains eleven subtests in five categories which may be used to assess both languages in bilinguals and the participant's primary language in monolinguals: Oral Expression, Spelling, Oral Verbal Understanding, Reading, and Rating Scales. Subtests are scored for accuracy of individual items on a three-point scoring system (0, 1, 2). Contained within these domains are The Token Test, Aural Comprehension of Words and Phrases and Visual Naming which naturally parallel fMRI and direct cortical stimulation behavioral assays already in place for clinical use (phonemic fluency, auditory responsive naming and confrontation naming respectively). The MAE is expected to take under 50 minutes."
75642951|NCT03496181|Diagnostic Test|Language paradigms + RS fMRI|10 monolingual patients: 2 language paradigms + RS fMRI = 7x3 = 21 minutes 10 early bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes 10 late bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes
75642952|NCT03496181|Diagnostic Test|Language paradigms + RS fMRI + one anatomical sequence|"10 monolingual English volunteers: 2 task language paradigms* + 1 Resting State fMRI + one anatomical sequence for a total of approximately 25 minutes.~10 late bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes.~10 early bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes."
75642953|NCT03473249|Drug|Contrast-Enhanced Ultrasound using Lumason|Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
75642954|NCT03453268|Other|STEP DOWN strategy|"reduction of the number of antihypertensive medication according to:~the systolic blood pressure levels,~co-morbidities"
75642955|NCT03453268|Other|Control|usual treatment
75642956|NCT03439137|Drug|MT-6548|Oral tablet
75927549|NCT02474576|Procedure|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
75642957|NCT03439137|Drug|Darbepoetin alfa|Intravenous administration
75927550|NCT02724956|Device|Ambu AuraGain|Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
76082876|NCT03389178|Diagnostic Test|Cohen Perceived Stress Scale-10 (PSS-10)|Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score < 19 will be entered into Phase II as control
76082877|NCT02559726|Procedure|Echocardiography (TEE)|
76082878|NCT02559726|Device|Magnetic resonance imaging (MRI) with gadolinium enhancement|
76082879|NCT02559726|Device|Magnetic resonance imaging (MRI) without gadolinium enhancement|
76082880|NCT02559726|Procedure|3D electrocardiographic mapping (ECM)|
76082881|NCT02559024|Drug|MEDI6469|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
76082882|NCT03391050|Drug|APR-246|Intravenous infusion
76082883|NCT03391050|Drug|Dabrafenib|Oral administration
76082884|NCT03397992|Other|Changing dialysate temperature|Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
75642958|NCT03439137|Drug|MT-6548-matching placebo|Oral tablet
75927551|NCT02724956|Device|Teleflex LMA Protector|Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
76082885|NCT03390972|Drug|Placebo|Placebo (NaCl 0.9%) TCI infusion
76082886|NCT03390972|Drug|Dexmedetomidine|Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml
76082887|NCT01550224|Drug|Temozolomide|An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.
76082888|NCT01550224|Drug|Vorinostat|A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.
75471886|NCT02577523|Drug|ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD|The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
75471887|NCT02499328|Drug|AZD9150|AZD9150
76082889|NCT01254474|Device|Cardiac chambers mapping with MAP 4|
76082890|NCT01491022|Drug|Ampyra first, then Placebo|10 mg po bid for 4 weeks followed by placebo 4 weeks.
76082891|NCT01491022|Drug|placebo first, then Ampyra|placebo
76082892|NCT00782184|Drug|ezetimibe/simvastatin 10/40|ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
76082893|NCT00782184|Drug|atorvastatin 40 mg|atorvastatin 40 mg tablet once daily for 6 weeks
76082894|NCT00782184|Drug|atorvastatin 20 mg|All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
76082895|NCT02979808|Device|Navina Smart|Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
76082896|NCT01448356|Procedure|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~25°C and 45% humidity;~25°C and 65% humidity;~30°C and 45% humidity;~30°C and 65% humidity~After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition."
75471888|NCT02499328|Drug|MEDI4736|MEDI4736
75471889|NCT02499328|Drug|AZD5069|AZD5069
75471890|NCT02499328|Drug|tremelimumab (treme)|tremelimumab
75471891|NCT02344810|Drug|c-Met inhibitor AMG 337|Given PO
75791291|NCT01358110|Other|Early palliative care consultation|Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
75471892|NCT02344810|Other|placebo|Given PO
75927552|NCT02724956|Device|Ambu aScope|Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
75471893|NCT02344810|Drug|oxaliplatin|Given IV
75927553|NCT04999436|Behavioral|APOL1 Counseling Training Program|The APOL1 counseling training program is designed for transplant nephrologists who evaluate live kidney donor candidates of African ancestry who are at risk for having APOL1 risk variants and kidney failure post-donation. The training program aims to increase transplant nephrologists' practical knowledge, self-efficacy, and skills in counseling live donor candidates about APOL1 in a culturally competent manner. The program will include training in: current APOL1 data; the value of APOL1 testing and meaning of positive test results for living donor clinical evaluation; risks of having two APOL1 gene variants on the donor's kidney health; how to engage in shared decision making about donation; how to address cultural concerns about genetic testing; and how to protect donor candidates' privacy and confidentiality with APOL1 test results. The APOL1 counseling training program will be delivered by a genetic counselor through webinars and other interactive modalities and last 2-4 hours.
75927554|NCT04991246|Other|Antigenic tests (on saliva samples)|SARS-CoV-2 screening tests: two massive antigenic tests campaigns (on salivary samples).
75471894|NCT02344810|Drug|leucovorin calcium|Given IV
75642959|NCT03439137|Drug|Darbepoetin alfa-matching placebo|Intravenous administration
75927555|NCT04991246|Other|Individual electronic sensor port|Individual electronic sensor recording contacts but not their location (in the form of a bracelet, a key ring or a badge) Contact data collection points (5 maximum, located at compulsory passage points for participants). When a sensor is close to one of these terminals, it discharges its contacts in seconds.
75471895|NCT02344810|Drug|fluorouracil|Given IV
75927556|NCT04991246|Other|Atmospheric measurements of CO2|Atmospheric measurements of CO2 in the relevant closed places of the faculty (lectures / practical work / BU / refectory): battery operated sensors. When a sensor is installed in a place, the ventilation conditions (number of open windows, etc.) as well as the number of people present will be noted.
75927557|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs~Injection dosage and volume of the study drugs:~Low dose: 1x10e7 cells/3mL~Number of injections : only once during the study period~Device: Ultrasound~Injection technique: Injection into the lesion by investigator"
75927558|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs~Injection dosage and volume of the study drugs:~Mid dose: 5x10e7 cells/3mL~Number of injections : only once during the study period~Device: Ultrasound~Injection technique: Injection into the lesion by investigator"
75471896|NCT02344810|Other|pharmacological study|Correlative studies
75471897|NCT02344810|Other|laboratory biomarker analysis|Correlative studies
75471898|NCT02333565|Drug|Everolimus|
75471899|NCT02333565|Drug|Octreotide|
75471900|NCT02333110|Radiation|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
75471901|NCT02278185|Drug|Enzalutamide|Given PO
75642960|NCT03425201|Drug|Niraparib plus Cabozantinib|Non-randomized trial will comprise 2 stages. A dose escalation phase will characterize the safety, tolerability, DLTs and MTD, of oral niraparib plus cabozantinib in patients with urothelial or renal cell carcinoma. Subsequently, the phase II will further evaluate the safety and antitumor activity of this combination in patients with urothelial carcinoma.
75642961|NCT03402386|Drug|MT-6548|Oral tablet
75642962|NCT03396341|Other|Salvia sample|salvia sample
75651869|NCT05101668|Device|Intracranial Thrombosis Aspiration Catheter|Direct Aspiration
75791292|NCT01358110|Other|Care as usual|Standard care as usual which may or may not include palliative care consultation
75791293|NCT00231179|Behavioral|Home visiting professional support model|Home visits and telephone calls keyed to well child visits.
75791294|NCT00231179|Other|Control|The control group received an information booklet on child/family services upon enrollment and transportation for the follow-up evaluations. They were called every 4 months to maintain contact information
75791295|NCT05459714|Device|MCE for obese patients|Sequence of stomach examination: The stomach examination is performed sequentially according to the order of fundus, cardia, gastric body, angulus, antrum, and pylorus, which should ensure the integrity of the observation of each part of the stomach and achieve the purpose of comprehensive observation by means of different observation distances such as distant view and close view, and different observation angles such as front and side.
75791296|NCT01071785|Dietary Supplement|guar gum|guar gum 10g/day for six weeks
75471902|NCT02278185|Drug|leuprolide acetate|Given SC or IM
75471903|NCT02278185|Drug|goserelin acetate|Given SC or IM
75471904|NCT02278185|Drug|histrelin acetate|Given SC or IM
75471905|NCT02278185|Drug|triptorelin|Given SC or IM
75471906|NCT02278185|Drug|degarelix|Given SC or IM
75471907|NCT02205060|Other|virtual reality exposure treatment|
75471908|NCT02205060|Other|cognitive and behavioral approaches therapy|
75471909|NCT02177695|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2, IV (in the vein) on Days 1 and 8 of each 21 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
75471910|NCT02177695|Drug|Cisplatin|"Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).~Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops."
75471911|NCT02177695|Drug|Methotrexate|Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
75471912|NCT02177695|Drug|Vinblastine|Vinblastine, 3 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
75791297|NCT03750656|Drug|Hyoscyamine|Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent
75642963|NCT03396341|Behavioral|Questionnaires|Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
75333842|NCT02403154|Procedure|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
75333843|NCT02381626|Device|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
75333844|NCT02381626|Behavioral|questionnaires|
75471913|NCT02177695|Drug|Doxorubicin|Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
75471914|NCT02177695|Drug|Filgrastim|Filgrastim, 5 mcg/kg, SubQ/IV (in the vein) on Days 3-7 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
75471915|NCT02158767|Biological|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
75927559|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs~Injection dosage and volume of the study drugs:~High dose: 1x10e8 cells/3mL~Number of injections : only once during the study period~Device: Ultrasound~Injection technique: Injection into the lesion by investigator"
75642964|NCT03389932|Behavioral|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
75642965|NCT03337087|Drug|Fluorouracil|Given IV
75642966|NCT03337087|Drug|Irinotecan Sucrosofate|Given IV
75642967|NCT03337087|Other|Laboratory Biomarker Analysis|Correlative studies
75642968|NCT03337087|Drug|Leucovorin Calcium|Given IV
75642969|NCT03337087|Drug|Rucaparib|Given PO
75642970|NCT03329196|Drug|MT-6548|Oral tablet
75642971|NCT03329196|Drug|Darbepoetin alfa|Subcutaneous
75791298|NCT03750656|Drug|Tamsulosin|Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
75927560|NCT00705536|Drug|Humalog|
75927561|NCT00705536|Drug|Humulin-R|
75927562|NCT00705536|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
75927563|NCT04940936|Behavioral|A Patient Decision Aid|The Patient Decision Aid informs about the pros and cons of each option
75927564|NCT02477540|Drug|Cellgram-CLI|"Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20~25℃~Injection Method: Intramuscular"
75927565|NCT02474264|Other|Endothelial function assessment|reactive hyperemia index
76082897|NCT03390816|Other|Nutritional assessment|Observational
76082898|NCT03397914|Drug|Colistimethate Sodium|Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections
75642972|NCT03318900|Biological|Aldesleukin|Given IV
75642973|NCT03318900|Drug|CD8-Positive T-Lymphocyte|Given IV
75791299|NCT01370200|Procedure|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
75791300|NCT03752294|Drug|Dabigatran|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
75791301|NCT03752294|Drug|Placebo - Cap|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
75333845|NCT02381626|Other|Log-book|PM and biological measurements
75333846|NCT02381626|Other|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
75333847|NCT05487300|Drug|Autonomic testing on and off levodopa|"Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa."
75333848|NCT01147042|Drug|IFN-gamma|Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.
75333849|NCT03840486|Device|Non-rebreather mask (NRBM)|The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM, 35 LPM, or Flush rate at 55 LPM).
75471916|NCT02106572|Drug|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
75471917|NCT02106572|Drug|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
75471918|NCT02005172|Device|Alivecor monitor and 14 day event monitor|Alivecor monitor and 14 day event monitor
75471919|NCT01898390|Procedure|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
75471920|NCT01840566|Drug|Carmustine|
75471921|NCT01840566|Drug|Etoposide|
75471922|NCT01840566|Drug|Cytarabine|
75471923|NCT01840566|Drug|Melphalan|
75471924|NCT01840566|Biological|Pegfilgrastim|
75471925|NCT01840566|Biological|19-28z T CELLS|
75471926|NCT01840566|Procedure|Autologous Stem Cell Transplantation|
75471927|NCT01719237|Drug|Ropivacine and Chloroprocaine mixture|Chloroprocaine is added to Ropivacaine
75471928|NCT01719237|Drug|Ropivacaine only|Ropivacaine diluted with normal saline instead of chloroprocaine
75333850|NCT03840486|Device|Non-invasive ventilator mask (NIV)|The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 50% FiO2 for 3 minutes, 75% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.
75791302|NCT03750578|Behavioral|Virtual Reality goggle (Oculus Rift ® Helmet)|as described
75791303|NCT03135028|Drug|Entospletinib|400 mg (2 × 200 mg tablets) orally twice daily
75642974|NCT03318900|Drug|Cyclophosphamide|Given IV
75927566|NCT02474264|Other|Cardiovascular biomarkers|Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
75927567|NCT02474264|Other|Endothelial cells|Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
75927568|NCT02474420|Drug|Amlodipine|amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
75927569|NCT02474420|Drug|Deferasirox|Deferasirox administered per standard of care by the treating physician
75927570|NCT05595980|Dietary Supplement|Probiotic|Participants will consume 1 capsule containing 2 billion CFU of a Bacillus strain spore preparation once daily for 56 days
76082899|NCT02214238|Device|PAP device|
76082900|NCT01450306|Drug|D-cycloserine|50 mg d-cycloserine, oral, 1 dose
76082901|NCT01450306|Behavioral|Exposure therapy|Single session graded in vivo exposure therapy, 60-180 minutes
76082902|NCT01450306|Drug|Placebo|Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
76082903|NCT03126708|Drug|cetuximab|cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
76082904|NCT03126708|Drug|cisplatin plus paclitaxel|Chemotherapy
76082905|NCT03390738|Drug|Nivolumab|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal
76082906|NCT03390660|Other|WIC program participation|WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
76082907|NCT03389100|Drug|18F-MK6240 injection|Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
76082908|NCT03385434|Device|Endorings-2|292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
76082909|NCT03390582|Drug|Methimazole Pill|Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
76082910|NCT03385356|Drug|Vitamin D|Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
76082911|NCT03385278|Other|rTMS|20HZ Repetitive Transcranial Magnetic Stimulation
76082912|NCT01913574|Device|Acupuncture|Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
76082913|NCT01913574|Procedure|Neurolytic celiac plexus block (NCPB)|An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
75333851|NCT03840486|Device|Nasal cannula EtO2 sensor|The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.
75333852|NCT03840486|Drug|Oxygen (NRBM)|Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM, 35 LPM, or flush rate at 55 LPM).
75642975|NCT03318900|Procedure|Leukapheresis|Undergo leukapheresis
75642976|NCT03318900|Biological|Utomilumab|Given IV
75642977|NCT03315364|Drug|Oral paclitaxel|Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
75642978|NCT03315364|Drug|Paclitaxel injection|Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
75791304|NCT03135028|Drug|Daunorubicin|60 mg/m^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
75791305|NCT03135028|Drug|Cytarabine|"100 mg/m^2 intravenous administration twice daily on Days 1 to 7 of each 28-day induction cycle~Hi-DAC: 3 g/m^2 IV administration twice daily on days 1, 3, and 5 (≤ 60 years of age) or 1 g/m^2 IV administration once daily on Days 1 to 5 (> 60 years of age) of each 28-day post-remission cycle"
75791306|NCT03752138|Drug|Group 1: TK216|Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
75791307|NCT03752138|Drug|Group 2: TK216|Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.
75791308|NCT03752138|Drug|Part 2: Decitabine 10mg/m2|10mg/m2 by vein on Days 1-10 of a 28 day cycle.
76082914|NCT03125850|Other|randomized to day ward|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
75333853|NCT03840486|Drug|Oxygen (NIV)|Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 50% FiO2, 75% FiO2 or 100% FiO2 for 3 minutes each.
75333854|NCT05485350|Drug|Anlotinib Hydrochloride|12 mg/d, d1-14, q3w
75333855|NCT05485350|Drug|penpulimab|200mg, ivgtt, d1, q3w
75333856|NCT05485350|Radiation|SBRT|55-180Gy
75471931|NCT01352429|Radiation|Proton Therapy|
75471932|NCT01352429|Radiation|IMRT|
75471933|NCT01274962|Drug|FOLFOX|"Oxaliplatin* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~Folinic Acid (Leucovorin)* 400 mg/m2 IV in 250 ml D5W over 120 minutes~5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~5-Fluorouracil** 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days."
75471934|NCT01274962|Radiation|high dose rate endorectal brachytherapy|High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
76082915|NCT03125850|Other|randomized to inpaitent|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
75471935|NCT01257594|Drug|erlotinib|"For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room."
75927571|NCT05595980|Dietary Supplement|Placebo|Participants will consume 1 capsule containing maltodextrin once daily for 56 days
75471936|NCT01257594|Procedure|Cytoreductive Surgery|Standard procedure
75791309|NCT03752138|Drug|Part 2: Decitabine 20 mg/m2|20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.
75791310|NCT03752138|Drug|Expansion Phase TK216|Expansion cohort will receive the RP2D of TK216
75791311|NCT03752138|Drug|Expansion Phase Decitabine|Expansion cohort will receive the RP2D of Decitabine
76082916|NCT03388866|Drug|Mite extract sublingual immunotherapy (SLIT)|Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
75927572|NCT02474108|Procedure|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
75927573|NCT02474108|Device|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
75927574|NCT02474186|Radiation|Radiation therapy|Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
75927575|NCT02474186|Drug|Xeloda|chemotherapy agent daily for two weeks
75927576|NCT02474186|Drug|paclitaxel|chemotherapy agent weekly for two weeks
76082917|NCT03388866|Other|Placebo|Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
76082918|NCT01873170|Drug|levonorgestrel exposure|
76082919|NCT01873170|Drug|DMPA exposure|
76082920|NCT01873170|Drug|etonogestrel exposure|
76082921|NCT01873170|Device|IUD insertion|
76082922|NCT01873170|Device|subdermal contraceptive implant insertion|
76082923|NCT03390348|Device|LENA Recorder|Use of the LENA recorder to document crying and fussing
76082924|NCT01856868|Drug|(-)-epicatechin|purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
76082925|NCT03390270|Other|Admission with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
76082926|NCT03125694|Drug|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
76082927|NCT03125694|Drug|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
76082928|NCT03385200|Drug|SonoVue|As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
76082929|NCT02731638|Drug|Intrastromal voriconazole|Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
76082930|NCT02731638|Drug|Natamycin|Subjects will receive topical 5% natamycin drops hourly for 3 days.
76082931|NCT01451632|Drug|MM-121|escalating doses MM-121 IV QW
76082932|NCT01451632|Drug|Irinotecan|180 mg/m2 IV Q2W
75791312|NCT03752138|Drug|Part 2: TK216|Recommended dose from Part 1.
75791313|NCT01370434|Drug|PAD combination|"Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~Doxorubicin 9 mg/m2/d iv on D 1-4~Dexamethasone 40mg/d po or iv on D1-4, 8-11"
76082933|NCT01451632|Drug|Cetuximab|escalating doses cetuximab IV QW
76082934|NCT03388710|Radiation|XRay|Xray to confirm the location of the endotracheal tube
76082935|NCT03390192|Device|Dual-mode stimulation|1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.
76082936|NCT03390192|Device|Single sham stimulation|1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
76082937|NCT01491490|Drug|GWP42003 : GWP42004 (40:1)|Capsules taken once a day for 6 weeks
76082938|NCT01491490|Drug|Placebo|Capsules taken once a day for 6 weeks
76082939|NCT03008200|Device|ultrasound examination|intrauterine fetal pulmonary artery acceleration time to ejection time ratio measurement via ultrasound
76082940|NCT03812016|Device|Magnetic device|The device comprises 1 or 2 matched pairs of one near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and one sensor (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet, and a biosignal acquisition module. The efficacy and safety were assessed using the magnetic device.
76082941|NCT02520492|Device|noninvasive method of ICP measurements (Elios)|
76082942|NCT01491958|Drug|atorvastatin|"donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first."
76082943|NCT01491958|Drug|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
76082944|NCT01491958|Drug|methotrexate|Day +1, +3, and +6 and +11
76082945|NCT01492582|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)|Given IM
76082946|NCT01492582|Other|laboratory biomarker analysis|Correlative studies
76082947|NCT01492582|Other|survey administration|Ancillary studies
76082948|NCT01492582|Other|medical chart review|Ancillary studies
76082949|NCT01493596|Drug|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
76082950|NCT01493596|Drug|Placebo|An equal volume of water mixed with juice will be administered.
76082951|NCT02214628|Drug|Fovista® (anti-PDGF BB) plus anti-VEGF|
76082952|NCT01552876|Device|etafilcon A|A daily wear contact lens
76082953|NCT01552876|Device|nelfilcon A|A daily wear contact lens
76082954|NCT01552876|Device|Filcon II 3|a daily disposable
76082955|NCT01495858|Drug|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
76082956|NCT01495858|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
76082957|NCT01495858|Drug|DPH 50 mg|Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
76082958|NCT01496248|Dietary Supplement|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
76082959|NCT01497496|Drug|High Dose Methylprednisolone (HDMP)|1000 mg/m^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
76082960|NCT01497496|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
76082961|NCT01497496|Drug|Lenalidomide|The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
76082962|NCT02208310|Drug|Cholecalciferol 10,000 IU|Cholecalciferol 10,000 IU po daily
75471937|NCT01004731|Drug|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
75642979|NCT03285438|Drug|Reduced dose of DOAC|The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
75927577|NCT02477462|Other|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
75927578|NCT02477462|Other|Baseline visit|Blood draw and quality of life surveys
75927579|NCT02477306|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
75927580|NCT02477306|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
75927581|NCT04868786|Drug|Mycophenolate Mofetil|Administer 15-20mg/kg of mycophenolate mofetil twice daily. Blood sampling for pharmacokinetics(PK) of mycophenolate mofetil will be performed in all patients who have taken the investigational drug for at least 3 days.
75927582|NCT02472548|Biological|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
75927583|NCT02472548|Biological|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
75927584|NCT02472548|Other|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
75927585|NCT02477228|Procedure|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
75927586|NCT02477228|Procedure|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
76082963|NCT02208310|Drug|Cholecalciferol 400 IU|Cholecalciferol 400 IU po daily
76082964|NCT01453894|Behavioral|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
76082965|NCT01454362|Drug|Nicotine|Inhalation of nicotine.
76082966|NCT01455064|Device|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
76082967|NCT01456000|Device|EAS-AC (HeartLight)|Pulmonary vien isolation
76082968|NCT01456000|Procedure|Control Arm Ablation|Treatment with standard ablation.
75642980|NCT03285438|Drug|Full dose of DOAC|The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
75642981|NCT03263559|Procedure|Haploidentical Bone Marrow Transplantation|Eligible patients with a first degree Human Leukocyte Antigen (HLA)- haploidentical donor will undergo Haploidentical bone marrow transplantation at Day 0 with non T-cell depleted bone marrow. For Graft-vs-Host Disease (GVHD) prophylaxis, patients will be given sirolimus and mycophenolate mofetil beginning on Day +5.
75642982|NCT03263559|Drug|Hydroxyurea|HU will be given daily at 30mg/kg from Day -70 through Day -10.
75642983|NCT03263559|Drug|Rabbit-ATG|Rabbit-ATG (rATG) will be given at 0.5mg/kg on Day -9, and at 2.0mg/kg on Day -8 and Day -7.
75642984|NCT03263559|Drug|Thiotepa|Thiotepa will be given at 10mg/kg on Day -7
75642985|NCT03263559|Drug|Fludarabine|Fludarabine will be given at 30mg/m2 from Day -6 to Day -2
75642986|NCT03263559|Drug|Cyclophosphamide|Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.
75642987|NCT03263559|Radiation|Total Body Irradiation|Total Body Irradiation will be given at 200cGy on Day -1
75642988|NCT03263559|Drug|Mesna|Mesna will be given at 40mg/kg on Days +3 and +4
76082969|NCT01554982|Drug|ferric citrate|Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
75642989|NCT03223753|Other|Educational Intervention|Receive educational handouts about to physical activity
75642990|NCT03223753|Other|Internet-Based Intervention|Access limited version of device app/website
75791314|NCT03754478|Other|Physical activity training|subjects will enter a 3-month supervised physical activity program during which they will take part to supervised and unsupervised physical activity sessions. Type of physical activity will be selected among a number of available activities (aquagym, aerobics, resistance training, outdoors activities) based on individual needs and preferences); it will consist in 2 weekly supervised activity sessions during which participants will be instructed by a specialist in adapted physical activity, and 2-3 weekly session of unsupervised physical activity which will be performed according to detailed instructions regarding intensity and duration.
75791315|NCT01370668|Behavioral|Functional remediation|"The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management."
75927587|NCT02473796|Other|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight <2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term & weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
75927588|NCT02477150|Biological|Zostavax|Vaccination of a zoster vaccine (Zostavax)
75927589|NCT02477150|Biological|placebo|placebo administration
75927590|NCT02472626|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
76082970|NCT01497808|Drug|Ipilimumab|
76082971|NCT01497808|Radiation|Stereotactic Body Radiation Therapy|
76082972|NCT01498588|Drug|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
76082973|NCT01498588|Drug|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
76082974|NCT01498588|Drug|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
76082975|NCT01498588|Drug|Pegfilgrastim|Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
76082976|NCT01498744|Drug|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
76082977|NCT01498978|Biological|ipilimumab|Given IV
76082978|NCT01498978|Other|laboratory biomarker analysis|Correlative studies
76082979|NCT01458418|Drug|Montelukast|Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
76082980|NCT01458418|Other|placebo|Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.
76082981|NCT01458418|Drug|5 mg Montelukast|Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
76082982|NCT01557322|Biological|etanercept|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
76082983|NCT01557322|Drug|methotrexate (MTX)|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
76082984|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
76082985|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
76082986|NCT01459588|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
76082987|NCT01459588|Drug|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
76082988|NCT01501162|Drug|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
76082989|NCT01501162|Drug|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
76082990|NCT01502332|Other|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways, followed by ventilation with PEEP = 13 cmH2O, during 4 hours of protective mechanical ventilation with tidal volume (VT) = 6 mL/kg/pbw.
76082991|NCT01502332|Other|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways, followed by ventilation with PEEP = 8 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
75642991|NCT03223753|Other|Internet-Based Intervention|Access full version of interactive reward-based device app/website
75642992|NCT03223753|Other|Laboratory Biomarker Analysis|Correlative studies
75642993|NCT03223753|Device|Medical Device Usage and Evaluation|Wear physical activity tracking device
75642994|NCT03223753|Other|Quality-of-Life Assessment|Ancillary studies
75642995|NCT03223753|Other|Questionnaire Administration|Ancillary studies
75642996|NCT03204916|Behavioral|Discussion|Participate in focus group
75333857|NCT01136668|Procedure|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
76082992|NCT01504672|Other|Medication review|"In the intervention, the pharmacist will evaluate:~Is there an indication for the drug?~Has the drug desired effect?~Is the dose correct and dosing scheme correct?~Side effects, contraindications, inappropriate drugs~Interactions~Treatment time~Cost effectiveness~Adherence to recommendation list~Problems with handling the drugs (for example crushing of the tablets)~Untreated indication~Double medications~Administration of drugs"
76082993|NCT01557790|Radiation|Proton Radiation Therapy|
76082994|NCT01557868|Device|hylan G-F 20|Three 2 cc injections at weekly intervals
75471938|NCT00987753|Drug|L-377202|For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
75471939|NCT00771017|Biological|GVAX prostate cancer vaccine|Given intradermally
75471940|NCT00771017|Drug|bicalutamide|Given orally
75642997|NCT03204916|Other|Medical Chart Review|Data abstraction and central review
75642998|NCT03204916|Other|Questionnaire Administration|Complete questionnaire
75642999|NCT03118050|Behavioral|Resistance exercise training|Supervised resistance exercise training, 3 times a week for 3 months
75643000|NCT03118050|Behavioral|Bed rest|Bed rest for 5 days, followed by standard rehabilitation for 2 days
75791316|NCT01370668|Behavioral|Psychoeducation|Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
75927591|NCT02472626|Drug|Cytarabine|Given IV
76082995|NCT01557868|Device|1% sodium hyaluronate|Three 2 cc injections at weekly intervals
75643001|NCT03118050|Behavioral|Intensive physical therapy|Intensive weight bearing PT, daily, during bed rest
76082996|NCT01559506|Device|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
75791317|NCT01370668|Behavioral|Treatment as usual|The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
75927592|NCT02472626|Drug|Daunorubicin Hydrochloride|Given IV
76082997|NCT02208466|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
76082998|NCT02208466|Drug|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
76082999|NCT02208466|Device|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
76083000|NCT02208466|Drug|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
75643002|NCT03101995|Drug|Gemcitabine|"Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy."
76083001|NCT02209948|Drug|Temozolomide|
76083002|NCT02981212|Drug|Mycophenolate Mofetil|less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally
75643003|NCT03093922|Drug|Atezolizumab|1200 mg/m^2
75643004|NCT03093922|Drug|Gemcitabine|1000 mg/m^2
76083003|NCT02981212|Drug|ACE inhibitor|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
76083004|NCT02981212|Drug|Corticosteroid|combination with Mycophenolate Mofetil
75471941|NCT00771017|Drug|goserelin|Given intramuscularly
75471942|NCT00771017|Drug|leuprolide acetate|Given intramuscularly
75471943|NCT00499291|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
75471944|NCT00499291|Procedure|gene expression analysis|
75471945|NCT00499291|Procedure|laboratory biomarker analysis|
75471946|NCT00499291|Procedure|pharmacological study|
75643005|NCT03093922|Drug|Cisplatin|70 mg/m^2
75643006|NCT03056755|Drug|Alpelisib|300 mg; oral; once daily
75643007|NCT03056755|Drug|Fulvestrant|500 mg; intramuscular injection on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
75643008|NCT03056755|Drug|Letrozole|2.5 mg; oral; once daily
75791318|NCT03754400|Biological|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
75791319|NCT03754400|Other|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
75927593|NCT05593952|Other|Dual task|exercise with dual task + usual treatment
75471947|NCT00499291|Procedure|polymerase chain reaction|
75927594|NCT05593952|Other|Single task|exercise without dual task + usual treatment.
75927595|NCT02472392|Drug|Rabbit anti-thymocyte globulin|Active treatment
75927596|NCT02472392|Drug|Busulfan|comparitor
75927597|NCT02472392|Drug|Melphalan|comparitor
75927598|NCT02472392|Drug|Fludarabine|comparitor
75927599|NCT02472392|Drug|Cyclophosphamide|comparitor
75927600|NCT02472158|Device|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
76083005|NCT02981212|Drug|ARB|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
76083006|NCT01560286|Biological|BMN 165 (rAvPAL-PEG)|Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
76083007|NCT01505764|Drug|Anamorelin HCl|100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
76083008|NCT01505764|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
76083009|NCT01464190|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
76083010|NCT01464190|Drug|Sevelamer carbonate|Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
75333858|NCT01136668|Procedure|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
75333859|NCT05487222|Device|ICON|hemodynamics variability in response to different fluid regiemens
75333860|NCT05485272|Other|Silver Diamine Fluoride combined with Potassium Iodide.|Riva Star, Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia.
75333861|NCT05485272|Other|Silver Diamine Fluoride.|A clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride.
75333862|NCT05485272|Other|High-Viscosity Glass Ionomer.|A Glass Hybrid material.
75643009|NCT03056755|Drug|Goserelin|Every 28 days (only for men in cohort B and premenopausal women). Administered as injectable subcutaneous implant (3.6 mg)
75643010|NCT03056755|Drug|Leuprolide|Every 28 days (only for men in cohort B and premenopausal women). Administered as injectable intramuscular depot (7.5 mg)
75643011|NCT03034473|Other|Translational Research and multimodal treatment|"Blood/biopsy samples (tumor & mucosa) are taken pretherapeutically. Blood samples (serum & plasma) are drawn at 11 time points during RCTx (e.g. for analysis of 5-FU metabolism, genomic DNA extraction). After pathohistological workup of the TME specimen, the formalin-fixed material will be transferred to the central biobank of KFO179. Blood samples (plasma & serum) will be drawn during 5y-follow-up. Treatment (based on CAO/ARO/AIO-94- and CAO/ARO/AIO-04-phase-III trials of the GRCSG):~Preoperative RCT: 28x1.8 Gy (total: 50.4 Gy, 5 fractions per week on d1-d38) combined with 5-FU (1000 mg/m2/d) as 120 h civ during 1st and 5th week.~TME-surgery is performed 6 weeks after RCTx. 4 to 8 weeks after surgery, patients receive either 4 cycles 5-FU (500 mg 5-FU/m2 iv, d1-5, repeat d 29-33) or 3 cycles (6 single appl.) of FOLFOX regimen [(400 mg FA/m2, 2-h civ, d 1; 100 mg oxaliplatin/m2, 2-h civ in 500 ml Glucose 5%, d 1; 2400 mg 5-FU/m2 as 46-h civ) on d1+d15, d30+d45 and d60+d75]."
75643012|NCT02967692|Biological|Spartalizumab|Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks
75643013|NCT02967692|Other|Placebo|Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks
75643014|NCT02967692|Drug|Dabrafenib|Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.
75333863|NCT01108666|Drug|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
75643015|NCT02967692|Drug|Trametinib|Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
75791320|NCT00228917|Biological|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
75333864|NCT02317276|Drug|Triamcinolone 0.1%|Topical ointment
75333865|NCT01662492|Biological|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
75791321|NCT00228917|Biological|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
75791322|NCT00228917|Biological|Mencevax-ACWY|Meningococcal Serogroups A, C, W-135 and Y Vaccine
75791323|NCT05190952|Drug|Bupivacaine|Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
75791324|NCT05190952|Drug|Ketamine|In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.
75333866|NCT01662492|Biological|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
75333867|NCT01662492|Drug|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
75927601|NCT02472158|Device|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
75927602|NCT02472080|Drug|gemcitabine -oxaliplatine combination|gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
75927603|NCT02473562|Drug|Varenicline|Tablet 1 mg BID
75927604|NCT02473562|Drug|Placebo (for varenicline)|Tablet 1 mg BID
75927605|NCT05585996|Biological|CD19 CAR-T and CD19 CAR-DC|Intravenously injected CAR DC cells and followed by CAR T cells 4 hours later
75927606|NCT02724020|Drug|Everolimus|Everolimus capsules.
75927607|NCT02724020|Drug|MLN0128|MLN0128 capsules.
75927608|NCT02724020|Drug|MLN1117|MLN1117 capsules.
75927609|NCT02660034|Biological|Tislelizumab|
75927610|NCT02660034|Drug|Pamiparib|
75927611|NCT02816736|Drug|LCZ696|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively."
76083011|NCT01466764|Drug|Anakinra|An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
75643016|NCT02949219|Other|Laboratory Biomarker Analysis|Correlative studies
75791325|NCT05190952|Drug|Dexamethasone|In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
76083012|NCT01466764|Other|Normal Saline|An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
76083013|NCT01563406|Other|15 second scrub|Scrub catheter hubs for 15 seconds before every access.
76083014|NCT01563406|Other|5 second scrub|Scrub catheter hubs for 15 seconds before every access.
76083015|NCT01563406|Drug|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
76083016|NCT01563406|Drug|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
75643017|NCT02949219|Biological|Pembrolizumab|Given IV
75643018|NCT02932280|Drug|Neratinib|Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
75791326|NCT01365832|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
75927612|NCT02816736|Drug|valsartan|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.~* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.~The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets)."
75927613|NCT02816736|Drug|LCZ696 placebo|LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
75927614|NCT02816736|Drug|valsartan placebo|Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
75927615|NCT02477072|Procedure|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
76083017|NCT01468012|Drug|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
76083018|NCT01468012|Drug|Placebo|matched placebo for LCE condition dosed twice daily
76083019|NCT01468558|Drug|MAP0004|MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
76083020|NCT01468558|Drug|IV DHE|IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
76083021|NCT01468558|Drug|Ketoconazole|Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
76083022|NCT03730662|Drug|Tirzepatide|Administered SC.
76083023|NCT03730662|Drug|Insulin Glargine|Administered SC
76083024|NCT01509040|Other|Standard Care|"Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours."
76083025|NCT01509040|Device|Low Volume Hemofiltration|"Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required."
75927616|NCT02477072|Procedure|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
75643019|NCT02923570|Radiation|Photon intensity modulated radiation therapy (IMRT)|Photon intensity modulated radiation therapy (IMRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
75643020|NCT02923570|Radiation|Proton beam radiotherapy (PBRT)|Proton beam radiotherapy (PBRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
75643021|NCT02907099|Drug|CXCR4 Antagonist BL-8040|Given SC
75791327|NCT04523870|Dietary Supplement|Botanical extract|One capsule
75791328|NCT04523870|Dietary Supplement|Main compound of the botanical extract|one capsule
75791329|NCT04523870|Dietary Supplement|Placebo|Maltodextrin, one capsule
75791330|NCT05189626|Other|Muscle energy technique|Post Isometric relaxation(muscle energy technique) 3 days/ week for 4 weeks
76083026|NCT01509040|Device|High Volume Hemofiltration|"Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required."
76083027|NCT01470118|Drug|alcaftadine 0.25% ophthalmic solution|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
76083028|NCT01470118|Drug|olopatadine 0.2% ophthalmic solution|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
76083029|NCT01470118|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo instilled in each eye at Day 0 and Day 14.
76083030|NCT03388554|Device|tDCS|
75791331|NCT05189626|Other|Kaltonborn mobilizations|Kaltonborn mobilizations grade II and III will be performed on Glenohumeral joints 3 days/ week for 4 weeks.
75791332|NCT03754166|Other|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
75791333|NCT03972683|Other|Handgrip Exercise Training|Signaling mechanisms that regulate blood flow will be studied before and after 7 weeks of handgrip exercise training with the non-dominant forearm. Training sessions will consist of 30 min of rhythmic contractions using a handgrip exercise device, and participants will complete four training sessions per week.
75643022|NCT02907099|Biological|Pembrolizumab|Given IV
75643023|NCT02907099|Other|Pharmacological Study|Correlative studies
75927617|NCT02477072|Procedure|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
75927618|NCT02477072|Procedure|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
75927619|NCT02477072|Drug|Heparin|Heparin doses will be administered according to the assigned group.
75643024|NCT02892201|Drug|Pembrolizumab|a constant dose of 200 mg every three weeks, for four cycles.
75643025|NCT02873195|Drug|Atezolizumab|Given IV
75333868|NCT00378976|Drug|valacyclovir|500 mg twice-daily oral
75333869|NCT00378976|Drug|matching placebo|twice daily as per experimental drug
75333870|NCT05485116|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
75643026|NCT02873195|Biological|Bevacizumab|Given IV
75643027|NCT02873195|Drug|Capecitabine|Given PO
75643028|NCT02873195|Other|Laboratory Biomarker Analysis|Correlative studies
75643029|NCT02873195|Other|Placebo|Given IV
75643030|NCT02846987|Drug|Abemaciclib|
75643031|NCT02836015|Behavioral|Shared Medical Visit|The Shared Medical Visits are a replacement for standard diabetic visits with PCP, and will occur completely in Spanish, the patients' preferred primary language. An interdisciplinary group including behavioral health, social work, pharmacy, MD, and diabetic educator will be involved in the visit. The focal point of the meeting is a 30 minute session in which all members are seated around a large table in the Midtown SMV area and each patient's blood sugars, labs, and medications are discussed in front of the entire group. Pertinent labs and vaccines are drawn/administered.
75643032|NCT02697396|Behavioral|Assessments|All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.
75643033|NCT02697396|Other|Text Message Reminder|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
75643034|NCT02697396|Other|No Text Messaging|Participants in this arm will receive no additional vaccination reminders.
75643035|NCT02643667|Drug|Ibrutinib|-Ibrutinib will be supplied by Pharmacyclics Inc.
75643036|NCT02643667|Procedure|Radical prostatectomy|-Standard of care
75643037|NCT02600156|Procedure|Focal laser ablation of the prostate|MR guided laser ablation of the focal prostatic lesion which has been identified by MRI and biopsy prior to ablation.
75791334|NCT03972683|Drug|Acetylcholine|Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.
75791335|NCT03972683|Drug|Adenosine Triphosphate|Vasodilatory sensitivity to adenosine triphosphate will be assessed during infusion of a dose of 10 μg/dl forearm volume/min administered via a brachial artery catheter over a total of 4 min.
75791336|NCT03972683|Drug|Atropine|Atropine will be used to inhibit muscarinic acetylcholine receptors in order to determine the contribution of acetylcholine to vasodilation during exercise. An initial dose of 0.2 mg will be infused via a brachial artery catheter over 3 min, then a maintenance dose of 0.067 mg will be infused over 1 min prior to each of 5 subsequent experimental trials.
75927621|NCT03490422|Procedure|Pulpotomy|Pulpotomy in mature carious permanent teeth
75927622|NCT05103410|Drug|ARIPiprazole 30 MG|Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
75927623|NCT05103410|Drug|Placebo|Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery
75927624|NCT04867746|Other|data collection by health questionnaires|Health questionnaires to assess scores concerning pain and function of the treated leg and overall health
75471948|NCT00391365|Procedure|Gait analysis|Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
75643038|NCT02584933|Drug|ceritinib|hard gelatin capsule or hard tablet for oral use up to 750 mg
76083031|NCT03388320|Device|A-CHESS|Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)
75927625|NCT04867746|Other|assessment of muscle strength|Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (5 repetitions) and 240°/s (15 repetitions). Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight.
75333871|NCT02297230|Radiation|Radiation Therapy (RT)|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
75333872|NCT02297230|Drug|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
75643040|NCT02422524|Drug|PA-824|Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
75643041|NCT02268682|Other|Patient-Guided|"The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program."
75643042|NCT02268682|Other|Educator-Guided|The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
75643043|NCT02252887|Drug|Gemcitabine|
75643044|NCT02252887|Drug|Trastuzumab|
75643045|NCT02252887|Drug|Pertuzumab|
75643046|NCT02205047|Drug|Cisplatin|
75791337|NCT03972683|Drug|Phenylephrine|Vasoconstriction to phenylephrine will be used to assess sensitivity to alpha 1 adrenergic stimulation. Phenylephrine will be infused via a brachial artery catheter at 0.125 or 0.25 μg/dl forearm volume/min (18-35 and 60-85 age groups, respectively), adjusted according to forearm blood flow, for a total of 16 min.
75927626|NCT04867746|Other|assessment of gait|Instrumented gait analysis on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany; 7168 sensors; area, 1.5 * 0.5 m; range, 1-120 N/cm2; precision, 1-120 N/cm2 ± 5%; sampling rate, 120 Hz) and on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz). Simultaneously with the plantar pressure or force data, kinematic and electromyographic (EMG) data will be collected. Participants will then walk for 1 minute at their preferred walking speed (0% slope and at 15% slope) and at 1.2 m/s (0% slope). For all conditions, kinematic, EMG and pressure data will be recorded for 1 minute. Subsequently, the treadmill speed will be increased to preferred running speed and 2.3 m/s (0% slope), and data for 1 minute running will be recorded. Subjects will then complete overground walking and running trials on the walkway with embedded force plates.
76083032|NCT01470196|Drug|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
75471949|NCT00318903|Drug|Irinotecan (drug)|50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
75471950|NCT00318903|Drug|Taxotere (drug)|Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
75643047|NCT02205047|Drug|5-fluorouracil or Capecitabine|
75643048|NCT02205047|Drug|Trastuzumab|
75643049|NCT02205047|Drug|Pertuzumab|
75643050|NCT02205047|Procedure|gastrectomy|D2 gastrectomy
75643051|NCT02185560|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
75643052|NCT02181114|Behavioral|Expert System Coaching|Patients will receive coaching and feedback over the phone and stag-appropriate educational materials (i.e. paphlets, brochures, personalized feedback report) based on their answers to the survey questions and where they are in their kidney transplant evaluation process.
75643053|NCT02136238|Device|Hosmer 5XA voluntary opening hook|"Voluntary opening prosthetic terminal device (hand)"
75643054|NCT02136238|Device|TRS Grip 3 voluntary closing hook|"Voluntary closing prosthetic terminal device (hand)"
75643055|NCT02106611|Other|Clinical Assessment|HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
75333873|NCT02297230|Drug|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
75927627|NCT04867746|Other|assessment of squatting and single leg hops|Participants perform three jumps on a force plate. Maximum jump length, Maximum flexion and extension angles and joint moments will be identified. Subsequently, participants perform three squats onto two force plates (one per foot). On- and off times will be computed for each muscle and condition.
75927628|NCT04867746|Other|assessment of postural stability|The length of the centre of pressure path will be measured during two 30-second unipedal stance trials using a force plate.
75643056|NCT02106611|Procedure|Stress cardiac MRI|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
75927629|NCT04704882|Other|omental patchwork|the omental flaps were sewn to lesser omentum and hepatorenal ligament to cover all the vessels
75333874|NCT02297230|Drug|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
75333875|NCT02282332|Drug|Ticagrelor|
75333876|NCT04016844|Device|transcranial direct current stimulation or SHAM|"A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.~In the sham condition, the participants will receive the initial 30 seconds of stimulation, after which the current will be set to 0. The same tDCS device (Soterix) will be used."
75333877|NCT02287636|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
75333878|NCT02287636|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
75791338|NCT03972683|Drug|Sodium Nitroprusside|Sodium nitroprusside will be infused via a brachial artery catheter as a control vasodilator to elevate resting forearm blood flow to a level similar to that during exercise. The dose will be adjusted to match forearm blood flow to a similar level as during handgrip exercise, with an anticipated average dose of 1 μg/dl forearm volume/min. The dose will be infused for a total of 14 min.
75791339|NCT01319032|Other|Extraction of whole blood|Extraction of DNA from whole blood
75927630|NCT02472236|Drug|PEX168|200µg,injected subcutaneously,once a week.
75927631|NCT02472236|Drug|Digoxin|0.5mg,oral,two times.
75643057|NCT02106611|Procedure|Stress echocardiogram|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
75643058|NCT02051062|Biological|Blood sample collection|One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration but within a maximum of 32 hours after administration.
75643059|NCT02026232|Drug|Hydroxychloroquine|200mg twice daily
75643060|NCT02026232|Other|Hydroxychloroquine Placebo|200mg placebo twice daily
75791340|NCT00227903|Behavioral|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
75927632|NCT03492294|Diagnostic Test|functional magnetic resonance imaging|Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
75643061|NCT02008656|Drug|Oxaliplatin (OXAL)|
75643062|NCT02008656|Drug|5-Fluorouracil (5-FU)|
75643063|NCT02008656|Drug|Leucovorin|
75643064|NCT02008656|Drug|Capecitabine (Xeloda®)|
75927633|NCT02193867|Drug|Sebelipase Alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
75927634|NCT02472002|Biological|Mesenchymal cell therapy|"Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow~Registry Type: autologous~Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).~Route of administration: endomyocardial injection~Dose administered: 120-140 x106 MSC (mesenchymal stem cells)"
75643065|NCT02008656|Radiation|intensity modulated radiotherapy (IMRT)|
75643066|NCT02008656|Behavioral|Quality of Life Questionnaires|
75643067|NCT02008656|Procedure|DRE-Endoscopy|
75643068|NCT02008357|Drug|Placebo|Administered IV
75643069|NCT02008357|Drug|Solanezumab|Administered IV
75643070|NCT01983410|Behavioral|The risk assessment questionnaire|
75643071|NCT01983410|Other|Blood specimens|
75643072|NCT01983410|Other|tumor tissue samples will be requested|
75643073|NCT01825603|Drug|ADH-1|Given IV
75643074|NCT01825603|Drug|Cisplatin|Given IV
75643075|NCT01825603|Drug|Gemcitabine Hydrochloride|Given IV
75643076|NCT01825603|Other|Laboratory Biomarker Analysis|Correlative studies
75791341|NCT00227903|Behavioral|Brief Advice|Advice and education
75791342|NCT01370824|Procedure|Punch biopsy|Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.
75791343|NCT01370824|Procedure|Surgical excision|"Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.~After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds."
75333879|NCT02287636|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
75333880|NCT02287636|Procedure|positron emission tomography|Undergo PET/MRI
75643077|NCT01784068|Drug|Nilotinib followed by treatment-free|Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
75643078|NCT01471483|Behavioral|geriatric assessment and telephone call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.
75643079|NCT01471483|Other|geriatric assessment and no call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
75791344|NCT04420546|Behavioral|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
75791345|NCT04420546|Behavioral|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding self-harm
75791346|NCT04411628|Drug|LY3819253|Administered IV.
75927635|NCT03108872|Device|left atrial appendage occlusion|Percutaneous exclusion of left atrial appendage with Watchman or ACP devices
75927636|NCT03108872|Drug|New oral anticoagulants|Include dabigatran, rivaroxaban, apixaban and edoxaban
75333881|NCT02287636|Procedure|magnetic resonance imaging|Undergo PET/MRI
75333882|NCT05479500|Other|Myofascial Chain Release Techniques|Myofascial release is a hands on technique which stretches the fascia and releases, bonds between muscles, integuments and fascia in order to eliminate pain, improve motion and to maintain myofascial balance within the body.
75927637|NCT03490266|Procedure|Robotic Repair|The surgeon will be utilizing a robotic system to repair the hernia.
75927638|NCT03490266|Procedure|Laparoscopic Repair|The surgeon will be repairing the hernia laparoscopically.
75927639|NCT02194491|Other|[11C]AS2471907|intravenous radiotracer
75927640|NCT02194491|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
75927641|NCT02194491|Drug|ASP3662|oral
75471951|NCT00318903|Procedure|Radiotherapy (procedure)|Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.
75791347|NCT04411628|Drug|Placebo|Administered IV.
75791348|NCT01370902|Drug|NNC 0141-0000-0100|Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part
75927642|NCT03108560|Procedure|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
75927643|NCT03108560|Procedure|lobectomy|patients receive lobectomy
75927644|NCT03487770|Drug|Aripiprazole Oral Solution|Aripiprazole 2~15 mg/day (2~15 mL/day)
75927645|NCT03487770|Drug|Placebo Oral Solution|Placebo 2~15 mg/day (2~15 mL/day)
75927646|NCT02194569|Drug|Citrate|
75927647|NCT03411356|Behavioral|Daily Caloric Restriction (DCR)|Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
75927648|NCT03411356|Behavioral|Intermittent Fasting (IMF)|Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
76083033|NCT01470196|Drug|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
75333883|NCT05479500|Other|Local Release Techniques|Local Release Techniques are a soft tissue method that focuses on relieving tissue tension via the removal of fibrosis/adhesions which can develop in tissues as a result of overload due to repetitive use.
75333884|NCT05486988|Drug|Immunotherapy|PD-1/PD-L1 inhibitors
75333885|NCT05486988|Drug|Chemotherapeutic Agent|2 cycles
75333886|NCT05486988|Drug|Chemotherapy|4~6 cycles
75471952|NCT00318903|Procedure|Esophagectomy (procedure)|After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
75471953|NCT00129090|Drug|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
75471954|NCT01952795|Behavioral|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
75471955|NCT01952808|Behavioral|Face-to-face family mentoring and education sessions|A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.
75927649|NCT02473328|Drug|Atazanavir 200 mg/r|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),~switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks.~The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir."
75927650|NCT03132090|Diagnostic Test|PET/MR (Biograph mMR)|The combination of PET and MRI allows for evaluation of metabolic, functional and morphological parameters such as glucose metabolism, perfusion, diffusion restriction or size in one examination. Due to the combination of MRI and PET in one scanner it is possible to align the acquired PET and MR datasets with high precision
75643080|NCT01290055|Biological|Yellow fever vaccine|The yellow fever vaccine (YFV-17D) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug Service (IDS) between 2 to 8 degrees Celsius as per the manufacturer's instructions. It will be transported to the Hope Clinic per the Standard Operating Procedures.
75791349|NCT01370902|Drug|placebo|Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
75643081|NCT01290055|Other|Deuterium (70% enriched 2H2O) labeled water|70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1 Liter containers. An Emory Investigational Drug Service (IDS) pharmacist will prepare sterile 50 milliliter aliquots with a tamper seal which will be transported to the Hope Clinic at room temperature.
75791350|NCT01370902|Drug|NNC 0141-0000-0100|Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.
75791351|NCT01370902|Drug|placebo|Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
75791352|NCT01370902|Drug|NNC 0141-0000-0100|Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part
75927651|NCT02473406|Drug|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
75927652|NCT02473406|Drug|normal saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
75927653|NCT03487536|Other|Nutritional assessment|BMI and cholesterol levels evaluation
75927654|NCT02194023|Drug|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
75927655|NCT02194023|Drug|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
75927656|NCT02194023|Drug|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
75927657|NCT02194023|Drug|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
75927658|NCT02473172|Device|Pressure Support ventilation|Assisted mechanical ventilation
75927659|NCT02473172|Device|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
75927660|NCT03490188|Behavioral|Discharge Mentoring|Phone Conversations on the importance of complying to discharge instructions delivered before discharge
75927661|NCT03534843|Procedure|Liver resection|Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
75927662|NCT03534843|Other|Transcatheter arterial embolization|Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
75927663|NCT02473016|Drug|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode [ipsilateral nostril].
75927664|NCT03131856|Behavioral|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
75927665|NCT03132012|Behavioral|Indoor tanning intervention|6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
75927666|NCT03132012|Behavioral|Standard of care control|One website with content similar to those available in dermatology offices on skin cancer prevention
75927667|NCT02473094|Drug|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
75927668|NCT02473094|Drug|Metformin|Metformin up to 2500mg/d
76083034|NCT01470196|Drug|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
75791353|NCT01370902|Drug|placebo|Single dose administered intravenously (into a vein), as a comparator at all dose levels
75791354|NCT03973619|Procedure|Labial Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft (labial graft).
76083035|NCT03389958|Other|Counseling and provision of contraception|Provider training, availability of contraceptive methods
76083036|NCT03389880|Procedure|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
76083037|NCT03389880|Procedure|Patellar denervation|circumpatellar electrocautery with monopolar coagulation diathermy
76083038|NCT01565356|Drug|florbetapir F 18|IV injection, 111 or 370MBq (3 or 10mCi), single dose
76083039|NCT04446234|Drug|Risperidone|Use medicine according to patients condition
76083040|NCT04446234|Drug|Aripiprazole|Use medicine according to patients condition
76083041|NCT04446234|Drug|Ziprasidone|Use medicine according to patients condition
76083042|NCT04446234|Drug|Amisulpride|Use medicine according to patients condition
76083043|NCT04446234|Drug|Quetiapine|Use medicine according to patients condition
76083044|NCT01510834|Behavioral|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
75643082|NCT01266096|Drug|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
75791355|NCT03973619|Procedure|Jugal Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft(inner cheek - jugal graft).
75791356|NCT03754010|Procedure|Scaling and root planning|Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.
75791357|NCT03754010|Drug|Hyaluronic acid gel (HA) and SRP|In Group 2, after SRP will be performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA will be applied intrasulcular.
75791358|NCT03754010|Drug|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse will be used as an irrigator after SRP.
75927669|NCT02473094|Radiation|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
75927670|NCT02473094|Drug|Placebo|Placebo up to 2500mg/d
75927671|NCT03534765|Diagnostic Test|CT abdomen +/- pelvis|Diagnostic CT scan (only if requested by responsible clinicians)
76083045|NCT03385044|Procedure|MOVT|ETT cuff will be inflated till the disappearance of audible air leak on auscultation, while abdominal carbon dioxide (CO2) inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
76083046|NCT03385044|Procedure|VE/VI ratio of Spirometer|ETT cuff will be inflated till the VE/VI ratio meets the initial VE/VI ratio, while abdominal CO2 inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
76083047|NCT03388086|Drug|Injection of Onabotulinum toxin|multiple injections of Onabotulinum toxin into the detrusor muscle
76083048|NCT03613506|Drug|Captopril 12.5 Mg|Taking captopril 12.5mg b.i.d for two months before radiotherapy.
76083049|NCT01565902|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
75927672|NCT03534765|Diagnostic Test|Edmunton Frailty Score|Patient completed previously valided questionnaire quantifying frailty.
76083050|NCT01566448|Drug|Ketamine|20mg/5ml swish and spit four times daily
76083051|NCT05565976|Drug|Dapagliflozin 10mg Tab|10mg PO q24h for 12 months
76083052|NCT05565976|Drug|Statins (Cardiovascular Agents)|Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h
75333887|NCT05484960|Other|cognitive assessment|The clinical diagnosis will be made based on the criteria set by the investigators. Clinical history and bedside objective assessment in the form of Montreal Cognitive Assessment-Philippines (MoCA-P) or Mini Mental Status Examination-Philippines (MMSE-P), supported by a neuroimaging study (if neuroimaging is not done, diagnosis will be supported by the Hachinski Ischemic Score).
75643083|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
75643084|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
76083053|NCT05565976|Drug|Platelet Antiaggregant|Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h
75643085|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
75791359|NCT03754010|Drug|HA mouthrinse+gel and SRP|In Group 4, after SRP will be performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel will be applied.
75791360|NCT04364854|Behavioral|SET (Speech Entrainment Therapy) 3 weeks|3 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
75927673|NCT03534765|Procedure|Emergency laparotomy for general surgical pathology|Emergency general surgical laparotomy (defined by the UK NELA body)
75927674|NCT03492138|Drug|ONC201|625mg
75927675|NCT03492138|Drug|Ixazomib|Dose to be determined in Phase 1 of study
75927676|NCT03492138|Drug|Dexamethasone|40mg
75927677|NCT02472938|Drug|dimethyl fumarate|dimethyl fumarate 120 mg capsules
76083054|NCT05565976|Drug|Antidiabetic|Previously established medical treatment for type 2 diabetes will be maintained.
75333888|NCT01083472|Device|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
75643086|NCT01065454|Drug|Placebo|Placebo three times a day
75927678|NCT02472938|Other|Placebo|Placebo for BG00012
75927679|NCT03131700|Biological|RPH001|Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
75333889|NCT01083472|Procedure|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
75333890|NCT05486832|Device|Cardiovalve TR valve replacement System|The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
75643087|NCT00870129|Procedure|MRI and advanced MRI sequences|This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
75791361|NCT04364854|Behavioral|SET (Speech Entrainment Therapy) 4.5 weeks|4.5 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
75791362|NCT04364854|Behavioral|SET (Speech Entrainment Therapy) 6 weeks|6 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
75643088|NCT00836862|Other|Biologic specimens|Banking of serum, DNA and tissue
75643089|NCT00775463|Drug|treprostinil diethanolamine|oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
75791363|NCT04364854|Other|No Therapy 6 Weeks|Participants will not be getting any SET for 6 weeks
75791364|NCT01366066|Device|Transcutaneous mechanical nerve stimulation|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
75791365|NCT05668910|Genetic|whole genomic methylation and fragmentation profile analysis of cfDNA|The assay for gastric cancer early detection will be built based on low-depth methylone sequencing followed with a multi-dimensional model construction with analysing several features such as methylation, fragmentation, and chromosomal copy number alternation.
75791366|NCT00227591|Drug|lenalidomide|Given orally (PO)
75927680|NCT03131700|Biological|Avastin®|R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
76083055|NCT01566526|Drug|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
75927681|NCT02194101|Procedure|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
75927682|NCT02471768|Procedure|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
76083056|NCT03185832|Device|CRT-D|This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
76083057|NCT03185832|Device|ICD|This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
75333891|NCT05479266|Other|Muscle Energy Technique|METS-Post isometric relaxation will be applied for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
75333892|NCT05479266|Other|Myofascial release|Myofascial Release will be done for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
75791367|NCT00227591|Drug|prednisone|Given PO
75791368|NCT00227591|Other|laboratory biomarker analysis|Correlative studies
75927683|NCT03534999|Device|Experimental. This was the group that received TENS|Patients that were on TENS . They were treated twice daily for 5 days. VAS and Hip Score scale were used to assess the pain intensity and disability level
75927684|NCT03534999|Other|No intervention|Patients in this group were on their drugs only. There was no physiotherapy intervention for the patient. VAS and Hip Score scale were used to ascertain the pain intensity and hip disability at the before the treatment and after the treatment
76083058|NCT03185832|Device|PM / CRT-P|This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
76083059|NCT03185832|Other|Non-device|Patient enrolled but not implanted with a Defibrillator or Pacemaker
76083060|NCT01566838|Drug|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
76083061|NCT01566838|Drug|Standard acute pain management|"A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.~Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
75927685|NCT02368002|Behavioral|Behavioral weight loss therapy|All participants start with behavioral weight loss therapy which consists of 20 weekly meetings wtih a weight loss coach. Session components will include weekly weigh-in, discussion of progress and challenges and discussion of scheduled session topic. Dietary goals and physical activity goals are set. After their first session, participants are randomized to have their weight assessed at either their 3rd session or their 7th session. Both the participant and their coach are blinded to the randomization. If the participant has lost the expected amount of weight, they continue with behavioral weight loss therapy for the full 20 session.
76083062|NCT05565664|Drug|Ketamine hydrochloride|"Ketamine hydrochloride will be made in a 20 ml syringe in a concentration of 1.25 mg/ml. Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication."
76083063|NCT05565664|Drug|Magnesium sulfate|"A 20 ml syringe will contain magnesium sulphate in a concentration 100 mg/ml (10%). Patients will receive 40 mg/kg of IV magnesium sulphate (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication."
76083064|NCT02930538|Other|Survey|Completing a survey on RedCap
76083065|NCT03384888|Device|Active tDCS|Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.
75643090|NCT00775463|Drug|placebo|
75927686|NCT02368002|Behavioral|Portion-controlled meals|"Participants continue with behavioral weight loss therapy, but this is augmented with portion-controlled meals (PCM). Adherence to energy intake goals is facilitated by consuming pre-prepared meals specifically designed to meet caloric intake guidelines. PCMs reduce individuals' motivationally- and self-regulatory-dependent planning and decision making around eating. PCMs also serve as a teaching tool regarding the amount and type of food people should eat in order to produce weight loss."
75927687|NCT02368002|Behavioral|Acceptance-based treatment|Switching the therapeutic approach to an enhanced behavioral weight loss therapy teaching acceptance-based behavioral skills theoretically addresses the root problem of many weight loss challenges and boosts long-term capacity for self-regulation. Acceptance based strategies are designed to help participants identify and internalize values and lasting commitment to behavior consistent with these values. The strategies focus on increasing people's ability to forgo more pleasurable options (e.g., hedonic pleasure of food) in favor of behavior that is distinctly less pleasurable or even aversive (remaining hungry, anxious, bored). The inability to tolerate such distress is directly associated with failure of self-regulation.
75927688|NCT04706936|Biological|anti-BCMA CAR-T|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.
75927689|NCT04706936|Drug|Cyclophosphamid|300mg/m2/d
75927690|NCT04706936|Drug|Fludarabine|30mg/m2/d
75927691|NCT02257203|Behavioral|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
75927692|NCT02257203|Behavioral|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
75927693|NCT02194881|Drug|CF patients with a G551D mutation and treated with Ivacaftor|
75927694|NCT02194959|Behavioral|Peer PN|Navigation by Peer Patient Navigators
75927695|NCT02194959|Behavioral|Pro PN|Navigation by Standard Hospital Navigators
76083066|NCT03384888|Device|Sham tDCS|Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
76083067|NCT01567150|Device|Novel Dressing|Topical wound dressing
76083068|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
76083069|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
76083070|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
75927696|NCT03534609|Device|Lutronic Genius System|Treatment of the neck using the Lutronic Genius System
75927697|NCT02194179|Drug|NVP XR 400 mg (KCR 25%)|
75927698|NCT02194179|Drug|NVP XR 400 mg (KCR 20%)|
75927699|NCT02194179|Drug|NVP XR 300 mg (KCR 25%)|
75927700|NCT02194179|Drug|NVP XR 300 mg (KCR 20%)|
76083071|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
76083072|NCT01568008|Drug|Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
75643091|NCT00406640|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
75643092|NCT00406640|Drug|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
76083073|NCT05565508|Procedure|new laparoscopic access technique for group a|new laparoscopic access technique through the epigastric region
76083074|NCT05565508|Procedure|Hasson's technique for laparoscopic access in group b|Hasson's technique for laparoscopic access in group b
76083075|NCT05658120|Drug|noradrenaline/adrenaline|norepinephrine adrenaline in patients with Swan-Ganz catheter monitoring during liver transplantation
76083076|NCT01514734|Drug|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
75333893|NCT00378664|Procedure|lumbar to sacral ventral nerve re-routing procedure|surgical nerve re-routing procedure
75643093|NCT00229931|Drug|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
75643094|NCT00229931|Procedure|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
75927701|NCT02194179|Other|high-fat breakfast|
75927702|NCT02194179|Drug|NVP IR 200 mg (Viramune®)|
75927703|NCT02194257|Drug|[14C]-cyclohexane ambroxol oral solution|
75927704|NCT02194257|Drug|[14C]-benzyl ambroxol oral solution|
75927705|NCT02194257|Drug|Ambroxol lozenge|
75927706|NCT02195115|Procedure|Laparoscopic Cholecystectomy|
75927707|NCT02195115|Drug|amitriptyline|
75927708|NCT02195115|Other|low-fat and low cholesterol diet|
76083077|NCT03380754|Dietary Supplement|Nutricia preOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
76083078|NCT03380754|Other|Nestle Splash Lemon Flavor Water (Placebo)|Placebo control drink. PURIFIED WATER, NATURAL FLAVORS, CITRIC ACID, SODIUM POLYPHOSPHATE, POTASSIUM SORBATE (PRESERVE FRESHNESS), POTASSIUM BENZOATE (PRESERVE FRESHNESS), SUCRALOSE, ACESULFAME POTASSIUM, CALCIUM DISODIUM EDTA, MAGNESIUM SULFATE.
75927709|NCT02194335|Drug|BIBN 4096 BS - in single rising doses|
76083079|NCT01515046|Drug|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
76083080|NCT03384576|Other|Music intervention|Classical music to be played in the Emergency waiting room
76083081|NCT03384576|Other|No music|No music played in emergency waiting room
75643095|NCT00150969|Dietary Supplement|vitamin K1 (phylloquinone)|
75927710|NCT02194335|Drug|Placebo|
75927711|NCT02031003|Dietary Supplement|Infant formula|Infant formula
75927712|NCT02195973|Drug|LDE225|After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
75927713|NCT02196129|Drug|Sinbaro-3|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
75927714|NCT02196129|Drug|Hwangryun|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
75927715|NCT02195193|Other|Integrated care|an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
75927716|NCT02257281|Device|Active Therapeutic Ultrasound|For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
75927717|NCT02257281|Device|Non-active Therapeutic Ultrasound|For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
76083082|NCT01568944|Drug|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
76083083|NCT01568944|Procedure|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
76083084|NCT03380598|Behavioral|CLOSS|Usual care plus using mobile application's to register weight and physical activity as well as for communication with the clinic. A web-based system enables health care professionals to follow the the patient's daily weight registration online.
75643096|NCT00150969|Dietary Supplement|placebo|1 pill daily
75643097|NCT00770770|Drug|Fluocinolone Acetonide|0.2 µg/day
75927718|NCT02196207|Drug|Eloctate Prophylaxis|Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.
75927719|NCT02196207|Drug|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
76083085|NCT03380598|Behavioral|Usual care|Usual care. The child and parent(s) at regular visits to the nurse at the clinic
76083086|NCT05565274|Drug|Pentazocine plus placebo|30mg of pentazocine and 2milliLitre of injection water
76083087|NCT03380520|Drug|Ferric Carboxymaltose|Ferric carboxymaltose will be administered according to product specification dosing
76083088|NCT03380520|Drug|Placebo|IV nacl 0.9%
76083089|NCT03387540|Drug|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
75643098|NCT00770770|Drug|Fluocinolone Acetonide|0.5 µg/day
75643099|NCT03656731|Other|Breast cancer exercise intervention|"The exercise-based intervention is comprised of:~Supervised and group-based exercise training at the hospital setting two times a week. Each session will last approximately 60 minutes.The program consists of warm-up, exercises for balance and flexibility, progressive resistance training (seven resistance training exercises targeting the large muscle groups), and stretching and relaxation.~Home-based walking with activity tracker assessment. Evaluation and goal-setting in relation to activity (step counts) will be conducted once weekly.~Serving of a protein supplement (protein drink or bar) after each supervised training session."
75643100|NCT00766636|Drug|Gemcitabine|"Arm A:~1000 mg/M^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.~Arm B:~400 mg/M^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day."
75643101|NCT00766636|Radiation|Radiation Therapy|1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy.
75927720|NCT02196207|Drug|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
75927721|NCT02196207|Drug|Eloctate ITI|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
75927722|NCT02195271|Device|Transcranial Direct Current Stimulation (tDCS)|
76083090|NCT05173662|Procedure|Providing education and brochures on non-pharmacological methods that can be applied during the heel blood collection process|Theeduvation initiative was implemented by the researcher at least 12 hours ago in the mothers' room and a brochure was given about the education.
76083091|NCT03387384|Other|Non-interventional study|Non-interventional study
76083092|NCT05173584|Drug|Levalbuterol|Levalbuterol nebulizer solution 1.25mg/3ml with a total dose of 5 mg (12ml) for each patient.
76083093|NCT05173584|Drug|Albuterol|Albuterol nebulizer solution 2.5 mg/3ml with a total dose of 0 mg (12ml) for each patient.
76083094|NCT04671030|Drug|Neostigmine and Glycopyrrolate|Intravenous followed by transdermal administration of the two drug combination.
76083095|NCT04671030|Device|Iontophoresis|Application of direct current to skin using an FDA-approved device
76083096|NCT04660890|Drug|ALXN2050|ALXN2050 will be administered orally twice daily as powder-in-capsule.
75643102|NCT00766636|Drug|Erlotinib|100 mg daily by mouth on days 1-42.
75927723|NCT02195271|Drug|Melatonin|
75333894|NCT05486754|Behavioral|Cognitive behavioral stress management|Participants will receive in-person weekly stress management group sessions (3-8 participants) for two hours per week for ten weeks total. Each session will consist of a half hour of relaxation training and one and a half hours of stress management skill training, including coping effectiveness training, anger management, assertiveness training, and stress awareness.
75333895|NCT05486754|Behavioral|Psychoeducational Control|Participants will receive one four-hour seminar in-person groups (3-8 participants) of educational information related to prostate cancer and abbreviated psychological information provided in cognitive behavioral stress management.
75791369|NCT01358344|Drug|Pantoprazole|40 mg delayed-release tablet administered orally in the morning of Days 1-7
75927724|NCT05124483|Biological|AKS-452X|subcutaneous injection of 90 µg AKS-452X
75927725|NCT02196285|Biological|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
75927726|NCT04229979|Biological|Galinpepimut-S|Sargramostim 70 µg (2 days), then galinpepimut-S admixed with the adjuvant Montanide following specified schedule
75927727|NCT04229979|Drug|Azacitidine|injection
76083097|NCT04660890|Drug|ALXN2050-matching Placebo|ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.
75333896|NCT02253394|Drug|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
75333897|NCT02253394|Drug|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
75333898|NCT05479110|Behavioral|Empathy experience courses and case-base clinical reasoning|Four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.
75333899|NCT05479110|Other|case studies|active control: case studies(text)
75333900|NCT05312788|Other|Effect of Barley Supplemented Wheat Bread on markers of Cardiovascular and Renal Health|Intervention will involve intake of 50% barley substituted wheat bread.
75333901|NCT05479032|Drug|Amantadine|2x100 mg Amantadine for 3-5 days (dosage can be doubled in case of missing response to treatment after 48 hours)
75333902|NCT02236546|Diagnostic Test|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
75643103|NCT00766636|Procedure|Surgery|Surgical removal of the pancreas and duodenum
75643104|NCT04103086|Drug|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
75643105|NCT04103086|Drug|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy
75643106|NCT02580097|Other|MRI|MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
75643107|NCT05023681|Drug|Recombinant Staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
75791370|NCT01358344|Drug|SCH 530348 (high percentage)|2.5 mg tablet containing ~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
75791371|NCT01358344|Drug|SCH 530348 (standard percentage)|2.5 mg tablet containing ~23% API as free base (STANDARD) administered orally on the morning of Day 5
75791372|NCT03750422|Device|Picoway|1064/532nm picosecond laser
75927728|NCT04229979|Drug|Venetoclax|tablet
75927729|NCT04229979|Drug|Decitabine|injection
75791373|NCT03750422|Other|Stratacel|a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties
75791374|NCT03750422|Other|Aquasonic|clear ultrasound gel
75791375|NCT01366222|Dietary Supplement|food concentrates: fruit, vegetable, fish oil and probiotics|comparison the effect of food concentrate
75927730|NCT04229979|Drug|Cytarabine|injection
75927731|NCT04229979|Other|Observation|palliative management
75927732|NCT02196441|Drug|2% tetracaine local anaesthetic drops|topical anaesthetic drops
75927733|NCT02196441|Drug|0.5% bupivacaine|was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
75927734|NCT02195661|Dietary Supplement|Melatonin|
75927735|NCT02195661|Drug|Chloral Hydrate|
75927736|NCT03534297|Drug|dapansutrile capsules|Hard opaque capsules containing 100 mg of API.
75927737|NCT03534297|Drug|Placebo capsules|Hard opaque capsules containing 0 mg of API.
75927738|NCT02196519|Device|Sylys Surgical Sealant|
76083098|NCT04660890|Drug|Moxifloxacin|Moxifloxacin will be administered as a single oral dose.
76083099|NCT04660890|Drug|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo will be administered as a single oral dose.
76083100|NCT04632264|Other|Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery|The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride
75333903|NCT02236546|Other|Molecular assays on biopsied tissue|Correlative studies
75791376|NCT03972605|Device|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
75333904|NCT02236546|Device|positron emission tomography|Undergo FDG-PET/CT
75643108|NCT05023681|Drug|normal saline|Intravenous injection of placebo(normal saline ) is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
75791377|NCT03752060|Behavioral|Resistance Exercise|Women assigned to the resistance exercise training group will complete progressive, full-body resistance exercise 3 times per week for 16 weeks.
75791378|NCT03752060|Behavioral|Aerobic Exercise|Women assigned to the aerobic exercise training group will complete progressive, aerobic exercise 5 times per week for 16 weeks. The aerobic training will progress first in duration, and then in intensity.
75791379|NCT01366300|Drug|Intravenous lidocaine infusion|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
75791380|NCT01366300|Other|Placebo (0.9% saline infusion)|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
75791381|NCT01366300|Drug|Propofol 1% (intravenous infusion)|Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
75791382|NCT01366300|Procedure|Placement of arterial line|An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
75791383|NCT03751982|Device|Transcranial Electrical Neuromodulation (TES)|TES phase-aligned with slow waves or not
75927739|NCT02195817|Drug|Selincro® 18 mg with continuous psychosocial support: Cohort A|
75927740|NCT02195817|Other|Initial psychosocial support: Cohort B|
75927741|NCT02200770|Drug|Inebilizumab|Participants will receive IV inebilizumab 300 mg.
75927742|NCT02200770|Other|Placebo|Participants will receive IV placebo matched to inebilizumab.
75333905|NCT02236546|Device|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
75643109|NCT03297229|Behavioral|Peer mentoring|Peers will be assigned to participants according to common socio-demographic characteristics. Each peer will be assigned up to 5 participants.
75643110|NCT03297229|Behavioral|Self-monitoring|"Along with providing patients with a BP monitor, a commitment contract will be signed, in which participants commit themselves to measure their blood pressure at home at least once a week during the 3 months of the intervention. Each participant will be given a form to weekly recording their blood pressure values."
75643111|NCT02581969|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered 20-30 IU/kg 3 times a week
75643112|NCT02581969|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered only for bleeding episodes
75643113|NCT00770692|Drug|Eszopiclone 1 mg- Elderly|"Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
75643114|NCT00770692|Drug|Eszopiclone 2 mg- Elderly|"Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
75643115|NCT00770692|Drug|Eszopiclone 3 mg- Non-elderly|"Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
75643116|NCT00770692|Drug|Eszopiclone 2 mg- Non-elderly|"Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
75791384|NCT05190796|Other|platelet indices|One sample of 20 mL venous blood was drawn by standard phlebotomy from all of the participants. This sample was kept for the evaluation of hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), erythrocyte count, leukocyte count, platelet count, platelet distribution width (PDW), MPV and plateletcrit by means of an automated commercial counter (Coulter counter, Max Instruments Laboratory). After this venous blood sample was conveyed into a sodium citrate tube, it was transported in a temperature-controlled container and collected in plastic provettes (Falcon blue cap) containing 3 mL of 3.8% sodium citrate dihydrate and 136 mM glucosium. Then the samples were sent to the laboratory.
75927743|NCT03534063|Genetic|CYP2D6-guided opioid therapy|Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.
76083101|NCT04632264|Other|Initiation of standard postpartum oxytocin immediately following placenta delivery|Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride
76083102|NCT04632264|Other|Saline Placebo|Saline placebo will be initiated post placenta delivery (within 15 seconds).
76083103|NCT04632264|Other|Saline Placebo|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).
75643117|NCT02602054|Procedure|Surgical treatment|Standard left thoracotomy
76083104|NCT04607928|Drug|Pirfenidone|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
75643118|NCT02602054|Drug|Control group|"- Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days"
75643119|NCT04100746|Procedure|supramalleolar osteotomy|surgical intervention by using low tibial osteotomy
75927744|NCT03534219|Device|EarPopper|The EP device is 510(K) regulated (510(K) Number K073401) as a non-surgical, non-drug related treatment for middle ear pressure problems. The device is based on the Politzer Maneuver, and works by opening the Eustachian tube by delivering a safe, constant stream of air into the nasal cavity. In clinical studies funded by the National Institutes of Health (Grant#: 5R44DC003613-03), the EarPopper has proven to be effective in reducing chronic middle ear effusions. By regularly aerating the middle ear, we hypothesize that the EarPopper device will be an effective prophylactic measure to reduce incidence of AOM in children with recurrent OM. The device delivers a jet of air pressure from the nozzle at 5.2PSI, at a volume velocity of 1,524mL/min.
76083105|NCT04607928|Drug|Placebo|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
76083106|NCT03610386|Other|Adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will receive menthoxypropanediol topically.
76083107|NCT03610386|Other|No adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will not receive menthoxypropanediol.
76083108|NCT03384420|Biological|CD34+ cells enriched with MNV-BLD|Transplantation of autologous stem cell enriched with MNV-BLD (blood-derived mitochondria)
75791385|NCT03753698|Device|eCoin|"Implantation of device electrodes subcutaneous in lower tibia area;~Stimulation of posterior tibial nerves:~Regimen 1 (months 0-3): Six stimulation treatments per week, one stimulation per day, for duration of 30 minutes each Regimen 2 (months 3-6): Three stimulation treatments per week, one stimulation per day, for duration of 30 minutes each. Stimulation is activated by the patient."
76083109|NCT03387228|Other|Pain education|"Pain education intervention we plan to use is based on Explain Pain developed by Moseley and Butler in 2003. The pain education handout and materials produced in Nepali will be proof-read and pre-tested in 5 - 10 Nepalese with LBP as needed, and corrected, if necessary.~Dosage: A single (approximately) one hour pain education will be delivered to the PEG.~Home advice: A printed handout of the pain education material will be provided only to the study participants in the PEG. Participants will be advised to read them (or have family members read them), followed by walking for 30 minutes."
76083110|NCT03387228|Other|Control group|"The control participants will receive physiotherapy care based on the recent clinical practice guidelines. This control group intervention will comprise of: (1) education (advice to remain active); (2) massage to back; (3) superficial heat; and (4) static cycling or (treadmill) walking with the aim to promote physical activity. Although superficial heat is recommended in the acute/subacute LBP, we included this as a common treatment for all types of LBP including chronic LBP, which could be a part of self-management.~Duration of treatment: 1 hour. Home advice: Participants will be advised to self-manage their back pain based on the information provided. Home exercise leaflet with emphasis on the value of exercise to increase strength and endurance, followed by a 30 minutes walking."
76083111|NCT04569786|Biological|V590|Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10^5 pfu/mL (Panels A, E), 2.40x10^6 pfu/mL (Panels B,F), 1.15x10^7 pfu/mL (Panels C, G), 5.55x10^7 pfu/mL (Panels D, H, I).
75643120|NCT02816203|Device|Hemostatic Intra-Uterine suction cup|The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
75791386|NCT04512482|Drug|Bromelain|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
75927745|NCT02197143|Drug|esomeprazole|40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
76083112|NCT04569786|Other|Placebo|Placebo administered via IM injection.
76083113|NCT04485624|Other|No intervention|Observational study
76083114|NCT04447170|Procedure|Simple repair or Graham technique|Simple suture with or without omental protective patch
75471956|NCT01952808|Behavioral|Telephone follow-up|During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
75643121|NCT03248557|Diagnostic Test|Spectral analysis of ventricular fibrillation tracings|Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
75791387|NCT04512482|Other|Powdered sugar|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
75471957|NCT01952821|Other|Six-Minute Walk Test|
76083115|NCT05172804|Behavioral|Progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement [11].
76083116|NCT05172804|Behavioral|Guided Imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin [11].
75791388|NCT05456204|Drug|Pharmacological cardioversion with Refralon|"the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~in the absence of effect (SR recovery did not occur), after 15 minutes,repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~in the absence of effect (SR recovery did not occur),after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
75643122|NCT04100668|Device|Sensifree's Alpha sensor|RF based, wrist mounted sensor, that acquires a high fidelity signal originating at the radial artery, and constructs a pressure waveform
75927746|NCT02197143|Drug|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
75471958|NCT01952821|Other|10-Meter Walk Test|
75643123|NCT04100668|Device|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
75643124|NCT04100668|Device|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
75643125|NCT02579551|Procedure|Therapeutic Conventional Surgery|Undergo surgical excision
75643126|NCT04099732|Drug|Rosuvastatin|Tablet
75643127|NCT04099732|Drug|BI 1358894|Tablet
75643128|NCT04099732|Device|Dabigatran etexilate|Capsule
75643129|NCT04074655|Device|Driving Simulator in a Virtual Reality Environment|Driving simulator in virtual reality environment is a game with the several level of difficulty and the goal of improving the cognition level of participants in general and their spatial cognition in particular. Moreover this game, will have a positive effect on its users' mood as well.
75643130|NCT02579785|Behavioral|Mhealth intervention|A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
75643131|NCT03183115|Procedure|Radiofrequency ablation|HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare). Because the HALO 360 balloon catheter has been phased out since 2019, a new Barrx™ 360 Express catheter was used thereafter.
75643132|NCT03183115|Device|Endoscopy|The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging
75643133|NCT03183115|Drug|Lugol's Solution (1.5%)|Before the RFA intervention, the participants will received Lugol staining over the esophagus
75643134|NCT04074499|Other|No intervention|There is no intervention.
75643135|NCT03922789|Diagnostic Test|6 minute walking test|change of 6MWT pre to post pulmonary rehabilitation
75643136|NCT02743897|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
75791389|NCT00226811|Drug|Sunitinib|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
75927747|NCT02197143|Drug|hydrotalcid|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
75927748|NCT02096874|Drug|Bevacizumab|Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month
75927749|NCT03489954|Other|Evaluation|Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
75927750|NCT02197299|Dietary Supplement|L-carnitine|
75927751|NCT02197299|Dietary Supplement|Placebo|
75471959|NCT01952821|Other|30-Second Chair Stand|
75791390|NCT03751904|Device|AcoustiCare|Electronic stethoscope
76083117|NCT05172804|Behavioral|Mindfulness Meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting) [11]."
76083118|NCT05172804|Other|Control group|Participants in the control condition will be instructed to sit with their eyes closed and relax during the intervention periods. Participants in the control group will follow an identical procedure and time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
75333906|NCT05484726|Other|perioral sensory motor stimulation|"Step 1 - 6 over 5 minutes~1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek~2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek~3 Move index finger from one corner to opposite one over both lips separately 7x each lip~4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum~5 Move the finger from front to back on the hard palate while applying gentle pressure 7x~6 Displace the center of the tongue with gentle pressure 7x~7 Offer pacifier at the end 2 minutes~Note: 7x means 7 times"
75471960|NCT01952821|Other|Linear Analog Scale of Function|
75791391|NCT05261516|Drug|Magnesium Sulfate|The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.
76083119|NCT03380442|Drug|Psilocybin|Psilocybin ingested orally
76083120|NCT03380442|Drug|Ketamine (Ketalar)|Ketamine administered intranasally
76083121|NCT03380364|Device|hystroscope|"Procedure: Hysteroscopy Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.~Other Name: ROH: Routine Office Hysteroscopy Device: Hysteroscope The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 5-mm diameter diagnostic rigid sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
76083122|NCT03558360|Diagnostic Test|Impedance measurement|Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.
76083123|NCT03387072|Other|Non interventional study|mental stress test and Blood (or salivary) sample
76083124|NCT05172570|Drug|Gabapentin|Gabapentin is a common medication used preoperatively and postoperatively as part of multimodal analgesia to help with acute pain.
76083125|NCT03386916|Procedure|CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer|
76083126|NCT03380286|Device|Firehawk|Firehawk stent
76083127|NCT02519868|Device|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
76083128|NCT02519868|Device|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
76083129|NCT05172414|Other|No intervention|The single group had no intervention. All followed the same procedures of different collection methods.
76083130|NCT03380130|Drug|Nivolumab|An anti-programmed death 1 monoclonal antibody
75471961|NCT01952821|Other|Modified Brief Fatigue Inventory|
75471962|NCT01952821|Other|FACIT-Fatigue|
75471963|NCT01952860|Other|Hatha Yoga|18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.
75471964|NCT01952860|Behavioral|Questionnaires|Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
75471965|NCT01952886|Drug|Granisetron|
75471966|NCT01952886|Drug|Ondansetron|
75643137|NCT02743897|Drug|Mavyret|Mavyret (glecaprevir 100 mg and pibrentasvir 40 mg) is taken by mouth for 8 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
75643138|NCT02743819|Drug|Pembrolizumab|Pembrolizumab given every 3 weeks (200 mg) by IV infusion.
75471967|NCT01952912|Procedure|PkEP|
75643139|NCT02743819|Drug|Ipilimumab|Ipilimumab given every 3 weeks (200 mg) by IV infusion for total of 4 doses.
75643140|NCT03922243|Other|retrospective|Retrospective study to assess treatment done by dental students
75643141|NCT04074421|Drug|Rifaximin|A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.
75791392|NCT03748004|Behavioral|IPS/SP|The 72 recruited clients receiving primary care services from one DTES clinical site who are employment ready will be randomly assigned to IPS and Peer Support (experimental group) or WorkBC control group
75791393|NCT03748004|Behavioral|WorkBC|36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services.
75471968|NCT01952912|Procedure|OP|
75471969|NCT01952925|Procedure|Renal Artery denervation|RA denervation performed as part of afib ablation procedure
75471970|NCT01952938|Procedure|LINK SL versus EnduRo|
75471971|NCT01952951|Drug|Capecitabine Oxaliplatin|after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
76083131|NCT03380130|Device|SIR-Spheres|Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
75927752|NCT02196753|Other|PET CT|"All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient's weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV> 40% of the background."
75927753|NCT01186848|Device|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
76083132|NCT03386838|Biological|Nivolumab|Specified dose on specified days
76083133|NCT03386838|Drug|BMS-986205|Administered 100mg orally once daily for a maximum of 104 weeks
76083134|NCT03386838|Biological|Cetuximab|400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason
76083135|NCT03386838|Drug|Cisplatin|Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)
75471972|NCT01952951|Radiation|pelvic radiation capecitabine 5-fluorouracil|50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
75927754|NCT01186848|Device|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
75927755|NCT02196909|Other|motor function and strength assessment|
75927756|NCT02196909|Other|NMR assessment|
75927757|NCT02196909|Other|24h urine and serum collection|
75927758|NCT03489876|Device|Synthetic Cartilage Implant|The Synthetic Cartilage Implant will be implanted in to the first metatarsal head according to the manufacturer's recommendations.
75643142|NCT04074421|Drug|Probiotic Formula|A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
75643143|NCT04074421|Drug|Placebo oral tablet|Placebo oral tablet that has no therapeutic effect
75643144|NCT02579707|Drug|AG120|AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
75643145|NCT02713009|Dietary Supplement|Pregnancy multi-vitamin (including 10μg vitamin D3)|
75643146|NCT02713009|Dietary Supplement|10μg vitamin D3|
75643147|NCT02713009|Dietary Supplement|0μg vitamin D (placebo)|
75643148|NCT03085225|Drug|Combination of trabectedin with durvalumab|"Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial."
75643149|NCT02580019|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
75643150|NCT02705287|Other|Vitamin D dynamics-pregnant|tracer dose of deuterated vitamin D3
75927759|NCT03489876|Procedure|Osteochondral Autograft Transfer|The osteochondral autograft transfer will be harvested from the ipsilateral lateral femoral condyle (or contralateral if a previous ipsilateral total knee anthroplasty or trauma) and the graft will be transferred to the first metatarsal head.
75927760|NCT02196987|Other|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
75643151|NCT02705287|Other|Vitamin D dynamics-nonpregnant|tracer dose of deuterated vitamin D3
76083136|NCT03386838|Drug|Carboplatin|Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)
76083137|NCT03386838|Drug|Fluorouracil|1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
75643152|NCT01004822|Drug|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
75791394|NCT00226655|Drug|hCRF [XERECEPT (corticorelin acetate injection)]|2mg/day
75791395|NCT03750344|Device|Diagnostic test|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
75927761|NCT02196987|Other|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
75927762|NCT03487458|Procedure|Rib Fixation Surgery|Rib Fixation Surgery
76083138|NCT03386760|Device|Laser Utilisation PicoSecond|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
76083139|NCT03386760|Device|Laser Utilisation Nano-second|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
76083140|NCT03384342|Device|Narrow-band UV-B therapy|"Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~For a total period of 12 months, narrow-band UV-B therapy is performed once a month."
76083141|NCT03386682|Device|ESTYME® MATRIX Breast Implants|Breast implant surgery in breast reconstruction or breast augmentation
76083142|NCT03384264|Other|Physical activity|The suspension device was securely attached to a fixed beam. The suspension programme included an initial 10 min warm-up with very low-intensity joint mobility exercises. The central part of the program had a duration of 40 min and included six exercises in which the level of intensity was based on the inclination of the body. The exercises were performed in a split routine, alternating by segment to prevent joint overload. Finally, participants performed 10 minutes of stretching.
76083143|NCT03384186|Drug|Danicopan Modified Release Prototype 1|Danicopan (400 milligrams [mg]) oral tablet.
76083144|NCT03384186|Drug|Danicopan Modified Release Prototype 2|Danicopan (400 mg) oral tablet.
75471973|NCT01952964|Other|JUC spray dressing|"Intervention group Care of Tenckhoff catheter exit site using spray dressing. The detailed procedures will be introduced by the nurse according to the protocol of the unit. Please refer to Appendix III for details.~Skin test with JUC spray will be carried out prior to the usage of JUC spray dressing for caring the exit site. For the first three days after patient has been discharged, study team members will perform telephone follow up. Patients are reminded to report for signs and symptoms of infection or physical damage of catheter noted. A routine follow up at the Renal Unit will be arranged at eight weeks intervals."
75927763|NCT02198547|Drug|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
75927764|NCT02198547|Drug|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
75927765|NCT01024608|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
75927766|NCT01024608|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered each morning for two weeks.
75927767|NCT02197533|Other|Written List|Written list of seven management strategies for OAB to be produced during verbal discussion about management.
75927768|NCT03487380|Procedure|Fecal sample collection|Fecal sample collection
75927769|NCT02198625|Other|Moderate FiO2 and Protective Lung Ventilation Using|
75927770|NCT03489798|Procedure|6 misoprostol|Up to 6 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
75927771|NCT03489798|Procedure|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
75927772|NCT02197689|Device|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
75927773|NCT05145114|Procedure|THERAPEUTIC POSITIONS|Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.
75927774|NCT02198703|Dietary Supplement|Probiotics bacterial strains|
75927775|NCT02198703|Dietary Supplement|Placebo|
75927776|NCT05144958|Device|Totally thoracoscopic LAAO - ATRICLIP|The device for surgical totally thoracoscopic left atrial appendage occlusion AtriClip® Gillinov-Cosgrove™ (AtriClip, AtriCure, Dayton, OH, USA) consists of an automatically closing clip placed in a deployment loop on a disposable holder with the head articulation of 60 degrees side-to-side and up/down. The several novel features of the system in comparison to previous ones, such as its length, maneuverability and releasing system, enable it to be used in a totally thoracoscopic fashion. The AtriClip® PRO has parallel titanium crossbars that equalize the force over the tissue trabeculations of the LAA during deployment, ensuring a sealed line at the base of the LAA orifice, as confirmed in preclinical and clinical studies. The clip can be opened and closed repeatedly before final deployment when only the correct placement is confirmed in TEE.
75643153|NCT01004822|Drug|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
75643154|NCT01004822|Drug|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
75643155|NCT01004822|Drug|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
75927777|NCT05144958|Device|Percutaneous LAAO - WATCHMAN|Using a modified Seldinger technique a vessel dilator and a guidewire are inserted into the femoral vein. Under trans-esophageal echocardiography and fluoroscopy guidance, an interatrial septum is punctured using typical trans-septal access. The pigtail catheter is placed in the distal portion of the left atrial appendage and then the access sheath is inserted. After choosing the appropriate Watchman size the device is deployed and seals the left atrial appendage.
76083145|NCT03384186|Drug|Danicopan Modified Release Prototype 3|Danicopan (800 mg) oral tablet.
75471974|NCT01952977|Dietary Supplement|Test breakfast|
75471975|NCT01953029|Procedure|cardiac imajing|Cardiac MRI
75471976|NCT01953042|Behavioral|Psychoeducation|4 educational sessions covering information on diagnosis, treatment, available resources and self care for OCD and OCD Spectrum Disorders
75471977|NCT01953055|Radiation|Stereotactic ablative radiotherapy|
75471978|NCT01953094|Procedure|Screening Anal Pap Smear - No High Resolution Anoscopy|
75471979|NCT01953094|Procedure|Screening Anal Pap Smear - With High Resolution Anoscopy|
75471980|NCT01953107|Other|Oral Ferrous Fumarate|
75471981|NCT01953107|Other|Placebo|
75643156|NCT01004822|Drug|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
75643157|NCT01004822|Drug|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
75791396|NCT03751826|Other|Incentivised network delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the first intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV themselves and in their peers and friends. They will be counselled to receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
76083146|NCT03379974|Drug|DDAVP Inhalant Product|For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
76083147|NCT03379974|Behavioral|Exercise Intervention|For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
76083148|NCT03384030|Other|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
75333907|NCT02175628|Device|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient."
75333908|NCT05484648|Drug|Dexamethasone|"Dexamethasone has been used to generally favorable results in peripheral nerve blocks as adjunct. Several studies have reported prolongation in the duration of ropivacaine, mepivacaine and bupivacaine when used in combination with dexamethasone.~Various mechanisms for the beneficial adjunctive effect of dexamethasone with Local Anesthetics (LA) have been proposed. One theory suggests that the improved analgesia and increased blockade duration is due to its anti-inflammatory properties. It also acts as a local vasoconstrictor and thus may act by reducing LA absorption. Furthermore, it also increases the activity of inhibitory potassium channels on nociceptive C-Fibers."
75927778|NCT05144958|Device|Hybrid- minimally invasive LAAO - LARIAT|LARIAT system consists of: A) endocardial magnet-tipped guidewire. It is placed inside the left atrial appendage through the introduction of a catheter into the femoral vein; B) epicardial magnet-tipped guidewire. It is placed on the outside of the left atrium through the atrial appendage puncture of the pericardium. Each wire has a magnet of opposite polarity enabling end-to-end alignment; C) A compliant occlusion balloon catheter to identify the LAA and allow for a very precise and effective seal of the left atrial appendage; D) The LARIAT suture delivery device. It is introduced by an earlier puncture of the pericardium in the vicinity of the left atrial appendage and guided over magnet wire onto the base of the LAAO. With the LARIAT suture delivery device, the lumen of the left atrial appendage is closed from outside the heart, resulting in the elimination of the thrombus source.
75471982|NCT01953133|Behavioral|Couples Counselling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
75927779|NCT04461522|Procedure|Ultrasound-guided drug injection|The injection drugs were glucocorticoids and anesthetic drugs (1ml+2% lidocaine hydrochloride 0.5ml+0.9% sodium chloride 0.5ml), and the injection sites were subacromion deltoid bursa/coracoid bursa/biceps longhead tenosynosheath/glenohumeral joint bursa, etc.
75927780|NCT02031081|Drug|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
76083149|NCT03379896|Other|Collect peripheral blood sample|Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
75471983|NCT01953172|Dietary Supplement|AMP-886|AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
75471984|NCT01953172|Other|Placebo|Placebo
75471985|NCT01953185|Other|Sham manual diaphragm release technique|For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone & Russo, 2006).
75643158|NCT01004822|Drug|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
75643159|NCT01004822|Drug|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
75643160|NCT03920761|Device|EarlySense Insight system|a small piezoelectric sensor pad that can be placed under the mattress and provide contact-free monitoring by measuring and recording a patient's vital signs and motion parameters
75643161|NCT03920761|Device|Advanced Neonatal Epidermal System|a system of neonatal non-invasive adhesive sensors. Sensors are attached directly on the patient's body and are capable of continuously measuring and recording heart rate, respiratory rate, oxygen saturation, and skin temperature.
75643162|NCT03022279|Procedure|TAP Blocks|ultrasound guided transversus abdominis plane block utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
75643163|NCT03022279|Procedure|local wound infiltration|local anesthesia provided at the surgical site utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
75927781|NCT02031081|Drug|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
75927782|NCT02198859|Drug|Lithium Carbonate|
75927783|NCT02198937|Other|Blood sample|
75927784|NCT02199093|Other|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
76083150|NCT03379818|Behavioral|Shape training intervention|This intervention is based on on a study conducted by Smith and colleagues (2002), where they found that teaching typically developing infants to attend to shape by the end of the second year of life significantly enhances their word learning. Participants will be taught that the significant property they should focus in when learning and extending novel labels is shape. This will be done through play-like sessions.
75643164|NCT04295408|Procedure|Pericapsular nerve group block with saline solution|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the saline solution was injected in 5-mL increments while observing for adequate fluid spread in this plane.a total volune of 40 ml saline solution was injected.
75927785|NCT02199093|Other|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
75927786|NCT02199171|Drug|carboplatin|Given via HIPEC
75927787|NCT02199249|Device|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
76083151|NCT03379818|Behavioral|Specific word training|"In this intervention, participants will be taught the names of 28 real objects. The target words have been selected from the Wordbank database, which is an open database that lists the proportion of children that know a specific word at a specific age. Twenty-eight words that are understood by 80% of the total child population at 25 months were randomly selected as target words. Techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used."
76083152|NCT03386370|Device|"Indigo Mechanical Thrombectomy System"|"Removal of acute clot (< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra"
75333909|NCT05484648|Drug|Dexmedetomidine|Dexmedetomidine is another promising drug being used as a local anaesthetic adjuvant in peripheral nerve blocks. It is an alpha-2 agonist, which has shown to have prolonged duration of postoperative analgesia when given with LA for peripheral nerve blocks with other beneficial effects such as reducing the opioid consumption. Alpha-2-agonists such as dexmedetomidine cause hyperpolarization-activated cation currents which inhibit the transmission of nociceptive fibers.
75333910|NCT02184520|Device|TRANSITION|
75333911|NCT02184520|Device|REVERE|
75333912|NCT05486598|Drug|AL8326 tablets|"Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach."
75333913|NCT01011634|Drug|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
75927788|NCT02199249|Device|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
75333914|NCT02137096|Drug|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
75333915|NCT02137096|Drug|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
75333916|NCT02137096|Drug|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
75333917|NCT02137096|Procedure|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
75333918|NCT02132884|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
75333919|NCT02132884|Procedure|therapeutic procedure|Receive standard of care treatment
75333920|NCT02132884|Drug|targeted therapy|Receive specific targeted therapy
75927789|NCT02257359|Drug|Epelsiban|Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
75927790|NCT00910650|Biological|F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
75927791|NCT00910650|Drug|non-myeloablative conditioning chemotherapy|Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
75927792|NCT02257437|Dietary Supplement|LNS snack|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
75927793|NCT02257437|Dietary Supplement|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
75333921|NCT02132884|Other|laboratory biomarker analysis|Correlative studies
75333922|NCT02130622|Drug|Promethazine|
75333923|NCT02130622|Drug|Sugar pill|
75333924|NCT02134912|Drug|crizotinib|Given PO
75333925|NCT02134912|Drug|pemetrexed disodium|Given IV
75333926|NCT02134912|Other|laboratory biomarker analysis|Correlative studies
75333927|NCT02134912|Other|pharmacological study|Correlative studies
75333928|NCT01226485|Drug|Taladegib|Administered IV
75333929|NCT05486442|Behavioral|ACT for weight-related experiential avoidance|Participants in the experimental group received weight concern-related ACT training in a group setting. Each session focused on different dimensions of ACT and included relevant exercises and homeworks. Dimensions studied included creative hopelessness, control strategies, mindfulness exercises, values and barries to values and commitment to action.
75333930|NCT05484336|Other|Glucose as reference food|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose diluted in 250ml, tested two times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
75333931|NCT05484336|Other|Beverage containing 4g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 4g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
75333932|NCT05484336|Other|Beverage containing 6g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 6g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
75333933|NCT05484336|Other|Beverage containing 8g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
75333934|NCT02094352|Drug|Ketamine Infusion + Epidural Infusion|The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
75333935|NCT02094352|Drug|Control Group + Epidural infusion|The saline and epidural infusions will be administered over 96 hours with appropriate titration.
75333936|NCT02094352|Drug|Ketamine Booster Infusion|Patients will receive three ketamine booster infusions over the course of three months.
75927794|NCT02257437|Dietary Supplement|Sprinkles|Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
75927795|NCT02257437|Dietary Supplement|LNS + borbor|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
75471986|NCT01953185|Other|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
75471987|NCT01953198|Other|Hypobaric hypoxia|Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
75643165|NCT04295408|Procedure|Pericapsular nerve group block with ropivacaine|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, local anesthetic was injected in 5-mL increments while observing for adequate fluid spread in this plane. a 2 mg.kg-1Ropivacaine in 40 ml of saline was injected
75643166|NCT02578537|Drug|Ticagrelor|Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
75471988|NCT01953302|Procedure|"modified open mesh technique"|We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.
75471989|NCT01953315|Biological|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
75333937|NCT02094352|Drug|Control Group Booster Infusion|Patients will receive three saline booster infusions over the course of three months.
75471990|NCT01953341|Drug|AMG 333|Oral administration available in varying dose strength.
75791397|NCT03751826|Other|Peer navigator delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the second intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV and then receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
75471991|NCT01953341|Drug|Placebo|Placebo containing no active drug
75471992|NCT01953367|Drug|Vantobra (tobramycin)|Inhalation
75927796|NCT04461366|Device|Monopolar radiofrequency|The RF electrode was moved randomly for 30 seconds over each scar. The total duration of the treatment session is only 5 minutes for each cheek. It takes 15 minutes if the forehead and 2 cheeks are affected.
75927797|NCT04461366|Device|Pulsed dye laser|PDL was applied for the affected areas with no pre-treatment regimens or topical anaesthetics. There was no requirement for skin cooling.
75927798|NCT02199327|Drug|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
75927799|NCT02199327|Drug|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
75927800|NCT00756288|Procedure|Topical retinoid and blue-light therapy with photosensitizing agent|Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
75471993|NCT01953367|Drug|TOBI (tobramycin)|Inhalation
75471994|NCT01953380|Behavioral|extended information|
75471995|NCT01953393|Other|Low-dose TNF-alpha|
75471996|NCT01953406|Drug|5-fluorouracil|5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
75471997|NCT01953406|Drug|Mitomycin|Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
75791398|NCT03751826|Other|standard of care|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the standard of care arm encourage females aged 18-24 to test for HIV, receive sexual and reproductive health services, contraception and condoms, and link to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
75643167|NCT02578537|Drug|Clopidogrel|Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
75791399|NCT03750188|Drug|ProHance|0.1 mmol/kg ProHance intravenous injection
75791400|NCT03672344|Device|Lookware TM|Lookware TM is a computer-based video game that requires the subject engage in social skills related exercises that include certain visual behaviors. These exercises combine techniques from applied behavior analysis (ABA) and use of gaze-contingent eye tracking technology during simulated social interactions with 3D animated characters to target certain social skills deficits in children with autism spectrum disorder (ASD). The game is delivered through a laptop computer, eye tracker, and game controller.
75927801|NCT00756288|Procedure|Photodynamic Therapy (PDT)|Photo-therapy with sensitizing agent - apply to AKs at week 4
75927802|NCT02198001|Drug|tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)|"BPs per os< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10"
76083153|NCT03383952|Biological|ICAR19 CAR-T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
75643168|NCT03011671|Drug|Acetazolamide|ACZ will be given at an initial dose of 250 mg twice a day (BID) and then escalated to 500 mg BID after 1 week. ACZ will be given on days 1-21 of each cycle.
75643169|NCT03011671|Drug|Temozolomide|For cycle 1 of the maintenance phase, TMZ will administered at 150 mg/m2 on days 1- 5 followed by 23 days with no drug. For cycles 2- 6, TMZ can be increased to 200 mg/m2 at the discretion of the treating investigator.
75643170|NCT00628706|Drug|Delta9-tetrahydrocannabinol (THC)|inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
75333938|NCT05486364|Diagnostic Test|Digital Monitoring|Subjects will perform self-measurements with a PPG based smartphone application (FibriCheck™) to monitor for AF recurrence after the PVI procedure. One-minute measurements will be performed twice daily starting one month before the PVI procedure and continue up to 12 months after the procedure.
75643171|NCT01001234|Drug|rizatriptan|"For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).~Rizatriptan dose administered was based on participant weight at Screening: those <40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
75333939|NCT05486364|Diagnostic Test|Standard of care|Subjects will wear a 24-hour holter monitor at 3, 6 and 12 months after the PVI procedure. Additionally, outpatient cardiology clinic visits are organised at 6 weeks, 3 months and 12 months after the PVI procedure (including a 12-lead ECG and cardiologist consultation).
75333940|NCT05478876|Radiation|carbon ion radiation therapy CIRT|"CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.~The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.~Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol."
75643172|NCT01001234|Drug|placebo|For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.
75643173|NCT01001234|Drug|rizatriptan|"For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder [moderate or severe pain 15 minutes after dose] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.~Rizatriptan dose administered was based on participant weight at Screening: those <40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
75643174|NCT01001234|Drug|placebo|For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
75927803|NCT02198001|Procedure|atraumatic extraction|Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
75927804|NCT03491982|Device|Remote Cardiac Rehab|Remote Cardiac Rehab
76083154|NCT03383796|Procedure|Three dimensional laparoscopic resection for pCCA|Three dimensional laparoscopic resection for pCCA
75927805|NCT02198079|Biological|Sputum|
76083155|NCT03383796|Procedure|Open resection for pCCA|Open resection for pCCA
75643175|NCT02578225|Other|Non interventional study|
75643176|NCT02954341|Device|CardioMEMS HF System|
75643177|NCT02870504|Procedure|Corneoscleral limbus group|Laser spot locates on the corneoscleral limbus
75643178|NCT02870504|Procedure|one spot group|Laser spot locates on one spot away from the corneoscleral limbus
75643179|NCT02870504|Procedure|two spots group|Laser spot locates on two spots away from the corneoscleral limbus
75643180|NCT02649829|Biological|dendritic cell vaccination plus chemotherapy|"A. Chemoimmunotherapy:~four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.~four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.~B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle."
75643181|NCT04294082|Behavioral|Mindfulness based intervention|"A four session, 120 mins per session mindfulness based course delivered weekly oer the course of four weeks. The mindfulness sessions are based on the model delineated by Kabat-Zinn (1992) and will encompass:~an introduction to mindfulness~body-scan exercises~sitting meditation~mindful movement exercises~individual and group reflections~homework exercises"
75791401|NCT03672344|Device|Lookware TM Control Module|Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises. The game is delivered through a laptop computer, eye tracker, and game controller.
75791402|NCT03747770|Biological|Bivalent HPV vaccine CERVARIX®|Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04)
75791403|NCT03747692|Procedure|study group|local anesthesia by mepicaine hydrochloride by intracervical local injection using 10 mm syringe.
75927806|NCT05147688|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75927807|NCT05116800|Drug|Gemcitabine|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
75927808|NCT05116800|Drug|9-ING-41|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
75927809|NCT05116800|Drug|Docetaxel|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
75927810|NCT02199405|Other|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
75927811|NCT02199405|Other|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
75927812|NCT02199405|Other|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
75927813|NCT02199405|Other|Cervical traction|
75927814|NCT03673254|Device|rotational atherectomy device|angioplasty with rotational atherectomy device on a nonselected population
75927815|NCT02198157|Other|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
75927816|NCT04078737|Drug|Ticagrelor and Aspirin|"Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg"
75927817|NCT04078737|Drug|Clopidogrel and Aspirin|"Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day"
75927818|NCT03491904|Drug|Fasinumab AI|Self-administered with auto injector
75927819|NCT03491904|Drug|Fasinumab PFS|Prefilled syringe administered by study staff
75927820|NCT03487146|Device|hemoperfusion(HP)|These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
75927821|NCT05039112|Device|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
75927822|NCT05039112|Device|Stenfilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
75927823|NCT05150808|Other|IRS insecticide: Vectron T500|public health insecticide
75927824|NCT02198313|Drug|BIIX 1 XX - D1|
75927825|NCT02198313|Drug|BIIX 1 XX - D2|
75927826|NCT02198313|Drug|BIIX 1 XX - D3|
75927827|NCT02198313|Drug|Placebo|
75927828|NCT03249090|Other|Patient Self-Reporting of Symptoms|"At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient."
75643182|NCT04295642|Drug|CVL-751|Oral tablet
75927829|NCT03249090|Other|Usual Care Delivery|Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
75927830|NCT02199561|Biological|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
75927831|NCT03533439|Diagnostic Test|Near infrared spectroscopy|Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management
76083156|NCT01570036|Drug|Herceptin|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
76083157|NCT01570036|Drug|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
76083158|NCT01570036|Drug|GM-CSF|For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
76083159|NCT03386136|Drug|100% Oxygen|To provide hospitalized ileus or pseudo-obstruction patient with 100% oxygen via non-rebreather face mask, for 6 hours
75927832|NCT03487068|Device|The FibroScan device|The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
76083160|NCT03379584|Drug|SGN-CD48A|Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
76083161|NCT03386058|Device|Temporary device deactivation|Patient-controlled, temporary deactivation of implanted device
76083162|NCT05564962|Diagnostic Test|Quality and Independence of Gait Classification Scale for Duchenne Muscular Dystrophy (QIGS-DMD)|MFM is a valid and reliable measure to evaluate the severity of the motor deficit of both ambulatory and non-ambulatory children with neuromuscular diseases. MFM consists of 32 items in 3 dimensions and is scored as a percentage of the maximum possible score which higher scores indicate better functional status. VLERS is a 10-item ordinal scale that identifies the functional status of the lower limbs. According to VLERS, level 1 indicates that the patient can walk independently and climb stairs without assistance while level 10 indicates is the patient is bedridden.
76083163|NCT03383718|Procedure|Revascularisation|Percutaneous coronary intervention or coronary artery bypass surgery
76083164|NCT03383718|Other|Optimal Medical Treatment/OMT|Standard of care in stable coronary artery disease or after acute myocardial infarction.
76083165|NCT01516684|Drug|placebo administration|Given topically
76083166|NCT01516684|Drug|EMLA|Given topically
76083167|NCT01516684|Drug|propofol|Given IV
76083168|NCT01516684|Drug|fentanyl citrate|Given IV
76083169|NCT03383640|Other|Active exercises|Active flexion movements every waking hour of the replanted digits
76083170|NCT04316754|Other|music|"During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group."
75333941|NCT02552238|Drug|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
75643183|NCT04297046|Device|PCA (patient controlled analgesia)|Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.
75791404|NCT03747692|Procedure|control group|each patient receives one tablet of NSAIDs (diclofenac sodium 50 mg) and 5ml of a placebo in form of normal saline are injected intracervical 5 minutes before the procedure using 10 mm syringe.
75791405|NCT04520412|Drug|GV-971|Administered PO
75643184|NCT02578459|Device|Intrathecal Drug Delivery System|The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.
75643185|NCT02578459|Other|Conventional Medical Management|Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
75643186|NCT02578381|Device|Boston Scientific Pressure Wire|St Jude Medical Pressure Wire
75927833|NCT02199873|Drug|BIIX 1 XX - single rising dose|
75927834|NCT02199873|Drug|Placebo|
76083171|NCT03383562|Procedure|operation in different stages of the day|operation was arranged in the morning ,afternoon or at night
75333942|NCT05478798|Other|ultrasonographic fetal weight estimation|An ultrasonographic estimate will be performed in our ultrasound unit and a calculation by the ultrasound machine is based on Hadlock's formula including measurement of biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL).
75643187|NCT02578381|Device|Validation of Boston Scientific pressure wire|
75791406|NCT04520412|Drug|Placebo|Administered PO
75791407|NCT03751748|Device|AFR implantation|Implantation of atrial flow regulator (AFR) device
75791408|NCT03751748|Device|Sham procedure|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
75791409|NCT03124108|Drug|Elafibranor 80 mg|Two coated tablets daily for 12 weeks
75791410|NCT03124108|Drug|Elafibranor 120 mg|Two coated tablets daily for 12 weeks
76083172|NCT01517074|Drug|Sirolimus|Subconjunctival injection
76083173|NCT03379350|Procedure|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
76083174|NCT01570348|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
76083175|NCT01570348|Drug|Cyclophosphamide|Given IV
76083176|NCT01570348|Drug|Fludarabine Phosphate|Given IV
76083177|NCT01570348|Other|Laboratory Biomarker Analysis|Correlative studies
76083178|NCT01570348|Drug|Mycophenolate Mofetil|Given PO
76083179|NCT01570348|Drug|Mycophenolic Acid|Given PO
76083180|NCT01570348|Other|Quality-of-Life Assessment|Ancillary studies
76083181|NCT01570348|Drug|Tacrolimus|Given IV or PO
76083182|NCT01570348|Radiation|Total-Body Irradiation|Undergo TBI
76083183|NCT03383484|Other|OMT|Weekly manipulation of Chapman points and rib raising techniques (osteopathic manipulative treatment)
75333943|NCT05478798|Other|clinical fetal weight estimation|A clinical weight estimate will be performed by using Leopold's maneuvers
75471998|NCT01953419|Drug|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
75471999|NCT01953445|Drug|paclitaxel|
76083184|NCT03383484|Other|Yoga|Yoga practice 3 times per week for 1 hour each time; hatha yoga poses, asanas, and breathing techniques
75333944|NCT05478798|Other|maternal subjective fetal weight estimation|the pregnant woman will tell her subjective estimation of fetal weight estimation
75333945|NCT01188421|Drug|Buprenorphine/naloxone|up to 8/2 mg Sublingual (SL) per day
75472000|NCT01953445|Drug|BKM120|
75927835|NCT04740606|Device|Augmented Reality Navigation System|Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.
76083185|NCT03383406|Drug|Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy|"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1~Day3 by Intravenous infusion."
76083186|NCT05564884|Other|no intervantion|no intervention
75333946|NCT01188421|Drug|Clonidine|up to 0.8 mg per day (oral)
75333947|NCT01188421|Drug|Tramadol ER|up to 600 mg per day
75333948|NCT04424082|Other|Removal of dead space filter|Dead space filters will be removed and Vcap parameters (VCO2 ml/min, PaCO2 kPa, alveolar dead space in ml) recorded before and after removal
75472001|NCT01953471|Other|Allergic rhinitis|Questionnaire
75333949|NCT01006018|Drug|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
75333950|NCT01006018|Drug|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
75472002|NCT01953484|Other|Change in extracorporeal carbon dioxide removal|
75333951|NCT01006018|Drug|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
75472003|NCT01953497|Drug|URC102|
75472004|NCT01953497|Drug|Placebo|
75472005|NCT01953523|Procedure|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
75472006|NCT01953536|Drug|Vintafolide 2.5 mg|During treatment, participants receive IV vintafolide 2.5 mg.
75472007|NCT01953536|Drug|Paclitaxel 80 mg/m^2|During treatment, participants receive IV paclitaxel 80 mg/m^2.
75472008|NCT01953536|Drug|Etarfolatide|During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
75472009|NCT01953536|Drug|Folic acid|During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
75472010|NCT01953536|Drug|Premedication for Paclitaxel|During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
76083187|NCT04445922|Drug|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
76083188|NCT04445922|Drug|reference-anastrozole tablet|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
76083189|NCT01572298|Device|allograft alone|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
76083190|NCT01572298|Device|allograft with autograft|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
76083191|NCT03379116|Other|enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.
76083192|NCT01518868|Device|Investigational contact lens|Worn on a daily wear basis for one week.
76083193|NCT01518868|Device|PureVision contact lens|Worn on a daily wear basis for one week
76083194|NCT04287348|Drug|Brolucizumab 6 mg solution for intravitreal injection|All consenting, enrolled patients (irrespectively of maximum recurrence-free interval under aflibercept pretreatment) will receive an intravitreal injection of brolucizumab 6 mg at baseline (week 0), at week 4 and each of the following treat and extend visits. At each visit all patients will undergo an OCT assessment. For all patients extension of treatment intervals is only possible 2-week-stepwise, e.g. 4, 6, 8 weeks etc.
75791411|NCT03124108|Drug|Placebo|Two coated tablets daily for 12 weeks
76083195|NCT03383328|Drug|NSAID + prednisolone, preoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
76083196|NCT03383328|Drug|NSAID + prednisolone, postoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
76083197|NCT03383328|Drug|NSAID, preoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
75333952|NCT05478642|Other|The Hospital Anxiety and Depression Scale.|"The study was carried out on the basis of the National Military Medical Clinical Center Main Military Clinical Hospital. All patients participated in Operation Joint Forces and received gunshot wounds during combat operations.~A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.~Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv."
75333953|NCT04424238|Behavioral|m-health management|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.
75333954|NCT04424160|Biological|PRP injection in the endometrium|Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.
76083198|NCT03383328|Drug|NSAID, postoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
75333955|NCT00996502|Drug|Docetaxel|"Phase I:~Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle"
75333956|NCT00996502|Drug|Bevacizumab|15mg/kg of Bevacizumab every 3 weeks
75472011|NCT01953549|Procedure|physical fitness training|
76083199|NCT03383328|Drug|Drop-less surgery|A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
75472012|NCT01953549|Procedure|relaxation|
76083200|NCT04445376|Other|Physical Exercises|Aerobic Training and Breathing Exercises.
76083201|NCT01573702|Procedure|Stereotactic Radiosurgery|21 Gy daily for 5 days
75333957|NCT00996502|Drug|Erlotinib|200 mg of Erlotinib PO daily days 2-16
75472013|NCT01953614|Other|Chiropractic adjustment|
75472014|NCT01953614|Other|Sham adjustment|
75472015|NCT01953627|Procedure|Surgical procedure with the system Kymerax|
75472016|NCT01953627|Device|The system Kymerax|
75643188|NCT01004510|Drug|zoledronic acid|Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
75643189|NCT02578303|Other|Vascular flow measurement by PC-MRI|participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
75643190|NCT04073953|Drug|RPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
75643191|NCT04073953|Drug|SPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
75643192|NCT04073953|Drug|Placebo|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
75643193|NCT02863783|Device|EUS with Fiducial|EUS will be used to place fiducial into pancreas tumor at time of biopsy
75643194|NCT04073017|Dietary Supplement|Enterade®|Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks
75643195|NCT04073017|Other|Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)|Ancillary studies
75643196|NCT02849041|Device|medical imaging|Low-dose CT-scanner
75643197|NCT02849041|Biological|Identification of Circulating Tumor Cells|Research of circulating tumor cells in blood
75643198|NCT02849041|Procedure|Psychological Questionnaires|"The procedure of screening test could be stressful. False positive results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells."
75643199|NCT01004432|Drug|Golimumab 50 mg SC|Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
75643200|NCT01004432|Drug|Golimumab 2 mg/kg IV|Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
75643201|NCT01004432|Drug|Methotrexate (MTX)|Participants will continue taking their current Methotrexate (MTX) treatment regimen.
75791412|NCT03946488|Device|Functional electrical stimulation|Functional electrical stimulation of finger's muscles in order to open the hand
75791413|NCT04487340|Behavioral|Education|Provide each center with relevant education of guidelines, and help the clinicians to improve medical quality.
76083202|NCT01573702|Drug|Erlotinib|150mg once daily
76083203|NCT04445298|Diagnostic Test|Transepidermal water loss|We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.
76083204|NCT04445298|Diagnostic Test|Skin tape stripping|Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
76083205|NCT04445298|Diagnostic Test|Blood draw|We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
76083206|NCT04445298|Diagnostic Test|Bacterial PCR swab|Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
76083207|NCT03379038|Other|Progressive Physical Therapy|Stretching of the tight muscle, positioning, abdominal co activation; rolling etc to decrease muscle tone and functional independence.
76083208|NCT03379038|Other|Maintenance Physical Therapy|Same Physical therapy protocol but aim was to maintain current level of spasticity and functioning
75927836|NCT05150730|Other|Multi professional care|Participants were instructed to respect their pain threshold during body practice and the evolution of the participants happened gradually and individually. Associated with the practice of exercise, workers received information about their disease, chronic pain, guidelines for daily activities, and the importance of physical exercise. In the second hour, the responsible psychologist addressed issues such as the repercussions of illnesses on the individual's social and affective life, self-esteem, self-image, conformism, and self-indulgence after the illness and prospects for the future. Throughout the program, participants also received informative lectures from other professionals, such as social workers, nurses, and dentists.
75333958|NCT00996502|Drug|Prednisone|5 mg of Prednisone PO bid
75791414|NCT04465812|Behavioral|Self-monitoring and personalized feedback on smartphone app|"Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index > 15 to assess detail clinical status and recommend outpatient visit if necessary;~Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS>49 or SDS>52 to assess detail clinical status and recommend outpatient visit if necessary;~Patients will complete cognitive training games every week on app;~Medical staff will send health information on app"
75791415|NCT04475588|Drug|Itolizumab IV infusion|"First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B"
75333959|NCT00984490|Drug|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
75472017|NCT01953653|Behavioral|Structured daily diary|The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
75472018|NCT01953666|Other|Rehabilitation program|"Rehabilitation program with an occupational therpasit~3 training sessions (one hour) per week for a month (12 sessions)"
75472019|NCT01953666|Other|Self - Training at home|Only instructions for a self - training at home
75472020|NCT01953679|Drug|Ulipristal Acetate|
75791416|NCT04475588|Drug|Best supportive care (BSC)|Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
75927837|NCT02199951|Drug|Dihydroartemisinin and piperaquine|Antimalarial
76083209|NCT03093246|Dietary Supplement|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
75472021|NCT01953705|Drug|Omega 3 PUFA|fish oil concentrate standardized to long chain n-3 PUFA content
75927838|NCT03533361|Drug|Lenvatinib|Oral capsules: 4 milligrams (mg) and 10 mg
76083210|NCT03093246|Drug|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
76083211|NCT03093246|Other|Placebo|Placebo pills over a period of 180 days
76083212|NCT03093246|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
76083213|NCT03000426|Procedure|Free gingival graft|Free gingival graft removal from palate for socket preservation
76083214|NCT03000426|Device|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
76083215|NCT05171634|Device|DiscoveryTM|Colonoscopy assisted by an artificial intelligence system (DiscoveryTM).
76083216|NCT05171634|Device|iSCAN|Virtual colonoscopy assisted by iSCAN
76083217|NCT03125460|Device|Xpert Bladder Cancer Monitor|in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
76083218|NCT02969928|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
76083219|NCT02969928|Drug|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
76083220|NCT02969928|Drug|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
76083221|NCT02969928|Drug|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
75333960|NCT00984490|Other|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
75333961|NCT05484102|Dietary Supplement|milk fermented with lactobacillus paracasei CBA L74|milk fermented with lactobacillus paracasei CBA L74 will be administered daily for 3 months to 100 children. Participants were supplied with the milk product in powder form, by Heinz Italia SpA, Segrate, Italy. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
75472022|NCT01953705|Drug|Placebo|
75472023|NCT01953731|Drug|Palbociclib|"In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.~In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose."
76083222|NCT05171556|Other|Cosmetic product|RV4942A is a face balm product
76083223|NCT02968446|Dietary Supplement|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
76083224|NCT02968446|Dietary Supplement|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
75333962|NCT05484102|Dietary Supplement|placebo milk formula|placebo milk formula containing maltodextrins will be administered daily for 3 months to 100 children. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
75333963|NCT05484024|Drug|Sintilimab|PD-1 inhibitor
75333964|NCT05484024|Radiation|Short-course radiotherapy|Pelvic radiation
75333965|NCT05484024|Combination Product|CAPOX/mFOLFOX|chemotherapy regimen
75333966|NCT02027272|Drug|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
75791417|NCT03946254|Other|Effect of strength training on executive functions in elderly people with mild cognitive impairment.|Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group
75333967|NCT05475444|Device|Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels|antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.
75927839|NCT03485742|Other|No intervention|No intervention. Collection of data on statin eligibility in patients admitted with MI
75927840|NCT02200029|Drug|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
75927841|NCT02200029|Drug|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
75927842|NCT03489642|Behavioral|Telehealth Program|Telehealth program delivered remotely to study participants. Program developed by Cambium Technologies.
75927843|NCT02200107|Behavioral|self management education|
75927844|NCT01433328|Drug|Lidocaine|Lidocaine
75333968|NCT05475444|Device|Ciprofloxacin paste and solution|Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection
75333969|NCT02012608|Drug|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
75333970|NCT02012608|Drug|Placebo|For subjects undergoing breast conserving therapy
75333971|NCT03725592|Other|Standard Treatment|Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
75333972|NCT03725592|Behavioral|Intensive Education|Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
75333973|NCT03472092|Behavioral|Cognitive Behavioral Therapy (CBT)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
75472024|NCT01953731|Drug|Rifampin|In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
75472025|NCT01953744|Drug|Fluconazole|Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.
75472026|NCT01953744|Drug|Meglumine Antimoniate|Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
75333974|NCT03472092|Drug|Placebo|The placebo pill will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study.
75472027|NCT01953757|Other|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
75927845|NCT01433328|Drug|Placebo|Placebo
75472028|NCT01953757|Dietary Supplement|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
75472029|NCT01953770|Drug|PEG-L-asparaginase ind|1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour
75472030|NCT01953770|Drug|PEG-L-asparaginase cons|1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).
75643202|NCT01004432|Drug|Placebo SC|Placebo matched to golimumab SC injection every 4 weeks.
75643203|NCT01004432|Drug|Placebo IV|Placebo matched to golimumab intravenous infusion every 8 weeks.
75927846|NCT02198469|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
76083225|NCT02968446|Drug|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
76083226|NCT03125382|Device|Carelink System|Patients start to perform device data transmission through Carelink system
76083227|NCT03125382|Device|In office standard visit|Patients start or mantain in office standard visits
76083228|NCT03383250|Dietary Supplement|Normal meal|
76083229|NCT03378960|Drug|Omeprazole 20mg|
75333975|NCT03472092|Drug|Amitriptyline|Amitriptyline will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study. For this study, a dose of 0.25 mg/kg/day will be provided for the 1st 2 weeks, followed by a dose of 0.5 mg/kg/day for 2 weeks, 0.75 mg/kg/day for 2 weeks and a maximum dose of 1.0 mg/kg/day for 2 weeks based on tolerability. Participants experiencing tolerability issues, may be held a current dose rather than titrated to the next dosage if deemed appropriate by the study doctor.
75333976|NCT03472092|Behavioral|Biofeedback-Assisted Relaxation Training (BART)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
75333977|NCT03472092|Behavioral|Cognitive Reappraisal Training (CR)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
75472031|NCT01953770|Drug|E.coli L-asparaginase|E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).
75472032|NCT01953770|Drug|High-dose Methotrexate|2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.
75472033|NCT01953770|Drug|Low-dose Methotrexate|30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
75472034|NCT01953770|Drug|Triple intrathecal therapy|Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
75472035|NCT01953770|Radiation|Cranial irradiation|12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients >3 years of age
75927847|NCT02198469|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
75472036|NCT01953770|Drug|Daunorubicin|Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
75643204|NCT02579005|Biological|Patients with a living donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
75472037|NCT01953796|Drug|clomiphene|For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
75643205|NCT02579005|Biological|Patients with a UCB donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
75643206|NCT02576275|Drug|Duvelisib|Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
75472038|NCT01953809|Drug|GSK1322322|Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
75472039|NCT01953809|Drug|EE/NE|Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
75472040|NCT01953809|Drug|GSK1322322 Placebo|GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
75472041|NCT01953809|Drug|EE/NE Placebo|EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
75472042|NCT01953822|Other|Data collection|Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
75643207|NCT02576275|Drug|Placebo|Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
75643208|NCT02576275|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
75643209|NCT02576275|Drug|Bendamustine|IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
75643210|NCT01000610|Drug|rituximab [MabThera/Rituxan]|1000 mg iv infusion on days 1 and 15
75643211|NCT01000610|Drug|methotrexate|10-25 mg weekly (oral or parenteral)
75927848|NCT04448574|Other|Chest Wall Deformities Questionaire|Questionaire about epidemiological data was sent to Patients and families
75927849|NCT02200185|Drug|IV titrated morphine|"Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:~SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times"
75927850|NCT02200185|Drug|Low dose nebulised morphine|10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
76083230|NCT02907996|Drug|Sofosbuvir|400 mg tablet administered orally once daily
75643212|NCT01000610|Drug|methylprednisolone|100 mg iv prior to each rituximab infusion
75643213|NCT04072939|Other|Patients having had a lens surgery|Dilated fundus exam
75643214|NCT01877655|Biological|ASP0113|Intramuscular injection
75643215|NCT01877655|Drug|Placebo|Intramuscular injection
75927851|NCT02200185|Drug|High dose nebulised morphine|20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
75927852|NCT03485664|Procedure|tooth extraction|tooth extraction
75927853|NCT02200263|Dietary Supplement|Lutein plus Zeaxanthin|dose: two softgels once a day with a meal
75927854|NCT02200263|Dietary Supplement|Placebo|two softgels once-daily with a meal
75927855|NCT02201043|Drug|Thalidomide 150mg|
75927856|NCT02201043|Drug|Thalidomide 100mg|
75472043|NCT01953835|Drug|GSK2586184 standard formulation|GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
75927857|NCT02201043|Drug|Placebo|
75927858|NCT02200341|Behavioral|MBCT|
75927859|NCT02200341|Behavioral|PRT-PsyEd|
75927860|NCT02956434|Behavioral|Brief Family Intervention|Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
76083231|NCT03378882|Biological|Parasitic serologies|"Suspected angiostrongylosis - Angiostrongylus cantonensis:~An aliquot of CSF and an aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies.~A CSF aliquot will be sent to the CDC for PCR.~Suspected angiostrongylosis- Angiostrongylus costaricensis:~- An aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies."
76083232|NCT03378882|Procedure|Biopsy|"Suspected angiostrongylosis - Angiostrongylus costaricensis:~- A piece of biopsy or intestinal resection will be sent to the pathology laboratory for parasitic elements suggestive of Angiostrongylus costaricensis infection"
76083233|NCT03383172|Behavioral|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
76083234|NCT03378804|Procedure|Programmed intermittent epidural bolus application (PIEB)|Instead of a continuous background infusion of 6ml/h, one bolus injection is performed at the same amount per hour.
76083235|NCT03378804|Procedure|Continous epidural analgesia|
76083236|NCT03385824|Behavioral|Self-Advocacy for Independent Life (SAIL)|SAIL program is based on an interactive workshop model. In -person sessions will focus on: enhancement of self-efficacy beliefs; enhancement of knowledge of TBI self-advocacy information; group process to instill hope and universality; and practice of self-advocacy behaviors in a supportive neuro-rehabilitation structured group environment.
75472044|NCT01953835|Drug|Simvastatin|Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
75472045|NCT01953835|Drug|Rosuvastatin|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
75643216|NCT04294238|Behavioral|Aerobic exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
75643217|NCT04296968|Device|Painful stimulation using a laser device (DEKA Stimul 1340, Calenzano, Italy)|In the experimental paradigm, 160 painful stimuli of two intensities (3 J, 3.5 J) will be applied to the dorsum of the left hand using the laser device listed above.
75927861|NCT02201121|Other|Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation|This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
75927862|NCT03485586|Device|Traditional ultrasound biometrics|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
75927863|NCT03485586|Device|Lenstar|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
75927864|NCT02200419|Other|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
75927865|NCT02200575|Drug|Telmisartan|
75927866|NCT03486756|Behavioral|Internet-CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
75927867|NCT03485508|Diagnostic Test|Transthoracic echocardiography|Transthoracic echocardiography Blood sample with assessment of biomarkers
75927868|NCT02201199|Drug|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75927869|NCT02201199|Drug|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
76083237|NCT03385746|Other|polyamide|metal reinforced polyamide denture base material
76083238|NCT03385746|Other|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
76083239|NCT03378726|Dietary Supplement|Micronutrients|Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.
76083240|NCT03378726|Behavioral|SPOON Group Counseling|SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.
76083241|NCT03378726|Behavioral|Interpersonal Counseling|SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.
75927870|NCT02201199|Drug|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75927871|NCT03533205|Diagnostic Test|Hypotension Probability Indicator|The accurary of the Hypotension Probability Indicator (HPI) is tested in the created offline database. This means data was prospectively collected but the HPI algorithm was not tested prospectively but after collection in the offline database.
76083242|NCT03378726|Dietary Supplement|SQ-LNS|SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.
75643218|NCT04296968|Device|Visual cueing|Preceding to each painful stimulus, visual cues (e.g., blue dot and yellow square) will be presented on a screen indicating the intensity of the subsequent stimulus (low and high intensity) with an accuracy of 75%. The contingencies of the visual cues will be explicitly stated to the participants.
75643219|NCT02871284|Behavioral|Exercise|
76083243|NCT03378726|Behavioral|Standard Counseling|Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
75791418|NCT03946020|Procedure|Guided bone regeneration with or without autologous bone|Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
75791419|NCT03750032|Procedure|Stapler appendectomy|The patients randomised for this intervention will undergo stapler appendectomy.
75791420|NCT03750032|Procedure|Endoloop|The patients randomised for this intervention will undergo appendicular stump closure using Endoloop.
75791421|NCT03750032|Procedure|Hem-O-Lock|The patients randomised for this intervention will undergo appendicular stump closure using Hem-O-Lock.
75791422|NCT04287556|Diagnostic Test|In vitro contracture test (IVCT)|In vitro study of muscle contraction after exposure to different substances (caffeine and halothane).
75791423|NCT04287556|Diagnostic Test|In vitro test of hypermetabolism in B lymphocytes|In vitro study of the activation of lymphocytes B after being incubated with a cocktail of primary antibodies and measuring the acidification in response to the RyR1, 4-CmC agonist, using ryanodine as a positive control.
76083244|NCT03378648|Drug|CHF6366|"Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366"
76083245|NCT03378648|Drug|Placebo CHF6366|"Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366"
76083246|NCT03378648|Drug|umeclidinium bromide and vilanterol trifenatate|Part 3 Single dose
75643220|NCT02523469|Biological|ALT-803|
75791424|NCT04287556|Diagnostic Test|Genetic test|Analysis of genes related to MH (CACNA1S and RYR1).
75791425|NCT03947580|Other|Use of the Dvectis Single pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Single pads compared to without using a pad."
75333978|NCT05478486|Drug|MSP008-22|"It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort."
75472046|NCT01953835|Drug|GSK2586184 new formulation|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
75643221|NCT02523469|Biological|Nivolumab|
75472047|NCT01953848|Drug|EC905|Oral
75472048|NCT01953861|Drug|EC905|Oral
75472049|NCT01953887|Drug|EC905|Oral
75472050|NCT01953887|Drug|solifenacin|oral
75472051|NCT01953887|Drug|tamsulosin|oral
75472052|NCT01953939|Other|Prosthetic Limb Users|There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
75472053|NCT01953952|Procedure|therapeutic conventional surgery|Undergo transoral eHNS
75643222|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
75791426|NCT03947580|Other|Use of the Dvectis Double pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Double pad compared to without using a pad,~Categorisation of adverse events,~Categorisation of deficiencies of a medical device in patients enrolled in treatment groups using Dvectis Single and Dvectis Double pad,~Number of patients with adverse events,~Number of patients with deficiencies of medical device enrolled in treatment groups using Dvectis Single and Dvectis Double"
75791427|NCT03947580|Other|Use of no pad|Description is not needed
75472054|NCT01953952|Radiation|intensity-modulated radiation therapy|Undergo IMRT
75472055|NCT01953952|Drug|cisplatin|Given IV
75472056|NCT01953952|Procedure|quality-of-life assessment|Ancillary studies
75472057|NCT01953952|Other|laboratory biomarker analysis|Correlative studies
75472058|NCT01953978|Drug|Dexamethasone|Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
75472059|NCT01953978|Other|Placebo|Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
75472060|NCT01953978|Drug|Morphine|Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
75472061|NCT01953978|Drug|Zofran|Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
75643223|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
75643224|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
75791428|NCT01371058|Drug|high maintenance clopidogrel|clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
75643225|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
75791429|NCT01371058|Drug|routine dual antiplatelet|clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
75643226|NCT00586924|Drug|CAT 8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
75643227|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
75643228|NCT02578147|Behavioral|Mighty Girls|
75791430|NCT01371058|Drug|policosanol plus dual antiplatelet|aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
75791431|NCT03751592|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
75791432|NCT03947736|Diagnostic Test|cfDNA was detected by dPCR|Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.
75791433|NCT01371136|Procedure|curricular training|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
76083247|NCT04063488|Drug|Metreleptin|This is an observational study in which the subjects will serve as their own controls. Study testing will be conducted at baseline (pre-treatment) and for 2 years, post-treatment with metreleptin.
75333979|NCT01996852|Behavioral|Cognitive-behavioral Meetings|"The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min."
75333980|NCT01996852|Drug|sildenafil citrate|"100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study."
75333981|NCT01996852|Device|Vacuum Constriction Device|"The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call."
75333982|NCT05478408|Other|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
75333983|NCT05478330|Drug|Flutamide 1% gel|Group A: Flutamide-treated patients: Consisted of 25 patients with acne vulgaris treated with 1% Flutamide topical gel on the face two times per day for a duration of 8 weeks.
75643229|NCT02578147|Behavioral|Game Girls|
75643230|NCT01794403|Radiation|Extended Hypofractionation Radiotherapy|A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
75643231|NCT01794403|Radiation|Accelerated Hypofractionation Radiotherapy|A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
75643232|NCT01000376|Drug|Eribulin alone|Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m^2 alone on Day 1, then eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.
75791434|NCT01105338|Behavioral|Green tea drink|Green tea drink
76083248|NCT04039542|Other|Compassion focused therapy (CFT)|Compassion focused therapy (CFT) sessions (developed from cognitive behavioural therapies) to target underlying shame and self-criticism - 10 x 90 minute sessions
75791435|NCT01105338|Dietary Supplement|green tea capsules|green tea capsules
75927872|NCT03486600|Other|Fluid Resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
76083249|NCT01519414|Other|Laboratory Biomarker Analysis|Optional correlative studies
76083250|NCT01519414|Other|Placebo|Given PO
75333984|NCT05478330|Drug|topical gel without flutamide|Group B: Consisted of 25 patients with acne vulgaris treated with topical gel with the same component as the other group, except for flutamide, on the face twice per day for a duration of 8 weeks.
75333985|NCT00978874|Radiation|fludeoxyglucose F 18|
75333986|NCT00978874|Radiation|fluorine F 18 EF5|
75333987|NCT05478096|Behavioral|GetStarted|Guided internet-based intervention for procrastination.
75643233|NCT01000376|Drug|Eribulin plus Ketoconazole|Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.
75643234|NCT01038635|Drug|5-Azacytidine|75 mg/m^2 IV daily x 5 days on days 1 to 5.
75643235|NCT01038635|Drug|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
75643236|NCT00619203|Drug|Glycerol and paracetamol|"glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7"
75643237|NCT00619203|Drug|Paracetamol|paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
75643238|NCT00619203|Drug|Paracetamol|paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
75643239|NCT00619203|Drug|Paracetamol|po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
75643240|NCT00619203|Drug|Placebo|2 placebos, one po, one suppository
75791436|NCT01105338|Other|Green tea placebo capsules|Green tea placebo capsules
76083251|NCT01519414|Drug|Tivantinib|Given PO
76083252|NCT01519570|Other|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
76083253|NCT01575106|Device|Heat pain applied using TSA or CHEPS|TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
75643241|NCT00619203|Drug|Paracetamol and glycerol|"35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses"
75643242|NCT00619203|Drug|Glycerol|glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
75643243|NCT04072471|Drug|Zurampic®|non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
75643244|NCT04072471|Drug|Control group: xanthine oxidase inhibitor monotherapy|non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
75643245|NCT04099654|Other|Core-Stabilization Exercise|A program consisting of core stabilization exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
75791437|NCT01105338|Dietary Supplement|Lycopene capsules|Lycopene capsules
75791438|NCT01105338|Other|Lycopene placebo capsules|Lycopene placebo capsules
75791439|NCT01105338|Other|Tomato rich diet|Tomato rich diet
75791440|NCT01371214|Behavioral|PLIÉ (Preventing Loss of Independence through Exercise)|Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
75927873|NCT02200653|Drug|High dose of MICARDIS®, once daily|
75927874|NCT02200653|Drug|Low dose of MICARDIS®, once daily|
75927875|NCT02200653|Drug|Low dose of COZAAR® / LORZAAR®, once daily|
75927876|NCT02200653|Drug|High dose of COZAAR® / LORZAAR®, once daily|
75927877|NCT02200653|Drug|Placebo|
75333988|NCT04331626|Drug|Gemcitabine Injectable Product|Low dose chemotherapy drug combined with pd-1 antibody, Gemcitabine should be administered at 50% of the recommended dose, i.e. 500mg/m2, for 30 minutes by intravenous drip. Day 1 and day 8 administration.
75333989|NCT00970606|Drug|Rosuvastatin (crestor)|20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
75333990|NCT00970606|Drug|Placebo|Placebo tablet identical to active therapy. 1 tablet per day
75333991|NCT01973062|Biological|rituximab|Given IV
75333992|NCT01973062|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
75333996|NCT00981370|Drug|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
75472062|NCT01953978|Drug|Paracetamol|Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
75472063|NCT01953978|Drug|Ibuprofen|Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
75472064|NCT01953991|Device|Dentures|Removable prosthesis to replace missing teeth
76083254|NCT01519882|Other|Placebo|"Placebo patches size equivalent to 4, 6 & 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day."
75333997|NCT00979810|Drug|18F-FLT PET Scan|The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
75333998|NCT00947284|Drug|nalbuphine plus naloxone|single dose administered intravenously
75333999|NCT00947284|Drug|nalbuphine plus saline|single dose administered intravenously
75334000|NCT00947284|Drug|naloxone plus saline|single dose administered intravenously
75643246|NCT04099654|Other|Counseling of physical activity|Only physical activity counseling will be given to the subjects in this group.
75643247|NCT03913975|Other|Neuromuscular training|The novel training program with real-time biofeedback added consists of 2 sets of 10 repetitions per session with a progression in exercise intensity (Squat: 40 repetitions during week 1; Squat Jump: 80 repetitions during weeks 2-3; Tuck Jumps: 120 repetitions during weeks 3-6) over the 6-week training period.
75643248|NCT01000064|Drug|Vyvanse|30 mg - 70 mg capsules taken every morning for 6 weeks.
75791441|NCT03747614|Drug|Fluorometholone|"Fluorometh010neEyeDrops:~Brand names: Allergan Pharmaceuticals Ireland, Serial number: J20130061, NDC 60758-880-05. Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452"
75927878|NCT04461444|Genetic|Skin biopsy|"COBBALT is considered as an interventional with minor associated risks and constrains study due to the presence of skin biopsies that may not all be part of the usual medical practice. Risks are those linked to the biopsy procedure:~risk of pain due to the procedure performed under local anaesthesia~can leave a visible scar (about 2 x 1 cm)"
75927879|NCT02257593|Other|Dietary protein|"Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein"
75927880|NCT04461132|Other|Manual Lymphatic drainage (MLD)|MLD vith vodder technique was applied to leg
75927881|NCT04461132|Other|Skin Care|Wound was cleaned with salin and covered by dressing without including active products
75643249|NCT01000064|Procedure|fMRI|Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
75643250|NCT01000064|Drug|Placebo|Placebo capsules taken every morning for 6 weeks.
75791442|NCT03747614|Device|Functional Slit-Lamp Biomicroscopy|A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.
75927882|NCT04461132|Other|Exercise|breathing and foot pump exercise was prescribed
75927883|NCT04461132|Other|Shame Manual Lymphatic drainage|manual lymphatic drainage was applied with light touch instead of real mld techniques
75927884|NCT02200731|Behavioral|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
75927885|NCT03999411|Drug|Nicoderm C-Q Transdermal Product|6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
75927886|NCT03999411|Behavioral|Adherence to Antiretroviral Therapy Counseling|Brief counseling on adhering to antiretroviral therapy with self-help materials.
75927887|NCT03999411|Behavioral|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
75927888|NCT03999411|Behavioral|"Crave-to-Quit app"|"Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention."
75927889|NCT03999411|Behavioral|"vDOT emocha app"|"Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence."
75927890|NCT03996876|Device|RePS (Resolving Psychological Stress) - Threat ABM Training|"This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iPhone Operating System (iOS) compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user."
75927891|NCT03996876|Device|RePS (Resolving Psychological Stress) - Neutral Attention Training|This app will be a placebo attention bias modification that will be used on an iOS compatible phone. The placebo will contain only neutral words.
75927892|NCT02200809|Device|MR-guided focal laser ablation|
75927893|NCT02201355|Radiation|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
75927894|NCT02200965|Other|My Diabetes, My Information, My Plan Document|A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
75334001|NCT04547556|Diagnostic Test|BioFire|"A molecular rapid syndromic testing platform, using the following panels:~BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)~BioFire FilmArray Pneumonia Panel plus (PP)"
75334002|NCT01946542|Drug|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
75334003|NCT01946542|Other|placebo|
75927895|NCT04979754|Other|standard of care|retrospective study : standard of care
75927896|NCT02206347|Behavioral|attention focus|
75927897|NCT02201511|Drug|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
76083255|NCT01519882|Other|Rotigotine|"Rotigotine patches of 4,6 & 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day."
76083256|NCT05562856|Combination Product|surface pre-reacted glass filler coating material|the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
75927898|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
75334004|NCT05483790|Behavioral|multidomain intervention|The intervention including： exercise training :The participants chose an activity that they could do for the long term, such as taiji, eight brocade, elastic belt, yoga and so on.which will consist of 5 times a week and lasting half an hour at most once time; cognitive intervention ：which including memory method/strategy and life application, attention training, lifestyle intervention, the development of brain function and will undergo 7 sessions, 90 minutes peer week)； man-machine intervention ：choose developed and mature module tasks, participants will operate on the computer with the help of the project team members, including spatial cognition, brain balance, clock, ATM simulation）programs will be 20-30 minutes peer day, 3 times a week, for a total of 12 training sessions.
75334005|NCT01921114|Device|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
75334006|NCT01921114|Device|Bard® Dual-Lumen PowerPICC SOLO2®|
75927899|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
75927900|NCT02201511|Drug|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
75927901|NCT05261997|Procedure|extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct|In addition to drug administrated in the control group, patients in this group would be treated with ESWL and endoscopic drainage of the main pancreatic duct.
75334007|NCT00932152|Drug|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
75334008|NCT00932152|Drug|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
75334009|NCT00932152|Drug|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
75334010|NCT00932152|Drug|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
75334011|NCT01916590|Drug|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
75334012|NCT01916590|Drug|placebo|
75334013|NCT05483478|Combination Product|mobile health combined Multi-course Program|mobile health combined Multi-course Program
75334014|NCT01890694|Drug|Tolvaptan|15 mg once daily
75334015|NCT01890694|Drug|Placebo|15 mg once daily
76083257|NCT01576120|Other|bowel prep regimen first boost 6 oz. and second boost 3 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)"
76083258|NCT01576120|Other|bowel prep regimen first boost 3 oz. and second boost 6 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)"
76083259|NCT01520038|Radiation|Proton therapy|
76083260|NCT01520038|Radiation|IMRT|
76083261|NCT03008044|Device|FiberSense system|A novel CGM system based on a FiberSense system placed through the dermis of the patient.
76083262|NCT01576276|Radiation|Integrated MR-PET scan|Integrated MR-PET scan using [11C]diprenorphine
75334016|NCT01890694|Behavioral|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
75927902|NCT05261997|Drug|pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)|Patients will receive drugs to control pancreatic insufficiency
76083263|NCT01576276|Drug|Ketorolac|3 administrations of ketorolac over course of study
76083264|NCT01576588|Drug|Rituximab|Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
76083265|NCT01576588|Drug|Glucocorticoid|Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
76083266|NCT01826981|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
76083267|NCT01826981|Drug|SOF|SOF 400 mg tablet administered orally once daily
76083268|NCT01826981|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76083269|NCT01826981|Drug|Peg-IFN|pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
76083270|NCT01826981|Drug|GS-9669|GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
76083271|NCT01826981|Drug|VEL|Velpatasvir (VEL) tablet(s) administered orally once daily
76083272|NCT02247154|Biological|Vigam® (Human Normal Immunoglobulin)|
75927903|NCT02206425|Drug|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
75927904|NCT02206425|Drug|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
75791443|NCT05206656|Drug|Eribulin Mesylate|Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.
75334017|NCT01890694|Behavioral|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
75334018|NCT01890694|Biological|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
75791444|NCT05206656|Drug|Anlotinib|12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.
75927905|NCT02206425|Drug|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
76083273|NCT01522924|Other|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
76083274|NCT01523704|Device|BIOTRONIK Home Monitoring System|Home Monitoring system transfers implantable device's data to the main server via internet.
76083275|NCT01523704|Device|BIOTRONIK Home Monitoring System with In-office Follow-up|
76083276|NCT02728752|Drug|Octagam 10%|Patients to be treated with Octagam 10%
76083277|NCT02728752|Other|Placebo|Patients to be treated with a Placebo
75643251|NCT04102696|Drug|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
76083278|NCT03007810|Drug|Hemay005|Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
76083279|NCT03007810|Drug|Placebos|Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
76083280|NCT01578772|Drug|Telmisartan|80mg tablets po daily for 6 weeks
76083281|NCT03007576|Biological|RegStem|RegStem, 1.5 ml, one injection
76083282|NCT01804049|Drug|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
76083283|NCT01804049|Drug|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
76083284|NCT02556762|Radiation|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
76083285|NCT02556762|Radiation|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
75643252|NCT04102696|Drug|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
76083286|NCT02556762|Drug|PF|Chemotherapy: Cisplatin and 5fluorouracil
76083287|NCT02383992|Drug|3% H2O2 solution|
76083288|NCT02383992|Drug|0.9% normal saline|
76083289|NCT02346630|Drug|Placebo|Placebo capsules daily for 3 weeks.
76083290|NCT02346630|Drug|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
76083291|NCT02346630|Device|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
75334019|NCT01890694|Biological|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
75643253|NCT01812603|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
75643254|NCT02870270|Other|Cancer treatment|Patients undergoing treatment for cancer in the head and neck region
75643255|NCT00766090|Drug|GW685698X|Inhaled Corticosteroid
75643256|NCT04211805|Drug|Tenofovir Alafenamide 25 MG for arm (A)|Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.
75791445|NCT05347004|Drug|BI 425809|BI 425809
75791446|NCT01371292|Behavioral|Transformational Teaching|Physical education teachers randomly assigned to the experimental condition will (through a 1-day workshop format) be provided with the resources to implement transformational approaches in their day-to-day work. In addition, these teachers will be involved in a follow-up support program following the workshop to help them to implement transformational teaching strategies that were developed in the workshop.
75927906|NCT02206425|Drug|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
75927907|NCT02206425|Dietary Supplement|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
75927908|NCT02206425|Drug|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
75927909|NCT02206425|Drug|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
76083292|NCT01826825|Behavioral|Cognitive Screen|Cognitive Screen
76083293|NCT01826825|Behavioral|Mini-Cog|Cognitive Screen
76083294|NCT03385668|Drug|Pirfenidone|Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
76083295|NCT01803737|Behavioral|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
76083296|NCT01803737|Behavioral|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
76083297|NCT03994848|Behavioral|Spirometry Group|Patients that are provided the incentive spirometer pre-operatively and instructed to use it for 4 cycles of 10 spirometry attempts on the day prior to surgery
76083298|NCT03378492|Device|Ultrasound Guided Epidural|Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.
75334020|NCT01890694|Procedure|Ascites Evaluation|Ascites will be assessed at every visit.
75791447|NCT01371292|Behavioral|Standard Educational Practices|Physical education teachers randomly assigned to the control condition will take part in a professional development day workshop provided by their respective School Board. This will involve the same amount of contact time, and will take place on the same day as the transformational teaching workshop. It should be noted that the focus of those alternative workshops is unrelated to transformational leadership training.
75334021|NCT01890694|Procedure|Edema|Edema will be assessed at every visit.
75643257|NCT04211805|Drug|Tenofovir Disoproxil Fumarate 300mg for arm (B)|Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.
75643258|NCT04303949|Other|Behavioral:|Facilitating couples reduce anxiety, depression and grief through e-book education.
75791448|NCT04353596|Drug|ACE inhibitor, angiotensin receptor blocker|In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.
75791449|NCT05107596|Drug|64Cu-DOTA-ECL1i|Inject PET Radioisotope for imaging
75791450|NCT03749954|Diagnostic Test|Detachable string magnetically controlled capsule endoscopy|Esophagogastroduodenoscopy is performed 2 hours after the magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
75927910|NCT02206425|Drug|Pomalidomide|Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
75927911|NCT02201667|Drug|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
75927912|NCT02201667|Drug|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
76083299|NCT03378492|Procedure|Standard Epidural|The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
75334022|NCT01883908|Device|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
75643259|NCT02871050|Other|Sample Collection|Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
75643260|NCT02874287|Drug|Hydroxychloroquine Sulfate Tablets|Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
75791451|NCT01105416|Behavioral|Brief Prevention Intervention (BPI)|Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.
75791452|NCT01105416|Behavioral|ESC|Enhanced standard care
75791453|NCT01366378|Drug|methylnaltrexone|
75791454|NCT03747536|Drug|Ipratropium bromide|ipratropium bromide via metered dose spray (21 micrograms per spray)
75334023|NCT01883908|Other|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
75334024|NCT03466866|Behavioral|COPDE|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
75334025|NCT03466866|Behavioral|Intensive Diabetes Education|In-home diabetes education
75791455|NCT03747536|Other|Placebo|normal saline delivered via metered dose spray
75791456|NCT01366456|Device|Moxibustion|Comparison of different kinds of moxibustion
75791457|NCT03921580|Other|Control Canned Tuna|210 g/day
75791458|NCT03921580|Other|Enriched Canned Tuna Variety 1|210 g/day
75791459|NCT03921580|Other|Enriched Canned Tuna Variety 2|210 g/day
75927913|NCT02201667|Drug|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
75927914|NCT02201667|Procedure|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
75927915|NCT02206503|Drug|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
75927916|NCT02206503|Drug|Lenalidomide|
76083300|NCT03378024|Device|oscillometric (Omron Colin co)|fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
76083301|NCT01826201|Drug|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
76083302|NCT01826201|Drug|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
75791460|NCT04350788|Other|Survivorship Care Plan|Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care
75791461|NCT04350788|Other|Enhanced Survivorship Care Plan|In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers. Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support
75927917|NCT02206503|Drug|Dexamethasone|
76083303|NCT03385590|Dietary Supplement|Soy-fiber-maize|Two servings of soy-maize porridge fortified with soy fiber (1.3 g per serving) will be consumed by the children each day for a period of six months.
75791462|NCT05096286|Device|Ethos Therapy|FDA-approved treatment planning system
75791463|NCT03852316|Device|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
76083304|NCT03385590|Dietary Supplement|Maize|Two servings of maize porridge will be consumed by the children each day for a period of six months.
75791464|NCT05062200|Drug|JNJ-77242113|JNJ-77242113 will be administered as an oral tablet.
75791465|NCT05062200|Drug|Placebo|Matching placebo will be administered as an oral tablet.
75791466|NCT01358500|Drug|Fentanyl|Intravenous infusion using STANPUMP
75927918|NCT02201823|Drug|ABTL0812|ABTL0812. Five cohorts and one extension phase.
76083305|NCT04947072|Procedure|Erector Spinae Plane Block|The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000
76083306|NCT04947072|Procedure|Spinal anesthesia|Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
76083307|NCT04942158|Procedure|Non-instrumentation technique with use of CTZ paste|After local anesthesia and rubber dam isolation, the pulp chamber will be accessed. After the location of root canals entrance, an initial irrigation will be conducted using 1% sodium hypochlorite. Then, a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste) will be placed in the pulp chamber floor, into the root canal entrances. Then, a layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
75791467|NCT05225870|Genetic|immunohistochemical staining|sections from colorectal carcinoma will be immunohistochemically stained by anti-Cortactin antobody.
75643261|NCT02874287|Drug|Placebo Tablets|Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
76083308|NCT04942158|Procedure|Instrumentation technique and filling with Zinc Oxide and Eugenol paste|After anesthesia and rubber dam isolation, pulp chamber will be accessed with burs, and the root canals entrance will be prepared using a Gates Glidden bur. The root canal length determination will be done subtracting 1 mm from the radiographic measurements performed on the different roots. The instrumentation will be performed with 21mm stainless steel endodontic hand K-files, with International Organization for Standardization (ISO) tip ranging from #08 to #35. Irrigation will be performed using 1% sodium hypochlorite. After the last file, a final irrigation will be conducted with ethylenediaminetetraacetic acid and tegentol (EDTA-T) and 0.9% sodium chloride solution, and the root canals will be dried with paper points. Then, the root canals will be filled with a Zinc Oxide and Eugenol paste (ZOE paste), inserted into the root canals with a lentulo spiral. A layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
76083309|NCT03382704|Diagnostic Test|Examination for presence or absence of lanugo hairs|Pre-operative examination for presence or absence of lanugo hairs
75643262|NCT00628784|Procedure|Endoscopic spray cryotherapy|A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
75791468|NCT03724942|Drug|Brexpiprazole|Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
75927919|NCT05261919|Procedure|Acupuncture manipulation|The investigator used directional supplementation and draining manipulation. The supplementation manipulation is defined as the angle of needle insertion to skin as 45 degrees with the needle tip in the same direction as the meridian. While the draining manipulation is defined as the angle of needle insertion at 45 degrees with the needle tip direction opposite to that of the meridian.
75927920|NCT02206581|Device|Hydration Monitor|
75927921|NCT02201979|Procedure|Vertical breast lift with implants|
75927922|NCT02206659|Drug|Telmisartan|
75927923|NCT02206659|Drug|Placebo|
75927924|NCT02206737|Device|No nicotine e-cigarette|
75791469|NCT01327794|Genetic|polymorphism analysis|
76083310|NCT03382626|Device|anodal tDCS|Anodal tDCS will be applied on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for EEG electrode placement) with the following parameters: electrode size of 25-35 cm², 2mA, 0.057 mA/cm² and duration of 20 minutes. The cathode will be placed over the supra-orbital region.
76083311|NCT03382626|Device|Computer-assisted training|The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.
75927925|NCT02206737|Device|Low dose nicotine e-cigarette|
75927926|NCT02206737|Device|High dose nicotine e-cigarette|
76083312|NCT03382626|Device|sham tDCS|Sham tDCS will be applied with the same parameters and electrode placement of active anodal tDCS. However, the current flow will be interrupted by the device after few seconds.
76083313|NCT03375450|Other|Standard of Care|Participants will be followed as per local routine primary healthcare practice
76083314|NCT03375372|Procedure|Scaling and Root Planing (S&RP)|dental Scaling and Root Planing and oral hygiene regimen
76083315|NCT03377946|Biological|probiotics|the probiotics group was taking probiotics 4 packets a day
76083316|NCT03377946|Biological|placebo|the placebo group was taking placebo 4 packets a day
75472065|NCT01954030|Drug|CTO and Bevacizumab|
75643263|NCT00628784|Procedure|Endoscopic spray cryotherapy|After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
75791470|NCT01327794|Other|immunologic technique|
75791471|NCT01327794|Other|laboratory biomarker analysis|
75927927|NCT02202057|Other|Respiratory resistive load on inhalation|"The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in."
75927928|NCT02202057|Other|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
75643264|NCT04211493|Behavioral|whole-body-workout|20 minutes whole-body-workout
75334026|NCT05474898|Other|Magnesium Sulphate Iontophoresis +conventional therapy|will receive Mgso4 Iontophoresis in addition to conventional therapy twice a week/4 weeks
75472066|NCT01954030|Drug|CTO alone|
75643265|NCT04211493|Device|EMS|Electromyostimulation-intensity 5 (muscle stimulation)
75643266|NCT04211493|Device|EMS-Placebo|Electromyostimulation-intensity 1 (no muscle stimulation)
75927929|NCT03660345|Procedure|PPV/MP|23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling
75643267|NCT04681313|Procedure|High-risk percutaneous coronary intervention|Percutaneous coronary interventions (PCI) deemed high risk based on patient-related risk features, hemodynamic criteria, clinical presentation and complexity of coronary anatomy.
75643268|NCT02871362|Dietary Supplement|IQP-AS-118|Take one a day
75643269|NCT02871362|Dietary Supplement|Placebo|Take one a day
75791472|NCT01327794|Other|medical chart review|
75791473|NCT01371370|Other|Resistance exercise training|The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
75472067|NCT01954043|Drug|Dabrafenib 150 mg twice a day (BID)|Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
75472068|NCT01954043|Drug|Rabeprazole 40 mg once daily (OD)|Rabeprazole dosed at 40mg each morning on Days 16 to 19
75472069|NCT01954043|Drug|Rifampin 600 mg OD|Rifampin dosed at 600mg each morning on Days 20 to 29
75791474|NCT01371370|Other|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
75791475|NCT01371370|Other|Resistance exercise training & diet|Combination of low intensity resistance exercise training and hypocaloric diet
75927930|NCT03660345|Drug|Intravitreal injection|Intravitreal ziv-Aflibercept
75927931|NCT02206893|Behavioral|Self-monitoring via Smartphone|
75927932|NCT02206893|Behavioral|Peer support via Smartphone|
75472070|NCT01954069|Device|Semi-quantitative pregnancy test|
75472071|NCT01954108|Device|hyaluronic acid sodium salt|
75472072|NCT01954108|Device|ESWT|
75472073|NCT01954147|Drug|GLP-1|GLP-1 therapy
75472074|NCT01954147|Biological|SC|Stem cell infusion
75472075|NCT01954147|Other|Standard Medical Treatment|Standard Medical Treatment
75472076|NCT01954186|Drug|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
76083317|NCT03125538|Other|Motor Imagery|"Together with physical rehabilitation performed with physiotherapists, participants from the experimental group will mentally rehearse 3 different locomotor exercises that they already physically performed beforehand.~Exercise 1: 10m Walk~Exercise 2: Timed Up and Go test (rise up from a chair, walk 3 meters, turn around, come back to the chair, turn around and sit down)~Exercise 3: Stairs climbing test (climb up 4 stairs, turn around, climb down the for stairs)~Two min of MIP will be scheduled 5 times/day, during rest periods, so that patients complete 10min of MIP per day."
76083318|NCT03125538|Other|Control Task|"Together with physical rehabilitation performed with physiotherapists, participants from the control group will spend equivalent time focusing on a cognitive task without impact on motor rehabilitation ((word scramble game).~Two min of this cognitive task will be scheduled 5 times/day, during rest periods, so that patients complete 10min of control task per day."
76083319|NCT03377868|Diagnostic Test|Optic coherence tomography|Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.
76083320|NCT03377868|Diagnostic Test|Pulmonary function test|Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.
76083321|NCT03382470|Other|Antimicrobial stewardship advice|A basic antimicrobial stewardship team will be created at each site. The team will provide advice on the treatment of urinary tract infections and asymptomatic bacteriuria during the second half of the study.
76083322|NCT03377712|Device|optoelectronic plethysmography|Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations
75643270|NCT00619593|Other|Intensified diagnostic and treatment measures following 1st appropriate ICD therapy|"Assessment of general health status (weight, BP, NYHA)~Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)~Echocardiography (LVEF, LVEDD, mitral regurgitation)~Non-invasive ischemia evaluation~Coronary angiography (if indicated by ischemia evaluation)~Upgrade to CRT, if indicated~Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)~24 hrs ECG Holter (Heart rate variability)~Further treatment (if applicable)~Changes in ICD settings, or medication"
75791476|NCT03751514|Biological|Bordetella Pertussis B1917|"The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally."
76083323|NCT03377712|Device|diaphragmatic ultrasound|Evaluates the diaphragmatic mobility through images, simple and non-invasive use
76083324|NCT03377712|Device|Postural evaluation|Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive
75791477|NCT03751514|Drug|Azithromycin 500 mg|To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
75927933|NCT02206893|Behavioral|Professional support via Smartphone|
75927934|NCT02206893|Behavioral|Self-monitoring via Web (Static)|
75927935|NCT02206971|Other|urine analyses feedback|biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
76083325|NCT03377712|Device|Pain evaluation|by means of questionnaires
76083326|NCT03377712|Device|Evaluation of the function|through questionnaires
76083327|NCT03377712|Device|Functional capacity assessment|Evaluated through the six-minute walk test, where the patient walks along a 30-meter corridor, simple, fast and safe assessment
75472077|NCT01954186|Procedure|after delivery of the fetus & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
75643271|NCT00619593|Other|Standard follow-up|Standard follow-up in patients without appropriate ICD therapy
75643272|NCT00580801|Drug|Telaprevir|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
75643273|NCT00580801|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
75472078|NCT01954199|Procedure|Neurodynamic Group|"All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.~In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;~In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;~In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner."
75927936|NCT02202213|Drug|Placebo|
75927937|NCT02202213|Drug|Lu AF11167|
75927938|NCT02207205|Drug|Blood drawn from indwelling catheters versus direct venipuncture|Evaluation of the source of blood samples on whole blood clotting time
76083328|NCT03377712|Device|Quality of life assessment|through questionnaire
76083329|NCT03947112|Behavioral|Physical activity registration|At start, participants and parents fills out a Self-report questionnaire and the UngKan-3 Questionnaire, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
76083330|NCT03396666|Other|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
76083331|NCT03387774|Drug|Cisplatin|"Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy."
76083332|NCT03387774|Radiation|Intensity Modulated Radiation Therapy|"Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225)."
76083333|NCT03387774|Drug|Ulinastatin|"Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy."
76083334|NCT04377594|Procedure|Radio frequency ablation|Two different radio frequency ablation procedures
75643274|NCT00580801|Drug|Placebo|Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
76083335|NCT03382392|Other|Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.|
76083336|NCT03124290|Other|paced auditory serial addition test (PASAT)|A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
75927939|NCT02202291|Genetic|Demonstration of genetic mutations causing Raynaud's phenomenon|"Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family."
76083337|NCT03382314|Combination Product|HDDO-1614|"Combination drug (Bazedoxifene + Cholecalciferol)~Incrementally modified drug~Not market authorized product"
76083338|NCT03382314|Drug|Bazedoxifene / Cholecalciferol|Co- Administration of Bazedoxifene and Cholecalciferol
76083339|NCT01523782|Drug|GRASPA|Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
76083340|NCT03124524|Drug|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
75643275|NCT00580801|Drug|Ribavirin|Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
75643276|NCT04303481|Other|normal diet|Control
75643277|NCT04303481|Other|weight loss program kit|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks [i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, and Botanical Liquid Sachet.
75791478|NCT03751514|Other|Sterile Saline|To compare against B. pertussis, some volunteers will be enrolled onto the Sham arm. These volunteers will not receive B. pertussis but instead be given sterile saline
76083341|NCT03124524|Drug|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
76083342|NCT03377400|Drug|Durvalumab|concurrent radiotherapy
76083343|NCT01525420|Behavioral|Acceptance Therapy (ACT)|ACT
76083344|NCT01525420|Other|Cognitive Behavioral Therapy (CBT)|CBT
76083345|NCT03377322|Drug|Probiotic Capsule|Probiotic - one capsule a day for four weeks
76083346|NCT03377322|Drug|Placebo Capsule|Placebo - one capsule a day for four weeks
76083347|NCT03382236|Other|osteopathy|osteopathic techniques
76083348|NCT01803269|Drug|topotecan hydrochloride|Given IV
76083349|NCT01803269|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
76083350|NCT03382080|Other|Dream School Program|The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
76083351|NCT03382080|Other|Mental Health Support Team|"MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~Co-location of services and staff working in services~One open door to increase accessibility to the services and staff for students~Focus on the transition from lower to upper secondary school~Close follow-up of students at risk to ensure tailored help to each student~Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools."
76083352|NCT03377166|Diagnostic Test|Bucket test and Smartphone-based evaluation of SVV|Bucket test and Smartphone-based evaluation of SVV
76083353|NCT01802879|Drug|Panobinostat|Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
76083354|NCT03145038|Drug|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
76083355|NCT03145038|Drug|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
75643278|NCT04303481|Other|weight loss program kit with A. muciniphila prebiotics|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks [i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, Botanical Liquid Sachet, and Probiotics Liquid Sachet
75643279|NCT00619671|Drug|Rituximab (Rituxan)|Four weekly IV infusions of Rituxan with dosage individually calculated per subject.
75643280|NCT00628550|Drug|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
75643281|NCT00628550|Drug|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
75643282|NCT01059539|Drug|Cariprazine|Cariprazine was supplied in capsules.
75643283|NCT00999908|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
75791479|NCT03621358|Other|Control gummy with free flavour (without encapsulating)|12 g/day (3 gummies)
75791480|NCT03621358|Other|Experimental gummy with 50% free/50% encapsulated flavour|12 g/day (3 gummies)
75927940|NCT03533127|Drug|LY01008|LY01008+Carboplatin/Paclitaxel
75927941|NCT03533127|Drug|Bevacizumab|Bevacizumab + Carboplatin/Paclitaxel
76083356|NCT03145038|Drug|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
76083357|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
76083358|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
75643284|NCT00999908|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
76083359|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
76083360|NCT01825577|Drug|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
76083361|NCT03382002|Diagnostic Test|TCL|evaluation of oxidative status
76083362|NCT03375138|Drug|belatacept|Specified dose on specified days
76083363|NCT03124914|Other|Neuromuscular tests|Neuromuscular tests
75472079|NCT01954212|Other|Enhanced complex oral health care|"Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:~Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.~Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.~Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available."
75643285|NCT00999908|Drug|Placebo|Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
75643286|NCT02576119|Drug|BMS-955176, Placebo (Part 1)|The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.
75791481|NCT03621358|Other|Experimental gummy with 100% encapsulated flavour|12 g/day (3 gummies)
75791482|NCT03615664|Drug|Bendamustine|Bendamustine (B) 90 mg/m2 i.v. day 1, 2
75643287|NCT02576119|Drug|BMS-955176, Moxifloxacin, Placebo (Part 2)|Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).
75643288|NCT04071535|Device|sudoscan、nerve conduction tests|To evaluate sudomotor nerve and macrofibropathy.
75643289|NCT02871518|Drug|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
75927942|NCT02207361|Drug|Paclitaxel, Carboplatin|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
76083364|NCT03381924|Other|Educational programme|In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
75643290|NCT02871518|Drug|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
75643291|NCT00619749|Dietary Supplement|juice rich in polyphenols|juice during 2 weeks
75927943|NCT02207361|Drug|Paclitaxel, Epirubicin|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
75927944|NCT03533049|Other|myFAMI|Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
76083365|NCT03381924|Other|Routine clinical practice|Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
76083366|NCT03124680|Combination Product|Opioid free|Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
76083367|NCT03124680|Combination Product|opioid group|Opioid anesthesia will follow the current standard approach of our hospital.
75643292|NCT00619749|Dietary Supplement|juice poor in polyphenols|juice during 2 weeks
75643293|NCT00580723|Other|PRK 124|Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
75643294|NCT04303754|Other|Diabetes-Specific Formula|Other: Diabetes Specific Formula
75791483|NCT03615664|Drug|Gemcitabine|Gemcitabine (G) 800 mg/m2 i.v. day 1, 4
75791484|NCT03615664|Drug|Dexamethasone|Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4
75791485|NCT03615664|Diagnostic Test|PET/CT|"PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:~in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment~in case of SMD - exclusion from the trial~in case of PMD - exclusion from the trial"
75791486|NCT03615664|Procedure|Autologous Stem Cell Transplant|"Must be performed within 3 months after the end of BGD treatment.~When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT."
75791487|NCT04335812|Behavioral|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
75927945|NCT02207517|Procedure|Office-based vergence/accommodative therapy|The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
75927946|NCT02202447|Drug|EC1169|"PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule."
76083368|NCT03124446|Behavioral|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
76083369|NCT03124446|Behavioral|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
75334027|NCT05474898|Other|High- Power Pain Threshold Ultrasound +conventional therapy|will receive HPPT-US on the upper trapezius in addition to conventional therapy twice a week/4 weeks
75334028|NCT05474898|Other|conventional theapy|will receive postural correction exercise-stretching and strengthening twice a week/4weeks
75334029|NCT04787536|Procedure|Non-cardiac surgery|Non-cardiac surgery excluding cranial neurosurgery
75643295|NCT04303754|Other|Bread with Spread|Other: White Bread with Spread
75791488|NCT05189548|Biological|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
75791489|NCT01562522|Other|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
75791490|NCT03513250|Drug|hyoscine-n-butylbromide|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
75791491|NCT03513250|Drug|control group|an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
75791492|NCT03749876|Other|Unfiltered Cigarettes|Participants will be given unfiltered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
75927947|NCT02202447|Other|EC0652|PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
76083370|NCT01802411|Drug|EXPAREL 266 mg|
75334030|NCT05483322|Drug|LAM-002A|25mg capsules
75472080|NCT01954225|Other|Udumbara Sutra|The Udumbara sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
75927948|NCT02202525|Drug|Micardis®|
75927949|NCT02202525|Drug|Other hypertensives|
75927950|NCT02202603|Drug|Teriparatide|single oral tablet
75927951|NCT02202603|Drug|Teriparatide|subcutaneous standard injection
76083371|NCT01802411|Drug|Placebo|
76083372|NCT03381846|Procedure|MOHS micrographic surgery|Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.
75472081|NCT01954238|Drug|GCC-4401C|"Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion."
75472082|NCT01954238|Drug|Rivaroxaban|Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
75643296|NCT04303754|Other|Rice Porridge|Other: Rice Porridge
75643297|NCT04301102|Device|Hemosphere platform® together with the FloTrac Acumen IQ® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management. It incorporates predictive parameters such as the hypotension prediction index and decision support parameters such as dynamic arterial elastance and maximum dP / dT.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
75927952|NCT02202603|Drug|placebo|Oral placebo
75927953|NCT02207595|Drug|UCB5857|"Active Substance: UCB5857~Pharmaceutical Form: Capsule~Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~Route of Administration: Oral Use"
75927954|NCT02207595|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Capsule~Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~Route of Administration: Oral Use"
76083373|NCT03381846|Procedure|Wide local excision|A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
76083374|NCT03374904|Behavioral|Video Feedback|first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.
76083375|NCT03374904|Behavioral|Control Group|Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
75334031|NCT05483244|Other|discontinuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
75334032|NCT05483244|Other|continuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
75472083|NCT01954238|Drug|Placebo|GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
75791493|NCT03749876|Other|Filtered Cigarettes|Participants will be given filtered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
75927955|NCT02207673|Procedure|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
75927956|NCT02202915|Behavioral|Behavioral Checklist|
75927957|NCT02202993|Drug|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
75927958|NCT02190357|Drug|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
75927959|NCT02257671|Drug|Oral contraceptive|Neovletta
75472084|NCT01954277|Device|Electroacupuncture|Eletroacupuncture performed using acupuncture needles.
75643298|NCT04301102|Device|Hemosphere platform® together with the FloTrac® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
75643299|NCT02870660|Other|Registry|
75927960|NCT02208219|Behavioral|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
76083376|NCT03381768|Biological|PD-L2 peptide|100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.
76083377|NCT03381768|Biological|PD-L2 and PD-L1 peptide|100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.
76083378|NCT03377088|Other|Rose oil|Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
76083379|NCT03377088|Other|Almond Oil|Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
76083380|NCT03377010|Other|Dietary intake -Food Frequency Questionnaire|Dietary intake will be assessed using 2014 full-length food frequency questionnaire. The Block 2014 questionnaire combines a full-length food frequency questionnaire with a brief physical activity screening tool. The food and beverage list includes 127 items in the past 1 month, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
75643300|NCT04676867|Drug|Dalcetrapib|Dalcetrapib 300 mg Film-Coated Tablets
76083381|NCT03377010|Other|Receptivity to Participating in Diet Interventions|Study participants will rate their interest in learning more about dietary interventions to stay healthy using items developed specifically for this study. The items will be rated on a 3-point Likert-type scale from 3 (extremely interested) to 1 (not at all interested).
75334033|NCT05477940|Device|Absorbable zinc alloy drug eluting coronary stent system|"Absorbable zinc alloy drug eluting coronary stent system (hereinafter referred to as stent system) consists of delivery system and drug stent (hereinafter referred to as stent) pressed on the balloon end of the delivery system"
75791494|NCT03634618|Other|Mirror Therapy|Mirror therapy is the treatment method in which mental performance of movements is performed by observing the movements of the healthy extremities. In the case of mirror treatment, the mirror box is placed on a fixed floor. The mirror is positioned so that the patient's body can be fully centered and the mirror image can be seen. While the affected limb is placed on the rear side of the mirror, the firm extremity is opposite to the mirror. The patient focuses on the mirror image of the moving healthy hand and, through artificial visual feedback, perceives the affected limb as moving. The exercises are as follows: flexor tendon gliding exercises, median motor exercises, wrist and forearm ROM exercises and function-oriented exercises.
75791495|NCT03634618|Other|Convantional Physiotherapy|The first two weeks involve only immobilisation with plaster. The next 4 weeks, patients do the exercises which follows: 15 minutes water bath, scar tissue massage, flexor tendon gliding exercises, median motor exercises, wrist flexion-extention, median nerve gliding exercise (in addition, one week after plaster removal), hand wrist stretching exercise (in addition, 2 weeks after plaster removal).
76083382|NCT02976948|Other|No intervention|
76083383|NCT03381690|Procedure|Epidural labor analgesia|Epidural catheter was inserted for labor analgesia using an 18-gauge Tuohy needle and a 20 gauge epidural catheter. In our institute, for epidural labor analgesia, 10 ml bolus of 0.075% levobupivacaine mixed with fentanyl 2 μg/ml was administered and same regimen was continuously infused by patient-controlled epidural analgesia (infusion rate : 10 ml/hr, bolus : 4 ml, lockout time: 30 min).
75791496|NCT03945942|Device|Near infrared spectroscopy with INVOS device|somatic and cerebral oximetry by INVOS in pediatric liver transplantation
75927961|NCT02208219|Behavioral|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
76083384|NCT03374748|Other|N/A - observational study|N/A - observational study
76083385|NCT03374670|Drug|Zimura|Zimura in combination with Eylea
76083386|NCT03374670|Drug|Eylea|Zimura in combination with Eylea
76083387|NCT01579084|Drug|AGN-199201 Formulation A|AGN-199201 Formulation A applied to the face as per protocol twice daily.
76083388|NCT01579084|Drug|AGN-199201 Formulation B|AGN-199201 Formulation B applied to the face as per protocol twice daily.
76083389|NCT01579084|Drug|AGN-199201 Formulation C|AGN-199201 Formulation C applied to the face as per protocol twice daily.
75334034|NCT03428958|Drug|NUC-3373 + leucovorin|NUC-3373 + leucovorin
75334035|NCT03428958|Drug|NUC-3373|NUC-3373
76083390|NCT01579084|Drug|AGN-199201 Vehicle|AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
76083391|NCT02963610|Drug|Lenalidomide|Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.
76083392|NCT02963610|Drug|Pembrolizumab|Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.
75334036|NCT03428958|Drug|NUFOX|NUC-3373 + oxaliplatin
75334037|NCT03428958|Drug|NUFOX + VEGF pathway inhibitor|NUC-3373 + oxaliplatin + bevacizumab
75334038|NCT03428958|Drug|NUFOX + EGFR inhibitor|NUC-3373 + oxaliplatin + cetuximab/panitumumab
75334039|NCT03428958|Drug|NUFIRI|NUC-3373 + irinotecan
75334040|NCT03428958|Drug|NUFIRI + VEGF pathway inhibitor|NUC-3373 + irinotecan + bevacizumab
75334041|NCT03428958|Drug|NUFIRI + EGFR inhibitor|NUC-3373 + irinotecan + cetuximab/panitumumab
75643301|NCT04676867|Other|Placebo|Placebo Tablets
75643302|NCT00770224|Biological|rituximab|
75643303|NCT00770224|Biological|tositumomab|
75643304|NCT00770224|Drug|cyclophosphamide|
75643305|NCT00770224|Drug|doxorubicin|
75643306|NCT00770224|Drug|prednisone|
75643307|NCT00770224|Drug|vincristine|
75643308|NCT00770224|Radiation|tositumomab|
75643309|NCT04301063|Other|RV3278A|RV3278A is a non-rinsed cosmetic cream intended to be used every day on adolescents and young adults with acne-prone skin.
75927962|NCT02208219|Behavioral|Conventional treatment|"This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~Passive mobilization: controlled manipulation of movements to release a joint.~Stretch and progressive resistance training.~Task-specific training: reaching and manipulation of different objects.~Intense physical training: repetition of sequence of movements."
75334042|NCT03428958|Drug|NUC-3373 + bevacizumab|NUC-3373 + bevacizumab
75927963|NCT02208453|Device|InSpace Implantation|InSpace device Implantation
75927964|NCT02190669|Other|exercise|Sprinting, walking on a treadmill, and stationary bicycle riding
75927965|NCT02208531|Behavioral|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
75927966|NCT01460160|Drug|Dasatinib|Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
75927967|NCT02203227|Dietary Supplement|Placebo|
75927968|NCT02203227|Dietary Supplement|BioTurmin (Curcuma longa rhizomes extract)|
75334043|NCT01869478|Drug|Intravenous Thrombolysis|
75334044|NCT01869478|Device|Endovascular Arterial Reperfusion|
75334045|NCT01844206|Drug|Epidural Morphine|Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
75334046|NCT01844206|Drug|Epidural Saline|Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
75791497|NCT03945942|Device|Near infrared spectroscopy with Foresight device|somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
75791498|NCT01366690|Behavioral|Peer Support|A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
75334047|NCT03626454|Drug|Norepinephrine Bolus|'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
75643310|NCT04122131|Diagnostic Test|Immunohistochemistry|Immunohistochemical analysis of biomarker in post-surgical sample
75643311|NCT02389465|Drug|Escitalopram + Celecoxib|Participants will receive celecoxib in addition to escitalopram
75643312|NCT02389465|Drug|Escitalopram + Placebo|Participants will receive a placebo in addition to escitalopram.
75791499|NCT03749798|Procedure|Cataract surgery|Intraoperative wavefront measurements will be carried out during cataract surgery
75791500|NCT01107288|Other|Music-based multitask exercises program|Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
75643313|NCT01057589|Drug|Pemetrexed|"Triplet Combination Therapy: 500 mg/m^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles~Maintenance Therapy: 500mg/m^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity"
75643314|NCT01057589|Drug|Cetuximab|"Triplet Combination Therapy: 400 mg/m^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.~Maintenance Therapy: 250 mg/m^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity"
75334048|NCT03626454|Drug|Norepinephrine infusion|an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
75334049|NCT03626454|Drug|Normal Saline Flush, 0.9% Injectable Solution|10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
75334050|NCT03626454|Drug|Normal Saline 0.9% Infusion Solution|50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
75334051|NCT00897910|Other|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
75334052|NCT00897910|Other|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
75334053|NCT00897910|Other|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
75334054|NCT05477706|Other|Personalized Support for Progress (PSP)|Personalized Support for Progress (PSP) is a Peer Specialist delivered intervention in which a peer supports Veterans in prioritizing their needs and attaining access to the Veterans' preferred services.
75334055|NCT05477706|Other|Tailored Referral (TR)|TR consists of detailed resource information and referral, consistent with standard practice.
75643315|NCT01057589|Drug|Cisplatin|Triplet Combination Therapy: 75mg/m^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
75643316|NCT01057589|Dietary Supplement|Folic Acid|Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
75791501|NCT01107288|Other|Music-based multitask exercises program|Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
75927969|NCT02203227|Dietary Supplement|BioTurmin-WD (Water dispersible curcuminoids)|
75927970|NCT02203227|Dietary Supplement|MaQxan|
75927971|NCT02208609|Other|Day 1: Maize Tortillas with 20% Amaranth|Subjects received Maize tortillas with 20% Amaranth added.
75927972|NCT02208609|Other|Day 2 Maize Tortillas without 20% Amaranth|Maize tortillas without Amaranth.
75927973|NCT02190825|Device|NeuGuide device|The NeuGuideTM device is indicated for anchoring sutures to ligaments of the pelvic floor
76083393|NCT03376932|Drug|FF/UMEC/VI|FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
76083394|NCT03376932|Drug|FP/SAL|FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
75334056|NCT01834144|Other|Exercise Training|
75334057|NCT01830790|Drug|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
75643317|NCT01057589|Dietary Supplement|Vitamin B12|Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
75643318|NCT02576197|Dietary Supplement|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
75643319|NCT02576197|Dietary Supplement|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
76083395|NCT03376932|Drug|Tiotropium|TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.
75643320|NCT02575885|Other|Electronic Cigarette|Receive different type of ENDS product at each visit
75643321|NCT02575885|Other|Electronic Cigarette|Receive BLU e-cigarette ENDS product
76083396|NCT03376932|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
75334058|NCT01662102|Drug|Zevalin|Zevalin administered intravenously.
75472085|NCT01954277|Device|Placebo Sham|Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
75472086|NCT01954290|Drug|Conivaptan|Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
75643322|NCT02575885|Other|Laboratory Biomarker Analysis|Correlative studies
75643323|NCT02575885|Other|Pharmacological Study|Correlative studies
75643324|NCT02575885|Other|Questionnaire Administration|Ancillary studies
75643325|NCT02575729|Drug|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
75643326|NCT02575651|Drug|Fluzoparib|Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
75643327|NCT02575573|Other|Factors influencing resuscitation decisions of patients|
75791502|NCT05190250|Diagnostic Test|Pipelle biopsy|Ultrasonographically confirmed implantation window. Collection of material with use of Pipelle biopsy. Collection of 5 ml venous blood.
75791503|NCT01366768|Other|Oral amino acid mixture|Amino acid mixture 2,93 ml/kg
75334059|NCT01662102|Drug|Rituximab|Rituximab administered intravenously.
75643328|NCT02575573|Other|Factors leading to not asking patients about resuscitation preference|
75643329|NCT01716117|Device|Surpass Flow Diverter|Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
75791504|NCT01366768|Other|Intravenous amino acid administration|Amino acid mixture 2,93 ml/kg
75791505|NCT01107366|Procedure|lupiae technique|it's a new hybrid technique for the treatment of aortic aneurism and dissection.
75334060|NCT04692766|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
75643330|NCT02577835|Device|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
75791506|NCT01107366|Procedure|lupiae technique|"LUPIAE technique~Hybrid repair of thoracic or thoraco-abdominal aneurysms of different etiology and type A dissections with a two-stage procedure:~surgical arch reconstruction with a Dacron multibranched surgical prothesis~endovascular implantation of a thoracic stent graft"
75927974|NCT02208687|Behavioral|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
75927975|NCT02208687|Other|Control group|Usual care
75927976|NCT02203383|Device|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
75927977|NCT01170702|Drug|0.9% Normal Saline|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
76083397|NCT03376932|Device|ELLIPTA DPI|The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.
76083398|NCT03376932|Device|DISKUS DPI|The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.
75334061|NCT04692766|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL in a polypropylene ampoule, 10 ampoules per labeled package
75334062|NCT03950076|Drug|Edoxaban|Edoxaban 60mg (or 30mg as determined by clinical criteria)
75643331|NCT00579553|Drug|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
75927978|NCT01170702|Drug|0.2% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
75643332|NCT00579553|Drug|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
75643333|NCT01650831|Device|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
75927979|NCT01170702|Drug|0.5% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
75927980|NCT01170702|Drug|0.75% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
75927981|NCT02258061|Procedure|DDD-80|Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
75927982|NCT02258061|Procedure|DDD-60|Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
75927983|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat|STRIBILD® QD, d1-14
76083399|NCT03376932|Device|RESPIMAT inhaler|The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.
75643334|NCT04211415|Drug|DS-2741a|Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks
75798869|NCT03857802|Behavioral|Sleep hygiene intervention|"An individual education will be carried out following a bidirectional feedback method. It is intended to develop skills to make conscious and autonomous decisions. The explanation will consist:~Information and reading with discussion of the educational sheet: The 9 tips for a healthy sleep will be read, point by point. The nurse will be open to discuss those that generate doubt.~Confrontation: even if the patient does not ask any questions about it, it will be necessary to ask if he has understood the advice.~Participated information: Questions will be asked to the patient such as: Did you already know any of these tips?.~A telephone call per month will be made as an educational reinforcement to the intervention."
75927984|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir|Truvada®/ Kaletra® 200/50 mg QD, d1-14
76083400|NCT03376932|Device|Metered Dose Inhaler|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
75643335|NCT04211415|Drug|Placebo|Single, subcutaneous injection administered weekly for 4 weeks
75643336|NCT02577757|Device|MRI|MRI
75643337|NCT04209933|Drug|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
75927985|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir|Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
75927986|NCT03489408|Device|Conventus Cage™ PH|Proximal humeral fracture fixation
76083401|NCT03376932|Device|Connected Inhaler System|The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.
76083402|NCT03007342|Drug|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|
76083403|NCT03007342|Drug|Placebo|
76083404|NCT03376854|Device|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
76083405|NCT03376854|Drug|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
76083406|NCT03376854|Device|Standard of Care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature >38°C will receive 650 mg acetaminophen and, if temperature remains >38°C, surface cooling will be initiated to return core temperature to 37-38°C.
75643338|NCT04209933|Drug|Colloidal pectin bismuth capsules containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
75643339|NCT04209933|Drug|Colloidal pectin bismuth particles A quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
75643340|NCT04209933|Drug|Colloidal pectin bismuth particles B quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
75643341|NCT00619905|Drug|ACZ885|
75643342|NCT00619905|Drug|ACZ885|
75643343|NCT04953273|Other|Vigitrauma|Case management algorithm using early phone contact
75791507|NCT01358656|Procedure|Single bundle anterior cruciate ligament reconstruction|The surgical technique includes ACL reconstruction with graft of two autologous tendons - the semitendinous and gracilis - fixed in one tibial tunnel and one femoral tunnel. Once the graft is obtained, the arthroscopy-assisted ACL reconstruction is performed using anterolateral, anteromedial and accessory anteromedial portals. The first tunnel to be built is femoral tunnel, through a Smith & Nephew femoral guide inserted into the anteromedial portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. The next tunnel is tibial tunnel. The tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45 degrees. The new ligament is fixed onto the tibia and femur with a biodegradable interference screw.
75643344|NCT02579395|Behavioral|Collaborative implementation Intentions|With spouse/romantic partner
75643345|NCT02579395|Behavioral|Individual implementation Intentions|Without spouse/romantic partner
76083407|NCT01579162|Device|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days"
76083408|NCT01580098|Other|Self-monitoring for patients with Diabetes mellitus type 2|Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
75791508|NCT01358656|Procedure|Double bundle anterior cruciate ligament reconstruction|The ACL reconstruction is performed with graft of two autologous tendons -the semitendinous and gracilis- fixed in two tibial tunnels and two femoral tunnels. The first tunnel to be built is the anteromedial (AM) femoral tunnel, through femoral guide inserted into the AM portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. Then we drill the PL femoral tunnel in its anatomical position from the accessory AM portal, with the knee at 120° of flexion. The next tunnels are the PM and AM tunnels. The PL tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45º. The AM tunnel has its point of entry more lateral, and a bone bridge of at least one cm must be left between the tunnels, and the tibial guide adjusted at 55º. Both bundles must be fixed onto the tibia and femur with a biodegradable interference screw.
75927987|NCT04880148|Dietary Supplement|Thyme and Honey-based oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
76083409|NCT01580098|Other|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are submitting the vital parameters of the patient via mobile device.
75643346|NCT02579395|Behavioral|Control|
75643347|NCT04072003|Device|intravascular ultrasound (IVUS)|use IVUS in the procedure
75791509|NCT03946176|Dietary Supplement|Symbiotic|HD patients follow a 8-weeks oral administration of the symbiotic supplement (2 bags/day)
75927988|NCT04880148|Dietary Supplement|Placebo oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
75927989|NCT02191059|Drug|Icotinib|
75927990|NCT02191059|Drug|Docetaxel|
75927991|NCT03586596|Behavioral|The Decídetext program|Decídetext participants will be directed to the tablet-based software. Participants will receive an interactive education session that will lead them through language-appropriate, culturally-relevant information about stopping smoking, collection of basic smoking history data, and choices/plans about preparing to quit. Quit plans include: 1) choice of quit date, 2) NRT preference, 3) plan to remove smoking cues, 4) identification of trigger situations and 5) choice of suggested coping strategies. Participant data and choices are used to generate a printed 1-page individualized treatment plan. Tablet components, assessment items, audio narrative, brief multimedia instructional video clips, and the printed treatment plan have been developed to address low-literacy levels.
75643348|NCT04072003|Other|coronary angiography|Coronary angiography is required for all PCI procedure.
75791510|NCT03946176|Dietary Supplement|Placebo|HD patients follow a 8-weeks oral administration of the placebo (2 bags/day)
75791511|NCT03946176|Device|DVB cartridge|On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
75927992|NCT03586596|Behavioral|Standard Care Control|Educational Material provided as of suggested by American Cancer Society and, the National Cancer Institute
75927993|NCT02203539|Other|exposure to normal light|exposure for 60 minutes in duration
75927994|NCT02203539|Other|exposure to bright light|exposure to bright light for 60 minutes of duration
75927995|NCT02203539|Other|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
75927996|NCT04460118|Procedure|Bristow surgery fixed by the screw|Bristow surgery fixed by the screw
75643349|NCT04209699|Drug|BMS-986165|Single dose
75643350|NCT04209699|Drug|Famotidine|Single dose
75927997|NCT04460118|Procedure|Bristow surgery fixed by the suture button|Bristow surgery fixed by the suture button
75927998|NCT02203617|Behavioral|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
75643351|NCT00620295|Drug|bortezomib|Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.
75798870|NCT01181232|Drug|Zolpidem MR|oral
75798871|NCT01181232|Drug|Zolpidem IR|oral
75798872|NCT01177644|Drug|PDS 1.0|
75927999|NCT02203617|Behavioral|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
75928000|NCT02209077|Device|OCT performed to collect data from the back of the eye|comparative retinal parameters with Spectralis OCT
76083410|NCT03376776|Procedure|Vitrectomy|
76083411|NCT03381534|Device|stenting with EPD|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
75791512|NCT01358812|Drug|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
75643352|NCT00620295|Drug|gemcitabine hydrochloride|Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m^2) on day 1 and day 8 of a 21 day cycle.
75643353|NCT00581893|Drug|Phenytoin|Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
76083412|NCT03381534|Device|stent assisted angioplasty|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
76083413|NCT03007654|Device|Mediclore|apply medical device fully around intrauterine surgery area
75643354|NCT00581893|Drug|Placebo oral capsule|Placebo
75791513|NCT05258942|Other|Observational|Blood samples will be collected within 30 days before scheduled surgical / interventional therapy for Heart Failure. The study will not impact patient treatment in any way.
75791514|NCT01371448|Drug|Paroxetine|
76083414|NCT03007654|Device|Adept|apply medical device fully around intrauterine surgery area
75791515|NCT03983070|Other|Seated Rowing Ergometer|Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures
76083415|NCT03007264|Device|Cold Atmospheric Plasma|CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
76083416|NCT03376620|Drug|1,4-Diaminobutane|Daily application to surgical breast scars of 1,4 diaminobutane on the active side
75643355|NCT04211025|Other|Modest|The modest intervention consists of a 30-minute appointment (by phone or in-person) with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, the designated staff follows-up with a phone call or email.
75643356|NCT04211025|Other|Intensive|The intensive intervention consists of a 30-minute appointment with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, a follow-up appointment is booked for 30 minutes, and progress on the plan is assessed. At 12 weeks after the initial meeting, the designated staff follows-up with a phone call or email.
75643357|NCT04211103|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
75643358|NCT04209777|Drug|Probiotic Blend Chewable Tablet|Lactobacillus-reuteri probiotics were used as an experimental drug.
75791516|NCT03983070|Other|Deadlift|Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.
75791517|NCT03983070|Other|Blood flow restriction|An occlusive cuff will be placed around each proximal thigh and inflated to 80% arterial occlusion during exercise sessions.
75791518|NCT01371526|Drug|depot tetracosactide|1mg, 3x weekly by sc injection
75791519|NCT03945708|Device|CytoSorb|Addition of a hemofilter to the cardiopulmonary bypass circuit
75791520|NCT05189392|Device|PICO|after hip arthroplasty application of visible opsite plaster on the surgical wound
75791521|NCT03943992|Drug|YYD601 40mg|Patients should take druges 30 minutes before breakfast.
75791522|NCT03943992|Drug|Nexium 40mg|Patients should take druges 30 minutes before breakfast.
75928001|NCT03356106|Device|Continuous positive airway pressure (CPAP)|A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
75928002|NCT02191215|Drug|Nevirapine (Viramune®)|
76083417|NCT03376620|Drug|10% Urea cream|Daily application to surgical breast scars of 10% Urea cream on the sham side
76083418|NCT03374514|Drug|Dexamethasone|instilation of the solution in the middle ear
75334063|NCT03950076|Other|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy as determined by the local investigator includes i) No antithrombotic therapy ii) Antiplatelet monotherapy, including de novo indication for antiplatelet monotherapy during course of the study
75334064|NCT05292976|Other|Methacholine Chloride|Serial Methacholine dilutions
75643359|NCT04209777|Drug|Antibiotics|Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.
75791523|NCT03943992|Drug|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
75791524|NCT01371604|Drug|IDX184|IDX184 50 mg tablet administered orally
75791525|NCT01371604|Biological|Peginterferon alfa-2a (Peg-IFN)|Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
75791526|NCT01371604|Drug|Ribavirin (RBV)|Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
75791527|NCT01371604|Drug|Placebo|Matching placebo to IDX184 50 mg tablet administered orally
75791528|NCT01107600|Procedure|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
75928003|NCT03104478|Procedure|Biological samples collection|In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
75928004|NCT02209155|Drug|R-verapamil 75 mg tablet|
75928005|NCT02209155|Drug|Placebo|
75928006|NCT03486366|Other|non interventional trial|other
76083419|NCT03374514|Drug|Sterile isotonic saline solution|Sterile isotonic saline solution
76083420|NCT03381456|Other|LICI|Paired pulse TMS to measure LICI and late cortical disinhibition
76083421|NCT03374436|Behavioral|High-Carbohydrate Sedentary|Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
75791529|NCT01107678|Other|Healthy Snacks and Organized Physical Activity|Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais
75643360|NCT01410123|Other|Integrated Stepped Care (ISC)|"At risk drinking:~Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy~Alcohol abuse/dependence:~Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare~Moderate Alcohol + Liver Disease:~Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy."
76083422|NCT03374436|Behavioral|High-Carbohydrate Active|"Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks."
76083423|NCT03374436|Behavioral|Low-carbohydrate Sedentary|Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
75334065|NCT05292976|Drug|Albuterol Sulfate HFA 0.09 mg (Reference)|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols.
76083424|NCT01526356|Drug|Placebo|Study cream is applied nightly to the affected areas on the face.
75334066|NCT05292976|Drug|Albuterol Sulfate HFA 0.18 mg (Reference)|One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
75334067|NCT05292976|Drug|Albuterol Sulfate HFA 0.09 mg (Test)|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols.
75334068|NCT05292976|Drug|Albuterol Sulfate HFA 0.18 mg (Test)|One actuation each from two different Test inhalation aerosols and one actuation each from two different placebo Reference inhalation aerosols.
76083425|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
75334069|NCT05292976|Drug|Placebo|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
75334070|NCT01808950|Drug|0.06% Resiquimod Gel - A|single 60mg dose
75643361|NCT01410123|Other|Treatment as Usual|The TAU arm will receive a handout with alcohol information embedded within general health-related information (exercise, smoking cessation, and flu vaccination) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.
75334071|NCT01808950|Drug|0.06% Resiquimod Gel - B|single 100mg dose
75334072|NCT01808950|Drug|0.06% Resiquimod Gel - C|shave biopsy of BCC followed by single 100mg dose
75643362|NCT00887523|Behavioral|radiation in prone position|radiation in prone position
75791530|NCT01371682|Drug|Ropinirole XL|Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
75334073|NCT01808794|Device|Mucograft|Mucograft Collagen Matrix
75334074|NCT01808794|Device|Dynamatrix|Dynamatrix
75334075|NCT00850720|Other|Blood draws|Samples of blood to be drawn before surgery, and nine hours after surgery.
75334076|NCT04706338|Device|TMS treatment|Using TMS to stimulate (5 Hz, 90%~110% resting motor threshold) patients' primary motor area and SMA.
75334077|NCT05477472|Drug|St John's Wort|daily intake of CERES St John's Wort mother tincture. Dose according to the treating physician.
75643363|NCT00887523|Behavioral|radiation in supine position|radiation in supine position
75643364|NCT02334865|Biological|Incomplete Freund's Adjuvant|Given SC
75643365|NCT02334865|Other|Laboratory Biomarker Analysis|Correlative studies
75643366|NCT02334865|Drug|Lenalidomide|Given PO
75791531|NCT01107756|Drug|LENOGRASTIM (GRANOGYTE 34)|Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
75791532|NCT01371760|Procedure|Venous PTA|PTA of the internal jugular and/or azygous vein
75791533|NCT01371760|Other|Catheter Venography|The patients will undergo catheter venography but not PTA
75791534|NCT03127384|Device|Restylane Lidocaine|Hyaluronic acid based filler
75791535|NCT03127384|Other|No-treatment control|No-treatment control
75791536|NCT03942900|Other|Additional biological samples|"Biomonitoring blood sample will be collected: 6 EDTA tubes (6 mL) for PBMC (peripheral blood mononucleated cell), 1 EDTA tube (6 mL) for plasma freezing and 2 EDTA tubes (4 mL) for ctDNA:~at baseline,~at first tumor assessment (phase 2 in OPTIMANAL study),~at second tumor assessment (phase 4 in OPTIMANAL study),~at end-point visit.~A tumor biopsy or archived tumor sample will be mandatory at baseline."
75791537|NCT01366924|Dietary Supplement|Essential Amino Acids|10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
75791538|NCT01366924|Other|Endurance exercise|60 minute endurance exercise session
75791539|NCT01111500|Device|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
76083426|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
76083427|NCT03812094|Device|Enurad 400|Alarm treatment
76083428|NCT03812094|Behavioral|Basic Bladder advice|Pre-specified Basic bladder advice
76083429|NCT04838964|Drug|MRG003|Administrated intravenously
75334078|NCT04512742|Other|biting by Phlebotomus duboscqi infected with Leishmania major|The first six subjects will be exposed to biting by Phlebotomus duboscqi infected by Leishmania major and assess the 'take rate', that is the number of subjects developing parasitologically confirmed cutaneous leishmaniasis (PCCL) lesions. If 6/6 subjects develop PCCL lesions no further recruitment will take place; if only < 6 subjects develop PCCL lesions, then an adaptive design will be followed.
75334079|NCT00843310|Drug|Lenalidomide (Revlimid)|
75334080|NCT00843310|Drug|Melphalan|
75334081|NCT00843310|Drug|Dexamethasone|
75643367|NCT02334865|Biological|Sargramostim|Given SC
75334082|NCT04706572|Other|Stimulation with external auditory bio-feedback|Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
75928007|NCT03485118|Drug|HS006+CHOP|"Drug:HS006 HS006 375 mg per square meter (mg/m^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
75928008|NCT03485118|Drug|HS006+CHOP|"Drug:HS006 HS006 500 mg per square meter (mg/m^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle."
75928009|NCT03485118|Drug|Rituximab+CHOP|"Drug:Rituxan Rituxan 375 mg per square metre (mg/m^2), administered by intravenous (IV) on Day 1 of each 21-day cycle.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
75928010|NCT02209233|Other|Massage Therapy|
75334083|NCT00809458|Drug|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
75334084|NCT05482932|Diagnostic Test|Health-related physical fitness assessment|Participants will complete several questionnaires and perform multiple health-related physical fitness tests
75334085|NCT04706182|Procedure|Platelet-rich fibrin (PRF)|Platelet rich fibrin (PRF) serves as a structural reservoir of cytokines such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), platelet factor 4 (PF4) and vascular endothelial growth factor (VEGF) which aids in healing and preventing infection. PRF will be prepared as recommended by the manufacturer (Intra-Lock International) by centrifuging 20 mL of the subject's venous blood for 12 minutes at 2700 rpm, followed by compression. The fibrin clot will then be applied to the SSO site prior to fixation. The blood draw for the PRF will be performed approximately 15 minutes prior to fixation of the mandible. 20 mL will be drawn for each PRF side treated. The blood venous draw will be from the subject's arm or from an existing intra-venous line.
75928011|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
75334086|NCT04706182|Procedure|Proximal segment grooving (PSG)|Proximal segment grooving is a mechanical method to create additional space within the inferior alveolar canal to allow the IAN to rest without compression or trauma. The surgeon uses a round or acrylic bur to cautiously remove any bony spicules, and remove cancellous bone in the proximal mandibular segment. PSG will be done by using an acrylic round bur on a surgical handpiece to remove 3 to 4 mm of cancellous bone where the IAN will passively rest into prior to fixation.
75334087|NCT00422968|Device|Percutaneous coronary intervention|Using silorimus eluting stent
75334088|NCT00422968|Procedure|coronary artery bypass graft|coronary artery bypass graft
75334089|NCT00379054|Behavioral|telephone based skills training intervention|
75334090|NCT04151134|Diagnostic Test|Step serial sectioning histological processing|Step serial sectioning histological processing
75334091|NCT00379132|Drug|131-I-TM-601 (chlorotoxin)|"Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.~Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)"
75643368|NCT02334865|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
75643369|NCT00620139|Biological|the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,|patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
75643370|NCT04073719|Dietary Supplement|Apple Cider Vinegar|Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.
75643371|NCT04073719|Dietary Supplement|Other Beverage|To what degree do other high citrate beverages impact urinary citrate output.
75643372|NCT04072081|Device|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
75643373|NCT04072081|Device|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
75643374|NCT00379431|Drug|Administration of rituximab and methylprednisolone|"Rituximab:~Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use."
75643375|NCT00620529|Dietary Supplement|Ocean Nutrition 2050|1000mg capsules, 4 capsules/day for 8 weeks
75334092|NCT01697332|Drug|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
75334093|NCT01701622|Drug|febuxostat|"If baseline allopurinol dose < 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose > 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks."
75334094|NCT01668940|Other|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
75334095|NCT01668940|Other|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
75643376|NCT00620529|Dietary Supplement|Olive oil capsules|Olive oil capsules, 4 per day for 8 weeks
75643377|NCT04210323|Device|ShotBlocker®|The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
75643378|NCT04210323|Device|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
75643379|NCT04210167|Behavioral|web-based training and telephone monitoring|web-based training and telephone monitoring and short message
75643380|NCT04210479|Procedure|Filled-bladder|Urinary bladder filling with 300 ml diluted methylene blue
75643381|NCT04210479|Procedure|non filled-bladder|Pull up the empty (non-filled) urinary bladder using Allis forceps
75643382|NCT04842201|Drug|CM326|subcutaneous injection
75643383|NCT04842201|Drug|Placebo|subcutaneous injection
75643384|NCT00620217|Genetic|intramyocardial injection of VEGF-A165/bFGF:placebo plasmid|The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
75791540|NCT01111500|Device|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
75791541|NCT01111578|Device|Enteral feeding tube|The esophageal and gastric pressure, measured with this new device, will be recorded and compared with those ones measured with a standard esophageal catheter
75791542|NCT03945630|Procedure|anterior Quadratus Lumborum Block|Interfascial plane block
75791543|NCT03945630|Procedure|Standard of Care|No QLB
75791544|NCT04212598|Drug|Sintilimab|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
75928012|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - active control session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
75928013|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - sham control session.|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
75928014|NCT02191293|Drug|Viramune® tablets|
76083430|NCT01526902|Device|omafilcon A / PC 1-D MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
75791545|NCT01109472|Other|patient magazine|patient magazine individually tailored to patient's prior feedback
75791546|NCT01358890|Other|low carbohydrate diet|Dietary carbohydrate diet was restricted to 20 gram/day within the first week, then increase gradually to 120 gram/day
75791547|NCT01358890|Other|Calories restricted diet|Total energy intake is restricted to 1200 kcal/day for women. Energy from carbohydrate, protein and fat will be kept to approximate 55%, 20% and 25%, respectively. Moreover, saturated fat and dietary cholesterol are restricted to at most 10% energy and 300 mg/day, respectively
75791548|NCT01111656|Drug|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
75791549|NCT01111656|Drug|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
75791550|NCT02819752|Drug|Pembrolizumab|Pembrolizumab
75791551|NCT02819752|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
75791552|NCT02819752|Drug|Chemotherapy|Chemotherapy - Standard Treatment
75791553|NCT03943524|Device|Interax-AI|Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
75928015|NCT03532815|Behavioral|Lifestyle Modification|
75928016|NCT02880540|Drug|Fentanyl|
75928017|NCT02880540|Drug|Morphine|
75928018|NCT02880540|Drug|Dexmedetomidine|
75928019|NCT02191371|Drug|propofol|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
75928020|NCT02191371|Drug|desflurane|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
75928021|NCT04460274|Other|Model Building|Model building
76083431|NCT01526902|Device|lotrafilcon B / Air Optix MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
75791554|NCT05189158|Diagnostic Test|Hypercapnic hyperoxic ventilatory response|"The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs.~By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear."
76083432|NCT03376542|Diagnostic Test|Cardiopulmonary Exercise Testing|Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
75791555|NCT05189158|Diagnostic Test|Hypoxic eucapnic ventilatory response|The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2. Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.
75791556|NCT03942978|Other|Longitudinal Equity Action Plan|Patients admitted to general medicine pod randomized to intervention will receive a Longitudinal Equity Action Plan (LEAP), which will include a program manager to ensure they are on appropriate medical therapy, that cardiology is consulted when appropriate, that patient is set up with appropriate follow-up appointment with cardiology, that transportation is set up for follow-up visits, and a post-discharge follow up call to remind patients of the appointment and identify any post-discharge issues. This is in addition to standard of care, and there will not be any drug or device interventions.
75791557|NCT02567578|Drug|YH12852 0.1 mg|
76083433|NCT02519946|Other|On-Line Diet and Exercise Intervention|Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
76083434|NCT02903160|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg PO daily
75334096|NCT01668940|Other|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
75334097|NCT01675960|Drug|Gabapentin|The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
75643385|NCT04954989|Biological|Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously
75643386|NCT04954989|Biological|Active comparator Erythropoietin Eprex® subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of Eprex® should be administered subcutaneously
75643387|NCT04187859|Behavioral|Education Session|Participants will receive an education session from their District Nurse, advising on how to improve their hydration.
75643388|NCT04187859|Device|Prompting Cup|The Droplet Cup is an electronic prompting cup that emits a sound and/or light to encourage the participant to take a drink
75791558|NCT02567578|Drug|YH12852 0.25 mg|
75791559|NCT02567578|Drug|YH12852 0.5 mg|
75791560|NCT02567578|Drug|Placebo|
75791561|NCT01328028|Other|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
76083435|NCT02903160|Drug|Prednisone|5 mg PO twice a day
75472087|NCT01954290|Drug|Hypertonic saline|Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
75791562|NCT01328028|Other|Data collection|Log sheet
76083436|NCT02903160|Drug|Radium-223 dichloride|50 kBq/kg IV monthly
76083437|NCT02903160|Drug|cabazitaxel|25 mg/m2 IV every 3 weeks
76083438|NCT02903160|Drug|Carboplatin|Carboplatin AUC 4 IV every 3 weeks
76083439|NCT02903160|Drug|Enzalutamide|160 mg PO daily
75472088|NCT01954290|Drug|Mannitol|Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
75472089|NCT01954303|Other|Progress of CHD|
75472090|NCT01954355|Drug|LDE225|400, 600 and 800 mg OD
75643389|NCT00620607|Drug|huC242-DM4|dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks
76083440|NCT03376464|Device|Xeomin Cosmetic|Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.
75643390|NCT02706171|Radiation|CyberKnife|
75643391|NCT05265663|Radiation|stereotactic ablative radiotherapy|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days within a maximum overall treatment duration of 14 days.
75791563|NCT03943602|Drug|Cabozantinib|Cabozantinib 60 mg/day orally
75791564|NCT02523274|Drug|Resveratrol|Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
76083441|NCT01528228|Device|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
75928022|NCT04460274|Other|Model validation|Model validation
75791565|NCT02523274|Drug|Placebo|Vegetable-based cellulose
75334098|NCT01675960|Drug|placebo|The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
75928023|NCT02209311|Procedure|Oral mucosa biopsy|
75791566|NCT02523274|Behavioral|Exercise|Multi-modal exercise regimen, 3 days/week
75791567|NCT03945474|Other|Sham|See description in sham arm.
75928024|NCT02209311|Procedure|Sinus lift with implantation of tissue engineered construction|
75928025|NCT02209311|Device|Dental implant|
75928026|NCT02209389|Device|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
75334099|NCT04053868|Other|JUUL|Electronic Cigarette
75928027|NCT03532737|Drug|Pembrolizumab|Adding PD-1 inhibitor to the standard of care
75334100|NCT04053868|Other|Tobacco|Tobacco Cigarette
75472091|NCT01954355|Drug|Paclitaxel|80 mg/m2 (days 1, 8, 15)
75472092|NCT01954368|Drug|Placebo|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
75928028|NCT05151978|Diagnostic Test|Transcranial Doppler|Transcranial Doppler on middle cerebral arteries
75472093|NCT01954368|Drug|Sufentanil|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
75472094|NCT01954381|Device|transthoracic echocardiographic|
75472095|NCT01954381|Device|Doppler ultrasound.|
75643392|NCT00313989|Procedure|Evaluation of the success rate of implants|Evaluation of the success rate of implants
75928029|NCT02209467|Other|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
75643393|NCT02691273|Behavioral|cellular application treating diabetes using breathing technique|
75643394|NCT00286533|Procedure|Clinical examination (implant stability, gingiva condition, etc.)|Clinical examination (implant stability, gingiva condition, etc.) to follow
75928030|NCT02741388|Drug|selinexor|
75928031|NCT02741388|Drug|Rituximab|
75928032|NCT02741388|Drug|Dexamethasone|
75928033|NCT02741388|Drug|Oxaliplatin|
75928034|NCT02741388|Drug|Cisplatin|
75928035|NCT02741388|Drug|Cytarabine|
75643395|NCT00286533|Procedure|Questionnaires|Questionnaires are used.
75643396|NCT04209231|Other|1.25(OH)2D3|
75928036|NCT02741388|Drug|Gemcitabine|
75928037|NCT02191527|Device|PIMA® for quantitative analysis of CD4-count|
75928038|NCT02191527|Device|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
75928039|NCT02191527|Device|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
75928040|NCT03484962|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
75334101|NCT04026178|Drug|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI
75334102|NCT03999970|Other|Sand fly bite|Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
75928041|NCT03484962|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
75928042|NCT03484728|Behavioral|placebo manipulation|application of nonactive body cream on forearm
75928043|NCT05261373|Other|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
76083442|NCT03381222|Diagnostic Test|epiaoryic scan|Epiaortic scan will be performed by use L15-7i Phillips®. Ultrasound probe cover with sterile cover. Five standard epiaortic views will be collected
76083443|NCT03376386|Radiation|Adaptive dose-Escalated multi-modality image-guided radiotherapy|FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
75334103|NCT00787618|Drug|50 mg Proellex|Single dose
75334104|NCT00749476|Biological|Factor IX recovery|
75472096|NCT01954381|Biological|blood samples|
75643397|NCT04209231|Other|25(OH)D|
75643398|NCT00621699|Drug|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
75643399|NCT00621699|Drug|1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany|administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
75791568|NCT03945474|Other|Osteopathic Manipulation, OMT|See description in OMT arm
75791569|NCT02461654|Other|Disc FX|Disc FX is an innovative system allowing for a safe and effective approach to a damaged disc without injury to the surrounding structures. The procedure consists of three phases: during the first phase, the disc is punctured with a special needle that functions as a working channel. This needle is used to remove part of the degenerate inner tissue. Then, using a radio-frequency probe, the disc is sealed to minimize the risk of repeated herniation. In the final step, the pathological nerves in the back part of the disc are destroyed with the use of radio-frequency.
75791570|NCT02432560|Drug|Sirolimus|Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
75791571|NCT02432560|Drug|Everolimus|Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
75928044|NCT05261373|Other|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
75791572|NCT01111734|Dietary Supplement|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
75928045|NCT05261373|Other|Behavioral: Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
75928046|NCT01331616|Drug|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
75928047|NCT02209623|Biological|TDAP|
75928048|NCT02191761|Drug|SM04755|Escalating Doses
75928049|NCT02209701|Drug|Porfiromycin|
76083444|NCT03376308|Diagnostic Test|Pain Score|"Four poin scala 0=No Pain~mild~intermediate~severe"
76083445|NCT03376308|Diagnostic Test|Withdrawal movement score|"Withdrawal movements~no movement response~movement limited to the wrist~movement limited to the elbow/shoulder,~generalized movement response."
76083446|NCT03376308|Diagnostic Test|hemodynamic response|Hemodynamic data were recorded in the patients taken in the operation room. (T0). Hemodynamic values (T1) measured 1 minute after administration of intravenous propofol were recorded. Hemodynamic values (T2) measured 1 minute after administration of intravenous rocuronium were recorded. Hemodynamic values (T3) measured 1 minute after administration of endotracheal intubation were recorded.
75791573|NCT01111734|Drug|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
76083447|NCT03381144|Drug|GDC-0334|Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
75928050|NCT02191839|Drug|Alpha 1-Antitrypsin|
75928051|NCT02191995|Behavioral|yoga|
75928052|NCT05261295|Diagnostic Test|PEEP|PEEP of 7 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
75928053|NCT05261295|Diagnostic Test|ZEEP|PEEP of 0 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
75928054|NCT03535467|Other|Caregiver's Burden Inventory|The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.
75928055|NCT02209779|Drug|BIBR 796 BS|
76083448|NCT03381144|Drug|Placebo|Participants will receive GDC-0334-matching placebo.
76083449|NCT03374280|Drug|pemetrexed/cisplatin intercalating gefitinib|
75643400|NCT00621699|Drug|1 tablet Ezetrol(R) + 1 capsules Prograf(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
75643401|NCT05662683|Other|Virtual Reality (VR)|Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. During the PAP-SMEAR application to be made with this device, watching a nature video with VR is within the framework of midwifery care applications and is not a treatment option for any treatment method, agent or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason.
75643402|NCT05662683|Other|Distraction Cards Practice Group|It will take about 3-5 minutes to show the cards. The selection of the cards to be used is based on the cards suggested in the literature.
75791574|NCT01698138|Drug|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
75791575|NCT01698138|Drug|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
75791576|NCT03942822|Dietary Supplement|Milled chia seeds|8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia
75928056|NCT02209779|Drug|Placebo|
75928057|NCT05238987|Dietary Supplement|Ferrous sulphate|Single dose of ferrous sulphate (120 mg of elemental iron)
76083450|NCT03374280|Drug|pemetrexed/cisplatin|
76083451|NCT03376230|Other|Collect of blood, urines, and intestinal biopsies|
76083452|NCT03381066|Drug|gefitinib, pemetrexed,cisplatin|"Intercalation phase (Duration: 3weeks x 4 cycles = 12 weeks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Gefitinib 250mg D5-18, every 3week~Maintenance phase (Duration: 1 year) Gefitinib 250mg D1-2"
76083453|NCT03381066|Drug|Vinorelbine, cisplatin|Duration: 3wks x 4 cycles = 12 weeks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3week
76083454|NCT03374124|Diagnostic Test|sinonasal outcome test-22|Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
76083455|NCT03380988|Other|Acute test meal with fiber-enriched buckwheat pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
75791577|NCT01111890|Drug|Azarga (brinzolamide 1% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
75643403|NCT05662683|Other|Virtual Reality (VR) Breathing Exercise Group|From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
75472097|NCT01954407|Behavioral|Smoking-Related Messages|
75928058|NCT04911075|Drug|85% TCA Solution|"TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes."
75472098|NCT01954420|Behavioral|Cognitive-Behavioral Intervention|Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
75472099|NCT01954420|Other|Attention Control|Standard care + Cancer education
75643404|NCT00612183|Drug|bendamustine hydrochloride|bendamustine hydrochloride is administered by 60-min drip infusion at 120 mg/m2/day for 2 consecutive days, and the course is then observed for 19 days. This is one cycle and administration is repeated for 3 - 6 cycles. From the second cycle, the dose is reduced or administration is discontinued as required based on adverse events observed in the previous cycle or observation of the course.
75643405|NCT04799769|Device|Percutaneous arterial closure device|Large hole percutaneous arterial closure device
75643406|NCT04209309|Device|repetitive transcranial magnetic stimulation|
75643407|NCT00620841|Other|genotyping|Restriction fragment lenght polymorphisms
75791578|NCT01111890|Drug|Cosopt (dorzolamide 2% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
75791579|NCT01111968|Biological|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
75472100|NCT01954433|Procedure|Operated TSA Patients|Total shoulder prosthesis: Anatomic or reverse total shoulder replacement is a well-standardized procedure usually performed under general anesthesia with the patient in a beach-chair position
75472101|NCT01954433|Procedure|Operated RCR Patients|Arthroscopic rotator cuff tear reconstruction. The shoulder arthroscopy is performed according to internal and international standard procedure with patients positioned in beach-chair position under general anesthesia.
75643408|NCT00770146|Drug|Mipomersen sodium|200 mg/mL
75928059|NCT02192073|Procedure|Suprapectoral Biceps tenodesis|
75643409|NCT00770146|Drug|Placebo|1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
75643410|NCT04747899|Other|Positional release technique|"Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.~Positional release technique position will maintained for almost 90 seconds. This technique will be repeated for three times each session, with 10 sec relaxation, 3 days/week.~Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions were given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
75928060|NCT02192073|Procedure|Subpectoral biceps tenodesis|
75928061|NCT02204163|Drug|Eutropin|
75928062|NCT02204163|Drug|Genotropin|
75928063|NCT05238441|Biological|SCTV01E|D0; intramuscular injection
75928064|NCT05238441|Biological|Comirnaty|D0; intramuscular injection
76083456|NCT03380988|Other|Acute test meal with corn pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
75472102|NCT01954433|Procedure|Resection interposition suspension arthroplasty (RISA)|"One of five surgical techniques can be used in this study, as routinely performed by each surgeon:~RISA with FCR-Ligament (flexor carpi radialis ligament) modified according to Epping~RISA with FCR-Ligament modified according to Weilby~RISA with APL-Ligament (abductor pollicis longus ligament)~RISA with Graftjacket modified according to Weilby~Resection arthroplasty"
75472103|NCT01954446|Device|3M|Conventional measuring of BP
75472104|NCT01954446|Device|ContiPressTM|"New way of measuring BP - ContiPressTM~Investigational device"
75472105|NCT01954446|Device|Mobil-O-Graph|2 different devices for oscillometric measurement of BP
75472106|NCT01954459|Device|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
75472107|NCT01954459|Device|Continuous glucose sensor|Glucose sensor inserted without warming patch
75643411|NCT04747899|Other|Traditional physical therapy|"Hot pack for 15-mins. Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions are given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
75791580|NCT01111968|Biological|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
75791581|NCT01111968|Biological|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
75791582|NCT01111968|Biological|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
75928065|NCT05238441|Biological|SCTV01E|D180; intramuscular injection
75928066|NCT05238441|Biological|Comirnaty|D180; intramuscular injection
75928067|NCT02190981|Device|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
75928068|NCT05263323|Other|Patient education|Providing patient education to hemodialysis patients according to Neuman Systems Model by the researcher.
75928069|NCT05263323|Other|Data Collecting, No Education|Data were collected at the beginning and end of the study without training the control group.
75928070|NCT02204397|Drug|INGAP Peptide, Ustekinumab|
75928071|NCT02192229|Drug|50.000 IU vitamin D3 (Biodal 50,000 IU)|
75928072|NCT02192229|Drug|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
75928073|NCT02192463|Drug|NVP ER 300 mg (KCR 20%) Medium Release|
75928074|NCT02192463|Drug|NVP ER 300 mg (KCR 25%) Medium Release|
75643412|NCT03975153|Biological|guselkumab|Treatment at the FDA-approved psoriasis dosing for 20 weeks
75791583|NCT01111968|Biological|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
75928075|NCT02192463|Drug|NVP ER 300 mg (KCR 30%) Slow Release|
75928076|NCT02192463|Drug|NVP ER 400 mg (KCR 25%) Medium Release|
75928077|NCT02192463|Drug|NVP ER 300 mg (KCR 40%) Slow Release|
75928078|NCT02192463|Drug|NVP ER 300 mg (ECR 20%) Fast Release|
76083457|NCT03374046|Procedure|Apneic Oxygenation|Supplemental oxygen will be provided via nasal cannula during intubation attempt
75334105|NCT01607320|Drug|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
75334106|NCT01607320|Drug|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
75334107|NCT01606150|Drug|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
75643413|NCT00915850|Drug|DCF|docetaxel, Cisplatin and 5-FU
75791584|NCT01111968|Biological|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
75928079|NCT02192463|Drug|NVP ER 400 mg (KCR 20%) Medium Release|
75928080|NCT02192463|Drug|NVP ER 400 mg (KCR 30%) Slow Release|
75928081|NCT02192463|Drug|NVP ER 400 mg (KCR 40%) Slow Release|
75928082|NCT02192463|Drug|NVP ER 400 mg (ECR 20%) Fast Release|
75928083|NCT02192463|Drug|Nevirapine immediate release (IR) 200 mg|
75928084|NCT02209935|Other|Early Rehabilitation Protocol|
75928085|NCT02209935|Other|Usual care|
76083458|NCT03380910|Behavioral|Pharmacy and Behavioral Health Team|An interdisciplinary approach using medications through pharmacy support and counseling through behavioral health team members will be used to improve smoking cessation rates.
76083459|NCT03380910|Behavioral|Motivational Interviewing|Patients not ready to quit will be offered motivational interviewing to increase readiness to quit.
75334108|NCT01606150|Drug|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
75334109|NCT00747916|Device|CryoSpray Ablation (TM) System|Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
75334110|NCT04706494|Dietary Supplement|AlphaWave® LTheanine|200 mg of AlphaWave® LTheanine
75334111|NCT04706494|Dietary Supplement|Placebo|microcrystalline cellulose
75334112|NCT00739024|Drug|Ramelteon|8 mg tablet, oral, once daily
75334113|NCT00739024|Drug|Placebo|Placebo tablet, oral, once daily
75334114|NCT01602016|Drug|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
75643414|NCT04208763|Drug|Imipenem|Inj Imipenem 1gm i.v. TDS
75643415|NCT04208763|Drug|Tigecycline|Inj Tigecycline 100mg stat f/b 50mg i.v. OD
75643416|NCT04208763|Drug|GMCSF|Inj GM-CSF 500mcg s.c. OD
75643417|NCT04208763|Drug|Colistin|Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
75643418|NCT04100356|Other|Exercise|Exercise program - indoor bicycle interval exercise, duration 60 min 3x week
75643419|NCT04100356|Other|Normal Diet|Normal diet recommended by the health authorities
75791585|NCT01111968|Biological|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
75791586|NCT01111968|Biological|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
75928086|NCT02204475|Drug|Grazoprevir/Elbasvir|Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
75928087|NCT02204475|Drug|Boceprevir|Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
75928088|NCT02204475|Drug|PegIntron|Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
75928089|NCT02204475|Drug|Ribavarin|Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
75928090|NCT02210169|Drug|Continuous infusion of vancomycin|Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
75928091|NCT02257047|Dietary Supplement|Tea|
75928092|NCT02257047|Dietary Supplement|RYR|red yeast rice
75791587|NCT01111968|Biological|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
75791588|NCT01111968|Biological|placebo group 14|All elements of the vaccine but antigen and adjuvant
75791589|NCT03942666|Drug|Treatment A|tablet of CHF 6532
75791590|NCT03942666|Drug|Treatment B|tablet of CHF 6532
75791591|NCT03942666|Drug|Treatment C|tablet of CHF 6532
75791592|NCT03942666|Drug|Treatment D|tablet of CHF 6532
75791593|NCT03942666|Drug|Treatment E|Placebo tablet of CHF 6532
75791594|NCT03942666|Drug|Treatment F|tablet of CHF 6532
75791595|NCT04398134|Drug|ABI-H2158|3 X 100 mg tablets for oral administration
75791596|NCT04398134|Drug|Placebo|Sugar pill manufactured to mimic the ABI-H2158 tablets
75791597|NCT04398134|Drug|Entecavir (ETV)|0.5 mg tablet for oral administration
75928093|NCT02210949|Drug|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
75928094|NCT02204553|Drug|Panobinostat|Treating patients with relapsed and/or refractory Multiple Myeloma
76083460|NCT02814786|Radiation|MRI scanner|"This examination is divided in 2 parts:~Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.~Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome."
75928095|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
75928096|NCT01109004|Drug|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
75334115|NCT01602016|Drug|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
75334116|NCT01591954|Device|Video Augmentation|Assessment of value of video-based navigation system
75334117|NCT00731770|Drug|Advair 250|1 puff bid inhaled
75334118|NCT00731770|Drug|Placebo- matched|1 puff bid inhaled
75472108|NCT01954472|Behavioral|Enhanced portfolio plus structured exercise|"Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute."
75472109|NCT01954472|Behavioral|High fiber diet plus routine exercise|"Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.~Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided."
75643420|NCT04100356|Other|LCHF Diet|LCHF Diet, a modified Atkins diet with high percentage of fat and very low percentage of karbohydrates
75334119|NCT00731770|Drug|Placebo|Placebo 1 puff bid inhaled
75334120|NCT00731770|Drug|Advair 250 - matched|i puff bid inhaled
75334121|NCT01589926|Device|Bi-level positive airway pressure device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
75334122|NCT01589926|Device|Sham CPAP|Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
75334123|NCT01590394|Device|Large plastic biliary stent|Stent placement for bile duct obstruction.
75472110|NCT01954485|Procedure|Dental implant placement with a final prosthetic abutment|
75643421|NCT00620919|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
75791598|NCT01112046|Procedure|Endoscopic submucosal dissection|Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives
75334124|NCT00719914|Drug|eptifibatide|Intra-coronary injection, weight based, of eptifibatide.
75334125|NCT00719914|Drug|eptifibatide|Intra-coronary injection, based on weight, of eptifibatide
75334126|NCT00719914|Drug|normal saline|Intra-coronary injection, weight based, of normal saline.
75334127|NCT01566370|Drug|Zonisamide|titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
75472111|NCT01954498|Dietary Supplement|Walnuts|
75472112|NCT01954498|Dietary Supplement|OTC multivitamin|
75643422|NCT00916552|Drug|Erythropoietin|40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
75643423|NCT03950037|Drug|Albendazole|Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
75791599|NCT01112046|Procedure|Laparoscopic resection|Surgical treatment performed under general anesthesia
75791600|NCT04281342|Drug|Aprocitentan 25 mg|Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
75791601|NCT04281342|Drug|Aprocitentan 100 mg|Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
75791602|NCT04281342|Drug|Matching placebo|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.
75791603|NCT04281342|Other|Moxifloxacin control to establish assay sensitivity|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.
75791604|NCT01108146|Drug|Arm 1 Hydrocortisone 10 mg|"Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone"
75334128|NCT01566370|Drug|Placebo|placebo
75334129|NCT01558492|Drug|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
75334130|NCT01558492|Drug|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
75334131|NCT03579472|Drug|Bintrafusp Alfa|Given IV
75334132|NCT03579472|Drug|Eribulin Mesylate|Given IV
75334133|NCT03371212|Device|Dual mobility cohort|Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell.
75643424|NCT04188171|Procedure|Polidocanol foam sclerotherapy|"Preparation of the foam is done according to the Tessari technique (2 disposable 20ml syringe, a three-way tap, reusable extender adapted to intravenous needle).~Sclerosant applied according to the Blanchard technique through a disposable transparent anoscope (patient in knee-chest position).~In each session, treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).~During the intervention period the participants are observed at 3-week intervals. The required number of sessions (maximum of 3) is determined by clinical and anoscopic evaluation.~After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
75928097|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
75643425|NCT00620997|Drug|Proparacaine drops 0.05%|topical, 0.05% drops, PRN continuously for up to 7 days
75472113|NCT01954511|Other|Manual therapy|The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes
75643426|NCT00620997|Drug|saline drops|saline drops continuously PRN for up to 7 days
75643427|NCT00622011|Drug|Risperidone and Zotepine for delirium|try risperidone or zotepine in the treatment of delirium
75643428|NCT04663113|Other|Control Group/1st group ( standard physiotherapy|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
75643429|NCT04663113|Other|2nd group- Standard physiotherapy + bicycle ergometer|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given."
75643430|NCT04663113|Other|3rd group- Standard physiotherapy + exercise protocol to be developed|"Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.~Portable indirect calorimetry will be used to measure the basal metabolic rates of the patients.~The basal metabolic rates of the patients will be measured before the exercise and aerobic exercise or resistant exercise will be given according to the metabolic state of the patient.~Ratings of perceived exertion (RPE) will be used as the aerobic exercise protocol and a 10-11 strength exercise will be given according to the RPE.~If resistance exercise will be given, the intensity of the exercise (12-14) will be determined according to the RPE. Sandbags attached to the ankle will be used as a resistance exercise and 9 exercises were determined. (Knee extension, knee flexion, trunk flexion, trunk extension, hip extension, hip flexion, hip abduction, shoulder flexion, shoulder abduction"
75643431|NCT00621075|Other|Pulmonary Arterial Hypertension - Lung Perfusion Scans|Correlation of data from non-invasive tests such as lung perfusion scans with hemodynamic measurements
75928098|NCT02204631|Other|Head and Neck Educational Handbook|
75643432|NCT04634175|Behavioral|Mind-body intervention|The mind-body intervention is composed of kundalini yoga techniques.
75643433|NCT04634175|Behavioral|Sham intervention|The sham intervention is composed of stretching and muscle flexion techniques.
75928099|NCT02211729|Drug|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
75928100|NCT02211729|Drug|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
75472114|NCT01954511|Other|Manual therapy|The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes
75643434|NCT00621231|Dietary Supplement|Placebo|Placebo
75643435|NCT00621231|Dietary Supplement|Protein|30 E% from protein
75643436|NCT00622089|Drug|DIO-902|150mg DIO-902 + 10mg atorvastatin
75643437|NCT00622089|Drug|DIO-902|300mg dose once per day for 24 weeks
75643438|NCT00622089|Drug|DIO-902|450mg dose once per day for 24 weeks
75643439|NCT05662449|Device|Syndesmosis fixation using Activascrew|as described prior
75643440|NCT04208373|Drug|JNJ-64417184|JNJ 64417184 tablets will be administered orally.
75643441|NCT04208373|Drug|Itraconazole|Itraconazole capsules will be administered orally
75643442|NCT04208373|Drug|Etravirine|etravirine tables will be administered orally.
75643443|NCT04547751|Other|targeted high-resolution mass spectrometry|"difference between the number of new substances identified using targeted analysis by liquid chromatography coupled with high-resolution mass spectrometry versus using targeted analysis. narcotics-new substance by liquid chromatography coupled with tandem mass spectrometry"
75643444|NCT00622245|Drug|Lu AA34893|per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
75643445|NCT00622245|Drug|Quetiapine fumarate|per oral, once daily, during 12 weeks, followed by a one-week tapering period
75791605|NCT01108146|Drug|Arm 2 Hydrocortisone 30 mg|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
75928101|NCT02212041|Other|disposable electronic cigarettes|"Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.~During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained."
75928102|NCT05151510|Procedure|Trigger point injection with 1% lidocaine|Previously discussed in prior section.
75928103|NCT05151510|Drug|Lidocaine patch 5%|Will place lidocaine patch onto skin overlaying point of maximal tenderness
75928104|NCT02212119|Drug|Botulinum Toxin|
75334134|NCT03371212|Device|Conventional cohort|Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell
75643446|NCT00622245|Drug|Placebo|per oral doses, twice daily as capsules during 13 weeks
75928105|NCT02212119|Drug|Saline|
75928106|NCT05151354|Other|Psychotherapy|Patients receive 8 weeks of inpatient psychotherapeutic treatment. Treatment consists of individual and group psychodynamic psychotherapy, as well as an individual combination of art, music, body-oriented and relaxation therapies, which are also carried out in group settings. Treatments is provided by an interdisciplinary team of psychotherapists with a medical or psychology degree, art of music therapists, social workers, physiotherapists and specialist nurses.
75334135|NCT05482620|Procedure|Nordic walking program|Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.
75334136|NCT05482620|Procedure|Educational sessions and usual care|Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
75334137|NCT05286190|Drug|Bupivacaine 0.25% Injectable Solution|Bupivacaine 0.25% Injectable Solution
75334138|NCT05477316|Radiation|Radiation treatment|Radiation treatment of IMRT to the cerebellum and SRS to the cerebrum
75334139|NCT05473260|Other|Control|In-patient care.
75643447|NCT01056341|Drug|Propranolol|Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
75334140|NCT05473260|Other|Experimental|Early discharge and outpatient follow-up.
75928107|NCT02257125|Behavioral|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
75334141|NCT00691444|Dietary Supplement|Melatonin|"Subjects will be given up to 0.5 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
75643448|NCT01056341|Drug|Placebo|Treatment with placebo for 6 months
75643449|NCT00999518|Biological|Tanezumab|1 mg dose given subcutaneously twice at an 8-week interval.
75643450|NCT00999518|Biological|Tanezumab|2.5 mg dose given subcutaneously twice at an 8-week interval.
75643451|NCT00999518|Biological|Tanezumab|10 mg dose given subcutaneously twice at an 8-week interval.
75928108|NCT02257125|Behavioral|low incentive|"Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards."
75928109|NCT03484650|Drug|Lidocaine Hydrochloride|Lidocaine bolus to be given 1 hour pre-operatively
75928110|NCT03484650|Drug|Lidocaine Hydrochloride|Lidocaine infusion will be started after the bolus and be continued for 24 hours post-operatively
75643452|NCT00999518|Biological|Tanezumab|20 mg dose given subcutaneously twice at an 8-week interval.
75643453|NCT00999518|Other|Placebo|Placebo dose given subcutaneously twice at an 8-week interval.
75643454|NCT00621387|Drug|ofloxacin and roxithromycin|150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
75643455|NCT00621387|Drug|placebo|placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
75643456|NCT00136149|Procedure|Immediate implants|Immediate implants are used.
75791606|NCT01207518|Behavioral|Intervention Group|This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.
75791607|NCT01207518|Behavioral|Control Group|This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.
75791608|NCT01108224|Behavioral|Psychosocial support|Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
75791609|NCT01109628|Dietary Supplement|Protein drink|Twice a day during 6 months
75334142|NCT00691444|Dietary Supplement|Melatonin|"Subjects will be given up to 10 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
75791610|NCT01109628|Dietary Supplement|Placebo drink|Twice a day during 6 months
75928111|NCT03484650|Other|Placebo|Control patients will receive a placebo bolus and infusion of saline to match the experimental arm.
76083461|NCT02814786|Other|Gait analysis|For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.
76083462|NCT04764552|Dietary Supplement|Yeahhh Baby Ointment|The ointment consists primarily of coconut oil (98%), with small amounts of herbal ingredients (tanner's bark, slippery root, sweet weed, velvet plant, walnut hulls, kidney root, green ginger, Indian pink, mad dogweed, and nigella seed) thought to reduce inflammation and to promote tissue healing.
76083463|NCT04764552|Other|Coconut oil ointment|Coconut oil ointment with a little olive oil.
76083464|NCT02647242|Behavioral|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
76083465|NCT03376074|Device|Hypothermic oxygenated perfusion (HOPE)|25 patients: Application of HOPE for 2 hours, perfusion rate 100-150 ml/min, pressure controlled, perfusion pressure < 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate solution (UWMP®), perfusate temperature 4-12 °C, perfusate oxygenation 40 KPa
76083466|NCT03376074|Other|Conventional cold storage|75 patients transplanted in Rennes between 2010 and 2015 with a cold stored grafts, matched (ratio 1: 3) using a propensity score calculated according to some parameters
76083467|NCT02520024|Behavioral|self-directed care|
76083468|NCT03370146|Behavioral|Mental training based on Motor Imagery|Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
75334143|NCT00691444|Biological|Melatonin|"Subjects will be given up to 20 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
75334144|NCT00693628|Device|compression shrinker|Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
75928112|NCT05151276|Behavioral|mobile phone-based distance video education group|Following the first interview, diabetes education videos created previously were sent to the mobile phones of the individuals in two episodes a week fashion. Video submission was completed in a total of four weeks. In the second interview, three months after the video submission had been completed, data collection forms were re-administered to the individuals, and blood analysis results were recorded.
75928113|NCT02213601|Behavioral|Yoga|
76083469|NCT03370146|Behavioral|Cognitive training|Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.
76083470|NCT03370146|Behavioral|Evaluation of gait abilities|All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
75334145|NCT05482464|Dietary Supplement|Casein glycomacropeptide (CGMP)|Casein glycomacropeptide (CGMP) supplementation for 3 weeks
75643457|NCT03655743|Device|LASIK, PRK, Phacoemulsification|"Please see:~https://en.wikipedia.org/wiki/LASIK https://en.wikipedia.org/wiki/Photorefractive_keratectomy https://en.wikipedia.org/wiki/Phacoemulsification"
75334146|NCT00689884|Drug|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
75334147|NCT05472870|Device|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
75334148|NCT01530880|Drug|Intravenous Ibuprofen|Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
75334149|NCT01530880|Drug|Acetaminophen (Standard of Care)|Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
75643458|NCT02873273|Drug|Dexamethasone|Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
75643459|NCT00627341|Behavioral|Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)|AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.
75643460|NCT00627341|Behavioral|Cognitive behavioral therapy (CBT)|CBT for anorexia nervosa sessions will focus on behaviorally normalizing eating patterns throughout the day and on cognitively addressing dysfunctional thinking that promotes disordered eating.
75643461|NCT04208841|Behavioral|Person-Centered Care Quality Improvement Collaborative Sustain|Sustain improvements during QI collaborative focused on PCC
75643462|NCT04208841|Behavioral|Person-Centered Care Quality Improvement Collaborative Spread|Implement change package developed during QI Collaborative
75643463|NCT01056263|Drug|axitinib: observational study|Non-interventional observational study
75928114|NCT02192697|Drug|ASP8273|Oral administration
75928115|NCT03486210|Behavioral|Food preference|The study will take place in two phases. A first phase will consist in the validation of translations and the selection of images on 20 healthy volunteers and 20 health professionals specialized in nutrition. They will have to fill a form with images of food and evaluate to what extend they think the pictures represent what we can eat in France. This step will adapt the questionnaire to our country.
75643464|NCT00637143|Drug|Tacrolimus|Oral
75791611|NCT01108302|Other|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
75791612|NCT01108380|Procedure|Plasma pheresis, Right portal vein embolization|"Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam."
76083471|NCT03375996|Drug|cyclopentolate 0.5% eye drops|cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
75791613|NCT03122860|Drug|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
75791614|NCT03122860|Other|Placebo|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
75791615|NCT03122860|Other|Sham|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
75791616|NCT05175586|Diagnostic Test|First data analysis|A series of questions were asked to a number of patients with diagnoses related to primary idiopathic stiff shoulder and/or extrinsic stiff shoulder secondary to trauma or surgery. These patients are part of the physiotherapy clinic receiving the research. This questionnaire answers basic questions for the structure of the study such as age and sex, physical behaviour during the week, endurance, athletic disability, reason for attending the clinic, exploratory motor tests, etc. Subsequently, physiotherapeutic tests related to the pathology within the research were performed consisting of joint range, percentage of shoulder disability and pain scale.
75791617|NCT05175586|Procedure|Second data analysis|Three treatment sessions of Percutaneous Neuromodulation (PNM) and Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 1) and three treatment sessions of Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 2) were performed at a rate of two sessions per month for three months. These therapies were compared with the clinical examination performed prior to each new session to verify changes in joint range, percentage of shoulder disability, strength and pain scale.
75791618|NCT05175586|Other|database|Age and sex were expressed as mean ± standard deviation (SD). The rest of the variables were expressed as mean, absolute and relative frequency. The chi-square test was used to analyse the differences between the examinations in terms of the time taken and the treatments used in the two groups. A confidence level of 95% was established, considering a value of p<0.05 as statistically significant.
75928116|NCT03486210|Other|Psychological assesment|"Phase performed with patients fasting for at least 2 hours before the different tests. The FLPQ will be compared between a group of patients suffering from unoperated obesity (OCt), a group of patients operated on a sleeve gastrectomy (OSl) and a group operated by a bypass (OBy) between 6 and 24 months post-surgery, randomized for the 6 combined tests (2 categories). The award can be made in 2 sessions of at least 3 of the 6 tests combined. Each test combines 2 of the 11 categories. The test will consist of 96 pairs of 16 food images presented on a computer screen in color. Participants will be invited to choose the food they most want to eat, by pressing the corresponding computer button (choices saved by counting the frequency scores in E-prime).~The level of hunger will be evaluated by an Analogical Visual Scale, ranging from 0 to 10.~Patients should also complete 3 self-questionnaires used routinely (Binge Eating Scale, The Yale Food Addiction Scale, The UPPS-P short version)."
75928117|NCT03486132|Procedure|repair of episiotomy|Different techniques for repair of episiotomy incsicion
75928118|NCT02030691|Device|Nasal continuous airway positive pressure (nCPAP)|
75928119|NCT02030691|Device|Nasal high frequency percussive ventilation (nHFPV)|
76083472|NCT01580410|Drug|mitomycin C|Given by HIPEC
75334150|NCT05482230|Other|Changes in intubation position|The change of intubation mode is accomplished in lateral position
75334151|NCT05482074|Drug|Olaparib|Oral, twice a day, dosage per protocol, per 28 day cycle
75334152|NCT03228472|Device|non invasive brain stimulation|"TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.~TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes."
75334153|NCT03228472|Device|sham stimulation|Placebo treatment
75643465|NCT00637143|Drug|Cyclosporine|Oral
76083473|NCT01580410|Drug|oxaliplatin|Given by HIPEC
76083474|NCT01580410|Procedure|therapeutic conventional surgery|Undergo surgery
76083475|NCT01580410|Other|quality-of-life assessment|Ancillary studies
75643466|NCT04208451|Dietary Supplement|Alixir 400 Protect|During 30 days all patients take every day 30ml of Alixir 400 protect
76083476|NCT01580410|Drug|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
76083477|NCT03373812|Procedure|Blepharoptosis repair|levator advancement or mullerectomy
75334154|NCT05476848|Diagnostic Test|ELISA test for Cytokines|ELISA tests specific for cytokines (IL-1, IL-6, IL-10) and immunoglobulins (IgA, IgG, IgM) will be performed by a biochemistry lab, both for blood samples and oral swap samples.
75643467|NCT01056107|Drug|ROSE-010|The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
75643468|NCT01056107|Drug|Placebo|Placebo subcutaneous injection daily
75643469|NCT03548805|Procedure|ologen® Collagen Matrix|Ologen is a collagen matrix used to modulate wound healing in the postoperative period to promote diffuse blebs
75643470|NCT03548805|Procedure|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC
75643471|NCT01003886|Drug|Doxazosin mesylate GITS|Doxazosin mesylate GITS 4mg to 8mg once daily
75791619|NCT01319188|Drug|0.5 mg of ranibizumab|Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
75791620|NCT01319188|Procedure|0.5 mg of ranibizumab + photodynamic therapy|Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
75791621|NCT01319188|Other|Sham injection|Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
76083478|NCT03373734|Device|Enjoy Your Bump|Online life skills course based on Cognitive Behavioural Therapy Principles.
76083479|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
76083480|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
75643472|NCT03541551|Procedure|CTT with ologen® Collagen Matrix|ologen® Collagen Matrix approved by Indian health authority with registration numberof MD-1517 will be provided by Aeon Ajanta India Pvt. Ltd. free of cost for this clinical research only.
75928120|NCT03481452|Behavioral|psychotherapy|NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.
75791622|NCT05167162|Diagnostic Test|State-Trait Anxiety Questionnaire|"The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~Not at all~Little~Sometimes~Almost always~Always"
75791623|NCT05167162|Diagnostic Test|Rating of Perceived Exertion|"The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~No pain~Little pain~Moderate~Severe~Very strong~Unbearable"
75791624|NCT05167162|Diagnostic Test|Motor coordination tests|"The motor coordination tests are divided into three:~Jumping with 2 feet together.~Throwing 2 balls from a given distance and space.~Proprioception turns"
75928121|NCT02204865|Device|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
75928122|NCT03481374|Diagnostic Test|autonomic function testing|"autonomic function testing, ergospirometry, three questionnaires~Other Names:~The autonomic function tests consist of five tests:~The Valsalva maneuver~The isometric handgrip test~The deep breathing test~The cold pressor test~A short head-up tilt test~A maximal ergospirometry~Three questionnaires:~EQ-5D-3L: quality of life~IPAQ: capacity to do physical activities"
76083481|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
76083482|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
76083483|NCT03370068|Other|ICSI|Oocytes retrieved from one ovary will undergo insemination by ICSI.
76083484|NCT03370068|Other|Conventional IVF|Oocytes retrieved from the second ovary will undergo insemination by conventional IVF
76083485|NCT01530178|Drug|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
75334155|NCT03195790|Behavioral|Family-based pediatric obesity treatment|Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
75334156|NCT03584022|Device|Biopsy + Nerve Repair|During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.
75334157|NCT03584022|Procedure|Biopsy Only|Standard sural nerve biopsy only, without nerve repair.
76083486|NCT01530178|Drug|Placebo Oral Tablet|
76083487|NCT03369990|Drug|Botulinum toxin type A|Botulinum toxin type A(DWP450)
75334158|NCT03556488|Diagnostic Test|US air bronchogram score|"On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment."
75334159|NCT01532362|Drug|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
75334160|NCT00678574|Drug|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
75643473|NCT03541551|Procedure|Trab Trab|combined trabeculotomy with trabeculectomy
75643474|NCT00627029|Behavioral|Care Coordination|Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
75643475|NCT04138641|Drug|Cangrelor|Cangrelor intravenous
75643476|NCT00621465|Behavioral|Critical Time Intervention (CTI)|CTI is designed specifically to enhance the continuity and focus of care during the transition from psychiatric hospital to community care. CTI does not replace community treatment and support, but instead is meant to complement available services. CTI will provide training in community living skills and in team-managed transfer of caregiving from hospitals to services and supports in the community. Participants will receive CTI for 9 months after hospital discharge.
75643477|NCT00621465|Behavioral|Usual care|Usual care will include the standard aftercare and community care services.
75643478|NCT04208607|Procedure|Bronchoscopy|Role of bronchoscopy in diagnosis of bronchiectasis
75791625|NCT05167162|Procedure|Physiotherapeutic intervention|Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.
75791626|NCT05167162|Other|Data Analysis|The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p<0.05 as statistically significant.
75791627|NCT01367314|Drug|NVC-422|Dermal Gel applied 3 times per day for 7 days
76083488|NCT03369990|Drug|Placebos|Normal Saline
76083489|NCT03375840|Behavioral|Text-only PWL|Control condition
76083490|NCT03375840|Behavioral|Low-emot PWL|Pictorial warning
76083491|NCT03375840|Behavioral|High-emot PWL|Pictorial warning
75334161|NCT00672178|Radiation|Stereotactic body radiation|Stereotactic body radiotherapy will be given in three cohorts of increasingly higher dose levels: Cohort 1: 6 Gy/fraction x 3 fractions (total=18 Gy) over 5 days; Cohort 2: 8 Gy/fraction x 3 fractions over 5 days; Cohort 3: 10 Gy/fraction x 3 fractions over 5 days.
75334162|NCT05476692|Other|AOFAS score and VAS|Clinical outcome by the Visual analogue scale (VAS) and the American Orthopaedic Foot and Ankle (AOFAS) score.
76083492|NCT03375840|Behavioral|Immediate posttest|
76083493|NCT03375840|Behavioral|delay posttest|
75643479|NCT01003184|Drug|exenatide once weekly|subcutaneous injection, 2mg, once a week
75928123|NCT03481218|Other|The World Health Organization Quality of Life (WHOQOL) -BREF|The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
75791628|NCT05167084|Drug|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
75334163|NCT05481918|Procedure|Home-based therapy after ACL reconstruction|Five physiotherapeutic supervisions (individual) take place within the first 12-13 weeks after ACL reconstruction with focus on home exercises
75791629|NCT05167084|Drug|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
75791630|NCT05167084|Drug|Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8 in a total daily dose of 19.9mg
75334164|NCT05481918|Procedure|Standardized ambulant therapy after ACL reconstruction|16 physiotherapeutic supervisions (groups+ individual) take place within the first 12-13 weeks after ACL reconstruction.
75334165|NCT00634582|Drug|paricalcitol|
75334166|NCT00634582|Other|immunoenzyme technique|
75643480|NCT01003184|Drug|insulin detemir|subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
75334167|NCT00634582|Other|laboratory biomarker analysis|
75643481|NCT02446821|Device|VeraCept|IUD placement of VeraCept
75643482|NCT01029353|Procedure|Laparotomy|Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.
75791631|NCT05167084|Drug|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8
75791632|NCT03798366|Drug|GLPG1690|Film-coated tablets of GLPG1690 for oral use.
75643483|NCT01029353|Procedure|Drainage|Initial drainage will involve placing a Penrose drain in the abdomen.
75643484|NCT01008410|Drug|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
75791633|NCT03798366|Drug|Placebo|Film-coated tablets of GLPG1690 matching placebo for oral use.
75928124|NCT03481218|Other|The Satisfaction With Life Scale - SWLS|The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.
75928125|NCT03481218|Other|Big Five Inventory - BFI; John in Srivastava, 1999|The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.
75928126|NCT02204943|Device|Biomarker analysis|Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples
75643485|NCT01008410|Drug|Placebo|Placebo matching to budesonide will be administered as per the schedule specified in the respective arm.
75643486|NCT00627653|Drug|fenofibrate|148mg daily for 30 days
75334168|NCT00634582|Procedure|dual x-ray absorptometry|
75334169|NCT00634582|Procedure|quality-of-life assessment|
75334170|NCT02551692|Drug|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
75334171|NCT02551692|Drug|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
75643487|NCT01023269|Device|InterStim Therapy|Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
75643488|NCT02347917|Drug|BBI608|480 mg orally twice daily (960 mg total daily dose)
75643489|NCT02347917|Drug|Pemetrexed|500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
75643490|NCT02347917|Drug|Cisplatin|75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
75643491|NCT01972035|Drug|Valacyclovir|Experimental Arm
75643492|NCT01972035|Drug|Valganciclovir|Standard of care
75643493|NCT00622479|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib will be administered at 400mg BID for a 28 day cycle.
75791634|NCT00867178|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo conformal radiation therapy
75791635|NCT00867178|Drug|Carboplatin|Given IV
75791636|NCT00867178|Drug|Cisplatin|Given IV
75791637|NCT00867178|Drug|Cyclophosphamide|Given IV
75791638|NCT00867178|Drug|Etoposide Phosphate|Given IV
75791639|NCT00867178|Drug|Isotretinoin|Given PO
75791640|NCT00867178|Other|Laboratory Biomarker Analysis|Correlative studies
75791641|NCT00867178|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
75791642|NCT00867178|Drug|Thiotepa|Given IV
75791643|NCT00867178|Drug|Vincristine Sulfate|Given IV
75791644|NCT00867178|Drug|Vorinostat|Given PO
75791645|NCT01209156|Drug|[18F] PBR111|Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of [18F]PBR111, followed by PET imaging.
75791646|NCT01209312|Other|Bolus timing and dosing|We will be altering the timing and dosages of the prescribed meal bolus.
75928127|NCT02204943|Drug|Administration of radium-223|Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
75928128|NCT05153928|Drug|Norethisterone acetate|Norethisterone acetate for 5 months
76083494|NCT03006874|Drug|CJ-12420 100mg QD|CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
76083495|NCT03006874|Drug|Esomeprazole 40mg|Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
76083496|NCT03006874|Drug|CJ-12420 50mg QD|CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
76083497|NCT03369912|Biological|CSJ148|Active
76083498|NCT03369912|Other|Placebo|No Drug
76083499|NCT03375684|Other|Conventional chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
76083500|NCT03375684|Other|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
76083501|NCT03373578|Device|earmuffs|to compare the neonate's sleep with and without earmuffs during Quiet time at the NICU
76083502|NCT01581970|Drug|Cyclophosphamide|Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
76083503|NCT01581970|Drug|Cetuximab|The initial dose of cetuximab 400 mg/m^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m^2 intravenously (IV) over 60 minutes.
75643494|NCT05661903|Other|Spinal Cord Stimulator Set to Minimal/No Stimulation Setting|Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.
75643495|NCT05661903|Other|Usual Care|Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.
75791647|NCT03945006|Other|Incontinence Severity|The Incontinence Severity Index (ISI) was used to assess the MS patients' incontinence severity.The first item is scored between 1 and 4 and the second item is scored between 1 and 3. The total score is calculated by the multiplication of these two answers. The index score is classified as 1-2 slight, 3-6 moderate, 8-9 severe, and 12 very severe.
75791648|NCT03945006|Other|Balance|The patients were assessed while their bladders were empty. The static balance of the patients was measured with a Technobody® stabilometric platform. The patients were assessed while their bladders were empty. The test was performed as the patients' arms on the sides, eyes open and closed, and on two feet. Ellipse area, anterior-posterior sway, and medial-lateral sway scores were recorded.
75791649|NCT03945006|Other|Trunk impairment|Trunk impairment was assessed with the Trunk Impairment Scale (TIS) while the participants' bladders were empty. The scale evaluates static and dynamic sitting balance and trunk coordination through 17 items. Each item is scored between 0 and 3. The total score ranges between 0 and 23, and higher scores indicate a better balance performance.
76083504|NCT01583452|Other|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
75791650|NCT03945006|Other|Fear of falling|Fear of falling was assessed using the Falls Efficacy Scale developed by Tinetti and colleagues. The scale has 10 items assessing the effect of fear of falling on the confidence level of the individuals while performing activities of daily living. Each items is scored by the participants between 0 (not at all concerned) and 10 (very concerned), and the total of the score ranges between 0 (low fall efficacy) and 100 (high fall efficacy)
75791651|NCT01109706|Other|biological parameters dosage|"200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up."
75791652|NCT03945396|Drug|Homeopathic Medication|A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
75928129|NCT02214771|Drug|Fidaxomicin|oral
76083505|NCT01583686|Drug|Fludarabine|Days -5 to Day -1: Fludarabine 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
75928130|NCT02214771|Drug|Treatment for CDI other than fidaxomicin Type|Oral
75643496|NCT01207011|Drug|Amrubicin hydrocloride|AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
75928131|NCT03484572|Diagnostic Test|Anthropometric measures|Weight (kg),Height (cm)Body mass index(kg/m²),Mid-upper arm-circumference(cm), tricipital skinfold (cm)
75928132|NCT02192853|Drug|sitagliptin|"In randomized order:~Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion"
75643497|NCT01207011|Drug|Docetaxel|DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
75928133|NCT02192853|Drug|Placebo|Day 4: placebo tablet
76083506|NCT01583686|Biological|Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
76083507|NCT01583686|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
76083508|NCT01583686|Drug|Aldesleukin|Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
76083509|NCT01532128|Drug|rasagiline|1 mg rasagiline (single-dose)
76083510|NCT01532128|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
76083511|NCT01584388|Drug|Rituximab|Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
75643498|NCT05264805|Drug|0.25% Bupivacaine|20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
75643499|NCT04272411|Device|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
76083512|NCT03007108|Other|blood withdrawal|
76083513|NCT01584544|Drug|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
76083514|NCT01584544|Drug|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
76083515|NCT01584544|Drug|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
75334172|NCT02551692|Drug|Placebo Nicotine Patch|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the VAR group, participants will wear a placebo patch while taking varenicline."
75334173|NCT02551692|Drug|Placebo Capsule|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches."
75334174|NCT00247000|Device|Routine Care in a HF clinic vs Home Telehealth Care for HF|
75334175|NCT00547456|Drug|Oxygen|Oxygen 2-3L Nasal cannula
75334176|NCT05481840|Device|Continence material with sensor|"Healthcare organizations are prepared for the use of smart continence care (for the intervention condition) using specially developed implementation guideline. They receive training, including how to apply continence material (only provided to intervention condition).~Each participating location will use the product for 12 weeks. Correct size and absorption level will be determined for each participant. The optimize the result, this can change. Evaluation meetings with the caregivers, supplier and researcher will be held. Resulting in suggestions for alterations in continence care provided or products used, or giving indications that a team needs support in any way to foster the implementation.~After 12 weeks, the implementation guidance from the research group will be phased out.~The waiting list group will continue their continence care as usual during data collection period. Thereafter they will receive support for implementing smart continence care."
75334177|NCT00542542|Procedure|Paravertebral Block|Paravertebral block given as a bolus injection into the paravertebral space.
75334178|NCT00542542|Drug|Propofol|2-2.5 mg/kg IV over 1-4 hours during surgery.
75334179|NCT00542542|Drug|Fentanyl|50-250 mcg IV over 1-4 hours during surgery.
75334180|NCT00542542|Drug|Ropivacaine|Ropivacaine given by injection into the paravertebral space along the spinal canal.
75643500|NCT04272411|Device|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
75643501|NCT04272411|Device|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
76083516|NCT01584544|Drug|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
75791653|NCT03945396|Other|Multidisciplinary intervention (Exercise program, diet, motivational support)|"Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight."
75791654|NCT03945396|Drug|Homeopathic placebo|A 30 ml bottle of 30% alcohol-distilled water.
75791655|NCT01209390|Device|Chondromimetic|"The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.~The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate."
75791656|NCT01109784|Drug|prasugrel|prasugrel 10 mg/day
76083517|NCT01584544|Drug|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
76083518|NCT03006952|Drug|Pentoxifylline|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
76083519|NCT03006952|Drug|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
76083520|NCT01532830|Device|n-VNS|
75334181|NCT00542542|Drug|Midazolam|0.08 mg/kg IV over 1-4 hours during the surgery.
75334182|NCT05476614|Other|Yoga (Robot-instructed)|Yoga that is instructed by a social robot
75334183|NCT05476614|Other|Yoga (Human-instructed)|Yoga that is instructed by a human
75334184|NCT00545506|Device|conventional bandage|
75334185|NCT00545506|Device|warming bandage|
75334186|NCT03333486|Drug|Cyclophosphamide|Given IV
75334187|NCT03333486|Drug|Fludarabine Phosphate|Given IV
75334188|NCT03333486|Other|Laboratory Biomarker Analysis|Correlative studies
75334189|NCT03333486|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
75334190|NCT03333486|Radiation|Total-Body Irradiation|Undergo TBI
75334191|NCT02703844|Device|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
75334192|NCT02703844|Device|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
75334193|NCT03546660|Device|SECM capsule|Subjects will swallow a SECM capsule and the SECM imaging will be performed
75643503|NCT05264493|Drug|NaxRedy ™|5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
75643504|NCT05264493|Drug|Naloxone Hydrochloride Injection, USP|2 mg IM (2mg/2 mL) injection into gluteal muscle
75791657|NCT01109784|Drug|clopidogrel|clopidogrel per os 150mg/day
75791658|NCT01112280|Device|cap-assisted chromoendoscopy|A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. For chromoendoscopy, 0.09% indigocarmine was administered via irrigation cap .
76083521|NCT01802333|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
76083522|NCT01802333|Drug|Cytarabine|Given IV
75643505|NCT05264493|Drug|Naloxone Hydrochloride Injection, USP|2 mg bolus IV (2mg/2 mL)
75791659|NCT01328262|Other|Calculated red blood cell transfusion|The subjects receive an amount of red blood cells that has been calculated from their body surface area.
75791660|NCT01328262|Other|Standard red blood cell transfusion|The subjects in this group receive the prescribed number of red blood cell units.
75791661|NCT04327388|Drug|Sarilumab SAR153191|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
75791662|NCT04327388|Drug|Placebo|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
75791663|NCT01112436|Drug|periarticular injection of multidrug regimen|periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
75928134|NCT05151042|Procedure|wafer-less approach|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position. CAD/CAM generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment & tooth bearing segment. Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts.~Removal of guide, then BSSO is performed. The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
76083523|NCT01802333|Drug|Daunorubicin Hydrochloride|Given IV
76083524|NCT01802333|Drug|Idarubicin|Given IV
76083525|NCT01802333|Other|Laboratory Biomarker Analysis|Correlative studies
75334194|NCT02598778|Drug|Chlorhexidine gluconate (0.12%)|30 second oral rinse of 10mL of solution
76083526|NCT01802333|Drug|Vorinostat|Given PO
76083527|NCT01585324|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly
76083528|NCT01585324|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
76083529|NCT03006484|Other|No intervention|No intervention will be needed.
76083530|NCT03006640|Drug|Subcutaneous nitroglycrin|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
75334195|NCT02598778|Drug|Sodium Fluoride (0.05%)|30 second oral rinse of 10mL of solution
75334196|NCT02598778|Other|Paraffin wax chewing gum (sugar-free)|Approximately two minutes of chew time
75334197|NCT02598778|Other|Deionized water|30 second oral rinse of 10mL of solution
75334198|NCT05470296|Behavioral|Move & Eat 2 Live|American Indians suffer disproportionately from several chronic diseases that may be prevented with healthier modifiable factors. Nutrition, physical activity and a healthy weight are key factors that may prevent and reduce risk of disease incidence. The major goals of this project are to develop a culturally adapted intervention that addresses barriers and uses positive cultural values as guiding principles for behavior changes to enhance program retention and improve behaviors. This project will pilot a 12-week standard lifestyle intervention in American Indians.
75334199|NCT00642382|Device|Agilus|Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
75643506|NCT00612261|Procedure|Arteriovenous Crossing Sheathotomy|In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.
76083531|NCT03006640|Drug|Subcutaneous saline|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
75643507|NCT00612261|Procedure|Intravitreal Triamcinolone Acetonide Injection|The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.
75791664|NCT01112436|Drug|none of medication preoperatively and intraoperatively|Patients in Group C wil receive none of medication preoperatively and intraoperatively
75791665|NCT03741114|Procedure|Foley's Catheter|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus.
75791666|NCT03741114|Drug|TA|patients received 1 gm tranexamic acid intravenous just before skin incision in 100 ml saline
75791667|NCT03741114|Drug|Placebo|patients received 100 ml saline just before skin incision
75791668|NCT01328340|Other|High-speed power training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
75791669|NCT01328340|Other|Slow-speed strength training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
75791670|NCT03796728|Device|Juvéderm® VOLIFT™ with Lidocaine|Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).
76083532|NCT01586962|Drug|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
76083533|NCT01588444|Device|cortical FDBA|cortical mineralized freeze-dried bone allograft
76083534|NCT01588444|Device|Cancellous FDBA|CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
76083535|NCT03006250|Drug|Desflurane|Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
75791671|NCT04323800|Biological|Anti- SARS-CoV-2 Plasma|SARS-CoV-2 convalescent plasma (1 unit; ~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
75643508|NCT05264181|Device|Percutaneous pulmonary valve implantation|Percutaneous pulmonary valve implantation using SAPIEN 3 valve in the context of routine care of patients with congenital heart diseases
75472115|NCT01954511|Device|Pressure biofeedback device|Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
76083536|NCT03006250|Drug|Sevoflurane|Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
76083537|NCT03006406|Drug|Long term GnRH-a (3.75mg)|patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
76083538|NCT00980655|Biological|13vPnC|"0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.~Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose."
76083539|NCT00980655|Biological|23vPS|0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
76083540|NCT04129437|Drug|Ibuprofen|Weight based ibuprofen dosing
76083541|NCT04129437|Procedure|Osteopathic manipulative treatment|Low velocity osteopathic manipulative treatment
76083542|NCT05609799|Other|Blood sample|Quantifying the volume of leucocyte subsets: NK-cells, B-cells, and T-cell subsets, including Treg, Th1, Th2 and Th17 in EDTA
76083543|NCT01535014|Drug|Dietressa|Comparison of different dosages (frequency) of drug
76083544|NCT01535014|Drug|Placebo|"Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)"
76083545|NCT05609721|Other|no intervention, only observational study|no intervention, only observational study
75334200|NCT00642382|Device|Normal saline|Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
75334201|NCT02203006|Biological|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
75334202|NCT05481372|Other|Imaging|Trans-perineal ultrasound and Magnetic resonance image acquisition
75334203|NCT05476380|Drug|camrelizumab|Camrelizumab:200 mg, IV., d1, q3w; Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w; Cisplatin:75 mg/m2, iv., d1,q3w
75334204|NCT00637312|Device|Cervical Artificial Disc (Advent™ Cervical Disc)|Advent™ Cervical Disc
75643509|NCT02693379|Device|D-VIA|"D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.~Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment."
75643510|NCT02693457|Procedure|Drain|One randomized knee will be assigned to receive an intra-articular drain procedure following bilateral total knee arthroplasty. The drain will be removed 24 hours post-operatively. The patient will be blinded to fluid output from intra-articular drain.
75643511|NCT02693457|Procedure|No Drain|The contralateral knee will be assigned to a placebo drain procedure following bilateral total knee arthroplasty. This will blind the patient as to which knee contains the functioning intra-articular drain. A non-suction/ non-functional subcutaneous drain will act as the placebo drain. This drain will not output any fluid and will also be removed 24 hours after post-operatively.
75791672|NCT04323800|Biological|SARS-CoV-2 non-immune Plasma|Normal human plasma collected prior to December 2019
76083546|NCT04588259|Drug|Faster aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
76083547|NCT04588259|Drug|Insulin aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
75791673|NCT01328418|Procedure|Lengthening over nail|External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
76083548|NCT04588259|Drug|Insulin degludec|Administered s.c. (subcutaneously, under the skin) for 16 weeks
76083549|NCT01535326|Procedure|air insufflation|insufflate air during the insertion of colonoscopy
75334205|NCT00637312|Device|Hallmark™ Anterior Cervical Plate System|Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
75791674|NCT01108536|Device|adaptive prosthetic socket|trans tibial socket with actuator zones (inflatable fluid bladders)
75791675|NCT04112862|Other|sodiumlactate|intravenous sodiumlactate 600mmol/L
76083550|NCT01535326|Procedure|water immersion|infuse water during insertion, aspirate water during withdrawal
76083551|NCT01535326|Procedure|water exchange|infuse and remove water during insertion phase of colonoscopy
76083552|NCT01801865|Device|GE OPTIMA MR430s with HDX/GE Electronics|
76083553|NCT01590238|Biological|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
76083554|NCT00980343|Drug|vismodegib|Given orally
75472116|NCT01954563|Biological|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
75472117|NCT01954589|Drug|ACT-462206 5 mg|
75472118|NCT01954589|Drug|ACT-462206 25 mg|
75472119|NCT01954589|Drug|ACT-462206 100mg|
75472120|NCT01954589|Drug|ACT-462206 200mg|
75472121|NCT01954589|Drug|ACT-462206 400mg|
75472122|NCT01954589|Drug|ACT-462206 1000 mg|
75472123|NCT01954589|Drug|ACT-462206 1500mg|
75472124|NCT01954589|Drug|Almorexant 400mg|
76083555|NCT00980343|Procedure|therapeutic conventional surgery|undergo surgery
76083556|NCT00980343|Other|laboratory biomarker analysis|correlative studies
75472125|NCT01954589|Drug|Placebo|
75643512|NCT05261217|Device|The motion 3D II appliance|The motion 3D II appliance treating class II malocclusion
76025396|NCT05080777|Behavioral|Caregiving During Crisis (Educational Program)|The attention control group will receive the self-guided Caregiving During Crisis program. Caregiving During Crisis is a fully online, asynchronous, professionally designed continuing education course aimed at developing the competency of informal caregivers of community-dwelling persons living with dementia to ensure the safety of that person and themselves during this time of the COVID-19 pandemic. The course, readily accessible by home computer or smartphone, describes methods of home infection control and prevention to create a Safe Home space, strategies for safely leaving and re-entering the home (e.g., to shop), additional strategies for safely allowing service personnel (e.g., home health aides or electricians) and select family members to enter the Safe Home space, and risk management strategies to frame decisions when/if COVID restrictions are relaxed or revoked.
75643513|NCT00636909|Drug|Cyclophosphamide|preparative cytoreduction
75643514|NCT00636909|Drug|fludarabine|preparative cytoreduction
76083557|NCT00980343|Other|pharmacological study|correlative studies
75791676|NCT03942276|Other|High intensity interval training|Consists of 60 seconds sets of high-intensity exercises, characterized by heart rate> 85% of maximal heart rate (HRmax), obtained through the formula (220-age), or by the Rated Perceived Exertion between 7 and 8 on the Borg scale, which ranges from 0 to 10. Of the 60 seconds of high intensity exercise, 30 seconds will be to get up and down a 16 cm step and 30 seconds of squats, with knee flexion greater than 90º, both at the highest possible speed. The recovery between sets is light walk for 60 seconds. If the volunteers do not reach the proposed intensity zone, they will be instructed to increase the number of squats and step ascents and descents.
76083558|NCT01801475|Drug|Ondansetron|Pregnant & non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
75334206|NCT05476302|Other|Cognitive digital treatment|The remote cognitive-rehabilitation treatment was based on Parkinson's adapted cognitive stimulation therapy (CST). Fourteen twice-weekly sessions were planned, followed by one session per week for a duration of six months for maintenance therapy. The treatment took place in groups of 4 patients in remote mode through the Microsoft-Teams platform. All subjects maintained the prescribed drug therapy and regular physiotherapy activity during the intervention.
75472126|NCT01954602|Procedure|Guide-wire cannulation|Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
75472127|NCT01954602|Procedure|Sphincterotome assisted guide-wire cannulation|Sphincterotome is inserted initially a few millimeters through the papillary orifice
75643515|NCT00636909|Drug|cyclosporine|immunosuppressive therapy
75643516|NCT00636909|Drug|methotrexate|immunosuppressive therapy
75643517|NCT00636909|Biological|G-CSF|foster engraftment
75643518|NCT05260983|Behavioral|Diabetes Prevention Education and Acceptance and Commitment Therapy|A brief diabetes prevention education and acceptance and commitment therapy engagement facilitation intervention. Acceptance and Commitment Therapy-informed materials (i.e. video, workbook, and activities) will retain facts about the condition, but will modify health messaging to clarify common inaccurate illness perceptions, reduce body size discrimination, and encourage psychological flexibility through framing illness perceptions, controllability awareness (i.e. ability to distinguish modifiable from unmodifiable components), non-judgmental awareness of what is occurring, willingness to allow experiences to occur, and the ability to step back from cognitions, acting according to personal values.
75791677|NCT03942276|Other|Moderate intensity continuous training|Consist of performing a 30 minute walk at 50% of reserve heart rate (HRR), calculated by (HRmax - HRmax) x% + HRmax. HRmax being obtained by means of the formula (220 - age).
75791678|NCT03942276|Other|Control|Consist of performing no exercise training.
75791679|NCT01207674|Other|Summons of patients and filling questionnaire|The study is conducted at the same time by 7 French specialised centres. The recruitment period is comprised between April 2009 and September 2011.For the first stage of the study, an initial evaluation will be performed at the time of recruitment. It consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and half hour, and focused mainly on gambling trajectory and severity, and on psychiatric and addictive comorbidities. The evaluation is completed by a set of self-administered questionnaires focused on cognitive distortions, temperament and character, ADHD, etc.For the second stage of the study, the cohort will be re-evaluated each year, based on the same questionnaires that for initial evaluation. Each participant will be followed-up during 5 years. The study will thus end up in September 2016.
75791680|NCT01328106|Drug|GSK1120212|Repeating oral dose
75791681|NCT01209468|Device|monobloc oral appliance|one piece oral appliance
75791682|NCT01209468|Device|twinblock oral appliance|two-piece oral appliance
75791683|NCT01109862|Procedure|Total hip arthroplasty|All cemented THA
75472128|NCT01954615|Drug|5 mg ACT-281959 prodrug formulation I (Group A)|
75643519|NCT05260983|Behavioral|Diabetes Prevention Education Only|A brief standard diabetes prevention education engagement facilitation intervention modeled from the Center for Disease Control and Preventions's National Diabetes Prevention Program.
75643520|NCT02697669|Other|18F-FDG PET|Imaging
75643521|NCT02697201|Drug|Intralipid|0.55 ml/kg/h
75643522|NCT02697201|Drug|Saline|0.55 ml/kg/h for
75334207|NCT00634972|Drug|ACULAR|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
75472129|NCT01954615|Drug|20 mg ACT-281959 prodrug formulation I (Group B)|
75472130|NCT01954615|Drug|ACT-281959 prodrug formulation I (Groups C to G doses to be defined)|
76083559|NCT01536184|Behavioral|Circle of Security (COS)|COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
76083560|NCT03063021|Drug|N-Acetyl Cysteine (NAC)|Oral tablets of N-acetyl-cysteine
76083561|NCT01536496|Biological|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
76083562|NCT01536496|Biological|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
76083563|NCT02337933|Drug|Ursolic acid|Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
75643523|NCT02697045|Drug|Aripiprazole 400mg LAI|Aripiprazole 400mg, IM, Once a month
75791684|NCT01109862|Procedure|Hemiarthroplasty|Cemented bipolar HAP
76083564|NCT02337933|Drug|Placebo|Calcined magnesia capsules of 150 mg, once a day before breakfast
76083565|NCT03062943|Drug|Nintedanib|
76083566|NCT01536886|Drug|LEO 90100|
75791685|NCT04321460|Drug|LRG-002|Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
76083567|NCT01536886|Drug|Betamethasone plus calcipotriol|
76083568|NCT01536886|Drug|Ointment vehicle|
76083569|NCT01536886|Drug|LEO 90100 vehicle|
75334208|NCT00634972|Drug|REFRESH TEARS|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
75334209|NCT00634972|Drug|placebo|
75334210|NCT02553330|Drug|Placebo Cream|
75643524|NCT02697357|Behavioral|Psychosocial Instruments|
75643525|NCT02697357|Behavioral|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|
75643526|NCT05661747|Device|Vivos Grow/Vivos Way Device|Children already using the device will be monitored to determined whether it improves symptoms of SDB
75643527|NCT01007942|Drug|everolimus|Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
75643528|NCT01007942|Drug|Placebo|Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
75643529|NCT01007942|Drug|vinorelbine|intravenous vinorelbine (25 mg/m2 weekly)
75643530|NCT01007942|Drug|trastuzumab|intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
75791686|NCT04321460|Drug|Placebo|Capsules containing placebo
75791687|NCT03943212|Other|Blood Flow Rate Reduction|Hemodialysis blood flow rate will be reduced by 100 mL/min, or to a minimum of 300 mL/min, whichever is higher. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
75928135|NCT05151042|Procedure|Computer Guided orthognathic surgery using occlusal wafers|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position.~dental casts will be scanned dental casts are superimposed to the CT cuts into the virtual software environment to produce final wafer CAD/CAM repositioning guide. the generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment & tooth bearing segment.~Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts. Removal of guide, then BSSO is performed.~The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
76083570|NCT01822925|Drug|DA-9801 300mg|300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
76083571|NCT01822925|Drug|DA-9801 600mg|600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
75334211|NCT02553330|Drug|Ruxolitinib Phosphate Cream|
75643531|NCT02691429|Other|Acai dye 10%|dye to be used during chromovitrectomy in humans
75791688|NCT03943212|Other|Control|No changes will be made to the dialysis prescription. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
75791689|NCT01209546|Other|control group|In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
75791690|NCT01209546|Other|Flutter group|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
76083572|NCT01822925|Drug|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
76083573|NCT01822925|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
76083574|NCT02247310|Drug|Interferon beta-1b (Betaferon®, BAY 86-5046)|Patients will be treated with Betaferon
76083575|NCT02247310|Device|BETACONNECT|Auto-injector device to support the injection of Betaferon
76083576|NCT03041415|Behavioral|ALED Alone Physical Activity Program|• 12-week class focused on teaching self-regulatory skills to increase regular PA
76083577|NCT03041415|Behavioral|ALED + Our Voice PA Program|"12-week class focused on teaching self-regulatory skills to increase regular PA~Neighborhood assessment, consensus-building, & advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity"
76083578|NCT00989001|Drug|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
76083579|NCT00989001|Drug|Placebo|Injection
76083580|NCT03061539|Drug|Nivolumab & Ipilimumab|"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"
76083581|NCT01590550|Procedure|Use of citrate based dialysate|Use of heparin free citrate based dialysate
75334212|NCT00529282|Drug|Ceftobiprole Medocaril|500 mg every 8 hours
75334213|NCT00529282|Drug|Cefepime with or without vancomycin|120-minute infusion [250 mL]
75334214|NCT00623974|Drug|Teriparatide (Forteo)|Subcutaneous Injection Every 12 Hours for 7 Days
75334215|NCT00623974|Drug|Calcium|1000 milligrams by mouth (PO) Every 12 Hours
75334216|NCT00623974|Drug|Calcitriol|0.25 micrograms PO Every 12 Hours
75334217|NCT02550288|Drug|Ezetimibe 10 mg|
75334218|NCT02550288|Drug|Atorvastatin 10 mg|
75334219|NCT02550288|Drug|Placebo for Ezetimibe 10 mg tablet|
75472131|NCT01954615|Drug|ACT-281959 prodrug formulation II (Group G dose to be defined)|
75334220|NCT02550288|Drug|Placebo for Atorvastatin 10 mg capsule|
75334221|NCT02550288|Behavioral|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
75334222|NCT01954576|Device|NovoTTF-100A|
75334223|NCT01954576|Procedure|Quality-of-life assessment|
75334224|NCT01954576|Genetic|Laboratory biomarker analysis|
75643532|NCT01023035|Drug|Boceprevir|800 mg given three times a day (TID), orally (PO)
75643533|NCT01023035|Drug|Peginterferon alfa-2b (PEG2b)|1.5 µg/kg/week given subcutaneously (SC)
75643534|NCT01023035|Drug|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
75643535|NCT01023035|Drug|Erythropoietin|Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
75643536|NCT04300361|Genetic|Sequencing of DPYD gene|The DPYD gene of non-Western patients will be sequenced to identify DPYD variants that are possibly associated with an increased risk of developing severe fluoropyrimidine-related toxicity.
75643537|NCT01028651|Drug|Treprostinil|"Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min."
75643538|NCT00627731|Drug|methylprednisolone sodium succinate (mPSL)|mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
75643539|NCT00627731|Drug|prednisolone (PSL)|PSL 40 mg per day for 10 days
75643540|NCT01028027|Drug|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
75643541|NCT01028027|Drug|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
75643542|NCT01007552|Drug|Gemcitabine, Capecitabine and Bevacizumab|Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
75643543|NCT02870192|Procedure|Laparoscopic ventral mesh rectopexy|Laparoscopic opening of the Daglous pouch, dissection till reach the levator ani muscle, mesh implementation and fixation, closure of the daglous. The mesh implemented may be synthetic or biological mesh.
75643544|NCT04452890|Diagnostic Test|Sonourethrography|Ultrasound of the urethra.
75928136|NCT03131778|Procedure|Liver resection|liver resections for colorectal liver metastases
75928137|NCT03486054|Device|INTERCEPT|The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD
75928138|NCT03486054|Device|Standard of Care|The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
75928139|NCT02205021|Other|No intervention|
75928140|NCT05153694|Procedure|Cystectomy|Removal of the urinary bladder
76025397|NCT05132309|Combination Product|enzyme replacement therapy|Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency
76025398|NCT04149691|Drug|CPL304110|CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
76025399|NCT01674725|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
76025400|NCT01674725|Drug|Ribavirin|Tablet
76025401|NCT03164083|Biological|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
75334225|NCT00610558|Device|Arm 1: Juvenile Myoclonic Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
75334226|NCT00610558|Device|Arm 2: Frontal Lobe Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
75334227|NCT00610558|Device|Arm 3: Normal Controls|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
75334228|NCT00380146|Drug|sulfadoxine-pyrimethamine|
75334229|NCT05476146|Procedure|Rerouting of the track in high anal fitula|Treatment of high anal fistula by rerouting
75334230|NCT03985176|Device|ROTEM|ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH
75472132|NCT01954615|Drug|ACT-246475 (Group G dose to be defined)|
75472133|NCT01954615|Drug|Placebo (Groups A to F)|
75472134|NCT01954641|Other|ACCURE Navigator|"The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the teachback method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions."
75791691|NCT01209546|Other|PEP group|Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
75791692|NCT01209546|Other|Group Sham|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
75791693|NCT03122548|Biological|CRS-207|Administered by IV infusion over 1 hour.
75791694|NCT03122548|Biological|Pembrolizumab|Administered by IV infusion over 30 minutes.
76083582|NCT05609253|Drug|Itraconazole in capsule form|Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
76083583|NCT05609253|Drug|Itraconazole in solution form|Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
76083584|NCT01591018|Procedure|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
75791695|NCT03942510|Other|eccentric exercise with blood flow restriction|High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
75791696|NCT03749642|Drug|trazodone/gabapentin 2.5/25 mg|The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
75791697|NCT03749642|Drug|trazodone/gabapentin 5/50 mg|The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
75791698|NCT03749642|Drug|trazodone/gabapentin 10/100|The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
75791699|NCT03749642|Drug|Gabapentin|"The total daily doses administered will be:~600 mg from day 0 to day 6 (±1)~900 mg from day 7 (±1) to day 13 (±1)~1200 mg from day 14 (±1) to day 20 (±1)~1800 mg from day 21 (±1) to day 56 (±2)"
76083585|NCT01591018|Procedure|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
76083586|NCT05609097|Other|PRIME|PRIME is a a 'hybrid' aerobic-resistance (cardio and weights) program designed to target all major muscle groups and address the muscle limitations responsible for reduced fitness in the elderly. This occurs by minimizing the central limitations to more traditional exercise by delivering an ideal exercise stimulus to muscles in a way in which the heart is not a limiting factor. Each exercise involves contractions of specific isolated muscle groups with a moderate load, defined as 40%-50% of their maximal voluntary capacity.
76083587|NCT05609097|Other|COMBO|"COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range."
76083588|NCT01801007|Device|Flow Re-Direction Endoluminal Device (FRED)|
75334231|NCT03985176|Procedure|EEG|Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH
75334232|NCT03985176|Procedure|bilateral compression ultrasound of the lower extremity veins|to exclude asymptomatic deep venous thrombosis once over days 3 to 7
75472135|NCT01954641|Other|Usual Care by Cancer Center Care Team|The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
75334233|NCT00379366|Device|External ionizing radiations|14 Gy in one time
75334234|NCT00500890|Drug|Carboplatin|350 mg/m^2 by vein, Over 2 Hours x 2 Days
75334235|NCT00500890|Drug|Cyclophosphamide|1 g/m^2 by vein, Over 1 Hour x 2 Days
75334236|NCT00500890|Drug|Etoposide|100 mg/m^2 by vein, Over 1 Hour x 5 Days
75334237|NCT00500890|Drug|Vincristine|1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5
75334238|NCT00500890|Radiation|Radiation Therapy|Radiation treatment over a period of about 6 weeks.
75472136|NCT01954654|Device|Custom-made compression sleeve and -gauntlet|Device: Compression garments worn for a minimum of six hours per day
75472137|NCT01954654|Other|Educational information, recommendation and instruction|Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
75643545|NCT02869880|Other|Enhanced Pre-Consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
75643546|NCT02869880|Other|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial
75643547|NCT04204694|Other|3-time blood sampling for septic shock patients|15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
75643548|NCT04204694|Other|Only one blood sampling for controls patients|15 mL blood are sampled from a blood donation
75643549|NCT01007396|Other|1-step tuberculin skin test (TST) and blood sampling|In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
75643550|NCT02869958|Other|Digital action plan for asthma exacerbations + Written action plan|Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
75643551|NCT02869958|Other|Written action plan|
75643552|NCT02870036|Drug|Simmitecan|
75791700|NCT03749642|Drug|Placebo oral capsule|Two capsules, three times a day, for 8 weeks.
75791701|NCT01359124|Behavioral|Exercise Cycle|Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
75791702|NCT01359124|Behavioral|Land-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
75791703|NCT01359124|Behavioral|Water-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
76083589|NCT05609019|Drug|SYHX2005|Tablets. Take orally.
75791704|NCT01108614|Behavioral|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
75791705|NCT03751358|Procedure|Unilateral Erector spinae plane block|Magnetic résonance imaging
75334239|NCT05469672|Other|Low-level laser therapy|For LLLT, laser treatment will be applied using gallium-aluminum-arsenide (GaAIAs, infrared laser) diode laser (Chattanooga, Mexico, USA) at a wavelength of 904 nm, output power of 240 Mw and a frequency of 5000 Hz. The spot area is about 0.5 cm2. A total of 9 points will irradiated along the glenohumeral joint, with a power density of 3 j/cm2 at each point. The application time was 50 seconds to each point. The total dose per shoulder was 27 J per treatment. Three sessions of LILT therapy per week will administered over a three-week period.
75472138|NCT01954680|Behavioral|COGFLEX-skill building levels|"COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).~In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.~All children will play COGFLEX twice per week for 8-weeks.~This same approach has shown great success in many psychiatric disorders including schizophrenia.~This is the first such study in children/adolescents with bipolar disorder."
75472139|NCT01954680|Behavioral|COGFLEX-control condition|"In the R33, the control condition will be the same COGFLEX game--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks."
75472140|NCT01954693|Drug|Placebo|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
75643553|NCT02870036|Drug|5-fluorouracil and Leucovorin Calcium|
76083590|NCT04120545|Device|Microcurrents|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7, L3 or S1.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
76083591|NCT04120545|Device|Placebo Microcurrents|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
76083592|NCT01822691|Drug|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
76083593|NCT01822535|Drug|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
75472141|NCT01954693|Drug|Everolimus (RAD001)|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily
75472142|NCT01954706|Other|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
75643554|NCT02870036|Drug|Thalidomide|
75472143|NCT01954706|Other|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
75472144|NCT01954719|Procedure|cervix dilated after surgery|The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
75472145|NCT01954719|Procedure|control group|surgeon not dilated cervix after surgery
75643555|NCT04296422|Drug|NSAIDs or oral contraceptives treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
76083594|NCT01537666|Drug|AeroVanc|Vancomycin hydrochloride dry powder for inhalation
76083595|NCT01537666|Drug|IV vancomycin hydrochloride|Vancomycin hydrochloride solution for intravenous administration
76083596|NCT01537900|Drug|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
75472146|NCT01954732|Drug|metformin hydrochloride|Given PO
75472147|NCT01954732|Other|pharmacological study|Correlative studies
75472148|NCT01954758|Other|personalized Embryo Transfer (pET)|
75472149|NCT01954758|Other|Frozen Embryo Transfer (FET)|
75472150|NCT01954758|Other|Fresh Embryo Transfer (ET)|
75472151|NCT01954784|Drug|fludarabine phosphate|
75472152|NCT01954784|Radiation|total-body irradiation|Undergo TBI
75472153|NCT01954784|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic SCT
75643556|NCT04296422|Device|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
75643557|NCT04296422|Device|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner
75643558|NCT04296656|Behavioral|The 5 S's infant calming intervention|5 simple steps to calm a fussy or crying infant. Steps include swaddling, side position, sound (white noise), swing and suck.
75791706|NCT05193292|Drug|Camrelizumab|200mg, iv, 21d for a treatment cycle
75791707|NCT05193292|Drug|Trastuzumab|8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle
75791708|NCT05193292|Drug|XELOX regimen|Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
75791709|NCT05193292|Drug|mFOLFOX6 regimen|Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)*2d, civ, 46h; q2w
75791710|NCT05193292|Drug|FOLFIRI regimen|Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)*2d, civ, 46h; q2w
75643559|NCT04278014|Procedure|ultrasound-guided continuous sciatic block with longitudinal approach|ultrasound-guided continuous sciatic block with longitudinal approach
75791711|NCT05193292|Drug|mXELIRI regimen|Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
75928141|NCT02216643|Procedure|Thrombectomy|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire FR® and/or thromboaspiration with Penumbra System® versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
75334240|NCT05469672|Other|High-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the shoulder area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first three sessions consisted of a 75-second intermittent phase analgesic effect at 8 W and 10 J/cm2 for a total energy of 100 J. The following six sessions consisted of a continuous 30-second bio stimulating effect with a dosage of 12 W 120 J/cm2. Over the course of three weeks, nine treatment sessions of HILT will be given.
75928142|NCT02216643|Device|Stentriever Solitaire FR® or Penumbra System®|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
75472154|NCT01954784|Drug|cyclosporine|Given PO
75472155|NCT01954784|Drug|mycophenolate mofetil|Given PO
75643560|NCT04296500|Other|Decision tree modeling|"A decision tree analysis was employed to explore the process of decision-making on types of pattern based on the existence or nonexistence of a symptom. At the end of tree presented is the proportion of patients who are categorised into each pattern.~In this study, the classification was performed by applying the classification and regression tree (CART) algorithm using Scikit-learn package of Python, which performs a division using the Gini coefficient or the decrement of dispersion. The Gini coefficient is one of the tools for measuring entropy or diversity in each node and it measures the decrement by comparing the information entropy before and after separation. To avoid overfitting, the maximum number of leaf nodes was limited to four and the pruning method which complied with the principle of minimum description length was applied."
75643561|NCT04293848|Other|Vibroacoustic therapy|listening to low-frequency sound of 40 Hz with biorhythmic sequential modulation combined to music
75643562|NCT04293848|Other|Only music (no vibrations)|listening to music, no vibrations
75791712|NCT05193292|Drug|mIRIS regimen|Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w
75928143|NCT04574154|Procedure|FIB|FIB with ultrasound: Ropivacaine 0.5% 40 ml
75928144|NCT04574154|Procedure|ESPB|ESPB (L4) with ultrasound: Ropivacaine 0.5% 40 ml
75334241|NCT00000736|Drug|Zidovudine|
75334242|NCT05480748|Device|monitoring|ORI warning time, SpO2 warning time, added time were recorded.
75334243|NCT00379444|Behavioral|Standard intervention (counseling + self-help written materials)|counseling
75334244|NCT00379444|Behavioral|Enhanced Intervention (same as standard treatment plus 10-15 min of counseling and a culturally tailored video)|counseling
75472156|NCT01954784|Drug|bortezomib|Given SC
75472157|NCT01954784|Drug|lenalidomide|Given PO
75472158|NCT01954784|Other|laboratory biomarker analysis|Correlative studies
75472159|NCT01954810|Biological|Japanese encephalitis chimeric vaccine (JECV)|Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
75472160|NCT01954823|Device|e-diary|"The e-diary can collect data on:~Medical data: information on diseases, treatments and attending physicians~Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data~Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails~Reports: textual and graphical reports of the data in the diary can be created"
75472161|NCT01954836|Behavioral|initial fasting|modified fasting with daily caloric intake of <400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
75643563|NCT00998738|Drug|Calcium Gluconate|Given IV
75791713|NCT03943056|Drug|BIIB091|Administered as specified in the treatment arm.
75791714|NCT03943056|Drug|Placebo|Administered as specified in the treatment arm.
75791715|NCT05193214|Drug|Recombinant anti-PD-1 humanized monoclonal antibody injection|Each subject received 609A 200 mg intravenous infusion, once every 3 weeks (Q3W), until disease progression, intolerable toxicity, death, informed withdrawal, early withdrawal from the study, loss to follow-up, or the end of the study, whichever occurs first Whichever prevails.
75791716|NCT01367392|Device|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
75798873|NCT01587534|Drug|Norzyme|Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
75643564|NCT00998738|Drug|Magnesium Sulfate|Given IV
75643565|NCT00998738|Other|Placebo|Given IV
75643566|NCT00998738|Other|Quality-of-Life Assessment|Ancillary studies
75643567|NCT00998738|Other|Questionnaire Administration|Ancillary studies
75643568|NCT00998738|Drug|Ixabepilone|Given IV
75643569|NCT00997334|Drug|Erlotinib|
75643570|NCT04293926|Other|Exercise|Resistance exercise program for 8 weeks, 3 times a week, with a 60 min session duration.
75643571|NCT04293770|Device|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
75928145|NCT04574154|Procedure|spinal anesthesia|bupivacaine 0,5% 2.2 ml
75928146|NCT03481140|Device|TissuGlu Surgical Adhesive|lysine-derived urethane adhesive
76083597|NCT03005938|Procedure|Spinal manipulation|"Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position."
76083598|NCT03005938|Procedure|Imitation of the spinal manipulation|Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
75643572|NCT04295018|Drug|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
75791717|NCT02529774|Drug|Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1"
75643573|NCT04295096|Device|Peripheral blood mononuclear cell apheresis|Peripheral blood mono-nuclear cell donation for tumor immunotherapy study of Universal CAR-T cells
75791718|NCT02529774|Drug|Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1"
75791719|NCT04459598|Drug|Efavirenz|Single oral dose, 600-mg tablet
75791720|NCT04459598|Drug|Quizartinib|Single oral dose, 60 mg (2 x 30 mg) tablets
75791721|NCT01207830|Device|Endo Bypass System|Subject is implanted with the device for up to 3 years.
75791722|NCT05167006|Other|routine physical therapy|Each participant will receive his/her arms training therapy. Only one participant per therapist, with or without caregiver observation. Consisting of many purposeful kinesthetic activities such as Graded pinch exercise, Bimanual placing cone, Arm bicycling, Shoulder curved arch, Double-curved arch, Block-stacking, Skateboard-supported arm sliding exercises on a tabletop, Putty kneading, Pegboard exercise, Picking up a ball and putting it into a basket, Plastic cone stacking. Therapists can offer passive, active-assistive, or active training, as deemed appropriate to the patient's ability
75472162|NCT01954836|Behavioral|Secondary fasting|modified fasting with daily caloric intake of <400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
75472163|NCT01954849|Dietary Supplement|Probiotic formulation|
75643574|NCT04281368|Other|Analysis of IUFD|Each team member in the audit group had access to all the medical patient charts from the hospitals and also the majority of the charts from the antenatal care clinics (ANC). Each team member independently assessed each case regarding causes of death, preventable/non-preventable deaths, the level of delay if there was any and the standard of healthcare provided to the patients with stillbirth, the postmortem examination of infant and mother and if there were any recommendations given for the next pregnancy
75643575|NCT04294940|Other|Wear an actigraph|"Between visits, tha patient will have to:~Follow the hygiene-dietetic recommendations given by their centre.~Wear the actigraph night and day Patients"
75791723|NCT05167006|Other|Perfetti's method|. Only one participant per therapist, with or without caregiver observation. Participant will be blindfolded during the exercises and asked to focus on sensing the position of the limb. The therapist will passively move the shoulder, elbow, wrist, or fing
75791724|NCT01114230|Drug|AGS-16M8F|IV
75791725|NCT01367470|Dietary Supplement|VSL#3 probiotic preparation|VSL#3 is a mixture of 8 different strains of lactic acid bacteria and bifidobacteria at a concentration of 900 billion bacteria per sachet. The suggested dosage is 1 to 2 sachets per day.
75791726|NCT01367470|Other|Placebo VSL#3|Placebo VSL#3 is a base of corn starch containing no active ingredient.
75928147|NCT02217813|Drug|Tafamidis|20 mg of current commercial formulation
75928148|NCT02217813|Drug|Tafamidis|20 mg of new formulation
75928149|NCT05232903|Biological|SVF therapy group|The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.
75928150|NCT03484416|Drug|Calcium Carbonate 1500 Mg with Vitamin D|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
75928151|NCT02257827|Radiation|IMRT|"The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy."
75928152|NCT02219295|Dietary Supplement|sweet block|oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin
75928153|NCT02219295|Dietary Supplement|bitter block|oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
75928154|NCT02219295|Dietary Supplement|umami-block|oral application of umami substances as glutamate with and without IMP, collection of blood samples as above
75928155|NCT02219295|Other|gastroscopy|gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
75643576|NCT04294940|Other|Use the mobile application CardiCare™ and wear an actigraph|"Between visits, tha patient will have to:~Follow the hygiene-dietetic recommendations given by their centre.~Wear the actigraph night and day Patients~wear their smartphone everyday and use the mobile application CardiCare™"
75791727|NCT03942354|Drug|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
75334245|NCT00379522|Drug|Vasopressin|10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
75334246|NCT00379522|Drug|Saline placebo|Placebo for arginine vasopressin
75791728|NCT03942354|Drug|Pretomanid|Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
75472164|NCT01954862|Other|Air Insufflation method.|Air Insufflation method.
75472165|NCT01954862|Other|CO2 insufflation|CO2 insufflation.
75643577|NCT04296578|Drug|Abiraterone Acetate|Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.
75643578|NCT04296578|Drug|Sodium Selenite|11 mg tablets
75643579|NCT04296578|Drug|Prednisone|SOC prednisone 5 mg PO twice daily
75791729|NCT03942354|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
75791730|NCT03942354|Drug|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
75791731|NCT03942354|Drug|Clofazimine|Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
75791732|NCT03942354|Drug|Directly observed therapy (DOT)|Standard therapy
75791733|NCT05165992|Drug|Nebulized Fentanyl|Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
75791734|NCT01359202|Biological|rfVIIa|80ug/kg IV bolus
75791735|NCT01359202|Other|Standard saline solution|Saline
75791736|NCT03942432|Other|Oral Glucose Tolerance Test (OGTT)|Blood samples at T0, T30min, T120min
75791737|NCT03942432|Other|Clinical exam|weight, length, waist measurement, cardiac frequency, blood pressure
75928156|NCT05153616|Diagnostic Test|Polysomnography|Full night attended polysomnography to diagnose periodic limb movements
75928157|NCT03484338|Behavioral|Accelerated Resolution Therapy|ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
75928158|NCT02219529|Device|MCE|
75928159|NCT02219529|Device|Standard gastroscopy|
76025402|NCT03164083|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
76025403|NCT03164395|Procedure|Internal Cardioversion|Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
76025404|NCT03164395|Procedure|External Cardioversion|External Cardioversion per institutional protocol
76025405|NCT05404061|Other|Gut hormones|"Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~0.9% saline,~GLP-1"
76025406|NCT03161041|Procedure|Cytoreductive surgery combined with HIPEC|Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
76025407|NCT03161041|Drug|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
75334247|NCT00437398|Biological|Islet Transplant|Purified pancreatic islets
75334248|NCT03496896|Other|TARGET|The pre-discharge component includes mainly patient information, medication reconciliation, patient education, planning of a first post-discharge primary care physician visit with a timely discharge summary sent to the primary care physician. Two follow-up phone calls are made by a nurse, at D3 and D14, and include the assessment of the general health condition, the verification of the follow-up care plan, a reinforcement of the patient education, and review with the patient of the medication list with assessment of potential adverse drug events.
75472166|NCT01954862|Other|Water Immersion/CO2|Water Immersion during insertion, CO2 insufflation during withdrawal.
75472167|NCT01954862|Other|Water Exchange/CO2|Water Exchange during insertion, CO2 insufflation during withdrawal.
75472168|NCT01954862|Other|Water Immersion/AI|Water Immersion during insertion, AI insufflation during withdrawal.
75472169|NCT01954862|Other|Water Exchange/AI|Water Exchange during insertion, AI insufflation during withdrawal.
75472170|NCT01954888|Procedure|Blind technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
75472171|NCT01954888|Procedure|Ultrasound-guided technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
75472172|NCT01954901|Device|Hyperbaric oxygen therapy|
76025408|NCT05123495|Behavioral|Device Briefing Tool|A 4-item supplement to the WHO Surgical Safety Checklist designed to improve teamwork and communication around new/complex surgical devices
76025409|NCT05123495|Behavioral|Surgical Safety Checklist|Reimplementation of the WHO Surgical Safety Checklist to improve adherence and utility of the checklist
76025410|NCT04139317|Drug|Capmatinib|Oral tablet
75334249|NCT03275064|Biological|LNA043|LNA043 intra-articular injection
75928160|NCT04459494|Procedure|Flapless implant surgery.|"Local anesthesia will be applied to the patients in the test group, and then the implant socket will be prepared without removing the flap and a dental implant will be placed.~Bite-wing film will be taken to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
75643580|NCT00996944|Drug|Ropinirole immediate release (IR)|"Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting much improved or very much improved in the CGI-I) without safety/tolerability problem."
75928161|NCT04459494|Procedure|Conventional implant surgery.|"Local anesthesia will be applied to the patients in the control group, and then the implant socket will be prepared after reflecting the flap and a dental implant will be placed.~Patients in the control group will receive a full thickness flap elevation and an implant socket will be prepared afterwards the implant will be placed and then the flap will be closed with 4-0 silk suture.~Bite-wing film will be taken from both groups to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
75928162|NCT02205255|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
75643581|NCT00996944|Drug|Placebo|Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
75643582|NCT04296266|Drug|Alda-341|Dietary supplement d-limonene orally administered as a drug.
75643583|NCT02869490|Other|Data collection|
75643584|NCT02869724|Other|Weekly divided delivery|
75643585|NCT02869724|Other|Monthly divided delivery|
75643586|NCT01002482|Device|CGAO-based Glucose Control|"Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.~CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.~The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control."
75643587|NCT01002482|Device|Standard-Care Glucose Control|"Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl)."
75928163|NCT02205255|Drug|Placebo|
75928164|NCT02220153|Biological|UCB7665 Intravenous 1|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
75928165|NCT02220153|Biological|UCB7665 Intravenous 2|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
75928166|NCT02220153|Biological|UCB7665 Intravenous 3|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
75928167|NCT02220153|Biological|UCB7665 Intravenous 4|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
75928168|NCT02220153|Biological|UCB7665 Intravenous 5|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
76083599|NCT01591408|Device|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
75334250|NCT03275064|Other|Placebo|Placebo intra-articular injection
75334251|NCT00593320|Radiation|Stereotactic Radiosurgery|
75334252|NCT00421954|Drug|Ziprasidone|subjects will use ziprasidone
75334253|NCT00392860|Device|Natural-Fit|Ergonomic handrim for wheelchairs
75334254|NCT00392860|Device|PalmRim|Ergonomic handrim for wheelchair
75643588|NCT01027949|Drug|Oral Treprostinil|Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
75798874|NCT03860532|Drug|HMPL-011 tablets|Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
75798875|NCT03860532|Drug|HMPL-011 capsules|Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
75798876|NCT01181310|Drug|A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.
75798877|NCT01181310|Drug|B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.
75798878|NCT01181310|Drug|C: MK-3134 25 mg + Scopolamine 0.5 mg|A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.
75334255|NCT00392860|Device|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
75334256|NCT01662336|Drug|Lopinavir / ritonavir|Prescribed according to the product monograph and physician's discretion.
75472173|NCT01954901|Device|Hyperbaric room air|
75643589|NCT01038323|Other|CBT and milnacipran|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
75472174|NCT01954914|Drug|Plerixafor|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
75643590|NCT01038323|Behavioral|CBT with a placebo|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week starter pack. Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
75791738|NCT03942432|Biological|Blood sample|Iron and cardiac markers Serum iron, serum transferrin, transferrin saturation, serum ferritin, AST, ALT, GGT, ALP, PT, Cell Blood Count, ceruloplasminemia , hyaluronic acid, cholesterolemia, HDL, LDL, triglyceridemia, hba1c
75928169|NCT02220153|Biological|UCB7665 Subcutaneous 1|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: subcutaneous infusion"
75928170|NCT02220153|Biological|UCB7665 Subcutaneous 2|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: subcutaneous infusion"
75791739|NCT03942432|Device|MRI|3 Tesla abdominal MRI
75928171|NCT02220153|Biological|Intravenous Placebo|"Active substance: Placebo~Pharmaceutical form: solution~Concentration: 0.9 % saline~Route of Administration: intravenous infusion"
75928172|NCT02220153|Biological|Subcutaneous Placebo|"Active substance: Placebo~Pharmaceutical form: solution~Concentration: 0.9 % saline~Route of Administration: subcutaneous infusion"
75928173|NCT04911582|Dietary Supplement|Cafestol 12 mg|Capsule with 12 mg cafestol
75472175|NCT01954940|Device|Whole Body Vibration Therapy|
75791740|NCT03942432|Device|Bioimpedance|Measurement of body composition
75791741|NCT03942432|Behavioral|Questionnaires|Quality of life, physical activity, alcohol consumption and eating habits
75791742|NCT01367548|Drug|IV Methylnaltrexone (MNTX)|
75791743|NCT01367548|Drug|Placebo|
75791744|NCT01110018|Drug|GSK573719 (SOLUTION)|20μg /mL solution for IV and Oral dosing
75791745|NCT01110018|Drug|GSK573719 (INHALATION POWDER)|500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
75791746|NCT01367626|Drug|letrozole|2.5 mg tablet
75928174|NCT04911582|Dietary Supplement|Placebo|Placebo capsule without cafestol
75928175|NCT04911582|Dietary Supplement|Cafestol 6 mg|Capsule with 6 mg cafestol
75928176|NCT03535389|Diagnostic Test|Knee 4DCT|Dynamic knee 4DCT
75928177|NCT03476772|Drug|Nalbuphine|Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
76025411|NCT04139317|Biological|Pembrolizumab|IV infusion
76025412|NCT05120219|Drug|FDC tablet|single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
76025413|NCT05120219|Drug|FDC tablet|single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
76025414|NCT05120219|Drug|FDC tablet|single and multiple doses of HR20033 FDC tablet
76025415|NCT05119517|Other|Osteopathic manipulative medicine pedal pump|In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
76025416|NCT05119049|Other|Exercise guideline|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
76025417|NCT05113355|Drug|Chidamide|30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
76025418|NCT05113355|Drug|Sintilimab|200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
76025419|NCT03163693|Drug|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
76025420|NCT03163693|Other|normal saline|receive equal volume of normal saline
76025421|NCT05054543|Drug|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
76025422|NCT05054543|Drug|Placebo|0.9% Sodium Chloride
76025423|NCT05044507|Device|BQ 2.0|frequency and intensity parameters will be set to zero so that no stimulation is delivered
76025424|NCT05044507|Device|BQ 2.0|The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
76025425|NCT05125757|Other|lifestyle modification|for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
76025426|NCT05125757|Other|usual lifestyle|the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
76025427|NCT04439617|Biological|blood examination|use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
76025428|NCT05030545|Drug|Eplerenone|After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
76025429|NCT03163927|Other|Simulation-based training|See arm description
76025430|NCT03106805|Procedure|early insertion|insertion at 4th postpartum week
76025431|NCT03106805|Procedure|late insertion|insertion at 6th postpartum week
76025432|NCT03164161|Device|Cold pressor test|Described before.
76025433|NCT03164161|Other|β-endorphins evaluation in saliva|Described before.
76025434|NCT03164161|Other|β-endorphins evaluation in blood plasma|Described before.
75928178|NCT02220231|Procedure|capnothorax|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
76083600|NCT01539070|Behavioral|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
76083601|NCT01592500|Drug|MOD-4023|Once weekly subcutaneous injection
76083602|NCT01592500|Drug|Somatropin|Once daily subcutaneous injection of Genotropin
76083603|NCT03002116|Other|Tissue thermometry using non-invasive microwave radiometry device|In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
76083604|NCT01799993|Drug|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
76083605|NCT01799993|Drug|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
75334257|NCT01662336|Behavioral|Kaletra Adherence Support Assistance Program|A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
76083606|NCT01593592|Dietary Supplement|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
75643591|NCT01038323|Drug|Educational with milnacipran|"Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
75643592|NCT05031221|Behavioral|Yoga + behavioral weight loss|A 12-week, one-arm proof-of-concept and feasibility study will be conducted at the University of Colorado Anschutz Medical Campus (CU-AMC) to assess the processes critical for the success of future randomized trials including: a) Evaluating the feasibility and acceptability of adding a multi-component yoga program to a standard BWL intervention and b) Examining pre-post changes in relevant clinical/cardiometabolic, psychological, and energy balance/behavioral outcomes to inform the design of future trials. Participants will receive a comprehensive, group-based BWL intervention consistent with current guidelines for obesity treatment and a carefully designed multi-component yoga intervention delivered through pre-recorded videos delivered through a cloud-based platform that will be completed in-person and at-home (BWL+yoga).
75643593|NCT01027871|Drug|LY2605541|subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
75791747|NCT01367626|Drug|letrozole|2.5 mg tablet
76083607|NCT01593592|Dietary Supplement|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
76083608|NCT01593592|Drug|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
75643594|NCT01027871|Drug|insulin glargine|subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
76083609|NCT01593592|Drug|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
76083610|NCT01593592|Drug|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
76083611|NCT03001960|Drug|Preloading before TAVI|Preloading with Aspirin and Clopidogrel before TAVI
76083612|NCT03001960|Drug|Postloading after TAVI|Postloading with Aspirin and Clopidogrel after TAVI
75643595|NCT02873507|Other|MRI of donor liver prior to transplant|MRI of the on ice donor liver within the transport cooler on its way to the operating room
75791748|NCT05118412|Other|Lucerne protein concentrate shake|At three out of five test days: Lucerne protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
75791749|NCT05118412|Other|Whey protein concentrate shake|At two out of five test days: Whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
75791750|NCT01110096|Behavioral|Parent Management Training - Oregon (PMTO)|Method to help parents and caregivers manage the behavior of the children they are responsible for.
75791751|NCT01110096|Behavioral|Motivational interviewing|Communication method to facilitate behavioral change and empower the parents.
75928179|NCT03476694|Procedure|ultra sound guided supraclavicular brachial plexus block|ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
75928180|NCT02220387|Other|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
75928181|NCT02220387|Other|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
75791752|NCT01110096|Behavioral|Dynamic group therapy|Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
75791753|NCT01112748|Drug|Topical lidocaine patch|Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
75791754|NCT05192902|Device|Computer-controlled Local Anaesthesia (CCLA)|The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.
75791755|NCT05192902|Device|Conventional Local Anaesthesia|Conventional dental local anaesthetic injections.
75791756|NCT01211808|Drug|BMS-914832|Tablets, Oral, 30 mg, once, 1 day
75791757|NCT01211808|Drug|Diltiazem|Tablets, Oral, 360 mg, once daily, 10 days
75791758|NCT05192824|Device|Orthokeratology lens|The intervention was according to the design of different optical zone and peripheral reverse curve
75791759|NCT03943134|Other|Minimally Processed Human Umbilical Cord Membrane|Implantation of minimally processed human umbilical cord membrane at the time of surgery
75791760|NCT03943134|Other|Standard Surgical Procedures|Standard surgical intervention for at least one targeted acute upper extremity trauma
75791761|NCT05192746|Other|control group|Exercise Therapy and hot pack This tendon exercise program is very effective if done consistently. There are five steps to the program: warm up, stretching exercise, strengthening exercise, stretching exercise, and heat.
75798879|NCT01181310|Drug|D: Donepezil 10 mg + Scopolamine 0.5 mg|A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
75928182|NCT04798872|Other|Web-based educational program|The mothers and fathers will be provided a website that consist of 6 session. at the end of the session, the lactation consultant will do video call to the mothers to discuss the questions from mothers and fathers. after delivery, telephone counseling will be conducted by lactation consultant to mothers at 2, 4, and 6. weeks postpartum
75928183|NCT03535233|Drug|Triamcinolone Acetonide|
75334258|NCT00387244|Device|Precision for Spinal Cord Stimulation|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
75643596|NCT04301375|Drug|Pertuzumab and trastuzumab FDC subcutaneous|Pertuzumab and trastuzumab FDC subcutaneous, A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg; day 1 of each 3 week cycle during 5 neoadjuvant cycles and 13 adjuvant cycles if complete response
75643597|NCT04301375|Drug|Paclitaxel|80 mg/m2, day 1,8,15 of each 3 week cycle during 4 cycles
75643598|NCT04301375|Drug|TDM1|3,6 mg/kg, 14 adjuvant cycles if not complete response
75643599|NCT04301375|Drug|Endocrine therapy|Adjuvant endocrine therapy will be administered as per local practice and according to recognized clinical practice guidelines
75643600|NCT04301375|Procedure|Omission surgery|Omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab
75643601|NCT04300439|Device|knee total arthroplasty with two types of ancillaries|"-For the Arm A, the surgical procedure of knee total arthroplasty will be done with metallic reusable ancillary.~For the Arm B, the surgical procedure of knee total arthroplasty will be done with Efficiency single use ancillary."
75643602|NCT04300907|Device|Provant Infinity Therapy System|Treatment with the Provant Infinity Therapy System, PEMF device
75643603|NCT04300829|Drug|cicaderma + simple hygiene rules|Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
75643604|NCT04300829|Other|Simple hygiene rules and a maximum of one topical treatment|Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment
75798880|NCT01181310|Drug|E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg|A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
75928184|NCT03535233|Drug|Minoxidil 5 % Topical Spray|
75928185|NCT03535233|Drug|clobetasol propionate|
75334259|NCT00000766|Drug|Foscarnet sodium|
75334260|NCT00000766|Drug|Ganciclovir|
75334261|NCT00000772|Drug|Ribavirin|
75334262|NCT00000772|Drug|Didanosine|
76025435|NCT02627183|Procedure|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
75334263|NCT05480436|Biological|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
76025436|NCT02627183|Behavioral|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
76025437|NCT04960475|Other|Hospital Anxious and Depression(HADS)|The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.
75334264|NCT05480436|Biological|COVID-19 vaccine|received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
75791762|NCT05192746|Device|extracorporeal shock wave therapy|Shock Master 500 device will be applied once a week for four weeks in total. Each treatment consists of 2000 shocks 3 bar pressure, 20 Hz. Each rESWT session will take about 10 minutes. rESWT application will be performed on the supraspinatus trigger point. In successive treatments, there will be using of an energy density equal to 0.28 mJ/mm2
75928186|NCT04712292|Procedure|Surgical procedure for confirmed or suspected colorectal cancer|"Surgical procedure for cancer may include:~any radical surgery (right or left hemicolectomy, rectal resection, abdomino-perineal resection, total colectomy, proctocolectomy, and others depending on the tumor site and other tumor characteristics),~surgery for radicalization of cancer polyps previously removed endoscopically~surgery for excision of large polyps which are not removable endoscopically~staging surgery (laparoscopy or laparotomy), in case of advanced-non operable cancer~palliative surgery (defined as any surgery with no curative intent)"
75928187|NCT02205411|Device|HeartAssist 5® VAD System|The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
75334265|NCT05480436|Biological|IIV4+PPV23|received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
75643605|NCT01021553|Drug|GSK557296|50 mg GSK557296
75928188|NCT02205411|Device|Control VAD|The HeartMate II® VAD or HVAD®
75643606|NCT01021553|Drug|GSK557296|150 mg GSK557296
75643607|NCT01021553|Drug|placebo|placebo
75643608|NCT01026389|Drug|Dotarem|DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
76083613|NCT01822223|Device|Dental implant-abutments|"At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a & 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b & 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration."
75334266|NCT00572260|Drug|daptomycin 6 mg/kg IV|daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
76083614|NCT01593670|Drug|Decitabine|administered intravenous (IV), 10 mg/m^2/day over 1 hour on days 1-5.
76083615|NCT01593670|Drug|Vorinostat|200 mg by mouth (PO) twice a day on days 6-15
76083616|NCT01593670|Biological|Interleukin-2|6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
76083617|NCT01593670|Other|Natural killer (NK) cells|infusion intravenously (IV) over 15 to 60 minutes day 17
76083618|NCT01593748|Drug|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
76083619|NCT01593748|Drug|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
75334267|NCT00000778|Drug|Isoniazid|
75334268|NCT00000778|Drug|Pyridoxine hydrochloride|
75334269|NCT00000778|Drug|Levofloxacin|
75334270|NCT02549352|Drug|LEO43204 gel|
75334271|NCT02549352|Drug|Vehicle gel|
75334272|NCT05480358|Dietary Supplement|Fasting-Mimicking Diet ProlonADTM|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
75334273|NCT00000796|Drug|Cycloserine|
75643609|NCT01026389|Drug|Gadovist|Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
75643610|NCT04300517|Drug|Three sachet of protein supplement to be mixed in with water used daily|Three sachet of protein supplement to be mixed in with water used daily
75643611|NCT01006616|Drug|Navarixin|Navarixin 10 mg and 30 mg capsules
75643612|NCT01006616|Drug|Placebo|Placebo to navarixin capsules
75643613|NCT01006616|Drug|Rescue medication|Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
75643614|NCT04261166|Drug|A1|Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)
75643615|NCT04261166|Drug|A2|Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)
75791763|NCT05192746|Device|high power pain threshold ultrasound|"High-power, pain-threshold, ultrasound therapy application (in W/cm2) in continuousmodes, to elicit threshold pain, the ultrasound probe must be kept static on the tendon.~Intensity will be gradually increased to the level of maximum pain the patient could bear. It will be kept at that level for 4 to 5 seconds and then will be reduced to the half-intensitylevel for another 15 seconds. This procedure will be repeated 3 times.High-power,"
75928189|NCT02205489|Drug|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
75928190|NCT02205489|Drug|cetirizine|Pharmaceutical form:tablet Route of administration: oral
75928191|NCT02205489|Drug|ranitidine|Pharmaceutical form:tablet Route of administration: oral
75334274|NCT00000796|Drug|Ethionamide|
75334275|NCT00000796|Drug|Capreomycin sulfate|
75334276|NCT00000796|Drug|Aminosalicylic acid|
75334277|NCT00000796|Drug|Streptomycin sulfate|
75334278|NCT00000796|Drug|Ethambutol hydrochloride|
75334279|NCT00000796|Drug|Amikacin sulfate|
75334280|NCT00000796|Drug|Isoniazid|
75334281|NCT00000796|Drug|Pyrazinamide|
75334282|NCT00000796|Drug|Pyridoxine hydrochloride|
75334283|NCT00000796|Drug|Levofloxacin|
75334284|NCT00000796|Drug|Rifampin|
75334285|NCT00000796|Drug|Clofazimine|
75334286|NCT00000802|Drug|Atovaquone|
75334287|NCT00000802|Drug|Dapsone|
75334288|NCT00271102|Procedure|anterior vaginal repair (colporrhaphy)|vaginal repair
75334289|NCT00271102|Procedure|abdominal paravaginal defect repair|abdominal repair
75334290|NCT02389946|Device|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
76083620|NCT01594294|Device|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
75334291|NCT02389946|Device|Xience DES|
75643616|NCT04261166|Drug|A3|Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)
75928192|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
75643617|NCT04261166|Drug|A4|Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)
75643618|NCT04261166|Drug|A5|Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)
75643619|NCT04261166|Drug|B1|Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)
75643620|NCT04261166|Drug|B2|Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)
75928193|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
75643621|NCT04261166|Drug|B3|Sublingual tablets. CBD 40 mg (1 tablet)
75643622|NCT04261166|Drug|B4|Sublingual tablets. CBD 40 mg (1 tablet)
75643623|NCT00996632|Procedure|ultrasonic knife (Ultracision®, Ethicon Endo Surgery)|mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
75643624|NCT00996632|Procedure|conventional diarthermy knife|mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
75643625|NCT01025843|Drug|MK-5478|In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
75643626|NCT01025843|Drug|Comparator: Candesartan cilexetil|Single dose administration of candesartan, 32 mg oral tablet
75643627|NCT01025843|Drug|Comparator: Pbo|Placebo
75643628|NCT02873351|Drug|carbidopa-levodopa 25-100 mg|included in arm description
75643629|NCT02873351|Drug|placebo for carbidopa-levodopa 25-100 mg|included in arm description
75643630|NCT04301999|Procedure|Photodynamic therapy|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visualradiography. The dilation catheter was then withdrawn to leavethe PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.
75791764|NCT05192668|Other|Quiet time care|This study is a non-self before and after control study. The data of VLBWIs in the control group is collected in the early stage, and the quiet time intervention is carried out in the later period, and the data of VLBWIs in the intervention group is collected
75791765|NCT01211964|Drug|LEO 22811|Oral administration of solution and tablet.
75791766|NCT03940638|Other|Data collection|Data collection
75928194|NCT02205489|Drug|aciclovir|Pharmaceutical form:tablet Route of administration: oral
75928195|NCT02205489|Drug|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
75928196|NCT02205489|Drug|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
75928197|NCT02205489|Drug|paracetamol|Pharmaceutical form:tablet Route of administration: oral
76083621|NCT01594294|Device|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
76083622|NCT01594294|Device|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
76083623|NCT01594294|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
76083624|NCT01594294|Device|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
76083625|NCT01594528|Other|pain tests|pain induction with pressure application or ischemia on the arm
75334292|NCT00245128|Drug|imatinib mesylate|Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
75334293|NCT00268450|Biological|bevacizumab|"Before surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 4 cycles~After surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 3 cycles"
75334294|NCT00268450|Drug|cisplatin|Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
75928198|NCT05230719|Procedure|Radial Artery Approach|dTRA or conventional TRA for radical artery approach
75334295|NCT00268450|Drug|gemcitabine hydrochloride|Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
75928199|NCT02205567|Dietary Supplement|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
75928200|NCT02220465|Behavioral|PA+ Smoking Cessation (LMPA)|
75928201|NCT02220465|Behavioral|Standard Care Smoking Counseling (SCC)|
75928202|NCT02220543|Other|Back on Track intervention|Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
75928203|NCT02220543|Other|Primary care as usual|Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
75928204|NCT02523846|Drug|morphine|"Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)"
76083626|NCT03005704|Drug|Antiplatelet treatment|Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
75334296|NCT00268450|Drug|paclitaxel|After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles
75334297|NCT00268450|Procedure|cysectomy|
75643631|NCT04301999|Procedure|radiofrequency ablation|an RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
75643632|NCT04302155|Other|balance-specific -games focusing on dynamic aspects of COP on Wii fit system.|"The participants were randomly assigned into two groups interventional and control. Total 18 minutes session was given to both groups wii fit group and traditional balance training group. All participants were given 3 sessions per week for 6.~Total 48 participants were initially accessed initially for eligibility , 13 participants were excluded because of having good balance and good balance age score on Wii fit assessment, 35 participants were recruited for balance training. These participants were randomly divided into Wii fit and traditional training group through sealed enveloped method 18 participants was recruited in Wii fit group and 17 in traditional balance training group. 3 participants drop out from Wii fit group and 2 from traditional balance training group.~Some examples include catching apples in a basket ,moving a golf ball around barriers towards a hole , popping rising balloons/bubbles and air hockey ."
75791767|NCT05192278|Other|erector spinae block|The patients will do the procedure under fluoroscopic guidance. The patients were placed in prone position. After the identification of the T4 transverse process, the targeted injection site was anesthetized with 3-4 ml of 2% lidocaine. A 25-gauge spinal needle was advanced until it contacted the transverse process at the T4 level. Next, a solution of 1mL of methylprednisolone 40mg/mL with 7 mL of 0.25% bupivacaine and 2mL of nonionic contrast in 10 ml saline 0.9% (group A) and in 20 ml saline 0.9% (group B) will injected. Then another photo will be taken with the fluoroscopy to determine the level of spread in each group. After finished, the patients will transfer to the post-operative care unit and will monitored for any complication for one hour.
75791768|NCT01207986|Radiation|Low dose computed tomography (CT)|
75928205|NCT02523846|Behavioral|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
75928206|NCT05262699|Device|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the fingers of the participants via C3 tactors (diameter: 2.03 cm, height: 0.64 cm, operating frequency: 180-320 Hz, see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
75928207|NCT05262699|Other|Placebo Control|Devices mounted, no stimulation
75334298|NCT00000808|Drug|Nevirapine|
75928208|NCT03480984|Other|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
75928209|NCT03480984|Other|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
76025438|NCT04960475|Other|Fear-Avoidance Belief Questionnaire (FABQ)|FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
76025439|NCT04960475|Other|The MOS 36-Item Short From Health Survey (SF-36)|The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. The SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.
76025440|NCT03163615|Drug|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
76025441|NCT03163615|Drug|Placebo oral capsule|4 capsules, po, from admission up to 84 days
75472176|NCT01955018|Device|New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.
75472177|NCT01955031|Other|telemonitoring|A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
76025442|NCT04439695|Biological|Low dose|Low dose of KBP-V001
76025443|NCT04439695|Biological|Intermediate dose|Intermediate dose of KBP-V001
76025444|NCT04439695|Biological|High dose|High dose of KBP-V001
75334299|NCT01892384|Drug|Placebo|matching placebo
75334300|NCT01892384|Drug|BI 409306|low dose
75334301|NCT01892384|Drug|BI 409306|medium dose
75334302|NCT01892384|Drug|BI 409306|high dose
75334303|NCT00000814|Drug|Nevirapine|
75334304|NCT00000814|Drug|Zidovudine|
76025445|NCT04439695|Biological|Placebo|Buffered Saline Solution
76025446|NCT05675215|Diagnostic Test|Psychopathology screening tests|"The assessment phase includes the SCID-5 (First et al., 2017), the D-PSY questionnaire and standardized questionnaires. The D-PSY questionnaire and the SCID-5 (First et al., 2017) will be counterbalanced in terms of the order of administration, with half of the participants taking the SCID-5 (First et al., 2017) first and then the D-PSY questionnaire and the others standardized; the other half will take the D-PSY first and then the SCID-5 (First et al., 2017) and the other questionnaires.~The other standardised questionnaires will be randomised for order of administration. These standardised questionnaires measure social desirability (Balanced Inventory of Desirable Responding, BIDR, Paulhus, 1985, 1991; in French: Cournoyer & Sabourin, 1991), dissociation (DIS-Q, Vanderlinden et al., 1993), phobia (the Fear Questionnaire, F.Q., Marks & Mathews, 1979; in French Cottraux et al., 1987) and autism (AQ, Baron-Cohen et al., 2001; in French, translation by Braun & Kempenaers, 2007)."
76025447|NCT03114787|Other|Study on patients with respiratory resuscitation|Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult
75334305|NCT00000814|Drug|Didanosine|
75791769|NCT01114386|Procedure|Lung function testing, echocardiography, blood sampling|"All patients will undergo to:~physical examination~6' Minute Walk test~pulmonary function testing (spirometry + volumes and reversibility testing)~carbon monoxide diffusing capacity (DLCO) with single-breathe technique~ECG~echocardiography"
75791770|NCT01372072|Device|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
75791771|NCT01208064|Drug|pazopanib hydrochloride|
75651870|NCT05096260|Behavioral|Motivational Interviewing based SMS/MMS and web content|Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
75791772|NCT01208064|Other|laboratory biomarker analysis|
75928210|NCT05224323|Other|Airway pressure, flow, esophageal pressure, ventilation distribution|After informed consent, baseline characteristics of patients will be collected. Airway pressure, flow and esophageal pressure will be recorded using high sampling rate and ventilation distribution using electrical impedance tomography will be recorded during the study. The ventilator will be set at a positive end-expiratory pressure of 15 cmH2O during 10 minutes. Then, respiratory rate will be decreased to 8 breaths/min, and positive end-expiratory pressure will be decreased to 5 cmH2O over one breath to measure the recruited volume. Then, three low-flow inflation and deflation pressure-volume curves will be performed before resuming clinical ventilator settings. Patients will be followed until Day 28 after inclusion or ICU discharge. Maneuvers performed are part of the usual care of patients with acute respiratory distress syndrome in our unit.
75928211|NCT03484260|Drug|Testosterone Product|Men used testosterone product following prescription
75928212|NCT05195775|Drug|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.
75791773|NCT01208064|Other|pharmacogenomic studies|
75791774|NCT01208064|Other|pharmacological study|
76083627|NCT03001648|Procedure|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
76083628|NCT01595386|Drug|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
76083629|NCT01595386|Drug|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
76083630|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
76083631|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
76083632|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
76083633|NCT01595854|Drug|dabigatran etexilate|low dose dabigatran
76083634|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
76083635|NCT01596088|Drug|Dexrazoxane|
76083636|NCT02228382|Drug|Bosutinib|100 mg and 500 mg tablets, once daily dosage up to 4 years duration
76083637|NCT02216422|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
75472178|NCT01955031|Other|Usual care|Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
75472179|NCT01955057|Behavioral|Research interviews|
75472180|NCT01955057|Behavioral|Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)|
75791775|NCT01208064|Procedure|quality-of-life assessment|
75791776|NCT05192044|Other|Fast track Care pancreatico-duodenectomy.|Enhanced recovery after pancreatico-duodenectomy, with early oral intake, mobilization & discharge
75791777|NCT05192044|Other|Conventional Care|Conventional Care
76083638|NCT02216422|Drug|Dasabuvir|Tablet
76083639|NCT02216422|Drug|Ribavirin (RBV)|Tablet
76083640|NCT03001570|Drug|Cetuximab plus Radiotherapy|Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
76083641|NCT03005548|Device|Transcranial direct current stimulation|"Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins."
76083642|NCT03005548|Drug|Morphine|"In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning."
75791778|NCT03634462|Other|CDT with graded negative pressure|Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise. The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
75928213|NCT05195775|Drug|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (Doppler US, exercise testing, clinical function) will be performed 3 hours after time of dosing.
75791779|NCT01209858|Drug|Perampanel and Microgynon-30|Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
75791780|NCT01209858|Drug|Perampanel and Microgynon-30|Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
75791781|NCT05191888|Drug|Vonoprazan and Amoxicillin|14-day vonoprazan high-dose two-in-one therapy
75928214|NCT03480906|Drug|Latanoprost|Latanoprost ophthalmic solution administered as a microdose spray
75928215|NCT03480906|Drug|Latanoprost|Latanoprost ophthalmic solution administered as an eyedrop
75928216|NCT04527198|Diagnostic Test|Brainstem Responses Assessment Sedation Score (BRASS)|"It consists of a standardized evaluation of brainstem reflexes with a score of 1 attributed for absence of pupillary light reflex, cough reflex and the combined absence of grimace and oculocephalic reflex, a score of 2 for absent corneal reflex and a score of 3 for absent grimace in the presence of oculocephalic The resulting sum ranges from 0 to 7.~It will be performed at two times points: a first time under sedation and a second time 3 to 5 days after sedation weaning."
76025448|NCT05125445|Procedure|Implants placed at bone crest|"Mid crestal incision will be performed and full-thickness envelope flap will be elevated to expose the alveolar ridge (no releasing incisions will be made).~Implant site will be prepared according to the manufacturer's instructions under sterile copious irrigation Implants will be placed at crestal level"
76025449|NCT05125445|Procedure|Implants placed 1mm Subcrestally|Implants will be placed 1mm subcrestally
76025450|NCT03114475|Radiation|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
76025451|NCT03114475|Other|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
76025452|NCT00754949|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
76025453|NCT00754949|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
76025454|NCT00754949|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
76025455|NCT03114709|Other|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
76025456|NCT03114709|Other|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
76025457|NCT05022121|Behavioral|Supported Biopsychosocial Self-Management (SBSM)|Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.
76025458|NCT05022121|Drug|Medical Care|Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
76025459|NCT05011045|Procedure|Magnetic Resonance Imaging|Undergo MRI
76025460|NCT05011045|Other|Neurocognitive Assessment|Undergo neurocognitive function assessment
76025461|NCT05011045|Other|Quality-of-Life Assessment|Complete questionnaires
76025462|NCT05011045|Other|Questionnaire Administration|Complete questionnaires
76025463|NCT05675137|Device|mobile-based|Participants who were randomly assigned to the mobile-based intervention group were provided multidomain programs based on scientific evidence of ways to improve brain-health and reduce dementia risk for 10 minutes per day and at least 50 minutes per week.
76025464|NCT05675137|Other|paper-based|Participants who were randomly assigned to the paper-based intervention group were provided with the Korean version of the dementia prevention booklet published by the WHO.
76025465|NCT04620707|Device|RGS based training and monitoring|The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
75928217|NCT04527198|Diagnostic Test|Electroencephalogram with EKG lead|"A 20 minutes clinical (12 electrodes) EEG with an EKG lead will be performed a first time under sedation and a second time 3 to 5 days after sedation weaning.~These EEG recordings will allow to measure the sympathic-parasympathetic ratio using spectral analysis of the EKG and also to measure quantitative markers of brain EEG activity (spectral power and connectivity in delta, theta, alpha, beta and gamma band; complexity)."
75472181|NCT01955057|Behavioral|Projective methods (Thematic apperception Test, Rorschach)|
75472182|NCT01955057|Behavioral|Carbon monoxide test|
75643633|NCT04302155|Other|mini trampoline and inflatable discs group|"High skipping and landing on a limb every time (2 repeats of 45 s each leg).Standing on one leg and try to catch the ball thrown at them in various directions by the researcher (2 repeats of 45 s each leg) Exercises in inFlated rubber hemisphere attached toa rigid platform (BOSU)~Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance (2 repeats of 45 s each leg).~Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance, while lifting the non-support leg forward and backward (2 repeats of 45 s each leg).~Standing on BOSU flat hard surface with both legs, in an attempt to maintain balance (3 minutes on both legs).~Standing on BOSUs flat hard surface with both feet, in an attempt to maintain balance, while trying to catch the ball thrown at them by the experimenter in various directions (3 minutes on both leg)"
75643634|NCT01021007|Drug|Iodine|Rinse 2 times per day for 6 weeks
75791782|NCT05191888|Drug|Vonoprazan, Amoxicillin and Clarithromycin|14-day vonoprazan triple therapy
75791783|NCT05191888|Drug|Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole|14th Rabeprazole reverse mixed therapy
75928218|NCT05262465|Biological|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|HLA-mismatched donor peripheral stem cell infusion
75472183|NCT01955070|Other|Multimedia Presentation for Ketamine sedation|PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
75928219|NCT05262465|Drug|Azacitidine|azacytidine 50-75mg/m2
75928220|NCT05262465|Drug|Venetoclax|Venetoclax 100-300mg/d ×3d，400mg 4-28d
76083643|NCT03373500|Other|Dietary salt reduction|Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
76083644|NCT03005392|Other|exercise|"An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention)."
76083645|NCT03369834|Device|Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
76083646|NCT03369834|Device|Infrared Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
75472184|NCT01955096|Procedure|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
75472185|NCT01955096|Procedure|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
75472186|NCT01955135|Drug|Ketamine|1mg/kg bolus intravenous, 0.25mg/kg/hour intravenous for maintenance of sedation
75791784|NCT02529618|Device|integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)|iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.
75928221|NCT02205645|Device|FibroFix™ Meniscus scaffold|"The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.~The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear."
75928222|NCT02193321|Biological|Amniotic Membrane Patch|
75928223|NCT02220621|Device|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
75928224|NCT02220621|Device|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
75928225|NCT04370418|Drug|short course chemo-radiation with 5-fluorouracil|neo-adjuvant short course chemo-radiation in locally advanced rectal cancer patients followed by delayed surgery
75334306|NCT02661932|Drug|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."
75334307|NCT00423124|Genetic|HSV-TK|Infusion of genetically modified lymphocytes (1x10^6-1x10^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
75334308|NCT02809586|Behavioral|SMI + I|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. Participants will earn incentives for interaction during the intervention (8 weeks).
76083647|NCT03369834|Device|Infrared and Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared and Red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
75334309|NCT02809586|Behavioral|SMI|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. This group will NOT receive incentives for their participation in the secret group.
75334310|NCT00177970|Drug|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff .
75334311|NCT00177970|Drug|Placebo|Placebo to be given IV to patients with C-Diff
75791785|NCT02529618|Device|Riddell High Impact Technology (HIT) System|The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
75334312|NCT01892618|Drug|Prevenar 13|13-valent pneumococcal conjugated vaccine
75791786|NCT02529618|Device|i1 Biometrics Vector Mouth Guard|The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
76083648|NCT03369834|Device|Sham|LED device off.
75334313|NCT01892618|Drug|Pneumovax|23-valent pneumococcal polysaccharide vaccine
75334314|NCT00088972|Drug|celecoxib|Given orally
75334315|NCT00088972|Other|placebo|Given orally
75791787|NCT05170906|Other|Reflex locomotion stimulus|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
75791788|NCT05170906|Other|sham stimulus|The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg.
75334316|NCT01892696|Device|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
75334317|NCT00089128|Drug|gemcitabine hydrochloride|
75334318|NCT00089128|Drug|irinotecan hydrochloride|
75643635|NCT01021007|Other|water|Use 2 times per day for 6 weeks
75643636|NCT02872883|Procedure|Expectant management|
75643637|NCT02872883|Procedure|Minimal Vaginal examinations (only when necessary)|
75643638|NCT02872883|Procedure|Active management|
75643639|NCT02872883|Procedure|Routine vaginal examinations|
75643640|NCT02873117|Other|Prostate biopsy, prostatectomy or prostate resection|Collection of prostate examination
75643641|NCT02872415|Biological|Blood puncture site|Blood puncture site
75643642|NCT04300283|Behavioral|Hypnosis|See previous description
75651871|NCT05070130|Device|dPR and FFR|OpSens non-hyperemic dPR and/or OpSens FFR
75791789|NCT01112826|Drug|Capecitabine|capecitabine 650 mg/m2 twice every day for 1 year.
75791790|NCT01367782|Device|repetitive transcranial stimulation (r-TMS)|Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
75928226|NCT02220777|Drug|ASP8477|oral
75928227|NCT02220777|Drug|omeprazole|oral
75928228|NCT02220777|Drug|Placebo|oral
75928229|NCT03484104|Diagnostic Test|Measurement of tissue oxygenation index (TOI)|TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest
75928230|NCT02205723|Behavioral|Asthma teaching in ER|Asthma teaching
75928231|NCT02205723|Behavioral|Smartphone Asthma Control|Smartphone Asthma Control
75928232|NCT03484026|Dietary Supplement|BioFe|BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
75643643|NCT04299971|Drug|Methotrexate Tablets|"The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead."
75643644|NCT04299971|Drug|Tofacitinib tablet|"The tofacitinib group is prescribed with tofacitinib tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of tofacitinib is maintained for another 24 weeks, otherwise (resistant), patients would be given methotrexate (15.0mg.qw.p.o.) for 24 weeks instead."
75791791|NCT01367782|Device|repetitive transcranial stimulation (r-TMS)|Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
75791792|NCT01359280|Behavioral|Adherence Counseling|5 Sessions of theory-based medication adherence counseling
75791793|NCT01359280|Behavioral|General Health Counseling|5 sessions of health improvement counseling
75791794|NCT01359280|Behavioral|Text Messages|Daily medication regimen tailored adherence reminders delivered by cell phone
75928233|NCT02258295|Drug|Intragel|Intragel has an average molecular weight of 800-1200 kDaltons.
75928234|NCT02258295|Drug|Saline|Saline
75928235|NCT03476616|Drug|Eplerenone (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM <130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added [indapamide (D) 1.25 mg od]. All groups at both arms will be evaluated at 24 wks by ABPM.
75928236|NCT03476616|Drug|Valsartan (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM <130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added [indapamide (D) 1.25 mg od]. All groups at both arms will be evaluated at 24 wks by ABPM.
76083649|NCT03005470|Device|TELEM|Participants in the telemonitoring home blood pressure (TELEM) group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made early in the morning (5:00 to 10:00) and in the evening (18:00 to 21:00) for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
76083650|NCT03005470|Device|TELEMEV|In the lifestyle telemonitoring group (TELEMEV), participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent out on four of the five days of the week at random times. The messages will be sent to the smarphones through a software developed for this study.
75334319|NCT00000832|Biological|MF59|
75334320|NCT00000832|Biological|rgp120/HIV-1 SF-2|
75334321|NCT01892774|Procedure|Radiofrequency catheter ablation|Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
75334322|NCT00000838|Drug|Lamivudine|
75334323|NCT00000838|Drug|Stavudine|
75791795|NCT01210014|Drug|zinc sulphate 220mg/day in one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
75928237|NCT02220933|Drug|MD1003 100mg capsule|
75928238|NCT02220933|Drug|Placebo|
75928239|NCT04248972|Device|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
75928240|NCT04248972|Other|PLACEBO PBM|A placebo whole body red light will be carried out during 20 minutes
76083651|NCT03005470|Device|TELEM-TELEMEV|Participants in the TELEM plus TELEMEV (TELEM-TELEMEV) will receive both interventions as previously described.
76083652|NCT03005470|Other|UCT|Participants in the control group will receive usual clinical treatment (UCT) on pre-scheduled visits, but will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
75334324|NCT00000838|Drug|Zidovudine|
75334325|NCT00000838|Drug|Didanosine|
75334326|NCT01892852|Procedure|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
75472187|NCT01955135|Drug|Sevoflurane|anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
75928241|NCT02205879|Drug|Pregabalin|
75928242|NCT02205879|Drug|Placebo|
75928243|NCT05007756|Radiation|UVB Challenge|UVB challenge will be administered dermally through Lumera Phototherapy System.
76083653|NCT03373422|Drug|BAY1128688|Various dosing OD (once daily) and BID (twice daily)
75643645|NCT01020773|Behavioral|spontaneous breathing trial|
75928244|NCT02193399|Other|Physiotherapy in patients with stem cell transplantation|"The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.~The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient."
75643646|NCT01020305|Drug|Temsirolimus|"Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)~IUPAC name: (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"
75643647|NCT01020305|Drug|Casodex (bicalutamide)|Casodex (bicalutamide) 50 mg/day PO
75928245|NCT03480828|Diagnostic Test|comparaison between DE and DTF in prediction of extubation success|diaphragm ultrasound and measurement of DE and DTF in patients meeting all extubation criteria during spontaneous breathing trial
75928246|NCT05262309|Drug|Pamrevlumab|"Pamrevlumab dosing, 30 mg/kg IV, will be administered at day 1, day 7 and day 14.~Based on Investigator's decision, treatment may be continued every 3 weeks after day 14, up to 11 weeks."
75334327|NCT02375126|Procedure|Electroencephalography|Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
75334328|NCT00001768|Drug|Intravenous immunoglobulin|
75334329|NCT00000844|Drug|Interferon alfa-n3|
75928247|NCT03483948|Drug|HMPL-523|HMPL-523 tablet
75928248|NCT03483948|Drug|Azacitidine|Azacitidine Injection
75643648|NCT00627575|Drug|lamotrigine|Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
75643649|NCT00627575|Drug|atorvastatin|Atorvastatin will available as 40 mg tablets.
75643650|NCT00627575|Drug|phenytoin|Phenytoin will available as 100 mg capsules.
75643651|NCT01036529|Device|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
75643652|NCT01036529|Procedure|Back Surgery|Different types of back surgery may be performed
76025466|NCT04620707|Behavioral|Therapy as usual|The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
76025467|NCT03160807|Drug|Levofloxacin|Levolet 500 mg OD for 5 days
76025468|NCT03160807|Drug|Levofloxacin|Levolet 500 OD for 10 days
76025469|NCT01674569|Drug|X-82 oral|X-82 oral for 24 weeks or until unacceptable toxicity develops
76025470|NCT01674569|Drug|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
76025471|NCT03160729|Drug|Dexamethasone|pre-operative, single-shot injection
76025472|NCT04589117|Behavioral|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to cultivate compassion & forgiveness~Week 3: Writing to nurture positive emotions~Week 4: Writing to invite insight, perspective, & growth"
76025473|NCT04439929|Biological|TUR01|Administered as a single 40 mg, subcutaneous dose
76025474|NCT04439929|Biological|Adalimumab-EU|Administered as a single 40 mg, subcutaneous dose
76025475|NCT05131841|Drug|Cipterbin Combined With Vinorelbine|"Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer"
76025476|NCT03163849|Drug|Sofosbuvir , daclatasvir|Tablets
76025477|NCT03163849|Drug|Placebos|oral tablets
76025478|NCT04520867|Other|STRENGTH|Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.
76025479|NCT04509947|Biological|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.
76025480|NCT04509947|Biological|Placebo|Placebo will be administered as IM injection.
76025481|NCT05131763|Biological|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
76025482|NCT03160495|Other|All patients|All patients are scanned with PET/MR prior to surgery.
76025483|NCT04160039|Device|Cycle ergometry|Lower extremity cycle ergometry, passive and/or active, up to 20 minutes per session, up to 5 sessions per week
76025484|NCT05178641|Device|Ninjamas Pyjama Pants|Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.
76025485|NCT05178641|Other|Participant's Overnight Current Standard of Care|Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.
75791796|NCT01210014|Drug|placebo: one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
75791797|NCT03940794|Other|Verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. A transabdominal Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
75791798|NCT01208142|Other|standard of care treatment|weekly standardized physical therapy and daily wear of an AFO
75791799|NCT01208142|Device|Ankle Flexion Dynasplint|Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
75791800|NCT05118256|Drug|Pirfenidone Oral Tablet|Patients will be treated with pirfenidone (oral tablets) during 6 months
75791801|NCT03940716|Behavioral|IntERact|"This intervention integrates motivational interviewing, cognitive behavioral skills therapy, and care management into a single behavioral counseling intervention delivered by a therapist. The intervention is delivered either in the emergency department or remotely over the subsequent 5 weeks for a total of six therapy sessions (~30 min each). A smartphone app is also loaded on the participant's phone and delivers additional behavioral intervention content, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact encouragement, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
76025486|NCT05676775|Other|No intervenetion|Observational inception cohort, with remote follow-up via participants and data record linkage
75334330|NCT00000844|Drug|Interferon alfa-n1|
75643653|NCT00627809|Drug|Streptokinase|intracoronary infusion, 250.000 Units
76083654|NCT03373422|Drug|Placebo|Matching placebo tablets
76083655|NCT03375606|Biological|CSL730|Solution for IV infusion
75643654|NCT00627809|Procedure|primary percutaneous coronary intervention|balloon catheter, stent
75791802|NCT01114542|Drug|insulin degludec|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
75791803|NCT01114542|Drug|insulin glargine|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
76083656|NCT03375606|Other|Placebo|Saline solution for IV infusion
75334331|NCT00014560|Biological|bispecific antibody 4G7xH22|
75334332|NCT00014560|Biological|sargramostim|
75334333|NCT02367092|Behavioral|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
75334334|NCT00020722|Biological|therapeutic autologous lymphocytes|"Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.~The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion."
75472188|NCT01955135|Drug|propofol|1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol
75643655|NCT01024751|Device|Bausch & Lomb Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
75643656|NCT01024751|Device|Ciba's Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
75643657|NCT02872649|Drug|Dabigatran|
75643658|NCT02872649|Drug|Phenprocoumon|
75643659|NCT04299737|Other|Treatment Bundle (as defined below)|Patient decolonization within one hour of incision, improved environmental cleaning (frequency and quality, including but not limited to targeted use of no touch disinfection with UV-C treatment), provider hand hygiene leveraging proximity, improved catheter disinfection, and surveillance optimization.
75791804|NCT01367938|Device|OMNI Apex Ultracongruent Knee Device|
75791805|NCT05121220|Device|fixed retainer|bonded lingual mandibular fixed retainer on frontal teeth 33-43
75791806|NCT05121220|Device|removable retainer|thermoplastic vacuum-formed removable mandibular retainer
76025487|NCT04501913|Procedure|Patient Monitoring|Undergo remote perioperative telemonitoring
76025488|NCT04501913|Other|Questionnaire Administration|Complete questionnaires
76025489|NCT03163537|Device|HealthPatch|Smart patch that is able to measure stress real time using an algorithm between HR and HRV
76025490|NCT03163381|Drug|Apatinib|Apatinib 500mg,po,qd,medicine to disease progression.
76083657|NCT03375528|Device|DES implantation|Coronary artery intervention using Drug eluting stent and Intravascular Ultrasound is performed.
76083658|NCT03363750|Behavioral|mind-body-skills group|mind-body skills group program incorporates meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement
76083659|NCT03373344|Behavioral|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
76083660|NCT03373344|Behavioral|Placebo control exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
76083661|NCT03373266|Drug|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
76083662|NCT03373266|Drug|Isoflurane|anesthesia was maintained with isoflurane 1-2%.
76083663|NCT03369366|Device|NobelActive|NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.
75334335|NCT00020722|Drug|Ifosfamide, carboplatin, and etoposide (ICE) regimen|"Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2"
75334336|NCT00020722|Drug|Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|"Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2."
75334337|NCT00020722|Procedure|Leukapheresis|Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
75643660|NCT04301921|Other|Traditional punkcture site and No anticoagulation|Traditional punkcture site and No anticoagulation
75791807|NCT02529540|Other|Adjustable glasses|The glasses will be used for refraction and wearing within professional instructions.
75791808|NCT02529540|Other|Custom standard glasses|The custom standard glasses are made by the traditional standards after refraction.
75928249|NCT02221011|Device|Shock wave|"Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases."
75928250|NCT02221089|Drug|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
76083664|NCT03369366|Device|KLS Martin Mandibular Reconstruction Implant|The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).
75643661|NCT04301921|Other|Traditional punkcture site and ACT-guided anticoagulation|Traditional punkcture site and ACT-guided anticoagulation
75643662|NCT04567511|Drug|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
75643663|NCT01019369|Drug|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
75643664|NCT01019369|Drug|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
75643665|NCT01019135|Behavioral|Cardiac Rehabilitation|comparison of multiple cardiac rehabilitation program models
75643666|NCT01018979|Drug|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
75643667|NCT01018979|Drug|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
75643668|NCT01572493|Biological|rh IL-15 (10 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) intravenous (IV) for first 10 days of each cycle
75643669|NCT01572493|Biological|rh IL-15 (5 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle
75643670|NCT02315443|Drug|Nerinetide (NA-1)|
75643671|NCT02315443|Drug|Placebo|
75643672|NCT01018511|Drug|Placebo tamsulosin hydrochloride OCAS 0.4 mg|tablet
75643673|NCT01018511|Drug|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|tablet
75643674|NCT01018511|Drug|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tablet
75643675|NCT01018511|Drug|tamsulosin hydrochloride OCAS 0.4 mg|tablet
75791809|NCT02529540|Other|Ready-made glasses|The glasses have been made already before the refraction in the hospital. And they will be chosen by prescription after refraction.
75791810|NCT05188924|Drug|DKF-306|Active ingredients
75791811|NCT05188924|Drug|Placebo|Placebo
75791812|NCT05045014|Other|Balance assessment|Romberg test and one-leg standing test will be used.
76083665|NCT02217904|Drug|1 mg islatravir|Single oral dose of 1 mg islatravir administered following ≥8 hour fast
76083666|NCT02217904|Drug|2 mg islatravir|Single oral dose of 2 mg islatravir administered following ≥8 hour fast
76083667|NCT02217904|Drug|10 mg islatravir|Single oral dose of 10 mg islatravir administered following ≥8 hour fast
76083668|NCT02217904|Drug|30 mg islatravir|Single oral dose of 30 mg islatravir administered following ≥8 hour fast
76083669|NCT02217904|Drug|0.5 mg islatravir|Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast
76083670|NCT02217904|Drug|0.25 mg islatravir|Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
76083671|NCT02981134|Procedure|Computed tomographic scan|after 1year of BVS implantation, computed tomographic scan will be performed
75928251|NCT02221089|Dietary Supplement|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
75643676|NCT01018511|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tablet
75791813|NCT05045014|Other|Unterberger test|During 50 steps, he will count in place with 45 degrees of hip flexion, and after 50 steps, the angle of rotation between the first position and the final position of the right foot will be measured with the help of a goniometer and the displacement distance.
75928252|NCT02221089|Other|Placebo|Placebo capsules identical in appearance to Retaron capsules
75791814|NCT05045014|Other|Corsi Block Tapping (mobıl app)|Spatial memory will be evaluated.
75791815|NCT05045014|Other|Navigation performance|Two triangles (one equilateral, one oblique triangle, at 30°, 60° and 90° angles respectively) with route segment lengths between 150 and 300 cm will be marked on the floor and the participants will be asked to complete the task with their eyes closed. The final deviation amount will be recorded.
75791816|NCT05045014|Other|Cobb angle measurement|It will be evaluated with the help of X-ray.
75791817|NCT05045014|Other|Scolio Detector (mobıl app)|The degree of rotation will be measured with the mobile application called Scolio Detector.
75928253|NCT03483870|Drug|Morphine Sulfate|200 ug morphine sulphate will be injected intrathecally
75928254|NCT03483870|Drug|Placebo|2 mL of normal saline 0.9% IV injection
75643677|NCT01018511|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|tablet
76083672|NCT03363516|Diagnostic Test|Cerebral 3 Tesla MRI|Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
76083673|NCT03363438|Other|no intervention survey|there was no intervention this was a survey
76083674|NCT02980900|Dietary Supplement|Post exercise protein-polyphenol supplement|Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
76083675|NCT02980900|Dietary Supplement|Post exercise placebo supplement|Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
75643678|NCT02577367|Drug|Levothyroxine|Administer Levothyroxine
75643679|NCT00996476|Drug|TMC435|One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
75643680|NCT00996476|Drug|PegIFNα-2a|One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
75643681|NCT00996476|Drug|RBV|300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
75643682|NCT04070911|Other|WATER|ORAL WATER
75791818|NCT05009290|Drug|SHR3680|"Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
75791819|NCT05009290|Drug|Placebo|"Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
75791820|NCT01208298|Device|Cold Sore Patch|All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
75928255|NCT03483870|Drug|Granisetron|2 mL of 2 mg granisetron IV injection
75928256|NCT02221167|Other|Donor Milk|"breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk comes in."
75928257|NCT02523612|Procedure|Biopsy|
75928258|NCT02523612|Procedure|Blood sample|
75928259|NCT02221245|Procedure|Tumor Biopsy via Ultrasound Endoscopy|The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
75928260|NCT03483792|Biological|Plasma dosage|4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
75928261|NCT03483792|Genetic|placental biopsy|Immediately following delivery (<12h postpartum), placental biopsies (Collection of 4 placental fragments)
75928262|NCT05262153|Procedure|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
76083676|NCT02980900|Dietary Supplement|Pre bed protein-polyphenol supplement|Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
76083677|NCT02980900|Dietary Supplement|Pre bed placebo supplement|Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
76083678|NCT03372876|Dietary Supplement|Protein and carbohydrate supplementation|Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
76083679|NCT03369288|Diagnostic Test|PET MRI|18F-fluoride PET-MRI
76083680|NCT03372798|Procedure|ICE/IVUS imaging during atrial fibrillation ablation|Intravascular ultrasound imaging of the left atrial wall thickness with ICE/IVUS during atrial fibrillation ablation
75643683|NCT04070911|Other|ICE APPLICATION|ICE APPLICATION
76083681|NCT03369132|Device|Angiflash|throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.
76083682|NCT03369132|Device|Placebo|water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
75643684|NCT04296344|Other|Acupuncture Therapy Treatments|10 consecutive weekly group acupuncture therapy treatments
75928263|NCT04960254|Behavioral|internet gaming addiction|"The Strengths and Difficulties Questionnaire (SDQ) parent : to asses behavioural change Socioeconomic Scale:It contains four main variables:1-The educational level of the father and mother.2-The occupation of the father and mother. 3-Total family income. 4-life style of the family.~Emotional Avoidance Strategy Inventory for Adolescents (EASI):The EASIA is a 17-item (Kennedy & Ehrenreich-May 2017) measure assessing the use of emotionally avoidant strategies in adolescents.~The internet gaming addiction scale : t is used to evaluate internet gaming addiction."
75643685|NCT04296344|Other|Yoga Therapy Sessions|8 consecutive yoga therapy sessions that occur immediately following in a room adjacent to acupuncture therapy.
75928264|NCT02221323|Drug|Insulin LISPRO|
75928265|NCT03483714|Procedure|Spinal Manipulation|HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
75928266|NCT02193477|Device|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
75928267|NCT02193477|Device|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
75928268|NCT03480516|Device|SDF|38% silver diamine fluoride solution
76083683|NCT05488600|Behavioral|Executive Function Assessment|Digit Span (Forward and Backward) Test, Stroop Test, Trail Making Test A and B forms, Tower of London Test were used to evaluate executive functions.
76083684|NCT03005158|Other|Validation Phase|Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
76083685|NCT03005158|Other|Randomization Phase|Standard care or HighSTEACS pathway.
76083686|NCT03005158|Other|Implementation Phase|Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are <5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
76083687|NCT01900002|Other|Laboratory Biomarker Analysis|Correlative studies
76083688|NCT01900002|Other|Quality-of-Life Assessment|Ancillary studies
76083689|NCT01900002|Drug|Sorafenib|Given PO
75334338|NCT00020722|Procedure|peripheral blood stem cell transplantation (PBSCT)|Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
75334339|NCT02650700|Radiation|spleen radiotherapy|Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
75334340|NCT04051996|Drug|Glasdegib|Glasdegib will be administered at the starting dose of 100 mg orally once daily.
75334341|NCT04051996|Drug|Decitabine|Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.
75643686|NCT03912961|Other|Picture of the retina with a handheld retinal camera|Patient with diabetes will have their undilated and dilated images taken, with the images being centered on the macula and on the optic disc.
75643687|NCT04258904|Combination Product|Skin Care Program|The intervention consists of a Skin Care Program including neat information regarding dermatological complications to the device use, prevention of these and moisturizer to keep healthy skin.
75643688|NCT00628940|Radiation|PET images with 18F-fluoromethylcholine|sequential PET images with 18F-fluoromethylcholine
75643689|NCT04294706|Dietary Supplement|Hemp arm|Hemp oil
75643690|NCT02869022|Drug|Custodiol-N|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
75643691|NCT02869022|Drug|Custodiol|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
75643692|NCT02869022|Procedure|organ perfusion for heart transplantation|
75643693|NCT04201340|Device|DRI OCT Triton with SS-OCT Angio software|The Topcon DRI OCT Triton with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
75643694|NCT04201340|Device|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
75643695|NCT04201340|Device|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
75643696|NCT04293692|Biological|UC-MSCs|0.5*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7
75928269|NCT03480516|Device|Fluoride varnish|5% sodium fluoride varnish
75928270|NCT03476460|Drug|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
76083690|NCT01900002|Drug|Sorafenib Tosylate|Given PO
76083691|NCT01900002|Radiation|Yttrium Y 90 Glass Microspheres|Given IA
76083692|NCT03005314|Procedure|chemotherapy|chemotherapy before surgery
76083693|NCT03005314|Procedure|Surgery|chemotherapy after surgery
76083694|NCT03005002|Biological|Durvalumab|Given IV
75334342|NCT02385292|Device|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
75334343|NCT02640638|Behavioral|CenteringPregnancy|8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
75334344|NCT01893086|Procedure|LH alone|LH, laparoscopic hysterectomy
75334345|NCT01893086|Procedure|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
75334346|NCT02126878|Drug|Kenalog|
75643697|NCT04293692|Other|Placebo|100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7
75643698|NCT04299815|Drug|Oral Sodium Lactate|25 grams of D/L lactate dissolved in 300mL water.
75643699|NCT04299815|Drug|Intravenous sodium lactate|intravenous sodium lactate + oral sodium-chlorid solution
75643700|NCT02269267|Drug|Imatinib (Stopping their TKI)|Patients with CML on treatment with imatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (> 4 log reduction) molecular response (>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) < 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
75334347|NCT02634008|Drug|Paritaprevir/ritonavir/ombitasvir|
75472189|NCT01955174|Drug|Esophageal endoscopic injection of botulinum toxin|Endoscopic injection of botulinum toxin in the esophageal muscle : one hundred units of type A botulinum toxin (Botox®, Allergan) diluted in 10 mL of normal saline and injected at the lower third of the esophageal wall in 10 sites between 2 and 10 cm above the Z-line.
75472190|NCT01955174|Other|No injection of botulinum toxin|Upper gastro-intestinal endoscopy without any injection
75928271|NCT03476460|Drug|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
75928272|NCT02193555|Device|Etafilcon A, Senofilcon A|1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
75928273|NCT02206113|Behavioral|Standing workstation|
75928274|NCT03131076|Diagnostic Test|IPMN follow up|Follow up with MRI and laboratory blood tests
75928275|NCT02221401|Drug|Linagliptin/Metformin FDC|
75928276|NCT02221401|Drug|Linagliptin|
75928277|NCT02221401|Drug|Metformin|
75334348|NCT02634008|Drug|Dasabuvir|
75472191|NCT01955187|Drug|TACROLIMUS|Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
75472192|NCT01955187|Drug|RITUXIMAB|A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
75472193|NCT01955187|Drug|METHYLPREDNISOLONE|Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
75472194|NCT01955187|Drug|CYCLOPHOSPHAMIDE|Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
75472195|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
75472196|NCT01955200|Drug|Cilostazol|(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
75472197|NCT01955200|Drug|Ticagrelor|(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
75472198|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
75472199|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
75472200|NCT01955213|Drug|methylnaltrexone|Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
75472201|NCT01955226|Other|Tegaderm CHG clear dressing|Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
75651872|NCT05067569|Behavioral|SleepFix mobile application|The SleepFix app is a novel, innovative way to deliver digital brief behavioural therapy for insomnia for adults.
75334349|NCT02634008|Drug|Ribavirin|
75334350|NCT02634008|Drug|Glecaprevir/pibrentasvir|
75334351|NCT00000850|Drug|Indinavir sulfate|
75334352|NCT00000850|Drug|Sargramostim|
75334353|NCT02802254|Behavioral|Patient-targeted individual physical-activity-feedback|At cardiac consultation receive an individual feedback on their personal physical activity level.
75334354|NCT02802254|Device|Pedometer|Patients receive a pedometer two weeks prior to cardiac consultation.
75334355|NCT00000856|Drug|Foscarnet sodium|
75334356|NCT00000856|Drug|Ganciclovir|
75334357|NCT04745858|Other|Bowen's Technique|In Bowen's Technique, sequence of short gentle moves are applied over Hamstrings. Skin slack is taken to the lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are given for 4 weeks. The treatment time for each session is 20 minutes.
75334358|NCT04745858|Other|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
75334359|NCT00001810|Drug|Voriconazole|
75334360|NCT02630498|Procedure|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
75334361|NCT00000862|Drug|Zidovudine|
75334362|NCT02344472|Drug|pertuzumab|HER2 targeted Therapy
75928278|NCT03483636|Drug|Lemborexant|Film-coated oral tablet
75928279|NCT03483636|Drug|Alcohol|0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).
76083695|NCT03005002|Other|Laboratory Biomarker Analysis|Correlative studies
76083696|NCT03005002|Biological|Tremelimumab|Given IV
75791821|NCT01359436|Device|Electrosensing antibody probing system (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
75791822|NCT03942198|Drug|Taodan Granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
75928280|NCT03483636|Drug|Placebo|Film-coated oral tablet
76083697|NCT03001336|Other|no intervention|This is a cross-sectional study
75791823|NCT03942198|Drug|Taodan Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
75791824|NCT01359514|Drug|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
75791825|NCT01359514|Drug|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
75928281|NCT03483558|Other|Control|A standardized diet without any vegetables was provided.
75928282|NCT03483558|Other|Spinach|A standardized diet with 200g spinach was provided.
75928283|NCT03483558|Other|Celery|A standardized diet with 200g celery was provided.
75928284|NCT03483558|Other|Onion|A standardized diet with 200g onion was provided.
75928285|NCT03483558|Other|Mixed Vegetables|A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
75928286|NCT02221479|Drug|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
76083698|NCT03123510|Dietary Supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides|Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
75334363|NCT02344472|Drug|Trastuzumab|HER2 targeted Therapy
75334364|NCT02344472|Drug|Capecitabine|Chemotherapy
75334365|NCT02344472|Drug|Paclitaxel|Chemotherapy
75472202|NCT01955226|Other|Standard clear Tegaderm dressing|Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
75928287|NCT02221479|Drug|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
75643701|NCT02269267|Drug|Dasatinib (Stopping their TKI)|Patients with CML on treatment with dasatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (> 4 log reduction) molecular response (>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) < 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
75791826|NCT01208376|Other|Fibroscan|Fibroscan and Serum Fibrose-marker
75791827|NCT01368016|Drug|Nicotine|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
75791828|NCT01368016|Drug|Nicotine|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
75928288|NCT03476382|Device|Ultrasound Bone Growth Stimulator|Active device emits ultrasound signals.
75928289|NCT02206269|Device|Alair System|The Alair system is used for doing bronchial thermoplasty.
75472203|NCT01955239|Radiation|Intensity-modulated Radiotherapy|
75928290|NCT03476304|Device|Endocrown restoration|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement
75928291|NCT03476304|Device|Post retained composite restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.
75928292|NCT03476304|Device|Post retained ceramic restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
76083699|NCT03123510|Dietary Supplement|Placebo|Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
76083700|NCT02247856|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
76083701|NCT02247856|Device|Jet Nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min"
75334366|NCT02344472|Drug|Vinorelbine|Chemotherapy
75334367|NCT02344472|Drug|Docetaxel|Chemotherapy
75334368|NCT02344472|Drug|Exemestane|endocrine therapy
75334369|NCT02344472|Drug|Letrozole|endocrine therapy
75334370|NCT02344472|Drug|Anastrozole|endocrine therapy
75334371|NCT02344472|Drug|Fulvestrant|endocrine therapy
75334372|NCT02344472|Drug|Ribociclib|CDK 4/6 inhibitor
75334373|NCT02344472|Drug|nab-Paclitaxel|chemotherapy
75334374|NCT02344472|Drug|eribulin|chemotherapy
75334375|NCT02344472|Drug|leuprorelin|endocrine therapy
75334376|NCT02344472|Drug|goserelin|endocrine therapy
75334377|NCT02376946|Device|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
75334378|NCT02376946|Device|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
75643702|NCT02269267|Drug|Nilotinib (Stopping their TKI)|Patients with CML on treatment with nilotinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (> 4 log reduction) molecular response (>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) < 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
75643703|NCT02269267|Drug|Bosutinib (Stopping their TKI)|Patients with CML on treatment with bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (> 4 log reduction) molecular response (>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) < 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
75643704|NCT04293536|Other|Cases study|Patients with a retained device or almost
75643705|NCT02575495|Drug|7 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
75643706|NCT02575495|Drug|14 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
75643707|NCT02575261|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
75643708|NCT01017731|Biological|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
75791829|NCT01208454|Drug|Isotretinoin|Given PO
75791830|NCT01208454|Other|Laboratory Biomarker Analysis|Correlative studies
75791831|NCT01208454|Other|Pharmacological Study|Correlative studies
75791832|NCT01208454|Drug|Vorinostat|Given PO
75791833|NCT01368094|Procedure|Drain removal at D4|If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.
75928293|NCT02224833|Behavioral|Pharmacist intervention|"Systematic review of treatments:~Identification of reasons for PPI.~Determination of recommended pharmacotherapeutic alternatives.~Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP."
76083702|NCT02247856|Device|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
75334379|NCT02338232|Drug|Telmisartan|
75334380|NCT01780636|Drug|botulinum toxin|
75643709|NCT01017731|Drug|Moxifloxacin|Administered orally
75791834|NCT01368094|Procedure|Standard drain removal|If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
75791835|NCT05188846|Other|SDF|"1. Group 1: cleaning the occlusal surface to be treated with toothbrush. Decayed tissue from the affected teeth will not be removed for the SDF group.~Clinical procedure for SDF application: it will apply according to the SDF manufacturer Instructions as follows:(1) the surrounding gingival tissues and lips will be protected with petroleum jelly to avoid staining and irritation,(2) the affected tooth will be isolated and keep dry with cotton rolls and saliva ejectors, (3) one drop of SDF (SDI RIVA STAR ), will be placed into a disposable dish, (4) SDF will be applied with a micro-sponge directly to the affected tooth surface(s), (5) allowed to soak in for 2 min, then air-dried. Then will be followed by the Potassium iodide (KI) liquid to decrease discoloration caused by SDF. The KI liquid will be reapplied until no more white perception observed to form."
75791836|NCT05188846|Other|SDF + ART (SMART technique )|2. Group 2: SDF+ART clinical procedure: (1)cleaning the occlusal surface to be treated with toothbrush.,(2) carious dentin will be removed using a small excavator (Spoon excavator ),(3) the cavity will be cleaned and dried, (4)cavity walls and floor will be conditioned for 10s, then washed and dried, (5) SDF will be applied as mentioned above followed by cavity restoration using resin-reinforced glass ionomer restorative material (SDI RIVA ).
75791837|NCT01110486|Drug|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
75791838|NCT01110486|Drug|ABT-348 and carboplatin|An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
75791839|NCT01110486|Drug|ABT-348 and docetaxel|ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
75791840|NCT01110486|Drug|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
75791841|NCT01110486|Drug|ABT-348|An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
75334381|NCT02973490|Device|Transanal Tube Drainage|Using transanal tube drainage after colorectal ESD
75334382|NCT00000868|Biological|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
75334383|NCT00000868|Biological|Aluminum hydroxide|
75334384|NCT00000868|Biological|MF59|
75334385|NCT00000868|Biological|rgp120/HIV-1MN|
75334386|NCT01893164|Procedure|simple decompression|decompression of the ulnar nerve
75334387|NCT01893164|Procedure|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
75334388|NCT01893164|Procedure|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
76083703|NCT04526964|Behavioral|Self-management curriculum|The Intervention starts during inpatient phase after relocation of potential study participants from the intensive care unit to normal ward and after informed consent to participate. Those subjects assigned to the CGr by randomization code receive standard care at the respective center. Subjects assigned to the IGr received, in addition to standard care, a multi-modular self-management training carried out at the respective center. The content of the self-management training should be deepened and consolidated through a supplementary app. Training is performed during inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up. The intervention lasts 3 months, plus a 9-month follow-up per subject. The content of the self-management training is based on current evidence and was written in a curriculum to achieve the highest possible standardization, taking into account the center specifics.
76083704|NCT03001102|Device|4% Chlorhexidine gluconate|Cationic biguanide - antimicrobial action rubbing in the skin.
75472204|NCT01955252|Drug|Azithromycin|"Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months"
76083705|NCT03001102|Device|10% PVPI degermante|Polymer soluble in water of iodine with polyvinylpyrrolidone (PVP) - antimicrobial action rubbing in the skin.
75334389|NCT05586464|Drug|Ban xia xie xin Decoction and bismuth quadruplicate group|Ban xia xie xin Decoction:10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
75334390|NCT05586464|Drug|Bismuth quadruplicate group|Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
75472205|NCT01955265|Behavioral|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
75643710|NCT01017731|Drug|Diphenhydramine|Administered IV
75472206|NCT01955265|Behavioral|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
75472207|NCT01955278|Device|Definitive end colostomy with mesh|In the mesh group, a synthetic prosthetic mesh low weight type Ultrapro (15x15 cm) will be used. It will be placed in a sublay position between the rectus abdominis muscle and the posterior rectus sheath, will be sutured to the posterior rectus sheath with absorbable multifilament stitches. Once positioned and fixed the mesh the bowel will be brought out through a cross cut in the center of the mesh Finally, colon will be fixed by colocutaneous end to end absorbable multifilament sutures.
75643711|NCT02575417|Behavioral|Conversation Game|The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
75791842|NCT01372306|Drug|Reminyl|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
75791843|NCT01114854|Drug|Topiramate IR|
75791844|NCT01114854|Drug|Topiramate ER|
75791845|NCT01359670|Drug|Tadalafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
75643712|NCT02577289|Procedure|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)|• The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)
75643713|NCT02577289|Procedure|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)|platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
75643714|NCT04302233|Other|New pharmaceutical support (NPS)|The only difference between these 2 groups is that patients in the NPS group benefit from additional visual and oral information on the characteristics of their implant and on medical device vigilance during their hospitalization.
75791846|NCT01359670|Drug|Sildenafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
75791847|NCT03942588|Behavioral|High-intensity interval training|
75791848|NCT04784806|Other|Ground beef|Subjects will consume a 106g patty of cooked ground beef.
75928294|NCT02221635|Procedure|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
75791849|NCT04784806|Other|Ground pork|Subjects will consume a 118g patty of cooked ground pork
75791850|NCT04784806|Other|Tofu|Subjects will consume a 113g patty of cooked tofu
75791851|NCT04784806|Other|Beyond Meat|Subjects will consume a 113g BeyondMeat patty.
75791852|NCT04688944|Other|observation|observation the difference between two groups
75928295|NCT02221635|Drug|Risperidone|Risperidone (2-4 mg) was took orally.
75928296|NCT04832334|Other|Kinesthetic and Visual Imagery Questionnaire, Box and Block Test, Hand Lateralization Test.|Imagery ability was determined.
75928297|NCT04832334|Other|Berg Balance Scale, Functional Reach Test|Balance level was determined.
75928298|NCT04832334|Other|Timed Up and Go Test, Functional Independence Scale|Functionality was evaluated.
75928299|NCT02224911|Device|Laser Interstitial Thermal Therapy|
75928300|NCT03483480|Procedure|NPWT for Pilonidal Surgery|After excision of pilonidal sinus Non powered-NPWT will be applied to the area
75928301|NCT03483480|Procedure|Excision of Pilonidal sinus with normal dressing|After excision of pilonidal sinus normal dressing will be applied to the area of surgery
75928302|NCT02230917|Drug|Sotatercept|
75928303|NCT02230917|Drug|Placebo|
75643715|NCT02575183|Drug|Varinecline (Chantix)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
75928304|NCT02224989|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
75643716|NCT02575183|Drug|Placebo (for Varenicline)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
75643717|NCT02575183|Behavioral|Behavioral Therapy|This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
75791853|NCT01115010|Device|Colonoscope stiffening device|"Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The standard stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the firm wire replaces the standard wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
75791854|NCT01115010|Device|Colonoscope stiffening device|"Standard stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the standard wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
75791855|NCT01115010|Device|Colonoscope stiffening device|"Firm stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the standard wire and so on until cecal intubation is achieved or the procedure is abandoned."
75928305|NCT03483402|Procedure|Micropulse laser trabeculoplasty|Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.
76025491|NCT05131295|Drug|Dapsone|Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.
76025492|NCT05131295|Drug|Aluminum Hydroxide Gel|Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
76025493|NCT04028167|Drug|Sequential FLOT followed by chemoradiation|Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
76025494|NCT05130905|Dietary Supplement|RiteStart Supplement|RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity [6, 7, 8]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
75643718|NCT01035905|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
75643719|NCT01035905|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
75643720|NCT04565821|Device|IPD Probe via TNIT|A total of 10 healthy adult volunteers will be enrolled in this study. All consented participants will be receive the same intervention. A Nasal tube will be inserted through nares until reaching the small intestine. This will be confirmed by m-mode OCT. Once secured, we will start infusing Ionic solution into the intestine so that IPD Probe can measure the potential difference between this and the control reading. The control reading is measured by infusing the same ionic solution subcutaneously on large muscle groups.
76025495|NCT03163459|Drug|selective brain cooling by cold saline perfusion|During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
76025496|NCT03163459|Device|mechanical thrombectomy|conventional mechanical thrombectomy using Solitaire
76025497|NCT05130749|Other|Questionnaire|The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
76025498|NCT05130203|Behavioral|MouvMat Exergaming|Sessions engaging with exergaming device.
75791856|NCT01368172|Behavioral|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
75791857|NCT01210248|Other|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
76083706|NCT03001102|Device|Soap without antiseptic|Liquid soap with glycerin, neutral pH. Skin cleansing
75334391|NCT01561378|Drug|Aspart insulin|40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
75643721|NCT02255305|Biological|FMT|Patients in the FMT group will receive ~50 grams of fecal material suspended in bacteriostatic normal saline and glycerol.
75334392|NCT01561378|Drug|Normal saline|200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
75643722|NCT02255305|Drug|Antimicrobials|Patients randomized to the control group will receive antimicrobials targeting C. difficile.
75643723|NCT00779584|Drug|MK-8776|IV infusion
75643724|NCT00779584|Drug|Gemcitabine|IV infusion
75643725|NCT04073641|Other|No intervention|No intervention
75791858|NCT05188768|Procedure|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
75928306|NCT02723864|Drug|Veliparib + VX-970 + Cisplatin|Ataxia-telangiectasia-related (ATR) protein kinase is central to the deoxyribonucleic acid (DNA) damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. Poly (ADP-ribose) polymerase (PARP) plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor M6620 (VX-970) synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a breast cancer gene (BRCA) null phenotype, and potentiation of the antitumor activity of cisplatin.
76025499|NCT05130203|Behavioral|Standard Recreational Programming|Conducted by recreational therapists.
75334393|NCT01561378|Device|Intranasal mucosal atomizer device|Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
75334394|NCT02628548|Behavioral|Cognitive training program|8 week cognitive training program
75334395|NCT03236662|Drug|(-)-Epicatechin|
75334396|NCT00000880|Drug|Cyclosporine|
75643726|NCT00995930|Drug|ACZ885|ACZ885 150 mg was administered subcutaneously once a month for 12 months.
75643727|NCT00995930|Drug|Placebo|Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
75643728|NCT02577133|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
75334397|NCT00000886|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
75334398|NCT01893242|Drug|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
75472208|NCT01955278|Other|Conventional definitive end colostomy|
75472209|NCT01955291|Device|Reinforced Feedback in Virtual Environment (RFVE)|"The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task."
75643729|NCT02577133|Dietary Supplement|Placebo|The placebo consisted of an identical bottle with distilled water
75643730|NCT00779506|Drug|Quetiapine Fumarate XR|oral, once daily, flexible dose
75643731|NCT04292132|Procedure|Implant placement|interforaminal placement of 2 implants
75643732|NCT04292132|Procedure|immediate loading|immediate loading with a locator retained mandibular overdenture
75643733|NCT04292132|Procedure|conventional loading|conventional loading with a locator retained mandibular overdenture 3 months postoperatively
75643734|NCT02575027|Radiation|Palliative Radiation Therapy|Undergo 4pi palliative radiotherapy
75643735|NCT02575027|Other|Questionnaire Administration|Ancillary studies
75643736|NCT02575027|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo 4pi radiation simulation and planning
75791859|NCT05188768|Procedure|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
76025500|NCT05124587|Other|No intervention group|No intervention group
76025501|NCT01374217|Drug|Tadalafil|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
76025502|NCT01374217|Drug|Lenalidomide|Lenalidomide will be administered as it was prior to study entry.
76025503|NCT01374217|Drug|Dexamethasone|Dexamethasone will be administered as it was prior to study entry.
76025504|NCT01374217|Drug|Clarithromycin|Clarithromycin will be administered as it was prior to study entry.
76025505|NCT04494815|Drug|SR419|Each participant will receive 1 dose of 20 mg SR419 oral suspension.
76025506|NCT04494815|Drug|active control|Each participant will receive 1 dose of 300 mg active control capsule.
76025507|NCT04494815|Drug|SR419 placebo|Each participant will receive 2 doses of SR419 placebo oral suspension.
76025508|NCT04494815|Drug|active control placebo|Each participant will receive 2 doses of active control placebo capsule.
76025509|NCT04494737|Behavioral|Active Comparator: Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
75334399|NCT01893242|Drug|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
75334400|NCT04757792|Other|File inquiry|Data extraction out of file registry
75643737|NCT04099420|Behavioral|Lifestyle counseling|An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students
75643738|NCT02577211|Dietary Supplement|Hipocaloric enteral nutrition|15 kcal/Kg of body weight
75643739|NCT02577211|Dietary Supplement|Normocaloric enteral nutrition|25 kcal/kg of body weight
75643740|NCT00995774|Device|robotic therapy|12 sessions of robot therapy for arm and hand function
75643741|NCT00995774|Other|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
75643742|NCT00995774|Device|robotic therapy|12 sessions of robot therapy for arm and hand function
75643743|NCT00995774|Other|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
75643744|NCT00765388|Device|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
75643745|NCT00765388|Device|Hollister|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
75928307|NCT02221791|Dietary Supplement|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
75334401|NCT02307500|Drug|Regorafenib|oral therapy
75334402|NCT02589938|Other|Standard Oral Hygiene|Oral hygiene care provided per individual institutions standard of care.
75334403|NCT02589938|Other|Standard Oral Hygiene + True Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
75334404|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
75643746|NCT02577055|Procedure|myomectomy|Surgical ablation of all fibroids
75643747|NCT02577055|Procedure|embolisation|Embolisation of the peri-myoma vascular network, with non-resorbable particles of >500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.
75643748|NCT02868866|Behavioral|Immediate Intervention|Committees from 40 churches will be trained in the Faith, Activity, and Nutrition program by Community Health Advisors. The training focuses on helping churches create healthier church environments for physical activity and healthy eating using Cohen's structural model of health behavior as a guide. Each church committee participates in a full-day training and submits a program plan and budget. Churches receive materials to support implementation of the program. After the full-day training, trained churches receive 12 monthly technical assistance calls to help them implement their program plan. The church coordinator receives 8 calls and the pastor receives 4 calls over the 12 months. In Phase 2, the intervention is open to any church in the SC Conference of the United Methodist Church.
75643749|NCT01385059|Drug|axitinib|Given PO
75643750|NCT01385059|Procedure|therapeutic conventional surgery|Undergo prostatectomy and pelvic lymph node dissection
75334405|NCT02292368|Behavioral|Questionnaires|At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
75334406|NCT02292368|Procedure|Acupuncture|Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
75334407|NCT02292368|Procedure|Electroencephalogram (EEG)|Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
75334408|NCT02286674|Other|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
75334409|NCT01893398|Other|Multidimensional stimulation group therapy|The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
75334410|NCT05586854|Procedure|Hydrolink NV membrane|"patient dialysis on a Hydrolink-NV® membrane with an anticoagulant dose decrease protocol.~Period 1 : conventional membrane with his usual anticoagulant for 4 weeks. Period 2 : Hydrolink-NV® membrane with maintenance of the previous doses of Orgaran® Period 3 : Hydrolink-NV® membrane with a decrease in Orgaran® Period 4 : Hydrolink-NV® membrane with the minimum effective dose of Orgaran® or without Orgaran® for a period of 3 months (M4, M5, M6)."
75334411|NCT05586386|Other|Cherry group|200 mL of DSC juice twice/day supplemented with 3g of DSC powder twice/day for 30 days
75334412|NCT05586386|Other|Placebo group|200 mL of placebo juice twice/day
75334413|NCT04757870|Other|frequency|Macro-scale risk factors for the frequency of and mortality of infection
75334414|NCT02279654|Drug|Lenalidomide|Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
75643751|NCT01385059|Other|enzyme-linked immunosorbent assay|Correlative studies
75643752|NCT01385059|Other|laboratory biomarker analysis|Correlative studies
75643753|NCT04292366|Procedure|Invitation procedure|Optimised invitation procedures in an organised colorectal cancer screening programme
75928308|NCT02221791|Dietary Supplement|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
75928309|NCT02221791|Dietary Supplement|Placebo|Participants will consume 70g white chocolate + placebo capsules
76083707|NCT02519556|Drug|Probiatop|Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
75334415|NCT02278718|Drug|NexoBrid|NexoBrid is an enzymatic debriding agent for Eschar Removal.
75334416|NCT02278718|Procedure|Standard of Care|Surgical or Non-Surgical methods for Eschar Removal
75334417|NCT02779478|Procedure|Bronchoscopy|
75334418|NCT04757948|Procedure|Acupuncture|Acupuncture of acupoints P-6 and St-36
75334419|NCT04757948|Device|TENS|TENS of acupoints P-6 and St-36
75334420|NCT04757948|Device|Sham-TENS|Sham-TENS of acupoints P-6 and St-36
75334421|NCT01893476|Other|Implementation educational programme|Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
75334422|NCT02773706|Other|Automated Psychology Services|The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.
75334423|NCT02773706|Other|Notification of Subspecialist|The automated screening tool determines a positive or negative screen, then informs the clinician.
75643754|NCT04551157|Other|Video Viewing|Two patient information videos containing practical advice from staff about the recovery process, images of the wound throughout the healing process and ways to cope with the range of emotional responses that patients report following an open fracture.
75791860|NCT01368328|Dietary Supplement|Chromium nicotinate|The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
75791861|NCT01210326|Procedure|extaction|TESE (testicular sperm extraction), which is actually a surgical biopsy of the testis; or TESA (testicular sperm aspiration), which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure
75791862|NCT01210326|Procedure|testicular sperm extraction|testicular sperm extraction
75791863|NCT01210326|Procedure|testicular sperm aspiration|testicular sperm aspiration
75928310|NCT03476148|Device|Home Rehabilitation using Interactive device|Rehabilitation is performed using interactive motion tracking augmented reality device. 6 exercises are included in one-day rehabilitation program. Each exercise is recorded in aspect of compliance, completion.
75928311|NCT03476148|Other|Inpatient Rehabilitation|Patients are given the exercises in the setting of inpatient rehabilitation
75928312|NCT02231073|Behavioral|Exercise and Education for Parkinson's Disease|Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
75334424|NCT02274896|Device|PD Catheter group|PD catheter
75334425|NCT02272556|Other|Brain MRS during hyperglycemic clamp|All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
75334426|NCT02272556|Other|Analysis of Metabolites in cerebrospinal fluid|All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
75334427|NCT02582918|Behavioral|Outreach with patient education and patient navigation services|"Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~If results are normal, the patient is invited to repeat screening in 6 months.~If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~If CT/MRI is unremarkable, the patient is referred back for routine screening.~If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."
75643755|NCT00769132|Drug|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
75643756|NCT00769132|Drug|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
75643757|NCT00769132|Drug|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
75643758|NCT00769132|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
75643759|NCT04527523|Diagnostic Test|Optical Coherence Tomography|OCT is an imaging method that uses light waves to create images of the retina.
75643760|NCT04070755|Drug|FMX-101|
75643761|NCT02576821|Other|Neurological examinations|
75643762|NCT02576821|Other|Neuropsychological examinations|
75791864|NCT01212120|Biological|Genetic profiling of bacterial cultures|Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
75643763|NCT02576821|Other|Clinical examinations|
75791865|NCT03940404|Drug|Anlotinib Hydrochloride|Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
75791866|NCT03940248|Radiation|Proton Accelerated Partial Breast Irradiation|38.5 Cobalt Gray Equivalent (CGE) given over 10 fractions
75791867|NCT01110642|Drug|Lovastatin|Topical lovastatin applied to red, rashy areas two times daily for 12 months
75928313|NCT05138757|Drug|Prebiotic|A prebiotic is a purified fiber of plant origin that has digestive health benefits by fostering the growth of beneficial microbes.
75928314|NCT05138757|Drug|Placebo|A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.
75928315|NCT03483168|Behavioral|Culturally sensitive pain education|The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.
75928316|NCT03483168|Behavioral|Standard pain education program|"For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators."
76083708|NCT02519556|Drug|Placebo|1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
75643764|NCT02576821|Radiation|MRI 3T|
75643765|NCT02576821|Radiation|MRI 7T|
75334428|NCT02268656|Drug|propofol concentration|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
75334429|NCT02564978|Drug|Minocycline|Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
75334430|NCT02554890|Drug|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
76083709|NCT03000946|Drug|Somatostatin|Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
75791868|NCT01115088|Dietary Supplement|Aspartame|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
75928317|NCT02231151|Behavioral|The type of CPR error(s) shown to the individual|Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
75928318|NCT05259618|Other|Tasso+ SST|alternative site blood sample collection.
75334431|NCT02554890|Drug|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
75643766|NCT04100434|Drug|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
75334432|NCT02554890|Drug|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
75643767|NCT00991952|Drug|alvocidib|Given IV
75928319|NCT02231229|Other|PCR-based strategy|Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
75472210|NCT01955291|Other|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
75472211|NCT01955304|Drug|fruquintinib|Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
75643768|NCT00991952|Drug|irinotecan hydrochloride|Given IV
75643769|NCT00991952|Other|laboratory biomarker analysis|Correlative studies
75928320|NCT02231229|Drug|conventional therapy|Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
75643770|NCT04522921|Dietary Supplement|Diet high on protein (25E%/day)|In a caloric restricted and increased physical activity setting, the control group will consume a low-moderate protein (15E%/day) diet whereas the intervention group will consume a higher protein (25E%/day) diet.
75643771|NCT04522921|Other|Increased follow-up contact after attending a weight loss camp|After leaving the camp, the children and their families with increased follow-up contact will be contacted once every month within the first 6 month and once every other month until 52-weeks follow-up (8 times total). The children and their families will be contacted by phone, facetime or skype as they prefer, within a predetermined and known timeframe. The conversation will focus on individual topics chosen by the child/parent.
75928321|NCT02523456|Behavioral|Training|The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
75928322|NCT02523456|Behavioral|Introduce EWS|An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
76083710|NCT03000946|Drug|Octreotide|Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
76083711|NCT03363282|Procedure|Pterygium Excision|Pterygium excision is the first step for repair
76083712|NCT03006718|Other|PROMIS for Pain Management App|At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
76083713|NCT03004768|Drug|BMS-986165|Oral solution dose of 24 mg [14C] BMS-986165 containing approximately 100 micro Ci of TRA
75643772|NCT00779038|Drug|Fentanyl ITS|40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
76083714|NCT03369054|Behavioral|Minority Stress Treatment|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
76083715|NCT03369054|Behavioral|Treatment As usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
76083716|NCT03005236|Drug|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
76083717|NCT03005236|Drug|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
76083718|NCT03363204|Device|BRUXENSE occlusal splint|Patients participating will put the BRUXENSE occlusal splint each night. During the night the device will collect data potentially related to bruxism. After each night the device will be cleaned with water and toothpaste and charged. This routine will be conducted over 10 consecutive nights.
75791869|NCT01115088|Dietary Supplement|Sucrose|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
75791870|NCT01115088|Dietary Supplement|Stevia|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
75928323|NCT02225067|Drug|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
75643773|NCT04293380|Procedure|amniosyntesis|
75928324|NCT00705146|Device|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
75928325|NCT00705146|Device|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
75472212|NCT01955317|Behavioral|Hand cleansing with chlorhexidine|Pregnant women in the intervention arm will receive an intensive hand cleansing promotion delivered at 3 in-home visits between one month prenatal and 1 week post natal. The intervention will promote and discuss with mothers the benefits of hand cleansing with chlorhexidine before breastfeeding, before umbilical cord care, after contact with respiratory secretions, and the convenience of using a waterless hand sanitizer especially during the neonatal period. Each mother will receive a half-liter pump bottle with chlorhexidine lotion. The program will also educate mothers about infectious causes of morbidity and mortality in neonates and promote understanding of the risk to the neonate from these diseases.
75643774|NCT04292990|Drug|Fentanyl|Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
75643775|NCT04292990|Drug|Morphine|Tablets taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
75791871|NCT02929498|Drug|GSK2879552|GSK2879552 will be administered orally as continuous daily dosing.
75928326|NCT03483090|Dietary Supplement|Swisse High Strength Deep Sea Krill Oil|Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.
75472213|NCT01955317|Behavioral|Mother and neonatal health counselling|This arms will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
76083719|NCT03004690|Device|PPE Suit A|In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
76083720|NCT03004690|Device|PPE Suit B|Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
75791872|NCT02929498|Drug|Azacitidine|Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
75643776|NCT04100278|Behavioral|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
76083721|NCT02519010|Drug|Amlodipine/Valsartan|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
75643777|NCT02197351|Procedure|White light biopsy|Endoscopy with biopsies guided by high definition white light
75791873|NCT01110720|Drug|Davunetide|Davunetide Nasal Spray 30 mg BID IN 52 weeks
75791874|NCT01110720|Drug|Placebo|Placebo Nasal Spray BID IN 52 weeks
75791875|NCT04645186|Device|bone graft substitute|Filling bone defects in current clinical practice
75791876|NCT01359826|Drug|Milnacipran|After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
75791877|NCT04576936|Other|AIRVO|Daily, at-home device use of AIRVO device in moderate to severe COPD patients.
75791878|NCT04535674|Biological|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
75791879|NCT03792672|Drug|TAK-653|TAK-653 tablets.
75791880|NCT03792672|Drug|Placebo|TAK-653 placebo-matching tablets.
75791881|NCT03792672|Drug|Ketamine|Ketamine intravenous infusion.
75791882|NCT01372540|Drug|Carfilzomib|Given IV
76083722|NCT02519010|Drug|Exforge|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
76083723|NCT03372642|Device|Subtalar endorthesis|Subtalar arthroereisis with endorthesis for pediatric flexible flat foot
75472214|NCT01955330|Procedure|Robotic Hybrid coronary artery revascularization|Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
75472215|NCT01955395|Behavioral|Relaxation Response Resiliency Program (3RP)|The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
75472216|NCT01955408|Other|Questionnaires, anticholinergic treatment, urodynamic study|
75472217|NCT01955421|Drug|Erlotinib 100mg qd|
75472218|NCT01955421|Drug|Gefitinib 250mg qd|
75472219|NCT01955447|Dietary Supplement|no added plant-based ingredients to starchy meal|no added plant-based ingredients to starchy meal
75791883|NCT01372540|Drug|Filanesib|Given IV
75791884|NCT01372540|Other|Laboratory Biomarker Analysis|Correlative studies
75791885|NCT01368484|Dietary Supplement|Sunflower oil|1500 mg sunflower/day for 10 weeks
75791886|NCT01368484|Dietary Supplement|Docosahexanoic acid|1500mg/day for 10 weeks
75928327|NCT03483090|Other|Placebo|No therapeutic effect
75791887|NCT05188690|Other|Data collection from medical records|Data collection from medical records
75928328|NCT02222025|Other|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
75472220|NCT01955447|Dietary Supplement|Low level plant-based ingredients added to starchy meal|Low level plant-based ingredients added to starchy meal
75472221|NCT01955447|Dietary Supplement|Medium level plant-based ingredients added to starchy meal|Medium level plant-based ingredients added to starchy meal
75472222|NCT01955447|Dietary Supplement|High level plant-based ingredients added to starchy meal|High level plant-based ingredients added to starchy meal
75791888|NCT01110798|Other|intraoperative complication management/prevention|
75928329|NCT03475836|Dietary Supplement|Mentha piperita|Commercially available essential oil suspended in an off-the-shelf vegetable oil.
75928330|NCT03475836|Dietary Supplement|Placebo|Inert placebo control in the form of vegetable oil. This matches the vegetable oil in the active intervention condition.
75791889|NCT01110798|Procedure|assessment of therapy complications|
75472223|NCT01955486|Other|flight simulation|
75643778|NCT02197351|Procedure|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
75643779|NCT02197351|Procedure|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
75928331|NCT02225379|Device|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
75928332|NCT03482934|Device|sphygmomanometer|device used for measurement of brachial blood pressure
75643780|NCT02869568|Other|Data collection|
75643781|NCT00916474|Drug|telaprevir|
75791890|NCT01110798|Procedure|gastrointestinal complications management/prevention|
75791891|NCT01110798|Procedure|quality-of-life assessment|
75791892|NCT01110798|Procedure|therapeutic conventional surgery|
76083724|NCT03004456|Other|Distraction|Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
76083725|NCT03363126|Procedure|Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery
76083726|NCT03004612|Combination Product|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
76083727|NCT03004612|Drug|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
75334433|NCT02554890|Drug|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
75334434|NCT02257112|Device|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
75334435|NCT00001864|Drug|Atropine|
75334436|NCT00001864|Device|Patch|
75334437|NCT04491552|Diagnostic Test|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
75334438|NCT00000106|Device|Whole body hyperthermia unit|
75643782|NCT04291742|Diagnostic Test|cognitive vs software|cognitive vs software
75643783|NCT00629174|Behavioral|Exercise|Endurance and resistence training, 90 minutes, 3 times weekly
75643784|NCT00629174|Behavioral|Mental activity|Participation at computer lessons, 3 times weekly, 90 minutes each
75791893|NCT01110954|Drug|PD L 506|Two different doses will be compared
75791894|NCT01113138|Dietary Supplement|Mablet (Magnesium-supplement)|Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS
75334439|NCT00001870|Drug|Acetylcholine|
75334440|NCT03252600|Drug|Cyclophosphamide|Given IV
75334441|NCT03252600|Drug|Dexamethasone|Given IV
75334442|NCT03252600|Biological|Elotuzumab|Given IV
75791895|NCT01113138|Drug|Magnesium Sulfate|Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
75791896|NCT01210404|Drug|filibuvir|Filibuvir, 600mg bid administered along with methadone on days 2-11
75791897|NCT03940170|Device|vistacam proof|Light fluorescence device
75334443|NCT03252600|Other|Laboratory Biomarker Analysis|Correlative studies
75334444|NCT03252600|Drug|Lenalidomide|Given PO
75334445|NCT03252600|Other|Pharmacological Study|Correlative studies
75334446|NCT00000118|Device|Sustained-Release Intraocular Drug Delivery System|
75334447|NCT00000124|Procedure|Brachytherapy|
75334448|NCT00000124|Procedure|Eye Removal|
75334449|NCT00001894|Procedure|pacemaker implantation|
75334450|NCT00001894|Procedure|percutaneous transluminal septal ablation (PTSA)|
75334451|NCT02749526|Drug|"Endostar"|30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
75643785|NCT02868710|Other|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
75643786|NCT02869256|Other|Practices evaluation|Practices evaluation
75643787|NCT00629096|Procedure|Intracoronary infusion of autologous bone marrow cells|Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
75791898|NCT03940170|Other|ICDASII|visual examination
75791899|NCT03940170|Procedure|fissurotomy|histological validation
75791900|NCT01115322|Drug|Tazarotene Foam without irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period.~This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
75928333|NCT03482934|Device|mobilogragh|device used for measurement of central blood pressure
75928334|NCT03482934|Diagnostic Test|ECG|Electrocardiogram
75928335|NCT03482934|Diagnostic Test|Echocardiography|Echocardiography
75928336|NCT02231307|Drug|SUBLIVAC FIX Birch|
75928337|NCT03475758|Drug|Goserelin|adding goserelin with chemotherapy
75928338|NCT03479970|Other|GNPT+ Social Cognition|Aplication of a computer based treatment focused on attention, memory, executive functions and social cognition.
75928339|NCT03479970|Other|GNPT|It's a computeritzed program of cognitive telerehabilitation
75928340|NCT03479892|Drug|NNC0194-0499|"Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
75928341|NCT03479892|Drug|Placebo|Participants will receive once weekly injections of NNC0194-0499 matched placebo.
76083728|NCT04525560|Other|PEG-ELS-S|2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.
76083729|NCT04525560|Other|PEG-ELS-L|PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.
76083730|NCT03363048|Behavioral|Restricted|Certain foods and beverages are not allowed to be purchased with food benefit dollars.
76083731|NCT03363048|Behavioral|Restriction plus Incentive|Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
76083732|NCT03000868|Procedure|Cold endoscopic mucosal resection|Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
75334452|NCT02749526|Drug|Liposo|135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
75334453|NCT02749526|Drug|cisplatin|25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
75334454|NCT02749526|Drug|Gimeracil and Oteracil Potassium （Tegafur）|40mg bid，D1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
75334455|NCT00000916|Drug|Indinavir sulfate|
75334456|NCT00000916|Drug|Lamivudine/Zidovudine|
75334457|NCT00000916|Drug|Hydroxyurea|
75334458|NCT00000916|Drug|Lamivudine|
75791901|NCT01115322|Drug|Tazarotene Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
75643788|NCT02868632|Drug|MEDI4736|anti-PD-L1 human monoclonal antibody
75928342|NCT02231385|Drug|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
75334459|NCT00000916|Drug|Stavudine|
75334460|NCT00000916|Drug|Zidovudine|
75334461|NCT00000916|Drug|Didanosine|
75643789|NCT02868632|Drug|Tremelimumab|anti-CTLA4 human monoclonal antibody
75928343|NCT02523768|Drug|ATG-F|
75334462|NCT04423770|Other|No intervention|No intervention; this is a purely observational study
75334463|NCT05475912|Other|Group A, excercises|Each group will receive treatment three times per week for 3 weeks total 7 sessions.
75334464|NCT00000928|Behavioral|Group counseling intervention|Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
75334465|NCT00000130|Drug|Intravitreal Antibiotics|
75472224|NCT01955538|Other|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
75472225|NCT01955538|Other|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
75643790|NCT02868632|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy (SBRT) will be administered at the standard dose of 6 Gy daily for 5 days.
75643791|NCT00765076|Biological|GSK Biologicals' influenza vaccine GSK2186877A|One intramuscular injection at Day 0
75643792|NCT00765076|Biological|GSK Biologicals' Fluarix|One intramuscular injection at Day 0
75928344|NCT02523768|Drug|Simulect|
75928345|NCT02225457|Other|Hypercaloric diet|"Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet."
75334466|NCT00000130|Procedure|Initial Pars Plana Vitrectomy|
75334467|NCT00000160|Procedure|Xenon Photocoagulation|
75334468|NCT00000160|Procedure|Argon Photocoagulation|
75334469|NCT00000160|Procedure|Photocoagulation|
75334470|NCT02552316|Device|NB-UVB Phototherapy|
75334471|NCT00000178|Drug|Prednisone|
75334472|NCT04423692|Other|labs|A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy
75334473|NCT00000190|Procedure|Parotid Gland|
75334474|NCT05480280|Drug|Dalpiciclib|Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days.
75334475|NCT05480280|Drug|Oxaliplatin injection|85mg/m², ivdrip, D1
75334476|NCT05480280|Drug|Calcium folinate|400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
75334477|NCT05480280|Drug|5-fluorouracil|400mg/m², iv, D1; and 2400mg/m², civ, 46-48h
75334478|NCT04757324|Other|breastfeeding education|
75334479|NCT00001906|Biological|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
75334480|NCT02208830|Other|pulmonary rehabilitation|Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
75334481|NCT02208830|Other|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
75334482|NCT00000196|Drug|Naltrexone|
75334483|NCT05480202|Other|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
75643793|NCT04021498|Drug|Simvastatin 40mg|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
75928346|NCT02225457|Dietary Supplement|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
75928347|NCT02225457|Dietary Supplement|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
75791902|NCT01115322|Drug|Tazarotene Foam with UVA, UVB, and visible light|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
76083733|NCT03000868|Procedure|Hot endoscopic mucosal resection|Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
76083734|NCT04527042|Drug|Rivaroxaban|It is determined by the clinician's routine clinical prescription.
75334484|NCT05480202|Other|Designed chest physical therapy program|Percussion, vibration and postural drainage
75334485|NCT00000946|Biological|HIV p24/MF59 Vaccine|
75643794|NCT04021498|Other|Placebo|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
75928348|NCT05259384|Procedure|Robotic pancreaticoduodenectomy|The Intervention of MIPD-ROB group
75928349|NCT05259384|Procedure|Laparoscopic pancreaticoduodenectomy|The Intervention of MIPD-LAP group
75928350|NCT05259384|Procedure|Robotic Distal Pancreatectomy|The Intervention of MIDP-ROB group
75928351|NCT05259384|Procedure|Laparoscopic Distal Pancreatectomy|The Intervention of MIDP-LAP group
75928352|NCT02222259|Procedure|GA and Integrated Care Plan|The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
75928353|NCT02225535|Other|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
75928354|NCT02225535|Other|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
75928355|NCT02225535|Other|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
75928356|NCT03482700|Behavioral|Intervention Arm|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
75928357|NCT03482700|Behavioral|Control Arm|Usual standard of care
75928358|NCT03479814|Radiation|IMRT-SIB plus sequential IG-RT boost|
75334486|NCT00000946|Biological|ALVAC-HIV MN120TMG (vCP205)|
75928359|NCT02225613|Other|Usual protocol|
75928360|NCT02225613|Other|Spa protocol|
76083735|NCT03000790|Device|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue"
76083736|NCT03372486|Drug|Bupivacaine plus naloxone|Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)
75334487|NCT00000946|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
75334488|NCT00000946|Biological|rgp120/HIV-1 SF-2|
75334489|NCT02543346|Drug|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
75472226|NCT01955538|Other|Mixed physical activity|20 weeks, 1 hour/week.
75643795|NCT00994682|Drug|Pioglitazone study drug|30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months
75643796|NCT00994682|Drug|Placebo|An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
75643797|NCT00994682|Drug|Pioglitazone Open Label|Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
75643798|NCT00768898|Other|2.5/5.0/10.0 ÂµL lissamine green|vital stain solution
75643799|NCT00994448|Drug|Bupropion SR 150mg tabs|Bupropion SR 150mg tabs (Zyban) twice daily
75643800|NCT00994448|Drug|Placebo tablets|One placebo tablet twice daily
75643801|NCT00991406|Device|FES|Surface stimulation to contract the muscles in the lower extremity
75643802|NCT04292444|Drug|Oxytocin nasal spray|Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.
75928361|NCT03479736|Drug|Oral Fluoroquinolones (FQ)|Participants will not receive any intervention as a part of this study. The FQ include all oral forms of FQ (24-hours extended release tablets, extended release tablets, oral solution, oral suspension, oral tablet, pack). The drugs included are ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin.
75928362|NCT03479736|Drug|Other Antibiotics|Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
75928363|NCT03479736|Other|Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure|Febrile illness not treated with antibiotics is defined as: concurrent diagnoses of viral disease with concurrent fever, and no concurrent prescription for any antibiotic during the 60-day period before and after the first date of viral disease diagnosis; or a diagnosis of influenza with no concurrent inpatient admission during the 60-day period pre- or post-influenza diagnosis, and no prescription for any antibiotics during the 60-day period pre- or post-influenza diagnosis.
75334490|NCT02543346|Other|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
75334491|NCT04390100|Drug|hyaluronic acid (Gengiegel 0.2% oral gel )|coverage of the free gingival graft area in the palate
75791903|NCT01115322|Drug|Vehicle Foam without irradiation|Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
75334492|NCT04390100|Other|Platelet rich fibrin|coverage of the free gingival graft area in the palate
75334493|NCT04390100|Other|Gel foam|coverage of the free gingival graft area in the palate
75334494|NCT00000202|Drug|Buprenorphine|
75334495|NCT00000208|Drug|Buprenorphine|
75334496|NCT00001930|Drug|Amantadine|
75643803|NCT04292444|Drug|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
75643804|NCT01017575|Drug|Daclatasvir|Tablets, Oral, 10 mg, daily, 24-48 weeks
75643805|NCT01017575|Drug|Daclatasvir|Tablets, Oral, 60 mg, daily, 24-48 weeks
75643806|NCT01017575|Drug|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
75928364|NCT02225691|Device|Paired testing of blood glucose Accu-Chek®|Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
75928365|NCT02225769|Other|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
75928366|NCT02225769|Other|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
75928367|NCT03479658|Behavioral|High intensity interval training|Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.
75928368|NCT03479658|Behavioral|Nutritional education|School-based nutritional education on healthy dietary habits
75928369|NCT02225847|Other|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
75643807|NCT01017575|Drug|Peginterferon alfa-2a|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
75928370|NCT02225847|Procedure|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
76025510|NCT04494737|Behavioral|Active Comparator: Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
76083737|NCT03372486|Drug|Bupivacaine|Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline
75334497|NCT00000964|Drug|Ranitidine hydrochloride|
75334498|NCT00000964|Drug|Foscarnet sodium|
75334499|NCT00000976|Drug|CD4-IgG|
75334500|NCT00000976|Drug|Zidovudine|
75334501|NCT00000226|Drug|Buprenorphine|
75334502|NCT00000982|Drug|Zidovudine|
75334503|NCT00000982|Drug|Didanosine|
75334504|NCT04818814|Behavioral|Mindfulness Meditation App|Listening to audio-guided meditation sessions using a mobile app.
75334505|NCT04818814|Behavioral|Engagement and Distraction App|Listening to engaging and distracting videos of interest to the participant using a mobile app.
75334506|NCT02549196|Drug|Donepezil|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
75334507|NCT02549196|Drug|Solifenacin|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
75334508|NCT00000988|Drug|Stavudine|
75334509|NCT00000232|Drug|Buprenorphine|
75334510|NCT00000238|Drug|Buprenorphine|
75334511|NCT00000244|Drug|Dynorphin 1 - 13|
75334512|NCT00000994|Drug|Zidovudine|
75334513|NCT00001006|Drug|AS-101|
75334514|NCT00001012|Drug|AL 721|
75334515|NCT00001954|Drug|Etanercept|
75643808|NCT01017575|Drug|Ribavirin|Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
75643809|NCT01017263|Drug|Lis-dexamphetamine|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
75643810|NCT02872181|Procedure|Supine|Placed in Supine position
75643811|NCT02872181|Procedure|Left uterine displacement|Placed in 15 degrees left uterine displacement
75643812|NCT00768664|Drug|PF-00299804|45 mg by continuous oral dosing
75928371|NCT02225847|Behavioral|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
75334516|NCT00001018|Drug|Letrazuril|
75928372|NCT03940092|Other|MRI|"This is a prospective, non-randomised, exploratory study on healthy female volunteers (>18 years), and female patients (>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery."
75928373|NCT03940092|Other|PET/MRI|Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI
75334517|NCT02904954|Drug|Durvalumab|Intravenously
75334518|NCT02904954|Other|Durvalumab plus SBRT|Intravenously plus radiotherapy
75334519|NCT00000250|Drug|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
75928374|NCT03203642|Drug|Tesevatinib|Pharmaceutical form: Tablet; Route of administration: orally
75643813|NCT04097782|Behavioral|Antenat education|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
75643814|NCT04097938|Drug|GLPG3667 oral suspension|GLPG3667 oral suspension
75334520|NCT00000250|Drug|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
75334521|NCT00001960|Device|Pacemaker therapy|
75643815|NCT04097938|Drug|Placebos|Placebo oral suspension
75643816|NCT04097938|Drug|GLPG3667 capsules|GLPG3667 capsules
75791904|NCT01115322|Drug|Vehicle Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
76083738|NCT05064670|Behavioral|Exercise|A twice weekly, 3-month supervised exercise program of whole body resistance training using body weight and a resistance band, and moderate to high intensity aerobic activities, consisting of a consecutive series of timed exercises performed one after the other (14-18 on the Borg scale). Classes are conducted live in groups through Microsoft Teams. Participants will not receive any contact or exercise support in the 3-month follow-up period following the initial 3-month intervention
76083739|NCT03372330|Drug|Standard care for sepsis and PAD|The standard medications care for the patient with PAD included antiplatelet agents.
76083740|NCT03372330|Drug|Standard care for sepsis|The standard care for the patient with sepsis.
76083741|NCT04525482|Other|Early goal-directed sedation programs|A. Provide sedation at the beginning of the titration of dextrometomidine; b. Optimize sedation when dextrometomidine is used alone and at a maximum dose not sufficient to provide comfort and safety to the patient and to achieve a level of sedation at any time specified by the treating physician. C. Provides immediate recovery and sedation, and can control sudden agitation at any time
75334522|NCT03244020|Drug|Aspirin 325mg|Aspirin 325 mg by mouth once daily
75334523|NCT03244020|Drug|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Enoxaparin 40 mg subcutaneous injection once daily
75334524|NCT00000262|Drug|30% Nitrous oxide|
75334525|NCT00000262|Drug|0.4% Sevoflurane|
75334526|NCT00000262|Drug|0.2% sevoflurane|
75334527|NCT00000262|Other|Placebo|
75334528|NCT01188499|Drug|Birinapant|
75334529|NCT00001024|Drug|Zidovudine|
75334530|NCT00001024|Drug|Didanosine|
75334531|NCT00000268|Drug|Bupropion|
75334532|NCT00001966|Drug|Mind-body therapy|
75334533|NCT02830152|Device|LAAO|The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
75334534|NCT02830152|Drug|Medical Therapy|Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
75643817|NCT02576743|Device|7 Tesla MRI|MR imaging using a 7 Tesla MR system.
75643818|NCT02184013|Procedure|Catheter ablation|Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).
75928375|NCT03203642|Drug|Placebo|Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
75928376|NCT03475680|Drug|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
75334535|NCT00001042|Biological|Aluminum hydroxide|
75334536|NCT00001042|Biological|Lipid A, Monophosphoryl|
75334537|NCT00001042|Biological|Lipid A, Liposome-encapsulated monophosphoryl|
75334538|NCT00001042|Biological|Syntex adjuvant formulation|
75334539|NCT00001042|Biological|MF59|
75334540|NCT00001042|Biological|Threonyl Muramyl Dipeptide|
75334541|NCT00001042|Biological|rgp120/HIV-1 SF-2|
75334542|NCT00001042|Biological|MTP-PE/MF59|
75334543|NCT00982865|Drug|MSC1936369B|
75334544|NCT00982865|Drug|MSC1936369B|
75334545|NCT00982865|Drug|MSC1936369B|
75334546|NCT00982865|Drug|MSC1936369B|
75334547|NCT05475756|Device|Intrauterine Biological Barrier|after Hysteroscopic adhesiolysis，use of Intrauterine Biological Barrier to repair uterine cavity
75928377|NCT03475680|Drug|Oral Gentamycin|Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
76083742|NCT05035888|Drug|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to < 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
76083743|NCT05035888|Drug|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
76083744|NCT03368820|Other|No intervention|Treatment left at the discretion of the participant
75334548|NCT05475756|Device|Intrauterine Adhesion Barrier Gel|after Hysteroscopic adhesiolysis，use of Intrauterine Adhesion Barrier Gel to repair uterine cavity
75334549|NCT00001972|Drug|15 O Water|
75334550|NCT02522468|Procedure|Radioactive Seed Localization|
75472227|NCT01955551|Behavioral|Motivational Interviewing|In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
75643819|NCT04840069|Drug|Fluciclovine PET guided Radiotherapy|PET+MRI Based There is no GTV_5400. The GTV_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV_5400 will include the GTV_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV_5400 must also include the entirety of the GTV_6000. There is no CTV_6000. PTV_5400 is the CTV_5400 plus a geometric 3 mm expansion in all dimensions; PTV_6000 is GTV_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV_5400 must contain the PTV_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV_6000. PTV_6000 will be defined as GTV_6000 plus a geometric 3 mm expansion in all dimensions.
75643820|NCT02574949|Radiation|Radiation: 15 FPS Cine 15 PPS|Radiation 15 FPS Cine 15 PPS
75643821|NCT02574949|Radiation|Radiation: 7.5 low Frame rate|Radiation: Frame rate 7.5 FPS, Cine 15 PPS
75791905|NCT01115322|Drug|Vehicle Foam with UVA and UVB and visible light irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
75928378|NCT03475680|Drug|Oral Ornidazole|"Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
76083745|NCT03000712|Biological|Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml|biological : Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml drug: saline solution
76083746|NCT03372252|Device|Electroencephalography|Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
75928379|NCT03475680|Drug|Oral placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
76083747|NCT03000478|Behavioral|Prolonged Exposure|
76083748|NCT03000478|Behavioral|Virtual Reality Exposure Therapy|
76083749|NCT03372018|Behavioral|Promotora-led Intervention (PLI)|Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
76083750|NCT03372018|Behavioral|Usual care (UC)|Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
75334551|NCT02522468|Procedure|Wire Localization|
75334552|NCT00001054|Drug|Valacyclovir hydrochloride|
75334553|NCT00380536|Behavioral|Peer-Led Health Education Class|Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
75334554|NCT01226719|Drug|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
75643822|NCT02574949|Radiation|Low Cine|Radiation: Frame rate 7.5 FPS, Cine 10 PPS
76083751|NCT03004300|Procedure|Rapid maxillary expansion|Device
76083752|NCT03004300|Procedure|Adenotonsillectomy|Surgery
76083753|NCT03362814|Drug|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
76083754|NCT03362814|Drug|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
75334555|NCT01226719|Drug|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
75334556|NCT01226719|Drug|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
75928380|NCT03475680|Drug|Oral placebo Ornidazole|"Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
75928381|NCT03475602|Diagnostic Test|PLA2R|Determination of serum concentration of anti PLA2R antibody
75928382|NCT03475602|Diagnostic Test|TSHD7A|Determination of serum concentration of anti TSHD7A antibody
75928383|NCT02231463|Other|neutral positioning, PEEP 0 cm H2O|neutral positioning, PEEP 0 cm H2O
75928384|NCT02231463|Other|neutral positioning, PEEP 5cm H2O|neutral positioning, PEEP 5cm H2O
75928385|NCT02231463|Other|neutral positioning, PEEP 10cm H2O|neutral positioning, PEEP 10cm H2O
76083755|NCT03362814|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
76083756|NCT03362814|Drug|Ribavirin 100 MG|Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(<75kg = 1000mg and ≥75kg = 1200mg)
76083757|NCT03362814|Drug|Ravidasvir Placebo|Ravidasvir Placebo tablet administered orally once daily
76083758|NCT03362814|Drug|Danoprevir Placebo|Danoprevir Placebo tablet administered orally twice daily
76083759|NCT03362814|Drug|Ritonavir Placebo|Ritonavir Placebo tablet administered orally twice daily
76083760|NCT03362814|Drug|Ribavirin Placebo|Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(<75kg = 5 tablets and ≥75kg = 6 tablets)
75334557|NCT01226719|Drug|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
75334558|NCT01226719|Drug|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
75334559|NCT00001060|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
75643823|NCT01253161|Drug|Pasireotide Long Acting Release (LAR)|Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
75643824|NCT00581113|Radiation|Radiotherapy|Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
75643825|NCT00709423|Drug|Moxaverine|
75643826|NCT00709423|Drug|Moxaverin 150mg|intravenous administration
75643827|NCT00709423|Drug|NaCl|intravenous administration
75643828|NCT02574871|Other|Psychological and biological data collection|Psychological and biological data collection for identification of the chronic stress presence
75643829|NCT00627887|Procedure|Electroconvulsive therapy|unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
75643830|NCT00627887|Drug|venlafaxine|extended release target dose of 300mg/day duration of one year
75643831|NCT00627887|Drug|Lithium|serum concentration 0,5-0,8 mmol/L, one year duration
75791906|NCT01115322|Drug|No Treatment without irradiation|Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
75928386|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 0 cmH2O|Trendelenburg positioning -20°, PEEP 0 cmH2O
75928387|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 5 cmH2O|Trendelenburg positioning -20°, PEEP 5 cmH2O
75643832|NCT02576665|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
75643833|NCT02576665|Drug|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
75643834|NCT02574793|Device|continuous glucose monitoring|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
75643835|NCT00627965|Drug|Sildenafil citrate|50mg tds
75643836|NCT00627965|Drug|Placebo|Placebo tds
75643837|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
75643838|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
75643839|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
75791907|NCT01115322|Drug|No Treatment with UVA and UVB irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
75928388|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 10 cmH2O|Trendelenburg positioning -20°, PEEP 10 cmH2O
75928389|NCT04621136|Drug|Ripasudil ophthalmic solution 0.4%|"Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin.~Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks."
75928390|NCT03475524|Drug|MetFORMIN 1000 Mg Oral Tablet|oral tablet 1ooomg systemic metformin will be given to group
75928391|NCT03475524|Drug|Placebos|oral placebos will be given to control beside trichloracetic acid peeling
75928392|NCT03475524|Drug|Trichloroacetic Acid Peeling|Trichloroacetic acid peeling to the three groups
75928393|NCT03475524|Drug|MetFORMIN 500 Mg Oral Tablet|oral tablet 500 mg
75928394|NCT02259075|Drug|Botulinum Toxin Type A|
75928395|NCT02471846|Drug|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle with the exception of biopsy cohort A, where atezolizumab administration will start on Cycle 2 Day 1.
76083761|NCT03004066|Drug|Daptomycin|standard care
76083762|NCT05004454|Dietary Supplement|Bacillus subtilis BS50 spore preparation|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
76083763|NCT05004454|Dietary Supplement|Maltodextrin|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
75334560|NCT02518256|Procedure|Lavage of the Cavum uteri and proximal fallopian tubes|
75334561|NCT00001072|Biological|ALVAC-HIV MN120TMGNP (vCP300)|
75334562|NCT00001072|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
75334563|NCT00001072|Biological|rgp120/HIV-1 SF-2|
75791908|NCT01115322|Drug|No Treatment with UVA and UVB and visible light irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
75791909|NCT01359982|Drug|RRx-001|Dose level 1 (10 mg/m2)
75643840|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
75643841|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
75791910|NCT01359982|Drug|RRx-001|Dose Level 2 (16.7 mg/m2)
75928396|NCT02471846|Drug|GDC-0919|Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, 400, 600, and 1000 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
75928397|NCT04458714|Procedure|Aortoiliac angioplasty|In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
75928398|NCT02259153|Behavioral|Changes in cholesterol metabolism|
75928399|NCT02259153|Other|Lean red meat diet|
75928400|NCT02259153|Other|Fat red meat diet|
75928401|NCT03108716|Procedure|hamate hook removal|The patients were assigned to treat with hamate hook removal.
75928402|NCT03108716|Procedure|microscrew internal fixation|The patients were assigned to treat with microscrew internal fixation after open reduction.
75928403|NCT03108716|Other|short-arm tube-type plaster fixation|The patients were assigned to treat with short-arm tube-type plaster fixation (conservative treatment).
75928404|NCT03482622|Diagnostic Test|Fast Raman|Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.
75928405|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
75928406|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is turned off.
75928407|NCT02231619|Behavioral|Baseline verbal instruction on LSUPT|
75928408|NCT02222415|Dietary Supplement|Exercise + Protein drink|
75643842|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
75643843|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
75791911|NCT01359982|Drug|RRx-001|Dose Level 3 (24.6 mg/m2)
75791912|NCT01359982|Drug|RRx-001|Dose Level 4 (33 mg/m2)
75791913|NCT01359982|Drug|RRx-001|Dose Level 5 (55.0 mg/m2)
75928409|NCT02737722|Drug|Bisphosphocin Nu-3|
75791914|NCT01359982|Drug|RRx-001|Dose Level 6 (83 mg/m2)
75791915|NCT01111188|Drug|PD 0332991|"PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.~(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg"
75791916|NCT01111188|Drug|bortezomib|"Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.~(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2"
75928410|NCT02737722|Drug|Placebo|
75928411|NCT02231853|Biological|MVST|MVST Infusion
75791917|NCT04231396|Other|Audiobooks for hearing loss App|Same as Arm 1
75791918|NCT01210482|Drug|Temsirolimus|The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30~60 minutes. The dosage is to be appropriately reduced according to patients' status.
75791919|NCT01113294|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
75791920|NCT01360060|Drug|Magnesium Sulphate|Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
75928412|NCT02231853|Biological|MVSTr|"PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr."
75928413|NCT02472782|Drug|Teriparatide|The study will include patients from pre-defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
76083764|NCT03362736|Drug|Ustekinumab|All participants will receive a single intravenous (IV) tiered dose of ustekinumab based on body weight at Week 0 (participants less than or equal to [<=] 55 kilogram [kg] will receive 260 milligram [mg] ustekinumab; > 55 kg to <= 85 kg will receive 390 mg ustekinumab; and > 85 kg will receive 520 mg ustekinumab infusion) during induction period. After the IV induction dose, all participants will receive the first maintenance dose of 90 mg ustekinumab subcutaneous (SC) injection 8 weeks later (Week 8). The participants with adequate response based on the physician's judgement will be subsequently treated with 90 mg ustekinumab SC injection with every 12 weeks through Week 80 and participants with an inadequate response to ustekinumab dosing every 12 weeks based on the physician's judgement will be subsequently treated with 90 mg of ustekinumab every 8 weeks through Week 80.
75334564|NCT02194868|Biological|Recipients|"Adult recipient:~collected 20 ml pre-transplant~collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,~collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360~Children recipients~collected residual blood pre-transplant~collected residual blood on day 20 post-transplant at engraftment for cell phenotype,~collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"
75334565|NCT02194868|Biological|Donors|"Adult donors :~collected 20 ml of blood, (if possible before granulocyte colony-stimulating factor (GCSF) administration)~collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.~Children donors samples~collected residual blood~2ml of bone marrow (bottom of tube)"
75928414|NCT02472860|Behavioral|Targeted Cognitive Training (TCT)|The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
75643844|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
75928415|NCT02472860|Other|Youth Appropriate Online Games|Engaging games not designed to improve cognition
76083765|NCT03004222|Drug|Bupivacaine|20 ml of 0.5% Bupivacaine
75334566|NCT04331470|Drug|Levamisole Pill + Budesonide+Formoterol inhaler|Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours
75334567|NCT04331470|Drug|Lopinavir/Ritonavir + hydoxychloroquine|Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
75334568|NCT00001078|Biological|Hepatitis A Vaccine (Inactivated)|
75643845|NCT02574559|Behavioral|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
75643846|NCT00709501|Behavioral|Disseminating Effective Habits for Long-term Weight Loss|Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).
75643847|NCT00709501|Behavioral|Achieve Together website|access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
75791921|NCT03741036|Procedure|Autogenous bone graft as space filling in immidiate implant placment|"The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with autogenous bone graft)~Patients will be subjected to CBCT (diagnostic for upper arch).~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~The procedure will be carried out flapless.~In the study group: Atraumatic extraction~The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
75928416|NCT02258607|Drug|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
75928417|NCT02258607|Drug|Trametinib|Trametinib tablet administered orally once daily
75928418|NCT02472704|Dietary Supplement|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
75928419|NCT02472704|Dietary Supplement|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
76083766|NCT03004222|Drug|Placebos|
75334569|NCT00983489|Behavioral|video demonstration|video will be shown to mothers
75334570|NCT00983489|Behavioral|counselling|breast feeding counselling
75334571|NCT02743832|Procedure|Resection for primary lesion and cervical lymph node dissection|Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.
75334572|NCT02743832|Procedure|Resection for primary lesion only|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
75334573|NCT02179736|Device|Restylane|
75334574|NCT00001090|Biological|APL 400-047|
75334575|NCT00001090|Biological|ALVAC-HIV MN120TMG (vCP205)|
75334576|NCT00001090|Drug|Sargramostim|
75334577|NCT01147627|Drug|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
75643848|NCT02576353|Drug|Fentanyl|Fentanyl Sublingual Spray (FSS)
75643849|NCT02576353|Drug|Fentanyl Citrate|Fentanyl Citrate IV (FCIV)
75643850|NCT04473235|Behavioral|Literacy training|Teaching adults how to read and write using the analytical and phonemic method
75643851|NCT04473235|Behavioral|Non-Literacy training|Attending classes in geography, history, sciences, without receiving the specific training in literacy
75928420|NCT02222571|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 weeks delivered in a community setting
75928421|NCT02222571|Behavioral|Supervision for Safety|group-based safety intervention for parents
75928422|NCT02472470|Device|rTMS|Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
75928423|NCT02226237|Procedure|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
76083767|NCT03368586|Device|Flash Glucose Monitoring|The camp comprised a structured daily routine with five fixed meals: breakfast, lunch, afternoon snack, dinner and evening snack. Capillary blood glucose (BG) values were measured in parallel with unmasked Flash Glucose (FG) measurements using the FGM reader's built-in glucometer at breakfast, lunch and dinner. Additional measurements were taken before snacks, between the meals or overnight and BG was measured only in cases of low (<4.0 mmol/L) or high (>15.0 mmol/L) FG values or when symptoms were discordant with sensor readings. Sensor-related issues were documented and a questionnaire assessing satisfaction and usability of the FGM was completed by patients and caregivers at study completion.
75643852|NCT01016015|Biological|Cixutumumab|Given IV
75643853|NCT01016015|Other|Laboratory Biomarker Analysis|Correlative studies
75791922|NCT03741036|Procedure|Deprotinized bovien as space filling in immidate implant placement|"The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with deprotinized bovien material)~Patients will be subjected to CBCT (diagnostic for upper arch).~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~The procedure will be carried out flapless.~In the study group: Atraumatic extraction~The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
76083768|NCT03000634|Drug|Elotuzumab|Administered through a small tube that goes directly into the vein
76083769|NCT03000634|Drug|Bortezomib|Administered as a subcutaneous injection under the skin
76083770|NCT03000634|Drug|Lenalidomide|Capsule taken by mouth
75643854|NCT01016015|Drug|Temsirolimus|Given IV
75334578|NCT01147627|Drug|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
75334579|NCT01147627|Drug|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
75334580|NCT02548962|Drug|Ibrutinib|
75334581|NCT02548962|Drug|Pomalidomide|
75643855|NCT00709579|Drug|RV3391A|A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
75643856|NCT00709579|Drug|Placebo|placebo
75643857|NCT00628043|Drug|epoetin beta|Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
75643858|NCT00628043|Drug|placebo|Subcutaneous administration of placebo once-weekly for 12 weeks
75643859|NCT00709657|Drug|ranibizumab, bevacizumab or pegaptanib|measurements are performed one week before and after anti-VEGF intravitreal injection
75791923|NCT03741036|Procedure|Nano-hydroxiapatite alloplast in immidiate implant placement|"The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with nano-hydroxiapatite alloplast material )~Patients will be subjected to CBCT (diagnostic for upper arch).~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~The procedure will be carried out flapless.~In the study group: Atraumatic extraction~The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
75643860|NCT04073173|Procedure|INSURE|Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.
75643861|NCT04073173|Procedure|LISA|Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.
75643862|NCT04073173|Drug|Analgesic, Opioid|Remifentanil (0.5-2 micrograms/kg/dose)
76083771|NCT03000634|Drug|Dexamethasone|Taken by mouth
76083772|NCT02518776|Behavioral|Neuropsychological tests|Neuropsychological tests
75334582|NCT02548962|Drug|Dexamethasone|
75334583|NCT02548962|Drug|Placebo|
75472228|NCT01955551|Behavioral|Anticipatory Guidance on Child Development|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
75472229|NCT01955577|Drug|Placebo orally everyday|
75472230|NCT01955577|Drug|Vitamin D3 cholecalciferol|
75643863|NCT01015703|Biological|CoVaccine HT|intramuscular injection, dose escalation
75643864|NCT00628121|Drug|Cetrorelix|1, 2 or 3mg, subcutaneouly dosed with single dose
75643865|NCT04073251|Dietary Supplement|KalobaTuss children|Syrup, dosage: 5 ml for 4 times a day for 8 days.
76083773|NCT03000400|Behavioral|The Traumatic Brain Injury Family System Intervention.|Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.
76083774|NCT03000400|Behavioral|Psycho-educational session at OUH|2.5 hour psycho-educational session for the patient's family members.
76083775|NCT02520102|Drug|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"
76083776|NCT03000556|Drug|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
76083777|NCT03371940|Behavioral|Program ACTIVE Exercise|Please see the Exercise arm description above.
76083778|NCT03371940|Behavioral|Program ACTIVE CBT|Please see the Talk Therapy arm description above.
76083779|NCT03371940|Behavioral|Program ACTIVE|Please see the Talk Therapy + Exercise arm description above.
76083780|NCT03371940|Behavioral|Usual Care - No intervention|Please see the Usual Care arm description above.
75334584|NCT00000274|Drug|Flupenthixol|
75334585|NCT04921072|Behavioral|Constant practice conditions|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
75643866|NCT04073251|Dietary Supplement|Placebo|Syrup, dosage: 5 ml for 4 times a day for 8 days.
76083781|NCT03368508|Behavioral|Simulating video|A 360-degree simulating video showing physiotherapy assessment in lumbar area
76083782|NCT03368508|Behavioral|Conventional video|A conventional video showing physiotherapy assessment in lumbar area
76083783|NCT03000322|Device|Cooling Vest|A cool therapy device intended to provide moderate, controlled cooling (approximately 15C/59F) by absorbing heat. The material in the vest is safe, non-toxic, and eco-friendly.
75334586|NCT04921072|Behavioral|Variable practice conditions|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
75334587|NCT02743598|Drug|Liraglutide|
75334588|NCT00000280|Drug|Nimodipine|
75643867|NCT00709813|Behavioral|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
75643868|NCT04634929|Procedure|bariatric surgery|bariatric surgery
75791924|NCT04154644|Device|CryoPop|The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
75791925|NCT01210638|Drug|Oxymorphone|10 mg tablet
75791926|NCT03120676|Drug|Atezolizumab|All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
75791927|NCT01111266|Device|xevonta|"Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers. In addition blood samples will be collected for determination of removal rates of different small molecules and protein."
75791928|NCT01115478|Dietary Supplement|Vitamin A|Daily oral dose of 2500 IU from enrollment until delivery
75791929|NCT01115478|Dietary Supplement|Zinc|Daily oral dose of 25 mg from enrollment until delivery
75791930|NCT01115478|Other|Placebo|Daily oral dose from enrollment until delivery
75791931|NCT01360138|Procedure|Cervical epidural steroid injection|cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
75791932|NCT01212276|Drug|MORAb-028|Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
75791933|NCT01111344|Dietary Supplement|Glizigen + Viusid|"Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~1 to 3.9 cm2 ______________3 daily applications~4 to 6.9 cm2 ______________4 daily applications~7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
76083784|NCT03371862|Drug|Liraglutide Pen Injector [Victoza]|Pilot study of liraglutide in patients with short bowel.
76083785|NCT03362580|Device|Slit lamp examination|The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.
76083786|NCT03362580|Device|Undilated 7-field color fundus photography|Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.
76083787|NCT03362580|Device|Color scan|Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.
75334589|NCT00983801|Drug|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
75334590|NCT00000286|Drug|Nefazodone|
75334591|NCT01188577|Drug|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
75334592|NCT01188577|Drug|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
75334593|NCT03948672|Device|CleanHands System|All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.
75334594|NCT02507336|Drug|Thalidomide|100-300 mg capsule taken by mouth once daily.
75334595|NCT00000292|Procedure|Cocaine|
75334596|NCT02734550|Other|Standard of care|Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
75334597|NCT02734550|Other|(1,3)-β-D-glucan guided therapy|Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
75334598|NCT00000298|Drug|Buprenorphine/naloxone|
75334599|NCT00984815|Drug|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
75643869|NCT04634929|Dietary Supplement|conservative diet|conservative diet
75643870|NCT04439071|Drug|PTC299|Oral tablets
75643871|NCT04439071|Other|SOC|As defined per local written policies or guidelines.
75643872|NCT04439071|Drug|Placebo|Oral tablets
75643873|NCT04069975|Other|Sedation|The group of patients who did endoscopies with or without sedation. (This is a choice of themselves)
76083788|NCT03362580|Device|Spectral domain optical coherence tomography|Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.
75334600|NCT00000304|Drug|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
75643874|NCT00709969|Drug|Artemether-lumefantrine|20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - < 10kg (BWG 1) = 6 doses of 1 tablet / 10 - < 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
75643875|NCT00710047|Drug|ZD4054|one single 10mg dose
75791934|NCT01111344|Dietary Supplement|Placebo|"Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~1 to 3.9 cm2 ______________3 daily applications~4 to 6.9 cm2 ______________4 daily applications~7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
75791935|NCT01208688|Device|FES Therapy|Treatment group received functional electrical stimulation and control group received conventional occupational therapy.
75334601|NCT00000304|Drug|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
75334602|NCT00000304|Drug|Placebo|Placebo
75643876|NCT04070677|Combination Product|Ziverel|Patients in treatments with radiotherapy alone (RT) or radiochemotherapy (RT-CH) with acute radiation-induced esophagitis grade 2 or superior according to the most recent CTCAE will received support treatment with ZIVEREL®
75643877|NCT02578927|Dietary Supplement|GT+Ex|In this session the volunteers ingested capsules with 2g of powder green tea before exercise
75643878|NCT02578927|Dietary Supplement|PL+Ex|In this session the volunteers ingested capsules with 2g of placebo before exercise
75643879|NCT02578927|Dietary Supplement|Green Tea|In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
75643880|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
75928424|NCT02226237|Procedure|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
75928425|NCT02471534|Procedure|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
75928426|NCT03096548|Behavioral|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
75928427|NCT03096548|Behavioral|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
75928428|NCT03792750|Drug|BMS-986205|Specified Dose on Specified Day
75928429|NCT03792750|Biological|Nivolumab|Specified Dose on Specified Day
75928430|NCT03311048|Other|Nasal swab|Nasal swab was collect to upper airways inflammation evaluation.
76083789|NCT03368430|Dietary Supplement|Melatonin|After performing scaling and root planing (SRP) in the test group, melatonin 10 mg oral capsule was taken once daily at night prior to bedtime for only 2 months during the 6-month study period
76083790|NCT03368430|Drug|Placebo|After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
76083791|NCT03371784|Drug|Hydrocortisone|I.V. administration
76083792|NCT03371784|Drug|Placebo|I.V. administration
75334603|NCT02548650|Drug|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
76083793|NCT03003832|Other|Change in electronic health record default for new opioid analgesic prescriptions|
76083794|NCT03368352|Dietary Supplement|Melatonin|Dietary supplement melatonin
75334604|NCT02548650|Drug|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
75643881|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
75643882|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
75643883|NCT00710125|Drug|GPX-150 for Injection|Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
75643884|NCT02573701|Drug|Guideline treatment (Risperidone, administered orally)|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
75643885|NCT02573701|Behavioral|"Psychosocial treatment"|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
76083795|NCT03368352|Other|Hypoxia|Sleep in a hypoxic tent simulating high altitude
76083796|NCT02248012|Drug|Everolimus , temozolomide|
76083797|NCT03371628|Device|Non invasive ventilation|Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
75334605|NCT02548650|Drug|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
75334606|NCT02734394|Behavioral|Exercise|Cardiovascular and resistance exercise training
75643886|NCT02573701|Drug|Treatment as Usual (any other antipsychotic)|Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
75643887|NCT01017029|Drug|Everolimus|
75791936|NCT01208688|Device|FES Therapy|Subjects will be divided into one of two groups: a) subjects that will be trained with neuroprosthesis for grasping and b) the control group. The control group will be administered standard occupational therapies appropriate for recovery of grasping function in SCI subjects. In group a), neuroprosthesis for grasping will be used to train subjects to reach, grasp and manipulate various objects in the activities of daily living.
75643888|NCT01017029|Drug|Mycophenolate mofetil + Everolimus|
75791937|NCT01208688|Other|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
75791938|NCT05365204|Procedure|Near infrared fluorescence navigated sentinel lymph node mapping|Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
75791939|NCT01212354|Radiation|Radiotherapy|7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
75791940|NCT01368796|Biological|Agriflu|0.5mL dose IM vaccination
75928431|NCT03311048|Other|Questionnaires|Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
75791941|NCT01368796|Biological|Fluad|0.5mL dose of vaccine given IM
75928432|NCT02226393|Behavioral|Prolonged exposure|The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
75928433|NCT02226393|Behavioral|Child-parent Play Therapy|Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
75928434|NCT02258763|Drug|Amoxicillin-Potassium Clavulanate Combination|Oral antibiotic for 10 days
75928435|NCT02258763|Drug|Placebo|Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
75928436|NCT03479424|Other|Observational|The MYIA in-home suite of devices.
75928437|NCT02469974|Drug|RUXOLITINIB / INC 424|Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
75928438|NCT02469974|Drug|Filgrastim|Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
76083798|NCT03003988|Dietary Supplement|Creatine monohydrate|Creatine monohydrate (6.0 g) + dextrose (0.5 g)
75334607|NCT05394077|Diagnostic Test|Active Release Technique|Using Active Release Technique
75334608|NCT05394077|Diagnostic Test|Abdominal Drawing-Maneuver|Using Abdominal Drawing-Maneuver Technique
75334609|NCT00000310|Drug|Risperidone|
75334610|NCT01227655|Drug|BIA 9-1067|Capsules will be used.
75334611|NCT01227655|Drug|Placebo|comparator
75334612|NCT01227655|Drug|Levodopa|
75643889|NCT00714649|Drug|cetuximab|Cetuximab 250mg/m²/week IV before surgery till surgery
75643890|NCT00710281|Radiation|Additional scan time on standard MR angiography|"Procedure/Surgery: Additional 5 minutes scan time to standard MR angiography~Using the Nova® Software, an additional 5 minutes scan time will be required in order to identify aneurysm, select target artery, and complete measurements~Arms:"
75643891|NCT00710359|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
75791942|NCT01368796|Biological|Intanza|0.5mL dose vaccine given IM
75791943|NCT01368796|Biological|Vaxigrip|0.5mL dose vaccine given IM
75334613|NCT01227655|Drug|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
75643892|NCT00714727|Procedure|acupuncture|8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
75643893|NCT02578849|Drug|L-DOPA|Patients and healthy controls are recruited to participate in [11C]yohimbine scans before and after L-DOPA challenge.
75643894|NCT00710437|Drug|Dexmedetomidine|Steady state infusion 0.007 mcg/kg/min
75643895|NCT00710515|Drug|AZD6244|75mg
75643896|NCT02574715|Drug|Levonorgestrel (Jaydess, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
75643897|NCT00714883|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of lesions in native coronary arteries using standard coronary intervention techniques. Intervention will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
75643898|NCT00710827|Drug|NEBIDO|Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
75643899|NCT00710827|Drug|PLACEBO|Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
75791944|NCT01210794|Procedure||The influence of different food components on zinc absorption in young adults consuming zinc fortified porridges prepared from maize, beans and sorghum
75791945|NCT01368952|Device|Pure prone positioning|Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
75791946|NCT01111422|Drug|N-acetylcysteine|N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
75791947|NCT01117506|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
75791948|NCT05188378|Biological|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
75791949|NCT05188378|Biological|EU-approved RoActemra,|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
75643900|NCT00994214|Drug|BIM 23A760|Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
75791950|NCT05358730|Other|Standard Exercise|Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).
75791951|NCT05358730|Other|Instrument Assisted Soft Tissue Mobilization (IASTM)|IASTM treatment was applied to the posterior-anterior-middle deltoid, latissimus dorsi, teres major, teres minor, supraspinatus and infraspinatus muscle fibers, superficial and deep fascia. IASTM was applied in parallel and vertical direction to the muscle fibers treated with the instrument at a 45° angle, each technique (SWEEP, BRUSH (straight short steps) techniques) for 20 seconds (Ikeda, Otsuka, Kawanishi, and Kawakami, 2019). It was performed two days per week for six weeks.
75791952|NCT05358730|Other|Home Exercise|"Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks."
75791953|NCT01210872|Other|questionnaire administration|
75791954|NCT01210872|Procedure|quality-of-life assessment|
75791955|NCT01210872|Procedure|standard follow-up care|
75791956|NCT03939702|Drug|BMS-986177|An orally administered anticoagulant to prevent and treat thromboembolic events
75791957|NCT05188300|Procedure|Freestyle pedicled perforators propellers flaps for meningomyelocele defects|Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.
75791958|NCT01212432|Drug|Daptomycin|Daptomycin kinetics in CRRT
75791959|NCT01115634|Biological|Fibroblast|20 million cell in three injection
75928439|NCT02469974|Drug|Busulfan|Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
75928440|NCT03131622|Behavioral|Digital Therapeutics|
75928441|NCT03131310|Other|clinical audit|is to assess the quality of care and management of children with cardiorespiratory arrest admitted to assuit university children hospital according to the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation
75334614|NCT01227655|Drug|Benserazide|DOPA decarboxylase inhibitor
75334615|NCT00000316|Drug|Cocaine|
75643901|NCT01034657|Drug|LBH589|LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
75643902|NCT01034657|Drug|Epoetin Alfa|Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
75643903|NCT02867696|Other|Standard Care|Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.
75791960|NCT01115634|Biological|fibroblast and gel|20 million cell in three injection plus filler
75791961|NCT01360216|Behavioral|LARC education and training|A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
75791962|NCT03938064|Drug|Prontogest 400 mg vaginal pessaries|natural progesterone in the form of vaginal suppositories 400 mg
75791963|NCT01213368|Drug|DRONEDARONE (SR33589)|"Pharmaceutical form: tablets~Route of administration: oral"
75791964|NCT01213368|Drug|placebo|"Pharmaceutical form: tablets~Route of administration: oral"
75791965|NCT01212510|Other|Blood sampling|blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA
75791966|NCT05336110|Other|Postponing surgery|Postponing surgery for patients with Sars-cov-2 infection
75791967|NCT01210950|Biological|cell and RPR injection|mesenchymal cells and Plasma reach Protein are injected to the callus center
75791968|NCT03938142|Other|Filling in an online survey regarding goalsettings|Patients are asked to fill in an online survey regarding their individual goalsettings.
75791969|NCT01211028|Biological|Expanded autologous ASCs|Drug: Expanded autologous adipose-derived adult stroma/stem cells
75791970|NCT01369186|Drug|Morphine|i.v. bolus injection
75928442|NCT03482544|Drug|Pragabalin|pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
75928443|NCT03482544|Other|Placebo|empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
75928444|NCT02750709|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
75928445|NCT02750709|Drug|Nitisinone 10 mg Tablet High Compritol|A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
75928446|NCT02750709|Drug|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
75928447|NCT03131544|Device|MRI Guided Transrectal Periuretheral Transitional Zone Ablation|Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
75791971|NCT01369186|Drug|Placebo|i.v. bolus injection
75791972|NCT01115712|Drug|Placebo|Placebo (to match pioglitazone 30 mg) once daily
75928448|NCT03131388|Diagnostic Test|Access AMH Assay|
75334616|NCT05459532|Drug|Molnupiravir 200 mg|The drug is orally bioavailable (and is indicated for treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. The recommended dose is 800 mg (four 200 mg capsules) taken orally 12-hourly for five days, and should be administered as soon as possible after diagnosis of COVID-19 has been made and within five days of symptom onset.
75334617|NCT02506556|Drug|BYl719|"Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days"
75334618|NCT00001990|Drug|Atovaquone|
75334619|NCT00000322|Behavioral|Tyrosine|
75334620|NCT01189123|Biological|High dose influenza vaccine Sanofi-Pasteur|High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
75334621|NCT01189123|Biological|fluzone by sanofi pasteur|standard dose fluzone
75651873|NCT05067569|Behavioral|Sleep Health Education|These internet-based modules provide an active control intervention consisting of 3 modules provided bi-weekly. The participant will receive a link to this information as each module is made available. Control participants will have full access to these modules for the duration of the study. They reflect basic educational information regarding sleep health for poor sleepers that is otherwise easily accessible on the internet.
75791973|NCT01115712|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg once daily
75791974|NCT01115712|Drug|Comparator: Hyperinsulinemic Euglycemic Clamp|Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
75791975|NCT01369264|Device|true left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor
75791976|NCT01369264|Device|Passive sham left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The passive (inactive) coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor. An active coil will be held vertically in a mechanical holder 50 cm behind the subject head and run at 10 Hz with an intensity set to 150% of motor threshold.
75928449|NCT02222649|Dietary Supplement|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
75928450|NCT02222649|Dietary Supplement|Placebo|Capsules of starch, no therapeutic action
75334622|NCT04423224|Other|GDFM|Stroke volume variation fluid management
75334623|NCT04423224|Other|USUAL CARE - CONTROL|Usual care fluid management
75334624|NCT00001096|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
75334625|NCT00001096|Biological|QS-21|
75334626|NCT00001096|Biological|rgp120/HIV-1MN|
75334627|NCT01026623|Biological|Cixutumumab|Given IV
75334628|NCT01026623|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
75472231|NCT01955590|Behavioral|Metacognitive therapy|8-12 sessions of manualized metacognitive therapy
75472232|NCT01955590|Behavioral|EMDR|8-12 sessions of manualized EMDR
75472233|NCT01955590|Behavioral|Treatment as usual|8-12 sessions of treatment of usual
76025511|NCT05676541|Other|Complex intervention to enhance care for patients with multimorbidity in general practice consisting of an extended overview consultation and supporting elements|The intervention consists of 1) an extended overview consultation lasting 30-45 minutes in general practice, 2) access to cross-sectoral video conferences with secondary care specialists and 3) an instruction material for GPs on how to organize the intervention and 4) an adaptive toolbox to support elements in the intervention (not yet developed)
75334629|NCT01026623|Drug|Temsirolimus|Given IV
75472234|NCT01955603|Drug|NNC0215-0384|A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.
75472235|NCT01955603|Drug|placebo|Placebo administered corresponding to NNC0215-0384 treatment
75651874|NCT05056870|Device|ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism|TEST
75651875|NCT05056870|Device|ACUVUE Oasys 1-Day with HydraLuxe Technology|CONTROL
75651876|NCT05055401|Procedure|Direct Laryngoscopy|The participant will perform a direct laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under limited cervical range of motion.
75651877|NCT05055401|Procedure|Laryngeal Mask Airways|The participant will perform LMA placement on a Laerdal SimMan 3G under healthy conditions and under full tongue edema.
75651878|NCT05055401|Procedure|Video Laryngoscopy|The participant will perform video laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under half tongue edema with pharyngeal obstruction.
75334630|NCT00001996|Drug|Atovaquone|
75334631|NCT00001996|Drug|Pentamidine isethionate|
75334632|NCT05433870|Other|Whether the PE or E patient combined with PRES|According to the Diagnostic criteria of PRES, all the patients grouped into two groups.
75334633|NCT02725424|Drug|S-1|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
75334634|NCT02725424|Drug|Trastuzumab|Her-2 positive patients with SOXT Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.
75334635|NCT02725424|Drug|Oxaliplatin|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
76083799|NCT03003988|Dietary Supplement|Creatine nitrate|Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
76083800|NCT03003988|Dietary Supplement|Placebo|Placebo (6.5 g dextrose)
76083801|NCT03003910|Behavioral|Best Possible Self|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
76083802|NCT03003910|Behavioral|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
76083803|NCT03362346|Device|intracranial pressure monitoring|The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
76083804|NCT03362268|Drug|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
75643904|NCT02867696|Behavioral|Technology-based Intervention (TECH)|"Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.~The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.~Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.~Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month."
75643905|NCT01014767|Drug|Carboplatin|"Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 & 6: 350 mg/m2 IV over 2 hours on day 2 and 3"
75643906|NCT01014767|Drug|Cisplatin|Cycles 1 & 2: 70 mg/m²/d IV over 6 hours on day 4
75791977|NCT03939936|Other|Psoriatic measurements|Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
76083805|NCT03362268|Drug|omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
76083806|NCT04901962|Device|JOBST® Confidence compression garments|JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.
76083807|NCT04523844|Drug|Brinzolamide-brimonidine Fixed Combination|In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection
76083808|NCT02248090|Drug|AZD9496|AZD9496
75643907|NCT01014767|Drug|Cyclophosphamide|"Standard Arm, Cycle 1: 1 g/m^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 & 5: 1 g/m^2 IV over 1 hour on day 2 and 3"
75791978|NCT03939936|Other|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
75791979|NCT03939936|Other|saliva samples|Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
75791980|NCT01117662|Drug|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
75791981|NCT01117662|Drug|Placebo|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
75791982|NCT01319266|Drug|Hydrocodone Bitartrate extended-release tablet|Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
75334636|NCT02725424|Drug|Docetaxel|Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
75334637|NCT01189279|Drug|bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
75334638|NCT01189279|Drug|bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
75334639|NCT01189279|Drug|bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
75643908|NCT01014767|Drug|Dactinomycin|Cycles 1 & 2: 45 µg/kg/day (max. 2 mg), IV on day 1
75643909|NCT01014767|Drug|Doxorubicin|Cycles 1 & 2: 25 mg/m²/day IV over 12 hrs on days 1-3
75643910|NCT01014767|Drug|Etoposide|"Standard Arm (1), Cycles 1 & 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5"
75643911|NCT01014767|Drug|Irinotecan|"Temozolomide Irinotecan arm (4), Cycles 1 & 2:~50 mg/m2/day x 5 days as 1 hour IV infusions"
75791983|NCT01115790|Drug|Prexasertib|Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
75791984|NCT01115868|Drug|Prevascar 5ng|100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
75791985|NCT01115868|Drug|Prevascar 25ng|• 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
75791986|NCT01115868|Drug|Prevascar 100ng|• 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
75791987|NCT01115868|Drug|Prevascar 250ng|• 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
75791988|NCT01115946|Drug|ASP1585|oral
76083809|NCT02248090|Drug|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
76083810|NCT03362034|Device|double transfer trays|double trays one soft and one hard
76083811|NCT03362034|Device|single transfer tray|single soft tray
75334640|NCT00001108|Drug|Ritonavir|
75334641|NCT00001108|Drug|Nelfinavir mesylate|
75334642|NCT00001108|Drug|Saquinavir|
75334643|NCT00001108|Drug|Nevirapine|
75472236|NCT01955642|Drug|Clopidogrel|75 mg milligrams per days of PLAVIX
75472237|NCT01955655|Drug|Baclofen|Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
75472238|NCT01955655|Other|Placebo|
75643912|NCT01014767|Drug|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
75643913|NCT01014767|Drug|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
75643914|NCT01014767|Drug|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
75643915|NCT01014767|Drug|Vincristine|"Standard Arm (1), Cycles 1 & 2 : 1.5 mg/m^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 & 2: 1.5 mg/m^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5"
75643916|NCT02016781|Procedure|Allogeneic Hematopoietic Cell Transplant|Bone marrow or peripheral blood stem cell transplant.from a fully matched related (6/6) or unrelated (8/8) donor. The specific transplant treatment regimen will be at the discretion of the treating physician but is required to be reduced-intensity.
75643917|NCT02016781|Procedure|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
75791989|NCT01115946|Drug|enalapril|oral
75791990|NCT01113372|Drug|Clopidogrel|Clopidogrel 75mg daily.
75791991|NCT03120520|Drug|Plecanatide|
75791992|NCT03120520|Drug|Matching placebo|
75791993|NCT03941340|Drug|[14]-AST2818|Volunteer will receive a single oral dose of 80 mg /100 u Ci [14C]-AST2818 as a solution on Day 1
75791994|NCT01117740|Behavioral|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
75791995|NCT01117818|Biological|active: AFFITOPE AD02|vaccination
75472239|NCT01955668|Drug|Administration of AZD6738|An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
75472240|NCT01955694|Drug|BAY94-8862|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
75472241|NCT01955694|Drug|Eplerenone|INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
75791996|NCT01117818|Biological|control: Placebo|vaccination
75791997|NCT01372930|Drug|Etanercept|Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
75791998|NCT01372930|Drug|saline|saline 1ml(subcutaneous injection) at 2h and 72h after PCI
75791999|NCT01117896|Other|Chest compression on adult and pedi manikins|Each participant will be required to perform chest compressions on all 2 manikins, one on each of 2 assigned days. Participants will be randomized to one of 2 groups differing only in the order of manikins compressed, i.e. pediatric-adult; adult-pediatric, etc.
75334644|NCT00001108|Drug|Lamivudine|
75334645|NCT00001108|Drug|Stavudine|
75472242|NCT01955694|Drug|Placebo|matching placebo
75334646|NCT00001108|Drug|Didanosine|
75643918|NCT01014689|Drug|Adapalene/ BPO gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
75643919|NCT01014689|Drug|Adapalene/ BPO vehicle gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
75792000|NCT01117896|Other|Use of stepstool during chest compressions|In the additional arm of the study, a new cohort of participants will use only the adult manikin on two separate sessions. Participants will be randomized to one of two groups differing only in the use of a stepstool.
75792001|NCT01328652|Drug|dexlansoprazole|dexlansoprazole 60 mg once daily for 3 months
75792002|NCT01373008|Drug|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
75792003|NCT01116180|Drug|Angiotensin II receptor antagonists (Candesartan)|Seven days of treatment with Candesartan 32 mg, capsules.
75792004|NCT01116180|Drug|Placebo|Placebo Capsule matching the active comparator. Given for 7 days once daily.
75792005|NCT01117974|Procedure|liposuction of the neck|Liposuction will be performed to the surgical endpoint (skin thickness in the suctioned areas similar to that of surrounding non-treated skin).
75792006|NCT05008744|Procedure|Fetoscopic laser ablation|"Under ultrasound guidance, a 2 mm skin incision will be made and a 10Fr Cook Check Flow valve cannula and trocar will be introduced into the amniotic cavity.~The communicating vessels will be located endoscopically using a Storz straight or curved semirigid fetoscopes in a fetoscopic sheath, a Humanitarian Use Device, used with permission of the Federal Drug Administration under a Humanitarian Device Exemption agreement with Karl Storz, Inc, and will be ablated with a diode laser fiber that is passed through the operating channel of the endoscope."
75792007|NCT01116258|Drug|AZD5847|oral suspension, 15 days
75792008|NCT01116258|Drug|Placebo|oral suspension, 15 days
75334647|NCT00000328|Drug|Opioid-Related Disorders|
75334649|NCT00380224|Drug|bifeprunox, olanzapine|
75334650|NCT03010189|Device|Actigraphy|A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.
75334651|NCT03010189|Device|Heart-rate variability monitoring|A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.
75472243|NCT01955759|Drug|Amiodarone tab 200 mg x 3|starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
75472244|NCT01955759|Drug|rosuvastatin 20 mg tab x1|starting 7 days before coronary by-pass surgery
75472245|NCT01955759|Drug|beta blockers Bisoprolol in adjusted dose|starting 7 days befoe coronary by-pass surgery
75472246|NCT01955772|Drug|Enteral nutrition alanyl-glutamin, Dipeptiven|Enteral nutrition versus parenteral nutrition
75472247|NCT01955785|Device|pressure controlled ventilator|
75472248|NCT01955785|Device|Pressure Regulated Volume Controlled Ventilator|
75334652|NCT03010189|Device|Pupillometry|A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
75334653|NCT01228435|Drug|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
75643920|NCT01014533|Drug|Placebo dispensed to subject.|Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
75643921|NCT01014533|Drug|Gabapentin dispensed to subject.|After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. (1 pill (600 mg) at bedtime on nights 1 and 2, 2 pills (totalling 1200 mg) at bedtime on nights 3-10, and 1 pill (600 mg) at bedtime on night 11, then D/C). On nights 8 - 10 of medication, subjects return to the lab and sleep 3 more nights with the same procedures.
75643922|NCT02013427|Drug|Naproxen|Take one 500mg naproxen capsule twice a day.
75643923|NCT02013427|Drug|Placebo|Take one placebo capsule twice a day.
75792009|NCT01113528|Other|Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
75643924|NCT02013427|Drug|Omeprazole|Take one 20mg omeprazole capsule twice a day.
76025512|NCT03688763|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
75334654|NCT00002002|Drug|Trimethoprim|
75334655|NCT00002002|Drug|Sulfamethoxazole|
75792010|NCT01113528|Drug|Sugar pill|3 times daily
75792011|NCT01213446|Biological|Biostate|"PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.~Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition."
75792012|NCT01369420|Device|NanoKnife Low Energy Direct Current (LEDC) System Ablation|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
75792013|NCT01113606|Other|Obagi New-Derm System|
75792014|NCT01113606|Other|Standard of Care|
75334656|NCT00002002|Drug|Leucovorin calcium|
75334657|NCT00380302|Drug|AVE1625|
75643925|NCT00628277|Behavioral|high caloric expenditure exercise|high caloric expenditure exercise plus dietary counseling
75643926|NCT00628277|Behavioral|low caloric expenditure exercise plus dietary counseling|low caloric expenditure exercise plus dietary counseling
75643927|NCT01014143|Drug|Fluoride|Half mouth toothbrushing twice a day for four days.
75643928|NCT01014143|Drug|Chlorhexidine digluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days.
75643929|NCT01014143|Drug|Fluoride, triclosan|Half mouth Brushing twice daily
76025513|NCT03906253|Device|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
76025514|NCT03278249|Other|Modified Atkins Ketogenic Diet|Less than 20 grams of carbohydrates per day
76025515|NCT04941937|Drug|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
75334658|NCT02535000|Drug|Duloxetine|duloxetine 60 mg
75334659|NCT02535000|Drug|Placebo|placebo
75643930|NCT00710983|Biological|Oral polio vaccine|
75643931|NCT00714961|Drug|Clopidogrel (SR25990)|plus acetylsalicylic acid (ASA)
75643932|NCT00714961|Drug|Placebo|plus acetylsalicylic acid (ASA)
75643933|NCT04285151|Procedure|Nd:YAG laser Hyaloidotomy|Using the YAG laser for opening the posterior hyaloid in eyes with premacular hemorrhage, and evacuating the entrapped hemorrhage
75643934|NCT02574403|Drug|eculizumab|eculizumab discontinuation
75643935|NCT01013753|Drug|Placebo|Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
75643936|NCT01013753|Drug|Olodaterol (BI 1744) high|Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
75643937|NCT01013753|Drug|Olodaterol (BI 1744) medium|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
75643938|NCT01013753|Drug|Olodaterol (BI 1744) very low|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
75643939|NCT01013753|Drug|Formoterol 12 mcg|Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
75643940|NCT01013753|Drug|Olodaterol (BI 1744) low|Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
75792015|NCT01369576|Drug|Placebo|3.75-7.5mg 14 doses 4 weeks
75792016|NCT01369576|Drug|Zopiclone|3.75-7.5mg 14 doses 4 weeks
75792017|NCT01113684|Device|Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.
75334660|NCT00380380|Drug|Vildagliptin|
75334661|NCT01228903|Drug|Allopurinol|Xanthine oxidase inhibitor- effective at lowering uric acid levels.
75334662|NCT01228903|Other|Placebo|Placebo tablets with no active ingredient
75334663|NCT05440552|Diagnostic Test|Qualitative Fecal immunochemical test + APCS score|Risk stratification using Qualitative Fecal immunochemical test and APCS score
75334664|NCT05440552|Diagnostic Test|Quantitative Fecal immunochemical test|Use Quantitative Fecal immunochemical only for risk stratification
75334665|NCT01189747|Biological|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
75334666|NCT01189747|Drug|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
75334667|NCT00001126|Drug|Cidofovir|
75334668|NCT00002008|Drug|Sargramostim|
75334669|NCT00001132|Drug|Abacavir sulfate|
75334670|NCT01149733|Drug|Tamsulosin|Test 0.4 mg Capsule
76083812|NCT03003754|Behavioral|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
75334671|NCT01149733|Drug|Tamsulosin|Reference Listed 0.4 Capsule
75334672|NCT00002014|Drug|Zidovudine|
76083813|NCT03003754|Behavioral|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
76083814|NCT03361878|Drug|Metformin Hydrochloride|Single dose of 500mg oral metformin
75334673|NCT00002014|Drug|Didanosine|
75334674|NCT01893866|Drug|1 x 30 mg/mL pegvisomant|Subcutaneous injection, 30 mg, single dose.
75334675|NCT01893866|Drug|2 x 15 mg/mL pegvisomant|Subcutaneous injection, 2 injections of 15 mg, single dose.
75334676|NCT00000334|Drug|Buprenorphine|
75334677|NCT00000340|Drug|Pemoline|
75334678|NCT00000346|Behavioral|counseling|
75334679|NCT01190527|Radiation|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
75643941|NCT00715039|Drug|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
75792018|NCT01113762|Device|articular surface replacement ASR, DePuy|posterolateral incision
75792019|NCT01113762|Device|ReCap/Magnum modular head, Biomet|posterolateral incision
75792020|NCT01113762|Device|Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet|posterolateral incision
75334680|NCT00002020|Drug|Zidovudine|
75334681|NCT04352023|Procedure|Patient-controlled analgesia|Intravenous patient-controlled analgesia Patient-controlled epidural analgesia
75334682|NCT00002026|Drug|Acyclovir|
75334683|NCT00000352|Drug|Dextromethorphan|
75334684|NCT00002032|Drug|Rifabutin|
75334685|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
75334686|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
75334687|NCT01229527|Drug|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
75643942|NCT00715039|Drug|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
75643943|NCT00715039|Drug|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
75643944|NCT00715195|Behavioral|Plurifocal educational program|intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
75643945|NCT00711217|Other|Medical Food|twice daily
75334688|NCT02723162|Drug|Varenicline (VRN)|VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
75643946|NCT00711217|Other|Drink mix calorically similar to experimental product|twice daily
75643947|NCT00711295|Biological|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
75792021|NCT01113762|Device|28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)|posterolateral incision
75792022|NCT03939780|Diagnostic Test|[F18]RO-948|Single radiotracer IV injection with subsequent emission scan
75334689|NCT02723162|Drug|N-Acetylcysteine (NAC)|NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
75334690|NCT02723162|Drug|Placebo|Matched placebo
75792023|NCT03939780|Diagnostic Test|[F18]MK-6240|Single radiotracer IV injection with subsequent emission scan
75792024|NCT03939780|Diagnostic Test|[F18]AV1451|Single radiotracer IV injection with subsequent emission scan
75792025|NCT01212666|Procedure|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
75792026|NCT01212666|Procedure|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
76083815|NCT03361800|Drug|Entinostat|oral drug, 5mg tablet given once weekly x 2 doses
76083816|NCT04523532|Other|Dietary folate and hazelnut oil|Intervention with folate-rich diet and hazelnut oil supplement in capsule
76083817|NCT02995642|Drug|18F-FPPRGD2|One single intravenous injection.
76083818|NCT02995642|Device|Positron emission tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
76083819|NCT02995642|Procedure|Computed tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
75334691|NCT00000358|Drug|Lofexidine|
75334692|NCT00000370|Behavioral|Cognitive behavior therapy|
75334693|NCT00000370|Behavioral|Performance-based exposure therapy|
75334694|NCT00000370|Behavioral|Psychosocial intervention|
75334695|NCT04757558|Device|C-MAC video-stylet|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
76083820|NCT02995642|Device|Magnetic Resonance Imaging|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
76083821|NCT02518932|Drug|Last 5 amino acids of GLP-1|To examine insulinomimetic properties of LVKGR
76083822|NCT02518932|Drug|placebo saline|
76083823|NCT02998606|Drug|Naloxegol|MOVANTIK™ 25 mg, daily
75643948|NCT00711295|Biological|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 3.75 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
75928451|NCT03130998|Behavioral|Remote Knowledge Broker (rKB)|The intervention is the tailored support received by a knowledge broker via technology in Group B. The rKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the rKB, learn new evidence, and work with the rKB on how to best implement the evidence.
75928452|NCT03130998|Behavioral|Emails|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
75643949|NCT00757042|Drug|Tezepelumab|Administered by subcutaneous or intravenous injection
75643950|NCT00757042|Drug|Placebo|Matching placebo administered by subcutaneous or intravenous injection.
75928453|NCT02859519|Drug|MOB015B|MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
75928454|NCT02859519|Drug|MOB015B Vehicle|MOB015B Vehicle without the active ingredient Terbinafine
75928455|NCT03475446|Device|real anodal tDCS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
75928456|NCT03475446|Device|real tACS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
75643951|NCT02574169|Other|alveolar recruitment maneuvers group 1|"Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
75792027|NCT01116336|Drug|Erlotinib|Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
75792028|NCT01116336|Dietary Supplement|Green Tea Polyphenon E|Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
75928457|NCT03475446|Device|sham tES healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
75928458|NCT03475446|Device|real anodal tDCS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
75928459|NCT03475446|Device|real tACS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
75928460|NCT03475446|Device|sham tES MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
75928461|NCT03475446|Device|real anodal tDCS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
75472249|NCT01955798|Procedure|Laparoscopic direct entry Trocar|Laparoscopic direct entry with trocar
75643952|NCT02574169|Other|alveolar recruitment maneuvers group 2|"Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
75643953|NCT00711373|Procedure|Allogeneic hand transplantation|Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
75643954|NCT02578615|Other|physiotherapy|physiotherapeutic intervention according to the principles of the Spiraldynamik® concept
75792029|NCT01116492|Other|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
75792030|NCT01116492|Other|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
75792031|NCT03941418|Dietary Supplement|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
75792032|NCT03941418|Dietary Supplement|Placebo|Patients will be administered with placebo of same appearance, colour and taste once daily.
75792033|NCT03941028|Device|3D printed titanium implant|The 3D printed titanium implant is fabricated by related companies. And some implants have been used in spinal disease in our hospital.
75928462|NCT03475446|Device|real tACS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
75928463|NCT03475446|Device|sham tES AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
75928464|NCT02222727|Drug|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
75928465|NCT03475368|Other|Vegetarian diet|People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
76025516|NCT04941937|Drug|Thalidomide|100mg/d, Po. on day1-28
75792034|NCT01213680|Drug|Monofer (iron isomaltoside 1000)|1000 mg iron isomaltoside administered as a infusion over 15 minutes
75792035|NCT01213680|Drug|Monofer|500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
75643955|NCT04099186|Procedure|catheter directed hydro-mechanical fragmentation of pulmonary embolism|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery , then 200 ml saline will be injected via power injector to aid fragmentation of thrombus
75643956|NCT02871869|Drug|vindesine|3 mg/㎡ (maximum dosage: <4mg), d1, 21 d as a cycle, for 4～6 cycles
75643957|NCT02871869|Drug|cyclophosphamide|750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
75643958|NCT02871869|Drug|Epirubicin|60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
75928466|NCT03475368|Other|Low carbs diet|People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)
75928467|NCT03475368|Other|Mediterranean diet|People randomized to this interventional group will take a traditional Mediterranean diet.
75334696|NCT04757558|Device|Macintosh laryngoscope|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
75334697|NCT00000376|Behavioral|Cognitive therapy|
75334698|NCT00000376|Drug|Desipramine|
75334699|NCT02721680|Other|Internal Awareness Training Program|
75334700|NCT02721680|Other|External Awareness Training Program|
75334701|NCT00000382|Behavioral|Infant-Parent Psychotherapy|
75643959|NCT02871869|Drug|prednisone tablets|100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
75643960|NCT02871869|Drug|Cinobufacini Tablets|0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
75643961|NCT02871869|Drug|Rituximab|375mg/㎡,one day before CHOP protocol
75643962|NCT02573545|Device|Planning@IFE and Standard@IFE Software|
75643963|NCT02573545|Device|MR Syngo (Numaris/4) software|
75643964|NCT01013597|Drug|LBH589|LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
75643965|NCT04548947|Procedure|Cold snare polypectomy in conjunction with a submucosal injection|The cold snare polypectomy in conjunction with a submucosal injection is a procedure during which the endoscopist resects the colorectal polyps during a colonoscopy, without any electrocautery.
75792036|NCT01113840|Behavioral|Exercise|Exercise classes three times per week in a controlled, supervised environment.
75792037|NCT01113840|Behavioral|Control|Control group continues daily life as prior to randomization.
75792038|NCT01116570|Other|Physical training|Physical training during 24 weeks
75792039|NCT01116570|Other|Control|No intervention
75792040|NCT01213758|Other|Measuring liver function by PET/CT|Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
75792041|NCT01113996|Behavioral|Protein supplementation and strength training|Protein supplementation and strength training
75792042|NCT01113996|Dietary Supplement|Protein supplementation|Protein supplementation
75928468|NCT02723786|Biological|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
75928469|NCT02723786|Drug|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
75928470|NCT03482466|Behavioral|Neurofeedback|Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.
75928471|NCT02222805|Procedure|Early (≤30 seconds) cord clamping|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
75928472|NCT02222805|Procedure|Delayed (≤180 seconds) cord clamping|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
76025517|NCT04941937|Drug|Lenalidomide|PO,Lenalidomide 25mg once daily from D1-21
76025518|NCT04941937|Drug|Pomalidomide|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
76025519|NCT04941937|Drug|Dexamethasone|Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
76025520|NCT05124431|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.
76025521|NCT05124431|Drug|everolimus|5mg po，qd
76025522|NCT04435613|Other|protective mechanical ventilation strategies|1. Reduce tidal volume from 7 ml/kg to 5 ml/kg. 2 Set end-inspiratory pausa. 3 respiratory rate reduction until 20% of the basal condition
76025523|NCT04955249|Drug|Dexmedetomidine|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
76025524|NCT04955249|Drug|Placebo|Patients in this group receive routine patient-controlled intravenous analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
76025525|NCT04876417|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
76025526|NCT04876417|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
75334702|NCT00000382|Behavioral|Child Protective Services|
75472250|NCT01955798|Procedure|Laparoscopic entry Veress needle|Laparoscopic entry with Veress needle
75472251|NCT01955798|Device|Trocar|
75472252|NCT01955798|Device|Veress needle|
75643966|NCT00715273|Drug|Atorvastatin|10 to 80 mg of atorvastatin each day
76083824|NCT02998606|Drug|Placebo Oral Capsule|Placebo 25 mg, daily
76083825|NCT04636528|Device|Digital rehabilitation|"Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health.~Patients in this group will performed home-based rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist."
76083826|NCT04636528|Device|Conventional rehabilitation|"Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program includes commonly used interventions adapted by the physical therapist to the specific needs of the participant.~In addition to the face-to-face sessions, PTs will also be communicating with participants in this group through a secure messaging system (Mychart) used at UCSF or, alternatively, through a telephone check-ins (10-15 min calls, up to twice per week)."
76083827|NCT05365438|Drug|Omega 3-Atorvastatin|Atmeg 2 capsules with 1 pack of Omethyl cutielet
76083828|NCT05365438|Drug|Omega 3-Atorvastatin|Atmeg 2 capsules
76083829|NCT05365438|Drug|Atorvastatin-Ezetimibe|ezetimibe/atorvastatin 10/20 mg
76083830|NCT05290558|Drug|Bu Shen Yi Jing Pill|"Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
76083831|NCT05290558|Drug|Placebo Drug|"Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
75334703|NCT00000382|Behavioral|Psychoeducational Home Visitation|
75643967|NCT00715273|Drug|Niacin|2000 mg of niacin each day
75334704|NCT00000382|Behavioral|Parent Education|
75334705|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
75643968|NCT00715273|Drug|Colesevelam|3.8 g of colesevelam each day
75643969|NCT00715273|Drug|Placebo Niacin|Placebo niacin each day
75334706|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
75643970|NCT00715273|Drug|Placebo Colesevelam|Placebo colesevelam each day
75643971|NCT01013285|Biological|bevacizumab|
75643972|NCT01013285|Drug|temozolomide|
75792043|NCT03937518|Drug|Strontium Ranelate|"Patients received strontium ranelate 2gm (one sachet daily with 50 ml water at bedtime at least 2 h after food), as the compliance of patient assessed by counting number of sachet that patient returns at every visit and safety is assessed by recording adverse effects as blood pressure and heart rate every visit and patients received physiotherapy program in the form of (US therapeutic acoustic radiation and exercise program) 3 times per week for 6 months.~Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min ("
75928473|NCT03475290|Behavioral|Personal resources' enhancement: self-efficacy and perceived social support|The condition reflects cultivation hypothesis and consists of 2 sequential modules with self-efficacy enhancement module (SE) preceding perceived social support enhancement module (SS). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SE: mastery experience, vicarious experience, and action planning, 2) SS: received support & cognitive distortions, social skills & peer support, action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
76083832|NCT02997670|Other|Algorithmic Cardiac Resynchronisation Therapy Optimisation|Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
75334707|NCT04757480|Procedure|Thoracolumbar Interfascial Plane Block (TLIP)|(20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
75334708|NCT04757480|Procedure|Bilateral Erector Spinae plane Block (ESB)|Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
75334709|NCT00001228|Drug|Interferon|
75334710|NCT01191541|Drug|DNR:|DNR：45mg/m2 d1-3
75643973|NCT01013285|Radiation|external beam radiation therapy|
75643974|NCT00715351|Drug|insulin detemir|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
75643975|NCT00715351|Drug|insulin NPH|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
75643976|NCT01943695|Behavioral|Aerobic Training|
75643977|NCT01943695|Behavioral|Educational Information|Subjects will be given material regarding cancer and it's impact.
75651879|NCT05053243|Device|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V2 and V4 in a sequential fashion along with the Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 7 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
76083833|NCT05132998|Other|Cardiac Rehabilitation Program|In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team
76083834|NCT05132998|Other|Community exercise intervention|In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
75334711|NCT01191541|Drug|Ara-c|DNR+ARA-C：DNR：45mg/m2 d1-3;Ara-C :1g/m2 d1-3
76083835|NCT05672914|Behavioral|Tablet-based sustained care|A tablet-based motivational-interviewing intervention, tailored specifically to smokers with psychiatric disorders, to motivate the use of evidence-based tobacco treatment and cessation in cigarette smokers upon discharge from an inpatient psychiatric hospitalization. In addition, participants will receive standard hospital tobacco care (see Usual Care Arm).
75928474|NCT03475290|Behavioral|Personal resources' enhancement: perceived social support and self-efficacy|The condition reflects enabling hypothesis and consists of 2 sequential modules with perceived social support enhancement module (SS) preceding self-efficacy enhancement module (SE). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SS: received support & cognitive distortions, social skills & peer support, and action planning, 2) SE: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
75643978|NCT01943695|Behavioral|Supervised Home Based Training|Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
75334712|NCT02141906|Other|Oncozene-DEB-TACE|ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
75643979|NCT00711451|Behavioral|Manual removal|Manual removal of placenta during cesarean delivery
75792044|NCT03937518|Other|physiotherapy|"Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (Medserve, England) (Huang et al., 2001). Patients were positioned in a supine position with the affected knee flexed at 90° and the sound head was held stationary over the tibiofemoral joint medial to the patellar tendon to enhance energy penetration into the joint space (White et al., 2007).~Exercise program:~The subjects were treated with a group-exercise program composed of a range of motion of all lower limb and 45 min strengthening exercises with 5 min stretching exercises of lower limb muscles 3 times per week under the supervision of the same physiatrist (Fitzgerald and Oatis"
75928475|NCT03475290|Behavioral|Personal resources' enhancement: self-efficacy|The condition consists of self-efficacy enhancement module (SE) and is comprised of 3 evidence-based, CBT-framed exercises: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
75334713|NCT02483936|Drug|Olmesartan medoxomil 40mg + chlorthalidone 12,5mg|1 tablet a day
75334714|NCT02483936|Drug|Olmesartan medoxomil 40mg + chlorthalidone 25mg|1 tablet a day
75928476|NCT03475290|Behavioral|Personal resources' enhancement: perceived social support|The condition consists of perceived social support enhancement module (SS) and is comprised of 3 evidence-based, CBT-framed exercises: received support & cognitive distortions, social skills & peer support, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
75334715|NCT02483936|Drug|Olmesartan 40mg + Hydrochlorothiazide 12,5mg|1 tablet a day
75643980|NCT00711451|Procedure|Expressed removal|Surgeon will perform an expressed delivery of the placenta
75643981|NCT04018885|Drug|ALA 2.5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
75643982|NCT04018885|Drug|ALA 5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
75928477|NCT02226705|Procedure|Multiple transnasal endoscopic surgeries|Transnasal endoscopic surgery extended to the skull base
76083836|NCT03003364|Drug|XCEL-UMC-BETA|Intrathecal allogeneic cell therapy in a blinded syringe
76083837|NCT03003364|Drug|Placebo|Placebo in a blinded syringe
76083838|NCT03003598|Other|Videolaryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
75334716|NCT02483936|Drug|Olmesartan 40mg + Hydrochlorothiazide 25mg|1 tablet a day
75334717|NCT00002038|Drug|Fluconazole|
75334718|NCT01150903|Other|no intervention|non-interventional study
75334719|NCT01150903|Other|no intervention|non-interventional study
75334720|NCT01894334|Drug|Ulinastatin|
75334721|NCT01894334|Drug|Tranexamic acid|
75334722|NCT01894334|Drug|Edaravone|
75334723|NCT00002044|Drug|Zidovudine|
75334724|NCT00001270|Drug|interleukin-1|
75334725|NCT00001282|Drug|Zidovudine (AZT) & Interleukin-2 (IL2)|
75334726|NCT01150981|Drug|Rosiglitazone|One 8mg capsule daily for 6 weeks.
75334727|NCT01150981|Drug|Placebo|One capsule daily for 6 weeks.
75334728|NCT00001288|Drug|15 O Water|
75334729|NCT00001288|Drug|FDG|
75334730|NCT00001300|Drug|doxorubicin|
75334731|NCT00001300|Drug|ifosfamide|
75472253|NCT01955811|Drug|Administration of platelet concentrate and taking blood samples|Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
75928478|NCT02471456|Other|Quality of Life Questionnaire|Quality of Life Questionnaire will be completed at least 1 year after their surgery.
76083839|NCT03003598|Other|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
76083840|NCT02981056|Other|Johnson's Baby Top-To-Toe Wash|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
75928479|NCT02471456|Other|MACCE review|MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
75928480|NCT03479346|Drug|GGT|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
75928481|NCT03479346|Drug|Placebo|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
75928482|NCT02222883|Genetic|Testing of BRCA status regarding germline and somatic mutation|
76083841|NCT02981056|Other|Johnson's Baby Lotion|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
76083842|NCT02981056|Other|Water (in lieu of bathing products)|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
75472254|NCT01955824|Drug|1% lignocaine|
76083843|NCT03003286|Behavioral|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
76083844|NCT03003286|Behavioral|Parents and Teachers Supporting Students (PATSS)|The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
76083845|NCT03003442|Dietary Supplement|Supradyn® Energy 3RDA|Multivitamin/mineral containing co-Q10
76083846|NCT03003442|Dietary Supplement|Placebo|Placebo
76083847|NCT03003208|Other|Pulmonary rehabilitation|An exercise and education program
76083848|NCT05437354|Other|survey|Oncology medical staff should respond to a survey
76083849|NCT05431036|Device|transthoracic ultrasonography|"The lung ultrasound score (LUS) will be calculated according to the observed worst ultrasound pattern and Finally, the LUSs of all the parts will added to obtain the total LUS for each patient (maximum36 points)~The diaphragmatic ultrasound will performed for assessment of diaphragmatic thickness and motion."
75472255|NCT01955824|Drug|2% lignocaine|
75472256|NCT01955850|Behavioral|Cognitive behavioral treatment for insomnia|Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
75472257|NCT01955863|Procedure|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
75472258|NCT01955863|Procedure|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
75472259|NCT01955863|Procedure|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
75472260|NCT01955876|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
75928483|NCT03310814|Other|Personalized nutrition|Receives individualized nutrition information
76083850|NCT03002896|Behavioral|Pep-Pal|Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.
75334732|NCT00001300|Drug|mesna|
75334733|NCT01230931|Device|Vitagel|Vitagel (by Stryker) is a topical surgical hemostat spray that results in coagulation. The components are as follows: autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors; this is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
75334734|NCT01230931|Procedure|Standard of care|Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
75334735|NCT00000394|Procedure|Acupuncture therapy|
75472261|NCT01955889|Behavioral|Mobile Health Technology|
75472262|NCT01955889|Behavioral|Stretching & Strengthening Exercises|
75472263|NCT01955889|Behavioral|Walking with Pedometer|
75472264|NCT01955928|Behavioral|Online Cognitive behavioral treatment for insomnia|
75472265|NCT01955967|Drug|Lidocaine|
75472266|NCT01956006|Drug|Milrinone|Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
76083851|NCT03002896|Other|Treatment as Usual|
76083852|NCT02248168|Drug|Pramipexole|
75334736|NCT00000400|Drug|Human parathyroid hormone [hPTH-(1-34)]|37 mcg once daily by self-administered sc injection
75472267|NCT01956019|Device|MRI scanning|
75792045|NCT01211496|Behavioral|High-speed power training|High speed resistance training, 3 sessions per week for 12 weeks
75472268|NCT01956045|Other|Patient's capacity|
75472269|NCT01956058|Radiation|brachytherapy remedial|brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
75472270|NCT01956136|Behavioral|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
75472271|NCT01956136|Other|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
75472272|NCT01956149|Drug|Cabazitaxel|20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
75643983|NCT04018885|Drug|ALA 10%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
75643984|NCT00711685|Procedure|coronary artery bypass grafting via midline sternotomy|
75643985|NCT02574325|Drug|Placebo|Control
75643986|NCT02574325|Drug|ARI-3037MO|Treatment
75643987|NCT00715507|Device|medication monitor|the medication monitor will aid in expertise and decision-making.
75792046|NCT01211496|Behavioral|Slow-speed strength training|Slow speed resistance training, 3 sessions per week for 12 weeks
75792047|NCT01116726|Behavioral|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
75792048|NCT01116726|Behavioral|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
75792049|NCT01118208|Other|Blister packaging medications|Dispensing prescription medications on pre-filled blister package cards.
75792050|NCT01118208|Other|Dispense as usual|Dispensing prescription medications in standard pill bottles.
75928484|NCT03310736|Diagnostic Test|Intrinsic Hepcidin IDx™ Test|ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.
75928485|NCT02222961|Drug|BIIR 561 CL|
76083853|NCT02248402|Biological|Vax-DC/MM|
76083854|NCT05672446|Other|simulation with standardized child patient|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients. In the simulation, a school-aged child was used as the standard patient.
76083855|NCT05672290|Other|Electrical stimulation 1|External electrical stimulation will be applied for 30 minutes 3 days a week during 6 weeks. Electrodes were placed around the pelvis.
76083856|NCT05672290|Other|Electrical stimulation 2|External electrical stimulation will be applied for 30 minutes one day a week during 6 weeks. Electrodes were placed around the pelvis.
76083857|NCT02997124|Procedure|local infiltration and TAP block|Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
76083858|NCT02997124|Procedure|local infiltration only|Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
75334737|NCT00000400|Drug|alendronate|70 mg/week by oral route
75472273|NCT01956162|Device|Orthèse Diabète|The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.
75472274|NCT01956162|Device|"Conventional Device"|Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
75643988|NCT02573389|Device|Boston Scientific or Cook pancreatic duct stents|Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
75334738|NCT02477774|Device|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
75643989|NCT00711841|Drug|dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
75643990|NCT00711841|Drug|Placebo|Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
75643991|NCT00711841|Drug|dexamethasone|dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
75928486|NCT02222961|Drug|Placebo|
75928487|NCT03479190|Procedure|ultrasound guided injection of Platelet rich plasma|Platelet rich plasma (PRP) injection into trochanteric area under ultrasound guidance
76083859|NCT03002428|Drug|Teriparatide (PF708)|Subcutaneous injection
76083860|NCT03002428|Drug|Teriparatide (Forteo)|Subcutaneous injection
75334739|NCT01195597|Device|E-Cigarette 7.2 mg nicotine|"Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges (Original cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer"
75334740|NCT00000406|Procedure|Progressive resistance exercise|
75643992|NCT00711919|Drug|Pitavastatin|"comparison of different target levels of lipid lowering using Pitavastatin~Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months."
75792051|NCT03937440|Drug|Deep neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for post-tetanic count (PTC) in deep neuromuscular group.
75928488|NCT03479190|Procedure|ultrasound guided injection of Normal Saline|ultrasound guided injection of Normal Salineinto trochanteric area under ultrasound guidance
75928489|NCT03000998|Behavioral|Web App Intervention Group|All baseline and follow-up data collection will be conducted via online surveys and a customized web portal and include parent self-reports and clinic records of vaccination of boys
75928490|NCT03000998|Behavioral|Usual Customary Care Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on HPV vaccination from the Centers for Disease Control and Prevention (CDC) in Portable Document Format (PDF) format.
75334741|NCT00002050|Drug|Thymopentin|
75334742|NCT04389866|Device|JUVÉDERM VOLUMA™ XC|Injectable gel
75643993|NCT00711919|Drug|Pitavastatin|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
75643994|NCT04073095|Other|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
75651880|NCT05051657|Dietary Supplement|PKU express plus|PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.
75651881|NCT05051527|Drug|Legalon® 140 mg|Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision
75792052|NCT03937440|Drug|Moderate neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for train-of-four (TOF) in moderate neuromuscular group.
75792053|NCT01114152|Drug|AZD9742|IV Formulation
75792054|NCT01114152|Drug|Placebo|IV Formulation
75792055|NCT01211574|Behavioral|peer coach|Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.
75928491|NCT02226783|Drug|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
75928492|NCT02226783|Drug|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
75928493|NCT02226783|Drug|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
75928494|NCT03479112|Behavioral|Flashcards|Participants will be provided with Flashcards depicting how to correctly apply a tourniquet to an extremity wound.
75928495|NCT03479112|Behavioral|Audio-kit|Participants will be provided with an audio-kit with accompanying visual cues describing and depicting how to correctly apply a tourniquet to an extremity wound.
75928496|NCT03479112|Behavioral|B-Con training|Participants will undergo the Bleeding control for the injured (B-Con) basic course.
75334743|NCT00000412|Drug|Alendronate|
75334744|NCT00000412|Drug|Calcitriol|
75334745|NCT00000412|Drug|Placebo Alendronate|
75334746|NCT00000412|Drug|Placebo Calcitriol|
75334747|NCT04390256|Other|Clove water extract|natural product
75334748|NCT04390256|Other|Carbopol|Bioadhesive polymer
75334749|NCT04390256|Other|Carboxymethyle cellulose|Bioadhesive polymer
75334750|NCT00002056|Drug|Pentamidine isethionate|
75334751|NCT03110562|Drug|Selinexor|oral 100 mg dose
75334752|NCT03110562|Drug|Bortezomib|subcutaneous dose of 1.3 mg/m2
75334753|NCT03110562|Drug|Dexamethasone|oral dose of 20mg
75334754|NCT00380614|Drug|Lamivudine|
75334755|NCT00000430|Drug|Alendronate|
75334756|NCT00000430|Drug|Estrogen/progestin therapy|
75334757|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
75334758|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
75334759|NCT01231399|Drug|fluorouracil|Given IV
76083861|NCT03002584|Other|completion of self-reported questionnaires|"Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale"
75928497|NCT03479112|Behavioral|B-Con training retention|Evaluation of retention of Bleeding Control for the injured basic course
76083862|NCT03002662|Other|colonoscopy|
75334760|NCT01231399|Drug|leucovorin calcium|Given IV
76083863|NCT02224612|Device|Medline Pediatric Face Masks|Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
76083864|NCT02224612|Device|KC Childs Mask|KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
76083865|NCT02225860|Behavioral|Diet and water adjustment|The dietary intervention consisted of three elements: low sodium (1500 mg/day), low protein (daily protein dietary allowance of 0.8 gram/kg body weight), and low urea (avoidance of preservatives, food additives, bulking agents, and chewing gum). Protein was factored by measured body weight to mirror the estimated average requirement (EAR) of healthy adults which is set on a grams per kilogram basis
75651882|NCT05037266|Biological|COVID-19 Vaccine Janssen (Ad26.COV2-S)|one dose (0.5mL) at D1 and one dose (0.5mL) at D57
76083866|NCT01377012|Biological|Secukinumab (AIN457)|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
76083867|NCT01377012|Biological|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
75334761|NCT01231399|Drug|oxaliplatin|Given IV
75472275|NCT01956175|Device|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
75472276|NCT01956175|Device|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
75472277|NCT01956188|Dietary Supplement|EPA and DHA supplementation|Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
75651883|NCT05034419|Device|Parasym|Stimulation will be done under anesthesia for 30 minutes. Stimulation parameters include a pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz. The Parasym devise (Parasym Health, London, UK) will be used for stimulation. The device will be connected to a clip electrode that will be attached to the external ear. In the active group, the ear clip electrode will be attached to tragus in the active stimulation group. This device has been deemed non-significant risk by the FDA. In the control group, no stimulation will be done.
75928498|NCT03310658|Device|Zip-Stitch Soft Tissue Closure System|The novel Zip-Stitch System employed a laparoscopic applicator, a series of bio-absorbable clips, and an application procedure to close the vaginal cuff during otherwise standard of care total laparoscopic hysterectomy.
75651884|NCT05034419|Device|Sham stimulation|Sham stimulation
75792056|NCT01211574|Behavioral|mentor|Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.
75928499|NCT02223117|Biological|Thrombosomes|Freeze-dried platelets
75928500|NCT02223117|Biological|Placebo|
76083868|NCT05672056|Procedure|Computer guided placement of a stock plate pre-bent on a 3D printed model|We aim to design a novel guide that can secure the construct of the fibular segments and pre bent plate onto the native mandible and effectively and efficiently translate the VSP into the surgical field.
75334762|NCT01231399|Drug|everolimus|Given orally
75792057|NCT01211574|Behavioral|Professional|Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
75334763|NCT01231399|Other|laboratory biomarker analysis|Correlative studies
75334764|NCT01231399|Other|immunohistochemistry staining method|Correlative studies
75334765|NCT01231399|Genetic|microarray analysis|Correlative studies
75334766|NCT00002062|Drug|Spiramycin|
75334767|NCT00000436|Behavioral|Self-efficacy and muscle strength training|
75334768|NCT00000436|Procedure|High-intensity strength training|
75472278|NCT01956188|Dietary Supplement|Placebo|Subjects will be given 3g/d of soy oil - 5 capsules per day.
75472279|NCT01956201|Drug|Atorvastatin 20mg|[Atorvastatin Run-in Period] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) [Treatment Period] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) [Extension Period] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)
75472280|NCT01956201|Drug|Fenofibrate 160mg|Refer to Intervention Description of Atorvastatin 20mg
75792058|NCT01118286|Drug|Nifedipine (Adalat, BAYA1040)|Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
75472281|NCT01956201|Other|Placebo (Fenofibrate 160 mg)|Refer to Intervention Description of Atorvastatin 20mg
75472282|NCT01956214|Other|FES Exercise|receive FES while exercising
75472283|NCT01956214|Other|Mock FES Exercise|participants will receive Mock FES
75472284|NCT01956227|Behavioral|Home-based exercise|exercise to look at balance and lower limb strength record in diary
75472285|NCT01956227|Behavioral|Education|sessions to discuss self-management ideas to modify risk of falling
75792059|NCT03937752|Other|3D endodanal ultrasound|Endoanal ultrasound performed with two different transducers preoperatively during a fistula treatment procedure.
75334769|NCT05432154|Device|Film forming silicone gel (7-0940)|"Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances."
75928501|NCT04559438|Other|Rotary Neoniti GPS file|Glide path creation will be achieved using Neoniti GPS file (15/.03). The file will be introduced passively inside the canal, in continuous rotation at a constant speed between 300 and 500 rpm and torque of 1.5 N.
75643995|NCT04073095|Other|modified-thoracolumbar interfascial plane block (Group T)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
75334770|NCT01231633|Drug|Ozurdex|Ozurdex, 0.7mg dexamethasone
75334771|NCT01231633|Drug|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
75643996|NCT00715585|Behavioral|Active Control|patients receive 3 individualized visits with a health educator focused on general diabetes education and health promotion
75334772|NCT00000442|Drug|naltrexone (Revia)|
75643997|NCT00715585|Behavioral|int arm 1|VVpatients receive 3 individualized visits with an rd-cde for education focused on modified plate method
75334773|NCT00002068|Drug|Fluconazole|
75334774|NCT00002068|Drug|Amphotericin B|
75334775|NCT02247037|Other|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
75643998|NCT00715585|Behavioral|int arm 3|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
75643999|NCT01033643|Drug|MK-3614|Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.
75334776|NCT00000448|Drug|naltrexone|Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
75644000|NCT01033643|Drug|Placebo for MK-3614|Participants were administered dose matched placebo tablets according to randomization.
75644001|NCT00715663|Drug|biphasic insulin aspart 30|No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
75644002|NCT04070599|Biological|Collection of biological samples|A collection of biological samples will be carried out, with the remainders of the immunological samples taken on dry tube: the serum of the patients, taken at the initial diagnosis, will be kept frozen at -20 ° C.
75644003|NCT01013207|Device|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
75651885|NCT05030987|Procedure|Renal Denervation|Renal denervation in patients with HFpEF and uncontrolled hypertension
75651886|NCT05030987|Procedure|Sham|Sham Treatment. After six months, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
75651887|NCT05006092|Device|ENDOMIND|CADe system for Polyp detection
75928502|NCT04559438|Other|Manual stainless steel K-files|Glide path preparation will be done by hand instrumentation using K-files #10 and 15.
75928503|NCT02226861|Device|CliniMACS CD34 selection system|Stem cells will be selected with the CliniMACS system before transplant.
75928504|NCT02226861|Biological|ULD IL-2|sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution
75928505|NCT02997020|Other|EDSPD|The equipment & conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
75334777|NCT00000448|Drug|Placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
75334778|NCT01234207|Device|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
75334779|NCT01234207|Device|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
75334780|NCT00001318|Drug|interferon gamma|
75334781|NCT00002074|Drug|Fluconazole|
75334782|NCT00002074|Drug|Amphotericin B|
75334783|NCT01234831|Device|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
75334784|NCT01234831|Other|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
75334785|NCT00001354|Drug|Interleukin-2/Zidovudine (AZT)|
75644004|NCT01013207|Device|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
75928506|NCT03482388|Behavioral|Crowdsourced materials|Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
75928507|NCT03482388|Other|Control|Participants will not view any images or videos promoting HBV and HCV testing.
76083869|NCT03371550|Drug|Docetaxel|Induction chemotherapy
75334786|NCT02546856|Other|Heart Failure (HF) nurse up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support."
75644005|NCT01013207|Device|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
75644006|NCT00715897|Procedure|Hyperbaric Oxygen Therapy (HBOT)|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
75334787|NCT02546856|Other|Heart Failure (HF) cardiologist up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist."
75334788|NCT00000454|Drug|nicotine replacement patch|
75334789|NCT03011437|Other|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
75334790|NCT00002080|Drug|Rifabutin|
75644007|NCT00712309|Device|Lifestent|Stent for endovascular treatment of popliteal artery lesions
75792060|NCT03940014|Other|Data collection from standard follow up|"Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months."
75792061|NCT01118364|Other|Cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving"
75928508|NCT02226939|Drug|BILN 2061 ZW|
75334791|NCT00000484|Drug|chlorothiazide|
75334792|NCT00000484|Drug|Rauwolfia alkaloids|
75472286|NCT01956227|Behavioral|Exercise plus Education|combination of exercise sessions with education sessions to modify fall risk
75472287|NCT01956253|Drug|Neratinib|240 mg orally once daily
75644008|NCT00712309|Device|balloon-angioplasty (PTA)|PTA for endovascular treatment of popliteal artery lesions
75644009|NCT02574091|Drug|1% icotinib hydrochloride cream|Topical administration for twice daily
75644010|NCT02574091|Drug|2% icotinib hydrochloride cream|Topical administration for twice daily.
75644011|NCT02574091|Drug|Placebo|Topical administration for twice daily.
75644012|NCT00712387|Behavioral|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
75644013|NCT00712465|Drug|AZD1305|Extended Release tablet, repeated administration
75644014|NCT00712465|Drug|Digoxin|Tablet, repeated administration
75644015|NCT00715975|Drug|halobetasol|The patients will be treated with halobetasol once a day for 15 days.
75644016|NCT00715975|Drug|clobetasol|The patients will be treated with clobetasol once a day for 15 days.
75792062|NCT01118364|Other|tobacco|"a cigarette tobacco trade mark Drum 45 minutes before simulating or real driving"
75792063|NCT03939468|Device|DES+DCB|A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease
75928509|NCT02226939|Drug|Placebo|
75928510|NCT02232165|Other|Hypotension avoidance|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP >= 65 mmHg is not inferior to induced hypertension.
75928511|NCT02232165|Other|Induced hypertension|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
75928512|NCT03482232|Drug|Benzodiazepines|Benzodiazepines for insomnia, agitation or delirium in people older than 65
75928513|NCT03482232|Drug|Non-steroidal anti-inflammatory drugs|Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
75928514|NCT03482232|Drug|paracetamol|paracetamol 1g for more than 3 days
76083870|NCT03371550|Radiation|concomitant radiotherapy|Pulmonary and mediastinal radiotherapy
76083871|NCT03371550|Drug|Cisplatin|Induction chemotherapy
76083872|NCT05671744|Other|Cell-based non-invasive prenatal testing|Blood sampling
76083873|NCT03371472|Device|Visualisation and measuring of paravalvular leak.|Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).
76083874|NCT03371394|Other|no intervention|no intervention
76083875|NCT02324920|Device|DDD-CLS|
76083876|NCT02324920|Device|ODO|
76083877|NCT03371316|Biological|ViaShield|Anti-adhesion scores using amnion patch
75928515|NCT03482232|Drug|Antimicrobial agent|antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
76083878|NCT03371238|Behavioral|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
76083879|NCT05671666|Diagnostic Test|Urea cycle flux study|Quantification of ureagenesis
76083880|NCT04527120|Other|indigenously developed ultrasound phantom (IDUP)|Ultrasound phantom model developed in the department of Emergency Medicine of Jubilee Mission Medical College, to train vascular access.
75644017|NCT01033487|Drug|placebo|oral inhaled formulation, single dose
75644018|NCT01033487|Drug|active comparator|oral inhaled formulation, single dose
76083881|NCT05670028|Drug|Hypotensive Drugs and/or Vasoactive Drugs|To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
75334793|NCT01151371|Device|narafilcon B contact lens|Silicone Hydrogel Daily Disposable Contact Lenses
75334794|NCT01151371|Device|nelfilcon A contact lens|Conventional Hydrogel Daily Disposable Contact Lenses
75334795|NCT01151371|Device|lotrafilcon B contact lens|Silicone Hydrogel Monthly Replacement Contact Lenses
75928516|NCT03482232|Drug|Lipid-lowering drug|Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
75928517|NCT03482232|Diagnostic Test|Prostate cancer|Screening for prostate cancer in asymptomatic patients
75928518|NCT03482232|Radiation|Lumbago|image tests in non-specific lumbago
75334796|NCT00000496|Drug|aspirin|
75334797|NCT00000496|Drug|dipyridamole|
75334798|NCT03011359|Other|Optimizing B.I (New) PCA mode|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: ~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr ~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).
75334799|NCT03011359|Other|Conventional PCA mode|(Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
75334800|NCT00002086|Drug|Zidovudine|
75334801|NCT00002086|Drug|Zalcitabine|
75644019|NCT01033487|Drug|Low Dose PF-03635659|oral inhaled formulation, single dose, low dose
75644020|NCT01033487|Drug|Mid Dose PF-03635659|oral inhaled formulation, single dose, mid dose
75472288|NCT01956266|Behavioral|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
75472289|NCT01956305|Drug|DS-7309|DS-7309 powder in bottle
75472290|NCT01956305|Drug|placebo|placebo to match DS-7309 powder in bottle
75472291|NCT01956305|Drug|Metformin|Metformin 500mg tablet for Cohort F
75644021|NCT01033487|Drug|High Dose PF-03635659|oral inhaled formulation, single dose, high dose
75644022|NCT00716053|Drug|BLVR|BLVR 20 mL
75644023|NCT04018963|Procedure|Single nostril approach endoscopic transsphenoidal pituitary surgery|Single nostril approach endoscopic transsphenoidal pituitary surgery
75334802|NCT00002086|Drug|Interferon alfa-n1|
75334803|NCT04713436|Drug|Differentiation Markers|Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
75334804|NCT01151449|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
75334805|NCT01151449|Other|laboratory biomarker analysis|Correlative studies
75334806|NCT00001384|Drug|Adriamycin|
75644024|NCT04018963|Procedure|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
75644025|NCT02572687|Drug|Ramucirumab|Administered IV
75644026|NCT02572687|Drug|MEDI4736|Administered IV
75644027|NCT04284527|Other|Observational study|a reliability - validity study
75792064|NCT01585506|Other|No treatment given|"Patients to complete the WHO-5 Well-being Index questionnaire"
75792065|NCT01585506|Other|No treatment given|"Physicians to complete two questionnaires, Demographic Data and Disease and Treatment Course and Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues"
75792066|NCT03787212|Device|MiBo ThermoFlo|Test Device
75792067|NCT03787212|Device|Bruder Mask|Control Device
75792068|NCT01585350|Biological|MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|"Cohort 1 will be divided into three sub-groups and will receive:~Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)~Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1~Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations"
75928519|NCT03482232|Drug|Antimicrobial agent|antibiotics for pharyngitis (infants)
75928520|NCT03482232|Drug|Mucolytic|mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
76083882|NCT03004378|Behavioral|Activity Tracker|Fitbit Alta
76083883|NCT03123900|Behavioral|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
76083884|NCT03123900|Behavioral|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
76083885|NCT03123900|Behavioral|Combined training|Subjects included in this group receive both types of intervention.
75928521|NCT03482232|Drug|Ibuprofen and paracetamol|treatment with ibuprofen and paracetamol (infants)
75334807|NCT00001384|Drug|cyclophosphamide|
75334808|NCT00001384|Drug|G-CSF|
75644028|NCT00712621|Behavioral|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
75644029|NCT00712621|Behavioral|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
75644030|NCT01033019|Drug|LDE225 0.75%|0.75% cream
75644031|NCT01033019|Drug|Vehicle|matching placebo cream to 0.75% LDE225 cream
75644032|NCT04205279|Other|Experimental: Treadmill training|Participants will be given thirteen slips and thirteen trips in stance and walking, followed by two slips and two trips at a higher intensity (posttest). Subjects would be consented if they would like to undergo fMRI pre and post-training. Participants not willing to undergo imaging would not be excluded. Three day training consisting of blocks of five consecutive gait-slips at varying intensities will be provided. Individuals with stroke would undergo an additional session (total 4 training sessions over 4 weeks (1session/week) since these individuals get easily fatigued and also might need more training sessions with sufficient rest interval to induce reactive adaptation. Training at a specific level will persist until the subjects show a recovery step response in at least 3/5 trials in a single block. Once subjects successfully adapt to this level, the perturbation intensity will be increased until they show a recovery response in at least 3/5 trials.
75644033|NCT04205279|Other|Experimental: Overground training|"Slips and trips could be induced under either of the limbs. The specialized walkway consists of two sliding platforms, each of which is mounted on two rows of low friction linear bearings (friction coefficient = 0.02). The base plate of each platform is bolted separately onto the top of a force platform embedded in the floor. An electronic-mechanical latch system is used to control the 2 states of the support platform; that is, the locked state for regular walking and the release state to initiate slipping are carefully controlled. The sliding top of the platform is released after the heel strike (vertical force to exceed 2% of the body weight). The slip distance would be adjusted between 30 to 60 centimeters depending upon the different population and their physical capacity."
75651888|NCT04992845|Device|Anterior Vertebral Body Tethering|The SCOLI-TETHER (MIScoli) System is intended for anterolateral vertebral body fixation and internal fastening of the convex side of the thoracic curvatures thereby reducing the deformity and preventing the progression of idiopathic scoliosis in growing children/adolescents at high risk for curve progression while preserving motion.
75792069|NCT01585350|Biological|MELITAC 12.1 + Montanide ISA-51 + polyICLC|"Cohort 2 will be divided into three sub-groups and will receive:~Group 2a: MELITAC 12.1 + polyICLC adjuvant~Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1~Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations"
75792070|NCT03937674|Behavioral|HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
75792071|NCT01121640|Procedure|CA125 assay on Abbott Architect i1000SR platform|Bead-based sandwich ELISA style assay
75792072|NCT01121640|Procedure|HE4 assay on Architect i1000SR platform|Bead-based sandwich ELISA style assay
75792073|NCT01121640|Procedure|Transvaginal Ultrasound|Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
75928522|NCT02996864|Other|Healthy Detours App|"The app features:~Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring."
75928523|NCT02996864|Other|Fat Secret App|Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
75928524|NCT03474978|Device|Peripherally Inserted Central Venous Cather (PICC)|Location of the PICC insertion will be randomized and compared
76083886|NCT05669872|Drug|Ferric Carboxymaltose 50Mg/Ml Inj 20Ml|ferric carboxymaltose 1000mg, fixed dose for intervention group
75334809|NCT00001384|Drug|paclitaxel|
75334810|NCT02122952|Biological|AVXS-101|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
75334811|NCT00000508|Behavioral|smoking cessation|
75334812|NCT00000508|Behavioral|diet, reducing|
75334813|NCT00000508|Behavioral|exercise|
75334814|NCT00000508|Behavioral|diet, fat-restricted|
75334815|NCT01151761|Procedure|Stereotactic Body Radiotherapy|Standard of care
75334816|NCT01151761|Drug|Gemcitabine|100 mg/m2, IV
75334817|NCT01151761|Drug|Cisplatin|25 mg/m2, IV
75334818|NCT01151761|Drug|Carboplatin|AUC 2, based on Calvert formula, IV
75334819|NCT01151761|Drug|Capecitabine|1000 mg/m2, PO
75334820|NCT01151761|Drug|5FU|200 mg/m2
75334821|NCT01151761|Procedure|Liver transplantation|
75334822|NCT00002092|Drug|Cimetidine|
75334823|NCT00380458|Device|Coblation (radiofrequency-based device)|
75334824|NCT00002098|Drug|Lentinan|
75334825|NCT00002098|Drug|Didanosine|
75334826|NCT01196377|Drug|Albuterol|Nebulized albuterol
75334827|NCT00001426|Drug|Cyclophosphamide|
75644034|NCT04205279|Other|Experimental: Surefooted training|During the first minute of each block, subjects would experience no perturbations followed by 3 minutes of single or multi-directional perturbations. A one minute break between each condition would be provided. Subject's fatigue would be assessed by Fatigue severity scale to determine the tolerability of 30 minute training protocol. The expected duration to complete the test would be a maximum of 1 hour including the preparation and training time.
75472292|NCT01956318|Behavioral|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
75472293|NCT01956344|Behavioral|Cognitive Behavioral Therapy|Group cognitive-behavioral therapy for hoarding disorder, 16 weeks
75472294|NCT01956357|Other|Aquatic exercise|
75472295|NCT01956357|Other|Land Exercise|
75644035|NCT00712777|Drug|Brimonidine 0.2 %|Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
75472296|NCT01956370|Device|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
75472297|NCT01956370|Procedure|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
75644036|NCT00603447|Drug|Carfilzomib|Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
75644037|NCT00603447|Drug|Lenalidomide|Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
75644038|NCT00603447|Drug|Dexamethasone|Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
75334828|NCT00001426|Drug|Paclitaxel|
75472298|NCT01956383|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
75472299|NCT01956396|Device|PrePex™ device|PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
75472300|NCT01956409|Drug|18F-FCH|
75472301|NCT01956409|Drug|Magnevist|
75472302|NCT01956422|Device|Continuous Positive Airway Pressure(CPAP)|
75334829|NCT00001426|Drug|Cisplatin|
75334830|NCT00001426|Drug|G-CSF|
75334831|NCT00002104|Drug|Thalidomide|
75334832|NCT01152307|Behavioral|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
75334833|NCT00001438|Drug|all-trans-retinoic acid with IFN-alpha2a|
75472303|NCT01956422|Device|Venturi Mask FiO2 40%|
75472304|NCT01956448|Device|Drug eluting stent|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
75472305|NCT01956474|Other|Theralight crosslinking and Riboflavin|Corneal Collagen cross linking with UV light and riboflavin
75472306|NCT01956487|Drug|Propafenone|Comparison of drug from 2 manufacturing sites
75644039|NCT00718627|Biological|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
75644040|NCT03989167|Other|Clinical decision support|Computer-based support tool for identification of patients with high levels of total cholesterol or LDL-C, at high risk of being affected by FH.
75644041|NCT00718705|Drug|Josamycin|josamycin with posology of 2 grams per day by oral way during 10 days
75644042|NCT00718705|Drug|Placebo|Placebo with posology of 2 grams per day by oral way during 10 days
75644043|NCT02687685|Other|Skin to skin contact immediate|Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
75651889|NCT04987255|Other|Free visit|The persons with sedentary (healthy) in this group will have to visit the museum freely (without a guide) for a period of 75 minutes.
75651890|NCT04987255|Other|Guided visit|The persons with sedentary (healthy) in this group will have to visit the museum with a guide for a period of 75 minutes.
75792074|NCT01118598|Drug|tredaptive (nicotinic acid/ laropiprant)|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
75792075|NCT01118598|Drug|placebo|placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
75792076|NCT01121718|Drug|ICG Intervention|NIR-guided sentinel lymph node mapping with indocyanine green (ICG)
75792077|NCT03939546|Other|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
76083887|NCT05669872|Drug|RBC|pack RBC transfusion
75472307|NCT01956500|Dietary Supplement|Instaflex|The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
75472308|NCT01956500|Dietary Supplement|Placebo|The placebo capsules will contain magnesium stearate, an inert substance.
75334834|NCT01235377|Other|Favor one of two thiazides for new prescriptions & attempt target dose|Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
75644044|NCT02687685|Other|skin to skin contact early|Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
75334835|NCT00001444|Drug|7-hydroxystaurosporine (UCN-01)|
75472309|NCT01956513|Other|MRI (Magnetic resonance imaging)|MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.
75472310|NCT01956526|Device|CORolla™ TAA device|
75472311|NCT01956552|Other|biopsy or cytopuncture|
75644045|NCT00639015|Drug|Phenylephrine|Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
75644046|NCT00639015|Drug|Norepinephrine|Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
75644047|NCT00718783|Other|Tissue samples taken from retinoblastoma|Tissue banking
75644048|NCT00718783|Other|5 ml peripheral blood|White blood cells will be isolated from the blood sample as a source of genomic DNA.
75644049|NCT04186143|Other|Closed Cinetic Chain Exercises|Sit to stand, mini squat, anterior lunge, step up exercises are performed as Closed Cinetic Chain Exercises.
75644050|NCT04186143|Other|Open Kinetic Chain Exercises|Isometric quadriceps, isotonic quadriceps, hip extension and hip adduction exercises are performed as Open Kinetic Chain Exercises.
75644051|NCT04186143|Other|Control Group|Control Group was followed up by conservative treatment and home program for 12 weeks and they were asked to apply the home program three days in a week. Exercise brochure was handed out for home program. Quadriceps strength and harmstring stretch exercises were applied.
75928525|NCT03474900|Device|PLGA implant, Bioretec ltd. Finland|The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
75334836|NCT00000544|Behavioral|diet therapy|
75334837|NCT01196533|Device|Non invasive peripheral blood monitoring|non invasive monitoring
75334838|NCT02700308|Device|Kyphoplasty|Placement and inflation of balloon prior to cement injection
75334839|NCT02700308|Device|Conventional vertebroplasty|Conventional vertebroplasty
75334840|NCT00000562|Procedure|extracorporeal membrane oxygenation|
75334841|NCT01196923|Device|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
75334842|NCT00000574|Drug|ibuprofen|
75472312|NCT01956565|Other|Inspiratory Muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
75472313|NCT01956578|Other|Breathing Exercise Cohort|All patients enrolled will be asked to wear a respiration band and perform a series of breathing exercises.
75472314|NCT01956591|Drug|Oxybutynin|All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
75334843|NCT00002110|Drug|Cysteamine|
75334844|NCT00002110|Drug|Zidovudine|
75334845|NCT00001450|Drug|paclitaxel|
75334846|NCT00001450|Drug|cisplatin|
75472315|NCT01956604|Drug|Clonidine|
75472316|NCT01956604|Drug|Placebo|
75472317|NCT01956617|Other|lumbar plexus block|
75472318|NCT01956630|Biological|Genetically modified DCs plus CIK cells|
75472319|NCT01956630|Biological|Donor leukocyte infusions (DLI)|
75472320|NCT01956643|Other|gum chewing|gum chewing
75644052|NCT00712855|Biological|mapatumumab|3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
75644053|NCT00712855|Drug|sorafenib|400 mg orally, twice a day continuously in each cycle
75644054|NCT04185987|Other|Leone slide low friction elastomeric ligature|Leone slide low friction elastomeric ligature application
75644055|NCT04185987|Other|RMO tough - o energy elastomeric ligature|RMO tough - o energy elastomeric ligature application
75644056|NCT04185987|Other|Dentsply sili tie elastomeric ligature|Dentsply sili tie elastomeric ligature application
75644057|NCT04185987|Other|AO twisted ended ligature wire|AO twisted ended ligature wire application
75644058|NCT02537925|Drug|Celecoxib|Celecoxib 200mg bid po, to the end of concurrent radiotherapy
75644059|NCT02537925|Drug|Nedaplatin|40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
75334847|NCT00381082|Drug|1) MOOV Head Lice Treatment (Ego Pharmaceutical).|
75334848|NCT00381082|Drug|Banlice Mousse Aerosol (Pfizer, Australia)|
75334849|NCT00381082|Drug|3) KP24 Medicated Foam (Nelson Laboratories)|
75334850|NCT00000580|Drug|immunoglobulins, intravenous|
75644060|NCT02537925|Radiation|Concurrent Radiotherapy|The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68~74 Gy for primary tumor (2.0~2.3 Gy/f/day, 5 day/ week, /6~7 weeks), and 50~54 Gy for lymphatic positive area (1.8 ~ 2 Gy/f/day, 5 day/week, /5.0~5.5 weeks).
75644061|NCT00713011|Drug|Adalat XL|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
76083888|NCT03124056|Device|Extracorporeal photopheresis|Extracorporeal photopheresis using non-open system
76083889|NCT04861948|Drug|IBI188|intravenous
75644062|NCT00713011|Drug|Tiazac XC|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
75644063|NCT02687295|Dietary Supplement|Thylakoids|
75644064|NCT02687295|Other|Control|
76083890|NCT04861948|Drug|GM-CSF|subcutaneous injection
75472321|NCT01956643|Other|Control|Routine care during NPO
75644065|NCT00716365|Device|HemCon bandage|5 cm X 5 cm
76083891|NCT04861948|Drug|Cisplatin/Carboplatin|intravenous
76083892|NCT04861948|Drug|Bevacizumab|intravenous
75644066|NCT02537769|Device|Left ventricular assist device (LVAD)|Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
75644067|NCT02537769|Procedure|Tricuspid Valve Repair (TVR)|Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
75644068|NCT03878823|Drug|ODM-209|co-administered with glucocorticoid and mineralocorticoid, orally daily
75651891|NCT04987255|Other|Guided visit (stroke)|The persons with motor disability after stroke in this group will have to visit the museum with a guide for a period of 75 minutes.
75792078|NCT02529462|Genetic|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
75792079|NCT02529462|Drug|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
75792080|NCT03937362|Diagnostic Test|First clinical response evaluation (CRE-1)|Consisting of: endoscopy with bite-on-bite biopsies
75792081|NCT03937362|Diagnostic Test|Second clinical response evaluation (CRE-2)|Consisting of: PET-CT, endoscopic bite-on-bite biopsies,EUS with FNA
76083893|NCT04861948|Drug|Sintilimab|intravenous
76083894|NCT04861948|Drug|Pemetrexed|intravenous
76083895|NCT04526496|Drug|FTP-198, single dose|Single dose of FTP-198, 6 dose levels, oral suspension
75792082|NCT01215864|Drug|TCD-717|"Patients will receive TCD-717 at the following dose levels:~2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m^2"
75792083|NCT01118754|Drug|DE-101 ophthalmic suspension|Ophthalmic suspention; QID
75792084|NCT01118754|Drug|DE-101 ophthalmic suspension|Ophthalmic suspension; QID
75792085|NCT01118754|Drug|DE-101 ophthalmic suspension vehicle|ophthalmic suspension vehicle; QID
75792086|NCT01216020|Drug|cetuximab|"Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.~Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
75792087|NCT01216020|Drug|cisplatin (associated to radiotherapy)|"CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.~Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
75792088|NCT01212978|Behavioral|Pedometer to Increase Physical Activity|The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
76083896|NCT04526496|Drug|Placebo, single dose|Placebo matched to FTP-198, oral suspension
75792089|NCT01118910|Drug|Vusion|Vusion will be applied to areas of intertrigo
76083897|NCT04526496|Drug|FTP-198, multiple doses|Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days
76083898|NCT04526496|Drug|Placebo, multiple doses|Placebo matched to FTP-198, oral suspension, 7 days
76083899|NCT04856956|Other|Diagnostic decision support software|Comparing use of decision support group (intervention group) to use only of common literature (control group) among pediatric trainees diagnosing patients with possible rheumatologic disorder
76083900|NCT04526184|Procedure|aerobic exercise with blood flow restriction|Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.
76083901|NCT04856332|Other|Telepresence robot installed at child's home during parent's hospitalisation|Telepresence robot installed at child's home during parent's hospitalisation in long term protective isolation for maintaining parent-child ink (only children aged 15 years or less are concerned)
76083902|NCT04526262|Device|transcranial magnetic resonance guided focused ultrasound BBB disruption|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
75472322|NCT01956656|Drug|lotus leaf mouthwash|Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
75644069|NCT04185675|Device|The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.|All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.
75644070|NCT04208061|Drug|Dabigatran Etexilate|Participants will receive single dose of dabigatran etexilate orally.
75644071|NCT04208061|Drug|DRV/COBI|Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
75644072|NCT04208061|Drug|Ritonavir|Participants will receive ritonavir orally.
76083903|NCT04526028|Drug|Fulvestrant Injectable Product|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
76083904|NCT04526028|Drug|Palbociclib|Palbociclib is in the form of oral capsules, which are divided into three specifications: 75 mg, 100 mg and 125 mg. The recommended dose is 125 mg once daily for 21 days, followed by 7 days (3/1 dosage regimen), 28 Day is a treatment cycle.
76083905|NCT04812184|Device|Tape Face Mask|Adding tape to face mask
75644073|NCT04208061|Drug|Darunavir|Participants will receive Darunavir orally.
76083906|NCT02518698|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
75472323|NCT01956669|Drug|Pazopanib|Pazopanib was supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension was a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
75644074|NCT02687373|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
75644075|NCT02687373|Other|Normal Saline|0.9% Sodium chloride
75644076|NCT00778258|Biological|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
75644077|NCT00778258|Biological|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
75644078|NCT00988208|Drug|Lenalidomide|25 mg lenalidomide orally once each day on Days 1-14
75644079|NCT00988208|Drug|Docetaxel|75 mg/m2 intravenous docetaxel on Day 1
75644080|NCT00988208|Drug|Prednisone|5 mg prednisone orally twice daily on each day of the treatment cycle
75644081|NCT00988208|Drug|Placebo|Oral placebo once each day on Days 1-14 of the treatment cycle
75644082|NCT04185597|Other|HFP Intervention: Delivered by Community Farmers|Homestead food production (HFP) supported by community farmers, Social and Behavior Change Communication (SBCC), strengthened health services, and referrals to health and other services
75928526|NCT03474900|Device|Titanium elastic stable nail|Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
75928527|NCT02227017|Drug|TPV capsule|
75928528|NCT02227017|Drug|TPV solution|
75928529|NCT02227017|Drug|RTV capsule|
75928530|NCT02227017|Drug|RTV solution|
75928531|NCT02227017|Other|standard meal|
75472324|NCT01956682|Dietary Supplement|HA formula + starch + L. reuteri|
75472325|NCT01956695|Drug|Lenalidomide|
75644083|NCT04185597|Other|HFP Intervention: Delivered by agricultural Retailers|HFP supported by retailers, SBCC, strengthened health services, and referrals to health and other services
75644084|NCT04185597|Other|Control|Current Standard of Practice
75644085|NCT05368779|Behavioral|The internet-based psychosocial intervention|Participants were provided psychoeducation on intimate partner abuse, psychological trauma, Social Learning Theory, and Cognitive Behavioral Therapy methods. Intimate partner abuse and psychological trauma were discussed in the context of sociocultural factors. Cognitive Behavioral Therapy approaches were used to attempt to normalize intimate partner abuse, psychological trauma and their effects on participants. Participants were exposed to trauma gradually with record of sessions watching and imaginary exposure methods for reducing avoidance behaviours. Schemas, intermediate beliefs, and automatic thoughts of participants were studied using Cognitive Behavioral Therapy approaches and cognitive restructuring was fulfilled. The universality of mental pain, the meaning of life, the integrate trauma into life histories of participants, expectations for the future romantic relationships, and post traumatic growth were all discussed in accordance with the goals and values of participants.
75928532|NCT04542200|Biological|Antibody testing|The antibody results include understanding modifications from environments at work and the community.
75928533|NCT04537832|Other|No Intervention|No Intervention
75928534|NCT02227095|Behavioral|Exercise|Heart rate monitors worn by each child at each session
75928535|NCT02227095|Behavioral|After-school program|Supervised recreational program with token economy
75928536|NCT02223273|Behavioral|Multifaceted Strategy|"Simulation Based Team Training~Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~Reminders -~Check lists - decision support algorithm~Distribution of educational materials: guidelines and recommendations for best practices"
75928537|NCT05259072|Diagnostic Test|99m-technetium pyrophosphate scintigraphy|Imaging test
75928538|NCT02227173|Drug|BMS-986020|
75928539|NCT02227173|Drug|Montelukast|
75928540|NCT02227173|Drug|Flurbiprofen|
75928541|NCT02227173|Drug|Digoxin|
75928542|NCT03482154|Procedure|Hematopoietic Stem Cell Transplant|Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.
75928543|NCT02468726|Device|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
76083907|NCT04143490|Other|Exercise|60 minutes of continuous exercise at 65% VO2peak and drink ingestion
75928544|NCT02468726|Drug|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
76083908|NCT03368274|Drug|T 614|Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
76083909|NCT03361644|Behavioral|High-Intensity Interval Training|Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.
76083910|NCT03361644|Behavioral|Moderate-Intensity Continuous Training|Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
75644086|NCT00639249|Drug|placebo|Oral administration
75472326|NCT01956695|Drug|Rituximab|
75644087|NCT00639249|Drug|SA4503 Low|Oral administration
75644088|NCT00639249|Drug|SA4503 High|Oral administration
75472327|NCT01956708|Procedure|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
75472328|NCT01956721|Procedure|Exercise training,|
75644089|NCT04185831|Drug|Atezolizumab|PD-L1 inhibitor
75644090|NCT04185831|Drug|Everolimus|MTOR inhibitor
75644091|NCT04185831|Drug|Cobimetinib|MEK inhibitor
75644092|NCT04185753|Diagnostic Test|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
75928545|NCT02872701|Drug|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
75928546|NCT02872701|Device|Near infrared camera imaging system|Near infrared camera imaging system
75472329|NCT01956721|Procedure|Muscle biopsy|
75472330|NCT01956734|Procedure|DNX2401 and Temozolomide|"Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.~Temozolomide oral 14 days after virus injection."
75472331|NCT01956747|Procedure|venapunction|
75472332|NCT01956747|Procedure|bone marrow punction|
75644093|NCT04185519|Device|AI (model)|The process of the experiment (brief describe) This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose. Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl. Once the failed rate by AI is higher than the physician is 5%, , the study will be terminated. There will be three periods, namely ry 3 months.
75644094|NCT02686983|Drug|Betamethasone and local anesthetic|Infiltration of the greater occipital nerve .
75644095|NCT02686905|Dietary Supplement|Chewable Multivitamin with Iron|Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
75644096|NCT02686905|Dietary Supplement|PatchMD Vitamin D3/Calcium Patch|Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
75792090|NCT03939078|Radiation|CO2 fractional ablative laser|3 intravaginal fractional ablative CO2 laser sessions, with one month interval between them.
75792091|NCT01121796|Dietary Supplement|Vitamin D|
75792092|NCT01121796|Other|Water or milk|
75792093|NCT01121796|Dietary Supplement|Vitamin D enriched milk|
75792094|NCT01121874|Procedure|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
75928547|NCT02872701|Procedure|Endoscopic or Thoracic Surgery|Endoscopic or Thoracic Surgery
75928548|NCT03479034|Other|ScalaMed ePrescription application|Mobile phone application (Android and Apple) for storing electronic prescriptions
75928549|NCT04489004|Procedure|Driver ablation+CPVI|Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).
75928550|NCT04489004|Procedure|Stepwise ablation|Patients receive stepwise ablation.
75928551|NCT02227407|Device|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
76083911|NCT04765462|Biological|Allogeneic γδ T cells|"Phase 1:Enrolled patents will be administered allogeneic γδ T cells from 2x10^6/kg, 1 x10^7/kg to 5x10^7/kg every 2-4 weeks to determine the recommended dose level.~Phase 2: Enrolled patents will be administered allogeneic γδ T cells at the recommended dose level to confirm the efficacy.~Whether or not in combination with other therapies will be determined by research physicians according to the disease status of enrolled patients."
76083912|NCT03361566|Behavioral|physical activity|3 different levels of physical activity
76083913|NCT03361566|Behavioral|energy intake|4 different types of energy intake
76083914|NCT04666558|Other|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.
76083915|NCT04666558|Other|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
75472333|NCT01956760|Other|Acupuncture and intradermal acupuncture|The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
75472334|NCT01956786|Drug|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)
75472335|NCT01956786|Drug|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)
75644097|NCT02686905|Dietary Supplement|PatchMD Multivitamin Patch|Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
75644098|NCT02686905|Dietary Supplement|PatchMD B12 Energy Plus Patch|Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
75644099|NCT02686905|Dietary Supplement|Chewable Calcium|Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
75928552|NCT03474822|Biological|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
75928553|NCT03482076|Diagnostic Test|transferrin receptor concentration|Sandwich radio-imunoassay
75928554|NCT02031549|Other|SpermComet assay|Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
75928555|NCT02227563|Device|Active tDCS|repetitive daily tDCS sessions for a period of one week
75928556|NCT02227563|Device|control|
75928557|NCT02469740|Drug|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
75928558|NCT02469740|Drug|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
75644100|NCT02686905|Dietary Supplement|Quick Dissolve B12|Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
75644101|NCT00990704|Drug|paricalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
75644102|NCT00990704|Drug|maxacalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
75644103|NCT00639327|Drug|S-1 + irinotecan|Irinotecan 150mg/m2 iv on day one and S-1 po days 1 to 14 every 3 weeks until PD
75644104|NCT00639327|Drug|irinotecan|Irinotecan 150mg/m2 iv on day one every two weeks until PD
75792095|NCT01121874|Procedure|Ligament Reconstruction with Tendon Interposition (LRTI)|commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
75792096|NCT01121874|Procedure|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
75792097|NCT01121952|Other|Chiropractic (HVLA) manipulation|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
75792098|NCT03937284|Other|Patients not treated|
75928559|NCT03474666|Procedure|Strict Glycemic Control Group|The strict protocol adopted to conduct the study was proposed by Keegan e Cols.(2010) to be used among adult LT recipients that consist of a continuous intravenous insulin infusion. The targeted blood glucose range is 80-130 mg/dL. The procedure must be stopped when the patient can ingest at least 50% of liquid diet or receive bolus tube feedings.
75928560|NCT03474666|Procedure|Standard Glycemic Control Group|"The targeted blood glucose range is 130-180 mg/dL~Blood glucose reading: ≤ 180 mg/dL - subcutaneous insulin dose: 0~Blood glucose reading: ≥181 mg/dL and ≤250 mg/dL - subcutaneous insulin dose: 5 IU~Blood glucose reading: ≥251 mg/dL and ≤300 mg/dL - subcutaneous insulin dose: 10 IU~Blood glucose reading: ≥301 - subcutaneous insulin dose: 15 IU"
75928561|NCT04459221|Drug|Gardasil 9, 9-Valent Intramuscular Suspension|access to HPV vaccination near the college in a health bus
75472336|NCT01956786|Drug|Amlodipine|5mg amlodipine,once daily
75472337|NCT01956825|Dietary Supplement|"slim water"|
75472338|NCT01956838|Dietary Supplement|umami|intraduodenal infusion of umami tastant
75472339|NCT01956838|Dietary Supplement|bitter|intraduodenal infusion of bitter tastant
75472340|NCT01956838|Dietary Supplement|sweet|intraduodenal infusion of sweet tastant
75472341|NCT01956864|Drug|Vitamin D|Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
75472342|NCT01956890|Drug|PET|18F-FLT PET and MRI of the breast
75928562|NCT04432220|Drug|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
75928563|NCT04457739|Other|Tidal volume challenge|Increasing tidal volume from 6 to 8 mL/kg during 1 min
75928564|NCT04457739|Other|End-expiratory occlusion test|Interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output
75928565|NCT04457739|Other|Trendelenburg maneuver|Patients remained in prone position with a 13° upward bed angulation throughout the study and then be positioned in a declining position at -12 ° for 1 minute
75928566|NCT04417712|Device|KONAR-MF™ VSD Occluder|All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).
75928567|NCT02223507|Drug|BIIR 561 CL|
75928568|NCT02223507|Drug|Placebo|
76083916|NCT03361488|Other|Trained anesthesiogist|
75792099|NCT03939624|Drug|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
75792100|NCT03939624|Drug|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
75792101|NCT01119144|Device|Polycaprolactone / Tri-Calcium Phosphate|Orbital implant for reconstruction of the orbital walls
75928569|NCT03478800|Procedure|Acupuncture|Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
75928570|NCT04405622|Drug|Toripalimab plus gemcitabine|Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
76083917|NCT02247544|Drug|Trabectedin|Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
76083918|NCT03368040|Device|Tcore|Monitoring system to measure body temperature based on heat-flux technology
75334851|NCT00381160|Behavioral|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
75472343|NCT01956903|Genetic|Allogenic Mesenchymal Stem Cell|"Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, Agencia Española de Medicamentos y Productos Sanitarios with number 06-076)"
75472344|NCT01956916|Dietary Supplement|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
75472345|NCT01956916|Dietary Supplement|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
75644105|NCT02867774|Behavioral|Physical Activity|"8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine."
75644106|NCT02686671|Other|Shoulder clinical examination testing|Shoulder clinical examination including resistive shoulder abduction with and without a humeral traction (Pull Test). Functional status will be measured using the Shoulder Pain and Disability Index (SPADI).
75644107|NCT04121234|Other|"Exposure:  being admitted to HDU with a red code to OEWS"|High Dependency Unit, a set of predefined variables was assessed at hospital admission, HDU admission and at discharge from HDU with the aim to investigate epidemiology, clinical outcomes and risk factors for mortality in critically-ill parturients admitted to an obstetric HDU in a high volume, urban resource-limited maternity hospital
75792102|NCT01119144|Device|Titanium Mesh|Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
75792103|NCT01117038|Drug|avanafil and enalapril|enalapril twice a day for 11 days avanafil/placebo once a day for 2 days
76083919|NCT03370848|Dietary Supplement|Psyllium|Aspirin 325 mg tablet and two 1.7gm psyllium wafers (3.4gm total) 30 minutes prior to niacin ER
76083920|NCT03370848|Drug|Aspirin|Aspirin 325 mg tablet 30 minutes prior to niacin ER
76083921|NCT03367884|Procedure|Neck dissection followed by radiotherapy(50Gy) according to risk factors|Neck dissection followed by radiotherapy(50Gy) according to risk factors
76083922|NCT03367884|Radiation|Definitive radiotherapy|Definitive radiotherapy (70Gy)
75334852|NCT00985517|Biological|CERE-120: Adeno-Associated Virus Delivery of Neurturin|
75472346|NCT01956929|Drug|Metformin|Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.
75472347|NCT01956929|Drug|Placebo|Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
75792104|NCT01117038|Drug|avanafil and amlodipine|amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days
75792105|NCT01216098|Behavioral|Doula support|A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
75792106|NCT01119300|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
75792107|NCT01119300|Other|Standard care|Standard care
75928571|NCT02223585|Other|Animal-based protein diet|
75928572|NCT02223585|Other|Vegan-based protein diet|
75334853|NCT00985517|Procedure|Sham Surgery|
75334854|NCT00002116|Drug|Cidofovir|
75334855|NCT02451176|Device|Davol Bard Soft Mesh synthetic|soft mesh synthetic
75334856|NCT02451176|Device|LifeCell Strattice Reconstructive Tissue Biologic|biologic mesh
75334857|NCT00001498|Drug|methotrexate|
75334858|NCT00001498|Drug|leucovorin|
75334859|NCT00001498|Drug|5-fluorouracil|
75334860|NCT00001498|Drug|cyclophosphamide|
75472348|NCT01956955|Drug|enoxaparin ,alteplase, unfractionated heparin|
75928573|NCT03478722|Other|Protein Meal|Ingestion of mixed meal containing 20 g of dietary protein
75644108|NCT02686749|Device|Catheter Ablation|"During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which disconnects the pathway of the AF."
75334861|NCT00001498|Procedure|peripheral blood progenitor cell|
75472349|NCT01956981|Drug|Magnesium Sulfate|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
75472350|NCT01956981|Drug|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
75928574|NCT03478722|Other|Stable Isotope Amino Acid Infusion|Continuous infusion of L-[1-13C]leucine (0.13 μmol⋅kg⋅min) and L-[ring- 2H5]phenylalanine (0.05 μmol⋅kg⋅min)
75472351|NCT01956994|Dietary Supplement|Whey protein supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
75472352|NCT01956994|Dietary Supplement|Carbohydrate supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
75472353|NCT01957007|Drug|Docetaxel|Docetaxel will be administered IV.
75644109|NCT02686749|Drug|FDA approved anti arrhythmic drug|Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
75644110|NCT04089553|Drug|AZD4635|"In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first."
75644111|NCT04089553|Drug|Oleclumab|In Module 2, participants will receive oleclumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q2W of 28-day cycle for the first 4 doses and Q4W thereafter until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
75792108|NCT01216254|Device|classic v high-frequency electrocoagulation|During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
75792109|NCT03938844|Procedure|BURCH Colposuspension|stress urinary incontinence surgery ( burch or tot)
75792110|NCT03938844|Procedure|TOT|
75792111|NCT01213056|Behavioral|Mindfulness Based Cognitive Therapy|Cognitive Behavioral (Active treatment condition)
75792112|NCT01119378|Other|Dual isotope technique|Dual isotope technique using stable isotopes
75928575|NCT02227641|Biological|CMV/EBV specific T-cell|Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
75928576|NCT02723084|Drug|ABT-493/ABT-530|Co-formulated tablet
75928577|NCT02723084|Drug|sofosbuvir (SOF)|Tablet
75928578|NCT02723084|Drug|ribavirin (RBV)|Capsule
75928579|NCT02750943|Drug|Stannous Fluoride|Dentifrice containing 0.454% w/w stannous fluoride
75334862|NCT00001498|Drug|paclitaxel|
75334863|NCT00001498|Drug|doxorubicin|
75472354|NCT01957007|Drug|vantictumab|Vantictumab will be administered intravenously
75472355|NCT01957033|Behavioral|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
75472356|NCT01957033|Behavioral|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
75472357|NCT01957033|Behavioral|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
75472358|NCT01957033|Other|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
75928580|NCT02750943|Drug|Sodium Monofluorophosphate|Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
75928581|NCT03446118|Diagnostic Test|MRI to detect inflammation and fibrosis in subjects with EoE|MRI will be performed on a 1.5T magnet. Patients will be scanned in an oblique prone position similar to how esophageal distention is assessed at barium fluoroscopy
75334864|NCT02696616|Drug|BI 655088|
75334865|NCT02696616|Drug|Placebo|
75334866|NCT00001504|Drug|9-cis-Retinoic Acid|
75334867|NCT02688140|Drug|Arsenic trioxide|
75334868|NCT02688140|Drug|Idarubicin|
75334869|NCT02688140|Drug|Cytarabine|
75334870|NCT02688140|Drug|Tretinoin|
75334871|NCT02688140|Drug|Mitoxantrone|
75334872|NCT02688140|Drug|Mercaptopurine|
75334873|NCT02688140|Drug|Methotrexate|
75334874|NCT00000616|Behavioral|diet, sodium-restricted|
75334875|NCT00000616|Behavioral|diet, fat-restricted|
75334876|NCT00000616|Behavioral|exercise|
75334877|NCT00000616|Behavioral|diet, reducing|
75334878|NCT00000616|Behavioral|alcohol drinking|
75334879|NCT00002122|Drug|Azithromycin|
75334880|NCT00002122|Drug|Rifabutin|
75334881|NCT00002122|Drug|Fluconazole|
75334882|NCT00001534|Drug|Losartan|
75644112|NCT04089553|Drug|Durvalumab|In Module 1 after monotherapy of AZD4635, participants will receive durvalumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q4W until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
75792113|NCT01213914|Device|An FDA approved continuous renal replacement device|"70ml/kg/hr for treatment group for 48 hours with the following requirements:~double lumen dialysis catheter should be placed in the internal jugular or femoral vein~Anticoagulation will be determined by prescribing physician~Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours~Blood flow rate will be set to ensure a filtration fraction of no more than 25%~Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours~Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized~All antibiotics will be dose adjusted for renal replacement therapy"
75792114|NCT01213914|Other|Control Group|Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
75792115|NCT03938766|Diagnostic Test|PSMA PET/CT|Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
75928582|NCT02471066|Device|rTMS|"Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session"
75928583|NCT03481920|Drug|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.
75928584|NCT03481920|Drug|Avelumab|Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
75928585|NCT02227797|Drug|Voriconazole|6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
75928586|NCT02470988|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|
75334883|NCT01027559|Drug|Sertraline|Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
75792116|NCT01119534|Drug|Guaiacol, eucalyptol, menthol and camphor suppository|2 times per day
75644113|NCT02867852|Drug|Abiraterone acetate|Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 [CYP17]), a key enzyme required for testosterone synthesis. This enzyme is found in the testes, adrenals, prostate tumors
75472359|NCT01957033|Other|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
75792117|NCT01119534|Drug|guaiacol suppository|2 times per day
75644114|NCT02686827|Drug|Paricalcitol|Vitamin D3 analogue
75644115|NCT02686827|Drug|Placebo (for paricalcitol)|Injection fluid to mimic paricalcitol injection
75644116|NCT04292678|Behavioral|Progressive muscle relaxation|The progressive muscle relaxation intervention will last for 20 minutes and comprise sessions involving tensing and relaxing the body with deep breathing. The participants will perform progressive muscle relaxation for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed accompanied with deep breathing. The participants will be instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Throughout this exercise, the participants will visualize a wave of relaxation flowing over their body using the deep-breathing technique.
75792118|NCT01119534|Drug|Guaifenesin syrup|4.19 mL - 4 in 4 hours
75792119|NCT01117116|Drug|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
75792120|NCT01117116|Drug|budesonide and formoterol|80/4.5 two puffs twice daily
75792121|NCT01117194|Device|Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)|Use an intelligent robot to assist upper limb rehabilitation.
75928587|NCT02470988|Behavioral|CBASP Without DPI|
75928588|NCT05784337|Device|Mi-thos® Transcatheter Mitral Valve Replacement System|Transcatheter Mitral Valve Replacement
75928589|NCT05784324|Other|No intervention|No intervention
75928590|NCT05784259|Behavioral|Transdiagnostic single-session treatment|Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
75928591|NCT05784233|Behavioral|Relevance (Likelihood Salient Item is Target)|The proportion of trials, when the salient visual item is present in the array, where the salient item is the search target.
75928592|NCT05784220|Behavioral|DPP Curriculum for Lifestyle Intervention|See arms.
75928593|NCT05784207|Other|Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern|The aim is to evaluate the performance of AI with the performance of doctors
75928594|NCT05784168|Other|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
75928595|NCT05784168|Other|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
76083923|NCT03123432|Dietary Supplement|immunomodulating nutrients enriched diet|
76083924|NCT03123432|Dietary Supplement|standard diet|
76083925|NCT02248792|Drug|Methotrexate|
75644117|NCT04292678|Other|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
75334884|NCT01027559|Behavioral|Cognitive Behavioral Therapy|Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
75644118|NCT02686515|Device|single-task balance training|The framework of progressive balance exercises in the single-task training will include body stability tasks (Stance activities), transitional activities (Sit to stand and walk), and body transfer tasks (Gait activities). These exercises target various systems for balance control, such as stability limits (standing with changes in base of support and weight shifting), sensory orientation (standing on compliant surfaces with eyes open and eyes closed), postural responses (reactions to balance perturbation, sit to stand and walk), and gait (treadmill walking with increasing speed).
75334885|NCT00002128|Drug|Adefovir dipivoxil|
75472360|NCT01957033|Other|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
75928596|NCT05784155|Drug|Test Drug(JW0302) or Reference Drug(C2206)|"Test Drug: single administration of JW0302 Reference Drug: single administration of C2206~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
75928597|NCT05784142|Radiation|hypofractionated radiation therapy|"Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."
75334886|NCT05466084|Procedure|tissue Glue for mesh fixation|one arm of the study had their mesh fixed with tissue glue applied at multiple sites
75472361|NCT01957033|Other|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
75472362|NCT01957033|Other|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
75472363|NCT01957033|Other|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
75472364|NCT01957046|Drug|Laxative|
75472365|NCT01957059|Drug|Regimen Selection Phase Group 2|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg"
75644119|NCT02686515|Device|dual-task balance training|Three cognitive tasks will be used for dual-task training while standing and walking: auditory discrimination tasks, verbal fluency tasks, and calculation tasks. In addition, motor tasks such as carrying a bag, holding a glass of water, alternating hand movement, carrying a tray with glasses, or getting keys out of a pocket will also be included as added tasks.
75792122|NCT01122186|Behavioral|Motivational Interviewing + Cognitive Behavioral Skills Training|The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
75472366|NCT01957059|Drug|Regimen Selection Phase Group 3|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg"
75644120|NCT02868320|Other|SMS messages|"Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.~Weekly reminder messages of blood glucose testing."
75644121|NCT02868320|Other|Instruction booklet|General detailed instructions addressing the same SMS categories.
75644122|NCT00713167|Drug|Grape Seed Extract (Vitagrape)|"Drug {Each Containing: Grape Seed Extract100 mg +...}~1 capsule twice daily for 2 months"
75928598|NCT05784090|Other|blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases|"Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation."
75928599|NCT05784077|Diagnostic Test|Polysomnography|Study of the sleep pattern
75334887|NCT05466084|Procedure|Metallic Tackers for mesh fixation|in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
75334888|NCT00001570|Drug|PSC 833|
75334889|NCT00001570|Drug|vinblastine|
75334890|NCT00985829|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
75334891|NCT00000628|Drug|L-697,661|
75334892|NCT00000628|Drug|Zidovudine|
75334893|NCT00000634|Drug|Nevirapine|
75334894|NCT01661790|Drug|Bevacizumab|Bevacizumab300mg&Cispltin30mg by intrapleural administration of each 2 week
75334895|NCT01661790|Drug|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
75644123|NCT00713167|Drug|Placebo of Grape Seed Extract|"Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}~1 capsule twice daily for 2 months"
75928600|NCT05784077|Behavioral|Lifestyle counselling|Weight loss counselling
75928601|NCT05784064|Behavioral|Survey|This is a nationalwide survey developed in order to know the management of patients diagnosed of acute uncomplicated diverticulitis.
75928602|NCT05784038|Diagnostic Test|Viral genomic|Evaluation of mpox viral genomic
75928603|NCT05784038|Diagnostic Test|Untargeted Metabolomics|Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.
75928604|NCT05783986|Other|randomly divided|500 patients of our hospital were randomly divided into testing group and internal validation group, and 100 patients in collabrative hospital were external validation group.
75928605|NCT05783947|Diagnostic Test|Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera|Sera and/or CSF samples are drawn from patients with a clinical suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome. Indirect immunofluorescence assays will be performed on commercial and in-house slides upon receipt in our center. In case of positive staining, additional tests such as cell-based assays, western-blots, ELISA or immunodots can be performed.
75928606|NCT05783934|Diagnostic Test|18F-florbetaben PET/CT|"The PET/CT study will be performed using a dual time acquisition protocol consisting of an early acquisition and a late acquisition.~Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.~A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.~Early acquisition will last 30 minutes. Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake."
75928607|NCT05783895|Diagnostic Test|Post screening diagnostic test|1) anti-PF4/heparin antibody test (ELISA) and 2) in vitro platelet aggregation tests. The diagnosis of HIT is made when both tests are positive or when a platelet aggregation test is positive.
75928608|NCT05783882|Drug|Prolgolimab|250 mg Q3W
75928609|NCT05783856|Combination Product|LiveSpo X-secret|In Vietnam, LiveSpo X-secret is manufactured as a Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
75644124|NCT04185129|Drug|Foster|a randomized study for comparison asthma patients using Foster or Relvar. The primary end point is lung function improvement evaluation
75928610|NCT05783856|Drug|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 15 mL-bottle that is used for LiveSpo X-secret.
75928611|NCT05783830|Drug|ACD856|IV injection 100 mcg
75928612|NCT05783778|Diagnostic Test|Free testosterone levels and toxoplasma igG|Free testosterone levels and toxoplasma igG in serum by ELISA
75472367|NCT01957059|Drug|Treatment Phase Group 4|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
75472368|NCT01957059|Drug|Regimen Selection Phase Group 1 (COMPLETED)|All doses of BMN053 have been administered as subcutaneous injections.
75792123|NCT01122186|Behavioral|Education Attention Control|"During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery."
75472369|NCT01957059|Drug|Dosing Extension|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
75792124|NCT01119612|Dietary Supplement|Iron|Daily oral dose of 60 mg from enrollment until delivery
75792125|NCT01119612|Other|Placebo|Daily oral dose from enrollment until delivery
75792126|NCT03937206|Dietary Supplement|NutriterraTM|Nutriterra 1000mg
75792127|NCT03937206|Dietary Supplement|Placebo|Corn Oil 1000mg
75792128|NCT01216488|Drug|Xylocaine|40 ml or 25 ml of Xylocaine injection
75928613|NCT05783752|Behavioral|Stair Stepping|1 minute of stair-stepping (30 seconds up, 30 seconds down) at a self-selected pace identified on day 0 starting 15 minutes after each meal
75928614|NCT05783752|Behavioral|No exercise control|Participants avoid exercise within 1 hour of eating a meal
75928615|NCT05783713|Other|Influenza Vaccination|Describe and measure any differences in total influenza vaccination coverage, in different categories of professionals and in different operational units.
75928616|NCT05783674|Other|Brain Breaks® Video Exercises|A total of at least 140 Brain Breaks® videos, each 3-4 minutes long, aerobic exercises including wide joint movements, movements specific to different sports branches such as yoga and volleyball, basketball, football, tennis, karate, judo, and warm-up-cooling movements. It includes national dances of different cultures. Horon, Zeybek, Scarf dance, morning gymnastics in Ürgüp Göreme, dribbling (volleyball, basketball), Pilates ball, and core area exercises. In each session, 2 videos will be applied and each will be repeated 2-3 times, and a 3-minute rest break will be given between each video. The total session will last for 20-30 minutes on average and physical activity will be performed twice a week, for a total of 8 weeks, 16 sessions.
75928617|NCT05783674|Other|Posture training|All participants, as the BB Video Exercise and Control Group, will be given a 20-minute hands-on training on the importance of proper posture once at the beginning of the study, and breathing control training will be given to maintain proper sitting, standing, lying postures, and proper posture.
75928618|NCT05783557|Drug|Clevidipine Butyrate Injectable Emulsion|intravenous injection
75792129|NCT01119690|Dietary Supplement|Cold-pressed turnip rapeseed oil (CTPRO)|"In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.~In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO."
76083926|NCT03367728|Drug|Ropivacaine|TAP and Rectus Sheath Block Injections of Ropivacaine
75334896|NCT05576246|Diagnostic Test|airway pressure occlusion measurement|Flow, airway pressure (Paw), and esophageal pressure (Pes) will be recorded for 10 minutes on different NIV settings: during each one, three end-expiratory airway occlusions will be applied at random intervals. Each occlusion was maintained for the duration of a single breath deflection in Paw from PEEP, confirmed by the return of Paw to baseline.
75334897|NCT00002134|Drug|Ganciclovir|
75472370|NCT01957072|Behavioral|Behaviour change intervention|"The behaviour change intervention consists of~feedback via a web-based food diary~'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails."
75472371|NCT01957098|Dietary Supplement|Placebo comparator: 0% pentose|14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours
75472372|NCT01957098|Dietary Supplement|Active comparator: 4% D-xylose|
75792130|NCT01119690|Dietary Supplement|milk fat|"In dietary period of 6 to 8 weeks: 37.5 grams of butter.~In the 5-hour oral glucose and fat tolerance test: glucose and cream"
75792131|NCT01122342|Drug|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
75928619|NCT05783557|Drug|Cleviprex®|intravenous injection
75472373|NCT01957098|Dietary Supplement|Active comparator: 8% D-xylose|
75792132|NCT03935802|Radiation|radiation|
75472374|NCT01957098|Dietary Supplement|Active comparator: 8% L-arabinose|
75472375|NCT01957124|Procedure|PRF (Platelet-Rich Fibrin)|
75792133|NCT01213212|Other|Caloric restriction|Caloric restriction.
75792134|NCT01213212|Other|No intervention|"Diet ad libitum"
75792135|NCT01119924|Drug|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
75792136|NCT01119924|Drug|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
75928620|NCT05783531|Other|VMood|VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
75792137|NCT01216566|Device|Occiflex Device|This device is a computerized robotic platform that allows continuous mobilization of the cervical spine in a three dimensional space. The patients undergoes biweekly 20 minute therapeutic session for 6 weeks
75792138|NCT01120002|Drug|Tamibarotene|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
75792139|NCT01120002|Drug|Placebo|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
75792140|NCT03935490|Procedure|emergency transrectus sheath pre-peritoneal mesh repair (e-TREPP)|"The Trans REctussheath PrePeritoneal mesh repair (TREPP) was developed in 2006 as an open preperitoneal technique to reduce CPIP. In short: a 4-5 centimeters (cm) transverse incision is made about 1 cm above the localization of the deep inguinal ring. The anterior rectus sheath is opened. After retracting the rectus muscle medially, the preperitoneal space (PPS) is bluntly dissected and a complete overview can be achieved. All possible hernia orifices can be visualized such as: a direct, indirect, pantaloon, and/or femoral hernia. A self-expandable mesh is then positioned in the PPS. Due to the upstream principle no mesh fixation is necessary."
75792141|NCT01213992|Drug|Iron isomaltoside 1000|Single dose of 500 mg administered as a bolus undiluted over 2 min.
75334898|NCT00985907|Drug|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
75334899|NCT00002140|Drug|Ethambutol hydrochloride|
75334900|NCT00002140|Drug|Clarithromycin|
75334901|NCT00002140|Drug|Azithromycin|
75334902|NCT00986453|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
75792142|NCT01213992|Drug|Iron isomaltoside 1000|Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
75928621|NCT05783531|Other|Enhanced treatment as usual|Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.
75928622|NCT05783518|Drug|desflurane|Intraoperative anesthesia maintenance
75928623|NCT05783518|Drug|propofol|Intraoperative anesthesia maintenance
76083927|NCT03367728|Drug|Normal saline|TAP and Rectus Sheath Block Injections of Normal Saline
76083928|NCT03361332|Other|Behavioral and fMRI|Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
75644125|NCT05368701|Behavioral|Volitional Help Sheet for self-harm|"The volitional help sheet (VHS) is a brief psychosocial intervention that significantly reduces thoughts and acts of self-harm in adults admitted to hospital following an initial episode of self-harm. It is based on IF-THEN statements that help people link critical situations to alternative appropriate responses. An example is: If I feel the urge to self-harm when I want to get relief from a terrible state of mind, then I will do something else instead of self-harming. IF-THEN statements are intended to act as automatic coping responses, especially in cases where people may feel the urge to self-harm.~The VHS has previously been successful in reducing self-harm in people recently admitted to hospital for self-harm. Recent data have also demonstrated that a web-based version of the VHS was acceptable among a large representative sample of UK adults with self-harm experiences. However, it is yet to be known whether this intervention is effective and acceptable among adolescents."
76083929|NCT03370692|Other|Cognitive assesment, Frailty assessment|Asking relatives (using a structured questionaire) about cognitive function at admission , likewise about frailty using the Clinical Frailty Score
75334903|NCT00986453|Procedure|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
75792143|NCT02529384|Other|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
75792144|NCT01216644|Drug|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
75928624|NCT05783492|Drug|Intranasal ketamine|10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
75928625|NCT05783479|Drug|estradiol|estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
75928626|NCT05783479|Drug|Hyaluronic acid|hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
75644126|NCT05260827|Other|Heated tobacco product|Sham heated tobacco product
75792145|NCT01216644|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
75928627|NCT05783453|Other|Cosmetic study|"LIPIKAR BAUME LIGHT AP+M~Formula: 2039055 06~Aspect: Emulsion~Batch nº: RAUO0063~Expiry date: 10/2022~Application area: Face and Body~Application mode: Apply to face and body twice a day.~Quantity of product to be applied: About 1 flask (400g) per month"
75928628|NCT05783440|Behavioral|direct patient feedback|"Participants in the intervention group report postoperative pain scores and other pain related outcomes with their own smartphone. Pain scores reported by smartphone > 3 (NRS 0-10) are immediately passed on to the nurse who will receive a notification on a smartphone.~All patient reported pain-scores by smartphone are stored in a database that is not accessible to medical or nursing staff from the nursing ward."
75928629|NCT05783284|Device|Holocare Studio 2 (HS2)|3D HV
76083930|NCT02519634|Procedure|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
75334904|NCT05465928|Device|Active rTMS|rTMS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each rTMS treatment, the magnetic field is generated by a coil which is placed on the head near the brain region of interest, and further, an electrical current is induced to modulate brain activity.
75334905|NCT05465928|Device|Sham rTMS|The sham rTMS stimulation is performed based on a sham coil which will mimic scalp sensations and the acoustic artifact of the active stimulation, without delivering any magnetic pulse.
75334906|NCT00000658|Drug|Bleomycin sulfate|
75334907|NCT00000658|Drug|Vincristine sulfate|
75472376|NCT01957189|Drug|Dutasteride and Tamsulosin|0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
75472377|NCT01957228|Procedure|bone biopsies|
75472378|NCT01957280|Drug|patritumab|
75472379|NCT01957293|Drug|Salbutamol|single oral administration, 4 mg
75644127|NCT00716521|Drug|placebo|single oral dose placebo
75644128|NCT00716521|Drug|zolpidem|single oral dose, 5 mg zolpidem
75644129|NCT00716521|Drug|zolpidem|single oral dose, 10 mg zolpidem
75644130|NCT00716599|Device|training in use of rapid diagnostic tests (RDTs) for malaria|training program and introduction of RDTs for use in case management of patients presenting for routine care at government health centers
75792146|NCT01216644|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
75792147|NCT01216644|Drug|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
75792148|NCT01216644|Drug|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
75792149|NCT01216644|Drug|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
75792150|NCT01216644|Drug|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
75792151|NCT01213290|Device|EUS - FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
75928630|NCT05783193|Drug|TGIR (Traditional Gastrointestinal Remedy)|TGIR botanical formulation
75928631|NCT05783193|Drug|Placebo|Placebo capsules
75928632|NCT05783154|Biological|Autologous Adipose Tissue-Derived Mesenchymal Stem Cell|"After cleaning the knee with 10% povidone-iodine (Povidep10% solution, manufactured by Jayson Pharmaceuticals limited, Bangladesh) and draping it in a sterile manner, the injection site will be anesthetized with 0.5% bupivacaine (Inj. Bupi Heavy 0.5%, Manufactured by Popular Pharmaceuticals limited, Bangladesh) superficially outside of joint capsule.~Within one hour of preparation, the autologous AT-MSC will be injected into each knee joint through medial tibio-femoral compartment in group -I using a 38-mm 18- gauge needle"
76083931|NCT02519634|Procedure|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
76083932|NCT02248870|Drug|Dexamethasone|Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
76083933|NCT02248870|Drug|Saline|Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
76083934|NCT03367650|Dietary Supplement|Blood sample and environmental survey|The intervention corresponds to a 10 ml of Blood sample and an environmental survey.
76083935|NCT02993380|Dietary Supplement|Stir-fried olive oil group|Stir-fried olive oil group taking food with extra-virgin olive oil in stir fried food or any food with olive oil in heated under 150 degrees of celsius minimal dose per week is 30gram, providing amount of olive oil with meals is 10gram, three times in a weeks
76083936|NCT02993380|Dietary Supplement|Natural olive oil group|Natural olive oil group taking food with extra-virgin any food with olive oil in , minimal dose per week is 30grams, providing amount of olive oil with meals is 10gram, three times in a weeks
76083937|NCT03361254|Biological|cryopreservation|cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months
76083938|NCT04073056|Drug|Bupivacaine|Bupivacaine Hcl 0.25% Inj
76083939|NCT03361098|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg oral tablet once daily
75472380|NCT01957293|Drug|Placebo|single oral administration
75472381|NCT01957306|Dietary Supplement|Dr. Tagliaferri's Menopause Formula|Administered as 2 grams PO BID
75472382|NCT01957319|Drug|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|
75472383|NCT01957319|Drug|sugar pill|
75472384|NCT01957345|Other|Blood punction|"T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested."
75644131|NCT00612417|Drug|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
75644132|NCT02689635|Other|Sodium Restricted Diet|Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)
75644133|NCT02689635|Other|Regular Diet|Non-Cardiac Diet, as defined by our Hospital Nutritional Services
75792152|NCT01213290|Device|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
75792153|NCT03125200|Drug|ADCT-502|Intravenous Infusion
75792154|NCT03938376|Diagnostic Test|Micro-Ultrasound guided biopsy|High-resolution imaging device
75792155|NCT01216722|Other|Resistance Strengthening Exercise Program|Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
75792156|NCT01369654|Behavioral|Computerized decision aid with 1 type of value clarification|Women will be instructed to view a computerized BSO decision support guide.
75792157|NCT01214070|Other|Vision Restoration Therapy|Therapy that enhances the neuronal plasticity of the visual system
75792158|NCT01214070|Behavioral|NVT Eye Scanning Therapy|Therapy that trains eye and head scanning into the blind hemianoptic visual field
75792159|NCT01214070|Behavioral|Eccentric Viewing Training|Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
76083940|NCT03361098|Drug|Exenatide|Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
75644134|NCT02572219|Dietary Supplement|Nutraceutical compound|
75644135|NCT02572219|Dietary Supplement|Placebo|
75644136|NCT00718939|Device|Rheos Baroreflex Activation Therapy System|The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
75644137|NCT00716833|Drug|Etoricoxibe|Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
75792160|NCT01214070|Behavioral|Sham|Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
75792161|NCT05188066|Diagnostic Test|Histology|Collect the placenta and fetal membranes and perfor either tissue culture or fixation for further analyses
75792162|NCT01216800|Procedure|adjuvant therapy|
75792163|NCT01216800|Procedure|assessment of therapy complications|
75792164|NCT01216800|Procedure|quality-of-life assessment|
75792165|NCT01216800|Radiation|3-dimensional conformal radiation therapy|
75792166|NCT01216800|Radiation|intensity-modulated radiation therapy|
75928633|NCT05783128|Other|Airway management techniques (exposure)|The exposure reffers to the different methods of airway management during general or regional anesthesia.
75928634|NCT05783115|Procedure|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion|transverse bone transport with bone marrow cell transplantation
75928635|NCT05783115|Procedure|Tibial Transportation|transverse bone transport
75928636|NCT05782959|Biological|BCD-245|BCD-245 is administered as prolonged intravenous infusions during each cycle
75928637|NCT05782933|Drug|Rituximab|Rituximab combined with or without cyclosporine
75928638|NCT05782933|Drug|Modified Ponticelli regimen|Corticosteroid and cyclophosphamide
75928639|NCT05782920|Device|Platelet rich plasma|PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.
75928640|NCT05782920|Device|non cross-linked hyaluronic acid|HA filling is a known modality for rejuvenation
75928641|NCT05782920|Device|topical HA gel|the standard treatment of vaginal atrophy and dryness
75928642|NCT05782829|Dietary Supplement|L-tyrosine supplementation|L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia
76083941|NCT03361098|Other|placebo exenatide|placebo b.i.d. exenatide
76083942|NCT03361098|Other|placebo dapagliflozin|placebo tablets dapagliflozin
76083943|NCT03367494|Diagnostic Test|Measurement of Sweat Chloride and Sweat Bromide|Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
76083944|NCT03370458|Dietary Supplement|Lactobacillus plantarum DR7|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
76083945|NCT03370458|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
76083946|NCT02519478|Behavioral|Helmetless Tackling Training (HuTT)|see previous sections
76083947|NCT05594290|Drug|Retifanlimab|Retifanlimab i.v. 500 mg day 1
76083948|NCT05594290|Drug|Cisplatin|Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)
76083949|NCT05594290|Drug|Etoposide|Etoposide 100 mg/sqm iv. day 1, 2, 3
75928643|NCT05782829|Dietary Supplement|Placebo supplementation|Placebo supplementation before surgery for inguinal hernia under general anaesthesia
75472385|NCT01957358|Behavioral|The Grief Recovery Method|The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
75472386|NCT01957371|Behavioral|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
76083950|NCT03370380|Drug|Aflibercept|Patients are treated according to authorization of Aflibercept
76083951|NCT03360864|Other|Education program|Patient will participate to a education program.
75792167|NCT01214148|Device|ORSIRO - Drug Eluting Coronary Stent|The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
75792168|NCT03936972|Procedure|ilizarov circular frame and uni-planarexternal fixator|both are types of external fixators, but one is circular frame and other is uni-planar frame
75792169|NCT04959760|Diagnostic Test|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2 in fingestick capillary blood and plasma samples.
75792170|NCT03935334|Biological|Biosimilar eptacog alfa, activated (AryoSeven)|A single dose of eptacog alfa biosimilar (AryoSeven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
75472387|NCT01957423|Dietary Supplement|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
75928644|NCT05782803|Behavioral|Exercises Group|A Pressure Biofeedback Device will be used in CCF training to increase awareness and focus on the desired muscle. After the person is brought to the hook position, the pressurized biofeedback device will be placed in the middle position between the craniocervical and cervical vertebrae or horizontally so that the protrusion between the earlobe and the chin is removed. It is inflated to a standard 20 mmHg to ensure surface-to-longitudinal contact. Participants are taught the correct craniocervical flexion movement without first working the superficial muscles. The patient is then asked to look with their eyes slightly toward the chest cavity. During the exercises, starting from 20 mmHg and increasing by 2 mmHg, the desired level of 30 mmHg will be reached. At each level, the movement is continued for 10 seconds, resting for 3-5 seconds, 10 repetitions are required. If the same level is maintained for 10 seconds and 10 repetitions, the next level is passed.
76083952|NCT03367416|Behavioral|NIATx model|"The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~educating executives on how to promote effective process change techniques~training staff teams in the theory and practice of organizational change techniques~training staff to develop and implement a process improvement intervention~implementing a sustainability plan to institutionalize change and avoid reverting to previous methods"
76083953|NCT04525170|Device|HPT treatment|
76083954|NCT04525170|Device|untreated|
76083955|NCT03360786|Other|Specific intervention|Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education
76083956|NCT03360786|Other|Control intervention|Education on concussion and concussion identification in addition to typical cardiovascular warmups
75644138|NCT00716833|Drug|Placebo|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
75644139|NCT00993668|Other|Placebo|Placebo - Two 0.9% saline subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by two sc injections of Open-Label (OL) CZP 200 mg at Weeks 6, 8 and 10, then one sc injection of OL CZP 200 mg every two weeks from Week 12 until last drug administration (up to Week 32).
76083957|NCT03367338|Other|Low-phosphate diet|Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
75644140|NCT00993668|Biological|Certolizumab pegol|Certolizumab pegol - Two 200 mg subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by one sc injection of Open-Label (OL) CZP 200 mg from Week 6 until last drug administration (up to Week 32).
75644141|NCT00778102|Drug|5-FU|Bolus 400mg/m2, day 1 every 2 weeks
75644142|NCT00778102|Drug|5-FU|3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
75644143|NCT00778102|Drug|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
75644144|NCT00778102|Drug|Irinotecan|165mg/m2 1-hour iv infusion, day 1 every 2 weeks
75644145|NCT00778102|Drug|Leucovorin|400mg/m2 2-hour iv infusion, day 1 every 2 weeks
75644146|NCT00778102|Drug|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
76083958|NCT04523610|Behavioral|Telehealth phone calls|The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).
76083959|NCT04523610|Other|Volunteer of TIP-OA Program|Participant is a volunteer of the TIP-OA Program
75792171|NCT03935334|Biological|Eptacog alfa, activated (Novoseven)|A single dose of eptacog alfa (Novoseven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
75792172|NCT04934566|Other|ECMO flow|Dynamic changes in ECMO flow and SvO2 measurement at the 3 different sites.
75792173|NCT01122420|Other|Goal-Setting Tool|Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
75928645|NCT05782777|Drug|ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.
75928646|NCT05782777|Drug|high-intensity statin monotherapy (atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
75928647|NCT05782764|Drug|To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).|immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
75928648|NCT05782751|Procedure|GROUPI|10 sites treated with Free connective tissue graft (FCTG) + growth factors enhanced matrix 21 s GEM 21S + coronally advanced flap (CAF)
75928649|NCT05782751|Procedure|GROUP II|10 sites treated withCollagen membrane + GEM 21S + coronally advanced flap (CAF)
75928650|NCT05781074|Drug|Sintilimab|a PD-1 immune checkpoint inhibitor
75928651|NCT05781074|Drug|Lenvatinib|Lenvatinib capsules
75928652|NCT05781074|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision
75928653|NCT05780541|Drug|PF-07304814|PF-07304814 is a phosphate ester prodrug of PF-00835231 (active moiety), a potent and selective inhibitor of the SARS-CoV-2 3CLpro.
76083960|NCT04523610|Other|Stakeholder of TIP-OA Program|Participant is a stakeholder of the TIP-OA Program
76083961|NCT02995174|Device|Dichoptic video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with 'contrast-balanced' images displayed on the screen of an i-Pod touch device. The eye with weaker eyesight will see the image with high contrast, and the good eye will see the image with low contrast. The subject will play the game one hour per day for 6 weeks.
76083962|NCT02995174|Device|Video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with equal contrast images displayed on the screen of an i-Pod touch device. Both eyes will see the image of same contrast. The subject will play the game one hour per day for 6 weeks.
76083963|NCT03360630|Biological|Anti-PD-1 plus DC-CIK|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal. DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
75644147|NCT00778102|Drug|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
75644148|NCT00778102|Drug|bevacizumab [Avastin]|5mg/kg iv day 1 every 2 weeks
75644149|NCT00713557|Device|drug-eluting stent|drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
75644150|NCT00713557|Drug|Tirofiban|upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
75334908|NCT00000658|Drug|Doxorubicin hydrochloride|
75644151|NCT05260281|Device|MONA algorithm|most artificial intelligence algorithms, like the MONA algorithm used in this study, are trained on 45-degree fundus photographs. In order to incorporate the use of the algorithm, the study intervention consists of taking 1 extra 45-degree fundus photograph per eye per patient using the Zeiss Cirrus Photo 800 system.
75644152|NCT00719017|Procedure|Upper vaginectomy|Laparoscopic surgery with upper vaginectomy
75644153|NCT00719017|Radiation|Post-operative brachytherapy|Laparoscopic surgery followed by brachytherapy
75644154|NCT00719017|Procedure|Standard procedures|Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
75644155|NCT03824145|Behavioral|Lifestyle Intervention|The lifestyle intervention is a 16-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.
75644156|NCT03824145|Behavioral|Attention Control|The attention control participants will receive a home/work organization intervention:
75792174|NCT01122420|Other|Health Web Sites|Access to publicly available health-related web sites
75792175|NCT01373320|Behavioral|Lay health advisor interactions|"For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening."
75928654|NCT05780541|Drug|Placebo|Commercially available 0.9% sodium chloride solution
75928655|NCT05780541|Biological|Remdesivir|Antiviral agent
75928656|NCT05780463|Drug|MP0420|MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
75928657|NCT05780463|Drug|Placebo|Commercially available 0.9% sodium chloride solution
75928658|NCT05780463|Biological|Remdesivir|Antiviral agent
75792176|NCT01214226|Drug|Pentoxifylline|400 mg prolonged-released tablets 3 time per day for 1 month.
75792177|NCT01214226|Drug|placebo|prolonged-release tablets 3 time per day for 1 month
76083964|NCT03360630|Biological|Anti-PD-1 alone|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
76083965|NCT03965104|Behavioral|Hypertension Canada Professional Certification Program: HC-PCP|The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
76083966|NCT03358446|Other|A group|"The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval."
76083967|NCT03358446|Other|S group|B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
76083968|NCT04414540|Drug|Metformin Extended Release Oral Tablet|Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily
76083969|NCT04414540|Drug|Pembrolizumab|Pembrolizumab q 3 weeks
76083970|NCT03358368|Device|Vitalscan|Vitalscan is a magnetocardiograph device
76083971|NCT03367260|Other|Preference Elicitation|Survey of patient preferences for treatment
76083972|NCT03360552|Other|Multidimensional fragility index questionnaire RAI-Home Care|Questionnaire for assessing deficits in Alzheimer's disease
75792178|NCT01360372|Drug|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
75792179|NCT01360372|Drug|Saline injection|Saline 0.4 to 0.8 ml injection
75792180|NCT01219062|Drug|morphine|periarticular infiltration with 0.25% Bupivacaine for 20 ml.
75792181|NCT01219062|Other|control|the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)
75928659|NCT05780047|Diagnostic Test|Mail-in Urine Test for EDCs|Million Marker provides a mail-in urine test for Bisphenol A (BPA) and phthalates. Users take a comprehensive exposure survey (via the MM app), send back their samples, view their personalized reports with tailored product recommendations, make changes to reduce their exposures, and retest to monitor their progress. Participants will also fill out surveys to assess changes in their environmental health literacy, readiness to change, and analyses of lifestyle behaviors and product use.
75928660|NCT05779657|Drug|Ketamine|Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
75928661|NCT05779657|Drug|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
75928662|NCT05779657|Drug|Placebo|Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
75928663|NCT05779267|Drug|NRX-101|D-cycloserine/lurasidone fixed dose combination
76083973|NCT03360552|Other|Usual care|Usual clinical evaluation
76083974|NCT04525248|Procedure|Laparoscopic total colectomy + low resection of rectum|Laparoscopic total colectomy + low resection of rectum
76083975|NCT04525248|Procedure|Laparoscopic total colectomy + High resection of rectum|Laparoscopic total colectomy + High resection of rectum
76083976|NCT03367182|Drug|Weekly paclitaxel|Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
76083977|NCT03367182|Drug|Topotecan|Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
76083978|NCT03367182|Drug|Pegylated liposomal doxorubicin|Drug: liposomal doxorubicin 40mg/m2 iv every 4 weeks
75334909|NCT00000658|Drug|Cyclophosphamide|
75334910|NCT00000658|Drug|Allopurinol|
75334911|NCT00000658|Drug|Methotrexate|
75334912|NCT00000658|Drug|Cytarabine|
75334913|NCT00000658|Drug|Leucovorin calcium|
75334914|NCT00000658|Drug|Sargramostim|
75334915|NCT00000658|Drug|Dexamethasone|
75792182|NCT01219062|Drug|Bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
75792183|NCT04812262|Drug|DD01|The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.
75792184|NCT04812262|Drug|Placebo|Placebo drug of DD01, administered in a 1mL volume for injection
75792185|NCT01120158|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
75792186|NCT01120158|Drug|Paclitaxel|Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
75792187|NCT01373398|Drug|EO9(Apaziquone)|immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
75792188|NCT01219140|Dietary Supplement|2 POMx Capsules|2 POMx Capsules daily
75792189|NCT01219140|Dietary Supplement|2 placebo Capsules|2 placebo Capsules daily
75792190|NCT01124526|Drug|Rituximab Fludarabine Cyclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)"
75792191|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.015mg/mL
75792192|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.05mg/mL
76083979|NCT03367182|Drug|Bevacizumab|Drug: bevacizumab [Avastin] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
76083980|NCT03360474|Behavioral|Delirium Screen|Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
76083981|NCT05561764|Drug|Imipenem/Cilastatin/Relebactam|Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.
76083982|NCT03358212|Drug|Denosumab|Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment
76083983|NCT04521816|Behavioral|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~Improve Veteran and staff satisfaction~Objectives:~Maintain the patient in the home setting as much as possible~Secure appropriate home environment to facilitate health and well-being~Utilize comprehensive team-based care~Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
76083984|NCT03358134|Drug|Secukinumab|anti IL17 therapy (subcutaneous)
76083985|NCT04334668|Dietary Supplement|Oral Sodium Chloride|Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days
76083986|NCT04334668|Other|Placebo|Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.
76083987|NCT03360318|Device|elbow cast|elbow cast
76083988|NCT03360318|Device|Removable elbow brace|Removable elbow brace
76083989|NCT03124134|Device|Gelesis200|Encapsulated hydrogel
75644157|NCT00719095|Drug|buprenorphine taper followed by naltrexone maintenance|direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
75644158|NCT00719095|Behavioral|Behavioral therapy|
75792193|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.15mg/mL or 0.025mg/mL
75792194|NCT01120314|Drug|OTAMIXABAN (XRP0673)|"Form: solution for injection~Route: intravenous"
75792195|NCT03633994|Drug|Heparin|Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
75792196|NCT03633994|Drug|Normal saline|Normal saline bladder instillation
75792197|NCT01328886|Drug|Omalizumab|omalizumab lyophilized 150 mg injection
75792198|NCT01120392|Other|treatment with Nintendo wii.|Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit
75792199|NCT01120392|Other|Physical therapy conventional.|Conventional exercises used with the same goals for the group with wii
75792200|NCT01216878|Drug|losartan potassium|100 mg tablet
75792201|NCT01374022|Other|ART Strategy|Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.
75792202|NCT01374022|Other|ARDSNet Strategy|Conventional mechanical ventilation strategy.
75792203|NCT01214304|Other|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
75792204|NCT01214304|Other|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
75792205|NCT04624984|Drug|PD-1 inhibitor|PD-1 Inhibitor, intravenous drip, d1.
75792206|NCT04624984|Drug|PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome|PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;
75792207|NCT01219218|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
75644159|NCT00916630|Drug|pemetrexed|Given intravenously over a 10 to 20 minute period once every 14 days.
76083990|NCT03124134|Other|Water, only (placebo)|300 mL of water
76083991|NCT04256980|Drug|Pemigatinib|Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule
76083992|NCT04222270|Behavioral|Champion Caregiver peer mentoring support to caregivers on child care and medication adherence to enhance achievement of viral suppression|Caregiver to caregiver peer support intervention through group/one-on-one education and counselling
76083993|NCT04522128|Behavioral|Behaviour Change Technique Intervention to Improve Quality of Life|"The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group."
76083994|NCT04193410|Behavioral|Various health-promoting initiatives|No intervention is allocated in this study other than activities planned by childcare centres in accordance with wishes and needs of childcare centre staff and parents.
75644160|NCT02572375|Drug|Codeine Phosphate/Guaifenesin ER Tablet|Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
75644161|NCT02572375|Drug|Codeine Phosphate/Guaifenesin IR Tablet|Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
75644162|NCT00716911|Drug|ganciclovir|
75644163|NCT00716911|Genetic|polymerase chain reaction|
75644164|NCT00716911|Other|flow cytometry|
75644165|NCT00716911|Other|immunologic technique|
75472388|NCT01957423|Dietary Supplement|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
75644166|NCT00716911|Procedure|allogeneic bone marrow transplantation|
75644167|NCT00716911|Procedure|allogeneic hematopoietic stem cell transplantation|
75644168|NCT00716911|Procedure|assessment of therapy complications|
75644169|NCT00716911|Procedure|peripheral blood stem cell transplantation|
75792208|NCT05187754|Other|Mindfulness-based breathing therapy program|Participant caregivers of palliative patients were randomized into the intervention and the control groups. Prior to randomization, participants and nurses were informed online abut the aim of the research and their written consent was obtained. Once the study ended, mindfulness-based breathing therapy were recommended to the patients in the control group. Data were collected online via Google forms survey and the interviews were conducted online via Zoom.
75792209|NCT01214382|Drug|Sertraline|Single dose sertraline 100 mg, tablet and solution
75644170|NCT05259111|Other|Home hospital|Acute care provided at home, including nurse/paramedic visits, physician visits, laboratory testing, imaging, continuous monitoring, 24/7 urgent visits, and specialty consultation.
75644171|NCT00716989|Biological|Tuberculin antigen|2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum
75644172|NCT00612495|Drug|oxaliplatin, 5 FU|"Oxaliplatin:130 mg/m² as a 2-hour intravenous (IV) infusion in 500 mL of 5% glucose solution on Day 1 and repeated every 3 weeks.~5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 to Day 4, repeated every 3 weeks."
75644173|NCT00719173|Drug|aprepitant|Given orally
75644174|NCT00719173|Drug|cyclophosphamide|Given IV
75792210|NCT01373476|Drug|Qideng Mingmu capsule|High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.
75792211|NCT01373476|Drug|Placebo Comparator|Placebo group (4 placebos each time):4#, po, tid,24 weeks.
75792212|NCT01216956|Drug|Extended-release nicotinic acid versus placebo|Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
75792213|NCT03132220|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive therapy is a 16 in-person hours intervention. The intervention in this population is designed to reduce symptoms of PTSD and BOS and increase resiliency scores.
75792214|NCT03132220|Behavioral|Book Club Active Control Intervention|Participants randomized to the book club active control intervention will meet for 16 in-person hours that are broken into sessions. Books will be assigned to read during homework time and discussions regarding the books will occur during the sessions. The time involved will be similar to the MBCT intervention.
75644175|NCT00719173|Other|placebo|Given orally
75644176|NCT00756886|Drug|Atorvastatin|40 mg QD 7 day continue after procedure for 14 days
75644177|NCT00756886|Drug|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
75644178|NCT05215041|Other|Non intervention|If the vaginal delivery is failed after spontaneous labor for up to 24h, they will receive cesarean section
75644179|NCT02574013|Device|Endoractor®|Endoscopic sponge for retraction of small intestine
75644180|NCT02686359|Biological|sample|
75644181|NCT00756730|Drug|ATV/r|Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
75644182|NCT00756730|Drug|DRV/r|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
75644183|NCT00713713|Procedure|Mechanical ventilation with low and high tidal volume|Tidal volume of 6 or 12 ml.kg-1, calculated on ideal body weight
75644184|NCT02573935|Drug|Clarithromycin|p.o. clarithromycin 500 mg twice daily for 63 days
75644185|NCT02573935|Drug|Placebo|Placebo tablet twice daily for 63 days
75644186|NCT02573935|Drug|VCD induction therapy|Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
75644187|NCT00984620|Drug|BI 201335|BI 201335
75644188|NCT00984620|Drug|BI 201335|BI 201335
75644189|NCT00984620|Drug|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha
75644190|NCT00984620|Drug|Ribavirin (RBV)|Ribavirin (RBV)
75644191|NCT00717145|Drug|risedronate|one risedronate 20 mg DR tablet
75792215|NCT02529228|Other|Meal (Eating) Frequency|Dividing meal intake into 2 or 6 meals with equal energy content
75792216|NCT02529228|Other|Protein Composition|Consuming meals with higher or lower protein.
75792217|NCT01217034|Drug|TACE with sorafenib|Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
75792218|NCT01217034|Procedure|TACE alone|TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
75792219|NCT01373554|Drug|Placebo|30mig/bid or 60mg/bid P.O
75472389|NCT01957449|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
75472390|NCT01957449|Drug|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
75472391|NCT01957501|Other|MDDScoreTM|The child will receive a single blood draw (about 10 mL).
75644192|NCT00717145|Drug|risedronate|One risedronate 20 mg DR tablet
75644193|NCT00717145|Drug|risedronate|One risedronate 35 mg DR tablet
76083995|NCT04190680|Behavioral|Kokkerelli Learning Street|"The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher."
75644194|NCT00717145|Drug|risedronate|One risedronate 35 mg IR tablet
76083996|NCT03358056|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.
76083997|NCT02993458|Other|DASH diet|DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat
76083998|NCT02993458|Other|Low Na diet|Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
76083999|NCT02993458|Other|High Na diet|Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.
75644195|NCT02686281|Drug|GMC-252-L-Lysine|
75644196|NCT02686281|Other|Placebo|
75644197|NCT02600728|Behavioral|Experimental Training|"The ET consisted of 3 phases being that the first one (Phase 1) was done only in the first session.~Phase 1: patients received a short and simple explanation about the deficiency in automatic movement resulting from PD. Following explanation, the patient memorized a sequence of declarative cues. Phase 2: the patient organized a sequence of cues using cards illustrating the subcomponent movements (key movement) involved in taking steps.~Phase 3: the patient had to train using declarative cues as a gait performance aid through 8 sets follow the instruction Walk in your ordinary speed. Use the key movements and going to saying each of them while you make them. The declarative cues had to be evoked verbally by the patients themselves, during gait, triggering the corresponding movement."
75792220|NCT01373554|Drug|Oltipraz|30mig/bid or 60mg/bid P.O
75792221|NCT02529150|Behavioral|Exercise|This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
76084000|NCT02993458|Other|Usual Diet|The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
75334916|NCT02085980|Device|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
75334917|NCT03016247|Behavioral|TRUST Intervention|The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.
75334918|NCT03016247|Behavioral|Enhanced Usual Care|Single meeting with a Nutritionist for physical activity and eating counseling.
75334919|NCT02546544|Drug|Linsitinib|
75334920|NCT00380848|Procedure|Hemodiafiltration|
75644198|NCT02600728|Behavioral|Control Training|"The CT consisted of 3 phases, being the first one (Phase 1) was done only in the first session of training, and the other two (Phase 2 and 3) were repeated at each of the 8 sessions.~Phase 1: Patients received a short and simple explanation about the deficiency in automatic movement resulting from PD.~Phase 2: Patients received a general verbal attentional instruction of pay attention to your steps and try to walk as better as you can, before starting the walk.~Phase 3: motor training of gait, where the patient had to perform 8 sets, following the instruction Walk in your ordinary speed, paying attention to your steps in the identical trajectories of ET. Additional instructions or cues were not provided."
75644199|NCT00713791|Drug|ZD4054|Treatment period 1: 10mg oral solution
75644200|NCT00713791|Drug|ZD4054|Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
75334921|NCT01027793|Drug|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
75644201|NCT00713791|Drug|ZD4054|Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
75644202|NCT00713791|Drug|ZD4054|Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
75644203|NCT00639483|Drug|Celecoxib|200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
75644204|NCT00639483|Drug|Placebo|Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
75644205|NCT00719251|Device|High voltage pulsed current|The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
75792222|NCT01319344|Drug|Eplerenone|25 mg o.d. per os
76084001|NCT03360084|Procedure|Percutaneous lung biopsy under CT guidance|Percutaneous lung biopsy under CT guidance
75792223|NCT03936816|Other|GBS vaginal double swab|The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
75644206|NCT00719251|Device|Low level laser|Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
75334922|NCT01027793|Device|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
75334923|NCT00002146|Drug|Magnesium sulfate|
75334924|NCT00002146|Drug|Foscarnet sodium|
75334925|NCT04389554|Other|Blood D-dimer assay|Blood samples will be taken from the patients and will be examined by the ELISA method.
75334926|NCT00380926|Drug|polyunsatturated fatty acids (fish oil)|
75472392|NCT01957514|Other|Cytology Specimen Collection Procedure|Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection
75472393|NCT01957514|Other|Laboratory Biomarker Analysis|Correlative studies
75644207|NCT00719251|Other|Standard nursing care|It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
75644208|NCT02867540|Other|MRI enterography|
75644209|NCT00777946|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet taken orally once a day with a glass of water.
75644210|NCT00777946|Drug|Aliskiren/Amlodipine 300/5 mg|Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
75644211|NCT00777946|Drug|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
75644212|NCT00777946|Drug|Placebo to Aliskiren|Placebo to Aliskiren tablet taken orally once a day.
75644213|NCT00777946|Drug|Placebo to Aliskiren/Amlodipine|Placebo to Aliskiren/Amlodipine taken orally once a day.
75644214|NCT04068883|Other|Q collar|An externally-worn medical device that applies mild jugular compression
75644215|NCT02686047|Device|HYAJOINT Plus|The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
75644216|NCT02686047|Device|Synvisc-One|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
75644217|NCT00639561|Dietary Supplement|10 g of fibres per day|10 g of fibres per day
75644218|NCT00639561|Dietary Supplement|40 g of fibres per day|40g of fibres per day
75644219|NCT00916084|Device|Fixed Tongue Appliance|A functional appliance used for maxillary protraction. It has two bands on first molars, expansion screw and long palatal plate in the canine area which cages the tongue and transfers the force of the tongue during physiological activity to the upper arch.
75644220|NCT00916084|Device|Fixed Face Mask|An extra-oral appliance used for treatment of maxillary deficiency in growing patients. It takes anchorage from the chin and forehead, has a fixed intra-oral appliance with an expansion screw and hooks for elastics that exert a force of 300 gr. It should be used 14 hours a day.
75644221|NCT00713947|Drug|during one week for the active treatments|during one week for the active treatments placebo during 25 weeks
75644222|NCT00713947|Drug|Pantoprazole|6 months at 20 mg
75644223|NCT00713947|Drug|Placebo Formula 515|26 weeks, one tablet per day
75644224|NCT00990314|Drug|Beraprost Sodium Modified Release|
76084002|NCT03123666|Drug|GMCSF|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
76084003|NCT03123666|Other|Placebo|Placebo identical to GMCSF will be given
76084004|NCT04160806|Device|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
75644225|NCT00909831|Drug|hydroxychloroquine|
75644226|NCT00909831|Drug|temsirolimus|
75644227|NCT00909831|Other|electron microscopy|
75334927|NCT05427552|Device|Intermittent theta-burst stimulation (iTBS)|The iTBS will be applied over lDLPFC with three different intensities. The investigators put the NIRS probe under the TMS coil to detect the hemodynamic signal simultaneously, and the applied rMT was adjusted based on Stokes et al., 2007. The equation is AdjMT% = MT + 2.8 * (Dsitex - Dm1), and the thickness of the probe is 6mm, therefore, 2.8*6=16.8(%) were added to the normal intensity.
75334928|NCT02444390|Procedure|Biopsy|biopsy of a metastasis
75334929|NCT03051516|Other|Laboratory Biomarker Analysis|Correlative studies
75334930|NCT03051516|Other|Placebo Administration|Given IM
75334931|NCT03051516|Other|Questionnaire Administration|Ancillary studies
75644228|NCT00909831|Other|high performance liquid chromatography|
75644229|NCT00909831|Other|immunologic technique|
75644230|NCT00909831|Other|laboratory biomarker analysis|
75644231|NCT00909831|Other|mass spectrometry|
75644232|NCT00909831|Other|pharmacological study|
75644233|NCT00909831|Procedure|autophagy inhibition therapy|
75334932|NCT03051516|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
75472394|NCT01957514|Other|Quality-of-Life Assessment|Ancillary studies
75472395|NCT01957514|Other|Questionnaire Administration|Ancillary studies
75472396|NCT01957527|Device|Peripheral arterial tonometry (EndoPAT)|
75472397|NCT01957540|Drug|Ticagrelor|
75472398|NCT01957540|Drug|Prasugrel|
75472399|NCT01957566|Procedure|APS|
75472400|NCT01957592|Other|No treatment given|Patients will fill out a questionnaire by interview.
75472401|NCT01957631|Drug|Corticosteroid injection (Bupivacaine and Depo Medrol)|The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
75644234|NCT00756652|Device|Mentor Silicone Gel-Filled Breast Implants|
75928664|NCT05777473|Behavioral|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The community health worker will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male community health workers will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
75928665|NCT05777473|Behavioral|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week. The husband groups will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
75334933|NCT01029587|Drug|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
75334934|NCT00000664|Drug|Interleukin-2, Polyethylene Glycolated|
75644235|NCT00756652|Device|Saline Breast Implants|
75792224|NCT01373632|Device|Firebird 2 sirolimus-eluting stent|the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform
75792225|NCT01373632|Device|Excel sirolimus-eluting stent|the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform
75792226|NCT04570774|Procedure|Repetitive transcranial magnetic stimulation|rTMS over cerebral motor cortex and cerebellar hemisphere
75792227|NCT04562974|Device|MRI-scanner|Only one group of 30 participants is constituted. All participants will perform perception and memory tasks inside a MRI-scanner. Functional activity (BOLD signal) will be registered, as well as anatomical and behavioural data.
76084005|NCT03357978|Diagnostic Test|bioelectrical impedance analysis|Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
75334935|NCT00000664|Drug|Zidovudine|
76084006|NCT03357978|Diagnostic Test|blood draw|Blood samples are taken from sober patients
75644238|NCT04097626|Other|nutrition education|The experimental group will receive nutrition education once during the study. It will occur at the beginning of the second week. This will consist of a 30-minute interactive lecture and a 15-minute question-and-answer session. The information covered will be basic nutrition principles for good health and to support regular exercise.
75644239|NCT04097626|Other|no nutrition education|This group will not receive nutrition education.
75644240|NCT04121624|Device|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the smartphone application and the non-invasive reference method (upper arm cuff).
75644241|NCT00717379|Drug|Tacrolimus|oral
75644242|NCT00717379|Drug|Mycophenolate Mofetil|oral
75644243|NCT00717379|Drug|Methylprednisolone or equivalent|oral
75644244|NCT00717379|Drug|Prednisone|oral
75644245|NCT04097392|Other|Experimental|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
76084007|NCT03357978|Diagnostic Test|transient elastography (FibroScan)|FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound
76084008|NCT03357978|Diagnostic Test|ataxia score|Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb
75644246|NCT04097392|Other|Active comparator|Isolated high-intensity inspiratory muscle training during 8 weeks
75644247|NCT02867228|Other|changes in ventilator settings|Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
75644248|NCT03919981|Other|Blood sampling|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
75644249|NCT02867306|Drug|ASP1707|Oral
75644250|NCT02867306|Drug|methotrexate (MTX)|Oral
75644251|NCT00777556|Drug|DR-104|One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
75644252|NCT00602979|Device|Macintosh laryngoscope|Used during laryngoscopy to facilitate intubation.
76084009|NCT03357978|Diagnostic Test|Five-Times-Sit-to-Stand Test|The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series
75644253|NCT00602979|Device|Airtraq® Optical Laryngoscope|Used during laryngoscopy to facilitate intubation.
75644254|NCT00602979|Device|Storz DCI Video Laryngoscope®|Used during laryngoscopy to facilitate intubation
75928666|NCT05777473|Behavioral|Adopt-a-Friend|"The Adopt a Friend approach aims to promote the dissemination and discussion of new information and ideas among peers who are not directly involved in program activities. This involves asking each participant to choose a friend with whom she will share what she learns in home visits and her reflections. Adolescent girls will support each other in seeking sexual and reproductive health information or services if needed."
76084010|NCT03109392|Drug|Nebulized Lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
76084011|NCT03109392|Drug|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
76084012|NCT03109392|Drug|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
76084013|NCT03357900|Device|Automated titration of propofol and remifentanil|Calculation of Consumption of propofol and remifentanil
75644255|NCT00602979|Device|GlideScope® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
75644256|NCT00602979|Device|McGRATH® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
75644257|NCT02867462|Other|Standard care|standard care
75644258|NCT02867462|Other|manipulator consultation radiotherapy added to standard care|
75644259|NCT04097080|Drug|NBTX-001|Active drug group will receive 6 doses of NBTX-001 given three times a week.
75644260|NCT04097080|Drug|Standard of Care|Placebo group will receive reconstituted air given three times a week.
75644261|NCT04081363|Drug|Centanafadine|Extended-release and immediate-release capsules.
75644262|NCT02685657|Drug|Drug: Selumetinib|
75792228|NCT01124682|Procedure|diagnostic cystoscopy|
75792229|NCT01124682|Procedure|diffusion-weighted magnetic resonance imaging|
75792230|NCT01124682|Procedure|implanted fiducial-based imaging|
75928667|NCT05774054|Drug|Crystalloid|received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)> 65 mmHg despite adequate fluid resuscitation
75644263|NCT02685657|Drug|Doxorubicin|
76084014|NCT03360006|Drug|ABBV-744|Tablet, oral
75644264|NCT02685657|Drug|Cyclophosphamide|
75644265|NCT02685657|Drug|Docetaxel|
75644266|NCT04290884|Drug|Tranexamic Acid|The recruited patients will be randomly assigned to two groups, 50% chance to the experimental group (use of tranexamic acid) and 50% chance to the control group (use of normal saline). After the reduction of the intertrochanteric fracture, 10ml of tranexamic acid is injected under the deep fascia around the fracture area before inserting a drain. As for the control group, 10ml of normal saline is injected instead. Blood will be taken on the third day post operation, and the patient will be seen at 6 weeks, and 3 months.
75644267|NCT00719407|Drug|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
75644268|NCT00639795|Procedure|Thoracic Paravertebral Nerve Block|One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
75644269|NCT00639795|Procedure|Thoracic Paravertebral Nerve Block|Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
75644270|NCT00714025|Drug|RAD001|RAD001 10mg, daily, PO
75644271|NCT02869412|Other|Computer-Assisted Intervention|Use BCG website
75644272|NCT02869412|Other|Computer-Assisted Intervention|Use passive website
75792231|NCT01124682|Procedure|quality-of-life assessment|
75792232|NCT01124682|Radiation|3-dimensional conformal radiation therapy|
75792233|NCT01124682|Radiation|image-guided radiation therapy|
75792234|NCT01124682|Radiation|selective external radiation therapy|
75928668|NCT05774054|Drug|noradrenaline|received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
76084015|NCT04525326|Drug|Cetuximab|mFOLFOX+Cetuximab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
76084016|NCT04525326|Drug|Bevacizumab|mFOLFOX+Bevacizumab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
76084017|NCT04525326|Drug|mFOLFOX/FOLFIRI ( Standard Chemotherapy)|Standard Chemotherapy
76084018|NCT03367104|Device|ECG Belt|Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.
76084019|NCT03359928|Behavioral|Boxing|as already discussed
76084020|NCT03359928|Behavioral|Stair stepping|as already discussed
76084021|NCT03359928|Behavioral|Stair climbing|as already discussed
76084022|NCT03357822|Drug|Pegylated interferon|180ug Pegylated interferon is injected subcutaneously once a week
76084023|NCT03357822|Drug|Entecavir|0.5mg entecavir is orally taken every day
75644273|NCT02869412|Other|Quality-of-Life Assessment|Ancillary studies
75644274|NCT02869412|Other|Questionnaire Administration|Ancillary studies
75792235|NCT03119662|Drug|Visipaque|100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
75792236|NCT03119662|Drug|Placebos|100 mL saline, followed by a 10 mL saline flush.
75792237|NCT01124760|Drug|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
75792238|NCT01124760|Drug|Diltiazem|Orally, daily beginning on Day 4 for 14 consecutive days
75792239|NCT01124760|Drug|ketoconazole|200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
75792240|NCT01217268|Behavioral|Training in person centered care by supervision using video-conference|The investigators will use video-conference for supervising and training of staff members in nursing homes
76084024|NCT03357822|Drug|Tenofovir disoproxil fumarate|300mg tenofovir is orally taken every day
75644275|NCT02685345|Drug|DS-8500a 25 mg|
75644276|NCT02685345|Drug|DS-8500a 75 mg|
75644277|NCT02685345|Drug|placebo|
76084025|NCT03367026|Drug|Ivabradine Oral Product|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.~Day 1 :~2.5 mg ivabradine b.i.d. if heart rate ≥90 bpm~Day 2,3,4:~2.5 mg ivabradine b.i.d. if 60bpm≥heart rate<90bpm. 5.0mg ivabradine b.i.d. if heart rate ≥90bpm"
76084026|NCT05445934|Drug|FB2001|FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
76084027|NCT05445934|Drug|FB2001 placebo|Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
75644278|NCT04102384|Other|e-PRO App|The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants. Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires.
75644279|NCT00717535|Other|cryopreservation|
75792241|NCT03936582|Behavioral|Treatment|information already included in arm/group descriptions
75792242|NCT02728804|Other|Quality-of-Life Assessment|Complete questionnaire
75792243|NCT02728804|Other|Questionnaire Administration|Complete questionnaires
75792244|NCT01217346|Other|no intervention is involved in this study|no intervention is involved in this study
75792245|NCT01217424|Other|questionnaire administration|
75928669|NCT05773651|Other|Data collection|The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature
75928670|NCT05766761|Behavioral|Intervention condition, the usual prenatal care plus the alcohol intervention|The intervention is theory-driven, based on Motivational Enhancement Theory (MET), and uses motivational strategies to promote alcohol reduction.
75928671|NCT05751148|Drug|Hyperbaric bupivacaïne|Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution
75928672|NCT05751148|Drug|Hyperbaric prilocaïne|Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
75928673|NCT05741697|Drug|bi-level ventillation|non-invasive mechanical ventilation
75928674|NCT05717985|Procedure|modified combined approach|A thin layer of epithelium will be excised from the harvested graft. This epithelium will be replaced at the donor site and sutured.
76084028|NCT03366948|Other|IGDT-10 self-administered questionnaire|"Patients and their parents will answer the French version of the IGDT-10 self-administered questionnaire (IGDT-10-P in the parents 'questionnaire).~The IGDT-10 is a self-administered questionnaire based on DSM-5 internet gaming disorder criteria and the IGDT-10-P is a parental version specially adapted from the IGDT-10 for this study."
76084029|NCT03357744|Other|distress barometer|not applicable, observational study
76084030|NCT03359772|Other|Kinesthetic Ability Trainer|Kinesthetic Ability Trainer
75644280|NCT00717535|Other|questionnaire administration|
75644281|NCT00717535|Other|study of socioeconomic and demographic variables|
75644282|NCT02869100|Other|Blood sample|
75644283|NCT02869100|Procedure|Sodium fluoride Positron Emission Tomography|
75928675|NCT05717985|Procedure|de-epithelized gingival graft|Only dressing material will be placed at the donor site after graft harvesting
75644284|NCT02869100|Other|Magnetic Resonance Imaging|
75644285|NCT02869100|Other|Radiography|
75644286|NCT04033965|Genetic|Corellation of Mutations, TILs and Age in Breast Cancer|
75644287|NCT04096768|Drug|Dexmedetomidine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
75644288|NCT04096768|Drug|Ketamine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
75644289|NCT04102462|Drug|BI 764198|Capsules
75644290|NCT04102462|Drug|Matching placebo|Capsules
75644291|NCT00714103|Drug|8-Chloro-Adenosine|45 mg/m^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
75644292|NCT02685501|Other|no intervention|
75644293|NCT02601430|Other|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
75644294|NCT00714181|Drug|hydroxychloroquine|
75644295|NCT00714181|Drug|temozolomide|
75644296|NCT00714181|Genetic|TdT-mediated dUTP nick end labeling assay|
75644297|NCT00714181|Genetic|western blotting|
75644298|NCT00714181|Other|electron microscopy|
75644299|NCT00714181|Other|high performance liquid chromatography|
75644300|NCT00714181|Other|immunoenzyme technique|
75644301|NCT00714181|Other|immunohistochemistry staining method|
75644302|NCT00714181|Other|laboratory biomarker analysis|
75644303|NCT00714181|Other|mass spectrometry|
75644304|NCT00714181|Other|pharmacological study|
75644305|NCT02685423|Behavioral|Binocular deprivation 10 days|Research participants will be asked to live 10 days in an experimentally-controlled dark environment.
75644306|NCT02685423|Behavioral|Vision training|Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
75644307|NCT03991702|Diagnostic Test|diagnostic test|The overall motor function of the patient will be assessed using the Medical Research Council (MRC) scale and Palmar dynamometer strength
75792246|NCT01217424|Procedure|aromatherapy and essential oils|
75792247|NCT01217424|Procedure|management of therapy complications|
75792248|NCT01217424|Procedure|massage therapy|
75792249|NCT01217424|Procedure|psychosocial assessment and care|
75792250|NCT01217424|Procedure|reflexology procedure|
75928676|NCT05711199|Drug|Glyceroltrinitrat|transdermal patch
75334936|NCT02444078|Other|Exercise|Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.
75334937|NCT02444078|Other|Social Activity|Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
75334938|NCT05427396|Drug|JS004|Usage and dosage: Inject 200mg once every 3 weeks
75334939|NCT05427396|Drug|Toripalimab Injection|Usage and dosage: Inject 240mg once every 3 weeks
75334940|NCT05440630|Dietary Supplement|Probiotics|Participants in this arm will receive a daily dose of 1x10^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
75334941|NCT05440630|Dietary Supplement|Postbiotic|Participants in this arm will receive a daily dose of 1x10^10 Colony Forming Unit (CFU) of a single strain postbiotic (Heat treated bacteria) for 16 weeks.
75334942|NCT05440630|Dietary Supplement|Placebo|Participants in this arm will receive an equivalent placebo for 16 weeks.
75334943|NCT01893944|Other|virtual reality|customized applications using virtual and augmented reality to be developed.
75334944|NCT00000670|Drug|Probenecid|
75644308|NCT04290962|Behavioral|Lifestyle Therapy|Complete web-based lifestyle intervention
75644309|NCT04290962|Other|Quality-of-Life Assessment|Ancillary studies
75792251|NCT01214694|Behavioral|Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)|Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
75792252|NCT01214694|Behavioral|Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)|Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
75792253|NCT01214694|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
75334945|NCT00000670|Drug|Zidovudine|
75334946|NCT00002152|Drug|WF10|
75334947|NCT00001630|Device|Isolex 300i|
75334948|NCT00988013|Radiation|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day.
75334949|NCT00988013|Radiation|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days.
75334950|NCT00988013|Radiation|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days.
75334951|NCT00988013|Radiation|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days.
75472402|NCT01957631|Biological|Platelet rich plasma injection|10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
75644310|NCT04290962|Other|Questionnaire Administration|Ancillary studies
75334952|NCT00002158|Drug|Nitazoxanide|
75334953|NCT00000694|Drug|Interferon alfa-2b|
75334954|NCT00000694|Drug|Zidovudine|
75334955|NCT00000694|Drug|Sargramostim|
75334956|NCT01894412|Biological|Etanercept (Enbrel)|
75334957|NCT01894412|Biological|HD203|
75334958|NCT00000700|Drug|Zidovudine|
75334959|NCT02440646|Radiation|Coronary computed tomography angiography|The coronary arteries will be visualized with the MSCT scan CT 5000 Ingenuity (Philips, The Netherlands) or systems from any other vendors.
75334960|NCT02440646|Radiation|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with Artis zee (Siemens, Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (with implantation of the medical device).
75472403|NCT01957670|Device|Lacrima medical Prototypes|
75472404|NCT01957683|Device|eCLIPs™ Family of Products|Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
75472405|NCT01957735|Drug|BP31510 monotherapy|
75472406|NCT01957735|Drug|BP31510 in combination with chemotherapy|
75644311|NCT00719485|Other|Educational program|Informing patients about their condition, treatment options, prioritization on the wait list, and post-operative care
75644312|NCT02600806|Drug|Azithromycin|Patients are given oral azithromycin when procalcitonin levels are < 0.5 ng/ml
75644313|NCT02600806|Drug|Levofloxacin|Patients are given oral levofloxacin when procalcitonin levels are >= 0.5 ng/ml.
75644314|NCT00639873|Drug|Artesunate|2 or 4 mg/kg/day for 7 days
75644315|NCT00639873|Drug|quinine-doxycycline|quinine-doxycycline for 7 days
75928677|NCT05703971|Biological|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
75334961|NCT00002164|Drug|Nelfinavir mesylate|
75334962|NCT02003690|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy
75334963|NCT02003690|Behavioral|Standard of Care Psychotherapy|Standard of Care Psychotherapy
75334964|NCT02003690|Other|Pharmacotherapy|Standard of Care Pharmacotherapy
75334965|NCT00000706|Drug|Quinine sulfate|
75334966|NCT00000706|Drug|Probenecid|
75334967|NCT00000706|Drug|Zidovudine|
76084031|NCT03542500|Behavioral|Youth Readiness Intervention (YRI)|The Youth Readiness Intervention integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
76084032|NCT03542500|Behavioral|Entrepreneurship Training|The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use.
76084033|NCT03366870|Behavioral|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
75334968|NCT00988325|Drug|Tamiflu|oral repeating dose
75792254|NCT01120080|Behavioral|Practical Counseling|To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
76084034|NCT03366870|Behavioral|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform.
76084035|NCT02248948|Dietary Supplement|Omega-3 Fatty Acids|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
76084036|NCT02248948|Dietary Supplement|Medium Chain Triglycerides|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
76084037|NCT03359694|Drug|DT group|Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
76084038|NCT03359694|Drug|ET group|Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
76084039|NCT03359694|Drug|NX group|Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
75644316|NCT02572921|Behavioral|Positive Psychotherapy|"The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:~positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the full life."
75792255|NCT01120080|Behavioral|Alcohol Intervention Counseling|The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
76084040|NCT03407716|Drug|American Ginseng|Given PO
75792256|NCT01217502|Behavioral|Self management program|Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
76084041|NCT03407716|Other|Laboratory Biomarker Analysis|Correlative studies
76084042|NCT03407716|Other|Placebo|Given PO
76084043|NCT03407716|Other|Questionnaire Administration|Correlative studies
76084044|NCT03359616|Procedure|Transanally curable surgical resection|Transanally, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
76084045|NCT03359616|Procedure|Laparoscopic total mesorectal excision|Conventionally by laparoscopic surgery, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
76084046|NCT02227810|Other|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
75334969|NCT00002296|Drug|Inosine pranobex|
75334970|NCT00002302|Drug|Epoetin alfa|
75334971|NCT00002170|Drug|Nelfinavir mesylate|
75334972|NCT00002308|Drug|Stavudine|
75334973|NCT00002314|Drug|Ro 24-7429|
75334974|NCT00000724|Drug|Trimetrexate glucuronate|
75334975|NCT00000724|Drug|Leucovorin calcium|
75334976|NCT00000730|Drug|Trimetrexate glucuronate|
76084047|NCT02227810|Other|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
76084048|NCT02227810|Other|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
76084049|NCT03357666|Drug|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
76084050|NCT03357666|Drug|HUDC_VT (Glucose 400mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
75334977|NCT00000730|Drug|Methylprednisolone|
75334978|NCT00000730|Drug|Pentamidine isethionate|
75334979|NCT00000730|Drug|Sulfamethoxazole-Trimethoprim|
75334980|NCT00000730|Drug|Leucovorin calcium|
75334981|NCT02435264|Other|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
75334982|NCT00002176|Drug|Hydroxyurea|
75334983|NCT00002176|Drug|Nelfinavir mesylate|
75334984|NCT00002176|Drug|Stavudine|
75334985|NCT00002176|Drug|Didanosine|
75792257|NCT01217502|Behavioral|self management program|Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
75334986|NCT00381316|Drug|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
75928678|NCT05703971|Biological|atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
76084051|NCT03357666|Drug|HUDC_VT (Glucose 400mg)|Vaginal administration, two tablets once a day for 7 days
75792258|NCT01214772|Drug|heparin|5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
75792259|NCT01120548|Other|ventilation therapy|"The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.~There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.~Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient."
75334987|NCT00381316|Drug|Thallous Chloride T1-201|Myoview SPECT Imaging
75334988|NCT02161133|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
75334989|NCT02161133|Behavioral|Health Education|Health Education provides didactic information about Gulf War Illness
75334990|NCT03830177|Drug|Natural Treatment|The participant will be given the treatment, which contains all natural ingredients, and a kit of all necessary materials to take home with them, which will include a set of instructions. The kit will contain the instruction handout and their treatment. They will be instructed to apply the treatment to their scalp, wait seven minutes, and then rinse their scalp. They will perform this entire procedure once per day for 14 days.
75334991|NCT01030289|Device|real tDCS|transcranial direct current stimulation
75334992|NCT01030289|Device|sham tDCS|transcranial direct current stimulation
75334993|NCT00002182|Drug|Megestrol acetate|
75472407|NCT01957774|Drug|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
75472408|NCT01957774|Drug|Placebo|
75472409|NCT01957800|Behavioral|Website|Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.
75644317|NCT02572921|Behavioral|Cognitive behavioral therapy|This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
75644318|NCT04291118|Procedure|Private system endoscopic sinus surgery|Patients that will undergo endoscopic sinus surgery though the private system. Beforehand they could of used medical management including, budesonide for their symptoms.
75792260|NCT01217658|Behavioral|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
75792261|NCT01217658|Behavioral|AAP Infant Colic counseling|Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
75644319|NCT04291118|Procedure|Public system endoscopic sinus surgery|Patients that undergo endoscopic sinus surgery though the public system after waiting for at least 1 year. Beforehand they could of used medical management, including budesonide for their symptoms.
75644320|NCT04291118|Drug|Budesonide|Patients will receive medical management for their symptoms that will consist of topical nasal steroid, budesonide and any other required medication for their disease.
75928679|NCT05703074|Dietary Supplement|Nicotinamide Riboside (NR)|4 capsules (a total of 1000 mg) 2 times daily for 84 days
75334994|NCT04756934|Drug|HX008|HX008: 200mg, Q3W
75334995|NCT04756934|Drug|LP002|LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W
75472410|NCT01957800|Behavioral|Usual Care|Participants will record their weight and complete surveys online.
75644321|NCT04096612|Procedure|Orbital decompression combined with MPT|Orbital decompression combined with MPT
75644322|NCT04069351|Dietary Supplement|High-calorie mass gainer supplement|A high-calorie mass gainer supplement will be provided to all participants to promote weight gain.
75644323|NCT04069351|Other|Resistance Training|All participants will complete a 6-week supervised resistance training program.
75644324|NCT04291586|Other|Virtual reality|Virtual Reality Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
75928680|NCT05703074|Behavioral|Mind-body reprocessing therapy (MBRT)|4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.
75928681|NCT05703074|Behavioral|Care as usual|A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner
75928682|NCT05703074|Dietary Supplement|Placebo|4 capsules (empty) 2 times daily for 84 days.
76084052|NCT03357666|Drug|HUDC_VT (Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
76084053|NCT03357666|Drug|Placebo|Vaginal administration, two tablets once a day for 7 days
76084054|NCT03366714|Device|nasal CPAP support with RAM cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.
76084055|NCT03366714|Device|nasal CPAP support with Hudson cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
76084056|NCT03357432|Other|gelatin, collagen, gummy dose|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a >24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours blood samples will be collected. Blood samples will be used for PINP analysis.
76084057|NCT03357354|Behavioral|collective workshop|diet, sports games, food budget, feeling of satiety and hunger, self-image
75334996|NCT00002320|Drug|Lamivudine|
75334997|NCT00002320|Drug|Zidovudine|
75334998|NCT01236391|Drug|PCI-32765|560 mg daily
75472411|NCT01957813|Behavioral|Lifestyle Counseling|"Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.~Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation"
75644325|NCT04291586|Other|Paper and Pencil|Paper and Pencil Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
75644326|NCT02868164|Drug|Fecal Microbiota Transplantation|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 6 month.
75644327|NCT02868164|Drug|Standard Treatment|Standard Treatment
75644328|NCT02868164|Other|Weight Reduction|routine exercise for weight reduction
75644329|NCT03352011|Behavioral|Primary Care Brief Mindfulness Training|Primary Care Brief Mindfulness Training consists of four 90-minute group classes that teach sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.
75792262|NCT01219452|Biological|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
75792263|NCT01124994|Procedure|Endoscopic mucosal resection|Confocal laser endomicroscopy will be used to target endoscopic mucosal resection of Barrett's oesophagus-associated neoplasia
75792264|NCT01329120|Procedure|Minimally invasive repair of pectus excavatum|Minimally invasive surgical technique basically consisting of inserting one or more convex steel bars under the sternum through small bilateral incisions in the thoracic wall
75792265|NCT01329120|Procedure|Open surgical repair of pectus carinatum|Open surgical removal the affected cartilages bilaterally and the excess cartilage over the sternum
75792266|NCT05187676|Device|Oxygen saturation measurement using the IPAM device|Skin oxygen saturation rate will be measured (%) using the non-contact optical device under evaluation called IPAM
75792267|NCT05187676|Device|Transcutaneous oxygen partial pressure (TcPO2) using the PeriFlux6000 device|Skin TcPO2 will be measured (mmHg) using the reference device called PeriFlux6000
75792268|NCT01120860|Device|MRI|MRI - routine imaging sequences, designed for anatomical quantification
75792269|NCT01125072|Other|Echocardiography with strain analysis|Clinical routine echocardiogram with additional off line strain analysis
75792270|NCT02699554|Procedure|Single-event multilevel surgery|
75792271|NCT01125150|Drug|Metformin|Dosage to be determined by Endocrinologist
75792272|NCT01125150|Behavioral|Dietary Modification|To be determined by Endocrinologist
75792273|NCT01217736|Drug|aliskiren|single dose, tablet
76084058|NCT03350620|Drug|NVK-002 Concentration 1|Study medication will be administered, once daily (QD)
75334999|NCT02167217|Drug|Prednisolone|Prednisolone (5mg per kg) will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
75335000|NCT00002326|Drug|Adefovir|
75335001|NCT00002326|Drug|Zidovudine|
75335002|NCT01152697|Drug|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
75335003|NCT01152697|Drug|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
75472412|NCT01957813|Other|Standard Health Services|Peer education and health services
75792274|NCT01217736|Drug|placebo|single dose, tablet
75792275|NCT01217736|Drug|VTP-27999|single dose, tablet
75792276|NCT01373710|Drug|Trastuzumab|One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg
75792277|NCT03935412|Procedure|Erector Spinae Plane Block|Erector Spinae Plane Block
75792278|NCT01360918|Device|Epicardial pulmonary vein isolation|After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
75792279|NCT01360918|Other|Usual care|Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
75792280|NCT04162600|Biological|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10^9 vp, 2.5 x 10^10 vp, 5 x 10^10 vp
75792281|NCT04162600|Biological|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units
75792282|NCT03935022|Other|Rice|"Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~80g of black rice Venere (Group A)~80g of black rice Artemide (Group B)~80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration."
76084059|NCT03350620|Drug|NVK-002 Concentration 2|Study medication will be administered, once daily (QD)
76084060|NCT03350620|Drug|Placebo|Vehicle (placebo) will be administered, once daily (QD)
75792283|NCT03936504|Behavioral|Control Group ：conventional exercise rehabilitation programs (CERP)|The participants in the control group will receive a conventional exercise rehabilitation programs (CERP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including ordinary warm-up exercises (10 minutes), aerobic activity (30 minutes), resistive exercise (10 minutes), and cool-down exercises(10 minutes). Each training session includes:(1) an active warm-up including arm-swinging, gentle stretches of the neck, shoulders, spine, arms, legs and so on;(2) aerobic activity mainly including aerobic radio exercise;(3) resistive exercise mainly including elastic belt exercise;(4) cool-down session involving active and static stretching exercises with primary body movements.
75928683|NCT05701865|Behavioral|Alcohol Intoxication- Ascending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the ascending limb
76084061|NCT03123276|Drug|Pembrolizumab|humanized IgG4 PD-1 blocking antibody
76084062|NCT03123276|Drug|Gemcitabine|Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
76084063|NCT03366558|Diagnostic Test|UPDRS questionnaires|UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
76084064|NCT03366558|Diagnostic Test|20-step walking test|20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
75335004|NCT01152697|Behavioral|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
75335005|NCT00002188|Drug|Alitretinoin|
75644330|NCT03352011|Behavioral|PTSD Psychoeducational Class|"The PTSD Psychoeducational Class is designed to provide a supportive environment for learning about PTSD-related issues and to help Veterans determine what recovery strategies will be most helpful for them. Session themes include Civilian Readjustment and PTSD, Trust, Safety, and Healing and Treatment Strategies."
75472413|NCT01957826|Other|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
75644331|NCT00717691|Device|Metatarsophalangeal Extension Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
75644332|NCT00717691|Other|Standard of Care|The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
75792284|NCT03936504|Behavioral|Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP)|Participants perform Tai Chi cardiac rehabilitation program(TCCRP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including Tai Chi warm-up exercises(10 minutes), Bafa Wubu of Tai Chi(30 minutes), Tai-Chi in conjunction with X-light-band resistance exercise(10 minutes), and Tai Chi cool-down exercises(10 minutes). All participants are encouraged to practice Tai Chi followed the instructional video until finishing 12-week exercise.
75928684|NCT05701865|Behavioral|Alcohol Intoxication- Descending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the descending limb
75928685|NCT05701865|Behavioral|No Alcohol Control|Participants will be assigned to a no alcohol control condition
75928686|NCT05701345|Device|OMNIFIT DTx-MDD|This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session
76084065|NCT03359382|Other|Resistance or home exercise combined with eccentric exercise|"First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )"
75472414|NCT01957826|Other|placebo intervention|placebo administration
75472415|NCT01957839|Drug|cabergoline treatment|cabergoline treatment for hyperprolactinemia group
75644333|NCT02867072|Procedure|Open appendectomy|
75644334|NCT02867072|Procedure|Laparoscopic appendectomy|
76084066|NCT03855904|Device|TC-325|TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.
76084067|NCT03357276|Biological|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
76084068|NCT04524936|Diagnostic Test|blood sample|
76084069|NCT04524780|Device|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
76084070|NCT03359226|Procedure|Submandibular gland biopsy|Needle biopsies of the right and left submandibular glands
76084071|NCT03359148|Device|Disposable ventilator system|
76084072|NCT03359148|Device|Conventional reused ventilator system|
76084073|NCT04521660|Device|Virtual reality glasses|Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.
76084074|NCT02249026|Drug|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
75335006|NCT04637230|Diagnostic Test|Electrocardiogram analysis by Artificial Intelligence|1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms
75335007|NCT01197547|Device|Genesys HTA|Genesys HTA Endometrial Ablation
75335008|NCT05105477|Device|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
75644335|NCT04068337|Procedure|Aortic root replacement with Freestyle biological prosthesis with and without hemiarch replacement|Aortic root replacement with Freestyle biological prosthesis. Some patients receive additional hemiarch replacement performing an open anastomosis to the aortic arch under antegrade cerebral perfusion through axillary artery. Comparison with patients, who were cannulated and perfused systemically
75644336|NCT02685579|Other|Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes|
75792285|NCT04109014|Other|FASTLANE II|"The intervention will consist of nine weekly hour-long individual counseling sessions. The FL II sessions utilize a combination of Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) to reduce sexual risk behaviors and mental health symptoms. Thus, individuals develop a toolbox for mood self-management to improve emotional self-regulation and reduce maladaptive coping mechanisms to minimize drug and sex risk behavior. Participants will be considered as completing the FASTLANE Intervention upon completion of the nine weeks of sessions."
75792286|NCT04073446|Device|Spinal Cord Stimulation|Patients eligible for SCS
75792287|NCT01125306|Device|Xal-Ease|Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
75792288|NCT03937882|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
75928687|NCT05701345|Other|standard treatment|"It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines."
75928688|NCT05684809|Other|Post Isometric relaxation Technique (PIR)|In PIR intervention, the patients were requested to lie down in a supine position and their neck was in a lateral flexion to the opposite side so that the target upper Trapezius muscle fibers would be in a lengthened position. The therapist performed a moderate isometric contraction (approximately 75% of maximal) of upper Trapezius muscles, held it for 5 seconds, then relaxed for 3 seconds before moving the cervical spine into the new barrier. In each session, this technique was repeated for four times, on alternate days for three weeks.
75335009|NCT05105477|Other|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
75335010|NCT00002332|Drug|Thymopentin|
75335011|NCT03011281|Drug|Tofacitinib|
75335012|NCT00002194|Drug|Erythromycin|
75644337|NCT02866916|Drug|SXL01|Treatment will be administered continuously over 24h through the subcutaneous route.
75792289|NCT03937882|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
75792290|NCT01125384|Other|additional swabbing|physician swabs patient's throat according to standard rules before referral of the patient to throat swabbing by nurse.
75792291|NCT03783780|Device|INVSENSOR00031|Noninvasive pulse oximeter sensor
75335013|NCT00002194|Drug|Nevirapine|
75335014|NCT00002194|Drug|Clarithromycin|
75335015|NCT00990509|Drug|Albumin|Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
75335016|NCT00990509|Drug|Placebo|Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
75335017|NCT00990509|Procedure|Brain MRI with and without contrast|"All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~Baseline~48 hours after enrollment(approximately Day 3)~96 hours after drug treatment begins (approximately Day 5)"
75335018|NCT00002338|Drug|Raluridine|
75644338|NCT04068571|Behavioral|I-PUSH|Innovative partnership for universal and sustainable healthcare
75644339|NCT00777088|Device|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach
75472416|NCT01957852|Other|FloSeal|
75644340|NCT02868944|Drug|experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).|
75644341|NCT02868944|Drug|control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.|
75792292|NCT03869866|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
75928689|NCT05684809|Other|Cervical Mobilization (CM)|Cervical Mobilization was delivered in prone lying with their foreheads resting comfortably on his hands, and the chin was tucked in.The treatment session was done on alternate days (3 days a week) for 3 weeks, hence the total number of sessions were 9.
75792293|NCT03783702|Drug|OxyCODONE 5 Mg (milligram) Oral Tablet|Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
75928690|NCT05684809|Other|conventional treatment|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10-second relaxation) were given, and isometric exercise of the neck((10 repetitions of two sets with 10 seconds hold) alternate days for three weeks.
75928691|NCT05680051|Device|Drug-eluting balloon|Drug eluting balloon was used in the experimental group
75928692|NCT05680051|Device|Drug-eluting stent|Drug eluting stent was used in the control group
75928693|NCT05676255|Behavioral|Cognitively-Based Compassion Training for Survivors|"CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
75644342|NCT04067323|Dietary Supplement|Soya bean oil|Participants will consume soya bean oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
75644343|NCT04067323|Dietary Supplement|MCT oil|Participants will consume MCT oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
76084075|NCT02249026|Drug|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
75792294|NCT03783702|Drug|Ibuprofen 600 Mg (milligram) Oral Tablet|Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
75928694|NCT05676255|Behavioral|Cognitively-Based Compassion Training for Dyads|"CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
76084076|NCT04521504|Device|Kinematic biofeedback with ISEO motion analysis system|Exercises are performed with the help of the ISEO motion analysis system, that provides a real-time biofeedback of shoulder kinematics. All exercises are administered by the Physical Therapist.
76084077|NCT03366402|Diagnostic Test|RT-PCR H1N1|At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
76084078|NCT03366324|Genetic|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.
76084079|NCT03366324|Procedure|Hematological stem cell transplantation|Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
76084080|NCT03133156|Other|Exercise Intervention|10-Week Aerobic Exercise Training
76084081|NCT04521192|Drug|Fluzoparib|the first period: test preparation; the second period: reference preparation
76084082|NCT04521192|Drug|Fluzoparib|the first period: reference preparation the second period: test preparation
76084083|NCT02995876|Procedure|Glaze layer|A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
76084084|NCT02995876|Procedure|E-max Press layer|A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
76084085|NCT03359070|Drug|Dapaconazole|Application of 1 gram on the lesion.
76084086|NCT03359070|Drug|Miconazole Nitrate|Application of 1 gram on the lesion.
75472417|NCT01957878|Biological|ProCervix|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
75644344|NCT03292809|Drug|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
75644345|NCT03292809|Drug|Vehicle topical ocular, eye drops|Vehicle
75644346|NCT00722839|Biological|PADRE-CMV fusion peptide vaccine|Given subcutaneously
75792295|NCT03783702|Drug|Acetaminophen 650 MG (milligram) Oral Tablet|All patients will receive acetaminophen as the first-line analgesic.
75792296|NCT01319734|Dietary Supplement|Vitamin C|Vitamin C supplementation 500mg
75792297|NCT01319734|Drug|glyburide|this group receiving glyburide 5 mg alone
75792298|NCT01121016|Drug|Montelukast|10mg, qn, 4 weeks
75792299|NCT01121016|Other|placebo to montelukast|same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
76084087|NCT03366246|Drug|Lidocaine / Prilocaine Cream|according randomized this side received placebo or active product
75792300|NCT03685240|Behavioral|SafelyYou Fall Prevention System|Technology + Quality Assurance Services Provided by SafelyYou
75928695|NCT05676255|Behavioral|Health Education|"HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support."
75792301|NCT03677752|Other|GP_Posit|Mother-infant dyads allocated to this arm will receive the GP_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
75792302|NCT01122810|Procedure|Coronary scanner|The ECG-gated contrast-enhanced multidetector computed tomography coronary angiography will be performed with a 64 or 256-row CT Philips, Brilliance. The contrast medium mean quantity used is 80-100 ml. The CT scan parameters, adapted to the patient's weight, include 120 kV, 800mA, 0.625 mm slice thickness, 0.42-s rotation time and 0.2 pitch. To determine X-Ray exposure, Dose Length Product (Gycm) will be measured. Reconstruction will be performed at 40 and 75 % of the cycle using ECG gating. A semi quantitative analyse of coronary narrowing will be performed blindly to coronary angiogram results by two experienced radiologists. The CT quality will be determined using a quality scale from 1 to 5. A Calcification score will also be determined. A segment analyse will be performed according to AHA classification. Only more than 1.5 mm diameter vessel segments will be analysed.
75792303|NCT01219608|Dietary Supplement|Glutamine 0.5 g/kg/day|Glutamine 0.5 g/kg/day
75928696|NCT05674721|Drug|Advil PM Liqui-Gels Minis|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule which is a size reduction of the currently marketed reference product.
75928697|NCT05674721|Drug|Advil PM Liqui-Gels|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule.
75928698|NCT05668598|Diagnostic Test|ecological MAI test|"Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.~Study test is ecological MAI."
75928699|NCT05667766|Diagnostic Test|Release of Extended Pharmacogenomics Report at Week 1|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) by Week 1. Whole genome sequencing on a broader number of actionable variants as per international guidelines for cancer supportive care (identical to study arm) will be reported on at Week 13.
75928700|NCT05667766|Diagnostic Test|Release of Extended Pharmacogenomics Report at Week 13|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.
75928701|NCT05664516|Drug|TNX-1900 (Tonix Pharmaceuticals)|oxytocin nasal spray
75644347|NCT00722839|Biological|tetanus-CMV fusion peptide vaccine|Given subcutaneously
75644348|NCT00722839|Drug|agatolimod sodium|Given subcutaneously
75928702|NCT05664516|Drug|Placebo|Nasal solution without oxytocin
75928703|NCT05664464|Drug|Gabapentin|Weekly dose escalations over 4 weeks of daily 3 x 300 mg up to 3 x 1200 mg
76084088|NCT03366246|Drug|placebo|according randomized this side received placebo or active product
76084089|NCT01623466|Drug|levonorgestrel|transdermal contraceptive delivery system
76084090|NCT04521036|Biological|Convalescent Plasma as Therapy for Covid-19 patients|Patients in the treatment group will receive 500 ml from COVID-19 recovered donors
76084091|NCT04524624|Device|AI-based CDSS|"Automatically identifying acute ischemic stroke lesions on DWI.~Classification of stroke subtypes and mechanisms.~Evidence-based alerts and guidelines for early stroke management.~Guideline-recommended secondary stroke prevention strategies."
76084092|NCT03366090|Procedure|Biopsies during coloscopy|During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.
75644349|NCT02868008|Procedure|Microsurgical resection of brain AVMs|fMRI guided microsurgical resection of brain AVMs
75644350|NCT04096924|Device|Guidewire for echo-guided interventions|Under echocardiography guided treatment of ASD with a novel interventional guidewire
75644351|NCT04096924|Device|Cook lunderquist guidewire|Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
75644352|NCT04069195|Dietary Supplement|DHA supplement|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through delivery of their infant
75792304|NCT01219608|Dietary Supplement|Glutamine 1 g/kg/day|Glutamine 1 g/kg/day
75792305|NCT01219608|Dietary Supplement|Enteral Nutrition|Ordinary Enteral Nutrition
75928704|NCT05664464|Drug|Sulfasalazine|Weekly dose escalations over 3 weeks of daily 3 x 500 mg up to 3 x 1500 mg
75928705|NCT05664464|Drug|Memantine|Weekly dose escalations over 4 weeks of daily 1 x 5-20 mg
75928706|NCT05664464|Drug|Temozolomide|Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days
75928707|NCT05664464|Radiation|Radiotherapy|30 x 2 Gy involved field radiotherapy with concomitant temozolomide
75928708|NCT05657457|Drug|Tenecteplase|intra-arterial tenecteplase
75928709|NCT05652647|Drug|Oral [14C]PF-07081532|A single oral dose of [14C]PF-07081532, will be administered as a liquid formulation in study period 1.
76084093|NCT01624168|Behavioral|Anxiety Management Education|written materials on management of anxiety for self-study
76084094|NCT01624168|Behavioral|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
76084095|NCT01624168|Behavioral|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
76084096|NCT03358914|Other|No intervention|Completion of surveys
76084097|NCT03365856|Other|observational study|as clinical practice
75792306|NCT03575572|Drug|Colchicine|Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
75792307|NCT01125462|Other|Quality of Life Questionnaire (FertiQoL)|Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
75928710|NCT05652647|Drug|Oral PF-07081532 and IV [14C]PF-07081532|In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-07081532 will be administered via intravenous infusion.
75928711|NCT05641831|Procedure|Biospecimen Collection|Undergo peripheral blood collection
75928712|NCT05641831|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
75928713|NCT05641831|Drug|Canakinumab|Given SC
75928714|NCT05641831|Procedure|Chest Radiography|Undergo chest x-ray
75928715|NCT05641831|Procedure|Echocardiography|Undergo ECHO
76084098|NCT03642574|Procedure|CNV|Embryo with euploid chromosome will transfer to uterus. The order of transfer is accroding to morphological grade.
76084099|NCT03358680|Device|noninvasive analgesia measurement|noninvasive analgesia measurement using index of consciousness(IOC2)
75928716|NCT05641831|Drug|Placebo Administration|Given SC
75644353|NCT04069195|Dietary Supplement|Corn Oil: Soybean Oil|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through
76084100|NCT04520958|Behavioral|Mindfulness of Breath|Mindfulness of Breath consisted of instruction in focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
76084101|NCT04520958|Behavioral|Mindfulness of Pain|Mindfulness of Pain consisted of instruction in how to (1) zoom in to deconstruct pain into its constituent physical sensations and precisely map each sensation's spatial location, (2) use mindful breathing to zoom out and broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that were absent of sensation and pleasant sensations), and (3) shift attention from unpleasant sensations to neutral/pleasant sensations or experiences.
75335019|NCT01238341|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
75928717|NCT05641831|Other|Quality-of-Life Assessment|Ancillary studies
75644354|NCT04290728|Device|Apnea with high-flow nasal cannula|Application of oxygenation with high-flow nasal cannula with a rate of 2L/kg/min
76084102|NCT04520958|Behavioral|Cognitive-Behaviorally Based Pain Psychoeducation|Cognitive-Behaviorally Based Pain Psychoeducation consisted of psychoeducation about the link between thoughts, emotions, and behavior and provided instruction in the use logic to dispute maladaptive thoughts about pain that might otherwise exacerbate pain and distress.
76084103|NCT04520646|Drug|Empagliflozin|empagliflozin of 10mg/day is added on the basis of primary care
76084104|NCT03357120|Other|Follow-up after neoadjuvant chemotherapy|"Sequential plasma samples for ctDNA mutations analysis will be taken during the post-surgery visit (within 2-5 weeks after surgery) and every 6 months (+/- 1 month) thereafter for 5 years. In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated). Next Generation Sequencing (NGS) analysis will be performed on post-neoadjuvant chemotherapy residual tumor tissue samples. The mutations identified by NGS in residual tumor will be tracked in ctDNA using personalized digital PCR (dPCR) or by an NGS technique whose bioinformatics pipeline is adapted to the analysis of ctDNA.~In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated)."
76084105|NCT03365700|Procedure|Radiofrequency Ablation|Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
75644355|NCT04290728|Other|Apnea|Apnea without any application of oxygenation
75335020|NCT04756622|Drug|N acetyl cysteine|N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
75472418|NCT01957878|Biological|Placebo|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
75472419|NCT01957904|Device|ArterX Surgical Sealant|
75644356|NCT04096690|Drug|Pegaspargase|Pegaspargase 3750IU administered by intramuscular injection on Day 1 of each 21-day cycle for 6 cycles in induction treatment
75644357|NCT04096690|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 2 of each 21-day cycle for 6 cycles in induction treatment Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1 of each 21-day cycle for up to 28 cycles in maintenance treatment
75335021|NCT00002344|Drug|Azithromycin|
75472420|NCT01957917|Other|NAC (Nutritional Assessment and Counseling)|
75472421|NCT01957917|Other|Cash Transfer|
75472422|NCT01957917|Other|Food Assistance|
75644358|NCT02868086|Device|OCT B-scans|
75644359|NCT02868086|Device|OCT angiography|
75644360|NCT00763282|Behavioral|Self Management (SM)|Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
75644361|NCT00763282|Behavioral|Motivational Interviewing (MI)|Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
75644362|NCT00763282|Behavioral|Education (ED)|The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
75792308|NCT01374100|Behavioral|Standard Exercise|The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
75792309|NCT01374100|Behavioral|Qigong Exercise|Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
75792310|NCT01122888|Drug|Cilengitide|Given IV
75928718|NCT05633797|Device|FibriCheck|During the patient's intensive care unit (ICU) stay, they will be monitored constantly to detect atrial fibrillation (standard care). After ICU dismissal, patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative. Patients need to use the FibriCheck application for a minimum of 3x/day and can perform extra measurements when symptoms are present.
75928719|NCT05633173|Procedure|Ultrasound-guided erector spinae plan block|Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.
76084106|NCT03365700|Procedure|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
75335022|NCT04756778|Procedure|Aortic surgery +/- aortic valve replacement|Replacement of aneurysmal proximal thoracic aorta +/- replacement of diseased bicuspid aortic valve
75335023|NCT00992927|Procedure|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
75644363|NCT00639951|Biological|A|20 vials up front in a Single Dose of Antivipmyn
75472423|NCT01957943|Dietary Supplement|SMOFLipid|
75644364|NCT00639951|Biological|Antivipmyn ®|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
75644365|NCT00988598|Drug|PF-04447943|25 mg of PF-04447943 orally every 12 hours for 7 days
75644366|NCT00988598|Drug|Placebo|25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
75644367|NCT04184739|Other|My Braces App|An App designed to support patients undertaking orthodontic treatment.
75644368|NCT00719797|Biological|bevacizumab|Given IV
75644369|NCT00719797|Drug|fluorouracil|Given IV
75644370|NCT00719797|Drug|irinotecan hydrochloride|Given IV
75644371|NCT00719797|Drug|leucovorin calcium|Given IV
75644372|NCT00719797|Drug|oxaliplatin|Given IV
75644373|NCT03988504|Diagnostic Test|Routine check up including genetic testing|Intervention is a routine check up including preemptive genetic testing
75644374|NCT04105413|Diagnostic Test|Blood culturs|CBC, Blood culture and CRP
75792311|NCT01122888|Other|Clinical Observation|Patients undergo a 2-week rest period
75792312|NCT01122888|Other|Laboratory Biomarker Analysis|Correlative studies
75792313|NCT01214928|Drug|Cholecalciferol|cholecalciferol 50,000 IU po once weekly for 12 weeks
75792314|NCT02625766|Procedure|LC fracture surgical fixation|
75792315|NCT02625766|Procedure|LC fracture non-operative management|
75792316|NCT03934788|Device|oxysoft (olifilcon C)|subjects meet certain criteria will be administered randomly oxysoft on both eye for one month on daily wear single use modality.
75792317|NCT03934788|Device|Si-Hy (olifilcon B)|subjects meet certain criteria will be administered randomly Si-Hy on both eye for one month on daily wear single use modality.
75335024|NCT00992927|Procedure|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
75472424|NCT01957943|Dietary Supplement|equivalent volume of 10% glucose solution|Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
75472425|NCT01957969|Device|Sacral Nerve Stimulation|
75472426|NCT01957995|Drug|nanosomal docetaxel lipid suspension|Given IV
75472427|NCT01957995|Other|pharmacological study|Correlative studies
75472428|NCT01958034|Dietary Supplement|Bilberry extract|
75472429|NCT01958047|Drug|ASP3652|Oral
75472430|NCT01958099|Behavioral|Education|
75792318|NCT01122966|Drug|intraocular injections of bevacizumab|intracameral and subconjunctival injections
75792319|NCT01123044|Biological|conservative|Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
75792320|NCT01123044|Procedure|Medical Therapy|Under usual care treatment
75792321|NCT01219686|Drug|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
75792322|NCT01219686|Drug|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
75792323|NCT01219686|Drug|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
75792324|NCT03116698|Drug|Low dose DFD07 once daily|Low dose DFD07 once daily
75792325|NCT03116698|Drug|High dose DFD07 once daily|High dose DFD07 once daily
75792326|NCT03116698|Drug|High dose DFD07 twice daily|High dose DFD07 twice daily
75928720|NCT05633173|Procedure|Ultrasound-guided caudal block|The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
76084107|NCT01624948|Drug|Everolimus|Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
75792327|NCT03116698|Drug|Placebo twice daily|Placebo twice daily
75335025|NCT04756466|Dietary Supplement|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
75792328|NCT01219764|Drug|Rabeprazole, metronidazole, Clarithromycin, Amoxicillin|"Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days."
75792329|NCT01219842|Procedure|INVASIVE (INV) treatment|Modern endovascular and/or open revascularisation according to the TASC II recommendations.
75335026|NCT04756466|Dietary Supplement|Lactobacillus|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
75472431|NCT01958138|Drug|comparison of group-I (low dose propofol with isoflurane)|Prior to LMA removal in group-I, isoflurane MAC awake (MAC less than 0.5) will be achieved in expiratory gases with 60% nitrous oxide and 40% oxygen. Propofol 1 mg/Kg will be combined with Isoflurane MAC awake and LMA will be removed after 20 seconds of propofol administration in group-I. The group-II LMA will be removed at end expiratory isoflurane MAC of 1.2% with 60% nitrous oxide and 40% oxygen
75472432|NCT01958151|Other|State-Trait Anxiety Inventory Scores|Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
76084108|NCT01624948|Drug|Mycophenolic acid dose reduction|Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
75792330|NCT01219842|Other|Best medical treatment (BMT)|Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
75792331|NCT01328730|Device|Firebird 2 SES|The FIREBIRD2™ Rapamycin-Eluting CoCr Coronary Stent is the second generation DES of MicroPort, which based on the new cobalt chromium alloy stent platform. It uses polyolefin polymer, which makes the coating property very remarkable.
75792332|NCT01328730|Device|Cypher SES|The Cypher SES is based on the 316L platform with Controlled-release, nonresorbable, elastomeric polymer coating.
75792333|NCT03936426|Drug|Cu-64 SARTATE and Cu-67 SARTATE|Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
75928721|NCT05633095|Device|Neuclare|It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
75928722|NCT05783089|Biological|Anti-mesothelin CAR-T cells|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
75928723|NCT05630989|Other|combination therapy with no MEKi|This cohort will receive combination therapy with no MEKi.
76084109|NCT03357042|Other|Aerobic exercise and balance retraining|Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.
76084110|NCT03357042|Other|Standard of care|Normal concussion treatment; physical and cognitive rest
75792334|NCT01125540|Device|Acuvue (Standard Daily Disposable Contact Lens)|
75792335|NCT01125540|Device|CIBA Dailies Aquacomfort Plus (Contact Lens - enhance lubricating)|
75928724|NCT05630989|Drug|combination therapy with MEKi-HCQ|This cohort will receive combination therapy with MEKi-HCQ.
75928725|NCT05630989|Drug|combination therapy with MEKi-EGFRi|This cohort will receive combination therapy with MEKi-EGFRi.
75928726|NCT05630989|Drug|combination therapy with MEKi.|This cohort will receive combination therapy with MEKi.
75928727|NCT05626530|Drug|Letermovir|Open label 480 mg given daily for 60 days
76084111|NCT03259204|Device|Adjuvant IPC|This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
76084112|NCT04520568|Combination Product|High flow nasal cannula|using sedation with the HFNC F&P AIRVOTM 2 to maintain oxygenation
75335027|NCT01198327|Drug|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
75335028|NCT01198327|Other|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
75335029|NCT00002200|Drug|Abacavir sulfate|
75335030|NCT00002350|Biological|APL 400-003|
75335031|NCT04694950|Procedure|Usual care|Intravenous morphine according to clinician´s discretion.
75335032|NCT02405234|Device|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
75335033|NCT02405234|Device|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
75792336|NCT01125618|Other|Health and development intervention package|The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication.
75792337|NCT01125618|Other|Routine services|Routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites.
75792338|NCT01121328|Biological|Autologous cord blood transfusion for preterm neonates|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.
76084113|NCT04520568|Combination Product|CONTROL|using general anaesthesia with one lung ventilation (OLV) technique
75644380|NCT00979628|Drug|sliding scale regular insulin (SSRI)|four-time daily in patients with T2DM admitted to general medicine and surgery wards.
75792339|NCT01121328|Biological|Autologous cord blood transfusion|"After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.~Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.~Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.~RBCs will be separated and kept till need (Hb less than 10 gm%)."
75792340|NCT01215084|Drug|BIIB041 (Fampridine-PR)|A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
75792341|NCT01123122|Other|Strict glucose control|Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
75792342|NCT03933228|Procedure|Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
75928728|NCT05624333|Other|Vegan diet (intervention)|The intervention diet will be a fully controlled vegan diet that will be consumed for a duration of 10 days. No animal-based food products will be included in the diet.
75928729|NCT05624333|Other|Omnivorous diet (control)|The control diet will be an a priori composed controlled omnivorous diet with a duration of 10 days. The omnivorous diet and the vegan diet will be isocaloric and isonitrogenous.
75928731|NCT05611853|Drug|BN301|BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.
75928732|NCT05610618|Other|Visual stimulation|Participants will be displayed with photographs of scenes and objects which predictability and sharpness will be manipulated
75928733|NCT05607381|Behavioral|Meditation|Participants will complete 8 sessions of meditation training with therapy as a means of coping with chronic pain and opioid-related issues.
75928734|NCT05607381|Other|Usual care|Participants will receive usual care for chronic low back pain (e.g., analgesic medication, pain management consultant from a physician, physical therapy, etc.).
75928735|NCT05601674|Other|: Conventional flow Anesthesia|During the initial wash-in period 2 L/min Fresh gas flow will be used.
75928736|NCT05601674|Other|Low Flow Anesthesia|Fresh gas flow rate will be 0.5 L/min throughout the procedure.
75928737|NCT05600855|Drug|Ruxolitinib|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (<0.1×10^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (<0.1×10^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
76084114|NCT03358602|Radiation|Radiotherapy|Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
76084115|NCT03358602|Procedure|Selective neck dissection|Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
75335034|NCT00002356|Drug|Fomivirsen sodium|
75472433|NCT01958177|Biological|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)|Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
75472434|NCT01958216|Other|Intravenous injection of deuterated cholesterol diluted in intralipid 20%|At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
75644381|NCT00979628|Drug|Basal Bolus|glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
75644382|NCT00979628|Drug|Basal Plus|glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
75644383|NCT04096534|Procedure|Normotonic partial nephrectomy|partial nephrectomy performing with avoidance of hypotension: mean blood pressure more or equal 65 mm Hg
75644384|NCT04096534|Procedure|Hypotonic partial nephrectomy|partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: mean blood pressure less than 65 mmHg
75644385|NCT02868788|Dietary Supplement|dietary fiber|
75644386|NCT00719875|Drug|Vorinostat|BID days -7, 1-7 and 15-21, 200 mg
75792343|NCT03933228|Procedure|Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
76084116|NCT01625104|Other|Non Intervention|Business as usual
75792344|NCT01215162|Radiation|Intra-operative radiation to tumor bed|IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
75792345|NCT03932838|Other|Clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
75792346|NCT03936348|Device|Exercise training program with and without FB|"Participants carried out a supervised RP for 8 weeks, 3 days per week. The training sessions lasted 60 minutes and included a warning up phase, the main phase and a recovery phase. After each session, Borg's perceived exertion was measured. The Rehabilitation Program (RP) included aerobic exercise on cycle ergometer and on treadmill (progressing since 10' to 30' and since 40 to 75% of the reserve heart rate (RHR) or 6-7 score based on Borg's perceived exertion), strengthening of lower and upper limb muscles groups, breathing exercises (pursed lip breathing, diaphragmatic and abdominal breathing and diaphragmatic mobility) and finally stretching exercises.~In the FB group, for restricted nasal breathing, at the beginning of the training program, the small size device was used (4 mm). The size of the device was progressively increasing according to the patient adaptation to the 5 or 6 mm device, depending on the score on Borg's perceived exertion scale."
75792347|NCT01125696|Drug|Tenofovir/lamivudine/lopinavir-ritonavir|Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350
75928738|NCT05599724|Other|Biocollection|"For the FERTITHEQUE, will be collected:~Clinical characteristics~Biological characteristics measured as part of the usual follow-up~consultation n°2 : DNA~consultation n°2 : plasma~consultation n°2 : serum~consultation n°2 : vaginal microbiota~consultation n°3 : follicular fluid (puncture fluid)~consultation n°4 : plasma~consultation n°4 : vaginal microbiota."
75335035|NCT00994175|Drug|Pioglitazone|
75335036|NCT00994175|Drug|Placebo|
75335037|NCT00002206|Drug|Adefovir dipivoxil|
75644387|NCT02685111|Drug|Filgrastim|Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
75644388|NCT02685111|Drug|Peg-filgrastim|Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
75644389|NCT00762970|Device|Test Lens 1|Investigational soft contact lens with asperic optical design to control myopia progression.
75644390|NCT00762970|Device|Test Lens 2|Investigational soft contact lens with asperic optical design to control myopia progression.
75644391|NCT00762970|Device|Control Lens|Spectacle Lenses.
75644392|NCT00717925|Drug|Inotuzumab Ozogamicin (CMC-544)|Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
75644393|NCT00988442|Behavioral|Enhanced nursing telephone support|Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.
75644394|NCT00988442|Behavioral|Standard care|Usual ACTG site care.
75792348|NCT01125696|Drug|Zidovudine/lamivudine/lopinavir-ritonavir|Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350
75792349|NCT03932916|Drug|Donepezil Pamoate for Injection 17mg|A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.
75792350|NCT03932916|Drug|Donepezil Pamoate for Injection 34mg|A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.
75928739|NCT05586880|Other|Experimental: EnXtra 300 mg/ capsule|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
75928740|NCT05586880|Other|Microcrystalline cellulose (MCC) 300mg|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
75928741|NCT05580263|Behavioral|aerobic exercise|The main AE program will be designed and controlled for at least moderate intensity of heart rate reserve (HRR) lasting 30 minutes. The goal of intensity will be set at least 40% of HRR during the first two weeks, and then progressively increase the targeted intensity at the end of 16 weeks with 60% HRR. The motions will design by involving core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).
76084117|NCT01625104|Other|Agressive Intervention Process Improvement Strategies|
75335038|NCT02403986|Device|Restylane Vital Skinboosters Lidocaine|
75335039|NCT01239355|Drug|Akt Inhibitor MK2206|Given PO
75335040|NCT01239355|Other|Laboratory Biomarker Analysis|Correlative studies
75335041|NCT02168153|Other|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
75335042|NCT02168153|Other|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
75472435|NCT01958242|Other|Preoperative blood harvesting|There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/
75928742|NCT05580263|Behavioral|resistance exercise|"In the process, the participants will be instructed by resisting the weight smoothly, and peaking at hold. RE prescription consist of 2-4 sets with 10-15 repetitions per set with a rest interval of 1-2 minutes between sets to improve muscular fitness.~The first two weeks will start with two sets of 10-15 repetitions and then gradually progress on four sets of 15 repetitions at the end of 16 weeks. The total duration of RE will lasting around 15 minutes."
75792351|NCT03932916|Drug|Donepezil Hydrochloride 5mg|A tablet of 5mg Donepezil Hydrochloride will be administered once.
75792352|NCT03931980|Procedure|Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection|we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer
75792353|NCT03116152|Biological|IBI308|IBI308 200mg Intravenous drip every three weeks；
75792354|NCT03116152|Drug|paclitaxel/ irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks
75792355|NCT01123278|Drug|Testosterone|Testosterone transdermal gel 50 mg/day (5 gr)
75792356|NCT01123278|Drug|Placebo|Placebo transdermal gel (5 gr)
75928743|NCT05559034|Behavioral|Cognitive intervention|This is a cognitive intervention consisting in the repetition according to three blocks, of cognitive tasks (Stroop and N-back tasks) at variating workload levels (low, middle and high levels). Each cognitive task will be presented for each workload level during three minutes.
76084118|NCT04445142|Procedure|fovea-sparing internal limiting membrane peeling|fovea-sparing internal limiting membrane peeling surgery
76084119|NCT03365544|Other|Time-restricted eating|Groups will be required to only ingest calories in their designated 8 hour eating window.
75792357|NCT01215396|Dietary Supplement|AminoVital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener.
76084120|NCT01625416|Behavioral|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
75335043|NCT04389476|Other|Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)|"Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors."
75792358|NCT01215396|Dietary Supplement|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and an amino acid mixture (2.4g of AA as: leucine, isoleucine, valine, arginine and glutamine).
75335044|NCT00002212|Drug|Bexarotene|
75792359|NCT01215396|Dietary Supplement|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and a double dose of the amino acid mixture (4.8 g of AA as: leucine, isoleucine, valine, arginine and glutamine).
75792360|NCT01218282|Behavioral|Home exercise training|20-30 min/day for at least 4 days/week
75335045|NCT03011203|Other|physical exercise|In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
75335046|NCT02402192|Drug|Corifollitropin alfa|
75335047|NCT00002362|Drug|Abacavir sulfate|
75792361|NCT01218282|Behavioral|NO Exercise Training|No intervention
75792362|NCT00226499|Biological|Priorix-tetra™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group
75335048|NCT00002362|Drug|Efavirenz|
75335049|NCT00002362|Drug|Emtricitabine|
75792363|NCT00226499|Biological|Priorix™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group
75792364|NCT00226499|Biological|Varilrix™|1 dose administered subcutaneously at Day 42 to subjects in OKAH Group
75792365|NCT01219920|Drug|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
75335050|NCT00002362|Drug|Stavudine|
75335051|NCT02168309|Drug|Labetalol|Titrate up for blood pressure control
75335052|NCT02168309|Drug|Nifedipine|Titrate up to achieve blood pressure control
75335053|NCT00002368|Drug|Nevirapine|
75335054|NCT00002368|Drug|Lamivudine|
75335055|NCT01894724|Device|NeuroSave device|
75335056|NCT01895582|Other|Blood samples|"4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)"
75335057|NCT04746014|Diagnostic Test|Clearblue Pregnancy Test|Urine Pregnancy Test
75335058|NCT00002218|Drug|CI-1012|
75792366|NCT01219920|Drug|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
75792367|NCT01400776|Drug|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
75792368|NCT01400776|Drug|Vehicle|Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
75792369|NCT01220076|Drug|tamoxifen|
76084121|NCT04520880|Diagnostic Test|Testing procedure for Binding antibodies|Levels of S-specific and N-specific binding antibodies will be measured by enzyme immune-sorbent assay (ELISA). Briefly, a purified, recombinant S or N proteins will be coated into 96-well plates and incubated for 1 hour at room temperature. The plates will be then washed with 1X PBS five times. The unbound regions of the coated S proteins are blocked by 5% non-fat dry milk. After overnight incubation at 4 C. The plates are washed several times with 5X PBS. Patients sera samples are added in duplicate and incubated for 1 hour at room temperature. After several washes. anti-human IgG HRP conjugate is added. After 1-hour incubation at room temperature, the plates are washed with 1X PBS five times 3,3', 5,5' tetramethylbenzidine (TMB) substrate is added to each wells and incubated for 5 minutes. The reaction will be then stopped with 0.2 M sulfuric acid and the absorbance is measured at 450nm.
76084122|NCT04520880|Diagnostic Test|Neutralizing antibodies|Neutralizing antibodies against the S protein of SARS-CoV-2 are measured by PV microneutralization assay. Briefly, individual plasmids expressing S.fl gene, luciferase genes, and reporter genes are co-transfected into 293T cells to produce luciferase-expressing pseudo-viruses. Then, pseudo-viruses are added at equal volume into 96 well plates and incubated at 37 for 1 hour. Then, the ACE2 expressing 293T cells are added into the 96well pates with 100 ul of patients' sera in duplicates. After, a single round of replication the cells are lysed with lysis buffer. Luciferase activity is measured by the luciferase assay kit. The activity of luciferases is proportional to the number of cells infected. Luciferase activity is then measured by the luminometer device and the neutralization rate is calculated.
75792370|NCT01220154|Drug|Paclitaxel|Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
75792371|NCT01220154|Drug|Carboplatin|Intraperitoneal Day 1 cycles 1-6 AUC
75335059|NCT01199965|Drug|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
75335060|NCT01199965|Drug|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
75335061|NCT00995501|Drug|Dexamethasone Sodium Sulfate|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
75335062|NCT00995501|Drug|Insulin|Insulin to maintain blood glucose 80-110 mg/dl.
75335063|NCT00995501|Drug|anesthesia management|Light anesthesia to maintain BIS about 55
75644395|NCT03258723|Behavioral|Lifestyle Intervention|"The lifestyle intervention consists of a series of workshops adapted from the East Harlem Partnerships for Diabetes Prevention that discuss diabetes prevention, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control.~The newly launched East Harlem Diabetes Prevention (EHDP) project's mobile app, iHEED will be used by intervention participants to help reinforce the content they learn during the workshop series."
75644396|NCT03258723|Drug|Metformin|At 6 months, intervention participants who have not been able to lose weight or bring their HbA1c below the high risk range of 6% (determined by point-of-care testing) will have Metformin prescribed by their provider. Metformin will be prescribed at 500mg twice a day. If no change is seen at 12 months follow up, the dose will be increased to 850mg twice a day.
75644397|NCT00720031|Biological|autologous Melan-A/MART-1 specific CTL clones|"By using patients' blood, several million to several billion of Melan-A/MART1 tumor reactive T cell clone(s) will be produced in vitro, then infused to the patient, 3 to 6 months after collecting blood sample. During this production period of the T cell clone, the patient will be treated with deticene at the dose of 250mg/m2/j by IV for 4 days each month.~After each T cell clone infusion (J1), the patient will receive IFN-α at the dose of 9 M/U 3 times a week for 4 weeks and Interleukin-2 at the dose of 9 M/U from Day 1 to day 5 and from Day 8 to Day 12."
75644398|NCT00640029|Procedure|Arthrodesis|"posterior,~anterior,~circumference approach"
75792372|NCT01220154|Drug|Bevacizumab|Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
75792373|NCT01182766|Drug|Topiramate with brief behavioral enhancement therapy|high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
75792374|NCT01182766|Drug|Placebo with brief behavioral enhancement therapy|placebo
75792375|NCT03932994|Behavioral|ACT on Health|This intervention consists of an online canvas course based on Acceptance and Commitment Therapy, focused on increasing healthy diet and physical activity and addressing barriers to change. The intervention also consists of weekly phone coaching calls.
75792376|NCT01220232|Drug|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 5 days
75792377|NCT01220232|Drug|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 10 days
75792378|NCT01220232|Drug|Lersivirine|Lersivirine 750 mg QD for 10 days
75792379|NCT05174494|Diagnostic Test|Evaluation of serum CRP and NT-proBNP|All patients were evaluated to 6-months post-treatment reduction of serum CRP and NT-proBNP
75792380|NCT01125852|Procedure|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
75792381|NCT01125852|Procedure|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
75928744|NCT05541237|Dietary Supplement|Food|Food
75928745|NCT05533190|Device|Wysa AI chatbot mental health app|Wysa is a guided self-help and triaging tool delivered to patients via an app. It includes a chatbot and makes use of a wide range of clinically underpinned modules to provide mental health support.
75928746|NCT05527314|Drug|Remimazolam|Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
75335064|NCT00995501|Other|Dexamethasone - placebo|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
75335065|NCT00995501|Other|Insulin - Placebo|Insulin to maintain blood glucose 180-200 mg/dl.
75335066|NCT00995501|Other|Anesthesia management -Placebo|Deep anesthesia to maintain BIS about 35
75792382|NCT03972293|Behavioral|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications have 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. To increase the category of interest, the notifications use two types of messages: life insights and tips. Life insights provide participants information on their historical data (for a given category) in order to help them self-monitor. Tips are non-data based notifications which provide general advice for improving the category of interest.
75792383|NCT03972293|Behavioral|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
76084123|NCT04520724|Dietary Supplement|plant fiber|The patients with NAFLD (study and control group) will receive low-processed rolls with an 12 g plant fiber content twice daily, which would be a convenient for easy replenishment of the amount of vegetable fiber (act as prebiotic) in the diet. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
76084124|NCT04520724|Dietary Supplement|maltodextrin bar|The patients with NAFLD (placebo group) will receive maltodextrin bars twice daily, which would be a convenient and easy-to-eat snack replacing the second breakfast and afternoon tea. The bars must be eaten with 180 ml of water or unsweetened liquid. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
76084125|NCT03477604|Device|MicroStent and Standard PTA|Self-expanding stent and standard PTA balloon
76084126|NCT03477604|Device|Standard PTA|Standard PTA balloon
76084127|NCT04520802|Diagnostic Test|18F-DPA-714 PET/CT neuroimaging|"Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI.~Longitudinal neuropsychological examinations (up to 6 months postoperatively)~Blood samples are drawn to assess the severity of the systemic inflammatory response"
76084128|NCT03365466|Drug|Low dose aspirin|LDA 25mg tid
76084129|NCT03365466|Drug|Low molecular weight heparin|LMWH 5000u IH qd
76084130|NCT03365466|Drug|Low dose aspirin plus low molecular weight heparin|LDA 25mg tid + LMWH 5000u IH qd
76084131|NCT03365466|Drug|no treatment|Patients who did not receive any treatment.
76084132|NCT03833284|Behavioral|Participant Barriers to TVU Screening|Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
76084133|NCT03833284|Behavioral|Provider Barriers to TVU Screening|Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
76084134|NCT03356964|Drug|follicle stimulating hormone|Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged
76084135|NCT03346252|Drug|Botulinum Toxin type A|"All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart."
76084136|NCT04522752|Other|Size and pathological type of benign epithelial gastric polyp|All subjects will undergo gastroscopy and biopsy to determine the size and pathological type of benign epithelial gastric polyps.The correlation between polyp size and type and polyp development was observed at 6 months, 12 months and 18 months after inclusion.
75644399|NCT00640029|Device|Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)|"SYNTHES : PRODISC-C® , PRODISC-L®~LDR : Mobi-C®, Mobidisc®~MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~SCIENT'X : DISCOCERV®"
75644400|NCT00992186|Drug|Carlumab|Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
75644401|NCT04184817|Other|Collection of clinical data registered in Easily software|Collection of clinical data registered in Easily software
75644402|NCT02684799|Drug|Cenicriviroc|
75644403|NCT02684799|Drug|Omeprazole|
75928747|NCT05527314|Drug|Sevoflurane|Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.
75928748|NCT05527314|Drug|Fentanyl|Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
75928749|NCT05527314|Drug|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
75928750|NCT05527314|Drug|Remifentanil|After the LoC, remifentanil 0.1~0.3 ug/kg/min inject intravenously until the end of surgery.
75928751|NCT05521802|Biological|B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell|Autologous 2nd generation BCMA-directed CAR-T cells, single infusion intravenously
76084137|NCT04522830|Drug|BTL-TML-COVID|"Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
76084138|NCT04522830|Drug|Placebo|"Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
76084139|NCT03365388|Drug|Sodium Hyaluronate|Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form
76084140|NCT03365388|Drug|Aerzhi|Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
75928752|NCT05497011|Device|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
76084141|NCT03365310|Drug|C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk|Polyherbal formulation along with standard of care
76084142|NCT03365310|Other|Standard of Care|Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
76084143|NCT03356808|Biological|Lung cancer-specific T cells|1 infusion, for 1x10^6~1x10^7 cells/kg via IV
75644404|NCT02684799|Drug|Famotidine|
75644405|NCT02685189|Other|Previous exposure to stannsoporfin|No intervention in this protocol
75792384|NCT01220310|Behavioral|Online diabetes workshop observation and learning sessions|We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
75928753|NCT05494242|Other|Surgical intervention|Pars-plana vitrectomy.
75928754|NCT05484505|Drug|Nicotine patch, Nicotine gums|"Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~14 mg: Next 4 weeks~7 mg: Last 4 weeks"
76084144|NCT04522986|Biological|Mesenchymal stem cell|1*10^8 cells are administered once a week, total four times intravenously.
76084145|NCT03123744|Drug|Palbociclib 125mg|Palbociclib 125 mg is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study evaluations include physical exams, performance status, vital signs, laboratory blood tests, and radiographic or MRI imaging.
76084146|NCT04522362|Other|Control task and Trier Social Stress Task|Same as Arm
75792385|NCT01126008|Drug|CCRT with weekly docetaxel & cisplatin|radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
75792386|NCT01073345|Procedure|Portal venous pressure|Portal venous pressure is measured by invasive means using an arterial canula
75792387|NCT01073345|Procedure|Portal venous flow|Portal venous flow is measures using a noninvasive method (Doppler flow meter)
75792388|NCT01073345|Procedure|Hepatic artery flow|Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
75792389|NCT01361074|Behavioral|In Vivo Exposure for Animal Phobia following Öst´s guidelines|"In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way."
75928755|NCT05484505|Behavioral|Brief Advice (5 A's & 5 R's)|Brief Advice (5 A's & 5 R's) at Day 0, 1 month, 3,6,9 & 12 months
75928756|NCT05484505|Drug|Nicotine Patch: Preloading for 4 weeks|Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
76084147|NCT03358524|Drug|Vitamin E 400 UNT|Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
76084148|NCT03358524|Drug|Placebo oral capsule|sugar capsule manufactured to mimic vitamin E capsule once per day
76084149|NCT03365232|Device|non custom base attachment|non custom base attachment
76084150|NCT03365232|Device|custom base attachment|custom base attachment
76084151|NCT04444986|Drug|FAVIR 200 MG FT|FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
75644406|NCT02684877|Other|Questionnaire|
75644407|NCT00992108|Drug|lidocaine|1cc 1%
75644408|NCT00992108|Drug|chemodenervation|botulinum toxin
75644409|NCT02684721|Other|8-week home-based exercise programme|8-week home-based exercise programme is assigned to patients in exercise group following discharge. This includes 3 follow-up telephone calls by physiotherapist.
75644410|NCT00752986|Drug|ZD6474 (Vandetanib at the dose of 100 mg)|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
75644411|NCT00752986|Drug|Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
75644412|NCT00752986|Drug|Fulvestrant|All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
75644413|NCT00752986|Drug|ZD6474 (Vandetanib at the dose of 300 mg)|300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
75928757|NCT05478161|Device|(ALLEGRA Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
76084152|NCT04444986|Drug|AVIGAN 200 mg FT|AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
76084153|NCT04444596|Diagnostic Test|Conjunctival swab and nasopharyngeal swab|Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.
76084154|NCT04444674|Biological|ChAdOx1 nCoV-19|Dose of 5-7.5x10^10vp of ChAdOx1 nCoV-19
76084155|NCT04444674|Biological|Normal saline 0.9%|Normal saline 0.9% as placebo
76084156|NCT03365076|Other|Physical activity|Aerobic physical activity as stated in Arm A
75644414|NCT00752986|Drug|Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)|Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
75928758|NCT05476822|Diagnostic Test|Obtain antibody titers|Obtain blood samples for antibody titers at the time of enrollment, at three months, six months and nine months post vaccine booster (+/- ten days).
75928759|NCT05473364|Drug|Acetazolamide|Diuretic and carbonic anhydrase inhibitor medication
75928760|NCT05453591|Device|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
75792390|NCT01361074|Behavioral|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|"Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli."
75792391|NCT01220388|Dietary Supplement|L-lysine|L-lysine, 4,95 G at day : 0,55 G 3 times a day, orally, during meals
75928761|NCT05443763|Other|An interdisciplinary intensive therapy program|Children will receive physical, occupation, and/or speech therapy 1-3 hours/day each for 4-5 days/week x 4 weeks.
75928762|NCT05428943|Drug|OPT101|15-mer peptide derived from the sequence of mouse CD154.
75928763|NCT05413811|Drug|5 Fluorouracil (5 FU) Cream|Intravaginal topical chemotherapy, 5-fluorouracil cream
75928764|NCT05413811|Drug|Placebo|Intravaginal topical placebo cream
75335067|NCT02397200|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
75335068|NCT02397200|Dietary Supplement|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals
75335069|NCT00002374|Drug|Ritonavir|
75644415|NCT02684487|Drug|vitamin D3|Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
75644416|NCT02684487|Drug|Placebo|Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
75644417|NCT02601274|Drug|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
75644418|NCT02684409|Drug|PROT-CL-NP101-015.01|
75928765|NCT05407974|Procedure|pleurectomy|"All patients will undergo resection of apical blebs with simultaneous pleurectomy or pleural abrasion.~Chest tube will be inserted in the pleural cavity and maybe connected on low-grade suction for first 24 h according to type of pneumothorax & surgeons' preference, after which the suction is disconnected.~Post Operatively both groups will be compared regarding the postoperative drainage amount, persistence of air leak (chest tube removal time), length of hospital stay, mortality and risk of recurrence.~Follow up Chest x-ray will be done immediate postoperatively, then each patient will be followed up after 6 months."
75928766|NCT05393804|Biological|Ide-cel (bb2121)|Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.
75928767|NCT05382494|Drug|Mometasone Furoate 50mcg Nasal Spray|Intranasal steroid (Mometasone Furoate 50mcg) one spray each nostril daily for 6 weeks
75928768|NCT05382494|Drug|Sodium Chloride 0.9 % Nasal Spray|Intranasal saline spray (Sodium Chloride 0.9%) one spray each nostril daily for 6 weeks
75928769|NCT05355545|Behavioral|Virtually supervised exercise|Participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
75928770|NCT05355545|Behavioral|Health education|Participants will first participate in a once weekly live health education class that they will access through a computer connected to the Internet. During the second half of the study, participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
75928771|NCT05351346|Drug|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
76084157|NCT03356574|Procedure|Single-ventricle palliation surgery|Single-ventricle palliation surgery
75335070|NCT00002374|Drug|Nelfinavir mesylate|
75335071|NCT00002374|Drug|Saquinavir|
75335072|NCT00002374|Drug|Stavudine|
75335073|NCT03011047|Procedure|endoscopic trans-antral approach|new surgical approach to repair the orbital floor fractures through the maxillary sinus
75335074|NCT03011047|Procedure|trans-orbital surgical approach|through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
75335075|NCT00002380|Drug|Nelfinavir mesylate|
75644419|NCT00762892|Drug|Raltegravir and truvada|Raltegravir 400 mg po bid, truvada 1 tab q daily
75644420|NCT00762892|Drug|Atazanavir, Norvir and Truvada|Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
75644421|NCT04290416|Diagnostic Test|Microwire electrodes|
75928772|NCT05351346|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
75928773|NCT05351346|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
75928774|NCT05351346|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
76084158|NCT02519166|Biological|1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing|
75335076|NCT00002380|Drug|Saquinavir|
75335077|NCT00002386|Drug|Indinavir sulfate|
75335078|NCT00002386|Drug|Lamivudine|
75792392|NCT01220388|Dietary Supplement|placebo|placebo, 3 times a day, orally, during meals
75792393|NCT03974009|Other|Calcaneal taping|Calcaneal taping will be given in long sitting position foot out of the edge.BSN Medical Leukotape P Sports Tape (3.8cm×137m,1.5inch× 15yds) on focusing the calcaneus with the aim of choosing dorsiflexion with eversion. First strap of tape will be applied below the medial malleolus,stretch towards lateral malleolus on affected side. Second strap of tape will be applied repetitively placing the first strap,another will be applied to fix the small tapes.
75792394|NCT03974009|Other|Sham taping|Sham taping will be given to the control group patients.Simple clinical tape will be applied on calcaneus without stretch.It will be applied for 3 days/week for 4 weeks.
75792395|NCT03974009|Other|Conventional therapy|Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward & backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.
75792396|NCT03938194|Procedure|Aquablation|a novel minimally invasive water ablation therapy combining image guidance and robotics for the targeted and heat-free removal of prostate tissue
75792397|NCT01073423|Behavioral|Music Therapy|1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.
75792398|NCT01073423|Behavioral|Yoga|1-hour yoga sessions administered in group format 3 times per week for 8 weeks
75928775|NCT05351346|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
76084159|NCT03356730|Drug|Vitamin D|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months."
76084160|NCT03356730|Other|Placebo|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo.~Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows:~• 10 drops per day for two months."
75335079|NCT00002386|Drug|Stavudine|
75335080|NCT00002386|Drug|Zidovudine|
75335081|NCT00002386|Drug|Zalcitabine|
75335082|NCT00002386|Drug|Didanosine|
75335083|NCT01942694|Dietary Supplement|Vitamin D (Cholecalciferol)|Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
75335084|NCT01942694|Other|Placebo|Administered as one soft-gel pill daily by mouth
75335085|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
75335086|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
75644422|NCT04290572|Drug|Isotretinoin capsules|Jelly capsules of isotretinoin
75335087|NCT01153711|Drug|Ketoconazole|400 mg tablet
75335088|NCT01153711|Drug|Ketoconazole|400 mg tablet
75335089|NCT02168855|Drug|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
75792399|NCT03131596|Procedure|IUB dilatation therapy|A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
76084161|NCT03354702|Other|Aerobic|Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
75335090|NCT02168855|Behavioral|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
75335091|NCT01938326|Procedure|Approach Method|SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
75335092|NCT05751850|Drug|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
75335093|NCT05751850|Drug|nab-paclitaxel; gemcitabine|nab-paclitaxel in combination with gemcitabine
75335094|NCT02168933|Device|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
75928776|NCT05351346|Drug|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
75928777|NCT05351346|Drug|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
75928778|NCT05351346|Drug|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
75928779|NCT05350904|Other|Hybrid of telehealth and in-person physical therapy services|The experimental group will receive a hybrid of telehealth and in-person physical therapy services to address an in-home functional skill in children with moderate to severe disability.
75644423|NCT04098562|Drug|LL37|cream
75644424|NCT04098562|Procedure|Standard Wound Care|Standard wound debridement
75644425|NCT04069429|Radiation|Computerized Tomography scan|imaging scan from a person's eyes to their thighs
75644426|NCT04069429|Radiation|Single Photon Emission Computed Tomography scans|imaging scan taken during, and after, the administration of the radioactive agent
75644427|NCT04069429|Drug|Technetium Tc 99M|subjects are administered radioactive heparin as part of study participation.
75644428|NCT04069429|Radiation|Planar Images|2 dimensional imaging - whole body planar scans
75644429|NCT04069429|Procedure|Esophagogastroduodenoscopy|esophagogastroduodenoscopy with tissue biopsies
75335095|NCT02168933|Device|Sham laser|Sham laser treatment to the control side biweekly for a total of 8 weeks.
75335096|NCT00002230|Drug|Hydroxyurea|
75335097|NCT00002230|Drug|Efavirenz|
75335098|NCT00002230|Drug|Stavudine|
75335099|NCT00002230|Drug|Didanosine|
75335100|NCT01239511|Drug|green tea polyphenols (STA-2)|2 capsules t.i.d., after meal
75472436|NCT01958255|Behavioral|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
75472437|NCT01958268|Procedure|Pretest and validation of a translated questionnaire|
75928780|NCT05327322|Behavioral|Glycemic load|Participants will be provided food to meet GL prescription for the duration of the trial.
75792400|NCT01218360|Drug|Physician standard-of-care|Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
75928781|NCT05327322|Behavioral|Calorie restriction|Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).
75928782|NCT05327322|Behavioral|Behavioral support|All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
75928783|NCT05323279|Device|artificial intelligence assistance system|The artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed and feedback the overspeed percentage.
75928784|NCT05323019|Behavioral|Psychotherapy|Participants will receive 8 remote therapy sessions conducted via phone or video, Therapy sessions consists of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participant. Participants will also receive supportive text messages on selected days during the 28 day study.
75928785|NCT05323019|Behavioral|Treatment as Usual|Participants will continue to receive the therapy that their treating physician felt was appropriate at the time of enrolment in the study, These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical exercise or relaxation.
75928786|NCT05323019|Drug|Intranasal Ketamine (esketamine)|Intranasal Ketamine (esketamine) - participants will receive a dose of 56 mg for a maximum of 2 weeks, followed by 56 mg or 84 twice a week for a total of 8 doses during the 28 -day study
75928787|NCT05319821|Behavioral|Receive ECHO training|Active Intervention
76084162|NCT03354702|Other|Stretching|Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
75335101|NCT05751772|Other|Patient therapeutic education|"The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes:~Targeted education on patient needs related to heart failure, heart failure medications and self-care;~a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan;~a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care)."
75335102|NCT03009877|Device|Optiflow F&P 850™ System|"Optiflow™ (Fisher & Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction."
75644430|NCT04290650|Behavioral|Modified CBT for insomnia|Nurses who are working closely with the patients around the clock will perform an adjusted and modified version of CBT for sleep disturbances, in addition to standard evidence based treatment for psychosis and affective disorders as per today.
75644431|NCT04290650|Behavioral|Treatment as usual|All patients on the two other psychosis wards will receive standard evidence based treatment for psychosis and affective disorders as per today.
75644432|NCT02572999|Procedure|Not applicable (observational design)|
75792401|NCT03816202|Device|Sundt carotid shunt|The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.
75792402|NCT03934476|Behavioral|Ketogenic diet|The study subjects randomized for this intervention will observe the ketogenic diet, as prescribed by the protocol.
75792403|NCT03934476|Behavioral|Exercise HIIT|The study subjects randomized for this intervention will observe the HIIT exercise programme, as prescribed by the protocol.
75792404|NCT03163732|Genetic|Blood and tumor samples|Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel
75792405|NCT01123824|Drug|CLOPIDOGREL|"Pharmaceutical form: tablets~Route of administration: oral"
75792406|NCT01123824|Drug|placebo|"Pharmaceutical form: matching tablets~Route of administration: oral"
75792407|NCT03093688|Biological|Infusion of iNKT cells and CD8+T cells|The eligible patients receive twice infusions of iNKT cells(1E8~1E10) and CD8+T cells(1E7~1E9) in one course of treatment.
75792408|NCT01126086|Drug|otamixaban XRP0673|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
75792409|NCT03936114|Behavioral|SMART|SMART program mindfulness training program
75928788|NCT05319821|Behavioral|Offered ECHO training in year 5|Delayed Intervention
75928789|NCT05315453|Behavioral|Brief Cognitive Rehabilitation|5-session Cognitive Rehabilitation intervention that can be administered over telehealth.
75928790|NCT05313555|Device|Ultraviolet Light (UV-B)|This control group will receive a UV-B exposure as a positive control. Participants will have punch biopsies after exposure.
75928791|NCT05313555|Device|Ultraviolet lights (UV-C)|Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will choose, based on availability, to be in groups that deliver 1 cycle, 10 cycles, 15 cycles or 25 cycles of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.
76084163|NCT03364998|Drug|Damoctocog (Jivi, BAY94-9027)|60 international units (IU)/kg, given as a 10 minute injection, 1 dose
76084164|NCT03364998|Drug|Elocta|60 IU/kg, given as a 10 minute injection, 1 dose
76084165|NCT03356418|Other|WBV exercise group|The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
76084166|NCT03356418|Other|Sham WBV exercise group|The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
76084167|NCT04520022|Drug|Human Umbilical Cord Blood-derived Mesenchymal Stem Cells|3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks
76084168|NCT04520334|Other|Zhineng Qigong intervention|"The intervention consisted of group activities which were performed in one group, as lectures, demonstrations, and Zhineng Qigong training, all planned and led by European Zhineng Qigong.~The group activities were performed during four weekends (12 hours each) and weekly training two times per week (each for two hours). Introductory lecture (two hours) was given at the evening before the first weekend. The respondents were recommended daily Zhineng Qigong training with help of an instructional training CD."
75472438|NCT01958333|Procedure|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
75792410|NCT01361152|Device|anatomic modular fixed-bearing|anatomic modular (AMK; DePuy) fixed-bearing prosthesis
75335103|NCT03009877|Device|facemask|We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
75335104|NCT03009877|Drug|Rocuronium|Rocuronium will be administered after the ability to mask ventilate is determined.
75335105|NCT03009877|Drug|Propofol|Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
75335106|NCT03009877|Drug|Fentanyl|Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
75335107|NCT03009877|Drug|Midazolam|midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
75335108|NCT03009877|Device|C-MAC Premium Video Intubation Platform-KARL STORZ|After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
75335109|NCT00002392|Drug|Thalidomide|
75335110|NCT00002398|Drug|Levocarnitine|
75644433|NCT04068025|Other|Assigned Interventions|"Information: In the information step of the bladder training program given through the IMB model, training was given about pelvic floor muscle exercises, bladder program formation, and lifestyle change. The training was conducted face-to-face by the nurse researcher for about 15-20 min, and the training booklet was given to the patients.~Motivation: The patients in the intervention group were interviewed by the nurse researcher by phone or face-to-face in the 1st, 3rd, and 6th months after the training. The patients were motivated by providing information and counseling on the necessary issues. This process was carried out using motivational interviewing principles. Patients were given positive behavioral feedback and encouraged to control urinary incontinence.~Behavioral Skills: Behavioral skills related to urinary incontinence were evaluated 6 months after the training,together with their effects on urinary incontinence symptom score and quality of life."
75792411|NCT01361152|Device|low contact stress rotating platform mobile-bearing|low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
75792412|NCT03934242|Other|Questionnaire on new born's bedding|Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
75928792|NCT05300100|Behavioral|sensorimotor activities|"The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests.~Trial 1 : Straightening: passage from sitting to sitting.~Trial 2 : Movement with difficulty of balance: heel-toe walking~Trial 3 : Movement with difficulty of balance with a structured visual environment: heel-toe walk in a contrasting fabric decoration to increase the impact of visual flow~Trial 4 : Move to a target, 5 m away~Trial 5 : Graphics: drawing of a tree. This test requires spatial skills and the establishment of median space in written transcription.~Trial 6 : Manual entry: collection of 12 small cubes arranged in an arc in front of the child using one hand, the choice of which will be left to the child.~All of these tests will be offered according to a so-called interlaced protocol, that is to say, each execution of an action will be followed by an action simulation, and this alternation will be repeated 5 times for each task. ."
75928793|NCT05297877|Other|Experimental AI Echo Machine|Participants will go through the training programme using an AI machine for learning.
75792413|NCT03635008|Device|tDCS|Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
75928794|NCT05297877|Other|Conventional Echo Machine|Participants will go through the training programme using a conventional machine for learning.
75928795|NCT05284877|Other|No intervention|The study is an observational study without intervention.
76084169|NCT04508946|Drug|vitamin c - thiamine- hydrocortisone|Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
76084170|NCT03364842|Drug|Furosemide|Administering furosemide
76084171|NCT04443972|Other|PD VitalOs cement®|PD VitalOs cement®* is a synthetic bone grafting cement designed for bone void filling and bone regeneration in dental surgery
76084172|NCT04443972|Other|Hydroxyapatite bone graft|a bioceramic bone substitute, providing a scaffold for bone deposition
76084173|NCT04443972|Other|biodegardable collagen membrane|provide efficacious barriers that were interposed between the flap and root surface.
75792414|NCT01126164|Behavioral|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
75792415|NCT01361230|Device|"Sedation Trial Monitor is the name of the device used."|This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
75792416|NCT03009838|Drug|Letrozole|oral tablets 2.5 mg
75792417|NCT03009838|Procedure|ovarian drilling|laparoscopic electrocauterization
76084174|NCT03356184|Device|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
75335111|NCT00002398|Drug|Adefovir dipivoxil|
75472439|NCT01958333|Procedure|Exercise 2|Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
75472440|NCT01958333|Procedure|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
76084175|NCT03356184|Device|The Earlysense System Device Group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
75644434|NCT00755716|Drug|Placebo (sugar pill)|patients receive
75792418|NCT01215552|Drug|HT-0712|A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
75792419|NCT01123902|Device|hand-held fan|Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.
76084176|NCT03364764|Drug|Sirolimus|On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
76084177|NCT02519400|Drug|Amitriptyline|Single oral dosing
75335112|NCT00997139|Drug|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
75335113|NCT00002236|Drug|Indinavir sulfate|
75792420|NCT01123902|Device|wristband|Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.
75792421|NCT01215630|Behavioral|Aerobic Interval Training|One interval training session
75792422|NCT01375894|Device|"imitation assessment using the 5-dt data glove."|measuring the speed of the hand during imitation
75792423|NCT01124058|Drug|warfarin|"Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose)."
75335114|NCT00002236|Drug|Delavirdine mesylate|
75335115|NCT00002236|Drug|Zidovudine|
75335116|NCT01241539|Drug|Dabigatran etexilate|150 mg capsule
75335117|NCT01241539|Drug|Dabigatran etexilate|75 mg capsule
75335118|NCT01241539|Drug|Dabigatran etexilate|110 mg capsule
75335119|NCT00002404|Drug|Valacyclovir hydrochloride|
75335120|NCT01242241|Drug|Propofol|Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
75644435|NCT00755716|Drug|Topiramate|25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
76084178|NCT02518542|Procedure|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
75792424|NCT01124058|Drug|Warfarin|"Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR."
75792425|NCT01375972|Drug|S-1 plus cisplatin|S-1 40 mg/m2 D1-D14 Cisplatin 60 mg/m2 D1 every 3 weeks
76084179|NCT02518542|Procedure|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
76084180|NCT02518542|Procedure|Endoscopic intervention C|Endoscopic balloon dilatation
75335121|NCT01242241|Drug|Propofol|This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
75335122|NCT00002248|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
75335123|NCT04962113|Other|TUBE BATH|Wrap Tube Baht (immersion)
75644436|NCT00755716|Drug|Nicotine patch|On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
75644437|NCT00629252|Drug|Sertindole|oral 12-20 mg/day
75644438|NCT00629252|Drug|Risperidone|oral 2-6mg / day
75644439|NCT04290338|Other|PIOMI|Intraoral and extraoral stimulation.
75644440|NCT04067167|Other|WB-EMS (Sham-intervention)|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS with low-threshold stimulation during a study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
75792426|NCT01375972|Drug|Gemcitabine plus Cisplatin|Gemcitabine 1000 mg/m2 IV D1, D8 Cisplatin 60 mg/m2 IV D1 Every 3 weeks
75792427|NCT03933150|Device|ultrasound guided caudal epidural injection|"A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor"
76084181|NCT02518542|Procedure|Laparoscopic Surgery|Laparoscopic Heller myotomy
75335124|NCT02393690|Radiation|Iodine I-131|Given PO
75335125|NCT02393690|Other|Placebo Administration|Given PO
75335126|NCT02393690|Drug|Selumetinib|Given PO
75335127|NCT05751616|Other|Laminate veneers with speed sintering|Zirconia specimens will be sintered using speed sintering cycle in a conventional furnace according to the manufacturer instructions.
75335128|NCT05751616|Other|Laminate veneers with conventional sintering|Zirconia specimens will be sintered using conventional sintering cycle in a conventional furnace according to the manufacturer instructions.
75335129|NCT05593679|Diagnostic Test|Tc-99m PYP Cardiac scan|Tc-99m PYP Cardiac scan
75792428|NCT05129644|Drug|P1101 (24 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.
75792429|NCT05129644|Drug|P1101 (48 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
75792430|NCT05129644|Drug|P1101 (90 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.
75928796|NCT05284071|Device|Device: Actiste 1.0 and the Companion app with TBL Backend|Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.
75928797|NCT05278949|Other|The surgical intervention|The participant's primary IOL is re-fixed without utilizing any new material.
75928798|NCT05276258|Device|cryoSPHERE Ablation|The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.
75928799|NCT05276258|Drug|Bupivacaine|A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
75928800|NCT05275946|Drug|Targeted alpha therapy|Single intravenous administration
75335130|NCT02189161|Device|Radiofrequency Ablation (Barrx™)|Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
75928801|NCT05275218|Procedure|Implementation of the KDIGO bundle)|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"
75335131|NCT02246959|Behavioral|Process Incentive|Daily sweepstake conditional on daily medication adherence
75335132|NCT02246959|Behavioral|Outcome Incentive|Incentives conditional on LDL cholesterol reduction
75335133|NCT04788953|Drug|Solriamfetol Oral Tablet|The administered drug is SUNOSI (solriamfetol) tablets for oral use. Initial U.S. Approval: 2019
75928802|NCT06145152|Procedure|Adaptive exercise training|The training recommendation for the day will be adjusted based on the readiness level. The adjustments can be both up or down (increased or decreased training)
75928803|NCT06145152|Procedure|Static exercise training|The training recommendation for the day will not be adjusted based on the readiness level.
75928804|NCT06145126|Other|Prednisolone|Predisolone is used as a tool to elicit a physiological response (toolbox trial) and not as a pharmaceutical agent/treatment.
75928805|NCT06145126|Other|Placebo|Placebo to predinisolon
75472441|NCT01958359|Behavioral|Short IVR|IVR-based alcohol diary with feedback
75472442|NCT01958359|Behavioral|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
75335134|NCT04788953|Drug|Placebo|Control subjects will receive placebo tablets for oral use.
75335135|NCT05751538|Other|No intervention|No intervention
75335136|NCT05593211|Device|Kronos Electrocautery Device|The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition
75472443|NCT01958372|Dietary Supplement|soy isoflavones|Given PO
75472444|NCT01958372|Drug|cisplatin|Given IV
75472445|NCT01958372|Drug|etoposide|Given IV
75472446|NCT01958372|Drug|pemetrexed disodium|Given IV
75472447|NCT01958372|Radiation|radiation therapy|Undergo RT
75472448|NCT01958385|Device|placement of g-Cath EZ suture anchors|
75472449|NCT01958385|Procedure|Sham procedure|
75472450|NCT01958385|Behavioral|Diet and Exercise|A structured diet and exercise plan
75472451|NCT01958398|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback.
75792431|NCT05129644|Drug|P1101 (180 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.
75792432|NCT05129644|Drug|P1101 (225 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.
75792433|NCT05129644|Drug|P1101 (270 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
75792434|NCT05129644|Drug|Pegasys|Pegasys for injection, 180 mcg/mL, 1.0 mL/vial, Dose/subject: 180 mcg subcutaneously.
75644441|NCT04067167|Other|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
75792435|NCT01220544|Biological|Haploidentical transplantation with donor NK cells|Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain > 8 x 10e6 CD34+ cells/kg and < 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
75792436|NCT00255047|Biological|DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|0.5 mL, Intramuscular
75792437|NCT00255047|Biological|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
75644442|NCT04067167|Other|Free WB-EMS|"Whole-Body Electromyostimulation (WB-EMS) using a mobile system:~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
75792438|NCT00255047|Biological|DTaP-IPV and ActHIB®|0.5 mL, Intramuscular
75792439|NCT00255047|Biological|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
75792440|NCT01220622|Drug|Nimodipine|Administration of nimodipine 30mg tid for 6 months
75792441|NCT01220622|Drug|Placebo|Administration of placebo 30mg tid for 6 months
75792442|NCT05123170|Drug|Dexmedetomidine Injectable Solution [Dexdomitor]|two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries
75928806|NCT06145113|Device|Continuous positive airway pressure (CPAP), ResMed AirMini|Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.
75792443|NCT05123170|Drug|Lidocaine IV|Intravenous regional anaesthesia
75928807|NCT06145100|Diagnostic Test|Ultrasound including color doppler ultrasound|Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.
75644443|NCT04067167|Other|Flexi band resistance training|"Flexi band resistance Training:~Training during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~patients perform resistance exercises using flexi bands~flexi band exercises are conceptualized to activate similar muscle groups as EMS exercise~time-effort per session: ~20 min~2 training sessions per week"
75644444|NCT04093726|Other|lollipop|chewing lollipop for 20min
75928808|NCT06145087|Dietary Supplement|"NOVOS Core supplement"|The supplement mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee once per day.
75335137|NCT01200433|Drug|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
75644445|NCT02866994|Behavioral|Project Connect Online|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family
75644446|NCT02866994|Behavioral|PCO PLUS|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
75335138|NCT01200433|Drug|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
75644447|NCT02572531|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge three times daily for 2 weeks
75644448|NCT02572531|Dietary Supplement|Placebo|Ingestion of placebo lozenge three times daily for 2 weeks
75792444|NCT01215708|Drug|Tamsulosin|tamsulosin 0,4mg every night for 30 consecutive days
75792445|NCT05114278|Drug|Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
75928809|NCT06145087|Dietary Supplement|Placebo|The placebo mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee.
75928810|NCT06145074|Drug|Propranolol|Oral administration.
75928811|NCT06145074|Drug|Placebo|Oral administration.
75936416|NCT05272085|Procedure|Ultrasound Guided Lavage|After local anesthesia of subcutaneous tissue, lavage will be performed under the guidance of ultrasound using an 18-gauge needle with injectors filled with 4 ml of saline. The needle will be advanced to the center of the calcific deposit. The injector will be kept as parallel to the ground as possible. The plunger of the injector will be pushed with a gently pressure and then released. Calcific deposits are expected to be filled into the syringe along with saline. It is predicted that the clear saline will gradually turn white and become cloudy due to the incoming calcific deposits. When the color of the liquid becomes cloudy, the syringe will be removed without moving the needle, and a new syringe containing 4 ml saline will be placed in its place. Thus, the aspirated calcific deposits will not be reinjected. The same process will be repeated with a new saline filled syringe. After the procedure, 2 ml dexamethasone and 3 ml lidocaine will be injected in subacromial bursa.
75335139|NCT02973022|Other|CC&S|Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
75335140|NCT04755686|Procedure|Fast-tracking|
75792446|NCT05114278|Drug|oral iron|All patients will receive an oral iron supplementation (100mg/day).
75928812|NCT06145061|Device|all patients and healthy people will receive at least 3 infrared thermal imaging examinations of acupoints and pain threshold examinations of acupoints.|Infrared thermal imaging detection scheme of acupoints:Detection equipment NEC R550 infrared thermal imager.Records the corresponding acupoints coordinates,and starts to collect the infrared thermal image.and 6 images will be taken continuously for each detected part.The infrared thermograms were stored and extract the temperature values of the corresponding coordinates of the acupoints.The average temperature values of the acupoints in the six infrared thermograms were calculated as their temperatures.Pain threshold detection scheme of acupoints:The instrument and equipment use the FDX25 hand-held pain threshold test instrument to explore the acupoints.Place the probe of the pain measuring instrument vertically on the pain measuring acupoint, slowly and steadily press downward at a constant speed, and stop pressing immediately when the subject begins to feel pain. At this point, the reading on the display is the subject's pain threshold. All acupoints shall be measured once in total.
75928813|NCT06145035|Biological|umbilical cord-derived mesenchymal stromal cells (UC-MSCs)|The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 1.6 million cells/min. The product will be infused into vein via intravenous line placed in the arm.
75644449|NCT04096144|Drug|Neuromuscular Blocking Agents|Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
75928814|NCT06145022|Behavioral|lifestyle modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and mind / body medicine. In this project, this program will be adapted to the specific needs of irritable bowel syndrome patients.
75644450|NCT02866604|Procedure|Sterofundin|
75792447|NCT01222026|Drug|Strontium Ranelate + Ca/Vitamin-D|2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D
75928815|NCT06145022|Behavioral|waitlist control group|Participants in this group receive a one-time education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
75928816|NCT06145009|Behavioral|Time restricted eating|Limit food intake to 10 hours per day as described in the experimental arm section.
76084182|NCT04518696|Procedure|suprachoroidal buckling|"Location, marking and freezing of the retinal tear on the scleral side . Subretinal fluid is released from the outside of the sclera as needed. In the quadrant of the retinal tear, the spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. After the choroid was exposed, a pocket is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube . The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Once confirmed in accord with the needle position, sodium hyaluronate injection, usually need 0.2 mL to 0.5 mL, application of anterior chamber puncture or subretinal fluid stable intraocular pressure. Exit the duct and close the incision with scleral presutures."
76084183|NCT04509258|Drug|N-acetyl cysteine|a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care
76084184|NCT04509258|Dietary Supplement|acetyl L-carnitine|Naturallu occuring amino acid derivative which can be taken as a dietary supplement involves in mitochondrial function and energy production and is suggested to have a role in lowering organ damage resulting from aluminium phosphide poisonong in addition to sodium bicarbonate and ondansetron as standard of care
75335141|NCT00002410|Drug|Indinavir sulfate|
75335142|NCT00002410|Drug|Lamivudine|
75644451|NCT02866604|Procedure|0.9% saline|
75644452|NCT00722995|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
75644453|NCT00722995|Procedure|Gastric Bypass|Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
75644454|NCT04095754|Procedure|Head-Up Position|Anti-Trendelenburg Position
75644455|NCT04095754|Drug|Dexmedetomidine|Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
75792448|NCT01222026|Drug|Placebo|Placebo 1000mg Calcium 800 IE Vitamin-D
75792449|NCT05095168|Drug|CAN106|CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.
75792450|NCT05095168|Drug|Placebo|placebo
75792451|NCT00225251|Drug|bupropion XL|Antidepressant medication
75335143|NCT00002410|Drug|Zidovudine|
75335144|NCT01894880|Procedure|early SSC|bonding straight after birth
75335145|NCT01894880|Procedure|late SSC|bonding after termination of operation
75335146|NCT01243333|Radiation|[F-18]fluorodeoxyglucose|Undergo PET scans with [F-18]fluorodeoxyglucose
75792452|NCT00225251|Other|Placebo|Placebo
75792453|NCT01220700|Other|Triclosane|Triclosane coated suture material
75792454|NCT01220700|Other|Control|Ordinary suture material
75792455|NCT01376128|Drug|Paroxetine|
75792456|NCT01220778|Behavioral|Exercise|
75792457|NCT01126242|Device|Tape|Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
75928817|NCT06144983|Drug|Alvogyl|In the first study group, (0.2gm) of Alvogyl paste (Septodont Inc., France), was inserted inside the alveolus, filling it entirely
75644456|NCT04095754|Drug|Induction and maintenance of anaesthesia|"Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim."
75644457|NCT00755326|Drug|HLXL|Two daily dosages will be investigated. Huo-Luo-Xiao-Ling (HLXL) dose (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/ day) for the subsequent 6 weeks.
75644458|NCT00720265|Drug|Prograf|oral
75644459|NCT00720265|Drug|MR4|oral
76084185|NCT04509258|Drug|medicated paraffin oil|refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care
76084186|NCT04509258|Drug|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
75335147|NCT01243333|Radiation|[F-18]fluorothymidine|Undergo PET scans with fluorine [F-18]fluorothymidine
75644460|NCT02600650|Dietary Supplement|Testosterone boosting supplement|Proprietary formulation of Testosterone boosting supplement administered daily
75644461|NCT02600650|Dietary Supplement|Placebo Comparator|Daily administration of Placebo Comparator
75644462|NCT03084471|Biological|MEDI4736 (Durvalumab)|A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).
75792458|NCT01126242|Device|Semi rigid brace|Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
75792459|NCT01126242|Device|Lace-up brace|Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
75644463|NCT03084471|Biological|MEDI4736 (Durvalumab) + Tremelimumab|"Durvalumab: A human mAb of IgG 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on IC.~Tremelimumab: A human Ig G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation [CD]152) with CD80 and CD86 and increase release of cytokines (interleukin [IL]-2 and interferon [IFN]-γ) from human T cells, peripheral blood mononuclear cells and whole blood."
76084187|NCT03354624|Drug|Sterile solutions of recombinant human nerve growth factor (NGF)|The intramuscular injections of NGF cause muscle soreness.
76084188|NCT03354546|Diagnostic Test|Frailty index|A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
75644464|NCT00723151|Behavioral|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
75792460|NCT00254501|Behavioral|Pharmacist Counseling|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
75928818|NCT06144983|Drug|Chlorhexidine Gluconate|in the second group (1ml) of Periokin (Kin Inc., Spain), containing 0.2% Chlorhexidine bioadhesive gel was injected to fill the entire socket
75792461|NCT00254501|Behavioral|Educational materials|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
75792462|NCT05045716|Drug|Lecanemab|Lecanemab IV infusion.
75792463|NCT05045716|Drug|Lecanemab|Lecanemab SC injection.
75928819|NCT06144970|Biological|TG-C High Dose|High Dose - 1 mL of the combined TG-C cells
75928820|NCT06144970|Biological|TG-C Mid Dose|Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
75928821|NCT06144970|Biological|TG-C Low Dose|Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
75928822|NCT06144970|Biological|Sham Control|Single subcutaneous injection of normal saline
76084189|NCT03354468|Behavioral|fall prevention program|fall prevention program in orthopedic department, consisting of 1) Seven examples of risk factors which might cause falls (diseases and medications, movement, cognitive behavior, vision, continence, nutrition, and the room and surroundings), 2) Methods to detect the risk factors, and 3) Measures to avoid falls or protect the patient in case of a fall.
76084190|NCT03355950|Procedure|Lichtenstein Repair|Well defined Lichtenstein Repair for inguinal hernias
76084191|NCT03355950|Procedure|TEP Repair|Laparoscopic totally extraperitoneal repair for inguianal hernias
76084192|NCT03364374|Behavioral|Postural counseling|A therapist will provide verbal/physical cues to improve the participants posture
76084193|NCT03364218|Drug|N-Acetyl Cysteine|Nebulized N-Acetyl Cysteine administered every 12 hours
75335148|NCT01243333|Procedure|Positron Emission Tomography|Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
75335149|NCT01243333|Radiation|Water O-15|Undergo PET scans with water O-15 tracers
75651892|NCT04980677|Device|Tangiball|"To enable baseline scores comparison, children will be matched according to age and score on the four-strand Hands-On assessment tool which takes 30 minutes to complete. Children will then play with the Smart Toy during a 20 minute session. Sessions will be recorded using an SD card within the Smart Toy which captures information on user speed and accuracy of placement of the detachable segments of the toy when placed into the main hub of the toy, allowing comparison between neuro-typical children and children with Autism. The intervention will run either in clinic (preferred option) or in children's homes-and in this case will be sent to them via post with the Standard Operating Procedure which can then be employed when children are taking part in the intervention via online video link (not recorded)."
75792464|NCT03934008|Other|MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE)|The MOTIVE tool incorporates the principles of motivational interviewing (MI) and provides a flowchart approach in which parental health beliefs have a corresponding MI-based strategy to further explore and/or address the hesitancy. The tool was developed from interviews with pediatricians and pediatric pharmacists, a review of the literature focusing on vaccine health beliefs, and the Parent Attitudes about Childhood Vaccines (PACV) Survey Tool. The tool was reviewed by multiple providers and feedback was provided on its usability in clinical practice when interacting with vaccine-hesitant parents and/or caregivers. The tool was then modified based on this feedback. Pediatric providers will complete four educational sessions on vaccine hesitancy, MI, and the use of the MOTIVE tool in clinical practice prior implementation.
75792465|NCT01376206|Drug|Fluticasone|Collection of safety data
75928823|NCT06144931|Procedure|PENG Block|With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer then slides medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks. Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a standard 22 gauge spinal needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 20 ml 0.25% bupivacaine diluted with preservative free normal saline then deposited in this plane, lifting the psoas tendon. Care should be taken to avoid puncturing the psoas tendon.
76084194|NCT04444284|Biological|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
75335150|NCT05593133|Other|Pnf exercises|"PNF techniques will comprise of Warm up, Rhythmic stabilization, Hold Relax, Contract Relax and light exercises and performed on three muscle groups ( Hamstring, Quad and Calf).~20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks."
75472452|NCT01958398|Behavioral|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
75792466|NCT03932058|Drug|Chemotherapy|all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
75792467|NCT01073501|Drug|Pregabalin|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
75792468|NCT01073501|Drug|Placebo|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
75792469|NCT03972059|Other|Exercise training - Phase 1|Phase 1 is the first 4 weeks of the 12-week training program.
75792470|NCT03972059|Other|Exercise training - Phase 2|Phase 2 is the next 4 weeks following phase 1 of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in phase 1.
75928824|NCT06144918|Drug|SBI-100 Ophthalmic Emulsion, 0.5%|0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
76084195|NCT04444284|Biological|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
76084196|NCT04444284|Other|Placebo|Single dose administered intranasally on Day 1
76084197|NCT04444284|Biological|Investigational RSV vaccine MV-012-968 (Dosage 3)|Single dose administered intranasally on Day 1
75335151|NCT05593133|Other|Gait training exercises|gait Training exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking. 20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
75335152|NCT01924052|Drug|CGRP|Calcitonin-gene-related-peptide (CGRP)
75335153|NCT00002416|Drug|Emtricitabine|
75335154|NCT00002416|Drug|Lamivudine|
75335155|NCT00381394|Drug|sitamaquine|
75472453|NCT01958450|Procedure|Er:YAG laser|acne scar treatment using Er:YAG laser
75472454|NCT01958450|Procedure|Bipolar radiofrequency with diode laser|acne scar treatment with bipolar radiofrequency combined with diode laser
75335156|NCT00002254|Drug|Alovudine|
75335157|NCT01243567|Drug|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
75335158|NCT01243567|Drug|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
75335159|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
75472455|NCT01958463|Procedure|Fecal Microbiota transplantation.|Fecal Microbiota transplantation during colonoscopy.
75472456|NCT01958502|Genetic|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
75651893|NCT04970875|Other|Questionnaire|QoL questionnaire
75335160|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
75335161|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
75792471|NCT03972059|Other|Exercise training - Phase 3|Phase 3 is the last 4 weeks of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in the previous phases.
75792472|NCT01222182|Drug|atorvastatin|All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
75928825|NCT06144918|Drug|SBI-100 Ophthalmic Emulsion, 1.0%|1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
75335162|NCT01001195|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
75792473|NCT03633682|Behavioral|Headspace - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
75792474|NCT03633682|Behavioral|Stop, Breathe, & Think - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, & Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
75644465|NCT04095910|Behavioral|Planet Nutrition program|"- Nutritional education sessions: The study team previously worked on the development of a handbook called Planet Nutrition which contains around 26 topics of nutrition and health. Interns from the Nutritional Sciences Degree of the University of Sonora implemented the sessions. 2 classes of 1 hour were given weekly, adding 18 sessions in total, during regular school hours. The program contemplates the establishment of different objectives.~- Physical activity: The classes were designed and implemented by interns from the Bachelor of Physical Culture and Sport from the University of Sonora along with a teacher from the study team. 3 weekly sessions of 1 hour were provided. The activities were held on the schoolyard court during normal school hours, independent of the physical activity classes of the school.~- Indirect family participation: Six information brochures with different nutrition and health topics were sent to parents."
75644466|NCT00718471|Drug|Enoxaparin|ENOXAPARIN IV 0.5 mg.kg
75928826|NCT06144918|Drug|SBI-100 Ophthalmic Emulsion, Placebo|Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
75928827|NCT06144905|Other|standard care treatment program|The standard care treatment consists of a program of psychotherapy and nutritional rehabilitation to achieve normalization of food-intake and weight gain.
75928828|NCT06144892|Device|Proactive Therapy|Uses AI to make predictions and preventions of future apneic events.
75928829|NCT06144879|Procedure|double rods without dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with traditional double rods (No dual-headed screw used)
75928830|NCT06144879|Procedure|three rods with one dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with three rods (one dual-headed screw used in unilateral side)
75928831|NCT06144879|Procedure|four rods with two dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with four rods (two dual-headed screw used in bilateral side)
75928832|NCT06144853|Other|scan|Fluorodeoxyglucose (FDG)-positron emission tomography/Computed tomography scan
75928833|NCT06144814|Drug|Hyaluronic acid vaginal gel|. Group II received 5 mg of vaginal hyaluronic acid every day for 14 days, then 2 days a week for the next 2 weeks. Hyaluronic acid gel for vaginal use was supplied by ORTHOGEN®. The treatment period lasted 1 month in both groups.
75335163|NCT00381472|Drug|Ropinirole|
75335164|NCT02185729|Drug|Intralipid|Infusion of Intralipid (soybean-derived fat)
75335165|NCT02185729|Drug|ClinOleic|Infusion of ClinOleic (olive oil-based)
75335166|NCT02185729|Drug|Dextrose|Infusion of dextrose (sugar) without fat
75335167|NCT02185729|Other|Saline (control)|Infusion of 0.9% normal saline
76084198|NCT03354312|Drug|Lidocaine Hydrochloride 1% Gel|Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
75335168|NCT01001975|Drug|Sunscreen Test Code: V53-028|Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
75335169|NCT01001975|Drug|Sunscreen Test Code: V53-030|Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
75335170|NCT01001975|Drug|Standard SPF 4 Sunscreen|8% Homosalate Standard SPF 4 Sunscreen
75335171|NCT05751460|Other|Straight leg raise|Diagnostic test, tool for *g*
75335172|NCT01201057|Drug|0.5% SPL7013 Gel|Vaginal gel
75644467|NCT00718471|Drug|UFH (unfractionated heparin)|UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
75644468|NCT00916708|Procedure|Intensive/Low-Risk follow up (IA G1; IA G2)|"- First 2 years of FU since the end of primary treatment: clinical visit* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months~- Since the third to the fifth year of FU: clinical visit* every 6 months; Pap test every 12 months~* clinical visit with gynecological exploration"
76084199|NCT03354312|Drug|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride|Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
76084200|NCT03354234|Other|Head up tilt (HUT)|Model of -Gz: HUT up to 75 degrees (maximum)
76084201|NCT03354234|Other|Lower body negative pressure (LBNP)|Model of -Gz: LBNP down to -100 mmHg (maximum)
75644469|NCT00916708|Procedure|Intensive/High-Risk follow up (≥ IA G3)|"- First 3 years of FU since the end of primary treatment: clinical visit*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months~- In the fourth and fifth years of FU: clinical visit*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months~* clinical visit with gynecological exploration"
75335173|NCT01201057|Drug|1.0% SPL7013 Gel|Vaginal gel
75335174|NCT01201057|Drug|3.0% SPL7013 Gel|Vaginal gel
75335175|NCT01201057|Other|Placebo Gel|Vaginal gel
75335176|NCT00002260|Drug|Alovudine|
75335177|NCT01444040|Device|iStent inject|Implantation of two iStent inject devices
75335178|NCT01444040|Drug|Travoprost|Travoprost drops
75335179|NCT05751382|Device|Surefil one|Restorative material (Dentsply Sirona). Used for direct restoration of class V NCCL.
75644470|NCT00916708|Procedure|Minimalist/Low-Risk follow up (IA G1; IA G2)|"- First 5 years of FU since the end of primary treatment: clinical visit* every 6 months.~* clinical visit with gynecological exploration"
75644471|NCT00916708|Procedure|Minimalist/High-Risk follow up (≥ IA G3)|"- First 2 years of FU since the end of primary treatment: clinical visit* every 4 months; chest, abdomen, pelvis CT every 12 months~- Since the third to the fifth year of surveillance: clinical visit* every 6 months.~* clinical visit with gynecological exploration"
75644472|NCT00723307|Drug|Metformin|White film-coated tablets, 850mg tablet twice daily, 1.5 years duration
75644473|NCT00723307|Drug|Placebo|White coated tablet; one tablet twice daily; 1.5 years duration
75792475|NCT02531789|Other|Observation|C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
76084202|NCT03354234|Other|Head down tilt (HDT)|Model of +Gz: HDT down to -30 degrees (maximum)
76084203|NCT03354234|Device|Tilt table|Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s
76084204|NCT03354234|Device|LBNP chamber|Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
76084205|NCT03364062|Procedure|cemented shoulder replacement|proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
76084206|NCT03363984|Drug|Midazolam|Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times
75335180|NCT05751382|Device|Venus Pearl|Restorative material. Traditional paste composite employed in combination with iBond universal adhesive.
75335181|NCT01002287|Device|SprayShield Adhesion Barrier System|Adhesion Barrier Device
75644474|NCT00723385|Dietary Supplement|Vitamin D (1000 or 2000 IU/day)|Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6
75644475|NCT00723385|Other|Placebo|Administration of placebo for 12 weeks with repeated D measurements
75644476|NCT02684565|Dietary Supplement|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
75792476|NCT01126320|Device|AnapnoGuard 100,|Respiratory guard system during mechanical ventilation with routine mechanical ventilator
75792477|NCT01126320|Device|routine mechanical ventilator|routine mechanical ventilation
75792478|NCT03971981|Dietary Supplement|100% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
75792479|NCT03971981|Dietary Supplement|22% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
76084207|NCT03363984|Drug|ID-082|Administration of ID-082 under fasted conditions/outside of meal times
75335182|NCT01002287|Procedure|Good Surgical Technique Alone|Good Surgical Technique Alone
75335183|NCT04294862|Drug|TNP-2092|TNP-2092 for injection 100mg/vial
75335184|NCT04769791|Device|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
75335185|NCT04769791|Device|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
75335186|NCT04769791|Device|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
75335187|NCT00002266|Drug|AS-101|
75335188|NCT01437176|Device|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
75335189|NCT01437176|Device|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
75335190|NCT05751304|Drug|Dexmedetomidine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg Dexametomidine.
75335191|NCT05751304|Drug|Ketamine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
75335192|NCT01202071|Drug|Rabeprazole sodium, 5 mg Tablets|"Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
75335193|NCT01202071|Drug|Rabeprazole sodium, 10 mg Tablets|"Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
75472457|NCT01958515|Other|research blood draw and tissue biopsy|research blood draw and tissue biopsy
75644477|NCT02684565|Dietary Supplement|BCAA Low Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
75644478|NCT00754936|Drug|Escitalopram|20 mg by mouth daily
75928834|NCT06144814|Drug|Estrogen vaginal use form|Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
75335194|NCT01202071|Drug|Rabeprazole sodium, 20 mg Tablets|"Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
75335195|NCT01202071|Drug|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|"Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, >=2 hours after the completion of breakfast."
75335196|NCT05592821|Procedure|dental implant placement|In both groups, dental implants of the same brand will be placed into the bone with the same protocol.
75644479|NCT02684643|Other|enhanced individualised therapy|additional dialysis dosage, modification of medication and prescribed dietary plan
75335197|NCT00002422|Drug|HE2000|
75335198|NCT00002428|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
75335199|NCT00002428|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
75335200|NCT01422746|Drug|Metformin|500-1000 mg PO BID (X12 weeks)
75335201|NCT00002272|Drug|Foscarnet sodium|
75335202|NCT01002755|Drug|Lenalidomide|Given PO
75644480|NCT02684643|Other|non-enhanced individualised therapy|modified medication, prescribed dietary plan and regular three times/week dialysis dosage
75644481|NCT02684643|Other|regular intervention|Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
75644482|NCT05373667|Procedure|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) - High Frequency at 10 kHz
75644483|NCT04095988|Procedure|Allogeneic microbiota reconstitution|gastroscopic microbiota Infusion (Verum)
75644484|NCT04095988|Procedure|Placebo-Allogeneic microbiota reconstitution|gastroscopic saline Infusion (placebo)
75644485|NCT02684019|Drug|Dexmedetomidine|added to propofol sedation
75335203|NCT01002755|Biological|Ofatumumab|Given IV
75335204|NCT04331314|Device|Use of Symbios Bone Graft Material|Patients will receive Symbios Bone Graft Material according to randomization Group.
75335205|NCT04331314|Device|Algipore Bone Substitution Material|Patients will receive Algipore Bone Substitution Material according to randomization Group.
75335206|NCT01887860|Other|Cetaphil Daily Facial Moisturizer SPF 50|Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
75335207|NCT01003067|Device|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
75335208|NCT00002434|Drug|Trimetrexate glucuronate|
75335209|NCT00002434|Drug|Leucovorin calcium|
75644486|NCT02684019|Drug|Magnesium Sulphate|added to propofol sedation
75644487|NCT00720421|Drug|AZD7325|AZD7325 10 mg oral 2 capsules
75644488|NCT00720421|Drug|AZD7325|AZD7325 1 mg oral 2 capsules
75644489|NCT00720421|Drug|AZD7325|AZD7325 Placebo oral 2 capsules
75644490|NCT00720421|Drug|Lorazepam|Lorazepam 1 mg oral 2 tablets
75644491|NCT00720421|Drug|Lorazepam|Lorazepam Placebo oral 2 tablets
75335210|NCT00002278|Drug|Diclazuril|
75335211|NCT01885130|Other|Cetaphil Daily Advance Ultra Hydrating Lotion|0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
75335212|NCT01003301|Drug|Omalizumab|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
75335213|NCT01003301|Drug|Placebo|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
75335214|NCT00002440|Drug|Indinavir sulfate|
75335215|NCT00002440|Drug|Ritonavir|
75644492|NCT02684175|Device|Remote CI Counseling|The remote setup includes a 500 series teleconference audio and video live set-up. The teleconference set-up will be situated on a telemedicine cart and placed within the sound-proof booth at the testing site (UK ENT practice in Morehead, KY). The audiologist will deliver the session remotely.
75644493|NCT02684175|Other|In-Person CI Counseling|The standard face-to-face counseling that will occur between the participant and audiologist is the standard of care. No technology will be used. The audiologist will deliver the session face-to-face with the participant in the same room (standard practice).
75644494|NCT04068259|Drug|PBI-4547|PBI-4547 tablet
75644495|NCT04068259|Other|Placebo|Placebo tablet
75928835|NCT06144801|Device|CoolSense Group|Patients in the CoolSense group received a CoolSense device that had been pre-chilled in the freezer for a minimum of one hour. The cover of the CoolSense device was removed, and the arteriovenous fistula, whose metal tip had been cleaned with batikon, was brought into contact with the area where the arteriovenous fistula cannulation would occur. This contact was maintained for 5 seconds, involving circular movements, and the fistula cannulation took place promptly.
75928836|NCT06144788|Drug|SGLT2 inhibitor|SGLT 1/2 dual inhibitor
75335216|NCT00002440|Drug|Abacavir sulfate|
75335217|NCT00002440|Drug|Amprenavir|
75335218|NCT00002440|Drug|Nelfinavir mesylate|
75335219|NCT00002440|Drug|Saquinavir|
75335220|NCT01421810|Drug|Dexamethasone|1 mg PO
75335221|NCT01421810|Drug|rhCG|25 mcg IV
75335222|NCT00002284|Drug|Zidovudine|
76084208|NCT03363828|Drug|Estrofem|Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment
75644496|NCT00762502|Device|senofilcon A toric contact lens|soft contact lens
75644497|NCT00762502|Device|balafilcon A toric contact lens|soft contact lens
76084209|NCT04508868|Behavioral|Brief Behavioral Activation with Mental Imagery|"Session 1:~Provide psychoeducation about depression; Provide treatment rationale for BA; Provide rationale and instructions for activity log; Plan activities for coming week.~Session 2:~Review activity log; Discuss life goals and values; Plan activities aligned with life goals and values for coming week; Provide rationale for Mental Imagery (MI); Go through MI-exercise for one of the planned activities.~Session 3:~Review activity log; Troubleshoot any problems carrying out activities; Plan activities aligned with life goals and values for coming week; Go through MI-exercise for one of the planned activities.~Session 4:~Review activity log; Troubleshoot any problems carrying out activities; Review treatment; Stress the importance of continuing to engage in activities aligned with life goals and values; Referral to additional services if necessary."
75335223|NCT01243957|Drug|LY2216684|LY2216684: 18 mg po QD on Days 1, 2, and 3 and Days 25-27
75472458|NCT01958541|Behavioral|Sleep Intervention I|Insomnia-focused behavioral treatment (4 sessions).
76084210|NCT04508868|Behavioral|Minimal Attention Control Intervention|Weekly call with follow-up of psychiatric symptoms and assessment of suicide risk.
76084211|NCT04524468|Diagnostic Test|Transthoracic echocardiography|Conventional 2-D transthoracic echocardiography was performed to all patients
76084212|NCT03354156|Drug|statin treatment|The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
75335224|NCT01243957|Drug|Fluoxetine|Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
75335225|NCT00002446|Drug|Posaconazole|
75335226|NCT00002446|Drug|Fluconazole|
75335227|NCT01895816|Dietary Supplement|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus & ZINGIBER OFFICINALE & Onion & Ocimum basilicum & Cinnamomum zelanicum & Citrullus lanatus & Citrullus vulgaris & Daucus carota
75335228|NCT02979847|Procedure|hybrid approach|Before transseptal puncture, epicardial puncture is performed through subxyphoid approach. Atrial epicardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Endocardial potentials are also recorded in the same fashion. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
75472459|NCT01958541|Behavioral|Sleep Intervention II|Insomnia-focused behavioral treatment (4 sessions).
76084213|NCT03519438|Other|Mepitel|Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
76084214|NCT04444206|Procedure|Transvaginal ultrasound cervical length screening|Cervical lenght and Consistence Cervical Index measurements performed, between 11 and 13 weeks + 6 days, in the , between 19 and 22 weeks and i between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy.
75472460|NCT01958554|Behavioral|Intervention Group|
75472461|NCT01958567|Other|Optical Coherence Tomography|
75644498|NCT02684331|Other|Cardiac Magnetic Resonance Imaging (CMR)|An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
75644499|NCT02684331|Other|Echocardiography|Standard measurements and strain.
75644500|NCT02684331|Other|Bood samples|HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
76084215|NCT04524078|Other|intensive integrated intervention care program|intensive integrated intervention care program [ICP] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
76084216|NCT03355716|Drug|bupivacaine|Bupivacaine 25 ml (0.25%)
76084217|NCT03355716|Drug|morphine|Morphine (3.0 mg)
75644501|NCT00723463|Procedure|3T MRI scan|Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.
75644502|NCT00723541|Procedure|Computer aided analysis of breast lesions|Tomosynthesis mammography and computer aided analysis of breast lesions to aid in detection of breast cancer.
75644503|NCT00762268|Drug|SAMe|"SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
75644504|NCT00762268|Drug|Placebo|
75644505|NCT02689713|Drug|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
75651894|NCT04965753|Drug|FHD-609|FHD-609 as a single, intravenously administered agent given twice-weekly (BIW). Alternative dosing regimens may be evaluated.
76084218|NCT03355716|Drug|fentanyl|fentanyl (30.0 Mc)
76084219|NCT03355716|Drug|Ketamine:|ketamine (0.5 mg/kg).
75335229|NCT02979847|Procedure|conventional endocardial approach|Atrial endocardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
75472462|NCT01958580|Drug|Gemcitabine Hydrochloride|Given IV
75472463|NCT01958580|Drug|Docetaxel|Given IV
75472464|NCT01958580|Radiation|Internal Radiation Therapy|Undergo brachytherapy
75472465|NCT01958580|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75472466|NCT01958580|Radiation|External Beam Radiation Therapy|Undergo EBRT
75472467|NCT01958580|Other|Laboratory Biomarker Analysis|Correlative studies
75472468|NCT01958632|Procedure|Nerve reconstruction|
75644506|NCT02689713|Drug|Topical Sterile Water Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
75792480|NCT01218750|Procedure|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
75792481|NCT01376284|Drug|Dutasteride|Collection of safety data
75644507|NCT05373589|Other|conventional ventilation, group C|In the conventional ventilation group, after stopping the administration of the inhalation gas, the emergence process is performed by the anesthesiologist assigned to the room. Basically, until spontaneous respiration of the patient is restored, an anesthesiologist can assist respiration by intermittent manual assistance if necessary.
75335230|NCT01884740|Drug|SIACI of Erbitux and Bevacizumab|Subjects will receive a single intra-arterial dose of Cetuximab (200 mg/m^2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
75335231|NCT00002290|Drug|Zidovudine|
75335232|NCT00002290|Drug|Acyclovir|
75335233|NCT01003769|Drug|Lenalidomide|Given PO
75335234|NCT01003769|Drug|R-(-)-Gossypol Acetic Acid|Given PO
75335235|NCT01003769|Other|Laboratory Biomarker Analysis|Correlative studies
75335236|NCT00002452|Drug|L-756423|
75335237|NCT00002452|Drug|Indinavir sulfate|
75335238|NCT01244503|Drug|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
75335239|NCT01004393|Drug|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
75644508|NCT05373589|Other|pressure support, group PS|In the pressure support group, after stopping the administration of the inhalation gas, switch to the pressure support mode at the emergence period. PEEP 5cmH20 is applied, and the safety backup ventilation rate is set to 12 breaths/min. The flow trigger is set to 1L/min, and the degree of support is made to be 7-8ml of the predicted body weight, and is decreased as the patient's spontaneous breathing is restored.
75651895|NCT04939753|Drug|Sevoflurane|Sevoflurane administration to sedate the patient
75335240|NCT00002458|Biological|monoclonal antibody 3F8|
75335241|NCT00002470|Biological|recombinant interferon alfa|
75335242|NCT00002470|Drug|fluorouracil|
75335243|NCT00002476|Biological|bleomycin sulfate|
75335244|NCT00002476|Drug|fluorouracil|
75335245|NCT00002476|Drug|leucovorin calcium|
75335246|NCT00002476|Drug|methotrexate|
75335247|NCT00002476|Drug|vincristine sulfate|
75335248|NCT00002476|Radiation|low-LET cobalt-60 gamma ray therapy|
75335249|NCT00002476|Radiation|low-LET photon therapy|
75335250|NCT00002476|Radiation|radiation therapy|
75335251|NCT01245439|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
75335252|NCT01876628|Drug|Flucloxacillin|Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.
75335253|NCT01876628|Drug|Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
75335254|NCT01876628|Drug|Placebo oral capsule|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
75335255|NCT01004705|Drug|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
75335256|NCT01004705|Drug|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
75335257|NCT00002482|Biological|antibody therapy|
75335258|NCT00002482|Biological|biological therapy|
75335259|NCT00002482|Biological|muromonab-CD3|
75651896|NCT05471401|Device|Balloon-tipped catheter|Gastric balloon
75792482|NCT03971903|Behavioral|Attention bias modification|The ABM training task was a variation of the computerized visual dot-probe task. During the training, each session includes 54 neutral-sad word pairs presenting 6 times (6 × 54=324 trials) during 20-minute. Participants received 12 sessions over 4 weeks (1 session every other day). In the active ABMT, 90% of the probes appeared at the neutral position and 10% at the sad position. At the placebo ABMT, 50% of the probes appeared at the neutral position and 50% at the sad position.
75335260|NCT00002482|Drug|cyclophosphamide|
75335261|NCT01417286|Radiation|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
75335262|NCT01417208|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
75335263|NCT00505310|Behavioral|Writing|20 minutes of writing on different topics at four different times.
75335264|NCT00505310|Behavioral|Questionnaire|Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
75335265|NCT01004939|Drug|fondaparinux|fondaparinux
75472469|NCT01958684|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|LNG-IUS once inserted will be effective for 5 years.
75472470|NCT01958684|Device|Copper-IUD|Copper-IUD once inserted will be effective for more than 10 years.
75472471|NCT01958723|Other|Hospitalists|Introduction of Problem Specific Templates
75644509|NCT04187313|Other|INSTEP2 intervention package|"The Intervention will comprise: An electronic notification system, a standardized education about the signs and symptoms of TB and TB management and an individualised plan for each PP with respect to their approach to the diagnosis and management of TB suspects.~The electronic system is a refinement of the electronic referral and report-back system using a mobile phone 'app'. The system will enable essential data to be uploaded, consistent with National TB Control Programme forms.~The education package will be focused on TB suspect identification, provisional diagnosis and referral, including how to use the mobile phone 'app'. We will also develop a simple individualised approach for the management of TB suspects, which takes into account the context around each PP's practice, identifying the most efficient and feasible approach to obtaining a diagnosis and notifying TB patients."
75644510|NCT02601508|Drug|Rocuronium|Continuous infusion of rocuronium for PTC 1 + Sugammadex
75644511|NCT02601508|Drug|cis-atracurium|Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine & Glycopyrrolate
76084220|NCT04524312|Procedure|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant
75644512|NCT00723775|Drug|GSK706769 & KALETRA|GSK706769 alone and GSK706769 + Kaletra
75644513|NCT04187157|Device|Blue-light filtering intraocular lens|Bilateral implantation of blue light-blocking intraocular lens
75644514|NCT04187157|Device|Conventional intraocular lens|Bilateral implantation of conventional intraocular lens
75928837|NCT06144775|Other|Kinematics measures|In a single session each child will be video-recorded while performing simple and complex rhythmic actions of the upper limbs with a social partner. The presence of characteristic motor behaviors, practice errors, perseverations, and movement variability will be observed. The study involves the use of three blocks of tasks of the neuropsychological battery (NEPSY-II): Finger Tapping, Visuo-Motor Precision, and Manual Motor Sequences. The order within each block will be randomized.
75928838|NCT06144749|Drug|HBI-002|Oral liquid carbon monoxide drug product.
75928839|NCT06144736|Procedure|Robot-assisted retroperitoneal lymph node dissection|"Robot-assisted, if possibe ipsilateral nerve-sparing, retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field (template)"
75928840|NCT06144736|Drug|Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin|The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
75928841|NCT06144723|Drug|HS-20105|Administered intravenously every 21 days.
75472472|NCT01958736|Other|Ballistic Strength Training|The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
75644515|NCT04184193|Other|Pulmonary Rehabilitation|Patients will perform a comprehensive, inpatient pulmonary rehabilitation program for 4 weeks duration
75928842|NCT06144710|Drug|SG301 SC Injection|"This Study consists of Parts A and B. Part A ：SG301 SC Injection In healthy volunteers at 1 mg/kg dose group (n=4) and 2 mg/kg dose group(n=4) ; all 4 participants in each group will receive a single dose of SG301 SC Injection by abdominal subcutaneous injection.~Part B：SG301 SC Injection/SG301 SC placebo MAD will be performed for SLE participants in 4 dose groups (n=10/group), namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups.~2 mg/kg dose groups:SG301 SC Injection (n=8) or SG301 SC placebo (n=2); 4 mg/kg, 8 mg/kg and 12 mg/kg dose groups, the first 2 participants in each group will receive the investigational drug SG301 SC Injection , and the remaining 8 participants will be randomized in a 6:2 ratio to receive multiple doses of SG301 SC Injection (n=6) or SG301 SC placebo will be subcutaneously injected every 2 weeks [Q2W] in a 2-week cycle for a total of 6 doses in the MAD study."
75928843|NCT06144697|Drug|BMS-986465|Specified dose on specified days
75928844|NCT06144697|Other|Placebo|Specified dose on specified days
75792483|NCT01222338|Biological|V-5 immunitor|once per day dosing for 2 months
75928845|NCT06144697|Drug|Pegasys|Specified dose on specified days
75928846|NCT06144697|Drug|Famotidine|Specified dose on specified days
75928847|NCT06144658|Device|Augmented Reality Headset / Hololens 2 or Varjo XR3|Augmented Reality Headset
76084221|NCT04524312|Diagnostic Test|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
76084222|NCT04524312|Device|NexGen Ps or Bioimplanti K-MOD implant|Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
75792484|NCT01376440|Other|household water treatment|household water treatment with 1.25% sodium hypochlorite
75792485|NCT01329042|Drug|Potassium-sodium citrate|The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment
75792486|NCT01126398|Procedure|ankle or distal tibia surgery|internal fixation for ankle or distal tibia fracture
75792487|NCT01376518|Procedure|positive end-expiratory pressure|Elevation of positive end-expiratory failure for recruitment
75792488|NCT00253643|Dietary Supplement|green tea catechin extract|Given orally 2 times/day
75792489|NCT00253643|Dietary Supplement|fish oil|Given orally 3 times/day
76084223|NCT04524156|Other|Physiology|"Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method)."
76084224|NCT03355638|Drug|Aflibercept Injection [Eylea]|patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
75792490|NCT00253643|Other|placebo|Given olive oil placebo orally 3 times/day
75792491|NCT00253643|Other|placebo|Given green tea placebo orally 2 times/day
75792492|NCT01222650|Drug|KSO-0400|
76084225|NCT03355638|Drug|Pranoprofen Eyedrops|Patients were given a bottle of eyedrops for self-administration of 0.1% pranoprofen (Pranoflog, Sifi SpA, Aci Sant'Antonio, CT, Italy). Pranoprofen dosage was 1 drop in the study eye, 3 times a day, over the 12-month study period
76084226|NCT03355638|Drug|Omega-3 Supplementation|Ppatients were given daily tablets of Omega-3 supplementation provided free of charge by the company (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
76084227|NCT03350646|Other|Volume of medium during embryo transfer|
75928848|NCT06144619|Genetic|Genomic and Histological Evaluation|Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)
75928849|NCT06144580|Other|Community Health and Wellbeing Worker|Each CHWW will be deployed to cover 120 households in defined geographies ('villages') in North and South Westminster. LSOAs in the bottom 20% deprivation have been identified as priority areas for the CHWWs to be deployed. All households in the villages allocated to receive the intervention will be approached by the CHWW allocated to that village, irrespective of demographic characteristics and previous needs. CHWWs will visit all households each month, building a longitudinal relationship with each household so that problems arising from one month to the next can be captured in good time.
75936417|NCT05272085|Procedure|Ultrasound Guided Subacromial Bursa Injection|2 ml dexamethasone and 3 ml %2 lidocaine will be injected in the subacromial bursa using a 21-gauge needle under ultrasound guidance.
75936418|NCT02431442|Drug|RM-493|
76084228|NCT03354078|Procedure|interrupted sutures|The way of closing subcutaneous tissue either by interrupted
76084229|NCT03354078|Procedure|continous sutures|The way of closure of subcutanous tissue is by continous sutures
76084230|NCT03350568|Other|Total dietary NEAC assessed at baseline|
75644516|NCT02570581|Other|Jelly with:Paracetamol|"A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions."
75644517|NCT02570581|Other|Jelly with Furosemide|
76084231|NCT01626664|Biological|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
76084232|NCT01626664|Drug|Pralatrexate|30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
76084233|NCT01626664|Drug|gemcitabine plus oxaliplatin|gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
76084234|NCT01626664|Drug|DHAP|dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
76084235|NCT04515966|Drug|Methylprednisolone Injection [Solu-Medrol]|A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine will be injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
75644518|NCT02570581|Other|Jelly with Levothyroxine sodium salt|
75644519|NCT02570581|Other|Jelly with Memantine|
75644520|NCT02570581|Other|Jelly with Zopiclone|
75644521|NCT02570581|Other|Jelly with Alprazolam|
75644522|NCT02570581|Other|Jelly with Oxazepam|
75644523|NCT02570581|Other|Jelly with Donepezil|
75644524|NCT02570581|Other|Jelly with Clopidogrel|
75644525|NCT02570581|Other|Jelly with Ramipril|
75644526|NCT02570581|Other|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
75644527|NCT02570581|Other|Plain jelly control|
75644528|NCT02570581|Other|Apple compote Paracetamol|
75644529|NCT02570581|Other|Apple compote Furosemide|
75644530|NCT02570581|Other|Apple compote Levothyroxine sodium salt|
75644531|NCT02570581|Other|Apple compote Memantine|
75644532|NCT02570581|Other|Apple compote Zopiclone|
75644533|NCT02570581|Other|Apple compote Alprazolam|
75792493|NCT01222650|Drug|KSO-0400|
75792494|NCT01222650|Drug|Silodosin|
75792495|NCT01222650|Drug|Placebo|
75792496|NCT01126476|Other|Proton Radiotherapy|
75792497|NCT03971825|Drug|CC-92252|CC-92252
75792498|NCT03971825|Other|Placebo|Placebo
75792499|NCT01072019|Other|Instrument|Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.
75792500|NCT01073579|Drug|Sabril®|"Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily."
75792501|NCT04813900|Other|Lung ultrasound|Lung ultrasound in order to calculate lung ultrasound score
75792502|NCT04806802|Device|APIOC Sphere and APIOC Astigmatism|Single Vision Contact Lenses
75792503|NCT03934320|Other|FAMCAT|The intervention is a computer-based software algorithm (FAMCAT) for use in general practice with a family history questionnaire.
76084236|NCT04515966|Device|wrist splint|A standard wrist splint
76084237|NCT03350490|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
76084238|NCT03350490|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
76084239|NCT03355404|Other|standing patient|patient goes standing to the surgery room
76084240|NCT02518386|Other|No intervention|No intervention is planned
76084241|NCT01626820|Biological|Fluviral®|1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
75792504|NCT01124136|Device|Neurostimulation + Medication Management (Standard of Care)|In addition to medication management, adding investigational implanted neurostimulator to heart
75472473|NCT01958736|Other|Usual Care Physiotherapy|This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
76084242|NCT04504656|Other|observation of postoperative leak, stenosis, mortality|detect complications in both groups
76084243|NCT04507932|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
75644534|NCT02570581|Other|Apple compote Oxazepam|
75472474|NCT01958749|Procedure|Fat graft with Platelet Rich Plasma|
75472475|NCT01958775|Drug|GLP-2|single subcutaneous dose of 1500mcg
75472476|NCT01958775|Drug|Placebo|
75472477|NCT01958801|Other|Supraclavicular block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
75472478|NCT01958801|Other|Interscalene block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
75472479|NCT01958814|Drug|Salbutamol|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
75472480|NCT01958814|Drug|Placebo|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
75472481|NCT01958866|Drug|Tinospora Crispa-extract Product|
75472482|NCT01958866|Drug|Acetaminophen|
75644535|NCT02570581|Other|Apple compote Donepezil|
75792505|NCT01124136|Drug|Standard of Care (Control)|Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
75472483|NCT01958866|Other|Placebo|
75792506|NCT04674436|Behavioral|Walking|6 minute casual walk
75472484|NCT01958879|Drug|ringer with corticosteroid|200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
75472485|NCT01958879|Drug|ringer without corticosteroid|200 mL Ringer solution
75472486|NCT01958892|Procedure|TURP, TUERP|
75472487|NCT01958905|Drug|Artemether-lumefantrine fixed combination|
75472488|NCT01958944|Drug|Nitric oxide|
75792507|NCT01218828|Other|LVEDP -Based hydration strategy|
75928850|NCT06144528|Other|QT robot|In a single session each child will be video-recorded while performing the task. The participant subjects will perform the same task at two different times, once with the human operator and once with the Qt robot. Both tasks will have a duration of approximately 4 minutes. During the first minute, both the operator and the Qt will introduce themselves and ask four questions to the child to deepen the acquaintance. In the second minute, the operator/Qt will tell a story. In the third minute, the operator/Qt will ask to imitate 4 motor movements, while in the fourth minute, the operator/Qt will ask to imitate 4 facial expressions.
75928851|NCT06144489|Dietary Supplement|Tart Cherry|Tart cherry supplementation in two doses
76084244|NCT04504110|Diagnostic Test|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Patients with epithelial ovarian cancer who are scheduled for surgical intervention will undergo a comparative 68Ga-FAPI-04 and 18F-FDG PET/CT study before the surgery.
75472489|NCT01958957|Drug|Ginkgolides Meglumine Injection|25mg, intravenous drip, once a day. Number of Cycles: 14 days.
75644536|NCT02570581|Other|Apple compote Clopidogrel|
75644537|NCT02570581|Other|Apple compote Ramipril|
75472490|NCT01958970|Drug|PINTA 745|"PINTA 745 will be administered once weekly by IV infusion.~Cohort dose schedules:~3mg/kg weekly for 12 weeks~3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
75472491|NCT01958970|Drug|Placebo|"Placebo will be administered once weekly by IV infusion.~Cohort dose schedules:~3mg/kg weekly for 12 weeks~3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
75472492|NCT01958983|Behavioral|Music Therapy Group Session|
75644538|NCT02570581|Other|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
75644539|NCT02570581|Other|Plain apple compote control|
75644540|NCT02689479|Procedure|Positron-Emission Tomography|Dynamic scanning is performed for 60 minutes. Image acquisition is performed in 3D and reconstructed using an iterative OSEM VUEPOINT algorithm
75644541|NCT02689479|Biological|11C-5-HTP|150-400 MBq [11C]5-HTP (approximately 2-5 MBq/kg) is administered manually as an intravenous bolus in a intravenous catheter in the arm prior to PET imaging.
75644542|NCT02689479|Procedure|Magnetic Resonance Imaging|Analysis will focus on adipose tissue distribution and composition in the liver.
75644543|NCT02689479|Procedure|Mixed-Meal Tolerance Test (MMTT)|
75644544|NCT02689479|Procedure|Continuous Glucose Monitoring System® (CGMS)|CGMS involves the subcutaneous (SC) placement of a glucose sensor connected by tubing to a pager-sized monitoring device that stores glucose data. Subjects will have the sensor placed in the clinic and wear it continuously for 72 - 84 hours (Gold) or 72-144 hours (iPro2).
75792508|NCT01218828|Other|Standard hydration|
75792509|NCT00221195|Drug|activated prothrombin complex concentrate (FEIBA)|"FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months~FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months"
75792510|NCT03933930|Other|Lactate-directed therapy|If the lactate level elevates, we transfuse pRBC to increase Hct>30%. If Hct >30%, dopamine infusion starts.
75472493|NCT01958996|Drug|idarubicin|
75792511|NCT03933930|Other|Goal-directed therapy|If SVV>15%, transfuse lactate ringer/normal saline alternatively to keep SVV<15%.
75792512|NCT04646590|Biological|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
75792513|NCT04646590|Biological|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
75792514|NCT03931668|Drug|TPN-672|single dose of TPN-672 maleate tablet
75792515|NCT00220805|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
76084245|NCT03353844|Behavioral|Intradialytic exercise|intradialytic exercise which start and finish in first hour of hemodiafiltration session
76084246|NCT03355248|Other|Oxycodone Acetaminophen|Decrease in opioid prescribing for post-operative cesarean pain management
76084247|NCT03350334|Drug|Duloxetine|Peri-operative Duloxetine administration
76084248|NCT03350334|Drug|placebo|Placebo administration
75335266|NCT05750836|Other|Specific nursing support|"3 mandatory on-site nursing consultations with the patient's caregiver at inclusion, 6 months and 12 months post-randomisation.The caregivers will complete the questionnaires (Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36, Caregiver's satisfaction).~interviews once a month with a nurse either by phone, on-site consultation or teleconsultation.~Nurses assess the general health of the caregiver and Identify the socio-professional situation of the caregiver"
75335267|NCT05750836|Other|Non-specific nursing support|Caregivers will only have to complete on site Health indicators, Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36 at inclusion, 6 months and 12 months post-randomisation.
75335268|NCT04389710|Drug|Convalescent Plasma|One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
75335269|NCT04239248|Dietary Supplement|Tasty&Healthy intervention group|"patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty&Healthy."
75335270|NCT04239248|Dietary Supplement|EEN intervention group|Oral exclusive feeding of formulated food (EEN), using Modulen formula only, for 8 weeks in amount based on the Daily Recommendations Intake. Those not tolerating oral EEN can receive EEN via a nasogastric tube.
75335271|NCT00002488|Drug|cisplatin|
75335272|NCT00002488|Drug|cyclophosphamide|
75335273|NCT00002488|Drug|etoposide|
75644545|NCT02689479|Procedure|Glomerular Filtration Rate Testing|
75792516|NCT00220805|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
75335274|NCT03015389|Procedure|Diagnostic Test|WATS3D brush biopsy
75335275|NCT01245595|Drug|Aminophylline|5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
75335276|NCT01245595|Drug|Placebo|Normal Saline
75335277|NCT01864772|Drug|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
75644546|NCT02689479|Procedure|Blood draw|
75792517|NCT04573816|Other|Use of an internet plateform|Use of an internet platform for remote monitoring of patients.
75792518|NCT03932448|Other|The proposed study is not interventional.|The proposed study is not interventional. However, if a treatable microorganism is detected, e.g. Borrelia or Anaplasma, suitable therapy, e.g. doxycycline, will be in initiated if appropriate.
75792519|NCT00220727|Drug|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
75792520|NCT01225770|Dietary Supplement|green tea|Gargling three times daily for 90 days
75644547|NCT00640263|Drug|lopinavir/ritonavir (LPV/r)|Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
75651897|NCT04924036|Drug|glycopyrronium cloths|Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
75792521|NCT01072097|Drug|Atorvastatin|Atorvastatin 20mg/day for 6 months
75792522|NCT01072097|Drug|Placebo|Placebo for 6 months
75928852|NCT06144489|Dietary Supplement|Placebo|Control group
75928853|NCT06144450|Other|Web-Based Monitoring Program|"The research will be carried out in three stages; (1) creating the content of the follow-up program, (2) designing the web page, (3) implementing the program with mothers. The topics to be included in the monitoring program will be prepared within the framework of the Empowerment Model. Knowledge and attitude-self-efficacy will be tried to be increased with the modules to be prepared. Accordingly, the program is planned to consist of 3 modules. These are Preparation for Hospital Discharge Module, Transitional Care Module and Home Care Module. The presented modules will be made accessible to mothers in the experimental group through a website. The modules will be completed in order and the necessary forms and follow-ups will be completed at the end of each module."
75936419|NCT02431442|Drug|Placebo|
75936420|NCT05163314|Drug|Soticlestat|Soticlestat mini-tablets or tablets
76084249|NCT04515108|Other|Clinical assessment|Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.
75792523|NCT03928782|Radiation|5 Gy or 10 Gy units of whole-body radiation|8 subjects will be received 5 Gy units of whole-body radiation or 10 Gy units of whole-body radiation.
75792524|NCT03971747|Biological|AFP Specific T Cell Receptor T Cells|Autologous T cells transduced with lentivirus encoding AFP specific TCR gene
75928854|NCT06144437|Diagnostic Test|Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Gastroscopy will be completed and reported by experienced endoscopists, requiring no more than 1 month between gastroscopy and ultrasound examination, and patients should fast for at least 8 hours before gastroscopy."
75644548|NCT00640263|Drug|Lamivudine (3TC)|"Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.~The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight."
75644549|NCT02683863|Drug|BG00012 (DMF) (Tecfidera®.)|Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
75644550|NCT00975884|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
75644551|NCT02865668|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
75644552|NCT02865668|Drug|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
76084250|NCT04513470|Biological|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
75644553|NCT02865668|Drug|Metformin Extended Release (XR)|Participants will receive 1 metformin XR tablet of 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
75644554|NCT04006808|Biological|PED-HZ/su|GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.
75928855|NCT06144411|Other|prevalence of preoperative malnutrition|prevalence of preoperative malnutrition
75335278|NCT03010891|Behavioral|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC > 45 minutes
75644555|NCT02689791|Dietary Supplement|Resistant Starch Type 4|single dose 26g fiber given at the breakfast meal
75644556|NCT04586595|Other|REVISiT intervention|REVISiT is a pharmacist-led retrospective review of prescribing followed by a feedback meeting to discuss the review findings.
75644557|NCT02867930|Drug|Dexmedetomidine|drug for moderate sedation in trans-esophageal echocardiography
75644558|NCT02867930|Drug|Ketofol(ketamine+propofol)|drug for moderate sedation in trans-esophageal echocardiography
75792525|NCT03931824|Other|PRP|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used(18, 19). To provide blindness, all injections were done using injectors coated with non transparent tape."
75792526|NCT03931824|Other|Exercise|All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
75792527|NCT01222806|Device|Repetitive Transcranial Magnetic Stimulation|
75928856|NCT06144372|Device|Electroconductive and Electrohydraulic types|The patients were randomly assigned to two types of lithotripter.
76084251|NCT03353766|Device|Early crossbite correction with Q-H Device|Crossbite treatment in deciduous dentition with Quad-Helix appliance
75335279|NCT03010891|Behavioral|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC < 20 minutes
75335280|NCT00002494|Drug|cyclophosphamide|
75335281|NCT00002494|Drug|cytarabine|
75644559|NCT02570893|Radiation|Adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
75335282|NCT00002494|Drug|dexamethasone|
75335283|NCT00002494|Drug|doxorubicin hydrochloride|
75792528|NCT03971357|Drug|Netarsudil|netarsudil opthalmic solution 0.02%
75792529|NCT03971357|Drug|Placebo|Placebo eye drops
75335284|NCT00002494|Drug|etoposide|
75335285|NCT00002494|Drug|ifosfamide|
75335286|NCT00002494|Drug|leucovorin calcium|
75792531|NCT04424212|Behavioral|Intervention group CoronaCope|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. Intervention's main purpose is to mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
75335287|NCT00002494|Drug|mesna|
75335288|NCT00002494|Drug|methotrexate|
75644560|NCT02570893|Radiation|Adjuvant radiotherapy|adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
75644561|NCT02570893|Drug|Paclitaxel and carboplatin|
75644562|NCT02538081|Drug|Risperidone plus Placebo|Standard of care including Risperidone plus Placebo
75644563|NCT02538081|Drug|Risperidone plus DMXB-A|Standard of care including Risperidone plus DMXB-A
75792532|NCT05760430|Combination Product|PVE+cTACE+Camrelizumab+Apatinib|After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
75644564|NCT02570971|Drug|Mannitol|
75644565|NCT02866292|Other|Pelvic floor muscle and sexual function evaluation|"PFM evaluation was performed by vaginal palpation and vaginal squeeze pressure. During vaginal palpation the physiotherapist introduced the index and middle fingers about 4cm inside the vagina, and requested to hold the maximum contraction of the PFM. Muscle function was classified by the Oxford Scale Modified.~The vaginal squeeze pressure was measured through Perineometer.To obtain the measurements, the subjects remained positioning and vaginal sensor was introduced into the vaginal cavity. The women were oriented and motivated verbally to perform three voluntary maximal contractions sustained for five seconds and one minute interval between them.~Sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The questionnaire consists of 19 multiple-choice questions, which involves six sexual response domains: desire, arousal, lubrication, orgasm, satisfaction and pain."
75792533|NCT05760430|Combination Product|cTACE+Atirizumab+Bevacizumab|After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
75792534|NCT04331158|Other|Dry cupping therapy|Dry cupping therapy application on the patient's skin
75792535|NCT01222962|Drug|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
75335289|NCT00002494|Drug|prednisone|
75335290|NCT00002494|Drug|therapeutic hydrocortisone|
75335291|NCT00002494|Drug|vincristine sulfate|
75335292|NCT00002494|Radiation|low-LET cobalt-60 gamma ray therapy|
75335293|NCT00002494|Radiation|low-LET photon therapy|
75335294|NCT02164721|Device|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
75335295|NCT00002506|Biological|recombinant interferon alfa|
75335296|NCT00002506|Drug|isotretinoin|
75644566|NCT02683629|Biological|NTCELL Implantation|NTCELL Implantation
75644567|NCT02683629|Other|Sham Surgery|Sham Surgery
75644568|NCT02866214|Drug|Febuxostat|Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session
75644569|NCT02866214|Drug|Placebo|"Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) ."
75644570|NCT04290182|Biological|MSC-KI-PL-204|Autologous MSC product
75644571|NCT02866448|Drug|Vehicle control|Described in arm
75644572|NCT02866448|Drug|Isoquercetin|Described in arm
75644573|NCT02866448|Drug|Aspirin|Described in arm
75335297|NCT01895894|Drug|Mycophenolate mofetil|Mycophenolate mofetil 20~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
75335298|NCT02165111|Drug|Onabotulinumtoxin A|
75335299|NCT02165111|Drug|sterile saline solution|
75335300|NCT05750680|Drug|DOACs|outpatients visited in anticoagulation clinics with a prescription of DOAC for atrial fibrillation and venous thromboembolism and concomitant antiepileptic drug will perform a blood draw for measurement of dabigatran, rivaroxaban, apixaban and edoxaban
75335301|NCT05750602|Dietary Supplement|LIMICOL|Suplementation with LIMICOL, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
75335302|NCT05750602|Dietary Supplement|PLACEBO|Suplementation with PLACEBO, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
75335303|NCT04755374|Other|Discharged ≤ 21 days|Discharged from palliative care unit in equal less than 21 days
75335304|NCT04755374|Other|Prolonged discharge|Discharged from palliative care unit in longer than 21 days
75335305|NCT04389788|Device|carboxy therapy|6 sessions of carboxy therapy every 2 weeks
75335306|NCT04389788|Device|Dermapen with topical glutathione|6 sessions of Dermapen microneedling with topical glutathione every 2 weeks
75792536|NCT01226082|Device|Transcranial Direct Current Stimulation|Patients will recieve tDCS in a 5-day period of treatment
75792537|NCT04310566|Device|JJVC Investigational Multifocal Contact Lens (senofilcon A c3)|TEST
75792538|NCT04310566|Device|Dailies Total 1® Multifocal Contact Lens|CONTROL
75792539|NCT01226160|Procedure|Postoperative face-down posturing|Postoperative face-down posturing for 10 days after surgery.
75792540|NCT01226160|Procedure|Postoperative non-posturing group|avoid a face-up position only for 10 days after surgery
75792541|NCT01221402|Drug|extended-release niacin (Niaspan)|Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
75792542|NCT04215952|Behavioral|Semantic Feature Analysis Treatment|On each treatment trial, the clinician will show the participant with aphasia a pictured object and ask them to name it. The clinician will then guide the participant in verbally generating semantic features for the target, using a chart that specifies five kinds of features: group, use/action, properties, location, and personal associations. When the participant cannot generate a given feature, cueing or other assistance will be provided. After feature generation, the clinician will ask the participant to name the picture again and provide cueing if needed. The clinician will then review the generated features and ask the participant to name the item once more, with cueing if needed. Finally, the clinician will ask the participant to say a sentence containing the target word and provide cueing if needed. Treatment will then proceed to the next item. Participants will receive approximately 20 hours of treatment on each of three 10-item lists, for a total of 60 hours of treatment.
75792543|NCT04214860|Drug|APR-246|APR-246 4.5 g/day
75792544|NCT04214860|Drug|Venetoclax|Venetoclax 400 mg once daily
75792545|NCT04214860|Drug|Azacitidine|Subcutaneous injection, or intravenous infusion
75792546|NCT01127490|Drug|Duloxetine|Subjects will be titrated onto Duloxetine over one week by taking 30 mg every day for seven days. Week 2 the subject will begin to take 60 mg per day until the end of the study. If the subject wishes to stop taking Duloxetine, she will be given 30 mg per day for one week for down titration.
75792547|NCT01127490|Procedure|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand
75792548|NCT01223040|Other|SYSTANE® Balance Lubricant Eye Drops|Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
75792549|NCT01126866|Drug|intensified chemotherapy (FOLFOXIRI/Bevacizumab)|intensified chemotherapy (FOLFOXIRI/Bevacizumab)
75792550|NCT01329432|Procedure|Take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.
75644574|NCT02866448|Drug|Isoquercetin plus Aspirin|Described in arm
75928857|NCT06144359|Other|specific MRI Acquisition (Diffusion Tensor Imaging) at 3T|"The imaging will be carried out on the technical stage of the 3T MRI Research of the University Hospital of Clermont-Ferrand with the following sequences:~- For traumatized and healthy subjects: MRI 3 Teslas (3D T1, T2 axial TSE, T2* axial, SWI axial, Sagittale cube FLAIR, DTI 20-direction sequence) The image processing will be carried out within the radiology department: morphological analysis and analysis of tractography and diffusion parameters (FA and ADC, diffusivity) on predefined and reproducible Regions of Interest (ROIs).~Regions Of Interest include: splenium of the corpus callosum, internal capsule, cortico-spinal tract, optic radiation."
75335307|NCT03998657|Device|Exablate Prostate Treatment|The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
75644575|NCT00578227|Biological|Cervarix™|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
75792551|NCT01329432|Procedure|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
75792552|NCT04103554|Drug|Sacubitril-Valsartan|Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID
75792553|NCT04103554|Drug|Standard of care|standard of care used for treating BP
75792554|NCT03931434|Dietary Supplement|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
75792555|NCT03931434|Dietary Supplement|Placebo|Placebo
75792556|NCT05760196|Drug|GM-CSF|PD1 antibody is held every three weeks, and GM-CSF is used once every three weeks on days 1-14. Until the patient progresses disease or intolerable toxicity.
75928858|NCT06144346|Radiation|Stereotactic Ablative Radiation Therapy|SABR to all metastatic lesions
75644576|NCT00578227|Biological|Twinrix ™ Paediatric|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
75644577|NCT02571127|Drug|Hidra1|"Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient."
75651898|NCT04924036|Drug|Placebo|Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
75792557|NCT03740568|Drug|Low Progesterone|"Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 <10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.~Group 2b (Restored Progesterone Group, P on D5 >10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is >10.64 ng /mL: the same P supplementation is continued. If P is <10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
75928859|NCT06144346|Procedure|Locoregional treatment|mastectomy or BCS for the primary tumor
75928860|NCT06144346|Other|Standard of Care|Systemic treatment and palliative treatment
75928861|NCT06144333|Diagnostic Test|RIPH2|"Blood sampling by capillary~Swab sampling~Blood sampling by venous punction~Salivary sample, sputum, expectoration:"
75335308|NCT05750524|Other|reflexology hand massage|Reflexology massage methods applied randomly to both trial groups.
75335309|NCT05750524|Other|classical hand massage|Classical hand massage methods applied randomly to both trial groups.
75335310|NCT02246387|Procedure|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
75651899|NCT04917744|Procedure|Biospecimen Collection|Undergo collection of blood samples
75651900|NCT04917744|Other|Laboratory Biomarker Analysis|Ancillary studies
75651901|NCT04917744|Other|Medical Chart Review|Review of medical charts
75928862|NCT06144307|Procedure|plane block|injection of local anesthetic to the myofascial plane
75644578|NCT00723853|Behavioral|Reach-Out Program, nutritional and exercise program|"This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise."
76084252|NCT01627288|Radiation|Boost radiation|Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
75644579|NCT00723853|Behavioral|Reach-In Program, standard of care|This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
75644580|NCT00720577|Drug|Simvastatin|40 Mg. tablet, 1 tablet daily
75928865|NCT06144229|Diagnostic Test|HPV test using Evalyn Brush|Self-swab collection kits, participates will self-collected vaginal swab for hrHPV test (at home or in the clinic)
75928866|NCT06144151|Device|NeurOptics® NPi®-300 Pupillometer|The pupilometer is a non-invasive device which will be placed in front of your eyes, one at a time. It looks like a handheld spotlight or scanner, with a small plastic guide sticking out that will be placed against your cheek to help keep the device in place during the scan. It will not touch your eye. Both your left and right eyes will be measured with the device each time. Scanning with the pupilometer will take less than 5 minutes total for both eyes.
76084253|NCT03350178|Drug|fecal microbiota transfer|transfer of fecal microbiota from healthy donor to the patients
76084254|NCT04513392|Procedure|Laser treatment|A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
76084255|NCT01628614|Other|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
75644581|NCT00720577|Drug|Losartan|50 mg., tablets, 1 tablet once daily
75644582|NCT00720577|Drug|Pioglitazone|30 mg, tablet, 1 tablet once daily
75644583|NCT03817021|Behavioral|CORE NAP SACC|Modify the food environment following a self-assessment of current food conditions
75644584|NCT03817021|Behavioral|ECE Provider|Provide online training for Head Start educators
75792558|NCT03740568|Drug|Normal Progesterone|"Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is >10.64 ng /mL: the same P supplementation is continued. If P is <10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
75792559|NCT00252239|Drug|tenecteplase|This study will compare 3 different doses of tenecteplase to tPA.
75792560|NCT00252239|Drug|tissue plasminogen activator, tPA|To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
76084256|NCT03350100|Dietary Supplement|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
76084257|NCT03122964|Diagnostic Test|AssureMDx|combined panel of methylation and mutation markers for the detection of bladder cancer
76084258|NCT02528500|Device|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
75644585|NCT03817021|Behavioral|Parent Intervention|Coach parents remotely to educate them on responsive feeding and parenting
75792561|NCT01126944|Device|heart mate II|left ventricular assist device
76084259|NCT04512612|Diagnostic Test|Chromoendoscopy|Participants randomised to Group A will undergo colonoscopic evaluation using dye-based chromoendoscopy
76084260|NCT04512612|Diagnostic Test|High definition white light colonoscopy|Participants randomised to Group B will undergo colonoscopic evaluation using high definition white light endoscopy
75792562|NCT01223118|Procedure|Vitrification and PGD|Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination. All embryos will undergo biopsy for PGD prior to transfer.
75792563|NCT01127022|Dietary Supplement|choline chloride|Women will consume a diet providing 380 mg/d total choline plus 100 mg/d supplemental choline [from choline chloride] for a total choline intake of 480 mg/d. The choline chloride will be administered in cran-grape juice.
75928867|NCT06144138|Behavioral|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
75928868|NCT06144125|Biological|fresh frozen plasma|transfusion of fresh frozen plasma
75928869|NCT06144125|Biological|prothrombin complex concentrate|prothrombin complex concentrate administration
75928870|NCT06144112|Biological|fresh frozen plasma|transfusion of fresh frozen plasma
75928871|NCT06144112|Biological|prothrombin complex concentrate|prothrombin complex concentrate administration
75928872|NCT06144073|Behavioral|Intervention (Mandala art therapy) group|Personal Information Form, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied to the students in both groups before mandala art therapy. The students in the experimental group will be given mandala activity by the researcher two days a week for 12 weeks/total 24 times. Three months after the first interview, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be administered as a post-test. One month after the end of the study, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied again as follow-up evaluation.
75928873|NCT06144060|Drug|HRS -8427|The dose and frequency of administration were adjusted according to the eGFR.
75928874|NCT06144060|Drug|Imipenem and Cilastatin Sodium|The dose and frequency of administration were adjusted according to the eGFR .
75928875|NCT06144047|Device|EEG SubQ subcutaneous EEG device|2-channel subcutaneous EEG device
75644586|NCT03817021|Behavioral|Child intervention|Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices
75928876|NCT06144034|Device|Air polishing with erythritol powder|Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.
75928877|NCT06144034|Device|Conventional treatment|Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.
75928878|NCT06143982|Behavioral|Brief Intensive Trauma Treatment|BITT is an outpatient, intensive, one-week individual trauma therapy program. BITT is based on well-established protocols, consisting of two 90-minutes trauma therapy sessions a day (trauma exposure in the morning and EMDR in the afternoon), two psychomotor therapy sessions a day (1x60 minutes, 1x45 minutes), one 90-minutes psycho-education and social support skill training for parents a day, and a 90-minutes family therapy session at the end of the week (sharing the trauma narrative).
75928879|NCT06143969|Procedure|ultrasound-assisted, catheter-directed thrombolysis|After 10 hours of alteplase infusion and EKOSTM ultrasound, the therapy is stopped, the EKOSTM catheter is removed, and the puncture site (internal jugular vein or femoral vein) has to be compressed.
75928880|NCT06143956|Drug|LY3305677|Administered SC. ISA specific interventions will be listed in the ISA.
75928881|NCT06143956|Drug|Placebo|Administered SC. ISA specific interventions will be listed in the ISA.
75928882|NCT06143930|Other|strengthening ex with BFR training|Therapeutic strengthening training with blood flow restriction of trained limb.
75644587|NCT00978380|Drug|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
75644588|NCT02572297|Other|video-EEG|Registration of seizures during video-EEG
75644589|NCT04005794|Behavioral|VR social skills training|Social skills game that we developed in the R21 phase will be used across 10 sessions of training in the lab. Each session is about 1 hour long. Participants come to the lab twice a week for 5 weeks.
75644590|NCT04005794|Behavioral|Cognitive training|Commercially available cognitive training program will be used to control for the time spent in the lab and associated social interactions as well as the total exposure to computerized games.
75792564|NCT01127022|Dietary Supplement|Choline Chloride|Women will consume a diet providing 380 mg/d total choline plus 550 mg/d supplemental choline [from choline chloride] for a total choline intake of 930 mg/d. The choline chloride will be administered in cran-grape juice.
75792565|NCT01221558|Dietary Supplement|lycopene|
75792566|NCT01226238|Other|Online self-help|Provision of online self-help
75792567|NCT01223274|Device|CPAP/PEEP|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
75792568|NCT01223274|Device|Standard management practices|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
75792569|NCT01221636|Drug|Abatacept|Solution for injection, Intravenous, 750 mg, 1 day
75792570|NCT05731804|Drug|SIM0417 600 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
75928883|NCT06143930|Other|strengthening ex|Therapeutic strengthening training program for lower extremities.
75792571|NCT05731804|Drug|SIM0417 375 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
75792572|NCT05731804|Drug|SIM0417 750 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
75644591|NCT05373277|Drug|Placebo|one tablet of placebo twice daily for two days
75644592|NCT05373277|Drug|Ticagrelor|Intervention Description: 90 mg tablet twice daily for two days
75792573|NCT01127568|Drug|Propranolol is available in generic form as the Wyeth product under the trade name Inderal.|The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
75644593|NCT05373277|Drug|Rosuvastatin|10 mg tablet, single dose
75644594|NCT01639105|Procedure|Laser treatment|10 600 NM ABLATIEVE FRACTIONATED LASER
75792574|NCT05198986|Other|Prone Position during Extra Corporeal Membrane Oxygenation (ECMO)|Pronation will be executed according to a predefined protocol: 4 caregivers will be required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube and the ventilator lines. The others will stand at each side of the bed. In the first step, the direction of the rotation will be decided giving priority to the side of the central venous lines. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. In the third step, the patient will be moved in the sagittal plane and maintained in that position for a short while to attach the cardiac electrodes to her/his back and to set a new bed sheet. In the last step, the patient will be turned to the complete prone position.
75792575|NCT03932292|Drug|Ectoin Mouth Wash|According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
75792576|NCT03932292|Drug|Supersaturated solution of calcium and phosphate ions|According to medical prescription of the instruction for use under consideration (4 times a day).
75792577|NCT05729542|Device|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
75792578|NCT05729542|Device|Synthes Fibulink|High-tensile strength suture syndesmosis repair
75792579|NCT01127100|Drug|transdermal fentanyl matrix, gabapentin|"transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained."
75792580|NCT05727514|Other|music composition|4-session music composition program for participants lead by a composer-mentor, includes optional viewing of online string quartet performances of final musical scores
75928884|NCT06143917|Behavioral|parent-child sleep intervention|The intervention plan is as follows: (1) Parent-child sleep education includes two in-person session and four pre-recorded online sessions. Additionally, it provides educational handbooks tailored to the course content, segmented into sections for both parents and newborns. Each session lasts approximately 20 minutes; (2) Heart rate variability measurement and Heart rate variability biofeedback are conducted in classes in person. It guides parents through breathing exercises to activate the parasympathetic nervous system, thereby easing emotions and improving psychological health; (3) Professional counseling and support are provided separately at two weeks, one month, three months, and six months postpartum.
75928885|NCT06143904|Drug|Genz-112638|Pharmaceutical form:Solution-Route of administration:IV
75928886|NCT06143904|Drug|Genz-112638|Pharmaceutical form:Capsule-Route of administration:Oral
75928887|NCT06143904|Drug|[14C]-Genz-112638|Pharmaceutical form:Solution-Route of administration:Oral
76084261|NCT04513158|Biological|Convalescent Plasma|Plasma obtained from individuals previously diagnosed with SARS-CoV-2 (COVID-19) is administered to hospitalized patients meeting inclusion/exclusion criteria and have provided informed consent.
76084262|NCT01629784|Behavioral|Cutaneous Lupus educational script|Subjects will listen to a short informational script on Cutaneous lupus and skin protection
75644595|NCT00720655|Other|Dietary intervention|Fatty fish at least 4 meals per week.
75644596|NCT00720655|Other|Dietary intervention|Lean fish at least 4 meals per week.
75644597|NCT00720655|Other|Dietary intervention|Control diet with lean meat and chicken.
75644598|NCT03908515|Device|Foldable Capsular Vitreous Body (FCVB)|FCVB can be regarded as an artificial vitreous and consists of a thin vitreous-shaped capsule, a drain tube, and a valve. After foldable implantation into the eye, then silicone oil is injected into the capsule which inflated to support the retina. The capsular material of FCVB is silicone rubber. The capsule was fabricated a computer simulation of the human and rabbit vitreous cavities. The control of the intraocular pressure is achieved with adjusting the amount of injected medium through the tube-valve system. After the medium was injected into the capsule through the tube-valve system, the valve was subsequently fixed onto the sclera surface similar to the glaucoma valve.
75644599|NCT00724087|Other|5.5-hour bedtime|16 days with sleep allowed only during a 5.5-hour bedtime period at night
75644600|NCT00724087|Other|8.5-hour bedtime|16 days with sleep allowed only during a 8.5-hour bedtime period at night
75644601|NCT00724165|Behavioral|Intervention|Culturally-modified, individually tailored physical activity print materials
75644602|NCT00724165|Behavioral|Control|Bilingual health education booklets
75644603|NCT00724321|Drug|iloprost|A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
75644604|NCT00724399|Behavioral|Survey on womens health Issues.|Cardiovascular health.
75651902|NCT04914923|Device|Muse|Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.
75335311|NCT01357460|Device|Implantation of intrabronchial valves (IBV) (Spiration IBV)|"In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of new air during inspiration."
75792581|NCT01127178|Drug|E7016 + TMZ|Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
75928888|NCT06143865|Other|Closed system aspiration|Aspiration catheter; it is part of the ventilator and the ventilator circuit. The catheter is stored in a protective sheath. Therefore, the catheter can be used repeatedly during the day.
75644605|NCT00720733|Behavioral|Skills-Building Intervention|A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.
76084263|NCT03350022|Procedure|Sham Feeding|Sham feeding will be offered to participants.
75335312|NCT05750446|Drug|Riociguat (BAY 63-2521)|A selective stimulator of soluble guanylate cyclase (sGC)
75792582|NCT05715580|Other|Nursing information with a Protocol|"The nursing intervention will consist of providing information to the patient with a kidney transplant.~To do this, a Committee of experts, made up of the 6 nurses from the kidney transplant Consultations of the Community of Madrid (Spain), will carry out an Information Protocol for adults with a kidney transplant, which will cover the healthy lifestyle habits described by the bibliography"
75792583|NCT05715580|Other|Usual clinical practice|Nursing information following the usual clinical practice
75928889|NCT06143826|Other|Progressive muscle relaxation exercises|Progressive muscle relaxation exercises involve contracting and relaxing 16 muscle groups in the body (hand, upper arm, forearm, forehead, nose, cheek, chin, neck, shoulder, chest, abdomen, waist, stomach, calf, hip, foot). During the exercise, the individual perceives the changes in the muscles during the contraction and relaxation of the muscles. Relaxation exercise is applied along with correct and deep breathing.
75928890|NCT06143813|Diagnostic Test|Selective nerve root block (SNRB)|CT/Fluoroscopy guided nerve root block
75928891|NCT06143800|Behavioral|reactivation|During the retrieval phase, cues are presented to participants to reactivate their memories; participants in the non-retrieval group go directly to cognitive reappraisal phase.
75928892|NCT06143800|Behavioral|cognitive reappraisal intervention|"Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it."
75928893|NCT06143787|Drug|Tranexamic acid|7 days Oral rinsing following tooth extraction
76084264|NCT03355092|Device|vBloc Therapy|The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
76084265|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
76084266|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
75335313|NCT05750446|Other|Placebo|Placebo
75792584|NCT01226394|Procedure|laparotomy plus HIPEC|Laparotomy + HIPEC
75792585|NCT03932604|Device|Atrial sensing On mode|Single lead VDD-ICD programmed as atrial sensing On mode.
75798881|NCT03858036|Drug|Ricrolin+|1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
75644606|NCT00720733|Behavioral|Personal Interview Group|There are 5 weekly sessions which will be approximately one hour long and will consist of personal interview. The interviews will include both quantitative and qualitative questions. Each session will have a separate theme including: Life 1) History; 2) Health History; 3) Personality; 4) Social Networking; and, 5) Meaning & Purpose.
75335314|NCT04756310|Dietary Supplement|Retilut|antioxidants, antiangiogenic, antiinflammatory micronutrients
75335315|NCT04756310|Dietary Supplement|Theavit|antioxidants micronutrients
75335316|NCT05750290|Drug|CKD-702 in combination with irinotecan|CKD-702 and irinotecan will be intravenously administered every 2 weeks.
75335317|NCT03845621|Device|Conventional Mouthguard|Use of a conventional custom-made mouthguard while playing water polo
75335318|NCT03845621|Device|Occlusal-adjusted Mouthguard|Use of an occlusal-adjusted custom-made mouthguard while playing water polo
75335319|NCT05750212|Diagnostic Test|Tone|Tone is a binary measurement of the pelvic floor muscle on physical examination
75644607|NCT00720811|Drug|Artemether-lumefantrine combination|20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
75644608|NCT00720811|Drug|amoxycillin|amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
75335320|NCT05750212|Diagnostic Test|Tenderness|Tenderness is a binary measurement of the pelvic floor muscle on physical examination
76084267|NCT02230696|Drug|Placebo nasal spray|Placebo nasal spray
75798882|NCT03858036|Device|VEGA UV-A system|The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.
76084268|NCT03353454|Drug|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
76084269|NCT03353454|Drug|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
75472494|NCT01959009|Other|HFOV combined with sigh breaths|"We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
75472495|NCT01959022|Drug|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
75472496|NCT01959061|Drug|Raltitrexed|4mg, every 4 weeks,transhepatic arterial infusion
75472497|NCT01959061|Drug|Oxaliplatin|100~150mg, every 4 weeks, transhepatic arterial infusion
75472498|NCT01959061|Drug|lipiodol|5-20ml, every 4 weeks, hepatic artery embolization
75472499|NCT01959074|Drug|Naftopidil|Naftopidil 75mg 1T qd hs
75472500|NCT01959074|Drug|Placebo for Naftopidil|Placebo 1T qd hs
75472501|NCT01959074|Drug|Standard treatment|aceclofenac 100mg on demand
75644609|NCT00720811|Drug|paracetamol|paracetamol 500mg tablet <36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
75644610|NCT00720811|Device|malaria rapid diagnostic test, respiratory rate timer|malaria dipstick, and breath timer
75928894|NCT06143774|Drug|TRX-920 Oral Gel (10 mg and 30 mg)|"TRX-920 Oral Gel will be administered orally at a week (BIW) in an 8-week cycle. No food should be taken 2 hours before and 1 hour after taking TRX-920. The dose escalation/de-escalation rules will be based on definitions of dose-limiting toxicity (DLT) and will be monitored during the first treatment cycle (i.e., the first 4 weeks post the first dose).~The starting dose will be 1 mg and the dosing frequency is twice every week (BIW). Subjects will be assigned to a dose level in sequential cohorts based on the order of their enrollment. The dose escalation will follow a 3+3 design and doses escalate from approximately 1 mg BIW, 2 mg BIW, 4 mg BIW, 8 mg BIW, and 16mg BIW and the doses for subsequent cohorts will be determined by Safety Review Committee (SRC). Dose escalation will be stopped till the maximum tolerated dose (MTD) is reached or identified."
75928895|NCT06143761|Drug|PD-1 inhibitor+carboplatin+albumin-bound paclitaxel|A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.
75928896|NCT06143748|Drug|Cadonilimab|Patients received cadonilimab 10 mg/kg every 3 weeks for up to 16 cycles.
75335321|NCT05750212|Diagnostic Test|Contraction|Contraction is a binary measurement of the pelvic floor muscle on physical examination
75335322|NCT05750212|Diagnostic Test|Relaxation|Relaxation is a binary measurement of the pelvic floor muscle on physical examination
75928897|NCT06143748|Drug|Paclitaxel and cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135 mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will not receive chemotherapy during radiotherapy.
76084270|NCT03353376|Behavioral|group care with Empowerment model|Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
76084271|NCT04507620|Device|cervical neck collar|devices used for cervical immobilization
76084272|NCT03355014|Drug|Combination of gemigliptin/metformin HCl sustained release 50/1000mg|Gemigliptin/Metformin HCl extended release 25/500mg 2tablets
76084273|NCT03355014|Drug|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg|Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
76084274|NCT03349944|Behavioral|Training|The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
75335323|NCT05750212|Diagnostic Test|Electromyography|Electromyography is a measurement of the pelvic floor muscle in microvolts
75335324|NCT05750212|Diagnostic Test|Transperineal|Transperineal measurements (in millimeters) of the pelvic floor muscle using an ultrasound
75335325|NCT05750212|Diagnostic Test|Pressure|Pressure measurements (in millimeters) of the pelvic floor muscle using an algometer
75472502|NCT01959100|Drug|Azithromycin|250 mg x 3/week per os during a meal for a period of 2 years
75472503|NCT01959100|Drug|Placebo|250 mg x 3/week during a meal for a period of 2 years
75472504|NCT01959126|Behavioral|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
75644611|NCT00720811|Drug|Artemether-lumefantrine combination|20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
75644612|NCT02571985|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation System|Zenith® Branch Endovascular Graft-Iliac Bifurcation (Branch Graft) with the ConnectSX™
75644613|NCT05338099|Drug|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10^5 cells/kg"
75798883|NCT02525250|Procedure|Realization of 3 Blood samples during study during treatment with lenalidomide|
75798884|NCT01288092|Drug|BEZ235|
75798885|NCT03858504|Other|Exercise|The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
75798886|NCT03858426|Other|no intervention|no intervention
75928898|NCT06143748|Radiation|intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
75792586|NCT05198440|Device|non-invasive neuromodulation|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
75792587|NCT05198440|Device|electroencephalography|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
75792588|NCT05198440|Device|anatomical MRI|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
75928899|NCT06143735|Drug|Efgbemalenograstim alfa|Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
76084275|NCT02231086|Procedure|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
76084276|NCT02231086|Drug|Standard adjuvant systemic chemotherapy|Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
75335326|NCT03015467|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 1
75335327|NCT03015467|Other|normal saline|normal saline and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 2
75335328|NCT04755296|Device|Low level laser therapy|Low level laser therapy was applied immediately before each aerobic exercise training session by using a multidiode cluster (with four diode spots; Polaris2, manufactured by Astar ABR, Poland) )on 12 sites on the lower limb (6 on quadriceps ( 2 centrally on rectus femoris and vastus intermedius,2 laterally on vastus lateralis, and two medially on vastus medialis), 4 on hamstrings and 2 on gastrocnemius) with the following parameters: 808 nm, continous output, 200 mW each diode (total of 800 mW) power output, 24 J energy on each site (6 J for each spot) , 40 seconds at each site (8 minutes of total treatment time in lower limb) and 288 J total energy delivered per lower limb, 48 irradiation points per lower limb ,3 sessions weekly for 12 weeks.
75472505|NCT01959152|Device|HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode|
75472506|NCT01959191|Drug|Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery|aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
75472507|NCT01959217|Behavioral|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
75644614|NCT05338099|Drug|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group B (High dose): 2.5x10^6 cells/kg"
75644615|NCT04292210|Device|Perisafe|A medical device simplifying the connection of tubing as well as breaking of the frangible which is done in a sterile environment with the help of levers and buttons.
75651903|NCT04914923|Behavioral|Cognitive Behaviour Therapy (CBT)|Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.
75792589|NCT01223430|Drug|Si-Ni-Tang/ Placebo of Si-Ni-Tang|The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal < 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
75928900|NCT06143722|Radiation|simultaneous with radiotherapy|Chemotherapy combined with immunotherapy simultaneous with radiotherapy
75928901|NCT06143722|Radiation|synchronous with radiotherapy|Chemotherapy combined with immunotherapy synchronous with radiotherapy
75644616|NCT00720967|Procedure|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
75644617|NCT00720967|Procedure|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP >75 mmHg, CVP > 12 mmHg, Htc > 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at ~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
76084277|NCT02231086|Procedure|Diagnostic laparoscopy|Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
76084278|NCT03353298|Drug|Allopurinol 300 mg|Allopurinol oral tablets 300 mg given to participants once daily for 9 months
76084279|NCT03353298|Drug|Placebo Oral Tablet|placebo oral tablets given to participants once daily for 9 months
76084280|NCT03354936|Biological|Blood sample|Blood samples will be collected to constitute cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy and possibly for complementary research
76084281|NCT03187210|Drug|Brentuximab Vedotin|Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
76084282|NCT03187210|Drug|BeEAM Regimen|standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
75651904|NCT04914923|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.
75651905|NCT04902885|Drug|Trilaciclib|Group 1: Trilaciclib, carboplatin, etoposide，or Topotecan Group 2: Trilaciclib, Topotecan Group 3: Placebo, carboplatin, etoposide，or Topotecan
75792590|NCT05198284|Diagnostic Test|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
75792591|NCT01221792|Drug|Carvedilol|"Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day)."
75792592|NCT01221792|Drug|Placebo|Non active comparator
76084283|NCT03349866|Drug|apatinib|apatinib：250mg qd po
76084284|NCT03349866|Drug|Capecitabine|1000mg/m2 bid d1-14
76084285|NCT03349866|Drug|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
76084286|NCT03349866|Radiation|Radiotherapy|45Gy/25f （1.8Gy/f/d，5 f/w）
75792593|NCT05702710|Other|Surgery (PIRS)|"Laparoscopic procedure for repair of inguinal hernia as described in:~1) Thomas DT, Göcmen KB, Tulgar S, Boga I. Percutaneous internal ring suturing is a safe and effective method for the minimal invasive treatment of pediatric inguinal hernia: Experience with 250 cases. J Pediatr Surg. 2016 Aug;51(8):1330-5. doi: 10.1016/j.jpedsurg.2015.11.024. Epub 2015 Dec 11. PMID: 26777889."
75798887|NCT01289262|Procedure|Purse string closure technique|Uterine incision will be closed with purse string closure technique.
75928902|NCT06143709|Other|DNA sample collection|Patients will be asked to provide a blood or mouth wash sample for DNA extraction
75928903|NCT06143696|Drug|Qingxin Zishen decoction|Oral administration, 1 dose daily, twice a day
75928904|NCT06143696|Drug|Femoston|Oral administration, 1 pill each time, once a day
75928905|NCT06143631|Drug|Letrozole 2.5mg|Oral letrozole 2.5mg/day
75928906|NCT06143631|Other|Placebo|Placebo capsule
76084287|NCT03354000|Behavioral|Take-home online training|We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.
76084288|NCT03354000|Behavioral|In-person online training|For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
75928907|NCT06143605|Procedure|salvage treatment|salvage radical surgery or endoscopic resection
76084289|NCT04503798|Behavioral|Online Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
76084290|NCT01629862|Device|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
75472508|NCT01959256|Behavioral|Visual perceptual learning|24 times of training for visual perceptual learning
75472509|NCT01959269|Drug|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
75472510|NCT01959295|Drug|ASP2151|200 mg once daily
75472511|NCT01959295|Drug|ASP2151 placebo|once daily
75472512|NCT01959308|Other||
75472513|NCT01959360|Procedure|Direct lateral|Total hip replacement; direct lateral approach
75472514|NCT01959360|Procedure|minimal invasive|Total hip replacement; minimal invasive approach
75472515|NCT01959360|Procedure|modified minimal invasive|Total hip replacement; modified minimal invasive approach
75472516|NCT01959373|Procedure|electroencephalograms (EEG)|
75792594|NCT03932526|Drug|Vinorelbine + placebo|Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
75792595|NCT03932526|Drug|Vinorelbine + Apatinib|Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
75644618|NCT00720967|Procedure|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs < 75 kg, and 4 hours if > 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
75644619|NCT00724633|Other|Lowering the dialysate sodium|Please see above
75472517|NCT01959373|Procedure|electro-myography (EMG)|
75472518|NCT01959386|Drug|Trastuzumab|Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
75472519|NCT01959399|Drug|ASP015K|oral tablet
75644620|NCT00577993|Drug|Fludarabine|Group 1= 25 mg/m^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
75472520|NCT01959399|Drug|Rosuvastatin|oral tablet
75644621|NCT00577993|Drug|Novantrone|Group 1 = 10 mg/m^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m^2 IV over 15 min. Day 2 of 3rd Sequence.
75644622|NCT00577993|Drug|Decadron|Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
75792596|NCT01127724|Drug|vitamin B12 treatment|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
75792597|NCT03932370|Procedure|endoscopic surgery|The procedure will be performed in an endourology room where a radiolucent operative table together with a C-arm, a video-camera unit and a Laser device are available. Irrigation fluids include normal saline and/or sterile water
75792598|NCT01226550|Procedure|cytoreductive surgery and HIPEC|"The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).~The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.~Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU)."
75792599|NCT03928470|Drug|EsoDuo Tab. 20/800mg|Nexium Tab. 20mg
75792600|NCT03927924|Procedure|High-intensity focused ultrasound|Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue
75472521|NCT01959438|Drug|Sodium selenite (Introselen)|Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
75792601|NCT01127412|Behavioral|Physical activity stimulating program|
75792602|NCT03103906|Other|Cream (Test product)|Moisturizing cream with SPF (Sun protecting factor) 20
75792603|NCT03103906|Other|Cleanser (Reference Product)|Moisturizing facial cleanser
75792604|NCT03103906|Other|Sunscreen (Reference Product)|SPF 50 sunscreen
75928908|NCT06143579|Drug|FOLFOX-HAIC+Lenvatinib+Envolizumab|"FOLFOX-HAIC: Oxaliplatin 130 or 85 mg/m2; leucovorin 200 mg/m2; fluorouracil 400 mg/m2 intravenous bolus followed by fluorouracil 2400 mg/m2 continuous infusion over 23 hours, Q3W, 2 to 4 cycles;~Lenvatinib: 8 mg/day (BW < 60 kg) or 12 mg/day (BW ≥ 60 kg), PO, 3-4 cycles;~Envolizumab: 300 mg, SC, Q3W, 3-4 cycles."
75472522|NCT01959438|Drug|Sodium selenite|Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
75472523|NCT01959451|Drug|Prasugrel|see Arm description
75472524|NCT01959451|Drug|Clopidogrel|see arm description
75472525|NCT01959477|Drug|busulfan|Given IV
75472526|NCT01959477|Drug|etoposide|Given IV
75472527|NCT01959477|Drug|cyclophosphamide|Given IV
75644623|NCT00577993|Drug|Rituximab|Group 1 = 375 mg/m^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m^2 IV Days 1 through 8 of 3rd Sequence.
75335329|NCT04755296|Other|Aerobic exercises|Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of <50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of<50% of the previously determined VO2max of each participant.
75792605|NCT01223664|Procedure|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
76084291|NCT01629862|Device|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
75335330|NCT04755296|Other|Traditional physical therapy program|Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
75472528|NCT01959477|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
75472529|NCT01959477|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
75928909|NCT06143553|Drug|Paclitaxel Polymeric Micelles for Injection|Subjects are given 300 mg/m2 of Paclitaxel Polymeric Micelles for Injection without special infusion device,intravenously administrated for ≥ 3 hours.Three weeks constituted one course of treatment.
75928910|NCT06143553|Drug|Eribulin Mesilate injection|Subjects are given 1.4 mg/m2 of Eribulin Mesilate injection on days 1 and 8 of the 21-day cycle.
75472530|NCT01959555|Other|No treatment given|Patients will not be treated with any specific product. Data collection only.
75928911|NCT06143553|Drug|Capecitabine Tablets|Subjects are given 1000-1250mg/m2 of Capecitabine Tablets on days 1 to 14 of the 21-day cycle ,and twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2).
76084292|NCT03354858|Procedure|Follicular flushing|Repeated follicle flushing up to 5 times using a double lumen needle for oocyte recovery
75335331|NCT01840046|Drug|Interleukin-2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5)."
75335332|NCT00437216|Drug|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
75472531|NCT01959568|Procedure|Vitrectomy and tamponade|"In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location."
76084293|NCT03354780|Other|Survey on first pregnancy after endometriosis diagnosis|rate of miscarriage was noted
76084294|NCT03354780|Other|Survey on first pregnancy|rate of miscarriage was noted
76084295|NCT04443894|Other|PECS block|PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
75335333|NCT00437216|Drug|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
75472532|NCT01959594|Drug|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
75472533|NCT01959594|Drug|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
75472534|NCT01959594|Drug|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
75644624|NCT00577993|Drug|Interferon|Group 1 = After Completion of Fludarabine, Novantrone, & Rituximab, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine & Novantrone, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year.
75644625|NCT00577993|Drug|Doxorubicin|25 mg/m^2 IV Days 2 & 3 of 1st Sequence.
75644626|NCT00577993|Drug|Vincristine|.7 mg/m^2 IV Days 2 & 3 of 1st Sequence; 1.4 mg/m^2 IV Day 2 of 3rd Sequence.
75792606|NCT01223664|Drug|Conserved therapy|Oral or intravenous administration
75792607|NCT01221870|Drug|Tesetaxel once every 3 weeks|Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
75792608|NCT01221870|Drug|Tesetaxel once weekly|Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
75792609|NCT05675098|Drug|Methylphenidate|This medication is a psychostimulant medication and is usually prescribed for individuals with Attention-Deficit/Hyperactivity Disorder to manage ADHD behavioral symptoms
75928912|NCT06143553|Drug|Gemcitabine Hydrochloride for Injection|Subjects are given 800-1200mg/m2 of Gemcitabine Hydrochloride for Injection on days 1, 8 and 15 of the 28-day cycle.
75928913|NCT06143553|Drug|Vinorelbine Tartrate Injection|Subjects are given 25mg/m2 of Vinorelbine Tartrate Injection every first day of the week.
75928914|NCT06143553|Drug|Paclitaxel (albumin-bound)|Subjects are given 260mg/m2 of Paclitaxel (albumin-bound) on day 1 of the 21-day cycle,intravenous administration for more than 30 minutes.
75928915|NCT06143527|Biological|AlloRx|Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
75928916|NCT06143501|Diagnostic Test|Blood Sample|6 ml blood (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
75928917|NCT06143501|Diagnostic Test|Stool Sample|pea-sized amount (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
76084296|NCT04443894|Other|local infiltration|local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
75335334|NCT00002524|Biological|Bleomycin Sulfate|
75928918|NCT06143501|Diagnostic Test|Urine Sample|8 ml (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
75928919|NCT06143475|Device|FPS group|"Vibration frequency ranged from 0 to 100 Hz. There were 3 modes of FPS application during rehabilitation course. 1) anti-spasticity mode (FV): the stimulators were placed in the middle of the muscles of the affected limb (i.e. unilaterally); 2) bilateral mode of proprioceptive facilitation; and 3) the unilateral mode of the proprioceptive facilitation.~The 2 first sessions were realized with bilateral FPS stimulations plus the anti-spasticity FV mode to reduce the level of hypertonia. Then for 6 consecutive sessions unilateral FPS stimulations of the affected sides imitating the drawing of a straight lines (horizontal, vertical, diagonal), preparing for writing (drawing a circle, triangle, square, spiral) were realized. At last, the 4 remaining FPS sessions were realized unilaterally imitating and promoting the realization of everyday life activities."
75928920|NCT06143475|Other|Conventional therapy group|Patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
75472535|NCT01959594|Drug|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
75335335|NCT00002524|Biological|Filgrastim|
75335336|NCT00002524|Drug|Cisplatin|
75335337|NCT00002524|Drug|Cyclophosphamide|
75335338|NCT00002524|Drug|Cytarabine|
75335339|NCT00002524|Drug|Doxorubicin Hydrochloride (DOX)|
75472536|NCT01959594|Drug|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
75472537|NCT01959620|Behavioral|1-Session Exposure Therapy|One exposure therapy session lasting one hour
75472538|NCT01959620|Behavioral|3-Session Exposure Therapy|Three exposure therapy sessions lasting one hour each, delivered one week apart
75472539|NCT01959646|Dietary Supplement|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
75472540|NCT01959646|Other|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
75644627|NCT00577993|Drug|Bleomycin|5 unit/m^2 IV Days 2 & 3 of 1st Sequence.
75472541|NCT01959646|Dietary Supplement|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
75644628|NCT00577993|Drug|Cyclophosphamide|750 mg/m^2 IV Day 2 of 1st Sequence.
75644629|NCT00577993|Drug|Etoposide|40 mg/m^2 IV Days 1 through 4 of 2nd Sequence.
75644630|NCT00577993|Drug|Cisplatin|25 mg/m^2 IV Days 1 through 4 of 2nd Sequence
75644631|NCT00577993|Drug|Ara-C|1.5 gm/m^2 IV Day 5 of 2nd Sequence.
75644632|NCT00577993|Drug|Methyl-Prednisolone|500 mg IV Days 1 through 5 of 2nd Sequence.
75644633|NCT00577993|Drug|Procarbazine|100 mg/m^2 PO Days 2 through 11 of 3rd Sequence.
75928921|NCT06143462|Drug|Usual care|Include anti-dizziness medications, diuretics, or hormone therapy.
75928922|NCT06143462|Other|Health Education|Include comprehensive health education, fall prevention and lifestyle adjustments.
75928923|NCT06143462|Behavioral|vestibular rehabilitation|Encompass office-based sessions of vestibular rehabilitation treatment once weekly, supplemented by home-based exercises conducted two or three times daily for the remaining duration of the study.
75472542|NCT01959711|Procedure|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
75472543|NCT01959711|Procedure|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
75472544|NCT01959724|Other|Vitrectomy|
75644634|NCT00577993|Drug|Prednisone|100 mg PO Days 1 through 5 of 3rd Sequence.
75644635|NCT00975806|Drug|Lenalidomide|Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
75644636|NCT00975806|Drug|Sunitinib|Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
75644637|NCT00725023|Device|TDP© Lamp|TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
75644638|NCT00725023|Device|Dummy TDP© Lamp|The dummy TDP© heat lamp is an electrical device with the heating element removed.
75644639|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection and mapping.
75644640|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection and mapping.
75644641|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
75644642|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
75644643|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
75928924|NCT06143423|Drug|AP026 (TQA2226) for injection|AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
75335340|NCT00002524|Drug|Etoposide|
75335341|NCT00002524|Drug|Fluorouracil|
75335342|NCT00002524|Drug|Ifosfamide|
75335343|NCT00002524|Drug|Leucovorin calcium|
75335344|NCT00002524|Drug|Methotrexate|
75335345|NCT00002524|Drug|Methylprednisolone|
75335346|NCT00002524|Drug|Pentamidine|
75335347|NCT00002524|Drug|Prednisone|
75335348|NCT00002524|Drug|Trimethoprim-Sulfamethoxazole|
75335349|NCT00002524|Drug|Vincristine Sulfate|
75335350|NCT00002524|Drug|Zidovudine (AZT)|
75335351|NCT00002524|Radiation|Radiation Therapy|
75472545|NCT01959737|Procedure|skin-to.skin-contact|Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
75792610|NCT05675098|Drug|Modafinil|This medication is a Central Nervous System stimulant and is usually used to treat neurological conditions, including Narcolepsy
75792611|NCT05675098|Other|Placebo|Participant will receive placebo tablets (Methylphenidate and Modafinil shape)
75792612|NCT01223742|Dietary Supplement|ACETYL-L-CARNITINE|2 g acetylcarnitine taken orally twice a day.
75928925|NCT06143423|Drug|AP026 (TQA2226) for injection matching placebo|AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.
75928926|NCT06143397|Device|TTNS (Transcutaneous tibial nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the tibial region will be activated, the parasacral electrodes will not be active. A Biolito (MTR+Vertriebs GmbH, Berlin) stimulator will be used to perform posterior tibial nerve stimulation. Stimulation will be delivered via two 50 mm x 50 mm adhesive electrode pads under the left medial malleolus and 5 cm proximal to the distal electrode. Appropriate electrode site will be confirmed by the presence of big toe plantar flexion during stimulation (stimulus intensity will be adjusted according to the patient's tolerance for 200 μs duration at 10 Hz frequency). Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
75335352|NCT05531357|Diagnostic Test|Transvaginal ultrasound scans|"Transvaginal ultrasound scans to map ovarian follicle growth and ovulation, finger-prick blood sampling for dried blood spot (DBS) hormonal assays and urine sampling for hormone metabolites, every consecutive day for an interovulatory interval.~Weekly venipuncture samples will be taken for standard ELISA hormonal assays. The hormones of interest are FSH, LH, estradiol, progesterone, AMH, inhibins A and B, GDF-9 and BMP-15."
75335353|NCT03736811|Device|Polyglactin 910 or polydioxanone|Vicryl or PDS II
75644644|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
75644645|NCT02865512|Procedure|thoracic epidural catheterization|thoracic epidural catheterization for the management of postoperative pain
75644646|NCT04288076|Other|PEEP Titrated Mechanical Ventilation|Subjects will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O and back down to 5 cmH20. Pleural pressure and intracranial pressure will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set > 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. At the completion of the study patients will be returned to the PEEP level they were on prior to titration of the ventilator.
75644647|NCT00721201|Drug|Mifepristone|Use of mifepristone 200mg bd for 8 weeks
75792613|NCT01223742|Drug|placebo|placebo twice per day
75792614|NCT03928002|Other|4D Flow magnetic resonance imagery|acquisition of anatomical, volume, right ventricular remodeling and intracardiac flow information
75792615|NCT03928002|Procedure|Cardiac catheterization|pulmonary vascular resistance calculation ;
75792616|NCT05197816|Device|Deep brain stimulation|Electrical pulses from implanted generator that adapts to patient activity and/or physiology
75792617|NCT05179330|Device|OMEGO®|Lower limb rehabilitation with and without visual feedback
75472546|NCT01959750|Behavioral|problem-based sessions|weekly sessions for small groups of caregivers, led by two psychologists acting as moderators and using a systemic approach, as suggested in other peer-support groups using a problem-based method
75335354|NCT03736811|Device|Polyester or polypropylene|Ethibond Excel or prolene
75335355|NCT03678467|Combination Product|EB-CMF|Autologous, anatomically shaped bone graft
75335356|NCT01349894|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
75335357|NCT00002536|Drug|cisplatin|
75335358|NCT00002536|Drug|vincristine sulfate|
75335359|NCT00002536|Procedure|surgical procedure|
75472547|NCT01959763|Behavioral|Weight loss counseling program|Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.
75472548|NCT01959776|Procedure|Vitrectomy|
75472549|NCT01959802|Procedure|Vitrectomy|
75472550|NCT01959828|Drug|IK-3001|
75472551|NCT01959854|Device|carboxymethylcellulose|0.25% carboxymethylcellulose preservative free
75472552|NCT01959854|Device|xanthan gum|0.2% xanthan gum preservative free
75335360|NCT00002536|Radiation|radiation therapy|
75335361|NCT01203319|Biological|60mcg/1.0ml recombinant hepatitis B vaccine|to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
75472553|NCT01959867|Device|SurgiMend® PRS|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
75792618|NCT01129518|Biological|Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine|"In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two."
75792619|NCT01129518|Biological|Routine schedule immunisations except monovalent MenC vaccine|Routine schedule immunisations will be given according to NHS guidelines.
75792620|NCT01226784|Behavioral|Physcial activity|Strenght training Relaxation exercise
75798888|NCT01289262|Procedure|Continuously locked closure technique|Uterine incision will be closed with continuously locked closure technique
75792621|NCT03740412|Behavioral|Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls|The intervention has multiple components in order to reduce sedentary behaviour, namely: incorporating individualised feedback on sitting time, education about sedentary behaviour, individualised goal-setting and environmental modification according to each participant's own behavioural patterns and capabilities, motivational interviewing, and biweekly phone calls.
75792622|NCT03924960|Behavioral|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
76084297|NCT03353142|Other|Equal Breathing|"Blood pressure recorded at baseline, immediately pre- and post-trial~Maximum Tolerable Breathing Ratio: Test run to determine the maximum tolerable time for inhalation and exhalation.~PRESSURE TOLERANCE: Pressure algometer device used to determine pain pressure tolerance. It will be applied to the first dorsal interosseous and deltoid, and pain pressure tolerance will be measured and recorded. Pressure will be applied at 1kg per second until the patient indicates that the pressure has become painful. Pain pressure tolerance will be performed 3 times at each anatomical location and an average will be determined for each location.~TRIAL: Participants will begin 5 minutes of Equal Breathing at their maximum tolerable equal breathing ratio that was previously determined. Immediately after 5 minutes of breathing, the pain pressure tolerance will be measured using pressure algometry"
75792623|NCT03924960|Behavioral|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
75928927|NCT06143397|Device|PNS (Parasacral nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the parasacral region will be activated, the tibial electrodes will not be active. For parasacral region stimulation, electrodes will be positioned symmetrically in the parasacral region under the posterior superior iliac spines to stimulate the S2 and S3 nerve roots. A duration of 200 μs at a frequency of 10 Hz will be set with the Biolito (MTR+Vertriebs GmbH, Berlin) stimulator. The intensity level will be adjusted according to the tolerance of the patient. Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
75928928|NCT06143397|Device|Sham stimulation|Electrodes will be placed in three areas simultaneously. These regions are the tibial and parasacral locations and the scapular region, with a distance of approximately 4 cm between the electrodes. Of these three regions, only the channel to the scapular region will be activated, the remaining two regions will be closed. Regarding the sham group, the parameters used in the scapular region will be applied with a frequency of 100 Hz, a pulse duration of 100 μs, and 30 minutes. This configuration is known as conventional transcutaneous electrical nerve stimulation and is commonly used for non-invasive and non-pharmacological treatment of pain.Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
75928929|NCT06143397|Behavioral|Behavioral treatment|It includes techniques and skills to prevent incontinence and restrain the urge to urinate. It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques. Additionally, advice on proper voiding position and an exercise protocol will be given. The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions. Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds. They will be told to do it twice a day, morning and evening. Participants will perform the behavioral training protocol at home.
75928930|NCT06143384|Device|Telemonitoring AirView (ResMed company)|Introduction of AirView telemonitoring of HMV, during a 6-months period.
75936421|NCT04717271|Other|Movement Guidance Group|"Participants of the MVG will received kinesthetic stimuli by manual assistance of the physiotherapist, which has the intention of guiding and improving the quality of movement during XBOX Kinect training for balance and gait.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
76084298|NCT01631110|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
75472554|NCT01959867|Other|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
75644648|NCT02865278|Other|Standard meal|The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
75644649|NCT02866370|Drug|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
75335362|NCT01203319|Biological|30mcg/1.0ml recombinant hepatitis B vaccine|to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
75335363|NCT01203319|Biological|10mcg/1.0ml recombinant hepatitis B vaccine|to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
75335364|NCT01344200|Drug|Celecoxib|In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
75644650|NCT02866370|Drug|Paclitaxel|"Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
75792624|NCT03924960|Behavioral|Control|Usual care control group
75798889|NCT02524782|Biological|MEDI-4166|MEDI-4166 administered subcutaneously
75798890|NCT02524782|Biological|Placebo|Placebo administered subcutaneously
75792625|NCT01131156|Behavioral|Smoking Relapse Prevention|Mothers were given information about normal newborn behaviors using books, DVDs, and handouts that were appropriate for their baby's gestational age and were also encouraged to participate in frequent skin-to-skin holding of their babies.
75335365|NCT01344200|Drug|Placebo|In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
75335366|NCT05521217|Diagnostic Test|MyotonPRO|"Evaluation of biomechanics and viscoelastic properties of posture muscle in children with Spinal Muscular Atrophy.~The biomechanical and viscoelastic properties of the posture muscle in children with Spinal Muscular Atrophy. will be measured with the MyotonPRO device."
75928931|NCT06143345|Other|High-Intensity Interval Training|"HIIT with Spin sessions that will include a 5-min warm-up, then an interval-based workout phase with steady up-tempo cadences, sprints, and climbs (interspersed with recovery periods), followed by a 5-min cool down.~All participants will wear Polar H10 chest strap heart rate sensors to ensure adequate intensity throughout each session and be instructed daily on their target heart rate range, computed using the Karvonen method. Phone calls will be made to the participants a day before each session to remind them about their scheduled session. Also, a log of the number of exercise sessions attended by each participant will be kept, which will be reviewed regularly to ensure high compliance with the intervention."
75928932|NCT06143345|Other|Standard exercise recommendations|Recommendation is ≥150 min of moderate-intensity physical activity per week distributed throughout the week with a minimum frequency of thrice a week.
75335367|NCT05696314|Diagnostic Test|Transoral Ultrasound|The oropharynx is scanned using high-frequency, small-footprint ultrasound transducers placed onto the suspected oropharynx sub-locations (e.g. tonsils or tongue base). Lidocaine spray or gel will be applied prior to scanning to reduce the gag reflex.
75335368|NCT05696314|Diagnostic Test|Transcervical Ultrasound|Curved low-frequency ultrasound transducers will be placed on the submental region on the skin of the neck, and the tongue base will be visualized in the midline in transverse and sagittal planes. The tonsils will be visualized adjacent to the tongue base on either side in oblique transverse and oblique sagittal planes, deep to the submandibular glands.
75472555|NCT01959958|Other|Questionnaire/Interview|Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
75472556|NCT01959971|Drug|alirocumab|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
75472557|NCT01959971|Drug|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
75644651|NCT02866370|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
75792626|NCT01223820|Drug|Capsaicin|5x nasal application in one day, 1 hour between each application
75792627|NCT03931044|Procedure|Image-Guided Robotic Gastrectomy|The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.
75928933|NCT06143345|Device|Continuous glucose monitoring (CGM) (Dexcom G6 Pro CGM sensor)|The CGM system includes a sensor, a transmitter, and a receiver. The sensor measures the interstitial fluid glucose levels every 5 minutes, and the transmitter sends glucose data wirelessly from the sensor to the receiver. Participants will undergo measurements at baseline and after 4 weeks of intervention.
75928934|NCT06143332|Other|Aerobic exercise training|Aerobic exercise training on a cycle ergometer
75792628|NCT01228266|Biological|autologous mesenchymal stem cells|A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
75335369|NCT01204255|Drug|lorazepam|Given topically
75335370|NCT01204255|Drug|diphenhydramine hydrochloride|Given topically
75335371|NCT01204255|Drug|haloperidol|Given topically
75335372|NCT01204255|Other|questionnaire administration|Ancillary studies
75335373|NCT01204255|Other|laboratory biomarker analysis|Correlative studies
75335374|NCT00002542|Drug|CMF regimen|
75335375|NCT00002542|Drug|cyclophosphamide|
75335376|NCT00002542|Drug|doxorubicin hydrochloride|
75335377|NCT00002542|Drug|epirubicin hydrochloride|
75335378|NCT00002542|Drug|fluorouracil|
75792629|NCT01131234|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
75792630|NCT01131234|Drug|Cediranib Maleate|Given PO
75792631|NCT01131234|Other|Pharmacological Study|Correlative studies
75792632|NCT01131234|Other|Laboratory Biomarker Analysis|Correlative studies
75792633|NCT03924726|Procedure|Micro-osteoperforation (MOP)|Micro-osteoperforation technique is used to accelerate orthodontic tooth movement.
75792634|NCT01129596|Drug|donepezil hydrochloride|This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
75792635|NCT04799158|Drug|Vonoprazan|Orally via capsules
75792636|NCT04799158|Drug|Placebo|Orally via capsules
75335379|NCT00002542|Drug|methotrexate|
75335380|NCT00002542|Drug|tamoxifen citrate|
75335381|NCT00002542|Radiation|radiation therapy|
75472558|NCT01959984|Other|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
75472559|NCT01959984|Other|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
75472560|NCT01959997|Procedure|Redo PVI|
75472561|NCT01959997|Procedure|PVI + RDN|
75792637|NCT03632980|Device|"Ablatherm Foc/Dyn or Focal One HIFU treatment"|"Non invasive treatment of localized prostate cancer by High Intensity Focused Ultrasound therapy, endorectal application.~or Non invasive treatment of localized prostate cancer recurrency by High Intensity Focused Ultrasound therapy after radiotherapy failure, endorectal application."
75792638|NCT03632902|Device|supraglottic device|airway management will be collected
75792639|NCT03930888|Dietary Supplement|Dietary supplement|Patients with preoperative nutritional support with special nutritional supplements vs. patients without special nutritional support.
75335382|NCT01333826|Behavioral|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
75644652|NCT02866370|Drug|Topotecan|"Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
75792640|NCT04677244|Procedure|Blood sample in portal vein|A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.
75792641|NCT03924882|Drug|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
75792642|NCT01223898|Drug|Tasigna|
75792643|NCT01223976|Other|Tuberculin skin test and Quantiferon -TB Gold test|"TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.~QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions."
75792644|NCT03924648|Other|Endocan levels|Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.
75928936|NCT06143280|Other|Data collection|Data collection using entries in the medical records of the respective patients (surgery reports, progress notes, consultation reports, imaging and pathology reports) who underwent surgery with the new dynamic technique for soft palate reconstruction.
75335383|NCT02246465|Drug|RXI-109|
75792645|NCT01127880|Drug|Ancef or Clindamycin|1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
75644653|NCT02866370|Drug|Carboplatin|"Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
75928937|NCT06143267|Other|Infusion of either NST or placebo at different blood glucose levels|In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
75335384|NCT01156597|Drug|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
75644654|NCT02866370|Drug|Doxorubicin|"Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
75644655|NCT05182801|Dietary Supplement|Placebo sachet|Blank
75792646|NCT01127880|Drug|Placebo|.9% Normal Saline as a placebo
75335385|NCT03015623|Biological|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
75928938|NCT06143241|Device|Threshold IMT|Threshold is used in respiratory muscle training in the form of resistance loading.
75928939|NCT06143241|Drug|Antiepileptic medication|They will continue their antiepileptic medication prescribed by their doctor.
75644656|NCT05182801|Dietary Supplement|Banana flower extract sachet|Happy Angel Banana Flower Extract sachet
75644657|NCT00721435|Procedure|3D Tomosynthesis and ultrasound imaging|3D tomosynthesis & ultrasound imaging for scanning masses or healthy breast tissue
75644658|NCT03906019|Procedure|ESP Block|Erector spinae plane block performed with 0,25% bupivacaine (0,5 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
75335386|NCT03015623|Device|Sham|The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
75335387|NCT01331408|Device|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
75472562|NCT01960023|Drug|Cetuximab|400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
75472563|NCT01960023|Drug|Neratinib|"Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study."
75472564|NCT01960036|Behavioral|Mindful Awareness in Body-oriented Therapy|
75472565|NCT01960036|Behavioral|Womens Health Education|
75644659|NCT03906019|Diagnostic Test|FLACC score|For up to 7 years old patients, Face, Legs, Activity, Cry and Consolability (FLACC) scores during postoperative 24h period.
75644660|NCT03906019|Diagnostic Test|NRS score|Patients older than 7 years, NRS scores during postoperative 24h period.
75644661|NCT00978068|Drug|Lopinavir/Ritonavir (LPV/r)|
75644662|NCT00978068|Drug|Nevirapine (NVP)|NVP will be used for children < 3 years of age
75644663|NCT00978068|Drug|Efavirenz (EFV)|EFV for children ≥3 years of age
75644664|NCT00978068|Drug|2 nucleoside reverse transcriptase inhibitor (NRTI)|The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
75792647|NCT01228344|Other|Artemether-lumefantrine|
75792648|NCT03924570|Behavioral|IPASS|IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
75335388|NCT01156987|Device|Magnetic resonance imaging|"Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~an IV line is placed by nurse,~patient is placed in the 4 T MRI scanner at CMRR,~initial scout images and manual linear shims are adjusted,~Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~continuous SWIFT acquisition begins immediately before contrast injection,~contrast injection,~continuous SWIFT acquisition continues for 12 min after contrast,~late enhancement images may also be obtained.~10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods."
75644665|NCT02863952|Other|Single photon emission computed tomography myocardial perfusion imaging|
75792649|NCT03927456|Drug|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
75792650|NCT03927456|Drug|Placebo|Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
75928940|NCT06143215|Behavioral|2 weeks revision|In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 2-4-6 weeks revision times could change diabetic foot reulceration rate.
75928941|NCT06143202|Device|Dexcom Pro CGM|Pediatric participants will wear a blinded Dexcom Pro CGM. Data will not be available, and therefore the device will not be used to modify medical management.
75928942|NCT06143189|Other|Hosting conditions|"Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments."
75928943|NCT06143189|Other|Hospital Clowns|"The HCs Palhaços D'Opital (PdO) have a program aiming to bring joy, affection and good mood to adults and elders in hospital environment. They work in pairs, dressed in colorful costumes and they prepared sketches in advance. Their performances recreate day-to-day situations (e.g., clowns trying to install a new TV screen; planning a wedding between the clowns and asking the public for their ideas), ending with specific closure, in order to indicate to the audience that the session had finished and to promote a positive environment after their departure. Each intervention lasted around 15 minutes."
75644666|NCT02863952|Device|novel cadmium-zinc-telluride (CZT) SPECT cameras|
75644667|NCT00725257|Other|Mediterranean diet|The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
75644668|NCT00725257|Other|Low-fat diet|The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
75792651|NCT03927456|Drug|Fulvestrant|Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
75928944|NCT06143176|Behavioral|VR-based occupational therapy|All patients will undergo 20 sessions of virtual reality based occupational therapy for 30 minutes a day, 5 days a week for 4weeks
75472566|NCT01960049|Procedure|ropivacaine + iv PCA|
75472567|NCT01960049|Procedure|saline and IV PCA|
75472568|NCT01960062|Device|Diabetes software and device|USB cord, CD-rom, and application to allow communication with provider
75472569|NCT01960088|Drug|HPV vaccine|
75792652|NCT01127958|Device|PCI with a drug-eluting balloon|PCI with a drug-eluting balloon for in-stent restenosis
75792653|NCT01127958|Device|PCI with a drug-eluting stent|PCI with a drug-eluting stent for in-stent restenosis
75792654|NCT01129752|Other|No intervention|there is no intervention for this study
75792655|NCT01129830|Dietary Supplement|dehydroepiandrosterone|DHEA supplementation 25 mg tid for 3 months
75792656|NCT01228422|Biological|Interferon alpha 2a|3MUI
75792657|NCT01319422|Drug|Pomalidomide|Comparison of different dosages and schedules of drug
76084299|NCT04507698|Other|Intensive Exercise Intervention|INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.
76084300|NCT03353064|Other|Vivify|A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.
75798891|NCT01290744|Drug|Clofazimine|Clofazimine 100mg daily for 12 months after completion of MDT.
75798892|NCT01290744|Drug|Placebo|Daily for 12 months
75798893|NCT01181388|Procedure|administration of tirofiban by thrombus aspiration catheter in infarct-related artery|a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
75798894|NCT01181388|Procedure|administration of tirofiban by guide catheter|a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
75798895|NCT01180452|Procedure|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
75798896|NCT01181466|Device|AeriSeal System|The AeriSeal System will be Administered at 3 to 4 Pulmonary Subsegments During a Single Treatment session.
75928945|NCT06143150|Other|transthoracic ultrasound|"The following parameters will be assessed by TUS:~Diaphragmatic copulae position and mobility (inspiratory time, excursion, diaphragmatic thickening fraction TF , excursion time E-T index )"
75792658|NCT03931122|Device|Ear Size Based Method (Ambu® AuraOnce™ Laryngeal Mask Airway)|"The Laryngeal Mask Airway (LMA) is one of the devices used to maintain airway during general anesthesia. Its appropriate size is selected according to patients body weight as recommended by the manufacturer.~However its appropriate size can also be selected via several other methods and one of them is patients external ear size. In this study the investigators will compare external ear size based method for LMA selection with the standard weight based method for LMA size selection.~Vertical Ear length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal Ear length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W)~LMA Size LMA Cuff Length (cm) corresponding to vertical ear length.~LMA Cuff Width (cm) corresponding to horizontal ear width."
75792659|NCT01228500|Device|PriMatrix|Dermal Repair Scaffold
75928946|NCT06143124|Drug|Bismuth Subcitrate|shorter duration of therapy (7 instead of classical 14 days) with four dugs instead of three (adding Bismuth subcitrate).
75792660|NCT05633290|Diagnostic Test|CMR|CMR Imaging 6-10 weeks post hospital discharge.
75644669|NCT04289558|Drug|Sodium Nitrite|Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
76084301|NCT03353064|Other|EMS|Emergency medical service scheduled home visits for face to face troubleshooting of the NIPPV, environmental check and end-tidal CO2.
75792661|NCT05633290|Diagnostic Test|hs-troponin|Biomarker of myocardial injury
75792662|NCT05633290|Diagnostic Test|NT-pro BNP|Biomarker for heart failure
75792663|NCT05633290|Diagnostic Test|CRP|Acute phase inflammatory marker
75792664|NCT05633290|Diagnostic Test|IL1-B|Inflammatory biomarker
75792665|NCT05633290|Diagnostic Test|IL-6|Inflammatory Biomarker
75792666|NCT05633290|Diagnostic Test|IL-10|Inflammatory Biomarker
75792667|NCT05633290|Diagnostic Test|TNF-alpha|Inflammatory Biomarker
75335389|NCT03015311|Drug|Intensive BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
75472570|NCT01960101|Other|LactoXeros|
75928947|NCT06143111|Device|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
75928948|NCT06143111|Device|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
75928949|NCT06143085|Procedure|Root surface debridement|Periodontitis patients are treated non-surgically by supra- and subgingival debridement followed by root surface debridement for moderately deep periodontal pockets (4 to 6mm)
76084302|NCT01631656|Drug|Azelaic acid|15% gel on half the face, twice daily, 6 weeks
76084303|NCT01631656|Device|Nd:Yag laser|Treatment with Nd:Yag laser , once at Week 2.
76084304|NCT04503876|Other|Increasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
75472571|NCT01960101|Device|Aequasyal|
75472572|NCT01960153|Drug|Tadalafil|Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
75644670|NCT00725335|Procedure|curative resection without Pringle|Radical excision of liver cancer without the procedure of pringle manoeuvre
75644671|NCT00725335|Procedure|curative resection with Pringle manoeuvre|curative resection liver cancer under pringle manoeuvre
75644672|NCT00629642|Drug|Solifenacin Succinate|Oral, 10mg
75644673|NCT00629642|Drug|Solifenacin Succinate|Oral, 5mg
75644674|NCT00629642|Drug|Oxybutynin Hydrochloride|Oral, 15mg
75644675|NCT00629642|Drug|Placebo|Oral
75644676|NCT02571751|Device|UNIGEL Silicone Gel-Filled Breast Implant|
75644677|NCT02865356|Drug|Cyclosporine 5% solution|topical solution
75792668|NCT01129986|Device|DermaStream|Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
75792669|NCT04545112|Device|CABG|Elective, on-pump coronary artery bypass (CABG) surgery. Each study subject will receive an internal mammary artery (IMA) conduit to the left anterior descending (LAD) coronary artery, one saphenous vein graft and one XABG medical device.
75792670|NCT03931278|Other|learning and recall of a sequence of body movements|The objective of this study to investigate, if learning and recall of a sequence of body movements (steps that realize a pattern on the ground) can be improved by self-produced music (having particular melodic-structures in relation to the pattern), compared to the same sound (a single tone) for each pattern in persons
75792671|NCT01227096|Device|Electrical acupuncture stimulation|electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
75792672|NCT05416606|Procedure|transurethral bipolar enucleation and resection of the prostate|transurethral bipolar enucleation and resection of the prostate
75792673|NCT05416606|Procedure|open surgical transvesical prostatectomy|open surgical transvesical prostatectomy
75798897|NCT03857568|Drug|SHR0410|drug will be dosed repeatedly
75798898|NCT03857568|Drug|Placebo|Placebo will be dosed repeatedly
76084305|NCT04503876|Other|Decreasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
76084306|NCT04507542|Behavioral|Enriched Music-Supported Therapy|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program is based on musical training, combining self-training sessions of music playing using an app for electronic tablets and music therapy group sessions.
76084307|NCT04507542|Behavioral|Graded Repetitive Arm Supplementary Program|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program comprises self-training sessions of mass repetition of movements and task-specific exercises for the upper extremity.
75928950|NCT06143033|Other|DIME Beauty Luminosity Eye Serum|Test product contains: Water/Aqua, Organic Aloe Vera Juice, Lycium Barbarum (Goji Berry) Fruit Extract, Vitis Vinifera (Grape Seed) Extract, Cucumis Sativus (Cucumber) Extract, Glycerin, Niacinamide, Squalane, Camellia Seed Oil, DL-Panthenol (Vitamin B5), Carbomer, Sodium Hyaluronate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Phenoxyethenol, Caprylyl Glycol, Acacia Senegal Gum, Caffeine, Helianthus Annuus (Sunflower) Seed Oil, Malus Domestica (Apple) Fruit Stem Cell Extract, Argania Spinosa (Argan) Sprout Stem Cell Extract, Tetrahexyldecyl Ascorbate (Vitamin C), Acetyl Tetrapeptide, Acetyl Hexapeptide-8, Vitamin E Mixed Tocopherols, Sodium Hydroxide.
75792674|NCT01224132|Drug|probiotic ® pur|daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
76084308|NCT01632202|Device|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
75644678|NCT02865356|Drug|Placebo|topical vehicle solution
75335390|NCT03015311|Drug|Standard BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
75335391|NCT03011125|Drug|dexlansoprazole injection|
75644679|NCT04287686|Drug|Recombinant human angiotensin-converting enzyme 2 (rhACE2)|In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
75644680|NCT00721669|Drug|IMGN388|IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
75644681|NCT02865200|Other|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique.
75644682|NCT02865200|Other|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
75644683|NCT00725569|Drug|Bellis perennis and Staphysagria (C6)|homeopathic remedy
75644684|NCT00725569|Drug|Bellis perennis and Staphysagria (C30)|Homeopathic Remedy
75644685|NCT00725569|Drug|Placebo|Placebo remedy, identical in size, shape and taste to treatment remedies
75335392|NCT03011125|Other|placebo|
75644686|NCT04287842|Drug|Desflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest.
75928951|NCT06143007|Drug|BB3008 tablet|BB3008 tablets will be administered orally once daily (QD).
75928952|NCT06142994|Dietary Supplement|Atusin CAP|This food supplement contains a distillate of 4 types of purified oils - eucalyptus, sweet orange, lemon and myrtle, rich in 1,8-cineol, limonene, alpha-pinene in the ratio: 66:32:1:1, bromelain and green Brazilian propolis in a gastro-resistant capsule. The product contains excipients: microcrystalline cellulose, silica dioxide, copovidone, magnesium stearate.
76084309|NCT01632202|Device|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
76084310|NCT02985190|Drug|Azacitidine|Azacitidine at 75mg/m²/j for 7 days.
76084311|NCT01634620|Device|NIOX MINO® Instrument (09-1100)|"FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)"
76084312|NCT01635244|Device|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
75644687|NCT04287842|Drug|Sevoflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
75335393|NCT05749978|Behavioral|Asana adjustment|Adjust the operating table to 15° head height and foot low in advance. The patient is then slowly turned over from the transport table to the operating table and completed in the prone position. After the patient's hemodynamic stability is smooth, adjust the operating table to the level.
75335394|NCT03015545|Device|paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
75335395|NCT03015545|Device|paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
75792675|NCT01227174|Drug|Propofol|Procedural sedation will be achieved using propofol
75792676|NCT03924258|Diagnostic Test|Iron status testing|Blood sample for iron status testing
75792677|NCT05415904|Other|HANTA-NE|Observational cohort study
75792678|NCT03924492|Drug|ZULRESSO (brexanolone) injection|ZULRESSO
75335396|NCT03015545|Device|non-paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
75335397|NCT03015545|Device|non-paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
75335398|NCT05749900|Drug|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
76084313|NCT01636102|Biological|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
75335399|NCT03541577|Device|TruePhysioTM Microcatheter|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
76084314|NCT01376310|Drug|GSK1120212|up to 2 mg/day
76084315|NCT01376310|Drug|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
76084316|NCT01376310|Drug|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
75335400|NCT03541577|Device|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
75472573|NCT01960153|Drug|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
75644688|NCT04287842|Procedure|Cardiac arrest|Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
75644689|NCT02864186|Device|control|Women wont use support bra 24 hours a days for six months
75644690|NCT02864186|Device|surgical support bra|Women will use surgical support bra 24 hours a day for six months
75644691|NCT02864186|Device|common support bra|Women will use common support bra 24 hours a day for six months
75644692|NCT00721747|Drug|Docetaxel, Liposomal doxorubicine and Cyclophosphamide|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
75644693|NCT00721825|Drug|Neuroaid|Neuroaid capsules, 4 capsules, three times per day, during one month
75644694|NCT00721825|Drug|Neuroaid matched Placebo|Neuroaid matched placebo 4 capsules three times per day during one month
75928953|NCT06142994|Dietary Supplement|Placebo|The placebo product will be identical in shape, appearance and color to the active product and will have the same composition but without the active ingredients.
75928954|NCT06142981|Biological|PRP and PBD-VSEL Stem Cell therapy|The intervention began with the administration of three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
75928955|NCT06142968|Diagnostic Test|laboratory tests|Laboratory tests inform of Complete blood count , liver function tests , kidney function tests abdominal ultrasound
75928956|NCT06142916|Other|Vırtual Realıty Traınıng On Mental Health Lıteracy And Stıgma|Nurses in the intervention group will be taken to a suitable room on the ward and virtual reality glasses will be worn. Mental health literacy training prepared by researchers by scanning the literature will be given using virtual reality glasses. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. Animations will be prepared for each topic. The training is planned to last 45 minutes.
75928957|NCT06142916|Other|Classical Education|Nurses in the control group will be given mental health literacy training using the classical method using brochures. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. The training is planned to last 45 minutes.
76084317|NCT01376310|Drug|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
75472574|NCT01960166|Behavioral|Active Distraction|iPad will be used as active distraction
75472575|NCT01960166|Behavioral|Passive Distraction|child will watch TV as passive distraction
75472576|NCT01960179|Drug|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
75472577|NCT01960192|Drug|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
75928958|NCT06142903|Other|7 versus 21 medically tailored meals per week|Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.
76084318|NCT01376310|Drug|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
76084319|NCT01376310|Drug|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
76084320|NCT01376310|Drug|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
76084321|NCT01376310|Drug|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
76084322|NCT01949506|Radiation|SBRT|Stereotactic Body Radiation Therapy
76084323|NCT03349788|Procedure|LCA-nP|The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.
76084324|NCT03349788|Procedure|LCA-P|The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
75928959|NCT06142877|Behavioral|Social Media Use Reduction|Participants will be incentivized to reduce their social media use by a pre-specified percentage from baseline.
76084325|NCT01829386|Other|MRI scans with non heme iron levels|"MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research."
75644695|NCT04859803|Procedure|Patients will be received rhomboid intercostal block under ultrasound guidance.|Following endotracheal intubation, patients allotted to the RIB group were positioned in the lateral decubitus position with the chest on the operating side lying superiorly. The ipsilateral arm was abducted from the chest to move the scapula laterally. The RIB was performed as described previously [8]. A high-frequency (6-12 MHz) linear ultrasound probe (LOGIQ e ultrasonic system, Deutschland GmbH & Co. KG, Solingen, Germany) was placed medial to the medial border of the scapula in the oblique sagittal plane. The landmarks, i.e., the trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung, were identified in the ultrasound. Under aseptic conditions, an 80-mm 21-gauge needle was inserted at the level of T6-7 in the ultrasound view. A single dose of 30 ml 0.25% bupivacaine will be injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography.
75644696|NCT04859803|Drug|conventional intravenous analgesia|Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
75644697|NCT00603525|Drug|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
75644698|NCT00603525|Drug|Placebo|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
75644699|NCT02570191|Drug|Peginterferon alfa-2a|180 uG in 0.5 mL solution administered once weekly for 48 weeks
75644700|NCT03680287|Drug|Within-Subject test of blinded study medication|On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
75644701|NCT02689401|Drug|Ferumoxytol|
75928960|NCT06142864|Other|Data collection|Data collection
75928961|NCT06142851|Other|Data collection|data collection
75928962|NCT06142838|Behavioral|community pharmacist intervention|The community pharmacist intervention comprises 2 parts: (1) first prescription counseling (oral and written information), and (2) a follow-up consultation (by telephone or in person) 7-14 days later, to identify problems with adherence/treatment
76084326|NCT04507386|Behavioral|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
76084327|NCT03349554|Other|body-scan meditation|15 minutes audio-guided body-scan meditation
75335401|NCT02973178|Device|Scanadu Urine Device|Device to allow lay user to perform urinalysis test at home.
76084328|NCT03349554|Diagnostic Test|Psychological evaluation|"NPI (Neuropsychiatric symptoms Inventory) - PAS (Parkinson's disease Anxiety Screening Questionnaire) - VAS measuring pain, anxiety and discomfort Before and after body-scan meditation"
76084329|NCT04506996|Behavioral|Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management|see arm/group descriptions
75335407|NCT05749666|Drug|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 24 weeks
75335408|NCT05749666|Drug|Prednisolone|Prednisolone taken daily according to preset tapering protocol
75644702|NCT02689401|Device|MRI 3T scanner|
75335409|NCT05749666|Other|Placebo of tofacitinib 5mg|Placebo of tofacitinib 5mg BID taken orally for 24 weeks
75335410|NCT05749666|Other|Placebo of prednisolone|Placebo of prednisolone taken daily according to preset tapering protocol for 24 weeks
75644703|NCT02570659|Behavioral|Information Video|A 14 minutes intervention video explaining the mechanism of the injury from cross-professional point of view and physiotherapeutic advise
75928963|NCT06142825|Other|Community-Facility Transfusion Committee (CFTC)|Community-Facility Transfusion Committees (CFTCs) are intended to incorporate diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care.
75928964|NCT06142799|Procedure|root canal treatment|The root canal completedwill be completed. Then randomly it will be decided if the planned and milled overlay is placed the same day or delayed one week
75928965|NCT06141252|Device|Hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated with hypothermia
75928966|NCT06140888|Drug|Ginkgo Biloba Extract|Ginkgo biloba extract 8 pills three times per day is administrated.
75928967|NCT06140511|Diagnostic Test|Polysomnography|Polysomnography for the assessment of the presence of REM sleep without atonia (RSWA). All Units will recruit subjects to be included in the cohort and this will ensure the inclusion of a sufficiently large sample of subjects without and, especially, with RSWA. From a previous study [Ferri et al. Sleep 2018:zsy187] that we carried out on a similar group of subjects, we know that we can expect to find RSWA in approximately 14% of individuals.
75644704|NCT02683551|Procedure|Sutureless Thyroidectomy|Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.
75792679|NCT03927534|Behavioral|Mindful Eating|The ME group will be composed by 7 weekly group sessions with a minimum duration of two hours, mixing theoretical contents with practices. Sessions will always be the same day of the week, except for bank holidays or eventualities, and will be conducted by a psychologist specially trained and certified in ME with experience in leading mindfulness groups. Group sizes will range between 10 and 12 participants. At the end of each session, participants will receive theoretical contents and homework activities to be practiced along the week.
75792680|NCT01329276|Drug|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
75928968|NCT06140485|Dietary Supplement|NW Low-Glu®|One NW Low-Glu® capsule contains Mas Cotek powdered Extract 300 mg (from leaves of Ficus deltoidea Jack by aqueous solvent extraction) + Cinnamomum cassia L. powdered Extract 100 mg + Black seed powdered extract 250 mg (from seeds of Nigella sativa L. by 70% hydro-alcoholic extraction).
75472578|NCT01960192|Drug|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
75644705|NCT00726115|Drug|SAM-531|
75644706|NCT00726115|Drug|placebo|
76084330|NCT04506996|Behavioral|Monday-Focused Written Messages for Weight Management|see arm/group descriptions
75335411|NCT03295799|Other|Patient Self-Management|Patient will manage their own warfarin therapy.
75644707|NCT00726193|Device|OsteoGen|OsteoGen Implatable stimulator
75472579|NCT01960205|Drug|Saxagliptin|5mg a day for 6 months
75644708|NCT00640497|Biological|IT-Combination|The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
75928969|NCT06140485|Drug|Metformin|Patients in the active comparator arm will receive a total of 2000 mg of metformin per day.
76084331|NCT04506996|Behavioral|Educational Materials|After the baseline assessment and the 1st follow-up (~8 weeks post randomization), participants received educational materials regarding physical activity and healthier diets. The study staff reviewed these materials with the participants
76084332|NCT04509882|Drug|bear bile pill|Bear bile pill (15 pills) taken orally three times a day after meals with water.
75472580|NCT01960205|Drug|saxagliptin|2.5 mg a day for 6 months
75472581|NCT01960205|Drug|metformin|500mg three times a day for 6 months
75644709|NCT00726271|Dietary Supplement|light olive oil, fish oil capsules, flax seed oil capsules|fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
75644710|NCT04293627|Behavioral|ATTAIN|ATTAIN is an 8-step model to identify co-occurring mental health conditions and facilitate linkage to mental health services for youth with an existing autism spectrum disorder diagnosis.
75644711|NCT00640575|Drug|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
75644712|NCT00640575|Drug|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
75644713|NCT04067791|Dietary Supplement|Prolonged-Release Melatonin|4.47 mg melatonin in a bi-layer prolonged-release capsule
75644714|NCT04067791|Dietary Supplement|Immediate-Release Melatonin|4.47 mg melatonin in a standard release bi-layer capsule
75644715|NCT00762034|Drug|Pemetrexed|Induction therapy 500 milligram per meter squared (mg/m^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
75644716|NCT00762034|Drug|Pemetrexed|Maintenance therapy 500 mg/m^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
75792681|NCT01224366|Drug|Vildagliptin|
75792682|NCT01224366|Drug|Placebo|
75928970|NCT06140394|Other|diode laser|low level diode therapy
75928971|NCT06140394|Other|non surgical scaling|non surgical scaling using ultrasonic
75928972|NCT06138990|Diagnostic Test|Pharmacoscopy|Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
75928973|NCT06138990|Drug|Clinical standard-of-care (physician's choice)|Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
76084333|NCT04509882|Drug|placebo|Placebo(15 pills) taken orally three times a day after meals with water.
76084334|NCT04509960|Device|direct laryngoskopy|Proseal Laryngeal mask inserted with direct laryngoskopy
76084335|NCT03352986|Biological|biological analysis|biological analysis will be performed in the 6 groups of patients
75335412|NCT05449535|Drug|JYB1904|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
75335413|NCT05449535|Drug|Omalizumab|Dosage form: injection, powder, lyophilized, for solution； Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.
75335414|NCT05449535|Drug|JYB1904 Placebo|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
75472582|NCT01960205|Other|lifestyle intervention|lifestyle intervention for 6 months
75472583|NCT01960231|Other|OGTT|
75472584|NCT01960270|Device|Device: INTERSTIM II|A second stimulator is implanted on controlateral site
76084336|NCT03352986|Other|peripheral arterial tonometry|peripheral arterial tonometry will be performed in the 6 groups of patients
76084337|NCT03349398|Procedure|Uncut Roux-en-Y reconstruction|Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
76084338|NCT03349398|Procedure|Roux-en-Y reconstruction|Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
76084339|NCT01585402|Drug|Etidronate|Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
76084340|NCT01585402|Device|MRI Scan|Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.
76084341|NCT01636414|Procedure|Hemovac drain|The Hemovac drain is a device placed under your skin used to collect blood during surgery.
76084342|NCT01636414|Procedure|Re-infusion drain|This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
76084343|NCT01636414|Procedure|Tranexamic drain|Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
75472585|NCT01960283|Drug|Methotrexate (Novatrex ®) + anti-H1|"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."
75472586|NCT01960283|Drug|Placebo + anti-H1|"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."
75472587|NCT01960309|Other|Minimal invasive cardiac imaging|"Coronary CT angiography (CCTA)~Coronary magnetic resonance imaging (CMR)~Echocardiography"
75472588|NCT01960322|Behavioral|Telemetric|A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
75644717|NCT00762034|Drug|Paclitaxel|Induction therapy 200 mg/m^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
75644718|NCT00762034|Drug|Carboplatin|Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
75644719|NCT00762034|Biological|Bevacizumab|Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
75644720|NCT00762034|Biological|Bevacizumab|Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
75644721|NCT02683317|Dietary Supplement|docosahexaenoic acid|Docosahexaenoic acid is a dietary supplement derived from algae.
75644722|NCT02683317|Dietary Supplement|sunflower oil|Sunflower similar to the excipient used in experimental group
75928974|NCT06138730|Behavioral|Appa Complete|Weekly mentorship meetings & guided CBT videos. Participants assigned to Appa Complete will have unlimited access to the Appa website and materials described in Appa Lite, along with weekly mentorship meetings with a trained and supervised near-peer mentor with whom they have been matched. Matching is based on preference for mentor gender, racial/ethnic minority status, and LGBTQ status and is designed to increase the sense of identification with the mentor and peer-mentor alliance. Virtual meetings begin with a review and discussion of the video and other materials for the week. Mentors ask about how clients are incorporating their CBT learnings into their life, share ways they have used the focal skills in their own lives, illustrate skills use in popular culture, and provide problem solving strategies. Each week has a specific prompt to ensure that clients are applying the concepts and skills they are learning and can talk about any questions or reflections with their mentors.
75936422|NCT04717271|Other|No Movement Guidance Group|"Participants of the NO-MVG will not received kinesthetic stimuli by manual assistance of the physiotherapist during XBOX Kinect training for balance and gait.~They will perform the exercises without any manual correction. Although, the physiotherapist will be present during all session to ensure their safety.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
76084344|NCT03352830|Behavioral|RANAS Behavior Change Intervention|The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.
75644723|NCT02571829|Drug|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
75644724|NCT02683395|Drug|PLX51107|
75644725|NCT00721903|Procedure|Ultrasound Scan|10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.
75644726|NCT00721903|Procedure|Mammography and Ultrasound|To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
75644727|NCT00722059|Procedure|Breast Tomosynthesis|3D breast imaging
75928975|NCT06138730|Behavioral|Appa Lite|Unguided EBP videos and materials. Participants assigned to the Appa Lite condition will have unlimited access to the Appa website, including short form CBT-based videos and materials such as an emotions wheel pdf and thoughts, feelings, and behavior worksheets. The website is structured so that the materials are presented in a developmentally appropriate manner consistent with evidence-based principles in a 12-week format, beginning with general psychoeducation to define mental health, proceeding to introducing CBT and basic CBT skills such as identifying thoughts, feelings, and behaviors, layering on applying specific CBT skills, and ending with reflective journal exercises. Client progress through the materials will be completely unguided.
75644728|NCT02386995|Device|BIS monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia monitoring are then compared.
75928976|NCT06138353|Drug|Shuxuening injection or placebo|Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
75644729|NCT02386995|Device|Entropy monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia
75644730|NCT00726349|Other|No intervention|Observational study.
75928977|NCT06138184|Behavioral|Anticoagulation Educational Materials|This includes new web-based patient educational materials that have been developed prior to the start of the study
75928978|NCT06138184|Behavioral|Control Group: Standard of Care|This will be the current practice for patient education
75928979|NCT06137755|Biological|CVI-VZV-001|Investigational Product
75928980|NCT06137755|Biological|Shingrix|Investigational Product
75644731|NCT00726427|Drug|AZD1656|Dose escalation to achieve maximum tolerated dose
75644732|NCT00726427|Drug|AZD1656|Oral single dose
75644733|NCT00761956|Device|NexGen CR-Flex Fixed Bearing Knee|NexGen CR-Flex Fixed Bearing femoral component
75644734|NCT00761956|Device|NexGen CR Knee|NexGen Complete Knee Solution Cruciate Retaining femoral component
75644735|NCT04183881|Drug|Brodalumab 210mg SC|210 mg, subcutaneous dosing, every 2 weeks
75792683|NCT05415826|Procedure|slow-release dexamethasone implant|The eyes with proliferative diabetic retinopathy underwent PPV with silicone oil filling with or without slow-release dexamethasone implant at the end of surgery.
75792684|NCT01227330|Behavioral|Medication adherence intervention|12-week behavioral feedback intervention to improve adherence to statin medication
75928981|NCT06137495|Diagnostic Test|Sensitization to House dust mites|The SPT is performed at the time of diagnosis and after six-months follow-up period. Serum specific IgE is measured by immunoblotting, chemiluminescence, and ImmunoCAP assays
75928982|NCT06136546|Drug|Infliximab|Intravenous infusion of infliximab
75928983|NCT06136546|Other|Placebo|Intravenous infusion of saline solution (matching in color and consistency in infliximab)
75928984|NCT06134973|Diagnostic Test|ultrasonic testing|ultrasonic testing
75928985|NCT06134414|Drug|MY008211A tablets|dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
75928986|NCT06134219|Other|MF course|A course consisting of six 2-hour-meetings every two-weeks with 10-15 participants (12 weeks in total). The meetings have different themes related to MF, such as understanding, practices for a deeper understanding of emotions, balance in everyday life with rest and activity, meditation practice to give time for brain rest, and mindfulness).
75928987|NCT06134219|Other|Usual health care|The usual health care consists of one or few follow-up visits with blood tests at Sahlgrenska university hospital in Gothenburg or follow-up at the primary care after the end of treatment for Graves' treatment.
75644736|NCT00638313|Biological|Placebo|Subjects will be given either Placebo or PF-04603629.
75644737|NCT00638313|Biological|PF-04603629|Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
75644738|NCT02600572|Other|Isometric exercises|Subjects will perform one session of isometric exercises at the end of Day 1
75644739|NCT02600572|Other|Eccentric exercises|Subjects will perform one session of eccentric exercises at the end of Day 2
75644740|NCT04093648|Genetic|TEGAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:DL1: 1x10^7/m2 DL2: 3x10^7/m2 DL3: 1x10^8/m2 DL4: 3x10^8/m2 DL5: 1x10^9/m2 If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10^6/m2 dose.~The first patient on each dose level has to be 28 days post-CAR T cell infusion before the second patient can be enrolled. The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
75644741|NCT04093648|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
75644742|NCT04093648|Drug|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
75644743|NCT04184115|Drug|DPI-386 Nasal Gel|1.5 mg reservoir of scopolamine to be delivered over a 72-hour period
75644744|NCT04184115|Drug|Placebos|Placebo Nasal Gel and placebo patch
75644745|NCT00722215|Drug|BQ-123 (selective endothelin A receptor antagonist)|Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
75644746|NCT00722215|Drug|0.9 % saline|Single 15ml 0.9% saline infused for 15 mins as placebo control
75644747|NCT00722215|Drug|Nifedipine|Single dose of nifedipine 10 mg given orally as active control
75792685|NCT01227330|Behavioral|Attention-control|Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
75792686|NCT05415748|Drug|Tamsulosin|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
75792687|NCT05415748|Drug|Placebo|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
75644748|NCT00640731|Device|OmniWave Endovascular System|Treatment with mechanical thrombolysis/thrombectomy
75644749|NCT02571595|Behavioral|Digital cognitive behavioural therapy for insomnia (dCBT-I)|dCBT-I is a computer-based treatment intervention that provides strategies to improve sleep and daytime function (concentration, productivity) in individuals with insomnia
75928988|NCT06133959|Behavioral|The-Optimal-Lymph-Flow (TOLF) Program|TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.
75928989|NCT06132477|Drug|GLP-1 receptor agonist|Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
75928990|NCT06132269|Dietary Supplement|AKK formula prebiotic sachet|"5 g/sachet, containing AKK formula, Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
75928991|NCT06132269|Dietary Supplement|Placebo sachet|"5 g/sachet, containing Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
75928992|NCT06130514|Device|Ultrasound|Ultrasound-guided stellate ganglion block with 1% mepivacaine 5 mL
75792688|NCT03927300|Device|Telemonitoring Software|Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.
75928993|NCT06130514|Device|Fluoroscopy|Fluoroscopic-guided thoracic sympathetic ganglion block with 1% mepivacaine 3 mL
75928994|NCT06129383|Procedure|serratus anterior plane block and pectointercostal plane block in breast surgery|Serratus anterior plane block and pecto intercostal plane block will be performed as a single injection using 0.25% bupivacaine and with the same practitioner.
75928995|NCT06125678|Diagnostic Test|Small intestinal contrast enhanced ultrasound followed by Computed tomography/Magnetic resonance enterography|First small intestinal contrast enhanced ultrasound shall be done followed by CT enterography or MR enterography
75644750|NCT00640809|Drug|Celecoxib|200 mg oral capsule twice daily for 2 weeks
75792689|NCT03924024|Device|Accelerated intermittent theta burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Stimulation intensity will be standardized to 80% of resting motor threshold.~Stimulation will be delivered to L-DLPFC using the Brainsway stimulator."
75792690|NCT01228578|Dietary Supplement|Multivitamin supplements B,C and E|One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
75928996|NCT06124937|Drug|Empagliflozin 10 MG|The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
75928997|NCT06124937|Drug|Placebo|The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.
75928998|NCT06118723|Procedure|Supramaximal resection|Supramaximal resection. Tumor resection continues until either the FLAIR abnormalities have been resected based on the neuronavigation (after updating the navigation intraoperatively), or when subcortical tracts are identified with intraoperative stimulation.
75928999|NCT06118723|Procedure|Maximal safe resection|Maximal safe resection. Tumor resection continues until maximal safe resection has been achieved as by the neurosurgeon's opinion.
76084345|NCT03352830|Other|Infrastructural Intervention - Direct Delivery|Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
76084346|NCT02518308|Behavioral|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
76084347|NCT01636882|Biological|CVA21|
75644751|NCT00640809|Other|Placebo|Matched placebo for 2 weeks
76084348|NCT04509492|Diagnostic Test|Endoscopic ultrasound ( EUS )|"- EUS will be done to all patients. During EUS examination the liver will be examined thoroughly to detect hepatic focal lesions with possible EUS-FNA of any detected lesions.~All EUS examination will being done by EUS linear array Echoendoscope, Pentax EG-3870UTK attached to Hitachi Avius US machine under Propofol deep sedation"
76084349|NCT03352752|Device|HTC Vive|Wearing VR helmet before operation
75644752|NCT00640809|Drug|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
75644753|NCT00754624|Drug|Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler|Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
75644754|NCT00722293|Drug|Doxorubicin|Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
75644755|NCT00722293|Drug|Pazopanib (GW786034)|Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
75792691|NCT03923946|Behavioral|Compassion focused therapy|Compassionate Imagery intervention based on compassionate imagery exercises in The Compassionate Mind Workbook by Irons and Beaumont, 2017
75798899|NCT01181544|Procedure|Heparin dose titration|Patients will begin the study using their currently prescribed heparin doses - both bolus and constant infusion - for three treatments to establish a baseline and provide information on inter-treatment variability in dialyzer clotting. Subsequently, the bolus and infusion rates will be titrated either upward or downward based on the Robbins-Monro process and an evaluation of dialyzer clotting during the preceding treatment. Heparin doses will be adjusted for a total of 30 dialyses.
75929000|NCT06116838|Device|Spinal motor evoked responses (sMERs)|Spinally Evoked Motor Responses (sMERs) will be obtained while stimulating with single pulses using various stimulation parameters. sMERs are the electromyograph (EMG) responses of the peripheral muscles to electrical stimulation of the spinal cord. sEMP will be used to test the integrity of the motor pathways of the spinal cord. This will be measuring by assessing the EMG responses in the lower limb muscles.
75929001|NCT06116838|Device|Continuous stimulation tolerance|Participants may receive up to 45 min of locomotion training (treadmill or overground training) with transcutaneous spinal cord stimulation. The goal will be for the investigators to determine what amount of intensity at each stimulation site the individual finds to be comfortable enough that they would be able to receive without pain or discomfort
76084350|NCT03352752|Other|Without HTC Vive|Wearing a blindfold before operation
76084351|NCT01638052|Drug|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
76084352|NCT03349164|Diagnostic Test|acute PE survivors|Patients from this group will be assessed by cardiologist, echocardiography and VQ scanning
75929002|NCT06115109|Other|Non intervention, Observational study|Non intervention, Observational study
76084353|NCT02518152|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
75644756|NCT00722293|Drug|Epirubicin|Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
75798900|NCT01184586|Device|Intervention - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)
75798901|NCT01184586|Device|CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
75798902|NCT02524860|Device|Focal-Fusion Bx|The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
75929003|NCT06109922|Dietary Supplement|Active|40g bio-active whey protein concentrate powder containing phospholipids
75644757|NCT04187235|Procedure|Laparascopic repair of parastomal hernia|Laparascopic repair of parastomal hernia
75929004|NCT06109922|Dietary Supplement|Placebo|Around 40g pea protein powder not containing phospholipids
75929005|NCT06109454|Drug|Huaier granule|The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.
75644758|NCT00726505|Drug|Dapagliflozin|Tablets, Oral, Once Daily, up to 29 days:
75644759|NCT02683005|Drug|ledipasvir/sofosbuvir|Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
75644760|NCT02689323|Device|repeated transcranial magnetic stimulation|
76084354|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
75644761|NCT00726583|Drug|PX-866|Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
75798903|NCT01184664|Drug|Nicotine Patch|Varenicline + nicotine patch
75798904|NCT01184664|Drug|Placebo|Varenicline + placebo patch
76084355|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
76084356|NCT01229878|Dietary Supplement|Cholecalciferol (Vitamin D)|50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
76084357|NCT03352674|Drug|Insulin Glargine Ezelin|Insulin Glargine (Ezelin) once daily at individually adjusted dose
76084358|NCT03352674|Drug|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
76084359|NCT02249260|Behavioral|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
76084360|NCT02518074|Other|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
76084361|NCT03352596|Other|low frutose diet|
76084362|NCT01639222|Drug|Calcium 500 mg and Vitamin D3 800 IU|Calcium 500 mg and Vitamin D3 800 IU chewable tablets
76084363|NCT01639222|Other|Low calcium meals|A normal Western European diet with reduced calcium content (400 mg per day).
76084364|NCT03352518|Device|WM3.4NR|The investigational medical device will collect spectral raman data from tissue.
76084365|NCT03349086|Behavioral|Voice Exercise|Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
76084366|NCT04502628|Procedure|Hyperbaric oxygen therapy|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished. Other classic measures to treatment HC such as hydration, alkalization, and bladder irrigation will also be carried out at the same time.
76084367|NCT05473338|Diagnostic Test|Stool and blood samples|fecal microbiome and metabolomics, as well as metabolites in plasma
76084368|NCT05473338|Other|Physical examination|physical examination performed by a physician to confirm CRPS diagnosis and assess patient's eligibility to participate in the study. The exam will include skin temperature measured using a laser/infrared skin thermometry.
76084369|NCT05473338|Other|Questionnaires|Questionnaires measuring pain level, sleep, mood and diet parameters.
75335415|NCT05749510|Other|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
75335416|NCT05749432|Drug|Hemay181|Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.
75472589|NCT01960335|Dietary Supplement|Whey Protein|Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
75792692|NCT03923712|Behavioral|Supervised Exercise Programme|The methodology will be multicomponent, including aerobic, strength, coordination-cognitive and balance-agility. The physical exercise sessions will be designed in such a way that they work the dimensions but being attractive and motivating for the participants. Each session will include 10 minutes of warm-up with smooth running and mobility exercises; 35-40 minutes of aerobic, strength, coordination-cognitive and balance-agility progressively developed; and 10 minutes back to calm at low intensity with stretching exercises. Nutritional intervention will not be included. For quality purposes, we will use small groups (10-15 pers). After each session participants will be asked about their subjective perception of the effort and the intensity will be controlled by heart rate monitors.
75929006|NCT06109454|Other|Control|The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg/m2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg/m2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg/m2, intravenous injection, first day) every three weeks, with a maximum of four cycles.
75929007|NCT06107114|Drug|Cetuximab|Cetuximab 400mg/m2 (The first week), 250mg/m2(Follow-up weekly) The drug was administered every week (QW). The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
75792693|NCT03102034|Biological|D46/NS2/N/ΔM2-2-HindIII|10^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops
76084370|NCT04443270|Drug|Chloroquine phosphate|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
76084371|NCT01598194|Device|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
76084372|NCT03349008|Drug|Entecavir|Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
76084373|NCT03349008|Drug|Magnesium Isoglycyrrhizinate|Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
75472590|NCT01960335|Dietary Supplement|Whey Protein and Resistance Exericse|Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
76084374|NCT03349008|Drug|Diammonium Glycyrrhizinate|Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
75472591|NCT01960335|Other|Whey Protein and RISE exercise routine|Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
75472592|NCT01960361|Device|ICE dental implant|ICE- Implant Classical Esthetic implant
75792694|NCT03102034|Biological|Placebo|Isotonic diluent; administered as nose drops
75644762|NCT04183959|Device|video stylet|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
75792695|NCT03774576|Drug|RO7017773|Single doses of RO7017773
75792696|NCT03774576|Drug|Itraconazole|Multiple doses of Itraconazole
75644763|NCT04183959|Device|fiberoptic|intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
75644764|NCT03583957|Device|Observational only|Device is only observational and used to record EEG.
75644765|NCT03583957|Behavioral|Psychological and Behavioral interaction with a seizure forecasting mobile app|Participants will be interacting with a mobile app to input perceived behavioral (e.g., number of hours slept and sleepiness) and psychological (perceived stress).
75792697|NCT03923634|Device|Princess® RICH|Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
75792698|NCT05415436|Other|Propofol slow administration|Propofol will be slowly administered over 120 seconds by anesthesia provider
75792699|NCT01227408|Drug|doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate|doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
75792700|NCT01130220|Other|Focus Group|"A single focus group will be held until a saturation of themes has been identified."
75792701|NCT02928952|Behavioral|Mind-STRIDE|Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
75792702|NCT03773796|Drug|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
75792703|NCT01131390|Device|Ventilator setting changes|Ventilator settings will be changed every 3 minutes as described above, simultaneously measuring respiratory mechanics and patients' comfort.
75792704|NCT02927938|Procedure|Allogeneic HCT|Allogeneic HCT
75792705|NCT02927938|Drug|Consolidation chemotherapy|Cytarabine-based consolidation chemotherapy
75792706|NCT01224522|Procedure|Visionaire|Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.
75792707|NCT01224522|Procedure|Standard surgical technique|Implantation of Genesis II Total Knee system by means of standard surgical technique.
75792708|NCT01227486|Device|Ultrasound|Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
76084375|NCT03349008|Drug|Magnesium Isoglycyrrhizinate Placebo|Magnesium Isoglycyrrhizinate Injection Placebo
76084376|NCT03349008|Drug|Diammonium Glycyrrhizinate Placebo|Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
76084377|NCT01598350|Device|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
76084378|NCT01598428|Procedure|anterior capsule polishing|polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
75792709|NCT01227642|Other|An ultrasound-based technique to identify prostate cancer|The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
75644766|NCT03583957|Combination Product|Seizure Alerting and Prediction System|The combination of Epilog (device) and the Aura app (psychological and behavioral interaction) will be used to create a real-time seizure alerting and an hourly seizure forecasting system.
75644767|NCT02176863|Biological|Flebogamma 5% DIF|Human plasma-derived immunoglobulin
75792710|NCT01227642|Other|pre-implant transrectal ultrasound images and planning|an ultrasound-based technique to identify cancer-containing areas within the prostate.
75792711|NCT01227642|Other|ultrasound-based cancer-specific images|ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
75792712|NCT03863860|Drug|Fluzoparib capsules|Fluzoparib capsules
75792713|NCT03863860|Drug|Placebo capsules|Placebo capsule
75792714|NCT01224600|Other|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
75929008|NCT06107114|Drug|Zimberelimab|Zimberelimab 240 mg, The drug was administered every week (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
75929009|NCT06107114|Drug|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
75929010|NCT06107114|Drug|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
75929011|NCT06104891|Dietary Supplement|Recharge Placebo Control 1|Participants will use their Radicle Recharge Placebo Control 1 as directed for a period of 5 hours.
76084379|NCT03352440|Device|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
76084380|NCT03352440|Device|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
75644768|NCT02176863|Drug|Placebo|Normal saline solution
75644769|NCT04237207|Device|Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software|Control cochlear implant sound processor
75929012|NCT06104891|Dietary Supplement|Recharge Active Study Product 1|Participants will use their Radicle Recharge Active Study Product 1 as directed for a period of 5 hours.
75472593|NCT01960374|Drug|Selumetinib|1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
76084381|NCT03352440|Device|Control Group - Kinect|Group with typical development that will perform the task on Kinect
76084382|NCT03352440|Device|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
75472594|NCT01960426|Other|Measurement of drug (Adalimumab/Infliximab)|Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
75335417|NCT04222985|Biological|HSV 2 Formulation 1|Route of administration: Intramuscular
75335418|NCT04222985|Biological|HSV 2 Formulation 2|Route of administration: Intramuscular
75335419|NCT04222985|Biological|HSV 2 Formulation 3|Route of administration: Intramuscular
75472595|NCT01960426|Other|Intensify treatment with the existing drug|Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
75644770|NCT04237207|Device|301-M062 sound processor & software|New cochlear implant sound processor
75644771|NCT02571283|Drug|Cocktail|Administered as a single dose injection.
75644772|NCT02571283|Drug|Exparel|Administered 20 minutes+ before additional medications.
75644773|NCT02571283|Drug|Marcaine|Administered 20 minutes or more after Exparel is administered.
75644774|NCT02682693|Drug|Denosumab|Denosumab 120 mg every 4 weeks for 6 cycles
75644775|NCT02682693|Drug|nab-Paclitaxel|nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
75792715|NCT03794206|Device|Vesair Balloon|Treatment with Vesair Balloon for one year
75798905|NCT01184664|Drug|Varenicline|All participants will receive a standard dose of varenicline (12 weeks).
76084383|NCT03352362|Drug|ibuprofen (caldolor 10 mg / kg)|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
75335420|NCT04222985|Biological|HSV 2 Formulation 4|Route of administration: Intramuscular
75335421|NCT04222985|Biological|HSV 2 Formulation 5|Route of administration: Intramuscular
75335422|NCT04222985|Biological|HSV 2 Formulation 6|Route of administration: Intramuscular
75335423|NCT04222985|Biological|Sodium Chloride 0.9%|Route of administration: Intramuscular
75472596|NCT01960452|Behavioral|Serial awakenings|The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
75472597|NCT01960478|Biological|(for each intervention)|
75798906|NCT01181700|Drug|Treatment A|PF-00241939 300 ug using inhaler A
75929013|NCT06104891|Dietary Supplement|Recharge Active Study Product 2|Participants will use their Radicle Recharge Active Study Product 2 as directed for a period of 5 hours.
75929014|NCT06104891|Dietary Supplement|Recharge Active Study Product 3|Participants will use their Radicle Recharge Active Study Product 3 as directed for a period of 5 hours.
76084384|NCT03352362|Drug|propacetamol (denogan 30 mg / kg)|Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
75472598|NCT01960478|Other|Blood test|
75472599|NCT01960491|Device|Device Closure of Atrial Septal Defect|"Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder"
75472600|NCT01960504|Device|Percutaneous Coronary Intervention (DREAMS) stenting|
75472601|NCT01960517|Device|ACS Catheter|
75472602|NCT01960543|Drug|fentanyl 15 microg|
75644776|NCT02682693|Drug|Epirubicin|Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
75644777|NCT02682693|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
75472603|NCT01960543|Drug|Bupivacaine 7 mg|
75644778|NCT02682693|Drug|Carboplatin|Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
75792716|NCT05365906|Other|Delphi-procedure consisting of four survey rounds|This study will use a modified Delphi approach, consisting of a set of iterative questionnaires. In round 1, an expert panel will grade the relevance of UTI-related items, after which a smaller core research team will compose a reference standard in a series of (online) meetings. In round 2, clinical vignettes will be used to party validate the reference standard and expert panel agreement with the new reference standard will be assessed.
76084385|NCT03352362|Drug|ibuprofen + propacetamol|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
75792717|NCT03923478|Drug|ABI-M201|Active Treatment
75792718|NCT03923478|Drug|Placebo|Control Treatment
75929015|NCT06104514|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
75335424|NCT05749354|Other|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through."
75335425|NCT05749276|Drug|Darzalex|"DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~Dose level 1 : 1800 mg Day 1~Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
75472604|NCT01960543|Drug|Bupivacaine 9 mg|
75472605|NCT01960543|Drug|Levobupivacaine 7 mg|
75472606|NCT01960543|Drug|Levobupivacaine 9 mg|
75472607|NCT01960556|Other|Simulation Training|Simulation training provided to one group
75472608|NCT01960569|Drug|active product ( Thrombexx) assigned to arm 1|Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
75472609|NCT01960569|Other|Placebo assigned to arm 2|
75472610|NCT01960582|Behavioral|New Practice Strategy|Application of a structured case management strategy on housing adaptation cases
75472611|NCT01960595|Procedure|IV fentanyl PCA|
75472612|NCT01960595|Procedure|local bupivacaine infiltration and post-OP IV fentanyl PCA|
75472613|NCT01960595|Procedure|Nerve Blocks and post-OP IV fentanyl PCA|
75472614|NCT01960608|Other|24_hours_urine_sodium|
75472615|NCT01960621|Drug|cyclodextrin|intravenous
75472616|NCT01960647|Device|Percutaneous transluminal angioplasty with uncoated balloon|
75472617|NCT01960647|Device|Percutaneous transluminal angioplasty with Paclitaxel balloon|
75472618|NCT01960660|Dietary Supplement|Omega-3 Fatty Acids|
75472619|NCT01960673|Device|LMA proseal|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
75472620|NCT01960673|Device|igel LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
75472621|NCT01960673|Device|air Q LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
75472622|NCT01960673|Device|ambu LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
75472623|NCT01960712|Device|Transpapillary plastic stent (7-10 Fr)|Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
75644779|NCT02682693|Drug|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
75644780|NCT02682693|Drug|Pertuzumab|Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
75644781|NCT02571517|Drug|Glucocorticoids|Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
75792719|NCT03690466|Device|Study device treatment|The ultrasound portable device comprises a tabletop control unit and a transducer connected to the control unit by a cord.
75929016|NCT06103552|Behavioral|Building Lifestyle Options for Orthopedic Mobility (BLOOM)|This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.
75929017|NCT06103331|Other|Invasive Fungal disease surveillance|Management of invasive fungal infection according to pathogen identification and susceptibility report.
76084386|NCT03348852|Device|Transcranial direct current stimulation|Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
76084387|NCT01598740|Drug|CLP|Oral administration
76084388|NCT01598740|Drug|Spironolactone|oral administration
75792720|NCT03690466|Device|Sham device treatment|A similar device as used for the study device treatment will be used, except that no energy will be delivered to the spleen.
75792721|NCT03923166|Drug|Pyrotinib|400mg qd
75792722|NCT03923166|Drug|capecitabine|capecitabine 500mg tid
75792723|NCT03923244|Diagnostic Test|OSDI survey|"Normal patient consultation schedule for cataract surgery with:~Preoperative appointment scheduled for the patient~Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
75644782|NCT02571517|Other|Placebo|Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
76084389|NCT03352284|Device|Straumann Pure Ceramic Implant|The surgical technique begins with the lift of a vestibular mucoperiosteal flap respecting the papillae of the adjacent teeth. After the alveolar bone is exposed, the sequence of drilling and placement of the intra-bone fixation are carried out. In case of fenestrations or dehiscence, they are treated by xenograft and collagen-absorbable membrane. Once the implant is placed, a healing cap or provisional prosthesis is placed depending on the torque achieved. Finally, the flap is replaced and sutured.
75335426|NCT05749198|Diagnostic Test|MRE|MRE was performed using a 3T system (Magnetom Skyra; Siemens, Erlangen, Germany) equipped with a combination of a 30-channel body and a 32-channel spine matrix coil.
75792724|NCT05332210|Drug|HBM9161 Injection (680mg)|HBM9161 Injection
75792725|NCT01224756|Drug|Tinoridine HCl|Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
75335427|NCT05749042|Drug|Sintilimab|Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.
75472624|NCT01960738|Other|A pre-dive checklist|The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
75929018|NCT06099444|Device|Conventional High Intensity Gait Training|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity. The participants will complete 18 training sessions.
75644783|NCT04066543|Device|TACE|The modified Seldinger puncture was used to puncture the cutaneous-femoral artery, insert the catheter and perform hepatic artery angiography. The location, morphology and blood supply of liver tissue lesions were comprehensively understood. The use of chemotherapeutic drugs and the dosage of iodized oil as the embolic agent were determined according to the general situation. The catheter was injected into the supply vessel of the tumor, and 5-FU and adriamycin were injected according to the situation. The embolic agent was injected with iodized oil as carrier, mixed with chemotherapeutic drugs at the same time, and then assisted with gelatin sponge for embolization. Antiemetic drugs were given before treatment and hepatoprotective drugs were given after operation. Until the disease progresses.
75644784|NCT04066543|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
75335428|NCT05749042|Radiation|Radiotherapy|Concurrent Chemoradiotherapy Based of Cisplatin
75335429|NCT03015077|Dietary Supplement|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
75335430|NCT03015077|Dietary Supplement|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
75335431|NCT03015077|Radiation|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
75472625|NCT01960751|Other|neurocognitive tests battery|The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
75472626|NCT01960764|Drug|Pre-Treatment with Dial liquid antibacterial soap|This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
75472627|NCT01960764|Other|Control|
75472628|NCT01960777|Procedure|Onstep|
75472629|NCT01960777|Procedure|Laparoscopic repair|
75472630|NCT01960803|Radiation|Intraoperative Electron Radiotherapy|Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
75472631|NCT01960829|Drug|Everolimus|
75472632|NCT01960868|Other|standard physiotherapy|
75472633|NCT01960868|Other|experimental physical therapy|
75644785|NCT00586846|Drug|Cisplatin|Cisplatin 120 mg/m^2
75472634|NCT01960920|Other|Filtered diesel exhaust|Mask-filtered exposure to diesel exhaust
75472635|NCT01960920|Other|Unfiltered diesel exhaust|Diesel Exhaust Inhalation
75792726|NCT01224756|Drug|Placebo|Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
75798907|NCT01181700|Drug|Treatment B|PF-00241939 300 ug using inhaler A
75929019|NCT06099444|Device|Standard FES to the Tibialis Anterior (TA)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while wearing a FES stimulator on the tibialis anterior muscle of their more affected leg. Stimulation will be triggered prior to swing phase to combat drop foot. The participants will complete 18 training sessions.
75929020|NCT06099444|Device|Synergy-Based Multichannel FES (MFES)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while FES is applied to multiple muscles of the leg throughout the gait cycle based on the healthy muscle synergies. The goal will be to have the FES applied for at least 20 minutes of each gait training session. The participants will complete 18 training sessions.
75792727|NCT03392428|Other|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
75644786|NCT00586846|Drug|Doxorubicin|75mg/m^2
75792728|NCT03392428|Drug|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
75929021|NCT06099444|Device|Muscle Synergy Visual Biofeedback|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while receiving visual feedback of the similarity of their muscle synergies to healthy muscle synergies. They will be instructed to try to optimize the similarity score. The participants will complete 18 training sessions.
75929022|NCT06099080|Drug|SM-020 gel 1.0%|Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.
75792729|NCT05308732|Drug|Copaiba|A 10% and 15% aqueous solution of copaiba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula: 10% copaiba oil (Copaifera Officinalis Resin) and 15% liquid mint aroma 5% , tween 80 1%, Aqueous solution (Distilled water + 0.1% Nipagin) qsp 100%.
75792730|NCT03926832|Device|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea Syndrome (OSAS) management when moderate-to-severe. Subjects with OSA will be trained in the use of CPAP and will be instructed to use it every night for 3 months. These subjects will then return for a post-treatment completion of questionnaires (ESS and FAS) and compliance analysis.
75929023|NCT06098170|Behavioral|Unguided use of the My SCI Toolkit program|Participants will be asked to use the My SCI Toolkit program for 8 weeks (without a coach), following the prompts and guides built into the program.
75929024|NCT06098170|Behavioral|Coached My SCI Toolkit|Participants will be asked to use the My SCI Toolkit program for 8 weeks, following the prompts and guides built into the program. Participants will also have weekly phone calls (the first is about 30-45 minutes, and the rest are about 15 minutes) with a study coach. The coach can help answer questions and tailor the skills more to the participant's goals and needs. The coaching sessions will be audio recording for fidelity purposes.
75644787|NCT00586846|Drug|Methotrexate|Methotrexate 12g/m^2
75929025|NCT06097910|Procedure|Watchful waiting|Conduct thoracic computed tomography scans every 12 months. If a solid component emerges of if there is an increase in the size of any lung nodules, the treamtent approach would involve surgery of radiotherapy.
75929026|NCT06095596|Drug|Upadacitinib|Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
75929027|NCT06095596|Drug|Vedolizumab|Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
75929028|NCT06095557|Device|Sponsor MCG device|unshielded device measuring cardiac magnetic fields
75929029|NCT06094842|Drug|Bendamustine|Given IV
75929030|NCT06094842|Procedure|Biopsy|Undergo tissue biopsy
75929031|NCT06094842|Procedure|Biospecimen Collection|Undergo blood sample collection
75792731|NCT01224834|Drug|Sublingual tablet of ragweed pollen allergen extract|administered once a day over 10 days
75929032|NCT06094842|Procedure|Bone Scan|Undergo bone scan
75929033|NCT06094842|Procedure|Bridge Therapy|Undergo bridging therapy
75472636|NCT01960920|Other|Clean air|No pollution and no filter mask
75472637|NCT01960946|Dietary Supplement|Modified Citrus Pectin (MCP) vs placebo|5 grams by mouth three times a day
75472638|NCT01960972|Other|Salt substitute|A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
75472639|NCT01960985|Other|Physicaltherapy|
75798908|NCT01181700|Drug|Treatment C|PF-00241939 300 ug using inhaler A
75472640|NCT01961037|Other|Tai Chi: Moving for Better Balance|Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
75929034|NCT06094842|Procedure|Computed Tomography|Undergo CT
75929035|NCT06094842|Drug|Cyclophosphamide|Given IV
75644788|NCT02569879|Other|Pertussis maternal immunization|Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.
75644789|NCT04098640|Genetic|FoundationOne CDx|FoundationOne CDx will be performed using archival tumor tissue
75644790|NCT02570269|Procedure|AuraGain|Fiberoptic Intubation
75644791|NCT02570269|Procedure|Slotted Guedeltubus|Fiberoptic Intubation
75644792|NCT00973700|Biological|MF59-eH1N1_f|MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
75929036|NCT06094842|Procedure|Echocardiography|Undergo ECHO
75929037|NCT06094842|Drug|Fludarabine|Given IV
75929038|NCT06094842|Procedure|Leukapheresis|Undergo leukapheresis
75929039|NCT06094842|Procedure|Multigated Acquisition Scan|Undergo MUGA
75929040|NCT06094842|Biological|T-cell Receptor-engineered T-cells|Given autologous L1CAM-specific CAR+EGFRt+ T cells IV
75929041|NCT06094842|Procedure|X-Ray Imaging|Undergo chest x-ray
75472641|NCT01961050|Behavioral|Dual-Focused Brief Physician Intervention (DFBPI)|The DFBPI is incorporated in OB/GYN clinic visit. The intervention consists of two brief (5 to 10 minutes) manualized counseling segments delivered face-to-face by an OB/GYN in the context of two clinic visits.
75792732|NCT03222856|Drug|Pembrolizumab|MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
75792733|NCT03222856|Drug|Eribulin|Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
75792734|NCT01130298|Drug|Testosterone Gel 1.62%|5 grams
75792735|NCT01227720|Drug|Experimental Nicotine Replacement Therapy (NRT) 2 mg|2 mg Single-dose of new NRT product (NSL2L)
75472642|NCT01961050|Other|Services as usual|Active Comparator: Standard OB/GYN clinic visits that include OB/GYN services as usual.
75644793|NCT00973700|Biological|eH1N1_f|Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
75644794|NCT04144465|Drug|NORADRENALIN|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
75644795|NCT04144465|Drug|PHENYLEPHRINE|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
75644796|NCT00754390|Dietary Supplement|Moderate Calcium, Low phytate Diet|Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
75644797|NCT00754390|Dietary Supplement|Moderate Calcium, High Phytate Diet|Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
75792736|NCT01227720|Drug|Experimental Nicotine Replacement Therapy (NRT)|4 mg Single-dose of new NRT product
75792737|NCT01227720|Drug|Marketed Nicotine Lozenge|2 mg Single-dose of marketed lozenge
75792738|NCT01227720|Drug|Marketed Nicotine Lozenge|4 mg Single-dose of marketed lozenge
75792739|NCT03175978|Drug|IGF/MTX|765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
75644798|NCT00754390|Dietary Supplement|High Calcium, Low Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
75644799|NCT00754390|Dietary Supplement|High Calcium, High Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
75644800|NCT04066621|Drug|Ceftriaxone Sodium and Sulbactam Sodium for Injection|daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days
75644801|NCT02883517|Genetic|Cytogenetic and molecular studies|Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
75792740|NCT03923088|Behavioral|jacobson's progressive muscle relaxation technique|This involves tensing specific muscle groups for 5-7 seconds, followed by 20 seconds of relaxation. The method can be demonstrated chairside, and should be practiced and rehearsed by the patient at home. Four major muscle groups are commonly tensed and relaxed. These are: 1) feet, calves, thighs, and buttocks; 2) hands, forearms, and biceps; 3) chest, stomach, and lower back; and 4) head, face, throat, and shoulders
75792741|NCT03923088|Behavioral|audio-visual distraction technique|audiovisual distraction not only leads to full involvement of scenes (visual and auditory), but it also induces a positive emotional reaction resulting in a relaxed experience.
75792742|NCT01224912|Behavioral|Cognitive Behavioral Treatment|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
75792743|NCT03923010|Drug|Itraconazole|Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
75792744|NCT01224990|Procedure|Whole body diffusion MRI|These studies will be performed on a 3Tesla (T) MR system (Achieva, Philips Medical Systems). A major advantage of 3T compared to 1.5 T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
75792745|NCT01227798|Drug|Interferon alfacon-1|15 mcg at fill volume of 0.5mL
75792746|NCT01227798|Drug|Placebo|Normal Saline
75792747|NCT01329354|Biological|Autologous effector lymphocytes expanded ex-vivo|Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
75792748|NCT03926676|Other|grandio blocks|nano hybrid composite blocks
75792749|NCT03926676|Other|emax|ceramic blocks
75644802|NCT00754234|Behavioral|My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7|Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks
75792750|NCT01130376|Biological|GTU-MultiHIV B clade vaccine1mg|Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
75792751|NCT01130376|Drug|Interleukin-2|5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
75792752|NCT01130376|Drug|GM-CSF|150 ug administered subcutaneously once daily 4 hours from IL-2 injections
75472643|NCT01961076|Other|overnight nutrition regime|Patients receive the specified overnight nutrition regimen
75472644|NCT01961102|Procedure|hysteroscopy/curettage in case of suspicious aspect will be done a rapid section|
75472645|NCT01961128|Behavioral|Exercise Intervention|
75472646|NCT01961154|Drug|Asthma medication reduction|The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
75644803|NCT00629330|Behavioral|Academic Detailing|Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
75792753|NCT01130376|Drug|Growth Hormone|4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
75644804|NCT02600416|Other|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
75792754|NCT03922776|Procedure|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~at diagnosis, before chemotherapy (pre-CT)~after chemotherapy (post-ct) Collection of two blood samples (5mL),~before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~and then, after chemotherapy (post-CT), up to 3 months after enrollment"
75792755|NCT03740178|Drug|MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive MK-4334 capsules administered orally, QD on Days 1-14. Participants will receive an initial loading dose of 120 mg (Day 1), followed by a maintenance dose of 60 mg (Days 2-14). Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
75792756|NCT03740178|Drug|Placebo to MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD)will receive placebo capsules matching MK-4334 administered orally, QD on Days 1-14. Participants will also receive open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
75792757|NCT03740178|Drug|Donepepzil|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
75792758|NCT01128348|Behavioral|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
75792759|NCT03926442|Other|Italian Herb meal|Italian Herb in active breakfast meal
75792760|NCT03926442|Other|Cinnamon Meal|Cinnamon in active breakfast meal
75792761|NCT03926442|Other|Pumpkin Spice meal|Pumpkin Spice Mix in active breakfast meal
75792762|NCT03926442|Other|Placebo meal|Placebo in breakfast meal
75792763|NCT03867552|Procedure|Altered gas (86% CO2, 10% N2O, 4% O2)|Assessment of pain degree after laparoscopic surgery with the altered gas (86% CO2, 10% N2O, 4% O2)
75929042|NCT06094101|Biological|Peptide vaccine IPX|"Peptide vaccine is a combination of~class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~control peptide derived from Survivin.~adjuvant: toll like receptor (TLR) 1/2 ligand XS15."
75792764|NCT03867552|Procedure|Standardized gas (100% CO2)|Assessement of pain degree after laparoscopic surgery with the standardized gas (100% CO2)
75929043|NCT06093113|Behavioral|Alba - Youth in grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains five main sections: Learning, Self-assessment, Manage symptoms, Find support and a Personal space.
75472647|NCT01961180|Drug|Cipralex|the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
75644805|NCT04289012|Diagnostic Test|Helicobacter Pylori screening by UBT|The UBT is based on the fact that Hp produces urease, which catalyzes the urea molecule into ammonia (NH3) and carbon dioxide (CO2). After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (tube, bag or breath card). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and Hp diagnosis is made based on previously established cut-off levels for Hp infection.
75792765|NCT01131468|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
75792766|NCT03930108|Other|SOFA score|Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.
75792767|NCT01225224|Drug|peficitinib|oral
75792768|NCT01225224|Drug|Placebo|oral
75792769|NCT01131546|Drug|Levamlodipine besylate|Once daily, 7AM - 10AM
75792770|NCT01131546|Drug|Amlodipine maleate|Once daily, 7AM - 10AM
75792771|NCT01225302|Drug|Linifanib|Low dose linifanib (once a day)
75792772|NCT01225302|Drug|Linifanib|High dose linifanib (once a day)
75792773|NCT01225302|Drug|Carboplatin|Given on Day 1 of every 21-day cycle
75792774|NCT01225302|Drug|Paclitaxel|Given on Day 1 of every 21-day cycle
75792775|NCT03922152|Radiation|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.
75792776|NCT01131624|Drug|ferrous sulphate|200 mg iron per day in a convenient dosage schedule.
75792777|NCT01131624|Drug|Ferinject|1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
75792778|NCT03926286|Drug|FMP-30|FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
75792779|NCT03926364|Other|Patients with referred pain|The project does not affect treatment or does not offer any intervention.
75792780|NCT01128582|Drug|Rozerem (ramelteon)|dosage= take 1 tablet(8 MG) 20 min. before bedtime
75792781|NCT01128582|Drug|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
75792782|NCT01130454|Device|Universal Electrophysiological Biofeedback Treatment|one 45 minute biofeedback treatment
75792783|NCT01130454|Device|Universal Electrophysiological Biofeedback Treatment|one 45 minute placebo treatment
75929044|NCT06093113|Behavioral|Control website|The website will contain information about grief and grief reactions similar to some of the information given in the app.
75472648|NCT01961180|Drug|Placebo|Placebo
75472649|NCT01961193|Device|contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
75929045|NCT06086054|Behavioral|Navigation and EMR referral to childcare facility|See arm description
75335432|NCT05659420|Behavioral|Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor|aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
75335433|NCT05653726|Other|Telemonitoring follow-up using medical devices and telematic consultations|Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months
75335434|NCT02940509|Drug|Ketamine plus Magnesium sulfate|"Patients will receive 2 IV infusions:~Ketamine (0.5mg/kg)~Magnesium sulfate (2g)"
75335435|NCT02940509|Drug|Placebo|Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
75335436|NCT05748964|Procedure|Laparoscopic pyeloplasty|Twenty patients presented with ureteropelvic junction obstruction [UPJO] will be divided into two equal groups. The first was subjected to trans-peritoneal pyeloplasty while the second was subjected to retroperitoneal pyeloplasty.
75335437|NCT02786615|Behavioral|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
75335438|NCT05652088|Procedure|Colonoscopy|Colonoscopy is a procedure where an instrument called colonoscope is inserted through the rectum to look at the entire internal surface of the intestine. Participants will be placed on a stretcher on the left side. A colonoscope will be advanced into the colon and into the terminal ileum. The entire procedure should take approximately 40 minutes
75335439|NCT05328713|Diagnostic Test|Cardiac MRI|This study will use Cardiac MRI to identify subclinical cardiac dysfunction.
75335440|NCT02246075|Drug|EVP-6124|
75335441|NCT02246153|Procedure|Laparoscopic gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
75792784|NCT01228890|Behavioral|CATCH-IT|"The CATCH-IT 2-R intervention has a motivational (3 PCP motivational interviews at time 0, 1.5 months and 12 months and 3 coaching phone calls at 2 and 4 weeks and 18 months) and an Internet component (with separate adolescent [14 modules] and parent [5 modules] programs). This revised and expanded intervention will include a comprehensive approach to reducing modifiable risk factors and enhancing resiliency factors associated with increased or decreased risk of depression, respectively, proposed by Spence and Reinecke.148 The revised CATCH-IT Tracker will monitor time in study and deploy elements of the intervention based on time since enrollment, including computer and human elements (e.g. calls, doctor visits)."
75798909|NCT01181700|Drug|Treatment D|PF-00241939 300 ug using inhaler B
75798910|NCT01181700|Drug|Treatment E|PF-00241939 300 ug using inhaler B
75335442|NCT02246153|Procedure|Open gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience."
75335443|NCT05650294|Dietary Supplement|PL+ omega 3 fatty acids|PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.
75335444|NCT05650294|Dietary Supplement|FO EE fatty acids|A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.
75335445|NCT03014999|Device|High frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 10Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
75335446|NCT03014999|Device|Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
75644806|NCT04094896|Drug|TCHP|Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
75644807|NCT04289168|Behavioral|Music|Music class was provided for the intervention group
75798911|NCT01181700|Drug|Treatment F|PF-00241939 300 ug using inhaler B
75798912|NCT01181700|Drug|Treatment G|PF-00241939 300 ug using inhaler B
75798913|NCT03858192|Procedure|Colorectal surgery procedure|Elective admission for colorectal surgery
75798914|NCT03858192|Procedure|Emergency abdominal surgery|Emergency admission necessitating emergency surgery
75644808|NCT02675491|Drug|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
75644809|NCT05592626|Drug|STAR0602|solution, intravenous infusion
75792785|NCT01228890|Behavioral|AMPE|The AMPE components are similar to those employed in previous primary care based quality improvement/Chronic Care Model Interventions (patient education [psycho-education described below], provider training [described in Case Finding and Recruitment], active monitoring and referral [case management, discussed under assessments], physician and nurse education and routine contact with PCP [study design rationale]). This Internet site will focus on assisting parents and adolescents in early identification of need for treatment and will also target stigma and negative attitudes toward treatment of mental disorders we have previously identified as barriers to seeking and adhering to treatment.
75792786|NCT03929484|Device|Nasal reservoir cannula|The experimental oxygen mask (nasal reservoir cannula) fits over a standard nasal cannula. The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.
75792787|NCT01229046|Drug|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
75792788|NCT03929406|Device|Brain Tissue Imprint|"Brain Tissue Imprint procedure (BTI) is performed during DBS surgery. Before the implantation of the electrode, the surgeon uses a dilator. It is a rigid stylet with a blunt end, intended to prepare the way for the final electrode. This dilator is lowered gently through the cerebral parenchyma up to the target then removed to be replaced by the electrode.~In our BTI study, the standard dilator used in DBS surgery will be replaced by a CE marked Medical Device. This brain imprint kit will be used for each hemisphere. The procedure is the following:~The guide tube with the first stylet is set up to the target~Withdrawal of the first stylet and insertion of the second stylet for one minute to have a spontaneous and adequate tissue adhesion~Withdrawal of the guide tube containing the stylet. This last step will prevent contamination of the harvested material on the stylet during the removal."
75792789|NCT03922074|Procedure|Sedation directed by an endoscopist|"The nurse begins with fentanyl infusion in bolus: 75 μg (1.5 ml) and initial propofol dose (10mg/ml) in bolus of 0.5 - 2.5 mg/Kg followed by a maintenance dose of 20 - 60ml/h through Target-controlled infusion (TCI) pump. In this way, we get a target level sedation between 1 - 3, according to Observer's Assessment of Alertness/Sedation Scale (OAAS).~The role of the nurse, directed by an endoscopist, it is exclusively the administration of intravenous drugs and the patient monitorship throughout the procedure."
75792790|NCT03922074|Procedure|Sedation directed by an anesthesiologist|The choice of the drugs and the target level sedation are directed by an anesthesiologist
75792791|NCT01225458|Other|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
75792792|NCT01225458|Other|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
75929046|NCT06085872|Behavioral|REThink Life Game|REThink Life Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of four levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change and positive bias.
75929047|NCT06085872|Behavioral|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive & Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. We will test the efficacy of the app adjunct to other therapeutic tools within the platform in our projects."
76084390|NCT01599286|Drug|Carbaglu|"Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients >15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste."
75644810|NCT02600338|Other|Legumes|beans, peas, chickpeas, lentils, soybeans, lupins, peanuts in whole or flour form
75792793|NCT01225458|Other|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
75792794|NCT03921684|Drug|Capecitabine|Capecitabine 825 mg/m2 orally twice-daily, 5 days a week for a total of 28 days, given with radiation therapy
75929048|NCT06085872|Behavioral|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
75929049|NCT06084988|Biological|Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given via ultrasound-guided intra-articular injection
75929050|NCT06083506|Device|NOVALOC TiN retained maxillary overdenture|4 implants immediately loaded by means of a NOVALOC TiN retained maxillary overdenture
76084391|NCT01599286|Drug|Placebo|Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
75644811|NCT00629564|Drug|Esomeprazole|20mg oral
75644812|NCT00629564|Drug|Esomeprazole|15 minute intravenous infusion
75651906|NCT04889027|Diagnostic Test|Standardized Infant NeuroDevelopmental Assessment|The neurological scale of SINDA is designed as a screening tool as follows: (1) in the first year of life after the neonatal period, that is, in the corrected age range of 6 weeks to 12 months; (2) covers all infant neurological areas; (3) it is standardized, that is, it has a set of items and criteria identical to that age range; (4) results in a score that is largely independent of the baby's age; (5) general pediatricians are easy to use and take about 10 minutes to do (including recording scores); (6) contains a substantial part of items assessing the quality of spontaneous movements; and (7) helps predict developmental outcome (Hadder-Algra et al., 2018).
75929051|NCT06080555|Drug|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.
75651907|NCT04886310|Diagnostic Test|Peabody Developmental Motor Scale II (PDMS-2)|is composed of six subtests (reflex, stationary, locomotion, object manipulation, grasping, and visual-motor integration) that measure inter-related abilities in early motor development. It was designed to assess gross and fine motor skills in children from birth through 5 years of age.
75651908|NCT04868058|Drug|Ropivacaine injection|Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine
75929052|NCT06080555|Drug|Ferric Carboxymaltose Injection [Ferinject]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
75929053|NCT06079294|Other|FDG PET|Brain FDG PET performed 3 months after treatment initiation
75929054|NCT06076681|Drug|TNP-2198|On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
75929055|NCT06076681|Drug|Rabeprazole Sodium|On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.
75792795|NCT03921684|Radiation|Radiation therapy|1.8 Gy/day, 5 days a week for a total of 28 days, given with Capecitabine
75792796|NCT03921684|Drug|mFOLFOX6|oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab
75929056|NCT06076681|Drug|Amoxicillin|On Days 1 to 14, all subjects in each group received Amoxicillin capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
76084392|NCT04503642|Procedure|Changing the surgical team for wound closure|The intervention consists of the exchange of the primary surgical team with a second surgical team that consists of one surgeon and one student. The first surgical team then may leave the operation theatre but is continuously accessible for questions.
75929057|NCT06076317|Behavioral|Telemedicine session|The content of telemedicine session is semi-standardized and includes: (1) evaluation of the tolerance and efficacy of drug treatment; (2) evaluation of depressive symptoms (PHQ9 scale); (3) identification of the daily difficulties; (4 ) personalized advice and orientation towards appropriate care pathways. Among the personalized advice, investigators will use the digital tools available to maintain remission, psychoeducation and monitoring tools (for example, application to learn mindfulness meditation, conversational chatbot coupled with artificial intelligence, etc.). Support on the use of these tools can be provided during telemedicine sessions.
75335447|NCT03014999|Device|sham rTMS (repetitive Transcranial Magnetic Stimulation)|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
75335448|NCT05647252|Drug|Whole Body and nasal decolonization with octenidin (Octenisan Set)|"Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period"
75472650|NCT01961193|Device|punctal plug|A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
75929058|NCT06069102|Other|BP Threshold for medication initiation|The usual care group will be given anti-hypertensive medications if a subject's BP consistently exceeds 150/100 mmHg at any point. The intervention group will receive BP meds if a subject's hospital BP consistently exceeds 140/90 mmHg or her home BP consistently exceeds 135/85 mmHg.
76084393|NCT01599832|Drug|pazopanib hydrochloride|Given PO
76084394|NCT01599832|Other|laboratory biomarker analysis|Correlative studies
75792797|NCT03921684|Drug|Nivolumab|Nivolumab 240mg IV, day 1 of each treatment cycle, every two weeks, given with mFOLFOX6
75792798|NCT03925974|Drug|KN026 10 mg/kg QW|10 mg/kg QW as safety run-in dosage
75792799|NCT03925974|Drug|KN026 20 mg/kg Q2W|20 mg/kg Q2W as target dosage
76084395|NCT01599832|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
76084396|NCT01599832|Other|pharmacogenomic studies|Correlative studies
75472651|NCT01961206|Other|bacteremia caused by ESBL producing E.coli or K.pneumoniae|community-onset bacteremia caused by ESBL producing E.coli or K.pneumoniae
75472652|NCT01961245|Device|nocturnal non-invasive ventilation|patients will undergo a non-invasive ventilation during the night
75472653|NCT01961258|Other|Computerized data base analysis and sampling of patients for outpatient clinic evaluation|
75472654|NCT01961284|Device|Zygomatic implant placement|
75472655|NCT01961284|Device|conventional implants and augmentation of maxilla|
75792800|NCT03925974|Drug|KN026 30 mg/kg Q3W|30 mg/kg Q3W as another target dosage
75792801|NCT03929094|Drug|Paclitaxel for Injection（Albumin Bound）|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
75798915|NCT03858192|Drug|Antibiotics|Treatment for infection and reason for admission
76084397|NCT01600222|Drug|LEO 90100|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
75792802|NCT03929094|Drug|Gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
75335449|NCT05647252|Behavioral|Questionnaire for study participants immediately after the decolonization|"A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).~The questionnaire is handmade and validated by the Investigators."
75335450|NCT02170649|Drug|BIA 2-093|
75335451|NCT05288699|Behavioral|Aliento|Aliento is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety delivered via a mobile application.
75929059|NCT06065631|Device|Eyeglasses|Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.
75335452|NCT05646160|Other|Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)|IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
75644813|NCT00753922|Device|Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface|Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
75644814|NCT04287530|Dietary Supplement|Poly-unsaturated fatty acids supplementation|Daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
75644815|NCT04287530|Behavioral|Neuropsychological intervention|"Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session."
75644816|NCT04287530|Dietary Supplement|Placebo|Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
75644817|NCT02407795|Radiation|conventional radiotherapy|1x8Gy
75929060|NCT06065631|Other|Prescription slip|Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial
75335453|NCT02316470|Biological|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
76084398|NCT05062096|Other|Blood samples|Blood samples at each protocol visit, T and NK cell analysis
75644818|NCT02407795|Radiation|stereotactic radiotherapy|1x20Gy or equivalent dose fractionation schedule
75792803|NCT01228032|Other|Care team|The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
75929061|NCT06063681|Drug|SR-8541A|orally administered ENPP1 inhibitor
76084399|NCT05062096|Other|Skin biopsy|Biopsy of the skin lesion (optional)
75929062|NCT06063590|Biological|StromaForte|100 millions allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
75335454|NCT02316470|Biological|Placebo|phosphate buffered saline (PBS) solution
75792804|NCT01131702|Drug|Ranitidine|Ranitidine Tablets, 300 mg
75792805|NCT03921762|Procedure|Cataract surgery with Artis Active IOLs|Patients will be implanted with the Artis Active IOLs during cataract surgery
75929063|NCT06063109|Drug|THP-00101 (Dapagliflozin) 10mg|Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B
75929064|NCT06063109|Drug|THP-00102 (Telmisartan) 80mg|Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
76084400|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
76084401|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
76084402|NCT03348696|Drug|Dexamethasone tapering dose|dexamethasone standard of care pre-medication + dexamethasone tapering dose
76084403|NCT03348696|Drug|Dexamethasone physician choice|Dexamethasone standard of care pre-medication + dexamethasone physician choice
75644819|NCT04289948|Drug|Phage|The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
75929065|NCT06056544|Behavioral|Client Centered Care Coordination|During the initial C4 sessions, participants will be offered PrEP. For participants who initiate PrEP, C4 staff will provide an individualized PrEP initiation plan. During subsequent C4 sessions, C4 staff will review the prevention plan and goals with participants and use autonomy supportive counseling to address the barriers that are identified by participants that impact their motivation to use PrEP and adhere to PrEP through referrals to support services (e.g, PrEP access programs, addiction medicine services, housing, and job resources). In addition, the C4 staff will ensure any medical issues related to PrEP adherence are addressed by the site medical providers.
75644820|NCT00761176|Device|The Provant Therapy System|The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
75644821|NCT04287296|Behavioral|Wakey!|Everyone who has downloaded the app will receive a 9-minute morning show as an alternative to an alarm clock every Mon-Fri for 12 weeks. The show is presented by a cast of presenters who appeal to the target demographic. The intervention content is theory and evidence led, drawing on approaches from cognitive and third-wave psychotherapies, positive psychology interventions (such as those based on resilience training and growth mindset), and lifestyle mental health interventions. Additional content will be provided on the app to support the theory and techniques that are covered in the show. Fun content will also be posted in an ad-hoc manner that complement the shows or relate to cultural dates and aim to increase engagement. Wakey! will avoid any polarising topics such as politics, religion and folk science. There are several features beside the show itself: a moderated live chat between 6-9AM, feedback for users (e.g. how many days they have seen the show, current energy levels).
75929066|NCT06054971|Other|Remote Administration of NSAA|Remote Administration of NSAA
75929067|NCT06052046|Device|TOTAL30 for Astigmatism Contact Lenses|Participants will be refit into TOTAL30 for Astigmatism Contact Lenses and followed for 1 month.
75792806|NCT03921762|Procedure|Cataract surgery with AT Lara IOLs|Patients will be implanted with the AT Lara IOLs during cataract surgery
75929068|NCT06050928|Drug|Oral EP262|Once daily
75929069|NCT06036641|Device|NIRS monitoring|All participants will undergo NIRS monitoring of muscle and cerebral tissue oxygenation intraoperatively.
75644822|NCT01613989|Procedure|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
75929070|NCT06036641|Device|Laser Doppler flowmetry|Cutaneous blood flow will be assessed intraoperatively via Laser Doppler flowmetry in all participants
75929071|NCT06036641|Other|Inflammatory and Oxidative stress biomarkers|Blood samples will be taken to measure biomarkers of inflammation and oxidative stress at specific time points
75929072|NCT06034327|Device|Single vision, impact-resistant spectacle lenses; Test Arm|Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia
75929073|NCT06034327|Device|Single vision, impact-resistant spectacle lenses; Control Arm|Single vision, impact-resistant spectacle lenses
75335455|NCT03014921|Other|iron injection|Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
75335456|NCT03014921|Other|saline solution injection|Injection of a 250mL saline solution
75792807|NCT03921918|Device|Breast Pump|Hydraulic Breast pump
75792808|NCT03740022|Procedure|ACL plasty|standard ligamentoplasty by Kenneth Jones
75792809|NCT03740022|Procedure|ACL + ALL plasty|standard ligamentoplasty and anterolateral plasty
75929074|NCT06033963|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
75929075|NCT06033963|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
75929076|NCT06032234|Other|This is an observational study|This is an observational study
75929077|NCT06031220|Other|deep breathing exercise inform of diaphragmatic and costal breathing|deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks,
75335457|NCT04094207|Drug|Placebo oral tablet|Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
75792810|NCT03925896|Drug|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
75335458|NCT04094207|Drug|Pentoxifylline|Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
75335459|NCT05645614|Other|EVALUATION OF PAIN|PAIN EVALUATION THANKS TO SCALES
75335460|NCT02144831|Drug|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
75335461|NCT05232461|Drug|PrimeC-ER 748 mg|PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
75792811|NCT03929328|Procedure|High flow oxygen therapy in spontaneous breathing trial|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
75929078|NCT06029309|Drug|Zanubrutinib|"Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~Phase 1 Dose Level 1: 320 mg~Phase 1 Dose Level -1: 240 mg~Phase 2: Recommended dose determined in Phase 1."
75929079|NCT06029309|Drug|Tafasitamab|"Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~Late Induction - Cycles 4 through 12: Days 1 and 15"
75929080|NCT06026410|Drug|KO-2806|Oral administration
75792812|NCT01228110|Drug|Hydrocortison|
75929081|NCT06026410|Drug|Cabozantinib|Oral administration
75929082|NCT06025344|Drug|PanCytoVir™ 100 mg/mL oral suspension|Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
75929083|NCT06025344|Drug|Probenecid 500 mg|Single oral dose of 1000 mg under fasted conditions
75335462|NCT05232461|Drug|Ciprofloxacin 750 MG|Ciprofloxacin
75335463|NCT05232461|Drug|Celecoxib 200mg|Celecoxib
75335464|NCT05748106|Device|Ultrasound-based imaging|Ultrasound-based imaging
75644823|NCT01613989|Procedure|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
75472656|NCT01961310|Biological|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
75644824|NCT05437276|Device|PoNS®|The PoNS device used in conjunction with rehabilitative physical therapy
75644825|NCT02865824|Drug|Continue thienopyridine|Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
75644826|NCT02865824|Drug|Discontinue thienopyridine|Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
75644827|NCT02570035|Drug|Mirabegron|oral
75644828|NCT02865980|Other|clove extract|in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.
75644829|NCT02865980|Other|Betadine|in control group, will be washed the Catheter with Betadine
75644830|NCT04098796|Drug|Anti-PD-1 antibody|Sintilimab will be administered 200 mg intravenous drip, every 3 weeks. Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years.
75644831|NCT04098796|Drug|XELOX|Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
75792813|NCT01228110|Drug|Saline Solution|
75792814|NCT01229124|Genetic|RNA analysis|
75792815|NCT01229124|Genetic|nucleic acid sequencing|
75792816|NCT01229124|Genetic|reverse transcriptase-polymerase chain reaction|
75335465|NCT01804790|Drug|mFolfirinox|Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles: oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-FU: 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800 mg/m² twice a day 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on the center's choice.
75335466|NCT01804790|Radiation|Radiotherapy 50 Gy|5 radiations per week of 2 Gy for 5 weeks
75335467|NCT01804790|Drug|Capecitabine|1600 mg/m² (800 mg/m² twice daily) for 5 weeks
75335468|NCT01804790|Procedure|TME surgery|
75335469|NCT01804790|Drug|mFolfox6 or capecitabine|oxaliplatine 85 mg/m² (day 1 of cycle; perfusion in 2h), folinic acid 400 mg/m² (day 1 of cycle perfusion in 2h), 5-FU (bolus 400 mg/m² in 10 min and 2400 mg/m² perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500 mg/m²/day (Each cycle consists of 1250 mg/m² twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
75472657|NCT01961310|Biological|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
75792817|NCT01229124|Other|laboratory biomarker analysis|
75792818|NCT02528994|Dietary Supplement|L-serine|Participants will take dietary serine supplementation daily
75798916|NCT05668494|Other|immediate loading of implants|This is a randomized control clinical trial including 24 implants, immediately loaded with definitive abutment protocol and 24 implants immediately loaded with with temporary abutment protocol
75929084|NCT06025318|Drug|PanCytoVir™|PanCytoVir™ 100 mg/mL oral suspension
75335470|NCT05747248|Device|Ultrasonography|Tracheal, diaphragmatic and lung ultrasonography
75335471|NCT05745922|Behavioral|Moderate intensity exercise|Treadmill walking/running with moderate intensity
75335472|NCT05745922|Behavioral|High intensity exercise|Treadmill walking/running with high intensity
75472658|NCT01961336|Drug|Testosterone|10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
75472659|NCT01961388|Drug|Bay G5421 Glucobay|Oral, dosage of Acarbose as per the directions of treating physician
75472660|NCT01961388|Drug|Metformin|Oral, dosage of Metformin as per the directions of treating physician
75472661|NCT01961401|Behavioral|exercise|
75472662|NCT01961414|Drug|Aflibercept|Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
75929085|NCT06020339|Other|The midwife-led continuous care model (MLCC)|"Continuity of midwife-led care has been defined as care in which the midwife is the leading professional in the planning, organization and delivery of care given to a woman from the initial assessment of the pregnant woman to the postpartum period.~ELSBM; It is the same midwife or midwife group providing the care and counseling needed by the woman during pregnancy, childbirth and postpartum period. In this care model, the midwife is the leading health care specialist who is responsible for planning and arranging the care given to women in the antenatal, natal and postnatal period. MLCC is woman-centered and is based on the idea that pregnancy and childbirth are normal life events.~This care model includes education, counseling and care according to the needs of the woman. It promotes vaginal delivery as a normal process and advocates minimal interventions. Continuity of midwifery-led care is associated with superior outcomes for women and infants than other models of care."
75792819|NCT01225536|Drug|ARQ 736|Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
75792820|NCT03925818|Drug|Bismuth Subcitrate Potassium|Pylera capsules
75792821|NCT03925818|Dietary Supplement|Gastrus|Gastrus 1 tablet
75644832|NCT00522145|Drug|XL647|Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
75929086|NCT06019884|Device|Caries detection method: Intraoral camera|A specialized intraoral camera (C50) with fluorescence signal and selective chromatic amplification will be used to record intraoral structures in the form of videos and/or photos. The camera has four modes (Daylight, Daylight+, Perio and Caries modes) which can differentiate the color of tissues to provide a reliable diagnosis. The camera will be used in a systemic sequence to video record and capture photos of intraoral conditions in both arches. The intraoral camera will be connected to a laptop screen, and the captured videos and/ or photos will be transferred to an electronic platform.
75929087|NCT06019884|Device|Caries detection method: Smartphone camera|This is a low-cost electronic system consisting of a smartphone positioned in front of the oral cavity to scan the upper and lower jaws from the cheek then the tongue sides. The smartphone camera resolution should be sensitive enough to capture the intraoral structures (at least 1000 pixels). The focus will be adjusted, and the inbuilt flash will be used to obtain clear and sharp images. The photos will be transferred to the electronic platform.
76084404|NCT04506450|Procedure|Peripheral nerve block|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected."
75644833|NCT02864030|Drug|ERIBULIN MESYLATE|"Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.~The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin."
75335473|NCT01317134|Device|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
75335474|NCT01317134|Biological|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
75792822|NCT03925740|Drug|MI Varnish|Application of MI varnish material versus the standard 1.23% APF.
75472663|NCT01961427|Dietary Supplement|sodium nitrate|Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
75472664|NCT01961427|Dietary Supplement|Beetroot juice|concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
75472665|NCT01961453|Drug|Isosorbide Mononitrate, sustained release|60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
75472666|NCT01961453|Drug|Placebo capsule|One capsule of placebo administered once daily at 8 am.
75472667|NCT01961466|Other|psychological and social self-administered questionnaires|
75472668|NCT01961479|Behavioral|Internet-based CBT for patients with PMS|Internet-based cognitive-behavioural self-help treatment
75644834|NCT02599636|Other|None intervention|Investigators will study the usual medical assistance
75644835|NCT00726817|Drug|Butyrate|
75792823|NCT03925740|Drug|PreviDent Varnish|Application of PreviDent Varnish material versus the standard 1.23% APF.
75792824|NCT03925740|Drug|1.23% APF|Standard 1.23% APF application
75792825|NCT01130688|Drug|Zileuton|Imatinib combined with Zileuton
75792826|NCT03928938|Device|Electronic patient reported outcomes|Electronic patient reported outcomes-tool
75792827|NCT03925662|Drug|Folfox with avastin|Folfox with avastin only
75792828|NCT03925662|Drug|Mebendazole|Folfox with avastin with mebendazole
75472669|NCT01961479|Other|Waiting list|During the waiting period, participants receive no treatment.
75472670|NCT01961492|Other|Fecal microbiota transplantation|A single fecal microbiota transplantation through colonoscope
75792829|NCT03921450|Device|1 Hz rTMS|1 Hz stimulation at 110% of resting motor threshold over supplementary motor area
75792830|NCT03921450|Device|iTBS|50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area
75792831|NCT03921450|Drug|Placebo|1 Hz stimulation with the placebo TMS coil without any magnetic emission
75792832|NCT01225614|Device|Bilevel pressure ventilator|Nocturnal home ventilation
75792833|NCT03921606|Behavioral|Motivational Interviewing (i-BMI)|A brief MI via WhatsApp/WeChat
75798917|NCT01184820|Biological|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.
75929088|NCT06019884|Other|Referral pathway: prevention specified|Child identified at higher risk using the The International Caries Classification and Management System (ICCMS) classification due to the presence of caries experience will be referred with explicit inclusion of preventive care using professionally applied fluoride. The children will also be referred to restorative care or pulp therapy depending on their needs.
75644836|NCT02599870|Genetic|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
75644837|NCT00726973|Drug|Ranibizumab|Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab. For 2 months injected intravitreal Ranibizumab will be given. At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab. If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness >100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.
75792834|NCT03921606|Behavioral|Individual face-to-face generic health advice|Individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese). A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs.
75644838|NCT00726973|Drug|Ranibizumab monotherapy|3 monthly intravitreal injections of Ranibizumab monotherapy. After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
75644839|NCT02956603|Other|Fine wire EMG electrodes|Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate
75644840|NCT00760552|Other|High Intensity Intervention|High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
75792835|NCT01229202|Drug|Bevacizumab|single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
75792836|NCT03928860|Other|OMT session|Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
75929089|NCT06019884|Other|Referral pathway: no prevention specified|This follows the standard practice adopted in dental clinics in public facilities. Care is planned by the receiving dentist, based on available resources, and hospital/ clinic policies. The screening/ sending dentist will inform the family of the oral health condition for which the child needs care and of available public and private facilities that offer this care. The management plan will not be predetermined, and decisions are left to the receiving dentists without explicit mention of the need for preventive care to control ECC.
75929090|NCT06017414|Behavioral|Systemic Psychotherapy-informed Growth Path|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention aims to support members to explore their relationships, situations, and goals.
75929091|NCT06017414|Behavioral|Systemic Psychotherapy-informed Listener Training|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention encourages listeners to explore their relationships, situations, and goals and think about how they would support members working through their own relationships, situations, and goals.
75929092|NCT06016556|Drug|nirmatrelvir, ritonavir|single cohort
75929093|NCT06006208|Device|Hamilton C1 ventilator during transport to the ICU|Instead of AMBU bag manual ventilation during transport to the ICU, intervention is using Hamilton C1 ventilator during transport to the ICU
75929094|NCT06005805|Dietary Supplement|Mastic gum|Mastic gum 3g/pack daily for 21 days
75929095|NCT06005805|Behavioral|Dietary modification|Adhere to the dietary recommendations for Korean dyspepsia patients
75929096|NCT06001827|Device|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.
75792837|NCT03921372|Diagnostic Test|Isometric exercise|Squatting for 5 minutes
75929097|NCT06001827|Procedure|Untreated AVF Control|AVF creation surgery without any intervention
75929098|NCT06000111|Behavioral|3 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 3-days and nights of face-down positioning post-operatively.
75929099|NCT06000111|Behavioral|7 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 7-days and nights of face-down positioning post-operatively.
75929100|NCT05999747|Drug|pudexacianinium chloride|Intravenous
75929101|NCT05999006|Device|ELIOS Procedure|Treatment with the ELIOS System
75929102|NCT05998941|Drug|TQB2868 injection|TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
75929103|NCT05998941|Drug|Paclitaxel injection|Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
75929104|NCT05998941|Drug|Cisplatin injection|Cisplatin injection can inhibit the DNA replication process of cancer cells
75929105|NCT05998941|Drug|Carboplatin injection|Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
75929106|NCT05998941|Drug|Bevacizumab injection|Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).
75929107|NCT05996965|Other|HemoVista|additional attatchment of non-invasive hemodynamic monitoring HemoVista with FloTrac
75644841|NCT00760552|Other|Low Intensity Intervention|Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, & possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
75644842|NCT00760552|Other|All- 6 month pharmacist intervention|All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
75644843|NCT04287140|Other|Bolus fluid administration|1000 ml of 0.9% normal saline bolus over one hour
75644844|NCT00753766|Other|Multifactorial Intervention|
75929108|NCT05993351|Diagnostic Test|Magnetic resonance imaging (MRI)|All participants will have 3 MRI scanning sessions to track brain health over time following the same protocol each time. The MRI sessions will occur acutely (<2 weeks post-concussion), 3-months and 6-months post-concussion. A series of MRI scans will be acquired including T1, T2, T2-FLAIR, SWI, ASL, rsfMRI, and DTI scans to characterize structural, microstructural, functional and tissue perfusion changes within the brain over time.
75929109|NCT05993351|Diagnostic Test|Urine and saliva samples|At each study visit all participants will be asked to provide small urine and saliva samples for a metabolomic analysis using a high throughput multi-segment injection-capillary electrophoresis-mass spectrometry technology. This will allow for rapid non-targeted analysis of polar/hydrophilic metabolites, as well as non-polar/ionic lipids with stringent quality control.
75929110|NCT05993351|Behavioral|Questionnaires|The Post-Concussion Symptom Scale (PCSS) and the Depression Anxiety Stress Scale (DASS-42) will be used to assess the self-reported presence and severity of known concussion-related symptoms.
75929111|NCT05992246|Diagnostic Test|Ratio of Femoral Vein Diameter to Femoral Artery Diameter|An ultrasound probe will be used to first scan the area of the upper thigh just below the inguinal ligament directing caudally seeking for the femoral vessels. The femoral artery and vein could be observed simultaneously. Under normal conditions, pulsation is an indication of the femoral artery, and its companion is the femoral vein. The mean femoral vein diameter and femoral vein diameter (3-5 diametral lines in different directions) will be measured during cough, crying, or performing the Valsalva maneuvers.
75929112|NCT05992155|Drug|TAK-279|TAK-279 capsules.
75929113|NCT05988463|Drug|Artesunate Oral Product|Artesunate capsules administered orally twice daily beginning at 10 mg for 4 weeks, followed by 20 mg for 4 weeks, and then 30 mg for 4 weeks.
75929114|NCT05985018|Other|Traditional Diet|Provided as an educational leaflet
75929115|NCT05985018|Other|Mediterranean Diet|Provided as an educational leaflet
75929116|NCT05984823|Other|Home based body weight type exercises with blood flow restriction|"The participant will be asked to complete blood flow restricted exercises described below three times per week for 6 weeks.~Exercise protocol: Two tourniquets will be placed around the upper part of each thigh, these tourniquets will be inflated to an individualised and maintained for the duration of each exercise (including the inter-set rest period) but deflated during the 5 min rest in between. Five Body weight Exercises will be performed: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand."
75929117|NCT05984823|Other|Home based body weight type exercises|The participant will be asked to complete body weight exercises for three times per week for 6 weeks. These exercises include: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand.
75929118|NCT05979974|Device|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A high energy of high-PEMF with a rate of 3 pulse per second is applied to the patient.
75929119|NCT05979974|Other|physiotherapy|Physiotherapy such as shoulder passive and active-assisted range of motion (ROM) exercises, Pendulum exercises, Codman's exercises and Cross-body reach exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
75929120|NCT05979974|Device|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(high energy, a rate of 3 pulse per second) with the difference that the energy output doesn't export to the patient.
75929121|NCT05979857|Drug|SP-3164|SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
75472671|NCT01961505|Drug|Topical compound tripterygium|Topical compound tripterygium was applied for the pain and swollen joints on non-woven fabric for 1 hour, twice per day.
75644845|NCT04287452|Other|Control|Control
75644846|NCT04287452|Other|Dog Therapy|Exposure to certified therapy dogs and their handler.
75644847|NCT02865902|Device|Low-Level Laser Therapy by Ezlase; Biolase®|comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
75644848|NCT02571361|Drug|Paracetamol (1g x 4)|Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively
75644849|NCT02571361|Drug|Ibuprofen (400 mg x 4)|Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
75792838|NCT01329510|Device|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
75644850|NCT02571361|Drug|Paracetamol (0,5 g x 4)|Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively
75792839|NCT01229280|Drug|Darifenacin|Single dose 7.5 mg tablets of darifenacin
75644851|NCT02571361|Drug|Ibuprofen (200 mg x 4)|Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
75644852|NCT02571361|Drug|Placebo (x4)|Given in 6 hour intervals the first 24 hours postoperatively
75792840|NCT01229280|Drug|Darifenacin|Single dose 7.5 mg tablets of Darifenacin
75644853|NCT04093102|Diagnostic Test|biomarkers|bio-markers testing will be made to all suspected OSA patients(CRP, Hba1C,uric acid, ESR, plasma fibrinogen, pentraxin3), and to control cases.
75644854|NCT04290260|Other|Use of breast bra|Patients will use a breast from admission to hospital discharge
75644855|NCT04290260|Other|Usual care (not use of bra)|
75644856|NCT04095130|Diagnostic Test|23Na Magnetic resonance imaging|Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
75644857|NCT00722605|Procedure|cone-beam CT|"You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.~During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.~For all scans, an external monitor will be used to record your breathing.~If needed, you will be repositioned by adjusting the radiation machine's treatment couch position."
75792841|NCT01225692|Behavioral|Head Injury Guideline|
75792842|NCT03929172|Biological|AAVLP-HPV|20μg/injection formulated in a ready to use solution containing 100mM sodium citrate, 2.5 mM MgCl2, 0.001% pluronic F-68, pH 6.0 for i.m. injection as 0.5 mL per injection.
75929122|NCT05979727|Drug|RE02|Low, medium or high dose of RE02
75644858|NCT04290104|Drug|1gr oral ampicillin/sulbactam group|Group prescribed 1 g oral ampicillin/sulbactam 2 times a day.
75644859|NCT02571205|Drug|Sustanon (testosterone)|Standard incremental regimen of Sustanon
75644860|NCT04290026|Drug|metoclopramide versus granisetron|ِِِِAssessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section by us
75644861|NCT01921803|Radiation|hypofractionation|
75644862|NCT00722683|Procedure|Ultrasound Imaging with Contrast|"An ultrasound contrast agent, Definity, will be administered started through the IV line already in use. The imaging will be performed to map vascular flow.~The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times."
75644863|NCT04287374|Behavioral|Multi-component Well-being Intervention|The intervention asks participants to complete exercises based on three different skills. These skills include cognitive restructuring, gratitude and behavioral activation. After completing the program, participants will pick their favorite exercise to complete on a weekly basis for homework. In order to increase compliance with the homework, participants will complete a short plan in which they will identify when, where and with who they will complete the homework. The whole intervention takes approximately 20-30 minutes to complete.
75644864|NCT04287374|Behavioral|Study Skills|Participants are taught three different study skills/strategies. They are asked to make a plan to continue using these strategies after completing the intervention. The whole intervention takes approximately 20-30 minutes to complete.
75929123|NCT05979727|Drug|Manitol|Placebo Comparator
75929124|NCT05976646|Drug|Placebo|Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
75929125|NCT05976646|Drug|Auvelity|Orally-administered combination of 45 mg dextromethorphan with 105 mg Bupropion (trade name Auvelity). Auvelity will initially be administered orally once daily for three days. After 3 days on once daily AUVELITY, the participants will begin taking AUVELITY twice daily for 4 additional days as recommended in the FDA-approved prescribing information.
75929126|NCT05976321|Drug|TAK-279|TAK-279 capsules.
75929127|NCT05975255|Drug|Remimazolam besylate|Intravenous administration of predetermined dose of Byfavo for 30 seconds
75929128|NCT05973903|Drug|Lenvatinib|Oral Lenvatinib 20 mg once daily
75929129|NCT05973903|Drug|Pembrolizumab|intravenous pembrolizumab 200 mg every three weeks
75792843|NCT03929172|Drug|Placebo|0.5 mL 100 mM Sodium Citrate, 2.5 mM MgCl2, 0.001% Pluronic F-68, pH 6 for i.m. injection as 0.5 mL per injection.
75792844|NCT01229358|Other|Surgical dressing|Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
75792845|NCT01132014|Biological|OCDC|OCDC,an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with either intravenous Daclizumab, or with a combination of Daclizumab and intravenous Bevacizumab.
75792846|NCT03921138|Other|Histopathologic tube anomalies|Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)
75792847|NCT01130766|Procedure|stereotactic radiosurgery (SRS)|Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
75798918|NCT01184820|Biological|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))|Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.
75798919|NCT03858270|Drug|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
75929130|NCT05973903|Device|Tumor Treating Fields (TTFields)|TTF extra-dermal scalp electrodes
75644865|NCT00640887|Drug|rifabutin in combination with efavirenz|"Ia. arm 1a:~D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);~Ib. arm 1b:~D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);"
75792848|NCT03920124|Other|Step and walk-based high intensity interval exercise|"Four hospital-based trials will include two step-based (3 x 20 sec with 120 sec rest, or 3 x 60 sec with 60 sec rest) and two walking-based (e.g. 3 x 60 sec with 60 sec rest or 3 x 180 sec with 180 sec rest) interval exercise protocols, in a randomised and counterbalanced order.~Unsupervised (At home) exercise intervention will incorporate patients' preferred stair and/or walking-based interval exercise (from those completed during hospital trials). Initially patients will complete their chosen protocol three days per week, and then gradually progress exercise load (i.e. reps, work-to-rest ratio, and/or sessions per week) as appropriate, to a maximum of 6 x 60 sec stepping / 5 x 180 sec walking, five times per week (i.e. maximum of ~30 min daily or ~150 min weekly)."
75792849|NCT03920046|Behavioral|Control Group|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents no smoking.
75929131|NCT05973110|Behavioral|Cognitive Remediation|In each of the 12 visits, participants will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for about 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
75929132|NCT05973110|Behavioral|Active Control|In each of the 12 visits, participants will complete exercises in virtual reality will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for around 10 to 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
75929133|NCT05971225|Other|remote monitoring only|remote monitoring only can replace in-office device monitoring
75929134|NCT05967455|Biological|Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
75929135|NCT05967455|Biological|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489
75644866|NCT00640887|Drug|rifabutin in combination with nevirapine|"IIa. arm 2a:~D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);~IIb. arm 2b :~D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);"
75792850|NCT03920904|Other|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
75792851|NCT03919890|Drug|ONO-7684|Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
75792852|NCT03919890|Drug|ONO-7684 Placebo|Placebo comparator
75792853|NCT03920748|Other|Group D|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 3-4 is defined as Group D
75792854|NCT03920748|Other|Group E|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 1-2 is defined as Group E
75929136|NCT05962229|Drug|(S)-Nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
75644867|NCT00640887|Drug|rifabutin in combination with lopinavir/ritonavir|"IIIa. arm 3a :~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);~IIIb. arm 3b:~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks)."
75644868|NCT04067869|Procedure|Blood samples|Blood sample containing 3 ethylene-diamine-tetra-acetic acid tubes (7ml), 3 dry tubes (7ml) and 5 citrated tubes, ie 9 tubes
75792855|NCT01131780|Drug|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
75792856|NCT01131858|Drug|Vigantol|Vigantol 4000IU/day
75792857|NCT01131858|Drug|Placebo|Placebo
75792858|NCT01130922|Drug|moxifloxacin per IV|intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
75929137|NCT05962229|Drug|(R)- nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (R)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
75929138|NCT05962229|Drug|Racemic nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 50% (R)-nicotine and 50% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
75929139|NCT05961124|Drug|Niraparib|Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
75644869|NCT04183647|Device|whole body vibration / local vibration|Both the whole-body vibration application and the local vibration application will be applied to the patients in our cross-over study. Between the two applications will be given a washout period of one week. Patients will be evaluated both local and whole body vibration applications, 1 minute and 60 minutes after the end of the applications. After the evaluation, the patient will be rested in the sitting position until the evaluation at the 60th minute.
75792859|NCT01130922|Drug|moxifloxacin per os|oral administration of 400 mg moxifloxacin in a single dose
75929140|NCT05960864|Drug|Celecoxib|If we find any behavior that affects the safety of patients in the experiment, we will stop
75929141|NCT05957003|Procedure|Combined end-expiratory occlusion and end-inspiratory occlusion test|"The EEO test will be performed by interrupting the mechanical ventilation at end-expiration over 15 seconds using the end-expiratory hold button available on the ventilator.~The EIO test will be performed by interrupting the mechanical ventilation at end-inspiration over 15 seconds using the end-inspiratory hold button available on the ventilator."
75929142|NCT05957003|Procedure|Tidal volume challenge test|elevating tidal volume from 6 ml/kg to 8 ml/kg for only 60 seconds
75472672|NCT01961505|Drug|Placebo|The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
75792860|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 100 mg, Single-dose
75929143|NCT05956821|Drug|SIACI of cetuximab and bevacizumab|Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)
75929144|NCT05946642|Drug|Sulphadoxine-Pyrimethamine/Amodiaquine|Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.
75929145|NCT05946642|Drug|Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)|"DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin.~Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach."
75929146|NCT05945147|Drug|Ketamine|An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
75929147|NCT05945147|Drug|Midazolam|A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
75335475|NCT01315340|Procedure|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
75929148|NCT05945147|Drug|Normal Saline|An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
75929149|NCT05944731|Device|Continuous glucose monitor|Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.
76084405|NCT04506450|Procedure|Spinal anesthesia|"In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected."
76084406|NCT03348618|Biological|IVIG|Intravenous immunoglobulin
75644870|NCT04067947|Drug|XG005|XG005 Tablet
75644871|NCT04067947|Drug|Placebos|Placebo Tablet
75644872|NCT04183569|Other|Sequencing RNA.|RNA-seq, central pivot between genomics and proteomics allows to make the connection between the observed mutations and alteration of protein expression with the identification and quantification of RNA. Thus, we can attest to the expression of mutations identified on DNA, protein and understand whether deregulation is linked to dysregulation of transcription or post-translational modification
75644873|NCT02682771|Device|Bilevel positive airway pressure|The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
75644874|NCT02682771|Device|PowerBreathe|Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
75929150|NCT05942560|Behavioral|Cognitive behavioural therapy-based intervention|"A specifically designed CBT-based intervention consisting of 8 weekly sessions with group format.~Each group will be comprised of 4-10 participants, and each session will last 1.5 hours.~The content of the weekly sessions will be based on Beck's cognitive theory and the cognitive therapy in groups guidelines.~The framework of every session will follow a pre-determined structure."
75792861|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 200mg, single dose
75792862|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 400 mg, Single-dose
75929151|NCT05942560|Behavioral|Educational group|The educational sessions are consisting of 8 weekly sessions with a group format. These sessions will focus on cancer-related information and care knowledge which will be delivered in daily routine care.
75929152|NCT05941286|Device|CGM system with glucose alerts on|the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts on
75929153|NCT05941286|Device|CGM system with glucose alerts off|the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts off
75929154|NCT05939596|Biological|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
76084407|NCT03352206|Drug|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
76084408|NCT03352206|Drug|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
76084409|NCT04503486|Diagnostic Test|handgrip strength|measure of handgrip strength using Jamar Dynamometer and a standardized protocol, strength expressed in kg
75335476|NCT01313702|Drug|polipillV1|polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
75335477|NCT01313702|Drug|polipillV2|Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
75335478|NCT01313702|Drug|usual care|the drugs used in clinical practice, defined by physician
75792863|NCT01131000|Other|Normal Saline|Normal Saline, 100 ml, Single-dose
75792864|NCT01132170|Drug|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
75792865|NCT03925428|Drug|Entinostat|Given PO
75792866|NCT03925428|Drug|Molibresib|Given PO
75798920|NCT03858270|Other|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week Placebo will be administered at 10 mg tablet twice/day for 51 weeks.
75798921|NCT01180530|Device|NovoPen Echo®|Prescribed insulin treatment delivered by NovoPen Echo®
75929155|NCT05939596|Other|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
76084410|NCT04503486|Diagnostic Test|quadriceps strength|maximal isometric quadriceps strength measured using a handheld dynamometer and a standardized protocol, strength expressed in Newton
76084411|NCT03352128|Dietary Supplement|Creatine|Participants will have to supplement themselves with creatine for 7 days (20g/day).
76084412|NCT03352128|Dietary Supplement|Calcium lactate|Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
76084413|NCT03122730|Combination Product|VentaProst|Part I - an equivalent dose of VentaProst compared to conventionally-administered aerosolized epoprostenol with subsequent dose titration to achieve a clinically significant hemodynamic response Part II - Dose titration to achieve a clinically significant hemodynamic response.
75335479|NCT04983446|Drug|Foralumab|Foralumab is a second generation fully human anti-CD3 antibody
75335480|NCT04983446|Other|Placebo|Placebo will be the vehicle for the foralumab nasal solution without active drug (25 mM sodium acetate/125 mM sodium chloride/0.02% polysorbate 80, pH 5.5 buffer).
75335481|NCT00365690|Behavioral|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
75472673|NCT01961583|Drug|18F-Fluciclatide|"Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy"
75472674|NCT01961596|Other|Cooling Ice Spray|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test."
75644875|NCT02682771|Procedure|Conventional Respiratory Physiotherapy (CRP)|CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
75644876|NCT00730093|Dietary Supplement|B12 vitamin (Cyanocobalamin)|Arm A: B12 vitamin (Cyanocobalamin)
75644877|NCT00727129|Drug|Divigel|
75644878|NCT00976898|Radiation|Proton Beam Irradiation|Given once a day, 5 days a week, for 3 weeks
75644879|NCT04183725|Drug|Reduning injection|"Reduning injection:~2≤Age≤5,0.5ml/kg/day,<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd*5.~Oseltamivir phosphate granules simulants:~Weight≤15kg,30mg,po,bid*5; 15<Weight≤23kg,45mg,po,bid*5; 23<Weight≤40kg,60mg,po,bid*5; Weight>40kg,75mg,po,bid*5."
75644880|NCT04183725|Drug|Oseltamivir phosphate granules|"Oseltamivir phosphate granules:~Weight≤15kg,30mg,po,bid*5; 15<Weight≤23kg,45mg,po,bid*5; 23<Weight≤40kg,60mg,po,bid*5; Weight>40kg,75mg,po,bid*5.~+Reduning injection simulants: 2≤Age≤5,0.5ml/kg/day,<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd*5."
75644881|NCT00730249|Drug|methylphenidate hydrochloride|sustained release, twice daily, dosage according to an individual titration schedule
75644882|NCT00730249|Drug|Placebo|twice daily according to an individual titration schedule
75644883|NCT02570347|Drug|Co-amoxiclav|Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
75644884|NCT02570347|Biological|Tetanus toxoid|Injection Tetanus toxoid 0.5 ml intramuscularly Stat
76084414|NCT05286372|Drug|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
75644885|NCT01648959|Other|EEG Recording|
75644886|NCT01632657|Drug|Sumatriptan|Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
75929156|NCT05936710|Device|ACETATE based dialysate|Intermittent hemodialysis with an acetate based dialysate.
75929157|NCT05936710|Device|CITRATE based dialysate|Intermittent hemodialysis with an citrate based dialysate.
76084415|NCT03122418|Behavioral|Personal Fitness Device|Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
76084416|NCT05281692|Diagnostic Test|Enhanced Preservation Media (EPM-IX)|EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.
76084417|NCT04505904|Drug|Syntocinon|Synthetic oxytocin spray, 24 IU per spray.
76084418|NCT04505904|Drug|Placebo|Placebo spray with no active ingredient.
76084419|NCT04505982|Other|Data extraction from medical files|Data extraction from medical files
76084420|NCT03348462|Drug|ethosomal preparation of anthralin|once daily with short contact topical application
76084421|NCT03348462|Drug|liposomal preparation of anthralin|once daily with short contact topical application
76084422|NCT04505514|Drug|Iron Isomaltoside 1000|"single dose of 1000 mg iron isomaltoside diluted in 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding"
76084423|NCT04505514|Drug|Placebo|"100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding"
76084424|NCT04505514|Drug|Iberet-Folic-500|once a day dose, to start 5 days after the intervention
76084425|NCT03352050|Dietary Supplement|mushroom|
76084426|NCT03352050|Other|ground beef|
76084427|NCT05256732|Drug|AT-527 fasted|AT-527 administered twice daily (BID) for 5 days fasted
75929158|NCT05934669|Drug|Intranasal Midazolam|Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
75792867|NCT01228188|Procedure|Inverted ILM Repositioning|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
75929159|NCT05934669|Drug|Intranasal Dexmedetomidine|See above
75929160|NCT05934669|Drug|Intranasal Ketamine|See above
75644887|NCT01632657|Other|Placebo|Single injection saline 0.5ml subcutaneously in recovery
76084428|NCT05256732|Other|Placebo Comparator fasted|Matching placebo administered twice daily (BID) for 5 days fasted
75644888|NCT00727207|Drug|everolimus|
75644889|NCT01460589|Procedure|timing to initiate the adjuvant chemotherapy|Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
76084429|NCT05256732|Drug|AT-527 fed|AT-527 administered twice daily (BID) for 5 days fed
75644890|NCT03950791|Behavioral|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials. It will also include mind-body science as it relates to pain and PC. Participants learn how to identify catastrophizing in the moment, and how to self-treat it. During the class, participants acquire skills and develop a plan to apply the learned skills to decrease physiological hyperarousal within the context of PC. Participants also acquire skills that improve the regulation of cognition and emotion, including PC reframing and thought restructuring, and develop a plan for implementing these skills in daily life. Finally, participants develop a plan to use behaviors that modulate attention and counteract helplessness.
75644891|NCT03950791|Behavioral|Health Education|Education about improving lifestyle factors to improve participants' overall health.
75644892|NCT02682459|Drug|Lisinopril|
75644893|NCT00727363|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 will be administered at a dose of ten to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital.
75644894|NCT00727363|Dietary Supplement|Placebo|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital.
75644895|NCT00640965|Drug|DP-VPA|DP-VPA dose escalation to 900mg, then continued for 8 weeks
75929161|NCT05931341|Dietary Supplement|Rosemary extract|Softgel capsule including rosemary extract
75929162|NCT05929859|Behavioral|Speech Motor Chaining|Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.
76084430|NCT05256732|Other|Placebo Comparator fed|Matching placebo administered twice daily (BID) for 5 days fed
75644896|NCT00640965|Drug|DP-VPA Placebo|Matching Placebo to Active, dose escalation, then continued for 8 weeks
76084431|NCT05256732|Drug|AT-527|AT-527 administered twice daily (BID)
76084432|NCT05256732|Drug|AT-527 single dose|AT-527 single dose fasted/fed cross-over
75644897|NCT01320657|Device|Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket|"Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks."
75792868|NCT01229514|Other|fMRI|fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
75798922|NCT01289730|Drug|Etanercept|Etanercept 25 mg subcutaneously twice a week
75472675|NCT01961596|Other|water|A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
76084433|NCT05208918|Procedure|Epidural steroid|Injection of Depo-Medrol of affected dermatomes
76084434|NCT05208918|Procedure|PRF plus steroids injection|Pulsed radiofrequency with temperature 42 degrees for 6 minutes to be applied to the dorsal root ganglion plus injection of Depo-Medrol of affected dermatomes
76084435|NCT03348384|Radiation|[C-11]|Radiolabel
76084436|NCT03348384|Drug|NOP-1A|Tracer
76084437|NCT02517762|Behavioral|Physical activity|
76084438|NCT03346980|Diagnostic Test|Esophagogastroduodenoscopy|All patients will be evaluated with both standard HD gastroscope and side-viewing duodenoscope; the latter to ensure proper visualization of the major papilla.
75792869|NCT03920592|Behavioral|Virtual Reality of Bullying|"Immersive videos (360º) filmed by 12-14 year old pupils who, guided by professional actors, represented the subjective experience of bullying.~Eight different potential situations designed depending on the sex of the pupil were filmed:~Girls:~Classmates steal her personal diary~Classmates tear her clothing~Classmates insult her and steal her belongings~Classmates deliberately exclude her in class~Boys:~Classmates exclude him while playing with a ball~Classmates bother him in the dining room~Classmates insult and steal him in class~Classmates insult him and steal his belongings"
75644898|NCT02682303|Device|Elastic Bandage (Idealplast C®)|"Elastic bandage~One anchor strip is applied around the ankle with no tension applied to the tape to avoid restricting blood flow. A supporting stirrup strap is applied from the inside of the ankle, under the heel with no tension up to this point. As the tape is passed up the outside of the ankle tension is applied to the tape with the foot in slight dorsiflexion and secured to the anchor strap (black arrow).~For heel lock, a second strip is applied on the outside of the ankle, taken across the front of the ankle and just above the bony part on the inside of the ankle and back towards the heel (red arrow). Then taken around and under the heel back the way you have just come and around the front of the ankle (orange arrow). The tape then passes above the bony part of the ankle on the outside and diagonally towards the heel, across to the inside of the ankle then around the top to finish"
75644899|NCT02682303|Device|Pretape cramer® (non standarized tape)|"Pretape cramer® was used.~The individual is in supine position keeping the foot and ankle in a neutral position.~The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.~This is the only intervention carried out in this group."
75929163|NCT05923944|Behavioral|Eco-Rescue|Ecorescue is a gamified adaptation of the multiple object tracking task (MOT) combined with a detection task. It requires to track the spatial position of specific moving targets among visually similar moving distractors, while at the same time detecting briefly flashed events. It was designed to load on attentional control and visuo-spatial working memory. Additionally, targets may express various facial emotions (happy, angry or neutral) requiring some emotional control in addition to attentional control.
75929164|NCT05923944|Behavioral|Bejelewed 3|Bejeweled 3 is a commercially available puzzle video game developed and edited by PopCap Games. The main objective is to swap two adjacent gems of seven colors to create a line or row of 3 or more gems of the same type. When these gems are aligned, they disappear, and points are earned. The goal is to get as many points as possible until it is impossible to line up gems. Bejeweled 3 offers a variety of game modes that players can freely explore at their own pace, enhancing the overall enjoyment and providing increased variability during each gaming session. These game modes typically have shorter durations, with a single game usually lasting less than 5 minutes. Bejeweled 3 was chosen as it requires fewer attentional resources compared to Eco-Rescue and because it was reported to reduce stress and anxiety in adult samples (Russoniello et al. 2009, 2013).
75792870|NCT03920514|Drug|hCG|Women will be given hCG before or with IUI
75792871|NCT03919812|Dietary Supplement|Cholecalciferol supplementation|supplementation received by subject according to their vitamin D status: insufficiency or deficiency.
75929165|NCT05923905|Drug|FB1006|30mg/day
75929166|NCT05923905|Drug|Placebo|30mg/day
75644900|NCT02620579|Drug|Propranolol LA (60 mg)|Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
75644901|NCT02620579|Drug|Placebo|Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
75644902|NCT02620579|Behavioral|Shoulder Anatomy Education|Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
75651909|NCT05192434|Behavioral|Expressive Writing|Expressive writing (EW) is a safe, acceptable, and effective intervention for improving psychological adjustment. Via brief directed writing sessions, EW facilitates disclosure of traumatic events. At a basic level, emotional expression and disclosure are important because they reduce the need to unconsciously direct psychological energy towards suppressing emotions from traumatic events.
75792872|NCT03919656|Drug|Dapagliflozin 10 mg|Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)
75792873|NCT03919656|Drug|Placebo Oral Tablet|Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
75929167|NCT05923138|Dietary Supplement|MULTIDOMAIN NUTRITIONAL INTERVENTION: DIET, EXERCISE AND NUTRITIONAL SUPPLEMENTS|"Nutritional intervention (diet, dietetic recommendations and/or supplements). Participants will receive specific recommendations about diet, energetic dietetic supplementation, oral nutritional supplements, exercise... The Nutrition Team (formed by cardiologists, dieticians, nurses...) will closely monitor patients with periodic visits and reassessment of nutritional status and compliance with recommendations."
75929168|NCT05923138|Dietary Supplement|CONTROL|Standard treatment (usual recommendations in patients with heart failure)
75929169|NCT05921604|Drug|Baclofen 10mg|which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.
75929170|NCT05921604|Drug|Gabapentin|which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
76084439|NCT04505748|Device|Self-transfusion device|The Transfusion filter set for salvaged blood (Summit Medical Ltd, Gloucestershire, UK) has been randomly used in 20 patients postoperatively. Patients, who received autologous blood, transfused with the collected amount of blood, only once, 6h postoperatively
76084440|NCT03351972|Drug|Klean Prep|Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
75644903|NCT02620579|Behavioral|Pain Processing Education|Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
75929171|NCT05917262|Behavioral|Mindfulness-based breathing|The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.
75335482|NCT00365690|Behavioral|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
75335483|NCT00365690|Behavioral|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
75335484|NCT04331392|Behavioral|Spatial Navigation Intervention|"The 16-week intervention is completed daily, 5 days/week, remotely from home on a designated study website. Each week participants learn a new city through navigation tasks which increase in difficulty day-to-day and have a total of 4 levels of difficulty, with the goal of being able to independently navigate the city by the end of the week via Google Street View. Participants complete end-of-day multiple-choice tasks, testing what they learned with 3 types of allocentric questions: 1) predicting the next street/landmark, 2) distance judgement and 3) vector mapping. Participants also complete a map placement task, which involves reporting the locations of all studied landmarks/streets.~Participants are presented with auditory rewards in the forms of short audio clips about landmarks, written encouragement in the form pop-ups (e.g., Good work, keep it up!), and coffee card rewards based on adherence to the intervention (e.g.,$5 bi-weekly if 100% of intervention is completed)."
75472676|NCT01961622|Device|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
75472677|NCT01961622|Device|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
75644904|NCT02682225|Drug|Intravenous placebo|Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
75644905|NCT02682225|Drug|Intranasal placebo|Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
75792874|NCT01132248|Drug|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
75792875|NCT01132248|Drug|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
75792876|NCT01229592|Drug|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
75792877|NCT01229592|Drug|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
75792878|NCT01131936|Drug|Amlodipine|Amlodipine Tablets, 10 mg
75929172|NCT05917262|Behavioral|HRV biofeedback|The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.
75929173|NCT05917262|Behavioral|cognitive-behavioral pain psychoeducation|The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
75929174|NCT05917028|Device|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
76084441|NCT03351972|Other|Clear liquids only|Participants randomised to clear liquids only will receive guidance to only drink clear liquids before their procedure
75792879|NCT05402670|Other||
75792880|NCT01231776|Other|electronic acupuncture|applying a stimula on neiguang and shenmen through electronic acupuncture
75792881|NCT01132404|Drug|Leuprorelin|Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
75792882|NCT01132404|Drug|TAK-448|"Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months"
75792883|NCT01229670|Other|exercise|"1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min"
75792884|NCT03919500|Drug|EPO|Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.
75929175|NCT05915910|Diagnostic Test|Specimen Donation|blood donation
75335485|NCT04331392|Behavioral|Educational Videos|The 16-week active control, remote video intervention is completed daily, 5 days a week by participants on a designated website. Participants placed in the active control group are trained on educational topics by watching videos of Ted Talks, to control for the effects of generalized environmental enrichment of the same dose as targeted navigation training. For each day of training, participants are asked to select between an option of 2 possible videos, watching a total of three videos per day. To ensure compliance and sufficient attention to the videos, at the end of each video, participants are asked to rate 5 aspects of the content (relevance, interest, comprehensibility, complexity, informative), and speaker (persuasiveness, quality of delivery, facial expression, convincingness, captivation), on a scale of 1 (lowest) to 5 (highest). Additionally, as with remote navigation participants, they are given written and monetary rewards.
75929176|NCT05915897|Diagnostic Test|Specimen Donation|blood donation
75335486|NCT00301184|Biological|pGA2/JS7 DNA|DNA Vaccine
75644906|NCT02682225|Drug|Intravenous racemic ketamine|Participants will receive 0.5 mg/kg racemic ketamine, intranasally, on Day 2 in sequence 1, on Day 1 in sequence 2, on Day 1 of Period 1 in Sequence 4, on Day 1 of Period 2 in Sequence 5, on Day 1 of Period 3 in Sequence 3, and on Day 1 of Period 4 in Sequence 6.
75644907|NCT02682225|Drug|Esketamine 112 mg|Participants will receive 112 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 6, on Day 1 of Period 2 in Sequence 3, on Day 1 of Period 3 in Sequence 5, and on Day 1 of Period 4 in Sequence 4.
75929177|NCT05910853|Diagnostic Test|Specimen Donation|Blood donation
75644908|NCT02682225|Drug|Esketamine 84 mg|Participants will receive 84 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 5, on Day 1 of Period 2 in Sequence 6, on Day 1 of Period 3 in Sequence 4, and on Day 1 of Period 4 in Sequence 3.
75929178|NCT05908708|Device|Medtronic 780G® hybrid closed loop|"Medtronic 780G® hybrid closed loop system uses the commercial auto-mode with an insulin pump and continuous glucose monitoring."
76084442|NCT04503330|Procedure|buccal mucosal graft to repair iatrogenic PUJO|Augmented buccal mucosal graft anastomosis to repair iatrogenic PUJO or long segment ureteric stricture disease
76084443|NCT05585424|Other|AOT intervention|"The treatment will last 4 weeks, with an intensity of 3 sessions per week. During the sessions the MCI patient will observe his MCI partner and perform a programme of upper limb motor activities. At the same time the mild patient imitates the movement performed by the physiotherapist, all based on the AOT.~The activities will be based on items of the FUGL-MEYER scale. The sessions will last between 15 and 20 minutes and will be held three days a week. The intervention will last 5 weeks, with an initial assessment, 11 intervention sessions and a final assessment."
75644909|NCT04066231|Device|VIPUN GMS|Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).
75644910|NCT04066231|Drug|Erythromycin Lactobionate|"Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.~Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium."
75644911|NCT00727519|Dietary Supplement|Pomegranate juice|
75644912|NCT00727519|Dietary Supplement|Placebo|
75644913|NCT04183491|Biological|Interferon beta-1a|Interferon beta-1a 7.5 µg administered IM
75792885|NCT03919500|Drug|Normal saline|Infants in control group are administered normal saline with the same volume and period as EPO.
75644914|NCT04183491|Biological|Interferon beta-1a|Interferon beta-1a 15 µg administered IM
75644915|NCT04183491|Biological|Interferon beta-1a|Interferon beta-1a 30 µg administered IM
75792886|NCT01229904|Behavioral|music therapy with guitar lessons|The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
75792887|NCT01229748|Behavioral|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
75792888|NCT01229748|Behavioral|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
75792889|NCT01229748|Behavioral|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
75792890|NCT01231854|Drug|Ciclosporin|In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
75929179|NCT05903001|Diagnostic Test|Diaphragm Ultrasound|Ultrasound of the Diaphragm at the end of inspiration and expiration
75335487|NCT00301184|Biological|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
75335488|NCT05374694|Diagnostic Test|Physiological invasive coronary evaluation|Performance of FFR, IMR and acetylcholine test (Only patients in groups 3 and 4 will undergo the acetylcholine test)
75335489|NCT04868708|Biological|AK104|Subjects will receive AK104 intravenously.
75335490|NCT04868708|Biological|Bevacizumab|Subjects will receive Bevacizumab intravenously.
75644916|NCT04183491|Biological|Peginterferon beta-1a|Peginterferon beta-1a 31.25 µg administered SC
75644917|NCT04183491|Biological|Peginterferon beta-1a|Peginterferon beta-1a 62.5 µg administered SC
75644918|NCT04183491|Biological|Peginterferon beta-1a|Peginterferon beta-1a 125 µg administered SC
75644919|NCT04183491|Biological|Placebo|Placebo (administered either IM or SC)
75929180|NCT05903001|Diagnostic Test|Intercostal Muscle Ultrasound|Ultrasound of the Intercostal Muscles at the end of inspiration and expiration
75929181|NCT05903001|Diagnostic Test|Borg scale|Questionnaire for Perceived Exertion (Borg Rating of Perceived Exertion Scale)
75792891|NCT01231854|Drug|Alitretinoin|In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
75792892|NCT01132560|Genetic|RNA analysis|
75929182|NCT05903001|Diagnostic Test|MRC Breathlessness Scale|The MRC Dyspnoea Scale allows the patients to indicate the extent to which their breathlessness affects their mobility.
75929183|NCT05903001|Diagnostic Test|Respiratory Questionaire|Specialized respiratory questionnaire with different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain)
75335491|NCT04868708|Drug|Paclitaxel|Subjects will receive Paclitaxel intravenously.
76084444|NCT05139732|Diagnostic Test|Magnetic Resonance Imaging (MRI)|In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
76084445|NCT03122340|Drug|Ropren|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
76084446|NCT03122340|Other|Oil|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
76084447|NCT03351894|Procedure|Femtosecond laser assisted cataract surgery|Ziemer Z8 femtosecond laser assisted cataract surgery
76084448|NCT03351894|Procedure|Conventional phacoemulsification|conventional phacoemulsification with infinity phaco
75644920|NCT03702283|Other|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
75644921|NCT00727675|Behavioral|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
75644922|NCT02681835|Device|C-MAC laryngoscope|Intubation performed using C-MAC laryngoscope
75644923|NCT02681835|Device|Macintosh laryngoscope|Intubation performed using laryngoscope with Macintosh blade
75644924|NCT00727753|Drug|Ranibizumab|ranibizumab (0.5 mg) will be injected intraocular
75644925|NCT00727753|Drug|Bevacizumab|Bevacizumab (1.25 mg) will be injected intraocular
75792893|NCT01132560|Genetic|gene expression analysis|
75792894|NCT01132560|Genetic|reverse transcriptase-polymerase chain reaction|
75929184|NCT05903001|Diagnostic Test|GINA classification of Asthma|Patients are classified according to the GINA classification of Asthma.
75929185|NCT05903001|Diagnostic Test|Measurement of respiratory mouth pressure|Inspiratory and expiratory Measurement of respiratory mouth pressure
75929186|NCT05903001|Diagnostic Test|SNIP|Measurement of Sniff Nasal Inspiratory Pressure
75929187|NCT05903001|Diagnostic Test|6-minute walking distance|The maximum walking distance achieved in 6 minutes
75644926|NCT00727753|Other|No treatment|No treatment
75644927|NCT05664399|Other|Surprise events|Subjects will be subjected to 4 surprise events, two using Virtual Reality simulations of falling out of a boat, and 2 involving falling into dunk tanks of cool and thermoneutral water.
75644928|NCT00727831|Drug|glucarpidase|
75644929|NCT00727831|Drug|leucovorin calcium|
75644930|NCT00727831|Drug|methotrexate|
75644931|NCT00727831|Other|laboratory biomarker analysis|
75644932|NCT00727831|Procedure|quality-of-life assessment|
75644933|NCT00727831|Radiation|radiation therapy|
75651910|NCT05192434|Behavioral|Contingency Management|Contingency management (CM) is a proven strategy to reduce drug use and HIV risk behavior. Also known as a conditional cash transfer, CM reinforces positive behavior with tangible rewards. In the context of substance use treatment, monetary incentives are typically used to reinforce drug-negative urine specimens.
75651911|NCT04844060|Other|Lumbar punction|Lumbar punction
75792895|NCT01132560|Other|laboratory biomarker analysis|
75792896|NCT03920436|Dietary Supplement|infrared water group|This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.
75792897|NCT03920436|Dietary Supplement|sham group|This group takes 1,8 L of drinking water using a tumbler at room temperature.
75798923|NCT05666544|Other|Web-based patient decision aid|After the clinic, use web-based patient decision aid of renal replacement therapy to conduct education.
75798924|NCT05666544|Other|Written health education leaflets|After the clinic, use a written health education leaflet on renal replacement therapy to conduct education.
75929188|NCT05903001|Diagnostic Test|60 seconds sit-to-stand test|number of repetitions achieved in sitting down and standing up in 60 seconds
75929189|NCT05903001|Diagnostic Test|Electromyography|electromyography of the muscles of respiration via superficial electrodes
75929190|NCT05903001|Diagnostic Test|Lung Function|Measurement of lung function via body plethysmography
76084449|NCT03351816|Procedure|Ablation of atrial fibrillation|Pulmonary vein isolation by radiofrequency or cryoablation.
76084450|NCT03351816|Procedure|Cardioversion|External electric shock delivery under general anesthesia.
76084451|NCT04505202|Drug|0.12% chlorhexidine gluconate|The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care
76084452|NCT04505202|Drug|Placebo|The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
75335492|NCT04868708|Drug|Cisplatin or Carboplatin|Subjects will receive Cisplatin or Carboplatin intravenously.
75335493|NCT05604274|Other|App to monitor stool consistency and symptoms|App to monitor stool consistency and symptoms
75335494|NCT05732272|Drug|Bupropion|150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
75335495|NCT05513872|Drug|Nicotine Replacement Therapy (NRT) Sampling|Participants randomized to this condition will receive a 4-week nicotine replacement therapy (NRT) starter kit containing both nicotine lozenges and patches in their original packaging.
75792898|NCT01229826|Radiation|MR Elastography|MRE is performed at the end of the examination after the standard MRI protocol. A test vibration is first applied on the patient to familiarize the patient with the vibration. The MRE sequence is performed with either a body coil or a pelvic-array coil. The total acquisition time is split into four periods of suspended respiration of 16 seconds for acquisition of wave images at four phase offsets. To obtain a consistent position of the fibroid for each phase offset, patients are asked to quietly breath and remain still.
75792899|NCT01132638|Drug|Magnesium Pantoprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
75792900|NCT01132638|Drug|Magnesium Esomeprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
75792901|NCT01233180|Other|Gua Sha|Single Gua Sha treatment of the neck and shoulder region
75792902|NCT01233180|Device|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region
75792903|NCT05483946|Device|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - for each participant, a pre-defined number of measurements will be conducted per leg and forearm
75792904|NCT05402124|Drug|acetylsalicylic acid delayed release tablets, 81mg|acetylsalicylic acid delayed release tablets, 81mg taken once per day for 90 days
75644934|NCT02569567|Procedure|Smart-Shear Wave(SSW) imaging|"All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.~The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.~Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement."
75792905|NCT01134432|Drug|prednisolone + mabthera|"Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks"
75792906|NCT01134432|Drug|Prednisolone|Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
75792907|NCT01232010|Drug|Mirodenafil|50mg Single Oral Dose of
75792908|NCT01132716|Drug|Valacyclovir Hydrochloride|1000 mg caplet
75644935|NCT02569567|Procedure|Transient elastography(TE)|"Using the M probe in patients with BMI <30 kg/m2.~Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.~Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results."
76084453|NCT04505124|Behavioral|FutureMe App|The FutureMe app provides visual and consequential feedback through a future-self avatar, meaning that the avatar changes its body shape and some additional characteristics based on the participants' activity and food purchasing behaviors. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
75929191|NCT05903001|Diagnostic Test|CAT-Questionnaire|COPD Assessment Test (CAT)
75929192|NCT05903001|Diagnostic Test|European Society of Cardiology (ESC)/ European Respiratory Society (ERS) risk group|Patients with pulmonary hypertension are classified according to the ESC/ERS risk group.
75929193|NCT05899114|Other|Transitional Multidisciplinary Pharmacotherapeutic Care|"A structured medication review with improved transitional care and multidisciplinary collaboration.~TMPC consists of the following four elements:~A structured pharmacotherapeutic analysis~A transitional multidisciplinary discussion.The treating physician in the hospital will be involved. The general practitioner and community pharmacist will be consulted.~An interview and discussion with the patient and/or legal representative by a member of the Pharmacotherapy-team, which will be performed before the patient is discharged from the hospital.~A discharge note with the pharmacotherapeutic care plan. This will be sent to the community pharmacist and the general practitioner."
75929194|NCT05896371|Drug|177Lu-PSMA-I&T - escalating renal absorbed dose|Personalized 177Lu-PSMA-I&T injected activity
75929195|NCT05896371|Drug|177Lu-PSMA-I&T - recommended phase 2 regime|Personalized 177Lu-PSMA-I&T injected activity
75929196|NCT05893979|Device|Spectacle Lenses|Standard Spectacle Lenses
75929197|NCT05893927|Other|Diabetes education web site application|The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.
75929198|NCT05893069|Drug|Oxandrolone|oral oxandrolone for 12 weeks
75929199|NCT05893069|Drug|Placebo|oral placebo for 12 weeks
75644936|NCT00641199|Other|Jarro-Dophilus EPS probiotics|Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
75792909|NCT03919110|Diagnostic Test|Collection of biological samples|"Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses."
75792910|NCT05402046|Other|"Mobile phone application ProRodinki"|"Patient were underwent photography using mobile phone and tested application ProRodinkijust before preplanned excisional or incisional biopsy.~Application AI result than will be compared with pathology report by independent investigator"
75792911|NCT05401812|Drug|Intravenous glucocorticoid therapy|Betamethasone, dexamethasone, or methylprednisolone
75792912|NCT01134588|Other|Paper questionnaire|
75792913|NCT01134588|Other|Touch screen questionnaire|
75798925|NCT01290900|Drug|NXL104|IV Solution
75798926|NCT01290900|Drug|Ceftaroline|IV Solution
75929200|NCT05890807|Diagnostic Test|Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.|The diabetologist will take a photograph of the patient's oral cavity in the diabetology department.
75929201|NCT05890222|Behavioral|Community Intervention|Community intervention strategies will be delivered by community volunteers (called Sangathis - which means companion in Konkani, one of the local languages) to i) enhance demand for the HAP treatment and ii) promote engagement with, and completion of, the HAP treatment. The community intervention is co-produced with local community members and includes strategies such as activities to increase awareness about depression (community meetings, street plays and health camps), and dissemination of psycho-educational materials (i.e., leaflets and posters), identify people with possible depression in the community, and facilitate access to HAP in the health centres. Additionally, the Sangathis will coordinate continuing care of people receiving HAP, through home visits to encourage behavioural activation, homework completion and following up with the counsellor, and engaging family members to support the patient in achieving treatment goals.
75792914|NCT05401734|Device|Observation and follow up measurement|"The measured variables include:~Questionnaires~Health related quality of life (Health Related Quality of Life Questionnaire)~Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~Walking ability (Walking Index for Spinal Cord Injury)~Independence in activities of daily living (SCIM III Questionnaire)~Pain (International SCI Pain Basic Data Set)~Resilience (Resilience Scale)~Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~Muscular strength and joint ROM (Manual Muscle Testing)~Spasticity (Modified Ashworth Scale)~Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)"
75929202|NCT05890222|Behavioral|Healthy Activity Program (HAP)|HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.
76084454|NCT04505124|Behavioral|Conventional TrackingApp|The Control Conventional Tracking app provides numeric and factual feedback through conventional data-dashboards. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
76084455|NCT04504890|Device|EYE-SYNC|Nystagmograph used to measure eye movement
76084456|NCT03348072|Procedure|Cardiac surgery|Cardiac surgery
75644937|NCT02569255|Procedure|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
75644938|NCT02681991|Drug|Renamezin capsule|
76084457|NCT03346746|Dietary Supplement|Low Glycaemic Diet|This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
76084458|NCT03346746|Dietary Supplement|High Glycaemic Diet|This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
75644939|NCT00727987|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.
76084459|NCT03122028|Device|LAA closure system|Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
76084460|NCT03351582|Behavioral|Grief and Communication Family Intervention|This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
75335496|NCT05513872|Behavioral|Practice Quitting (PQ) Counseling|Practice Quitting (PQ) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. The goals of the counseling sessions are 1) to gradually expose patients to nicotine withdrawal symptoms through practice quitting, and 2) to reduce fear and avoidance of the physical sensations associated with nicotine withdrawal.
75644940|NCT00727987|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
75644941|NCT00727987|Drug|Methotrexate (MTX)|6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
75472678|NCT01961635|Device|dental implants|place implant according fabricant guidelines, 2mm sub-crestally
75472679|NCT01961635|Device|Zirconia abutments|place zirconia abutment on the day of implant placement
75472680|NCT01961635|Device|Titanium Abutments|place titanium abutment on the day of implant placement
75644942|NCT05664321|Other|Observational, case-control study|obese [(BMI ≥30 kg/m2), (n=44)], and non-obese [(BMI= 18.50-24.99 kg/m2), (n=48)].
75644943|NCT00733915|Device|L.C.S. Complete Knee (DePuy Low Contact Stress Complete Knee System)|L.C.S. Complete mobile-bearing total knee system
75644944|NCT02681913|Drug|Adenosine|This group receives intermittent warm blood cardioplegia enriched with adenosine
75644945|NCT04065217|Procedure|Diode laser 980-nm|Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) [ONLY MEDICAL; CAT No. R331/72394/P001] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles [CE; DIR 8001100L4]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.
75644946|NCT02681679|Drug|0.1% bromfenac ophthalmic solution|
75644947|NCT02681679|Procedure|femtosecond laser cataract surgery|
75929203|NCT05889416|Other|Audit and feedback through a quality registry|Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.
75335497|NCT05513872|Behavioral|Motivational Interviewing (MI) Counseling|Motivational Interviewing (MI) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. Counseling content will incorporate MI-consistent principles, such as open questions, simple and complex reflections, and affirmations to facilitate participant statements in favor of behavior change. Discussion will focus on the motivational topics outlined in the USPHS guidelines for smokers not ready to quit: 1) relevance of smoking cessation or reduction to the individual, 2) risks of continued heavy smoking, 3) rewards of quitting and reduction, and 4) roadblocks to success, on a 5) repeated basis.
75335498|NCT05473936|Behavioral|Community Health Worker led curriculum|The intervention arm will consist of a CHW-based health educational program via Zoom, where participants will be provided with information about COVID-19, COVID-19 resources and services in Los Angeles County, and engagement with Los Angeles County Department of Health Services CHWs who will lead the curriculum and be available to answer questions of the intervention arm patients.
75929204|NCT05889416|Other|Implementation support|On-site support to implement guidelines on secondary prevention applying practice facilitation - a multifaceted approach carried out by CR experts who enable personnel at intervention centres to address and overcome challenges in implementing guidelines.
75335499|NCT05554666|Biological|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
75792915|NCT01137552|Drug|AMG 780|AMG 780 will be administered by IV infusion every 2 weeks
75792916|NCT01137630|Drug|K40a|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
75335500|NCT05553574|Behavioral|Stop signal food task|The participants need to classify pictures of food and not food. They were asked to hold their response if they see a white frame around the picture.
75929205|NCT05887479|Drug|Botulinum toxin type A|Toxin of Clostridium Botulinum
75792917|NCT01137630|Drug|K40b|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
76084461|NCT05098704|Drug|clopidogrel treatment|75 mg daily during 24 months
76084462|NCT05098704|Drug|Placebo|75 mg daily during 24 months
76084463|NCT05585268|Other|Medication reconciliation supplemented with MedSafer and deprescribing brochures|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
76084464|NCT05584956|Drug|L_carnitine|l-carnitine stabilizes red blood cell membranes and thus improves the anemic state[
75335501|NCT00382330|Drug|Ciclopirox|
75335502|NCT05449834|Drug|Fibrinogen Concentrate|3g Fibrinogen Concentrate
75792918|NCT01137630|Drug|Placebo|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
75335503|NCT05449834|Other|Cryoprecipitate|10U WB or 4U Apheresis Cryoprecipitate
75644948|NCT00728065|Dietary Supplement|White Bread|About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
75644949|NCT00728065|Dietary Supplement|White bread with added 7.32g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
75644950|NCT00728065|Dietary Supplement|White bread with added 15.58g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
75644951|NCT00728065|Dietary Supplement|White bread with added Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
75644952|NCT00728065|Dietary Supplement|Rice milk|Rice milk containing 50g of available carbohydrates
75644953|NCT00728065|Dietary Supplement|Enriched rice milk containing 7.32g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
75792919|NCT01137708|Drug|ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
75792920|NCT01137708|Drug|CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
75798927|NCT01290900|Drug|Placebo Infusion|IV Saline
75798928|NCT01290900|Drug|Ceftazidime|IV Solution
75798929|NCT01290900|Drug|Moxifloxacin|Tablet (1)
75798930|NCT01184976|Biological|VGX-3400|Plasmid DNA delivered via IM injection with electroporation
75929206|NCT05887479|Drug|%0,9 NaCl|%0,9 NaCl
75929207|NCT05883267|Device|Virtual reality glasses|"PICO model neo 2 VR glasses"
75929208|NCT05883267|Device|Vocal-guided affective imagery|Audio via telephone
76084465|NCT05584956|Drug|Sildenafil|selective and potent inhibitor of cGMP-specific phosphodiesterase 5 (PDE5), which promotes smooth muscle relaxation in lung vasculature, has been used successfully in the treatment of primary and secondary PH.
76084466|NCT04502004|Device|App for health=mhealth|Cognitive-Behavioural Therapy and Clinical Practice Guide that recommends 5 Aes: Ask about tobacco, Advise smoking cessation, Assess tobacco consumption, Assist and Arrange (Fiore et alt., 2008)
76084467|NCT03351504|Other|Solar lighting system|consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
75929209|NCT05882643|Other|moderate to deep neuromuscular blockade|"Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count > 1)~Rocuronium (intravenous, 1.0 mg/kg at induction period)"
75335504|NCT05443750|Behavioral|Motivational Behavioral Economic Alcohol Intervention|The intervention combines an alcohol brief motivational intervention (US-THRIVE [Tertiary Health Research Intervention via Email]) with the Substance-Free Activity Session (SFAS), shown to reduce drinking and related negative consequences by increasing future orientation and engagement in pro-social alternatives to drinking. The intervention will be delivered using a web-based platform appropriate for the young adult target population whose social networks operate through such communications.
75929210|NCT05882643|Other|shallow to minimal neuromuscular blockade|"Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count < 0.9)~Rocuronium (intravenous, 0.3 mg/kg at induction period)"
75929211|NCT05879120|Drug|Pembrolizumab|Given by IV (vein)
75929212|NCT05879120|Device|Exablate MRgFUS + neoadjuvant pembolizumab|Given by IV (vein)
75335505|NCT05443750|Behavioral|Health Education|Participants view web-based health educational material about alcohol, sleep, and nutrition of a similar length and style to the experimental intervention materials.
75335506|NCT05520892|Drug|intravenous immunoglobulin|To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
75335507|NCT04567498|Other|exhaled breath sampling|The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
75335508|NCT04567498|Other|exhaled breath sampling|The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
75335509|NCT04436692|Behavioral|Nudging|Use nudging approach by using smaller plates and glasses and increasing the availability of fruits and vegetables
75792921|NCT03765138|Combination Product|PE/Pramipexole|"Experimental: PE/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation.~Pramipexole: In addition to receiving PE as described above, patients will have Pramipexole treatment. Daily dose will be started at 0.25 mg/day and increased by 0.25 mg/day every 3-4 days to a target of 2.5mg day by week 5. Beginning week 6 daily dose will be increased weekly by 0.5 mg/day to a maximum dose of 4mg. Dose will be increased as tolerated unless the patient has achieved remission and will be decreased in the event of intolerable adverse events."
75335510|NCT05432752|Device|Concussion Pen|Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.
75792922|NCT03918564|Device|Laparoscopic Gastric Vest (LGV)|"The Laparoscopic Gastric Vest (LGV), branded the ReShape Vest™, is a long-term, silastic, implantable system that is placed around the stomach to encompass the gastroesophageal junction to the Incisura Angularis.~The main materials used to make the LGV is Implant Grade Silicone (95%) and Barium Sulfate (5%).~The LGV is indicated for weight reduction for obese people with a Body Mass Index (BMI) between ≥35 kg/m2 and ≤55 kg/m2. It is indicated for use in adult patients (≥22 to ≤65 years) who have failed one or more conservative weight reduction alternative(s), such as supervised diet, exercise, and behavior modification program(s)."
75792923|NCT01233414|Behavioral|Parent Training|The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
75335511|NCT05235412|Other|Not applicable: Observational study without any interventions.|Exposures of interest: Maternal diet and lifestyle, demographics, anthropometrics, infant's health outcomes
75335512|NCT05422378|Drug|STP705|STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.
75335513|NCT05447572|Other|FIT + FC|FIT + FC
75644954|NCT00728065|Dietary Supplement|Enriched rice milk containing 15.58g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
75929213|NCT05874804|Device|Carry Life UF|A 5-hour treatment with the Carry Life UF used with a 1.36% glucose PD fill.
75929214|NCT05874804|Drug|2.27% glucose peritoneal dialysis dwell|A 5-hour CAPD dwell with a 2.27% glucose PD fluid.
75929215|NCT05873842|Device|Trans-femoral TAVI|Trans-femoral TAVI (Trans-catheter Aortic Valve Implantation) with calcified ilio-femoral arteries via PTA (Percutaneous transluminal angioplasty ) or IVL (Intra-vascular Lithotripsy)
75929216|NCT05872828|Other|No intervention|Observational study. No intervention will be adopted.
75472681|NCT01961635|Device|cad-cam acrylic abutments|place cad-cam acrylic abutment on the day of implant placement
75644955|NCT00728065|Dietary Supplement|Enriched rice milk containing 24g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
75929217|NCT05868330|Procedure|Interscalene Catheter|Pre-operatively the patient will have a interscalene catheter placed by a regional skilled anesthesiologist. The initial block will be with 20 cc of 0.5% Bupivacaine and maintained on an infusion post-operatively at 8cc/hr of 0.2% ropivacaine as is our intuitions protocol
75472682|NCT01961635|Procedure|Subcrestal|place implant 2mm below crestal bone
75472683|NCT01961635|Device|platform-switch|abutment platform is narrow than implant diameter
75644956|NCT00753688|Drug|PAZOPANIB|800 mg once daily orally
75644957|NCT00753688|Drug|Placebo|matching placebo 800 mg once daily orally
75651912|NCT04841447|Other|Study sample collection|Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.
75651913|NCT04828993|Drug|tafamidis meglumine|Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
75929218|NCT05868330|Procedure|Exparel Single Shot Interscalene Block|Pre-operatively the patient will have a interscalene single shot block with 133 mg Liposomal Bupivacaine and 10 ccs 0.5% Bupivacaine placed by a regional skilled anesthesiologist.
75472684|NCT01961635|Procedure|one-time one-abutment|place the final abutment on the day of surgery and not remove it
75792924|NCT01233414|Other|Psychoeducational Program|The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
75792925|NCT01137864|Other|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
75644958|NCT04033887|Diagnostic Test|13 Rapid Diagnostic Tests and reference tests|"Rapid diagnostic tests:~HCV antibody test (under development); bioLytical Laboratories~DPP® HCV (under development); Chembio Diagnostic Systems~HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~Rapid Anti-HCV Test; InTec~First Response HCV Card Test; Premire Medical Corporation~Signal HCV Ver 3.0; Arkray healthcare~TRI DOT HCV; J. Mitra & Co~Triplex HIV, HCV, HBsAg; Biosynex SA~Standard Q HCV Ab; SD Biosensor~HCV Hepatitis Virus Antibody Test; Artron Laboratories~SD Bioline HCV; Abbott Diagnostics~OraQuick HCV; OraSure~Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0"
75644959|NCT00730561|Biological|Hematopoietic stem cell transplantation|Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
75792926|NCT01134666|Drug|Cetuximab|FOLFOX Oxaliplatin 100 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 FOLFIRI Irinotecan 180 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 CETUXIMAB Cetuximab administered at loading dose of 400 mg/m2/week over 120 min followed by maintenance dose of 250 mg/m2/ week over 60 min, till disease progression or dose limiting toxicity
75792927|NCT03739788|Drug|BMS-986165|Oral administration of tablet and 15-minute intravenous BMS-986165 solution for infusion
75929219|NCT05864443|Procedure|Severe complications following emergency surgery|The respondents are limited to surgeons who had previously experienced severe complications following emergency surgery as chief surgeons.
75929220|NCT05864261|Drug|JT1801 60ug|JT1801, 60ug, IV injection
75929221|NCT05864261|Drug|NESP 60ug|NESP, 60ug, IV injection
75929222|NCT05862077|Device|Wearable Hip Assist Robot(EX1)|EX1 is a hip-type assist device developed by Samsung Electronics.
75929223|NCT05862077|Behavioral|Exercise Program 1|Exercise program 1 for fast walking by applying resistance and assist mode of EX1
75929224|NCT05862077|Behavioral|Exercise Program 2|Exercise program 2 for normal walking by applying resistance and assist mode of EX1
75929225|NCT05862077|Device|Without Wearable Hip Assist Robot(EX1)|Overground walking without EX1
75929226|NCT05861089|Diagnostic Test|end-tidal CO2 measurement|Measurements will take place day before surgery, under resting conditions (while sitting in a quiet room with no disruptions) using the Capnography monitor from Nonin Medical (breath by breath data will be recorded and analyzed). Patients will be allowed to get used to the nasal cannula for the first two minutes. Mean end-tidal CO2 value will then be calculated from the following two minutes of spontaneous breathing.
75929227|NCT05857631|Radiation|Hypofractionated Image guided External Beam Radiation Therapy (EBRT)|"External beam radiotherapy to pelvis:~Post operative hypofractionated external beam radiotherapy with intensity modulated/arc technique, to a dose of 39 Gy in 13 fractions, at 3 Gy per fraction, delivered once daily, 5 days a week, over 2.5-3 weeks."
75929228|NCT05857631|Drug|Cisplatin|Patients who require adjuvant chemotherapy along with radiation, based on predefined risk features, will receive 5 cycles of cisplatin on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT.
75929229|NCT05857631|Radiation|Vaginal brachytherapy|Vaginal brachytherapy, two fractions of 6 Gy each, delivered 1 week apart.
75644960|NCT04183257|Drug|oral vitamin D|oral Vitamin D 400IU will be given and will be escalated every 2 weeks.
75792928|NCT03918954|Device|Virtual sensory room|A pair of virtual reality glasses (Oculus Go) with installed the program Calm Place, a program designed for anxiety reduction.
75929230|NCT05856305|Drug|Chlorophyllin, Sodium Copper Complex|Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
75929231|NCT05856305|Drug|Placebo|Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
75929232|NCT05846425|Other|Nose-breathing training|13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
75929233|NCT05846425|Other|Mouth-breathing training|13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
75792929|NCT03918954|Other|Sensory room|A room with calming elements that patients can use to feel calm.
75792930|NCT01134978|Behavioral|Practice Order|"Blocked order - predictable~Random order - unpredictable"
75792931|NCT01230138|Drug|Placebo|Placebo tablets
75792932|NCT01230138|Drug|FP187|High daily dose of 750mg administered as 250mg TID
75929234|NCT05844449|Drug|VNZ/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
75929235|NCT05844241|Other|Music and Theta Auditory Beat Stimulation|Listening to music and ABS for 30 minutes.
75929236|NCT05844241|Other|Audiobooks|Listening to audiobooks for 30 minutes
75929237|NCT05840055|Behavioral|Acceptance and Commitment Therapy|"Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a third wave behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis."
76084468|NCT03351426|Device|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
75792933|NCT01230138|Drug|FP187|High daily dose of 750mg administered as 375mg BID
75929238|NCT05839366|Drug|Esketamine|"Load dose of 0.25 mg/kg, and the fixed infusion rate of 0.15 mg/kg/h.The load dose will be injected intravenously within 1-2 minutes.Maintain the infusion at a fixed rate of 0.15 mg/kg/h for 72 hours; after 72 hours, change to a fixed rate infusion of 0.06 mg/kg/h.~Preparation: 46ml of saline + 4ml of eskeamine."
75792934|NCT01230138|Drug|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
75929239|NCT05839366|Drug|Saline|As a placebo,normal saline at the same dose as esketamine.Saline is also administered intravenously.
75929240|NCT05839366|Drug|Remifentanil + propofol|Remifentanil + propofol
75335514|NCT05413408|Other|Education and contact|"The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).~The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks."
75335515|NCT05397964|Device|Radiopaque Calcium Hydroxide Composition|Treatment of exposed pulp tissue with radiopaque calcium hydroxide composition as a direct pulp capping material
75335516|NCT04330924|Other|Create Real-life Experience And Teamwork In Virtual Environment (CREATIVE)|3D virtual hospital environment where participants can perform physical and social interaction and presence using avatars.
75335517|NCT00002548|Biological|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)"
75335518|NCT00002548|Drug|carmustine|20 mg/m2 I.V. day 1 q 35 days
75335519|NCT00002548|Drug|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
75335520|NCT00002548|Drug|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
75335521|NCT00002548|Drug|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
75644961|NCT01558921|Other|M1 scheme|short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
76084469|NCT01376700|Biological|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
75335522|NCT00002548|Drug|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
75335523|NCT00002548|Drug|prednisone|40 mg/m2 PO days 1-7 q 35 days
75335524|NCT00002548|Drug|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
75335525|NCT00002548|Procedure|allogeneic bone marrow transplantation|day 0
75335526|NCT00002548|Procedure|autologous bone marrow transplantation|day 0
76084470|NCT04504578|Procedure|contact lens assisted corneal cross linking|40 eyes of 30 patients underwent CACXL. The central 9 mm of corneal epithelium was abraded , Iso-tonic riboflavin 0.1% was applied every 2 minutes for 10 minutes on the debrided cornea. A disposable soft Contact lens without an ultraviolet filter (Soflens, Bausch & Lomb) was placed in the inferior fornix during soaking of the stroma with riboflavin for 10 minutes. The contact lens was applied on the corneal surface and the cornea was exposed to ultraviolet-A irradiation at fluence of 3.0 mW/cm2 for 30 minutes The uncorrected (UDVA) and best corrected (BDVA) visual acuity, and maximum (K max) keratometric values, were assessed before, and after 9 months CXL. Endothelial cell count was assessed before and 3 months after CXL. Anterior segment OCT was done 1 month after CXL to evaluate the presence and depth of the corneal stromal demarcation line.
76084471|NCT01797965|Drug|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
75335527|NCT00002548|Procedure|peripheral blood stem cell transplantation|day 0
75335528|NCT00002548|Radiation|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
75644962|NCT01558921|Other|standard long course chemoradiotherapy|long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
75644963|NCT04182945|Other|Data collection for algorithm development|50% of the research prototypes (4 pieces) will be mounted to the patient on left side of the body (sub clavicula, lateral ribcage, upper arm and wrist), after being admitted to the ICU and having signed the informed consent. As soon as a patient gets fever, the other 50% of the research prototypes (4 pieces) will be applied on the right side of the body (sub clavicula, lateral ribcage, upper arm and wrist). Data will be collected unobtrusively (no diagnosis will be made) and used for fever detection algorithm development.
75335529|NCT02087306|Drug|Brincidofovir|BCV administered twice weekly, dose depending on weight.
75335530|NCT00002554|Drug|busulfan|
75335531|NCT00002554|Drug|cyclophosphamide|
75644964|NCT02681445|Device|Breath Collection|breath will be collected from patients in breath bag for analysis for observational study.
75792935|NCT01230138|Drug|FP187|Oral tablets, up to 3 times daily for 20 weeks.
75792936|NCT05401500|Biological|blood sample|blood sampling
75792937|NCT01137942|Drug|clarithromycin, metronidazole, proton pump inhibitor|appropriate dose of antibiotics and proton pump inhibitor
75792938|NCT01233492|Drug|boron phenylalanine|
75792939|NCT01233492|Drug|mannitol|
75792940|NCT01233492|Other|biologic sample preservation procedure|
75792941|NCT01233492|Radiation|radiation therapy treatment planning/simulation|
75792942|NCT01135056|Device|SIR-Spheres|One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
75792943|NCT01135056|Drug|Sorafenib tosylate|Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
75792944|NCT01132794|Drug|Intranasal dexmedetomidine|1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
75335532|NCT00002554|Drug|methotrexate|
75335533|NCT00002554|Procedure|allogeneic bone marrow transplantation|
75335534|NCT00002554|Radiation|radioimmunotherapy|
75335535|NCT05190172|Radiation|Radiation therapy|Radiation therapy either with protons or photons
75644965|NCT04094740|Device|Jet Injector without A Needle|Patients in the experimental group will use a needle - free jet injector to inject insulin, which delivers insulin at a high velocity into subcutaneous tissue and dispenses insulin over a larger area than a syringe.
75644966|NCT00641355|Procedure|No intervention|No intervention
75792945|NCT01132794|Drug|Placebo|Intranasal nasal saline
75792946|NCT01135212|Drug|Fimasartan 60mg|Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
75792947|NCT01135212|Drug|Fimasartan 120mg|Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
75792948|NCT01135212|Drug|Candesartan cilexetil|Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
75792949|NCT01138176|Procedure|Cooling|Reduction of rectal temperature to 33.5 C
75792950|NCT01233570|Drug|Tacrolimus|Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
75929241|NCT05839366|Procedure|Pain and Sedation Assessment|"RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring."
75929242|NCT05838716|Procedure|Biospecimen Collection|Undergo collection of blood
75929243|NCT05838716|Dietary Supplement|D Vitamin|Given PO
75644967|NCT00728143|Dietary Supplement|Highly viscous polysaccharide enriched biscuits|10 g of highly viscous polysaccharide
75792951|NCT01132950|Behavioral|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
75644968|NCT00641433|Device|oxidized regenerated cellulose collagen-silver|Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.
75644969|NCT00641433|Drug|topical silver sulfadiazine cream|Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.
75644970|NCT00734227|Procedure|Emergency portacaval shunt|
75644971|NCT00734227|Other|Emergency TIPS|
75792952|NCT01132950|Other|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
75792953|NCT01135290|Drug|Aquaphor|
75792954|NCT01135290|Drug|HP828-101|
75792955|NCT01230216|Drug|control systolic blood pressure less than 120 mmHg|use losartan to control blood pressure
75792956|NCT01230216|Drug|control systolic blood pressure less than 140 mmHg|use losartan to control blood pressure
75929244|NCT05838716|Procedure|Dual X-ray Absorptiometry|Undergo DXA scan
75929245|NCT05838716|Drug|Placebo Administration|Given PO
75929246|NCT05838716|Other|Quality-of-Life Assessment|Ancillary studies
75929247|NCT05838716|Other|Questionnaire Administration|Ancillary studies
75929248|NCT05836662|Other|CrashCourse Concussion Education in Virtual Reality|The TeachAids concussion education, including CrashCourse and Brain Fly-Through, will be shown in 3D (via a Virtual Reality headset). These educations are the exact same content as the 2D versions viewed on a laptop, but the modality (via a VR headset) is different.
75335536|NCT00289094|Device|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee System
75644972|NCT00641511|Drug|SYN117 (nepicastat)|120 mg per day
75644973|NCT00641511|Drug|Placebo comparator|once per day placebo capsules
75644974|NCT00728221|Dietary Supplement|Korean Red Ginseng|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: whole root in capsules (3g)"
75792957|NCT01138254|Device|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt<mw>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
75792958|NCT01138254|Other|no intervention|no intervention
75792959|NCT03918174|Device|Dart splint orthosis|The Dart Splint orthosis was fitted to the subjects in the research group on their first evaluation session. They received oral and written instructions regarding the donning and manner of exercise. Specifically, they were instructed to use the Dart splint orthosis at home. For each 10-minute exercise session, they were asked to perform 5 minutes of radial-extension under resistance and then 5 minutes ulnar-flexion under resistance. In addition, this group was required to fill in a chart at the end of each practice session (morning, noon and evening), throughout the intervention period.
75335537|NCT00289094|Device|Total knee replacement|Fixed Cruciate Retaining Knee System
75335538|NCT01293578|Other|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
75335539|NCT00002560|Biological|monoclonal antibody 3F8|
75335540|NCT00002560|Biological|sargramostim|
75335541|NCT00002566|Drug|carboplatin|
75335542|NCT00002566|Drug|cisplatin|
75335543|NCT00002566|Drug|cyclophosphamide|
75335544|NCT00002566|Drug|etoposide|
75335545|NCT00002566|Drug|ifosfamide|
75335546|NCT00002566|Drug|vinblastine sulfate|
75644975|NCT00728221|Dietary Supplement|Korean Red Ginseng (Panax ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total ginsenoside fraction in capsules"
75929249|NCT05832138|Behavioral|ONLOOP program|Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
75929250|NCT05822960|Device|far-infrared radiation|far-infrared radiation on foot acupoints (Yinlingquan and Sanyinjiao acupoints) during dialysis
75335547|NCT00002566|Procedure|autologous bone marrow transplantation|
75644976|NCT00728221|Dietary Supplement|Cornstarch|Placebo
75644977|NCT00728221|Dietary Supplement|Korean Red Ginseng (Panax Ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total polysaccharide fraction (panaxans) in capsules"
75644978|NCT00641589|Drug|epoetin alfa|
75644979|NCT02681367|Other|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
75644980|NCT04065997|Device|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
75644981|NCT05664165|Other|dry needling|The needle inserted in the trigger point and stimulation was performed by manipulating it up and down several times. The needle was kept in the trigger point for 1-3 minutes and removed after the muscle spasm regressed
75644982|NCT05664165|Other|cold spray and stretching|The cooler spray (in its content; 0.06% menthol, 2.06% isopropyl alcohol, 2% isopropyl alcohol) was sprayed to the surface at an angle of 30° from a distance of approximately 30-50 cm, while passive stretching was applied.
75644983|NCT00734383|Drug|Propofol|Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
75644984|NCT00734383|Drug|Propofol|Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
75644985|NCT02681133|Other|Epidemiological study Survey|
75644986|NCT00728299|Drug|PomWonderful Juice|8 oz per day each day for 78 weeks
75644987|NCT00728299|Drug|Placebo juice|8 oz per day for 78 weeks
75644988|NCT02681289|Other|Early goal directed neuromotor therapy|Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
75644989|NCT00586612|Biological|Menitorix™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
75644990|NCT00586612|Biological|Infanrix™ penta|Intramuscular injection, 3 doses in the primary study
75644991|NCT00586612|Biological|Prevenar™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
75644992|NCT00586612|Biological|Infanrix™ IPV|Intramuscular injection, 1 dose in the Booster study.
75644993|NCT00728377|Behavioral|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
75792960|NCT03918174|Other|Conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions. Specifically, they were instructed to exercise at home for 10-minute in each session, three times a day (morning, noon and evening), throughout the intervention period.
75792961|NCT05401422|Other|treatment|types
75792962|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days
75792963|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days
75792964|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days
75792965|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days
75792966|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 1 mg, once on Day 1 only, 2 days
76084472|NCT05017506|Other|A survey will be made.|A survey will be made.
76084473|NCT01601236|Drug|Repository Corticotropin Injection|H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups [8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)].
75335548|NCT00002566|Procedure|conventional surgery|
75792967|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
75335549|NCT00002566|Procedure|peripheral blood stem cell transplantation|
75335550|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
75335551|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
75792968|NCT03739632|Drug|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks
75644994|NCT00728377|Behavioral|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
75792969|NCT03739632|Other|Placebo|Placebo tablets will be given orally, twice daily, for 6 weeks
75792970|NCT01138332|Genetic|western blotting|
75792971|NCT01138332|Other|laboratory biomarker analysis|
75792972|NCT01230450|Procedure|sub-urethral tape (TVT-O)|Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape
75792973|NCT01230450|Other|stand standard mid-urethral sling (TVT-O)|
75335552|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
75335553|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using escalating product prices
75335554|NCT01800500|Other|questionnaire administration|Ancillary studies
75335555|NCT01800500|Other|quality-of-life assessment|Ancillary studies
75335556|NCT01800500|Other|laboratory biomarker analysis|Correlative studies
75335557|NCT01800500|Other|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
75335558|NCT01800500|Other|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
75335559|NCT00002572|Biological|aldesleukin|
75335560|NCT00002572|Biological|muromonab-CD3|
75335561|NCT00002572|Biological|therapeutic tumor infiltrating lymphocytes|
75335562|NCT00002572|Procedure|conventional surgery|
75644995|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
75644996|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
75644997|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
75644998|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)
75644999|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)
75792974|NCT01138410|Biological|SCIB1|Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
75792975|NCT01135602|Drug|Topiramate|Topiramate 50-300 mg/day Orally Twice per day
75792976|NCT01133028|Behavioral|Behavioral contingency management|Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
75792977|NCT01133028|Behavioral|Tolerance training|Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
75792978|NCT05401344|Diagnostic Test|test strips,sponges and cold dry air test|Test strips were used to evaluated the degree of dry nose, sponges were used to obtain the nasal secretion and cold dry air test was used to making diagnosis of vasomotor rihinitis.
75792979|NCT05401188|Other|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day-surgery unit where they were discharged according to ALDRETE criteria.
75792980|NCT05401188|Other|hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward.
75792981|NCT05308212|Biological|Flu-M Tetra [Inactivated split influenza vaccine] w/p|solution for intramuscular injection, 0.5 ml
75792982|NCT05308212|Biological|Flu-M Tetra [Inactivated split influenza vaccine] w/o/p|solution for intramuscular injection, 0.5 ml
75792983|NCT05308212|Biological|Ultrix [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
75798931|NCT01180608|Other|MR Spectroscopy|"During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~gamma-aminobutyric acid (GABA)~glutamate (Glu)~glutamine (Gln)~N-acetylaspartate (NAA)~Choline-containing compounds (Cho)~Creatine plus phophocreatine (total creatine: Cr)~Myo-inositiol (Ins)~Choline (Cho)~Glucose (Glc)~Lactate (Lac)"
75798932|NCT01185054|Other|½ strength apple juice|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.
75335563|NCT00002578|Drug|cytarabine|
75335564|NCT00002578|Drug|gallium nitrate|
75335565|NCT00002578|Drug|leucovorin calcium|
75335566|NCT00002578|Drug|methotrexate|
75335567|NCT04668742|Device|DYNAtraq|Tracheostomy alignment with DYNAtraq
75335568|NCT05355454|Device|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
75792984|NCT01133106|Behavioral|Brief pleasurable events/behavioral therapy|"Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients."
75792985|NCT01133106|Other|Standard care|The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
75792986|NCT01133184|Biological|Sci B vac|Sci B vac
75792987|NCT01138488|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
75792988|NCT01232166|Other|Auscultation|
75792989|NCT01232166|Other|Observation of symmetric chest movements|
75792990|NCT01232166|Other|Tube depth|
75792991|NCT01232166|Other|All three|
75792992|NCT01135680|Drug|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
75792993|NCT01135680|Drug|HPN-100 or Placebo|single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
75792994|NCT01135680|Drug|Placebo|single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
75792995|NCT01135680|Drug|Moxifloxacin|single oral 400-mg dose on study Day 3
75792996|NCT01135680|Drug|HPN-100|single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
75792997|NCT01135680|Drug|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
75792998|NCT01135758|Drug|Ketamine|Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
75792999|NCT05295498|Device|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
75793000|NCT05295498|Device|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
75793001|NCT05401032|Drug|Tamsulosin|Oral medication, once a day for 6 months.
75793002|NCT05401032|Drug|5-hidroxitriptophan|Oral medication, 3 times a day for 6 months.
75793003|NCT01133340|Radiation|Radiation|No treatment intervention is planned. Patients will be scanned and treated as per department standards. The patient will have MRI at the time of their standard plan. They will then have clips inserted to mark the tumor after the standard scan is performed. The MRI and additional imaging with clips in place will be processed by 3 investigators who will contour based on the experimental image and compare this with the standard treated plan. Comparison of volumes in a blinded manner between investigators will also occur. The patients treatment will not be affected by the MRI or clip placement.
75793004|NCT01135836|Procedure|Pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
75335569|NCT05355454|Device|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
75335570|NCT00002596|Biological|bleomycin sulfate|
75335571|NCT00002596|Biological|filgrastim|
75645000|NCT00728455|Drug|placebo|Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
75645001|NCT00728455|Drug|placebo|Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
75645002|NCT00728455|Drug|placebo|Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
75793005|NCT01135836|Procedure|Intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
75793006|NCT01135836|Procedure|Control group|CO2 was removed by passive exsufflation through the port site.
75335572|NCT00002596|Drug|carboplatin|
75645003|NCT00728455|Drug|placebo|Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
75645004|NCT00728455|Drug|placebo|Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
75645005|NCT02680977|Other|MP-Equivalent|Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.
75645006|NCT02680977|Other|MP-Low|Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI
75645007|NCT02680977|Other|MP+DDCI|Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.
75645008|NCT02680977|Drug|LD+DDCI|Levodopa plus Benserazide
75645009|NCT02680977|Drug|LD-DDCI|Levodopa without any DDCI
75645010|NCT02680977|Other|Placebo|Groundnuts powder
75335573|NCT00002596|Drug|cisplatin|
75335574|NCT00002596|Drug|cyclophosphamide|
75335575|NCT00002596|Drug|etoposide|
75645011|NCT04064905|Biological|mRNA-1893|Zika vaccine
75929251|NCT05822258|Other|Walk under 3 conditions (normal, physical tasks, verbal tasks)|"Each patient will have 2 visits :~First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~Normal condition without addition of additional physical and verbal tasks~Condition with added physical tasks: The physical task of holding a ball in the center of a tray~Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions."
75645012|NCT04064905|Other|Placebo|0.9% sodium chloride
75793007|NCT03768726|Drug|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
75793008|NCT03768726|Drug|Placebo|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
75929252|NCT05819814|Genetic|Disclosure of high polygenic risk result for coronary artery disease|The disclosure of a high polygenic risk result for coronary artery disease involves a clinical report coupled with a virtual meeting with a genetic counselor.
76084474|NCT01601236|Drug|Placebo|Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
75929253|NCT05810792|Drug|Histamine Dihydrochloride (HDC)|HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.
76084475|NCT05584878|Other|Curodont repair Self- assembling peptide P11-4|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Curodont
76084476|NCT05584878|Other|Ph-chi phosphorylated - nano-chitosan|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Ph-chi phosphorylated - nano-chitosan
75645013|NCT02680899|Behavioral|Curricular Intervention|The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
75335576|NCT00002596|Procedure|autologous bone marrow transplantation|
75645014|NCT00728533|Drug|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
75645015|NCT00728533|Drug|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
75645016|NCT00734695|Dietary Supplement|vitamin c|Subconjunctival daily or bid
75645017|NCT00734695|Dietary Supplement|vitamin c|topical and systemic
75793009|NCT01138722|Radiation|hypofractionated radiation therapy followed by surgery|hypofractionated radiation therapy followed by surgery
75793010|NCT01585740|Drug|0.9% Normal Saline|Crystalloid fluid
75793011|NCT01585740|Drug|Ringer's Lactate|Crystalloid fluid
75793012|NCT01138878|Other|Questionnaire|Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
76084477|NCT05584878|Other|"CCP-ACP  +ve control  Casein phosphopeptide amorphous calcium phosphate"|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by CCP-ACP
76084478|NCT01601782|Procedure|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
75335577|NCT00002596|Procedure|bone marrow ablation with stem cell support|
75335578|NCT00002596|Procedure|conventional surgery|
75335579|NCT00002596|Procedure|peripheral blood stem cell transplantation|
75335580|NCT00002596|Radiation|radiation therapy|
75335581|NCT00199082|Drug|Adriamycin|
75645018|NCT00734695|Dietary Supplement|vitamin c|topical systemic
75645019|NCT00586690|Device|NK Cell infusion using CD56 monoclonal antibody|The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
75335582|NCT00199082|Drug|Cyclophosphamide|
75335583|NCT00199082|Drug|Cytarabine|
75335584|NCT00199082|Drug|Dexamethasone/Prednisolone|
75645020|NCT00586690|Procedure|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
75645021|NCT04182711|Device|Device|Phase 1: Time taken for each patient is 25 mins Phase 2: Time taken for each patient is 30 mins
75793013|NCT01138878|Other|Focus Group Discussion|FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
75793014|NCT01138878|Other|HIV test (serum or salivary)|An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
75793015|NCT01138878|Other|Semi-structured telephone interview|Telephone interview administered to patients offered an HIV test during the pilot period
75929254|NCT05810792|Drug|Interleukin-2 (IL-2)|IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
75929255|NCT05810168|Other|Dietary modifications|TDA and low FODMAP diet
75929256|NCT05809258|Procedure|Supraclavicular block|brachial plexus nerve block by supraclavicular route
76084479|NCT01601782|Device|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
75645022|NCT00728611|Biological|PRGF|intra auricular injection 6mg
75645023|NCT00728611|Drug|hyaluronic acid|20 mg / 2 ml
75645024|NCT00728611|Drug|placebo|physiological water 3cc + lidocain 3cc
75645025|NCT02680509|Procedure|Sympathicotomy R3|sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
75645026|NCT00728767|Other|Brief intervention|"The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.~The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.~The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.~Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?"
75645027|NCT00728767|Other|Control group|The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
75645028|NCT05663775|Drug|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA)
75645029|NCT05616715|Device|Peek device|Participants with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
76084480|NCT01601860|Other|Use of non-pharmacological|"Other: Non-pharmacological resources~A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~Walking (with cervical dilation between 4 and 5 cm)~Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm)~Shower (with dilation> 7 cm);"
76084481|NCT01601860|Other|Other: Routine care|Other: Routine care Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
76084482|NCT01376388|Drug|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
75335585|NCT00199082|Drug|VP16|
75335586|NCT00199082|Drug|Ifosfamide|
75645030|NCT05616715|Other|Crown lengthening/gingivectomy|Participante with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
75645031|NCT00976820|Biological|GSK2340274A|Two intramuscular injections
75793016|NCT01138956|Drug|N-acetylcysteine|N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days
75793017|NCT01138956|Drug|Pentavalent antimonial|Pentavalent antimonial, 20mg/kg/day, 28 days, IV
75793018|NCT01139034|Device|Self-designed surface functional electrical stimulator|Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.
75793019|NCT03917706|Other|Questionnaire|Patients will be contacted by phone in order to fill in a questionnaire regarding their quality of life.
75793020|NCT05287542|Other|Hypnotic suggestion|The intervention group will receive four weekly 60 min. sessions with hypnosis treatment including induction followed by hypnotic suggestion.
75929257|NCT05809258|Procedure|Axillary block|brachial plexus nerve block by axillary route
76084483|NCT01643902|Drug|tPA|IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
76084484|NCT03347994|Drug|Minnelide|Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
76084485|NCT01644058|Procedure|Immediate loading|
75335587|NCT00199082|Drug|Methotrexate|
75335588|NCT00199082|Drug|G-CSF|
75335589|NCT00199082|Drug|Rituximab|
75645032|NCT00976820|Biological|GSK2340273A|Two intramuscular injections
75793021|NCT05287542|Other|Mindfulness|The active control group will receive four weekly 60 min. sessions of induction and mindfulness-based instructions.
75793022|NCT01232244|Other|GLP-1 infusion|1 pmol/kg/min
75793023|NCT01232244|Other|Glucagon infusion|3ng/kg/min
75929258|NCT05806554|Device|Continuous glucose monitoring device|Continuous glucose monitoring device
75929259|NCT05806450|Behavioral|Intervention|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
75929260|NCT05806450|Other|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
75929261|NCT05801042|Dietary Supplement|Maltodextrin|Placebo product
75929262|NCT05801042|Dietary Supplement|Encapsulated Lactocaseibacillus rhamnosus|Probiotic product
75929263|NCT05801042|Dietary Supplement|Non-encapsulated Lactocaseibacillus rhamnosus|Probiotic product
75929264|NCT05796167|Drug|Pimavanserin|Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
75929265|NCT05792163|Drug|SNP318 (A)|Capsule for oral administration
75645033|NCT00909987|Drug|Capecitabine|PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
75929266|NCT05792163|Drug|Placebo (B)|Placebo capsules matching the SNP318 capsules
75645034|NCT00909987|Drug|Oxaliplatin|IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
75645035|NCT00909987|Drug|Bevacizumab|IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
75645036|NCT00909987|Radiation|Radiotherapy|Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
75645037|NCT00909987|Drug|Capecitabine during all Radiotherapy period|825 mg/m2 bid
75645038|NCT00909987|Procedure|Total Mesorectal Excision (TME)|4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
75645039|NCT00729001|Biological|Human Rotavirus Vaccine - two different formulations|Two oral doses
75645040|NCT00729001|Biological|Prevnar|Three-dose intramuscular injection (US subjects only)
75645041|NCT00729001|Biological|IPOL|Two-dose intramuscular injection (US subjects only)
75645042|NCT00729001|Biological|Infanrix|Three-dose intramuscular injection (US subjects only)
75645043|NCT00729001|Biological|OmniHIB|Three-dose intramuscular injection (US subjects only)
75645044|NCT00729001|Biological|Pentacel|Three-dose intramuscular injection (Canada only)
75645045|NCT04182789|Drug|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
75645046|NCT00730795|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)
75645047|NCT05663619|Device|Virtual Reality Distraction during dental treatment of children.|One of the behavior management techniques used with children in dental clinics to allow for delivering quality dental treatment is the use of Virtual Reality distraction (VRD). Virtual reality distraction immerses the patient in an environment generated by a computer and works by simulating as many senses as possible: vision, hearing, and touch. In dentistry, VRD has exhibited great results in reducing anxiety and fear among children and adolescents compared to those who received no intervention or more conventional BMTs. VRD may allow the dentist to provide more efficient dental treatments, ranging from simple anesthesia to more advanced forms of dental treatment
75645048|NCT05663619|Other|Control: watching cartoon on screen as distraction during dental treatment of children.|"The American Academy of Pediatric Dentistry (AAPD) recommends a series of non-pharmacological behavior management techniques for managing children during dental care including distraction. Distraction is defined by AAPD as the technique of diverting the patient's attention from what may be perceived as an unpleasant procedure. It is widely used as it provides an effective and relaxing experience during treatment."
75793024|NCT01232244|Other|Oxyntomodulin infusion|3 pmol/kg/min
75793025|NCT01232244|Other|GLP-1 and glucagon infusion|1 pmol/kg/min 3 ng/kg/min
75793026|NCT01232244|Other|Placebo|NaCl 9 g/L infusion
75793027|NCT03917862|Combination Product|TDM-621|The TDM-621 is a topic hemostatic product which will be used during ascending aortic surgery.
75793028|NCT05400876|Drug|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)
75793029|NCT05400876|Drug|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)
75793030|NCT05192538|Device|Endoscopic endoloop pre-test treatment|A novel endoloop was inserted into the gastric cardia by forceps through the single-channel endoscopy. After adjustment of the endoloop's location and angle, it was anchored onto the edge of the gastric cardia with clip and another 1 or 2 clips were inserted to hold the opposite side of endoloop at about 1/2 circumference. Then the hook was connected with the endoloop, which was tighted by slight pulling together of all the clips.
75793031|NCT03917784|Drug|Curcumin|Oral supplementation with curcumin 500 mg oral dosing for 3 months
75793032|NCT03917784|Drug|Starch|Oral supplementation with starch 500 mg oral dosing for 3 months
75793033|NCT01133496|Drug|Alendronate Sodium Tablets, 70 mg|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
75929267|NCT05789264|Device|Nasal Compression Device|Participants assigned to the NasaClip arm will not receive routine care as the objective of this study is to compare the NasaClip device to routine digital compression in terms of feasibility, comfort, and efficacy. Limited data previously discussed in the background section indicates that application of nasal compression devices may be superior to digital compression.
75929268|NCT05789264|Diagnostic Test|Routine Care|Most first aid instructions for epistaxis management tell patients to apply firm digital pressure for 10 to 20 minutes, use a topical vasoconstrictor and apply an ice pack over the nose.
75929269|NCT05788172|Other|Iron isotope dilution|Menstrual blood loss will be determined using the iron isotope dilution technique and compared to the amount determined via the alkaline hematin method.
75929270|NCT05788172|Other|Alkaline hematin method|Menstrual blood loss will be determined using the alkaline hematin method and compared to the amount determined via the iron isotope dilution technique.
75929271|NCT05784766|Diagnostic Test|30-second ECG using the Kardia Mobile|30-second ECG using the Kardia Mobile
75929272|NCT05784766|Other|routine care|medical review
75645049|NCT00730873|Device|Continuous positive airway pressure|
75793034|NCT01233804|Other|Opting Out|Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
75929273|NCT05783232|Dietary Supplement|Placebo Control Form 1 Capsules|Participants will use their Placebo Control Form 1 Capsules as directed for a period of 4 weeks.
75929274|NCT05783232|Dietary Supplement|Health Active Study Product 1.1 Capsules|Participants will use their Radicle Health Active Study Product 1.1 Capsules as directed for a period of 4 weeks.
75929275|NCT05783232|Dietary Supplement|Health Active Study Product 1.2 Capsules|Participants will use their Radicle Health Active Study Product 1.2 Capsules as directed for a period of 4 weeks.
75929276|NCT05783232|Dietary Supplement|Health Active Study Product 1.3 Capsules|Participants will use their Radicle Health Active Study Product 1.3 Capsules as directed for a period of 4 weeks.
76084486|NCT04966338|Biological|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) will be administered via intravenous (IV) infusion.
76084487|NCT04966338|Biological|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) will be administered via intravenous (IV) infusion.
76084488|NCT03347916|Drug|Strawberry juice as (placebo)|Patients received strawberry juice 5 ml volume, one hour before induction.
75335590|NCT00199082|Drug|Vincristine/Vindesine|
75645050|NCT00730951|Dietary Supplement|Korean Red Ginseng|500mg Capsulated Ground Dried Korean Red Ginseng Root
75645051|NCT00730951|Dietary Supplement|Corn Starch|500mg Capsulated Corn Starch
75645052|NCT02680275|Drug|Dead Sea Peloid Gel|intravaginally
75645053|NCT00760474|Drug|Pregabalin, then placebo|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
75645054|NCT00760474|Drug|Placebo, then pregabalin|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
75645055|NCT00731029|Biological|Thiomersal free trivalent influenza split vaccine 2002/2003|Single dose, intramuscular injection
76084489|NCT03347916|Drug|Gabapentin Oral Solution [Neurontin]|Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
75335591|NCT00199082|Procedure|Irradiation (in specific conditions)|
75472685|NCT01961635|Procedure|Torque 20 n/cm2|the amount of torque applied to the abutment
75472686|NCT01961648|Device|Rebreathing bag|
75472687|NCT01961648|Device|Sham rebreathing|
75472688|NCT01961648|Device|Mask|
75472689|NCT01961661|Dietary Supplement|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 capsule/die for 1 month"
75645056|NCT00731029|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003|Single dose, intramuscular injection
75645057|NCT02680353|Procedure|Bilateral superficial cervical plexus block|A kind of anesthetic nerve block type performed to block the nerve function temporarily by administrating local anesthetics through the trajectory of the nerve.
75645058|NCT02680119|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA.|oral, crossover
75645059|NCT02680119|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, crossover
75645060|NCT00734773|Biological|Rituximab|Infusion will be given at week 2, week 4, week 6 and week 8. Infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
75472690|NCT01961661|Dietary Supplement|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
75472691|NCT01961674|Dietary Supplement|Capsinoid/placebo and rice|The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
75645061|NCT00734773|Drug|Cytarabine|Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
75645062|NCT00734773|Drug|Methotrexate|Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
75472692|NCT01961700|Other|Physiotherapy|Physiotherapy treatment
75793035|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with normal renal function
75793036|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with mild renal impairment
75793037|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
75793038|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with severe renal impairment
75793039|NCT01139346|Drug|darinaparsin|dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
75793040|NCT01232400|Drug|Esmolol|"The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:~Heart rate less than 70 bpm.~Systolic blood pressure less than 120 mmHg~Maximum dose of esmolol of 200 mcg/kg/minute is reached."
75929277|NCT05782205|Procedure|Severe complications following radical gastrectomy|The respondents are limited to surgeons who had previously experienced severe complications following radical gastrectomy as chief surgeons.
75472693|NCT01961726|Biological|Placebo|Coronary Sinus Delivery
75472694|NCT01961726|Biological|30 mg dose of JVS-100|Coronary Sinus Delivery
75472695|NCT01961726|Biological|45 mg dose of JVS-100|Coronary Sinus Delivery
76084490|NCT03350958|Dietary Supplement|Alginate Bread|100g Alginate Bread, toasted with 20g of butter.
76084491|NCT03350958|Other|Control Bread|100g standard White Bread (control), toasted with 20g of butter.
76084492|NCT03350802|Diagnostic Test|procalcitonin test|All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
76084493|NCT01821677|Drug|Danazol Capsules|
76084494|NCT01821677|Drug|Placebo|
75929278|NCT05780021|Behavioral|Motivational Support Program Emotiv|A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.
75793041|NCT01136148|Behavioral|A medical and mental health unit|A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
76084495|NCT01797731|Device|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
76084496|NCT01797731|Device|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
75929279|NCT05778968|Procedure|low etco2|Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg
76084497|NCT05651958|Other|Nebulizer|Active Comparator: Nebulization every 3 days with the other medicine to the active comparator.
76084498|NCT05651958|Other|Breathing Technique|15 repeatations of Breathing in morning and evening
76084499|NCT04785456|Device|Active TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
75793042|NCT01232478|Behavioral|Comprehensive Adherence Program (CAP)|The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
75645063|NCT00734773|Drug|Motexafin gadolinium|"Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).~For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.~During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter."
75645064|NCT00734773|Drug|Procarbazine hydrochloride|Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
75929280|NCT05778968|Procedure|normal etco2|Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg
75645065|NCT00734773|Drug|Vincristine sulfate|Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
75929281|NCT05778968|Procedure|high etco2|Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg
75929282|NCT05778942|Device|Eyestil SYNFO|Instillation of study drug in both eyes: preservative-free ophthalmic solution based on sodium hyaluronate and xanthan gum
75929283|NCT05777018|Procedure|conventional recruitment maneuvers|"The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings"
75929284|NCT05777018|Procedure|ultrasound-guided recruitment maneuvers|"Ultrasound guided maneuver will be performed at T2, T3 and T4.~The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure."
76084500|NCT04785456|Device|Sham TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
76084501|NCT03062280|Drug|Hydrocortisone|Modified release hydrocortisone
76084502|NCT00709722|Drug|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
76084503|NCT03121872|Procedure|Root Coverage Surgery with T-PRF|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
76084504|NCT03121872|Procedure|Root Coverage Surgery with CTG|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
76084505|NCT01645306|Drug|Revacept|single intravenous injection
76084506|NCT01645306|Drug|Placebo|single intravenous injection
76084507|NCT01820585|Drug|Placebo|Tablets
76084508|NCT01820585|Drug|ESL 400 mg|tablets
76084509|NCT01820585|Drug|ESL 800 mg|tablets
76084510|NCT01820585|Drug|ESL 1200 mg|tablets
75645066|NCT00734773|Radiation|Radiation therapy|Given at weeks 11 through 16.
75645067|NCT04182165|Device|Gili BioSensor System/ Gili Pro X BioSensor System|Usability study
75645068|NCT04065061|Dietary Supplement|Erinacine A-enriched Hericium Erinaceus Mycelia|
75645069|NCT04065061|Dietary Supplement|Placebo|Placebo supplement was given to the participants.
75793043|NCT01230606|Other|discharge vs. overnight stay|At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
76084511|NCT02593188|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
75929285|NCT05775653|Other|ADAPT program|The ADAPT program is a structured and individualized group-based program, in which two occupational therapists teach groups of people the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT program 3.0 includes 10 two-hour sessions and is followed by two booster sessions to support sustainable gains.
75645070|NCT04182243|Other|Evaluation of job satisfaction in emergency health care providers by questionnaire|
75335592|NCT04755998|Other|Use of virtual reality glasses during vaccination applications in children|"To the experimental group:~Before the vaccine administration;~Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.~Cartoons and virtual reality glasses that the student wanted to watch were prepared.~While the nurse was preparing the vaccines, the student was put on virtual reality glasses and the distance settings of the lenses were adjusted and the cartoons he chose to watch during the vaccination applications started to be shown. Since virtual reality glasses can cause anxiety attacks manifested by nausea in some children, this was also tested beforehand. It took about two minutes to administer the vaccine and watch cartoons.~Those applied after the vaccine administration;~- Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student."
75929286|NCT05775653|Other|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focus on improving ADL ability e.g. by practicing the performance of ADL task. UOT typiccally includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement.
75929287|NCT05774067|Drug|Saline|patient received normal saline 4ml/kg/hr with deflation of tourniquet
76084512|NCT01797263|Other|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
75798933|NCT01185054|Other|Pediatric Electrolyte|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
75645071|NCT00731107|Procedure|laparoscopic surgery|XCEL bladeless trocar laparoscopic entry
75645072|NCT00731107|Procedure|laparoscopic surgery|Veress Needle laparoscopic entry
75645073|NCT04289090|Drug|Sevoflurane Inhalant Product|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
75645074|NCT04289090|Drug|Propofol 10 MG/ML|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
75645075|NCT02680197|Drug|CHF5259 or Placebo administration|Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
75645076|NCT00735163|Other|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
75645077|NCT04286984|Other|unified protocol of Patient Blood Management measure|upPBM description: After performing a laboratory work-up 2 to 4 weeks before surgery, preoperative iron supplementation in case of iron deficiency anemia at least 7 days before surgery was recommended. Preoperative anemia was defined by a Hb level < 13 g/dL for both sexes. In anemic patients, iron status study was recommended and iron supplementation with intravenous iron was indicated if Hb<12g/dL and/or ferritin <300 mg/l. Intravenous iron (ferric sucrose or carboxymaltose) was administrated with the goal of recovering iron deficit, calculated using the Ganzoni formula or by the simplified strategy, only available for ferric carboxymaltose. Recommended transfusion triggers were: Hb < 9 g/dL for patients with risk factors and/or anemia symptoms; and Hb < 7 g/dL for the rest of patients in absence of active bleeding.
75645078|NCT00731263|Drug|AZD8055|Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
75645079|NCT02680431|Other|Blood sample|10 mL venous blood sample for analysis of plasma
75645080|NCT00975416|Behavioral|Cognitive Behavioral Therapy|Intranasal oxytocin given in the context of cognitive behavioral therapy
75645081|NCT00975416|Drug|Intranasal Oxytocin|Intranasal oxytocin given in the context of cognitive behavioral therapy
75645082|NCT00975416|Drug|Placebo|Placebo given in the context of cognitive behavioral therapy
75798934|NCT03855306|Drug|Glibesyn|1 tablet contains 5 mg Glibenclamide
75798935|NCT03855306|Drug|Daonil|1 tablet contains 5 mg Glibenclamide
75798936|NCT03855384|Drug|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|TQB2450 1200mg IV ，cisplatin 75 mg/m^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
75929288|NCT05774067|Drug|Norepinephrine|patient received noradrenaline infusion at rate 0.1 mcg/kg/min. with deflation of tourniquet
75929289|NCT05774067|Drug|glypressin|patient receive glypressin infusion at rate 2 mcg/kg/hr.
75929290|NCT05774015|Dietary Supplement|Magnesium Oxide tablet 500 mg|To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
75929291|NCT05773495|Other|I-SITE Intervention|I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.
75793044|NCT01230684|Procedure|Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)|The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
75929292|NCT05773495|Other|Usual Care Teleophthalmology|All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
75929293|NCT05773196|Other|Biospecimen Collection|"Cohort 1-Huntington's Disease:~The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum).~Sample Collection:~10 mL EDTA Vial (Box 1; Frozen)~o Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped frozen (on dry ice) FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 1.~10 mL EDTA Vial (Box 2; Ambient)~Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped ambient FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 2."
76084513|NCT01797263|Other|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
75929298|NCT05769036|Device|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation of the left ventricular pacing lead will be performed by cannulating one of the tributaries of the coronary sinus using delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed for biventricular pacing.
76084514|NCT01602172|Behavioral|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
76084515|NCT01602172|Other|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
75645083|NCT00729079|Behavioral|DPP|"The primary outcome measure is weight loss with a goal of 7% of initial weight.~Secondary outcomes are adherence to behavior changes:~Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~Fat intake less than 25% and saturated fat less than 10%~Fiber intake of at least 25 grams per day~Fasting blood sugar < 100 mg/dL~Absence of tobacco use"
75645084|NCT00729079|Behavioral|DPP|"The primary outcome measure is weight loss with a goal of 7% of initial weight.~Secondary outcomes are adherence to behavior changes:~Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~Fat intake less than 25% and saturated fat less than 10%~Fiber intake of at least 25 grams per day~Fasting blood sugar < 100 mg/dL~Absence of tobacco use"
75645085|NCT02679963|Drug|Olaparib|
75645086|NCT02679963|Drug|Placebo|
75645087|NCT00760084|Drug|Decitabine|Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
75645088|NCT00729235|Device|Ovatio CRT 6750|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
75645089|NCT00729235|Device|Ovatio CRT 6750|Slow VT zone programmed with ATP therapies (therapy arm).
75793045|NCT01136304|Drug|Imiglucerase|Imiglucerase intravenous infusions regardless of dose or schedule of administration.
75793046|NCT02528760|Drug|Metaclopramide|23. Metoclopromide to be given 10mg iv 8 hourly
75793047|NCT02528760|Drug|Erythromycin|Erythromycin to be given 70mg iv 12 hourly.
75793048|NCT02528760|Other|Placebo|
75929299|NCT05769036|Device|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation to the left bundle branch will be performed by using special delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed left bundle branch pacing.
75929300|NCT05763043|Drug|Ferric derisomaltose|Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
75793049|NCT05594472|Drug|Ozonated olive oil|Topical treatment will be applied for 5 consecutive days on the erosions.
75472696|NCT01961739|Drug|2% lidocaine|Topical application, twice per day for 15 consecutive days
75929301|NCT05761015|Drug|therapeutic program including intermittent drug intake and multimodal rehabilitation program|"The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~gastric/duodenal risk: age >65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~cardiovascular risk (according to Agostino scale & SCORE);~The molecule with therefore be:~no risk: niflumic acid, 250 mg per intake;~gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~cardiovascular risk only: ketoprofen, 50-100 mg per intake;~double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week."
75929302|NCT05753033|Drug|SR750 tablet|Ascending single and multiple doses of SR750 orally
75929303|NCT05753033|Drug|Placebo|Ascending single and multiple doses of placebo orally
75929304|NCT05752266|Dietary Supplement|AMILI Probiotic pills|AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.
75929305|NCT05752266|Dietary Supplement|Placebo pills|Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.
75645090|NCT04289636|Behavioral|Behavioral weight loss program|Using a combination of individual (~1x/month) and group-based (~3x/month) meetings, participants will be taught behavioral approaches for changing diet and exercise behaviors. This intervention will be 15 weeks in duration and will be delivered remotely using a video-conferencing platform.
75645091|NCT04289636|Behavioral|Self-compassion|This 8-week, group-based program will help train individuals on how to handle difficult emotions with greater ease, how to transform difficult relationships, and how to motivate and encourage oneself, rather than being self-critical.
76084516|NCT02378298|Drug|Rituximab|Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
76084517|NCT02378298|Drug|Iv Methylprednisolone|Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
75645092|NCT04289636|Behavioral|Nutrition and cooking education|This 8-week, group-based program will help individuals to improve the quality of their diet through nutrition education and basic cooking skills for preparing healthy meals.
75793050|NCT05594472|Drug|Topical garamycin cream|Conventional topical treatment will be applied for 5 consecutive days on a comparable erosion
75793051|NCT01139424|Device|endoscopic suturing|endoscopic suturing of the anastomotic leak
75793052|NCT05205018|Behavioral|Motivational interviewing performed remotely through videocalls|Remote motivational interviewing will be performed seven time over 12 months, through videocalls. The first four interventions will be performed within two months and the following three will be performed at five, eight and eleven months from enrollment.
75472697|NCT01961739|Drug|placebo|topical application, twice per day for 15 consecutive days
75472698|NCT01961752|Drug|Saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
75645093|NCT02679651|Other|Ultrasound of the foot|An ultrasound will be used to determine the thickness of the fat pad
75645094|NCT02679651|Other|Pedobarograph Measurements|This non-invasive device measures the force and pressure of the foot while standing and walking.
75645095|NCT02679651|Other|Manchester Foot Pain and Disability Index|This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
75793053|NCT01139502|Behavioral|Work rehabilitation based on the cognitive therapeutical model|Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.
75793054|NCT01139502|Behavioral|Work rehabilitation with the addition of cognitive training|Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
75472699|NCT01961752|Drug|Bupivacaine + saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
75793055|NCT01230762|Drug|dapoxetine|60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
75793056|NCT01136538|Drug|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
75645096|NCT04286828|Other|Position Sense|Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
75793057|NCT03917550|Behavioral|Recovery (Transdiagnostic & self)|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.
75793058|NCT03917550|Behavioral|Transdiagnostic|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
75793059|NCT01133574|Drug|SLV354 capsules|20 mg
75793060|NCT01133574|Drug|SLV354 capsules|60 mg
75793061|NCT01133574|Drug|SLV354 capsules|120 mg
75793062|NCT01133574|Drug|SLV354 capsules|250 mg
75793063|NCT01133574|Drug|SLV354 capsules|500 mg
75793064|NCT01133574|Drug|SLV354 capsules|750 mg
75793065|NCT01133574|Drug|SLV354 capsules|1000 mg
75793066|NCT01133574|Drug|SLV354 capsules|1250 mg
75793067|NCT01133574|Drug|Placebo capsules|placebo
75793068|NCT01133574|Drug|SLV354 capsules|low dose group 1
75793069|NCT01133574|Drug|SLV354 capsules|high dose group 1
75793070|NCT01133574|Drug|SLV354 capsules|low dose group 2
75793071|NCT01133574|Drug|SLV354 capsules|high dose group 2
75793072|NCT01133574|Drug|Placebo capsules|placebo
75793073|NCT05571462|Other|Activity monitor group|No intervention will be applied. All included patients will be monitored with body-worn physical activity monitors during two periods.
75793074|NCT03917628|Drug|SCT630|SCT630 single s.c. injection
75793075|NCT03917628|Drug|adalimumab-EU source|adalimumab-EU source single s.c. injection
75793076|NCT01230840|Dietary Supplement|wheat dextrin|5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
75793077|NCT01230840|Dietary Supplement|placebo|cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
75793078|NCT01230918|Radiation|99mTc-NC100692|"HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.~Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images."
75793079|NCT01329588|Drug|Monthly antibiotic|Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
75793080|NCT01329588|Drug|Monthly placebo|Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
75793081|NCT01136850|Drug|chloroquine, sulphadoxine pyrimethamine, LLIN|"> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~Given at enrolment, 14-26 weeks gestation, by mouth."
75793082|NCT01136850|Drug|azithromycin, sulphadoxine pyrimethamine, LLIN|"sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation."
75793083|NCT05054244|Other|standard wound treatment|Standard treatment includes dressings, debridement, antibiotics, and bacterial load relief. The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with formed granulation tissue. The progression of the wound and the need for specific treatment will be evaluated weekly by dermatologist and vascular surgeon specializing in wound care, and appropriate treatment conducted according to wound assessment (antibiotics, bandage, dressing change, debridement, amputations).
75793084|NCT05054244|Procedure|Hyperbaric oxygenation (HBOT)|The HBOT sessions will be performed 5 days a week, in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2 with effective treatment lasting for 90 min. The sessions will be supervised by doctors trained in hyperbaric medicine.
75793085|NCT01133652|Device|Veinviewer|Veinviewer machine
75793086|NCT01133652|Device|Ultrasound|Ultrasound
75793087|NCT01133652|Other|Conventional technique|Conventional IV placement by nurses
75793088|NCT01234116|Drug|emtricitabine/tenofovir disoproxil fumarate|Each health care worker will receive one of the Treatment Arms for 28 days.
75793089|NCT01136928|Drug|American ginseng|Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
75793090|NCT03917004|Drug|Nitroglycerin|"The starting rate of nitroglycerin was 0.25 μg / kg / min and the mean arterial pressure (MAP) decreased to 80% of the baseline but not less than 70%.The drug infusion rate was adjusted so that the MAP was maintained in the range to the suture, and the administration was stopped and the blood pressure was gradually returned to the pre-depressurization level."
75793091|NCT01232712|Biological|ImMucin, hGM-CSF|"Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin~After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.~In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected."
75472700|NCT01961752|Drug|Bupivacaine + triamcinolone acetonide|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
75645097|NCT04286828|Other|Balance|"To measure postural stability and Limits of Stability this study used a balance device, the Biodex Balance System.~Postural Stability: The participants were focused on a characteristic dot (COP, centre of pressure) on the monitor screen. The participant's task was to balance the body in such a way that the dot was in the centre of a circle displayed on the monitor at the point of intersection of the coordinate axes. Test consisted of three 20-second trials, each separated by 10-second breaks. Measurements were repeated three times while their eyes were open/close and analyzed by calculating the average value of measurements.~Limits of Stability: The participants are asked to complete the directional tasks displayed on a screen as quickly as possible, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s."
75793092|NCT01139736|Dietary Supplement|VSL#3|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
75793093|NCT01133730|Drug|Active treatment|US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
75793094|NCT01133730|Drug|Placebo Arm|US-guided TFP block with 20ml of 5% dextrose solution
75793095|NCT01230996|Drug|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
75793096|NCT01230996|Radiation|Intensity-modulated radiation therapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
75793097|NCT01230996|Procedure|Intracavitary brachytherapy|Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
75472701|NCT01961765|Drug|cabozantinib|
75793098|NCT01137084|Drug|solu medrol|total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
75793099|NCT01137084|Drug|a steroid-free immunosuppression protocol|receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
75793100|NCT01133886|Drug|Decitabine|Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
75793101|NCT01137240|Procedure|gastric emptying scan|"subjects will eat a solid meal (scrambled eggs, etc) or drink liquid (water or juice) mixed with approximately 0.5 millicuries of radioactive material. A scanner/external gamma camera will be placed over the subject's stomach at 15 minute intervals for a duration of 90 minutes (monitoring the amount of radioactivity in the stomach). As the radioactively-labeled food empties from the stomach, the amount of radioactivity in the stomach decreases. The rate at which the radioactivity leaves the stomach reflects the rate at which food is emptying from the stomach. The radioisotope has a half life of approximately. 6 hours and is totally eliminated from the body within 24 hours.~In subjects with gastroparesis, the food and the attached radioactive material remain in the stomach longer than normal (usually hours) before emptying into the small intestine. As a result, the scanner continues to show radioactivity in the area of the stomach for hours after the test meal."
75793102|NCT01140126|Drug|Antibody UB-421|Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
75793103|NCT01231074|Drug|Metformin|Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
75793104|NCT03917394|Drug|rHuEPO|rHuEPO was administrated daily with 10000 IU or 20000 IU
75793105|NCT03917394|Drug|Iron sucrose|Iron sucrose was administrated daily with 100mg or 200mg
75793106|NCT01133964|Dietary Supplement|dairy proteins|Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
75793107|NCT04938726|Dietary Supplement|Ketone Monoester|Ketone supplement will be taken by mouth at a dose of 15 mL twice per day
75793108|NCT03769896|Drug|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
75793109|NCT03769896|Drug|Placebo|capsule, corn starch, daily basis
75793110|NCT01234194|Drug|rising remifentanil concentrations|remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
75793111|NCT01234194|Drug|falling remifentanil concentrations|remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
75793112|NCT04913922|Drug|Azacitidine Injection|s.c. 75 mg/m2 BSA for 7 days
76084518|NCT02378298|Drug|peroral methylprednisolone and Methotrexate|Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
76084519|NCT02253108|Device|Everolimus eluting bioresorbable polymer stent|
75472702|NCT01961791|Procedure|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
75793113|NCT04913922|Drug|Nivolumab|480 mg i.v.
75645098|NCT04286828|Other|Dual Task Performance|"The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases."
75793114|NCT04913922|Drug|Relatlimab|80-160mg i.v.
75645099|NCT00735241|Device|SIR-Spheres microspheres|SIR-Spheres yttrium-90 microspheres
75645100|NCT00735241|Drug|FOLFOX6 cycles 1-3|Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
75793115|NCT01233024|Dietary Supplement|Control|Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
75793116|NCT01233024|Dietary Supplement|Soluble corn fiber|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
75793117|NCT01233024|Dietary Supplement|Resistant starch|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
75645101|NCT00735241|Drug|FOLFOX6 cycles 4 onwards|Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
75793118|NCT01233024|Dietary Supplement|Fructooligosaccharide|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
75793119|NCT01233024|Dietary Supplement|Inulin|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
75793120|NCT05495256|Device|Respimetrix|The Respimetrix device has a low resistance airflow sensor with an inhaler to measure patients inspiratory airflow and volume. This device will thereby provide quantifiable measures of lung function and bronchodilator delivery.
75645102|NCT00735241|Drug|Bevacizumab cycles 3 onwards|Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy
75645103|NCT00729313|Drug|Lanreotide microparticles|
75645104|NCT00729313|Drug|Placebo|
75793121|NCT01585818|Other|Low Glycemic Index (LGI) intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
75793122|NCT01585818|Other|Standard Diet Intervention|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
75793123|NCT01137318|Behavioral|Cognitive remediation and Parent Training|Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
75793124|NCT02528682|Biological|MiHA-loaded PD-L-silenced DC Vaccination|Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
75793125|NCT01233102|Drug|Conserved Therapy|Conserved Therapy
75793126|NCT01233102|Procedure|Hepatic artery infusion or Intravenous infusion|Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.
75793127|NCT01140282|Other|questionnaire administration|Administered within 3 days of baseline testing and at post-trial visit
75793128|NCT01140282|Procedure|quality-of-life assessment|Administered within 3 days of baseline testing and at post-trial visit
75793129|NCT01140282|Procedure|management of therapy complications|Assessed within 3 days of baseline testing and at post-trial visit
75793130|NCT01140282|Behavioral|exercise intervention|12 week exercise intervention
75793131|NCT03739944|Procedure|Laparotomic radical hysterectomy|Laparotomic radical hysterectomy for patients without fertility requirement
75793132|NCT03739944|Procedure|Laparotomic radical trachelectomy|Laparotomic radical hysterectomy for patients with fertility requirement
75793133|NCT03739944|Procedure|Laparoscopic radical hysterectomy|Laparoscopic radical hysterectomy for patients without fertility requirement
75793134|NCT03739944|Procedure|Laparoscopic radical trachelectomy|Laparoscopic radical hysterectomy for patients with fertility requirement
75793135|NCT01134120|Drug|LY2784544|LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
75793136|NCT01234272|Drug|morphine|ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
75793137|NCT01234272|Drug|Ropivacaine|PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
76084520|NCT02253108|Device|Biolimus eluting bioresorbable polymer stent|
75472703|NCT01961804|Drug|Reversion|Administration of prothrombin complex concentrates: KANOKAD before CT Scan
75645105|NCT00641901|Behavioral|counseling|"The 8-week study includes 3 visits to the dental facility at the Center for Women's Reproductive Health at UAB. Study visits are scheduled to coincide with pre-natal visits in the same facility.~Each visit will include individually tailored one-to-one discussion with a dental professional coupled with a demonstration and instructions for using oral hygiene products. Home-care kits will be dispensed, to include a helpful digital video disk (DVD), a high-tech powered toothbrush, dental floss, toothpaste and alcohol-free mouth rinse and subjects will have their teeth professionally cleaned.~First and final visits will include collection of gingival crevicular fluid and blood samples and subjects will complete pre and post study questionnaires."
75793138|NCT01231308|Procedure|Roux-en-Y-Gastric Bypass|Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
75793139|NCT01231308|Behavioral|Intensive lifestyle modification and Optimal medical Therapy|Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
75793140|NCT01140438|Drug|metformin+ NPH insulin|Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
75793141|NCT01140438|Drug|metformin + sitagliptin +/- repaglinide|Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
75929306|NCT05747989|Procedure|two-component skin adhesive, Glubran Tiss 2|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
75929307|NCT05747989|Procedure|skin is stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
75793142|NCT01234506|Dietary Supplement|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
75335593|NCT01797458|Procedure|Hall Technique|"Technique:~Removal of dental plaque and rest of aliments from the cavity~Selection of the SSC~If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~Dry the crown and fill with glass-ionomer luting cement~Place the crown over the tooth~Removal of cement excesses from the crown margins~The child should be asked to keep biting on the crown until the cement has set"
75929308|NCT05741112|Device|Wearable device|The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
75929309|NCT05730764|Diagnostic Test|Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making|With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results
75929310|NCT05730764|Diagnostic Test|Clinicians follow a routine protocol|Treatment is performed by the clinician according to the usual protocol.
75929311|NCT05719116|Behavioral|Physical exercise|The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.
75335594|NCT01797458|Procedure|Non-Restorative Caries Treatment|"Technique:~A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~Show the cavity to patient/parents and give them tooth-brushing instructions~Tell to parents that good plaque control is the key for this treatment~The recall interval for these patients is every 3 months."
75335595|NCT01797458|Procedure|Conventional Restoration|"Technique:~Local anesthesia should be used when needed~Perform complete caries removal and cavity preparation~Use a matrix band and a wedge to tightly hold the band against the tooth~Place the material (Compomer)~Check contacts and occlusion, and polish the restoration"
76084521|NCT04500990|Radiation|MRI test|Patients will receive diagnostic MRI test on d0.
76084522|NCT04500990|Radiation|MRI test|Patients will receive diagnostic MRI test on d8±1.
75335596|NCT00002602|Radiation|3D-CRT|3 dimensional conformal radiation therapy
75472704|NCT01961817|Other|Retromolar Vocal Cord Visualisation|For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack & Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
75472705|NCT01961817|Other|Conventional Vocal Cord Visualisation|The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack & Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
75472706|NCT01961830|Drug|ME1100 inhalation solution|
75793143|NCT03916536|Procedure|Holmium Laser|Holmium laser enucleation of large sized prostate
75335597|NCT00194090|Drug|celecoxib|
75793144|NCT03916536|Procedure|Thulium Laser|Thulium laser enucleation of large sized prostate
75793145|NCT03916536|Procedure|Bipolar diathermy|Bipolar enucleation of large sized prostate
75793146|NCT01234584|Procedure|spk|implants using SPK Abutments
75793147|NCT01234584|Procedure|CPK Abutments|implants using CPK Abutments
75335598|NCT00002608|Drug|cisplatin|
75793148|NCT04751604|Dietary Supplement|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide [1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)] for 4 weeks
75793149|NCT04751604|Dietary Supplement|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
76084523|NCT04500990|Radiation|MRI test|Patients will receive diagnostic MRI test on d30±2.
75335599|NCT00002608|Drug|doxorubicin hydrochloride|
75335600|NCT00002608|Drug|tamoxifen citrate|
75793150|NCT02528604|Procedure|Catheter ablation|Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
75929312|NCT05713643|Procedure|ESPB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral to the spinous procedure of T8 to obtain a parasagittal view. An echogenic needle will be introduced from the caudal end of the probe and advanced in-plane direction until the needle tip hit the tip of the transverse process. Bupivacaine will be afterwards injected into the erector spinae plane block. Linear spread cranially and caudally below the muscle upon injection will be visualized on the US screen indicating successful block.
75793151|NCT02528604|Procedure|Pacemaker and AV node ablation|Permanent pacemaker implant followed by AV node ablation
75793152|NCT02528604|Procedure|DC Cardioversion|Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
75929313|NCT05713643|Procedure|TPVB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral and parallel to 8th spinous process till transverse process, superior costotransverse ligament, and pleura will be visualized then lateral tilt of the probe was done for better visualization of the PVS between the superior costotransverse ligament and the pleura. An echogenic needle was introduced at caudal end of transducer using the in-plane technique till piercing the superior costotransverse ligament . Bupivacaine will be injected into the PVS with downward displacement of the pleura indicating a successful block.
75645106|NCT00735319|Device|Transcutaneous Bilirubinometer|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
75929314|NCT05713643|Procedure|QLB Technique|"The patient will be in lateral position. The probe will be placed above the iliac crest. The Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique and transversus abdominus muscles) will be detected. Both the external oblique and internal oblique muscles will be followed posteriorly until the layers of the thoracolumbar fascia appear as a bright hyperechogenic line. The quadratus lumborum muscle appears below to the latissimus dorsi muscle. While performing the quadratus lumborum block, Shamrock sign is identified; the transverse process of L4 appears as a stem whereas the three muscles psoas muscle, quadratus lumborum muscle and erector spinae appear as the leaves. A 22G (50mm) needle was inserted using an in-plane technique along the posterior edge of the ultrasound probe in the anteromedial direction. The needle tip was placed between the quadratus lumborum muscle and the Erector spinae muscle."
75929315|NCT05709171|Drug|18F-FDG|PET/CT scan approximately 60 min after injection of 18F-FDG
75645107|NCT00641979|Drug|budesonide|Current product
75929316|NCT05709171|Drug|64Cu-Dotatate|PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
75335601|NCT00002608|Procedure|conventional surgery|
75335602|NCT00002608|Radiation|radiation therapy|
75929317|NCT05701748|Other|Stimuli|placement of oral pacifier, electrical stimulation, and laryngoscopy
75335603|NCT00002620|Drug|carmustine|
75645108|NCT00641979|Device|Budesonide|New type device
75645109|NCT00641979|Drug|Placebo|
75929318|NCT05701111|Behavioral|Start with the Heart Students|The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.
76084524|NCT01603420|Drug|Luteinizing hormone-releasing hormone (LHRH)|Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
75645110|NCT02679417|Behavioral|exercise|12 weeks of aerobic or resistant exercise
75472707|NCT01961843|Drug|Abiraterone|Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
75645111|NCT02679339|Drug|CNTX-2022 (lidocaine gel, 40%)|
75645112|NCT02679339|Drug|Placebo|
75335604|NCT00002620|Drug|chemotherapy|
75335605|NCT00002620|Drug|mitolactol|
75335606|NCT00002620|Radiation|low-LET cobalt-60 gamma ray therapy|
75335607|NCT00002620|Radiation|low-LET photon therapy|
75335608|NCT01895192|Other|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
75335609|NCT04160000|Device|Catheter ablation|Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature
75645113|NCT02679261|Drug|Atorvastatin|Oral administration atorvastatin 20 mg per day
75645114|NCT02679261|Drug|Placebo|Oral administration placebo
75645115|NCT02679183|Dietary Supplement|Medically-Graded Honey|Honey added to the baby formula once a day for 2 weeks.
75793153|NCT02528604|Device|Implantable loop recorder|
75793154|NCT01231542|Drug|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
75793155|NCT01231542|Drug|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
75793156|NCT01231542|Drug|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
75793157|NCT01234428|Procedure|Laparoscopic surgery|Gastric banding
75793158|NCT01234428|Procedure|gastric banding|laparoscopic gastric banding
75793159|NCT01234662|Procedure|SPA|Spinal anesthesia and opioids
75793160|NCT01234662|Procedure|CSE|CSE and epidural opioids
75793161|NCT01234662|Procedure|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
75793162|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
75793163|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
75793164|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
75645116|NCT02679183|Other|Premature Milk Formula|Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
75793165|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
75793166|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
75793167|NCT01140672|Drug|PF-04634817|Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
75793168|NCT01231698|Drug|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
75793169|NCT01231698|Other|control|standard treatment without strict heart rate control
75335610|NCT04160000|Drug|Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation|Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation
75793170|NCT01142778|Drug|Bevacizumab|Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
75929319|NCT05701111|Behavioral|Start with the Heart Teachers|Pure Edge Inc will train teachers to deliver the Start with the Heart curriculum. The training emphasizes the neuroscience of stress and educator self-care. The teachers will implement the training in their respective classrooms for 6-8 weeks.
75929320|NCT05701111|Behavioral|Cue Centered Therapy Counselors|The Early Life Stress and Resilience Program team members will train school counselors on Cue-Centered Therapy through self-paced online modules, virtual and in-person live training, and office hours as needed. Counselors will implement the intervention with eligible students for 15-18 weeks.
75929321|NCT05701111|Behavioral|Cue Centered Therapy Students|Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.
75929322|NCT05701111|Genetic|iSWAB-DNA|Eligible students will give DNA buccal swabs at 2-3 time points for later analysis of genetic markers.
75929323|NCT05700916|Drug|Milk Polar Lipid-Rich Dairy Powder|Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
75929324|NCT05700916|Dietary Supplement|Dairy Powder|Effects of dairy control powder
75929325|NCT05698693|Behavioral|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.
76084525|NCT01603420|Drug|Docetaxel|Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
76084526|NCT01603420|Other|Conformal Radiation Therapy (RT)|1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
75645117|NCT02679027|Other|Protrude tongue maximally and upward (PTMU)|The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).
75645118|NCT02679027|Other|Protrude tongue maximally and downward (PTMD)|The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).
76084527|NCT02064036|Radiation|Stereotactic Radiosurgical Boost|Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
76084528|NCT02064036|Drug|Casodex|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
76084529|NCT02064036|Drug|Leuprolide|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
76084530|NCT05645484|Drug|18F-PFPN|18F-PFPN (dose: 3.0-5.4 MBq/kg) will be injected intravenously prior to imaging.
76084531|NCT05645484|Drug|18F-FDG|18F-FDG (dose: 3.7-5.4 MBq/kg) will be injected intravenously prior to imaging.
76084532|NCT03347682|Other|Satisfaction with Prosthesis -SATPRO|questionnaire 1
75335611|NCT04160000|Device|Insertion of CardioMems Hemodynamic monitor|Insertion of wireless hemodynamic monitor to provide hemodynamic data to guide heart failure therapy to achieve heart failure improvement.
75645119|NCT00752206|Drug|Saracatinib|Oral Agent
75645120|NCT00752206|Drug|Placebo|Oral Agent
76084533|NCT03347682|Other|Nottingham Health Profile-NHP|questionnaire 2
76084534|NCT03347682|Other|Prosthesis donning and doffing questionnaire|questionnaire 3
76084535|NCT04551300|Drug|VS-505|4 dosages of experimental drug
76084536|NCT04551300|Drug|Sevelamer Carbonate|Active Comparator
76084537|NCT02232022|Device|Reveal LINQ Insertable Cardiac Monitor|
75645121|NCT02679105|Drug|ALK Alutard birch or 5-grasses|3 injections with 4-5 weeks interval.
75645122|NCT02679105|Drug|ALK diluent|0,3% human albumin
75645123|NCT04182009|Device|Omron NE-U17 Ultrasonic nebuliser|The Omron Ultrasonic nebuliser dispenses sterile saline from a medication cup as an aerosol, which is inhaled.
75793171|NCT01142778|Drug|Docetaxel|Docetaxel at a dose of 100 mg/m^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
75793172|NCT01142778|Drug|Trastuzumab|Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
75793173|NCT01142778|Procedure|Surgery|All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
75793174|NCT01142778|Radiation|Radiotherapy|All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
75793175|NCT01142778|Drug|Hormonal Therapy|Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
75793176|NCT01237938|Behavioral|Low Glycemic Diet|Changing to low glycemic diet
75793177|NCT01142856|Biological|autologous mesenchymal stem cells|single intrathecal dose of 10x6 cells by lumbar puncture.
75645124|NCT04182009|Device|Akita Jet Inhalation System|The Akita Jet Inhalation System is a breath actuated nebuliser, which works with a positive pressure.
75793178|NCT03750708|Device|Ara® KOLIBREE tooth brush|"Use of the Ara® KOLIBREE tooth brush by the child one month before alveolar bone graft up to the time of surgery.~The Ara® KOLIBREE tooth brush saves brush tracking data."
75929326|NCT05698693|Behavioral|Contact Control|This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
75929327|NCT05686044|Drug|Buntanetap|HPMC (vegetarian source) capsule shells
75929328|NCT05686044|Drug|Placebo|HPMC (vegetarian source) capsule shells
76084538|NCT04437186|Behavioral|Recovery program|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
76084539|NCT04974580|Drug|Nicotine patch|NRT will be discussed and dosed by the study quit coach during coaching calls per quitline dosing protocols. NRT treatment will consist of up to an 8 week supply of nicotine patch, gum, and/or lozenge. NRT will be sent in two 4 week shipments. Participants may be dosed for a single form of NRT or combination NRT (patch plus gum or lozenge) based on coach assessment of nicotine use and participant preference.
75793179|NCT01142934|Device|Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)|The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.
76084540|NCT04974580|Behavioral|Phone Counseling|Participants in all four arms of the study will receive two proactive phone-based behavioral coaching calls for quitting vaping, which will include making a quit plan, learning to cope with urges to vape, and education on strategies for quitting and staying quit. Calls utilize the quitline evidence-based protocol. The first call lasts approximately 20 minutes, the second calls lasts approximately 10 minutes, and participants are encouraged to call in for ad hoc calls if they would like additional support.
75645125|NCT05663229|Device|Ankle foot orthosis|We evaluate the difference of with or without ankle foot orthosis
75645126|NCT02678949|Drug|Inhaled Fluticasone 50 mcg/twice day|After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
75793180|NCT04722978|Drug|Gemcitabine and carboplatin plus antibiotic (moxifloxacin)|Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)
75929329|NCT05685589|Behavioral|MINDful TIME|The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
75929330|NCT05681572|Drug|Midazolam|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
75929331|NCT05681572|Drug|Dexmedetomidine|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
75929332|NCT05681572|Drug|Placebo|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
75929333|NCT05676034|Drug|AMX0035|AMX0035
75929334|NCT05674071|Behavioral|Articulation/HVT|Osteopathy 1
76084541|NCT04974580|Behavioral|Digital Coaching|Intervention descriptionText-based vaping cessation program that utilizes evidence-based content from the quitline tobacco cessation protocol, as well as links directing participants to additional online educational content (brief videos, audio content, quizzes, and educational activities).
76084542|NCT01605292|Procedure|Ultrasound guidance|Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.
76084543|NCT01605292|Procedure|Palpation|Manual palpation for localizing radial artery for inserting needle.
75793181|NCT04722978|Drug|Gemcitabine combined with carboplatin plus placebo|Standard chemotherapy (gemcitabine and carboplatin) plus placebo
75929335|NCT05674071|Behavioral|Soft-tissue massage|Osteopathy 2
75929336|NCT05674071|Behavioral|Craniosacral techniques|Osteopathy 3
75929337|NCT05674071|Behavioral|Combination of the three interventions: HVT, soft-tissue and craniosacral techniques|This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral techniques
75929338|NCT05671874|Behavioral|Web/mobile/tablet-based digital decision aid + communication (DA+C) tool|The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.
75929339|NCT05669560|Combination Product|PerioProtect ™= plastic tray +1.7% hydrogen peroxide|Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
75929340|NCT05669105|Diagnostic Test|Specimen sample|Participants will have up to 100 mL of whole blood collected.
75929341|NCT05659264|Drug|mRNA-0184|mRNA-0184 dispersion for intravenous (IV) infusion
75929342|NCT05659264|Drug|Placebo|0.9% sodium chloride (normal saline) injection
75929343|NCT05651919|Biological|Blood test|During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.
75645127|NCT02678949|Drug|Inhaled Fluticasone 100 mcg/twice day|After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
75929344|NCT05651919|Behavioral|quality of life Questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~Level 1 is coded as a '1' (indicating no problem)~Level 2 is coded as a '2' (indicating some problems)~Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems."
75645128|NCT02678949|Drug|Inhaled Albuterol|The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
75793182|NCT03739398|Device|LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR))|1. LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR)) : Fractional Microneedle Radiofrequency (FMR) equipment is a device that penetrates the epidermis and irradiates the high frequency by entering the dermis. The generated radiofrequency transfers heat energy and induces thermal denaturation in the surrounding tissue. Using this principle, FMR equipment is being used as a very effective treatment for scarring, enlarged pores, hyperhidrosis as well as wrinkles. Unlike conventional treatments, FMR equipment has the advantage of a short recovery time after treatment because it minimizes damage to the epidermis because the insulated microspheres penetrate the skin and generate high frequency only at the end of the microspheres.
75793183|NCT03739398|Device|LASEMED laser(The Thulium laser with 1,927nm wavelength)|"2. LASEMD laser(The Thulium laser with 1,927nm wavelength) The Thulium laser with 1,927nm wavelength is a device that effectively removes various skin diseases present in the epidermis while minimizing the side effects such as scarring and pigmentation because it induces thermal damage to the only skin surface compared to conventional laser equipment. In recent years, not only skin lesions on the epidermis but also pigment disease and wrinkles have been reported to have a good effect.~In this study, we investigated the effect and stability of combined treatment of Thulium laser with 1,927nm wavelength in addition to FMR equipment which has already proven to be effective in improving skin aging."
75793184|NCT01140828|Drug|Rabeprazole|Rabeprazole 20mg once daily
75793185|NCT01140828|Drug|Rabeprazole Placebo|one tab once daily
75793186|NCT01234740|Drug|bafetinib|Given orally
75793187|NCT01234740|Procedure|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
75793188|NCT01234740|Other|pharmacological study|Correlative studies
75793189|NCT01234740|Other|liquid chromatography|Correlative studies
75793190|NCT01234740|Other|mass spectrometry|Correlative studies
75793191|NCT01234740|Other|laboratory biomarker analysis|Correlative studies
75929345|NCT05651919|Behavioral|Diet habits questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients."
75645129|NCT00752128|Device|Endeavor Resolute Zotarolimus-Eluting Coronary Stent System|Stent implantation
76084544|NCT03121794|Procedure|Ultrasonographic exam|The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks
76084545|NCT03121794|Device|ultrasound machine|Regular ultrasound machine used at Cleveland Clinic
75645130|NCT00642135|Drug|Mydriasert®|Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
75793192|NCT01234740|Genetic|protein expression analysis|Correlative studies
75793193|NCT01234740|Genetic|western blotting|Correlative studies
75472708|NCT01961843|Drug|Prednisone|Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
75793194|NCT01234740|Other|immunohistochemistry staining method|Correlative studies
75793195|NCT01234740|Procedure|therapeutic conventional surgery|debulking craniotomy
75793196|NCT01238016|Device|experimental|
75793197|NCT01234818|Device|Mirena (LNG-IUS)|General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
75793198|NCT01143012|Other|Group eczema education session|Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
75793199|NCT01143012|Other|Control group|The control group will not attend the group eczema education session.
75793200|NCT03714594|Drug|Dapagliflozin 10mg|Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.[
76084546|NCT01797185|Drug|SPARC1104 modified dose regimen I|Subjects who exited study CLR_09_21
76084547|NCT01797185|Drug|SPARC1104 modified dose regimen II|Subjects who received prior treatment regimen I
75793201|NCT03714594|Drug|Saxagliptin 5mg|Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
75793202|NCT03714594|Drug|Saxagliptin 5mg + Dapagliflozin 10 mg|Please see Intervention 1 and 2
75793203|NCT01144884|Other|Procedure (education and exercise)|education/exercise
75793204|NCT04624776|Drug|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
75793205|NCT04624776|Drug|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
75645131|NCT00642135|Drug|phenylephrine and tropicamide eyedrops|Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
75793206|NCT01234896|Drug|Nicotine Medicated Gum|Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
75929346|NCT05649553|Behavioral|digital game and video animation based diabetes education|While creating the digital game and video animation, an agreement was made with a software company and this company was responsible for the software and repair of the game. Digital games and video animations cover the basic educational topics of Type 1 diabetes. Expert opinions were received from experts in the field of Child Health and Disease Nursing to ensure the suitability of the content of the educational material. The name of the game site and how to use it were explained to the children in the intervention group by the researcher. In addition, children in the intervention group were given usernames and passwords to log in to the site. Game Sections; What is Diabetes? Medical Nutrition Treatment in Diabetes, Insulin Treatment and Application, Exercise and Physical Activity in Diabetes, Complications of Type 1 Diabetes Mellitus, Diabetes Management at School.
76084548|NCT01797185|Drug|SPARC1104 modified dose regimen III|Subjects who received no prior treatment regimen
76084549|NCT04501770|Drug|Chort 1 of M802|Cohort 1, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 2 μg, and the maintenance dose during core treatment period and extended treatment period is 5 μg.
76084550|NCT04501770|Drug|Chort 2 of M802|Cohort 2, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 5 μg, and the maintenance dose during core treatment period and extended treatment period is 10 μg.
76084551|NCT04501770|Drug|Cohort 3 of M802|Cohort 3, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 10 μg, and the maintenance dose during core treatment period and extended treatment period is 20 μg.
76084552|NCT04501770|Drug|Cohort 4 of M802|Cohort 4, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 20 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
76084553|NCT04501770|Drug|Cohort 5 of M802|Cohort 5, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
76084554|NCT04501770|Drug|Cohort 6 of M802|Cohort 6, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 150 μg.
76084555|NCT04501770|Drug|Cohort 7 of M802|Cohort 7, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1 is 150 μg, and on D8, D15, D22 is 225 μg.
76084556|NCT04501770|Drug|Cohort 8 of M802|Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
76084557|NCT01691326|Biological|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
76084558|NCT01691326|Biological|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
75645132|NCT04094272|Diagnostic Test|transthoracic doppler-echocardiography (TTE)|Transthoracic doppler-echocardiography (TTE) in patients with a new diagnosis of HCV before and after treatment with DAA medication.
76084559|NCT04501692|Procedure|VivaSight|see above
76084560|NCT04501692|Procedure|Videolaryngoscopy|see above
76084561|NCT04501068|Device|Ambu® AuraGainTM|Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia
75793207|NCT01234896|Drug|4 mg Nicotine Gum|Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
75793208|NCT01234896|Drug|2 mg Nicotine Gum|Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
75793209|NCT01234896|Drug|4 mg Nicotine Lozenge|Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
75793210|NCT01238094|Drug|Simvastatin|simvastatin 40 mg qd daily until disease progression
76084562|NCT01606852|Drug|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
76084563|NCT01691560|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
76084564|NCT01691560|Drug|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
76084565|NCT01691560|Drug|Sodium monofluorophosphate dentifrice|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
75645133|NCT02678637|Other|MRI and muscle dynamometer|
75645134|NCT02678559|Other|tee measurement|
75645135|NCT02678559|Other|flotrac measurement|
75645136|NCT02678559|Other|clearsight measurement|
75645137|NCT04093960|Dietary Supplement|Lactobacillus plantarum PS128|10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
75793211|NCT01236612|Drug|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
75793212|NCT01236612|Biological|Immunization|Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
75793213|NCT01236612|Biological|Plasmodium falciparum Bloodstage challenge|Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
75793214|NCT01236612|Biological|Plasmodium falciparum mosquito challenge|Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
75793215|NCT01236612|Drug|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
75929347|NCT05647564|Diagnostic Test|F-fluorodeoxyglucose positron emission tomography (FDG PET)|Imaging scan
75793216|NCT03633630|Drug|Amla|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
75929348|NCT05647564|Diagnostic Test|prostate-specific membrane antigen positron emission tomography (PSMA PET)|Imaging scan
75929349|NCT05645588|Behavioral|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT)|To prepare patients for the TF-SPT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-SPT units.
75929350|NCT05645588|Behavioral|Trauma-focused standard psychotherapy (TF-SPT)|Patients wait for 10 TF-SPT units and then are offered to learn pranayama
75929351|NCT05639218|Drug|Inclisiran|Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy
76084566|NCT01691560|Drug|Sodium fluoride dentifrice|Dentifrice containing 1100 ppmF as sodium fluoride
75335612|NCT04160000|Drug|Empiric heart failure drug therapy|Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
75335613|NCT00002638|Biological|filgrastim|
75335614|NCT00002638|Biological|sargramostim|
75335615|NCT00002638|Drug|carmustine|
75335616|NCT00002638|Drug|cyclophosphamide|
75335617|NCT00002638|Drug|cytarabine|
75335618|NCT00002638|Drug|etoposide|
75335619|NCT00002638|Procedure|peripheral blood stem cell transplantation|
75335620|NCT00002638|Radiation|radiation therapy|
75335621|NCT05120362|Drug|Cream containing JAK Inhibitor|The study drug is a cream containing JAK Inhibitor.
75929352|NCT05630976|Drug|Isavuconazole|This is a single arm study, all enrolled participants will receive the study intervention.
75929353|NCT05625087|Drug|Alpelisib|Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days
75929354|NCT05625087|Drug|Ribociclib|Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
75929355|NCT05624359|Drug|FA plus ropivacaine|Th group will receive 0.17% FA and 0.5% ropivacaine for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
75929356|NCT05624359|Drug|ropivacaine alone|The ropivacaine alone group will receive 0.5% ropivacaine alone for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
75929357|NCT05623501|Drug|Dihydromyricetin|Dose-escalation and lysine preparation
75929358|NCT05620641|Drug|Ondansetron 8mg|50 patients will receive intravenous ondansetron 8 mg before the end of surgery.
75929359|NCT05620641|Drug|Gabapentin|50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.
75929360|NCT05619939|Dietary Supplement|Protein isolate|The indicated protein isolates will be given to subjects as their major protein source
76084567|NCT02517606|Other|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
76084568|NCT02517606|Other|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
76084569|NCT03346278|Behavioral|Text Messaging Intervention|After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
75335622|NCT04330768|Procedure|PRF pulp capping|PRF is injected in the site of exposure
75335623|NCT04330768|Procedure|MTA pulp capping|conventional pulp capping procedure
75335624|NCT01896440|Drug|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
75335625|NCT01217216|Behavioral|Group-based Intervention|compared effects of a group-based intervention on weight loss and physical activity.
75335626|NCT01217216|Behavioral|Telephone-based Intervention|compared telephone-based intervention to weight loss and physical activity.
75335627|NCT00086762|Behavioral|MR Therapy|Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
75335628|NCT00086762|Behavioral|Relaxing Music (RM) Therapy|Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
75335629|NCT00086762|Behavioral|Standard Symptom Management|Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
75335630|NCT00086762|Behavioral|Questionnaires|Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
75472709|NCT01961856|Drug|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
75645138|NCT00642291|Drug|Emtricitabine|emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if <30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to <15kg; 10/2.5 mg/kg BID if >=15 to <=40 kg)
75645139|NCT00642291|Drug|Emtricitabine|emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
75645140|NCT02600260|Drug|Enoxaparin|Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
75793217|NCT03633630|Drug|Placebo|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
75793218|NCT01234974|Drug|Pasireotide|Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose
75793219|NCT01234974|Drug|Everolimus|given as an oral tablet every day on days 1-28, 10 mg per day
75472710|NCT01961856|Drug|Ticagrelor|Ticagrelor 180mg loading dose
76084570|NCT03346200|Drug|Tamoxifen Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
75793220|NCT01144962|Procedure|Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
76084571|NCT03346200|Drug|Placebo Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
76084572|NCT04501458|Other|Training of youth, community health assistants and community health workers.|Training of youth, community health assistants, and community health workers in the screening, detection, contact tracing, prevention, and management of COVID-19 with concurrent maintenance of essential health services.
76084573|NCT04501458|Other|Training clinicians in basic critical care and the management of severe COVID-19 cases|Training clinicians in basic critical care and the management of severe COVID-19 cases with concurrent maintenance of essential health services.
75335631|NCT00002656|Drug|pyrazoloacridine|"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
75335632|NCT00002662|Drug|docetaxel|
75335633|NCT00002662|Drug|paclitaxel|
75335634|NCT01750112|Device|Macrolane VRF20|Injection treatment with Macrolane VRF20
75335635|NCT00054314|Drug|ortataxel|
75335636|NCT02973334|Other|Ingestion of artificially-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
75645141|NCT02600260|Other|No intervention|Hospitalized patients that score less than three are not prescribed enoxaparin.
76084574|NCT01819727|Drug|BMN 165|After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.
76084575|NCT01649362|Other|prefeeding oral stimulation program|"The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.~The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day."
75335637|NCT02973334|Other|Ingestion of sugar-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
75645142|NCT02678325|Other|Standardized high protein enteral nutrition|A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
75793221|NCT01144962|Procedure|Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
75793222|NCT01143168|Biological|autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells|First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
75793223|NCT04578288|Procedure|INDIVIDUALIZED BLOOD PRESSURE MANAGEMENT DURING ENDOVASCULAR TREATMENT OF ACUTE ISCHEMIC STROKE UNDER PROCEDURAL SEDATION|The individual target range is defined as: bSBP ± 10 mmHg. The lowest possible SBP target range is 100-120 mmHg. The highest SBP target range is determined on the basis of whether patients receive concurrent IV fibrinolytic therapy or not. In patients where IV fibrinolytic therapy is applied, the highest SBP range is 160-180 mmHg, in patients without concurrent fibrinolytic therapy the highest SBP range is 180-200 mmHg.
75798937|NCT03855384|Drug|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|placebo 1200mg IV ，cisplatin 75 mg/m^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
75798938|NCT01185132|Radiation|accelerated partial breast irradiation - 3D-conformal planning|38.5 Gy, 10 fractions over 5 days
75645143|NCT02678325|Other|Standardized normal protein enteral nutrition|double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
75645144|NCT04181931|Procedure|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
75472711|NCT01961895|Procedure|Continuous lumbar plexus (LP) block analgesia|
75645145|NCT04181931|Procedure|Surgery alone|hepatic resection remove the liver tumor and portal vein tumor thrombus
75645146|NCT04094116|Procedure|ear wax syringing without pre ear oil treatment|Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment
75645147|NCT02678481|Device|MR-guided in-bore prostate biopsy|2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
75645148|NCT02678481|Device|TRUS-guided prostate biopsy|24-28 systematic biopsy core (saturation scheme)
75793224|NCT01140984|Drug|Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)|Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
75793225|NCT01141062|Device|Philips MR-guided HIFU|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
75793226|NCT01235052|Radiation|Positon Emission Tomography using 18F-FMISO|We will introduce a pretherapy [18F]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. [18F]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe [18F]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
75793227|NCT01145430|Other|Laboratory Biomarker Analysis|Correlative studies
75793228|NCT01145430|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75793229|NCT01145430|Other|Pharmacological Study|Correlative studies
75793230|NCT01145430|Drug|Veliparib|Given PO
75793231|NCT01141140|Behavioral|Healthy|Favourable nutritional characteristics.
75793232|NCT01141140|Behavioral|Diet|Benefits of an ingredient/nutrient for weight management
75793233|NCT01141140|Behavioral|Unhealthy|Hedonic characteristics and less healthy ingredients.
75793234|NCT03389724|Drug|Capoten®|ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
75793235|NCT05382000|Diagnostic Test|Advanced triage tool for Gynecology and Obstetrics emergencies based on artificial intelligence algorithms.|"After the conventional triage, a second independent doctor will make the suit with the Mediktor Hospital tool.. In less than 3 minutes and with an average of 14 questions, Mediktor performs an interrogation very similar to what an emergency doctor would do. The professional version allows the health professional to modify the course of the questions in the middle of the evaluation, if he considers it necessary to go deeper into some aspect of the anamnesis. The system allows you to see in real time the diseases that Mediktor considers possible during the evaluation.~At the end of the triage process, Mediktor offers the level of urgency and a list of possible diagnoses based on the signs and symptoms answered. The professional can change the level of urgency if he considers it beneficial for the patient.~Once the two triages (Conventional and Mediktor) have been carried out, the patient will be seen according to the care protocols of the center."
75793236|NCT01585974|Other|No intervention|All dosage, frequency and duration for drugs will be under the decision of the treating physician
75793237|NCT01586052|Drug|Erythropoietin|250 IU/kg, Twice a week for 4 weeks
75793238|NCT01141218|Other|internet-based protocol and physician referral|collection and review, dna and lab biomarker analysis, gene mapping
75793239|NCT01145586|Drug|Lactase Oral Tablets|3 tablets/day for 42 days Take with breakfast, lunch and dinner
75793240|NCT05796739|Diagnostic Test|Non-invasive stress test|Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging
75793241|NCT05796739|Diagnostic Test|Medical treatment without further testing|Optimal medical treatment for primary prevention.
75793242|NCT05796700|Procedure|Microwave Ablation|"Microwave Ablation: A minimally invasive technique for HCC, MWA has the potential to eradicate larger HCCs with larger coagulation areas and is less affected by the heat sink effect caused by vessels around the tumor.~Laparoscopic Hepatectomy: The technique has been widely promoted worldwide with technical progress. In patients with cirrhosis, LLR has the potential advantage of reducing the risk of postoperative liver decompensation"
75793243|NCT05796635|Other|Herpecin L|Participants in the Herpecin L arm will use the test product daily as a preventive product by applying the product twice daily. Also, participants will be told they can reapply the product if going outside into the cold, wind, or sun. If participants in the Herpecin L arm do experience a cold sore or fever blister, they will be instructed to use the product at the first sign of the cold sore and then at least four more times during the day until the cold sore is gone (they can use the product more often if they plan to go outside into the cold, sun, or wind).
75793244|NCT05796622|Behavioral|HIVST-Chatbot (HIV self-testing services with counseling provided by a Chatbot)|Promote and implement HIVST-Chatbot
75793245|NCT05796622|Behavioral|HIVST-OIC (HIV self-testing services with counseling provided by administrators)|Promote and implement HIVST-OIC
75793246|NCT05796596|Behavioral|Experimental: Virtual Reality (VR) distraction|Children in the VR distraction group will begin interacting with the virtual environment (VE) 2 minutes prior to the skin prick test and will continue playing throughout. The VR environment is a game in which the child draw a 360 degree image.
75793247|NCT05796596|Behavioral|Active Comparator: Distraction by the book|In the book distraction group, the child will be invited to find and count animals in various landscapes. The book will be given 2 minutes prior to the skin prick test and continued reading throughout.
75793248|NCT05796466|Behavioral|How-to talk so kids will listen and listen so kids will talk|The How-to Parenting Program focuses on how expectations, rules, and values are better communicated (vs. what rules ought to be). It includes skills related to the three components of authoritative parenting, namely affiliation, structure, and autonomy support. 1) Affiliation: Parents learn how to listen and respond to their children in a way that helps them feel accepted unconditionally. 2) Structure: Parents learn how to communicate expectations, give feedback, follow through, and use joint problem-solving in a factual, non-judgmental way. 3) Autonomy support: Parents learn how to validate emotions, encourage initiatives, and free children from roles. Finally, the How-to program can be endorsed by parents of various cultural backgrounds, as suggested by the large number (> 30) of languages in which the material is translated. This advantage is crucial in ethnically diverse regions such as Canada.
75929361|NCT05619185|Behavioral|CRAFT Web-Based Intervention|Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
75793249|NCT05796466|Behavioral|Nobody's Perfect|Nobody's Perfect is delivered in family resource centers across Canada to support parents of infants and preschoolers. Its focus is on developing parents' capacity to problem solve, providing child development information, and helping parents recognize their strengths and find their own positive ways to interact with their children. It thus does not teach specific parenting skills and does not suggest specific rules to put into practice in the home-environment.
75793250|NCT05796362|Drug|Azithromycin Oleogel (Oral and Rectal)|"Exploratory study of a novel oleogel dosage form of Azithromycin (Zithromax)"
75793251|NCT05796349|Diagnostic Test|multifrequency EIT-based for detecting intracranial abnormalities|For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.
75929362|NCT05619185|Behavioral|Phone-Based CRAFT|The phone-based CRAFT intervention consists of six individual sessions with a CRAFT clinician that will explore what they learned from the WBI and additional skills they need. Session content includes positive reinforcement of non-drinking SM behaviors, refraining from interfering in SM's consequences of alcohol use, communication skills, and self-care.
76084576|NCT05584020|Procedure|ACL Repair|Patients are undergoing arthroscopic anterior cruciate ligament repair. The native ACL is repaired using very strong sutures. This device is used to repair the native ACL and restore knee stability.
76084577|NCT05584020|Procedure|ACL Reconstruction|Patients are undergoing arthroscopic anterior cruciate ligament reconstruction. The torn ligament is removed and replaced with a band of tissue that usually connects muscle to bone. The graft tendon is taken from another part of your knee or from a deceased donor.
76084578|NCT03346590|Behavioral|Energy metabolism of patients suffering from RA|Energy metabolism of patients suffering from RA
76084579|NCT01692340|Other|Isotopically labeled lycopene, phytoene or phytofluene|We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
76084580|NCT03346512|Procedure|Cardiac surgery|Cardiac surgery
75645149|NCT00643305|Behavioral|Skills Building with Motivational Interviewing|Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
75793252|NCT05796323|Other|No intervention.|The subjects will complete a survey related to workplace violance.
76084581|NCT02517450|Behavioral|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
76084582|NCT02517450|Other|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
75335638|NCT02973334|Other|Ingestion of water|From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
75335639|NCT00381784|Behavioral|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
75472712|NCT01961895|Drug|Intravenous patient-controlled analgesia|
75472713|NCT01961908|Drug|Proellex|
75472714|NCT01961934|Drug|Sodium Acetate C11 PET/CT Imaging|
75472715|NCT01961947|Biological|ASP7374|subcutaneous
75793253|NCT05796310|Diagnostic Test|Salivary collection|Collection of saliva via swab for miRNA processing
75793254|NCT05796310|Diagnostic Test|eye-tracking recorder|Administration of eye-tracking session recording Saccadic Eye Movements, fixation duration and pupillary response.
75472716|NCT01961947|Biological|approved egg-derived TIV|subcutaneous
75472717|NCT01961960|Biological|ASP7374|intramuscular
75645150|NCT00643305|Behavioral|Skills Building|Participants are provided with information and training in skills critical for reducing HIV risk.
75645151|NCT02675985|Other|Physical Therapy|Early Intensive Physical therapy in the ICU
75793255|NCT05796310|Diagnostic Test|neuropsychological assessment|Administration of neuropsychological tests and collected patient medical history
75798939|NCT01185132|Radiation|accelerated partial breast irradiation - IMRT planning|38.5 Gy, 10 fractions over 5 days
75798940|NCT01181856|Biological|MVA 85A|Single injection of 1 x 108 pfu MVA85A
75798941|NCT01181934|Other|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
75798942|NCT01181934|Drug|placebo|placebo - three times daily during each treatment period
75798943|NCT01181934|Other|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
76084583|NCT02517372|Drug|CRD007|
75793256|NCT05796284|Behavioral|Breast pressure relief intervention at the end of pregnancy|When teaching pregnant women, the researchers will use tablet computers and models to explain the operation of breast combing and acupressure one-on-one, and use the model to demonstrate. Emphasis on breast grooming during pregnancy, twice a day, once in the morning and evening, 5 minutes on one breast each time, 10 minutes on both sides; strengthen breast grooming and acupressure after delivery. The first breast combing, 5 minutes on one breast each time, and 10 minutes on both sides 4 to 6 times a day. After combing, according to expert advice, massage the 6 acupoints around the breast for 5-10 seconds, and then use hand expressing or breastfeeding to discharge the milk .
75929363|NCT05619185|Behavioral|CRAFT Workbook|The self-directed CRAFT workbook Table 1.Partners Connect WBI has a parent and partner version that uses CRAFT to help the CP help with understanding, self-care, communication, and actions (e.g., how to react when a partner has been using substances and when they have not been using substances, how to talk to partner so that they are more likely to be heard) and includes more information about communicating than the WBI and several interactive worksheets.
75929364|NCT05619185|Behavioral|Gottman Self-Guided Resources|"To match time spent reviewing the website, CPs will receive an orientation guide that includes the website URL and a 4-week guide for how they can navigate this website for 20-30 minutes per week (e.g., read article 'It's Not My Fault!': Why Defensiveness is Damaging and write down one tool to dissolve defensiveness you're willing to try). We will send reminder emails each week to visit the website and include questions in the emails and our first online follow-up survey asking CPs approximately how many times they visited the website and how long they spent viewing content on the website. Reminder emails will be programmed such that CPs get directed automatically to the website if the CP notes no time spent on it."
76084584|NCT01692496|Drug|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
75929365|NCT05617157|Other|Stair stepping|stepping up and down 32 stairs for 1 minute
76084585|NCT05583240|Drug|Essences and Essential Oils|Participants will received Essential Oils through a nasal stick during 4 weeks.
76084586|NCT01692964|Device|InflammaDry|A noninvasive immunoassay for detecting MMP-9 levels in tears.
76084587|NCT02517216|Other|parabolic flight|
75335640|NCT00381784|Behavioral|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
75335641|NCT00002674|Biological|filgrastim|
75793257|NCT05796284|Other|Routine care|Cases in the routine care group received routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery.
75793258|NCT05796271|Drug|R-Chop and Roflumilast|All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
75793259|NCT05796258|Diagnostic Test|NTRK fusion assessment|To evaluate NTRK fusion presence by MCG, Immunohistochemistry or NGS
75793260|NCT05796219|Radiation|Low dose mammogram|Low dose mammogram
75929366|NCT05610462|Behavioral|Guided Exercise Training Program|The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).
75929367|NCT05610462|Behavioral|Usual Care|Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
75929368|NCT05609084|Procedure|Speech therapy|Patients will connect on an interface to pratice speech therapy
76084588|NCT02517216|Device|MRI|
76084589|NCT01649596|Device|Warming Gown|Forced air warming Gown and portable warming unit that follows patient from pre-operative through surgery and into post-operative recovery.
76084590|NCT01649596|Other|Standard of care warming|The intervention is standard of care, placing warm blankets on the patient at time of pre operative preparation through the procedure and into recovery.
75335642|NCT00002674|Drug|cytarabine|
75335643|NCT00002674|Drug|etoposide|
75335644|NCT00002674|Drug|hydroxyurea|
75335645|NCT00002674|Drug|mitoxantrone hydrochloride|
75335646|NCT00002674|Procedure|peripheral blood stem cell transplantation|
76084591|NCT03346122|Drug|JNJ-64991524 Dose Level 1|Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
76084592|NCT03346122|Drug|JNJ-64991524 Dose Level 2|Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
76084593|NCT03346122|Drug|JNJ-64991524 Dose Level 3|Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
76084594|NCT03346122|Drug|JNJ-64991524 Dose Level 4|Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
76084595|NCT03346122|Drug|JNJ-64991524 Dose Level 5|Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
76084596|NCT03346122|Drug|JNJ-64991524 Dose Level 6|Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
76084597|NCT03346122|Drug|Placebo|Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
75929369|NCT05609084|Procedure|Speech therapy assessment|Patients will be followed by an speech therapist
75645152|NCT04020562|Other|Mild Resistive Expiratory Technique|"Mild Resistive Expiratory Technique (EMST150- five-week training protocol):~The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for five weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
75793261|NCT05796193|Other|Alpha-cypermethrin and PBO LLIN|Veeralin Long lasting insecticidal net with Alpha-cypermethrin Pyrethroid insecticide and PBO
75793262|NCT05796193|Other|Alpha-cypermethrin and Clorfenapyr LLIN|Interceptor G2 dual active ingredient LLIN with with Alpha-cypermethrin Pyrethroid insecticide and Clorfenapyr
75793263|NCT05796193|Other|Alpha-cypermethrin only LLIN|reference: standard pyrethroid LLIN
75793264|NCT05796154|Device|ear blood pressure monitor|The ear blood pressure monitor is a biometric monitoring device that collects blood pressure non-invasively from the ear.
75793265|NCT05796128|Procedure|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|In this group, infants will receive NIPPV during LISA procedure.
75793266|NCT05796128|Procedure|Nasal continuous positive airway pressure (NCPAP)|In this group, infants will receive NCPAP during LISA procedure.
75929370|NCT05605080|Device|Gelfoam|Use Gelfoam as a hemostatic agent after anal surgery.
75929371|NCT05605080|Other|Bosmin gauze|Use bosmin gauze as a hemostatic agent after anal surgery.
75929372|NCT05602987|Procedure|enema|receiving enema at the night before anal surgery
75929373|NCT05602987|Procedure|no enema|no enema before anal surgery
75929374|NCT05599347|Drug|Azithromycin Pill|Tablet - 500 mg azithromycin (as dihydrate)
75645153|NCT04020562|Other|Conventional Training|"Breathing exercise: Deep breathing 10-15 repetitions twice a day. Assistive Coughing: 5-6 repetitions twice a day. ROM Exercises: Both active and passive limb ROM exercises 10-15 repetitions twice a day.~Sustained stretching: Both upper and lower limbs, 10 repetitions, held for 5 seconds, twice a day.~Splinting: According to patient's injury level Bracing: According to patient's injury level Functional Mobility: Mobilizing patient according to injury level Tilt table standing: 10-15 minutes once a day"
75793267|NCT05796115|Procedure|Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS on the basis of Procalcitonin and Presepsin values measured within the first 3 hours of life.
75793268|NCT05796115|Procedure|Antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS.
75793269|NCT05796076|Device|Virtual reality|Participants in the intervention group will be received VR during the suture procedure. Virtual reality is a three dimensions of width, height and depth that is generated digitally in a computer-generated environment that allows a user to interact with it 16.
75793270|NCT05796011|Device|hearing aids|Hearing aid(s) fitted for one or two sides of ear.
75793271|NCT05796011|Other|without hearing intervention|neither earing aids nor other heaing treatment were applied.
75793272|NCT05796011|Other|healthy control|healthy control
75335647|NCT01743872|Procedure|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
75645154|NCT00976508|Drug|figitumumab|IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
75645155|NCT00976508|Drug|pegvisomant|growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
75645156|NCT02600104|Device|PicoWayTM|The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier
75645157|NCT02866058|Procedure|Cesarean Section|
75645158|NCT02675673|Procedure|GJ-Tube|Insertion of a GJ tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
75645159|NCT02675673|Procedure|G-Tube|Insertion of a G-tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
75793273|NCT05795998|Other|Adaptation of the Sabotage in Romantic Relationships Scale into Turkish and its validity and reliability analyzes|Approval was obtained from the local ethics committee before starting the study. Permission was obtained from Racquel PEEL, who developed the scale. The scale was administered to 495 participants and they were informed about the study by a specialist psychiatrist. Language validity, construct validity and reliability analyzes of the scale were performed. The findings were discussed in the light of the literature.
75793274|NCT05795946|Dietary Supplement|Whole food-based B and D vitamins|Looking at whole food-based B and D vitamins to reduce TMAO levels and if this can modulate gut diversity
75793275|NCT05795920|Drug|Utidelone injection in combination with gemcitabine|Utidelone injection: 30mg/m2, for days 1-5, once a day, 21 days for a treatment week Period; Gemcitabine: 1000mg/m2, Q3W on day 1 and day 8, 21 days for a treatment cycle
75793276|NCT05795907|Drug|SAR443820|Capsule / Oral
75793277|NCT05795907|Drug|Placebo|Matching Capsule / Oral
75793278|NCT05795868|Device|Compression stocks|Pregnant women in the compression stockings group will wear the socks given for 3 weeks.
75793279|NCT05795868|Other|Knee socks|Pregnant women in the Knee socks group will wear the socks given for 3 weeks.
75929375|NCT05599347|Other|Placebo|Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
75929376|NCT05595161|Behavioral|Bright Bodies|The Bright Bodies intensive, family-based lifestyle intervention uses group sessions including nutrition education, behavior modification, and exercise to improve weight and weight-related outcomes among children and adolescents with obesity.
75929377|NCT05589948|Dietary Supplement|Radicle Calm Study Placebo Control 1|Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.
75929378|NCT05589948|Dietary Supplement|Radicle Calm Study Placebo Control 2|Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.
75929379|NCT05589948|Dietary Supplement|Radicle Calm Study Active Product 1.1|Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.
75793280|NCT05849428|Device|Freestyle Libre 3|Freestyle Libre 3 consists of a sensor that is applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor will continuously read interstitial glucose readings every minute and syncs with the Freestyle View app. At the completion of the study, the sensor is discarded per protocol.
75929380|NCT05589948|Dietary Supplement|Radicle Calm Study Active Product 2.1|Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.
76084598|NCT03346122|Drug|JNJ-64991524 Dose Level 7|Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
76084599|NCT03346122|Drug|JNJ-64991524 Dose Level 8|Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
75645160|NCT04289246|Device|Medication Ambient Display (MAD)|"MAD was implemented for Android tablets to provide the following external cues:~Abstract and stylized representations of medication adherence. The MAD shows a virtual birdcage, which has the aim of raising elders' consciousness about how they have to take responsibility for caring for their health, in a way similar to willingly caring for a pet. Each day, a newborn pet grows to represent medication compliance. By touching any point on the parakeet's virtual cage, the MAD presents information on the participants' daily medication compliance.~Auditory and visual reminders. The parakeet provides auditory reminders (a parakeet whistle) and pictograms to inform the medication to take.~After participants take their medication, they move the MAD closer to the pill container to indicate that the medication was taken. This functionality was implemented through Near Field Communication (NFC) technology. Afterward, the parakeet acknowledges that the medication was registered as taken."
75645161|NCT02537379|Drug|SOF|SOF 400 mg tablets administered orally once daily
75645162|NCT02537379|Drug|COPE|COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
75645163|NCT00973622|Device|repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)|All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
75929381|NCT05589948|Dietary Supplement|Radicle Calm Study Active Product 2.2|Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
75645164|NCT00973622|Device|repetitive transcranial magnetic stimulation (rTMS) 20Hz|All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
76084600|NCT03346122|Drug|JNJ-64991524 Dose Level 9|Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
76084601|NCT02516826|Drug|Rosuvastatin|
75645165|NCT00973622|Device|SHAM repetitive transcranial magnetic stimulation (rTMS)|The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
75651914|NCT04781465|Device|Immersive Virtual Reality|"Dedicated virtual reality sessions.~Duration 20 minutes per session.~The virtual reality session will be supervised by a health professional trained in this tool after 1.5 hours of training by the team responsible for the equipment (use of the equipment, and use of the 20 minutes of VR). This supervising professional may be a doctor, an occupational therapist, a caregiver or any other health professional trained in the tool under this protocol.~The exercises proposed will be standardized virtual reality exercises with the same exercises for all, but adapted to the level and abilities of each patient."
75929382|NCT05589935|Dietary Supplement|Relief Study Product Usage|Participants instructed to use study product daily as directed for a period of 4 weeks
76084602|NCT02516826|Drug|Olmesartan|
76084603|NCT02516826|Drug|Combination|Rosuvastatin/Olmesartan(Combination)
75793281|NCT05849402|Device|Active Comparator: Active aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
76084604|NCT02516826|Drug|Placebo of Rosuvastatin|
76084605|NCT02516826|Drug|Placebo of Olmesartan|
75793282|NCT05849402|Device|Sham Comparator: Sham aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
75798944|NCT01180686|Device|Activator IV single impulse instrument|This is a manually operated device that delivers a single thrust into the joint involved.
75798945|NCT01180686|Device|Multiple thrust Impulse adjusting instrument|A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
76084606|NCT02516826|Drug|Placebo of Rosuvastatin/Olmesartan(Combination)|
76084607|NCT01650298|Other|Drug (Direct thrombin or Factor Xa inhibitor)|Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
76084608|NCT01795937|Drug|Itraconazole|twice daily
75798946|NCT01289808|Drug|Glucose 25%|1ml of glucose 25% once
75798947|NCT01289808|Drug|Glucose 25%|1ml glucose once per os
75929383|NCT05588609|Drug|Afatinib Oral Tablet|anti epidermal growth factor receptor (EGFR)/HER2 agent
75929384|NCT05588609|Drug|Enzalutamide Pill|second-generation androgen receptor antagonist
75929385|NCT05588609|Drug|Abiraterone acetate tablets|androgen synthesis inhibitor
76084609|NCT01795937|Drug|Atorvastatin|single dose
76084610|NCT01795937|Drug|Faldaprevir|once daily
76084611|NCT01795937|Drug|Rosuvastatin|single dose
76084612|NCT01795937|Drug|Faldaprevir|once daily
76084613|NCT04139382|Other|Telephone Consultation|A telephone consultation comprising clinical history, contraception planning, explanation of medical method of abortion
76084614|NCT04139382|Other|Face-to-Face Consultation|A face-to-face consultation comprising clinical history, contraception planning, explanation of medical method of abortion
75645166|NCT04180137|Procedure|Endovenous laser ablation of great saphenous vein (GSV) and microphlebectomy of varicose veins|"Surgical treatment is performed as endovenous laser ablation of GSV and microphlebectomy of varicose branches according to a standard protocol:~The intervention includes treatment of the pathological upright reflux and varicose veins. Ultrasound-guided GSV puncture at the upper third of the leg under local anesthesia. The light guide is inserted into the vein lumen and pushed through to the saphenofemoral junction. Under ultrasound guidance the light guide is positioned at v. epigastrica superficialis junction. Under ultrasound guidance tumescent anesthesia is produced around the GSV from puncture site up to the saphenofemoral junction. Laser coagulation (with radial light guide), linear energy density - 75 J/cm, automatic traction of the light guide at the speed 0.7 mm/sec. Varicose veins are resected through skin punctures using Varady hook 1-2 mm."
75929386|NCT05588609|Biological|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
76084615|NCT01608100|Device|ARCHITECT STAT High Sensitive Troponin I Assay|"Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.~Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit."
76084616|NCT05581368|Other|Chronic Cannabis use|The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
76084617|NCT04501224|Drug|Tenofovir alafenamide fumarate|Patients would take tenofovir alafenamide fumarate, 25mg，once per day
75645167|NCT04180137|Drug|Pharmacotherapy|After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.
75793283|NCT05849376|Behavioral|Emergent Multi-Class Imitation Training|Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments.A minimum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 20-25 min to conduct. Each session will consist of the instructor presenting imitation training trials and probe trials. During baseline sessions, participants will not receive rewards for correct imitation. During training, participants will receive rewards for correct imitation and evidence-based teaching strategies that are commonly employed in ABA therapy will be used to help participants learn how to imitate new responses. Novel probe trials will be embedded throughout all sessions to continuously evaluate the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.
75645168|NCT02865746|Drug|Bethametasone|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
75645169|NCT02865746|Drug|Placebo|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
75793286|NCT05849324|Device|Straight needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, straight needle is going to be used.
75793287|NCT05849324|Device|Bent needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, bent needle is going to be used.
75793288|NCT05849285|Other|TLC Clinic|Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team
75645170|NCT04093804|Device|Glenosphere size for Reverse Shoulder Arthroplasty|Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
75645171|NCT00629486|Genetic|Polymorphism of IL-1 beta and TNF-alpha|To analyze the role of polymorphisms of IL-1beta and TNF-alpha gene on risk of hepatitis B-related chronic liver disease and hepatocellular carcinoma
75793289|NCT05849246|Drug|Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed|"Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
75793290|NCT05849246|Drug|Sintilimab+Carboplatin or Cisplatin+Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
75793291|NCT05849246|Drug|Tusamitamab ravtansine+Sintilimab|"Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
76084618|NCT04501224|Drug|Entecavir or Tenofovir disoproxil fumarate|Patients would take entecavir 0.5 mg once per day, or tenofovir disoproxil fumarate 300 mg once per day
76084619|NCT01817777|Drug|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
75793292|NCT05849233|Other|no intervention|no intervention
75929387|NCT05581641|Biological|BNT165b1|RNA vaccine for active immunization against malaria administered as intramuscular injection
75929388|NCT05581641|Other|Placebo|Placebo
75929389|NCT05580783|Other|Test meal labelled with 54Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
75929390|NCT05580783|Other|Test meal labelled with 57Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
75929391|NCT05580783|Other|Test meal labelled with 58Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
76084620|NCT01817777|Drug|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
75929392|NCT05580744|Other|Traditional occupational therapy|Motor training targeted to goals that are relevant to the functional needs of the patient
76084621|NCT05576844|Behavioral|8-week interpersonal and social rhythm intervention|The development of the intervention strategies are based on social rhythm theory, interpersonal and social rhythm therapy, and previous research results, and the intervention aims to improve sleep by stabilizing participants' social rhythm and increasing the amount of interpersonal communication.
75793293|NCT05849220|Drug|Dapagliflozin|Dapagliflozin
75793294|NCT05849220|Other|Standard of Care|Standard of Care
75929393|NCT05580744|Other|Mirror therapy using a mirror box|Mirror therapy using a mirror box
75929394|NCT05580744|Other|Augmented reality-based mirror therapy|Augmented reality-based mirror therapy
75929395|NCT05580445|Drug|CT-707|Focal Adhesion Kinase (FAK) inhibitor
76084622|NCT05576844|Other|Usual care|Control group participants received usual care, including daily disease management and routine drug guidance.
76084623|NCT05617170|Other|Rehabilitation|"50 case of acute cerebrovascular stroke patients will subject to implanted early rehabilitation programme based on telemedicine if avilable .~50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques ."
76084624|NCT01693900|Procedure|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves.
76084625|NCT01693900|Procedure|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
76084626|NCT02516748|Behavioral|Feedback|Less experienced endoscopists in optical diagnosis will receive feedbacks about their own accuracy of optical diagnosis.
76084627|NCT01650844|Other|School-Based Telemedicine Enhanced Asthma Management|
76084628|NCT01650844|Other|Enhanced Usual Care|
76084629|NCT01795547|Drug|Aripiprazole and aripiprazole once-monthly|Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
76084630|NCT01795547|Drug|Paliperidone and paliperidone palmitate|Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
76084631|NCT01695304|Other|Ceramic water filter|In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
75335648|NCT01743872|Procedure|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
75645172|NCT04179747|Behavioral|Cognitive Behavioral Psychotherapy|The Cognitive Behavior Psychotherapy was provided for a period of maximum 3 months.
75472718|NCT01961973|Procedure|Cultured Chondrocytes|This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery.
75645173|NCT04179747|Drug|Sildenafil Citrate 50Mg Tab|The participants in control group arm received Sildenafil Citrate 50mg tablet on demand for a period of maximum 3 months.
75645174|NCT02600026|Device|DriveCam|Video event monitoring device
75645175|NCT02600026|Behavioral|Feedback|Video feedback intervention
75645176|NCT02675127|Drug|Daktavira|1 tablet contains 60 mg Daclatasvir
75645177|NCT02675127|Drug|Daklinza|1 tablet contains 60 mg Daclatasvir
75651915|NCT04708769|Behavioral|Smartphone App Participants (APP)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
75793295|NCT05848986|Other|Flow cytometry|Analysis of blood samples from a health sample's allergic patients and analysis with flow cytometry
75793296|NCT05848934|Device|magnetic resonance image|Imaging data were collected in a strong magnetic field
75793297|NCT05848934|Diagnostic Test|Neuropsychological scale|Multi dimensional neuropsychological test
75793298|NCT05848921|Device|magnetic resonance image|Imaging data were collected in a strong magnetic field
75793299|NCT05848921|Diagnostic Test|Neuropsychological scale|Multi dimensional neuropsychological test
75793300|NCT05848661|Device|AUDISSEE|AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.
75929396|NCT05580445|Drug|Toripalimab|Programmed Death 1(PD-1) antibody
75929397|NCT05580445|Drug|Gemcitabine|nucleoside inhibitor
75929398|NCT05579678|Behavioral|Supportive nursing, nutritional and physical activity with a handheld 'app'|Supportive nursing, nutritional and physical activity with a handheld 'app'
75929399|NCT05578274|Radiation|SBRT + LDRT|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV."
75645178|NCT04044716|Device|Auricular acupressure|Trained nurses in auricular acupressure will place acupressure beads on 5 acupoints on each ear (cingulate gyrus, thalamus, omega-2, point zero, and Shen Men). The nurse will do the initial activation of the acupressure site by applying pressure for 30 seconds to each point until the participant reports tingling or moderate degree of pressure. Participant will be given instructions to do this three times a day for a total of 5 days. Acupoints were selected based on recommendation of faculty acupuncturist.
75793301|NCT05848661|Device|Placebo|The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.
75929400|NCT05578274|Radiation|SBRT alone|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions."
75929401|NCT05575024|Device|oXiris membrane|Perform continuous renal replacement therapy with oXiris membrane
75929402|NCT05575024|Device|Polysulfone membrane|Perform continuous renal replacement therapy with polysulfone membrane
75929403|NCT05574075|Diagnostic Test|Diffusion tensor imaging|white matter imaging markers
75929404|NCT05569954|Biological|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
75929405|NCT05569954|Biological|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
75645179|NCT04044716|Other|Standard of care pain management|The participant post-operative pain will be managed following the standard protocol by the treating physician.
75929406|NCT05567744|Other|Registry|Registry
75929407|NCT05566600|Biological|Human (allogeneic) iPS-cell-derived cardiomyocyte|10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium
75645180|NCT05494749|Other|zirconomer|teeth meeting the inclusion criteria are assigned to receive Zirconomer® restorations
75645181|NCT05494749|Other|HVGI-Equia Forte|teeth meeting the inclusion criteria are assigned to receive HVGI-Equia Forte® restorations.
75645182|NCT02675283|Device|Simtomax|Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
75645183|NCT02675205|Drug|Clopidogrel|clopidogrel: efficacy and safety in cerebral aneurysm stenting
75645184|NCT02675205|Drug|Ticagrelor|ticagrelor:efficacy and safety in cerebral aneurysm stenting
75645185|NCT02675205|Drug|aspirin|
75645186|NCT04041284|Drug|Fremanezumab|Monthly 225 mg subcutaneous
75645187|NCT04041284|Drug|Placebo|Matching Placebo
75645188|NCT00753454|Drug|Certolizumab pegol|Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 & Week 4, followed by 200 mg every 2 weeks).
75645189|NCT05277129|Other|Analysis of post-stroke immune responses|Analysis of immune responses in peripheral blood
75645190|NCT02675361|Behavioral|Transition program|Participants will be part of a transition program with eight key components: 1. A transition coordinator; 2. Education on congenital heart disease (CHD), treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the Grown-Up Congenital Heart Disease (GUCH) program: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Transfer to Grown-Up Congenital Heart Disease clinic. The intervention will be implemented by specialized nurses at the outpatient clinic of pediatric cardiology. Overall, 60 to 90 minutes per patient are spent over the 2.5 years.
75645191|NCT00976274|Dietary Supplement|Korean red ginseng|5 capsules (300 mg/capsule) three times everyday for 12 weeks
75645192|NCT00976274|Dietary Supplement|starch|5 capsules three times everyday for 12 weeks
75645193|NCT00643461|Device|Adhesive A|Applied per manufacturer's instructions.
75645194|NCT00643461|Device|Adhesive B|Applied per manufacturer's instructions.
75645195|NCT00643461|Device|Adhesive C|Applied per manufacturer's instructions.
75793302|NCT05848635|Drug|Hydromorphone Hydrochloride|Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation
75793303|NCT05848635|Drug|Morphine hydrochloride|Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation
75793304|NCT05848609|Diagnostic Test|Geriatric Assessment|Geriatric assessment to evaluate cognitive function, functional status and quality of life before and after surgery
75793305|NCT05848570|Other|Keeping it LITE|observational cohort only
75929408|NCT05562622|Device|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
75929409|NCT05562622|Device|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
75929410|NCT05562271|Radiation|low-dose radiation therapy|low-dose radiation therapy to involved knee joint
75645196|NCT02863016|Device|SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
75793306|NCT05848544|Dietary Supplement|Very low-calorie ketogenic diet for patients with symptomatic knee osteoarthritis|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
75793307|NCT05848544|Dietary Supplement|Very low-calorie ketogenic diet for patients with fibromyalgia|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
75793308|NCT05848531|Drug|Clonidine|Comparing Clonidine with Morphine PCIA for the treatment of Vaso-Occlusive crisis in Sickle Cell disease patient
75793309|NCT05848505|Drug|Dexmedetomidine|Intranasal administration Dosage 2 mcg/kg
75793310|NCT05848492|Drug|Fluconazole|Fluconazole will be given for prevention of invasive candidiasis in preterm and very low birthweight babies.
75793311|NCT05848492|Drug|Saline|0.9% Saline 2cc intravenous will be given to preterm babies in placebo group.
75929411|NCT05562271|Radiation|sham radiation therapy|sham radiation therapy to involved knee joint
75929412|NCT05552898|Dietary Supplement|Sleep Study Product Usage|Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
75929413|NCT05551403|Device|Eyes-closed rest-EEG registration|Recording of spontaneous brain activity while eyes are shut for the duration of 7 minutes using a tablet with instructions
75929414|NCT05551403|Device|Transcranial Magnetic Stimulation during EEG and EMG registrations|Recording of TMS-evoked EEG and EMG responses according to various stimulation protocols
75929415|NCT05551403|Device|Photic stimulation during eyes-closes EEG registration|Recording of visual evoked potentials in the EEG during flash stimulation by light-emitting diode (LED) goggles (while eyes are closed)
75929416|NCT05541380|Other|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
75929417|NCT05537636|Other|Rehabiltiation using exercise and manual therapy|"A licensed Physical Therapist will provide manual therapy to help restore spinal and scapular mobility. In association with this patients will be prescribed home exercises using a phased approach.~Phase 1 to gain mobility of the spine and scapular motor control Phase 2 to gain shoulder mobility to strengthen scapular and spine musculature Phase 3 shoulder strengthening with long lever arms."
75793312|NCT05848466|Drug|BAT8010 for Injection|Intravenous
75929418|NCT05537038|Biological|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
75793313|NCT05848401|Device|Biosound Therapy System|Biosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content.
75793314|NCT05848388|Other|Molar incisor malformation presence|the presence of radiographic features of molar incisor malformation
75793315|NCT05848362|Other|Blood Glucose Measurement Values Taken by Different Methods|"In total, blood samples will be collected from 3 different sites (central venous catheter, capillary, arterial catheterization) in the same patient. In total, with 5 different techniques from 3 different regions from the same patient;~ARTERIAL BLOOD SAMPLE i) Washing with 5 cc 1% Heparin fluid ii) Washing with 10 cc 1% Heparin fluid CAPILAR BLOOD SAMPLE iii) Right / Left Fingertip iv) Thumb base CENTRAL VENOUS CATHETERIZATION BLOOD SAMPLE will be collected."
75929419|NCT05537038|Biological|BNT164b1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
75929420|NCT05537038|Other|Placebo|Placebo
76084632|NCT03920826|Device|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
76084633|NCT03920826|Device|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
76084634|NCT01794923|Drug|IBU BID|10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
75645197|NCT00643539|Drug|Zithromax|azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
75645198|NCT00643539|Drug|Clamoxyl|Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
75793316|NCT05848336|Behavioral|Gluten Free Casein Free Diet|Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).
75929421|NCT05536453|Device|Lumbar Interbody Fusion Devices|Posterior Lumbar Interbody Fusion device placed to treat symptoms associated with degenerative disc disease
75929422|NCT05533814|Drug|Perampanel|Perampanel tablets.
75929423|NCT05519059|Drug|Pelareorep|Pelareorep at 1.5×10^10 TCID50, 3×10^10 TCID50, 4.5×10^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m^2 on Day 1/8/15 per cycle
75929424|NCT05516953|Drug|Baclofen Tablets|10 mg oral baclofen 1 h before anesthesia
75929425|NCT05516524|Diagnostic Test|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
75929426|NCT05516524|Diagnostic Test|PSG|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
76084635|NCT01794923|Drug|Placebo BID|10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
76084636|NCT01794923|Drug|IBU TID|10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
76084637|NCT01794923|Drug|Placebo TID|10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
75335649|NCT01743872|Procedure|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
75335650|NCT01743872|Procedure|Heparinized Normal Saline Injection|Media #4: Heparinized Normal Saline (Heparin NS) will be hand injected using 20 mL (2 U/mL) in antegrade fashion.
75335651|NCT00002680|Biological|filgrastim|
75335652|NCT00002680|Drug|cyclophosphamide|
75472719|NCT01961973|Procedure|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
75645199|NCT00759148|Drug|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%|Eye drops
75645200|NCT00759148|Other|Moxifloxacin AF Vehicle|Inactive ingredients used as a placebo for masking purposes
75645201|NCT02864810|Drug|[18F]GP1|[18F]GP1 PET/CT imaging for detecting thromboembolism
75645202|NCT00910065|Drug|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
75793317|NCT05848284|Device|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
75645203|NCT00910065|Drug|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
75793318|NCT05848245|Device|Suction|Dental sections are used to absorb aerosol particles generated when using dental instrument such as ultrasonic and high air driven handpieces, this aerosol is mixture of blood, saliva, infectious agents, and dental materials.
75793319|NCT05848102|Drug|dapagliflozin|FORXIGA（Dapagliflozin Tablets), manufacturer/marketer: AstraZeneca, salt composition: Dapagliflozin (10mg), one tablet once and once a day.
75929427|NCT05515419|Biological|Allogeneic cord blood treatment|Allogeneic cord blood treatment
75335653|NCT00002680|Drug|megestrol acetate|
75929428|NCT05513859|Procedure|Craniotomy|Undergo craniotomy
75929429|NCT05513859|Device|Quantitative Oblique Back-Illumination Microscopy|Undergo intraoperative microscopy utilizing qOBM
75335654|NCT00002680|Drug|melphalan|
75335655|NCT00002680|Drug|tamoxifen citrate|
75645204|NCT00910065|Drug|Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet|Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
75645205|NCT02601040|Biological|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-16 years \6.50 lgCCID50/ml in adults aged 17 up to 65 years old
75645206|NCT02601040|Biological|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \320EU/Vial in children aged 3-16 years \640EU/Vial in adults aged 17 up to 65 years old\boost at month 6\two-dose
75645207|NCT02601040|Biological|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
75645208|NCT04288934|Biological|Collection and expansion of BM-MSC|MSCs collection from patients owns marrow using a volume of 20 ml of bone marrow obtained from iliac crest of SCI patients under local anesthesia. Manipulations of blood and bone marrow are to be done according to Good Laboratory Practice (GLP) using the gradient sedimentation method.
75929430|NCT05512689|Device|Ventilations while using a respiratory function monitor|Healthcare professionals are able to use a feedback device to guide their ventilations.
75929431|NCT05511818|Dietary Supplement|Rest Study Product Usage|Participants will use their Radicle Rest study product as directed for a period of 4 weeks.
75335656|NCT00002680|Drug|thiotepa|
75335657|NCT00002680|Procedure|conventional surgery|
75335658|NCT00002680|Procedure|peripheral blood stem cell transplantation|
75335659|NCT00002680|Radiation|radiation therapy|
75335660|NCT00002692|Drug|fluorouracil|
75335661|NCT00002692|Drug|isolated perfusion|
75335662|NCT00002692|Drug|leucovorin calcium|
75335663|NCT04747340|Behavioral|Training for Awareness Resilience and Action (TARA)|See arm-description
75335664|NCT04747340|Other|Standard treatment|See arm-description
75335665|NCT00382486|Procedure|Reduce the risk of allograft rejection|
75335666|NCT05293210|Drug|Dexamethasone|"A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.~Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily)."
75335667|NCT01895348|Drug|Propofol|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
76084638|NCT02517138|Other|Parabolic flight|
76084639|NCT02517138|Other|Measurements of eye movements and perception|
76084640|NCT02516514|Procedure|Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia|Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
76084641|NCT02516904|Drug|CD101 IV|antifungal
76084642|NCT02516904|Drug|Placebo|normal saline
75335668|NCT01895348|Drug|propofol-remifentanil|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
75793320|NCT05848037|Device|cymactiv catheter device|A new type of catheter has recently been submitted for CE marking as a Class IIb device and will soon be available in the UK market. Ingenion Medical's cymactive™ Catheter is designed to remain in situ for up to 30 days, does not extend outside the patient's body and has an integral, magnetically controlled valve that allows the user to control their own urination. The patient will be supplied with their own magnet so they are in control of valve and their own voiding. The magnet is strong and care will need to be taken to keep it at least 6 inches from magnetically-sensitive items.
75793321|NCT05848037|Device|Foley-type catheter device|Routine standard of care
75335669|NCT01895348|Drug|Dexmedetomidine-remifentanil|Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
75335670|NCT05292040|Drug|LY3857210|Administered orally.
75335671|NCT05280184|Behavioral|Coin2Dose|Behavioral Economics incentive intervention that also combines automated text message reminders to dose for insulin
75645209|NCT04288934|Diagnostic Test|VI-SCI evaluation and patients' follow up|"At 6, and 12 months post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline.~The (ASIA)/(ISNCSCI) score will be repeated every 3 months to evaluate any motor or neurological changes~The Spinal Cord Independence Measure (SCIM III) score will be repeated every 3 months to evaluate the effect on daily activities.~Blood samples will be withdrawn from patients at 3 months interval for biomarkers detection."
75645210|NCT02864966|Device|Condom|This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.
75793322|NCT05847998|Device|Standardized measurement of capillary refill time by second generation DICART prototype|"Capillary refill time is measured by two independent operators, each one blinded from the other, with second generation DICART prototype.~Each operator performs two series of three consecutive measurement on the finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax"
76084643|NCT03346044|Device|Carpentier-Edwards SAV bioprostheses|Performance of these bioprostheses
76084644|NCT03346044|Device|Medtronic Mosaic bioprostheses|
76084645|NCT04502940|Diagnostic Test|Flow Cytometric analysis|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups
76084646|NCT03347604|Diagnostic Test|Supine spirometry, MIPs and MEPs|We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
76084647|NCT01794845|Drug|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
76084648|NCT01794845|Drug|Taxotere|Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
76084649|NCT01794845|Radiation|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
75335672|NCT04271852|Device|bio-feedback treatment|50 patients will treated with phenix u2 and phenix u4 treating equipment。
75335673|NCT05278546|Drug|ILB2109|ILB2109 tablets by mouth once per day at dosages prespecified by the protocol
75335674|NCT04784078|Procedure|Coronary Angiography and Intervention|Transradial access puncture site
76084650|NCT01794689|Drug|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
76084651|NCT01794689|Drug|Saline Placebo|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
75335675|NCT05073718|Drug|Low-dose acetylsalicylic acid|In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
75335676|NCT05073718|Drug|Placebo|Placebo
75472720|NCT01961999|Procedure|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours"
75472721|NCT01961999|Procedure|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (<0,5ml/Kg/h >12h), despite therapy refractory extravascular fluid overload azotemia >40mmol/L or 240mg/dL metabolic acidosis (pH<7,2) hyperkaliemia (k+>6mmol/L)"
75472722|NCT01962012|Device|AcceleDent Aura|
75472723|NCT01962012|Device|Sham Device|
75472724|NCT01962038|Behavioral|Combined Aerobic and Resistance Exercise|Gym and home based aerobic and resistance exercises
75472725|NCT01962038|Behavioral|Stretching Exercises|Gym and home based stretching exercises
75472726|NCT01962038|Behavioral|Cognitive Training|Group-based cognitive training
75472727|NCT01962051|Device|Amplatzer Cardiac Plug|
75472728|NCT01962064|Behavioral|Cognitive assessment|
75472729|NCT01962064|Other|Brain imaging examination MRI|
75472730|NCT01962077|Procedure|MedCem MTA pulpotomies in primary teeth.|
75645211|NCT04179435|Behavioral|Behavioral testing on cognitive computerized tasks|Testing on cognitive computerized tasks
75645212|NCT04179435|Other|brain MRI|Brain MRI scans
75645213|NCT04179435|Other|TMS|Measure of the cortical inhibitory capacity using TMS measures
75335677|NCT04784000|Drug|Period 1: AT-527 550 mg|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1
75929432|NCT05506241|Device|Dynavision D2|Use of the Dynavision will be comprised of six 3-minute or nine 2-minute sessions with 30 seconds to one-minute rest in between. All Dynavision sessions require clients to scan the 4' by 4' vertical board and hit the lit targets one at a time. Participants will be able to depress targets with their left or right hand, in standing or sitting.
75645214|NCT04270916|Diagnostic Test|High frequency pure tone audiometry|Hearing test carried out routinely, non invasive
75335678|NCT04784000|Drug|Period 2: carbamazepine|Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25
76084652|NCT01794689|Behavioral|Forced Awakenings|Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
75335679|NCT04784000|Drug|Period 3: AT-527 550 mg + carbamazepine|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
75645215|NCT04179513|Biological|GB224 10mg|"10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10~15 mg/week), oral administration, a total of 32 doses."
75335680|NCT04784000|Drug|Period 3: AT-527 1100 mg + carbamazepine|AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
75645216|NCT04179513|Biological|GB224 20mg|"20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10~15 mg/week), oral administration, a total of 32 doses."
75793323|NCT05847998|Diagnostic Test|Clinical measurement of capillary refill time|"Capillary refill time is clinically measured by two independent operators, each one blinded from the other.~Each operator performs, two series of three consecutive measurement on the second finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax, inverted relative to DICART measurements."
75335681|NCT05271292|Drug|Chiauranib|"Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles"
75335682|NCT04783688|Other|Full Face Snorkel Mask (FFSM)|A mask used for snorkeling that covers the entire face, as opposed to a conventional snorkel, which is held in the mouth only.
75472731|NCT01962090|Other|Thoracic Spine Thrust in Seated Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
75645217|NCT02863640|Device|Color retinography|
75645218|NCT02863640|Device|Optical coherence tomography|
75645219|NCT02863640|Device|Fundus autofluorescence imaging|
75645220|NCT05460507|Drug|Retreatment Rhenium Liposome|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
75645221|NCT02865044|Other|Wax Ester Marine Oil|Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules) consumed once, in clinic, at t=0.
75645222|NCT02865044|Other|Ethyl Ester Marine Oil|Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule), consumed once, in clinic, at t=0
75645223|NCT02675049|Drug|0.9% saline|0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
75793324|NCT05847972|Procedure|MWM (Mobilization with movement)|This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.
75929433|NCT05503108|Other|Fasting Mimicking diet program|Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
75929434|NCT05502900|Drug|Melatonin|White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
75929435|NCT05502328|Dietary Supplement|Energy Study Product Usage|Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
76084653|NCT01794689|Behavioral|Uninterrupted Sleep|Participants will receive an 8 hour period of undisturbed sleep
76084654|NCT01794299|Biological|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
76084655|NCT01817075|Procedure|Chlorhexidine Gluconate Skin Cleanser|Given CHG cleansing
76084656|NCT01817075|Other|Laboratory Biomarker Analysis|Correlative studies
76084657|NCT01817075|Procedure|Mild Soap Skin Cleanser|Given control cleansing
76084658|NCT01817075|Other|Questionnaire Administration|Ancillary studies
76084659|NCT01816763|Behavioral|NRS pain one week|Eligible patients will be randomly assigned to complete a patient-reported 'NRS one week' on a tablet prior to making contact with a nursing staff vital signs screener.
75645224|NCT02675049|Drug|dexmedetomidine 1µg.kg-1|dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
75645225|NCT02675049|Drug|dexmedetomidine 1.5µg.kg-1|Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
75335683|NCT05261620|Dietary Supplement|red wine|Subjects in the intervention arm (SoC+WISE) will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men. Total polyphenolic contents and antioxidant activity (Folin-Ciocalteu method with calibration curve in gallic acid), antioxidant/radical scavenger capacity [DPPH (2,2-diphenyl-1-picrylhydrazyl) test] and phenolic profiles [HPLC (High Performance Liquid Chromatography)/DAD (diode-array detector) /ESI-MS (Electrospray Ionisation Mass Spectrometry) analysis] will be performed for wine selection for the clinical trial.
75793325|NCT05847972|Device|Plantar orthoses|"Procedure: MWM All participants will undergo MWM. This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.~Procedure: Plantar orthoses The moulds will be taken immediately after the manipulation. The PO will be made of resin (0.8mm +1.2mm), 2mm hard EVA heel stabiliser, 3mm semi-hard EVA cover. The PO should be worn for 3 months to obtain the results of the study."
75793326|NCT05847959|Drug|Traditional Chinese medicine prescription：XinKang-I|XK-I will be used in intervention group (20 grams of radix astragalus, 20 grams of radix codonopsis, 10 grams of stir-fried semen lepidii, 8 grams of sweet apricot kernel, 10 grams of cassia twig, 15 grams of poria cocos, 10 grams of atractylodes, 5 grams of honey-roasted licorice, 15 grams of radix et rhizoma salviae miltiorrhizae, 10 grams of chuanxiong rhizoma, 5 grams of tangerine peel).Patients will take XK-I once a day, divided into morning and evening administration. The treatment lasted for 8 weeks.
75793327|NCT05847907|Device|Implant placement|Implant placement in subject with type 2 diabetes mellitus. Implant placement in subjects with type 2 diabetes mellitus. Implants with BA surface will be placed in one group of subjects and implants with SA surface in the other group.
75335684|NCT04783844|Diagnostic Test|Virtual modelization.|3D-MSP technology is used to make virtual 3D models based on conventional CT.
75335685|NCT01113476|Drug|Nab-paclitaxel|Starting dose of 50 mg/m^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
75335686|NCT01113476|Drug|Bevacizumab|Starting dose of 5 mg/m^2 on Day 1 + 15 every 28 days (+/- 2 days)
75335687|NCT01113476|Drug|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
75645226|NCT02675049|Drug|Dexmedetomidine 2µg.kg-1|dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
75645227|NCT04179279|Device|Gili Biosensor System (Gili Pro Biosensor)|Non-contact monitoring of heart and respiratory rates using an optical device
75645228|NCT02794285|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
75645229|NCT02794285|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
75645230|NCT00643695|Behavioral|Home-based walking program|The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.
75645231|NCT00643695|Other|Educational intervention|Participants in the control group will receive a packet of information regarding hepatitis C
75645232|NCT02674737|Drug|dexmedetomidine, tramadol and flurbiprofen|
75793328|NCT05847881|Behavioral|Self-guided at home activities|After the kick-off meeting participants will complete the cultural probe kit for 3 weeks. This kit is a design research tool, to prompt participants to document, map, journal, and reflect on various aspects of daily lives. Following this, participants will attend a facilitated workshop and then complete the next at-home kits.
75929436|NCT05500196|Device|Per Oral Endoscopy Myotomy (POEM)|POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to reach the inner circular muscle bundles of the LES to perform myotomy, while preserving the outer longitudinal muscle bundles. The result is decreased resting pressure of the LES, facilitating the passage of ingested material.
75936423|NCT04921865|Device|DPS VA-LCP® Clavicle Plate 2.7 System; DPS VA-LCP® Clavicle Hook Plate 2.7 System|"The DPS VA-LCP® Clavicle Plate 2.7 System is indicated for the fixation of clavicle bone fragments. The system consists of three plate types: lateral, shaft, and medial, each available in different sizes and materials (titanium alloy and stainless steel). Each plate is available in left and right.~The DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 System is indicated or the fixation of lateral clavicle fractures and AC joint dislocations. The Clavicle Hook Plate system consists of three plate types: long, short and button plates."
75335688|NCT01718600|Behavioral|Neuropsychological testing|
75335689|NCT04839718|Behavioral|ADAPT|The Achieving Depression and Anxiety Patient Centered Treatment (ADAPT) Program is a novel collaborative psychiatric care model that is designed to unburden PCPs and psychiatrists, increase access to quality specialty mental healthcare for Kaiser Permanente members, and improve patient depression and anxiety treatment outcomes by utilizing technology-driven appointments. This program uses principles of collaborative care, including patient-centered care, population-based care, evidence-based care, measurement-based treatment to target, and accountable care.
75335690|NCT04783766|Drug|CK-3773274|CK-3773274- Tablets
75335691|NCT04783766|Drug|Placebo|Placebo- Tablets
75335692|NCT01107236|Drug|IW-6118|Single dose
75335693|NCT01107236|Drug|Matching Placebo|Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
75335694|NCT01107236|Drug|Naproxen Sodium|Single dose
75335695|NCT00002704|Biological|filgrastim|
75472732|NCT01962090|Other|Thoracic Spine Thrust in Supine Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
75472733|NCT01962116|Drug|Citrate 4%|
75472734|NCT01962116|Drug|unfractionated heparin|
75472735|NCT01962129|Biological|Sampling of blood|
75472736|NCT01962142|Other|Assessment of activity capacities|
75472737|NCT01962168|Device|Evolution® Biliary Stent - Uncovered|Commercially available device
75472738|NCT01962181|Drug|Ritalin|Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
75645233|NCT02674737|Drug|tramadol and flurbiprofen|
75645234|NCT02674893|Drug|Liraglutide|
75645235|NCT02674893|Other|Observation alone|
75793329|NCT05847868|Device|Moment Tumour Hip Prothesis|"In the case of irreversible bone loss due to bone tumors, large and multi-part fractures, and pseudarthrosis in the proximal region of the femur bone, the defective bone area is removed and implants made of artificial materials are placed in order to replace the integrity of the bone. In addition, implant applications are made to the proximal femur region for the purpose of revision arthroplasty, which is typically replaced by total hip prosthesis depending on the wear condition.~In this way, the bone integrity will be preserved, long-term stabilization will be provided to the patient and existing pain will be eliminated.~Moment Tumor Hip Replacement Systems consist of proximal main body, extension pieces and intramedullary stems. Components are available in a variety of sizes to meet anatomical requirements and surgeon needs."
76084660|NCT01816763|Behavioral|PEG|Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.
76084661|NCT01816763|Behavioral|DVPRS|Eligible patients will be randomly assigned to complete a patient-reported 'DVPRS' on a tablet prior to making contact with a nursing staff vital signs screener.
76084662|NCT04578353|Device|The AquaPass System|The AquaPass device is a capsule that creates relatively homogenous temperature around the patients' lower body, while controlling and maintaining at a low percentage the relative humidity within the capsule thus enabling controlled environment that enhances sweat rate.
76084663|NCT01816685|Device|CPAP|
76084664|NCT01653028|Drug|Alisertib|Given PO
76084665|NCT01653028|Other|Laboratory Biomarker Analysis|Correlative studies
76084666|NCT00708552|Drug|SB-742457|investigational drug
75335696|NCT00002704|Drug|asparaginase|
75645236|NCT02674815|Other|High Intensity Interval Training Exercise programme|High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
75645237|NCT02717455|Drug|LBH589|"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."
75645238|NCT00643773|Dietary Supplement|Leucine|capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
75793330|NCT05847855|Diagnostic Test|Fragmentomic profiles of plasma cfDNA|Blood collection and early detection testing based on fragmentomic profiles of plasma cfDNA
75335697|NCT00002704|Drug|cyclophosphamide|
75335698|NCT00002704|Drug|daunorubicin hydrochloride|
75335699|NCT00002704|Drug|dexamethasone|
75645239|NCT00643773|Dietary Supplement|Wheat flour|Wheat flour
75645240|NCT02674425|Device|Dark Adaptometer|
75793331|NCT05847842|Procedure|Anterior quadratus lumborum block|20 mL of 0.25% bupivacaine will be given
75929437|NCT05489172|Behavioral|Hola Bebe|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
76084667|NCT00708552|Drug|Donepezil|comparator
76084668|NCT00708552|Drug|Placebo|comparator
76084669|NCT02516436|Drug|BEMA Buprenorphine NX|Buprenorphine with naloxone
76084670|NCT02516436|Drug|Buprenorphine|Buprenorphine
75335700|NCT00002704|Drug|etoposide|
75335701|NCT00002704|Drug|leucovorin calcium|
75335702|NCT00002704|Drug|liposomal cytarabine|
75335703|NCT00002704|Drug|mercaptopurine|
75335704|NCT00002704|Drug|mesna|
75335705|NCT00002704|Drug|methotrexate|
75335706|NCT00002704|Drug|therapeutic hydrocortisone|
75335707|NCT00002704|Drug|thiotepa|
75335708|NCT00002704|Drug|vincristine sulfate|
75335709|NCT00002704|Radiation|low-LET electron therapy|
75472739|NCT01962181|Drug|Placebo|
75645241|NCT00729391|Behavioral|Woman-Focused Intervention (Women's Health CoOp)|Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
75645242|NCT00729391|Behavioral|Nutrition (Attention-Control)|Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
75335710|NCT00002704|Radiation|low-LET photon therapy|
75335711|NCT00002716|Drug|dexamethasone|
75335712|NCT00002716|Drug|floxuridine|
75645243|NCT00729391|Behavioral|VCT Only|Participants in this group will receive VCT only.
75793332|NCT05847842|Procedure|Transversus abdominis plane block|20 mL of 0.25% bupivacaine will be given
75793333|NCT05847842|Procedure|Local infiltration|20 mL of 0.25% bupivacaine will be given
75335713|NCT00002716|Drug|fluorouracil|
75335714|NCT00002716|Drug|leucovorin calcium|
75335715|NCT00002716|Procedure|laparotomy|
75335716|NCT00002716|Procedure|conventional surgery|
75472740|NCT01962194|Device|Deep Brain Stimulation|"In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, Activa PC+S, which has therapy equivalent to Activa PC, and has a new sensing programmer."
75645244|NCT02674581|Drug|Oral BMS-663068 (pro-drug)|Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
75929438|NCT05484414|Drug|SRP-3D (diethylamide)|SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
75929439|NCT05484414|Drug|Placebo|Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
75929440|NCT05475002|Other|care empowerment program|dementia care e-books, dementia virtual reality activity and family support group
76084671|NCT03347526|Drug|Cosyntropin Injectable Suspension, 1 mg/mL|Injectable
75929441|NCT05475002|Other|dementia education|dementia education manual and family support group
75936424|NCT02434640|Drug|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
76084672|NCT03347526|Drug|Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin|Injectable + oral solution
76084673|NCT03347526|Drug|Vigabatrin|oral
75335717|NCT02533674|Drug|Gemcitabine plus PM060184|
75335718|NCT04756544|Dietary Supplement|Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175|probiotic
75335719|NCT04756544|Other|placebo|placebo
75335720|NCT00002722|Drug|cisplatin|
75335721|NCT00002722|Drug|fluorouracil|
75335722|NCT00002722|Drug|leucovorin calcium|
75335723|NCT00002734|Biological|recombinant interferon alfa|
75335724|NCT00002734|Drug|chemotherapy|
75645245|NCT04065919|Drug|Liposomal bupivacaine|20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
75793334|NCT05847816|Other|Experimental group: infrared vascular imaging|"Experimental group - infrared vascular imaging;Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - isometric hand exercise; Stress balls will be given to patients 10 minutes before the PIVC procedure and they will be asked to perform hand-clamping exercises with both hands. Processing will then begin."
75793335|NCT05847803|Other|No intervention, questionnaire survey|No intervention, questionnaire survey
76084674|NCT03742752|Other|Enteral nutrition|administration of enteral nutrition
76084675|NCT03742752|Other|Parenteral nutrition|administration of parenteral nutrition
76084676|NCT02516280|Device|Cryoton ™|In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.
76084677|NCT02516280|Device|Control ice bag|In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
75335725|NCT00002734|Drug|paclitaxel|
75645246|NCT04065919|Drug|0.25% Bupivacaine with epinephrine|0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
75645247|NCT02674347|Drug|3 g or 6 g Zidebactam|IV for over a duration of 60 minutes
75793336|NCT05847777|Radiation|CBCT|cone beam computer tomography
75793337|NCT05847764|Drug|RC48+Tislelizumab+carboplatin|RC48+PD-1/PD-L1 inhibitor+chemo in treatment-naive patients harboring HER2 alterations
75335726|NCT00002734|Drug|topotecan hydrochloride|
75335727|NCT00002734|Radiation|lutetium Lu 177 monoclonal antibody CC49|
75335728|NCT00002734|Radiation|yttrium Y 90 monoclonal antibody CC49|
75335729|NCT04783610|Other|Ethanol|Ethanol will be administered via oral route.
75645248|NCT02674347|Drug|Placebo|IV matching the Investigational drug
75645249|NCT04065529|Combination Product|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
75645250|NCT04065529|Combination Product|placebo + ORS + Zinc supplementation|placebo + ORS + Zinc supplementation
75645251|NCT04179045|Device|The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.
75645252|NCT00731419|Device|SEMS|Comparing plastic and metal stents
75645253|NCT02674269|Drug|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
75793338|NCT05847764|Drug|RC48+Furmonertinib, 1L|RC48+Furmonertinib in treatment-naive patients harboring EGFR mutations as well as HER2 alterations
75936425|NCT02434640|Drug|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
75936426|NCT02434640|Drug|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
75335730|NCT00002740|Biological|filgrastim|
75335731|NCT00002740|Drug|carboplatin|
75335732|NCT00002740|Drug|cyclophosphamide|
75335733|NCT00002740|Drug|doxorubicin hydrochloride|
75335734|NCT00002740|Drug|etoposide|
75335735|NCT00002740|Drug|mesna|
75645254|NCT02674269|Drug|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
75645255|NCT02674269|Device|TC-3 Gel|Intravesical instillation of 60 ml TC-3 gel
76084678|NCT03347370|Drug|SC Peginterferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics [SmPC]).
76084679|NCT03347370|Drug|SC interferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics [SmPC]).
76084680|NCT03347370|Drug|SC interferon beta-1b|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.
76084681|NCT02516124|Procedure|Autologous HSCT|1st AHSCT
76084682|NCT02515968|Drug|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
76084683|NCT02515968|Drug|Propofol|
76084684|NCT03345966|Diagnostic Test|Bmi-1 antibody|B-lymphoma Moloney murine leukemia virus insertion region-1
75793339|NCT05847764|Drug|RC48+Furmonertinib, 2L+|RC48+Furmonertinib in patients who failed at least one line of standard treatment and harboring HER2 alterations
76084685|NCT03345888|Other|predictive power of end-tidal carbon dioxide|end-tidal carbon dioxide predicts resuscitation outcomes
75335736|NCT00002740|Drug|vincristine sulfate|
75335737|NCT00002740|Procedure|conventional surgery|
75335738|NCT00002740|Procedure|peripheral blood stem cell transplantation|
75645256|NCT00731497|Device|Solar Water Disinfection (SODIS)|Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
75645257|NCT00643929|Drug|Eltrombopag|Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
75335739|NCT00002740|Radiation|low-LET cobalt-60 gamma ray therapy|
75335740|NCT00002740|Radiation|low-LET photon therapy|
75335741|NCT00002746|Biological|aldesleukin|
75793340|NCT05847738|Behavioral|Pain assessment|Pain was assesd postoperatively in both groups at time intervals
75793341|NCT05846685|Other|Patient Phone Interviews|Collecting perceptions about automated falls-risk screening and referral tool
75793342|NCT05846685|Other|Patient In Person Interviews|Interviews will be aimed at collecting patient input necessary to adapt the design of the intervention at these sites.
75793343|NCT05846607|Dietary Supplement|Intervention oral supplement|The oral supplement used as intervention for the study will be DongzheSutang(DAISY FSMP,Jiangsu,China). The formula contains only carbohydrate:12.5g in 100ml of product(glucose syrup and maltodextrin)，with a caloric density of 16.32kcal/g.
75793344|NCT05846555|Procedure|urologic surgery|surgery
75793345|NCT05846503|Behavioral|1. Quality and info management system|"The intervention package prioritizes information and quality management with a focus on HTN screening, diagnosis, and treatment. From the point-of-care, flow charts placed in the patient file will ensure that vitals are performed in accordance with national guidelines.~The care coordinator will present data to clinic staff in multi-disciplinary meetings, providing an opportunity for programmatic feedback and discussion.~Patients will be encouraged to complete the vital signs measurements at each clinic visit. They will be provided with their BP readings and given info about what their reading means. They will be issued with pocket sized color coded booklets providing info on the measurement and what to do to control their BP.~Task shifting: A care coordinator will be the champion of the intervention package for the clinic.~All staff will receive apt training on how to use the patient flow chart, info management system and how to respond to abnormal BP values."
75793346|NCT05846490|Device|CPAP|Continuous positive airway pressure
75645258|NCT00735631|Device|SISO model-based predictive closed-loop system|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
75645259|NCT00970268|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
75645260|NCT00970268|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
75793347|NCT05846477|Device|MySpine|patient specific guide for screw positioning
75793348|NCT05846464|Device|Meta Quest 2|The Meta/Oculus Quest (along with the SignWave software) delivers an immersive audio/visual-based game environment where the users hand is created and displayed in the virtual environment and matches target gestures to the beat of the music.
75335742|NCT05073406|Other|Altitude exposure in hypobaric normoxic condition|Altitude exposure with oxygen supplementation to achieve normoxia at altitude
75645261|NCT00729547|Behavioral|Neurofeedback|enhance relative activity level of left frontal activity
75645262|NCT00729547|Behavioral|Psychotherapy placebo|These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
75645263|NCT02673957|Other|Blood pressure cuff protocol|4 cycles of pneumatic blood pressure cuff inflation to 200mmHg for 5 minutes followed by 5 minutes of deflation. Each subsequent cycles commences as soon as the previous cycle is completed.
75793349|NCT05846438|Other|Showering 48 hours after surgery|Our main intervention is allowing patients to shower 48 hours after surgery
75793350|NCT05846412|Other|Catheter Ablation and M-TEER|Already included in arm descriptions.
75793351|NCT05846386|Behavioral|Resistance training|moderate-intensity resistance training: three sessions per week for one month. Participants had been instructed to perform exercises at a 4:2:4 tempo; that is, four sets of concentric contraction, two sets of isometric hold, and four sets of eccentric contraction. Participants had been instructed to complete a single set until volitional fatigue or been instructed to stop by the physiotherapist when the technique falters
76084686|NCT03347136|Device|CPAP|
76084687|NCT03347136|Device|NIPPV|
76084688|NCT03346356|Behavioral|Teenagers as cross-age SHCP teachers for younger youth|Implementation of the SHCP using teenagers as cross-age teachers for younger youth
76084689|NCT03122574|Other|Lavender Aromatherapy|100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
75335743|NCT05073406|Other|Altitude exposure in hypobaric hypoxic condition|Altitude exposure with air supplementation to obtain a sham comparator arm
75335744|NCT01662024|Device|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
75335745|NCT04783298|Other|App|An application to deliver a series of behavioral questionnaires and decision-making game
75335746|NCT01049945|Drug|bendamustine hydrochloride|Given IV
75335747|NCT01049945|Drug|lenalidomide|Given orally
75335748|NCT01049945|Drug|dexamethasone|Given orally or IV
75335749|NCT00002752|Radiation|iodine I 131 monoclonal antibody 81C6|
75335750|NCT04500080|Behavioral|PE Intervention|"Each single exercise session will last for one hour and will consist of a combination of the following elements:~Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities"
75335751|NCT01050647|Drug|17-Hydroxyprogesterone Caproate|Weekly injections of 17-hydroxyprogesterone caproate.
75645264|NCT00729625|Device|robotic device|"The device has a small air muscle that when activated will slowly lift their fingers and wrist from your resting wrist position. This device is classified as a non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient should not experience any pain or discomfort during this stretching activity. If they do experience any pain or discomfort they can activate a stop switch located on the control box with their unimpaired hand."
75335752|NCT01050647|Other|Caster Oil injections|Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.
75645265|NCT00644007|Drug|Placebo|Placebo as a substitute of SK3530 100mg
75645266|NCT00644007|Drug|SK3530|SK3530 100 mg
75645267|NCT00735865|Procedure|Punctal plugs, punctal cautery|25 subjects(20 silicone punctal plugs, 5 punctal cautery) The procedure will be based on clinical indication. Randomized one eye for study. Baseline cultures of lid margin & tarsal/inferior fornix conjunctiva obtained & plated according to protocol
75335753|NCT00002764|Biological|filgrastim|
75645268|NCT00735865|Procedure|Punctal Plug, Punctal thermocauterization|"Up to 5 subjects. Subjects in need of punctal occlusion(No preference for punctal thermocauterization or punctal occlusion by silicone plug). Randomize one eye to silicone punctal plug occlusion, the other eye to punctal thermocauterization.~This group ONLY, cultures will be obtained of the lid margin & conjunctiva/inferior fornix of BOTH eyes"
75645269|NCT00735865|Procedure|Silicone plug or thermodynamic hydrophobic acrylic plug|"Up to 5 subjects. Subjects in need of punctal occlusion(not preference for punctal occlusion by silicone plug or by the thermodynamic hydrophobic acrylic plug). Randomize one eye to silicone punctal plug occlusion, the other eye to acrylic punctal plug occlusion.~In this group ONLY cultures will be obtained of the lid margin and conjunctiva/inferior fornix of BOTH eyes"
75645270|NCT00735865|Other|Previous subjects with Punctal occlusion|"Up to 20 subjects(15 subjects with silicone punctal plug closure and 5 subjects with punctal closure by thermocauterization)Subjects who have previously had punctal occlusion who have symptoms and/or signs thought to be secondary to punctal occlusion.~Lid margin and conjunctiva/inferior fornix of eye with greatest sign or symptoms will be cultured/plated according to standard protocol."
75645271|NCT00910143|Procedure|conventional rectal surgery|type of rectal surgery before the introduction of TME
75645272|NCT00910143|Procedure|total mesorectal excision|total mesorectal excision
75793352|NCT05846386|Behavioral|Aerobic training|"The exercise program consisted of ten minutes warm-up, 45 minutes of moderate aerobic exercises upper extremity aerobic bulk muscles training and arm ergometer and cool-down in five minutes, respectively. That was done as 3 sessions/week for 4 weeks."
75793353|NCT05846373|Drug|Nicotinic Acid 500 MG Extended Release Oral Tablet|Nicotinic acid 500 mg for 12 weeks
75793354|NCT05846373|Drug|Nicotinic Acid 1000 MG Extended Release Oral Tablet|Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
75793355|NCT05846373|Other|Placebo|Placebo 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
75793356|NCT05846334|Device|mindfulHeart|'mindfulHeart' is an interactive, self-guided and patient-oriented mHealth intervention for the reduction of stress in patients with IHD and includes automated feedback via visualization of changes in patient reported outcome measures (PROMs).
75793357|NCT05846308|Behavioral|Structured synchronous physical training|"The instructors and the participants will form a circle facing each other while doing the physical exercises. To facilitate interpersonal synchrony, the participants will be instructed to do the same physical exercises (spatial synchrony) together at the same pace (rhythmic synchrony). Each session will consist of four parts:~Warm-up (10 minutes)~Social Game (10 minutes)~Main training (30 minutes): Each session will contain two sets, each consisting of seven fixed exercises with a resting period of 10-15 seconds between each. Each exercise will be performed at one of three different paces: Slow - one movement cycle per 2 seconds, Medium - one movement cycle per 1 second and Fast - two movement cycles per 1 second.~Cool-down (10 minutes)"
75335754|NCT00002764|Drug|doxorubicin hydrochloride|
75335755|NCT00002764|Drug|ifosfamide|
75335756|NCT00002764|Procedure|conventional surgery|
75793358|NCT05846308|Behavioral|Structured non-synchronous physical training|The participants will do the same physical exercises as the participants in the synchronous group but in the form of circuit training with seven stations. The circuit training will require the participants to do a different physical exercise at a different pace at each station. A detailed description of the exercises will be provided for each station. The instructors will demonstrate all the exercises before the beginning of training. The participants will be instructed to do the exercise for a set period of time, the same duration used in the synchronous group. The circuit training stations will be in the form of a circle but will be set up so that the participants do not to face each other when doing the exercises to prevent spontaneous synchronization. Each session will consist of four parts, the same as in the synchronous intervention.
75335757|NCT05045326|Behavioral|Smoking cessation program|"Participants will receive intensive treatment for smoking cessation during day hospital admission.~The intervention is carried out individually and in an open-ended group. The treatment, provided by trained and multidisciplinary professionals (nursing, psychiatry, psychologist, occupational therapist, social work), includes psychological, psycho-educational support, and pharmacological treatment advice.~The group intervention takes place once a week and is divided into six structured sessions that are repeated. Sessions include nicotine addiction and withdrawal, health consequences, benefits of quitting, motivation for change, triggers, coping responses, social support, decision making, pharmacological treatment advice and healthy lifestyle habits."
75335758|NCT05045326|Behavioral|Placebo Comparator: Brief Counselling|Participants will receive brief counseling on smoking cessation during their hospital stay. This brief intervention is based on motivational techniques to increase motivation to reduce tobacco use or to initiate treatment.
75645273|NCT03732560|Other|Non-Interventional|Non-Interventional
75335759|NCT05167175|Drug|Olaparib tablet|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily.
75335760|NCT05167175|Drug|Abiraterone acetate|Qingkeshu (Abiraterone acetate tablets) 1000 mg should be taken orally once daily.
75645274|NCT03905473|Behavioral|Accelerometer measurements|To validate the questionnaires about physical activity, some patients will be wearing an accelerometer for one week. An accelerometer is a little device worn in a belt around the hip, which can measure intensity of the patient's activity level. The accelerometer is worn 24 hours a day for one week and is only removed when bathing.
75335761|NCT05167175|Drug|Prednisone tablet|Prednisone Tablets should be taken 5 mg once daily.
75645275|NCT02674113|Drug|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
75793359|NCT05846282|Behavioral|STRIVE|The STRIVE intervention will include all activities and BREATHE skill training components of L2B with content framed within the needs of high achieving college-bound BIPOC students who can benefit from health promoting practices to offset the costs of resilience. The intervention will include twelve 60-minute group sessions, with two sessions on each of the six core themes. Each session will include an opening mindful movement, short didactic presentation of the topic or theme of that week, group activities that illustrate the theme, guided discussion about the activity, and in-session group mindfulness meditation practice.
75645276|NCT02674113|Drug|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
75335762|NCT00002590|Biological|filgrastim|
75645277|NCT04286672|Diagnostic Test|Metadherin|study alterations of MTDH gene expression in the serum of bladder cancer patients
75645278|NCT00729703|Device|Ovatio DR 6550|Dual-chamber ICD therapy with minimized ventricular pacing
75645279|NCT00729703|Device|OVATIO DR 6550|Single-chamber device therapy with settings which are common in clinical practice.
75645280|NCT00644085|Drug|aspirin|oral administration of aspirin 100 mg
75645281|NCT00644085|Drug|placebo|oral administration of placebo
75793360|NCT05846282|Behavioral|Study Skills|The sessions will focus on goal setting (4 sessions), organization and time management (3 sessions), and study skills for reading comprehension, writing papers, note-taking, and test-taking (4 sessions). Parallel to the final L2B session, the last meeting will include activities to share and reflect on how students plan to incorporate and sustain new skills.
75793361|NCT05846269|Other|Educational Intervention|Educational intervention addressing trauma-informed care and resiliency.
75645282|NCT00731575|Drug|prednisolone|First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
75645283|NCT02674191|Device|mini-plates supported molar intrusion|(Stryker, Leibinger, GmbH& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence
75645284|NCT02674191|Procedure|Application of ULTRACARE benzocaine 20%,|topical anesthesia (Ultradent Products, Inc)
75645285|NCT02674191|Procedure|Administration of , Mepivacaine-l|local anesthesia
75645286|NCT02674191|Procedure|BETADINE povidone-iodine 10%|a local disinfectant
75645287|NCT02674191|Drug|(150g Clindamycin/tds) for 1 week|Postoperative antibiotic
75645288|NCT02674191|Drug|(Cataflam 25mg), are prescribed post-operatively|an analgesic
75645289|NCT00731809|Radiation|FDG PET CT|FDG PET CT
75645290|NCT00969332|Drug|Omegaven|0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday
75645291|NCT00736021|Drug|Escitalopram|Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
75793362|NCT05846256|Other|Sperm DNA Fragmentation|Sperm DNA Fragmentation analysis.
75793363|NCT05846243|Biological|VAC∆6 vaccine (10⁷ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: single intradermal dose of 10⁷ PFU/0.2 ml of vaccinia virus."
75936427|NCT03185780|Other|Acupuncture|"Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas."
75936428|NCT03185936|Procedure|pars plana vitrectomy with internal limiting membrane (ILM) peeling|pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
75936429|NCT03185624|Drug|Rifaximin|Antibiotics
75936430|NCT02434718|Drug|Aducanumab|As described in the treatment arm
75645292|NCT04178655|Drug|Tranexamic acid injection|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
75645293|NCT04178655|Drug|PLACEBO|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
75645294|NCT02863094|Device|transcranial magnetic stimulation|
75645295|NCT00738517|Device|Immunoadsorption / Immunoglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
75645296|NCT04178577|Drug|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
75645297|NCT02568787|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
75335763|NCT00002590|Drug|cyclophosphamide|
75335764|NCT00002590|Drug|cytarabine|
75335765|NCT00002590|Drug|daunorubicin hydrochloride|
75335766|NCT00002590|Drug|doxorubicin hydrochloride|
75335767|NCT00002590|Drug|etoposide|
75335768|NCT00002590|Drug|leucovorin calcium|
75335769|NCT00002590|Drug|methotrexate|
75335770|NCT00002590|Drug|pegaspargase|
75335771|NCT00002590|Drug|prednisone|
75335772|NCT00002590|Drug|thioguanine|
75335773|NCT00002590|Drug|vincristine sulfate|
75335774|NCT00002590|Radiation|radiation therapy|
75335775|NCT04782908|Device|Transcatheter tricuspid valve edge-to-edge repair|Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.
75645298|NCT02568787|Dietary Supplement|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
75645299|NCT02673879|Other|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
75645300|NCT02673879|Other|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated
75793364|NCT05846243|Biological|VAC∆6 vaccine (10⁶ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: two intradermal doses of 10⁶ PFU/0.2 ml of vaccinia virus (given 28 days apart)."
75335776|NCT00002788|Biological|filgrastim|
75335777|NCT00002788|Drug|cyclophosphamide|
75335778|NCT00002788|Drug|dexamethasone|
75645301|NCT03692468|Behavioral|Psychotherapy|Participants will complete 5, 60 minutes sessions. At each session, participants will learn strategies that have been shown to improve pain functioning and/or mood for patients who have chronic pain. The intervention will be delivered in the patient's primary care clinic.
75335779|NCT00002788|Drug|etoposide|
75645302|NCT02674035|Procedure|Correction of diastasis of the rectus abdominis muscles|Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
75645303|NCT00738595|Drug|EVT 302|EVT 302 5 mg once daily
75645304|NCT00738595|Drug|Placebo|Placebo to match EVT 302, 5 mg
75645305|NCT00738595|Drug|EVT 302 plus open label Nicotine replacement|Double-blind EVT 302 plus open label nicotine replacement
75793365|NCT05846243|Biological|Live Smallpox Vaccine|"Live smallpox vaccine (Smallpox vaccine) (manufactured by the Federal State Unitary Enterprise NPO Microgen of the Ministry of Health of Russia).~Batch No. Т30 (expiry date: March, 2021). Dosage: Single 1x10⁶ PFU dose administered by multiple-pricking technique on the 30th/60th day after full series of vaccination with VAC∆6."
75793366|NCT05846243|Other|Placebo (Sodium chloride bufus, 0.9%)|"Sodium chloride bufus, a 0.9% solvent for the preparation of a dosage form for injections (manufactured by JSC Pharmaceutical manufacturing company Obnovlenie, Russia).~Batch: 391219 (expiry date: January, 2025)."
75335780|NCT00002788|Procedure|peripheral blood stem cell transplantation|
75335781|NCT00002788|Radiation|radiation therapy|
75645306|NCT00738595|Drug|Placebo plus open label Nicotine Replacement|Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
75645307|NCT04016493|Procedure|Connective tissue graft|The patient received 600 mg of ibuprofen (paracetamol 1 g in case of allergy) prior to surgery, and chlorhexidine mouthwash 0.2% was provided for 2 min. Patients received local anaesthesia at the donor and recession sites (articaine hydrochloride 7200 mg/1.8 ml, adrenalin 1800 mcg/1.8 ml). CTG harvesting was performed prior to the preparation of the reception site to avoid any bias. The graft dimension was calculated according to the recession dimensions; a minimum of 3 mm of the graft was submerged mesially, distally and apically. The CTG was harvested from the palate with single edge incision and sutured with 4.0 silk. The patient was subsequently assigned randomly to the control (CAF+CTG) or the test group (TUN+CTG).
75793367|NCT05846217|Device|Multiwave Locked System|Multiwave Locked System laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
75645308|NCT02673723|Drug|Docozine|dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
75645309|NCT02673723|Drug|Saline|The same amount of saline is given for 10 seconds after surface anesthesia
75645310|NCT00968864|Device|CliniMACS® (T cell depletion)|Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
75793368|NCT05846191|Diagnostic Test|serum pentraxin 3 and high sensitive CRP|serum pentraxin 3 and high sensitive CRP
75793369|NCT05846165|Device|Field-Cycling Imaging (FCI)|FCI scan
75793370|NCT05846152|Device|Intervention|"Patient wounds will be examined:~by eye by the principal investigator~using a ruler by the principal investigator~by WoundCare algorithms (AKA WoundTrack) using smartphone photography by the principal investigator~by eye by a second investigator~using a ruler by a second investigator~by WoundCare (AKA WoundTrack) algorithms using smartphone photography by a second investigator."
75793371|NCT05846139|Combination Product|PerioTabs® brushing solution|PerioTabs® contains a non-antibiotic biofilm removal complex called NitrAdine®.Its anti-biofilm action is based on the combination of surfactant-induced protein denaturation and slow release of a non-toxic concentration of hypochlorite (0.02%).
75793372|NCT05846139|Combination Product|Chlorhexidine 0.12 %|chlorhexidine 0.12 % toothpaste and chlorhexidine 0.2% mouth rinse
75793373|NCT05846100|Procedure|Preprocedural spinal ultrasound|a preprocedural spinal ultrasound was performed in a non sterile manner with a sitting position.Both paramedian and transverse planes The intersection of the longitudinal and transverse lines is the point of needle insertion The distance from the skin to the dura mater is noted
75936431|NCT02434718|Drug|Placebo|IV administration of 0.9% sodium chloride
75335782|NCT04352933|Drug|Hydroxychloroquine - Daily dosing|"Active HCQ:~Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (~3 months),~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (~3 months)"
75335783|NCT04352933|Drug|Hydroxychloroquine - Weekly Dosing|"Active HCQ:~Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (~3 months)~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (~3 months)"
75793374|NCT05846100|Procedure|fictional preprocedure spinal ultrasound|fictional preprocedure spinal ultrasound Fictional ultrasound identification Screen device shut down
75645311|NCT00644163|Behavioral|Eban HIV/STD Risk Reduction Intervention|The eight-session Eban HIV/STD Risk Reduction Intervention is embedded in a cultural context and is gender tailored in its prevention messages and activities. Sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations.
75936432|NCT03190772|Other|Placebo nasal spray|The placebo nasal spray consists of sesame oil and does not contain any active drug.
75645312|NCT00644163|Behavioral|Eban Health Promotion Intervention|The eight-session Eban Health Promotion Intervention is guided by a social cognitive approach that engages health promotion skills. Sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence.
75645313|NCT04016337|Dietary Supplement|Beverages|The beverages were all made with lemon and maqui extracts, and different sweeteners
75645314|NCT04285970|Other|cycle detection|6-minute test on a treadmill at pedestrian speed (5km/h) with 2 instruments (dynamometric wheel and inertial centre) on a standardised wheelchair
75335784|NCT04352933|Other|Matched Placebo Hydroxychloroquine|"Matched placebo HCQ - daily dosing:~Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (~3 months)"
75335785|NCT05246696|Other|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
75335786|NCT04783792|Dietary Supplement|Ascorbic acid / phytochemical supplement|Ascorbic acid / phytochemical supplement
75335787|NCT04783792|Dietary Supplement|Ascorbic acid|Ascorbic acid
75645315|NCT04285970|Other|detection of effort intensity|6-minute test on an urban course with 2 instruments (dynamometric wheel and inertial units) on a wheelchair
75645316|NCT04177407|Procedure|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
75335788|NCT02981381|Device|NEST-1|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.
75335789|NCT02981381|Device|SHAM|The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.
75645317|NCT05273775|Drug|HRS5091 Tablets|HRS5091 Tablets once daily
75645318|NCT05273775|Drug|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
75645319|NCT05273775|Drug|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
75645320|NCT05273775|Drug|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
75645321|NCT05273775|Drug|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
75645322|NCT05273775|Drug|Digoxin Tablets|Digoxin Tablets single dose
75793375|NCT05846061|Other|Prevalence study population|No intervention
75335790|NCT02981381|Device|NEST-2|The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.
75793376|NCT05846035|Diagnostic Test|Triphasic C.T abdomen and pelvis|for cirrhotic patients to ensure hepatocellular carcinoma
75793377|NCT05845983|Dietary Supplement|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2*10^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
75335791|NCT01680302|Behavioral|High intensity exercise|
75335792|NCT01680302|Behavioral|Moderate intensity exercise|
75793378|NCT05845983|Dietary Supplement|Maltodextrin|Maltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
75793379|NCT05845970|Other|Pamprin Botanicals|Participants will take Pamprin Botanicals only. Participants will take 450mg of Pamprin Botanicals two days before their predicted period and then take it every day during their period. Participants can also take Pamprin Botanicals two days after the bleeding has concluded.
75936433|NCT03190772|Other|Film sequence|All groups watch the film sequence that is supposed to induce sadness.
75645323|NCT05273775|Drug|Rosuvastatin Calcium Tablets|Rosuvastatin Calcium Tablets single dose
75936434|NCT02707640|Drug|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
75936435|NCT02707640|Drug|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
75936436|NCT02707640|Drug|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
75645324|NCT04177017|Behavioral|Mindfulness-based intervention|"The behavioral intervention was carried out once a week during 60 minutes from May to November, and included mindfulness-based practices sought to foster self-awareness, and dyadic activities sought to awakening subtle perception of the other.~Group activities, which entailed more than two participants, were also conducted to foster empathic collaboration and prosocialness. Diverse collaborative games were carried out in which mutual help was needed for achieving shared goals in an amusing way .~Perspective-taking was encouraged within the group, by sharing each participant's experience, which included expressing how each child had felt (i.e., if neglected, ignored or cared for) and whether they had enjoyed helping their peers or no."
75936437|NCT03190694|Drug|Dapagliflozin 10mg|Tablet
75645325|NCT04177485|Behavioral|SMS text reminders|SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
75645326|NCT02671851|Drug|Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs with 20mL bupivacaine 0.375% at the level of T3-T4 as an adjunct to GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
75793380|NCT05845970|Combination Product|Pamprin Botanicals + Pamprin Menstrual Pain Relief|Participants will repeat taking Pamprin Botanicals two days before their second predicted period and continue to take it each day during their period. However, during the second period, participants will also take Pamprin Menstrual Pain Relief per the over-the-counter directions (2 tablets every 6 hours with water).
75645327|NCT02671851|Drug|IV metamizole sodium, paracetamol|Patients received only standardized GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
75645328|NCT04093947|Other|Observational study|Observational and prospective study
75929442|NCT05461976|Behavioral|Home-based self-management exercise program|Session 1 will includes education about stroke. Session 2 will includes feedback on behaviour performance on initial measurement outcomes, health consequences of the physical inactivity, answering an exercise preferences questionnaire, generation of a list of goals, delivering a smartband and a diary to self-monitoring. Session 3 will includes reviewing of goals and strategies to self-monitoring, encouragement, rising barriers to exercise and potential solutions to them, development of a weekly schedule physical exercise, implementation of the physical exercise session with participant and delivering a paper-exercise guide. Session 4 will includes reviewing of goals and weekly schedule physical exercise, encouragement, problem solving/coping planning, reviewing strategies to self-monitoring and showing to participant a video with another stroke survivors which are physically active. Sessions 5 and 6 will be the same as session 4 with exception of vicarious reinforcement.
75929443|NCT05459337|Behavioral|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
75929444|NCT05453994|Drug|H. pylori eradication|PPIs-based Antimicrobial agents for H. pylori eradication
75929445|NCT05451563|Device|Double-S|Wearable device for intercourse
75645329|NCT02672163|Procedure|CABG surgery|Elective CABG surgery
75929446|NCT05445349|Device|Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy|The DPI inhaler devices are empty, without any active ingredient or/and carrier substances. Patients are not inhaling drug doses because of the study. They are inhaling only the type and quantity of aerosol drugs that they would inhale because of their treatment. The study does not influences the undergoing treatment by medication in any way.
75936438|NCT02430272|Drug|Glycopyrrolate|Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
75335793|NCT01680302|Behavioral|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
75645330|NCT02672163|Procedure|AADC therapy|Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
75645331|NCT04176861|Device|home-based Brainwave Entrainment Technology|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights
75645332|NCT04091685|Device|Gamma camera imaging|Use gamma camera in detection of renal cortical defects
75645333|NCT04088955|Other|DigiMeds|Digitized Capecitabine
75645334|NCT02671695|Drug|Spirulina|Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
75793381|NCT05845957|Other|Digital Education Group|Providing training on safe pediatric intravenous drug administration with digital storytelling method
75936439|NCT02430506|Biological|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
75335794|NCT01676402|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
75335795|NCT01676402|Biological|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
75335796|NCT01670006|Device|Cochlear Nucleus Cochlear Implant System|
75335797|NCT01052831|Drug|Naltrexone|50-100 mg qd for 8 weeks
75335798|NCT01052831|Drug|Placebo|50-100 mg qd for 8 weeks
75645335|NCT02671695|Drug|Amlodipine|Amlodipine in a dose of 5 mg/day orally for 3 months
75645336|NCT00736177|Procedure|Embryo cryopreservation|Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
75645337|NCT00736177|Procedure|Fresh embryo transfer|Subjects in the Control group will receive fresh embryo transfer.
75645338|NCT02671617|Other|High intensity interval training (HIIT)|Preoperative HIIT protocol.
75645339|NCT00731887|Procedure|Blood and urine testing|complete blood count, routine chemistries, liver function test, retinol binding protein, transferrin, prothrombin time, partial thromboplastin time, fibrinogen, Vitamin A and Zinc, Insulin Growth Factor levels and binding proteins, cytokines (interleukins 1, 6, 12), insulin, thyroid hormones, cortisol, 25-hydroxyvitamin D, and osteocalcin.
75645340|NCT00736411|Procedure|acupuncture|16 treatments over 8 weeks
75645341|NCT00736411|Procedure|IVF|one 4 week IVF cycle
75645342|NCT02671773|Drug|Inhaled corticosteroid dose/type|
75645343|NCT02671539|Genetic|rAAV2.REP1|single subretinal injection
75645344|NCT00731965|Biological|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
75645345|NCT00644631|Drug|sildenafil|sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
75793382|NCT05845944|Other|Video-supported education group|Providing training on nutrition with a nasogastric tube in pediatric patients with a video-supported education method
75929447|NCT05444608|Behavioral|Breast milk olfactory stimulation|Before the intervention, 2 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.
76084690|NCT03122574|Other|Jojoba Aromatherapy|100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
76084691|NCT02507700|Procedure|Popliteal block|In group P, popliteal block will be performed with ultrasound guidence.
76084692|NCT02507700|Drug|Sevoflurane|Sevoflurane will be used to all patient's for anesthesia induction and maintenance
75929448|NCT05444608|Behavioral|White noise auditory stimulation|Before the intervention, a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure and will continue to listen for 5 minutes after the procedure.
76084693|NCT02507700|Device|Ultrasound|For recognize the nerve (sciatic nerve), ultrasound will be used in group P.
76084694|NCT02507700|Other|Plaster cover|Plaster cover will be used to control group for sham procedure
75335799|NCT01005368|Genetic|fluorescence in situ hybridization|
75335800|NCT01005368|Genetic|mutation analysis|
75335801|NCT01005368|Genetic|nucleic acid sequencing|
75929449|NCT05436652|Drug|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
76084695|NCT02507700|Drug|bupivacaine|Bupivacaine 0.25% will be performed for popliteal block to group P.
76084696|NCT02507700|Other|Laryngeal mask airway|After anesthesia induction, laryngeal mask airway will be inserted to all patients
75335802|NCT01005368|Genetic|polymerase chain reaction|
75645346|NCT00644631|Drug|placebo|placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
75645347|NCT02671383|Drug|Darunavir|Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
75645348|NCT02671383|Drug|Lopinavir|Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
75793383|NCT05845905|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by the inflation of an automated cuff to the pressure rising by 20 mmHg from baseline systolic pressure. RIC will be conducted twice daily for 7 days.
75929450|NCT05436652|Drug|SPI-62 matched placebo|Inactive tablets identical in appearance to SPI-62 tablets
75651916|NCT04708769|Behavioral|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
75793384|NCT05845905|Procedure|Sham remote ischemic conditioning|Sham-RIC is performed in the same way as the treatment group except that the blood pressure cuff is inflated to 60 mmHg, which produces mild pressure sensations but has no blocking impact on blood flow.
75335803|NCT01005368|Genetic|western blotting|
75335804|NCT01005368|Other|flow cytometry|
75335805|NCT01005368|Other|laboratory biomarker analysis|
75335806|NCT04330300|Drug|Thiazide or Thiazide-like diuretics|Anti-hypertensive (Active Arm)
75793385|NCT05845892|Other|stress ball|The use of the stress ball by the experimental group patients will be reminded by a hemodialysis nurse who was not involved in the study.
75793386|NCT05845866|Behavioral|Modified Body Project|The Body Project, an evidence-based body image intervention developed for young women at risk for eating pathology, was adapted for use among adult women with high weight and shape concern and high body weight who want to lose weight.
75793387|NCT05845866|Behavioral|Facts about obesity, myths about weight loss|This intervention is designed to help individuals prepare for weight loss and is focused on facts about obesity, myths about weight loss, and the importance of a varied diet.
75793388|NCT05845866|Behavioral|Lifestyle intervention for weight loss|This 24-week behavioral weight management program is based on the Look AHEAD and Diabetes Prevention Program manuals. It is designed to facilitate 7-10% weight loss of initial body weight through dietary and physical activity changes with use of behavioral strategies to support lifestyle changes over time.
76084697|NCT02513004|Drug|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
76084698|NCT02513004|Drug|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
75335807|NCT04330300|Drug|Calcium Channel Blockers|Anti-hypertensive (Active Arm)
76084699|NCT04500522|Drug|INH|3 vaginal tablet of isonicotinic acid hydrazide 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
76084700|NCT04500522|Drug|Placebo|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
76084701|NCT02507310|Other|thermostat|ambient temperature as modified by thermostat
76084702|NCT03345732|Diagnostic Test|ICG and SPY system for wound complications|
76084703|NCT02513082|Procedure|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
75335808|NCT04330300|Drug|ACE inhibitor|Anti-hypertensive (Control Arm)
75335809|NCT04330300|Drug|Angiotensin receptor blocker|Anti-hypertensive (Control Arm)
75335810|NCT04352855|Drug|Ceftolozane/tazobactam|Administration
75929451|NCT05436652|Drug|Prednisolone 10mg|Standard of care prednisolone
75645349|NCT00738751|Drug|Panobinostat (LBH589)|Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
75793389|NCT05845853|Other|scapular PNF technique|"PNF Technique is based on movement patterns to facilitate and correct sensory-motor function,then correct the impaired impulses emerging from proprioceptive receptors in the muscle. Therefore, it decreases pain and improve the strength of muscles.~PNF position renders a greater amount of sensory input coming from the periphery than that in the neutral position ."
75793390|NCT05845801|Other|Register|Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.
75793391|NCT05845775|Procedure|Percutaneous dilatational tracheostomy|The percutaneous dilatational tracheostomy procedure will be performed via fiberoptic bronchoscopy
75793392|NCT05845775|Device|Bronchoscopy|Fiberoptic bronchoscopy
75929452|NCT05436652|Drug|Additional prednisolone|Over encapsulated prednisolone
75929453|NCT05436652|Drug|Additional prednisolone matched placebo|Inactive capsules identical in appearance to over encapsulated prednisolone
75929454|NCT05432583|Biological|BNT163|Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection
75929455|NCT05432583|Other|Placebo|Placebo
75929456|NCT05427318|Behavioral|PATH|The intervention integrates two theoretically-grounded interventions - one with a strong peer navigator component and the other with a scalable mHealth component - into the intervention called Peers plus mobile App for Treatment in HIV (PATH)
75929457|NCT05423951|Drug|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.
75929458|NCT05423951|Drug|Propofol|For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.
75929459|NCT05423951|Drug|Rocuronium|After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed
75929460|NCT05423951|Drug|Sufentanil|During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
75929461|NCT05422781|Drug|ITI-3000|ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
75929462|NCT05421065|Drug|Psilocybin|1 25mg oral dose
75929463|NCT05421065|Drug|Ketamine|1 200mg oral dose
76084704|NCT02507232|Device|NovoTTF-200A|12 cycles
75929464|NCT05417789|Drug|Emactuzumab|Emactuzumab administered once every 2 weeks (q2w)
75929465|NCT05417789|Drug|Placebo|Matching placebo administered once every 2 weeks (q2w)
75335811|NCT04782128|Biological|RC28-E injection|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
75645350|NCT00738751|Drug|erlotinib|Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
75645351|NCT05243823|Drug|Vagifem®|According to local clinical practice - independent of inclusion in this study
75793393|NCT05845775|Device|ultrasonography|ultrasonography
75929466|NCT05407311|Drug|64Cu-SAR-BBN|64Cu-SAR-BBN
75929467|NCT05397886|Drug|Remimazolam Besylate|Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
75929468|NCT05397886|Drug|Flumazenil|Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
75929469|NCT05397886|Drug|Propofol|Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
75929470|NCT05396118|Drug|18F-FDG|Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
75929471|NCT05396118|Drug|Injection of hyperpolarized [1-13C]Pyruvate|Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized [1-13C]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized [1-13C]Pyruvate followed by MRS / MRSI.
75929472|NCT05396118|Procedure|PET/MR/MRS/MRSI scanning|Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized [1-13C]Pyruvate.
76084705|NCT02507232|Drug|Temozolomide|50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
76084706|NCT02506998|Biological|DLE|Adjuvant treatment
76084707|NCT02506998|Other|Second generation anti histamines + Nasal corticosteroids|Standard treatment
75929473|NCT05390814|Drug|PET-MRI|[18F]-Fludarabine imaging in the diagnostic workup of primary central nervous system lymphomas: a PET-MRI pilot study
75929474|NCT05384873|Dietary Supplement|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
76084708|NCT01608490|Device|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
76084709|NCT04500444|Other|exercise training|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.
75645352|NCT05243823|Drug|Non-Vagifem® LDVE, Estradiol|According to local clinical practice - independent of inclusion in this study
75645353|NCT00736801|Drug|Salmeterol and Salmeterol / Fluticasone|Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
75793394|NCT05845775|Diagnostic Test|Bronchoscopy application|Fiberoptic bronchoscopy application
75793395|NCT05845775|Diagnostic Test|Ultrasound examination|Ultrasound examination
75793396|NCT05845723|Drug|tocilizumab|Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
75793397|NCT05845723|Drug|tofacitinib|Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.
75793398|NCT05845723|Drug|cyclophosphamide|Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
75793399|NCT05845606|Behavioral|Benzodiazepine Taper|The BZ-TP is a 14-week intervention that assists participants in reducing their benzodiazepine prescription through a gradual taper at approximately 10%-20% reduction per week for a total of 12 weeks. Dose reduction will be recommended but not required. This intervention is identical in both arms.
75793400|NCT05845606|Behavioral|Cognitive Behavioral Therapy (CBT)|The telehealth delivered CBT is an 11-week intervention that includes psychoeducation, interoceptive exposure, somatic skills, and cognitive restructuring.
76084710|NCT04498338|Other|Neural mobilization combined with conventional physical therapy program|Neural mobilization of sciatic nerve combined with TENs and exercise program applied 3 times/week for successive 6 weeks.
76084711|NCT04498338|Other|Conventional physical therapy program|TENs and exercise program applied 3 times/week for successive 6 weeks.
76084712|NCT02507076|Drug|isolated limb perfusion|Undergo ILP with melphalan
75645354|NCT00738829|Drug|Lenalidomide|"Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage."
75645355|NCT00738829|Drug|Fludarabine|25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
75793401|NCT05845606|Behavioral|Health Education|The Health Education (HE) intervention will include 11 weeks of an interactive health education program to match for therapy time. The HE is a published multimedia program addressing various health, wellness and lifestyle topics such as nutrition, dental care, immunizations, health screening, smoking, and time management.
75645356|NCT00738829|Biological|Rituximab|"Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage."
75645357|NCT02671227|Drug|intrathecal Mg sulfate.|intrathecal Mg sulfate 50 mg.
75645358|NCT02671227|Drug|intrathecal bupivacaine 15 mg.|intrathecal bupivacaine 15 mg.
75645359|NCT00644709|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
75793402|NCT05845567|Drug|Givinostat|ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.
75793403|NCT05845567|Drug|Clarithromycin|Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.
75793404|NCT05845528|Device|s-tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
75793405|NCT05845528|Device|a- tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
75793406|NCT05845515|Procedure|laparoscopic orchiopexy|laparoscopic or open orchiopexy and comparison between the two groups
75793407|NCT05845502|Biological|SZ003 CAR-NK|Drug: SZ003 CAR-NK In the escalation study, the minimum initial dose was 5.0×10^6 cells, then increased to 1.0×10^8 ,2.0×10^8 and5.0×10^8 cells. The infusion is given every 2 weeks.
75793408|NCT05845463|Device|Cerebro endoscopy quality control tool|The AI provides feedback via a separate screen to the endoscopists to inform them which part of the upper GI tract have been adequately visualised.
75793409|NCT05845424|Drug|Guideline directed statin therapy|At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
75936440|NCT02430506|Biological|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
75936441|NCT04586855|Diagnostic Test|Diagnostic Ultrasound|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
76084713|NCT02507076|Drug|melphalan|Undergo ILP with melphalan
76084714|NCT02507076|Procedure|quality-of-life assessment|Ancillary studies
76084715|NCT01609348|Drug|Placebo|Capsule matching active drug to be taken once a day for 12 weeks
76084716|NCT01609348|Drug|Venlafaxine|225 mg daily for 12 weeks
76084717|NCT04500678|Drug|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
76084718|NCT02992366|Procedure|implant placement|implant placement
76084719|NCT02515812|Drug|I-123-MIBG|
76084720|NCT02515812|Device|CZT Camera (D-SPECT)|
76084721|NCT02515812|Device|Anger Camera|
75929475|NCT05384873|Other|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
75929476|NCT05379608|Procedure|Intermittent hypoxic-hyperoxic training|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~Each patient will undergo a hypoxic test to assess the individual response to hypoxia. The minimum safe SpO2 value is 82%, and the maximum allowable heart rate increase during exercise is + 50% of the starting value. When these parameters are reached, an automatic switch to the supply of a hyperoxic gas mixture (35-40% oxygen) occurs till the SpO2 level is 100%. During each training session a hypoxic gas mixture is supplied to the patient in an intermittent mode, alternating with the supply of a hyperoxic gas mixture. On average, each workout includes 6 of the above cycles. The total time of inhalation of a hypoxic gas mixture during one procedure is 20-30 minutes."
75793410|NCT05845424|Drug|High intensity statin plus ezetimibe therapy|Rosuvastatin 20 mg + Ezetimibe 10 mg
75929477|NCT05379608|Procedure|Intermittent hypoxic-hyperoxic training/control|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~A control group of 30 patients will undergo a simulated IHHT course (with the same exposure time and number of sessions as intervention group - 15 sessions, 40-minutes long each, 5 workouts per week for 3 weeks). Patients of this group will breathe normoxic gas mixture (ordinary humidified air is supplied through the mask) during the entire session."
75645360|NCT00738985|Drug|ezetimibe/simvastatin 10/20 mg + placebo|Patients will receive placebo (sugar tablets) for up to 22 weeks.
75929478|NCT05377853|Behavioral|Cognitive-Kinesthetic Navigational Training|Training with tactile maps to improve spatial memory capability for enhanced navigational capabilities.
75929479|NCT05372068|Other|Concrete household floor|Household soil floors will be replaced with concrete floors
75645361|NCT00738985|Drug|ezetimibe/simvastatin 10/20 mg + MK0524A|ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
75929480|NCT05370495|Drug|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
75929481|NCT05370495|Drug|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
75793411|NCT05845411|Behavioral|Mindful Eating|Nutritional advice through expository content, group discussion, and exchange of experiences on self-knowledge, food awareness, and relationship with food and the body.
75929482|NCT05370495|Drug|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
75929483|NCT05370495|Drug|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
75929484|NCT05369793|Drug|Alpha lipoic acid|Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
76084722|NCT02512770|Procedure|endoscopic dilatation|
75645362|NCT05216211|Drug|Bupivacaine Hydrochloride|1 ml / kg, % 0.25 bupivacaine
75645363|NCT00732043|Dietary Supplement|pomegranate extract|8 oz per day, 48 months
75645364|NCT00732043|Dietary Supplement|pomegranate juice|8 oz per day, 48 months
75645365|NCT00732043|Dietary Supplement|placebo|8 oz per day, 48 months
75645366|NCT02670993|Behavioral|Singing sessions.|Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
75645367|NCT02670993|Behavioral|Painting sessions.|Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
75645368|NCT00732121|Drug|Sitagliptin|100 mg daily for 4 weeks
75645369|NCT00732121|Drug|Placebo|Placebo
75645370|NCT02537223|Drug|BYL719|
75793412|NCT05845411|Other|Standard dietary treatment|Hypocaloric dietary prescription and nutritional education.
75645371|NCT02537223|Drug|Cisplatin|
75645372|NCT02537223|Radiation|Intensity modulated radiation therapy (IMRT)|
75793413|NCT05845385|Procedure|postoperative analgesic methods|lumbar epidural analgesia Transversus abdominis plane block wound infiltration
75793414|NCT05845346|Other|Electrotherapy-Transcutaneous Electrical Stimulation (TENS)|Ten electrotherapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
75793415|NCT05845346|Other|Massage therapy|Ten massage therapy sessions lasting 20 minutes each were carried out. Techniques such as superficial rubbing, deep rubbing, kneading and gliding pressure were performed on the cervical region.
75793416|NCT05845346|Other|Stretching exercises|Ten stretching exercise sessions.The stretching exercise modality performed consisted of passive static stretching with a sequence of 30s-10s-30s-10s.
75929485|NCT05369793|Drug|Roflumilast|Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
75929486|NCT05365698|Behavioral|Community Health and Nutrition Program|"The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods."
75929487|NCT05357859|Dietary Supplement|solubilized vitamin D3|solubilized vitamin D3
76084723|NCT02506920|Dietary Supplement|Six different types of fat in a meal in random order|Oral fat tolerance test
76084724|NCT02512458|Drug|Cabazitaxel|
76084725|NCT02515578|Other|Enhanced practice transformation support|
76084726|NCT02515578|Other|Standard practice transformation support|
76084727|NCT02507154|Drug|Cetuximab + NK cells|
76084728|NCT02515734|Drug|fluorouracil|
76084729|NCT02515734|Drug|Leucovorin|
76084730|NCT02515734|Drug|irinotecan|
76084731|NCT02515734|Drug|oxaliplatin|
76084732|NCT02515734|Biological|bevacizumab|
76084733|NCT02515734|Biological|cetuximab|
75929488|NCT05357859|Dietary Supplement|medium chain triglyceride|MCT with same amount
75929489|NCT05348356|Drug|Nirogacestat|nirogacestat oral tablet
75645373|NCT02568943|Drug|Panobinostat|Panobinostat (PAN [LBH589]) is an orally administered pan-deacetylase inhibitor (DACi) belonging to a structurally novel class of compounds deregulating cell proliferation and survival mechanisms of cancer cells.
75929490|NCT05348252|Other|Patient Journey App|The group will receive all information and insctructions on discontinuing PPI use through the Patient Journey App which timely deliveres all information.
76084734|NCT02506608|Procedure|Operation of sensorized hand prosthesis|"Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
76084735|NCT02512536|Drug|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
75793417|NCT05845346|Other|Ischaemic Compression Technique|Ten Ischaemic Compression Technique sessions. The execution of the technique is described as follows: after locating a painful point (trigger point), pressure is applied until pain is generated, then a position is sought where the pain disappears, the position of maximum comfort, which is maintained for 90 seconds (sec), after which time the patient is returned to the starting position in a passive manner.
76084736|NCT02506842|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
76084737|NCT02506842|Drug|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
76084738|NCT02506842|Drug|oxaliplatin|Patients receive oxaliplatin 85 mg/m^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
76084739|NCT02506842|Drug|folinic acid|Patients receive folinic acid 200 mg/m^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
76084740|NCT02506842|Drug|fluorouracil|Patients receive fluorouracil 2000 mg/m^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
75335812|NCT05100875|Behavioral|"Social Skills and Emotion Regulation Training SSERT"|The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.
75645374|NCT04176237|Other|UV Dosimetry Laboratory|The UV Dosimetry Laboratory is a one hour lesson that incorporates science and health education - kids hypothesize what UV levels will be around the school yard, go and measure UV, review their results, and then come up with a SunSmart plan for playing in the school yard.
75793418|NCT05845333|Other|Decision task|Participants will complete a simple and/or moral decision making functional MRI task.
75793419|NCT05845294|Procedure|Routine Care|Routine care for patients undergoing colorectal cancer stoma
75645375|NCT02671149|Dietary Supplement|Water|Participants will receive two cups of 150ml plain water
75793420|NCT05845294|Procedure|Short-term structured psychological Care|Short-term structured psychological care for colorectal cancer stoma patients based on conventional care
75793421|NCT05845268|Combination Product|Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
76084741|NCT02512614|Other|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
76084742|NCT04500054|Other|Music Listening|The music type was chosen by the patients and researchers did not have any influence on their choices.
76084743|NCT03345498|Drug|Entecavir|Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
76084744|NCT04497558|Diagnostic Test|Endometrium biopsy|In the experimental group, those patients undergo endometrial receptivity array. In the control group, those patients do not receive any treatment before next cycle of transfer. In the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. In the control group, no intervention will be performed.
75929491|NCT05348252|Other|Information folder|The group will receive all information and instructions on discontinuing PPI use through an information folder.
75929492|NCT05338866|Radiation|Magnetic resonance guided radiotherapy|Radical radiotherapy boosting for low rectal cancer through magnetic resonance guided radiotherapy linear accelerator.
75929493|NCT05338866|Drug|Chemotherapy|"For patients with AJCC stage II and III and age < 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses."
75335813|NCT00995150|Drug|LNG20|levonorgestrel-releasing intrauterine system for contraception
75335814|NCT00995150|Drug|Mirena|Mirena intrauterine system
75335815|NCT00382642|Drug|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
75929494|NCT05336045|Procedure|trigger finger release|The A1 pulley and tendon sheath is divided in local anaestethic through a small incision in the palm
75936442|NCT04586855|Diagnostic Test|Transnasal Fiberoptic Laryngoscopy|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
75929495|NCT05334407|Procedure|Implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
75929496|NCT05334407|Behavioral|Dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
75929497|NCT05334407|Procedure|Delayed implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Delayed (4 months) implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
76084745|NCT03121638|Biological|VARIVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
76084746|NCT03121638|Biological|ZOSTAVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
75645376|NCT00732277|Drug|hydrocortisone|Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
75645377|NCT04084821|Other|none - observation only|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
75645378|NCT00737035|Behavioral|Interactive Healthcare Communication Application|"The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH."
75645379|NCT00737035|Behavioral|Control Web sites|Only publicly available Web sites on parenting, child development, and trauma will be used.
76084747|NCT03121638|Biological|NBP6081|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
76084748|NCT03121638|Biological|NBP6082|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
76084749|NCT03121638|Biological|NBP6083|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
75645380|NCT04176315|Other|Conventional Home-based Rehabilitation Plan|Usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients. Participants receive inpatient care and rehabilitation for 2 weeks. At discharge, they receive a 5-exercise home-based rehabilitation plan. For the sake of homogeneity of all participants, they receive from 2 to 4 of training prior to discharge. At home, participants shall perform the exercises in the rehabilitation plan daily.
75651917|NCT04703439|Behavioral|Medication-taking reminders & educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
75651918|NCT04703439|Behavioral|Educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
75651919|NCT04695210|Behavioral|Virtual peer-to-peer support|See arm description
75651920|NCT04676906|Drug|NNC0113-6861|Study compound 1 - Each participant will receive a single intravenous (i.v) dose of [14C]-NNC0113-6861
75651921|NCT04676906|Drug|NNC0113-6860|Study compound 2 - Each participant will receive a single i.v dose of [14C]-NNC0113-6860
76084750|NCT02506686|Drug|Meropenem|Meropenem i.v.
76084751|NCT02515500|Behavioral|Gradual Cessation|
76084752|NCT02515500|Behavioral|Gradual Cessation w/ Quitbit|
76084753|NCT04499742|Radiation|Using Isotope (Tc99m-Sulfur Colloid) to label glucose and administer this directly into duodenum.|Patients will be undergoing Standard of Care procedure EAGBT for collection of duodenal fluid (aspirate and culture) and placement of a catheter into the duodenum. This catheter will be used for infusion of glucose isotope into the small bowel. Subsequently Standard of Care nuclear medicine imaging will be used to track the location of the isotope in the gut.
75793422|NCT05845268|Combination Product|Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
76084754|NCT02512380|Drug|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
76084755|NCT02512380|Drug|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
76084756|NCT02512146|Procedure|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
75335816|NCT00382642|Drug|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
75335817|NCT01054079|Other|laboratory biomarker analysis|Correlative study
75335818|NCT01054079|Procedure|quality-of-life assessment|Ancillary study
75793423|NCT05845255|Device|mjn-SERAS|Using of wearable, non-invasive device for EEG recording and forecasting of epileptic seizures
75793424|NCT05845229|Dietary Supplement|High-N-acylethanolamine meal|Milk (150 mL), white bread (46 g), jam (10 g), cocoa powder (15 g), whole-grain cereals (30 g).
75793425|NCT05845229|Dietary Supplement|Low-N-acylethanolamine meal|Milk (150 mL), whole-grain bread (80 g), jam (10 g), butter (5 g), instant coffee (2 g), dried apples (30 g).
75793426|NCT05845203|Diagnostic Test|perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere|perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere
75645381|NCT04176315|Device|ReHub Home-based Rehabilitation Plan|"Combination of the usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients with ReHub, a telerehabilitation platform that serves as a guide to perform the TKA rehabilitation exercises.~Participants receive inpatient care and rehabilitation at San Camillo for 2 weeks. At discharge, a 5-exercise home-based rehabilitation plan is carried out by a site physiotherapist by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor. Participants receive from 2 to 4 sessions of ReHub prior to discharge.~At home, participants shall perform the exercises in the rehabilitation plan with ReHub daily. The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. Participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
75645382|NCT02569333|Other|Educational video|iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
75645383|NCT04176471|Other|Therapeutic Hypothermia|Therapeutic hypothermia involves use of a servo-controlled device and blanket to lower the core body temperature by 3°C for 72 hours followed by a period of re-warming in which the temperature is increased by 0.5°C per hour for 6 hours until normothermia is achieved.
75929498|NCT05334407|Behavioral|Delayed dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
75929499|NCT05327803|Drug|Epetraborole|500 mg taken orally QD
75929500|NCT05327803|Drug|Placebo|Placebo taken orally QD
75929501|NCT05327452|Behavioral|Supervised Home-Based Exercise|Online supervised aerobic and resistance exercise
75929502|NCT05327452|Behavioral|Unsupervised Home-Based Exercise|Unsupervised aerobic and resistance exercise (UNSUP)
75929503|NCT05327452|Behavioral|Attention Control|Stretching Program
75929504|NCT05327023|Procedure|donor lymphocyte infusion|The DLI will be given on Day +7 (Day +21 for dose level -1). If a recipient participant is deemed too critically ill/unstable to receive DLI on the protocol specified day, the DLI will be delayed up to 4 days at the discretion of the PI and given within this time frame once the recipient participant s clinical status has stabilized or improved. If the DLI cannot be given during this time frame, the recipient participant will be taken off study and not considered evaluable for DLT, outcomes, or adverse events since the experimental intervention will not have been given.
75929505|NCT05327023|Drug|Cyclophosphamide|HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
75929506|NCT05327023|Drug|Busulfan|AUC targeted dose based on busulfan test dose, with a default dose of 130 mg/m2/day, given as IV infusion over 3 hours each day for 4 days Transplant days -6 through day -3
75645384|NCT04176471|Other|Normothermia|Normothermia will be achieved using the same servo-controlled device and blanket to assure normothermia of the control arm. The goal temperature for normothermia is 36.5-37.3°C for 72 hours.
75645385|NCT00732355|Device|Syph-Check POC|Rapid membrane test for syphilis antibodies
75645386|NCT00739219|Device|Apieron Insight eNO monitor|The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
75645387|NCT04083573|Other|application of medical augmented reality glasses|Endoscopic images from medical monitor and medical augmented reality glasses will be collected and reviewed. Outcomes from both series of images will be compared
75645388|NCT00739375|Procedure|Primary arterio-venous vascular access creation|Primary arterio-venous vascular access creation, ECHO with pulmonary artery pressure measurements, Assessment of blood NO metabolite levels
75929507|NCT05327023|Drug|Mycophenolate mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
75929508|NCT05327023|Drug|Fludarabine|40 mg/m2 IV infusion over 30-60 minutes once daily for 4 days Transplant days -6 through -3
75335819|NCT01054079|Other|questionnaire administration|Ancillary study
75335820|NCT01054079|Drug|cinacalcet hydrochloride|Given PO
75645389|NCT00739453|Drug|OSI-906|administered orally
75335821|NCT00991094|Other|Quality-of-Life Assessment|Complete questionnaires
75335822|NCT00991094|Other|Questionnaire Administration|Complete questionnaires
75645390|NCT00739453|Drug|erlotinib|administered orally
75651922|NCT04676906|Drug|NNC0113-6891|Study compound 3 - Each participant will receive a single i.v dose of [14C]-NNC0113-6891
75651923|NCT04652596|Other|Produce prescription program|A monthly $150 stipend will be provided to participants for 6 consecutive months to purchase fresh food items at mobile markets and independent farmers markets across Boston.
75793427|NCT05845190|Other|aerobic exercises|aerobic exercises in form of walking on treadmill
75793428|NCT05845190|Other|resistance exercises|60% of One-repetition maximum 3 sets ( 8 to 12 ) repetitions
75929509|NCT05327023|Drug|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, maximum initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +70 with no taper. Doses should be modified as appropriate for drug interactions.
75929510|NCT05308641|Procedure|radial extracorporeal shockwave therapy_4000_20|application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz
75335823|NCT01054703|Device|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
75335824|NCT02544750|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
75929511|NCT05308641|Procedure|radial extracorporeal shockwave therapy_500_2|application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz
76084757|NCT04497792|Drug|Empagliflozin 10Mg Tab|Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication
76084758|NCT04497792|Drug|hypoglycemic therapy|hypoglycemic therapy.
75335825|NCT01662050|Drug|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
75645391|NCT02668575|Behavioral|Supportive Care Intervention|Patients in the intervention arm of the study will see a SC specialist during regularly-scheduled CF clinic visits; per usual care, these visits should occur on a quarterly basis. Using a structured intervention manual, these visits will span 30-60 minutes each. Each visit will have a specific focus, such as: 1) comprehensive palliative care assessment; 2) symptom assessment and self-management; 3) advance care planning; and, 4) coping and resilience. Patients requiring follow up with SC before the next CF appointment will receive telephone follow up or an extra SC visit at the discretion of the SC provider.
76084759|NCT02506530|Procedure|intensive decongestive treatment|intensive decongestive treatment
75335826|NCT04330456|Radiation|Preoperative stereotactic radiation therapy in hypofractionation mode|"At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.~At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.~GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy."
75645392|NCT02668497|Drug|Botulinum Toxin Type A|
75645393|NCT00737113|Drug|Genotropin (Recombinant Human Growth Hormone)|Patients will begin daily subcutaneous (SC) therapy at a starting dose of ~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.
75793429|NCT05845164|Device|tDCS|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~tDCS: The anode and cathode are two large 5 cm by 5 cm gel-based pads which are placed on the scalp. This reduces the risk of burn or irritation and increases conduction. The 2 electrodes are connected to the tKIWI device which delivers a low intensity electrical current (</=2A), thereby polarizing membrane potential of neurons in the stimulated area. Current that flows from the cathode to the anode has an inhibitory effect on the stimulated area, while current that flows from the anode to the cathode is typically excitatory. We will be initiating bilateral stimulation of the Dorsolateral pre-frontal cortex (DLPFC), which has been shown in the literature to elicit a significant decrease in ambiguous risk-taking behavior in healthy human subjects and a decrease in impulsivity on a non-ambiguous risk task."
75793430|NCT05845164|Device|tDCS Sham|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~The sham group will receive ramped up current from 0.0mA to no more than 0.5mA for the first minute at the initiation of each of the three ramp ups, after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle. The current delivered by tDCS is not strong enough to trigger an action potential in a neuron; instead its sub-threshold changes the pattern of already active neurons."
75793431|NCT05845151|Diagnostic Test|68Ga-FAPI-04 PET|Activation of renal fibroblast is quantified using 68Ga-FAPI-04 PET in patients with LN.
75929512|NCT05308641|Procedure|standard multimodal pain therapy|standard multimodal pain therapy
75929513|NCT05303064|Drug|OLZ/SAM|OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
75929514|NCT05303064|Drug|Olanzapine|The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
75929515|NCT05300074|Other|Inspiratory Muscle Training|IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.
75929516|NCT05288751|Behavioral|Contingency Management|Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
75929517|NCT05286749|Procedure|Workshop plus Clinician-Collected Cervical Swab|clinician-collection methods using speculum and cervical swabs
75929518|NCT05286749|Device|Workshop plus Participant-Collected Cervical Swab|Evalyn® Brush (Rovers® Medical Devices, Netherlands)
75929519|NCT05286749|Diagnostic Test|HPV testing on Participant-Collected Cervical Swab Samples|Roche Cobas4800 HPV Test System (Roche Molecular Systems Inc., Rotkreuz, Switzerland)
75929520|NCT05280366|Device|Streamline Surgical System|Completion of the Streamline Surgical System procedure
76084760|NCT02506530|Device|Cellu M6|Use of Cellu M6
76084761|NCT02511990|Biological|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
76084762|NCT02511990|Biological|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
75645394|NCT00737191|Drug|olanzapine|Given orally
75645395|NCT00737191|Other|placebo|Given orally
75645396|NCT00758680|Drug|MK-1006|MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
76084763|NCT02511990|Biological|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
76084764|NCT02506218|Dietary Supplement|10 + 20 g protein consumption|whey isolate
76084765|NCT02506218|Other|30 g protein breakfast|30 g mixed meal breakfast
76084766|NCT02506218|Other|10 g protein breakfast|10 g mixed meal breakfast
75645397|NCT00758680|Drug|Comparator: Placebo comparator|Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
75645398|NCT00732433|Procedure|digital mammography|Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
75645399|NCT04175067|Diagnostic Test|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
75793432|NCT05845125|Other|Physiotherapy alone|Physiotherapy focusing on increasing the shoulder range of motion.
75929521|NCT05280366|Device|iStent Inject W|Implantation of competitor device
75929522|NCT05277194|Behavioral|KeepCalm app|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism.
75929524|NCT05270044|Drug|Encorafenib and Binimetinib|Encorafenib 450 mg (6 × 75 mg capsules) once daily (QD) and binimetinib 45 mg (3 x 15 mg tablets) twice daily (BID) orally for a maximum of 12 months.
75929525|NCT05270044|Drug|Placebo to match Encorafenib ; Placebo to match Binimetinib|Encorafenib (6 × 75 mg placebo capsules) QD and binimetinib (3 × 15 mg placebo tablets) BID placebos orally for a maximum of 12 months.
75929526|NCT05267041|Other|Quality of life questionnaire|One questionnaire between diagnostic annoucement and first line treatement
75929527|NCT05267041|Biological|Blood sample|One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
75929528|NCT05267041|Other|Quality of life questionnaire|One questionnaire 6 months later after first line treatment
75929529|NCT05267041|Other|Quality of life questionnaire|One questionnaire before second line treatment
75929530|NCT05267041|Other|Quality of life questionnaire|One questionnaire 6 months later after second line treatment
75929531|NCT05258773|Drug|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.
75929532|NCT05258539|Other|Questionnaire|"Telephone calls at 2, 3 and 5 years with :~Lifestyle follow-up questionnaire.~Satisfaction questionnaire."
75929533|NCT05254756|Device|Bouquet speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
75335827|NCT04330456|Procedure|Surgery|In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
75645400|NCT04175067|Diagnostic Test|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
75645401|NCT02668107|Other|Hammock positioning|Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
75645402|NCT02668029|Drug|oxygen|information already included in arm/group descriptions.
75645403|NCT02668029|Drug|medical air|Placebo
75929534|NCT05254756|Device|Traditional plastic 2-blade disposable speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
75929535|NCT05253118|Drug|Tislelizumab|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed.
75929536|NCT05253118|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
75929537|NCT05251974|Diagnostic Test|Quest beta blocker assay|Blood assay to detect presence of beta blocker medications
75929538|NCT05251714|Drug|CFI-402257|Oral once daily in 28 day cycles
75335828|NCT04330456|Radiation|Postoperative conformal radiation therapy in normofractionation mode|"In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.~PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery."
75335829|NCT02654028|Procedure|Autotransfusion|These group of patients will receive autotransfusion before liver resection.
75929539|NCT05251714|Drug|Fulvestrant|500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle
75929540|NCT05251493|Drug|Iron Isomaltoside 1000, ferric derisomaltose|iron isomaltoside 20 mg/mL
75929541|NCT05251493|Drug|Iron sucrose|iron sucrose 100 mg/mL
75929542|NCT05246709|Device|Cyanoacrylate glue|"Adhesive to be applied on the PICC line site prior to usual standard film dressing over the site, such as SecurePortIV® Catheter Securement Adhesive by Adhezion Biomedical® Cyanoacrylate adhesive that is FDA-approved for securement of vascular access devices.~Securement method that provides microbial protection by sealing the insertion site."
75929543|NCT05246709|Device|Standard transparent film dressing|A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.
75929544|NCT05240807|Diagnostic Test|Photon counting computed tomography (PC-CT)|Cardiac CT imaging will be performed using a newly developed CT scanner that uses photon-counting detectors and the results compared to those from conventional CT, MRI, or nuclear medicine imaging systems
75929545|NCT05240235|Other|Education, compression and exercise therapy|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home.
75936443|NCT03626597|Diagnostic Test|Urine Pregnancy Test|CHV will provide all participants with in-person urine pregnancy tests (UPTs)
75936444|NCT03626597|Behavioral|CHV-based post-test counseling & referral|CHVs will provide in-person post-test counseling & referral to care
75335830|NCT02654028|Other|Control group|These group of patients will not receive autotransfusion before liver resection.
75335831|NCT02536092|Device|755nm and 1064nm Nd:YAG laser|Dual wavelength 755nm and 1064nm Nd:YAG laser
75335832|NCT04748848|Drug|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.
75793433|NCT05845125|Drug|Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy|"The patient will lie supine on the radiology table. Proper skin disinfection will be done with Soluprep x 3 and sterile draping will be applied. An anterior view of the shoulder will be obtained with the fluoroscopic C-arm. Location of the injection site will be obtained with a radio-opaque stylus. Proper local anesthesia will be performed using approximately 1cc of 0.5% Bupivacaine intradermal. A 22G 3.5 spinal needle will be placed in the glenohumeral joint under fluoroscopic guidance using the anterior approach. A small amount (1cc) of iodine-based contrast agent (Omnipaque) will be injected under live fluoroscopic imaging to confirm the intra-articular position of the needle in the glenohumeral joint. In the event of a known iodine contrast allergy, no contrast agent will be used. A combination of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine will be injected into the glenohumeral joint."
75793434|NCT05845112|Diagnostic Test|Molecular Diagnostics|pooled sputum samples will be used at the site of sample collection on the EDGE platform using Xpert ULTRA cartridges
75335833|NCT04748848|Drug|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.
75335834|NCT04748848|Drug|Azacitidine|Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2
75793435|NCT05845112|Diagnostic Test|Qualitative C-Reactive Protein (CRP)|CRP qualitative (POC) rapid tests are immunochromatographic based assays for qualitative or semiquantitative determination of CRP circulating in blood, serum or plasma at the Point of Care with a time to result in 5 minutes.
75793436|NCT05845112|Diagnostic Test|Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP|CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.
75793437|NCT05845112|Diagnostic Test|Urine lateral flow tests|The assay combines a pair of high affinity monoclonal antibodies directed towards largely Mycobacterium tuberculosis-specific lipoarabinomannan epitopes and a silver-amplification step that increases the visibility of test and control lines. This enables the detection of urinary lipoarabinomannan concentrations that are approximately 30 times lower than that detected by a previous test called AlereLAM and improved analytical specificity compared with AlereLAM.
75793438|NCT05845112|Diagnostic Test|Portable Chest X Ray Image Acquisition|Qure.ai (Qure.ai, New York, USA) is a computer aided detection (CAD) software for the automated screening of tuberculosis. Qure.ai is a mobile based interpretation software that screens chest X-Ray to detect TB in less than a minute. Qure.ai can distinguish abnormal scans from normal and detect abnormalities in the lungs, pleura, mediastinum, bones, diaphragm, and heart.
75793439|NCT05845034|Procedure|PVI + SPEs ablation|electrophysiology substrate mapping is the critical difference between both groups.
75793440|NCT05845034|Procedure|PVI ablation|electrophysiology substrate mapping is the critical difference between both groups.
75793441|NCT05844930|Drug|Corticosteroid|Triamcinolone 20 mg (1cc)
75793442|NCT05844930|Other|ActiveMatrix|1cc ActiveMatrix (Skye Biologics, Inc.)
75793443|NCT05844930|Drug|Lidocaine|Lidocaine 10 mg/mL (5cc)
75793444|NCT05844917|Device|ultrasound|Ultrasound detection of subclinical arthritis among Patients With SLE
75793445|NCT05844826|Device|SIMBA Capsule|Participants will swallow capsule
75793446|NCT05844800|Procedure|Nuss repair of Pectus Excavatum|The Nuss procedure is a minimally-invasive repair technique of PE (MIRPE), whereby one to three curved metal bars are inserted behind the sternum to correct the shape of the anterior chest wall. The bars are left in situ for three years and then removed.
75793447|NCT05844800|Drug|Epidural anesthesia|The Nuss procedure of pectus excavatum repair surgery is performed under general anesthesia. Epidural anesthesia, with a constant infusion of 0.25% bupivacaine, was routinely used and was maintained in the early postoperative period.
75793448|NCT05844787|Drug|MT101-5|Tablet
75793449|NCT05844774|Device|HPI (using HemoSphere) - guided algorithm|Treatment of hypotension guided by the hypotension prediction index. Patients will receive treatment following the predetermined HPI-algorithm when the HPI exceeds 85%.
75793450|NCT05844774|Device|Treatment of hypotension following standard of care|Patients receive standard of care treatment for hypotension, with a goal-mean arterial pressure (MAP) of 65mmHg.
75936445|NCT03626597|Behavioral|Phone-based post-test counseling & referral|Participants will call/SMS or be called/SMSed for phone-based counseling & referral to care
75936446|NCT03188978|Drug|Atorvastatin 40mg|one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
75936447|NCT03188978|Other|Placebo|one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
75335835|NCT04748848|Drug|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle
75335836|NCT04748848|Drug|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.
75335837|NCT04782206|Procedure|superior hypogastric plexus block|superior hypogastric plexus chemical neurolysis
75335838|NCT04782206|Procedure|pulsed radiofrequency at S3 root plus superior hypogastric plexus block|pulsed radiofrequency neuromodulation at S3 root plus superior hypogastric plexus chemical neurolysis
75335839|NCT02526342|Device|V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)|Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
75335840|NCT02171195|Drug|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
75793451|NCT05844761|Radiation|Triggered imaging on TrueBeam with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the TrueBeam triggered imaging motion management technique.
75335841|NCT02171195|Drug|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
75335842|NCT04739878|Procedure|Airway Ultrasound|Comparison between Airway ultrasound and CT cervical
75335843|NCT04782440|Other|Telerehabilitaton|Patients will receive telerehabilitation sessions that include strengthening, stretching and range of motion exercises
75335844|NCT04782440|Other|Home exercise|Patients will be given a home-based exercise program without telerehabilitation supervision
75335845|NCT00382798|Drug|RO5024048|
75335846|NCT04781738|Diagnostic Test|Cardiopulmonary exercise test|"CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages~Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test.~SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items).~Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state)."
75645404|NCT00645489|Behavioral|psychoeducational|Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
75335847|NCT03015155|Procedure|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
75335848|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
75472741|NCT01962220|Behavioral|Study Intervention for Retention (APFU)|"Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).~Mama Mshauri tasks will include:~Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.~Providing tailored individualized health education during home visits.~Additional intervention components include:~Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.~Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment."
75472742|NCT01962233|Biological|mesenchymal stem cells|"Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.~Intravenous infusion of umbilical cord derived mesenchymal stem cells"
75645405|NCT00645489|Other|wait list|Wait list
75645406|NCT00758602|Drug|mycophenolate mofetil|0.75-1 g PO BID from Day 0 through Month 12
75645407|NCT00758602|Drug|tacrolimus, standard dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
75793452|NCT05844761|Radiation|Synchrony MLC tracking on fiducials with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique.
75936448|NCT02431286|Drug|Aprepitant|aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
75335849|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
75472743|NCT01962259|Behavioral|Physical activity|
75472744|NCT01962272|Behavioral|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
75472745|NCT01962272|Dietary Supplement|Forticare®.|
75472746|NCT01962285|Drug|propofol targel controlled infusion|slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
75645408|NCT00758602|Drug|tacrolimus, low dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
75793453|NCT05844761|Radiation|Synchrony MLC tracking and lung adaptive model with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique for lung cancer.
75793454|NCT05844748|Other|diabetes education with motivational interview technique|Techniques such as developing empathy, developing disengagement, turning with resistance, supporting self-efficacy, avoiding advice, a simple decision, importance-trust scale, open-ended questions, reflection and segmentation in motivational interviews.
75936449|NCT02431286|Drug|Placebo|Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
75936450|NCT02431286|Drug|Dexamethasone|Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
75335850|NCT01620788|Drug|Hyzaar®|1 tablet of Hyzaar®, oral, a day
75335851|NCT01620788|Drug|Hyzaar®|1 tablet of Hyzaar®, oral, a day
75335852|NCT04983628|Other|Tumor molecular profiling|targeted DNA NGS
75335853|NCT03014843|Drug|Naloxone|20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
75472747|NCT01962311|Procedure|lumbar puncture|lumbar puncture at enrollment in study
75472748|NCT01962350|Device|Deep Brain Transcranial Magnetic Stimulation|H1-Coil deep brain rTMS at cortex prefrontal.
75472749|NCT01962363|Drug|EPI-743|EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
75929546|NCT05240235|Other|Education, compression and exercise therapy manual lymph drainage|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home. In addition, patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
75929547|NCT05231746|Biological|hSTC810|hSTC810 will be administered as an intravenous infusion (IV)
75929548|NCT05230732|Device|neuromodulation device|Active LLTS will be performed by use of a neuromodulation device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks
75929549|NCT05230732|Device|SHAM|Sham LLTS will be performed by use of a neuromodulation device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks
75929550|NCT05227755|Dietary Supplement|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
75335854|NCT03014843|Drug|Methylnaltrexone Bromide|12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
75335855|NCT03014843|Other|Placebo|0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
75645409|NCT00758602|Drug|corticosteroids|According to center's practice
75793455|NCT05844722|Behavioral|Mindfulness-based intervention therapy|Mindfulness-based cognitive therapy consists of meditation techniques to stay in the present moment with acceptance (breathing exercises, body scan, gentle yoga, awareness of thoughts and feelings) and some aspects of cognitive therapy, and psycho-education.
75793456|NCT05844722|Other|usual care|Usual care means received standard multidisciplinary stroke care
75793457|NCT05844709|Other|IVH care Bundle|"The experimental group received bundle nursing care within 3 days after birth in addition to routine nursing care after consent was given and the informed consent form was signed.~IVH care Bundle: 1. Maintaining midline head position 2. Avoid prone, place in supine or side-lying position 3. Incubator tilted 15-30 degrees 4. Slow withdrawal and flushing for UAC, UVC, and PAL."
75793458|NCT05844683|Other|2% chlorhexidine digluconate solution|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
75793459|NCT05844683|Other|usual baths|Bathing will be performed at least daily using shampoo and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
75929551|NCT05227755|Dietary Supplement|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
75929552|NCT05227456|Drug|Etonogestrel 68mg implant|Implant will be inserted
75929553|NCT05227456|Device|Etonogestrel 68mg implant|Implant will be inserted
75929554|NCT05223894|Biological|hiPSC-CM therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
75929555|NCT05223894|Other|Control|Coronary artery bypass grafting surgery only.
75335856|NCT02540538|Biological|HBVaxPro|3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
75335857|NCT02540538|Biological|HBAI20|2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
75929556|NCT05220904|Device|spectacles|Spectacle is the the most common treatment for refractive errors.
75929557|NCT05220904|Device|perceptual learning|Blurred vision from the eyes can be improved by enhancing the brain's visual processing.
75335858|NCT05081375|Drug|Enoxaparin Injectable Product|Not holding prophylaxis dose prior to surgical procedure
75335859|NCT05081375|Drug|Sodium chloride|Holding prophylaxis dose of Enoxaparin replacing with placebo
75645410|NCT02667717|Behavioral|Mirror therapy|The intervention is a mirror therapy. The mirror therapy consists in performing some movements with a mirror, the hand that is painful is hidden and the image of the healthy hand is reflected in the mirror. Patients looking at this image seems to see their painful hand moving.
75645411|NCT02667717|Behavioral|Usual care|Patients will have the usual care as an intervention.
75645412|NCT02667795|Other|Monitored walking based exercise|Monitored walking based exercise
75645413|NCT02601118|Other|Micro Expression Training Tool|The Micro Expression Training Tool (METT) and the Subtle Expression Training Tool (SETT) to help improve the non-verbal communication skills
75645414|NCT02667561|Drug|Testosterone gel 1% 2.2 mg|Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
75929558|NCT05220735|Dietary Supplement|Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA)|"3 three fish oil capsules providing 2.1 g n-3 PUFA; 1.27 g Docosahexanoic acid (DHA) and 0.86 g Eicosapentanoic acid (EPA) capsules.~The absorption study test meals will consist of white bread with butter and honey, 6mg of labeled iron as ferrous sulfate and 300 g of distilled water. The meal will be given on two days without and with ascorbic acid. The test meals without ascorbic acid will contain 6 mg 57Fe as ferrous sulfate whereas the meals containing ascorbic acid will contain 6 mg 58Fe as ferrous sulfate."
75929559|NCT05220397|Biological|Janssen Ad26.CoV2.S Vaccine|Single dose vaccine of 0.5 mL administered via intramuscular injection, typically in the deltoid muscle
75929560|NCT05220397|Other|Reduction in Immunosuppression Medication|Reduction in immunosuppression medication dosage
75929561|NCT05220397|Other|Maintenance in Immunosuppression Medication|Maintain current immunosuppression medication dosage
75929562|NCT05219617|Drug|Carisbamate|"Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg (not to exceed a total of 400 mg per day).~Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg (not to exceed a total of 600 mg per day)."
75793460|NCT05844670|Drug|Vincristine|"The initial vincristine dosage will be according to institutional treatment protocol. After vincristine administration, three blood samples will be taken at T=1, T=1.5 and T=4 hours. The concentration of vincristine will be analyzed in the samples. If the concentration of 2 or more samples is lower than the reference concentration and there is no toxicity, an advice will be given to increase dosage by 20%. Whether or not a dosage is given, vincristine concentrations will be measured again for the next dose administration.~For the feasibility study, both venous blood samples and finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 2 times.~For the rest of the study, finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 3 times.~Toxicity will be monitored through physical exam and questionnaire, bilirubin levels and clinical status of the patient."
75929563|NCT05218642|Drug|KX- 826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
75335860|NCT02201628|Device|Nasopharyngeal and oesophageal temperature probes|
75335861|NCT04980898|Device|WoundEL medical device|"The WoundEl system is composed by: a class IIa device , a class IIb dressing electrode and a class I disperser electrode.~Applied to the leg ulcer, WoundEL® reproduces the endogenous electrical current to stimulate all the factors contributing to healing. Electrical current is evenly spread over the Dressing Electrode which also maintains a moist wound healing environment."
75645415|NCT02667561|Drug|Testosterone gel 1% 4.4 mg|Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
75645416|NCT02667561|Drug|Testosterone gel 1% 8.8 mg|Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
75645417|NCT02667561|Drug|Placebo of Testosterone Gel 1%|Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
75793461|NCT05844644|Dietary Supplement|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
75929564|NCT05218642|Drug|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
75929565|NCT05218642|Drug|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
75929566|NCT05218642|Drug|Matching placebo to KX-826|Placebo applied topically to scalp twice daily or once daily for 24 weeks
75929567|NCT05216666|Procedure|Lateral approach|Total hip arthroplasty performed through a lateral surgical approach (Gammer)
75929568|NCT05216666|Procedure|Posterior approach|Total hip arthroplasty performed through a posterior surgical approach (Moore)
75929569|NCT05209074|Drug|Ivosidenib|Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.
75929570|NCT05209074|Drug|mFOLFIRINOX|mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.
75929571|NCT05208619|Procedure|Regional anaesthesia|Patients receive either a thoracic epidural analgesia or paravertebral block as an regional anaesthetic adjunct to general anaesthesia for thoracic surgery
75929572|NCT05206838|Procedure|Surgical reconstruction of gluteus medius with Achilles tendon allograft|Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
75929573|NCT05201339|Procedure|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
75929574|NCT05201339|Procedure|Hean and Neck Rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
75929575|NCT05200897|Device|Transdermal trigeminal electrical neuromodulation(Cefaly)|The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes
75929576|NCT05196737|Behavioral|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
75929577|NCT05195645|Drug|Abatacept 250 MG|Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
75929578|NCT05195060|Drug|casirivimab with imdevimab|Monoclonal antibody
75929579|NCT05195060|Drug|sotrovimab|Monoclonal antibody
75929580|NCT05195060|Drug|molnupiravir|antiviral agent
75929581|NCT05188040|Other|Virtual Reality Exercises|Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
75936451|NCT02431208|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
75335862|NCT04980898|Other|Standard cares|Cleaning and monitoring
75645418|NCT02667405|Procedure|Hot Pack|Patients have a hot pack and 2 layers of towel wrapped around the wrist and forearm for 15 minutes
75645419|NCT02667405|Procedure|Whirlpool|Patients immerse their arm, from elbow to hand, in a whirlpool bath of 104 degrees Fahrenheit for 15 minutes
75645420|NCT00732511|Drug|carvedilol|capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
75793462|NCT05844631|Dietary Supplement|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
75929582|NCT05182775|Procedure|Fecal bacteria transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from the feces of a healthy person into the gastrointestinal tract of a patient, thereby reestablishing the intestinal flora with normal function. FMT promotes the treatment of intestinal microecology by eliminating single microorganisms or certain pathogens (such as vaccines and antibiotics) and increasing beneficial bacteria (such as prebiotics and probiotics) to the reconstruction of intestinal microecology. The best treatment indication for FMT is Clostridium difficile infection, which is a treatment choice confirmed by expert consensus and guidelines in many countries and regions. Meanwhile, FMT has been used in the treatment and research of many intestinal microbiome related diseases worldwide.
75929583|NCT05178849|Other|Hypnosis|Hypnosis
75929584|NCT05178849|Drug|Local anesthetic|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
75929585|NCT05177094|Drug|LY3526318|Administered orally
75645421|NCT00732511|Drug|metoprolol extended release|tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
75645422|NCT02667249|Other|clinical pathway|implementation of a standardized clinical pathway
75472750|NCT01962376|Drug|Oxaliplatin;Capecitabine|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
75645423|NCT00739531|Device|Exhaled nitric oxide (eNO)|Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
75645424|NCT05047887|Procedure|Modified socket shield technique with autogenous dentin graft material (in one side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then Tooth particles will be demineralized using 2% HNO3 (El-Gomhouria CO. Egypt) for 20 minutes to expose the dentin organic matrix.
75793463|NCT05844605|Procedure|Non-invasive neuromodulation (TMS and/or tDCS)|Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
75793464|NCT05844592|Drug|INV-101|subjects will be randomized 3:1 ratio
75929586|NCT05177094|Drug|Placebo|Administered orally
75929587|NCT05176574|Behavioral|Questionnaire|A questionnaire will be developed via the Delphi method, will be pilot tested and implemented to assess physicians' perceptions and behaviors on physical activity and exercise in chronic, non-communicable diseases.
75929588|NCT05172973|Device|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
75929589|NCT05167786|Device|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform lower limb locomotor activities.
75929590|NCT05167786|Device|Noninvasive spinal stimulation|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation to subjects.
75929591|NCT05167786|Device|Conventional gait training|Subjects will receive lower limb locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
75472751|NCT01962376|Drug|Oxaliplatin;Capecitabine;Bevacizumab|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
75472752|NCT01962389|Device|Winsor Laser Catheter|
75472753|NCT01962402|Drug|lorcaserin|Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
75472754|NCT01962402|Behavioral|Intensive dietary counseling|All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
75793465|NCT05844553|Device|Measurement of inhaled measuring hydrogen peroxide in exhaled breath|Participant exhales from device
75929592|NCT05167786|Other|Sham|Subject will not receive either transcutaneous electrical spinal cord stimulation or perform lower limb locomotor activities.
75929593|NCT05167786|Other|Exploratory Phase - Optimization of Gait Training and Spinal Stimulation|Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
75929594|NCT05165173|Dietary Supplement|NanoD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of nanoparticles of D3 and instructed to consume it in the morning with a meal.
75929595|NCT05165173|Dietary Supplement|MicroD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of microparticles of D3 and instructed to consume it in the morning with a meal.
75929596|NCT05164367|Drug|Atropine sulfate gel (0.01%)|A research nurse will measure 1 gram of gel using a calibrated measuring spoon and will provide it to the participant for self-administration.
75929597|NCT05161793|Device|Tele-Monitor DM|Remote monitoring of CGM data to identify, contact, and provide diabetes management for patients who are having episodes of hypoglycemia, hyperglycemia and/or difficulty using their CGM device.
75929598|NCT05156203|Drug|T-1301 Capsules|T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
75929599|NCT05155800|Device|SDx3|The SENSE Device (SDx3) is a non-invasive device that detects differences in the absorption of transmitted RF energy across the skull and brain and is intended to be used to evaluate intracranial hemorrhage.
75929600|NCT05152966|Device|Ablation|Ablation using the FARAPULSE™ Cardiac Ablation System Plus
75472755|NCT01962454|Drug|Deuterated Water|D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
75472756|NCT01962454|Drug|Testosterone enanthate|Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
76084767|NCT03345264|Behavioral|Online, interactive self-help program|Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
75793466|NCT05844540|Procedure|harvesting bone block|Under local anesthesia, a sulcular incision was performed between lower right and left second premolars with an oblique incision distal to each one. After that, a full thickness mucoperiosteal flap was elevated to expose the anterior mandible including the entire symphysis and both mental nerves. By using piezo-surgery unit (Surgic Touch, Woodpecker, China), a rectangular bone block was harvested from the symphysis about 8mm in depth and 2mm wider than the recipient site to allow for contouring. The bone cuts were performed 5mm far from the apices of the anterior teeth, mental foramina, and inferior border of the mandible. Finally, thin curved osteotomes was used to detach the bone blocks. The harvested bone block was trimmed to form L-shape block and kept in normal saline. After hemostasis, the flap was closed with 4/0 vicryl interrupted sutures.
76084768|NCT02511834|Device|VEST External Support|
75793467|NCT05844540|Procedure|Recipient site preparation|At the maxillary recipient site, after induction of local anesthesia, a mid-crestal incision that continued in the sulcus for two teeth on either side of the defect with bilateral oblique incisions were performed. After that, the full thickness mucoperiosteal flap was elevated. While for mandibular recipient site, it was the same flap used for harvesting symphyseal bone block. For both upper or lower recipient sites, perforations (bone marrow penetration) were done to the recipient site by using a fissure surgical bur. The L-shape block graft was trimmed to obtain optimal adaptation to the recipient site, then it was fixed to the residual ridge with two 1.5mm self-tapping titanium screws. After attaining graft stability, any sharp edges were smoothed and any gap between the graft and underlying alveolar bone was filled with particulate bone curetted from the donner site.
76084769|NCT02511834|Procedure|Coronary Artery Bypass Surgery|
76084770|NCT02511912|Procedure|V-Wave|The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
76084771|NCT04497714|Diagnostic Test|Ultrasonic image collection|Ultrasonic image collection,consist of three static images and one dynamic image
75793468|NCT05844540|Procedure|implant insertion|"Implant insertion:~After 6months, the surgical site was opened to remove fixation screws and insert dental implants, and the final restoration was done 4months after implant insertion."
75929601|NCT05149651|Drug|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
76084772|NCT03344952|Drug|Botulinum toxin type A|Repeated injections to hypertonic muscles
75929602|NCT05149651|Drug|MTA|ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
75929603|NCT05145335|Device|Autoregulated Blood Flow Restriction Cuff (smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which autoregulates so when the quadriceps muscle contracts, the total amount of pressure doesn't increase, as the tourniquet will lower the pressure to keep the total amount of pressure constant.
76084773|NCT03344952|Other|Physical therapy|3 weeks intensive program 1 week -10 days after BoNT-A injections
76084774|NCT02511756|Device|Computed tomography X-ray system|Contrast-enhanced computed tomography of liver metastases
76084775|NCT02515266|Other|nutrition: protein intake|additional protein fortification of human milk
76084776|NCT02506452|Other|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
76084777|NCT02506452|Other|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
76084778|NCT02515422|Drug|Ketamine|Subcutaneous infiltration of ketamine
75472757|NCT01962454|Drug|Placebo to match testosterone enanthate|Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
75472758|NCT01962467|Drug|FF/LEV FDC|Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
75472759|NCT01962467|Drug|FF|Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
75472760|NCT01962467|Drug|LEV|Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
75929604|NCT05145335|Device|Non-autoregulated blood flow restriction cuff ((smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training)|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which does not autoregulate so when the quadriceps muscle contracts, the total amount of pressure will increase, as the tourniquet will not lower the pressure to keep the total amount of pressure constant.
75929605|NCT05125055|Drug|Toripalimab (anti-programmed death-1 inhibitor)|The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.
76084779|NCT02515422|Drug|Bupivacaine|Subcutaneous infiltration of bupivacaine
76084780|NCT02515422|Drug|Placebo (0.9% saline solution)|
75472761|NCT01962480|Procedure|The hernia gap is sutured intracorporally|The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson & Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
76084781|NCT02515344|Other|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
75929606|NCT05125055|Drug|Albumin paclitaxel|The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
75929607|NCT05125055|Drug|Cisplatin|The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m^2 of Cisplatin will be used intravenously on the first day of each cycle.
75929608|NCT05125055|Drug|Docetaxel|The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m^2 of Docetaxel will be used intravenously on the first day of each cycle.
76084782|NCT02515344|Other|Providing general information about CRC sreening|
75929609|NCT05125055|Drug|5-Fluorouracil|The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
75929610|NCT05117775|Other|No intervention - Just description and predictive models|All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).
75929611|NCT05115955|Drug|DS group|In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
76084783|NCT02506296|Drug|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
76084784|NCT02506296|Device|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
76084785|NCT02506140|Drug|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
76084786|NCT02506140|Drug|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
76084787|NCT02515188|Drug|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
76084788|NCT02515188|Drug|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
75929612|NCT05115955|Drug|Control group|In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
75929613|NCT05108844|Procedure|Videocapsule endoscopy|Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
75929614|NCT05107921|Drug|Bromfenac Sodium|The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
75929615|NCT05104749|Drug|Homeopathic Medication|Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
75929616|NCT05104749|Other|Placebo|Inert lactose pellets
76084789|NCT02506062|Device|Manual blood pressure cuff inflation over brachial artery|A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
76084790|NCT02505672|Radiation|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
76084791|NCT01696084|Drug|CPX-351|First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
76084792|NCT01696084|Drug|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
76084793|NCT02515032|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
76084794|NCT02515032|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
75793469|NCT05844514|Diagnostic Test|Breath test|Patients must be fasted for a minimum of four hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
76084795|NCT02514876|Device|Foresight ICE System|The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
76084796|NCT02511600|Other|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
75793470|NCT05844488|Device|PrecivityAD|Measure risk for amyloid plaques in the brain and will include a test for certain genetic variants (specifically, ApoE proteins in the blood revealing APOE genotype) known to be associated with Alzheimer's disease.
75793471|NCT05844410|Drug|Corticosteroid|Adults patients admitted to the hospital after a confirmed COVID-19 infection, irrespective of the stage and severity of the disease, were included in the study. Only those receiving corticosteroids as a treatment were in the study sample, with no preferences based on race or ethnicity
75793472|NCT05844397|Device|WaveLight EX500 Excimer Laser System|LASIK Refractive Surgery Using Contura with Phorcides
75793473|NCT05844397|Device|VisuMax Surgical Laser|SMILE Refractive Surgery
76084797|NCT02511600|Other|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
76084798|NCT02511600|Behavioral|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
76084799|NCT02228824|Drug|Very low nicotine content cigarettes|0.07 mg nicotine delivery
76084800|NCT02228824|Drug|Normal nicotine content cigarettes|0.8 mg nicotine delivery
75929617|NCT05102981|Procedure|emergency procedure|The difference between groups is the timing or type ie emergency as opposed to planned
75929618|NCT05098041|Drug|Soticlestat|Soticlestat tablets.
75645425|NCT05047887|Procedure|Modified socket shield technique with alloplast graft material (in contralateral side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then alloplast graft will be used
75645426|NCT04174599|Biological|F-627|Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein
75472762|NCT01962519|Dietary Supplement|Early oral feeding|Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
75472763|NCT01962532|Drug|Part 1: JNJ-42756493|JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
75645427|NCT00739609|Drug|1-methyl-D-tryptophan|D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
75645428|NCT02667483|Drug|DS-5141b|DS-5141b, Subcutaneous injection
75929619|NCT05098041|Drug|Rifampin|Rifampin capsules.
75929620|NCT05088356|Drug|Purified regulatory T-cells (Treg) plus CD34+ HSPC|"Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells (CD34+ HSPC), Manufactured at SCTT Laboratory, dose 1x10^6 cells/kg to 3x10^6 cells/kg"
75929621|NCT05088356|Drug|Fludarabine|Fludarabine (160 mg/m2)
75929622|NCT05088356|Drug|Melphalan|Melphalan (50 mg/m2) in Arm A; Melphalan (100 mg/m2) in Arm B
75929623|NCT05088356|Device|CliniMACS CD34 Reagent System|The CliniMACS® CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations is manufactured by Miltenyi Biotec
75929624|NCT05088356|Drug|Tacrolimus|4-6ng/mL
75793474|NCT05844384|Device|Nanodropper|Nanodropper delivers 1/5 of eye drop volume compared to regular droppers
75929625|NCT05088356|Drug|Cyclophosphamide|40mg/kg
75929626|NCT05088356|Drug|Plerixafor|Dose 0.24 mg/kg, manufactured by Genzyme
75929627|NCT05088356|Drug|Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent|Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL
75929628|NCT05084391|Device|stereotactic ablative radiotherapy (SABR)|is safe for treating heart arrhythmias (irregular heartbeat
75929629|NCT05084391|Other|Standard of Treatment|Standard of care
75472764|NCT01962532|Drug|Part 2: JNJ-42756493|Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).
75472765|NCT01962545|Drug|OAC alone|Single APT with either aspirin or clopidogrel is discontinued in this arm.
75645429|NCT00739687|Drug|ALT-711|200 mg tablet BID for 9 months.
75645430|NCT00739687|Drug|Placebo|200 mg tablet BID for 9 months.
75645431|NCT00645723|Drug|Colistin|intravenous colistin and nebulized colistin
75645432|NCT00645723|Drug|Colistin and saline solution|intravenous colistin and nebulized saline solution
75793475|NCT05844384|Device|Regular dropper|Delivers full eye drop volume
75793476|NCT05844371|Drug|tirelizumab|Tirelizumab (200 mg, q3w) was added and maintained until one year, starting with adjuvant chemotherapy after surgery.
75793477|NCT05844371|Drug|chemotherapy with oxaliplatin + heroda|chemotherapy with oxaliplatin + heroda
75793478|NCT05844358|Device|MySpine MC|Spinal stabilization throught the support of patient specific guide, MySpine MC according to cortical bone trajectory technique
75793479|NCT05844319|Other|tele-education|The treatment of the patients will be carried out by tele-education method.
75929630|NCT05081310|Device|superior vena cava isolation|SVC isolation by the means of cryoballoon
75929631|NCT05081310|Device|pulmonary vein isolation|conventional pulmonary vein isolation by the means of cryoballoon
75929632|NCT05079984|Behavioral|Graded exposure treatment (GET)|Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.
75929633|NCT05079035|Biological|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
75929634|NCT05079035|Biological|Saline|2 mL Sterile, preservative free 0.9% NaCl
75929635|NCT05076838|Drug|Diazepam Nasal Spray [Valtoco]|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
75929636|NCT05076760|Biological|MEM-288 Intratumoral Injection|Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
75929637|NCT05076760|Biological|Nivolumab|anti-PD1 monoclonal antibody
75793480|NCT05844306|Procedure|Computed Tomography|Undergo [18F]-FDG PET-CT
75793481|NCT05844306|Other|Fludeoxyglucose F-18|Given via injection
75793482|NCT05844306|Other|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
75793483|NCT05844306|Device|Positron Emission Tomography|Undergo [18F]-FDG PET-CT
75929638|NCT05076279|Procedure|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
75929639|NCT05069857|Drug|Camrelizumab (anti-PD-1 inhibitor)|The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.
75929640|NCT05069857|Drug|Apatinib (anti-VEGFR inhibitor)|The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
75929641|NCT05068674|Drug|Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells|50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.
75929642|NCT05068674|Drug|Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells|150M cells delivered in a dose of 15M cells per injection over 10 injections
76084801|NCT02505828|Procedure|Articular punction, salivary samples, blood sample|
75929643|NCT05068674|Drug|Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells|300M cells delivered in a dose of 30M per injection over 10 injections
75929644|NCT05059275|Procedure|modified ostium obstruction surgery|An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
76084802|NCT02511366|Other|Ileal infusion of casein|Intraileal infusion of casein
76084803|NCT02511366|Other|Ileal infusion of tap water|Intraileal infusion of tap water
75793484|NCT05844254|Procedure|novel overlapping rotated double (NORD) flap|"After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Patients will be randomly allotted to either group by stratified block randomization after taking baseline measurement with respect to periodontal phenotype(PP) [using transparency of periodontal probe through the gingival margin, when probe is visible, thin PP and when not visible, thick PP] so that patients with thick and thin PP get an equal chance of being allocated to NORD and Sub epithelial connective tissue group.~Group 1(NORD group)- Patients treated with NORD flap~Group 2 (Sub epithelial connective tissue group)- Patients treated with sub epithelial connective tissue graft Patients will be followed up after 1 month,6, 12 and 15 months. 30 patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification."
75793485|NCT05844215|Diagnostic Test|MMP-9 and TIMP-1|Examine level of serum MMP-9 and TIMP-1
75793486|NCT05844202|Drug|Alveavax-v1.2|BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19
76084804|NCT02230540|Device|SelfCath (comparator)|Commercially available CE-marked catheter for urinary drainage.
75335863|NCT04755062|Behavioral|Micronutrient-dense plant-rich Intervention|"The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes."
75793487|NCT05844202|Drug|Janssen Ad26.COV2.S|COVID-19 vaccine by Janssen / Johnson & Johnson
75793488|NCT05844189|Procedure|Physical therapy modalities on pelvic floor (manual therapy)|Intravaginal treatment (perineal massage)
75335864|NCT04284436|Behavioral|Treadmill walking|Treadmill walking 4 days per week for 30 minutes in the target heart rate
75335865|NCT03014531|Other|almond|
75335866|NCT03014531|Other|high-carbohydrate control food|
75335867|NCT01895504|Device|ColoAssist|Screening colonoscopy with the test instrument
75335868|NCT01895504|Device|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
75335869|NCT03852797|Drug|Oxytocin|Oxytocin solution, 20nM concentration
75335870|NCT03852797|Drug|Ketamine|Ketamine in solution, 10-4M to 10-7M
75335871|NCT03852797|Drug|Propofol|Propofol in solution, 10-4M to 10-7M
75472766|NCT01962571|Drug|Erythropoietin alfa|
75645433|NCT00737347|Behavioral|Lifestyle modification|lifestyle intervention includes meal planning, food preparation, food label reading, dining out, and physical activity counseling
75929645|NCT05049863|Drug|Mycophenolate Mofetil|Mycophenolate mofetil is commercially available.
75335872|NCT03852797|Drug|Etomidate|Etomidate in solution, 10-4M to 10-7M
75335873|NCT00900224|Genetic|DNA analysis|
75335874|NCT00900224|Genetic|DNA methylation analysis|
75335875|NCT00900224|Genetic|gene expression analysis|
75335876|NCT00900224|Genetic|mutation analysis|
75335877|NCT00900224|Genetic|polymerase chain reaction|
75335878|NCT00900224|Genetic|reverse transcriptase-polymerase chain reaction|
75472767|NCT01962571|Drug|Placebo|
75472768|NCT01962597|Other|aerobic exercise|
75335879|NCT00900224|Other|high performance liquid chromatography|
75335880|NCT00900224|Other|laboratory biomarker analysis|
75335881|NCT01055171|Drug|Propranolol|40 mg; Single Administration.
75335882|NCT01055171|Drug|Placebo|40 mg; Single Dose.
75335883|NCT04941053|Diagnostic Test|laboratory test|seroprevalnce
75472769|NCT01962597|Other|resistance training|
75472770|NCT01962610|Other|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit.
75472771|NCT01962623|Other|IPT-MBD|IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
75472772|NCT01962649|Biological|ICG|
75472773|NCT01962649|Device|Optical molecular imaging|
75645434|NCT02568865|Other|Physiological Sensors|Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).
75645435|NCT02568865|Other|Sleep Monitoring Device|The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.
76084805|NCT02230540|Device|Product A SelfCath and urine bag, Conveen Security+|SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
76084806|NCT02230540|Device|Product B SelfCath and urine bag, Conveen Contour|SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
75929646|NCT05049863|Drug|Allopurinol|Allopurinol is commercially available.
76084807|NCT02514954|Drug|Biochaperone® Combo|Subcutaneous injection of an individualized dose
75929647|NCT05049863|Drug|Irinotecan|Irinotecan is commercially available.
75335884|NCT04714996|Drug|ES-481|"Treatment Period Week 1 - 25 mg qd, Week 2 - 25 mg bid, Week 3 - 50 mg bid, Week 4 - 75 mg bid.~Step-down and Washout Period Day 1 - 125 mg, Day 2 - 100 mg, Day 3 - 75 mg, Day 4 - 50 mg, Day 5 - 50 mg, Day 6 - 25 mg, Day 7 - 25 mg, Days 8 to 14 - 0 mg"
75936452|NCT02431208|Drug|Daratumumab|Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
75335885|NCT04714996|Drug|Placebo|Placebo on Week 1, Week 2, Week 3 and Week 4
75335886|NCT04714996|Drug|Open-Label Extension Study|Dosing will be at the discretion of the Investigator with a minimum dose of 25 mg/day (25 mg qd) to a maximum dose of 150 mg/day (75 mg bid).
75335887|NCT00888290|Drug|Sodium bicarbonate|Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
75335888|NCT00888290|Drug|Placebos|Placebo at 3 different doses to match Sodium bicarbonate dosing
75335889|NCT01057277|Drug|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
75335890|NCT04697056|Drug|Imsidolimab|Humanized Monoclonal Antibody
75335891|NCT04697056|Biological|placebo|placebo
75335892|NCT00866840|Drug|riluzole|100 mg orally twice daily
75472774|NCT01962662|Other|EMG biofeedback training|EMG biofeedback assisted tibialis anterial force level control
75472775|NCT01962662|Other|U/E exercise|strengthening and stretching
75472776|NCT01962740|Device|Drug-eluting stent implantation|
75472777|NCT01962766|Behavioral|Myofunctionnal therapy|
75472778|NCT01962766|Behavioral|instructions|
75645436|NCT02568865|Other|Vocal Monitoring|The participants will be provided with a phone app to leave audio diary recordings.
75472779|NCT01962779|Other|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
75645437|NCT02568865|Other|Mobile Phone|A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.
75472780|NCT01962805|Drug|Proellex Formulation A|
75472781|NCT01962805|Drug|Proellex Formulation B|
75645438|NCT04991337|Behavioral|Detraining group|Detraining is defined as exercise corresponding to a heart rate ≤75% of maximum heart rate and ≤80% of the self-reported average weekly amount of exercise (hours/week) during the past six months, for a period of 16 weeks.
75793489|NCT05844189|Device|CRMRF|"CRMRF application on pelvic floor:~Externally over the urogenital triangle of the patient,~Intracavitary application (intravaginal)~Externally over the urogenital triangle of the patient while the physical therapist performs the intracavitary manual therapy (intravaginal),~The device used is named Intradermik and it is the portable CRMRF device of the brand RÖS'S Estética SL.~It has these features:~Frequency: 448kHz~Capacitive power: 450 voltamperes~Resistive power: 200 watts"
75793490|NCT05844189|Device|Sham CRMRF|The physical therapist applies the same treatment as the Treatment Group but the device is switched off.
75793491|NCT05844163|Other|observation|observation
76084808|NCT02514954|Drug|Humalog® Mix25|Subcutaneous injection of an individualized dose
75335893|NCT01057901|Drug|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
75335894|NCT01057901|Drug|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
75335895|NCT04755608|Other|Low Intensity Exercises with Blood Flow Restriction|In the exercise protocol, people exercised resistance between 20% and 30% of 1 MaxRepetition with free weight. In addition, blood flow was restricted in 70% of the arterial occlusion pressure of the individual with the help of a cuff during exercise.
75335896|NCT04755608|Other|High Intensity Resistant Exercise|People included in the study did resistance exercise with free weight at 70-80% of 1 MT.
75335897|NCT04686916|Drug|IP2018|Test drug
75335898|NCT04686916|Drug|Placebo|Placebo
75335899|NCT04349722|Drug|Hyoscine Butylbromide|Intervention is given once a participant is in established labor
75472782|NCT01962831|Drug|Dinoprostone|
75472783|NCT01962831|Device|Single balloon foley catheter|
75335900|NCT04349722|Other|Placebo|Intervention is given once a participant is in established labor
75472784|NCT01962844|Dietary Supplement|Coconut Oil|Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
75472785|NCT01962844|Behavioral|Diet|Patients were instructed to follow the dietary treatment for 6 months
75472786|NCT01962857|Behavioral|Exercise|4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
75793492|NCT05844124|Other|Exercise for Knee Osteoarthritis -(Land Based Treadmill or Community Walking)|Standard-of-care Land-based walking exercise
75793493|NCT05844124|Other|Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking)|Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise
75793494|NCT05844124|Other|Exercise for Knee Osteoarthritis - (Aquatic Walking)|Aquatic Walking exercise
76084809|NCT04443036|Drug|Albumin-Bound Paclitaxel|"125mg/m2 IV d1、8，Q3W~until disease progression, lost follow-up visit, death , unacceptable toxicity"
76084810|NCT04443036|Drug|Toripalimab|"240 mg，IV d1，Q3W~until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months"
76084811|NCT02514720|Other|cigarette|Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
76084812|NCT01653418|Drug|Bortezomib|
76084813|NCT01653418|Drug|Carmustine|
76084814|NCT01653418|Drug|Etoposide|
76084815|NCT01653418|Drug|Cytarabine|
76084816|NCT01653418|Drug|Melphalan|
76084817|NCT01653418|Procedure|Stem cell infusion|
76084818|NCT02514642|Drug|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
75929648|NCT05029206|Procedure|Autologous hematopoietic stem cell transplantation|"The therapeutic intervention of AHSCT consists of four parts: the mobilization of hematopoietic stem cells (HSC), the harvest of HSC, the ablation (conditioning) of the immune system and the reinfusion of autologous HSCs.~In Sweden, the mobilization of HSCs has been made by a combination of cyclophosphamide (2 g/m2) and granulocyte-colony-stimulating factor.~A minimum of 2 × 10^6 CD34+ cells/kg is harvested and cryopreserved. No in vitro manipulation is done to the stem cells.~Two conditioning regimens have been used in Sweden for ablation. The BEAM-ATG protocol include carmustine (BCNU) 300 mg/m2, etoposide 800 mg/m2, cytarabine arabinoside (ARA-C) 800 mg/m2 and melphalan 140 mg/m2 + rATG or hATG. The Cy-ATG protocol include cyclophosphamide 200 mg/kg + rATG/hATG with 1000 mg Metylprednisolone given day -5 to -1.~After a minimum of 24 hours after the last administration of chemotherapy have passed, the reinfusion of autologous CD34+ cells is performed."
75929649|NCT05027282|Device|CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.|CLEAR + BRILLIANT TOUCH(R) diode laser 1440-nm and 1927-nm Combination Wavelength Treatment.
75929650|NCT05026580|Behavioral|Joint Academy exercise and education smart phone application|The Joint Academy® (www.jointacademy.com) program for people with hip or knee OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period.
75929651|NCT05026008|Drug|SR1375|The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water
76084819|NCT02514642|Drug|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
76084820|NCT02511210|Behavioral|regional anesthesia|preoperative anxiety
75645439|NCT04991337|Behavioral|Control group|At least three weekly sessions of high intensity exercise, corresponding to a heart rate ≥85% of maximum heart rate, and otherwise continue endurance exercise as usual.
75645440|NCT00711529|Behavioral|Hypnotherapy|Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. surveys. The therapist will be prohibited from asking subjects about clinical responses to the hypnosis sessions. The patients will also be instructed on self-hypnosis techniques to be used at home.
75645441|NCT00711529|Drug|gabapentin|Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
75645442|NCT02667171|Behavioral|Supervised COPD Rehabilitation (control group)|"The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).~Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises."
75645443|NCT02667171|Behavioral|Online COPD rehabilitation (experimental)|"Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.~Educations consists same information as for the control group."
75645444|NCT02667327|Drug|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
76084821|NCT02511210|Behavioral|general anesthesia|preoperative anxiety
76084822|NCT01653964|Diagnostic Test|Molecular breast imaging|Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)
75645445|NCT02667327|Other|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
75645446|NCT00732589|Drug|1% xylocaine|10 cc. of 1%xylocaine, once a week
75645447|NCT00732589|Other|ultrasound|ultrasound at shoulder area about 10 mins.
75645448|NCT00737425|Device|PainShield|
75645449|NCT00737425|Device|Sham PainShield|
75645450|NCT02569099|Other|Caregiver training|One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
75645451|NCT04083027|Device|MRI|Breast MRI
75793495|NCT05844098|Device|K-wire|K-wire No. 2.0 insertion was done additionally from arthroscopic assisted CC-stabilization by inserting K-wire from acromion process to distal clavicle.
75929652|NCT05026008|Drug|Matching placebo|The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
75929653|NCT05015660|Device|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
75645452|NCT04064203|Other|Oral glucose tolerance test|50 grams OGTT
75645453|NCT04064203|Other|Clamp experiment|insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT
75929654|NCT05015660|Device|Right ventricular active fixation lead|Active fixation lead (standard)
76084823|NCT03344874|Device|Stethee®|Stethee® is a new wireless digital stethoscope.
76084824|NCT03344874|Device|3MTM Littmann® Classic IIITM|3MTM Littmann® Classic IIITM is the conventional stethoscope.
76084825|NCT02505438|Behavioral|Exercise|
75645454|NCT02667015|Behavioral|Psychotherapy (Anxiety Sensitivity Intervention)|3 week, 6-session psychotherapy targeting anxiety sensitivity
75929655|NCT05005221|Behavioral|Automated text messages|Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
76084826|NCT02237950|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
76084827|NCT02237950|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
76084828|NCT02237950|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
76084829|NCT04497480|Behavioral|Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System|The Passive, Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System is designed for patients conﬁned to bed at the long-term care facilities hospitals, in early rehabilitation. This system can induce a natural movements of the upper/lower limb with safe motorized passive movement, as well as motor-assisted and active resistive muscle training to stimulate nerves, increase blood circulation of aﬀected tissue, cell metabolism and improve joint mobility, in promoting upper/lower extremities motor recovery.
76084830|NCT02238028|Behavioral|Wear respirator|Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
76084831|NCT02511054|Drug|Chloroquine (CQ)|Chloroquine Phosphate is a 4-aminoquinoline compound that is commercially available for oral administration. It is a white, odorless, bitter tasting, crystalline substance freely soluble in water; and widely used for the treatment andprophylaxis of malaria. It is supplied and manufactured in tablets of 500 mg (equivalent to 300 mg chloroquine phosphaste base)
76084832|NCT02511054|Drug|Pyrimethamine (PYR)|PYR is a folic acid antagonist that is commercially available; and has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide. It is manufactured in tablets of 25 mg.
75335901|NCT01058993|Drug|AMD3100 or plerixafor|The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
75335902|NCT04677322|Drug|Adult patients diagnosed and treated for high blood pressure|Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.
75335903|NCT04652518|Drug|LYT-100|oral administration
75335904|NCT04652518|Other|Placebo|oral administration
75335905|NCT01059305|Drug|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
75335906|NCT04650490|Radiation|Stereotactic Radiosurgery|Timing of stereotactic radiosurgery relative to immunotherapy
75335907|NCT04650490|Drug|Immunotherapy|Physician's choice of immunotherapy per standard of care
75335908|NCT04649788|Device|Ultrasound-guided axillary vein access|Venous access is performed through ultrasound-guided axillary vein puncture and Seldinger technique. After venous access is obtained, a guide-wire is advanced through the access needle, and the tip of the guide-wire is positioned in the right cardiac atrium.
75335909|NCT04649788|Device|Cephalic vein access|Venous access is performed through a cephalic vein cutdown approach. After venous access is obtained, a guide-wire is advanced and the tip of the guide-wire is positioned in the right cardiac atrium.
75929656|NCT04996693|Diagnostic Test|Imaging on Scanner with Spectral Imaging Capabilities|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.
75929657|NCT04996693|Diagnostic Test|CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)|Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
75645455|NCT00737503|Biological|Rotavirus Vaccine (ROTARIX)|Rotavirus Vaccine two doses four weeks apart
75645456|NCT00645879|Drug|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
75645457|NCT00645879|Drug|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
75645458|NCT00645879|Drug|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
75645459|NCT04174287|Drug|F-18-AV45|The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
75929658|NCT04996693|Diagnostic Test|CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)|Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
75645460|NCT00737659|Drug|Mycophenolate mofetil (CellCept® )|Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg*h\L) measured on Days 7,14,Months 1,3,6 and 12.
75645461|NCT00737659|Drug|Mycophenolate mofetil (CellCept® )|Fixed Dose group, MMF dosage will be adjusted based on standard care
75793496|NCT05844072|Procedure|Mobilization with movement|All participants will receive the MWM intervention with weight bearing ankle dorsiflexion range of motion measured prior to the intervention, immediately following the intervention, and 24 hours (+/- 3 hours) following the intervention. The participant will first place their foot on a 16-inch box to assist in performance of the intervention by the therapist. A licensed physical therapist (PT) will then stabilize the talus for a proper joint mobilization to be performed. The therapist will then mobilize the distal tib/fib in the posterior to anterior direction at end range DF reached through a forward lunge, using a Mulligan's mobilization belt around the distal tibia-fibula. The participant will perform 3 sets of 10 repetitions of the forward lunge and the PT will perform a bout of overpressure at end range during each repetition. Two other investigators will be on either side of participant to assist with balance during the intervention if needed.
75929659|NCT04995627|Dietary Supplement|Salt (NaCl)|12 grams of salt (NaCl) per day
75472787|NCT01962883|Other|Osteopathic treatment|"The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.~Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release~Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.~Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.~Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye."
75472788|NCT01962909|Drug|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
75472789|NCT01962935|Drug|AZD4721|Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
75645462|NCT02666703|Device|CytoSorb|CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
75793497|NCT05844059|Other|Validated questionnaires|BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
75645463|NCT02666703|Drug|Methylprednisolone|
75645464|NCT04174209|Behavioral|Cylinder|Patients who receive the Jackson Cross Cylinder Method
75645465|NCT04174209|Behavioral|Dial|Patients who receive the Astigmatic Dial Technique Method.
75645466|NCT04174209|Behavioral|Slit|Patients who receive the Stenopeic slit Method.
75645467|NCT02666859|Device|Virtual Reality|During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.
75645468|NCT02666625|Procedure|saliva samples|
75645469|NCT02666625|Procedure|blood samples|
75645470|NCT04936815|Diagnostic Test|Transthoracic echocardiography|Transthoracic echocardiography for the detection of congenital or acquired structural heart disease.
75645471|NCT00645957|Procedure|penrose drain|incision and drainage of the infection with placement of a penrose drain
75645472|NCT00645957|Procedure|red rubber drain|incision and drainage of infection and placement of a red rubber drain
75645473|NCT02666391|Biological|umbilical cord mesenchymal stem cells|
75645474|NCT02537067|Drug|CHONDRON|"Harvesting of ankle or knee cartilage~The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue."
75929660|NCT04995627|Other|Placebo|Placebo
75645475|NCT04174131|Device|Restylane + Lidocaine|Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.
75645476|NCT04174131|Device|Restylane® Lyft|Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).
75645477|NCT04173897|Other|LIBERATE website|The LIBERATE intervention is a self-management, symptom monitoring and signposting website tailored to the supportive needs of women living with secondary breast cancer. Components include; holistic health information specific to secondary breast cancer, symptom monitoring and self-management advice, case studies, signposting to services & support and support for family & loved ones.
75929661|NCT04993313|Other|Counseling|Undergo verbal counseling
75929662|NCT04993313|Other|Educational Intervention|View photo guide
75929663|NCT04993313|Behavioral|Questionnaire|Complete questionnaires
75929664|NCT04987658|Drug|OLZ/SAM|Olanzapine and Samidorphan taken once daily over a max period of 21 days
75929665|NCT04987229|Drug|OLZ/SAM|Olanzapine and Samidorphan fixed dose coated tablet taken once daily
75929666|NCT04981067|Other|Maintain the concentration of ropivacaine as same as those used in the previous participant|Maintain the same concentration of ropivacaine used in the previous participant with an 89% chance through a random assignment
75929667|NCT04981067|Other|Decrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Decrease ropivacaine concentration by 0.05% from the concentration used in the previous participant with an 11% chance through a random assignment
75645478|NCT04174053|Device|Enteric capsule|Enteric capsule to measure body temperature will be ingested every 24 hours during aplasia. the temperature measured with this technique will be compared with auricular temperature measurement (in current practice nurse measure temperature every 4 hours during aplasia).
75645479|NCT00646035|Drug|paricalcitol capsules|baseline iPTH/60
75645480|NCT02666469|Other|Hyperbaric Oxygen Therapy (HBOT) and Exercise Program|HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
75645481|NCT02666469|Other|Exercise Program|Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
75335910|NCT04641832|Other|Soccer heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
75335911|NCT03014687|Drug|Placebo|PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
75472790|NCT01962935|Drug|Placebo|Part A - multiple ascending dose daily
75645482|NCT02666469|Device|Hyperbaric Multiplace Chamber|Patients will receive treatment in a multiplace Hyperbaric Chamber
75645483|NCT02666235|Procedure|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
75645484|NCT02666235|Procedure|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
75645485|NCT00646191|Drug|adalimumab|40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
75929668|NCT04981067|Other|Increase the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Increase ropivacaine concentration by 0.05% from the concentration used in the previous participant.
75929669|NCT04980703|Device|Grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the patient feels burning or a little pain, put out moxa with gauze and keep for 10 seconds, so as to ensure enough heat to be penetrated into the acupoint. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
75929670|NCT04980703|Device|Sham grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the moxa burns to half （the patient hasn't feel hot or feel a little hot）, take the moxa away with tweezers. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
75929671|NCT04980703|Other|Standard care|Participants in the wait-list control with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.). And after waiting for 12 weeks, these patients will be treated with the same grain moxibustion as the grain moxibustion group.
75929672|NCT04977882|Procedure|abdominal drainage|19 Fr abdominal drainage placed intraoperatively in right colic gutter
75929673|NCT04977882|Drug|Postoperative antibiotico-prophylaxis|Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
75929674|NCT04977882|Procedure|Laparoscopic radical right colectomy with CME and D3 lymphadenectomy (RRC)|the dissection starts over the landmark given by SMV. The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue. Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels. The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH. No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas. At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure. The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia. The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
75929675|NCT04977882|Procedure|Laparoscopic standard D2 right hemicolectomy (STANDARD)|A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV). The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon. The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
75929676|NCT04965597|Drug|Treosulfan|Given IV
75472791|NCT01962935|Drug|AZD5069|Part B - one dose decided after part A, twice a day
75472792|NCT01963013|Device|Non-returning catheter valve|
75472793|NCT01963013|Device|Conventional urine bag|
75645486|NCT00646191|Drug|adalimumab|40 mg weekly through Week 48 (OL Week 12 - 48)
75645487|NCT00646191|Drug|adalimumab|80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
75651924|NCT04652596|Other|Grocery store gift cards|A monthly value of $150 in grocery store gift cards redeemable at conventional grocery stores will be provided to participants for 6 consecutive months.
75929677|NCT04965597|Drug|Fludarabine Phosphate|Given IV
75929678|NCT04965597|Drug|Tacrolimus|Given IV and PO
75645488|NCT02666313|Behavioral|Exercise|"The physiotherapist will select exercises which are appropriate to that participant. Participants will complete online exercise diaries which are reviewed remotely by the physiotherapist. Depending on progress, exercises can be progressed, added or removed from the patient's individualised programme.~Participants will be encouraged to undertake their exercise programme, according to evidence base guidelines, five days/week for 30 minutes/day. Participants will receive weekly phone calls for the first two weeks of the programme. Thereafter, every two weeks the physiotherapist will review the exercise diary of each participant and remotely alter the participant's exercise programme as appropriate, by changing any combination of exercises, level of difficulty or number of repetitions."
75335912|NCT03014687|Drug|Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole|Oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
75645489|NCT02666079|Device|LightPath® Imaging System.|Intra-operative use of the LightPath® Imaging System.
75645490|NCT02666157|Drug|Dabigatran etexilate|this drug is administered twice per day for the entire study period
75645491|NCT02666157|Drug|Rivaroxaban|this drug is administered once per day for the entire study period
75645492|NCT02666157|Drug|Apixaban|this drug is administered twice per day for the entire study period
75645493|NCT00646269|Behavioral|Standard intervention protocol|The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.
75645494|NCT00646269|Behavioral|Standard intervention protocol + Cognitive training therapy|"Cognitive training therapy is provided in small groups of 5 to 8 patients. It consists in classroom type sessions designed to provide general cognitive stimulation. A set of standard cognitive exercises (involving memory, attention, or problem-solving…) related to activities of daily living is realized at each session."
75645495|NCT00646269|Behavioral|Standard intervention protocol + Reminiscence therapy|"Reminiscence therapy is provided in small groups of 5 to 8 patients. This therapy involves the discussion of past activities, events and experiences enhanced by aids such as photographs, familiar items, songs, or personal recordings. A particular topic of life (i.e. a wedding) is discussed at each session."
75472794|NCT01963026|Other|ToCUEST featuring a 'variable practice' approach.|Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module [17] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. [17]. Intervention B will be called 'ToCUEST variability' in the present project.
75645496|NCT00646269|Behavioral|"Standard intervention protocol + Made-to-measure program"|"The made to measure program involves no systematic intervention. The psychologist is asked to choose among the two possible therapies (Cognitive training therapy or Reminiscence therapy) the one more suitable for the patient after considering his clinical characteristics including socio-demographic characteristics, disease severity or cognitive and behavioural disturbance. It is an individualized approach emphasizing the importance of flexibility to allow adjustment to individual needs."
75645497|NCT02666001|Drug|BMS-663068|BMS-663068
75645498|NCT02666001|Drug|Methadone|Methadone
75645499|NCT02666001|Drug|Buprenorphine and Norbuprenorphine|Buprenorphine and Norbuprenorphine
75645500|NCT02665845|Drug|5-ASA|5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
75645501|NCT02665845|Drug|Corticosteroids|Corticosteroids will be given to all patients.
75645502|NCT00646347|Other|Conventional upper limb stroke rehabilitation|"Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks."
75645503|NCT00646347|Device|Neuro Hand Orthosis Program (NHOP)|"The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis."
75645504|NCT00646425|Drug|Basiliximab|40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
75645505|NCT00646425|Drug|Placebo|Placebo to match basiliximab
75793498|NCT05844046|Biological|durvalumab, tremelimumab, bevacizumab|durvalumab, tremelimumab and bevacizumab will be administered in the respective arms either as up-front triple treatment or as combined treatment with durvalumab and tremelimumab followed by the addition of bevacizumab
75793499|NCT05843994|Other|online survey|Participants will complete an online survey and submit photographs.
75929679|NCT04965597|Drug|Methotrexate|Given IV
75929680|NCT04965597|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
75929681|NCT04965597|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
75929682|NCT04965597|Procedure|Allogeneic Bone Marrow Transplantation|Undergo bone marrow transplant
75929683|NCT04965597|Other|Quality-of-Life Assessment|Ancillary studies
75929684|NCT04965597|Procedure|Echocardiography|Undergo ECHO
75335913|NCT04296292|Other|In-depth interviews|In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
75335914|NCT04629274|Procedure|Blood sampling|The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interval between these 2 samples.If the results obtained with the 2 initial samples would be of interest to the Sponsor, the patient will be asked to come back for additional samplings with a maximum of 6 additional blood draws
75929685|NCT04965597|Procedure|Multigated Acquisition Scan|Undergo MUGA
75335915|NCT03824405|Drug|BTX 1204|BTX 1204 liquid formulation
76084833|NCT02511054|Biological|Sanaria PfSPZ Challenge (NF54)|Sanaria PfSPZ Challenge are aseptic, cryopreserved P.falciparum sporozoites used for CHMI trials, produced by the biotechnology company; Sanaria Inc. In brief, manufacture includes the production, under traditional environmental conditions, of eggs from a colony of A. stephensi mosquitoes housed in a controlled environmental chamber. The sporozoites are purified, counted, and, at a specified concentration, cryopreserved. Cryopreservation commences with the addition of cryoprotective additives to the purified sporozoites to produce the Sanaria PfSPZ Challenge product. Sanaria PfSPZ Challenge is dispensed into screw-cap vials containing 15,000, 50,000, or 100,000 PfSPZ in a 20 L aliquot. Sanaria PfSPZ Challenge is stored in liquid nitrogen vapour phase at 140 (Infinite)C to -196 (Infinite)C.
76084834|NCT04499118|Drug|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
76084835|NCT04499118|Drug|TP regimen|Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
76084836|NCT01612546|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
75335916|NCT03824405|Drug|Vehicle|Vehicle liquid formulation
75335917|NCT02246699|Device|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
75335918|NCT02246699|Other|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
75335919|NCT04199572|Drug|Diclofenac and Paracetamol|analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
75335920|NCT04177966|Behavioral|pre-prepared video describing the cesarean surgery|a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation - from the woman's perspective - from the time they were admitted to the department, preparation for surgery, entrance to the operating r
75645506|NCT02665767|Device|Smartphone-based Telesonography|The 30 participating examiners were randomly divided into two groups. In phase one, group A performed ultrasonography under onsite mentoring and group B performed the same procedure under remote mentoring. Each examiner was randomly assigned one expert and three SPs for phase one. Four weeks later, they were partnered with the same expert and SPs to whom they had been assigned in phase one and performed the procedure under the other type of mentoring (phase two). The examination order of the SPs was randomly assigned by choosing a number between one and six (1: A-B-C, 2: A-C-B, 3: B-A-C, 4: B-C-A, 5: C-A-B, 6: C-B-A) in each phase.
75335921|NCT04177966|Behavioral|general information|In the control group - women will receive general information about the surgery as part of informed consent, without watching a pre-prepared film.
75645507|NCT04173351|Behavioral|Education and Counseling|Following the pretests between the 28th and the 34th gestational weeks, nulliparous women in the intervention group received a presentation on childbirth preparation at a room of the obstetrics clinic. The education was completed in two sections in a single day. Each session took about 45 minutes there was a 15-minute break between the sessions. Following the education, the questions of the participants were responded and educational brochures on childbirth preparation were given to the participants. One of the researchers of this study telephoned the participant women in the intervention group one week after the childbirth education and provided counseling service about the demands and the points that the nulliparous women wondered.
75645508|NCT02665533|Drug|Dexamethasone|Dexamethasone 8 mg
75645509|NCT02665533|Drug|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg
75645510|NCT02665611|Behavioral|intervention for improvement of adherence|intervention for improvement of adherence
75645511|NCT02665611|Behavioral|treatment as usual|The control group will be treated according to the usual stadard of care.
75929686|NCT04965597|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
75645512|NCT00646503|Drug|Telbivudine|600 mg/day, oral telbivudine for 52 weeks
75929687|NCT04965597|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
75335922|NCT02169479|Drug|BIA 9-1067|OPC, Opicapone
75929688|NCT04965597|Procedure|Biospecimen Collection|Undergo blood sample collection
75335923|NCT02169479|Drug|Placebo|PLC, Placebo
75335924|NCT02169479|Drug|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
75929689|NCT04963803|Device|Active transcranial direct current stimulation (tDCS)|Active transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session for 10 sessions.
75929690|NCT04963803|Device|Sham transcranial direct current stimulation (tDCS)|Sham transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session. Participants in this arm will receive sham stimulation for 10 sessions.
75929691|NCT04963803|Behavioral|Language Specific Attention Treatment|This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this treatment.
75929692|NCT04963374|Other|risk evolution scale|Padua score、Caprini score、Prime score
76084837|NCT01612546|Other|Laboratory biomarker analysis|Correlative studies
76084838|NCT01612546|Other|Pharmacological studies|Correlative studies
76084839|NCT02514564|Behavioral|Exercise|Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
76084840|NCT02514486|Behavioral|Questionnaire|
76084841|NCT04499898|Drug|Carvedilol|Carvedilol
76084842|NCT04499898|Procedure|Endoscopic band ligation|Endoscopic band ligation
76084843|NCT01613014|Drug|ABT-436|Target dose - 400mg BID
76084844|NCT01613014|Drug|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
76084845|NCT02514330|Other|Interval Training at 1% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
76084846|NCT02514330|Other|Interval Training at 10% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
76084847|NCT02510976|Drug|prucalopride|
76084848|NCT02510976|Drug|placebo|
76084849|NCT02505516|Other|metformin|
76084850|NCT02510898|Behavioral|6-week Writing to Heal course|"During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.~Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways."
76084851|NCT02514408|Procedure|Catheter Management|Insertion of venous catheter under ultrasound guidance
76084852|NCT02514408|Other|Cytology Specimen Collection Procedure|Collection of blood samples
75472795|NCT01963026|Other|ToCUEST featuring a 'constant practice' approach.|Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
75645513|NCT04173039|Diagnostic Test|Serum anti-CarP antibodies detection|Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
75645514|NCT00646659|Biological|cetuximab|
75645515|NCT00646659|Drug|carboplatin|
75645516|NCT00646659|Drug|cisplatin|
75645517|NCT00646659|Drug|docetaxel|
75645518|NCT00646659|Drug|fluorouracil|
75793500|NCT05843981|Device|Implant placement|Common procedures: implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation. Test procedure (experimental): use of TSIII Implant. Control procedure (contro group): use KS Implant. After osseointegration, both dental implants will receive definitive prosthesis.
75793501|NCT05843929|Diagnostic Test|LSCI|"A technician delivers a service at the home of the patient, who may be subject to different risk of ulcer, with the aim to analyse his/her foot through an integrated set of measurement technologies, based on:a-the piezoelectric insole that replaces missing pain sensation;b- Laser speckle contrast imaging technique (LSCI) that measures the blood flow;c- the multi points temperature device.~Data collected by the technician are sent via internet~On the basis of the clinical evaluation and doctor's report on points of foot sensitivity, a 3D model of the foot is created and used by the chiropodist;~Using the 3D model of the foot, the chiropodist uses a 3D Editor to design the 3D Model of the insole to enable the production of a tailored insole for the patient shoes~The final manufactured insole is then delivered to the patient;~A check survey is periodically carried out by the technician to scan the diabetic foot status progress"
75793502|NCT05843903|Behavioral|Peer Health Coaching|Young adult, Black WIC moms will be trained as peer health coaches to first, address social needs and second, support health behavior change in pregnant, Black adolescents enrolled in WIC. Health coaching is a client-centered technique that leverages the power of lived experiences and motivational interviewing to strengthen one's drive for behavior change by linking personal goals with values. Training racially concordant health coaches will mitigate internalized and interpersonal racism, leverage moms' connection with WIC, and supplement WIC services by providing a scalable telehealth peer health coaching intervention.
75929693|NCT04963127|Diagnostic Test|Computed Tomography of the skeleton using a Dual-Energy-/Multi-Energy-/Spectral acquisition mode|CT acquisition using a Dual-Energy / Multi-Energy / Spectral acquisition mode
75929694|NCT04963127|Diagnostic Test|Computed Tomography of the skeleton using a conventional single-energy / non-spectral acquisition mode|CT acquisition using a standard single energy / non-spectral acquisition mode
75929695|NCT04959929|Device|Focal vibration therapy|Myovolt is a wearable rehabilitative device that delivers vibration to the region of the body where the motors are worn. Participants are asked to apply the vibration to specific leg locations twice a day, for about 30 minutes at a time, and to record their response using a provided log. They may be asked to try applying the device at different location or using different vibration parameters (pulse frequency or intensity).
75929696|NCT04956536|Other|Demographic data and MRI images were extracted and analyzed|Demographic data and MRI images were extracted and analyzed. Related factors for anterior tibial subluxation were examined in anterior cruciate ligament-injured patients.
75929697|NCT04951999|Other|Blood sampling|For 10 visits (out of the 12 of the protocol), ~40 ml of blood is sampled for research purposes in addition to care sampling.
75645519|NCT00646659|Genetic|fluorescence in situ hybridization|
75645520|NCT00646659|Genetic|molecular genetic technique|
75645521|NCT00646659|Genetic|reverse transcriptase-polymerase chain reaction|
75645522|NCT00646659|Other|immunoenzyme technique|
75645523|NCT00646659|Other|immunohistochemistry staining method|
75645524|NCT00646659|Other|laboratory biomarker analysis|
75645525|NCT00646659|Procedure|biopsy|
75645526|NCT00646659|Radiation|3-dimensional conformal radiation therapy|
75645527|NCT00646659|Radiation|intensity-modulated radiation therapy|
75929698|NCT04949542|Behavioral|Bolster|Bolster is a native mobile app that provides on-demand content to caregivers of young adults with early psychosis to support their caregiving skills and knowledge of psychosis.
76084853|NCT02514408|Other|Laboratory Biomarker Analysis|Correlative studies
76084854|NCT02505360|Other|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
76084855|NCT04499586|Combination Product|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) per week. Radiation: 45-55Gy/25-30Fx
76084856|NCT01656460|Radiation|Stereotactic radiation Arm 1|"Dose Levels Dose per Fraction Total Dose~1 8 Gy 16 Gy"
75793503|NCT05843903|Behavioral|#BabyLetsMove|The #BabyLetsMove digital health intervention uses a multi-level, systems-change approach. At the systems-level, racially concordant young adult WIC moms will be trained as health coaches. At the person level, adolescent WIC clients will be given empirically supported behavior goals, self-monitoring text messages with automated feedback, tailored skills training materials, a FitBit device, and tailored peer coaching support. The #BabyLetsMove intervention design is based on formative Teen Mom Study findings to build social cognition, affect, and skills to modify 3 concrete, achievable, and easily monitored behavioral targets: (1) Limit television viewing time to less than 2 hours per day; (2) Walk at least 10,000 steps per day; and (3) Do 20 minutes or more of exercise per day.
75793504|NCT05843851|Diagnostic Test|Diagnostic test|Test for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.
75793505|NCT05843825|Procedure|Surgical placement of dental implants|Three dental implants were placed (one anterior in midline area and two posterior at first molar area).
75793506|NCT05843825|Device|Overdenture supported by locator attachment system|"Implants were loaded after three months by using locator attachments.~Control group:Iocator attachments picked up using block out spacer.~Study group:Iocator attachments picked up without using block out spacer"
75929699|NCT04949542|Behavioral|Control|Exemplar resources provided in the control arm will include a selection from the National Alliance on Mental Illness and Mental Health America designed to support caregivers helping loved ones access care.
75793507|NCT05843812|Drug|Magnesium Sulfate 10 MG/ML|Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
75793508|NCT05843760|Other|personal information form|undergraduate student(participants) will be asked; age, weight, height, smoking and alcohol use, and headache.
75793509|NCT05843760|Other|headache-specific questionnaires|ıd migraine test, numeric rate scale, hit-6 headache impact test, headache information form
75793510|NCT05843760|Other|Questionnaires for assessing biopsychosocial status|hospital anxiety depression, Discomfort Intolerance Test, pittsburgh sleep quality index, fatigue severity scale, self compassion scale, Body Awareness Questionarre, cervical range of motion, İnternational Physical Activity Questionnaire, 12-Item Short-Form Health Survey
75793511|NCT05843734|Procedure|Equia forte HT|Restoration of anterior class III caries lesions
75793512|NCT05843682|Device|Using the Avatr App|The patients will use the mobile application called Avatr, which will monitor their health data, as well as provide individualized care and early intervention through alerts generated for the multidisciplinary team.
75793513|NCT05843656|Other|Non-invasive brain stimulation|based on sleep-physiology (slow-wave and spindles)
75793514|NCT05843630|Diagnostic Test|without|without
75793515|NCT05843617|Dietary Supplement|Liposomal Vitamin C (Liposovit-C)|1000 mg of ascorbic acid in liposomal formulation
75645528|NCT02663661|Procedure|Metabolic Challenge Admission|A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
75645529|NCT02663661|Other|CGM home test|A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
75645530|NCT00648531|Drug|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
75645531|NCT00648531|Drug|Colazal® Capsules 750 mg|3x750mg, single dose fasting
75645532|NCT04171713|Behavioral|Mindfulness-Based Health Promotion + Treatment as usual|Structured and developed over eight weeks (8 sessions), participants meet weekly for an average of 2 hours to experience the techniques and conceptual learning about mindfulness and can be adapted to one or 1.5 hour sessions. to be applicable within the contexts of health, education, and organizations. Plus participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
75645533|NCT04171713|Behavioral|Attachment-based compassion therapy + Treatment as usual|It is a program based on one of the fundamental psychological constructs that explain individuals' interpersonal relationships, attachment styles. It lasts 8 weeks in which participants meet for 2 or 2.5 hours at each meeting.
75793516|NCT05843617|Dietary Supplement|Traditional Vitamin C|1000 mg of ascorbic acid in traditional formulation
75793517|NCT05843591|Behavioral|aerobic exercise or Tai Chi Chuan interventions|8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)
75793518|NCT05843526|Device|Experimental healing abutment|"Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment"
75929700|NCT04946084|Procedure|Tympanocentesis|When acute otitis media is diagnosed, local anesthetic applied, small hole placed in eardrum, middle ear fluid extracted.
75929701|NCT04946084|Other|Nasal Phalangeal Swab and Wash|Nasal phalangeal swab used to retrieve sample. Nasal wash used to retrieve sample.
75929702|NCT04946084|Other|Blood Draw|Venipuncture
75929703|NCT04944693|Other|Different ATS values.|"Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts."
75929704|NCT04931745|Device|Virtual reality|VR headset will be used 5-10 minutes prior to and during port access
75929705|NCT04931745|Device|Tables distraction|Tablet distraction will be used 5-10 minutes prior to and during port access
76084857|NCT01656460|Radiation|Stereotactic radiation Arm 2|Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
75645534|NCT04171713|Behavioral|Treatment as usual|participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
75645535|NCT04171401|Other|In-patient stroke rehabilitation.|An in-patient multi-disciplinary stroke rehabilitation program was performed.
75929706|NCT04931745|Other|No or non-technologic distraction|This approach will be used 5-10 minutes prior to and during port access
75929707|NCT04927637|Procedure|imaging 24 hours following intravenous administration of ICG|Patients will be administered a single, FDA approved, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. ICG fluorescence images will be acquired By a FDA approved surgical imaging device prior to surgical debridement. The wound will be irrigated as per standard procedure and another ICG fluorescence image will be acquired. The need for repeat debridement or tissue cultures will be left up to the treating surgeon.
75335925|NCT04313530|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS treatment fatigue is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks connectivity changes involved in the processing of fatigue signals.
75335926|NCT04302454|Radiation|Radiotherapy|Radiotherapy
75645536|NCT00648609|Other|Palliative home care in advanced COPD|Interdisciplinary palliative care team on community based self care management of advanced COPD.
75645537|NCT00648609|Other|Standard of care|Usual care for COPD patients
75645538|NCT00648687|Behavioral|suck 12.5% dextrose in water 5 minutes before the procedure|Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
75645539|NCT00648765|Drug|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
75793519|NCT05843474|Behavioral|Take it Personal!|Take it Personal! is a six-week indicated prevention program for youth with a mild intellectual disability or borderline intellectual functioning. The program aims to teach youngsters skills to reduce their substance use (alcohol, cannabis, and other drugs). The prevention program differentiates four personality profiles associated with a higher risk for problematic substance use: sensation seeking, impulsivity, anxiety sensitivity and negative thinking. For each of the four personality profiles, different program outlines were developed that are similar in structure but have their own personality-specific materials, games and (psychomotor) exercises. There are weekly individual- and group sessions with three to four participants, led by a clinical psychologist and a psychomotor therapist. Motivational interviewing and cognitive behavioral therapeutic principles are applied, both of which have proven effectiveness in decreasing substance use the target group.
75929710|NCT04912817|Other|Off the Shelf VR|"Operates using Oculus quest VR HMD and uses auditory and visual stimuli during the pain rehabilitation treatment. The Off-the-shelf VR program for Oculus Quest VR features a suite of off-the shelf applications that can be tailored by the PT and used with participants including. PR-VR sessions will be 30 minutes in total with approximately 20 minutes in the virtual experience and 10 minutes for set-up, screening, instructions, and rest breaks. The Off-the-shelf VR intervention group will also receive 30 minutes of usual care, and Standard Virtual Physiotherapy Treatment (SVPT) during the same appointment, for a total 1-hour usual care session length."
75929711|NCT04912817|Other|Custom VR|Operates using Oculus Quest VR HMD with PR-VR software developed with two gaming options: Fruity Feet and Space Burgers 2. Game settings are manipulated by the physiotherapist in session to target specific limb movements and intensity and also motivates participants to cycle using a leg ergometer. Motion sensors on the ergometer track the participants revolutions per minute. For participants in this study arm, a leg ergometer (DeskCycle) will be provided to them during the study phase alongside the Actigraph and Oculus Quest HMD. During the 30min VR portion of the session, 20 minutes will be dedicated to gaming and exercise, and 10 minutes dedicated for set up, tear down, and rest breaks. During the 20 minutes gaming time, a minimum of 15 minutes will be dedicated to Custom VR, with 5 minutes for 'free play' where the participant can opt to try an off-the-shelf VR game.
76084858|NCT01656460|Radiation|Stereotactic radiation Arm 3|Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
76084859|NCT01656460|Radiation|Stereotactic radiation Arm 4|Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
76084860|NCT02505282|Other|Vitamin K status|Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
76084861|NCT03343938|Other|Embryo handling in a closed station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
76084862|NCT01656772|Device|Vdrive Lasso navigation|Remote robotic Lasso navigation
75645540|NCT00648765|Drug|Agrylin® Capsules 1 mg|1mg, single dose fed
75335927|NCT04302454|Drug|Leuprorelin|Hormonal therapy
75645541|NCT04171557|Behavioral|Bicycling|Total bicycling is reported in categories of: (0 - reference), (>0 to <60), (≤60 to >150), (≤150 to < 300) and (≥300) minutes/week
75645542|NCT02663583|Behavioral|Symptom Questionnaires|"Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months."
75645543|NCT02663583|Behavioral|Dysphagia Inventory Questionnaire|"Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months."
75645544|NCT02663583|Behavioral|Activity Bands|Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
75645545|NCT04171245|Other|Laughie laughter prescription|Creation of a Laughie; laughing with their Laughie 3x a day
75645546|NCT04171245|Device|Sleep tracking equipment|Tracking sleep using equipment
75645547|NCT02663427|Device|serological examination and gastroscope|
75929712|NCT04907669|Other|Brief contact intervention|"The BCI in this study is a series of structured messages, and messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details are yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.~Noted, the same messages will also be sent to patients' LHSs."
75793520|NCT05843422|Drug|0.1% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
75929713|NCT04905810|Drug|Azacitidine|Given IV
75793521|NCT05843422|Drug|0.3% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
75793522|NCT05843422|Drug|0.8% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
75793523|NCT05843422|Drug|1.5% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
75793524|NCT05843396|Behavioral|Neonatal Massage|caregivers providing therapeutic touch techniques on their neonate
75793525|NCT05843344|Drug|erector spinae plane block with a combination of ropivacaine and morphine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. Serratus Anterior Plane Block (SAPB) will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine + 2 mg (1mL) of morphine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 6 mg of morphine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
75793526|NCT05843344|Drug|erector spinae plane block with a combination of ropivacaine and dexmedetomidine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +0.5 mcg/kg (1mL) of dexmedetomidine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 200 mcg of dexmedetomidine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
75929714|NCT04905810|Drug|Decitabine|Given IV
75929715|NCT04905810|Drug|Venetoclax|Given PO
75929716|NCT04893421|Device|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
75793527|NCT05843344|Drug|erector spinae plane block with ropivacaine only|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +1 mL of normal saline will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 3 mL of normal saline will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
75929717|NCT04892342|Drug|ESG401|Administered via intravenous (IV) infusion
75929718|NCT04891809|Drug|Isatuximab-Irfc 20 MG/ML [Sarclisa]|Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
75929719|NCT04891809|Drug|Lenalidomide|"Induction: 25mg*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) < 50 mL/min) starting dose is 10 mg"
75929720|NCT04891809|Drug|Dexamethasone Oral|"Induction:~Patients aged <75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly"
75929721|NCT04883242|Drug|Carfilzomib|Given IV
75929722|NCT04883242|Drug|Dexamethasone|Given PO or IV
75929723|NCT04883242|Biological|Isatuximab|Given IV
75929724|NCT04883242|Drug|Pomalidomide|Given PO
75929725|NCT04881019|Device|Continuous glucose monitoring|Continuous monitoring of blood sugar over a 10-day period.
75929726|NCT04871308|Drug|Dexmedetomidine|"Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins."
75929727|NCT04871308|Drug|Control|During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
75793528|NCT05843331|Procedure|implants|Four implants in the maxilla with locator attachments
75793529|NCT05843305|Drug|BPI-452080|Subjects will receive BPI-452080 until disease progression
75793530|NCT05843292|Drug|Taxane and Carboplatin|"Nab-paclitaxel 100mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.~or Docetaxel 75mg/m2+ Carboplatin AUC5 by intravenous (IV) infusion on day1, every 3 weeks, for 4 cycles.~or Paclitaxel 80mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles."
75929728|NCT04864067|Drug|Oxaliplatin|Consolidation Chemotherapy
75929729|NCT04864067|Drug|5-Fluoracil|Consolidation Chemotherapy
75929730|NCT04864067|Drug|Leucovorin|Consolidation Chemotherapy
75929731|NCT04864067|Drug|Capecitabine|Consolidation Chemotherapy
75929732|NCT04864067|Radiation|5x5 Gy|Neoadjuvant Radiotherapy
75929733|NCT04864067|Behavioral|Quality of Life Questionnaires|Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)
75929734|NCT04864067|Procedure|DRE/ Endoscopy|Flexible Sigmoidoscopy and Digital Rectal Exam
75929735|NCT04859504|Device|transcranial alternating current stimulation (NE Starstim)|dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
75929736|NCT04856176|Drug|Granulocyte-Macrophage Colony-Stimulating Factor|250 mcg
75929737|NCT04856176|Drug|Pembrolizumab|200mg every 3 weeks
75929738|NCT04856176|Drug|pemetrexed|500mg/m2
75929739|NCT04856176|Drug|Paclitaxel|200mg/m2
75793531|NCT05843292|Drug|Short-term Sintilimab|Sintilimab 200mg by intravenous (IV) infusion on day1, every 3 weeks, for 2 cycles.
75793532|NCT05843292|Procedure|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
75793533|NCT05843240|Procedure|Repetitive transcranial magnetic stimulation|After enrollment, patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
75645548|NCT02663505|Procedure|Patients receiving the surgery planned for them|"For each patient the following potential influence (risk) factors are documented:~sex, urgency of the operation, BMI, age, ASA classification, preconditions, physical fitness, Hb value.~In phase 2 only selected influence factors will be recorded.~No intervention will be performed apart from the surgery planned for each patient."
75793534|NCT05843240|Procedure|Sham repetitive transcranial magnetic stimulation|After enrollment, patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
75793535|NCT05843227|Other|questionnaire on the organizational management|Data are collected through a questionnaire on the organizational management of the pre-operative / intraoperative / postoperative periods.
75793536|NCT05843214|Other|Non-invasive neuromonitoring evaluation (transcranial doppler, optic nerve envelope diameter and quantitative pupillometry)|4 days Post-operation follow-up. Data will be gathered before the surgery and at regular times after the surgery until day 4
75793537|NCT05843201|Device|The AquaPass System|The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.
75645549|NCT00648843|Drug|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fed
75645550|NCT00648843|Drug|Ditropan XL® Tablets 5 mg|4x5mg, single dose fed
75335928|NCT01059851|Drug|Suvorexant|single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with ~240 mL of water after an 8 hour fast
75793538|NCT05843162|Drug|Telmisartan|Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
75793539|NCT05843162|Drug|Losartan|Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
75929740|NCT04856176|Drug|Carboplatin|AUC 5/6
75929741|NCT04853277|Behavioral|Education|Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
75335929|NCT02169869|Device|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
75929742|NCT04849806|Diagnostic Test|Assessments of the sympathetic nerve activity axis|"For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed."
75335930|NCT02169869|Device|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
75929743|NCT04849806|Diagnostic Test|OSA severity|OSA is defined as apnoea-hypopnoea index [AHI] >15/h and obstructive apnoea index [OAI] >5/h) and sleep architecture
75335931|NCT01059929|Drug|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
75645551|NCT02663115|Other|Biopsy of the diaphragmatic muscle|
75335932|NCT01059929|Drug|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
75335933|NCT01059929|Drug|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
75335934|NCT01059929|Drug|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS>+2)
75645552|NCT02663115|Other|Skeletal muscle biopsy|
75645553|NCT02663193|Other|No Intervention|Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
75645554|NCT02662959|Drug|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
75645555|NCT02662647|Drug|Decitabine 20 mg/m²/day for 5 days|
75645556|NCT02662725|Drug|IPILIMUMAB|
75645557|NCT02662725|Radiation|Stereotactic radiosurgery|
75645558|NCT00648921|Drug|Olanzapine Tablets 5 mg|5mg, single dose fasting
75645559|NCT00648921|Drug|Zyprexa® Tablets 5 mg|5mg, single dose fasting
75645560|NCT02662803|Other|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
76084863|NCT01656772|Procedure|Manual Lasso navigation|Manually maneuver a Lasso catheter
75645561|NCT02662803|Other|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
75645562|NCT02662491|Dietary Supplement|Vitamin D and calcium|
75793540|NCT05843136|Other|physiotherapy treatment|this is an interventional study of the use of 3 physiotherapy treatment techniques in order to evaluate the effectiveness of interferential current in relieving chronic low back pain
75793541|NCT05843123|Other|Respiratory support a|Invasive mechanical ventilation mode
75793542|NCT05843123|Other|Respiratory support b|Invasive mechanical ventilation mode
75793543|NCT05843110|Other|Decision-making process|Retrospective evaluation using scales, questionnaires and a semi-structured interview
75793544|NCT05843084|Procedure|7T MRI network analysis for deep brain stimulation in Parkinson's disease|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in PD patients.
75793545|NCT05843071|Device|Nasal sprays with sea salts|Nasal sprays for nasal congestion and dryness
75793546|NCT05843058|Behavioral|laughter yoga|The effect of laughter yoga on psychologıcal wellness ın women wıth gynecologıcal cancer has been evaluated.
75793547|NCT05843006|Diagnostic Test|Examination and analysis of sweat and blood samples at baseline and at follow up|Subjects will be assessed at baseline (as inpatients) and at 4-6 weeks at follow-up as outpatients according to standard operating procedures. Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Further examinations include measurement of left ventricular ejection fraction by echocardiography at baseline and blood pressure, heart rate, risk scores and health information will be collected at baseline and follow up.
75793548|NCT05843006|Diagnostic Test|Examination and analysis of sweat and blood samples at baseline|Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Blood pressure, heart rate, risk scores and health information will collected.
75793549|NCT05842980|Other|sepsis|collect 5ml blood from patient
75929744|NCT04849806|Diagnostic Test|Determination of PH and right HF severity|(defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography
75929745|NCT04849806|Diagnostic Test|Comprehensive lung function and inspiratory muscle function testing.|Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 <55 mmHg) and hypercapnia (PaCO2 >45 mmHg) using capillary blood gas analysis.
75929746|NCT04849806|Diagnostic Test|Assessment of systemic inflammation|Based on blood samples taken.
75929747|NCT04837755|Diagnostic Test|Cytokine measurements|The serum concentrations of multiple cytokines are measured.
75929748|NCT04828967|Other|Hypnosis|Hypnosis is added to the conventional group
75929749|NCT04824677|Other|Hospital treatment of COVID disease|Hospital treatment of COVID disease
75929750|NCT04819425|Device|Elastic Adhesive Strips|Securement of Endotracheal tube with Elastic Adhesive Strips
75929751|NCT04819425|Device|Lace in A Protective Sheath|Securement of Endotracheal tube with Lace in A Protective Sheath
75929752|NCT04814355|Drug|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
76084864|NCT01816295|Drug|Testosterone Solution|Administered topically to axillae.
76084865|NCT01816295|Drug|Placebo Solution|Administered topically to axillae.
76084866|NCT02514018|Biological|Live-attenuated varicella-zoster virus vaccine|Commercial vaccine used to prevent shingles
76084867|NCT02513862|Device|Autologous Platelet-Rich Plasma Harvest Technique|15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
76084868|NCT01659268|Other|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
75645563|NCT02662491|Dietary Supplement|Vitamin D|
75645564|NCT02662491|Dietary Supplement|Calcium|
75645565|NCT02662491|Dietary Supplement|Placebo|
75645566|NCT04171011|Device|Stimulator device|The stimulator device will be used to electrically stimulate the NVB
75645567|NCT02662413|Other|Validation of Asthma Control Questionnaire|This is an observational study so there is no planned intervention.
75645568|NCT02662335|Other|Computer-Assisted Cognitive Training|Participate in Cogmed computerized working memory training
75645569|NCT02662335|Other|Questionnaire Administration|Ancillary studies
75645570|NCT02662335|Procedure|Standard Follow-Up Care|Undergo standard follow-up care
75645571|NCT02662101|Device|Exsalt SD7, Exsalt T7 Wound Dressing|
75645572|NCT00648999|Drug|lopinavir/ritonavir|lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
75645573|NCT02662179|Other|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
75645574|NCT02662179|Other|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
75793550|NCT05842850|Behavioral|Caloric restriction intervention|The intervention consist of 4-weeks limiting daily food intake to a window of 8 hours (8am to 4pm) and water-fasting for the remaining hours of the day. Participants (LBW NAFLD individuals only) will be instructed to eat a balanced diet according to the current dietary guidelines reduced by 20% calories to ensure energy deficit.
75929753|NCT04812691|Biological|JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
75929754|NCT04809558|Behavioral|Tongue resistance exercise|Participant will complete tongue resistance exercises.
75929755|NCT04802564|Other|regular hand therapy|edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
76084869|NCT01659268|Other|Exhibition-dialogued class|"The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.~Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes."
76084870|NCT02510586|Drug|Sevoflurane|administer 1.0 MAC (1.7~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
75645575|NCT02662179|Other|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
75645576|NCT02662179|Other|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
75645577|NCT02661945|Device|Near focus with narrow band imaging|
75645578|NCT02661867|Behavioral|delivery|delivery either vaginal or by cesarean section
76084871|NCT01704196|Drug|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
76084872|NCT01704196|Drug|Placebo|
75335935|NCT01059929|Behavioral|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
75645579|NCT02661711|Drug|Aflibercept|"2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye."
75645580|NCT02661789|Drug|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
75645581|NCT02661789|Drug|Placebo|Injection of saline
75645582|NCT02661555|Other|Aerobic exercise|
75645583|NCT02661633|Device|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
75645584|NCT02661633|Device|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
75645585|NCT02661321|Other|No intervention was used in this study, this was an observational study|
75645586|NCT02661477|Drug|pegylated interferon alfa 2|
75645587|NCT02661477|Other|Placebo|0,9% natrium chlorine solution
75335936|NCT04353011|Other|questionnaire assesment|questionnaire assesment
75793551|NCT05842850|Other|No intervention|No intervention
75793552|NCT05842798|Drug|TNM002|TNM002, intramuscular injection
75793553|NCT05842798|Drug|Placebo|Placebo, intramuscular injection
75793554|NCT05842785|Drug|Phase I dose escalation|The eligible subjects will receive TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
75793555|NCT05842785|Drug|Phase II-HNSCC|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
75335937|NCT04866953|Other|Blood transfusion|Number of units of blood received within 24 hours of admission
76084873|NCT01610297|Drug|ICL670|Oral dose of ICL670 at 10 mg/kg daily
76084874|NCT03343782|Combination Product|Expanded autologous bone marrow-derived mesenchymal stem cell|Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
76084875|NCT01660672|Drug|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
75335938|NCT03579641|Device|HeartLogic Sensors|HeartLogic Sensors
75335939|NCT04162522|Drug|Escitalopram|Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.
75335940|NCT04162522|Drug|Brexpiprazole|Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
75335941|NCT04896658|Drug|Belantamab Mafodotin, Cyclophosphamide and Dexamethasone|Study drug
75645588|NCT02661243|Device|Biohorizons Laser-lok bonelevel dental implants|Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture
75793556|NCT05842785|Drug|Phase II-Advanced melanoma|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
76084876|NCT02505048|Drug|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
75335942|NCT01062269|Drug|Cholestyramine|Cholestyramine 4 grams one time dose
75335943|NCT01062269|Drug|Cholestyramine|Cholestyramine 12 grams one dose, one day
75645589|NCT02661087|Procedure|Hysteroscopic resection with bipolar energy|Hysteroscopic resection with bipolar energy
75335944|NCT01062269|Drug|Tang|Tang one dose one day
75335945|NCT04156828|Drug|Copanlisib|Given IV
75335946|NCT04156828|Drug|Gemcitabine|Given IV
75645590|NCT02661087|Procedure|Hysteroscopic resection with monopolar energy|Hysteroscopic resection with monopolar energy
75645591|NCT04170699|Procedure|Port-a-cath replacement|Implantation of a subcutaneous venous port-a-cath
75645592|NCT00601419|Drug|Somatropin|"Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.~Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.~Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration."
75645593|NCT04170387|Other|Relaxometer|Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
75645594|NCT02660931|Other|AKI Risk Notification|When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
75645595|NCT02660697|Procedure|Extraction site development|In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
75645596|NCT02660541|Device|Betafoam|Comparison between 2 medical devices
75793557|NCT05842785|Drug|Phase II-solid tumors or lymphomas|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
75793558|NCT05842772|Other|Shared decision making intervention for patients with kidney failure when planning end-of-life care|Testing a shared decision making intervention and a patient decision aid for patients with kidney failure, their relatives, and the health professionals.
75793559|NCT05842746|Drug|Elemene|Elemene of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
75793560|NCT05842746|Drug|Placebo|Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
75793561|NCT05842720|Procedure|un-sedated colonoscopies|un-sedated colonoscopies in high risk patients with ASA>=3
75793562|NCT05842707|Drug|dualCAR-NK19/70 cell|Given by IV (vein)
75793563|NCT05842681|Drug|Azithromycin|A single daily oral dose of Azithromycin tablet 500 mg for five days
75793564|NCT05842681|Drug|Methylprednisolone|methylprednisolone 500 mg single intra-venous daily dose for three days
75793565|NCT05842655|Procedure|The wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth|A novel digital technique to analyze the wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth as antagonist
76084877|NCT01793051|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
75335947|NCT04156828|Drug|Carboplatin|Given IV
75335948|NCT04156828|Drug|Dexamethasone|Given PO
75335949|NCT04156828|Biological|Rituximab|Given IV
75335950|NCT04156828|Biological|Pegfilgrastim|Given SC
75335951|NCT01062893|Other|Sterile normal saline 0 mls|at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
75335952|NCT01062893|Other|15 mls sterile normal saline|After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
75335953|NCT01063049|Drug|Gatorade/Miralax|Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
75335954|NCT01063049|Drug|NuLytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
75335955|NCT01063049|Drug|Bisacodyl|Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
75335956|NCT01063049|Drug|Placebo|Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
75645597|NCT02660541|Device|Allevyn Silver Dressing|Comparison between 2 medical devices
75645598|NCT02660463|Other|"Registration of the diagnosis CTEPH"|Registration of risk factors for thromboembolic events
75645599|NCT00649077|Drug|Meloxicam Tablets 15 mg|15mg, single dose fasting
75645600|NCT00649077|Drug|Mobic® Tablets 15 mg|15mg, single dose fasting
75645601|NCT02660619|Other|Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)|
75645602|NCT02660307|Other|PROGRESS group|
75645603|NCT02656251|Drug|0.12% Clorhexidine with alcohol|Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
75645604|NCT02656251|Drug|placebo|Use of placebo every 12 hours for 04 days
75645605|NCT02656251|Drug|0.12% Clorhexidine without alcohol|Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
75645606|NCT02656095|Drug|Heparin|Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
75645607|NCT00649935|Drug|Azithromycin Tablets 600 mg|600mg, single dose fed
75645608|NCT00649935|Drug|Zithromax® Tablets 600 mg|600mg, single dose fed
75645609|NCT02655939|Dietary Supplement|Reflex Plus|Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
75645610|NCT02655939|Dietary Supplement|Placebo|Fructose,Orange flavor and sucralose
75645611|NCT02655783|Other|5% dextrose|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
75645612|NCT02655783|Other|normal saline|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
75645613|NCT04421313|Drug|Dietary Fiber Supplementation|12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)
75793566|NCT05842616|Other|Transcranial doppler pulsatility index guided protocol|Norepinephrine titration that will be guided by Transcranial doppler pulsatility index.
75929756|NCT04802434|Behavioral|Strengthening Skills Program|The Strengthening Skills Program is a new, multi-component intervention. It includes three components: (1) Forming habits to compensate for the difficulties many adults with ASD have with thinking flexibly, planning, and time management. It will emphasize habit-forming behaviors to compensate for weaknesses in functional skills by training on practical techniques; (2) Content from the PEERS Social Skills program to target social challenges, and (3) strategies derived from Mindfulness Based Stress Reduction to target emotion regulation.
75929757|NCT04802434|Behavioral|PEERS Social Skills Program|PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
75929758|NCT04798833|Device|Integrated Newborn Care Kit (iNCK)|"Contents of the integrated newborn care kit:~Clean birth kit: sterile blade, clean plastic sheet, plastic gloves, hand soap, cord ties/clamp, maternity pad to absorb post-natal bleeding, 10 cotton balls for applying Chlorhexidine (CHX) to the umbilical stump.~3x200 µg dissolvable tablets of misoprostol to be ingested prophylactically following delivery of the baby and before delivery of the placenta to prevent post-partum hemorrhage~4% CHX solution (15 mL)~Sunflower oil emollient (50 mL)~Temperature monitoring strip or sticker~Fleece blanket for the newborn~Click to heat warmer~Pictorial guide that illustrates how and when to use each kit component~Handheld electronic scale with suspended cloth sling (the scale will not be included with the kit but rather one will be issued to each Lady Health Worker in the experimental arm)~Other Names: Neonatal Care Kit"
75929759|NCT04793334|Procedure|sleeve gastectomy|routine sleeve gastrectomy
75335957|NCT04104178|Drug|Clindamycin|Investigating whether a significantly higher number of MRSA throat carriers succeed in becoming MRSA free, when using Clindamycin on top of our general recommended topical treatment of Mupirocin nasal ointment + chorhexidin baths
75929760|NCT04759716|Other|Health Literacy-based Weight Control Intervention|intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
75929761|NCT04759274|Device|Diuretic Tuner|Mobile device application for diuretic dose titration
75929762|NCT04748939|Biological|recombinant subunit herpes zoster vaccine|vaccine administration
75929763|NCT04735705|Device|Cerviron|Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
75929764|NCT04735419|Other|No intervention|No intervention
75929765|NCT04732000|Drug|N-acetyl cysteine|Intravenous infusion started during the clinically indicated surgery at a rate of 50mg/kg over 1 hour followed by 50mg/kg over 3 hours. This will be an accumulated total of 100 mg/kg over 4 hours.
75929766|NCT04732000|Other|Normal Saline|Intravenous infusion at a time and rate to mimic the active treatment. The infusion will be given over 4 hours beginning during the clinically indicated surgery
75929767|NCT04720157|Drug|177Lu-PSMA-617|administered intravenously once very 6 weeks (1 cycle) for 6 cycles
75929768|NCT04720157|Drug|68Ga-PSMA-11|Single intravenous dose of approx. 150 Megabecquerel (MBq)
75929769|NCT04720157|Drug|ARDT|Administered orally on a continuous basis as per package insert and guideline
75929770|NCT04720157|Drug|ADT|ADT are administered as per physician order
75335958|NCT04104178|Drug|Placebo|Placebo
75645614|NCT02655705|Drug|Cyclosporine A|Male 200 mg/day, Female 150 mg/day for 16 weeks
75645615|NCT02655705|Drug|Methotrexate|Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
75645616|NCT02655861|Other|Observation|
75645617|NCT02655627|Other|Internet based exercise training|
75793567|NCT05842616|Other|Mean arterial blood pressure guided protocol|Norepinephrine titration that will be guided by Mean arterial blood pressure (MAP).
75793568|NCT05842603|Behavioral|Cardiac Lifestyle Program|12-week, tailored nutrition and physical activity program comprised of virtual and in-person classes.
75645618|NCT02655627|Other|group exercise training|
75645619|NCT02655627|Other|Physical activity counselling via a brochure|
75645620|NCT02655471|Drug|"Raltegravir and Zidovudine"|Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
75645621|NCT04418037|Device|Digital Health Feedback System(DHFS)|We will investigate the feasibility of using the DHFS in hospitalized individuals living with HIV to support ARV adherence.
75793569|NCT05842590|Other|Composite Veneer Restoration|This is a single-arm study. Direct composite veneer Restorations will be performed to all patients.
75793570|NCT05842564|Other|Blood samples|Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)
75929771|NCT04713345|Other|Virtual Reality Observations|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
75929772|NCT04713345|Other|Relaxation|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
75645622|NCT02655549|Biological|Px563L, RPA563, or placebo|Two intramuscular injections
75793571|NCT05842564|Other|Biopsies|5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy
75793572|NCT05842486|Other|Anti-C5 antibody treatment|Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)
75929773|NCT04710498|Drug|Atezolizumab|Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
75929774|NCT04684628|Drug|68Ga-PSMA PET/CT|Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
75929775|NCT04682158|Drug|Carboplatin|Given IV
75929776|NCT04682158|Radiation|3 Dimensional Conformal Radiation Therapy|Undergo 3D CRT
75929777|NCT04682158|Drug|Propranolol|Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks
76084878|NCT01793051|Other|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
76084879|NCT01793051|Behavioral|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
75645623|NCT04168749|Combination Product|Numeta G13|10 days
75645624|NCT00650013|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fed
75645625|NCT00650013|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fed
75793573|NCT05842447|Dietary Supplement|367 mg Pomanox group|Treatment with 367 mg Pomanox®P30 during 12 weeks
76084880|NCT02510508|Behavioral|Group CRAFT|CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
76084881|NCT02510508|Behavioral|Self-Directed CRAFT Delivery|CRAFT self-help book (Self Directed CRAFT Delivery)
75645626|NCT04168905|Device|AOTI Inc. TWO2 topical oxygen therapy equipment|Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
75335959|NCT03661138|Drug|Upadacitinib|Upadacitinib is administered orally.
75335960|NCT03661138|Drug|Placebo for upadacitinib|Placebo is administered orally.
75793574|NCT05842447|Dietary Supplement|700 mg Pomanox group|Treatment with 700 mg Pomanox®P30 during 12 weeks
75793575|NCT05842447|Dietary Supplement|Control group|Treatment with maltodextrin during 12 weeks
75793576|NCT05842421|Device|optical coherence tomography, in vivo reflectance confocal microscopy, 3D total body photography|each lesion is in addition to examination with dermoscopy examined with optical coherence tomography, in vivo reflectance confocal microscopy, each patient is photographed with 3D total body photography
76084882|NCT02510508|Other|Non-intervention|Non-intervention
76084883|NCT01661764|Drug|Eicosapentanoic acid and docosahexanoic acid|1395 mg EPA plus 1125 mg DHA daily for 24 weeks
75645627|NCT00712933|Drug|belimumab|"Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days."
75645628|NCT02654847|Drug|Norepinephrine|
75645629|NCT02654847|Drug|Normal Saline|0.9% sodium chloride solution, used as a diluent.
75645630|NCT02654925|Procedure|Adipose Tissue Biopsy|
75645631|NCT02536209|Drug|MT-8554 low dose|
75645632|NCT02536209|Drug|MT-8554 high dose|
75645633|NCT02536209|Drug|Oxycodone hydrochloride|
75645634|NCT02536209|Drug|Placebo|
76084884|NCT01661764|Drug|Oleic Acid|Placebo
75335961|NCT03661138|Drug|Topical Corticosteroids (TCS)|It is administered concomitantly with upadacitinib or placebo.
75645635|NCT02568631|Other|serious game JeStiMulE|The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.
75645636|NCT02568631|Other|control video game|The patients will play 6 sessions of one hour with the control video game
75645637|NCT02655003|Other|TIME|
75793577|NCT05842408|Drug|DA-5212|Test drug: DA-5212
75793578|NCT05842408|Drug|DA-5212-R|Control drug: DA-5212-R
75929778|NCT04682158|Radiation|Intensity Modulated Radiation Therapy|Undergo IMRT
75929779|NCT04682158|Drug|Paclitaxel|Given IV
75929780|NCT04681807|Behavioral|Emotion Recognition Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of an emotion recognition training exercise on iPad, lasting for a period of ~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
75929781|NCT04681807|Behavioral|Active Control Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of a control training exercise on iPad, lasting for a period of ~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
75929782|NCT04670315|Diagnostic Test|Telematic evaluation of motor function|Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
76084885|NCT02510430|Behavioral|Re-Patterning Sitting Time Group|This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
76084886|NCT02510430|Behavioral|Reducing Sitting Time Group|This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
76084887|NCT02510430|Behavioral|Usual Care|This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
76084888|NCT01816061|Behavioral|Experimental - COMPASS|Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
75929783|NCT04666831|Behavioral|Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)|The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
75929784|NCT04663607|Behavioral|Use of PretermConnect App|Participants will receive health education via a mobile app, PretermConnect, in addition to the standard of care, and complete additional surveys on the social determinants of health
75793579|NCT05842395|Drug|Vitamin C|Participants with distal radius fractures will take vitamin C supplementation with a daily dose of 1g orally for three months.
75929785|NCT04662580|Drug|ARX517|ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
75645638|NCT02655003|Other|Education-only intervention|The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
75472796|NCT01963039|Device|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
75472797|NCT01963039|Procedure|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer (PMMA) is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
75472798|NCT01963052|Drug|AGS15E|intravenous (IV) infusion
75472799|NCT01963104|Procedure|Automated hearing test|Subjects will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
75472800|NCT01963104|Procedure|Pure-tone Screener test|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
75645639|NCT00739921|Procedure|Nasal swab under endoscopic guidance|"After the application of pontocaine and neosynephrine spray, the following will be done:~A small sponge applicator will be used to swab the inside of your mouth for saliva collection~A blood sample (6cc - one tube) will be collected~A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)~Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you~You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well~The samples will be refrigerated and analyzed using PCR to detect and speciate fungus."
75793580|NCT05842395|Drug|Placebo|Participants with distal radius fractures will take daily Placebo orally for three months.
75793581|NCT05842317|Drug|Lenvatinib Plus Tislelizumab|Lenvatinib is 12mg/d for body weight >= 60kg, 8mg/d for body weight <60kg, once daily orally, once a day, after meals (take at the same time every day as much as possible); Tislelizumab is administered intravenously at a dose of 200mg/q3w.
75793582|NCT05842317|Device|Transarterial Chemoembolization(TACE)|A catheter is inserted through a small incision in the groin and guided to the hepatic artery, which supplies blood to the liver;A contrast dye is injected through the catheter to help visualize the blood vessels in the liver; A mixture of chemotherapy drugs and an embolic agent (such as small beads or gel foam) is injected through the catheter and into the artery that feeds the tumor;The embolic agent helps to block the blood flow to the tumor, which starves it of oxygen and nutrients; The chemotherapy drugs are then trapped in the tumor.
75793583|NCT05842187|Procedure|Biopsy of tumor tissue for organoid culture|By collecting fresh tumor tissues (including ascites, pleural effusion, biopsy tissues, palliative surgery specimens, etc.) and culturing them into organoids in vitro, this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
75645640|NCT02655081|Dietary Supplement|high arginine nutritional supplement (Nestle's Impact AR)|Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
75793584|NCT05841862|Device|2C-QD|Quantum Dot
75929786|NCT04662580|Drug|Enzalutamide|Enzalutamide is the FDA approved drug
75929787|NCT04658160|Behavioral|Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients|access to/use of the tracking platform
75929788|NCT04653064|Behavioral|Placebo Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.
75929789|NCT04653064|Behavioral|Control Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect.
76084889|NCT01816061|Behavioral|Control - COMPASS|Increased hours of patient-provider interactions Group.
76084890|NCT02510274|Drug|ASP3325|oral
76084891|NCT03121482|Device|HFNC|Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
76084892|NCT03121482|Device|NIV|Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
75929790|NCT04651504|Other|Colorectal Cancer Toolkit|The intervention toolkit will include patient education materials and supportive materials for providers. Tracking systems and supports will be jointly developed with participating clinic and providers, in order to maximize their existing systems and develop processes that meet their needs and preferences, and training will be offered to help providers/teams efficiently use the tracking system and clinic resources. The study team will provide technical assistance and support through email, phone and zoom to support the clinic in their implementation process.
75929791|NCT04648241|Biological|TBE vaccine 0.5 mL|TBE vaccine 0.5 mL (intramuscular injection).
75929792|NCT04648241|Biological|TBE vaccine 0.25 mL|TBE vaccine 0.25 mL (intramuscular injection).
76084893|NCT01662778|Drug|1.5 microns at 50mg|STAG generated monodisperse 1.5micron particles
75793585|NCT05841862|Device|Sham 2C-QD|Sham Intravitreal Injection
75793586|NCT05841108|Device|force feedback rehabilitation robot (SEM™ Glove)|In the experimental group, the therapists were asked to illustrate and demonstrate the motor points of the cylindrical grasping and spherical grasping movements, and the patients were instructed to imitate them with nonparalytic hand, while the latter patients wore SEM™ Glove were used for task-oriented training, such as inserting pegs, grasping a ball into a barrel, and drinking water exercises. The difficulty of task-oriented training can be adjusted according to the patient's actual condition, such as changing the shape, weight, size of the target or changing the distance, duration, and so on during training
75929793|NCT04646460|Behavioral|Observed Success|"The demonstrator in video gets a placebo treatment, Levoderm analgesic cream, which will be shown to be effective at relieving pain."
75793587|NCT05841108|Other|assisted by a therapist|The control group received task-oriented training assisted by a therapist to complete the same task as the experimental group. Therapists need to instruct patients to try to grasp items and give appropriate assistance to guarantee their completion of the grasping task. If finger extension is weak, the therapist assists the patient in extension of the digits before grasping the items, and if the finger flexion angle does not meet the grasp function needs, it should assist in flexion finger movements
75929794|NCT04646460|Behavioral|Observed Failure|The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
76084894|NCT01662778|Drug|6 microns at 50mg|STAG generated monodisperse 6 micron particles
75929795|NCT04646460|Behavioral|Experienced Success|The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.
76084895|NCT01662778|Drug|Placebo Comparator|No drug just solvent
75645641|NCT00740077|Other|Low calorie, sugar-free cranberry juice cocktail (54% juice)|Single-dose, 24 hour pharmacokinetic trial of 8 oz dose administered orally.
75645642|NCT04168827|Behavioral|Questionnaire|Questionnaire completed by the parents of severe traumatized child, between 3 to 6 months after the leaving of the child out of intensive care unit
75929796|NCT04646460|Behavioral|Experienced Failure|The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.
75929797|NCT04642469|Drug|Durvalumab|Intravenous administration of Durvalumab
75929798|NCT04642469|Other|Placebo|Placebo Comparator
75929799|NCT04631406|Biological|Neural Stem Cells|NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
75929800|NCT04630730|Drug|Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)|1 dose of VPM1002BC, live, 1-19.2 x 108 colony forming units (CFU) on day 1, 8 (+/- 1 day) and 15 (+/- 1 day)
75929801|NCT04630730|Drug|Atezolizumab|Neoadjuvant immunotherapy with atezolizumab, 4 cycles 1200 mg fixed dose iv infusion on d1 q3w starting 4-16 weeks after date of surgery
75929802|NCT04630730|Drug|Cisplatin|Neoadjuvant chemotherapy with cisplatin: 4 cycles 70mg/m2 iv infusion on d1 q3w (starting on d22)
75929803|NCT04630730|Drug|Gemcitabine|Neoadjuvant chemotherapy with gemcitabine: 4 cycles 1000 mg/m2 iv infusion on d1 and d8 q3w (starting on d22)
76084896|NCT01662778|Drug|MDI FP|
76084897|NCT03121326|Diagnostic Test|blood and urine sampling|Ten mL blood and 15mL urine are collected.
76084898|NCT03121560|Device|Hysteroscopy|Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.
75645643|NCT00740155|Biological|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
75645644|NCT00740155|Biological|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
76084899|NCT03121560|Device|Hysterosonography|Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
76084900|NCT02510196|Behavioral|reminder|
76084901|NCT01792115|Drug|Vitamin E 200 IU/d|Supplement-low dose
76084902|NCT01792115|Drug|Vitamin E 400 IU/d|Supplement-intermediate dose
76084903|NCT01792115|Drug|Vitamin E 800 IU/d|Supplement High Dose
75645645|NCT00740155|Biological|Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
75645646|NCT00740155|Biological|Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
75645647|NCT00740155|Biological|JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
75645648|NCT02654535|Other|Dietary tree nuts & peanuts|An intervention in which tree nuts and/or peanuts are included in the diet
75645649|NCT00732745|Drug|docetaxel|Given IV
75645650|NCT00732745|Drug|oxaliplatin|Given IV
75645651|NCT00732745|Drug|vandetanib|Given orally
75645652|NCT00732745|Other|placebo|Given orally
75645653|NCT02654457|Procedure|Women with Breast Cancer|IVD Study
75793588|NCT05840848|Dietary Supplement|Control beta-carotene supplement plus Placebo|15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule.
75793589|NCT05840848|Dietary Supplement|Control beta-carotene supplement plus iron Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH & Co. KG, Boeblingen, Germany)
75793590|NCT05840848|Dietary Supplement|Control beta-carotene supplement plus zinc Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH & Co. KG, Boeblingen, Germany)
75793591|NCT05840835|Drug|IMX-110 combined with Tislelizumab|Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
75793592|NCT05840562|Drug|Capsaicin|Application of capsaicin patches 179 mg
76084904|NCT01792115|Behavioral|Diet and Exercise|Diet and Exercise for all Arms of the study at baseline
76084905|NCT02505126|Device|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
76084906|NCT02505126|Device|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
75793593|NCT05840562|Drug|Duloxetine|Administration of duloxetine
75793594|NCT05840471|Drug|Tranexamic acid injection|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
75793595|NCT05840471|Other|Glucose water 5%|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
75793596|NCT05840289|Other|fractionated first dose rituximab|Patients at high-risk to develop tumor lysis syndrome received a initial fractionated dose of rituximab over 2 or 3 days
75793597|NCT05839938|Other|Vitamin D|Vitamin D (2000IU/day) for 6 months
75793598|NCT05839938|Other|Placebo|Placebo
75929804|NCT04630249|Behavioral|Listening to Women|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.
75929805|NCT04627701|Device|Omega|Omega Implantation
75793599|NCT05839756|Drug|budesonide|2 ml nebulized budesonide (containing 1 mg) diluted in 3 ml of normal saline will be nebulized preoperatively
75793600|NCT05839756|Drug|normal saline|5 ml normal saline will be nebulized preoperatively
75929806|NCT04624126|Device|3D-Erect|3D-printed erectile device for intercourse
75929807|NCT04614779|Drug|CN128 Tablets|Iron chelator, oral tablets
75929808|NCT04614584|Drug|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
75929809|NCT04614584|Drug|Methamphetamine|Methamphetamine 30 mg IV once
75929810|NCT04609644|Other|Digital Tools for Asthma Self-Management|Please see description of active study arm.
75929811|NCT04606264|Drug|Neuraxial Analgesia|This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
75929812|NCT04606264|Drug|Regional Block 1: Paravertebral|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
75929813|NCT04606264|Drug|Perphenazine|This randomized group will receive 8 mg of perphenazine orally preoperatively.
75929814|NCT04606264|Drug|Aprepitant|This randomized group will receive 40 mg of aprepitant orally preoperatively.
75929815|NCT04606264|Drug|Dimenhydrinate|This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
75929816|NCT04606264|Drug|Ondansetron 4 MG|This randomized group will receive 4 mg of ondansetron orally.
75929817|NCT04606264|Drug|Dexamethasone|This randomized group will receive 4-5 mg of dexamethasone intravenously.
75929818|NCT04606264|Drug|Regional Block 2: QL1|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
75929819|NCT04605263|Device|STN-PPN DBS Surgery|Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets
75929820|NCT04605263|Procedure|Deep Brain Stimulation Surgery (DBS)|DBS lead implantation of bilateral STN
76084907|NCT02504814|Device|Nasal Highflow (NHF)|changes in breathing physiology in NHF
76084908|NCT01791803|Behavioral|hypnotherapy|One 90 minute session within 2 weeks of hospital discharge
76084909|NCT01791803|Drug|Nicotine|free one month supply after hospital discharge
76084910|NCT01662856|Biological|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
76084911|NCT01662856|Procedure|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
75929821|NCT04604782|Drug|Regadenoson|Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
75929822|NCT04603781|Dietary Supplement|CBD Isolate|300 mg. daily dose of CBD Isolate Oil
75929823|NCT04603781|Dietary Supplement|Full Spectrum CBD Oil|300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
75929824|NCT04603781|Dietary Supplement|Broad-Spectrum CBD Oil|300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
75929825|NCT04603781|Dietary Supplement|Placebo Oil|MCT Oil with mint flavoring
75929826|NCT04602598|Drug|Zanubrutinib 80 MG|Zanubrutinib 80 MG for 24 weeks
76084912|NCT01791725|Drug|ELND005|
76084913|NCT01791725|Drug|Placebo|
75793601|NCT05839496|Other|Cervical stabilization exercises|Patients learned the activation of deep cervical flexor and extensor muscles. Then, during the activity of deep cervical muscles, superficial cervical muscles and upper extremity muscles were also strengthened. Thus, it was aimed to strengthen all neck muscles and upper extremity muscles in different positions synchronously and to increase their endurance.
75929827|NCT04601376|Behavioral|Mobile Monitoring Tool|a text-messaged based outcomes collection system
75929828|NCT04593862|Other|High-Intensity Interval Training|The intervention will be performed on a treadmill and will include a warm-up and cool-down at 50-60% and 40% of the VO2peak respectively, for up to five minutes. The HIIT protocol will be 4x4, which consists of four bouts of four minutes at a workload corresponding to vigorous intensity (75-95% of the baseline and 6-week VO2peak) alternating with three minutes of recovery intervals at 40% of the VO2peak. The exercise session will last 35 minutes and include 16 minutes of high intensity exercise.
76084914|NCT04499976|Drug|Isonicotinic Acid|Drug: Isonicotinic Acid then misoprostol Drug: Isonicotinic Acid 300mg total dose 900 mg per day for 3 days
75335962|NCT04086160|Device|Transcranial direct current stimulation device (Soterix Medical, New York, NY)|Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
75929829|NCT04589832|Drug|PAC-1|Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
76084915|NCT04499976|Drug|Placebo|Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
76084916|NCT04499976|Drug|Misoprostol|Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
75335963|NCT04081792|Procedure|Antibiotic therapy|Postoperative randomizations regarding the duration of systemic antibiotics
75645654|NCT00732823|Device|Placebo - No device worn|
75645655|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
75645656|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
75645657|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
75645658|NCT02654613|Other|Quality Improvement Model of Care|"QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context."
75645659|NCT00737815|Dietary Supplement|Magnesium Citrate: a total of 500 mg elemental magnesium|500 mg elemental magnesium
75645660|NCT00737815|Other|Placebo|Inactive placebo pill
76084917|NCT02504658|Behavioral|Lifestyle text messages|"Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website."
76084918|NCT02504658|Behavioral|Attention Control Group|"Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over."
75335964|NCT04053088|Device|INSPIRIS RESILIA Aortic Valve™|Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
75335965|NCT04562038|Behavioral|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|The Young Children's Participation in Environment Measure (YC-PEM) is an evidence-based option for comprehensive proxy assessment of a young child's current and desired participation in occupations across home, daycare, and community settings. The YC-PEM is an electronic patient-reported outcome (e-PRO) that provides individual caregivers a valid, reliable, and feasible way to communicate information about their child's current participation in home and community activities and areas of participation need. The gained information is then summarized and shared with the child's EI provide team to identify intervention priorities and goal attainment strategies in partnership with families. For quality improvement, EI programs can aggregate the YC-PEM e-PRO data to examine trends in participation as a function of EI service use. It is therefore a promising electronic health systems intervention to enhance the parent-practitioner relationship, and an NIH common data element for trials.
75335966|NCT04041778|Other|Catheter ablation|Substrate ablation. Pulmonary vein isolation.
75645661|NCT02654379|Biological|Rituximab|Rituximab use in non-oncology indications
75645662|NCT04065373|Device|ivWatch Model 400 with SmartTouch and fiber optic sensor|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored tissue at common IV sites over a 24 hour period.
75645663|NCT00732979|Procedure|Infrahepatic inferior vena cava clamping|The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
75645664|NCT00732979|Procedure|No infrahepatic inferior vena cava clamping|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below < 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
75793602|NCT05839106|Drug|PM1032 injection|Subjects will receive PM1032 by intravenous administration.
75929830|NCT04589832|Drug|Entrectinib|Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
75335967|NCT04038970|Biological|KN019, 5mg/kg|Solution, intravenous, 5 mg/kg
75645665|NCT02654301|Dietary Supplement|Test 1|sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g
75645666|NCT02654301|Dietary Supplement|Test 2|sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g
75645667|NCT02654301|Dietary Supplement|Test 3|sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g
75645668|NCT02654301|Dietary Supplement|Control|sucrose 50 g + deionized water 100 g
75793603|NCT05839093|Device|Inferior Alveolar Nerve Block Group|A standard IANB injection with a conventional dental injector and a 27-G needle. After determining the injection site and performing aspiration, 1.8 mL of solution was injected at a rate of 1 mL/min to block the inferior alveolar nerve. After achieving lip anesthesia, infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. The needle insertion point was the middle of the mesiodistal distance of the crown. Five minutes later, the teeth were isolated and the endodontic procedure was started.
75929831|NCT04589312|Biological|Standard of care vaccines|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)
75929832|NCT04589312|Biological|Boostagen, (BioNet-Asia)|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
75929833|NCT04585308|Device|transShield Embolic Protection System|Used for embolic protection during TAVR.
75929834|NCT04573192|Drug|L19TNF|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
75929835|NCT04573192|Drug|Lomustine|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
75929836|NCT04570891|Procedure|Ultrasound-guided fascia iliaca compartment block|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
75929837|NCT04570891|Procedure|Control|No regional block is provided at the end of surgery.
75929838|NCT04564521|Drug|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy to reduce the cardio-respiratory side effects.
75929839|NCT04564521|Drug|Normal saline|Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.
75929840|NCT04559919|Other|Seizure status|We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.
75929841|NCT04559919|Diagnostic Test|Tests|We will collect results from imaging, electroencephalogram, and laboratory tests.
75929842|NCT04559919|Other|Epilepsy|We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.
75929843|NCT04559919|Other|Demographics and psychosocial|We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.
75929844|NCT04559919|Other|Health care|We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs
75929845|NCT04557995|Procedure|Erythropheresis|Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
75929846|NCT04540497|Drug|Inebilizumab|Inebilizumab is a monoclonal antibody that depletes B cells.
75929847|NCT04540497|Other|Placebo|Placebo
75929848|NCT04524013|Other|There is no intervention. It is an observational study.|There is not intervention
75929849|NCT04518124|Drug|Propranolol|Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
75929850|NCT04515095|Other|Water-only Fasting|Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
76084919|NCT01791413|Drug|depot medroxyprogesterone acetate|DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
76084920|NCT01614574|Biological|velaglucerase alfa|60 U/kg every other week intravenous infusion
76084921|NCT01610063|Other|Pharmacogenomic algorithm|Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
76084922|NCT04499040|Biological|Blood sample|Blood samples to assess biological parameters such as:
76084923|NCT04499040|Other|Fecal samples|Microbiota analysis
76084924|NCT04499040|Behavioral|Neuropsychological|Neuropsychological assessment
75335968|NCT04038970|Biological|KN019, 10 mg/kg|Solution, intravenous, 10 mg/kg
75335969|NCT04038970|Biological|Placebo|Solution, intravenous, Placebo
75335970|NCT04038970|Combination Product|Methotrexate|Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition
75335971|NCT05426304|Drug|Agomelatine|agomelatine 25 mg/day for 180 days
75335972|NCT05426304|Drug|Placebo Tablets|placebo 25 mg/day for 180 days
75645669|NCT04349007|Dietary Supplement|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in after cooking
75645670|NCT04349007|Dietary Supplement|School food ready-to-use|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, maize, and vitamin and minerals
75645671|NCT04349007|Dietary Supplement|School food ready-to-use plus Milk|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, non-fat dried milk and vitamin and minerals
75793604|NCT05839093|Device|Intraligamentary Injection Group|An infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. Then, an intraligamentary injection was performed with a special pressure injection syringe (Sopira Citoject, Kulzer, Hanau, Germany) and a 30-G needle. The needle was placed alongside the tooth and inserted at a 30 angle relative to the longitudinal axis of the crown with the needle between the teeth and the bone. Then, in the mesiobuccal, distobuccal, mesiolingual and distolingual portions of teeth, 0.18 mL of the solution was injected. Five minutes later, the teeth were isolated and the endodontic procedure was started.
75645672|NCT04341129|Drug|Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)|To test the diagnostic effectiveness of an abbreviated MRI to a full MRI in the evaluation of breast lesions using Dotarem
75793605|NCT05838638|Behavioral|eSSET-CINV|Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
75645673|NCT00712543|Drug|lactulose (Kristalose®)|Crystals to be dissolved in water and taken as prescribed.
75793606|NCT05837728|Behavioral|Health promoting assessment of older adults living at home|Based on the results of the first assessment of the older person's health determinants, healthcare professionals will recommend and tailor measures to the individual's needs to reduce the risk of functional decline and maintain their health while living at home.
75929851|NCT04507685|Other|Lifestyle (Diet and Exercise)|"The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week."
75929852|NCT04504136|Procedure|Serial Biopsy|"During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach."
75335973|NCT03955198|Combination Product|Radiotherapy + durvalumab|Radiotherapy will be administered in combination with Durvalumab
75335974|NCT02991144|Genetic|scAAV8OTC|non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)
75929853|NCT04487834|Drug|Simethicone Solution|Oral daily treatment for four weeks
75929854|NCT04487834|Dietary Supplement|Vivatlac Baby|Oral daily treatment for four weeks
75929855|NCT04482634|Other|Remote controlled exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
75929856|NCT04482634|Other|Home exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
75472801|NCT01963104|Procedure|Digits-in-noise test|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
75929857|NCT04474353|Device|Optune|Noninvasive, portable device which generates tumor treating fields (TTFields) manufactured by Novocure
75929858|NCT04474353|Drug|Gadolinium|Gadolinium contrast medium
75929859|NCT04474353|Drug|Temozolomide|Chemotherapy agent
75929860|NCT04474353|Radiation|Stereotactic radiosurgery (SRS)|Standard of Care: SRS (35 Gy in 5 fractions of 7 Gy), 5-day treatment from Day 2
76084925|NCT02510118|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
75645674|NCT00712543|Drug|liquid lactulose|Liquid to be taken as prescribed.
75645675|NCT02654067|Procedure|photograph|photograph of airway
75793607|NCT05837611|Behavioral|Deposit Contract|A deposit contract requires individuals to put down money that is earned back contingently upon meeting their goals.
75929861|NCT04473716|Drug|Toripalimab|Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22
75929862|NCT04473716|Drug|Paclitaxcel|Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22
75929863|NCT04473716|Drug|Cisplatin|Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22
76084926|NCT02510118|Drug|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks
76084927|NCT02510118|Drug|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
75645676|NCT00740311|Device|MBCP gel TM|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
75645677|NCT00650169|Drug|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fed
75645678|NCT00650169|Drug|Plavix® Tablets 75 mg|75mg, single dose fed
75645679|NCT04064125|Drug|FMX-101|
75645680|NCT02653989|Biological|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
75645681|NCT00740389|Drug|TMC125|
75929864|NCT04473716|Procedure|Radical surgery|Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.
75645682|NCT00740467|Biological|anti-thymocyte globulin|
75645683|NCT00740467|Drug|busulfan|
75645684|NCT00740467|Drug|cyclophosphamide|
75645685|NCT00740467|Drug|cyclosporine|
75645686|NCT00740467|Drug|fludarabine phosphate|
75645687|NCT00740467|Drug|mycophenolate mofetil|
75645688|NCT00740467|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
75929865|NCT04473716|Radiation|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
75929866|NCT04469855|Drug|semaglutide|Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.
75929867|NCT04458259|Drug|PF-07265807|Given 2 weeks on/1 week off
75929868|NCT04458259|Drug|Sasanlimab|Given SC Q3W
75645689|NCT00740545|Drug|enoxaparine 40 mg daily|Women inject ourselves every days with 40 mg of enoxaparine
75645690|NCT00740545|Drug|placebo|Women inject ourselves every days with placebo
75793608|NCT05837611|Other|Transdermal Alcohol Monitoring|Using a SCRAM-Cam device participants will be monitored for their alcohol use.
75793609|NCT05837546|Other|Animal-assisted intervention|presence of a dog, contact between dog and participant
75793610|NCT05837546|Other|Factice dog intervention|presence of a factice dog, contact between factice dog and participant
75929869|NCT04458259|Drug|Axitinib|Dosed per package label starting with 5 mg PO BID
75929870|NCT04456621|Radiation|PBT|Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
75929871|NCT04444973|Procedure|Balloon pulmonary angioplasty|Balloon dilatation of sub segmental pulmonary artery web disease
75929872|NCT04432623|Drug|Benserazide Only Product|Investigational drug
76084928|NCT02510118|Drug|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
76084929|NCT02509806|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
75645691|NCT02653833|Drug|Tadalafil 20 MG|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
75645692|NCT02653833|Other|beetroot juice extract|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
75793611|NCT05837546|Other|Plant intervention|presence of a plant, contact between plant and participant
75793612|NCT05835414|Device|Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)|Approximately 2000 pulses per session (x30 sessions) of midline prefrontal, repetitive transcranial magnetic stimulation at 50% or less of motor threshold, calibrated via EEG to a resonant alpha frequency of the participant, and given over approximately 12 minutes. Given as an adjunct to standard of care and integrative treatment for TSRD.
75793613|NCT05834816|Behavioral|Negative Affect Task|fMRI stress task
75793614|NCT05831553|Diagnostic Test|Tissue Immune Profile|Tissue samples of the patients will be analized for the presence of TILs, CD73 and PDL1 (>=1%)
75793615|NCT05830903|Behavioral|VR-assisted occupational training|VR-assisted occupational training
75645693|NCT00733057|Drug|Minocycline|Minocycline as an add-on drug (200 mg/day)
75645694|NCT00733057|Drug|Placebo (200 mg/day)|
75645695|NCT04168359|Device|absorbable semi-barbed suture|Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device
75645696|NCT04168593|Procedure|Acupuncture|20 min of Acupuncture section follow by 10 min of cupping around the knee
75645697|NCT02569021|Device|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~Current best/optimized DBS setting (considered baseline)~DBS off for 30 minutes as a washout period~Biphasic pulse stimulation mode (assessment at 0.5hr)~Biphasic pulse stimulation mode (assessment at 1hr)~Biphasic pulse stimulation mode (assessment at 2hr)~Biphasic pulse stimulation mode (assessment at 3hr)"
75929873|NCT04432454|Drug|Lasofoxifene and abemaciclib (VERZENIO (R)).|Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
75929874|NCT04431258|Drug|ABTL0812|ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.
75929875|NCT04431258|Drug|Folfirinox|"FOLFIRINOX will be dosed according to the standard following regimen:~oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~leucovorin 400 mg/m2, administered as 2-hour iv infusion~irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities."
75645698|NCT02569021|Other|Unified Parkinson's Disease Rating Scale|UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
75929876|NCT04431258|Drug|Placebo|Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
76084930|NCT02509728|Dietary Supplement|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
76084931|NCT02509728|Dietary Supplement|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
76084932|NCT02509728|Dietary Supplement|standard nutrition|standard nutrition
76084933|NCT02509338|Device|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
76084934|NCT02501616|Drug|Metformin|
75335975|NCT02991144|Drug|Reactive Corticosteroid Taper Regimen|"Oral prednisone [or oral prednisolone] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301."
75335976|NCT02991144|Drug|Prophylactic Corticosteroid Taper Regimen|"Oral prednisone [or oral prednisolone] 60 mg/day at least 5 days prior to DTX301 administration, tapered over 9 weeks.~A prophylactic corticosteroid taper regimen will be administered to prevent or minimize transient vector-induced hepatic effects."
75335977|NCT05426226|Device|laser acupuncture|using laser acupuncture device on sleep acupoints during sleep
75335978|NCT05426226|Device|sham device|using sham device on sleep acupoints during sleep
75335979|NCT03468166|Other|Chronic stroke|The data for motor function and gait pattern analysis was obtained.
75645699|NCT02569021|Other|Tremor Rating Scale|TRS is used by neurologists to rate the severity of a tremor.
75645700|NCT02569021|Device|Kinesia accelerometer|The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
75645701|NCT02569021|Device|Trigno wireless system|The Trigno system measure muscle contractions.
75645702|NCT02569021|Other|GaitRite walking assessment.|GaitRite records a patients gait pattern.
75645703|NCT04168281|Diagnostic Test|Magnetic resonance imaging (MRI)|instead of PCI patients will be followed-up with MRI
75645704|NCT00737971|Drug|Bevacizumab intravitreal|Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
75645705|NCT00737971|Drug|Triamcinolone|Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
75645706|NCT00737971|Drug|Triamcinolone + Bevacizumab|Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
75793616|NCT05829577|Other|Executive Function Strategies and Training|will be conducted by primary investigator and trained therapist ,EF strategies will be implemented during DLS and SI training and these strategies will target following area which proved by evidences within the context of functional training: Using monitoring system for each child , Improving sense of time, Externalize important information , Externalize Motivation, Provide consequences: Immediately, more frequently, Higher magnitude and more powerful, Richer degree of incentive, Rotated or changed more frequently, Personalize the command, praise, instruction, reprimanding, Process training, remediation and training on executive function skill
75793617|NCT05829577|Other|Daily Life skill training|each child will receive 25 minute of DLS training which will focus on training children on Grooming, feeding, dressing undressing, toileting and community reintegration tasks aligned with facilitation fine motor skills for children and Using several techniques for ADL training including : prompting, shaping, forward and backward chaining, and modeling ,training children based on level of independency identified by WeeFIM score
75929877|NCT04426591|Drug|Biotin Labeled Red Blood Cells|On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of ~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion hemoglobin (Hb), sickle cell hemoglobin (HbS), and body weight, per clinical protocol.
75929878|NCT04426591|Device|INTERCEPT Blood System|In addition to the blood drawn for the main study, individuals participating in this optional intervention will have additional tubes of peripheral venous blood will be drawn for evaluating treatment-emergent antibodies specific to INTERCEPT RBCs and acridine surface label monitoring. Tests for treatment-emergent antibodies specific to INTERCEPT RBCs will be performed according to procedures developed by Cerus Corporation.
76084935|NCT02501616|Drug|Dapagliflozin|
76084936|NCT02501460|Other|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
75335980|NCT04499092|Behavioral|Neuropsychological treatment|Neuropsychological treatment
75472802|NCT01963104|Procedure|No screening test|This group of subjects will not receive a screening test. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
75645707|NCT02653911|Other|Acupuncture|Hwato Brand, Suzhou Medical Appliance Factory, China
75645708|NCT02653911|Other|Sham-acupuncture group|Hwato Brand, Suzhou Medical Appliance Factory, China
75645709|NCT02653677|Other|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
75645710|NCT02653521|Radiation|Dose adaptation|Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
75645711|NCT04064281|Other|the healthy Cantonese diet|After a 1-week run-in period, the intervention group will eat the healthy Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
75645712|NCT04064281|Other|the typical Cantonese diet|After a 1-week run-in period, the control group will still eat the typical Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
75645713|NCT00740701|Device|Cerebellar transcranial magnetic stimulation|single pulse TMS or repetitive TMS at 1 Hz frequency
75645714|NCT00650247|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fed
75645715|NCT00650247|Drug|Imitrex® Tablets 100 mg|100mg, single dose fed
75645716|NCT02568709|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
75793618|NCT05829577|Other|Sensory Integration /Processing training|each patient will receive 20 min of SI/SP training Manualized SI/SP intervention which will be used is based on the principles of sensory integration as outlined by Ayres ,such as deep pressure, brushing, weighted vests, and swinging will used , individually-tailored treatment activities might include activities such as using a carpeted scooter board while in the prone position to pull oneself up a ramp, then working to turn the scooter board around to ride down the ramp and land in a cushioned area of mats and pillows that are covered with various textures. Intervention is contextualized in play with active involvement of the child will be conducted in a large gym equipped with mats, a variety of suspended swings, large balls, a climbing wall, carpeted barrels, large inner tubes and foam blocks with opportunities for active, guided, sensory motor play.
75793619|NCT05829499|Device|HPMC-HA eyedrops|Ocular drops based upon HPMC and HA
75793620|NCT05827809|Behavioral|Unified Protocol (UP-C/A) for children and youth with anxiety disorders and /or depression|A transdiagnostic psychological group treatment, Unified Protocol (UP-C/A), one intervention, is tested for children and youth with anxiety disorders and/or depression seeking help in routine care in two primary care locations. Parents are at the same time offered parent training in a group format coupled with the module the children are working on. Feasibility, acceptability and effect of the intervention will be studied, with child self-report, parent-report and therapist assessment.
75645717|NCT02568709|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
75793621|NCT05825573|Drug|Vitamin K antagonist|VKA study medications (Warfarin, Fluindione and Acenocoumarol) will be prescribed and supplied in the usual setting of patient care with respect of the international guidelines and recommended dose protocols and will not be specifically supplied for the trial. Anticoagulant treatment will be prescribed for 6 months. The recommended INR target will be [2-3] and [2-2.5] for patients treated with concomitant antiplatelet therapy. Biological monitoring will be performed at discretion of physicians as usual care.
75929879|NCT04425616|Other|Exercise|"At least one and up to three supervised sessions per week including:~aerobic exercise at a rating of perceived exertion of 11-14 (6-20 scale) accumulating 20 minutes per session~resistance exercise of 8-10 exercises for 2x 8-15 repetitions performed in a controlled manner and covering the whole body~Range of motion exercise performed through pain free range of motion covering the whole body to be maintained in good alignment for 10-30 seconds, with some movements held for a second set of 10-30 seconds if stiff"
75929880|NCT04425616|Behavioral|Psychological and Behaviour Change Support|Instructors will be trained in Healthy Conversation Skills (HCS), Making Every Contact Count (MECC) or equivalent. This will enable them to deliver brief participant centred empowering interventions informed by social cognitive theory. This skill set will be used to support participants in adopting and maintaining the prescribed exercise and diet programme as well as adopting and practicing strategies to self-manage psychological well-being. Participants will be given the option to be provided with a SMARTER goal setting sheet to assist with goal planning. Applicable standardised psychological support resources will be made available to the participants though the Macmillan resource repository that they can access online or in alternative format as necessary, for example relaxation and mindfulness exercises
75929881|NCT04425616|Other|Nutrition|Instructors will receive training in generic nutritional principles in line with recommendations from World Cancer Research Fund (WCRF) and British Dietetic Association, and will work with participant to review own diet and eating habits against WCRF recommendations to enable goal setting and identify links to existing resources reputable websites, outputs and on-line forums. These would include: principles of healthy eating ('eat well' advice), weight management, symptom management, prehab advice before treatment starts, rehab advice during and after treatment. The participant will be asked if they are eating and drinking well or have any concerns at the beginning of each exercise session. Further support will be provided to instructors to address participant concerns or requests for additional information.
75929882|NCT04417257|Drug|LAU-7b|LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
75929883|NCT04417257|Drug|Placebo oral capsule|Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
75929884|NCT04396587|Drug|Sufentanil|Sufentanil(0.1μg/kg) was administered before anesthesia induction.
75929885|NCT04396587|Drug|Hydromorphone|Hydromorphone(20μg/kg)was administered before anesthesia induction.
75929886|NCT04396587|Drug|Oxycodone|Oxycodone(60μg/kg) was administered before anesthesia induction.
75929887|NCT04396587|Drug|normal Saline|normal saline 10ml
75929888|NCT04393506|Drug|Camrelizumab|Inductive therapy with Camrelizumab of 200mg, iv, qd, on day 1, 15, 29.
75929889|NCT04393506|Drug|Apatinib|Inductive therapy with Apatinib of 250mg, po, qd, initiating on day 1, ending on the fifth day before surgery.
75929890|NCT04393506|Procedure|Radical surgery|Radical surgery will be performed on the 42th-45th after initiation of inductive therapy
75929891|NCT04393506|Radiation|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathologic diagnosis.
75645718|NCT04168047|Procedure|Barostat procedure|Pressure threshold will be measured during the barostat procedure
75645719|NCT04168047|Other|Anxiety and Depression Evaluation|Anxiety and Depression will be measured using HAD anxiety and depression scale
75645720|NCT04168047|Other|Assessment of sleep quality|Sleep quality will be measured using Pittsburg sleep quality index
75335981|NCT04781660|Device|Implantable Alginate Hydrogel|"Implantable Alginate Hydrogel is a single use, multiple component device. It is expected to be used as a space-occupying material implanted into the myocardium to affect the shape of the left ventricle and reduce the clinical symptoms of patients with left ventricular ischemia and non-ischemic cardiomyopathy.~The hydrogel serves as an artificial myocardial filler to stop the continuous expansion of the ventricle and restore it to a more favorable shape and size. The expected clinical effect of the Implanted Alginate Hydrogel is to reduce the clinical symptoms of patients and improve the quality of life by improving the structure and function of the failing heart."
75335982|NCT02973750|Procedure|Baseline Biopsy|Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
75335983|NCT02973750|Procedure|Tissue Collection|Tissue collection during debulking surgery.
75335984|NCT02973750|Procedure|Blood Draws|Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
75335985|NCT03934606|Behavioral|Genetic testing for hereditary predisposition|Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
75645721|NCT02653365|Device|Non-invasive ventilation|Noninvasive ventilation (NIV) was performed with a noninvasive ventilator (BiPAP Synchrony®, Respironics Inc., Murrysville, PA, USA).
75645722|NCT00740935|Biological|Rotateq vaccine|"Vaccination against rotavirus~Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose."
75645723|NCT04647175|Other|Fermented aronia|Given twice daily for 8 weeks
75645724|NCT04647175|Other|Aronia|Given twice daily for 8 weeks
75645725|NCT04647175|Other|Placebo|Given twice daily for 8 weeks
75645726|NCT02653209|Drug|Sitagliptin - DPP4i|DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
75793622|NCT05825573|Drug|Direct oral anticoagulant|DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care and will not be specifically supplied for the trial. The usual doses of DOA will be prescribed: dabigatran 150mg twice a day, apixaban 5mg twice a day and rivaroxaban 20mg once a day. The adjusted doses (dabigatran 110mg twice a day, apixaban 2.5mg twice a day and rivaroxaban 15mg once a day) will be prescribed according to clinical practice treatment guidelines.
75793623|NCT05825352|Device|Carmellose eye drops|Ocular drops based upon carmellose
75793624|NCT05824494|Drug|Cadonilimab|Cadonilimab 10mg/kg,every 3 weeks,IV infusion
75793625|NCT05824494|Drug|Nab paclitaxel|Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
75793626|NCT05824000|Device|Eye drops for itchy and water eyes|Ocular drops for itchy and watery eyes
75793627|NCT05823961|Device|Cross-linked hyaluronic acid eye drops|Cross-linked hyaluronic acid (CLHA)-based eyedrops
75645727|NCT02653209|Drug|Canagliflozin - SGLT2i|SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
75645728|NCT02653209|Drug|Pioglitazone - TZD|Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
75645729|NCT00733447|Device|CardioWest temporary Total Artificial Heart (TAH-t) System|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) System is a pulsatile biventricular device that replaces a patient's native ventricles and valves, and pumps blood to both pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external pneumatic driver connected by drivelines.
75645730|NCT02653131|Drug|Dipeptidyl peptidase-4 inhibitor|
75793628|NCT05823506|Combination Product|PDE5 inhibitor (tadalafil) and BTL-6000 fSWT|The mechanism of low-intensity shockwave therapy in patients with ED based on the effect on the endothelium of the cavernous arteries, the release of NO and the enhancement of vascularization due to release of angiogenic factors.
75793629|NCT05823506|Drug|PDE5 inhibitor (tadalafil)|Tadalafil improves erectile function by inhibiting PDE5 isoenzyme, thereby blocking cGMP degradation. As a result, the PDE5 inhibitors act synergistically with NO to markedly increase the levels of cGMP, which in the presence of sexual stimulation, lead to an erection. In the absence of sexual stimulation, NO is not released locally and the PDE5 inhibitors do not affect the penis. Thus, sexual stimulation is needed to initiate the erectile mechanism for the PDE5 inhibitors to take effect.
75793630|NCT05823129|Behavioral|Tele-rehabilitation caregiver empowerment enhanced post- discharge rehabilitation directive|The intervention group will receive an implemented TUG test-based telerehabilitation program. The TUG test-based telerehabilitation involves patients routinely doing two TUG tests by themselves twice daily. Each patient will be provided with a unique link to the TUGstopwatch, a prerecorded video outlining instructions on how to properly conduct a TUG test, and support and guidance for patients and caregivers throughout the study period.
75793631|NCT05822895|Device|CADe enabled programme (GI Genius)|CADe enabled programme (GI Genius)
75793632|NCT05822817|Drug|sevoflurane|Anesthesia is maintained with inhalation of sevoflurane. The concentration of sevoflurane was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
75793633|NCT05822817|Drug|propofol|Anesthesia is maintained with an effect-site target-controlled infusion of propofol (2-6ug/ml) based on the Marsh mode. The concentration of propofol was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
75793634|NCT05821335|Other|Leap motion assisted rehabilitation|Hand Therapy via leap motion sensor
75929892|NCT04381559|Behavioral|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
75335986|NCT02532972|Device|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
75645731|NCT02652897|Procedure|Exposure to glioma resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
75929893|NCT04381559|Behavioral|Applied Relaxation|12 sessions of AR will serve as our second, control arm. In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response.86 AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety.87 This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition.88 Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety.87 However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
75929894|NCT04379752|Device|Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment|Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
75335987|NCT05450406|Other|Physical activity|The participants will receive the possibility to attend weekly endurance, resistance and yoga exercise sessions administered by the Healthy Life Center. They will also receive personalized follow-up from the Healthy Life Center, and have the possibility to exercise at the local gym.
75645732|NCT02652897|Procedure|Exposure to colon resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
75929895|NCT04366726|Combination Product|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto an sMTS array for transdermal administration of abaloparatide.
75929896|NCT04333771|Drug|SHR0302|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
75793635|NCT05821335|Other|Traditional program|Hand Therapy by physiotherapist via traditional methods
75929897|NCT04333771|Drug|Placebo|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
75929898|NCT04319510|Procedure|Craniosacral therapy|The first experimental group of patients will receive 24 units à 45 minutes over 12 weeks (2 consecutive units per week) offered by a trained craniosacral therapist within a 1:1 setting. Treatment as usual is allowed.
75929899|NCT04319510|Procedure|Craniosacral self-help group training|The second experimental group of patients will receive 24 teaching units (TUs) à 45 minutes over 12 weeks offered by a trained craniosacral therapist within a group setting. The group training will start with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients have to agree to participate in the introductory day and 90% of the following TUs. All patients will receive a script with theoretical CST information and descriptions of the learned techniques, which should facilitate the correct practice at home. Treatment as usual is allowed.
75645733|NCT04168125|Device|Tilapia skin|Application tilapia skin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
75793636|NCT05820555|Behavioral|Timed evening technology and digital media use (tablet use)|timing of children's evening tablet device use relative to bedtime
75793637|NCT05820555|Behavioral|no technology and digital media use (screen media use)|no screen media use relative to bedtime (Tablets, computers, TV, moble devices, smart phone)
75793638|NCT05818462|Diagnostic Test|Uroflow testing|Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.
75793639|NCT05818462|Diagnostic Test|Bladder Scan|Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.
75793640|NCT05818462|Other|Dysfunctional Voiding Scoring System Survey|The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.
75793641|NCT05818462|Diagnostic Test|DEXA Scan of pelvis and sacral spine|DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.
75793642|NCT05818462|Diagnostic Test|Urine tests for specific biomarkers|Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
75335988|NCT03921502|Procedure|Gall bladder transmural drainage with LAMS|Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be *placed on it to generate the anastomosis between the aforementioned structures.
75335989|NCT03919396|Device|Breath-O orthokeratology lenses|"Specially designed rigid gas permeable lenses which~reshapes corneal profile for myopia control~has higher elasticity compared to traditional lens material."
75793643|NCT05817903|Drug|Axitinib|Axitinib will be started at the standard dose of 5 mg BID until progression of disease, unacceptable toxicity, patient' or physician' decision.
75335990|NCT03351712|Behavioral|ACT-Based Intervention and Activity Tracker WITH Feedback|Combining ACT and Behavioral Change
75645734|NCT04168125|Device|Surgical Wound Dressing|Application surgical wound dressing as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
75335991|NCT03351712|Behavioral|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Medical Rehabilitation, Motivational Support and Psycho-Education
75793644|NCT05817903|Drug|Nivolumab|Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision
75793645|NCT05814692|Diagnostic Test|blood and urine samples|blood and urine samples
75793646|NCT05814406|Drug|JW0201|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
75335992|NCT03351712|Behavioral|Gold Standard Intervention and Activity Tracker WITH Feedback|Behavioral Change Condition - Activity Tracker
75335993|NCT03351712|Behavioral|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|ACT-Based Intervention Standalone
75793647|NCT05814406|Drug|Placebo|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
75335994|NCT00382954|Drug|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
75645735|NCT00733603|Other|Global Therapeutic Massages (GTM)|Non-specific somatic treatment with full-body Western massage.
75793648|NCT05812196|Diagnostic Test|Lung function test|Spirometry to assess lung volumes, forced oscillations to measure respiratory mechanics, whole body plethysmography to assess static lung volumes and airway resistance, lung diffusion capacity measurements.
75793649|NCT05812196|Biological|COVID infection|Verified COVID-19 infection.
75793650|NCT05810896|Other|AF at Home|The AF at Home education program will be delivered via Zoom videoconferencing technology and will include 6, 1-hour long sessions that involve education on AF self-monitoring and self-management. Each session will include a didactic presentation and open Q&A. Supplementary educations materials will be made available to participants.
75793651|NCT05808218|Other|Community-Led Total Sanitation|"The community-led total sanitation intervention is implemented across an entire Traditional Authority and includes the following village-level activities:~Triggering:~Village transect walks and open defecation site mapping~Demonstrations of food contamination and medical expense calculations~Development of a Community-Action Plan and identification of natural leaders~Post-triggering: routine follow-up by selected natural leaders to track and monitor progress against the Community Action Plan~In addition to the activities above, the WASH for Everyone team will:~Train a cadre of local masons on sanitation construction~Support the District Health office in the implementation of existing sanitation and hygiene promotion at village markets and other public spaces"
75929900|NCT04319510|Procedure|Treatment as usal / wait list|The control group will receive no specific study treatment for a waiting period of six months. Treatment as usual is allowed. Afterwards they were offered 2 treatments (4TUS) of 1:1 CST and the participation in the group training.
75929901|NCT04318717|Drug|Pembrolizumab|Pembrolizumab is commercially available
75929902|NCT04318717|Radiation|Hypofractionated radiation therapy|It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.
75929903|NCT04318041|Drug|Artrodar|"Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal"
75929904|NCT04318041|Drug|Placebos|"Placebo:~D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal"
75645736|NCT00733603|Other|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
76084937|NCT02501460|Other|Resistance training|"Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed."
75335995|NCT00382954|Drug|Idarubicin|I.V., 8, or 10 or 12 mg/m^2 weekly (days 1, 8, 15, and 22) for 4 weeks
75645737|NCT02652585|Drug|Naltrexone|
75645738|NCT02652585|Drug|Placebo|capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
75645739|NCT00733681|Device|PFC Sigma RP TC3 Revision knee system|Orthopaedic implant system for revision total knee replacement
75645740|NCT02652819|Drug|FG-4592|
75645741|NCT02652819|Drug|Placebo|
75645742|NCT00741169|Drug|TMC435350|200 mg taken by mouth once daily for 7 days
75645743|NCT00741169|Drug|Rifampin|600 mg taken by mouth once daily for 7 days
75645744|NCT00741169|Drug|TMC435350+rifampin|The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
75929905|NCT04298242|Device|ExAblate 2100|A non-invasive thermal ablation device fully integrated with an MR imaging system
75929906|NCT04291885|Drug|Avelumab|Avelumab IV infusion
75929907|NCT04291885|Drug|Placebo|Placebo IV infusion
75929908|NCT04289987|Biological|CVI-HBV-002|Investigational Product
75335996|NCT03879070|Device|Ankle active and passive mobilization using an Ankle mobilization device|The treatment consists in 20 rehabilitation sessions, 5 times/week for 4 weeks. The device is capable of generating ankle dorsi/plantarflexion movements using two activation modes: passive and assistive. In the passive mode the device generates a movement pattern which the patient follows passively without exerting any force on the device. During the assistive mode, the device follows the active movement of the patient. During the intervention, these two modes will be alternated.
75335997|NCT03234556|Procedure|Biopsy of Prostate|Undergo SR-Bx
75335998|NCT03234556|Other|Laboratory Biomarker Analysis|Correlative studies
75335999|NCT03234556|Diagnostic Test|Magnetic Resonance Imaging|Undergo MRI
75645745|NCT02652975|Procedure|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
75645746|NCT02652975|Procedure|SphygmoCor|"Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously."
75645747|NCT02652975|Procedure|24hour blood pressure|24 hour blood pressure measurement
75645748|NCT02652975|Procedure|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
75793652|NCT05808218|Other|Care Groups|"Orientation and training of village-level Care Group members on CLTS, latrine construction, and hygiene promotion~Routine house-to-house follow-up of Care Group members to provide peer-to-peer counselling and support on sanitation and hygiene behaviours."
75793653|NCT05807061|Behavioral|EmBARK|The narrated training teaches parents about children's biases and introduces multiple strategies for addressing children's biases. Families receive children's books to help practice the strategies.
75793654|NCT05807061|Behavioral|Popular guidance|The popular press articles teach parents about children's biases and guide parents about how to talk to children about race. Families receive children's books focused on race to help practice talking about race.
75793655|NCT05807061|Behavioral|Practice first|Animal books are provided to parents to help them practice talking to their children when reading books. Then, families receive a training program about race as well as children's books about race.
75929909|NCT04289987|Biological|Normal Saline(placebo)|Investigational Product
75336000|NCT03234556|Diagnostic Test|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
75793656|NCT05805605|Biological|Peripheral Blood Stem Cell Transplant|On day 0, a target dose of 5 x 106 CD34 cells/kg will be infused.
75336001|NCT04420078|Procedure|Catheter Ablation|Ventricular fibrillation substrate
75336002|NCT01246063|Drug|carfilzomib|
75336003|NCT01246063|Drug|pegylated liposomal doxorubicin (PLD)|
75336004|NCT01246063|Drug|Dexamethasone|
75336005|NCT04330612|Other|Perioperative Updates|In the intervention group, the families received additional standardized electronic updates via pagers at three pivotal moments: 1) Initial skin incision has been made; 2) Critical part of the case is completed and closure has begun; and, 3) Closure is complete, and patient will be transferred to the recovery room when ready.
75793657|NCT05805605|Drug|Allopurinol 300 MG|300 mg/day from day -7 to day 0. Allopurinol 150mg/m2/day for pediatric participants.
75793658|NCT05805605|Drug|Fludarabine|30 mg/m2 IV over 1 hour. Administered on day -6 to day -2.
75793659|NCT05805605|Drug|Cyclophosphamide|Administered as a 2 hour IV infusion on day -6, +3, and +4.
75793660|NCT05805605|Biological|Bone Marrow Cell Transplant|On day 0, a target dose of 3 x 108 nucleated cells/kg recipient weight will be infused.
75793661|NCT05805605|Radiation|Total Body Irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
75793662|NCT05805605|Drug|Sirolimus Pill|"All participants begin +5 to day +100.~Loading dose on day +5 of 5 mg/m2/day orally once (max dose of 8 mg).~Maintenance dose 2.5 mg/m2 orally daily to maintain a level of 8-12 ng/ml (max dose of 4 mg)."
75929910|NCT04273542|Other|liquid biopsy|Blood sample collection during follow-up of the three cohorts of patients
75929911|NCT04270682|Drug|Blinded CDCA 250 mg TID|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
75929912|NCT04270682|Drug|Placebo|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
75929913|NCT04270682|Drug|Open-Label CDCA 250 mg TID|Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
75929914|NCT04270682|Drug|Rescue Medication CDCA 250 mg TID|CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
75929915|NCT04270682|Drug|CDCA Weight-Based Dose TID|Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
75929916|NCT04269850|Biological|allogeneic fecal microbiota|Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.
75929917|NCT04269850|Drug|Ruxolitinib|Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
75793663|NCT05805605|Drug|Mycophenolate Mofetil|"All patients begin day +5 through day +35.~3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (maximum of 1 gram per dose) every 8 hours."
75793664|NCT05805072|Drug|Selinexor|Selinexor 60 mg/day, orally on d1,4,8,11
75929918|NCT04269850|Drug|Methylprednisone|Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
75929919|NCT04269590|Behavioral|Dual Task (DT) training|Participants will practice the Swipe Slide Pattern (SSP) task in combination with a secondary task, i.e. counting red or green lights. On day 1, participants perform 2 runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, 9 trials of 30s are performed, alternated with rest periods of 14s. Instructions are provided before each trial (i.e. view of the pattern in combination with instruction to count red or green lights, 4s), as well as an answer option (i.e. participants have to indicate how many red or green lights they counted by circling a number from zero to nine, 6s). For the following 4 days, participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. During at home practice, the same pattern as during scans is included, in combination with 2 new patterns.
75336006|NCT03836014|Combination Product|Daratumumab/Lenalidomide/Dexamethasone for 24 months|"Conditioning regimen: 16 mg/kg IV :~Weekly (Cycles 1 and C2)~Every two weeks (C3 to C6)~Monthly from C7 up to 24 months in total (Arm 1)~Infusion reaction prophylaxis :~Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle up to 24 months in total (Arm 1)~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle up to 24 months in total (Arm 1)"
75645749|NCT02652975|Biological|Laboratory blood samples|"Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen."
75793665|NCT05805072|Drug|Homoharringtonine|Homoharringtonine 1 mg/day intravenously on days 3 to 9
75793666|NCT05805072|Drug|Cytarabine|cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9
75793667|NCT05805072|Drug|Aclacinomycin|aclacinomycin 10 mg/day intravenously on days 3 to 6
75929920|NCT04269590|Behavioral|Single Task (ST) training|Participants will practice the Swipe Slide Pattern (SSP) task without the presence of a secondary task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
75929921|NCT04261855|Drug|Avelumab|All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
75929922|NCT04261855|Radiation|External Beam Radiation Therapy (EBRT)|Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
75645750|NCT00741247|Procedure|EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions. EUS-FNA is a procedure to obtain samples through the esophagus under real-time ultrasound guidance. In this study, EUS-FNA will be applied using a ultrasonic bronchoscope (EUS-B-FNA).
75645751|NCT00741325|Drug|granulocyte colony-stimulating factor (G-CSF)|
75645752|NCT00741325|Drug|plerixafor|
75645753|NCT00741325|Drug|Placebo|
75793668|NCT05805072|Drug|Granulocyte Colony-Stimulating Factor|granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,
75793669|NCT05805072|Drug|Decitabine|Decitabine 20 mg/m2/day intravenously on days 1 to 5.
75793670|NCT05805072|Drug|Azacitidine|Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7
75793671|NCT05801666|Other|Acupuncture|Acupuncture 5 points
75793672|NCT05800821|Procedure|Carotid revascularization|Carotid revascularization
75793673|NCT05800119|Behavioral|Brain-level condition|Participants will receive a brief reading passage about the neurobiological effects of psychotherapy.
75793674|NCT05800119|Other|Mind-level condition|Participants will receive an active control consisting of a brief reading passage about the effectiveness of psychotherapy.
75793675|NCT05799001|Behavioral|Dance therapy|"Patients will be randomized in 2 groups, experimental or control.~The experimental group will have 4 months of dance therapy with a professional dancer and will then resume there usual activities.~The control group will start with their usual activities in the nursing home for the first 4 months and then, they will have dance sessions with a nurse previously trained by the dancer."
75793676|NCT05798416|Drug|Exercise under inhalation CO2|Participants perform shuttle walk test at high altitude while using the novel portable device for inhalation of CO2
75793677|NCT05798416|Other|Exercise under inhalation ambient air|Participants perform shuttle walk test at high altitude while inhaling ambient air
75793678|NCT05797090|Drug|Crystalloid Cardioplegic solution|To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
75336007|NCT03836014|Combination Product|Daratumumab/Lenalidomide/Dexamethasone until progression|"Conditioning regimen: 16 mg/kg IV :~Weekly (Cycles 1 and C2)~Every two weeks (C3 to C6)~Monthly from C7 until disease progression (Arm 2).~Infusion reaction prophylaxis :~Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle until disease progression (Arm 2).~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle until disease progression (Arm 2)."
75645754|NCT00741403|Drug|CPI-613|CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
75793679|NCT05796843|Procedure|360 Degrees virtual reality-based mirror therapy|Participants will receive mirror therapy using a virtual reality device (Pico G2 VR 4K, Pico, China). They will be asked to follow tasks that are played in HMD using their paralyzed hand. The video played using HMD will be video taped using 360 degree camera prior to the treatment. The 360MT will last 30 minutes/session, 3 sessions a week for 4 weeks. The tasks are finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions.
75929923|NCT04261855|Radiation|Lutetium-177 (177Lu)-DOTATATE|Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart
75336008|NCT04403620|Radiation|Intensity-modulated Radiation Therapy (IMRT)|Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection
75472803|NCT01963104|Procedure|Automated hearing test/Motivation video|Subjects will take an automated hearing test that presents tones at different pitches and volumes.Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
75645755|NCT02652741|Drug|Enalapril Orodispersible Minitablet|8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
75645756|NCT05741281|Behavioral|Physical exercises program|- Physical exercise program is an innovative exercise program-consisting of three basic parts (warm up - physical fitness - cool down). It was developed previously by the researcher under the supervision of experienced trainer of physical exercise. The session will begin with a 5- to 10-minutes warm-up consisting of stretching and bending movements. This will be followed by physical fitness phase for 30 to 35 minutes which consist of rapid walking accompanied by a variety of arm and leg movements. The session will be ended by a 5- to 10-minutes cool down phase similar to the warm-up. The total time needed for finishing the physical exercise intervention will be approximately 1 hour.
75645757|NCT02652507|Drug|Dexmedetomidine|2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
75645758|NCT02652507|Drug|Ketamine|Bolus dose 2 mg/kg after first set of research images are obtained
75645759|NCT00738127|Procedure|Open reduction and internal fixation|Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
75645760|NCT02652273|Drug|Abatacept|Abatacept 125mg/ml
75645761|NCT05741203|Diagnostic Test|lung ultrasound|lung ultrasound
75645762|NCT00650325|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fasting
75645763|NCT00650325|Drug|Zoloft® Tablets 100 mg|100mg, single dose fasting
75793680|NCT05796843|Procedure|Traditional mirror therapy|Participants will receive mirror therapy using an acrylic mirror (40cm x 40cm x 3cm) that reflects unparalyzed side of them. They will be asked to perform tasks including finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions. They will be asked to follow the reflection on mirror using their paralyzed limb. The TMT will last 30 minutes/session, 3 sessions a week for 4 weeks.
75929924|NCT04261413|Drug|RS-0139|RS-0139 will be administered for the indication of NSCLC.
75929925|NCT04259398|Drug|Propofol|propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
75929926|NCT04259398|Drug|Sevoflurane|sevoflurane is administered for induction and maintenance of anesthesia
75929927|NCT04256486|Behavioral|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.
75645764|NCT02652351|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
75929928|NCT04256018|Drug|Mogamulizumab|Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
75929929|NCT04256018|Radiation|LD TSEBT|Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
75929930|NCT04251975|Device|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
75929931|NCT04250064|Drug|Bevacizumab Injection|Additional concurrent low-dose Bevacizumab with standard EBRT
75645765|NCT04032873|Other|Monetary Cost of Immobilization Treatments|Information regarding the monetary cost of casting and splinting patient's buckle fracture to be presented to adult subject/payer.
75645766|NCT04032873|Other|Physician|The monetary cost information is relayed by the patient's physician
75645767|NCT04032873|Other|Study Team|The monetary cost information is relayed by a member of the study team
75793681|NCT05796843|Procedure|Conventional Physical Therapy|Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises
75645768|NCT04032873|Other|Before Initial Treatment Decision|Monetary cost information is relayed during the initial consult, before the treatment decision is made.
75793682|NCT05794932|Diagnostic Test|Stress test|"Diagnostic Test:~Maximum effort test (CPET) on a cycloergometer~Leg muscle strength assessment~Leg muscle mass, composition and water compartments (segmental bioelectrical impedance)~Spirometry, arterial blood gaz, NO/CO transfer"
75793683|NCT05792891|Other|Collecting biological material from frail patients, with or without COVID-19|The study planned to collect demographic information, disease history, COVID-19 symptomatology, COVID-19 molecular test details, COVID-19 serological test results, and biobanking of biological specimens (PBMCs, sera, plasma). In addition, clinical analyses, anamnestic data, and pharmacological treatment pieces of information were collected.
75929932|NCT04250064|Radiation|Ultra-low-dose RT|Ultra-low-dose EBRT instead of standard dose RT
75929933|NCT04248803|Other|GLUMA (Kulzer GmbH, Germany) desensitizing agent|GLUMA desensitizer is used to reduce tooth sensitivity
75336009|NCT04398160|Other|HVLA C3/C4 manipulation|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical. This procedure will increase the tension of the soft tissues to reduce the remaining slack and, finally, the thrust will be applied in pure rotation. Subsequently the head of the volunteer will be repositioned in the neutral position without applying any pressure and will wait 10 seconds in this position. Finally, the previous procedure will be repeated to the opposite side.
75645769|NCT04032873|Other|After Initial Treatment Decision|Monetary cost information is relayed after the initial consult with the treating physician, after the treatment decision is made.
75929934|NCT04245514|Drug|Durvalumab|Immunotherapy
75336010|NCT04398160|Other|Sham technique|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical until the perception of tissue tension at the point of contact, holding this position for 10 seconds. The investigator then repositions the head of the volunteer in the neutral position without applying pressure, holding again this position for 10 seconds. Finally, the previous procedure will be repeated for the opposite side.
75929935|NCT04245514|Radiation|Radiotherapy|Immune-modulatory radiotherapy to the primary tumor, with either Cohort A: 20 x 2 Gy weekdaily Cohort B: 5 x 5 Gy weekdaily Cohort C: 3 x 8 Gy q2d
75336011|NCT04394650|Biological|CC-98633|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633.~During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection."
75645770|NCT00923611|Drug|Fimasartan|
75645771|NCT00650403|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fed
75645772|NCT00650403|Drug|Paxil® 40 mg Tablet|40mg, single dose fed
75645773|NCT00733837|Other|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
75645774|NCT02648373|Behavioral|Patient Education|An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.
75645775|NCT02648373|Other|Control|Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
75645776|NCT02568319|Drug|LIPO-202|
75645777|NCT02568319|Drug|Placebo|
75645778|NCT02648451|Dietary Supplement|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
75793684|NCT05787444|Diagnostic Test|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 & Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative and differential detection of nucleocapsid viral antigens from SARS-CoV-2, influenza A, and influenza B in an anterior nares sample (from both nostrils) collected by a healthcare professional for individuals aged 2 years and older. The test is authorized for individuals with symptoms of COVID-19, influenza A and B within the first 6 days of symptom onset.
75793685|NCT05786703|Diagnostic Test|Biochemical, weight measurements, Blood pressure and blood sugar level|At first visit short interview using the STEPwise approach of the STEPS surveillance tool for NCDs from the WHO will be conducted. On subsequent visits, hypertension and blood sugar level and cholesterol levels will be measured and adherence to medication will be assessed. The patient's registry will be developed following recommendation from the HEARTS technical package of World Health Organization (WHO) with some modification if needed.
75793686|NCT05784701|Drug|TSCV (Full-strength)|TSCV (Full-strength)
75793687|NCT05784701|Drug|TSCV (Half-strength)|TSCV (Half-strength)
75793688|NCT05784701|Drug|Typbar-TCV|Typbar-TCV
75793689|NCT05784701|Drug|Placebo|Placebo
75929936|NCT04233398|Device|Device: Echopulse (HIFU ablation)|High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
76084938|NCT02501460|Dietary Supplement|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
75929937|NCT04220463|Other|Hypnosis + NIV|For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.
75929938|NCT04220463|Other|NIV|In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
76084939|NCT02501460|Other|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
76084940|NCT01790633|Other|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
75336012|NCT01205503|Drug|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
75645779|NCT02648607|Device|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthosis (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
75645780|NCT00920803|Drug|Placebo|Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
75645781|NCT00920803|Drug|SRT501|SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
75929939|NCT04211129|Other|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
75336013|NCT01205503|Drug|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
75336014|NCT01205503|Drug|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
75336015|NCT01205503|Drug|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
75336016|NCT01158157|Biological|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
75793690|NCT05783245|Other|Polarcare Machine|Use of Polar Care ice machine as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
75336017|NCT03187834|Drug|Azithromycin|Children in this arm will receive Azithromycin once a day.
75336018|NCT03187834|Drug|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
75336019|NCT03187834|Drug|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
75336020|NCT03187834|Drug|Placebo|Children in this arm will receive Placebo once a day.
75336021|NCT01206595|Drug|SKY0402|Single dose of SKY0402 administered as a nerve block
75336022|NCT01206595|Drug|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
75336023|NCT04385992|Drug|177Lu-Dotatate|Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE
76084941|NCT01790633|Other|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
75336024|NCT01158703|Drug|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
75336025|NCT01158703|Drug|sugar pill|sugar pill by mouth daily for 12 months
75336026|NCT01158703|Drug|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
75336027|NCT03010969|Procedure|Acute abdominal surgery|Acute abdominal surgery within 72 hours of admission to the department of surgery
75645782|NCT02648529|Procedure|MRI|"Patients are investigated with the following sequences:~High-resolution 3D T1-weighted anatomical MRI.~DTI with 48 directions (to examine white matter)"
75793691|NCT05783245|Other|Standard of care ice therapy|Use of commercial reusable ice packs as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
75793692|NCT05782283|Device|ACE (AI-Cirrhosis-ECG) 2.0|An electrocardiogram (ECG) based artificial intelligence (AI) powered tool for detection of undiagnosed cirrhosis in primary care practices. And email alert is sent to providers which will display whether the ACE 2.0 result is positive or negative for the likelihood of advanced liver disease.
75793693|NCT05780619|Diagnostic Test|Transcranial Doppler|Measurement of resistance index on the middle cerebral artery (MCA) (index test) and the Holter (reference test). Patients will be randomized for order of tests
76084942|NCT01788215|Drug|doxycycline|200mg/day in divided doses of 100mg twice daily
76084943|NCT01788215|Other|Sugar Pill|1 pill twice a day
76084944|NCT02503956|Device|Perforated Punctal plugs|Perforated punctal plugs
76084945|NCT02503956|Procedure|Crawford tube insertion|
76084946|NCT02503956|Device|Crawford lacrimal tube|
76084947|NCT01787825|Device|PillCam SB2 capsule|Capsule Endoscopy system
76084948|NCT01787825|Device|CapsoCam SV-1|Capsule endoscopy
75793694|NCT05778877|Drug|SEL-302|"SEL-302 Drug: MMA-101 (1.0E13 vg/kg)~Drug: SEL-110 (0.15 mg/kg or up to 0.3 mg/kg)~Other Names:~SEL-110.36, ImmTOR"
75793695|NCT05776511|Procedure|eVOG|video digital oculography
75645783|NCT02648529|Procedure|functional MRI (fMRI)|"fMRI investigations will be focused on :~language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~Social cognition: investigations on social cognition skills~Memory :~Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups."
75929940|NCT04211129|Other|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
75645784|NCT02648529|Behavioral|neuropsychological assessment|Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
75929941|NCT04206553|Drug|dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
75929942|NCT04206553|Drug|Matching Placebo|Matching dupilumab without active substance
75645785|NCT04063423|Procedure|blood sample|Blood sample at start and at the end of the dialysis session; membrane scoring after dialysis; total cell volume measurement of dialyzer after dialysis; micro-CT of dialyzer after dialysis.
75336028|NCT01159015|Drug|KetoNaph|Ophthalmic Solution administered BID for 6 weeks
75645786|NCT05742061|Drug|Corticosteroid|The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
75793696|NCT05776199|Diagnostic Test|Sonoelastography, tensiomyography and mechanosensitivity|To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.
75793697|NCT05774470|Device|Owlet OSS 3.0|The Owlet OSS 3.0 is a non-invasive monitoring device. The Sock secures the Sensor to the baby's foot. The Sensor measures the baby's SpO2, heart rate, and movement, and transmits the baby's readings to the Base Station. The Base Station records and monitors the baby's readings and can indicate prompts as needed based on the data sent from the Sensor.
75336029|NCT01159015|Drug|Vehicle|Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
75645787|NCT05742061|Other|Platelet Rich Plasma|PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.
75645788|NCT04316169|Drug|Abemaciclib|150 mg b.i.d
75793698|NCT05773079|Drug|Toripalimab|Within 4 to 12 weeks after the first line of treatment, the maintenance treatment of Toripalimab was started, and 240 mg of Toripalimab was injected intravenously every 3 weeks (the maintenance treatment time was not more than 1 year, until there was an intolerable toxic reaction, or disease progression, or withdrawal of consent, or the investigator judged that it was necessary to withdraw from the treatment, or the subject had received treprizumab treatment for a cumulative period of 1 year or other reasons specified in the protocol). During the treatment period, tumor imaging evaluation shall be conducted every 3 months to see the research process description for details, and the evaluation shall be conducted according to the evaluation criteria of recist. If the evaluation is progress, the treatment shall be stopped.
75793699|NCT05772364|Other|Loading of low-calcium water first, then high-calcium water|All cohort subjects are asked to consume water with less than 5 mg/L of calcium first, then are asked to consume water with at least 400 mg/L of calcium
75929943|NCT04206553|Drug|Oral corticosteroids (OCS)|Prednisone or prednisolone per standard of care to obtain control of disease activity.
75929944|NCT04202926|Device|real coil|active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
75929945|NCT04202926|Device|sham coil|sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
75929946|NCT04197102|Drug|CBD Isolate|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD isolate oil will be taken once daily for 8 weeks for participants randomized to the CBD Isolate arm.
75336030|NCT03009643|Drug|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
75336031|NCT03009643|Device|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
75645789|NCT04316169|Drug|Hydroxychloroquine 200 mg|Dose level: 200 mg b.i.d.
75645790|NCT04316169|Drug|Faslodex|Cohort B will receive Faslodex.
75645791|NCT04316169|Drug|Anastrazole|Cohort A will receive anastrazole or letrozole.
75645792|NCT04316169|Drug|Letrozole|Cohort A will receive anastrazole or letrozole.
75645793|NCT04316169|Drug|Hydroxychloroquine 400 mg|Dose level: 400 mg. b.i.d.
75645794|NCT04316169|Drug|Hydroxychloroquine 600 mg|Dose level: 600 mg b.i.d.
75929947|NCT04197102|Other|CBD Broad Spectrum|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD Broad Spectrum oil will be taken once daily for 8 weeks for participants randomized to the CBD - Broad Spectrum arm.
75929948|NCT04197102|Other|Placebo oil|Placebo solution will be taken once daily for 8 weeks by participants randomized to the placebo arm.
75929949|NCT04188964|Drug|Burosumab|Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
75336032|NCT03009643|Device|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
75929950|NCT04187820|Other|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
75336033|NCT01207765|Drug|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
75336034|NCT01207765|Drug|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
75336035|NCT03157258|Behavioral|Social Network Training|Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
75793700|NCT05770180|Biological|Recombinant COVID-19 variant vaccine (Sf9 cell)|WSK-V102
75645795|NCT02536287|Procedure|total PTX without autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,but without autotransplantation.
75645796|NCT02536287|Procedure|total PTX with autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,and then a portion of the smallest, preferably nonnodular parathyroid gland was chosen for autotransplantation,sliced into pieces measuring 1*1 *1 mm,and placed into the subcutaneous of the forearm.
75645797|NCT02648295|Procedure|Effects of IV TXA on TEG in patients undergoing THA or TKA|Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.
75645798|NCT05538949|Drug|EB-203|"Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5~Day8."
76084949|NCT03344484|Other|Surgical approach|Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
75793701|NCT05770180|Biological|Recombinant COVID-19 vaccine (CHO cell)|control 1
75793702|NCT05770180|Biological|Recombinant COVID-19 vaccine (Sf9 cell)|control 2
75793703|NCT05765682|Other|Mepivacaine Spinal|spinal block using 60mg of mepivacaine
76084950|NCT01813019|Drug|AFQ056|mGluR5 antagonist
76084951|NCT01813019|Drug|Placebo|Matched placebo
75336036|NCT03157258|Behavioral|Single Care-Related Counseling Session and Referral to Care|Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
75645799|NCT05538949|Drug|Placebo|Placebo 1Drop, QD / Day1, BID / Day5~Day8.
75645800|NCT02648139|Drug|Dentifrice|3x/day for 7 days.
75793704|NCT05765682|Other|Bupivacaine Spinal|spinal block using 10mg of bupivacaine
75793705|NCT05765604|Biological|Recombinant COVID-19 variant vaccine(Sf9 cell)|IM
75793706|NCT05765604|Biological|Recombinant COVID-19 vaccine(CHO cell)|IM
75793707|NCT05762575|Other|knotting methods|The volunteers in experimental group study new knotting technology.
75645801|NCT00651339|Drug|botox|botox injection
75645802|NCT05740969|Drug|5Fluorouracil|Cream
75793708|NCT05760820|Behavioral|SES Children (SES Mini & SES Nxt)|"SES Children (SES Mini & SES Nxt) is a digital intervention aiming to develop children's self-efficacy and ability to overcome the challenges that come with a divorce and major life crises, thereby reducing the negative impacts of these on children's overall mental health and wellbeing. The intervention formatted to specific age groups between the ages of 3 and 17, and is relevant to all children whose parents have split up, regardless of whether they experience a higher or lower degree of conflict between the parents, a or higher or lower degree of strain from the judicial divorce.~The intervention covers a variety of topics, including when my parents fight, a bonus family, packing the overnight bag, to live in two places, and children's rights."
75793709|NCT05757076|Procedure|Blood test for ARR|Blood test for calculating aldosterone and renin ratio (ARR)
75793710|NCT05753592|Drug|Part 1; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
75929951|NCT04184999|Drug|dexamethasone intraocular suspension, 9%|single dose intracameral corticosteroid
75929952|NCT04184999|Drug|Prednisolone Acetate 1% Oph Susp|topical ophthalmic steroid drop
76084952|NCT02509572|Behavioral|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
76084953|NCT02503878|Device|Masimo Sedline brain function monitors|"Masimo Sedline brain function monitors are sensors (stickers) placed on a the forehead to monitor levels of sedation based on a bilateral 4-channel electroencephalogram (EEG). The purpose of this study is to observe the effectiveness of the Sedline monitor to detect the unilateral hemispheric EEG changes seen in Wada testing"
76084954|NCT01787591|Other|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
76084955|NCT01787591|Other|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
75645803|NCT05740969|Drug|Imiquimod|Cream
75645804|NCT05740969|Drug|Melatonin|Cream
75645805|NCT02647983|Drug|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
75645806|NCT00651417|Dietary Supplement|Organic Germanium|Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
75645807|NCT00651417|Dietary Supplement|Placebo|Placebo tablets orally 3 - 5 times per day as tolerated
75793711|NCT05753592|Drug|Part 2; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
75793712|NCT05752136|Biological|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
75929953|NCT04173416|Behavioral|Youth Opioid Recovery Support (YORS)|The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
75929954|NCT04168528|Drug|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
75929955|NCT04168372|Other|High fructose, fructose labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose
75929956|NCT04168372|Other|High fructose, pyruvate labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate
76084956|NCT01787591|Other|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
76084957|NCT01787591|Other|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
76084958|NCT02504034|Procedure|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
75336037|NCT03786796|Drug|Olaparib|Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
75336038|NCT03089866|Drug|Midazolam (0.02mg/kg)|Quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
75645808|NCT02568241|Other|Interferon Alfa-2b|High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
75645809|NCT05551897|Drug|Camizestrant|Subjects will be administered a single oral dose of Camizestrant on Day 1 of treatment period 1 and treatment period 3.
75645810|NCT05551897|Drug|Itraconazole|Subjects will be administered Itraconazole twice a day on Day 1 and once daily on Day 2 and Day 3 of treatment period 2, and once daily on Day 1, 2 and 3 of treatment period 3.
75645811|NCT02647671|Drug|Aquamin®|90 days of Aquamin
75645812|NCT02647671|Drug|Calcium Carbonate|90 days of Calcium Carbonate
75645813|NCT02647671|Drug|Placebo|90 days of placebo
75645814|NCT05740891|Drug|BCMA CAR-T cells injection|Autologous hematopoietic stem cell transplantation combined with BCMA CAR-T cells
75645815|NCT00651495|Behavioral|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
75645816|NCT04578613|Drug|ICP-022|ICP-022 at a dose of 150mg, QD
75793713|NCT05742828|Behavioral|Virtual Seating Coach|Power wheelchair intervention
75793714|NCT05740384|Device|Sonotubometry Assessment|"The exact order of the measurements will be randomised:~Recording type 1: No sound applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~Recording type 2: White noise applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~Ask for subjective feedback (did you hear a change in the sound in your ear on swallowing?) after each recording~This is repeated using the contralateral ear and nostril. After successful recording, the microphone will be removed.~For comparison, tubomanometry measurements will be performed on each ear. Tubomanometry is an alternative method to assess the middle ear and Eustachian tube. Afterwards, the participant's involvement in the study will be complete. The entire involvement will take about 50 minutes."
75793715|NCT05738005|Other|Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)|Amyloidosis patients will use MyFitnessPal application to track dietary intake and use of herbal/alternative supplements in from week 2-9. Patient's usage of the application and questionnaires completed by the patient at the start, Week 2 and Week 10 will determine feasibility.
75929957|NCT04168372|Other|Low fructose, fructose labeled meal|Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose
76084959|NCT02504034|Device|6-French sheath|
76084960|NCT02504034|Device|22-gauge chiba needle|
76084961|NCT02504034|Device|260-cm-long stiff shaft wire|
76084962|NCT02504034|Device|Balloon catheter|
76084963|NCT02504034|Device|Bare metal stent|
76084964|NCT02504034|Device|Covered stent|
76084965|NCT02503644|Drug|IVA337|Capsules of 200mg IVA337
76084966|NCT02503644|Drug|Placebo|Identical capsules without active substance
75645817|NCT04578613|Drug|Chlorambucil|0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
75645818|NCT04578613|Drug|Rituximab|375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
75645819|NCT02647515|Drug|ranibizumab|
75645820|NCT04064047|Procedure|Trans rectal ultrasound guided prostate biopsy|The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
75336039|NCT00002890|Biological|lintuzumab|
75929958|NCT04168372|Other|Low fructose, pyruvate labeled meal|Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
75929959|NCT04167163|Drug|Abaloparatide|18 month ABL treatment
75336040|NCT03081910|Genetic|Autologous CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10^7 cells/m2~Dose level two: 5×10^7 cells/m2~Dose level three: 1×10^8 cells/m2"
75645821|NCT04064047|Procedure|Trans rectal ultrasound|Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
75645822|NCT04064047|Procedure|Prostate biopsy|Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
75645823|NCT04064047|Procedure|Periprostatic nerve block|Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
75929960|NCT04167020|Device|High definition surface electromyography (HD-sEMG)|HD-sEMG data will be collected by Mobita 32® (TMSi) device
75929961|NCT04147884|Device|Millipede Transcatheter Annuloplasty Ring System (Millipede System)|The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
75929962|NCT04145401|Device|Revision Knee implants|Primary knee arthroplasty or a revision knee that requires a revision procedure.
75929963|NCT04137692|Other|Red Blood Cell Transfusion|The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
75929964|NCT04132505|Drug|Binimetinib|Given PO
75929965|NCT04132505|Drug|Hydroxychloroquine|Given PO
75929966|NCT04131829|Drug|Fluoxetine - immediate treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
75929967|NCT04131829|Drug|Fluoxetine - delayed treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
75929968|NCT04124952|Device|Panoptix|Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
76084967|NCT01812707|Drug|Alirocumab|Two SC injections in the abdomen only
76084968|NCT01812707|Drug|Placebo (for alirocumab)|"Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen"
75336041|NCT03081910|Genetic|Allogeneic CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10^7 cells/m2~Dose level two: 5×10^7 cells/m2~Dose level three: 1×10^8 cells/m2"
75336042|NCT00002896|Drug|chemotherapy|
75336043|NCT00002896|Drug|fluorouracil|
75336044|NCT00002896|Drug|leucovorin calcium|
75336045|NCT00002896|Procedure|conventional surgery|
75336046|NCT00002896|Radiation|low-LET cobalt-60 gamma ray therapy|
75336047|NCT00002896|Radiation|low-LET photon therapy|
75645824|NCT03818763|Biological|Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII|"Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU).~The infusion volume of transduced cells will not exceed 20 ml/kg body weight."
75645825|NCT02536053|Procedure|Limb salvage|
75645826|NCT02647125|Drug|Huachansu|Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
75645827|NCT02647125|Radiation|thoracic radiation|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
75645828|NCT02647047|Procedure|Spinal analgesia|Administration of morphine 0.2 mg in subarachnoid space.
75645829|NCT02647047|Procedure|Epidural analgesia|Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space
75645830|NCT02647047|Procedure|Transversus Abdominis Plane block|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
75645831|NCT02647047|Procedure|Surgical wound infiltration|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
75645832|NCT02647047|Drug|Acetaminophen|Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
75929969|NCT04117555|Diagnostic Test|Pupil response to light stimuli|Objective and accurate measurement of pupillary responses to light stimuli
75929970|NCT04114227|Behavioral|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
75929971|NCT04114227|Behavioral|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
76084969|NCT01812707|Drug|Atorvastatin|"Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening"
76084970|NCT02509182|Drug|60% oxygen|An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
76084971|NCT02509182|Drug|100% oxygen|An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
76084972|NCT04497090|Device|fixed-EPAP|In the fixed-EPAP mode, the device kept EPAP fixed at the prescribed value
76084973|NCT04497090|Device|auto-EPAP|In the Auto-EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
76084974|NCT01787279|Drug|Peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
76084975|NCT02728206|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
75929972|NCT04111549|Other|Home-based telehealth GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI via in-home video telehealth.
75929973|NCT04111549|Other|In-person GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI in person.
75929974|NCT04107285|Behavioral|neurocognitive evaluations|The test battery consists of validated and reliable measures of attention, executive functions and memory.
75929975|NCT04107285|Diagnostic Test|brain MRIs|Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).
75929976|NCT04107285|Other|Blood samples|Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
75645833|NCT02647047|Drug|Ketorolac|Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
75793716|NCT05737797|Procedure|cervical cytology during surgery.|Cervical cytology will be performed by the surgeon in the operating theatre before hysterectomy.
75793717|NCT05733728|Other|any therapy suitable|any therapy suitable
75793718|NCT05731908|Drug|BI 690517|BI 690517
75793719|NCT05731440|Drug|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.
75793720|NCT05724498|Behavioral|Brief CBT-I|4 session CBT-I
75793721|NCT05724498|Behavioral|Standard CBT-I|Standard VA 6 session CBT-I
75929977|NCT04101968|Diagnostic Test|PET scan|3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
75929978|NCT04101968|Diagnostic Test|neuroQWERTY|Analysis of free-text typing in a computer and/or a touch-screen device.
75929979|NCT04091243|Drug|Romosozumab|Experimental drug for the treatment of glucocorticoid induced osteoporosis
75929980|NCT04089930|Diagnostic Test|Immunogenicity|anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)
75929981|NCT04088864|Drug|Fludarabine|Fludarabine is a purine antagonist antimetabolite
75929982|NCT04088864|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative alkylating agent
75929983|NCT04088864|Drug|Autologous CD22 CAR T|Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)
75929984|NCT04084301|Procedure|High CPB flow|Target CPB flow 2.9 L/min/m2 throughout the CPB period
75929985|NCT04081896|Other|Exercise|"Exercise prescribed to participants includes spine-specific strengthening exercises targeting core musculature (i.e. Multifidus, Erector Spinae, Transversus Abdominus, Obliques, and Rectus Abdominus). The in-clinic exercise program recommends a minimum of 20 visits at 2 visits/week, with a goal of 24 total visits over a 12-week period. Exercise is progressed by 5-10% of their exercise load once they are able to do >20 repetitions. If they are able to reach >10 but <20 repetitions, exercise load remains the same. If they are unable to reach 10 repetitions, exercise load is decreased 5-10% at their next visit.~The online exercise program includes non-machine based home exercises targeting the same muscles of interest, and are personalized to each participant based on their home resources and comfort level.~Concurrent interventions may or may not include nutrition education, mindfulness, cognitive behavioral therapy."
75929986|NCT04080180|Behavioral|Contingency Management|Contingency management (CM) is a behavioral method that employs external rewards for target behavior. For this study, participants will receive gift cards for adhering to Medication-Assisted Treatment (attending physician visits and adhering to buprenorphine-naloxone as determined by urine toxicology panel) during their first four visits while randomized to this condition. Participants will draw a gift card from a fishbowl each visit they are adherent. Gift cards range from $25-$100.
75929987|NCT04080180|Behavioral|Brief Motivational Interviewing + Substance Free Activities + Mindfulness|Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM) is an intervention that uses Motivational Interviewing and Behavioral Economics strategies to increase the salience of delayed rewards by eliciting personal goals, developing opioid-free activities, and engaging in reward bundling and episodic future thinking. Participants will be offered a menu of substance free activities that has been developed in pilot work. Activities will be discussed, and participants will be asked to engage in selected activities as homework. Engagement in substance free activities will be assessed at each subsequent visit. Mindfulness components will also be included in the intervention.
75336048|NCT03778060|Device|Cala TWO stimulator|Treatment intervention will consist of subjects undergoing 40 minute sessions of transcutaneous stimulation with the Cala TWO stimulator twice daily for 3 months to reduce hand tremors prior to their undergoing deep brain stimulation 'surgery for treatment of essential tremor at Mayo Clinic.
75336049|NCT01249027|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
75645834|NCT02647047|Drug|Ropivacaine|Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL
75645835|NCT02647047|Drug|Sufentanil|Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
75645836|NCT02647047|Drug|Ropivacaine|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
75645837|NCT02647047|Drug|Ropivacaine|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
75793722|NCT05718596|Other|sweeps laser to use irrigation activation|The SWEEPS fiber tip (25 µs ultra-short dual pulse mode-Auto SWEEPS mode) was inserted into the Er:YAG laser source (2,940 nm, 20 mJ per pulse, 15 Hz, 0.3 W power, and 50 µs pulse frequency). 3% NaOCl solution was activated in three periods of 20 s. Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
76084976|NCT04576793|Drug|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
76084977|NCT04576793|Drug|18F-MK6240|MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
76084978|NCT04576793|Drug|18F-Florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
75336050|NCT03046342|Diagnostic Test|Molecular method (PCR)|"Stool samples are being processed through molecular method (PCR) for children with GE.~Epidemiology of acute Gastroenteritis in the pediatric population in Qatar"
75793723|NCT05718596|Other|PUI to use irrigation activation|The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 2 mm behind the working length without touching the canal walls.
75336051|NCT00002902|Drug|irinotecan hydrochloride|
75336052|NCT00002902|Drug|raltitrexed|
75336053|NCT02992756|Drug|Growth Factors|one dose 3-6 mL of PRP obtained by PRGF Endoret
75336054|NCT01250899|Dietary Supplement|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
75336055|NCT03716830|Device|verum acupuncture|Participants will receive real acupuncture treatment.
75336056|NCT03716830|Device|sham acupuncture|Participants will receive sham acupuncture treatment.
75793724|NCT05712434|Other|Long Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 2 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 6-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
75793725|NCT05712434|Other|Mid-length Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 4 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 4-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
75793726|NCT05712434|Other|Short Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 6 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 2-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
75793727|NCT05712421|Drug|North Star|North Star
75929988|NCT04077281|Other|Medication Coordinated care|"Clinical Pharmacology & Toxicology consult~CPT team completes detailed circle of care communication~Telemedicine followup by CPT team (approximately 48 hrs post-discharge & 1 week to1 month post-discharge)"
75929989|NCT04058990|Device|Device: Paclitaxel-Coated PTCA Balloon Catheter|Percutaneous Transluminal Coronary Angioplasty
75929990|NCT04058990|Device|SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel|Percutaneous Transluminal Coronary Angioplasty
76084979|NCT04576793|Procedure|Lumbar Puncture|Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
75336057|NCT03716830|Device|real tDCS|Participants will receive real transcranial direct current stimulation.
75793728|NCT05712421|Drug|Levothyroxine|Levothyroxine
75929991|NCT04028466|Drug|Vonoprazan|Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
75929992|NCT04028466|Drug|Omeprazole|Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
76084980|NCT02500992|Procedure|Transrectal sigmoidectomy|
75336058|NCT03716830|Device|sham tDCS|Participants will receive sham transcranial direct current stimulation.
75336059|NCT01212445|Drug|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
75336060|NCT00002908|Drug|bryostatin 1|
75336061|NCT00002908|Drug|vincristine sulfate|
75336062|NCT00002920|Drug|medroxyprogesterone|
75336063|NCT00002920|Drug|tamoxifen citrate|
75336064|NCT00002920|Procedure|adjuvant therapy|
75336065|NCT01250977|Drug|Donepezil|
75336066|NCT01250977|Drug|Placebo|
76084981|NCT01811225|Drug|Low-dose Progesterone|"The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM)."
76084982|NCT01811225|Drug|High-dose Progesterone|"The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM)."
76084983|NCT02503566|Device|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
76084984|NCT01809197|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
75793729|NCT05712226|Device|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 35 minutes.
75336067|NCT01251757|Other|Interactive Voice Recognition (IVR) phone calls|"The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population."
75336068|NCT01251757|Other|Educational mailings and follow-up for nonadherence|Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
75645838|NCT05741983|Procedure|Microfracture (MFx)|The ankle arthroscopy will be a standard procedure. The lesion will be identified, measured and prepared with curettage and soft tissue shaver. Preparation includes debridement of the unstable cartilage and in case of a chondral defect associated with a bone defect, the subchondral cyst is debrided. After debridement, the defect is classified and the lesion size is measured again.The microfracture will be performed with a microfracture awl. In cases of a chondral defect associated with a bone defect (osteochondral defect) the bone lesion must be treated concomitantly. Portal closure will be with steri-strips. All patients will follow the standard postoperative rehabilitation protocol including post op non-weight bearing and range of motion exercises for 6 weeks.
75336069|NCT01252147|Other|No treatment|No treatment (intervention) will be provided in this study
75336070|NCT01161121|Drug|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
75336071|NCT01161121|Drug|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
75336072|NCT03010579|Drug|erythropoietin|Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
75336073|NCT03010579|Drug|iron supplementation|If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
75336074|NCT01214083|Drug|N-acetylcysteine + high-dose naltrexone (150 mg)|All subjects will be evaluated weekly for 12 weeks.
75645839|NCT05741983|Device|Chondro-Gide®|After the microfracture is performed and before the concomitant treatment of a bony lesion (if present), the defect size will be templated, and the membrane cut into its correct size. The joint is then drained and the membrane will be applied over the defect and stabilised with Fibrin glue. In cases of a osteochondral defect the bone lesion must be treated concomitantly. Once the bone defect has been treated, the Chondro-Gide® membrane is used to cover the site, and to support new cartilage tissue formation at the joint interface. Fluid will be reintroduced, and the stability of the membrane will be confirmed arthroscopically.
75645840|NCT02646813|Procedure|Intraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed intraluminally
75645841|NCT02646813|Procedure|Extraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed extraluminally
75645842|NCT00651651|Drug|budesonide/formoterol|
75645843|NCT00651651|Drug|budesonide|
75645844|NCT00651651|Drug|formoterol|
75645845|NCT00709111|Drug|Maraviroc|The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
75645846|NCT00651729|Biological|Botulinum Toxin Type A|Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg
75929993|NCT04007796|Behavioral|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
76084985|NCT01809197|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
75336075|NCT01214083|Drug|High-dose naltrexone (150 mg) alone|All subjects will be evaluated weekly for 12 weeks.
75336076|NCT01214083|Drug|Low-dose naltrexone (50 mg) alone|All subjects will be evaluated weekly for 12 weeks.
75336077|NCT03010813|Procedure|Robotic single port surgery and NOTES|Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
75645847|NCT02646735|Drug|Fulvestrant 500 mg|Fulvestrant 500mg will be given monthly.
75645848|NCT02646735|Drug|Exemestane 25 mg|Exemestane 25mg will be given once daily.
75645849|NCT02646579|Procedure|Spinal and Peripheral Dry Needling|Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
75645850|NCT02646579|Procedure|Peripheral Dry Needling|Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
75645851|NCT02646501|Drug|Antiarrhythmic drug|Antiarrhythmic drug
75645852|NCT02646501|Procedure|percutaneous stellate ganglion block (PSGB)|percutaneous stellate ganglion block (PSGB)
75929994|NCT04007796|Behavioral|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
75929995|NCT04007666|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms.
75336078|NCT03010735|Dietary Supplement|probiotics|Daily take 4.0E+10 CFU of probiotics
75336079|NCT03010735|Dietary Supplement|Placebo|
75336080|NCT01254877|Drug|ondansetron|ondansetron 0.2 mg bid, oral preparation, 16 weeks
75336081|NCT01254877|Drug|placebo ondansetron|Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
75336082|NCT01254877|Drug|Ondansetron|Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
76084986|NCT01809197|Device|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
76084987|NCT01809197|Device|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
76084988|NCT02508870|Drug|Atezolizumab|Participants will receive atezolizumab as per the schedule described in individual cohort.
75336083|NCT02189317|Drug|Exparel|For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
75336084|NCT03713944|Drug|Carboplatin|Carboplatin, AUC 5
75336085|NCT03713944|Drug|Pemetrexed|Pemetrexed 500mg/m2
75336086|NCT03713944|Drug|Atezolizumab|Atezolizumab 1200mg
75336087|NCT03713944|Drug|Bevacizumab|Bevacizumab 15mg/kg
75929996|NCT04007666|Behavioral|Control Group|Coping-focused treatment drawn from material already offered in selected facilities.
75645853|NCT04063891|Device|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
75645854|NCT04063891|Device|Low-magnitude high-frequency vibration (LMHFV)|Placebo group will have sham treatment by standing on the LMHFV platform for 20 minutes/day
75645855|NCT02646657|Drug|Vedolizumab 300 mg|Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
75645856|NCT00652041|Drug|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4
75645857|NCT00652041|Drug|Thalidomide|Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is <Grade 2, dose should be increased to 200 mg/24 h. in day 15
76084989|NCT02508870|Drug|Azacitidine|Participants will receive azacitidine as per the schedule described in individual cohort.
76084990|NCT02508792|Device|LASER|Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
76084991|NCT02508792|Device|LASER PLACEBO|The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
76084992|NCT01786109|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
76084993|NCT01786109|Drug|Placebo|Placebo will match study drug; taken as one dose orally with water.
76084994|NCT02509104|Drug|FDC capsule of dutasteride and tamsulosin|Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
75336088|NCT01256983|Behavioral|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
75336089|NCT01256983|Behavioral|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
75336090|NCT02986048|Other|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
75336091|NCT01214161|Drug|2% lidocaine gel|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
75645858|NCT00652041|Drug|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
75645859|NCT02646111|Drug|12 weeks without Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.
75645860|NCT02646111|Drug|12 weeks with Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
75645861|NCT02646111|Drug|24 weeks with Ribavirin|24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
75645862|NCT00652119|Drug|Paclitaxel|Cycle 1 = 60 mg/m^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m^2 IP weekly over 1 hour x 3 weeks of each cycle.
75929997|NCT04007393|Behavioral|Lifestyle Modification Therapy (LSMT)|LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
75929998|NCT04007393|Drug|Phentermine Pill|Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
76084995|NCT02509104|Drug|Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet|Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
76084996|NCT02500914|Drug|SC-002|SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
76084997|NCT02503488|Behavioral|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
76084998|NCT02503488|Behavioral|Treatment as Usual|See arm description
75645863|NCT00652119|Drug|Carboplatin|Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
75645864|NCT00652119|Drug|Avastin|Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
75645865|NCT05740657|Drug|Fentanyl|Drug application during hospital stay
75645866|NCT02646345|Procedure|Surgical checklist|Use of the World Health Organization Surgical checklist
75645867|NCT05741749|Device|Socket Seal Abutment|Customized Healing Abutment
75645868|NCT04166955|Behavioral|Promoting Physical Activity through mobile application|Students will be randomly assigned to either the intervention or the control group. WhatsApp groups will be formed within each study group. The control participants will have the WhatsApp group only for communications. And they will keep their usual activity for 10 weeks. The intervention participants will have the intervention WhatsApp group which will be for communication and providing the intervention materials. The intervention group will receive a brief (15-minute) orientation on exercise, and benefits of keeping a healthy life pattern. They will receive 3-4 health-promotional (Physical activity) messages per week via WhatsApp for 10 weeks; group interaction is optional without adding more messages aiming to promote physical activities from any participants.
76084999|NCT02500680|Biological|MER4101|
75645869|NCT05740579|Procedure|laparoscopic cryopreservation of one ovary|Laparoscopic removal of one ovary as child. In adulthood cortical tissue is replaced in the abdomen in order to improve fertility and pregnancy rates in Turner syndrome women.
75645870|NCT02646267|Drug|standard intensity warfarin|target international normalised ratio(INR) was 2.1-3.0
75645871|NCT02646267|Drug|low intensity warfarin|target international normalised ratio(INR) was 1.7-2.2
75645872|NCT02646267|Drug|dabigatran etexilate|110mg, twice a day, oral
75645873|NCT00710749|Device|Disposable device|Disposable urine flow meter
76085000|NCT02500680|Biological|Inactivated Influenza Vaccine|Fluzone quadrivalent Influenza Vaccine
76085001|NCT04496778|Device|low level laser therapy ( laser acupuncture combined with nasal laser irradiation)|"Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity"
75929999|NCT04007393|Drug|Topiramate Pill|Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
76085002|NCT04496778|Other|aerobic exercise|3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve
75930000|NCT03999203|Drug|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
75645874|NCT00710749|Device|Digital device|Digital urine flowmeter
75645875|NCT00710749|Device|Clinic flow measurement|Clinic gold standard flow measurement
75645876|NCT02646189|Drug|REP 2139-Ca|REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
75645877|NCT02646189|Drug|Zadaxin|Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
75645878|NCT02646189|Drug|Pegasys|Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
75645879|NCT03900247|Device|REMAP EEG based BCI and SEM-Glove BioServo|EEG-based brain computer interface (BCI) will be adapted to individual ALS patients and modified to control external robotic devices
75645880|NCT02645877|Procedure|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
75930001|NCT03999203|Device|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
75930002|NCT03999203|Other|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
75793730|NCT05707117|Other|Tendon neuroplastic training (TNT)|Subjects will attend physical therapy for three non-consecutive days per week for a total 4 consecutive weeks. Exercise would involve isolated flexion, extension with a dumbbell. This exercise would be paced with external audio/visual cue on smart phone using proMetronome app. Patients will listen to the sound and track the movement of metronome with the eyes. Pace of metronome will be set at 20 beats per minute such that each beat will be 3 sec apart. This will allow a 3sec concentric and 3 sec eccentric phases.4 sets of 8 repetitions would be completed with a 2-minute rest between each set. Exercise will begin with 3 pounds weight, but it would be made sure that this wouldn't cause pain during exercise (more than 5/10), gradual progression in weight to 5 pounds after 2nd weeks.
75930003|NCT03999203|Other|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
75930004|NCT03996265|Drug|Bupropion Hydrochloride Controlled-release|Given PO
75930005|NCT03996265|Other|Placebo Administration|Given PO
75336092|NCT01214161|Other|placebo|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
75645881|NCT05741671|Other|Questionnaire|Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.
75645882|NCT02645799|Drug|LABR-312|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
75645883|NCT02645799|Drug|Saline (placebo)|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
75645884|NCT04063735|Dietary Supplement|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia supplement for 3 months
75645885|NCT04063735|Dietary Supplement|Placebo|Placebo was given to participants.
75645886|NCT04063813|Behavioral|Experimental: 40 minute up trial|
75645887|NCT04063813|Behavioral|Experimental: 40 minute down trial|
75645888|NCT04063813|Behavioral|Experimental: Two 20 minute up trials|
75645889|NCT04063813|Behavioral|Experimental: Two 20 min down trials|
75930006|NCT03996265|Other|Quality-of-Life Assessment|Ancillary studies
75930007|NCT03996265|Other|Questionnaire Administration|Ancillary studies
76085003|NCT02500446|Drug|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
76085004|NCT02500446|Other|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
75645890|NCT04063813|Behavioral|Active Comparator: Sedentary trial|
75645891|NCT02645721|Behavioral|Extended self-help program with guidance|See arm description for Experimental
75645892|NCT02645721|Behavioral|Briefer Self-help program, no guidance|See arm description for Active Comparator
75645893|NCT02645721|Behavioral|WL: Extended self-help program, choice of guidance intensity|See arm description for Waiting list.
75645894|NCT03897985|Device|Narcotrend TM|Measurement of anesthesia depth
75645895|NCT02645565|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
75336093|NCT02984410|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection
75645896|NCT02645565|Drug|Azathioprine|azathioprine will be given at 2 mg/kg.
75645897|NCT02645565|Drug|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
75645898|NCT02645643|Other|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
75645899|NCT00652275|Biological|MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP|189 children will receive 3 doses of experimental vaccine
75793731|NCT05707117|Other|group B Conventional treatment|Subjects assigned to this group will undergo static stretching of Extensor carpi radialis brevis and myofascial release for 4 weeks, 3 sessions a week. Myofascial release technique will be applied for 5 minutes and 2 reptations per session
75930008|NCT03994887|Device|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
75930009|NCT03994471|Drug|XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght|XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
75930010|NCT03994471|Drug|1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution|Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.
75930011|NCT03989466|Biological|Alemtuzumab|Given IV
75930012|NCT03989466|Drug|Itacitinib|Given PO
76085005|NCT02500524|Drug|Cocamide diethanolamine|Topical lotion
76085006|NCT02500524|Drug|Permethrin|Topical creme rinse
76085007|NCT02508714|Device|Orsiro|stents will be implanted in case of significant coronary artery disease
75793732|NCT05705323|Behavioral|Internet-delivered cognitive behavioral therapy (iCBT)|This CBT is specifically adapted for individuals experiencing tinnitus
75793733|NCT05705323|Behavioral|Internet-delivered mindfulness-based tinnitus stress reduction (iMBTSR)|This is a mindfulness-based intervention specifically adapted for individuals experiencing tinnitus
75930013|NCT03988400|Behavioral|Sensory Augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
75930014|NCT03988400|Behavioral|Random Vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
75930015|NCT03987425|Device|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
76085008|NCT02508714|Device|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
75336094|NCT02984410|Procedure|Trans Oral Surgery (TOS)|TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection
76085009|NCT02508558|Other|motion perception and locomotor operation performance measurements|
76085010|NCT02508558|Other|parabolic flight|
75336095|NCT01257217|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
75645900|NCT00652275|Biological|Verorab vaccine|189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
75645901|NCT03628287|Other|Revised Care Coordination Program|Greater focusing, tailoring and cues for delivery of key components of Care Coordination
75645902|NCT03628287|Other|Original Care Coordination Program|Original Care Coordination
75645903|NCT00699907|Drug|flutamide|Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.
75793734|NCT05704673|Drug|nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study.|investigate the effect of Iv nalbuphine on postoperative nausea and vomiting and pain with intrathecal morphine on inguinal hernia repair surgery.
75793735|NCT05702671|Diagnostic Test|Total Immunoglobulin E, Obtained From Fingerstick Sample|The Kenota 1 System is intended to be a specialized tool in a professional allergist setting. It will help streamline the patient testing process by bringing quantitative, minimally invasive fingerstick IgE blood testing to the allergy clinic.
75793736|NCT05699265|Diagnostic Test|Measures of arterial stiffness and endothelial function|baseline cMRI, vascular reactivity studies, and CPET
75793737|NCT05699265|Diagnostic Test|Ambulatory blood pressure monitoring|A manual blood pressure with a mercury sphygmomanometer will be performed in order to have an accurate baseline measurement. The SphygmoCor SCOR-PVx System (Atcor Medical, Syndey, Australia), previously validated in the young, will be used for the assessment of PWV (pulse wave velocity) and the Heart Rate Variability (HRV).
75793738|NCT05699265|Diagnostic Test|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing will be performed, and the patients will have a baseline oxygen uptake at rest to determine the rates for testing. A 12 lead ECG, heart rate, a 12 lead rhythm strip, and a 6 lead rhythm strip will be recorded. Oxygen consumption and carbon dioxide production will be measured. Blood pressure will be measured. Perceived exertion will be obtained during each workload using the Borg Scale. The results for submaximal effort testing will be derived from completed maximal testing. The outcome measures will be obtained once the subject reaches anaerobic threshold.
76085011|NCT02503098|Behavioral|Recovery Record adaptive smartphone application|
76085012|NCT02503098|Behavioral|Recovery Record standard smartphone application|
75336096|NCT01257217|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
75645904|NCT00652353|Other|44-55-66-PM|"The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.~44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar"
75645905|NCT00652353|Other|control|Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
75645906|NCT00652509|Behavioral|Interactive Dialogue to Educate and Activate (IDEA)|IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
75645907|NCT00652509|Behavioral|Individual Education (IE)|IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
75645908|NCT02645097|Procedure|Saphenous Nerve Block|A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
75645909|NCT02645175|Dietary Supplement|TW1025|20ml, 3 times per day (daily dose: 60 ml)
75645910|NCT02645175|Dietary Supplement|Placebo|20ml, 3 times per day (daily dose: 60 ml)
75645911|NCT03182361|Device|Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants|Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone
75930016|NCT03984214|Drug|Dronabinol in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets) per day; dose increased by 2.5 mg (3 x 1 droplet) every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 30 mg ≙ 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 5 mg (3 x 2 droplets) Safety follow-up: 4 weeks after end of treatment
75930017|NCT03984214|Drug|Placebo in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 3 x 1 droplet up to 3 x 12 droplets per day; dose increased by 3 x 1 droplet every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 3 x 2 droplets Safety follow-up: 4 weeks after end of treatment
75930018|NCT03982381|Drug|Metformin|Active comparator
75930019|NCT03982381|Drug|Dapagliflozin 10 MG|Experimental treatment
75793739|NCT05699265|Diagnostic Test|Serum and urine biomarkers|Clinical labs drawn will include plasma and urine globotriaosylsphingosine (lyso-Gb3), globotriaosylceramide (GL3), blood urea nitrogen, creatinine, cystatin C, urinalysis, urine protein, urine microalbumin and urine creatinine. Labs specific for this study will include N-acetyl-β-glucosaminidase, urine neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1). All data will be obtained at three different time intervals: enrollment, 1 year and 2 years.
75930020|NCT03979365|Drug|Envarsus XR|Twice daily tacrolimus vs. Envarsus XR
75930021|NCT03979365|Drug|Tacrolimus twice daily|Twice daily tacrolimus vs. Envarsus XR
75930022|NCT03971630|Other|Telemedicine|Patients will be followed up using the MyVENT System and APP
75930023|NCT03971448|Device|LPWB|The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.
76085013|NCT04498962|Drug|Danzhu Fuyuan Granule|Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
75645912|NCT00710593|Biological|HPV vaccine for strains -6, -11, -16, and -18|All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
75645913|NCT00599313|Drug|Sunitinib|50 mg/day orally each of Days 1-28 of each 6 week cycle
75645914|NCT00708175|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
75645915|NCT00708175|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
75645916|NCT02641665|Procedure|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
75645917|NCT02641509|Device|NBI during polypectomy|NBI to perform the polipectomy
75793740|NCT05698667|Diagnostic Test|Transoral ultrasound|Under local anesthetic with xylocaine spray in the oropharynx, the tonsils and tongue base are scanned with small-footprint, high-frequency ultrasound transducers (such as the 18XL5s hockey-stick from BK Medical)
75793741|NCT05698667|Diagnostic Test|Transcervical ultrasound|The tongue base and tonsils are scanned externally via the neck, where a (preferably low-frequency) transducer is placed onto the skin above the hyoid bone to visualize the tongue base. The tonsils are visualized adjacent to the tongue base on either side and are located deep to the submandibular glands in a oblique coronal plane.
75793742|NCT05697835|Behavioral|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
75930024|NCT03971448|Device|AKWC|If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
75930025|NCT03969823|Drug|Tagrisso|Osimertinib 80mg once daily until disease progression
75930026|NCT03958838|Behavioral|Peer Support Integrated with Primary Care|Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
75336097|NCT01257217|Device|Acri.LISA® 366D IOL|Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
75645918|NCT02641509|Device|no NBI during polypectomy|no NBI to perform the polypectomy
75930027|NCT03948373|Device|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
75645919|NCT05740345|Drug|Metformin|Metformin
75645920|NCT02641431|Procedure|mapping/ablation|Mapping/ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar catheter will be positioned at the right ventricle apex. High-density endocardial and epicardial electroanatomical maps will be performed using the CARTO3 system to define areas of delayed fragmented prolonged potentials during stable sinus rhythm and during spontaneous or ajmaline-induced type 1 BrS ECG pattern. Ajmaline (1mg/Kg in 5 minutes) will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms as characterized by prolonged fragmented ventricular signals
75336098|NCT01257217|Device|Acri.LISA® 466TD Toric IOL|Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
75336099|NCT00383656|Drug|GnRH|75 ng/kg GnRH IV
75793743|NCT05697835|Other|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
75930028|NCT03943238|Biological|Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs|Living donor kidney transplant recipients will receive after a preparatory regimen of total lymphoid irradiation, total body irradiation and anti-thymocyte globulin an infusion of purified donor CD34+ of >10 x10^6 cells /Kg, 100 x 10^6 donor T cell/ Kg and and an escalated dose of recipient Tregs starting at 25 x10^6/Kg.
75336100|NCT00383656|Device|Pump|portable, infusion pump for GnRH
75645921|NCT02641431|Drug|Ajmaline|Epicardial mapping will be performed before and after ajmaline (1mg/Kg in 5 minutes).
75930029|NCT03939689|Drug|I-131-1095|I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) at 75 mCi or 100 mCi each, administered at least 8 weeks apart as determined by dosimetry evaluation and occurrence of dose-limiting events.
75930030|NCT03939689|Drug|Enzalutamide|Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
75930031|NCT03917940|Dietary Supplement|Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral|Omega 3 fatty acids 1000 mg per day oral
75336101|NCT01214317|Procedure|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
75336102|NCT00383734|Device|Newfill|1 to 7 injections of drug
75336103|NCT00383734|Device|Eutrophill|1 to 7 injections of drug
75336104|NCT00383812|Drug|Intravitreal Bevacizumab|
75645922|NCT02641431|Procedure|ablation|Radiofrequency will be delivered on areas of the abnormal electrograms using an externally irrigated 3.5-mm tip ablation catheter.
75793744|NCT05697835|Other|Care as usual|Care as usual, with written resources provided
75793745|NCT05690763|Other|XP-endo Finisher to use irrigation activation|XPF : The canals were flushed with 2.5 mL 2.5% NaOCl for 30 s and activated by a XPF instrument that was placed in the canal to 1 mm short of the WL and powered by the motor at 800 rpm (1 N-cm torque) for 30 s according to the manufacturer's instructions. Then the canals were rinsed with 2.5 mL of 2.5% NaOCl, followed by activation of the substance with the XPF instrument for 30 seconds, the same way as above. A new XP-endo Finisher file was used for each canal.
75793746|NCT05690763|Other|EndoActivator to use irrigation activation|The root canals were irrigated with 2.5 mL of 2.5% NaOCl for 30 s, followed by sonic activation of this solution with EndoActivator red tip size #25/0.04, inserted into the root canal 1 mm short of the WL, at 10,000 cpm/min. for 30 seconds. The EA polymer tip moved vertically from apical to coronal part of the canal during activation.
75793747|NCT05690633|Device|Pulse oximetry|Noninvasive method of measuring the saturation of oxygen in the blood.
75930032|NCT03917940|Drug|Glimepiride|glimepiride 2 mg or 3 mg per day oral
75336105|NCT02912104|Biological|human amniotic epithelial cells (hAECs) transplantation|hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.
75336106|NCT02189629|Drug|CD5789 (trifarotene)|
75336107|NCT04330066|Diagnostic Test|Abdominal ultrasound measurement of the endometrial lining|On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
75336108|NCT00002926|Drug|cytarabine|
75336109|NCT00002926|Drug|etoposide|
75645923|NCT02641431|Procedure|mapping|A re-map focusing on the targeted area will be obtained after ablation. Re-mapping and ajmaline reinfusion will be used to confirm the elimination of all the abnormal electrogram and BrS-ECG pattern disappearance.
75645924|NCT05741437|Drug|CKD-378, QD, PO Drug: D745, D150, QD, PO|Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
75336110|NCT00002926|Drug|idarubicin|
75336111|NCT00002926|Procedure|allogeneic bone marrow transplantation|
75336112|NCT00002926|Procedure|peripheral blood stem cell transplantation|
75336113|NCT01281007|Drug|Famciclovir|Famciclovir 125 mg every 12 hours for 5 days
75336114|NCT01281007|Drug|Aciclovir|Aciclovir 200 mg every 4 hours fo 5 days
75336115|NCT02898610|Drug|Colchicine|
75336116|NCT01281475|Drug|Levodopa|"Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
75336117|NCT01281475|Drug|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
75336118|NCT03009721|Drug|Other: Not applicable-observational study|
75336119|NCT01587092|Behavioral|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
75336120|NCT01587092|Behavioral|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
75336121|NCT00002932|Drug|cisplatin|
75336122|NCT00002932|Radiation|radiation therapy|
75336123|NCT01572662|Drug|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
75645925|NCT02641275|Other|Structured self-management-training|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions
75645926|NCT04063345|Procedure|IVUS-guided PCI|Performing intravascular ultrasound before or/and after percutaneous intervention
75645927|NCT04063345|Procedure|Angiography-guided PCI|Performing percutaneous intervention without intravascular ultrasound guidance
75930033|NCT03911531|Diagnostic Test|Whole Exome Sequencing|Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
76085014|NCT02508402|Drug|Dexamethasone|"The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using"
75793748|NCT05689944|Behavioral|Dance-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~5 mn of welcome and presentation of the upcoming session~5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~15 mn of body warm-up with taught contemporary dance exercises~15 mn of creative research based on dance improvisation on a given theme~15 mn of sharing for the elaboration of a choreography~At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session if he/she wishes (e.g. think of a choreography, remember what was done etc. ....) in order to encourage the commitment to care. These sessions will be based on contemporary dance and dance improvisation techniques."
76085015|NCT02508402|Drug|Placebo|two milliliters of normal saline given to placebo group .
76085016|NCT02500134|Other|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
76085017|NCT02500212|Drug|ENVARSUS®|
76085018|NCT02500212|Drug|ADVAGRAF®|
76085019|NCT01615120|Drug|GTx-758 125 mg|One 125 mg tablet once a day
75336124|NCT01572662|Drug|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
75336125|NCT01572662|Procedure|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
75645928|NCT02641197|Device|AngioDefender|"Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.~Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators."
75645929|NCT00733525|Behavioral|Cognitive Behavioral Therapy|Therapy focusing on skills needed to alter eating patterns
75645930|NCT00733525|Drug|Fluoxetine|20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
75645931|NCT00733525|Behavioral|Guided Self-Help|Manual designed to impart teachings of cognitive behavioral therapy
75645932|NCT00910923|Drug|JNJ-38431055|
75930034|NCT03911531|Diagnostic Test|Whole Genome Sequencing|Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
75930035|NCT03906669|Drug|Letrozole|PO daily for 14 days
75336126|NCT01572662|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
75930036|NCT03906669|Drug|Letrozole and Prometrium|PO daily for 14 days
75930037|NCT03906669|Drug|Tamoxifen and Prometrium|PO daily for 14 days
75930038|NCT03906149|Combination Product|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
75930039|NCT03906149|Combination Product|Standard medical care|Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
76085020|NCT01615120|Drug|GTx-758 250 mg|two 125 mg tablets once daily
76085021|NCT04496934|Behavioral|Exercise|Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
76085022|NCT02508168|Drug|Alogliptin|Alogliptin 12.5 mg tablets
75336127|NCT01572662|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
75336128|NCT01572662|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
75336129|NCT02884102|Genetic|genetic sequencing|
76085023|NCT02508168|Drug|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
76085024|NCT02508168|Drug|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
76085025|NCT01616056|Biological|graft versus host disease prophylaxis/therapy|Wear bandage lenses
76085026|NCT01616056|Other|questionnaire administration|Ancillary studies
76085027|NCT01616056|Procedure|optical coherence tomography|Optional ancillary studies
76085028|NCT02503176|Drug|KCT-0809 ophthalmic solution|
76085029|NCT02508246|Drug|Cisplatin|Given IV
76085030|NCT02508246|Drug|Docetaxel|Given IV
76085031|NCT02508246|Other|Laboratory Biomarker Analysis|Correlative studies
76085032|NCT02508246|Other|Pharmacological Study|Correlative studies
76085033|NCT02508246|Procedure|Therapeutic Conventional Surgery|Undergo surgery
76085034|NCT02508246|Drug|WEE1 Inhibitor AZD1775|Given PO
75793749|NCT05689944|Behavioral|Art-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~5 mn of welcome and presentation of the upcoming session~5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~10 mn of discovery of a new technique (acrylic painting or collage).~35 mn of practice in a project fixed beforehand~At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session (e.g. collecting plants for collage....) in order to encourage commitment to the treatment. The sessions will be based on acrylic painting or collage techniques."
75930040|NCT03889912|Drug|Cemiplimab|Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 5-12 weeks prior to scheduled surgery
75336130|NCT04781582|Procedure|Lung volume reduction surgery|Surgical lung volume reduction
75336131|NCT04781582|Procedure|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction by endobronchial valves
75336132|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
75336133|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
75336134|NCT01258153|Drug|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
75472804|NCT01963104|Procedure|Pure-tone Screener/Motivation video|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
75645933|NCT05740267|Procedure|Natural Orifice Specimen Extraction|After bowel resection, all bowel anastomoses are created via side-to-side intracorporeal anastomosis, either isoperistaltic or antiperistaltic. The surgical steps of NOSE with the transrectal method are illustrated in Figure 1. First, the rectosigmoid colonic lumen is blocked with a bowel clamp. After rectal irrigation with povidone-iodine water, a transanal endoscopic microsurgery (TEM) scope or Alexis wound protector is inserted through the anus, reaching the upper rectum. Enterotomy is performed at the upper rectum, and a suction device is used to clean any fecal spillage. The TEM scope is pushed forward beyond the rectal opening, and the specimen is extracted with the TEM scope. The rectal opening is closed with a barbed suture, and an air leak test is performed to identify anastomotic leakage.
75645934|NCT02568085|Device|Arista|Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
75645935|NCT02641041|Biological|BIIB033|single or multiple dose
75336135|NCT01555268|Biological|trebananib|Given IV
75645936|NCT02641041|Other|Placebo|single or multiple dose
75930041|NCT03885167|Other|Specimen Collection|No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
75930042|NCT03882060|Drug|erythropoietin|Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery.
75930043|NCT03882060|Drug|Normal saline|Control group, no intervention.
75930044|NCT03873636|Other|Stimulation via noninvasive brain stimulation systems|Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, & Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
75930045|NCT03839784|Combination Product|Neurocognition Interventions|EEG, Neurocognitive Battery Testing, and Immune Profiles
75930046|NCT03836079|Device|preCARDIA system|Intermittent occlusion of the SVC
75930047|NCT03834961|Drug|Larotrectinib Sulfate|Given PO or via NG or G tube
75930048|NCT03831295|Biological|Anti-OX40 Antibody BMS 986178|Given IT or IV
75930049|NCT03831295|Drug|TLR9 Agonist SD-101|Given IT
75336136|NCT01555268|Drug|cytarabine|Given SC
75645937|NCT02567149|Drug|Cidofovir|Cidofovir
75336137|NCT01555268|Other|laboratory biomarker analysis|Correlative studies
75336138|NCT01555268|Other|pharmacological study|Correlative studies
75336139|NCT00002938|Procedure|conventional surgery|Salvage prostatectomy
75336140|NCT04781270|Drug|mFOLFOXIRI regimen|oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
75336141|NCT04781270|Drug|mFOLFOX regimen|oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
75336142|NCT04781270|Drug|Bevacizumab|5 mg/kg on day 1
75336143|NCT02745028|Dietary Supplement|Monosodium glutamate|A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
75336144|NCT00003394|Drug|carboplatin|
75336145|NCT00003394|Drug|endocrine-modulating drug therapy|
75336146|NCT00003394|Drug|estramustine phosphate sodium|
75645938|NCT00707239|Drug|tigecycline|An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
75645939|NCT00707239|Drug|tigecycline|An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
75645940|NCT00707239|Drug|imipenem/cilastatin|Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
75336147|NCT00003394|Drug|goserelin acetate|
75336148|NCT00003394|Drug|leuprolide acetate|
75645941|NCT00968708|Drug|Alogliptin|Alogliptin tablets
75793750|NCT05689944|Behavioral|Yoga|"This session will take place once a week between weeks 1 and 15 of the protocol.~5 mn welcome~5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~50 mn of Vinyasa type yoga (warm-up, breathing, balance, strength and flexibility, relaxation)~5 mn of closing of the session~At the end of the session, 5mn of self-evaluation of the pain thanks, the thymia, the fatigue and the level of appreciation of the session (VNS).~These sessions engage the body without entering into a therapy protocol turned towards art as in the two previous interventions."
75793751|NCT05688865|Other|urinary markers|urinary marker testing
76085035|NCT01617148|Drug|Aflibercept|Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
76085036|NCT01618240|Other|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
75930050|NCT03830190|Other|Parkinson's disease nurse specialist care|Specialized nursing care provided by a Parkinson's disease nurse specialist
75930051|NCT03818191|Drug|Acamprosate|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
75930052|NCT03818191|Other|Placebo|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
75930053|NCT03814967|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
75930054|NCT03810131|Other|'A Bite of ACT' (BOA)|An online Acceptance and Commitment Therapy transdiagnostic psychoeducational intervention called 'A Bite of ACT' (BOA)
75336149|NCT00003394|Drug|paclitaxel|
75472805|NCT01963104|Procedure|Digits-in-noise test/Motivational video|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
75645942|NCT00968708|Drug|Placebo|Alogliptin placebo matching tablets
76085037|NCT01618240|Other|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
75793755|NCT05683041|Device|Hyalobarrier|Hyalobarrier is a viscous, transparent gel and is used as a preventive measure for post-operative adhesions in the abdominal and uterine cavity.
75793756|NCT05681689|Combination Product|PyloPlus UBT System|Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
75793757|NCT05681689|Diagnostic Test|Histology|Biopsy specimen fixed with 10% buffered formalin cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist.
75793758|NCT05681689|Diagnostic Test|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
75793759|NCT05681689|Combination Product|Comparator Breath Test|Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
75793760|NCT05681689|Diagnostic Test|Stool Antigen Test|An antigen test performed via a laboratory to test patient's stool for H. pylori
75793761|NCT05681520|Behavioral|PEEPS|Working with a peer specialist for six 30-minute sessions to enhance engagement in pain management approaches/treatments
75930055|NCT03800134|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
75930056|NCT03800134|Other|Placebo|Placebo IV (intravenous infusion)
75930057|NCT03800134|Drug|Carboplatin/Paclitaxel|Carboplatin/Paclitaxel, as per standard of care
75930058|NCT03800134|Drug|Cisplatin/Gemcitabine|Cisplatin/Gemcitabine, as per standard of care
75930059|NCT03800134|Drug|Pemetrexed/Cisplatin|Pemetrexed/Cisplatin, as per standard of care
75336150|NCT00003400|Biological|filgrastim|
75336151|NCT00003400|Drug|carmustine|
75336152|NCT00003400|Drug|cisplatin|
75336153|NCT00003400|Drug|melphalan|
75336154|NCT00003400|Drug|vinorelbine tartrate|
75336155|NCT00003400|Procedure|peripheral blood stem cell transplantation|
75336156|NCT04348370|Biological|BCG Vaccine|BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.
75336157|NCT04348370|Biological|Placebo Vaccine|Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.
75336158|NCT00002944|Drug|carboplatin|Given IV
75336159|NCT00002944|Drug|lomustine|Given IV
75336160|NCT00002944|Drug|procarbazine hydrochloride|Given PO
75336161|NCT00002944|Drug|thioguanine|Given PO
75336162|NCT00002944|Drug|vincristine sulfate|Given PO and IV
75336163|NCT04778306|Procedure|Transoral Laser Surgery|Remove of the laryngeal tumour via diode laser
75930060|NCT03800134|Drug|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin, as per standard of care
76085038|NCT03344406|Other|Telephonic interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with asthma.
75930061|NCT03792763|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
75930062|NCT03792763|Drug|Placebo 1.7 ml Subcutaneous Solution|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
75645943|NCT00920881|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.
75336164|NCT04778072|Dietary Supplement|Ferrous sulfate 14mg once daily|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
75336165|NCT04778072|Dietary Supplement|Ferrous sulfate 25mg once daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
75336166|NCT04778072|Dietary Supplement|Ferrous sulfate 25mg twice daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily
75336167|NCT04778462|Device|extracorporeal shock wave and conventional treament|"Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band will be applied as low energy 2 sessions per week for 2 weeks The will be used as a radial type of shock wave therapy.~Strengthening, stretching exercises and ischemic compression:~Isometric neck extensor exercise:~Isometric neck flexor exercise:~Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
75645944|NCT05735821|Other|Giving breastfeeding training|The control group will not be interfered with. Breastfeeding training will be given to the video and simulator group and the 3 groups will be compared.
75645945|NCT05417269|Drug|IMCY-0141|"The investigational medicinal product (IMP) consists in a small synthetic peptide (23 amino acids - IMCY-0141) combining a known human epitope of MOG flanked with a thioredox motif, presented in the form of a freeze-dried sterile powder and diluent for subcutaneous (SC) administration. The diluent includes the adjuvant aluminium hydroxide (alum) at a concentration of 900 μg/mL. Treatment will be injected within 4h of resuspension of the powder with the diluent.~Treatment will consist of 6 immunizations (separated by 14 days) of the IMP by SC injection in the upper arm, in the region of the triceps (lateral part of the arm, midway between the elbow and the shoulder). Half of the dose to be administered will be injected concomitantly in both arms."
75645946|NCT05417269|Drug|Placebo|"The placebo will be administered by subcutaneous route, once every two weeks for 6 times. Placebo will be administered to patients randomized in the placebo group during Phase II only."
75645947|NCT05417269|Drug|Dimethyl Fumarate|"Dimethyl Fumarate (DMF) will be given orally, according to its SmPC for the whole duration of the study.~Dimethyl Fumarate (DMF) will be administered to patients randomized in the active control group during Phase II only."
75645948|NCT05733793|Other|NGS tests|"This study is an observational, the patients with have an available NGS report performed in context of clinical practice or collected in clinical trials.~Patients enrolled in the current study will be managed as for clinical practice and no additional genetic tests or other procedure will be required."
75645949|NCT00921037|Procedure|Erbium-YAG laser vaporization|spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz
75645950|NCT02567071|Other|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
75645951|NCT02567071|Other|clean swab|After planned C-section birth, newborns will suck on clean swab.
75793762|NCT05678400|Behavioral|Hypopressive abdominal techniques|Both training protocols were carried out in a single intervention for each of the participants assigned to either the HAT or the PNF stretching group. The intervention began with the measurement of hip flexion using the EPR test, and ended with a post-intervention measurement of hip flexion to observe the effects of the treatment. All measurements, as well as the interventions for each of the patients in the two groups, were carried out by the same registered physiotherapist. In order to standardise an order of examination of the lower limbs in the EPR test, the right lower limb was assessed first, followed by the left lower limb. Likewise, the same order was standardised for stretching in the PNF group.
75793763|NCT05678400|Behavioral|Stretching of proprioceptive neuromuscular facilitation|Stretching of proprioceptive neuromuscular facilitation
75793764|NCT05678205|Drug|AB-201|NK Cell Therapy
75793765|NCT05678205|Drug|Cyclophosphamide|Lymphodepleting chemotherapy
75793766|NCT05678205|Drug|Fludarabine|Lymphodepleting chemotherapy
75793767|NCT05675527|Biological|Low-dose PRP|Injection
75793768|NCT05675527|Biological|High-dose PRP|Injection
75793769|NCT05675527|Other|Saline|Injection
75793770|NCT05671562|Dietary Supplement|Lycopene|Capsule containing lycopene 7mg x 2 daily for 12 weeks
75793771|NCT05671562|Dietary Supplement|Placebo|Capsule containing inactive substance 7mg x 2 daily for 12 weeks
75793772|NCT05670756|Other|Survey|Parents/guardians will complete a survey about when the medication allergy was identified and the exact symptomatology that resulted in determination of the allergy.
75930063|NCT03792347|Drug|Pembrolizumab|Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
75930064|NCT03791788|Diagnostic Test|QFR assessment|QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
75936453|NCT02431208|Drug|Lenalidomide|Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
75930065|NCT03775330|Radiation|Stereotactic Radiosurgery (SRS)|"SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy > 2 cm and ≤ 3 cm: 15-18 Gy > 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions > 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions > 15 Gy) when patient is randomized to SRS + WBRT arm"
75930066|NCT03775330|Radiation|Whole brain radiation (WBRT)|WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
75930067|NCT03771651|Drug|Aspirin 81 mg|Subjects will take aspirin daily for 14 days leading up to surgery to determine whether it impacts inflammation of fallopian tubes.
75336168|NCT04778462|Device|high pain threshold ultrasound and conventional treatment for myofascial pain syndrome trigger points|"will be applied in continuous mode, with the probe placed directly on the TrP and held motionless. To elicit threshold pain, the US probe will be kept static on the TrP. Intensity gradually will be increased to the level of maximum pain the patient could bear. It will be kept at that level for 3 to 4 seconds, then will be reduced to the half-intensity level for another 15 seconds. This procedure was repeated 3 times.the intensity of US will be dependent on the patient's level of pain. intensity will be applied in the range of 0.5 to 2.0 Watt per/cm2. Patients continually report their pain level and its localization and nature High-power pain threshold US will be applied 4 times, with a 3-day interval 2 sessions per week for 2 weeks .~1)Isometric neck extensor exercise2)Isometric neck flexor exercise3)Isometric neck side bending muscle exercise,Stretching exercise:Passive stretching for the neck extensor muscles ,stretching of the neck side-bending muscles,Ischemic compression"
75336169|NCT04778462|Other|conventional treatment for myofascial pain trigger point|"Strengthening, stretching exercises and ischemic compression:~Isometric neck extensor exercise:~Isometric neck flexor exercise:~Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
75930068|NCT03770182|Device|NEUROLITH|transcranial pulse stimulation (TPS)
75930069|NCT03768986|Behavioral|Standard referral for HIV testing|Participants receive standard referral for HIV testing in the community.
76085039|NCT03344406|Other|E-RS: COPD|E-RS questionnaire will directly measure respiratory symptom severity.
75793773|NCT05664763|Drug|[18F]FPEB with PET|radioactive tracer [18F]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging
75793774|NCT05664763|Behavioral|Cannabis abstinence|Motivational enhancement and contingency management (CM) to promote and maintain cannabis abstinence after the baseline scan.
75793775|NCT05654818|Drug|Vitamin D|100,000 UI
75336170|NCT04778228|Device|mechanical ventilation|"critically ill patients requiring mechanical ventilation (MV) were ventilated using high tidal volumes (Vt) and high airway pressures, until the pivotal ARDS net randomized controlled trial (RCT) demonstrated that a lung-protective MV strategy using a Vt of 4-8 mL/kg predicted body weight (PBW) and moderate levels of positive end-expiratory pressure (PEEP) improved survival (2). Since then, limitation of Vt to 4-8 mL/kg PBW, plateau pressures (Pplat) to a maximum of 30 cm H2O, and application of PEEP 10 -16 cm H2O represent the standard for MV in ARDS patients."
75793776|NCT05654818|Drug|Placebo|The placebo is identical in appearance to the active treatment: a drinkable solution in ampoules that is clear, yellowish in color with a slightly lemony odor and an oily, slightly sweet, lemony taste.
75930070|NCT03768986|Behavioral|Online risk reduction training|Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
76085040|NCT03344406|Other|Supplemental asthma items|Supplemental asthma items will include one question on wheeze and an item on breathlessness with activities to evaluate shortness of breath associated with strenuous activities.
76085041|NCT03344406|Other|Daily diary|Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
75930071|NCT03768986|Behavioral|Reinforcement|Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
75793779|NCT05637047|Procedure|pulsed radiofrequency|ultrasound-guided intramuscular and interfascial pulsed radiofrequency ablation
75793780|NCT05637047|Procedure|Dry needling|ultrasound-guided intramuscular and interfascial dry needling
75930072|NCT03738696|Drug|Exparel|A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
75930073|NCT03738696|Drug|Ropivacaine|A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
75930074|NCT03735992|Behavioral|Mind-body medicine group program|The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
75930075|NCT03735589|Biological|Alpha-type-1 Polarized Dendritic Cells|Given ID
75930076|NCT03735589|Biological|Autologous Natural Killer Cell-like CTLs|Given IP
75930077|NCT03709680|Drug|Palbociclib|Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle
75930078|NCT03709680|Drug|Temozolomide|Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
75930079|NCT03709680|Drug|Irinotecan|Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
76085042|NCT03344406|Other|Sociodemographic questionnaire|Sociodemographic questionnaire will capture subject's demographic characteristics, including age, gender, and the highest level of educational attainment.
76085043|NCT03344406|Other|Clinical questionnaire|Clinical questionnaire will capture subject's clinical characteristics including the number of asthma exacerbations in the past 12 months, absenteeism due to asthma in the past month, and the presence of comorbid conditions.
76085044|NCT02249338|Drug|BIIL 284 BS|
75336171|NCT00002950|Biological|sargramostim|
75930080|NCT03709680|Drug|Topotecan|Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
75793781|NCT05636800|Device|Swift System|"Localized microwave energy applied to the distinct AK lesion. Each subject will receive treatment for a maximum of 2 visits (4-week interval between treatment).~For AK lesions assessed as Thin AK (Olsen Grades 1 and 2): Set at 3W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions). There will be approximately 20 seconds between each repeat dose.~For AK lesions assessed as Thick AK (Olsen Grade 3): Set at 4W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions).~As the AK lesions may be larger than 3mm in diameter, the dose administered to one AK lesion may require overlapping applications with the applicator tip. Ensure there is approximately 20 seconds between each repeat dose administered"
75930081|NCT03709680|Drug|Cyclophosphamide|Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
75930082|NCT03703609|Behavioral|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
75930083|NCT03686306|Drug|Sildenafil|"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
75930084|NCT03686306|Drug|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
75336172|NCT00002950|Drug|topotecan hydrochloride|
75336173|NCT02739022|Behavioral|Early Psychological Support for the Critically Ill (EPSCI)|early psychological support based on positive therapeutic suggestion
75336174|NCT00002956|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
75336175|NCT00777140|Drug|Deferoxamine|"Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group."
75336176|NCT00003406|Drug|carboplatin|
75336177|NCT00003406|Drug|docetaxel|
75336178|NCT00003406|Drug|ifosfamide|
75645952|NCT05732545|Behavioral|enteral nutrition program for patients with abdominal hypertension guided by abdominal pressure|There are 4 aspects of intra-abdominal pressure monitoring, source control and treatment for the etiology of increased abdominal pressure, enteral nutrition program, enteral nutrition tolerance evaluation and treatment
75336179|NCT00003406|Procedure|autologous bone marrow transplantation|
75336180|NCT00003406|Procedure|bone marrow ablation with stem cell support|
75336181|NCT00003406|Procedure|peripheral blood stem cell transplantation|
75336182|NCT04304768|Biological|Fluzone Quadrivalent|0.5 ml prefilled syringe administrated intramuscularly
75472806|NCT01963104|Procedure|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
75645953|NCT04062565|Drug|Treprostinil Injectable Product|Injection
75645954|NCT04062565|Drug|Riociguat Pill|Tablet
75930085|NCT03681652|Drug|Azathioprine|Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
75930086|NCT03681652|Drug|Anti-TNF Drug|Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
76085045|NCT02249338|Drug|Placebo|
76085046|NCT02503020|Dietary Supplement|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
75645955|NCT00967694|Drug|Nitrous oxide|Nitrous oxide sedation by inhalation
75645956|NCT04288388|Behavioral|massage group|In recent years, in the literature, it is known that many non-pharmacological techniques are applied to reduce the pain of birth in addition to local anesthesia. One of these nonpharmacological methods is the application of pressure to LI4 point on hand with ice.
75645957|NCT04288700|Drug|oral propranolol|oral propranolol therapy at a dose of 1 mg/kg/d (Inderal 20 mg/5 mL) in three divided doses. If the child will tolerate the treatment with no side effects, therapy will continue in an outpatient clinic. Blood glucose level will be also measured in a periodic manner during therapy. The dose will be increased gradually to 2 mg/kg/d in three divided doses if there will be no adverse effects from the initial therapy.
75336183|NCT02732080|Device|deferred coronary stenting|Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
75336184|NCT02732080|Device|immediate stenting|Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
75336185|NCT00003412|Biological|recombinant interleukin-12|
75336186|NCT02715622|Procedure|Hernia repair|Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
75793782|NCT05636696|Behavioral|Samen Minder Moe (Dutch intervention name)|'Samen Minder Moe' is a mindfulness-based cognitive behavioral therapy for cancer-related fatigue directed at couples.
75930087|NCT03681262|Device|High frequency spinal cord stimulation|We will use Senza® (Nevro Corp., Palo Alto, CA) trial and implant systems to deliver high frequency spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. High frequency waveform will be delivered with following parameters: frequency of 10,000 hertz, pulse width of 20 microseconds, and amplitude of 0-15 milliamperes.
75793783|NCT05634252|Behavioral|Education|All conditions will receive education on skin cancer and strategies to prevention skin cancer, including sun protection strategies and avoidance of intentional and unintentional tanning.
76085047|NCT02503020|Dietary Supplement|Preterm infants formula B|"Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age."
76085048|NCT01618942|Device|pressure algometer|
76085049|NCT02499978|Drug|Darunavir/Cobicistat|Fixed dose combination medication
75930088|NCT03681262|Device|Burst spinal cord stimulation|We will use BusrtDRTM (Abbott Saint Jude Medical, St. Paul, MN) trial and implant systems to deliver burst spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. The parameters of the stimulation are as below: each burst includes 5 pulses of electrical stimulation at intra-burst frequency of 500 hertz without time for discharge in between pulses. These bursts will be repeated at inter-burst frequency of 40-60 hertz. The amplitude will range between 0 and 15 milliamperes.
76085050|NCT02499978|Drug|Dolutegravir|single tablet medication
76085051|NCT02502942|Behavioral|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
76085052|NCT02502942|Behavioral|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
76085053|NCT01620190|Other|Laboratory Biomarker Analysis|Correlative studies
75336189|NCT04780958|Other|Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.|Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)
75336190|NCT00759434|Procedure|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
75336191|NCT00759434|Procedure|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
75336192|NCT00002968|Biological|edrecolomab|Given IV
75336193|NCT00002968|Other|laboratory biomarker analysis|Correlative studies
76085054|NCT01620190|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
76085055|NCT03121170|Other|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.
76085056|NCT03121170|Other|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
76085057|NCT04496856|Dietary Supplement|Whey protein and Collagen supplementation|Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.
75472807|NCT01963104|Procedure|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
75793784|NCT05634252|Behavioral|Action Plan|Participants will be guided through a worksheet for creating a personalized action plan for creating individualized sun protection and tanning plans for situations in which they receive UVR exposure. For the tanning worksheet, participants who report any tanning identify the locations at or activities during which they tan, select a tanning behavior to plan for, and then are guided through the steps of making a specific plan for an alternate activity that meets their goals while minimizing tanning and using sun protection.
75336194|NCT04780412|Drug|Misoprostol|Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.
75472808|NCT01963104|Procedure|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss.~Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care."
75645958|NCT04288700|Drug|Oral Captopril|A test dose of 0.1 mg kg) will be administered orally with pulse rate and blood pressure monitored at 0.5, 1 and 2 h and at each follow up. If the test dose is tolerated, captopril administration will start at 0.15 mg kg) per dose 8-hourly. Pulse rate and blood pressure will be monitored 4-hourly and doses will be withheld if hypotension is documented. After 24 h, the dose will be increased to 0.3 mg kg) per dose 8-hourly .
75793785|NCT05634252|Behavioral|UV Photo|Participants will receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system. Participants will receive a handout of their photos accompanied by an explanation of UV light, its harmful effects on skin, and that using sun safe behaviors early in life will have the greatest impact and help to decrease risk for skin cancer.
75930089|NCT03677596|Drug|inotuzumab ozogamicin-dose level 2|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.
75930090|NCT03677596|Drug|Inotuzumab ozogamicin-dose level 1|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
75930091|NCT03660722|Other|blood and urinary samples|blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks
76085058|NCT03120858|Behavioral|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
76085059|NCT04498884|Drug|Rinsulin® mix 30/70|one subcutaneous injection at a dose of 0.4 IU/kg
76085060|NCT04498884|Drug|Humulin® M3|one subcutaneous injection at a dose of 0.4 IU/kg
76085061|NCT04498494|Device|ECG|12-lead ECG
75336195|NCT04780412|Drug|Placebo|Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
75336196|NCT00754598|Device|Tomosynthesis digital mammography imaging system|a full-field digital mammography system where multiple images are acquired at various angles near the normal to the detector. Breast compression is performed in a standard geometry. The acquired images are reconstructed using mathematical algorithms, not unlike CT reconstructions, to generate a set of thin slices parallel to the breast platform. The reconstructed slices can be viewed individually or in a movie format.
75336197|NCT00002974|Drug|carboplatin|
75645959|NCT04288700|Drug|intralesional propranolol injection|intralesional propranolol injection 1 mg/mL
75645960|NCT04288700|Drug|topical Timolol maleate 0.5% eye drops|To be Applied on the surface of the lesions three times daily
75645961|NCT02863406|Other|Bronchoalveolar lavage|Bronchoalveolar lavage in order to determine rate of dust
75645962|NCT03664232|Drug|JNJ-42165279|Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
75793786|NCT05634252|Behavioral|MC1R Test|Participants will provide a saliva sample using an Oragene® clinical-grade saliva kit. Once sequenced, participants will receive their MC1R testing results via web as well as a standardized booklet that addresses personal risk level and population risk level, strategies to reduce skin cancer risk, and number to call or email for further information.
75930092|NCT03632343|Other|Pain Squad+ with Nurse Support|Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
75930093|NCT03632343|Other|Pain Squad+|Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
75336198|NCT00002974|Drug|etoposide|
75336199|NCT00002974|Drug|ifosfamide|
75336200|NCT00002974|Procedure|hyperthermia treatment|
75336201|NCT00754364|Drug|Pemetrexed/Carboplatin|"Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.~Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day."
76085062|NCT01621672|Drug|Revlimid|10 mg/day in the morning same time each day
76085063|NCT03344328|Drug|Bortezomib|The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.
76085064|NCT02499822|Drug|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
76085065|NCT02499822|Drug|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
76085066|NCT01663012|Drug|Etirinotecan pegol|
76085067|NCT02499744|Device|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
76085068|NCT02499744|Device|HHFNC|"For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
75930094|NCT03614741|Drug|Tinzaparin continuous infusion|4500 IU continuous infusion of Tinzaparin
75930095|NCT03614741|Drug|Tinzaparin bolus|4500 IU bolus of Tinzaparin
75930096|NCT03548454|Drug|Duloxetine|Open label prescription
75793787|NCT05634213|Drug|normal saline|Once the patient is placed on cardiopulmonary bypass, the product will be injected into the left atrial wall using a 27 gauge needle as 4 injections of 200 μL each. Two will be placed in the atrial appendage. The remaining 2 injections will be placed equidistant on the anterior atrial free wall. Each injection will be performed just under the surface of the atrial epicardium over 30 seconds. The needle will stay in place for 10 seconds after the injection to limit back flow from the site of injection.
75930097|NCT03548454|Drug|Desipramine|Open label prescription
75930098|NCT03537729|Behavioral|Salient Cues|Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
75930099|NCT03537729|Behavioral|Spaced Retrieval Education|Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
75930100|NCT03534934|Diagnostic Test|Vital signs|"Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight"
75930101|NCT03534934|Diagnostic Test|Urine Pregnancy Test|Urine pregnancy test done on woman of childbearing potential.
76085069|NCT02499588|Device|Esteem Plus with ConvaTec Moldable Technology|
76085070|NCT02499588|Device|Natura with ConvaTec Moldable Technology|
75645963|NCT03664232|Drug|Placebo|Participants will receive a matching placebo orally twice daily for 12 weeks.
75645964|NCT04286048|Other|Weight implement|"The technique will be done by making the same movement of the launch, but with the weight implement. The physiotherapist will be next to the pitcher, noting that there is no pain or discomfort when launching. The session will be held for 15min with 30 seconds of rest between each launch, until reaching 15 pitches.~The sessions will be directed by a physiotherapist, in charge of supervising that the pitcher is correctly making the requested movement."
75645965|NCT02863562|Other|Kinesio taping|Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.
75645966|NCT02863562|Other|Proprioceptive exercises|Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.
75645967|NCT02863562|Other|Placebo Kinesio taping|
75793788|NCT05632068|Drug|Xian-Hua-Cha|Zizyphus jujuba Mill., Nelumbo nucifera Gaertn, Citrus reticulata Blanco, Rosa rugosa Thunb., Cassia obtusifolia L., Stevioside, resistant starch, and water
75793789|NCT05631561|Device|Endovascular denervation System (Generator and Catheter )|All patients receive endovascular denervation (EDN) treatment
75930102|NCT03534934|Other|Questionnaires|Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
75930103|NCT03534934|Diagnostic Test|Blood Test|Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
75793790|NCT05625009|Procedure|Procedure/Surgery: Transversus Abdominis Plane Block (TAPB)|Patients received TAPB postoperatively
75793791|NCT05625009|Procedure|Procedure/Surgery: Erector Spinae Plane Block (ESPB)|Patients received ESPB postoperatively
75793792|NCT05624398|Device|Vivity IOL|Cataract surgery with implantation of the Vivity IOL along with concurrent implantation of the Hydrus Microstent
75793793|NCT05620173|Device|Vedea Amblyopia Therapy (VAT)|Children will use the VAT for 5 days per week, 30 minutes per day. They play VR-games using a VR-headset, which content is optimized for dichoptic training.
76085071|NCT02499588|Device|Natura Accordion with ConvaTec Moldable Technology|
75645968|NCT00629720|Drug|alfuzosin (SL770499)|
75930104|NCT03534934|Diagnostic Test|Duel-energy X-ray absorptiometry scan|Bone density measurement
75930105|NCT03534934|Diagnostic Test|Multi-detector computed tomography|Hip and ankle CT scan
75930106|NCT03534934|Diagnostic Test|Dual-energy X-ray absorptiometry scan|Vertebral fracture assessment
75930107|NCT03517891|Behavioral|WIC+|"intervention was based on the Health Self-Empowerment Theory. It will be adapted for the web-based platform using the Persuasive Technology and Persuasive System Design models. These models focus on the human-computer interface and how technology can/is used as a persuasive tool for behavior change. We will also include Bandura's Social Cognitive Theory.~The intervention will be delivered through the combination of:~educational modules provided through an interactive distance learning platform designed to provide learning experiences using multiple modalities; short messaging platforms to promote adoption of healthy behaviors and use of the educational platform; one to one sessions with the interventionist over the telephone."
75930108|NCT03516838|Drug|ACTIVA™ BioACTIVE|Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
75930109|NCT03516838|Drug|Compomer|Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
75930110|NCT03513211|Drug|SUBA-itraconazole|150mg PO BD
75930111|NCT03513211|Drug|Hydroxychloroquine|Escalating doses in Rolling 6 Phase I
75930112|NCT03504826|Device|Hybrid Assistive Limb (HAL)|Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
75930113|NCT03468868|Behavioral|Exercise program for people with MS|The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
76085072|NCT02499588|Device|Esteem synergy Plus with ConvaTec Moldable Technology|
76085073|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
75930114|NCT03458520|Diagnostic Test|PET/MR imaging|undergo PET/MR imaging
75930115|NCT03458520|Diagnostic Test|MR imaging|Undergo MR imaging
75930116|NCT03458520|Diagnostic Test|PET/CT imaging|Undergo PET/CT imaging
75930117|NCT03458429|Drug|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
75930118|NCT03448757|Other|measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure|"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.~Patients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma."
75930119|NCT03448718|Drug|Olaparib|1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
75930120|NCT03436979|Device|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
75336202|NCT00754364|Drug|Gemcitabine|Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
75336203|NCT02612896|Drug|Mass drug administration, praziquantel 10mg/kg|see previous, in elimination study arm only
75336204|NCT02612896|Behavioral|Health education|in all study arms, using village meetings, posters, pamphlets.
75645969|NCT03797690|Procedure|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure
75645970|NCT03797690|Procedure|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
75645971|NCT00967616|Drug|CS7017|CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
75645972|NCT00967616|Drug|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)|"FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~Irinotecan, 180 mg/m^2 IV infusion over 30 to 120 minutes~Leucovorin, 400 mg/m^2 IV infusion to match the duration of the irinotecan infusion~5-FU, 1200 mg/m^2/day x 2 days (total 2400 mg/m^2 over 46 to 48 hours continuous infusion)"
75793794|NCT05620173|Device|Occlusion therapy|Children are given an eye patch to occlude their dominant eye with for a prescribed number of hours per day. This may typically range anywhere between 2-8 hours per day, depending on the severity of the amblyopia.
75793795|NCT05617443|Device|stackable guide|different types of stackable guide
75930121|NCT03431129|Diagnostic Test|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
75936454|NCT02431208|Drug|Pomalidomide|Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
75336205|NCT00002980|Drug|decitabine|
75336206|NCT04777682|Procedure|ultrasound, double balloon enteroscopy|compare intestinal ultrasound versus double-balloon enteroscopy in diagnosis of malabsorption syndrome
75336207|NCT00002986|Drug|carmustine|
75336208|NCT00002986|Drug|topotecan hydrochloride|
75336209|NCT04780256|Procedure|Endoscopic resection|"The endoscopic resection is the procedure that allows to remove cancerous or precancerous conditions of digestive tract. Endoscopic resection can be preformed by several techniques:~Endoscopic mucosal resection (EMR): it allows to remove mucosal lesions~Endoscopic submucosal dissection: it allows to remove mucosal lesions that involved submucosal layer and large lesions~Full-thickness resection: it allows to remove infiltrating lesions by the resection of a little piece of the entire gastrointestinal wall"
75336210|NCT00003418|Drug|exemestane|
75793796|NCT05616039|Procedure|Standard Liver Surgery|Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours
75936455|NCT02431208|Drug|Dexamethasone|Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
75336211|NCT00003418|Drug|tamoxifen citrate|
75336212|NCT04777526|Other|Proprioception exercises|Exercises for recognition of thumb position and thumb force sense.
75336213|NCT04777526|Other|Joint protection program|Reeducation in the activities daily life
75336214|NCT04777526|Other|Thumb orthosis|Thumb night orthosis
75336215|NCT04777526|Other|Manual distraction|Manual distraction of CMC joint
75793797|NCT05616039|Diagnostic Test|Indocyanine Fluorescent Image Guided Surgery (I-FIGS)|Use of I-FIGS in accurate identification of tumours and their margins
75936456|NCT03107078|Drug|Glucocorticoids|Intravenous Glucocorticoids (GCs)
75936457|NCT03188900|Biological|A collection of maternal plasma and serum|A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
75936458|NCT05693597|Drug|Imtenan Oil|Cold Press Oil
75645973|NCT00629876|Drug|Peginesatide|"Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.~Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen."
75645974|NCT04288232|Drug|Aflibercept Injection [Eylea]|Intravitreal aflibercept Injection 2.0mg/0.05 ml
75645975|NCT04288466|Dietary Supplement|maltodextrin|maltodextrin solution 450ml
75793798|NCT05613205|Biological|TYP04A Low Dose without adjuvant investigational vaccine|2 doses of TYP04A Low Dose without adjuvant investigational vaccine administered intramuscularly, at Day 1 and Day 169, to participants in the Step 1a low dose without adjuvant Group.
75793799|NCT05613205|Biological|TYP04B Full Dose without adjuvant investigational vaccine|2 doses of TYP04B Full Dose without adjuvant investigational vaccine administered intramuscularly, at Day 1 and Day 169, to participants in the Step 2 full dose without adjuvant Group.
75645976|NCT02864264|Drug|BMS-986184|
75793800|NCT05613205|Biological|TYP03A Low Dose adjuvanted investigational vaccine|2 doses of TYP03A Low Dose adjuvanted investigational vaccine administered intramuscularly, at Day 1 and Day 169, to participants in the Step 1b low dose with adjuvant Group.
75793801|NCT05613205|Biological|TYP03B Full Dose adjuvanted investigational vaccine|2 doses of TYP03B Full Dose adjuvanted investigational vaccine administered intramuscularly, at Day 1 and Day 169, to participants in the Step 2 full dose with adjuvant Group.
75336216|NCT04777604|Other|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as neoadjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within patients with resectable pancreatic cancer after neoadjuvant chemotherapy, the investigators aim to strategize appropriate neoadjuvant chemotherapy before surgery, thus developing a platform to predict the outcomes of each patient.
75930122|NCT03422627|Drug|Efavaleukin Alfa|"Phase 1: This study will be conducted as a multiple ascending dose (MAD) study. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen for up to an additional 208 weeks through an extended dosing period. All subjects who continue to receive efavaleukin alfa during the extended dosing period will be reevaluated every 6 months for their response to treatment.~Phase 2: All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for 52 weeks."
75645977|NCT02864264|Drug|Placebo matching BMS-986184|
75645978|NCT00971204|Device|CardioFocus HeartLight Endoscopic Ablation System|PVI ablation
75930123|NCT03422003|Radiation|Radiation Therapy|"For the conventional fractionation arm: Each fraction will consist of 200 cGy per day. Total dose = 5000 cGy to the chest wall and 4600-5000 cGy to the lymph nodes.~For the hypofractionation arm: Each fraction consists of 266 cGy per day. Total dose = 4256 cGy to the chest wall and 3990 cGy to the lymph nodes."
75930124|NCT03403621|Drug|Pentamidine Isethionate|Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.
75930125|NCT03403621|Drug|Placebo|No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
75930126|NCT03387917|Drug|TLD-1|TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.
75930127|NCT03387917|Drug|Caelyx|Caelyx is a liposomal formulation of the anthracycline doxorubicin
75930128|NCT03370900|Other|Testing|Participants either received 20 case testing with or without feedback
75336217|NCT04777838|Drug|Citalopram 10 MG|10 mg of citalopram every day
75645979|NCT02640963|Other|Exercise|to determine the feasibility of the GrACE (Group Aged Care Exercise) programme in RAC, with the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength.
75645980|NCT02640963|Other|Control|to compare with the GrACE (Group Aged Care Exercise) programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention group
75930129|NCT03361735|Drug|Leuprolide Acetate|Intramuscular or subcutaneous injection
75930130|NCT03361735|Drug|Goserelin Acetate|Subcutaneous injection
75930131|NCT03361735|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75930132|NCT03361735|Radiation|Radium Ra 223 Dichloride|Given IV
75930133|NCT03361735|Other|Laboratory Biomarker Analysis|Correlative studies
75645981|NCT02640885|Device|Foley's cather ballon|
75645982|NCT02640729|Drug|Nelotanserin|once daily, oral, 20-mg tablets
75930134|NCT03361735|Drug|Degarelix|Subcutaneous injection
75930135|NCT03353974|Device|Video game therapy|Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
75645983|NCT02640729|Drug|Placebo|once daily, oral, matching tablets
75645984|NCT02640651|Device|DC-Stimulator (PLUS version)|transcranial direct current stimulation
75645985|NCT02640417|Drug|Nucleotides + B12|Oral treatment with either Nucleotides + Vitamin B12
75645986|NCT02640417|Drug|B Vitamins|Oral treatment with vitamins B1, B6, and B12
75645987|NCT00653679|Other|exercise|1 hour of endurance or resistance exercise
75930136|NCT03353974|Device|Balance platform therapy|Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
75930137|NCT03320837|Dietary Supplement|Infant formula|Breast milk substitute containing synbiotics
75930138|NCT03320837|Other|Breast milk|Breast milk
76085074|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
75645988|NCT02640495|Drug|Intravenous Artesunate as part of standard medical practice|Intravenous Artesunate 2.4 mg/kg
75645989|NCT02535897|Dietary Supplement|Flavoured water|
75936459|NCT05693597|Drug|Baraka Capsules|Soft Gelatin Capsules
75936460|NCT02430350|Drug|Compound Edaravone Injection|
75936461|NCT02430350|Drug|Edaravone Injection|
75936462|NCT02430974|Drug|Icotinib|Patients in experimental group will receive oral Icotinib for 4-8months.
75793802|NCT05613205|Biological|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the Step 1a control, Step 1b control, and Step 2 control groups.
75336218|NCT04777838|Drug|Amitriptyline|25mg of Amitriptyline every
75336219|NCT04777838|Device|Bite Splint|Night use of occlusal splint
75336220|NCT04777448|Procedure|telerehabilitation|24 sessions (less Thant 1h hour each) of tele rehabilitation. Patients can choose among several activities (gym, dance, cardio training, ...)
75645990|NCT02535897|Dietary Supplement|Flavoured water + carbohydrate|
75645991|NCT02535897|Dietary Supplement|Flavoured water + carbohydrate + protein|
75645992|NCT00653757|Drug|goserelin acetate|
75793803|NCT05613205|Biological|GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the Step 1a control, Step 1b control, and Step 2 control groups.
75793804|NCT05610046|Device|Infrared sauna heating|Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
75930139|NCT03306979|Drug|N Acetylcysteine|Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
75930140|NCT03306979|Other|Placebo oral capsule|Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
75930141|NCT03298243|Behavioral|Vibrotactile stimulation|Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in off-the-shelf activity monitors.
75930142|NCT03276273|Device|recording of Bispectral Index|recording of Bispectral Index
75930143|NCT03264534|Procedure|limbal relaxing incisions|Manually performed surgical procedure
75930144|NCT03264534|Procedure|astigmatic keratotomy|femtosecond laser guided surgical procedure
75930145|NCT03244293|Other|no intervention|
75930146|NCT03225105|Drug|M3541|Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).
75930147|NCT03225105|Radiation|Palliative Radiotherapy (RT)|Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).
75930148|NCT03217071|Drug|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
75336221|NCT00003424|Drug|tamoxifen citrate|
75336222|NCT04779944|Other|other|questionnaire
75336223|NCT02572024|Device|BAT|Baroreflex activation therapy device ON
75336224|NCT02572024|Other|Placebo|Baroreflex activation therapy device OFF
75645993|NCT00653757|Drug|leuprolide acetate|
75645994|NCT00653757|Radiation|image-guided radiation therapy|
75645995|NCT00653757|Radiation|intensity-modulated radiation therapy|
75645996|NCT02640183|Drug|EMLA|
75645997|NCT02640183|Other|Placebo|
75645998|NCT02640027|Procedure|Cast removal at home using a telemedicine tool|Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
75645999|NCT02639949|Behavioral|Cognitive-behavioral adherence promotion program|A culturally sensitive group cognitive behavioral therapy combined with adherence promotion.
75646000|NCT02639949|Behavioral|Standard Care|
75646001|NCT02639793|Procedure|catheter ablation|Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
75646002|NCT02639403|Radiation|Conformal three-dimensional Radiotherapy|Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
75646003|NCT02639481|Behavioral|Standard physiotherapy|Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
75646004|NCT02639481|Device|Erigo®Pro group without FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
75793805|NCT05610046|Device|Sham sauna|Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.
75930149|NCT03217071|Radiation|stereotactic radiation therapy (SRT)|Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
75930150|NCT03217071|Procedure|Surgery (Non-interventional, standard of care)|Standard of care surgery to remove cancer
75930151|NCT03199053|Drug|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
75930152|NCT03199053|Drug|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
75930153|NCT03199053|Drug|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
75930154|NCT03195699|Drug|TTI-101|Oral capsule
75930155|NCT03195699|Drug|TTI-101|Oral tablet
75930156|NCT03186079|Drug|Xiaojidaozhi Decoction|Mixture of twelve Chinese herbal medicines granule
75472809|NCT01963156|Behavioral|Prescription synchronization|"Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.~Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point."
75793806|NCT05609786|Behavioral|Personalized safety planning tool|The myPlan Kenya app is a web-based safety planning tool that is secure, private, free and personalized to the user. The app includes multiple, evidence-based modules: Strategies (safety strategies tailored to the user's needs and violence experience); Resources (referrals to local health, safety and justice resources and services); About You (questionnaires that help the user assess their relationship safety and tailor their Strategies, including My Relationship, Red Flags, My Safety, My Priorities); Understanding (knowledge sections that share information on relationships and violence, including Healthy Relationships, Harmful Beliefs About Abuse, About Violence).
75930157|NCT03186079|Drug|Placebo|Mixture of 10% Chinese herbal medicines granule and 90% artificial gum
75336225|NCT04777370|Other|posterior glide mobilization|The participant will be positioned supine on a plinth, with their scapula stabilized against a firm wedge on the table, and the shoulder joint in the resting position (approx. 55 degrees abduction, 30 degrees horizontal adduction, and slight external rotation). With the extremity held in the same position, the researcher will then apply a grade III (into tissue stretch) PG mobilization. This will consist of five 30-second bouts of sustained gr III posterior glide mobilizations.
75336226|NCT04777370|Other|Sleeper stretch|All participants randomized to the stretching group will perform five 30-second holds of the sleeper stretch. This is performed by lying on the side to be stretched, elevating the upper arm to 90° on the support surface with the elbow bent 90°, then passively internally rotating the shoulder with force provided by with the opposite arm.
75472810|NCT01963182|Drug|Irinotecan|
75472811|NCT01963195|Drug|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
76085075|NCT02502552|Other|blood specimen|blood specimen
75336227|NCT04777370|Other|thoracic manipulation|"Individuals will then undergo a single supine grade V thrust manipulation. All manipulations will take place at the T3-4 segment. If a cavitation (pop) is not heard or felt by either the subject or examiner, a second thrust will be performed."
75336228|NCT04777136|Other|Home visit and comprehensive geriatric assessment|Home-visit from the geriatric team, who will do a full geriatric assessment and targeted interventions
75336229|NCT04777136|Other|Control group, no designated follow up|Only follow-up on patients own initiative with contact to the general practitioner
75336230|NCT00003430|Drug|L-778,123|
75472812|NCT01963221|Radiation|fludeoxyglucose(18f)|
75472813|NCT01963221|Other|blood sample|
75472814|NCT01963221|Other|cardiac and aortic magnetic resonance imaging|
75793807|NCT05599412|Drug|Lorviqua|As provided in real world practice
75793808|NCT05596591|Device|Focused extracorporeal shockwave therapy|High energy level shockwaves (between 0.28-0.60 mJ/mm^2) will be focused over the subchondral bone with the bone marrow lesion, previously localized on MRI.
75930158|NCT03186079|Drug|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
75930159|NCT03186079|Behavioral|Toilet training|Toilet training has been considered a routine method in treatment of constipation
75930160|NCT03176173|Radiation|Image-guided Radiation Therapy|"Ablative treatment as 50 Gy in 5 or 10 fractions.~Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions."
75930161|NCT03176173|Drug|Immunotherapy (physician's choice for standard of care immunotherapy)|Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.
76085076|NCT02499510|Device|GoldenFlow Stent|The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
76085077|NCT04496622|Other|WBV technique|"Whole body vibration with frequency of 16-25 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
76085078|NCT04496622|Other|Whole body vibration technique|"Whole body vibration with frequency of 26-35 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
75336231|NCT00002998|Drug|cisplatin|
75336232|NCT00002998|Drug|gemcitabine hydrochloride|
75336233|NCT02088788|Device|Board|Also has radio-dense pelvic shielding
75336234|NCT02088788|Device|No Board|Radio-lucent armboard for radial access with radio-dense drape across pelvis
75336235|NCT00003004|Drug|alvocidib|
75472815|NCT01963221|Other|carotid femoral pulse wave velocity|
75472816|NCT01963221|Radiation|positron emission tomography|
75472817|NCT01963221|Radiation|computed tomography|
75472818|NCT01963273|Procedure|Video Assisted Ablation of Pilonidal Sinus|
75472819|NCT01963286|Device|ICD with enhanced SVT discriminators|ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
75930162|NCT03170453|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
75793809|NCT05593510|Behavioral|No prep ready-to-eat meals|"Pantry clients will select no prep ready-to-eat meals for up to 14-days' worth of meals for themselves and 2-members of their household using an online food selection platform. The food retailer supplying the meals produces over 70 meals. We have elected to study 14-days of meals to offer clients variety and determine which flavors are most desirable to clients. After ordering, meals will be retrieved from a refrigeration unit, boxed by pantry staff, and brought to the participant to take home. An example dinner is Teriyaki Chicken with Roasted Potatoes and Broccoli, and an example breakfast is Omelet with Peppers and Zucchini. Meals can be stored in a refrigerator or freezer and eaten immediately or after reheating depending on the meal and consumer preference."
75930163|NCT03170453|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
75930164|NCT03168880|Drug|Paclitaxel + Carboplatin|Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
75930165|NCT03168880|Drug|Paclitaxel only|
75930166|NCT03149575|Drug|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
75930167|NCT03149575|Drug|Physician's Choice of Salvage Therapy - temozolomide|"The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle."
75930168|NCT03149575|Drug|Physician's Choice of Salvage Therapy - lomustine|"The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.~The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks."
75930169|NCT03149575|Drug|Physician's Choice of Salvage Therapy - carboplatin|"The product label for (Paraplatin) carboplatin Injection provides the following dosing information.~As a single agent at a dosage of 360mg/m2 IV on day 1 every 28 days Alternatively, the carboplatin dose may be calculated by the Calvert formula below Calvert formula for carboplatin dosing: Total Dose (mg) = (target AUC) x (GFR + 25), where AUC = area under the curve and GFR = glomerular filtration rate."
75930170|NCT03149185|Behavioral|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
75936463|NCT02430116|Procedure|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
75936464|NCT02429960|Device|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
75936465|NCT02429960|Device|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
75936466|NCT02429960|Device|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
75646005|NCT02639481|Device|Erigo®Pro group with FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
75646006|NCT04164927|Other|Manual Lymphatic Drainage|"Lymphatic correction method was used via the KinesioTaping® to patients group.~Standardized 30-minute Manuel Lymphatic Drainage treatment was applied to the MLD group.~Control group received only physiotherapy treatment."
75336236|NCT00003004|Drug|cisplatin|
75336237|NCT00003004|Drug|paclitaxel|
75336238|NCT04776512|Procedure|ESP Block With Bupivacain|bilateral lumbar ESP block using 0.375% Bupivacain
75336239|NCT04776512|Procedure|Epidural Analgesia|Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil
75336240|NCT04329910|Other|no intervention|no intervention - observational only
75336241|NCT04776590|Drug|Tislelizumab|neoadjuvant immunotherapy
75336242|NCT00637676|Procedure|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
75336243|NCT00637676|Procedure|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
75336244|NCT00003436|Drug|amsacrine|
75336245|NCT00003436|Drug|asparaginase|
75336246|NCT00003436|Drug|cytarabine|
75336247|NCT00003436|Drug|daunorubicin hydrochloride|
75336248|NCT00003436|Drug|etoposide|
75336249|NCT00003436|Drug|methotrexate|
75336250|NCT00003436|Drug|mitoxantrone hydrochloride|
75336251|NCT00003436|Drug|therapeutic hydrocortisone|
75336252|NCT00003436|Procedure|allogeneic bone marrow transplantation|
75336253|NCT02469662|Device|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
75646007|NCT04164927|Other|Kinesio Taping|Depending on the size of the leg two or three fan cut tapes were applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Kinesio taping was applied by certified Kinesio Tape practitioner once a week to Kinesiotaping group.
75336254|NCT02325154|Device|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
75336255|NCT02432378|Biological|Cisplatin + celecoxib + DC vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
75336256|NCT02432378|Biological|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
75336257|NCT00003454|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75336258|NCT04779788|Device|I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)|An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent
75336259|NCT04779788|Device|Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)|Bare self-expanded metal stent
75336260|NCT00003466|Drug|temozolomide|
75472820|NCT01963299|Drug|5 ml Ropivacaine 10% + physiological saline|
75646008|NCT04164927|Other|Control|Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.
75646009|NCT00654225|Drug|Rosuvastatin|
75646010|NCT00654225|Drug|Atorvastatin|
75646011|NCT00974090|Drug|Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
75646012|NCT00974090|Drug|Teneli / Teneli + SU|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
75646013|NCT00654303|Drug|Rosuvastatin|
75646014|NCT02639169|Other|Music Therapy|apply live music through the techniques of music therapy
75646015|NCT02863484|Other|surgery|pealing of the outer layer of the cavernous sinus
75646016|NCT02639091|Drug|BAY 94-9343|"In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)"
75646017|NCT02639091|Drug|Pemetrexed|Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
75646018|NCT02639091|Drug|Cisplatin|Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
75336261|NCT05605652|Procedure|microosteoperforations|"Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire."
75336262|NCT00003478|Procedure|conventional surgery|
75936467|NCT02429960|Drug|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
75936468|NCT02429804|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
75336263|NCT00003478|Radiation|iodine I 131 monoclonal antibody 81C6|
75336264|NCT00003478|Radiation|radiation therapy|
75472821|NCT01963299|Drug|5 ml Ropivacaine 10% + Clonidine 1 µg/kg|
75472822|NCT01963312|Procedure|Transarterial Supraselective Embolization of the prostate|
75472823|NCT01963312|Procedure|Transurethral Resection of the prostate|
75472824|NCT01963325|Drug|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
75646019|NCT04286750|Drug|ACT-1004-1239|ACT-1004-1239 administered as hard capsules for oral use.
75646020|NCT04286750|Drug|Placebo|Matching placebo administered as hard capsules for oral use.
75646021|NCT02638935|Device|Ultrasound- Virtual Touch Tissue Imaging Quantification|Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
75646022|NCT02864654|Procedure|ADRC injection|10 mL of autologous ADRC suspension will be injected intramuscularly
75646023|NCT02864654|Other|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 10 ml of normal saline.
75646024|NCT02864654|Procedure|Liposuction|
75646025|NCT02639013|Procedure|transducer technique|the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
75646026|NCT00971048|Device|HP828-101|Topical test article applied once daily
75646027|NCT00971048|Device|Hydrogel/Hydrocolloid|Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
75936469|NCT02429804|Drug|Fludeoxyglucose F-18|Given IV
75930171|NCT03149185|Behavioral|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
75930172|NCT03138629|Drug|VAL-083|VAL-083 will be administered intravenously
75336265|NCT05605418|Behavioral|CHESS intervention|The multi-faceted CHESS intervention includes: (1) home blood pressure monitoring (HBPM) for patients, and the data will be uploaded to central electronic health records (EHR) automatically; (2) a Smart Reminder and Alert System (SRAS) to send educational messages and reminders to support patients on HBPM, improve blood pressure medication adherence and lifestyle modification; (3) a decision support system (DSS) to provide physicians with antihypertensive medications prescriptions and referral recommendations; (4) regular quality assessment reports will be provided to health care providers automatically to improve the quality of hypertension management at PHC level.
75930173|NCT03137472|Device|Transcranial Magnetic Stimulation (TMS)|The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
75793810|NCT05593510|Behavioral|Ingredient bundles (e.g. meal kits)|Ingredient bundles will group individual meal ingredients (e.g., chicken, teriyaki, broccoli, potatoes) in a bag or box and pair those healthy food items with a recipe that instructs the client on how to make a healthier meal. Similar to the no prep ready-to-eat meal initiative, clients will select ingredient bundles for themselves and 2-members of their household using the food pantry online food selection platform. The ingredient bundles will closely replicate the no prep ready-to-eat meals.
75793811|NCT05592730|Genetic|AMHR2 polymorphism in blood|1 tube of blood taken at the first application
75793812|NCT05592730|Genetic|AMHR2 polymorphism in granulosa cell|Extraction of granulosa cell from the follicle fluid obtained during OPU
75930174|NCT03063749|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
75472825|NCT01963338|Device|Intradermal injection in the forearm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device.
75336266|NCT00003016|Drug|tamoxifen citrate|
75646028|NCT02535819|Procedure|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete
75336267|NCT00003016|Procedure|adjuvant therapy|
75336268|NCT00003022|Radiation|iodine I 131 monoclonal antibody 3F8|
75336269|NCT04779632|Dietary Supplement|Experimental: Fish Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.
75646029|NCT02535819|Procedure|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
75472826|NCT01963338|Device|Intradermal injection in the upper arm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device in the upper arm (deltoid region).
75793813|NCT05589181|Drug|High Dose Buprenorphine|32mg of BUP split as 16mg at 0 minutes and 16mg at 30-60 min as an induction dose
75793814|NCT05589181|Drug|Standard Buprenorphine Dose|12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose
75336270|NCT04779632|Dietary Supplement|Comparator: Safflower Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing ~ 3000 mg of linoleic acid) for 4 weeks.
75336271|NCT00383344|Procedure|FDG PET/CT|
75472827|NCT01963338|Drug|Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)|This injection is conducted by needle and syringe in the upper arm (deltoid region).
75472828|NCT01963364|Dietary Supplement|Inulin challenge|On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
75646030|NCT00911001|Behavioral|No Drug|Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
75930175|NCT03063749|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
75930176|NCT03042936|Behavioral|Insulin Superheroes Club Curriculum|This curriculum promotes healthier physical activity, nutrition, sleep, and stress coping practices. The intervention lasts 12-months: registration, six evaluation sessions (2-3 hours per evaluation: Weeks 1, 8, and 16, 6-month, 9-month, and 12-month), and 16-weekly, 3-bi weekly, 6-monthly educational and physical activity sessions each lasting 90 minutes.
75930177|NCT03029884|Device|Open-Loop DBS|Conventional brain stimulation that is tonically providing stimulation, without feedback
75930178|NCT03029884|Device|Sham Stimulation|No Active Stimulation
75936470|NCT02429804|Drug|Fluorine F 18 Sodium Fluoride|Given IV
76085079|NCT02499432|Behavioral|Motivational Enhancement|Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
75336272|NCT00003028|Drug|sabarubicin|
75336273|NCT04776122|Device|Therapy|Device-assisted breathing for relaxation
75646031|NCT00654459|Dietary Supplement|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
75646032|NCT02638779|Biological|Blood sampling|Specific Blood sampling will be performed in patients and healthy volunteers
75646033|NCT03896126|Other|Observational|There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
75646034|NCT00654537|Drug|Rosuvastatin|
75646035|NCT00654537|Drug|Atorvastatin|
76085080|NCT02502474|Other|Staphylococcus aureus carriage|nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
75793815|NCT05586555|Other|Pupillometry (Eve-tracking measurements)|Pupillometry measurements are carried out by a dedicated device (eye tracker), which includes cameras allowing the measurement of pupillary dilation. The subject stands in front of a screen and fixes a point in the center of the screen, the cameras placed on the screen allowing a measurement of the pupillary dilation in a non-invasive way. These eye-tracking measurements are performed simultaneously with an auditory task and allow to study the pupil's response to different stimuli.
75793816|NCT05584124|Device|High frequency repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
75793817|NCT05584124|Device|Sham repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
75930179|NCT03029884|Device|Closed-Loop DBS|Feedback enabled brain stimulation, where stimulation is provided on demand in response to pain biomarkers.
75930180|NCT03027388|Drug|LB-100|LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m^2.
75336274|NCT04776122|Other|No device|Breathing platform without device
75336275|NCT01258387|Drug|Glial growth factor 2/ Neuregulin 1β3|
75646036|NCT00654537|Drug|Pravastatin|
75646037|NCT00654537|Drug|Simvastatin|
75646038|NCT02638857|Procedure|TACE|lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.
76085081|NCT02499276|Device|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
76085082|NCT04496700|Procedure|Whole blood donation and transfusion|"The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only."
75646039|NCT02638857|Biological|Dendritic Cell|DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
75646040|NCT02638857|Drug|lipiodol|lipiodol 10-20ml,hepatic arterial infusion
75646041|NCT02638857|Drug|Mitomycin (MMC)|MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.
75646042|NCT02638857|Drug|Epirubicin(EADM)|EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.
75930181|NCT03026582|Device|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
75930182|NCT03010150|Procedure|Biospecimen Collection|Provide blood samples
75646043|NCT02638857|Biological|Precision Multiple Antigen T Cell|PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
75646044|NCT02638545|Drug|Dexmedetomidine|Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
75793818|NCT05583877|Behavioral|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
75930183|NCT03010150|Other|Questionnaire Administration|Ancillary studies
75930184|NCT03007589|Drug|otc sunscreens|Sunscreens of various SPF levels and ingredients
75930185|NCT03007589|Other|sun protection fabrics|fabrics
75930186|NCT03007589|Other|Optical Filters|Optical band pass or long pass filters or surfaces/mirrors used in solar simulators
75930187|NCT03005145|Other|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
75936471|NCT02429804|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
75336276|NCT01258387|Other|Placebo|
75336277|NCT00003484|Drug|carmustine|
75336278|NCT00003484|Drug|irinotecan hydrochloride|
75336279|NCT00003484|Procedure|surgical procedure|
75336280|NCT00003484|Radiation|iodine I 131 monoclonal antibody 81C6|
75336281|NCT05605262|Drug|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
75336282|NCT02227654|Procedure|Abnormal Ovarian Ultrasound|Ultrasound
75336283|NCT05605184|Other|Survey|Survey
75336284|NCT00003490|Biological|sargramostim|
75336285|NCT00003490|Drug|cyclophosphamide|
75336286|NCT00003490|Drug|prednisone|
75336287|NCT00003490|Drug|vincristine sulfate|
75646045|NCT00654693|Other|Rapid Response Team|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
75646046|NCT02638467|Drug|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
75646047|NCT02638467|Procedure|Bone Marrow Transplant|"Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.~The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.~The goal is to transplant > 3 x 106 CD34+ cells/kg BW recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow"
75646048|NCT02638467|Drug|Bone Marrow cells|
75646049|NCT02864420|Other|Home hospitalization|
75646050|NCT02864420|Other|Inpatient Hospitalization|
75793819|NCT05583877|Behavioral|Usual Care|Participants will receive usual care for DSMT.
75793820|NCT05581927|Device|modified Whole-Body Hypothermia|patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure
75793821|NCT05581927|Device|standard Whole-Body Hypothermia|patients were allocated to standard Whole-Body Hypothermia
75793822|NCT05577351|Device|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System paired with a single-use, disposable tubing set specific for use with the RapidPulseTM Aspiration System
75793823|NCT05572424|Other|Adaptated Physical Activity (APA) + pedometer watch|"Adapted physical activities program : 12 weeks, 2 40-minutes sessions per week ( one broadcast live via online video conferencing and other one in autonomy according to a sequence of different personalized exercises defined by the APA's professional). Children are divided into 6 groups. Each session will be broken down into three parts: the warm-up (10mins), the session's corps alternating between five to eight of muscle strengthening, proprioception, and endurance exercises (20mins) and a cool-down with stretching (10mins). The physical activity performed during the sessions will be quantified with a heart rate monitor and the range of 60-70% of the maximum theoretical heart rate for each child will be respected.~A pedometer watch will wear during 1 year and will provide the number of steps."
75793824|NCT05567887|Drug|maplirpacept (PF-07901801)|maplirpacept (PF-07901801)
75336288|NCT05605106|Diagnostic Test|speckle tracking echocardiography|"Speckle tracking is a recent development in image processing that uses proprietary software to automatically determine the movements of these points, which appear sonographically as speckles, within the myocardium over time. Tracking the movements of these speckles throughout the cardiac cycle yields positive values when the two points are moving away from one another, as in diastole, and negative values when they are moving towards one another, as in systole"
75930188|NCT03005145|Other|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
75336289|NCT05605106|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.
75646051|NCT00654771|Other|urine collection|clean catch urine collection and catheterized urine collection
75472829|NCT01963364|Dietary Supplement|oligofructose supplement|Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
75646052|NCT03883802|Drug|Foxy-5|Lyophilized powder for solution for intravenous infusion
75646053|NCT03883802|Drug|FOLFOX regimen|6 months treatment regimen
75646054|NCT03883802|Procedure|Tumour resection (colon cancer surgery)|Surgical removal of patients colon cancer
75646055|NCT02638233|Drug|Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)|
75646056|NCT00654849|Procedure|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
75646057|NCT00654849|Procedure|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
75793825|NCT05567874|Other|Nosocomial SARS-COV 2 Infection proportion|Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
75793826|NCT05562349|Drug|Clavulanic Acid Only Product|Drug will be given in 250mg capsules
75930189|NCT02993029|Drug|99Tc-MDP|99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
75930190|NCT02993029|Drug|Celecoxib|Celecoxib capsule 200mg qd by mouth.
75930191|NCT02992964|Drug|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
75936472|NCT02429804|Procedure|Positron Emission Tomography|Undergo PET/MRI
75936473|NCT03185156|Drug|Propofol|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
75936474|NCT03185156|Drug|Normal saline|first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
75936475|NCT03188744|Other|Assessment of the pelvic floor function|Vaginal palpation and perineometry.
75336290|NCT00003496|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75336291|NCT00003502|Drug|antineoplaston A10|
75336292|NCT00003502|Drug|antineoplaston AS2-1|
75472830|NCT01963377|Device|O2 through nasal cannulae|supplementation of O2 through nasal cannulae during bronchoscopy
75472831|NCT01963377|Device|O2-channel|supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy
75472832|NCT01963390|Drug|Testosterone Therapy|In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
75472833|NCT01963416|Dietary Supplement|macro- and micro-nutrient matched control (240 ml)|
75472834|NCT01963416|Dietary Supplement|Orange juice|
75472835|NCT01963416|Dietary Supplement|whole orange fruit|
75646058|NCT04285268|Drug|Bortezomib|Given IV or SC
75646059|NCT04285268|Biological|Rituximab|Given IV
75646060|NCT04285268|Drug|Venetoclax|Given PO
75646061|NCT00655005|Other|questionnaire administration|Newly diagnosed HNC patients
75646062|NCT00655005|Procedure|quality-of-life assessment|following treatment
75646063|NCT04285190|Drug|T89|The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.
75646064|NCT00699751|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.
76085083|NCT04495140|Drug|[14C]PF-06882961, 50 mg|A single oral dose of [14C]PF-06882961, will be administered as a liquid formulation.
76085084|NCT04495140|Drug|PF-06882961, 50 mg and [14C]PF-06882961, 100 ug|A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-06882961 will be administered via intravenous infusion.
76085085|NCT03343548|Drug|magnesium sulfate|2cc of magnesium sulfate ( 50%) will be administered epidurally
76085086|NCT03343548|Drug|normal saline|2cc of normal saline will be administered epidurally
76085087|NCT02507934|Device|Lubricin|Lubricin 150 µg/ml eye drops
75336293|NCT00003502|Procedure|alternative product therapy|
75336294|NCT00003502|Procedure|biological therapy|
75336295|NCT00003502|Procedure|biologically based therapies|
75646065|NCT00699751|Drug|Placebo|Isotonic saline 6 IV administrations separated by 4 weeks intervals.
75646066|NCT00699751|Drug|Best standard of care (BSoC)|Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
75646067|NCT01842399|Dietary Supplement|Resveratrol|Nutriceutical
75646068|NCT01842399|Drug|Placebo|2x/day orally
75646069|NCT01585857|Biological|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.
75793827|NCT05562349|Drug|Placebo|Capsule with no active medication - identical to drug capsule
75793828|NCT05561673|Combination Product|GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide|Three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide administered intramuscularly in the non-dominant arm, one each at Day 1, Day 31 and Day 181.
75793829|NCT05561673|Biological|GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system|Two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
75793830|NCT05561673|Biological|GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system|Two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
75793831|NCT05561673|Biological|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
75793832|NCT05561673|Biological|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
75793833|NCT05558475|Behavioral|Virtual Coaching|The core coaching components are motivational support, clinical health education, and technical support. The specific objectives are: support PTBS engagement, foster subsequent treatment adherence, ensure appropriate implementation of guidelines for Sleep Restriction Therapy and Stimulus Control, identify and triage PTBS candidates who are not appropriate or need more intensive treatments, and provide PTBS course technical support.
75793834|NCT05550181|Behavioral|intraoperative mechanical ventilation with hypocapnia (etCO2 < 35 mm Hg)|A patient is considered 'hypocapnic' if the etCO2 was < 35 mm Hg at any point during surgery, from start of the study till end of the study and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
75793835|NCT05536713|Device|Guardant SHIELD blood-based colorectal cancer screening test|The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.
75793836|NCT05532046|Drug|BAY2413555 Dose 1|BAY2413555 Dose 1
75793837|NCT05532046|Drug|BAY2413555 Dose 2|BAY2413555 Dose 2
76085088|NCT02507934|Device|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
76085089|NCT02234128|Device|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
76085090|NCT02504112|Other|there is no intervention|
76085091|NCT01622296|Drug|Sodium bicarbonate|8.4% neutralizing solution
76085092|NCT01622296|Drug|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
76085093|NCT02728830|Drug|Pembrolizumab|Pembrolizumab 200mg IV
75336296|NCT00003502|Procedure|cancer prevention intervention|
75336297|NCT00003502|Procedure|complementary and alternative therapy|
75336298|NCT00003502|Procedure|differentiation therapy|
75336299|NCT00003034|Drug|doxorubicin hydrochloride|Given IV
75336300|NCT00003034|Drug|ranpirnase|Given IV
75336301|NCT03862352|Device|Covered coronary stent|Insertion of covered coronary stent as part of standard care
75336302|NCT00003040|Procedure|laser surgery|CO2 supraglottic laryngectomy within 28 days following registration with neck dissection as needed
75336303|NCT00003040|Radiation|radiation therapy|200 cGy per day, five days per week for approximately 6 weeks, to begin 14 days after laser surgery
75336304|NCT04389398|Device|pocket compression fixation belt|Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
75336305|NCT00383890|Drug|Dexmedetomidine HCL Injection|
75336306|NCT00383890|Drug|Placebo|
75336307|NCT00003046|Biological|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
75336308|NCT00003052|Drug|doxorubicin hydrochloride|
75336309|NCT00003052|Drug|etoposide|
75336310|NCT00003052|Drug|ifosfamide|
75793838|NCT05532046|Drug|Placebo to BAY2413555|Placebo to BAY2413555
75793839|NCT05529706|Other|Brain Health Program|The Brain Health Program employs 1-hour/week group-based training and education regarding modifiable Alzheimer's disease dementia risk factors delivered over a 12-week period. Participants will be assigned into a group of up to 20 participants, and participants will engage the Brain Health Program collaboratively, as administered by the program content leader (instructor), while also being monitored and supported by the tech leader (in accordance with the Diabetes Prevention Program model).
75646070|NCT01585857|Biological|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.
75793840|NCT05524233|Device|Active Transcranial Direct Stimulation|Subjects will receive a stimulation device to use up to 20 minutes daily for 4 weeks.
75793841|NCT05520541|Other|Exercise|Both groups will receive exercise-based training
75646071|NCT00970502|Drug|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
75930192|NCT02951338|Behavioral|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
75336311|NCT00003052|Procedure|conventional surgery|
75930193|NCT02951338|Other|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
75930194|NCT02934282|Drug|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
75930195|NCT02900976|Biological|Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes|Given IV
75930196|NCT02900976|Biological|Rituximab|Given IV
75930197|NCT02877433|Device|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
75930198|NCT02877433|Device|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
76085094|NCT01705288|Procedure|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
75336312|NCT00003052|Procedure|hyperthermia treatment|
75336313|NCT00003052|Radiation|radiation therapy|
75930199|NCT02862210|Drug|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
75930200|NCT02862210|Drug|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
75930201|NCT02825901|Dietary Supplement|Placebo|Ingest placebo drink 100ml/day for 8 weeks
75930202|NCT02825901|Dietary Supplement|Djulis-Buckwheat|Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
76085095|NCT01705288|Drug|intravenous narcotics|given for pain management after surgery per physician orders
76085096|NCT01705288|Drug|standard anesthesia|inhalant or intravenous during surgery
75336314|NCT03843944|Drug|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
75646072|NCT01329081|Other|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
75646073|NCT01329081|Other|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
75336315|NCT04754828|Other|Assigned to a rounding style|Team rounded on new admissions either in hallway or at the bedside
75336316|NCT00003058|Drug|troglitazone|
75336317|NCT04775732|Biological|infliximab therapeutic drug monitoring|dose optimization of infliximab based on a predefined dosing algorithm
75336318|NCT00003514|Drug|antineoplaston A10|
75336319|NCT00003514|Drug|antineoplaston AS2-1|
75336320|NCT00003514|Procedure|alternative product therapy|
75336321|NCT00003514|Procedure|biological therapy|
75336322|NCT00003514|Procedure|biologically based therapies|
75336323|NCT00003514|Procedure|cancer prevention intervention|
75336324|NCT00003514|Procedure|complementary and alternative therapy|
75336325|NCT00003514|Procedure|differentiation therapy|
75472836|NCT01963416|Dietary Supplement|Processed whole orange|
75793842|NCT05516459|Biological|Pfizer BNT162b2 Vaccine|The Pfizer-BioNTech COVID-19 vaccine (INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada
75793843|NCT05508763|Genetic|Genetic test for 14 pharmacogenes|Genotyping with the Global Diversity Array-8 v1.0 BeadChip with enhanced PGx
76085097|NCT01705288|Drug|regional anesthesia|given by spinal or epidural infusion
76085098|NCT01705288|Drug|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
75336326|NCT04775498|Behavioral|Face-to-face psychoeducation group|All of the investigation centers participating in this study have a psychoeducation programme on bipolar disorders labeled and monitored by their Regional Health Agency. For this, he must respect the decree of January 14, 2015 relating to the specifications of therapeutic education programs for the patient. Patients will be receive by an investigator, for inclusion and baseline evaluation and at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
75646074|NCT04286204|Other|Basic Life Support training based on ICTs|This intervention is defined as a self-training course consisting of a 5-minute educational video in basic life support and a Kit with the elements to build the home dummy and the home DEA allowing integrally students to develop the steps as the video. The Kit will be delivered at the beginning of the study and every month the necessary materials will be complemented. The strategy will be carried out by the students every month and supervised by their teachers. Students will have constant access to an educational platform based on ICTs.
75793844|NCT05505617|Other|Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.|"Device: Jaeger Masterscreen TM (PFT Pro, Vyaire, Hoechberg, Germany)~Device: HypAir Medisoft (Medisoft, Dinant, Belgium)"
75793845|NCT05500274|Other|Education|Testimonial videos will be played including those that describe the testing experience and their motivations for testing. This approach combines self-affirmation with misinformation correction to take advantage of the ability to promote adaptive COVID-19 prevention behaviors. The self-affirmation activity will always precede the presentation of the testimonial videos as leading with misinformation correction can be construed by some as a threat to one's self-adequacy.
75793846|NCT05500274|Other|Motivational|This is a Type I network intervention that includes specific training on mobilization of network members. Training occurs in a group-based setting of 8-10 enrolled participants facilitated by a community facilitator and Motivational Interviewing trained interventionist. At 30 days, a 15-20-minute phone booster communication session reinforces the intervention content
75793847|NCT05497531|Diagnostic Test|ctDNA Blood Collection|Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
75793848|NCT05496231|Biological|HPV9 High formulation|3 doses of a high formulation investigational adjuvanted HPV9 vaccine intramuscularly (IM) on Day 1, Month 2, and Month 6.
75793849|NCT05496231|Biological|HPV9 Medium formulation|3 doses of a medium formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.
75793850|NCT05496231|Biological|HPV9 Low formulation|3 doses of a low formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.
75930203|NCT02825901|Dietary Supplement|Buckwheat|Ingest Buckwheat drink 100ml/day for 8 weeks
75930204|NCT02717962|Drug|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
75930205|NCT02693535|Drug|Palbociclib|drug
75930206|NCT02693535|Drug|Sunitinib|drug
75930207|NCT02693535|Drug|Temsirolimus|drug
75930208|NCT02693535|Drug|Trastuzumab and Pertuzumab|drug
75930209|NCT02693535|Drug|Vemurafenib and Cobimetinib|drug
75930210|NCT02693535|Drug|Regorafenib|drug
75930211|NCT02693535|Drug|Olaparib|drug
75930212|NCT02693535|Drug|Pembrolizumab|drug
75930213|NCT02693535|Drug|Nivolumab and Ipilimumab|drug
75930214|NCT02693535|Drug|Abemaciclib|drug
75930215|NCT02693535|Drug|Talazoparib|drug
75930216|NCT02693535|Drug|Atezolizumab and PHESGO|drug
75930217|NCT02693535|Drug|Atezolizumab and Talazoparib|drug
75930218|NCT02693535|Drug|Entrectinib|drug
75930219|NCT02693535|Drug|Larotrectinib|drug
75930220|NCT02693535|Drug|Tucatinib plus Trastuzumab Subcutaneous (SC)|drug
75930221|NCT02693535|Drug|Futibatinib|drug
76085099|NCT02507778|Device|CellCollectorTM (Gilupi, Germany) needle|needle will be inserted before and after biopsy and will measure circulating tumor cells.
76085100|NCT01707238|Device|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
76085101|NCT01707238|Device|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
76085102|NCT02507622|Other|measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|
76085103|NCT02507622|Other|Parabolic flight|
76085104|NCT02507466|Behavioral|exercise|Variable conditions of stepping practice
76085105|NCT03343002|Drug|fentanyl at 10-15 min before end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
75793851|NCT05496231|Biological|Gardasil 9|3 doses of the marketed HPV vaccine (Gradasil 9) administered IM on Day 1, Month 2, and Month 6.
75930222|NCT02693080|Device|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
75930223|NCT02693080|Drug|Isovue-200|Contrast agent
75336327|NCT04775498|Behavioral|SIMPLe mobile application|The experimental intervention consists of 12 months use SIMPLe smartphone application who has been developed by the Barcelona Institute of neuroscience. The purpose of this application is to deliver individualized psychoeducation messages to the patient's clinical condition. The psychoeducational messages correspond to the contents of the different modules and sessions carried out in face-to-face psychoeducation groups (Colomm & Vieta ; 2015). Patients will be receive by an investigator for inclusion and baseline evaluation, at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
75646075|NCT04286204|Other|Classic Basic Life Support training|It is defined as a module carried out by trained personnel in basic resuscitation (pre-hospital care program staff of the UdeA medical school), which includes two subcomponents of the conventional BLS course that are basic resuscitation and DEA in adults. The duration of the subcomponents is a theoretical part of 30 minutes and a practical part in a low fidelity simulator with 1.5 hours duration.
75472837|NCT01963429|Procedure|radiofrequency ablation|"* RFA(radiofrequency ablation )~RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)~performed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm~the duration of a single RFA session was 10 min to 15 min."
75472838|NCT01963429|Radiation|Proton beam therapy|"* Proton~66 GyE /10 fx, 6.6 GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume),TLV30<40%,and/orRLV30<30%)"
75472839|NCT01963442|Radiation|Chest X-ray|at Day 0, Day 30 and relapse
75472840|NCT01963442|Biological|blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|
75472841|NCT01963442|Drug|Augmentin|2 tablets 3 times a day for 5 days from Day 3
75472842|NCT01963442|Drug|Placebo (for Augmentin)|2 tablets 3 times a day for 5 days from Day 3
75646076|NCT02635815|Procedure|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
75793852|NCT05495555|Device|INTREPID® Hybrid tip|INTREPID® Hybrid tip for cataract removal
75793853|NCT05494255|Other|Recruitment maneuver|In Group RM (intervention group) after skin closure, mechanical ventilation settings will be set to FiO2:100%, I:E=1:1, respiratory rate: 6, and then tidal volume will be increased gradually by 150 ml until reaching a plato pressure of 30 mmHg. After 3 breaths in this state, RM will be considered accomplished. LUS evaluation will be made just before and after the RM.
75793854|NCT05493358|Procedure|Laparoscopic distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
75793855|NCT05490316|Drug|IBI353 (Orismilast)|dose 1 or dose 2
75793856|NCT05490316|Drug|placebo|placebo
75472843|NCT01963442|Drug|Beta-Lactams|administered from Day 0 to Day 3
76085106|NCT03343002|Drug|fentanyl at end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
76085107|NCT03120936|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open-label emtricitabine 200mg/tenofovir 300mg
76085108|NCT03120936|Behavioral|PrEP support|HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
76085109|NCT03121092|Drug|ACEI or ARB|Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
76085110|NCT02234752|Drug|Galantamine ER|
75472844|NCT01963455|Biological|paraurethral injection of MDCs|MDCs transplantation by paraurethral injection .
75472845|NCT01963468|Behavioral|Early language intervention|Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
75646077|NCT02635893|Drug|D-Cycloserine|100 mg of Seromycin by mouth will be administered
75930224|NCT02693080|Radiation|Computed Tomography Perfusion Imaging|
75930225|NCT02672917|Drug|MVT-5873|intravenous infusion (IV)
75646078|NCT02635893|Drug|Placebo|placebo pill will be administered instead of medication by mouth
75646079|NCT02635893|Other|Training|walking around a designated track at different speeds both forward and backward
75646080|NCT02635893|Other|Stimulation|magnetic stimulation and electrical stimulation may be applied
75646081|NCT02635893|Other|Placebo Stimulation|this is a fake stimulation that is administered but will be unknow to the subject.
75646082|NCT02635581|Device|Delta TT acetabular cup|
75646083|NCT02861456|Other|Standard Model of Care|
75930226|NCT02672917|Drug|modified FOLFIRINOX (mFOLFIRINOX)|IV
75930227|NCT02672917|Drug|gemcitabine + nab-paclitaxel|IV
75930228|NCT02672475|Drug|Galunisertib|Given PO
75930229|NCT02672475|Other|Laboratory Biomarker Analysis|Correlative studies
75930230|NCT02672475|Drug|Paclitaxel|Given IV
75930231|NCT02654015|Device|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
75930232|NCT02654015|Other|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
76085111|NCT02234752|Drug|Memantine XR|
75472846|NCT01963494|Behavioral|Dyadic planning intervention|Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
75793857|NCT05485428|Other|High-intensity interval training|12-weeks of high intensity interval exercise, 30 minutes thrice weekly
75336328|NCT00003520|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75793858|NCT05484466|Drug|ZM-H1505R|There are three groups in this study. ZM-H1505R will be used in group A and Group B ，Subjects can use it for 48 weeks Group A: 30 subjects； ZM-H1505R 50 mg QD +ZM-H1505R placebo； Group B: 30 subjects； ZM-H1505R 100 mg QD
76085112|NCT04496388|Behavioral|exercise|different type of exercise
75930233|NCT02620319|Device|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
75646084|NCT02861456|Other|Alternative Model of Care|
75930234|NCT02601755|Behavioral|iCanCope app and website|"In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources."
75646085|NCT04162509|Other|AR app|Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
75936476|NCT03188744|Other|Questionnaire application|Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.
76085113|NCT04496388|Behavioral|No exercise intervention|No exercise intervention
75646086|NCT04266314|Device|Maternal-fetal monitoring|Maternal-fetal monitoring evaluates fetal and maternal heart rate, maternal respirations, fetal movement, and maternal skin conductance (a way to monitor emotional response)
75793859|NCT05484466|Other|ZM-H1505R placebo|There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD
76085114|NCT02502084|Device|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
75336329|NCT04754750|Drug|Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]|
75336330|NCT04754750|Drug|Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]|
75336331|NCT00003532|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
75336332|NCT00003538|Biological|graft versus host disease prophylaxis/therapy|
75336333|NCT00003538|Procedure|allogeneic bone marrow transplantation|
75336334|NCT04779164|Diagnostic Test|knee ultrasonography|The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
75472847|NCT01963494|Behavioral|Individual planning intervention|Target persons form action plans on their own.
75472848|NCT01963494|Behavioral|General motivational treatment|Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
75472849|NCT01963507|Behavioral|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
75472850|NCT01963546|Other|different types of anesthesia|
75646087|NCT04266314|Other|NICU Network Neurobehavioral Scale|Evaluates neurobehavioral organization, neurological reflexes, motor development, and signs of stress and withdrawal of substance-exposed infants.
75793860|NCT05484466|Combination Product|Baraclude|All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
75793861|NCT05481996|Other|App-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a smartphone application created especially for the study that will contain a program of progressive physical exercises with images and descriptions, educational messages and an online booklet for the study subjects, totaling 8 weeks of training and pain education.
75793862|NCT05481996|Other|Online booklet|An online booklet containing information about chronic low back pain and weekly messages about low back pain causes, suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
75793863|NCT05479383|Other|Not applicable, this is an observational study|Not applicable, this is an observational study
76085115|NCT01664806|Device|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
75930235|NCT02601755|Behavioral|Attention control group|"The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies."
75930236|NCT02591563|Other|procedures|Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
75930237|NCT02572843|Drug|MEDI4736 (anti-PD-L1)|fixed dosing 750 mg
75930238|NCT02571946|Radiation|Proton beam therapy|
75930239|NCT02546583|Drug|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
75930240|NCT02546583|Drug|IV Chlorothiazide|
75472851|NCT01963546|Drug|Dexmedetomidine|After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
75793864|NCT05474352|Device|Allon System|Water garments (Allon system) already pre-filled with warm water will be set up before induction of anesthesia. After the induction of general anesthesia, the water garment will cover the lower and upper extremities, the lateral portion of the chest, and the entire back of the patient, which accounts for 70% of the body surface. The water garment will be opened temporarily on the upper extremities for intravenous access and arterial line placement and will be continued intraoperatively until the patient is transferred from the OR table to the stretcher
75930241|NCT02542696|Drug|APL-130277|"Used to treat up to 5 OFF episodes per day"
75930242|NCT02526329|Biological|donor regulatory T lymphocytes|Given IV
75930243|NCT02526329|Other|laboratory biomarker analysis|Correlative studies
75336335|NCT01958086|Device|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
75646088|NCT02635503|Procedure|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
75930244|NCT02503722|Other|Laboratory Biomarker Analysis|Correlative studies
75930245|NCT02503722|Drug|Osimertinib|Given PO
75930246|NCT02503722|Other|Pharmacological Study|Correlative studies
75336336|NCT05589662|Other|Clinical and functional assessment|The dependent variables (muscle strength, muscle activation, pressure pain threshold and joint status) and the outcome measures used to measure these variables will be: pressure dynamometer, surface electromyography, pressure algometer and Hemophilia Joint Health Score
75336337|NCT00003064|Biological|filgrastim|
75930247|NCT02503722|Drug|Sapanisertib|Given PO
75930248|NCT02464007|Biological|rSIFN-co|Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
75930249|NCT02378636|Device|600S|Monofocal Aspheric Intraocular Lens (IOL)
75930250|NCT02375165|Procedure|phlebotomy|phlebotomy for collection of plasma and serum, ~30 cc
75930251|NCT02346253|Radiation|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
75930252|NCT02346253|Drug|Bicalutamide|Given PO
75930253|NCT02346253|Drug|Leuprolide Acetate|Given IM or SC
75930254|NCT02346253|Drug|Goserelin Acetate|Given SC
75930255|NCT02346253|Drug|Triptorelin Pamoate|Given IM
75930256|NCT02346253|Drug|Degarelix|Given SC
75930257|NCT02346253|Other|Laboratory Biomarker Analysis|Correlative studies
75930258|NCT02346253|Other|Quality-of-Life Assessment|Ancillary studies
75930259|NCT02339740|Drug|Arsenic Trioxide|Given IV
75930260|NCT02339740|Drug|Cytarabine|Given IV
75930261|NCT02339740|Drug|Dexamethasone|Given PO or IV
75930262|NCT02339740|Drug|Idarubicin|Given IV
75930263|NCT02339740|Other|Laboratory Biomarker Analysis|Correlative studies
75930264|NCT02339740|Drug|Mitoxantrone Hydrochloride|Given IV
75930265|NCT02339740|Other|Quality-of-Life Assessment|Ancillary studies
75930266|NCT02339740|Other|Questionnaire Administration|Ancillary studies
75930267|NCT02339740|Drug|Tretinoin|Given PO
75930268|NCT02311179|Device|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
75930269|NCT02311179|Device|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
75930270|NCT02306993|Other|Healthy volunteers without SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
75936477|NCT04483700|Drug|Filgotinib|Tablets administered orally once daily
75930271|NCT02306993|Other|Healthy volunteers with SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
75793865|NCT05469334|Behavioral|DeStress for Health Program Participants|Behavioral: DeStress for Health Program The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals, with an additional class five as a check in that will be used for survey completion. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
75646089|NCT02635503|Procedure|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
75930272|NCT02306993|Other|Volunteers with SCD|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
75930273|NCT02290145|Drug|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
75930274|NCT02290145|Procedure|surgery group|The patients in the control group received the radical surgery and post-operative radiotherapy.
75930275|NCT02290145|Radiation|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
75930276|NCT02285543|Drug|TPF induction chemotherapy|"TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy"
75336338|NCT00003064|Drug|carboplatin|
75336339|NCT00003064|Drug|etoposide phosphate|
75336340|NCT00003064|Drug|paclitaxel|
75646090|NCT02635269|Other|Sugar|10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
75793866|NCT05466747|Biological|RYMPHYSIA|RYMPHYSIA administered through an IV injection.
75793867|NCT05466747|Biological|Another Available A1PI|Another available A1PI administered through an IV injection.
75930277|NCT02285543|Procedure|surgery|In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
75930278|NCT02285543|Radiation|radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
75336341|NCT00003064|Drug|thiotepa|
75336342|NCT00003064|Drug|topotecan hydrochloride|
75336343|NCT00003064|Procedure|peripheral blood stem cell transplantation|
75336344|NCT00003544|Drug|irinotecan hydrochloride|
75336345|NCT00003544|Procedure|surgical procedure|
75472852|NCT01963559|Drug|Lidocaine/prilocaine 1g (topical administration)|Cutaneous blood flow measurement using laser Doppler
75472853|NCT01963572|Other|SG will be screened every time when they visit the clinics.|
75472854|NCT01963624|Device|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
75472855|NCT01963637|Device|gastric tomodensitometry with gas at 3 months and 12 months|
75336346|NCT03475394|Other|Chlorhexidine gel|0.1 ml of Chlorhexidine gel was administered into the periodontal pocket
75336347|NCT03475394|Other|Morus alba gel|0.1 ml of Morus alba gel was administered into the periodontal pocket
75336348|NCT03475394|Other|Placebo|0.1 ml of Placebo gel was administered into the periodontal pocket
75336349|NCT01269424|Biological|MGMTP140K-encoding retroviral vector|
75336350|NCT01269424|Drug|O6-benzylguanine|
75336351|NCT01269424|Drug|temozolomide|
75336352|NCT01269424|Other|laboratory biomarker analysis|
75336353|NCT01269424|Procedure|autologous hematopoietic stem cell transplantation|
75336354|NCT01269424|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75336355|NCT01269424|Radiation|radiation therapy|
75472856|NCT01963663|Drug|Metformin|metformin 1000 mg daily in two divided doses of 500 mg tablets
75472857|NCT01963663|Drug|Pioglitazone|pioglitazone 30 mg daily in two divided doses of 15 mg tablets
75472858|NCT01963689|Other|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
75472859|NCT01963689|Other|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
75472860|NCT01963689|Other|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
75472861|NCT01963702|Drug|Docetaxol|
75472862|NCT01963702|Drug|Oxaliplatin|
75930279|NCT02234219|Procedure|Heart-shape anastomosis|a new operation approach for Hirschsprung disease
75930280|NCT02215928|Genetic|mutation analysis|Correlative studies
75930281|NCT02215928|Other|cytology specimen collection procedure|Correlative studies
75336356|NCT03395912|Drug|Intervention|After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
75646091|NCT02567773|Drug|GSK2881078|GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
75793868|NCT05463874|Behavioral|Mindful Self-Compassion Program|The intervention consists of 8 sessions, one per week for 8 weeks, that last 1 hour and 30 minutes each. These sessions will cover a variety of mindfulness and self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice.
75793869|NCT05463705|Behavioral|Intervention to address diffusion of responsibility|PCPs will receive an email from a peer offering encouragement and support in prescribing SGLT-2is and GLP-1RAs that includes specific components designed to reduce diffusion of responsibility. Specifically, these elements will be adapted from interventions that mitigate diffusion of responsibility in other contexts, including: (1) assigning responsibility to individuals or smaller groups, (2) increased perceived harm of the situation to be addressed (3) highlighting competence to act, and (4) modeling the desired behavior. The email will also contain a link to clinical and administrative information to support prescribing and an offer for direct support from the peer.
75793870|NCT05463705|Behavioral|Intervention to address diffusion of responsibility + simplification of prescribing|"PCPs will receive the same contact addressing diffusion of responsibility as in the Intervention to address diffusion of responsibility arm, but will additionally have access to an experienced administrative team for diabetes medication insurance authorization support, by routing their clinic note through the EHR. PCPs will be informed, suing the same email outreach, how to access the administrative team, which consists of medical and administrative assistants and currently supports prescribing within the endocrinology division. The team will follow up with the pharmacy to determine coverage, complete prior authorizations, determine alternate covered options, and track progress."
75793871|NCT05462561|Other|Quality-of-Life Assessment|Ancillary studies
75793872|NCT05462561|Procedure|Robotic Vascularized Composite Bladder Allograft Transplantation|Undergo robotic VCBA transplantation.
75930282|NCT02215928|Other|laboratory biomarker analysis|Correlative studies
75930283|NCT02163395|Device|FullCeram implant|FullCeram implantation
75930284|NCT02161900|Other|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
75930285|NCT02139605|Procedure|D3 Lymphadenectomy|D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
75930286|NCT01916317|Drug|0.5% lignocaine 60mM|
75930287|NCT01913132|Device|Negative pressure wound therapy with PICO (Smith & Nephew)|Negative wound pressure therapy
75930288|NCT01911897|Device|MobiusHD|Implant that is placed in the carotid sinus to control hypertension.
75930289|NCT01910909|Radiation|Stereotactic body radiotherapy|Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
75930290|NCT01785420|Drug|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
75646092|NCT02567773|Drug|Placebo|Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
75930291|NCT01785420|Drug|Placebo|A 90 minute intravenous infusion of saline as placebo
75930292|NCT01719887|Device|Conservative treatment|Conservative treatment with functional brace.
75930293|NCT01719887|Procedure|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
75930294|NCT01719887|Other|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
75930295|NCT01682941|Dietary Supplement|Arm I Soy Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
75930296|NCT01682941|Dietary Supplement|Arm II Soy-Almond Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
75930297|NCT01660607|Biological|Conventional T cells (Tcon) and Regulatory T cells (Treg)|A baseline cell dose of conventional T cells of 1x10^6/kg will be used with escalation to the maximum tolerated dose up to 1x10^7/kg
75930298|NCT01631292|Dietary Supplement|600 IU Vitamin D3|Once daily
75930299|NCT01631292|Dietary Supplement|2000 IU Vitamin D3|Once daily
75930300|NCT01631292|Dietary Supplement|4000 IU Vitamin D3|Once daily
75930301|NCT01589302|Drug|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
75936478|NCT04483700|Drug|Placebo to Match Filgotinib|Tablets administered orally once daily
75336357|NCT00003556|Biological|ALVAC-hB7.1|
75472863|NCT01963702|Drug|Capecitabine|
75646093|NCT02567773|Drug|Itraconazole|Subjects will be administered as two capsules of itraconazole 100 mg (200 mg) orally with water.
75646094|NCT04162197|Device|GEO|Robot-Assisted Gait Training (RAGT) The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
75930302|NCT01589302|Other|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
75930303|NCT01589302|Other|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
75930304|NCT01523223|Biological|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
75930305|NCT01447667|Procedure|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
75336358|NCT00003556|Biological|canarypox-hIL-12 melanoma vaccine|
75646095|NCT04162197|Device|GEO and HUNOVA|Robot-Assisted Gait Training (RAGT) and Balance Training. The Balance Group (GHG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland) and a Balance training using a robotic proprioceptive platform (Hunova - Movendo Technology, Italy).
75646096|NCT00967226|Drug|propranolol|propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
75646097|NCT00967226|Drug|Prednisolone|1.0 mg/kg orally, 2 per day 4-6 months
75646098|NCT00706381|Drug|Sincalide|
75793873|NCT05460754|Behavioral|Conventional-fed beef|Participants in the conventional-fed treatment of the study will consume a conventional-fed steak meal for breakfast one morning.
75930306|NCT01397552|Drug|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
75930307|NCT01397552|Drug|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
75930308|NCT01256710|Device|Trifecta™ aortic bioprosthesis|Surgical aortic valve replacement with the Trifecta™ valve.
75930309|NCT01096368|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
75930310|NCT01096368|Drug|Carboplatin|Given IV
75930311|NCT01096368|Drug|Cisplatin|Given IV
75930312|NCT01096368|Other|Clinical Observation|Patients undergo observation
75930313|NCT01096368|Drug|Cyclophosphamide|Given IV
75930314|NCT01096368|Drug|Etoposide|Given IV
75930315|NCT01096368|Biological|Filgrastim|Given SC or IV
75930316|NCT01096368|Other|Laboratory Biomarker Analysis|Optional correlative studies
75930317|NCT01096368|Drug|Mesna|Given IV
75930318|NCT01096368|Drug|Vincristine|Given IV
75472864|NCT01963715|Drug|IMGN289|
75472865|NCT01963741|Drug|leukotriene D4|Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was <30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.
75646099|NCT00706381|Drug|Ursodiol|
75646100|NCT00706381|Procedure|Fat Meal|600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate
75646101|NCT00706381|Procedure|Carb meal|600 calorie meal containing 100% carbohydrate
75646102|NCT00706381|Drug|Placebo|IV and/or oral placebo
75646103|NCT04283396|Combination Product|systemic treatment|Oxygen therapy, antiviral therapy, antibiotics, hormones, globulin
75646104|NCT04283474|Drug|XG005-03|3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation
75646105|NCT04283474|Drug|Placebo|Placebo topical formulation
75793874|NCT05460754|Behavioral|Organic grass-fed beef|Participants in the organic grass-fed treatment of the study will consume a organic grass-fed steak meal for breakfast one morning.
75793875|NCT05459454|Device|A digital health program for patients with Breast Cancer|A digital solution that supports healthy lifestyle changes, provides disease and side effect education as well as daily tasks for patients diagnosed with breast cancer.
75793876|NCT05456607|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
75930319|NCT01090908|Drug|Antibiotic|
75930320|NCT01057173|Procedure|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
75930321|NCT01057173|Procedure|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
75930322|NCT01048281|Procedure|Blood draw|
75930323|NCT01048281|Procedure|Tissue tumor biopsy|
75930324|NCT01020903|Procedure|Aprepitant|40 mg po pre-op
75930325|NCT01020903|Drug|Placebo|Orally, pre-op
75930326|NCT00984321|Behavioral|group intervention and questionnaires|Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
75936479|NCT02434406|Behavioral|internet-What Am I Worried About|This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
75936480|NCT02708966|Drug|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
75793877|NCT05456607|Behavioral|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
75930327|NCT00984321|Behavioral|individual phone intervention and questionnaires|Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
75930328|NCT00984321|Behavioral|expressive writing (arm will not be include in the randomization)|"intervention facilitate reappraisal through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions."
75930329|NCT00938587|Drug|PF-04171327 10 mg|PF-04171327 10 mg tablet every day for 14 days
75930330|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
75930331|NCT00938587|Drug|PF-04171327 25 mg|PF-04171327 25 mg tablet every day for 14 days
75930332|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
75930333|NCT00938587|Drug|Prednisone 5 mg|Prednisone 5 mg tablet every day for 14 days
75930334|NCT00938587|Other|Placebo for PF-04171327|Placebo for PF-04171327 every day for 14 days
75930335|NCT00938587|Other|Placebo|Placebo tablet every day for 14 days
75930336|NCT00938587|Other|Placebo for PF-04171327|Placebo tablet every day for 14 days
75930337|NCT00937937|Drug|Dinaciclib|Given IV
75930338|NCT00900497|Biological|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
75930339|NCT00898313|Genetic|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
75646106|NCT05727865|Behavioral|Online CBT following cardiac surgery|It will include psychoeducation, behavioral activation to address post-operative fatigue and depression, interoceptive exposure to reduce fear of cardiac-related symptoms and in-vivo exposure to reduce avoided situations, and activities to enhance physical activity and wellbeing. Labeling (i.e., describing post-operative and/or cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure and pain management
75793878|NCT05456607|Behavioral|Mood Monitoring|The mood monitoring intervention is based on mood tracking principles in broader mood management interventions, but without any psychoeducational content or cognitive-behavioral exercises. Instead, participants will get access to a mobile optimized web app that allows users to enter their mood, tag related events, and view trends over time to raise awareness of how activities influence certain mood states.
75336359|NCT03393338|Behavioral|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
75793879|NCT05452733|Behavioral|differences of behavior between sleepwalking and non sleepwalking patient|movement registry done by camera when low intensity sound are send to patient during sleep.
75930340|NCT00898313|Genetic|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
75930341|NCT00898313|Genetic|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
75930342|NCT00898313|Other|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
76085116|NCT02498886|Dietary Supplement|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
76085117|NCT02498886|Dietary Supplement|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
75336360|NCT00384436|Drug|escitalopram|
75336361|NCT04778696|Procedure|PASO Pacemapping|Using the PASO pacemapping visualisation module of CARTO3
75646107|NCT05727553|Radiation|Online adaptive radiotherapy|Postoperative radiotherapy will be indicated conform the standard medical care and guidelines. The radiation is delivered with online adaptive radiotherapy performed on the Ethos. This technique will be evaluated.
75646108|NCT05723185|Other|Outpatient visit|Patients will be seen and treated at the outpatient clinic like in the usual care
75646109|NCT05721469|Behavioral|Art therapy|Determining the mothers of children with eating disorders with the data obtained from the questionnaires and scales and separating them into randomized experimental and control groups, 8-12 sessions of 90 minutes of music, painting, ceramics, etc. were given to the mothers participating in the experimental group. Art Therapy Studies
75930343|NCT00898313|Procedure|nasal brushing|Using a brush, superficial cells are removed from the nose.
75930344|NCT00898313|Procedure|Blood draw|Venous blood will be collected
75930345|NCT00898313|Procedure|Urine collection|Subjects will be asked to provide a urine specimen.
75930346|NCT00898313|Procedure|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
75930347|NCT00898313|Procedure|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
75936481|NCT02708966|Drug|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
75336362|NCT04778696|Procedure|Conventional Pacemapping|without visualisation in 3D mapping
75793880|NCT05433298|Biological|Mesenchymal stem cell|Administration of advanced cell product
75646110|NCT00964886|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
75793881|NCT05433298|Other|Placebo|Ringer's lactate, albumin and heparin solution
75930348|NCT00898313|Procedure|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
76085118|NCT02499042|Drug|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
76085119|NCT01665040|Device|Neurostimulation device implantation|"Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan."
75646111|NCT00964886|Drug|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
75930349|NCT00898313|Procedure|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
75930350|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
75930351|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
75930352|NCT00810693|Drug|Placebo|Matching Placebo tid orally for 12 weeks
75930353|NCT00709150|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
75930354|NCT00709150|Behavioral|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
75336363|NCT00384514|Device|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
75336364|NCT00003562|Drug|carboplatin|
75336365|NCT00003562|Drug|docetaxel|
75336366|NCT04775576|Other|Pleth Variability Index|Conventional fluid management is widely used in clinical practice. In this method, the fluid need of the patient is decided according to pulse, arterial blood pressure, central venous pressure, urine output and clinical condition. In the targeted fluid therapy method, besides static parameters such as pulse, arterial blood pressure, central venous pressure; Dynamic parameters such as Stroke volume variability (SVV), pulse pressure variability (PPV), pleth variability index (PVI), continuous hemoglobin (SpHb) are also used noninvasively.
75336367|NCT04775576|Other|Conventional fluid theraphy|8-10 ml / kg / hour iv fluid maintenance will be started for the control group. If the mean arterial pressure (MAP) is <65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
75472866|NCT01963741|Drug|histamine|Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was <30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
75472867|NCT01963754|Device|Dental Implants in Posterior Mandible|Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
75472868|NCT01963754|Drug|Subperiosteal 1:100.000 Articaine 4% epinephrine|Administration of subperiosteal anesthesia for implant placement
75646112|NCT00964886|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
75472869|NCT01963754|Drug|Loco-regional 1:100.000 Articaine 4% epinephrine|Administer loco-regional anesthesia for implant placement in posterior mandible
75646113|NCT00964886|Drug|benztropine mesylate 0.125 mg daily|benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
75472870|NCT01963806|Behavioral|Smartphone-supplemented iCBT|"The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support."
75646114|NCT00964886|Drug|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
75646115|NCT02861222|Drug|Doxorubicin|
75646116|NCT04062019|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 once every other day, for 3 months.
75646117|NCT02862158|Device|FDT visual field|
75646118|NCT02862158|Device|Standard HVF|
75930355|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
75930356|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
75930357|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
75930358|NCT00655200|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75930359|NCT00381641|Other|Laboratory Biomarker Analysis|Optional correlative studies
75793882|NCT05411393|Other|ADL-enhanced program|The ADL-enhanced program consists of six home visits delivered by a study occupational therapy staff. The study therapy staff will use the compensatory approach and the restorative approach during the visits to enhance patients' activity engagement. The compensatory approach uses strategies to reduce the activity demand to make every task easier. For example, using the sitting position to perform self-care tasks. The restorative approach uses strategies to increase the demand of the task to increase the patient's functional capacity. For example, carrying a full-load laundry basket versus an empty laundry basket.
75336368|NCT04775576|Other|Anesthesia method|All patients included in the study will be premedicated with 1mg of midazolam after monitoring with pulse, non-invasive blood pressure, oxygen saturation. Then, invasive arterial cannulation will be applied and continuous blood pressure monitoring will be done. In the PVI group, non-invasive PVI and SpHb monitoring will also be performed from the other upper extremity without arterial cannulation. After two minutes of preoxygenation, anesthesia induction will be started. Anesthesia induction doses used routinely in our clinic include iv 2 mg / kg propofol, 0.6 mg / kg rocuronium and 2 μg / kg fentanyl. Sevoflurane will be administered by inhalation during anesthesia maintenance after tracheal intubation.
75930360|NCT00381641|Other|Pharmacogenomic Study|Optional correlative studies
75793883|NCT05411393|Other|Usual home health rehabilitation therapy|Usual home health rehabilitation therapy is prescribed by the home health agency. It often includes occupational therapy and physical therapy delivered in one to three home visits per week for one to two months.
75930361|NCT00381641|Drug|Sunitinib|Given PO
75930362|NCT00381641|Drug|Sunitinib Malate|Given PO
75930363|NCT00334815|Biological|Bevacizumab|Given IV
75646119|NCT04061863|Drug|Nivolumab|Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
75646120|NCT02862236|Drug|Hypericum perforatum extract|250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.
75793884|NCT05409807|Device|Ultrasound guided smart glasses assisted|Ultrasound guided smart glasses assisted interscalene nerve block
75930364|NCT00334815|Drug|Cisplatin|Given IV
75930365|NCT00334815|Drug|Docetaxel|Given IV
75930366|NCT00334815|Drug|Etoposide|Given IV
75930367|NCT00334815|Biological|Filgrastim|Given SC
75930368|NCT00334815|Biological|Pegfilgrastim|Given SC
75336369|NCT00003568|Biological|aldesleukin|
75472871|NCT01963806|Behavioral|Therapist support|The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.
75472872|NCT01963806|Other|Active waiting list|Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
75930369|NCT00334815|Radiation|Radiation Therapy|Undergo thoracic radiotherapy
75336370|NCT00003568|Biological|gp100 antigen|
75336371|NCT00003568|Biological|incomplete Freund's adjuvant|
75336372|NCT00003070|Drug|enalapril maleate|
75472873|NCT01963819|Other|Endometrial biopsy|The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
75472874|NCT01963832|Drug|Fluoxetine|
75472875|NCT01963832|Drug|Placebo|
75472876|NCT01963832|Procedure|eCMIT|
75646121|NCT04063111|Device|vacuum assistant closure|Expose the open wound bed to negative pressure. This pressure removes edema or hemorrhage, mechanically pulls on the wound edges, decreases in wound surface area, improves circulation, and enhances proliferation of granulation tissue that filled the soft tissue defect.
75646122|NCT04063111|Device|CONVENTIONAL DRESSING|CONVENTIONAL DRESSING for wound of open fracture of tibia grade III B
75646123|NCT04284878|Genetic|PCR-RFLP|PCR-Restriction fragment length polymorphism
75793885|NCT05409807|Device|Ultrasound guided|Ultrasound guided interscalene nerve block
75793886|NCT05408988|Diagnostic Test|hs-TnT (high-sensitive cardiac troponin T) plasma concentration|hs-TnT plasma concentration measured once every 12 hours
75793887|NCT05408988|Diagnostic Test|CK-MB (creatine kinase myocardial band) plasma concentration|CK-MB plasma concentration measured every 12 hours
75793888|NCT05408988|Diagnostic Test|CPK (creatine phosphokinase) plasma concentration|CPK plasma concentration measured every 12 hours
75930370|NCT00186147|Procedure|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
75930371|NCT05269563|Other|Surgical intervention|Pars Plana Vitrectomy for Macular Hole Closure
75930372|NCT05267834|Procedure|Conization and/or Hysterectomy|Women undergoing cervical conization or simple/modified/radical hysterectomy with or without pelvic lymphadenectomy
75930373|NCT05266287|Dietary Supplement|a supplement containing 2'-fucosyllactose (2'-FL)|Participants will be asked to take a commercially available dietary supplement containing 833 mg of 2'-FL, 220 mg of a blend of organic beet root and okra fruit, 100 mg of Collinsonia root, 37.5 mg organic rice hull concentrate, and 14 mg calcium stearate.
75930374|NCT05266287|Dietary Supplement|Placebo Supplement|Participants will be asked to take a placebo supplement containing 510.9 mg organic sucanat, 385.4 mg calcium phosphate, 304.7 mg cellulose, 143.4 mg date powder, 39.4 mg rice bran powder, 9.0 mg gum arabic, and 7.2 mg calcium stearate.
75930375|NCT05253547|Behavioral|Healthy climate-friendly dietary guidelines|Personalised climate-friendly healthy dietary recommendations
75930376|NCT05253547|Behavioral|Healthy dietary guidelines|Personalised healthy dietary recommendations
75930377|NCT05233982|Drug|Olaparib Oral Product|Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
75930378|NCT05226702|Biological|COVAC-2|Intramuscular vaccine against SARS-CoV-2
75930379|NCT05226702|Biological|Saline Placebo|Intramuscular injection of saline placebo
75930380|NCT05221450|Procedure|primary endodontic treatment|
75936482|NCT02429726|Drug|rAdp53|Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
75336373|NCT00003070|Procedure|quality-of-life assessment|
75472877|NCT01963832|Procedure|Usual Care|
75472878|NCT01963858|Procedure|Functional relaxation|Functional relaxation during colonoscopy
75472879|NCT01963858|Procedure|No relaxation|No relaxation during colonoscopy
75646124|NCT04285502|Procedure|SURGICAL DRAIN|A surgical drain is a tube used to remove blood, abscess and any type of fluid at the site of the place it is inserted
75646125|NCT02568163|Other|Non surgical periodontal treatment|
75646126|NCT02861378|Drug|Phentolamine mesylate|Injection of 1ml at lidocaine injection site
75646127|NCT02861378|Drug|Water|Injection of 1ml of physiologic saline water at injection site
75646128|NCT03630224|Drug|Plasmalyte Viaflo|Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
75646129|NCT03630224|Drug|NaCl 0.9%|Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
75646130|NCT04062955|Dietary Supplement|Dietary Intervention|Receive dietary counseling
75646131|NCT04062955|Procedure|Dual X-ray Absorptiometry|Undergo DXA scan
75646132|NCT04062955|Other|Questionnaire Administration|Ancillary studies
75646133|NCT03616028|Device|left atrial appendage closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the CLAAS device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
75646134|NCT03601832|Procedure|4-D navigated stereotactic radiosurgical ablation|4-D Navigated Non-invasive radiosurgical ablation of ventricular tachycardia in patients with sustained monomorphic ventricular tachycardia/tachycardias after myocardial infarction.
75646135|NCT00705757|Drug|latanoprost|Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
75646136|NCT00705757|Drug|bimatoprost|Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
75646137|NCT00705757|Drug|travoprost|Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
75646138|NCT04284644|Drug|Induction using propofol|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.
75646139|NCT04284644|Drug|Induction using sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 8% inhalational sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen.
75646140|NCT04284644|Drug|Induction using propofol and sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 4% sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
75930381|NCT05218967|Other|Virtual Reality Headset|A head-worn apparatus that completely covers the eyes for an immersive 3D experience. The VR headset will be worn during the procedure.
75930382|NCT05209100|Procedure|Sigmoidoscopy|During the sigmoidoscopy, biopsy tissue will be obtained for research purposes. Biopsies will be performed based on typical standard of care procedures without an antecedent bowel prep.
75930383|NCT05209009|Biological|COVAC-2|Intramuscular vaccine against SARS-CoV-2
75930384|NCT05209009|Biological|Saline Placebo|Intramuscular injection of saline placebo
75930385|NCT05208567|Diagnostic Test|Echocardiogram|Cardiac Ultrasound Scan - using an abbreviated protocol
75930386|NCT05199493|Drug|Angiotensin II|Patients with Delta-renin >= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.
75930387|NCT05199493|Drug|Control|Patients with Delta-renin >= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo
76085120|NCT04494984|Drug|INM005|The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
75930388|NCT05193279|Biological|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
76085121|NCT04494984|Drug|Placebo|Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
76085122|NCT01665508|Drug|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
75936483|NCT02429726|Drug|Cisplatin|Cisplatin will be administered by intra chest cavity infusion
76085123|NCT02507544|Drug|TRX-818 capsules|
76085124|NCT03344094|Drug|ocrelizumab|FDA-approved MS drugs
75336374|NCT03240536|Other|Choosing Wisely form|"The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.~The three guidelines included will be:~Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).~Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology~Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management."
75336375|NCT00003076|Drug|eflornithine|
75336376|NCT01896518|Drug|Nicotine polacrilex|
75336377|NCT01896518|Drug|Tobacco lozenge|
75336378|NCT00003082|Biological|monoclonal antibody A27.15|
75336379|NCT00003082|Biological|monoclonal antibody E2.3|
75336380|NCT04775186|Procedure|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
75336381|NCT00003088|Drug|cyclophosphamide|given IV
75336382|NCT00003088|Drug|doxorubicin hydrochloride|given IV
75336383|NCT00003088|Drug|paclitaxel|given IV
75336384|NCT04774874|Drug|Topical formulation|Topical administration on the scalp once daily for 16 weeks
75930389|NCT05189236|Procedure|Control Group (Only Algorithm of Febrile Neutropenia Management)|"Common Procedure Steps~The child is admitted to the unit and evaluated.~The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.~The inclusion and exclusion criteria are evaluated.~The group of the child to be included in the study is determined in accordance with the randomization order.~The first section of the patient information and follow-up form is filled out.~The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.~Procedure Steps for Control Group:~Common procedure steps are followed.~The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
75930390|NCT05189236|Procedure|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|"Procedure Steps for Experiment Group:~Common procedure steps are followed.~Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).~The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
75930391|NCT05178017|Diagnostic Test|Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program|The LEAP program is based on the in-vitro Leukocyte Activation Assay (LAA-MRT) results and initially prepared with the least immune reactive foods and chemicals, and subsequent foods will be added depending on the degree of immune reactivity in a nutritionally balanced manner.
75930392|NCT05157906|Behavioral|Education based|The interventional materials will be provided digitally for 12 weeks, with the monthly theme featured from the educational Grow Happy book and related tips and videos that will be released weekly.
75930393|NCT05157906|Behavioral|Control|At enrollment, subject will be provided with the Mother and Child booklet, which is the Indonesian standard of care for parenting guidance.
75930394|NCT05112536|Drug|Trilaciclib|Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
75930395|NCT05112536|Drug|Cylophosphamide|Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
75336385|NCT00003094|Other|preventative dietary intervention|
75336386|NCT04775030|Drug|CBD occlusal appliance|Occlusal appliance manufactured with CBD molecules released from material to patients oral cavity during sleep time
75336387|NCT04775030|Device|Acrylic resin occlusal appliance|Acrylic resin occlusal appliance during sleep time
75336388|NCT00003100|Dietary Supplement|soy isoflavones|
75646141|NCT05330143|Drug|ASC22 1mg/kg|ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.
75646142|NCT05330143|Drug|ASC22 2.5mg/kg|ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.
75793889|NCT05408988|Diagnostic Test|NT-proBNP (N-terminal prohormone of brain natriuretic peptide) plasma concentration|NT-proBNP plasma concentration measured every 12 hours
75793890|NCT05408988|Diagnostic Test|Metanephrine concentration in urine|Metanephrine concentration measured in 12-hour urine collection using spectrophotometry.
75793891|NCT05406362|Drug|VAD044|capsules to be taken once daily for 12 weeks
75930396|NCT05112536|Drug|Doxorubicin|Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
75930397|NCT05112536|Drug|Paclitaxel|Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
75646143|NCT05330143|Drug|Antiretroviral Therapy|standard antiretroviral therapy including Integrase inhibitors (INSTIs)
75646144|NCT05330143|Drug|Placebo|0.9% saline vials administered subcutaneously once 4 week.
75793892|NCT05404581|Device|neuromodulation|"During the inpatient phase of the study, insular mapping will be performed with electrical stimulation to implanted SEEG electrodes in order to optimize the region for trial stimulation.~Subjects who respond favorably to trial stimulation in the hospital, will progress to the outpatient clinical trial phase where a DBS system will be implanted. All subjects will be blindly randomized to 3 months of stimulation and 3 months of sham stimulation."
75793893|NCT05399654|Drug|TAC-001|TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)
75793894|NCT05395793|Other|Support Group|Support Group with moderator
75793895|NCT05393791|Other|Patient-specific adaptive therapy|Patients will start taking abiraterone or enzalutamide (AA/ENZ) daily. PSA will be measured every month as well as radiological evaluation by CT-scan and bone scan. Treatment will be continued until PSA has dropped >50%. The treatment will then be paused. Once the PSA has risen again above the pretreatment baseline, treatment will be re-initiated. AA/ENZ will be stopped again after the PSA declines >50% from the baseline. This will be continued until criteria for treatment failure are met (death by any cause or at least 2 out of 3 of the following events while on treatment: radiographic progression on CT-scan and/or bone scan, PSA progression or clinical progression).
75793896|NCT05393791|Drug|Abiraterone acetate|Use of abiraterone or enzalutamide
75793897|NCT05393791|Drug|Enzalutamide|Use of abiraterone or enzalutamide
75336389|NCT00755560|Drug|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
75336390|NCT00755560|Drug|Placebo|Placebo BID for 15 days
75336391|NCT05405894|Drug|Zoledronic acid|Once-yearly infusion of zoledronic acid following denosumab discontinuation
75336392|NCT00003118|Drug|cisplatin|
75336393|NCT00003118|Drug|fluorouracil|
75336394|NCT00003118|Procedure|surgical procedure|
75336395|NCT00003118|Radiation|radiation therapy|
75336396|NCT00003124|Drug|flutamide|
75336397|NCT00003124|Drug|leuprolide acetate|
75336398|NCT00003124|Radiation|radiation therapy|
75336399|NCT00003574|Procedure|surgical procedure|
75336400|NCT00003574|Radiation|brachytherapy|
75336401|NCT00003574|Radiation|intraoperative radiation therapy|
75336402|NCT00003574|Radiation|iodine I 125|
75930398|NCT05112536|Drug|Carboplatin (Investigator discretion)|Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
75930399|NCT05112536|Biological|Pembrolizumab (Investigator discretion)|Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).
75646145|NCT04284956|Procedure|Proximal and distal segment of saphenous vein harvested by No-Touch technique|two longitudinal incisions are made on the thigh and shank from unilateral lower limb (for harvesting of proximal segment of saphenous vein, incision is started from about 3 or 4cms inferolateral to the pubic tubercle and then extended downward). As previous reported. the adventitia and perivascular tissue are carefully kept intact to avoid damage. Then a margin of about 5 mm from both sides of the vein is created to include the fat pedicle using electrocautery, and all visible side branches are ligated with 4-0 silk or by metal clipping (branches are divided at the pedicle margin rather than the vein trunk). The saphenous vein is then separated from its bed using scissors and electrocautery, together with surrounding tissue.
75930400|NCT05109455|Dietary Supplement|MANOSAR®|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
76085125|NCT03343392|Drug|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
76085126|NCT03343392|Drug|Placebo group|One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
76085127|NCT03344016|Other|Contact by clinical center|Patients will be acitvely contacted by the clinical center for follow-up procedure
75472880|NCT01963871|Other|Yoga|Twice weekly one hour sessions of Hatha Yoga for 12 weeks
75336403|NCT00003580|Drug|amifostine trihydrate|
75336404|NCT00003580|Drug|cisplatin|
75472881|NCT01963884|Procedure|Tooth Extraction|Tooth from the maxillary anterior area extracted and alveolar socket remains intact
75646146|NCT02566837|Procedure|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
75646147|NCT02566837|Procedure|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
75930401|NCT05109455|Dietary Supplement|Proanthocyanidins|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
75930402|NCT05105269|Other|Treatment from a physiotherapist|Any treatment provided by a physiotherapist e.g. exercise, advice and massage
75930403|NCT05097014|Drug|CHF5993|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
75930404|NCT05097014|Drug|CHF1535|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
75930405|NCT05097014|Other|Matched placebo|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
75930406|NCT05085483|Dietary Supplement|Nutritional Ketogenic Supplement|This trial has 5 steps: (1) a 4-week run-in baseline; (2) a 4-week intervention phase to either active or placebo (3) a 4-week phase of washout; (4) the cross-over to the second 4-week active or placebo phase; (5) a 4-week follow-up.
75930407|NCT05085483|Dietary Supplement|Isocaloric placebo supplement|Isocaloric placebo supplement
75930408|NCT05079360|Drug|Sabizabulin|32mg each day by mouth
75930409|NCT05079360|Drug|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
75930410|NCT05078060|Biological|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
75930411|NCT05078060|Biological|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
75930412|NCT05066373|Drug|EDP1815 capsule A|EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
75472882|NCT01963884|Radiation|Cone-Beam technology evaluation|Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.
76085128|NCT03342924|Other|Flanker Test and physical fitness test|Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
76085129|NCT02498496|Drug|Magnesium Sulfate|Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
76085130|NCT02498496|Drug|Placebo|Administration of 100 mL of Normal Saline
75336405|NCT00003580|Radiation|radiation therapy|
75336406|NCT00056498|Drug|Placebo|Placebo capsule daily for 16 weeks
75336407|NCT00056498|Drug|Risperdal|Risperdal 4 mg per day for 16 weeks
75472883|NCT01963884|Other|Measure Alveolar Socket Remodeling|In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
75336408|NCT03066050|Other|MV Repair|Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
75336409|NCT03066050|Other|MV Replacement|Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
75336410|NCT03066050|Other|CABG|Participants underwent coronary artery bypass grafting
75930413|NCT05066373|Drug|EDP1815 capsule B|EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
75930414|NCT05066373|Drug|EDP1815 tablet|EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
75930415|NCT05063786|Biological|Trastuzumab|"6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule)*, or 600 mg SC every 3 weeks.~* If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
75930416|NCT05063786|Drug|Alpelisib|300 mg oral once daily.
76085131|NCT02502708|Drug|Indoximod|Indoximod will be administered orally twice daily.
76085132|NCT02502708|Drug|Temozolomide|Temozolomide will be administered on days 1-5 of every 28 day cycle.
76085133|NCT02502708|Radiation|Conformal Radiation|Conformal radiation will be administered on days 3-7 of induction cycle.
76085134|NCT02502708|Drug|Cyclophosphamide|Cyclophosphamide will be administered orally daily.
76085135|NCT02502708|Drug|Etoposide|Etoposide will be administered orally daily.
76085136|NCT02498574|Device|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
76085137|NCT02498574|Behavioral|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
76085138|NCT05473182|Other|IndieTrainer system|The IndieTrainer system is comprised of the IndieGo device and video-game modules. The IndieGo device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. The video-game modules are integrated into the IndieGo device such that the video games can be played on a TV screen using the specific access method used to control the IndieGo (i.e., switch or joystick). The IndieTrainer system is designed to allow a child to practice power wheelchair skills as part of the video-game modules or as part of more traditional power wheelchair skills training activities wherein children are able to actively explore the environment and practice executing actual wheelchair skills.
75336411|NCT04330144|Drug|Hydroxychloroquine as post exposure prophylaxis|1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
75930417|NCT05063786|Drug|Fulvestrant|500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.
75930418|NCT05063786|Drug|Vinorelbine|Oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.
75336412|NCT04330144|Other|Others(No intervention)|No treatment. Close monitoring and quarantine.
75336413|NCT00003130|Drug|paclitaxel|
75930419|NCT05063786|Drug|Capecitabine|1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.
75930420|NCT05063786|Drug|Eribulin|1.23 mg/m2 IV on days 1 and 8, every 3 weeks.
75930421|NCT05054335|Other|Functional Assessment|Undergo walking function assessment with optical motion capture
75472884|NCT01963910|Drug|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
75646148|NCT04284722|Drug|Metformin Hydrochloride|Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals
75930422|NCT05054335|Procedure|X-Ray Imaging|Undergo bi-plane dynamic X-ray imaging
75936484|NCT02429726|Drug|rAdp53 plus cisplatin|Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
75936485|NCT02429882|Drug|Brodalumab 210 mg|210 mg brodalumab will be administered subcutaneously
75936486|NCT02429882|Drug|Placebo|Placebo will be administered subcutaneously
75936487|NCT02429648|Procedure|DCC first then PVI|DCC performed prior to PVI
76085139|NCT02728596|Other|Preventive Intervention|Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN
75336414|NCT00058370|Drug|cisplatin|
75336415|NCT00058370|Drug|lomustine|
75336416|NCT00058370|Drug|vincristine sulfate|
75336417|NCT00058370|Procedure|adjuvant therapy|
75336418|NCT00058370|Radiation|iodine I 131 monoclonal antibody 3F8|
75336419|NCT00058370|Radiation|radiation therapy|
75336420|NCT00059228|Drug|17beta Estradiol|Alora 100 microgram per day by skin patch for 6 weeks.
75336421|NCT00059228|Drug|Placebos|Placebo skin patch for 6 weeks
75336422|NCT00060008|Radiation|fludeoxyglucose F 18|
75336423|NCT00060008|Radiation|gadopentetate dimeglumine|
75336424|NCT00062738|Drug|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
75336425|NCT00062738|Drug|Nortriptyline|nortriptyline 25 - 75 mg q hs
75336426|NCT00062738|Other|placebo|matching placebo
75646149|NCT04283240|Drug|Sildenafil|50 mg sildenafil, one dose
75646150|NCT04283240|Drug|Placebo|Placebo
75646151|NCT02862314|Biological|Blood sample|
75646152|NCT03588884|Drug|Calcifediol Oral Capsule|Capsule, daily
75646153|NCT03588884|Drug|Calcifediol Oral Product|Capsule, once a month
75646154|NCT03588884|Drug|Cholecalciferol|Capsule, once a month
75646155|NCT03588884|Drug|Paricalcitol Oral Capsule|Capsule, daily
75646156|NCT04285736|Drug|Ivabradine|Ivabradine (5mg twice daily)
75646157|NCT04285736|Drug|Conventional Treatment|
75936488|NCT02429648|Procedure|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
76085140|NCT02728596|Other|Quality-of-Life Assessment|Ancillary studies
76085141|NCT02728596|Other|Questionnaire Administration|Ancillary studies
76085142|NCT01707472|Biological|Simtuzumab|700 mg intravenously for a total of 12 infusions.
76085143|NCT01666210|Drug|OTX-DP (Dexamethasone punctum plug)|Sustained and tapered release of dexamethasone from hydrogel punctum plug
76085144|NCT01666210|Drug|Placebo Vehicle Punctum Plug|Hydrogel punctum plug without dexamethasone
76085145|NCT01666912|Drug|Contraceptive implant|
76085146|NCT03341988|Drug|Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram|To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
75793898|NCT05388773|Procedure|therapeutic conventional surgery|Transoral surgical resection of tumor(s).
75930423|NCT05045040|Behavioral|Mobile-based empathetic communication support program to promote ACP discussion|Patients in the intervention group are provided a mobile-based empathic communication support program-an app on a mobile phone. The app comprises a QPL (46 questions in eight categories) and questions about the patient's preferred treatment and end-of-life care based on their values and goals. Then, they proceed with the content themselves, at home or anywhere, at any time. Between app registration and the next outpatient visit, the patient is interviewed (by phone or in person) by a nurse or a clinical psychologist, who helps them prepare for the discussion with the physician and asks questions based on the patient's app responses for 30 minutes to an hour. During the outpatient visit, feedback is provided to patients and their physicians based on the interview. The duration between the start of app use and the next consultation is a minimum of one week and a maximum of four weeks.
75930424|NCT05036915|Procedure|Pacifier randomly|"Common Action Steps:~Legal representatives of newborns are informed about the study purpose, participants read and sign the informed consent form so their consent is obtained.~Inclusion and exclusion criteria are evaluated.~Study group is determined in line with the randomization order of the newborn to be included in the study.~First part of the patient information and follow-up form is completed.~Feeding content, amount and method are determined by the physician.~Action Steps of the Control Group:~* Pacifier is randomly given to the infant for 30 min independent from feeding during the day.~Common procedure steps are applied.~Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~Second part of the patient information and follow-up form is completed daily."
76085147|NCT02501850|Drug|Liraglutide|Treatment with liraglutide, exenatide or lixisenatide
75646158|NCT02862704|Biological|MG7-CART|Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
76085148|NCT02501850|Drug|metformin|Treatment with metformin and/or sulphonilurea
76085149|NCT01709032|Drug|Deferasirox and deferiprone|
76085150|NCT02498340|Dietary Supplement|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
75336427|NCT00063362|Drug|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
75336428|NCT00063362|Drug|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
75472885|NCT01963910|Drug|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
75472886|NCT01963936|Device|Supreme LMA|
75646159|NCT02862860|Biological|blood sample|
75646160|NCT02862860|Biological|urine sample|
75646161|NCT02862860|Device|installation of Holter|
75646162|NCT02862782|Drug|hCG (Ovitrelle 250 mcg mcg - Merck Serono)|
75646163|NCT02862782|Drug|hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)|
75646164|NCT00630188|Other|You Decide|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
75472887|NCT01963936|Device|Facial mask|
75472888|NCT01963962|Drug|Copper IUD|
75472889|NCT01963962|Drug|Levonorgestrel IUD|
75646165|NCT00630188|Other|Reducing Your Risks in the Crash|Publicly available video on highway safety and reducing individual risks in a crash
75646166|NCT04283162|Drug|Calcium Dobesilate|use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months
75646167|NCT04283162|Other|conventional treatment|maintain lifestyle habits and the usual treatment
75646168|NCT02861924|Other|microcirculatory responses|"The effect of the duration and intensity of the pressure; reproducibility and correlation with ischemic hyperemia post.~measurements are made with the Imager SPECKLE imager (LSCI) give the microvascular perfusion data in arbitrary units called perfusion units (UP)."
75646169|NCT04282772|Diagnostic Test|Impacted|Until an active treatment for the PFM is started or the early exfoliation of PSM occurs, the tooth remains in a self-locking position
75646170|NCT04282772|Diagnostic Test|Self-corrected|The ectopic erupted permanent molar can disregard the self-locking position and continue in a normal direction, but the distal root of the PSM remains more or less a significant atypical resorption
75646171|NCT02859818|Other|therapeutic education program|
75646172|NCT02860052|Drug|SB208 2%|Apply once daily to one or both feet for 14 days
75646173|NCT02860052|Drug|SB208 4%|Apply once daily to one or both feet for 14 days
75646174|NCT02860052|Drug|SB208 16%|Apply once daily to one or both feet for 14 days
75793899|NCT05388773|Other|laboratory biomarker analysis|Correlative studies
75793900|NCT05388773|Other|quality-of-life assessment|Ancillary studies.
75793901|NCT05388773|Radiation|intensity-modulated radiation therapy|Low-dose IMRT
75793902|NCT05388773|Drug|Cisplatin|Given IV.
75793903|NCT05388773|Drug|Carboplatin|Given IV
75793904|NCT05386537|Combination Product|MyoMo orthosis and VR games|Combining Wearable Robotic Orthosis with Visual and Haptic Feedback to Enhance the Recovery of Upper Extremity Motor Function and ADL in Persons with Acute SCI
75793905|NCT05386537|Device|MyoPro robot only|Using the MyoPro wearable robotic orthosis only
75793906|NCT05386537|Other|Games only|Using VR-video games only
75793907|NCT05386537|Other|Control|conventional UE therapy at a rehabilitation facility
75930425|NCT05036915|Procedure|Pacifier other|"Procedure Steps of the Experimental Group:~Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.~Common procedure steps are applied.~Pacifier is given for 5 min before each feeding.~Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~Second part of the patient information and follow-up form is completed daily."
75646175|NCT02860052|Drug|Vehicle Gel|Apply once daily to one or both feet for 14 days
75646176|NCT02861066|Behavioral|Mindfulness-based Intervention|MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
75336429|NCT00063362|Drug|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
75472890|NCT01963988|Procedure|Transurethral Coagulation (TUC)|
75472891|NCT01963988|Procedure|Transurethral Resection(TUR)|
75793908|NCT05385952|Device|GATT-Patch|"GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
75793909|NCT05385952|Drug|TachoSil|"TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge.~TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical."
75793910|NCT05384808|Behavioral|Standard Psychotherapy|Participants receive a standard psychotherapy session with no dog being present.
75472892|NCT01964001|Dietary Supplement|Vitamin B-6|Vitamin B-6 50 mg/d
75472893|NCT01964001|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 300 mg
75793911|NCT05384808|Behavioral|Canine-assisted psychotherapy with dog actively integrated.|A dog is present and actively integrated into the therapeutic narrative.
75793912|NCT05384808|Behavioral|Canine-assisted psychotherapy with dog passively integrated.|A dog is present but not actively integrated into the therapeutic narrative.
75646177|NCT00960752|Drug|gp100|1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
75646178|NCT00960752|Drug|R848 gel|Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
75793913|NCT05383521|Drug|Tinidazole 56|Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
75793914|NCT05383521|Drug|Tinidazole 42|Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
75930426|NCT05032612|Device|PBM Therapy|After the endodontic treatment, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, NC, USA), with an 8mm tip diameter.The laser tip will be placed on the following external surfaces in a contact mode: mesiobuccal, distobuccal, mesiolingual and distolingual . The power output of the laser will be 50mW and will be verified by Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2 .
75930427|NCT05032612|Device|PBM Sham|For the PBM sham similar procedure as PBM therapy will be performed without activating the laser.
75930428|NCT05012787|Biological|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Participants will receive 1 intramuscular (IM) injection of 30 microgram (mcg) SCB-2019 with CpG 1018/Alum adjuvant on Day 1 and on Day 22.
75930429|NCT05012787|Biological|Havrix|Participants will receive Havrix (Hepatitis A vaccine) containing 1440 Enzyme-linked Immunosorbent Assay (ELISA) units (EL.U.) in 1.0 mL dose on Day 1.
75930430|NCT05012787|Other|Placebo; 0.9% saline|Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 22.
75930431|NCT04996316|Other|Electronic Health Record Review|Health record reviewed
75930432|NCT04996316|Other|Interview|Participate in interview
75930433|NCT04996316|Other|Media Intervention|Use MammoScreen
76085151|NCT01667536|Drug|Drug: 99mTc-MIP-1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
75472894|NCT01964001|Dietary Supplement|Vitamin B-6+Coenzyme Q10|Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)
76085152|NCT02496078|Drug|Daclatasvir|Daclatasvir tablet 60mg
76085153|NCT02496078|Drug|Asunaprevir|Asunaprevir soft capsule 100 mg
75472895|NCT01964001|Other|Placebo|starch
75646179|NCT00960752|Drug|MAGE-3|1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
76085154|NCT02496156|Behavioral|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
75646180|NCT04281524|Drug|CSL312|CSL312 administered as an IV infusion
75646181|NCT04281524|Drug|Placebo|Solution of 70% 0.9% saline / 30% CSL312 diluent
75646182|NCT02859740|Other|SIGAM Questionnaire|
75646183|NCT00758524|Drug|LCI699|LCI699 oral capsules
75646184|NCT00758524|Drug|Eplerenone|Eplerenone oral capsules
75646185|NCT00758524|Drug|LCI699-matching Placebo|LCI699-matching placebo oral capsules
75646186|NCT00758524|Drug|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
75646187|NCT05466292|Other|Survey1|Closed-ended survey on the level of knowledge, use, and dissemination of the CEC.
75646188|NCT05466292|Other|semi-structured interview_1|the semi-structured interview concerns participants'motivations/expectations for implementing CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered
75930434|NCT04996316|Other|Survey Administration|Complete survey
75646189|NCT05466292|Other|semi-structured interview_2|semi-structured interview concerns participants motivations and expectations to be a member of the CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered.
75930435|NCT04996316|Other|Training and Education|Undergo training
75930436|NCT04991740|Drug|JNJ-78306358|JNJ-78306358 will be administered.
75930437|NCT04990167|Drug|Tiotropium Bromide|Using Tiotropium as a single agent asthma controller medication
75930438|NCT04988087|Drug|MHV370|MHV370 for 24 weeks
75336430|NCT00063362|Drug|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
75930439|NCT04988087|Drug|Placebo|Placebo for 24 weeks
75930440|NCT04981717|Drug|REGN1908-1909|Subcutaneous (SC) for a total of 5 administrations
75930441|NCT04981717|Drug|Matching Placebo|SC for a total of 5 administrations
76085155|NCT02496156|Behavioral|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
75930442|NCT04978207|Behavioral|A Faithful Response to COVID-19|See previous description
75930443|NCT04969575|Other|Insemination and culture|All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.
75930444|NCT04969575|Other|Media refreshment Group 1|Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3).
76085156|NCT01667848|Device|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
75930445|NCT04969575|Other|Culture media preparation and refreshment|"30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator."
75930446|NCT04969575|Other|Embryo grading|Should be done prior to media refreshment. For group 2, embryo grading and media refreshment is done prior to blastocyst biopsy.
75930447|NCT04969575|Other|Media refreshment Group 2|Zygote scoring on day 1 (18-20hpi). Culture media refreshment will be done 114-118 hours post insemination (Day5).
75930448|NCT04967183|Diagnostic Test|Annual FIT|"Patients will be offered an annual FIT and colonoscopy will be performed if fecal hemoglobin concentration is ≥10µg / g of feces. After performing a colonoscopy the FIT will be sent to the patient:~After one year if the unscheduled colonoscopy has been incomplete or a lesion requiring endoscopic surveillance has been completely resected.~After five years if the colonoscopy has evaluated the entire mucosa, it is normal or with lesions that do not require endoscopic surveillance (1-2 non-advanced adenomas)."
75930449|NCT04967183|Procedure|Endoscopic surveillance.|First surveillance colonoscopy will be performed in three-year time. If an advanced adenoma or at least three non-advanced adenomas are detected, colonoscopy will be repeated after 3 years. In contrast, if colonoscopy is normal or 1-2 non-advanced adenomas are detected, colonoscopy will be repeated after 5 years.
75930450|NCT04962035|Other|Neurocognitive Follow-up|Standard clinical and parent-reported outcomes on cognitive development, temperament and overall health conditions.
75930451|NCT04946292|Behavioral|Theory-derived intervention|The intervention will be delivered through multimedia materials and group activities, as appropriate. Participants will spend approximately 30-45 minutes for the intervention. Intervention materials and activities will be carefully designed to address all the constructs/ domains of the selected theoretical model(s). The effectiveness of the interventions will be evaluated using behavioural outcomes (diet, brushing, flossing) and clinical outcomes (oral hygiene, caries and periodontal conditions).
75930452|NCT04946292|Behavioral|Conventional health education|The conventional health education will be delivered through an oral health talk and oral health booklet. Topics covered are: (i) common oral diseases and its consequences; (ii) common dental problems among older adults; (iii) importance of oral health measures (healthy diet, toothbrushing and dental flossing); and (iv) proper techniques for toothbrushing and dental flossing.
75930453|NCT04918927|Drug|Favipiravir|Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7
75930454|NCT04918927|Drug|Nitazoxanide|Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7
75930455|NCT04918927|Other|Nitazoxanide Placebo|Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.
75930456|NCT04907084|Dietary Supplement|Serine|Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)
76085157|NCT01667848|Device|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
76085158|NCT02501694|Other|Auscultation|Electronic stethoscope
76085159|NCT02495922|Drug|elotuzumab|10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
75472896|NCT01964014|Drug|advagrf|"All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat."
75646190|NCT05466292|Other|semi-structured interview_3|semi-structured interview concerns participants' experiences with the ethics consultation service provide by the Clinical Ethics Committee
75930457|NCT04907084|Drug|Fenofibrate|Fenofibrate 160mg pill, taken orally
75930458|NCT04901247|Behavioral|media refreshment|20µL of culture medium is aspirated using Eppendorf PCR tips, and freshly, overnight equilibrated 20µL global total LP will be added to the same well
76085160|NCT02495922|Drug|Lenalidomide|25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
76085161|NCT02495922|Drug|Bortezomib|all arms: 1,3 mg/m^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
76085162|NCT02495922|Drug|Dexamethasone|"20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).~8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).~20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).~12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2)."
76085163|NCT01669096|Biological|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
76085164|NCT01709422|Drug|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
75793915|NCT05378854|Other|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home senor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
75336431|NCT00064844|Behavioral|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
75472897|NCT01964027|Drug|second line chemoregime for advanced gastric cancer|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
75646191|NCT05466292|Other|survey_2|survey of 20 multiple-choice questions and supplemented by free-text questions.
75646192|NCT02601196|Drug|Ulipristal acetate|"Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.~Another IVF cycle."
75646193|NCT00757588|Drug|Saxagliptin, 5 mg + insulin|Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)
75646194|NCT00757588|Drug|Placebo + insulin|Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
75646195|NCT02597764|Behavioral|Diaphragmatic Breathing|
75793916|NCT05376683|Device|Curate.AI|Personalized, continuous recommendations on anti-hypertensive medication dose titration using an AI-derived platform also known as Curate.AI
75793917|NCT05376683|Behavioral|Telemonitoring|Patients will report their blood pressure to a telemonitoring health platform
75930459|NCT04901247|Behavioral|embryo grading|embryo grading should be done prior to media refreshment
75930460|NCT04865913|Other|Observational|A brief 15 min phone call 1 week, 30 and 90 days post discharge.
75930461|NCT04857983|Drug|Memantine|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
75930462|NCT04857983|Drug|Placebo|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
75930463|NCT04850729|Other|non-intervention|non-intervention
75930464|NCT04846790|Behavioral|Nature Only|See above for description.
75930465|NCT04846790|Behavioral|Nature+Mindfulness|See above for description.
75930466|NCT04817267|Device|reSET-O app|The reSET-O app, a prescription digital therapeutic, provides cognitive behavioral therapy for opioid use disorder. The app provides psychoeducation related to opioid use, coping skills, and skills to avoid relapse.
76085165|NCT01709422|Drug|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
76085166|NCT01709422|Drug|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
76085167|NCT01669642|Drug|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
76085168|NCT01669720|Drug|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
75930467|NCT04800588|Diagnostic Test|California Cognitive Assessment Battery|The California Cognitive Assessment Battery (CCAB) is a collection of computerized cognitive tests that will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories. Previous versions of CCAB tests have been described in 16 manuscripts which describe (a) the psychometric characteristics of normative data collected in large participant populations (300 to 2,300 subjects for different tests) and (b) the sensitivity of CCAB tests for detecting performance abnormalities in patients with traumatic brain injury (TBI) and in control participants simulating the cognitive deficits that follow mild TBI.
76085169|NCT01670110|Drug|Pasireotide LAR|Injectible, 60mg per month
76085170|NCT01670110|Drug|Placebo|To be injected once per month
75793918|NCT05372289|Dietary Supplement|Immuno-nutrition|The experimental group of 68 older adults will be subjected to a preoperative immuno-nutrition for 30 days prior to surgery and up to 3 days after surgery. The oral feed provides energy, omega-3 fatty acids, arginine, nucleotides, and soluble fibre.
75793919|NCT05368506|Drug|Wee1 Inhibitor ZN-c3|Given PO
75930468|NCT04788836|Other|Questionnaire (Survey and Food Frequency Questionnaire (FFQ))|Each participant will be asked to fill a web-based questionnaire that captures sociodemographic, lifestyle, physical and mental health information (Survey) and dietary intake patterns (FFQ). This will be done pre-treatment (only for those included pre-treatment), 6 months after the start of obesity treatment, 1 year after the start of the treatment and then yearly until 5 year after the start of the treatment.
75930469|NCT04788836|Other|Collection of digital receipts from grocery shopping|"Participants will create their BitsaboutMe-account (GDPR-compliant data sharing platform from Bern, Switzerland) with the help of study team members. Data from digital receipts will be obtained from Migros Cumulus and Coop Supercard via their BitsaboutMe-account. The data collection allow retrospective digital receipts collection for up to 2 years and automatically continuous collection during study duration.~GDPR: General Data Protection Regulation"
75336432|NCT00064844|Drug|Nicoderm CQ nicotine patch|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
75336433|NCT00064844|Drug|Placebo gum|Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
75336434|NCT00064844|Drug|Nicotine gum - Nicorette®|Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
75930470|NCT04784117|Other|Dispatcher protocol change|In the beginning of 2019 dispatcher protocol was changed to shorten the time of death detection
76085171|NCT01672996|Drug|Ioforminol 160 mgI/mL|Given as s single administration to the subject
76085172|NCT01672996|Drug|Ioforminol 200 mgI/mL|Given as a single administration to the subject
75336435|NCT01896908|Other|Sodium restriction|"Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY __ / __ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis."
75646196|NCT02597764|Behavioral|Standard Urotherapy|
76085173|NCT01672996|Drug|Iopamidol 300 mgI/mL|Given as a single administration to the subject
76085174|NCT01674478|Dietary Supplement|Microlipid with fish oil|Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
75336436|NCT01897376|Procedure|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
75336437|NCT01897376|Procedure|vertical skin incision|vertical skin incision at time of cesarean section
75336438|NCT04774562|Behavioral|Video-Assisted Discharge Education (VADE)|Video-Assisted Discharge Education (VADE): Information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities.
75336439|NCT04774562|Behavioral|Physiotherapy (PT) Program|Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.
75646197|NCT04092712|Drug|[14C]-CTP-543|Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
75646198|NCT04090294|Drug|Roflumilast|"Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months"
75793920|NCT05365542|Other|Hemodialyzer scanning|After the hemodialysis session, the used dialyzer is rinsed and dried before scanning in a Micro Computed Tomography scanner. From cross-sectional images, the number of patent fibers is quantified.
75793921|NCT05365542|Other|Bleeding Questionnaires|The ISTH Bleeding Assessment Tool and the HASBLED questionnaires are asked
75793922|NCT05365542|Other|Quality of life questionnaire|The EQ5D questionnaire is asked.
75793923|NCT05365542|Other|Visual inspection of the limbs|Visual inspection is done of the patient's limbs in order to quantify bruising.
75793924|NCT05365347|Behavioral|Cognitive Enhancement Therapy (CET)|Cognitive enhancement therapy is an evidence based intervention for schizophrenia focused on improving the cognitive domains of memory, attention span and learning ability. It has shown efficacy in reducing substance use as an indirect outcome but this will be the focus of this intervention.
75793925|NCT05364437|Dietary Supplement|Dietary Fibres Mix|The Fibre Mix, which comprises of a mix of dietary fibres (inulin, pectin and oat beta-glucan) will need to be taken by participants twice daily for 2 weeks with their usual food.
75793926|NCT05364437|Dietary Supplement|Placebo|The placebo, which comprises of cellulose will need to be taken by participants twice daily for 2 weeks with their usual food.
75646199|NCT04090372|Device|evaluation of pre-op planning using Traumacad|The study will be compare pre-op planning with standard condition or with TraumaCad
75646200|NCT00744796|Procedure|DSAEK|Endothelial Keratoplasty
75646201|NCT00744796|Diagnostic Test|Anterior Segment Optical Coherence Topography (OCT)|Non-contact, high resolution, cross sectional imaging of the anterior segment of the eye.
75793927|NCT05361850|Procedure|Extubation|Removal of the endotracheal tube
75930471|NCT04777708|Biological|Nanoplexed Poly I:C BO-112|Given by intratumoral injection
75793928|NCT05358938|Other|Exercise|30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
75793929|NCT05358938|Drug|Checkpoint Blockade, Immune|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
75930472|NCT04777708|Biological|Pembrolizumab|Given IV
75336440|NCT04753502|Procedure|Laparoscopy|laparoscopic removal of pathologic appendix
75646202|NCT00744796|Diagnostic Test|Best Spectacle Corrected Visual Acuity (BSCVA)|Visual acuity determined using a combination of detecting hand motion, counting fingers displayed and reading Snellen charts at specific distances.
75646203|NCT00917254|Drug|YM150|oral
75793930|NCT05354713|Drug|NVP-1805|NVP-1805 (80/10/20.8mg)
75793931|NCT05354713|Drug|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
75793932|NCT05353790|Other|Meals + snacks: control|8 weeks meal plans matched in calories (but not macronutrients or fiber) equivalent to 1 avocado + 1 cup of mango per day
75793933|NCT05353790|Other|Meals + snacks: Avocado mango|8 weeks meal plans provide1 avocado + 1 cup of mango per day
75793934|NCT05353400|Other|Early urinary catheter removal|Early catheter removal
75930473|NCT04774016|Other|Test formula A without added pre- and pro-biotic|An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.
75930474|NCT04774016|Other|Test formula B with synbiotic|Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
75930475|NCT04774016|Other|Test formula C with HMOs|Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
75930476|NCT04769648|Drug|Pro-ocular™ Topical Gel 1%|Pro-ocular™ is a topical gel applied dermally to forehead twice-daily
75930477|NCT04769648|Drug|Placebo|Placebo is a vehicle topical gel without active ingredient applied dermally to forehead twice-daily
75930478|NCT04765852|Other|High dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
75930479|NCT04765852|Other|Low dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
75336441|NCT00067028|Drug|Clofarabine 40mg/m^2|40 mg/m^2 by vein over 1 hour daily for 5 days.
75646204|NCT00917254|Drug|Placebo|oral
75336442|NCT00067028|Drug|Idarubicin 10mg/m^2|"10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
75336443|NCT00067028|Drug|Ara-C 0.75 g/m^2|0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
75336444|NCT00067028|Drug|Clofarabine 22.5mg/m^2|22.5 mg/m^2 by vein over 1 hour daily for 5 days.
75336445|NCT00067028|Drug|Ara-C 1 g/m^2|1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
75646205|NCT00917254|Drug|Enoxaparin|injection
75646206|NCT02599792|Drug|CTP-656|
75646207|NCT02599792|Drug|Placebo for CTP-656|
75646208|NCT02599792|Drug|Kalydeco|
75646209|NCT00705679|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tablet
75646210|NCT00705679|Drug|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet
75646211|NCT00705679|Drug|Tenofovir disoproxil fumarate|300 mg tablet
75646212|NCT00705679|Drug|Tenofovir disoproxil fumarate placebo|placebo tablet
75646213|NCT00705679|Drug|Tenofovir 1% vaginal gel|1 gm/100 ml of 1% gel
75646214|NCT00705679|Drug|Tenofovir placebo|placebo gel
75646215|NCT02597608|Behavioral|CLP: Livelihoods|Capital for purchase of income generating asset, physical infrastructure (plinths, latrines, tubewells), livelihood maintenance stipend, monthly asset maintenance cost stipend, agricultural livelihood training, non-agricultural livelihood training, financial training, health and nutrition training.
75793935|NCT05353400|Other|Urinary catheter removal on POD 3|Catheter removal on POD 3
75793936|NCT05352399|Other|NeuViCare application|Intervention arm participants will engage with NeuViCare AI, including all variations of its 5 components: 1) NeuViCare Planner - enables review of ordered tests and external resources recommended by the care provider; 2) NeuViCare Task-Support Service - provides context-sensitive, personalized text-based assistance to help patients' complete care plan captured in the NeuViCare Planner; 3) NeuViCare Resource Advisor - presents trusted, unbiased advice to locate nearby resources listed within their care plan; 4) NeuViCare Advisor - educates and trains Persons Living With Dementia (PLWD) and their care partners at the moment of need; and 5) NeuViCare Community Hub - a safe virtual space which enables care partners to interact with other peer care partners to gain their experiential knowledge and emotional support.
75793937|NCT05349526|Other|None, pure observational study|None, pure observational study
75793938|NCT05349474|Drug|Metformin 500 Mg Oral Tablet, up to 4 tablets a day|Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose
75793939|NCT05349474|Drug|Placebo oral tablet identical to metformin, up to 4 tablets a day|Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose
75646216|NCT02597608|Dietary Supplement|CLP: Nutrition|Counseling on breastfeeding and complementary feeding; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children 7-23 months dosage of 120 sachets per year; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester; identification and referral of acute malnutrition; facilitation of government campaigns on nutrition.
75646217|NCT02597608|Behavioral|Shiree: Livelihoods|Financial training; input support for livelihoods (cropping, livestock, poultry, fishing, bamboo working, small businesses, tailoring etc.); capacity building (mobilising Self Help Groups, facilitating community based organizations (CBOs), skills transfer); innovation support (market linkage and access to value chains); credit and savings groups; support in mobilizing communities to advocate for their needs.
75793940|NCT05349097|Drug|IMG-004 or placebo|Each participant will be randomized to receive either a single dose of 30mg IMG-004 oral capsule(s) or a single dose of matching placebo.
75930480|NCT04765852|Other|Placebo|One placebo stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
75472898|NCT01964040|Drug|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia"
75793941|NCT05349097|Drug|IMG-004 or placebo|Each participant will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.
76085175|NCT01674478|Dietary Supplement|Microlipid|A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
75793942|NCT05349097|Drug|IMG-004 or placebo|Each participant will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo in the fasted and fed condition.
75930481|NCT04763512|Dietary Supplement|Intact Cow's Milk Protein Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 4 months.
75930482|NCT04763512|Dietary Supplement|Partially Hydrolysed Whey Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 16 months.
75930483|NCT04760093|Dietary Supplement|Low polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.
76085176|NCT02245360|Drug|Phleum pratense grass pollen allergen extract|Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
76085177|NCT02245360|Drug|placebo|placebo tablet given once daily over 60 days
76085178|NCT02245516|Drug|KPI-121 0.25% Ophthalmic Suspension|KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
76085179|NCT02245516|Drug|KPI-121 1.0% Ophthalmic Suspension|KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
76085180|NCT05710822|Device|pulmonary vein isolation|pulmonary vein isolation utilizing the QDOT Micro ablation catheter
76085181|NCT01677286|Drug|Doxycycline 100 mg po bid x 12 months|100mg by mouth twice daily for 1 year.
75336446|NCT00067028|Drug|Idarubicin 6 mg/m^2|6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
75793943|NCT05349097|Drug|IMG-004 or placebo|Each participant will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.
76085182|NCT02246062|Behavioral|info|the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.
75336447|NCT05194748|Other|No intervention, observational only|No intervention, observational only
75336448|NCT00067808|Drug|Decitabine|10 mg/m^2 by vein over 1 hour daily for 10 days
75793944|NCT05349097|Drug|IMG-004 or placebo|Each participant will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.
75793945|NCT05347446|Procedure|Hybrid ESD|Method of removing colon lesion
75793946|NCT05347446|Procedure|Non-hybrid ESD|Method of removing colon lesion
75793947|NCT05345093|Device|Ialuxid gel|"Ialuxid® Gel is intended for topical external use. It is formulated with the appearance of white to pale yellow coloured consistent gel.~Ialuxid® Gel will be used for 8 weeks, 2-3 times a day."
75793948|NCT05343481|Biological|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus immunotherapeutic
75336449|NCT00067808|Drug|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
75336450|NCT00067808|Drug|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
75793949|NCT05343481|Biological|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus immunotherapeutic
75793950|NCT05343481|Biological|Nivolumab|Human immunoglobulin G4 monoclonal antibody
76085183|NCT02246062|Behavioral|smartphone|the child received smartphone application immediately before entering the operating room
75336451|NCT00493870|Drug|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
75793951|NCT05340764|Drug|Infliximab|Infliximab is an effective and commonly used medication to treat patients with IBD
75793952|NCT05327361|Drug|Liftactiv B3|Participants will apply a dime size amount of the serum to 1 side of the face.
75472899|NCT01964053|Behavioral|PATCH intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
75646218|NCT02597608|Dietary Supplement|Shiree: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
75646219|NCT02597608|Behavioral|UPPR: Livelihoods|Monetary support for communities to improve infrastructure (drains, footpaths, latrines and water dwells, access to roads and markets); financing for apprenticeships; grants for small businesses; education grants for girls; grants for urban food production activities; financial training; establishment of savings and credit groups; support for communities in advocating for their needs; microcredit; improving access to health facilities; improving housing conditions; provision of plinths.
75793953|NCT05327361|Other|Sunscreen|Participants will apply a dime size amount of sunscreen to cover the other half of the face.
75793954|NCT05326529|Other|Hospital Based Cardiac Rehabilitation Exercise Classes|Participants will attend 8 Hospital based CR exercise sessions. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
75930484|NCT04760093|Dietary Supplement|High polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.
76085184|NCT05147038|Device|Tele-coaching|"The participants are instructed to use a Fitbit fitness tracker to record the number of steps. This device is compatible with the m-PAC App, which was developed for this specific group of participants (individuals suffering from a chronic lung disease). The participants receive a feedback via the m-PAC App every day and they also receive a week report to be albe to adjust their step goal. They are asked to increase or keep their week goal every Sunday after reviewing a weekly report. The participants also receive tips for their PA improvement and they are asked for medication change specification (every Wednesday)."
76085185|NCT01678846|Behavioral|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good_school_toolkit.php).
76085186|NCT02502630|Device|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
76085187|NCT04498260|Drug|Local steroid - triamcinolone acetonide|(triamcinolone acetonide)
76085188|NCT04498260|Drug|Oral steroid - predonisolone|(predonisolone)
75930485|NCT04746248|Other|Outpatient labor induction|The participants stay at home during til labor induction process and are admitted to hospital at the onset of labor or if a complication occur. Outpatient consultations once a day.
75930486|NCT04746248|Other|Inpatient labor induction|The participants are induced following standard inpatient care
75336452|NCT00493870|Drug|Doxorubicin|• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
75336453|NCT00493870|Drug|Cyclophosphamide|600 mg/m2 IV over 15-30 minutes on Day 1.
75336454|NCT05146622|Behavioral|Workplaces in the World|Formative research activities to better understand attitudes and behaviors of outdoor workers with respect to UV safety.
75336455|NCT03287336|Drug|Tranexamic Acid|Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
75336456|NCT00003136|Biological|filgrastim|
75930487|NCT04743206|Device|Standard Airway Clearance device|A large majority of our patients will be using VEST therapy as their standard of care airway clearance
75930488|NCT04743206|Device|Portable Internal Airway Percussion device|Smart One® portable home spirometer
75336457|NCT00003136|Drug|amifostine trihydrate|
75336458|NCT00003136|Drug|carboplatin|
75336459|NCT00003136|Drug|cyclophosphamide|
75336460|NCT00003136|Procedure|peripheral blood stem cell transplantation|
75336461|NCT00003598|Drug|tretinoin|
75336462|NCT00003604|Biological|aldesleukin|
75336463|NCT00002794|Drug|carboplatin|
75793955|NCT05326529|Other|Web-based Cardiac Rehabilitation Exercise Sessions|Participants will complete 8 weeks of Web-based CR exercise sessions using the MyHeart app. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
75793956|NCT05324085|Behavioral|High-intensity interval training|Supervised exercise intervention, three times a week for eight weeks.
75930489|NCT04730349|Biological|Nivolumab|Specified dose on specified days
75930490|NCT04730349|Biological|NKTR-214|Specified dose on specified days
75930491|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 10 mg) or placebo
75336464|NCT00002794|Drug|vincristine sulfate|
75336465|NCT00003610|Dietary Supplement|capsaicin|
75336466|NCT00003610|Other|placebo|
75336467|NCT00003610|Radiation|radiation therapy|
75336468|NCT00003616|Drug|irinotecan hydrochloride|
75336469|NCT01063829|Drug|60 mg AIC246|Oral administration
75793957|NCT05324085|Behavioral|Treatment as usual|The content of TAU is broadly individualized but most often includes various forms of group therapy, psychotherapy, psychoeducation and physical activity. The physical activity schedule for the patients typically includes gym-based exercises, individualized by preference of each patient, and various outdoors activities, four times per week all together.
75793958|NCT05323864|Biological|Hypoxia|Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.
75793959|NCT05321095|Diagnostic Test|Albuminuria test|During participation, subjects are asked to collect one or more urine samples for albuminuria determination.
76085189|NCT05341336|Procedure|total surgical excision|"patients will be operated under general anesthesia. Pressure is applied along the incision line while staying away from the palpable margin of the AVM lesion and used Raney clips to control bleeding.~Once the skin flap was raised, the lesion could be seen through the galea. The galea around the lesion is incised, and the lesion will be separated from the underlying skin using a combination of bipolar diathermy and sharp dissection.~The nidus is often located in galeal aponeurosis. Dilated arteries and veins extended into subcutaneous tissue, which was separated with special care to prevent accidental nidus rupture and avoid excessive cauterization to prevent postoperative scalp necrosis.~Ligation is applied on feeder arteries, then applied to veins with total excision of the lesion.~After excision of the lesion, the skin flap was replaced with interrupted stitches.~The wound was allowed to heal primarily along with intravenous administration of antibiotics."
75930492|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 30 mg) or placebo
75930493|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 100 mg) or placebo
75930494|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 300 mg) or placebo
75930495|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 500 mg) or placebo
75336470|NCT01063829|Drug|120 mg AIC246|Oral administration
75336471|NCT01063829|Drug|240 mg AIC246|Oral administration
75646220|NCT02597608|Dietary Supplement|UPPR: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
75336472|NCT01063829|Other|Placebo|Oral administration
75472900|NCT01964053|Behavioral|Usual care|Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
75646221|NCT02597608|Other|UPPR: Control|No interventions provided.
75472901|NCT01964066|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography balloon dilatation
75472902|NCT01964066|Procedure|Thoracic epidural analgesia|Thoracic epidural analgesia between thoracic vertebrae VII-VIII (Ropivacaine 0.5%-10ml)
75646222|NCT03979300|Other|Learning process during role play on psychiatric interview|"Methodology: Mixed method study with:~Quantitative features:~Self-reported questionnaries :  Learning Effectiveness Inventory Scale  (18)~Sociodemographical data and others questions~Qualitative : Grounded Theory~Video-record of simulation and audio-record and briefing and debriefing, quoted with conversational analysis~Semi-structured interview of learners and teachers"
75930496|NCT04720443|Drug|NIP292 tablets|NIP292 (oral tablet at dosage 1) or placebo
75930497|NCT04720443|Drug|NIP292 tablets|NIP292 (oral tablet at dosage 2) or placebo
76085190|NCT01679314|Device|AlphaCore device|Each study group will go under the same treatment regimen and assessments.
76085191|NCT01680172|Drug|Ketamine|Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
76085192|NCT01680172|Drug|Placebo|Single dose of liquid placebo solution taken by mouth
75472903|NCT01964066|Procedure|Premedication|For premedication used trimeperidine 2%-1ml intravenously.
75646223|NCT04062487|Device|Mixed Reality technology|combine image with real body
75646224|NCT04092868|Other|Blood samples PK/ PD protamine|PK/ PD protamine
75793960|NCT05321095|Diagnostic Test|HbA1c test|During the screening visit, HbA1c will be measured with a point-of-care test (Affinion HbA1c, Abbott).
75930498|NCT04719637|Device|PRDS-001 Renal Denervation Ultrasound System|Renal Denervation Ultrasound System
75930499|NCT04704856|Behavioral|Supervised exercise|Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.
75930500|NCT04685252|Other|(BL) NCC3001|Probiotic strain (BL) NCC3001 packed in stickpack, to be consumed daily.
75930501|NCT04685252|Other|Placebo|Matching placebo containing maltodextrin packed in stickpack, to be consumed daily.
75930502|NCT04676451|Device|Femto-AK|Astigmatic Keratotomy / Arcuate Incisions for the correction of astigmatism
75930503|NCT04673513|Other|Psychotherapy|In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.
75930504|NCT04671719|Biological|blood sample|blood sample for circulating autotaxin measurement (5ml).
75336473|NCT00072566|Biological|Bevacizumab|Given IV
75336474|NCT00072566|Drug|Cyclophosphamide|Given PO
75336475|NCT00072566|Other|Laboratory Biomarker Analysis|Correlative studies
75336476|NCT00003622|Drug|paclitaxel|
75336477|NCT00003622|Drug|vinorelbine tartrate|
75336478|NCT00003148|Biological|aldesleukin|
75336479|NCT00003154|Drug|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
76085193|NCT01680328|Other|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
75930505|NCT04655092|Biological|P1101 (Ropeginterferon alfa-2b)|The subjects who have completed the 52-week treatment duration in Study A19-201 will be treated with P1101, starting at the dose at Week 50. The dose during this study may be increased or decreased up to 500 μg depending on the condition. This study will be continued as a post-marketing clinical study after acquisition of the marketing approval of P1101.
76085194|NCT01680328|Drug|sodium chloride 0.9% solution|Solution for injection.
76085195|NCT02235064|Drug|Sertraline|Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
75646225|NCT04092556|Device|transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
76085196|NCT02235064|Drug|Placebo|Capsule containing cellulose powder of same color as experimental arm
76085197|NCT05710588|Other|motor-motor dual-task training|The intervention compromises balance-related tasks which are selected among the tasks often used in balance rehabilitation and motor secondary tasks might be required hand dexterity like popping a fidget toy or reaching ability like touching wall. All sessions will be individual. The initial training session will be undertaken in University of Plymouth. This will be followed by a recorded training video programme which can be accessible through Panopto- a University-led, web-based platform- undertaken in the participants' home for 30 minute sessions, three times a week over 6 weeks.
76085198|NCT05710588|Other|motor-cognitive dual-task training|The intervention compromises (1) balance-related tasks which are selected among the tasks often used in balance rehabilitation and (2) cognitive secondary tasks might required to activate sensory and cognitive systems like listening podcast and memorizing the details about it or reading a tongue twister and repeating. intervention delivery will be the same with M-DTT group.
76085199|NCT01680640|Dietary Supplement|Synbiotic|The synbiotic to be used is fructo-oligosacharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
75930506|NCT04639518|Other|Preterm formulas with HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
76085200|NCT01680640|Dietary Supplement|Maltodextrin|
76085201|NCT02249806|Other|PH target therapy according to physician|Patients receiving PH target therapy
76085202|NCT05118490|Drug|Daily rifapentine and isoniazid for 4 weeks|Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)
76085203|NCT05118490|Drug|Weekly rifapentine and isoniazid for 12 weeks|Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
75930507|NCT04639518|Other|Preterm formulas without HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
75646226|NCT02598544|Other|adipose tissue sampling|adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
75793961|NCT05321095|Diagnostic Test|Creatinine test|During the screening visit, creatinine will be measured with a point-of-care test (i-STAT Alinity handheld analyser, Abbott).
76085204|NCT05710510|Behavioral|Local Care + Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive 6 quarterly clinic visits with their local primary care provider focused on medical management of obesity."
76085205|NCT05710510|Behavioral|Team Care Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive an intensive 18-month group lifestyle intervention (30 total sessions) led by a study lifestyle coach via Zoom, and 6 quarterly 1:1 visits via Zoom with their lifestyle coach. Participants also receive 6 quarterly clinic visits with their local primary care provider; the study lifestyle coach joins the visits via telemedicine. All three parties may meet via telemedicine if needed. The group lifestyle intervention is led by obesity treatment specialists with relevant graduate training and experience."
76085206|NCT05710432|Other|Quasi-Isometric Neck Flexion|Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).
75336480|NCT04773860|Other|Muscle Energy Techniques|A 4 week intervention will be carried out consisting of Muscle Energy Techniques on the accessory muscle of respiration. That is, Pectoralis Minor, Sternocleidomastoid, Upper trapezius, Scalene muscles and Latissimus Dorsi
75646227|NCT00916942|Drug|capsaicin 8%|High concentration capsaicin 8% dermal patch applied for one hour
75646228|NCT00916942|Drug|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
75793962|NCT05309369|Behavioral|Preferred Music|Participants will listen to selected music using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
75793963|NCT05309369|Behavioral|Nature Sounds|Participants will listen to nature sounds using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
75793964|NCT05305014|Diagnostic Test|blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP)|Bioassays of blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP) from sera babcocked in the HYCORE mother study.
76085207|NCT05710432|Other|Inspiratory Muscle Training|"Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique [IO], external oblique [EO], transversus abdominis [TrA] and rectus abdominis [RA] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued."
75930508|NCT04627545|Other|2h exposure to sperm for IVF|Oocytes will only be briefly (2h) exposed to progressive motile sperm for insemination
75930509|NCT04627545|Other|overnight exposure to sperm for IVF|Oocytes will be exposed for a longer duration (overnight, 16-20h) to progressive motile sperm for insemination
75930510|NCT04610346|Behavioral|Persons with Aphasia Training Dogs Program|Participants will learn and apply positive reinforcement training techniques for working with dogs to train them in basic obedience behaviors (e.g., SIT, STAY).
75930511|NCT04605497|Diagnostic Test|Continuous glucose monitoring (CGM)|Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission & discharge + additional 10 days during postpartum period
75930512|NCT04605497|Diagnostic Test|Self-Capillary Blood Glucose Monitoring (SCBG)|Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
75930513|NCT04597450|Drug|Lu AG06466|Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
75930514|NCT04597450|Drug|Placebo|Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
76085208|NCT02246608|Device|NPWT Standard of Care plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
76085209|NCT02246608|Device|Routine NPWT Standard of Care|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
76085210|NCT02237092|Procedure|Measurement of IAP|The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
76085211|NCT05710120|Other|Hepatitis C Screening Alerts in CHORUS™|"ZS Associates developed a machine learning-based model that provides a numeric % chance of returning a positive hepatitis C test for a patient without diagnosed hepatitis C infection. The data used to develop the model included a US-based large scale data source including electronic medical records, medical claims, and pharmacy claims as well as social determinants of health identified from open-source data.~Clinical Health Outcomes Reporting & Utilization Service (CHORUS™) is a web-based reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients who have a scheduled appt in the coming week and may require attention. In the after period of this study, the alert will identify patients who are eligible to be screened for hepatitis C infection and provide the % chance of returning a positive hepatitis C infection test."
76085212|NCT05710120|Other|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients who are eligible to be screening for hepatitis C infection will be disseminated.
76085213|NCT01681030|Biological|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
76085214|NCT01681030|Biological|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
75930515|NCT04569435|Drug|ANX005|IV Infusion
75472904|NCT01964079|Drug|Amlodipine|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
75930516|NCT04539639|Drug|Jaktinib|In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.
75793965|NCT05302986|Drug|Tranexamic acid injection|The dose will be 0.1 mg / kg (= 10 mg/kg) and diluted in a 100 mL infusion bag of sodium chloride. The product will have to be administered as a slow infusion over 10 minutes during the shoulder surgery.
75793966|NCT05302986|Drug|Placebo|Surgery with intravenous injection of Placebo (0.9% sodium chloride). A 100 mL infusion bag of sodium chloride will be administered as a slow infusion over 10 minutes during shoulder surgery.
75930517|NCT04539639|Drug|Jaktinib|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.
75930518|NCT04539639|Drug|Jaktinib|In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.
75930519|NCT04539639|Drug|placebo|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
75930520|NCT04535245|Diagnostic Test|LCI testing|all subjects will have LCI testing then contacted via a phone interview or EMR review yearly times 5 to determine if they have subsequently developed ILD
75336481|NCT00384046|Drug|Testosterone|patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
75336482|NCT00384046|Drug|Placebo|patch, placebo, patch changed every 3-4 days, 24 weeks
75930521|NCT04517396|Other|Fenofibrate/fenofibric acid|The randomized intervention will be fenofibrate (Tricor) at a dose of 145 mg/d or dose-equivalent preparation of fenofibrate or fenofibric acid, for 10 days. In all cases, appropriate dose reductions will be implemented for patients with chronic kidney disease as per the approved preparation label. The intended duration of randomized treatment will be for 10 days.
75930522|NCT04517396|Other|Placebo|The control intervention will be a placebo, for 10 days.
75930523|NCT04517396|Other|Usual care|All participants will otherwise receive usual medical care
75930524|NCT04509765|Radiation|Linac Based VMAT TBI|Use of linac based Volumetric Arc Therapy (VMAT) to deliver Total Body Irradiation (TBI). The study intervention is a VMAT based delivery technique using a 6 MV photon beam from a Varian TrueBeam® (Palo Alto, CA) equipped with a Millennium multi-leaf collimation (MLC) system3. TBI will be delivered using a Varian TrueBeam linear accelerator with photon beam VMAT capability. VMAT is a radiation technique combining dynamic photon fluence modulation using multi-leaf collimation (MLC) with gantry rotation to deliver a highly conformal dose distribution with improved target coverage and sparing of organs at risk (OARs).
75646229|NCT04959019|Behavioral|Supervised combined endurance and resistance training (CERT)|Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
75646230|NCT04959019|Behavioral|Delayed supervised combined endurance and resistance training (CERT)|After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
75930525|NCT04506619|Other|No Intervention|This is a non-interventional study.
76085215|NCT01681030|Other|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
76085216|NCT01681810|Drug|14Nitrogen Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times a day for 12 weeks
75646231|NCT05672485|Diagnostic Test|SPECT/CT imaging with 99mTc-P137 nuclide probe|inject the tracer 99mTc-P137 to subjects and perform SPECT/CT scans
75646232|NCT00751348|Biological|PriorixTM|Subcutaneous administration in left upper arm
75930526|NCT04483167|Drug|99mTccAbVCAM1-5 injection|intravenous injection of 99mTccAbVCAM1-5 with dose increase
75930527|NCT04471623|Behavioral|Use of DeTAP App and Home Devices|DeTAP App (data collection, televisit function, information and reminders), Bluetooth-connected 6-lead home (electrocardiogram) EKG device, Bluetooth-connected blood pressure (BP) cuff
76085217|NCT01683526|Procedure|Direct laryngoscopy|
76085218|NCT01683526|Device|Video laryngoscopy (Glidescope)|
76085219|NCT02249416|Drug|Tipranavir (TPV) low|
76085220|NCT02249416|Drug|Ritonavir (RTV) low|Norvir®
76085221|NCT02249416|Drug|Tipranavir (TPV) high|Retrovir®
76085222|NCT02249416|Drug|Ritonavir (RTV) high|
75336483|NCT05074862|Dietary Supplement|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
75336484|NCT05074862|Dietary Supplement|Maltodextrin and fat-based placebo|Dosis isocaloric to the KetoneAid Arm
75930528|NCT04435392|Drug|Jaktinib Hydrochloride Cream|Subjects in each group were scheduled to give the drug for 8 weeks.
75930529|NCT04435392|Drug|Placebo|Placebo
75930530|NCT04423146|Other|The evocation of reproducible motor evoked potential according to the different BIS levels|The evocation of reproducible motor evoked potential and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
75930531|NCT04416672|Other|PRO-CTCAE items|"Enrolled patients will be asked to complete a subset of the PRO-CTCAE items based on cancer type, and the following instruments used as anchors to measure psychometric properties:~the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life disease-specific module, if a linguistically validated Italian version exists, or the General QLQ-C30, if the Italian version is not available.~the Hospital Anxiety and Depression Scale (HADS)~The Patients' Global Impression of Change (PGIC) Scale."
76085223|NCT02249416|Drug|Zidovudine|
76085224|NCT01685242|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
76085225|NCT01685242|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
76085226|NCT01685320|Procedure|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
76085227|NCT04937296|Behavioral|Physical activity|Participants will be asked to perform resistance exercises 3-times a week on alternating days for 12 weeks. Exercises will be performed with a TheraBand and will include the squat, lunge, press-up, cross body reach, reverse fly, lateral raise, biceps curl, triceps extension, frontal raise and bridge. In addition to the resistance exercises, the participants will perform aerobic exercise. They will be asked to download a specific exercise app to record the number of steps on day 1 of the intervention and participants who do not possess the required phone technology will be provided with a pedometer. They then will be asked to add 2000 steps on to their daily steps; this amount will then become their daily step goal. Once they have reached this goal on 4 out of 5 days, they will be asked to increase their new step step goal by an extra 500 per day.
76085228|NCT04937296|Other|Usual care|Usual care.
76085229|NCT00708162|Drug|Elvitegravir|Elvitegravir (EVG) tablet administered orally once daily with food
75336485|NCT00002800|Biological|filgrastim|
75930532|NCT04402593|Behavioral|Modified Heidelberg Model of Neuro-Music Therapy|6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
75930533|NCT04390828|Behavioral|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
75930534|NCT04383080|Procedure|Acupuncture|acupuncture at specific acupuncture points
76085230|NCT00708162|Drug|Raltegravir|Raltegravir tablet administered orally twice daily according to prescribing information
75646233|NCT00751348|Biological|VarilrixTM|Subcutaneous administration in right upper arm
76085231|NCT00708162|Drug|EVG placebo|Placebo to match elvitegravir administered orally once daily
76085232|NCT00708162|Drug|RAL placebo|RAL placebo administered orally twice daily.
75336486|NCT00002800|Biological|lintuzumab|
75336487|NCT00002800|Drug|cytarabine|
75336488|NCT00002800|Drug|etoposide|
75646234|NCT00751348|Biological|Priorix-Tetra®|Subcutaneous injection in left upper arm
75336489|NCT00002800|Drug|idarubicin|
75336490|NCT00002806|Drug|lomustine|
75646235|NCT00920959|Drug|FP 100mcg|Once-daily dosing
75646236|NCT00920959|Drug|FSC 100/50mcg|Once-daily dosing
75646237|NCT00920959|Drug|Placebo|Once-daily dosing
75646238|NCT04092322|Device|Actical accelerometers (Philips Respironics)|patients with stroke will be evaluated by using PASE scale and accelerometer results (accelerometer will be held from Monday to Friday
75793967|NCT05300451|Biological|Daratumumab and hyaluronidase-fihj|Daratumumab and hyaluronidase-fihj for subcutaneous (under the skin) injection has different dosing and administration instructions compared to daratumumab for intravenous (in the vein) infusion. Daratumumab and hyaluronidase-fihj contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes. Subjects will receive a 1800mg/30000u injection subcutaneously weekly for a total of 8 doses
75336491|NCT00002806|Drug|procarbazine hydrochloride|
75336492|NCT00002806|Drug|vincristine sulfate|
75336493|NCT00002806|Radiation|low-LET photon therapy|
75336494|NCT00003160|Drug|paclitaxel|
75793968|NCT05298631|Other|Stabilization exercises|The activation of deep cervical muscle to reduce the activity of surface muscles is known as stabilization exercises
75793969|NCT05298631|Other|Dynamic exercises|The exercises in which muscle tension remains constant but muscle length changes is known as dynamic exercises
75930535|NCT04383080|Device|Low-level laser therapy|low level laser emission on specific acupuncture points
76085233|NCT00708162|Drug|Background regimen|Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
76085234|NCT04930042|Drug|Stelara|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
76085235|NCT04930042|Drug|AVT04|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
76085236|NCT04898920|Drug|Normal saline|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
76085237|NCT04898920|Drug|Dexamethasone|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
76085238|NCT02249884|Drug|Urea Dose A|Urea cream for topical use.
76085239|NCT02249884|Drug|Urea Dose B|Urea cream for topical use.
76085240|NCT02249884|Drug|Urea Dose C|Urea cream for topical use.
75336495|NCT00002812|Drug|asparaginase|Given IV
75336496|NCT00002812|Drug|cyclophosphamide|Given IV
75336497|NCT00002812|Drug|cytarabine|Given IV
75336498|NCT00002812|Drug|daunorubicin hydrochloride|Given IV
75336499|NCT00002812|Drug|dexamethasone|Given IV
75336500|NCT00002812|Drug|doxorubicin hydrochloride|Given IV
75336501|NCT00002812|Drug|idarubicin|Given IV
75336502|NCT00002812|Drug|mercaptopurine|Given IV
75336503|NCT00002812|Drug|methotrexate|Given PO
75336504|NCT00002812|Drug|pegaspargase|Given IV
75336505|NCT00002812|Drug|prednisone|Given PO
75336506|NCT00002812|Drug|thioguanine|Given IV
75336507|NCT00002812|Drug|vincristine sulfate|Given IV
75646239|NCT04092322|Other|PASE|Physical Activity Scale for Elderly
75646240|NCT04090138|Dietary Supplement|Setria performance blend|Oral capsules
75646241|NCT04090138|Dietary Supplement|Placebo|Oral capsules
75793970|NCT05296122|Device|TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.|The main purpose with the study is to investigate safety and feasibility of the TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation together with SmartTwist™ MR Hand Drill with the SmartTip™ MR Drill Kit for MR-guided laser thermal ablation of brain lesions.
75336508|NCT00002812|Radiation|radiation therapy|
76085241|NCT02249884|Drug|Chamomile Dose A|Chamomile gel for topical use.
75930536|NCT04382352|Biological|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.|Usage: intravenous infusion; B002, doses 2, 6, 12, 16, 20 mg / kg, intravenous drip. The infusion time was 120 ± 10 minutes for the first time; if the patient was tolerated, the follow-up time was adjusted to 60 ± 10 minutes. Pre-treatment was performed using phenergan (25 mg, intramuscular) within 30 minutes prior to each study drug infusion. The dosing cycle is administered once every 3 weeks for one cycle and can be administered continuously until the disease progresses or is intolerable.
75930537|NCT04372693|Other|impliminting Online Distance Learning|as a result of (COVID-19) social distancing measures, the Online Distance Learning will be implemented without prior planning for undergraduate nursing students
76085242|NCT02249884|Drug|Chamomile Dose B|Chamomile gel for topical use.
75336509|NCT01258855|Biological|Aldesleukin|Given IV
75646242|NCT02597530|Device|TEAS|According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
76085243|NCT02249884|Drug|Chamomile Dose C|Chamomile gel for topical use.
76085244|NCT03342846|Device|rTMS|the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
75336510|NCT01258855|Other|Laboratory Biomarker Analysis|Correlative studies
76085245|NCT01686646|Drug|paracetamol + caffeine|paracetamol with caffeine
75646243|NCT00751114|Drug|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
75930538|NCT04328207|Other|No Financial Incentive|Standard of care eye health education
76085246|NCT01686646|Drug|paracetamol|paracetamol
76085247|NCT02498262|Other|Virtual Reality System|The participants will use a virtual reality system that is like a large video game and complete some job skill tasks in the virtual world video game.
75336511|NCT01258855|Biological|Ziv-Aflibercept|Given IV
75336512|NCT00003166|Drug|bryostatin 1|Given IV
75336513|NCT00003166|Drug|vincristine sulfate|Given IV
75336514|NCT00003166|Other|laboratory biomarker analysis|Correlative studies
75336515|NCT00003172|Biological|filgrastim|
75336516|NCT00003172|Biological|recombinant interferon alfa|
75336517|NCT00003172|Drug|docetaxel|
75336518|NCT00003172|Drug|doxorubicin hydrochloride|
75336519|NCT00003172|Drug|fluorouracil|
75646244|NCT00751114|Drug|Sitagliptin|Oral administration. 100 mg film-coated tablets.
75646245|NCT00751114|Drug|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
76085248|NCT02501772|Device|acupressure by ankle band|
76085249|NCT02495688|Procedure|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
76085250|NCT02495688|Procedure|General anesthesia|Standard procedure.
76085251|NCT01687036|Device|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
75336520|NCT00003172|Drug|hydroxyurea|
75336521|NCT01259011|Behavioral|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
75336522|NCT00003634|Biological|oregovomab|
75336523|NCT03010111|Other|QFT-IT Test and other blood sampling|In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
75336524|NCT04712578|Dietary Supplement|Caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse caffeinated pre-workout supplement (Legion Athletics, Inc.).
75336525|NCT04712578|Dietary Supplement|Non-caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse non-caffeinated pre-workout supplement (Legion Athletics, Inc.).
75336526|NCT04712578|Dietary Supplement|Placebo|The intervention will consist of consuming a standardized meal followed by a placebo beverage.
75336527|NCT02191033|Behavioral|Smoking counseling|
75336528|NCT02191033|Behavioral|Text messaging|
75336529|NCT02191033|Drug|Nicotine patch|
75336530|NCT00002818|Drug|cytarabine|
75336531|NCT00002818|Drug|deoxycytidine|
75336532|NCT00003640|Biological|filgrastim|
75336533|NCT00003640|Drug|cisplatin|
75336534|NCT00003640|Drug|doxorubicin hydrochloride|
75336535|NCT00003640|Drug|methotrexate|
75336536|NCT00003640|Drug|vinblastine sulfate|
75336537|NCT00003640|Procedure|surgical procedure|
75336538|NCT00003640|Radiation|radiation therapy|
75646246|NCT00960440|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
75646247|NCT00960440|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
75646248|NCT00960440|Drug|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
75646249|NCT00960440|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
75930539|NCT04328207|Behavioral|Financial Incentive|Patients who are referred for an in-person follow-up exam will receive a financial incentive once the referral visit is completed.
76085252|NCT02325856|Device|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
76085253|NCT02325856|Behavioral|Clinical judgement|
76085254|NCT02495766|Drug|XCEL-MC-ALPHA|Single infusion
76085255|NCT02495766|Drug|Placebo|Single infusion
76085256|NCT01687114|Other|cranberry juice|27% cranberry juice
75472905|NCT01964079|Drug|Losartan|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
75336539|NCT01260493|Other|integrated health care chain|Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
75336540|NCT00002824|Biological|gene therapy|
75930540|NCT04317794|Drug|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
75336541|NCT00002824|Drug|chemotherapy|
75336542|NCT00002824|Drug|ganciclovir|
75336543|NCT00002824|Procedure|conventional surgery|
75336544|NCT00003646|Drug|allovectin-7|
75336545|NCT00003178|Biological|filgrastim|
75336546|NCT00003178|Drug|cladribine|
75336547|NCT00003178|Drug|idarubicin|
75472906|NCT01964118|Other|Intermittent Fasting group|Intermittent fasting for 12 months
75472907|NCT01964118|Other|control group|usual diet for 6 months and intermittent fasting for other 6 months
75472908|NCT01964131|Drug|D961H sachet 20 mg|"Each subject will be randomised evenly to one of Treatment: A-->B (Sequence 1) or Treatment: B-->A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
75472909|NCT01964131|Drug|D961H HPMC capsule 20 mg|"Each subject will be randomised evenly to one of Treatment: A-->B (Sequence 1) or Treatment: B-->A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
75646250|NCT00960440|Drug|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
75646251|NCT00960440|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
75646252|NCT04092478|Other|Spinal Anesthesia Position|The patient positions during the spinal anesthesia
75646253|NCT04089436|Diagnostic Test|CSF sampling|CSF sampling by lumbar puncture
75646254|NCT04089436|Diagnostic Test|Blood sampling|Blood sampling by blood test
75646255|NCT04089436|Diagnostic Test|Nasopharyngeal and rectal sampling|Nasopharyngeal and rectal sample by swabbing
75646256|NCT02598466|Drug|Abatacept|
75646257|NCT00630266|Device|CorCap CSD|The surgical procedure includes implantation of the CorCap CSD with concommitant mitral valve surgery through a sternotomy.
75646258|NCT05973461|Device|Exercise and virtual reality|Riding a cycle ergometer while experiencing virtual reality
75646259|NCT05973461|Other|Riding a cycle ergometer|Riding on a cycle ergometer without experiencing virtual reality
75646260|NCT05973409|Device|scleral lens|scleral lens with and without hydra-peg coating
75646261|NCT05973396|Other|Physical Fatiguing Task only|Control group: 20-25 minutes [Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort] without mentally fatiguing task during low intensity effort pace
75336548|NCT01260649|Drug|ketamine|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
75336549|NCT01260649|Other|IV Saline|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
75336550|NCT01260649|Procedure|ECT|ECT will be administered as per standard of care
75336551|NCT01260649|Drug|Muscle Relaxant|All participant will receive routine course of muscle relaxant with ECT as per standard of care
75336552|NCT01260649|Drug|Anesthetic Agents|All participant will receive routine course of anesthetic agents with ECT as per standard of care
75336553|NCT01260883|Drug|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
75336554|NCT01260883|Drug|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
75336555|NCT01260883|Drug|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
75472910|NCT01964144|Drug|Dovitinib|Dovitinib 500mg (5 capsules x 100 mg/day) for 5 consecutive days and 2 days rest
75472911|NCT01964157|Drug|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
75472912|NCT01964170|Drug|degarelix|subcutaneous
75646262|NCT05973396|Other|Physical and Mental Fatiguing Task|Experimental group: 20-25 minutes [Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort] with mentally fatiguing task during low intensity effort pace (which includes: stroop test)
75646263|NCT05973370|Drug|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
75646264|NCT05973370|Drug|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.
75646265|NCT05973357|Procedure|Sub-crestal implant|Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization
75646266|NCT05973357|Procedure|Equi-crestal implant|Patients receiving delayed implant placed equi-crestal level with immediate provisionalization
75930541|NCT04317092|Drug|Tocilizumab Injection|Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). A second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the Investigator.
75646267|NCT05973331|Other|Pancreatic Cancer Risk Model (PRISM)|A neural network model (PrismNN) and a logistic regression model (PrismLR) that use routinely collected EHR data to stratify individuals from the general population into PDAC risk groups
75930542|NCT04311866|Device|Synthetic pants|The use of synthetic materials is preferred (glass fiber), resistance, durability and low weight makes them optimal. To give some extra strenght to the cast, fiber strips are placed anterior and posterior at the level of the groin, this can facilitate the transportation of the patient avoiding the use of a bar.
76085257|NCT03342768|Other|Smartphone-based messages|"For the TID arm, the messages' contents include the tobacco industry's (TI's) anti-smoking campaigns that made smoking more grown-up and more appealing to youth; the TI's role in smoking in movies; etc.~For the sugar sweetened beverage (SSB) arm, the messages' contents include the disease conditions linked to SSBs, and the interference of sugar industry in scientific research."
76085258|NCT05709730|Diagnostic Test|HPV genotyping|"HPV genotyping of samples classified that were positive for other HPV"
76085259|NCT04495920|Drug|CGB-S-100|Alcohol and choline geranate
76085260|NCT01687972|Combination Product|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
76085261|NCT01687972|Combination Product|Absorbable sutures|placement of absorbable sutures at cesarean section
76085262|NCT03342612|Procedure|Brain Magnetic Resonance Imaging (MRI)|
76085263|NCT01688596|Drug|Bupivacaine|Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
75472913|NCT01964170|Drug|Goserelin|subcutaneous
75646268|NCT05973318|Drug|Dorzotimol eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
75646269|NCT05973318|Drug|Cosopt eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
75472914|NCT01964183|Drug|tolterodine|Oral
75472915|NCT01964183|Drug|mirabegron|Oral
75646270|NCT05973305|Drug|Dorzol 20 mg/ml|dosing schedule t.i.d.
75930543|NCT04311866|Device|Spica cast|The use of the spica cast is a standard practice for the management of the femoral shaft fractures, however its use, under some circumstances has been related to a wrong management of the cast, auto-retrieval, patient discomfort, and a difficult situation trying to maintain personal hygiene for the patient.
76085264|NCT02495532|Other|Lymph node clearing technique with Carnoy solution|"Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
75646271|NCT05973305|Drug|Trusopt 20 mg/ml|dosing schedule t.i.d.
76085265|NCT02495532|Other|Lymph node clearing technique with GEWF solution|"Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
76085266|NCT02498184|Other|acupuncture|
76085267|NCT04869592|Biological|low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
75646272|NCT05973292|Other|resin cement containing phosphate ester monomer 10-methacryloyloxydecyl dihydrogen phosphate|Adhesive resin cement containing an MDP agent that is added to bonding agents to enhance bonding to ceramics like Ziconia and E-max
75646273|NCT05973292|Other|Non MDP containg resin cement|Adhesive resin cement not containing an MDP agent
75646274|NCT05973253|Drug|prepared drop of medroxy progestrone acetat 1%|In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
75646275|NCT04285424|Biological|Fecal Microbiota Transplantation|The fecal collection produced from a single healthy donor, unrelated to the patients
75646276|NCT05973227|Device|use of the TRIDENT system|usage of Trident System v1.0, just before the final resection, to obtain some images of the tissue oxygenation.
75930544|NCT04311424|Drug|14C Tirzepatide|Administered SC.
76085268|NCT04869592|Biological|high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
76085269|NCT04869592|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
76085270|NCT05709652|Diagnostic Test|Aortic CTA, .23s|Aortic CTA performed with short (0.23 sec) gantry rotation time.
76085271|NCT05709652|Diagnostic Test|Aortic CTA, .28s|Aortic CTA performed with standard (.28 sec) gantry rotation time.
75472916|NCT01964196|Drug|ASP1517|Oral administration
75472917|NCT01964196|Drug|Placebo|Oral
75472918|NCT01964235|Drug|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
75472919|NCT01964235|Drug|Placebo|Placebo will be administered orally and continuously on a twice a day dosing schedule.
75472920|NCT01964248|Drug|Placebo|Placebo cream applied 2 hours before blood sample
75472921|NCT01964248|Drug|lidocaïne/prilocaïne 5%|Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
75472922|NCT01964287|Drug|GEMBRAX|
76085272|NCT02498028|Procedure|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
76085273|NCT02498028|Procedure|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
75646277|NCT05973214|Behavioral|Cognitive Behavioral Therapy|CBT for IEI
75646278|NCT05973201|Device|Virtual reality headset|"A HEALTHY MIND® brand VR headset is dedicated to the study. The kit includes a noise-reducing audio headset, a face mask diffusing the visual part, a touchscreen tablet connected to the two VR headset systems, and a microphone connected to the tablet.~The available software allows patients to choose between 5 natural environments in which a hypnotic speech is broadcast, available in several languages (French, English, Spanish, Russian, Arabic)."
75646279|NCT05973188|Drug|Warfarin|Anticoagulant
76085274|NCT04495842|Other|Essential Oil Blend|5 drops of on a tester strip
76085275|NCT04495842|Other|Control Blend|5 drops on a tester strip
75336556|NCT00076622|Drug|Antidepressant medication|Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
75646280|NCT05973188|Drug|Rivaroxaban 20 MG Oral Tablet|Anticoagulant
75646281|NCT05973188|Drug|Apixaban 5mg or 2.5mg oral tablet|Anticoagulant
75336557|NCT00076622|Drug|No antidepressant medication|Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.
75793971|NCT05293834|Behavioral|Virtual Reality Aggression Prevention Training (VRAPT)|"VRAPT consists of sixteen 45- to 60-minute sessions that take place once or twice per week (total duration of the intervention = 8 to 16 weeks). Session time and intensity will be adapted to the individual participant and the sessions will be delivered by specially trained VRAPT therapists in individual settings. The immersive and interactive three-dimensional virtual environment will be presented via headphones and head-mounted displays, using software developed by CleVR. In the virtual environment, participants will interact with virtual characters that are controlled by the psychotherapist and practice new skills . The therapy program is targeted at factors and processes related to aggression and the underlying theoretical framework is based on cognitive behavioural therapy and the General Aggression Model (GAM).~The VRAPT consists of 4 phases:~Introduction (Session 1)~Inventory phase (Sessions 2-6)~Skills-training (Sessions 6-15)~Evaluation (Session 16)"
75930545|NCT04307394|Behavioral|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge.
75472923|NCT01964287|Drug|FOLFIRINOX|
75646282|NCT05973149|Drug|QLH12016|according to the scheme description
75646283|NCT05973136|Other|Telerehabilitation program based on cardiorespiratory principles|The intervention consists of a hybrid program. The participant will receive rehabilitation sessions in presence (aerobic component of the intervention based on maximal oxygen uptake measured before intervention by means on a ergospirometric test) and at home via a telerehabilitation platform. The length of the intervention is 12 weeks. For the in-presence sessions, they are going to be 75 minutes, 2x/week. For the at-distance sessions, they are going to be 45 minutes, 1x/week in groups of 3 to 4 participants. The intervention will consist of a warm-up, endurance, postural, and strengthening exercises, cool down and respiratory exercises. An exercise book with final recommendations is provided to the participants at the end of the intervention.
75646284|NCT05973123|Behavioral|Group Nature Outings|A 6 week nature-based intervention for pediatric anxiety. Every other week group outings for families in nature, alternating with every other week nature-based goals for families at home.
75646285|NCT05973123|Behavioral|Family Outings|6 weeks of weekly outings into nature. These will be supported by the research team through a weekly text message and written materials on skill building and activities to do outdoors.
75930546|NCT04301765|Drug|testosterone 1.62% gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
75930547|NCT04301765|Other|placebo gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
75930548|NCT04301414|Drug|BMS-986218 and Degarelix|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.
75930549|NCT04301414|Drug|Degarelix|Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy
75930550|NCT04291456|Drug|Minocycline 100mg|Single-arm trial of minocycline 100 mg twice daily
75336558|NCT00423202|Drug|ambrisentan|
75336559|NCT00003184|Biological|BCG vaccine|
75930551|NCT04290845|Behavioral|Relief-Hybrid|A 9-week behavioral intervention for primary care patients designed to reduce depression and pain-related disability.
75930552|NCT04284449|Other|Whole-practice cognitive optimization|This intervention is a whole-practice intervention that may include nutritional assessment & supplementation, determination of food sensitivities and dietary changes, natural products such as herbal anti-inflammatories, assessment of whole body-burden of toxicants (such as heavy metals and fungal toxins) and steps to reduce exposures, and behavioral changes such as exercise, meditation, and sleep hygiene optimization.
75930553|NCT04266977|Drug|Dexamethasone|restrictive use of DEX, based on standardized clinical and radiological criteria.
76085276|NCT03336996|Biological|stem cell transplantation|the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal.
76085277|NCT03336996|Procedure|BOLD-fMRI drived DTI scanning|All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.
75336560|NCT00003184|Biological|CD80 breast cancer vaccine|
75336561|NCT00003184|Biological|sargramostim|
75336562|NCT00003190|Drug|cytarabine|Given IV
75336563|NCT00003190|Drug|daunorubicin hydrochloride|Given IV
75472924|NCT01964339|Other|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.|Venous blood gas, basic metabolic panel, PSG variable data collection.
75472925|NCT01964339|Other|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.|Arterial blood gas, basic metabolic panel, PSG variable data collection
75930554|NCT04263480|Drug|Carfilzomib + Ibrutinib|"Carfilzomib:~Cycle 1, day 1: 20 mg/m² i.v. Cycle 1, day 8, day 15: 70 mg/m² i.v. Cycle 2 - 12, day 1, day 8, day 15: 70 mg/m² i.v. Cycle 13 - 24, day 1, day 15: 70 mg/m² i.v.~Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
75930555|NCT04263480|Drug|Ibrutinib|"Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
76085278|NCT02495298|Procedure|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
75930556|NCT04250441|Device|Focused Transcranial Ultrasound|The FDA has determined that power intensity limits of 720 mW/cm squared at 2 megaHertz is safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion.
75930557|NCT04250376|Device|Focused Transcranial Ultrasound|The FDA has determined the power intensity limits that are safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion (for example for hippocampal targets, there will be a delayed recall memory test).
75930558|NCT04245540|Dietary Supplement|Pau d' Arco|Encapsulated herbal Pau d' Arco.
76085279|NCT02495298|Procedure|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
76085280|NCT01690000|Drug|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
76085281|NCT02495220|Drug|SB dexmedetomidine bupivacaine block|SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
75336564|NCT00003190|Drug|etoposide|Given IV
75336565|NCT00003190|Drug|valspodar|Given IV
75646286|NCT05973097|Drug|total glucosides of paeony treatment|Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.
75646287|NCT05973097|Other|photodynamic therapy treatment|Cover the lesion with photosensitizer and fix it. Remove the photosensitizer and treat with laser diode.
75336566|NCT00003652|Drug|cisplatin|
75930559|NCT04196023|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
75336567|NCT00003652|Drug|fluorouracil|
75336568|NCT00003652|Procedure|neoadjuvant therapy|
75336569|NCT00003652|Radiation|radiation therapy|
75472926|NCT01964365|Drug|Cresto 20mg|tablet, rosuvastatin 20mg
75472927|NCT01964365|Drug|Fenofibric acid 135mg|capsule, fenofibric acid 135mg
75472928|NCT01964365|Drug|Cresto 20mg, Fenofibric acid 135mg|rosuvastatin 20mg, Fenofibric acid 135mg
75472929|NCT01964391|Drug|Trastuzumab|Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
75472930|NCT01964391|Drug|Doxorubicin|Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
75472931|NCT01964391|Drug|Cyclophosphamide|Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
75472932|NCT01964391|Drug|Paclitaxel|Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
75472933|NCT01964391|Drug|Docetaxel|Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
75472934|NCT01964391|Drug|Carboplatin|Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
75472935|NCT01964391|Drug|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
75472936|NCT01964404|Drug|Marijuana|Smoked plant with THC
75472937|NCT01964404|Drug|Dronabinol|Capsule with THC
75646288|NCT05973097|Other|glucosides of paeony and photodynamic therapy combined treatment|Glucosides of paeony and photodynamic therapy are combined for the treatment
75646289|NCT05973071|Behavioral|Tuune Supplemented Contraceptive Visit|Participants complete the Tuune contraceptive decision aid health questionnaire (Tuune for clinics) as part of their standard OBGYN clinic appointment.
75646290|NCT05973071|Behavioral|Traditional Contraceptive Visit|Participants will complete a standard OBGYN clinic appointment without using the Tuune contraceptive decision aid health questionnaire (Tuune for Clinics).
75646291|NCT05973045|Procedure|Operative Hysteroscopy 24 Centigrade Degree|Operative hysteroscopy will be performed at room temperature distention medium.
75646292|NCT05973045|Procedure|Operative Hysteroscopy 37 Centigrade Degree|Operative hysteroscopy will be performed using a heated distention medium.
75930560|NCT04196023|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
75472938|NCT01964404|Drug|Placebo|Capsule with no active ingredient
75472939|NCT01964417|Drug|Colonoscopy after bowel cleansing|
75472940|NCT01964456|Other|Joint perception task|
75472941|NCT01964456|Behavioral|Body Shape Questionnaire|
76085282|NCT02495220|Drug|intravenous dexmedetomidine|received 1µ/kg IV dexmedetomidine
76085283|NCT01690546|Drug|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
75930561|NCT04172922|Drug|Topical Sirolimus|Open label, topical sirolimus (1%) cream will be applied to cutaneous component of complicated vascular anomalies twice daily for 4 weeks and once daily thereafter- for the duration of study.
76085284|NCT01690546|Drug|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
75793972|NCT05288803|Other|Clinical decision support tool (CDS tool)|The investigators will integrate the CDS tool into clinical practice at each participating clinic after data collection for the Control cohort is complete. All physical therapists at the participating clinic locations will use the CDS tool to inform rehabilitation decision making for Veterans with total knee arthroplasty. The CDS tool will provide personalized information regarding each Veterans' recovery in addition to personalized visit utilization guidelines. Clinicians will use the CDS tool with Veterans at their initial postoperative visits and every 2weeks throughout their course of care thereafter.
75793973|NCT05285904|Other|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab, that have started before inclusion of the patient into the study will be enrolled.
75646293|NCT05972980|Other|COVID-19|The investigators stratified our population based on COVID-19 virus positivity to identify any risk factors in this population compared to the NON-COVID-19 population.
75793974|NCT05283083|Drug|Dexmedetomidine|A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.
75793975|NCT05279157|Procedure|Implantation|Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient
75930562|NCT04168567|Diagnostic Test|Microbiome analysis|Samples from the vagina, endometrium and anus and analyzing microbiome with NGS technique.
76085285|NCT01690546|Drug|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
76085286|NCT02495376|Behavioral|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
75930563|NCT04144140|Drug|E7766|E7766, solution, intratumorally
75930564|NCT04139772|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
75930565|NCT04139772|Drug|Abiraterone Acetate or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
76085287|NCT05709418|Behavioral|Intensiv support for first graders in Norway|Intervention targeting early numeracy skills that are known to be important for mathematical development, focusing on counting skills, counting strategies, number knowledge, word problem solving and basic understanding of addition and subtraction
75646294|NCT05972967|Drug|OMS906 Study Drug - 3 mg/kg|All patients will receive 3 doses of OMS906 of 3 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.
75646295|NCT05972967|Drug|OMS906 Study Drug - 5 mg/kg|All patients will receive 3 doses of OMS906 of 5 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.
75793976|NCT05279157|Procedure|Lipoaspiration|"Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.~Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient"
75793977|NCT05276557|Combination Product|PyloPlus Urea Breath Test System|System containing a kit containing 13C urea and breath collection bags, and an analyzer to test breath samples pre and post 13C ingestion.
75930566|NCT04129281|Procedure|Surgery|Surgery acconding to clinical practice
75930567|NCT04121832|Device|Biofeedback training treatment in Fibromyalgia, a pilot study|The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
75930568|NCT04121832|Other|Control (treatment as usual)|The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
75472942|NCT01964456|Other|Measure of the heart rate|
75472943|NCT01964469|Behavioral|mobile & web-based action plan|Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
75472944|NCT01964482|Other|Strength training|Strength training followed by intake of a protein drink
75472945|NCT01964534|Drug|ABI-007|ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
75793978|NCT05276557|Diagnostic Test|Stool Antigen Test|An antigen test performed via a laboratory to test patients' stool for H. pylori
75793979|NCT05265637|Device|Visian|Visian implantable collamer lens (ICL)
75793980|NCT05265624|Behavioral|Early disclosure of genetic testing results|Early disclosure group receives results of genetic testing at Month 1
75930569|NCT04091204|Drug|Olaparib tablets|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
75930570|NCT04075721|Drug|M3258|Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) or twice per week on Day 1 and Day 4 until disease progression.
75930571|NCT04075721|Drug|M3258 20 mg|Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.
76085288|NCT02498106|Dietary Supplement|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins [B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene] and minerals [Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid [EPA] and docosahexaenic acid [DHA])
76085289|NCT03120390|Other|Best Practice|Undergo usual care
76085290|NCT03120390|Behavioral|Exercise Intervention|Undergo AE
76085291|NCT03120390|Behavioral|Exercise Intervention|Undergo RE
75646296|NCT05972967|Drug|Ravulizumab|Participants must be on prescribed stable dose of ravulizumab (IV dose per approved summary of medicinal product characteristics) for at least 2 doses (4 months) prior to baseline. During the Run-in period - ravulizumab only. During the Treatment period all patients will receive 3 doses of ravulizumab at 8-week intervals. Clinical responders at Week 24 will not receive additional ravulizumab. Incomplete responders may receive an additional 3 doses of ravulizumab with OMS906 at 8-week intervals. Non responders will return to treatment with ravulizumab or standard of care.
75472946|NCT01964534|Drug|Gemcitabine|1000 mg/m² IV /30min (day 1, day 8, day 15)
75472947|NCT01964534|Drug|simplified LV5FU2|Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
75472948|NCT01964573|Drug|Rotigotine|"Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
75472949|NCT01964573|Other|Placebo|"Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.~Frequency:~Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
75646298|NCT05972928|Drug|Sitagliptin 100mg|Sitagliptin at a dose of 100 mg every 24 hours for 3 months
75646299|NCT05972915|Diagnostic Test|Separation sign|The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta.
75646300|NCT05972902|Drug|Dydrogesterone|Dydrogesterone molecular structure and pharmacologic effects are closely related to endogenous progesterone
75646301|NCT05972902|Drug|Cetrorelix acetate|GnRH antagonist
75646302|NCT05972902|Drug|Triptorelin|GnRH agonist
75646303|NCT05972876|Behavioral|Blood flow restriction training|BFR will be achieved using an automatic personalized tourniquet system (MAD-UP, Angers, France) designed to automatically calculate limb occlusion pressure
75793981|NCT05265624|Behavioral|Late disclosure of genetic testing results|Late disclosure group receives results of genetic testing at Month 12
75793982|NCT05260736|Procedure|Infraclavicular brachial plexus block|Named after the anatomical site; patients will be applied infraclavicular brachial plexus block with costoclavicular lateral, costoclavicular medial or lateral sagittal approach.
75472950|NCT01964586|Drug|Dexmedetomidine|2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
75793983|NCT05260645|Behavioral|Back School|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
75930572|NCT04074304|Other|I-HoME|A multi-component technology-based care intervention.
76085292|NCT03120390|Other|Laboratory Biomarker Analysis|Correlative studies
75472951|NCT01964586|Drug|Lidocaine|10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
75472952|NCT01964586|Drug|Adrenaline|12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
75472953|NCT01964599|Dietary Supplement|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
75472954|NCT01964599|Dietary Supplement|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
75472955|NCT01964599|Dietary Supplement|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
75472956|NCT01964599|Dietary Supplement|Control|
75472957|NCT01964625|Other|PET-CT Scan|PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
75472958|NCT01964638|Procedure|Targeted Biopsy|
75472959|NCT01964651|Drug|JNJ-42165279 50 mg|JNJ-42165279 50 mg orally administered once daily for 10 days.
75472960|NCT01964651|Drug|JNJ-42165279 100 mg|JNJ-42165279 100 mg orally administered once daily for 10 days.
75472961|NCT01964651|Drug|JNJ-42165279 30 mg|JNJ-42165279 30 mg orally administered once daily for 10 days.
75472962|NCT01964651|Drug|Placebo|Matching placebo orally administered once daily for 10 days.
75930573|NCT04063514|Other|Focused Ultrasound|With focused ultrasound, there is an expected accentuation of local perfusion and potential temporary opening of the blood brain barrier with the aim is to provide better delivery of therapeutic agents including medication, particulates and cellular elements for treatment of neoplastic, inflammatory and degenerative brain diseases. The present study seeks to investigate differences in perfusion between areas treated and untreated by this modality in order to further explore its use in clinical application for the treatment of brain disease.
75930574|NCT04058418|Other|Survey Administration|Completion of a short survey.
75930575|NCT04028245|Drug|Spartalizumab|Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion
75930576|NCT04028245|Drug|Canakinumab|Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion
76085293|NCT03120390|Device|Monitoring Device|Receive Polar heart rate monitor
75930577|NCT04019444|Biological|ChAd155-RG|The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.
75336570|NCT04389164|Procedure|Tissue-engineered skin grafts of autologous scar dermal scaffolds|"scar excision. The thickness of scar tissue in the middle of scar is removed with a roller cutter and the thickness is about 0.01 -- 0.02mm.~take autologous skin slices of the patient with an electric skin knife, cut out a small piece of skin, and prepare autologous epidermal basal cell suspension for use;The rest of the skin should be the same size as the wound.~the prepared autogenous scar dermal stent was grafted onto the scar resection wound surface, and the prepared autoepidermal basal cells were sprayed between the mesh and on the dermal stent, and autologous skin slices were grafted onto the wound surface and fixed with pressure bandaging;~after the operation, the outer dressing should be changed regularly according to the conventional treatment, and the wound surface condition should be observed and recorded according to the experimental scheme."
75930578|NCT04019444|Other|Placebo|0.9% Sodium Chloride, USP injection.
75930579|NCT04019444|Biological|Rabies Vaccine|The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
75336571|NCT04773236|Drug|sodium bicarbonate 8.4%|mixing the sodium bicarbonate with 2%lidocaine and 1:80.000 epinphrine using mixing pen (onset buffering system)
75646304|NCT05972876|Behavioral|Resistance training|Resistance training will be performed without any blood flow restriction
75930580|NCT03994406|Drug|CLM2 topical gel|Active topical gel for forehead dermal application
75930581|NCT03994406|Drug|Placebo topical gel|Placebo topical gel for forehead dermal application
75646305|NCT05972837|Device|Surface electrical stimulation (SES)|Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.
75646306|NCT05972837|Other|Remote medical support|The remote medical support includes a session of video call with a rehabilitation doctor in the first week and weekly telehealth visits with a live physical therapist or physician. The contents of the video calls contain patient education, stretching exercises teaching and instructions of using SES for MPS.
75930582|NCT03990051|Drug|Pro-ocular™ topical gel|Topical gel for forehead dermal application
75930583|NCT03990051|Drug|Placebo topical gel|Topical gel for forehead dermal application
75646307|NCT05972798|Other|Omega-3 fatty acids|2.2 g/d omega-3 PUFAs (1.2g EPA and 1g DHA per day) in patients with LLD
75793984|NCT05259553|Other|Blood samples|"Peripheral blood sampling will be performed at different time points of the study, for a total volume of 20-40 mL:~Sampling before MM treatment,~Sampling during MM treatment (at 3 months post-initiation if no autograft or before autograft),~Only for Patients treated with Apixaban or Eliquis®, 2 additional samplings during MM treatment for pharmacokinetics analysis."
75793985|NCT05257733|Other|None, pure observationnal study|pure observationnal study
76085294|NCT03120390|Other|Quality-of-Life Assessment|Ancillary studies
75646308|NCT05972798|Other|Soybean oil|Soybean oil in patients with LLD
75646309|NCT05972785|Drug|Calcium channel blocker|Drugs with ATC code C08 will be categorised as calcium channel blockers.
75646310|NCT05972785|Drug|Beta blocker|Drugs with ATC code C07 will be categorised as beta-blockers.
75793986|NCT05252403|Genetic|PTG-CARCIK-CD19|PTG-CARCIK-CD19 cells is a gene therapy medicinal product (GTMP) composed of genetically modified allogeneic T lymphocytes formulated as cell suspension in normal saline solution and freezing media
75793987|NCT05248321|Drug|Tranexamic Acid Powder|2g tranexamic acid powder will be given via the endoscopy directly to the peptic ulcer
75793988|NCT05245357|Behavioral|Lentil|Participants in the lentil arm of the study will consume a meal containing 140 g of lentils for breakfast one morning.
75336572|NCT04773236|Drug|2%lidocaine with 1:80.000 epinphrine|injection
75336573|NCT04773236|Device|Mixing pen (onset buffering system)|Premixing of the two solutions sodium bicarbonate and lidocaine with epinphrine before the local anesthesia adminstration to the patient
75646311|NCT05972785|Drug|Diuretic|Drugs with ATC code C03 will be categorised as diuretics.
75646312|NCT05972785|Drug|RAS|Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
75793989|NCT05245357|Behavioral|Control|Participants in the control arm of the study will consume a meal containing 0 g of lentils for breakfast one morning.
75793990|NCT05241106|Drug|HYML-122|each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
75930584|NCT03975114|Drug|Chemotherapy|Any approved first line chemotherapy regimen at Investigators' choice
75930585|NCT03975114|Drug|Durvalumab|Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
75930586|NCT03975114|Drug|Tremelimumab|Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)
75930587|NCT03969355|Other|Mortality|Patients who died during PICU stay
75930588|NCT03957343|Device|Pacing and Planning App|Participants will download and use the Pacing and Planning app through mybrainpacer.ca. The app will be used to track and monitor their daily tasks and symptoms at any time, for as long as they would like to use the app. While using the app, participants will also fill out short assessments, including the Rivermead Post-Concussion Questionnaire once a month (to monitor symptoms) and an overall symptom question once a week (to rate how they feeling in general from a lot better to a lot worse).
75930589|NCT03955783|Drug|Venetoclax|Given by mouth
75930590|NCT03955783|Drug|Selinexor|Given by mouth
75930591|NCT03942120|Drug|Ustekinumab|Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
76085295|NCT03120390|Other|Questionnaire Administration|Ancillary studies
76085296|NCT03276286|Device|Nativis Voyager|Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
76085297|NCT03336918|Drug|Lithium|"Open-label lithium treatment for Bipolar Disorder Subjects~Healthy Controls only repeat testing - no intervention"
75930592|NCT03941613|Procedure|SEEG guided RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.
75336574|NCT00003658|Biological|filgrastim|
75930593|NCT03941613|Procedure|Anterior temporal lobectomy|classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere
75930594|NCT03940742|Drug|Tirzepatide|Administered SC
76085298|NCT04724746|Behavioral|Written Exposure and Cognitive Behavioral Therapy|Intervention involves writing details about a recent sexual assault and coping skills for substance use.
75336575|NCT00003658|Biological|rituximab|
75930595|NCT03918070|Device|Yukon Choice PC and Yukon Chrome PC|The Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
75930596|NCT03917654|Biological|Pfs230D1M-EPA/AS01|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
75336576|NCT00003658|Drug|cyclophosphamide|
75336577|NCT00003658|Drug|pentostatin|
75646313|NCT05972785|Drug|Other AHT|Drugs with ATC code C02 will be categorised as other antihypertensives.
75646314|NCT05972785|Drug|None AHT|None AHT
75336578|NCT00078728|Behavioral|Family-Based Anxiety Prevention Program|Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
75336579|NCT00078728|Behavioral|Evaluation only|Participants will undergo evaluations without active treatment for 8 weeks.
75646315|NCT05972746|Device|Telemonitoring with electronic alerts|Patients assigned to this group will receive standard care plus a telemonitoring program.
75646316|NCT05972746|Other|Standard of care|Standard of care
75646317|NCT05972694|Dietary Supplement|Freeze dried grape powder|46g/d freeze-dried grape powder
75793991|NCT05241093|Drug|HYML-122; cytarabine|HYML-122 is administered orally consecutive with 400mg bid or 600mg bid or dose adjusted by DMC judgement in each 28-day treatment cycle. cytarabine is administered by intravenous infusion with 100mg/m2 or dose adjusted by DMC judgement once daily on the first to 7th day of each treatment cycle. Upon completion of each 28-day treatment cycle, patients may continue to receive HYML-122 and cytarabine if they are benefit from the treatment and the toxicity is tolerable.
75793992|NCT05240573|Other|SKI App|"The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion.~The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information."
75793993|NCT05240144|Other|IHG|Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.
75793994|NCT05240144|Other|Aerobic exercises|Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.
76085299|NCT02494830|Drug|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
75336580|NCT00002836|Biological|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
75336581|NCT00002836|Drug|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
75336582|NCT00002836|Drug|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
75336583|NCT00002836|Drug|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
75336584|NCT00002836|Drug|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
75336585|NCT00002836|Drug|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
75930597|NCT03917654|Biological|HAVRIX|HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
75646318|NCT05972668|Device|Smartphone Apps|The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
75646319|NCT05972642|Device|HIFU-treatment|The investigator will sedate the subject and perform the HIFU procedure with the investigational medical device according to the pre-established procedure plan (see Table 11 for procedure plan) (procedure may take up to 2 hours). During the procedure, the investigator may modify the pre-established procedure plan by checking in with the subject occasionally to assess the presence of heat and pain at the site of the investigational device application.
75646320|NCT05972616|Biological|Natural Matrix Protein (NMP)|human bone allograft
75930598|NCT03917654|Biological|TYPHIM Vi (Salmonella typhi vaccine)|TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
75793995|NCT05240144|Other|Sham IHG|Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period
75930599|NCT03917654|Biological|Menactra|Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
75930600|NCT03917654|Biological|AVAXIM|AVAXIM - Pediatric [Hepatitis A Vaccine Inactivated] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
75646321|NCT05972603|Procedure|1.0 g Vancomycin powder into the wound|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation and additional application 1.0 g Vancomycin powder into the wound
75646322|NCT05972603|Procedure|0,35% povidone-iodine solution lavage|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation
75793996|NCT05236556|Behavioral|Best practice advisory (BPA)|"For patients who are not on oral anticoagulation (AC) but have elevated stroke risk, the practice advisory will fire, which is to say it will be active in the providers workflow during outpatient encounters with a patient's primary care provider (PCP) or cardiology provider."
75793997|NCT05233163|Drug|Empagliflozin|Empagliflozin 10 mg oral daily for 12 weeks
75793998|NCT05231083|Device|Genital Nerves Stimulation|Transcutaneous electrical stimulation of the genital nerves using a TENS device and skin adhesive surface electrodes
75793999|NCT05229991|Drug|Lonafarnib|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
75794000|NCT05229991|Drug|Ritonavir|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
75794001|NCT05227105|Behavioral|Physical Activity|Physical activity will be encouraged up to an amount of 150 minutes per week.
75794002|NCT05227105|Behavioral|Delayed intervention|Physical activity will be encouraged at the end of the trial.
75930601|NCT03903120|Behavioral|ASSIST|"Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice."
75930602|NCT03893240|Diagnostic Test|Neutralizing Antibody to SPK-3006 capsid|Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
75930603|NCT03875274|Drug|Ropivacaine, Morphine|Morphine added to ropivacaine for fascia iliaca compartment block
75930604|NCT03875274|Drug|Ropivacaine, Saline|Normal saline added to ropivacaine for fascia iliaca compartment block
75930605|NCT03794050|Other|Resistance training exercise|randomized complete crossover for acute resistance training exercise session
75930606|NCT03794050|Other|Aerobic training exercise|randomized complete crossover for acute aerobic exercise training exercise session
75930607|NCT03775850|Biological|EDP1503|4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10^10 colony-forming units (CFU)
75930608|NCT03775850|Biological|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
75930609|NCT03762109|Drug|Dantrolene|muscle relaxant
75930610|NCT03762109|Drug|Placebo Oral Tablet|inactive pill
75930611|NCT03732664|Drug|Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab|One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.
75930612|NCT03727789|Drug|FACT Complex-targeting Curaxin CBL0137|Given IA
76085300|NCT03215836|Procedure|Bronchoscopy and Nasal Epithelium Brush Sampling|After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
75930613|NCT03703583|Other|There is no intervention in this observational study.|There is no intervention in this observational study.
75930614|NCT03679260|Other|Carbohydrate restricted diet|20 grams total carbs/day
75930615|NCT03679260|Other|Non-restricted diet|Subject follows normal diet
75930616|NCT03679260|Other|Phone counseling with dietitian|Weekly calls with dietitian
75930617|NCT03657576|Biological|C134|C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
75930618|NCT03651154|Procedure|Hypovolemic Phlebotomy|Removal of 7-10ml/kg of blood from participant, as tolerated after patient is under anesthesia, before liver resection start time
76085301|NCT03341832|Drug|NVP-1203|oral dose for 7 days
76085302|NCT03341832|Drug|NVP-1203-R|oral dose for 7 days
76085303|NCT03341832|Drug|NVP-1203 placebo|oral dose for 7 days
75646323|NCT05972590|Other|Biological samples collection (blood + feces)|Blood + stools samples will be collected from each volunteer
75646324|NCT05972577|Other|Health Promotion and Education|Undergo GO!
75646325|NCT05972577|Other|Medical Device Usage and Evaluation|Wear accelerometer
75646326|NCT05972577|Other|Quality-of-Life Assessment|Complete quality of life assessments and diary entries
75646327|NCT05972577|Other|Questionnaire Administration|Complete questionnaires
75646328|NCT05972538|Device|Osstell ( Osstell AB, Goteborg, Sweden).|Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery
75646329|NCT05972538|Device|periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein|Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery
76085304|NCT03341832|Drug|NVP-1203-R placebo|oral dose for 7 days
75794003|NCT05213884|Drug|Camrelizumab|200 mg, intravenous infusion over 30 minutes (Q3W); 1~3 cycles of camrelizumab before radiotherapy and camrelizumab are maintained for 16 cycles (1 year) after the end of radiotherapy.
75930619|NCT03617237|Other|Retrospective Populations|"All patients who are currently treated by any physician at the University of Texas Southwestern campus Aston Clinic, Seay Clinic, PHHS Clinic, Moncrief Radiation Oncology, St. Paul West Campus Radiation Oncology, East Radiation Oncology Clinic will be included in the registry. The data from the charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number.~The research involves no more than minimal risk to the subjects.~The waiver will not adversely affect the rights and welfare of the subjects.~The research could not practicably be carried out without the waiver.~Whenever appropriate, the subjects will be provided with additional pertinent information after participation."
76085305|NCT05484180|Other|training and counseling supported guided imagery application|After the preparation process, as a nursing attempt to the individuals in the experimental group; Training and consultancy supported guided imagery based on the health promotion model will be implemented. This initiative; It will take a total of 12 weeks, including 6 weeks of training program and 6 weeks of counseling program and guided imagery.
76085306|NCT02239744|Behavioral|Air purifiers|The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
76085307|NCT04351048|Procedure|Stepwise Excavation|"stepwise excavation includes selective caries removal to soft dentine on pulpal wall in the first stage of the excavation and~after six months, the second stage of intervention includes re-entring the cavities and wall selective removal to firm dentine on pulpal wall."
75336586|NCT00002836|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
75336587|NCT04773548|Other|VR-JIT|Job interview with virtual interviewer
75472963|NCT01964664|Behavioral|Mindfulness Meditation Training|6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.
75646330|NCT05972538|Other|questionnaire for patient satisfaction|A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.
75646331|NCT05972499|Other|task-oriented training with pretend play|"Pretend play: Children engage in pretend play by acting out themes, taking on roles, assigning attributes to inanimate objects, and using objects as if they were something else Props will be added to hold the child interest. Role play costumes, or occupation props (police officer's suit), stimulate pretending elements.~Task-oriented training: It is involving the active, repetitive practice of functional activities to learn or relearn a motor skill. Training implies that the behavioral experiences are not just repetition of the same sensorimotor skill but involves progressive challenges to a participant's capabilities and involves tasks that are meaningful to the participant. It is based on the following principles: functional goal-directed training focus on practicing specific activities of importance to the child during daily activities; planning activity-focused interventions by adapting knowledge of motor learning ; and allowing for the interest and participation of the children."
75794004|NCT05213884|Drug|Concurrent cisplatin chemotherapy|cisplatin is given at a dose of 40 mg/m2 via intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy every week for 6 cycles.
75930620|NCT03617185|Other|High Intensity Interval Training (HIIT)|Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
75930621|NCT03617185|Other|Routine Exercise|Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
75930622|NCT03617185|Procedure|Bariatric surgery|Patients will undergo bariatric surgery as part of their routine care
75930623|NCT03613025|Diagnostic Test|Sampling of non-invasive and/or non-targeted respiratory tract specimens|Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
75336588|NCT00003664|Biological|aldesleukin|
75336589|NCT00003664|Biological|recombinant interferon alfa|
75336590|NCT00003664|Drug|fluorouracil|
75336591|NCT00003664|Drug|gemcitabine hydrochloride|
75336592|NCT00003196|Drug|chemotherapy|Undergo cytoreductive chemotherapy
75336593|NCT00003196|Radiation|total-body irradiation|Undergo TBI
75336594|NCT00003196|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
75472964|NCT01964664|Behavioral|Audio Group|Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
75472965|NCT01964677|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
75472966|NCT01964703|Drug|Rubus occidentalis extract|
75472967|NCT01964729|Device|rTMS|The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
75794005|NCT05213884|Radiation|Intensity-modulated radiotherapy (IMRT)|70 Gy/ 35 fractions/7 weeks, 5 fractions/week, 1 fraction/day.
75794006|NCT05211024|Drug|Penicillin G Benzathine|Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
75794007|NCT05210439|Drug|Short-treatment of any active antibiotic regimen|7 days of any active antibiotic treatment for BSI-PA
75930624|NCT03561207|Diagnostic Test|EV3D Assay|The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.
75930625|NCT03458234|Device|16 French Foley Catheter|"A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex."
75930626|NCT03424109|Behavioral|healthcare service utilization in the six months following the ED visit|The analysis of the effect of PRIM-ER on ED disposition using a generalized linear binomial model with random site level effects.
76085308|NCT04351048|Procedure|One Step Excavation|*one step excavations is completed in the first stage via performing selective removal to soft dentine on pulpal wall of the cavities.
76085309|NCT03336840|Drug|Metformin tablets|0.5g (1 pill) of Metformin tablets administered three times a day orally before meal
76085310|NCT03336840|Drug|ProMetS probiotics powder|4g (2 strips) of ProMetS probiotics powder administered orally every night
76085311|NCT03336840|Drug|1. Metformin tablets; 2. ProMetS probiotics powder|"0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~4g (2 strips) of ProMetS probiotics powder administered orally every night"
76085312|NCT03336762|Diagnostic Test|Intra spinal pressure monitoring|Sub dural pressure monitoring using a FDA approved intracranial pressure monitor
76085313|NCT03336762|Diagnostic Test|Intra spinal microdialysis monitoring|Sub arachnoid microdialysis monitoring using a FDA approved hepatic microdialysis catheter
75472968|NCT01964729|Device|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
75472969|NCT01964742|Genetic|blood samples|
75794008|NCT05210439|Drug|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment for BSI-PA
75472970|NCT01964768|Other|Skin prick-test|
75472971|NCT01964781|Drug|Tranexamic Acid|Topical administration - does it reduce surgical bleeding?
75472972|NCT01964781|Drug|Bupivacaine|Topical Bupivacaine- does it reduce surgical pain?
75646332|NCT05972460|Drug|IMM2510|IMM2510 is administered intravenously every 2 weeks, every 28 days for a treatment cycle.
75646333|NCT05972447|Procedure|Immediate implant placement of Ultrawide diameter dental implants|immediate placement of ultrawide diameter dental implants in a fresh extraction socket of mandibular molar teeth
75646334|NCT05972434|Other|Sunscreen A|Participants will apply sunscreen A topically.
75646335|NCT05972434|Other|Sunscreen B|Participants will apply sunscreen B topically.
75472973|NCT01964781|Drug|Adrenaline|Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
75472974|NCT01964781|Drug|tranexamic acid plus saline|
75472975|NCT01964781|Drug|saline|
75646336|NCT05972421|Other|High Intensity Proactive Outreach|phone calls + mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
75646337|NCT05972421|Other|Low Intensity Proactive Outreach|mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
75646338|NCT05972408|Procedure|percutaneous nephrlolithotomy|Endoscopic removal of renal stones
75646339|NCT05972408|Genetic|VDR gene, CASR gene|checking possible mutations of VDR and CASR genes
75646340|NCT05972395|Other|Localized vs Widespread Mechanical Pain Hypersensitivity|Based on pressure pain threshold mapping, participants will be classified as having either localized mechanical pain hyperalgesia (hyperalgesia limited to the lumbosacral region) or widespread mechanical pain hyperalgesia (hyperalgesia extending beyond the lumbosacral region).
75646341|NCT05972382|Diagnostic Test|Quantitative Sensory and Neurophysiological Testing|"Participants will undergo the following quantitative sensory and neurophysiological diagnostic tests:~Surface electromyography (EMG) of the neck flexor muscles during the craniocervical flexion test to assess neck flexor muscle fatigue. EMG sensors will be placed over the sternocleidomastoid and longus colli muscles. Cervical joint position error testing to evaluate proprioceptive awareness and cervicocephalic kinesthetic sensibility. Participants will be seated upright and blindfolded."
75646342|NCT05972369|Other|12-Week Tailored Exercise Intervention|12-week individually tailored exercise therapy program based on patient presentation. Supervised physiotherapy plus home exercise
75646343|NCT05972330|Dietary Supplement|VRx MyBiotics Oral Lozenges|VRx MyBiotics Oral Lozenges are composed of prebiotics, probiotics, and postbiotics.
75930627|NCT03410784|Drug|Pembrolizumab|Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles
75930628|NCT03410784|Drug|Paclitaxel|Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles
75930629|NCT03410784|Drug|Carboplatin|Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles
75930630|NCT03396367|Behavioral|PARTNER|The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
75930631|NCT03396367|Behavioral|Education Intervention|The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
76085314|NCT03336684|Behavioral|Patient education|Rheumatoid arthritis patients will be provided with disease education literature
76085315|NCT03049072|Radiation|Protons and Carbon Ions|
76085316|NCT02497872|Procedure|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
76085317|NCT02497638|Drug|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
76085318|NCT02497638|Drug|Atorvastatin|Atorvastatin 20 mg once daily until progression.
76085319|NCT02497638|Drug|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
76085320|NCT02497638|Drug|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
75336595|NCT00003196|Drug|cyclosporine|Given IV or PO
75336596|NCT00003196|Drug|mycophenolate mofetil|Given PO
75336597|NCT00003196|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
75930632|NCT03363841|Drug|SCY-078|Oral SCY-078
75930633|NCT03355482|Drug|Methylprednisolone|160mg IM at baseline
75336598|NCT00003196|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
75336599|NCT04777292|Device|Use of a mobile health application until app completion|Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
75336600|NCT00002848|Procedure|psychosocial assessment and care|
75336601|NCT00002848|Procedure|quality-of-life assessment|
75336602|NCT00003202|Drug|cisplatin|
75336603|NCT00003202|Drug|gemcitabine hydrochloride|
75336604|NCT00003202|Radiation|radiation therapy|
75472976|NCT01964820|Behavioral|Positive Affect Skills Training|"Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.~The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.~For a full description, see A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test (Moskowitz et al., 2012)."
76085321|NCT02495064|Drug|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
75930634|NCT03355482|Drug|Placebos|IM saline injection at baseline
75930635|NCT03329417|Other|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
75930636|NCT03323580|Other|GDFT|Target parameter will be titrated with fluid bolus, and thus individual amount varied depending on the parameter value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
75930637|NCT03323580|Other|traditional fluid therapy|Fluid therapy will be done without goal directed. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
75930638|NCT03315260|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
75930639|NCT03310619|Biological|JCAR017|Gene modified autologous T cells
75930640|NCT03310619|Drug|Durvalumab|Anti-PD-L1
75930641|NCT03310619|Drug|CC-122|Pleiotropic Pathway Modifier
75930642|NCT03310619|Drug|Ibrutinib|Ibrutinib
75930643|NCT03310619|Drug|CC-220|CC-220
75930644|NCT03310619|Drug|Relatlimab|Relatlimab
75930645|NCT03310619|Drug|Nivolumab|Nivolumab
75930646|NCT03310619|Drug|CC-99282|CC-99282
75930647|NCT03280589|Other|Sheetali/Sheekari Pranayama|Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex [6]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.
76085322|NCT02494908|Behavioral|Playing a computer game simulating a car race|Playing a computer game simulating a car race
76085323|NCT02494752|Procedure|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
76085324|NCT02494752|Procedure|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
76085325|NCT02494674|Behavioral|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
76085326|NCT02493192|Drug|pethidine and haloperidol injection|
75336605|NCT00003670|Drug|arzoxifene hydrochloride|
75336606|NCT04738682|Other|Digital dietary registration|"The purpose of the intervention is to test whether digital dietary registration can yield more precise and consistent data, than conventional pen and paper based registration.~Furthermore a subjective evaluation of the use of digital registration will be conducted by the staff upon completion of the intervention. The format will be individual interviews held by the investigators."
75336607|NCT04738682|Other|Conventional dietary registration|The conventional way of doing dietary registration. This is done by a paper form, with the dietary options listed. The form is then filled in and logged by staff working in the afternoon.
75336608|NCT00002854|Biological|filgrastim|
75336609|NCT00002854|Drug|carboplatin|
75336610|NCT00002854|Drug|cisplatin|
75336611|NCT00002854|Drug|cyclophosphamide|
75336612|NCT00002854|Drug|etoposide|
75336613|NCT00002854|Drug|ifosfamide|
75336614|NCT00002854|Drug|mesna|
75336615|NCT00002854|Drug|paclitaxel|
75336616|NCT00002854|Procedure|peripheral blood stem cell transplantation|
75336617|NCT02308202|Drug|doxazosin|
75336618|NCT02308202|Drug|Perindopril|
75336619|NCT02308202|Drug|Placebo|
75336620|NCT00003214|Drug|carboplatin|
75336621|NCT00003214|Drug|cisplatin|
75336622|NCT00003214|Drug|cyclophosphamide|
75336623|NCT00003214|Drug|doxorubicin hydrochloride|
75336624|NCT00003214|Drug|in vitro sensitivity-directed chemotherapy|
76085327|NCT02493192|Other|birth ball|
76085328|NCT02749084|Biological|T reg DLI|"Purified Treg cells will be obtained from the original HSC donor (T reg DLI).~Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.~The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.~T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.~Release Criteria of Treg cell preparation will be defined.~The product will be infused into the recipient through a venous catheter."
76085329|NCT03341754|Biological|D/ChAd63-CA|Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA
76085330|NCT03341754|Biological|D/ChAd63-CAT|Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT
75930648|NCT03280589|Other|Sitting Quietly|Participant breaths in their natural way with out instruction
76085331|NCT03341754|Other|Infectivity Control (IC) Group|Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
75930649|NCT03280589|Other|Deep breathing|Participant is required to pay attention to each breath
75930650|NCT03279510|Device|hearing aids|Subjects are fit with hearing aids.
75930651|NCT03256240|Other|side-to-side functional end anastomosis|type of anastomosis
75336625|NCT00003214|Drug|paclitaxel|
75336626|NCT00002860|Procedure|Surgery|Complete surgical resection of metastatic melanoma
75336627|NCT03148964|Biological|blood sampling|Blood Sampling at J0, M1, M3, M6, M12, M24 and every 12 months until the end of the study
75930652|NCT03256240|Other|Kono-S analstomosis|antimesenteric anastomosis
75930653|NCT03244696|Behavioral|Step Tracking|The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
75930654|NCT03244696|Behavioral|Water Tracking|The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
75930655|NCT03201198|Behavioral|Active Life|The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
75930656|NCT03201198|Behavioral|Chair exercises|Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
75336628|NCT00384592|Drug|Esomeprazole|
75930657|NCT03190785|Other|Benzoic acid washout and exposure|see above
75930658|NCT03188627|Biological|Bronchial basal cells|Transplantation of autologous bronchial basal cells
75930659|NCT03153683|Other|Registry|Collect standard of care clot, tissue and arterial blood during standard of care cerebrovascular procedure for lab analysis.
76085332|NCT05705752|Other|Balance training|12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.
76085333|NCT05705752|Other|Pilates training|12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
76085334|NCT03341598|Procedure|CAF|Periodontal surgical technique to treat gingival recessions.
76085335|NCT03341598|Procedure|R|Restorative procedure to treat tooth structure loss.
76085336|NCT03341598|Procedure|MC|Xenogenous graft placed in the surgical site.
76085337|NCT02497716|Drug|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban granules
76085338|NCT02238808|Drug|Estradiol|Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
75336629|NCT00384592|Procedure|Physical exam|
75336630|NCT00384592|Procedure|Pregnancy test if applicable|
75336631|NCT00003220|Drug|bryostatin 1|
75336632|NCT00002866|Biological|filgrastim|
75336633|NCT00002866|Drug|docetaxel|
75336634|NCT00002866|Drug|epirubicin hydrochloride|
75336635|NCT00003232|Drug|clodronate disodium|
75336636|NCT00003232|Drug|mitoxantrone hydrochloride|
75336637|NCT00003232|Drug|prednisone|
75336638|NCT00003232|Procedure|quality-of-life assessment|
75336639|NCT00003238|Drug|perillyl alcohol|
75336640|NCT04329052|Behavioral|Adventure-based training with health educational talk|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
75336641|NCT00002884|Drug|chemotherapy|
75336642|NCT00002884|Drug|cisplatin|
75336643|NCT00002884|Drug|fluorouracil|
75472977|NCT01964833|Procedure|Periodontal treatment|"Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.~Patient will receive sham PDT."
76085339|NCT02497794|Other|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
75930660|NCT03123042|Procedure|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
75930661|NCT03093064|Drug|Natalizumab|Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
75930662|NCT03093064|Other|Placebo: normal saline|Normal saline, intravenous infusion
75930663|NCT03060577|Drug|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
75472978|NCT01964833|Procedure|Periodontal treatment and PDT|Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
75472979|NCT01964846|Dietary Supplement|Resveratrol, curcumin|
75930664|NCT03060577|Drug|Evolocumab|Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
75646344|NCT05972317|Other|Low FODMAP dietary regimen|"intervention will include a guidance by a clinical dietitian about low FODMAP diet~The FODMAP diet has three phases:~Elimination - Avoidance from high-FODMAP foods (2-6 weeks)~Reintroduction -Structured challenges of specific food groups each time (6-8 weeks).~Maintenance - personalized diet, according to the response in step 2."
75336644|NCT00002884|Radiation|brachytherapy|
75336645|NCT00002884|Radiation|radiation therapy|
75646345|NCT05972304|Device|Nasal positive airway System by Vyaire Medical|Incidence of Hypercarbia and Hypoxia in interventional group and its monitoring using transcutaneous (SpO2) and (tCO2) Sensor
75930665|NCT02940236|Other|Ultrasound|Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
75930666|NCT02916810|Device|Active rTMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
75930667|NCT02916810|Device|Sham rTMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
75930668|NCT02872714|Drug|pemigatinib|Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
75336646|NCT00003682|Drug|doxorubicin hydrochloride|
75336647|NCT00003682|Drug|methylprednisolone|
75336648|NCT00003688|Biological|dactinomycin|
75472980|NCT01964846|Dietary Supplement|Placebo|
75646346|NCT05972252|Device|Cerebrovascular Interventional Procedural Control System|The Cerebrovascular Interventional Procedural Control System is intended for use in the remote delivery and manipulation of guidewires and rapid deliver stent catheters, and remote manipulation of guide catheters during cerebrovascular intervention procedures.
75930669|NCT02872714|Drug|pemigatinib|Pemigatinib once a day by mouth continuously.
75930670|NCT02863380|Procedure|Functional magnetic resonance imaging used to individualize rTMS protocol|Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
75930671|NCT02863380|Device|Individualized rTMS (transcranial magnetic stimulation)|
75930672|NCT02863380|Device|Classical rTMS (transcranial magnetic stimulation)|
75930673|NCT02863380|Device|Classical tDCS (transcranial direct current stimulation)|
75930674|NCT02797275|Drug|Albuterol|Beta agonist respiratory inhaler
75930675|NCT02797275|Drug|Placebo|respiratory inhaler with no medication
75336649|NCT00003934|Drug|tretinoin|Given orally
75336650|NCT00003934|Drug|daunorubicin hydrochloride|Given IV
75336651|NCT00003934|Drug|cytarabine|Given IV
75336652|NCT00003934|Drug|mercaptopurine|Given IV
75336653|NCT00003934|Drug|methotrexate|Given IV
75336654|NCT00003934|Drug|arsenic trioxide|Given IV
75336655|NCT00003694|Drug|omacetaxine mepesuccinate|Given IV
75336656|NCT00003694|Drug|cytarabine|Given IV
75930676|NCT02787005|Biological|Pembrolizumab|Intravenous infusion
75930677|NCT02755467|Device|KTP laser|Dual Wavelength Laser Emitting 532 nm Laser Energy
75930678|NCT02734290|Drug|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
75930679|NCT02734290|Drug|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
75336657|NCT00003694|Other|laboratory biomarker analysis|Correlative studies
75930680|NCT02734290|Drug|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
75930681|NCT02673333|Drug|Pembrolizumab|
75930682|NCT02656394|Drug|GL101|Topical Gel
75930683|NCT02656394|Drug|Placebo|Placebo topical gel
75930684|NCT02633189|Drug|Erlotinib|given orally 150 mg daily
75930685|NCT02633189|Drug|Bevacizumab|15 mg/kg intravenously every 21 days.
75646347|NCT05972239|Other|Standard pulmonary rehabilitation program|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load (watts) determined starting from the 6MWT using the Hill equation and will be increased to reach a perception of moderate-intense fatigue and/or dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be calibrated to allow the execution of 12 consecutive repetitions and will be progressively increased by 0.5 kg in order to cause a moderate/intense fatigue and/or dyspnea. Group exercises aimed at improving flexibility of the trunk, lower and upper limbs, lasting at least 30 minutes, 5/6 days a week, for a total of 12-14 sessions.
75646348|NCT05972239|Other|Balance training added on standard pulmonary rehabilitation|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load determined from the 6MWT (Hill equation) and will be increased based on dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be progressively increased. Supervised balance training sessions lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The sequence of the exercises will be personalized according to the result of the Berg Balance Scale and modified according to the progress.
76085340|NCT01483612|Behavioral|Interdisciplinary lifestyle intervention|"Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity."
75794013|NCT05185271|Behavioral|Dyad-focused strategy training|"Rehabilitation therapists will be hired to deliver the intervention to the stroke survivors-caregiver dyads on a one-to-two base. The therapist will ask the dyad to identify their shared goals and provide them the global strategy Goal-Plan-Do-Check (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
76085341|NCT02497560|Dietary Supplement|proprietary formula|
75794015|NCT05176080|Drug|Famitinib|Famitinib orally, daily or every other day
75646349|NCT05972174|Biological|mRNA-1018 for H5N8|Sterile liquid for injection
75646350|NCT05972174|Biological|mRNA-1018 for H7N9|Sterile liquid for injection
75794016|NCT05176080|Drug|SHR6390|SHR6390 orally, daily for 3 weeks followed by 1 week off
75646351|NCT05972174|Biological|mRNA-1018 for H5 Only|Sterile liquid for injection
75646352|NCT05972174|Biological|mRNA-1018 for H7 Only|Sterile liquid for injection
75794017|NCT05176080|Drug|Fulvestrant|Fulvestrant
75646353|NCT05972174|Biological|mRNA-1018 for H5 Only-CG|Sterile liquid for injection
75646354|NCT05972161|Device|Thermal Imaging camera|Thermal Imaging camera used to measure respiratory flow.
75646355|NCT05972096|Behavioral|Combination DBT, self-compassion and contextual-based skills|Psychotherapy combination. Skills of DBT plus self-compassion and contextual skills
75646356|NCT05972070|Device|ROMTech Portable Connect|The ROMTech PortableConnect Rehab System is a continuous rehabilitative exercise therapy device that uses assisted movement to measure, evaluate, exercise, re-educate and strengthen muscles, and to increase joint range of motion.
75794018|NCT05165082|Drug|Timolol maleate 0.5% ophthalmic solution|Apply on affected finger or toes twice daily for 8 weeks
75794019|NCT05165082|Procedure|Cryotherapy with liquid nitrogen|Conducted on affected finger or toes every other week for four sessions.
75930686|NCT02633085|Device|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
75794020|NCT05159531|Drug|PrEP|Participants will receive Descovy® 200/25mg 1 tablet once daily for 72 weeks.
75794021|NCT05159531|Other|mHealth Model of Care|Freddie® allows for asynchronous contact between patients and care providers, meaning that it does not require both groups to be connected in real time, instead allowing communication over a number of days.
75794022|NCT05159531|Other|Standard of Care|Delivery of PrEP care through the local standard of care
75930687|NCT02621242|Procedure|Upper endoscopy|Upper endoscopy with biopsies
75930688|NCT02621242|Procedure|Anoscopy|Anoscopy with biopsies
75930689|NCT02621242|Drug|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
76085342|NCT03336294|Radiation|SRM P31|All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
75930690|NCT02619435|Drug|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
75930691|NCT02618850|Procedure|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
75930692|NCT02618850|Drug|first-line chemotherapy|as prescribed by oncologist
75930693|NCT02526368|Drug|Pyruvate (13C)|Given IV
75930694|NCT02526368|Drug|Hyperpolarized 13C,15N2-urea|Given IV
75930695|NCT02526368|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
75930696|NCT02514083|Drug|Ibrutinib|Ibrutinib 420mg PO daily for the duration of the study.
76085343|NCT02497326|Drug|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
76085344|NCT02497326|Drug|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
75336658|NCT00003250|Drug|fenretinide|
75794023|NCT05144893|Behavioral|Virtual Mindfullness-Based Intervention|Virtual administration of the social support components of an adapted 4-week Mindfulness Based Cognitive Therapy for Postpartum Depression (MBCT-PD) intervention. Each session includes a review of assigned online mindfulness practice and barriers to practice, other homework if also assigned, psychoeducation, and mindfulness practices relevant to the session's theme.
75930697|NCT02514083|Drug|Fludarabine|Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4
75930698|NCT02500576|Biological|Aldesleukin|Given IV or SC
75930699|NCT02500576|Drug|Cyclophosphamide|Given IV
75930700|NCT02500576|Drug|Fludarabine Phosphate|Given IVPB
75930701|NCT02500576|Other|Laboratory Biomarker Analysis|Correlative studies
75930702|NCT02500576|Biological|Pembrolizumab|Given IV
75930703|NCT02500576|Other|Quality-of-Life Assessment|Ancillary studies
75930704|NCT02500576|Biological|Therapeutic Tumor Infiltrating Lymphocytes|Given IV
75930705|NCT02441777|Device|Polarization-Sensitive OFDI|OCT Imaging of the eye
76085345|NCT02497326|Drug|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score >4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
76085346|NCT02497170|Behavioral|Education of goal setting and achievement|Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
75646357|NCT05971992|Dietary Supplement|Chicory-derived inulin-type β-fructans|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of prebiotic. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-weeks intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of prebiotic per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
75794024|NCT05144282|Procedure|intravitreal injection of anti VEGF|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF).
75794025|NCT05144282|Procedure|laser photocoagulation|The treatment for ROP was either primary laser photocoagulation.
75794026|NCT05135975|Drug|Cabozantinib|Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
75930706|NCT02395848|Drug|Fidaxomicin|200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
75930707|NCT02364791|Device|standard techniques used to achieve air leak control|
75930708|NCT02364791|Device|Hemopatch|
75930709|NCT02340585|Device|Next Generation Neuroform Stent System|The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
75930710|NCT02214381|Drug|Myocet|
75930711|NCT02214381|Drug|Cyclophosphamide|
75930712|NCT02214381|Drug|Paclitaxel|
75930713|NCT02081326|Biological|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
75930714|NCT02081326|Biological|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
75930715|NCT02061761|Biological|BMS-986016|Specified Dose on Specified Days
75930716|NCT02061761|Biological|BMS-936558|Specified Dose on Specified Days
75930717|NCT01990053|Behavioral|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
75930718|NCT01944332|Procedure|gamete treatment|Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The spermatozoa will be prepared in the standard fashion and utilized for injection or intrauterine insemination after exposure to a membrane permeabilizing agent. Human recombinant PLC-zeta will also be used if the spermatozoa have been confirmed to be PLC-zeta deficient. The injected oocytes will then be exposed to activating agents for the purpose of inducing embryo development. The oocyte activating agent is calcium ionophore and for sperm membrane permeabilization to assist in sperm DNA decondensation is streptolysin O (SLO).
75930719|NCT01927068|Device|"Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)"|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
75930720|NCT01898104|Radiation|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
75930721|NCT01898104|Drug|Valproic Acid|
75930722|NCT01898104|Drug|Capecitabine|
75930723|NCT01817452|Drug|Trastuzumab|
75930724|NCT01817452|Drug|Pertuzumab|
75930725|NCT01817452|Drug|Paclitaxel|
75930726|NCT01815242|Drug|nab-Paclitaxel|
75930727|NCT01815242|Drug|Gemcitabine|
75930728|NCT01815242|Drug|Carboplatin|
75930729|NCT01802749|Drug|Bevacizumab|
75930730|NCT01802749|Drug|Paclitaxel|
75930731|NCT01802749|Drug|Carboplatin|
75930732|NCT01802749|Drug|pegylated liposomal doxorubicin|
75930733|NCT01802749|Drug|Gemcitabine|
76085347|NCT03341442|Procedure|No hip precautions|No hip precautions practiced after THA surgery
76085348|NCT02245672|Drug|MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
76085349|NCT02245672|Drug|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
76085350|NCT02245672|Drug|Placebo|Placebo administered via the CRC749 and Diskus devices
75794027|NCT05132543|Device|High density micro-electrocorticography for neural speech prothesis|ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.
75794028|NCT05132257|Procedure|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
75794029|NCT05129995|Other|Passive heat treatment|Participants will be subjected to an 8-week (3 x pw) passive heat treatment, by means of infrared sauna bathing, intervention.
75794030|NCT05128955|Device|Splenic artery embolization with vascular embolic coils or plugs|Splenic artery embolization with vascular embolic coils or plugs
75794031|NCT05128071|Drug|Progesterone|Randomized to 400 mg (200 mg twice daily) oral micronized progesterone daily
75930734|NCT01801904|Drug|Panitumumab|6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
76085351|NCT03336138|Other|AMA (Assistance for ambulatory patients)|telephone follow-up modality
75930735|NCT01781338|Other|Induction therapy|The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
76085352|NCT03341286|Drug|TK3|Tryptophan and thiamine as on oral supplement
76085353|NCT03336060|Diagnostic Test|Cortical Correlates of Jump Landing Task|The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
76085354|NCT04477330|Other|Transcranial direct current stimulation (tDCS)|1 mA tDCS
75336659|NCT01896596|Biological|Menjugate|Administered with routine vaccinations at 3 months of age
75336660|NCT01896596|Biological|Menitorix|Administered with routine vaccinations at 3 months
75336661|NCT01896596|Biological|NeisVac-C|Administered with routine vaccinations at 3 months
75336662|NCT00003256|Drug|alvocidib|
75336663|NCT04772846|Drug|Oral tablet|Oral 250mg chloroquine tablets
75336664|NCT04772846|Drug|Placebo|Oral placebo tablets
75336665|NCT00003946|Drug|danazol|
75336666|NCT04695002|Behavioral|MIRA|Based on the initial assessment, the citizen and professional agree what outcomes the citizen should report in MIRA. This could be pain, mood, sleep quality, energy level, dependent on the priorities of the citizen. Similarly, different activities are reported, e.g. exercise, social activities, prolonged sitting or work-related tasks. The citizen and the professional agree how often the citizen reports the outcomes and tasks, and the citizen is notified by the MIRA-app when it's time for reporting. The data will be visualized in a graph for the professional in the back-end of the system, making it possible for the citizen and the professional to view the same, real-time reported data. This provides the base for discussing and adjusting the course of rehabilitation as symptoms change over time. At the same time, this increases the citizen's knowledge of how symptoms, mood, sleep and activities all interact, thereby giving them the tools better cope with their health condition.
75472981|NCT01964872|Drug|JNJ-38877618: Part 1a|Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
75472982|NCT01964872|Drug|JNJ-38877618: Part 1b|Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
75794032|NCT05128071|Drug|Placebo|Randomized to placebo twice daily
75794033|NCT05127122|Drug|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Injectable
75794034|NCT05127122|Other|Saline|Placebo Saline
75794035|NCT05126225|Behavioral|Stigma reduction|The intervention is modularized to have eight weekly sessions of 2-hour group discussions, led by a trained facilitator. The facilitator applies the principle of CBT and provides psychoeducation to promote the awareness and understanding of HIV stigma as well as training to help participants acquire alternative coping skills, such as relaxation techniques.
75930736|NCT01779206|Drug|Epirubicin|
75930737|NCT01779206|Drug|Cyclophosphamide|
75930738|NCT01779206|Drug|Docetaxel|
75930739|NCT01779206|Drug|Paclitaxel|
75930740|NCT01745965|Drug|T-DM1|
75930741|NCT01745965|Drug|Trastuzumab|
75930742|NCT01706120|Drug|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
75930743|NCT01706120|Drug|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
75930744|NCT01706120|Drug|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
75930745|NCT01656551|Drug|Gemcitabine|
75930746|NCT01656551|Drug|Pemetrexed|500 mg/m2 day 1 every 3 weeks
75930747|NCT01656551|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks
75930748|NCT01649674|Drug|polyethylene glycole (PEG) solution|
75930749|NCT01649674|Drug|sodium picosulphate and magnesium citrate solution|
75930750|NCT01628211|Procedure|Laparoscopy|second look laparoscopy to evaluate for peritoneal carcinosis
75930751|NCT01628211|Procedure|peritonectomy|for patients with PCI < 20
76085355|NCT04477330|Other|Ankle motor training|Visuomotor target tracking task
76085356|NCT04477330|Behavioral|High intensity interval speed based treadmill training (HIISTT)|Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
76085357|NCT03341208|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed before and after subject has undergone catheter directed therapy
76085358|NCT04461418|Drug|Glucocorticoid therapy|The study intervention is defined as treatment with either prednisone or dexamethasone as palliative therapy for the control of neurological symptoms; patients with symptomatic brain metastases with a requirement for glucocorticoid therapy will be treated with an available, standard-of-care immune checkpoint inhibitor regimen.
76085359|NCT02497092|Other|Technique of injection|
75930752|NCT01628211|Drug|Folinic Acid|20 mg/m2 IV given just before HIPEC for patients with PCI < 20
76085360|NCT05667610|Other|Immune-supportive diet|The intervention includes a immune-supportive diet over a period of 4 months
75794036|NCT05121324|Drug|Standardized seizure protocol|The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
76085361|NCT02497014|Device|1 Stent|Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
75472983|NCT01964872|Drug|JNJ-38877618: Part 1c (optional)|Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
75472984|NCT01964872|Drug|JNJ-38877618: Part 2|Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
75930753|NCT01628211|Drug|5-Fluorouracil|400 mg/m2 IV given just before HIPEC in patients with PCI < 20
75930754|NCT01628211|Drug|Oxaliplatin|460 mg/m2 intraperitoneal hyperthermic perfusion for patients with PCI < 20
75472985|NCT01964872|Drug|JNJ-38877618: Part 3|Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
75646358|NCT05971992|Dietary Supplement|Maltodextrin|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of maltodextrin. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-week intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of placebo per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
75930755|NCT01628211|Drug|systemic chemotherapy|according to national Italian (AIOM) guidelines and may include biotherapies for patients with PCI > 20
75930756|NCT01593488|Drug|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
75646359|NCT05971979|Other|No intervention|No intervention
75930757|NCT01453127|Drug|I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)|I-123 Ioflupane solution for injection into a living test subject. The iodine introduced during manufacture is a radioactive isotope, I-123, and it is the properties of this isotope that makes the solution visible to a gamma camera on SPECT imaging. I-123 has a half-life of approximately 13 hours and a gamma photon energy of 159 keV making it an good radionuclide for medical imaging. DaTscan is administered by intravenous cannula. The scan is carried out 3-6 hours post injection.
75930758|NCT01453127|Device|Single photon emission computed tomography (SPECT) scan|Single-photon emission computed tomography(SPECT)is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera. However, it is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.
75930759|NCT01406691|Device|Flashes|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
75930760|NCT01405586|Drug|Gemcitabine|1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
75930761|NCT01405586|Drug|Gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
75930762|NCT01405586|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks for 6 cycles
75930763|NCT01309230|Biological|Vigil™|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
75930764|NCT01238692|Drug|LBH589|Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
75930765|NCT01238692|Drug|Rituximab|"Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:~Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL)."
75472986|NCT01964872|Drug|JNJ-38877618: Part 4 (optional)|Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
75472987|NCT01964872|Drug|Placebo: Parts 1a, 2, 3, and 4 (optional)|Administered orally matched to study drug
75930766|NCT01173341|Diagnostic Test|Echocardiography|Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
75472988|NCT01964885|Dietary Supplement|IQP-AS-105|
75930767|NCT01173341|Other|Blood Collection|Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
75930768|NCT01173341|Other|Symptoms Questionnaire|Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
75930769|NCT01035112|Procedure|MRI|
75930770|NCT00996983|Drug|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
75930771|NCT00819832|Procedure|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
75930772|NCT00819832|Procedure|Vertebroplasty|Medical cement will be injected into broken back bone.
75930773|NCT00819832|Device|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
75646360|NCT05971901|Diagnostic Test|BV|The use of the BV test, ordered at the discretion of the treating physician
75646361|NCT05971862|Drug|SKI-G-801|Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.
75646362|NCT05971771|Other|Placebo|Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed
75646363|NCT05971771|Dietary Supplement|Treatment|14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed
75646364|NCT05971758|Drug|Fimepinostat|The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.
75646365|NCT05971706|Device|Ozone therapy using a device (Ozone DTA Ozone Generator, Denta Tec Dental AS, Norway)|Ozone therapy procedures will be performed immediately after non-surgical periodontal treatment and three times (every third day) within one week using a device equipped with a periodontal tip according to equipment producer recommendations. The periodontal tip will be halted 1 mm short of the pocket depth. Ozone will be applied only to the pockets; which depth is equal to or greater than 5 mm. Ozone application time to the pockets will be 30 seconds at a fixed concentration of 2,100 ppm (80% oxygen) through a connected handpiece.
75646366|NCT05971706|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal treatment consists of oral hygiene instructions, full mouth supragingival scaling using hand instruments, ultrasonic devices, polishing, and subgingival debridement under local anesthesia with sharp Gracey and Universal curettes and ultrasonic instruments in a single appointment.
75646367|NCT05971680|Drug|VITAMIN B1 500mg|VITAMIN B1 (High Potency) 500mg tab every day for 3 months
75646368|NCT05971680|Device|intra-uterine contraceptive device|intra-uterine contraceptive device
75930774|NCT00660842|Procedure|carboplatin|AUC 6 IV day 1 every 21 days
75930775|NCT00660842|Drug|paclitaxel|175 mg/m2 IV day 1 every 21 days
75930776|NCT00660842|Drug|carboplatin|AUC 2 IV every week
75930777|NCT00660842|Drug|paclitaxel|60mg/m2 IV every week
75930778|NCT00642057|Drug|tetrabenazine|25 mg titrated to optimal dose per patient
75930779|NCT00526396|Drug|cisplatin|80 mg/m2 on day 1 for 6 cycles
75930780|NCT00526396|Drug|etoposide|100 mg/m2 on days 1,2,3 for 6 cycles
75646369|NCT05971654|Drug|azithromycin|azithromycin.:500 mg PO once for 5 days every month
75646370|NCT05971628|Procedure|RAPID procedure|RAPID procedure stands for Resection And Partial Liver Transplantation with Delayed Hepatectomy for hepatocellular carcinoma
75646371|NCT05971615|Other|peripheral venous blood gases|peripheral venous blood gases
75646372|NCT05971589|Biological|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
75646373|NCT05971576|Biological|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
75472989|NCT01964885|Dietary Supplement|Placebo|
75646374|NCT05971563|Dietary Supplement|Casein|Natural protein
75646375|NCT05971563|Dietary Supplement|L-amino acids|Synthetic amino acids based protein substitute for Phenylketonuria
75646376|NCT05971563|Dietary Supplement|CGMP-AA|Glycomacropeptide based protein substitute for Phenylketonuria
75646377|NCT05971550|Other|Absence of antibiotic treatment|Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to STI or positive PCR at 3 months)
75930781|NCT00526396|Drug|cisplatin|cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
75930782|NCT00526396|Drug|etoposide|etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
75930783|NCT00499421|Procedure|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
75930784|NCT00431704|Drug|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
75930785|NCT00431704|Drug|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
75930786|NCT00431704|Drug|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
75930787|NCT00412022|Drug|tamoxifen|20 mg daily for 5 years
75930788|NCT00412022|Drug|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
75930789|NCT00412022|Drug|letrozole|2.5 mg daily for 5 years
75930790|NCT00412022|Drug|zoledronic acid|4 mg every 6 months
75930791|NCT03474510|Drug|local infiltration of liposomal bupivacaine|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
75930792|NCT03474510|Other|continuous infusion of ropivacaine interscalene nerve block|"All patients will receive a single injection of 30mL, 0.5% preservative-free ropivacaine.~Those patients randomized to receive CINB will then have an indwelling catheter placed and held in place by Dermabond and Tegaderm. Placement will be confirmed by ultrasound. Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer."
75930793|NCT02227953|Device|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
75930794|NCT02227953|Device|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
75930795|NCT02470832|Drug|RG1662|
75930796|NCT02470832|Drug|itraconazole|
75930797|NCT05258682|Drug|Bromelains|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
75930798|NCT05258682|Drug|Acetylcysteine|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
75930799|NCT03310112|Behavioral|4-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
75930800|NCT03310112|Behavioral|2-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
75930801|NCT02258841|Behavioral|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
76085362|NCT02497014|Device|2 Stents|"Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion."
76085363|NCT05654428|Other|Mckenzie Extension Exercises|The exercises used to create space between under lying structures of lumber spine which help centralization of pain and can be performed in prone lying such as prone press ups, prone on elbow, and head lift in prone.
76085364|NCT05654428|Other|William Flexion Exercises|Exercises for strengthening of gluteal and abdominal muscles which help to reduce pressure on the nerve root by promoting flexion at lumber spine such as knee to chest, double knee to chest, bridging(Gluets bridge), and straight leg raise (SLR).
75646378|NCT05971550|Drug|Ceftriaxone|Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal PCR again positive for NG during follow-up
75646379|NCT05971537|Drug|antibiotic lock|"In the intervention arm, in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution . Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below:~Cefazolin 10mg/mL Ceftazidime 10mg/mL Vancomycin 10mg/mL Gentamicin 5mg/mL Tienam 50mg/mL"
75646380|NCT05971537|Drug|conventional IP antibiotics|In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines
75646381|NCT05971524|Dietary Supplement|6-BT|2,4 or 8mg of 6-BT once daily for 4 weeks
75646382|NCT05971524|Dietary Supplement|Placebo|A placebo capsule once daily for 4 weeks
75646383|NCT05971511|Other|Questionnaire|Questionnaire
75646384|NCT05971472|Procedure|Arthroscopic Repair|Arthroscopic Repair for medial meniscus posterior Root tears
76085365|NCT05641792|Device|CGM (Dexcom G6)|Dexcom G6 system consists of a transmitter and sensor that measure interstitial glycaemia every 5 minutes. Measurements are transmitted via Bluetooth to a compatible device, that uploads the data on a virtual drive. This allows for remote real-time glycaemia monitoring on another device.
75646385|NCT05971472|Procedure|High tibial osteotomy|Open Wedge High tibial osteotomy for medial meniscus posterior Root tears
76085366|NCT03335982|Procedure|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
75794037|NCT05121324|Drug|Conventional seizure protocol|"The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal.~for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg)."
75646386|NCT05971459|Behavioral|Improvised Active Music Therapy|During the music improvisation process, the accredited music therapist will carefully listen to the participant's initial musical expression, including tempo, rhythmic structure, dynamics, and beat. The accredited music therapist will then join, reflecting or confirming aspects of the participant's musical expression using standard music therapy improvisation techniques such as mirroring, matching, dialoguing, and containing on their electronic instrument. By comparing the participant's and therapist's musical responses over the sessions, it will be possible to identify note frequency, velocity of movement, synchronization, and acquisition of rhythmic complexity.
75794038|NCT05116540|Biological|HB-adMSCs|Autologous product
75794039|NCT05116540|Drug|Placebo|Normal Saline
75930802|NCT02258841|Behavioral|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
75930803|NCT02258841|Behavioral|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
75794040|NCT05113056|Device|Acutus Medical Pulsed Field Ablation System|All subjects will be treated using the Acutus Medical Pulsed Field Ablation System (PFA System) to treat their atrial fibrillation.
75794041|NCT05109611|Drug|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
75930804|NCT02258841|Behavioral|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
75794042|NCT05109611|Device|Nasal spray with isotonic saline|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
75794043|NCT05108987|Behavioral|Exercise Morning|Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the morning.
75794044|NCT05108987|Behavioral|Exercise Afternoon|Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the afternoon.
75930805|NCT02258841|Behavioral|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
75930806|NCT05258604|Procedure|argon plasma coagulation|APC Standard APC equipment will be used, consisting of a high-frequency electrosurgical generator (ICC 350; ERBE, Tübingen, Germany), an argon source which is regulated automatically (APC 300) and APC probe.
75930807|NCT05258604|Procedure|endoscopic band ligation|endoscopic band ligation will be carried out using a Saeed Multi-Band Ligator (Cook Medical, WinstonSalem, NC), and ligation bands were placed on the GAVE.
75930808|NCT03310034|Dietary Supplement|NAD-precursors|Intervention product containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan (total of 204 NE per serving) in a whey protein source for 31 days.
75930809|NCT03310034|Dietary Supplement|Control|Control product containing amino-acid mixture resembling whey-protein not containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan. To be taken for 31 days.
75930810|NCT02228031|Drug|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
76085367|NCT03335904|Other|Hyperoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
76085368|NCT03335904|Other|Hypoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
76085369|NCT03335904|Other|Repeated Hypoxic Apneas|Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
75646387|NCT05971446|Device|Visual Evoked Potential (VEP)|Small gold-cup electrodes will be placed on the participant's head using a small dot of adhesive paste. The handheld device is then connected to the electrodes, and the participant's eyes are exposed to a light flicker. Each eye will be tested separately, and while testing one eye, the other eye may be patched.
75794045|NCT05106153|Drug|Suvorexant|Suvorexant will be administered orally as per assigned treatment sequence.
75794046|NCT05106153|Drug|Zolpidem|Zolpidem will be administered orally as per assigned treatment sequence.
75794047|NCT05106153|Drug|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
75794048|NCT05106153|Drug|Placebo|Placebo will be administered orally as per assigned treatment sequence.
75794049|NCT05102591|Drug|Ketorolac|Intervention in syringe for target dose of 0.5 mg/kg, maximum 30 mg of ketorolac (1 mL), and administer as a direct IV push over 1-5 minutes
75794050|NCT05102591|Drug|Metoclopramide|Intervention in 50 mL mini bag of normal saline (0.9% NaCl) for target dose of 0.15 mg/kg, maximum 10 mg of metoclopramide (2 mL), and administer as infusion over 15-30 minutes
75646388|NCT05971446|Device|Electroretinogram (ERG)|Skin electrodes will be placed under each eye. Eyes will then be exposed to a flashing light. Each eye will be tested separately and while testing one eye, the other eye may be patched.
75794051|NCT05102591|Device|Active Remote Electrical Neuromodulation Device|The REN device is a battery-powered, wirelessly controlled neuromodulation device that attaches via armband to the upper arm. The REN device is controlled by a smartphone application and administers electrical stimulation to the local C and Aδ nociceptive sensory nerves of the upper arm. This stimulation is achieved using a symmetrical, biphasic, square pulse, modulated at a frequency between 100-120 Hz. Each pulse has a width of 400 µs and the user, via the smartphone application, can adjust the output current to apply a maximum of 40 mA. Each stimulation session occurs over 45 minutes and each device can administer up to 12 stimulation sessions.
75930811|NCT02228031|Other|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
75646389|NCT05971420|Other|VR activity-based|VR games activities were chosen for simulated cognitive-motor training in the VR group. The VR training modules for this study included fire drill, walking exercise, balancing game activities and community shopping practices. These training modules involved dual task components; the participant was expected to train up his/her physical and cognitive motor performances in an 8-week VR activity-based program. VR group participants received 2-sessions per week, 16 training sessions in total.
75930812|NCT02400944|Behavioral|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
75930813|NCT02400944|Other|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
75930814|NCT01799265|Device|Somnetics Transcend Auto|
75336667|NCT04695002|Behavioral|Control|Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
75472990|NCT01964911|Drug|Ropivacaïne|"The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN <3/10 : non opioids, EN 3-5/10 : weak opioids, EN>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days)."
75472991|NCT01964937|Biological|DNA-HIV-PT123|The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
75472992|NCT01964937|Biological|NYVAC-HIV-PT1|The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10^8 PFU.
75646390|NCT05971420|Other|Exercise-based (Baduanjin)|The exercise group used a traditional Chinese Qigong Baduanjin exercise incorporating with a fall prevention education strategy.
75646391|NCT05971394|Device|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
75646392|NCT05971355|Device|LimpiAD cream 2,5% plus|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
75646393|NCT05971355|Other|Vehicle|"Vehicle of LimpiAD cream 2.5 % plus which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus cream but without the HAc-40 component."
75794052|NCT05102591|Drug|Placebo|0.9% NaCl will be administered to participants through IV in identical dosages, methods, and duration as the ketorolac and metoclopramide interventions described above.
76085370|NCT03335904|Other|Hypoxic Sleep Study|Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
76085371|NCT03335904|Drug|Losartan|Losartan, 50mg, BID
76085372|NCT03335904|Drug|Placebo|Placebo, 50mg, BID
75646394|NCT05971355|Other|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
75646395|NCT05971342|Drug|Gelatin sponge-loaded apoptotic vesicle complex（Kuaikang®)|The experimental group
75646396|NCT05971342|Drug|Gelatin sponge only （Kuaikang®)|The positive control group
75930815|NCT01799265|Device|Respironics REMstar Auto with C-Flex|
76085373|NCT05233020|Device|robotic|fifteen patients undergo robotic operation
76085374|NCT05233020|Device|hybrid|fifteen patients undergo hybrid operation
76085375|NCT03335826|Procedure|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia.
75794053|NCT05102591|Device|Sham Remote Electrical Neuromodulation Device|The sham REN device is identical to the active REN device but the stimulation parameters are different, administering a modulated symmetrical biphasic square electrical pulse, modulated frequency of ~0.083 Hz and a modulated pulse width of 40-550 µ. These sham parameters are designed to induce a sensation that will be perceptible to participants, similar to stimulation from the active REN device, but at a frequency that is low enough so as to not modulate the nociceptive sensory nerves.
75794054|NCT05093829|Biological|NmCV-5|NmCV-5 is a pentavalent meningococcal (A, C, Y, W, X) polysaccharideconjugate vaccine composed of capsularpolysaccharides (PS) from Neisseria meningitidis serogroups A, C, Y, W, and X individually conjugated to a protein carrier, either mutant diphtheria toxoid (CRM197) or tetanus toxoid (TT).
75794055|NCT05093829|Biological|MenACWY-TT|MenACWY-TT (the comparator meningococcal vaccine) is a WHO-PQ quadrivalent meningococcal (A, C, Y, W) polysaccharide-conjugate vaccine manufactured by Pfizer.
75794056|NCT05093686|Behavioral|RUBIES|RUBIES is an 8 module intervention that begins with foundational education on ASD (Session1), followed by introducing basic applied behavior analysis principles (Session 2). Instruction is then provided on strategies that can prevent problematic behaviors from occurring (Session 3 and 4). Reinforcement (Session 5) reviews the use of tangible and social reinforcers tools to promote new/desired behaviors while planned ignoring and functional communication training (Session 6) teaches that disruptive behavior can serve as a form of communication while ignoring disruptive communicative attempts. Sessions conclude with instruction on effective ways to deliver commands to promote compliance (Session 7) and targeting approaches to ensure positive behavior gains can maintain over time and strategies can be used across classrooms and staff (Session 8).
75794057|NCT05093686|Behavioral|Usual Care Training|Usual Care Training is an 8 module psychoeducation program that will provide foundational information on autism spectrum disorders, including the diagnostic criteria, appropriate educational services, common interventions, and how to promote social skills in the classroom.
75930816|NCT02328872|Device|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
75930817|NCT02328872|Device|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
75930818|NCT02232321|Other|PsA MDA|
75930819|NCT03478410|Procedure|Epicardial fat biopsy|A 1 cm (~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
75930820|NCT02232399|Drug|Levosimendan|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
75930821|NCT02232399|Drug|Milrinone|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
75930822|NCT00704522|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
75930823|NCT00704522|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
75646398|NCT05971316|Device|Foam Roller|General Warm-up + Foam Roller
75646399|NCT05971303|Other|Questionnaire|Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies
75646400|NCT05971290|Device|Continuous positive airway pressure|Continuous positive airway pressure administered by face mask
75646401|NCT05971290|Device|Ambient air|Air (fraction of inspired oxygen) at 14000 feet in elevation
76085376|NCT03335826|Procedure|General anesthesia|General anesthesia and postoperative intravenous analgesia.
76085377|NCT03335748|Other|Cognitive training Cogmed program|Cognitive training Cogmed program
75646402|NCT05971277|Device|Halo Wearable data device|A wrist-worn tracker with heart-rate monitor and pedometer (step counter), as well as a mobile app.
75930824|NCT00704522|Behavioral|Patient assistance program|"Assistance programs will be classified as follows:~Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."
76085378|NCT01711294|Device|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
75646403|NCT05971264|Diagnostic Test|Near infrared-spectroscopy|Comparison of regional intestinal oxygen saturation (measured with near infrared-spectroscopy) and indirect intraabdominal pressure measurement (bladder pressure) in muscle-relaxed, sedated patients compared to awake, non-sedated patients.
75646404|NCT05971238|Other|Indoor vs. outdoor scenes|Light conditions in indoor (artificial light) and outdoor (daylight) settings
75646405|NCT05971212|Behavioral|Behavioural sleep clinic access|Access to behavioural Sleep Clinic
75646406|NCT05971199|Drug|Fruquintinib|Fruquintinib:5 mg capsule orally once daily on day 1-21 in 28-day cycles；
75646407|NCT05971199|Drug|Sintilimab|Sintilimab: 200 mg i.v. every 3 weeks
75646408|NCT05971199|Device|Transcatheter arterial chemoembolization（TACE）|Transcatheter arterial chemoembolization（TACE）
75646409|NCT05971186|Drug|Ibuprofen 400 mg|Dosage Form: Tablet Dosage: 1 tablet of Ibuprofen (400 mg) Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption
75646410|NCT05971186|Other|Young Coconut Water|Dosage Form: Liquid (coconut water) Dosage: 330 ml (milliliters) of young coconut water Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
75930825|NCT03474432|Device|Optical Coherence Tomography|OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
75930826|NCT02228109|Device|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
75930827|NCT02228109|Device|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
75930828|NCT02228109|Device|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
75930829|NCT03309956|Device|Holter Monitor|A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.
75930830|NCT03309956|Device|Zio Patch|The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
75336668|NCT04679480|Drug|Cemiplimab Injection [Libtayo]|"Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion (as described in SmPC (Fachinformation Swissmedic) Libtayo, see Appendix) at the trial site and administered as a flat 350mg dose in 100ml NaCl 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial."
75336669|NCT00003262|Biological|bleomycin sulfate|
75646411|NCT05971186|Other|Dark Chocolate Bar|Dosage Form: Solid (dark chocolate bar) Dosage: 35 grams of 70% dark chocolate Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
75930831|NCT04458558|Drug|Mifepristone|Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
75930832|NCT04872777|Behavioral|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~Noom application set-up and troubleshooting on smartphone (license provided)~Digital scale provision (subjects may keep the scale)~Capture of available clinical information over preceding 28-days."
76085379|NCT01711294|Device|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
76085380|NCT01711294|Device|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
75336670|NCT00003262|Biological|filgrastim|
75472993|NCT01964937|Biological|NYVAC-HIV-PT4|The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10^6 PFU IM, for a planned maximum dose of 1.1×10^7 PFU.
75472994|NCT01964937|Biological|AIDSVAX B/E®|The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
75646412|NCT05971134|Behavioral|Acupreesure applied|Acupressure was applied to the LI4 acupuncture point for 3 minutes by the researcher for the intervention group
75646413|NCT05971121|Drug|ciprofol|Ciprofol were used for sedation in ICU hypotensive patients
75646414|NCT05971095|Device|Percutaneous neuromodulation using the EPTE® Bipolar System device|"The two stimulation protocols will be applied consecutively. Firstly, the high-frequency protocol (HFS) will be applied in order to produce potentiation of the non-nociceptive pathway, using the pulsed square waveform and 5 bursts of stimulation lasting 5 seconds at a frequency of 100 Hz separated by 55 s interval between bursts. Adjustments to amplitude and pulse width are made until the patient experiences paresthesias at a perceptible but not painful intensity, and the intensity will be set 200 μA above the detection threshold for each subject.~In order to depress the nociceptive pathway, the low-frequency protocol (LFS) with stimulation at 2 Hz for 16 min with an intensity of 1000μA will subsequently be switched to. To ensure the recruitment of higher threshold type C nociceptive fibers, the intensity level will be programmed at the pain threshold for each subject."
75646415|NCT05971069|Procedure|Group1|Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
75646416|NCT05971069|Procedure|Group2|Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
75646417|NCT05971069|Procedure|Group3|No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
75646418|NCT05971030|Device|Cortical brain stimulation of mPFC and dlPFC|Left medial prefrontal cortex combined with dorsolateral prefrontal cortex electrical stimulation
75472995|NCT01964937|Biological|Placebo vaccine|The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
75472996|NCT01965015|Device|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
75472997|NCT01965028|Device|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
75646419|NCT05971017|Dietary Supplement|Control Group|Lettuce without any biostimulation was assigned to each participant belonging to the control group which ate 100gr every day for 15 days
75646420|NCT05971017|Dietary Supplement|Biostimulated group|Intervention biostimulated group 100gr of biostimulated lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 15 days
75646421|NCT05971004|Device|Arthrys (Collagen Peptide solution)|one injection of collagen peptide solution (Tiss'You, Republic of San Marino) at the site of the inflamed ligament attachment point
76085381|NCT03340818|Other|Bone Marrow Concentrate|Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance
75336671|NCT00003262|Drug|Stanford V regimen|
75794058|NCT05091684|Drug|Fibrinogen Concentrate Human|Refractory transfused patients who present grade ≥ 2 hemorrhagic symptoms will receive a single injection of fibrinogen concentrate (1.5g) followed by platelet transfusion within 2 hours. Blood sampling will be done at different time points to measure clot viscoelasticity: at baseline, after fibrinogen injection, after platelet transfusion and the day after transfusion or before the next platelet transfusion if < 24 hours.
75794059|NCT05080972|Behavioral|in-the-kNOW mobile app|"in-the-kNOW is a mobile app with restricted access through a single-use registration code.~The app will be developed with regular input from Black women enrolled in Atlanta Healthy Start Initiative (AHSI).~The app will have culturally- and contextually targeted HIV prevention and optimal sexual health messaging.~Each participant will have 4 months to engage with the app, with e-reminders in time intervals preferred by the participants (a minimum of 3 times per week) via push notifications. During the 4-month study period, participants will receive push notifications to encourage the use of all app domains: My Logger, My Test, My Resources, and My Circle.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
75930833|NCT02228187|Device|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
75646422|NCT05971004|Drug|Depo medrol|one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
75472998|NCT01965041|Drug|aflibercept|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
75930834|NCT03309800|Drug|HL301|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
75930835|NCT03309800|Drug|HL301(Placebo)|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
75472999|NCT01965054|Dietary Supplement|Fish Oil Supplement Group|1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
75473000|NCT01965080|Drug|Exemestane|One tablet Exemestane 25 mg daily
75646423|NCT05970991|Behavioral|Brief Online Training (BOLT) for measurement-based care (MBC)|Brief Online Training (BOLT) for measurement-based care (MBC) is a series of 4 interactive, self-paced, online training modules that takes approximately 75 - 120 minutes to complete. Clinicians are trained on the core functions, procedures, and best practice approaches for delivering MBC in the school mental health setting. MBC is the systematic collection of patient-reported data to support collaborative clinical decision-making from intake to termination.
75930836|NCT04035174|Diagnostic Test|LTS-2 DEC patch|After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (< 50% skin surface under the patch), medium reaction (> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).
75930837|NCT04035174|Diagnostic Test|Skin snips|Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.
75646424|NCT05970991|Behavioral|Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT)|The Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT) is a brief (45-minute), self-paced, interactive online training module designed to help school-based mental health clinicians understand and manage their implicit bias in clinical interactions.
75646425|NCT05970991|Behavioral|Live Post-Training Consultation|Two 1-hour long small group consultation sessions with an expert consultant designed as additional opportunities to support knowledge elaboration and skills generalization.
75646426|NCT05970991|Behavioral|Asynchronous Discussion Board|An expert facilitated online Discussion Board for additional opportunities of knowledge clarification, practice reinforcement, and community building to support implementation sustainment.
75646427|NCT05970328|Device|Hexoskin Medical System|Participant wears both the Hexoskin Medical System and the Nasiff Holter Monitor at the same time to acquire ECG recordings.
75930838|NCT02232477|Drug|Intrathecal recombinant human alpha iduronidase|Intrathecal recombinant human alpha iduronidase every 3 months
75930839|NCT03478332|Drug|Yangxinshi pill|0.6g/tablet
75930840|NCT03478332|Drug|conventional coronary heart disease medicine|the conventional treatment includes medicines treating coronary heart disease
76085382|NCT03340818|Other|Placebo|Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
76085383|NCT05622760|Other|Audiovisual information|The information provided to this group is in audiovisual format. This information is what has been designed with the aim of reducing the level of anxiety of patients who participate in cervical cancer screening.
75336672|NCT00003262|Drug|doxorubicin hydrochloride|
75336673|NCT00003262|Drug|epirubicin hydrochloride|
75473001|NCT01965093|Procedure|perioperative desaturation|children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
75473002|NCT01965093|Procedure|no perioperative desaturation|children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
75336674|NCT00003262|Drug|etoposide|
75336675|NCT00003262|Drug|mechlorethamine hydrochloride|
75336676|NCT00003262|Drug|prednisone|
75336677|NCT00003262|Drug|vinblastine sulfate|
75336678|NCT00003262|Drug|vincristine sulfate|
75336679|NCT02092610|Device|Novel Implant BI300|The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
75794060|NCT05080972|Behavioral|Control|"The control condition will be a one-time virtual women's health counseling session with a healthcare provider. Participants will get information on~Sexual Transmitted Infections (STI)/HIV prevention,~Family planning, and~General health promotion (e.g., exercise and diet).~The control condition provides access to HIV prevention materials that are publicly available but that do not offer the dynamic and individually customized features of the health communication/new media research approach proposed herein.~Control group participants will continue to receive the usual care associated with Atlanta Healthy Start Initiative (AHSI) enrollment.~The control group will not have access to intervention content (e.g. commodity ordering) until after the study has concluded.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
75794061|NCT05080426|Behavioral|Family Supportive Supervisor Training 2.0|FSST 2.0 is a workplace intervention package designed to increase supervisors' family and leave supportive behaviors and leave supportive behaviors. The package includes Workplace Assessment tool, 2 45-60 minute online training modules (family-supportive supervisor training and supervisors' leave supportive behavior training), a webinar, behavior training, and individualized feedback reports.
75794062|NCT05074992|Drug|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
75794063|NCT05072132|Other|Personal information on genetic susceptibility to arsenic toxicity|The intervention groups will receive information regarding their genetic results that informs them of their arsenic metabolism efficiency. They will receive this information through a factsheet appropriate for a lay audience. The factsheet will contain information regarding arsenic metabolism and its role in removing arsenic from the body. The factsheet will describe how there is variability among individuals with respect to the efficiency with which arsenic is removed from the body, due to inherited differences in genes that affect arsenic metabolism. The factsheet describe how slower metabolizers remove arsenic slower from the body, which leads to increased in toxicity risk. The factsheet will inform participants in the intervention groups that they have been identified as a slow/fast metabolizer of arsenic based on their genes. This information will be given to participants by the URB staff, with a study physician available to address questions and concerns from the participant.
75794064|NCT05072132|Other|standard information on arsenic exposure reduction|In this study, intervention and control groups will receive a standard informational intervention which will remind them of the effects of arsenic exposure and potential strategies that can be implemented to reduce their exposure.
75794065|NCT05067205|Procedure|Carpal tunnel release surgery|Preoperative, 3 days, 2 weeks, 4 weeks and 24 weeks postoperatively
75794066|NCT05064813|Behavioral|Mindfulness Based Stress Reduction MBSR Intervention|MBSR is an 8-week group-based course developed by Jon Kabat-Zinn (1990) and colleagues at the University of Massachusetts' Center for Mindfulness. Weekly 2.5 hour long classes are given once a week, as well as one day-long weekend class. The classes instruct participants in the theory and practice of several forms of mindfulness meditation, breathing awareness, and mindfulness stretching exercises. Teaching of the theory of mindfulness and experiential practice are both utilized during weekly classes and at-home CD-guided practice sessions.
75646428|NCT05970276|Device|Deep Sleep (N3) Enhancement with TES|As participants sleep, their sleep EEG will be measured and automatically scored by the computer to determine stage of sleep. When slow wave sleep is detected, low-level current (.5-1 mA total) will be applied through pre-set electrodes.
75646429|NCT05969925|Diagnostic Test|new biomarkers for heart failure|assess efficacy of new biomarkers for heart failure
75646430|NCT05969652|Other|Heavy slow resistance training|"Patients will perform the exercises in the concentric and eccentric phases with the maximum amount of weight tolerated at a rate of 3 seconds/repetition. The number of sets*repetitions is given below. 2-3 minutes rest between sets will be given.~1st week 3*15 2-3.week 3*12 4th-5th week 3*10 6th week 3*8"
75646431|NCT05969652|Other|Eccentric exercise training|"Among the patients in the eccentric exercise group, only the eccentric phase of the exercises in the HSR group, will be asked to actively engage with the affected party. The eccentric contraction rate will be set to 6 seconds. Each exercise will be done 3 sets of 15 repetitions. In the next week, progress will be made in exercise intensity according to tolerance and 500 g will be added to the previous weight.~will be continued. If patients cannot tolerate the new weight or there is an increase in pain, the same weight will be continued for another week."
75794067|NCT05064813|Behavioral|Stress Education Control Condition (SE)|Stress Education (SE) was designed to provide an active comparator condition that does not include overlapping active components of mindfulness meditation with MBSR. It will also be delivered over 8-weekly, in-person, 2.5 hour group sessions of the same size (n=4 to 6). In SE, participants receive extensive information about stress and health, but will not receive any MBSR or other mind-body training. Instead, stress relevant psycho-educational information will be taught.
75794068|NCT05063656|Drug|Gabapentin|8 weeks of gabapentin, titrated up to 20 mg/kg in 3 divided doses daily
75794069|NCT05060237|Combination Product|BF-200 ALA and red light LED lamp|"Photodynamic therapy (PDT) using BF-RhodoLED® XL (ALA-PDT, Ameluz®-PDT):~Topical application of 3 tubes BF-200 ALA on the expanded treatment field (60 cm²), followed by red light illumination with BF-RhodoLED® XL after 3 h incubation of study medication under light-tight, occlusive dressing."
75794070|NCT05054829|Behavioral|PEERS®: program for the education and enrichment of relational skills|providing evidence-based social skills treatment to preschoolers, adolescents, and young adults with autism spectrum disorder (ASD)
75646432|NCT05968534|Behavioral|MOSAIC Plus|"This is a single-arm study. Participants will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
75794071|NCT05047601|Drug|PF-07321332|PF-07321332
75794072|NCT05047601|Drug|Placebo for PF-07321332|Placebo
75336680|NCT02092610|Device|Standard Implant BI300|The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
75336681|NCT00003700|Biological|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC > 5,000 uL after nadir: 7 day minimum for Courses I & IV
75794073|NCT05047601|Drug|Placebo for Ritonavir|Placebo
76085384|NCT05622760|Other|Written information|The information provided to this group is in written format. This information is what is distributed to patients in the midwife's consultation and is available on the website of the health organization (Osakidetza)
76085385|NCT03340740|Drug|Cetirizine Hydrochloride 1 MG/ML|Cetirizine oral suspension
76085386|NCT03340740|Drug|Placebo - Concentrate|Similar-appearing liquid to cetirizine oral suspension
75336682|NCT00003700|Drug|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I & IV
75336683|NCT00003700|Drug|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I & IV (pts < 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II & V
75336684|NCT00003700|Drug|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, & 3: Courses II & V
75336685|NCT00003700|Drug|daunorubicin hydrochloride|80mg/sq m (pts<60y/o)OR 60mg/sq m (pts =/>60y/o) IV infusion over 5-10 min Days 1,2,& 3: Courses I & IV
75336686|NCT00003700|Drug|leucovorin calcium|"Courses III & VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX <0.05 uM after ea IV dose"
75336687|NCT00003700|Drug|mercaptopurine|60mg/sq m/d PO every day Course VII
75336688|NCT00003700|Drug|methotrexate|15mg intrathecal Day 1 Courses II & V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, & 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III & VI.
75336689|NCT00003700|Drug|prednisone|60mg/sq m/day PO Days 1-21 (pts<60y/o) OR Days 1-7 (pts >/= 60y/o) Courses I & IV and Days 1-5 of ea 4 cycle in Course VII
75794074|NCT05047601|Drug|Ritonavir|Ritonavir
75794075|NCT05043506|Drug|Palbociclib + aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
75794076|NCT05043506|Drug|Aromatase inhibitor|Aromatase inhibitor monotherapy
75794077|NCT05031208|Diagnostic Test|Memory task|Word recognition task
75794078|NCT05025189|Other|Table Grape Powder|Freeze Dried Whole Table Grape Powder
75794079|NCT05025189|Other|Beige Diet|Low Fiber, low polyphenol Diet
75794080|NCT05022329|Biological|Pfizer-BioNTech COVID-19 Vaccine|This arm receives Pfizer-BioNTech COVID-19 Vaccine
75930841|NCT03478332|Drug|Placebos|Yangxinshi simulant
75930842|NCT04105062|Drug|LS301|-LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
75930843|NCT04105062|Device|Cancer Vision Goggles|-Non-significant risk device
75930844|NCT02223741|Other|Korean medical treatment|acupuncture and herbal drugs
75930845|NCT03930498|Drug|PD-1 blocking antibody|Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.
75930846|NCT03930498|Drug|Chemotherapy|Cisplatin and Gemcitabine
76085387|NCT01711372|Device|Groundskeeper game for controls|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
76085388|NCT01711372|Device|Groundskeeper game for ADHD|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
76085389|NCT03340662|Drug|CC-122|CC-122
75336690|NCT00003700|Drug|vincristine sulfate|2 mg total IV infusion Days 1,8,15,& 22 Courses I & IV and Days 1, 8, & 15 Courses III & VI, and Day 1 of ea 4 wk cycle in Course VII
75336691|NCT00003700|Drug|Allopurinol|300mg PO q day Days 1-14 Course I
75336692|NCT02093234|Behavioral|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
75336693|NCT02093234|Behavioral|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
75336694|NCT02093234|Behavioral|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
75336695|NCT00003706|Drug|pemetrexed disodium|
75336696|NCT00003958|Biological|dactinomycin|Given IV
75336697|NCT00003958|Drug|vincristine sulfate|Given IV
75794081|NCT05022329|Biological|MODERNA SARS-CoV-2 Vaccine|This arm receives MODERNA SARS-CoV-2 Vaccine
75794082|NCT05011760|Radiation|Baseline [C-11]NPA PET Scan|Radiotracer
75794083|NCT05011760|Drug|d-amphetamine|Oral, 0.5 mg/Kg
75930847|NCT03930498|Radiation|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
75930848|NCT02228265|Other|Cytology Specimen Collection Procedure|Undergo blood and tissue collection
75930849|NCT02228265|Drug|Enzalutamide|Given PO
75930850|NCT02228265|Other|Laboratory Biomarker Analysis|Correlative studies
76085390|NCT03340662|Drug|Itraconazole|CYP3A Inhibitor
76085391|NCT03340662|Drug|Fluvoxamine|CYP1A2 Inhibitor
75336698|NCT00003958|Drug|cyclophosphamide|Given IV
75336699|NCT00003958|Procedure|therapeutic conventional surgery|Undergo surgery
75336700|NCT00003958|Radiation|radiation therapy|Undergo radiotherapy
75336701|NCT00003958|Drug|topotecan hydrochloride|Given IV
75336702|NCT00003958|Biological|filgrastim|Given SC
75336703|NCT00003958|Biological|sargramostim|Given SC
75336704|NCT00003958|Other|laboratory biomarker analysis|Correlative studies
75336705|NCT03044054|Device|ECHOPULSE|HIFU Under ultrasound guidance
75336706|NCT04101292|Other|Characterization of tumor tissue by fluorescence|"HSI Imaging of the resected specimen, from the serum and the mucous side~FF-OCT imaging of the tumor and the healthy tissue biopsies~Local application of Bevacizumab-IRDye800CW and visualization with the Surgvision Explorer system~Standard anti-VEGF Immunohistochemistry and pathology"
75794084|NCT05011760|Radiation|Post-amphetamine [C-11]NPA PET Scan|Radiotracer
75794085|NCT05008146|Radiation|Baseline [C-11]NOP-1A PET Scan|Radiotracer
75794086|NCT05008146|Drug|Hydrocortisone|Intravenous, 1mg/Kg
75794087|NCT05008146|Radiation|Post-hydrocortisone [C-11]NOP-1A PET Scan|Radiotracer
75794088|NCT05006599|Drug|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
75794089|NCT05006599|Drug|Placebo|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
76085392|NCT03340662|Drug|Rifampin|CYP3A Inducer
75794090|NCT05006599|Device|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
75930851|NCT03130920|Procedure|Preconditioning|"Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ."
76085393|NCT03342300|Drug|pegylated liposomal doxorubicin|Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
75336707|NCT00003712|Drug|temsirolimus|"•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.~The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.~•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II."
75473003|NCT01965119|Drug|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
75473004|NCT01965145|Drug|Gevokizumab|Sterile solution administered subcutaneously
75473005|NCT01965145|Drug|Placebo|Sterile solution administered subcutaneously
75646433|NCT05968339|Other|Survey|"The survey will be distributed via scientific anesthesiology societies and will be open for a total of 12 consecutive months.~Participation in the survey will be voluntary and anonymous - individual consent will be implied by willingness to complete the survey.~The survey will be conducted via SurveyMonkey. SurveyMonkey allows Health Insurance Portability and Accountability Act (HIPAA)(12) compliant surveys to be created. These follow strict rules around the protection of health information. Of note, SurveyMonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored. Access to the database will be password protected and only the authors will have access for the purpose of data analysis at the end of the survey period. Analysis using chi squared tests and logistic regressions will be performed by trained statisticians."
75930852|NCT03817554|Drug|Pramipexole|Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
75930853|NCT03817554|Other|placebo|Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
75646434|NCT05967143|Device|SIRT|Selective internal radiation therapy with SIR-Spheres Y90 resin microspheres.
75646435|NCT05966909|Diagnostic Test|Doppler Ultrasound|Ultrasound diagnosi of asymptomatic and symptomatic upper extremities vein thrombosis
75930854|NCT02223897|Drug|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
75930855|NCT02223897|Drug|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
75930856|NCT02723630|Drug|Lenvatinib 10 mg|"Treatment 1: low Type-C crystal level <12%~Treatment 2: reference* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level >26%"
75930857|NCT04459962|Diagnostic Test|Breath Test & Cheek Swab|Breath Sample and Cheek Swab of participants will be used for machine learning (NBT - Nanobiotechnology Biomarkers Tagging) system to develop a profile which can be used later on for Covid-19 Diagnosis.
75930858|NCT02228655|Drug|FMX-8|
75930859|NCT02128802|Procedure|Gastric Bypass|
75930860|NCT02128802|Other|Weight Loss Program|
75930861|NCT02866227|Drug|TOL-463|TOL-463 vaginal gel
75930862|NCT02866227|Drug|TOL-463|TOL-463 vaginal insert
75930863|NCT05258136|Drug|low-dose CD20 monoclonal antibody injection|To comprehend the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
75930864|NCT02228733|Drug|KBP-5074|Comparisons of different doses of study drug
75930865|NCT02224131|Drug|Aspirin and clopidogrel|modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
75930866|NCT02224131|Drug|Aspirin and clopidogrel|aspirin and clopidogrel maintenance doses (according to international guidelines)
75930867|NCT02469584|Procedure|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
76085394|NCT03342300|Drug|pirarubicin|Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
76085395|NCT01711918|Drug|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
76085396|NCT03120468|Drug|Topiramate and N-Acetyl Cysteine|Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
76085397|NCT03120468|Drug|Topiramate and Placebo|Topiramate up to 200 mg/day and Placebo for 12 weeks
75336708|NCT00003268|Drug|amifostine trihydrate|
75336709|NCT00003268|Drug|cytarabine|
75336710|NCT00003268|Drug|idarubicin|
75336711|NCT00083720|Biological|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
75336712|NCT00003274|Biological|gp100 antigen|
75794091|NCT04998669|Drug|Loncastuximab tesirine|"Induction Phase (Cycles 1 through 4):~150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 & 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle."
76085398|NCT02493270|Behavioral|Smoking cessation therapy|Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques
76085399|NCT02493270|Procedure|Non-surgical periodontal therapy|full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
75473006|NCT01965210|Other|Rye + high dose inulin + low dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
75794092|NCT04998669|Drug|Rituximab|"Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician."
75794093|NCT04980638|Biological|ER004|Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26
75646436|NCT05966298|Other|Core stabilization training|First, while focusing on the activation methods of deep cervical flexor, transversus abdominus and multifidus muscles in individuals; In the next stages, exercises will be performed that will preserve the contraction of the deep cervical flexor, transversus abdominus and multifidus muscles and activate the other muscles of the body.
75794094|NCT04978545|Other|calciumhydroxide, intracanal medicament|In the CH group, calcium hydroxide powder (Calxyl; OCO Products, Dirnstein, Germany) was mixed with saline in a ratio 1:1 and the paste was inserted into the canal by using lentulo spirals (Malleifer-Dentsply).
75794095|NCT04978545|Other|chlorhexidine, intracanal medicament|, chlorhexidine gel 2% (Gluco-Chex 2% gel, Cerkamed, Stalowa Wola, Polland) was placed into the root canals of this group with an Ultradent Capillary Tip (Ultradent products).
75336713|NCT00003274|Biological|incomplete Freund's adjuvant|
75336714|NCT00003274|Biological|sargramostim|
75646437|NCT05966298|Other|Standart Rehabilitation|This treatment includes shoulder exercises and conventional therapy (Infrared, ultrasound, TENS).
75794096|NCT04968249|Other|Observational|Observational Cohort to understand risk factors for early COPD.
75930868|NCT03474120|Procedure|IVF treatment|Relationship between IVF treatment outcome and genotypes in POI//DOR/ovarian dysgenesis patients
75646438|NCT05966103|Other|Exercises|For control group; Cervical conventional exercises. For treatment group; scapulothoracic exercises including strengthening, proprioceptive and stabilization exercises in addition to cervical conventional exercises
75930869|NCT03474042|Drug|GLPG2737|GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
75930870|NCT03474042|Drug|Placebo|Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
75930871|NCT03309722|Other|biomarker study|
75930872|NCT02810184|Radiation|cone-beam computed tomography (CBCT)|additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
75930873|NCT03473964|Drug|H.P. Acthar gel|"H.P. Acthar gel:~Injection 40 mg twice weekly"
75930874|NCT03309644|Other|Peripheral nerve blockade|Participants who receive a peripheral nerve block identified through the medical chart.
75930875|NCT03309644|Other|No peripheral nerve blockade|Participants who did not receive a peripheral nerve block identified through the medical chart.
75336715|NCT00003274|Biological|tyrosinase peptide|
75336716|NCT00003280|Biological|rituximab|
75336717|NCT04772924|Behavioral|fasting|more than 12 hour of fasting as ceremony of Ramadan
75473007|NCT01965210|Other|Rye + equal doses of inulin & gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
75473008|NCT01965210|Other|Rye + low dose inulin + high dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
75646439|NCT05964517|Other|Fascial Distortion Model|Facial Distortion is a manual therapy technique applied by model physiotherapists. It is a deep tissue massage to the fascial tissue.
76085400|NCT01712230|Drug|GnRH agonist|"Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months"
76085401|NCT01712230|Behavioral|Supervised cardiovascular exercise|Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
76085402|NCT01712230|Drug|Placebo|Placebo
75336718|NCT04772924|Behavioral|not fasting|preferred not to take long term fasting
75336719|NCT02972710|Other|Supine thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
75794097|NCT04960384|Drug|FGF-2|The FGF-2 method of use comprises a pledget of gelatin sponge, with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of fibrin glue used for applications in ear surgery. The concentration of the FGF-2 solution will be 100μg of FGF-2 per 1 mL with an estimated dose of about 20 μg in 0.2ml. Fibrin glue will be applied to secure gelatin sponge after placement according to the size of the membrane perforation. Application of the study treatment will occur at Visit 1 and may be repeated at each follow up visit as needed for a maximum of three treatments in the Randomized Treatment Phase (Visit 1, Visit 2, and Visit 3).
75794098|NCT04960384|Drug|Placebo|FGF-2 will be replaced with sterile water to saturate a pledget of gelatin sponge. The method will be otherwise identical to the FGF-2 intervention.
75930876|NCT04319445|Behavioral|Mindfulness session(s)|The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).
75930877|NCT04459572|Diagnostic Test|suPAR|Soluble Urokinase Plasminogen Activator Receptor (suPAR)
75930878|NCT02470598|Other|Treatment with Adapted Automated Peritoneal Dialysis (aAPD)|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists
75930879|NCT03478020|Drug|AQX-1125|Investigational Drug
76085403|NCT03335514|Diagnostic Test|expression of GALNT4|Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
76085404|NCT01712776|Device|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
75336720|NCT02972710|Other|Seated thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
75336721|NCT00384124|Drug|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
75794099|NCT04958811|Drug|Tiragolumab|600mg IV administered every 3 weeks.
75794100|NCT04958811|Drug|Atezolizumab|1200mg IV administered every 3 weeks.
75336722|NCT00003718|Drug|temozolomide|
75336723|NCT02024360|Behavioral|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
75336724|NCT00003970|Drug|irinotecan hydrochloride|Given IV
75473009|NCT01965210|Other|Large non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
75473010|NCT01965210|Other|Small non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
75473011|NCT01965210|Other|Refined wheat bread|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
75473012|NCT01965223|Radiation|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
75473013|NCT01965223|Radiation|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
75473014|NCT01965236|Dietary Supplement|sodium chloride|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
75473015|NCT01965236|Dietary Supplement|Placebo|
75794101|NCT04958811|Drug|Bevacizumab|15mg/kg IV administered every 3 weeks.
75794102|NCT04950530|Drug|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
75794103|NCT04940741|Drug|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
75794104|NCT04940741|Other|Placebo|comparator without active ingredient
75930880|NCT03478020|Drug|Combined Oral Contraceptive|COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
75930881|NCT02224209|Device|Abbott EPD systems (Accunet/Emboshield), a balloon, stent|"Standard method of endovascular interventional treatment:~Method of stage-1 angioplasty~The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;~Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.~Method of stage-2:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;~After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
75930882|NCT02224209|Device|a balloon, stent|"Routine stenting procedure:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;~After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
76085405|NCT01712776|Device|Nature's Tears Sterile Water|Topical stream 4-10 seconds duration to skin
76085406|NCT02496390|Biological|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
76085407|NCT02496390|Biological|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
76085408|NCT03342222|Device|Interference Screws|tibial fixation for ACL reconstruction
75930883|NCT03481764|Genetic|HRC-test|"Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used."
75930884|NCT05235360|Behavioral|Episodic future thinking|Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.
75930885|NCT05235360|Behavioral|Positive affect imagery|Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.
75930886|NCT05235360|Behavioral|Action planning|Participants will listen to a guided thinking task directing them to think about the remainder of their week and when, where, and how they plan to attain their remaining activity for the week.
75930887|NCT05235360|Behavioral|High dose|Participants will listen to the audio-recording with the guided thinking tasks 5 times/week.
75930888|NCT05235360|Behavioral|Recent thinking|Participants will listen to a guided thinking task directing them to think about a regular habit or activity they completed in the past week and to imagine that activity in specific and vivid detail.
75930889|NCT05235360|Behavioral|Neutral imagery|Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).
75930890|NCT05235360|Behavioral|Low dose|Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.
75930891|NCT01733433|Procedure|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
75930892|NCT02008292|Drug|Physostigmine|All subjects will receive physostigmine to induce elevated ACh levels in the brain.
76085409|NCT03340584|Other|the Nine Castle Net Format Taping|The intervention group received traditional rehabilitation and Taping throughout all rehabilitation period.The taping including a Nine Castle Net Format of taping in both side of surgery knee.We will exchange the new taping for every two days， for a week.Traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
75473016|NCT01965275|Drug|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
75794105|NCT04937699|Drug|Standard-DAPT of Ticagrelor plus aspirin|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months
75794106|NCT04937699|Drug|Sequential monotherapy of Ticagrelor and clopidogrel|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
75794107|NCT04931758|Other|Pain Questionnaire|Subjects will take the FreBAQ questionnaire at Day 0 and a subgroup of 35 controls and 15 patients will take the same questionnaire at Day 7
75930893|NCT02228811|Drug|DCC-2701 tablet|
75930894|NCT02224287|Procedure|Technologist control of fluoroscopy|Technologist control of fluoroscopy
75930895|NCT02224287|Procedure|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
75930896|NCT04809519|Other|Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives|In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.
75930897|NCT04809519|Other|Ongoing treatment|The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
75930898|NCT03477864|Biological|Ipilimumab|Given via intraprostatic injection
75930899|NCT03477864|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
75930900|NCT03477864|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
75930901|NCT03477864|Biological|Anti-PD-1 Monoclonal Antibody REGN2810|Given IV
75930902|NCT02229045|Drug|Albumin Bound Paclitaxel|Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
75930903|NCT02229045|Drug|5-FU|5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
76085410|NCT03340584|Other|traditional rehabilitation|traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
75473017|NCT01965301|Drug|BP1.5375 suspension|single oral dose
75473018|NCT01965301|Drug|Diphenhydramine|single oral dose of Diphenhydramine 50mg
75473019|NCT01965301|Drug|Placebo|Single oral dose
75473020|NCT01965314|Other|Simulation based training|In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device
75794108|NCT04929756|Behavioral|Visual Feedback|Gaze-contingent visual feedback
75930904|NCT02229123|Drug|Intravenous Levetiracetam|Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
75930905|NCT02682810|Device|DNA PCR HIV diagnostic test|standard of care
75930906|NCT02682810|Device|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
75930907|NCT02229201|Drug|Propofol|4-6 mg/kg/h during anaesthesia
75930908|NCT02229201|Drug|Sevoflurane|0.8 MAC
75930909|NCT03164226|Device|Digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain|To verify the contribution of digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
75930910|NCT02224365|Dietary Supplement|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
75930911|NCT02224365|Dietary Supplement|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
75930912|NCT03477786|Combination Product|drug adjustment and behavioral modification|anti-hypertension drug prescription by physician and case management by health educator
75930913|NCT02224443|Drug|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
75930914|NCT02224443|Drug|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
75930915|NCT02224443|Drug|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
75930916|NCT02224443|Drug|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4~5μg.kg-1 fentanyl,1.0~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
75930917|NCT02224443|Drug|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05~0.1mg.kg-1.h-1cisatracurium besylate,4~8mg.kg-1.h-1propofol,0.1~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%~1.0%
75930918|NCT04184037|Behavioral|Mindfulness meditation delivered via a mobile app|"This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided."
75473021|NCT01965314|Other|Traditional training|Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
75646440|NCT05964478|Other|Multi-component hand hygiene intervention in primary schools not connected to functional water supply system in Nigeria and Palestine|Each participating school receives: (i) Two Gravit'eau handwashing stations (http://www.graviteau.ch): these systems recycle on-site greywater and operate through gravity and a manual foot pump, and can be produced locally. (ii) Behavior change activities: Developed by a group of expert psychologists (http://www.ranasmosler.com/ranas), utilizing the risks, attitudes, norms, abilities, and self-regulation (RANAS) approach. (iii) WASH infrastructure rehabilitation and soap dispenser installation. (iv) Controlled chlorine monitoring: Equipment provided for monitoring chlorine concentration in water storage, with staff training. (v) Preventive maintenance: Trained circuit rider inspects infrastructure regularly under WASH committee supervision
76085411|NCT03335436|Drug|Gabapentin|Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
76085412|NCT03335436|Drug|Placebo|Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
75473022|NCT01965340|Other|Systematic Therapeutic Drug Monitoring for the intervention group|
75646441|NCT05962866|Other|I and II. Performing Leopold Maneuvers by the pregnant|24-32 and 32-38 days of pregnancy by the pregnant woman. 1st and 2nd leoppold maneuvers are performed by the pregnant woman, 2 times between weeks.
75646442|NCT05956951|Device|Closed-loop auditory stimulation|Closed-loop auditory stimulation will be administered by a wearable EEG device (Philips SmartSleep Deep Sleep Headband). The EEG device will deliver auditory stimulation when slow-wave (deep) sleep is detected. Auditory stimulation will consist of 50ms long tones separated from each other by a fixed one-second inter-tone interval. The volume of each tone will be linearly modulated by sleep-depth such that louder (or softer) tones were played during deeper (or shallower) sleep.
75930919|NCT02229279|Device|Teleconsulting|
75930920|NCT02229357|Biological|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
75930921|NCT02224521|Drug|GSK2190915 Solution.|Aqueous Solution, 10mg/mL.
75930922|NCT02224521|Drug|GSK2190915 Granule Capsule (A)|GSK2190915A granule filled in to Gelatin capsules
75930923|NCT02224521|Drug|GSK2190915 Semi-solid Lipid Capsule (B)|GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
75930924|NCT02224521|Drug|GSK2190915 Liquid Lipid Capsule (C)|GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
75930925|NCT02224521|Drug|GSK2190915 Milled Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
75930926|NCT02224521|Drug|GSK2190915 Micronised Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
75930927|NCT01944800|Drug|Ticagrelor|Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
75794109|NCT04921683|Device|BX Pulsar 1002 (LIFUP) Low intensity Focused Ultrasound Pulsation|"Administration of LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone, over the temporal window in order to minimize bone absorption and refraction. Accurate aiming will be ensured employing the BrainSight neuronavigation device, customized for tracking our LIFUP transducer (total ~10 min). Once satisfactory aiming is achieved, the LIFUP exposure will be initiated employing the settings described previously (which meet the FDA safety limits: ISPPA <= 190W/cm2, ISPTA <= 0.72W/cm2). Accurate aiming will be monitored in real-time throughout exposure using the Brain Sight Neuronavigation interface."
75794110|NCT05118191|Other|OOLER|Following the baseline block (first four weeks), participants will use the OOLER device to power a cooling mattress pad each night during sleep for four weeks.
75646443|NCT05956951|Device|Sham auditory stimulation|Sham auditory stimulation consists of closed-loop auditory stimulation not being administered. A wearable EEG device (Philips SmartSleep Deep Sleep Headband) will not deliver closed-loop auditory stimulation and tones will not be played.
75930928|NCT01944800|Drug|Prasugrel|Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/> 75 years or < 60 kg
75930929|NCT03617367|Biological|daxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
75930930|NCT02470676|Device|Pessary|Two optional pessary sizes with the following dimensions: 65/17/35 or 70/17/35 and 200 mg daily progesterone vaginal suppositories (Utrogestan)
75930931|NCT02470676|Drug|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
75930932|NCT02229669|Procedure|Horizontal incisions|Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
76085413|NCT02494284|Drug|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
76085414|NCT02494284|Drug|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
76085415|NCT01713400|Drug|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
76085416|NCT01713400|Drug|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
76085417|NCT01713400|Drug|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
76085418|NCT01713400|Drug|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
76085419|NCT03342066|Diagnostic Test|reproducability of caries risk assessment|reproducability of caries risk assessment CAMBRA verses cariogram
75646444|NCT05954715|Other|Ischaemic Preconditioning|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
75646445|NCT05954715|Other|Sham|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
75646446|NCT05954325|Procedure|Immunoadsorption vs. sham immunoadsorption|5 treatments within 14 days
75646447|NCT05952583|Diagnostic Test|Ultrasound|Additional ultrasound measurements during pregnancy
75473023|NCT01965353|Drug|Panobinostat|- Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
75646448|NCT05944263|Behavioral|weRISE; The gratitude, kindness and hope (GKH) program|weRISE is an arts based train the trainer intervention that promotes positive mental health through cultivating gratitude, kindness and hope among youth in schools and informal settlements in India and Kenya
75646449|NCT05944263|Behavioral|The [adapted] Stan Kutcher Teen Mental Health (TMH) program|The 'Teen Mental Health' curriculum developed by Dr. Stan Kutcher, aims to increase mental health literacy among young people ;will be used in the control group (active comparator group). The control intervention consists of eight sessions (45 minutes each) delivered by older groups of young people (ages 18-24) in schools and community settings through a didactic approach.
75646450|NCT05938062|Procedure|the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)|the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
75646451|NCT05933525|Biological|Travelan|6 Travelan tablets (1200mg) administered orally for 7 days
75794111|NCT05118191|Other|EmbrWave|Following the baseline block (first four weeks), participants will use the Embr Wave 2 device to provide pulsed warm sensations to the inner wrist each night during sleep for four weeks.
75794112|NCT04907175|Biological|HB-adMSCs|Subject has completed 10 infusions and has been authorized for an additional 12 infusions over 1 year.
75794113|NCT04894396|Device|Aetrex L2305 Premium Memory Foam Orthotics W/ Metatarsal Support|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body & help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. For medium to high arches with forefoot pain, featuring a cupped heel to cushion and stabilize the back of foot and a metatarsal pad to redistribute weight to relieve ball-of-foot discomfort. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
76085420|NCT04226872|Behavioral|My Tools for Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
76085421|NCT02496312|Behavioral|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
76085422|NCT03335358|Behavioral|Dyadic (couples-based) positive psychology intervention|Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
76085423|NCT02248246|Device|Harmonic ACE®+7 Shears|"Vessel sealing performance assessed for transection and sealing of the following named vessels:~Inferior mesenteric artery (IMA)~Inferior mesenteric vein (IMV) (if identified)"
76085424|NCT03335280|Drug|68Ga-citrate PET/MR|Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
76085425|NCT04494828|Drug|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
76085426|NCT04494828|Drug|Normal saline group|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
75646452|NCT05933525|Other|Placebo|6 tablets of placebo (1200mg) administered orally for 7 days
75646453|NCT05931783|Procedure|skeletonized harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in skeletonized technique. Thereby, only the artery itself is harvested.
75930933|NCT02229669|Procedure|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
75930934|NCT01933724|Drug|5 mg prednisone|Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
75930935|NCT01933724|Drug|0 mg prednisone|Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
75930936|NCT02229747|Drug|Meloxicam|
75930937|NCT02229747|Drug|Diclofenac|
75930938|NCT02229747|Drug|Nimesulide|
75930939|NCT02232789|Drug|Mephedrone|Single oral dose mephedrone
75930940|NCT02232789|Drug|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
75930941|NCT02232789|Drug|Placebo|Single oal dose placebo
75930942|NCT03030222|Drug|Empagliflozin 10 mg Tab|Empagliflozin 10 mg Tab
75930943|NCT03030222|Drug|Placebo Oral Tablet|Empagliflozin matching placebo
75930944|NCT04089735|Drug|APP13007, 0.05%|APP13007 eye drop, 0.05%
75930945|NCT04089735|Drug|APP13007, 0.1%|APP13007 eye drop, 0.1%
75930946|NCT04089735|Drug|APP13007 Placebo, 0.05%|APP13007 placebo eyedrop, 0.05%
75930947|NCT04089735|Drug|APP13007 Placebo, 0.1%|APP13007 placebo eyedrop, 0.1%
75930948|NCT02892708|Procedure|Surgery|partial or complete resection followed by radiotherapy
75930949|NCT02892708|Radiation|radiotherapy|radiotherapy after a brain biopsy
75930950|NCT02523222|Dietary Supplement|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
75930951|NCT01921062|Behavioral|Motor imagery|The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
76085427|NCT01713868|Behavioral|Safe Sleep Nursery Education|Nursery-based program for safe sleep
75646454|NCT05931783|Procedure|pedicled harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in pedicled technique. Thereby, the artery will be harvested together with the accompanying veins, the endothoracic fascia and fatty tissue in order to create an 1-2 cm broad pedicle.
75646455|NCT05930808|Drug|First Test Concor (Fasted)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
75646456|NCT05930808|Drug|First Reference Concor (Fasted)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition
75646457|NCT05930808|Drug|First Test Concor (Fed)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
75930952|NCT02232867|Behavioral|Arm and Leg Cycling Exercise Program|Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
75930953|NCT05224596|Diagnostic Test|Blood draw and blood-based biomarkers analyses|blood-based biomarkers analyses
75930954|NCT02232945|Drug|placebo of oseltamivir phosphate|
75930955|NCT02232945|Drug|oseltamivir phosphate|
75930956|NCT02232945|Drug|Banlangen (Radix Isatidis) granules|
75930957|NCT02232945|Drug|placebo of Banlangen(Radix Isatidis) granules|
75930958|NCT01876784|Drug|Vandetanib (SAR390530)|"Pharmaceutical form: tablet~Route of administration: oral"
75930959|NCT01876784|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
75930960|NCT02546622|Biological|Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
75930961|NCT02546622|Biological|Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
75473024|NCT01965353|Drug|Dexamethasone|Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period
75646458|NCT05930808|Drug|First Reference Concor (Fed)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.
75646459|NCT05928676|Dietary Supplement|Vascanox® HP|Vascanox® HP is a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide aimed at increasing the levels and duration of nitric oxide biosynthesis. Vascanox® HP contains an advanced blend of berry extracts in addition to beet root powder, black garlic, vitamin C, and minerals known to influence nitric oxide biosynthesis and metabolism. Because of the particular combination of ingredients, Vascanox® HP is expected to affect both canonical and non-canonical pathways of nitric oxide production and to augment nitric oxide reservoir in the body leading to an increased and prolonged nitric oxide bioavailability.
75646460|NCT05924256|Drug|SHR-A1811|SHR-A1811
75646461|NCT05924256|Drug|SHR 3680 + leuprolide|SHR 3680 + leuprolide
75646462|NCT05924256|Drug|SHR-A1921|SHR-A1921
75794114|NCT04894396|Device|Aetrex L2300 Premium Memory Foam Orthotics|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body & help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
75794115|NCT04894383|Device|Aetrex L420 Compete Orthotic|An orthotic insole to be inserted into shoes. Orthotic for low arches to flat feet with no forefoot pain, featuring a posted heel to control over-pronation and provide balance. Features Aetrex Arch Support to help biomechanically align the body & help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia.
75930962|NCT02229903|Device|Active DTMS Treatment|H-coil Deep TMS 29 TMS treatments over 6 weeks.
75930963|NCT02229903|Device|Sham Treatment|29 treatments over 6 weeks.
75930964|NCT05218746|Procedure|Serratus anterior plane block|High-frequency linear transducer will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, Then, using ultrasound guidance, the needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib . one millileter normal saline will be injected to confirm placement and to hydro-dissect the fascial layers and open the potential space.
75930965|NCT05218746|Procedure|Erector spinae block|A high-frequency linear ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes is identified, spinal needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle.
76085428|NCT01713868|Behavioral|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
76085429|NCT01713868|Behavioral|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
75794116|NCT04894383|Device|Aetrex indoor comfort sandal with built-in arch support|An indoor comfort sandal with built-in arch support to be used at home. Provides extreme cushioning, shock absorption and durability. Arch support helps to stabilize and align feet and also helps to relieve common foot pain & plantar fasciitis.
75794117|NCT04891068|Drug|Azacitidine|5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5
75794118|NCT04884789|Device|COFIS 3D|Patient have to wear the COFIS 3D 20h a day for at least 6 month
76085430|NCT01713868|Behavioral|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
76085431|NCT04494906|Other|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
76085432|NCT04494906|Other|Square stepping exercise|Square stepping exercise
76085433|NCT01714024|Device|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
75336725|NCT00085436|Biological|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
75473025|NCT01965353|Drug|Lenalidomide|Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period
75473026|NCT01965353|Drug|Bortezomib|Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
75473027|NCT01965379|Other|Restriction on food containing phosphorus additives|The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.
75473028|NCT01965379|Other|Standard care|The control group mantained the usual renal diet oriented prior to the study with a booklet.
75473029|NCT01965392|Other|Health education intervention|'Health education intervention'
75473030|NCT01965418|Drug|Fufang Biejia Ruangan Tablet|
75473031|NCT01965418|Drug|Placebo|
75473032|NCT01965483|Radiation|once-weekly breast irradiation|
75473033|NCT01965496|Drug|PEX168|A injection administered subcutaneously
75473034|NCT01965509|Drug|PEX168 or placebo|injection has to administered subcutaneously weekly
75646463|NCT05921162|Biological|Gene Therapy product:vMCO-I|Safety evaluation to monitor long term effects of previously injected vMCO-I in RP patients
75646464|NCT05916352|Dietary Supplement|Caffeine Supplement|Caffeine tablet
75646465|NCT05898789|Behavioral|CaRE@Home intervention|participants randomized to the intervention arm will complete a virtual 8 week exercise and education program.
75930966|NCT05195658|Device|Thrombectomy and Stenting under neuroprotection|"Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection.~Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever.~Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center.~Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center."
75930967|NCT04205162|Device|Verafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
75930968|NCT04205162|Device|Etafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
75930969|NCT02229981|Drug|ABC294640|
75930970|NCT02523378|Behavioral|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
75930971|NCT02523378|Behavioral|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
75930972|NCT03309566|Drug|Efavirenz, tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
75930973|NCT00735657|Device|needle|Peribulbar blockade with standard (25 mm) needle
75930974|NCT00735657|Device|needle|Peribulbar blockade with short (12.5 mm) needle
75930975|NCT00735657|Procedure|Pars Plana Vitrectomy|Peribulbar block
76085434|NCT01714024|Device|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
75646466|NCT05894460|Device|Chocolate balloon|Vascular preparation with chocolate balloons prior to drug-coated balloon angioplasty
75646467|NCT05892211|Diagnostic Test|Polysomnography|Polysomnography is performed by 3-channel electroencephalography ((EEG; F4-M1, C4-M1, O2-M1), 2-channel electrooculography (EOG), chin electromyography (EMG), surface EMG recording from tibialis anterior muscles of the right and left leg, body position, oronasal thermal airflow sensor, nasal pressure sensor, thoracic and abdominal respiratory belts for assesing the respiratory effort, electrocardiography (ECG), pulse, recording of respiratory sounds, oxygen saturation and synchronous video recording. The sleep stages are scored by the current criteria of American Academy of Sleep Medicine.
75646468|NCT05892211|Diagnostic Test|Skin conductance|The sympathetic skin response recordings are performed with a four-channel electromyography apparatus (Nihon-Kohden). They are recorded from both sides of the sternum with the active and reference electrodes placed 2 cm apart from the midline.
75794119|NCT04880499|Dietary Supplement|Iron plus folic acid, vitamin B2, B6, B12, C, and E|A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.
75794120|NCT04879979|Behavioral|MAAT|MAAT consists of 8 weekly visits of 45 minutes duration and can be delivered effectively through videoconference technology (Vidyo). Participants will be asked to download the Vidyo App on their mobile phone or tablet. Vidyo is a HIPPA compliant, encrypted software with adequate bandwidth for highest quality videoconferencing intended for telehealth. It is the primary software for UPMC Telemedicine. Survivors are provided a workbook to reinforce learning, mastery and application of skills in daily life covered in each MAAT visit. The workbook provides reading structured within each of the 8 visits with guides for application of strategies as homework
75794121|NCT04872816|Device|Continuous airway positive pressure|The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months
75336726|NCT00085436|Biological|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
75336727|NCT00085436|Biological|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
75794122|NCT04855812|Device|MyoMo|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
75336728|NCT00003724|Procedure|surgical procedure|
75336729|NCT00384202|Drug|Tacrolimus|Immunosuppression
75336730|NCT00086138|Drug|Sertraline (Zoloft)|Sertraline: range of 25 to 125 mg per day for 24 weeks
75336731|NCT00086138|Drug|Placebo|Placebo designed to mimic sertraline taken daily for 24 weeks
75473035|NCT01965522|Drug|Melatonin|Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
75473036|NCT01965522|Drug|Vitamin D|Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
75473037|NCT01965522|Drug|Placebo (melatonin)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
75794123|NCT04855812|Other|Myo-SB|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
75473038|NCT01965522|Drug|Placebo (vitamin D)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
75473039|NCT01965548|Procedure|Treatment of splenic injury|"There are four possible treatments of splenic injury in this study:~splenectomy~splenic artery embolisation~non-operative management~any combination of the three treatments mentioned"
75473040|NCT01965574|Procedure|Trendelenburg position|
76085435|NCT01714336|Drug|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
75336732|NCT04329130|Drug|Chidamide, Lenalidomide|All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.
76085436|NCT01714336|Drug|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
75336733|NCT00384280|Drug|Rifampin|
75646469|NCT05892211|Genetic|ALU and LINE-1 DNA methylation analysis|2 cc peripheric venous blood is drawn from the participants to the test tubes with EDTA. DNA isolation is done by Nucleospin Blood Kit (REF:740951.250, Macherey-Nagel). Epitect Fast DNA Bisulfite Kit (REF:59824, Qiagen) is used to do DNA bisulfite modification. ALU and LINE-1 site specific methylation primer is designed and the methylation patterns are compared between the groups by Epitect Methylight PCR Kit (Cat. No:59496, Qiagen).
75336734|NCT00003976|Drug|indisulam|
75336735|NCT00003730|Drug|fluorouracil|
76085437|NCT01714492|Device|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
75336736|NCT00003730|Drug|vinorelbine tartrate|
75336737|NCT01881308|Drug|TNF inhibitors|
75336738|NCT01881308|Drug|Synthetic DMARD(s)|
75336739|NCT01881308|Drug|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
75646470|NCT05892211|Diagnostic Test|The Menopause-Specific Quality of Life Questionnaire (MENQOL)|The Menopause-Specific Quality of Life Questionnaire (MENQOL) is filled by each participant to assess the health related quality of life before the polysomnography test.
75930976|NCT03309488|Diagnostic Test|Oral food challenge|Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.
75930977|NCT02230059|Other|No Intervention|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
75336740|NCT00003982|Drug|sabarubicin|
75930978|NCT03309410|Diagnostic Test|Venous to arterial conversion (v-TAC)|This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
75930979|NCT02230137|Behavioral|Text message arm|Text message sent before each injection of insulin
75930980|NCT05232422|Behavioral|Hatha yoga course|Participants will join a free hatha yoga course, conducted by a professional yoga teacher, over a time period of eight weeks with a frequency of at least three up to five times a week. The quality of the implementation of the intervention will be checked through post-monitoring by short questionnaires to be filled out by participants.
75930981|NCT02470442|Drug|Sevoflurane/Desflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
75930982|NCT02470442|Drug|Sevoflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
75930983|NCT04021797|Device|transcutaneous vagal nerve stimulation|The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.
75930984|NCT02470520|Procedure|CRRT|continuous renal replacement therapy
75930985|NCT03519711|Drug|PTC923|PTC923 will be administered per dose and schedule specified in arm description.
76085438|NCT01714804|Device|Accell Evo3 Prospective Use|
76085439|NCT01716208|Drug|Ofatumumab + Fresh Frozen Plasma|
76085440|NCT00706992|Biological|ALVAC-MART-1 vaccine|Given subcutaneously
76085441|NCT00706992|Biological|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
76085442|NCT00706992|Biological|Aldesleukin|Given subcutaneously
76085443|NCT00706992|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
76085444|NCT00706992|Biological|incomplete Freund's adjuvant|Given subcutaneously
75336741|NCT00003292|Drug|ifosfamide|
75336742|NCT00088634|Drug|Lurasidone|80 mg AM dosing once daily
75336743|NCT00088634|Drug|Placebo|Matching Placebo to 40mg lurasidone tablets
75336744|NCT00003736|Drug|motexafin gadolinium|
75336745|NCT00003736|Procedure|biopsy|
75336746|NCT00003736|Procedure|breast imaging study|
75336747|NCT00003736|Procedure|comparison of screening methods|
75336748|NCT00003736|Procedure|magnetic resonance imaging|
75336749|NCT00003736|Procedure|study of high risk factors|
75336750|NCT04772066|Other|Measure of medication adherence|Measure of medication adherence
75336751|NCT00003994|Procedure|therapeutic conventional surgery|Undergo surgical resection
75336752|NCT00003994|Drug|cisplatin|Given IV
75336753|NCT00003994|Drug|vincristine sulfate|Given IV
75336754|NCT00003994|Drug|fluorouracil|Given IV
75336755|NCT00003994|Drug|amifostine trihydrate|Given IV
75336756|NCT00003994|Drug|carboplatin|Given IV
75336757|NCT00003742|Drug|cisplatin|
75336758|NCT00003742|Drug|irinotecan hydrochloride|
75336759|NCT00003742|Drug|paclitaxel|
75336760|NCT01636544|Procedure|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
75336761|NCT00003304|Drug|temozolomide|
75336762|NCT00004006|Biological|filgrastim|
75336763|NCT00004006|Drug|carboplatin|
75336764|NCT00004006|Drug|cyclophosphamide|
75336765|NCT00004006|Drug|doxorubicin hydrochloride|
76085445|NCT02249728|Drug|IV PBT2 microtracer and oral PBT2 single dose|
76085446|NCT02249728|Drug|oral 14C-PBT2|
76085447|NCT03335202|Diagnostic Test|analysis of microbiome|microbial profiling by next generation sequencing
76085448|NCT03340194|Radiation|Radiography|Radiography of the hand and feet (face incident) the day of the inclusion
75930986|NCT03108950|Behavioral|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
75336766|NCT00004006|Drug|etoposide|
75930987|NCT04491734|Dietary Supplement|maltosyl-isomalto-oligosaccharides (MIMO)|Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.
75930988|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
75930989|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
75930990|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
75930991|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
75336767|NCT00004006|Drug|topotecan hydrochloride|
75336768|NCT00004006|Procedure|autologous bone marrow transplantation|
75473041|NCT01965587|Procedure|novasure mirena IUS combined|novasure mirena IUS combined
75473042|NCT01965626|Drug|Oseltamivir|Oseltamivir 75 mg twice per day, 10 consecutive days
75646471|NCT05892211|Diagnostic Test|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is done by each participant to assess the sleep quality and disturbances before thepolysomnography test.
75646472|NCT05889637|Diagnostic Test|Gastric ultrasound|Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.
75646473|NCT05883800|Radiation|On-couch adaptive radiotherapy|A new treatment plan, guided by volumetric images, is created at each treatment session
75930992|NCT01320956|Behavioral|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
75930993|NCT01320956|Other|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
75930994|NCT02230215|Device|Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation|The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
76085449|NCT03340194|Procedure|Veinous punction|Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
76085450|NCT03335124|Drug|Vitamin C|Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.
76085451|NCT03335124|Drug|Hydrocortisone|Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
75646474|NCT05875922|Device|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
76085452|NCT03335124|Drug|Thiamine|Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
75646475|NCT05875922|Device|IOL implantation active comparator (TECNIS Eyhance)|Implantation of EDOF IOL TECNIS Eyhance
75646476|NCT05866445|Device|Wearable BP device|Wearable study BP device to be worn for 8 hours within study participation.
75646477|NCT05866445|Device|24-hour ambulatory blood pressure monitor|24-hour ambulatory blood pressure monitor to be worn for 24-hours during study participation.
75646478|NCT05863624|Procedure|Open hernioplasty|Inguinal hernia is operated using open surgery
75646479|NCT05863624|Procedure|TEP hernioplasty|Inguinal hernia is operated using laparoendoscopic technique
75646480|NCT05862727|Behavioral|Telehealth Intervention|Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.
75646481|NCT05852340|Drug|Ritlecitinib|"ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)"
75646482|NCT05850442|Diagnostic Test|Questionary|Patients will be asked to fill Fibromyalgia Impact Questionary, WHO Short Quality of Life Questionary, McGill Pain Questionary and Beck Anxiety Questionary
75930995|NCT03970538|Device|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia
75930996|NCT02230293|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
75930997|NCT02230293|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
75930998|NCT04491656|Other|WALANT Technique|A technique commonly used in hand surgeries where the combination of lidocaine and epinephrine is used for local blood control, thus performing the procedure without a tourniquet
75930999|NCT02499900|Drug|Copaxone®|Subcutaneous Injections
75336769|NCT00004006|Radiation|radiation therapy|
75336770|NCT00003316|Drug|gemcitabine hydrochloride|
75336771|NCT00003322|Drug|cisplatin|
75336772|NCT00003322|Drug|paclitaxel|
75336773|NCT00003322|Procedure|quality-of-life assessment|
75336774|NCT00519818|Drug|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
75336775|NCT00519818|Drug|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
75646483|NCT05847465|Other|Bike stress test|This is an incremental exercise under maximal pedaling on an Excalibur® type bike with electromagnetic brake over 36 minutes during which gas exchanges are continuously measured through a face mask (Cosmed®).
76085453|NCT03335124|Drug|0.9% Sodium Chloride Injection|0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
76085454|NCT04102150|Drug|Valemetostat Tosylate|Once a day, 200 mg, oral administration
76085455|NCT05465460|Drug|Banana Blossom|Banana Blossom 225 mg tablet orally four times per day for 14 days
76085456|NCT05465460|Drug|Placebo|Placebo tablet orally four times per day for 14 days
75646484|NCT05847465|Other|Heat Tolerance Test|"The test consists of a walk on a treadmill in shorts, bare chest or bra for women, at 5 km/h and 2% slope in an environment at 40°C, 40% relative humidity, without convection.~During the test, rectal temperature, heart rate and skin temperature will be monitored continuously.~The blood pressure will be measured manually every 30 minutes during the test."
76085457|NCT04072744|Device|Heartfelt measurements|"The measurements taken using the Heartfelt device do not require contact with the participant. For the measurements to take place, the participant will simply walk in the field of view of the device. As the device(s) will have been installed at a location allowing the best view of where the participant goes in an out of bed, the participant is not expected to change anything to their routine.~The device can also take measurements in the dark, so if the participant walks in front of the device in the dark, this information will also be captured.~The Heartfelt device is a CE (European Conformity) marked product. Neither the participant, or the medical team will be able to see the data collected by the Heartfelt device during the study. They will be blinded to the data until each participant has completed the study. At that point they can choose to review the data from participant individually or wait until all the data from all participants is available."
75336776|NCT00003748|Drug|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
75646485|NCT05847465|Other|Heat nociception test|"This test consists in applying a thermal flux generated by an infrared light source on a beam of 1 cm diameter on 2 areas of the dominant lower limb (glabrous face of the forearm and thenar eminence).~Participants will be instructed to remove their limb as soon as the sensation of heat begins to become uncomfortable.~The time between the beginning of the stimulus and the moment of withdrawal will be recorded."
75646486|NCT05837390|Device|Cervical stiffness assessment|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
75794124|NCT04855812|Other|Control|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
75794125|NCT04855799|Drug|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
75794126|NCT04853719|Drug|Rivaroxaban 2.5 Mg Oral Tablet|oral anticoagulants plus antiplatelet agent
75794127|NCT04852484|Drug|local anesthetic-morphine|Before the operation, 19 mL of 0.5% Ropivacaine + 2 mg of morphine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 6 mg of morphine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
75794128|NCT04852484|Drug|local anesthetic-ketamine|Before the operation, 19 mL of 0.5% Ropivacaine + 50 mg of ketamine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 200 mg of ketamine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
75931000|NCT03505749|Behavioral|Trauma Informed Mindfulness-Based Relapse Prevention|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
75931001|NCT03505749|Behavioral|Treatment As Usual (TAU)|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
75931002|NCT03901430|Behavioral|Group navigation model|In a series of peer group sessions facilitated by Guadalupe Fuentes, a CHW who designed the model, we will create a culturally-appropriate, non-stigmatizing group intervention. The group process will allow participants to explore their own MEH, better understand the ways that mental health influences well-being and everyday dynamics of their lives, and to develop empowering knowledge and action plans through the support of other women.
75931003|NCT03314090|Drug|Silicone Gels|silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
76085458|NCT04072744|Device|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link."
76085459|NCT03340116|Procedure|Burn surgery|Burn surgery including wound debridement, skin grafting
75336777|NCT00089102|Drug|gemcitabine hydrochloride|1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle
75336778|NCT00089102|Drug|irinotecan hydrochloride|100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle
75336779|NCT00004012|Drug|capecitabine|
75336780|NCT04771988|Radiation|yttrium-90 radioembolization|selective/superselective treatment using resin microspheres labeled with Yttrium-90
75473043|NCT01965626|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
75931004|NCT03314012|Device|Catheter-Based Carotid Body Ablation|The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
75931005|NCT02230371|Drug|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
75646487|NCT05837390|Other|Cervical length measurement|Cervical length measurement will be obtained via transvaginal ultrasound using a GE Voluson E10 ultrasound machine and 7.5MHz transvaginal probe. All measurements will be performed with the woman in a supine position with an empty bladder in the sagittal plane measuring from the internal to external cervical OS. The full length of the cervical canal will be visualized with the closed portion of cervix remaining being measured. Three measurements are taken with the shortest being documented as the final assessment.
76085460|NCT03340116|Diagnostic Test|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
76085461|NCT03340038|Other|Non-ICU Specialty ward|
76085462|NCT03339960|Other|Ergonomic measurement|Ergonomic measurement of the surgeon and assistant
75336781|NCT00086450|Procedure|Coronary Artery Bypass Graft|For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
75794129|NCT04852484|Drug|local anesthetic|Before the operation, 19 mL of 0.5% Ropivacaine + 1 mL of normal saline (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
75794130|NCT04850872|Behavioral|PLAYwithHEART Programme for adolescent athletes|PLAYwithHEART programme for adolescent athletes is an intervention programme based on Mindfulness, Acceptance, and Compassion for adolescent athletes
75473044|NCT01965639|Other|Extension of Care|Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.
75473045|NCT01965678|Other|Osteopathic Manipulative Treatment|
75646488|NCT05837390|Other|Fetal fibronectin|Vaginal swab collection. The specimen will be obtained from the posterior fornix over 10 seconds using the polyester tipped swab provided in the Hologic specimen collection kit. This sample will be then be stored frozen and processed using the Rapid fFN 10Q System (HOLOGIC, Marlborough, MA, USA) within 3 months.
75646489|NCT05834400|Behavioral|The Optimal Lymph FLow (TOLF)|Participants in TOLF intervention will complete initial in-person 40-minute session on TOLF lymphatic exercise training and daily monitoring, and 3 virtual 15-minute telehealth sessions to enhance their skills over the course of 4 weeks. These sessions will be conducted by the TOLF interventionist of the study. For 4-week study duration, participants will be asked to practice the set of 8 lymphatic exercises twice a day.
75646490|NCT05834400|Behavioral|Daily Monitoring|Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
75646491|NCT05833334|Behavioral|Public health infographic (AIM 3)|Standard public health infographic about home air radon testing, plus information about requesting a free home air radon test kit
75646492|NCT05833334|Behavioral|Online health promotion intervention tailored by smoking status (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit
75794131|NCT04846569|Behavioral|Transition Theory-based Intervention|The behavioral intervention is a theoretically driven curriculum focused on supporting mothers from pregnancy through postpartum in order to promote sustained HIV treatment adherence. Sessions utilize motivational interviewing and consist of a range of topics including motherhood, preparing for baby, disclosure, HIV education, adherence, birth experiences, support systems, and living positively.
75931006|NCT02230371|Drug|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
75931007|NCT03859700|Biological|DBV712 250 mcg|DBV712 250 mcg, once daily
76085463|NCT02248558|Behavioral|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
76085464|NCT02248558|Behavioral|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
75931008|NCT03996447|Drug|gadopiclenol|single intravenous (IV) bolus injection at a rate of 2ml/second
75931009|NCT03996447|Drug|Gadobutrol 1Mmol/mL Solution for Injection Vial|single intravenous (IV) bolus injection at a rate of 2ml/second
75931010|NCT01111110|Device|anti-static then static|Albuterol using static chambers
75931011|NCT01111110|Device|Static then anti-static chamber|albuterol with Static then anti-static chambers
75931012|NCT05338736|Diagnostic Test|LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)|Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients
76085465|NCT03339882|Drug|Remifemin|Remifemin 0.2g po bid*12 weeks at the beginning of the LHRH-a treatment
76085466|NCT03339804|Other|Chemotherapy|In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
75794132|NCT04846569|Behavioral|Enhanced Standard of Care Control|In addition to standard of care, participants receive the first session of the Transition Theory-based Intervention curriculum which focuses on motherhood and preparation for baby but does not discuss the transition from pregnancy to postpartum or the postpartum period.
75794133|NCT04845477|Device|Magnetic tape|magnetic tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
75794134|NCT04845477|Device|Kinesiology tape|kinesiology tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
75931013|NCT05338736|Diagnostic Test|LIAISON SARS-CoV2-IgM (DiaSorin)|Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients
75931014|NCT05338736|Diagnostic Test|Human IFN-g ELISpot PLUS (ALP) (AUROGENE)|Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)
75931015|NCT03473652|Other|Adapted walking platform|The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
75931016|NCT03436797|Drug|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
75931017|NCT03313934|Combination Product|Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.
75931018|NCT03313934|Combination Product|Hyaluronic Acid Filler and Saline|This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.
75931019|NCT03941301|Device|Light therapy|Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
75931020|NCT03313856|Drug|Guazuma Ulmifolia plus Tecoma Stans|Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
75931021|NCT03313856|Drug|Calcinaned magnesia|Calcined magnesia 400 mg per capsule
75931022|NCT04548024|Device|Short term monitoring|By using the Biobeat monitoring device, we will monitor CHF patients during an outpatient visit and during treatment with diuretics.
75931023|NCT02230605|Other|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
75931024|NCT02230605|Other|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
75931025|NCT02230605|Other|Geriatric Depression Scale|To be completed at the Screening Visit and at POD 90
75931026|NCT02230605|Other|Charlson Comorbidity Index|To be completed at the Screening Visit and at POD 90
75931027|NCT02230605|Other|Short Form 36 Health Survey|To be completed at the Screening Visit
75931028|NCT02230605|Other|Confusion Assessment Method|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
75646493|NCT05833334|Behavioral|Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit, plus reminder messages about home air radon testing sent over two months
75794135|NCT04842799|Other|Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform|"Participants will receive a link to the digital pre-test information. This will consist of text covering: Genetics and cancer risk; Genetics testing; What will happen if your test is positive; What will happen if your test is negative; Implications for insurance.~Where relevant, parts of the text will be linked through to additional information, such as insurance advice from the Association of British Insurers. Participants will be able to call a genetic counsellor on the hotline during weekday office hours, should they have any questions or require further information."
75931029|NCT02230605|Other|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
75931030|NCT02230605|Other|Postoperative Quality of Recovery Scale|To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
75931031|NCT03313700|Procedure|Robotic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.
75931032|NCT03313700|Procedure|Laparoscopic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
75931033|NCT03473496|Biological|CART therapy in Relapsed/Refractory multiple myeloma|one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
75931034|NCT05137626|Drug|AT-527 + digoxin|"Day 1: A single dose of digoxin will be administered.~Day 15: A single dose of AT-527 and digoxin will be co-administered."
75931035|NCT05137626|Drug|AT-527 + digoxin|"Day 1: A single dose of digoxin will be administered.~Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later)."
76085467|NCT02248636|Drug|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
75646494|NCT05833334|Behavioral|Focus group with educational overview (AIM 1)|90-minute online focus group discussion about home air radon testing, plus an educational overview about home air radon testing using a standard public health infographic
75646495|NCT05821660|Other|Five-day hypocaloric and ketogenic programme|Dietary intervention
75646496|NCT05813964|Drug|TDF/FTC 300mg/200mg fixed-dose combination tablets|Event-driven dosing regimen
75794136|NCT04842799|Other|Digital Delivery of Genetic Test Results via the BRCA-DIRECT Platform|Participants will receive a digital message that their results are available. When they click this, they will receive digital notification of their negative (normal) result in short form. Full details will be provided in an individualised letter.
75646497|NCT05813964|Drug|TAF/FTC 25mg/200mg fixed-dose combination tablets|Event-driven dosing regimen.
75794137|NCT04840667|Drug|REPLAGAL|Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
75794138|NCT04838223|Other|Hyperosmolar Response|A single drop of hypertonic sodium chloride solution at room temperature will be instilled in each eye and change in pain/other symptoms after up to 90 seconds of application (to account for any initial irritation symptoms) will be observed.
75794139|NCT04838223|Other|Proparacaine Challenge Test|A single drop of Proparacaine hydrochloride ophthalmic solution, (Alcaine®, 0.5%) will be used on each eye respectively and any change in pain/other symptoms will be noted after 90 seconds (to account for initial discomfort from the preservative in Proparacaine solution).
75931036|NCT05114226|Drug|Tetrahydrobiopterin|BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
75931037|NCT02233023|Drug|Pramipexole|
75931038|NCT02233023|Drug|Bromocriptine and other dopamine agonists|
76085468|NCT02248636|Drug|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
75473046|NCT01965691|Dietary Supplement|Protein intake|"Oral consumption of eight hourly experimental meals-~4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil~4 isotopically labeled experimental meals."
75646498|NCT05797636|Device|transcranial magnetic stimulation|"The study intervention is modulation of cortical excitation to inhibition (E/I) balance in the dorsolateral prefrontal cortex (dlPFC) by means of 2 trains of spaced continuous theta burst stimulation (cTBS) using a transcranial magnetic stimulation device. As prior work (Huang et al 2005; Chung et al. 2018) has shown that cTBS reliably decreases the cortical E/I ratio with diverse cortical targets, the Investigators expect to replicate a reduction in E/I balance when applied. The mechanism of action is thought to be an increase in inhibitory neurotransmission across diverse timescales. The endpoint of this stimulation will be a decrease in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2018).~In separate sessions, all participants will receive stimulation to either the dorsolateral prefrontal cortex (dlPFC) or to the angular gyrus (AG). The Investigators will contrast the effects of dlPFC cTBS with control cTBS to the AG."
75931039|NCT03473106|Device|Pneumatic tourniquet use|Surgery requiring a pneumatic tourniquet on the thigh
75931040|NCT03322137|Drug|SNA-120|Pegcantratinib ointment
75931041|NCT03322137|Drug|Vehicle|Placebo ointment to mimic Pegcantratinib ointment
75931042|NCT03710642|Drug|Prazosin|Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
75931043|NCT03710642|Drug|Placebo oral capsule|Placebo capsule matched to appearance of active drug.
75931044|NCT04458870|Behavioral|Acceptance and Commitment Therapy|Participants will receive 10 weekly individual acceptance and commitment therapy by a trained coach through zoom video-conferencing.
75646499|NCT05777889|Other|Forward Looking InfraRed Camera|"Forward Looking InfraRed Camera:~We will use a FLIR T420 or T62101 camera with a resolution of 320*240.~Each image will be captured perpendicularly with a 1-inch gap on all four sides.~A Myler blanket placed in the background will separate the feet from the background.~The camera will be normalized to a temperature range of 15°C to 40°C.~The images will be saved in radiometric JPEG format.~Once the images have been transferred to a computer, we will remove the background.~Next, we'll make a temperature histogram with 0.1°C temperature bin resolution.~The before and after histograms (IB, IA) will be compared to see which one indicates more extreme temperature distributions.~Those who improve by 30% or more are considered to have had a successful spinal cord stimulation."
75931045|NCT02259309|Drug|Misoprostol - buccal|buccal administration
75646500|NCT05771103|Device|thermal Radiofrequency neurolysis of Stellate ganglion|Stellate ganglion block with alcohol injection versus thermal RF neurolysis of Stellate ganglion
75794140|NCT04838223|Other|Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Optional; only for Contact Lens Wearers|The CLDEQ-8 is a validated eight-item scaled questionnaire developed to reflect the overall opinion of soft contact lenses.
75794141|NCT04838223|Other|Ocular Pain Assessment Survey (OPAS)|Twenty seven-item quantitative questionnaire designed to provide an assessment of the symptoms and quality of life effect of ocular pain [18]. The 27 items of the OPAS questionnaire are graded on a scale of 0 to 10, or 10 to 100, where 0 indicates none and 10 or 100 indicate maximum.
75473047|NCT01965730|Drug|epsilon-aminocaproic acid (EACA)|
75931046|NCT02259309|Drug|Misoprostol - vaginal|vaginal administration
75931047|NCT04459026|Procedure|combination|instillation and infiltration of ropivacaine
75931048|NCT04459026|Procedure|infiltration|local infiltration ropivacaine
75931049|NCT04459026|Procedure|instillation|intraperitoneal ropivacaine instillation
75931050|NCT02470052|Device|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
75931051|NCT04286958|Drug|Camrelizumab|Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)
75931052|NCT03473418|Drug|Ketoconazole|Ketoconazole as a topical vaginal gel
75931053|NCT03473418|Drug|Terconazole|Terconazole 80 mg as a topical vaginal cream
75931054|NCT03917511|Behavioral|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
76085469|NCT02494362|Other|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
76085470|NCT03339648|Behavioral|Professional Development Enhancement|Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
75794142|NCT04838223|Other|Visual Analogue Questionnaire|Symptoms of ocular comfort and dryness will be graded for each eye on a scale of 0-10, where 0=extremely uncomfortable, extremely dry and 10=excellent comfort, no dryness. An average rating will be provided for the morning, afternoon and evening.
75646501|NCT05750732|Behavioral|Weight loss diet|Participants in the study group will be given training on the weight loss diet, which is a routine part of their treatment.
75931055|NCT03917511|Behavioral|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
75931056|NCT04282278|Drug|Camrelizumab/sintilimab+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
75931057|NCT04282278|Drug|Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po
75931058|NCT04282278|Drug|Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
75931059|NCT03916731|Device|STARgraft AV|Implant of STARgraft AV shunt in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
76085471|NCT02248714|Dietary Supplement|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
76085472|NCT02494128|Other|Education|Education in group leadership
76085473|NCT03331224|Device|OTSC|OTSC placement
76085474|NCT03331224|Device|Endoscopic Standard therapy (combining two methods)|endoscopic standard therapy (two methods, e.g. clip and injection)
75646502|NCT05743647|Device|Observation (OBS)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject only observe the movement on the screen during the recordings. The subject does not produce any movement."
75646503|NCT05743647|Device|Observation and imagination (OBS-IM)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement but also imagine to realized it."
75646504|NCT05743647|Device|Observation and realization (OBS-REAL)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement on the screen and realized it"
75646505|NCT05739006|Drug|BCD-201|up to 8 treatment cycles
75931060|NCT03916731|Device|ePTFE AV graft (control)|Implant of standard ePTFE AV shunt as a control in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
75931061|NCT00705224|Biological|Pegylated Interferon|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
75794143|NCT04835363|Other|Early Occupational Therapy intervention|four-week OT intervention program with the support of the main caregiver in patients who have suffered a stroke with the aim of improving the functional result and facilitating the return home by providing knowledge to the caregiver about specific care and neurorehabilitation.
76085475|NCT03331146|Drug|Saline|A placebo (saline infusion) will be administered after induction of general anesthesia.
76085476|NCT03331146|Drug|Sodium Nitrite|Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
76085477|NCT02491866|Other|to develop and validate a Computerized Adaptative Testing|"Elaboration of a pool of items, based on literature review and interview with patients.~Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.~Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.~Metrological validation of the CAT.~Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients."
76085478|NCT03331068|Behavioral|online questionnaire of MAX-PC|Scale measuring of the anxiety specific of prostate cancer, French version.
76085479|NCT02491554|Device|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
76085480|NCT02491554|Device|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
75646506|NCT05739006|Drug|Keytruda|up to 8 treatment cycles
75646508|NCT05727930|Behavioral|High-intensity, task-specific (i.e., walking) interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve higher cardiovascular intensities
75646509|NCT05727930|Behavioral|High-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve higher cardiovascular intensities
75646510|NCT05727930|Behavioral|Low-intensity, task-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve lower cardiovascular intensities
75794144|NCT04830761|Behavioral|Motivation|The key constructs targeted by the motivational module are attitudes towards the target behavior, risk perception, outcome expectancies and self-efficacy. The intervention includes the following techniques: information about health consequences, salience of consequences, goal setting (behavior), problem solving, verbal persuasion about capabilities, focus on past success (Michie et al., 2013)
75931062|NCT00705224|Drug|Ribavirin|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
75931063|NCT04217382|Other|patient with melanoma pre transplantation|survival time without melanoma recurrence
75931064|NCT03267147|Other|no intervention is given|no intervention is given
75931065|NCT02457156|Procedure|Blumgart Anastomosis|"Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~Pancreatic duct to jejunal mucosa sutures, inserted and tied.~Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied."
75931066|NCT02457156|Procedure|Cattell-Warren Anastomosis|"Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~Pancreatic duct to jejunal mucosa sutures, inserted and tied.~Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied."
75931067|NCT02457156|Drug|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
75931068|NCT03313466|Behavioral|Internet cognitive behavioral therapy for insomnia (iCBTI)|An internet-based program for providing individually tailored CBTI based on participant responses to questions and performance on weekly guided sleep strategies.
75931069|NCT03313466|Behavioral|Class in sleeping well and improving insomnia|A group education session providing advice on healthy sleep habits and ways to improve common forms of insomnia.
76085481|NCT02491320|Other|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
76085482|NCT02491320|Drug|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
75646511|NCT05727930|Behavioral|Low-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve lower cardiovascular intensities
75473048|NCT01965743|Behavioral|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths
75646512|NCT05725824|Device|BTE hearing aid with compatible earmolds|Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = ~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.
75646513|NCT05722834|Behavioral|SOAR intervention|"This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients."
75646514|NCT05720013|Dietary Supplement|Beetroot Juice supplement|The experimental arm includes orally ingesting 140 mL Beet-It Sport Nitrate 400.
75931070|NCT02470130|Behavioral|relaxation|5 min of conversational relaxation red by one of the instructor between simulation and debriefing
75931071|NCT02523300|Procedure|TEVAR|The patients will be undertaken TEVAR
75646515|NCT05720013|Dietary Supplement|Placebo supplement|he placebo arm involves orally ingesting a 140 mL placebo solution with the dietary nitrate removed.
75931072|NCT02523300|Drug|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
75931073|NCT02523300|Drug|saline|The other 120 patients will be given saline as control group
75931074|NCT03313388|Dietary Supplement|Drink|Beverage to be consumed
75931075|NCT03471546|Behavioral|Palliative Care|Initial consultation and follow-up with a palliative care provider
75931076|NCT04491500|Behavioral|High attitude environment|The participants will go to 4000m altitude to work for two weeks.
76085483|NCT02491242|Other|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
76085484|NCT03330990|Drug|Entrectinib|600 mg oral capsule (fasted and fed)
76085485|NCT03330990|Drug|Midazolam Hydrochloride|2 mg oral syrup (fasted)
75646516|NCT05713383|Behavioral|Auditory Feedback|Sound amplification is used to accentuate participants' footsteps, while asking them to step softly so as to reduce this sound.
75646517|NCT05702021|Behavioral|Science to Service Laboratory|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
75931077|NCT05057871|Device|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 50 Hz frequency, 85 Gauss (8.5 milliTesla) intensity and for 30 minutes. The treatment period was 5 days a week for 4 weeks, in total. It was applied as 20 sessions.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
75794145|NCT04830761|Behavioral|Habit|The goal of the habit module is to guide participants to perform correct hand hygiene at self-selected key times repeatedly. The aim is that the behavior will be translated into a habit. The intervention includes the following techniques: Information about antecedents, self-monitoring of behavior, action planning, prompts/cues, habit formation, behavioral practice/ rehearsal, prompts/cues (physical cue) (Michie et al., 2013).
75794146|NCT04830761|Behavioral|Social|The key constructs targeted by the social module are perceived norms including descriptive norms and injunctive norm. The intervention includes the following techniques: Monitoring of behavior by others, social incentive, social comparison, social reward, restructuring the physical environment, information about others approval, credible source, information about health consequences, feedback on behavior (Michie et al., 2013).
75794147|NCT04830267|Drug|Camrelizumab|Camrelizumab 200mg IV starting day 1 and then every 2 weeks thereafter. Treatment with Camrelizumab will continue until progression or unacceptable toxicity.
75794148|NCT04830267|Radiation|Stereotactic body radiotherapy|Image guided, stereotactic body radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Camrelizumab).
75931078|NCT05057871|Device|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 20 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
75931079|NCT03471468|Procedure|kinetics of microparticles under chemotherapy|Blood samples done before chemotherapy and 6 hours later for each of six chemotherapies required by the protocol.
75931080|NCT05278286|Behavioral|Crawling stimulation with the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5 minutes session everyday at home with a trained therapist. During each session the infant is prone wrapped on the crawliskate and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the therapist.
75794149|NCT04827147|Device|Multi-Periscopic Prism (MPP) glasses|Spectacles with multi-periscopic prisms mounted as oblique peripheral prism segments
75931081|NCT05278286|Behavioral|Tummy time without the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5-minutes session everyday at home with a trained therapist. During each session the infant is prone directly ona mattress and cannot benefit from any assistance from the therapist to move forward.
75646518|NCT05700630|Biological|FT538|FT538 is an investigational off-the-shelf cryopreserved NK cell product derived from an iPSC that contains three functional modifications: 1) a novel high affinity, non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface and remains fully functional after NK cell activation, thus augmenting ADCC; 2) an IL-15 receptor fusion that promotes NK cell activity and enhances cell persistence; and 3) the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.
75646519|NCT05700630|Drug|Vorinostat|Vorinostat is a histone deacetylase inhibitor (HDACi) that is FDA approved for the treatment of cutaneous T-cell lymphoma and, under investigation in HIV as disruptor of HIV latency.
75931082|NCT02325960|Drug|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
75646520|NCT05695027|Drug|Dietary supplements - Nicotinamide and Pyruvate|Nutritional supplements
75646521|NCT05695027|Drug|Placebo|Placebo
75646522|NCT05694182|Other|Other: Oral superfruits supplement|The supplement contain superfruits that are beneficial for human health
75646523|NCT05676580|Procedure|cross-linking surgery or intra corneal ring|After keratoconus diagnosis the patient was assigned to surgery
75646524|NCT05676580|Other|abstention|No surgery
75646525|NCT05631795|Drug|Alpelisib|Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
75646526|NCT05631795|Drug|Fulvestrant|Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
75794150|NCT04827147|Device|Fresnel Peripheral Prism (FPP) glasses|Spectacles with conventional permanent Fresnel prisms mounted as oblique peripheral prism segments
75794151|NCT04823975|Behavioral|Health Insurance Education Program (HIEP)|[See arm/group description]
75794152|NCT04815226|Device|Peristeen Transanal Irrigation|Using Peristeen Transanal Irrigation twice per week for 12 weeks
75794153|NCT04814953|Other|questionnaires|EQ-5D-5L questionnaire questioning their overall health on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). In addition patients will have to fill in the generic 15D questioning 15 specific dimensions on 5 levels as well as the BaSQoL, which is a disease specific questionnaire for patients with KC. The Time-trade off task is the final question.
75794154|NCT04811521|Behavioral|Primary care follow-up|Those randomized to primary care and enhanced primary care coordination will receive the minimal intensity treatment that includes: (1) assistance in identifying a primary care provider for participants who do not have one, (2) sharing results of diagnostic testing (including anxiety screening) with the primary care provider (results sent via EMR note, mailed letter, or delivered by participant at appointment); and (3) an educational brochure on anxiety and treatment.
75473049|NCT01965769|Other|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
75794155|NCT04811521|Behavioral|Online Self-Administered Anxiety Management Program plus Peer Support Guidance|Individuals randomized to the online Cognitive Behavioral Therapy (CBT) + peer support guidance arm will receive access to six online, evidence-based CBT modules in the This Way Up Generalized Anxiety Course to be completed weekly or bi-monthly. Individuals who screen positive on the PHQ panic measure will complete 2 additional panic-specific homework assignments applying exposure therapy to panic (in addition to Generalized Anxiety Disorder) experiences aligned with content from the This Way Up Panic Course.
75794156|NCT04811521|Behavioral|Therapist-Administered Cognitive Behavioral Therapy|Individuals randomized to therapist-led CBT via telehealth will receive 8 one-hour sessions over the course of 8 to 10 weeks via telehealth (HIPAA compliant software such as Zoom Health or AmWell) or telephone. Therapists will be master's-degreed or eligible clinicians trained in CBT by our study psychologist. Therapists will follow a manualized protocol for delivering CBT for anxiety, specifically, with a primary focus on anxiety and worry management. Individuals who screen positive on the PHQ panic measure will have training in exposure therapy added to CBT. Although many CBT trials have a standard length of 12 sessions, brief CBT lasting 4-8 sessions is equally efficacious.
75646527|NCT05629637|Behavioral|Mindfulness-Based Resilience Training (MBRT)|MBRT is designed to enhance resilience in the presence of acute and chronic LEO stressors. MBRT will be delivered in a hybrid format. An intensive, 22-hour in-person training will be offered, followed by 4 weekly 90-minute zoom classes. The in-person portion of the training will span 3 days: 4 hours day 1, 6 hours day 2, and 6 hours day 3. MBRT contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions. MBRT is designed to address stressors inherent to police work, including critical incidents, job dissatisfaction, public scrutiny, and interpersonal, affective and behavioral challenges.
75794157|NCT04806568|Other|Cognitive Training|The cognitive training treatment is a Greek adaptation of BrainHQ developed by Posit Science Corporation. The intervention will target speed, attention, working memory, and executive function through the visual and auditory domains via a set of 15 exercises. Each daily training session consists of four exercises chosen from an active set of six. Participants will be instructed to train for one hour per day, three days per week, over 12 weeks via a tablet. Each subject will receive at least 29 sessions of computerized cognitive training.
75794158|NCT04801212|Other|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
75794159|NCT04801212|Other|core stability exercises|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
75646528|NCT05623865|Other|kinesiotaping|"Kinesio tape will be attached with lymphedema technique.~The bands will be removed prior to each assessment so that they do not affect the evaluator's blinding. After evaluation, the new tape will be fitted by the invesitgatör"
75794160|NCT04789486|Drug|AGuIX|Injected gadolinium-based nanoparticles
75646529|NCT05623865|Other|exercise|"Wrist, finger, elbow range of motion and stretching exercises will be taught to the patients and given as home exercises.~In addition, patients will be given a leaflet containing illustrated and explanatory exercise visuals."
75931083|NCT02325960|Drug|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
75646530|NCT05619107|Device|Active Transauricular nerve stimulation|The first allocated intervention will be undertaken for 30 minutes. The electrode placement and stimulation parameters are described in the arm/group section. After the 30-minute intervention, day 1 of the protocol will be complete. The investigator will remain present in the room with the participant to ensure compliance and adherence to the protocol. The allocated intervention will then be repeated by the participant at a similar time of day for 7 consecutive days. The investigator will arrange video-calls with the participant whilst off-site to ensure ongoing compliance and adherence to the protocol. On the seventh day, participants return to the clinical research facility to take the final first allocated intervention. A 14-day rest period will follow. Then the participants will perform the same 7-day protocol for the opposite intervention to their first treatment allocation.
75794161|NCT04789486|Radiation|Radiotherapy|Stereotactic magnetic resonance-guided adaptive radiation therapy
75794162|NCT04786873|Drug|Macimorelin|Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.
75931084|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
75931085|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
75931086|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
75931087|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
75931088|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
75931089|NCT03471390|Other|ProQuaS 2 Intervention|Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
75931090|NCT05265650|Drug|BO-112 in combination with ablative radiotherapy (SABR) and nivolumab|Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
75931091|NCT05265650|Procedure|Tissue Biopsies|Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
75931092|NCT04136730|Behavioral|Home-based|Resistance exercise carried out unsupervised at home
75931093|NCT03313232|Other|ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations
75646531|NCT05619107|Device|Sham transauricular nerve stimulation|Protocol as for active but sham ear leads are applied, unable to deliver current.
75931094|NCT03313232|Other|ROAT with oxidized R-limonene at 1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
75931095|NCT02234349|Procedure|pancreas kidney transplantation|
75931096|NCT02234349|Procedure|kidney transplantation|
75931097|NCT02234505|Procedure|Prosthetic alignment perturbation|Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
75931098|NCT03304808|Device|Exercise Programme +device+ lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
75931099|NCT03304808|Behavioral|Exercise Programme + lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
75931100|NCT04458636|Drug|Prednisolone|Oral
75473050|NCT01965795|Dietary Supplement|Whole Coffee Fruit Concentrate (WCFC)|Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain-Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
75646532|NCT05608668|Device|Pro2 - 60% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
75646533|NCT05608668|Device|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition
75646534|NCT05605483|Other|Salad bar|Schools where the school district has installed salad bars
75646535|NCT05605483|Other|Waitlisted control|Schools where the school district has not yet installed salad bars
75646536|NCT05605483|Other|Salad bar post-COVID|Schools where the school distract has re-opened salad bars will have methods repeated in a subset of schools post-COVID-19
75646537|NCT05602662|Behavioral|Music|Music therapy during mechanical ventilation
75646538|NCT05598528|Other|Genomic profiles detection|The Paraffin-embedded tumor tissue at diagnosis is collected and assessed by Next- generation gene sequencing
75646539|NCT05598528|Other|circulating tumor DNA detection|The Plasma at diagnosis and at 1-month treatment are collected and assessed by Next-generation gene sequencing
75646540|NCT05598034|Device|Left DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.
75646541|NCT05598034|Device|Right DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.
75794163|NCT04786873|Diagnostic Test|Arginine|For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.
75794164|NCT04786873|Diagnostic Test|Clonidine|"For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg.~After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally."
75931101|NCT02469350|Other|Serious game|Rehabilitation with serious game
75931102|NCT05000619|Behavioral|Outreach mailer|Postcard or letter
75931103|NCT05000619|Behavioral|Humor/Salience|Funny cartoon
75931104|NCT05000619|Behavioral|Doctor's authority|Letter from a doctor
75931105|NCT05000619|Behavioral|Information|Information about benefits of the appointment
75931106|NCT03304652|Drug|Zaleplon|Sleep Aid; 10mg; Oral; Single Use
75473051|NCT01965795|Dietary Supplement|Nutrim|Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
75473052|NCT01965808|Drug|LY2157299|Administered orally
75646542|NCT05598034|Behavioral|Cognitive task|Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS
75794165|NCT04781881|Drug|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
75931107|NCT03304652|Other|Natural Sleep|Natural Sleep without medication
75794166|NCT04779333|Behavioral|LEAP|LEAP will be delivered through the typical 9 weekly BMT group sessions lasting 90 minutes. Plus wrist worn activity tracker & facebook group.
75646543|NCT05597462|Drug|Minocycline hydrochloride capsules|Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.
75646544|NCT05597462|Other|Placebo|Placebo capsules will be administered orally once daily for 16 weeks.
75794167|NCT04779333|Behavioral|Standard BMT|Weekly BMT groups sessions which follow the Barkley curriculum
75794168|NCT04773899|Diagnostic Test|Procedure : Multimodal microvascular assessment at study inclusion|"Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~Morphological analysis of the microcirculation by sublingual videomicroscopy."
75794169|NCT04772378|Biological|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
75794170|NCT04771728|Drug|Metronidazole vaginal suppositories|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
75794171|NCT04771728|Drug|Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days）
75794172|NCT04767074|Other|Non-pharmacological Cough control Therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management.~Session 1 General assessment Prescription and taught of one cough suppression technique.~Session 2 Cough principles: mechanism, cough reflex, chronic cough, the importance of cough and negative effects of repeated coughing.~Cough control: identify triggers, use cough suppressions and distractions techniques.~Session 3 Breathing pattern retraining and laryngeal hygiene: reinforce nasal breathing and pursed lips breathing as strategies to avoid the urge to cough, identification of risk factors for laryngeal dehydration and hydration education.~Session 4 Reinforcement: Clarification of doubts, techniques' reinforcement and application during daily life situations."
75794173|NCT04764474|Drug|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
75794174|NCT04763330|Behavioral|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) consists of Collaborative Safety Planning, a VA usual care practice. It is a tool that Veterans can use when they are in an acute suicidal crisis. The condition is considered enhanced because Veterans in this condition receive 6 sessions total, Safety Planning which is delivered in 1-2 sessions and 4-5 sessions of check-ins with a brief assessment. Safety Planning involves a worksheet completed by the patient in collaboration with a health provider.
75931108|NCT03898323|Device|Alcohol Approach Bias Modification|Computerized training
75931109|NCT02722148|Device|Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
75931110|NCT03471312|Drug|Magnesium|magnesium therapy
75931111|NCT03162783|Drug|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
75931112|NCT03162783|Drug|ADX-102 Ophthalmic Solution (0.1%)|ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
75931113|NCT03162783|Drug|ADX-102 Ophthalmic Lipid Solution (0.5%)|ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
75931114|NCT02523144|Drug|Chloral Hydrate|70mg/kg chloral hydrate
75336782|NCT00086450|Device|Percutaneous Coronary Intervention|"For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.~The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery."
75336783|NCT00003754|Drug|cyclophosphamide|
75931115|NCT02523144|Drug|Dexmedetomidine|2mcg/kg
75931116|NCT02523144|Drug|Dexmedetomidine|3mcg/kg
75931117|NCT02523144|Drug|Placebo|Flavored placebo syrup
75931118|NCT03304574|Behavioral|Integrated personalized feedback|Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
75931119|NCT02469272|Drug|Fecal Microbiota Transplantation|Administration of frozen fecal materials into gastrointestinal tract
75931120|NCT05154942|Device|DOXO+electroacupuncture|DOXO+electroacupuncture
75336784|NCT00003754|Drug|thalidomide|
75646545|NCT05595135|Other|Text Message-Based Navigation Intervention|Receive interactive text messaging.
75646546|NCT05595135|Other|Behavioral, Psychological or Informational Intervention|Receive medication reminders via smart pill bottle
75646547|NCT05595135|Other|Survey Administration|Ancillary studies
75646548|NCT05595135|Other|Quality-of-Life Assessment|Ancillary studies
75646549|NCT05588986|Other|ultrasonography|Umbilical artery Doppler evaluation by ultrasonography just before the first dose of antenatal corticosteroid, 24 hours and 48 hours after the last dose.
76085486|NCT03335046|Behavioral|Home Visit|The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.
75794175|NCT04763330|Behavioral|Problem Solving Therapy (PST) plus EUC|"Veterans randomized to this condition received EUC and PST. EUC is delivered in both conditions to ensure the safety of all Veterans enrolled in the study. In addition to EUC, Veterans in this condition receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by older Veterans with mental health disorders and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
75794176|NCT04762602|Drug|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
75931121|NCT03894306|Other|Medication lock box|given a lock box and instructed on how to use the device.
75931122|NCT03894306|Other|medication lock bag|given a lock bag and instructed on how to use the device.
76085487|NCT03335046|Behavioral|Standard Care|Standard care will refer to the procedures carried out by the school district to address students with chronic absenteeism. This includes parent-teacher and parent-school administrator meetings and communications and may also include home visits carried out by classroom teachers or student support center staff.
75931123|NCT03894306|Other|brief counseling|After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage
76085488|NCT03330912|Device|Neutral seat height|Seat height set relative to participant's leg length with neutral set at the measured lower leg length
76085489|NCT03330912|Device|Very low seat height|"Seat height set relative to participant's leg length, 2 below the measured lower leg length"
76085490|NCT03330912|Device|Low seat height|"Seat height set relative to participant's leg length, 1 below the measured lower leg length"
76085491|NCT03330912|Device|Very high seat height|"Seat height set relative to participant's leg length, 2 above the measured lower leg length"
76085492|NCT03330912|Device|High seat height|"Seat height set relative to participant's leg length, 1 above the measured lower leg length"
76085493|NCT03339414|Other|collect blood|collect blood at different time point
76085494|NCT03339336|Drug|BIIB074|Administered as specified in the treatment arm.
76085495|NCT03339336|Drug|Placebo|Administered as specified in the treatment arm.
76085496|NCT01785875|Drug|Etelcalcetide|Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
75646550|NCT05572671|Behavioral|Laboratory task modeling smoking lapse behavior|Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.
75646551|NCT05571384|Behavioral|high intensity body-weight circuit|"Bodyweight and suspension training equipment (TRX® Fit System) with modified movements. Modified Squats: participants will be instructed to hold the handles of the band with arms extended, participants will then lean back in a standing position and perform a squat within a comfortable range of motion while weight is being distributed to the band. Modified Rows: participants will grab the bands with arms and legs extended. They will find a comfortable angle by which to perform a row (pulling the handles to the rib cage) with arms at a 45-degree angle. Modified Push-Ups: perform push-ups on their knees with a flat back and hands underneath their shoulders. They will be instructed to lower their chest towards the ground in a controlled manner and as far as comfort will allow them. Modified Crunches: participants will lay on their back with feet approximately 8-10 inches from their buttocks, and asked to lift their shoulders slightly off the ground."
75794177|NCT04761614|Biological|Bevacizumab|Given IVPB
75794178|NCT04761614|Drug|Fluorouracil|Given IV
75931124|NCT00704132|Drug|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
75931125|NCT00704132|Drug|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
75931126|NCT03304496|Drug|Nitroglycerin 100 MCG/ML Injectable Solution|Previously described.
75931127|NCT03304496|Drug|Saline Solution|Previously described.
75931128|NCT03746964|Procedure|Cardiac MRI|Preoperative cardiac MRI
76085497|NCT02496546|Drug|LEO 32731 cream|Applied for 3 weeks
76085498|NCT02496546|Drug|LEO 32731 cream vehicle|Applied for 3 weeks
76085499|NCT03330756|Procedure|laparoscopic Roux-en-Y gastric bypass|laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb
76085500|NCT03330756|Procedure|laparoscopic Mini gastric bypass|laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
76085501|NCT03334890|Diagnostic Test|plasma mSEPT9 level|the plasma level of methylated SEPT9
76085502|NCT03330678|Dietary Supplement|Probiotic (VSL#3)|Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
76085503|NCT03330600|Behavioral|aquatic physicotherapy|Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
75931129|NCT03746964|Other|in-vitro elasticity tests|in-vitro elasticity tests performed on a segment of ascending aorta collected during surgery
75931130|NCT03313154|Other|Neuropsychiatric screening|"Psychiatric diagnosis through:~clinical interview~the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~HAM-D (Hamilton Scale for Depression);~PHQ-9 (Patient's Health Questionnaire-9 items);~MDQ (Mood Disorders Questionnaire);~YMRS (Young Mania Rating Scale);~ASRM (Altman Self Rating Mania scale);~BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~Assessment of Quality of Life:~SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R)."
75931131|NCT03128853|Device|Rad-67 and DCI Mini Sensor|
75931132|NCT02469428|Other|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
76085504|NCT03330600|Behavioral|immersion|The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
76085505|NCT04576559|Other|Modified dental visual aids|Modified Dental visual aids in the form of pictures created by the main investigator
76085506|NCT04576559|Other|Regular dental visual aids|Regular dental visual aids
76085507|NCT03330522|Other|Love, Sex, & Choices video series|Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.
75646552|NCT05571384|Behavioral|traditional exercise intervention (TEI)|150 min a week of moderate aerobic exercise
75794179|NCT04761614|Drug|Leucovorin Calcium|Given IVPB
75794180|NCT04761614|Drug|Oxaliplatin|Given IVPB
75646553|NCT05564559|Other|multifamily group psychoeducation|The intervention involves 8 weeks of multifamily psychoeducation for families. Duration of sessions: 75 minutes on average Context: First session: psychoeducation on substance-abuse disorders; second session; effects of addiction on the family; third session; illness management; fourth session; supporting recovery; fifth session; improving stress coping skills/stress management; sixth session; developing problem-solving skills; seventh session; strengthening the family; eighth session; working with stigma Preferred approach: face-to-face, multi-family Approach: Psychoeducation
75646554|NCT05558202|Other|Turkish validity and reliability|"Explanation of the Turkish version of the scale.~Translating the Turkish version of the scale into English to ensure consistency with the original scale.~First application of scales to participants by two examiners separately.~Second application of the scales to the participants by one examiner.~Statistical analysis and scaling"
75794181|NCT04761614|Drug|Riluzole|Given PO
75794182|NCT04760860|Drug|Terazosin Hydrochloride|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
75794183|NCT04760860|Other|Placebo|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
75794184|NCT04759131|Drug|efanesoctocog alfa (BIVV001)|Pharmaceutical form:solution for injection Route of administration: Intravenous
75794185|NCT04755803|Procedure|Penoplasty|"Modified penoplasty technique:~Degloved the penile skin and excise the inner prepuce.~Advanced penoscrotal skin to cover penile shaft~Fixed the penis base and reconstructed the penoscrotal angle"
75336785|NCT04771910|Other|Topical cream with live probiotic bacteria|Application of the probiotic cream once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as placebo cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
75794188|NCT04750850|Other|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
75794189|NCT04750850|Other|Usual care|Usual routine as walking and activities of daily living.
75794190|NCT04747587|Other|Reaching Session|"Two x 45 minutes sessions of reaching tasks. Patients in the stroke group will perform the task with the paretic arm using a weight reduction system, allowing movement in the horizontal plane.~Subjects in the control group will perform the task with the randomly selected arm weighted at 80% of their maximum voluntary shoulder torque"
75794191|NCT04743908|Other|Social Network Strategy + COVID-19 messaging|Contextually adapted and theory-driven messages - misinformation correction and self-affirmation - to increase awareness, self-efficacy and community engagement in our adapted Social Network testing Strategy (SNS). SNS is an evidence-based testing intervention that has been widely used in multiple settings with marginalized individuals (ie substance-users) who facilitate the recruitment of their social contacts into testing services.
75794192|NCT04729933|Device|V-Wave Shunt Placement|After the MitraClip Placement and after final screening, the existing transseptal puncture used for MitraClip placement is used to place the V-WAVE Shunt device.
75336786|NCT04771910|Other|Placebo cream|Application of the placebo cream (same formulation as probiotic cream except live probiotic bacteria) once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as probiotic cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
75931133|NCT02469428|Other|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
75336787|NCT00003328|Drug|porfiromycin|
75931134|NCT03643146|Behavioral|Lifestyle Management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
75931135|NCT03643146|Behavioral|Control Group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
75931136|NCT03312998|Radiation|Xrays|Plain x-rays anteroposterior and lateral views to determine system failure
75336788|NCT00003328|Radiation|radiation therapy|
75336789|NCT04771832|Procedure|ERAS|Enhanced Recovery After Surgery (ERAS) protocol is an evidence-based multimodal perioperative protocol focused on stress reduction and the promotion of a return to function
75336790|NCT00004024|Biological|aldesleukin|
75931137|NCT04897035|Device|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
75931138|NCT03304340|Device|functional electrical stimulation (FES)|Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
75931139|NCT03304340|Device|transcutaneous nerve stimulation (TENS)|Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device & Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
75931140|NCT03304340|Other|standard rehabilitation (SR)|The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
75931141|NCT03527238|Other|PPM-based Computation Assisted Drug Dosing|Tacrolimus dosing based on application of PPM.
75931142|NCT03527238|Drug|Tacrolimus|Dosing of calcineurin inhibitor, tacrolimus
75931143|NCT02469506|Device|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
75931144|NCT03832179|Drug|Bevacizumab|Bevacizumab
75931145|NCT03832179|Drug|Ranibizumab|Ranibizumab
75336791|NCT00004024|Biological|autologous tumor cell vaccine|
75336792|NCT00004024|Biological|muromonab-CD3|
75336793|NCT00004024|Biological|sargramostim|
75336794|NCT00004024|Biological|therapeutic autologous lymphocytes|
75336795|NCT00004024|Procedure|surgical procedure|
75336796|NCT00004024|Radiation|radiation therapy|
75336797|NCT00003334|Drug|paclitaxel|
75336798|NCT00003334|Drug|pegylated liposomal doxorubicin hydrochloride|
75336799|NCT00093782|Drug|temsirolimus|Given IV
75336800|NCT00093782|Other|laboratory biomarker analysis|Correlative studies
75336801|NCT00003760|Drug|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
75646555|NCT05526105|Diagnostic Test|Gastric Ultrasound|Gastric ultrasound in the supine and right lateral decubitus position for patients going for operative intervention with a protected airway.
75646556|NCT05514067|Procedure|Electro-Acupuncture|A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
75646557|NCT05506358|Diagnostic Test|High performance liquid chromatography|High performance liquid chromatography (HPLC) using the D10 System by Bio-Rad Laboratories will be used as the gold standard test.
75931146|NCT03832179|Drug|Aflibercept|Aflibercept
75931147|NCT03832179|Drug|Ozurdex|Ozurdex
75794193|NCT04724902|Other|Elastic bandage compression|The compression will be applied with the volunteer in the supine position on a stretcher, with both lower limbs extended and relaxed. The intervention in the Compression group will be with elastic bandages involving the entire surface of the knee, positioned considering anatomical aspects: femoral condyles and the anterior tibial tuberosity. The level of compression must be maintained between 30 mmHg and 60 mmHg, according to the researched literature. The variations within these values will be stipulated according to the volunteer's self-report (comfortable and painless compression). The Shan Group will have the bandage wrapped around the knee without any compression force being exerted. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days. The Control group will be composed of volunteers who make up a study waiting list and will carry out the evaluations at the same time intervals as the other groups, but will not receive any type of intervention.
76085508|NCT03330522|Other|Messages in text|"The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. …. If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension."
76085509|NCT03339024|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
75336802|NCT04771754|Drug|Dolutegravir|50 mg once daily orally
75794194|NCT04724096|Diagnostic Test|Oxygen Enhanced MRI scan|Dynamic MRI scanning switching from breathing room air to high concentration oxygen part way through the scan.
75931148|NCT03312764|Behavioral|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
75931149|NCT03312764|Behavioral|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
75931150|NCT05154630|Drug|TQB2858 injection|TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
75336803|NCT00003766|Drug|O6-benzylguanine|
75336804|NCT00004030|Drug|VX-853|
75336805|NCT00004030|Drug|pegylated liposomal doxorubicin hydrochloride|
75646558|NCT05506358|Device|Automated sickling test|The standard sickling test using 2% sodium metabisulphite will be augmented using an automated microscope (such as Octopi) and machine learning, and will be used as one of the low-cost tests.
75336806|NCT04389320|Drug|Hydroxychloroquine|assess its role in the coarse of covid 19 virus infection
75336807|NCT00003340|Drug|cyclophosphamide|
75336808|NCT00003340|Drug|topotecan hydrochloride|
75336809|NCT00004036|Biological|sargramostim|
75336810|NCT00004036|Drug|amifostine trihydrate|
75646559|NCT05506358|Diagnostic Test|HbS solubility test|Standard HbS solubility test currently used in Nepal (e.g. Sicklevue) will be used as one of the low-cost tests
75646560|NCT05506358|Device|HemoTypeSC|A point-of-care lateral flow assay, HemoTypeSC (https://www.hemotype.com/), will be used as one of the low-cost tests
75794195|NCT04723719|Behavioral|SIESTA|SIESTA is a CBT sleep training for adolescents with ADHD with a focus on sleep hygiene, motivational interviewing and planning and organization.
75794196|NCT04723719|Other|Treatment as usual for ADHD|Participants continue their treatment as usual for ADHD.
75931151|NCT03312608|Diagnostic Test|Navigated transcranial magnetic stimulation|
75931152|NCT05154396|Drug|Neratinib|Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
75336811|NCT00004036|Drug|carboplatin|
75336812|NCT00004036|Drug|cyclophosphamide|
75336813|NCT00003346|Drug|acetaminophen|
75646561|NCT05506358|Device|Sickle SCAN|A point-of-care lateral flow assay, Sickle SCAN (https://www.biomedomics.com/products/hematology/sicklescan/), will be used as one of the low-cost tests
75646562|NCT05506358|Device|Gazelle Hb Variant Test|A portable electrophoresis machine, Gazelle diagnostic device (https://hemexhealth.com/), will be used as one of the low-cost tests
75794197|NCT04722458|Other|Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29)|LURN SI-29
75794198|NCT04722458|Other|IPSS|International Prostate Symptom Score
75794199|NCT04722458|Other|UDI-6|Urogenital Distress Inventory
75336814|NCT00003346|Drug|acetylcysteine|
75336815|NCT00003346|Drug|carmustine|
75336816|NCT00003772|Procedure|quality-of-life assessment|
75336817|NCT00096122|Drug|cytarabine|Given IV
75336818|NCT00096122|Drug|idarubicin|Given IV
75336819|NCT00096122|Drug|tipifarnib|Given orally
75336820|NCT00003778|Drug|dolastatin 10|
75336821|NCT00004042|Biological|monoclonal antibody F19|
75336822|NCT00004042|Radiation|iodine I 131 monoclonal antibody F19|
75336823|NCT00003784|Drug|CHOP regimen|
75336824|NCT00003784|Drug|cyclophosphamide|
75336825|NCT00003784|Drug|doxorubicin hydrochloride|
75336826|NCT00003784|Drug|prednisone|
75336827|NCT00003784|Drug|vincristine sulfate|
75646563|NCT05501171|Behavioral|DREAMLAND|"DREAMLAND is self-administered psychological app for patients with AML that includes four modules, focused on:~Supportive psychotherapy strategies to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance.~Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social support.~Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty.~Self-care to promote positive health behaviors and enhance patients´ sense of control especially as they transition from the hospital to outpatient care.~Each module takes 20 minutes to complete. DREAMLAND also includes three optional models that also take 15 minutes to complete.~Other names BNT200"
75794200|NCT04710199|Drug|Maraviroc experimental group|300-milligram dose of the drug two times daily , oral way. During 14 days.
75931153|NCT03185234|Device|anodal tDCS|2 mA, 10 min, 5 sessions
75931154|NCT03185234|Device|sham tDCS|sham stimulation, 10 min, 5 sessions
75931155|NCT02600130|Biological|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
75931156|NCT02600130|Biological|Placebo|via peripheral intravenous infusion
75931157|NCT04740645|Other|NOCDURNA Cohort|Non intervention
75931158|NCT04740645|Other|LUTS Cohort|Non intervention
75336828|NCT00003784|Radiation|tositumomab and iodine I 131 tositumomab|
75931159|NCT03312452|Device|Hospira plum pump|The Hospira plum pump enables the clinician to program a specific volume of intravenous fluid and define a period of time over which to administer this fluid.
75931160|NCT03312452|Device|Gravity drip device|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
75931161|NCT02497248|Procedure|Pulmonary vein ablation|Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
75931162|NCT04441970|Procedure|Neutral position|The cuff pressure will be recorded at the neutral head position.
75336829|NCT00003352|Drug|cyclophosphamide|600 mg/m2, IV, every 3 weeks
75336830|NCT00003352|Drug|Taxotere|60 mg/m2, IV, every 3 weeks
75336831|NCT00003352|Drug|Adriamycin|60 mg/m2, IV, every 3 weeks
75336832|NCT00004048|Biological|filgrastim|
75336833|NCT00004048|Drug|doxorubicin hydrochloride|
75336834|NCT00004048|Procedure|autologous bone marrow transplantation|
75336835|NCT00004048|Procedure|peripheral blood stem cell transplantation|
75336836|NCT00004048|Radiation|indium In 111 monoclonal antibody MN-14|
75336837|NCT00004048|Radiation|yttrium Y 90 monoclonal antibody MN-14|
75336838|NCT00003358|Drug|chemotherapy|
75336839|NCT00003358|Drug|cisplatin|
75336840|NCT00003358|Drug|gemcitabine hydrochloride|
75646564|NCT05501171|Behavioral|CERENA|"CERENA is a self-administered physical health app that includes 4 modules focused, focused on:~Education about general wellness.~Nutrition.~Exercise.~Cancer prevention.~Each module takes 20 minutes to complete. CERENA also includes three optional modules that also take 15 minutes to complete."
75646565|NCT05495906|Biological|Nonavalent HPV vaccine|Routine dosing form and dosage
75646566|NCT05484687|Drug|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation|Administer 1.5 mg/kg lidocaine
75794201|NCT04710199|Other|Standard treatment|It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
75794202|NCT04707781|Diagnostic Test|chest CT|assessment of interstitial lung disease using chest CT
75794203|NCT04699240|Drug|clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
75794204|NCT04699240|Drug|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months
75794205|NCT04698460|Procedure|Hybrid coronary revascularization|A staged procedure with a minimally invasive direct coronary artery bypass grafting of left anterior descending artery by left internal mammary artery (LIMA-LAD MIDCAB) at first stage, and percutaneous stenting of iFR-significant lesions in non-LAD arteries at the second stage
75794206|NCT04698460|Procedure|Coronary artery bypass grafting|A conventional procedure of median thoracotomy with on-pump bypass grafting of left anterior descending artery by left internal mammary artery and saphenous vein grafting of circumflex and/or right coronary artery
75794207|NCT04688658|Drug|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
75794208|NCT04688658|Drug|Duvelisib|Duvelisib is a potent inhibitor of both γ and δ isoforms. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
75794209|NCT04680130|Drug|C-11 PiB|Completing PET scan looking for amyloid protein
75794210|NCT04680130|Drug|AV1451 Tau|Completing PET scan looking for tau protein
75794211|NCT04680130|Drug|C-11 ER176|Completing PET scan looking for neuroinflammation
75794212|NCT04679870|Drug|GB2064|GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
75931163|NCT04441970|Procedure|Head extension position|The cuff pressure will be recorded at the head extension position.
75931164|NCT04441970|Procedure|Head flexion position|The cuff pressure will be recorded at the head flexion position.
75931165|NCT04441970|Procedure|Head rotation position|The cuff pressure will be recorded at the head rotation position.
75931166|NCT02469194|Other|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
76085510|NCT03339024|Other|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
76085511|NCT06038526|Procedure|Biospecimen Collection|Undergo buccal, nasal, and blood sample collection
75336841|NCT00003790|Genetic|polymerase chain reaction|
75336842|NCT00003790|Other|flow cytometry|
75336843|NCT00004060|Drug|exatecan mesylate|
75336844|NCT00384826|Drug|erlotinib|Erlotinib 150 mg/day (until progression)
75336845|NCT00384826|Drug|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
75336846|NCT00003364|Drug|cisplatin|
75336847|NCT00003364|Drug|cyclophosphamide|
75336848|NCT00003364|Drug|doxorubicin hydrochloride|
75336849|NCT00003364|Drug|etoposide|
75336850|NCT00003364|Drug|vincristine sulfate|
75336851|NCT00003364|Radiation|radiation therapy|
75336852|NCT00384982|Procedure|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
75794213|NCT04679441|Device|The Computerized Functional Skills Assessment and Training Program|The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.
75794214|NCT04679441|Device|Brain HQ Double Decision|Cognitive speed training program
75794215|NCT04658784|Device|2-0 dioxanone, glycolide and trimethylene carbonate|delayed absorbable, monofilament barbed suture
75794216|NCT04658784|Device|2-0 polydioxanone|delayed absorbable, monofilament non-barbed suture
75794217|NCT04657640|Dietary Supplement|Iron and folic acid (IFA)|Weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) for 3 months intermittently
75336853|NCT00004066|Biological|filgrastim|
75336854|NCT00004066|Drug|docetaxel|
75336855|NCT00004066|Drug|gemcitabine hydrochloride|
75336856|NCT00003370|Drug|irofulven|
75646567|NCT05481892|Device|Cellular Home blood pressure (BP) monitoring|Patients receiving intervention will receive cellular home blood pressure (BP) monitoring devices. Some patients will also receive pharmacist support for treatment intervention.
75646568|NCT05480384|Drug|Nivolumab|Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)
75646569|NCT05480384|Drug|Trastuzumab deruxtecan|Given in combination with Nivolumab.
75794218|NCT04657640|Dietary Supplement|Multiple Micronutrient Supplements (MMS) and loading dose of Iron and Folic Acid (IFA)|"Daily regimen of MMS for 3 months intermittently. MMS is the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) tablet containing fifteen micronutrients including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg).~For the first 5 weeks of the study, participants will also receive weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) as a loading dose, in addition to daily MMS."
75794219|NCT04648072|Procedure|Adductor Canal Block|As previously described.
75794220|NCT04648072|Procedure|Periarticular Injection|As previously described.
75794221|NCT04644042|Procedure|Glenohumeral arthroscopy + Arthroscopic Subacromial Decompression|In addition to the glenohumeral athroscopy a lateral portal will be used to access the subacromial space. The subacromial space will be decompressed with removal of inflamed bursal tissue and acromioclavicular osteophytes, release of the coracoacromial ligament, and, if deemed necessary by the surgeon, acromioplasty performed ad modum Caspari.
75794222|NCT04644042|Procedure|Glenohumeral arthroscopy + lateral skin incision|Glenohumeral arthroscopy is performed as a standard investigational procedure. The patient is put under general anesthesia and positioned in the 'beach chair position'. An anteriorsuperior portal and a posterior mid-glenoid portal are used as entry to the joint. The following structures are investigated as a minimum: the articular surface of the humeral head and the glenoid, labrum, the long biceps tendon and its attachment at the superior labrum, the undersurface of the supraspinatus and the infraspinatus tendon, the subscapularis tendon and the glenohumeral ligaments. To allow for the best possible blinding a skin incision (mimicking the one used for arthroscopic subacromial decompression) is performed on the lateral side of the shoulder of the participants in the control group. The obturator is introduced in the subcutaneous tissue and a slight circular release is performed. The deltoid fascia is not perforated and the subacromial space is not entered.
75794223|NCT04635787|Device|ANNE One|Wireless vital sign monitoring device
75336857|NCT00003382|Biological|filgrastim|
75794224|NCT04634708|Other|No intervention|No intervention due to observational design
75794225|NCT04629586|Other|No intervention|Observational research study
75931167|NCT04458480|Combination Product|Fast Inpatient Rehabilitation|Routine inpatient rehabilitation protocol, administered by licensed Physical Therapist, duration period of 1.5h-2h each time, 2 times for weekdays and 1 time for weekends, totally lasting for 1 week, are applied to the exposed group. After the fast inpatient rehabilitation for 1 week, the patients can get discharged if reaching to the rehabilitation goals of symptoms of pain and swell reduced, knee flexion ≥ 90° and knee extension ≥ 0°, quadriceps femurs and hamstrings muscle strength enhanced, recovery to aided standing and walking, and acquiring of rehabilitation training methods.
75931168|NCT02802813|Drug|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)|
75336858|NCT00003382|Drug|gemcitabine hydrochloride|
75336859|NCT00003382|Drug|topotecan hydrochloride|
75336860|NCT00004828|Drug|liothyronine I 131|
75336861|NCT00004834|Drug|imipramine|
75336862|NCT00004834|Behavioral|cognitive-behavioral therapy|
75336863|NCT00004840|Drug|thyrotropin-releasing hormone|
75336864|NCT00004846|Drug|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
75336865|NCT00004852|Drug|Efavirenz|
75336866|NCT00004852|Drug|Lamivudine|
75336867|NCT00004852|Drug|Zidovudine|
75336868|NCT00004858|Biological|B43-genistein immunoconjugate|
75336869|NCT00004864|Drug|GEM 231|
75336870|NCT00004864|Drug|docetaxel|
75336871|NCT00003796|Drug|irofulven|
75336872|NCT00003802|Drug|pyrazoloacridine|
75336873|NCT02972866|Drug|Budesonide|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
75336874|NCT00003814|Drug|eflornithine|
75646570|NCT05476484|Drug|SQ SLIT-tablet|SQ grass SLIT-tablet and/or SQ house dust mite SLIT-tablet
75646571|NCT05471154|Device|High Definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
75646572|NCT05469412|Device|iPad®|Use of Technology.
75646573|NCT05469412|Drug|Midazolam|Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
75336875|NCT00003832|Drug|bromodeoxyuridine|Given IV
75931169|NCT02802813|Drug|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo|
75336876|NCT00003832|Procedure|conventional surgery|Undergo surgery
75794226|NCT04628910|Other|Simulated Flotation Therapy|"The Zerobody is a new technology designed to simulate the effects of traditional Float-REST therapy, but without the contact with salt water. The system has a very thin membrane that cradles the body and provides a warm sensation, similar to that experienced in a traditional flotation tank. The system will be housed in a room that allows for significant reductions in light and sound to mimic the experience of a flotation tank. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks using the Zerobody, also termed dry floating, as one of the two interventions."
75931170|NCT05134584|Drug|Linaclotide|290μg once daily, 4 weeks
75336877|NCT00003832|Other|laboratory biomarker analysis|Correlative studies
75646574|NCT05465382|Device|Saline Lavage|Three rounds of 10cc of sterile 0.9% normal saline will be injected into the injured ankle joint and withdrawn from the joint using an anteromedial 16-gauge needle attached to a 10cc syringe.
75646575|NCT05462392|Device|robot-assisted surgery|urological surgeries, such as partial nephrectomy, radical cystectomy, and radical prostatectomy was performed for patients using the Micro Hand S robot group.
75646576|NCT05462392|Device|robot-assisted surgery|urological surgeries, such as partial nephrectomy, radical cystectomy, and radical prostatectomy was performed for patients using the da Vinci robot group
75794227|NCT04628910|Other|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks as one of the two interventions.
75931171|NCT05134584|Drug|Lactulose|20mL once daily, 4 weeks
75931172|NCT05134584|Drug|Omeprazol|20mg twice daily for the first 10 days
75931173|NCT05134584|Drug|Itopride|50mg three times daily for the first 10 days
75931174|NCT02468960|Device|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
75931175|NCT02468960|Device|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
75931176|NCT02468960|Device|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
75931177|NCT02468960|Procedure|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
75931178|NCT02468960|Other|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
75931179|NCT03792555|Drug|Paltusotine|Paltusotine, capsules, once daily by mouth
75931180|NCT03792555|Drug|Placebo|Placebo, capsules, once daily by mouth
75931181|NCT01811862|Procedure|Acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
75931182|NCT01811862|Procedure|Sham acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
75931183|NCT05095610|Device|Flash|Use of the device FreeStyle Libre, only commercialized system for intermitent continuous glucose monitoring.
75336878|NCT00003850|Drug|thalidomide|
75646577|NCT05434013|Behavioral|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
75646578|NCT05434013|Behavioral|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
75931184|NCT05633277|Procedure|Polidocanol|Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.
75931185|NCT05070572|Device|Accuryn Monitoring System|Utilization of the Accuryn Monitoring System to measure intraabdominal pressure and urine output during laparoscopic inguinal hernia repair surgery.
75931186|NCT03469830|Other|SSCP|Insert
75931187|NCT03469830|Other|SPMS|Pressure therapy
76085512|NCT06038526|Procedure|Bronchoscopy|Undergo bronchoscopy
75336879|NCT00004072|Drug|O6-benzylguanine|Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
75931188|NCT04490954|Device|brain biological electrical impedance tomography|Patients diagnosed with brain supratentorial tumors through MRI/CT are evaluated with brain biological electrical impedance tomography. And the brain biological electrical impedance tomography is used to monitor the cerebral edema situation of patients with brain edema
75931189|NCT04490954|Device|MRI/CT|Patients diagnosed with brain supratentorial tumors through MRI/CT
75931190|NCT04458402|Radiation|Hypofractionated WPRT|Cohort 1: 41.25 Gy in 15 fx Cohort 1: 38 Gy in 10 fx
76085513|NCT06038526|Biological|Canakinumab|Given SC
75794228|NCT04622813|Drug|nefopam, ketoprofen, paracetamol|Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
75336880|NCT00004072|Drug|carmustine|Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
75336881|NCT00004078|Drug|irinotecan hydrochloride|Given IV
75336882|NCT00003856|Drug|temoporfin|
75336883|NCT00014222|Biological|epoetin alfa|40,000 IU
75646579|NCT05434013|Behavioral|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
75646580|NCT05427201|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique designed to alter network function
75646581|NCT05427201|Behavioral|Acceptance and Commitment Therapy|ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
75794229|NCT04622813|Drug|saline infusion, ketoprofen, paracetamol|Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery
75794230|NCT04619056|Combination Product|CEB-01 membrane loaded with SN-38|CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
76085514|NCT06038526|Procedure|Carbon Monoxide Measurement|Undergo CO testing
76085515|NCT06038526|Other|Survey Administration|Ancillary studies
76085516|NCT06038474|Drug|Descartes-08|Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
76085517|NCT06038461|Drug|Surufatinib Combined With Temozolomide and S-1|"Phase I:~Surufatinib: 250mg, QD, PO, Q3W; Temozolomide: 200-300mg, d10-d14, QD, PO, Q3W; S-1: 40-60mg, d1-d14, BID, PO, Q3W.~Phase II:~Surufatinib, Temozolomide and S-1：RP2D"
75794231|NCT04616963|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
75336884|NCT00014222|Biological|filgrastim|5 mg/kg/d - days 2-13
75794232|NCT04616963|Drug|Emtricitabine Tenofovir Alafenamide 200/25 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
75336885|NCT00014222|Drug|cyclophosphamide|75, 600 and 830 mg/m2
75336886|NCT00014222|Drug|doxorubicin hydrochloride|60 mg/m2
75336887|NCT00014222|Drug|epirubicin hydrochloride|60 mg/m2
75336888|NCT00014222|Drug|fluorouracil|500mg/m2
75336889|NCT00014222|Drug|paclitaxel|175 mg/m2
75336890|NCT00004870|Biological|oblimersen sodium|
75336891|NCT00004870|Drug|irinotecan hydrochloride|
75336892|NCT00004084|Radiation|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
75336893|NCT00004084|Radiation|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
75646582|NCT05426655|Other|Self management|"The program will consist of 3 sessions in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game the painometer will be played and a meditation session will be held."
75794233|NCT04613921|Other|Observational Protocol|The cohorts will be followed for one year after LT transplantation except for group 3 (1-year follow-up after inclusion)
75336894|NCT00004876|Drug|carboplatin|
75931191|NCT03312140|Drug|Choline Chloride|
75931192|NCT03469752|Behavioral|Parent education classes|8 weekly classes for fathers and youth (10-14 years) at community centers focused on improving parenting skills, youth energy balance related behaviors and weight status
76085518|NCT06038422|Drug|GTP regimen|Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
75336895|NCT00004876|Drug|thalidomide|
75336896|NCT00003862|Drug|cisplatin|
75473053|NCT01965821|Device|Continuous control of Pcuff followed by manual control|continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer
76085519|NCT06038409|Drug|Ketamine|The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
75473054|NCT01965821|Device|Manual control of Pcuff followed by continuous control|24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
75931193|NCT03303638|Behavioral|Multi-sensory Environment|Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
75794234|NCT04612348|Diagnostic Test|Ultrasound|Point of care ultrasound to measure gastric contents.
75794235|NCT04611217|Other|Dietary fiber: 10-25g|10-25 g/day of fiber
75794236|NCT04611217|Other|Dietary fiber: 5g|5 g/day of fiber
75794237|NCT04610762|Diagnostic Test|GeneXpert HCV VL Fingerstick test|The participants will have a molecular test (GeneXpert HCV VL Fingerstick, Cepheid) that quantifies hepatitis C virus (HCV) RNA levels directly from a fingerstick blood sample.
75794238|NCT04606394|Drug|Trelegy Ellipta 100/62.5/25Mcg Inh 30D|Administration of Trelegy in all patients
75794239|NCT04606394|Drug|Ventolin 90Mcg/Actuation Inhalation Aerosol|2 hours after the administration of Trelegy, administer Ventolin in all patients
75794240|NCT04591782|Other|PomJuice|Drink 8 oz pomegranate juice
75794241|NCT04591782|Other|Water|Drink 8 oz water
75794242|NCT04591782|Other|Sugar Water|Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in
75931194|NCT02233179|Device|Removable cast walker|Offloading device that can be removed by patients.
75931195|NCT02233179|Device|Irremovable cast walker|Offloading device that cannot be removed by patients.
75931196|NCT03312062|Other|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets.
75931197|NCT03303482|Behavioral|Enhancing Trauma Awareness (Diane Wagenhals, MEd-Lakeside Global Institute)|The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
75473055|NCT01965847|Behavioral|Medication therapy management|
75931198|NCT03759795|Behavioral|ACTr (Acceptance and Commitment Training)|The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
76085520|NCT06038383|Device|Group A - Intervention with Virtual Reality (VR)|Group of people with kidney disease that performed VR intervention during hemodialysis.
75646583|NCT05425550|Device|medidux™ app|Use of the regular medidux™ application for 12 (maximum 16) weeks
75646584|NCT05416632|Diagnostic Test|Athrometer|Arthrometer
75794243|NCT04588649|Drug|THK-5351|[18F]THK-5351 PET Imaging
75794244|NCT04588649|Drug|AV-45|[18F]AV-45 PET Imaging
75794245|NCT04588363|Other|SARS-CoV-2 and/or MIS-C Exposure|This is an observational cohort study.
75794246|NCT04586088|Drug|Apatinib plus Camrelizumab|Subjects receive Apatinib, 250mg, QD and Camrelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
75794247|NCT04585451|Diagnostic Test|ALGOS System|A Quantitative Electroencephalography (QEEG) based pain biomarker assessment that scales with patient reported Numeric Rating Scale (NRS)
75646585|NCT05415072|Drug|DYP688|Single agent DYP688
75794248|NCT04579510|Biological|Novel monovalent oral poliovirus vaccine type 2 (nOPV2)|nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.
75794249|NCT04579510|Biological|Bivalent oral poliovirus vaccine (bOPV)|The live types 1 & 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 & 3 attenuated Polio viruses (Sabin strains).
75646586|NCT05399784|Behavioral|Early postpartum visit|The early postpartum visit will be an in-person visit with a medical provider at 14-21 days postpartum.
75646587|NCT05399784|Behavioral|Standard postpartum visit|The standard postpartum visit will occur at 35 to 56 days postpartum.
75646588|NCT05397704|Device|brain pulse oximeter|brain oxygen monitoring during hypoxia
75646589|NCT05396222|Device|3D-printed custom-made non-rigid biomimetic implant|We developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.
75794250|NCT04579120|Drug|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for [11C] PIB. A PET-certified medical professional will prepare and administer the [11C] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of [11C] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
75794251|NCT04579120|Drug|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for [18F] AV-1451. A PET-certified medical professional will prepare and administer the [18F] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of [18F] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
75794252|NCT04574089|Drug|Experimental: Baofukang Suppository 7 days|Experimental: Baofukang Suppository 7 days
75931199|NCT05159154|Device|Myocardial Work|Myocardial work (MW) is emerging as an alternative tool for studying LV myocardial systolic function, because it incorporates both deformation and load into its analysis. In this context, MW could be considered as an advancement of myocardial strain, allowing to investigate LV performance also in cases of changes in afterload that could lead to misleading conclusions if relying only on strain analysis. This parameter will be evaluated by using an echographer equipped with a specific software for the analysis (Ecog Vivid E95 Ultra GE®)
75794253|NCT04574089|Drug|Experimental: Baofukang Suppository 14 days|Experimental: Baofukang Suppository 14 days
75794254|NCT04572477|Drug|[18F]THK-5351|F-18 THK PET Imaging
75931200|NCT03311984|Diagnostic Test|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
75931201|NCT02233257|Drug|Lorenzo's Oil|Oral use of Lorenzo's oil to lower very long chain fatty acids
76085521|NCT06038383|Device|Group B - Intervention with Stationary Bike (SB)|Group of people with kidney disease that performed SB intervention during hemodialysis.
76085522|NCT06038383|Device|Group A - Intervention with Stationary Bike (SB) - Crossover|Group of people with kidney disease that performed SB intervention during hemodialysis after the washout period.
75646590|NCT05392855|Other|Symptom driven performance of airway clearance|Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
75646591|NCT05392855|Other|Continuous daily performance of airway clearance|Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
75646592|NCT05388149|Drug|Neratinib|Neratinib administered as 40mg tablets
75931202|NCT03311906|Drug|0.8% Hyaluronic Acid|Application of 0.8% hyaluronic acid after scaling and root planing
75931203|NCT03311906|Procedure|Scaling and Root Planing|Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
75646593|NCT05380115|Behavioral|Cognitive Behavioral Therapy (CBT)|weekly one on one video or telephone interviews with a study coach
75646594|NCT05374642|Behavioral|cognitive training|tablet-based cognitive training for 12 weeks, 30 minutes each time, at least 5 times a week
75646595|NCT05374642|Behavioral|active control|tablet-based cognitive training tasks with weak or no difficulty changes, 5 times a week, 30 minutes each time for 12 weeks
75646596|NCT05368532|Other|Temperature|The temperature will be reduced for approximately one hour.
75931204|NCT04458246|Other|Exercise training group|Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
75931205|NCT02259465|Behavioral|low FODMAP diet|Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
75646597|NCT05364502|Device|Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter|The Embrace Hydrogel Embolic System (HES) is indicated for embolization of peripheral arterial bleeds in vessels ≤6mm
75646598|NCT05351255|Device|Transcranial Magnetic Stimulation (TMS)|Aim 2 of the study includes an intervention where participants receive a repetitive TMS protocol called theta burst stimulation (TBS) to study its effect on motor learning behavior.
75646599|NCT05349656|Procedure|TQL block|Ultrasonography-guided quadratus lumborum block (QLB) where we will infiltrate local anesthetic solution adjacent to the anterolateral aspect of the quadratus lumborum muscle
75646600|NCT05349656|Procedure|PENG block|Ultrasound-guided local anesthetic infiltration will be injected in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
75931206|NCT02259465|Dietary Supplement|Oligofructose|Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
75646601|NCT05343455|Drug|DFD-29|DFD-29 (40 mg) extended release capsules
75794255|NCT04572477|Drug|[18F]AV-45|F-18 AV45 PET Imaging
75931207|NCT02259465|Dietary Supplement|Maltodextrin|Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
75931208|NCT03303326|Behavioral|Immediate interview|A women's health interview that obtains information about physical, mental, and sexual health, particularly relatively private sexual health-related attitudes and experiences, as well as conflicts and stress related to sexuality.
75931209|NCT03469596|Diagnostic Test|MRI sequence|several MRI sequence before and after contrast product injection.
75931210|NCT03311750|Drug|Panitumumab|6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
76085523|NCT06038383|Device|Group B - Intervention with Virtual Reality (VR) - Crossover|Group of people with kidney disease that performed VR intervention during hemodialysis after the washout period.
76085524|NCT06038370|Behavioral|Self-induced cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
75336897|NCT00003862|Drug|fluorouracil|
75646602|NCT05343455|Drug|Doxycycline|Doxycycline 40 mg capsules
75646603|NCT05343455|Drug|Placebo|Placebo capsules
75794256|NCT04563078|Device|Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of active Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
75794257|NCT04563078|Procedure|Sham Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of sham control.
75794258|NCT04557735|Drug|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.
75794259|NCT04557735|Other|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
75794260|NCT04553081|Drug|Dual versus triple therapy in treatment of HIV-1 infection.|cfr arm decsription
75794261|NCT04552990|Drug|Jet injection of ALA|The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).
75336898|NCT00003862|Drug|leucovorin calcium|
75336899|NCT00003862|Drug|paclitaxel|
75336900|NCT00003862|Procedure|conventional surgery|
75646604|NCT05327686|Biological|Avelumab|Given IV
75931211|NCT04911972|Procedure|Functional muscle transfer|Muscle transfer to restore lower limb function
75336901|NCT00003862|Procedure|neoadjuvant therapy|
75336902|NCT00003862|Radiation|radiation therapy|
75336903|NCT00003868|Drug|cyclophosphamide|
75336904|NCT00003868|Drug|methotrexate|
75336905|NCT00003868|Procedure|allogeneic bone marrow transplantation|
75336906|NCT00003868|Procedure|peripheral blood stem cell transplantation|
75646605|NCT05327686|Drug|Axitinib|Given PO
75646606|NCT05327686|Drug|Cabozantinib|Given PO
75646607|NCT05327686|Biological|Ipilimumab|Given IV
75646608|NCT05327686|Drug|Lenvatinib|Given PO
75646609|NCT05327686|Biological|Nivolumab|Given IV
75646610|NCT05327686|Biological|Pembrolizumab|Given IV
75646611|NCT05327686|Radiation|Stereotactic Ablative Radiotherapy|42 Gy in 3 fractions
75646612|NCT05312710|Drug|APG-157|Treatment
75646613|NCT05310240|Procedure|Hip arthroscopy|Arthroscopic surgery of the hip
75794262|NCT04552990|Procedure|Surgical excision|In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).
75794263|NCT04552990|Procedure|Illumination|For patients 5-16,after 3h incubation (+/- 30 min), the tumor will be illuminated with red light corresponding to a dose of 75 J/cm2 570- 670 nm or equivalent dose of narrowband red light. The intervention will be repeated at after 14 days in patient 5-16. If the wound is not healed at two weeks, the treatment may be postponed to allow healing (patient 5-16).
75931212|NCT03311672|Drug|[18F]F-Ara-G|Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
75931213|NCT03311672|Drug|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
75931214|NCT03311672|Radiation|PET/CT scan|Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
75931215|NCT03303014|Device|5-0 Prolene, 5-0 Fast Absorbing Gut|The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
75931216|NCT03311516|Other|New functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
75931217|NCT03311516|Other|functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
75931218|NCT03311438|Other|Oral health intervention program|Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
75336907|NCT00003868|Radiation|iodine I 131 monoclonal antibody BC8|
75336908|NCT00003868|Radiation|radiation therapy|
75336909|NCT00003874|Biological|monoclonal antibody CD19|
75336910|NCT00003874|Biological|monoclonal antibody CD20|
75336911|NCT00003874|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75336912|NCT00004090|Drug|cisplatin|
75336913|NCT00004090|Drug|gemcitabine hydrochloride|
75336914|NCT00004102|Drug|FOLFOX regimen|
75336915|NCT00004102|Drug|fluorouracil|
75336916|NCT00004102|Drug|leucovorin calcium|
75336917|NCT00004102|Drug|oxaliplatin|
75336918|NCT00003880|Biological|recombinant adenovirus-p53 SCH-58500|
75336919|NCT00003880|Drug|carboplatin|
75336920|NCT00003880|Drug|paclitaxel|
75336921|NCT00004108|Drug|exatecan mesylate|
75336922|NCT00004900|Biological|filgrastim|
75336923|NCT00004900|Drug|anastrozole|
75336924|NCT00004900|Drug|carboplatin|
75336925|NCT00004900|Drug|cisplatin|
75336926|NCT00004900|Drug|cyclophosphamide|
75336927|NCT00004900|Drug|etoposide|
75336928|NCT00004900|Drug|thiotepa|
75336929|NCT00004900|Procedure|peripheral blood stem cell transplantation|
75336930|NCT00004900|Radiation|radiation therapy|
75646614|NCT05303324|Drug|ALXN1840|Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
75646615|NCT05291234|Drug|ABBV-916|Intravenous administration
75646616|NCT05291234|Drug|Placebo|Intravenous administration
75646617|NCT05284838|Other|Error Management Training (Difficult)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter difficult questions.
75646618|NCT05284838|Other|Error Management Training (Easy)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter easy questions.
75646619|NCT05284838|Other|Error Avoidance Training|Error Avoidance Training used to teach head computed tomography interpretation.
75646620|NCT05268198|Drug|APR002|Active Investigational Product
75646621|NCT05268198|Drug|Placebo|Placebo
75794264|NCT04552990|Other|Incubation|After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).
75931219|NCT04678206|Drug|BLU-5937|Oral administration of BLU-5937 Tablets
75931220|NCT04678206|Drug|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
75931221|NCT03302858|Device|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
75931222|NCT03311360|Device|drug-coated balloon|Orchid and Dahlia DCB
75931223|NCT03311360|Device|bare metal stent|any type of bare metal stent
75931224|NCT03311282|Device|infants bottles|"angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;~extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~flexors at the base to enhance elasticity and flexibility of the teat"
75931225|NCT03311282|Device|Infants Bottles|"large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.~flexors at the base to enhance elasticity and flexibility of the teat"
75931226|NCT03311282|Device|Infants Bottles|"teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.~flexors at the base to enhance elasticity and flexibility of the teat"
75336931|NCT00004114|Biological|filgrastim|
75336932|NCT00004114|Drug|cyclophosphamide|
75646622|NCT05252052|Other|Interviews/Surveys|This is a cross sectional survey and interviews of adolescents 14- 18 years old and HCPs living in rural Haiti
75794265|NCT04550169|Other|Intensive Care Coordination|"Intensive care coordination will include:~Discharge instructions and contacts for following up on care and treatment~Referral information~Appointment scheduling~Medication instructions~Intensive care coordination by a social worker, case manager, nurse, or care coordinator to connect Medical Assistance (MA) recipient to a primary care provider or to a managed care organization~Information about other health and social resources, such as transportation and housing~Sharing of information (discharge instructions, medication information, and care plan information) with managed care organization in which patients are enrolled, if applicable"
75794266|NCT04549974|Other|Heat exposure|Participants will be exposed to heat exposure via a water-perfused suit to increase internal body temperature by 1.5 degrees Celsius.
75931227|NCT03302702|Other|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
76085525|NCT06038357|Behavioral|CBITS|The CBITS program is a skills-based group and individual intervention, which uses evidence-based cognitive-behavioral techniques (e.g. psychoeducation, relaxation, social problem solving, cognitive restructuring, and exposure) and is designed for delivery by mental health professionals. The program consists of 10 45-minute group sessions (about 6-8 students/participants per group), 1-3 individual sessions, 2 parent/caregiver psychoeducational sessions, and 1 teacher/ child welfare staff educational session. For this study, we will specifically train and supervise study therapists to deliver the intervention within child welfare programs.
75931228|NCT02234661|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
75931229|NCT04596072|Combination Product|Chinese traditional rehabilitation|Chinese traditional rehabilitation including acupuncture and herbs
75931230|NCT03311204|Device|BlephEx|BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.
75931231|NCT03311204|Other|Lid Hygenix|Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
75336933|NCT00004114|Drug|cytarabine|
75336934|NCT00004114|Drug|fludarabine phosphate|
75336935|NCT00004114|Procedure|peripheral blood stem cell transplantation|
75336936|NCT04394156|Behavioral|Brief cognitive intervention|See the information provided in the experimental arm description.
75336937|NCT00004906|Biological|filgrastim|
75336938|NCT00004906|Drug|anastrozole|
75336939|NCT00004906|Drug|carboplatin|
75336940|NCT00004906|Drug|cisplatin|
75336941|NCT00004906|Drug|cyclophosphamide|
75336942|NCT00004906|Drug|docetaxel|
75336943|NCT00004906|Drug|doxorubicin hydrochloride|
75336944|NCT00004906|Drug|etoposide|
75336945|NCT00004906|Drug|pamidronate disodium|
75336946|NCT00004906|Drug|thiotepa|
75336947|NCT00004906|Procedure|peripheral blood stem cell transplantation|
75336948|NCT00004918|Biological|PR1 leukemia peptide vaccine|Given SC
75336949|NCT00004918|Drug|Montanide ISA 51 VG|Given SC
75336950|NCT00004918|Biological|sargramostim|Given SC
75336951|NCT00004918|Other|laboratory biomarker analysis|Correlative studies
75336952|NCT00003892|Drug|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
75336953|NCT00003898|Dietary Supplement|glutamine|Oral
75646623|NCT05249816|Biological|NVX-CoV2373|A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant
75646624|NCT05249816|Biological|BBIBP-CorV vaccine|BBIBP-CorV vaccine administered per manufacturer instructions.
75646625|NCT05238207|Drug|BBI-001|Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
75646626|NCT05238207|Dietary Supplement|Original Fibre Metamucil|Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
75931232|NCT04490876|Procedure|3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method|After the injection of Brilliant Blue-G (BBG) into the vitreous cavity, the epiretinal membrane (ERM) with cellular proliferation on the surface of the retina did not stain clearly, while the internal limiting membranes did stain clearly. We peeled off the internal limiting membrane (ILM) underlying the ERM using the ILM forceps for the macular area and the serrated forceps for the remaining ILM beyond the vascular arcades (Grieshaber, Alcon Laboratories, Inc., Fort Worth, Texas (Figure1) and enhanced membrane viewing with filters on the Ngenuity system. Restaining with BBG was needed and perfluorocarbon liquid PFCL was injected with a coaxial Dual Bore cannula (MedOne) to flatten the retina.
75336954|NCT00004132|Biological|filgrastim|
75646627|NCT05230693|Behavioral|Sarcoidosis Patient Assessment and Resource Companion App|"The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day"
75646628|NCT05230693|Behavioral|Enhanced Standard Care|Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
75931233|NCT02811939|Drug|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally
75931234|NCT02811939|Drug|Active Pregnenolone|1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)
75931235|NCT02811939|Drug|Placebo Dronabinol|Control: Placebo pill (no active cannabinoids) administered orally
75931236|NCT02811939|Drug|Placebo Pregnenolone|Control: Placebo given sublingually (under the tongue)
75931237|NCT02468882|Dietary Supplement|Watercress|100g of watercress daily during radiation therapy
75646629|NCT05213104|Drug|Flecainide|Flecainide 150 mg 6 months in addition to standard of care
75336955|NCT00004132|Biological|palifermin|
75646630|NCT05213104|Drug|Flecainide|Flecainide 150 mg 3 months in addition to standard of care
75336956|NCT00004132|Drug|cyclophosphamide|
75336957|NCT00004132|Drug|etoposide|
75336958|NCT00004132|Drug|ifosfamide|
75336959|NCT00004132|Procedure|quality-of-life assessment|
75646631|NCT05208710|Biological|Vaccination with PANHPVAX 10µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen
75646632|NCT05208710|Biological|Vaccination with PANHPVAX 40µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen
75646633|NCT05208710|Biological|Vaccination with PANHPVAX 100µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
75646634|NCT05195177|Drug|Anti-histamine cream 1 hour|At the start of session 1, one area of the middle forearms of the participant will be located (4x4cm). On the area, anti-histamine cream will be applied for approximately 1 hour.
75336960|NCT00004132|Radiation|radiation therapy|
75336961|NCT00004138|Procedure|positron emission tomography|
75336962|NCT00004138|Procedure|radionuclide imaging|
75336963|NCT00004138|Radiation|fludeoxyglucose F 18|
75336964|NCT04712500|Drug|AND017|AND017 oral capsule
75336965|NCT05777057|Diagnostic Test|Diagnodent|using DIAGNDENT depends on the principle that when 655nm wavelength of Diode laser is irradiated on dental surface, intraoral bacteria metabolites will absorb it and then metabolites emit a red fluorescence. The dental surface will reflect this fluorescence and gives number between 0 and 99 on the screen of the DIAGNdent.
75336966|NCT05777044|Behavioral|Yoga|Participation in Hatha Yoga twice a week for 45 minutes for 10 weeks. The total potential dose is 900 minutes over the course of the intervention.
75336967|NCT05776940|Drug|Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules(250mg/time, bid,up to 3 months).
75336968|NCT05776940|Drug|Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy without any probiotics (Blank Control).
75336969|NCT05776810|Diagnostic Test|Diagnostic Test: Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT [protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes]"
75336970|NCT05776810|Device|Device: Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
75336971|NCT05776784|Procedure|dental procedure|questionnaire for patient with dental procedure
75336972|NCT05776745|Behavioral|Speech|Patients read specific words and sentences
75646635|NCT05195177|Drug|Local anesthetic cream 1 hour|At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will be applied for approximately 1 hour.
75931238|NCT05157984|Procedure|ZPOEM|Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)
75931239|NCT01329549|Drug|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
75931240|NCT01329549|Drug|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
75931241|NCT01329549|Drug|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
75336973|NCT05776745|Device|Stereoelectroencephalography|Using stereoelectroencephalography to record the Intracranial EEG of the patient
75931242|NCT03302546|Procedure|Incremental hemodialysis|Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
75931243|NCT03302546|Procedure|Conventional hemodialysis|Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
75931244|NCT02234739|Drug|Voriconazole|2-week long intravenous instillation of voriconazole
75931245|NCT04442516|Other|Questionnaire, sampling of blood, urine and saliva|We are following patients who are receiving Cisplatin as part of their cancer therapy.
75931246|NCT02736474|Drug|Naltrexone|3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
75931247|NCT02736474|Drug|Placebo Naltrexone|Placebo Naltrexone created and masked by the pharmacy to be used as a control.
75931248|NCT02736474|Drug|Bupropion|1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
75931249|NCT02736474|Drug|Placebo Bupropion|Placebo Bupropion created and masked by the pharmacy to be used as a control.
75931250|NCT04490798|Procedure|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat the different painful syndromes. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation.
75931251|NCT02234895|Device|Lateral wedge|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
75931252|NCT02234895|Device|Lateral wedge plus medial arch support|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
75931253|NCT04442672|Procedure|acute compartment syndrome model of health volunteer|the acute compartment syndrome model of health volunteer is induced by pressurizing the calves by the cuff, and the cuff is inflated and pressurized to a pressure value of 20, 30, 40, 50, 60, 70, 80 mmHg. the pressure inside the cuff was up to 10 s during pressurization and maintained stable for 1 min, measured and the above indicators were recorded within 3 min.
75646636|NCT05192577|Other|Electrical stimulation|At the beginning of the session, an electrode will be attached to the participant's ankle. Electrical stimulation will be applied to estimate the electrical perception threshold. This threshold will be used as condition stimuli when different thermal thresholds are assessed.
75646637|NCT05169385|Behavioral|Parent SMART|Parent SMART experimental intervention
76085526|NCT06038357|Other|TAU+|In the control condition (TAU+), child welfare programs will follow their usual procedures (i.e. routine care of child welfare, referral to medical practitioners and psychotherapists, handling of prescribed medication, referral to inpatient treatments in case of risk to self and others) which reflects treatment as usual in child welfare programs and the mental health care system in Germany. Additionally, participants in the control condition will receive the same baseline assessment and reporting of screening results as participants in the treatment condition after each assessment.
75336974|NCT05776732|Other|3M CaviionTM|3M CaviionTM is mainly composed of acrylate trimer, non-toxic, alcohol-free, and compatible with chlorhexidine gluconate and povidone iodine.
75931254|NCT04442672|Procedure|sham|surrounding the cuff but not inflate it.
75931255|NCT02233491|Behavioral|Active lifestyle intervention|Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
75336975|NCT05776654|Device|Biometric wearable devices|Passive data collection using biometric wearable devices.
75646638|NCT05169385|Behavioral|Treatment as Usual|Residential treatment as usual
75646639|NCT05165433|Biological|NG-350A plus Pembrolizumab|Patients receive three doses of NG-350A by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion
75336976|NCT05776615|Other|mobile application|"In the collection of Mobile Application group data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Questionnaire in the Neonatal Intensive Care Unit(NICU); System Availability Scale will be applied."
75646640|NCT05150431|Drug|Parecoxib|Parecoxib 40mg will be administered to the experimental group if the patient has no contraindication.
75646641|NCT05150431|Drug|Placebo|This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
75931256|NCT02233491|Other|Control|No additional support other than lifestyle advice by clinician
75931257|NCT05157750|Other|Recording of major clinical events|During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
75931258|NCT02234973|Behavioral|Quality Improvement|Community and Clinical Teams engaged in implementing Quality Improvement initiatives to improve diabetes prevention and management within their First Nations community and clinic.
75931259|NCT04320732|Behavioral|Observation of behavior and COVID-19 infection will be conducted.|No intervention, only prospective observation of behavior will be conducted by a questionnaire.
75646642|NCT05148923|Procedure|Direct current cardioversion (DCCV)|DCCV is a safe and effective method of treating atrial fibrillation.
75646643|NCT05140564|Behavioral|STEADY intervention|STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
75646644|NCT05138601|Other|Virtual Collaborative Care Clinic|Trained clinical pharmacists will monitor BP, prescribe and adjust medications and monitor for side effects of medications under the license of, and in communication with, the patient's physician.
75794267|NCT04536480|Behavioral|Time Limited Eating|The TLE intervention arm will involve instructing participants to consume their usual kind and amount of food and beverages (all calories) within a pre-specified 8-hour period, fasting for the remaining 16-hours. They will be free to divide their food and beverage intake into as many meals or snacks as desired during the 8-hour period. Participants will be allowed to consume non-caloric beverages (water, tea, coffee) during the fasting period. No energy restriction will be required.
75794268|NCT04536480|Behavioral|Components Common to All Study Arms.|All participants will receive two hours of standard nutrition counseling recommended for adolescents living with T2D. No specific caloric restriction will be recommended. All participants will maintain their usual lifestyle, including physical activity and sleep patterns. Physical activity and sleep recommendations consistent with the American Academy of Pediatrics guidelines for adolescents will be encouraged but not formally prescribed.
75336977|NCT05776589|Device|The mechanical ventilation mode|Changing the mechanical ventilation mode
75336978|NCT05776537|Device|Fibreoptic bronchoscopy|different endoscopies used for confirmation of diagnosis
75336979|NCT05776485|Other|Progressive resistance training|Only the control group: 3 exercise bouts within the study period. Comparison between exercised and non-exercised leg.
75336980|NCT05776485|Other|Cross-sectional comparison between healthy and tendinopathic group|Comparison of primary and secondary outcomes.
75336981|NCT05776407|Drug|ThisCART19A|Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
75336982|NCT05776407|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
75336983|NCT05776407|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
75794269|NCT04536480|Behavioral|Control|Participants assigned to the control arm will be instructed to consume food over a 12-h or more eating window. No energy restriction will be required.
75794270|NCT04536480|Device|Continuous Glucose Monitor|All participants will be trained to wear a blinded continuous glucose monitor sensor using manufacturer educational materials under the supervision of research staff. Participants will be asked to wear the CGM for the duration of the study. During each study visit, the CGM reader will be connected to the site database to create an individual participant report. Participants will be provided enough sensors to replace the sensor every 14 days. The participants and guardians will be educated on how to use the CGM and receive 1:1 coaching on how to change the sensor, which will be completed either independently or under study team guidance. At each weekly phone meeting, study staff will monitor any challenges related to CGM wear, including participant discomfort, skin adherence, and other issues.
75794271|NCT04534673|Drug|Lambda 180 mcg S.C|Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7
75794272|NCT04527900|Drug|carboplatin and paclitaxel|carboplatin and paclitaxel 5-6 cycles (dosage per standard of care according to treating oncologist)
75336984|NCT05776407|Drug|Etoposide|Etoposide is used for lymphodepletion.
75336985|NCT05776212|Radiation|18F-fluoride PET|Positron emission tomography using 18F-fluoride as a tracer
75336986|NCT05776186|Drug|Spinal anesthesia with heavy bupivacaine|Spinal anesthesia
75336987|NCT05776173|Genetic|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
75473056|NCT01965405|Drug|Bupropion|Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
75336988|NCT05776082|Other|Questionnaire survey and specimen collection|Questionnaire survey, clinical follow-up and specimens collection.
75336989|NCT05776043|Drug|Empagliflozin 10 MG|once daily for 6 or 9 months
75336990|NCT05776043|Drug|Dapagliflozin 10 MG|once daily for 6 or 9 months
75336991|NCT05776043|Drug|Placebo|once daily for 3 months
75336992|NCT05775965|Drug|Rivaroxaban 10mg|Rivaroxaban 10mg daily for 35 days post hip fracture surgery
75336993|NCT05775965|Drug|acetylsalicylic acid (ASA) 81mg Oral Tablet|acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
75336994|NCT05775952|Biological|HRV-39|We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.
75336995|NCT05775900|Drug|Cetuximab|Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.
75336996|NCT05775900|Drug|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)
75336997|NCT05775874|Drug|AZD4547|Initiation dose: 80mg BID,po.
75336998|NCT05775874|Drug|Tislelizumab|Tislelizumab:200mg Q3W
75473057|NCT01965405|Behavioral|Brief Counseling|Participants are provided with brief counseling for smoking cessation.
75646645|NCT05130255|Drug|GD2-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA, both will be administered as an IV infusion
75794273|NCT04527900|Radiation|pelvic IMPT (Intensity Modulated Proton Therapy)|whole pelvis will receive a total dose of 4500 cGy in 25 fractions to 5040 cGy in 28 fractions
75473058|NCT01965405|Behavioral|High-magnitude prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
75931260|NCT03302390|Procedure|Shave Biopsy of Psoriasis Lesion|The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than <3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
75931261|NCT03726957|Behavioral|Improved Cookstoves|Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove or to an improved cookstove. Once the participating villages had been selected, the investigators used their list of eligible households within each village to randomly order these households. Within each village, the investigators then approached the eligible households in the order that had been randomly chosen and continued that process until four households within each village had agreed to participate. The selection of villages and households preceded randomization and was pursued with the clear understanding that group assignment would be random, and that participation reflected a willingness to be randomized to either study group.
75931262|NCT05124834|Diagnostic Test|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
75931263|NCT05124834|Diagnostic Test|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
75931264|NCT03712371|Drug|Chitosan|The starting dose for Chitosan is 500mg twice a day, the second dose level is 1000mg twice a day, the third dose level is 1500mg twice a day, and the fourth dose level is 2000mg twice a day. Each dose level lasts for 28 days.
75931265|NCT02467088|Other|Individualised Homeopathic Remedy|Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
75336999|NCT05775861|Drug|single shot interscalene brachial plexus block group with dexmedetomidine added to ropivacaine group|"For the single shot group with dexmedetomidine added to ropivacaine group (Group D), after local analgesia with 3 mL of 1% lidocaine, the block will be performed under ultrasound guidance using an in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany).~The perineural solution will be pre-mixed in a 30 mL syringe before the realization of the block.~A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block."
75337000|NCT05775861|Drug|continuous interscalene brachial plexus block|The block will be performed under ultrasound guidance using an in-plane approach with a 17G Tuohy needle (Arrow FlexBlock). A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
75646646|NCT05119764|Procedure|Manual Lymphatic Drainage|"Manual Lymphatic Drainage is a form of physical therapy with the primary goal of accelerating lymphatic drainage.~In this study, the manual lymphatic drainage is applied by experienced physical therapists 5 days in a row for 30 minutes each; after and/or before the surgery."
75646647|NCT05115851|Other|Anodal tDCS cerebellar stimulation group|three-session ctDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
75646648|NCT05115851|Other|Anodal tDCS cerebral (M1) stimulation group|three-session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
75646649|NCT05115851|Other|Sham Group|three-session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
75646650|NCT05077527|Biological|Axicabtagene Ciloleucel|Given IV
75794274|NCT04518397|Behavioral|Theatre|6-week participatory arts culturally-informed theatre program
75931266|NCT02235129|Other|breath-holding|
75931267|NCT05727956|Procedure|Aneurysmectomy|Complete aneurysmectomy with end-to-end anastomosis for the true aneurysm or partial aneurysmectomy with a direct repair.
75931268|NCT03469518|Dietary Supplement|β-Cx plus PS plus GOS|
75931269|NCT03469518|Dietary Supplement|β-Cx plus PS|
75473059|NCT01965405|Behavioral|Monitored support to quit smoking|Brief supportive sessions and monitoring of smoking cessation efforts.
75794275|NCT04518358|Behavioral|Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges|During the GAINS sessions, the Direct Support Professional (DSP) will follow the pre-programmed teaching protocol in the expert guiding technology. The system will provide step-by-step verbal prompts to the DSP throughout sessions. This includes which prompt to use for each step of the target skill, when to provide reinforcers, and which target task to work on. The system will also monitor the participant's (adults with ASD/ID) progress and notify the DSP if the target skill is mastered.
75931270|NCT03302078|Drug|BI 1015550|Fed state
75337001|NCT05775835|Other|Whole body vibration and strengthening exercise|Prior to commencing training, all subjects will undergo a pre-screening that includes a thorough history and physical examination to monitor compliance with the inclusion criteria. Evaluation parameters will be evaluated before and after 6 weeks of exercise. Training sessions will be held 3 days a week for 6 weeks, with a minimum of 48 hours between training sessions. All exercise groups include a warm-up period and a cool-down period (stretching exercises). Stretching exercises for the hamstring, gastrocnemius, soleus, and quadriceps muscles will be performed for 15-30 seconds and 3-5 repetitions. The total average application time (including warm-up and cool-down exercises), consisting of exercise and rest periods, was planned as 45-60 minutes for the WBV, SE, and WBV+SE groups.
75646651|NCT05077527|Drug|Cyclophosphamide|Given IV
75794276|NCT04549168|Drug|Lemborexant|Lemborexant 10 mg tablet.
75931271|NCT03302078|Drug|BI 1015550|Fasted state
75931272|NCT04378920|Drug|LEAF-4L6715|LEAF-4L6715
75931273|NCT03473028|Procedure|transabdominal ultrasound guided embryo transfer|400 female with body mass index more than 30undergo transabdominal ultrasound guided embryo transfer
76085527|NCT06038344|Behavioral|Gluten-free food guide teaching|Teaching the gluten-free food guide will be done over Zoom within 1-2 weeks of the dietitian's standard of care teaching (group Zoom session). This teaching will take 30-45 minutes and will be conducted by a trained researcher. The investigators will use the gluten-free food guide as teaching materials with a focus on the GF plate model, the rationale for the GF plate model, nutritional consideration of gluten-free diet and content related to the additional 24 teaching materials (e.g. folate, fibre, eating out, school lunches etc.) contained within the guide. Individualized dietary suggestions based on participants' food records will also be provided.
75473060|NCT01965405|Behavioral|No additional treatment|No additional treatment will be given.
75646652|NCT05077527|Drug|Fludarabine|Given IV
75646653|NCT05057637|Device|Optical coherence tomography measurements|Optical coherence tomography measurements in femoropopliteal tract
75931274|NCT03473028|Procedure|transvaginal ultrasound guided embryo transfer|400 female with body mass index more than 30 undergo transvaginal ultrasound guided embryo transfer
75931275|NCT03712137|Device|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
75931276|NCT03712137|Other|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
75931277|NCT03472950|Drug|Ranolazine 500 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
75931278|NCT03472950|Drug|Ranolazine 1000 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
75931279|NCT02467244|Drug|Levothyroxine|At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
75931280|NCT03706521|Drug|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study.
75931281|NCT03301688|Biological|Toripalimab|To compare the different drug batch number with different process
75931282|NCT02259543|Other|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
75473061|NCT01965405|Behavioral|Prize contingency management for abstinence|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
75473062|NCT01965405|Behavioral|Low intensity prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
75646654|NCT05013502|Drug|Empagliflozin 10 MG|empagliflozin 10mg PO once daily
75646655|NCT05007392|Drug|Dotinurad|Dotinurad oral tablets.
75646656|NCT05007392|Drug|Febuxostat|Febuxostat oral tablets.
75646657|NCT05007392|Other|Dotinurad Matched Placebo|Dotinurad matched placebo oral tablets.
75646658|NCT05007392|Other|Febuxostat Matched Placebo|Febuxostat matched placebo oral tablets.
75646659|NCT05000749|Behavioral|DBT-SG|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
75646660|NCT05000749|Behavioral|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
75794277|NCT04549168|Drug|Placebo|Placebo tablet matched to lemborexant 10 mg tablet.
75794278|NCT04509050|Drug|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators
75794279|NCT04504955|Other|Observational Non-Interventional Registry|Observational Non-Interventional Registry
75794280|NCT04504682|Behavioral|Ambulation|Patients will be encouraged to ambulate for 20 minutes of every hour.
75794281|NCT04496544|Other|Retrospective data collection|No intervention; retrospective data collection
75794282|NCT04490642|Other|Questionnaire|Final version Childhood Bladder and Bowel Dysfunction for 5-12 years old questionnaire in Korean language to patients who never encountered beforehand in other available languages (Dutch, English).
75794283|NCT04489693|Behavioral|Ambulatory Care Coordinator Team (ACCT)|See arm description
76085528|NCT06038292|Radiation|DXA Scan|DEXA (dual x-ray absorptiometry) Scans which measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip, the spine and the bones of the hands and can easily diagnose osteoporosis.
75794284|NCT04489693|Behavioral|Comprehensive Care Physician Program (CCP)|see arm description
75794285|NCT04489693|Behavioral|Comprehensive Care Community & Culture Program (C4P)|see arm description
75931283|NCT05727722|Biological|a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy|"A single course will be divided into an accelerated titration design phase and a 3+3 design phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The accelerated titration design phase starts at a starting dose of 0.15x10^9, moving to the 3+3 design phase at the dose of 0.5x10^9. According to the semi-logarithmic incremental (10^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored."
75337002|NCT05775835|Other|Whole body vibration exercise|The application will be carried out with a whole body vibration device that gives 35 Hz constant vertical vibration. The exercises will be performed on the vibration platform in a standing position and with vibration. 5 static squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squat on the fingertip (120 degrees knee extension), right and left lunge positions, which will be accepted as 180 degrees full knee extension exercise protocol. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For static exercises, the duration will be 3 sets of 30-60 seconds in each practice position. There will be 30-60 second rest breaks between sets.
75473063|NCT01965873|Dietary Supplement|Enteral nutrition|Same as arm description
75794286|NCT04486755|Radiation|Hypofractionated Radiation Therapy|All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.
75794287|NCT04486677|Behavioral|Caring Cards Group|Group of Veteran card-makers.
75794288|NCT04486677|Behavioral|Caring Cards Recipients|Group of Veteran card-recipients.
75794289|NCT04483921|Other|Acute exercise|Participants will complete a morning exercise bout at 70% of their individual maximal aerobic capacity to burn 200 kilocalories above their basal metabolic rate.
75794290|NCT04470284|Other|Mobile Application|SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.
75794291|NCT04470284|Other|Standard SMBP|Standard treatment (SMBP-alone)
75931284|NCT03723369|Device|accupuncture|accupuncture
75931285|NCT03301610|Other|Mobile Education Delivery|Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.
75931286|NCT03301610|Other|Standard Verbal and Written Education|Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
76085529|NCT06038279|Drug|INI-2004|INI-2004 (a toll-like receptor [TLR]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.
75473064|NCT01965886|Procedure|Medial approach|Total knee replacement performed through a longitudinal incision medial to the patella
76085530|NCT06038279|Drug|Placebo|The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
76085531|NCT06038266|Procedure|cardiac surgeries|predict perioperative risk factors for readmission after cardiac surgeries
75473065|NCT01965886|Procedure|Keblish approach|Total knee replacement performed through a longitudinal incision lateral to the patella
75473066|NCT01965925|Drug|Modafinil|Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
75646661|NCT04979429|Behavioral|Perioperative Pain Self-management (PePS)|4 sessions of telephone CBT-based pain self-management.
75794292|NCT04469803|Behavioral|Intra-Shift Napping|The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.
75794293|NCT04460573|Device|Boot|Smart boot in one of three configurations provided to participants
75646662|NCT04974892|Diagnostic Test|Blood test|Blood tests will be taken at 12, 20, 28 and 36 weeks gestation to assess the immune profile and omic profile.
75646663|NCT04958434|Drug|TST005|TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
75646664|NCT04948099|Drug|VIB1116|VIB1116
75473067|NCT01965925|Drug|Placebo|For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
75646665|NCT04948099|Drug|Placebo|Placebo
75646666|NCT04922112|Diagnostic Test|Obstructive sleep apnea testing|"Functional Outcomes of Sleep Questionnaire (FOSQ-10)~European Organization for Research and Treatment of Cancer Head and Neck Survey (EORTC HN 35)~Epworth Sleepiness Scale (ESS)~Adult Comorbidity Evaluation (ACE 27)~University of Washington Quality of Life Questionnaire (UW-QOL)~Chronic Pain Assessment Questionnaire"
75794294|NCT04456439|Biological|Remestemcel-L|Participants may receive up to 2 infusions of 2 x 10^6 remestemcel-L within a 5-day period.
75794295|NCT04456439|Drug|Hydrocortisone|Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
75794296|NCT04456439|Drug|Diphenhydramine|Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
75794297|NCT04454216|Other|No intervention|This is an observational study that consists of data abstraction from patient medical records.
75794298|NCT04445714|Drug|dapagliflozin and saxagliptin|Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
76085532|NCT06038214|Other|core exercises|"1.5 minutes walking 2. Stretching exercise~hallowing in supine and side lying position~Bracing in supine and side lying position~Bracing on the prone and forearms~Bracing in the crawling position~Bracing in laptop, half-lap and standing position~Heel slide exercise~Bridge building exercise~Unilateral limb flexion exercise in crawling position~Reciprocal heel slide exercise in supine position~Bilateral lower extremity lifting exercise~Unilateral lower extremity flexion in bridging position~Side bridging exercise with knees extended~Unilateral lower extremity extension in crawling position~Contralateral lower and upper extremity lift in the crawling position~Straight and oblique trunk flexion~Straight and oblique trunk flexion with hip and knee flexed to 90°~bracing on the ball~squat~bracing while walking"
75794299|NCT04445116|Device|Action Video Game Treatment|Endeavor™ is a digital, non-drug investigational treatment that is delivered through an action video game and is designed to target cognitive deficits in adolescence and young adults with pediatric onset MS.
75794300|NCT04443153|Device|Personalized Feedback|Provides tailored information to the user about what glycemic risk they may be facing as well as how glycemic control and system use looked in the past week. Treatment decision and therapy changes are entirely left to the decision of the user.
75931287|NCT02235207|Behavioral|Neuromuscular exercise|"Fustra20 Neck & Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~improve movement control in different posture and movements of the neck and back~improve flexibility with active functional movements~improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
75931288|NCT05727566|Other|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
75337003|NCT05775835|Other|Strengthening exercise|"The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
75646667|NCT04911751|Drug|KBL697|1 capsule BID of KBL697 or Placebo
75646668|NCT04911751|Drug|KBL697|5 capsules BID of KBL697 or Placebo
75646669|NCT04909853|Drug|PF-07321332/ritonavir|PF-07321332 in combination with the PK boosting agent, ritonavir, being developed for the treatment of COVID-19
75646670|NCT04902573|Other|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
75646671|NCT04898855|Behavioral|Cognitive Behavioral Therapy for Insomnia|Treatment includes sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
75646672|NCT04898348|Drug|KBL697|3 capsules twice a day dosing of KBL697
75646673|NCT04898348|Drug|Placebo|3 capsules twice a day dosing of Placebo
75794301|NCT04443153|Device|Decision Support System|CGM-based system that includes Personalized Feedback (PF) and further assists with treatment recommendations for common metabolic challenges
75794302|NCT04443153|Device|Sensor Augmented Mode|A mode in Diabetes Assistant (DiAs) that combines Diabetes Assistant, Insulin pump or Multiple Daily Injections, CGM, ketone meters, and glycemic treatment guidelines together to manage diabetes.
75646674|NCT04878354|Drug|SQ tree SLIT-tablet|Sublingual allergy immunotherapy tablets
75646675|NCT04878354|Drug|Placebo|Placebo
75646676|NCT04861623|Other|Orange juice|Orange juice will be purchased commercially.
75794303|NCT04442100|Procedure|valve prosthetics|"prosthetics of heart valves with dentures MedEng-Bio"
75794304|NCT04437667|Behavioral|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application. Participants will be instructed to engage in a minimum of 10 hours of gameplay over the holiday period each year. The game will automatically collect for analysis data related to participants' in-game behavior, e.g. time spent playing, scores on knowledge-based mini-games, choices made in the narrative game, components to which the player was exposed. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma; and promote parent-child dialogue.
75931289|NCT03301454|Drug|pursuit of chemotherapy|Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
75931290|NCT02467790|Drug|PEX168|PEX 168: 200µg,Subcutaneous,one time.
75646677|NCT04861623|Other|Placebo juice (Fanta)|Fanta will be purchased commercially.
75646678|NCT04849507|Device|transcutaneous auricular vagus nerve stimulation|Stimulation of the auricular branch of the left vagus nerve paired with oromotor feeding.
75646679|NCT04825574|Drug|Avapritinib|avapritinib tablet
75646680|NCT04811664|Biological|Moderna COVID-19 Vaccine|A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.
76085533|NCT06038214|Other|home exercises|"Right and left rotation of the head~lateral flexion of the head~Flexion and extension of the head~Stretching the neck extensors~pectoral stretch~Stretching the hip extensors~Hamstrig stretching~Stretching the lumbar extensors~Abdominal strengthening~bridging~Hip abduction strengthening~hip extension strengthening~Upper extremity resistant flexion~Upper extremity resistant abduction~Upper extremity relaxation exercise~Capsule stretching~Stretching the hip flexors~Stretching the lower extremity adductors~relaxation exercise"
76085534|NCT06038201|Procedure|LAMS placement for cholecystostomy|The EUS-guided cholecystostomy entails placing a 10 mm x 10 mm or 10mm x 15mm Electrocautery-Enhanced LAMS for direct cholecystoscopy with a transnasal gastroscope. Then, the cholecystostomy will be performed with an echoendoscope, assisted by fluoroscopy to allow the puncturing of the gallbladder form either the duodenal bulb (cholecysto-duodenoscopy) or the gastric antrum (cholecysto-gastrostomy). Subsequently, from the most optimal anatomic point it will be tutored with a 10mmx10mm or 10mm x 15mm LAMS to create anastomosis between the structures. Then, the stone clearance will be performed by endoscopy (basket catheters) or by cholangioscopy (mechanical lithotripsy with or without basket catheters).
76085535|NCT06038201|Procedure|Laparoscopic cholecystectomy|A laparoscopic biliary exploration along with an elective laparoscopic cholecystectomy will be performed by experienced laparoscopic surgeons (over 100 laparoscopic procedures yearly) by three or four-trocar technique with transection of the cystic duct and artery.
76085536|NCT06038149|Diagnostic Test|Transthoracic echocardiogram|A painless ultrasound scan of the heart.
75931291|NCT02235363|Procedure|thread lift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
75931292|NCT03469440|Other|Continuous central venous oxygenation monitoring|"Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.~First, isotonic crystalloid, 10 up to 20 mL/kg, will be administered in boluses to achieve continuous central venous oxygen saturation higher than 65% in non-cyanogenic and 55% in cyanogenic.~Second, if not achieved with fluid administration, will be targeted by initiating and titrating inotropics (dobutamine or milrinone). If the mean arterial pressure is lower than 50 mm Hg will be associated epinephrine.~If the ScvO2 is lower than 65% in non-cyanogenic and 55% in cyanogenic and the hemoglobin was lower than 8g/dl, red blood cells (20mL/Kg) will be transfused to achieve a hemoglobin level of at least 8g/dL."
76085537|NCT06038110|Diagnostic Test|axillary ultrasound|usefulness of axillary ultrasound in predicting need for chemotherapy or upfront surgery
76085538|NCT06038097|Procedure|Radiofrequency Pallidotomy|Radiofrequency bilateral simultaneous pallidotomy
76085539|NCT06038084|Drug|Bronpass Tab.|Twice a day
76085540|NCT06038084|Drug|Placebo of Erdos capsule|Three times a day (It is for the masking.)
76085541|NCT06038084|Drug|Erdos capsule|Three times a day
76085542|NCT06038084|Drug|Placebo of Bronpass Tab.|Twice a day (It is for the masking.)
75794305|NCT04437667|Behavioral|Control Mobile Phone Game|Independent gameplay of control game. Total respondent burden: participants will be invited to engage in at least 10 hours of gameplay during each long school holiday (November-December).
75794306|NCT04435704|Drug|Oxytocin|Intravenous Oxytocin
75794307|NCT04433741|Drug|Oxytocin|Oxytocin administered intravenously
76085543|NCT06038058|Drug|BRY812 for injection|BRY812 for injection will be administered by intravenous drip, tentatively once per cycle spanning 3 weeks on D1 of each cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
76085544|NCT06038019|Diagnostic Test|Oral food challenge|Patients will undergo oral food challenge with increasing amounts of food allergen
76085545|NCT06038006|Diagnostic Test|Sleep Respiratory Monitoring System|Millimeter-Wave radar-based Sleep Respiratory Monitoring System to be used on each participant undergoing PSG
76085546|NCT06037954|Other|Questionnaires|Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
76085547|NCT06037954|Other|Interviews|Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
75794308|NCT04433741|Drug|Placebo|Placebo administered intravenously
75794309|NCT04431700|Other|Anti-inflammatory diet|Anti-inflammatory diet with increased vegetables, fruit, plant polyphenols, lean proteins, foods rich in omega-3s and unsaturated fats as well as decreased in processed refined foods.
75794310|NCT04431700|Other|Regular diet|Focus on food journal and recording all food intake.
75794311|NCT04431206|Drug|Oxytocin|Oxytocin administered by IV infusion
75794312|NCT04429971|Other|PrEP screening program|ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
75794313|NCT04429971|Other|PrEP starter pack|emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil
75794314|NCT04427709|Drug|Oxytocin|Intramuscular injection of Oxytocin (Pitocin®)
75794315|NCT04427709|Drug|Placebo|Intramuscular placebo injection
75931293|NCT03469440|Other|Standard protocol|The control group will keep the standard therapy to achieve mean arterial pressure higher than 50mmHg, central venous pressure 8 to 12 mmHg, urinay debit higher than 0,5ml/kg/h, hemoglobin higher or equal than 8g/dL, arterial oxygen saturation higher or equal than 92% in non-cyanogenic and 80% cyanogenic, central venous oxygen saturation higher or equal than 65% in non-cyanogenic and 55% in cyanogenic.
75931294|NCT02801331|Device|Stochastic Vibrotactile Stimulation (SVS)|Infant crib mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle vibrations and sounds during mattress stimulations.
75931295|NCT03234738|Drug|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
75931296|NCT03234738|Drug|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
75337004|NCT05775822|Diagnostic Test|CT scan and blood sample collection|"Each enrolled patient performs:~preventive clinical cardiology assessment visit, addressed to individualized risk profile assessment and addressed to chest CT scan.~a blood sampling (1 citrate tube of 5 ml) will be done the same day just the chest CT scan and analyzed locally also for future research of biomarker discovery (single sample, for those patients who agree in ICF)~CT scan"
75337005|NCT05775783|Procedure|Transvenous lead extraction|Each TLE procedure was started using the single traction method. If this attempt was not sufficient to extract the lead, then the following methods were used: mechanical extraction sheaths (Byrd, Cook Vascular Inc., Leechburg, PA, USA), locking and nonlocking stylets (Liberator® Beacon® Tip Locking Stylet, Cook® Medical, Leechburg, PA, USA), powered extraction sheaths (Evolution or Evolution II Mechanical Dilator Sheath, Cook® Medical, Leechburg, PA, USA). A side retrieval snare loop (Needle's Eye Snare, Cook® Medical, Leechburg, PA, USA) was used for the femoral approach when the subclavian-only approach was insufficient.
75931297|NCT03301142|Procedure|Laser|The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.
75931298|NCT03301142|Procedure|kinesiotherapy|"Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions."
75931299|NCT04457388|Other|Tele-Yoga Therapy|Yoga practices combining with joint loosening exercises (Sukshma Vyayama), postures (Asana), breathing exercises (Pranayama), relaxation techniques and chanting ( A, U, M, and AUM { ૐ}) syllable chants meditation. Each session ended with home practice exercises given to the participants to practice everyday.
75931300|NCT03302000|Other|Early Visual Stimulation|Early visual stimulation
75337006|NCT05775770|Drug|Insulin|insulin therapy
75646681|NCT04811261|Drug|Intravenous Infusion of UCLSCs|The first 3 subjects will be administered 50 x 10^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
75646682|NCT04795674|Behavioral|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
75794316|NCT04422912|Biological|DSG3-CAART|Intravenous infusions of DSG3-CAART alone at different doses and different fractionations. Subjects may also receive varying doses of DSG3-CAART as part of a sub-study, which will employ pre-treatment with intravenous immunoglobulin, cyclophosphamide, and with or without fludarabine to potentially increase the in vivo expansion, persistence and activity of DSG3-CAART.
75794317|NCT04421482|Other|Standard room temperature (RTS) feeding of milk/formula|Evaluate the infant's sucking, swallowing, and breathing patterns using a non-invasive FDA approved equipment (nFant® Feeding Solution) under two separate feeding conditions: standard room temperature (RTS) and cold temperature (CS, at 4-9°C) of milk/formula for an entire feeding (15-20 minutes). The two feedings will be done on the same day but may not necessarily be two consecutive feedings (depending on the baby's eagerness to feed orally). The order of each condition will be randomized to control for fatigue.
75931301|NCT03302000|Other|standard care|standard care
75337007|NCT05775757|Radiation|Hypofractionated radiation therapy|Both 3-week and 1-week hypofractioanted radiation therapy are allowed. (simultaneous or sequential tumor bed boost is allowed.) A 3-week regimen includes 42.4 Gy in 16 fractions. A 1-week regimen includes 26 Gy in 5 fractions or 28.5 Gy in 3 fractions, 30 Gy in 5 fractions.
75337008|NCT05775705|Drug|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.
75337009|NCT05775692|Drug|fluconazole|According to the models of population pharmacokinetics,the investigators and want to correlate use of fluconazole with treatment effectiveness and safety in newborns
75337010|NCT05775666|Biological|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
75646683|NCT04795674|Behavioral|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
75646684|NCT04782570|Device|Verum TMS|Intensity of 100% of the resting motor threshold with iTBS. 600 stimuli applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s.
75646685|NCT04782570|Device|Sham TMS|Sham stimulation with same protocol, but without magnetic stimulation
75646686|NCT04771780|Drug|KHK7791|oral administration
76085548|NCT06037954|Other|30-minute telephone or videoconference sessions|"Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are:~Provide education about depression and treatment options~Identify treatment preferences and a personal goal achievable with mental health care~Assess barriers to treatment initiation~Recommend a referral using standardized referral options~Address barriers to accessing care"
76085549|NCT06037941|Diagnostic Test|E-Nose testing|At baseline (before any treatment is administered) and at three points after treatment (1, 3, and 6 months). A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.
75931302|NCT05727410|Drug|nivolumab, docetaxel, cisplatin Group|Patients will be treated with nivolumab 360mg and plus docetaxel 60mg/m2 and cisplatin 60mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive radiation 59.4 Gy in 27 fractions. Boost RT of 6.6 Gy in 3 fractions to tumor bed and/or gross tumor will be optional in patients who had R1-R2 resection. If tumors are regarded inoperable after neoadjuvant therapy (due to high risk of post-operative complication, or metastatic disease), they will be off from this study and receive the appropriate treatment, though they will be also included in the efficacy and safety analyses.
76085550|NCT06037941|Diagnostic Test|Research blood|Research blood tests will be obtained at baseline, 1, 3, and 6 months post-treatment to determine whether serum biomarkers of MPM.
76085551|NCT06037902|Device|CPAP|patients undergo simulation twice, with and without CPAP
75337011|NCT05775640|Behavioral|serious game|The forms were applied to the children in the experimental group and the parents of the children on the 0th day of hospitalization. After the forms were applied, a serious game developed by the researchers was played. Children were given access to the game by giving a game link. The game can be played on digital platforms such as computers, tablets, etc. For children who do not have an electronic device, the game was downloaded to the computer in the hospital and the children were allowed to play. On the third day of hospitalization, the children and their parents were surveyed again and the Game Evaluation Questionnaire was filled. Access to the game will be closed at the end of the study.
75337012|NCT05775614|Device|UroTainer®|Clinical effect of preventive treatment - catheter flushing with UroTainer®
75337013|NCT05775614|Device|Saline|Clinical effect of preventive treatment - catheter flushing with saline solution
75337014|NCT05775588|Procedure|Lung volume reduction surgery with endobronchial valve implantation|the patient would undergo Lung volume reduction surgery with endobronchial valve implantation
75646687|NCT04759443|Other|Image processing of skin|Image processing will be used to extract skin features that correlate with loss of small skin fibers.
75646688|NCT04755569|Device|ODOCOR II CCM LEADS|ODOCOR II CCM LEADS Implantation
75646689|NCT04733534|Drug|Dasatinib plus Quercetin|Dasatinib (100 mg/day) plus Quercetin (500 mg twice daily) on days 1, 2, 3, 30, 31, 32 taken orally under observation of the study nurse.
75794318|NCT04421482|Other|Cold temperature (CS, at 4-9°C) of milk/formula|Evaluate the infant's sucking, swallowing, and breathing patterns using a non-invasive FDA approved equipment (nFant® Feeding Solution) under two separate feeding conditions, standard room temperature (RTS) and cold temperature (CS, at 4-9°C) of milk/formula for an entire feeding (15-20 minutes). The two feedings will be done on the same day but may not necessarily be two consecutive feedings (depending on the baby's eagerness to feed orally). The order of each condition will be randomized to control for fatigue.
75931303|NCT03653715|Device|Clerio Vision LIRIC-modified Bifocal Contact Lens|Within this arm the investigational acofilcon B material bifocal contact lens, which has been modified with the laser and is the focus of the study, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
75931304|NCT03653715|Device|Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens|Within this arm the control etafilcon A material bifocal contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
75931305|NCT03653715|Device|Johnson & Johnson 1-Day Acuvue Moist Contact Lens|Within this arm the control etafilcon A material single vision contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
75337015|NCT05775575|Drug|TQB3909 tablets|TQB3909 is an inhibitor targeting BCL-2 protein
75337016|NCT05775536|Drug|Aspirin 500Mg Tab|Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
76085552|NCT06037850|Device|Test orthokeratology lens|Randomized to test orthokeratology lens worn during sleep every night
76085553|NCT06037850|Device|Control orthokeratology lens|Randomized to control orthokeratology lens worn during sleep every night
76085554|NCT06037837|Procedure|Robotic Surgery|Surgeons will perform and participants will undergo robotic surgery according to the standard of care. No additional interventions will be performed on participating participants.
75337017|NCT05775536|Dietary Supplement|Dr. Böhm® Omega 3 complex 870 mg|Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
75646690|NCT04733534|Drug|Fisetin|Fisetin (20mg/kg/day) on days 1, 2, 30 and 31 taken orally under observation of the study nurse. Fisetin will be dispensed based on weight of 20 mg/kg/day on the four separate days.
76085555|NCT06037824|Other|cryotherapy|"cryotherapy was added to rehabilitation*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
76085556|NCT06037785|Behavioral|Self-Paced Self-Management (SPSM)|(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.
76085557|NCT06037772|Other|subcutaneous injection administration game|The subcutaneous injection practice game was developed to examine nursing students' injection practice skills and its effect on their satisfaction with learning.
75646691|NCT04727307|Drug|Atezolizumab (neoadjuvant)|Atezolizumab 1200mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in neoadjuvant, for 2 cycles. The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 (± 10) minutes.
75931306|NCT03653715|Device|Clerio Vision Single Vision Contact Lens|Within this arm the control acofilcon B material single vision contact lens, the material of which is commercially available from Contamac Ltd, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
75798948|NCT03858114|Other|Mild-to-moderate physical activity|"According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:~warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;~Active phase (45 minutes), from >40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;~cool down (10 minutes), < 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length."
75337018|NCT05775497|Behavioral|Behavioral weight loss intervention (Online; Rx Weight Loss)|Rx Weight Loss is a fully automated online behavioral obesity treatment that includes 3 core components: weekly online video lessons, submission of self-monitored weight, calorie intake, and activity data, and personalized automated feedback. Participants set goals for weight loss (e.g., 10%), daily calorie intake, and activity (e.g., 200 mins/week of moderate-to-vigorous intensity physical activity). Online lessons discuss healthy eating, physical activity, and behavioral skills (e.g., stimulus control, goal-setting, problem solving). To maintain participant engagement, lessons are interactive, use audio and video, and include experiential learning opportunities. Based on their progress, participants receive automated feedback that provides encouragement, praise for meeting goals, and constructive feedback. To enhance adherence, participants who do not view the weekly lesson or enter monitoring data receive e-mail reminders to re-engage.
75473068|NCT01965951|Other|Computerized Plasticity-based Adaptive Cognitive Training|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
75931307|NCT02467010|Drug|Bortezomib|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
75931308|NCT02467010|Drug|Cyclophosphamide|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
76085558|NCT06037772|Other|control group|only
76085559|NCT06037733|Radiation|CTV omitted or delineated|Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
76085560|NCT06037720|Device|Coaguchek testing|Patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.
75473069|NCT01965951|Other|Commercially available computerized training|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
75473070|NCT01965964|Procedure|Questionnaire|
75473071|NCT01965977|Drug|Bortezomib|Bortezomib 1.3mg/m2, on day 1 and 15 SC Repeat every month for 12months
75646692|NCT04727307|Procedure|Percutaneous Radiofrequency|Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.
75646693|NCT04727307|Drug|Bevacizumab (adjuvant)|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle in adjuvant, for 15 cycles maximum. The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 (± 10) minutes then over 30 (± 10) minutes.
75646694|NCT04727307|Drug|Atezolizumab (adjuvant)|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in adjuvant, for 15 cycles maximum. The dose will be delivered over 30 (± 10) minutes.
75646695|NCT04726930|Procedure|Intercostal nerve blocks|Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.
75646696|NCT04726930|Procedure|Paravertebral block|Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen
75646697|NCT04725773|Device|Deep brain stimulation effect on apraxia|We will evaluate the effect of DBS on apraxia
75646698|NCT04683939|Biological|BNT141|Intravenous (IV)
75646699|NCT04683939|Drug|Nab-paclitaxel|Intravenous (IV)
75646700|NCT04683939|Drug|Gemcitabine|Intravenous (IV)
75646701|NCT04680598|Drug|ICI|Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)
75646702|NCT04680598|Drug|Antiviral Prophylaxis|Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir
76085561|NCT06037655|Drug|Total Neoadjuvant Treatment|Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
76085562|NCT06037642|Behavioral|ABC 0-2 years|Four 1 hour meetings and homework
76085563|NCT06037642|Other|waiting list|Will be put on hold for four weeks
76085564|NCT06037577|Drug|CM-101|Anti-human CCL24 monoclonal antibody (CM-101)
75646703|NCT04669340|Other|E-learning patient education|"The intervention implies patient education through an e-learning program. The program consists of three learning modules covering knowledge of rheumatoid arthritis, medication, examinations, complications and daily living with RA. Module 1 consists of 'need to know' information about disease management, symptoms and medication. Thus, it is mandatory and must be completed before entering module 2 and 3. In module 2 and 3, patients can move around on the basis of their individual needs.~The duration of the full program is approximately two hours, but may vary dependent on the individual user needs. The program may be used as much as needed throughout the study period."
75646704|NCT04669340|Other|Standard face-to-face patient education|The intervention implies usual care, i.e. face-to-face patient education in a one-hour session with a nurse at the hospital. This form of patient education is based on the patients individual need for information and guidance in relation to rheumatoid arthritis and medication. Thus, aspects of daily life with the disease is discussed at the beginning and forms the conversation. However, as a standard, information of the disease, disease management, symptoms and medication must be discussed with the patient and relatives.
75798949|NCT03858114|Other|Cultural group program|A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.
75798950|NCT01180764|Drug|Lovaza (Omega-3 acid ethyl esters)|1g capsules, 4 capsules po daily
75931309|NCT02467010|Drug|Dexamethasone|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
75931310|NCT02232555|Drug|Duloxetine|
75931311|NCT02232555|Drug|Placebo|
76085565|NCT06037577|Drug|Placebo|Placebo Comparator
76085566|NCT06037551|Diagnostic Test|blood glucose measuremen subject|measurement of the blood glucose concentration of subject using BGM and capillary finger tip blood
76085567|NCT06037551|Diagnostic Test|blood glucose measuremen reference|measurement of the blood glucose concentration of subject using reference method and capillary finger tip blood
76085568|NCT06037538|Diagnostic Test|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
76085569|NCT06037538|Diagnostic Test|blood glucose measurement with reference|blood glucose measurement with reference method using finger tip capillary blood
76085570|NCT06037512|Diagnostic Test|subject|blood glucose measurement by subject
76085571|NCT06037512|Diagnostic Test|reference|blood glucose measurement with reference
76085572|NCT06037499|Diagnostic Test|Glucometer Test|measurement of blood glucose concentration using different BGM and Reference Method
76085573|NCT06037486|Diagnostic Test|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
76085574|NCT06037473|Drug|Polyethylene glycol recombinant human growth hormone injection|0.1-0.3mg/kg.w
76085575|NCT06037460|Drug|Tocilizumab treatment|"1 injection/2 weeks from W0 to W12: W0, W2, W4, W6, W8, W10, W12~Then 1 injection/4 weeks until W24: W16, W20, W24"
75646705|NCT04669002|Drug|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
75646706|NCT04669002|Drug|Olaparib tablets|Olaparib is a PARP inhibitor (poly [adenosine diphosphate-ribose] polymerase inhibitor)
76085576|NCT06037460|Other|questionnaires|HAQ, SF-36, FACIT-Fatigue score
76085577|NCT06037460|Biological|Blood samples|Additionnal blood samples for immunomonitoring
76085578|NCT06037460|Procedure|18FDG PET scan|PETVAS calculation (to be performed between W0 and W8) (optional).
76085579|NCT06037395|Biological|CT-P41|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
76085580|NCT06037395|Biological|US-licensed Prolia|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
76085581|NCT06037356|Device|Prostatic Urethral Lift|Prostatic urethral lift uses permanent implants to retract the prostate lobes away from the prostate urethra to allow unobstructed passage of urine. These implants are made of Nitinol, non-absorbable monofilament suture material (Poly Ethylene Terephthalate), Stainless Steel
76085582|NCT06037356|Procedure|TURP|Using monopolar or bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH
75798951|NCT01180764|Drug|Placebo|Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
75798952|NCT01182012|Behavioral|Lifestyle counseling|Depending on the results of cardiovascular risk factor indexes, the treatment (including drugs, if needed) may be modified or adjusted. A nurse visit will be programmed to explain the lifestyle behaviour the patient should have.
75798953|NCT01289886|Drug|BR-A-657|20, 60, 120, 240, 360, 480mg or placebo tablet
75798954|NCT04986618|Other|One-way Nordic Exercise|Participants in this group will be given the standard Nordic Hamstring exercise.
75798955|NCT04986618|Other|Two-way Nordic Exercise|In addition to the standard Nordic Hamstring exercise, participants in this group will do the same exercise backwards for the quadriceps.
76085583|NCT06037330|Drug|Nalbuphine|Nalbuphine was injected intravenously. The target CPOT score was <2, and the target RASS score was -2 ~ 1. 40 mg of nalbuphine was diluted into 50 mL solution, the load was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was <2, and the maximum daily dose was 160mg.
75794319|NCT04415476|Drug|Assigned Interventions|This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T
75337019|NCT05775497|Behavioral|Minority stress intervention|The Minority Stress Intervention will teach cognitive and behavioral strategies for coping with minority stress with a focus on how minority stress impacts weight loss behaviors. The treatment will primarily address stressors due to sexuality and weight but will also cover how minority stress intersects with other facets of identity. The intervention, while innovative, is adapted from evidence-based treatments using cognitive behavioral therapy (CBT) to address minority stress.Lessons will provide psychoeducation on minority stress related to sexuality, gender, and weight, how it intersects with other aspects of identity, and how it can interfere with weight loss (e.g., unhealthy eating, avoiding exercise and healthcare, reduced motivation, disengaging from the program).The treatment will be delivered in 12 8-10-min lessons/week (a duration comparable to previous treatments) viewed directly after Rx Weight Loss lessons in Wks 1-12.
76085584|NCT06037330|Drug|Sufentanil|Sufentanil was injected intravenously, and the target CPOT score was <2, and the target RASS score was -2 ~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was <2 points
75646707|NCT04655079|Device|Anodal transcranial direct current stimulation (a-tDCS)|tDCS is delivered by a battery-driven constant current stimulator thought a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the left dlPFC (F3) according to the 10 to 20 international electroencephalogram coordinates) and the cathode is placed over the right deltoid muscle. During real stimulation a constant current of 2mA (milli Ampere) is applied for 20 minutes.
75646708|NCT04655079|Device|Sham Condition|For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation.
75646709|NCT04640493|Drug|Dapagliflozin|If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.
75798956|NCT01180842|Other|Yoga treatment program|yoga program designed specifically for the patient with CF
75798957|NCT01187862|Drug|caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam|
75646710|NCT04640493|Device|WatchPat|HF patients undergo SDB testing with the WatchPat device. (non-experimental)
75931312|NCT02235441|Other|Cardiopulmonary Exercise Test (CPET)|All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
75931313|NCT02235519|Drug|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
76085585|NCT06037304|Other|no intervention|no intervention
76085586|NCT06037291|Dietary Supplement|Coriander Seed Oil|The study foresees the intake of 1 capsule per day during 56 days
75798958|NCT01289964|Procedure|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
75931314|NCT02235519|Drug|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
75931315|NCT03300908|Behavioral|Project ADHERE|"This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals."
75646711|NCT04636190|Device|Triathlon All-Polyethylene Tibia Knee|Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
75646712|NCT04617262|Behavioral|Remote Problem Management Plus|Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support
75931316|NCT03300908|Behavioral|MACE|This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
75931317|NCT05376501|Dietary Supplement|Astaxanthin|8 mg Astaxanthin per capsule, taken once a day with meal
75931318|NCT05376501|Other|Placebo|Modified food starch
75931319|NCT02466932|Device|Galilei Dual-Scheimpflug Analyzer|Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
75931320|NCT05727254|Behavioral|Agility training|Multi-component (strength, balance, cognition) exercise training.
76085587|NCT06037291|Dietary Supplement|Placebo|The study foresees the intake of 1 capsule per day during 56 days
76085588|NCT06037278|Device|MyPAO|use of MyPAO surgical guide to support periacetabular osteotomy procedures for treatment of acetabular dysplasia
75337020|NCT05775497|Behavioral|Social support intervention|The Social Support Intervention will provide sexual minority women with online opportunities to give and receive real-time social support for weight loss efforts. The treatment is based on Social Learning Theory and evidence-based online social support programs used in behavioral weight loss. The intervention will include one video lesson outlining the value of social support for weight loss and well-being, strategies for eliciting support, and an orientation to using the online platform (hosted within Rx Weight Loss). The platform will feature a private forum where participants can post to provide support and discuss their weight loss goals, challenges, and successes. To foster engagement, discussion topics will be automated to post 4 times/week and those who do not participate will be reminded via e-mail to engage (1x/month).
75473072|NCT01965990|Other|NEP|A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
75473073|NCT01966016|Procedure|Pacing|"In this study we intend to include patients that have indication to and are intended to undergo CRT implantation with an additional electrode on LV, that have inclusion criteria and have signed an informed consent.~In this study we will include 20 patients for each study arm (overall 100)- each patient will have both treatment configurations and these two will be compared"
75473074|NCT01966029|Drug|BMN 110|All pateints receive treatment with BMN 110
75473075|NCT01966055|Drug|Solithromycin|
75646713|NCT04617093|Device|PrismaLung+|Overall, 50 adult patients will be initiated on ECCO2R using PrismaLung+. A minimum of approximately 15 patients will be treated with ECCO2R using PrismaLung+ as stand-alone therapy and another minimum of approximately 15 patients (maximum of 20) will receive ECCO2R using PrismaLung+ in combination with CRRT.
75646714|NCT04612933|Other|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment."
75794320|NCT04390321|Other|LLMcare|Participants will undergo 20 sessions of computerized cognitive and physical training, during a 2 month period. Both components have a duration of 30 minutes and are consecutive, but their sequence is pseudo-randomized. All sessions are conducted under supervision. Cognitive training uses the greek adaptation of the BrainHQ software (Posit Science Corporation), utilizing audiovisual stimuli, and targets memory, attention, cognitive-processing speed, orientation and social skills. Physical training is based on the WebFitForAll protocol and uses the motion sensor device Kinect. It consists of warm-up, aerobic, flexibility, strength, balance and cool down exercises.
75794321|NCT04389567|Drug|Famotidine|Use of oral Famotidine.
75794322|NCT04386967|Biological|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
75794323|NCT04386967|Drug|Keytruda|Anti-PD-1 antibody
75931321|NCT05727254|Behavioral|Exercise recommendations|Participants are being given the standard recommendations how much exercise and what type older adults should do.
75473076|NCT01966081|Other|Blood sample|
75473077|NCT01966081|Other|tissue samples from abdominal subcutaneous adipose|
75473078|NCT01966133|Drug|Ethiodized Oil + Doxorubicin|TACE using doxorubicin-lipiodol mixture
75473079|NCT01966146|Device|Echography GE Healthcare Vivid E9|Echography GE Healthcare Vivid E9
75473080|NCT01966172|Drug|Ibuprofen|oral ibuprofen 400mg 4 times daily
75646715|NCT04597112|Other|Myofascial Release Technique|Myofascial release focuses on reducing pain by easing the tension and tightness in the trigger points. Therapist will gently massage the myofascia and feel for stiff or tightened areas. Normal myofascia should feel pliable and elastic. The therapist will begin massaging and stretching the areas that feel rigid with light manual pressure. The therapist then aids the tissue and supportive sheath in releasing pressure and tightness. The process is repeated multiple times on the same trigger point and on other trigger points until the therapist feels the tension is fully released.
75646716|NCT04597112|Other|Exercise|"Exercise is recommended by physical therapists for most cervical radiculopathy patients.~In this study, a customized exercise program will be applied for patients with cervical radiculopathy."
75794324|NCT04384367|Drug|Rizatriptan 10 mg + Naproxen 550mg|oral - single dose
75794325|NCT04384367|Drug|Maxalt 10Mg Tablet|oral - single dose
75794326|NCT04384367|Drug|Flanax 550mg|oral - single dose
75794327|NCT04384367|Drug|Placebo oral tablet|oral - single dose
75794328|NCT04378933|Device|Amber Glasses|Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.
75794329|NCT04378933|Device|Clear Lens Glasses|Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.
75794330|NCT04372563|Other|aortic prosthetics|aortic prosthetics
75794331|NCT04371536|Drug|Ferrous Sulfate|Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
75794332|NCT04371536|Behavioral|IRONCHILD|"Delivery of the intervention at each visit should take 15 minutes or less.~Baseline visit (Session 1) content will be viewed~At 1-month follow-up visit, additional (Session 2) content will be viewed~At 3-month final visit, patients will view final (Session 3) content"
75931322|NCT05727254|Behavioral|Exercise diary|Participants are instructed to write down their physical activity and exercises.
75931323|NCT02235675|Device|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
76085589|NCT06037265|Device|PAVmed PortIO™ Intraosseous Infusion System|The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
76085590|NCT06037239|Drug|Linperlisib in combined with Chidamide|"Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly.~Phase 2：dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle"
76085591|NCT06037226|Behavioral|Postpartum pelvic floor rehabilitation|biofeedback with Pelvic floor muscle training (PFMT)
76085592|NCT06037200|Device|Urin-based test by the DOASENSE Dipstick Device|Routinely assessed urine is tested by the DOASENSE Dipstick device for presence of direct oral anticoagulants. Readout is performed after 10 minutes visually and by a automated reader.
76085593|NCT06037161|Procedure|Mandibular Incisor root coverage procedure|Mucogingival procedure to cover mandibular incisor tooth with receded gums
76085594|NCT06037109|Device|Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test|Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
76085595|NCT06037096|Other|Attend-PE model|A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.
75931324|NCT02235753|Behavioral|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
76085596|NCT06037083|Device|Oxygen saturation probe|The high-accuracy oxygen saturation signal will be continuously acquired for 168 hours post extubation from a separate pulse oximeter (Radical-7®, Masimo ROOT platform, MasimoCorp, Irvine, LA).
75646717|NCT04593732|Device|STERN FIX (Sternal Stabilization System)|Sternotomy closure with STERN FIX and supplemented with wires
75646718|NCT04553432|Device|Amniotic membrane Omnigen[TM]|17mm circular disk of processed amniotic tissue donated by mother after birth with a 6mm laser cut aperture to allow unimpeded vision https://www.nu-vision.co.uk/omnigen
75794333|NCT04364568|Radiation|Magnetic Resonance Imaging|IRM Sequences T1, T2, FLAIR, T2*, Cerebral Blood Flow (CBF) et mean diffusivity (MD)
75931325|NCT02235753|Behavioral|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
75931326|NCT04269447|Diagnostic Test|Structured imaging follow-up|Structured imaging follow-up protocol with ultrasound (US) and computed tomography (CT) examinations as compared to current standard surveillance protocol for individualized estimations of AAA growth.
76085597|NCT06037083|Device|Near infrared spectroscopy sensors|The cerebral and splanchnic regional oxygen saturation signals will be acquired continuously for 168h post extubation using two near infrared spectroscopy sensors (Masimo ROOT platform, MasimoCorp, Irvine, LA), one placed on the forehead for cerebral oxygenation and one on the abdomen (for splanchnic oxygenation).
76085598|NCT06037083|Device|Electrical impedance tomography|"The regional lung ventilation will be measured using Electrical Impedance Tomography (TIMPEL, USA) at three time points:~From 1 hour pre-extubation to 2 hours post extubation (total 3 hours)~Between 24 and 48 hours post extubation (total 3 hours)~Between 72 and 96 hours post extubation (total 3 hours)"
76085599|NCT06037057|Other|no intervention name|no intervention description
76085600|NCT06037044|Other|Sensory integration therapy for balance and gait training|Sensory integartion Walking pathway with obstacles x10 rep, standing on one leg with eyes op5-10 sec x10 rep)
76085601|NCT06037044|Other|Traditional Physiotherapy for balance and gait training|Traditional Physiotherapy walking pathway with obstacles x10 rep, standing on one leg with eyes open 5-10 sec x10 rep
76085602|NCT06037018|Biological|CC312|Doses from 0.3 to 45 µg/dose by intravenous infusion
76085603|NCT06037005|Other|Cognitive Behavioral Therapy Group|Group intervention program based on cognitive behavioral approach of ten sessions; It was completed in approximately one and a half months (May-June 2022) in the Faculty of Nursing, by dividing the experimental group into two separate groups, two days a week for each group. Each session was held for approximately one hour. The last measurement was made three months after the last therapy session (September 2022).
75646719|NCT04553432|Device|Bandage soft Contact Lens OmniLenz[R]|18mm soft silicone-hydrogel contact lens https://www.nu-vision.co.uk/omnilenz
75646720|NCT04552704|Biological|CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc|Given IV
75646721|NCT04552704|Drug|Placebo Administration|Given IV
75646722|NCT04528173|Drug|Ketorolac|Ketorolac (0.5mg/kg; maximum 15mg intravenously) will be given at end of procedure after evaluation for hemostasis.
75646723|NCT04528173|Drug|Dexmedetomidine|Dexmedetomidine (1ug/kg with maximum 50ug intravenously) will be given at beginning of procedure.
75646724|NCT04528173|Drug|Morphine|Morphine (0.05-0.1 mg/kg intravenously) will be given intra-operatively per institutional standard clinical care.
75646725|NCT04528173|Drug|Fentanyl|Fentanyl (0.5-2 ug/kg intravenously) will be given intra-operatively per institutional standard clinical care.
75798959|NCT01290042|Drug|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
75798960|NCT01290042|Other|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
75473081|NCT01966172|Drug|Gabapentin|Oral Gabapentin 300mg twice daily
75473082|NCT01966172|Drug|Morphine|10 mg morphine orally 4 times daily
75473083|NCT01966172|Drug|Paracetamol|oral paracetamol 1000mg four times daily
75646726|NCT04519944|Drug|Edoxaban|This is an observational, prospective study; no treatment will be administered.
75798961|NCT03852732|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
75931327|NCT00702650|Drug|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
75931328|NCT03230916|Drug|IMI/REL FDC|IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
75931329|NCT04203147|Behavioral|Supportive Therapy (Control)|Description: 8-weekly sessions of in-home, supportive therapy and monthly booster sessions from months 3-12 via telephone.
75931330|NCT04203147|Behavioral|Home DM-BAT|Description: 8-weekly sessions of in-home, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) and monthly booster sessions from months 3-12 via telephone.
75931331|NCT03300596|Behavioral|Brief intervention to prevent suicide attempt|A patient-centered, 3-session intervention that calls for videotaping the narrative story of a patient's suicide attempt, in his/her own words (session 1); reviewing segments of the tape to arrive at a shared understanding of the attempt and the sequence of events that led to it (session 2); and using this information, along with a homework task completed by the patient in-between sessions, in order to develop a collaborative, comprehensive written safety plan that addresses the patient's unique vulnerabilities (session 3).
75931332|NCT03300596|Behavioral|Enhanced treatment as usual|Safety procedures' control intervention. For these procedures we will share summary results of the research assessments regarding suicidal thoughts, suicidal behaviors, alcohol and drug use and related problems, and depressive symptoms with appropriate hospital clinical staff. We will also arrange to send this information, with participants' permission, to their ongoing therapist or treatment program and, if none exists, to the therapist or program to which they are being referred. In this regard, the research assessment protocol serves a dual function of helping with additional monitoring of high-risk patients in addition to providing data for the study.
75931333|NCT01337115|Procedure|SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
75931334|NCT01337115|Procedure|CFNB|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
75931335|NCT03761784|Drug|S6G5T-3|Once a day topical cream
75931336|NCT03761784|Drug|S6G5T-8|Once a day topical cream
75931337|NCT04100187|Biological|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
75931338|NCT03300440|Dietary Supplement|Probiotics and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
75931339|NCT03300440|Dietary Supplement|Placebo and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
75931340|NCT02236065|Procedure|Umbilical cord blood therapy|
75931341|NCT02236065|Biological|Filgrastim|
75473084|NCT01966185|Other|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
75473085|NCT01966198|Other|Tilt test|The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
75646727|NCT04519801|Other|Blood Flow Restriction (BFR) therapy|BFR therapy beginning after first MD follow up appointment after ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion.
75646728|NCT04519801|Other|Standard REHAB|Standard post-operative rehabilitation regimen (REHAB) beginning after first MD follow up appointment ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion
75931342|NCT02467556|Drug|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
76085604|NCT06036979|Procedure|Paravertebral plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the transverse processes clearly visualized . Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique toward the paravertebral space, immediately above the pleura and below the superior costotransverse ligament. The position of the needle is confirmed by the descent of the pleura when injecting 2 to 3 ml of saline solution for hydrolocalization. Then 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
75337021|NCT05775497|Behavioral|Negative body image intervention|The Negative Body Image Intervention will teach CBT skills for improving negative body image and reducing its impact on weight loss behaviors. The treatment is derived from evidence-based CBT interventions targeting body image for women with obesity during behavioral weight loss and will be adapted to reflect the unique body image ideals and concerns of sexual minority women. Lessons will teach CBT strategies for coping with negative body image and reducing interference with weight loss efforts. The intervention will be delivered in 12 weekly 8-10-minute lessons, a treatment duration comparable to previous treatments and will be viewed immediately following Rx Weight Loss lessons during Weeks 1-12.
75337022|NCT05775445|Procedure|Blood draw|2 6ml blood tubes will be collected from patient
75337023|NCT05775419|Combination Product|Consolidation chemotherapy (4 courses)|Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen;
75337024|NCT05775419|Combination Product|Concurrent chemotherapy (2 courses)|Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week*2cycles; DDP 75mg/m2 ivgtt, d2, 3week*2cycles;
75337025|NCT05775393|Procedure|Serratus anterior plane block for MRM|"They will randomly assigned to two groups of 30 patients each, at 1:1 allocation ratio using computer-generated random numbers concealed in sealed opaque envelopes.~Group (A):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0 .25 % and dexamethasone 4 mg).~Group (B):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0.25% and dexamethasone 4mg with ketamine 50 mg).~All the medications were prepared by an anesthesiologist not participating in the study."
75337026|NCT05775354|Diagnostic Test|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
75794334|NCT04362982|Other|ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.|Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.
75794335|NCT04362189|Biological|HB-adMSC|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
75794336|NCT04362189|Other|Placebo|Saline
75794337|NCT04360486|Biological|Anti-Sars-CoV-2 Convalescent Plasma|Fresh frozen plasma, Plasma Frozen for 24 hours (PF-24), or Liquid plasma
75794338|NCT04350762|Dietary Supplement|Protein shake + Fish Oil|2 shakes of protein as well as 1 fish oil daily.
75931343|NCT02467556|Behavioral|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
75794339|NCT04342624|Dietary Supplement|Cinnamon|Cinnamon supplement
75794340|NCT04342624|Other|Placebo|Placebo
75931344|NCT02467556|Other|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
75931345|NCT02262585|Drug|BIBR 277 tablet|
75931346|NCT02262585|Drug|BIBR 277 capsule|
75337027|NCT05775302|Other|IASTM of Gastrocnemius + Conventional therapy|The SWEEP technique will be performed downwards from the popliteal region to the Achilles tendon for 60 seconds, 30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
75337028|NCT05775302|Other|IASTM of AchillesTendon + Conventional Therapy|Participants will receive a maximum of 60 seconds<30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
75337029|NCT05775276|Procedure|Proline mesh in hernioplasty|Hernioplasty using proline mesh then follow up for incidence of infection
75473086|NCT01966224|Biological|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose."
75931347|NCT03309254|Other|High Glycemic Index|High Glycemic Index Food
75931348|NCT03309254|Other|Low Glycemic Index|Low Glycemic Index Food
75931349|NCT03195894|Device|TripleA|
75931350|NCT02262663|Drug|Vilaprisan (BAY1002670)|
75931351|NCT03309176|Drug|Medroxyprogesterone Acetate 10 MG|Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
75931352|NCT03309176|Other|Stair step protocol without Medroxyprogesterone Acetate|No administration of Medroxyprogesterone Acetate prior to each cycle. Stair step method: rapidly increasing the dose of clomiphene citrate in case of no follicular response
75337030|NCT05775211|Biological|Intrauterine administration of PBMC immunomodulated with IFNt|Standard density gradient centrifugation will be performed to obtain autologous PBMC from patients' peripheral blood (9 ml). Isolated cells will be suspended in RPMI 1640 supplemented with 10% HSA (human serum albumin) and incubated in the presence of 500 IU/ml IFNt for 24 h at 37˚C. The cultured cell suspension will be introduced into the uterine cavity via a catheter.
75337031|NCT05775198|Biological|PBMC immunomodulated with IFNt|Autologous peripheral blood mononuclear cells (PBMC) isolated using a standard protocol will be cultured in the presence of interferon tau (IFNt) for 24 hours at 37 ˚C and administered in the uterine cavity of patients 1 day prior to embryo transfer.
75646729|NCT04497376|Procedure|upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo EI-VOM, followed by the '2C3L' ablation step. The details include: (1). EI-VOM procedure: An 8.5-French-long sheath or a steerable long sheath is sent to the coronary sinus (CS) via the femoral vein. A JR4.0 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a BMW wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated with 6 to 8 atm in the VOM. A selective venogram of the VOM is obtained by slowly injecting 1 mL of contrast medium. Then, ethanol is slowly injected into the VOM and selective venography of the VOM is repeated. (2) . After EI-VOM, radiofrequency ablation was performed to achieve bilateral pulmonary vein isolation and bidirectional block of mitral isthmus line, roof line, and cavotricuspid isthmus line. (3). Any organized AT observed during the procedure will be targeted as well.
75646730|NCT04497376|Procedure|pulmonary vein antral isolation|After reconstructing the left atrial geometry, PVI will be performed (the right PV antrum (PVA) will be ablated first, followed by the left PVA. ) in a wide area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished. The endpoint of the circumferential PVA ablation procedure is to achieve electrical bilateral PV isolation, that is, the PV potentials associated with atrial electrical activity cannot be recorded during sinus rhythm or CS pacing (entrance block). A waiting period of at least 20 min (after the last PV is isolated) will be used during which spontaneous PV reconnection will be related. , and tDemonstration of exit block (he by pacing in the PV cannot be and proving the absence of transmitted conduction to capture the atrium) may be performed but is not mandatory. Any organized AT observed during the procedure will be targeted as well.
75646731|NCT04495751|Dietary Supplement|Muscadine grape extract|Four pills twice daily
75794341|NCT04341259|Drug|Ipatasertib|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.
75931353|NCT05727020|Diagnostic Test|Breath test|Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.
75931354|NCT05727020|Diagnostic Test|Collection of matched samples of breath, biofluids and pancreatic tissue|In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.
75931355|NCT02602353|Drug|Loxoprofen Pain Patch|One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
75931356|NCT02602353|Drug|Placebo Patch|One Placebo Patch applied daily for 3 days
75931357|NCT02602353|Drug|No Treatment|No Treatment for 3 days
75473087|NCT01966250|Device|electroacupuncture and usual care|"Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.~Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated."
75473088|NCT01966250|Device|Usual care|Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
75646732|NCT04495751|Drug|Placebo|Four pills twice daily.
75646733|NCT04495751|Other|Quality of Life Assessment|Ancillary studies
75646734|NCT04495751|Other|Questionnaires|Ancillary studies
75646735|NCT04495751|Other|Participant Feedback|Ancillary studies
75931358|NCT03472794|Other|"web portal:  Mon réseau cancer du sein  (My Breast cancer Network)"|"web portal:  Mon réseau cancer du sein "
75794342|NCT04341116|Drug|TJ003234|patients receive a single infusion
75794343|NCT04341116|Drug|Placebo|patients receive a single infusion
75931359|NCT02467634|Biological|HuCNS-SC sub-retinal transplantation|HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
75794344|NCT04335188|Other|Prospective oberservational registry|Non interventional study.
75794345|NCT04335006|Drug|Carelizumab|Participants receive SHR-1210 intravenously (IV)
75794346|NCT04335006|Drug|Nab-paclitaxel|administered intravenously every 4-week cycle
75794347|NCT04335006|Drug|Apatinib|administered orally every 4-week cycle
75794348|NCT04333108|Drug|Masitinib|Masitinib 6 mg/kg/day
75794349|NCT04333108|Other|Placebo|Matching placebo
75646736|NCT04485728|Behavioral|Sleep Improvement Protocol Intervention for Hospitalized Antepartum Patients|Patients are getting sleep hygiene education and a sleep hygiene kit.
76085605|NCT06036979|Procedure|Erector spinae plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the tips of the transverse processes clearly visualized . The following muscles seen from superficial to deep layer are trapezius, rhomboid major and erector spinae muscles. Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique to reach the interfascial plane between the transverse process and the erector spinae muscle. Following confirmation of the accurate position of the needle tip with 3-5 ml normal saline solution, 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
76085606|NCT06036966|Drug|Hetrombopag|All the enrolled 34 patients will be given hetrombopag 5mg per day for 8 weeks when they start to take Niraparib as maintenance therapy
76085607|NCT06036953|Device|electrical muscle stimulation|The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
76085608|NCT06036940|Other|Preoperative patient education given with three different methods|To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.
76085609|NCT06036901|Diagnostic Test|Coronary CT|Coronary CT evaluation
76085610|NCT06036888|Other|questionaries completion|Answer to the DASH and SF-12 questionaries, for an estimated duration of 15 minutes.
75337032|NCT05775172|Procedure|Sleeve gastrectomy|laparoscopic sleeve gastrectomy was done under general anesthesia by the same surgeon in the SBAHC. Routine preoperative, and postoperative care (including early post-operative dietary management) were done. Baseline assessment was taken within the last week before the surgery during the preoperative preparation and the final assessment was recorded 6 months after the surgery date.
76085611|NCT06036875|Other|Non-Interventional Study|Non-interventional study
75337033|NCT05775172|Dietary Supplement|Lifestyle intervention|balanced 500 to 1000-calorie-deficit diet, personalized physical activity plan, and customized behavioral modification
75337034|NCT05775172|Other|Control|No interventions were applied
75337035|NCT05775120|Diagnostic Test|OLGA and H.pylori culture|Upper endoscopy will be performed by endoscopists using modern endoscopes (Fujinon EG-590WR, Olimpus GIF-H190 and others) while patient is sedated. Using sterile biopsy forceps, biopsy specimens will be taken from five areas of the stomach (two biopsy specimens - greater and lesser curvature of the antrum of the stomach; two biopsy specimens - lesser and greater curvature (or anterior and posterior wall) of the body of the stomach and one from the corner of the stomach) for pathology assessment. Pathology assessment of the gastritis stage and degree will be conducted according to the OLGA system developed by the international group of gastroenterologists and pathologists (Atrophy Club).
75337036|NCT00004126|Drug|oxaliplatin|
75646737|NCT04455074|Other|FN scale auto-questionnaire|Patients will be asked to fill in the NF scale questionnaire together with other tests and rating scales, during a routine L-Dopa test, in 2 conditions: OFF-med and ON-med.
75337037|NCT00004126|Drug|paclitaxel|
75646738|NCT04453553|Diagnostic Test|Q16 testing|Nasal swab tested on a rapid near patient device
75646739|NCT04453553|Diagnostic Test|Nasopharyngeal swab and main laboratory|Standard of care testing
75646740|NCT04449666|Diagnostic Test|Neuropsychological assessment and structural MRI|Complex neuropsychological assessment testing attentional and memory functions. Additionally, a structural MRI is measured.
75646741|NCT04445649|Diagnostic Test|Coma-Recovery-Scale-Revised (CRS-R)|CRS-R assessments (15 minutes) are repeated weekly after study entry
75646742|NCT04430452|Biological|Durvalumab|Given IV
75931360|NCT04983498|Drug|Ondansetron 4 MG|PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis.
75931361|NCT04983498|Drug|Lactated Ringers, Intravenous|Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).
75794350|NCT04333108|Other|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
75794351|NCT04330001|Device|Alcon Fluid Accommodating Intraocular Lens|Intraocular lens intended to treat presbyopia by dynamically adjusting power, resulting in a continuous range of vision from distance to near.
75931362|NCT04983498|Other|Early Mobilization|Patient transferred up to the chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters and patient safety.
75931363|NCT04983498|Other|Early PO Intake|Patient will be offered PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters and patient safety.
75646743|NCT04430452|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
75646744|NCT04430452|Biological|Tremelimumab|Given IV
75646745|NCT04430257|Other|HIV and PrEP education|Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.
75794352|NCT04330001|Other|Top Con Autorefractor|Device intended to automatically determine the focusing characteristics of the eye
75798962|NCT03857412|Procedure|Capsular polishing|Capsular polishing taking place during cataract surgery
75798963|NCT03857412|Other|Non capsular polishing|No capsular polishing taking place during cataract surgery
75931364|NCT04831424|Behavioral|Trier social stress test|The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
75337038|NCT05775055|Other|Composition of oral rehydration solutions|Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.
75337039|NCT05774964|Drug|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area
75337040|NCT05774964|Drug|S1|Orally on d2-d15 at 20 mg three times daily
75337041|NCT05774964|Drug|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
75337042|NCT05774964|Drug|Metronidazole|Metronidazole 0.4g/time, qd
75337043|NCT05774964|Drug|Vitamin A|Vitamin A 5,000 units/time, qd
75337044|NCT05774964|Drug|Folic acid|Folic acid 5 mg/time, qd
75337045|NCT05774938|Procedure|Standard Endovascular aneurysm repair (sEVAR)|Standard EVAR treatment with Medtronic Endurant IIs (Medtronic, Inc. - Minneapolis, Minnesota), Gore Excluder AAA (W. L. Gore & Associates, Inc. - Newark, Delaware), Gore Excluder Conformable AAA (W. L. Gore & Associates, Inc. - Newark, Delaware), Cook Zenith Flex (Cook Medical, Inc. - Bloomington, Indiana).
75794353|NCT04321876|Behavioral|Collaborative Behavioral Health Program|Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.
75794354|NCT04319120|Other|questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed. A dedicated telephone line and e-mail address will be used as a support if necessary (for questionnaires, emails or sending photos). The referring nurse and the clinical research assistant of the service will be in charge of centralizing the data collected.
75931365|NCT02621736|Other|blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.
75931366|NCT01337973|Behavioral|MI-CBT|Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches
75931367|NCT01337973|Behavioral|MI-CBT+CC|Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention
75931368|NCT01337973|Behavioral|E-TAU|Enhanced Treatment as Usual
75931369|NCT03300362|Drug|Seasonal influenza vaccine|Seasonal influenza vaccine
75931370|NCT03300362|Drug|MVA-NP+M1|Trial vaccine
75931371|NCT03300362|Drug|Sodium chloride|Saline placebo
75931372|NCT04787874|Behavioral|Prehabilitation Program|"Nutrition component: Participants will receive information on how to follow a healthy diet (Mediterranean-style diet) with emphasis on whole foods, plants, lean protein, olive oil; restriction of red meats, processed meats, processed foods, added sugar)~Exercise component: Participants will receive an activity tracker to use during the study period (3+ weeks before surgery, and 30 days after surgery). Participants will be assigned strength exercises to work on core strength and proximal muscle strength (biceps/triceps, quads, hamstrings, calves).The exercises will mainly be focused on strengthening the abdominal wall. Exercises will be tailored to patients' individual capabilities. They will also be assigned cardio exercises - either low-intensity steady state cardio vs High Intensity Interval training. Level of cardio exercise will be tailored based on patient's Duke Activity score and baseline activity."
75337046|NCT05774938|Procedure|Complex Endovascular Aneurysm Repair (cEVAR)|Complex EVAR treatment with custom made devices (CMD's) from Cook Medical (Cook Medical, Inc. - Bloomington, Indiana) including fenestrated or branched devices or off-the-shelf T-branch device (Cook Medical, Inc. - Bloomington, Indiana).
75337047|NCT05774912|Other|Ultrasound evaluation|Fetal ultrasound evaluation will be collected longitudinally during the prenatal period from the weeks 14 every 4-5 weeks, for a total of maximum 6 ultrasound scans
75473089|NCT01966276|Drug|Methyl-P plus Nutrient Formula|"Week 1 (take the following together twice a day-at breakfast and lunch)~One tablet of Methyl-P (5mg)~Four tablets of CFS Nutrient Formula~Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~Two tablets of Methyl-P (10mg)~Four tablets of CFS Nutrient Formula"
75794355|NCT04315233|Drug|Ribociclib|Ribociclib Dose Level 0 (starting dose) 200mg QD Dose Level 1A 400mg on Days 8-28 Dose Level 1B 200mg QD Dose Level 2 400mg on Days 8-28
75337048|NCT05774821|Procedure|Tricuspid valve surgery|Surgical repair or valve prosthesis implant to treath the regurgitation of the tricuspid valve
75337049|NCT05774808|Procedure|Aortic valve replacement|An aortic valve prosthesis is surgically implanted to treat AR
75931373|NCT03469206|Procedure|intra-arterial thrombectomy|It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)
75931374|NCT03469206|Drug|Intravenous thrombolysis|alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
75931375|NCT02467400|Drug|Atenolol|beta blocker
75931376|NCT02467400|Drug|Nebivolol|beta blocker
75931377|NCT02467400|Drug|Propranolol|beta blocker
75337050|NCT05774808|Procedure|Mitral valve annuloplasty|Surgical repair of the mitral valve in which a prosthetic ring is implanted to treat MR
75473090|NCT01966276|Drug|Methyl-P plus Nutrient matched placebos|"Week 1 (take the following together twice a day-at breakfast and lunch)~One tablet of Methyl-P Placebo~Four tablets of CFS Nutrient Placebo~Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~Two tablets of Methyl-P Placebo~Four tablets of CFS Nutrient Placebo"
75473091|NCT01966289|Drug|CY|CY is administered intravenously at 200 mg/m2
75798964|NCT01187940|Behavioral|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
75931378|NCT02467400|Drug|placebo|placebo
75931379|NCT02467322|Drug|Albumin|MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
75931380|NCT02467322|Drug|ascitic fluid|
76085612|NCT06036862|Procedure|Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction|Laparoscopic or open surgery was selected according to the patient's condition, surgical history and surgeon's experience.According to the extent of the rectal stenosis, the proximal colon was dissected.A circular incision was made above the dentate line and the broken end was sutured. After the intestinal cavity was closed, a single port was inserted through the anus, and a transanal endoscopic platform was established after pneumoperitoneum infusion.The stenotic and scar segments were removed free upward.Through the pelvic cavity and into the abdominal cavity from the bottom up. The narrow rectum and proximal colon were pulled out of the anus through the anus, and the diseased bowel was removed. According to the distance of the remaining distal rectum, stapler or manual anastomosis or Bacon operation was selected.
76085613|NCT06036849|Procedure|Spinal manipulation|The manipulation will be delivered to the articular pillar of the most painful level of the cervical spine, as determined by the patient history & physical examination, by a registered and practicing chiropractor. The participant will be positioned supine with the head supported by the clinician's hands. The articular process of the involved vertebra will be contacted by the antero-lateral aspect of the proximal phalanx of the second digit of the clinician's index finger. The head will be taken into flexion, ipsilateral lateral flexion and contralateral rotation to the pre-manipulative position. A rapid, controlled low-amplitude thrust will be applied in a further posterior-anterior line of drive. Ipsilateral in this instance means the same side as the primary contact i.e. for manipulation applied to the right side, the right side of the participant's neck will be contacted.
75337051|NCT05774795|Procedure|Mitral valve surgery|Mitral valve repair or replacement to treat mitral regurgitation
75337052|NCT05774795|Procedure|Aortic valve surgery|Aortic valve replacement to treat aortic regurgitation
75337053|NCT05774769|Procedure|Commissural edge to edge mitral valve repair|Edge to edge is the suture of mitral valve leaflets tissue in the regurgitant spot. If the regurgitant jet is near a mitral commissure, it is called a commissural edge to edge.
75931381|NCT03472638|Device|Dorsomedial prefrontal rTMS|Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.
75931382|NCT03914469|Behavioral|Behavioral Intervention Group|The active intervention will include eight tele-delivered health coach sessions, three tele-based outcome assessments, and up to two semi-structured interviews at 6 months post-intervention. Each tele-based outcome assessment is roughly 45-60 minutes and will be conducted by a member of the research team. Each intervention session will be delivered by a trained health coach over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
75337054|NCT05773872|Other|Questionary|"In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)"
75337055|NCT05773677|Dietary Supplement|Specific Diet|"A specific diet will be developed for each patient, which will also take into account any food allergies or intolerances.~Each diet will be then eventually modified and revised throughout the pregnancy, according to the evolution of the same."
75337056|NCT05773404|Other|Passive Neurodynamics and Passive axial hip mobilisation/distraction|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles.
75337057|NCT05773404|Other|Active therapy|Active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves
75473092|NCT01966289|Biological|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
75337058|NCT05773404|Other|2.5.3. Combined therapy|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles and active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves.
75337059|NCT05773222|Drug|Apixaban|Single Group Assignment
75337060|NCT05772754|Genetic|study of molecular and protein pathways|42 ml peripheral venous blood sample.
75337061|NCT05772325|Other|Individually tailored diet counseling|Participants in the intervention group will receive a 60 min individually tailored heart-friendly diet consultation by a dietitian
75646746|NCT04430257|Behavioral|Motivational interviewing|Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.
75646747|NCT04430257|Behavioral|Problem-solving and planning|Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.
75337062|NCT05772325|Other|The brief standardized 4-minute heart healthy dietary advice|The brief standardized 4-minute heart healthy dietary advice will be provided by an experienced cardiologist or rheumatologists
75337063|NCT05768594|Other|Blood sample|After blood sampling, patients will undergo a Color Doppler Echocardiogram, a non-invasive method
75473093|NCT01966289|Drug|SGI-110|SGI-110 is administered subcutaneously at 60 mg/m2
75473094|NCT01966302|Drug|BPS-314d-MR|15-150 mcg po BID,
75473095|NCT01966328|Drug|36% Resolvine Intravitreal Injection|36% Resolvine Intravitreal Injection
75473096|NCT01966328|Drug|9% Resolvine Intravitreal Injection|9% Resolvine Intravitreal Injection
75646748|NCT04430257|Behavioral|Patient navigation|Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites
75646749|NCT04430257|Other|PrEP information|A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.
75646750|NCT04430257|Other|Referrals|Study staff will provide basic information about PrEP and referrals to PrEP clinicians.
75646751|NCT04353661|Drug|Azithromycin|Azithromycin will be administered orally.
75646752|NCT04353661|Other|HP xenon (¹²⁹XE)|HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
75646753|NCT04346225|Drug|Hyperpolarized C13|Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
76085614|NCT06036849|Procedure|Spinal mobilization|The mobilization will consist of one set of posterior-anterior spinal mobilization applied with either a crossed-thumb or pisiform contact centrally over the spinous process of the most painful level of the cervical spine by a registered and practicing health care practitioner (i.e. physiotherapist).
75794356|NCT04315233|Drug|Belinostat|"Belinostat Dose Level 0 (starting dose) 600mg/m2 on Days 1-7 Dose Level 1A 600mg/m2 on Days 1-7 Dose Level 1B 1000mg/m2 on Days 1-7 Dose Level 2 1000mg/m2 on Days 1-7~*Administration on 5 consecutive days is preferred. Administration within 7 days allowed as needed to accommodate holidays and infusion schedules."
75931383|NCT03308864|Behavioral|Interpersonal Psychotherapy for Adolescents|Experimental: Interpersonal Psychotherapy for Adolescents (IPT-A) IPT-A is a manualized intervention for depression that targets adolescents' interpersonal context and social supports as mechanisms of change. It will be provided in accordance with the treatment manual by Child and Adolescent Outpatient Service clinicians over the course of 12-16 50-minute sessions.
76085615|NCT06036797|Drug|Hydromorphone|For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone
76085616|NCT06036797|Drug|Sufentanil|For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil
76085617|NCT06036797|Drug|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
75646754|NCT04346225|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
75794357|NCT04313088|Drug|Eluxadoline 100 mg|Eluxadoline 100mg by mouth twice daily with food
75931384|NCT03308864|Behavioral|Treatment as usual|Treatment as usual will consist of the standard care for adolescent depressive symptoms at CAOS. TAU is not manualized; it is consistent with care typically provided in community settings. Therapists establish a working alliance, are empathetic, reflect expressed affect, and discuss options for coping with concerns as initiated by the adolescent.
75794358|NCT04301986|Device|Cytosponge|In a seated position, subjects will swallow the Cytosponge capsule with 150-250 mL of water. Seven minutes and 30 seconds to ten minutes after ingestion, the sponge is then withdrawn by gentle traction on the suture. After retrieval, the string is cut and the retrieved foam sphere containing the cytological specimen is immersed in fixative and stored refrigerated (1° to 12°C [34° to 54°F]).
75794359|NCT04301986|Device|Transnasal Endoscopy (TNE)|In an upright position, the scope will be inserted via the nares to examine the posterior pharynx, esophagus and proximal stomach with the transnasal endoscopy approach. The scope will be withdrawn from the nares following completion of the exam.
75931385|NCT03446352|Other|Psychomotor exercise program|"Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (40 min), cool-down (10 min), and finishing ritual (5 min).~At the initial stage, the activation of different muscle groups will be performed, providing an elevation of the neurophysiological parameters. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation- physical performance (cardiovascular, strength, balance, flexibility, agility and movement accuracy)- alternating with exercises mainly focused on cognitive stimulation- executive functions (planning ability, information processing speed, attention and dual-task performance).~At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants share their sensations experienced."
75931386|NCT03446352|Other|Combined exercise program|"The EG2 intervention combines the psychomotor exercise program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.~The WBV will integrate 3 sessions / week of 6 minutes each, with programed increased exercise time, series, and frequencies throughout the intervention."
76085618|NCT06036771|Device|Voice-activated Intelligent Personal Assistant (VIPA)|Apple HomePod mini is selected as the intervention medium of this study as it is the only available smart speaker that supports Cantonese
76085619|NCT06036758|Diagnostic Test|VIDAS® NEPHROCLEAR™ CCL14 Test|Urine samples previously collected from persons with stage 2/stage 3 AKI will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
75337064|NCT05763524|Procedure|Adrenalectomy with or without lymphadenectomy|Regarding lymphadenectomy extent, it will be described as locoregional or systematic depending on availability of data in the Eurocrine database.
75337065|NCT05762393|Biological|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
75931387|NCT03308708|Drug|Norepinephrine infusion|Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
75931388|NCT03443700|Device|EKSO-GT|Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).
76085620|NCT06036745|Drug|Pembrolizumab + SOX|Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
76085621|NCT06036706|Radiation|Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning|Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy…)
75337066|NCT05761626|Other|MP < 17 J/min|assessment of the ventilatory variables according to the MP value (< or >= 17 J/min)
75473097|NCT01966341|Behavioral|CBT/ Hypnotherapy|The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
75473098|NCT01966341|Drug|Routine Management|Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
75794360|NCT04301986|Device|Esophagogastroduodenoscopy|Laying on the subjects' left side, the flexible endoscope is inserted through the mouth to allow visualization of the esophageal mucosa from the upper esophageal sphincter all the way to the esophagogastric junction (EGJ).
75794361|NCT04301531|Other|Mass testing using RDTs|To determined the prevalence of asymptomatic malaria parasitaemia. In arm 1 all participants will be tested six times over the study period while in arm 2 the participants will be only be tested at baseline and evaluation.
75931389|NCT03443700|Procedure|Standard neurorehabilitation locomotor training|Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
76085622|NCT06036706|Radiation|Hypo-fractionated stereotactic brain irradiation|Patients receiving hypo-fractionated stereotactic brain irradiation
75794362|NCT04301531|Drug|Treatment for all cases confirmed positive malaria cases with ACTs|During each mass testing, all confirmed positive cases are treated in both arms.
75931390|NCT03897465|Device|Lomatuell Pro|Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
75931391|NCT03897465|Device|UrgoTul|Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
75931392|NCT03472482|Diagnostic Test|non-invasive retinal imaging|
75931393|NCT03143556|Device|Magnetic stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
75931394|NCT04476615|Dietary Supplement|Fasting-Mimicking Diet (ProLon®)|Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
76085623|NCT06036706|Radiation|Normo-fractionated proton therapy brain irradiation|Patients receiving normo-fractionated proton therapy brain irradiation
76085624|NCT06036706|Other|Cognitive assessment by a trained neuropsychologis|Participants without any meningioma, cancer history or neurological comorbidities will undergo cognitive assessment by a trained neuropsychologist, similarly as for patients
75794363|NCT04301531|Other|Determination of Hb|Hb of all children in the subgroup study are measured using a haemocure photometer.
75794364|NCT04301531|Other|Household survey|Determine the prevalence of febrile illnesses among children in the subgroup study
75794365|NCT04301531|Other|Community-base management of malaria|Between interventions, participant who become febrile are tested and treated if confirmed positive for malaria by CHWs
75794366|NCT04299373|Drug|Alcohol: Oral administration|Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.
75794367|NCT04299373|Drug|Alcohol: Intravenous administration|Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
75794368|NCT04296734|Behavioral|Mothers and Babies|Mothers & Babies (MB) is a program that promotes healthy mood management by teaching pregnant women and new moms how to effectively respond to stress in their lives through increasing the frequency of thoughts and behaviors that lead to positive mood states. Designed as a perinatal depression prevention, the Mothers & Babies targets three specific risk factors: limited social support, lack of pleasant activities, and harmful thought patterns.
75931395|NCT04476615|Dietary Supplement|Placebo bars|"Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day.~5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total)."
75931396|NCT02929056|Biological|AmnioExCel dressing and compression therapy|Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
75931397|NCT02929056|Procedure|SOC alginate dressing and compression therapy|Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
75931398|NCT02262741|Biological|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
75931399|NCT02262741|Biological|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
76085625|NCT06036667|Procedure|"28Fr coaxial smart drain chest tube"|"To evaluate the efficacy of one 28Fr chest tube (coaxial smart drain versus standard chest tube according to local practice, types of drainage availability in each centre, surgeon's choice etc) after Uniportal- or Biportal-VATS upper lobectomies."
76085626|NCT06036654|Device|infrared thermotherapy instrument|Only a single target nail was chosen among multiple onychomycosis to receive local hyperthermia treatment.
76085627|NCT06036615|Other|Exercise Intervention|Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 4-month de-training period, continuing their normal physical activity.
76085628|NCT06036602|Biological|cAD3-Sudan Ebolavirus Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
76085629|NCT06036602|Other|Placebo|0.9% NaCl solution for injection.
76085630|NCT06036589|Drug|CA and BAM8-22|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
75473099|NCT01966367|Biological|CD34 Stem Cell Selection Therapy|The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
75794369|NCT04293276|Drug|Pyrotinib|Pyrotinib Tablets
75794370|NCT04293276|Drug|SHR6390|SHR6390 Tablets
75794371|NCT04292808|Drug|Methoxyflurane|Methoxyflurane inhaler during out-patient aesthetics surgery or facial dermal fillers.
75794372|NCT04276194|Procedure|Intensity-Modulated Proton Therapy|Undergo intensity modulated proton therapy
75794373|NCT04276194|Procedure|Magnetic Resonance Imaging|Undergo MRI
75794374|NCT04271436|Device|FDG PET/CT|A single dose of 10 mCi FDG will be given by bolus injection approximately 60 minutes prior to the first planned imaging procedure.
75794375|NCT04271436|Device|FLT PET/CT|. A single dose of 10 mCi FLT will be given by bolus injection approximately 80 minutes prior to the first planned imaging procedure.
75794376|NCT04271436|Device|PET/MR|MR imaging will be performed on a Siemens Biograph mMR or an MRI scanner, if the PET/MR is unavailable.
75794377|NCT04271436|Drug|[F-18] flurothymidine|-Radiopharmaceutical
75794378|NCT04267822|Drug|RV521 oral tablet|Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
75931400|NCT04659408|Dietary Supplement|Multistrain probiotic preparation|One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.
75931401|NCT04659408|Dietary Supplement|Oat Bran|5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.
75931402|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
75931403|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
75931404|NCT02233569|Device|Ventralight ST implant|
75931405|NCT02233569|Device|ETHICON PHYSIOMESH®|
75931406|NCT02582073|Biological|Placebo (0.5ml)|
75646755|NCT04340154|Biological|chimeric antigen receptor T cell|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given twice（anti-CD19 CAR-T first, then anti-CD22 CAR-T). All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
75931407|NCT02582073|Biological|Placebo (1.0ml)|
75931408|NCT02582073|Biological|Grass MATA MPL (0.5ml) 5100SU|
75931409|NCT02582073|Biological|Grass MATA MPL (1.0ml) 10200SU|
75931410|NCT02582073|Biological|Grass MATA MPL (1.0ml) 18200SU|
75931411|NCT02582073|Biological|Grass MATA (0.5ml) 5100SU|
75646756|NCT04310735|Behavioral|Verbal smoking expectancy manipulation|Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.
75646757|NCT04305366|Other|Tissue collection|Blood draw, Fine Needle Aspiration, Saliva Swab, Tumor/tissue sample
75646758|NCT04236388|Dietary Supplement|Ketone drink|Pre- and post-testing will be completed before and after participants receive 42 doses of ketone supplement drink over a 2-week period (3x/day for 14 days).
75646759|NCT04236388|Dietary Supplement|Placebo drink|Pre- and post-testing will be completed before and after participants receive 42 doses of placebo supplement drink over a 2-week period (3x/day for 14 days).
75794379|NCT04267822|Drug|Placebo oral tablet|Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
75794380|NCT04261777|Drug|Ferrotran® (Ferumoxtran-10)|"Ferrotran® in a dose of 0.13 mL/kg body weight of the reconstituted freeze-dried preparation (i.e. 2.6 mgFe/kg body weight). The recommended dose should be diluted in 100 mL of NaCl 9 mg/mL (0.9%) solution for injection/infusion prior to administration via the infusion filter as a slow intravenous infusion over 30 minutes (at a maximum rate of 4 mL/min).~Ferrotran® will be administered once to each patient. Histologically confirmed diagnosis and pre-operative staging are performed prior to the study as part of standard care. Surgery (RP with ePLND) and sampling of tissue specimens is performed after the Ferrotran®-enhanced MRI as part of standard care."
75931412|NCT02769000|Radiation|10 GY in 5 daily fractions|Subjects 1-15 10 GY in 5 daily fractions
75931413|NCT02769000|Radiation|20 GY in 10 daily fractions|Subjects 16-30 20 GY in 10 daily fractions
75931414|NCT02633670|Device|Hemopatch|
75931415|NCT02633670|Device|No Hemopatch|
75931416|NCT00250341|Drug|QVAR|480 mcg
75931417|NCT00250341|Drug|Advair|250/50 mcg
75931418|NCT00250341|Drug|Servent Diskus|50 mcg
75798965|NCT01182090|Procedure|Colposacropexy|In open approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
75931419|NCT03472248|Behavioral|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
75931420|NCT03711903|Drug|Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).|The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
75931421|NCT03711903|Drug|0.9% Sodium-chloride|normal saline
75931422|NCT01995396|Procedure|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
76085631|NCT06036589|Drug|Vehicle and BAM8-22 application|Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
76085632|NCT06036589|Drug|CA|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application to a previously determined area on the volar forearm
76085633|NCT06036589|Drug|vehicle|Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm
76085634|NCT06036576|Drug|Levothyroxine Pill|all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
75646760|NCT04223102|Procedure|Tissue collection|A flexible sigmoidoscopy is a procedure in which a flexible tubularized camera approximately 1 cm in diameter is inserted into the anus and advanced proximally to the sigmoid colon (approximately 20 cm). At that time a rectal biopsy of the tumor will be obtained as well as a sample from >5cm proximal to the tumor, with a separate biopsy forcep. Tattoo injection, as standard of care, will be performed within 1 cm distal to the tumor to identify the location in the future or for surgical intervention. If there is inability to get proximal to the tumor then a location at least 5 cm adjacent in any direction will be sufficient so long as it is grossly normal appearing.
75646761|NCT04222998|Other|Home-based growth charts|The growth chart contains simple information of nutritious food, health, and sanitation information at the top and height chart is located at the bottom where caregivers can measure their child's linear growth. Growth charts will be installed in intervention group homes just after the baseline survey.
75646762|NCT04222998|Other|Home visits for baseline surveys|Households will be visited for baseline surveys.
75646763|NCT04222998|Other|Home visits for end line surveys|Households will be revisited after 1 year of grace-period for baseline end line surveys.
75646764|NCT04222998|Other|Measurement of child's height-for-age and weight-for-age|The child's height-for-age and weight-for-age will be measured for participating dyads at the time of the baseline and end line surveys.
76085635|NCT06036550|Diagnostic Test|Doppler ultrasound measurement|Doppler sonographic assessment of the uterine artery was performed transabdominally. Patients underwent six sets of Doppler ultrasounds measurements of both right and left uterine artery.
75931423|NCT01995396|Procedure|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
75931424|NCT05196633|Other|radial extracorporeal shock wave therapy|rESWT (Endopuls 811; Enraf Nonius B.V. Va-reseweg 127, 3047 AT Rotterdam MedTech, Wessling, Germany) will be applied on the myotendinous junction of both the gastrocnemius and the soleus muscles in post-stroke spasticity patients. 2000 shots will be applied on the gastrocnemius and soleus myotendinous junction with a frequency of 10 Hz and energy density of 60 mJ (1 bar) within tolerable pain limits.
75931425|NCT05196633|Other|sham radial extracorporeal shock wave therapy|The control group will receive sound over the myotendinous junction of gastrocnemius and soleus with transducer-like contact.
75931426|NCT03471000|Other|Short implants Treatment|Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
75931427|NCT03471000|Other|Regular implants Treatment|Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
75931428|NCT03702465|Other|DNA-based dietary intervention|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
75931429|NCT03702465|Other|DNA-based dietary intervention using an app|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
76085636|NCT06036537|Diagnostic Test|diagnosis of Interstitial lung disease|Serum marker detection，High resolution computed tomography scan
75646765|NCT04214093|Drug|AZD0466|"In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort."
75931430|NCT03702465|Other|Control arm|Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
76085637|NCT06036498|Device|Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography|We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.
76085638|NCT06036485|Device|Kerecis Omega 3|Decellularized intact fish skin developed for the management of chronic wounds
75646766|NCT04205513|Device|Medly|Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
75646769|NCT04199091|Procedure|Craniosacral Therapy (CST) self-help techniques|Manual self-help techniques based on Craniosacral Therapy (group setting).
76085639|NCT06036485|Procedure|Surgical debridement|Superficial sharp surgical debridement technique
76085640|NCT06034431|Other|Ride Share|"The Investigators' proposed study addresses the Prostate Cancer Research Program overarching challenge of Advancing Health Equity and Reducing Disparities in PCa by examining and addressing travel burden to PCa treatment centers. Investigators will focus on Black men (including those of Caribbean descent), a high-risk population experiencing poorer health outcomes for unjust and preventable reasons.~This research will inform efforts to reduce travel burden in the healthcare acquisition process and improve the timeliness of treatment in Black men with PCa in Massachusetts and other states. This project will improve the quality of life and enhance outcomes and overall health and wellness for this group. Investigators will use findings from this pilot study to obtain future funding for a multicenter randomized clinical trial that will estimate the effect of equity - oriented programs that remove transportation barriers to treatment and reduce Black-White disparities in PCa outcomes"
76085641|NCT06034405|Diagnostic Test|Tc99-PYP or Tc99-HDMP Scan|Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.
75337067|NCT05760443|Behavioral|Learning to BREATHE|"Learning 2 BREATHE (L2B) is an empirically-supported, manualized mindfulness-based group program (Broderick, 2021). Participants attend 6 sessions of approximately 1.5 hours per session. BREATHE is an acronym: Body, Reflections, Emotions, Attention, Tenderness, Habits, Empowerment; each week's lesson is centered around one of the letters (week 1 encompasses both Body and the overall theme of the sessions, Empowerment). Sample activities of L2B include psycho-education on emotion and self-regulation, body scanning, sitting meditation, non-aerobic yoga, and walking meditation, designed to promote moment-to-moment awareness of mind-body experiences. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants will have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
76085642|NCT06034197|Drug|VGT-309|0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
75646770|NCT04199091|Procedure|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation according to Jacobsen (group setting).
76085643|NCT06034171|Device|dental implant|Dental implant surgery in the lower jawbone.
76085644|NCT06034145|Other|No intervention|No intervention
76085645|NCT06034132|Other|Stock healing abutments|2ND stage surgery will be performed and stock healing abutment were placed
76085646|NCT06034132|Other|Compoiste healing abutments|2ND stage surgery will be performed and composite healing abutment were placed
76085647|NCT06034119|Behavioral|Split belt treadmill|Participants will walk on a dual belt treadmill with each belt moving at a different speed which is known as a split belt treadmill to provide implicit modifications of the walking pattern
76085648|NCT06034119|Behavioral|Biofeedback|The Gait Real-time Analysis Interactive Lab (GRAIL) system has an immersive virtual reality screen that provides real-time information to participants of their walking pattern and provides visual instructions on how to walk more symmetrically
75646771|NCT04196803|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
75646772|NCT04196803|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
75646773|NCT04190953|Other|Twin block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion
75794381|NCT04259424|Device|Aerobic Exercise + Duck Duck Punch|"Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. On each session the target intensity of aerobic exercise will be 70% heart rate reserve.~Following a 10-minute rest break subjects will perform 200 repetitions on an upper extremity rehabilitation game called Duck Duck Punch (DDP). Duck Duck Punch is an interactive game with an old school carnival theme. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. A therapist will oversee the subject's safety and progress during DDP. DDP will be dosed based on the number of repetitions performed. A repetition is recorded when the player moves his/her arm so that the avatar leaves a start position. The goal dose for subjects will be 200 repetitions per DDP session."
75794382|NCT04258332|Dietary Supplement|High Salt Diet|Patients will be randomized to be on a high salt diet for 7 days.
75646774|NCT04190953|Other|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement
75646775|NCT04169568|Procedure|Manual cuff blood pressure|Blood pressure will be obtained using a sphygmomanometer. Only Registered Nurses will apply BP cuff after careful inspection of the upper extremity for bruising, swelling or tenderness.
75646776|NCT04154982|Drug|Acetyl cysteine|1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
75646777|NCT04141449|Other|Potlako intervention|Combined provider, patient, and health system intervention to expedite cancer diagnosis and care.
75794383|NCT04258332|Dietary Supplement|Low Salt Diet|Patients will be randomized to be on a low salt for 7 days.
75931431|NCT02233725|Device|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
75931432|NCT05157204|Procedure|measurment of interleukin-6 at exhaled condensate|the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants
75646778|NCT04141449|Other|Enhanced care|Provider education and limited patient counseling.
75646779|NCT04124029|Device|No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.|No intervention will be used.
75931433|NCT02236299|Procedure|Right Coronary Artery Percutaneous Coronary Intervention|
75931434|NCT02236299|Other|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
75931435|NCT02236299|Other|GLP-1 Infusion|30 minute infusion GLP-1
75931436|NCT02236455|Behavioral|Audio Relaxation Technique|Audio relaxation technique created by an Icelandic Registered Nurse.
75931437|NCT02236455|Behavioral|Medical Music Intervention|Audio recordings of non-lyrical relaxing music
75931438|NCT02236455|Behavioral|Nature Therapy without Music|Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
76085649|NCT06034106|Behavioral|Pomegranate (Punica granatum) peel compress|Pomegranate (Punica granatum) peel compress was applied 3 days a week for 3 weeks by turning the powder into porridge check.
75794384|NCT04251481|Radiation|PET/MRI with FDG|For the PET/MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for both the MRI and PET portions of the examination. The dye for the PET portion will be 18F-fluorodeoxyglucose (FDG). FDG is an FDA-approved radioactive substance (isotope) that contains chemicals that can be traced by PET/MRI. The dye for the MRI portion will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
75794385|NCT04251481|Radiation|MRI scan without contrast|MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner to scan the neck ; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
75931439|NCT02236455|Behavioral|Nature Therapy with Music|Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
75931440|NCT02578095|Drug|VK5211|Capsule
75337068|NCT05753982|Other|Kinesiotape placement|Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
75337069|NCT05743426|Other|Survey|Patient Reported Outcome (PRO) questionnaire
75337070|NCT05743426|Other|Toxicity Assessments|Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).
75931441|NCT02578095|Drug|Placebo|Capsule
75931442|NCT00545766|Drug|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
75337071|NCT05735912|Procedure|Endoscopic ultrasound-guided radio frequency ablation|Radiofrequency ablation performed under endoscopic ultrasound guidance of pancreatic insulinoma
75337072|NCT05735912|Procedure|Surgery|Surgical resection of pancreatic insulinoma
75931443|NCT02262819|Drug|S. aureus|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
75337073|NCT05727839|Drug|JCXH-211 Injection|JCXH-211 administered once every 28 days
75473100|NCT01966393|Other|60-hours intervention|Interventions will be conducted at the research centre (RC) or at the patient's home based on the patient's preference. If the study takes place at the RC, patients will be admitted at 7:00. If the study takes place at the patient's home, a research team member will be at the patient's home at 7:00. Closed-loop strategy will start at 8:00 on day 1 and end at 20:00 on day 3. During the interventions conducted at the RC, patients will have access to entertainment activities such as movies, video games, board games, foosball, etc. During the interventions conducted at the patient's home, patients will do their usual activities. For interventions conducted at the RC, patients will freely choose their meals from a large choice of prepared frozen meals. For interventions conducted at the patient's home, patients will freely choose their meals. Participants will be encouraged to conduct their usual physical activities whether they conduct the study at the RC or at the patient's home.
75931444|NCT02236533|Dietary Supplement|whole grain pasta|Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
75473101|NCT01966406|Device|Nasogastric tube|
75931445|NCT05156970|Drug|Camrelizumab|Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months
75931446|NCT05156970|Drug|Cisplatin|Cisplatin 75 mg/m^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
75931447|NCT05156970|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
76085650|NCT06034106|Behavioral|Hot compress|Hot compress was applied 3 days a week for 3 weeks.
76085651|NCT06034093|Device|Real-time AI-assisted muscle ultrasound|RAIMUS software provides automatic segmentation and size measurement for the RFCSA
76085652|NCT06034080|Other|Changes to the electronic health record (EHR)|"EHR changes will include minor changes to prescription fields to make it easier for clinicians to order wait and see antibiotics to be filled only if the child worsens or does not improve rather than antibiotics to take immediately."
76085653|NCT06034080|Other|Individualized audit and feedback reporting for clinicians|Automated audit and feedback reports detailing participating clinicians' antibiotic prescribing habits for AOM both individually and in comparison to their peers will be shared with clinicians on a quarterly basis throughout the intervention period.
76085654|NCT06034080|Other|Clinician education sessions|Virtual education sessions will be held for clinicians to learn more about national guidelines for antibiotic prescribing for AOM, etc. The sessions will be recorded and distributed to clinicians who were unable to attend. Attendance of these sessions will apply toward continuing medical education credits for participants.
75337074|NCT05719194|Other|Standard SBT|Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.
75473102|NCT01966406|Other|No nasogastric tube|
75473103|NCT01966484|Drug|Succinylcholine|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
75646780|NCT04124029|Procedure|No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.|No intervention will be used.
75931448|NCT05156970|Drug|Apatinib Mesylate|Apatinib 250mg qd for up to 24 months
75931449|NCT05156970|Drug|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)
75931450|NCT02233881|Drug|Atrovent® - inhalets|
75931451|NCT00157755|Device|Enterra Therapy|Gastric electrical stimulation using Enterra Therapy.
75931452|NCT02261571|Other|Moxibustion|"In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.~The moxibustion will be removed when the patient feel hotness and require remove them"
75337075|NCT05719194|Other|SBT with T-piece or PSV|"- Risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.~If it increase by more then 5% then it signs a weaning induced pulmonary oedema.~Step 3 : Reconnect the patient to the ventilator for 1 hour and then extubate if SBT is successful.~If SBT failed or WIPO : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.~- No risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.~Step 3 : Reconnect the patient to the ventilator for 1 hour and then extubate if SBT is successful."
75337076|NCT05716477|Procedure|Biospecimen Collection|Undergo blood sample collection
75337077|NCT05716477|Other|Survey Administration|Complete survey
75931453|NCT02234037|Drug|Decitabine|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
75931454|NCT02234037|Behavioral|Exercise|Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise > 10 minutes of muscle strengthening, > 10 minutes of aerobic exercise (treadmill walking or cycling), > 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
75931455|NCT04476771|Behavioral|Feliz-Mente (third generation psychotherapy)|The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
75337078|NCT05676658|Behavioral|Coherent breathing|Guided audio of coherent breathing pre-recorded by trained breathwork facilitator: ~5.5bcpm (with equal inhalation/exhalation durations of ~5.5secs each) for ~10mins/day over four weeks / 28 days. Delivered remotely through audio link.
75337079|NCT05676658|Behavioral|Placebo coherent breathing|Same audio of coherent breathing but paced at: ~12bcpm (with equal inhalation/exhalation durations of 2.5secs each) for ~10mins/day over four weeks / 28 days.
75337080|NCT05666011|Device|M22 IPL|IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.
75473104|NCT01966484|Drug|Mivacurium|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
75931456|NCT02234193|Device|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
75931457|NCT02234193|Procedure|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
75931458|NCT04476459|Drug|Camrelizumab|Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.
75931459|NCT04476459|Drug|Apatinib|"Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase."
75931460|NCT02262897|Drug|Nab-paclitaxel|Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
75931461|NCT02653599|Drug|TTP273|
75931462|NCT02653599|Drug|Placebo|
75931463|NCT02653443|Biological|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
76085655|NCT06034080|Other|Use of a shared decision-making (SDM) aide|A previously validated SDM aide for AOM will be used by clinicians during visits with children with AOM. The aide will be available online and in paper form.
75337081|NCT05658237|Procedure|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
76085656|NCT06034080|Other|Shared decision-making (SDM) education|Clinicians will receive education on SDM and how to use the aid via virtual, recorded sessions.
75473105|NCT01966510|Other|Cord Blood Transplantation|
75646781|NCT04119414|Behavioral|Spear and Shield (S&S) Program|The S&S Program is a comprehensive sexual risk reduction intervention consisting of 4 weekly 90-minute manualized group sessions conducted by a trained Community Health Center (CHC) facilitator.
75337082|NCT05644756|Behavioral|IMPACT Methods to Identify and Prioritize Determinants (Challenge I), Challenge and Match strategies to Prioritized Determinants (Challenge II)|IMPACT Center developed two methods for identifying determinants that involved providers, staff, and youth at community mental health centers in site visit 1: Rapid Ethnographic Assessment, Design Probes. Then, practice partners engage in a facilitated group activity to rate the criticality, chronicity, and ubiquity of the list of determinants in Site Visit 2. Finally, practice partners engage in a third site visit where they create Causal Pathway Diagrams that allow them to match strategies to prioritize determinants and create Implementation Plans.
75337083|NCT05638594|Drug|Pyrotinib|320mg, qd
75337084|NCT05638594|Drug|Trastuzumab|8 mg/kg first dose, then 6 mg/kg，q3w
75794386|NCT04251481|Radiation|MRI with gadolinium|For the MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for MR scans. The dye for the MRI will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
75794387|NCT04250805|Drug|Lidocaine|Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
75337085|NCT05638594|Drug|Dalpiciclib|125mg , qd，d1-21, q4w
75337086|NCT05638594|Drug|Letrozole|2.5mg，qd
75337087|NCT05638594|Drug|Pertuzumab|840 mg first dose, then 420 mg, q3w
75337088|NCT05638594|Drug|Docetaxel|75 mg/m2, q3w
75337089|NCT05638594|Drug|Carboplatin|AUC 6, q3w
75337090|NCT05638594|Drug|Gonadotropin-releasing hormone agonist|Every 4 weeks for 5 cycles, premenopausal patients only
75473106|NCT01966523|Behavioral|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
75794388|NCT04250805|Drug|Ropivacaine|Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
75931464|NCT02653443|Biological|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
75931465|NCT02723006|Drug|TAK-580|TAK-580 tablets
75931466|NCT02723006|Drug|TAK-202|TAK-202 infusion
75931467|NCT02723006|Drug|vedolizumab|vedolizumab infusion
75931468|NCT02723006|Drug|nivolumab|nivolumab infusion
75931469|NCT02723006|Drug|ipilimumab|ipilimumab infusion
75337091|NCT05638152|Other|implementation of a bundle of non-pharmacological interventions aimed at stress reduction|"The bundle consists of 4 interventions:~natural imagery in the PACU (wall length decorations and lighted ceiling panels with sky views~Aromatherapy with fragrances selected for anxiolytic and antiemetic properties~Music available to patients~Comfort Talk communication course for PACU nurses"
75337092|NCT05620368|Behavioral|Mindfulness and Compassionate Living Course (MCLC)|"The course will be held online (using the Zoom platform) with weekly sessions lasting 2.5 hours each, as well as a day of silent practice (mini-retreat of 4 hours) between sessions 6 and 7.~On the structural level, every course session consists of four elements: (1) an educational input, (2) mindfulness and compassion exercises (eg, sitting meditation, body scan, mindful walking, self-compassion break), (3) a reflection of one's practice (inquiry), (4) and home assignments."
75473107|NCT01966523|Other|Control|
75794389|NCT04242901|Diagnostic Test|Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo|Quantitative Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
75931470|NCT03308630|Behavioral|Yoga based Energy Alignment and Mantra|"Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated."
75931471|NCT03308552|Radiation|SIB-IMRT|PTV:50.4Gy/28f, PGTV:59.92Gy/28f
75931472|NCT03308552|Drug|Paclitaxel|45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
75931473|NCT03308552|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
75931474|NCT03308552|Drug|Paclitaxel|150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
75931475|NCT03308552|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
75931476|NCT03308318|Procedure|The supratemporalis approach|The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
75931477|NCT03308240|Behavioral|Magic Therapy|As described in the arm description
76085657|NCT06034054|Other|nursing counceling|"Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~Answering the information and questions that the patient needs in addition, and receiving contact information in October.~Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive."
75931478|NCT03308162|Behavioral|Cognitive behavioral experiential group therapy|The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
76085658|NCT06034041|Drug|Mediclore|After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
76085659|NCT06034041|Drug|Normal Saline|After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
76085660|NCT06034015|Drug|APL-1202 and APL-1501 (Single ascending dose)|Period 1 drug adminstration (APL-1202 IR tablet , single dose of 375mg will be administered orally on Day 1; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered as single dose on Day 4.
76085661|NCT06034015|Drug|APL-1202 and APL-1501 (Multiple Ascending dose)|Period 1 drug adminstration (APL-1202 IR of 375mg will be administered thrice a day (TID) orally from Day 1 to Day 5; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered twice daily (BID) from Day 9 to 13.
76085662|NCT06033989|Drug|Hyaluronic acid|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
75337093|NCT05620368|Behavioral|Usual care intervention|"If necessary, psychological support is organized at the request of the parent.~Support includes individual support of a psychologist (1h / week), consultation with a teacher (special pedagogue and early school education teacher, 1h / week), individual consultation with observation of a child with a Venetian mirror (1h / week)."
75337094|NCT05612672|Other|GeoHAI|A Geographic healthcare-associated infection (HAI) visualization and assessment tool (GeoHAI) which uses spatio-temporal Bayesian models to identify clusters of National Healthcare Safety Network (NHSN)-defined hospital onset Clostridium difficile (CDI) and multidrug resistant organisms (MDRO), and predict potential high risk areas given hospital and patient risk factors.
75337095|NCT05590702|Drug|First line therapy|"Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).~Patients will be treated and managed according to the decision of their physicians and the related MDM. No treatment plan is recommended in the setting of this non-interventional study."
75473108|NCT01966536|Procedure|CD133+ cells transplantation into ovarian artery of one ovary|
75646782|NCT04119414|Behavioral|Like Father Like Son (LFLS) Program|The LFLS Program is a private 2 90-minute session conducted by a trained CHC facilitator. The sessions will be focused on exploring issues relevant to parental decision making related to voluntary medical male circumcision (VMMC) and early infant male circumcision (EIMC). Session 1 will be conducted antenatal and Session 2 will be immediately post-partum.
75646783|NCT04113616|Drug|KRT-232|KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
75646784|NCT04113616|Drug|Cytarabine|Cytarabine is an anti-cancer chemotherapy drug taken via injection.
75931479|NCT03308084|Drug|Methylprednisolone|Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
75646785|NCT04113616|Drug|Decitabine|Decitabine is an anti-cancer chemotherapy drug taken via injection.
75931480|NCT03308084|Drug|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
75931481|NCT02468492|Biological|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
75931482|NCT02468492|Other|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
75931483|NCT00702962|Drug|Vorinostat, Carboplatin, Etoposide|"Study originally a Phase I standard dose escalation of the study medication Vorinostat with sequential cohorts of 3-6 participants entered to 3 dose levels (200mg, 300mg, 400mg). Dose escalation stopped after participant 1 on dose level 2 due to recently published research identifying an appropriate dosing regimen. A set dose was then to be administered to all subsequent participants. This regimen (a cycle) consisted of Vorinostat on Day 1 through Day 4, Carboplatin AUC 6 on Day 3, and Etoposide 100 mg/m2 on Day 3 through Day 5. Treatment cycles were repeated every 21 days (3 weeks) for 4 cycles total."
75931484|NCT01379508|Drug|telbivudine|600 mg film-coated tablets taken as 600 mg once daily
75931485|NCT01379508|Drug|tenofovir disoproxil fumarate|300 mg tablets taken as 300 mg once daily
76085663|NCT06033989|Drug|sandblasted, and acid-etched|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
76085664|NCT06033989|Procedure|Delayed dental implant|Surgical procedure of delayed dental implant in posterior maxilla after application of surface treatment to enhance Osseointegration and healing .
76085665|NCT06033976|Procedure|Endoscopic submucosal dissection (ESD)|Endoscopic injection of fluid into the gastrointestinal submucosal space followed by endoscopic knife dissection around and under the lesion so as to remove the lesion specimen in one piece with lesion free resection margins.
76085666|NCT06033937|Device|PFO occlusion|Patients in PFO occlusion group received PFO closure using devices.
75646786|NCT04040231|Biological|Galinpepimut-S|Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.
75646787|NCT04040231|Drug|Nivolumab|Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.
75646788|NCT04040231|Biological|Sargramostim|All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle
75646789|NCT04026256|Drug|Teriparatide|teriparatide daily subcutaneous injection
75646790|NCT04026256|Drug|Denosumab|denosumab subcutaneous injection
75794390|NCT04239144|Procedure|Bilateral sympathectomy|Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.
75931486|NCT03300206|Device|Breast Biopsy|A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
75931487|NCT03300128|Behavioral|Incredible Years - ASD|The IY-ASD intervention is designed for parents of children with autism spectrum disorder. The programs uses a mix of videos, collaborative brainstorming sessions, and role plays to deliver content on child-directed play and positive discipline practices.
75931488|NCT03300128|Other|Circle of Parents|"Circle of Parents is an open parent support group led by a parent leader. Participants are encouraged to share resources and other support both during groups, and between meetings."
75931489|NCT03299972|Dietary Supplement|Whey Protein|25 g whey protein supplementation twice daily (breakfast and lunch)
75931490|NCT03299972|Dietary Supplement|Control|23.75 g maltodextrin twice daily (breakfast and lunch)
75931491|NCT03299972|Other|Resistance Exercise|60 minutes of resistance exercise twice a week
75931492|NCT02261649|Device|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
75931493|NCT02261649|Procedure|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
75931494|NCT02261649|Device|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
75931495|NCT02261649|Other|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
75931496|NCT03299894|Procedure|systematic calculation of qSOFA|calculation of qSOFA for each patient
75931497|NCT05129397|Behavioral|Mom Power|Virtual Mom Power is a manualized multi-family group intervention consisting of 10 virtual group + 2 individual sessions led by two masters-level co-facilitators. Virtual groups are 90 minutes, following a structured format via secure HIPAA compatible video platform. The curriculum includes 5 core components: (1) Attachment-Focused Parenting Education; (2) Self-Care; (3) Parenting Practice (4) Social Support; & (5) Connection to Resources. Individual sessions combine motivational interviewing with MP core components and focus on identifying goals and barriers. Weekly between-group phone/text check-ins are also a part of the curriculum, used to strengthen connection, build trust, ensure safety, and assess basic needs.
75931498|NCT05129397|Behavioral|Mom Power Informational Mailing|This active comparison condition intervention includes two individual sessions along with 10 weeks of informational mailing with content related to Mom Power core concepts.
75931499|NCT04377672|Biological|Anti-SARS-CoV-2 Human Convalescent Plasma|"1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL."
75931500|NCT02263053|Procedure|POSTERIOR MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
75931501|NCT02263053|Procedure|CAUDAL MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
75931502|NCT03299738|Biological|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg
75931503|NCT04457934|Drug|Plenvu|All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines
75931504|NCT05726630|Drug|Divozilimab|anti CD20 monoclonal antibody
75931505|NCT05726630|Drug|Placebo|Placebo
75931506|NCT04306146|Drug|CAD-9303|Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
75931507|NCT04306146|Drug|Placebos|Capsules
75931508|NCT02558439|Drug|CNTX-4975|
75931509|NCT02558439|Other|Placebo|
75931510|NCT05162430|Drug|Propofol|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg, kg, 0.5mg/kg Propofol was injected to five groups of P1, P2, P3, P4 and P5, respectively, and 5mg dexamethasone sodium phosphate was given to groups P1, P2, P3, P4, P5 and D1 after 30s
75646791|NCT03984643|Device|Vim-Deep Brain Stimulation|This study consists of testing additional model-derived DBS settings during initial and regular follow-up clinical visits every 6 months for up to 2 years in which individuals with DBS implants are re-evaluated by a clinician to make sure that the stimulation settings employed during the previous clinical visit remain therapeutic. It is important to note that this study is post-surgical and all procedures (i.e. stimulation settings that will be tested in the clinic) are within the FDA-approved range of stimulation settings available on the implanted pulse generator.
75646792|NCT03955250|Behavioral|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
75646793|NCT03955250|Behavioral|Mobile app attention control|The control app provides ecological momentary assessment and psychoeducation about illness.
75931511|NCT05031026|Drug|Dexmedetomidine|dexmedetomidine infusion rule in prevention of IRI
75931512|NCT05031026|Drug|Normal Saline|normal saline infusion as a placebo
76085667|NCT06033924|Behavioral|Walking Program: Internet-based|Internet pages allow participants to see step-count goals, progress over time and access to walking tips for 12 weeks. Among participants who do not increase their step counts (>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
76085668|NCT06033924|Behavioral|Walking Program: Telehealth-based|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator for 12 weeks. Among participants who do not increase their step counts (>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
75794391|NCT04239144|Procedure|Catheter ablation|Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
75794392|NCT04233190|Drug|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg|one inhalation, twice daily
76085669|NCT06033846|Drug|Minocycline|treatment with minocycline combined with first/second-line drugs for autoimmune encephalitis
76085670|NCT06033794|Device|Fluorescence laparoscopic system|Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
75931513|NCT05156502|Device|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina and vestibule, following the IFU of the device.
76085671|NCT06033755|Other|Norwegian psychomotor physiotherapy|"The intervention consisted predominantly of Norwegian Psychomotor Physiotherapy (NPMP) in which participants received individually tailored treatment based on the body examination and reported respiratory distress. NPMP addresses bodily tension, postural de-alignments and dysfunctional breathing patterns. The consultations also included a cognitive dimension, that is a conversation, in which thoughts and behaviours about training and competing were addressed and where participants were provided with self help measures that could improve breathing during training and competing. A rehabilitation plan for each participant was designed to limit further impairments and maintaining aerobic capacity without intensifying EILO symptoms. The intervention lasted 5 months."
76085672|NCT06033742|Drug|HS-10374 tablets|Single or multiple dosing of HS-10374 orally in a fasting state
75473109|NCT01966562|Behavioral|WHOLE-BODY VIBRATION TRAINING|The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
75794393|NCT04231578|Behavioral|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson & Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
75794394|NCT04225507|Behavioral|Diet and exercise coaching|All participants will receive diet and exercise goals and coaching.
75794395|NCT04225507|Other|CPAP Treatment|CPAP treatment for sleep apnea and CPAP education and adherence coaching.
75794396|NCT04214834|Drug|Morphine|Rapid-wean: 176 treated Slow-wean: 75 treated
75794397|NCT04214834|Drug|Methadone|Rapid-wean: 176 treated Slow-wean: 75 treated
75794398|NCT04207281|Dietary Supplement|Raw Honey|Canada #2 white raw honey (1.5 tablespoons) supplied by SweetHeart Pollinators (Janeil Enterprises, Eatonia, SK) administered for 7 days
75794399|NCT04207281|Dietary Supplement|Comparator|Honey comparator(1.5 tablespoons) administered for 7 days
75931514|NCT05156502|Device|Fractionated Laser (Pixel CO.2-Alma)|Device: Fractionated Laser (Pixel CO2-Alma) The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina only, following the IFU of the device.
75794400|NCT04181788|Drug|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.
75931515|NCT02615067|Drug|99mTc-MIP-1404 Injection|A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
75337096|NCT05585684|Other|Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection|Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
75337097|NCT05585242|Behavioral|Infertility ACTion Program|Seven 15-minutes videos of Acceptance and commitment therapy adapted for women with infertility with assigned homework and summaries of the videos.
75931516|NCT02615067|Diagnostic Test|Whole-Body Planar and pelvic SPECT/CT scan|A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
76085673|NCT06033742|Drug|HS-10374-matched placebo tablets|Single or multiple dosing of HS-10374-matched placebo orally in a fasting state
76085674|NCT06033729|Drug|Remifentanil TCI|REMI-TCI administration begun 5 minutes before the procedure, starting from an initial target at the effect site of 1 ng/ml and gradually increasing by 0.5 ng/ml until reaching an adequate level of sedation (Ramsey score between 2-3).
76085675|NCT06033729|Drug|Midazolam injection|Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached
75936489|NCT02425358|Other|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
76085676|NCT06033729|Drug|Fentanyl|Bolus adminitration of fentanyl (50-100 mcg) until a Ramsey score 2-3 was reached
76085677|NCT06033729|Drug|Propofol|Bolus adminitration of propofol until a Ramsey score 2-3 was reached
76085678|NCT06033716|Other|Measurement correlation variable|resilience and anxiety and depression
76085679|NCT06033690|Behavioral|multidisciplinary guide|use of the food guide for education, clarification of doubts
75794401|NCT04181684|Device|Procedure: LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
75794402|NCT04181684|Radiation|Hypo-Fractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
75473110|NCT01966562|Behavioral|MULTICOMPONENT TRAINING|This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
75473111|NCT01966575|Drug|Progestin|The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
75337098|NCT05570617|Behavioral|Transition Coach Intervention|The Transition Coach Intervention will include 8, 1-hour sessions over 6-months. The transition coach will independently meet one-on-one with each youth using an individualized, patient-centred approach beginning with an introductory session, followed by 5 sessions covering each topic in the Youth Transition Roadmap. These topics include: Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. The clinical psychologist will lead 2 sessions beginning with the Patient Health Questionnaire for Anxiety and Depression as a screening tool. The clinical psychologist will discuss psychological and social well-being in the context of their disease covering personally relevant issues/concerns.
75473112|NCT01966588|Other|Blood samples for whole genomic/transcriptomic sequencing|Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
75473113|NCT01966588|Other|UKU Side Effect Rating Scale|Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
75794403|NCT04173221|Other|Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
76085680|NCT06033651|Radiation|x-ray|A sample of blood will be taken and sent to a lab in Surrey to check for metal ions.
75473114|NCT01966614|Drug|PRX302|Single intraprostatic bilateral injection at a dose of 0.6 µg/g
75473115|NCT01966614|Other|Placebo|Single intraprostatic bilateral injection of vehicle only
75473116|NCT01966627|Other|ogtt|oral glucose tolerance test
75473117|NCT01966627|Other|genotyping|genotyping to look for risk alleles
75473118|NCT01966627|Other|abdominal and liver magnetic resonance imaging|magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
75794404|NCT04173221|Other|Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
76085681|NCT06033612|Drug|RV299|Oral Suspension
75473119|NCT01966627|Other|stool sample|stool sample taken to investigate metabolites
75794405|NCT04161118|Drug|CTL019|IV Infusion
75794406|NCT04159480|Device|Experimental - Cogito Companion|Cogito Companion
75794407|NCT04159480|Behavioral|Active Control|Use of MyCAP
76085682|NCT06033612|Drug|Placebo|matching placebo
76085683|NCT06033612|Drug|Midazolam|pre-filled oral syringe
76085684|NCT06033599|Other|MORE and MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.
76085685|NCT06033599|Other|MORE and No MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.
76085686|NCT06033599|Other|Support Group and MI and NRT|Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.
76085687|NCT06033599|Other|Support Group and No MI and NRT|Eight group support group sessions and and nicotine replacement therapy.
76085688|NCT06033573|Diagnostic Test|contrast-enhanced spectral mammography|After enrollment, subjects should undergo contrast-enhanced spectral mammography again within 4-6 hours post completing previous routine ductography to obtain a late-phase ductal image, which contains a low-energy image and a subtracted image obtained from the post processing
76085689|NCT06033560|Device|High flow nasal oxygen (HFNO, more than 15 L/min)|Non-invasive respiratory support strategy
76085690|NCT06033547|Drug|Cabotegravir Formulation F|Cabotegravir Formulation F will be administered
76085691|NCT06033547|Drug|Cabotegravir Formulation G|Cabotegravir Formulation G will be administered
76085692|NCT06033521|Drug|Menopausal hormone therapy Intervention Type: Drug|Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
75931517|NCT05006612|Procedure|Serratus Anterior Plane Block|"SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle."
75931518|NCT05005520|Drug|DTRI-031|Investigational drug
75646794|NCT03954717|Behavioral|Shepherd CAN DO Program|CAN DO Shepherd is a four-day participatory program held at the Shepherd Center, in Atlanta, Georgia or people with MS. The four-day program comprises evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a health life beyond their MS.
75337099|NCT05570617|Behavioral|Standard of Care- Youth Transition Roadmap|All participants will receive the Youth Transition Roadmap (standard of care) which discusses 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. This is an informational pamphlet and will not require any additional meetings with the patient beyond their normal healthcare interactions
75794408|NCT04137900|Drug|TAB004|Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection
76085693|NCT06033482|Procedure|The reasonable range of No.12a lymph node dissection|The lymph node overlying the proper hepatic artery is defined as No.12aa. The lymph node overlying the left side of the portal vein is defined as No.12av. Observation of lymph node metastasis rates in two groups.
75337100|NCT05563909|Other|Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
75337101|NCT05563909|Other|Wrist Splint|Patients participating in the study will not receive any intervention other than exercise and splint.
75794409|NCT04137900|Drug|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
75794410|NCT04130737|Device|TORUS Stent Graft System|The TORUS Stent Graft is an intravascular prosthesis intended to improve blood flow in the area in which it is implanted and the TORUS Stent Graft Delivery System is a standard pin-and-pull delivery system used to implant the SG in the desired area. Use of the TORUS Stent Graft allows for improving blood flow in the peripheral vasculature.
75794411|NCT04121897|Other|Therapist Education and Massage for Parents of Extremely Preterm Infants|"TEMPO includes these components:~Early Parent Education Session~Weekly Parent Education Sessions~Infant Massage Parent Education Sessions~Discharge Parent Education Session~Parent Education Post-Discharge~Bi-weekly emails (or texts)~2 Month Follow-up Massage Review Session"
75337102|NCT05563909|Other|Virtual Reality Mediated Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
75337103|NCT05553470|Drug|Miricorilant|600 mg miricorilant
75794412|NCT04120194|Biological|NanoFlu|Investigational quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
75794413|NCT04120194|Biological|Fluzone Quadrivalent|Licensed quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
75337104|NCT05545839|Behavioral|Transition coaching|Transition coaching sessions (8 sessions), covering paediatric to adult care, self-advocacy, medication management, general health, lifestyle and behaviours, future planning, screening for mood disorders and coping skills.
75473120|NCT01966627|Other|liver biopsy|liver biopsy to examine for cellular change and steatosis
75794414|NCT04119570|Behavioral|CKD Report Card|The CKD Report Card is a handout based on a NKDEP Educational Sheet that includes basic information about kidney disease and spaces where patient can record information about their own kidney disease
75473121|NCT01966653|Drug|nitrofurantoin|nitrofurantoin 100 mg po tid for 5 days
75473122|NCT01966653|Drug|fosfomycin|fosfomycin 3g po single dose
75473123|NCT01966666|Drug|TPI-287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
75473124|NCT01966666|Drug|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
75473125|NCT01966666|Drug|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
75473126|NCT01966666|Drug|Placebo|500mL 0.9% sodium chloride.
75473127|NCT01966679|Drug|AZD7325|
75646795|NCT03928288|Drug|Cabergoline 0.5 MG|Medication
75646796|NCT03928288|Drug|Placebo - Cap|Placebo capsule
75646797|NCT03925883|Behavioral|Patient navigation|Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy
75646799|NCT03789604|Biological|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
75794415|NCT04119037|Procedure|Cordotomy|Undergo cordotomy
75931519|NCT05005520|Drug|Placebo|Matching placebo to DTRI-031
75936490|NCT02425358|Other|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
76085694|NCT06033469|Drug|Infliximab|Pediatric patients with IBD suitable for treatment with infliximab
76085695|NCT06033469|Drug|Adalimumab|Pediatric patients with IBD suitable for treatment with adalimumab
76085696|NCT06033456|Procedure|Radiofrequency stellate ganglion block using ultrasound guidance (SGB)|"Visualization of C6-C7 level will be targeted under fluoroscopic posterior-anterior (PA) guidance. Skin will be infiltrated with 1% lidocaine using a 25-gauge needle. Next, the RF needle will be inserted under a trajectory approach toward the target. Then, with ultrasound guidance, using a superficial linear ultrasound probe to guide further needle penetration so that the needle-tip will lie anterior to the longus colli muscle, the exclusion of vascular structures will be confirmed by duplex(8).~Then, 5 to 1 mL of omnipaque dye (iohexol) will be injected. Subsequently, a 100 mm length Baily RF electrode will be inserted and connected to the generator. The RF needle will be positioned alongside the stellate ganglion in the thermal RF technique. With repeated sensory and motor stimulation before RF lesioning"
75337105|NCT05516771|Device|Tcore™ system|"The Tcore sensor is a double-sensor-heat-flux (DHF) thermometer and consist of two sensors separated by a known thermal resistance. One side is placed directly at the patient's skin and the other is facing the environment. After some equilibration time the core temperature can then be calculated. The sensors are placed above the eye and the sinus frontalis.~Intended use The Tcore system is a thermometer intended for non-invasive, continuous measurement of the core body temperature of children from 5 years of age, adolescents, and adults. The Tcore system consists of a sensor and an adapter. The adapter is reusable. The sensor is intended for single use. The Tcore system works in adjusted mode, i.e., the core body temperature is determined by a dual sensor.~Off-Label/Investigational Use In context of this clinical study the Tcore-system will be investigated outside its approved and intended use, namely in children below the age of five and toddlers."
75473128|NCT01966679|Drug|Placebo|
75473129|NCT01966692|Drug|Fluticasone Propionate Formulation 1|Fluticasone Propionate dry powder inhaler Formulation 1
75646800|NCT03789604|Biological|CS1001 placebo|Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
75473130|NCT01966692|Drug|Fluticasone Propionate Formulation 2|Fluticasone Propionate dry powder inhaler Formulation 2
75646801|NCT03767348|Biological|RP1|Genetically modified herpes simplex type 1 virus
75646802|NCT03767348|Biological|nivolumab|anti-PD-1 monoclonal antibody
75646803|NCT03765307|Device|SyMap Bronchial Ablation System|The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
75646804|NCT03765307|Device|Boston Scientific Alair System|The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
75646805|NCT03762265|Drug|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
75646806|NCT03762265|Drug|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
75931520|NCT05162352|Drug|Donafenib+sintilimab|"Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle.~Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.~Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity."
75646807|NCT03735420|Drug|Xanthohumol|The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
75646808|NCT03735420|Drug|Placebo oral capsule|The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
75646809|NCT03721393|Device|Wearable heart monitor|Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
75646810|NCT03718832|Other|Fresh Food Farmacy|Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
75794416|NCT04119037|Drug|Morphine|Given via injection
75931521|NCT04490408|Procedure|long surgical bypass|long surgical bypass and hybrid approaches in patients with multilevel critical lower limb ischemia.
75646811|NCT03704051|Behavioral|Mode of Feeding (breastfeeding versus bottle-feeding)|Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
75646812|NCT03662074|Drug|Gemcitabine|Given IV
75646813|NCT03662074|Biological|Nivolumab|Given IV
75646814|NCT03642938|Behavioral|Walking Exercise|Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.
75646815|NCT03642938|Behavioral|Control|The Control group will perform 30 minutes of quiet rest.
75794417|NCT04119037|Other|Questionnaire Administration|Ancillary studies
75794418|NCT04119037|Procedure|Sham Intervention|Undergo fake cordotomy
75794419|NCT04109937|Radiation|External beam radiation therapy|The post-operative radiation will cover entire prosthesis/surgical fixation device and will consist of the dose fractionation of: 20 Gy in 5 fractions or 30 Gy in 10 fractions.
75794420|NCT04108455|Other|Specimens Collected|Serum will be collected from patients at multiple times during pregnancy for later analysis.
75794421|NCT04103359|Other|Physiological tests to measure fatigue level|Physiological tests to measure fatigue level
75794422|NCT04090853|Device|Venus Bliss|The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
75931522|NCT04490408|Procedure|Hybrid approach|Hybrid approach including bypass and endovascular revascularization
75931523|NCT05087121|Behavioral|Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F)|The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) 6-week training course has been derived from existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group therapy protocols. Participants in this intervention will receive psychoeducation on sleep and practice skills standard of CBT-I including, stimulus control techniques, sleep restriction, counter-arousal skills, cognitive restructuring, sleep hygiene, goal setting, and relapse prevention skills. Weekly sessions will include discussions regarding difficulties specific to occupational barriers and how to mitigate the impact of occupational requirements on sleep quality.
75931524|NCT05087121|Device|Fitbit Inspire HR Wrist Worn Device (NCT04176926)|"The Fitbit Inspire HR wrist worn device will be worn by eligible participants throughout the duration of the intervention and for two weeks following completion of the 6-week intervention to collect objective data on enduring sleep changes. This device is an FDA-registered medical device that is not the object of investigation and is being used on label only to gather data.~501(K) Number: K200948 Device Name: Fitbit ECG App Regulation Number: 870.2345 Classification Product Code: QDA Clinical Trials: NCT04176926"
75931525|NCT05156424|Other|Exercise|An individualised, progressive and autoregulated exercise programme, supervised by a trained professional.
75931526|NCT03307928|Diagnostic Test|Cardiopulmonary Exercise Test Protocol|The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.
75936491|NCT02425358|Other|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
75936492|NCT02425358|Other|PCI only|The saline was intracoronary infusion with the use of microtubular.
75646816|NCT03635632|Genetic|C7R-GD2.CART cells|"Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10^7 on day 0 and day 7~Dose Level 3b = 1 x 10^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI."
75646817|NCT03602859|Drug|Niraparib|Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg).
75646818|NCT03602859|Drug|Dostarlimab (TSR-042)|Participants will receive 30 minutes intravenous (IV) infusions of 1000 mg dostarlimab on Day 1 every 6 weeks.
75646819|NCT03602859|Drug|Standard of care|Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
75646820|NCT03602859|Drug|Dostarlimab-Placebo|Participants will receive 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
75794423|NCT04089111|Other|Minute volume target of 100%|Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).
75794424|NCT04089111|Other|Minute volume target to reach PaCO2 less than 45% (high tidal volume)|Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
75794425|NCT04072809|Other|No intervention|This study does not involve any interventions.
75473131|NCT01966692|Drug|Fluticasone Propionate Formulation 3|Fluticasone Propionate dry powder inhaler Formulation 3
75473132|NCT01966692|Drug|Fluticasone Propionate Formulation 3*|"Fluticasone Propionate dry powder inhaler Formulation 3*~*(The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation."
75936493|NCT02425436|Drug|Ginkgo Biloba Extract|
75646821|NCT03602859|Drug|Niraparib-Placebo|Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
75646822|NCT03580655|Drug|Avapritinib|Avapritinib tablet
75794426|NCT04071769|Drug|Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
75794427|NCT04068896|Biological|NGM120|NGM120 Dose 1
75794428|NCT04068896|Biological|NGM120|NGM120 Dose 2
75794429|NCT04068896|Biological|NGM120|NGM120 Dose 3
75794430|NCT04068896|Biological|NGM120|NGM120 Dose 4
75794431|NCT04068896|Biological|NGM120|NGM120 Dose 5
75794432|NCT04068896|Biological|NGM120|NGM120 Dose 6
75794433|NCT04068896|Other|Placebo|Placebo
75794434|NCT04068649|Radiation|Palliative Radiation Therapy|Undergo palliative RT
75794435|NCT04068649|Other|Quality-of-Life Assessment|Ancillary studies
75794436|NCT04068649|Other|Questionnaire Administration|Ancillary studies
75794437|NCT04068649|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75794438|NCT04063501|Other|Bronchoscopy|The patient will then return within a week for a research bronchoscopy to sample the upper and lower airways
75936494|NCT02425436|Other|Placebo|
75936495|NCT02425046|Behavioral|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
76085697|NCT06033456|Procedure|Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance (TPVB)|Radiofrequency sympathectomy will be performed with the patient in the prone position. Under fluoroscopic guidance, the T2, T3 vertebral bodies will be identified in an anteroposterior view. For radiofrequency sympathectomy, 10 cm curved, sharp radiofrequency insulated needle with an active tip of 10 mm, needle entry will be performed, and the final placement of the needle tip will be located at the posterior third of the vertebral body in lateral view and just lateral to the body in the anteroposterior view. Once the correct position is confirmed, 0.5 to 1 ml of Omnipaque will be injected, then a 10 cm electrode will be introduced through the RF needle. Before lesioning, a sensory and motor test stimulation is performed to verify the location.
76085698|NCT06033456|Procedure|Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block|Combination between radiofrequency of stellate ganglion block and thoracic T2, T3 paravertebral block.
76085699|NCT06033443|Other|Collaborative Learning Group|The experimental group is the group that receives nursing education based on collaborative learning.
76085700|NCT06033365|Behavioral|care navigation|Dedicated care navigation throughout study enrollment and follow-up period. Care navigation consists of addressing social support needs (e.g. transportation, communication, housing).
76085701|NCT06033339|Other|Blood sampling|Collection of 10 ml of blood on EDTA tubes per patient. Once collected, the blood tubes will be transported within 24 hours to the IRB (Biotherapy Research Institute) of Montpellier University Hospital, where the monocytes will be isolated by magnetic sorting on the basis of expression of surface marker CD14+, after a preliminary step of Ficoll. Monocytes will then be frozen in nitrogen at -196°C until use (biobank).Gain-of-function experiments will then be performed on monocytes by transfecting them with the microRNA of interest or control. The expression of the pyrin protein and its phosphorylation rate will be evaluated after induction by immunoprecipitation experiments followed by western blot. The activity of the pyrin inflammasome will also be studied by looking at pyroptosis and toxicity rate using LDH test. All these experiments will be carried out in the absence and in the presence of the microRNA in order to study its role in the pathophysiology of FMF.
75337106|NCT05513443|Procedure|Irreversible electroporation, IRE|IRE involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death. The technique is used in Sweden today in radical ablative therapies in the treatment of tumors in the liver, kidney and pancreas. Prior to treatment a Foley catheter is placed. During the treatment, which takes place under anesthesia, the patient is placed in gynecological position and the tumour lesion is located with BK transrectal fusion ultrasound. Thereafter the needles are placed transperineal around the tumor in the prostate using a brachytherapy grid (17Ga Civco brachytherapy grid), guided by the ultrasound/MRI fusion images. Through the needles electrical pulses are then sent to treat the tumor in the center using the Nanoknife technique. After treatment patients are treated with diuretics to flush the kidneys post treatment.
75794439|NCT04063501|Other|Research Procedures|electrocardiogram, blood work (CBC, chemistry, coagulation profile and liver function tests, pregnancy test if applicable), X-ray and pulmonary function (spirometry) testing, and provide the patient with a stool collection kit.
75931527|NCT03307928|Diagnostic Test|Polysomnography Assessment|The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
75794440|NCT04057638|Procedure|Combined Craniomaxillofacial and Upper Extremity Allotransplantation|Combined Craniomaxillofacial and Upper Extremity Allotransplantation
76085702|NCT06033313|Behavioral|Negatively Framed text messages|Negatively Framed text messages delivered to participants three times per week for 8 weeks.
76085703|NCT06033313|Behavioral|Positively Framed text messages|Positively Framed text messages delivered to participants three times per week for 8 weeks.
76085704|NCT06033300|Biological|blood sample|blood sample
76085705|NCT06033287|Drug|Different treatment regimens following progression on CDK4/6 inhibitors.|This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.
75337107|NCT05513443|Procedure|Radical prostatectomy|Radical prostatectomy
75337108|NCT05513443|Radiation|Radiation therapy|Radiation therapy for prostate cancer
75794441|NCT04052685|Procedure|Selective removal to soft dentin (SRSD)|In order to prevent pulp exposure in deep caries lesions radiographically extending at least 3/4 of dentin, periphery of the cavity prepared to hard dentin while reasonable amount of soft carious tissue over the pulp is left. This caries removal strategy is termed selective removal to soft dentine.
75794442|NCT04052685|Procedure|Selective removal to firm dentine (SRFD)|Carious tissue is totally removed until hard dentin dry in appearance and hard on probing. This carious removal strategy is strongly recommended for shallow or moderately deep carious lesions.
75794443|NCT04052568|Drug|Psilocybin|Participants will undergo up to four moderate to high dose psilocybin sessions. Dosing at the first session will be 20 mg. For subsequent sessions participants will either remain at their previous dose, or increase by increments of 5 mg up to a maximum of 30 mg.
75794444|NCT04050670|Drug|Tirzepatide|Tirzepatide administered SC
75931528|NCT02234271|Other|Mobile Health Application|Mobile Health application for contraception information
75931529|NCT02234271|Other|Health Educator Counseling|Counseling via health educator
75936496|NCT02425046|Behavioral|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
75936497|NCT03183050|Behavioral|Question Prompt List|Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.
75646823|NCT03573401|Combination Product|Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
76085706|NCT06033274|Device|Transcatheter Tricuspid Valve Replacement|All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease
76085707|NCT06033248|Diagnostic Test|urine sample|urine sample will be collected
76085708|NCT06033235|Diagnostic Test|CT scan in critically ill patients in the intensive care unit|CT scan in critically ill patients in the intensive care unit
76085709|NCT06033183|Biological|Blood sample|Blood sample collection : 2 X 5 ml
75337109|NCT05507814|Behavioral|Episodic Future Thinking (EFT)|Participants will generate descriptions of vivid positive future events.
75337110|NCT05507814|Behavioral|Control Episodic Thinking|Participants will generate descriptions of vivid positive future events.
75337111|NCT05493475|Behavioral|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at court sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
75794445|NCT04049084|Biological|autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)|ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
75794446|NCT04048824|Behavioral|Inhibitory Learning-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on maximizing the mismatch between participant's feared outcome and what actually occurred (i.e., expectancy violation). This condition includes techniques that incorporate associative learning principles such as exposure to multiple feared stimuli (i.e., deepened extinction), exposure variability in contexts and stimuli, occasional reinforcement, and mental reinstatement of inhibitory learning.
75794447|NCT04048824|Behavioral|Habituation-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on fear reduction from initial fear ratings. This condition includes theoretically-consistent techniques such as staying in the situation until fear declines, repetition of exposures until fear has declined, and a gradual approach to feared stimuli using an exposure hierarchy.
75794448|NCT04047602|Radiation|Reduced Dose SRS|Subjects will receive SRS treatment at a reduced dose based on the brain tumor size
75931530|NCT03307850|Other|Observation During Exercise and Stress|"Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study."
75931531|NCT02264769|Drug|Carbetocin|
75936498|NCT02429492|Device|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
76085710|NCT06033170|Device|CELOX™ PPH|Celox™ PPH is intended to be a physical haemostatic treatment for control and treatment of uterine postpartum hemorrhage (PPH) when conservative management is warranted.
75794449|NCT04032106|Other|Best Practice|Receive standard information about HPV and HPV vaccine
75794450|NCT04032106|Other|Informational Intervention|Receive Outsmart HPV intervention
76085711|NCT06033144|Diagnostic Test|Diagnosis of Tapia's Syndrome|"The diagnostic includes :~Lingual clinical examination~Nasofibroscopy~Ultrasonography"
76085712|NCT06033118|Drug|gemcitabine ,oxaliplatin,anlotinib,Sintilimab|Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
76085713|NCT06033105|Device|ELISA|Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.
76085714|NCT06033092|Drug|Tamoxifen 10 Mg Tablet|One tablet of Tamoxifen 10 mg every other day for 6 months
75794451|NCT04032106|Other|Questionnaire Administration|Ancillary studies
75794452|NCT04032106|Behavioral|Text Message-Based Intervention|Receive unidirectional text message vaccine reminders
75794453|NCT04032106|Behavioral|Text Message-Based Intervention|Receive interactive text message vaccine reminders
76085715|NCT06033092|Other|Intermittent caloric restriction|"5:2 diet: 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)"
76085716|NCT06033092|Behavioral|Step counter Device|Participants will receive personal advice on healthy lifestyle and a step counter
76085717|NCT06033053|Device|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
75337112|NCT05471596|Device|NeuWave Microwave Ablation System|The NEUWAVE System supports target ablation or linear coagulation in surgical liver resection procedures. The System offers a versatile probe portfolio, multi-probe synchrony and CO2 cooling to help control the shape, size and burn pattern of your ablations.
75337113|NCT05463341|Behavioral|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at Project DAWN sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
75337114|NCT05453708|Other|Survey|One 15-20-minute survey
75337115|NCT05433506|Drug|HU6 Tablet|Six subjects will receive a tablet formulation.
75646824|NCT03573401|Combination Product|Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
75646825|NCT03562767|Behavioral|Group-based Cognitive Behavioral Intervention|This intervention will include six 1-hour group sessions held biweekly for twelve weeks. Each sixty-minute session will consist of 15 minutes of diabetes education regarding exercise and food planning and approximately 45 minutes of CT-CB presentations/engagement activities. Participants will be encouraged to bring along their family members or friends for support.
75646826|NCT03562767|Behavioral|Web-based Cognitive Behavioral Intervention|This intervention will include six 1-hour web-based sessions held biweekly for twelve weeks. Subjects in the web-based CT-CB will be asked to reserve a 1 hour period for a web call from the Behavioral Interventionist team. Text reminders will be sent to the participants prior the sessions. During this period, approximately 15 minutes will be reserved for diabetes exercise and food planning education and approximately 45 minutes of CT-CB engagement activities.
75794454|NCT04016714|Drug|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
75646827|NCT03562767|Behavioral|Usual Care|Usual care group participants will continue to receive care and follow up from their primary care providers as per the American Diabetes Association guidelines with log books, education regarding self-management strategies and appropriate referrals as needed.
75794455|NCT04016714|Drug|Prevenar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
75931532|NCT05162040|Device|Use of PedaleoVR|"All participants must undergo an evaluation of their motor skills through the application of physical assessment metrics performed by the physician. The metrics are the Timed Up-and-Go Test (TUG) and the 6-minute walk test.~Next, they must perform a pedaling exercise on a bicycle or stationary pedaling station synchronizing the physical activity with the visual feedback from the virtual reality application. Two pedalling sets of 10 minutes each are performed, with 5 minutes of rest between sets. Finally, the participant is asked to rate the usability: System Usability Rating Scale (SUS), activity credibility (Credibility and Expectancy Questionnaire, CEQ) and intrinsic motivation (Intrinsic Motivation Inventory, IMI) of the virtual reality application."
75931533|NCT03307772|Dietary Supplement|Probiotics|
75794456|NCT04016714|Drug|Vaxelis™|Intramuscular 0.5 mL single dose
75931534|NCT03307772|Dietary Supplement|Prebiotics|
75337116|NCT05433506|Drug|HU6 Capsule|Six subjects will receive the capsule formulation
75931535|NCT03307772|Dietary Supplement|Prebiotics and Probiotics|
75337117|NCT05429970|Behavioral|Mind-body resilience training|MBRT is a meditation technique used to achieve relaxation)
75646828|NCT03558893|Behavioral|Forced Desynchrony|All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
75794457|NCT04016714|Drug|M-M-R®II|Subcutaneous 0.5 mL single dose
75794458|NCT04016714|Drug|VARIVAX™|Subcutaneous 0.5 mL single dose
75794459|NCT04009733|Biological|Blood sample|A study specific blood sample will be collected.
75931536|NCT03307772|Dietary Supplement|Placebo|
75794460|NCT04009733|Biological|Blood sample|Pre-collected serum of cohort OFELY and MODAM for women, STRAMBO for men will be used for the study.
75931537|NCT02264847|Drug|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
75931538|NCT02264847|Drug|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
75931539|NCT05156190|Other|bright classrooms with light level over 1000 lux|Grade 2 primary school students at the intervention groups will study in bright classrooms for three years and incidence of myopia will be compared with those in conventional classrooms
75931540|NCT02262195|Other|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
75931541|NCT05161962|Combination Product|One group received standard oral care.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
76085718|NCT06033040|Other|MRI|Functional sequence imaging (MDME, IVIM) sequences were added to the routine MRI scan of patients with bladder tumor
76085719|NCT06032988|Dietary Supplement|LactoLevure|Participants will receive LactoLevure^R probiotic dietary supplement or matching placebo once a day.
75337118|NCT05429970|Behavioral|Music therapy|Music listening was found, in multiple trials, to significantly reduce self-reported anxiety, physiologic indicators of anxiety, and/or sedation requirements
75337119|NCT05429970|Drug|Propofol|Pre-op: 20 mg BID p.o. (preop D7 - preop D1) Day of Surgery: total intravenous anesthesia/TIVA using propofol as the main anesthetic drug Post-op: 20 mg BID p.o. (until POD 14)
75337120|NCT05429970|Drug|Etodolac|Pre-op: 400 mg BID p.o. (preop D7 - preop D1) Post-op: 400 mg BID p.o. (until POD 14)
75646829|NCT03542175|Drug|Rucaparib|one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
75646830|NCT03542175|Radiation|Radiotherapy|50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
75646831|NCT03519230|Drug|Pamiparib capsule|60 mg twice daily (BID), orally (per os-PO)
75794461|NCT03997578|Procedure|NIPSA (Non-incised papilla surgical approach)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the regenerative biomaterials will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
75794462|NCT03997578|Procedure|NIPSA plus connective tissue graft|In these patients, the following methodology will be added to the technique described for the NIPSA group: once the biomaterials are applied, a connective tissue graft, taken at the level of the first upper molar, will be sutured to the base of the soft supra-alveolar tissue and to the palatal tissue, which has not been disinserted, using simple sutures.
75794463|NCT03997435|Drug|Control arm|neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy.
75931542|NCT05161962|Combination Product|It was applied to the other group by aspiration.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
75931543|NCT05726552|Other|Laughter therapy|"Laughter therapy will be applied for 50 minutes, 12 sessions, 3 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality.~The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
75794464|NCT03997435|Drug|Experimental arm|Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy.
75794465|NCT03997409|Other|Dietary Intervention|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
75794466|NCT03988530|Drug|Scopolamine|Subjects will self-administer DPI-386 Nasal Gel (0.2 mg / 0.12 g) or placebo nasal gel (0.12 g) on Treatment Day 1, and on Treatment Days 2 -4 all subjects will self administer DPI-386 Nasal Gel (0.2 mg / 0.12 g).
75931544|NCT03469128|Behavioral|Cognitive processing therapy|Psychological treatment for patients suffering from PTSD and SUD symptoms.
75931545|NCT03469128|Drug|Sertraline|Sertraline for the treatment of post-traumatic stress and SU disorders
75931546|NCT03469128|Other|Placebo Control|Placebo Control
75931547|NCT02542215|Drug|Cobiprostone|Cobiprostone 30 mcg oral spray
75931548|NCT02542215|Drug|Placebo|Matching placebo oral spray
75931549|NCT02542215|Drug|Standard Care - Chemotherapy|Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
75931550|NCT02542215|Radiation|Standard Care - Radiation|Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
75931551|NCT05270174|Other|no intervention|no intervention
76085720|NCT06032962|Procedure|salpingectomy|surgical removal of the fallopian tubes
75337121|NCT05406973|Device|SBK microkeratome versus femtosecond laser in flap creation|prospective comparative non randomized interventional clinical study
75337122|NCT05406908|Biological|tozinameran|Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
75337123|NCT05400512|Behavioral|Cognitive Training|Computerized cognitive training targeting the underlying cerebral networks associated with depression.
75337124|NCT05400512|Device|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system).
75337125|NCT05400512|Device|tDCS (sham stimulation)|Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
75337126|NCT05396079|Other|tahini and bread|Fifthy grams of tahini with 2 slices of white bread
75646832|NCT03519230|Drug|Placebo capsule|60mg BID, PO
75646833|NCT03508479|Biological|RG-HRV16|0.25 mL inoculum intranasally delivered into each nostril (0.5 mL total delivered). Total cumulative dose of 1000 median tissue culture infective dose at 50% of cells inoculated (TCID50).
75646834|NCT03485014|Drug|Exparel|EXPAREL 4 mg/kg
76085721|NCT06032936|Drug|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
75794467|NCT03988530|Other|Placebo Nasal Gel|Placebo Nasal Gel (0.12g) twice a day on Treatment Day 1.
76085722|NCT06032936|Drug|osimertinib|Osimertinib is a mutant-selective, third-generation EGFR inhibitor that targets both EGFR-activating mutations (e.g., exon 19 deletion and L858R) and EGFR-dependent on-target resistance mutation toward the 1st generation EGFR inhibitor (i.e., T790M). It is currently a first-line therapy for EGFR-mutant (EGFRmut) NSCLC, with average progression-free survival of approximately 19 months in previously untreated subjects.
75931552|NCT03299582|Device|Hypothermia|Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
76085723|NCT06032910|Device|Surgical mesh|Prophylactic synthetic non-absorbable keyhole mesh placement upon construction of ileal conduit.
76085724|NCT06032897|Other|Individualized music listening (IML)|The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The Individualized music listening (IML) were performed twice a week for four weeks, for a total of eight times.
75646838|NCT03402503|Drug|Montelukast buccal film|Film with active investigational product (montelukast) inserted and applied on inner cheek
75337127|NCT05396079|Other|margarine, cheese and bread|46 g of margarine and 38 g of cheese with 2 slices of white bread
75337128|NCT05376904|Drug|HR18034|HR18034 low dose
75646839|NCT03402503|Other|Placebo buccal film|Film with placebo (no active drug) inserted and applied on inner cheek
75794468|NCT03981003|Diagnostic Test|Blood sample|2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
75337129|NCT05376904|Drug|HR18034|HR18034 midium dose
75794469|NCT03980769|Drug|Thiotepa|Given IV
75794470|NCT03980769|Drug|Treosulfan|Given IV
75794471|NCT03980769|Drug|Fludarabine Phosphate|Given IV
75794472|NCT03980769|Biological|Rabbit Anti-Thymocyte Globulin|Given IV
75794473|NCT03980769|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT via infusion
75794474|NCT03978741|Device|Yōni.Fit Test Device|The Yōni.Fit Test Device is a silicone pessary.
75794475|NCT03978741|Device|Yōni.Fit Comparator Device|The Yōni.Fit Comparator Device is a silicone pessary with a different configuration.
75931553|NCT03299582|Device|Cryocompression|Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
75931554|NCT02264925|Device|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
76085725|NCT06032884|Procedure|continuous renal replacement therapy (CRRT)|renal replacement therapy (RRT).
75646840|NCT03389412|Drug|Desmopressin|The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
75646841|NCT03389412|Device|Conditional alarm|Eight weeks of treatment.
75931555|NCT03299504|Other|Exercise|5 days per week, 2.5 hours per day strength, balance and endurance training on an outpatient basis
75931556|NCT05161572|Drug|Oxaliplatin|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1.
75794476|NCT03972657|Drug|REGN5678|Administered at the assigned dose level (DL) by intravenous (IV) infusion or subcutaneous (SC) administration
75794477|NCT03972657|Drug|Cemiplimab|Administered at the assigned DL by intravenous (IV) infusion
75931557|NCT05161572|Drug|Tegafur-Gimeracil-Oteracil|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. S-1 is administered orally at 40-60 mg twice a day for 14 consecutive days. Then, the patients will have a one-week rest period. The dose of S-1 is according to the body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily.
75794478|NCT03972657|Drug|Sarilumab|Administered by IV infusion
75794479|NCT03963856|Other|parbolic flight|weightlessness during parabolic flight
75794480|NCT03948243|Dietary Supplement|Licorice|Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days
75794481|NCT03948243|Drug|Alprazolam 2 MG|probe substrate
75794482|NCT03948243|Drug|Caffeine 100 MG|probe substrate
76085726|NCT06032884|Procedure|Intermittent hemodialysis (IHD)|renal replacement therapy (RRT).
76085727|NCT06032871|Procedure|high frequency chest wall oscillation|Patients receive airway clearance by high frequency chest wall oscillation for 30 minutes twice a day.
76085728|NCT06032858|Drug|Apremilast 30mg|Apremilast 30mg twice daily
76085729|NCT06032845|Drug|Tislelizumab|a PD-1 immune check inhibitor
76085730|NCT06032845|Drug|Lenvatinib|Lenvatinib capsules
75337130|NCT05376904|Drug|HR18034|HR18034 high dose
75337131|NCT05376904|Drug|ropivacaine HCl.|ropivacaine HCl.
75337132|NCT05348291|Device|ventilation tubes|Transtympanic pressure equalising devices.
75473133|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are guided by a therapist. Treatment is delivered via the Internet."
75794483|NCT03948243|Drug|Tolbutamide 250 mg|probe substrate
75794484|NCT03948243|Drug|Dextromethorphan 30mg|probe substrate
75794485|NCT03948035|Drug|Elotuzumab|i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.
75794486|NCT03948035|Drug|Carfilzomib|i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
75794487|NCT03948035|Drug|Lenalidomide|hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
75646842|NCT03334942|Behavioral|Child and Family Traumatic Stress Intervention|The Child and Family Traumatic Stress Intervention (CFTSI) is a 5-8 session intervention, initiated within 60 days of trauma exposure for youth reporting acute PTSS. CFTSI is designed for children age 7 and older, and requires the involvement of a caregiver who knows the child well enough to report changes in the child's behavior and symptoms. CFTSI targets modifiable risk and protective factors during the early post-trauma period to promote recovery and reduce PTSS via caregiver-child communication and cognitive and emotional processing. CFTSI uses skill modules (e.g., sleep disturbance, intrusive thoughts, anxiety) to teach effective strategies to decrease a child's PTSS. Coping and communication skills are taught and practiced in caregiver-child sessions and in the home.
75931558|NCT05161572|Drug|Sintilimab|The immunotherapy includes perioperative treatment and postoperative maintenance treatment. The PD-1 mAb used will be sintilimab, and the dose is 200 mg intravenously every three weeks. Regardless of which arm, the courses of immunotherapy that will be received by the enrolled patients are the same: 3 times preoperatively, 3 times postoperatively, and then maintained until one year after surgery.
75646843|NCT03334500|Device|[18F]FluorThanatrace|Fluorine-18 labeled FluorThanatrace [18F]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is < 10 μg.
75931559|NCT05161572|Radiation|Concurrent chemoradiation|The radiotherapy (RT) consists of 45 Gy delivered in 25 fractions every five days per week for five weeks. The dose of concurrent ChT is 60 mg/m2 S-1 orally, oral tablets twice daily, days 1-5 of each week.
75931560|NCT05161572|Procedure|D2/R0 gastrectomy|Gastrectomy with standard D2 lymphadenectomy is recommended. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle third tumors, the gastric margin is recommended to be more than 5 cm, and a total gastrectomy is performed. For lower third tumors, a 2 cm duodenal margin is recommended, and a subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
76085731|NCT06032845|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
76085732|NCT06032832|Other|soy protein concentrate-meat analog|Baked Meat analogs-soy protein concentrate containing 57Fe as ferrous sulfate
76085733|NCT06032832|Other|soy protein concentrate-meat analog_dephytinization|Baked dephytinized_Meat analogs-soy protein concentrate containing 58Fe as ferrous sulfate
75337133|NCT05333497|Device|the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument|Conventional electrical stimulation does not produce coordinated movement of multiple joints by stimulating several locally generated single ones simultaneously. The stimulation after the improved program, through different time output electrical stimulation on different parts of the muscles or muscle groups, forming the programmed motion. The purpose of this study is to achieve the rehabilitation goal of single joint - multiple joint - extensive movement, promote the coordination recovery of affected limb movement and relieve muscle fatigue.
75337134|NCT05333497|Device|the fourth generation of low-frequency acupoint electric stimulation therapy instrument|In this study, the instrument of alternate acupoint electrical stimulation of flexor and extensor muscles combines traditional acupoint therapy with modern low-frequency electric stimulation technology, has the advantages of non-invasive and convenient application, and has a good effect on improving the range of motion of joints, relieving spasm, enhancing muscle strength, promoting the recovery of the central nervous system and other aspects.
75337135|NCT05323448|Device|Control Group|During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent).
75337136|NCT05323448|Device|ARISTA|"During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent). Before surgical wound closure, the corresponding amount of ARISTA-AH will be applied to completely cover the bleeding site :~5g for 5 to 8 instrumented vertebra~10g fo 9 or more instrumented vertebra"
75646844|NCT03334500|Drug|Poly(ADP Ribose) Polymerase 1|Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
75646845|NCT03333941|Device|ReCell® Autologous Cell Harvesting Device|RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.
75931561|NCT02524197|Drug|CR845 0.25 mg|Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
75337137|NCT05318222|Diagnostic Test|Whole genome sequencing (WGS)|WGS will identify copy number variations (CNVs), single nucleotide variants (SNVs), as well as triplet repeat disorders in children with rare diseases
76085734|NCT06032832|Other|Farinata|Pancake made from chickpea flour contains 57Fe as ferrous sulfate
75794488|NCT03948035|Drug|Dexamethasone|orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
76085735|NCT06032832|Other|Farinata_dephytinization|Pancake made from dephytinized chickpea flour contains 58Fe as ferrous sulfate.
76085736|NCT06032806|Other|moderate intensity|"Arm circles~Leg swings~Lunges"
76085737|NCT06032806|Other|High intensity|"Arm circles~Leg swings~Lunges~Butt kicks"
76085738|NCT06032793|Other|Breathing exercises|Pursed lip breathing, Diaphragmatic breathing and powered breathing
76085739|NCT06032728|Drug|Sunitinib|The investigators randomly assign multimodal recurrence scoring system defined high risk patients of stage III ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation
75337138|NCT05298670|Drug|MetFORMIN 1000 Mg Oral Tablet|Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.
75473134|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered via the Internet."
75646846|NCT03327805|Dietary Supplement|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
75337139|NCT05298670|Drug|Interferon beta-1a|Disease Modifying Therapies (DMTs)
75337140|NCT05297851|Drug|Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)|10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
75337141|NCT05297851|Drug|Control|Standard treatment accordind to the routine clinical practice
75646847|NCT03327805|Dietary Supplement|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
75931562|NCT02524197|Drug|CR845 0.50 mg|Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
75931563|NCT02524197|Drug|CR845 1 mg|Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
75931564|NCT02524197|Drug|CR845 5 mg|Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
75337142|NCT05297279|Behavioral|Home delivery Omega-3 rich Food|The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.
75337143|NCT05297279|Behavioral|Dietary Motivational Coaching|The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.
75337144|NCT05297279|Behavioral|Home delivery Food|The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
75646848|NCT03315754|Drug|TOOKAD Soluble 4 mg/kg|Vascular targeted photodynamic therapy using TOOKAD Soluble
75337145|NCT05286294|Biological|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
75646849|NCT03271762|Device|percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW|percutaneous mitral valve repair Percutaneous MitraClip Device Implantation
75646850|NCT03271762|Procedure|cardiac surgery|mitral valve repair or mitral valve remplacement
75646851|NCT03260023|Biological|TG4001|PhIb: Dose escalation PhII: Established RP2D for TG4001
75646852|NCT03260023|Drug|Avelumab|Anti PD-L1
75646853|NCT03220477|Drug|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
75646854|NCT03220477|Drug|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
75646855|NCT03220477|Drug|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
75646856|NCT03215199|Other|NAPT|Web-based depression and distress monitoring application
75337146|NCT05284955|Device|CardioMEMS HF System|The CardioMEMS HF System is a wireless pulmonary artery pressure monitor. We will use measurements from the device to guide medical heart failure therapy.
75337147|NCT05284955|Drug|Standard heart failure medical therapy|Standard heart failure medical therapy as recommended by guidelines.
75337148|NCT05277558|Other|Observational|Investigators are observing brain health over time (21 months) in these groups
75337149|NCT05264038|Drug|OC514 (Low dose)|Low dose level of OC514
75337150|NCT05264038|Drug|OC514 (Mid dose)|Mid dose level of OC514
75337151|NCT05264038|Drug|OC514 (High dose)|High dose level of OC514
75337152|NCT05264038|Other|Placebo|Placebo to match
75473135|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered in book form."
75473136|NCT01966783|Drug|Budesonide 2 mg suppository|per day
75473137|NCT01966783|Drug|Budesonide 4 mg suppository|per day
75473138|NCT01966783|Drug|Mesalazine 1 g suppository|per day
75473139|NCT01966783|Drug|Budesonide 2 mg suppository/Mesalazine 1 g suppository|per day
75931565|NCT05161416|Behavioral|Bubble Blowing|Active Distraction Methods
76085740|NCT06032702|Procedure|tooth alignment|Alignment will be assessed by Little's Irregularity Index
76085741|NCT06032689|Combination Product|Xtra-fill|the material was placed in bulk.
75473140|NCT01966822|Drug|Dolutegravir, 50mg every 24 hours|Dolutegravir, 50mg every 24 hours
75473141|NCT01966822|Drug|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir
75646857|NCT03186898|Radiation|Proton Therapy (Radiation Therapy)|Undergo proton therapy
75646858|NCT03186898|Radiation|Photon Therapy (Radiation Therapy)|Undergo photon therapy
75646859|NCT03182998|Other|Internet-Based Intervention|"Receive Knowing your Options decision aid"
75931566|NCT05161416|Behavioral|Cartoon Watching|Passive Distraction Methods
75931567|NCT02262273|Other|Data Collection|Colleciton of data from medical records only
76085742|NCT06032689|Combination Product|x-base|The x-base liner was placed and then veneered with Xtra-fill.
76085743|NCT06032689|Combination Product|Admira fusion x-tra|bulk placement of the restoration Admira fusion -xtra.
75931568|NCT02722928|Other|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
76085744|NCT06032689|Combination Product|Admira fusion x-base|Admira fusion x-base liner was used and then veneered by Admira fusion x-tra.
76085745|NCT06032663|Diagnostic Test|PET-MRI|Patients that participate in the current study will have an extra PET-MRI scan, which will expose them to a small amount (4 - 6 mSv) of extra radiation.
75931569|NCT03470844|Behavioral|Face-to-face neurocognitive tests|Assessment of attention, processing speed, working memory and executive function
75931570|NCT03470844|Behavioral|Psychological screening|Screening for the symptoms of depression, anxiety and post-traumatic stress disorder
75931571|NCT03470844|Other|fMRI|Brain volume, chemical markers, functional outcome
75931572|NCT03470844|Behavioral|Quality of Life Self-Assessment data|EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs
75646860|NCT03182998|Other|Internet-Based Intervention|"Receive Prostate Choice decision aid"
75646861|NCT03182998|Other|Best Practice|Undergo usual care
75337153|NCT05263440|Device|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
75646862|NCT03182998|Other|Quality-of-Life Assessment|Ancillary studies
75794489|NCT03948035|Other|autologous stem cell transplant|autologous stem cell transplant
76085746|NCT06032637|Procedure|Pfannenstiel incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
75794490|NCT03946813|Other|Autologous PRP preparation|For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide
75794491|NCT03946124|Drug|Fesoterodine|Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.
75931573|NCT03472170|Dietary Supplement|Enteral administration of bovine lactoferrin (bLf)|The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.
75337154|NCT05252598|Drug|Psilocybin|1mg encapsulated psilocybin
75646863|NCT03182998|Other|Questionnaire Administration|Ancillary studies
75646864|NCT03182998|Other|Survey Administration|Ancillary studies
75646865|NCT03182998|Other|Laboratory Biomarker Analysis|Correlative studies
75646866|NCT03161067|Device|BiCNS|Surgical implantation
75646867|NCT03151798|Behavioral|Phase II: Lifestyle treatment|Subjects will undergo energy restriction and exercise training over a 9 month period.
75646868|NCT03151798|Behavioral|Phase II: Control treatment|Subjects will receive dietary advice and receive information on a stretching program.
75646869|NCT03151798|Other|Phase I: Observational studies|The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
75794492|NCT03942224|Drug|Bortezomib|Given SC
75794493|NCT03942224|Biological|Daratumumab|Given IV
75794494|NCT03942224|Drug|Dexamethasone|Given IV and PO
75794495|NCT03942224|Drug|Ixazomib|Given PO
75794496|NCT03938701|Drug|Adalimumab-800CW|Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging
75794497|NCT03938701|Device|Fluorescence Imaging|"Fluorescence Imaging Rheumatoid Arthritis (RA):~Open-air camera - a camera that enables detection of fluorescent signals.~Fluorescence Imaging inflammatory bowel disease (IBD):~Molecular Fluorescence Endoscopy - a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy."
75794498|NCT03937323|Other|Blood lymphocyte subtypes and serum cytokines|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine the proinflammatory cytokines
76085747|NCT06032637|Procedure|Supra-umbilical transverse incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision 3-4cm above the umbilicus, extending laterally to the semilunar lines, without panniculus retraction. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. The rectus sheath will be incised transversely using electrocautery for hemostasis, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually along the midline using blunt dissection. The peritoneum will be transversely incised and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
76085748|NCT06032624|Procedure|combined ultra-sound guided femoral and sciatic nerve block.|Femoral nerve block, The femoral area will be scanned behind the midpoint of the inguinal ligament and the depth of the image will be set at 3-5 cm, and a linear high frequency 8-12MHz) probe will be placed perpendicular to the course of the femoral nerve., the volume of 15 ml of bupivacaine will be injected to perform the block. Sciatic nerve block, A curvilinear low-frequency (3-9 MHz) probe will be used to do a scan of the sub-gluteal region below a line from the ischial tuberosity and greater trochanter which are seen as two hyperechoic bony prominences,A volume of 25 ml of bupivacaine will be injected to perform the block.
76085749|NCT06032611|Diagnostic Test|COGNUM_ALZVR|"Participants will complete a battery of tests/quizzes:~cognitive tests~medical questionnaire~lifestyle/fragility questionnaire~digital clock test~fine motor skills tests They will also wear a connected watch for 7 days."
75337155|NCT05252598|Drug|Inonotus Obliquus Whole Extract|1mg encapsulated chaga mushroom
75337156|NCT05245526|Device|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
75931574|NCT03472170|Other|Enteral administration of placebo|Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
75337157|NCT05243888|Diagnostic Test|self-sampling|eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter
75646870|NCT03126266|Radiation|re-irradiation|if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
75931575|NCT04156698|Drug|Docetaxel|Docetaxel is a chemotherapy drug.
75931576|NCT04156698|Drug|Cisplatin|Cisplatin is a chemotherapy drug.
75337158|NCT05241990|Behavioral|Practice Facilitation|A practice coach will offer tools, resources, hands-on guidance, and content expertise to assist sites in offering a stepped care model of alcohol treatment to patients with unhealthy alcohol use.
75337159|NCT05241990|Behavioral|Alcohol Stepped Care|Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
75473142|NCT01966835|Behavioral|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
75337160|NCT05236920|Device|Resuscitative Endovascular balloon occlusion of the aorta using a REBOA catheter device|In-hospital use of a REBOA catheter device during advanced cardiac life support
75473143|NCT01966848|Device|Wich prosthesis is used|
75473144|NCT01966861|Other|weaning guided by LUS (lung ultrasound)|Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score >14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required [CPIS>6], hemglobin>8g/dl triggers transfusion)
75473145|NCT01966887|Genetic|MYDICAR-single intracoronary infusion|AAV1/Serca2a
75646871|NCT03114553|Genetic|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
75646872|NCT03095612|Drug|Selinexor|Selinexor once weekly oral or twice weekly oral
75646873|NCT03095612|Drug|Docetaxel|Docetaxel once every 3 weeks (75 mg/m2 IV)
75794501|NCT03912662|Device|Mesh augmented reinforcement|Abdominal wall sutureline reinforcement with ProgripTM Self-Gripping Polyester Mesh
75931577|NCT04156698|Drug|Capecitabine|Capecitabine is a chemotherapy drug.
75337161|NCT05236439|Device|Interposition supraciliary implant|Surgical placement of SV22 interposition supraciliary implant in the supraciliary space
75794502|NCT03906435|Behavioral|Cognitive Behavioral Therapy|The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
75337162|NCT05223491|Procedure|En Bloc resection|Tumour is resected and removed from the bladder in one piece, if possible.
75337163|NCT05223491|Procedure|Conventional TURB|Tumour is resected piecemeal.
75473146|NCT01966887|Genetic|Placebo; single intracoronary infusion|single intracoronary infusion
75646874|NCT03083288|Drug|[18F]FluorThanatrace|[18F]FluorThanatrace is a radiotracer for PET/CT
75931578|NCT04156698|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
75931579|NCT03108326|Biological|Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra|The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.
76085750|NCT06032572|Procedure|VRS100 robotic-assisted PCI|The VRS100 is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
75794503|NCT03905356|Behavioral|Exercise Therapy|Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.
75931580|NCT03307694|Diagnostic Test|Ultrasound|All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
76085751|NCT06032572|Procedure|Manual PCI|Use the traditional technique of manually advancing intracoronary guidewires, balloons, and stents at the patient's tableside.
76085752|NCT06032559|Behavioral|MORE|MORE plus TAU
76085753|NCT06032559|Behavioral|SMP|SMP plus TAU
75931581|NCT03307694|Diagnostic Test|Shear wave elasticity imaging|"Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue."
76085754|NCT06032559|Other|TAU|TAU only
76085755|NCT06032520|Behavioral|FAST|FAST includes around 3 hours of face-to-face direct treatment time weekly and consists of a maximum of 10% online direct treatment time (i.e., treatment via phone, video-calling or texting). The treatment stage of FAST lasts five to nine months depending on the individual goals of the juvenile and the caregiver(s) and is followed by a period of aftercare.
76085756|NCT06032507|Procedure|Bone lavage previous to cementation|Bone lavage previous to cementation in total knee arthroplasty
76085757|NCT06032481|Procedure|surgery|Patients confirmed cervical cancer were undergone radical hysterectomy with pelvic lymphadenectomy
75794504|NCT03894553|Device|ExAblate Neuro|Unilateral stereotactic focused ultrasound lesioning of the contralateral mesencephalon
76085758|NCT06032468|Device|ARC Intellicare|wearable devices to guide rehabilitation exercise
76085759|NCT06032468|Other|Rehabilitation sheets|rehabilitation exercise sheets to guide rehabilitation exercise
76085760|NCT06032442|Dietary Supplement|ARTNEO|"Dietary Supplement: undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)~Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
76085761|NCT06032442|Drug|Artra|"Active ingredients:~Glucosamine hydrochloride 500 mg Chondroitin sulfate sodium 500 mg~Excipients:~dibasic calcium phosphate, microcrystalline cellulose, croscarmellose sodium, stearic acid, magnesium stearate.~Orally; adults and children over 15 years of age are prescribed 1 tablet 2 times a day for the first three weeks; 1 tablet 1 time per day for the next weeks and months."
76085762|NCT06032429|Other|Shared Medical Appointments|SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.
75337164|NCT05214209|Behavioral|Digital health supported|Participants will be issued a fitness tracker, a Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (weekly bite-sized content over 4 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
76085763|NCT06032403|Behavioral|flexible patient centred consultations|In the intervention group, the set-up will be flexible patient-centred consultations. The first consultation for the participant will be with the doctor and depending on the participant's need, the following consultations can be scheduled as either a doctor- or a nurse consultation. After each consultation, it will be decided in collaboration between the healthcare professionals and the participant whether a nurse or a doctor consultation will be relevant next. The consultations (whether it is with the doctor or nurse) will be centered around the participant's choice of topics by use of an atopic dermatitis dialogue tool developed in the department. Additionally, the nurse consultation will focus on therapeutic patient education (TPE) in atopic dermatitis. The interval between consultations will depend on the participant's need
75473147|NCT01966913|Drug|Bevacizumab|
75473148|NCT01966913|Drug|ICE chemotherapy regimen|Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
75473149|NCT01966965|Drug|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
75473150|NCT01966965|Drug|NEDAX|AS SPECIFIED AT THE LEAFLET
75473151|NCT01967004|Device|Morph|Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
75337165|NCT05214209|Behavioral|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
75337166|NCT05212922|Drug|YH001 + Toripalimab|YH001 + Toripalimab
75337167|NCT05199415|Behavioral|Health and Well-being Committee|Health and Well-being Committees (HaWCs) will be introduced in treatment sites as a means to facilitate on-going problem identification and collaborative processes for developing action plans, implementing small-scale, site-based improvements. HaWCs will involve 10-14 workers and frontline supervisors, with a worker and manager co-chair. HaWCs will identify challenges to safety, health, and well-being spanning physical hazards, COVID-19 protocols as relevant, other conditions of work (e.g., schedules, pace of work), and policies (e.g., absenteeism, performance management). They will then design and implement mitigating solutions and track outcomes. As such, HaWCs have a broader scope than traditional safety committees and will actively solicit worker voice regarding policies and practices that are not labeled as health and safety policies.
75794505|NCT03881631|Behavioral|Mindfulness Based Stress Reduction Program|Group-based intervention
75337168|NCT05199025|Diagnostic Test|Biomarker|Perioperative biomarker analyses
76085764|NCT06032390|Other|AI assisted mammography screening interpretation|Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in consensus. Examinations with an AI score of 9.8 and above will be selected to consensus by default. Risk scores and AI image markings are provided to the readers only in consensus. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).
75794506|NCT03881631|Behavioral|Living Well Program|Group-based intervention
75794507|NCT03879798|Drug|DS-3201b|100 mg daily
76085765|NCT06032390|Other|Standard mammography screening interpretation|Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in consensus, and the readers will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.
75473152|NCT01967017|Drug|Lidocaine|
75473153|NCT01967017|Drug|Placebo|
75794508|NCT03879798|Drug|irinotecan|Irinotecan 125 mg/m^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
75931582|NCT03307694|Diagnostic Test|Multi-angle compound shear wave elasticity imaging|The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
75931583|NCT01439919|Drug|SSR411298|"Form: tablet~Route: oral administration with food"
75931584|NCT01439919|Drug|Placebo (for SSR411298)|"Form: tablet~Route: oral administration with food"
75931585|NCT03470766|Device|Nevro Senza System (HF10 Therapy)|Nevro 10kHz High Frequency Spinal Cord Stimulation
75931586|NCT02262351|Other|30 Second Pulse Check|To detect atrial fibrillation
75931587|NCT02262351|Device|Watch BP Home A|Blood pressure device that detects atrial fibrillation
75931588|NCT02262351|Device|HeartCheck Hand-held ECG device|To detect atrial fibrillation
75931589|NCT04034082|Device|Intermittent hypoxia therapy|Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
75931590|NCT04034082|Other|Conventional phase 2 cardiac rehabilitation programme|The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
75931591|NCT03307538|Radiation|Stereotactic body radiation therapy|15 fractions of 3-4,5 Gy (risk-adapted)
75473154|NCT01967043|Drug|Oraxol|Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
75473155|NCT01967082|Behavioral|APPSPIRE|Given APPSPIRE app
75473156|NCT01967082|Behavioral|Focus Group|Attend focus group
75473157|NCT01967082|Other|Survey Administration|Complete survey
75794509|NCT03872960|Procedure|Transfer to cardiac arrest centre|Patients in the intervention arm will be taken directly to a the catheter lab of a heart attack centre.
75794510|NCT03872206|Biological|HPN536|Dose escalation: HPN536 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains
75794511|NCT03872206|Biological|HPN536|Dose expansion: HPN536 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains
75794512|NCT03870633|Other|Medical Chart Review|Undergo medical chart abstraction
75794513|NCT03870633|Other|Interview|Complete telephone interview
75794514|NCT03870633|Other|Questionnaire|Ancillary studies
75931592|NCT05131464|Drug|CM310|CM310, 300 mg/2 mL, SC, every 2 weeks
75931593|NCT04964024|Diagnostic Test|SARS-CoV-2 antibodies|Analysis of the results of the serological response to COVID-19 and/or Vaccine
75794515|NCT03870633|Other|Quality-of-Life Assessment|Ancillary studies
75794516|NCT03856463|Behavioral|Lay Navigator Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.
76085766|NCT06032377|Behavioral|cognitive behavioral therapy for sleep, anxiety, and depression|This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.
76085767|NCT06032377|Behavioral|education about healthy nutrition habits and communication in older age|This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings
75794517|NCT03856463|Other|Usual Care|Usual care as provided by local oncologists
75794518|NCT03852017|Behavioral|Audio Program|
75794519|NCT03852004|Other|ostheopathy|standardized osteopathic treatment
75931594|NCT03810144|Genetic|Vectra MBDA Test|Vectra Guided versus Usual Care
75931595|NCT03299270|Other|Questionnaires|Quality of Life and Functional recovery questionnaires
75646875|NCT03075748|Device|TAAA Debranching Stent Graft System|The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
75646876|NCT03028350|Drug|Ifetroban Oral Capsule|Subjects will be treated with oral ifetroban daily for 8 weeks
75646877|NCT03028350|Drug|Placebo Oral Capsule|Subjects will be treated with oral placebo daily for 8 weeks
75646878|NCT03022825|Drug|N-803 and BCG|BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
75646879|NCT03022825|Drug|N-803|N-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
75646880|NCT02918370|Drug|Aripiprazole|Aripiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders. It works to restore the balance of neurotransmitters.
75646881|NCT02918370|Drug|Placebo|Inactive ingredient matching the active comparators in appearance.
75646882|NCT02914405|Drug|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.
75794520|NCT03852004|Other|simulated osteopathic treatment|standardized simulated osteopathic treatment
75931596|NCT03470688|Biological|Originator|Originator anti-TNF agents
75794521|NCT03826771|Behavioral|Power training|high-intensity lower extremity resistance training
75794522|NCT03826771|Behavioral|Stretching|upper and lower body range of motion exercises
75794523|NCT03818685|Drug|Nivolumab|Radiotherapy will be maintained in each Arm.
75794524|NCT03818685|Drug|Ipilimumab|Radiotherapy will be maintained in each Arm.
75931597|NCT03470688|Biological|Biosimilar|Biosimilar anti-TNF agents
75931598|NCT02262429|Other|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
75931599|NCT02262429|Other|ONS Standard Feeding|Standard of care
75931600|NCT03307460|Drug|68Ga-NOTA-AE105|PET/MRI scan
75931601|NCT05072886|Drug|AT193|Topical applied to affected areas daily
75337169|NCT05197725|Device|Face mask|Individuals in intervention communities will be given surgical or KF94 face masks.
75337170|NCT05197725|Behavioral|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
75794525|NCT03818685|Drug|Capecitabine|Radiotherapy will be maintained in each Arm.
75794526|NCT03816228|Drug|F 18 T807 Flortaucipir|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
75794527|NCT03815578|Other|Clinical examination|"Number of painful joints,~Number of swollen joints,~Patient Global assessment VAS (0 - 100)~and Physician Global assessment VAS (0 - 100)"
75794528|NCT03815578|Other|Pain assessment|"Pressure Pain Thresholds (PPTs),~Mechanical Temporal Summation (MTS)~and Diffuse Noxious Inhibitory Control (DNIC)"
75794529|NCT03815578|Other|blood sample|18 ml whole blood for ELISA analysis and miRNAs detection
75794530|NCT03815578|Other|Patient Reported Outcomes|"Health Assessment Questionnaire (HAQ),~Rheumatoid Arthritis Impact of Disease score (RAID),~Daily joint pain intensity VAS (0-100),~Hospital Anxiety and Depression scale~and Coping Strategy Questionnaire."
75931602|NCT02466542|Drug|Placebo group|Patients will receive regular general anesthesia
75931603|NCT02466542|Drug|Esmolol group|Patients will receive regular general anesthesia plus esmolol infusion
75931604|NCT05067270|Drug|Sodium Citrate|Administered SC infusion.
75931605|NCT05067270|Drug|Treprostinil|Administered SC infusion.
75931606|NCT05067270|Drug|Humalog diluent|Administered SC infusion.
75931607|NCT05067270|Drug|Magnesium Chloride|Administered SC infusion.
75931608|NCT01437735|Drug|QAW039|QAW039 po
75931609|NCT01437735|Drug|Montelukast|Montelukast 10 mg po
75794531|NCT03813472|Device|Hydration Sensor|This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.
75931610|NCT01437735|Drug|Placebo|Placebo
75931611|NCT02722304|Biological|ARALAST NP 60 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
75931612|NCT02722304|Biological|ARALAST NP 120 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
75931613|NCT02722304|Biological|GLASSIA 60 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
75931614|NCT02722304|Biological|GLASSIA 120 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
75931615|NCT02722304|Biological|Human Albumin 2%|Human albumin 2% (by appropriate dilution with normal saline solution)
75931616|NCT04984902|Device|Extracorporal therapy|Extracorporal therapy
75931617|NCT01437657|Drug|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
75931618|NCT01437657|Drug|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
76085768|NCT06032325|Diagnostic Test|Neutrophil Gelatinase and Kidney Injury Molecule-1|To assess Neutrophil Gelatinase associated Lipocalin and Kidney Injury Molecule-1 as biomarkers of acute kidney injury in children with Diabetic Ketoacidosis
75646883|NCT02914405|Drug|Ch14.18/CHO|APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
75646884|NCT02911090|Other|Data Registry|Data Registry
75646885|NCT02868567|Drug|dalfampridine|Pill open label
75646886|NCT02761811|Device|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
75931619|NCT01437657|Drug|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
75931620|NCT03299192|Behavioral|Tai Chi|Yang Style Tai Chi
75931621|NCT03299192|Behavioral|Health Education|Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
75931622|NCT03299192|Other|Usual Medical Care|Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
75931623|NCT05728112|Other|Hydrogen Inhalation|The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.
75931624|NCT05728112|Other|Ordinary Air Inhalation|The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
76085769|NCT06032312|Other|description|no intervention, just description of the groups
76085770|NCT06031597|Radiation|radiotherapy|"Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week."
75646887|NCT02723955|Drug|feladilimab (GSK3359609)|
75646888|NCT02723955|Drug|GSK3174998|
75646889|NCT02723955|Drug|Pembrolizumab|
75646890|NCT02723955|Drug|Docetaxel|
75646891|NCT02723955|Drug|Pemetrexed|
76085771|NCT06031597|Drug|Platinum-Based Drug|Cisplatin 25 mg/m2 once per week for a total of 5-6 cycles. For participants who have not completed 4 cycles of conversion chemotherapy in combination with immunotherapy, the original chemotherapy regimen may also be used, with the total number of chemotherapy cycles not exceeding 6 cycles.
75646892|NCT02723955|Drug|Paclitaxel plus Carboplatin|
75646893|NCT02723955|Drug|Gemcitabine plus Carboplatin|
75646894|NCT02723955|Drug|Fluorouracil (5-FU) plus carboplatin or cisplatin|
75646895|NCT02723955|Drug|Dostarlimab|
75646896|NCT02723955|Drug|Cobolimab|
75794532|NCT03812029|Drug|Vonafexor|Oral tablets
75794533|NCT03812029|Other|Placebo|Oral tablets
75794534|NCT03811301|Device|BrainConnexion|A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.
75931625|NCT03470610|Drug|Progesterone|6 mg estradiol and vaginal and rectal progesterone
75931626|NCT01436487|Biological|MultiStem|single infusion 1-2 days following ischemic stroke
75931627|NCT01436487|Biological|Placebo|single infusion 1-2 days following ischemic stroke
75931628|NCT04653714|Procedure|Scaling and root planing|Patients with periodontitis in the test group will be treated by conventional non-surgical root debridement and in the control group by low-intensive supragingival plaque removal with mechanical brush and professional tooth paste only.
75931629|NCT04653714|Device|Probiotic lozenges|Patients with gingivitis in the test group will be treated with supragingival debridement and with probiotic lozenges with strains of Lactobacillus brevis and Lactobacillus plantarum once a day for 3 months and in the control group by low-intensive supragingival plaque removal, as a placebo treatment, and placebo probiotics lozenges.
75931630|NCT02509845|Drug|C16G2|Antimicrobial peptide
75931631|NCT02509845|Other|Placebo|Placebo
75931632|NCT04628754|Other|Exercise and protein|Home based exercise regime and dietary protein guidance
75931633|NCT03307148|Drug|ATRA|Administered orally on D1-15 of each 28 day cycle.
75931634|NCT03307148|Drug|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
75931635|NCT03307148|Drug|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
75931636|NCT03984591|Drug|Eplerenone|Eplerenone according to guidelines
75931637|NCT03984591|Drug|Spironolactone|Spironolactone according to guidelines
75794535|NCT03808727|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
75337171|NCT05197725|Behavioral|Face mask promotion through community values or individual information|"In intervention communities randomized to mask promotion through community values, promotional discussions and media will focus on encouraging groups of people to wear masks as a reflection of their values.~In intervention communities randomized to mask promotion through individual information, promotional discussions and media will target individuals and focus on the instrumental value of wearing masks (preventing the inhalation of viral particles)"
75337172|NCT05195827|Drug|PRM-125|Antihypertensive
75931638|NCT04568538|Other|Training program|"A training program and booklet content for the education to be given to mothers includes the following topics.~What is shaken baby syndrome and what is its cause?~What are the harms caused by shaken baby syndrome?~How is shaken baby syndrome understood?~What problems can shaken baby syndrome cause?~What are the measures to be taken? For the training and the content of the booklet, expert opinion was obtained from 10 academic members who are experts in the field of Child Health. An evaluation form was created for pre-test and post-test measurements. Expert opinions were also received for these forms.~Mothers of 2-4 months old babies who applied to Akdeniz University Hospital Pediatric Outpatient Clinic for check-up were randomized with a sealed envelope and accepted the study. In this way, intervention and control groups can be determined. After the pre-test is done in the intervention group, 2-month training, booklet and tele-consultancy services will be provided."
75931639|NCT04816058|Behavioral|Determining the level of ankle instability|Ankle instability
75931640|NCT02503137|Drug|Topical SM04554 solution|
75931641|NCT02503137|Drug|Topical Vehicle solution|
75337173|NCT05180734|Biological|JS001/Placebo|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
75337174|NCT05180734|Biological|JS001/placebo combine with Postoperative Adjuvant Chemotherapy|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
75646897|NCT02723955|Drug|Bintrafusp alfa|
75646898|NCT02637934|Drug|[18F]FluorThanatrace|
75646899|NCT02637934|Radiation|PET/CT imaging sessions|
75646900|NCT02632175|Biological|Adalimumab|every other week or weekly subcutaneous injection
75646901|NCT02566304|Drug|Fludarabine|Given IV
75646902|NCT02566304|Radiation|Total-Body Irradiation|Undergo TBI
75646903|NCT02566304|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo DLI
75794536|NCT03801122|Drug|Tranexamic acid|Administration of tranexamic acid, with 3 injections/8 hours.
75931642|NCT03470532|Drug|buccal infiltration of 4% Articaine with Epinephrine|Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
75931643|NCT03470532|Drug|buccal infiltration of 2% Mepivacaine with Epinephrine|Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
75931644|NCT02468336|Device|AngioDefender|
75931645|NCT02468336|Device|Ultrasound|
75931646|NCT02502669|Drug|Finasteride 23.5 mg tablets|
75931647|NCT02502669|Drug|Finasteride 33.5 mg tablets|
75931648|NCT02502669|Drug|Placebo tablets|
75931649|NCT04839510|Drug|MRG002|Administrated intravenously
75931650|NCT03306914|Other|Albumin resuscitation|Albumin 5% is used as the intra-operative colloid
75931651|NCT03306914|Other|Hydroxyethylstarch resuscitation|Hydroxyethyl starch 6% is used as the intra-operative colloid
75337175|NCT05180006|Drug|Atezolizumab Injection|Patients randomized to an atezolizumab arm will receive atezolizumab 840 mg IV on D1 (15 days +/- 48 h before the surgery date or the biopsy prior to the start of standard of care neoadjuvant systemic treatment.).
75337176|NCT05180006|Drug|Ipatasertib|Patients in the atezolizumab plus ipatasertib arm will receive treatment (ipatasertib) for 2 weeks unless unacceptable toxicity occurs. Patients will receive ipatasertib at a dose of 400 mg orally once a day on Days 1-14 until the day before the surgery or the biopsy before start standard of care neoadjuvant systemic treatment..
75337177|NCT05180006|Drug|Bevacizumab|Patients in the atezolizumab plus bevacizumab arm will receive a unique dose of bevacizumab as 10 mg/kg administered by IV infusion over 60 mins on day 1 cycle 1 (15 days before surgery +/- 48 h), the same day as atezolizumab.
75337178|NCT05180006|Drug|Pertuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of pertuzumab on day 1 administered IV. Pertuzumab will be administered IV at a loading dose of 840 mg.
75646904|NCT02566304|Drug|Cyclophosphamide|Given IV
75646905|NCT02566304|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
75646906|NCT02566304|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC transplant
75646907|NCT02566304|Drug|Tacrolimus|Given PO
75646908|NCT02566304|Drug|Mycophenolate mofetil|Given IV
75646909|NCT02566304|Other|Laboratory Biomarker Analysis|Correlative studies
75646910|NCT02495090|Genetic|Exome sequencing|Plain DNA sequencing
75646911|NCT02440711|Device|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
75646912|NCT02440711|Device|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
75646913|NCT02358031|Biological|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months.
75794537|NCT03800758|Behavioral|Expressive Helping|Expressive Helping (EH) is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using previously-tested EH instructions, adapted for this population.
75931652|NCT03306914|Drug|Albumin 5%|Infusion of Albumin 5% intra-operatively
75931653|NCT03306914|Drug|Hydroxyethylstarch 6%|Infusion of Hydroxyethylstarch 6% intra-operatively
75931654|NCT03135093|Other|No intervention|No Intervention
75931655|NCT03306836|Drug|Heparin Sodium|Infused with 5000 IU of Heparin Sodium
75931656|NCT03306836|Drug|Heparin Sodium|Infusion Heparin Sodium at a rate of 18 IU / kg.h
75931657|NCT04487145|Drug|Dihydroartemisinin-piperaquine|It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
75931658|NCT02265081|Procedure|ultrasound|pelvic floor ultrasound
76085772|NCT06031597|Drug|Immunotherapy|Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.
75337179|NCT05180006|Drug|Trastuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of Trastuzumab on day 1 administered IV. Trastuzumab will be given at a loading dose of 8 mg/kg.
75931659|NCT02265081|Procedure|uroflow-meter|uroflow meter: measurement of passed urine volume
75931660|NCT01252641|Biological|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
76085773|NCT06031597|Drug|Immunotherapeutic Agent|All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.
75646914|NCT02358031|Drug|Cisplatin|Cisplatin 100 mg/m^2 IV on Day 1 of each 3-week cycle (6 cycle maximum).
75931661|NCT00709956|Drug|iloprost (5 µg)|Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
75931662|NCT00709956|Drug|placebo|Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
76085774|NCT06031571|Procedure|dynamic cupping|Dynamic cupping is a form of massage therapy that involves using Hijamat cups without skin injury while applying suction then performing circular and transverse movements
75931663|NCT03306758|Drug|Sodium Bicarbonate|Sodium Bicarbonate was given 1g tid for one month
75931664|NCT02268201|Drug|Advagraf|oral
75931665|NCT02268201|Drug|Prograf|oral
75931666|NCT03306602|Device|Filtek Bulk Fill Posterior Restorative|Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.
75931667|NCT03306602|Device|Filtek Z350 XT|Filtek Z350XT is a material for incremental layered composite resin restorations
75931668|NCT02265159|Procedure|Focal Therapy Using High Intensity Focused Ultrasound|
76085775|NCT06031571|Procedure|Myofacial release|Myofascial release is a form of manual therapy using hands-on techniques to regain tissue extensibility and elasticity
76085776|NCT06031571|Procedure|traditional exercise (neck stretching and strengthening exercses)|Stretching exercises are therapeutic exercises that aim to improve ranges of motion and tissue elasticity. Strengthening exercises are therapeutic exercises that aim to improve muscle power and maintain the gained ranges of motion
76085777|NCT06031467|Device|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|The laser group received mechanical therapy followed by Er;Cr;YSGG laser. Laser application was performed using the bottom-up technique. Therefore, the tip was retracted about 1 mm after it was placed on the bottom of the pocket and slowly moved in the coronal direction to the parallel to the implant surface.
75337180|NCT05162911|Behavioral|Ask, advise, Assist and refer to the Quitline|A nurse will ask, advise, assist and refer patient to the Quitline
75646915|NCT02358031|Drug|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum).
75931669|NCT05722574|Behavioral|Romantic Competence Intervention|Online, 30-minute self-administered relationship competence program for youth ages 16-20
75931670|NCT05722574|Behavioral|Information Only Control Condition|Online, 30-minute self-administered relationship education activity for youth ages 16-20
75931671|NCT02265315|Other|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
75931672|NCT02265315|Behavioral|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
75931673|NCT02268279|Drug|solithromycin|
75337181|NCT05162911|Behavioral|Ask, advise, Assist and referral to onsite counselor|A nurse will ask, advise, assist and refer patient to a counselor
75337182|NCT05162911|Behavioral|Ask, advise, Assist and referral to onsite counselor and NRT|A nurse will ask, advise, assist and refer patient to a counselor and provide nicotine replacement therapy in the form of gum
75337183|NCT05149144|Diagnostic Test|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule
75646916|NCT02358031|Drug|5-FU|5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
75794538|NCT03800758|Behavioral|Factual Writing|Factual Writing has been used with cancer patients and in the investigators' prior EH trial. It is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using standard Factual Writing instructions.
75931674|NCT03306524|Device|SIPPV_VG_0_08|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes
75646917|NCT02358031|Biological|Cetuximab|Cetuximab on Day 1 at a dose of 400 mg/m^2 IV, and then 250 mg/m^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity
75646918|NCT02266758|Other|GDM Screening Methods|
75646919|NCT02223767|Device|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and intertrial interval (ITI) of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
75794539|NCT03797066|Drug|ZEPATIER 50Mg-100Mg Tablet|Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA> 800,000 iu/ml or baseline NS5A resistance.
75931675|NCT03306524|Device|SIPPV_VG_0_16|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes
75931676|NCT03306524|Device|SIPPV_VG_0_24|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes
75931677|NCT03306524|Device|SIPPV_VG_0_32|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes
75931678|NCT03306524|Device|SIPPV_VG_0_40|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes
75931679|NCT03306524|Device|PSV_VG_0_08|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
75931680|NCT03306524|Device|PSV_VG_0_16|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
76085778|NCT06031467|Device|Non-surgical mechanical therapy|Traditional non surgical mechanical therapy Mechanical instrumentation in all groups was made with titanium curettes.The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt.
76085779|NCT06031311|Diagnostic Test|Echocardiography and HRCT|Echocardiography:is non invasive and easily accessible tool in the diagnosis of any patient with suspected PH.HRCT: is a non-invasive and easily accessible tool to detect pulmonary hypertension in COPD patients.
76085780|NCT06030843|Drug|Empagliflozin 10 MG|Empagliflozin 10 MG
76085781|NCT06030843|Drug|Placebo|Matching placebo containing Lactose content (0.26 gram)
76085782|NCT06030362|Dietary Supplement|Probiotic|Dietary Supplement taken once daily for 3 months (90 days).
76085783|NCT06030362|Dietary Supplement|Placebo|Dietary Supplement taken once daily for 3 months (90days).
76085784|NCT06030024|Device|repetitive Transcranial Magnetic Stimulation|Magnetic pulses delivered to the Fz area of the brain in a low frequency (1 Hz) manner.
76085785|NCT06029556|Other|Mobility out of Bed|Active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conduct on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low-intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned
75337184|NCT05149144|Behavioral|audio signal dataset creation and validation; machine learning analysis, empirical evaluations|The project tests and adapts the technology developed at MIT for vocalization collection and labeling, and contributes to data gathering among Italian subjects (and their quality validation) in order to create a multi-cultural dataset and to enable cross-cultural studies and analyses. Next, the focus is placed on the analysis of harmonic features of the audio in the vocalizations of the dataset to identify recurring individual features and patterns corresponding to specific communications purposes or emotional states. Supervised and unsupervised machine learning approaches are developed and different machine learning algorithms will be compared to identify the most accurate ones for the project goal. Last, an exploratory evaluation of the vocalization-understanding machine learning model is conducted to test the usability and utility of the tool for vocalization interpretation.
75646920|NCT02223767|Device|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
75646921|NCT02177617|Drug|Botox injection|Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
75646922|NCT02177617|Behavioral|Physical Therapy|Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
75646923|NCT02177617|Procedure|Transcranial magnetic stimulation (TMS)|For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
75646924|NCT02145741|Drug|Xentuzumab, low dose, every week (qw)|Patient to receive low dose of Xentuzumab IV
75646925|NCT02145741|Drug|Xentuzumab, middle dose, qw|Patient to receive middle dose of Xentuzumab IV
75646926|NCT02145741|Drug|Xentuzumab, high dose, qw|Patient to receive high dose of Xentuzumab IV
75646927|NCT01956773|Other|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
75646928|NCT01946529|Drug|vincristine|Dosage and route of administration: Infants < 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m^2 IV day 1 (max. dose 2 mg).
75646929|NCT01946529|Drug|doxorubicin|Dosage and route of administration: Infants < 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants > 1 year of age 75 mg/m^2 CI over 48 hours, days 1-2.
75646930|NCT01946529|Drug|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
75646931|NCT01946529|Drug|ifosfamide|Dosage and route of administration: Infants < 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants > 12 months of age 1800 mg/m^2 IV over 60 minutes x 5 days, days 1-5.
75646932|NCT01946529|Drug|etoposide|Dosage and route of administration: Infants < 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children > 1 year 100 mg/m^2 daily IV over 60 minutes days 1-5.
75931681|NCT03306524|Device|PSV_VG_0_24|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
76085786|NCT06029556|Other|Ergometry in Bed|Ankle pumps (5*2), knee extension (5*2), breathing exercises with elbow flexion and extension(5*2), spirometry and progressive early ambulation (from bed to wheelchair and wheelchair to standing and from standing to few steps), and conventional chest physical activity (5 minutes on precursor)
75931682|NCT03306524|Device|PSV_VG_0_32|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
75931683|NCT03306524|Device|PSV_VG_0_40|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
75931684|NCT04425096|Other|Skin to skin contact|Skin to skin contact
75931685|NCT02268357|Drug|Propranolol|Oral propranolol capsules
75794540|NCT03789864|Diagnostic Test|Biodynamic imaging (BDI) of mycosis fungoides|Skin punch biopsy samples from cutaneous lesions will be profiled for sensitivity to gemcitabine using ex vivo Biodynamic imaging (BDI). A biodynamic profile, of either phenotypic responder or phenotypic non-responder, will be assigned.
75931686|NCT05430386|Drug|HS-10241|"Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy."
75931687|NCT04416906|Drug|Biktarvy|Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit
75931688|NCT02268435|Drug|dovitinib plus imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
75931689|NCT02466464|Device|Microporous Polysaccharide Hemospheres|Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
75473158|NCT01967095|Drug|erlotinib|Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 & D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 & D2, & will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 & 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 & 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
75646933|NCT01946529|Drug|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m^2 PO once daily, days 1-5.
75337185|NCT05148884|Drug|NLX-112|NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.
75931690|NCT02466464|Device|Nasal Tampon|8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
75337186|NCT05148884|Drug|Placebo|Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
75337187|NCT05110430|Other|Deep learning based detection of metastatic bone disease on bone scintigraphy scans.|The aim is to investigate whether deep learning algorithms can detect bone metastasis with high accuracy and specificity.
75646934|NCT01946529|Drug|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m^2 IV once day 1 and day 8.
75646935|NCT01946529|Drug|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
75337188|NCT05099926|Behavioral|Reducing Exercise Sensitivity with Exposure Training|"Participants complete 2, home-based intervention visits on a secure video visit platform. Video visits include psychoeducation, interoceptive exposure, and interoceptive counseling. For homework, participants are asked to document their weekly physical activity and exercise sensations in a journal.~Psychoeducation: Participants are educated about the benefits and safety of exercise and cardiac rehabilitation, the role of fear and anxiety in exercise avoidance, and the concept of interoceptive exposure.~Interoceptive Exposure: A gradual six-minute walk (G6MW) serves as a low-risk form of interoceptive exposure. Exercise sensations and ratings of perceived intensity and distress are collected before and after the G6MW.~Interoceptive Counseling: Participants review and reflect upon their pre-walking and post-walking physical sensations and ratings (intensity and distress) with a research team member. Homework is also reviewed."
75337189|NCT05070065|Device|Cognitive remedy intervention with virtual reality (CEREBRUM)|Cognitive Remedial method Virtual Reality (CEREBRUM)
75337190|NCT05049135|Device|Somnofy® sleep monitor|Registration of sleep score and apneas with radar sensor technology at time of primary investigation and 12 weeks after treatment initiation with continuous positive airway pressure (CPAP)
75337191|NCT05042817|Drug|100 mcg morphine|The effect of intrathecal morphine on vesical function and the need for bladder re-catheterization after a cesarean delivery
75337192|NCT05042817|Drug|0.9% NaCl|NaCl 0.9%
75337193|NCT05042817|Drug|50 mg prilocaine + 2.5 mcg sufentanil|50 mg prilocaine + 2.5 mcg sufentanil
75337194|NCT05042817|Procedure|bilateral transverse abdominal plane block|20 mL of ropicavaine 0.375% on each side
75646936|NCT01946529|Drug|sorafenib|Dosage and route of administration: 90 mg/m^2/dose PO BID
75646937|NCT01946529|Procedure|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
75646938|NCT01946529|Radiation|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
75931691|NCT04402944|Drug|Pulmozyme|Pulmozyme 2.5 mg BID
75931692|NCT04402944|Drug|Placebo|Saline 2.5 mL BID
75931693|NCT01423149|Drug|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
75931694|NCT01235559|Drug|Placebo|Oral doses, once a day for 52 weeks
75931695|NCT01235559|Drug|bitopertin [RO4917838] level 1|Oral dose level 1, once a day for 52 weeks
75931696|NCT01235559|Drug|bitopertin [RO4917838] level 2|Oral dose level 2, once a day for 52 weeks
75931697|NCT04207476|Device|EMF|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
75931698|NCT04207476|Device|Placebo|No magnetic field exposure will be given while patients are assigned to this arm for a duration of 1 hour.
75931699|NCT03470454|Drug|Linagliptin Oral Tablet|Linagliptin for blood glucose control
75646939|NCT01876524|Device|Transcranial Random Noise Stimulation|Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
75794541|NCT03786185|Behavioral|MusicPlast|"Each subject will receive 20 sessions of the computerized training based on a simplified music reading protocol. The training will be provided via a smartphone or a tablet. Each training session will last for 20 minutes and the log file will be directly available to the researcher, allowing him/her to follow subject's timely participation. The stimuli used in the training protocol will consist of a visual image showing a circle on top of a background of 5 horizontal lines. The auditory part of the stimulus will consist of piano melodies of known songs. The position of the circle within the five lines will either follow the rule the higher the pitch of the tone, the higher the position of the circle or it will violate the above rule. The task requires audiovisual integration."
75794542|NCT03786185|Behavioral|MusicPlast Control|Each subject will receive 20 sessions of the computerized training within a period of 4 weeks, aiming to train visual search via spot-the-difference tasks and identification of dissonance in music. Auditory and visual stimuli are concurrently presented, but do not require audiovisual integration.
75794543|NCT03777020|Behavioral|Service Dog Training Program|Participate in 8 weekly dog training sessions using a positive reinforcement method and curriculum under the direct supervision of trainer at the Warrior Canine Connection facility in Boyds (Montgomery County) MD.
75931700|NCT04490252|Dietary Supplement|Fasting mimetic diet|Fasting mimetic diet for 5 days, another cycle after 25 days
75931701|NCT03130842|Drug|Sublingual alprazolam|Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
75931702|NCT03130842|Drug|Oral midazolam|Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
75931703|NCT03130764|Drug|Durvalumab|1500 mg, IV over 1 hour Every 4 weeks for 1 year
75931704|NCT03130764|Drug|Tremelimumab|75 mg, IV over 1 hour Every 4 weeks for 4 doses
75473159|NCT01967108|Other|chest physiotherapy|chest physiotherapy, up to one hour from extubation, in ICU patients
75931705|NCT01234779|Drug|bitopertin [RO4917838]|10 mg orally daily, 4 weeks
75931706|NCT01234779|Drug|bitopertin [RO4917838]|30 mg orally daily, 4 weeks
75931707|NCT01234779|Drug|olanzapine|15 mg orally daily, 4 weeks
75931708|NCT01234779|Drug|placebo|orally daily, 4 weeks
75931709|NCT01234311|Drug|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
75931710|NCT01234311|Drug|Placebo|
75931711|NCT03223350|Drug|Capsaicin 0.1% Cream|Topical application
75931712|NCT03223350|Drug|Placebos|placebo cream
75931713|NCT04581642|Device|PMD200|The NOL technology is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
75473160|NCT01967186|Procedure|Intraportal islet transplantation|
75473161|NCT01967186|Procedure|Intramuscular islet transplantation|
75473162|NCT01967186|Procedure|Intramuscular transpl with stemcells|
75473163|NCT01967186|Procedure|Kidney transplantation|All patients will undergo kidney transplantation regardless of arm
75646940|NCT01760915|Other|NC100182 Hyperpolarized 3He|Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.
75646941|NCT01695863|Drug|comparing 2 drugs on their effect on the bowel preparation for colonoscopy|the effects of the drug on the colon preparation for colonoscopy
75646942|NCT01666808|Drug|FACBC|FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings
75473164|NCT01967199|Device|Everolimus-eluting balloon expandable stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
75646943|NCT01666808|Radiation|Radiation therapy|External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
75646944|NCT01539122|Device|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
75646945|NCT01539122|Device|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
75931714|NCT03306368|Behavioral|Youth Opioid Recovery Support|"The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management."
75931715|NCT02840136|Drug|Piperacillin-tazobactam combination product|
75931716|NCT02840136|Drug|Meropenem|
75646946|NCT00878254|Biological|G-CSF|Granulocyte-colony stimulating factor (G-CSF) 480 mcg subcutaneously (SQ) starting on Day 13 of Cycles 1 and 3; and Day 7 of Cycles 2 and 4, per study protocol.
75646947|NCT00878254|Drug|Rituximab|Rituximab 375 mg/m^2 intravenously (IV) on Day 1 for 4 Cycles, per study protocol. For study participants achieving complete remission, during maintenance therapy every 6 months for up to three years, per study protocol.
75646948|NCT00878254|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m^2 IV on Day 1 and 200 mg/m^2 IV on Days 2 through 5 of Cycles 1 and 3, per study protocol.
75646949|NCT00878254|Drug|Cytarabine|Cytarabine 2 grams/m^2 IV on Days 1 and 2 of Cycles 2 and 4, per study protocol.
75646950|NCT00878254|Drug|Doxorubicin|Doxorubicin 45 mg/m^2 IV bolus Day 1 of Cycles 1 and 3, per study protocol.
75646951|NCT00878254|Drug|Etoposide|Etoposide 60 mg/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
75931717|NCT02840136|Drug|Ceftazidime|
75931718|NCT04491188|Dietary Supplement|Bacillus subtilis DE111|1 x10-9 CFU Bacillus subtilis DE111 probiotic
75931719|NCT04491188|Dietary Supplement|Placebo|Maltodextrin placebo
75931720|NCT02468258|Procedure|endometrial flushing|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
75931721|NCT04015050|Other|milk based infant formula|Cows milk ased infant formula
75931722|NCT02263287|Other|LeSCoD scale|LeSCoD is a clinical scale
75794544|NCT03777020|Other|Dog Training Education|Learn about training dogs by watching 8 weekly dog training online modules programs at the Warrior Canine Connection facility in Boyds (Montgomery County) MD. After completing this education the participants will participate in the service dog training program.
75646952|NCT00878254|Drug|Ifosfamide|Ifosfamide 1.5 grams/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
75794545|NCT03771677|Drug|Nucleotide Analog|such as Entecavir,entecavir 0.5mg per day
75794546|NCT03771677|Drug|Interferon Alfa-2A|Peginterferon alfa-2a 180ug per week
75794547|NCT03770767|Drug|Faster-acting Aspart insulin Fiasp|Randomization to treatment with insulin Fiasp
75794548|NCT03770767|Drug|Control (insulin Novorapid)|Randomization to standard treatment with insulin Novorapid
75794549|NCT03769155|Biological|Ipilimumab|Given IV
76085787|NCT06028880|Behavioral|Free2Be|Free2Be is a manualized 13-week face-to-face group intervention for SM individuals with one pre-session and plus 12 intervention sessions. The themes of each session are: Human nature & Relation with suffering (S1), Emotional regulation & Multiple selves (S2), Creative hopelessness & Values (S3), Compassionate attention (S4), Compassionate acceptance (S5), Self-criticism; Compassion & Flows of compassion (S6), Compassionate imagination; Compassionate self (S7), Early experiences; Stigma and shame; & Compassionate cognitive desfusion (S8), Compassionate thinking (S9), Difficult emotions: Shame & Anger (S10), Coming out & Compassionate behaviour (assertiveness) (S11), Positive emotions & Preparing for the future (S2).
76085788|NCT06028607|Dietary Supplement|QD-27|Oral Protein gel with greater Leucine proportion and vitamin D Consumption of 2 each day for 3 months to be taken at breakfast and lunch
76085789|NCT06028165|Procedure|Coronary artery bypass grafting based on conventional coronary angiography|Revascularized coronary arteries are decided based on conventional coronary angiography.
75473165|NCT01967199|Device|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
76085790|NCT06028165|Procedure|Coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve.|Revascularized coronary arteries are decided based on cardiac computed tomography-derived fractional flow reserve.
75794550|NCT03769155|Biological|Nivolumab|Given IV
76085791|NCT06028126|Procedure|Intermittent Superficial Parasternal Intercostal Plane Block - Experimental|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.2% ropivacaine), intermittent boluses of 10 mL 0.2% ropivacaine per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
75473166|NCT01967212|Device|Game-based swallow biofeedback|"The intervention are divided into two parts：~Traditional swallowing training 30 min by speech therapist.~Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator."
75473167|NCT01967212|Behavioral|Swallow training without biofeedback|"The intervention are divided into two parts：~Traditional swallowing training 30 min by speech therapist.~Mendelsohn's maneuver and effortful swallow without biofeedback 30 min."
75794551|NCT03769155|Biological|VX15/2503|Given IV
75473168|NCT01967251|Drug|Udenafil|Udenafil tablets
75473169|NCT01967251|Drug|Placebo|Udenafil placebo-matching tablets
75646953|NCT00878254|Drug|Leucovorin|Leucovorin: 100 mg/m^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is < 0.1 µmol/L during Cycles 1 and 3 per study protocol.
75646954|NCT00878254|Drug|Mesna|Mesna 360 mg/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
75646955|NCT00878254|Drug|Methotrexate|Methotrexate 1,200 mg/m^2 in 250 mL D5W IV over 1 hour, followed by Methotrexate 3,000 mg/m^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3, per study protocol.
75646956|NCT00878254|Drug|Vincristine|Vincristine 1.5 mg/m^2 IV push (maximum of 2 mg) on Days 1 and 8 of Cycles 1 and 3, per study protocol.
75646957|NCT00813423|Drug|Hydroxychloroquine|Given PO
75646958|NCT00813423|Other|Laboratory Biomarker Analysis|Correlative studies
75794552|NCT03769155|Procedure|Surgery|Undergo therapeutic conventional surgery
75794553|NCT03761875|Other|blood sample CHB patients|"During a boold sample at only one follow up visit:~3 tubes EDTA 10 ml per patient~1 tube Paxgene 1ml~1 dry tube per patient"
75794554|NCT03761875|Other|boold sample Control group|"2 tubes EDTA ideally age and sex matched to CHB patient.~1 tube Paxgene 1ml~1 dry tube"
75794555|NCT03760926|Device|May Health Kit|The intervention consists in the realisation of the May Health Procedure using the May Health Kit, which comprises two elements: a disposable device (May Health Device) and a radiofrequency (RF) energy generator (May Health System). The May Health Device is a short-term invasive device delivered and positioned through the vagina to deliver RF energy inside the ovary in order to ablate ovarian tissue.
75473170|NCT01967264|Drug|Udenafil|Udenafil tablets
75473171|NCT01967264|Drug|Placebo|Placebo tablets
75473172|NCT01967290|Device|Vibratory feedback and 3D movement analysis|Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
75473173|NCT01967290|Device|Only 3D movement analysis|Hand-to-mouth task performed under 3D continuous movement analysis only
75473174|NCT01967329|Drug|Standard Triple|Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
75646959|NCT00813423|Other|Pharmacological Study|Correlative studies
75794556|NCT03753776|Drug|Placebo pills of Radium bromatum|Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
75794557|NCT03753776|Drug|Radium bromatum pills|Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
75646960|NCT00813423|Drug|Sunitinib Malate|Given PO
75646961|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
75931723|NCT03306290|Drug|Serum dosage of antibiotic prophylaxis CEFOXITIN|"Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (~30 min), 1 tube (5 ml) of blood will be withdrawn~Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn"
75794558|NCT03753776|Drug|Radium bromatum/Apis mellifica/Belladonna placebo pills|Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
75931724|NCT01616199|Drug|PX-866|"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
75931725|NCT01616199|Drug|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
75931726|NCT03306212|Drug|Botulinum toxin A|
75931727|NCT03306212|Other|Occupational Therapy|
75931728|NCT03306212|Other|Intermittent serial casting|
75931729|NCT04506138|Drug|Camrelizumab|Camrelizumab 200mg D1, D22
75931730|NCT04506138|Drug|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound) 100mg/m^2 D1, D8, D22, D29
75794559|NCT03753776|Drug|Radium bromatum/Apis mellifica/Belladonna pills|Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
75931731|NCT04506138|Drug|Carboplatin|Carboplatin AUC5 D1, D22
75931732|NCT03306134|Diagnostic Test|Dysphagia|"An overall assessment is going to be carry out by a multidisciplinary team during the visit.~Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire [4]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.~All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)"
75931733|NCT04456452|Biological|Ampion|Ampion, administered by intravenous infusion
75931734|NCT04456452|Other|Standard of Care|Standard of Care
75931735|NCT01598103|Drug|SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
75931736|NCT01598103|Drug|Placebo to SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
75646962|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
75794560|NCT03752892|Other|intervention -1-leg cycle training|partitioned aerobic exercise training
75794561|NCT03752892|Other|usual care - 2-leg cycle training|conventional aerobic exercise training
75931738|NCT04456530|Drug|Aveed 750 MG in 3 ML IM Injection|Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.
75931739|NCT04456530|Other|Normal Saline 3 ML IM Injection|Participants in the Control Group will receive two IM normal saline injections 1 month apart.
75931740|NCT05395754|Device|App Intervention|Use of the PCheck app, an app encouraging STI prevention behaviors.
75931741|NCT02268591|Device|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
75931742|NCT04456374|Other|Performance testing|Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.
75931743|NCT03471936|Diagnostic Test|Acquisition of pressure-volume-loops|Diagnostic workup including cardiac MRI, Echocardiography and cardiopulmonary exercise test (CPET) followed by invasive acquisition of RV and left ventricular (LV) pressure-volume-loops
75646963|NCT00146562|Drug|Darbepoetin Alfa|Given day before chemotherapy of red blood cell count is below normal
75646964|NCT00146562|Drug|Pegfilgrastim|Given as an injection the day before chemotherapy for a total of 8 injections
75646965|NCT00146562|Drug|Paclitaxel|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
75931744|NCT02268669|Other|Reperfusion strategies|Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
75646966|NCT00146562|Drug|Doxorubicin|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
75646967|NCT00146562|Drug|Cyclophosphamide|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
75794562|NCT03747575|Drug|MSTT1041A|Participants will receive subcutaneous (SC) MSTT1041A
75794563|NCT03747575|Drug|Placebo|Participants will receive SC placebo
75794564|NCT03747419|Drug|Avelumab|Avelumab is a form of immunotherapy, which means it is designed to help the patient's immune system kill cancer cells.
75337195|NCT05030337|Device|Closed-loop automated oxygen control (Oxygenie, SLE 6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
75646968|NCT00017953|Behavioral|Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
75794565|NCT03747419|Radiation|Radiation|Cancer treatment that uses ionizing radiation to kill cancer cells.
75646969|NCT00017953|Behavioral|Diabetes Support and Education|Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
75794566|NCT03733145|Drug|Angiotensin II|Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
75931745|NCT01407003|Drug|LIK066|Participants will receive a single or multiple doses of LIK066
75931746|NCT01407003|Drug|Placebo|Participants will receive a single or multiple doses of a matching placebo
75931747|NCT02724774|Behavioral|Promoting First Relationships®|"PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting."
75931748|NCT05359952|Behavioral|Starting the Conversation|The Starting the Conversation intervention consists of a brief educational video and accompanying workbook with activities to help prepare patients to discuss sexual and menopausal types of health concerns effectively with gynecologic cancer providers, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback. In addition, participants receive a list of sexual and menopausal resources.
75931749|NCT05359952|Behavioral|Sexual and Menopausal Health Resources Only|A list of resources on sexual/menopausal health both within and outside the institution, including websites.
75337196|NCT05017675|Other|High fructose diet|"4 week high fructose diet.~Intended composition (En%):~Carbohydrates: 60-70 Fat: 20-30 Protein: 10-15 Fructose: 20 SFA: 5"
75337197|NCT05017675|Other|High saturated fat diet|"4 week high saturated fat diet.~Intended composition (En%):~Carbohydrates: 35-45 Fat: 40-50 Protein: 10-15 Fructose: 5 SFA: 20"
75337198|NCT04926675|Behavioral|Psychological Therapy|Participants will be receiving their one-to-one psychological therapy from IAPT as usual. They typically receive between 6 and 12 sessions with a psychological practitioner.
75337199|NCT04926675|Behavioral|Debt Advice|Participants will receive one-to-one support from a Citizen's Advice (CA) money advisor for as long as needed to resolve any money worries currently affecting their mental health.
75646970|NCT04015882|Other|Exercise therapy|The exercise therapy group will make by physiotherapist supervision.
75646971|NCT04089592|Drug|Dexmedetomidine|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
75646972|NCT04089592|Drug|Fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline
75646973|NCT04092400|Device|Micro-invasive Glaucoma Surgical Devices|Safety and efficacy of Micro-invasive Glaucoma Surgical Devices
75646974|NCT00964028|Biological|Infanrix™-IPV/Hib|Intramuscular, three doses
75646975|NCT02862002|Other|"therapeutic education of type caratif"|"study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology"
75337200|NCT04914234|Drug|Atenolol Succinate Oral Tablet|Atenolol 50 mg
75337201|NCT04914234|Drug|Metoprolol Succinate Oral Tablet|Metoprolol 100 mg
75337202|NCT04913649|Drug|Ferric Derisomaltose 100 MG/ML|Postoperative treatment with a single dose IVI (ferric derisomaltose), with a dose of 20mg/kg in approximately 60 minutes.
75337203|NCT04913649|Drug|Sodium chloride|Postoperative treatment with a single dose NaCl 0.9% in approximately 60 minutes.
75337204|NCT04896398|Device|ESWT|In the study group, a total of 5 sessions of focused ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the affected wrist within 2 weeks.
75646976|NCT02862002|Other|Standard care|patients receiving standard care of cancer pain.
75646977|NCT02861144|Other|Ma ka hana ka ̒ike|Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.
75794567|NCT03715972|Drug|Hydroxyurea|info included in arm group
75794568|NCT03715972|Drug|Acetazolamide|Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.
75931750|NCT01233375|Drug|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
75931751|NCT05346302|Drug|Pneumovax 23|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
75337205|NCT04895566|Biological|Monoclonal antibody (Mab) sB24M|200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.
75337206|NCT04889937|Device|PointCheck|PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose
75337207|NCT04880538|Procedure|Endoscopic procedure|Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.
75337208|NCT04864561|Biological|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide 2 vaccinations 28 days apart
75337209|NCT04864561|Biological|AZD1222|2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein.
75337210|NCT04864561|Biological|VLA2001 - adolescent part|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later.
75337211|NCT04864561|Biological|Placebo|2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium )
75473175|NCT01967329|Drug|Sequential|Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
75473176|NCT01967329|Drug|Quadruple|Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
75473177|NCT01967355|Other|lipid apheresis|
75646978|NCT02861144|Other|Hanapū Provider Toolbox|Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
75794569|NCT03702218|Drug|Direct Acting Antivirals|"Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
75794570|NCT03699761|Procedure|Closure of the pelvic peritoneum|Closure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
75794571|NCT03699761|Procedure|Nonclosure of the pelvic peritoneum|Nonclosure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
75794572|NCT03690050|Procedure|Diode 577 nm subthreshold micropulse laser|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The DSML surgery will be performed by an Ophthamologist
75794573|NCT03690050|Procedure|Standard threshold laser (532 nm laser)|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The standard laser surgery will be performed by an Ophthamologist
75794574|NCT03657043|Drug|tisotumab vedotin|Intravenous (IV) infusion
75931752|NCT05346302|Drug|Typhim VI|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
75931753|NCT05346302|Other|Saline|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
75473178|NCT01967368|Drug|Intanza|Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
75473179|NCT01967368|Drug|Vaxigrip|Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
75473180|NCT01967381|Drug|Methamphetamine (Desoxyn®)|The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
75646979|NCT00960206|Device|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
75646980|NCT00960206|Device|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
75646981|NCT00960206|Device|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
75931754|NCT01232595|Drug|LFF571|
75931755|NCT01232595|Drug|Vancomycin (POC)|
76085792|NCT06028126|Procedure|Intermittent Superficial Parasternal Intercostal Plane Block - Sham|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.9% Saline), intermittent boluses of 10 mL 0.9% Saline per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
75337212|NCT04848298|Behavioral|mHealth Intervention|"The Mobile Health Arm will receive standard of care including tailored prescription of physical activity as well as the mobile health intervention, which will have the following features:~Goal setting for frequency and duration of exercise sessions~Graphic feedback and reinforcement with educational and motivational messages tailored to user's exercise adherence.~Problem-solving support~Library with educational tips and information regarding physical exercise."
75794575|NCT03655223|Diagnostic Test|Confirmatory Testing|If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
75646982|NCT00751036|Drug|Nilotinib|Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
75794576|NCT03646669|Behavioral|PEF Feedback|Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
75473181|NCT01967394|Other|Use of internet based social marketing intervention|"Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention."
76085793|NCT06027931|Procedure|Conservative Access Opening, Traditional Access Opening|Conservative Access Opening will be used and evaluated for cleaning ability versus Traditional Access Opening.
75646983|NCT00751036|Drug|Imatinib|Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
75794577|NCT03646669|Behavioral|Asthma education|General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
75794578|NCT03646240|Drug|ABI-009|For dose finding, ABI-009 will start at 5 mg/m2/dose IV, once a week for three weeks, in cohorts of 3 participants each using the standard 3+3 dose-finding design
76085794|NCT06027645|Behavioral|Crawling stimulation with a mini-skateboard (i.e. the crawliskate)|Consists of 8 weeks of daily training. Infants benefit from a 10 minutes session everyday at home with either a trained therapist or his/her parents. Parents are trained by the therapist at the begining of the 8 weeks. During each session the infant is prone wrapped on a mini-skateboard (i.e. the crawliskate) and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the adult (therapist or parent).
76085795|NCT06027359|Other|Therapeutic play hospital fear and nursing interventions|"Children assigned to the study group will be divided into 5 groups, with a maximum of 8 children. The researcher will perform a therapeutic play activity with each group consisting of maximum 8 children one day of the week in the room and time determined by the school. Each activity will last an average of 30 minutes. Therapeutic play activities will be completed in 4 weeks.~Therapeutic play activities will not be performed with the children in the control group.~One week after the completion of the therapeutic play intervention, the researcher will re-fill the Child Nursing Interventions and Fear of Materials Scale-uncommon materials sub-dimension face-to-face with the children in the study and control groups."
76085796|NCT06026267|Biological|20% High Dose Albumin|A]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy
75794579|NCT03637387|Drug|BIIB074|Administered as specified in the treatment arm
75794580|NCT03637387|Drug|Placebo|Administered as specified in the treatment arm.
75794581|NCT03634540|Drug|Belzutifan|Belzutifan tablets administered orally.
76085797|NCT06026267|Other|Standard Medical Treatment|Standard Medical Treatment
75337213|NCT04826835|Behavioral|Prehabilitation intervention|"Participants will:~Receive four supervised exercise classes (twice per week for two weeks) one-to-one by an exercise specialist;~Practice six sessions of home-based exercise (three times per week for two weeks);~Practice unsupervised respiratory muscle training at home (twice daily for two weeks);~Receive usual care."
75794582|NCT03634540|Drug|Cabozantinib|Cabozantinib tablets administered orally.
75794583|NCT03619876|Drug|Abatacept|125 MG/ML subcutaneous injections
75646984|NCT00961298|Drug|Duloxetine|All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
76085798|NCT06026267|Biological|20% Reduced Dose Albumin|B]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy
75337214|NCT04826835|Behavioral|Health education control|"Participants will:~Receive four recorded health education talks (twice per week for two weeks)~Receive a brief health education booklet on dietary education for chronic lung conditions, preoperative preparation, and postoperative recovery~Receive usual care."
75337215|NCT04806113|Biological|Moderna COVID-19 vaccine|Two doses from the Moderna vaccine will be administered intramuscularly. The time between dose 1 and dose 2 of the vaccine will be 28 days.
75337216|NCT04779320|Drug|Vedolizumab IV|Vedolizumab IV
75337217|NCT04769869|Drug|AZD4604 for inhalation via DPI|Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
75794584|NCT03619876|Drug|Adalimumab|40 Mg/0.8 mL Subcutaneous Kit
75337218|NCT04769869|Drug|Placebo for AZD4604 for inhalation via DPI|"Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10."
75337219|NCT04769869|Drug|AZD4604 for IV administration|Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
75337220|NCT04769869|Drug|AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
75337221|NCT04769869|Drug|AZD4604 for inhalation via DPI|Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
75337222|NCT04769011|Diagnostic Test|Clinical evaluation|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule, Social Responsiveness Scale, Children Behavior Check List, Conners' Scale
75473182|NCT01967394|Other|No use of social media|No social media ads will be available in these counties.
75473183|NCT01967407|Procedure|Irreversible Electroporation (IRE)|Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
75473184|NCT01967420|Behavioral|Cognitive remediation|CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
75473185|NCT01967420|Behavioral|Social cognition training|The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
75473186|NCT01967459|Drug|Cholecalciferol|Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)
75473187|NCT01967459|Drug|Cholecalciferol|Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
75646985|NCT00744328|Drug|Transdermal Estradiol|Estradiol patch ranging in dose from 50 to 200 mcg/day
75646986|NCT00744328|Drug|Sertraline|Sertraline dose will range from 50 - 200 mg/day
75794585|NCT03608280|Procedure|Bone autograft|The principle of this surgery is based on the removal of a portion of the outer bone layer from the vault of the skull in order to have a flat and solid bone element (cortical bone), which can be carved freehand to better replace the defective bone wall.
75931756|NCT02721498|Procedure|Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)|An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)
75931757|NCT02721498|Other|Rest period|A 30-60 minute of resting
75931758|NCT05305820|Behavioral|Exercise|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing treatment and for a six-week period when deemed fit post-surgery.
75931759|NCT05305820|Behavioral|Nutrition|Participants will be screened for their nutritional health and tailored advice and education will be provided on an individualised basis. An online dietary recall tool will be used to track patients' dietary habits. This will occur from diagnosis until point of surgery and recommence for 6 weeks post-surgery once deemed physically fit.
75931760|NCT04472676|Drug|LY3473329|Administered orally.
75931761|NCT04472676|Drug|Placebo|Administered orally.
75931762|NCT01231347|Drug|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
75931763|NCT01231347|Drug|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
75931764|NCT01231347|Drug|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
75931765|NCT01231347|Drug|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
75931766|NCT02466152|Drug|GSK2894512 Topical Cream|GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram [mg/g]) and 1.0% (10 mg/g)
75337223|NCT04769011|Diagnostic Test|Neuropsychological evaluation|The participants' motor skills are measured using the Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007), the Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007), and the kinematic analysis of a reach-to-drop task (Forti et al., 2011; Crippa et al., 2015).Sensorimotor domain will be also further investigated with NEPSY-II (Korkman et al., 2007) (Fingertip Tapping, Imitating Hand Positions, Manual Motor Sequences, and Visuomotor Precision).
75646987|NCT00744328|Other|Placebo|Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
76085799|NCT06025760|Other|patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness|All patients after ICU admission will be started enteral nutrition through a nasogastric tube within 24-48 hours. The target caloric intake is 25-30 kcal/kg/day. patients in the interventional group will receive 2 gm protein/kg/day, while patients in the control group will receive 1.2 gm protein/kg/day. Quadriceps thickness and Diaphragm thickening fraction will be assessed by ultrasound from the time of admission on days 0, 3, 5, and 7 then weekly till the fourth week.
76085800|NCT06024980|Procedure|Open partial horizontal laryngectomy(OPHL), Type I-III|An open partial horizontal laryngectomy(OPHL) was performed for patients with T2 supraglottic and glottic carcinoma, according to the American Joint Committee on Cancer(AJCC) criteria. Type I OPHL: Entails the resection of the supraglottis, including the pre-epiglottic space and the upper half of the thyroid cartilage. Type II OPHL: Entails the resection of the entire thyroid cartilage, with the inferior limit represented by the upper edge of the cricoid ring. Type III OPHL: Entails the resection of the entire supraglottic, glottic, and part of the subglottic sites, sparing both or at least one functioning crico-arytenoid unit.
76085801|NCT06024980|Procedure|Transoral endoscopic laser cordectomy|"For patients with T1 glottic laryngeal carcinoma, according to the criteria of the American Joint Committee on Cancer(AJCC), transoral endoscopic CO2 laser(2-40Watts) cordectomy was performed. The classification comprises eight types of cordectomies:~A subepithelial cordectomy (type I) is a resection of the epithelium of the vocal fold.~A subligamental cordectomy (type II) is a resection of the epithelium, Reinke's space, and vocal ligament.~Transmuscular cordectomy (type III), which proceeds through the vocalis muscle.~Total cordectomy (type IV).~Extended cordectomy encompasses the contralateral vocal fold and the anterior commissure (type Va).~Extended cordectomy, which includes the arytenoid (type Vb).~Extended cordectomy, which encompasses the subglottis (type Vc).~Extended cordectomy, which consists of the ventricle (type Vd)."
75646988|NCT00917332|Behavioral|"relaxation (breathing and muscles) and guided imagery (safe place)"|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
75337224|NCT04769011|Diagnostic Test|Neurophysiological evaluation|Magnetic Resonance Imaging (structural MRI and DTI)
75337225|NCT04769011|Diagnostic Test|Genetic evaluation|Either blood or saliva will be obtained for participants for DNA collection. DNA will be extracted in the Molecular Biology Laboratory at the Scientific Institute IRCCS Medea. Captured exome libraries will be sequenced using the Illumina NextSeq 500 in 100 bp paired end reads. Postsequencing reads will be aligned using BWA Enrichment application on BaseSpace. VCF file will be then marked using wANNOVAR (Wang Genomics Lab). The analysis will be focused on non-synonymous variants enrichment in Gene Ontology and Human Phenotype.
75337226|NCT04762199|Drug|Flt3/MerTK Inhibitor MRX-2843|Given PO
75337227|NCT04762199|Drug|Osimertinib|Given PO
75337228|NCT04755881|Other|Occurence of biphasic reaction following anaphylaxis|Prospective observation for biphasic reaction following anaphylaxis and subsequent analysis (comparison between usual care and the care that would have been suggested by the three proposed clinical decision rules).
75337229|NCT04750720|Other|Sampling by venipuncture (and eventually by nasopharyngeal swab)|"Biological samples :~Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test~PBMC (peripheral blood mononuclear cells)~Nasopharyngeal samples (not mandatory)~Associated data :~Demographic data~Description of clinical manifestations related to SARS-CoV-2 infection~Notion of hospitalization/ambulatory follow-up~Blood Fractioning~Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)~Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells"
75337230|NCT04734951|Other|Power/resistance exercise program|participants will complete a power/resistance program during 14 weeks. The exercise program will consist of training to improve muscle strength, neuromotor skills, flexibility, endurance, and a greater emphasis on maximum strength and power. The intensity will be set according the estimated repetition to failure.
75646989|NCT04019782|Drug|Collagen-PVP|Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine, administered by intraarticular injections (three doses, one each 7 days)
75646990|NCT04019782|Device|Hylan G-F 20|Infiltrations of 2 mL 0.8% Hylan G-F 20 (16 mg) solution, administered by intraarticular injections (three doses, one each 7 days)
75646991|NCT04092088|Device|tDCS-r|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).
75794586|NCT03608280|Procedure|Orbital reconstruction by 3D-printed porous titanium implant|"From data of a patient's CT-scan, it is possible to perform a mirroring. The unaffected orbit is mirrored onto the affected orbit, via a virtual treatment planning, in order to rely on facial symmetry to virtually restore healthy anatomy. From this simulation, the implant is 3D-printed by Selective Laser Melted (SLM) technique using titanium powder. This technique enabling the creation of custom-made implants is called computer-aided design and computer-aided manufacturing (CAD-CAM).~After sterilization, the implant is ready to be placed during a surgical procedure."
75794587|NCT03605901|Drug|Standard dosing of methadone|Subject will receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
75794588|NCT03605901|Drug|Aliquots of methadone titrated to apnea|Subjects will receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals.
76085802|NCT06024876|Biological|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
75646992|NCT04092088|Device|TENS-r|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..
75931767|NCT03470376|Dietary Supplement|Nutraceutical combination (NC)|An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen
76085803|NCT06023537|Behavioral|Behavioral weight loss program|All participants will participate in the same remote, behavioral weight loss program. As part of the baseline assessment, participants will be asked to watch a series of custom-made videos on the study's dietary and physical activity prescriptions, dietary self-monitoring, self-weighing, and cognitive-behavioral skills to facilitate engagement in study prescriptions. Participants will be prescribed a reduced-calorie diet that will be individualized based on the individual's starting weight and weight loss goal (recommended goal of 5-10% weight loss over 12 weeks). Participants also will be prescribed a goal of 150 minutes of moderate-to-vigorous physical activity per week. They are also given, free of cost, a Fitbit Charge 5 health tracker, the Fitbit Aria Air digital scale, and a MyFitnessPal Premium subscription for the duration of the study.
76085804|NCT06023173|Diagnostic Test|Deep radiomics-based fusion model|This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
76085805|NCT06022809|Behavioral|Dada Kwa Dada (individual-level)|Dada Kwa Dada (DKD) intervention is an adapted version of Sister to Sister (S2S) intervention (a brief, health profession-led, individual-level intervention proven to increase condom use and decrease STIs among African American women). Intervention is a 1hr to 1.5hrs session and offered in English or French.
76085806|NCT06022809|Behavioral|DADA (group-level)|DADA intervention is an adapted version of Sisters Informing Sisters about Topics on AIDS (SISTA) intervention (a peer-led, group-level intervention proven to increase condom use and decrease STIs among African American women). This is a 6hrs intervention implemented in two three-hour sessions and offered in English or French.
76085807|NCT06016205|Procedure|intrathecal morphine injection|Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia
76085808|NCT06016205|Procedure|ultrasound guided PECS2 block|ultrasound guided PECS2 block will be performed with 30 ml bupivacaine 0.25%
76085809|NCT06015204|Procedure|Interscalene brachial plexus block targeting the C5-to-C6 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C6 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
75646993|NCT04092088|Device|tDCS-s|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).
75794589|NCT03605368|Behavioral|Virtual Reality Intervention|Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.
75931768|NCT03470376|Behavioral|No nutraceutical combination (noNC)|Prosecution of standardized diet regimen for 3 months
75931769|NCT02719028|Drug|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
75646994|NCT04092088|Device|TENS-s|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).
75646995|NCT02599480|Drug|mirabegron|50 mg daily during 12 months
75337231|NCT04734951|Dietary Supplement|HMB supplementation|Daily oral supplementation with 237 ml of a polymeric nutritional formula added with 1.5 g of HMB (Ensure Advance®)
75473188|NCT01967472|Drug|amodiaquine-artesunate (AQAS) fixed-dose|
75473189|NCT01967472|Drug|Artemether-lumefantrine combination (AL) dispersable|
75337232|NCT04733157|Drug|Tranexamic acid injection|Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section
75473190|NCT01967485|Other|Text- Messaging|Text messages will be sent to the parents of children enrolled in the study.
75931770|NCT02719028|Drug|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
75931771|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
75931772|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
75337233|NCT04733157|Other|Normal saline placebo|10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group
75337234|NCT04711239|Diagnostic Test|PGT-A / niPGT-A|PGT-A and niPGT-A will be performed using next generation sequencing (NGS) analysis for chromosome copy number variation (CNV). Embryo transfers will rely solely on the results of PGT-A for trophectoderm biopsies.
75473191|NCT01967485|Other|Treatment as usual|Children will receive stimulant treatment for ADHD.
75473192|NCT01967498|Drug|Montelukast|
75473193|NCT01967524|Drug|botulinum toxin A + ropivacaïne|"D0 :~Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~QDSA (Saint-Antoine pain questionnaire)~QCD (Pain questionnaire)~MPI (Multidimensional Pain Inventory)~Beck scale~HAD (Hospital Anxiety and Depression scale)~SF36 (Short Form 36)~injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
75646996|NCT02599480|Procedure|Echocardiography|Echocardiography
75794590|NCT03605368|Behavioral|Video Modeling Intervention|The video modeling intervention is a subset of the BE SAFE The Movie Curriculum Lessons (https://besafethemovie.com/curriculum/) that were selected to match Floreo PSM on length. The BE SAFE The Movie Curriculum consists of video-based instruction on police officer interaction expectations and safety. Within each of three sessions, participants will watch videos, complete worksheets, and discuss topics related to police safety knowledge and behaviors with the study administrator.
75646997|NCT02599480|Procedure|Cardiac MRI|Cardiac MRI
75646998|NCT02599480|Procedure|Maximal exercise capacity|Maximal exercise capacity
75794591|NCT03605368|Behavioral|No intervention|Participants will follow all study procedures with the exception of the VR-based intervention including assessments.
75646999|NCT02599480|Procedure|Blood sampling|Blood sampling for study assessments and future exploratory studies.
75647000|NCT02599480|Procedure|Endothelial function measurement|EndoPAT assessment
75794592|NCT03584165|Genetic|BIIB111|Administered as specified in the treatment arm.
75794593|NCT03584165|Genetic|BIIB112|Administered as specified in the treatment arm.
75794594|NCT03579771|Drug|Cisplatin|Given IV
75931773|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
75931774|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
75931775|NCT01230957|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular on Days 0, 7, and 30
75931776|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 180
75931777|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 30, and 180
75931778|NCT03306056|Other|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
75931779|NCT03306056|Other|Standard Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:~5 strength training exercises (chest, upper/lower back, abdominals, legs)~3 sets per exercise~time-effort per session: ~90 min~2 training sessions per week~duration of exercise intervention: 12 weeks"
75931780|NCT03306056|Other|Low-volume Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:~5 strength training exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~2 training sessions per week~duration of exercise intervention: 12 weeks"
75931781|NCT03306056|Other|Whole-Body Electromyostimulation (WB-EMS)|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:~time-effort per session: ~20 min~duration of exercise intervention: 12 weeks"
75931782|NCT01228383|Biological|Rabies virus-specific monoclonal antibodies|CL184 20 IU/kg intramuscularly on Day 0.
75931783|NCT01228383|Biological|human polyclonal rabies immune globulin (HRIG)|HRIG 20 IU/kg intramuscularly on Day 0.
75931784|NCT01228383|Biological|Placebo|Placebo intramuscularly on Day 0.
75931785|NCT01228383|Biological|Human diploid cell vaccine (HDCV)|Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
75931786|NCT01228383|Biological|Purified verocell rabies vaccine (PVRV)|Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
75931787|NCT03305978|Device|Ultra low dose chest CT|An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
75931788|NCT03305978|Device|Low dose chest CT|standard diagnostic low dose chest CT
75647001|NCT02599480|Radiation|18FDG-PET|PET scanning for beige/brown fat activation
75647002|NCT04091854|Drug|HMS5552|To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
75647003|NCT03245840|Drug|Budesonide oral suspension|BOS 10 mL twice daily.
75647004|NCT04090216|Device|Primary Percutaneous Coronary Intervention|Primary PCI will be done for patients with STEMI in both groups of patients
75647005|NCT04091698|Drug|Co-Enzyme Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
75647006|NCT02598232|Device|1,414nm Nd:YAG Laser System|It has high absorption coefficient in water and a short pulse width.
75794595|NCT03579771|Drug|Gemcitabine|Given IV
75794596|NCT03579771|Drug|Nab-paclitaxel|Given IV
75794597|NCT03578081|Drug|Palonosetron Hydrochloride|Given IV
75794598|NCT03578081|Drug|Ondansetron Hydrochloride|Given IV or PO
75794599|NCT03578081|Drug|Dexamethasone|Given PO
75794600|NCT03578081|Drug|Fosaprepitant Dimeglumine|Given IV
75794601|NCT03578081|Drug|Olanzapine|Given PO
75794602|NCT03578081|Other|Placebo|Given IV
75794603|NCT03563131|Device|Persona® total knee arthroplasty|Insertion of the cemented or uncemented Persona® total knee arthroplasty
75794604|NCT03551262|Device|OTSC|Positioning of OTSC in bleeding peptic ulcer
75794605|NCT03551262|Device|TTS clip|Positioning of TTS clip in bleeding peptic ulcer
75794606|NCT03536312|Procedure|Thoracic Aortic Surgery|Thoracic aortic surgery to treat thoracic aortic aneurysm
75931789|NCT01594983|Drug|LCQ908|
75931790|NCT01594983|Drug|Fenofibrate|Fenofibrate once daily 12 weeks
75931791|NCT01594983|Drug|Fish Oil|Fish Oil once daily for 12 weeks
75931792|NCT01594983|Drug|Placebo of LCQ908|Matching placebo of LCQ908
75931793|NCT01594983|Drug|Placebo of fenofibrate|Matching placebo of fenofibrate
75931794|NCT01594983|Drug|Placebo of fish oil|Matching placebo of fish oil capsule
75931795|NCT03305900|Other|No Intervention|Cross-sectional study requiring a single serum sample
75931796|NCT01404585|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
75473194|NCT01967524|Drug|Ropivacaïne|"D0 :~Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~QDSA (Saint-Antoine pain questionnaire)~QCD (Pain Questionnaire)~MPI (Multidimensional Pain Inventory)~Beck scale~HAD (Hospital Anxiety and Depression scale)~SF36 (Short Form 36)~injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
75931797|NCT01404585|Drug|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
76085810|NCT06015204|Procedure|Interscalene brachial plexus block targeting the C5-to-C8 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C8 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
76085811|NCT06014983|Dietary Supplement|Ferrous fumarate|Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.
76085812|NCT06014983|Dietary Supplement|Ferrous bisglycinate|Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
75647007|NCT04281290|Procedure|Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|"Procedure: Electrochemotherapy Exploration, anesthesia, pancreatic cancer resection, bleomycin administration, electroporation, formation of all anastomoses.~Device: Cliniporator Vitae® Positioning of plate electrodes according to landmarks, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization, approximately 1000V/cm), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization.~Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP) Intravenous bolus administration of bleomycin (15 mg/m2)"
75647008|NCT04091932|Drug|Pembrolizumab|Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
75647009|NCT04090840|Behavioral|Intermittent Fasting|Time restricted eating for 8 hours per day, with 16 hour fast. During the daily fast, patients are encouraged to drink water, black coffee, or green tea without sugar, cream, milk, or sweeteners.
75794607|NCT03527420|Other|Exercise training|Twelve weeks of aerobic exercise training
76085813|NCT06014411|Other|Time to bathing (delayed)|Delayed bathing-- patients will be told to begin showering after wound exam and suture removal (10-20 day postoperative).
76085814|NCT06014411|Other|Time to bathing (early)|Early bathing--Patients will be told to remove dressings and begin showering with body soap on postoperative day 3.
76085815|NCT06013826|Other|Telenursing|Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated.
76085816|NCT06009263|Other|Conventional treatment|"Application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
76085817|NCT06009263|Other|Open chain segmental control|"Application of open chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
76085818|NCT06009263|Other|Closed chain segmental control|"Application of closed chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
75794608|NCT03526861|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.
76085819|NCT06008379|Drug|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
75794609|NCT03526861|Drug|Placebos|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
75931798|NCT01404585|Drug|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
75931799|NCT03305510|Diagnostic Test|vitamin D is below 20ng/ml|
75931800|NCT01224795|Drug|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
76085820|NCT06008379|Drug|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
75931801|NCT01224795|Drug|Placebo Comparator|Placebo Peramivir, administered intravenously.
75931802|NCT02263443|Procedure|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
75931803|NCT02263443|Procedure|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
75931804|NCT02263443|Procedure|No enema|Patients NPO groups will NPO and no bowel preparation.
75931805|NCT02265627|Drug|BIIL 284 BS|
76085821|NCT06008366|Drug|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
75931806|NCT01402401|Drug|AUY922|
75931807|NCT01402401|Drug|Trastuzumab|
75931808|NCT02720510|Drug|Revlimid|Revlimid was used with dexamethasone to treat patients with multiple myeloma
75794610|NCT03520322|Device|Mastoid Oscillator|The oscillator will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
75794611|NCT03520322|Device|Control Device|The control device will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
75931809|NCT02720510|Drug|Velcade|Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
75337235|NCT04688047|Behavioral|Nursing care based on the transtheoretical model|Nursing care consists of urinary incontinence training, motivational interview and telephone/mail counseling processes.
75647010|NCT00959894|Drug|Etravirine (Intelence)|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
75647011|NCT00959894|Drug|Truvada|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
75337236|NCT04685044|Device|IH 1Tx32Rx Head Array|BrainPET insert
75647012|NCT00917566|Device|Airtraq|intubation with airtraq
75794612|NCT03517475|Behavioral|SHS Low-Income|An intervention to train caregivers to supervise their children appropriately.
75647013|NCT00917566|Device|Macintoch|use Macintoch laryngoscope for intubation
75647014|NCT04019938|Radiation|Dual-energy X-ray absorptiometry|Cystatin C is measured as a part of routine investigation at the time of admission.
75794613|NCT03510884|Drug|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous injection
75931810|NCT02720510|Drug|dexamethasone|Dexamethasone was a steroid used to treat patients with multiple myeloma.
75931811|NCT02720510|Drug|Farydak|FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
75931812|NCT02263521|Other|No intervention employed. Study is based on a cross-sectional observational design.|
75337237|NCT04662034|Device|CMIC|The C-MIC System consists of three implantable parts: a transvenous and an epicardial lead which are both connected to an implanted power source, and an external programing device. The patch lead is placed over the free wall of the left ventricle and fixated with sutures. When lead placement is achieved, the leads are then tunneled subcutaneously to the infraclavicular region and connected to the power source.
75337238|NCT04662034|Drug|Standard of Care (SOC)|Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator
75337239|NCT04653662|Device|Earol|Treated with Earol on both ears and subsequent removal after 6 days of application
75337240|NCT04633122|Drug|Ripretinib|Oral kinase inhibitor
75337241|NCT04633122|Drug|Sunitinib|second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
75337242|NCT04630379|Other|Palliative Therapy|Visit with palliative care team
75337243|NCT04630379|Other|Quality-of-Life Assessment|Ancillary studies
75473195|NCT01967589|Drug|NNC0113-0987|Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
75337244|NCT04630379|Other|Supportive Care|Visit with neuro-oncologist
75337245|NCT04630379|Other|Survey Administration|Complete survey
75337246|NCT04629924|Device|sleeper one|anesthesic injection with sleeper one device
75337247|NCT04629924|Device|conventional technis|anesthesic injection with the conventional technic
75473196|NCT01967589|Drug|placebo|Once-daily doses for oral administration
75473197|NCT01967654|Other|Technical Assistance, training and clinical reminders|
75473198|NCT01967654|Other|Referral to Community Health Worker|
75473199|NCT01967667|Dietary Supplement|Liposomal glutathione|Escalating dose steps
75473200|NCT01967667|Dietary Supplement|Placebo|escalating dose steps
75473201|NCT01967680|Procedure|Non-sedation for intubated, mechanically ventilated patients|
75647015|NCT04091620|Procedure|Transanal Total Mesorectal Excision|As above
75647016|NCT04091620|Procedure|Robotic Total Mesorectal Excision|As above
75647017|NCT02859350|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
75794614|NCT03510884|Drug|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
75794615|NCT03510884|Drug|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
75794616|NCT03510884|Drug|Simvastatin|Pharmaceutical form:Tablet Route of administration: Oral
75794617|NCT03510884|Drug|Pravastatin|Pharmaceutical form:Tablet Route of administration: Oral
75794618|NCT03510884|Drug|Lovastatin|Pharmaceutical form:Tablet Route of administration: Oral
75794619|NCT03510884|Drug|Fluvastatin|Pharmaceutical form:Capsule Route of administration: Oral
75794620|NCT03510884|Drug|Ezetimibe|Pharmaceutical form:Tablet Route of administration: Oral
75794621|NCT03510884|Drug|Cholestyramine|Pharmaceutical form:oral suspension Route of administration: oral
75794622|NCT03510884|Drug|Nicotinic acid|Pharmaceutical form:Tablet Route of administration: Oral
75794623|NCT03510884|Drug|Fenofibrate|Pharmaceutical form:Tablet Route of administration: Oral
75794624|NCT03510884|Drug|Omega-3 fatty acids|Pharmaceutical form:capsule Route of administration: oral
75794625|NCT03510884|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous injection
75794626|NCT03497975|Drug|Nalbuphine ER Tablets|Active Nalbuphine ER Tablets
75794627|NCT03497975|Other|Matching Placebo Tablets|Matching Tablets with no active substance
75931813|NCT01220271|Drug|LY2157299|Administered orally
75794628|NCT03497975|Drug|Nalbuphine ER Tablets|Open Label Extension
75794629|NCT03497169|Drug|Lisdexamfetamine Dimesylate|Patients are tested for their normal prescription lisdexamphetamine medication
75794630|NCT03497143|Drug|Lamotrigine|Patients are tested for their normal prescription lamotrigine medication
75931814|NCT01220271|Drug|Radiation|Administered as approved
75931815|NCT01220271|Drug|Temozolomide|Administered orally
75931816|NCT03305432|Combination Product|sleeve + preoperative PPI|sleeve + preoperative PPI
75931817|NCT03305432|Combination Product|sleeve + preoperative Placebo|sleeve + preoperative Placebo
75337248|NCT04626609|Other|Biopsy samples|Esophageal mucosal biopsies are collected during gastroscopy
75337249|NCT04626609|Other|Blood samples|Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes
75473202|NCT01967680|Procedure|Controlgroup, sedation with daily wake-up trial|
75647018|NCT02859350|Biological|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
75647019|NCT02859350|Other|Normal Saline|0.9% Sodium chloride
75647020|NCT02859350|Biological|PfSPZ Challenge (for PfSPZ-CVac)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
75647021|NCT02859506|Other|Respiratory quotient|
75647022|NCT02859506|Other|Olfactory liking|
75647023|NCT04284176|Other|Mirror therapy and action-observation therapy|The mirror therapy and action-observation therapy group will receive for 20 days a daily therapy of 15 minutes at home of MT and 45 of AOT, whereas the action-observation therapy group will receive 60 minutes of AOT.
75647024|NCT00750880|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv (60 minute infusion)
75794631|NCT03491007|Drug|DHEA|Subjects will be randomized to receive a one-time oral dose of DHEA (400mg) or PBO and sustained administration of the study drug for 6 weeks. There will be a 2 week placebo lead-in period [all participants], followed by subjects continuing in the randomization block of DHEA or placebo for 6 weeks following acute administration).
75794632|NCT03488472|Device|NovoTTF-200A|Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.
75794633|NCT03488472|Radiation|Stereotactic Radiosurgery (SRS)|SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.
75794634|NCT03472664|Other|low carbohydrate/high fat diet|Modified Mediterranean-Ketogenic Diet is a low carbohydrate/high fat diet.
75794635|NCT03472664|Other|low fat/high carbohydrate diet|American Heart Association Diet is a low fat/high carbohydrate diet.
75794636|NCT03456453|Behavioral|NIDA Standard for HIV Prevention|The NIDA Standard is a manualized, HIV prevention education intervention focused on reducing risky sexual and drug use practices. It will be adapted for Facebook in this pilot trial.
75931818|NCT01396785|Drug|33525|Daily for 14 days
75647025|NCT02599168|Drug|Propofol|
75647026|NCT02599168|Drug|Dexmedetomidine|
75931819|NCT01396785|Drug|Placebo|Daily for 14 days
75931820|NCT02468102|Drug|Rivaroxaban (Xarelto, BAY59-7939)|"Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).~Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban [od], tablets).~Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
75931821|NCT02468102|Drug|Standard of care drugs|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
75931822|NCT04491266|Dietary Supplement|FBA|N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
75931823|NCT04491266|Dietary Supplement|placebo|maltodextrins
75647027|NCT02599168|Drug|Placebo (normal saline)|
75647028|NCT00746590|Drug|Prolarix (tretazicar co-administered with caricotamide)|Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
75647029|NCT03975868|Other|Analysis of associated factors for cut-out in internal fixation of extracapsular proximal femoral fracture.|Identification of factors for mechanical failure of internal fixation of extracapsular proximal femoral fracture in over 75 year olds
75931824|NCT01204749|Drug|AMG 386|Weekly Intravenous (IV) AMG 386 15 mg/kg
75931825|NCT01204749|Drug|AMG 386 Placebo|Weekly Intravenous (IV) placebo 15 mg/kg
75931826|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
75337250|NCT04605666|Biological|CD19-CAR-T2 Cells|CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
75337251|NCT04591171|Procedure|n-of-1 trial guided clinical decision making|The n-of-1 trial will, on the level of the individual patient, test which treatment strategy produces superior blood pressure reduction without unacceptable side effects. After discussion with the patient/caregiver dyad to identify whether they have specific concerns about particular medications, the nephrologist (clinician) will decide which two drugs and dosages will be tested in the n-of-1 trial (the protocol does not determine drug or dose). The two drugs chosen by the clinician will be assessed at clinician-selected dosing in a randomized treatment order (e.g., ABAB) for two weeks per treatment period and two treatment periods per drug.
75647030|NCT03979222|Device|Extracorporeal Membrane Oxygenation|ECMO provides extracorporeal gas exchange through use of a membrane oxygenator. Blood is drained from a central vein and returned after oxygenation into either the venous or arterial circulation dependent on configuration.
75647031|NCT02599012|Drug|Ferinject®|intravenous Ferinject 1000mg injection
75647032|NCT01032629|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily
76085822|NCT06008366|Drug|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
75647033|NCT01032629|Drug|Canagliflozin (JNJ-28431754) 100 mg|One 100 mg capsule taken orally (by mouth) once daily
75931827|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
75931828|NCT02466698|Procedure|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
75337252|NCT04535050|Device|Renal denervation|Renal Denervation: DENEX system
75931829|NCT02466698|Drug|Vancomycin|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
75647034|NCT01032629|Drug|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg capsule taken orally (by mouth) once daily
75647035|NCT04205201|Drug|Drugs, Investigational|To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
75647036|NCT02873897|Dietary Supplement|Session A: Experimental products (selected enriched products)|
75931830|NCT02466698|Drug|PEG|Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
75931831|NCT02466698|Drug|Metronidazole|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
76085823|NCT06005961|Behavioral|Module-Based Psychological (MBP) Intervention|Participants will receive one core module related to emotional management and maximum two tailor-made modules according to the participant's needs. Each weekly session lasts for 1 hours. The core module will last for 6 weeks and the tailor-made modules will last for 3 - 4 weeks.
76085824|NCT06001567|Drug|Avatrombopag|Avatrombopag (platelet count [PLT] <40×10^9/L, 60mg P.O. QD; PLT of 40-75×10^9/L, 40mg P.O. QD) will be administered to the patients and last 5-10 days. When the PLT reaches ≥100×10^9/L, the treatment will be discontinued.
76085825|NCT06000579|Other|EFT|Each student will be asked to voluntarily give their phone number and last menstrual cycle date, and the day will be determined for the first session. Then, the first EFT session will be made by the researchers by calling 14 days before the menstruation date. In the 2nd and 3rd sessions, a total of 3 sessions of EFT will be applied face-to-face by the researchers 14 days before menstruation. After each student completes three menstrual cycles, the researchers will meet with the student and PMSS will be applied as a post-test.
76085826|NCT06000462|Drug|Dapagliflozin 10mg Tab|Mentioned in detailed description.
76085827|NCT06000085|Procedure|restoration of proximal cavities of primary molars with flowable giomer|removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x
75337253|NCT04535050|Procedure|Renal angiography|Renal angiography
75473203|NCT01967693|Procedure|Retrospective analysis of data|Retrospective data analysis
75473204|NCT01967745|Procedure|laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
75473205|NCT01967745|Procedure|open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
75647037|NCT02873897|Dietary Supplement|Experimental session: to select enriched products|
75647038|NCT02873897|Dietary Supplement|Session B: Control (standard products without enrichment)|
75647039|NCT02873897|Dietary Supplement|Control session|
75647040|NCT00749944|Drug|varenicline|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
75647041|NCT00749944|Drug|placebo|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
75647042|NCT03979144|Behavioral|Observational study|This was an observational study of a medical device, through the usability assessment, for the registration of a self-test for the immunodeficiency virus (HIV) screening.
76085828|NCT06000085|Procedure|restoration of proximal cavities of primary molars with highly viscous glass ionomer cement|removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte
76085829|NCT06000007|Device|2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app|2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.
75794637|NCT03455829|Drug|G1T38|CDK 4/6 inhibitor
75794638|NCT03455829|Drug|Osimertinib|EGFR TKI; 80 mg
75931832|NCT05244590|Other|Consultation model for patients with palliative care needs|"Training in PC for GPs The training program for GPs will meet the main training needs of GPs according to our previous study and feedback from elements of the Palliative Care Study Group of the Portuguese Association of General and Family Medicine (GESPal). The training program will have a total duration of 24 hours and will consist of two modules.~Consultation model for patients Consultations will take place every 3 weeks for a total period of 12 weeks. The consultation model will be divided into five areas (Summarize clinical information, Objective symptoms' management, Assessment and coding of chronic diseases and symptoms, planning clinical approach, (other) problems/concerns) to be addressed during the assessment. The five areas were constructed to be intuitive for GPs, following the records' structure used in Portuguese primary care."
75931833|NCT02720198|Drug|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
75931834|NCT02720198|Drug|Quetiapine|Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
75931835|NCT05212467|Behavioral|AIR-program|This is a guided self management program that is added on the treatment as usual.
75931836|NCT05212467|Behavioral|HUS Internet therapy|This is a guided self management program that is added on the treatment as usual.
75931837|NCT05212467|Behavioral|Treatment as usual|The patients receive routine care from their physician which may include drugs, visits or rehabilitation
75647043|NCT04091230|Device|TRUSbx|Trans Rectal UltraSound guided Prostate Biopsy
75647044|NCT00917410|Behavioral|SMS support|"The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.~Remember to take your preventive asthma medication (sent at 8.00 am).~Were you awakened during the night due to your asthma? Answer YES or NO.~How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.~What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study)."
75647045|NCT02597140|Drug|lidocaine|Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
75931838|NCT05231876|Other|Recording of pathology-related information on the Wilson Register|Age, gender, date of diagnosis, clinical symptoms, ethnic charateristics and family tree will be collected and recorded on the Wilson Register during routine clinical care
75794639|NCT03454828|Dietary Supplement|obese carbohydrate diet|The experimental diet will consist of 30% carbohydrates (CHO), 35% protein, and 35% fat. Since the experimental diet is lower in CHO, the fiber and sugar content will be calculated based on total CHO in the same percentage as the control (0.25 g fiber per each kcal of CHO and 18.2% sugar for total CHO).
75337254|NCT04529343|Other|Virtual reality mediated upper extremity rehabilitation|"Game-based exercise will be applied for different range of motion of the upper extremity. Gamified exercise program consisting of 4 different scenarios will be applied 3 days a week for 6 weeks to the patients in the virtual reality group. A session takes an average of 45 minutes.~Games to be applied;~Finger flexion-extension (10 minutes / session)~Wrist flexion, extension, ulnar and radial deviation (10 minutes / session)~Forearm pronation and supination (10 minutes / session)~Elbow flexion-extension-shoulder internal and external rotation (15 minutes / session) will have scenarios controlled with. All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes."
75337255|NCT04529343|Other|Classical exercise therapy for upper extremities|All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
75647046|NCT02597140|Drug|normal saline|Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
75931839|NCT01194375|Drug|Low Strength IDP-107|Once a day for 16 weeks
75931840|NCT01194375|Drug|High Strength IDP-107|Once a day for 16 weeks
75931841|NCT01194375|Drug|Placebo|Once a day for 16 weeks
75931842|NCT01193361|Drug|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
75647047|NCT02597140|Drug|propofol|Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
75647048|NCT02598310|Drug|nab-paclitaxel|nab-paclitaxel 260mg/m2 q3w
75647049|NCT02598310|Drug|Trastuzumab|trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
75794640|NCT03454828|Dietary Supplement|lean carbohydrate diet|The control diet composition will follow the American Dietary Guidelines of 55% carbohydrates (CHO), 15% protein, and 30% fat. CHO content will be primarily complex CHO of high quality (14 g fiber/1,000 kcals and <10% of total kcals in the form of sugar).
75794641|NCT03453489|Other|Carbon C 11 Alpha-methyltryptophan|Undergo AMT-PET
75794642|NCT03453489|Other|Laboratory Biomarker Analysis|Correlative studies
75794643|NCT03453489|Procedure|Positron Emission Tomography|Undergo AMT-PET
75794644|NCT03453489|Drug|Telotristat Etiprate|Given PO
75794645|NCT03442894|Procedure|Standard Physical Therapy Treatment|All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
75931843|NCT01193361|Drug|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
75931844|NCT01193361|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
75931845|NCT01193361|Drug|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
75337256|NCT04519983|Drug|Aumolertinib Oral Tablet|Aumolertinib 110 mg p.o. qd+ SRT(32Gy/4fx)
75337257|NCT04500158|Drug|Lidocaine|2% Lidocaine with 1:100,000 epi
75794646|NCT03442894|Procedure|Dry Needling|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits (they will occur at the same time). In 6 of the scheduled 10 visits, dry-needling intervention will be performed. They will have one DN session per week, which is consistent with typical clinical practice. After they complete their standard PT treatment, and while still in the clinic, the rotator cuff and periscapular muscles will be evaluated for the presence of MTrPs. Once located, the MTrPs will be treated with DN technique, as this is consistent with routine clinical practice. Potential muscles to receive TPDN treatment include the following: suprapsinatus, teres minor, infraspinatus, deltoid, upper trapezius, middle trapezius, levator scapula, pec major and pec minor.
75794647|NCT03442894|Procedure|Sham Dry Needling|In addition to the standard PT treatment, patients in the sham DN group will receive what appears to be a DN treatment, but it will not be done with the acupuncture needles and the skin will not be punctured. The Sham DN procedure will be performed over the site of identified MTrPs using a guide tube and a toothpick. A guide tube is positioned firmly over the area to be treated and a toothpick is inserted in the guide tube. The clinician taps the toothpick to mimic the skin prick from a needle and the guide tube is removed. The clinician maintains pressure on the end of the toothpick and moves the end furthest from the skin in different directions to mimic the pistoning and changes in needle angle that occur in actual dry needling. Care will be taken to treat from 1-3 muscle groups for 5-10 seconds per MrTP identified.
75794648|NCT03441334|Device|High Frequency rTMS|Participants in the intervention group will receive 1200 stimuli at the intensity of 90% of resting motor threshold via an air-filmed coil placed on the vertex. The stimulation will be delivered across 24 sessions (in 10 weeks). Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
75931846|NCT01193361|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
75931847|NCT03305354|Behavioral|CBTI app intervention|Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
75931848|NCT03305354|Behavioral|Physical Activity intervention|Self-management guided motivation to increase physical activity by increasing daily step counts
76085830|NCT06000007|Other|Treatment as usual|Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
75337258|NCT04466852|Other|telemedicine-guided consultation|Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
75647050|NCT04091074|Drug|Ticagrelor|Half of patients undergoing carotid stenting take ticagrelor+aspirin
75647051|NCT04091074|Drug|Clopidogrel|Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin
75647052|NCT04091074|Procedure|Carotid stenting|Patients with carotid stenosis will undergo carotid stenting
75647053|NCT03975712|Other|Not applicable, no intervention|Not applicable, no intervention
76085831|NCT05997641|Drug|DF-003|Oral administration by capsules (1 mg, 5 mg, or 25 mg).
76085832|NCT05997641|Drug|Placebo|Visually matching 0 mg DF-003 capsules.
75647054|NCT00749398|Biological|Infliximab|According to local country regulations.
75337259|NCT04426838|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference|The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.
75647055|NCT04089670|Behavioral|Online Acceptance and Commitment Therapy Intervention|"The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week."
75337260|NCT04396834|Drug|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
75473206|NCT01967758|Biological|Cohort 1|Four doses of IV ADU-623 at a dose of 3 x 10^7cfu
75647056|NCT04090996|Diagnostic Test|Dual TAsk|"Motor assessment includes:~posturographic examination in Single-task (ST) and Double-task (DT)~an analysis of ST and DT walking;~Timed Up and Go (TUG) performances in real (rTUG) and imagined (iTUG) versions;"
75473207|NCT01967758|Biological|Cohort 2|Four doses of IV ADU-623 at a dose of 3 x 10^8cfu
75473208|NCT01967758|Biological|Cohort 3|Four doses of IV ADU-623 at a dose of 3 x 10^9cfu
75647057|NCT04091152|Other|usability assessment|"Usability of ardoiz will be assesse using a validated usability questionnary"
75647058|NCT00746356|Device|Testing of the autocapture features of the device|Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
75473209|NCT01967758|Drug|Antibiotics|A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
75794649|NCT03441334|Device|Sham rTMS|Participants in the sham group will receive the same duration of stimulation via a sham coil placed on the vertex.Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
75794650|NCT03440190|Drug|Methylphenidate|Patients are tested for their normal prescription methylphenidate medication
76085833|NCT05994859|Procedure|SIRT|The patients will receive 1-2 sessions of SIRT. If the patients have invasive tumors, extensive liver involvement or vascular invasion, systematic treatment will be added.
75647059|NCT00746356|Device|Testing of the autocapture features of the device|Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
75647060|NCT01012973|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
75647061|NCT01012973|Other|Sham treatment|Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
75647062|NCT00748540|Device|Vibrant Soundbridge|Mixed and conductive hearing loss using round window stimulation
75647063|NCT03974464|Diagnostic Test|copeptin, PS100|"Age, sex and time between dizziness onset and ED visit were collected using Resurgences® software. PS100 concentrations were measured on serum samples by electro-chemiluminescence assay. Copeptin concentrations were measured on serum samples by the Kryptor method. The positivity threshold for copeptin was set at strictly above 10 pmol/L and that of PS100 was set at strictly above 0.105 μmol/L.~And after, we compared results with results of brain imaging: Magnetic Resonance Imaging alone, CT scan alone or both. Depending on clinical presentation, the imaging tests were performed during ED stay, during hospitalization or externally. Presence or absence of stroke was established on diffusion-weighted brain MRI . In case of normal contrast CT alone, a specialized opinion should exclude the need for diffusion-weighted MRI according to clinical presentation."
75337261|NCT04396834|Drug|Placebo oral tablet|Placebo Oral Tablet (BID)
75337262|NCT04396262|Other|Food-1|HTD-blueberry beverage with white bread.
75337263|NCT04396262|Other|Food-2|Sweetened water with white bread as a control.
75473210|NCT01967771|Drug|DTG|DTG will be supplied as 50 mg tablet to be administered orally
75647064|NCT01012739|Drug|Indacaterol 150 μg via the Concept1 dry-powder inhaler|Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
75337264|NCT04339517|Procedure|Aspiration of seroma fluid|Fluid will be collected from the lumpectomy site of patients between one to six weeks post-surgery and tested for the presence of persistent tumor cells (PTCs).
75337265|NCT04332471|Procedure|Radial shockwave therapy|Target intensity will be within a range of 3.5-5.0 bar at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
75337266|NCT04332471|Procedure|Focused shockwave therapy|Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
75337267|NCT04332471|Device|Shockwave therapy device|The shockwave therapy device will be used to administer either radial or focused shockwave therapy.
75337268|NCT04332471|Other|Home therapy|Stretching and ice massage
75337269|NCT04320810|Other|no intervention|It's only observational study. No interventions.
75337270|NCT04304755|Drug|Zoledronic Acid 5 MG in 5 ML Injection|Zoledronic acid
75337271|NCT04304755|Drug|Placebos|NaCl 0.9%
75337272|NCT04302428|Biological|Serum Zn|The investigators will obtain an additional 2 mL of blood in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
75337273|NCT04302428|Biological|Red Blood Cell Zn|If the participant is greater or equal than 5 kg, an additional 2 mL of blood will be obtained in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
75647065|NCT01012739|Drug|Indacaterol 60 μg via the Simoon dry-powder inhaler|Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
75647066|NCT01012739|Drug|Indacaterol 120 μg via the Simoon dry-powder inhaler|Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
75337274|NCT04273165|Drug|Etravirine Tablets|Daily etravirine BID with 100 or 200 tablets for 4 months
75647067|NCT01012739|Drug|Placebo to indacaterol via the Concept1 dry-powder inhaler|Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
75337275|NCT04179968|Drug|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
75647068|NCT04298645|Other|Glycaemic response to high GI carbohydrates consumed at morning versus evening meals.|Controlled nutrition trial on the glycaemic response to morning and evening meals with high glycemic index carbohydrates among students with early and late chronotypes.
75337276|NCT04179968|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
75337277|NCT04115371|Behavioral|Intervention|Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
75473211|NCT01967771|Drug|CBZ|CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
75647069|NCT04299035|Procedure|Erector spinae plane block|Erector spinae plane block
75647070|NCT00742924|Drug|cisplatin|Given IV
75647071|NCT00742924|Drug|dexrazoxane hydrochloride|Given IV
75647072|NCT00742924|Drug|doxorubicin hydrochloride|Given IV
75794651|NCT03439371|Other|HLA-mismatched micro-transplantation after induction chemotherapy|HLA-mismatched micro-transplantation after induction chemotherapy
75794652|NCT03437941|Drug|CORT125281|CORT125281 is supplied as capsules for oral dosing
75794653|NCT03437941|Drug|Enzalutamide (Xtandi)|Enzalutamide will be taken orally
75794654|NCT03437941|Drug|Placebo|Placebo capsules to match the appearance of the CORT125281
75794655|NCT03436615|Drug|SB206 4%|Twice daily
75794656|NCT03436615|Drug|SB206 8%|Twice daily
75794657|NCT03436615|Drug|SB206 12%|Once or twice daily
75794658|NCT03436615|Drug|Placebo|Once or twice daily
76085834|NCT05994183|Drug|Dexamethasone Oral|Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)
75794659|NCT03429244|Diagnostic Test|68Ga-PSMA-11 PET-MRI|Patients will undergo injection of 68Ga-PSMA-11 at the time of pre-treatment MRI scan and followed until biopsy and/or surgical resection.
75794660|NCT03409133|Device|Stimulating nerve electrodes and intramuscular recording electrodes|See Arm Description
75794661|NCT03408587|Biological|CVA21|Oncolytic virus
75794662|NCT03408587|Biological|Ipilimumab|Fully human IgG1 monoclonal antibody that binds to the CTLA-4 receptor expressed on activated T cells.
75794663|NCT03392935|Device|1540 nanometer Erbium glass laser|Subjects will receive laser treatment by dermatologist at week 0 and week 4.
75931849|NCT02263677|Drug|Sitagliptin|60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
75931850|NCT01390545|Drug|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
75647073|NCT00742924|Drug|etoposide|Given IV
75931851|NCT01591473|Drug|Poly I:Poly C12U 50 ug|Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
75931852|NCT01591473|Drug|Poly I:Poly C12U 200 ug|Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
76085835|NCT05992740|Device|bronchoscope|bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy
76085836|NCT05992584|Drug|Lenvatinib, sintilimab plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. QD and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
76085837|NCT05991739|Behavioral|Familias Inmigrantes Empoderándose contra eStrés Tomando Acción (FIESTA)|FIESTA is a 10-session, group intervention led by community health workers that offers strategies related to individual stress management, family coping and communication, and community navigation.
76085838|NCT05989490|Other|Static stretching|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort and to the point of pain.
76085839|NCT05986825|Other|Verneuil questionnaire Validation|Request patient to Complete the questionnaire for validation of the French version
75337278|NCT04110236|Behavioral|PriCARE|PriCARE is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. Since PriCARE's initial and successful pilot, the intervention has been enhanced in order to increase engagement and effectiveness.
75647074|NCT00742924|Drug|ifosfamide|Given IV
75647075|NCT00742924|Drug|leucovorin calcium|Given IV or orally
75647076|NCT00742924|Drug|methotrexate|Given IV
75647077|NCT00742924|Drug|zoledronic acid|Given IV
75647078|NCT00742924|Procedure|adjuvant therapy|
76085840|NCT05986656|Procedure|Atlas-Standard method|Hardware acupressure of the suboccipital muscles according to the Atlas-Standard method for the reduction of chronic subluxation of the first cervical vertebra.
75794664|NCT03389035|Biological|CARCIK-CD19|Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene
75647079|NCT00742924|Procedure|neoadjuvant therapy|
75647080|NCT00742924|Procedure|therapeutic conventional surgery|Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
75647081|NCT00742924|Biological|filgrastim|Given SC
75647082|NCT00742924|Drug|Mesna|Given IV
75647083|NCT04090606|Other|FTC Method Smoking Regimen|cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes
75647084|NCT04090606|Other|Massachusetts Method Smoking Regimen|45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes
75647085|NCT04090606|Other|Health Canada Intense Smoking Regimen|55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes
75794665|NCT03348748|Other|Laboratory Biomarker Analysis|Correlative studies
75794666|NCT03348748|Other|Quality-of-Life Assessment|Ancillary studies
75794667|NCT03348748|Drug|Stereotactic Body Radiation Therapy|Undergo lowest-dose of SBRT
75794668|NCT03348748|Drug|Stereotactic Body Radiation Therapy|Undergo lowest- or higher-dose of SBRT
75794669|NCT03348748|Drug|Stereotactic Body Radiation Therapy|Undergo highest-dose of SBRT
75794670|NCT03348748|Procedure|Thoracic Surgical Procedure|Undergo thoracic surgery
75931853|NCT01591473|Drug|Poly I:Poly C12U 500 ug|Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
75931854|NCT01591473|Drug|Poly I:Poly C12U 1250 ug|Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
75931855|NCT01591473|Drug|Placebo|Placebo; 3 doses; nasal administration every 28 days
76085841|NCT05981443|Device|Dermabond|Use of Dermabond to close surgical incisions instead of non-absorbable sutures
76085842|NCT05981443|Other|Non-Absorbable Sutures|Use of conventional non-absorbable sutures to close surgical incisions
75794671|NCT03347539|Device|Nexplaon|This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.
75794672|NCT03314636|Drug|Carfilzomib|See in arm description
75794673|NCT03314636|Drug|Lenalidomide|See in arm description
75794674|NCT03314636|Device|PET-CT|See in arm description
75473212|NCT01967797|Behavioral|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
75794675|NCT03314636|Drug|Dexamethasone|See in arm description
75931856|NCT01591473|Drug|FluMist|FluMist 0.2 ml; 3 doses; nasal administration every 28 days
75931857|NCT02265861|Drug|HCG|
75931858|NCT01192035|Drug|Efavirenz or Nevirapine|"2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count >250 cells/mm3. Females beyond childbearing age will be treated with efavirenz."
75931859|NCT01192035|Drug|Ritonavir-boosted lopinavir|2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
76085843|NCT05981274|Diagnostic Test|serum biomarker.|serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)
75473213|NCT01967823|Biological|Anti-NY ESO-1 mTCR PBL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
75647086|NCT02596984|Drug|Caspofungin|Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
75473214|NCT01967823|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenously (IV) in 250 mL dextrose 5% in water (D5W) infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
75647087|NCT00698815|Other|Laboratory Biomarker Analysis|Correlative studies
75647088|NCT00698815|Drug|Pemetrexed Disodium|Given IV
75647089|NCT00698815|Drug|Sunitinib Malate|Given PO
75647090|NCT04089124|Procedure|surgery of zone II cut flexor repair|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture
75647091|NCT04090450|Radiation|chemo-radiotherapy|The study will not have a direct intervention. It will recruit patients who have had chemo-radiation as part of their standard of care treatment for rectal cancer.
75647092|NCT04019860|Behavioral|High Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.
75794676|NCT03310541|Drug|AZD5363|AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
75794677|NCT03310541|Drug|Enzalutamide|Enzalutamide 160 mg PO once daily
75931860|NCT02268747|Drug|Dacomitinib|"The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction."
76085844|NCT05979948|Drug|Zanubrutinib|Zanubrutinib, 160 mg oral capsules twice daily for 12 months
75473215|NCT01967823|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
75647093|NCT04019860|Behavioral|Time-Restricted Eating|Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
75647094|NCT02599090|Drug|Temozolomide|"Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
75647095|NCT02599090|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
75647096|NCT02599090|Drug|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
75647097|NCT05662345|Diagnostic Test|CellSearch Circulating Tumor Cells|Serial CTC enumeration
75794678|NCT03310541|Drug|Fulvestrant|500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
75794679|NCT03287765|Drug|18F-AV-1451|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
75794680|NCT03279861|Drug|Entresto|First line therapy in Entresto arm
75794681|NCT03279861|Drug|Valsartan|"First line therapy in usual meds arm"
75931861|NCT01590459|Drug|VX-509|50 mg oral tablet
75931862|NCT01590459|Drug|VX-509 matching placebo|0 mg oral tablet
76085845|NCT05979948|Drug|Bendamustine|Bendamustine, 70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles.
76085846|NCT05979948|Drug|Rituximab|Rituximab, 375 mg/m2 intravenously on day 0 of each cycle for 6 cycles
76085847|NCT05977998|Drug|Paclitaxel|Given by IP (Intraperitoneal injection)
76085848|NCT05977998|Drug|Dexamethasone|Given by IV (vein)
76085849|NCT05977998|Drug|Diphenhydramine|Given by IV (vein)
76085850|NCT05977998|Drug|Famotidine|Given by IV (vein)
75337279|NCT04110236|Behavioral|Positive Discipline Module|The PriCARE Positive Discipline Module is a pilot group caregiver training program designed to teach caregivers positive discipline techniques, including appropriate timeout procedures. The sessions are offered in the primary care setting or virtually. This training will supplement the content of the main PriCARE intervention and provide caregivers with skills for addressing difficult behaviors not reduced through positive attention and strategic ignoring. This module will be offered to a subset of CHOP participants who were randomized to the intervention arm, successfully completed the main study interviews, and attended at least 4 out of the 6 PriCARE sessions.
75473216|NCT01967823|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenously (IV) (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
76085851|NCT05975671|Behavioral|Multifaceted de-implementation strategy to reduce vancomycin overuse|"Clinical guidelines and group-level feedback on vancomycin use will be provided to clinicians/sepsis stakeholders at each site.~The semi-structured interviews will be performed by a trained member of the research team, under the supervision of a medical sociologist who is one of the co-investigators. A semi-structured interview guide will be used during the interviews. Interviews will be recorded and transcribed, then uploaded to a qualitative analysis software for management and coding. Names will not be recorded, and pseudonyms will be used in notes, communications about the study, and any presentations. Verbal consent will be obtained before conducting and recording the interviews.~The surveys will be performed using REDCap survey software, and participation will be voluntary. No identifiers will be collected."
75473217|NCT01967875|Drug|Capecitabine+Cisplatin|Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
75473218|NCT01967875|Drug|Docetaxel+Capecitabine|Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
75473219|NCT01967901|Behavioral|Self-care management program|The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
75473220|NCT01967914|Other|PVI|Measurement of PVI (plethysmography variability index)
75337280|NCT04072055|Device|MOTO Medial|MOTO medial unicompartmental knee system
75337281|NCT04041128|Drug|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
75473221|NCT01967927|Drug|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
75337282|NCT04030962|Drug|AGN-242428|Ophthalmic solution administered as a topical eye drop
75337283|NCT04030962|Drug|AGN-231868|Ophthalmic solution administered as a topical eye drop
75337284|NCT04030962|Other|AGN-242428 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
75647098|NCT02566915|Device|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
75473222|NCT01967953|Procedure|EVLP Group|"EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.~Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy"
75647099|NCT00745498|Drug|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
75794682|NCT03269149|Other|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.
75794683|NCT03269149|Behavioral|Educational lectures|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q&A will be encouraged.
75794684|NCT03258463|Other|Change in Texas Law|The change in Texan laws occurring from July 2013-January 2014
75794685|NCT03250832|Drug|TSR-033|TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.
75337285|NCT04030962|Other|AGN-231868 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
75473223|NCT01967966|Drug|GDC-0032|Single oral dose
75473224|NCT01967966|Drug|GDC-0032|Single IV dose
75473225|NCT01967979|Drug|RO5285119|Single dose, alone and after repeated administration of itraconazole or fluoxetine
75473226|NCT01967979|Drug|fluoxetine|Multiple doses
75473227|NCT01967979|Drug|itraconazole|Multiple doses
75473228|NCT01967992|Behavioral|Behavioral: Low Carbohydrate, Ketogenic Diet|
75647100|NCT04876963|Device|Holter-monitor|7-day holtermonitoring of each patient
75337286|NCT04030962|Drug|Lifitegrast|Ophthalmic solution administered as a topical eye drop
75473229|NCT01967992|Behavioral|American Diabetes Association Diet|
75473230|NCT01967992|Behavioral|Mindfulness and Positive Affect Skills|
75473231|NCT01968005|Drug|Etoreat®(Etodolac-Lidocaine Topical Patch)|
75473232|NCT01968005|Drug|Placebo|
75647101|NCT04089748|Combination Product|neoadjuvant chemotherapy with cisplatine|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
75647102|NCT00917098|Behavioral|Behavior Therapy|Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary
75647103|NCT00917098|Behavioral|Supportive Counseling|Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
75473233|NCT01968018|Drug|Tramadol HCI/acetaminophen|Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
75473234|NCT01968044|Drug|Gemigliptin|
75931863|NCT01384383|Drug|GS-5885|GS-5885 30 mg tablet administered orally once daily
75473235|NCT01968044|Drug|Placebo to Linagliptin|
75794686|NCT03250832|Drug|Dostarlimab|Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.
75794687|NCT03250832|Drug|mFOLFOX6|mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.
75931864|NCT01384383|Drug|GS-9451|GS-9451 200 mg tablet administered orally once daily
75473236|NCT01968083|Biological|RSV cps2 Vaccine|10^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
75473237|NCT01968083|Biological|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
75473238|NCT01968096|Device|home-based ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
75473239|NCT01968122|Device|intravascular stent therapy|Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
75473240|NCT01968161|Drug|Asenapine|
75473241|NCT01968239|Drug|Ranibizumab|comparison of different re-treatment criteria for intravitreal injection of ranibizumab
75473242|NCT01968252|Other|Concurrent TTE and TEE|All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
75473243|NCT01968265|Drug|ISIS-GCCRRx|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
75473244|NCT01968265|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
75473245|NCT01968278|Other|Baked milk|
75473246|NCT01968291|Behavioral|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
75473247|NCT01968304|Other|Iron status follow up|
75473248|NCT01968330|Behavioral|Go!®to sleep|
75473249|NCT01968343|Behavioral|Cognitive-behavioral therapy.|Subjects receive 22 sessions of cognitive-behavioral therapy.
75647104|NCT05270473|Procedure|uterine compressive sutures|uterine compression sutures comaprison
75794688|NCT03250832|Drug|FOLFIRI|FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.
75794689|NCT03250832|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.
75931865|NCT01384383|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
75931866|NCT01384383|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
75473250|NCT01968343|Other|Supportive therapy.|Subjects receive 22 sessions of supportive therapy.
75473251|NCT01968369|Dietary Supplement|tomato sauce|We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
75473252|NCT01966640|Biological|Basophil Activation Test|blood sample for Basophil Activation Test
75473253|NCT01968395|Drug|Caspofungin 70 mg|Intravenous use
75473254|NCT01968408|Dietary Supplement|Lactobacillus reuteri DSM 17938|10(9) CFU/daily
75647105|NCT00917176|Device|Occipital nerve stimulation|
75647106|NCT02596828|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
75647107|NCT02596828|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
75647108|NCT02596828|Drug|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
75931867|NCT01557777|Drug|Navitoclax|QD
75931868|NCT02268825|Drug|MK-3475|"MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose"
75794690|NCT03250117|Drug|Ropinirole oral product|oral immediate-release ropinirole
75794691|NCT03250117|Drug|Ropinirole Implant|ropinirole hydrochloride/ethylene vinyl acetate
75794692|NCT03240341|Behavioral|Patient Activation Measure Questionnaire|Measure the level of patient engagement in cancer care pathway
75794693|NCT03236935|Drug|L-NMMA|pan-nitric oxide synthase inhibitor
75794694|NCT03236935|Drug|Pembrolizumab|PD-1 inhibitor
75794695|NCT03234335|Other|Data collection|Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
75794696|NCT03233399|Device|Sham TMS3 stimulation|half of the subjects will receive sham stimulation first
75794697|NCT03233399|Device|rTMS of left or right angular gyrus (AG) or frontal cortex (FC)|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
75794698|NCT03233399|Device|Anodal tDCS of left or right AG or FC|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
75794699|NCT03233074|Other|Bone marrow analyses|This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
75794700|NCT03232931|Behavioral|Therapist skin-to-skin Care|"Skin-to-skin (STS) holding is part of the multisensory intervention where the therapist will wear a clean 100% cotton T-shirt with a clean hospital gown on top of the shirt and wrap the kangaroo positioner securely over the gown. A gauze square scented with parent's skin will be used to provide olfactory stimulation. Therapist STS sessions occur with simultaneous playing of mother's voice contingent on infant pacifier sucking."
75794701|NCT03232931|Device|Contingent parent's voice exposure|The Pacifier Activated Lullaby® (PAL®) device, is a digital music delivery system that integrates a sensor, a pacifier routinely used in the NICU, and a receiver. It delivers a predetermined 10 seconds of recorded parent's voice singing lullabies upon detection of a suck that meets a preset pressure threshold. The original systems were modified for research use by decreasing the lower limit of activation thresholds for delivering the recording. Minimal effort is required to trigger the device. However, the settings ensure that regular attempts are needed to continue to receive continual presentation of the recording of mother's voice by requiring another suck after 10 seconds. The auditory stimulation with PAL will be provided when the infants are still awake (i.e., at the beginning of the session).
75794702|NCT03232931|Behavioral|Parental skin-to-skin care|The standard of care includes parental skin-to-skin care and exposure to parent's voice. During parental skin-to-skin care, infants are placed in a prone position with head positioned over the sternum, allowing transmission of breath and heart sounds to the developing ear. Deeper pressure is applied to offer support and feedback to the child's bottom. Session length is set to a minimum of 45 minutes per unit protocols.
75794703|NCT03232931|Device|Recorded parent's voice|Per standard of care, preterm infants in the NICU currently receive noncontingent recorded parents' voice during two 20 minute sessions per day. Recordings are standardized and are played through a sterilizable device (DINO-egg).
75931869|NCT01381731|Drug|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
75931870|NCT01381731|Drug|placebo|opthalmic solution 2 drops in each eye QID
75931871|NCT02268903|Drug|Diuretics : Furosemide|Furosemide 80mg in one single direct intra venous injection
75931872|NCT02268903|Drug|Placebo|Placebo in one single direct intra venous injection
75931873|NCT01381107|Drug|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
75647109|NCT02596828|Drug|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
75473255|NCT01968408|Dietary Supplement|Placebo|
75931874|NCT01381107|Drug|Placebo|Sublingual administration once daily for 7 consecutive days.
75931875|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
75931876|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
75931877|NCT02268981|Device|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
75931878|NCT02269059|Drug|MK-7680|MK-7680 10 mg and 100 mg capsules
75931879|NCT03135405|Behavioral|Automated messages|Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
75931880|NCT03135405|Behavioral|Home BP monitors|Participants will have the option of receiving home blood pressure monitors.
75931881|NCT03135405|Behavioral|Care partner reminders|Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
75931882|NCT01369095|Drug|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C&D)
75931883|NCT01369095|Drug|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C&D)
75473256|NCT01968473|Device|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
75473257|NCT01968486|Drug|PDT standard fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
75647110|NCT03896815|Drug|INCB054329|
75647111|NCT02598856|Drug|Intranasal (IN) naloxone 1x|Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
75647112|NCT02598856|Drug|Intranasal (IN) naloxone 2|Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
75931884|NCT01369095|Drug|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B&C)
75794704|NCT03230838|Drug|Ceftolozane/Tazobactam|12 to <18 years of age: Ceftolozane 1 g/dose; Tazobactam 0.5 g/dose via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days. <12 years of age: Ceftolozane 20 mg/kg with Tazobactam 10 mg/kg (not to exceed Ceftolozane 1 g and Tazobactam 0.5 g) via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days.
75794705|NCT03230838|Drug|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.
75337287|NCT04009837|Behavioral|Hip-focused rehabilitation intervention|The hip-focused intervention includes a blend of hip-focused rehabilitative techniques and some basic lumbar spine-directed techniques. The hip-focused arm includes tailored manual therapy, progressive strengthening exercises, and flexibility exercises for the hip, as well as spinal flexibility and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
75647113|NCT02598856|Drug|Intravenous (IV) naloxone|Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
75794706|NCT03222102|Device|Phasix mesh|After the closure of the Abdomen, Phasix mesh will be placed and affixed on the exposed fascia.
75337288|NCT04009837|Behavioral|Spine-focused rehabilitation intervention|The spine-focused rehabilitation intervention is a direct and comprehensive lumbar spine rehabilitative program, but it does not include hip treatment. The spine-focused arm includes spinal manual therapy, spinal flexibility exercises, and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
75794707|NCT03220945|Other|Yoga|Receive yoga instruction
75794708|NCT03217136|Drug|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.
75337289|NCT03997162|Other|Best Practice|Complete standard of care enhanced recovery after surgery protocol
75337290|NCT03997162|Other|Quality-of-Life Assessment|Ancillary studies
75337291|NCT03997162|Other|Questionnaire Administration|Ancillary studies
75931885|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
75931886|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
75931887|NCT01369095|Drug|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
75931888|NCT01369095|Drug|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
75931889|NCT03135561|Behavioral|pedometer-plus-email|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. During the intervention period, patients will receive 8 counselling emails based on behavioural techniques.
76085852|NCT05967741|Other|Erythritol|Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)
75337292|NCT03991962|Drug|mFOLFIRINOX|Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks
75647114|NCT02598856|Drug|Intramuscular (IM) naloxone|Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
75794709|NCT03217136|Drug|Metronidazole|Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if > 2 kg are dosed 10 mg/kg every 8 hours.
75794710|NCT03217136|Drug|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.
76085853|NCT05967741|Other|Aspartame|Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
75337293|NCT03991962|Radiation|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
75337294|NCT03951753|Drug|Tirzepatide|Administered SC
75337295|NCT03951753|Drug|Semaglutide|Administered SC
75337296|NCT03951753|Drug|Placebo|Administered SC
75337297|NCT03947671|Device|Rapr Rounds Hyper/Hypothermia Wraps|Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature
75337298|NCT03947671|Drug|Acetaminophen|Acetaminophen will be administered as it would be per standard of care
75794711|NCT03217136|Drug|Placebo for Metronidazole|Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
75794712|NCT03201939|Drug|Lisinopril|ACE-inhibitor (lisinopril)(intervention arm
75794713|NCT03201939|Other|Placebo Oral Tablet|Comparator placebo (control arm)
75794714|NCT03184922|Procedure|Adjustable versus fixed suspensory loop femoral side graft fixation|A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
75794715|NCT03179761|Biological|Quadrivalent Inactivated Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine given intramuscularly
75794716|NCT03179761|Other|Laboratory Biomarker Analysis|Correlative studies
75794717|NCT03179761|Biological|Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine given intramuscularly
75794718|NCT03171493|Biological|MV-NIS|Attenuated measles virus encoding NIS (MV-NIS)
75794719|NCT03169634|Procedure|short or long stemmed rTKR cemented|An evaluation of the outcomes of different ways of performing revision total knee replacement surgery
75794720|NCT03169634|Procedure|Cone with short stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with short stems is cemented in to it
75794721|NCT03169634|Procedure|Cone with long stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with long stems is cemented in to it
75794722|NCT03163030|Device|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
75794723|NCT03158064|Drug|Durvalumab|1500 mg by IV
75794724|NCT03158064|Drug|Tremelimumab|"75 mg by IV~*300mg"
75931890|NCT03135561|Behavioral|pedometer-only|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. There will be no further interaction during the intervention period unless they fail to upload data, in which case they will be offered technical support.
75337299|NCT03947346|Other|Urine sample|The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
75337300|NCT03944499|Drug|FS-1502|"Dose-Escalation Phase (Phase 1a)： FS-1502 dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle in the V1.2 and V2.0 regimens; IV, once per 21 days, 21 days as a cycle in the V3.0 regimens..~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg. If 1.3mg/kg is still tolerated safely and in line with linear kinetic characteristics, and combined with the results of PK, PD, safety and effectiveness, a comprehensive assessment is made to determine whether to continue the dose escalating. The subsequent dose increase ratio is 33% (the dose increase ratio can be adjusted according to the previous data results) until MTD or RP2D.~Dose-expansion Phase (Phase 1b) : RP2D determined in phase 1a, IV."
75931891|NCT02269215|Drug|BIII 890 CL|
75931892|NCT02269215|Drug|Placebo|
75647115|NCT04061551|Other|EC clinic support - whole of practice interventions delivery through nurse-led model|"The primary interventions will be delivered through a team of nurses, an evaluation team and practice support team that will be working with each of the services to improved Hepatitis C service delivery.~The EC project team will predominantly be involved in working with providers and staff at EC sites to implement key interventions that have been collated into a Primary Care Practice Toolkit, which cover three domains; patient support, provider support and practice Support. The toolkit is designed to be an educational and implementation resource that the nursing team will support services to deliver.~Patient support to reduce the impact of hepatitis C and other blood borne viruses~Provider support to reduce the impact of hepatitis C and other blood borne viruses~Practice support to reduce the impact of hepatitis C and other blood borne viruses"
75647116|NCT04815031|Biological|BNT162b2|Comirnaty is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose. Individuals 16 years of age and older.
75931893|NCT02266095|Device|Oval-8 Splint|Splinting with Oval-8
75931894|NCT02266095|Device|Tee Pee Splint|Splinting with Tee Pee
76085854|NCT05966285|Other|suture repair|Suture repair was used to reinforce the abdominal wall, including Bassini, Ferguson, McVay, or Halsted technique.
75337301|NCT03941964|Drug|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
75337302|NCT03941964|Drug|Azacitidine|The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
75337303|NCT03941964|Drug|Decitabine|The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
75794725|NCT03155841|Behavioral|Life Skills Coaching|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics and geographic location.
75337304|NCT03935100|Procedure|Endoscopic clipping|Endoscopic clips fired to close mucosa over diverticular defects.
75337305|NCT03935100|Other|Placebo - colonoscopy without clipping|Colonoscopy performed, no clipping of diverticula
75647117|NCT04810273|Behavioral|Early mobilization|The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 5 days).
75647118|NCT02597998|Drug|14C-BI 409306|
75794726|NCT03155841|Behavioral|Community Resources|The investigators will provide a resource locator as the attention-control condition. The resource locator provides a list of health (e.g., HIV testing) and social (e.g., support groups) resources across study regions.
75794727|NCT03114891|Device|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. In this study, we used administered theta burst TMS stimulation.
75794728|NCT03114891|Behavioral|Task|Subject completes a working memory task (Letter Nback) between the two rounds of theta burst stimulation.
75931895|NCT02266095|Device|Forearm Based Splint|Splinting with Forearm based
75931896|NCT02266173|Drug|Pertuzumab|Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
76085855|NCT05966285|Other|mesh repair|Mesh repair was conducted using a synthetic and biological mesh in the Lichtenstein or open preperitoneal techniques.
75337306|NCT03932240|Drug|Fibrinogen Concentrate (FC)|The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
75337307|NCT03932240|Drug|Cryoprecipitate|Standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 345mg/dL
75337308|NCT03931772|Behavioral|Automated Self-Hypnosis|Self-Hypnosis will be delivered through an interactive application administered through Amazon Alexa or Reveri.com.
75931897|NCT01168713|Drug|Levofloxacin|"Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5"
75931898|NCT01168713|Drug|CEM-101|"CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5"
75931899|NCT02269293|Drug|Paclitaxel|
75794729|NCT03114891|Procedure|fMRI-guided TMS target|Administration of TMS to individualized targeting from the participant's fMRI scans. Our preliminary data suggest this target region is particularly effective at influencing the sgACC.
75794730|NCT03108885|Other|Blood and Tissue Collection|Blood DNA will be isolated from plasma. Tumor DNA will be purified with a kit and amplified regions of 10 genes discovered to by mutated in whole exome sequencing.
75794731|NCT03098511|Diagnostic Test|Neurological Diagnostic Evaluation|"Clinical Data:~Demographic data~Daily data (clinical exams, laboratory data)~Drug administration~Additional clinical or ancillary neurological determination test~Diagnostic Intervention:~CT-Perfusion~CT-Angiography reconstructions~Reference Standard:~- Clinical Neurological Exam~Blood Samples (Pharmacokinetics, Inflammatory & Nanovesicles Parameters):~At the time of patient enrolment~6 hours after patient enrolment~At the time of the clinical neurological exam~Secondary Outcome measures at 6 months:~extended Glasgow Outcome Scale (GOSe)~modified Rankin Scale (mRS)"
75931900|NCT02269293|Drug|Carboplatin|
75931901|NCT02269293|Drug|Selinexor|
75647119|NCT00744874|Procedure|RF Ablation procedure|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
75931902|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
75647120|NCT02595658|Dietary Supplement|Meal composition|
75647121|NCT02595658|Drug|Rapid-Acting Insulin Dose|
75931903|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
75931904|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
75647122|NCT00576901|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
75794732|NCT03087708|Drug|Naloxegol|Given PO
75794733|NCT03087708|Other|Placebo|Given PO
75794734|NCT03087708|Other|Laboratory Biomarker Analysis|Correlative studies
75794735|NCT03087708|Other|Quality-of-Life Assessment|Ancillary studies
75794736|NCT03070132|Drug|BIIB074|Administered as specified in the treatment arm
75794737|NCT03070132|Drug|Placebo|Matched placebo
75794738|NCT03058783|Drug|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
75931905|NCT01545453|Drug|placebo|subcutaneous dose every 4 weeks
75931906|NCT04476303|Drug|BEY2153|Capsule
75931907|NCT04476381|Procedure|Dry needling|Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
75931908|NCT01161615|Drug|MRX-7EAT|Application of up to two patches for up to 7 days.
75931909|NCT01161615|Drug|Placebo|Application of up to two patches for up to 7 days.
75931910|NCT01366131|Drug|MEGF0444A|Intravenous repeating dose
75931911|NCT01366131|Drug|bevacizumab|Intravenous repeating dose
75647123|NCT00576901|Drug|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
75647124|NCT00576901|Drug|Xeloda|2000mg/m2 po on days 1-15 of each 3 week cycle
75647125|NCT02596672|Behavioral|The friendly walking group|A 12 week peer led walking group for adults and older adults (> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
75794739|NCT03058783|Drug|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
75794740|NCT03057847|Drug|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
75794741|NCT03047161|Device|fetal MCG|assess fetal heart rate and rhythm
75794742|NCT03042143|Biological|Human umbilical cord derived CD362 enriched MSCs|Infusion of Human umbilical cord derived CD362 enriched MSCs
75794743|NCT03042143|Biological|Placebo (Plasma-Lyte 148)|Infusion of placebo
75794744|NCT03024424|Behavioral|Early disclosure|
75794745|NCT03024424|Behavioral|Late disclosure|
75931912|NCT01366131|Drug|carboplatin|Intravenous repeating dose
75931913|NCT01366131|Drug|paclitaxel|Intravenous repeating dose
75931914|NCT01366131|Drug|placebo|Intravenous repeating dose
75931915|NCT01365195|Drug|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
75931916|NCT01365195|Drug|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
75931917|NCT01365195|Drug|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
75931918|NCT02269371|Other|Auricular Acupuncture|Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
75931919|NCT02269371|Other|Sham Acupuncture|Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
75931920|NCT02269449|Device|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
75931921|NCT02269449|Device|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
75931922|NCT02269449|Procedure|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
75931923|NCT02269449|Procedure|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
75931924|NCT01359969|Drug|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
75931925|NCT01160601|Drug|Paclitaxel / Carboplatin|Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
75931926|NCT01160601|Drug|bavituximab|Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
75931927|NCT02269527|Other|Live music|Providing 1-hour live music 5 days/ week.
75794746|NCT03022773|Other|Carotenoid measurements|"Carotenoid measurements of the eye (macula) are obtained through non-invasive ophthalmic photographs using the Heidelberg Spectralis imaging system.~Carotenoid measurements of the skin are measured by a laboratory instrument that uses a painless blue laser light for exposure of the skin and a photodetector for scattered light.~Carotenoid measurements in the blood are obtained through routine venipuncture."
75794747|NCT03020797|Drug|Perampanel|
75794748|NCT03020797|Drug|Placebo Oral Tablet|
75794749|NCT03002571|Drug|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
75337309|NCT03931746|Device|Porcine xenograft|The EZ-DERM™ porcine xenograft is a biosynthetic dressing made from porcine collagen containing aldehyde crosslinking. It has been most commonly applied to the management of 2nd degree burns, both partial-thickness and full-thickness defects. This dressing can be used for two healing purposes, either for primary healing or as an intermediate in the preparation for a skin graft
75473258|NCT01968486|Drug|PDT reduced fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
75794750|NCT03002571|Drug|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
75931928|NCT01529853|Drug|SAR156597|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75931929|NCT01529853|Drug|Placebo (for SAR156597)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75931930|NCT01357395|Drug|Amuvatinib|Amuvatinib 300 mg PO TID
75931931|NCT02269605|Other|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
75931932|NCT02269605|Drug|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
75931933|NCT02269605|Drug|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
76085856|NCT05966259|Other|Intervention Group- Intensive Multilevel Intervention|intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
76085857|NCT05966259|Other|Control Group|The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
76085858|NCT05965219|Drug|Emraclidine|Emraclidine tablets.
75931934|NCT02269683|Procedure|Robot-assisted distal pancreatectomy|
75931935|NCT02269683|Procedure|Laparoscopic distal pancreatectomy|
75931936|NCT01356849|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
75931937|NCT01356849|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
75931938|NCT02266407|Procedure|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
75931939|NCT01521663|Drug|IPX159|
75337310|NCT03920410|Other|serotonergic stimulation|Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.
75931940|NCT01521663|Drug|Placebo|
75931941|NCT02266485|Drug|BIBB 515 BS|
75931942|NCT02266485|Drug|Pravastatin|
76085859|NCT05965219|Drug|Itraconazole|Itraconazole oral solution.
76085860|NCT05965219|Drug|Carbamazepine|Carbamazepine tablets.
76085861|NCT05965219|Drug|Metformin|Metformin tablets.
75473259|NCT01968486|Drug|ranibizumab|In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
75473260|NCT01968512|Device|Transcranial Direct Current Stimulation|This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.
75794751|NCT03001479|Dietary Supplement|Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid|HMF with additional hydrolyzed protein
75794752|NCT02995681|Other|Balance training|Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.
75931943|NCT02266485|Drug|Placebo|
75931944|NCT01344993|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
75931945|NCT02269839|Device|rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
75931946|NCT02263989|Drug|Telmisartan film coated tablet|
75794753|NCT02995681|Other|Pulmonary rehab|Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
75794754|NCT02989025|Drug|17 OHPC|The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
75647126|NCT02566681|Biological|MSC construct for Osteonecrosis|"30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.~The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures."
75794755|NCT02988466|Biological|Haplo HCT <55 years old|"Fludarabine (Flu)~Cyclophosphamide (Cy)~Melphalan (Mel)~Total body irradiation (TBI)~Non-T-cell depleted donor bone marrow stem cell infusion Day 0"
75931947|NCT02263989|Drug|Telmisartan conventional tablet|
75794756|NCT02988466|Biological|Haplo HCT ≥55 years old|"Fludarabine (Flu)~Cyclophosphamide (Cy)~Melphalan (Mel): Dose reduction by 30%~Total body irradiation (TBI)~Non-T-cell depleted donor bone marrow stem cell infusion"
75931948|NCT02266563|Drug|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
75931949|NCT02266563|Drug|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
75931950|NCT02264067|Drug|Talsaclidine|
76085862|NCT05963451|Other|No intervention|No intervention will be given in our study since, the investigators are recruiting people who will receive already a facet thermal ablation.
76085863|NCT05957809|Other|Structured exercise training|"This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks. • Warm-up program - 10 minutes~Strength training on unstable surfaces - 25 minutes~Aerobic exercise - 25 minutes~Cool-down program - 10 minutes"
76085864|NCT05957484|Device|Investigational brainstem neuromodulation device|This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.
75473261|NCT01968512|Device|Sham|Same character of Transcranial Direct Current Stimulation but without current
75794757|NCT02988466|Drug|GVHD Prophylaxis|"Cyclophosphamide (Cy)~Tacrolimus (Tac)~Mycophenolate mofetil (MMF)"
75473262|NCT01968525|Biological|pre-oxygen|3 min of preoxygenation before anesthesia induction.
75794758|NCT02988466|Biological|Haplo HCT ≥55 and < 65 years old|"Fludarabine (Flu)~Cyclophosphamide (Cy)~Melphalan (Mel)~Total body irradiation (TBI)~non-T-cell depleted donor bone marrow stem cells"
75794759|NCT02988466|Biological|Haplo HCT ≥65 and ≤75 years old|"Fludarabine (Flu)~Cyclophosphamide (Cy)~Total body irradiation (TBI)"
75794760|NCT02980575|Other|Music|
75931951|NCT02264067|Drug|Placebo|
76085865|NCT05954546|Drug|Enco+bini|Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment
76085866|NCT05953012|Drug|PMC-403|PMC-403 will be administered Intravitreal.
75337311|NCT03920410|Other|no serotonergic stimulation|Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
75337312|NCT03888053|Biological|BB-101|Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.
75337313|NCT03878030|Drug|nusinersen|Subjects will receive nusinersen and be observed with motor assessments for 24 months
75473263|NCT01968564|Drug|Placebo pill|sugar and other inert substances
75473264|NCT01968564|Drug|High-dose curcumin pill|2000mg curcumin pill/day
75473265|NCT01968564|Drug|Low-dose curcumin pill|500mg curcumin pill/day
75794761|NCT02980575|Other|Exercise|
75794762|NCT02961322|Other|lobo-isthmectomy assisted robot|
75794763|NCT02946463|Biological|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to <60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to <100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
75931952|NCT02269995|Device|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
75931953|NCT02270073|Behavioral|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 25 sessions, while on average every fourth is supervized by an CBT expert therapist.
75931954|NCT02270151|Device|MyDiagnostick|Diagnostick strategy with MyDiagnostick
75931955|NCT02266641|Behavioral|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
75931956|NCT02266641|Dietary Supplement|multivitamin supplement|
75931957|NCT02270853|Device|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
75931958|NCT02271633|Dietary Supplement|Sodium nitrate|
75931959|NCT02271633|Dietary Supplement|Beetroot juice|
75931960|NCT02271633|Dietary Supplement|Spinach|
75931961|NCT02271633|Dietary Supplement|Rocket salad|
76085867|NCT05951881|Other|Emergency Care Unit - medicines|"The same group of patients admitted to the emergency room will respond separately to a pharmacist and a pharmacy assistant about their daily medication.~The two medical records will be compared in order to evaluate the work of the pharmacy assistant on the basis of 3 sources :~the Electronic Medical Record~the patient's medication history~the reference pharmacy"
76085868|NCT05947474|Drug|ORB-011|Drug: ORB-011 is dosed via IV infusion
76085869|NCT05946798|Drug|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10^-10M - 10^-1 M) for 5 minutes each
75931962|NCT04475601|Drug|Enzalutamide Pill|The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
75931963|NCT01516203|Drug|AZD5847|Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
76085870|NCT05946798|Drug|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10^-8M - 10^-4 M) for 10 minutes each
75337314|NCT03837509|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.
75647127|NCT02595736|Drug|Placebo (SC)|Administered SC
75337315|NCT03837509|Biological|Daratumumab SC|Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
75337316|NCT03822117|Drug|Pemigatinib|Pemigatinib administered orally once daily (QD).
75473266|NCT01968577|Drug|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
75647128|NCT02595736|Drug|LY3200327 (SC)|Administered SC
75794764|NCT02946463|Biological|Eculizumab|All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.
75794765|NCT02933008|Other|aNMT Biofeedback|"aNMT utilizes well-established visual feedback strategies to promote efficient, rapid and robust learning of complex movements. Athletes can discover how to move to create the desired feedback, even without explicit, conscious knowledge of how their movements relate to the visual pattern. aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention."
75794766|NCT02933008|Other|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases.
75794767|NCT02933008|Other|Neuromuscular Training|Participants will complete a 12-week, pre-season training program, over 6 weeks.
75794768|NCT02931266|Device|PASS MIS®|Posterior mini-invasive osteosynthesis
75931964|NCT01516203|Drug|Ethambutol, isoniazid, pyrazinamide, rifampin|Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
75931965|NCT01321359|Drug|Vehicle versus NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
75931966|NCT00703118|Drug|Telaprevir|Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
75931967|NCT00703118|Drug|Peg-IFN-alfa-2a|Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
75931968|NCT00703118|Drug|Ribavirin|Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
76085871|NCT05946785|Drug|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10^-10M - 10^-1 M) for 5 minutes each
75473267|NCT01968616|Drug|Ranibizumab, 0.5mg, Intravitreal|
75473268|NCT01968629|Drug|Eovist|
75473269|NCT01968642|Behavioral|Educational Intervention|
75473270|NCT01968655|Biological|OBI-1|OBI-1 is a B domain deleted recombinant porcine factor VIII
75473271|NCT01968668|Drug|BAY94-8862|1.25 mg BAY94-8862 tablet once daily in the morning
75473272|NCT01968668|Drug|BAY94-8862|2.5 mg BAY94-8862 tablet once daily in the morning
75473273|NCT01968668|Drug|BAY94-8862|5 mg BAY94-8862 tablet once daily in the morning
75473274|NCT01968668|Drug|BAY94-8862|7.5 mg BAY94-8862 tablet once daily in the morning
76085872|NCT05946785|Drug|insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10^-8M - 10^-4 M) for 10 minutes each
75647129|NCT02595736|Drug|LY3200327 (IV)|Administered IV
75647130|NCT02595736|Drug|Placebo (IV)|Administered IV
75647131|NCT00917488|Other|Standardization of allergenic extract (Gly. domesticus)|Allergenic extract for cutaneous prick-test
75647132|NCT04732975|Device|CardioFlux|Non-invasive screening for ACS
75647133|NCT02597842|Device|TEAS (transcutaneous electrical acupoint stimulation)|Electric stimulation was given through electrode attached to specific acupoints
75647134|NCT02597686|Behavioral|SD-PB training|
76085873|NCT05945719|Behavioral|Behavioral therapy|Behavioral and supportive therapy
76085874|NCT05945394|Other|No intervention|This is an obvertional study, and there is no intervention.
76085875|NCT05944978|Drug|GNC-035|GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
76085876|NCT05941819|Device|ARC-IM Thoracic System implantation|Implantation of the ARC-IM Thoracic Lead on the low thoracic level of the spinal cord and implantation of the ARC-IM IPG in the abdominal region
76085877|NCT05940961|Drug|Inotuzumab Ozogamicin|intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
75931969|NCT00703118|Drug|Placebo|Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
76085878|NCT05939518|Other|Lactated Ringer's Fluid Bolus Response to Low Urinary Output|During the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains <0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches >0.3 ml/kg/h.
76085879|NCT05939518|Other|Post-Anesthesia Care Unit Lactated Ringer's Fluid Management Protocol|During their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.
76085880|NCT05934500|Drug|Cannabidiol Oil|Subjects will self administer CBD sublingually
76085881|NCT05934019|Device|EMPATIA 1|The internet-program EMPATIA is hosted on a secure website https://selfhelp.psy.unibe.ch run by the Faculty of Human Sciences and is accessible from any regular internet browser. The software is not CE-marked as it has been developed for research purposes only. EMPATIA consists of 8 sessions and 1 booster session 3 weeks after the last session. It targets transdiagnostic mechanisms that have been identified in several mental disorders in adolescents: behavioral avoidance, repetitive negative thinking including intolerance of uncertainty, emotion, self-critical perfectionism and rejection sensitivity. The contents of EMPATIA are evidence-based and well-established cognitive-behavioral interventions dedicated to the respective transdiagnostic mechanism. The self-help program consists of psychoeducation, cognitive restructuring, relaxation and acceptance-based interventions, exposure and behavioral experiments and behavioral activation as treatment components.
76085882|NCT05930925|Drug|[phenyl-14C]ARV-471|Participants will receive a single dose of [phenyl-14C]ARV-471 by mouth
76085883|NCT05930925|Drug|[oxoisoindolin-14C]ARV-471|Participants will receive a single dose of [oxoisoindolin-14C]ARV-471 by mouth
76085884|NCT05926947|Dietary Supplement|Verum A|Formulation of polyphenols from olive leaf extract, blackcurrant extract, pomegranate extract, grapefruit extract
76085885|NCT05926947|Dietary Supplement|Verum B|Formulation of polyphenols from olive leaf extract, blackcurrant extract, white kidney bean extract, chromium picolinate and Zinc bisglycinate
75337317|NCT03810404|Dietary Supplement|Sodium bicarbonate supplementation|"Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0.15-, 0.25-, 0.35- and 0.50 g/kgFFM (0.12-, 0.20-, 0.28- and 0.40 g/kgBM), respectively). SB (Alkala, SANUM, Poland) will be administered as dissolved form in a 750 ml of fluid (water + fruit juice). On testing days the SB will be taken before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced."
75337318|NCT03810404|Dietary Supplement|Placebo treatment|"Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 750 ml of fluid (water + fruit juice). On testing days the PLA will be taken before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced."
75337319|NCT03808077|Drug|Rocuronium 0.3mg/kg/hr|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
75473275|NCT01968668|Drug|BAY94-8862|10 mg BAY94-8862 tablet once daily in the morning
75473276|NCT01968668|Drug|Placebo|Placebo tablet once daily in the morning
75473277|NCT01968668|Drug|BAY 94-8862|15 mg BAY 94-8862 tablet once daily in the morning
75473278|NCT01968668|Drug|BAY 94-8862|20 mg BAY 94-8862 tablet once daily in the morning
75473279|NCT01968681|Procedure|Alexandrite laser|3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
75473280|NCT01968759|Drug|Sevelamer|
75473281|NCT01968759|Drug|Ramipril and Irbesartan|
75473282|NCT01968772|Other|Transdermal Magnesium Chloride|Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
75647135|NCT04088812|Other|Placebo meat derivative + Placebo satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water
75647136|NCT04088812|Other|Placebo meat derivative + Satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water
75647137|NCT04088812|Other|Experimental meat derivative + Placebo satiating control|Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water
75647138|NCT00699283|Drug|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
75647139|NCT00699283|Drug|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
75931970|NCT01510119|Drug|Hydroxychloroquine|
75931971|NCT01510119|Drug|RAD001|
76085886|NCT05926947|Dietary Supplement|Placebo|Micro crystalline cellulose
76085887|NCT05926167|Diagnostic Test|blood tests drawn days 1, 8, 22 and 90 of the study|Blood tests related to Factor VIII activity that are not a part of standard of care
75931972|NCT01501383|Drug|VX-765 Part A|Tablets of VX-765 given at different doses based on treatment group in Part A
75473283|NCT01968798|Drug|Aspirin|100mg enteric-coated aspirin, taken daily
75931973|NCT01501383|Drug|Placebo|Matching placebo
75931974|NCT01501383|Drug|VX-765 Part B|Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
75931975|NCT04475367|Other|App hypercross group|hypertensive patients using HyperCrossApp
75931976|NCT04475367|Other|without App hypercross group|Interdisciplinary health care
75931977|NCT01150695|Other|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
75794769|NCT02907944|Behavioral|Implementation Facilitation|"Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.~External Facilitator: Outside content expert who assists site~Local Champion: Site stakeholder who promotes change~Provider Education and Academic Detailing: Provision of unbiased peer education~Stakeholder Engagement: Aligning goals of implementation and those impacted~Tailor Program to Site: Addressing site specific needs based on Aim 1~Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results~Formative Evaluation: Quant. and qual. determination of impact~Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders~Program Marketing: Increase attention to availability of on-site addiction treatment services"
75931978|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine [approximately 1x10^9 colony forming units (cfu)/mL] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
75931979|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
76085888|NCT05923788|Diagnostic Test|T1 mapping measurement|T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
76085889|NCT05920863|Procedure|TACE|TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.
76085890|NCT05920863|Drug|Tislelizumab, Lenvatinib|Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight <60kg, 8mg/day; weight ≥60kg, 12mg/day.
75473284|NCT01968798|Drug|Placebo|100mg enteric-coated placebo, taken daily
75473285|NCT01968824|Procedure|Brachial Plexus Nerve Block|The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
75473286|NCT01968837|Other|Cervical cancer screening|
75473287|NCT01968850|Drug|alendronate/vitamin D|once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.
75473288|NCT01968876|Other|Medication Adherence Smartphone App|MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
75647140|NCT00740584|Drug|3% SPL7013 Gel (VivaGel)|A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
75647141|NCT02596438|Other|Hepatitis B|Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
75647142|NCT04062721|Drug|Chemotherapy|Chemotherapy (at the investigator's choice) for ≥ 2 months before RFA (with controlled disease) and resumed 4-6 weeks after RFA to achieve 6-month total duration.
75647143|NCT04062721|Procedure|Radiofrequency ablation (RFA)|Complete macroscopic ablation by RFA.
75647144|NCT04062721|Drug|In situ immunotherapy|Hydrogel combining TLR or NOD2 agonist and GM-CSF will be injected in 1, 2 or 3 distinct lesions after RFA.
75647145|NCT04062643|Diagnostic Test|Obesity assessment|Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height
75794770|NCT02891759|Other|Alloderm RTU|-Most commonly used acellular dermal matrices
75794771|NCT02891759|Other|Cortiva 1mm Allograft Dermis|-Tutoplast processed dermis
75647146|NCT01023815|Drug|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
75647147|NCT01023815|Drug|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
75647148|NCT01023815|Drug|Prednison (continuous steroids)|continuous steroids
75794772|NCT02891759|Procedure|Skin or nipple-sparing mastectomy|-Standard of care
75931980|NCT02272023|Behavioral|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
76085891|NCT05920096|Other|Diabetes specialist nurse-led multi-component smoking cessation intervention|"Aims to:~inform participants on the association between smoking and diabetic complications;~motivate and encourage smokers to quit;~support participants in using the appropriate behavioural skills to quit smoking and avoid relapse.~In the first session, the participants will be supported to set a Target Quit Date (TQD) within two weeks. Participants will be followed up within a week (or two weeks max.) from their TQD. Those who report having not smoked (for ≥24 hours from the time of assessment) will be provided with a final follow-up session within five weeks from their set TQD (three sessions in total). Conversely, those who report still smoking will be encouraged to set another TQD and will be seen again in one (or two weeks max.) and five weeks from their new TQD (four sessions in total). The participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) nicotine patch and/or spray to use for a few days prior to their TQD and on quitting."
76085892|NCT05920096|Behavioral|Health Promotion and Disease Prevention Directorate's one-to-one smoking cessation service (standard care)|A behavioral smoking cessation intervention based on motivational interviewing and delivered by trained tobacco cessation facilitators within community health centres. Participants will be provided with 20-minute counseling sessions based on their needs.
75931981|NCT02272023|Behavioral|Single session of Motivational Interviewing|
75647149|NCT04062331|Device|Transcranial Magnetic Stimulation (TMS)|"By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months."
75931982|NCT05660642|Drug|BPL-003|Single dose administered intranasally
75931983|NCT02272179|Behavioral|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
75931984|NCT02272179|Behavioral|Brite|Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.
75794773|NCT02891759|Other|Breast Q|"15 questions~10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time"
75794774|NCT02891759|Procedure|Surgery|"To address the tissue expander~Standard of care"
75931985|NCT02272179|Behavioral|Treatment as Usual|Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.
75647150|NCT04062331|Drug|Placebos|Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
75931986|NCT05205044|Diagnostic Test|Apelin-13, Apelin-36|Serum levels of Apelin-13 and Apelin-36
75931987|NCT01302249|Drug|Latanoprost 0.005%|q.d.
75647151|NCT02595580|Device|Glucopred|
75931988|NCT01302249|Drug|AR-12286 Ophthalmic Solution 0.5%|
75931989|NCT01302249|Drug|Timolol maleate ophthalmic solution 0.5%|
76085893|NCT05919368|Dietary Supplement|Yam pill|It consists of sweet potato, white art and ginseng
76085894|NCT05917587|Drug|Metformin Hydrochloride|12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.
75473289|NCT01968889|Other|Non invasive phrenic nerve stimulation|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
75473290|NCT01968902|Biological|incabotulinumtoxinA|A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
75647152|NCT02567383|Radiation|Radiation|5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
75647153|NCT02567383|Device|Hyperthermia; Thermotron RF-8|40 minutes within 2hr after irradiation
75794775|NCT02860039|Biological|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
75473291|NCT01968902|Biological|Placebo|Saline injection on the day of injection visit
75473292|NCT01968915|Drug|LCL161|Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
75473293|NCT01968915|Drug|Paclitaxel|Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
75647154|NCT02567383|Drug|Cisplatin|20mg/m2 per week for 6 weekly cycles before radiotherapy
75794776|NCT02860039|Biological|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
75794777|NCT02860039|Other|Laboratory Biomarker Analysis|Correlative studies
75794778|NCT02819024|Drug|Dexamethasone|Given PO BID
75794779|NCT02819024|Device|Device for PET|Undergo 18F-FLT PET scan
75931990|NCT02261636|Drug|mesalazine|
75931991|NCT02272257|Behavioral|Early Direct Access Physical Therapy|Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
75931992|NCT02272257|Behavioral|Physician management|Physician management including advice, medication, and referral to physical therapy or other provider.
75931993|NCT05191706|Drug|Dexamethasone|single anterior chamber injection
75931994|NCT05191706|Drug|Prednisolone Acetate Ophthalmic|topical administration four times a day for 28 days, followed by treatment taper
75931995|NCT03305198|Biological|Capillary blood sampling from the earlobe|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
75931996|NCT05628519|Behavioral|Captain Sonar Exposition|Captain SonarTM is a naval battle game where two teams each composed of four participants clash. Each player has a well-defined role and it is imperative to communicate in a closed loop to advance in the game. This game also includes components similar to support for Trauma care: stress, speed of action, central communication and teamwork of four protagonists (Team Leader- Captain, intern-Second, nurse-Mechanic, Caregiver-Detector). This short video describes the rules and the Game progress: https://vimeo.com/173614346.
75931997|NCT05628519|Behavioral|Monopoly Exposition|Participant will be invited to play to Monopoly during 60 min
75931998|NCT03305120|Other|pain VAS evaluation|each patient has to answer to a questionnaire about pain
75931999|NCT05628441|Other|Computer Aided Detection system for Barrett's neoplasia|CADe system running in the back, not directly interfering with patient care
75932000|NCT01493505|Drug|AMG 386|AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
76085895|NCT05917587|Other|placebo|12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.
75647155|NCT02567383|Drug|Taxotere|10-12mg/m2 per week for 6 weekly cycles before radiotherapy
75932001|NCT01493505|Drug|Paclitaxel|Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
75932002|NCT01493505|Drug|AMG 386 Placebo|AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
75647156|NCT01023659|Drug|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
75794780|NCT02819024|Other|Laboratory Biomarker Analysis|Correlative studies
75794781|NCT02819024|Procedure|Positron Emission Tomography|Undergo 18F-FLT PET scan
75932003|NCT01493505|Drug|Carboplatin|Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
75932004|NCT02464748|Other|TiM telehealth arm|
75932005|NCT02464592|Procedure|Transbronchial lung biopsy.|Transbronchial lung biopsy with cryoprobe and with conventional forceps.
75932006|NCT04813718|Dietary Supplement|Omni-Biotic Pro Vi 5|Pre- and probiotic
75337320|NCT03808077|Drug|Rocuronium 1.5mg/kg/hr|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
75337321|NCT03737500|Device|B-Lite® light weight breast implant|Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant
75337322|NCT03737500|Device|Standard silicone-based breast implant|Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution
75794782|NCT02805530|Other|First line systemic treatment|Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
75794783|NCT02805530|Other|Radical treatment|to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
75794784|NCT02805530|Radiation|radiation therapy|Patients will receive dose and fraction regimen according to the metastatic site.
75647157|NCT01023659|Drug|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
75647158|NCT01023659|Behavioral|motivational emails|brief motivational emails, sent weekly for 12 weeks
75647159|NCT04062253|Diagnostic Test|HCV rapid test|Individuals who test positive for either HIV or HCV are offered PCR (polymerase chain reaction) testing with the xpert technology. Patients with a confirmed active infection are offered delivery and are taken into hospital.
75337323|NCT03681132|Other|Stop of therapy|The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
75337324|NCT03676647|Other|Diagnostic DNA Methylation Signature|Undergo collection of tissue samples
75337325|NCT03603184|Drug|Atezolizumab|Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
75337326|NCT03603184|Drug|Placebos|Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
75647160|NCT02567617|Dietary Supplement|Polyphenols|Capsules with five substances (polyphenols) at a concentration of 3000mg per day
75647161|NCT02567617|Dietary Supplement|Placebo controlled|Starch capsules
75932007|NCT04813718|Dietary Supplement|Placebo|Placebo
75932008|NCT01493271|Drug|Placebo|Placebo to RO5093151
75932009|NCT01493271|Drug|RO5093151|oral doses twice daily for up to 28 days
76085896|NCT05914116|Drug|DB-1311|Administered I.V.
76085897|NCT05908799|Drug|Pembrolizumab + Pemetrexed-Platinum|Medication records in EHR database used to define exposure group
76085898|NCT05908799|Drug|Pemetrexed-Platinum|Medication records in EHR database used to define comparator group
75337327|NCT03603184|Drug|Paclitaxel|Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.
75337328|NCT03603184|Drug|Carboplatin|Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.
75473294|NCT01968993|Device|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
75473295|NCT01969006|Drug|Marcaine ½%|
75473296|NCT01969006|Procedure|Needle prick|
75473297|NCT01969019|Drug|methylprednisolone, prednisone|
75473298|NCT01969032|Drug|Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
75473299|NCT01969045|Device|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy
75473300|NCT01969045|Device|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
75473301|NCT01969071|Drug|Levosimendan|The effects of levosimendan on renal function
75932010|NCT01301781|Drug|BLI801|BLI801 laxative - oral solution
75932011|NCT01301781|Drug|Placebo|BLI801 placebo - oral solution
75932012|NCT02466308|Device|SAM Ultrasound Diathermy Device|
75932013|NCT01301157|Drug|M518101|Proper quantity twice a day
75932014|NCT01301157|Drug|placebo|Proper quantity twice a day
75932015|NCT01301157|Drug|Dovonex|Proper quantity twice a day
75932016|NCT02465996|Device|pCLE examination|All FD patients received pCLE examination.
75932017|NCT02465996|Drug|Puyuanhewei|FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
76085899|NCT05907824|Other|Histopathological review, long-term prognosis and quality of life follow-up|Histopathological review, long-term prognosis and quality of life follow-up
76085900|NCT05906303|Drug|Caffeine and Sodium Benzoate Injection|Provide caffeine to shorten second stage of labor and augment pushing efforts
76085901|NCT05906303|Drug|Normal Saline|Provide normal saline to serve as a placebo
76085902|NCT05905718|Other|assessment|Assessments of thoracic kyphosis angle, balance performance, and gait performance.
75647162|NCT00740116|Drug|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery
75647163|NCT00740116|Drug|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
75647164|NCT02567461|Drug|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
75647165|NCT02567461|Drug|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
75647166|NCT02567461|Drug|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
75932018|NCT01296087|Drug|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
76085903|NCT05904392|Other|Music|Music played prior to injection
76085904|NCT05903053|Behavioral|Early Self-Regulation Intervention|"Participants enrolled in a separate protocol (UC Davis IRB ID#1077801) will be invited to participate upon meeting eligibility criteria. All participants will receive the intake and exit assessment battery, with the intake assessment battery being completed as part of IRBNet ID#1077801. A multiple baseline design across participants will be used with varying introduction of treatment elements for a subset of enrolled intervention participants. An intense intervention phase will follow the baseline phase in which 45-60 minute intervention sessions will occur two times per week for approximately 4-6 weeks for a total of 8 sessions. At the conclusion of the intense intervention phase, coaches will provide booster sessions once weekly for a month (4 sessions total)."
76085905|NCT05900427|Drug|Liposomal bupivacaine|Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
76085906|NCT05900427|Drug|Bupivacaine|Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
76085907|NCT05897840|Device|Fiber-optic probe CeVOX|Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
76085908|NCT05897307|Drug|Ropivacaine|dexmedetomidine
76085909|NCT05897086|Drug|Polyethylene Glycol 3350|Topical irrigation with approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water
75794785|NCT02805530|Other|Chemoradiotherapy|Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
75932019|NCT01296087|Drug|Placebo|Matching placebo capsule given once daily on Days 1 to 28
75932020|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - low|
75932021|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - medium|
75932022|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - high|
76085910|NCT05896683|Drug|Lazertinib|Lazertinib will be administered orally.
75337329|NCT03519009|Behavioral|IPS Plus Abstinence-Contingent Wage Supplement|Participants are offered abstinence-contingent wage supplements if they obtain and maintain competitive employment. The wage supplements are designed to promote employment while reinforcing drug abstinence. To help participants obtain and maintain competitive employment, participants will receive Individual Placement and Support (IPS) supported employment. IPS is a supported employment intervention that has been proven effective in promoting employment in adults with severe mental illness. To promote employment and prevent relapse to drug use, participants will receive IPS Plus Abstinence-Contingent Wage Supplements.
75337330|NCT03507452|Drug|BAY2287411|"Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days)."
75337331|NCT03507452|Drug|BAY2287411|"Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation."
75337332|NCT03497897|Drug|LYS006 20 mg|LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
75337333|NCT03497897|Drug|LYS006 2 mg|LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
75647167|NCT02567461|Drug|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
75647168|NCT03966352|Other|Questionnaire|Enrolled subjects will complete a questionnaire to ascertain information on treatment considerations, obstacles, motivations, and outcomes encountered on their pathway to fatherhood.
75647169|NCT00698581|Drug|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
75932023|NCT02264145|Drug|Ethanolic Solution From Respimat®|
75932024|NCT02266953|Behavioral|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
75932025|NCT02266953|Behavioral|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
76085911|NCT05894772|Behavioral|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the Power over Pain Portal for 4 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference. The overall objective is to determine the implementation (guided by Proctor's implementation conceptual framework) and clinical effectiveness of the PoP Portal in a sample of youth (12-18 years of age) who are on the waitlist for tertiary care consultation at any pediatric CP clinic in Canada.
76085912|NCT05887102|Behavioral|PACHA Program|Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
76085913|NCT05885373|Dietary Supplement|SIM01|SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
75337334|NCT03497897|Drug|Placebo|Matching placebo, capsules, oral administration, BID, for 12 weeks
75337335|NCT03493490|Drug|Neodolpasse|Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
75337336|NCT03493490|Drug|Diclofenac|Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
75337337|NCT03493490|Drug|Placebo|Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
75337338|NCT03489746|Other|ICS withdrawal protocol|A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
75647170|NCT00698581|Drug|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
75337339|NCT03489746|Other|Standard care|Normal clinically indicated inhaled therapy
75932026|NCT02267031|Procedure|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
75337340|NCT03428217|Drug|CB-839|Oral glutaminase inhibitor
75337341|NCT03428217|Drug|Cabozantinib|Oral receptor tyrosine kinase inhibitor
75337342|NCT03428217|Drug|Placebo|Placebo tablets
75337343|NCT03410927|Drug|TAS0728|TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
75473302|NCT01969071|Drug|Dobutamine|Standard Inotropic agent
75647171|NCT03964870|Diagnostic Test|Diagnostic of polymorphisms in malignant hyperthermia|Identify and catalogue the variants or polymorphisms in the RYR1 and CACNA1S genes in the Spanish population.
75647172|NCT02595346|Drug|Hydroxychloroquine|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
75647173|NCT02595346|Drug|placebo|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
75647174|NCT05380258|Other|stress ball|Pregnant women with 4-5 cm cervical dilatation were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes when their contractions came, and when the cervical opening was 6-8 cm, they were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes.
75798966|NCT01182090|Procedure|Colposacropexy|In laparoscopic approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
75798967|NCT03739242|Dietary Supplement|Nutraceutical combination|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
75798968|NCT03739242|Other|Placebo|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
75932027|NCT02264301|Drug|Puerarin injection 400 mg|
75932028|NCT02264301|Drug|Qingkailing injection 40 ml|
75932029|NCT02267109|Biological|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
75932030|NCT02267109|Biological|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
75932031|NCT05596838|Procedure|Intracorneal rings placement|Intracorneal rings placement in keratoconus using laser
75932032|NCT01487109|Drug|CTP-499|600 mg tablet twice daily
75932033|NCT01487109|Drug|Placebo|Matching placebo tablet
75932034|NCT02465918|Device|motor cortex stimulation (Change of Stimulation Timing)|
75647175|NCT05380258|Other|chewing gum|Pregnant women with 4-5 cm cervical dilatation were asked to squeeze the ball for 5 seconds and loosen it for 2 seconds as soon as their contractions came and within 20 minutes, and when the cervical opening was 6-8 cm, they chewed gum again for 20 minutes.
75932035|NCT04476069|Drug|IBUPROFEN|given to children 30 minutes before extraction / orally for one time only
75932036|NCT04475913|Other|DIG Axial|patients received 4 axial implants and digital impression
75932037|NCT04475913|Other|DIG Tilted|received two anterior axial implants and two distal tilted implants, and digital impression
75932038|NCT04475913|Other|CIG Axial|patients received 4 axial implants and conventional impression
75932039|NCT04475913|Other|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
76085914|NCT05884619|Device|Dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
76085915|NCT05875025|Other|Placebo formulated with HFA-152a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
75337344|NCT03399851|Device|Amplatzer Amulet for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Amplatzer Amulet will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
75794786|NCT02800785|Drug|Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin|Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
75794787|NCT02800785|Procedure|Appendectomy|Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
75794788|NCT02782663|Drug|ABT-494|Tablet: Oral
75794789|NCT02765854|Drug|Dexamethasone|Given PO
75794790|NCT02765854|Drug|Ixazomib|Given PO
75794791|NCT02765854|Drug|Lenalidomide|Given PO
75794792|NCT02761694|Drug|Vevorisertib|Administered as an oral dose every day or every other day.
75794793|NCT02761694|Drug|Fulvestrant|Administered as an intramuscular (IM) injection.
75794794|NCT02761694|Drug|Paclitaxel|Administered as an intravenous (IV) infusion.
75794795|NCT02760030|Drug|Fulvestrant|Given IM
75337345|NCT03399851|Device|Watchman/FLX for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Watchman/FLX will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
75473303|NCT01969097|Device|tDCS|transcranial direct current stimulation (tDCS)
75473304|NCT01969097|Behavioral|Motor training|Motor training of the affected upper extremity (5 days, 25 min/day).
75473305|NCT01969110|Dietary Supplement|Oral IMPACT|Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
75473306|NCT01969123|Drug|Drug: EVP-6124|
75473307|NCT01969123|Drug|Placebo|
75794796|NCT02760030|Other|Laboratory Biomarker Analysis|Correlative studies
75794797|NCT02760030|Drug|Palbociclib|Given PO
75932040|NCT05627973|Device|Aortic Valve Replacement|Surgical replacement of aortic valves
75932041|NCT02464826|Drug|Nailprotex|Nailprotex apply to the abnormal nail twice daily
75932042|NCT02464670|Biological|INO-4201|INO-4201 delivered IM followed by Electroporation
75932043|NCT02464670|Biological|INO-4202|INO-4202 delivered IM followed by Electroporation
75932044|NCT02464670|Biological|INO-4201|INO-4201 delivered ID followed by Electroporation
75932045|NCT02464670|Biological|INO-4212|INO-4212 delivered IM followed by Electroporation
75932046|NCT02464670|Biological|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
75932047|NCT02464670|Biological|INO-4201 + INO-9012|INO-4201 + INO-9012 delivered ID followed by Electroporation
75932048|NCT02267265|Other|TMW-Newborn Intervention video|This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
75932049|NCT02267265|Other|Safe Sleep for your Baby (SIDS) educational video|It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
75932050|NCT01481571|Device|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
76085916|NCT05875025|Other|Placebo formulated with HFA-134a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
76085917|NCT05874453|Other|eye care protocol|The lower conjunctiva of the eye to be treated is opened, 1-2 drops of gel are applied, the eye is closed. Cleaning eye secretions is done with sterile distilled water. A gel containing trehalose, hyaluronic acid and carbomer will be applied every 2-4 hours in accordance with intensive care eye care protocol. In order to determine the exposure keratopathy, staining with Fluorescein Sodium will be performed by the ophthalmologist on days 0, 5 and 10, and a blue light pen will be used for evaluation. In order to determine the degree of dry eye, the Schirmer I test will be performed on the 0th and 10th days
76085918|NCT05869760|Other|Carotenoid Intake|Carotenoid intake calculated from food diary records reported by guardians.
76085919|NCT05869760|Other|Serum carotenoid concentrations|Serum carotenoid concentrations measured by HPLC.
76085920|NCT05868863|Other|datas of medical record.|"Analysis datas of medical record:~Feasibility of the technique~Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~Analgesic intake before and after the procedure~Functional criteria: early rising, walking"
75473308|NCT01969136|Drug|Drug: EVP-6124|
75932051|NCT05529758|Behavioral|Internalized Weight Bias Intervention|ACT-based programs and self-compassion have shown promise throughout research for lowering IWB (Berman et al., 2016; Levin et al., 2018; Lillis et al., 2009; Palmeira, Cunha, & Pinto-Gouveia, 2017; Palmeira, Pinto-Gouveia, & Cunha, 2017; Forbes et al., 2020). Therefore, using techniques from prior ACT- and self-compassion based programs, a weight bias reduction intervention will be administered. Session topics will include psychoeducation and coping for weight bias and internal weight bias, and these topics will be viewed through a self-compassionate and ACT-based lens (for example, participants may defuse from internal critical thoughts rather than challenge them). Sessions will also cover acceptance, cognitive defusion, mindfulness, committed action, and the dialectical behavioral therapy (DBT) DEARMAN skill.
75932052|NCT01124565|Drug|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
75932053|NCT02465840|Procedure|custom-made dynamic hand splint|custom-made dynamic splinting with more early active exercises intervention.
75932054|NCT02465840|Procedure|custom-made protective hand splint|Immobilization splint with gentle ROM exercises
75932055|NCT02465840|Other|physical therapy and occupational therapy|both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
75932056|NCT01123785|Drug|INO-8875|eye drops for 14 days in one eye
75932057|NCT01123785|Drug|Placebo|Matched vehicle-control
75932058|NCT01293669|Drug|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
76085921|NCT05856539|Procedure|Erector spinae plane (ESP) block|ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
76085922|NCT05849389|Drug|Vosoritide|Vosoritide administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
75647176|NCT02596594|Device|fetal nutrition port system|Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
75932059|NCT01293669|Drug|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
75932060|NCT02465762|Device|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
75932061|NCT02465684|Procedure|unicondylar knee arthroplasty|
76085923|NCT05843786|Drug|Interferon gamma|Daily subcutaneous administration of Interferon gamma during 5 days
76085924|NCT05843786|Drug|Placebo|Placebo during 5 days
76085925|NCT05841615|Other|Renal Denervation operation|RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W~12W for 40 seconds
75932062|NCT01480479|Drug|Rindopepimut (CDX-110) with GM-CSF|"Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF."
75932063|NCT01480479|Drug|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
76085926|NCT05841615|Other|Pulmonary vein isolation|PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
75473309|NCT01969136|Drug|Placebo|
75473310|NCT01969149|Drug|Exenatide|
75473311|NCT01969149|Drug|Insulin|
75473312|NCT01969175|Other|Low-glycemic-load and milk-free diet|
75473313|NCT01969266|Drug|Treatment A: PCI-32765|840 mg capsule formulation administered by mouth on Day 1
75473314|NCT01969266|Drug|Treatment B: PCI-32765|840 mg solution formulation administered by mouth on Day 1
76085927|NCT05839808|Other|Reliability and validity study|To evaluate the validity and reliability of the Stroke Exercise Preference Inventory
76085928|NCT05839795|Other|Assessment study|Evaluation of musculoskeletal-related pain, posture, spine function, lumbar and neck regions, musculoskeletal disorder, fatigue, and quality of life
76085929|NCT05829629|Biological|FluBHPVE6E7|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule
76085930|NCT05829629|Drug|Placebo|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at determined schedule
76085931|NCT05829525|Other|Evaluation of sleep quality, sleep duration, heart rate and step count|Evaluation of sleep quality with the Pittsburgh Sleep Quality Index Evaluation of sleep duration, heart rate, and step count with the Fitbit® Inspire 2 (Fitbit, Inc., San Francisco, California, USA) Evaluation of quality of life with the Nottingham Health Profile
75473315|NCT01969292|Other|Colometer|Real time software based image analysis tool.
76085932|NCT05825742|Device|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
75794798|NCT02760030|Other|Questionnaire Administration|Correlative studies
75932064|NCT01480479|Drug|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
75932065|NCT01116141|Drug|CH-4051|Different doses CH-4051 to be compared
75932066|NCT01116141|Drug|Methotrexate (MTX)|20 mg MTX weekly
76085933|NCT05825742|Other|Standard oral health instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
76085934|NCT05824208|Behavioral|PRENAYOGA - prenatal yoga|The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
76085935|NCT05823623|Drug|Inetetamab|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
75337349|NCT03377491|Device|NovoTTF-200T|Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
75337350|NCT03377491|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
75337351|NCT03377491|Drug|nab paclitaxel|nab-paclitaxel 125 mg/m^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
75337352|NCT03331250|Drug|Eribulin|It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
75337353|NCT03307044|Procedure|Laser Therapy|Undergo fractional CO2 laser therapy
75647177|NCT04061395|Biological|Guselkumab|See study arm description.
75647178|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
75647179|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
75647180|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
75794799|NCT02760030|Drug|Aromatase Inhibitors|Given PO
75794800|NCT02728284|Procedure|cardiovascular MRI (CMR)|CMR is used to demonstrate cardiac abnormalities and assess cardiac function in many patients
76085936|NCT05823623|Drug|Pyrotinib|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
76085937|NCT05823623|Drug|Oral Vinorelbine Tartrate|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
75794801|NCT02728284|Procedure|Conventional Cardiologic Evaluation|ECG (gating), and respiratory motion effects
75794802|NCT02710253|Radiation|External Beam Radiation Therapy|Undergo EBRT
75794803|NCT02710253|Other|Laboratory Biomarker Analysis|Correlative studies
75932067|NCT01116141|Drug|Folic Acid|1 mg folic acid daily
76085938|NCT05822856|Other|Blood sampling and others interventions|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
76085939|NCT05821699|Behavioral|LCS (Life Care Specialist)|"The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~Opioid Risk Education~Therapeutic Intervention~Clinical Pain Coordination"
75337354|NCT03307044|Other|Questionnaire Administration|Ancillary studies
75337355|NCT03298087|Procedure|radical prostatectomy|surgical removal of the prostate
75337356|NCT03298087|Radiation|stereotactic body radiotherapy|Highly targeted radiation
75337357|NCT03298087|Drug|Leuprolide|Lowers serum testosterone
75337358|NCT03298087|Drug|apalutamide|antiandrogen
75794804|NCT02710253|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75794805|NCT02704351|Procedure|Surgery|Sugammadex to reverse neuromuscular blockade
75794806|NCT02698111|Drug|Donafenib|donafenib 200mg，bid
75794807|NCT02697812|Procedure|slow sternal retraction|the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
75794808|NCT02683512|Other|No intervention|This is an observational study that consists of data abstraction from patient medical records.
75794809|NCT02641093|Drug|Pembrolizumab|Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
75794810|NCT02641093|Procedure|Surgery|gross total surgical resection
75932068|NCT01287585|Drug|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
75932069|NCT01287585|Drug|Placebo|weekly, intramuscular, until disease progression or toxicity.
75932070|NCT01287585|Other|Best Supportive Care|treatment of disease-related symptoms throughout the study.
75932071|NCT01284387|Biological|ACC-001 (vanutide cridificar)|Comparisons of 2 different doses of ACC-001 or placebo for 24 months
75932072|NCT02264457|Device|T-flex Aspheric Toric IOL|
75794811|NCT02641093|Radiation|Radiation Therapy|60-66 Gy over 6 weeks
75794812|NCT02641093|Drug|Cisplatin|Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
75647181|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
75794813|NCT02614768|Device|Glucose Sensor|"The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received conformité européenne (CE) certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled for investigative use only."
75794814|NCT02612454|Drug|Dupilumab|Weight-tiered dosing administered subcutaneous (SC)
75794815|NCT02603237|Other|Glucose tolerance test|Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
75647182|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
75647183|NCT02566447|Device|Solana Trichomonas Assay Testing|Specimen collection of urine and/or vaginal swabs for testing
75647184|NCT02567695|Drug|GBT440|Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
75647185|NCT05214859|Behavioral|The Dyadic Expressive Arts Group Therapy|This therapy utilizes different art modalities, such as visual art, music, movement, dance, drama, and writing, as therapeutic means. With multiple sensory stimulations from different art forms, the therapy facilitates communication, expression, perception, and interactions. The therapy consists of 8 weekly 90 minutes sessions, with 3-4 mother-child dyads in each therapy group. Each session will follow the basic structure of Expressive Arts Therapy, including check-in, warm-up, core art-making, sharing, and closure. The following themes related to the mother-child relationship will be included, such as communication, relationship, expression, empathy, interaction, love, gratitude, and connection.
75647186|NCT01023581|Drug|Alogliptin|Alogliptin tablets.
75647187|NCT01023581|Drug|Metformin|Metformin capsules
75647188|NCT01023581|Drug|Alogliptin Placebo|Alogliptin placebo-matching tablets.
75647189|NCT01023581|Drug|Metformin Placebo|Metformin placebo-matching capsules.
75647190|NCT05571787|Drug|HMPL-523|700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26
75647191|NCT05571787|Drug|Rabeprazole|40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26
75647192|NCT04063189|Drug|Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen|Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23
75647193|NCT02567929|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation.
75647194|NCT02567929|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation.
75647195|NCT04298489|Diagnostic Test|Personalized drug sensitivity test|"The patients underwent surgery to remove tumor and took out tumor specimens for research. The tumor cells were expanded ex vivo drug sensitivity assay.~The drugs used in the study were 5-fluorouracil, Oxaliplatin, and irinotecan at C0 = 10 mM, 2.5 mM and 0.02 mM, respectively. They were applied either as single agents or in combinations of 5-fluorouracil and Oxaliplatin, 5-fluorouracil and irinotecan, or all three agents, or others. After 7 days of treatment, the tumor cells were stained with EdU, Hoechst and EpCAM with the Cell Quantitative Detection Kit. Images were acquired with an automated microscopic image-scanning system and analyzed with the built-in software."
75647196|NCT05190523|Drug|ASC42 5 mg|5 mg of ASC42 tablets orally once daily for 12 weeks.
75794816|NCT02603237|Other|Fat tolerance test|Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
75932073|NCT02264457|Device|AT TORBI toric IOL|
75932074|NCT01280565|Drug|Masitinib|Masitinib 7.5 mg/kg/day
75932075|NCT01280565|Drug|Dacarbazine|IV bolus at 1,000 mg/m2 once every 3 weeks
75932076|NCT04476147|Other|Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.|This is an observational study. All the patients evaluate with CHA2DS2-VASc, HAS-BLED and Fried Scale, and observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with NVAF.
75932077|NCT01113957|Drug|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
75337359|NCT03298087|Drug|abiraterone|Inhibits androgen synthesis
75473316|NCT01969292|Other|Sham Software|Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
75647197|NCT05190523|Drug|ASC42 10 mg|2 x 5 mg of ASC42 tablets orally once daily for 12 weeks.
75647198|NCT05190523|Drug|ASC42 15 mg|15 mg of ASC42 tablets orally once daily for 12 weeks.
75647199|NCT05190523|Drug|Placebo|Placebo tablets orally once daily for 12 weeks.
75798969|NCT01185444|Procedure|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
75798970|NCT01185444|Procedure|Hyalgan|The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
75932078|NCT01113957|Drug|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
75932079|NCT01113957|Drug|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
75932080|NCT01111773|Drug|Heated Lidocaine and Tetracaine Patch|Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
75337360|NCT03189719|Biological|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
75337361|NCT03189719|Drug|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
75337362|NCT03189719|Drug|Cisplatin|80 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
75337363|NCT03189719|Drug|5-FU|800 mg/m^2/day (4000 mg/m^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
75337364|NCT02969525|Other|Placebo|
75473317|NCT01969305|Behavioral|Kazakhstani Family Together|Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
75647200|NCT04298333|Drug|BP-C1|"BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days."
75647201|NCT05188417|Drug|Tirofiban 0.05 MG/ML|intravenous injection of the drug according to different body weights and arms
75647202|NCT05188417|Drug|0.9% sodium chloride solution|intravenous injection of the drug according to different body weights and arms
75647203|NCT00962780|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
75794817|NCT02578732|Drug|FOLFOXA|"Schema:~1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~Antiemetics will be administered as per standard institutional policy."
75794818|NCT02574481|Device|ELUVIA (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
75932081|NCT04339959|Other|Remote Assessment of Physical Function with Direct Observation|An android tablet with Wi-Fi and cellular will be used to compare videoconferencing with face-to-face assessment of 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up & Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
76085940|NCT05821699|Behavioral|Standard of Care|Patients will receive the current standard-of-care for pain management in the aftermath of surgery: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
75337365|NCT02969525|Drug|Bimekizumab|Bimekizumab in different dosage regimens.
75337366|NCT02889081|Other|maternal biological folate level|supplementation status and serum level
75337367|NCT02889081|Other|maternal biological Vitamin D level|supplementation status and serum level
75337368|NCT02866578|Procedure|Open lung protective ventilation strategy|
75337369|NCT02856594|Drug|Dexmedetomidine|Dexmedetomidine
75647204|NCT00962780|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
75647205|NCT00962780|Procedure|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
75647206|NCT00962780|Procedure|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
75647207|NCT02567851|Drug|Brentuximab Vedotin|Monoclonal antibody drug conjugate
75647208|NCT02566291|Device|Success|Success rate and time for insertion
75647209|NCT02566213|Other|Parabolic flight|
75647210|NCT02566213|Other|Motor skills measurements|"the kinematics measurements of the right hand with a motion analysis system;~the measurements of forces applied by the hand on the object to be grasped and moved with a 6 degree of freedom force sensor;~the measurement of position of the moved object with an inductive position encoder."
75647211|NCT02859662|Procedure|ruptured aortic aneurysm|All patients with ruptured abdominal aortic aneurysm may be included in this study, whatever the surgical treatment.
75794819|NCT02574481|Device|Zilver PTX (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
75794820|NCT02519452|Drug|Daratumumab Subcutaneous (SC) Administration|Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
75798971|NCT01188018|Behavioral|Brief Advice (BA)|Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
75337370|NCT02856594|Drug|Placebo|Placebo
75337371|NCT04232215|Device|HeraBEAT™|A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy
75794821|NCT02519452|Drug|Recombinant Human Hyaluronidase [rHuPH20]) SC Administration|Participants will receive Recombinant Human Hyaluronidase [rHuPH20]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
76085941|NCT05816915|Behavioral|Cognitive behavioral therapy|Subjects will receive professional lifestyle intervention conducted by STOB organization. Using CBT and the so-called third wave of CBT, especially mindfulness, the patients will be guided by certified experts to increase motivation and to change eating and exercise habits, which will be mapped before and after the intervention.
75337372|NCT04232215|Device|Doppler fetal heart rate monitor|A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.
75337373|NCT02840539|Drug|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim|"Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle~Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older~Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle~Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles"
75473318|NCT01969305|Behavioral|Usual Care Alone|"Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:~Facts and Myth about HIV. HIV/STIs modes of transmission;~Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;~Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use."
75473319|NCT01969318|Drug|Placebo /Metformin|Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too
75473320|NCT01969318|Drug|SP2086(50 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks
75473321|NCT01969318|Drug|SP2086 (100 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
75647212|NCT00739882|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week. The treatment period will be 24 weeks divided into two phases: 1) double-blind for 12 weeks, and 2) open-label for 12 additional weeks, in which all subjects from the placebo group and those subjects from the Raptiva ® group with ≥ 50% of improvement will be allocated to extended treatment with Raptiva ® for 12 additional weeks while non-responders to Raptiva ® (improvement ≤ 50%) will be followed in an observational manner for 12 additional weeks without treatment.
75647213|NCT00739882|Drug|Placebo|Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
75647214|NCT04281056|Procedure|Tooth removal and their replacement by means of a denture|Teeth have been removed and replaced by means of dentures for at least one year
75337374|NCT02774954|Behavioral|Change the Cycle|See previous response
75337375|NCT02639442|Device|ClearRing™|
75473322|NCT01969331|Dietary Supplement|Normia|One capsule twice a day/14 days
75473323|NCT01969331|Dietary Supplement|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
75473324|NCT01969357|Drug|Placebo|Tablets(n=4),once daily for 84 days
75473325|NCT01969357|Drug|50 mg SP2086|Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
75473326|NCT01969357|Drug|100 mg SP2086|Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
75473327|NCT01969357|Drug|200 mg SP2086|Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
75473328|NCT01969357|Drug|100 mg Sitagliptin|Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
75473329|NCT01969370|Behavioral|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
75473330|NCT01969383|Other|Heated pool training|
75473331|NCT01969396|Device|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
75647215|NCT00961220|Drug|Carmustine|Applied topically
75647216|NCT00961220|Other|Laboratory Biomarker Analysis|Correlative studies
75647217|NCT00961220|Drug|O6-Benzylguanine|Given IV
75647218|NCT00734656|Drug|dutasteride + ethanol|4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
75647219|NCT00734656|Drug|placebo medication + ethanol|placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
75647220|NCT00734656|Drug|dutasteride + placebo alcohol|4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
75647221|NCT00734656|Drug|placebo medication + placebo alcohol|placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
75647222|NCT04644289|Drug|olaparib|Olaparib tablets are administrated orally 300 mg twice daily.
75794822|NCT02505984|Drug|Oxytocin|Study participants will be randomized to a placebo or drug group.
75794823|NCT02505984|Drug|Placebo|Study participants will be randomized to a placebo or drug group.
75794824|NCT02489214|Drug|donafenib tosilate tablets|200mg bid
75794825|NCT02477280|Drug|Methylphenidate|Cross-over
75794826|NCT02477280|Drug|Placebo|Medikinet
75794827|NCT02444416|Procedure|blood sample|
76085942|NCT05814497|Other|Multisensory Task|Reversing checkerboard, tones, and finger opposition.
75647223|NCT04644289|Drug|durvalumab|Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .
76085943|NCT05814497|Other|Graphesthesia|Trace numbers on skin.
75647224|NCT00921271|Device|Monitoring of StO2|Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
75647225|NCT02565979|Dietary Supplement|resveratrol|Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
75647226|NCT02565979|Dietary Supplement|placebo|A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
75794828|NCT02438722|Drug|Afatinib Dimaleate|Given PO
75794829|NCT02438722|Biological|Cetuximab|Given IV
76085944|NCT05814497|Other|Divided attention|Divide attention between two noxious stimuli.
76085945|NCT05805306|Behavioral|Entre Herman@s|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, & sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
75473332|NCT01969396|Device|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
75647227|NCT04062175|Drug|cephalosporin|72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
75794830|NCT02438722|Other|Laboratory Biomarker Analysis|Correlative studies
75794831|NCT02414347|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
76085946|NCT05805306|Behavioral|Vaccines for Health|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, & sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
76085947|NCT05800366|Drug|Glofitamab|human IgG1-bispecific antibody, via IV infusion
76085948|NCT05800366|Drug|Polatuzumab|an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion
76085949|NCT05800366|Drug|Rituximab|Per standard care, via IV infusion
75473333|NCT01969422|Procedure|observation|intervention is the contact with online question answering serice ad subseudd
75473334|NCT01969461|Behavioral|Motivational Enhancement Therapy (MET)|The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
75473335|NCT01969474|Drug|Cannabis|Cannabis capsules given once daily for a month
75473336|NCT01969474|Drug|Placebo|Placebo
75473337|NCT01969487|Other|Preoperative warm-up on simulator|
75647228|NCT04062175|Drug|Azithromycin Tablets|72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
75647229|NCT02859584|Biological|Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL|
75647230|NCT00921193|Device|Radiation Therapy Positioning System (RTPS)|
75647231|NCT02567305|Other|Markers of NET formation|i.e. Plasma DNA, Histone, MPO, DNase
75647232|NCT04391569|Drug|Ganaxolone|Ganaxolone will be administered.
75647233|NCT04391569|Drug|Placebo|Placebo will be administered.
75794832|NCT02408770|Drug|ulipristal acetate|selective progesterone receptor modulator
75794833|NCT02385279|Device|MiStent|Percutaneous Coronary Intervention
75794834|NCT02385279|Device|XIENCE EES|Percutaneous Coronary Intervention
75794835|NCT02376829|Device|Invisalign System|The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
75794836|NCT02368665|Drug|Amlodipine 5mg|- Daily oral administration for 8 weeks
75794837|NCT02368665|Drug|Amlodipine 5mg, Candesartan cilexetil 16mg|- Daily oral administration Amlodipine 5mg for 8 weeks
75794838|NCT02368665|Drug|Amlodipine 10mg, Candesartan cilexetil 16mg|- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
75794839|NCT02368652|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
76085950|NCT05800366|Drug|Doxorubicin Hydrochloride|Per standard care, via IV infusion
76085951|NCT05800366|Drug|Cyclophosphamide|Per standard care, via IV infusion
76085952|NCT05800366|Drug|Prednisone|Per standard care, orally
76085953|NCT05799183|Drug|SHR-1210|Subjects will receive treatment SHR-1210 before process changes 20 mg
76085954|NCT05799183|Drug|SHR-1210|Subjects will receive treatment SHR-1210 after process changes 20 mg
75794840|NCT02368652|Drug|Amlodipine 10mg, Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
75794841|NCT02332577|Drug|PRISTINAMYCIN XRP7263|Pharmaceutical form:tablet 500 mg Route of administration: oral
75932082|NCT04339959|Other|Remote Assessment of Physical Function|An android tablet with Wi-Fi and cellular will be mailed to study participants to remotely assess 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up & Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
75932083|NCT01103037|Drug|QAV680|QAV680 500 mg (5 x 100 mg capsules) four times per day
75932084|NCT01103037|Drug|QAV680 Placebo|Placebo to QAV680 5 capsules four times per day
75932085|NCT01280331|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
75932086|NCT01280331|Drug|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
75932087|NCT01280331|Drug|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
75932088|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
75932089|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
75647234|NCT05324917|Drug|Rituximab|Chemotherapy for children with lymphoma: rituximab (375mg/m2 BSA) was added intravenously from COPADM1 regimen. once every 3 weeks to 4 weeks, combined with corresponding chemotherapy, a total of 4 times.
75647235|NCT05324917|Drug|Rituximab (once a week)|"Rituximab (375mg/m2 BSA) was administered intravenously for lymphoproliferative diseases and EB virus-associated B lymphoproliferative diseases after hematopoietic stem cell transplantation. Once a week, a total of 4 times.~ITP and AIHA patients received rituximab (100mg/m2 BSA) intravenously once a week, a total of 4 times."
75647236|NCT00739648|Drug|MP-376|MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
75932090|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
75932091|NCT01474083|Drug|Placebo|Dose-matched placebo. Oral administration.
75932092|NCT01266525|Drug|SAR110894|"Pharmaceutical form: Capsule~Route of administration: Oral"
76085955|NCT05797025|Other|To assess pressure pain threshold and pinch grip strengths.|To assess pressure pain threshold and pinch grip strengths.
75647237|NCT00739648|Drug|Placebo|same frequency as study drug using the same method of delivery
75473338|NCT01969513|Procedure|PROCEDURE: EPLEY MANOEUVRE|The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
75647238|NCT02566057|Biological|PGx testing guided treatment (PGT)|Genecept Assay (GeneceptTM Assay) will provide information on genotypes of genetic variants that are relevant to psychiatric drug response. The provider can use the information to decide on which psychotropic drugs to use.
75932093|NCT01266525|Drug|placebo (for SAR110894)|"Pharmaceutical form: Capsule~Route of administration: Oral"
75932094|NCT01266525|Drug|Donepezil|5 mg or 10 mg once daily continued as taken before inclusion
75932095|NCT01472991|Drug|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
75932096|NCT01472991|Drug|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
75932097|NCT01472991|Drug|Placebo|Placebo capsules will be taken once daily for 4 weeks
75932098|NCT01266135|Drug|QAX576|QAX576 10 mg/kg intravenous infusion
75932099|NCT01266135|Drug|Placebo|Placebo to QAX576 intravenous infusion
75932100|NCT01265901|Drug|Sunitinib|As per label.
75932101|NCT01265901|Biological|GM-CSF|Intradermal injection of GM-CSF as adjuvant.
75932102|NCT01265901|Drug|Cyclophosphamide|One single low-dose i.v. infusion prior to the first vaccination
75932103|NCT01265901|Drug|IMA901|Intradermal vaccinations with IMA901 vaccine.
75932104|NCT02267499|Other|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
75932105|NCT05627505|Diagnostic Test|metagenomic next-generation sequencing|Collection of bronchoalveolar lavage fluid
75647239|NCT01032239|Drug|intrathecal baclofen|ITB test, implant, 6 months follow-up
75647240|NCT04061629|Device|Cuffed ETT|Cuffed endotracheal tube.
75647241|NCT05139901|Drug|Dornase Alfa|inhalations twice daily
75794842|NCT02332577|Drug|Amoxicillin|Pharmaceutical form:capsule 500 mg Route of administration: oral
75794843|NCT02332577|Drug|Amoxicillin Placebo|Pharmaceutical form: capsule Route of administration: oral
75794844|NCT02332577|Drug|PRISTINAMYCIN Placebo|Pharmaceutical form:Tablet Route of administration: Oral
75794845|NCT02330926|Other|standard care|
75794846|NCT02330926|Other|nutritional supplements and advice|
75794847|NCT02330926|Other|home-based self-assisted exercise program|
75794848|NCT02330926|Drug|Ibuprofen|
75794849|NCT02312245|Biological|Bevacizumab|Given IV
75794850|NCT02312245|Drug|Gemcitabine Hydrochloride|Given IV
75794851|NCT02312245|Drug|Paclitaxel|Given IV
75932106|NCT05627427|Drug|Surufatinib|250mg, p.o., qd, q3w, until disease progression or other treatment termination criteria
75932107|NCT05627427|Drug|Sintilimab|200mg, IV, D1, q3w, until disease progression or other treatment termination criteria
75932108|NCT02267733|Drug|Fluzone|Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
75932109|NCT02264535|Drug|0.1mg/ml Ginkgolides Meglumine Injection|
75932110|NCT02264535|Drug|1mg/ml Ginkgolides Meglumine Injection|
75932111|NCT02264535|Drug|5mg/ml Ginkgolides Meglumine Injection|
75932112|NCT02264613|Drug|ALRN-6924|ALRN-6924 will be administered as an IV infusion
75932113|NCT02267889|Procedure|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
75932114|NCT02267889|Device|D-SPECT dedicated cardiac nuclear camera|
75932115|NCT01850082|Procedure|Vein Harvesting Procedures|"Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH."
75647242|NCT05139901|Drug|Saline|inhalations twice daily
75794852|NCT02312245|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75794853|NCT02312245|Drug|Topotecan Hydrochloride|Given IV
76085956|NCT05797012|Other|To assess headache severity, head posture, cervical muscle endurance and neck disorders.|To assess headache severity, head posture, cervical muscle endurance and neck disorders.
76085957|NCT05795309|Device|Hybrid Automated Insulin Delivery|Consists of an insulin pump and real-time continuous glucose monitoring (CGM)
76085958|NCT05794633|Other|Acupuncture|"The patients will be recieved two days a week for 8 sessions with sterile 25*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
75647243|NCT02871713|Other|Bilateral Quadratus lumborum block with 0.5% ropivacaine|Bilateral Quadratus lumborum block with 0.5% ropivacaine
76085959|NCT05794633|Other|Placebo acupuncture|"The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
76085960|NCT05794308|Behavioral|Non-Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot does not, or only minimally, provide relational behavioral cues. Participants will view their progress of daily step counts.
76085961|NCT05794308|Behavioral|Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot provides relational behavioral cues. Participants will view their progress of daily step counts.
76085962|NCT05794295|Other|Acoustic Stimulation (AS)|Acoustic Stimulation will be administered while participants have their sleep monitored during one night in the UC Davis Epilepsy Monitoring Unit (EMU).
76085963|NCT05794295|Other|SHAM Stimulation|No stimulation will be administered while participants have their sleep monitored during one night in the UC Davis Epilepsy Monitoring Unit (EMU).
75647244|NCT02871713|Other|Intrathecal Morphine with 100 mcg morphine|Intrathecal Morphine with 100 mcg morphine
75794854|NCT02307578|Drug|Perampanel|Perampanel will be available in 2-milligrams (mg), 4-mg and 8-mg tablets and as 0.5 milligram per milliliter (mg/mL) oral suspension. Participants will start this EAP with the dose that they were receiving at the end of their participation in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401. Doses of perampanel can be adjusted based on clinical judgment.
75794855|NCT02297438|Drug|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
75932116|NCT01463397|Drug|SAR292833|"Pharmaceutical form: capsule~Route of administration: oral"
75647245|NCT04342975|Drug|Nicotinamide Riboside + Pterostilbene|It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 2 capsules of Basis™ (each capsule 250 mg of NR and 50 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
75932117|NCT01463397|Drug|placebo|"Pharmaceutical form:capsule~Route of administration: oral"
75932118|NCT05231382|Procedure|Raltitrexed, oxaliplatin (SALOX) treatment|Hepatic arterial infusion (HAI) of Raltitrexed, oxaliplatin (SALOX) treatment
75647246|NCT04342975|Drug|Placebo|The correspondent placebo will be administered in a regimen of 2 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
75794856|NCT02297438|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
75794857|NCT02297438|Drug|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
75794858|NCT02297438|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
75794859|NCT02297139|Drug|Dasatinib|
75794860|NCT02247843|Biological|βAS3-FB vector transduced peripheral blood CD34+ cells|CD34+ from the peripheral blood of patients with sickle cell disease (SCD) are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.
75794861|NCT02137759|Radiation|Standard Radiation Therapy|Radiation therapy to 60 Gy
75794862|NCT02137759|Drug|Standard Temozolomide|Temozolomide given orally
75473339|NCT01969513|Procedure|PROCEDURE: SHAM MANOEUVRE|Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
75932119|NCT05231382|Procedure|Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment|Hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
75932120|NCT05627037|Device|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will be randomly allocated to receive Temporary restoration after 30 days and definitive restoration after 90 days
75932121|NCT05627037|Device|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will receive definitive restoration after 90 days
75932122|NCT03949140|Procedure|Laser hair removal|Those who consent to participate in the study will be treated with up to 8 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
75932123|NCT02267967|Drug|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
75932124|NCT01262235|Drug|TKM-080301|Repeat dose IV infusion.
75932125|NCT01262001|Drug|FG-3019|Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
75932126|NCT01262001|Drug|FG-3019|Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
75932127|NCT05161026|Other|Bone osteodensitometry|Evaluation of bone osteodensitometry
75932128|NCT01100151|Drug|RDC-1036 (ALKS 37)|Capsules for oral administration
75337376|NCT02583113|Device|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
75473340|NCT01969526|Other|Multifactorial intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
75473341|NCT01969591|Procedure|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
75932129|NCT01100151|Drug|Placebo|Capsules for oral administration
75932130|NCT01460511|Drug|E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
75932131|NCT01460511|Drug|Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
75337377|NCT02544100|Other|Database Entry/Biospecimen Collection|blood, urine, CFS samples and medical data collected
75473342|NCT01969591|Other|conventional postoperative surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
75647247|NCT04298801|Procedure|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing|"A self-administered questionnaire on HIV exposure factors will be offered to all patients of ages 18-64 able to complete it. This questionnaire will be available in a paper-based format, electronic format on the patient phone or can be conducted verbally by the nurse. According to the answers, the nurses will suggest performing a rapid test to patients belonging to key populations. A finger-stick rapid HIV test will be performed and results will be disclosed by the nurse assisted by a physician if necessary.~If needed, a follow-up visit with an infectious disease specialist will be scheduled within 72 hours."
75647248|NCT04298801|Other|Physician-directed diagnostic testing|Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
75647249|NCT05112835|Other|brolucizumab|There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study
75647250|NCT00734578|Drug|SPD503-AM|SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
75647251|NCT00734578|Drug|SPD503-PM|SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
75647252|NCT00734578|Drug|Placebo|Placebo matched to Guanfacine Hydrochloride Extended Release
75794863|NCT02137759|Drug|Belinostat|Belinostat dose to be determined, given intravenously over 30-45 minutes
75794864|NCT02137122|Device|Sham Stimulation|Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
75794865|NCT02137122|Device|Transcranial Direct Current Stimulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
75794866|NCT02107573|Procedure|Rotator Cuff Repair without Suprascapular Nerve decompression|Traditional rotator cuff repair without Suprascapular nerve decompression
75932132|NCT01458405|Biological|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells
75932133|NCT01458405|Drug|Placebo|Single, blinded, intracoronary infusion of a placebo solution
75932134|NCT03135171|Drug|Trastuzumab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
75932135|NCT03135171|Drug|Pertuzumab|Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.
75932136|NCT03135171|Drug|Tocilizumab|Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
75932137|NCT01449591|Drug|BFH772 1% ointment|
75932138|NCT01449591|Drug|Vehicle ointment|
75932139|NCT01449591|Drug|Noritate® 1% cream|
75337378|NCT02457845|Biological|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
75337379|NCT02399813|Drug|Axalimogene filolisbac|
75337380|NCT02362802|Device|Implantable Cardioverter Defibrillator|
75337381|NCT02342782|Biological|Yttrium Y 90 Basiliximab|Given IV
75337382|NCT02342782|Drug|Carmustine|Given IV
75337383|NCT02342782|Drug|Etoposide|Given IV
75337384|NCT02342782|Drug|Cytarabine|Given IV
75337385|NCT02342782|Drug|Melphalan|Given IV
76085964|NCT05790486|Behavioral|Take a Break plus Nicotine replacement therapy (NRT) Sampling|"Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal."
76085965|NCT05790486|Behavioral|The Comparison|The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.
75337386|NCT02342782|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
75794867|NCT02107573|Procedure|Rotator Cuff Repair with Suprascapular Nerve decompression|Traditional rotator cuff repair with Suprascapular nerve decompression
75647253|NCT04298411|Device|Falcon|The Falcon contains a selection of 25+ games that require wrist extension and challenges children to grasp the controller with their affected hand. As children progress, they may advance to more difficult games that challenge the child to work against a resistance and/or apply greater grip forces. Therapists will be trained on the system, games, and given a guide summarizing the available games and the motor function areas targeted in the game. Using this guide, therapists can choose the games that are most suited to the child's abilities and goals. As multiple games will target many of the same motor function areas, children will have the option of choosing the games they like best to maximize motivational value. While this introduces some variability in the intervention, this flexibility is required to ensure that the therapy is targeting the specific interests, needs and goals of each individual child and is reflective of how ICP is used in a clinic setting.
75647254|NCT00637715|Drug|Alfuzosin|
75647255|NCT00628433|Drug|Placebo|Placebo
75932140|NCT04475445|Other|Ultrasound-guided transforaminal epidural steroid injection|Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
75932141|NCT04475445|Other|Interlaminar epidural steroid injection|Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
75647256|NCT00628433|Drug|HE3286|daily for 28 days
75794868|NCT02100722|Procedure|FFR guided PCI|
75794869|NCT02100722|Procedure|CABG|Coronary Artery Bypass Graft Surgery (CABG)
75794870|NCT02100722|Device|Resolute Integrity Stent|Durable polymer zotarolimus-eluting stent
75932142|NCT00909753|Drug|Ursodiol|Ursodiol Tablets, 500 mg
75794871|NCT02100722|Device|Resolute Onyx Stent|Durable polymer zotarolimus-eluting stent
75932143|NCT00909753|Drug|Urso Forte™|Urso Forte™ Tablets, 500 mg
75932144|NCT01444365|Drug|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
75794872|NCT02090998|Procedure|SPG Block with 5% Lidocaine gel|cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia
75932145|NCT01444365|Drug|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
75932146|NCT03991377|Behavioral|Eye movement desensitization and reprocessing therapy|"EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history.~Patient preparation.~Patient assessment.~Memory desensitization.~Installing the positive cognition.~Body scan.~Closure.~Reevaluation."
76085966|NCT05790486|Other|Community Paramedicine Standard Plus Enhanced Implementation Program|Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.
76085967|NCT05790486|Other|Community Paramedicine Standard Implementation Program|In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
75337387|NCT02342782|Other|Laboratory Biomarker Analysis|Correlative studies
75794873|NCT02090998|Drug|Amitriptyline|The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
75337388|NCT02342782|Other|Pharmacological Study|Correlative studies
75337389|NCT02341924|Other|Portfolio of functional foods|
75337390|NCT02341924|Other|Control foods|
75337391|NCT02291055|Drug|ADXS11-001|
75337392|NCT02291055|Drug|MEDI4736|
75337393|NCT02112864|Drug|Dexamethasone|10 mg (2.5 ml)
75337394|NCT02112864|Drug|Normal Saline|2.5 mL normal saline
75337395|NCT01981837|Drug|ALN-TTRSC (revusiran) for subcutaneous administration|
75337396|NCT01897558|Device|Pacemaker implantation|
75337397|NCT01847625|Other|simulator|
75337398|NCT01267500|Procedure|Non surgical therapy|patching or fusion exercises
75337399|NCT01237457|Drug|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
75337400|NCT00723697|Drug|buprenorphine|0.4, 2, or 8 mg sublingual tablets
75794874|NCT02043665|Biological|CVA21/pembrolizumab|
75794875|NCT02028988|Drug|Enzalutamide|
75794876|NCT02028988|Radiation|External Beam Radiation|
75932147|NCT03991377|Drug|Treatment as usual|Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
75794877|NCT02006511|Device|Incisional Neg Pressure Wound Therapy (Prevena™)|Negative pressure wound therapy dressing applied over closed surgical incision
75932148|NCT01442337|Drug|ASP8597|one time IV dose
75794878|NCT02006511|Other|Standard of Care wound therapy|Gauze type dressing.
75932149|NCT01442337|Drug|Placebo|one time IV dose
75932150|NCT01098435|Drug|RDC-0313 (ALKS 33)|Capsules for daily oral administration
75932151|NCT01098435|Drug|Placebo|Capsules containing lactose and no active drug for daily oral administration
75932152|NCT05626959|Drug|NTI164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
75932153|NCT00909597|Drug|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
75337401|NCT00684073|Drug|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
75337402|NCT00684073|Drug|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
75337403|NCT00603109|Drug|rimonabant|rimonabant capsule 20 mg per day PO for 6 months
75932154|NCT00909597|Drug|taspoglutide|10mg sc once weekly
75932155|NCT00909597|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
75647257|NCT02596282|Procedure|Neonatal circumcision under topical anesthesia|"The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine <1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care."
75337404|NCT00603109|Drug|placebo|Subjects take 20 mg placebo capsule one a day PO for 6 months
75337405|NCT00199095|Drug|Adriamycin|
75337406|NCT00199095|Drug|Cyclophosphamide|
75647258|NCT00739102|Device|S.M.A.R.T. ® Stent|The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
75647259|NCT02596360|Drug|Pulmodexane® 30mg|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
75647260|NCT02596360|Drug|lactose|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
75647261|NCT02593708|Drug|Neratinib|
75647262|NCT02593708|Drug|Paclitaxel|
75647263|NCT02593708|Drug|Pertuzumab|
75794879|NCT02004236|Device|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
75794880|NCT02004236|Device|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
75794881|NCT02004236|Device|tRNS with sham|the subjects receive 35 session with sham
75794882|NCT01961986|Procedure|TSR - traditional subscapularis release|Total Shoulder Replacement surgery performed using the traditional subscapularis release approach.
75794883|NCT01961986|Procedure|TSR - rotator cuff sparing|Total Shoulder Replacement surgery performed using the rotator cuff sparing approach.
75798972|NCT01188018|Behavioral|Motivational Interviewing (MI)|Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
75932156|NCT05626881|Drug|PRP|"It will include patients with melasma treated with PRP sessions every two weeks for three months. 10 ml of venous blood will withdraw by means of a wide bore needle and a vacutainer containing an anticoagulant (Acid citrate dextrose).~Double centrifugation will be done. First centrifugation, will be done for 10 minutes. After the first centrifugation, three layers will be seen , Second centrifugation will be done for 10 min, after which the platelets separate and form a grayish pellet at the bottom of the tube and the rest will be platelet-poor plasma. About 1 ml of this platelet-poor plasma will be decanted off and the platelet pellet will be resuspended in the remaining plasma to get PRP. With 10 ml blood, about 1-1.5 ml of PRP will be obtained.~PRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe."
75337407|NCT00199095|Drug|Cytarabine|
75337408|NCT00199095|Drug|Dexamethasone|
75337409|NCT00199095|Drug|Idarubicin|
75337410|NCT00199095|Drug|Ifosfamide|
75337411|NCT00199095|Drug|Methotrexate|
75337412|NCT00199095|Drug|Mercaptopurine|
75337413|NCT00199095|Drug|VM26|
75337414|NCT00199095|Drug|Vincristine|
75337415|NCT00199056|Drug|Dexamethasone / Prednisolone|
75337416|NCT00199056|Drug|Cyclophosphamide|
75337417|NCT00199056|Drug|Methotrexate|
75337418|NCT00199056|Drug|Vincristine / Vindesine|
75337419|NCT00199056|Drug|Daunorubicin|
75337420|NCT00199056|Drug|Asparaginase|
75337421|NCT00199056|Drug|G-CSF|
75337422|NCT00199056|Drug|Cytarabine|
75337423|NCT00199056|Drug|6-Mercaptopurine|
75337424|NCT00199056|Drug|VP16|
75932157|NCT05626881|Drug|sylimarin cream|Silymarin was manufactured with concentration of 1.4%
75337425|NCT00199056|Drug|Adriamycin|
75473343|NCT01969604|Behavioral|Motivational Lifestyle Counselling|"The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand."
75932158|NCT01094067|Drug|ACT-050089|5 mg/h intravenously, Tezosentan
75337426|NCT00199056|Drug|Thioguanine|
75337427|NCT00199056|Drug|VM26|
75647264|NCT02593708|Drug|Trastuzumab|
75473344|NCT01969617|Drug|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
75473345|NCT01969617|Drug|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
75794884|NCT01929005|Other|Comprehensive Care|Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
75932159|NCT01094067|Other|Placebo|Matching placebo
75932160|NCT01077297|Drug|Tezosentan|single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
75932161|NCT05653245|Drug|RGD Peptide|adhesion molecules
75932162|NCT04766931|Drug|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
75337428|NCT00199056|Drug|Idarubicin|
75337429|NCT00199056|Drug|Fludarabine|
75337430|NCT00199056|Drug|Ifosfamide|
75337431|NCT00199056|Procedure|CNS irradiation|
75337432|NCT00199056|Procedure|Mediastinal irradiation (if residual tumor)|
75932163|NCT04766931|Drug|FB2001 Placebo|Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
75932164|NCT00905385|Biological|NTHi Strain 2019|Nontypeable Haemophilus influenzae (NTHi) strain 2019 StrR Number 1 is an antibiotic susceptible clinical strain that has a point mutation in the rRNA that renders the isolate resistant to streptomycin. This agent will be introduced by nasal droplets.
75337433|NCT00199056|Procedure|stem cell transplantation|
75337434|NCT00199030|Drug|Alemtuzumab (MabCampath)|
75337435|NCT00199030|Drug|Cladribine|
75337436|NCT00198978|Drug|Cyclophosphamide|
75473346|NCT01969630|Device|PEB|Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
75473347|NCT01969630|Device|PES|Systematic Paclitaxel eluting stent angioplasty
75473348|NCT01969656|Drug|2MD|
75473349|NCT01969656|Drug|Calcitriol|
75647265|NCT00959192|Biological|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
75647266|NCT00959192|Other|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
75647267|NCT00959192|Other|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
75647268|NCT00696787|Drug|Desvenlafaxine Sustained Release (DVS SR)|
75647269|NCT00696787|Drug|Lyrica® (Pregabalin)|
75337437|NCT00198978|Drug|Dexamethasone / Prednisolone|
75337438|NCT00198978|Drug|Cytarabine|
75337439|NCT00198978|Drug|Idarubicin|
75337440|NCT00198978|Drug|Granulocyte-Colony-Stimulating Factor|
75337441|NCT00198978|Drug|Mercaptopurine|
75337442|NCT00198978|Drug|Methotrexate|
75337443|NCT00198978|Drug|Rituximab|
75337444|NCT00198978|Drug|HDARAC|
75337445|NCT00198978|Drug|Vincristine|
75337446|NCT00198978|Drug|Depocyte|
75337447|NCT00198978|Drug|Asparaginase|
75337448|NCT00109395|Drug|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
75337449|NCT00109395|Drug|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
75337450|NCT00109395|Drug|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
75337451|NCT00003916|Radiation|radiation therapy|
75337452|NCT00003916|Radiation|stereotactic radiosurgery|
75337453|NCT01215643|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
75337454|NCT01215643|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
75473350|NCT01969656|Drug|Placebo|
75473351|NCT01969669|Drug|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
75473352|NCT01969669|Drug|Ketoconazole|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
75473353|NCT01969682|Drug|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
75473354|NCT01969682|Drug|Rifampin|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
75473355|NCT01969695|Drug|ABT-199|ABT-199 continuous once daily dosing
75473356|NCT01969734|Device|Zephyr endobronchial valve placement|
75647270|NCT00696787|Drug|Placebo|
75647271|NCT01012037|Drug|linagliptin low dose|patient to receive tablets containing low dose linagliptin twice daily
75647272|NCT01012037|Drug|placebo|patient to receive placebo tablet(s) matching linagliptin
75647273|NCT01012037|Drug|linagliptin medium dose|patient to receive a tablet containing medium dose linagliptin once daily
76085968|NCT05782868|Other|Expressive writing in response to vignette|Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.
76085969|NCT05782868|Other|Expressive writing about events of the day|Participants in the control condition will be asked to write about the events of their day and thoughts and feelings that occurred in response to those events.
75473357|NCT01969760|Behavioral|Healthy Families DC Program|A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
75794885|NCT01912651|Drug|cephalexin|This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
75794886|NCT01912625|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
75647274|NCT04546087|Device|Ultrasound|Ultrasound scan of the cricothyroid membrane
75647275|NCT04284566|Behavioral|TAU + multicomponent treatment FIBROWALK|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (30 min.)~Cognitive restructuring (30min.)~Mindfulness techniques (30 min.)~Physical exercise(30 min.)~Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
75647276|NCT04284566|Behavioral|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
75794887|NCT01912625|Drug|Carboplatin|Given IV
75647277|NCT00630110|Drug|docetaxel|docetaxel (75 mg/m2)
75647278|NCT00630110|Drug|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
75794888|NCT01912625|Radiation|Image Guided Radiation Therapy|Undergo IGRT
75932165|NCT05379855|Drug|0.01% atropine eye drops|using 0.01% atropine eye drops for both eyes every night
75932166|NCT05379855|Drug|placebo eye drops (0.9% preservative free sodium chloride)|placebo eye drops (0.9% preservative free sodium chloride)
75932167|NCT03731910|Diagnostic Test|MRI|liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.
75794889|NCT01912625|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75794890|NCT01912625|Other|Laboratory Biomarker Analysis|Correlative studies
75794891|NCT01912625|Drug|Paclitaxel|Given IV
75794892|NCT01912625|Other|Pharmacological Study|Correlative studies
75932168|NCT01070433|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
75932169|NCT01070433|Other|Standard of Care|Topical application twice a day
76085970|NCT05782868|Other|Letter of Gratitude|Participants will be directed to compose a brief letter of gratitude to an individual to whom they have not previously expressed gratitude, and who has provided meaningful and affirming support to them as a TNB person.
76085971|NCT05781347|Procedure|Radiofrequency Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under general anesthesia which uses radiofrequency (RF) energy delivered to the lower esophageal sphincter and cardia.
76085972|NCT05781347|Device|Stretta|Stretta is a FDA approved device for the management of GERD.
75473358|NCT01969773|Drug|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
75473359|NCT01969773|Drug|Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
75473360|NCT01969864|Behavioral|HRSA Video Intervention|
75473361|NCT01969864|Behavioral|PI Video Intervention|
75473362|NCT01969864|Behavioral|CDC Health Website Intervention|
75794893|NCT01912625|Drug|Trametinib|Given PO
75794894|NCT01894672|Drug|LGX818|
75794895|NCT01814813|Biological|HSPPC-96|intradermal infusion
75794896|NCT01814813|Drug|bevacizumab|intravenous
75932170|NCT03715764|Other|Physical therapy assessment|Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.
75473363|NCT01969877|Drug|cetuximab|
75473364|NCT01969877|Drug|cisplatin|
75794897|NCT01774071|Drug|89Zr- DFO-MSTP2109A|"If you are enrolled onto Group 1:~Once you are given the diagnostic agent, the following procedures will be done:~PET scans at the approximate times:~1-4 hours after the injection~24 hours after the injection (the next day, Day 2)~48-120 hours after the injection (on either Day 3, 4, or 5)~144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,~Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.~At each time of your scheduled PET scan."
75932171|NCT03715764|Other|Physician assessment|Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
75932172|NCT00904683|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
75932173|NCT00904683|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
75932174|NCT02718326|Drug|Intravitreal aflibercept injection [IAI]|
75932175|NCT02718326|Drug|Sham|
75794898|NCT01774071|Drug|89Zr DFO-MSTP2109A|"If you are enrolled onto Group 2:~Once you are given the study drug, the following procedures will be done:~You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (~ 3-7 days after injection).~No research blood work will be drawn in Group 2"
75647279|NCT00734032|Drug|SB480848 40mg EC Tablet|1 tablet once a day
75794899|NCT01720836|Biological|Vaccine + PolyICLC|The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
75794900|NCT01667120|Drug|Ketorolac|Ketorolac 0.5mg/kg IV q8h x 72h.
75794901|NCT01667120|Drug|placebo|0.9% normal saline 1ml/kg
75794902|NCT01642251|Drug|Cisplatin|Given IV
75794903|NCT01642251|Drug|Etoposide|Given IV
75794904|NCT01642251|Drug|Veliparib|Given PO
75794905|NCT01642251|Drug|Placebo|placebo of Veliparib
75794906|NCT01606137|Drug|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
75932176|NCT03691584|Drug|TP-6076|The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).
75932177|NCT03691584|Procedure|Bronchoalveolar lavage|Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.
76085973|NCT05778812|Behavioral|Full Sleep|"Daily lessons about sleep and skills that can help with sleep. Participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach, for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
75337455|NCT01215643|Drug|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
75794907|NCT01532518|Drug|Nepadutant|Nepadutant oral solution
75794908|NCT01489813|Drug|Genistein|30 mg of genistein supplement by mouth three times daily (PO TID).
75794909|NCT01489813|Drug|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
75794910|NCT01489449|Device|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
75794911|NCT01489449|Combination Product|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
75794912|NCT01420874|Drug|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
75794913|NCT01420874|Biological|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
75794914|NCT01405521|Biological|Vaccine placebo (excipients only)|single oral dose,
75794915|NCT01405521|Biological|Ty21a|3 oral doses, alternate days
75794916|NCT01405521|Biological|M10ZH09 vaccine|single oral dose
75794917|NCT01278914|Biological|Dendritic Cells (DC) prostate|
75794918|NCT01246947|Procedure|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
75794919|NCT01246947|Other|Mitral surgery alone|Randomized to Mitral surgery alone
75794920|NCT01221389|Drug|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
75794921|NCT01083030|Device|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
75932178|NCT03683628|Procedure|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
75932179|NCT03683628|Drug|No PB-MNC therapy|Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
75932180|NCT05160792|Device|Pressure monitoring system under compression bandages on index leg|Adding a Graducheck device under the compression bandages on the index leg and comparing to other leg, which has compression but without the device.
75337456|NCT00004924|Drug|irinotecan hydrochloride|
75337457|NCT00004924|Drug|paclitaxel|
75647280|NCT00734032|Drug|SB480848 80mg EC Tablet|1 tablet once a day
75647281|NCT00734032|Drug|SB480848 160mg EC Tablet|1 tablet once a day
75647282|NCT00734032|Drug|SB480848 Placebo Tablet|1 tablet once a day
75647283|NCT04284098|Other|General anesthesia (GA).|Patients received standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
75647284|NCT04284098|Other|PECS block using bupivacaine .|The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%, after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
75647285|NCT04284098|Other|PECS block using bupivacaine and dexmedetomidine|D group:The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%+dexmedetomidine (1µg/kg) after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
75932181|NCT03470298|Procedure|Endometrial scratching|The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure
75794922|NCT01083030|Combination Product|DCB|Drug Coated Balloon Angioplasty
75794923|NCT01027000|Biological|rituximab|
75337458|NCT00004144|Drug|bryostatin 1|
75794924|NCT01027000|Drug|busulfan|
75337459|NCT00004144|Drug|gemcitabine hydrochloride|
75337460|NCT00004150|Drug|fluorouracil|
75337461|NCT00004150|Drug|leucovorin calcium|
75647286|NCT01010633|Drug|Vehicle of Loteprednol Etabonate|1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
75647287|NCT01010633|Drug|Loteprednol Etabonate|1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
75647288|NCT00733954|Drug|clobetasol propionate spray|Apply twice daily
75647289|NCT00733954|Drug|clobetasol propionate ointment|Apply twice daily
75647290|NCT04283006|Drug|CD20/CD22 dual Targeted CAR T-cells|Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
75794925|NCT01027000|Drug|cyclophosphamide|
75337462|NCT00004150|Procedure|adjuvant therapy|
75647291|NCT04297943|Device|Orthosis fabrication|see summary
75794926|NCT01027000|Drug|fludarabine phosphate|
75794927|NCT01027000|Drug|methotrexate|
75794928|NCT01027000|Drug|sirolimus|
75932182|NCT04009512|Device|Valiant Thoracoabdominal Stent Graft System|This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
75337463|NCT00004930|Drug|doxorubicin hydrochloride|
75337464|NCT00004936|Drug|iodinated contrast dye|
75337465|NCT00004936|Procedure|computed tomography|
75337466|NCT00004936|Procedure|magnetic resonance imaging|
75337467|NCT00004936|Radiation|gadopentetate dimeglumine|
75337468|NCT01261819|Device|cystoscopy|
75337469|NCT00003928|Drug|cisplatin|Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
75337470|NCT00003928|Drug|gemcitabine hydrochloride|Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
75337471|NCT00004156|Biological|MUC1-KLH vaccine/QS21|
75337472|NCT01262131|Device|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
75337473|NCT01262131|Device|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
75337474|NCT01262131|Device|placebo therapy|Application of inactive magnetic fields using the Resonator device
75337475|NCT00004162|Biological|sargramostim|
75337476|NCT00004162|Drug|methotrexate|
75337477|NCT00004162|Drug|pegylated liposomal doxorubicin hydrochloride|
75337478|NCT00004162|Drug|vincristine sulfate|
75337479|NCT01262599|Device|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
75473365|NCT01969890|Drug|G-CSF administration|Zarzio - 5 microg/kg bis in die for 6 days
75473366|NCT01969903|Drug|Precedex injection|
75647292|NCT04297943|Device|Thermal Sensor Monitoring of Orthosis Use|see summary
75647293|NCT04297943|Diagnostic Test|4D CT Scan|see summary
75647294|NCT04280900|Behavioral|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
75647295|NCT04280900|Behavioral|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
75647296|NCT04297865|Drug|A dose as CJ-15314|A dose as CJ-15314, 1 capsule
75647297|NCT04297865|Drug|B dose as CJ-15314|B dose as CJ-15314, 1 capsule
75647298|NCT04297865|Drug|C dose as CJ-15314|C dose as CJ-15314, 1 capsule
75647299|NCT04297865|Drug|D dose as CJ-15314|D dose as CJ-15314, 2 capsules
75647300|NCT04297865|Drug|E dose as CJ-15314|E dose as CJ-15314, 1 capsule
75647301|NCT04297865|Drug|F dose as CJ-15314|F dose as CJ-15314, 2 capsules
75647302|NCT04297865|Drug|Placebo|Placebo, 1 capsule
75647303|NCT04297865|Drug|Placebo|Placebo, 1 capsule
75647304|NCT04297865|Drug|Placebo|Placebo, 1 capsule
75647305|NCT04297865|Drug|Placebo|Placebo, 2 capsules
75647306|NCT04297865|Drug|Placebo|Placebo, 1 capsule
75647307|NCT04297865|Drug|Placebo|Placebo, 2 capsules
75647308|NCT03368833|Diagnostic Test|Electrocardiogram|12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.
75647309|NCT04283084|Device|Virtual Reality Based Balance and Coordination Exercises|With the developed virtual reality based balance and coordination training system, balance and coordination exercises will be applied twice a week (12 sessions in total) for 6 weeks.
75794929|NCT01027000|Drug|tacrolimus|
75794930|NCT01027000|Procedure|allogeneic stem cell transplant|
75794931|NCT00949819|Other|Active surveillance|Serial, long term data collection and active surveillance
75798973|NCT01188018|Behavioral|Health Education (HE)|Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
75798974|NCT03857334|Biological|Injection of autologous platelet rich plasma|
75932183|NCT05527262|Behavioral|Queen Square Upper Limb Neurorehabilitation Programme|A timetable will be implemented including a minimum of 45 hours of active time on task over 3 weeks 5-days a week (first and last day will involve the assessment procedures) (timetabled, 90-hours). Our unpublished in-service audits suggest that this equates to 45-60 hours of active upper limb training. The remainder of the time is spent on rest (in-session, between-session), cardiovascular fitness, and education (promoting self-efficacy). The programme is staffed with a 1:1 staff/patient ratio (4 physiotherapists, 4 occupational therapists, 4 rehabilitation assistants for 12 patients at any one time). Participants in this trial will receive two daily sessions each of physiotherapy and occupational therapy, supplemented with tailored, individualised interventions delivered by rehabilitation assistants either singly or in groups.
75794932|NCT00935090|Device|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
75932184|NCT05527262|Device|Immersive gaming therapy|The treatment group will receive a minimum of 45 hours of active time on task over 3 weeks, 5 days a week (first and last day will involve the assessment procedures) to complete arm, hand and finger training (overseen by a physiotherapist). Patients will engage with MindPod Dolphin (shoulder/elbow) and other interfaces (hand/fingers) in a customised immersive game-based platform set.
75932185|NCT03891888|Procedure|Intramedullary Bone Graft|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
75337480|NCT01262599|Device|Ivivi Torino II PEMF Device|"The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC."
75337481|NCT01262755|Behavioral|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
75647310|NCT02595268|Drug|Pitavastatin|Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
75337482|NCT00004984|Drug|Parenteral Insulin|Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.
75647311|NCT02595268|Drug|JNJ-63623872|Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
75647312|NCT00921505|Drug|Ibuprofen|Tablet ibuprofen 400 mg oral single dose (1 tablet)
75794933|NCT00861068|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
75794934|NCT00861068|Other|Placebo|Placebo tablets two times a day for 10 weeks
75932188|NCT05160402|Drug|IGM-6268|Active comparator
75932189|NCT05160402|Drug|Placebo|Placebo comparator
75932190|NCT05052086|Diagnostic Test|Magnetomotoric ultrasound|Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.
75337483|NCT00004984|Other|Close Observation|Study visits every 6 months including an oral glucose tolerance test
75337484|NCT00004984|Drug|Oral Insulin|Capsules oral insulin, 7.5 mg of recombinant human insulin crystals
75647313|NCT00921505|Drug|Ibuprofen|Tablets (2 x 600 mg) oral single dose (2 tablets)
75647314|NCT00921505|Drug|Paracetamol (acetaminophen) 1000 mg|Tablets (2 x 500 mg) oral single dose (2 tablets)
75794935|NCT00844285|Drug|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
75794936|NCT00841789|Drug|Etanercept|etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
75794937|NCT00841789|Drug|Placebo|Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
75794938|NCT00711646|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
75473367|NCT01969929|Procedure|20G Vitrectomy|
75337485|NCT00004984|Drug|Placebo|Placebo for oral insulin
75337486|NCT00004174|Biological|filgrastim|
75337487|NCT00004174|Drug|cyclophosphamide|
75337488|NCT00004174|Drug|paclitaxel|
75337489|NCT00004174|Drug|thiotepa|
75337490|NCT00004174|Procedure|peripheral blood stem cell transplantation|
75337491|NCT00004174|Radiation|radiation therapy|
75473368|NCT01969929|Procedure|23G vitrectomy|
75473369|NCT01969942|Biological|allogeneic stem cell transplantation|
75473370|NCT01969942|Drug|Clyclophosphamide|
75473371|NCT01969942|Drug|Fludarabina|
75647315|NCT00921505|Drug|Paracetamol + ibuprofen|Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
75794939|NCT00711646|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
75473372|NCT01969942|Drug|Busulfan|
75473373|NCT01969942|Drug|Melphalan|
75473374|NCT01969955|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
75798975|NCT03857334|Drug|Injection of cortivazol : Altim®|Corticosteroids
75647316|NCT00628511|Device|ARES (Apnea Risk Evaluation System)|application of portable monitoring device with PSG
75647317|NCT04280588|Drug|Fingolimod 0.5 mg|Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
75794940|NCT00702468|Drug|Sativex|containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
75932191|NCT03468972|Drug|Immunosuppressive treatment|At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria < 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
75932192|NCT03468972|Other|intensive supportive care|During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of <130/80 mmHg, and protein restriction diet. If proteinuria does not decrease < 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
75932193|NCT03468894|Behavioral|Treadmill desk walking|See intervention arm description
75932194|NCT03471858|Device|Cervical balloon|To assess if a cervical balloon catheter (foleys catheter) for mechanical induction of labour is comparable to prostaglandin usage for induction of labour in women who have had a previous caesarean section.
75932195|NCT03471858|Drug|Prostaglandins|Prostin will be used in the control arm.
75932196|NCT03600714|Drug|Peg-interferon lambda|Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated interferon (IFN) lambda and a 20-kDa linear pegylated (PEG) chain.
75932197|NCT03600714|Drug|Lonafarnib|Oral prenylation inhibitor
75932198|NCT03600714|Drug|Ritonavir|Booster of lonafarnib action
76085974|NCT05778812|Behavioral|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
75337492|NCT01284517|Drug|Lurasidone|Tablets 20-120 mg, PM dosing,daily for 6 weeks
75337493|NCT01284517|Drug|Placebo|Equivalent to Lurasidone dosing
75337494|NCT00004990|Drug|Dexamethasone|
75647318|NCT02593552|Device|DriveCam|Video event monitoring device
75647319|NCT04298021|Drug|AZD6738|"In AZD6738+Durvalumab cohort~- AZD6738 240 mg bid on D15-D28 Every 4 weeks~In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks"
75647320|NCT04298021|Drug|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
75647321|NCT04298021|Drug|Olaparib|Olaparib 300 mg bid on D1-28 Every 4 weeks
75647322|NCT02595190|Procedure|sacral canal cyst microscopic tamponade|sacral canal cyst microscopic tamponade treatment
75794941|NCT00702468|Drug|Placebo|Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
75794942|NCT00681538|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
75647323|NCT02595190|Drug|gabapentin + tramadol|dose range：gabapentin 400-1200mg tid, tramadol 100-200mg bid
75794943|NCT00681538|Drug|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
75794944|NCT00640133|Device|Active DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
75794945|NCT00640133|Device|Sham DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
75794946|NCT00588250|Other|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
75932199|NCT05493488|Biological|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with tinea pedis
76085975|NCT05775913|Device|Tubal Selective Delivery System (TSDS)|A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.
75337495|NCT01216735|Drug|Fluticasone|220 ug twice a day for 3 weeks
75337496|NCT01216735|Drug|Placebo|Placebo for 3 weeks
75337497|NCT00004186|Drug|carboplatin|
75337498|NCT00004186|Drug|etoposide|
75337499|NCT00004186|Drug|ifosfamide|
75337500|NCT00004186|Drug|topotecan hydrochloride|
75337501|NCT00004186|Radiation|radiation therapy|
75337502|NCT01285843|Procedure|Anterior Minimally Invasive Approach (AMIS)|
75337503|NCT00005002|Drug|Lamivudine/Zidovudine|
75337504|NCT00005002|Biological|HIV-1 Immunogen|
75337505|NCT00005002|Drug|Nelfinavir mesylate|
75647324|NCT02595190|Device|resting state functional magnetic resonance imaging (rfMRI)|First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
75932200|NCT05493488|Biological|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with tinea pedis
75932201|NCT05493488|Biological|Aqueous Gel|Topical application of Aqueous gel on foot/feet affected with tinea pedis
76085976|NCT05773118|Device|orthokeratology lens|Subjects will wear orthokeratology lens at night. Axial length elongation over a period of 12-month will be recorded.
76085977|NCT05773118|Device|multifocal soft contact lens|Subjects will wear multifocal soft contact lens during the day time. Axial length elongation over a period of 12-month will be recorded.
76085978|NCT05773118|Device|Single vision spectacles|Subjects will wear single vision spectacles during the day. Axial length elongation over a period of 12-month will be recorded.
76085979|NCT05771909|Other|NeurodigitX|"The NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day)."
76085980|NCT05771909|Other|Control|"The Control Group does not receive the NeurodigitX application."
75794947|NCT00582062|Other|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
75932202|NCT03112902|Device|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
75932203|NCT02720042|Device|Phasix™ Mesh|A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)
75932204|NCT03471780|Diagnostic Test|ultrasound|Transperineal us are made to pregnant ladies in labour
75932205|NCT01352793|Biological|rLP2086 vaccine|120 mcg, 3 doses, at month 0, 2, and 6.
76085981|NCT05771896|Drug|Darolutamide|"Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (>56 days between cycles). Any participant requiring dose interruption >28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly."
76085982|NCT05771896|Drug|Radium-223|"Radium-223 should be given for 6 cycles, administered IV on Day 1 of each cycle or until radiological progression, withdrawal, death, termination, or study completion. The placebo will be administered in precisely the same fashion as the active drug.~Subsequent cycles 2-6 should be scheduled to occur every 28 ± 7 days following the previous cycle, but dosing may be delayed up to 28 days per cycle (maximum 56 days between cycles). Any participant requiring dose interruption >28 consecutive days (>56 days between cycles) may restart treatment with radium-223/placebo if clinical benefit is anticipated and after discussion with the Medical Monitor. Participants will continue with darolutamide irrespective of Radium-223 administration.~Upon radiological progression, further treatments are decided by the site investigator according to standard local practice."
76085983|NCT05769465|Drug|disease modifying treatments|Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
75794948|NCT00523003|Dietary Supplement|high protein|2.2 g protein/kg of LBM per day
76085984|NCT05767567|Behavioral|Brief Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
76085985|NCT05764863|Radiation|fMRI|The participant will then complete a series of working memory tasks under three distinct conditions as described above (visual spatial, visual non-spatial, auditory). The instructions and tasks will be administered via an MRI compatible monitor and headset system (NordicNeuroLab). During the tasks, the participant's brain activity will be recorded. Finally, at the end of the experiment, a high-resolution anatomical image of the brain will be acquired in order to facilitate the subsequent data processing steps and to define the position of the interparietal sulcus for each subject. The visit will be completed by a visual imaging questionnaire.
76085986|NCT05764642|Drug|Definity|Ultrasound contrast agent administered intravenously
75647325|NCT04061473|Drug|Sitagliptin 100mg|"2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
75794949|NCT00523003|Dietary Supplement|standard protein|1.1 g protein/kg LBM/day standard protein diet
75794950|NCT00497029|Drug|fluoride varnish|
75794951|NCT00497029|Behavioral|patient education|
75794952|NCT00456573|Procedure|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
75794953|NCT00455351|Drug|Vorinostat|Increasing dosing, phase I
75932206|NCT01352793|Biological|control|HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
75647326|NCT04061473|Drug|Empagliflozin 25 MG|2 tablets of empagliflozin 25 mg.
75794954|NCT00379340|Radiation|3-Dimensional Conformal Radiation Therapy|
75794955|NCT00379340|Procedure|Conventional Surgery|
75794956|NCT00379340|Drug|Cyclophosphamide|Given IV
75794957|NCT00379340|Biological|Dactinomycin|Given IV
75794958|NCT00379340|Drug|Doxorubicin Hydrochloride|Given IV
75647327|NCT04061473|Other|Placebo tablet|"2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
75647328|NCT02595112|Other|Staphylococcus aureus carriage|Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
75647329|NCT00733408|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
76085987|NCT05764642|Diagnostic Test|Super-resolution ultrasound imaging|Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
75794959|NCT00379340|Drug|Etoposide|Given IV
75794960|NCT00379340|Drug|Vincristine Sulfate Liposome|Given IV
76085988|NCT05763914|Behavioral|Change in the incidence of hand eczema|Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.
75794961|NCT00301808|Drug|Cisplatin|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
75932207|NCT03470142|Procedure|traditional laparoscopy-assisted surgery|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
75794962|NCT00301808|Drug|Docetaxel|Docetaxel 75 mg/m2 on day 1 of each cycle
75932208|NCT03470142|Procedure|total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, NOSES)|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice (anal).
75932209|NCT04631900|Behavioral|Christianity approach as framework for spiritual intervention|Intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group. Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose.
75932210|NCT03471702|Device|Smart External Drain - SED|Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.
75932211|NCT04590326|Drug|REGN5668|REGN5668 will be administered by once weekly intravenous (IV) infusion.
76085989|NCT05763914|Behavioral|Change in severity of hand eczema|Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.
75647330|NCT00733408|Biological|bevacizumab|Given IV
75794963|NCT00301808|Drug|Pemetrexed disodium|Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
75794964|NCT00301808|Radiation|Radiation therapy|Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
75794965|NCT00254670|Drug|Naltrexone|
75794966|NCT00204048|Behavioral|Observation (behavior)|Inpatients admitted in GenMed at the University of Chicago will be consented to participate in an inpatient interview that consists of questions related to quality of care and satisfaction. The patient will also be interviewed over the phone 30 days after discharge and will be asked questions related to current health and their satisfaction during their stay at University of Chicago.
75794967|NCT00138931|Procedure|Blood draw (genetic testing)|Blood draw (genetic testing)
75932212|NCT04590326|Drug|Cemiplimab|For Module 1, after a minimum of a 3-week monotherapy lead-in of REGN5668, cemiplimab will be administered concomitantly every 3 weeks (Q3W) by IV infusion.
75932213|NCT04590326|Drug|REGN4018|For Module 2, a 4-week monotherapy lead-in of REGN4018 will be administered by once weekly IV infusion. After lead-in, REGN5668 and REGN4018 will be administered concomitantly.
75932214|NCT03468738|Other|Blood transfusion|Transfusion of blood products in the perioperative period in patients undergoing major surgery
76085990|NCT05763914|Behavioral|Change in the number of self-reported days with absence from work due to having hand eczema|Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.
75794968|NCT00138801|Drug|Ceftriaxone|
75794969|NCT00138801|Drug|Doxycycline|
75794970|NCT00113659|Dietary Supplement|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
75794971|NCT00113659|Dietary Supplement|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
75794972|NCT05795829|Device|disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument|Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.
75794973|NCT05795803|Other|Forced isolation context|Exposure to the forced isolation context provided by the ongoing Covid-19 pandemic restrictive measures
75647331|NCT00733408|Drug|erlotinib hydrochloride|Given PO
75794974|NCT05795725|Diagnostic Test|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
75794975|NCT05795725|Procedure|Colonoscopy|Colonoscopy procedure
76085991|NCT05763914|Behavioral|Change in the number of participants being forced to change their job due to having hand eczema|Self-reported change of job due to having hand eczema. Change between baseline and 6 months.
76085992|NCT05763914|Behavioral|Change in The Quality Of Life in in relation to hand eczema|Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.
75647332|NCT01010867|Drug|Lactobacillus plantarum strains 299 and 299v|"Patients will receive a daily dose of Lactobacillus plantarum: 1 x10^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.~Colony forming units (CFU)"
75647333|NCT05270122|Device|Mechanical thrombectomy with ThrombX Retriever|Revascularization
75647334|NCT04297163|Other|Telemedicine|Remote CPAP monitoring, mobile app and voice mail
75647335|NCT04297163|Other|In Hospital|Face-to-face follow up
75647336|NCT04501757|Biological|Naxitamab/GM-CSF|naxitamab/GM-CSF for 5 Cycles
75647337|NCT04296383|Drug|Azithromycin plus Xiyanping injection|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d;Xiyanping injection intravenously, 0.4mL / (kg.d) daily, Qd
75647338|NCT04296383|Drug|Azithromycin|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d
75794976|NCT05795712|Other|Therapy Change from Baseline|The patient will be followed up from the point of view of therapy according to symptoms and flare-ups irrespective of systemic or peripheral eosinophil assessment
75794977|NCT05795673|Other|Peer support program (intervention phase)|"Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints."
76085993|NCT05763914|Behavioral|Change in the level of knowledge regarding skin care and protection.|Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.
76085994|NCT05756465|Device|Smartphone-based virtual reality relaxation (SVR)|SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) that is attached to the head of a cancer patient undergoing chemotherapy, displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical instruments. SVR device is paired with smartphone using operating system either Android (minimum generation 11, Android 4.4 KitKat) or OS version 12, minimum screen size of 5.5-inch and maximum of 6.0-inch, screen resolution of at least 1080 x 1920 pixels, can connect to WIFI/ internet and provides a YouTube app to access 360-degree videos. SVR content uses original 360o videos produced by researchers using a video editor software for ± 10 minutes duration.
76085995|NCT05755217|Dietary Supplement|Dark chocolate|Single oral dose of 1g/kg of dark chocolate (70% cocoa).
75337506|NCT01263301|Device|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
76085996|NCT05755217|Dietary Supplement|White chocolate|Single oral dose of 1g/kg of white chocolate (4% cocoa).
76085997|NCT05750030|Combination Product|FMT combined with Atezolizumab plus Bevacizumab|Single FMT from patients with HCC who responded to PD-(L)1-based immunotherapy to patients with HCC who failed to achieve complete or partial response (according to mRECIST) to atezolizumab/bevacizumab. After single FMT, patients will continue to receive atezolizumab/bevacizumab every 21-days according to protocol.
76085998|NCT05743985|Other|Cannabigerol|Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
76085999|NCT05742958|Drug|Intrathecal morphine|The study will be conducted in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery under spinal anesthesia. In this arm, 0.1 mg intrathecal morphine in addition to spinal anesthesia will be used for perioperative pain management. A placebo addctor canal block will also be performed for masking in these patients. The quality of recovery will be evaluated with a postoperative quality of recovery scale (QoR-40 questionnaire) at postoperative 24-hour and 14-day.
76086000|NCT05742958|Drug|Adductor canal block|After providing complete sensory block in the lower extremities with spinal anesthesia, the thigh where the surgery will be performed will be brought into slight abduction and external rotation while the patient is in the supine position. The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle from the mid-medial part of the thigh under ultrasound guidance. The quality of recovery will be evaluated with QoR-40 questionnaire at postoperative 24-hour and 14-day.
76086001|NCT05742841|Drug|moderate- or high-intensity statin/ rosuvastatin|moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
76086002|NCT05742672|Other|ABDOMINAL MASSAGE APPLICATION|"Experiment group twice a day in the morning and evening and 30 minutes after the feeding meal, for 15 minutes. For a period of time, effusion, petrissage, vibration massage movements will be applied by the researcher in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.- On the 3rd day (short term), 5th day (mid term) and 7th day (long term) to the massaged experimental group, the Constipation Severity Scale (CQS) and the Constipation Quality of Life Scale (QQQL) will be administered to determine the effect.~Day 7 Rome Ш Constipation Diagnostic Criteria (Annex: 2) will be applied again and the patient's constipation status will be evaluated for the last time.~Routine treatment and care practices in the clinic will continue."
75647339|NCT04297553|Procedure|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
75337507|NCT01264705|Drug|bavituximab (0.3 mg/kg) and sorafenib|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
75337508|NCT01264705|Drug|bavituximab (1.0 mg/kg ) and sorafenib|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
75337509|NCT01264705|Drug|bavituximab (3.0 mg/kg) and sorafenib|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
75337510|NCT00004204|Drug|temozolomide|
75337511|NCT01217515|Drug|Diltiazem hydrochloride 4% cream|3 times daily
75337512|NCT01217515|Drug|Diltiazem hydrochloride 2% cream|3 times daily
75337513|NCT01217515|Other|Placebo|3 times daily
75647340|NCT04297553|Procedure|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
75647341|NCT00576823|Drug|Alfuzosin|"Dose: 0.2 mg/kg/day~Route: oral"
75647342|NCT00732940|Drug|Belimumab 100 mg SC|Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
75932215|NCT04590014|Device|Control HVNI Device|During this session, patients will be placed on HVNI therapy using Vapotherm's conventional HVNI device design (Precision Flow). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
75932216|NCT04590014|Device|Test HVNI Device|During this session, patients will be placed on HVNI therapy using Vapotherm's new HVNI device design (V2.0). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
75794978|NCT05795660|Biological|platelet rich plasma|platelet rich plasma injection
75932217|NCT04489862|Biological|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion，Cyclophosphamide 300 mg/m2/day IV infusion on days -5, -4 and -3. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10^5 CAR+ T cells/kg will be infused on day 0.
75932218|NCT05163366|Drug|GROUP A|Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.
75473375|NCT01969981|Procedure|PICC placement with Sherlock 3CG|
75473376|NCT01969994|Other|Controlled dietary background|Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (-)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.
75647343|NCT00732940|Drug|Belimumab 100 mg SC|Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
75647344|NCT04217005|Device|Sensory Feedback|Subjects will receive a sensory feedback provided by electrical stimulation
75794979|NCT05795556|Other|Assessing sarcopenia and potential biomarkers of sarcopenia in fall patients|Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles (ultrasound), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)
75794980|NCT05795543|Procedure|Subtalar Arthrodesis by Screws|Instruments: cannulated screws Steps: supine position , tournique over the thigh, using a extended lateral approach or sinus tarsi approach with joint debridement and preparation. Single-screw fixation was most often placed from posterior to anterior and double screws fixation was placed triangular pattern
75932219|NCT05163366|Drug|GROUP B|The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
75932220|NCT04489784|Device|Infrared Laser|An aluminum gallium arsenide (AlGaAs) diode laser device (Twin laser, MMOptics, São Carlos, SP, Brazil) was used. The irradiation parameters were as follows: infrared laser (808 nm wavelength) with a spot area of 0.04 cm2, and an average optical power of 100 mW operated in a continuous mode during 1 minute per point, leading to an irradiance of 2,500 mW/cm2, energy of 6 J and fluence of 125 J/cm2 per point. The laser was applied on ballerina's feet twice a week during three months.
75932221|NCT05004428|Other|No intervention|Retrospective population-based study utilizing administrative data without any intervention.
75932222|NCT01038843|Drug|VA106483|"Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above"
75932223|NCT02462954|Device|ContraGel|
75932224|NCT02462954|Device|HEC Universal Placebo gel|
75932225|NCT05159232|Procedure|hospital stay|hospital stay in in inguinal hernia repair
76086003|NCT05736653|Device|Task-specific PCMS|120 pairs of TMS and PNS volleys will be administered during electromyography-triggered functional electrical stimulation (FES)-assisted task-specific training (task-specific PCMS). In the task-specific PCMS, participants will first grasp a spherical ball when prompted by an auditory 'Ready' cue, and upon seeing a visual 'Go' cue will voluntarily extend the wrist and fingers to release the ball. After the 'Go cue', our customized stimulation delivery algorithm triggers the TMS and PNS only when the extensor digitorum communis (EDC) muscle activity exceeds a pre-determined threshold. The algorithm will then trigger FES to EDC after detecting EDC activity (~2 ms after PNS) for the next 2 seconds, allowing the pairing of PCMS (TMS and PNS) with the voluntary movement of EDC without the confounding effects of FES.
75647345|NCT04061317|Other|Frailty Assessment|"We will use validated measures to determine existence of frailty prior to interventional cardiac procedures (PRISMA-7, Edmonton and FRIED Frailty Index). We will repeat the measures at 6 weeks and 6 months post procedure. We will also collect clinical data to assess any links between frailty and clinical outcomes.~We are also keen to understand the effects of health-related quality of life on frailty and will be collecting generic data via the SF-36 and EQ5-D."
75647346|NCT00962390|Drug|S-equol|10mg S-equol 50mg S-equol, & 150mg S-equol
75337514|NCT00005014|Drug|Risperidone|
75337515|NCT03009799|Drug|Iota-Carrageenan|One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
75337516|NCT03009799|Drug|Carmellose|1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
75337517|NCT00005026|Drug|carboplatin|
75337518|NCT00005026|Drug|paclitaxel|
75647347|NCT00962390|Drug|Placebo|Placebo
75794981|NCT05795530|Procedure|cochlear implantation|surgery for bilateral hearing loss
75337519|NCT00005026|Drug|topotecan hydrochloride|
75337520|NCT00004210|Other|loss of heterozygosity analysis|
75337521|NCT00004210|Other|microsatellite instability analysis|
75337522|NCT00004210|Other|mutation analysis|
75337523|NCT00004210|Other|counseling intervention|
75337524|NCT00016718|Drug|Didanosine (ddI)|Antiretroviral Didanosine (ddI) : 240 mg/m^2 up to a maximum of 400 mg once daily
75794982|NCT05795478|Drug|Oxycodone and Pregabalin|Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1~7,75mg QD for POD8~14
75932226|NCT02462408|Procedure|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
75932227|NCT02462408|Procedure|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
75932228|NCT00900783|Drug|valacyclovir|1 gram, three times a day for seven days
75932229|NCT00900783|Drug|FV-100|400 mg, once daily, for seven days
75932230|NCT00900783|Drug|FV-100|200 mg, once daily, for seven days
75932231|NCT00900783|Drug|Valacyclovir placebo|three times a day, for seven days
75932232|NCT00900783|Drug|FV-100 placebo|once daily, for seven days
75932233|NCT05139576|Diagnostic Test|serum 25OHD testing|Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels >150 ng/ml were contacted via telephone.
75932234|NCT04993196|Diagnostic Test|T1rho imaging|Magnetic Resonance Imaging using T1rho
75932235|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
75932236|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
75932237|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
75932238|NCT01035879|Drug|Sitagliptin|tablets and capsule once daily
75932239|NCT01035879|Drug|placebo|tablets and capsule once daily
75647348|NCT05377528|Drug|AGEN1571|A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.
75647349|NCT05377528|Drug|Balstilimab|A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.
75647350|NCT05377528|Drug|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
75647351|NCT00742729|Behavioral|Arm 1|Educational small group session with free FOBT kit
75647352|NCT00742729|Behavioral|Arm 2|Educational small group session with no FOBT kit
75647353|NCT00742729|Behavioral|Arm 3|Educational small group session, exercise
75794983|NCT05795478|Drug|Oxycodone and placebo capsules|Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point
75794984|NCT05795478|Drug|Pregabalin and NS|Pregabalin: 150mg preoperatively, 75mg BID for POD1~7,75mg QD for POD8~14 NS: Equal volume NS for 3 days postoperatively
75794985|NCT05795478|Drug|placebo capsules and NS|placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
75794986|NCT05795400|Drug|Dapagliflozin 10mg Tab|10 mg tablets given once daily, per oral use
75794987|NCT05795400|Drug|Placebo|tablet of placebo drug dosed once daily
75932240|NCT05164536|Drug|Amyvid|All participants will undergo a single β-amyloid PET scan with Amyvid.
75932241|NCT01029873|Drug|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
75932242|NCT01029873|Biological|ALT-801|"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)"
75932243|NCT05164380|Other|Picture naming tasks|PWA and CG had to name 128 pictures presented on a tablet, in addition to 8 trial images.
75932244|NCT01026051|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
75932245|NCT02462642|Dietary Supplement|Brahmi|Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
75932246|NCT02462642|Other|Placebo|Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
75932247|NCT02462642|Dietary Supplement|Brahmi|Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
75932248|NCT02462642|Other|Placebo|Placebo capsules - Dry starch filled in identical hard gelatin capsules
75932249|NCT01024101|Drug|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
75932250|NCT04489706|Drug|Arsenic trioxide for injection|Arsenic trioxide for injection, 0.16 mg/kg (maximum single dose is 10 mg), daily IV drip, d1 to d14, once every 28 days, for six cycles of treatment or until one of the following events occurs: Initiation of new anti-tumor therapy, disease progression, withdrawal of Informed consent form (ICF) and/or death.
75932251|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
75932252|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
75932253|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
75932254|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
75932255|NCT05118516|Drug|ASC43F|One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
75932256|NCT00818493|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
75932257|NCT00818493|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
75932258|NCT00818493|Drug|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
75932259|NCT05164068|Behavioral|Information video|The video contents were clear and adapted to the characteristics of the population of Guatemala. The video provided a simple description of the biopsy, its risks and benefits, complications and general recommendations, and was presented preoperatively
75932260|NCT02717546|Device|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
76086004|NCT05736653|Device|Task-specific sham-PCMS|120 pairs of sham-PCMS stimuli will be administered during task-specific practice. The TMS coil will be placed ~10 cm behind the participant's head, and PNS electrodes will be placed in the same position as for task-specific PCMS, but no stimulation will be delivered. Like the task-specific PCMS condition, participants will perform the same grasp and release a ball task in an identical manner. FES will be delivered after detecting voluntary EDC activity, similar to the task-specific PCMS condition.
76086005|NCT05736653|Device|PCMS-rest|120 pairs of TMS and PNS volleys will be administered with the EDC muscle at rest every 10 s (~20 min, 0.1 Hz). TMS will be used to elicit motor-evoked potentials (MEPs). Antidromic activation of spinal motor neurons will be elicited by supramaximal peripheral nerve stimulation (PNS) applied to the radial nerve near the elbow. Volleys will be timed to arrive in the spinal cord based on central and peripheral conduction times calculated for each subject so that the pre-synaptic terminal is depolarized via TMS ~1-2 ms before spinal motor neurons are depolarized via PNS at a pulse duration of 200us. We will also perform stimulation of the cervical roots (C-root) by placing the coil behind the neck and stimulating the C-root (C6 and C7 vertebrae), which innervate the finger extensor muscles. Conduction times will be calculated from latencies of the primary motor area (M1) MEP, C-root, and M-wave.
75794988|NCT05795387|Other|Video-based self-regulated training on the mental status exam|Authentic patient videos for self-regulated training as well as written e-course material, both on the mental status exam
76086006|NCT05736068|Procedure|Non-surgical treatment|If allocated to non-surgical group, cast optimization in the outpatient clinic may be necessary if the cast from the emergency room is considered insufficient.
75337525|NCT00016718|Drug|Efavirenz (EFV)|Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
75647354|NCT02860754|Other|Six-minute walk test to perform before surgery|During the outpatient preoperative assessment, eligible patients will perform the six-minute walk test.
75647355|NCT02594956|Device|no nasogastric tube|
75647356|NCT02594956|Device|nasogastric tube|
75647357|NCT02564575|Biological|HPIV3-EbovZ GP Vaccine|Administered intranasally by a VaxINator device
75647358|NCT03317678|Dietary Supplement|BioKefir|BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.
75932261|NCT04455126|Drug|Preservative-free tafluprost eye drops|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
75794989|NCT05795387|Other|E-course with written material on the mental status exam|Written material on the mental status exam
75794990|NCT05795322|Other|Sound healing with tuning forks|"Over the course of a half-hour virtual session, a specially developed triple OM track created by tuning forks was played."
75794991|NCT05795283|Drug|Citalopram i.v. and p.o|"Citalopram:~i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28"
75794992|NCT05795283|Drug|Citalopram p.o|"Citalopram:~p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28"
75932262|NCT03134469|Dietary Supplement|Probiotic supplement|Probiotic supplement
75932263|NCT03134469|Dietary Supplement|Placebo supplement|Placebo supplement
75647359|NCT03317678|Dietary Supplement|Non-fermented milk|A non-fermented milk drink.
75647360|NCT02564341|Behavioral|Collaboration with an IT enabled nurse care manager|The nurse care manager at each site will collaborate with intervention physicians to implement key essential elements of guideline driven care, namely opioid treatment agreements, urine drug testing, random pill counts and periodic checking of on-line Prescription Monitoring Programs. The nurse care manager will use an electronic registry to retrieve pain medication information from the electronic medical record (EMR). Registry data will be collected on the patients of the intervention group providers. The nurse care manager will be able to use the registry to generate reports that will allow him/her to monitor those patients who are receiving opioids for chronic pain.
75647361|NCT02564341|Behavioral|Education and academic detailing|All intervention participants will receive a 60 minute group didactic session by a national expert on opioid prescribing for pain. Physicians will receive two academic detailing sessions, and will be given the option of having a third, booster academic detailing session if desired.
76086007|NCT05736068|Procedure|Surgical treatment|Closed reduction with or without fixation
76086008|NCT05735561|Diagnostic Test|X-Ray|Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.
75337526|NCT00016718|Drug|Emtricitabine (FTC)|Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
75337527|NCT00004216|Biological|salmonella VNP20009|
75337528|NCT00004216|Drug|cefixime|
75647362|NCT02564341|Behavioral|Facilitated access to a specialist in addictions|The nurse care manager will encourage and arrange referral of challenging patients with potential abuse or dependence to prescription opioids to an addiction specialist.
75794993|NCT05795270|Other|Treatment|Nocturnal ventilotherapy, positional therapy and oro-mandibular devices
75794994|NCT05795231|Device|Macintosh Laryngoscope Vs Video Laryngoscope|Evaluate incidence of first trial success and complications
75794995|NCT05795218|Device|Deep Brain Stimulation|implant and DBS therapy with the directSTIM™ DBS system
75794996|NCT05795179|Behavioral|Cold-Pressor Task (CPT)|CPT is a physiological stress task in which participants continuously submerge their hand and forearm in ice-water (0-4°C) for 3 minutes.
75794997|NCT05795179|Behavioral|Trier Social Stress Test (TSST)|The TSST is a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges.
75794998|NCT05795179|Behavioral|Modified Non-Stress CPT|The modified non-stress CPT involves participants continuously submerging their hand and forearm in warm water for 3 minutes.
75337529|NCT00004216|Drug|ceftriaxone sodium|
75337530|NCT00004216|Drug|ciprofloxacin|
75337531|NCT00004216|Drug|trimethoprim-sulfamethoxazole|
75337532|NCT00005566|Behavioral|Desperation Scale|
75337533|NCT01897064|Behavioral|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
76086009|NCT05735535|Drug|Antiviral Agents|two-drug one-pill once day
75337534|NCT01897064|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
75794999|NCT05795179|Behavioral|Modified Non-Stress TSST|For the modified non-stress TSST, participants are asked to prepare for a speech that they will practice alone to themselves and complete math problems alone on a piece of scrap paper.
75337535|NCT00005032|Biological|oblimersen sodium|
75647363|NCT04280510|Genetic|Blood sample collection; gastrointestinal biopsy|Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
75795000|NCT05795179|Device|Functional Magnetic Resonance Imaging (fMRI)|Participants will complete the self-control task in the fMRI scanner.
75795001|NCT05795127|Procedure|First metatarsophalangeal joint arthrodesis|Surgery leadin to bony uninon in firts metatarsophalangeal joint
75473377|NCT01969994|Other|(-)-[2-14C]epicatechin intake|Single oral intake of an aqueous solution of a mixture of non-radiolabeled (-)-epicatechin and a single-carbon-14 radiolabeled (-)-[2-14C]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (-)-[2-14C]epicatechin.
75473378|NCT01970020|Drug|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
75473379|NCT01970033|Drug|Placebo|"Run in period ：oral tablets of Placebo twice daily for 2 weeks~Phase A : oral tablets of Placebo twice daily for 24 weeks~Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks"
75647364|NCT02858960|Device|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.
75795002|NCT05795088|Device|Continuous theta burst stimulation|Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease
75795003|NCT05795036|Device|Mhealth|Using a mHealth intervention to promote physical activity in Phase III cardiac rehabilitation clients
75795004|NCT05795010|Other|MRD test|ctDNA detection based on tumor whole exon sequencing
75795005|NCT05794919|Drug|Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g|A generic product manufactured by Hainan Linheng Pharmaceutical Co., Ltd.
75795006|NCT05794919|Drug|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®）produced by OM pharma S.A.
75932264|NCT05119062|Other|Usual care|Families in the control group will be provided with routine care, including regular antenatal check ups, one bed side education (within 24 hours after delivery), one group session with discharge precautions (3rd to 5th day postpartum), two home visits (first week and second week after discharge respectively), and two physical body check at hospital on the 30th and 42nd day postpartum. Contents of the bed side education, pre-discharge education and home visits focuses on health related information, such as postpartum care, infant care and breastfeeding, etc.
75337536|NCT00005032|Drug|paclitaxel|
75473380|NCT01970033|Drug|SP2086 50 mg b.i.d.|"Run-in period: placebo twice daily for 2 weeks~Phase A:SP2086 50 mg b.i.d for 24 weeks~Phase B:SP2086 50 mg b.i.d for 28 weeks"
75647365|NCT02858960|Device|The Venturi Mask|Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
75647366|NCT04060615|Procedure|percutaneous coronary intervention|PCI of the chronic total occlusion of the coronary artery
75647367|NCT04282928|Biological|Human umbilical cord mesenchymal stem cells|Definitive Human umbilical cord mesenchymal stem cells selected by immunomodulatory assay through coculture with BV2 cell
75647368|NCT04282928|Procedure|Routine treatment|"According toInfluenza diagnosis and treatment plan (2019 version)"
76086010|NCT05732285|Behavioral|CRT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
75337537|NCT00004234|Procedure|management of therapy complications|
75337538|NCT00004234|Radiation|radiation therapy|
75337539|NCT00005038|Biological|aldesleukin|
75337540|NCT00005038|Drug|histamine dihydrochloride|
75337541|NCT00019682|Biological|Aldesleukin|Given IV
75337542|NCT00019682|Biological|gp100 Antigen|Given SC
75473381|NCT01970033|Drug|SP2086 100 mg q.d.|"Run-in period:placebo twice daily for 2 weeks~Phase A: SP2086 100 mg q.d. for 24 weeks~Phase B: SP2086 100 mg q.d. for 28 weeks"
75647369|NCT00743041|Behavioral|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
75647370|NCT02859194|Procedure|Veno-veno-arterial ECMO|
75337543|NCT00019682|Drug|Montanide ISA 51 VG|Given SC
75337544|NCT00019682|Other|Quality-of-Life Assessment|Ancillary studies
75337545|NCT00019682|Other|Questionnaire Administration|Ancillary studies
75337546|NCT00019682|Other|Laboratory Biomarker Analysis|Correlative studies
75473382|NCT01970046|Drug|Placebo/Metformin|"Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks"
75647371|NCT02565277|Biological|Influenza Vaccine|
76086011|NCT05732285|Behavioral|CBT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
76086012|NCT05732285|Behavioral|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
76086013|NCT05732285|Behavioral|Usual care Psychoeducation|"Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
76086014|NCT05730855|Diagnostic Test|Real-time Polymerase Chain Reaction technique|Real-time Polymerase Chain Reaction technique
75795007|NCT05794893|Behavioral|Good Behavior Game|Universal school-based intervention reinforcing prosocial behaviors and discouraging disruptive behaviors in young students.
76086015|NCT05727774|Other|Water Biking in hot water condition|Training protocol includes 10 water biking sessions in hot water temperature (35°C) for this group
75795008|NCT05794867|Diagnostic Test|clinical weaning criteria|Xray chest and calculation of thr rapid shallow breathing rate
75795009|NCT05794854|Other|Abdominal aerobic endurance exercise|Subjects combined treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 days per wk for 10 weeks
75337547|NCT00005050|Drug|ethynyluracil|
75337548|NCT00005050|Drug|fluorouracil|
75337549|NCT00005050|Drug|oxaliplatin|
75337550|NCT00005578|Biological|bleomycin sulfate|
76086016|NCT05727774|Other|Water Biking in neutral water condition|Training protocol includes 10 water biking sessions in neutral water temperature (25°C) for this group
76086017|NCT05721729|Drug|Mizagliflozin|Encapsulated
76086018|NCT05721729|Drug|Placebo|Encapsulated
76086019|NCT05720715|Drug|cyclosporine A 0.05% eye drops|"Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months."
75337551|NCT00005578|Biological|filgrastim|
76086020|NCT05720169|Diagnostic Test|Doppler ultrasound|Doppler ultrasound at 13, 16, 20 and 26 weeks for assessment of uterine arteries according to ISUOG criteria.
75337552|NCT00005578|Drug|cyclophosphamide|
75337553|NCT00005578|Drug|dexrazoxane hydrochloride|
75647372|NCT02565277|Drug|Placebo|
75337554|NCT00005578|Drug|doxorubicin hydrochloride|
75337555|NCT00005578|Drug|etoposide|
75337556|NCT00005578|Drug|prednisone|
75337557|NCT00005578|Drug|vincristine sulfate|
75337558|NCT00005578|Radiation|radiation therapy|
75647373|NCT00732472|Drug|GSK573719|7 day repeat dose
75647374|NCT00960986|Drug|Duloxetine hydrochloride|po, QD
75647375|NCT00732238|Other|Shortened course of antibiotic therapy|By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
75647376|NCT00732238|Other|Standard Therapy|Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
75647377|NCT00958880|Behavioral|Group Cognitive Behavioral Therapy|"5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy."
75337559|NCT00022490|Drug|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
75647378|NCT00958880|Drug|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
75647379|NCT00958880|Drug|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
75337560|NCT00022490|Drug|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
75337561|NCT00386230|Drug|ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
75337562|NCT00386230|Drug|ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
75337563|NCT00386230|Drug|ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
75337564|NCT00386230|Drug|ZDV Long (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
76086021|NCT05720169|Diagnostic Test|Blood sample|Blood sampling at 13, 16, 20, 26 weeks of gestation to determine the sFlt-1/PlGF ratio
75932265|NCT05119062|Other|an online intergenerational co-parenting programme+usual care|The program is proposed to include five sessions, with three antenatal sessions to be offered weekly during the 34-36 weeks gestation and two postnatal sessions weekly starting from the first week after discharge from hospital. The intervention will be delivered online.The program is designed for the intergenerational co-parenting families to undertake with parents together with grandmothers. The online courses will be delivered by an online platform in the study hospital. The first session will be pushed to participants in the intervention group within 2 days (around 34 weeks gestation) after recruitment. The second and third session will be pushed around 35 and 36 weeks gestation separately. The first postnatal session will be provided around the first to second week postpartum; and second postnatal session will be provided around the third to fourth week postpartum.
76086022|NCT05720169|Diagnostic Test|Blood sample|Blood sampling at week 13 for DNA extraction for genomic studies
76086023|NCT05720169|Diagnostic Test|Doppler ultrasound|Fetal morphological ultrasound at 13, 16 and 20 weeks.
76086024|NCT05718895|Drug|ATG-022|"Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design."
75337565|NCT00097448|Drug|prednisone|Oral, 19 days
75795010|NCT05794854|Other|Control training intervention|Subjects performed treadmill running (45 minutes) at 70% HRmax 4 days per week for 10 weeks
75795011|NCT05794841|Diagnostic Test|Tongue coating sample collection and multi-omics analysis|Tongue coating sample collection and multi-omics analysis for building a diagnostic model
75795012|NCT05794737|Biological|Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.
75337566|NCT00097448|Drug|methylprednisolone sodium succinate|Four intratympanic injections delivered to the middle ear over 2 weeks
76086025|NCT05716425|Drug|STI-1558|STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
76086026|NCT05716425|Drug|STI-1558 placebo|STI-1558 placebo will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 0 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
76086027|NCT05711537|Device|Auricular Acupressure with Vaccaria 600t ear seeds|Auricular Acupressure utilizing vaccaria 600 t ear seeds applied to 5 designated sites to each ear. Both ears will have seeds applied. Participants will be asked if they consent to having their intervention session photographed and audio recorded in collaboration with the BAA press training and intervention fidelity study.
76086028|NCT05709496|Radiation|De-escalated radiotherapy to be delivered on the Elekta Unity Unity MR-linac|30 Gy in 5 fractions to the whole prostate with 45 Gy in 5 fractions to the dominant lesion
76086029|NCT05698173|Biological|blood sample|48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
76086030|NCT05698173|Biological|blood sample|blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
76086031|NCT05696561|Device|Canaloplasty Device|Canaloplasty
76086032|NCT05695196|Biological|nasal microbiota transplant (NMT)|nasal microbiota transplant
76086033|NCT05695196|Biological|Placebo|Placebo sterile saline
76086034|NCT05682053|Diagnostic Test|Multiparametic MRI|patients will have a Multiparametric MRI
76086035|NCT05681741|Procedure|current versus high pump flow|during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
75337567|NCT00004246|Drug|Fludarabine Phosphate|IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
75337568|NCT00004246|Radiation|Radiation Therapy (RT)|Days 1-5 for 7 weeks
75337569|NCT00423280|Drug|6R-BH4|6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
75795013|NCT05794646|Other|Hybrid effectiveness-implementation study type 2|Diagnosis of hepatitis C; Assessment of hepatic fibrosis; Treatment of hepatitis C; Assessment of psychological disorders and treatment or referral.
75795014|NCT05794607|Other|Rehabilitation group|The intervention group will be given strength training to improve muscle strength and flexibility, and aerobic exercise training to improve exercise capacity with function.
75795015|NCT05794594|Device|3D printed personalized extendable prosthesis|3D printed personalized extendable prosthesis replacement for limb preservation in children
75795016|NCT05794529|Other|There are no interventions in the present study|There are no interventions in the present study
75798976|NCT01185678|Drug|Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)|One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
75798977|NCT01185756|Radiation|MIBG for diagnostic purpose|All patients will undergo the diagnostic test specific to the study.
75932266|NCT05622903|Other|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
75932267|NCT05622903|Other|No Cash Benefit|No monthly cash benefit.
75337570|NCT00028262|Drug|Cystagon|
75337571|NCT04771286|Drug|BI 1015550 (C-14)|BI 1015550 (C-14)
75337572|NCT00005056|Drug|bryostatin 1|
75337573|NCT00004252|Drug|fluorouracil|
75337574|NCT00004252|Drug|leucovorin calcium|
75337575|NCT00004252|Drug|semaxanib|
75337576|NCT00005062|Radiation|radiation therapy|
75337577|NCT00005590|Drug|levofloxacin|
75337578|NCT00004258|Drug|cilengitide|dose escalation of cilengitide
75795017|NCT05794373|Procedure|Standard physiotherapy for low back pain in a municipality setting|Patients (N=100) referred to a municipality-based rehabilitation for low back pain are included. The physiotherapists choose the rehabilitation strategy based on what they consider relevant for the patients. After the first 100 patients have been discharged from municipality care, the physiotherapists will participate in an educational intervention (12 sessions) focusing on the management of low back pain within a multidimensional framework. In the educational intervention, the participants will learn how to identify the presence of unhelpful thoughts and emotions and how to address these as part of the intervention. The course will thus be a mix of theoretical and practical teaching, including case supervision and feedback. Following the educational intervention, an additional 100 patients referred to the rehabilitation program will be included. The intervention is aimed at the physiotherapists where the patients will receive the best available care, before or after the intervention.
75795018|NCT05794256|Other|No interventions are planned|No interventions are planned
75932268|NCT00893139|Drug|AL-38583 ophthalmic solution 0.05%|
75932269|NCT00893139|Drug|AL-38583 ophthalmic solution 0.10%|
75932270|NCT00893139|Drug|AL-38583 vehicle|Inactive ingredients used as a placebo comparator
75932271|NCT01378962|Drug|erlotinib|150 mg orally once a day for 12 months
75932272|NCT00892203|Drug|BGG492|
76086036|NCT05681065|Device|TeNDER tool|"The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor."
75647380|NCT02860910|Behavioral|Cognitive Behavioral Group Therapy|
75647381|NCT00732160|Drug|Aldosterone infusion (A)|Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
75932273|NCT00892203|Drug|Sumatriptan|
75932274|NCT00892203|Drug|Placebo|
75932275|NCT05377983|Other|Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes|During the hospitalization period after CABG surgery, 2% lavender oil (Lavandula angustifolia) inhalation will be applied to the intervention group three times a day.
75932276|NCT05113524|Other|Dance|The dance program consists of 3 months of dance classes. Classes are specifically designed for people with Parkisnon's and lead by a qualified dance instructor experienced in teaching this population. The in-person dance classes are conducted in an appropriate room with chairs and ballet barres once a week. In addition, the participants received a CD containing a video of the recorded dance routine to be performed at home once a week. The class typically included a warm-up (10-15 min.), barre ballet exercises (10-15 min.), general dance-related activities (15-20 min), and a cool-down (10-15 min).
76086037|NCT05680792|Drug|Nitazoxanide|1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
75337579|NCT00005596|Drug|cyclophosphamide|
75337580|NCT00005596|Drug|cytarabine|
75647382|NCT00732160|Drug|Vehicle Infusion (V)|Vehicle infusion for 12.5 hours
75647383|NCT00732160|Other|High Sodium Diet (HS)|160 mmol/d sodium diet for 7 days
76086038|NCT05680792|Drug|Atazanavir/ritonavir|300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
76086039|NCT05677880|Other|Study Procedures|"Participants will experience~Neurocognitive Tests and Self-Report Measures~Clinical Interviews~Neurological Exam~MRI screening at baseline, 18 months, 36 months~Fasted Blood draw"
76086040|NCT05676814|Drug|Pecto-intercostal Fascial Block (PIFB)|PIFB done with bupivacaine and epinephrine
76086041|NCT05676814|Drug|PIFB with adjuvants|PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone
75647384|NCT00732160|Other|Low Sodium Diet (LS)|20 mmol/d sodium diet for 9 days
75647385|NCT04088344|Dietary Supplement|isocaloric diet|a 7-day isocaloric diet
75647386|NCT04088344|Dietary Supplement|Hypercaloric diet|A 7-day hypercaloric diet supplemented with carbohydrate-rich food (+ 50% of the subject's energy needs).
75647387|NCT04088344|Other|Liquid meal|
75647388|NCT04088344|Radiation|PET imaging|
75647389|NCT04088344|Other|perfusions of stable tracers|
75647390|NCT04088344|Device|Indirect calorimetry|
75647391|NCT02595034|Drug|Clindamycin and Benzoyl Peroxide Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
75647392|NCT02595034|Drug|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
75647393|NCT02595034|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
75647394|NCT00958724|Drug|Neratinib|
75647395|NCT00958724|Drug|Vinorelbine|
75795019|NCT05794217|Behavioral|This is a non-interventional study|This is a non-interventional study
75795020|NCT05794113|Device|Mobile app - CanImmunize|Using a mobile app
75795021|NCT05794113|Device|Web based notification|Using a web-based version of a survey
75795022|NCT05794100|Other|Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator|One pack of each product (1 to 10) will be consumed on a separate occasion
75795023|NCT05793580|Device|Vibrant Soundbridge active middle ear implant|active middle ear implant
75932277|NCT05113524|Other|No intervention|Controls, not alter their personal lifestyle, but will undergo the same testing as the exercise intervention group.
75932278|NCT05342922|Procedure|Ultrasound group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
75337581|NCT00005596|Drug|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
75337582|NCT00005596|Drug|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
75795024|NCT05793541|Behavioral|Phone call|A phone call from a trained study clinician that uses a standardized phone script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the call, as well as briefly identifying and troubleshooting barriers to using the safety plan.
75795025|NCT05793541|Behavioral|Text messaging|A text message conversation initiated by a trained study clinician that uses a standardized text messaging script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the text messaging interaction, as well as briefly identifying and troubleshooting barriers to using the safety plan.
75795026|NCT05793541|Behavioral|Automated interactive smartphone-based tool|An automated interactive, smartphone-based tool that will (a) (at High risk only) guide the participant through a risk assessment and (b) (at High and Medium Risk) present recommendation to use the safety plan, a review of the safety plan, as well as briefly identifying and troubleshooting any barriers to using the safety plan.
75795027|NCT05793541|Behavioral|Non-interactive pop-up messages|Automated non-interactive, static pop-up messages that recommends use of the safety plan or its components.
75795028|NCT05791968|Procedure|Whole blood standard donation|Effects of a standard whole blood donation on iron stores and insulin sensitivity.
75795029|NCT05791786|Other|Patient|affected individuals diagnosed with AFE
75795030|NCT05790174|Behavioral|"ROS chubby and healthy - a multidisciplinary family-based weight-loss treatment program"|"The weight-loss treatment program ROS is family-based and delivered by a multidisciplinary team of physicians, nurses, dieticians, and psychologists. The treatment is based on an individualized tailored plan made together with the family. The plan consists of dietary changes, more physical activity, regular weight checks, and motivational conversations. The program includes options of cooking classes, group session with a psychologist and participation in structured physical activity called ROS sports twice a week. Follow up visits are scheduled every 2-3 months at the different health care professionals."
75795031|NCT05787132|Other|Balance Board therapy|Balance board therapy will be performed. balance board therapy has been shown to improve the sitting balance in children with cerebral palsy
75337583|NCT00005596|Drug|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
75337584|NCT00005596|Drug|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC > 500/μL and platelets > 75,000/uL
75795032|NCT05787132|Other|Perceptual Motor therapy|Perceptual motor therapy will be performed, it has been shown to improve dynamic sitting in children with cerebral palsy.
75795033|NCT05783401|Other|Data acquisition: Speech acquisition|Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.
75795034|NCT05783401|Diagnostic Test|Data acquisition: G8 Screening tool|The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.
75795035|NCT05783401|Diagnostic Test|Data acquisition: Distress Thermometer|The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.
76086042|NCT05676242|Drug|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
75337585|NCT00005596|Drug|methotrexate|"IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22."
75337586|NCT00005596|Drug|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; > or = 1 day after the IT MTX
75337587|NCT00005596|Drug|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC > or = 500/ul and platelets > or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
75337588|NCT00005596|Drug|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
75337589|NCT00005068|Drug|fluorouracil|
75337590|NCT00005068|Drug|irinotecan hydrochloride|
75337591|NCT00005068|Drug|leucovorin calcium|
75337592|NCT00005068|Drug|oxaliplatin|
75337593|NCT00004264|Drug|amifostine trihydrate|
75337594|NCT00004264|Drug|cisplatin|
75337595|NCT00004264|Drug|docetaxel|
75337596|NCT00005074|Drug|alvocidib|
75647396|NCT02858570|Biological|MenCC-BIO Vaccine|The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein, with 10 microgram of capsular polysaccharide of group C, 10-20 microgram of tetanus toxoid per dose and aluminum hydroxide at a concentration of 1 milligram dose (0.35 milligram Al3 +) with phosphate buffered saline as diluent. The vaccine is lyophilized and must be reconstituted with diluent and homogenized at the time of application. The lyophilised vaccine is presented as a white powder and the sterile diluent is translucent. Both are presented in vial of colorless neutral glass.
75337597|NCT00005602|Drug|carboplatin|
75337598|NCT00005602|Drug|cereport|
75337599|NCT00005602|Radiation|radiation therapy|
75337600|NCT00004276|Drug|thalidomide|
75337601|NCT00005080|Drug|nelarabine|Given IV
75337602|NCT00004288|Drug|olsalazine|
75337603|NCT00005086|Drug|cisplatin|
75337604|NCT00005086|Drug|docetaxel|
75795036|NCT05779735|Diagnostic Test|Transperineal ultrasound measurements of AOP|The angle of progression (AOP) defined as the angle between the pubic bone axis and the leading part of the fetal head
76086043|NCT05669404|Behavioral|Salt Restriction Group (SRG)|Patients assigned to the SRG continued to consume their usual diet, but they had to restrict their sodium intake to 2,000 mg/ day. They were given a detailed booklet containing information about table salt, foods rich in sodium, and practical ways to decrease salt consumption. During each 45-min individual session, they received intensive counselling and training to increase adherence to salt restriction. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
75647397|NCT02858570|Biological|Combined - CRM197|The comparison is against meningococcal C vaccine produced by the Foundation Ezequiel Dias (FUNED), licensed by ANVISA and currently provided by the National Immunization Program in the child's immunization schedule. This vaccine containing 10 microgram of meningococcal C oligosaccharide conjugate 12,5-25microgram of CRM197 protein of Corynebacterium diphtheriae, and presents aluminum hydroxide (0.3 to 0.4 milligram Al3 +) in its formulation. It is also a lyophilized product must be reconstituted and homogenized before use. The meningococcal C vaccine adsorbed (combined - CRM197) comprises two frascos- ampoule, containing a white or off-white lyophilized powder and another vial containing a white opalescent suspension (diluent).
75795037|NCT05779579|Drug|HS-10517 Dose 1|HS-10517 Dose 1+Ritonavir
76086044|NCT05669404|Behavioral|DASH Diet combined with salt restriction Group (DDG)|Patients assigned to the DDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the DASH diet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the DASH diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
76086045|NCT05669404|Behavioral|Mediterranean Diet combined with salt restriction Group (MDG)|Patients assigned to the MDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the MedDiet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the MedDiet diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
76086046|NCT05669222|Diagnostic Test|FAST Technique|The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.
76086047|NCT05669222|Diagnostic Test|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
75337605|NCT00005086|Drug|gemcitabine hydrochloride|
75337606|NCT00005086|Drug|methotrexate|
75337607|NCT00385372|Procedure|elimination diet|
75337608|NCT00385372|Procedure|provocation diet|
75337609|NCT00005614|Drug|Gemcitabine hydrochloride|Gemcitabine via IV
75647398|NCT04280432|Procedure|CESAREAN|Women hospitalized for cesarean section
75337610|NCT00101036|Drug|lapatinib ditosylate|Given PO
75337611|NCT00101036|Other|laboratory biomarker analysis|Correlative studies
75337612|NCT00004294|Genetic|human glucocerebrosidase gene into autologous peripheral blood stem cells|
75337613|NCT00004300|Drug|bromocriptine|
75337614|NCT00004300|Drug|sertraline hydrochloride|
75337615|NCT04770818|Device|Modified Brostrum procedure with Internal Brace Augmentation|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability with InternalBrace augmentation.
75337616|NCT04770818|Device|Modified Brostrum procedure|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability
75337617|NCT00005626|Drug|Irinotecan|Irinotecan as outlined in treatment arm
75647399|NCT00738400|Drug|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
75647400|NCT00738400|Drug|Placebo|Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
75795038|NCT05779579|Drug|HS-10517 Dose 2|HS-10517 Dose 2+Ritonavir
75795039|NCT05779579|Drug|HS-10517 Dose 3|HS-10517 Dose 3+Ritonavir
75795040|NCT05779579|Drug|HS-10517 Dose 4|HS-10517 Dose 4+Ritonavir
75795041|NCT05779579|Drug|Placebo|Dose level A of placebo
75337618|NCT00005092|Drug|Cyclophosphamide|IV over 2 hours on days 2 and 3
75795042|NCT05768958|Other|Exercise|45 min exercise bout performed on bicycle ergometer. The exercise bout will consist of a 10 min warm-up period at 40 % Watt max followed by 4 cycles of 4 min at 85 % Watt max and 3 min at 50 % Watt max. A cool-down period (7 min) will be performed at 40 % Watt max.
75795043|NCT05768958|Other|Control|45 min rest during the same time period as the exercise bout on exercise study visits.
75795044|NCT05763238|Other|INTERVENTION GROUP|"Preoperative Protocol:~DAY 1: Incentive spirometry 1 set of 2 repetitions(each repetition includes 05 deep inhalations) 3 times a day.~Active ROMS (3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 10 steps thrice a day. DAY 2: Incentive spirometry 1 set of 3 repetitions (each repetition includes 08-10 deep inhalation) 3 times a day.~Active ROMS, 3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 15 steps thrice a day. DAY 3: Incentive spirometry,1 set of 3 repetitions(each repetition includes 10 deep inhalation) 3 times a day Active ROMS 3 sets of 5 repetitions of both upper and lower limbs thrice a day. Walk, Static marching to 20 steps thrice a day. Postoperative Protocol: Conventional protocol of respective cardiac setup"
75795045|NCT05763238|Other|CONTROL GROUP|"Preoperative: Patients' parents will be educated about the disease process, surgery, it's possible complications, and precautions.~Postoperative: Conventional protocol of respective cardiac setup"
75795046|NCT05752149|Drug|CRGD-ZW800-1|Intravenous administration of study drug at lesat 2h prior to surgery
75795047|NCT05750225|Other|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
75932279|NCT05342922|Procedure|Landmark group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
75932280|NCT00890409|Device|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
75932281|NCT05163756|Drug|DW1903|q.d. PO, DW1903 + Placebo of DW1903-R1
75932282|NCT05163756|Drug|DW1903-R1|q.d. PO, Placebo of DW1903 + DW1903-R1
75932283|NCT00889473|Drug|Larazotide acetate|gelatin capsule
75932284|NCT00889473|Drug|Placebo|gelatin capsule
75932285|NCT00889473|Dietary Supplement|Gluten 900 mg|gelatin capsule
75932286|NCT05391204|Other|Functional Tests|Various physical exercices of inferior members
76086048|NCT05664867|Other|Mainstream Genetic Testing Model|Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
76086049|NCT05664867|Other|Enhanced Standard of Care Model|Enhanced Standard of Care Model of Cancer Genetic Service Delivery
76086050|NCT05663580|Drug|Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
76086051|NCT05660863|Drug|MN-08 24 mg/day|Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
75337619|NCT00005092|Drug|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
75647401|NCT01009463|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
75647402|NCT01009463|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
76086052|NCT05660863|Drug|MN-08 60 mg/day|Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
75337620|NCT00005092|Drug|Thiotepa|IV over 2 hours on day 1
75647403|NCT00958568|Drug|Olanzapine and Fluoxetine combination (OFC)|"Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.~Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.~Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks."
75932287|NCT00810147|Drug|BMS-708163|Capsules, Oral, 25 mg, once daily, 24 weeks
76086053|NCT05655598|Drug|Palbociclib Oral Product|125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
76086054|NCT05655598|Drug|TAS-116|120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
75337621|NCT00005092|Procedure|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
75647404|NCT00958568|Drug|Fluoxetine|25 or 50 mg/day fixed dosing for 27 weeks
75647405|NCT04284020|Behavioral|Therapeutic educational program|See arm/group descriptions
75647406|NCT04284020|Other|PFMT|See arm/group descriptions
75795048|NCT05750225|Other|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
75932288|NCT00810147|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 24 weeks
75932289|NCT00810147|Drug|BMS-708163|Capsules, Oral, 100 mg, once daily, 24 weeks
75932290|NCT00810147|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 24 weeks
76086055|NCT05655598|Drug|TAS-116|80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
75795049|NCT05743790|Dietary Supplement|RS2-control-RS4|Group A: Treatment 1 = RS2 (Hi-Maize 260), Treatment 2 = Control (Amioca TF), Treatment 3 = RS4 (Versafibe 1490)
75795050|NCT05743790|Dietary Supplement|RS4-control-RS2|Group B: Treatment 1 = RS4 (Versafibe 1490), Treatment 2 = Control (Amioca TF), Treatment 3 = RS2 (Hi-Maize 260)
75932291|NCT00810147|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 24 weeks
75932292|NCT04375956|Drug|Pembrolizumab|Experimental
75932293|NCT04495478|Drug|Ramucirumab - IV|Administered IV.
76086056|NCT05655598|Drug|TAS-116|40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
75337622|NCT00005092|Procedure|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
75337623|NCT00005092|Radiation|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
75337624|NCT00005632|Biological|MUC1-KLH vaccine/QS21|
75337625|NCT00005638|Drug|cisplatin|
75337626|NCT00005638|Drug|irinotecan hydrochloride|
75932294|NCT04495478|Drug|Placebo - IV|Administered IV.
75932295|NCT04495478|Drug|Ramucirumab - SC|Administered SC.
75932296|NCT04495478|Drug|Placebo - SC|Administered SC.
75932297|NCT04308564|Diagnostic Test|Blood test|Blood test for the identification of biomarkers
75932298|NCT04487444|Drug|Thymalfasin|Synthetic 28 amino acid peptide identical to naturally circulating compound
75337627|NCT00005638|Radiation|radiation therapy|
75337628|NCT00005104|Drug|clomiphene citrate|
75647407|NCT04284020|Other|TTNS|See arm/group descriptions
75932299|NCT00152763|Behavioral|Cognitive Behaviour Therapy (CBT)|Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
75932300|NCT00152763|Other|Usual Cardiac Care (UCC)|Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
75337629|NCT00005104|Drug|metformin|
75932301|NCT02717156|Procedure|Computed Tomography|Correlative studies
75932302|NCT02717156|Other|Laboratory Biomarker Analysis|Correlative studies
76086057|NCT05655234|Behavioral|Music Breathing|"The MB programme consists of four stages: 1. Silent breathing for grounding (SB), 2. Music breathing for grounding (MBG), 3. Music breathing for modulation (MM), 4. Music breathing for working (MW).~After completing the silent breathing and music breathing practices, the participants will draw pictures of their body images of breathing space and centre. The form of the imagined breathing space expressed in the drawing and the meaning and content of the experience will be explored through a process facilitated by the therapist. The therapist's understanding of the participants' difficulties and progress will guide the next step, particularly the selection of music for the next sessions. The whole session takes about 2 hours. Weekly home practice is advised."
75337630|NCT00005110|Drug|Salmeterol|
75795051|NCT05734859|Device|Electrolyzed Alkaline Ionizer|Patients will drink EHARW calculated by 20 mL/kg body weight/day which can be divided into several times a day for drinking. The patient is recommended to drink water in an empty stomach and to drink water generated from the device as soon as possible.
75795052|NCT05726097|Drug|polyethylene glycol|colonic preparation
75795053|NCT05726097|Drug|sodium phosphate|colonic preparation
75795054|NCT05726097|Drug|polyethylene glycol + ascorbic acid|colonic preparation
75795055|NCT05726097|Drug|gastrografin|colonic preparation
75337631|NCT00005110|Drug|Albuterol|
75337632|NCT00004330|Drug|luteinizing hormone-releasing factor|
76086058|NCT05655234|Behavioral|Control condition|The control condition consists of 30-min mental health education programme with topics on stress management, music playing, and breathing exercise provided in the first and 6th weeks. A take-home kit which consists of the fact sheet information of the health talk and the video link of the breathing exercise and musical pieces will be provided to the participants after the first meeting. They are instructed to practice the breathing exercise and listening to the musical pieces at home.
75473383|NCT01970046|Drug|SP2086 50 mg b.i.d/Metformin|"Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks"
75647408|NCT04283630|Dietary Supplement|Dietary nitrate in the form of beetroot juice for all participnats|participants asked to consume dietary nitrate in the form of beet juice everyday in the morning and then one hour later, the vitamin C capsules.
75647409|NCT04283630|Dietary Supplement|Nature Made vitamin c 1000 mg|vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the daily vitamin C supplement (1000 mg) or placebo one-hour post beetroot juice supplementation.
75647410|NCT04283630|Dietary Supplement|Placebo|Vitamin C matched Placebo capsules that made from starch.
75647411|NCT04283708|Procedure|Submental liposuction|Advancement Genioplasty With Submental Liposuction
75647412|NCT04282538|Device|Active rTMS|4-week (5 days per week) active rTMS (90%rMT, M1, 10Hz for 10s, 50s interval, 20 trains)
75795056|NCT05726097|Drug|magnesiumoxid + sodium picosulfate|colonic preparation
75932303|NCT02717156|Biological|Pembrolizumab|Given IV
75795057|NCT05726097|Drug|prucalopride|colonic preparation
75795058|NCT05724394|Other|Culturally Adapted Getting Better Bite By Bite (Ca-GBBB) intervention|The Ca-GBBB strongly focuses on enhancing participant's motivation and belief in their ability to change. The intervention will be comprised of 16-week training program delivered over four months.
75798978|NCT01188174|Drug|Clofarabine|The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.
75798979|NCT01588002|Drug|danoprevir|multiple oral doses
75798980|NCT01588002|Drug|efavirenz|multiple oral doses
75932304|NCT02717156|Procedure|Positron Emission Tomography|Correlative studies
75932305|NCT02717156|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
75337633|NCT00005116|Behavioral|psychotherapy|
75337634|NCT00005668|Drug|Itraconazole oral solution|
76086059|NCT05652296|Device|External Ventricular Drainage (EVD)|EVD of Cerebral Spinal Fluid from the lateral ventricles of the brain
76086060|NCT05651867|Device|EPIONE device|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
75473384|NCT01970046|Drug|SP2086 50 mg q.d./Metformin|"Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks"
75473385|NCT01970059|Drug|Extended-Release Carvedilol Sulfate|
75473386|NCT01970059|Drug|Sustained-release Metoprolol Succinate|
75473387|NCT01970072|Drug|Remimazolam Tosylate|
75473388|NCT01970072|Drug|Midazolam|
75473389|NCT01970098|Drug|KPS-0373, High dose|28 weeks
75647413|NCT04282538|Device|Sham rTMS|4-week (5 days per week) sham rTMS
75795059|NCT05714956|Behavioral|Mothers and Babies Online (eMB)|"This study's intervention is called Mothers and Babies Online or eMB, which consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention."
75795060|NCT05712343|Drug|Valacyclovir group|The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)
76086061|NCT05646472|Diagnostic Test|Frailty multidimensional assessment|"Each Centre will administer SUNFRAIL frailty assessment tool to the enrolled older adults and, according to the specific alerts triggered by the answers provided, older adults will be subjected (at the same time or subsequently) to one or more validated in-depth tests (already included in the SUNFRAIL+ platform) in order to perform further diagnostic or dimensional evaluations.~During the observation phase, subjects will be given different health promotion activities, depending on the assessment.~During the follow-up phase, 6 months after enrolment, SUNFRAIL tool and in-depth tests will be administered again. In addition, during the follow up, the extent to which exposure to interventions has influenced the quality of life of older adults will be measured and the number of users enrolled by territorial services, based on user care needs. In addition, the level of satisfaction and usability of the SUNFRAIL+ solution by health and social care professionals will be measured."
76086062|NCT05644132|Device|InDx Implant for the carpometacarpal joint|Treatment of thumb base joint arthritis with the InDx Implant
76086063|NCT05643027|Behavioral|Acceptance and Commitment Therapy|Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer
75647414|NCT04282538|Device|Active tDCS|4-week (5 days per week) active tDCS (2mA, DLPFC, 20 min)
75647415|NCT04282538|Device|Sham tDCS|4-week (5 days per week) sham tDCS
76086064|NCT05639270|Device|use of an auricular electrode|Use of the auricular electrode throughout the duration of the study (30minutes/day) combined with assessment of pain, tolerance, vagal tone.
76086065|NCT05633602|Drug|Chemotherapy|Receive standard of care chemotherapy
75647416|NCT04282538|Other|Walking training|4-week (5 days per week) walking training
75647417|NCT04282538|Other|Cognition training|4-week (5 days per week) cognition training
75337635|NCT00030992|Drug|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
75647418|NCT00958412|Drug|Proellex®|one (1) 25 mg capsule daily
75795061|NCT05712343|Other|Control group|The control group will receive placebo medication, three times a day for 3 days.
75795062|NCT05707130|Other|gaze stabilization exercises|patients will perform gaze stabilization exercise, Static neck exercise, and Habituation exercise. Neck isometric exercises like isometric flexion, extension, lateral bending will be performed.
75337636|NCT00030992|Drug|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
75337637|NCT00030992|Drug|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
75795063|NCT05707130|Other|neck isometrics|Patients in Conventional group will get neck isometric exercises like isometric flexion, extension, lateral bending.
75795064|NCT05704283|Device|Ultrasound Imaging|Undergo 3D-US
75473390|NCT01970098|Drug|KPS-0373, Low dose|28 weeks
75473391|NCT01970098|Drug|Placebo|28 weeks
75473392|NCT01970111|Drug|KPS-0373, High dose|
75473393|NCT01970111|Drug|KPS-0373, Low dose|
75647419|NCT00630500|Drug|Memantine|Tablets, 5 or 10 mg, twice daily
75647420|NCT00630500|Drug|Placebo|Tablets corresponding to 5 or 10 mg, twice daily, 6 months
75647421|NCT02860676|Drug|cirmtuzumab|cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
75795065|NCT05703425|Drug|Sulfasalazine|Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
75647422|NCT02858804|Drug|Etoposide|50 mg/m2, IV d1-4
75647423|NCT02858804|Drug|Doxorubicin|10 mg/m2, IV, d1-4
75647424|NCT02858804|Drug|Dexamethasone|30 mg/d, d1-5
75647425|NCT02858804|Drug|Vincristine|0.4 mg/m2, IV, d1-4
75647426|NCT02858804|Drug|Cyclophosphamide|750 mg/m2 ,d5
75647427|NCT02858804|Drug|Cytarabine|2g/m2, q12h, d1
75647428|NCT02858804|Drug|Cisplatin|100mg/ m2,IV, d1
75795066|NCT05701033|Other|Access to heritage|Unmediated access to heritage sites for wellbeing
75647429|NCT02858804|Drug|Rituximab|375 mg/m2 IV, d1
75647430|NCT02858804|Drug|Thalidomide|50-150mg/d, po, d1-28
75647431|NCT02858804|Drug|Prednisone|0.5mg/Kg, po, qod
75795067|NCT05693220|Device|Zymot Multi sperm separation device|Sperm preparation with Zymot Multi sperm preparation device
75932306|NCT03181542|Device|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
75932307|NCT00809679|Drug|T-62 Dose 1|Capsule dosage form 100 mg bid
75932308|NCT00809679|Drug|T-62 Dose 2|Capsule dosage form 200 mg bid
75932309|NCT00809679|Other|Placebo|Capsule dosage form placebo bid
75932310|NCT00884715|Drug|Octreotide|short acting octreotide
75932311|NCT03603080|Drug|Administration of weight loss drug (Metformin or Topiramate)|Patients in this arm will receive either Metformin (500 mg, twice per day) or Topiramate (50 mg, once per day) starting at 4 weeks after laparoscopic sleeve gastrectomy
76086066|NCT05633602|Biological|Pembrolizumab|Given IV
76086067|NCT05633602|Biological|Ramucirumab|Given IV
76086068|NCT05629780|Drug|Resuscitation fluid|Cristalloid fluids given as a resuscitational intervention
76086069|NCT05621044|Behavioral|FitBrothers smartphone active app|The FitBrothers smartphone active app is designed to assist African American men with adopting and maintaining PA. The app will be developed with significant input from African American men and contain self-monitoring, goal setting, reward, and educational components. The app will include additional elements including PA adoption strategies, competitions, incentives, health information, and greater compatibility with activity monitoring devices. The intervention is based on the Social Cognitive and Self-Determination theories and is culturally tailored.
76086070|NCT05621044|Behavioral|Nike Training Club|The app is designed to increase fitness in users through a variety of mechanisms. Users are able to track and monitor their physical activity level, set goals, engage in competitions, and upload activity data from a wearable. They will also be provided with preset workouts, receive guidance from an expert, and receive personalized plans that automatically adapt to user behavior.
75337638|NCT00032630|Procedure|Coronary artery bypass - on-pump|CABG procedure performed on heart lung machine
75337639|NCT00032630|Procedure|Coronary artery bypass - off-pump|CABG procedure performed without the use of the heart lung machine
75337640|NCT00005674|Drug|Creatine|
75337641|NCT00004360|Drug|chlorothiazide|
75337642|NCT00004378|Procedure|Stem Cell Transplantation|
75337643|NCT00385450|Drug|Nelfinavir/placebo|1250mg/twice each day/four days.
75337644|NCT00004390|Drug|desipramine|
75337645|NCT00004390|Drug|methadone|
75795068|NCT05693220|Other|Density gradient centrifugation|Sperm preparation with density gradient centrifugation
75795069|NCT05690503|Drug|CI-581a|Medication infusion intravenously over 90 minutes.
75795070|NCT05690503|Drug|CI-581b|Medication infusion intravenously over 90 minutes.
75337646|NCT00004390|Drug|morphine|
75337647|NCT00004390|Drug|nortriptyline|
75337648|NCT00004396|Drug|heme arginate|
75337649|NCT00004396|Drug|tin mesoporphyrin|
75795071|NCT05690451|Diagnostic Test|non-contrast abbreviated MRI|"Liver MRI without contrast injection. The following sequences will be obtained from all of the participants.~Axial heavily and regular T2 WI~precontrast fat-suppressed T1 WI~Diffusion-weighted image using b-value of 0, 50 or 400, and 800 or 1000"
75337650|NCT00004366|Procedure|Physical therapy|
75337651|NCT00004402|Drug|calcitriol|
75337652|NCT00004402|Drug|interferon gamma|
75337653|NCT00004408|Drug|poloxamer 188|
75337654|NCT00004414|Drug|sincalide|
75337655|NCT00004420|Drug|gamma-Linolenic acid|
75337656|NCT00004426|Drug|gonadotropin releasing hormone|
75337657|NCT00004426|Drug|leuprolide|
75337658|NCT00004438|Drug|leuprolide|
75337659|NCT01217749|Drug|PCI-32765|420 mg PO daily
75337660|NCT01217749|Drug|ofatumumab|per package insert as an IV infusion
75337661|NCT01217827|Behavioral|Clinical Reminder|
75337662|NCT02197273|Drug|Liposomal bupivacaine|
75795072|NCT05690451|Diagnostic Test|Contrast enhanced liver CT|"Liver CT with iodine contrast injection This test will be served as a standard diagnostic test. The following phases will be obtained~precontast, arterial phase, portal venous phase and delayed phase"
75795073|NCT05678309|Other|Blood samples|"At inclusion :~52.5 ml of blood :~24 ml plasma~20 ml serum~6 ml DNA~2.5 ml RNA"
75795074|NCT05678309|Other|skin swab sample|At inclusion a skin swab sample will be collected
75795075|NCT05678309|Other|skin biopsy sample|At inclusion a skin biopsy sample will be collected
75795076|NCT05678309|Other|Questionnaires|At inclusion, at 6 months and every year, the patient will respond to 5 questionnaires : Brest questionnaire, 5-D itch scale, Dermatology Life Quality Index, Itchy Quality of Life and Hospital Anxiety and Depression Scale
75337663|NCT02197273|Drug|Standard of care analgesia|
75337664|NCT00004444|Drug|paromomycin|
75337665|NCT00004444|Drug|streptomycin|
75337666|NCT00004450|Drug|glyceryl trierucate|
75337667|NCT00004450|Drug|glyceryl trioleate|
75337668|NCT00004450|Drug|interferon beta|
75337669|NCT00004450|Drug|thalidomide|
75337670|NCT01288027|Biological|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
75337671|NCT00004468|Drug|calcitriol|
75337672|NCT00005758|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
75337673|NCT00005758|Biological|HIV-1 Immunogen|
75337674|NCT01288807|Drug|Milnacipram|Titration to 200mg PO daily
75337675|NCT00005764|Drug|Lamivudine/Zidovudine|
75337676|NCT00005764|Drug|Abacavir sulfate|
75337677|NCT00005764|Drug|Lamivudine|
75337678|NCT01289275|Drug|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
75337679|NCT01289275|Behavioral|Telephone Counseling|Up to 5 proactive counseling sessions from California Smokers' Helpline.
75337680|NCT01289275|Behavioral|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
75337681|NCT00004474|Drug|Anti-thymocyte globulin|Given via IV over 4 hours
75337682|NCT00004474|Drug|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
75337683|NCT00004474|Procedure|Bone marrow transplantation|Given on Day 0
75337684|NCT01289431|Drug|Mapracorat|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
75795077|NCT05666141|Device|Pharyngeal Electrical Stimulation|"A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters."
75798981|NCT01588002|Drug|ritonavir|multiple oral doses
76086071|NCT05617742|Diagnostic Test|68Ga-FAPI-46|68Ga-FAPI-46 is a radioactive diagnostic agent for PET imaging in the detection of Fibroblast Activation Protein (FAP) positive tumor cells in cancer patients
76086072|NCT05605288|Procedure|Coronary angiography +/- percutaneous coronary intervention|Coronary angiography +/- percutaneous coronary intervention
75932312|NCT03126552|Biological|Necator americanus L3 larvae|50 Necator americanus L3 larvae
75932313|NCT01019187|Procedure|Quality-of-Life Assessment|Ancillary Studies
75932314|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
76086073|NCT05604040|Behavioral|Lifestyle Modifications|Home BP monitoring with self-monitoring of emotions, diet, physical activity, with shared medical appointment program for lifestyle changes and coping skills
76086074|NCT05601869|Device|UNYQ Prosthetic Ankle-Feet System|The UNYQ system includes a single prosthetic ankle joint that can be easily attached to 3D printed feet. The feet are designed to fit specifically within different footwear.
76086075|NCT05601440|Drug|RP-6306|Dose and schedule will be assigned at enrolment
75337685|NCT01289431|Drug|Vehicle|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
75337686|NCT00005770|Device|Acupuncture|
75647432|NCT02858648|Behavioral|Behavior intervention with smart phone based self-monitoring|Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies
75647433|NCT02858648|Behavioral|Behavior intervention with paper diary based self-monitoring|Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
75795078|NCT05666141|Other|Sham treatment|In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
75795079|NCT05664841|Behavioral|magic trick training|A typical session will begin with the magician demonstrating a magic trick then revealing the secret move of the trick.The participants will learn and practice each trick. With assistance from the magician, participants will develop an oralstory presentation for the trick. After participants master one trick, the magician will demonstrate and teach the next.
75795080|NCT05659355|Other|Constraint Induced Movement Therapy (CIMT)|I will apply CIMT on effected hand to observe the hand dexterity and grip strength
75795081|NCT05659355|Other|Mirror Therapy (MT)|I will apply Mirror Therapy on effected hand to obeserve the hand dexterity and grip strength
75795082|NCT05658133|Other|Survey of sports nutrition knowledge|Questionnaire
75795083|NCT05653180|Drug|IBI310|2mg/kg IV,3 weeks later, 1mg/kg IV Q6W
75337687|NCT00004480|Drug|botulinum toxin type A|
75337688|NCT01289665|Procedure|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
75337689|NCT01289665|Procedure|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
75647434|NCT00958256|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.
75795084|NCT05653180|Drug|sintilimab|200mg IV Q3W
75932315|NCT01019187|Other|Placebo|Given orally
75932316|NCT01019187|Procedure|Fatigue Assessment and Management|
75932317|NCT01019187|Procedure|Sleep Disorder Therapy|
75932318|NCT01019187|Drug|Armodafinil|Given orally
76086076|NCT05601440|Drug|Gemcitabine|Dose and schedule will be assigned at enrolment
75337690|NCT00004486|Drug|fluoxetine|
75337691|NCT00004492|Drug|clotrimazole|
75337692|NCT00004492|Drug|hydroxyurea|
75337693|NCT00005776|Drug|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
75337694|NCT00005776|Drug|Placebo|100% Oxygen
75337695|NCT00005782|Drug|Granulocyte colony-stimulating factor|
75337696|NCT00005782|Procedure|Leukapheresis|
75795085|NCT05649501|Other|Proprioceptive neuromuscular facilitation techniques.|Proprioceptive neuromuscular facilitation stretching which include hold-relax and contract-relax for 6 sec hold, 10 repetitions and 2 min rest in between, for 5 day/week for 4 weeks along with conventional treatment for 40 minutes.
75932319|NCT01019187|Procedure|Quality-of-life assessment|Ancillary studies
75932320|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
75932321|NCT01019187|Procedure|Fatigue Assessment and Management|
75932322|NCT01019187|Procedure|Management of Therapy|
75932323|NCT01019187|Procedure|Sleep disorder therapy|
75932324|NCT01019187|Procedure|cognitive assessment|
75932325|NCT01019187|Procedure|Quality of Life assessment|Ancillary Studies
75932326|NCT01019187|Other|Questionnaire Administration|Ancillary studies
75932327|NCT01019187|Other|Placebo|Given orally
75932328|NCT01019187|Procedure|Fatigue assessment and management|
75932329|NCT01019187|Procedure|Management of therapy and complications|
75932330|NCT01019187|Procedure|Sleep disorder therapy|
75932331|NCT01019187|Drug|Armodafinil|Given orally
75932332|NCT01019187|Procedure|Cognitive Assessment|
76086077|NCT05601440|Other|Observation|Monitoring arm
76086078|NCT05601440|Drug|Niraparib|Dose and schedule will be assigned at enrolment
76086079|NCT05601440|Drug|Fulvestrant|Dose and schedule will be assigned at enrolment
76086080|NCT05599295|Drug|Oritavancin|Oritavancin for IV infusion
76086081|NCT05598580|Drug|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy.
76086082|NCT05598580|Drug|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
76086083|NCT05597280|Drug|BE-PEP Bedaquiline|bedaquiline
76086084|NCT05597280|Drug|SDR-PEP Rifampicin|SDR-PEP: rifampicin
76086085|NCT05597280|Drug|BE-PEP Rifampicin|BE-PEP rifampicin
75337697|NCT01290913|Drug|Omalizumab|Omalizumab is an antibody that helps decrease allergic responses in the body
75337698|NCT01267045|Behavioral|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
75932333|NCT01019187|Procedure|Quality of Life Assessment|Quality of Life Assessment
76086086|NCT05596175|Behavioral|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise, nutritional support and optimisation of AF-related clinical risk factors.
76086087|NCT05593965|Device|Delta-beta TMS|TMS will be delivered in a delta-beta pattern in which triplets of pulses delivered at 20 Hz (50 milliseconds between each pulse) are sent every 3 Hz (333 milliseconds between the start of each triplet).
75795086|NCT05649501|Other|Traditional physical therapy|Conventional therapy (ROMs, stretching, strengthening) of lower limbs for 40 minutes.
75647435|NCT00958256|Drug|Rituximab|375 mg/m^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.
75647436|NCT00958256|Drug|Cyclophosphamide|300 mg/m^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
75337699|NCT00004498|Genetic|Adenoviral Vector-Mediated Gene Transfer|
75795087|NCT05647863|Other|Functional Cognitive and Sensory Treatment (F-CaST)|F-CaST, a client-centered care, is a functional cognitive sensory intervention focusing on improving Executive Function (EF) and sensory modulation impairments using a modification of the Functional and Cognitive Occupational Therapy Treatment.
75795088|NCT05627180|Behavioral|Tailored Health Literacy follow-up in cancer|"Participants are invited to a consultation with the project nurse where the project nurse will use baseline data to identify the patient's HL needs, QOL, symptom burden and issues related to self-management of their cancer and treatment. These data will be used together with an interview questionnaire specifically developed to communicate HL needs (i.e. CHAT), which form the basis for the individualized HL support.~Actions: Based on results of the consultation, the project nurse and the patient will use a worksheet of possible actions to identify those most relevant to the patient's individual needs. Based on this, different self-management tasks and actions will be offered, and an individual tailored follow-up plan will be made. The patient and the project nurse will use a workbook containing information on the follow-up plan that will be added into medical record.~Telephone/digital conversations with the project every second month for a period of 9 months."
75795089|NCT05626361|Other|Dysphagia training|Training using PowerPoint and simulation. Training includes anatomy physiology, screening and management sections. Simulation will be used for practice. Reading material will also be provided
75795090|NCT05626361|Other|Reading material|Reading material provided to nurses covering knowledge related to nursing evaluation and caring for dysphagia patients
75795091|NCT05624606|Biological|Quadrivalent Influenza mRNA Vaccine MRT5410|Pharmaceutical form: Liquid frozen solution for injection in a vial Route of administration: Intramuscular
75932334|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
76086088|NCT05593965|Device|Theta-gamma TMS|TMS will be delivered in a theta-gamma pattern in which triplets of pulses delivered at 50 Hz (20 milliseconds between each pulse) are sent every 5 Hz (200 milliseconds between the start of each triplet).
76086089|NCT05593965|Device|Arrhythmic TMS|TMS will be delivered in an arrhythmic pattern in which pulses are delivered with a random inter-pulse interval. The number of pulses and duration is matched to that of the Delta-beta TMS and Theta-gamma TMS.
75647437|NCT00958256|Drug|Mesna|600 mg/m^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.
75647438|NCT00958256|Drug|G-CSF|5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
75932335|NCT01019187|Procedure|Fatifue assessment and management|
75337700|NCT00004552|Drug|acamprosate (Campral)|
75337701|NCT00101660|Drug|Dasatinib|Tablets; oral; 70 mg BID, depending on response
75337702|NCT01267279|Drug|Zoledronic acid|Zoledronic acid per protocol
75337703|NCT01267279|Other|Placebo|Placebo
75337704|NCT00005794|Drug|perifosine|
75337705|NCT00004558|Behavioral|dietary n-3 polyunsaturated fatty acids|
75337706|NCT00005800|Biological|Filgrastim|
75337707|NCT00005800|Drug|Docetaxel|
75647439|NCT02860442|Behavioral|Smartphone brief intervention (SP-BI)|"Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan."
75647440|NCT02860442|Other|Enhanced Usual Care (EUC)|Those assigned to EUC will receive an informational brochure with resources available to members of the military related to mental health and alcohol use. They will be contacted to complete 4-, 8-, and 12-month follow-up assessments.
75932336|NCT02464514|Other|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
75932337|NCT02464514|Other|High fat meal|58% fat, 17% protein, and 25% carbohydrate
75337708|NCT00005800|Drug|Doxorubicin|
75473394|NCT01970124|Drug|KPS-0373, High dose|
75473395|NCT01970124|Drug|KPS-0373, Low dose|
75932338|NCT05084508|Biological|Investigational varicella vaccine low potency|1 dose of a low-potency investigational varicella vaccine administered subcutaneously in the upper arm
75932339|NCT05084508|Biological|Investigational varicella vaccine medium potency|1 dose of a medium-potency investigational varicella vaccine administered subcutaneously in the upper arm
75647441|NCT00696709|Biological|Comparator: V212|0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered ~30 days apart
75337709|NCT00005800|Procedure|Surgery|Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
75932340|NCT05084508|Biological|Investigational varicella vaccine high potency|1 dose of a high-potency investigational varicella vaccine administered subcutaneously in the upper arm
75932341|NCT05084508|Biological|Marketed varicella vaccine Lot 1|1 dose of a marketed varicella vaccine of Lot 1 administered subcutaneously in the upper arm
75932342|NCT05084508|Biological|Marketed varicella vaccine Lot 2|1 dose of a marketed varicella vaccine of Lot 2 administered subcutaneously in the upper arm
75932343|NCT05084508|Biological|Measles, mumps, and rubella vaccine|1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm
75932344|NCT05084508|Biological|Hepatitis A vaccine|1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh
76086090|NCT05593757|Drug|Quinidine|Oral quinidine
76086091|NCT05593757|Drug|Verapamil|Oral verapamil
75337710|NCT00004564|Drug|Clopidogrel|
75473396|NCT01970137|Drug|KPS-0373, High dose|
75473397|NCT01970137|Drug|KPS-0373, Low dose|
75647442|NCT00696709|Biological|Comparator: Placebo|Placebo; 4-dose regimen administered ~30 days apart.
75647443|NCT01006265|Drug|ACT-128800 Dose 1|ACT-128800 (Dose 1) administered orally once daily
75795092|NCT05624606|Biological|Quadrivalent Recombinant Influenza vaccine RIV4|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
76086092|NCT05586451|Behavioral|Traditional High Load Resistance Exercise (HLRE)|Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.
75337711|NCT00004564|Drug|Atorvastatin|
75337712|NCT00386386|Other|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
75795093|NCT05624606|Biological|Quadrivalent Inactivated Influenza Standard Dose QIV-SD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
75795094|NCT05624606|Biological|Quadrivalent Inactivated Influenza High Dose QIV-HD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
75795095|NCT05615545|Procedure|Cryoablation|Cryoablation of selected tumor lesions
75795096|NCT05591027|Drug|Centella asiatica product|A sachet of powdered product containing 4 g of a dried hot water extract of Centella asiatica as the active ingredient, combined with inactive ingredients (excipients) for color and taste dissolved in 10 oz of warm or room temperature water and consumed orally.
76086093|NCT05586451|Behavioral|Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)|Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
75337713|NCT00385528|Behavioral|Multi-faceted psychiatric intervention|
75337714|NCT01268527|Drug|0.03% E6201|Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
75337715|NCT01268527|Drug|0.1% E6201|Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
75337716|NCT01268527|Drug|0.2% E6201|Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
75473398|NCT01970150|Device|rTMS real|
75473399|NCT01970163|Other|DermACELL|Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).
75473400|NCT01970163|Other|GraftJacket|Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).
75647444|NCT01006265|Drug|Placebo|Matching placebo administered orally once daily
75647445|NCT01006265|Drug|ACT-128800 Dose 2|ACT-128800 (Dose 2) administered orally once daily
75647446|NCT01006265|Drug|ACT-128800 Dose 3|ACT-128800 (Dose 3) administered orally once daily
75473401|NCT01970163|Other|Conventional Care Dressings|"Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing:~If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound.~Hydrogels can also be used if the wound is in need of moisture.~For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration.~A secondary dressing may be desired to add either loft or cushion."
75795097|NCT05591027|Drug|Placebo|A sachet of powdered inactive ingredients (excipients) for color and taste identical in volume to those found in the active arm (CAP) dissolved in 10 oz of warm or room temperature water and consumed orally.
75337717|NCT01268527|Drug|0.005% E6201|Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
75795098|NCT05588648|Drug|Vactosertib|Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.
75795099|NCT05580796|Drug|KSH01 injection|TCR-T cell injection
75795100|NCT05571267|Drug|Zimura|Zimura 2 mg, administered by intravitreal injection
75795101|NCT05571267|Drug|Avastin|Avastin 1.25 mg, administered by intravitreal injection
75795102|NCT05571267|Drug|Lucentis|Lucentis 0.5 mg, administered by intravitreal injection
75932345|NCT05084508|Biological|13-valent pneumococcal conjugate vaccine|1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh
75795103|NCT05571267|Drug|Eylea|Eylea 2 mg, administered by intravitreal injection
75795104|NCT05568472|Other|Best Practice|Standard of care hormone therapy and standard visit with clinician
75647447|NCT04280120|Other|Neural Mobilisation|Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest.
75795105|NCT05568472|Procedure|Biospecimen Collection|Undergo correlative studies
75932346|NCT01018875|Drug|ABT-288|Subjects will take 4 capsules once daily for 12 weeks.
75647448|NCT04280120|Other|Massage therapy|Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.
75647449|NCT04280120|Diagnostic Test|Faradic electrical stimulation|Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.
75647450|NCT04280120|Other|Exercises|Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes.
75647451|NCT02861690|Drug|Liposomal Paclitaxel|Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
75647452|NCT02861690|Drug|Nedaplatin|Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
75473402|NCT01970202|Drug|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
76086094|NCT05586451|Behavioral|Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)|Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
75337718|NCT01268527|Drug|0.01% E6201|Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
75337719|NCT01268527|Drug|0.05% E6201|Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
75337720|NCT01268527|Other|Placebo - 0.03% gel vehicle|Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
75337721|NCT01268527|Other|Placebo - 0.1% gel vehicle|Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
75473403|NCT01970202|Drug|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
75473404|NCT01970202|Other|Control|no treatment
75473405|NCT01970215|Drug|TA-8995|
75473406|NCT01970215|Drug|Atorvastatin|
75473407|NCT01970215|Drug|Rosuvastatin|
75473408|NCT01970215|Drug|TA-8995 0mg (placebo)|
75473409|NCT01970215|Drug|Placebo Statin|
75795106|NCT05568472|Procedure|Endocrine Drug Therapy|Undergo endocrine therapy
75795107|NCT05568472|Behavioral|Health Education|Receive list of websites
75795108|NCT05568472|Other|Questionnaire Administration|Ancillary studies
75795109|NCT05568472|Other|Symptom Specific Assessment Tool|Receive a weblink via email or text message and asked 6 brief questions about symptoms
75795110|NCT05550194|Drug|ValACYclovir 1000 MG|Valacyclcovir is a targeted anti-viral for varicella zoster virus (VZV).
75795111|NCT05550194|Biological|Shingrix|Vaccine indicated for prevention of herpes zoster
75795112|NCT05547217|Device|Hand Therapy using the MyHand System|The MyHandTM System is a smart-mechatronic device programmed with proprietary hand function training regiments (protocols) based on deep research in neuroplasticity. It provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy. Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
75795113|NCT05545579|Other|circuit trainng|Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes. The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
75798982|NCT01291212|Drug|Testosterone and FSHr-LHr|75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
75932347|NCT01018875|Drug|donepezil|Subjects will take 4 capsules once daily for 12 weeks.
75932348|NCT01018875|Drug|placebo|Subjects will take 4 capsules once daily for 12 weeks.
75932349|NCT01018173|Drug|placebo|sc weekly
75932350|NCT01018173|Drug|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
75932351|NCT04453956|Diagnostic Test|Colonoscopy with the assistance of EndoAngel's polyp detection function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.
75473410|NCT01970228|Diagnostic Test|68Ga-citrate and 18F-FDG PET/CT imaging|Single-day study of the two PET tracers
75473411|NCT01970267|Procedure|Laser Ablation of Floaters|
75647453|NCT02565745|Combination Product|Skin dressing|Pre-determined skin areas at risk for PUs (3 or more, depending on the prevaliing body position, prone, supine or Sims') will be covered. Dressings will be changed every 6-7 days unless found wet/contaminated
75932352|NCT04453956|Diagnostic Test|Colonoscopy with the assistance of EndoAngel's quality monitoring function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.
75337722|NCT01268527|Other|Placebo - 0.2% gel vehicle|Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
75932353|NCT04453956|Diagnostic Test|Colonoscopy without the assistance of EndoAngel's any function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's both functions.
75932354|NCT03271190|Behavioral|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills (21 hours), leisure activities (music lessons or Spanish lessons) (27 hours), selected videogames to practice variable attention strategies (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by a trained therapist for formal sessions and a professional music or Spanish teacher for leisure sessions.
75795114|NCT05545579|Other|trunk stabilization techniques|The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
75337723|NCT01268527|Other|Placebo - 0.05% gel vehicle|Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
75647454|NCT02565745|Other|Moisturizing cream|It will be applied twice a day to the same skin areas as the experimental group
75647455|NCT04281836|Behavioral|Interoceptive breathing awareness through use of audio and visual virtual technology aid|Participants are asked to focus on their breathing while (a) listening to their breathing sounds with headphones and (b) watching the 3-D image of their lungs inhaling and exhaling in real-time using the Oculus Rift 3D virtual imaging equipment and plethysmography belt. During this time fNIRS and tQST data will be collected (more detail provided below).
75647456|NCT04281836|Behavioral|Interoceptive breathing awareness without use of audio or visual virtual reality|Participants are asked to focus on their breathing. During this time fNIRS and tQST data will be collected (more detail provided below).
75647457|NCT02858882|Other|Screening|Screening of elite swimmers
75795115|NCT05539833|Drug|KSH01 injection|TCR-T cell injection
75647458|NCT02565121|Drug|corticosteroids|
75647459|NCT02565121|Behavioral|olfactory stimulation|stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
75647460|NCT05141552|Drug|Dapagliflozin 10Mg Tab|In both group, subjects keep blood purification and anti heart failure treatment, including ARNI, RASi, Aldosterone inhibitors and beta receptor blocker.
75647461|NCT02564107|Drug|Ibandronate|Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
75647462|NCT04297475|Diagnostic Test|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld 3D PA/US probe, and able to provide 3D volume data of dual-wavelength PA imaging of small joints, in addition to real-time 2D PA/US imaging.
75647463|NCT00628667|Drug|Esomeprazole|40mg orally twice daily
75795116|NCT05532709|Other|Plyometric training|m level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps
75932355|NCT03271190|Behavioral|ENGAGE DISCOVERY|Educational content about brain and healthy aging (21 hours), leisure activities (watching documentaries followed by group discussion and debate) (27 hours), selected non-stimulating videogames (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by the same trained therapist as in the ENGAGE arm.
75932356|NCT04155450|Other|Extension Biased External Limb Loading Exercises|"Begin in the quadruped position and progress the intensity by~Flexing one upper extremity~Extending one lower extremity with a leg slide~Extending one lower extremity by lifting it off the mat~Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~Progress to prone position:~Extending one lower extremity~Extending both lower extremity"
75932357|NCT04155450|Other|McKenzie Extension Exercise Protocol|"Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
75932358|NCT04155450|Other|Moist Heat|Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
75337724|NCT01268527|Other|Placebo - 0.01% gel vehicle|Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
75337725|NCT01268527|Other|Placebo - 0.05% gel vehicle|Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
75337726|NCT01268527|Drug|Calcipotriene|Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
75647464|NCT00628667|Drug|Placebo|
75647465|NCT04281758|Other|Beverage|16 oz (473.2 ml)
75647466|NCT00743353|Drug|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
75647467|NCT02858258|Drug|R-CHOP/R-DHAP|Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
75932359|NCT04455204|Diagnostic Test|Serum asymmetteric dimethyl arginine|Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay
75337727|NCT00005806|Drug|carboplatin|
75337728|NCT00005806|Drug|gefitinib|
75337729|NCT00005806|Drug|paclitaxel|
75932360|NCT04455204|Diagnostic Test|serum lipid profiles|serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits
75932361|NCT04455204|Diagnostic Test|Serum vaspin|vaspin concentrations will be assayed using commercially available ELISA kits
75647468|NCT02858258|Drug|Ibrutinib (Induction)|Ibrutinib: only in cycle 1,3,5 on Day 1-19
75647469|NCT02858258|Drug|ASCT conditioning|"ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)"
75647470|NCT02858258|Drug|Ibrutinib (Maintenance)|Ibrutinib (Maintenance), daily 560 mg for 2 years;
75647471|NCT02564185|Other|Usual practice|
75647472|NCT02564185|Other|Education program|
75795117|NCT05532709|Other|Circuit training|"The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes."
75932362|NCT04455204|Diagnostic Test|Serum resistin|resistin concentrations will be assayed using commercially available ELISA kits
75795118|NCT05518864|Device|IALURIL Prefill|GAG therapy (bladder instillations with glycosaminoglycans)
75795119|NCT05515237|Behavioral|Grade 2-5 CI Therapy + Sensory Components|All participants will receive CI Therapy + Sensory Components over a 2-3 weeks time frame. The treatment intervention will apply all CI Therapy treatment components to include: 1) a behavioral set of techniques called the Transfer Package (TP) to promote carry-over of skills that were gained in the laboratory into the participant's life situation, 2) the use of motor training called shaping to make progress in small approximations 3) the use by the participant of a mitt on the less-affected hand to encourage use of the more-affected hand and 4) home skills and home work will be provided each day for at least 30 minutes. Sensory component training strategies will be added to stimulate sensory input through the more-affected arm an dhand as well as to train sensory discrimination skills.
75795120|NCT05512312|Procedure|Conventional Esthetic crown lengthening|Conventional Surgical Esthetic Crown Lengthening
75795121|NCT05512312|Procedure|Computer guided Esthetic crown lengthening|Computer guided Esthetic crown lengthening
75795122|NCT05477459|Drug|LSD tartrate|LSD tartrate equivalent to 25 microgram LSD base
75795123|NCT05477459|Drug|Placebo|Placebo vials with equal appearance
75795124|NCT05469841|Other|Systemic pain assessment|Pain will be evaluated via i) pupillometry with 3 successive measurements ii) Behaviour Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT) score evaluated by an investigator (physician) iii) evolution of physiological parameters (ie heart rate, blood pressure, respiratory rate) iv) Nociception Level Index (NOL) index.
75795125|NCT05461001|Other|Warm Up Exercises|The daily warm up exercises for male football players include full body stretch, high knees, lunges, squat and burpees.
75795126|NCT05461001|Other|Endurance Based Exercises|Sport-specific endurance-running (duration [in minutes], total distance [in meters], mean speed [in meters per minute], high-speed running >15 km·h-1, and relative high-speed running [>75% and >85% of maximal velocity]) will be given to the experimental group. Athletes will run in excess of 15 km of total distance (TD) and 4 km of high-speed (>15 km·h-1) distance per session 3 to 4 running-based endurance sessions per week for 6 weeks.
75795127|NCT05437406|Behavioral|Parent-based treatment- All caregivers (PBT-AC)|PBT-AC provides all the elements of FBT, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
75337730|NCT04351789|Other|Psychoeducational intervention|"The written and verbal information provided at discharge to patients in the intervention arm will consist of:~An explanation of the normal recovery period after hospitalization due to COVID-19. What can the patient expect physically, psychologically and emotionally, and what coping mechanism might be appropriate Social support in the recovery period and how this can be used constructively. In case of worsening of symptoms - physically or psychologically, where can the patient get help after discharge from hospital.~These points are based on crisis psychology, enhancing the patients empowerment and self-management after discharge from hospital."
75337731|NCT00004576|Drug|LY300164|
75337732|NCT00005812|Drug|temozolomide|
75647473|NCT01008995|Drug|placebo|Subcutaneous injection at Week 0 and 4
75647474|NCT01008995|Drug|ustekinumab|45 mg subcutaneous injection at Week 12 and 16
75647475|NCT01008995|Drug|placebo|Subcutaneous injection at Week 12
75647476|NCT01008995|Drug|ustekinumab|45 mg subcutaneous injection at Week 0, 4 and 16
75795128|NCT05437406|Behavioral|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
75932363|NCT00806403|Drug|reteplase 10+10 U|comparison to primary PCI
75337733|NCT01270555|Drug|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
75337734|NCT00004582|Drug|Lopinavir/Ritonavir|
75647477|NCT04295993|Drug|Methylene Blue|The patient will receive Methylene Blue bolus with a dose of 2 mg/kg over 10 minutes.
75647478|NCT04295993|Drug|Norepinephrine infusion|The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg
75647479|NCT00743587|Drug|Placebo|Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
75647480|NCT00743587|Drug|Oxycodone|Oral, 1 x 20mg controlled-release tablets
75647481|NCT00743587|Drug|Tramadol|Oral, 2 x 50mg immediate release capsules
75647482|NCT00743587|Drug|Naproxen|Oral, 1 x 500mg enteric-coated
75795129|NCT05426486|Drug|ARX788|HER2 antibody-drug conjugate
75795130|NCT05426486|Drug|Pyrotinib maleate|EGFR/HER2 dual inhibitor
75795131|NCT05426486|Drug|Trastuzumab|anti-Her2 monoclonal antibody
75932364|NCT00806403|Procedure|primary PCI|comparison to thrombolysis
75795132|NCT05426486|Drug|Pertuzumab|anti-HER2 monoclonal antibody
75932365|NCT04852874|Procedure|Ultrasound-guided Quadratus Lumborum Block|"Low dose spinal anesthesia will be done at L3-4 lumbar vertebrae with bupivacaine 2.5 mg (0.5 ml Marcaine 0.5%) and fentanyl 25 µgm (0.5 ml) of fentanyl amp (100 µgm/ 2ml) to be added to 1.5 - 2 ml of free water to form total volume of 2.5- 3ml according to the patient height aiming level of T6 sensory level.~Quadratus lumorum block:~After 4 to 5 minutes, ultrasound guided quadratus lumborum block (QL 1,2,3) will be done unilaterally, using low-frequency convex probe, taking into consideration the total volume of injectate not exceeding 0.4 ml /kg of (bupivacaine 0.5%) to avoid local anesthesia systemic toxicity. This is equal to 0.8 ml/kg of (bupivacaine 0.25%).~After confirming the correct position of the needle, 0.2-3 ml/kg of 0.25% bupivacaine plus 1.5 mg dexamethasone and magnesium sulphate of 100 mg will be injected in each site of the QL 1,2,3 using the lean body weight. The lean body weight will be calculated by omni lean body mass online calculator."
75932366|NCT04076280|Behavioral|Sodium Watcher Program-Hypertension|The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education [4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.
75647483|NCT04205123|Genetic|sickle cell syndrome|"Academic Study prospective multicenter observational factors responsible for nephropathy in patients with sickle cell disease followed by Belgium and the Nord-Pas -De- Calais Region and creating a biobank of blood and urine.~In the population of patients with SCD followed in all participating centres.~Know the prevalence of nephropathy and the relationship between it with their some of their genotypic mutations and clinical phenotype promoting mutated hemoglobin polymerization.~Determine the behaviour of dense cells in the basal state and in a hypeosmolaire environment~Determine the place of the erythrocyte microparticles as a biomarker of sickle cell nephropathy~Studying genes known as risk factor for proteinuria~Create a BioBank of samples of sickle cell patients in clinically stable condition for other research purposes."
75795133|NCT05426486|Drug|Docetaxel|Cytotoxic chemotherapy
75795134|NCT05426486|Drug|Carboplatin|Cytotoxic chemotherapy
75795135|NCT05412134|Device|Pro2 - 75% of participant's MIP|"Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP."
75932367|NCT04076280|Behavioral|Usual Care|Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
75932368|NCT05399940|Diagnostic Test|Serum PSA,Delta Neutrophil Index(DNI),WBC|Urine culture, prostate volume
75932369|NCT02465294|Dietary Supplement|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
75932370|NCT02465294|Behavioral|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
75932371|NCT02465294|Other|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
75932372|NCT02465294|Other|Blood Test|All subjects will have blood tests performed.
75795136|NCT05412134|Device|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
75932373|NCT02465294|Dietary Supplement|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
75473412|NCT01970267|Procedure|Sham Laser Treatment|Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
75795137|NCT05404971|Other|Joint integrity exercises|patients with three strokes followed by 3 sec rest period. Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set.
75798983|NCT01291212|Drug|testosterone and FSHr alone|FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
75798984|NCT01291290|Procedure|Platelet|2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
75795138|NCT05404971|Other|Mirror therapy|A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
75647484|NCT04190251|Other|Inteprofessional medication adherence support program (IMAP)|In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.
75932374|NCT05390658|Other|Not application|Not application
75795139|NCT05404646|Other|Thoracic mobility exercises with conventional physical therapy for cervical radiculopathy|Thoracic mobility exercises These techniques include mobilization, manipulation and glides to check and treat the joints. Here, these techniques will be used to mobilize the thoracic spine. In this treatment mobility exercises (Unilateral posterior anterior, Central posterior anterior and transverse glides) + hot pack (10 min) + neck stretching (neck flexors, extensors, side benders) + cervical Traction will be given to patient. A total session time will be 45 min and thrice a week on alternate days for three weeks.
75932375|NCT00883311|Device|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
75932376|NCT02464982|Procedure|Tattoo|tattoo device with EC standards, and sterile single-use only needle
75932377|NCT05390424|Diagnostic Test|Blood collection using Dried Blood Spot|Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
75932378|NCT00802425|Drug|AM-111|single intratympanic injection
75932379|NCT00802425|Drug|placebo|single intratympanic injection
75337735|NCT00004582|Drug|Efavirenz|
76086095|NCT05586087|Other|Experimental group|The High-Speed Resistance Training program has 16 weeks, with three sessions per week with 50-60min, each session being comprised of five-six exercises, two-three sets, and six-ten reps/exercise. The intensity is gradually increased after each session in accordance with the movement velocity (>1.3 to 0.75 m/s) representing approximately 20% to 60% of one repetition maximum. Participants execute the exercises rapidly and explosively making all repetitions for each shortening phase (concentric phase) performed as quickly as possible with the lengthening phase of the muscle (eccentric phase) being controlled for 2-3 s. The velocity of the concentric phase in each exercise is monitored through a BEAST™ sensor (Beast Technologies, Brescia, Italy).
75473413|NCT01970280|Drug|Enoxaparin|
75473414|NCT01970293|Other|Introduction to AA volunteer|In-person, in jail introduction to an AA volunteer, who will offer assistance in attending 2 AA meetings.
75473415|NCT01970358|Biological|Poly-ICLC|
75647485|NCT00957944|Drug|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours
75473416|NCT01970358|Biological|Peptides|
75473417|NCT01970384|Device|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
75932380|NCT02464358|Behavioral|IMB Intervention Group|Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
75647486|NCT02871323|Biological|Durvalumab|Given IV
75647487|NCT02871323|Other|Laboratory Biomarker Analysis|Correlative studies
75647488|NCT04296149|Drug|Y90-DOTA-Tyr3-Octreotide|Patients enrolled for surgery will receive a small amount of Y-90-DOTATOC, in order to check beta- radioactivity by the probe
75932381|NCT02464358|Behavioral|Attention Control|Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
75337736|NCT01270711|Drug|Study Drug|non interventional study - usage as per usual care
75647489|NCT02861612|Procedure|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
75337737|NCT00004642|Drug|SDZ MSL-109|
75337738|NCT01340053|Drug|RDX5791|Capsule, QD
75337739|NCT00004654|Drug|soy protein isolate|
75337740|NCT00004660|Radiation|Radiotherapy|
75337741|NCT00004660|Radiation|Sham treatment|
75337742|NCT00004690|Drug|monolaurin cream|
75337743|NCT01270867|Device|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
75337744|NCT00004696|Drug|morphine|
75473418|NCT01970384|Device|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
75473419|NCT01970423|Device|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
75647490|NCT01005875|Drug|Sorafenib|Nexavar in bottles of 120 tables
75647491|NCT01005875|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT
75337745|NCT00004744|Drug|immune globulin|
75473420|NCT01970423|Device|conventional right ventricular stimulation|
75473421|NCT01970436|Other|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
75795140|NCT05404646|Other|Thoracic stretching exercises with conventional physical therapy for cervical radiculopathy|Thoracic stretching exercises Thoracic stretching exercises. Thoracic stretching exercises are used to correct the musculature of thoracic region. In this treatment group stretching exercises (passive stretches and therapist facilitated exercises) +hot pack (10 min) +neck stretching (neck flexors, extensors, side benders) + tractions will be given to patient. A total of 45 min session thrice a week on alternate days for three weeks will be given. Only the eligible patients who fulfil the inclusion criteria will be included in the study.
75795141|NCT05399290|Drug|Doxycycline Hyclate|100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
75795142|NCT05395078|Other|Conventional physical therapy treatment along with thoracic extension exercises|"Thoracic Extension Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic spine extension and trunk muscle flexibility. A specialized program of thoracic extension in sitting, in prone lying, in quadruped position, on foam roller, wall angle stretch, corner stretch + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks.~Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week."
75795143|NCT05395078|Other|Conventional physical therapy treatment along with thoracic stabilization exercises|Thoracic Stabilization Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic musculature, static and dynamic thoracic posture. A specialized program of Draw- in and chin tucks in crook lying, prone, sitting and standing, prone chin- tuck elevation exercises with arm at sides, arms behind head or overhead (4) + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week.
75795144|NCT05393960|Other|Lumbosacral manual therapy mobilization, lumber mobility exercises and home based self strechings program.|Manual therapy, mobility exercise therapy and a home-based self-stretching program. Manual mobilization postero-anterior glides at lumber facets joints, Transverse glides at spinous process & Posterior-anterior glides at SI joint. Glides will be performed 3 times with 5 repetitions. Mobility exercise therapy.
75798985|NCT01182168|Drug|gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)|Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
75932382|NCT05399862|Dietary Supplement|Lactobacillus reuteri DSM 17648 probiotic|Lactobacillus reuteri DSM 17648 is a single-strain probiotic used as adjunct treatment in H.pylori infection
75932383|NCT05399862|Other|Placebo|Placebo capsule with no microbial cell preparation
75932384|NCT00802347|Drug|I5NP|"Single IV injection of I5NP~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
75932385|NCT00802347|Drug|Saline|"Single IV injection of saline~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
75932386|NCT02464280|Other|Tomosythesis scan of the lung or the wrist|All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
75932387|NCT02464280|Other|CT scan of the lung or the wrist|All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
76086096|NCT05573867|Other|Physical activity on prescription|"All participants, regardless of group affiliation, receive routine written and verbal information about PSF and information about recommended level of physical activity. Intervention group receive as add on individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke."
76086097|NCT05569941|Drug|ABI-4334 Tablet|ABI-4334 Tablet
76086098|NCT05569941|Drug|ABI-4334 Placebo|Placebo to ABI-4334 Tablet
76086099|NCT05567393|Drug|TAK-951 Placebo|TAK-951 placebo-matching SC injection
76086100|NCT05567393|Drug|TAK-951|TAK-951 SC injection
76086101|NCT05563181|Behavioral|Control bar code label|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
75337746|NCT01271413|Behavioral|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
75337747|NCT03009565|Other|coronary artery disease|
75473422|NCT01970449|Biological|DNA Nat-B env vaccine|The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
75473423|NCT01970449|Biological|NYVAC Nat-B env vaccine|NVYAC Nat-B env vaccine will be administered as a 3 × 10^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
75337748|NCT01292005|Drug|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
75337749|NCT01292005|Drug|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
75473424|NCT01970449|Biological|DNA CON-S env vaccine|The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
75473425|NCT01970449|Biological|NYVAC CON-S env vaccine|NVYAC CON-S env vaccine will be administered as a 3 × 10^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
75932388|NCT02464280|Other|conventional X-ray of the lung or the wrist|All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
75795145|NCT05393960|Other|home based self strechings program only.|Home based self-stretching program includes 3 repetitions of 15 seconds duration stretch (with 20 seconds rest between each repetition). Repeat stretching exercises twice a day for 3 alternate days for 1 week. Piriformis stretch: in supine crook lying, placing the lateral side of the foot over the contralateral knee and pulling towards the chest with the hands. Quadriceps stretch: stand on your left leg, one knee touching the other, hold a chair or the wall to keep you steady if needed, grab your right foot, using your right hand, and pull it towards your butt. Hamstring stretch: To stretch the right leg, sit on the ground with the left leg bent at the knee with the foot facing inward. This is called the butterfly position. Extend the right leg, keeping it slightly bent at the knee. Bend forward at the waist, making sure to keep the back straight.
76086102|NCT05563181|Behavioral|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
76086103|NCT05563181|Behavioral|Informational campaign poster about added-sugar warning labels|Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
75795146|NCT05393323|Other|conventional physical therapy with distraction technique|Distraction will be at suboccipital level and patients will ask to assume a supine position with the head on the plinth. The therapist will use fingertips in both hands from digits 2 through 5, and cups the suboccipital region of the patient and supports the posterior skull. The therapist provides a light distraction to the posterior skull. Distraction will be applied for 10 min with pull for 10 sec and5 sec will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 minute with total intervention period of 4 weeks with 5 sessions per week.
75932389|NCT04253444|Behavioral|slow deep breathing|Participants in this arm will be asked to do slow deep breathing (4 seconds inhalation and 6 seconds exhalation) for 10 minutes twice a day during the study period.
76086104|NCT05562713|Behavioral|Present Bias without Loss Aversion|Small prize for each step completed; large prize for independent CIC
76086105|NCT05562713|Behavioral|Present Bias with Loss Aversion|Prizes only if fully independent CIC demonstrated
76086106|NCT05562310|Drug|Total parenteral nutrition (TPN). This is total nutrition provided by central vein.|phenylalanine, methionine and histidine intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
76086107|NCT05561790|Behavioral|eCBT-I|Automated digital administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy modules via mobile or web application, lasting approximately six weeks.
76086108|NCT05560607|Drug|AZD7503 Intervention|"Part A: Participants will be screened for histologic evidence of NAFLD or NASH and all eligibility criteria in part A prior to enrollment in part B.~Part B: Participants consented to part B will be administered the study drug over the course of 31 days. At the end of the study a liver biopsy will be collected to measure for endpoints."
75337750|NCT00004756|Procedure|Tailored educational program|
75337751|NCT00004756|Procedure|Educational materials|
75337752|NCT00004762|Drug|cladribine|
75337753|NCT01292629|Device|iSert 251 intraocular lens|aphakic intraocular lens
75337754|NCT00004786|Drug|iloprost|
75932390|NCT04253444|Behavioral|sham breathing|Participants in this arm will be asked to do sham breathing for 10 minutes twice a day during the study period.
75337755|NCT01272583|Drug|Sitagliptin|100 mg once daily for six weeks
75337756|NCT01272583|Drug|Placebo|placebo, once daily for six weeks
75337757|NCT00004804|Drug|interferon alfa|
75337758|NCT00386074|Drug|NaFeEDTA, Electrolytic Iron|
75932391|NCT01912950|Device|Prowave LX IPL|
75932392|NCT03134391|Drug|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
75473426|NCT01970449|Biological|DNA Mosaic env vaccine|The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
75473427|NCT01970449|Biological|NYVAC Mosaic env vaccine|NVYAC Mosaic env vaccine will be administered as a 3 × 10^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
75337759|NCT00004810|Drug|-aminosalicylic acid|
75337760|NCT00004816|Drug|monoclonal antibody M-T412|
75337761|NCT01341301|Radiation|Total Body Irradiation|Undergo TBI
75337762|NCT01341301|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
75337763|NCT01341301|Drug|Cyclophosphamide|Given IV
75337764|NCT01341301|Drug|Tacrolimus|Given IV or PO
75337765|NCT01341301|Drug|Mycophenolate mofetil|Given IV or PO
75337766|NCT01341301|Procedure|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
75337767|NCT01341301|Other|Laboratory biomarker analysis|Correlative studies
75337768|NCT01342471|Behavioral|TV commercial stepping|"Participants were instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
75337769|NCT01342471|Behavioral|30-min walk|"Participants were instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
75473428|NCT01970449|Biological|Placebo|Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
75795147|NCT05393323|Other|conventional physical therapy with traction technique|In cervical traction, patients will ask to lie supine on the treatment table. Head will cradle by physiotherapist from chin and the occiput, and then the physiotherapist will apply traction force in 25 degree neck flexion. Traction will be applied for 10 minutes with pull for 10 sec and 5 sec rest will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 min with total intervention period of 4 weeks with 5 sessions per week. All outcome measurements will be assessed before treatment and then reassessed at the end of 4th week.
75795148|NCT05392517|Other|self-mobilization technique along with conventional therapy|"Group A will be treated with self-mobilization technique of thoracic spine with the frequency of 2 sets of 10 repetitions thrice per week for a total of six weeks and conventional treatment.~Self-mobilization technique will be comprised of self-mobilization technique using tennis balls and foam roller. The participant will be supine with knees in 90-degree flexion.~Mobilization Technique 1: Cross your arms over your chest so that you are in slight flexion and then slowly begin to move your shoulders and head closer to the floor placing the mid back into extension over the balls joined to make mobilization device. Hold this position for 3 seconds and then return to the flexed position.~Mobilization Technique 2: Lying lengthwise on the foam roller, clasp your hands together in front of you, above your chest with arms straight. Slowly move your arms above your head until you feel a good stretch. This exercise should be pain free. Hold stretch for 30- 60 seconds."
75795149|NCT05392517|Other|conventional therapy|Group B will be treated with the conventional treatment (heating pad, ultrasound, thoracic strengthening exercises
75795150|NCT05392036|Other|baseline physical therapy treatment along with shockwave therapy|Group A, this group will receive conventional therapies along with shockwave therapy. Basic treatment includes icing (15-20 min) to control inflammation, rest, cessation of pain causing activity, anti-inflammatory (NSAIDs) and basic stretching and strengthening exercises. Shockwave therapy is a non-invasive therapeutic modality with convenience, effectiveness and safety. It is used to treat various musculoskeletal disorders without surgery. A session of 30-45 min will include icing 15 min and 5-10 min of shock wave therapy session will be commenced with strengthening and stretching exercises.
75795151|NCT05392036|Other|baseline physical therapy treatment along with therapeutic ultrasound|"This group will receive therapeutic ultrasound along with conventional treatment. Conventional therapy includes icing, rest, anti-inflammatory drugs, and basic strengthening and stretching exercises. A session of 30-45 min will include icing for 10-15 min therapeutic ultrasound 15min with a frequency 1-3MHz and the session will be ended with strengthening and stretching exercises.~Only eligible patients who have fulfilled the inclusion criteria will be included. A daily session of 30-45min for 2 consecutive weeks will be given. A baseline assessment will be done and the patient will be allocated randomly to both groups for two weeks. Re-assessment will be done after 2 weeks. For long term, effects re-assessment will be done after 6 weeks"
75795152|NCT05392023|Other|Relaxation Exercises and Scapular Stabilization exercise program|Scapular Stabilization Program (3 sets of 10 reps each/day). This exercise program is for muscles affecting scapular alignment due to chronic neck pain. A specialized program of non-resistive scapular upward rotation, wall facing arm lift, backward rolling arm lift, overhead arm raise, shoulder abduction in scapular plane above 120˚, shoulder shrugs, levator scapulae and pectoralis minor stretching. Hot pack (10 min) and relaxation exercises including myofascial release and stretching of neck and scapular region muscles. A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long-term effects at the end of 6th week.
75795153|NCT05392023|Other|Relaxation Exercises of cervico- scapular region|Relaxation exercises of the cervico-scapular region including neck stretches of scapular muscles and myofascial release will be given to patients three times a week on alternate days for 3 weeks. Assessment will be done at baseline, at the end of the 3rd week, and for long-term effects at the end of the 6th week.
75795154|NCT05389852|Drug|Dexmedetomidine|After completion of supraclavicular brachial plexus block patients will receive intravenous dexmedetomidine 1 mcg/kg
75795155|NCT05386914|Drug|Sirolimus|1 mg of Sirolimus taken orally once a day for 4 weeks.
75795156|NCT05382754|Diagnostic Test|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
75795157|NCT05382754|Diagnostic Test|In-lab polysomnography|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
75473429|NCT01970449|Device|Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)|All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
75647492|NCT04296929|Other|Complex Decongestive Physiotherapy|Complete decongestive therapy (CDT), also called complex decongestive therapy, is an intensive program that combines many of the different treatment approaches, including bandaging, compression garments, manual lymphatic drainage, exercise, and self care.
75647493|NCT02701088|Drug|5Fluorouracile and Mitomycin-C|All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
75337770|NCT01273207|Drug|Cyclosporine Inhalation Solution (CIS)|CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
75647494|NCT02701088|Radiation|Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy|SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
75647495|NCT04060225|Other|Coffee|Starbuck's brand blonde roast coffee, 20 ounces
75647496|NCT04279106|Procedure|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
75647497|NCT04279106|Procedure|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
75647498|NCT04279106|Procedure|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
75932393|NCT02463968|Procedure|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
75932394|NCT02463968|Procedure|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
75932395|NCT05399394|Drug|Chemotherapy|The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
75932396|NCT05399394|Radiation|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by the Clinical Target Volume (CTV) with a safety margin to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied through cone-beam computed tomography systems (CBCT) for all patients to evaluate the precision of the set-up.
75932397|NCT05399316|Dietary Supplement|Inulin|Natural fiber supplement extracted from chicory
75795158|NCT05379231|Other|BiCROS fitting|Each participant will be fitted with the experimental CROS device on the unaidable ear and with a compatible hearing aid on the other ear.
75932398|NCT05399316|Dietary Supplement|Maltodextrin|Natural non-fermentable sugar
75932399|NCT05399238|Device|The objective is to measure the temperature of the lingual dorsum|Subjects will make one visit to our clinic with burning mouth syndrome and control healthy . They will be asked to acclimate to room temperature for at least 20 minutes. Subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations.
75932400|NCT01007721|Drug|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
75932401|NCT01007721|Drug|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
75932402|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
75647499|NCT04279106|Procedure|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
75647500|NCT00743743|Dietary Supplement|Longevinex brand resveratrol supplement|1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient
75647501|NCT00743743|Dietary Supplement|placebo|1 capsule of placebo daily for 52 weeks
75647502|NCT02641496|Behavioral|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
75647503|NCT02641496|Behavioral|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
75795159|NCT05379231|Other|Monaural hearing aid fitting|"Each participant will be fitted with a hearing aid on the better hearing ear and no device on the unaidable ear.~Monaural hearing aid fitting acts as control intervention."
75795160|NCT05379231|Other|Unaided condition|"No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.~Unaided condition acts as control intervention."
75932403|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
75932404|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
75932405|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
75932406|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
75932407|NCT01007721|Drug|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
76086109|NCT05560113|Other|Continuous theta burst stimulation (cTBS)|cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
75647504|NCT01005719|Drug|Zegerid|Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
75647505|NCT01005719|Drug|Prevacid®|Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
75647506|NCT00630578|Behavioral|Cognitive Processing Therapy|Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
75795161|NCT05363488|Drug|Bosutinib|Patients receiving bosutinib treatment
75932408|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
75647507|NCT02858102|Behavioral|Physical activity program|The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
75647508|NCT02856854|Drug|EMB-001|EMB-001 is a combination of metyrapone (720mg per dose in this study) and oxazepam (24mg per dose in this study)
75932409|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
75932410|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
75932411|NCT01007721|Drug|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
75932412|NCT01007721|Drug|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
75932413|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
75647509|NCT02856854|Drug|Placebo|EMB-001 matched placebo
75795162|NCT05355181|Other|Scar mobilization techniques|"Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges."
75932414|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
75932415|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
75932416|NCT01007721|Drug|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
75932417|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
75932418|NCT01007721|Drug|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
75647510|NCT02856854|Drug|Cocaine IV|Cocaine administered at doses of 20 and 40mg
75647511|NCT02856854|Drug|Saline IV|Cocaine matched placebo
75795163|NCT05355181|Other|Core stabilization exercises|Core stabilization exercises
75647512|NCT00921583|Device|Long-term examination|Follow-up dental implants 20 year in function
75647513|NCT04088383|Other|Amnios™ RT|Acellular human allograft
75647514|NCT04088383|Other|Saline|Sterile saline
75795164|NCT05352828|Drug|Nivolumab|Dose: 480 mg or 6 mg/kg Q4W
75795165|NCT05352828|Drug|Autologous CD30.CAR-T|Dose: 2 x 10e8 cells/m2
75795166|NCT05352828|Drug|Fludarabine|Dose: 30 mg/m2/day x 3 days
75795167|NCT05352828|Drug|Bendamustine|Dose: 70 mg/m2/day x 3 days
75795168|NCT05347251|Other|Cervicothoracic mobility program|"Participants in this group will receive mobilization at a cervical and thoracic level along with conventional physical therapy protocol like Hot packs and exercise therapy.~At the cervical, PA glides (central) and transverse glides will be given for mobilization.~At thoracic, PA glides (central) and transverse glides will be given for mobilization.~Exercise therapy includes stretching and strengthening both cervical and thoracic muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck~stretching exercises (flexors, extensors, side benders~and rotators) will perform as well. Similarly, at the thoracic~level, strengthening and stretching of thoracic muscle will be performed"
75932419|NCT01007721|Drug|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
75932420|NCT00701558|Drug|Erlotinib|150 mg po daily
75932421|NCT00701558|Drug|Gemcitabine|1000 mg/m^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
75932422|NCT04832958|Drug|99m-TC-PSMA-I&S|"99mTc-PSMA-I&S intravenous injection the day before surgery~99mTc-PSMA-I&S SPECT/CT imaging~99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations"
76086110|NCT05560113|Other|Sham continuous theta burst stimulation (cTBS)|This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
76086111|NCT05556434|Diagnostic Test|radiological evaluation|"All patients undergoing hepatectomy receive imaging evaluation and laboratory test before and after surgery to define clinical parameters.~diseases"
76086112|NCT05548283|Drug|Beta-lactam antibiotic|Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
76086113|NCT05548283|Drug|Aminoglycoside|Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
76086114|NCT05547672|Device|UroMems artificial urinary sphincter|Implantation of the device
75647515|NCT02857166|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
75647516|NCT04297085|Biological|Biologic sample|Biological samples will be taken from the subjects included
75647517|NCT04061005|Procedure|Cold snare polypectomy|CSP, which does not include electrocautery to do a polypectomy with a snare.
75647518|NCT04061005|Procedure|Hot snare polypectomy|HSP, which uses the electrocautery to do a polypectomy with a snare.
75932423|NCT03233828|Biological|Aldesleukin|500,000 IU in 0.1mL
75932424|NCT03233828|Other|Saline|0.1 mL of sterile saline solution (0.9% m/v)
75932425|NCT04454814|Other|Protaper Universal instruments|Root canal treatment using Protaper Universal instruments
75932426|NCT04454814|Other|Reciproc Blue instruments|Root canal treatment using Reciproc Blue instruments
75647519|NCT04061005|Procedure|Endoscopic margin observation method|Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.
75647520|NCT02856932|Other|Conventional high viscosity glass ionomer|Dental restorative material
75647521|NCT02856932|Other|Glass ionomer with glass hybrid technology|Dental restorative material
75932427|NCT03882177|Drug|Pravastatin|Tablets, administered orally
75932428|NCT03882177|Drug|Rifafour|Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
75932429|NCT03882177|Dietary Supplement|Vitamin B6|Administered orally.
75932430|NCT01007097|Drug|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
75932431|NCT01007097|Drug|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
75932432|NCT01007097|Drug|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
75932433|NCT01007097|Drug|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
75932434|NCT01007097|Drug|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
75795169|NCT05347251|Other|Conventional Treatment|"It will be the control group. The participants who will be allocated in this group receive the only conventional physical therapy protocol (Hot pack and exercise therapy). Exercise therapy includes stretching and strengthening of neck and upper back muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck stretching exercises (flexors,~extensors, side benders, and rotators) will perform~as well. Similarly at the thoracic level, strengthening and stretching of thoracic muscle will be performed."
75795170|NCT05318248|Drug|Clonidin|0,15mg Clonidin orally versus placebo pill
75932435|NCT01007097|Drug|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
75337771|NCT02195713|Device|Accuryn|Accuryn is a novel electronic urine output monitor
75337772|NCT01342549|Drug|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
75337773|NCT01342549|Drug|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
75795171|NCT05318248|Drug|Placebo|placebo pill
75795172|NCT05306249|Drug|CBD LGP 50|Patients will receive CBD LGP 50 at a dose of 1 mg/kg twice a day in the form of oil dispensed through a graduated pipette until the end of week 12.
75795173|NCT05306249|Drug|Placebo|Patients will receive the MCT oil placebo without CBD until the end of week 12.
75795174|NCT05299658|Drug|CNMAu8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
75795175|NCT05298930|Other|Physical activity program|"The supervised sessions will be offered 4 times a week in the participants' rooms by the APA teachers and will include moderate intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient will also be able to perform unsupervised sessions (on their own), following the advice given by the APA teacher. These unsupervised sessions can be done independently on the bike.~In order to encourage patients to perform these unsupervised sessions, patients and their relatives will be given a connected device and will have access to a mobile application developed by the Kiplin company, which offers connected physical activity games to be performed in teams (from 2 to 4 participants). These games, lasting from 1 to 3 weeks, use the participants' daily PA level as a unit of animation and are punctuated by challenges."
75932436|NCT01007097|Drug|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
75337774|NCT01343095|Device|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
75337775|NCT01343095|Device|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
75337776|NCT01343485|Behavioral|Computer reminder system|Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
75795176|NCT05298397|Other|EAT-PTSD adapted for youth for anxiety|"This is an eight session (90 minute sessions) weekly experiential group treatment. The first session includes psychoeducation, orientation to treatment, a barn tour, and ends with meeting the horses. Subsequent sessions involve increasingly complex encounters and interactions with horses accompanied by feedback and direction from the treatment. Early phase treatment exercises acquaint patients with the horse, with grooming exercises, leading with a rope or a wand, and directing the horse. The middle phase furthers patients' mastery and comfort with the horse in individual and teamwork exercises. The final session includes a graduation ceremony. All intervention sessions begin with Opening Circle and end with Closing Circle. Opening Circle incorporates a grounding exercise and is orients participants to the session to check in regarding thoughts and feelings. Closing Circle reviews lessons learned during the session, eliciting participant feedback and facilitating discussion."
75932437|NCT02461082|Device|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
75932438|NCT02461082|Other|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
75337777|NCT01345513|Other|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
75337778|NCT01294267|Device|Circulatory Support System|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
75337779|NCT01276171|Procedure|Ultrasound|Participants will place arterial line using ultrasound technique
75932439|NCT01663402|Drug|Alirocumab|Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
75932440|NCT01663402|Drug|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
75337780|NCT01276171|Procedure|Doppler|Participants will place arterial line using doppler technique
75337781|NCT01276171|Procedure|Palpation|Participants will place arterial line using Palpation technique
75337782|NCT01346683|Device|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
75337783|NCT01295515|Drug|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
75337784|NCT03008941|Biological|FMT|Capsules with fecal microbiota from healthy donors
75337785|NCT03008941|Other|Placebo|Placebo capsules
75337786|NCT01277341|Drug|Bepotastine Besilate Nasal Spray 2% Twice a day|nasal spray
75337787|NCT01277341|Drug|Bepotastine Besilate Nasal Spray 3% Twice a day|nasal spray
75337788|NCT01277341|Drug|Bepotastine Besilate Nasal Spray 4% Twice a day|nasal spray
75337789|NCT01277341|Drug|Placebo Nasal Spray|nasal spray
75795177|NCT05260034|Other|FAST Program|This program aims to teach how to effectively reduce impact forces during a sideways fall by 1) changing the trunk/knee angles during descent to decrease body acceleration, 2) using a rolling movement to allow for an optimal distribution of impact forces applied to any site along the contact path; and 3) tucking the chin to protect the head.
75795178|NCT05260034|Other|Otago Exercise Program|The Otago Exercise Program (OEP) was chosen, rather than no control intervention, to increase the level of evidence required to demonstrate efficacy, and because, similar to the safe fall training used here, it was designed to be performed individually or in small groups.
75932441|NCT01663402|Drug|LMT|Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
75337790|NCT01346839|Behavioral|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
75337791|NCT04769635|Device|CPAP therapy|All studied patients were received CPAP therapy with average cumulative adherence ⩾4 h/day of >70% nights [380] obtained from device download with AHI<5 /hr
75337792|NCT04351477|Device|Massage chair|Mechanical massage chair
75647522|NCT02564965|Device|Double Pigtail Plastic Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
75337793|NCT00101816|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
75337794|NCT00102518|Drug|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
75795179|NCT05240209|Other|The researcher will give training to the training group about skin cancer, skin self-examination and sun protection behaviors.|Materials used in education; Colorful brochures on the subject will be given to reinforce the slide show and post-training information.
75795180|NCT05219266|Drug|midostaurin|Patients receive midostaurin
75795181|NCT05204862|Drug|TU2218|orally administered
75337795|NCT02090894|Device|UV Light (Laser Genesis)|
75337796|NCT00103376|Drug|Velcade|"Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break"
75337797|NCT00103376|Drug|LH-RH Agonist|given as a 3 month depo-injection
75337798|NCT00103376|Drug|Androgen Receptor Antagonists|given orally daily for 3 months
75337799|NCT00042224|Procedure|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
75337800|NCT00042224|Drug|Clozapine|Patients with psychotic symptoms will receive clozapine
75337801|NCT01296763|Drug|Irinotecan|Irinotecan 70 mg/m2 IV, Days 1 and 8
75337802|NCT01296763|Drug|Cisplatin|Cisplatin 25 mg/m2 IV, Days 1 and 8
75337803|NCT01296763|Drug|Olaparib (for levels 1 and 5)|Olaparib 100 mg bid oral, Days 1 and 8
75337804|NCT01296763|Drug|Olaparib (for dose level 2)|Olaparib 100mg bid oral, Day 1-3, Day 8-10
75473430|NCT01970514|Device|ARO Spinal System|The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
75647523|NCT02564965|Device|AXIOS Metal Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
75647524|NCT02701153|Procedure|Conventional Surgery|Undergo surgery
75647525|NCT02701153|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
75647526|NCT02701153|Other|Laboratory Biomarker Analysis|Correlative studies
75647527|NCT02701153|Other|Questionnaire Administration|Ancillary studies
75647528|NCT02563951|Drug|GNS Spray 0.5mg|
75647529|NCT02563951|Drug|GNS Spray 1.0mg|
75647530|NCT02563951|Drug|GNS Spray 2.0mg|
75647531|NCT02563951|Drug|Kytril 1mg (IV injection)|
75337805|NCT01296763|Drug|Mitomycin-C|Mitomycin 5 mg/m2 IV, Day 1
75337806|NCT01347541|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
75473431|NCT01970553|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
75473432|NCT01970553|Drug|Gemcitabine|1000 mg vial, powder for injectable solution
75473433|NCT01970566|Other|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
75473434|NCT01970566|Other|Behavioral|Intense Exercise/Moderate Calorie Restriction
75473435|NCT01970566|Other|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
75473436|NCT01970566|Other|Behavioral|Intense Exercise/Moderate Calorie Restriction
75647532|NCT02563951|Drug|Kytril 1mg (Tablet)|
75795182|NCT05204862|Drug|Anti-PD-1 antibody|Intravenously administered
75795183|NCT05203965|Drug|Mavoglurant (AFQ056)|Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.
75795184|NCT05203965|Drug|Placebo|Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.
75795185|NCT05203380|Drug|dupilumab|Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)
75932442|NCT04454892|Other|Amyotrophic lateral sclerosis|AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3
75932443|NCT03223298|Drug|Botulinum toxin type A|37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
75932444|NCT03223298|Drug|0.9% Sodium Chloride Injection|1cc syringe
75473437|NCT01970579|Device|Paclitaxel coated balloon|"Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD~Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~If two treatment balloons are necessary overlap between the balloon must be 10 mm~Inflation pressure 7-10 atm~Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting"
75932445|NCT05399160|Behavioral|Nurse-led Supportive Care|Nurse-led supportive care was given to women who had breast surgery and planned to receive chemotherapy. Nurse-led supportive care was applied to women for eight weeks in the form of face-to-face clinic and telephone interviews.It took an average of 30 minutes to interview women with breast cancer at the clinic, and 15 minutes on average by phone.
75932446|NCT05390346|Behavioral|Nutrition education|The intervention programs consist of nutrition monitoring and diet intervention.
75932447|NCT03297086|Procedure|cataract surgery|cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
76086115|NCT05540210|Device|measurement of PSP|one or two blood samples
75647533|NCT00743899|Procedure|The aggressive group|Stents were implanted in lesions with diameter stenosis >50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis >50% and RD ≥2.0 mm and <2.25 mm.
75647534|NCT00743899|Procedure|The conservative group|Stenting was performed only in lesions with diameter stenosis >70% and reference diameter (RD) ≥2.25 mm
75647535|NCT00953576|Drug|ketoconazole|
75932448|NCT00869661|Drug|Copegus|1000/1200mg po daily for 24 or 48 weeks
75932449|NCT00869661|Drug|Copegus|1000/1200mg po daily for 48 weeks
75932450|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
75932451|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 48 weeks
75932452|NCT00869661|Drug|RO5024048|1000mg bid for 24 weeks
75932453|NCT00869661|Drug|RO5024048|500mg bid for 12 weeks
75932454|NCT00869661|Drug|RO5024048|1000mg bid for 8 weeks
76086116|NCT05539196|Device|Exablate Pallidotomy, Unilateral|Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.
76086117|NCT05532618|Procedure|Adductor canal block|Before anterior cruciate ligament surgery an adductor canal block will be placed using ultrasound.
76086118|NCT05532618|Drug|Levobupivacaine|Levobupivacaine
76086119|NCT05532618|Drug|Placebo|10 ml of sodium chloride 0.9%
76086120|NCT05530304|Device|Triple inner branched arch stentgraft|New findings regarding treatment planning and management of patients with aortic arch pathologies.
75647536|NCT00953576|Drug|hydrocortisone|
75647537|NCT00953576|Drug|dutasteride|
75647538|NCT00953576|Drug|lapatinib|
75647539|NCT00743977|Drug|Phenazopyridine HCl|100mg tablet in fasting state
75932455|NCT00869661|Drug|RO5024048|1000mg bid for 12 weeks
75932456|NCT03192566|Drug|Tylenol|Dosing of Tylenol for post operative pain control
75932457|NCT04455984|Other|Date collection|Retrospective data analysis
75932458|NCT03297008|Other|No internvetion|No intervention, this is an observational study
76086121|NCT05527704|Drug|salbutamol|Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
75337807|NCT01347541|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
75337808|NCT01347541|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
75647540|NCT02565823|Other|Exercise bout|Participants will exercise for 45min at 75% of VO2peak
75647541|NCT02857088|Behavioral|olfactory assessment|determination of olfactory sensitivity through olfactory threshold assessment (butanol) determination of hedonicity and intensity of 16 usual odors
75647542|NCT02857088|Behavioral|image visualization|20 images (from the IAPS-international affective picture systems) are presented to the subject. He has to determine the hedonicity of each picture.
75647543|NCT02857088|Behavioral|psychophysiological assessment|during the olfaction assessment and the image visualization, skin conductance reactivity (SCR) is recorded to assess unconscious emotional reactivity
75932459|NCT03296930|Drug|Sofosbuvir 400 MG Oral Tablet,|Interferon free direct acting antiviral drugs used for treatment of HCV.
75932460|NCT03296930|Drug|Ombitasvir/paritaprevir/ritonavir|Interferon free direct acting antiviral drugs used for treatment of HCV.
75932461|NCT04605510|Other|Passive Cervical Joint Mobilization|It will be applied to the cervical spine, whose dysfunction is detected as a result of the evaluation. The participant will be in the prone position and Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied for 3 sets, 30 seconds, to the segment to be treated.
75932462|NCT05563545|Biological|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m2 (D-5~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m2 (D-5~D-3), determined by tumor burden at baseline.
75932463|NCT04607772|Drug|Selinexor|Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
75932464|NCT04607772|Drug|Rituximab|Dose: 375 mg/m^2
75932465|NCT04607772|Drug|Bendamustine|Dose: 90 mg/m^2
76086122|NCT05527704|Drug|0,9% Chloride Sodium|3 mL nebulized 0.9% NaCl administered for 30 min.
76086123|NCT05526222|Drug|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
76086124|NCT05523856|Procedure|Active Surveillance|It consists on monitoring the cancer with regular tests including PSA, blood test and digital rectal examination every 6 months, a magnetic resonance imaging and prostate biopsy at the first year, and based on clinical decision thereafter. If there was a change on the results, the patient is considered for treatment.
75932466|NCT04607772|Drug|Polatuzumab Vedotin|Dose: 1.8 mg/kg
75932467|NCT04607772|Drug|Ibrutinib|Dose: 420, 560 mg
75932468|NCT04607772|Drug|Lenalidomide|Dose: 20, 25 mg
75932469|NCT04607772|Drug|Tafasitamab|Dose: 12 mg/kg
75932470|NCT04607772|Drug|Venetoclax|Dose: 200, 400, 600, 800 mg
75932471|NCT04607772|Drug|Gemcitabine|Dose: 1000 mg/m^2
75932472|NCT04607772|Drug|Oxaliplatin|Dose: 100 mg/m^2
75932473|NCT03296852|Diagnostic Test|SONAS Ultrasound Device|To assess a baseline value, ultrasound will be transmitted following an automated protocol to increase subsequently the output voltage from 5 volts to 50 volts. At each voltage step the received signals will be acquired and stored. Once the maximum output voltage of 50 Volts has been reached an additional 10 ultrasound pulses will be transmitted and the received data acquired. The total duration of this first data acquisition is 20 seconds. Following the IV bolus injection of Lumason™, ultrasound will be transmitted and received signals acquired following the same protocol as before.
75932474|NCT03296852|Drug|Lumason|An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
76086125|NCT05523856|Procedure|Robot-Assisted Radical Prostatectomy|It consists on the removal of the prostate gland and seminal vesicles with neurovascular preservation whenever anatomically and oncologically possible, with the Da Vinci procedure. Access is made through 5 or 6 small incisions, less than 1 cm. An extended pelvic lymph node dissection is performed when the risk estimation of node involvement is above the 5%. After surgery, the patient will be hospitalized for about 3 days and will probably resume his work activity between 3 and 5 weeks.
75337809|NCT01347541|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
75337810|NCT01296841|Device|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
75647544|NCT02563873|Device|Tailored pacemaker settings|Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
75647545|NCT00744133|Biological|NF54 P. falciparum isolate|1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
75932475|NCT02464124|Drug|Nitazoxanide|• Nitazoxanide dosing: 500 mg tablets twice daily
75932476|NCT02464124|Drug|Lactulose|• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
76086126|NCT05523856|Radiation|Intensity-Modulated Radiotherapy|Patients in this group undergo volumetric modulated arc therapy under daily image-guided radiation therapy in the supine position. Radiation is delivered in 2-3 Gy daily fractions, 5 days per week, with a prescription dose of 60-70 Gy to the prostate.
76086127|NCT05523856|Radiation|Real-time brachytherapy|Patients in this group receive I125 permanent seeds (low dose rate). The images are obtained with a transrectal ultrasound probe and are transferred to a planning system for calculating the number and position of the seeds. The prescrption dose is 145 Gy to the reference isodose (100%).
76086128|NCT05520476|Device|Neuroliten MVP system|The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.
75337811|NCT01349491|Drug|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
75337812|NCT01349491|Drug|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
75647546|NCT01005329|Biological|Bevacizumab|Given IV
75647547|NCT01005329|Drug|Carboplatin|Given IV
75647548|NCT01005329|Drug|Cisplatin|Given IV
75647549|NCT01005329|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75647550|NCT01005329|Drug|Paclitaxel|Given IV
75647551|NCT00921349|Procedure|Ligation of varices|all varices are ligated until obliteration
75647552|NCT00921349|Drug|Nadolol|Nadolol (beta-blocker)
75647553|NCT02857010|Biological|Allogenic mesenchymal stem cells|Cell therapy
75647554|NCT02857010|Other|Placebo|Serum without stem cells
75647555|NCT01005251|Drug|lesogaberan (AZD3355)|60 mg, oral, capsules, bid for 4 w
75647556|NCT01005251|Drug|lesogaberan (AZD3355)|120 mg, oral, capsules, bid for 4 w
75932477|NCT00859521|Drug|Levetiracetam|1000 mg Tablet
75932478|NCT00859521|Drug|Keppra®|1000 mg Tablet
75932479|NCT04455672|Device|splints|"Scaning of the maxillary and mandibular cast in the centric relation.~The CAD/ CAM splints will be designed using Exocad s.~The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~All patient will be asked to wear their spints during sleeping only.~In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months ."
75932480|NCT02463890|Other|Training|
75932481|NCT02463890|Other|Control|
75932482|NCT05390268|Behavioral|Mobile app-assisted behavioral treatment|"The app-assisted training group have access to a newly developed app in which they are taught how to handle tics. A new app session is released at each new treatment session and the content of the app videos is comparable to the information and training at face-to-face individual treatment, as defined by the manual Niks to Tics["
75932483|NCT05398770|Dietary Supplement|Vitamin D supplementation (30 µg/d)|The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
75932484|NCT04649775|Device|AirFLO2|Mask device
75932485|NCT05398692|Other|Virtual vs On Site Pulmonary Rehabilitation|As part of the on site or virtual visits, the subject will receive standard pulmonary rehabilitation educational instruction on balance and strength training, stretching, nutrition, hydration, pacing, proper breathing, small or mini-lectures, and information on relaxation techniques. If post exertional malaise is present, the patient will only receive the educational sessions, no aerobic training.
75932486|NCT03130374|Biological|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
75932487|NCT04159454|Device|PITA|Patients will have PITA turned on to patients' existing Medtronic devices, such that patients will be RV-paced from midnight to 6 AM each night at a rate ~10 beats per minute (BPM) above patients' baseline heart rates during this time period as determined by Holter monitors.
75932488|NCT00843687|Drug|Risperidone long-acting injectable|
75932489|NCT03176004|Other|Attention Bias Modification|A computer game is used to facilitate attention away from threatening words.
75932490|NCT04642131|Dietary Supplement|Caffeine supplementation|Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.
75932491|NCT04642131|Device|Personalized insoles|Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine
75932492|NCT04642131|Other|Control condition|Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
75932493|NCT05390190|Device|Non ablative radiofrequency|Device
75647557|NCT01005251|Drug|lesogaberan (AZD3355)|180 mg, oral, capsules, bid for 4 w
75932494|NCT02866526|Other|Patient questionnaire|quantitative and qualitative data collection will be proposed.
75932495|NCT05398614|Biological|SENL101|Patients will be treated with CD7 CAR-T cells
76086129|NCT05518669|Device|Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)|Subjects with biopsy of peripheral pulmonary nodule using electromagnetic navigation bronchoscopy and mobile cone-beam CT.
76086130|NCT05517837|Drug|BMS-986421|Specified dose on specified days
75647558|NCT01005251|Drug|lesogaberan (AZD3355)|240 mg, oral, capsules, bid for 4 w
75647559|NCT01005251|Drug|Placebo|oral,capsules, bid for 4 w
75647560|NCT03048578|Drug|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
75647561|NCT03048578|Drug|Placebo|Subcutaneous Saline Solution
75647562|NCT04295369|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep, stress management, and Chinese dietary recommendations.
75647563|NCT02856464|Other|DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)|
75647564|NCT02856464|Other|DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice|
75647565|NCT02858414|Other|additional blood sample|
75647566|NCT02856776|Dietary Supplement|Vitamin D3|Vitamin D provided in capsule form
75647567|NCT04296851|Drug|Niclosamide|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
75932496|NCT05398458|Procedure|Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap|By this procedure it has helped in reduction and complete resolution of the lymphocele with no recurrence in the past 2 years
75932497|NCT01001715|Drug|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
75932498|NCT01001715|Drug|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
75932499|NCT04473729|Other|Audiovisual speech training in noise for children|Children will participate in listening training in the form of an iPad app
75932500|NCT02463812|Drug|Intralipid|
75932501|NCT02463812|Drug|Saline|
75932502|NCT00789633|Drug|Masitinib|Masitinib at 9 mg/kg/day given orally twice daily
75932503|NCT00789633|Drug|Placebo|Matching placebo given orally twice daily
75932504|NCT00789633|Drug|Gemcitabine|Gemcitabine at 1000 mg/m2 by intravenous infusion
75932505|NCT04460040|Behavioral|Exercise training|"The first phase of the study will comprise two weeks of control phase when participants will not engage in any exercise training but will be monitored for total daily energy expenditure and its components (REE, SMR, and DIT) and assessed volume of metabolic organs and skeletal muscle efficiency.~Next, participants will start the active phase. In the first two weeks, participants will perform 150 - 200 min/week of a moderate intensity exercise so that they can adapt to the new regime and avoid injury. All exercise training will be monitored using heart rate sensor (HR) to track exercise adherence and HR range goals. Changes in daily non-exercise physical activity and sedentary behavior will be assessed for 10 days pre- and post-intervention by a tri-axial accelerometer. All study participants will be instructed to consume their habitual diet and to maintain the same caloric intake."
75932506|NCT02463188|Behavioral|Sleep Fitness Intervention|The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
75932507|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
75932508|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
75932509|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
75932510|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
75932511|NCT00788541|Other|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
75932512|NCT03296618|Drug|NSI-566|Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
75932513|NCT03296540|Drug|Prasugrel (Crushed tablets)|loading dose of 6 crushed tablets 10mg Prasugrel
75932514|NCT03296540|Drug|Prasugrel (Integral tablets)|loading dose of 6 integral tablets of 10mg Prasugrel
76086131|NCT05517837|Other|Placebo|Specified dose on specified days
75932515|NCT00787059|Drug|Ad5.hAC6|Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10^9 vp to 10^12 vp in 5 dose groups
75337813|NCT01298167|Device|Cyanoacrylate tissue glue versus Fast absorbing gut|All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
75647568|NCT04296851|Drug|placebo|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
75473438|NCT01970579|Device|uncoated PTA catheter|"Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD~Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~If two treatment balloons are necessary overlap between the balloon must be 10 mm~Inflation pressure 7-10 atm~Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting."
75473439|NCT01970605|Procedure|Surgical reconstruction|"In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.~Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.~Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible."
75337814|NCT01280695|Drug|Placebo|Placebo Capsules
75337815|NCT01280695|Drug|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
75473440|NCT01970618|Drug|RV1162 single dose|Safety and tolerability of single escalating doses
75647569|NCT02615600|Device|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
75647570|NCT04261946|Other|Quality of life survey|Unilateral patulous eustachian tube surgically treated were interviewed about our life's quality by a survey
75647571|NCT01008449|Device|Surgical staples|Surgical staples will be used once for wound closure.
75647572|NCT01008449|Device|Absorbable Surgical Suture|Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
75647573|NCT02858024|Drug|Dapivirine Vaginal Ring-004 and no tampons|Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
75795186|NCT05193851|Drug|ricolinostat|"This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period."
75795187|NCT05193318|Drug|Ketamine-assisted psychotherapy|Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
75337816|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
75337817|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
75337818|NCT01280695|Drug|Pioglitazone|Pioglitazone 45 mg Capsules
75473441|NCT01970618|Drug|RV1162 matching placebo single dose|Safety and tolerability of single escalating doses
75473442|NCT01970618|Drug|RV1162: 7 day repeat dose|Safety and tolerability of a repeat dose
75473443|NCT01970618|Drug|RV1162 matching placebo: 7 day repeat dose|Safety and tolerability of a repeat dose
75473444|NCT01970618|Drug|RV1162: 14 day repeat dose|Safety and tolerability of repeat escalating doses
75473445|NCT01970618|Drug|RV1162 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
75647574|NCT02858024|Drug|Dapivirine Vaginal Ring-004 with tampons|followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
75647575|NCT02858024|Drug|Dapivirine Vaginal Ring-004 with no menses|Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
75647576|NCT02858024|Drug|Dapivirine Vaginal Ring-004 and same ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
75647577|NCT02858024|Drug|Dapivirine Vaginal Ring-004 and new ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
75795188|NCT05186493|Procedure|robot-assisted total pelvic exenteration|Patients with locally advanced pelvic cancer that require pelvic exenteration considered eligble, are operated minimmally invasive robot-assisted
75795189|NCT05183295|Other|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food
75795190|NCT05171868|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|Each participant in the intervention group will receive 8 individual, weekly EMDR sessions over 8 weeks. Each session will take approximately 60-90 minutes. The sessions will be delivered at a place convenient to the participant. Trained EMDR therapists will deliver the intervention.
75932516|NCT00787059|Drug|Sucrose (3%)|
75932517|NCT04489160|Drug|C1 Inhibitor, Human|6000 IU C1-INH
75932518|NCT04489160|Drug|Placebo|0.9% saline
75932519|NCT00786201|Drug|Placebo|Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
75932520|NCT00786201|Drug|CNTO 888 1 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
75932521|NCT00786201|Drug|CNTO 888 5 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
75647578|NCT04297007|Other|PECS block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
75647579|NCT04297007|Other|Rhomboid intercostal block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
75647580|NCT02857946|Drug|Prevaglip (linagliptin)|1 tablet contains 5 mg linagliptin
75647581|NCT02857946|Drug|Trajenta (linagliptin)|1 tablet contains 5 mg linagliptin
75647582|NCT04400435|Device|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
76086132|NCT05517707|Device|Nasogastric Tube|Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
76086133|NCT05516797|Device|Continuous Glucose Monitoring (CGM)|Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring
75647583|NCT02857712|Drug|Axitinib|Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
75647584|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
75647585|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
75647586|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
75647587|NCT00696241|Drug|Olmesartan|Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
75647588|NCT00696241|Drug|Placebo|Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
75647589|NCT04941365|Diagnostic Test|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
75647590|NCT00957008|Behavioral|Group weight loss program|Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.
75647591|NCT00957008|Other|Group weight loss program plus use of the Senseware Armband|Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.
75647592|NCT00957008|Device|Use of the senseware armband alone program|Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
75795191|NCT05170425|Device|Prospera|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of donor derived cell-free DNA (dd-cfDNA) in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
75795192|NCT05163041|Drug|BT7480|Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
75795193|NCT05163041|Drug|Nivolumab|Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
75795194|NCT05138575|Drug|Empagliflozin + Potassium Chloride|"Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control."
75647593|NCT00630968|Drug|Levetiracetam (Keppra)|
75647594|NCT02565667|Device|KOL|KOL staple was used for rectal anastomosis
75647595|NCT02565667|Device|traditional staple|traditional staple was used for rectal anastomosis
75647596|NCT00744289|Other|Incentive condition|Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
75795195|NCT05138575|Drug|Empagliflozin + Potassium Nitrate|Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
75795196|NCT05138575|Drug|Potassium Chloride + Placebo for Empagliflozin|Active control.
75795197|NCT05133947|Other|Non interventional|Non interventional
75932522|NCT00786201|Drug|CNTO 888 15 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
75932523|NCT05536557|Other|Bilateral External Oblique İntercostal (EOI) Plane Block|External Oblique İntercostal (EOI) Plane Block will be provided for postoperative pain for Laparoscopic Cholecystectomy with Bupivacaine. And patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
75932524|NCT05536557|Other|Standard perioperative and postoperative multimodal analgesia|Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol for Laparoscopic Cholecystectomy.
75932525|NCT03296384|Other|Clinical and environmental evaluation|For schizophrenic's patients, specific assessment will be perform
75932526|NCT00841815|Drug|Amlodipine Besylate|10 mg Tablet
75932527|NCT00841815|Drug|Norvasc®|10 mg Tablet
75932528|NCT03296306|Drug|Treatment duration of cisplatin based chemotherapy|"GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks"
75932529|NCT04440280|Drug|N-acetyl cysteine (NAC) 10% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
75473446|NCT01970631|Behavioral|Motivational Interviewing (MI)|The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the nine months following participants' total knee replacement (TKR).
75647597|NCT03968809|Diagnostic Test|CardioFlux Magnetocardiography|All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.
75932530|NCT04440280|Drug|N-acetyl cysteine (NAC) 20% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.
75932531|NCT04440280|Drug|Visine Dry Eye Relief eye drops|Visine Tears Dry Eye Relief artificial tears ophthalmic solution
75932532|NCT03296228|Radiation|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
75932533|NCT03296228|Radiation|Flexibility Radiographs (awake traction)|awake traction
75932534|NCT03296228|Radiation|Flexibility Radiographs (STUGA)|supine traction under GA
75932535|NCT04572412|Radiation|Low dose Radiotherapy|"External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.~A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved."
75337819|NCT03008785|Other|exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
75337820|NCT03008785|Other|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
75647598|NCT00952484|Biological|asfotase alfa|2 mg/kg subcutaneous injection three times per week for 6 months.
75647599|NCT00952484|Biological|asfotase alfa|3 mg/kg subcutaneous injection three times per week for 6 months.
75647600|NCT02484079|Procedure|Polypectomy|
75795198|NCT05128890|Procedure|Resection techniques for pancreatic and liver tumors|to compare open versus minimally invasive pancreatic resection techniques and analyze the different outcome variables from the clinical standpoint
75795199|NCT05122559|Drug|N-acetyl cysteine|N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.
75795200|NCT05122559|Drug|Placebo|Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF
75337821|NCT03008785|Other|Placebo|Daily supplementation in 1 capsule per day containing starch of corn.
75337822|NCT00103844|Drug|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
75337823|NCT00103844|Drug|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
75337824|NCT01402141|Dietary Supplement|Chungkookjang|Chungkookjang(35g/say)for 12 weeks
75337825|NCT01402141|Dietary Supplement|Placebo|Placebo(35g/day) for 12 weeks
75337826|NCT01402375|Drug|Hydrocodone (first trial)|Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
75647601|NCT01974362|Device|Dental Implant|Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
75647602|NCT01974362|Device|Monolithic Zirconia (MZ)|rehabilitation with monolithic zirconia implant-prosthesis with bucal feldspathic veneer
75647603|NCT01974362|Device|Zirconia-Feldspathic (PVZ)|restore dental implants with a zirconia suprastructure and feldspathic veneers
75795201|NCT05115045|Diagnostic Test|plasmatic SARS-CoV-2 RNA quantification|plasmatic SARS-CoV-2 RNA was quantified by droplet digital PCR
75932536|NCT03295916|Radiation|Stereotactic Body Radiotherapy|Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
75932537|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
75932538|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
75932539|NCT00782535|Drug|Placebo|Inhaled solution, single dose of placebo
75932540|NCT00841659|Drug|Paroxetine HCl|40 mg Film-Coated Tablet
75932541|NCT00841659|Drug|Paxil®|40 mg Film-Coated Tablet
75932542|NCT04061252|Drug|KHK4827|brodalumab 210mg Q2W, SC
75932543|NCT04061252|Drug|Placebo|Q2W, SC
75932544|NCT05503654|Behavioral|Nutrition education|Those interventional groups will take nutrition education by Gada System leaders for 6 consecutive months
75932545|NCT04057586|Procedure|Nonintubated|During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.
75932546|NCT04057586|Procedure|Intubated|During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
75473447|NCT01970631|Other|Financial Incentives|The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.
75473448|NCT01970644|Radiation|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
75647604|NCT01974362|Device|Monolithic Zirconia (FCMZ)|Full contour full arch zirconia rehabilitation
75795202|NCT05112679|Device|PROPRIO FOOT® by Ossur|Active prostheses like the PROPRIO FOOT® offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and transepidermal water loss measurement to check skin health.
75932547|NCT05079243|Biological|Scaffold and adipose-derived stromal cell enriched fat grafts|eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer
75932548|NCT04473417|Drug|Forxiga|single dose administration after 10hr fasting
75337827|NCT01402375|Drug|Codeine (first trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
75337828|NCT01402375|Drug|Oxycodone (for second trial)|Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
75337829|NCT01402375|Drug|Codeine (for second trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
75932549|NCT04473417|Drug|DA-2811|single dose administration after 10hr fasting
75932550|NCT04473417|Drug|DA-2811|single dose administration after 10hr fasting
75337830|NCT01402375|Drug|Oxycodone (third trial)|Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
75337831|NCT01402375|Drug|Hydrocodone (third trial)|Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
75932551|NCT04473417|Drug|DA-2811|single dose administration after high fat and calorie fed diet
75932552|NCT05503576|Device|reminder mobile application|After thyroidectomy, patients will be reminded of medication and control appointments. In addition, patients will be able to access up-to-date and short trainings.
75932553|NCT01001091|Drug|AL-38583 ophthalmic solution|
75932554|NCT01001091|Drug|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
75337832|NCT01299103|Device|Pelleve Wrinkle Treatment System|comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
75337833|NCT01302379|Drug|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
75337834|NCT01302379|Drug|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
75337835|NCT01302379|Behavioral|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
75337836|NCT01302379|Behavioral|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
75337837|NCT01404559|Device|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
75337838|NCT01404559|Device|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
75473449|NCT01970657|Biological|No treatment specified|No intervention
75473450|NCT01970657|Biological|No treatment|None specified
75647605|NCT04117724|Other|Survey|Patients will be asked to complete a 4 question survey assessing adherence. Follow up via patient's preferred method of contact will be conducted after the patient's intended antibiotic completion date and covariates for antibiotic regimens will be recorded including antibiotic type, number of doses, antibiotic duration, reason for non-adherence, pills remaining, and number of other medications.
75647606|NCT00689611|Drug|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
75647607|NCT00689611|Drug|Placebo|Placebo
75932555|NCT01001091|Drug|Dexamethasone ophthalmic suspension, 0.1%|
75337839|NCT01404559|Device|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
75337840|NCT01351753|Drug|Metformin|
75473451|NCT01970683|Dietary Supplement|VSL #3 BID|
75932556|NCT05076045|Device|Personal sound amplification products|Participants will be tested with bilateral personal sound amplification products.
75932557|NCT02716298|Device|fanfilcon A|contact lens
75932558|NCT02716298|Device|lotrafilcon B|contact lens
75932559|NCT05076682|Drug|Choline|Choline 300mg tid or 500mg bid, p.o
75932560|NCT05076682|Drug|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
75932561|NCT05076682|Drug|Sodium Cromoglicate|Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
75932562|NCT05076682|Drug|Efavirenz|Efavirenz 600mg qd, p.o
75473452|NCT01970748|Drug|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
75473453|NCT01970748|Procedure|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
75473454|NCT01970774|Other|MTM with PGx|Patients will attend MTM sessions and receive PGx testing
75932563|NCT05066139|Other|EPODIG-G program (coordination of supportive care)|EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)
76086134|NCT05514964|Behavioral|Feasibility study|"Individuals interested to participate in this study were informed about the intervention via the project website and Facebook page of the project. Prior to the start of the study, participants were invited to read the Informed Consent and express their agreement to participate. Only after the Informed Consent was electronically signed, participants were able to complete the screening questionnaires online.~The intervention program (based on Acceptance and Commitment Therapy) consists of six treatment modules adapted to the online environment. Each module was structured like a therapy session and contained at least two or three homework assignments. Each participant was assigned to an online psychotherapist. At the end of the six modules, participants completed the post-intervention measures."
76086135|NCT05504421|Other|Sustainability education in nursing to be given with two different teaching methods|Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
75337841|NCT01351753|Drug|Orlistat|
75337842|NCT01351753|Drug|Topiramate|
75337843|NCT01351753|Drug|Placebo|Placebo pills and capsules for metformin, orlistat and topiramate
75337844|NCT01353079|Biological|Short Ragweed Pollen Allergenic Extract|Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
75473455|NCT01970800|Drug|Growth Hormone|Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
75647608|NCT02859974|Behavioral|Respiratory retraining for PVFMD|"Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.~Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.~Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase."
75647609|NCT04278170|Other|no attempt was made to patients|no attempt was made to patients
75647610|NCT02563795|Drug|Bupivacaine|To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
75647611|NCT02563795|Drug|Fentanyl|To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
75647612|NCT04281680|Drug|Pasireotide 0.9 MG/ML|900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital
75647613|NCT00744445|Drug|r-HuEPO|r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
75647614|NCT02857868|Drug|ABL001|
75932564|NCT00840879|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
75932565|NCT00840879|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
75932566|NCT05503498|Other|DATA RECORDING|RECORD PLASMA FIBRI LEVELS AFTER FIBRINOGEN ADMINISTRATION
75932567|NCT02163434|Drug|Gabapentin|
75932568|NCT02163434|Drug|Metoclopramide|
76086136|NCT05503134|Biological|Universal Donor Natural Killer Cells|Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
76086137|NCT05497349|Other|Leukocyte Rich- PRP injection|Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
76086138|NCT05497349|Other|Leukocyte Poor- PRP injection|Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
76086139|NCT05496972|Behavioral|Survey Administration|Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
76086140|NCT05496738|Drug|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously in single ascending doses
76086141|NCT05496738|Drug|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously in multiple ascending doses
75337845|NCT01353079|Biological|Placebo|Placebo: Glycero-COCAs sublingual
75337846|NCT00104234|Drug|N-acetylgalactosamine 4-sulfatase|
75337847|NCT00104234|Drug|Placebo/rhASB|
75337848|NCT01303939|Diagnostic Test|magnetic resonance imaging (MRI) of the brain|High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.
75337849|NCT00104858|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
75337850|NCT00104858|Drug|Cyclosporine|Given PO
75337851|NCT00104858|Drug|Fludarabine Phosphate|Given IV
75337852|NCT00104858|Other|Laboratory Biomarker Analysis|Correlative studies
75337853|NCT00104858|Drug|Mycophenolate Mofetil|Given PO
75337854|NCT00104858|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
75337855|NCT00104858|Other|Pharmacological Study|Correlative studies
75337856|NCT00104858|Biological|Rituximab|Given IV
75337857|NCT00104858|Radiation|Total-Body Irradiation|Undergo TBI
75337858|NCT01354015|Device|DRMS|USE OF TEXT MESSAGING SYSTEM
75337859|NCT01407523|Drug|Levetiracetam|"Formulation: concentrate for solution for infusion~Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~Frequency: twice daily"
75337860|NCT01304407|Other|Calcium stable isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
75473456|NCT01970813|Device|acupuncture and bee venom acupuncture point injection|acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
75932569|NCT04638946|Behavioral|Titration to high intensity exercise (T-HIE)|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Participants will begin at low intensity with the goal of titrating to high intensity by 2 weeks prior to the end of trial (Week 6). If a participant achieves at least 70% of the duration goal at the target heart rate, he/she will be titrated to the next dose level (moderate intensity). This will continue until high intensity exercise is achieved. Prescription is based on heart rate reserve((maximum heart rate [220-age] - resting heart rate)*intensity percent - resting heart rate. Intensity percent lower/upper limits for moderate intensity are 40-59% and for high intensity are 60-84%.
75932570|NCT04638946|Behavioral|Low intensity exercise prescription|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Prescription is based on heart rate reserve ((maximum heart rate [220-age] - resting heart rate)*30-39% (lower/upper limit of zone) - resting heart rate.
75932571|NCT05563324|Genetic|DNA extraction and genotyping of candidate genetic polymorphisms|
75932572|NCT05563324|Other|self-assessment questionnaires|
75795203|NCT05112679|Device|Empower ankle by Ottobock|Active prostheses -such as the Empower ankle offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and trans epidermal water loss measurement to check skin health.
76086142|NCT05496738|Other|Intravenous placebo|Placebo will be administered intravenously in single ascending doses
75337861|NCT00106106|Procedure|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
75932573|NCT00840411|Drug|Clarithromycin ER 500 mg tablets|1 x 500 mg
75932574|NCT00840411|Drug|BIAXIN® XL 500 mg tablets|1 x 500 mg
75795204|NCT05112666|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Clinical Practice Research Datalink (CPRD) GOLD and Aurum Hospital Episode Statistics (HES)-linked datasets in UK.
75795205|NCT05112666|Drug|other DOACs|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
75932575|NCT00840099|Drug|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fed
75932576|NCT00840099|Drug|Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension|1 x 600 mg/42.9 mg/5 mL, single-dose fed
75932577|NCT03108248|Drug|ethiodized oil; doxorubicin;Gelfoam;|Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
76086143|NCT05496738|Other|subcutaneous placebo|Placebo will be administered subcutaneously in multiple ascending doses
76086144|NCT05495854|Diagnostic Test|PCR test in the stool|"Patients randomized to the new strategy arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment."
76086145|NCT05494424|Behavioral|Goal Management Training (GMT)|Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.
76086146|NCT05491447|Drug|BMX-010|Ointment
76086147|NCT05491447|Drug|Placebo|Ointment
76086148|NCT05491031|Other|magnetic resonance spectroscopy|Investigation of the association, in patients with multiple sclerosis, between MRI biomarker data at inclusion and progression of physical disability during follow-up (6, 12, 18 and 24 months) assessed by a composite endpoint EDSS plus (EDSS, 9HPT, T25FW)
76086149|NCT05490238|Procedure|Complex PCI with Ultimaster Tansei (Terumo Corp., Japan) drug-eluting stent|Large-bore radial access for complex PCI with Ultimaster Tansei (Terumo Corp., Japan) drug-eluting stent
76086150|NCT05490043|Drug|ATG-101|ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
75337862|NCT00106106|Drug|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
75473457|NCT01970813|Device|sham acupuncture and normal saline injections|sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
75795206|NCT05112666|Drug|LMWH|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
76086151|NCT05482815|Device|Provox Vega Voice prosthesis|Voice prosthesis for speech rehabilitation, Provox Vega Voice prosthesis
76086152|NCT05480683|Diagnostic Test|CT exam|Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.
76086153|NCT05465954|Procedure|Biospecimen Collection|Correlative studies
75337863|NCT01304641|Other|Atorvastatin Initiators|Retrospective database analysis no intervention performed.
75473458|NCT01970826|Procedure|Single Dental Implants|place single unit dental implants, 2 mm below crestal bone and follow manufacturer guidelines.
76086154|NCT05465954|Biological|Efineptakin alfa|Given IM
76086155|NCT05465954|Biological|Pembrolizumab|Given IV
76086156|NCT05464199|Other|Neurofeedback training|"Self-administered neurofeedback treatment using headset and tablet-based application, designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own brain EEG signals associated with activity in brain networks related to pain perception and pain modulation.~Visual feedback will be provided onscreen representing the participant's real time EEG activity measured by the headset. Each session will be split into five blocks of five minutes each, with a one-minute rest period in between, in order to avoid fatigue and allow the participant to move around and adjust their position. After each rest block, participants will be asked if they are ready to proceed and when ready, the next block can be started. After the end of the session (5 blocks) the participant will then be asked to perform a post-session eyes-open EEG recording, similar to the eyes-open baseline taken at the start of the session."
75932578|NCT03108248|Device|stent; idoine-125|In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
75932579|NCT04634890|Behavioral|Exercise intervention|Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.
75932580|NCT00836901|Drug|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
75795207|NCT05097027|Device|Blood flow restriction recovery|Soccer players included in experimental group I will carry out this program for 1 week setting the blood pressure to ~ 60% of limb occlusion pressure (LOP). After a month they will carry out the program without restriction of blood flow. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
75932581|NCT00836901|Drug|Augmentin®|400 mg-57 mg chewable tablet
75932582|NCT04466384|Device|BIS|Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
76086157|NCT05462756|Drug|Insulin Efsitora Alfa|Administered SC
75337864|NCT01304641|Other|Simvastatin Initiators|Retrospective database analysis no intervention performed.
75337865|NCT01305265|Device|cuff manometer|endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
75337866|NCT04545320|Behavioral|Usual care control group|Health education
75473459|NCT01970826|Procedure|Sterilized Aseptic|Operatory room will be prepared totally aseptic
75473460|NCT01970826|Procedure|Sterilized Clean|Operatory room will be prepared clean but not aseptic
76086158|NCT05462756|Drug|Insulin Lispro (U100)|Administered SC
75795208|NCT05097027|Other|Active recovery|Soccer players included in experimental group II will carry out this program for 1 week. After a month they will carry out the program with blood flow restriction. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
75932583|NCT05503420|Device|Masticatory muscle training exerciser|In addition to the normal stroke rehabilitation training, the participants will be instructed on an active range of motion (AROM) exercise to improve coordination of the masticatory muscles. This part will be performed with a 5-second hold at the end of the range of motion for each motion, with 10 repetitions performed for each motion. In addition, each participant will be provided with a device, a U-shaped apparatus covered by silicon and having 3 small springs inside to provide resistance during chewing to be placed inside the mouth for carrying out a chewing exercise. The participant will be instructed to perform a chewing exercise using the device for around 10 minutes each time, twice a day, and 7 days per week. The exercise includes isotonic and isometric muscle training.
75932584|NCT04444466|Drug|UCB8600|Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.
76086159|NCT05462756|Drug|Insulin Glargine (U100)|Administered SC
76086160|NCT05455775|Device|Camera-based monitoring technology|Unobtrusive, vital sign measurement with remote photoplethysmography and laser speckle vibrometry
75932585|NCT04444466|Other|Placebo|Study participants will receive Placebo in a pre-specified sequence during the Treatment Period matching UCB8600.
76086161|NCT05454358|Drug|Letrozole 2.5mg|Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
76086162|NCT05453721|Procedure|Indocyanine green fluorescence imaging method|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
75337867|NCT04545320|Behavioral|HIIT group|Once-a-week HIIT
75337868|NCT04545320|Behavioral|MICT group|Once-a-week MICT
75337869|NCT01305655|Drug|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is >250 µM, 36 hour levels >30 µM or 42 hours levels >10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
75473461|NCT01970826|Procedure|Full-Mouth Dental Implants|dental implants for full-mouth implant rehabilitation.
75473462|NCT01970826|Procedure|Partial Rehabilitation|two or more implants to support partial rehabilitation
75473463|NCT01970826|Procedure|Duration of Surgery|it will be measure the amount of time to perform the dental implant surgery. It will be measured from the time that the surgeon does the first incision until the last suture is made.
75473464|NCT01970839|Device|tourniquet, sensory nerve conduction abnormality|
75473465|NCT01970852|Other|Standard tablet computer|No special enhancements or links to personal health information.
75473466|NCT01970852|Other|Enhanced tablet computer|Tablet computer with personalized access to data from the patient's electronic health record.
75473467|NCT01970891|Device|neuromuscular stimulation device|Effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait amelioration.
75473468|NCT01970904|Drug|Alisporivir|Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
75473469|NCT01970904|Drug|Ribavirin|Ribavirin tablets of various strengths for oral administration
75473470|NCT01970904|Drug|Peg-IFNα2a|Peg-IFNα2a solution for subcutaneous injection
75473471|NCT01970917|Device|Olixia pure eye drops|
76086163|NCT05453721|Procedure|Modified inflation-deflation method|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
75932586|NCT04460560|Drug|Terlipressin|"For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump"
75932587|NCT03295838|Behavioral|Mentalization-based treatment|See Arm description
75795209|NCT05092659|Behavioral|Patient interview|Each patient included will be interviewed 3 times : before surgery, 3 and 6 months after surgery
75932588|NCT04288804|Device|Smartphone microphone sensor|The volunteer will record themselves sustaining the short a vowel sound for 10 seconds.
75932589|NCT04288804|Device|Smartphone accelerometer sensor|The volunteer's smartphone's accelerometer will record accelerometer data (positions on the x, y, and z axes) while the volunteer maintains 4 positions, each for 10 seconds.
75932590|NCT04537689|Biological|Ixekizumab|Ixekizumab for 6 months, given 160mg at weeks 0, followed by 80mg at 2, 4, 6, 8, 10 and 12, then 4 weekly till 6 months. Given subcutaneously.
75932591|NCT04537689|Drug|Methotrexate|Oral tablet up to 15mg per week
75932592|NCT04537689|Drug|Cyclosporin A|Oral capsule up to 200mg per day
75932593|NCT04537689|Drug|Acitretin|Oral capsule up to 25mg per day
75473472|NCT01970917|Device|Placebo|0.9% physiological saline solution
75932594|NCT02462096|Device|ReLeaf|The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
75647615|NCT00921427|Behavioral|Vision Restoration Therapy (VRT)|30 min, twice a day, 3 days a week, 12 weeks
75647616|NCT00921427|Device|Transcranial direct current stimulation (tDCS)|2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
75932595|NCT03295760|Drug|Q10 Coenzyme|
75647617|NCT02860208|Procedure|3 years follow-up|Examination 3 years after surgical treatment of peri-implantitis
75795210|NCT05091879|Genetic|Multigene pharmacogenomics test|This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
75932596|NCT05563012|Drug|Sintilimal Injection|Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.
75932597|NCT03295604|Procedure|SCTG+EMD|Miller class I-II gingival recession defects were operated with SCTG+EMD
75932598|NCT03295604|Procedure|SCTG|Miller class I-II gingival recession defects were operated with SCTG only and
75932599|NCT04501653|Drug|Psilocybin|Psilocybin is a naturally occurring psychedelic compound produced by psilocybin mushrooms, and has been shown to have antidepressant and anti-anxiety effects after one dose of 25 mg. Common side effects are slight elevations in blood pressure and heart rate. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
75932600|NCT04501653|Drug|Methylphenidate|Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is used as an active control for this study because it is metabolized similarly to psilocybin and has similar effects on heart rate and blood pressure. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
75932601|NCT04730206|Drug|Camostat|100 milligram tablets
75473473|NCT01970930|Procedure|Blood specimen|4 green top tube 40 cc of blood draw
75473474|NCT01971021|Device|PICC or subcutaneous venous port|
75473475|NCT01971034|Drug|Paclitaxel|80 mg/m2, IV, Day 1, Day 8 and Day 15.
75647618|NCT02983370|Procedure|Minicraniotomy|The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
75647619|NCT02854748|Drug|Empagliflozin 25mg|Empagliflozin 25 mg QD for 5 days
75647620|NCT02854748|Drug|Lobeglitazone 0.5mg|Lobeglitazone 0.5mg QD for 5 days
75932602|NCT04730206|Drug|Placebo|oral tablets, identical in size and shape
75932603|NCT04730206|Drug|Molnupiravir|200 milligram tablets
75932604|NCT02463344|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
75932605|NCT00781443|Drug|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
75473476|NCT01971034|Drug|Metformin|850mg, PO, every 8 hours, daily.
75473477|NCT01971047|Drug|Regular Insulin|"Group 1 Treatment Arm,Follow dosing for BG >180 per the following formula:~Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose"
75647621|NCT02854748|Drug|Empagliflozin 25mg/Lobeglitazone 0.5mg|Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
75647622|NCT00689299|Biological|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
75647623|NCT00689299|Biological|Placebo|Placebo Sublingual Drops
75932606|NCT00781443|Drug|placebo|Repeating subcutaneous injection
75932607|NCT03134937|Device|High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
75932608|NCT05503342|Other|Mobile Application|Use of the cell phone application to include information about asthma symptoms which had returned with guidance on self-management.
75932609|NCT05503342|Other|Asthma control assessment|Asthma control assessment questionnaire application in paper format
75932610|NCT04473027|Diagnostic Test|Blood sample collection|Whole venous blood of participants will be collected in EDTA tubes (max. 10 mL) at baseline, before start of first immunotherapy round. The Belgian Red Cross will perform serological blood group diagnostics, and molecular RBC typing.
76086164|NCT05450887|Drug|Obeticholic Acid Tablets（OCA）|Obeticholic Acid：Once a day (QD) by mouth (PO).
76086165|NCT05450887|Drug|UDCA|UDCA：13~15 mg/kg/day
75795211|NCT05080764|Combination Product|1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 1 hour. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
75795212|NCT05080764|Combination Product|1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 1h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
75932611|NCT04432480|Procedure|NIPE (Newborn Infant Parasympathetic Evaluation) monitoring|Non invasive monitor connected to standard anesthesia monitor (no part of the device in contact with the patient) during anesthesia.
75932612|NCT00990327|Drug|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
75647624|NCT02506244|Device|iRhythm ZIO XT Patch|Single-lead ECG monitoring via a wearable patch
75337870|NCT04442438|Other|Monthly moral case deliberation|Once per month, ICU professionals will take part in moral case deliberation. As part of the intervention, two or three ICU professionals (physicians and nurses) are tasked with selecting a case for moral discussion. Moral case deliberation is attended by around thirty individuals per month per unit. A feedback system will be developed used to spread the knowledge/insights from the case deliberation to all professionals in the unit.
75337871|NCT04753112|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor
75337872|NCT01305811|Device|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
75337873|NCT04770194|Drug|SP-8008 Prototype Capsule A|Oral
75932613|NCT00990327|Drug|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
75932614|NCT03050814|Drug|Avelumab|10 mg/kg intravenous (IV) over 30-60 min on Day 1
75647625|NCT02506244|Device|Wristband by Amiigo|Determines pulse rate using photoplethysmography.
75932615|NCT03050814|Biological|Ad-CEA vaccine|Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
75932616|NCT03050814|Drug|Bevacizumab|5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
75932617|NCT03050814|Drug|5-Fluorouracil (FU)|400mg/m^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.
75932618|NCT03050814|Drug|Leucovorin|400mg/m^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
75932619|NCT03050814|Drug|Oxaliplatin|85mg/m^2 (Arm A) or 68mg/m^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
75932620|NCT03050814|Drug|Capecitabine|625 mg/m^2 twice a day by mouth. Part of the standard of care therapy.
75932621|NCT03050814|Drug|5-Fluorouracil (FU)|2400 mg/m^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
75932622|NCT04430218|Device|iSens|The study involves a surgical implant of cuff electrodes on the nerves in the amputated limb, and muscle recording electrodes the remaining muscles. These will be connected to an implanted stimulator. The stimulator will connect wirelessly to an advanced prosthesis. This may allow a user to move the prosthetic hand intuitively and feel what your prosthesis is touching.
75337874|NCT04770194|Drug|SP-8008 Prototype Capsule B|Oral
75337875|NCT04770194|Drug|Placebo|Oral
75473478|NCT01971047|Drug|Humalog|"Group 2 treatment arm. Follow dosing for Blood glucose > 180, per the following formula:~Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose"
75473479|NCT01971060|Device|surgery utilizing V-Loc suture|V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
75473480|NCT01971073|Device|transcranial direct current stimulation|"arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.~The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions )."
75647626|NCT02565043|Device|RENASYS TOUCH Negative Pressure Wound Therapy System|RENASYS TOUCH NPWT System was administered to all participants.
76086166|NCT05450887|Drug|Placebo|Placebo：Once a day (QD) by mouth (PO).
76086167|NCT05448222|Diagnostic Test|Diagnostic Test: gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
75647627|NCT03889171|Behavioral|Behaviour|Comparison to psychological, medical and emotional Influencing communication and achievement factors to Oncogenetics tests
75647628|NCT00948974|Behavioral|Cognitive Therapy|"Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., if I attempt to initiate a conversation I'll humiliate myself), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005)."
75337876|NCT05606588|Behavioral|Playful sensorimotor training|"For the max. duration of the first in-hospital phase (3weeks), all children will receive supervised training. When children go home they will be supplied with a manual, specific exercises and the necessary training devices. Regular supervision will allow to ensure that the training is performed at maximum benefit. Each session will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises chosen from a standardized pool of exercises according to the child's age, with increasing difficulty in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue."
75932623|NCT04429750|Procedure|Immediate umbilical cord clamping|"In the immediate cord clamping group, the umbilical cord will be clamped within the first 20 seconds after birth and the infant will be transferred to the resuscitation room. The newborn infant will be intubated and mechanically ventilated as quickly as possible on the resuscitation table as recommended in the French Programme National de Soins.~After cardiorespiratory stabilization (i.e. heart rate>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%), the infant will be transferred to the neonatal intensive care unit (NICU). Oxytocin is infused to the mother as recommended in the local protocol (usually just after birth or cord clamping)."
75932624|NCT04429750|Procedure|intact cord resuscitation|The umbilical cord will be kept intact during the initial phase of the resuscitation. The infant will be placed on a specifically designed compact trolley with a warmed platform, suitable for commencing resuscitation between the mother's legs in case of vaginal birth or near the operating table beside the mother in case of cesarean section. This trolley will be fully equipped for resuscitation, including a suction device, gas flowmeter/blender, ventilatory support, and monitoring system. Its height can be adjusted in order to position the infant close to the maternal perineum. The infant will be intubated and mechanically ventilated on this trolley. The cord will be clamped once cardiorespiratory stabilization will be obtained (i.e. heart rate>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%) or in case of spontaneous placental expulsion. The infant will be then transferred to the neonatal intensive care unit (NICU).
75337877|NCT01409239|Drug|Intravenous insulin|24 hr IV insulin administered according to hospital guideline
75337878|NCT01409239|Drug|Subcutaneous Insulin|basal bolus insulin using carb counting technique and insulin analogues
75473481|NCT01971073|Device|sham tDCS|the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
75473482|NCT01971099|Drug|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
75473483|NCT01971099|Other|Placebo|patients will take one pill a day (the same shape of the drug)
75647629|NCT00948974|Behavioral|Acceptance and Commitment Therapy|ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, & Emmelkamp, 2009).
75647630|NCT03881917|Diagnostic Test|Cystatin c and beta 2 microglobulin kits|Kits for measurement concentration
75932625|NCT05390112|Biological|DNA|ctDNA; cfDNA
75932626|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
75932627|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
75932628|NCT02462174|Drug|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
75932629|NCT02462174|Drug|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
75932630|NCT02564146|Drug|nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
76086168|NCT05444634|Behavioral|Distraction Card|"Suitable for children over 3 years old. 1 set of 32 pieces of thick cardboard cards It has been prepared by child development experts in line with pedagogical principles.~Size: 13cm x 8cm, Each card illustrates the skills and actions the children do."
75473484|NCT01971112|Dietary Supplement|Multivitamins and minerals|Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
75473485|NCT01971138|Other|this is a survey|
75795213|NCT05080764|Combination Product|3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 3 hours. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
75473486|NCT01971151|Behavioral|Exposure therapy|"Treatment protocol:~1) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments."
75473487|NCT01971164|Drug|JTZ-951|Subjects will receive JTZ-951 or Placebo
75473488|NCT01971164|Drug|Placebo|
75795214|NCT05080764|Combination Product|3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 3h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
75795215|NCT05066581|Device|Live Chat|Subjects from the intervention group will be able to ask for a medical intervention if needed with the phisycians from the sleep unit. After the following period, we expect to see better sleep habits in this group when compared to the no intervention one
75932631|NCT02564146|Drug|gemcitabine mono and nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
75932632|NCT03747276|Other|Clinical Trial Kiosk|Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
75932633|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
75647631|NCT02564809|Behavioral|Fit Brains Training|These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
75647632|NCT02564809|Behavioral|Exercise + Fit Brains Training|These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
75647633|NCT02564809|Behavioral|Balanced And Tone|These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
75647634|NCT02378233|Dietary Supplement|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
75795216|NCT05065151|Other|Stimulation on|Stimulation from Percept PC DBS will be on while the patient is playing a decision-making game on a computer-based application.
75795217|NCT05065151|Other|Stimulation off|Stimulation from Percept PC DBS will be off while the patient is playing a decision-making game on a computer-based application.
75795218|NCT05065151|Behavioral|Decision Making Task|Patients will be playing a decision making task through a computer-based application.
75932634|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
75932635|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
75932636|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
75795219|NCT05061537|Biological|PF-07263689|Genetically engineered oncolytic vaccinia virus
75932637|NCT02462252|Drug|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
75932638|NCT02462252|Drug|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
76086169|NCT05444634|Behavioral|Stress Ball|Brain Shaped Stress Ball, White rope in the form of mesh around the inner silicone Size: Approx 2.4 inches (6 cm), Color: Colorful, When squeezed, the silicone structure comes out in the mesh spaces and turns into a bunch of grapes.
75795220|NCT05061537|Biological|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2
75795221|NCT05054725|Drug|RMC-4630|RMC-4630 administered orally as a capsule
75795222|NCT05054725|Drug|Sotorasib|Sotorasib administered orally as a tablet
75795223|NCT05046522|Drug|Palmitoylethanolamide sold as Levagen +|Investigational product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
75795224|NCT05046522|Drug|Placebo comparator - maltodextrin and microcrystalline cellulose mix|Placebo product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
75795225|NCT05046132|Drug|Setmelanotide|Subcutaneous (SC) setmelanotide: SC injection: 2 mg × 7 days followed by 3, 5, and 7 mg × 3 days per dose level
75337879|NCT00108524|Behavioral|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
75647635|NCT02378233|Dietary Supplement|Placebo|Patients are given a non-iodine containing multivitamin tablet
75932639|NCT02462252|Drug|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
75337880|NCT00108524|Drug|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
75473489|NCT01971177|Device|Femtosecond laser cataract surgery|"The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.~The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.~Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.~All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform."
75795226|NCT05046132|Drug|Moxifloxacin|Moxifloxacin 400 mg capsules for oral administration (active comparator)
75473490|NCT01971177|Procedure|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
75473491|NCT01971190|Drug|Intravitreal Aflibercept injection|"2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~Central subfield thickness is thicker than the previous exam~BCVA letter score is worse than the previous exam (because of the persistent CSC)"
75932640|NCT02462252|Drug|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
75932641|NCT04613362|Behavioral|TENACITY Telehealth Cognitive Behavioral Therapy for Migraine|Clinical health psychology therapy delivered via telehealth
75932642|NCT04613362|Behavioral|Behavioral Usual Care|Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW.
75473492|NCT01971190|Drug|Sham injection|"Sham injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~Central subfield thickness is thicker than the previous exam~BCVA letter score is worse than the previous exam (because of the persistent CSC)"
75647636|NCT02563717|Device|T-piece used for respiratory support (several manufacturers)|Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
75647637|NCT02563717|Device|New system used for respiratory support|Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
75647638|NCT00744679|Drug|Natalizumab|Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
75795227|NCT05046132|Drug|Oral Placebo|Placebo capsules for oral administration (identical in appearance to oral moxifloxacin treatment)
75795228|NCT05046132|Drug|SC Placebo|Placebo for SC injection (vehicle only; identical in appearance to SC setmelanotide treatment)
75795229|NCT05038176|Behavioral|MANUP|Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
75932643|NCT03130452|Drug|Lansoprazole 30mg|lansoprazole 30 mg tablet
75932644|NCT03130452|Drug|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
75337881|NCT00108524|Behavioral|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
75795230|NCT05030610|Behavioral|BeatIt-ASD|BeatIt-ASD, designed to be implemented with autistic individuals, is an adaptation of BeatIt. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
75795231|NCT05026034|Device|non-invasive Cardiopulmonary Management (CPM) wearable device|non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure
75337882|NCT01410097|Behavioral|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
75337883|NCT01410097|Behavioral|Diabetes Support Education|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
75337884|NCT05606354|Other|Intervention group|Experimental
75932645|NCT03130452|Drug|Clarithromycin 500mg|Clarithromycin 500mg tablet
75932646|NCT03130452|Drug|Metronidazole 500 mg|Metronidazole 500 mg tablet
75932647|NCT04473495|Device|educational video|educational video before intervention
75932648|NCT00979251|Drug|Oseltamivir Phosphate|Oseltamivir Phosphate, q8h
75932649|NCT00979251|Drug|ADS-8902|Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
75932650|NCT03108170|Other|perineal massage program|The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day
76086170|NCT05443230|Diagnostic Test|gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
76086171|NCT05443217|Diagnostic Test|questionnaire survey|All patients received lifestyle questionnaire, physical performance, and imaging evaluation before treatment.
75932651|NCT03108170|Other|Pelvic floor muscle exercise program|The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day
75795232|NCT04997954|Drug|MediCabilis CBD oil|"The investigational product (MediCabilis 5% (50mg/ml) CBD Oil) will be supplied by BOD Australia, an Australian licensed manufacturer of medical grade cannabis.~The main components of MediCabilis 5% (50 mg/mL) CBD extract in MCT Oil are:~Cannabis sativa L. dry extract~Medium chain triglycerides (Ph Eur 0868) which are added in order to adjust the active constituent (cannabidiol) to the target content.~Each mL of MediCabilis provides:~50 mg of Cannabidiol (CBD+CBDA)~Less than 2 mg tetrahydrocannabinol (THC)~Non-active ingredient: Medium Chain Triglycerides (MCT) oil sourced from coconut"
75932652|NCT03108170|Other|Educational pelvic floor dysfunction prevention program|This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
75473493|NCT01971190|Procedure|Half-fluence photodynamic therapy|"At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~Central subfield thickness is thicker than the previous exam~BCVA letter score is worse than the previous exam (because of the persistent CSC)"
75932653|NCT04551352|Drug|RO7293583|RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
75932654|NCT04551352|Drug|Tocilizumab|Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).
76086172|NCT05431101|Procedure|Carpal Tunnel Release|Transection of flexor retinaculum for patients who have carpal tunnel syndrome
75337885|NCT02093702|Behavioral|Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach|
76086173|NCT05430815|Behavioral|Enhanced Postpartum Care System|The intervention consists of a comprehensive postpartum care system that integrates American College of Obstetrician and Gynecologist's (ACOG) postpartum care guidelines together with American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the prevention of cardiovascular disease in women, as well as patient preferences for care coordination and communication. The system consists of: 1) a tailored postpartum care plan that is collaboratively developed with patient and provider input and addresses both social and medical needs; 2) an electronic medical record (EMR) based tool for documenting the plan and monitoring postpartum care; and 3) a postpartum follow-up phone call at 1 week postpartum.
75337886|NCT02093702|Behavioral|Unstructured Physical Activity and Exercise Education|
75337887|NCT00052442|Drug|pralatrexate|
75473494|NCT01971216|Behavioral|Relaxation|
75473495|NCT01971229|Other|Carbohydrate based drink|After consumption of the test drink to record the insulin response and gastric emptying.
76086174|NCT05426902|Behavioral|SLE@Duke|SLE@Duke is a set of tools to implement the Type 1 & 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 & 2 SLE.
76086175|NCT05426746|Drug|ALT-100|intravenous infusion of drug substance diluted in 0.9% normal sterile saline
75337888|NCT01410409|Other|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
75337889|NCT01410409|Drug|Paracetamol|1 g x 4/day
75473496|NCT01971229|Other|Whey protein based drink|After consumption of the test drink to record the insulin response and gastric emptying.
75473497|NCT01971242|Drug|Exenatide|2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
75473498|NCT01971242|Other|Placebo|Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
75473499|NCT01971268|Device|Dental Implant|place dental implants according to manufacturer guidelines
75473500|NCT01971268|Device|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
75473501|NCT01971268|Device|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
75473502|NCT01971281|Device|NovoTTF-100L|Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
75795233|NCT04979858|Device|Focal Mask|The treatment group will receive and use the focal mask.
75932655|NCT04551352|Drug|Obinutuzumab|If implemented, it will be given either on D-7 or D-7 and D-6.
75932656|NCT04551352|Drug|Adalimumab|If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
76086176|NCT05426746|Other|Normal Saline|intravenous infusion of placebo (0.9% normal sterile saline)
75337890|NCT01410409|Drug|Burana|400 mg x 3/day for three weeks
75337891|NCT01410409|Drug|Pantoprazol|20mg x 1/day for three weeks
75337892|NCT01410409|Behavioral|Dietary counseling|For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
75932657|NCT02462798|Other|Whole grain rye bread|Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)
75473503|NCT01971281|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
75932658|NCT02462798|Other|Whole grain sourdough rye bread|Whole grain rye bread fermented with sourdough culture before baking
75337893|NCT01410409|Behavioral|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
75795234|NCT04969718|Other|LEADS Plus educational posters|This intervention covers depression and its symptoms, the link between depression and suicide, the risk and protective factors associated with suicide, the warning signs of suicide, seeking help and overcoming barriers to seeking help, and school and community suicide prevention resources. Six educational posters will also be displayed in class rooms
75795235|NCT04969718|Other|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers, originally developed in the USA which to train teachers/school staff to identify the suicide risk in students and encourage students at risk of suicide to seek professional help. Six educational posters will also be displayed in classrooms.
75795236|NCT04969718|Other|Screening by Professionals programme plus educational posters|This is an indicated or selective intervention which is based on students' responses to the baseline questionnaires. Participating health professionals review students' responses to the questionnaires used in the study and students whose scores meet pre-established cutoff points will be invited to participate in a professional mental health clinical assessment and if needed, referred to clinical services. Six educational posters will also be displayed in classrooms.
75795237|NCT04969718|Other|educational posters|Six educational posters will be displayed in all schools in this cluster.
75337894|NCT01410409|Procedure|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
75795238|NCT04969718|Other|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents), originally developed in the USA which to train parents to support the young people at risk of suicide. Six educational posters will also be displayed in classrooms.
75932659|NCT05398224|Drug|Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab|"Induction therapy: Zanubrutinib will be given as 160mg bid orally between days 1 and 14 of each 14-day cycle; rituximab will be given at 375mg/m2 intravenously on day 1 of each cycle; methotrexate at 3.5g/m2 for patients ≤65 or 1.5g/m2 for patients >65 (standard hydration/leucovorin support) will be given intravenously on day 2 of each 14-day cycle; for 6 cycles.~Consolidation therapy: For patients ≤65, autologous hematopoietic stem cell transplantation (ASCT with a conditioning regimen of thiotepa/carmustine) will be given as consolidation treatment after induction therapy.~Maintenance therapy:Drug: zanubrutinib. Zanubrutinib will be given as 160mg bid orally continuously until progression of the disease (PD), intolerable toxicity, death, or patient/investigator discretion."
75932660|NCT04496271|Device|RIC (Receiver in channel)- device|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
75932661|NCT04542304|Drug|Metolazone|Participants will be given a metolazone for the 1-week study period.
75932662|NCT04542304|Drug|Placebo|Participants will be given a placebo for the 1-week study period.
75932663|NCT02463110|Drug|Sertraline|Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
75795239|NCT04953728|Device|Transcutaneous Electrical Acustimulation (TEA)|Each participant will undergo 5 sessions total at two different frequencies (25 Hz and 100Hz) with electrodes placed at two different locations (wrist and knee) and a placebo session.
75932664|NCT02463110|Drug|No treatment|
75932665|NCT02463110|Drug|Placebo|
75337895|NCT01410409|Other|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
75337896|NCT01356277|Behavioral|Action-focused problem-solving|"Adherence Support Team (patient, parent, Coach)~standardized education on immunosuppressive medications~identification of adherence barriers~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient"
75337897|NCT01356277|Device|Electronic pillbox monitoring, dose reminders, and feedback|"Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~text message, email, or visual cue dose reminders"
75337898|NCT01410565|Drug|Apaziquone|Apaziquone 4 mg in 40 mL diluent
75337899|NCT01410565|Drug|Placebo|Placebo for Double Blind Phase
75337900|NCT01357135|Drug|Metformin|
75337901|NCT01357135|Drug|Sitagliptin|
75337902|NCT01357135|Drug|Sulfonylurea|
75795240|NCT04915482|Drug|Combined use of TPO-RAs with low-dose anti-CD20 antibody|Experimental: Combined use of TPO-RAs with low-dose anti-CD20 antibody The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
75932666|NCT05398146|Behavioral|mathematical operations|Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.
75932667|NCT05398146|Behavioral|ball squeezing|For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.
75932668|NCT05398146|Behavioral|listening to music|Children were allowed to listen to music with headphones during dressing changes.
75795241|NCT04915482|Drug|The best available therapy|The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
76086177|NCT05404022|Other|Tailored nutrition and physical activity programme|"Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~Information on side-effects that may affect eating and their mitigation~Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~Feedback on assessment of food intake and how to improve~a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~a recipe book Making the most of every bite~tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required"
75795242|NCT04897971|Diagnostic Test|Medium enriched for newly synthesized antibodies in spine infection|Medium enriched for newly synthesized antibodies titers in patients with Staphylococcus aureus infections of orthopedic spine implants at baseline and in the post operative period
76086178|NCT05393765|Behavioral|Yönetebilirim|"Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses."
75337903|NCT01357135|Drug|Antihyperglycemic Medication|
76086179|NCT05382091|Drug|naltrexone implant|3.6 g per implant set each containing 60% naltrexone
75337904|NCT02324335|Drug|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
75337905|NCT02324335|Other|Placebo|
75337906|NCT01411501|Other|acupuncture|"Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks."
75337907|NCT01411501|Drug|mosapride citrate|4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
75337908|NCT03008473|Device|video laryngoscope and chest CT iminge|
75337909|NCT03008473|Device|Conventional intubation of uniblocker|
75337910|NCT01309867|Device|Investigational Toric Lens|Bausch & Lomb investigational toric contact lens worn on a daily wear basis for 2 weeks.
75795243|NCT04891263|Procedure|Suture-Septoplasty|Patients receive suture-septoplasty for repair of nasal septal deviation.
75932669|NCT05398146|Other|kontrol grubu|No application was made during dressing change in children. Routine dressing change of the clinic was applied.
75932670|NCT05241314|Behavioral|Learning to BREATHE|A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
75932671|NCT05241314|Behavioral|After Deployment Adaptive Parenting Tools (ADAPT)|A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
75932672|NCT04473573|Device|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the *2, *3 and *17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
76086180|NCT05377229|Device|MarginProbe2.0|The MarginProbe System is an adjunctive diagnostic tool for identification of cancerous tissue at the margins of the ex-vivo lumpectomy specimen following primary excision and is indicated for intraoperative use, in conjunction with standard methods (such as intraoperative imaging and palpation) in patients undergoing breast lumpectomy surgery for previously diagnosed breast cancer.
75337911|NCT01309867|Device|PureVision Toric Lens|Currently marked Bausch & Lomb PureVision Toric Lens worn on a daily wear basis for 2 weeks.
75337912|NCT04351633|Other|questionnaire assesment|questionnaire assesment
75337913|NCT01357525|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:~12 Gy x 3 fractions (36 Gy total)"
75337914|NCT01310179|Genetic|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
75473504|NCT01971281|Drug|nab-Paclitaxel|nab-paclitaxel 125 mg/m^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
75473505|NCT01971307|Other|SGE-PsyScan|
75473506|NCT01971320|Device|Urostim I stimulation|Urostim I stimulation will be done during meals for 6 weeks
75473507|NCT01971398|Behavioral|Positive FASD education brochure|Exposure to a positive FASD education brochure
75647639|NCT03811171|Device|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
75647640|NCT04060459|Drug|Paclitaxel-binding albumin|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
75647641|NCT00744835|Procedure|Ablation procedure and/or cardioversion|Ablation Frontiers Cardiac Ablation System
75647642|NCT01007435|Drug|Tocilizumab|Tocilizumab was supplied in vials.
75647643|NCT01007435|Drug|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
75795244|NCT04891263|Device|Surgical suture|Suture used for closure during septoplasty surgery.
76086181|NCT05373121|Behavioral|Online Peer Support|Signposting to online peer support groups and forums
76086182|NCT05371509|Device|Myofunctional therapy (MT) nozzle|Water bottle nozzle designed to allow the user to repeatedly perform the tongue suction, tongue press, and swallow exercise movements while also providing targeted resistance to train and improve tongue, soft palate, and pharyngeal muscle strength and endurance.
75337915|NCT01412281|Biological|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
75337916|NCT01412281|Biological|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
75337917|NCT01359007|Drug|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
75795245|NCT04866290|Device|HepaSphere Microspheres|
75337918|NCT01361113|Drug|Pazopanib|800 mg orally once daily for 8 weeks, prior to nephrectomy
75337919|NCT01414153|Drug|4.0 mg iSONEP|4.0 mg iSONEP given monthly intravitreously for 4 months
75337920|NCT01414153|Drug|0.5 mg iSONEP|0.5 mg iSONEP given monthly intravitreously for 4 months
75795246|NCT04857827|Drug|QLS-101|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
75795247|NCT04857827|Drug|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
75932673|NCT04535908|Radiation|Hypofractionated radiotherapy|Hypofractionated radiotherapy in prostate cancer patients
75932674|NCT04438629|Drug|COVID-19 treatment|COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
75932675|NCT05502952|Drug|Pentoxifylline|Combined microneedling and topicalpentoxifylline vesrus intalesional pentoxifylline in Alopecia Areata patches in the same patient
75932676|NCT05498194|Diagnostic Test|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (~ 1cm3 ) are collected during surgery
75932677|NCT05389059|Procedure|CAF+CM|Periodontal surgery including CAF+CM application
75932678|NCT05389059|Procedure|I-PRF|Periodontal surgery including CAF+CM application with i-PRF
75932679|NCT04414449|Other|ICT-enabled Social-emotional Learning|ICT-enabled Social-emotional Learning
75932680|NCT04441658|Biological|Umbilical Cord Mesenchymal Stem Cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
76086183|NCT05371509|Other|Placebo nozzle|The placebo bottle nozzle will look similar to the MT nozzle; but is not expected to function the same as the MT nozzle.
76086184|NCT05370430|Biological|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL
75337921|NCT01414153|Drug|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
75647644|NCT01007435|Drug|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
75647645|NCT01007435|Drug|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
75647646|NCT00948896|Drug|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
75647647|NCT00948896|Drug|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
75647648|NCT00948896|Drug|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
75647649|NCT01004159|Drug|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
75647650|NCT00948818|Drug|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
75795248|NCT04841902|Other|Life Style Intervention Manual (With Exercise Under Supervision)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.
75795249|NCT04841902|Other|General Advice|General advice to stay healthy and active
75932681|NCT04441658|Biological|saline|saline containing human albumin will be infused to the control group
75932682|NCT04441580|Device|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a FIT-positive screening population.
75932683|NCT03295526|Procedure|Lymph nodes debulking surgery.|Radical hysterectomy and selective enlarged lymph node dissection
75932684|NCT03295448|Other|Low carbohydrate diet|Diet low in carbohydrates (38%E), but higher in total and saturated fat.
75932685|NCT03295448|Other|High carbohydrate, high sugar diet|Diet high in carbohydrates (53%E) and sugars, but low in wholegrain, rye and wheat fibre.
75932686|NCT03295448|Other|High carbohydrate, low sugar diet|Diet high in carbohydrates (53%E), wholegrain, rye and wheat fibre, but low in sugars.
76086185|NCT05364190|Drug|Canagliflozin|Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
76086186|NCT05364190|Drug|Empagliflozin|Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
75795250|NCT04841902|Other|Life Style Intervention Manual (Home Based)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.
75795251|NCT04829500|Behavioral|Montessori Approaches to Person-Centered Care (MAP-VA)|Montessori approaches to person-centered care (MAP-VA) introduces practical strategies that frontline staff can use for successful engagement of residents through retained abilities. Staff are also introduced to concrete strategies that improve dignity, control, and independence. MAP-VA is based on the work of Maria Montessori who demonstrated that a structured, supportive environment and meaningful, active roles in the classroom enabled children to fulfill their greatest potential physically, mentally, and emotionally. Montessori principles have been applied to dementia care for more than 20 years to promote functional independence, meaningful engagement, and dignity.
75795252|NCT04799197|Behavioral|Kicking it with the Gurlz|The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
75932687|NCT00835575|Drug|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
75795253|NCT04796584|Other|Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus|mRNA vaccination for SARS-CoV-2 is not provided by the study
75795254|NCT04794621|Device|Electroceutical Dressing Technology-EDThi|Use of EDThi for 3 weeks post enrollment
75337922|NCT01414153|Drug|sham injection|administered monthly for 4 months
75337923|NCT03008629|Device|Podofix nail brace|Podofix nail brace
75932688|NCT00835575|Drug|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
75337924|NCT03008629|Device|Combiped nail brace|Combiped nail brace
75795255|NCT04794621|Device|Adding EDTlo (Procellera®) for 3 weeks after use of EDThi|Use of EDTlo (Procellera®) for additional 3 weeks
75795256|NCT04759976|Behavioral|Robotic motor training|The experiments consist in performing motor tasks with upper-limb robotic devices.
75932689|NCT03295370|Procedure|Electrical Stimulation|A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
75932690|NCT03295292|Biological|Stem cells|Mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in fibrin sealant
75932691|NCT03295292|Other|Vehicle|50uL of commercially available fibrin sealant (Baxter, TISEEL)
75932692|NCT00777309|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
75932693|NCT00777309|Drug|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
75932694|NCT00777309|Drug|Placebo|The placebo is provided as a capsule
75932695|NCT03295214|Drug|Acetaminophen|Acetaminophen given for pain relief
75795257|NCT04754126|Behavioral|Amazing Me|The Amazing Me Program is an evidence-based program designed to help children between the ages of 9 and 11 build self-esteem, body confidence, and eliminate weight-based bullying and teasing. This school-based curriculum satisfies national educational health requirements and provides tools for teachers to implement in 4th and 5th grade classrooms.
75932696|NCT04604704|Drug|Naltrexone|Naltrexone at 4.5 mg/day
75932697|NCT04604704|Dietary Supplement|NAD+|NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.
75932698|NCT03295058|Drug|Non ATG Conditioning regimen|50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
75932699|NCT03295058|Drug|GVHD Prophylaxis|Cyclosporine A (CsA 3 mg/kg) start day +5
75932700|NCT03295058|Procedure|Allogenic Stem Cell Transplantation|using peripheral blood stem cells
75932701|NCT03295058|Drug|ATG conditioning regimen|the other 50% of the patients will receive Cyclophosphamide + ATG
75932702|NCT00777231|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
75337925|NCT03008629|Device|Podofix and then Combiped nail brace|Podofix and then Combiped nail brace
75337926|NCT01311895|Drug|H2O|2 mg IV hydromorphone
75337927|NCT01311895|Drug|1+1|"1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
75337928|NCT03009175|Device|Implantable Cardiac Defibrillator, Cardiac Resynchronization Therapy Defibrillator/Pacemaker|
75932703|NCT02462018|Device|WalkAide|"Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES."
75932704|NCT00776373|Drug|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
75932705|NCT04601194|Behavioral|Coaching and Virtual Provider Program Practice|4 weekly goal setting/coaching sessions, coupled with Virtual Provider program training and practice
75473508|NCT01971398|Behavioral|Negative FASD education brochure|Exposure to a negative FASD education brochure
75337929|NCT01362127|Drug|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
75337930|NCT01362127|Radiation|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
75337931|NCT01312519|Device|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
75795258|NCT04752592|Diagnostic Test|SeroSelectTB rapid TB test|The SeroSelectTB test is a rapid blood-based immunochemical lateral flow assay for the detection of active tuberculosis.
75795259|NCT04752501|Other|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
75795260|NCT04752501|Other|Biomedical Education (Control)|This arm will provide education of basic knee anatomy, lower extremity mechanics, and simple exercises and will not address maladaptive psychological behaviors
75795261|NCT04725149|Other|500 ml base solution|Color, taste, aroma, and calorie matched water base
75795262|NCT04725149|Other|500 ml containing 30 ml tart cherry concentrate diluted with water and base solution|Montmorency cherry concentrate
75795263|NCT04725149|Other|500 ml containing 60 ml tart cherry concentrate diluted with water only|Montmorency cherry concentrate
75647651|NCT00948818|Drug|Matching placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
75795264|NCT04716075|Drug|Acalabrutinib 2x100 MG Oral Capsule + alloSCT|Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
75795265|NCT04701957|Behavioral|Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
75795266|NCT04694924|Other|standard of care|"No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation.~Clinical outcomes will be reported via predefined electronic forms, integrated into the electronic health record (EHR). Patient-reported outcomes will be collected electronically.~All treatment decisions will be made at the discretion of the investigator or treating physician."
75795267|NCT04691700|Drug|Goreisan|Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
75795268|NCT04691700|Drug|Standard Treatment|Standard therapy without Goreisan
75795269|NCT04690595|Biological|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-ALL
75795270|NCT04688931|Drug|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
76086187|NCT05363930|Device|Novel motorized spiral enteroscopy|Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
75337932|NCT01312519|Device|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
75337933|NCT01312675|Device|S.A.F.E.BT|Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
75337934|NCT01362205|Drug|Dexmedetomidine|
75337935|NCT01362205|Drug|Placebos|Inactive placebo (normal saline)
75337936|NCT01362907|Device|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
75337937|NCT01362907|Device|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
75647652|NCT02854592|Drug|rtPA|intravenous thrombolysis with rtPa
75647653|NCT02854592|Drug|urokinase|intravenous thrombolysis with urokinase
75647654|NCT00948506|Drug|1% topical cidofovir|1% topical cidofovir
75647655|NCT00948506|Drug|3% topical cidofovir|3% topical cidofovir
75337938|NCT00052910|Drug|cisplatin|Given IV
75337939|NCT00052910|Drug|epirubicin hydrochloride|Given IV
75337940|NCT00052910|Drug|fluorouracil|Given IV
75337941|NCT00052910|Drug|leucovorin calcium|Given IV
75337942|NCT00052910|Radiation|radiation therapy|Given 5 days a week for 5 weeks
75647656|NCT00948506|Drug|Placebo|topical placebo
75647657|NCT00955682|Biological|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
75647658|NCT00955682|Biological|Meningitec™|One intramuscular dose (Booster)
75647659|NCT00689221|Drug|Cilengitide|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
75932706|NCT04373577|Procedure|erector spinae plane block|the patient will be placed in the lateral position with the surgical side up for performing erector spinae plane block. After skin preparation, superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation 1-2cm lateral to the midline at the sacral level. The L2 level will be identiﬁed by counting upward from the sacrum. Following identiﬁcation of the erector spinae muscle (ESM) and transverse process, a 21 G needle will be inserted deep to the erector spinae muscle (ESM) in a cranio-caudal direction. After negative aspiration, the correct needle position will be conﬁrmed with the administration of 0.5-1ml LA. A total volume of 0.5 mL/kg local anesthetic solution will be injected interfascial plane between erector spinae muscle and transverse process for block performance.
75795271|NCT04688931|Procedure|TURBT|The current standard of care for treatment of LG IR NMIBC is TURBT under general anesthesia.
75795272|NCT04630769|Drug|IP FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation
75795273|NCT04630769|Drug|Enoblituzumab|Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy
75647660|NCT00689221|Drug|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
75337943|NCT01416025|Drug|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
76086188|NCT05363930|Device|Single balloon enteroscopy|Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
76086189|NCT05362032|Device|Biopsy|Undergo transrectal MRI-targeted biopsy
76086190|NCT05362032|Procedure|Endorectal Magnetic Resonance Imaging|Endorectal MRI
76086191|NCT05352893|Drug|Imsidolimab high dose|intravenous
75337944|NCT01363843|Drug|FOLFOX6|FOLFOX6
75337945|NCT01363843|Radiation|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
75337946|NCT01363843|Procedure|Surgery|
75337947|NCT01417741|Device|Acupuncture Needle|A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
75647661|NCT00689221|Radiation|Radiotherapy|Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.
75647662|NCT02007733|Other|Serial Weights|We will collect serial weights on all children enrolled in this study.
75647663|NCT02007733|Other|IVC/Aorta Ultrasound|We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
75647664|NCT02007733|Other|Clinical Assessment|We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
75795274|NCT04630769|Drug|IL-2|IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is <45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
75795275|NCT04610138|Drug|CNM-ZnAg|ZnAg liquid solution
75647665|NCT04060771|Drug|Palonosetron|prophylaxis of postoperative nausea and vomiting
75795276|NCT04610138|Drug|Placebo|Water
75795277|NCT04581434|Behavioral|Prolonged Exposure Therapy|Prolonged Exposure Therapy is an individually-delivered treatment for PTSD that includes in vivo exposure to trauma reminders and imaginal exposure to the trauma memory delivered in 90-minute weekly sessions.
75795278|NCT04581434|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an individually-delivered treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to the trauma, with an optional written trauma account during weekly 60-minute sessions
75473509|NCT01971398|Behavioral|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
75795279|NCT04581434|Behavioral|Present Centered Therapy|"Present Centered Therapy is an individually-delivered treatment for PTSD that focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to current life difficulties and stress identified by patients, and emotional support and validation"
75795280|NCT04572659|Other|Group psychosocial intervention|Several couples attended a total of six group psychotherapy sessions conducted by a psychologist. Between 4 and 7 couples were treated in each group session.
75795281|NCT04572659|Other|Couple psychosocial intervention|The couple attended a total of six psychotherapy sessions conducted by a psychologist. Each couple was attended particularly.
75647666|NCT04060771|Drug|Dexamethasone|prophylaxis of postoperative nausea and vomiting
75647667|NCT00744913|Drug|Nicoderm patches|Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
75647668|NCT00744913|Other|Counselling|Women in this arm of the study will receive standard counseling only.
75647669|NCT01875445|Drug|Inositol|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
75473510|NCT01971411|Drug|Calcium 500mg with 200 IU Vitamin D - 2 tablets daily|
75473511|NCT01971411|Procedure|Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH|
75473512|NCT01971411|Behavioral|Usual sun exposure documentation|
75473513|NCT01971411|Behavioral|Dietary intake of calcium, vitamin D, magnesium|
75473514|NCT01971424|Dietary Supplement|Mg oxide|
75473515|NCT01971424|Other|healthy diet|
75795282|NCT04571021|Other|I-DEPT|Implementation of the novel triage algorithm
75473516|NCT01971437|Procedure|Cystodistension & Cystoscopy|Women with refractory OAB receiving Cystoscopy and cystodistension
75647670|NCT01875445|Drug|Placebo|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
75795283|NCT04571021|Other|DEPT|Existing triage algorithm
75795284|NCT04543188|Drug|PF-07284890|PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
75647671|NCT03779113|Drug|HMPL-523|Oral HMPL-523
75795285|NCT04543188|Drug|Binimetinib|Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
75647672|NCT02564653|Behavioral|Technical Assistance, training and clinical reminders|Technical Assistance, training and clinical reminders (TTC)
75795286|NCT04543188|Drug|Midazolam|Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15
75795287|NCT04534712|Diagnostic Test|LYMPHOCYTE MONOCYTE RATIO|Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
75795288|NCT04526067|Behavioral|CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home on weekly visits to cue adaptive behaviors and establish healthy habits.
75795289|NCT04526067|Behavioral|R-CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home using remote weekly visits to cue adaptive behaviors and establish healthy habits.
75795290|NCT04525027|Diagnostic Test|intra-abdominal pressure in severe acute pancreatitis|daily intra abdominal pressures in patients admitted to ICU will be measured and noted for intial 5 days and followed up until end outcome
75795291|NCT04506463|Drug|MM-II dose I|Intra-articular injection
76086192|NCT05352893|Drug|Imsidolimab low dose|intravenous
76086193|NCT05352893|Other|Placebo|intravenous
76086194|NCT05349617|Biological|CHIKV VLP/adjuvant|PXVX0317 vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
75795292|NCT04506463|Drug|MM-II dose II|Intra-articular injection
75932707|NCT04373577|Procedure|pericapsular nerve group block|the patient will be in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
75932708|NCT04065802|Radiation|Stereotactic Radioablation|External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
75932709|NCT00772785|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
76086195|NCT05349617|Biological|Placebo|Placebo is comprised of formulation buffer
76086196|NCT05346042|Other|duration infectiousness|is the probability and the duration of being infectious in hospitalized COVID-19 patients, consequently influencing the decision on cessation of isolation
76086197|NCT05341921|Behavioral|Alternate Nostril Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
75473517|NCT01971450|Drug|Iloprost (Ventavis, BAYQ6256)|
75473518|NCT01971502|Drug|Placebo to BI 1060469|single rising doses
75473519|NCT01971502|Drug|BI 1060469|food effect
75647673|NCT02564653|Behavioral|TTC+Referral to Community Health Worker|TTC+ referral to a VHW for additional counseling and follow-up
75647674|NCT04060537|Other|Laboratory analysis of samples|RNA sequencing, immunohistochemistry, immunofluorescence, and cytometry of tumour tissues
75473520|NCT01971502|Drug|BI 1060469|single rising doses
75647675|NCT04060537|Other|Application of machine learning|Using machine learning to interrogate data generated from analysis of Renal Cell Cancer tumours using RNA sequencing, immunohistochemistry, immunofluorescence, cytometry, and MRI imaging of tumours.
75647676|NCT03763591|Behavioral|Trauma Systems Therapy for Refugees Group Intervention|Psychological skills group for youth of refugee and immigrant backgrounds.
75647677|NCT03893773|Device|doppler ultrasonagraphy|"The following parameters will be measured:~Hepatic artery Resistance index (HARI), Diameter, peak systolic velocity (HAPSV, cm/s).~Portal vein peak velocity (PVPV) and diameter at the anastomotic and non-anastomotic sites.~Hepatic vein peak velocity and wave form"
75647678|NCT00745069|Drug|tapentadol HCl|
75647679|NCT00745147|Drug|Chinese herbal formula (CCH1)|initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
75647680|NCT00745147|Drug|Duphalac|initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
75647681|NCT00688909|Drug|letrozole|2.5 mg daily by mouth for 6 months
75647682|NCT00948428|Drug|imiquimod|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
75647683|NCT00948428|Drug|Aldara™|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
75795293|NCT04506463|Drug|MM-II dose III|Intra-articular injection
75795294|NCT04506463|Drug|Placebo|Intra-articular injection
75795295|NCT04506463|Drug|Placebo|Intra-articular injection
75795296|NCT04506463|Drug|Placebo|Intra-articular injection
75795297|NCT04477512|Drug|Cabozantinib|Supplied by Exelixis
75795298|NCT04477512|Drug|Nivolumab|Supplied by Bristol-Myers Squibb
75795299|NCT04477512|Drug|Abiraterone acetate|Commercially available
75932710|NCT02461706|Drug|cannabidiol|All subjects will have a dosing titration starting with 25 mg/kg/day and will be titrated weekly as tolerated based on clinical response. All subjects will be clinically evaluated at baseline, once a month for three months and every three months thereafter. In order to ensure safe use at higher doses, patients receiving more than 600 mg of daily CBD will be evaluated at least monthly until they achieve steady state at the final fixed maintenance dose.
75795300|NCT04477512|Drug|Prednisone|Commercially available
75337948|NCT00112112|Biological|FluMist|"The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
75337949|NCT00112112|Biological|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
75337950|NCT02092298|Drug|Mitomycin C|Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
75795301|NCT04477512|Procedure|Peripheral blood collection|Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment
75337951|NCT02092298|Drug|Cisplatin|Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
75337952|NCT02092298|Drug|Sodium Thiosulfate|Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
75337953|NCT00115076|Drug|Efalizumab|24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
75932711|NCT02461706|Other|Blood Test|All subjects will have the following clinical laboratory tests including changes in bone marrow (CBC), liver (AST, ALT), and kidney function (creatinine, electrolytes, BUN) will be assessed at baseline, each month during months 1 to 3, and every 3 months thereafter.
75647684|NCT00948428|Drug|Vehicle Cream|Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
75647685|NCT02856308|Device|Hairstetics hair implant device|
75647686|NCT02854982|Procedure|therapeutic management of the prostate Cancer as usual|
75647687|NCT00948194|Drug|Nitric Oxide|Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
75647688|NCT00691483|Drug|placebo|placebo tablet taken orally twice daily for 12 weeks
75647689|NCT00691483|Drug|varenicline|varenicline tablets, 1 mg taken orally twice daily for 12 weeks
75647690|NCT02565433|Other|questionnaire administration|Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
75647691|NCT00691093|Drug|fesoterodine|4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
75647692|NCT03646825|Dietary Supplement|Natural Antioxidant supplement|1 capsule orally three times a day for 12 weeks
75647693|NCT00745225|Drug|Pioglitazone|pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
75647694|NCT00745225|Drug|placebo comparator|1 capsule daily, 96 weeks.
75795302|NCT04468841|Diagnostic Test|cfDNA testing|peripheral blood samples collected before initiation of standard therapy, after 2 cycles of therapy, at the completion of 6-8 cycles of induction therapy, and then every 6 months for a total of 2 years from the initiation of therapy using a cfDNA assay. For retrospective patients, blood samples will be collected once.
75795303|NCT04468841|Other|sample of saliva or fingernail clipping|collected in clinic one time
75932712|NCT05497648|Behavioral|Choose to Move|"CTM (phase 3) is a 6-month, flexible, evidence- and choice-based program for low active older adults.~CTM includes~One-on-One Consultation Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~Group Meetings Over the first three months, participants will attend five, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic and provide time and space for social connection between participants.~Check-ins Over the six month program, activity coaches will provide six brief telephone check-ins (approximately 15 minutes each and once/month) to discuss their Action Plan and ask questions."
75337954|NCT05605808|Other|Aerobic exercises|Aerobic exercise by using the treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes in weeks 2-12.
75795304|NCT04468841|Diagnostic Test|pre-treatment test specimen|From bone marrow, blood, lymph node, or alternate site to identify tumor-specific mutations. For retrospective patients initial tumor tissue (if available).
75647695|NCT00745303|Procedure|Tai Chi Cuan|Tai Chi Cuan training for 3 months
75647696|NCT00947882|Drug|Placebo|Mannitol 50 mg/mL solution
75647697|NCT00947882|Drug|Degarelix 10 mg|10 mg degarelix, 40 mg/mL solution
75647698|NCT00947882|Drug|Degarelix 20 mg|20 mg degarelix, 40 mg/mL solution
75647699|NCT00947882|Drug|Degarelix 30 mg|30 mg degarelix, 40 mg/mL solution
75647700|NCT00745381|Other|questionnaire, Blood specimens|All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
75647701|NCT00745459|Drug|NPO-11|20 mL NPO-11
75647702|NCT02856386|Dietary Supplement|polyphenol supplement|8 mL once daily
75795305|NCT04468841|Diagnostic Test|PET/CT, CT, or MRI testing|PET/CT scans are required at baseline and at the patient's end-of-treatment visit. The other standard-of-care scan timepoints can be performed using PET/CT, dedicated CT, or MRI per the treating investigator's discretion.
75795306|NCT04429061|Behavioral|SKILLZ-Girl curriculum|Participation in the SKILLZ-Girl curriculum and SKILLZ-Club
75795307|NCT04407325|Device|electronic nose device|electronic nose device will be tested as a triage instrument for tuberculosis in a high risk population
75647703|NCT04204226|Behavioral|Social Worker|The social worker will discuss the clinician's recommendations for needed services and how to access the services. The family will be provided the social worker's contact information and be encouraged to reach out with more questions or if more information is needed.
75795308|NCT04407325|Device|dig chest Xray with automated readings|software for tuberculosis detection on digital Chest Xray providing a probability score from 0-100
75932713|NCT04474665|Device|Reverse shoulder arthroplasty utilizing Blueprint Software|Reverse shoulder arthroplasty utilizing Blueprint Software
75932714|NCT02460848|Other|Outpatient therapeutic program, counseling and cash transfer|"Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.~The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption."
75647704|NCT04204226|Behavioral|Autism Behavioral Health Navigation (ABHN)|The goal of the ABHN intervention is to ensure access to recommended community behavioral health services, decrease parent stress levels, and/or improve child sleep and activity levels in order to reduce disruptive behaviors. Navigators will check-in at least weekly by telephone, email, or text message (as per family preference) during the first 4 weeks of the intervention and at least every 2 weeks for the remainder of the intervention or until ABHN and family agree that all goals and action steps in the Family Care Plan are completed.
75795309|NCT04362306|Behavioral|Planned Intervention|Intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic.
75795310|NCT04362306|Behavioral|No planned intervention|Anxiety and patient satisfaction questionnaires will be completed prior to CT simulation.
75795311|NCT04356183|Other|SWET: Supervised Weight loss and Exercise Training|Weight loss will occur via a dietitian-led intervention targeting weight loss over 16 weeks, with weekly weigh-ins and group support sessions. Exercise training will consist of three times per week of an interval-based aerobic program plus twice-weekly resistance training. Both weight loss and exercise training will be supervised to maximize safety and adherence.
75932715|NCT02460848|Other|Outpatient therapeutic program and counseling|
76086198|NCT05341921|Behavioral|Bhramari Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
76086199|NCT05341921|Behavioral|Sheetali Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
76086200|NCT05339594|Device|NeuraGen|NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
76086201|NCT05339594|Device|NeuraGen 3D|NeuraGen 3D Nerve guide matrix is a resorbable implant for the repair of peripheral nerve gaps.
75795312|NCT04356183|Other|CHAT: Counseling Health As Treatment|Control Arm over 16 weeks.
75795313|NCT04349124|Drug|Nifedipine Extended-Release Tablets|Antihypertensive
75795314|NCT04348292|Drug|Durvalumab|Given IV
75795315|NCT04348292|Drug|Sirolimus|Given PO
75932716|NCT04474431|Other|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
76086202|NCT05337150|Behavioral|Lifestyle Modification Intervention|For the first 12-weeks of the study, participants will complete weekly web modules in which they will learn cognitive-behavioral strategies to support lifestyle modification. Participants will also receive weekly phone coaching calls for the first 12-weeks of the study, and monthly coaching calls thereafter for the remainder of the 24-week study period.
76086203|NCT05337150|Behavioral|Balanced Calorie Deficit Eating Plan|Participants will be prescribed a calorie target between 1200 and 1800 depending upon baseline weight and personal preference. Participants will be asked to monitor their dietary intake using MyFitnessPal and to submit food logs weekly. Calorie reduction content will be based primarily on the Diabetes Prevention Program protocol and adapted from existing behavioral treatment protocols. Individuals will receive general guidelines on eating a healthy diet, including reducing saturated fat, processed foods, refined sugars, and refined carbohydrates, and increasing intake of lean proteins, whole grains, and fruits and vegetables, but will be encouraged to flexibly decide which areas of their diet to modify to reduce calorie intake.
75337955|NCT05605808|Other|Diet protocol|A specific diet for three months is designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins.
75647705|NCT04204226|Behavioral|Social work + ABHN|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN
75795316|NCT04341662|Behavioral|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination & Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case."
75337956|NCT00254072|Procedure|3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass|The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
75337957|NCT00151814|Drug|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
75337958|NCT00153842|Drug|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg"
75647706|NCT04204226|Behavioral|Social work + ABHN + CAP|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN+Complex Autism Program (CAP)
75647707|NCT02857634|Device|Cellvizio dual band|Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.
75337959|NCT00153842|Drug|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg"
75795317|NCT04341662|Behavioral|Usual care|Health facilities will continue to follow usual care as per the baseline period for the remainder of the intervention phase.
75932717|NCT03294902|Device|Pedra Tissue Perfusion Monitor|This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
75932718|NCT05497570|Drug|Tenoxicam Injectable Product|After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
75337960|NCT01314001|Drug|Varenicline|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
75795318|NCT04316676|Diagnostic Test|PET-MPI Protocol|Patients with suspected CAD who are referred to a clinical PET-MPI will undergo the standard clinical protocol applied in the Emory Nuclear Medicine department.
75795319|NCT04316676|Diagnostic Test|CT-MPI|"For the CT-MPI, dynamic volume CT myocardial perfusion applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium. The dynamic shuttle mode consists of an image acquisition during rapid, yet smooth back-and-forth movement of the CT scanner table, so that contrast media bolus passage can be evaluated within the entire left ventricle in a time-resolved fashion. This scan acquisition will be performed during pharmacologically induced stress and during rest conditions. CT-MPI studies will be contrast medium enhanced by 50-70 ml of iodinated contrast agent, administered at a flow rate of 5 mL/s."
75932719|NCT00963885|Drug|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
75932720|NCT00963885|Drug|Pegasys|180micrograms sc weekly for 24 or 48 weeks
75473521|NCT01971515|Drug|MSC2363318A|"Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.~Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle)."
75932721|NCT00963885|Drug|Placebo|po for 12 weeks
75932722|NCT00963885|Drug|Placebo|po for 24 weeks
75932723|NCT00963885|Drug|RO5190591 (Danoprevir)|300mg po q8h for 12 weeks
75337961|NCT01314001|Drug|Placebo|"Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch"
75337962|NCT01314001|Drug|Transdermal Nicotine|Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
75337963|NCT00154466|Behavioral|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
75337964|NCT00117806|Behavioral|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
75337965|NCT00117806|Behavioral|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
75337966|NCT01363999|Drug|atorvastatin|single dose of atorvastatin on day 1
75337967|NCT01363999|Drug|dalcetrapib|single dose of dalcetrapib on day 1
75647708|NCT04277390|Other|clinical intervention for microbial analysis and MIR155 as biomarker|Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated
75795320|NCT04316676|Diagnostic Test|CT-FFR|Coronary CT angiography (CCTA) will be performed for delineation of the coronary arteries, detection of potential coronary stenosis and FFR calculation. CCTA will be performed at rest following administration of intravenous contrast agent (50-70 mL of iodinated contrast material at a flow rate of 4-5 mL/s). A total radiation dose of approximately 8 millisievert (mSv) has expected to be administered with the stress/rest protocol to the patient. The total amount of contrast agent will not exceed 140 ml.
75932724|NCT00963885|Drug|RO5190591 (Danoprevir)|600mg po q12h for 12 weeks
75932725|NCT00963885|Drug|RO5190591 (Danoprevir)|900mg po q12h for 12 weeks
75795321|NCT04316676|Drug|Regadenoson|Pharmacological stress testing for the CT-MPI scan will be performed with a single injection of 0.4 mg of regadenoson (Lexiscan).
75337968|NCT00257894|Drug|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
75795322|NCT04313192|Device|pulse rate of 2 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
75337969|NCT00257894|Drug|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
75337970|NCT00258128|Drug|Salsalate|Active
75932726|NCT00963885|Drug|RO5190591 (Danoprevir)|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
75932727|NCT02461862|Behavioral|Application of the Visual Analog Scale of pain|Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
75932728|NCT02461862|Procedure|Evaluation of blood pressure|Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
75337971|NCT00258128|Drug|Placebo|Placebo for salslate, used only in the third trial
76086204|NCT05337150|Behavioral|Ad Libitum Whole Food Plant-Based Eating Plan|Participants will be prescribed a whole food plant-based (WFPB) low-fat vegan diet promoting intake of fruits, vegetables, starches, legumes, and whole grains. Participants will be encouraged to avoid processed foods, refined oils, and animal products (meat, fish, eggs, and dairy products), and to minimize consumption of high-fat plant-based foods. An adapted traffic-light diet chart will outline foods to eat daily, limit, and avoid. Participants will be advised to eat until satiation and not restrict energy intake. Participants will be asked to consume 50 μg vitamin B12 (methylcobalamin) daily. WFPB nutrition counseling content will be based upon existing successful programs. Each week, participants will complete a simplified dietary self-monitoring food frequency questionnaire aligned to correspond with the traffic light diet chart.
75337972|NCT01364623|Drug|Low dose testosterone nasal gel, single dose|Low dose testosterone nasal gel, single dose
75337973|NCT01364623|Drug|Medium dose testosterone nasal gel, single dose|Medium dose testosterone nasal gel, single dose
75337974|NCT01364623|Drug|High dose testosterone nasal gel, single dose|High dose testosterone nasal gel, single dose
75647709|NCT02856542|Drug|calcipotriol/betamethasone dipropionate gel in Applicator|Topical treatment of scalp using applicator device. The study as such is non-interventional as the intervention has been decided prior to and independently from the inclusion of the patient in the cohort to be observed.
75647710|NCT00688753|Drug|RAD001|
75647711|NCT02854514|Procedure|Aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
75795323|NCT04313192|Device|pulse rate of 10 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
75932729|NCT02461862|Procedure|Evaluation of radial pulse|Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
75932730|NCT02461940|Behavioral|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
75932731|NCT00958971|Drug|TKI258|All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
75932732|NCT03294824|Other|blood sample|peripheral blood samples are collected
75337975|NCT01364623|Drug|Medium dose testosterone nasal gel, multiple dose|Medium dose testosterone nasal gel, multiple dose
75337976|NCT00258206|Biological|rituximab|
75337977|NCT00258206|Drug|cyclophosphamide|
75337978|NCT01063907|Drug|KW-2478|Administered Days 1, 4, 8 and 11 of a 21 day cycle
76086205|NCT05336903|Behavioral|APP-led model of care for chronic pain management|"The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~taking a comprehensive history~screening for pathologies contributing to the participant's chronic pain~a physical assessment~screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~identifying psychosocial risk factors associated with pain and disability~evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options."
75337979|NCT01063907|Drug|Bortezomib|Administered on Days 1, 4, 8 and 11 of a 21 day cycle
75337980|NCT01316263|Biological|Olaratumab|Administered IV
75337981|NCT03014765|Other|EDOP|no intervention
75337982|NCT03015857|Drug|phenylephrine|- phenylephrine; a vasopressor drug given to prevent post spinal hypotension
75337983|NCT03015857|Drug|Norepinephrine|- norepinephrine; a vasopressor drug given to prevent post spinal hypotension
75337984|NCT03015857|Drug|Bupivacaine|intrathecal bupivacaine 10 mg will be given in both groups
75647712|NCT04204382|Drug|Levofloxacin Injection|Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.
75647713|NCT04204382|Drug|Compound Kushen Injection（CKI）|CKI, 20mL each time, once a day, intravenous drip. Treatment course is 7 days.
75647714|NCT00745537|Other|repeated mood measures and phone depression care management|The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
75932733|NCT04228276|Device|Repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
76086206|NCT05330897|Procedure|Implantation of an eCLIPs™ device|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
76086207|NCT05330897|Device|eCLIPs™ Electrolytic Bifurcation Systems|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
76086208|NCT05322928|Behavioral|Engagement in daily occupations|"The 12-week occupational therapy individual person-centered intervention will be delivered by an occupational therapist according to the individual intervention plan, with a 1-hour video appointment (Region Zealand VDX-connection) a week in four weeks and a maintenance phase of similar session format every second week in two months.~The intervention will include identification of occupational problems that limit compliance with the PA recommendations, setting tailored occupational goals to enhance physically active lifestyle, supervised goal work and goal evaluation. Through active involvement in value-based prioritizing, planning and performance of meaningful everyday activities, the participants will reduce their sedentary time. Changing health behaviour in a stepwise manner, the participants will become prepared for continuous lifestyle goal work as self-management which will allow for sustainable lifestyle changes, and thus, improved long-term health and quality of life."
75647715|NCT02856152|Drug|GDC-0276 capsule|Three 90 milligram [mg] capsules of GDC-0276 administered orally.
75647716|NCT02856152|Drug|GDC-0276 tablets|Three 90 mg GDC-0276 tablets administered orally.
75647717|NCT03534193|Other|Molly Center Diabetes Care Guide (Paper-based)|Diabetes education with Registered Nurse in addition to Paper based education modules
75647718|NCT03534193|Other|Tablet based interactive diabetes education modules|Molly Center Standard Diabetes Education plus access to interactive diabetes education modules through bedside tablet.
75647719|NCT02856230|Device|Ranger SL DEB|BTK angioplasty using Ranger SL DEB
75647720|NCT02563483|Behavioral|yoga and compassion meditation program|25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
75795324|NCT04313192|Device|pulse rate of 150 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
75795325|NCT04303494|Biological|immunisation|combined diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, ± Haemophilus influenzae type B and simultaneous pneumococcus (PCV13) vaccination
75795326|NCT04292600|Diagnostic Test|POCKiT diagnostics' algorithm for LVO detection|Measurement of blood biomarkers and integration within Pockit diagnostics' algorithm for LVO detection
75932734|NCT05497414|Behavioral|Sleep deprivation|Overnight sleep deprivation.
75932735|NCT00835497|Drug|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
75932736|NCT00835497|Drug|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
75932737|NCT05491564|Device|SoftStitch™|The SoftStitch™ meniscal repair system includes a unique knotless all-inside meniscal repair implant with all suture fixation, eliminating the traditional hard plastic PEEK anchors used in the previous devices.
76086209|NCT05320237|Other|Immersive Virtual Reality Intervention|Eight week intervention with two sessions a week. Each session will be 30 minutes in duration and will involve participants partaking in VR and such games include targeting individual finger movement (playing piano); grasp and release and one game (catching falling stars) includes holding a controller for elbow flexion and extension (Whack-a-mole).
76086210|NCT05319236|Device|Gabi System|See arm description
76086211|NCT05317234|Genetic|Whole-exome sequencing|The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
76086212|NCT05315479|Drug|N1539|Once daily
75337985|NCT03015857|Drug|Fentanyl|intrathecal fentanyl 20 mcg will be given in both groups
75337986|NCT03015857|Drug|Placebo (normal saline)|
75337987|NCT03295487|Procedure|TVT-O|transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
75337988|NCT03015935|Procedure|visual-assisted entry|First trocar entry will be performed with visual-assisted trocar
75647721|NCT02855996|Other|Fathers in Action/Padres Activos (FA/PA) program|The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
75647722|NCT00631046|Dietary Supplement|Fish Oil|Daily dosage of 5 ml of fish oils from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
75795327|NCT04276610|Behavioral|Low Vision Reading Rehabilitation|Following Time 1, participants will receive the full complement of vision rehabilitation services available and deemed suitable by their clinical staff and rehabilitation professionals of either rehabilitation centre, according to the provision of assistive devices and services regulated by the Quebec Health Insurance (RAMQ). These services are include but are not limited to: a full optometric exam to determine functional vision, including refraction and the prescription of appropriate near and distance glasses and optical devices, an assessment by a low vision therapist and/or occupational therapist, the loan provision of hand-held optical magnification devices, electronic non-optical magnification devices (e.g., portable or table-top closed-circuit televisions), or computer software for screen content magnification (e.g., ZoomText), with appropriate training and follow-up sessions in the home, if required.
75647723|NCT00631046|Dietary Supplement|Sunflower Oil|Daily dosage of 5 ml of sunflower oil from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
75795328|NCT04270604|Other|Biological sample collection|Biological sample collection for biobanking and research
75647724|NCT00631124|Drug|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
75647725|NCT00631124|Drug|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
75795329|NCT04257253|Other|Targeted exercise program|Participants in this experimental intervention group will perform a combination of motor control and isolated lumbar extensor strenghtening exercises. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
75795330|NCT04257253|Other|General exercise program|Participants in this active intervention group will perform a generalized exercise program comprising upper-body and lower-body and hip strengthening exercises, as well as flexibility. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
75795331|NCT04228952|Combination Product|Modified Natural American Spirit-Tan or Green cigarettes injected with labeled NNK|American Spirit cigarettes will be modified by adding 0.300 μg [pyridine-D4]NNK to each cigarette so that the amount of total (deuterated plus unlabeled) NNK in these cigarettes is below 0.700 μg/g tobacco.
75932738|NCT00763503|Drug|CD 2027|3µg/g Oily Spray
75932739|NCT00761709|Drug|AL-39256 Ophthalmic Suspension, 1%|
75647726|NCT02855762|Other|High polyunsaturated fatty acid diet.|The investigators hypothesize the diet will improve gut health and psychiatric clinical outcomes.
75647727|NCT04275206|Other|Harkány medicinal water|The aim is to prove the effectiveness of Harkány medicinal water on patients suffering from psoriasis and rheumatoid arthritis. The control group is treated with tap water.
75647728|NCT04275206|Other|Tap water (placebo control)|The control group is treated with tap water.
75647729|NCT04275128|Device|Cooled radiofrequency ablation|Cooled radiofrequency thermal treatment uses the electrical current produced by radio waves to destroy a part of nerve tissue and relieve pain.
75647730|NCT04275128|Device|Conventional radiofrequency ablation|Genicular nerve ablation involves using radiofrequency to heat up the genicular nerve until it dies, causing relief of pain. This is a minimally invasive treatment that does not require any medication.
76086213|NCT05315206|Dietary Supplement|Citicoline|"The patient will be given 10 ml of Citicoline oral solution (Neurotidine ®) once a day in the morning for 1 year. To patients will be given 4 bottles containing 500 ml of Citicoline and the relative instructions for administration. After 6 months, the patient will bring back the used bottles and will be given additional 4 bottles containing Citicoline (Neurotidine ®). Again at the end of this 6 month period the patient will bring back the used bottles.~Each bottle of Neurotidine will contain: water; fructose; Citicoline (500 mg per 10 ml); acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavine."
75647731|NCT02854202|Other|Arm1: Whey protein|Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast
75647732|NCT02854202|Other|Arm 2 Breakfast- other proteins|Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast
75932740|NCT00761709|Drug|Latanoprost Ophthalmic Solution, 0.005%|
75932741|NCT00761709|Drug|Vehicle|Inactive ingredients used as a placebo comparator
75932742|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
75932743|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
75932744|NCT04976049|Procedure|Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery|Patients will be administered FDA approved oral 5-ALA and imaged by a FDA approved surgical fluorescence imaging device (Spy Elite) which is 0.5 meter away from the subject.
75932745|NCT00759135|Drug|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
76086214|NCT05315206|Dietary Supplement|Placebo|The patient will be given 10 ml of an oral solution of Placebo. Each bottle of Placebo, the solution of which will be indistinguishable from the active product in terms of appearance and flavor, will contain: water; fructose; acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavin
75647733|NCT02854202|Other|Arm 3 Breakfast- low protein|Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
75647734|NCT02854280|Biological|Pedalling exercise on a cycle ergometer|At 80% of the maximal aerobic power, until exhaustion
75647735|NCT02854280|Biological|Isolated contractions of the quadriceps|Until exhaustion
75647736|NCT02855684|Drug|Insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75337989|NCT03015935|Procedure|Veress entry|First trocar entry will be performed with Veress
75337990|NCT03016091|Drug|Pembrolizumab|anti PD-L1
76086215|NCT05311254|Drug|Fosfomycin Calcium|Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count >0,5x109/L.
75795332|NCT04208243|Behavioral|Creative Arts Therapy|"The intervention will consist of approximately weekly CAT in the infusion center during cancer therapy. The interventionist is a Master's prepared, licensed dance/movement therapist who is experienced in music and art therapies as well. The CAT includes dance/movement such as playing with a parachute, simple yoga breathing and postures, and work with physioballs. The music includes singing, listening to music, and playing instruments. The art consists of drawing, finger painting, working with clay. The CAT may occur in individual sessions in private infusion rooms, or in groups in the middle of the infusion center. The CAT is not only a distraction, but also a therapeutic process addressing the stressors of cancer and its treatment. The dose of CAT will be recorded (number and type of sessions) and will be factored into the analysis."
75647737|NCT02855684|Drug|Insulin glargine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75647738|NCT02855684|Drug|Non-insulin antihyperglycemic drugs|"Pharmaceutical form: capsule/tablet~Route of administration: oral"
75932746|NCT00759135|Drug|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
75932747|NCT00759135|Drug|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
75932748|NCT05439447|Diagnostic Test|Patients scheduled for VFSS testing group|Patients scheduled for VFSS testing, patient with voice.
75932749|NCT04474041|Device|EyeQue Insight|The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
76086216|NCT05303376|Biological|IBIO123|5 or 10 mg
75647739|NCT02855840|Other|completion of the quality of life questionnaire|
75647740|NCT02857556|Biological|Blood sample|
75647741|NCT02857556|Other|Retinal photography:|
75932750|NCT00835263|Drug|Lamotrigine|200 mg Tablet
75932751|NCT00835263|Drug|Lamictal®|200 mg Tablet
75795333|NCT04206449|Other|Therapeutic decision PSG|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
75795334|NCT04206449|Other|Therapeutic decision Infrared thermgraphy system|Also randomizing for Infrared thermography system
75795335|NCT04192214|Drug|BC 007|1350 mg of BC 007
75795336|NCT04181047|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|Psychotherapy.
75932752|NCT04946019|Combination Product|Unity-based MR-Linac guided FSRT|The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
75932753|NCT02639910|Biological|Tafasitamab|tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion
75932754|NCT02639910|Drug|Idelalisib|idelalisib dose: 150 mg twice daily orally
75932755|NCT02639910|Drug|Venetoclax|venetoclax dose: 400 mg once daily orally
75932756|NCT04892667|Other|intervention|The patient participating in the study needs to respect a minimum of 12-hour fasting period, a high protein and a low-carbohydrate diet prior to performing PET/CT in order to limit physiological 18F-FDG myocardial fixation.
75932757|NCT00954057|Drug|LIPO-102|intraorbital injection
75932758|NCT00954057|Drug|Placebo|intraorbital injection
76086217|NCT05303376|Other|Placebo|matching placebo
76086218|NCT05302583|Other|Aromatherapy Inhaler|Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler
76086219|NCT05300633|Behavioral|Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)|Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation. Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving. A happiness scale will be completed at each session. Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
76086220|NCT05299580|Drug|dabrafenib|Dabrafenib 150 mg bid
75647742|NCT02857556|Other|dialyse|
75647743|NCT02854358|Drug|mixed powder of A. digitata and M. sylvestris|
76086221|NCT05299580|Drug|Trametinib|Trametinib 2mg qd
75647744|NCT02854358|Drug|Hypozalix spray (artificial saliva)|Hypozalix spray (artificial saliva)
75647745|NCT01667744|Drug|Citalopram|10 mg/day
75647746|NCT00951080|Device|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
75647747|NCT00951080|Device|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
75647748|NCT04269980|Other|MAP|MAP
75647749|NCT02351492|Procedure|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
75932759|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
75932760|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
75932761|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
75932762|NCT05397990|Behavioral|Exercise|12 weeks of moderate intensity exercise, three times a week.
75932763|NCT04454502|Other|Oral colostrum administration|In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered into the cheek and on the tongue for the infants weighing between 1001-1500 g.
75932764|NCT04454580|Drug|Venetoclax|treatment with azacitidine or decitabine in combination with venetoclax
75932765|NCT05389878|Other|rehabilitation|All patients addressing intemsive inpatient post stroke rehabilitation undergo a shared evidence based Integrated Care pathway that is routinely adopted in all the participating Centres
75932766|NCT00948909|Drug|Placebo|Placebo intervention
75647750|NCT02351492|Procedure|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
75795337|NCT04181047|Other|Usual care|Access to usual care, including psychiatrist, medications, mental health therapist, general community mental health programs. TAU will NOT include electroconvulsive therapy or another trauma specific psychotherapy.
75795338|NCT04158297|Procedure|ESWL vs SOPIL|To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.
75795339|NCT04131179|Behavioral|Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP)|"Y-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the self-harm attempt, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking,relapse prevention strategies and training on anger management and assertiveness."
75795340|NCT04101487|Other|Cash Transfer|Monthly cash transfers
75795341|NCT04101487|Other|Cash Transfers and Nutrition Education|Cash transfers every month and structured nutrition education provided at household level by community health assistants based on a nutrition education handbook
75795342|NCT04096560|Drug|TAK-994|TAK-994 tablets.
75795343|NCT04096560|Drug|Placebo|TAK-994 placebo-matching tablets.
75795344|NCT04081714|Drug|CNM-Au8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids). Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to 0.5 mg/L (500 ppm). CNM-Au8 will be administered orally in volumes of 60 mL from single-dose HDPE containers. Participants will orally receive 30 mg of CNM-Au8 once daily.
75795345|NCT04054856|Device|Body Sensor Network|"The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person."
75932767|NCT00948909|Drug|ABT-126|Experimental intervention
75647751|NCT02351492|Device|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
75932768|NCT00948909|Drug|donepezil|Active comparator intervention
75932769|NCT03735576|Behavioral|Psychotherapy|15-session individually-delivered CBT specific for LLD in comparison with a supportive unspecific intervention (SUI) of the same quantity
75932770|NCT03735576|Diagnostic Test|Questionnaires|There will be a total of four assessments (see primary & secondary endpoints). The first visit of the study will be a screening and baseline (T0) visit. After the baseline assessment, the subjects will be randomized to either of the two treatment arms. Within one week, the first of the successive bi-weekly 50-minute individual face-to-face treatment sessions will be performed by a study therapist. After 7 therapy sessions, the primary and secondary outcomes will be obtained in week 5 (T1) by the blinded rater. This will be followed by the treatment sessions 8 to 15 which will be carried out by the therapist. End-of-treatment primary and secondary outcomes will be obtained in week 10 (T2). The final follow-up assessment (T3) will be performed 6 months after randomization by the blinded rater.
76086222|NCT05294757|Other|Physical exercise|1. Hospital exercise cohort: Participants will be consecutively recruited from the scheduled patient list of the falls unit and the outpatient clinics of Hospital 1. After informed consent acquisition, patients will receive a baseline clinical evaluation. Ultrasound measurements and DXA scan will be conducted, and blood samples will be collected, processed, and stored. Patients will be included in the 16-week multicomponent physical exercise program described below. After the completion of the exercise program, at 16-week follow-up, clinical evaluation, ultrasound, DXA, and blood-sample testing will be repeated.
76086223|NCT05289557|Drug|Bonjesta|Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
76086224|NCT05289557|Drug|Placebo|Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
75337991|NCT03206489|Device|noninvasive high-frequency ventilation (nHFOV)|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome
75337992|NCT03206489|Device|nasal continuous positive airway pressure (nCPAP)|nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
75647752|NCT02351492|Device|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
75647753|NCT00946322|Behavioral|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
75337993|NCT03015779|Other|cultured autologous oral mucosal epithelial cell sheet|a prospective study,Before and after self control
75795346|NCT04050501|Device|non-invasive Vagus Nerve Stimulator|Two stimulations of two minutes each will be applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The stimulation side in the neck will be the radiological side of the stroke.
75795347|NCT04030598|Drug|Donidalorsen|Donidalorsen administered SC
75932771|NCT03735576|Other|Magnetic Resonance Imaging|Underlying mechanisms are examined using neuroimaging. MRI data are acquired at four scanning sites and will be performed at baseline, end-of-treatment and follow-up to obtain a high-resolution structural T1-weighted image, a T2-weighted FLAIR image, a resting state fMRI, and diffusion tensor imaging (DTI) of the subjects' brain.
75647754|NCT04274270|Drug|Endostar|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
75795348|NCT04030598|Drug|Placebo|Placebo matching solution administered SC
75795349|NCT04028284|Device|HoloLens-guided epidural|To determine whether using the HoloLens tool increases the success of epidural insertion.
76086225|NCT05283187|Behavioral|Mindfulness Based Cognitive Therapy Group|Mindfulness Based Cognitive Therapy
76086226|NCT05278676|Drug|Dotinurad|Dotinurad oral tablet.
76086227|NCT05277831|Other|Guided Imagery Intervention|Participants in the Guided Imagery Intervention receive 6 sessions of a Guided Imagery plus standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to create or revise guided imagery scripts. After the session, coaches record the script as a digital audio file and send to the participant. Participants listen to their audio file every day and practice behavioral skills between sessions.
75647755|NCT02857322|Other|Accompanying patient's specific perioperative|
75647756|NCT02855372|Procedure|Lung transplantation|
75647757|NCT02855528|Device|Tin Filter|
75647758|NCT02855294|Drug|COC containing 30 μg of EE and 3mg of drospirenone|treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
75932772|NCT03735576|Other|Blood analysis|Blood sampling will be acquired in order to investigate the underlying mechanisms in LLD and the specific effects of psychotherapy. Blood samples are acquired at five sites at baseline (T0), T1, T2 and T3 for genetic and epigenetic analyses, measurement of Amyloid-β, Neurofilament light chain (NFL), Peripheral Blood Mononuclear Cells (PBMCs), Metabolomics, Proteomics and miRNA analyses.
75647759|NCT02855216|Other|Manual technique of sub-occipital inhibition|
76086228|NCT05277831|Other|Standard Behavioral Control|Participants in the Standard Behavioral Control condition receive 6 sessions of a standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to identify lifestyle changes to support tobacco cessation, and set a schedule for practicing new behavioral strategies. Participants complete exercises in a quit booklet every day and practice behavioral skills between sessions.
76086229|NCT05276947|Other|position with peanut ball|The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
75337994|NCT03015701|Drug|Mifepristone|a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
75647760|NCT02855216|Other|Self-treatment by way of Occipivot®|
75647761|NCT00950690|Drug|Xalatan 0.005% eye drops|ophthalmic solution dosed once daily for 3 months
75647762|NCT01535066|Procedure|acupuncture therapy|Receive acupuncture
75647763|NCT01535066|Procedure|sham acupuncture|Receive sham acupuncture
75647764|NCT02855138|Drug|oral isotretinoin|
75337995|NCT03015701|Other|Placebo|placebo matching mifepristone
75647765|NCT00694369|Drug|Comparator: etoricoxib|etoricoxib 90 mg; 120 mg (once daily) over three days.
75647766|NCT00694369|Drug|Comparator: ibuprofen|ibuprofen 2400 mg (600 mg Q6h) over three Days
75795350|NCT04028284|Other|US-guided epidural|traditional thoracic epidural procedure
75795351|NCT03994016|Behavioral|WiseGuyz|"The WiseGuyz program was developed by the Centre for Sexuality (Calgary, AB), and aims to reduce male-perpetrated adolescent dating violence, improve mental and sexual health, and support youth to build healthier, more inclusive relationships in their peer groups, schools and communities, by helping participants identify and deconstruct gender role norms.~WiseGuyz is offered during instructional time by community-based facilitators from the Centre for Sexuality. WiseGuyz is comprised of 20 sessions across four modules. These sessions typically take the full school year (September-May) to implement."
75795352|NCT03991403|Drug|Atezolizumab(Tecentriq)|Atezolizumab(1200 mg IV);Over 60 (± 15) min (for the first infusion); 30 (± 10) min for subsequent infusions if tolerated Frequency: Day 1 of every 21 days Induction: Four or Six Cycles Maintenance : until PD
75337996|NCT04353089|Other|Basic life support courses|4 hours certified basic life support courses
75647767|NCT00694369|Drug|Comparator: acetaminophen + codeine|acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
75647768|NCT00694369|Drug|Comparator: placebo|matching placebo over three Days
75647769|NCT00745693|Drug|Endothelin-1|Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
75647770|NCT00745693|Drug|BQ-123 and BQ-788|1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
75647771|NCT02563405|Drug|Doxazosin|Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
75647772|NCT02563405|Drug|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
75337997|NCT01068821|Other|Gel pad|A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
75337998|NCT01068821|Other|Egg crate foam mattress|An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
75795353|NCT03991403|Drug|Pemetrexed|"Induction Period (Four or Six Cycles)~(1) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w~Maintenance Period (Until PD) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w"
75795354|NCT03991403|Drug|Bevacizumab|Bevacizumab(15 mg/kg IV);Over 90 (±15) min (for the first infusion); shortening to 60 (± 10) then 30 (± 10) min for subsequent infusions if tolerated
75932773|NCT04419090|Other|web-based centralized service and message|Perform three cycles of cascade screening through several generation of family members of an index case. The contact of relatives will be initiated by the index case and supported by a web-based centralized service. The index case will be provided with a prepared email or Whatsapp message that the index case can further forward to his first-degree relatives. The email/message will contain a link to a secured web application with a code for the connection. By clicking on the link, the relative will connect to a specifically designed app. The app will provide information about the transmission mode of FH, the cardiovascular risk associated with FH and the way how to reduce this risk. The relative can then fill out information and provide agreement to be contacted for the study. The nearest specialized clinic will then contact the relative to organize further screening with similar processes.
75932774|NCT02522910|Drug|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
75932775|NCT00948753|Drug|Maraviroc 150 MG|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
75337999|NCT03830021|Behavioral|Salt reduction program|Dietary and behavioural change program, led by nutritionists, including low sodium dietary advice; use of aromatic herbs and spices in food instead of salt; motivational activities; food diaries; restrict salty processed foods; eat more fresh foods and seasoning advice; problem solving exercises; digital bulletins; individual counselling reinforced at each clinic visit and shopping counselling at local supermarket.
75338000|NCT03830021|Behavioral|Healthy lifestyle program|Participants receive an educational healthy lifestyle program that includes 1) methods to cook healthier and the Mediterranean diet based on a high intake of fresh fruit and, vegetables, beans, grain legumes, lentils, nuts, cereals, and olive oil as source of fat; moderate intake of fish, poultry, yoghurt and cheese, low intake of salt, red meat, processed meats and sugar; 2) physical activity; 3) drink more water and reducing alcohol consumption; and 4) sleep education.
75647773|NCT02564419|Device|Medtronic Activa PC+S|Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
75338001|NCT04780061|Drug|Vitamin D3 50,000 IU|This is a loading dose of Vitamin D. Vitamin D (cholecalciferol [vitamin D3]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.
75473522|NCT01971515|Drug|MSC2363318A plus Trastuzumab|"Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion."
75647774|NCT00513019|Drug|Lamictal (lamotrigine)|once daily from beginning to end of study. Dosage varies.
75647775|NCT00513019|Drug|Placebo|daily
75647776|NCT00053677|Drug|Naltrexone|For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
75647777|NCT00053677|Drug|Placebo|For subjects who were randomly assigned to placebo.
75795355|NCT03991403|Drug|Carboplatin|Carboplatin(AUC 5 or 5.5 IV a); Over approximately 15-30 min
75795356|NCT03991403|Drug|Paclitaxel|Paclitaxel(175 mg/m2 IV); Over 3 hours
75795357|NCT03991403|Drug|Carboplatin or cisplatin|Carboplatin(AUC 5.5 IV);Over approximately 30-60 minutes on Day 1 q3W or Cisplatin(75 mg/m²) ; Over 1-2 hours on Day 1 q3w
75795358|NCT03985930|Device|Distraction with virtual reality|Distraction content delivered through virtual reality goggles
75795359|NCT03985930|Other|Treatment as Usual|Treatment as Usual
75795360|NCT03973827|Drug|ProTrans|Single infusion of 25, 100 or 200 million cells per patient.
75932776|NCT00948753|Drug|Maraviroc 300 mg|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
75795361|NCT03973827|Drug|Placebo|Placebo Comparator: Sham transplantation (placebo) Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)
75795362|NCT03970525|Device|Venturi pump|The venturi pump makes use of the venturi effect to create a vacuum. The venturi effect creates a vacuum by the flow of a fluid, typically air, over an opening. In many phacoemulsification machines, this requires nitrogen tanks or a self-contained air compressor. The vacuum level is created within a rigid drainage cassette, to which the phaco aspiration tubing is connected. Since there is no milking of the aspiration line, the phaco tubing can be made rigid with low compliance.
75647778|NCT03385681|Other|Tailored Educational Intervention|The intervention will be a one-day seminar for nurses working at the units, with lectures and workshops with main focus on the subjects showing the lowest pediatric pain management competence. In addition, there will be clinical supervision in pediatric postoperative pain management (two or three days per unit). The intervention will be conducted by two experts (nurse and physician) in pediatric postoperative pain management. After the intervention there will be different reminders every week for the first month, and then every month (in different forms) about pediatric pain management during six months of time.
75795363|NCT03970525|Device|Peristaltic vacuum pump|"The peristaltic pump uses rollers to compress the phacoemulsification outflow tubing in a peristaltic manner, thereby creating flow and vacuum. The compression of the rollers on the tubing with the rotation of the pump physically moves fluid and creates a continuous milking action on the fluid column, The phaco machine can directly control this flow level, hence the term flow based, however, the preset vacuum level is only achieved once there is occlusion of the outflow line, typically at the phaco needle tip with cataract material."
75795364|NCT03932760|Behavioral|UPLIFT Program|UPLIFT is based on cognitive behavioral therapy and mindfulness-based practices. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
75795365|NCT03932760|Behavioral|Attention Control Group|Program is based on standard prenatal, childbirth, infant feeding, and parenting education curriculum. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
75795366|NCT03930680|Drug|Dexrazoxane|One dose of dexrazoxane
75795367|NCT03905369|Other|Decision aid and SDM booster|The investigators develop the decision aid and SDM booster. The scope of the investigators of decision making combines the clinical and patient perspective. The decision aids are developed for patients with TC either newly diagnosed or patients with advanced disease, presently in the follow-up at the participating centers, covering the whole treatment trajectory of these patients (Figure 4). Three treatment decisions are considered: 1) the extent of thyroid resection, 2) the use of RAI, and 3) the initiation of TKIs.The SDM-booster is developed alongside the decision aids, as the SDM-booster (or values clarification exercise) is often a component developed together with a decision aid. The SDM-booster aims to shape patients' values regarding aspects of the decision and ensuing treatment preferences.
75932777|NCT00948753|Drug|Maraviroc 300 mg Phase II|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
75932778|NCT05397834|Drug|Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
75932779|NCT05397834|Drug|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
75932780|NCT03991650|Behavioral|Monitoring with a device|Participants will be monitored by an App.
75932781|NCT03134547|Drug|low dose sevoflurane group|low volume volatile anesthetics (1.0%)
75647779|NCT00954512|Drug|Carboplatin|
75647780|NCT00954512|Drug|Epirubicin|
75647781|NCT00954512|Biological|Trastuzumab|
75647782|NCT00954512|Drug|Everolimus|
75932782|NCT03134547|Drug|high dose sevoflurane group|high volume volatile anesthetics (2.5%)
75932783|NCT02522676|Procedure|Endoscopic kidney stone surgery|Conventional PCNL will be performed.
75932784|NCT02522676|Procedure|Endoscopic kidney stone surgery|Mini PCNL will be performed.
75932785|NCT02522676|Procedure|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
75932786|NCT02522676|Procedure|Endoscopic kidney stone surgery|Micro PCNL will be performed.
75932787|NCT02522676|Procedure|Endoscopic kidney stone surgery|Retrograde intrarenal surgery will be performed.
75932788|NCT02522676|Procedure|Non-invasive kidney stone treatment|Extracorporeal shock wave will be performed.
76086230|NCT05276297|Drug|GSK3228836|2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.
75647783|NCT00954512|Drug|Gemcitabine|
75647784|NCT00954512|Biological|Robatumumab|In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.
75647785|NCT00954512|Biological|Cetuximab|
75647786|NCT00954512|Drug|Paclitaxel|
75647787|NCT00954512|Drug|Cisplatin|
75647788|NCT00954512|Drug|5-FU|
75647789|NCT00954512|Drug|Erlotinib|
75647790|NCT00954512|Drug|Irinotecan|
75647791|NCT00954512|Drug|Folinic Acid|
75647792|NCT00741481|Procedure|FDG-PET imaging|FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
75932789|NCT05397756|Other|observer tool|The observer tool used will be the Anaesthetist Non-Technical Skills (ANTS) tool previously published by Fletcher et al. and translated in French. The ANTS scoring system uses four categories assessing task management, teamworking, situation awareness and decision-making. The observers will use an observer tool it when they will be not role role-playing
75932790|NCT01963208|Drug|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
75338002|NCT04780061|Dietary Supplement|Vitamin C/Zinc|This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.
75795368|NCT03905369|Other|Deliberation training|The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
75932791|NCT01963208|Drug|Placebo|placebo
75932792|NCT00834873|Drug|Carvedilol 25 mg tablets|1 x 25 mg
75932793|NCT00834873|Drug|COREG® 25 mg tablets|1 x 25 mg
75932794|NCT03294746|Other|Clinical evaluations|At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.
75338003|NCT04780061|Dietary Supplement|Vitamin K2/D|This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 [vitamin K2]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss
75338004|NCT04780061|Other|Microcrystalline Cellulose Capsule|Placebo equivalent of Vitamin C/Zinc and Vitamin D3.
75338005|NCT04780061|Other|Medium Chain Triglyceride Oil|Placebo equivalent of Vitamin K2/D
75338006|NCT04644731|Device|Aquadex™ System|Ultrafiltration for fluid removal
75647793|NCT02565355|Other|Dietary Exclusion|The IgG antibody results will be disclosed ONLY to the patients in the lifestyle modification group by phone approximately one week after clinic visit.. 'Dietary Exclusion' will be advised by a dietitian. Patients are advised to eliminate a maximum of two foods as identified by high IgG antibody titres.
75795369|NCT03897439|Drug|Nicotine patch|Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
75795370|NCT03897439|Drug|Varenicline Tartrate|VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
75795371|NCT03897439|Drug|Bupropion|BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
75932795|NCT03294746|Other|Thoracic CT|At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
75932796|NCT01377480|Drug|Posaconazole|POS 40 mg/mL oral suspension
75932797|NCT01377480|Drug|Placebo for posaconazole|Placebo oral suspension
75338007|NCT01070693|Procedure|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
75795372|NCT03883100|Drug|HQP1351|40 mg tablet, taken orally once every other day
75795373|NCT03883087|Drug|HQP1351|40 mg tablet, taken orally once every other day of a 28-day cycle
75338008|NCT01070693|Device|Prolene Hernia System|Prolene Hernia System
75647794|NCT02565355|Other|Standard Treatment|The standard therapy group will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relievers as appropriate.
75647795|NCT02853890|Other|Questionnaires during hospitalization for delivery|Questionnaires during hospitalization for delivery (one questionnaire completed by doctors about different technic of analgesia and anesthesia and one questionnaire completed by women about pain, and feeling about the different techniques of analgesia and anesthesia used during delivery, eventually caesarean section or uterine revision)
75647796|NCT00745771|Drug|Diractin|
75647797|NCT00745771|Drug|Diractin|
75647798|NCT03893461|Radiation|x|Stereotactic body radiation therapy for localized NSCLC
75647799|NCT00745927|Other|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
75932798|NCT01377480|Drug|Benznidazole|BNZ 100 mg oral tablet
75932799|NCT04263909|Drug|Sublingual Tablet|sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery
75932800|NCT04488848|Other|bolus glucose|bolus Glucose
75932801|NCT04488848|Other|continuous clucose|continuous clucose
75932802|NCT00754455|Biological|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
75932803|NCT00754455|Biological|Placebo|Placebo as a single injection of 0.5 mL.
75932804|NCT01421264|Drug|Gabapentin|300mg capsules by mouth
75932805|NCT04415840|Diagnostic Test|acetic acid test|using acetic acid to unmask dysplastic lesions on the cervix uteri
75932806|NCT04415840|Diagnostic Test|Lugol's solution test|using Lugol's solution after acetic acid test to unmask dysplastic lesions on the cervix uteri
75932807|NCT05397522|Other|Supervised Exercise by a physiotherapist via face to face|The exercises are performed by the participants under the supervision of a physiotherapist via face-to-face.
75932808|NCT05397522|Other|Supervised Exercise by a physiotherapist via video conference|The exercises are performed by the participants under the supervision of a physiotherapist via video conference.
75932809|NCT00946569|Drug|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
75338009|NCT01070693|Procedure|Lichtenstein technique|Lichtenstein technique
75338010|NCT02171819|Biological|IVACFLU-A/H5N1, 7.5 mcg|Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.
75338011|NCT02171819|Biological|IVACFLU-A/H5N1, 15 mcg|Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose
75647800|NCT00746005|Dietary Supplement|fish oil|3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg
75647801|NCT00746005|Dietary Supplement|placebo, sunflower oil|3 g of sunflower oil
76086231|NCT05276297|Biological|GSK3528869A|"The GSK3528869A chronic Hepatitis B targeted immunotherapy (CHB-TI) consisting of 4 doses administered intramuscularly as follows:~1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period.~1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period.~2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period."
75338012|NCT02171819|Other|Placebo Comparator|PBS, pH 7.2 in 0.5 mL single-dose vials.
75338013|NCT02172755|Drug|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
75795374|NCT03882359|Diagnostic Test|Echocardiogram|"Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (<0.3) and one round of very low MI imaging (<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (<0.3) and one round of very low MI imaging (<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3."
75932810|NCT00946569|Drug|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
75338014|NCT02173535|Device|etafilcon test contact lens Variant AP|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
75338015|NCT02173535|Device|etafilcon test contact lens Variant JG|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
75338016|NCT02173535|Device|etafilcon test contact lens Variant CS|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
75338017|NCT02173535|Device|etafilcon test contact lens Variant VC|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
75338018|NCT02173535|Device|etafilcon test contact lens Variant LA|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
75338019|NCT04621175|Dietary Supplement|EAA+W & Carbohydrate|Essential amino acid plus whey beverage with added carbohydrate
75338020|NCT04621175|Dietary Supplement|EAA+W & EAA|Essential amino acid plus whey beverage with added essential amino acid
75647802|NCT00746083|Behavioral|Challenge!|"Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer."
75647803|NCT00746161|Procedure|Reconstruction after total gastrectomy|Roux-en-Y
75647804|NCT00746161|Procedure|Reconstruction after total gastrectomy|double tract reconstruction
75647805|NCT00746317|Drug|GC33|IV administration at 4 escalating dose levels.
75795375|NCT03882359|Drug|MVT-100|After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
75795376|NCT03882359|Drug|Definity|After randomization, Definity, the active comparator, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
75795377|NCT03878719|Drug|binimetinib|taken orally
75795378|NCT03878719|Drug|encorafenib|taken orally
75932811|NCT04488614|Procedure|Breast Concervative or Meastectomy|National treatment guidelines in Norway
75932812|NCT05397444|Other|No intervention|This is an observational study with no intervention.
75932813|NCT03134859|Behavioral|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
75932814|NCT04293159|Dietary Supplement|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
76086232|NCT05276297|Drug|Control|4 doses of non-active control administered intramuscularly in the deltoid region of the non-dominant arm at Days 1, 57, 113 and 169 to participants in ASO24 and ASO12 control groups during Treatment 2 period.
76086233|NCT05272956|Procedure|enteral feeding with pushed syringe by the parents|enteral feeding pushed by parents with a syringe
75338021|NCT02986217|Other|regular structured assessment of surgical performance|
75338022|NCT02973737|Drug|pyrotinib|400 mg once daily
75338023|NCT02973737|Drug|placebo|400 mg once daily
75338024|NCT02973737|Drug|Capecitabine|1000 mg/m2 per day on day 1 through 14, every 21 days.
75338025|NCT02762669|Drug|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
75338026|NCT01072331|Drug|MP-513|MP-513 10 mg, once a day, for 4 weeks
75338027|NCT01072331|Drug|MP-513|MP-513 20 mg, once a day, for 4 weeks
75338028|NCT01072331|Drug|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
75338029|NCT01072409|Device|Nucleus 5 Cochlear implant|Cochlear implant surgery
75338030|NCT01072409|Device|Cochlear implantation|Implantation
75647806|NCT00741559|Device|magnetoencephalography|MEG studies are performed using a whole-head Omega 151-channel gradiometer system.
75795379|NCT03831698|Drug|Omega-3 fatty acid ethyl esters (2 gram)|Omega-3 fatty acid ethyl esters (2 gram)
75795380|NCT03777436|Drug|Apremilast|Oral
75795381|NCT03777436|Other|Placebo|Oral
75795382|NCT03773302|Drug|BGJ398|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
75932815|NCT00834795|Drug|Carvedilol 25 mg tablets|1 x 25 mg
75932816|NCT00834795|Drug|COREG® 25 mg tablets|1 x 25 mg
75932817|NCT00834717|Drug|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
75932818|NCT00834717|Drug|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
75932819|NCT00834639|Drug|divalproex sodium|delayed-release 500 mg tablet
75932820|NCT00834639|Drug|Depakote®|delayed-release 500 mg tablet
75932821|NCT00940095|Drug|Clazosentan 5 m/h|Continuous intravenous infusion of clazosentan (5 mg/h)
75795383|NCT03773302|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
75795384|NCT03773302|Drug|Cisplatin|Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
75338031|NCT01072643|Drug|Dexmedetomidine|This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
75647807|NCT00741559|Device|Positron emission tomography (PET)|An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.
75795385|NCT03690791|Drug|MediCabilis CBD Oil|50 mg of CBD: <2mg of THC in one ml. The cannabis oil consists of CBD extract in MCT oil.
75932822|NCT00940095|Drug|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
75932823|NCT00940095|Drug|Placebo|Continuous intravenous infusion of placebo-matching clazosentan
75338032|NCT04352543|Behavioral|Active Video Game Exercise|Play during 30 minutes in the easy level
75338033|NCT04352543|Behavioral|Treadmill walking exercise|30 minutes (65 - 75% heart rate maximal)
75338034|NCT04352543|Behavioral|Sedentary Behavior|Quiet Rest: 30 minutes
75338035|NCT04590209|Other|Blood sampling|Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
75338036|NCT04590209|Other|Skin biopsy|Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
75338037|NCT01073657|Other|Supported Education|Rehabilitation counseling using peers to achieve educational goals
75338038|NCT01073657|Other|General Peer Support|Matched peer support for any personal goal other than education
75795386|NCT03690791|Drug|Placebo Oil|Placebo will contain only hemp seed oil.
75795387|NCT03607188|Drug|Alkotinib|Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
75795388|NCT03592992|Drug|Spinal Hydromorphone|75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
75795389|NCT03592992|Drug|Spinal Morphine|150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
75932824|NCT00834561|Drug|Lamotrigine|200 mg Tablet
75932825|NCT00834561|Drug|Lamictal®|200 mg Tablet
75932826|NCT00939237|Drug|Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
75932827|NCT00939237|Drug|Placebo|
75932828|NCT00754221|Drug|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
75932829|NCT00753285|Device|Renal Denervation|
75932830|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
75932831|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
75338039|NCT01074125|Drug|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
75338040|NCT02618213|Device|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
75647808|NCT00741559|Device|Magnetic resonance imaging|MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
75932832|NCT00834405|Drug|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
75932833|NCT00834405|Drug|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
75932834|NCT00834249|Drug|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
75932835|NCT00834249|Drug|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
75932836|NCT00751803|Drug|BI 44370 TA Low Dose|
75932837|NCT00751803|Drug|Eletriptan|
75932838|NCT00751803|Drug|Placebo|
75932839|NCT00751803|Drug|BI 44370 TA Medium Dose|
75932840|NCT05420961|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
75932841|NCT05420961|Biological|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile solution
75932842|NCT05420961|Biological|PPSV23|Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
75932843|NCT05402397|Drug|Losartan Potassium|Patients will receive losartan potassium for 30 days.
75932844|NCT00833937|Drug|Zolpidem 10 mg tablets|1 x 10 mg
75932845|NCT00833937|Drug|AMBIEN® 10 mg tablets|1 x 10 mg
76086234|NCT05249868|Other|Exposure SARS-CoV-2 Infection|"The exposure variable is confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.~Positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for <5 days is positive on a PRAg test."
76086235|NCT05244486|Device|RestoreX 1-6 months (randomized phase)|Study participants are recommended utilize the device for 30-60 minutes, 5-7 days a week starting at 1 month post-prostatectomy and continuing until 6 months.
76086236|NCT05244486|Device|RestoreX 6-9 months (open label phase)|Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).
75932846|NCT04245111|Other|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
75795390|NCT03536559|Drug|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
76086237|NCT05237440|Biological|Biological dosage|Metabolic, hormonal and psychometric evaluations will be carried out during inclusion inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out at inclusion
75338041|NCT02618213|Device|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
75795391|NCT03536559|Drug|Placebo|Placebo is liquid with identical color and taste
75795392|NCT03522025|Device|Unicompartmental Knee Arthroplasty (UKA)|Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
75932847|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
75338042|NCT01108835|Other|Comprehensive care programme|"Intervention group:~Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions~Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)~Respiratory physician assessment and optimization of treatment~Patients will also be taught about a personalized action plan by the physician and respiratory nurse.~Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries."
75795393|NCT03490253|Behavioral|DIAMANTE Adaptive|In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.
75795394|NCT03490253|Behavioral|DIAMANTE Static|The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
76086238|NCT05231187|Diagnostic Test|T2Resistance Panel|"The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~blaKPC~blaCTX-M~blaNDM / blaVIM / blaIMP~blaOXA-48 Group~vanA / vanB~mecA / mecC~AmpC (blaCMY / blaDHA)"
75795395|NCT03489733|Other|Hydrolyzed Formula|Infant formula with extensively hydrolyzed proteins and pre- and probiotics.
75795396|NCT03489733|Other|Control formula|Infant formula with intact proteins and pre- and probiotics.
75932848|NCT00831051|Drug|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
76086239|NCT05230576|Diagnostic Test|Deep learning training cohort|train the deep learning model
76086240|NCT05230576|Diagnostic Test|Deep learning validation cohort|evaluate the model
76086241|NCT05227599|Other|Online survey questionnaire|Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
75338043|NCT03014141|Other|Oat bran (Oatwell 28)|11 g oat bran containing 3.1 gram oat beta-glucan
75795397|NCT03447808|Biological|Daratumumab|Given IV
75795398|NCT03447808|Drug|Ibrutinib|Given PO
75338044|NCT03014141|Other|Maltodextrin|11 g of Maltodextrin
75473523|NCT01971515|Drug|MSC2363318A plus Tamoxifen|"Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration."
75473524|NCT01971528|Device|Electronic muscle stimulator|Participants will perform 8 weeks of electrical stimulation for Quadriceps muscle belly(30 minutes/time, 3 times/week).
75795399|NCT03447808|Other|Laboratory Biomarker Analysis|Correlative studies
75795400|NCT03447808|Other|Pharmacological Study|Correlative studies
75795401|NCT03406585|Drug|ProTrans: Allogeneic transplantation with WJMSCs|The drug is a cell suspension with allogeneic mesenchymal stromal cells derived from umbilical cord tissue.
75795402|NCT03406585|Drug|Placebos|Placebo treatment
75932849|NCT00831051|Drug|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
75932850|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
75932851|NCT00831051|Drug|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
75647809|NCT05319145|Behavioral|Intervention group|1) Multi-component exercise intervention program based on Vivifrail©. It consists of 1 daily-30 minutes session, twice a week, for 10 consecutive weeks supervised by an experienced exercise specialist. Exercises (resistance, gait retraining, balance training) are personalized depending on the person's functional capacity (evaluated by the SPPB and a walking speed test) and the risk of falling. Between sessions, individual, unsupervised training by the own patient, supported in the case by the caregiver, will be stimulated, through the recommendations of ViviFrail©. 2) Nutrition. Personalized recommendations according to nutritional and medical status (active oncologic treatment, remission, or palliative stage) will be offered according to the ESPEN recommendations for cancer patients, aimed at compensating for inadequate energy intake, improving patients' malnutrition risk stage (assessed by means of the MNA-SF).
75795403|NCT03366766|Biological|Nivolumab|Given IV
75795404|NCT03366766|Drug|Cisplatin|Given IV
75932852|NCT00831051|Drug|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
76086242|NCT05226260|Behavioral|Default Duration order Panel|The SSTI order panel will present itself when a provider types in either a drug name or diagnosis (cellulitis, impetigo, etc). Clinicians in control clinics will have access to a basic order panel which will include diagnosis and corresponding antibiotic of choice. Clinicians in intervention clinics will have access to order panels with the following additional components: prepopulated order duration fields that default to the recommended treatment duration.
75795405|NCT03366766|Drug|Pemetrexed Disodium|Given IV
76086243|NCT05222438|Drug|loncastuximab tesirine|loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
76086244|NCT05219487|Drug|Risdiplam|"Risdiplam is administered orally once daily and the recommended dosage is determined by age and body weight (see Table 1) [as outlined in the US Prescribing Information for EVRYSDI™(risdiplam)].~Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight: US Prescribing Information~Age and Body Weight (Recommended Daily Dosage): 2 months to less than 2 years of age (0.2 mg/kg); 2 years of age and older weighing less than 20 kg (0.25 mg/kg); 2 years of age and older weighing 20 kg or more (5 mg)"
76086245|NCT05209997|Other|Source document data collection|Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be colected in the study.
76086246|NCT05205616|Device|Sonopet ultrasonic saw|Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side
76086247|NCT05205616|Device|Reciprocating saw|See above description
75647810|NCT05319145|Other|Control group|General recommendations (written and videos) will be offered.
76086248|NCT05199870|Device|Echo FX Stem with RingLoc Bipolar Acetabular Cup and Femoral Head|Patients that have been implanted with a Echo FX stem with RingLoc Bipolar acetabular cup and femoral head.
76086249|NCT05199701|Device|Mammography|Hologic pre-market Mammography
76086250|NCT05199012|Dietary Supplement|Black pepper extract|Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1
75338045|NCT01076231|Radiation|proton beam radiation therapy|
75338046|NCT01076231|Drug|cisplatin|Given IV
75795406|NCT03366766|Drug|Gemcitabine Hydrochloride|Given IV
76086251|NCT05197998|Behavioral|Color Brave Program|The intervention will consist of a 6-week multi-module program that will be delivered via a mobile application. This program is designed for parents of children in K-2nd grade. Each module in the program will take approximately 30 minutes to complete, with lessons facilitated through interactive storytelling, videos, and games.
75338047|NCT01076231|Drug|etoposide|Given IV
75795407|NCT03308448|Drug|Recombinant human erythropoietin|Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
75795408|NCT03301675|Other|Orange Juice (500 mL/d)|Nutritionists prescribed the same balanced diet for both groups keeping suffice energy to maintain the current weight, estimated from total energy expenditure (TEE) for each individual and based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ/ banana or other fruits and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were colected every two weeks; blood samples and dietary questionnaires, monthly.
75795409|NCT03299309|Drug|PEP-CMV|Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.
75932853|NCT00750633|Drug|Moxidex otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
75932854|NCT00750633|Drug|Moxifloxacin otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
75932855|NCT00750633|Drug|Dexamethasone phosphate otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
75932856|NCT00750633|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
75932857|NCT00750243|Drug|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
75932858|NCT00750243|Drug|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
75338048|NCT01076231|Procedure|therapeutic conventional surgery|
75338049|NCT00117962|Biological|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
75338050|NCT00117962|Drug|carboplatin|AUC = 5 q 21 days for 4 cycles
75647811|NCT00691015|Biological|rituximab|Given IV
75647812|NCT00691015|Drug|busulfan|Given IV
75338051|NCT00117962|Drug|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
75795410|NCT03292679|Procedure|3D template|"A 3D-printed model of relevant portions of the patient's facial skeleton, based on patient's CT scan will be created. This model will be used to bend titanium reconstruction plates that are used to stabilize the facial fracture for subjects in the treatment group.~Bending of the plates will be performed in the operating room during the patient's surgery. Titanium reconstruction plates are used to stabilize the fracture whether or not the individual is in the study. However, for patients that are in the treatment arm of the study, the plates are bent with the aid of the 3D-printed model as template, rather than by free-hand."
75795411|NCT03258788|Procedure|Biopsy and blood samples|"Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.~Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.~Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment."
75795412|NCT03256760|Biological|Endotoxin|Endotoxin
75795413|NCT03256760|Biological|Placebo|Placebo
75795414|NCT03254927|Drug|CDX-3379 and cetuximab|Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
75795415|NCT03238599|Behavioral|Pedometer-based activity monitoring after ASCT|Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
75932859|NCT05380011|Other|Constraint Induced Movement Therapy and Bimanual Task Training|Constraint-Induced Movement Therapy and Bimanual Task Training will be performed. Constraint-Induced Movement Therapy has been shown to improve the uni-manual capacity of the impaired limb as well as improvement in quality and efficiency of movement and greater grasp function, whereas Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
75932860|NCT05380011|Other|Bimanual Task Training|Bimanual Task Training will be performed. Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
75338052|NCT00117962|Radiation|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
75647813|NCT00691015|Drug|carmustine|Given IV
75338053|NCT01109069|Drug|PCI-32765|Dose based on parent protocol
75338054|NCT00118274|Biological|incomplete Freund's adjuvant|Given intradermally and subcutaneously
75338055|NCT00118274|Biological|melanoma helper peptide vaccine|Given intradermally and subcutaneously
75338056|NCT00118274|Biological|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
75647814|NCT00691015|Drug|cyclophosphamide|Given IV
75795416|NCT03226678|Drug|APL-2|Complement (C3) Inhibitor
75795417|NCT03156023|Drug|Rozibafusp Alfa|Administered by subcutaneous injection once every 2 weeks.
75795418|NCT03156023|Drug|Placebo|Administered by subcutaneous injection once every 2 weeks.
75795419|NCT03101826|Behavioral|Listening Project Protocol|The filtered music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
75338057|NCT00118274|Biological|tetanus toxoid helper peptide|Given intradermally and subcutaneously
75338058|NCT00118274|Drug|cyclophosphamide|Given IV
75338059|NCT01109147|Other|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
75338060|NCT01109147|Genetic|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
75338061|NCT01898000|Behavioral|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
75338062|NCT01898000|Behavioral|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
75647815|NCT00691015|Drug|cytarabine|Given IV
75647816|NCT00691015|Drug|etoposide|Given IV
75647817|NCT00691015|Drug|fludarabine phosphate|Given IV
75647818|NCT00691015|Drug|melphalan|Given IV
75647819|NCT00691015|Radiation|total body irradiation (TBI)|Given once or twice daily
75647820|NCT00691015|Drug|anti-thymocyte globulin IV|Given IV
75647821|NCT00741637|Biological|CholeraGarde®|"Live attenuated oral Cholera vaccine~Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials"
75647822|NCT00741637|Biological|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
75647823|NCT00950300|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
75795420|NCT03100539|Other|Therapist treated massage|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
75795421|NCT03039036|Procedure|Amniotomy|Artificially rupturing membranes
76086252|NCT05197972|Other|cardiac coherence program coupled with hypnosis|"At home the patient will perform the cardiac coherence sessions between 7 days and a maximum of 15 days before the surgery through the application Respirelax: 3 sessions per day, lasting 5 minutes with a breathing frequency of 6 cycles/min for a period of 7 days minimum and maximum 15 days.~An audio tape read in a hypnotic tone can be listened to by the patient during the cardiac coherence program or at another time of the day (see the text of the audio tape)."
76086253|NCT05197075|Drug|DRV/COBI FDC|DRV/COBI FDC tablet dispersed in water will be administered orally.
75338063|NCT01109381|Drug|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
75338064|NCT01110395|Diagnostic Test|MR Spectroscopy|MR spectroscopy of myocardial
75338065|NCT00166166|Drug|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
76086254|NCT05195398|Device|Anodal transcranial Direct Current Stimulation (A-tDCS)|Participants randomized to tDCS will undergo 5 weeks of A-tDCS + CCT.
75647824|NCT00950300|Drug|Cyclophosphamide|Participants will receive cyclophosphamide, 500 mg/m^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
75647825|NCT00950300|Drug|Docetaxel|Participants will receive docetaxel, 75 mg/m^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
75647826|NCT00950300|Drug|Epirubicin|Participants will receive epirubicin, 75 mg/m^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
75647827|NCT00950300|Drug|Herceptin IV [trastuzumab]|Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
75647828|NCT00950300|Drug|Herceptin SC [trastuzumab]|Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
75647829|NCT00949988|Drug|Dasatinib and Rituximab|"In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional"
75647830|NCT00731692|Drug|FTY720|Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
75338066|NCT00166166|Drug|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
75647831|NCT00731692|Drug|Placebo|Matching placebo capsules were administered orally once daily
75647832|NCT02593474|Drug|Naltrexone|Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
75647833|NCT00687193|Drug|Placebo|Placebo BID, 3 blinded tablets administered BID for 12 weeks
75338067|NCT00166166|Drug|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
75647834|NCT00687193|Drug|CP-690,550|10mg BID, 3 blinded tablets administered BID for 12 weeks
75647835|NCT00687193|Drug|CP-690,550|15mg BID, 3 blinded tablets administered BID for 12 weeks
75647836|NCT00687193|Drug|CP-690,550|1mg BID, 3 blinded tablets administered BID for 12 weeks
75932861|NCT04438707|Other|Pilates Method combined with Therapeutic exercice.|Children must perform specific exercices in this combined method with the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
75932862|NCT04438707|Other|Therapeutic exercise|Children must perform specific exercices without the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
75338068|NCT00166166|Drug|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
75338069|NCT00166166|Drug|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
75338070|NCT00166166|Drug|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
75338071|NCT00166166|Drug|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
75338072|NCT03014219|Drug|Only 1 arm: treatment with MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
75338073|NCT04265378|Device|anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
75647837|NCT00687193|Drug|CP-690,550|3mg BID, 3 blinded tablets administered BID for 12 weeks
75647838|NCT00687193|Drug|CP-690,550|5mg BID, 3 blinded tablets administered BID for 12 weeks
75647839|NCT02594878|Drug|Pamidronatdinatrium|
75647840|NCT02594878|Other|Natrium chloride 9mg/ml|
75647841|NCT00917878|Dietary Supplement|Milk|500 mL low-fat milk added to high-fat meal
75647842|NCT00917878|Dietary Supplement|Protein|Milk protein in 500 mL water added to high-fat meal
75647843|NCT00917878|Dietary Supplement|Calcium|Milk calcium in 500 mL water added to high-fat meal
75647844|NCT00917878|Dietary Supplement|Control|Lactose in 500 mL water added to high-fat meal
75932863|NCT00748605|Drug|S-2367 Placebo|Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
75932864|NCT00748605|Drug|S-2367 1600 mg q.d. 54 Weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks
76086255|NCT05195398|Device|Sham Intervention|Participants randomized to sham-intervention will undergo 5 weeks of sham + CCT.
76086256|NCT05187013|Behavioral|mHealth for Hypertension in Homeless Persons|SMS text messages sent to participants' mobile phones
76086257|NCT05182567|Drug|GLS-5310 (Group 1)|GLS-5310 DNA plasmid vaccine
75647845|NCT03969550|Other|Measure of overall survival|Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.
75932865|NCT00748605|Drug|S-2367 1600 mg q.d. 60 weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks
75932866|NCT00748605|Other|LCD (low calorie diet)|A low calorie diet was utilized during the first 6 weeks of the study
75795422|NCT03039036|Device|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
75932867|NCT00748605|Other|RCD (reduced calorie diet)|A reduced calorie diet was used during the last 54 weeks for the study
75932868|NCT00924170|Drug|LMB-2|Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
75932869|NCT00924170|Drug|Fludarabine|"Days 1-3:~Patients 1-7, 10-14, and >18:25mg/m^2/day Patients 8 - 9:30 mg/m^2/day Patients 15- 17:20 mg/m^2/day"
75932870|NCT00924170|Drug|Cyclophosphamide|"Days 1-3:~Patients 1-7, 10 -14, and >18:250 mg/m^2/day Patients 8 - 9:300 mg/m^2/day Patients 15-17:200 mg/m^2/day"
75932871|NCT00747123|Biological|ACE-011|ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
75647846|NCT00730912|Drug|loratadine|Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
75647847|NCT00730912|Drug|loratadine|loratadine 10 mg tablet once daily for 4 weeks
75647848|NCT00730912|Drug|loratadine|loratadine 10 mg tablet once daily for 4 weeks
75647849|NCT04059601|Diagnostic Test|Magnetic resonance cholangiography|preoperative MRCP in acute cholecystitis before cholecystectomy
75647850|NCT04059601|Diagnostic Test|Intraoperative cholangiography|Intraoperative cholangiography in acute cholecystitis during cholecystectomy
75647851|NCT00730756|Drug|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
75795423|NCT03039036|Drug|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
75795424|NCT03025880|Drug|Pembrolizumab|Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.
75932872|NCT00747123|Biological|Placebo|Placebo given by the subcutaneous route of administration monthly for 4 doses.
75932873|NCT03294512|Behavioral|MAWDS data entry on app|Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
75932874|NCT04809285|Device|Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app|Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
75932875|NCT00920985|Drug|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
75932876|NCT00920985|Drug|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
75932877|NCT04808349|Other|no intervention|no intervention
75932878|NCT05388747|Drug|Cefuroxime|Population pharmacokinetics, effectiveness, and safety of cefuroxime
75932879|NCT00828321|Drug|Ramipril 10 mg capsule|1 x 10 mg
75932880|NCT00828321|Drug|Altace® 10 mg capsule|1 x 10 mg
75932881|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
75932882|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
75647852|NCT00730756|Other|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
75647853|NCT00730132|Drug|Ezetimibe|Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
75647854|NCT00730132|Drug|Statin|Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
75932883|NCT01352715|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
75932884|NCT01352715|Drug|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
75647855|NCT00737464|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
75647856|NCT02594722|Device|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
75647857|NCT02594722|Device|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
75795425|NCT03025880|Drug|Gemcitabine|Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
75932885|NCT01352715|Drug|Abacavir/lamivudine/zidovudine|Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
75647858|NCT00729586|Other|Laboratory Biomarker Analysis|Correlative studies
75647859|NCT00729586|Drug|Megestrol Acetate|Given PO
75647860|NCT00729586|Drug|Tamoxifen Citrate|Given PO
75647861|NCT00729586|Drug|Temsirolimus|Given IV
75932886|NCT01352715|Drug|Abacavir/lamivudine|Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
75932887|NCT01352715|Drug|Lamivudine/zidovudine|Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
75932888|NCT01352715|Drug|Abacavir|Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
75932889|NCT01352715|Drug|Zidovudine|Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
75932890|NCT01352715|Drug|Lamivudine|Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
75932891|NCT00743925|Drug|Varespladib Methyl (A-002)|2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
75932892|NCT00740727|Drug|Human recombinant hyaluronidase (HRH)|150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
75932893|NCT00740727|Procedure|Enzymatically Augmented Subcutaneous Infusion (EASI) line placement|Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
75932894|NCT00826059|Device|Active Sphenopalatine Ganglion (SPG) Stimulation|SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
75932895|NCT00826059|Device|Sham Sphenopalatine Ganglion (SPG) Stimulation|Sham SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
75647862|NCT00949910|Drug|Erlotinib|Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
75647863|NCT04313543|Dietary Supplement|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes. Then, they take 50g of longan syrup in 250 ml of water in 5 minutes
75647864|NCT02594800|Drug|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
75647865|NCT02593162|Drug|Faldaprevir|
75647866|NCT02593162|Drug|TD-6450|
75647867|NCT02593162|Drug|Ribavirin|
75647868|NCT00686959|Drug|Pemetrexed|infusion over 10 minutes
75647869|NCT00686959|Drug|Cisplatin|infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
75647870|NCT00686959|Drug|Etoposide|administered per local practice guidelines over a minimum of 30 minutes
75647871|NCT00686959|Drug|Vinorelbine|administered over 6-10 minutes infusion per local practice guidelines
75647872|NCT00686959|Drug|Paclitaxel|administered as a 3-hour infusion
75647873|NCT00686959|Drug|Carboplatin|administered per local practice guidelines over 30 minutes
75647874|NCT00686959|Radiation|Thoracic Radiation Therapy (TRT)|
75647875|NCT02594566|Drug|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
75647876|NCT04088110|Drug|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
75647877|NCT04088110|Drug|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
75647878|NCT04088110|Drug|Aromatase Inhibitors|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
75647879|NCT02594488|Device|Medtronic Reveal LINQ implantable cardiac monitor|The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
75795426|NCT02962297|Drug|Vitamin E softgel|All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
75795427|NCT02962297|Drug|Placebo|"All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).~Height and weight, waist-to-hip ratio Review of diet and exercise"
75932896|NCT00825513|Device|Akreos Toric IOL|Lens implant following cataract surgery
76086258|NCT05182567|Drug|GLS-5310 (Group 2)|GLS-5310 DNA plasmid vaccine
75795428|NCT02908308|Procedure|Targeted temperature management to 33°C|Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.
75795429|NCT02908308|Procedure|Standard care with early treatment of fever|Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C
75932897|NCT00825513|Device|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
75647880|NCT04087954|Behavioral|Stigma reduction program|"Participants in the intervention group received treatment as usual, supported with stigma reduction program booklets each fortnight for 26 weeks. The stigma reduction program includes three modules; psychoeducation, cognitive behavioural therapy and social skills training. The program aims to enhance patient understanding of Schizophrenia and foster communication skills which supposed to increase self-confidence and strengthen communication networking with society.~Psychoeducation module purposes at introducing about the concepts of schizophrenia, providing patient with essential information about schizophrenia, including nature of disease, sign/symptoms, treatment strategies, side effects of medication. Social Skills Training (SST) module purposes at fostering communication skills among patient diagnosed with schizophrenia. This assists the participants to be re-integrated in the society and build a harmonious atmosphere in the community."
75932898|NCT00919893|Drug|Cernilton|Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
75932899|NCT00919893|Drug|Placebo|Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
76086259|NCT05182567|Drug|GLS-5310 (Group 3)|GLS-5310 DNA plasmid vaccine
76086260|NCT05182567|Drug|GLS-5310 (Group 4)|GLS-5310 DNA plasmid vaccine
75647881|NCT04088266|Combination Product|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA®
75932900|NCT04789863|Device|SMILe-Integrated Care Model|"Four self-management intervention modules will be delivered by human and technology: 1) monitoring & follow-up; 2) infection prevention; 3) medication adherence; 4) physical activity.~Human. A CC will provide structured and tailored self-management and behavioural support regarding all 4 modules via 12 face-to-face meetings congruent with planned clinic follow-up visits. The CC will be connected with the patients via the SMILe technology, enabling rapid responses to early signs of health deterioration.~Technology. The SMILe technology consists of the SMILeApp and SMILeCare. The latter is the interface of the monitoring component to connect the patient with the CC supporting fast recognition of symptoms and health deterioration. The SMILeApp enables to daily record a set of medical, behavioural and symptom-related data. A lexicon provides self-management and behavioural information. All data will be transferred to the clinic to be monitored, with the patient's consent, via SMILeCare."
75647882|NCT05311579|Combination Product|Niraparib plus anlotinib|"Niraparib QD D1-21 plus Anlotinib 10mg QD D1-14 until disease progression or intolerable toxicity~21days/cycle"
75647883|NCT00741871|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
75647884|NCT00749437|Radiation|3-dimensional conformal accelerated partial breast irradiation|Accelerated partial breast irradiation following lumpectomy with placement of Acculoc fiducial markers.
75647885|NCT02853968|Procedure|Blood draw/buccal swab|The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
75647886|NCT00602342|Drug|Terbinafine|
75795430|NCT02908048|Other|Blood samples|Blood samples collected at varying intervals over a two to three year period.
75795431|NCT02880163|Device|ResQFoam|Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma
75795432|NCT02827617|Drug|Ibrutinib|Treatment with ibrutinib 420 mg quaque die in the clinical practice
75795433|NCT02750566|Procedure|Osteopathic Manipulative Treatment|Manual treatment of musculoskeletal restrictions that may be prevent proper healing post-concussion.
75795434|NCT02750566|Other|Counseling|Patients will be counseled on concussion awareness, symptoms, and treatment for 30 minutes by a physician.
75795435|NCT02733601|Other|NIS (Non Interventional Study) observational study|NIS observational study : Epidemiologic registry
75795436|NCT02661646|Device|Advanced Pneumatic Compression Device|Advanced Pneumatic Compression Device
76086261|NCT05178498|Procedure|Follow-Up|Undergo follow up
76086262|NCT05178498|Procedure|Physical Examination|Complete physical measurements
76086263|NCT05178498|Other|Questionnaire Administration|Complete questionnaires
76086264|NCT05169788|Device|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
76086265|NCT05169697|Drug|A:YH002+YH001|YH002 on CnD1,YH001 on CnD8,Q3W
76086266|NCT05169697|Drug|B:YH002+YH001|YH002 and YH001 on same day,Q3W
75647887|NCT00602498|Drug|Clarithromycin|
75647888|NCT02852252|Drug|OTL38|Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.
75647889|NCT02852252|Drug|ICG|Patients will be given imaging agent 24 hours before surgery to assist in imaging.
75795437|NCT02652078|Device|Extracorporeal shockwave therapy|Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
76086267|NCT05169697|Drug|YH002+YH001|A traditional 3+3 dose escalation algorithm
75795438|NCT02518555|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
75795439|NCT02518555|Drug|Ibrutinib|Given PO
75795440|NCT02518555|Other|Laboratory Biomarker Analysis|Correlative studies
75795441|NCT02518555|Other|Pharmacological Study|Correlative studies
76086268|NCT05168735|Drug|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
76086269|NCT05168735|Behavioral|Brief Mindfulness Exercises|30min guided training in mindfulness meditation immediately prior to infusion
75338074|NCT04265378|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
75338075|NCT00118352|Biological|alemtuzumab|Given IV
75932901|NCT04789863|Other|Usual Care|The control group (CG) participants will receive usual care, which includes no specific counselling. USB outpatient appointment frequency follows a standard schedule: during the first 3 months post-alloSCT, depending on their health status, most patients (73%) return 1 to 3 times per week for follow-up at the USB outpatient clinic, where they are mainly seen by a junior or senior physician. Depending on health status and recovery, follow-up intervals extend to weekly or monthly within 1 year post-alloSCT. A research assistant (RA) will just contact CG participants for data collection. If participants raise concerns about any symptoms, the RA will encourage them to contact their physicians.
75932902|NCT04472871|Device|Left atrial appendage closure|The left atrial appendage (LAA) is a small, ear-shaped sac in the muscle wall of the left atrium (top left chamber of the heart). It is unclear what function, if any, the LAA performs. In patients with heart failure and atrial fibrillation, reduced left atrial appendage (LAA) emptying velocities leads to LAA thrombus formation therefor a higher rate of stroke and embolism are observed even on oral anticoagulants. FDA approved devices for left atrial appendage closure will be used under guidance of angiography and trans-esophageal echo with highly efficient and trained personnel.
75932903|NCT00738387|Drug|ASA404|1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
75932904|NCT00738387|Drug|Placebo|Placebo i.v. on day 1 of each 21 day cycle
76086270|NCT05168735|Behavioral|Academic Exercises|30min of mental math and other academic cognitive puzzles completed silently/mentally
76086271|NCT05164822|Other|Necrotizing Vasculitis|"Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters."
76086272|NCT05163782|Device|New ankle foot orthosis with anterior support|New ankle foot orthosis with anterior support developed by Turbomed
76086273|NCT05163782|Device|Ankle foot orthosis with anterior support|Ankle foot orthosis with anterior support from Turbomed
75338076|NCT00118352|Radiation|total-body irradiation|Undergo low-dose TBI
75338077|NCT00118352|Drug|fludarabine phosphate|Given IV
75338078|NCT00118352|Drug|cyclosporine|Given PO or IV
75338079|NCT00118352|Drug|mycophenolate mofetil|Given PO
75647890|NCT00604136|Biological|tumor infiltrating lymphocytes|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro. Tumor infiltrating lymphocytes from these cultures will be assessed for tumor reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x2 days IV)and fludarabine (25 mg/mE2/day IV x5days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV every 8 hours for up to 15 doses).
75647891|NCT00742495|Drug|Forodesine|PK study
75647892|NCT00749359|Drug|Paxil CR|Paxil CR 37mg tablet manufactures at two different sites
75795442|NCT02518555|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
75795443|NCT02518555|Other|Quality-of-Life Assessment|Ancillary studies
75647893|NCT02854046|Other|Calcific Uremic Arteriolopathy|
75647894|NCT02562079|Biological|Blood samples|"biological features of the standard follow-up~2 more blood tube for the biological collection (serum and PBMC)"
75647895|NCT02562079|Biological|Biopsy|Skin biopsies
75647896|NCT00946088|Drug|Progesterone|Progesterone 400 mg per vagina qhs.
75647897|NCT00946088|Drug|Polyethylene glycol&hydrogenated vegetable oil.|Placebo Comparator: Polyethylene glycol 400 distearate & hydrogenated vegetable oil per vagina qhs.
75795444|NCT02518555|Biological|Trivalent Influenza Vaccine|Given IM
75795445|NCT02348749|Radiation|18F-MFBG (meta-fluoro benzylguanidine)|About 8mCi of 18F-MFBG will be administered to adult patients. Pediatric dose will be based upon adjustment using BSA to the dose of 8 mCi for 1.7m2 BSA ± 10% with maximum activity of 8 mCi. The tracer will be given intravenously.
76086274|NCT05163782|Device|Ankle foot orthosis from competitor 1|Ankle foot orthosis with posterior support from competitor 1
76086275|NCT05163782|Device|Ankle foot orthosis from competitor 2|Ankle foot orthosis with posterior support from competitor 2
75338080|NCT00118352|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
75338081|NCT00118352|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
75338082|NCT00118352|Biological|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
75338083|NCT00118352|Other|laboratory biomarker analysis|Correlative studies
75338084|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
75338085|NCT01111331|Drug|Warfarin 25 mg|25 mg Warfarin single dose
75338086|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
75338087|NCT01111331|Drug|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
75338088|NCT00167102|Drug|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
75338089|NCT03014375|Drug|BIA-5-453|Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
75338090|NCT01859819|Drug|Rituximab|
75338091|NCT01859819|Drug|IT Cytarabine|
75338092|NCT02176031|Drug|Natalizumab|
75338093|NCT02176031|Drug|Methylprednisolone|
75795446|NCT02348749|Device|Positron emission tomography (PET) imaging|Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
76086276|NCT05163288|Drug|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
76086277|NCT05163288|Other|Placebo|Matching Placebo Sachet
76086278|NCT05156853|Dietary Supplement|Insect menus|The insect menus will consist of 6 different products: flatbread, spice-mix, paste, minced meat, sausage and falafels. The products are based on either crickets, mealworms or buffaloworm larvae.
75647898|NCT02562313|Drug|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
75647899|NCT02562313|Drug|Humalog®|Humalog® bolus infusion followed by test meal intake
75647900|NCT00736996|Drug|Pioglitazone|30 - 45mg tablet daily for 6 months
75647901|NCT00736996|Drug|Placebo|Matching tablet daily for 6 months
75647902|NCT00736996|Behavioral|Endurance Exercise Training|Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
75647903|NCT00741949|Drug|Propofol|Sedation in TCI with propofol
75647904|NCT00741949|Drug|Placebo|Isotonic saline solution infusion
75647905|NCT01410344|Drug|Fludarabine and Busulfan|"RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:~Days -6 to -2: Flu (30 mg/m^2/day, total dose of 150 mg/m^2)~Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m^2 IV, respectively)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
75647906|NCT01410344|Drug|Fludarabine and Melphalan|"RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m^2, Melphalan total dose: less than or equal to 150 mg/m^2. Recommended regimen:~Days -5 to -2: Flu (30mg/m^2/day, total dose of 120 mg/m^2)~Day -1: Mel (140mg/m^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage."
75647907|NCT01410344|Drug|Busulfan and Fludarabine|"MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:~Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively)~Days -5 to -2: Flu (30 mg/m^2/day, total dose of 120 mg/m^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
75795447|NCT02348749|Other|Blood draws|Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
75795448|NCT02107638|Procedure|OMM treatment arm|"OMM is a gentle hand-on manual therapy. The research team created a protocol coined PARK-OMM protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion."
75932905|NCT00738387|Drug|docetaxel|75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
75932906|NCT04472715|Procedure|follicular unit extarcation and platelet rich plasma|hair transplantation procedure
75932907|NCT00645177|Drug|ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
75932908|NCT00645177|Drug|paclitaxel|90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
75932909|NCT00645177|Drug|Placebo for ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
75932910|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
75932911|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
75932912|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
75932913|NCT00643383|Drug|Combination drug (Acetaminophen + Tramadol)|
75932914|NCT00643383|Drug|Placebo|
76086279|NCT05156853|Dietary Supplement|Plant menus|The plant menus will be based on products which can be purchased in normal supermarkets and chosen to be as equal to the insect-based products as possible.
75338094|NCT02176343|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
75338095|NCT02177201|Other|Group 1|Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
75338096|NCT02177201|Other|Group 2|Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
75338097|NCT03013361|Drug|Bupivacaine|Post operative pain control
75338098|NCT03013361|Drug|Ropivacaine|Post operative pain control
75338099|NCT03013361|Other|Normal Saline|Acts as comparator
75338100|NCT01365793|Drug|0.45% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
75338101|NCT01365793|Drug|0.9% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
75338102|NCT01365793|Drug|0.45% saline intravenous fluid|0.45% saline fluid
75338103|NCT01365793|Drug|0.9% saline Intravenous fluid|0.9% saline fluid
75338104|NCT01077401|Drug|Ranibizumab|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
75338105|NCT01077401|Drug|ranibizumab|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
75338106|NCT01316341|Drug|BI10773|patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
75338107|NCT01316341|Drug|Placebo|patient to receive two placebos
75338108|NCT01316341|Drug|Placebo|patient to receive two placebos
75647908|NCT01410344|Drug|Cyclophosphamide and Total Body Irradiation|"MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~Days -7 to -4: TBI (total dose of 1200-1420 cGy)~Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight."
75338109|NCT01316341|Drug|Placebo|patient to receive two placebos
75338110|NCT01316341|Drug|BI10773|patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
75647909|NCT02594410|Device|stent|patients receiving renal artery stenting for renal artery atherosclerosis
75795449|NCT02107638|Other|Counseling|Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
75795450|NCT02027376|Drug|LDE225|
75647910|NCT02594410|Drug|Aspirine|100mg Qd
75647911|NCT02594410|Drug|Clopidogrel|75mg Qd
75795451|NCT02027376|Drug|Docetaxel|
75647912|NCT02594410|Drug|Lercanidipine|10-20mg Qd
75473525|NCT01971528|Other|Muscle strength training|Participants will perform 8 weeks of isotonic contraction muscle strength training for lower extremities.
75473526|NCT01971541|Behavioral|Mindfulness-Based Stress Reduction|A validated 8-week group program that teaches mindfulness meditation
75338111|NCT01112735|Biological|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
75338112|NCT01112735|Procedure|Standard of care|Standard of care
75338113|NCT03014297|Drug|everolimus|everolimus
75338114|NCT03014297|Drug|fosbretabulin|fosbretabulin
75338115|NCT01113983|Device|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transapical and transfemoral approach
75338116|NCT01034111|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.
75338117|NCT01034111|Drug|Metformin|Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
75338118|NCT01114997|Drug|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
75338119|NCT01114997|Drug|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
75338120|NCT01114997|Drug|Lidocaine + Esmolol (Combo)|"Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)~Maintenance Infusion rate after Induction:~Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
75338121|NCT00118742|Drug|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
75647913|NCT00746629|Behavioral|FOCUS|"Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit."
75647914|NCT00746707|Device|1. Dermabond Topical Skin Adhesive 2-Octyl Cyanoacrylate|adhesive of perineal tears
75647915|NCT00746707|Procedure|3. traditional suturing with vicryl rapid 2X0|suturing of perineal tears grade one with vicryl rapid 2X0
75647916|NCT02562001|Device|Outpatient active group|active tDCS during 20 minutes before Lokomat training for outpatients
75647917|NCT02562001|Device|Outpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for outpatients
75647918|NCT02562001|Device|Inpatient active group|active tDCS during 20 minutes before Lokomat training for inpatients
75647919|NCT02562001|Device|Inpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for inpatients
75647920|NCT00954122|Drug|Quetiapine XR (Seroquel XR)|Tablet, oral, once daily
75647921|NCT02563171|Other|non surgical periodontal treatment|"SRP under local anaesthesia, in a total of 2-3 clinical visits.~Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
75647922|NCT02563171|Other|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
75795452|NCT02024542|Other|Surgery|Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing & counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.
75795453|NCT02005289|Biological|MOR00208|Given by IV infusion
75795454|NCT02005289|Drug|lenalidomide|Given PO
75795455|NCT02005289|Other|Correlative Studies|Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
75795456|NCT01937052|Other|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
75795457|NCT01937052|Behavioral|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
75932915|NCT02559622|Drug|Secukinumab|300 mg secukinumab
75338122|NCT00118742|Drug|Tacrolimus|As prescribed, for 12 months
75338123|NCT00118742|Drug|Cyclosporine|As prescribed, for 12 months
75338124|NCT00118742|Drug|Sirolimus|2-4 mg orally once daily for 9-11 months
75473527|NCT01971541|Behavioral|Cognitive Processing Therapy|A validated group program of PTSD treatment, which focuses on cognitive processing.
75795458|NCT01924533|Drug|Olaparib|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
75338125|NCT01034579|Other|Blood sampling|Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
75473528|NCT01971606|Drug|Rosuvastatin|"Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period."
75473529|NCT01971632|Drug|Oxycodone & naloxone combination, prolonged release|
75795459|NCT01924533|Drug|Paclitaxel|IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
75795460|NCT01924533|Drug|Placebo|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
75795461|NCT01906905|Device|Transcranial Magnetic Stimulation|
75338126|NCT01034579|Other|Blood sampling|Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
75338127|NCT01317667|Biological|RVEc|
75338128|NCT00167180|Procedure|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10^8 CD3+T-cells/kg
75338129|NCT00167180|Drug|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
75338130|NCT01035047|Other|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
75338131|NCT01317901|Drug|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
75795462|NCT01879657|Diagnostic Test|68Ga-DOTATATE injection and PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
75795463|NCT01827709|Other|A polymerase chain reaction -based hypoxia classifier|"Recently, a polymerase chain reaction (PCR) -based hypoxia classifier gene signature was published that can be easily applied. Using this classifier, patients will be divided in hypoxic or non-hypoxic subgroups.~These subgroups will be correlated to locoregional control. The hypoxic signature will also be related to parameters on DCE-MRI, DWI and FDG-PET."
75932916|NCT02559622|Other|Placebo|Placebo followed by 300 mg secukinumab
75473530|NCT01971632|Drug|placebo oxycodone / naloxone|
75473531|NCT01971658|Drug|Thalidomide®|
75473532|NCT01971658|Drug|Cyclophosphamide|
75473533|NCT01971658|Drug|Velcade®|
75473534|NCT01971658|Drug|Dexaméthasone|
75473535|NCT01971671|Other|no intervention.|
75647923|NCT00586066|Drug|Memantine|Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
75647924|NCT00586066|Drug|Placebo|Inactive comparator. Placebo-matching memantine tablet.
75647925|NCT00742105|Drug|BGT226|
75647926|NCT05259826|Other|biopsy sampling|"Biopsies are homogenised in buffer and used for the determination of mucosal IgE and inflammatory parameters.~Biopsies are used to isolate organoids, stimulate them with blood cells and food antigens and to study gene and protein expression."
75647927|NCT04273958|Device|Virtual reality helmet|During a painful procedure, the patient will watch a virtual world in a virtual reality helmet, while wearing a noise-canceling headset with soothing music.
75647928|NCT04273958|Device|Computer screen|During a painful procedure, the patient will watch the same virtual world, while wearing a noise-canceling headset with the same soothing music.
75795464|NCT01827709|Other|Functional imaging before treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with pathology.
75932917|NCT02559622|Other|Placebo|Placebo followed by 150 mg secukinumab
75932918|NCT02559622|Drug|Secukinumab|150 mg secukinumab
75932919|NCT05491486|Behavioral|Mindfulness-based Group Therapy|see above
75473536|NCT01971684|Drug|Second Line ITP agents|The treating physicians will select the second line agent and clinical data will be collected.
75473537|NCT01971710|Behavioral|Community leader engagement|Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH
75473538|NCT01971710|Behavioral|Community days|The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day
75473539|NCT01971710|Behavioral|Community Peer Groups|Pregnant women in community peer groups receiving information and education on PMTCT/MCH through 4 weekly peer-led classes . Men in community peer groups receiving information and education on their role in supporting women and families through 4 peer-led education sessions.
75473540|NCT01971749|Procedure|Coronary stent procedure (CSP)|
75473541|NCT01971749|Procedure|Coronary-artery bypass grafting (CABG)|
75473542|NCT01971762|Behavioral|Follow recommendations based on scientific evidence to S. aureus bacteremia management|
75473543|NCT01971762|Behavioral|Not to follow recommendations based on scientific evidence to S. aureus bacteremia management|
75473544|NCT01971775|Device|Ultrasonically activated Shears|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
75473545|NCT01971775|Device|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
75473546|NCT01971788|Device|Optical Coherence Tomography of the infarct related artery|
75338132|NCT01317901|Drug|Bendamustine|Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
75647929|NCT00630890|Radiation|External beam radiation and Cyberknife radiosurgery boost and capecitabine|External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
75932920|NCT05491408|Device|Cough assist device|A device that facilitates airway secretion clearance in COPD patients, thus avoiding hospitalisations and preventing pneumonias and episodes of respiratory failure [4,5].
75338133|NCT01317901|Drug|Rituximab|Rituximab by IV administration at 375 mg/m^2 on Day 2 of each 28 day cycle.
75932921|NCT04285450|Dietary Supplement|Vitamin K|1mg
75647930|NCT00728494|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Peginterferon alfa-2b will be administered according to the product's labeling.
75647931|NCT00728494|Drug|Rebetol (ribavirin; SCH 18908)|Ribavirin will be administered according to the product's labeling.
75338134|NCT03008551|Drug|Empagliflozin|Each participant will receive empagliflozin 25mg daily for 3 months.
75647932|NCT00728494|Behavioral|Patient Assistance Program|"The patient assistance program includes the following:~Training by physicians or specialized nurses.~Informational materials based on the To beat HCV program.~Management of specific side effects."
75647933|NCT02854904|Drug|Dexmedetomidine intervention|Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.
75647934|NCT02854904|Drug|Placebo|Placebo controlled
75338135|NCT03008551|Drug|Metformin|Each participant will receive metformin 1500mg daily for 3 months.
75647935|NCT04269746|Diagnostic Test|CCAT1|Long Non coding RNA
75647936|NCT00728416|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
75932922|NCT04285450|Other|Placebo|Lactose
75647937|NCT00728416|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
75473547|NCT01971801|Dietary Supplement|Vitamin D3 50,000 IU|Capsule given by mouth once a week
75473548|NCT01971801|Other|Placebo|One capsule given by mouth weekly
75338136|NCT01366495|Behavioral|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
75338137|NCT01366885|Drug|Vitamin D3|5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
75338138|NCT01424215|Drug|Indocyanine Green (ICG)|Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
75338139|NCT01370629|Drug|Vernakalant|Prescribed at the discretion of the physician in accordance with their usual practice
75338140|NCT02094872|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
75338141|NCT02094872|Drug|MEK 162 therapy or molecularly targeted therapy|molecularly targeted therapy, MEK 162 therapy
75338142|NCT02094872|Procedure|therapeutic procedure|
75338143|NCT02094872|Other|laboratory biomarker analysis|Correlative studies
75647938|NCT02854826|Other|SAFE Care model of care|"SAFE Care Model Site Intervention:~Endorse best practices for frail patients;~Identify frail patients promptly using multi-dimensional screening and assessments;~Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~Develop electronic health record templates for patient-centered interprofessional frailty notes;~Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail."
75647939|NCT02853734|Other|SEVERE PERIODONTITIS|Patients exhibiting moderate to severe periodontitis
75647940|NCT02853734|Other|NO PERIODONTITIS|Patients without existing periodontitis or exhibiting mild periodontitis
75932923|NCT05497102|Drug|Lenalidomide maintenance|Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
75932924|NCT05496946|Other|Head bathing skill|A group of students will practice the head bathing skill in a model with low proximity to reality, while the students in the other group will practice on a healthy individual (Standardized patient) pretending to be patient.
75932925|NCT03998254|Drug|V503|9vHPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine
75932926|NCT03998254|Drug|Gardasil|qHPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine
75647941|NCT00728182|Drug|NA-1|single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
75647942|NCT00728182|Drug|Placebo|single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
75647943|NCT00941330|Drug|Exemestane|25 mg daily by mouth for 6 to 12 months.
75932927|NCT03994978|Procedure|elective sigmoidectomy|elective sigmoidectomy
75932928|NCT05496400|Radiation|Echocardiographic and Doppler studies|"Echographic and Doppler studies will be performed using machine: model GE Vivid iq premium,WUXI,China and we will measure:~Cardiac output:~Cerebral, intestinal and renal blood flow velocities:"
75338144|NCT02094872|Other|quality-of-life assessment|Ancillary studies
75338145|NCT01424293|Device|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
75338146|NCT01424293|Device|The SPY® Intraoperative Imaging System|
75338147|NCT01899170|Procedure|Deep brain stimulation|Implantation of a deep brain stimulation electrode into pain processing brain areas
75338148|NCT01899170|Device|Cervel Neurotech, Multi-coil TMS|Non-invasive selective stimulation of deep brain areas using magnetic fields.
75473549|NCT01971814|Drug|Infliximab|All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.
75473550|NCT01971827|Behavioral|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
75473551|NCT01971840|Behavioral|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
75647944|NCT00941330|Drug|Docetaxel|Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
75647945|NCT00941330|Drug|Cytoxan|Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
75647946|NCT02594332|Drug|Mepolizumab|100 mg SC every 4 weeks for 13 injections
75647947|NCT02594332|Drug|Placebo|
75647948|NCT02852642|Other|Exercise|Plyometric training
75647949|NCT02857478|Drug|BAY 987519, SPF 50, Y51-002|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
75647950|NCT02857478|Drug|BAY 987519, SPF 50, P04-147|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
75647951|NCT02593084|Behavioral|Higher Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
75647952|NCT02593084|Behavioral|Lower Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
75647953|NCT00686881|Biological|Peginterferon alfa-2b (PegIFN-2b)|PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
75647954|NCT00686881|Drug|Comparator: Stronger neo minophagen C (SNMC)|SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
75647955|NCT02857244|Drug|Duloxetine|Patients will first receive Duloxetine for 4 weeks starting at 30mg, 60mg, 90mg then 120mg (if tolerated). Increases in dosage amounts will occur every week.
75647956|NCT02857244|Drug|Donepezil|Patients will receive Donepezil after 4 weeks of dosing with Duloxetine. Patients will receive Donepezil in combination with the highest dose of Duloxetine that was tolerated. Patients will remain on this for 2 weeks with increasing doses at each week. One week of 5mg, one week of 10mg.
75647957|NCT02857244|Drug|Modafinil|Patients will receive Modafinil after a 4 week washout period (after dosing with donepezil & duloxetine in combination). Patients will receive Modafinil for two weeks with increasing doses at each week. One week at 100mg, one week at 200mg.
75647958|NCT04273256|Drug|Myo-inositol|patients who will be supplemented with 2 grams of Myo-inositol daily for 3 months prior to their in-vitro fertilization cycle
75647959|NCT00921661|Drug|AVE0005 (aflibercept)|IV infusion
75647960|NCT00749827|Drug|Bicarbonate Hydration|"Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.~Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours."
75647961|NCT00749827|Drug|Hypotonic hydration|Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
75647962|NCT04088032|Drug|Abemaciclib, durvalumab and aromatase inhibitor|Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
75647963|NCT00742261|Drug|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
75647964|NCT00727558|Device|nelfilcon A|spherical soft contact lens
75932929|NCT05490628|Other|Cognitive Rehabilitation|Language, memory, attention and executive function exercises are performed for the participants' deficient cognitive functions.
75932930|NCT05490628|Other|Conventional Therapy|Strengthening, walking, balance and coordination exercises are performed according to the needs of the participants.
75647965|NCT00727558|Device|narafilcon A|spherical soft contact lens
75932931|NCT05496088|Procedure|Re-PVI only|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
75647966|NCT02852408|Procedure|Laparoscopic cholecystectomy|
75647967|NCT02852096|Other|Dual or Multiple Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
75647968|NCT02852096|Other|One Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With One Tumor Tissue Paraffin Blocks
75932932|NCT05496088|Procedure|Re-PVI + substrate ablation|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
75932933|NCT04175938|Device|Wearing of contact lens|All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
75932934|NCT04173208|Other|Fecal microbial transplant|Fecal microbial transplant
75932935|NCT04173208|Other|Placebo|Placebo
75932936|NCT05490160|Drug|Tranexamic acid|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
75647969|NCT02853266|Other|laboratory biomarker analysis|Archived serum samples are analysed for measurement of biomarker NCRA
75795465|NCT01827709|Other|Immunohistochemical staining|At 3 levels of the tumour, chosen by the radiologist on the functional imaging modalities, 4µm thick slices will me taken. On each level an immunohistochemical staining will be carried out (GLUT-1, CA-IX, HIF-1alpha, VEGF, KI 67). The result of this staining will be correlated with parameters derived from the functional imaging modalities.
75932937|NCT05495620|Drug|Carfilzomib|"Intravenous~carfilzomib, lenalidomide, dexamethasone"
75932938|NCT05495620|Drug|Lenalidomide|Oral
75932939|NCT05495620|Drug|Dexamethasone|Oral or intravenous
75932940|NCT05490082|Drug|Mirabegron, Propevirine, Solifenacin|Efficacy comparison
75932941|NCT02559310|Drug|lefamulin|antibacterial agent
75473552|NCT01971879|Procedure|Remote ischemic preconditioning|"A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
75647970|NCT02851940|Procedure|Rubber Band Ligation|Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
75647971|NCT02851940|Procedure|Hypertonic Saline Infusion|Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
75647972|NCT00688597|Drug|Duvoglustat|Powder in a bottle for dissolution in water for oral administration
75647973|NCT00735904|Drug|AG-013736|AG-013736 5 mg tablets orally, twice daily, until disease progression
75647974|NCT00735904|Drug|gemcitabine|200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
75647975|NCT00735904|Drug|cisplatin|1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
75473553|NCT01971879|Procedure|Control|"A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
75647976|NCT00602732|Behavioral|The Reach Out for a Safe Environment (ROSE) program|Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
75647977|NCT00602732|Behavioral|Enhanced care as usual (ECU)|Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
75647978|NCT02561923|Drug|Rivaroxaban|A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
75647979|NCT02561923|Drug|Tranexamic acid|1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
75795466|NCT01827709|Other|MRI of the resection specimen|To account for the shrinkage of the tumour due to fixation, the resection specimen will be placed in a box and scanned with an MRI. From this a shrinkage factor will be calculated using the original pre-treatment MRI.
75932942|NCT02559310|Drug|Moxifloxacin|antibacterial agent
75932943|NCT02559310|Drug|Linezolid|antibacterial agent
75932944|NCT05495542|Other|ShotBlocker|ShotBlocker (Bionix, Toledo, OH) is one of the methods that can be used to reduce pain caused by IM injections. This small, flat, U-shaped plastic device used by holding it on the skin surface during injection did not have any side effects [5]. ShotBlocker has a surface of 2 mm thick with rounded nubs to stimulate the skin (Figure 1). The surface of the plastic device is placed on the skin just before the injection; there is a hole in the center where the injection is administered [6]. The rounded nubs on the surface of the plastic device do not damage the skin, these rounded nubs that create a slight pressure provide a warning for the Gate Control Theory [7]
75473554|NCT01971892|Other|Non Invasive ventilation (facial mask and NIV ventilator)|Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
75473555|NCT01971892|Other|Standard oxygen therapy with facial mask|facial Venturi mask
75473556|NCT01971918|Biological|anti drug antibodies dosage|anti drug antibodies dosage
75647980|NCT02561923|Drug|Kcentra, a 4-factor PCC|Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 [international units] IU/min) on Day 4.
75647981|NCT02561923|Drug|Saline|Saline [Kcentra saline control or TXA saline control] on Day 4.
75647982|NCT02852174|Behavioral|Mindfulness meditation training|Mindfulness meditation training
75647983|NCT00918190|Drug|Placebo|Saline
75932945|NCT05490004|Other|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
75932946|NCT04150276|Procedure|ZEEP during awakening|ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
75932947|NCT04150276|Procedure|PEEP during awakening|PEEP will be maintained throughout emergence preoxygenation and awakening.
75795467|NCT01827709|Other|Tumour volume delineation and comparison|On the imaging modalities the tumor volume will be delineated. This will also be done on the resection specimen. Later on the different tumour volumes will be correlated.
75647984|NCT00918190|Drug|Ondansetron, Dexamethasone|Use of ondansetron and dexamethasone as combined antiemetics
75647985|NCT00918190|Drug|Midazolam, dexamethasone|use of midazolam and dexamethasone as combined antiemetic
75647986|NCT02852018|Genetic|Identification of genetic polymorphisms|
75647987|NCT00749905|Other|low fiber diet|Low fiber diet for 5 days prior to colon capsule
75647988|NCT00749905|Other|regular diet|Regular diet until 1 day before colon capsule
75647989|NCT02563327|Drug|Rifapentine|A rifamycin with activity against Mycobacterium tuberculosis
75647990|NCT02563327|Drug|Moxifloxacin|A fluoroquinolone
75647991|NCT02563327|Drug|Rifampin|A rifamycin with activity against Mycobacterium tuberculosis
75795468|NCT01683955|Drug|Tranexamic acid|Topical tranexamic acid (2g/100mL 0.9% saline)
75795469|NCT01683955|Drug|Placebo|100mL 0.9% sterile saline
75795470|NCT01606436|Drug|LY2140023|Administered orally.
75932948|NCT05495308|Procedure|neoadjuvant treatment|We study the number of patients who achive a complete pathological response after neoadjuvant treatment with radiochemotherapy.
75647992|NCT02563327|Drug|Isoniazid|An anti-tuberculosis agent
75647993|NCT02563327|Drug|Pyrazinamide|An anti-tuberculosis agent
75795471|NCT01606436|Drug|Placebo|Administered orally.
75795472|NCT01606436|Drug|Moxifloxacin|Administered orally.
75932949|NCT04149808|Device|Mepilex Ag (burn dressing)|Dressing for low to medium exuding burns and wounds.
75932950|NCT04149808|Device|Xeroform Dressing|Standard of care dressing for low to medium exuding burns and wounds.
75932951|NCT05495152|Drug|Sintilimab|Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.
75647994|NCT02563327|Drug|Ethambutol|An anti-tuberculosis agent
75647995|NCT02563327|Dietary Supplement|Pyridoxine|An essential vitamin
75647996|NCT04268186|Device|Direct tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AFz and CPz of the 10-10 electrode system.
75647997|NCT04268186|Device|Indirect tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
75338149|NCT01899170|Drug|11C-Carfentanil|PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
75338150|NCT01425229|Drug|Bosentan|"Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"
75338151|NCT00258362|Drug|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
75647998|NCT04268186|Device|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used will be optimized to stimulate key nodes connected to MCC, including anterior insula, MFG and supramarginal gyrus, and designed using an individual head model that will be combined with each subject's measured connectivity map. The number of electrodes will be minimally 2 and maximally 32.
75795473|NCT01453088|Drug|Melphalan|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
75795474|NCT01453088|Drug|Bortezomib|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
75932952|NCT04147624|Drug|Souvenaid|Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.
75932953|NCT04147624|Other|Placebo|The Placebo used in this study is an oral beverage vitamin mixture containing Vitamins A, B1, B2, B3 and B5.
75932954|NCT05489848|Drug|Paclitaxel|Paclitaxel: paclitaxel dose of 135~175mg / m2, about 3 hours after the infusion, the use of pretreatment drugs before the infusion according to the drug instructions. Every 21 days is one session.
75932955|NCT05489848|Drug|Carboplatin|Carboplatin: Doses were given at AUC=5 - 6 and used after paclitaxel. Based on the calculated amount, the maximum dose of carboplatin per chemotherapy does not exceed 750mg.
75932956|NCT05489848|Drug|Cisplatin|Concurrent cisplatin intravenous chemotherapy on radiotherapy days 1 and 29,50mg / m2, a total of 2 times.
75338152|NCT00258362|Drug|docetaxel|75 mg/m^2 on Day 1 of each course
75338153|NCT00258362|Radiation|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
75338154|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
75338155|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
75338156|NCT02095340|Other|Positive Interpretation Bias Training|
75338157|NCT02095340|Other|Neutral Interpretation Bias Training|
75338158|NCT02539368|Drug|CT-P13|biosimilar infliximab
75338159|NCT02539368|Drug|Remicade|infliximab
75338160|NCT01425307|Drug|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
75338161|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340274A|One or two doses administered intramuscularly
75338162|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340273A|Two doses intramuscularly
75338163|NCT01035749|Biological|Placebo (saline)|One dose intramuscularly
75795475|NCT01345175|Drug|Rifaximin|Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
75647999|NCT04268186|Device|Sham tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. Placebo stimulation will be applied by ramping the current up and immediately down over 30 seconds. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
75648000|NCT00918034|Drug|talaporfin sodium|LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)
75932957|NCT05489848|Radiation|EBRT|50.4Gy/28 / 6 weeks; common iliac node positive or paraaortic node positive plus extended field.The radiation extension field should include the entire pelvic cavity, the common iliac vessels and the paraaortic lymph node area.The range above the extension field is determined based on the clinical status, but at least 1-2cm above the renal vascular level.
75932958|NCT05489848|Radiation|VBT|Subnormal vaginal mucosa was 0.5cm, 30Gy / 5times /5weeks.
75648001|NCT00918034|Device|Transurethral illumination with light emitting diodes|A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes
75932959|NCT05489770|Dietary Supplement|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid has been used as a supplement since 1991 with no reports of adverse effects received by the Manufacturer.
75932960|NCT05489770|Dietary Supplement|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra)|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra) Liquid Constituents: 70% (w/w) of glucose syrup, Flavouring agent: Elderberry Blossom
75932961|NCT05489692|Procedure|hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)|"FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks."
75932962|NCT05494684|Other|Multisensoral Nature-based Intervention|The intervention includes a multi-sensory nature experience using natural materials and a virtually created natural environment.
75648002|NCT00918034|Procedure|Placement|Placement of device in prostate urethra
75932963|NCT05489536|Behavioral|A web/smartphone-based lifestyle program package|"There are two platforms for the lifestyle program, namely Health and Nutrition Education (HNE) website and HNE app. The participants are requested to download and register on the HNE website and the HNE app. The HNE app is Android and IOS compatible. Both the HNE website and app are designed to support self-directed learning and independently monitor their GWG and dietary intake during pregnancy. Both the HNE website and app will be passcode protected throughout the study period such that access is restricted to only participants in the intervention group.~The web/smartphone-based lifestyle program package consists of:~I. Health and Nutrition Education (HNE) resources II. Gestational Weight Gain (GWG) monitoring III. Dietary intake monitoring"
75473557|NCT01971983|Other|High-velocity, low-amplitude (HVLA)|With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.
75932964|NCT05489458|Procedure|Resection|Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.
75473558|NCT01971983|Other|Muscle energy (ME)|This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.
75932965|NCT05489458|Procedure|No Resection|Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.
75932966|NCT00640419|Drug|ABT-089|Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
75932967|NCT00640419|Drug|placebo|Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
75932968|NCT00640185|Drug|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
75932969|NCT00640185|Drug|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
75932970|NCT00721695|Drug|OMS302|OMS302 Irrigation Solution
75932971|NCT00721695|Drug|OMS302-PE|OMS302-PE HCI Irrigation Solution
75932972|NCT00721695|Drug|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
75473559|NCT01971983|Other|Sham|Individuals in this group received a sham intervention type, in order to simulate an intervention.
75932973|NCT00625833|Drug|Placebo|Oral tablet once a day dosing for 10 weeks.
75932974|NCT00625833|Drug|[S,S]-Reboxetine|Oral tablet once a day dosing for 10 weeks.
75932975|NCT00735267|Drug|PD 0332334|Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
75932976|NCT03299114|Other|Whirlpool|
75932977|NCT03294356|Other|FT210771|An electronic cigarette
75932978|NCT03294356|Other|FT210751|An electronic cigarette
75932979|NCT03294356|Other|6T30134157764|An electronic cigarette
75932980|NCT03294356|Other|G41A7C071|An electronic cigarette
75932981|NCT03294356|Other|M011161212|An electronic cigarette
75932982|NCT03294356|Other|FT21002|A combustible cigarette
75932983|NCT00718965|Drug|AVE5530|one tablet in the evening with dinner
75932984|NCT00718965|Drug|Placebo|one tablet in the evening with dinner
75795476|NCT01345175|Drug|Placebo|Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
75795477|NCT01257139|Procedure|Dual-agent therapy or docetaxel alone or best supportive care|"ARM B: (245 patients)~Treatment if the SGS screening test is negative:~non epidermoid tumor:~Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.~epidermoid tumor:~Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management."
75795478|NCT01246739|Procedure|Adrenalectomy|Adrenalectomy (open or laparoscopic)
75648003|NCT04272164|Other|technical taekwando training|Light jogging followed by star jump, Different running styles (forward, backward and sideways), Stretching exercises (Upper and lower Limb), Pushups and sit ups, Punches (single, double, triple, nonstop punches including speed and power, punches with forward and backward stepping), Kicks (rising kick, front kick, middle kick, drop kick ( in +out+center), Stances (walk stance, punching stance, front deep stance, kicking stance), Blockings (solar block, upper block and lower block), Self -defense (neck gripping, hand gripping, locking), Sand bag drills, Balance training 10 repeatitions of 1 set each, 3 days a week for 8 weeks
75648004|NCT04272164|Other|weighted rope jump training|Basic bounce step with both feet 2. Bell jump with both feet 3. Skier's jump 4. Right foot skipping 5. Left foot skipping, 6. Alternate foot step 7. Boxer shuffle 8. Side straddle 9. Scissors 10. Bonus jump with both feet After the preparatory weighted rope jump training (WRJT) for 1 week, subjects in experimental group followed jumping training by repetition method 3 days in a week for 8 weeks in addition to the routine taekwondo training program. 3 sets per week with 30 seconds training duration and 30 seconds rest duration. with progressive increase in the intensity and no. of sets.
75648005|NCT02593942|Drug|Remifentanil|0.1-0.5 mcg/kg/min infusion
75648006|NCT02593942|Drug|Propofol|75-200 mcg/kg/min infusion
75795479|NCT01243190|Drug|Ofatumumab|Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
75795480|NCT01058018|Drug|RVX000222|RVX000222 twice a day for 12 weeks
75795481|NCT01058018|Drug|Placebo|Placebo twice a day for 12 weeks
75795482|NCT00777712|Other|Blood draw|Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
75795483|NCT03843710|Drug|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
75795484|NCT00470639|Device|Transcranial Magnetic Stimulation|
75648007|NCT05381870|Behavioral|Test Preparation-Reference preparation|Under fasting conditions, subjects randomly divided into TR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period.
75648008|NCT05381870|Behavioral|Reference preparation-Test Preparation|Under fasting conditions, subjects randomly divided into RT group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period.
75795485|NCT00442533|Drug|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
75795486|NCT00186992|Radiation|image-guided radiotherapy|Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
75338164|NCT00123110|Drug|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
75648009|NCT00749983|Dietary Supplement|Creatine supplementation|
75648010|NCT00749983|Dietary Supplement|Dextrose supplementation|
75795487|NCT00177593|Behavioral|behavioral weight loss|
75795488|NCT01235208|Other|"The Dr. Fedon Lindbergs Vektcoach Treatment"|Diet and lifestyle treatment
75795489|NCT01141296|Drug|fenofibrate|fenofibrate 200 mg PO daily for 1 year
75795490|NCT01141296|Drug|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
75795491|NCT01238328|Drug|Conditioning regimen|"For sibling full match:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~Fludarabine 160 mg/m^2"
75932985|NCT03294200|Device|TriCinch Coil System implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
75932986|NCT03108404|Other|Validation of a diagnostic test|Validation of a diagnostic test
75932987|NCT03290924|Behavioral|Low dose high frequency health worker training approach|"Two 4-day training sessions for skilled birth attendants~1-day peer practice coordinator training after first training session~Weekly, peer-led practice sessions using MamaNatalie® and NeoNatalie™ anatomic models~SMS reminder messages and quizzes~Routine telephone calls between master mentors and peer practice coordinators, and between project staff and master mentors~Health information officer training~Data collection and use training~Supply of simulators, newborn resuscitation equipment, and delivery sets"
75338165|NCT00123110|Drug|leuprolide injection|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
75932988|NCT03290924|Behavioral|Active Comparison|Training on data collection and reporting
75932989|NCT03299036|Device|Taiwan ACE Beads with doxorubicin|Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
75473560|NCT01972009|Procedure|Cardiac catheterisation|Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
75473561|NCT01972022|Device|EES SYNERGY™|percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
75648011|NCT02593240|Behavioral|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food|The intensive iDiet® group behavioral weight loss program will be delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the iDiet® intervention will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.
75795492|NCT01238328|Drug|Graft-versus-host disease (GVHD) prophylaxis|"Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po~10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)"
75473562|NCT01972022|Device|ZES, RESOLUTE Integrity™|percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
75473563|NCT01972048|Behavioral|mMammogram|Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.
75473564|NCT01972048|Other|Print brochure|Mailed print brochure about breast cancer screening and community resources.
75932990|NCT03290846|Drug|Secretin Human|Randomized, single-blinded secretin hydrochloride infusion.
75338166|NCT00123110|Drug|placebo pill|matching pill twice a day for 12 weeks
75338167|NCT00123110|Drug|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
75932991|NCT03290846|Drug|Saline Solution|Randomized, single-blinded saline infusion.
75932992|NCT03290846|Other|Cold exposure|All subjects will undergo a cold exposure PET scan.
75473565|NCT01972087|Behavioral|Telephone simulation training|The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
75932993|NCT03298958|Drug|Rapamycin|Subject will be randomized to one of the 2 arms
75932994|NCT03298958|Drug|Placebo Oral Tablet|Subject will be randomized to one of the 2 arms
75473566|NCT01972100|Device|Low-level laser therapy (808nm)|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
75338168|NCT01898156|Drug|BIW-8962|"Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops."
75338169|NCT02096276|Other|Data collection|Initial and follow-up data will be collected using questionnaires.
75338170|NCT01425853|Drug|Chondroitin/Glucosamine (Droglican)|Experimental
75338171|NCT01425853|Drug|Celecoxib|Active comparator
75473567|NCT01972100|Other|isokinetic exercise|
75795493|NCT01238328|Procedure|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~Sibling full match~Other related full match~Sibling or other related with 1 mismatch antigen~Cord Blood~Haploidentical"
75795494|NCT01238406|Device|MD-logic Artificial Pancreas (MDLAP)|Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
75795495|NCT01238406|Device|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
75795496|NCT03724890|Drug|M3814|Participants will receive M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.
75338172|NCT01426867|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
75338173|NCT01426867|Drug|Brinzolamide ophthalmic suspension, 1%|
75338174|NCT01426867|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
75338175|NCT02203747|Other|Administration of patient self-assessment|
75473568|NCT01972100|Device|Placebo low-level laser therapy|
75473569|NCT01972113|Dietary Supplement|Placebo-Control|one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
75795497|NCT03724890|Drug|M3814|Participants will receive M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.
75795498|NCT03724890|Drug|Avelumab|Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.
75795499|NCT03724890|Radiation|Radiotherapy|Participants will receive radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
75932995|NCT03294122|Radiation|External beam radiotherapy for prostate cancer|Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
75473570|NCT01972113|Dietary Supplement|Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
75648012|NCT02593240|Behavioral|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher|The intensive iDiet® group behavioral weight loss program delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the Diet® intervention will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
75936499|NCT02429180|Other|Rehabilitation|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
75795500|NCT01145664|Drug|Herbal concentrate-granules plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
75648013|NCT02593240|Behavioral|Human Performance Institute©|The Human Performance Institute© (HPI) training workshop is a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
75648014|NCT00742339|Drug|Terlipressin plus albumin|The terlipressin will be give at the initial dose of 3 mg/24 hours by intravenous continuous infusion. If during the following 48 hours the serum value of creatinine will not change or will go down less than 25%, the dose of terlipressin will be increased to 6 mg/24 hours. If no response will ensue, the dose of terlipressin will be increased to the maximal dose of 12 mg/24 hours. Twenty percent human albumin solution will be administrate together with terlipressin at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
75795501|NCT01145664|Drug|Reduning Injection plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
75338176|NCT00168428|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
75338177|NCT00168428|Other|placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
75795502|NCT01145664|Drug|Western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
75338178|NCT01427881|Drug|cyclophosphamide|Given IV
75795503|NCT01236690|Drug|Cinobufacin injection|Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
75795504|NCT01141452|Drug|Extra-fine hydrofluoroalkane beclomethasone MDI|Step-up in baseline BDP-equivalent ICS dose
75795505|NCT01141452|Drug|Chlorofluorocarbon beclomethasone metered dose inhaler|Step-up in baseline BDP-equivalent ICS dose
75338179|NCT01427881|Drug|cyclosporine|Given IV
75473571|NCT01972113|Dietary Supplement|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
75795506|NCT01141452|Drug|Fluticasone propionate metred dose inhaler|Step-up in baseline BDP-equivalent ICS dose
75473572|NCT01972165|Procedure|Mini-incision carpal tunnel release|
75473573|NCT01972165|Procedure|Endoscopic carpal tunnel release|
75338180|NCT01427881|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
75338181|NCT01427881|Radiation|total-body irradiation|Undergo TBI
75338182|NCT01427881|Drug|fludarabine phosphate|Given IV
75338183|NCT01427881|Drug|busulfan|Given IV
75338184|NCT01427881|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
75473574|NCT01972230|Drug|Sevoflurane|
75473575|NCT01972230|Drug|Diprivan + Remifentanil TCI|
75473576|NCT01972269|Drug|Bupivacaine-fentanyl|0.125% bupivacaine-fentanyl 5mcg/mL
75473577|NCT01972269|Drug|Lidocaine|2% lidocaine
75795507|NCT01141452|Drug|Fluticasone propionate metred dose inhaler|Initiation of ICS therapy
75795508|NCT01141452|Drug|Hydrofluoroalkane beclomethasone metred dose inhaler|Initiation of ICS therapy
75795509|NCT01141452|Drug|Chlorofluorocarbon beclomethasone dipropionate|Initiation of ICS therapy
75795510|NCT01141530|Other|No intervention|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
75795511|NCT01145742|Behavioral|home health/primary care collaboration|self-management support and telemonitoring of BP and blood glucose
75795512|NCT01238484|Other|Standard of care|shoe modification home stretching exercises
75795513|NCT01238484|Device|Dynasplint|shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
75795514|NCT01145820|Dietary Supplement|Juice plus|Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
75648015|NCT00742339|Drug|Midodrine plus octreotide plus human albumin|Midodrine will be give orally at the initial dose 7.5 tid together with octreotide at the initial dosage of 100 µg subcutaneously tid. If during the following 96 hours the serum value of creatinine will not change or will go down less than 25%, the dose of midodrine will be increased to 12.5 mg tid Twenty percent human albumin solution will be administrate together with midodrine and octreotide at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
75795515|NCT00219557|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
75932996|NCT03294122|Radiation|External beam radiotherapy for head and neck cancer|Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
75932997|NCT02461394|Device|Blood glucose monitoring systems for self-testing|
75338185|NCT00258908|Biological|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
75338186|NCT01319539|Drug|Akt Inhibitor MK2206|Given PO
75648016|NCT02594020|Procedure|air abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
75932998|NCT03294044|Behavioral|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
75932999|NCT03294044|Behavioral|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
75648017|NCT02594020|Procedure|sono abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
75933000|NCT02460770|Drug|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
75473578|NCT01972321|Other|Technology supported supervision|"CHWs will be provided with mobile phones and solar chargers to carry out the following:~Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.~Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians~Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance."
75648018|NCT02594020|Procedure|dental bur|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
75933001|NCT03298724|Behavioral|Teachers and Parents as Partners|A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
75648019|NCT02592928|Other|Inclusion of Spirometry into the Electronic Health Records|Inclusion of the Forced Spirometry into the Electronic Health Records
75338187|NCT01319539|Procedure|Therapeutic Conventional Surgery|Undergo surgery
75338188|NCT01319539|Other|Pharmacological Study|Correlative studies
75933002|NCT03290456|Drug|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
75933003|NCT03290456|Drug|Placebo 5mg/day extended of 12 additionnal months.|1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 13
75933004|NCT02555878|Drug|Rivaroxaban|Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
75648020|NCT02563249|Other|Parabolic flight|
75338189|NCT01319539|Other|Laboratory Biomarker Analysis|Correlative studies
75338190|NCT01319617|Device|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
75338191|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
75338192|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
75648021|NCT02563249|Other|movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements|
75795516|NCT00219557|Drug|AG-013736|Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
75795517|NCT00219557|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
75795518|NCT01141764|Procedure|Positron Emission Tomography (PET) Scan|"The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.~This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days."
75933005|NCT02555878|Drug|Placebo|Placebo tablet will be administered orally once daily for 180 days.
75933006|NCT02460536|Behavioral|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
75933007|NCT02460536|Behavioral|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
75795519|NCT01141764|Procedure|Magnetic Resonance Imaging (MRI)|MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
75795520|NCT01141764|Other|Neuropsychological Testing|"On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on."
75933008|NCT02460536|Behavioral|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
75933009|NCT02460536|Behavioral|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
75648022|NCT02592772|Other|Reduced Nicotine Non-Menthol (RNC)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
75648023|NCT02592772|Other|Reduced Nicotine Menthol (RNC-Men)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
75933010|NCT03298646|Drug|Lidocaine Hydrochloride|10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
75795521|NCT01235286|Procedure|remote ischemic preconditioning|"A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.~The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia."
75795522|NCT05282940|Drug|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Investigational Medicinal Product
76086280|NCT05154006|Behavioral|Information about benefits of the behavior|The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply [5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)]
75795523|NCT05282940|Drug|Microgynon CD|Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
75338193|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
75795524|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
75933011|NCT03298646|Drug|Diclofenac|100 mg Diclofenac oral tablet one hour before the procedure.
75933012|NCT03298568|Dietary Supplement|DAOsin|DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake.
75338194|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
75338195|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
75338196|NCT01319851|Drug|Alefacept|0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
75648024|NCT02592772|Other|Conventional Nicotine Non-Menthol (CN)|Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
75648025|NCT02853188|Other|venous thromboembolism|
75648026|NCT00688519|Drug|U0267|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
75648027|NCT00688519|Drug|Vehicle|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
75648028|NCT02594176|Device|FLEXISEQ®|applicable gel
75933013|NCT05494372|Other|safety precautions|Nursing safety precautions on CPB
75933014|NCT05489224|Biological|CT-P47|CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)
75933015|NCT05489224|Biological|EU-approved RoActemra|EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W
75933016|NCT02460614|Procedure|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
75933017|NCT02460614|Procedure|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
75933018|NCT02460614|Other|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
75648029|NCT02594176|Device|Placebo|applicable gel
75933019|NCT03293732|Biological|DCB07010|A protein based adjuvant originated from prokaryotic organism.
75933020|NCT03293732|Biological|HA antigens|HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
75933021|NCT04139980|Other|Virtual Reality (VR)|Each VR session is 30 minutes long. Participants are able to pause or discontinue at any time. Each participant will receive one VR sessions five times per week over the course of a two-week period.
75473579|NCT01972321|Behavioral|Community supported supervision|CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.
75473580|NCT01972321|Other|Integrated community case management|Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
75473581|NCT01972334|Biological|FMT|as explained in study arm
75473582|NCT01972334|Biological|placebo|salt water or saline will be given as placebo
75338197|NCT04351867|Drug|docetaxel plus oxaliplatin and capecitabine|docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
75473583|NCT01972373|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure
75338198|NCT04351867|Drug|oxaliplatin plus capecitabine|oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
75338199|NCT02539134|Drug|TAK-935|TAK-935 oral solution
75473584|NCT01972373|Device|NIR fluorescence endoscopy|48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
75648030|NCT00631202|Drug|Epoetin alfa|Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
75933022|NCT03290222|Other|TRACK questionnaire|TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
75338200|NCT02539134|Drug|Placebo|TAK-935 placebo-matching oral solution
75473585|NCT01972386|Device|Spectrum Image Analysis using a Linear Array Ultrasound Bronchoscope|
75473586|NCT01972399|Procedure|Laser|This is a surgery that the patient will undergo and the laser will be used to clean the surface of the implant.
75648031|NCT00747019|Behavioral|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9. PBPA participants also earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity.
75648032|NCT00747019|Behavioral|Physical Exercise (PE)|The PE condition is a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9.
75648033|NCT04269122|Other|No Intervention|No intervention
75648034|NCT02851784|Biological|adoptive immunotherapy|HCC (D ≤5 cm, fewer than three tumors) patients were treated with radical MWA and 4-6 courses of immunotherapy with CIK every year.The immunotherapy were started at 2 weeks, 4 weeks, 6 weeks, 10 weeks, 14 weeks, 18 weeks and then every 12 weeks after MWA. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed DCs and effector cells. DC-CIK and CTL were injected into the abdominal cavity. CIK was infused intravenously.
75795525|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
75795526|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
75338201|NCT00262730|Drug|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
75338202|NCT00262730|Drug|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
75338203|NCT00262730|Radiation|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
75338204|NCT01320553|Drug|SPARC1102 I|SPARC1102 I will be administered in both eyes
75473587|NCT01972399|Procedure|Mechanical debridement|This is a surgery that the patient will undergo to have the surface of the implant cleaned using hand instruments.
75473588|NCT01972412|Behavioral|telephone support|Telephone support for four months about healthy diet, physical activity and medication use.
75473589|NCT01972425|Other|Biomarker-based diagnostic|The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
75473590|NCT01972451|Procedure|Colonoscopy with enhanced dye|
75473591|NCT01972477|Drug|DLBS1449|Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
75473592|NCT01972477|Other|Placebo|Placebo will be given every day for 8 weeks.
75795527|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
75473593|NCT01972490|Drug|avastin|Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or unacceptable toxicity.
75338205|NCT01320553|Drug|SPARC1102 II|SPARC1102 II will be administered in both eyes
75648035|NCT02851784|Procedure|MWA|ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up
75933023|NCT05494294|Procedure|Intraorally de-epithelialization|In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
75933024|NCT05494294|Procedure|Extraorally de-epithelialization|In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
75648036|NCT02851628|Device|Alternative sizing model based trial mask|A trial full face mask to be used for this trial for the treatment of obstructive sleep apnea using CPAP therapy.
75338206|NCT01320553|Drug|SPARC1102 III|SPARC1102 III will be administered in both eyes
75648037|NCT02851628|Device|Prototype Full Face Mask|A prototype full face mask with previous clinical trial experience used for the treatment of obstructive sleep apnea using CPAP therapy.
75795528|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
75338207|NCT01320553|Drug|Vehicle|Vehicle will be administered in both eyes
75473594|NCT01972490|Drug|mFOLFOX6|mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
75473595|NCT01972503|Drug|5-FU and oxaliplatin|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
75473596|NCT01972503|Procedure|colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
75473597|NCT01972542|Dietary Supplement|Oral fat tolerance test|
75648038|NCT00721630|Drug|capecitabine, lapatinib|Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
75648039|NCT00686725|Drug|Temozolomide|
75648040|NCT00686725|Radiation|Radiotherapy|
75795529|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
75795530|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
75795531|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
75795532|NCT01329666|Dietary Supplement|Placebo|Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.
75795533|NCT01329666|Dietary Supplement|Vitamin D3|"Baseline:~50,000 IU/week for 8 weeks~Week 8:~Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.~Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks."
75795534|NCT01141920|Behavioral|low threshold care|Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.
75338208|NCT04262934|Drug|Cholecalciferol 100.000 UI administration|One oral Administration - Every month
75338209|NCT04262934|Other|No vitamin D administration|No vitamin D administration
75338210|NCT03009253|Other|order of treatment|the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
75338211|NCT00262964|Drug|Niacin|Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
75473598|NCT01972555|Procedure|Minimally invasive aortic valve replacement|
75473599|NCT01972555|Procedure|Conventional aortic valve replacement|
75473600|NCT01972581|Other|Reaction Time Training|
75473601|NCT01972594|Procedure|Targetted protocol with pedometer|12 week protocol based on targetted steps are given to the patient along with a pedometer.
75473602|NCT01972594|Device|Accelerometer(ActivPAL)|
76086281|NCT05154006|Behavioral|Instruction on how to perform a behavior|"For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) [4.1 Instruction on how to perform a behavior (Michie et al., 2013)]"
76086282|NCT05154006|Behavioral|Self-efficacy|Self-efficacy will be promoted by the four sources of self-efficacy (Bandura, 1977): 1) Mastery Experiences (experience that one is able to successfully apply the behavior), vicarious experience (observing successful others performing the safe carrying behavior), verbal persuasion (receiving positive feedback when performing the behavior and encouraging messages to do so) and emotional state (e.g. being in a positive emotional state when performing the behavior). [6.1 Demonstration of the behavior; 8.1 Behavioral practice/rehearsal; 15.1 Verbal persuasion about capability; 15.2 Mental rehearsal of successful performance; 15.3 Focus on past success;15.4 Self-talk; 5.4 Monitoring of emotional consequences (Michie et al., 2013)]
76086283|NCT05154006|Behavioral|Social Support|A self-selected social partner from the same or neighboring household (e.g. husband, mother-in-law) will be involved in the learning process (observational learning, feedback). The partner will participate in the intervention activities and will be instructed to provide emotional social support and practical informational support. [3.2 practical support, 3.3 emotional support; 6.3 Information about others' approval (Michie et al., 2013).]
76086284|NCT05148338|Other|Comprehensive risk factor treatment|"Apnea screening with Home Sleep Apnea Test. Referral to sleep physician if apnea-hypopnea index (AHI) is greater than 5~Weight management counseling by dietician if body mass index (BMI) is above 27 kg/m2~Physical activity program under supervision of physiotherapist at a specialized cardiac rehabilitation centre if BMI is over 27 or if there are complaints during exercise~Smoking cessation at specialized outpatient clinic~Blood pressure control, lipid management, glycaemic control, alcohol intake reduction by specialized AF nurse~Motivation and education through a digital health platform"
75338212|NCT00262964|Drug|fenofibrate|Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
76086285|NCT05148338|Other|Standard of care|Standard usual care: Treatment by cardiologist conform existing guidelines
76086286|NCT05147532|Procedure|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
76086287|NCT05135819|Behavioral|Cyber School for Grandparents|Educational program for secondary school students to become cyber tutors for their grandparents or for senior citizens, who are interested to learn new digital use and skills.
75338213|NCT00262964|Drug|placebo|Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
75338214|NCT01321177|Behavioral|Integrated Treatment|"Integrated program of treatments and services delivered by a coordinated team of providers that includes:~education about schizophrenia and its treatment for the participants and their family members~medication for symptoms and preventing relapse that uses a computerized decision support system~strategies for managing the illness and building personal resilience~help getting back to school or work using a supported employment/education model"
75338215|NCT01321177|Behavioral|Community Care|"Standard mental health treatments and services offered at the local agency that may include :~medication for symptoms and preventing relapse~psychosocial therapy which may include a range of behavioral treatments and supportive services~Case management"
75338216|NCT01372813|Drug|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
75338217|NCT00124514|Drug|Triptorelin pamoate|IM injection given monthly
75338218|NCT00124514|Drug|Triptorelin Pamoate|IM injection given monthly
75338219|NCT00124514|Drug|Triptorelin Pamoate|IM injection given monthly
75338220|NCT00124514|Drug|Triptorelin Pamoate|IM injection given monthly
75473603|NCT01972607|Other|Exercise Training|12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
75795535|NCT01141920|Behavioral|stepped-based care|Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
75795536|NCT01236846|Dietary Supplement|Fortified Yogurt Drink|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
75795537|NCT01236846|Dietary Supplement|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
75473604|NCT01972620|Drug|Bupivacaine|A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
75795538|NCT01141998|Drug|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
75795539|NCT01141998|Drug|Cholecalciferol|38 micrograms daily. Week 0-10.
75795540|NCT01141998|Radiation|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
75338221|NCT00124514|Other|placebo|placebo 0.9% normal saline IM injection
75338222|NCT01373671|Device|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
75338223|NCT02538900|Behavioral|Exercise|Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
75473605|NCT01972633|Procedure|Laser|Endovenous Laser (1470nm) ablation of great or small saphenous vein
75473606|NCT01972633|Procedure|Radiofrequency|Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
75473607|NCT01972672|Drug|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
76086288|NCT05120960|Drug|tepotinib|Given by PO
76086289|NCT05120960|Drug|tepotinib plus osimertinib|Given by PO
75338224|NCT02538900|Other|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
75338225|NCT01899248|Drug|Sevoflurane|
75795541|NCT01141998|Radiation|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
75795542|NCT01141998|Drug|Cholecalciferol|38 micrograms daily. From week 14 to 52.
75795543|NCT05632302|Device|nICP|The nICP probe contains infrared light sources that illuminate the deep brain tissue of the frontal lobe. Photodetectors in the probe detect the backscattered light, which is modulated by pulsation of the cerebral arteries.
75795544|NCT01142076|Drug|Xinju Xiaogao Prescription|treatment group
75795545|NCT01142076|Drug|placebo|Therapeutic dose of 10%
75795546|NCT01235364|Device|Foley catheter|The Foley catheter was placed with the digital method
75795547|NCT01235364|Device|Foley catheter|The Foley catheter was placed with a speculum
75795548|NCT01236924|Other|Global postural reeducation|
75795549|NCT01238718|Drug|Lidocaine|lidocaine 1.5 mg/kg intravenously
75338226|NCT01899248|Drug|Desflurane|
75338227|NCT01322815|Drug|chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
75338228|NCT01322815|Drug|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
75338229|NCT05463432|Drug|HR19024|Intravenous infusion
75473608|NCT01972685|Procedure|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchial vs. VATS biopsy
75648041|NCT04204070|Procedure|Accuro|A research coordinator recorded the depth of the EDS from skin, the number of attempts to perform the epidural anesthesia, the repositioning of the epidural needle either in the same space or in different space, the time taken for space localisation (it is defined as time taken in seconds from skin puncture until the successful space localisation).the total time of the procedure ( time measured from the patient is fully draped and in the proper sitting position till the end of insertion of the epidural catheter ) Any complications such as paresthesia during catheter insertion, dural puncture, blood in catheter and root irritation will be recorded
75338230|NCT00265538|Behavioral|Patient educational letter to engage provider in hypertension rx discussion|Patients will receive a customized/tailored letter (education) including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s). All the intervention arms (A, B and C) receive the letter.
75473609|NCT01972685|Procedure|Transbronchial Biopsy|
75795550|NCT01238718|Drug|Placebo|normal saline
75795551|NCT04284072|Device|Sensor Dot|Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).
75795552|NCT01238796|Drug|telavancin|Intravenous
75473610|NCT01972685|Procedure|VATS biopsy|
75648042|NCT04204070|Procedure|APAD|APAD
75648043|NCT04055623|Biological|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections
75648044|NCT04055623|Other|Monthly placebo infusions + 3 times per week placebo injections|For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections
75648045|NCT04055623|Biological|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.
75648046|NCT02561845|Drug|rosuvastatin|5mg, 10mg, 20mg
75795553|NCT01238874|Device|Cardiac Resynchronization Therapy|All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
75795554|NCT01235520|Drug|Placebo|Oral doses, once a day for 52 weeks
75795555|NCT01235520|Drug|RO4917838|Oral dose level 1, once a day for 52 weeks
75795556|NCT01235520|Drug|RO4917838|Oral dose level 2, once a day for 52 weeks
75795557|NCT01143948|Drug|Glargine & Glulisine|Basal Glargine & bolus Glulisine
75795558|NCT01143948|Drug|Regular insulin|Sliding scale regular insulin
75795559|NCT01143948|Drug|NPH & regular insulin|Basal NPH & bolus regular insulin
75795560|NCT01145976|Drug|Cy-ATG|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
75795561|NCT01145976|Drug|Flu-ATG|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
75795562|NCT01238952|Drug|NK012 and carboplatin|NK012 and carboplatin via infusion once every 28 days
75795563|NCT01142154|Drug|Prodarsan|Prodarsan TID, oral solution, 6-8 days
75795564|NCT05667636|Radiation|salvage SBRT|steretactic body radiation therapy in the setting of salvage radiotherapy for prostate cancer
75795565|NCT01239108|Drug|SGI-1776|SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.
75795566|NCT01144104|Behavioral|Public Service Announcement|
75338231|NCT00265538|Behavioral|Financial incentive (Arms B and C) and health educator phone call (Arm C)|Patients may receive a financial incentive for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the financial incentive discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt. The Financial incentive is part of both Arms B and C. The health educator phone call is only in Arm C.
75473611|NCT01972698|Other|Self-directed and simulation-assisted training|"All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~Participant will have access to an ultrasound simulator.~Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm)."
75473612|NCT01972698|Other|Traditional apprenticeship training|"All participants will attend an half-day ultrasound introductory course.~Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer."
75795567|NCT01144104|Behavioral|Interactive Multi-Media Computer Program|
75795568|NCT01144104|Behavioral|Sleep Hygiene Video|
75795569|NCT05158998|Drug|propofol infusion|For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)).Propofol infusion will be stopped at the end of surgery.
75795570|NCT05158998|Drug|sevoflurane inhalation|For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
75795571|NCT01235676|Behavioral|diet|calorie restriction to reduce weight gain
75338232|NCT05449002|Behavioral|Practicing the Opposite (PTO)|This 30-45-minute digital program is designed to help youths on the waitlist feel better prior to treatment and may also improve their treatment engagement and outcomes.
75473613|NCT01972711|Drug|SEP-363856|SEP-36385625 as a single oral dose of 50 mg
75473614|NCT01972711|Drug|Amisulpride|Amisulpride as a single oral dose of 400 mg
75473615|NCT01972711|Drug|Placebo|single oral dose placebo
75648047|NCT05381636|Procedure|Esophageal arterial infusion chemotherapy|Percutaneous femoral artery puncture was performed to search for feeding arterial vessels corresponding to the lesion, and chemotherapeutic drugs were directly injected into the tumor vessels via targeted blood vessels.
75648048|NCT05381636|Drug|Systemic intravenous chemotherapy|Albumin paclitaxel 125 mg / m2, D1, D8 + cisplatin 75 mg / m2, D1, every 3 weeks for 1 cycle
75795572|NCT01235676|Behavioral|Exercise|Exercise to reduce weight gain
75795573|NCT01239186|Other|methylation analyses on spermatozoa from infertile men|microarray analysis(www.EPIGENOMICS.com)
75795574|NCT05632380|Procedure|Autologous hematopoietic stem cell transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection. If previously collected stem cells are available, no stem cell mobilization or collection is required, and patients will receive conditioning directly.
75648049|NCT00727246|Drug|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
75473616|NCT01972737|Biological|Ad5-hGCC-PADRE vaccine|A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
75648050|NCT00727246|Drug|Placebo|Treatment with placebo for 6 weeks
75648051|NCT04055701|Other|assesment of thymus volume|assesment of thymus volume
75338233|NCT05449002|Other|Usual Clinical Care|Usual care provided by participating youth mental health clinics in the United States.
75473617|NCT01972750|Drug|Dovitinib|daily oral intake of capsule
75648052|NCT05381558|Drug|Triamcinolone Injection|local injection in sinus tarsi
75648053|NCT04055233|Drug|Polihexanide; Serasept|"Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
75338234|NCT00176228|Drug|Lamotrigine|"It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg."
75648054|NCT04055233|Drug|NaCl; saline|"Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
75648055|NCT02592850|Other|osteopathic manipulative treatment|"This intervention will not be protocol-based but the treating D.O. will compulsory have to include the evaluation (and possible treatment) of temporo-mandibular joint disorders and cervical dysfunctions (semi-structured treatment). Specifically, OMT will focus on correcting those osteopathic dysfunctions found during the initial evaluation; both structural (including myofascial release and HVLA), visceral and craniosacral techniques will be administered as appropriate.~Duration: 45 minutes. Administered once a week for four weeks."
75795575|NCT05632380|Biological|C-CAR088|C-CAR088 is an BCMA targeted Chimeric Antigen Receptor-T cell product. Patients will receive C-CAR088 single dose infusion 3 days after ASCT. The dose level of C-CAR088 will be determined by the investigator.
75795576|NCT01144260|Drug|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
75795577|NCT03852264|Behavioral|Pet dog|Children will interact freely with their pet dog for 25 minutes.
75795578|NCT03852264|Behavioral|Unfamiliar dog|Children will interact freely with an unfamiliar dog for 25 minutes
75933025|NCT05489068|Behavioral|Motivational Interviewing at Intake (MII)|The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.
75933026|NCT05489068|Behavioral|Intake as Usual (IAU)|In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.
75933027|NCT03290066|Device|kinesiotape|For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
75933028|NCT03290066|Other|Usual care|Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
75795579|NCT03852264|Behavioral|Nonsocial control|Children will play with age-appropriate toys/games for 25 minutes.
75795580|NCT03835260|Device|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
75795581|NCT01235988|Drug|Eltrombopag|Eltrombopag 50mg & standard of care
75795582|NCT01235988|Drug|Placebo|Placebo + standard of care
75338235|NCT00176306|Drug|Levofloxacin 750 mg IV|PK in obesity
75338236|NCT01429987|Drug|plecanatide|Subjects receive experimental study drug for 12 weeks.
75338237|NCT01429987|Other|Placebo|Subjects receive experimental study drug for 12 weeks.
75473618|NCT01972763|Drug|Ranibizumab|Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
75795583|NCT01142544|Other|Evaluation oxygenation under standard ventilator settings|Measure of PaO2 under standard FiO2-PEEP
75795584|NCT01237236|Drug|LEE011|
75795585|NCT05631366|Behavioral|Alcohol Avoidance Training|Participants are instructed to react with a joystick to the tilt of pictures, presented on a computer screen. For instance, participants make an approach movement (pull) with left-tilted pictures, and make an avoidance movement (push) with right-tilted pictures. After the correct movement is made, the pictures disappear, otherwise they do not, until the correct response is made.
75795586|NCT01239498|Procedure|Injection of Saline + Lidocaine/Adrenaline|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.~Injection of Saline + Lidocaine 1%"
75338238|NCT00265616|Drug|propofol|liquid, mg/kg.h, titrated after EEG
75795587|NCT01239498|Procedure|Lidocaine/Adrenaline only|Injection of Lidocaine/Adrenaline only
75795588|NCT00251927|Drug|esomeprazole|40 mg oral tablet administered daily
75795589|NCT00251927|Procedure|Laparoscopic fundoplication (surgery)|Surgery
75795590|NCT01237392|Device|Contact ultrasonic debridement device|Cavitational ultrasound wound debridement device
75795591|NCT01236066|Other|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children <5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
75795592|NCT03971201|Procedure|hepatic resection|removal of portion of liver containing cancer
75338239|NCT00265616|Drug|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
75338240|NCT04351399|Other|questionnaire assesment|The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine
75795593|NCT03971201|Drug|Sorafenib|sorafenib either as adjuvant therapy after resection or as only treatment
75338241|NCT01430299|Device|Demineralized Bone Matrix|Accell Evo3 in posteriolateral fusion (prospective cohort)
75338242|NCT01430299|Device|rh-BMP2|rh-BMP2 in posterolateral fusion (retrospective cohort)
75795594|NCT01236144|Drug|Plerixafor|Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
75795595|NCT01236144|Drug|AC220|Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
75795596|NCT01236144|Drug|Ganetespib|Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
75933029|NCT03289988|Other|blood sampling|NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
75338243|NCT01431313|Drug|Inhaled Nitrite|Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
75933030|NCT05488990|Drug|AKVANO-Calcipotriol formulation 1|Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
75473619|NCT01972828|Drug|FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
75933031|NCT05488990|Drug|AKVANO-Calcipotriol formulation 2|Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)
75473620|NCT01972828|Drug|STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
75648056|NCT02592850|Other|sham|"In this intervention, the operator will be restricted to the assessment of the cranial rhythmic impulse (CRI), temporo-mandibular joint disorders and cervical dysfunctions, spending a similar amount of time to that being spent on OMT-treated patients. Any found osteopathic dysfunction will not be corrected.~Duration: 45 minutes. Administered once a week for four weeks."
75648057|NCT00604448|Other|Dietary advise|Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.
75473621|NCT01972880|Drug|ASP1941|Oral
75648058|NCT00604448|Other|Diet enriched with a meal containing pulses|Subjects in pulse group will consume the commercially available pulses for 8 weeks
75648059|NCT04268966|Drug|Brincidofovir|
75648060|NCT04086706|Procedure|Retroflexion in the Right Colon|Prospective evaluation of an every day technique (retroflexion) used in our department for many years. The protocol of ascending colon examination encompassed 2 phases: A first phase (1) divided in Forward view (1a) videlicet insertion from the right flexure to the caecum followed by a second forward view (1b) namely withdrawal till the right flexure and reinsertion to the caecum maintaining the endoscope straight and a second phase (2, Retroflexion) with U-turn of the colonoscope in the caecum till the right flexure and then redressing to the forward view and reinsertion to the caecum.
75338244|NCT00176852|Drug|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
75648061|NCT04269278|Drug|0 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine
75648062|NCT04269278|Drug|0.25 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine
75795597|NCT02528526|Drug|OXY111A|OXY111A intravenous infusion
75795598|NCT03971279|Drug|Dexamethasone Ophthalmic implant|intravitreal injection of ozurdex implant
75795599|NCT01329744|Drug|mecasermin|a subcutaneous injection twice a day
75795600|NCT01329744|Drug|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
75795601|NCT00165503|Drug|Cisplatin|
75933032|NCT05488990|Drug|AKVANO vehicle formulation 1|Novel lipid based formulation (AKVANO) vehicle 1
75338245|NCT00176852|Drug|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC >2500 x 2 days.
75795602|NCT00165503|Drug|Sodium Thiosulfate|
75795603|NCT00165503|Drug|ALIMTA|
75338246|NCT00176852|Drug|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
75338247|NCT00176852|Radiation|Total Body Irradiation|300 cGY Day -1
75338248|NCT00176852|Procedure|Stem cell infusion|Given Day 0
75338249|NCT01323517|Drug|Ipilimumab, Melphalan and Dactinomycin|Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
75933033|NCT05488990|Drug|AKVANO vehicle formulation 2|Novel lipid based formulation (AKVANO) vehicle 2
75933034|NCT05488990|Drug|Daivonex solution|Daivonex solution containing Calcipotriol (50 μg/g)
75648063|NCT04269278|Drug|0.5 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine
75648064|NCT04269278|Drug|0.75 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine
75338250|NCT01323595|Drug|Celecoxib|Celecoxib 200mg PO BID x 6 days
75338251|NCT01323595|Drug|Sugar Pill|Sugar pill PO BID x 6 days
75338252|NCT01324453|Procedure|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
75338253|NCT01324453|Procedure|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
75338254|NCT01376557|Drug|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
75648065|NCT02562937|Behavioral|text messages related to sedentary behaviour|texts sent twice daily encouraging reduced sedentary behaviour
75795604|NCT03971123|Drug|Tricaprilin|Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
75795605|NCT03971123|Drug|Tricaprilin|Tricaprilin formulated as AC-LMP-01 50g of AC-LMP-01 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
75933035|NCT05488990|Drug|Daivonex cream|Daivonex cream containing Calcipotriol (50 μg/g)
75795606|NCT03971123|Drug|Placebo|Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
75933036|NCT03293576|Behavioral|Volitional Help Sheet|"This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan)."
75933037|NCT03289832|Dietary Supplement|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
75933038|NCT03289832|Dietary Supplement|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
75933039|NCT02461472|Other|not intervention|This is a cross-sectional study, no intervention was performed.
75933040|NCT02555722|Device|fanfilcon A (test)|silicone hydrogel lens
75933041|NCT02555722|Device|enfilcon A (control)|silicone hydrogel lens
75933042|NCT05493748|Other|Bladder training|Bladder training for overactive bladder syndrome.
75933043|NCT04119388|Other|Adapted sports practices|Adapted sports practices for 30 minutes twice a week
75933044|NCT03289598|Behavioral|A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals|"The intervention consists of two parts:~Education of the health care staff with three day's education focusing of aspects of food, meals and nutrition to old people.~The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication."
75933045|NCT03293342|Behavioral|D CBT|"Intervention:~a 3-5 session treatment of dental fear.~Psychoeducation about anxiety~Exploration of the individual anxiety~Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
75338255|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
75338256|NCT01376557|Drug|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
75648066|NCT02592616|Behavioral|CON|No exercise intervention.
75648067|NCT02592616|Behavioral|CW|One hour of continuous walking on a treadmill.
75648068|NCT02592616|Behavioral|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
75648069|NCT02853578|Drug|Busonid (budesonide 200mcg and 400mcg)|"cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks."
75338257|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
75648070|NCT02562781|Drug|Oxygen|Oxygen in sufficient quantity to maintain SpO2 > 98%
75648071|NCT02562781|Other|Air|Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
75648072|NCT02591680|Other|Neuromuscular training|
75338258|NCT01376557|Drug|Placebo|Subjects will receive placebo once daily.
75338259|NCT01324687|Other|Telemedicine care|Availability of telemedicine
75338260|NCT01431391|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
75648073|NCT02591680|Other|Muscle strengthening|
75795607|NCT03971123|Drug|Tricaprilin|Tricaprilin formulated as AC-1202 60g of AC-1202 (20g caprlic triglyceride) mixed in 240mL dosing liquid at Hour 0 Day 1
75795608|NCT01144650|Drug|Dapsone|Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
76086290|NCT05116163|Behavioral|Individuation Intervention plus implicit bias educational modules|"Providers in the intervention are will be instructed to watch a brief set of freely available educational lessons and then they will meet with study team members to discuss their individuation countermeasure intervention. Providers will be given a choice of several individuation-related questions to better understand the unique characteristics of each patient. Once the provider decides on his/her choice phrases, the research team will assist with the development of a smart phrase (also called dot phrase) to allow them to incorporate this into a note. Once a week, providers in the intervention arm will receive an email reminding them to incorporate this question and the documentation into their encounters."
76086291|NCT05116163|Other|Implicit bias educational modules|Providers in the comparator arm will be given the same implicit bias educational modules to complete.
76086292|NCT05111405|Procedure|CMC Arthroplasty|Surgical intervention to treat CMC arthritis
76086293|NCT05108558|Drug|CCH administration|Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
75338261|NCT01431391|Drug|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
75338262|NCT04346641|Diagnostic Test|Facial Measurements and Tooth Size and Pulp Volume|Radiographic images of patients who have been indicated for cone-beam computed tomography for the upper jaw for various reasons (such as impacted teeth, sinusitis, skeletal anomalies) will be reviewed retrospectively. Facial measurements (lower face height, midface height, inter-zygomatic distance, inter-pupillary distance, inter alar distance, epicanthus distance, the distance between commissures) of the patients who received cone beam computed tomography will be measured in the clinic. Mesiodistal distance, buccal palatal distance, root length, pulp volume of maxillary sixth tooth will be measured using cone beam computed tomography. The data obtained will be compared.
75648074|NCT02591680|Device|Sensorimotor|
75473622|NCT01972893|Drug|ZYD1|"Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
75473623|NCT01972893|Drug|Placebo|"Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
75648075|NCT02562859|Drug|500 mg GLPG1837 as oral suspension|A single dose of 500 mg GLPG1837 administered as oral suspension
75648076|NCT02562859|Drug|500 mg GLPG1837 as oral tablet|A single dose of 500 mg GLPG1837 administered as oral tablet
75795609|NCT01144650|Drug|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
75933046|NCT03293342|Combination Product|Control|"Intervention:~Traditional treatment of dental fear common sense/ benzodiazepine"
75933047|NCT03293186|Combination Product|MEDICLORE|use MEDICLORE at the end of surgery as antiadhesive product
75933048|NCT02461316|Other|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
75933049|NCT03289520|Drug|Clopidogrel|
75933050|NCT03289520|Drug|Placebo|
75933051|NCT03298100|Other|Scoring model|Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
75338263|NCT03009097|Biological|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
75473624|NCT01972906|Device|moxibustion|apply moxibustion according to traditional Chinese medicine
75473625|NCT01972906|Drug|Ibuprofen Sustained Release Capsules|apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
75648077|NCT00918268|Biological|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
75648078|NCT02851238|Other|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
75648079|NCT02592694|Drug|cocktail|Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
75648080|NCT02592694|Device|thrombus aspiration|manual thrombus aspiration
75648081|NCT00686647|Device|AngioSculpt® Scoring Balloon Catheter|Use of a stent for the main branch of a bifurcation lesion and use of a scoring balloon for the side branch of the same bifurcation lesion
75648082|NCT00686647|Device|AngioSculpt Scoring Balloon Catheter|Treatment of the side-branch vessel of true bifurcation lesions using the AngioSculpt device
75648083|NCT02591836|Drug|Gemcabene|Gemcabene
75648084|NCT02591836|Drug|Atorvastatin|Atorvastatin
75648085|NCT02591836|Drug|Placebo|
75648086|NCT00603122|Behavioral|ascent protocol|ascent protocol for the two groups has different acclimatization time
75648087|NCT04056871|Diagnostic Test|Frailty Screening Tools|This is an observational and prospective study of patients who are going for elective surgery, thus no intervention will be given.
75795610|NCT00162773|Drug|omalizumab|150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
75795611|NCT00162773|Other|Placebo|150-375 milligrams depending on body weight and serum IgE.
75795612|NCT00209339|Device|Percutaneous mitral valve repair (MitraClip Implant)|Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardiovascular Valve Repair System.
75795613|NCT03970889|Device|Klue|Klue is a software program the uses an Apple watch to detect hand motions which are indicative of eating.
75795614|NCT03968003|Dietary Supplement|Inulin|Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.This study evaluates the changes of gut microbiota composition and diversity, body weight, body fat, SCFAs, plasma amino acids, satiety hormones (PYY and GLP-1), Inflammatory cytokines (IL-1β, TNF-α and IL-6) after 6-month studied period
75933052|NCT03289442|Procedure|supine position|patients were positioned on their supine position to receive colonoscopy insertion
76086294|NCT05108558|Drug|Control - Crossover to CCH|Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
75795615|NCT03970577|Drug|Rituximab|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
76086295|NCT05108558|Device|RestoreX|Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
75795616|NCT03970577|Drug|Prednisone|exclusive oral steroid therapy (progressively tapered with the same procedure for all patients) for a total exposure of 24 weeks (taking into account the initial oral steroid therapy administered during 8 weeks in addition with the oral steroid treatment given after randomization). Each patient will be followed up until 18 months after randomization.
75473626|NCT01972945|Procedure|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
75473627|NCT01972945|Procedure|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
76086296|NCT05104645|Other|Analysis of the walk|Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)
75473628|NCT01972958|Other|comprehensive care|comprehensice assessment,physical activity training, community resources referral, health education.
75473629|NCT01972971|Other|patient education|one by one patient education
75648088|NCT02851472|Drug|Inhaled Nitric Oxide|Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.
75648089|NCT02851472|Drug|Placebo|Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems specifically adapted for this study.
75795617|NCT01073813|Drug|Minocycline|100mg twice daily
75795618|NCT03970421|Other|Observation|Check clinical status at different time intervals during 3 months
75795619|NCT03823391|Drug|ABBV-3373|ABBV-3373 is administered as intravenous (IV) infusion
75933053|NCT03289364|Device|Penguin Cold Caps|Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
75933054|NCT03289286|Other|Dedicated and coordinated e-follow-up.|"In pre- and post-surgery:~Completion of questionnaires using an electronic tool,~Telephone follow-up if necessary between the nurse and the patient."
76086297|NCT05104645|Other|Analysis of the race|Analysis of running in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Healthy volunteers: 2 times (between 3 and 20 days apart)
75795620|NCT03823391|Drug|Placebo for ABBV-3373|Placebo for ABBV-3373 is administered as IV infusion
75795621|NCT03823391|Drug|Adalimumab|Adalimumab is administered as subcutaneous (SC) injection
75795622|NCT03823391|Drug|Placebo for adalimumab|Placebo for adalimumab is administered as subcutaneous (SC) injection
75933055|NCT03293108|Drug|Denosumab|Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.
75933056|NCT03293108|Dietary Supplement|calcium|All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.
75933057|NCT03293108|Dietary Supplement|vitamin D|All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.
75933058|NCT03292796|Drug|Prostaglandins|
75933059|NCT03292718|Device|MyCyFAPP|use of the MycyFAPP with all its features during 6 months
75933060|NCT03288896|Behavioral|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
75933061|NCT03288818|Drug|Mechlorethamine Hydrochloride Gel|Given topically
75933062|NCT03288818|Procedure|Total Skin Electron Beam Radiation Therapy|Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
75933063|NCT03288740|Drug|Semaglutide 0.5 mg|A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
75933064|NCT03288740|Drug|Placebo (semaglutide 0.5 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
75933065|NCT03288740|Drug|Semaglutide 1.0 mg|A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
76086298|NCT05104645|Other|Unipodal and bipodal jumps on flat ground|Healthy volunteers: 2 times (between 3 and 20 days apart)
75473630|NCT01972984|Drug|Anastrozole|Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
75473631|NCT01972997|Device|SENSIMED Triggerfish|
75473632|NCT01973010|Other|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
76086299|NCT05101681|Diagnostic Test|Teledentistry|Teledentistry using mobile photographs
76086300|NCT05086705|Device|EMBr Wave|Use EMBr Wave
75648090|NCT02562703|Device|Transcutaneous Vagus Nerve Stimulation|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
75648091|NCT04268030|Other|collection of LFPs|collection of local field potentials (LFPs) at rest and during hand opening and closing
75648092|NCT04267952|Behavioral|Hand hygiene intervention program developed according to planned behavior theory|The perception of the importance of hand hygiene with expression of damages of microorganisms (stories about illnesses etc.). Visually assisted hand hygiene training experiments to ensure the visibility of microorganisms in the environment. Demonstration and application of the correct hand washing technique with music. All applications will take place in three lessons (120-minute).
75933066|NCT03288740|Drug|Placebo (semaglutide 1.0 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
75933067|NCT03297632|Behavioral|Functional resistance exercise|Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
75933068|NCT03288662|Other|CT and histopathological classification|Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
76086301|NCT05086705|Other|Questionnaire Administration|Ancillary studies
76086302|NCT05084924|Device|Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
76086303|NCT05070104|Drug|CPI-613|250-1000mg/m2 -14 day cycle
75338264|NCT03009097|Drug|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
75338265|NCT01325311|Drug|Cholecalciferol|Given PO
75338266|NCT01325311|Drug|Genistein|Given PO
75648093|NCT04267952|Behavioral|Classical hand hygiene education|expression of hand hygiene with verbal presentation method in a 40-minute lecture
75648094|NCT00687973|Drug|Valsartan/amlodipine 80/5 mg tablets|
75648095|NCT00687973|Drug|Amlodipine 5 mg capsules|
75648096|NCT00687973|Drug|Amlodipine 10 mg capsules|
75338267|NCT01325311|Other|Laboratory Biomarker Analysis|Correlative studies
75648097|NCT00687973|Drug|Atenolol 50 mg tablets|
75795623|NCT03970187|Other|Exposure-based eye contact training in Virtual Reality (VR)|"The intervention is an App for virtual reality. The VR App provides three different virtual scenarios. Participants will be asked to stand in front of a virtual audience and to maintain eye contact with audience members. The advance to higher difficulty levels is according to a pre-defined exposure scheme. Participants will be given all instructions via the App.~There will be three sessions on one day (duration of 20 min each) in study phase 1. The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking. In the study phase 2, there will be nine sessions spanning over two weeks (duration of 20 min each, with maximally one session per day). The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking."
75795624|NCT01075529|Drug|fluoxetine|fluoxetine 20 mg/d
75795625|NCT01073891|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions
76086304|NCT05070104|Drug|modified FFX|Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
76086305|NCT05070104|Drug|Bevacizumab|5mg/kg IV
75338268|NCT01325311|Other|Pharmacological Study|Correlative studies
75648098|NCT00687973|Drug|Atenolol 100 mg tablets|
75338269|NCT01325311|Other|Placebo|Given PO
75795626|NCT01073891|Drug|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions
75338270|NCT01432015|Drug|fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
75338271|NCT01432015|Drug|aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
75648099|NCT00747097|Drug|gemcitabine + cetuximab|gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment
75648100|NCT00747253|Device|AutoLITT system|laser treatment with the AutoLITT system
75795627|NCT01073891|Drug|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions
76086306|NCT05069259|Other|Stool sample collection|collection for measuring calprotectin levels
75648101|NCT00747331|Drug|Fenoldopam mesilate|Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
75338272|NCT01432015|Other|Oral Placebo|One pill administered on days 1-3 in conjunction with Fosaprepitant.
75795628|NCT03970031|Drug|MSDC-0602K|MSDC-0602K tablet
75933069|NCT03108092|Other|STRIP intervention|The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up
75933070|NCT03108092|Other|Control|Standard care in the department where the trial is conducted
75338273|NCT01432015|Other|IV placebo|100 cc of IV placebo administered on day in conjunction with Aprepitant
75338274|NCT01080209|Drug|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
75338275|NCT01080209|Other|Sham|Patients who recieved sham in a previous study.
75648102|NCT00747331|Drug|Placebo|"Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug"
75648103|NCT00747409|Drug|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
75648104|NCT00747409|Drug|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
75795629|NCT03970031|Drug|Placebo|Matching tablet
75795630|NCT00209027|Other|fMRI|fMRI scanning during behavioral reward task
75933071|NCT03292328|Other|Yoga|Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
75338276|NCT01080677|Drug|caffeine/propranolol combination tablet|caffeine/propranolol combination tablet administered orally once daily
75338277|NCT01080677|Drug|placebo|placebo to match caffeine/propranolol combination tablet administered orally once daily
75338278|NCT01378273|Drug|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
75338279|NCT01378273|Other|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
75795631|NCT00209027|Drug|Aripiprazole|30 mg by mouth once daily
75795632|NCT00208325|Device|P.F.C Sigma Fixed Bearing total knee system|Orthopaedic implant for total knee replacement
75933072|NCT03292328|Other|Wait List Control|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
75473633|NCT01973010|Drug|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
75473634|NCT01973023|Other|Motion analysis|Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
75933073|NCT03292172|Drug|Atezolizumab|Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.
75933074|NCT03292172|Drug|RO6870810|RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
76086307|NCT05066854|Procedure|integron research|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Urine samples will be sent to the laboratory for culture and integron PCR according to routine practice.~Results of the integron search will be given to the investigator. Patients in the experimental group with a positive or uninterpretable PCR will also receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.~Patients in the experimental group with a negative PCR will receive a treatment with SXT at the recommended dose."
75473635|NCT01973101|Drug|Cisplatin|50 mg/m2 - Day 1
75473636|NCT01973101|Drug|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
75473637|NCT01973101|Drug|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
75473638|NCT01973101|Radiation|Radiotherapy|45 Gy
75648105|NCT00752011|Drug|TAS-106|Starting dose 2.0 mg/m^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
75648106|NCT00752011|Drug|Carboplatin|Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
75648107|NCT00721396|Biological|rMenB+OMV NZ|
75795633|NCT00208325|Device|P.F.C Sigma RP Mobile Bearing knee system|Orthopaedic implant for total knee replacement
75648108|NCT00721396|Biological|combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine|
75795634|NCT00160667|Drug|Placebo|Daily oral dose of two equal intakes.
75795635|NCT00160667|Drug|Brivaracetam|Daily oral dose of two equal intakes.
75795636|NCT00206375|Drug|Growth hormone|Growth hormone + Synthroid + Lupron
75795637|NCT00206375|Drug|Growth hormone treatment and puberty|Lupron once a month and growth hormone daily
75795638|NCT00160199|Drug|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
75648109|NCT00721396|Biological|Pneumococcal vaccine|
75473639|NCT01973101|Radiation|Brachytherapy|80 Gy
75473640|NCT01973114|Drug|Latanoprost|
75473641|NCT01973114|Other|Placebo|
75648110|NCT00943826|Drug|Bevacizumab|10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
75795639|NCT00160199|Drug|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
76086308|NCT05066854|Procedure|usual practice|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Patients in the control group will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
76086309|NCT05063513|Biological|Autologous Hematopoietic Stem Cell Transplantation|Experimental arm will undergo mobilisation with CY 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
76086310|NCT05063513|Drug|Rituximab|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
75795640|NCT00157157|Biological|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.~For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.~Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.~rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion."
76086311|NCT05062629|Genetic|Whole Genome Sequencing|Whole Genome Sequencing
76086312|NCT05048810|Radiation|68Ga-DOTA-NT-20.3|In this study, all patients will receive one injection of 68Ga-DOTA-NT-20.3, a PET radiopharmaceutical selective for neurotensin receptor 1 (NTR-1). For the injection, subjects will receive a target dose of 2-4 MBq per kg of body weight as a bolus injection. 68Ga-DOTA-NT-20.3 injection will be followed by a 10 ml saline flush.
75338280|NCT01432405|Drug|Exenatide|Type 2 diabetic subjects will be randomized to receive exenatide 10 micrograms injected subcutaneously twice daily for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
75648111|NCT00943826|Drug|Temozolomide|75 mg/m^2 once daily for 6 weeks, followed by 150-200 mg/m^2 once daily on days 1-5 of six 4 week cycles.
75648112|NCT00943826|Radiation|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
75648113|NCT00943826|Drug|Placebo|Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
75795641|NCT00203411|Drug|Capecitabine (Xeloda)|1000mg/m^2 administered orally twice daily for two weeks followed by one week rest period
75933075|NCT02460926|Procedure|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
75933076|NCT03291938|Drug|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
75648114|NCT04268888|Drug|Nivolumab and TACE/TAE|Immunotherapy and TACE/TAE
75648115|NCT04268888|Procedure|TACE/TAE|TACE/TAE (as per local practice)
75648116|NCT00603356|Drug|OSI-930 and erlotinib|OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
75648117|NCT04269044|Diagnostic Test|non-contact EKG|ultra-sensitive, non-contact EKG pad will be placed beneath the infant
75795642|NCT00203411|Drug|Bevacizumab|7.5 mg/kg IV will be administered every 3 weeks
75795643|NCT00203021|Drug|Glatiramer acetate|Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
75795644|NCT00201851|Drug|Tamoxifen|20 mg po daily x 5 years
75933077|NCT03291938|Other|Pharmacodynamic Study|Correlative studies
75933078|NCT03291938|Other|Pharmacokinetic Study|Correlative studies
75933079|NCT03288584|Drug|Tocilizumab (Actemra®)|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
75933080|NCT03288584|Drug|Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
75933081|NCT03288584|Drug|Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
75933082|NCT02461004|Drug|CKD-391|Investigational product is prescribed to all of radomized subjects for two times.
75933083|NCT02461004|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
75933084|NCT03288428|Drug|Nalbuphine|patient controlled analgesia with Nalbuphine
75933085|NCT03288428|Drug|Morphine|patient controlled analgesia with Morphine
75933086|NCT03288350|Drug|mDCF + Avelumab|Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
75933087|NCT04488380|Other|dental restoration|Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin
75933088|NCT03291860|Procedure|Ovum retrievum|assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles
75933089|NCT02461238|Other|Vouchers|The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
75933090|NCT02461238|Other|Nutrition education|Nutrition education workshops taught by a dietician
75933091|NCT03291782|Drug|D-0120|oral, single dose
75933092|NCT03291704|Device|Thermal therapy device|Thermal therapy of blocked Meibomian glands
75933093|NCT03288272|Radiation|Whole Brain Radiotherapy|Radiotherapy of the whole brain
75933094|NCT03288272|Other|Best Supportive Care|Best Supportive Care including nutrition, pain medication, steroids as needed
75795645|NCT00201851|Procedure|Surgery: Oophorectomy|Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
75933095|NCT03297320|Other|In-depth conversation about Goals of Care and ACP|In-depth conversation regarding Goals of Care and ACP by an experienced practitioner
75933096|NCT03288116|Diagnostic Test|Scheimplug imaging and contrast and sensitivity test|examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
75795646|NCT03969485|Device|Hybrid Fractional Laser|Hybrid Fractional Laser Device
75933097|NCT00003224|Biological|QS21|vaccine adjuvant
75933098|NCT00003224|Biological|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
76086313|NCT05045677|Other|digital DBT skills intervention|The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.
75338281|NCT01432405|Drug|Pioglitazone|Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
75338282|NCT01082159|Procedure|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
75648118|NCT02853110|Radiation|Hypo-FLAME study|SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
75648119|NCT02851316|Other|Whole Body Vibration|Participants will stand in a squatted position on a platform that provides a brief vibratory stimuli.
75648120|NCT02851394|Drug|Levobupivacaine|
75648121|NCT02851394|Drug|levobupivacaine|
75648122|NCT02851394|Drug|tramadol|
75933099|NCT00003224|Biological|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
75933100|NCT00003224|Biological|p946/tet-p|This peptide is a longer version of p946 (gp100 [280-288]) sythesized colinearly with the tetanus helper peptide (Tet-p)
76086314|NCT05045677|Other|Standard Care|Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
76086315|NCT05043675|Drug|[18F]APN-1607|Subjects will receive one injection of [18F]APN-1607 (0.1~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. [18F]APN-1607 injection will be followed by a 10 ml saline flush.
75648123|NCT02851160|Other|semi-structured interview conducted by a clinical psychologist|semi-structured interview conducted by a clinical psychologist
75648124|NCT02851160|Other|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
75648125|NCT00603434|Drug|OROS-MPH|18 mg bid on days 1 and 2
75648126|NCT00603434|Drug|OROS-MPH|27mg bid on days 3 and 4
75648127|NCT00603434|Drug|OROS-MPH|35 mg bid on days 5-9
75648128|NCT05381402|Other|Questionnaire|Questionnaire to assess the impact of COVID 19 on psoriasis patients
75795647|NCT00200057|Device|InterStim Sacral Nerve Stimulation Therapy|Open label study. All subjects that qualify for the study will be implanted.
75648129|NCT02852876|Drug|ASP2151|Oral
75648130|NCT02852876|Drug|Placebo|Oral
75648131|NCT02851082|Other|Endurance training program|"Exercise intensity will be fixed to the corresponding powers for ventilatory thresholds, if applicable for pain tolerance. The endurance interval training workout is known to induce metabolic and physiological adaptations. For intermittent workout training protocol, recovery periods at moderate intensity between periods at high intensity help to sustain repeated high intensity periods of exercise. If pain disturbs exercise tolerance, power will be lowered as necessary.~A set of 3 training sessions per week of 45 minutes each for 6 consecutive weeks will be proposed (one session every two days). This scheme is usually encouraged for patients suffering from chronic diseases."
75648132|NCT01004003|Drug|Sorafenib|
75648133|NCT01004003|Drug|BIBF 1120|Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
75648134|NCT02871245|Procedure|Laparoscopic Surgery|
75648135|NCT02871245|Device|Acupuncture treatment|
75648136|NCT00943670|Biological|pertuzumab|Intravenous repeating dose
75795648|NCT01073969|Other|wheat bran extract|Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
75795649|NCT01073969|Other|control wheat bran extract|Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
75795650|NCT03967769|Device|High Flow nasal Cannula|Apnoeic Oxygenation by High Flow Nasal Cannulae
75933101|NCT00003224|Biological|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
75933102|NCT03291548|Dietary Supplement|Quinoa biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
75933103|NCT03291548|Dietary Supplement|Control biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
75933104|NCT04489316|Other|Narrative medicine curriculum|The curriculum will consist of three sessions in narrative medicine- i.e. discussing texts and poetry, and engaging in reflective writing as a group
75338283|NCT01432561|Drug|Cysteamine bitartrate|500 mg total, single dose taken orally on visits 2, 3 & 4 which must occur within a 14 day period.
75795651|NCT01074203|Drug|Nitazoxanide|"Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.~Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery >12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses~All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given."
75795652|NCT01074281|Drug|Enalapril maleate (10 mg) + nitrendipine (20 mg)|The drug was administered as per the Summary of Product Characteristics (SPC)
75933105|NCT03288038|Drug|Rosuvastatin|
75933106|NCT03288038|Drug|Ezetimibe|
75648137|NCT00943670|Biological|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
75338284|NCT01116401|Drug|leuprolide|Leuprolide acetate is a widely used GnRH agonist. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women (one 3.75-mg intramuscular injection).
75648138|NCT02851004|Drug|Napabucasin|"1 cycle is 21days.~BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.~[Additional cohort to the Phase II part] Oral administration at a dose of 240mg mg BID, every day~The therapy will be repeated until meeting the discontinuation criteria."
75338285|NCT03008317|Device|PEEK|a metallic denture base
75648139|NCT02851004|Drug|Pembrolizumab|"1 cycle is 21days.~Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle~[Additional cohort to the Phase II part] Administration at a dose of 200 mg/body on Day 1 of each cycle.~The therapy will be repeated until meeting the discontinuation criteria."
75648140|NCT02850692|Other|measure of endothelial function|Arterial tone index measured by EndoPAT®. Patient should neither eat nor drink at least 4 hours before exam and should neither smoke 3 hours before the exam.
75648141|NCT02850692|Biological|Blood sample|21 ml of blood to measure : hepatic workup, complete blood count (CBC), platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), C-reactive protein (CRP), lipid test, ionograms, creatinine, tissue plasminogen activator factor (tPA), plasminogen activator inhibitor-1 (PAI-1), tissue factor pathway inhibitor (TFPI), Willebrand factor, soluble thrombomodulin, blood levels of endoglin and syndecan. And level beta human chorionic gonadotropin (beta-HCG) for woman only.
75648142|NCT02850692|Other|Hepatic elastography|Hepatic elastography by Fibrocan®. Patient should neither eat nor drink at least 2 hours before exam. 10 successive measurements are made.
75648143|NCT02850692|Diagnostic Test|Injected abdominal CT|"Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit."
75795653|NCT03129100|Drug|Ixekizumab|Administered SC
75795654|NCT03129100|Drug|Placebo|Administered SC
75933107|NCT03283358|Behavioral|Person-centered follow up|
75933108|NCT03287960|Drug|Setmelanotide|Once daily subcutaneous injection
75933109|NCT03287960|Drug|Placebo|Once daily subcutaneous injection
75933110|NCT03287882|Dietary Supplement|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
75933111|NCT03287882|Behavioral|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
75338286|NCT01433107|Drug|Terbinafine|1% single application
75338287|NCT01433107|Drug|Terbinafine Placebo|single application
75338288|NCT01082939|Drug|Fludarabine|25 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
75338289|NCT01082939|Drug|Cyclophosphamide|250 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
75338290|NCT01082939|Drug|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
75338291|NCT01082939|Drug|Rituximab|"Cycle 1 (Week 1): 375 mg/m^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV on Day 2 over 4- 6 hours"
75795655|NCT03101020|Other|Active Visceral Manipulation|Visceral manipulation techniques consists of deep manual pressure in certain points of the abdomen and the amount of pressure will be respected according to the participant discomfort or pain. It will be performed cardia mobilization, pylori mobilization, Oddi's sphincter mobilization, duodenum-jejunum valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.
75795656|NCT03101020|Other|Standard care physiotherapy|The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.
75648144|NCT00938366|Drug|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
75648145|NCT00938366|Drug|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
75795657|NCT03101020|Other|Placebo Visceral Manipulation|The placebo intervention involves light touch at the same regions of the techniques the active visceral manipulation, and no intention on the part of the therapist to impart any therapeutic technique
75795658|NCT05294692|Behavioral|Financial Health Incentives|"After registration on the Caterpillar App, participants will be instructed to 'carry their phone' as much as possible during a 5-day baseline period to assess their daily step counts. In Month 1, participants will earn daily rewards (3¢ per day personalized daily step goal met; BE present bias). In Month 2, users will earn weekly rewards (25¢ per week goal met 5+ times; BE fresh start). In Month 3, users will earn team-based rewards (35¢ per week if 10+ goals are reached collaboratively with someone they know e.g., friend; BE herd mentality). Participants are expected to earn $1.25 CAD (or 0.75 British pounds) over the course of the 12-week intervention (about $5/person/yr). Rather than offer daily incentives indefinitely, Caterpillar will offer daily incentives as a temporary feature-moving to larger, less frequent, less certain (team-based) incentives as PA becomes habitual."
75795659|NCT03100006|Drug|Nivolumab|240mg of IV Nivolumab is administered over 30 mins every 2 weeks
75795660|NCT03100006|Drug|Oregovomab|IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
75933112|NCT03287726|Dietary Supplement|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
75648146|NCT00943592|Drug|Clofarabine|Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
75933113|NCT03287726|Dietary Supplement|placebo|Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
75933114|NCT03291314|Drug|Axitinib|1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) [7].
75933115|NCT03291314|Drug|Avelumab|2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
75933116|NCT03291236|Other|Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.
75933117|NCT03283280|Other|Ever X Posterior|Resin composite restoration can be made as a direct onlay
75933118|NCT03287648|Diagnostic Test|optical coherence tomography and blue-fundus autofluorescence|Simultaneous infra-red and optical coherence tomography (cube and radial pattern) centered on the fovea Simultaneous fundus autofluorescence and optical coherence tomography (radial pattern) centered on the fovea
75933119|NCT03287570|Device|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
75933120|NCT03287570|Procedure|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
75933121|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
76086316|NCT05037656|Behavioral|School-based curriculum|Participants will be randomized, at the school level, to receive either the e-cigarette/tobacco/areca nut use prevention curriculum or the standard of care (i.e., control). The curriculum will be implemented using 5 intensive in-class lessons over the span of 6 weeks. All sessions of the curriculum follow the same basic format: a) an introduction and/or review of the past lesson, b) a cultural wall activity, c) a video, d) 1-2 interactive activities, and e) a wrap-up activity. Lessons are designed such as to help improve knowledge about drugs and correct cognitive misperceptions and to train on skills to resist normative social influence. Participants will complete identical survey questionnaires for assessments at 3 time-points: pretest (baseline, before implementing the intervention), immediate posttest (following the end of the intervention), and six-month follow-up. The surveys will be administered in the classroom, during regular school hours.
75795661|NCT03030664|Dietary Supplement|L.reuteri|Each day, at about the same time, the subjects will be given 5 drops (1x10^8 CFU) of the study product in connection with feeding
75795662|NCT03030664|Drug|Placebo|Same formulation as study product, without probiotics.
75795663|NCT03100942|Drug|Lanraplenib|1 x 30 mg tablet administered orally once daily
75795664|NCT03100942|Drug|Filgotinib|1 x 200 mg tablet administered orally once daily
75795665|NCT03100942|Drug|Tirabrutinib|1 x 40 mg tablet administered orally once daily
75795666|NCT03100942|Drug|Lanraplenib placebo|1 x tablet administered orally once daily
75795667|NCT03100942|Drug|Filgotinib placebo|1 x tablet administered orally once daily
75795668|NCT03100942|Drug|Tirabrutinib placebo|1 x tablet administered orally once daily
75648147|NCT00943592|Drug|Melphalan|Doses ranging from 100 to 140 mg/m2
75648148|NCT00943592|Drug|Campath|20mg/d x5
75648149|NCT00943592|Procedure|Stem Cell Transplant|Infusion of donor, bone marrow and auto.
75648150|NCT00943124|Drug|MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
75648151|NCT00943124|Drug|MK0524A (ER niacin + laropiprant)|Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
76086317|NCT05019963|Behavioral|NexJ Connected Wellness|NexJ Connected Wellness is an electronic case management platform with a patient-facing smart phone application and a clinician-facing web dashboard.
75338292|NCT01327963|Device|Transoral Incisionless Fundoplication|Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized Transoral Incisionless Fundoplication 2.0 technique iteration (TIF2.0) protocol.
75338293|NCT01381471|Drug|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
75338294|NCT01328743|Behavioral|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
75795669|NCT05239780|Procedure|Brain stimulation|Brain stimulation will be performed after collection of clinical seizure data. Bipolar stimulation to one or several adjacent electrodes will be applied. Stimulation design will be either determined prior to testing or designed according to results from neurobehavioral assessments. Stimulation will consist of biphasic, constant-current trains of stimulation pulses at 100 Hz, with 100 ms pulse width or a sinusoidal wave of a predefined mean band frequency (i.e. 6Hz for θ, 11Hz for α, 20Hz for β, etc.). Stimulation intensity will be ≤6 mA, consistent with parameters used for clinical mapping, for the duration of the behavioral task or for short (2-3 s) periods of time at given epochs during the task (i.e. outcome evaluation). Clinical personnel will be available during stimulation to help monitor stimulation-induced after-discharges; if any are detected, stimulation intensity will be dialed down or terminated.
75795670|NCT02476474|Procedure|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
75795671|NCT02476474|Procedure|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
75795672|NCT05211076|Other|Music Group|"The Introductory Information Form will be filled in by researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.On the 1st day of the post-op,mothers will be able to listen to Classical Turkish Music works in the forms of Saz Semaisi,Peşrev,Medhal in Rast,Uşşak,Kürdi,Muhayyer makams for 30 minutes via their phone at 11:00am.~While the mother continues to listen to the music,at the 16th minute,the researcher will manually milk the mother for at least 15 minutes until milk comes out.At the end of the milking process,the milk accumulated in the container will be measured by the researcher with injector,recorded in the Breast Milk Follow-up Form.At the end of the music session,it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~The same procedure will be applied to the mother atb05:00pm.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
75933122|NCT03283202|Drug|Avadomide (CC-122)|Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.
75933123|NCT03283202|Drug|Rituximab|Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
75933124|NCT03283202|Drug|Cyclophosphamide 750mg/m2 by IV infusion|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
75933125|NCT03283202|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
75933126|NCT03283202|Drug|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
75933127|NCT04570358|Other|Static stretching|During the static stretching training for the calf muscles, the ankle joint is moved into maximal dorsiflexion until the point of discomfort is reached. The ankle joint is then held in this maximal position for 30 s followed by a rest period of 30 s. Afterwards, the procedure is repeated with the knee in flexed position to stretch the soleus muscle.
75933128|NCT04570358|Other|Proprioceptive neuromuscular facilitation stretching|During the proprioceptive neuromuscular facilitation stretching, the ankle joint is moved into maximal dorsiflexion. While the foot is kept in this position, the child will perform a (sub-) maximal isometric contraction of the plantar flexors against the resistance of their parents. Afterwards, the ankle joint will be moved further into greater dorsiflexion and is held there for the remaining seconds followed by 30 s of rest. Subsequently, the stretch will be applied with the knee flexed.
75933129|NCT03283124|Procedure|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
75338295|NCT01329679|Dietary Supplement|Energy Drink|Energy drink, 2oz twice daily for 7 days
75933130|NCT03283046|Drug|Nivolumab|"Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle."
76086318|NCT05019963|Other|Usual Care|Participants will receive a treatment plan as decided on with their clinician(s).
75338296|NCT01329679|Other|Placebo|Water, lime juice and cherry flavoring
75338297|NCT05422092|Drug|Canagliflozin|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
75338298|NCT05422092|Drug|Pioglitazone|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
76086319|NCT05016219|Device|Circadian-Effective Light|Narrowband blue light
76086320|NCT05016219|Device|Rhythmic Light|40 hertz (Hz) flicker
76086321|NCT05016219|Device|Placebo Light|Narrowband red light
76086322|NCT05016219|Device|Placebo Rhythmic Light|Random flicker for placebo rhythmic effect
76086323|NCT05012176|Behavioral|Behavioral Intervention|Participate in EFT
76086324|NCT05012176|Behavioral|Behavioral Intervention|Participate in ERT
75933131|NCT03283046|Drug|Lenalidomide|"Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21."
75933132|NCT03283046|Drug|Dexamethasone|Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
76086325|NCT05012176|Other|Quality-of-Life Assessment|Ancillary studies
76086326|NCT05012176|Other|Questionnaire Administration|Ancillary studies
76086327|NCT05001516|Drug|LM-302|All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.
76086328|NCT05000827|Device|PSMA-PET/CT|In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).
75648152|NCT00943124|Drug|Simvastatin|Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
75648153|NCT05381246|Other|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, and pericardial meridian 6th point (PC6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected three different points will also be applied to the other extremity, a total of 18 minutes of compression will be applied to each point, provided that it is three minutes.
75648154|NCT05381246|Other|Reiki|In the reiki group, the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.
75795673|NCT05211076|Other|Marmet Technique Group|"Consent will be obtained from those who agree to participate in the study. The Introductory Information Form will be filled by the researcher using face-to-face interview technique.~It will be ensured that the mother fills the State Anxiety Scale with her own statement.~The Marmet Technique will be applied to the mothers at 11:00am for 20-30 minutes by the researcher.~At the end of the milking process performed in accordance with the technique, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~At 05:00pm, the same procedure will be applied to the mother. At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
75795674|NCT05211076|Other|Control group|"The Introductory Information Form will be filled by the researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.The mothers will milk the mother manually by the researcher at 11:00am for at least 15 minutes until the milk does not come.~At the end of the milking process, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form in ml.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement. At 05:00pm, the same procedure will be applied to the mother.~At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
75795675|NCT03099694|Procedure|noninvasive high-frequency ventilation (nHFOV)|NHFOV will be provided by a high frequency ventilator (CNO, Medin, Germany or SLE 5000, UK). NHFOV will be provided via binasal prongs.
75933133|NCT03283046|Drug|Ipilimumab|"Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion)."
76086329|NCT05000827|Other|Nomogram|Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI >5%
76086330|NCT04990726|Behavioral|Assessment|Undergo medical assessments
76086331|NCT04990726|Procedure|Biospecimen Collection|Undergo collection of blood samples
75338299|NCT05448456|Drug|Tranexamic acid|1 gram of tranexamic acid in 100 ml of 0.9% normal saline
75338300|NCT05448456|Drug|Placebo|100 ml of 0.9% normal saline
75338301|NCT01433731|Drug|placebo for SHAPE (SHP-141)|topical gelled solution
75338302|NCT01433731|Drug|SHAPE (SHP-141) 0.1% BID|topical gelled solution
75338303|NCT01433731|Drug|SHAPE (SHP-141) 0.5% BID|topical gelled solution
75933134|NCT03287258|Other|3 program|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date
75933135|NCT03287258|Other|one program|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
76086332|NCT04990726|Other|Quality-of-Life Assessment|Ancillary studies
76086333|NCT04990726|Other|Questionnaire Administration|Complete questionnaires
76086334|NCT04989790|Other|PICU Up!|PICU Up! incorporates the screening process for determining a patient's appropriate activity level into the daily rounding workflow for all PICU patients, with a tiered activity plan based on clinical parameters to individualize goals based on each child's unique needs. While the patient's PICU Up! level is based on objective criteria, the interprofessional team collectively determines the daily activity goal(s) through shared decision-making which is documented in the medical record on morning rounds. The intervention facilitates daily discussion of 1) analgesia; 2) extubation readiness testing; 3) sedation level and goal; 4) delirium screening and management; 5) mobility goal including physical and occupational therapy consultation by PICU Day 3; 6) sleep promotion; and 7) family engagement in mobility.
76086335|NCT04973085|Device|Cold circulated water|Cold water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
76086336|NCT04973085|Device|Body-temperature circulated water|Body-temperature water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
76086337|NCT04973007|Drug|Gadoxetate disodium|Gadoxetate disodium is now mainly used for the purpose of HBP liver MR imaging to save MR scanner time and total examination time.
75648155|NCT02850926|Other|Soccer head gear|Each head gear model consists of lightweight materials with a cross strap design that is fully adjustable or a single elastic headband. All models meet or exceed the American Society for Testing and Materials (ASTM) testing standards for soccer headgear and are approved by the National Federation of High Schools and The Fédération Internationale de Football Association (FIFA) for use by interscholastic soccer players. Players will be allowed to choose the brand of head gear to use and wear it for each practice and game during the soccer season.
75795676|NCT03099694|Procedure|nasal continuous positive airway pressure (nCPAP)|Infants assigned to the NCPAP group will be started on a pressure of 6 cmH2O (range: 6-8 cmH2O) by CPAP system (CNO Medin, Germany, Carefusion, USA)
76086338|NCT04973007|Drug|Gadobenate dimeglumine|The most commonly used MR contrast agent in abdominal imaging is gadobenate dimeglumine, which has mainly the characteristics of an extracellular agent used for most indications of MR examinations.
75648156|NCT00285974|Device|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
75795677|NCT03099538|Drug|Ixekizumab|Subcutaneous injection
75795678|NCT03099304|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
75795679|NCT03099304|Drug|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
75933136|NCT03287180|Behavioral|Adolescent Community Reinforcement Approach (A-CRA)|The A-CRA is a modified version of the Community Reinforcement Approach for adolescents and transitional age youth. The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. In the current study, 12-weeks of A-CRA treatment will be provided to the intervention group.
76086339|NCT04963673|Other|calcineurin inhibitor dosage|The dosage of calcineurin inhibitors will be done as usual by the toxicology pharmacology laboratory of the CHU Amiens-Picardie. If the patient does not object, the determination of protein-bound uremic toxins from the rest of the collected blood tube will be performed using high performance liquid chromatography.
76086340|NCT04962009|Combination Product|Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug|Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
76086341|NCT04954599|Drug|CP-506|CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3
76086342|NCT04954599|Drug|Carboplatin|Antineoplastic agent, ATC Code: LO1X A02
76086343|NCT04954599|Drug|Immune checkpoint inhibitor|Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4
76086344|NCT04948697|Drug|Ociperlimab|900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
76086345|NCT04948697|Drug|Tislelizumab|200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
76086346|NCT04948697|Drug|BAT1706|15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
76086347|NCT04943523|Dietary Supplement|Krill Oil|Krill oil supplements 4g/day
76086348|NCT04943523|Dietary Supplement|Vegetable Oil|vegetable oil supplements 4g/day
76086349|NCT04932265|Dietary Supplement|HRG80™ Red Ginseng|Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product
76086350|NCT04932265|Combination Product|HRG80™ Red Ginseng + gamma cyclodextrin|Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
75338304|NCT01433731|Drug|SHAPE (SHP-141) 1.0% BID|topical gelled solution
75338305|NCT05448378|Dietary Supplement|D-chiro-inositol|D-chiro-inositol 600 mg twice per day on an empty stomach for one month
75338306|NCT05447130|Procedure|phacoemulsification|phacoemulsification with corneal endothelial evaluation by specular microscopy
75338307|NCT01434121|Drug|Ascorbic Acid|The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
75338308|NCT01434121|Drug|Placebo|
75648157|NCT00726622|Procedure|Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection.
75648158|NCT00726622|Procedure|Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection.
75648159|NCT04086394|Procedure|Pectoral Nerve Block|Patients who were given 20 cc of 0.25% Marcaine as part of the pectoralis nerve block
75648160|NCT04086394|Procedure|Surgery without Nerve Block|Patient's underwent indicated procedure without regional pectoralis nerve block
75648161|NCT00940316|Biological|panitumumab|Given intravenously 6mg/kg every 2 weeks
75648162|NCT00940316|Drug|erlotinib hydrochloride|Given orally 150mg daily
75648163|NCT00940316|Drug|irinotecan hydrochloride|Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
75795680|NCT05165368|Other|Intraneural Facilitation (INF)|INF plus dietary education with weekly follow-up by a physical therapist. Includes meal preparation ideas and sample menus promoting a gluten-free diet.
75933137|NCT03287180|Other|Combination of buprenorphine/naloxone 4/1|Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
75933138|NCT03287102|Procedure|Macular hole surgery|Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
75933139|NCT03287024|Device|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
75933140|NCT03286946|Procedure|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
75933141|NCT03286946|Procedure|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
75648164|NCT02850770|Behavioral|Pedometers and Walking Logs|Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.
75933142|NCT03286868|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
75933143|NCT03286868|Device|Total Knee Arthroplasty with Verasense sensor|Total Knee Arthroplasty with Verasense sensor
75648165|NCT02850770|Behavioral|Phone Messaging|Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.
75648166|NCT02850770|Behavioral|Family/Friend Support|Participants identified a family member or close friend (FF) to receive short text or voice messages (depending on FF preference) with suggested behaviors that are perceived as supportive by individuals making physical activity behavior changes.
75648167|NCT02850614|Behavioral|gaming application to encourage physical activity|
75648168|NCT02850614|Device|FitBit|
75648169|NCT02850848|Drug|Entigin Film Coated Tablet 0.5mg|
75648170|NCT02850848|Drug|(Baraclude 0.5mg Tablets|
75648171|NCT00604526|Radiation|High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds|"Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL~*After 1 year, will follow up with doctor about every 6 months."
75648172|NCT05381168|Dietary Supplement|Calcium from fish bone|Calcium from fish bone contained calcium 312 mg and vitamin D 100 IU per capsule.
75648173|NCT05381168|Dietary Supplement|Calcium carbonate|Calcium carbonate contained calcium 600 mg and vitamin D 200 IU per capsule.
75648174|NCT00263432|Procedure|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
75795681|NCT05165368|Other|INF|"INF only (INF™ is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to pressurize the entire system The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside holding chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or holds are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle.)"
75795682|NCT05064904|Drug|never received RAAS blockers or received RAAS blockers before AKI.|"Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).~All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, <130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge."
75338309|NCT01435603|Behavioral|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
75648175|NCT00604604|Behavioral|Peer support|Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
75933144|NCT03974204|Procedure|Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.
75795683|NCT03632512|Dietary Supplement|Hericium honey bolus|The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
75933145|NCT03974204|Procedure|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~When suspected metastatic meningitis symptoms arise and~at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases."
75795684|NCT03632512|Dietary Supplement|Placebo honey bolus|The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
75795685|NCT05016856|Behavioral|Adherence Promotion With Person-centered Technology (APPT) System|A personalized and adaptive text message reminder system.
75933146|NCT03974204|Procedure|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~1 month after the beginning of the specific treatment,~3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment."
75933147|NCT03921320|Procedure|Bilateral sequential sympathectomy|Bilateral videothoracoscopic sequential R4 sympathectomy
75795686|NCT05016856|Behavioral|Standard Reminder System (Active Control)|A typical text message reminder system.
75933148|NCT03921320|Procedure|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy in dominant side (right side)
75933149|NCT03921320|Procedure|Contralateral sympathectomy|Contralateral (left side) videothoracoscopic R4 sympathectomy
75933150|NCT03282734|Other|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
75933151|NCT03282734|Other|Conventional home rehabilitation exercise|Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
75933152|NCT03918980|Drug|LOU064|LOU064 will be administered as oral capsules in parts 1 to 6.
75933153|NCT03918980|Drug|Placebo|Matching placebo capsules will be administered in parts 1,2, 4 and 6.
75933154|NCT03286790|Other|Data collection on pneumonia events|
75933155|NCT03282578|Device|Sternalock 360 sternal plating system|The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
75933156|NCT03282578|Device|Sternal Wires|"Stainless steel wires are applied in a figure of 8 configuration to close the sternum"
75933157|NCT02460146|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
75933158|NCT02460146|Other|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
75648176|NCT05383040|Procedure|Percutaneous release|Percutaneous release of A1 pulley release will be performed in the well-managed operation theater set up, using an 18 gauge hypodermic needle, after preparation of the skin and injection of 1ml 2% plain lidocaine. The proper location of the pulley will be defined using surface landmarks in each digit after waiting a few minutes to allow the anesthetic to take effect the 18 gauge needle will be longitudinally moved to keep the level of the needle parallel with the tendon grating sensation will be elucidated confirming the cut of pulley until there is no grating sensation felt and improvement of symptoms. A sterile dressing will be placed.
75648177|NCT04268810|Procedure|Bladder instillations|bladder instillations with either solution (DMSO or Uracyst)
75795687|NCT05015530|Device|Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract|Healsea® Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
75795688|NCT00883480|Drug|Docetaxel|Docetaxel 75 mg/day 1 x 4 cycles
75795689|NCT00883480|Drug|Cisplatin|Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
75795690|NCT00883480|Drug|Gemcitabine|"Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles"
75795691|NCT00883480|Drug|Erlotinib|Erlotinib 150 mg/day x 21 days
75648178|NCT00726388|Drug|DIC075V (intravenous diclofenac sodium)|multiple doses up to 5 days
75648179|NCT00572455|Drug|PF-04217329 - Lowest Dose|1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
75648180|NCT00572455|Drug|PF-04217329 - Low Dose|1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
75648181|NCT00572455|Drug|PF-04217329 - Middle Dose|1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
75648182|NCT00572455|Drug|PF-04217329 - High Middle Dose|1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
75648183|NCT00572455|Drug|PF-04217329 - High Dose|1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
75795692|NCT05418946|Drug|Dapagliflozin 10mg|Treatment of T2D and cardio-renal prevention
75795693|NCT05418790|Device|TASSO device|During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
75795694|NCT03097588|Drug|Netupitant|300 mg, Given PO, QD
75795695|NCT03097588|Drug|Palonosetron Hydrochloride|0.5 mg, Given PO, QD
75795696|NCT03097588|Other|Questionnaire Administration|Ancillary studies
75795697|NCT05418166|Drug|Evolocumab|evolocumab 140mg subcutaneous injection after regular take Ticagrelor and Aspirin for 5 days.
75795698|NCT04852588|Procedure|Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)|Chest lymph node sampling procedure by EBUS
75795699|NCT04852588|Procedure|Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)|Chest lymph node sampling procedure by EUS
75933159|NCT02460302|Drug|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
75933160|NCT02460302|Drug|Placebo|Placebo suppository inserted vaginally
75933161|NCT03282500|Behavioral|Mindfulness Based Cognitive Therapy|The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
75933162|NCT04264910|Behavioral|Calm App|Calm is a subscription-based meditation app which provides guided meditations, sleep stories, soundscapes and calming music. Calm offers 7 Days of Calm for those new to meditation, the daily Calm, a meditation posted daily and a library of unique 10-12 minute meditations with topics related to acceptance, anxiety, self-compassion, and physical pain (to name a few).
75933163|NCT03680846|Device|HF10 Therapy|Senza 10 kHz Spinal Cord Stimulation
75933164|NCT03680846|Other|CMM|Conventional Medical Management
75933165|NCT03650816|Other|Doppler ultrasonography|Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
75933166|NCT03650816|Other|Biospecimen collection|Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity
76086351|NCT04926545|Drug|Xiao Chai Hu Tang (XCHT)|"XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients."
75648184|NCT00572455|Drug|PF-4217329 - Highest Dose|1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
75648185|NCT00572455|Drug|PF-04217329 - Vehicle|1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
75648186|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
75648187|NCT00572455|Drug|PF-04217329 - Low Dose|Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
75648188|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
75648189|NCT00572455|Drug|PF-04217329 - Middle Dose|Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
75648190|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
75648191|NCT00572455|Drug|PF-04217329 - High Dose|Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
75648192|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
75648193|NCT00572455|Drug|PF-04217329 - Low Dose|Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
75648194|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
75648195|NCT00572455|Drug|PF-04217329 - Middle Dose|Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
75648196|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
75648197|NCT00572455|Drug|PF-04217329 - High Dose|Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
75648198|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
75648199|NCT00572455|Drug|PF-04217329 - Vehicle|Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
75648200|NCT01003691|Biological|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
75648201|NCT01003691|Biological|Placebo|Intravenous, multiple dose with experimental dose
75648202|NCT00752323|Drug|aminolevulinic acid|Given orally
75648203|NCT00752323|Procedure|Surgical Resection|Surgical resection - 6 biopsies from 3 fluorescent regions
75648204|NCT00686335|Drug|Lodotra|Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
75648205|NCT00686335|Drug|Cortancyl|Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
75648206|NCT01002989|Device|Doppler Ankle-Brachial Index measurement|Measurement of the Ankle-Brachial Index by Doppler.
75648207|NCT01002989|Device|WatchBP Office Ankle-Brachial Index measurement.|Measurement of Ankle-Brachial Index by WatchBP Office device.
75648208|NCT00685945|Drug|Control (bradykinin)|Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
75795700|NCT05417542|Other|EEG|EEG recording during prematurity or around term
75795701|NCT05417542|Other|NIRS|NIRS recording during prematurity or around term
75795702|NCT04846036|Drug|Sonlicromanol|Oral administration of sonlicromanol twice daily
75795703|NCT04846036|Drug|Placebo|Oral administration of matching placebo twice daily
75795704|NCT04802902|Other|home-based hospitalization|management in a hospital-at-home programme of patients treated by immunotherapy and chimiotherapy combo for bronchial cancer
75795705|NCT05417230|Drug|RC48-ADC|2.5mg/kg, IV, d1, every 2 weeks;
75795706|NCT05417230|Drug|Envafolimab|200mg, SC, d1, every 2 weeks;
75795707|NCT04713670|Drug|(A) T-V14|vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)
75338310|NCT01435603|Behavioral|Advice Plus Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
75338311|NCT02438202|Device|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
75648209|NCT00685945|Drug|L-NMMA + bradykinin|Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
75795708|NCT04713670|Drug|(B) T-V7|vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)
75795709|NCT04713670|Drug|(C) D-V14|vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)
75648210|NCT00685945|Drug|Isosorbide + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
75648211|NCT00685945|Drug|Sildenafil + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
75648212|NCT00628823|Dietary Supplement|Gluten-free diet|Gluten containing foods removed from diet
75795710|NCT04713670|Drug|(D) HD-V14|vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)
75795711|NCT04713670|Drug|(E) BQ-V14|vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)
75795712|NCT04713670|Drug|(F) RH-V14|vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)
75795713|NCT04713670|Drug|(G) BQ-L14|lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)
75795714|NCT04713670|Drug|(H) T-L14|lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
75795715|NCT01631214|Biological|Romosozumab|Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.
75795716|NCT01631214|Drug|Alendronate|Alendronate 70 mg tablet taken once a week
75795717|NCT01631214|Drug|Placebo to Romosozumab|Administered by subcutaneous injection once a month during the double-blind treatment phase.
75338312|NCT01381861|Biological|Carotuximab (TRC105)|Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
75648213|NCT04296461|Genetic|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
75648214|NCT00747487|Drug|Idebenone|Idebenone 900 mg/day
75648215|NCT00747487|Drug|Placebo|Placebo
75648216|NCT00747175|Drug|AZD1656|Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
75648217|NCT00747175|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose, 1 month treatment
75648218|NCT00750217|Drug|Buprenorphine patch and sublingual tablets|"Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.~Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake."
75648219|NCT01007123|Drug|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
75648220|NCT00687739|Drug|leuprolide acetate|3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
75648221|NCT00687739|Drug|Estradiol Transdermal|0.075 mg patch per day for 5 months
75648222|NCT00687739|Behavioral|progressive resistance exercise training|45 minute exercise sessions 4 times per week for 5 months
75795718|NCT01631214|Drug|Placebo to Alendronate|Matching placebo tablet taken once a week during the double-blind treatment phase.
75795719|NCT04688398|Dietary Supplement|Seal oil|Consumption of seal oil once per day (at breakfast)
75936500|NCT03117452|Behavioral|Visual Training|The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
75795720|NCT04688398|Dietary Supplement|Control|Consumption of vegetable oil once per day (at breakfast)
75795721|NCT04684108|Drug|SG301|During study treatment, subjects will receive SG301 treatment via IV infusion once every week at doses of 0.01, 0.03, 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, 12.0 and 16.0mg/kg
75795722|NCT01567774|Drug|Atorvastatin|os, 20 mg, once per day, for 30 days
75795723|NCT01567774|Drug|Rosuvastatin|os, 10 mg, once per day, for 30 days
75795724|NCT04619524|Diagnostic Test|Cervical mucus will be collected from patients undergoing IVF|Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.
75795725|NCT04619524|Diagnostic Test|Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos|Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.
75795726|NCT05415280|Behavioral|Mindfulness Based stress reduction|The aim of the psychological intervention to reduce the mental health problems of the participants.
75795727|NCT05413564|Other|optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months|optimized self-exclusion procedure A
75795728|NCT01567930|Drug|Temsirolimus|Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
75795729|NCT05185986|Behavioral|Home-Based Pilates exercise|The Home-based Pilates is the two Pilates classes at home, twice weekly, for a period of eight weeks.
75795730|NCT05185986|Other|Home-based Cognitive Rehabilitation|Home-based Cognitive Rehabilitation is the 3 sessions per week and 8 weeks of cognitive rehabilitation exercises at home. Each session consists of two Pen and paper exercises. Exercises are active in the areas of planning, cognitive organization, cognitive flexibility and working memory. Each session will take 30 to 45 minutes.
75933167|NCT03107936|Behavioral|smokeSCREEN game|smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
75933168|NCT04255550|Diagnostic Test|Esophageal doppler|It is a prospective observational clinical study to correlate hemodynamic monitoring between non-invasive Electrical Cardiometry and minimally invasive Esophageal Doppler during major abdominal surgery.
75933169|NCT03282422|Device|Home-based protocol in specific tasks|The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
75933170|NCT03282422|Device|Upper-limb splint|In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
75933171|NCT03286712|Drug|Renogen|Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
76086352|NCT04926545|Other|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.
76086353|NCT04926545|Drug|FOLFIRI regimen|Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
76086354|NCT04916548|Drug|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
76086355|NCT04887831|Drug|Trilaciclib|Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
75473642|NCT01973127|Other|Verum rTMS|rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.
75648223|NCT00752401|Drug|Cholecalciferol|6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels >2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.
75648224|NCT00752401|Drug|Placebo|An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
75933172|NCT03286478|Behavioral|Mindfulness|Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
75933173|NCT03286478|Behavioral|Dissonance|Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
75933174|NCT03286478|Behavioral|Dove Confident Me|Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
76086356|NCT04887831|Drug|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
76086357|NCT04887831|Drug|Cisplatin|Cisplatin administered IV on Day 1 of each 21-day cycle
76086358|NCT04887831|Drug|Carboplatin|Carboplatin administered IV on Day 1 of each 21-day cycle
76086359|NCT04887831|Drug|Avelumab|Avelumab will be dosed on Day 1 of each 14-day maintenance cycle
75795731|NCT05185986|Other|waiting list group|This group act as the control group and will maintain their physical and cognitive activities as the preintervention. Following the 8 weeks of intervention the home-based pilates and cognitive rehabilitation exercises will be provided to them for their own use.
75795732|NCT04604548|Drug|Oral administration of 100 mg KH176 twice daily|Drug: KH176
75933175|NCT02458586|Dietary Supplement|Dietary intervention / counseling|dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
75933176|NCT03417674|Combination Product|Lifestyle intervention|Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
75933177|NCT03282188|Biological|Reolysin|Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
75933178|NCT03282188|Drug|GM-CSF|GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
75933179|NCT03384212|Drug|Cladribine|
75933180|NCT03384212|Drug|Fludarabine|
75933181|NCT03384212|Drug|Busulfan|
75933182|NCT03384212|Drug|Cytarabine|
75933183|NCT03272516|Behavioral|Mindfulness based cognitive therapy (MBCT)|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
75933184|NCT03272516|Other|Treatment as usual (TAU)|Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
75933185|NCT03271658|Behavioral|Web based life support patient decision aid|The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.
76086360|NCT04886635|Other|Active surveillance|Patients will undergo two clinical response evaluations (CREs) after nCRT. During CRE-1 (5-6 weeks) patients will undergo oesophagogastroduodenoscopy (OGD) with bite-on-bite biopsies. During CRE-2 (10-12 weeks) patients will undergo positron emission tomography with computed tomography (PET-CT), endoscopy with bite-on-bite biopsies and endoscopic ultrasonography (EUS) plus fine-needle aspiration (FNA). If cancer is detected, surgery will be performed. Patients with cCR are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer. Delayed oesophagectomy will be offered to patients with highly suspected or profen locoregional regrowth, without distant metastases. The safety and feasibility of active surveillance depends on several factors monitored in the SANO trial. So far, these stopping rules have not been met. In case one of the stopping rules is reached, further inclusion in the SANO-2 study will be stopped and surgical resection is offered.
76086361|NCT04886011|Combination Product|placebo gel|just methyl cellulose gel was applied to the ulcer
75473643|NCT01973127|Other|Sham rTMS|TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
75648225|NCT02871089|Device|Closed-loop system (Florence M or CamAPS FX)|"The automated closed-loop system (FlorenceM) will consist of:~Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.~The automated closed-loop system (CamAPS FX) will consist of:~Dana R or RS insulin pump~Dexcom G6 real-time CGM~CamAPS FX App on an unlocked android smartphone.~Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue)."
75648226|NCT02871089|Other|Multiple Daily Injections|"Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.~Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed."
75648227|NCT00750451|Drug|low molecular weight heparin (enoxaparine sodium)|1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
75648228|NCT00750451|Drug|crinone 8% gel|routine luteal phase support with progesterone gel
75648229|NCT00747721|Drug|Dexmedetomidine|2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
75795733|NCT03758040|Other|Slips on Turns|Subjects will be administered a slip at 3 different times in the gait cycle for each of 3 different patch curvatures and 2 different legs for a total of 18 slip episodes. Slips will be delivered while walking along a straight path (infinite radius), or curved paths with radii 2, or 1 meters.
75795734|NCT03758040|Other|Slips on Slopes|Slips will be administered at 3 different times in the gait cycle over sloped ground surface of no slope, ±5.0 and ±10.0 degrees slopes in the direction of walking, and 5.0 and 10.0 degrees perpendicular to the direction of walking. On slopes perpendicular to the direction of walking, slips will be administered to the uphill or downhill foot. A total of 27 slip episodes will be administered. Sloped walking surfaces will be generated with the CAREN system treadmill.
75795735|NCT01142622|Drug|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
75473644|NCT01973140|Drug|Tolvaptan|Adult male volunteers will be given a given a 60mg or a 30 mg dose of tolvaptan. Blood and urine samples will be collected at specified time points for the next 24 hours.
75473645|NCT01973140|Drug|Hypertonic saline infusion|A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
75933186|NCT03271658|Behavioral|Decision coaching|During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
76086362|NCT04886011|Combination Product|camel whey protein gel|camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
75648230|NCT01006889|Drug|Exenatide|The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
75648231|NCT02561767|Other|bone marrow-derived mesenchymal stem cells|BM-MSCs is harvested from third-party health volunteer donors.
75933187|NCT02460068|Drug|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
75933188|NCT02460068|Drug|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
75648232|NCT02561767|Other|Saline|Saline as placebo of MSCs
75648233|NCT02561767|Drug|Induction therapy (ATG or Basiliximab)|ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
75648234|NCT02561767|Drug|Maintenance therapy (Low-dose CNI + MPA + steroids)|Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
75648235|NCT04060069|Other|Ringer Lactate|Fluids
75648236|NCT00747799|Drug|Sorafenib plus Cisplatin and 5-fluorouracil|"Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~Sorafenib 400 mg bid per daily . Every 21-day cycles.~Cisplatin 80 mg/m2 day d1, every 21 days cycle.~5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles"
75648237|NCT04294823|Diagnostic Test|Helicobacter Pylori Diagnostic|"Helicobacter Test INFAI with standard test Meal (1g citric acid as test meal and 75 mg C^13 urea)~+ The C^13 UBT with the new test (REFEX). All patients will take Nexium mups (40 mg) orally once daily 30 min before breakfast from day 1 to 28."
75933189|NCT02460068|Drug|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
75933190|NCT03286322|Other|manuel therapy cervical spine|the manuel therapy in physiotherapy is focused on the cervival spine
75933191|NCT03286322|Other|control group|the manuel therapy in physiotherapy is classic and not focused on the cervival spine
75648238|NCT04294823|Device|Vital signs measurments|No description;
75795736|NCT01142622|Drug|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
75795737|NCT01142700|Drug|BMS-824393|Capsule, Oral, 10 mg, once daily
75933192|NCT03286244|Drug|CM082 plus paclitaxel|"CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles."
75933193|NCT03282110|Device|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
75933194|NCT03282110|Other|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
75933195|NCT03282110|Drug|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
76086363|NCT04883749|Biological|Acalabrutinib|Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
76086364|NCT04881656|Other|Help is in Your Hands|HIIYH is a set of 16 online educational modules for caregivers of children with social-communication delays or elevated likelihood of ASD.
75648239|NCT04294823|Diagnostic Test|endoscopy|Upper endoscopy where 6 biopsy samples will be obtained . Two biopsies will be taken from antrum and corpus for histology. The biopsies will be stained with Haematoxylin & Eosin and Giemsa stains, and gastritis wilt be scored using the Updated Sydney System 12,13 Two biopsies will be taken from antrum and corpus for rapid urease test (RUT) and two biopsies will be taken from antrum and corpus for culture. All biopsy samples will be analysed in the local laboratory of the centre.
75648240|NCT04294823|Drug|Nexium Pill|patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast Nexium mups 40 mg will be discontinued after Day 28.
75648241|NCT02870543|Drug|Phytolacca decandra|Treatment of bruxism
75648242|NCT02870543|Drug|Melissa officinalis|Treatment of bruxism
75795738|NCT01142700|Drug|BMS-824393|Capsule, Oral, 30 mg, once daily
75795739|NCT01142700|Drug|BMS-824393|Capsule, Oral, 100 mg, once daily
75795740|NCT01142700|Drug|Placebo|Capsule, Oral, 0 mg, once daily
75795741|NCT01142700|Drug|Peginterferon Alpha-2a|Syringe, subcutaneous 180 mcg/0.5 mL, weekly
75795742|NCT01142700|Drug|Ribavirin|Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
75795743|NCT01236222|Behavioral|Cycling to school|Regular cycling to school
75795744|NCT01146132|Dietary Supplement|Conventional diet +/- wine|usual eating habits
76086365|NCT04874870|Drug|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex]|1 injection of 0.58mg will be injected into applicable cord.
76086366|NCT04874870|Combination Product|Xiaflex + Hand-Based Custom Orthosis|1 injection of 0.58mg will be injected into applicable cord followed by use of hand-based custom orthosis to maintain finger extension
76086367|NCT04874480|Drug|Decitabine|Given IV
75795745|NCT01146132|Dietary Supplement|Luxembourg variant of Mediterranean diet + physical activity +/- wine|"Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet"
75795746|NCT01237470|Procedure|Desarda technique|no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
75933196|NCT03282032|Other|One-lung ventilation|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1."
75933197|NCT03270878|Drug|Glasdegib Oral Tablet|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
75795747|NCT01237470|Procedure|Lichtenstein technique|hernioplasty with the usage of plain polypropylene mesh
75795748|NCT04909242|Drug|DZD9008|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.
75795749|NCT04909242|Drug|Placebo|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.
75795750|NCT04909242|Drug|DZD9008|In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.
75933198|NCT03270878|Drug|Glasdegib IV infusion|Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
75933199|NCT02459522|Other|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
75473646|NCT01973244|Drug|somapacitan|"A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.~Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation."
75648243|NCT02870543|Drug|Phyt.decandra + Melissa offic.|Treatment of bruxism
75648244|NCT04294433|Biological|Infanrix-hexa, Twinrix-Junior|Vaccines administrated according to product monographs' recommendations
75648245|NCT04294511|Drug|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
75648246|NCT01001429|Drug|Dexmedetomidine infusion|bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug
75795751|NCT04909242|Drug|DZD9008|Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).
75795752|NCT04545814|Device|Stereotactic Radiosurgery|Maximum Tumor Diameter ≤ 2 cm = 20-24 Gy; Maximum Tumor Diameter 2.1-3.0 cm = 18 Gy; Maximum Tumor Diameter 3.1-5.0 cm = 15 Gy
75795753|NCT01144728|Drug|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
75795754|NCT04540354|Drug|Optimal Medical Therapy (OMT)|Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.
75795755|NCT04540354|Device|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
75795756|NCT04615026|Diagnostic Test|duplex sonography|all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
75933200|NCT03269942|Procedure|Endovascular Flow-Diversion|Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
75933201|NCT03269942|Procedure|Cerebral Revascularization|Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
75795757|NCT01239654|Device|stent implantation|implantation of everolimus-eluting stent vs zotarolimus-eluting stent
75933202|NCT03269786|Diagnostic Test|Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)|Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes
75933203|NCT03269786|Device|biannual ultrasonography|portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes
75933204|NCT03269864|Procedure|perforator flaps|40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
76086368|NCT04874480|Drug|Tegavivint|Given IV
75473647|NCT01973244|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
75473648|NCT01973257|Procedure|imaging diagnostics|
75648247|NCT01001429|Drug|propofol|propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
75648248|NCT04294121|Other|Food marketing on product packaging|Participants will be exposed to product packages displaying varying child- and parent-appealing marketing techniques and different degrees of marketing power
75795758|NCT03093454|Drug|Lavender Essential Oil|Lavender essential oil will be applied topically and by inhalation to the lavender group.
75933205|NCT03285932|Radiation|post-operative stereotactic radiosurgery (SRS)|"For radiosurgery, patients will be immobilized. Treatment planning including the MRI and planning CT should be performed 1 -2 weeks before SRT and treatment finished at latest 3-4 weeks after surgery. Planning should be as close to SRT as possible.~Organs at risk such as the brain stem, optic nerves, chiasm and spinal cord will be contoured. The Clinical Target Volume 1 (CTV1) will be defined as the resection cavity based on MRI and CT including T1 contrast enhanced changes around the resection cavity. The Clinical Target Volume 2 (CTV2) will be defined as a 3mm margin added to CTV1 by isotropic expansion and slightly adjusted as deemed appropriated by the experienced contouring physician. The Planning Target Volume (PTV) will be an additional margin of 1mm added to CTV2 by isotropic expansion.~Treatment planning will be performed using Accuray's Multiplan or subsequent approved treatment planning systems for Cyberknife."
75933206|NCT03285932|Radiation|Whole brain radiotherapy (WBRT)|"For WBRT, an individual head fixation mask is manufactured for each patient, and treatment planning is performed as virtual simulation or 3D-conformal RT planning based on CT-imaging. The portals include the whole brain with special focus as including the skull base areas and lamina cribrosa. For low infratentorial lesions, the treatment volume may include the whole brain down to the second cervical vertbra.~RT will be applied with two portals (e.g. 87°and 273°) using a 6 MeV linear accelerator.~For WBRT, a total dose of 30 Gy in 3 Gy fractions will be applied."
75933207|NCT03285698|Device|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue and is applied to the wound in standard of care fashion.
75933208|NCT03285698|Device|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue and is applied to the wound in standard of care fashion.
75933209|NCT03285620|Drug|AL-034|Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2
75933210|NCT03285620|Drug|Placebo|Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
75933211|NCT02459600|Other|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
75933212|NCT03285464|Other|Triplanar Rotary Resistance|Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
75933213|NCT03269708|Behavioral|Education regarding telomere length|Teaching concepts of cellular aging and telomere length
75648249|NCT01000961|Drug|Cystagon® (Cysteamine Bitartrate)|"Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used"
75795759|NCT01239810|Drug|Hyaluronic Acid|Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
75795760|NCT01239888|Drug|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
75933214|NCT02459912|Procedure|Unilateral Nerve-Sparing Cryoablation of the Prostate|The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
75933215|NCT02459912|Device|Precise Cryoablation System with IceRod Needles|Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
75473649|NCT01973270|Behavioral|Neuroadaptive cognitive training|TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). [Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
75648250|NCT01000961|Drug|Cysteamine Bitartrate Delayed-release Capsules (RP103)|"Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks"
75795761|NCT01239888|Drug|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
75795762|NCT01239888|Drug|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
75795763|NCT01318486|Other|Heparin free dialysis technique|Saline flushes or predilution
75933216|NCT03269630|Other|No intervention. Biospecimen collection only|Biospecimen collection
75933217|NCT03281642|Other|Tobacco management|Training of healthcare teams for tobacco management by trained nurses. The intervention will consist of 3 minimum interviews, about 30 minutes each.
75795764|NCT01318486|Device|Evodial|Evodial dialyer
75933218|NCT03285386|Behavioral|Priming exercise|"All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions."
75648251|NCT01000805|Drug|Duloxetine|Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
75648252|NCT01000805|Drug|Placebo|Participants received placebo QD, po for 8 weeks.
75795765|NCT04226586|Dietary Supplement|Essential Amino Acid (EAA) group|Eligible children will be supplemented with Essential Amino Acids (EAA) for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
75795766|NCT04226586|Dietary Supplement|Placebo|Eligible children will be supplemented with a placebo for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
75795767|NCT03636490|Behavioral|Psychological Stress Intervention|Participant will be shown a series of words for five minutes and a research coordinator will ask him/her to name the color of each (Stroop Color-Word Conflict Task). Then, for another five minutes, the participant will be asked to count backwards out loud by sevens starting from 1,000 (Mental Arithmetic Task). The research assistant will ask the participant to work as quickly and accurately as possible for both tasks.
75795768|NCT01237548|Other|Smoking Narghile for 30 min|No Other intervention will be used
76086369|NCT04872543|Drug|ASTX727|ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
76086370|NCT04860297|Biological|mRNA-1273|Sterile liquid for injection
75648253|NCT02870387|Other|Comprehensive Care with Inpatient consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
75648254|NCT02870387|Other|Usual Inpatient Care|High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
75795769|NCT01144806|Behavioral|Nutrition education|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
75795770|NCT01144806|Dietary Supplement|RUTF|Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
75933219|NCT03285386|Behavioral|Control Exercise|All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
75933220|NCT03285074|Other|No intervention|No intervention
75933221|NCT03284996|Device|Doppler ultrasonography|Examination of the whole cases & controls by doppler ultrasound to measure renal resistive index.
75933222|NCT03269240|Behavioral|Acquisition of Knowledge and clinical skills|LDHF is a novel training approach that is being compared to the traditional training approach
76086371|NCT04857372|Drug|IAG933|Capsule
76086372|NCT04851509|Procedure|Dynamic Rotational Locking|Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
76086373|NCT04851509|Procedure|Static Locking|Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.
76086374|NCT04848480|Drug|insulin icodec|insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
76086375|NCT04848480|Drug|insulin degludec|insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
76086376|NCT04848480|Drug|insulin aspart|insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
76086377|NCT04848389|Procedure|Skin Adhesive procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
76086378|NCT04848389|Procedure|Standard suture procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable thread of the 3/0 Vicryl-type, the cutaneous plane is closed with the same thread with an subcutaneous stitch.
76086379|NCT04843436|Device|Symani Surgical System|Robotically Assisted Microsurgery
75648255|NCT00684307|Drug|AZD0837|ER tablet, PO, once daily for a period of 3-9 months.
75795771|NCT03436108|Diagnostic Test|Measurement of Bisphenol in urine|to see level of this material in blood of women
75648256|NCT00684307|Drug|Vitamin-K antagonist at INR 2-3|Tablet, PO for a period of 3-9 months.
75648257|NCT00684307|Drug|AZD0837|ER tablet, PO, twice daily for a period of 3-9 months
75933223|NCT03269240|Other|Onsite training|Participants are training at their health facilities
75933224|NCT03269240|Other|Off-site training|Participants from different health facilities are gathered together in a central location for training, away from their workplaces
75933225|NCT03281486|Device|HA formulation Oral Spray|It is an HA formulation of FDA listed ingredients
75933226|NCT03281486|Device|Placebo|Placebo formulation without the active ingredients
75648258|NCT00683917|Drug|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
75933227|NCT03269318|Drug|Montelukast or Salmeterol or Theophylline or Steroid|Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
75933228|NCT03268928|Behavioral|Story Starters Intervention|Shared reading intervention
75933229|NCT03268928|Behavioral|Wait-list Control|Wait-list control
75933230|NCT03268850|Other|Standard of Care|All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
76086380|NCT04841018|Drug|High dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.5mg/kg of intravenous dexamethasone
76086381|NCT04841018|Drug|Low dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.15mg/kg of intravenous dexamethasone
76086382|NCT04837859|Drug|Tislelizumab|age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients
76086383|NCT04837066|Diagnostic Test|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
75473650|NCT01973296|Behavioral|ED to home care transition|The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
75648259|NCT00683917|Drug|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
75795772|NCT02969824|Behavioral|Supervised Aerobic Exercise|The AE protocol will consist of eight sessions that proceed in a stepwise fashion in terms of duration and intensity over 11 days. Exercise will be performed on the Velotron Pro stationary cycle ergometer (RacerMate Inc., WA, USA), which will be digitally connected to a heart rate monitor and programmed to monitor the wattage of the bike based on the participant's heart rate. Exercise duration (15min-20min) and intensity (60%-75% max HR) will increase over the intervention period. For the remotely supervised sessions, exercise intensities and heart rate will be monitored via FitBit.
75795773|NCT03633916|Behavioral|Classroom sensitization session|"A one-off classroom information and engagement session will be delivered in addition to school-level sensitization activities. Individual classroom sessions will be conducted by a 'lay' counsellor with support from a researcher.~The classroom session will start with a short animated video which provides age-appropriate information about types, causes, impacts and ways of coping with common mental health problems. The video will be followed by a guided group discussion, structured around a standardized script that builds on the topics covered in the video. In case of technical difficulties that may prevent the video from being shown, a flipchart based on still illustrations from the video will be used.~At the end of the session, students will be handed a self-referral form which includes normalizing information and question-based prompts to assist with self-identification of mental health problems."
75795774|NCT03633916|Behavioral|School-level sensitization activities|"The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~A drop-box for student self-referral slips will be set up in a prominent location at each school.~Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial."
75795775|NCT02870218|Drug|Smoking research cigarettes with e-cigarette|Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
75795776|NCT02870218|Drug|Nicotine discrimination thresholds|Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.
75795777|NCT02614690|Procedure|No Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to No Split Cast will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
75933231|NCT03268850|Behavioral|Wage Reimbursement A|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
76086384|NCT04833855|Biological|Tezepelumab Dose 1|Subcutaneous injection.
76086385|NCT04833855|Biological|Tezepelumab Dose 2|Subcutaneous injection.
75473651|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
75473652|NCT01973309|Drug|Vantictumab combined with paclitaxel|Vantictumab combined with paclitaxel will be administered IV.
75473653|NCT01973322|Other|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
76086386|NCT04833855|Biological|Omalizumab|Subcutaneous injection.
76086387|NCT04833855|Biological|Placebo|Subcutaneous injection.
76086388|NCT04827355|Device|External Upper Esophageal Sphincter (UES) Compression Device|External Upper Esophageal Sphincter (UES) Compression Device fit to manufacturer guidelines.
76086389|NCT04827355|Device|Sham Device|External Upper Esophageal Sphincter (UES) Compression Device fit to pressure known not to provide treatment.
76086390|NCT04824547|Other|exercise|All exercises programs will applied two sessions per week, totally eight week..
75473654|NCT01973322|Other|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
75648260|NCT00683917|Drug|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
75648261|NCT00750529|Drug|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
75473655|NCT01973322|Other|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
75648262|NCT04053595|Diagnostic Test|Dynamic parameters of fluid responsiveness protocol|Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume >10% after fluid administration.
75648263|NCT04053595|Diagnostic Test|Estimated oxygen extraction protocol|Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
75933232|NCT03268850|Behavioral|Wage Reimbursement B|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
75933233|NCT03284918|Dietary Supplement|Plant stanol ester|
75933234|NCT03284918|Dietary Supplement|Placebo|
75933235|NCT03284840|Diagnostic Test|Assessement of nutritional status|Nutritional status for vitamin D, folic acid, vitamin B12 and iron.
75933236|NCT03284840|Diagnostic Test|Thyroid size|Thyroid size by ultrasound.
75933237|NCT03284762|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
75933238|NCT03284684|Other|Blood test|plasma concentration of circulating DNA of specific genes
75933239|NCT03268694|Behavioral|Working Memory Task|"Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily."
75648264|NCT02561689|Other|Fissure sealing|"Procedure:~The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~The occlusal surface is sealed by the dentist or dental hygienist.~Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years"
75648265|NCT00747877|Drug|cyclophosphamide|Given orally
75648266|NCT00747877|Drug|melphalan|Given IV
75648267|NCT00747877|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous hematopoietic stem cell transplantation on day 0.
75648268|NCT00750763|Drug|Colonlytely|Bowel preparation
75933240|NCT03268694|Behavioral|Reward Learning Task|Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
75648269|NCT00750763|Drug|Picolax/Picoprep|Bowel preparation
75933241|NCT03268694|Behavioral|Facial Emotion Recognition Task|On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
75648270|NCT00750763|Drug|Fleet|Bowel preparation
75648271|NCT04056091|Procedure|Back rub stimulation|Immediately after birth, all infants with an expected birthweight >1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (back rubs). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
75648272|NCT04056091|Procedure|Foot flicks stimulation|Immediately after birth, all infants with an expected birthweight >1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (foot flicks). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
75648273|NCT00752635|Drug|Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol|
75648274|NCT00752713|Procedure|cardiac MRI|cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
75648275|NCT02562391|Device|Surgical ablation of the left atrium (PVI+Box lesions)|
75473656|NCT01973322|Biological|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
75648276|NCT02562391|Device|Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting|
75648277|NCT00748111|Other|Blood sample|Blood sample and thrombus sample
75795778|NCT02614690|Procedure|Univalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Univalve Cast will have a cast that is split on only one side of the cast, this is known as univalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
75473657|NCT01973361|Device|Ultrasound debridement|Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
75473658|NCT01973361|Device|Best practice wound care|Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
75473659|NCT01973374|Behavioral|Text Message Intervention|
75473660|NCT01973400|Dietary Supplement|Tocotrienol|Palm-Oil derived Vitamin E, tocotrienol
75933242|NCT02458664|Genetic|Genetic analysis on tumor kept in tumor bank|
75473661|NCT01973400|Dietary Supplement|Placebo|Placebo
75473662|NCT01973426|Device|Isolated Orthosis for Thumb Actuation (IOTA)|In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
75648278|NCT00750997|Drug|hypertonic saline|patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
75648279|NCT00748267|Other|questionnaire administration|
75648280|NCT00748267|Procedure|hypnotherapy|
75648281|NCT00748267|Procedure|therapeutic conventional surgery|
75648282|NCT00748345|Drug|Caspofungin (drug)|pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
75648283|NCT00752869|Drug|dutasteride|0.5mg by mouth one time per day for 1 year
75648284|NCT00752869|Drug|placebo|one tablet per day for 1 year
75648285|NCT00751153|Drug|Raltegravir and Atazanavir|Rategravir 400 BID, Atazanavir 400 mg daily
75648286|NCT00748423|Drug|Nitric Oxide|NO in inhalation for 3 days
75648287|NCT00748423|Drug|Placebo|Placebo in inhalation for 3 days
75933243|NCT03269006|Device|Inesfly Paint|"Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin"
75933244|NCT03269006|Device|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
75648288|NCT00751309|Other|Non-interventional|Post-transplantation observational study
75648289|NCT00751465|Behavioral|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997).
75648290|NCT00751465|Behavioral|Standard CBT|Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
75648291|NCT00687271|Drug|MK-6213|MK-6213 160 mg for 4 weeks.
75648292|NCT00687271|Drug|Atorvastatin calcium|atorvastatin calcium 20mg for 4 weeks.
75648293|NCT00687271|Drug|Placebo for MK-6312 160 mg|
75648294|NCT00687271|Drug|Placebo for Atorvastatin 20 mg|
75648295|NCT02562625|Drug|Pembrolizumab|Powder solution for infusion
75648296|NCT02562625|Radiation|Radiotherapy|24Gy
75473663|NCT01973465|Biological|Stool|Implanting fecal matter via colonscope
75473664|NCT01973478|Device|DBS|
75473665|NCT01973478|Device|SHAM|
75473666|NCT01973504|Drug|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
75648297|NCT00752947|Drug|moxifloxacin|Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
75648298|NCT00752947|Drug|levofloxacin|Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
75648299|NCT00752947|Drug|metronidazole|metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
75648300|NCT04617275|Drug|PF-06882961|PF-68882961 will be provided as tablets twice a day (BID)
75648301|NCT04617275|Other|Placebo|Placebo comparator will be provided as tablets twice daily for 12 weeks
75648302|NCT04614545|Drug|Phentermine 37.5 Mg|Patients will receive 37.5 mg of phentermine daily for a 12 week duration
75648303|NCT04614545|Behavioral|Dietary program|Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician
75648304|NCT04614545|Behavioral|Exercise program|Patients will be provided with a personalized exercise program
75648305|NCT04611503|Drug|subretinal injection of rAAV.hPDE6A|"The first 3 patients (C1) will receive the intermediate dose 1x1010 vg. After injection of the 3rd patient of C1, the DMC will give a go/no go decision. If 'nogo', a lower dose (5x109 vg) will be given to the next group of 3 patients (C2). The DMC will give a go/no go decision. In case of a go decision, 3 further patients (C3) will be treated with the same dose. In the case of a no-go decision, the next dose will be the minimal dose 1x109 vg. In case of a 'go' decision of the DMC after the third patient, the next 3 patients will receive a subretinal injection of vector at the highest dose 5x1010 vg. The DMC will give a go/no go decision after review of all safety data available at D30 of cohort 2. If safety data is considered favourably by the DMC, then 3further patients (cohort 3) will be treated with the same dose (5x1010 vg). Should any safety concerns arise, the last three patients (cohort 3) will receive the intermediate dose (1x1010 vg)."
75648306|NCT01031537|Biological|FSME-IMMUN 0.5ml Baxter|Vaccine
75648307|NCT01031381|Drug|RAD001|RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
75648308|NCT01031381|Drug|bevacizumab|bevacizumab will be administered intravenously (IV) once every 14 days.
75648309|NCT00685399|Drug|AIN457|AIN457 subcutaneous dose
75648310|NCT00685399|Drug|AIN 457|AIN457 low dose (i.v)
75648311|NCT00685399|Drug|AIN457|AIN457 high dose (i.v)
75933245|NCT03269006|Device|ITN (KO-Tab 123)|Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
75933246|NCT03269006|Device|IRS (Delthamethrin)|Indoor residual spraying with Delthamethrin in the living rooms
75338313|NCT01382719|Drug|bremelanotide|"Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product."
75338314|NCT01037309|Drug|PRO044 SC|Subcutaneous injection, once a week, for five weeks
75338315|NCT01037309|Drug|PRO044 IV|Intravenous injection, once a week, for five weeks
75648312|NCT00751543|Radiation|CT, radiation therapy|Computed tomography (CT) is the mainstay for evaluating lung cancer. The advance of multi-row detector CT (MDCT) provides volumetric acquisition within a breath hold, and enables detailed evaluation of tissue and organ perfusion with excellent resolution
75795779|NCT02614690|Procedure|Bivalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Bivalve Cast will have a cast that is split on both sides of the cast, this is known as bivalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
75795780|NCT01374646|Behavioral|JOIN Intervention|Behavioral group treatment for overweight and obese children and teens, that focuses on decreasing energy dense foods and sedentary behaviors.
75648313|NCT00753025|Procedure|Bone marrow aspiration, injection of cells|"Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle"
75933247|NCT04172558|Biological|OnabotulinumtoxinA|a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.
75338316|NCT01038557|Biological|RBC units|When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
75338317|NCT04352387|Behavioral|Montessori Method for Dementia|The Montessori Method highlights the importance of considering the past experiences, identifying interests and maximizing spared capacity and abilities of each individual.
75338318|NCT04352387|Behavioral|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
75473667|NCT01973504|Drug|Control|Crystalloid solution IV infusion drip to keep vein open
75648314|NCT00753025|Procedure|Bone marrow aspiration , injection of isolated CD 133+ cells|"arm CD133 receives injection of isolated CD 133+ cells"
75648315|NCT00753025|Procedure|Bone marrow aspiration, injection of saline|"arm placebo receives injection of saline"
75648316|NCT00751699|Drug|Asacol|Asacol tablets, 6 tablets per day at 7 am for 7 days
75648317|NCT00751699|Drug|Asacol|Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days
75933248|NCT04172558|Drug|Trimix|on demand ICI of Trimix
75648318|NCT00751699|Drug|Lialda|Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
75795781|NCT02414386|Other|biospecimen retention|biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
75933249|NCT03107858|Drug|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
75933250|NCT03107858|Drug|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
75795782|NCT01374724|Behavioral|Tobacco Use Ban|Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
75795783|NCT01374724|Behavioral|Tailored Pamphlet|A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.
75795784|NCT01374724|Behavioral|Informational Pamphlet|"The National Cancer Institute Pamphlet Clearing the Air was provided to subjects."
75933251|NCT03281330|Behavioral|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
75933252|NCT03284528|Other|hypothermia therapy|newborn infants with hypoxic-ischaemic encephalopathy are cooled for 72 hours with a target temperature of 33-34°C (whole body cooling).
75933253|NCT03269162|Drug|Jinfukang Koufuye|30ml per time, tid, po (d6-21, q21)
75933254|NCT03269162|Drug|Docetaxel|75mg/m2,ivgtt 30mins, d1
75338319|NCT01117727|Device|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
75473668|NCT01973517|Drug|Feraheme|Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
75473669|NCT01973517|Drug|Gadolinium-based contrast|Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
75648319|NCT00753103|Biological|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
75648320|NCT00753103|Drug|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
75648321|NCT00753103|Drug|Prednisolone|Daily oral 1mg/kg tapered over 12 months
75648322|NCT00753103|Drug|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
75648323|NCT00753103|Procedure|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine > 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
75648324|NCT00753103|Drug|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
75933255|NCT03269162|Drug|Pemetrexed|500mg/m2, ivgtt 30mins, d1
75933256|NCT03269162|Drug|Cisplatin|75mg/m2, ivgtt >2h, d1
75795785|NCT01374724|Behavioral|Relapse Prevention Intervention|A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
75933257|NCT03268772|Drug|PLD and IFO|PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
75933258|NCT03268616|Device|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
75933259|NCT03268304|Other|VR-based training including AO and MI|Virtual Reality-based training intervention including Action Observation and Motor Imagery using the YouGrabber® training device
75338320|NCT01040819|Drug|Pioglitazone|Patients will receive PIO 15 mg/d for one month, then 55 patients continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. Other non-diabetes drugs should not be changed. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin >162 mg/d, steroids and prostaglandin analogs will be prohibited.
75933260|NCT03268460|Diagnostic Test|Arterial blood gases|blood PH, HCO3
75338321|NCT01041209|Behavioral|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
75338322|NCT01041209|Behavioral|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
75933261|NCT03268460|Diagnostic Test|Blood anion gap|(Na+) - (Cl- + HCO3-)
75648325|NCT00753103|Drug|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
75648326|NCT00753181|Other|Nutritional Formula|nutritional shake daily
75648327|NCT00753181|Other|Usual diet|usual dietary habits
75648328|NCT00753181|Other|Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.|nutritional shake, diabetes specific cereal and diabetes snack bar daily
75648329|NCT02562547|Device|Hem-Avert Perianal Stabilizer|The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
75648330|NCT00748735|Procedure|Implantation of a cardiac resynchronization therapy device|
75648331|NCT00748735|Procedure|Echocardiography (myocardial deformation imaging)|
75648332|NCT00748813|Biological|Influenza Vaccine, Formulation 2008-2009|1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
75648333|NCT00748891|Drug|Recentin (Cediranib)|30mg once daily, oral dose
75648334|NCT00685165|Drug|Primidone 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
75648335|NCT00685165|Drug|Primidone (Mysoline®) 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
75648336|NCT00749047|Drug|Pioglitazone|15-45 mg/day
75648337|NCT00753259|Other|AF Clinic|Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
75795786|NCT02387398|Procedure|Early Angiography|Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
75795787|NCT01442194|Drug|other disease-modifying therapy|
75795788|NCT01442194|Drug|Fingolimod|
75338323|NCT01084265|Drug|Recombinant human luteinizing hormone (r-hLH)|One r-hLH (75 International Units [IU]) injection s.c. once daily.
75338324|NCT01084265|Drug|Recombinant human follicle-stimulating hormone (r-hFSH)|One r-hFSH (150 IU) injection s.c. once daily.
75338325|NCT01084265|Drug|Human chorionic gonadotropin (hCG)|After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
75338326|NCT01084499|Drug|Femara (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
75648338|NCT00753259|Other|Care as Usual|Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
75648339|NCT04052815|Behavioral|Diabetes prevention program culturally tailored|Diabetes prevention Program (DPP) as specified by the CDC, physical activity prior to DPP sessions, motivational interviewing individual and in group. Culturally tailored nutrition tips and recipes.
75648340|NCT00683449|Drug|Dose Group 1|IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
75795789|NCT00468130|Drug|Aripiprazole|Subjects under 40 kg will be started on 2.5mg per day of aripiprazole for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
75933262|NCT03268460|Diagnostic Test|serum electrolytes|Na+ , K+ , Cl- and calcium
75933263|NCT03268460|Diagnostic Test|renal function test|blood urea and serum creatinine
75933264|NCT03268460|Diagnostic Test|urine analysis|urine PH, specific gravity, aminoaciduria, glycosuria, phospaturia and 24 hr urine calcium
75933265|NCT03284450|Other|DPFT|The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.
75648341|NCT00683449|Drug|MN-221 placebo|i.v. infusion of placebo for 15 minutes
75648342|NCT00683449|Drug|Dose Group 2|i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
75648343|NCT00683449|Drug|Dose Group 3|i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
75795790|NCT00468130|Drug|Placebos|"Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects"
75795791|NCT05197582|Other|tele-monitoring|The symptoms of the patients were evaluated by calling the patients on the 1st, 5th, and 9th days of the quarantine by the researchers.
75795792|NCT05197114|Other|summerlunch+ At Home Food Skills Program|The summerlunch+ At Home program a virtual eight-week food skills program that teaches cooking, nutrition and environmental sustainability to children. The program has been adapted for those with Type 1 Diabetes to teach important food skills specific to diabetes management.
75795793|NCT05196880|Device|MolecuLight DX Imaging Device|The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
75795794|NCT05196802|Combination Product|mHeart.4u|The mHeart.4U is a multiple-components intervention entailing the adoption and use of technological devices and self-management recommendations tailored to behavioural modifications (e.g. physical exercise and dietary patterns)
75795795|NCT05196724|Behavioral|Mentalization Based Therapy MBT|The focus is on improving the core components of secure attachment, particularly by developing the reflective functioning for all professionals working with children in out-of-home care, which is subsequently proposed to increase the psychosocial adjustment of the child and decrease emotional and behavioral problems. MBT treatment consists of up to 12 weekly sessions with the foster parents and child covering three core components: 1) psycho-education about mentalizing, trauma, and attachment for foster parents; 2) support for reflective practice in the professional network, and 3) mentalization-based therapy for the foster family [41].
75795796|NCT05196724|Behavioral|Usual care|The control group will receive the usual care offered to foster families such as supervision
75795797|NCT05196490|Device|Micro-CT|Micro computed tomography (micro-CT) is an imaging method in which cross-sectional images are obtained and these images are transferred to the computer through specific software, processed and stored.
75795798|NCT05196490|Device|CAD/CAM|CAD/CAM (computer aided design-computer aided manufacturing) is a production method that is frequently used in many areas of technology. These systems are composed of a data acquisition unit, software for designing virtual restoration, and a computerized milling device.
75795799|NCT05196256|Procedure|Dural puncture|Dural puncture with a 25 Gauge needle without injection of local anesthetics into the dural space
75795800|NCT05196256|Procedure|Combined spinal epidural analgesia|Standard epidural preceded by a dural puncture with a 25G sequential needle and intrathecal injection of 2.5 ug of Sufentanil and 2.5 mg of normobaric Levobupivacaine
75933266|NCT03284450|Other|SSRS|The SSRS (Howatson & Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
75933267|NCT03284372|Behavioral|Text Message Only|The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
75338327|NCT01084499|Drug|Peratra (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
75648344|NCT02561533|Other|BRAF detection on fine needle aspiration biopsy (FNAB)|
75648345|NCT03878173|Other|No intervention|No intervention
75648346|NCT00751855|Behavioral|Prolonged Exposure therapy|10 weekly sessions
75648347|NCT00751855|Drug|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
75795801|NCT05196256|Procedure|Epidural analgesia|Epidural analgesia
75795802|NCT05196256|Drug|Sufentanyl/Levobupivacaine|Epidural analgesia
75795803|NCT05196178|Procedure|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565;Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
75338328|NCT01084499|Drug|Femara (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
75338329|NCT01084499|Drug|Peratra (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
75648348|NCT00751855|Drug|placebo|placebo
75648349|NCT00755833|Drug|biphasic insulin aspart 50|Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.
75648350|NCT00753493|Drug|intravenous topiramate|Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
75648351|NCT00753571|Drug|Cistanche Total Glycosides|"Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd*9months Arms: 1 Drug: blank capsules 6 capsules po Qd*9months~Arms: 2"
75648352|NCT02561143|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients will be given 100 grams of Improved Atta (to make unleavened bread) everyday for consumption for six months.
75648353|NCT02561143|Dietary Supplement|Wheat flour|Whole wheat flour 100 grams (to make unleavened bread) will be given everyday for consumption for six months to the patients.
75795804|NCT01375270|Procedure|Glucotoxicity|Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.
75933268|NCT03284372|Behavioral|Text message + Incentive 1|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
75933269|NCT03284294|Drug|Cholecalciferol|cholecalciferol 2000 IU oral daily for 8 weeks
75933270|NCT03284294|Drug|Placebo|Oral placebo daily for 8 weeks
75933271|NCT03284216|Procedure|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion."
75933272|NCT03284216|Procedure|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
75933273|NCT03284216|Behavioral|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
75933274|NCT03281018|Behavioral|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session|The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
75933275|NCT03284060|Behavioral|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~pen and paper tasks focusing on specific emotion recognition component (20 min),~computerized tasks focusing on the same process (20 min),~a proposal of a home-based task (during 20 min)."
75933276|NCT03283904|Other|Multicomponent physical activity intervention|School-based multicomponent intervention
75648354|NCT02561143|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
75648355|NCT02561143|Other|Nutritional counseling|Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
75933277|NCT02558296|Drug|Bexagliflozin|20 mg, tablet
76086391|NCT04805489|Other|Mask|"The sequence of mask wearing will be done by drawing lots, in double blind. Only the nurse will be informed of the mask sequence. The doctor will take measurements without seeing the type of mask placed between the athlete's face and the VO2 mask.~The patient will not know which mask will be applied. He will have been informed that he will test three masks (a so-called high-tech mask which will in fact be without a mask, a surgical mask and a general public mask). When the mask is put on, the athlete's eyes will be closed, the sequence without a mask, presented to the subject as a high-tech mask, will be done with a mask that will be put on like a surgical mask or a mask for the general public, except that it will be hollowed out in its center.~The effort tests will be done on a carpet with a filter called COVID on the VO2 masks."
76086392|NCT04799886|Other|Semi structured interview|Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.
75338330|NCT01085513|Device|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
75473670|NCT01973530|Procedure|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
75648356|NCT04055857|Other||There is no Intervention.
75338331|NCT01986348|Drug|Selinexor|One cycle is 28 days (4 weeks).
75338332|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
75338333|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
75648357|NCT00683293|Procedure|Conventional Laparoscopic Hysterectomy|Removal of uterus via standard laparoscopic techniques
75648358|NCT00683293|Procedure|Robot-assisted (Da Vinci®) laparoscopic hysterectomy|Removal of uterus by robot-assisted laparoscopic technique
75795805|NCT01375270|Procedure|Lipotoxicity|Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
75795806|NCT05195554|Other|Psycho-educational intervention|Psycho-educational intervention will consist of between 10 and 12 people led by two professionals.
75795807|NCT01375348|Drug|Ultiva (remifentanil) or placebo|0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
75933278|NCT02558296|Drug|Placebo|20 mg tablet to match active comparator
75473671|NCT01973530|Procedure|femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
75795808|NCT05195086|Drug|endoxan|Immunosuppressant
75795809|NCT05195086|Drug|cellcept|Immunosuppressant
75933279|NCT03268226|Drug|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
75933280|NCT03283748|Device|Wearable sensors|Wearable sensors will be given to the participants to be worn and movement data will be collected
75933281|NCT05234996|Device|3 Virtual Reality headset (VR Headset),|The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.
75933282|NCT03268148|Device|LaserPen|low level laser is used before heel-lancing for newborn screening
75933283|NCT03283592|Other|Rank-Heat Plot|provides a visual presentation of treatment hierarchy across multiple outcomes
75933284|NCT03283592|Other|SUCRA Plot|provides a visual presentation of treatment ranking for a single outcome.
75933285|NCT03280862|Device|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator|Implantation of CRT-P/-D device
75933286|NCT03283514|Other|Complete denture|questionnaire
75933287|NCT02737475|Drug|BMS-986178|Specified dose on specified days
75648359|NCT02561611|Behavioral|Intervention Group|The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
75648360|NCT00753727|Drug|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
75933288|NCT02737475|Drug|Nivolumab|Specified dose on specified days
75933289|NCT02737475|Drug|Ipilimumab|Specified dose on specified days
75933290|NCT02737475|Biological|Tetanus vaccine|Specified dose on specified days
75933291|NCT02737475|Biological|DPV-001 vaccine|DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
75933292|NCT02737475|Drug|Cyclophosphamide|Specified dose on specified days
75933293|NCT03265262|Diagnostic Test|The basophil activation test (BAT)|Single sample: 5 mL of venous blood
75933294|NCT02459834|Other|Allulose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
75933295|NCT02459834|Other|Fructose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
75933296|NCT02459834|Other|Control|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
75933297|NCT05488834|Other|Critical-Care Pain Observation Tool|"The Critical Care Pain Observation Tool (CPOT) was created to help assess pain in critically ill patients who were unable to self-report pain.~The CPOT instrument evaluates facial expression, body movement, muscle tension, and compliance with ventilator or vocalisation to evaluate an individual's pain. The total score ranges from 0 to 8, where 8 is the worst pain. Patients are observed for 60 seconds while resting and during nociceptive procedures such as turning or wound dressings to detect any change in behaviour that could indicate pain. Further, the patient must be observed before and at the peak of analgesia medications administered to evaluate pain treatment effectiveness."
75933298|NCT03280706|Dietary Supplement|Maltodextrin|Maltodextrin 50g in water 500ml
75933299|NCT03280706|Dietary Supplement|Orange Juice|Orange juice 480ml + 20ml of water
75933300|NCT03280706|Dietary Supplement|Coffee with milk|Coffee with milk (330 ml of milk + 220 of water)
75933301|NCT05493592|Biological|Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)|"Supervised re-training by an Adapted Physical Activity (APA) professional combined 100 g of pigeon peas 3 times a week~Physical activity protocol is standardized. It's the same than in the control arm.~The preparation of pigeon peas and their consumption will be standardized in terms of species cultivated, geographical origin and culinary preparation.~A follow-up of the food intakes standardized plus follow-up logbook, recording the weekly pigeon pea intake, will also be filled out by the participant. The addition of 100 grams of pigeon peas to the diet corresponds to an intake of about 980 mg of polyphenols, 360 mg of carotenoids and 570 mg of vitamin C (24). Thus, the patient's diet will be fortified with approximately 420 mg of polyphenols per day. This level of polyphenol supplementation is known to have beneficial effects on human health."
75933302|NCT02457806|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
75933303|NCT02457806|Drug|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
75933304|NCT05493514|Device|Robotic Assisted Gait Training with G-EO system|Robotic-assisted gait training is a rehabilitation treatment that applies robotic technologies to improve mobility of patients with stroke or other neurological disorders. In this study, participants will use the G-EO system robotic device according to the daily clinical practice of the Don Gnocchi Foundation.
75648361|NCT00753727|Radiation|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
75648362|NCT00755989|Drug|morphine topical gel|morphine gel 0.1%, applied every 12 hours to stage 2-3 wound, during their hospital stay
76086393|NCT04795401|Device|FRAME FR IFU|The surgeon will use the medical device FRAME to perform the plication procedure. The device will be selected and implanted according to the product IFU.
76086394|NCT04790201|Behavioral|Friendship Bench Delivered by Professional Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a professional counselor.
75795810|NCT03633760|Drug|Bilastine 40mg single dose|Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine
75795811|NCT03633760|Drug|Bilastine 20mg single-dose followed by multiple-dose|Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.
76086395|NCT04790201|Behavioral|Friendship Bench Delivered by Lay Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a trained lay counselor.
76086396|NCT04790201|Behavioral|Enhanced Usual Care|Enhanced usual care (EUC) will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care. Information will be collected in follow-up interviews to characterize the care that patients receive. These activities will occur in all three arms, but they are the only activities in the EUC arm.
75338334|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
75795812|NCT05194852|Procedure|ultrasound-guided posterior hydrodilatation|Group I was treated through posterior approach; The injection needle is introduced at the skin surface just lateral to the transducer and in an oblique lateral to medial direction. Group II was treated through anterior rotator interval approach. A 21-gauge needle is introduced into the rotator interval using an oblique path within the imaging plane of the transducer; from lateral to medial, the needle tip is imaged in real time throughout its passage from superficial to deep and is positioned in the biceps tendon sheath between the coracohumeral ligament above and biceps tendon below. Both groups were given the same guided stretching and strengthening exercise program
75648363|NCT00755989|Drug|placebo|topical gel without morphine
75648364|NCT00756067|Biological|Pneumococcal vaccine GSK2189241A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
75648365|NCT00756067|Biological|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
75648366|NCT00726232|Drug|Ruxolitinib|Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
75795813|NCT05194852|Drug|corticosteroid, saline, and local anesthetic|corticosteroid, saline, and local anesthetic
75795814|NCT05194852|Other|guided stretching and strengthening exercise program|guided stretching and strengthening exercise program
75933305|NCT02457572|Procedure|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
75933306|NCT02457572|Other|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
75933307|NCT02459756|Other|Beverage: Spray dried blackcurrant powder dissolved in water|
75933308|NCT02459756|Other|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
75933309|NCT02557672|Drug|Prothrombin complex concentrate (Human)|PCC (Kcentra)
75933310|NCT02557672|Biological|Fresh frozen plasma (FFP)|FFP
75933311|NCT02459678|Behavioral|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
75933312|NCT02459678|Other|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
75933313|NCT03280472|Behavioral|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
75933314|NCT03280472|Behavioral|Symptom tracking|Participants will track their symptoms
75933315|NCT03267602|Device|CPAP|"If following patients are suffering from sleep apnea and agree to receive treatment,~older than 18 years, AHI> 15 and present obvious symptoms or~less than 18 years, AHI still> 5 after tonsillectomy and present obvious symptoms.~Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months."
75933316|NCT03267446|Device|3D Doppler Ultrasound|3D volumes will be obtained in automatic sweeps using a motorized curved-array transducer while the women held their breath. In order to interpret the data consistently, the settings of power, On Voluson E10; GE Medical Systems)
76086397|NCT04788823|Drug|Prednisone|Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
76086398|NCT04786106|Drug|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)|Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments.
75338335|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689)|Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
75795815|NCT05194774|Procedure|Greater Trochanter epiphysiodesis|epiphysiodesis by cortical screw and washer
75795816|NCT01375426|Drug|Oral amoxicillin|
75795817|NCT05194150|Device|non-diffractive monofocal IOL|Rayone EMV
75795818|NCT05194150|Device|standard EDOF IOL|Acrysof IQ Vivity
75795819|NCT05193838|Drug|Allopurinol Tablet|examined patients with dilated cardiomyopathy will receive allopurinol for 6 months
75795820|NCT01375504|Behavioral|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
75933317|NCT03267992|Behavioral|COPD Co-Pilot AIR App|App. For COPD symptoms after Coil procedure
75933318|NCT02458196|Drug|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
75933319|NCT02458196|Drug|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
75795821|NCT01375504|Behavioral|Mindfulness Training Program|The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
75795822|NCT05186116|Procedure|Living donor liver transplant|Transplantation of part of the liver from a living donor
75933320|NCT02502071|Drug|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
75933321|NCT03265184|Dietary Supplement|green coffee extract|Patients in treatment group take 400 mg GCE supplements twice a day for tow month
75933322|NCT05207735|Drug|Sintilimab|"Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles."
75933323|NCT03264950|Diagnostic Test|Elastography|"an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well"
75933324|NCT03264638|Drug|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
75933325|NCT03264638|Drug|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
75933326|NCT03264638|Drug|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
75933327|NCT05741801|Other|interviews|observations of healthcare professionals working in hospitals (outreach/sepsis team), one-on-one interviews with healthcare professionals, and focus groups or interviews with ex-patients/family members.
75648367|NCT05434975|Procedure|Interscalene brachial plexus block|"For single shot-ISBP block, 15 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine, a total of 25 ml of local anesthetic, will be administered to all patients.~For the block procedure, an imaginary horizontal line drawn from the thyroid cartilage to the sternocleidomastoid (SCM) muscle will followed and the lateral of the SCM muscle will be cleaned with povidine iodine. At the C6 level to be blocked, the nerve roots will be detected by ultrasound. 25 ml of local anesthetic will be injected around the plexus roots with a 22 G 80 mm echogenic needle. The distribution of the local anesthetic applied to the area, which expands the tissues and separates the nerve roots from other tissues, will be seen on ultrasound."
75648368|NCT00753805|Dietary Supplement|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
75795823|NCT01375738|Procedure|Roux-en Y gastrojejunostomy|After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30~40cm from the new gastric-jejunal junction.
75795824|NCT01375738|Procedure|Gastroduodenostomy|After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
75795825|NCT05173558|Behavioral|Uninterrupted motionless standing|Participants remained 20 minutes of uninterrupted motionless standing
75795826|NCT05173558|Behavioral|Uninterrupted motionless sitting|Participants remained 20 minutes of uninterrupted motionless sitting
75795827|NCT05173558|Behavioral|Sit-to-stand transitions|20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
75795828|NCT01375816|Drug|FOLFIRI 1-Bevacizumab|
75795829|NCT01375816|Drug|fluorouracil|
75933328|NCT02714426|Behavioral|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
76086399|NCT04786106|Procedure|Penile Plication Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment.
76086400|NCT04786106|Procedure|Incision and Grafting (I&G) Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment.
75795830|NCT01375816|Drug|irinotecan hydrochloride|
75795831|NCT01375816|Drug|leucovorin calcium|
75795832|NCT01375816|Drug|liposome-encapsulated irinotecan hydrochloride PEP02|
75795833|NCT01375816|Drug|Bevacizumab|
75795834|NCT05172154|Diagnostic Test|GlowTest COVID-19 Antigen Home Test Kit|The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection
75338336|NCT01118273|Drug|DPH 50mg|Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
75473672|NCT01973543|Biological|VY-AADC01|Neurosurgical delivery of VY-AADC01 to the brain.
75795835|NCT05167552|Biological|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
76086401|NCT04786106|Device|RestoreX Penile Traction Device|RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD.
75338337|NCT01118273|Drug|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
75648369|NCT05354596|Procedure|STRICT LUNG|Stereotactic body radiation therapy: Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation.
75795836|NCT05167552|Other|Standard treatment of type Allergic Rhinitis according to the clinical protocols|Standard treatment of type Allergic Rhinitis according to the clinical protocols
75795837|NCT05167552|Other|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
75795838|NCT03632824|Drug|Tranexamic Acid|"One gram( 2 ampules ) of tranexamic acid was received by the participant intravenously twice daily for 48 hours followed by 500 mg tranexamic acid tablet three times daily for 5 days .~follow up of the patient was done by recurrence of the bleeding latter on during pregnancy . the course of treatment was repeated again ."
75795839|NCT05603962|Behavioral|Visual training|Visual training is the main type of management for CI patients clinically; however, the existing training protocol required patients to make several visits to the clinic for visual training, which might increase the burden for patients and result in higher failures in training. Therefore, this study will use a simple training method by utilizing prisms for CI patients to train at home, then compare visual symptoms and binocular vision after the training.
75795840|NCT05403892|Diagnostic Test|level laser lunge test|In order to perform the Level Laser Test, the operator 1 places a laser lever on the ground one metre aside and 50 cm forward the ankle to be examined. This laser (a 2-class laser not harmful to the eyes) maintains a linear laser light beam perpendicular to the floor. The examined leg is placed further forward to the other one, as it happens in the DLT. The teenage performs a forward lunge perpendicularly to the laser line, the heel positioning 50 cm from the laser line. Operator 1 has the subject perform a lunge while operator 2 measures the distance from the kneecap to the laser line. The measurement, deducted by 50 cm, leads to the heel-to-wall distance (value used to DLT).
75795841|NCT05403892|Diagnostic Test|dorsiflexion Lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the teenage stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The teenage is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The teenage steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
75795842|NCT00911820|Drug|Bevacizumab|
75795843|NCT00911820|Drug|Cisplatin|
75795844|NCT00911820|Drug|Irinotecan|
75795845|NCT00911820|Device|Docetaxel|
75795846|NCT05348122|Drug|TG103,Q2W|TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
75795847|NCT05348122|Drug|TG103,QW|TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
76086402|NCT04782479|Procedure|hand position|For tracheal intubation with a stylet for a manikin, one time, the position of the hand holding the tube was placed in the air, and the other time, the position of the hand holding the tube was placed on the cheek of the patient, while the assistant pulling back the stylet.
76086403|NCT04765943|Device|Implantable Loop Recorder implant|Patients will be undergone to an Implantable Loop Recorder implant and monitored for the next 6 months.They will then undergo a cardiac MRI and an ICD will be implanted according to clinical practice guidelines. A minimum follow-up of 2 years is scheduled.
75795848|NCT05348122|Drug|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
75795849|NCT05348122|Drug|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
75795850|NCT05348122|Drug|Dulaglutide,QW|Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
76086404|NCT04762277|Drug|Spesolimab|Spesolimab
76086405|NCT04762277|Drug|Placebo|Placebo
76086406|NCT04751552|Procedure|Erector Spinae Plane Block (for postoperative pain relief)|A ultrasound guided single bolus injection of 20 ml of levobupivacaine or placebo between the erector spinae muscle and process transversus of vertebra T5.
76086407|NCT04751409|Procedure|Chest Radiography|Undergo CXR
76086408|NCT04751409|Procedure|Computed Tomography|Undergo CT-chest
75338338|NCT05420142|Dietary Supplement|Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey|The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.
75338339|NCT04423848|Other|Home Hospital for Lymphoma|Remote monitoring and home-based care designed for hospitalized patients with lymphoma
75338340|NCT01085825|Procedure|D & C abortion|Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
75338341|NCT04265742|Radiation|bone densitometry|Bone Mineral Density (BMD), body composition, vertebral fractures
75338342|NCT04265742|Radiation|High resolution peripheral QCT|High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
75473673|NCT01973556|Other|Pharmacist-Physician Collaborative Medication Therapy Management|
75648370|NCT05354596|Procedure|STAR LUNG|Stereotactic body radiation therapy: Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.
76086409|NCT04751409|Procedure|Follow-Up|Undergo intense follow-up
76086410|NCT04751409|Procedure|Follow-Up|Undergo limited follow-up
75648371|NCT04053205|Drug|Gentuximab|Administered intravenously (IV)
75648372|NCT04053205|Drug|Paclitaxel|Administered intravenously (IV)
75648373|NCT02559973|Drug|RBP-6000|RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
76086411|NCT04751409|Procedure|Imaging Technique|Undergo imaging
75933329|NCT02714426|Other|Brain health|Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
75933330|NCT04500821|Device|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
75933331|NCT03264794|Drug|Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Gefitinib Tab （CTTQ），First medication,250mg；
75795851|NCT01239966|Device|Combined ECCOR and RRT|Insertion of a membrane oxygenator (Hilite 2400 LT, Medos, Germany) within an hemofilter circuit (M150,PrismaFlex, Hospal); either upstream or downstream of the hemofilter.
75933332|NCT03264794|Drug|Gefitinib tablets (Yi Ruisha），First medication|Gefitinib tablets (Yi Ruisha），First medication,250mg；
75933333|NCT03264794|Drug|Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.|From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
75933334|NCT02925923|Drug|Ticagrelor|After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
75933335|NCT02925923|Drug|Eptifibatide|After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
75933336|NCT02925923|Drug|Clopidogrel|
75933337|NCT03267368|Behavioral|Comprehensive Care Program|Pulmonary rehabilitation and smoking cessation
76086412|NCT04751409|Other|Questionnaire Administration|Ancillary studies
76086413|NCT04751396|Other|Best Practice|Receive standard educational information
75648374|NCT02559973|Drug|SUBOXONE Sublingual Film|Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
75648375|NCT00753883|Drug|simvastatin|simvastatin 20 mg/QD for 6 Weeks.
75648376|NCT00753883|Drug|Ezetimibe|Ezetimibe 10 mg/QD for 8 weeks.
75648377|NCT00753961|Other|fermented dairy product|fermented dairy product (2 bottles/day during 16 weeks)
75648378|NCT00753961|Other|non fermented dairy product|non fermented dairy product (2 bottles/day during 16 weeks)
75795852|NCT05038618|Biological|MVC-COV1901(S protein with adjuvant)|Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
75795853|NCT01237704|Behavioral|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
75795854|NCT01237704|Behavioral|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
75933338|NCT03267290|Diagnostic Test|Sonazoid- CEUS, CEMRI, CECT|Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
75933339|NCT03280316|Procedure|surgery|patients with SVMs receive surgery
76086414|NCT04751396|Other|Educational Intervention|Navigate educational tool
76086415|NCT04751396|Other|Interview|Participate in interview
76086416|NCT04751396|Other|Questionnaire Administration|Complete questionnaire
75338343|NCT04265742|Diagnostic Test|Collection of biological samples|Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition
75648379|NCT02561377|Behavioral|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
75648380|NCT02561377|Behavioral|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
75933340|NCT03280316|Procedure|sacral neuromodulation|sacral neuromodulation (SNM) with InterStimTM
75933341|NCT03280316|Procedure|botulinum toxin A injection|BOTOX
75933342|NCT03280316|Drug|M receptor antagonist|Tolterodine
75933343|NCT02410343|Drug|TV-1106|A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
75933344|NCT02410343|Drug|Placebo|Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
76086417|NCT04751396|Other|Survey Administration|Complete surveys
76086418|NCT04747496|Drug|Edoxaban|This is a non-interventional, observational study.
76086419|NCT04747145|Device|Radiation|60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
76086420|NCT04747145|Drug|Concurrent Chemotherapy (Temozolomide)|75mg/m^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
76086421|NCT04747145|Drug|Adjuvant Chemotherapy (Temozolomide)|Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
76086422|NCT04736654|Other|Survey study|Headache Disability Questionnaire (HDQ) will be applied.
76086423|NCT04734535|Device|HEMOBLAST™ Bellows|Intraoperative bleeding during epidural spine surgery will be treated with HEMOBLAST™ Bellows
76086424|NCT04734535|Device|absorbable gelatin sponge with thrombin|Intraoperative bleeding during epidural spine surgery will be treated with absorbable gelatin sponge with thrombin
75648381|NCT00720382|Drug|0.15% azelastine hydrochloride|1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
75648382|NCT00720382|Drug|Mometasone furoate|200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
75795855|NCT05031052|Device|End-ischemic normothermic oxygenated machine perfusion|Application of end-ischemic normothermic oxygenated machine perfusion at physiological temperatures for 4 hours.
75795856|NCT05031052|Procedure|Static cold storage|Immediate implantation of kidney allograft after conventional and static preservation on ice
75795857|NCT01244880|Other|Saline|Saline infusion for 56 minutes
75795858|NCT01244880|Drug|PF-02545920|PF-02545920 10 mg single dose
75795859|NCT01244880|Other|Ketamine|"Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes~PF-02545920 10 mg tablet"
75795860|NCT01244880|Drug|PF-02545920|PF-02545920 10 mg tablet single dose
75795861|NCT01244880|Other|Saline|Saline infusion for 56 minutes
75795862|NCT01244880|Other|Placebo|Placebo tablet single dose
75795863|NCT01244880|Other|Ketamine|Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
75795864|NCT01244880|Other|Placebo|Placebo tablet single dose
75933345|NCT03267056|Device|drug eluting balloon catheter (trade name: Orchid)|use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
75933346|NCT03264872|Behavioral|Peer-Enhanced Motivational Interviewing|Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
75933347|NCT03264872|Other|Waitlist Control|After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
75933348|NCT03264716|Device|HepaSphere TACE (transarterial chemoembolization)|100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
75933349|NCT03064841|Drug|No Treatment|No treatment
75933350|NCT02457416|Other|Peanut|Treatment with peanut in increasing doses until a maintenance dose
75933351|NCT03280238|Diagnostic Test|Measurement of pupil dilation and analgesia nociception index|painful electrical stimuli of various intensities were administered to the subjects after which changes in pupil diameter and analgesia nociception index were measured
75933352|NCT03280082|Other|MUAC Program|All children admitted to the PB program will receive standard care according to the national Protocol and that of MSF, including preventive and therapeutic care at admission as well as hospital care in case of clinical complications. There will be no change in the Protocol for the hospital care to the CRENI (Center of Intensive Nutritional Rehabilitation). RUTF (Ready-to-Use therapeutic food) will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
75933353|NCT03280082|Other|Standard Program|All children admitted to the standard program will receive standard care according to national and MSF protocols, including preventive and therapeutic care on admission as well as hospital care in case of clinical complications. RUTF will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
75338344|NCT04265742|Other|questionnaires|Epidemiologic and nutritional questionnaire and physical activity scale
75338345|NCT04265742|Other|clinical tests|physical performance tests and grip strenght measurement
75338346|NCT01085903|Drug|Modafinil|200 mg once daily with morning meal for three days administered only to stroke patients
75338347|NCT01085903|Drug|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
75648383|NCT00754039|Drug|colesevelam HCl tablets and fenofibrate tablets|Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
75648384|NCT00754039|Drug|fenofibrate tablets and Welchol placebo tablets|fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
75648385|NCT00754039|Drug|fenofibrate tablets and Welchol placebo tablets|fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
75795865|NCT01244958|Biological|Rituximab|1000 mg Rituximab infusion
75795866|NCT01244958|Drug|Placebo|infusion of Sodium citrate, Polysorbate, Sodium chloride
75795867|NCT01240434|Procedure|Trocar site closure|The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
75795868|NCT01245348|Genetic|SULT4A1-1 genetic test|SULT4A1-1 haplotype result (+/-)
75338348|NCT01085903|Behavioral|Baseline|Observations made at baseline before any intervention
75795869|NCT03856398|Device|C- MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
75795870|NCT05549674|Other|The COPAIN study is observational. There is no intervention.|The COPAIN study is observational. There is no intervention.
75795871|NCT00603642|Drug|Placebo|Subcutaneously administered, once a week, for 12 weeks
75795872|NCT00603642|Drug|AMG 531|Subcutaneously administered, once a week, for 12 weeks
75933354|NCT02045303|Device|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
75795873|NCT00246324|Drug|Interferon beta 1a, oral doxycycline|Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
75795874|NCT05507788|Device|Wheelchair air cushion|Reaching tasks during each of the seating conditions decribed in the Arms section.
75795875|NCT00102336|Biological|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
75648386|NCT00756145|Procedure|At start of the session, at the inlet line|Injection of LMWH at the inlet line, at the start of the hemodiafiltration session
75648387|NCT00756145|Procedure|5 minutes after the start of the session, at the inlet line|Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session
75795876|NCT00102336|Drug|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
75648388|NCT00756145|Procedure|At the start of the session, at the outlet line|Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
75648389|NCT02592538|Device|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
75648390|NCT02592538|Drug|S-1|In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if <1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
75648391|NCT02592538|Device|Stent|Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
75648392|NCT02560909|Biological|FLUAD® influenza vaccine|MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
75648393|NCT02560909|Biological|FLUVIRAL®|Standard 2015-2016 nonadjuvanted vaccine
75648394|NCT00756223|Drug|Arm A|Dose escalation Arm A (4 weeks)
75648395|NCT00756223|Drug|Arm B|Dose escalation Arm B (3 weeks)
75648396|NCT02592226|Procedure|Anesthesia: alveolar recruitment maneuver|
75648397|NCT02592226|Procedure|Anesthesia: standardized|
75648398|NCT00756301|Other|Lidocaine local anesthesia- Alternative|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
75933355|NCT02045303|Device|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
75933356|NCT05234840|Drug|platelet rich plasma|1. 26 ml of blood was obtained from each patient (6ml each in 4 CPDA and 2ml in EDTA for CBC) 2. First-spin of 900g for 5 minutes (Kokusan, H-19alpha, 25°C) 3. Three layers formed: transfer top layer (platelet poor plasma) and middle layer (platelets and WBC) to another sterile tube (about 3.3 ml), discard bottom layer (RBC) 4. Second-spin of 1000g for 10 minutes 5. The upper one third was discarded (platelet poor plasma) by pipet, the remaining was mixed by turning 10 times 6. Total 4 ml of PRP
75933357|NCT05234840|Drug|Triamcinolone|40 mg triamcinolone with 1% lidocaine, total of 2 ml
75933358|NCT03264482|Procedure|M-TURP|endoscopic resection of the prostatic adenoma
75933359|NCT03264482|Procedure|THUVAP|vaporization of prostatic adenoma via THULIUM laser
75933360|NCT03266744|Diagnostic Test|Computerised Tomography|
75933361|NCT03266744|Diagnostic Test|Whole Body Magnetic Resonance Imaging|
75933362|NCT03266744|Diagnostic Test|Bone scan|
75648399|NCT00756535|Procedure|Exercise training|Group-based exercise training 5 days a week during hospitalization
75648400|NCT00756535|Procedure|usual treatment and rehabilitation|usual treatment and rehabilitation
75648401|NCT00756691|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient
75648402|NCT00720226|Drug|Losartan|Losartan 100 mg daily
75648403|NCT00720226|Drug|Placebo|Placebo pill daily
75795877|NCT01146210|Other|laboratory biomarker analysis|Correlative studies
75795878|NCT01237782|Drug|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
75795879|NCT01237782|Drug|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
75795880|NCT05152680|Drug|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
75795881|NCT03632668|Drug|AD-2071 10/20mg|AD-2071 10/20 mg tablet
75795882|NCT03632668|Drug|AD-2072 80/5mg|AD-2072 80/5mg tablet
75795883|NCT03632668|Drug|AD-2071 10/20mg + AD2072 80/5mg|AD-2071 10/20 mg + AD-2072 80/5mg tablet
75795884|NCT01237860|Device|NESS L300 Plus System|The patients will receive the device for daily use of six (6) weeks.
75795885|NCT01586130|Other|Exercise in eccentric or concentric mode|In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
75795886|NCT04860726|Other|Joint mobilization|Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes
75795887|NCT04860726|Other|Myofascial Release|"Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min ii. heating pad for 15 minutes"
75795888|NCT04860726|Other|Joint mobilization & Myofascial Release|"Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes iv. Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min"
75795889|NCT01245660|Drug|LAPATINIB|Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
75648404|NCT04049929|Drug|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
75648405|NCT05434507|Device|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
75338349|NCT01085903|Behavioral|CPS|Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
75338350|NCT01085903|Behavioral|Post CPS|20 minutes following the CPS condition.
75795890|NCT03693768|Behavioral|Health coaching|Health coaching
75648406|NCT00725920|Drug|Topiramate|patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day
75933363|NCT05740163|Dietary Supplement|Egg product including egg white and yolk allergens|Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
75933364|NCT03266822|Other|No intervention|Observational study
75933365|NCT03280004|Drug|Moxifloxacin Hydrochloride and Sodium Chloride Injection|Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
75933366|NCT05759585|Behavioral|person-centered lifestyle intervention|Lifestyle intervention is a combined approach that encourages individuals to change their lifestyles by increasing participation in meaningful readings. This program aims to facilitate the individual's self-development of healthy routines and habits; It includes techniques such as patient education, occupational self-analysis, problem-solving, motivation generation, and implementation of behaviors to prevent and manage disease-related symptoms.
75473674|NCT01973647|Behavioral|Cognitive Behavioral Therapy for Insomnia|Six weekly sessions of cognitive behavioral therapy for insomnia
75648407|NCT00725920|Drug|placebo control group|initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
75648408|NCT00754195|Other|Thoracic epidural catheter|Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
75795891|NCT04743778|Behavioral|Virtual Diabetes Self-Management Education and Support|Diabetes self-management education and support delivered through Zoom for health.
75795892|NCT04743778|Behavioral|Resources|Newsletters, pedometers, and community resources.
75795893|NCT03686904|Drug|Benzalkonium Gel|antibiofilm solution (BlastX) topical wound gel
75795894|NCT03686904|Other|standard of care topical gel|standard of care topical gel (hydrocolloid topical gel)
75933367|NCT03279068|Other|Teaching and EFM Paper|Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
75933368|NCT03628937|Dietary Supplement|Decaffeinated Green Tea Polyphenol|Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%). Participants need take it once a day after breakfast for 12 weeks.
75338351|NCT01085903|Behavioral|Follow up|Follow up testing occurred at 3 months
75338352|NCT05419128|Behavioral|PartnerCHESS|"The following ABCT services, from PartnerCHESS, will be available in the FamCHESS-C app but not in ACHESS-C:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between drinker and partner to follow key principles. Trigger identification and removal. Cravings discussion. Relapse plan. Reminders."
75338353|NCT05419128|Behavioral|ACHESS|ACHESS-C offers the following, which are also available in FamCHESS-C: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
75338354|NCT01439035|Device|MGH OFDI Imaging|Imaging of Duodenum with OFDI system
75473675|NCT01973647|Behavioral|COPD Education|Six weekly sessions of COPD education
75795895|NCT03686904|Procedure|Debridement|Removing dead tissue from infected wound (in clinic)
75933369|NCT03628937|Other|Placebo control|The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule. The use frequency and duration are consistent with intervention group.
75933370|NCT03266666|Behavioral|WellnessRX Lifestyle Change Classes|Lifestyle change classes on nutrition, physical activity, and stress management.
75648409|NCT00754273|Other|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
75933371|NCT03266666|Other|Thrive Market Grocery Credits (4x$25 each)|Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
75648410|NCT00725842|Biological|Peg-IFN alfa-2b|Peg-IFN alfa-2b administered in accordance with approved labeling
75338355|NCT05446350|Procedure|transcranial alternating current stimulation (tACS)|transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception
75648411|NCT00725842|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
75338356|NCT05446350|Procedure|electroencephalography (EEG)|analyse rhythmic electroencephalography responses that outlast the stimulation
75648412|NCT04051723|Drug|The dexamethasone plus ropivacaine|The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
75933372|NCT03266510|Other|Inspiratory muscle strength training|Subjects will perform inspiratory muscle strength training for 6 weeks.
75338357|NCT05446350|Procedure|brain imaging (fMRI)|Using brain imaging (fMRI) to predict optimal stimulation protocols for individual participants
75648413|NCT04051723|Drug|The ropivacaine|The local infiltration solution containing 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
76086425|NCT04729205|Drug|Promitil|The first 6 patients recruited to the study will receive 1.6 mg/kg Promitil. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued. In parallel, on days 1 and 15 of each cycle, patients will be treated with the mFOLFOX6 regime, which involves concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h).
75795896|NCT03686904|Drug|benzalkonium irrigation|washing and lavaging in clinic with benzalkonium irrigation
75795897|NCT03686904|Other|Saline Irrigation (SOC Irrigation)|Normal Saline Irrigation (SOC Irrigation)
75795898|NCT04627168|Device|Non-invasive, surface electrical stimulation device, DS5 Digitimer|Transcutaneous abdominal electrical stimulation will be delivered through the commercially available equipment, a DS5 Digitimer.
76086426|NCT04727151|Biological|TAC01-HER2|"TAC01-HER2 and:~fludarabine and cyclophosphamide, or~clofarabine and cyclophosphamide, or~bendamustine, or~cyclophosphamide"
75795899|NCT04461964|Device|Machine-vision Image Guided Surgery (MvIGS) spine navigation system.|"The intended use of the MvIGS navigation system is to provide high quality intraoperative imaging with no radiation exposure. Use of the proprietary integrated surgical light with embedded tracking technology and Flash™ registration allows for continuous and direct visualization of the surgical field. The MvIGS system is exempt from IDE regulations as the device cleared Premarket Notification FDA-510(k) (K162375). The device includes:~A single mobile cart with a boom arm and an integrated surgical light with embedded tracking technology (P/N 10-0001);~Proprietary imaging software (P/N 60-0007); and,~Kit of tacked surgical instruments including a spine reference clamp, awl tip, pedicle probe (P/N 11-0006)."
75338358|NCT05446350|Procedure|electroencephalography (EEG) with neurofeedback|Using neurofeedback to teach participants to enhance their own neural entrainment
75338359|NCT01118741|Drug|Disulfiram|Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
75338360|NCT01439581|Device|Mapping System|Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
75338361|NCT01439581|Device|Non-Mapping System|Standard ICU bed with no mapping system
75338362|NCT01439815|Drug|Fluticasone Propionate Nasal Spray|two sprays in each nostril once daily
75795900|NCT03913806|Drug|Bevacizumab-IRDye800CW|dose finding:10mg; 25mg; 50mg
75933373|NCT03266510|Other|Sham training|Subjects will perform sham training for 6 weeks.
75933374|NCT05214521|Device|"digital interactive technology Smart glove SensoRehab"|"Participants will receive rehabilitation program including sessions on the Smart glove SensoRehab (SGSR) system. The program for IS patients includes 10 sessions with the SGSR: 15-30 minutes once a day for the affected hand, 2 weeks."
75933375|NCT03264326|Other|Blood Flow Restriction Training|Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.
75933376|NCT03264326|Other|Sham Blood Flow Restriction Training|Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.
75338363|NCT01439815|Drug|Saline Nasal Spray|two sprays in each nostril once daily
75338364|NCT01332253|Drug|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
75933377|NCT03264326|Other|Eccentric Exercise|Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
75933378|NCT05189951|Other|circular motion|The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.
76086427|NCT04727151|Biological|TAC01-HER2 plus pembrolizumab|"TAC01-HER2 plus pembrolizumab and:~fludarabine and cyclophosphamide, or~clofarabine and cyclophosphamide, or~bendamustine, or~cyclophosphamide"
75795901|NCT01250808|Drug|Bortezomib/Dexamethasone/Melphalan|"Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.~Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.~ASCT therapy:~Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times."
75933379|NCT05189951|Other|vertical motion|The phlebotomy site was wiped vertically from top to bottom with a single maneuver.
75933380|NCT05189951|Other|circular+vertical motion|The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside.
75933381|NCT02459444|Device|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
75933382|NCT02459444|Other|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
75933383|NCT03264170|Diagnostic Test|Prediction of pregnancy outcome|The intervention group will receive the individualised prediction of their pregnancy (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant.
75933384|NCT03277976|Device|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
75933385|NCT03277976|Device|PVI using ThermoCool® SmartTouch SF® Catheter|PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
75933386|NCT03266120|Other|Art|Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
75933387|NCT03266120|Other|Gardening|Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
75933388|NCT01841333|Drug|PF-04449913|100mg given orally
76086428|NCT04726306|Diagnostic Test|Otic Barotrauma Grading System|Otic Barotrauma Grading System Placards for TEED Score and the OGS grading system.
76086429|NCT04723446|Drug|Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate|Corsodyl® Alcohol-free is a clear to slightly opalescent oromucosal solution with an odour of peppermint that contains 0.2% w/v chlorhexidine digluconate which is an antimicrobial preparation for external use. It is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is active against a wide range of important oral pathogens and is therefore effective in the treatment of many common oral conditions.
75338365|NCT01332253|Other|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
75648414|NCT00918424|Drug|Oxcarbazepine Extended Release|OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.
75648415|NCT00756847|Drug|XL147 (SAR245408),|Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
75648416|NCT00756847|Drug|paclitaxel|Intravenous injection dosed once every three weeks
75648417|NCT00756847|Drug|carboplatin|Intravenous injection dosed once every three weeks
75338366|NCT01332487|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
75648418|NCT02591602|Other|Teleradiology Service|Teleradiology Service at home or in nursing homes
75648419|NCT04051567|Drug|Aspirin 100mg|In LDA group, patients were asked for taking 100mg aspirin per night;
75338367|NCT01332721|Drug|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
75338368|NCT01384591|Drug|N-acetylcysteine|50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
75338369|NCT01384591|Drug|Losartan|25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
75648420|NCT03952702|Procedure|Myopic overcorrection|Myopic overcorrection
75648421|NCT00756925|Drug|Acthrel|1 ug/kg, i.v., 1 minute
75648422|NCT05427097|Device|Helical® patches|Active Helical® patches and non-active patches (placebo) are placed at cervical tension points
75648423|NCT00757081|Drug|phosphatidylcholine and deoxycholate|50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
75648424|NCT00757159|Device|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
75648425|NCT00757159|Device|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
75648426|NCT00757315|Device|NdYag Laser(hair removal laser) plus topical corticosteroid|NdYag laser and topical corticosteroid are applied to one half of the scalp.
75648427|NCT00757315|Drug|Topical corticosteroid alone|topical corticosteroid alone is applied to one half of the scalp
75648428|NCT00757393|Dietary Supplement|Vitamin D + Calcium + Exercise program|Subjects is this arm of the study will receive a) a supplementation with vitamin D3, 1000 IU daily b) a dietary calcium intake set at DRI for age and a supplement used as needed to meet the requirement and c) a weight bearing exercise program appropriate for the underlying medical condition
75933389|NCT03277742|Behavioral|Community intervention|Training of patients, health personnel and community health workers. Bidirectional screening. Monitoring blood glucose levels. Home visits. Medical referral. DOTS.
75933390|NCT03277742|Drug|Standard of care|DOTS plus standard DM2 care
75933391|NCT03266354|Procedure|specular microscopy before and after Artisan PIOL|specular microscopy will be performed before and after implantation of the rigid Artisan iris-fixated pIOL to analyze the change in corneal endothelial cell count
75933392|NCT03619967|Device|Multispectral imager|"Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign"
75648429|NCT00757393|Drug|Vitamin D + Calcium + Exercise program + Humatrope|Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
75933393|NCT03266432|Other|blood samples|three blood samples : first one pre intervention and the other two blood samples post-intervention
75933394|NCT05234918|Device|Pediatric Rotary File Systems|"Kedo S plus (p1 molar file ) (A1 anterior file)~Kidzo-file system 25/4 30/4 30/6"
75795902|NCT04807608|Other|Usability Assessment|A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.
75933395|NCT02459288|Drug|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
75933396|NCT02459288|Drug|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
75933397|NCT03064451|Procedure|cartofinder guided ablation followed by PVI|cartofinder guided ablation followed by PVI
75933398|NCT00734253|Drug|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
75933399|NCT00734253|Drug|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
75933400|NCT00734253|Drug|Placebo|Placebo capsules taken twice a day for 1-year
75933401|NCT00730665|Drug|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
75933402|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
75648430|NCT00754351|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
75648431|NCT00754351|Drug|Docetaxel|Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
75648432|NCT00754351|Drug|Gemcitabine|Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
75795903|NCT04380922|Other|Periodontal screening|Periodontal data collection (PPD, REC, CAL)
75795904|NCT01146678|Drug|Insulin glargine HOE901|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
75795905|NCT01146678|Drug|Lixisenatide AVE0010|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
75795906|NCT05429866|Drug|Checkpoint Blockade, Immune|Immune checkpoint blockade drugs target the immune system by blocking control pathways regulating anti-tumor immunity and thereby reinvigorate their activities against cancer.
75795907|NCT01241526|Other|Disease Management|"Individual, group and phone education sessions~Telephone supporter follow-up~LTOT monitoring"
75933403|NCT00730665|Drug|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
75933404|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
75933405|NCT00730665|Drug|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
75933406|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
75338370|NCT01384591|Drug|Placebo losartan|Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
75933407|NCT00730665|Drug|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
75933408|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
75933409|NCT00730665|Other|Placebo|Capsule, Placebo, every 12 hours (twice a day)
75933410|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
75933411|NCT03263858|Device|Stent|Implantation of coronary stent in de novo coronary artery lesions
75795908|NCT01241526|Other|Usual site management|"Usual education as per site protocol~Usual follow-up as per site protocol~LTOT monitoring"
75795909|NCT05417464|Other|Use of flowchart|Use of flowchart for screening, monitoring and management of conductive disorders after TAVR
75933412|NCT03277508|Device|BCI Robot Assisted Hand Therapy|"18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).~Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.~Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.~Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control"
75933413|NCT03277508|Device|CPM Robot Assisted Hand Therapy|18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
75933414|NCT02280681|Other|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
75933415|NCT03058679|Other|Diet|food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
75933416|NCT02280759|Drug|Gelatin Tannate|
76086430|NCT04723446|Drug|Colgate Peroxyl® -1.5% Hydrogen peroxide|Peroxyl mouthwash is a clear aqua-blue liquid oromucosal solution which 100ml of solution contains 1.5g of Hydrogen peroxide (as 30% Hydrogen Peroxide solution). It is an oral antiseptic cleanser for external use. The principal action is brought about by contact of hydrogen peroxide with peroxidases and catalases present in tissues and saliva, which causes the rapid release of oxygen. This provides mechanical cleansing which flushes out mouth debris and helps in the treatment of oral irritations. This mouthwash is used as a cleanser in the symptomatic relief of minor mouth and gum irritations.
75648433|NCT02561065|Behavioral|Lifestyle intervention|"Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.~The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.~A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday."
75795910|NCT03913338|Procedure|LasikXtra|By randomized selection, one eye was treated with the LASIK Xtra procedure that consists of fs-LASIK treatment combined with intraoperative accelerated continuous UV-riboflavin crosslinking. After laser ablation, the corneal bed under the flap was coated with riboflavin, rinsed with saline solution, and after 90 seconds the corneal flap was repositioned. The eye was irradiated at 30 mW/cm2 for 90 seconds with continuous UVA.
75933417|NCT02280759|Drug|Placebo|Placebo consists of an identical formulation, except active substance
75933418|NCT03275948|Other|whole grain|whole grain rye
75933419|NCT03275948|Other|reference|white wheat bread
75933420|NCT00714597|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
75933421|NCT00714597|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
75933422|NCT02457104|Procedure|Colonoscopy|Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
75933423|NCT02457104|Behavioral|Weight and diet questionnaire|Brief questionnaire outlining weight history, type and dose of PPI, and diet.
75933424|NCT02280837|Other|Determination of plasma GLP-1 level|Determination of GLP-1 level in samples of oral glucose tolerance tests
75933425|NCT00729027|Drug|25 mg/day AVE5530|"one tablet in the evening with dinner~in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
75933426|NCT00729027|Drug|50 mg/day AVE5530|"one tablet in the evening with dinner~in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
75648434|NCT00725764|Drug|GSK1363089 (foretinib)|Multitargeted tyrosine kinase inhibitor
75933427|NCT00729027|Drug|placebo|"one tablet in the evening with dinner~in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
75933428|NCT03265886|Drug|Warm bupivacaine at (37°c)|Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
75648435|NCT00754429|Drug|losartan|losartan 50mg qd for 30 weeks.
75648436|NCT00754429|Drug|amlodipine|amlodipine 5 mg q.d for 30 weeks.
75648437|NCT00754507|Drug|colesevelam HCl tablets, and atorvastatin tablets|colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
75648438|NCT00754507|Drug|colesevelam HCl placebo tablets and atorvastatin tablets|colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
75795911|NCT03913338|Procedure|LASIK|Femtosecond-assisted preparation of a corneal flap and subsequently excimer-laser ablation of corneal stroma. Repositioning of the corneal flap and installation of a therapeutic contact lens.
75795912|NCT03913494|Device|Transoral Neurostimulation Device (Snoozeal)|Use of the Transoral Neurostimulation Device for 20 minutes, morning and night, every day for at least 4 weeks.
75795913|NCT01250886|Drug|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
75933429|NCT03265886|Drug|Bupivacaine at operating room temperature (23°c)|Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
75933430|NCT00728091|Drug|Satavaptan|tablets
75933431|NCT00728091|Drug|placebo|tablets
75933432|NCT03275792|Drug|D5-0.9%NS|Admission for intravascular volume expansion
75933433|NCT03275792|Drug|Routine home oral rehydration|Routine oral fluids as is given at home to all children with acute diarrheal disease
75933434|NCT03275090|Drug|Smoflipid ®|
75933435|NCT03382821|Procedure|Transforaminal ESI with dexamethasone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with dexamethasone sodium phosphate 1.5 mL (10 mg/mL) and 1 ml 1% lidocaine (total volume 2.5 mL).
76086431|NCT04723446|Other|Oral-B® Gum & Enamel Care -Cetylpyridinium chloride|The Oral-B® Gum & Enamel Care mouthwash is an oromucosal solution containing Cetylpyridinium chloride (CPC) and used as an adjunct to oral hygiene.
75795914|NCT01250886|Drug|Normal saline solution|Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
75795915|NCT01250886|Drug|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
75795916|NCT03632590|Dietary Supplement|Magnesium Citrate|450 mg of Magnesium Citrate per day (6 capsules per day) for 24 weeks
75795917|NCT03632590|Dietary Supplement|Magnesium Sulfate|450 mg of Magnesium Sulfate per day (6 capsules per day) for 24 weeks
75795918|NCT03632590|Dietary Supplement|Magnesium Oxide|450 mg of Magnesium Oxide per day (6 capsules per day) for 24 weeks
75338371|NCT01384591|Drug|Placebo N-acetylcysteine|Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
75648439|NCT00754585|Device|Logic Back Grahl Duo Back Model DB11-01|The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
75648440|NCT00725608|Drug|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
75933436|NCT03382821|Procedure|Transforaminal catheter-targeted ESI with triamcinolone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with triamcinolone acetonide 2 mL (40mg/mL) and 1 ml 1% lidocaine (total volume 3 mL).
75648441|NCT00757471|Procedure|Brillant Blue|Membrane Peeling with Brillant Blue
75648442|NCT00757471|Procedure|Indocyanine Green|Membrane Peeling with indocyanine Green
75795919|NCT03632590|Drug|Placebo|The placebo capsules will contain starch (Amylum solani) for 24 weeks
75933437|NCT03382821|Drug|Dexamethasone Sodium Phosphate 10 MG/ML|Transforaminal ESI with dexamethasone 1.5 mL of dexamethasone sodium phosphate in group #1
75933438|NCT03382821|Drug|Lidocaine|1 mL of 1% lidocaine as diluent for the steroid in both group #1 and group #2
75933439|NCT03382821|Drug|Triamcinolone Acetonide 40mg/mL|Transforaminal catheter-targeted ESI with triamcinolone acetonide 2 mL in group #2
75933440|NCT02557516|Drug|monalizumab|"During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks."
75933441|NCT03263624|Device|fractional carbon dioxide laser|One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
75933442|NCT03263624|Drug|Tazarotene Cream 0.1%|tazarotene cream 0.1% once daily
76086432|NCT04723446|Other|No rinsing|No rinsing
76086433|NCT04721860|Behavioral|Backward Locomotion Treadmill Training (BLTT)|12-training sessions of reverse treadmill training (no bodyweight support) over four weeks.
75338372|NCT01086605|Drug|pixantrone dimaleate|Given IV
75338373|NCT00265850|Biological|bevacizumab|Given IV
75338374|NCT00265850|Biological|cetuximab|Given IV
75473676|NCT01973647|Behavioral|Attention Control|Six weekly sessions of non-sleep, non-COPD health education
75473677|NCT01973660|Drug|Lapatinib|
75648443|NCT00725452|Biological|Infliximab|Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
75648444|NCT00725296|Biological|Remicade (Infliximab)|Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
75648445|NCT02591524|Other|Bronchoalveolar and Nasal Lavage|A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
75795920|NCT05667480|Behavioral|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
75795921|NCT05667480|Behavioral|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and pre-recorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
75795922|NCT05376670|Drug|Intravesical aminoglycoside instillations|Overnight instillation of an aminoglycoside (CIC), varying treatment regimens
75933443|NCT01976247|Device|High Intensity Focused Ultrasound Device|
75933444|NCT01976247|Device|Noninvasive Cryolipolysis Device|
75933445|NCT03274544|Other|PROLUNG|"Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~Huang Qi (Radix Astragali Membranaceus): 2 g~Dan Shen (Radix Salviae Miltiorrhizae): 1 g~Jiang Huang (Rhizoma Curcumae Longae): 1 g~Yin Xing (Semen Gingko Bilobae): 1 g~Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~Bai He (Bulbus Lilii): 1g~Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~Zi Su Ye (Folium Perillae Frutescentis): 1 g~Yin Yang Huo (Herba Epimedii): 1g"
76086434|NCT04721860|Behavioral|Forward Locomotion Treadmill Training (FLTT)|12-training sessions of forward treadmill training (no bodyweight support) over tfour weeks.
76086435|NCT04717570|Device|Foldax TRIA Mitral Valve|Mitral Valve Replacement
76086436|NCT04712877|Diagnostic Test|ctDNA, tumor NGS|Testing for actionable oncogenic drivers
76086437|NCT04710862|Behavioral|Breathing training without a device|Breathing training without a mouth device
76086438|NCT04710862|Behavioral|Breathing training with a device|Breathing training with a mouth device
75648446|NCT02591368|Procedure|Ligament reconstruction tendon interposition|In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
75473678|NCT01973660|Drug|Trastuzumab|
75648447|NCT02591368|Procedure|Suspensionplasty with one-suture construct|In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
75648448|NCT02591368|Procedure|Suspensionplasty with two-suture construct|In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
75648449|NCT04019392|Device|Game Ready® device|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
75795923|NCT01250964|Procedure|Lens insertion during cataract surgery|After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
75795924|NCT03913416|Device|3D printed model|Before surgery, the surgeon will have a 3D printed model of the pulmonary malformation as well as the lung, the rib cage and the tracheal trunk based on the initial scanner images. He will then be able to train and plan the surgical strategy, as well as to discuss the pulmonary exclusion with the anesthetist.
75795925|NCT03913416|Other|Control group|The control group is composed of patients operated with standard surgery
75795926|NCT01242774|Drug|Panobinostat|Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.
75795927|NCT05630898|Diagnostic Test|CMV PCR|Saliva CMV PCR
75795928|NCT05630742|Other|chronic non-neoplastic pain|comparison of questionnaires scores
75795929|NCT04716192|Other|Positional release technique|"Positional Release Technique The subject lies supine with therapist standing on the affected side; tender points are located along the upper fibres of the trapezius. Pressure will applied by pinching the muscle between the thumb and fingers. The subject's head is laterally flexed toward the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90° a slight flexion or extension is added to obtain fine-tune. The ideal position of comfort achieved is held for a period of 90 seconds and followed by a passive return of the body part to an anatomically neutral position continued for 5 minutes.~Mayofascial Release Technique Therapeutic Ultrasound"
75933446|NCT02280915|Other|Savoury food product|
75933447|NCT05493436|Diagnostic Test|MII pH-meter|using multichannel impedance pH-meter
75933448|NCT00711555|Drug|aprepitant, ondansetron, dexamethasone|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."
75933449|NCT05488756|Other|Group 1|Physical therapy agents and isometric exercise training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and isometric training 3 times a week for 4 weeks by the physical therapist.
75933450|NCT05488756|Other|Group 2|Physical therapy agents and deep cervical flexor muscle training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and muscle training 3 times a week for 4 weeks by the physical therapist. Training of the craniocervical flexor muscles is going to be focused on the deep flexor muscles such as longus capitis and longus colli muscles, making neck flexion, not the head.
75933451|NCT05488756|Other|Group 3|Physical therapy agents and core stabilization training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and stabilization training 3 times a week for 4 weeks by the physical therapist. These exercises will be performed for 10 repetitions with 10 seconds of contraction and 5 seconds of relaxation.
75933452|NCT00701181|Procedure|Laser Treatment|Necessity of laser treatment is assessed every three months.
75338375|NCT00265850|Drug|FOLFOX or|Patients receive oxaliplatin 85 mg/m^2 IV infused over two hours followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus, then 2400 mg/m^2 continuous IV infusion over 46-48 hours
75338376|NCT00265850|Drug|FOLFIRI|Patients receive irinotecan 180 mg/m^2 IV infused over 90 minutes followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus following leucovorin then 2400 mg/m^2 continuous IV infusion over 46-48 hours.
75338377|NCT01385137|Dietary Supplement|omega-3 fatty acid|Given orally
75338378|NCT01385137|Other|placebo|Given orally
75338379|NCT01086761|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye.
75338380|NCT00125372|Drug|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
75933453|NCT00701181|Drug|PF-04523655 high|3 mg intravitreal injection
75933454|NCT00701181|Drug|PF-04523655 middle|1 mg intravitreal injection
75338381|NCT01087541|Behavioral|Educational program 6-hour standardized|6-hour standardized program for adults ( doctors and nurses )
75338382|NCT01385293|Drug|BKM120|BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
75338383|NCT00125528|Drug|D-cycloserine|D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
75338384|NCT00125528|Drug|placebo|placebo bid
75338385|NCT00125762|Device|FibroScan|
75473679|NCT01973660|Drug|Endocrine Therapy|Letrozole or tamoxifen will be prescribed according to patient's menopausal status
75473680|NCT01973660|Drug|Paclitaxel|Only administrated if tumor progression is observed by US on week 6
75933455|NCT00701181|Drug|PF-04523655 low|0.4 mg intravitreal injection
75933456|NCT03263390|Procedure|Bariatric Surgery|Sleeve gastrectomy or Roux-en-Y Gastric Bypass
75648450|NCT04019392|Other|Wetted Ice Bag with Elastic Wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied using an elastic wrap to each participants' lower leg for 30 minutes. An elastic wrap applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half will be applied over the wetted ice bag.
75648451|NCT00719680|Biological|IgPro20|
75648452|NCT02592460|Other|poor-polyamines diet|Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
76086439|NCT04695171|Device|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
75338386|NCT01333813|Biological|Engerix-B™ Kinder|Intramuscular, single dose
75648453|NCT02592460|Other|high polyamines diet|Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
75648454|NCT02592304|Device|Dual energy computed tomography|one extra scanning with a dual energy ct.
75338387|NCT04346485|Procedure|SP TFL RIRS with 145 mcm fiber|retrograde intrarenal surgery
75338388|NCT04346485|Procedure|SP TFL RIRS with 200 mcm fiber|retrograde intrarenal surgery
75338389|NCT04346485|Procedure|Ho:YAG RIRS with 200 mcm fiber|retrograde intrarenal surgery
75648455|NCT03956758|Other|Semi-directed interview|Semi-directed interview on ChemSex practice
75648456|NCT00719212|Biological|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
75648457|NCT00585052|Drug|Paclitaxel|Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly
75338390|NCT01390909|Drug|Anti-epileptic drug (AED)|Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
75648458|NCT00585052|Drug|Lovastatin|Lovastatin, 80 mg, po, daily will be self-administered by the subject.
75338391|NCT01041521|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
75338392|NCT01042145|Drug|Prednisone|2 mgs/kg for 3 days
75648459|NCT00724282|Drug|Eszopiclone|Eszopiclone 3 mg by mouth daily at bedtime for 9 days
75648460|NCT00724282|Drug|Placebo|Placebo by mouth daily at bedtime for 9 days
75648461|NCT04086238|Drug|Decitabine|Capsules containing a combination of decitabine and THU
75648462|NCT02591992|Other|Cardiac CT as the first diagnostic modality in suspected CAD|Performation of non-invasive cardiac CT angiogram
75648463|NCT02591992|Other|Invasive coronary angiography as indicated by the guidelines|Patient undergoes invasive coronary angiography
75795930|NCT04716192|Other|Myofascial release technique & Ultrasound|"Myofascial Release Technique~Position of the patient - sitting comfortably with supported back, elbow flexed with forearm placed on a pillow. A low load, long duration stretch is applied along the lines of maximal fascial restrictions. The fascia is palpated and the pressure is applied directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. The pressure will be applied for 90 to120 seconds. This procedure will carried out without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.~Therapeutic ultrasound with the frequency of 3Mhz , with continuous mode and an intensity of 0.1-1.5 W/cm2 for a duration of 5 min will given with the patient position back rest."
75795931|NCT01146444|Other|UV A and B irradiation|UV irradiation
75338393|NCT01042145|Drug|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
75338394|NCT01334827|Other|high volume gel|4 mL HEC
75648464|NCT00724126|Drug|Rifaximin|
75648465|NCT00724126|Drug|Placebo|
75648466|NCT04085926|Device|Sealed therapeutic shoe|Off-the-shelf therapeutic shoe and custom-made insole
75933457|NCT03263390|Drug|Anti Obesity Drugs|Response to FDA approved anti obesity medications
75933458|NCT04277182|Biological|burn wound dressing|"st. group: It will be considered as a control group and rats will not be treated.~nd. group: Vehicle group, Propolis vehicle will be applied topically to rats for 21 days.~rd group: Silver Sulfadiazine group, 1% Silver Sulfadiazine will be applied topically to rats for 21 days.~th. group: Nitrafurozon group, 0.2% Nitrafurozon will be applied topically for 21 days.~th. group: 10% Propolis group, 10% Propolis will be applied topically for 21 days.~th. group: 15% Propolis group, 15% Propolis will be applied topically for 21 days."
75338395|NCT01334827|Other|low volume gel|2 mL HEC
75338396|NCT01334827|Other|vaginal film|"1 x 2 intravaginal quick-dissolving film"
75338397|NCT01042613|Procedure|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
75473681|NCT01973673|Behavioral|Bone health educational materials|
75648467|NCT04085926|Device|Total contact cast|Custom-made total contact cast
75648468|NCT04086004|Other|Group I Experimental Motor Imagery|The experimental group will receive dual task balance training for 30 minutes/day with additional mental imagery for 10 minutes/day, three days/week, for a period of eight weeks
75648469|NCT04086004|Other|Dual task training|group will receive dual task balance training for 40 minutes for three days/ week for eight weeks
75648470|NCT02592070|Behavioral|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
75648471|NCT02591212|Behavioral|Green Dot|Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
76086440|NCT04695171|Procedure|Fundoplication|A surgical procedure where the fundus of the stomach is wrapped around and sutured to the distal esophagus to restore the function of the lower esophageal sphincter in limiting stomach contents from refluxing into the esophagus.
75648472|NCT02591212|Behavioral|Wellness Initiatives for Student Empowerment|Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
75648473|NCT00723892|Biological|Peginterferon alfa-2b (PegIntron)|Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg^kg^week
75648474|NCT00723892|Drug|Rebetol (Ribavirin)|Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg^day
75338398|NCT01042613|Procedure|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
76086441|NCT04689828|Drug|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
75338399|NCT01043393|Drug|Desoximetasone 0.25% spray|Desoximetasone spray applied to affected areas twice daily for 28 days
75338400|NCT01335061|Biological|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
75648475|NCT00723892|Behavioral|Psychotherapy support program|Each site has implemented a psychotherapy support program.
75648476|NCT00718666|Biological|Meningococcal vaccine GSK134612|One dose, as intramuscular injection
75648477|NCT04086940|Drug|Esmolol|preventive
75648478|NCT04085692|Behavioral|Low-Dose, High-Frequency Simulation-Based Training|"Twelve weeks of LDHF training~The simulation-based training sessions take place at the EMDC, at extra workstations set-up as ordinary EMD workstations in an out-of-the-way area. Before each session, the EMD is informed about the simulation call and receives instructions concerning technical differences from a regular call. The instructor acts as a standardised caller, guided by a computer program. This program, the Danish version of Resuscitation Quality Improvement for Telecommunicators (Laerdal Medical AS, Stavanger, Norway), is a training program for DA-CPR based on the simulation platform Laerdal Learning Application. This modified version of the RQI-T program has, one test scenario, one data collection scenario and six different cardiac arrests scenarios as well as a feedback checklist based on the Danish dispatcher protocol Danish Index for Emergency Care.~Each simulation session takes approximately 20 minutes, including introduction and feedback"
75648479|NCT00718510|Drug|L-Arginine|3 grams, twice daily, oral administration
75795932|NCT01243086|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
75795933|NCT01243086|Drug|OZURDEX|OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
75795934|NCT01243554|Behavioral|Exercise|Exercise training at the hospital
75795935|NCT01246830|Radiation|Panoramic radiograph, Cephalometric radiograph|2D images that are used for orthodontic treatment planning
75795936|NCT01246830|Radiation|Cone-beam computed tomography (CBCT)|CBCT data will be used in 3D cephalometric analysis softwares
75795937|NCT01247376|Device|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
75795938|NCT03908814|Drug|Whole Human Anti-PD-L1 Antibody Injection (LDP)|Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.
75795939|NCT01253382|Biological|ecallantide|10 - 30mg subcutaneous injection.
76086442|NCT04689828|Drug|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
75338401|NCT01335061|Biological|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
75338402|NCT01087931|Drug|Bupivacaine|Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
75338403|NCT01087931|Other|Normal Saline|Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
75473682|NCT01973686|Behavioral|Physical activity|
75473683|NCT01973699|Other|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
75473684|NCT01973712|Procedure|Locked Compression Plating|
75473685|NCT01973712|Procedure|Retrograde Intramedullary Nailing (RIMN)|
75473686|NCT01973751|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 2 puffs (200mcg) twice a day for 8 weeks
75473687|NCT01973764|Procedure|Ultrasound guided ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed under ultrasound guidance.
75473688|NCT01973764|Procedure|landmark-based ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed without any guiding devices and is based on anatomical landmarks.
75473689|NCT01973790|Drug|Z-338|100mg TID
75473690|NCT01973816|Drug|Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;|Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
75473691|NCT01973816|Procedure|rectal shaving; rectal disc excision; colorectal resection|
75795940|NCT01147614|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
75795941|NCT01147614|Behavioral|Specialty mental health care referral (SMHC)|SMHC: specialty mental health care referrals provided
75795942|NCT01148160|Drug|voriconazole|intravenous, oral administration
76086443|NCT04689828|Drug|ARDT|administered orally on a continuous basis, as per package insert and guidelines
76086444|NCT04689828|Other|Best supportive care|Best supportive/best standard of care as defined by the local investigator
75933459|NCT03273920|Procedure|Robotic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
75933460|NCT03273920|Procedure|Laparoscopic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
75933461|NCT02280993|Drug|DHAP|DHAP
75933462|NCT02280993|Drug|Brentuximab Vedotin|Brentuximab Vedotin
75933463|NCT02280993|Other|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
75933464|NCT02459210|Behavioral|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
75933465|NCT02459210|Behavioral|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
75933466|NCT05493202|Device|Mira Fertility Tracker|Non-interventional: observational, documenting urine E3G levels during gonadotropin stimulation.
75933467|NCT02459132|Behavioral|High-intensity aerobic interval exercise|See arm/group description
75933468|NCT05493124|Drug|Manpixiao|A traditional Chinese medicine composition
75648480|NCT02590900|Drug|intravenous paracetamol (acetaminophen)|paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
75648481|NCT00585286|Device|10,600 nm fractional carbon dioxide laser system|1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2
75933469|NCT05493124|Drug|Active comparator|Other drugs that may have therapeutic effects
75933470|NCT03263312|Behavioral|Exercise|Exercise training all patients enrolled.
75933471|NCT05493046|Behavioral|Interactive Hand Exercise Game|Interactive Hand Exercise Game to Improve Vascular Maturity and Grip Strength in Patients undergoing Arteriovenous Fistula Surgery
75933472|NCT05493046|Behavioral|Soft ball exercise ( routine care)|Soft ball exercise ( routine care)
75933473|NCT03263468|Procedure|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
76086445|NCT04683172|Device|Active Transcranial Direct Current Stimulation|"tDCS consists of delivering a low-intensity (1 to 2 milliamperes) direct electrical current by means of a pair of electrodes (anode and cathode) applied to the scalp. Electrodes generally have a diameter (round electrode) or a diagonal (rectangular electrodes) ranging from 2 to 3.5 cm.~To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode. In this study, the stimulation intensity will be 1.5 mA using round sponge electrodes 3.5 cm in diameter."
75338404|NCT03009409|Drug|Ketamine Injectable Solution|"Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely."
75338405|NCT03009409|Other|Placebo|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
75473692|NCT01973816|Drug|Cyproterone acetate 50 mg; estradiol 0.5% percutaneous|Daily intake for 18 months
75648482|NCT03955822|Other|Phone survey|Phone Survey in order to evaluate adverse effect of the permanently implanted birth control device for women (Essure) will be proposed to wmen Treated between 2002 and 2017 with Essure.
75648483|NCT02591914|Drug|Fovista™|Anti-PDGF-B pegylated aptamer
75933474|NCT03263468|Procedure|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting >48 hours to 45 days post primary PCI
75933475|NCT05492968|Drug|Epinephrin|Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
75933476|NCT05492968|Drug|Norepinephrine|Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
75648484|NCT02591914|Drug|Lucentis®|Anti-VEGF
75648485|NCT02591914|Drug|Avastin®|Anti-VEGF
75648486|NCT02591914|Drug|Eylea®|Anti-VEGF
75648487|NCT00723190|Drug|CLONICEL (Clonidine HCl sustained release)|0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
75648488|NCT02591758|Device|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
75933477|NCT05492968|Drug|Phenylephrine|Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
75933478|NCT02457026|Drug|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
75933479|NCT02457026|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
75933480|NCT02457026|Drug|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
75933481|NCT05488210|Dietary Supplement|FontActiv DiaBest HP/HC|Daily intake of two FontActiv DiaBest HP/HC during 2 months
75933482|NCT02458898|Behavioral|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
75933483|NCT05488132|Drug|anti-siglec-6 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
75933484|NCT02456870|Other|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
75933485|NCT05492890|Device|Dexcom G6|Continuous glucose monitoring
76086446|NCT04683172|Device|Sham Transcranial Direct Current Stimulation|"The tDCS device has a Sham mode that allows for true placebo stimulation. A simulated session is thus designed as a real stimulation session without its effects. Sensations similar to tDCS are created by generating currents only at the start of the session.~Same modalities as for the Active tDCS procedure will therefore be put in place: a pair of electrodes (anode and cathode) are applied to the scalp.To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode."
76086447|NCT04677374|Other|Standard of care|Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.
76086448|NCT04677374|Behavioral|Intensified Health Education|More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC
76086449|NCT04677374|Behavioral|SMS/telephonic Tracing|SMS tracing to remind participants of VMMC appointments
76086450|NCT04677374|Behavioral|Transportation Reimbursement|Transportation reimbursement to offset the cost of transportation for VMMC appointments
75648489|NCT02591758|Behavioral|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
75795943|NCT03913572|Procedure|Injection of adipose-derived stem cells into perianal fistula|The plastic surgery team will perform fat graft harvest. Tumescent solution will be infiltrated into the area of liposuction, generally the abdomen, flanks, or thighs. Approximately a00ml of liposuction aspirate will be retrieved. It will be washed and condensed down to about 5-25 ml of good-quality fat graft using the REVOLVE System by Acelity. This will then be loaded into a syringe fitted with an injection cannula. The colorectal surgeon will perform an exam under anesthesia and determine if any additional procedure such as ligation of fistula tract, fistulotomy, endorectal advancement flap, or seton placement/exchange is needed. Severity of disease at time of surgery will be recorded by the attending surgeon. Following any indicated procedure, the lipoaspirate will be injected into the soft tissues around the fistula tract.
76086451|NCT04671797|Behavioral|Early dinner|Dinner at DLMO-3, sleep at DLMO+2
75473693|NCT01973816|Drug|Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral|Daily intake during 24 months
75795944|NCT03913260|Drug|LY3375880|Administered SC
75795945|NCT03913260|Drug|Buffer Matrix (No LY3375880)|Administered SC
75795946|NCT03913260|Device|Autoinjector (AI)|AI used to administer LY3375880 or Buffer Matrix
75795947|NCT03913260|Device|Manual Syringe|Manual syringe used to inject LY3375880
75933486|NCT03273842|Biological|PF-06881894|pre-filled syringe 6 mg
76086452|NCT04671797|Behavioral|Late Dinner|Dinner at DLMO+1, sleep at DLMO+2
76086453|NCT04671797|Behavioral|Late Dinner + Late Sleep|Dinner at DLMO+1, sleep at DLMO+6
75473694|NCT01973829|Other|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
75473695|NCT01973842|Drug|0.1 mg triptorelin|
75473696|NCT01973842|Drug|0.2 mg triptorelin|
75473697|NCT01973842|Drug|0.4 mg triptorelin|
75648490|NCT02591758|Other|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
75648491|NCT02591758|Other|Angina assessment with the angina diary, the SAQ and the SF-36|
75933487|NCT03273842|Biological|US-approved Neulasta|pre-filled syringe 6 mg
75933488|NCT05492812|Other|Sedation and Nursing Management in EEG Recording in Children|Evaluation of the effect of sedative agents applied during EEG recording in children
75933489|NCT05492812|Drug|Chloral Hydrate|Chloral Hydrate
75933490|NCT05492812|Drug|Hydroxyzine|Hydroxyzine
75933491|NCT05492812|Drug|Melatonin|Melatonin
75933492|NCT05492734|Drug|EDG-5506|single oral dose
75933493|NCT03265418|Device|BioXmark liquid fiducial markers|Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
75933494|NCT03265418|Other|Imaging|"As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy."
76086454|NCT04665648|Drug|Nicorandil|6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention
76086455|NCT04665648|Drug|Placebo|placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
75648492|NCT02591758|Other|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
75933495|NCT03265418|Procedure|surgery or wait-and-see|"As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol."
75473698|NCT01973855|Drug|Western Medicine|Physical cooling,Hydrocortisone
75648493|NCT02591758|Other|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
75795948|NCT03908424|Other|Epidural Blood patch.|"An epidural blood patch is a surgical procedure that uses autologous blood in order to close one or many holes in the dura mater of the spinal cord, usually as a result of a previous lumbar puncture. A small amount of the patient's blood is injected into the epidural space near the site of the original puncture; the resulting blood clot then patches the meningeal leak. An epidural needle is inserted into the epidural space at the site of the cerebrospinal fluid leak and blood is injected. The clotting factors of the blood close the hole in the dura."
75795949|NCT01147692|Biological|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
75933496|NCT05487976|Drug|Recombinant human activated coagulation factor VII for injection|Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
75933497|NCT05487898|Device|Cycling wheelchair|Apply the mechanical principle of pedaling on a bicycle to a conventional wheelchair
75795950|NCT03913182|Drug|apatinib|500mg po Qd
75795951|NCT02528292|Procedure|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
75795952|NCT02528292|Drug|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
75933498|NCT03265652|Device|Intense Pulsed Light (IPL) therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
75933499|NCT03265652|Device|Sham therapy|Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
75933500|NCT03265028|Behavioral|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
75933501|NCT02458118|Drug|Secretin|Secretin 1 IU/kg over 3 min
75933502|NCT05487742|Drug|Dexmedetomidine|dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient
75473699|NCT01973855|Drug|TCM and Western Medicine|Third Infectious diseases soup recipe
75473700|NCT01973868|Drug|Regorafenib (Stivarga, BAY73-4506)|
75473701|NCT01973868|Drug|Cetuximab (ERBITUX)|
75933503|NCT05487742|Drug|placebo salin infusion|salin infused as aplacebo for 72 hours
75933504|NCT02457650|Drug|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
75933505|NCT02457650|Drug|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
76086456|NCT04646226|Device|AV graft|The purpose of the surgery is to connect a large vein in the arm to a nearby artery indirectly by inserting a graft material (graft surgery)
76086457|NCT04646226|Procedure|surgical intervention for creation of a fistula|The purpose of the surgery is to connect a large vein in the arm to a nearby artery directly (fistula surgery)
75648494|NCT00722800|Drug|drospirenone and ethinyl estradiol (YAZ)|1 tablet daily for 24 weeks
75648495|NCT00722800|Drug|Placebo|1 tablet daily for 24 weeks
75648496|NCT00718042|Device|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
75648497|NCT00718042|Device|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
75648498|NCT04087252|Biological|tumor neoantigen|tumor neoantigens
75648499|NCT00741598|Drug|Galantamine-ER|Galantamine-ER 8 to 24 mg per day for 16 weeks
75648500|NCT00741598|Drug|Galantamine placebo|Galantamine placebo 8 to 24 mg per day for 16 weeks
75648501|NCT02590978|Procedure|Early cholecystectomy|Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
75648502|NCT02590978|Procedure|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed once complete resolution of abdominal tenderness, oral feeding and trending down in pancreatic laboratory is achieved
76086458|NCT04644952|Other|Electronic Health Record Review|Review of medical records
76086459|NCT04637815|Behavioral|Motivational Network Intervention|See earlier description
76086460|NCT04637815|Other|Usual Care|See earlier description
76086461|NCT04637594|Drug|Pembrolizumab|Given IV
76086462|NCT04637594|Drug|Nivolumab|Given IV
76086463|NCT04637594|Drug|Atezolizumab|Given IV
76086464|NCT04637594|Drug|Durvalumab|Given IV
75338406|NCT00176930|Biological|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
75338407|NCT00176930|Drug|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
75338408|NCT00176930|Radiation|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
75338409|NCT00176930|Drug|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
75338410|NCT00176930|Drug|Equine ATG (ATGAM)|UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
75648503|NCT04084600|Other|Kinesiotherapy Protocol|Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
75473702|NCT01973894|Procedure|Blood and urine sampling|"Blood and urine sampling will follow this schedule:~24h: blood (3ml)~48h: blood (3ml) and urine~End of infusion: blood (3ml)~6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
75648504|NCT04084600|Other|Manual Therapy Protocol|Manual therapy protocol: is a manual treatment intended to the release of fascias and soft tissues.
75648505|NCT04084600|Other|Traditional Massage|Traditional Massage is a gentle and superficial massage.
75795953|NCT03908190|Behavioral|Personalized Support for Progress|Participants will receive the Personalized Support for Progress Intervention from a peer support provider including sessions with the peer support provider to complete a prioritization task, develop a personalized care plan, and receive support for implementing the personalized care plan.
75795954|NCT03913026|Biological|Transplant with an expanded ECT-001 cord blood|"Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises."
75933506|NCT02457650|Biological|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
75933507|NCT02456948|Drug|Minocycline|6 weeks 200mg/day Minocycline add-on
75933508|NCT02456948|Drug|Placebo|6 weeks Placebo add-on
75933509|NCT05487508|Drug|Dexamethasone|Administration of intraoperative 1 mg/kg body weight dexamethasone
75933510|NCT05487508|Drug|Normal saline|Placebo (NaCl 0.9%)
76086465|NCT04637594|Drug|Avelumab|Given IV
75338411|NCT00176930|Biological|CD4+/CD25+ cells|On days -2, patients will receive CD4+/CD25+ cells intravenously.
75338412|NCT01473745|Procedure|conventional alar base cinch|The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
75648506|NCT00717886|Radiation|isosulfan blue dye|"At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies day of mapping for patient convenience."
75648507|NCT03947632|Diagnostic Test|serum ferritin and hemoglobin test|Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.
75648508|NCT04085770|Drug|Alfacalcidol 1 MCG Oral Capsule|2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay
75648509|NCT02589886|Other|Education and self-help internet intervention|The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
75648510|NCT00741286|Drug|Aspirin|Asprin (100mg) plus placebo
75648511|NCT00741286|Drug|cilostazol|Aspirin (100mg) plus cilostazol (200mg)
75795955|NCT02713386|Drug|Carboplatin|Given IV
75795956|NCT02713386|Drug|Paclitaxel|Given IV
76086466|NCT04635111|Drug|TURALIO™|This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
76086467|NCT04633057|Drug|TJ101|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
76086468|NCT04633057|Drug|NordiFlex|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
76086469|NCT04627493|Behavioral|Online exercise|Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
75338413|NCT01473745|Procedure|modified alar base cinch|The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
76086470|NCT04625751|Other|CO2-enriched air|To assess cardiovascular reactivity
75338414|NCT01088711|Drug|Omarigliptin|Once-weekly 50 mg capsule
75338415|NCT01088711|Drug|Placebo|Once-weekly placebo capsule
75648512|NCT05684926|Other|Telerehabilitation yoga|Yoga consists of bodily postures or poses called asanas, breathing practices called pranayama, and meditation sections that provide focus. Children's yoga aims to teach pre-school (3-6 years) and school (7-12 years) children to breathe correctly, to practice yoga postures using their imaginations, to preserve their existing body flexibility and to teach correct posture. It consists of compositions such as postures, breathing exercises, imitations of living things in nature, memory games. They also relax with the pranayama breathing exercises done during the session. It aims to develop children's creativity through relaxation exercises, moving poses and stories told. Children's yoga also serves an artistic aspect with activities such as listening to music, singing, rhythm games, and drawing.
75795957|NCT02713386|Drug|Ruxolitinib Phosphate|Given PO
75933511|NCT04185142|Combination Product|cryoballoon ablation combining with left atrial appendage closure|cryoballoon ablation using either 1st or 2nd generation of cryoballoon and left atrial appendage closure using devices including WATCHMAN, Lefort and Lacbes.
75933512|NCT04175704|Drug|UB-221|Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
75933513|NCT02713490|Drug|EXPAREL|EXPAREL and bupivacaine HCl
75933514|NCT02713490|Drug|Bupivacaine|Single dose of bupivacaine HCl 0.5%
75933515|NCT05491954|Device|Dexcom G6|Continuous glucose monitoring
75338416|NCT00127790|Behavioral|CBT for Insomnia (CBT-I)|
75338417|NCT00127790|Behavioral|CBT for Pain (CBT-P)|
75338418|NCT03008395|Behavioral|EMMA|Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management
75338419|NCT03008395|Other|Treatment as Usual|Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
75338420|NCT01120223|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
75648513|NCT02596204|Other|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. Fitbit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (CDE, NP and/or MD) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
75648514|NCT02596204|Device|FitBit|All subjects will wear a FitBit activity monitor.
75933516|NCT03263234|Other|8 weeks of circadian adjusted LED-based lighting (CALED)|The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
75933517|NCT05487430|Behavioral|Positive Self-Affirmation|Each participant of the intervention group was given a set of earphones and an MP3 player which included an audio recording with a background sound of birds crowing and river-like flowing water together with the positive affirmation sentences. The self-affirmation sentences were created by the first author by paying special attention to not using negative predicates and words with negative meanings such as pain, nausea, and discomfort. In the audio recording, the affirmative sentences were verbalized by the first author with a soothing voice. Between each sentence, a pause is given so that the patient can repeat each sentence verbally or internally. The audio recording lasted 5 minutes 40 seconds and the patients were asked to listen to it at least once a day, however, they were encouraged to listen to it as much as they wanted.
76086471|NCT04625751|Other|Meal response test|Meal response test to assess changes in splanchnic blood flow.
76086472|NCT04625283|Drug|Ketamine|Participants in the ketamine arm will receive intraoperative and postoperative ketamine.
76086473|NCT04625283|Drug|Placebo|Participants in the placebo arm will receive intraoperative and postoperative saline.
76086474|NCT04623099|Drug|Escitalopram|Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.
76086475|NCT04619680|Drug|Nintedanib|150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
76086476|NCT04619680|Drug|Placebo|placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
75338421|NCT00178178|Device|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
75338422|NCT00178178|Drug|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
75338423|NCT00178178|Drug|Placebo|Drug: Placebo
75338424|NCT03008239|Device|FiberSense sensor|The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
75338425|NCT03008239|Device|Dexcom Sensor|Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
75795958|NCT02713386|Procedure|Therapeutic Conventional Surgery|Undergo TRS
75795959|NCT01253616|Device|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
75795960|NCT01967238|Biological|IM Pneumococcal, meningococcal, or flu vaccine|Volunteers given one of the 3 vaccines
75795961|NCT05616000|Drug|Acetyl-l-carnitine, folic acid|Acetyl-l-carnitine 2gm once a day& folic acid will be given to 43 primary infertile men
75795962|NCT03908112|Behavioral|Standard Community Concussion Care (SC)|temporary rest, gradual increase in activity, and return to school and sports. In some cases vestibular an balance therapy are necessary, aerobic exercises, medication, counseling.
76086477|NCT04614571|Dietary Supplement|Gluten Powder|Administered orally daily for 14 days
75338426|NCT01441843|Drug|Lorazepam|Once 1mg <75kg body weight, 1.5mg 75kg and >75kg body weight, IV, before surgery
75338427|NCT01441843|Drug|NaCl 0.9% (Sodium Chloride)|Once 1ml <75kg body weight, 1.5ml 75kg or >75kg body weight, IV, before surgery
75795963|NCT03908112|Behavioral|SC plus Simple Convergence Exercises (SC+)|In addition to standard community care in this intervention the participants must perform convergence therapy every day at home
75933518|NCT02459054|Device|SynCardia 50cc temporary Total Artificial Heart (TAH-t)|Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
75933519|NCT05487352|Other|hyperglycemia exposure in the first trimester|The exposure means the hyperglycemia identified by the 75g oral glucose tolerance test before the 14 weeks of gestation
75338428|NCT00178646|Drug|Botox|Botox 75-150 units, single treatment only
75338429|NCT02204761|Radiation|Proton Beam Radiation Therapy|Undergo proton beam re-irradiation therapy
75648515|NCT02589730|Device|Welltang App|This App is a large platform of individualized diabetic management
75648516|NCT02596048|Other|Iomeron|Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
76086478|NCT04613778|Procedure|Laser acupuncture|Laser acupuncture is a low-level laser technique with no invasive procedure
76086479|NCT04595630|Other|data collection from the hospital records|The clinical data from the patients enrolled in the study, such as the medical history, functional state, and EuroSCORE, and the hematological, basic renal, hepatic, and metabolic chemistry findings (including cTn as defined per the protocol), the operative data (operating time, blood loss, cardiopulmonary and cross-clamp time, number of arterial and venous grafts, the number of distal anastomoses, flow measured at all bypass grafts at the end of the intervention and the need for an assist device) and CCT scan data (at discharge from hospital facility) will be obtained from the hospital records. The data will be entered into a database.
76086480|NCT04590547|Drug|GLS-1027|GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
76086481|NCT04590547|Drug|Placebo|Placebo looks like GLS-1027
75648517|NCT04085302|Device|Digital Behaviour Change Intervention|14 days
75648518|NCT05684770|Other|4G tablet|Participants will receive for the whole period of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.
75648519|NCT04085224|Drug|Somatropin|LG Somatropin
75648520|NCT05282524|Device|Transvaginal ultrasound performed by a woman herself (with remote healthcare professional supervision)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
75648521|NCT03944590|Other|patient survey|patient survey on clinical outcome after screw osteosynthesis of radial head fractures
75648522|NCT03944590|Other|analysis of radiographs|analysis of radiographs on radiological outcome after screw osteosynthesis of radial head fractures
75648523|NCT02590744|Behavioral|eye patch|cover the sick eye with eye patch preoperatively for 3 hours
75648524|NCT02590744|Behavioral|non-eye patch|do not cover the sick eye with eye patch preoperatively
75795964|NCT03908112|Behavioral|SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)|In addition to standard community care in this intervention the participants must come to the office once a week for a 1-hour therapy session with a therapist. Office-based vergence/accommodative therapy is performed for 12 weeks with home reinforcement.
76086482|NCT04587752|Behavioral|CBT for Weight Bullying|Cognitive-behavioral therapy for weight-related bullying delivered by audio/video telehealth.
76086483|NCT04579367|Drug|Bempedoic acid and/or its fixed-dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.
75338430|NCT01089569|Drug|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
75338431|NCT01089569|Drug|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
75338432|NCT01898234|Device|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
75338433|NCT01898234|Device|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
75338434|NCT01898234|Device|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
75648525|NCT04084132|Procedure|Pulmonary valve replacement|Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.
75795965|NCT03907722|Other|Long pentraxin 3|Primary PCI
75795966|NCT03912480|Biological|Stem cells from human exfoliated teeth|Intravenous infusion of pulp mesenchymal stem cells
75795967|NCT01248546|Procedure|Digital breast tomosynthesis|The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
75933520|NCT03263156|Behavioral|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
75795968|NCT03907956|Other|Dry Needling with Fascial Winding Technique|"For placement of Dry Needling (DN) needles with Fascial Winding Technique (FWT) according to the Four-pole Carpal Dry Needling (FCDN) approach model, only anatomical references are used, in all cases from a carpal ventral approach. The needles used are the Chinese type with silver handle and guide tube, measuring 25x0.30 mm., Agupunt® brand. Four needles are placed, at the level of the bones: scaphoid, pisiform, trapezius and hamate. The four needles follow an oblique direction, always on the back and looking for the midline of the center of the carpal tunnel, with an inclination of approximately 45º, both in the cranio-caudal and medial-lateral directions. In each of the needles, it deepens until it reaches a firm elastic stop, attributable to the Transverse Carpal Ligament. Next, the FWT is applied to each of the needles, consisting of rotating them in the same direction until you feel the final stop of the needle grasp."
75795969|NCT03912714|Procedure|Laparoscopic appendectomy|Surgery will be performed under general anaesthesia. The laparoscopic appendectomy can be performed with the use of 3 trocars; one subumbilical, one suprapubic and one in the lower right quadrant of the abdomen. The appendix is removed using a laparoscopic endostapler enabling a safe and complete appendectomy with the cross stapling line at coecal base. Laparoscopic appendectomy will be performed by a gastrointestinal surgeon with sufficient experience in laparoscopic appendectomies (>20).
75795970|NCT03912714|Procedure|Endoscopic appendix biopsies|Appendix biopsies will only be taken when the scope easily slides into the lumen of the appendix (the scope will not be pushed into the appendix lumen)
75933521|NCT04057144|Behavioral|ACT|Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.
75933522|NCT04057144|Behavioral|mindfulness exercises and audio recordings|mindfulness exercises introduced in the ACT sessions. In addition daily home meditation exercises based on the program developed by Kabat-Zinn 2005 and with help of audio recordings.
75933523|NCT04057144|Behavioral|Education program|"Self-management education program. Information given by a qualified health professional on pain and symptom management, stress, sleep, eating habits, mental health problems. Group discussions about thoughts and experiences.~communication skills and physical activity"
75933524|NCT05487118|Device|Placebo PBMT + MCE|Placebo PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, without any emission of therapeutic dose. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
75795971|NCT03912402|Biological|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
75338435|NCT01898234|Device|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
75648526|NCT05040334|Drug|Group 1: Antibiotic receiving group|Group 1; receiving antibiotic prophylaxis; single dose of oral doxycycline (200 mg) tablet and metronidazole (500 mg) tablet 2 hours before the surgical evacuation Group B ;receiving placebo 2 hours before the surgical evacuation
75795972|NCT03912402|Biological|Bevacizumab|IV infusion
75338436|NCT01043939|Other|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
75933525|NCT05487118|Device|Active PBMT + MCE|Active PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, with a dose of 30 J per site. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
75933526|NCT03262844|Behavioral|Conservative treatment|The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.
75933527|NCT03262844|Procedure|Capsule surgery|"In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.~Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually."
75933528|NCT03265106|Biological|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
75933529|NCT03265340|Device|dTMS|
75338437|NCT01043939|Other|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
75338438|NCT01899482|Other|Manual Lymphatic Drainage|
75648527|NCT03943810|Other|No intervention|There is no intervention
75933530|NCT02457884|Other|Temporal Group|Visual Processing Training
75933531|NCT02457884|Other|Spatial Group|Spatial visual span training
75933532|NCT02457884|Other|Combined Group|Visual processing speed and spatial visual span training
75338439|NCT01899482|Behavioral|Education|Behavioral education.
75648528|NCT00716092|Drug|Placebo (linagliptin)|once daily for 28 days
75648529|NCT00716092|Drug|Placebo (linagliptin)|once daily for 28 days
75648530|NCT00716092|Drug|Sitagliptin|100 mg once daily for 28 days
75648531|NCT00716092|Drug|Placebo (sitagliptin)|once daily for 28 days
75648532|NCT00716092|Drug|Placebo (sitagliptin)|once daily for 28 days
75648533|NCT00716092|Drug|Linagliptin|5mg once daily for 28 days
75648534|NCT05684380|Drug|MAZ-101association|Experimental drug
75648535|NCT05684380|Drug|DYMISTA®|Active comparator
75648536|NCT02590510|Drug|methotrexate|The quantity of methotrexate is different in the two groups.
75648537|NCT05245864|Other|blood flow restriction|Blood flow to the legs will be mostly restricted temporarily during physical therapy exercises for the initial several weeks of physical therapy.
75648538|NCT05245864|Other|physical therapy standard of care|the current standard of care after surgery for ACL repair.
75648539|NCT02590666|Procedure|Bipolar Polypectomy|Polyps resection with bipolar electrode
75338440|NCT03013907|Behavioral|UPLIFT|Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping & Relaxing Session 4: Attention & Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure & the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks
75338441|NCT03013907|Behavioral|Usual care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study
75648540|NCT02590666|Procedure|Mechanical Polypectomy|Polyps resection with microscissors or graspers
75648541|NCT02590666|Device|Bipolar electrode|Bipolar electrode used to performs polypectomy
75648542|NCT02590666|Device|Microscissors or graspers|Mechanical instruments used to performs polypectomy
75648543|NCT00919204|Drug|AG-013736 (axitinib)|Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
75648544|NCT00715624|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
75648545|NCT00715624|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
75795973|NCT03912402|Drug|Paclitaxel|IV infusion
75795974|NCT03912402|Drug|Cisplatin (or carboplatin)|IV infusion
75795975|NCT03908034|Other|presence of uncontrollable risk factor|the presence of an uncontrollable / unremovable risk factor for a disease
75795976|NCT03908034|Other|induction of anticipated regret|higher level of elaboration on potential regret
75795977|NCT01147770|Drug|progesterone|duration
75795978|NCT01148316|Drug|fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
75933533|NCT02457884|Other|Control Group|Leisure reading activities
75933534|NCT05387954|Procedure|Transcatheter PFO closure|PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.
75933535|NCT05387954|Drug|Oral Anticoagulant, Direct-Acting|Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
75933536|NCT05387954|Drug|Antiplatelet therapy|Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
75933537|NCT05074784|Device|IOPI Therapy|Obtain IOPI reading at start of session, record the best of 3 readings as baseline strength. Calculate exercise resistance for session at 60% of baseline strength. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets.
75933538|NCT05074784|Device|Tongue Depressor Traditional Intervention|Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set
75933539|NCT03944018|Behavioral|Intervention with rehabilitation coordinator|Intervention with rehabilitation coordinator in orthopedic care
75933540|NCT03262688|Drug|Bupivacaine HCl collagen-matrix implant|Placement of the bupivacaine collagen-matrix in the surgical site
75933541|NCT03262688|Drug|Bupivacaine HCl infiltration|Infiltration of the surgical site
75933542|NCT05486884|Procedure|Maintain MAP ≥ 90 mmHg|Maintain MAP ≥ 90 mmHg for the 24 hours following inclusion by perfusion of norepinephrine
75933543|NCT05486884|Procedure|Maintain MAP ≥ 65 mmHg|Maintain MAP ≥ 65 mmHg for 24 hours after randomization through the perfusion of norepinephrine
75338442|NCT00128180|Drug|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
75338443|NCT00128180|Drug|Placebo|Placebo
75338444|NCT01899560|Procedure|Measure lung and chest wall elastance with esophageal catheter|"Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated [9]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.~A low flow pressure/volume curve from 0 to 40 cmH2O will be performed."
75648546|NCT00715624|Drug|Basal Insulin|Dose to be kept stable.
75648547|NCT00715624|Drug|Metformin|Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.
75648548|NCT00715624|Device|Pen auto-injector|
75648549|NCT02589574|Other|electronic text message|"Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.~it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority."
75648550|NCT00919282|Drug|gemcitabine, folinic acid, 5-FU|gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
75795979|NCT01148316|Behavioral|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
75795980|NCT03912168|Other|Question Prompt List|Question prompt list for common orthopaedic conditions
75795981|NCT03912168|Other|3 questions list|3 questions from the AskShareKnow model
75795982|NCT03916380|Dietary Supplement|Grapefruit Juice|Single 8 ounce administration of oral grapefruit juice
75933544|NCT02458820|Procedure|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
75933545|NCT03262532|Other|Web-base simulator|Training manipulation of TEE using a Web-based simulator
75338445|NCT01899560|Other|non-invasive method for measuring the lung elastance|by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
75338446|NCT01121939|Drug|Bevacizumab|"15 mg/kg IV Day 1. The first dose should be administered over~90 minutes. If no adverse reactions occur after the initial dose, the second dose should~be administered over a minimum of 60 minutes. If no adverse reactions occur after the~second dose, all subsequent doses should be administered over a minimum of 30~minutes. Bevacizumab will be infused prior to pertuzumab."
75648551|NCT02590276|Behavioral|characterization|
75795983|NCT03907254|Other|Service Dog Training Program|Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
75795984|NCT03915990|Diagnostic Test|umbilical and middle cerebral artery Doppler|Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
75648552|NCT00754663|Behavioral|exercise training|walking training at least 3 times a week
75795985|NCT01249638|Drug|Capecitabine|Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
75795986|NCT01249638|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1 q day 21
75933546|NCT03262532|Other|No web-base simulator|Training manipulation of TEE with out a web-base simulator
75933547|NCT05485792|Diagnostic Test|18F-FAPI PET/CT and 18F-FDG PET/CT|Each subject undergo both 18F-FDG and 68Ga-FAPI PET/CT scans within 1 week
75933548|NCT03870464|Diagnostic Test|CT-scans extended|CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
75933549|NCT03870464|Diagnostic Test|MRI scan of the brain|MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
75933550|NCT03870464|Other|Prospective registration of irAEs|irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
75933551|NCT03870464|Behavioral|Quality of Life questionnaires|Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
75933552|NCT05485402|Dietary Supplement|Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
75648553|NCT00757549|Biological|cetuximab|
75648554|NCT00757549|Drug|cisplatin|
75648555|NCT00757549|Genetic|TdT-mediated dUTP nick end labeling assay|
75795987|NCT01249638|Drug|Capecitabine|Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
75795988|NCT01249638|Drug|Irinotecan|Irinotecan: 200 mg/m2 day 1 , q day 21
75795989|NCT01249638|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1, q day 21
76086484|NCT04572256|Drug|Montelukast|The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
75338447|NCT01121939|Drug|Pertuzumab|"840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.~If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later."
75338448|NCT01121939|Drug|Sandostatin LAR® Depot|30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
75338449|NCT00181610|Drug|Recombinant Human Prolactin|60 mcg/kg every 12 hours
75648556|NCT00757549|Other|3'-deoxy-3'-[18F]fluorothymidine|
75933553|NCT05485402|Dietary Supplement|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
75933554|NCT05485402|Dietary Supplement|Maltodextrin|The dosage will be 7,5 g/day of maltodextrin.
75933555|NCT05485402|Dietary Supplement|Prebiotic (FOS and inulin)|The dosage will be 7,5 g/day of prebiotic supplement (FOS and inulin).
75933556|NCT05485402|Other|Nutritional and physical activity recommendations|The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.
75648557|NCT00757549|Other|immunohistochemistry staining method|
75648558|NCT00757549|Other|laboratory biomarker analysis|
75648559|NCT00757549|Radiation|fludeoxyglucose F 18|
75648560|NCT00757549|Radiation|radiation therapy|
75648561|NCT05398159|Device|Trim II|"Eligible subjects will receive 3 bi-weekly treatments (once in 2 weeks) with Trim II hands-free applicator belt according to the study protocol.~Trim II hands-free applicator composed of 4 units applied to the abdominal area, using a single-use belt.~Each treatment duration will be 45-60 minutes. Study duration for each subject is approximately 6 months (including screening, 3 treatments and 2 follow-up visits at 1 and 3 months post last treatment)."
75648562|NCT00576199|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
75795990|NCT01251666|Other|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
75795991|NCT03912012|Drug|Iohexol renal clearance measurement|intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.
75795992|NCT03912012|Device|microcirculation assessment through Laser Doppler associated to iontophoresis.|endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).
75795993|NCT03912012|Device|Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement|carotid ultrasound (during Day 1)
75795994|NCT03912012|Biological|Blood sampling|37 mL of blood sample will be performed at Day 1
75795995|NCT03912012|Biological|Urine sampling|The urinary collection will be done during the Day 1, on the first morning urination
75933557|NCT05485324|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
75933558|NCT03797924|Drug|Receive ICBN with ropivacaine|ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
75795996|NCT03912012|Device|High-resolution peripheral quantitative computed tomography (HR-pQCT)|assessment of the Body Mass Index by HR-pQCT (during the Day 1)
75933559|NCT03797924|Behavioral|No ICBN block|The site of injection will be prepped with tinted chlorhexidine
75795997|NCT03912012|Radiation|Dual-energy X-ray (DXA)|assessment of bone parameters by DXA (during the Day 1)
75933560|NCT02456792|Procedure|IVF|Women will undergo one IVF cycle
75933561|NCT02456792|Procedure|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
76086485|NCT04572256|Drug|Placebo|An oral placebo will be taken daily for 6 months post surgery.
76086486|NCT04571580|Drug|Normal Saline|intracoronary infusion with normal saline
75648563|NCT00576199|Procedure|Transarterial chemoembolisation (TACE)|"TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.~Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE."
75933562|NCT05486650|Drug|PD-1 inhibitor|After receiving PD-1 inhibitor treatment in the first three cycles, patients with locally advanced or advanced NSCLC whose curative effect is evaluated as stable disease receive SBRT combined with PD-1 inhibitor treatment
75933563|NCT02458976|Device|PDL|
75933564|NCT05074628|Drug|Nitrofurantoin capsules|methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.
75933565|NCT02458742|Drug|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
76086487|NCT04571580|Drug|Reteplase Injection 9mg|low-dose intracoronary fibrinolytic therapy with reteplase 9mg
76086488|NCT04571580|Drug|Reteplase Injection 18mg|low-dose intracoronary fibrinolytic therapy with reteplase 18mg
76086489|NCT04567108|Behavioral|Maintain usual SSBs|Instruction/guidelines to maintain baseline intake of SSBs (months 0-6); then switch to water only (months 6-12)
76086490|NCT04567108|Behavioral|Substitute to non-SSBs|Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)
76086491|NCT04567108|Behavioral|Study app|Engage with a motivational mobile app to track beverage intake and complete study data collection
76086492|NCT04567108|Behavioral|Beverage delivery|Select from approved beverages for a monthly at-home delivery (months 0-6)
76086493|NCT04557748|Other|Observational|"Treatment:~Up to five interactions: In-person visits at Baseline, 3 months, and 12 months after initial visit, and phone/online interaction at 6 months and 9 months after initial visit.~Each in-person follow up visit is expected to last up to 2 hours and each phone/online interaction is expected to last up to 1½ hours.~Answering questions about your general health and urinary symptoms - may be done remotely Physical exam Completing Self- Reported Measures questionnaires - may be done remotely Completing voiding/intake and food diaries, either online or on paper Weekly text message survey regarding symptom and treatment changes~Biosample collection:~At baseline: Up to 4 tablespoons of whole blood, dried blood spots, and urine At baseline: Whole blood will be collected with other biospecimens At 3 months: Up to 4 tablespoons of blood, dried blood spots and urine At 12 months: Dried blood spots"
75648564|NCT02560831|Behavioral|Therapeutic exercise and Pompage|Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
75648565|NCT02560831|Behavioral|Educational lectures|Educational lectures in four meetings for 12 weeks (Control Group)
75648566|NCT00754819|Drug|Colchicine|1mg once daily
75648567|NCT00754819|Drug|Placebo|1 capsule daily
75648568|NCT00715078|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
75648569|NCT02589652|Drug|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
75648570|NCT02589652|Drug|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
75648571|NCT02589652|Drug|Entecavir|ETV 0.5mg oral daily for 48 weeks
75795998|NCT03907098|Drug|Endostar|an anti-angiogenesis drug
75795999|NCT03907098|Drug|Chemotherapy|Physician's choice
75796000|NCT03915756|Procedure|Drainage of surgical wound|Introduction of a drain before full fascial closure
75796001|NCT01148394|Other|Multimodal rehabilitation|
75796002|NCT03915834|Device|Endovascular treatment|Mechanical thrombectomy and/or Aspiration
75933566|NCT02458742|Drug|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
75933567|NCT03237910|Diagnostic Test|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
75796003|NCT01249716|Dietary Supplement|individual nutritional therapy|individual nutritional therapy provided by a registered dietician by means of three follow-up home visits
75796004|NCT01251822|Drug|PEG 3350 plus electrolytes|Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
75796005|NCT01251822|Drug|Prucalopride|"Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days."
75796006|NCT01253694|Drug|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
75933568|NCT03237910|Procedure|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
75338450|NCT00181610|Biological|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
75933569|NCT03237910|Procedure|CPR|chest compressions and ventilations at a rate of 30:2
75933570|NCT03262766|Other|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
75648572|NCT02590042|Biological|ADSC-SVF-002|"ADSC-SVF with the following identity:~Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10^6 cells/g of liposuctioned (hydrated fat)"
75648573|NCT00679627|Drug|Galantamine|8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
75648574|NCT00679627|Drug|Placebo|Matching placebo
75648575|NCT00714688|Drug|prolonged release (PR) OROS methylphenidate 54 mg|18+36mg once daily for 13 weeks
75648576|NCT00714688|Drug|prolonged release (PR) OROS methylphenidate 72 mg|2x36mg once daily for 13 weeks
75648577|NCT00714688|Drug|Placebo|2xplacebo once daily for 13 weeks
75796007|NCT03911934|Other|Polypharmacy intervention|A physician from the Department of Clinical Pharmacology prepares a critial medication review before the first visit in the outpatient clinic through critical review of the patient's medical journal and communication with the patient's GP. During the visit in the outpatient clinic, medications are changed based on the medication review with consent from the patient. After the visit the GP is notified of the changes. It is possible to see the patient more than one time in the outpatient clinic (might be needed if tapering or lots of changes) and possible to follow-up on medication changes by telephone with the patient.
75796008|NCT03911934|Other|Usual care|Usual care in the geriatric outpatient clinic with geriatric assessment from a trained geriatrician
75933571|NCT03262766|Behavioral|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
75933572|NCT03262766|Other|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
75933573|NCT05486494|Other|Treatment (non- surgical/surgical)|Treatment Outcome based on different aspects
75933574|NCT02403310|Drug|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~Dose Level 2: 80 mg twice weekly.~Dose Level 1 (starting dose): 60 mg twice weekly.~Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
75933575|NCT02403310|Drug|Daunorubicin|"Induction: Daunorubicin 60 mg/m^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m^2/day (days 1-2)."
75933576|NCT02403310|Drug|Cytarabine|"Induction: Cytarabine 100 mg/m^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m^2/day (continuous infusion on days 1-5)."
76086494|NCT04557748|Other|Observational Controls|One in-person visit that is expected to last up to 2 hours Answering questions about your general health and urinary history Physical exam Completing Self- Reported Measures questionnaires Completing voiding/intake and food diaries, either online or on paper Biosample collection of up to 4 tablespoons of whole blood, dried blood spots, and urine
75338451|NCT00181610|Biological|Normal Saline|twice per day
75338452|NCT03013751|Drug|Udenafil|Active drug
75338453|NCT02205307|Device|PINPOINT|
75338454|NCT02205307|Device|SPY Elite|
75338455|NCT01897844|Drug|ITF2984 (100, 2000, 3000 mcg bid)|
75338456|NCT01897844|Drug|Placebo|
75338457|NCT00131378|Drug|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
75648578|NCT05165212|Drug|Amoxicillin|Patients will be given 10% of a standard weight-based dose of amoxicillin and observed for signs/symptoms of allergic reaction for 30 minutes. If no reaction occurs, they will given the remaining 90% of the standard dose and observed for an additional 30 minutes.
75648579|NCT00679549|Device|CPAP Therapy|CPAP therapy is provided as an inpatient.
75648580|NCT00754975|Device|JACTAX LD DES|Drug Eluting Stent
75933577|NCT03258944|Other|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
76086495|NCT04557748|Other|Central Sensitization|"One in-person visit expected to take up to 30 minutes, that include:~Segmental Mechanical Hyperalgesia - a hand-held device with a small flat rubber surface will be placed above the pubic bone and forearm, and will apply pressure. Participant will be asked about the intensity and unpleasantness that they experience.~Pinprick Temporal Summation - participant will receive tactile stimulation by a pointed skin probe (pinprick stimulator) being placed above the pubic bone and forearm. Participant will be asked to rate the sensation they are feeling.~Current treatment information including prior surgery or procedures, medication use, other current treatment/therapy used at the time of the visit.~Self-reported measures questionnaires"
76086496|NCT04557748|Other|Physical Activity and Sleep Tracker|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period starting at baseline prior to treatment and again at 3 months. During each 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
76086497|NCT04557748|Other|Physical Activity and Sleep Tracker Controls|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period at baseline prior to treatment. During the 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
76086498|NCT04557748|Other|Organ-Based|"One in-person visit involving:~Urethral vibratory sensation threshold Urethral Pressure Profilometry Cystometry Uroflowmetry Lidocaine Pre-Treatment Cystometry"
76086499|NCT04557748|Other|Qualitative Assessment of Patients with Urinary Urgency|"Participation will include two interviews with a research assistant over the phone and are expected to take up to 60 minutes for each interview. The first interview will be done within four weeks from enrollment, before the start of treatment. The interview will include questions about participant's urinary urgency, including symptoms experienced, the onset of symptoms and other factors that affect urgency.~Approximately three months after the start treatment the participant will be interviewed again. This interview will cover changes in symptoms and experience with treatment, such as side effects and satisfaction with treatment."
75648581|NCT00754975|Device|TAXUS™ Libertè™ DES|Drug Eluting Stent
75648582|NCT05163418|Device|Foot orthosis for flat feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
75648583|NCT05163418|Device|Foot orthoses for high arches feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
75648584|NCT00918502|Device|AVIVO system|Non invasive external monitoring device
75796009|NCT03906864|Other|Care Pathway|"The intervention group had the following as part of the integrated care pathway:~Medical assessment on admission for risk factors for falls.~A weekly assessment of complications including pain, deep venous thrombosis, anaemia, wounds and pressure ulcers, etc. The Confusion Assessment Method and the Geriatric Depression Scale were utilized.~Physiotherapy and occupational therapy guidelines with recommended milestones (set for the full, partial and non-weight bearing groups)~Physiotherapy Clinical Outcome Variables Scale (PTCOVS)16 was used by the physiotherapists in the intervention group to assess the baseline mobility, to define outcome goals and to direct treatment plans.~A postoperative hip precaution handout (containing information on avoiding hip prosthesis dislocation in patients with total hip replacement or hemiarthroplasty) was given to patients and their caregivers."
75796010|NCT03906942|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content in the form of 152 BET I CAN challenges [1]. Behavior challenges are intended to increase a participant's capabilities to set a goal and to create positive habits. Emotion challenges are intended to increase a participant's capabilities to cope with negative emotions and to cultivate positive emotions. Thought challenges are intended to increase a participant's capabilities to challenge negative assumptions and to create a new narrative for their life. Interaction challenges are intended to increase a participant's capabilities to communicate and connect with others. Context challenges are intended to increase a participant's capabilities to read cues and to change cues in the environment. Awareness challenges are intended to increase a participant's capabilities to know herself/himself and to know the issue. Next steps challenges are intended to increase a participant's capabilities to make a plan and to stick with a plan.
75933578|NCT01665274|Drug|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
76086500|NCT04556513|Other|Paraclinical examination|Respiratory functional tests
76086501|NCT04556513|Other|Clinical Examination|Clinical Examination
76086502|NCT04556513|Other|Semi-directive interview|By phone
76086503|NCT04556513|Other|quality of life questionnaires|SF36, VSRQ, IESR, HADS
76086504|NCT04553198|Behavioral|Backward Locomotion Treadmill Training (BLTT)|9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
75933579|NCT01665274|Drug|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
75933580|NCT01665274|Procedure|D2 resection|D2 resection
76086505|NCT04550741|Other|telerehabilitation|After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
76086506|NCT04542070|Drug|Cabotegravir Tablets|CAB tablets will be available as film coated tablets for oral administration.
76086507|NCT04542070|Drug|Cabotegravir Injectable Suspension (CAB LA)|CAB LA will be available as sterile suspension for injection in GSK1265744 for administration as IM injection.
76086508|NCT04542070|Drug|Rilpivirine Tablets|RPV will be administered as tablets for oral administration.
75648585|NCT04051099|Procedure|Bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 16 ml)|bilateral superficial cervical plexus
75648586|NCT04051099|Drug|Dexmedetomidine plus propofol infusion|Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion
75473703|NCT01973907|Other|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
75338458|NCT00131378|Drug|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
75648587|NCT04051099|Procedure|Local infiltraion analgesia|local infiltration analgesia with 2%lidocaine with adrenaline 5 ug/ml 10 ml
76086509|NCT04542070|Drug|Rilpivirine Injectable Suspension (RPV LA)|RPV LA will be available as a sterile suspension of RPV to be administered as an IM injection.
75338459|NCT01445821|Biological|Peripheral Blood Stem Cells|Mobilized leukapheresis product
75338460|NCT01445821|Drug|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
75473704|NCT01973920|Drug|Oshadi Icp|
75796011|NCT03906786|Behavioral|motivational interviewing|The intervention will consist of 4 structured medical consultations in the form of a motivational interviewing compared to usual care, covering a 12-month intervention period. In both groups, the frequency of visits (c / 3 months) and the variables collected will be the same.
75796012|NCT01250106|Dietary Supplement|Lactobacillus reuteri|twice daily
75796013|NCT01148004|Drug|Fenofibrate|
75933581|NCT03259256|Procedure|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
75933582|NCT03262064|Combination Product|Pulmonary function tests,Bronchiectasis severity index score|"Pulmonary function tests: including spirometry, DLCO, and lung volumes. Sputum investigations: The following investigations will be performed on fresh sputum samples; gram stains and culture, smear and culture for mycobacteria and fungi and antibiotic sensitivity tests Bronchoscopy: Bronchoscopy with bronchoalveolar lavage will be used to obtain specimens for staining and culture to identify type of colonization.~Radiology: All patients will have a chest radiograph (PA and lateral) and high-resolution computed tomography (HRCT) scan.~Bronchiectasis severity index score parameters FACED Score"
75933583|NCT03262298|Biological|Anti-CD22-CAR-transduced T cells|a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
75338461|NCT01445821|Drug|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
75338462|NCT01445821|Drug|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
75338463|NCT01445821|Drug|Methylprednisolone|Steroid
75473705|NCT01973933|Drug|Metformin and Pyrimethamine|
75473706|NCT01973946|Other|Symptom Alert and Coaching|Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
75473707|NCT01973985|Other|Pleural Manometry|Intrapleural pressure will be monitored with the use of an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device).
75648588|NCT04051099|Procedure|General anesthesia with endotracheal tube|Induction with Propofol and intubation with cisatracurium
75648589|NCT02589418|Procedure|Acupuncture|Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
75648590|NCT02589418|Procedure|Sham-Acupuncture|Needle insertion and manipulation at 4 non-acupoints
75648591|NCT02589418|Procedure|No Acupuncture|Control intervention: No needle insertion and manipulation
75648592|NCT01031069|Biological|GSK Biologicals' HPV vaccine 580299|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
75648593|NCT01031069|Biological|Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
75796014|NCT01148004|Drug|Ritonavir|
75796015|NCT01148004|Drug|Lopinavir/Ritonavir|
75796016|NCT01252056|Drug|Probucol|250mg,Bid
75796017|NCT01252056|Drug|Probucol and Cilostazol|50-100mg,Bid
75796018|NCT03906552|Other|nonpharmalogocial methods|neonates received acupressure (acupressure group) or massage (massage group) before heel lancing procedure
75796019|NCT03906630|Diagnostic Test|Telehealth clinical exam|This is a pseudo telehealth clinical exam for patients presenting with shoulder pain
75796020|NCT03906630|Diagnostic Test|Standard clinical exam|This is a standard in-person clinical exam for patients presenting with shoulder pain
75796021|NCT03906396|Device|Xbox 360 Kinect|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant. Games uses for the activity are Sports Kinect and Sports Kinect 2. Xbox 360 Kinect - the players themselves become the ''game controller'' via their body movements and gestures, Kinect-enabled game titles lend themselves comfortably to the class of exercise games.
75796022|NCT01148082|Procedure|Self administered Surveys|
75796023|NCT01148082|Procedure|Interviews|
76086510|NCT04542070|Drug|BIKTARVY Tablets (BIK)|BIK will be a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
76086511|NCT04538950|Diagnostic Test|PET/CT|Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
76086512|NCT04538950|Drug|radioactive drug (tracer)|A radioactive drug (tracer) is used in the PET scan.
75796024|NCT01252212|Behavioral|SMS medication adherence|SMS messages to cell phones.
75796025|NCT01252212|Behavioral|No SMS adherence reminder|In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
75796026|NCT03911544|Device|BIS monitor|Participants allocated to the intervention group will receive TIVA anesthesia adjusted by the BIS monitoring in addition to clinical signs of poor anesthesia.
75796027|NCT03911310|Diagnostic Test|[18F]PSMA-11|[18F]PSMA-11 PET/CT
75796028|NCT03911310|Diagnostic Test|[68Ga]PSMA-11|[68Ga]PSMA-11 PET/CT
75933584|NCT05484856|Biological|Autologous adipose tissue derived stromal cells|autologous adipose tissue derived stromal cells is recovered as pellet after non enzymatic processing with sonication using ultrasound . This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ , the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC,2-- 20%), plus a wide number of CD34+ hematopoietic cells (40%)
75933585|NCT05387876|Dietary Supplement|Vitamin D intervention|Nordic Naturals vitamin D gummies (1000 IUs/gummie), 4 gummies per day for 12 weeks
75933586|NCT05387876|Dietary Supplement|Placebo intervention|Organic gummie candies (no vitamin D), 4 gummies per day for 12 weeks
75933587|NCT02456402|Device|Drug Coated Balloon|If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
75933588|NCT02456402|Device|Bare Metal Stent|BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.
75933589|NCT05074004|Other|Psychoeducation|Psychoeducation sessions were conducted by two psychiatric nurses (İK, SS) who are experts in their fields and have psychoeducation and group leadership certificates. Each session was held once a week in 30-45 minutes sessions. The training was carried out interactively; approximately the first 5 minutes were spent on warm-up, the basic information of that day's session was given for 25 minutes, and the last 10 minutes were in the form of questions and answers. Two separate groups were formed according to the day hospital program of the patients, and the psychoeducation program was carried out in two separate groups to conduct psychoeducation effectively.
75933590|NCT03262220|Radiation|Volumetric Arc Therapy (VMAT)|Total Marrow Irradiation: 12 Gy in 3 fractions of 4 Gy on 3 consecutive days with a concomitant simultaneous integrated boost (SIB) of 4.5 Gy x 3 fractions delivered to active bone marrow (ABM).
75933591|NCT04560166|Drug|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"Irinotecan, solution for infusion (20 mg/mL)~Temozolomide, capsules (5 mg, 20 mg and 100 mg)~The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)"
75933592|NCT03262376|Dietary Supplement|Minerals + Vitamins|A mineral and vitamin tablet
75933593|NCT03262376|Dietary Supplement|Botanical A|Botanical extract administered in capsule form
75933594|NCT03262376|Dietary Supplement|Botanical B|Botanical extract administered in capsule form
75933595|NCT03262376|Other|Placebo|Cellulose crystalline tablet
75933596|NCT03259100|Other|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
75933597|NCT03261986|Radiation|Radiostereometric Analysis|RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
75933598|NCT03261986|Procedure|total hip arthroplasty with RSA bead implantation|Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
75933599|NCT04344340|Diagnostic Test|clinical examination|clinical examination
75933600|NCT02456714|Drug|FOLFIRINOX|
75933601|NCT05480020|Other|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
76086513|NCT04530305|Drug|Upadacitinib <15 MG [Rinvoq]|Patients with RA for who the introduction of upadacitinib has been decided will be proposed the study. If they accept, they will be followed for 6 months with 3 visits (baseline, 3 and 6 months) which is the usual standard care. In addition to routine markers, stool and blood will be collected at baseline and 3 months specifically for the study.
76086514|NCT04522388|Dietary Supplement|Ensure Enlive|Ensure Enlive shake twice a day
76086515|NCT04513951|Drug|5Fluorouracil|phase II
76086516|NCT04513951|Drug|L-leucovorin|phase II
76086517|NCT04513951|Drug|Irinotecan|phase II
75796029|NCT01250262|Other|normal medical care and follow up|physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
75796030|NCT01250262|Other|Isolated Lumbar Resistance Exercise Program|lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
75796031|NCT01250262|Other|Total Body Resistance Exercise Program|exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
75933602|NCT05480020|Other|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
75933603|NCT05480020|Other|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 100 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
76086518|NCT04513951|Drug|Oxaliplatin|phase II
76086519|NCT04513951|Drug|Cetuximab|phase II
76086520|NCT04513951|Drug|Avelumab|phase II
75933604|NCT03259646|Behavioral|Universal Education|Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
75796032|NCT02528448|Drug|Plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
75796033|NCT02528448|Drug|0,9% saline|Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
76086521|NCT04510558|Device|Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position|"Antibioprophylaxis using cefuroxime and metronidazole~Standard disinfection and sterile draping~Circular incision around the stoma using the scalpel blade~Dissection around the stoma until entering the abdominal cavity~Closure of the stoma using a linear stapler~A midline laparotomy may be performed or not~Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~No subcutaneous stitches~Partial purse string skin closure using Monocryl 3-0~Standard wound dressing"
76086522|NCT04510558|Procedure|Stoma closure without mesh|"Antibioprophylaxis using cefuroxime and metronidazole~Standard disinfection and sterile draping~Circular incision around the stoma using the scalpel blade~Dissection around the stoma until entering the abdominal cavity~Closure of the stoma using a linear stapler~A midline laparotomy may be performed or not~Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~No subcutaneous stitches~Partial purse string skin closure using Monocryl 3-0~Standard wound dressing"
75473708|NCT01973985|Other|Thoracic ultrasonography|"Thoracic ultrasound scan will be done before drainage of pleural effusion - all participants.~Thoracic ultrasound scans will also be done during drainage of pleural effusion and the results will be recorded after every 100mL of pleural fluid drained - all participants.~Thoracic ultrasound scan will be done after drainage of pleural effusion - all participants.~Thoracic ultrasound scan will also be be done during clinic follow-up as part of routine clinical care - all participants."
75796034|NCT03915522|Procedure|Single adductor canal block|The operated leg is slightly externally rotated and prepared for a block with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and after a subcutaneous injection of 2 ml of 1% lidocaine a total of 20 ml of 0'5% ropivacaine is injected into the canal using a 22 gauge ultrasound-visible needle. In the end, a sterile apposite is placed at the puncture site
75796035|NCT03915522|Procedure|Simulated adductor canal block|The operated leg is slightly externally rotated and prepared with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and at this leve a subcutaneous injection of 2 ml of 1% lidocaine . After, a sterile apposite is placed at the puncture site.
75473709|NCT01973985|Procedure|Pleural aspiration catheter OR chest drain (standard care)|Insertion of pleural aspiration catheter OR intercostal chest drain under ultrasound guidance - all participants (standard care).
75796036|NCT03915600|Other|Quinoa|Personalized diet added with quinoa
75796037|NCT03915600|Other|Flaxseed|personalized diet added with flaxseed
75796038|NCT03915600|Other|Quinoa and Flaxseed|personalized diet added with quinoa and flaxseed
75796039|NCT03915288|Other|Group continuous training at moderate intensity|70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
75796040|NCT03915288|Other|Group high Intensity Interval Training|70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
75796041|NCT03915288|Other|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
75796042|NCT01148472|Drug|Escitalopram|20mg once daily; orally
75796043|NCT01148472|Drug|Duloxetine|60mg once daily; orally
75796044|NCT01147146|Drug|propofol, fentanyl, atracurium|general anesthesia
75796045|NCT01147146|Drug|bupivacaine|spinal anesthesia
75796046|NCT01147146|Drug|bupivacaine, Midazolam|spinal anesthesia & sedation
75796047|NCT01250340|Drug|Aspirin|100 mg/day for 30 days
75796048|NCT01250340|Drug|Placebo|1 cp day for 30 days
75933605|NCT03258866|Drug|Rituximab|given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
75933606|NCT03258866|Drug|Rituximab|given with a single dose of 375mg/m2
75933607|NCT04078282|Behavioral|Intervention group|see above
75933608|NCT02456324|Device|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
75933609|NCT02456324|Device|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
75933610|NCT05484232|Procedure|Laparoscopic Cholecystectomy|Early laparoscopic cholecystectomy in patients with acute calcular cholecystitis
75796049|NCT03914898|Other|Nurse led intervention group|This program is based on cognitive restructuring tecniques.
75933611|NCT03258476|Drug|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
75933612|NCT03258476|Behavioral|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
75933613|NCT03258476|Drug|Placebo|Placebo oral capsule
75933614|NCT03258398|Drug|eFT508|eFT508 will be taken orally (PO) twice a day (bid).
75473710|NCT01973985|Procedure|Talc slurry pleurodesis via chest drain (standard care)|Talc slurry pleurodesis via intercostal chest drain where/when clinically indicated as part of routine clinical care participants with intercostal chest drain only (standard care).
75473711|NCT01974011|Procedure|Performing dorsal penile nerve block (DPNB)|
75648594|NCT04084912|Drug|Dexamethasone Sodium Phosphate|intravenous injection of one ampoule dexamethasone Sodium phosphate 2 ml 8 mg
75648595|NCT04084912|Drug|Saline Solution|intravenous injection of one ampoule saline
75648596|NCT00679081|Device|CelTx|Single application; split-mouth design
75648597|NCT00679081|Other|Autologous sub-epithelial connective tissue graft|Single application; split-mouth design
75648598|NCT05325892|Combination Product|This is an observational study|This is an observational study
75933615|NCT03258398|Drug|Avelumab|Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
76086523|NCT04509596|Drug|DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C|"Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg. If tolerated, dose will be escalated in subsequent cohorts until MTD.~Part B is twice daily oral dosing of DZD1516 in combination with capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle or with trastuzumab 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each 21-day cycle.~Part C is twice daily oral dosing of DZD1516 in combination with T-DM1 3.6 mg/kg intravenously (IV) once every 21 days"
75338464|NCT01445821|Drug|Filgrastim|Granulocyte-colony stimulating factor (G-CSF); a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
76086524|NCT04499235|Drug|Mometasone furoate|Topical mometasone furoate
76086525|NCT04499235|Drug|AKST4290|Oral AKST4290
75338465|NCT01445821|Drug|Fludarabine|Purine analog which inhibits DNA synthesis or repair
76086526|NCT04499235|Drug|Placebo|Oral placebo
75338466|NCT01092767|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
75338467|NCT02543892|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
75338468|NCT02543892|Biological|Placebo|Normal Saline
75338469|NCT00182000|Drug|seromycin|100mg tablet administered 1 hour prior to each therapy session
75648599|NCT00757939|Other|MRI|During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.
75338470|NCT00182000|Behavioral|Behavior Therapy|10 weekly hour-long behavior therapy sessions
75338471|NCT01092923|Drug|sevoflurane on air/O2|sevoflurane on air/O2
75338472|NCT01092923|Drug|sevoflurane in N2O/O2|sevoflurane in N2O/O2
75648600|NCT00757939|Other|FDG-PET|2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
75648601|NCT00755053|Drug|Clotrimazole, vaginal ovule|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
75648602|NCT00755053|Drug|Clotrimazole, vaginal tablet|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
75648603|NCT02590198|Other|ANAES algorithm|care as recommended by ANAES, with ANAES algorithm
75648604|NCT02590198|Other|PCT algorithm|care based on PCT algorithm
75648605|NCT00755209|Drug|tranexamic acid|Loading 1 gram (~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
75648606|NCT02589340|Drug|Buspirone|
75648607|NCT02589340|Drug|Placebo|Sugar Pill
75648608|NCT00682435|Drug|Hydromorphone|"1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
75796050|NCT03915054|Drug|AREG-TRIGGER|"Oocytes in AREG-TRIGGER medium will be mature in AREG + FSH + HSA + Insulin + Estradiol medium.~Per case (6mL) 5940 µL Basal Medium~60 µL IVM MIX Do not need to filtrate media."
75796051|NCT03915054|Drug|CONTROL-TRIGGER|"Oocytes in CONTROL-TRIGGER medium will be mature in FSH + hCG + GH + HSA medium.~Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)"
75796052|NCT03915132|Drug|Nimotuzumab|Nimotuzumab 200mg/m2 IV on d1 of a week before radiotherapy , and 100mg/m2 IV on d1 weekly for 7 cycles
75796053|NCT03915132|Radiation|VMAT|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume.
75796054|NCT01250574|Other|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
75933616|NCT05479942|Other|Graded motor imagery training paradigm|"Graded motor imagery is the psychological representation of attention doing movement of a part of body, without actually moving that part, it broken down into three unique stages of treatment techniques:~Left/right discrimination (Implicit motor imagery):~Explicit motor imagery~Mirror Therapy"
75796055|NCT01250574|Other|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
75933617|NCT05479942|Other|conventional therapy (task-oriented active/passive range of motion training)|"Patient will do 3 tasks as: drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, and combing their hairs.~Practice shoulder flexion and abduction active ROM, and passive ROM training"
75338473|NCT03013049|Procedure|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
75648609|NCT04294979|Other|Physical Therapy|The rehabilitation program will consist of both passive and active therapeutic exercises specifically aimed at restoring or maintaining muscular flexibility, range of motion, balance, coordination of movements, postural passages and transfers, and ambulation. . Furthermore, advanced robotic therapy such as Lokomat® exoskeleton (Hocoma AG, Volketswil, Switzerland), Biodex® Stability System (BSS, Biodex, Inc, Shirley, NY), G-EO System™ (Reha Technology AG, Olten, Svizzera) and Indego® Therapy (Parker USA), will be used to personalize rehabilitation treatment.
75648610|NCT00758017|Other|Acupuncture 1|Application of individualised acupuncture
75933618|NCT03261752|Diagnostic Test|blood sample|Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 &STK31 by RTPCR.
75648611|NCT00758017|Other|Acupuncture 2|Application of standardised acupuncture
75473712|NCT01974024|Drug|methylprednisolone|Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).
75648612|NCT05340205|Drug|Tranexamic acid|Patients will receive 1 gm tranexamic acid diluted in 20 ml of Glucose 5% 15 minutes prior to skin incision and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following delivery of the baby.
75933619|NCT03261596|Drug|Mebendazole|Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
75796056|NCT01250652|Drug|Levocetirizine|20 mg levocetirizine for 5 days
75933620|NCT04072588|Procedure|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
75933621|NCT04488458|Diagnostic Test|MIC or MBEC+MIC based treatment algorithm|"i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.~ii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks."
75933622|NCT05479864|Procedure|anterior cervical corpectomy and fusion|removal of damaged vertebrae and intervertebral disc that are compressing the spinal cord and spinal nerves
75933623|NCT03261908|Genetic|detection of genotype|detection of genotype by next generation sequencing
75933624|NCT03825874|Other|Amikacin|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
75933625|NCT03825874|Other|usual antibiotic treatment|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
75933626|NCT03772574|Device|Facemask preoxygenation|Standard facemask preoxygenation
75933627|NCT03772574|Device|THRIVE preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
75936501|NCT03182816|Biological|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
75473713|NCT01974037|Dietary Supplement|Capsaicin|Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups
75473714|NCT01974037|Dietary Supplement|NaCl|NaCl in various concentrations was desorved in the test solutions in Salt_effect subgroups
75473715|NCT01974076|Device|Active tDCS + CBT|
75648613|NCT05340205|Drug|Misoprostol|"Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).~."
75648614|NCT05340205|Drug|Oxytocin|Patients will receive an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
75648615|NCT00758173|Genetic|polymorphism analysis|
75796057|NCT01250652|Drug|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
75796058|NCT03911232|Drug|sugammadex|standard general anesthesia protocol with sugammadex
75473716|NCT01974076|Device|Sham tDCS + CBT|
75796059|NCT01252368|Biological|hypertension|patients taking daily ACE inhibitors or sartanes
75473717|NCT01974115|Device|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
75648616|NCT00758173|Other|laboratory biomarker analysis|
75648617|NCT00758173|Other|questionnaire administration|
75648618|NCT00713830|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
75648619|NCT00713830|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
75648620|NCT00713830|Device|Pen auto-injector|
75796060|NCT03910842|Biological|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
75933628|NCT05483842|Other|Reiki|"Consisting of the words rei meaning spirit and ki meaning universal life force, Reiki means spiritually directed life force energy. Reiki practice has an important place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, is safe, effective and economical.~In the Reiki method, which is one of the complementary and alternative methods, energy is transferred through the hands. Its basis is based on the principle that when there is a blockage in an energy center, disease occurs and the energy transferred by touching, strengthens and heals the body's self-healing ability by opening the blockages. Reiki practitioners who have received training and initiation perform the practice by holding their hands in certain positions on the recipient's body."
75796061|NCT03910608|Device|MagPro X100 device (MagVenture, Farum, Denmark)|Each cPAS experimental session contained 100 pairs of stimuli at 0.2 Hz. The experimental conditions differed in the interstimulus interval of the paired pulses. DLPFC stimulation precedes IPL/MPFC stimulation by 10 ms (DLPFC+10) or by 4 ms (DLPFC+4), and IPL/MPFC stimulation precedes DLPFC stimulation by 4 ms (IPL/MPFC+4) or by 10 ms (IPL+10).
75933629|NCT05483842|Other|Sham Reiki|Sham means to pretend; therefore, in this study, the sham Reiki placebo provider pretended to perform a Reiki session by moving her hands on the patient's body in a specific order for a 30-minute period following strictly operationalized measures.
75933630|NCT05479786|Other|Expectant management|Follow-up with beta-HCG dosages and transvaginal ultrasound scans
75933631|NCT05479786|Procedure|Salpingectomy|Removal of the affected Fallopian tube by laparoscopy
75933632|NCT05479786|Procedure|Salpingostomy|Removal of the ectopic pregnancy from the Fallopian tube, without removing the whole Fallopian tube, by laparoscopy
75933633|NCT05499208|Other|Giving side position with patient turning and movement system|To provide effective breastfeeding by placing the mother in position.
75933634|NCT04319380|Biological|Tetanus/diphtheria toxoids|One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.
75933635|NCT04319380|Drug|SMC with SP+AQ|Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
75933636|NCT04319380|Biological|RTS,S/AS01|One booster dose of RTSS/AS01 (June) in year 1 and 2.
75933637|NCT04319380|Drug|SMC placebo|Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
75933638|NCT05479708|Device|ctDNA-based MRD detection|Postoperative circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection for predicting relapse and survival benefit
75933639|NCT02456558|Drug|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
75473718|NCT01974128|Procedure|ASC isolation and implantation|This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy
75473719|NCT01974154|Other|Cohort I|We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
75473720|NCT01974154|Other|Cohort II|Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
75933640|NCT02456558|Drug|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
75933641|NCT03798080|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75933642|NCT03798080|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
75933643|NCT03798080|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
75933644|NCT05498974|Other|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
75933645|NCT03258242|Drug|Keluo Xin capsule|four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
76086527|NCT04487548|Other|Remote smoking cessation bundle|"The bundle is a remote version of what has previously been described in prior literature, which includes:~A brief (<5 minutes) advice~Preoperative smoking cessation video prepared by QuitNow~Patients will be provided brochures on smoking cessation~A referral will be faxed (or internet-registered) to the Quitnow.ca Smokers' Helpline~All patients will be requested to participate in the provincial Smoking Cessation program that provides a free 12-week supply of NRT once per year."
75473721|NCT01974167|Drug|Eldecalcitol|Eldecalcitol 0.75 microgram once daily orally
75473722|NCT01974167|Drug|Alfacalcidol|Alfacalcidol 1 microgram once daily orally
75933646|NCT03258242|Drug|Placebo oral capsule|four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
75796062|NCT03906474|Biological|Blood-stage controlled human P. falciparum malaria infection|Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.
75473723|NCT01974193|Drug|Floseal|application of floseal on intervention arm
75933647|NCT03258086|Diagnostic Test|blood sample test|blood sample will be taken from all diabetic children for assessment of vitamin D level
75933648|NCT03257930|Drug|ethanol injection|inject ethanol in cystic thyroid nodule and follow up until complete recovery
75796063|NCT03906084|Procedure|Corticotomy and low laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
75796064|NCT03906084|Procedure|Corticotomy facilitated Orthodontics|Corticotomy is carried out under local anesthesia in right side.
75933649|NCT03257852|Drug|ASP5094|intravenously administration
75933650|NCT03257852|Drug|Placebo|intravenously administration
75933651|NCT03257852|Other|Methotrexate therapy|MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
75933652|NCT05498896|Drug|Atezolizumab|IV infusion
75933653|NCT05498896|Drug|Ipatasertib|Oral
75933654|NCT05498896|Drug|Paclitaxel|IV infusion
75648621|NCT00713830|Drug|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
75648622|NCT00713830|Drug|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day [except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea]) up to the end of treatment.
75933655|NCT05498896|Drug|Doxorubicin|IV infusion
75648623|NCT00681811|Drug|HGT-1111|Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.
75933656|NCT05498896|Drug|Cyclophosphamide|IV infusion
75933657|NCT04765358|Other|Virtual Clinic|CGM, Clinical Care Support and Behavioral Health Support
75933658|NCT03257774|Other|Adhesive strip A|Strip consisting of a newly developed adhesive
76086528|NCT04476446|Drug|Esketamine|Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
75473724|NCT01974258|Drug|Cobimetinib|Escalating dose
75933659|NCT03257774|Other|Adhesive strip B|Strip consisting of a newly developed adhesive
75933660|NCT03257774|Other|Adhesive strip C|Strip consisting of a newly developed adhesive
75933661|NCT04779476|Other|Socket Dressing|Following dental extraction immediately, the socket will be dressed with one of the materials tested
75933662|NCT04667156|Drug|SHR6390|SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
75933663|NCT03257540|Device|Small Bone Intramedullary Nail|Patients undergoing a Lapidus Arthrodesis procedure for hallux valgus correction who are receiving a Phantom Small Bone Intramedullary nail will begin weight-bearing at 2 weeks and follow a pre-determined post-operative protocol.
75473725|NCT01974258|Drug|Cobimetinib|Orally administered once daily for 21 consecutive days, followed by 7 days off.
75933664|NCT02455700|Device|Interproximal Enamel Reduction|removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
75933665|NCT03257306|Procedure|ureteral double-J stent removal using magnet|Double-J ureteric stent removed using magnet
75933666|NCT03257306|Procedure|ureteral double-J stent removal using cystoscopy|Double-J ureteric stent removed using cystoscopy
75933667|NCT03252704|Other|resistant starch (high fiber muffin top)|Muffin top contained 11 g of fiber per portion
75933668|NCT03252704|Other|control (low fiber muffin top)|Muffin top contained 1 g of fiber per portion
76086529|NCT04465344|Device|Implantation of trifocal IOL, Isatis TF (device under investigation)|Patients will be implanted with study IOL in both eyes
75473726|NCT01974258|Drug|Onartuzumab|Administered by IV infusion every 2 weeks
75473727|NCT01974258|Drug|Vemurafenib|Orally administered twice daily
75473728|NCT01974297|Drug|Atorvastatin 10mg, fenofibric acid 135mg|Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks
75473729|NCT01974297|Drug|atorvastatin 20mg|Atorvastatin 20mg/day PO for 12weeks
75473730|NCT01974310|Procedure|Vitrectomy & Intraocular gas fill|
75473731|NCT01974310|Procedure|Postoperative face-down positioning|
75473732|NCT01974336|Drug|ursodeoxycholic acid|
75648624|NCT00755443|Device|Drug eluting stent|Drug eluting stent implantation
75648625|NCT00755443|Device|Bare metal stent|
75648626|NCT05159440|Drug|TORL-2-307-MAB|monoclonal antibody
75796065|NCT01253928|Drug|Pioglitazone|45mg qd for 4 months
75796066|NCT03910686|Combination Product|Transcranial magnetic stimulation and cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
75796067|NCT03906006|Drug|ABP-671|Drug: ABP-671, single oral dose
75933669|NCT03257462|Drug|SPR001|SPR001 Capsules
75933670|NCT03257228|Genetic|comparative semiquantitative immunohistochemistry|
75933671|NCT03257072|Biological|50 Necator americanus L3 larvae|1x50 Necator americanus L3 larvae
75933672|NCT03257072|Biological|100 Necator americanus L3 larvae|2x50 Necator americanus L3 larvae
76086530|NCT04465344|Device|Implantation of monofocal IOL, Isatis (control device)|Patients will be implanted with Control IOL in both eyes
76086531|NCT04465071|Drug|AEONTM Repair and AEONTM Protect Plus lubricating eye drops|AEONTM Repair and AEONTM Protect Plus lubricating eye drops
76086532|NCT04447222|Other|Quality-of-Life Assessment|Ancillary studies
76086533|NCT04447222|Other|Questionnaire Administration|Ancillary studies
76086534|NCT04447222|Other|Survey Administration|Complete survey
76086535|NCT04445688|Drug|AD036|Oral administration before bed
75796068|NCT03906006|Other|Placebo|Other: Placebo, single oral dose
75648627|NCT02589184|Other|Hypergravity|the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
75648628|NCT02589184|Other|isometric load|at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
75796069|NCT01252524|Drug|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
75796070|NCT01252524|Drug|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
75933673|NCT03257072|Biological|150 Necator americanus L3 larvae|3x50 Necator americanus L3 larvae
75933674|NCT03252470|Procedure|Laparoscopic Roux-en-y Gastric Bypass Surgery|Laparoscopic Roux-en-y Gastric Bypass Surgery
75933675|NCT03261518|Procedure|inferior vena cava ultrasound|Place the patient in the supine position. The degree of elevation of the head of the bed has not been shown to make a significant difference in measurements. The diameter of the IVC for calculation of the caval index should be measured 2 cm from where it enters the right atrium .An alternative way to visualize respiratory variation is to use M-mode, with the beam overlying the IVC 2 cm from the right atrium.The inspiratory and expiratory diameter can then be measured on the M-mode image, at the smallest and largest locations, respectively.
75933676|NCT03256604|Diagnostic Test|left-over sputum|Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
75933677|NCT03256838|Drug|Ferric Citrate|Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
75933678|NCT02743221|Drug|Trifluridine/tipiracil + bevacizumab|Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.
75933679|NCT02743221|Drug|Capecitabine + bevacizumab|Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.
75933680|NCT03256682|Behavioral|Stress management counseling|stress management counseling based on CBT and relaxation
75933681|NCT03261128|Other|Self-questionnaire|Filling of a self-questionnaire before each chemotherapy cure
75933682|NCT03252158|Behavioral|Availability of healthier vs. less healthy foods|"Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2&3 and 5&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7)."
75933683|NCT03260972|Drug|Chloroprocaine Hcl 2% Inj|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
75933684|NCT03260972|Drug|Normal saline|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
75933685|NCT03370263|Drug|Benlysta|Benlysta will be administered intravenously or subcutaneously.
75933686|NCT03260816|Behavioral|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
76086536|NCT04445688|Drug|Atomoxetine|Oral administration before bed
76086537|NCT04445688|Drug|Placebo|Oral administration before bed
76086538|NCT04442737|Drug|D/C/F/TAF FDC|A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
76086539|NCT04442737|Drug|TAF/FTC FDC|TAF/FTC ARV regimen will be administered once daily.
75648629|NCT02589184|Other|normal gravity|the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
75933687|NCT03260816|Other|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
75933688|NCT00692445|Drug|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
76086540|NCT04442737|Drug|INI Based Regimen|The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
76086541|NCT04439643|Device|vascuCAP|time to event and phenotype classification model
76086542|NCT04437914|Diagnostic Test|Electrocardiogram diagnosis|Electrocardiographic diagnosis will be made in a double-blind manner by two specialists in cardiology and cardiac arrhythmias and the results will be compared between the groups studied.
76086543|NCT04437862|Device|Q Revascularization System|Q Revascularization System for mechanical thrombectomy
75648630|NCT05685160|Diagnostic Test|MRI with contrast|MRI of the forefoot with contrast (Gadovist)
75648631|NCT05685160|Diagnostic Test|Ultrasound|Ultrasound imaging of the forefoot
75648632|NCT00755521|Drug|etoricoxib|"Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg"
75796071|NCT03914586|Device|oXiris filter|Continuous Renal Replacement Therapy with oXiris filter
75796072|NCT03914430|Other|Food|The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
75796073|NCT03905850|Drug|somapacitan|5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)
75796074|NCT03906162|Behavioral|Motivational interviews|"During the 12-week intervention, the participants will receive seven telephone calls from a physical therapist. The interviews will be held in week 1, 2,3,5,7,9, and 12.~The telephone call will consist of a motivational interview focused on enhancing the daily level of physical activity in the participants.~MI is a form of counselling aiming at prompting increases in self-efficacy, which may leave people more open to and invested in changing their behaviours and shows potential for significant effects for exercise behaviour change.~In addition to the telephone based motivational interviews, the experimental group will also receive the base intervention which is described in detail under the control intervention paragraph."
75933689|NCT00692445|Drug|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
76086544|NCT04436250|Drug|Active comparator|The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
75796075|NCT03906162|Behavioral|Base intervention|"The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity."
76086545|NCT04436250|Drug|S-Ketamine Low dose|The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
76086546|NCT04436250|Drug|S-Ketamine High dose|The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
75473733|NCT01974349|Drug|selumetinib (oral)|Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
75796076|NCT03910374|Procedure|Dural closure|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
75473734|NCT01974375|Drug|micafungin|Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing <40 kg)
75473735|NCT01974375|Drug|Fluconazole|Fluconazole 100~200mg/day, IV care until oral medication becomes possible
75796077|NCT03914352|Drug|PD-1 antibody|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
75796078|NCT03914352|Procedure|TACE|In this group enrolled patients were treated with TACE at the30 days after hepatic resection.
75796079|NCT01254006|Drug|forskolin, rutin and vitamins B1 and B2|
75933690|NCT03256370|Procedure|milk collection|"Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~After completed informed consent, demographic data was collected and filled in case record form~Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method"
75933691|NCT03256058|Procedure|Reinflation after early deflation|the tourniquet would be inflated immediately before incision and deflated after the use of the cement , and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation. The total time of tourniquet inflation is controlled within 90 minutes.
75933692|NCT03256058|Procedure|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
75936502|NCT03117374|Behavioral|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
75473736|NCT01974388|Procedure|LSG started 2 cm from the pylorus|Laparoscopic sleeve gastrectomy started 2 cm from pylorus
75473737|NCT01974388|Procedure|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
76086547|NCT04433910|Drug|Convalesscent Plasma|Transfusion
76086548|NCT04423484|Other|Data collection|Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
76086549|NCT04419779|Device|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
76086550|NCT04419779|Device|Duodenal Mucosal Resurfacing (Sham)|The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
76086551|NCT04414046|Biological|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
75648633|NCT05156866|Drug|TORL-2-307-ADC|antibody drug conjugate
75648634|NCT05684536|Device|liagsure device|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall, with dissection around ligament of berry and inferior thyroidal artery
75648635|NCT00755599|Procedure|no-stirrup vaginal examination|Vaginal speculum examination done with feet on table extender.
75648636|NCT00755599|Procedure|Vaginal speculum examination done with stirrups.|Speculum examination done with feet in stirrups.
75933693|NCT03836625|Other|CareConekta|CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
75473738|NCT01974401|Device|supragingival irrigators containing chlorhexidine|patients received irrigation by oxyjet supra gingival irrigators containing chlorhexidine for at least 3 minutes for all dentulous regions of jaws which was performed by researchers once daily.
75648637|NCT03939442|Procedure|Sleeve gastrectomy with jejunoileal anastomosis|The sleeve gastrectomy was performed first, after using a sealer and divider device to dissect the omentum away from the greater gastric curvature from approximately 5 cm proximal to the pylorus up to the angle of His. Excision of the fundus and the body of the stomach was then performed with a laparoscopic linear stapler upon a 36 French orogastric tube (bougie). An isoperistaltic side-to-side anastomosis between the jejunum (at 50 cm distal to the Treitz ligament) and the distal ileum ( at 200 cm proximal to the ileocecal valve) was then created using the same linear stapler with a blue cartridge (3.5 mm). A soft Penrose drain was left at the subdiaphragmatic space, and the abdominal wound was closed.
75796080|NCT03914274|Device|Technical sock|Socks were of two types: technical socks, designed for high performance sports use (Lurbel brand, models Tierra and Set), and non-technical socks for everyday use. The socks had different composition: Tierra (50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra); Set (75% cotton, 17% polyamide, 8% lycra) and cotton (98% cotton, 2% elastane).
75796081|NCT03914040|Other|IPSE program|"Pre-immersion preparation. A self-study course will be offered about lifestyle modification. Some readings will be suggested to introduce students to the concepts of health promotion and prevention of metabolic syndrome.~Immersion. Four different learning methods will be provided: I) four hours of didactic lectures followed by group discussion, II) four hours per student of role playing, III) 30' per students of standardized patient experiences and IV) 30' per students of a new immersive advanced simulation learning environment (e-REAL). Four case-studies will be used to create scenarious, including woman with menopause weight gain, obese young adult, obese child and adult with unhealthy behaviours."
75796082|NCT02528136|Drug|Carbetocin|
75933694|NCT03252236|Behavioral|Tai Chi|Modified 12-form Yang style Tai Chi.
75933695|NCT03252236|Behavioral|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
75933696|NCT03256292|Drug|Testosterone replacement|Testosterone replacement therapy
75796083|NCT02528136|Drug|Oxytocin|
75933697|NCT03256292|Behavioral|lifestyle|lifestyle intervention consisting of diet and increased physical activity
75933698|NCT04473261|Drug|Iodine Complex|Iodine Complex capsule (200mg) will be given three times a day
75933699|NCT04473261|Drug|Iodine Complex|Iodine Complex syrup form (40ml) will be given three times a day
75933700|NCT04473261|Drug|Placebo|Empty capsule will be given as placebo
75933701|NCT04473261|Drug|Idoine Complex|Iodine Complex spray form 2 puffs will be given three times a day
75933702|NCT01358968|Drug|LY2603618|Administered intravenously as a 1-hour infusion.
75933703|NCT01358968|Drug|Desipramine|Administered orally
75933704|NCT01358968|Drug|Pemetrexed|Administered intravenously as a 10-minute infusion.
75933705|NCT01358968|Drug|Gemcitabine|Administered intravenously as a 30-minute infusion.
75933706|NCT03256214|Procedure|Closed suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
75933707|NCT03256214|Procedure|Open suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
75933708|NCT04473339|Procedure|CRS+HIPEC|"Patients will undergo only CRS, HIPEC and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
75933709|NCT04473339|Procedure|CRS alone|Patients will undergo only CRS and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.
75933710|NCT03260738|Device|Rehabilitation program with Poppy robot|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.
75933711|NCT03260738|Other|Usual rehabilitation program|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
75933712|NCT02281071|Procedure|laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe|The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
75933713|NCT05498740|Device|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
75936503|NCT02430896|Drug|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
75473739|NCT01974414|Drug|orally administered cedar honey|
75473740|NCT01974453|Radiation|Radiation dose|Radiation dose adsorbed by operators
75473741|NCT01974466|Other|Goal A|controled fluid therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
75648638|NCT00681187|Drug|lanreotide (Autogel formulation)|90 mg or 120 mg once every 28th day
75933714|NCT03260660|Device|Magnetic Resonance Elastography|The investigators plan to prospectively assess the agreement of liver stiffness measurements obtained using standard of care MR elastography techniques vs. MR elastography with varying amounts of imaging acceleration using compressed sensing in adult volunteers
75473742|NCT01974466|Other|Goal B|"controled fluid therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:~1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
75796084|NCT01252680|Biological|Healive+Healive|Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
75796085|NCT01252680|Biological|Healive+Havrix|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
75796086|NCT01252680|Biological|Havrix+Havrix|Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
75473743|NCT01974479|Biological|anti-CD19 redirected NK cells|Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
75648639|NCT05131516|Diagnostic Test|Alveolar recrutment maneuver|alveolar recruitment maneuver (30 mmHg for 30 seconds)
75648640|NCT00681109|Drug|2.5% IL-1Ra|2.5% custom made topical IL-1Ra three times a day in both eyes for three months
75796087|NCT01252680|Biological|Havrix+Healive|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
75933715|NCT02281227|Procedure|skin compression|skin compression with an indicator for determination of needle entry point
75933716|NCT03252080|Behavioral|short-term intensive education|The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.
75933717|NCT03252080|Behavioral|Holistic management|The specialist nurses talk individually with the patients for 10-15 min per week. The nurses ask the patients about their results of self-blood glucose monitoring, help them find the reasons of poor blood glucose control as well as answer the patient's questions.
75933718|NCT02281305|Drug|Colchicine|
75933719|NCT03251846|Device|Pops! One personalized mobile platform|Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
75933720|NCT00624351|Biological|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
75933721|NCT00624351|Other|Placebo|Phosphate-buffered Saline (PBS) infusion.
75933722|NCT03251690|Drug|Tenofovir/Emtricitabine/Rilpivirine|Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
75933723|NCT03251690|Drug|Tenofovir/Emtricitabine/Efavirenz|as a active comparator
75933724|NCT00620685|Drug|Placebo|Tablet, once daily for 4 weeks
75933725|NCT00620685|Drug|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
75933726|NCT00620685|Drug|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
75933727|NCT03260582|Other|LifePod®|The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
75933728|NCT05498584|Behavioral|exercise based cardiac rehabilitation|The types of exercise are treadmill walking/walking-jogging/jogging, ergometer cycling, stair climbing, or elliptical machine training. The training intensity is gradually increased fortnightly to reach the targeted Borg's rate of perceived exertion (RPE) of 12-14. The training duration is 40 minutes, which included 5-10 minutes of warm-up and cool-down exercises. The training frequency is three sessions per week, with 36 sessions concluding a complete course.
75933729|NCT03252002|Drug|BAY1101042|Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
76086552|NCT04382755|Drug|Zilucoplan®|14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®
76086553|NCT04382755|Drug|Placebo|standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
75473744|NCT01974492|Procedure|Upper leg vein harvesting|Patients whose saphenous veins are harvested from upper legs.
75648641|NCT00681109|Drug|Placebo|custom eye drop to be applied three times a day in both eyes for three months
75648642|NCT00681109|Drug|5% IL-1Ra|5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
75648643|NCT00755677|Other|Pulses|subjects consume 1 pulse food daily for eight weeks
75648644|NCT05684302|Other|The free-toroidal design lenses|Participants were asked to wear the new design lenses (the free-toroidal design lenses) for 1 week
75648645|NCT02588950|Drug|U-500R|
75648646|NCT05684224|Behavioral|Dynamic accommodation|Dynamic accommodation will be tracked using the Tobii Glasses
75473745|NCT01974492|Procedure|Lower leg vein harvesting|Patients whose saphenous veins are harvested from lower legs.
75648647|NCT02588794|Device|CytoSorb 300 ml device (3804606CE01)|additional cytokine adsorber
75648648|NCT00680407|Other|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
75338474|NCT03013049|Procedure|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
75338475|NCT03013439|Drug|Iron Isomaltoside|The trial is a dose escalating trial.
75648649|NCT00680407|Drug|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
75796088|NCT05667402|Drug|TBF regimen|The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.
75796089|NCT05667402|Drug|modified BuCY2 regimen|The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.
75648650|NCT00680407|Drug|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
75796090|NCT03910062|Procedure|Lower limb angiography via the reperfusion cannula and NIRS monitoring|Data collection only (lower limb angiography, lower limbs NIRS values).
75648651|NCT05322616|Drug|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
75796091|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 1|
75796092|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 2|
75648652|NCT05322616|Drug|Matching Placebo|Vehicle control
75648653|NCT02560519|Drug|Albumin solution|"Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.~During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision."
75648654|NCT02560519|Drug|Ringers acetate solution|"The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.~During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision."
75648655|NCT00918658|Other|biologic sample preservation procedure|All specimens will be collected using the Pathology Residual Tissue Procurement.
75648656|NCT00918658|Other|immunologic technique|Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
75796093|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 3|
75933730|NCT03252002|Drug|Placebo|Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
75933731|NCT05478928|Other|Dynamic dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point. A movement with the needle will be done at 1 Hz for 120 seconds.
75796094|NCT01252758|Other|Placebo|
75796095|NCT01252758|Drug|Albuterol|
75796096|NCT01252758|Drug|Albuterol|
75796097|NCT03913962|Other|indirect calorimetry|Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
75796098|NCT03913884|Procedure|Concentrated growth factor|CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
75796099|NCT03913884|Other|Non-Concentrated growth factor Group|To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
75338476|NCT00131456|Drug|Venlafaxine|375mg/day
75338477|NCT00131456|Drug|Placebo|Placebo
75338478|NCT05461872|Other|No intervention|No intervention
75338479|NCT01897922|Other|An investigational infant formula containing a probiotic source|
75338480|NCT01897922|Other|Control: Marketed routine infant formula|
75338481|NCT01093469|Drug|Atopiclair Nonsteroidal Cream|
75338482|NCT01093469|Other|Aquaphor Healing Ointment|
75338483|NCT01093469|Drug|EpiCeram|
75338484|NCT01045187|Radiation|brachytherapy|Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
75338485|NCT01045187|Radiation|Xoft Axxent Electronic Brachytherapy System|21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
75473746|NCT01974505|Device|intubation using optiscope|Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
75473747|NCT01974518|Drug|Rituximab and Cyclophosphamide IV|
75796100|NCT01147224|Drug|Alvesco|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
75796101|NCT03909984|Device|Nightwatch|Nocturnal monitoring for 2 months with three different seizure detection devices.
75933732|NCT05478928|Device|Fixed dose dynamic MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. A movement with the needle will be done at 1 Hz with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
75933733|NCT05478928|Other|Static Dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point for 120 seconds.
75796102|NCT03905616|Device|functional Magnetic Resonance Imaging|In a 2-hour session, the subject we be shown different control and experimental conditions (all being visual stimuli) in perceptive tasks.
75796103|NCT03910140|Procedure|TILA-TACE treatment|TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China ) that was advanced from celiac artery to common hepatic artery, proper hepatic artery, hepatic artery and ultimately to tumor feeding arteries which are defined by angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate was infused alternatively with doxorubicin-lipiodol emulsion. Finally, the artery was embolized with PVA (Embosphere®, BioSphere Medical, Paris, France) and microcoil ( Tornado ®, COOK Medical, USA).
75796104|NCT03913650|Procedure|0.25% bupivacaine|nerve block procedure will be decided by patients' will for post-op pain
75796105|NCT03905304|Biological|Medytoxin|Intramuscular injection up to 300U.
75796106|NCT03905304|Biological|Botox|Intramuscular injection up to 300U.
75796107|NCT03903510|Device|Virtual Reality (VR)|Participants in the experimental group will receive an AppliedVR virtual reality headset during their cast removal.
75796108|NCT03909906|Drug|Euphytose®|(50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
75933734|NCT05478928|Device|Fixed dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
75933735|NCT05478928|Device|Algorithm-based dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically, at 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed. Treatment will finish when the patient does not refer any discomfort for a period longer than 60 seconds. Total dose in mC will be registered.
75796109|NCT03909906|Drug|Placebo Oral Tablet|Placebo comparator
75796110|NCT05571540|Biological|U-CAR-T Cells (LstCAR019)|"LstCAR019 will be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one: 1×10^6 cells/kg;Dose level two: 2×10^6 cells/kg;Dose level three: 5×10^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of LstCAR019 at the best dose verified in the first portion."
75796111|NCT03909672|Other|Cupping Therapy|application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
75796112|NCT01149174|Drug|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
75796113|NCT01252836|Device|AWBAT-D|Application of AWBAT-D bioengineered device
75933736|NCT05478928|Other|Placebo|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly up to 3 mm deep into the upper trapezius trigger point for 120 seconds.
75796114|NCT01254084|Dietary Supplement|Gynostemma Pentaphyllum tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
75796115|NCT01254084|Dietary Supplement|Placebo tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
75796116|NCT04353778|Drug|Pyridostigmine|Eight weeks of low-dose pyridostigmine
75796117|NCT04353778|Drug|Placebos|matching placebo x 8 weeks
75933737|NCT00620451|Drug|larazotide acetate|gelatin capsule
76086554|NCT04365556|Behavioral|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
75796118|NCT04353778|Procedure|non-invasive vagal nerve stimulation|stimulation of the vagus nerve
75796119|NCT01252992|Genetic|Genetic analysis|"identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction."
75796120|NCT01252992|Radiation|Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
75796121|NCT01252992|Other|Immunologic analysis|For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
75338486|NCT02543658|Drug|Neostigmine Methylsulfate 1 MG/ML|The initial dose was 1mg, intramuscular injection(IM) once every 12 hours. If there is no defecation after 12 hours, the dose is increased to 1mg IM once every 8 hours; if there is no defecation after 24 hours, the dose is increased to 1mg IM once every 6 hours. If the abdominal pressure drops below 12mmhg, neostigmine will be stopped, otherwise it will be used continuously for 7 days.
75796122|NCT01252992|Other|QuantiferonTB Gold test|at M0, M2, M6 and in case of PR+.
75796123|NCT03903354|Other|Incidence of infections within 7 days postoperatively|Measure blood glucose concentration intraoperatively and evaluate incidence of infections 7 days after surgery
75933738|NCT00620451|Drug|placebo|gelatin capsule
75933739|NCT03255278|Biological|Single GamTBvac vaccination (0.25 dose)|Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
75933740|NCT03255278|Biological|Placebo administration|Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
75933741|NCT03255278|Biological|Double GamTBvac vaccination (0.25 dose)|Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
75936504|NCT02430896|Drug|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
76086555|NCT04356469|Biological|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
76086556|NCT04355832|Drug|Glucagon-like peptide-1|Infusion of Glucagon-like peptide-1
76086557|NCT04355832|Drug|Placebos|Infusion of normal saline solution that will mimic Glucagon-like peptide-1
76086558|NCT04330820|Drug|Venetoclax Oral Tablet|"This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I.~The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3."
76086559|NCT04322539|Drug|Fruquintinib|Oral VEGFR inhibitor
75648657|NCT00918658|Other|laboratory biomarker analysis|Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
76086560|NCT04322539|Drug|Placebo|Placebo capsule
75338487|NCT02543658|Combination Product|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
75338488|NCT01045265|Other|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
75338489|NCT00183092|Drug|Quinacrine|100mg by mouth three times a day
75648658|NCT02560441|Other|chemotherapy followed by radiotherapy|
75648659|NCT02560441|Other|radiotherapy followed by chemotherapy|
75648660|NCT02560441|Drug|IPGDP regimen chemotherapy|
75648661|NCT02560363|Drug|AZD9977 immediate release (IR) oral suspension|120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
75648662|NCT02560363|Drug|AZD9977 extended release (ER) capsules [fast]|120 mg (2 x 60mg capsules) single dose
75648663|NCT02560363|Drug|AZD9977 extended release (ER) capsules [intermediate]|120 mg (2 x 60mg capsules) single dose
75796124|NCT03903432|Other|MRI|candidates for ESS will be referred to conventional CT scans of the sinuses. If surgery is to be performed, the patients will sign an informed consent and be referred for a sinus MRI.
75796125|NCT03903276|Other|rehabilitation|Tens
75933742|NCT03255278|Biological|Double GamTBvac vaccination (0.5 dose)|Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
75933743|NCT03255278|Biological|Double GamTBvac vaccination (1.0 dose)|Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
75338490|NCT00183092|Drug|Placebo|100mg by mouth three times a day
75648664|NCT02560363|Drug|AZD9977 extended release (ER) capsules [slow]|120 mg (2 x 60mg capsules) single dose
75648665|NCT05310838|Behavioral|Behavioral Activation for First Episode Psychosis|Sessions will be offered weekly and dyads can complete the intervention during a 6-month period to accommodate competing demands encountered by the population.
75796126|NCT04711408|Device|SootheVR: AppliedVR, Los Angeles, California a head-mounted displa|"For the study group, virtual reality content will be administered to the participant for the duration of the examination through a head-mounted display, RelieVRTM. The VR content for the trial will be swimming with dolphins."
75796127|NCT01148628|Drug|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
75648666|NCT05310838|Behavioral|Treatment As Usual|Given this condition, patients may also receive individual rehabilitation and/or group psychosocial interventions as part of typical clinic care.
75648667|NCT00758329|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
75648668|NCT04007809|Other|Glucagon|Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).
75648669|NCT03878251|Device|Quantitative attention evaluation criteria in intellectual disability|Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)
75648670|NCT02589964|Dietary Supplement|Florajen-3|The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
75933744|NCT03251768|Drug|rHSA-GCSF 2.4mg|Human Serum Albumin GCSF 2.4mg at day 3 and day 7
75933745|NCT03251768|Drug|GCSF|GCSF 5 mcg/kg/day
75933746|NCT00617331|Biological|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
75933747|NCT05483374|Other|observation|Not applicable, it is an observational registry
75933748|NCT02455778|Dietary Supplement|Cinnamon|
75933749|NCT02455778|Dietary Supplement|Placebo|
76086561|NCT04307862|Drug|ZEP-3Na 0.1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
76086562|NCT04307862|Drug|ZEP-3Na 1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase, with optional 2 weeks of open label with ZEP-3Na 1%.
76086563|NCT04307862|Drug|Placebo Vehicle only|he Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
76086564|NCT04305327|Drug|Brodalumab|Solution for subcutaneous injection.
76086565|NCT04305327|Drug|Ustekinumab|Solution for subcutaneous injection.
76086566|NCT04305327|Drug|Placebo|The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.
75338491|NCT05445258|Device|InnoCath AB® hyper-compliant balloon catheter|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
75933750|NCT03260270|Diagnostic Test|color doppler ultrasound|All patients are going to be examined by color Doppler ultrasound and the high risk patients are going to be examined by direct MDCT venography .
75933751|NCT00687687|Drug|paclitaxel|Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
75933752|NCT00687687|Drug|carboplatin|Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
75796128|NCT01254708|Drug|Ambisome ®|liposomal amphotericin B
75933753|NCT00687687|Drug|BSI-201 (Iniparib)|BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
75933754|NCT04268758|Device|tulipon|Tulipon is a new kind of hygienic device, used to collect the secreted menses during the bleeding phase of the menstruation.
75933755|NCT03251534|Procedure|Centromedullary nailing|
75933756|NCT03952312|Behavioral|Oncotool Intervention (symptom reporting + TKI education)|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.
75933757|NCT03952312|Behavioral|Oncotool Control (health information)|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
75648671|NCT02589964|Other|Placebo|The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
75648672|NCT00919360|Procedure|collection of maternal blood specimen prior to delivery|approximately 5 cc. of maternal blood will be drawn prior to delivery
75796129|NCT01254708|Drug|Regular standard of care medication|Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
75796130|NCT01254786|Procedure|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio <0.3 and R.R 60 breaths/min for further 30 min."
75796131|NCT01254786|Procedure|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio <0.3 and R.R 60 breaths/min for further 30 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min"
75796132|NCT03909594|Drug|Bupivacaine|Bupivacaine
75796133|NCT03909594|Drug|Ketamine|Ketamine
75933758|NCT00685113|Drug|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
75933759|NCT00685113|Drug|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
75933760|NCT00685113|Drug|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
75933761|NCT03260114|Other|Personal Activity Intelligence|Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.
75933762|NCT05498350|Procedure|Ovulatory trigger timing|Timing of medication to induce final oocyte maturation
75933763|NCT04267900|Drug|99mTc-HPArk2|99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
75936505|NCT02425280|Behavioral|Narrative Exposure Therapy|
75648673|NCT00919360|Procedure|collection of placental cord blood after delivery|approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
75648674|NCT00919360|Procedure|collection of placental tissue|within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
75648675|NCT00919360|Procedure|collection of strip of decidua from uterine lining from cesarean section deliveries|A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
75648676|NCT04083664|Diagnostic Test|NGAL and Hepcidin|Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia
75796134|NCT04636762|Procedure|Radiation Therapy|Thoracic Radiation Dose: 3Gy, QD, total dose: 30-45Gy; Particpants with brain metastases：metastatic lesions≤3:whole brain radiotherapy with local simultaneous PGTV:50Gy/10F；metastatic lesions>3:whole brain radiotherapy PTV:30Gy/10F.
75796135|NCT03909438|Procedure|Endovascular Thrombectomy|Endovascular therapy includes direct mechanical thrombectomy or intravenous thrombolysis with mechanical thrombectomy. Endovascular Thrombectomy Device: Trepo trevor Retriever Device: SolitaireTM FR Revascularization Device
75933764|NCT02978859|Drug|MGCD516|Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
76086567|NCT04298450|Behavioral|Active SMS Intervention|Welcome message letting participant know they will be contacted to book an appointment, followed by appointment reminders and other clinic information, psychoeducational materials, and a distress check-in with two-way feedback to their care team, all sent by SMS/text message at the participant's preferred time of day. If they indicate that they are in high distress, or they request, their care provider will be notified and asked to reach out to them. They will also receive crisis resources.The intervention will continue until the patient attends the first consultation appointment, or for up to 30 days if the patient does not attend, which reflects the program's practice of closing referrals for non-attending patients.
76086568|NCT04298450|Behavioral|Sham SMS|Single welcome message letting participant know they will be contacted to book an appointment.
76086569|NCT04278144|Drug|BDC-1001|Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
76086570|NCT04278144|Drug|Nivolumab|Programmed death receptor-1 (PD 1)-blocking antibody
76086571|NCT04270422|Other|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial approach
75648677|NCT05202730|Procedure|New local anesthesia injection site and new local anesthetic drug formulation.|The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.
75648678|NCT05201950|Other|Virtual simulation|Virtual simulation using Full-Code, a virtual simulation software with a bank of emergency medicine cases
75933765|NCT04267588|Other|Navio Mobile App|Participants will use the Navio Mobile App to track participants' pain and pain treatment
75933766|NCT00615693|Drug|AEB071|
75933767|NCT00701090|Drug|sitagliptin|Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
76086572|NCT04270422|Other|Usual physiotherapy|Usual evidence based physiotherapy
76086573|NCT04257929|Drug|Pitolisant oral tablets|Pitolisant 4.45 mg or 17.8 mg tablets
76086574|NCT04257929|Drug|Placebo oral tablet|Matching placebo tablets
76086575|NCT04257695|Behavioral|TapPro|Manualized intervention administered by a clinician to facilitate opioid tapering during clinical visits.
76086576|NCT04255810|Procedure|Surgical collection of biospecimens|Systemic blood and implant capsule tissue will be collected from two cohorts with breast implants, systemic blood only will be collected from Mastopexy cohort
76086577|NCT04250116|Drug|NOAC monotherapy|Patients enrolled in the anticoagulation mono therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. In case of renal impairment, reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) or Warfarin would be considered.
75648679|NCT05201950|Other|Team based in situ simulation|In situ simulation, using a high fidelity manikin in the critical care area of the emergency department, with team members consisting of multiple junior doctors and nurses, facilitated by senior emergency medicine doctors and nurses.
75648680|NCT00677365|Drug|MP-376|3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days
75648681|NCT00677365|Drug|Placebo|same frequency as study drug using the same nebulizer
76086578|NCT04250116|Drug|Dual therapy with apixaban and clopidogrel|Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. In case of renal impairment, reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) or Warfarin would be considered.
76086579|NCT04249882|Drug|Placebo|Matched to active medication
76086580|NCT04249882|Drug|Naltrexone|50 mg once a day
76086581|NCT04249882|Drug|Varenicline|1 mg twice a day
75648682|NCT05155657|Biological|Conventional therapy plus low dose UCMSCs treatment|Patients will receive the conventional therapy plus low dose UCMSCs treatment (0.5×10^6 UCMSCs/kg body)
75648683|NCT05155657|Biological|Conventional therapy plus medium dose UCMSCs treatment|Patients will receive conventional therapy plus medium dose UCMSCs treatment (1×10^6 UCMSCs/kg body)
75796136|NCT04529980|Dietary Supplement|Lactobacillus rhamnosus GG (LGG) Probiotic|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
75796137|NCT04529980|Dietary Supplement|Placebo|Placebo
75933768|NCT00701090|Drug|Comparator: glimepiride|glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
75933769|NCT00701090|Drug|open-label metformin|open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
75933770|NCT00614601|Biological|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
75936506|NCT02425280|Behavioral|Treatment as Usual|
75936507|NCT03184844|Drug|Thalidomide|thalidomide:50mg/d p.o at bedtime
76086582|NCT04249401|Drug|Rivaroxaban (Xarelto)|NOAC, reduced dose
76086583|NCT04249401|Drug|Apixaban|NOAC, reduced dose
76086584|NCT04249401|Drug|Dabigatran|NOAC, reduced dose
76086585|NCT04249401|Drug|Warfarin|VKA
76086586|NCT04245748|Drug|Escitalopram|Escitalopram, a SSRI, commercially known as LexaproTM, is commonly prescribed for anxiety disorders and is FDA-approved for acute and maintenance treatment of MDD and GAD.
75933771|NCT03255356|Other|Survey|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
75933772|NCT02283489|Drug|recombinant human endostatin adenovirus|"Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study."
75933773|NCT02283489|Drug|Cisplatin injection|Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
75338492|NCT01045499|Device|Laparoscopic adjustable gastric banding (Allergan Lap Band)|Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
75338493|NCT00132002|Drug|vorinostat|Given PO
75338494|NCT00132002|Other|laboratory biomarker analysis|Correlative studies
75338495|NCT00183794|Drug|Docetaxel and Gemcitabine|Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
75648684|NCT05155657|Biological|Conventional therapy plus high dose UCMSCs treatment|Patients will receive conventional therapy plus high dose UCMSCs treatment (2×10^6 UCMSCs/kg body)
75648685|NCT02559193|Other|Observational study, data collection only trial.|Data collection only trial design.
75933774|NCT02283489|Drug|Paclitaxel injection|Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
75933775|NCT02455232|Procedure|upper limb muscle block|
75933776|NCT02455232|Drug|4cc of lidocaïne®|
76086587|NCT04245748|Drug|Duloxetine|Duloxetine, a SNRI, commercially known as CymbaltaTM, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults.
76086588|NCT04245436|Drug|Duloxetine|Encapsulated duloxetine 30 mg, 60 mg; once-daily
76086589|NCT04245436|Drug|Escitalopram|Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily
75338496|NCT00270296|Drug|Trizivir|300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
75338497|NCT00270296|Drug|Lamivudine/Zidovudine|150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
75648686|NCT05196958|Other|GLP1 analogues|This cohort study has 2 phases: an observation phase to collect all initial clinical and biological parameters and an intervention phase (prescription of GLP1 analogues) of 6 months including a visit at 3 and 6 months.
75796138|NCT03904992|Other|Progressive web app|Access to a progressive web app for the promotion of healthy habits in preescholers through the participant's smatphone
75796139|NCT04492072|Drug|Oxytocin|Intervention
75933777|NCT03259958|Drug|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
75933778|NCT03259958|Drug|Aricept|Aricept Tablet
75933779|NCT03251456|Other|Tertiary care|"Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders~The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines~Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
75933780|NCT03251456|Other|Usual Care|"Inform the parents that there are abnormalities after eye disease screening of their children~Inform the parents that they should take their children to the hospital for further consultation~Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
75933781|NCT00679731|Drug|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
75933782|NCT00679731|Drug|Methotrexate|5.0 to 25 mg weekly
75473748|NCT01974544|Drug|Best medical treatment|If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
75933783|NCT00605553|Drug|Placebo|"Placebo oral capsules~Placebo for 7 days"
75338498|NCT00270296|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
75338499|NCT00270296|Drug|Nevirapine|200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
75338500|NCT00270842|Behavioral|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
75796140|NCT04492072|Drug|Misoprostol|Control
75933784|NCT00605553|Drug|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
75933785|NCT00678171|Device|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
75936508|NCT02429102|Drug|MT-8554|
75936509|NCT02429102|Drug|Placebo|
75936510|NCT03185390|Procedure|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
75338501|NCT00270842|Behavioral|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
75933786|NCT02455934|Dietary Supplement|D-allulose|Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or >5 days and <12 days apart.
75796141|NCT03909516|Device|iovera°|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded. Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events. Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
75933787|NCT00507741|Drug|Vintafolide|Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
75933788|NCT00507741|Drug|Ertafolide|
75933789|NCT03251066|Other|Proponent Nasal Spray|The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
75933790|NCT00677313|Drug|metreleptin|metreleptin injection
75933791|NCT02455856|Drug|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6.
75933792|NCT02455856|Drug|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
75648687|NCT05039944|Drug|SI-B001|In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.
75933793|NCT02283645|Drug|3 % minoxidil lotion|
75933794|NCT02283645|Drug|Placebo|
75933795|NCT02283723|Other|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.
75933796|NCT02283723|Other|Usual care|While waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
75933797|NCT03259412|Dietary Supplement|Fish Oil|Fish Oil Capsule
75933798|NCT03259412|Dietary Supplement|Placebo|Olive Oil capsule manufactured to mimic fish oil capsule
75933799|NCT00602745|Drug|S-1|oral administration
75933800|NCT00602745|Drug|5-Fluorouracil|intravenous bolus
75933801|NCT03251222|Drug|Dexmedetomidine|Intranasal aplication of dexmedetomidine
75648688|NCT05039944|Drug|Irinotecan|Administration by intravenous infusion, 180 mg/m2 Q2W.
75648689|NCT05039944|Drug|FOLFIRI Protocol|FOLFIRI is administered intravenously at the standard dose recommended by the guidelines(Q2W).
75648690|NCT05039944|Drug|FOLFOX Protocol|FOLFOX is administered intravenously at the standard dose recommended by the guidelines(Q2W).
75796142|NCT03909360|Procedure|drainage tube|sub-hepatic drainage tube for laparoscopic cholecystectomy
75796144|NCT03909126|Biological|Boostrix administered during gestational diabetes screening|Boostrix administered during gestational diabetes screening
75796145|NCT03909126|Biological|Boostrix administered in high volume obstetric clinic|Boostrix administered in high volume obstetric clinic
75796146|NCT03905382|Other|Qualitative|Focus group and 1:1 telephone interviews
75648691|NCT05038462|Dietary Supplement|Lactoferrin and DHA|The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
75796147|NCT01568164|Device|PliCath HF System|This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
75796148|NCT03909048|Behavioral|Interactive - Psychoeducation|Individuals will receive interactive psychoeducation in the lab over the course of a week period. Each session will take approximately 30 minutes.
75796149|NCT03909048|Behavioral|Non-interactive Psychoeducation|Individuals will receive non-interactive psychoeducation over the course of a week period. Each session will take approximately 30 minutes.
75796150|NCT04181008|Drug|Amiloride|Amiloride Nasal Spray
75796151|NCT04181008|Drug|Amiloride|Amiloride Nasal Spray
75796152|NCT04181008|Drug|Amiloride|Amiloride Nasal Spray
75796153|NCT03902886|Diagnostic Test|gait analysis|gait analysis using an optoelectronic system and a surface EMG
75933802|NCT03251222|Other|Placebo - Concentrate|Intranasal aplication of 0.9% NaCl
75933803|NCT04487912|Drug|Tilmanocept|Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept
75338502|NCT00270842|Behavioral|Education Control group|This control group participated in 10 weeks of general health education classes.
75338503|NCT01046669|Device|TORAYMYXIN PMX-20R (PMX cartridge)|TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
75338504|NCT01046669|Other|Standard medical care for septic shock|Standard medical care for septic shock
75933804|NCT04487912|Drug|Nanocolloid|Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid
75933805|NCT04471857|Behavioral|Hypnosis|
75338505|NCT01047527|Drug|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
75338506|NCT03013127|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy.
75338507|NCT01047839|Biological|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
75796154|NCT01254162|Drug|MTC896 Gel|0.75% w/w gel applied daily for 28 days to the forehead
75338508|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
75796155|NCT04396132|Diagnostic Test|Subjective Visual Vertical with Virtual SVV instrument|The deviation angle will be measured with 15, 30 and 45-degree head tilt to the left and right side while they are standing
75933806|NCT04471389|Other|Incidence and risk factors of hypertension|During the follow-up period, General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc). Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness, IMT, FMD) will be collected.
75933807|NCT02281461|Device|Male circumcision using a non-surgical device|Male Circumcision
75933808|NCT04487600|Other|Active voiding trial|
75933809|NCT02281539|Device|Neuromotus|
75338509|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
75338510|NCT01048697|Drug|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
75338511|NCT01049243|Drug|Fluocinonide Cream 0.1%|0.1% Cream, One Application, Twice Daily, 14 Days
75338512|NCT03013205|Procedure|Intraarticular triamcinolone injection|triamcinolone 10mg/mL
75796156|NCT03902730|Other|Traditional Back Squat|Participants will complete traditional back squat in this four treatment crossover design.
75796157|NCT03902730|Other|Barefoot Back Squat|Participants will complete barefoot back squat in this four treatment crossover design.
75796158|NCT03902730|Other|Box Squat|Participants will complete box squat in this four treatment crossover design.
75796159|NCT03902730|Other|Traditional Back Squat with Chains|Participants will complete traditional back squat with chains in this four treatment crossover design.
75796160|NCT03632278|Behavioral|Mindfulness psychoeducation Programme|"A MBPP will be conducted for 2 hours for each session, one a week for eight weeks. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien & Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).~The programme will be integration of mindfulness and psychoeducation to cultivate the client's mindfulness attitude. The clients will learn to apply the mindfulness in illness management and daily difficulties."
75796161|NCT03902496|Other|HIT-6 Questionnaire|Headache Impact Test
75796162|NCT03902496|Device|Avulux Spectacles|Avulux™ Optical Filter in the Form of Spectacle Lenses
75933810|NCT03250910|Drug|Sofosbuvir and Velpatasvir|All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
75933811|NCT03250910|Drug|Ribavirin|Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
75338513|NCT03013205|Procedure|Intraarticular Xylocaine injection|Xylocaine 1% 4ml
75338514|NCT03013205|Procedure|Coracohumeral ligament triamcinolone injection|triamcinolone 10mg/mL
75338515|NCT03013205|Procedure|Physiotherapy|
75338516|NCT03013283|Other|self questionnaire|"Interface side effects and degree of satisfaction of the patients~Technician evaluation and device measures."
75338517|NCT01094717|Drug|Acitretin 25Mg Oral Capsule|Acitretin 25 mg oral daily for 12 weeks
75338518|NCT01094717|Device|Excimer laser|Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.
75338519|NCT01094717|Drug|Tazarotene 0.1% Gel,Top|Topical tazarotene 0.1% gel was applied daily to active lesions.
75338520|NCT01094717|Device|Sham excimer laser|Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
75338521|NCT01095497|Biological|CINRYZE|C1 esterase inhibitor (human)
75933812|NCT02283801|Drug|Eslicarbazepine acetate|
75933813|NCT02283801|Drug|Lamotrigine|
75933814|NCT02455154|Drug|Letrozole|Letrozole endocrine therapy for 2.5mg qd po.
75933815|NCT02455154|Drug|Zhongyaofufang|Traditional Chinese Medicine for patients with Osteoporosis
75933816|NCT02455154|Drug|Xianlinggubao|Traditional Chinese Medicine for patients with Osteoporosis
75933817|NCT00502515|Drug|SSR180575|Oral, once daily dosing
75933818|NCT00502515|Drug|Placebo|Oral, once daily dosing
75933819|NCT03254810|Biological|SYN060|a single subcutaneous 0.57 mg/kg dose of SYN060
75933820|NCT03254810|Biological|Adalimumab North American source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
75933821|NCT03254810|Biological|Adalimumab European source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
75933822|NCT00501735|Drug|Forodesine 200 mg|2 x 100mg tablets once daily
75796163|NCT03902496|Device|Sham Spectacles|Sham
75796164|NCT03908658|Other|Inspiratory muscle Training and Nasal High Flow|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght
75796165|NCT03908658|Device|Inspiratory muscle training and Venturi mask|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
75933823|NCT03255122|Behavioral|I-CALM|Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, & Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.
76086590|NCT04241848|Device|Keeogo|A new and novel type of robotic-device (Keeogo, B-temia, Inc.) was developed to provide powered assistance at the knee for persons with stroke. This device provides assistance for both knee extension and knee flexion during ambulation, transfers to standing and sitting, in addition to ascending and descending stairs. As this device isn't able to fully control the movement, it requires the ability of the patient to stand and initiate stepping. The approach the Keeogo uses to monitor the desired movement in order to appropriately provide assistance. This promotes intuitive learning for the user, minimizing the amount of instruction and practice needed to effectively ambulate allowing users to independently ambulate within one session. This device does not restrict leg movement, so the user can side-step and walk backwards. However, it does not provide assistance during these movements.
75648692|NCT05038462|Other|Placebo|Product with the same physical appearance and taste as the main intervention but without therapeutic effect
75933824|NCT03255122|Behavioral|Delayed I-CALM|Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
75796166|NCT03904836|Drug|Tobramycin|5 milligrams per kilogram intravenous for one dose
75796167|NCT03908580|Drug|Meditoxin|Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
75796168|NCT01254240|Device|UVA / UVB phototherapy|UVA / UVB phototherapy
75796169|NCT01254240|Device|UVB phototherapy|UVB phototherapy
75933825|NCT03255044|Drug|Atorvastatin|Atorvastatin administered as well as standard heart failure therapy
75933826|NCT03255044|Drug|Rosuvastatin|Rosuvastatin administered as well as standard heart failure therapy
75933827|NCT03255044|Other|guideline directed therapy|standard heart failure therapy
75933828|NCT00499239|Drug|GS-9219|"GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.~GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days."
75933829|NCT03246464|Device|Orthokeratology lenses|Rigid gas permeable contact lenses
75933830|NCT03246464|Device|Single-vision spectacles|Regular single vision spectacles
75933831|NCT02281617|Behavioral|Smart-device apps as memory aids|Patients will be taught to use software running on smartphones and smart tablets to help compensate for memory difficulties
75933832|NCT02454998|Other|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
76086591|NCT04241848|Other|Ambulation training|Ambulation training will consist of mobility activities affecting daily life including: walking; squatting (or getting in and out of a chair); bending, kneeling or stooping (for picking an item up off of the floor); and ascending and descending stairs. Sessions will be monitored and tailored to the individual, based on their functional ability and to ensure their safety.
75933833|NCT00677079|Drug|Iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
75338522|NCT05308121|Other|Evaluation of biomechanics and viscoelastic properties of Achilles tendon|The biomechanical and viscoelastic properties of the Achilles tendon will be measured in the side lying position. Measurements will be taken from three different points with the ankle in the neutral position.
75338523|NCT05308043|Diagnostic Test|Deep learning algorism|A deep learning algorism that was developed previous would be applied to identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. The decision of two different senior ophthalmologists would be the gold standard.
75933834|NCT03250988|Diagnostic Test|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
75933835|NCT03245996|Device|AAI 40 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study
75933836|NCT03245996|Device|AAI 60 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study
75648693|NCT03719131|Drug|Nivolumab|Receive standard of care nivolumab therapy
75648694|NCT03719131|Biological|Rituximab and Hyaluronidase Human|Given IV or SC
75648695|NCT03719131|Drug|Ipilimumab|Receive standard of care ipilimumab therapy
75648696|NCT05684458|Procedure|Reiki|Reiki, a non-invasive, free and safe complementary therapy method, is practiced with a series of hand positions held on the patient's body to help balance the life force energy.
75796170|NCT05340400|Other|ROME IV Criteria|Collaborators will use Rome IV criteria for diagnosing IBS by the presence of the abdominal pain at least once a week in the last 3 months, in addition to at least two of the following: abdominal pain related to defecation, change in stool frequency, or shape.
75796171|NCT03904680|Drug|Methotrexate|Methotrexate 2.5 mg tablet
75796172|NCT03904680|Drug|Vitamin D|Vitamin D 200,000 IU ampules
76086592|NCT04241419|Behavioral|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
75338524|NCT01095887|Drug|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
75338525|NCT01096823|Behavioral|Iyengar Yoga|Iyengar Yoga classes twice a week for six weeks
75648697|NCT00921739|Radiation|Esophageal sparing IMRT|6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
75648698|NCT04083352|Dietary Supplement|Pruvit Ketomax Ketone Salt|6-week supplementation with ketone salts
75648699|NCT04083352|Dietary Supplement|Placebo|Placebo was taken for 6-weeks and was calorie and flavor matched to the ketone salt supplement.
75648700|NCT05435599|Diagnostic Test|Serum regucalcin level|During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
75933837|NCT03245996|Device|AAI 90 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study
75933838|NCT03245996|Drug|Atenolol Pill|50 or 100 mg of atenolol is administered to subjects in the second part of the study
75933839|NCT03245996|Drug|Nebivolol Pill|5 mg of nebivolol is administered to subjects in the second part of the study
76086593|NCT04233970|Behavioral|web-based intervention programme|"The intervention will be designed as an individualized, dialogue-based system that will provide PwMS coordinated, individually tailored information based on the software platform broca®. The intervention programme will consist of three sections:~EBPI/decision aid (five modules plus decision aid in case of an acute relapse) provided by the broca® programme. The key element of the EBPI/decision aid is the information on glucocorticosteroids for the treatment of acute relapses.~A webinar led via WebEx by a trained MS nurse with questioning/chat session (approx. 60-75min).~A supervised chat room provided via the DMSG (https://www.dmsg.de/ms-connect). In addition, email reminders will be used to enhance involvement of participants."
75796173|NCT04426396|Diagnostic Test|FFR|FFR measured by pressure wire, CT-FFR computed by coronary CT angiography
75796174|NCT01150266|Drug|Alteplase (tPA)|0.9mg/KG (maximum 90mg), 10% bolus over one minutes, remainder over one hour.
75796175|NCT01256268|Drug|Ridaforolimus|Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.
75796176|NCT01256268|Drug|Paclitaxel|Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.
75796177|NCT01256268|Drug|carboplatin|Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
75338526|NCT03110315|Drug|Suvorexant|See detailed information in associated Arm Description.
75338527|NCT03110315|Drug|Placebo|Sugar pill manufactured to mimic suvorexant 10 mg tablet.
75338528|NCT02983487|Procedure|Nasopharyngeal sampling|Nasopharyngeal sample by aspiration or swabbing
75338529|NCT02983487|Procedure|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
75338530|NCT03013595|Behavioral|TRAM feedback|
75338531|NCT05307341|Drug|sufentanil|One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
75338532|NCT02912351|Other|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
75338533|NCT01099475|Procedure|Pringle manoeuvre 15 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 2-times 15 minutes with 5 minutes reperfusion
75338534|NCT01099475|Procedure|Pringle manoeuvre 30 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 30 minutes with 5 minutes reperfusion
75648701|NCT05435521|Behavioral|Personalized multicomponent exercise program (strength, resistance, balance, and flexibility) (PMEP)|"Physical activity expert will design for each participant a personalized exercise program according to baseline situation and previous physical activity. Both will be measured prior to initiation of activity program. Each participant is free to perform physical activity program at his house, outdoor or in a gym as long as it fulfills the prespecified requirements. Exercise programs will be acquired a more personalized shape during the course of the study.~In order to motivate participants, personal motivational messages will be sent each week through mail contact or using WhatsApp Social Media.~Physical activity will be registered in an activity wristband delivered to each participant at baseline evaluation."
75648702|NCT05435521|Other|Body composition|Analyze the effects of PMEP on body composition in each evaluation using an impedance threshold device
75796178|NCT01256346|Device|Apparatuses|Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
75796179|NCT01149252|Other|Psoralait|Cream to be used as instructed.
75796180|NCT01149252|Other|Placebo cream.|Cream to be used as instructed
75796181|NCT01255020|Drug|α-Keto Acid with restricted protein diet|"α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d"
75933840|NCT03245996|Drug|Ivabradine Pill|5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
75648703|NCT05435521|Other|Musculoskeletal and visceral Ultrasound|Quadriceps muscle ultrasound (US) of the rectus femoris measured in each evaluation in order to analyze the effects of PMEP Visceral fat will be analyzed in each visit
75796182|NCT01255020|Drug|Placebo plus restricted protein diet|"placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d."
75796183|NCT01148706|Device|ActiSight Needle Guidance System|The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
75796184|NCT01148784|Procedure|ACL reconstruction|Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
75796185|NCT03902106|Drug|salbutamol|subjects ingest salbutamol
75933841|NCT05209503|Other|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio > 0.80, then no PCI revascularization of target blood vessels will be carried out.
75933842|NCT05209503|Other|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
75933843|NCT03254966|Drug|SHR0302|Oral tablets
75933844|NCT03254966|Drug|Placebo|Oral tablets
75933845|NCT03786484|Drug|PBF-999|Phosphodiesterase 10 inhibitor (PDE10i)
75933846|NCT02281929|Drug|Amoxicillin|Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
75933847|NCT02281929|Drug|Placebo|Placebo in three daily doses during 30 days
75933848|NCT02281929|Drug|Prednisolone|Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
75933849|NCT03254498|Device|Endocuff|It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
75933850|NCT03254498|Device|cap assisted colonoscopy (CAC)|cap assisted colonoscopy (CAC)
75933851|NCT02283879|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
75933852|NCT04424056|Drug|Anakinra +/- Ruxolitinib (stages 2b/3)|administration of Anakinra +/- ruxolitinib, depending of evolution
75933853|NCT04424056|Drug|Anakinra and Ruxolitinib (Advanced stage 3)|administration of Anakinra and ruxolitinib
75933854|NCT04424056|Drug|Tocilizumab +/- ruxolitinib (stages 2b/3)|administration of Tocilizumab +/- ruxolitinib, depending of evolution
75933855|NCT04424056|Drug|Tocilizumab and Ruxolitinib (Advanced stage 3)|administration of Tocilizumab and Ruxolitinib
75933856|NCT04424056|Other|Standard of care|Treatment with drugs or procedures in routine clinical practice
75933857|NCT02454374|Procedure|Knee Loading protocol|The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
75933858|NCT02454374|Procedure|Routine Physiotherapy Care|Routine Physiotherapy Care
75933859|NCT03250442|Device|PrevenaTM Device|The PrevenaTM Incision Management System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision.
75933860|NCT03250442|Other|Standard Dry Dressing|These are customary dry dressings.
75933861|NCT00497757|Biological|enriched hematopoetic stem cell infusion|Enriched Hematopoetic Stem Cell Infusion
75933862|NCT05478772|Drug|CTP-543|12 mg on Day 1 and Day 7
75796186|NCT03902106|Other|exercise|subjects undergo 6 weeks of endurance training (3 times weekly)
75933863|NCT05478772|Drug|Fluconazole|200 mg once daily on Days 3 through to Day 8
75933864|NCT02945852|Drug|apatinib|apatinib 500mg/d until progressive Disease
75933865|NCT03245684|Diagnostic Test|assessment of inflammatory response during PSV|assessment cytokines level in BAL and plasma
75933866|NCT00672009|Drug|Ixabepilone|Ixabepilone 35 mg/m^2 intravenously over 3 hours every 21 days for 4 cycles.
75796187|NCT03902340|Device|ActiTENS|ActiTENS is a rechargeable box, weighing 64g attached by Velcro to an adhesive support, which can be positioned on the skin at any position chosen by the patient. The patient will use the programme (P4) prescribed by his doctor and will regulate the intensity of stimulation using an application downloaded to his smartphone which will communicate with the box via Bluetooth.
75933867|NCT03245528|Drug|LJPC-501|angiotensin II
75933868|NCT00495885|Drug|volinanserin (M100907)|oral, one tablet taken around bedtime
75933869|NCT00495885|Drug|Placebo|oral, one tablet taken around bedtime
75933870|NCT03245606|Procedure|Liver biopsy|Measurement of liver fibrosis
75933871|NCT03245606|Device|Abdominal MRI|Measurement of liver fibrosis
75933872|NCT03245606|Device|Transient elastography|Measurement of liver fibrosis
75933873|NCT00592995|Drug|Creatine monohydrate|10 to 30 grams daily
75933874|NCT00592995|Drug|Placebo|10 to 30 grams daily
75933875|NCT03254030|Other|Colonic inspection|Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
75933876|NCT03254186|Drug|Propranolol Hydrochloride|Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
75933877|NCT03254186|Drug|Placebo Oral Tablet|Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
75933878|NCT04272424|Procedure|laparoscopic mesh fixation|laparoscopic mesh fixation by non fixation,tacker and histoacryl
75933879|NCT03250598|Drug|AG-348|50 mg single-dose
75933880|NCT03250598|Drug|AG-348|5 mg single-dose
75933881|NCT03250598|Drug|AG-348|200 mg single-dose
75796188|NCT03902340|Drug|Level 2 Analgesic Treatments|"There are 4 level 2 oral analgesic treatments indicated for chronic nociceptive pain of moderate to severe intensity (between 4 and 7 on a simple numerical scale of 11 points) (12):~Tramadol immediate release formulation (IR, one intake every 6 hours) or prolonged release formulation (PR, one intake every 12 hours); maximum posology 400mg/24h.~Dihydrocodeine: 60mg every 12 hours; maximum posology 120mg/24h.~Combination of paracetamol and codeine in a fixed combination every 6 hours; maximum posology of codeine: 300mg/24h.~Combination of paracetamol and tramadol in a fixed combination; maximum posology of tramadol: 8 tablets/24h ie 300mg/24h."
76086594|NCT04233970|Behavioral|web-based information material offered via the same platform (broca®) in addition to usual care|Participants in the control group will have access to web-based information material offered via the same platform (broca®) in addition to usual care. The control group intervention will be based on material of the German Multiple Sclerosis Society (DMSG) on relapse management. The programme will accompany the participants over a period of 4 weeks and a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
75338535|NCT01099631|Biological|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10^5, Level 2 = 10^6, Level 3 = 10^7, Level 4 = 10^8, Level 5 = 10^9, Level 6 = 10^10.
75338536|NCT05307029|Procedure|rehabilitation with fixed full-arch prosthesis|
75338537|NCT01100255|Drug|Ketamine infusion|0.5mg/kg IV over 40 minutes
75796189|NCT01149330|Drug|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
75796190|NCT03901872|Device|Contemporary endovascular venous intervention by Zelante pharmacomechanical thrombolysis|All patients will undergo ultrasound guided micro puncture venous access of the enrolled ipsilateral lower extremity popliteal vein followed by a diagnostic venogram to define thrombus burden and anatomic extent of DVT. Prior to and every 30 minutes during the endovascular procedure, an activated clotting time (ACT) will be obtained. Intravenous unfractionated heparin will be administered to keep the ACT between 250 - 300. A Zelante catheter will be utilised to perform pharmacomechanical thrombolysis of the enrolled lower extremity. If there is involvement of the popliteal and/or femoral vein, pharmacomechanical thrombolysis should also be performed of these veins. Venous stenting may be implemented to address areas of residual venous stenosis or outflow obstruction following pharmacomechanical thrombolysis. Stent placement in the common iliac, external iliac, and common femoral vein are routinely done to address inflow or outflow issues after pharmacomechanical thrombolysis.
75933882|NCT02282085|Drug|Aripiprazole Once-Monthly|
75933883|NCT02282085|Drug|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
75933884|NCT05482984|Other|video-recorded role-play and guided reflection|The experimental group was divided into 6 teams. Before the course, the teacher in charge and each group developed six scenarios: restraint, suicidal intent, respiratory distress, chronic heart failure, medication refusal, and accidental amputation. The researcher guided each group to write scripts about the clinical situations (30 minutes), create role-play videos (50 minutes), and share literature that was helpful in understanding this context (30 minutes). Each student played a role in the filming process. The final film was viewed by all the students during class. Each live class session was 50 minutes in length, with one session per week for 6 weeks. All students were asked to attend six video-viewing sessions and participate in a reflective discussion.
75933885|NCT05475496|Other|Measurements of quality of life and burnout|"WHOQOL-Bref questionnaire to assess the health related quality of life of the elderly cardiac patients. WHOQOL-Bref assesses Physical health (7 items), Psychological health (6 items), Social relationships (3 items) and the environment ( 8 items ), in addition to two items asking about overall perception of life and general health. Items are rated on a 5 point ordinal scale, domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life).~Maslach Burnout Inventory questionnaire to measure burnout among caregivers, it includes 3 components: emotional exhaustion (9 items), depersonalization(5items) and personal accomplishment(8 items)."
76086595|NCT04221997|Drug|sertraline|Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)
76086596|NCT04208919|Biological|Donor-derived DCreg|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to the start of immunosuppression weaning.
76086597|NCT04202003|Drug|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
76086598|NCT04194554|Drug|Niraparib|given PO per dose escalation schedule
76086599|NCT04194554|Drug|Leuprolide|22.5 mg q3 month
75338538|NCT01100255|Other|Saline|saline infusion
75338539|NCT03012347|Drug|BAY987517|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
75473749|NCT01974544|Procedure|gastric bypass|For the gastric bypass, the gastric pouch will be adjusted to a volume of 15-20 ml. The alimentary limb will be a standard 150 cm and the biliopancreatic limb 50 cm. A hand-sewn gastro-jejunal anastomosis will be performed over a 34 French bougie
75473750|NCT01974544|Procedure|sleeve gastrectomy|The sleeve gastrectomy will be done using laparoscopic staplers over a 34 French bougie.The greater curvature will be dissected 4 cm proximal to the pylorus leaving the antrum. Short gastric vessels will be dissected using the harmonic scalpel up to the gastro-esophageal junction. The stapler will be reinforced. The resected stomach will be removed in a plastic bag through the left flank trocar
75473751|NCT01974544|Drug|General interventions for all groups: blood presure|Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
76086600|NCT04194554|Drug|Abiraterone Acetate|1000 mg daily
76086601|NCT04194554|Radiation|Stereotactic body radiotherapy (SBRT)|5-6 fraction SBRT (total dose: 37.5-40 Gy)
76086602|NCT04193605|Behavioral|Mindfulness|The traditional MBSR intervention consists of the following: (1) a series of eight weekly session of 2.5 to 3 hours; (2) a silent retreat during the sixth week; (3) daily home assignments including formal and informal mindfulness practices; and (4) didactic presentations on stress and the consequences of stress. We are culturally tailoring the intervention with the goal of maintain fidelity.
76086603|NCT04191889|Combination Product|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets~Procedure:~On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on day 8 in the first HAIC cycle, once a day, for continuous medication.~The first dose of Camrelizumab was administered on day 4 of the second HAIC cycle, at a dose of 200 mg intravenously, every three weeks.~The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
76086604|NCT04181255|Drug|Curosurf|This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
75796191|NCT02527980|Other|No intervention: observation only|For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.
75338540|NCT03012347|Drug|BullFrog Gel Sunscreen Land Sport SPF-50|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
75338541|NCT03012737|Device|Trilogy 100 ® (Philips Respironics)|Trilogy 100 ® (Philips Respironics) on MPV mode.
75796192|NCT01568242|Device|Phacoemlsification|Transurgical measurement of temperature
75338542|NCT01100723|Other|Cinacalcet, active vitamin D analogue|Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
75933886|NCT00671073|Drug|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
75933887|NCT00671073|Drug|Placebo|Placebo, oral administration, once daily for 12 weeks
75933888|NCT00671073|Drug|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
75933889|NCT00671073|Drug|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
76086605|NCT04181255|Drug|Sham|This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
76086606|NCT04170894|Other|Periods of Apnea|Periods of apnea throughout atrial fibrillation ablation.
76086607|NCT04170894|Other|Control Arm - No Periods of Apnea|Standard of care atrial fibrillation ablation.
75648704|NCT05118022|Other|Artificial Intelligence identified Dyskalemia using Electrocardiogram (AIDE) system|Once the AIDE indicates high risk of dyskalemia, an obvious message by scarlet letter was appeared in the HIS operation interface to corresponding physicians. To avoid the alert fatigue, we selected the cut-off points with expected positive predictive values of ≥40% according to previous data, which was the consensus of enrolled physicians before the trial considering the clinical loading. The physicians received the AIDE alerts as long as they were operating HIS logged in by their account, even if they were caring other patients. Physicians can review the AIDE predictions of patients in the intervention group. Therefore, this was a single-blind study since HIS presented different information for patients in intervention and control groups. The participated physicians understood the likelihood of dyskalemia and cardiac risk for those patients with ECG-dyskalemia, and provided suitable medical care according to patients' conditions.
75648705|NCT00680017|Drug|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
75648706|NCT00680017|Drug|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
75648707|NCT04083040|Procedure|transcatheter aortic valve implantation|"Tilt angle.~Depth of implantation of the valve.~Type of the valve.(Medtronic core valve self expandable valve ,Edwards sapient balloon expandable valve"
75933890|NCT03245216|Behavioral|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
75933891|NCT03245216|Behavioral|rest|Seated rest before motor learning
75933892|NCT03245216|Behavioral|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
75933893|NCT03245294|Procedure|lumbar epidural injection|the pattern of pressure decrease from ligamentum flavum to epidural space
75933894|NCT04471467|Procedure|Fixed tracheal tube|Tracheal tube fixation is determined by the surgeon according to the needs of the operation and is an independent process. Our research simply installed a monitoring device between the tube and the nose. The tube fixation takes place whether the observation of pressures is agreed to or not, as per standard protocol.
76086608|NCT04169737|Drug|Acalabrutinib|Given PO
76086609|NCT04169737|Biological|Obinutuzumab|Given IV
76086610|NCT04169737|Drug|Venetoclax|Given PO
75933895|NCT03250754|Device|Electroacupuncture|Needles on the extremities were stimulated by electro-stimulation device applied by a biphasic pulse generator apparatus at a frequency of pulses alternated between 2 Hz and 100 Hz and the maximum tolerable intensity.
75933896|NCT03245060|Behavioral|Adapted Solution Focused Brief Therapy|Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
75648708|NCT05029570|Device|Conduction System Pacing (pacemaker implantation)|Conduction System Pacing (pacemaker implantation) and Atrioventricular node ablation
75648709|NCT00919516|Procedure|Bone marrow mononuclear cell implantation|Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
75648710|NCT05024500|Other|ARDSNet table|The setting of the lowest PEEP level and FiO2 match stated by the table to achieve a goal oxygenation.
75933897|NCT03250364|Device|Multilayer bandage|See arm/group descriptions
76086611|NCT04165291|Behavioral|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
76086612|NCT04165291|Behavioral|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
76086613|NCT04153760|Drug|Aspirin 81 mg|Aspirin 81 mg p.o. daily
76086614|NCT04153760|Drug|Placebo|Placebo p.o. daily
76086615|NCT04128709|Device|Urodynamics Testing|The non-invasive device connects to the end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device the patient presses a single button in order to obtain a pressure measurement which is recorded and stored in the device along with the time and date. The measurement(s) can later be transmitted wirelessly to a smart phone that contains an app for the device.
76086616|NCT04125862|Diagnostic Test|MRI-based Neuroimaging|During evoked pain fMRI, noxious pressure and heat stimuli will be applied in the two anatomical sites noted above. During fMRI data acquisition, a total of 5 pressure stimulations and 5 heat stimulations will be delivered. Both types of pain stimuli will be applied in a 36/17-sec off/on cycle. The off-condition will correspond to a baseline temperature of 35C and the on condition will match the subject-specific and site-specific 7/10 pressure and heat pain thresholds defined during QST procedures. VAS pain ratings associated with evoked pain stimulation will be collected at the end of each scan. The investigators will also explore the structural properties of the CNS by implementing high-resolution anatomical MRI (gray matter volumes) and diffusion tensor imaging (white matter pathway integrity). All CNS imaging will take approximately 50-60 minutes to complete
75648711|NCT05024500|Other|Driving Pressure|The setting of the lowest PEEP level by the lowest correspondent driving pressure, which is defined by the difference of plateau pressure, after a modified alveolar recruitment maneuver.
75648712|NCT05024500|Other|Electrical Impedance Tomography|The setting of the PEEP level above the intersection of the curves representing relative alveolar overdistention and collapse, after a modified alveolar recruitment maneuver.
75648713|NCT02589262|Drug|AUT00206|
75648714|NCT00676663|Drug|entinostat|Entinostat 5 mg tablet orally once per week
75648715|NCT00676663|Drug|exemestane|Exemestane 25 mg tablet orally once daily
75648716|NCT00676663|Drug|Placebo|Placebo-matching entinostat tablet orally once per week
75933898|NCT03250364|Device|Double compression bandage|See arm/group descriptions
75648717|NCT02559583|Other|Chronic Lymphocytic Leukemia (CLL)|This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.
75648718|NCT02559583|Other|Multiple Myeloma (MM)|This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.
75648719|NCT02559583|Other|Non-Hodgkin's lymphoma (NHL)|This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
75933899|NCT03250364|Device|Cohesive bandage|See arm/group descriptions
75933900|NCT03250364|Device|Adhesive compression bandage|See arm/group descriptions
75933901|NCT03250364|Device|Kinesiotaping bandage|See arm/group descriptions
75933902|NCT03250364|Other|Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression|"MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg."
75933903|NCT03250364|Other|Upper limb exercises|After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
75933904|NCT03250364|Behavioral|Educational strategy|Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
75933905|NCT03245138|Procedure|Endoscopic Third Ventriculostomy|patients receive an endoscopic third ventriculotomy as surgical procedure
75933906|NCT03245138|Procedure|Ventriculo-Peritoneal Shunting|patients receive an ventriculo-peritoneal shunt as surgical procedure
75933907|NCT03244982|Drug|Fluorescein Na 10% Inj 500mg|Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
75933908|NCT03244982|Drug|Fluorescein Na 10% Inj 250mg|Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
75338543|NCT01101971|Other|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
75933909|NCT03250286|Device|EUS|"Endoscopic ultrasound (EUS) is performed with radial scanning echo endoscope (Olympus GF UE260) by four endosonographers.~EUS examination is performed first, and if there is choledocholith, ERCP is performed."
75933910|NCT03250286|Device|ERCP|"Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP."
75933911|NCT03244748|Procedure|Ventricular tachycardia ablation|Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
75933912|NCT04487366|Other|reaching targeted area on the phantom model|resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution
75933913|NCT03253640|Other|Exposure|Healthcare associated infection (HAI)
75648720|NCT03590041|Behavioral|Standardized SMA|Patients receiving the Standardized SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, delivered only by health educators. The Standardized SMA approach will be uniformly administered at each practice. Topics will be covered in a predetermined order and patients will not have a say in terms of what content they wish to cover. Patients receive the Standardized SMA approach if their practice is randomly assigned to the Standardized SMA arm. Practices are cluster-randomized to deliver a standardized or patient-driven group visit model.
75648721|NCT03590041|Behavioral|Patient-driven SMA|Patients receiving the Patient-driven SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, but patients are in control of time spent and order of the topics. The Patient-driven SMA will be delivered by a multidisciplinary team consisting of a Health Educator, medical provider, Behavioral Health Professional, and a diabetes peer mentor. Patient-driven SMAs may be delivered differently at each practice, as patients choose the topics that are most important to spend the most time on. All topics will be covered, but the order and time spent is up to the group. Patients receive the Patient-driven SMA approach if their practice is randomly assigned to that arm. Practices are cluster-randomized to deliver a standardized or patient-driven SMA model.
75796193|NCT03898518|Other|12-week jump rope exercise program|Each jump rope exercise session of the program was performed for 50 minute, with a 5 minute warm-up and cool-down. Sessions were performed once a day, 5 days a week, for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool-down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased form 40-50% heart rate reserve (HRR) in weeks 1-4 and 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Ever subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
75933914|NCT03250208|Dietary Supplement|Probiotic|Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
75933915|NCT03250208|Other|Placebo|Participants randomized to the control group will receive a placebo containing no active ingredients
75933916|NCT03253484|Radiation|NAFL-treatment|non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
75933917|NCT03244670|Other|Observation study only, no specific intervention|Observation study only, no specific intervention
75933918|NCT03250130|Behavioral|hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
75933919|NCT03249974|Device|Enlite sensor communicating with Minimed 640G pump|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
76086617|NCT04125862|Diagnostic Test|Non-contrast MRI|Musculoskeletal imaging of the affected lower extremity. Patients will be allowed to watch a movie during data acquisition. The following MRI procedures will be completed in order to identify soft tissue lesions in active or painful regions. Fast spin echo (FSE) T2 fat saturated, T1 weighted MRI, FSE proton density MRI, Short-TI Inversion Recovery (STIR), Diffusion weighted MRI (DW-MRI) and 3D Double Echo Steady State (DESS) will be collected. All musculoskeletal MRI will take approximately 30 minutes to complete.
75796194|NCT01150344|Drug|Malarone (atovaquone + proguanil combination)|4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
75796195|NCT01150344|Drug|RIAMET (artemether + LUMEFANTRIN combination)|4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
75796196|NCT02865070|Device|Skin Sensor|Wireless vitals monitor
75933920|NCT03244592|Drug|Minocycline|200 mg/day
75933921|NCT03244592|Drug|Sugar pill|Matched placebo
75933922|NCT03244514|Other|Intervention|Implementation of the cardiovascular AKI bundle (see arm description)
75933923|NCT03253328|Drug|Active Arm N-acetyl cysteine (NAC)|N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
75933924|NCT03253328|Drug|Placebo Arm|Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
75933925|NCT03253874|Behavioral|No Pre-Op Testing for Cataract Surgeries|Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
75796197|NCT01150422|Other|Alternative follow-up|After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
75933926|NCT03253406|Behavioral|Polar M400 + Facebook Group (PM400+FG)|Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
76086618|NCT04125862|Diagnostic Test|18F-FDG-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-FDG with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be ~3-4 mSv.
76086619|NCT04125862|Diagnostic Test|18F-NaF-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-NaF with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be ~3-4 mSv.
75796198|NCT05759884|Drug|Anti-VEGF|Intravitreous injection of anti-VEGF drugs
75796199|NCT05759884|Radiation|subthreshold micropulse laser|577nm micropulse laser photocoagulation therapy
75796200|NCT01150578|Drug|No intervention|No intervention
75933927|NCT03253406|Behavioral|Facebook Only Group (FG)|Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
75933928|NCT03253250|Drug|ETV；TDF；ADV|NAs
75338544|NCT05306405|Drug|Vaginal Tablet|"Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score >8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score < 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation"
75338545|NCT03012893|Device|Ultrasound sagittal scan|Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
75796201|NCT05759806|Device|Nephronyx system (Perfuser)|Temporary deployment of the Nephronyx system (Perfuser)
75796202|NCT01256580|Drug|Bevacizumab (Avastin; Genentech, Inc.)|1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
75796203|NCT01256580|Drug|Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy|Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
75796204|NCT03901794|Device|Non-invasive hemodynamic monitor|MAP, HR, CO, SVI, from Non-invasive hemodynamic monitor
75796205|NCT02658136|Other|Cardiac Computed tomography|
75796206|NCT03901716|Drug|Sufentanil|Patients in Group S received sufentanil 0.1 mcg/kg.
75796207|NCT03901716|Drug|Fentanyl|Patients in Group F received fentanyl 1 mcg/kg.
75933929|NCT03253250|Drug|Peginterferon Alfa-2a|peginterferon
75933930|NCT03253562|Drug|Metformin Pill|a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
75648722|NCT02589028|Dietary Supplement|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
75648723|NCT02589028|Other|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
75648724|NCT02559427|Other|3-week immediate SPA treatment|a comprehensive program soon after randomization including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
75796208|NCT03901716|Drug|Remifentanil|Patients in Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml.
75796209|NCT03901716|Drug|Midazolam|Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
75796210|NCT04113538|Drug|Aflibercept|Intraocular injection of 2 ml (40mg/ml)
75796211|NCT03904368|Procedure|Open myomectomy|laparotomy then enucleation of the myoma followed by closure of the myometrial cavity
75796212|NCT03904368|Drug|Gonadotropins|Gonadotropin stimulation of follicular growth
75933931|NCT03253562|Drug|Vildagliptin 50 mg|Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
75933932|NCT03244280|Drug|MOB015B|Topical formulation
75933933|NCT03244436|Procedure|Surgery following catheterization|Emergency surgery following pediatric cardiac catheterization
75933934|NCT03249818|Device|HITT device|Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
75796213|NCT03904368|Drug|Human chorionic gonadotropin|HCG triggering of ovulation
75933935|NCT03249896|Behavioral|Habits-GDM mobile app|The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
75473752|NCT01974544|Drug|General interventions for all groups: dysilipidemia|Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration >4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (>4.0 mmol/L).
75648725|NCT02559427|Other|3-week late SPA treatment|a comprehensive program after 4.5 months, including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
75648726|NCT02560207|Drug|Cefotaxime|To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.
75648727|NCT02559661|Other|Training on a virtual simulator in eye surgery|
75796214|NCT03904368|Procedure|Ovum pick up|34 to 36 hours after HCG triggering
75796215|NCT03904368|Procedure|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
75796216|NCT03898206|Other|Breaking up sitting with walking breaks|See Breaking up sitting with walking breaks arm description
75933936|NCT03253016|Diagnostic Test|vaginal swab -microbiome test and blood test for cytokines|vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
75933937|NCT03250052|Drug|(fimasartan or linagliptin) x 7days|Part A: fimasartan, Part B: linagliptin
75933938|NCT03250052|Drug|(fimasartan and linagliptin) x 7days|Part A & Part B: Co-administration of fimasartan and linagliptin
75933939|NCT02455310|Behavioral|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
75933940|NCT05478382|Drug|Pregabalin 25 MG|Patients are given 0 to 3 capsules per administration according to their allocated group.
75933941|NCT05478382|Drug|Placebo|Patients are given 0 to 3 capsules per administration according to their allocated group.
75933942|NCT03244358|Drug|Epalrestat|Epalrestat 50mg tid added to standard chemotherapy treatment
76086620|NCT04125017|Device|ICSI with laser pulse|Using laser pulse before ICSI
76086621|NCT04125017|Device|ICSI with micro needle technique|Using micro needle technique before ICSI
76086622|NCT04124341|Device|Prefrontal Cortical Stimulation (PCS)|Prior to surgery, subjects will undergo a high resolution structural scan to identify anatomical landmarks for rostral anterior and lateral prefrontal cortex. Following identification of target areas, PCS quad leads will be projected over the anterior and lateral prefrontal cortex. Subjects will be kept in the hospital for a minimum of 72 hours for observation during which the investigators will obtain a high resolution spiral CT scan without contrast to confirm lead placements post-operatively and rule out any intra-cranial bleeds. Patients will receive analgesics which they may continue as an outpatient on as needed basis. During this 2-3 weeks recovery period, the attention to pain control and mood is critical. The research team will contact patients at least twice per week to check on their status.
76086623|NCT04099342|Device|FEAST|FEAST with standard electrode configuration and current flow
76086624|NCT04099342|Device|FEAST RP|FEAST with standard electrode configuration and reversed current flow
75648728|NCT00678691|Drug|armodafinil|50-250mg/d
75796217|NCT03898206|Other|Prolonged sitting|See Prolonged sitting arm description
75796218|NCT01150656|Genetic|gene expression analysis|
75796219|NCT01150656|Genetic|microarray analysis|
75796220|NCT01150656|Genetic|protein expression analysis|
75796221|NCT01150656|Genetic|reverse transcriptase-polymerase chain reaction|
75796222|NCT01150656|Genetic|western blotting|
75796223|NCT01150656|Other|laboratory biomarker analysis|
75796224|NCT01150656|Other|pharmacological study|
75796225|NCT03922750|Drug|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
76086625|NCT04097717|Behavioral|"My Decision tubal sterilization decision aid"|"The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization."
75648729|NCT00678691|Drug|placebo|matching placebo
75648730|NCT05103046|Drug|UCT-03-008|Orally available kinase inhibitor
75648731|NCT05003752|Radiation|External beam radiation therapy, High-dose-rate brachytherapy|Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)
75796226|NCT03922750|Drug|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine OD for 16 weeks
75796227|NCT03903978|Behavioral|Cognitive Behavioral Therapy|"The training protocol consists of 6 weekly modules:~0.Welcome:Introduction module to the program, with an explanation about the tools and the way to use CORE~Psychoeducation: Explanation of psychological wellbeing and the concept of resilience~Autonomy, building my way: Enhancement of autonomy~Mindfulness and self-compassion:Training in mindfulness, savoring, and an attitude of self-compassion~Overcoming obstacles: Development of coping strategies to deal with daily difficulties in life~Connecting to others:Acknowledge the relevance of relationships and how they can be helpful in the construction of well-being~Purpose in life and personal growth:Approach the future with a positive attitude, planning goals for the future."
75473753|NCT01974544|Behavioral|General interventions for all groups: lifestyle|Exercise is an important part of the diabetes management plan. The ADA recommendations for the adults with diabetes is at least 150 min/week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate), with no more than two consecutive days without exercise. A kinesiologist will design an individual plan of physical training for each patient. Also, a nutritionist will be design an individual dietitian plan, this plan should be formulated as a collaborative therapeutic alliance among the patient and family, physician, and other members of the health care team.
75648732|NCT05003752|Drug|Goserelin 10.8 mg|Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
75796228|NCT03903978|Behavioral|Healthy lifestyle|"Beginning of a lifestyle change The patient will learn to identify healthy and risky behaviors and recognize obstacles that prevent them from adopting a healthy lifestyle.~Physical activity The importance of moving on and activating behavior will be taught through regular exercise information to improve mood.~Diet This module is dedicated to teaching the importance of diet for good physical and mental health. The Mediterranean diet will be taken as an example for a balanced and balanced diet, because it does not differ from the habits of other countries.~Sleep The importance of good sleep will be addressed with information and strategies for understanding the relationship between sleep and overall health."
76086626|NCT04097717|Other|Usual Care|Usual medical care will vary among participants.
76086627|NCT04094688|Drug|Bevacizumab|Given IV
75338546|NCT03012893|Device|Ultrasound transverse scan|Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
75473754|NCT01974557|Other|Exercise|
75648733|NCT04997980|Drug|Amiodarone Injection|
75648734|NCT02588014|Other|Magnetoencephalography|Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
75648735|NCT05683912|Drug|Aflibercept|Intravitreal aflibercept as used in the routice clinical practice
75796229|NCT03898128|Drug|Anti-CD22 Immunotoxin|Clinical data (treatment, survival, adverse events) of patients treated with anti-CD22 immunoconjugates from 2014 will be collected
75796230|NCT03628768|Other|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
75796231|NCT03897894|Behavioral|Child Friendly Space|Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
75796232|NCT01150812|Drug|AZD8165|Oral suspension, 2 mg/mL and 20 mg/mL, single doses
75796233|NCT01149408|Drug|Decitabine (Dacogen)|Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
76086628|NCT04094688|Drug|Oxaliplatin|Given IV
76086629|NCT04094688|Drug|Leucovorin Calcium|Given IV
75648736|NCT00679939|Drug|Rosiglitazone|up to 8mg/day
75936511|NCT03185312|Diagnostic Test|skin biopsy|"Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression."
75936512|NCT02425202|Drug|Ketamine|Post-operative continuous infusion until 0600 the next day
76086630|NCT04094688|Drug|Fluorouracil|Given IV
76086631|NCT04094688|Drug|Irinotecan Hydrochloride|Given IV
76086632|NCT04094688|Drug|Irinotecan|Given IV
75648737|NCT00679939|Drug|Metformin|up to 2000mg/day
76086633|NCT04094688|Dietary Supplement|Cholecalciferol|Given PO
76086634|NCT04094688|Other|Quality-of-Life Assessment|Ancillary studies
76086635|NCT04094688|Other|Questionnaire Administration|Ancillary studies
76086636|NCT04085094|Dietary Supplement|high-salt diet (V1) and low salt diet (V2)|Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
75338547|NCT03012893|Procedure|Fluoroscopic technique|C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
75338548|NCT04352621|Drug|intranasal ketamine|Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
75648738|NCT04082260|Drug|Alemtuzumab Injection [Lemtrada]|"Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days."
75648739|NCT02587390|Drug|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
75473755|NCT01974570|Dietary Supplement|Marealis refined peptide concentrate|2 tablets, once per day before noon
75648740|NCT02587390|Drug|Simvastatin 80 mg|2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
75648741|NCT00919828|Device|Avivo System|Non invasive external monitoring device
75648742|NCT00760903|Other|Conventional MRI of the brain|
75648743|NCT00760903|Other|MR spectroscopy (MRS)|
76086637|NCT04085094|Diagnostic Test|Contrast-enhanced ultrasound (CEUS)|Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
76086638|NCT04085094|Diagnostic Test|functional MRI|Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
75648744|NCT00760903|Other|MR Diffusion Tensor Imaging (DTI)|
75338549|NCT04352621|Device|rTMS treatment|patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
75338550|NCT02246855|Biological|Gammaplex® (Human Normal Immunoglobulin)|
75648745|NCT00760981|Drug|Imatinib|The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.
75648746|NCT00919906|Device|My Scrivener(R)|Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
75648747|NCT00761059|Drug|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
75648748|NCT00761059|Drug|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
75648749|NCT02588716|Drug|Terlipressin|Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.
75648750|NCT02588716|Drug|normal saline|Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
75648751|NCT00673933|Drug|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
75648752|NCT00761449|Drug|lenalidomide|Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
75648753|NCT04968106|Drug|Doxorubicin|Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
75648754|NCT04968106|Drug|Ifosfamide|Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
75648755|NCT04968106|Drug|INCMGA00012|Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
75648756|NCT00919594|Behavioral|Interpersonal Psychotherapy for Mothers (IPT-MOMS)|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
75648757|NCT00919594|Behavioral|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
75648758|NCT04957966|Behavioral|self-selected relaxing music|20 minutes music listening
75648759|NCT00919438|Device|AVIVO™ Mobile Patient Management System|Non Invasive monitoring device
75796234|NCT01255176|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
75796235|NCT01568398|Drug|TAK-438|
75796236|NCT03631966|Drug|Dysport|BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s). Total dose per leg will be 400 units, 200 per injection site. Injections will be performed with the aid of real-time ultrasound (Sonosite, Bothwell, WA) guidance.
75648760|NCT04082182|Biological|Dendritic cell immunotherapy|Intravenous infusions of MIDRIX4-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
75648761|NCT04082182|Biological|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIX4-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
75796237|NCT03904212|Procedure|Adipose tissue injection|Injection with freshly harvested autologous adipose tissue
75796238|NCT03904212|Procedure|saline|injection with saline
75936513|NCT02425202|Other|Saline infusion|Post-operative continuous infusion until 0600 the next day
75338551|NCT05272397|Drug|Methylphenidate 20 Mg Oral Tablet|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
75338552|NCT05272397|Drug|Placebo|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
75338553|NCT05272397|Behavioral|Language Task|The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
75338554|NCT05272397|Behavioral|Rest Recording|Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
75473756|NCT01974570|Dietary Supplement|Placebo|2 tablets, once per day before noon
75338555|NCT05272397|Behavioral|Go/No-Go Task|A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall & Smith (2011) will be employed.
75473757|NCT01974583|Procedure|regrafted with thin split-thickness skin graft|Group A (the treatment group) were regrafted with thin split-thickness skin graft
75473758|NCT01974583|Procedure|covered with the occlusive hydrocellular dressing|group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
75933943|NCT05482750|Other|Resistance training in the fasted state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
76086639|NCT04085094|Other|Pilocarpine test|Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
75796239|NCT03901326|Diagnostic Test|CT-FFR|When subjects are randomized to the CTA/CT-FFR arm, FFR based on the coronary CTA imaging will be measured. DeepFFR workstation is very dedicated software utilizing the original CTA imaging to meter simulated FFR values in artificial intelligence model.The first step is to extract a 3D coronary artery model and generate coronary centerlines which are similar to the routine reconstruction of coronary CTA. The centerlines are extracted using a minimal path extraction filter. Then a novel path-based deep learning model, referred to DeepFFR, is used to predict the simulated FFR values on the vascular centerlines. Deep learning algorithm is used to establish characteristic sample database of coronary hemodynamics characteristic parameters. When deep training model is proved to be valid, it is applied to a new lesion-specific measurement. Lesion-specific CT-FFR is defined as simulated FFR value 2-3cm downstream of an interest lesion.
75338556|NCT05272397|Behavioral|Processing Speed|A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
75648762|NCT04082182|Biological|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
75648763|NCT00571519|Drug|Rivoglitazone HCl|0.5 mg tablets administered orally, once daily
75648764|NCT00571519|Drug|rivoglitazone HCl|1.0 mg tablets administered orally, once daily
75648765|NCT00571519|Drug|rivoglitazone HCl|1.5 mg tablets administered orally, once daily
75648766|NCT00571519|Drug|placebo|placebo tablets matching rivoglitazone tablets administered orally, once daily
75473759|NCT01974583|Procedure|covered with paraffin gauze|Group C covered with paraffin gauze
75648767|NCT00571519|Drug|pioglitazone HCl|15 mg capsules administered orally, once daily
76086640|NCT04082312|Other|No intervention|No intervention
76086641|NCT04081805|Procedure|LASER|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
76086642|NCT04081805|Procedure|Micro Ablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
76086643|NCT04081805|Drug|Promestriene|The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
75648768|NCT00571519|Drug|pioglitazone HCl|30 mg capsules administered orally, once daily
75648769|NCT00571519|Drug|pioglitazone HCl 45 mg|45 mg capsules administered orally, once daily
75648770|NCT00571519|Drug|placebo|placebo capsules for pioglitazone administered orally, once daily
75648771|NCT00571519|Drug|metformin|Oral tablets. Rescue medication.
75648772|NCT02588404|Drug|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
75648773|NCT00761839|Behavioral|After-care summary|"The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals."
75648774|NCT00761839|Behavioral|Control group|Patients in the control group will receive usual counseling for self-management.
75648775|NCT00761917|Device|Tear Film Analyzer|tear film images
75473760|NCT01974596|Dietary Supplement|Probiotic tablets of Lactobacillus reuteri|
75473761|NCT01974596|Dietary Supplement|Placebo tablets|
75473762|NCT01974622|Drug|Visudyne|Half fluence verteporfin
75473763|NCT01974648|Drug|propofol|
75648776|NCT02587702|Other|β-Palmitate Content|
75648777|NCT02587702|Other|Placebo|
75648778|NCT02587702|Other|β-Palmitate Content Naturely in Human Milk|
75933944|NCT05482750|Other|Resistance training in the fed state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
76086644|NCT04075656|Behavioral|Standard of Care|Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.
75933945|NCT03249740|Drug|GB-102|Intravitreal injection of GB-102
76086645|NCT04075656|Behavioral|UrApp|Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
75933946|NCT03249740|Drug|Aflibercept|Intravitreal injection of Aflibercept.
76086646|NCT04070534|Other|PALS|patient activated learning system
76086647|NCT04068922|Behavioral|Resilience Intervention|Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
76086648|NCT04066517|Procedure|SBRT|Multimodal-imaging guided SBRT for VT ablation.
75473764|NCT01974648|Drug|propofol and remifentanil|
75473765|NCT01974661|Biological|COMBIG-DC (ilixadencel)|Allogenic dendrite-cell based therapeutic vaccine
75648779|NCT02558647|Behavioral|CBT for insomnia (CBT-I)|CBT-I is an online, fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
75648780|NCT02558647|Behavioral|Psycho-Education about Sleep (PE)|PE provides online information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
75933947|NCT05478226|Other|drugs or BPA|PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
75933948|NCT03057977|Drug|Empagliflozin|once daily
75933949|NCT03057977|Drug|Placebo|once daily
75648781|NCT00919672|Device|Sacral nerve stimulation|The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
75933950|NCT03244046|Behavioral|Psychotherapy|The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
76086649|NCT04051866|Procedure|Non-surgical periodontal treatment: Scaling and root planing (SRP)|Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.
75648782|NCT00761995|Drug|Azopt|topical eye drop dosed 1 drop 3 times daily
75648783|NCT00761995|Drug|Cosopt|topical eye drop dosed 1 drop 2 times daily
75648784|NCT00762151|Other|Negative Control (Regular Toothpaste)|Regular Toothpaste
75648785|NCT00762151|Other|Positive Control (anti-plaque/anti-bacterial toothpaste)|Standard anti-plaque and anti-bacterial toothpaste
75648786|NCT00762151|Drug|Prototype (AN0128 Toothpaste)|AN0128 Toothpaste
75648787|NCT02558413|Drug|BTA-C585 oral capsules|BTA-C585; Single ascending doses from 50 mg to 800 mg
76086650|NCT04051866|Other|Oral hygiene instructions|Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
76086651|NCT04045379|Procedure|LASER|Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
75473766|NCT01974674|Procedure|Allogeneic transplantation of intrahepatic islet|
75648788|NCT02558413|Drug|BTA-C585 matching placebo|Single ascending doses to match 50 to 800 mg BTA-C585 capsules
75648789|NCT04082026|Behavioral|Early Adolescent Skills for Emotions EASE)|"EASE is conducted in 7 weekly group sessions with adolescents. EASE sessions help adolescents:~Identify their feelings and body reactions~Practice breathing exercises~Get active: Make a plan to positively change their actions~Manage their problems"
75796240|NCT03897972|Behavioral|Non-personalised diet advice delivered via the eNutri app (control)|Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).
75648790|NCT02559037|Device|Acupuncture and moxibustion|"Acupuncture acupoints: CV12, bilateral ST36, ST37, SP6, SP9, SP4, LR3 and LI3. Disposable acupuncture auxiliary device and 0.30*40mm or 0.30*25mm acupuncture needles (hwato, suzhou medical supplies factory co., LTD.) were used. The needles were directly inserted 20-30mm into the skin and elicited a de-qi sensation. The needle was kept for 30 min.~Moxibustion acupoints: bilateral ST25 and ST36. Using mild-warm moxibustion, The surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint. Moxibustion and acupuncture were performed at the same time, once every other day, three times a week, a total of 12 weeks of treatment. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
75338557|NCT05272397|Behavioral|Operation Span|In the operation span task, participants are instructed to solve math operations (e.g., (1*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
75796241|NCT03897972|Behavioral|Personalised diet advice delivered via the eNutri app (intervention)|Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
75648791|NCT02559037|Device|Sham acupuncture and moxibustion|"The acupoints used are same to the experimental group. Same disposable acupuncture auxiliary device and 0.35 * 40mm acupuncture needle (flat and blunt needle tip, Hwato, Suzhou Medical Supplies Factory Co., Ltd.) was selected. When the needle was pricked to the acupoint, it did not penetrating into the skin. The subject only felt slight pain and do not have the de-qi sensation.~Sham moxibustion : by using the same moxa stick, The surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint. Sham acupuncture and sham moxibustion were performed at the same time. They were treated once every other day, three times a week, a total of 12 weeks. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
75648792|NCT00921973|Biological|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
75648793|NCT00921973|Biological|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
75648794|NCT00676195|Drug|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
75796242|NCT01149018|Drug|Tetrahydrocannabinol|Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
75933951|NCT03244046|Behavioral|Physiotherapy|This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
75933952|NCT05482594|Diagnostic Test|ELISA|During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.
75933953|NCT05482594|Diagnostic Test|Videocapillaroscopy|Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.
75933954|NCT03252782|Device|Herbst Appliance|Acrylic Splint Herbst Appliance
75933955|NCT03252782|Device|Distal Jet Appliance|Anterior Median Palate Implant Borne Distal Jet Appliance
75933956|NCT03249506|Drug|Canagliflozin|Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
75933957|NCT03249506|Drug|Empagliflozin|Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
75933958|NCT03249506|Drug|Dapagliflozin|Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
75933959|NCT03249506|Drug|Dipeptidyl Peptidase-4 Inhibitor (DPP-4)|Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
75933960|NCT03249506|Drug|Glucagon-Like Peptide-1 Agonist (GLP-1)|Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
75933961|NCT03249506|Drug|Thiazolidinedione (TZD)|Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
75933962|NCT03249506|Drug|Sulfonylureas|Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
75796243|NCT01149018|Drug|Placebo|Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
75933963|NCT03249506|Drug|Insulin|Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
75933964|NCT03252860|Other|Observation of compliance with the World Health Organisation Surgical Safety Checklist|Observation of use and compliance with the surgical safety checklist and associated perioperative surgical outcomes
75933965|NCT03244202|Other|Decision Aid Plus Counselling|The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
75338558|NCT05272397|Behavioral|Reading Span|Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
75338559|NCT05272397|Behavioral|Barratt Impulsiveness Scale|The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
75796244|NCT03903900|Behavioral|Lifestyle-oriented Occupational Therapy added to current treatment of chronic non-malignant pain|The participants are recruited from the outpatient cohort admitted at The Multidisciplinary Pain Center (MPC) at Naestved Hospital (Zealand Region, Denmark). The participants receive both, the current treatment based on Cognitive Behavioural Therapy (CBT) and delivered by physicians, nurses, physical therapists and a social worker as usual care, and a lifestyle-oriented Occupational Therapy intervention. The Occupational Therapy intervention targets meaningful daily occupations, physical activity, and eating habits and routines. The intervention is delivered by graduated occupational therapists once á week during the 15 weeks after the initial 5-weeks compulsory psychoeducation course at the MPC. The intervention contains in-person contacts with OTs every other week (e.g. two 1-hour individual sessions at the hospital and/ or at-home and five 2-hours group sessions) and seven phone consultations in the opposite weeks.
75338560|NCT00481403|Behavioral|Microarray analysis|Microarray analysis
75338561|NCT00481403|Behavioral|Microarray|Microarray
75338562|NCT01127087|Drug|Oxazyme|"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
75796245|NCT03901248|Other|No Intervention|Observational study
75473767|NCT01974726|Other|ET Stress test|Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
75648795|NCT02558959|Drug|Irinotecan|
75648796|NCT02558959|Drug|Capecitabine|
75648797|NCT02558881|Procedure|Virtual colonoscopy|
75648798|NCT02558881|Procedure|Colon capsule|
75648799|NCT05067010|Other|Detailed ophthalmologic examination|"Visual acuity~Eye pressure measurement~Eye crystalline examination~Fundus examination~Optical coherence tomography of the retina~Retinophotos"
75796246|NCT03900936|Diagnostic Test|Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
75933966|NCT03244202|Other|Genetic Counselling Only|Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
75933967|NCT03249662|Procedure|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
75933968|NCT03249662|Drug|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
75933969|NCT02454062|Drug|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
75648800|NCT02674945|Device|Wireless Activity tracker: Fitbit|Patients will wear a Fitbit flex
75648801|NCT02558725|Drug|two capsules of aktiferrin F|two capsules of Aktiferrin F or Foliferrin
75648802|NCT04801732|Other|mulligan thoracic Sustained Natural Apophyseal Glides|"Extension Thoracic Sustained Natural Apophyseal Glides :~Patient position: The patient sits astride the end of the table with hands placed behind the neck to protract the scapulae allowing access to the mid thoracic spine for the therapist's hand.~Therapist position: Therapist stands on their most efficient side for a centrally applied Sustained Natural Apophyseal Glides.~Therapist grasp: The therapist's mobilizing hand (ulnar border) will apply a cephalad glide in line with the facet joint plane of the involved spinal level and the other arm holds the thoracic wall above the level to be mobilized.~Traction is applied prior to glide, which is achieved by therapist knee extension~Repetitions: Three sets of ten repetitions will be done after a trial for the patient to be familial with the technique.~and traditional treatment."
75933970|NCT02454062|Drug|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
75933971|NCT03239444|Device|Intracardiac echocardiography imaging|Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
75933972|NCT03239366|Other|BioK+ 100% probiotic|The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
75933973|NCT03239366|Other|Placebo|The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
75933974|NCT03239288|Other|Control digestible carbohydrate|Single serving of control product
75933975|NCT03239288|Other|Test resistant starch type 4|Single serving of test product
75933976|NCT03249428|Device|Improved Quality of Life of low-income Canadians that smoke tobacco and other substances|Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
76086652|NCT04045379|Procedure|Microablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
76086653|NCT04045379|Drug|Estriol|The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
75473768|NCT01974726|Other|Sonotubometry|Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
75648803|NCT04801732|Other|traditional treatments|"includes: Ice pack and Pendulum exercise and shoulder range of motion (elevation, depression, flexion, abduction, rotations).Stretching exercise for internal rotators and posterior capsule.~Strengthening exercise will be isometric in nature include external shoulder rotators, internal rotators, biceps, deltoid, and scapular stabilizers (rhomboids, trapezius, serratus anterior, Latissimus Dorsi , and pectoralis major muscles)."
75648804|NCT04082962|Drug|Dexamethasone intravitreal implant|Ozurdex™ is an intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR® solid polymer drug delivery system (NOVADUR™ system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix, which slowly degrades to lactic acid and glycolic acid.). Ozurdex™ is preservative-free. It is supplied in a foil pouch with a single-use plastic applicator.
75648805|NCT00675103|Drug|pegloticase 8 mg i.v.|pegloticase 8 mg i.v. every 2 weeks for 24 weeks
75648806|NCT02471833|Drug|Telmisartan 20mg|Participants will be given 20 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
75796247|NCT03904056|Procedure|ISQ-RP|"Patients were treated with single-spot targeted retinal photocoagulation directed toward areas of retinal nonperfusion detected by fluorescein angiography. In this group, laser treatment was performed in two sessions (week 0 and 2), with a shot duration of 100 ms, but spots were placed 1/2 burn apart and power modulated in order to generate moderately white spots on the retina.~Retinal photocoagulation was performed with single-spot full-scatter PRP using Purepoint green diode laser (Alcon, Fortworth, Texas) with an Ocular Mainster PRP 165 lens with a dynamic field of view of 180 degrees, and a 200 micron spot size (which produces a 392 micron spot size on the retina). Intravitreal injection of 0.5 mg (0.05 ml) ranibizumab (Lucentis®) (IVR) were performed 180 minutes after the first laser session (week 0) by a single retina specialist."
75796248|NCT03904056|Procedure|ETDRS-PRP group|Panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab
75796249|NCT01256736|Drug|Tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
75796250|NCT01256736|Drug|DMARDs|DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
75796251|NCT03903588|Device|Optical Coherence Tomography|Imaging of the Retina
75933977|NCT05213975|Device|Kinesio tape|Kinesio taping
75933978|NCT03243812|Biological|Blood sampling|Blood sampling will be performed to assess hematological and hemorheological parameters
75933979|NCT03243812|Other|Maximum Voluntary Contraction (MVC) test force|Maximum Voluntary Contraction (MVC) test force will be performed before and after a localized muscle endurance test
75933980|NCT03243812|Other|Localized muscle endurance test|Subject will perform 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
76086654|NCT04045067|Procedure|Isolation of pulmonary veins|Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
76086655|NCT04045067|Procedure|Ablation by radiofrequency of low-voltage areas|The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
76086656|NCT04039789|Behavioral|Project active legs|Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
76086657|NCT04039789|Procedure|Usual care|Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
76086658|NCT04031521|Diagnostic Test|Near infrared spectroscopy|NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
75796252|NCT01256814|Behavioral|SystemCHANGE-HIV|SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
75933981|NCT03243812|Other|Self-paced six-minute walk test|Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society
75933982|NCT05751161|Other|conventional gait training|The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
75933983|NCT03243500|Drug|Atracurium|5mg in 1 ml normal saline
75933984|NCT03243500|Drug|Lidocaine 2%|
75933985|NCT03243500|Drug|Bupivacaine 0.5%|
75933986|NCT03243500|Drug|hyaluronidase powder|1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
75933987|NCT03243500|Procedure|per-caruncular peribulbar injection|The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
75933988|NCT00941915|Radiation|SBRT Prostate|Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
75933989|NCT02454218|Device|Transcranial Direct Current Stimulation|"The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions."
75933990|NCT03243578|Other|None as this is an observational study|
75933991|NCT05213819|Other|Carpal Tunnel Syndrome|
75933992|NCT03238898|Drug|Botulinum toxin type A|"botulinum toxin type A injections~Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
75933993|NCT03238898|Other|Normal saline|"Normal saline injections~The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
75933994|NCT03249194|Drug|Direct acting Anti-Viral Therapy using Epclusa or Zepatier|All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
75473769|NCT01974726|Other|Forced Response Test (FRT)|The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
75473770|NCT01974726|Other|Inflation Deflation Test (IDT)|The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
75933995|NCT03062891|Procedure|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
75933996|NCT04486508|Drug|intermediate dose Enoxaparin/ unfractionated heparin|Intermediate dose anticoagulation according to creatinine clearance and weight
75933997|NCT04486508|Drug|standard prophylactic dose Enoxaparin/ unfractionated heparin|Standard prophylaxis anticoagulation according to creatinine clearance and weight
75933998|NCT04486508|Drug|Atorvastatin 20mg|Statin
75933999|NCT04486508|Drug|Matched placebo|Matched placebo to atorvastatin 20 mg
75934000|NCT03243266|Diagnostic Test|CBC/Diff Reference Interval|Results will not be used to manage patients
76086659|NCT04018651|Behavioral|PrEP Master Adherence Intervention|"The PrEP Master Adherence Intervention consists of 4 face to face individual education sessions and a series of telephone contacts to identify barriers and facilitators to optimal PrEP adherence over a six-month period. Each PrEP Master education session includes a review of an individualized plan to reduce risk, review of information about PrEP, and different discussion points. Key messages include:~Importance of daily adherence;~Three week delay for full effectiveness describing PrEP like taking the birth control pill;~Condom use for other sexually transmitted infection (STI) prevention;~Pregnancy prevention plans;~Plans for follow up calls~Referral to other treatment services if necessary"
76086660|NCT04015167|Device|T2 Alpha Tibia Nailing System|The T2 Alpha Tibia Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
75473771|NCT01974726|Other|Maneuver Sequence|The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
75648807|NCT02471833|Drug|Telmisartan 40mg|Participants will be given 40 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
75934001|NCT02552212|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringe~Concentration: 200 mg / ml~Route of Administration: Subcutaneous injection"
75648808|NCT02471833|Drug|Placebo|Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.
75648809|NCT05680168|Device|Extracorporeal electromagnetic stimulation|Electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia).
75648810|NCT05680168|Behavioral|Pelvic floor exercises|Pelvic floor muscle training in serial training sessions with our therapist
75648811|NCT04895410|Biological|Lemzoparlimab|Intravenous (IV) infusion
75648812|NCT04895410|Drug|Dexamethasone|Oral tablet or IV infusion/injection
75648813|NCT04895410|Drug|Carfilzomib|IV infusion
75934002|NCT02552212|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Prefilled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous injection"
75934003|NCT02454764|Drug|Tenofovir + Interferon alpha 2b|
75934004|NCT02454764|Drug|Tenofovir disoproxil Fumarate|
75648814|NCT04895410|Drug|Pomalidomide|Oral capsule
75648815|NCT04895410|Biological|Daratumumab|Subcutaneous (SC) injection
75648816|NCT00675025|Drug|Donepezil hydrochloride (Aricept)|Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
75648817|NCT01772329|Other|Cognitive Therapy|CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.
75648818|NCT01772329|Other|Routine Care|Routine Care. No Cognitive Therapy Intervention
75648819|NCT04049461|Diagnostic Test|Bone alkaline phosphatase|Hematologic indicators reflecting ossification.
75648820|NCT04049461|Radiation|Abdominal CT scan|Observe whether HOAI occurs.
75648821|NCT02587624|Procedure|catheter ablation|Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
75648822|NCT01275313|Device|Lightweight wheelchair|Seating and wheeled mobility assessment and fitting of a lightweight wheelchair
75648823|NCT01275313|Device|Skin Protection Cushion|Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
75648824|NCT00758407|Drug|Methylphenidate hydrochloride|sustained release, dosage according to an individual titration schedule
75648825|NCT00758407|Drug|Placebo|dosage according to an individual titration schedule
75648826|NCT02587078|Drug|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
75648827|NCT02587078|Drug|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
75934005|NCT03243188|Other|Qualitative interview|Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
75934006|NCT00685919|Drug|Carbidopa|200 mg every 6 hours for 5 doses given orally
75934007|NCT00685919|Drug|Placebo|every 6 hours for 5 doses, given orally, and matching Carbidopa
75934008|NCT03243344|Device|Surgiflo|using device during the endonasal surgery.
75934009|NCT03243344|Device|Floseal|using device during the endonasal surgery.
75934010|NCT03243344|Device|Algosteril|using device during the endonasal surgery.
75936514|NCT02425124|Behavioral|PC101+Mental Health|Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
75936515|NCT03185468|Genetic|4SCAR-PSMA|PSMA-specific 4th Generation CART
76086661|NCT04015154|Device|Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
76086662|NCT04006613|Other|Circuit Training|20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.
75338563|NCT00271154|Device|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
75338564|NCT00136214|Diagnostic Test|MR brain and neuropsychiatric tests|
75934011|NCT03243110|Diagnostic Test|breathing test|Spirometry is a non-invasive means of measuring lung function: The participant is asked to take a deep breath and then exhale into the sensor as hard and as long as possible. Soft nose clips may be used to prevent air escaping through the nose. If the participant does not show a definitive diagnosis of asthma, a methacholine challenge test will be performed to elicit bronchoconstriction in participants. In methacholine challenge test, the participant breaths in standardized dose of nebulized methacholine again. Methacholine challenge test is widely accepted and standardized method for assisting the diagnosis of asthma and there will be no experimental altercation in the method methacholine challenge is performed.
75648828|NCT00758641|Device|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
75648829|NCT00758641|Drug|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
75648830|NCT02587546|Procedure|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
75934012|NCT03238820|Procedure|Robotic gastric gastrointestinal stromal tumors resection|Robotic gastric gastrointestinal stromal tumors resection
75934013|NCT03239054|Behavioral|Physical activity|pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
75934014|NCT03239054|Behavioral|Control group|Information will be given as part of standard care
75934015|NCT03238742|Drug|Xuebijing Injection|100ml Xuebijing Injection every 12 hours for 5 days
75934016|NCT03238742|Drug|normal saline|200ml normal saline every 12 hours for 5 days
75648831|NCT02587546|Procedure|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
75796253|NCT03897660|Dietary Supplement|Omega-3 + vitamin K2 (TG form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
75796254|NCT03897660|Dietary Supplement|Omega-3 + vitamin K2 (EE form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
75934017|NCT05478148|Device|Gingival thickness|After the classification the phenotype, gingival thickness was measured with Endodontic File and Modified Florida Probe from the 3 different points. First point was the probing depth level, second one was 1mm apical to this level and third one from the 2mm apical to probing depth.
75934018|NCT03243032|Drug|Ibuprofen 600 mg|Ibuprofen 600mg given 30 minutes prior to beginning of surgery
75934019|NCT03243032|Drug|Local anesthetic Group 1|0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.
75934020|NCT03243032|Drug|Placebo oral capsule|Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
75934021|NCT03243032|Drug|Local anesthetic Control|2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
75934022|NCT05478070|Device|Dexcom G6|Continuous glucose monitor
76086663|NCT04006613|Other|Usual Care|Exercises aimed at improving mobility and balance
76086664|NCT04002115|Drug|Clofarabine|"Clofarabine to be administered pre-stem cell transplant infusion (Day 0) once a day for 5 days total."
76086665|NCT04002115|Drug|Fludarabine|Fludarabine will be administered once a day for 4 days as part of the transplant conditioning regimen.
76086666|NCT04002115|Drug|Busulfan|Busulfan will be administered once a day for 2 days as part of the transplant conditioning regimen.
76086667|NCT04002115|Procedure|Total Body Irradiation (TBI)|TBI will be administered at a dose of 200cGys on Day -1 prior to transplant
75338565|NCT01127321|Other|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
75338566|NCT01127321|Biological|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
75338567|NCT01127321|Biological|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
75338568|NCT01127321|Biological|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
75338569|NCT01127321|Biological|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
75648832|NCT02587546|Procedure|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
75648833|NCT04081870|Diagnostic Test|3D power doppler US|Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration.
75648834|NCT04786990|Drug|SPN-812|Viloxazine extended-release capsule
75648835|NCT04082494|Device|Music via internet and noise canceling headphones|Optional music via internet and noise canceling headphones will be offered.
75648836|NCT04082494|Other|Beverages|Beverages will be optionally offered (with and without sugar, warm or cold).
75648837|NCT00758797|Other|Photoimmunotherapy|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
75934023|NCT03249038|Other|Measurement of external blood loss|
75934024|NCT03249038|Diagnostic Test|Serum Hemoglobin concentration|
75934025|NCT05473546|Other|ARTIFICIAL NUTRITION|ARTIFICIAL NUTRITION
76086668|NCT04002115|Drug|Cyclophosphamide|Cyclophosphamide will be given once a day for 2 days after the transplant infusion.
76086669|NCT04002115|Drug|Granulocyte Colony-Stimulating Factor|G-CSF will be administered to subjects starting on Day +5 and will continue as clinically indicated
75338570|NCT00272168|Behavioral|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
75648838|NCT02558803|Behavioral|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
75648839|NCT00759265|Other|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
75648840|NCT05683210|Behavioral|Cup feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The feeding process was completed at the end of 30 minutes even if the infant did not take all of the food. The infant was followed up for 30 minutes after the end of feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
75648841|NCT05683210|Behavioral|Bottle feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. During the feeding period, heart rate and oxygen saturation were continuously recorded. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The infant was followed up for 30 minutes after the end of the feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
75338571|NCT00272168|Other|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
75648842|NCT00759421|Drug|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
75648843|NCT00759421|Drug|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
75648844|NCT04081948|Other|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
75796255|NCT03897660|Dietary Supplement|Omega-3 + vitamin K2 [MaxSimil (MAG form of omega-3)]|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. At each blood draw time points, a questionnaire will be administered to the particpant to monitor if they experiencec side effects with the dietary supplement they ingested in the morning."
75796256|NCT01256892|Procedure|induction of labour|
75796257|NCT03901170|Drug|Letrozole 2.5mg|oral administration of letrozole 2.5mg/tab, 1tab once per day from stimulation Day 7 to hCG Day.
75796258|NCT03900858|Drug|Isoniazid；Rifapentine|1 months (12 doses) of three-weekly rifapentine at a dose of 450mg plus isoniazid at a dose of 400mg given under direct observation
75934026|NCT03061331|Drug|LUM/IVA|LUM 400 mg/IVA 250 mg every 12 hours (q12h)
75338572|NCT00185900|Drug|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
75796259|NCT01149564|Drug|iv ibuprofen|
75796260|NCT01149564|Drug|oral ibuprofen|
75796261|NCT03900702|Behavioral|Gaze-driven training games|Training games are played on a PC with attached eye-tracker. Games include embedded training principles to improve attentional control including resistance to distraction and inhibitory control.
75796262|NCT03894072|Device|CPAP|Conventional CPAP
75934027|NCT03061331|Drug|Placebo|No Active Drug
75934028|NCT05482438|Device|Polyethylene|Wear measurement
75934029|NCT03242876|Other|Control|Control will be 109 g white bread to be consumed together with 200 mL water
75934030|NCT03242876|Other|Test|Test will be 109 g white bread to be consumed together with 3.819 g citric acid and 119 mg malic acid dissolved in 200 mL water adjusted to pH 3.2.
75934031|NCT00700778|Biological|recombinant human chorionic gonadotropin|
75934032|NCT00700778|Genetic|microarray analysis|
75934033|NCT00700778|Other|immunohistochemistry staining method|
75934034|NCT00700778|Other|laboratory biomarker analysis|
75934035|NCT00700778|Procedure|needle biopsy|
75796263|NCT03894072|Device|HFHO|A device that can provide heated humidified oxygen up to 30-60 liter per minute, FiO2 (fraction of inspired oxygen) 0.21-0.95
75338573|NCT00185900|Drug|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
75338574|NCT00186056|Drug|Mifepristone|Glucocorticoid antagonist
75338575|NCT00186056|Drug|Placebo Oral Tablet|Inactive placebo tab
75648845|NCT04081948|Other|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
75648846|NCT00762775|Dietary Supplement|Calcium and vitamin D supplementation|Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
75648847|NCT02587468|Dietary Supplement|Juice Plus+(R)|before-after comparison of plasma phenolics
75796264|NCT02527746|Biological|F-627|F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
76086670|NCT04002115|Drug|Tacrolimus|Tacrolimus will be administered to subjects starting on Day +5 and will continue as clinically indicated
76086671|NCT04002115|Drug|Cellcept|Mycophenolate Mofetil will be administered to subjects starting on Day +5 and will continue as clinically indicated
76086672|NCT04002063|Behavioral|CBT MobileWork-V plus CBT|a smartphone app to assist with CBT homework skills practice plus CBT
75796265|NCT02527746|Drug|EC regimen|Epirubicin 100 mg/m2 (in vein) and Cyclophosphamide 600 mg/m2 (in vein) on Day 1 of each cycle for 4 cycles.
75796266|NCT01586286|Drug|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
75796267|NCT01586286|Drug|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
75796268|NCT01257048|Drug|Formoterol Turbuhaler|9 microgram on visit 5 single dose
75796269|NCT01257048|Drug|Budesonide/Formoterol Turbuhaler|320/9 microgram twice daily during 8 weeks
75796270|NCT01257048|Drug|Formoterol Turbuhaler|9 microgram twice daily during 8 weeks
75796271|NCT03893994|Other|Stretching exercises|Stretching exercises will be applied 6 days a week, 30sec / 5 reps
75934036|NCT05213585|Drug|Ivermectin cream|Topical application of ivermectin cream to eyelashes of treatment eye.
75934037|NCT03238664|Procedure|Biopsy|Undergo biopsy of bladder tumor
75934038|NCT03238664|Device|High-Intensity Focused Ultrasound Ablation|Undergo laparoscopic HIFU
75934039|NCT03238664|Other|Laboratory Biomarker Analysis|Correlative studies
75934040|NCT03238664|Procedure|Radical Cystectomy|Undergo RARC
75934041|NCT03238664|Device|Ultrasonography|Undergo CEUS
75934042|NCT03238508|Procedure|Deferred stenting|Previously described
75934043|NCT05213429|Other|non interventional study|non interventional
75934044|NCT03238586|Behavioral|WELL Program|
75936516|NCT03185468|Genetic|4SCAR-FRa|FRa-specific 4th Generation CART
75338576|NCT00186446|Drug|bupropion and smoking cessation behavioral intervention|
75338577|NCT01899638|Drug|UMEC/VI 125/25 mcg|Combination in high dose
75338578|NCT01899638|Drug|UMEC/VI 62.5/25 mcg|Combination in low dose
75796272|NCT03900390|Procedure|cross-preconditioning|After the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions.
75796273|NCT03900780|Procedure|PGT-A|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
75338579|NCT01899638|Drug|UMEC 125 mcg|LAMA mono in high dose
75338580|NCT01899638|Drug|UMEC 62.5 mcg|LAMA mono in low dose
75338581|NCT01899638|Drug|VI 25 mcg|LABA mono
75338582|NCT00136760|Drug|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
75338583|NCT00136760|Drug|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
75338584|NCT00136760|Drug|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
75338585|NCT00136760|Drug|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
75338586|NCT00136838|Behavioral|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
75338587|NCT00189098|Drug|Sulfamethoxazole-trimethoprim|18 mg/kg, two times a day
75338588|NCT00189098|Drug|Placebo|
75338589|NCT00145418|Drug|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
75338590|NCT04751474|Other|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
75796274|NCT03900780|Procedure|Control|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
75936517|NCT02430662|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
75936518|NCT02430662|Device|NanoKnife|
76086673|NCT04002063|Behavioral|CBT alone|CBT therapy individual
75934045|NCT05209607|Other|Mobile Medical and bundle management|Based on the current follow-up management platform of respiratory disease, the WeChat official account will be designed and used to provide health education for patients, such as smoking cessation, reasonable diet, appropriate exercise, etc., and monitor some physiological indicators (such as body temperature, weight, the score of mMRC, etc.) and guide patients to standardize medication and pulmonary rehabilitation.
75934046|NCT05209607|Other|Mobile Medical and standard of care|Based on the mobile medical, participants will receive advice on standard medication only.
76086674|NCT03999021|Drug|NAC effervescent tablets|After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
76086675|NCT03996499|Diagnostic Test|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
76086676|NCT03990233|Drug|BI 765063|mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor
76086677|NCT03990233|Drug|BI 754091|mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
76086678|NCT03976544|Drug|Estradiol Valerate|Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
75934047|NCT03683680|Other|MPT Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
75934048|NCT03683680|Other|CLDN15/VIM Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
75934049|NCT02453828|Procedure|Non-cardiac surgery|patients having non-cardiac surgery
75934050|NCT05482282|Biological|Recombinant Hepatitis B new Bulk vaccine|"1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma)~1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region."
75934051|NCT05482282|Biological|DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine|3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
75934052|NCT05482282|Biological|Recombinant Hepatitis B vaccine (Registered BioFarma)|1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)
75934053|NCT05482282|Biological|Pentabio|3 doses of Pentabio
75648848|NCT00763087|Behavioral|weightbearing exercise|All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
75648849|NCT00763087|Behavioral|nonweightbearing exercise|All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
75934054|NCT03238274|Device|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
75934055|NCT05209529|Drug|olaparib|olaparib 300 mg per os BID
75934056|NCT05209529|Drug|Durvalumab|durvalumab 1500 mg IV Q4 weeks
75934057|NCT04424134|Drug|Bromhexine and Spironolactone|Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days
75934058|NCT04424134|Drug|Base therapy|Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
75934059|NCT04486430|Drug|Neu2000KWL|1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
75934060|NCT04486430|Drug|Neu2000KWL|1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
75934061|NCT04486430|Drug|Neu2000KWL|1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
75934062|NCT04486430|Drug|Placebos|1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
75934063|NCT05213117|Behavioral|Co-Localization with Nursing|Co-localize 15 residents to one of 6 general medical floors to complete all 8 weeks of general medicine on this floor
75934064|NCT05482204|Other|Low Climate Impact label|Menu labels indicating low climate impact on chicken, fish, and vegetarian food items on a simulated online fast food menu.
75934065|NCT05482204|Other|High Climate Impact label|Menu labels indicating high climate impact on beef food items on a simulated online fast food menu.
75338591|NCT04751318|Drug|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
75934066|NCT05209373|Behavioral|Intervention Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
75934067|NCT05209373|Behavioral|Positive Control Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
76086679|NCT03976544|Drug|Micronized progesterone|If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
76086680|NCT03971656|Dietary Supplement|Nutritional Supplement|Oral nutritional supplementation
75648850|NCT00763087|Behavioral|nonexercising control|All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
75934068|NCT03248726|Drug|Polyethylene glycol and bisacodyl|Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.
75648851|NCT04854694|Device|FaceView Mask™|transparent surgical N95 respirator designed to improve communication
76086681|NCT03971656|Behavioral|Preoperative Dietitian Consult|Nutritional assessment
76086682|NCT03971656|Behavioral|Education|Informational materials about nutrition
75338592|NCT04751318|Drug|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
75338593|NCT01105247|Drug|PCI-32765|420 mg daily or 840 mg daily
75338594|NCT01107665|Drug|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
75338595|NCT05272007|Procedure|EUS-biliary drainage|EUS-GBD with LAMS
75648852|NCT04854694|Device|conventional surgical N95 respirator|standard N95 respirator
75934069|NCT03248726|Drug|Split-dose polyethylene glycol|Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
75934070|NCT04486274|Other|MOSE|After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.
75934071|NCT04486196|Device|Medency Primo Diode Laser Device (Medency, Vicenza, Italy)|Root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle.
76086683|NCT03968172|Behavioral|EBBC programme|"Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~Diagnosis and disease progression~Support in disease processing~Techniques for coping with stress and depressive symptoms as well as developing positive emotions~Optimisation of dietary behaviour~Optimisation of physical activity behaviour~Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules."
75338596|NCT03012659|Behavioral|Contraceptive Counseling Training|"Intervention sites will receive:~In person training: All staff at an intervention health center will participate in a one-day counseling training.~On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.~Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance."
75338597|NCT01447225|Drug|MM-121|MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
75338598|NCT01447225|Drug|Carboplatin|administered at AUC 6
75338599|NCT01447225|Drug|Pemetrexed|administered IV at 500 mg/m2
75338600|NCT01447225|Drug|Cabazitaxel|administered IV at 20 mg/m2 or 25 mg/m2
75338601|NCT01447225|Drug|Gemcitabine|administered IV at 1000 mg/m2 or 1250 mg/m2
75338602|NCT01447849|Drug|lubiprostone|24mcg twice a day (BID) 1 week
75338603|NCT01447849|Drug|placebo|Placebo pills twice a day for one week.
75338604|NCT00277394|Drug|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
75648853|NCT00763165|Drug|Triclosan|Brush twice daily
75648854|NCT00763165|Drug|Fluoride|Brush twice daily
75648855|NCT00763165|Drug|Fluoride|Brush twice daily
75338605|NCT00277394|Drug|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
75338606|NCT01450189|Behavioral|Standard HIV prevention messages|A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
75648856|NCT00919750|Other|Cytology Specimen Collection Procedure|Correlative studies
75648857|NCT04049227|Drug|Abemaciclib|Given PO
75648858|NCT04049227|Drug|Letrozole|Given PO
75648859|NCT04049227|Procedure|Therapeutic Conventional Surgery|Undergo standard of care hysterectomy
75648860|NCT04048993|Other|Biobank development and integrative physiological analysis|Collection of biological samples (blood, urine, interstitial fluid, adipose tissue and muscle) from subjects enrolled in the Section registry, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
75648861|NCT04752007|Radiation|ASLR; CT; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
75648862|NCT04752007|Radiation|Fig.Four; CT; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
75648863|NCT04752007|Radiation|Supine; CT; SI joint movement: supine position|Baseline position
75648864|NCT04752007|Radiation|ASLR; RSA; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
75648865|NCT04752007|Radiation|Fig.Four; RSA; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
75338607|NCT01450189|Behavioral|BI: Information-Motivation-Behavioral Skills Model|The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
75338608|NCT01450189|Drug|Raltegravir|raltegravir (400 mg) administered orally twice daily for 12 weeks
75648866|NCT04752007|Radiation|Supine; RSA; SI joint movement: supine position|Baseline position
75648867|NCT04683250|Drug|TAS0953/HM06|Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
75648868|NCT04683250|Drug|TAS0953/HM06|Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
75648869|NCT02558257|Behavioral|Survey|Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
75648870|NCT04081558|Device|Electronic patient reported outcomes tool|Electronic patient reported outcomes
75648871|NCT00763399|Dietary Supplement|probiotics (antibiophilus(Lactobacillus casei), bio-three)|probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10^8CFU/day
75648872|NCT00763477|Biological|ghrelin|subcutaneous injection
75796275|NCT03900312|Behavioral|Asdzaan Be'eena' Program|The program will consist of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices. The program will be conducted over 2.5-3 months with one session occurring every week for 11 weeks.
75338609|NCT01450189|Drug|emtricitabine/tenofovir disoproxil fumarate|emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
75473772|NCT01974726|Other|9-Step Test|This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.
75934072|NCT04486196|Procedure|2.5% NaOCl, %17 EDTA, Distilled water, 30-gauge, side-opening needle (Canal Clean, Biodent, South Korea),|Final conventional irrigation
75934073|NCT03248804|Behavioral|Soy group|
75934074|NCT03248804|Behavioral|Non-soy group|
75934075|NCT04557280|Combination Product|Selatogrel|A single subcutaneous injection of 16 mg.
75338610|NCT00278876|Drug|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
75648873|NCT00759733|Procedure|echocardiography|A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.
75648874|NCT00759733|Procedure|blood draw for serum B-type natriuretic peptide|A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
75648875|NCT04777864|Behavioral|Decision Aid|In addition to usual care, participants (parents and adolescents) receive the newly developed decision aid as part of their clinic visit(s). Clinicians receive an implementation guide to facilitate use of the decision aid.
75648876|NCT00760045|Drug|Hydroxypropyl Guar Galactomannan|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
75648877|NCT00760045|Drug|0.1% sodium hyaluronate ophthalmic solution|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
75934076|NCT04557280|Drug|Selatogrel|A single subcutaneous injection of 16 mg.
75934077|NCT03242330|Device|Subperiosteal implant|Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
75934078|NCT05477992|Procedure|Endovascular embolization|Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels.
75934079|NCT03248414|Dietary Supplement|Lactobacillus sakei|1 pack contained 5 x 109 cfu
75934080|NCT04961021|Procedure|Strabismus surgery|Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle
75936519|NCT02706938|Other|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
75338611|NCT01474213|Drug|dexmedetomidine group|1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
75338612|NCT01474213|Drug|remifentanil group|target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
75338613|NCT04752410|Procedure|Selective Brachial Plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
75338614|NCT03008863|Other|Education|
75338615|NCT00147212|Drug|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
75338616|NCT01474915|Drug|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
75934081|NCT05208827|Drug|Vitamin D3|Participants began to take medication at 12 weeks of gestation, and participants in the second trimester began to take medication at the time point of enrollment.The dosage is 2 tablets per day, taken orally for 12 weeks.The drug in the intervention group was fat-soluble vitamin D3, which was produced by Sinopril Holding Starfish Pharmaceutical (Xiamen) Co., LTD. Each tablet contained 800 units of vitamin D3, vegetable oil and starch as auxiliary material.
75934082|NCT05208827|Drug|The placebo(not contain vitamin D)|Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
75934083|NCT03242564|Device|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
75338617|NCT01474915|Drug|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
75338618|NCT01474915|Drug|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
75473773|NCT01974726|Other|Tubomanometry|The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
75648878|NCT00760123|Other|Early Physical Therapy and Educational strategy|"Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy"
75648879|NCT04049305|Device|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
75934084|NCT03242486|Device|toric intraocular lens|
75934085|NCT04947059|Drug|Gemcitabine Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
75934086|NCT04947059|Drug|Epirubicin Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
75338619|NCT01474915|Drug|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
75936520|NCT02706938|Other|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
75936521|NCT02430584|Other|Observational - no intervention|
75338620|NCT00280826|Drug|Efalizumab|Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
75338621|NCT01899794|Procedure|TVT-O/Oxytrol|
75338622|NCT01899794|Device|TVT-O|
75338623|NCT01899794|Drug|Oxytrol|
75338624|NCT00147446|Behavioral|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
75648880|NCT04049305|Procedure|conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
75648881|NCT04049305|Procedure|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
76086684|NCT03968172|Behavioral|Control group programme|"Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~Disease progression~Invisible symptoms of multiple sclerosis~Symptomatic therapy~Immunotherapy decision support~Coping strategies~Autonomy~Fatigue~Quality of life~Physical activity~Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme."
76086685|NCT03964415|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
76086686|NCT03964415|Biological|Clade C and Mosaic gp140 HIV bivalent vaccine|Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
76086687|NCT03964415|Biological|Placebo|Participants will receive matching placebo.
75648882|NCT04080154|Drug|Anlotinib|12mg orally (p.o.) every day (qd) for 2 weeks of every 3 week cycle (i.e. 2 weeks on, 1 week off)
75648883|NCT02584348|Device|Gastric ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed for each children admitted for emergency surgery
75648884|NCT00678379|Drug|lidocaine (1%) + bupivacaine (0.5%)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~B - lidocaine (1%) + bupivacaine (0.5%)"
75648885|NCT00678379|Drug|Normal saline|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline"
75648886|NCT00678379|Drug|Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)"
75648887|NCT00760279|Drug|Azithromycin|
75648888|NCT00674323|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, light application of 50 J/cm^2 to the study eye was begun 15 minutes after the start of infusion.
75648889|NCT00674323|Drug|Ranibizumab|Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
75648890|NCT00763633|Drug|vitamin B6|high dose of vitamin B6
75648891|NCT00763633|Drug|vitamin B6|low vitamin B6
75648892|NCT00763711|Device|Needle Guided Periurethral Injection|Bulking Agent injection using a needle guide
75648893|NCT04580446|Radiation|Hypofractionated intensity modulated radiotherapy|Hypofractionated intensity modulated radiotherapy with concurrent chemotherapy (weekly cisplatin)
75798986|NCT01182246|Drug|AXP107-11|"The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa."
75934087|NCT05481970|Drug|dexmedetomidine,ketamine,lidocaine,propofol|Group (A): Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
75936522|NCT03182504|Drug|nacubactam|Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
76086688|NCT03960866|Drug|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
76086689|NCT03960866|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
76086690|NCT03959826|Behavioral|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
75648894|NCT00763789|Other|local anaesthesia and remifentanil sedation|
75648895|NCT00763789|Other|total intravenous anaesthesia|
75648896|NCT04081402|Biological|HU-014|Hutox Inj(Clostridium botulinum type A)
75648897|NCT04081402|Biological|Botox Inj|Botox Inj(Clostridium botulinum type A)
75648898|NCT00763945|Other|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
75648899|NCT04115956|Drug|Melphalan-Flufenamide (Melflufen)|Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.
75648900|NCT04115956|Drug|Dexamethasone|Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
75648901|NCT02584192|Behavioral|entailing an early home-based CR program|enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)
75648902|NCT02584192|Other|enter the usual care program|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
75648903|NCT02587156|Dietary Supplement|Meal serving at high dietary protein|Participants are habituated to a high level of dietary protein intake for 21 days.
75648904|NCT02587156|Dietary Supplement|Meal serving at low dietary protein|Participants are habituated to a low level of dietary protein intake for 21 days.
75648905|NCT02587156|Dietary Supplement|Meal serving|To investigate impact of habituated protein level
75648906|NCT04579042|Procedure|cartilaginous batten graft septoplasty|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
76086691|NCT03959826|Behavioral|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
76086692|NCT03955510|Other|Right time eating|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have right time eating with alcohol , the second time the will have this intervention without alcohol."
76086693|NCT03955510|Other|Delayed time eating|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have delayed time eating with alcohol , the second time the will have this intervention without alcohol."
75648907|NCT04079608|Behavioral|FLASH curriculum|High School FLASH is a 15-session comprehensive sexual health curriculum designed for classroom settings in grades 9 to 12. The basis of High School FLASH is a public health approach to behavior change. The primary strategy used in the FLASH curriculum for preventing teen pregnancy, sexually transmitted diseases (STDs), and sexual violence is to address student behaviors and attitudes. To this end, FLASH uses a harm reduction and behavior change framework, implements best practices as outlined in the research on effective programs, addresses risk and protective factors for program goals, and rests on the theory of planned behavior. The instructional approach of High School FLASH employs key concepts in every lesson, which enables teachers to hone in on the risk and protective factors outlined in the curriculum logic model.
75648908|NCT04079608|Behavioral|Sexual Health Education for Adolescents|Sexual Health Education for Adolescents is a five-session knowledge-based sexual health curriculum designed for classroom settings. The lessons cover the reproductive system, pregnancy, birth control, abstinence, human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs), and healthy relationships. The goal of the curriculum is to increase student knowledge in all content areas. The primary strategy employed by Sexual Health Education for Adolescents is to address the cognitive learning domain. The curriculum aligns to national health education standards and is intended to be implemented by classroom teachers. The lessons can be delivered according to the schedule that works best for schools (e.g., twice a week, once a week, every days) within a school semester.
75648909|NCT04081480|Drug|Valacyclovir|PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution
75648910|NCT00678301|Biological|GSK Biologicals' Synflorix™|3 IM doses.
75648911|NCT00678301|Biological|GSK Biologicals' Polio Sabin™|3 oral doses
75648912|NCT00678301|Biological|GSK Biologicals' Zilbrix™ Hib|3 IM doses.
75648913|NCT02586454|Procedure|Transmuscular quadratus lumborum block|
75648914|NCT02586454|Drug|morphine|
75648915|NCT02586454|Drug|ropivacaine|
76086694|NCT03955510|Procedure|Sigmoidoscopy|Subjects will undergo unprepped sigmoidoscopy to collect tissue and stool sample at each intervention visits (visit 2, 3, 4, and 5). Flexible sigmoidoscopy will not require any colon cleansing and it will be very limited to the most distal (closest to the end of the anus) 20 centimeters (approximately 8 inches) of the colon and thus will be far less uncomfortable than the routine flexible sigmoidoscopy.
75338625|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
75648916|NCT02586376|Device|0J LLLT|Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
75648917|NCT02586376|Device|4J LLLT|4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.
75934088|NCT05481970|Drug|fentanyl,propofol|In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
75934089|NCT03237962|Device|High Flow Nasal Cannula|High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.
75936523|NCT03182504|Drug|meropenem|Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
75648918|NCT02586376|Device|6J LLLT|6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.
75648919|NCT02586376|Device|8J LLLT|8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
75648920|NCT02586298|Other|Autologous mitochondria with ICSI|Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.
75648921|NCT02586298|Other|STANDARD ICSI PROCEDURE|STANDARD ICSI PROCEDURE
75648922|NCT00939770|Drug|Crizotinib|Given PO
75648923|NCT00939770|Other|Laboratory Biomarker Analysis|Correlative studies
75648924|NCT00939770|Other|Pharmacological Study|Correlative studies
75648925|NCT00939770|Other|Questionnaire Administration|Ancillary studies
75648926|NCT02558569|Drug|Levobupivacaine|L form of bupivacaine with less cardiotoxicity.
75648927|NCT02558569|Other|NSS|Clear intravenous fluid looks alike local anesthetic.
75648928|NCT04079530|Drug|K-877 IR 0.2 mg/day|K-877 IR 0.1 mg tablet
75338626|NCT01475305|Drug|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
75338627|NCT01475305|Drug|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
75338628|NCT00280904|Device|Shunt catheter|standard of care implantation of shunt (any brand). Subjects are followed for 90 days to obtain information about whether or not an infection occurred.
75648929|NCT04079530|Drug|K-877 CR 0.4 mg/day|K-877 CR 0.4 mg tablet
75648930|NCT04079530|Drug|K-877 CR 0.8 mg/day|Two K-877 CR 0.4 mg tablet
75338629|NCT02103218|Behavioral|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
75648931|NCT00939692|Drug|Topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
76086695|NCT03955510|Procedure|Optional 24h circadian assessment in the Biological Rhythms lab|"Subjects may choose to participate in the 24 hour circadian assessment in the Biological Rhythms Research Lab. During this assessment, a saliva sample will be taken every hour, a mouth swab will be done every 2 hours, and rectal swab will be done twice (every 12 hours). Subjects will be kept awake in dim light on a recliner chair. Subjects can watch a television with dimmed light. Subjects will be provided with food and drink during the assessment.~If subjects choose this intervention they will be asked to complete 4 assessment during the course of the study period."
76086696|NCT03955510|Other|Alcohol|Moderate alcohol drinking means 0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 2 alcohol intervention weeks. The order of conditions will be random.
75934090|NCT03237962|Device|Nasal Cannula|Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
75934091|NCT04945967|Procedure|New Method|Physiological flexion in therapeutic positioning, oral stimulation, stimulation of synergistic movements, and stimulation for non-nutritive sucking by using special designed pacifier for premature infant.
75934092|NCT04945967|Procedure|Conventional Method|Oral stimulation and non-nutritive sucking stimulation using usual pacifier.
75934093|NCT05477914|Other|questionnaire|questionnare about nutritional knowledge of pregnant women
75934094|NCT03238118|Other|Attention bias modification training|"Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
75934095|NCT03238118|Other|Attention Control Training|"Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
75934096|NCT03238118|Other|Psychoeducation|Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
75934097|NCT04935905|Device|Mechanical Insufflator-Exsufflator|This device augments a cough by applying a positive pressure via the upper airway or tracheostomy to increase lung volume to maximal inspiratory capacity, followed by a rapid and quick change to negative pressure to increase expiratory flow and simulate normal cough mechanism
75934098|NCT04934657|Other|no intervention|no intervention
75936524|NCT02430428|Device|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
75648932|NCT00920608|Drug|AZD9056|Tablets for oral use. 400 mg once daily for 7 days
75648933|NCT00920608|Drug|Methotrexate|Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
75338630|NCT02103218|Behavioral|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
75338631|NCT01391299|Biological|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
75338632|NCT01391299|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
75648934|NCT04674514|Drug|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
75648935|NCT04674514|Drug|Rd|Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone administered at a dose of 40 mg (or 20 mg for patients>75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle.
75648936|NCT04672252|Drug|CBD Oral Disintegrating Tablet (ODT)|Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen
75648937|NCT04672252|Other|Placebo ODT|"Cohort 2 will not receive CBD; but a visually indistinguishable placebo ODT instead.~The resident physician, physician assistant, anesthesiologist, surgeon and study team members will remain blinded. Additionally, all patients will receive a traditional upper extremity interscalene block as per routine."
75648938|NCT04081012|Drug|N-acetyl cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
75648939|NCT04081012|Drug|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
75338633|NCT02099084|Drug|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
75338634|NCT02099084|Drug|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
75473774|NCT01974726|Other|Videoendoscopic assessment of ETF|The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
75473775|NCT01974726|Other|Pressure chamber ET test|Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
75473776|NCT01974739|Drug|Hydrochloorthiazide|
75473777|NCT01974739|Drug|placebo|
75473778|NCT01974778|Dietary Supplement|Meal|Meal
75648940|NCT02584114|Behavioral|Peak app for memory training|
75648941|NCT02584114|Behavioral|Non-memory training group|
75934099|NCT05212805|Behavioral|Aerobic exercise|Interventions will be delivered through twenty supervised 40-minutes aerobic sessions (3 times a week). Patients will be trained on a bicycle ergometer (5-minute warm-up, 30 minute of intense training, 5-minute cool-down). Warm-up will be performed at the 30% of the maximal heart rate, while training will be performed at the 50-70% of the maximal heart rate as recommended by the general guidelines for aerobic exercise training specific for MS. Actual heart rate will be constantly monitored by a wearable heart rate monitor.
75473779|NCT01974791|Behavioral|GET Living|GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
75473780|NCT01974843|Drug|Levobupivacaine|in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
75648942|NCT02584036|Biological|Vaccine administration by a pharmacist|Administration, number and types, of vaccine(s) by a pharmacist
75648943|NCT02584036|Behavioral|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
75648944|NCT02584036|Behavioral|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
75648945|NCT04760002|Device|NightOwl|The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
75648946|NCT00584740|Drug|AIN457|10 mg/kg
75934100|NCT05212805|Behavioral|Task-oriented upper-limb training|The training will consist in twenty 1-hour sessions (3 times a week) of exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, including unimanual and bimanual task-oriented exercises.
75934101|NCT05212805|Behavioral|Sport events participation|A subgroup of participants will also be involved in events promoting sports activity including both aerobic and task-oriented exercises (e.g., water sports such as sailing, windsurfing, canoeing) in order to evaluate their potential role to increase adherence to training, participation and quality of life.
75934102|NCT03248960|Diagnostic Test|iTreat Flu A+B Test|The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
75934103|NCT03248960|Diagnostic Test|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
75338635|NCT02099786|Other|COMP-VA|Hearing testing at each treatment interval by the comp-va audiologist
75338636|NCT02099786|Other|Standard of care|Hearing testing done in the audiology clinic after oncology referral or patient self referral
75338637|NCT02100410|Device|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
75338638|NCT02100410|Device|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
75338639|NCT02100410|Device|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
75648947|NCT00584740|Drug|Placebo|Matching placebo to AIN457
75648948|NCT04081090|Behavioral|Brain HQ Cognitive Modules|Online personalized cognitive therapy modules to address and improve neuroplasticity.
75648949|NCT02586922|Device|Three-dimensional (3D) ultrasonography|A longitudinal section of fetal chest will be obtained that clearly depicts the lung. A 3D window will be activated . After complete electronic sweep and assurance of absence of fetal or maternal movements to avoid motion artifacts, 3D multi-planar view will be then obtained
75648950|NCT00942968|Drug|dalteparin|Daily subcutaneous injection 200IU/kg dalteparin
75648951|NCT00942734|Drug|Erlotinib|One tablet (150 mg) by mouth every day of each 28 day study cycle.
75648952|NCT00942734|Drug|RAD001|1 tablet (5 mg) by mouth every day of each 28 day study cycle.
75934104|NCT03248960|Diagnostic Test|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
76086697|NCT03953833|Biological|Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.|"Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage.~Infusion time：90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle."
76086698|NCT03949465|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks
76086699|NCT03944512|Drug|Pravastatin|20 mg Pravastatin taken daily
75338640|NCT02100410|Device|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
75338641|NCT02100410|Device|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
75648953|NCT00584194|Biological|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to < 1:40.
75648954|NCT02586142|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
75648955|NCT02586142|Other|Stretching exercise|After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
75796276|NCT03897504|Procedure|feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap|the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.
75796277|NCT01258218|Device|Implantation of an Accent MRI device|Implantation of an Accent MRI device
75934105|NCT03248960|Diagnostic Test|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
75934106|NCT03248648|Drug|Neostigmine|patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
75934107|NCT03248648|Drug|ketamine|patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
76086700|NCT03944512|Other|Placebo|Identical appearing placebo pill
75473781|NCT01974843|Drug|Bupivacaine|in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
75473782|NCT01974869|Drug|Anti-tumor necrosis factor alpha agents|Treatment with biologics
75473783|NCT01974882|Other|Ice pack|Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
75473784|NCT01974908|Procedure|Fibrillatory Factor calculation (FF)|During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
75473785|NCT01974921|Device|ALAIR Catheter. Radiofrequency system.|Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
75473786|NCT01974934|Drug|Desvenlafaxine Succinate|
75648956|NCT00919984|Drug|IP chemotherapy|IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
75648957|NCT00942422|Dietary Supplement|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
75338642|NCT02100410|Device|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
75338643|NCT01477567|Drug|LY3009385|
75338644|NCT01477567|Drug|Placebo|
75338645|NCT01391611|Drug|Pazopanib|800 mg; PO
75338646|NCT00281918|Drug|Rituximab|Intravenous repeating dose
75338647|NCT00281918|Drug|Cyclophosphamide|Intravenous repeating dose
75338648|NCT00281918|Drug|Fludarabine Phosphate|Intravenous repeating dose
75338649|NCT00201734|Drug|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
75338650|NCT00201734|Drug|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
75648958|NCT00942422|Genetic|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
75648959|NCT00942422|Genetic|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
75648960|NCT00942422|Other|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
75648961|NCT02585986|Dietary Supplement|Probiotic|daily intake of 1 capsule probiotic
75648962|NCT02585986|Dietary Supplement|Placebo|daily intake of 1 capsule containing placebo
75796278|NCT01150968|Behavioral|End of life education|Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
75796279|NCT01255254|Procedure|Gingival scaling|Oral hygeine instruction and gingival scaling using hand and ultrsonic instruments.
75796280|NCT03900234|Other|No intervention will be administered|No intervention will be studied. Clinical and ultrasound examinations will be used to find the prevalence of CVD.
75796281|NCT01257126|Drug|diclofenac potassium|
75796282|NCT01257126|Drug|nimesulide|
75796283|NCT03897426|Behavioral|Mediterranean Diet - Remote Coaching using a Mobile App|Patients randomized to the intervention arm will be then given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD.
75796284|NCT03897738|Dietary Supplement|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
75796285|NCT03897738|Dietary Supplement|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
75934108|NCT01563575|Other|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
75934109|NCT03237806|Drug|Deep sedated|Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
75934110|NCT03237806|Drug|Light sedated|Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
75934111|NCT03237728|Drug|0.06mg/kg,KB|0.06mg/kg,Q8h,Day1-Day7
75934112|NCT03237728|Drug|0.12mg/kg,KB|0.12mg/kg,Q8h,Day1-Day7
75934113|NCT03237728|Drug|0.24mg/,KB|0.24mg/kg,Q8h,Day1-Day7
76086701|NCT03930797|Behavioral|Intimacy Enhancement|The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
76086702|NCT03930797|Behavioral|Living Healthy Together|The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
75648963|NCT00603824|Drug|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if >100 kg
75796286|NCT03897738|Dietary Supplement|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
75796287|NCT03893760|Diagnostic Test|Ventriculo-arterial coupling assessment (R-V/A)|R-V/A was achieved by computing the R-Elv/P-Ea ratio (Right ventricular elastance/Pulmonary arterial elastance). R-Elv was computed as PAPm / end-systolic area (ESA) of the right ventricle. P-Ea was obtained as (PAPm-PCWP)/ right ventricle stroke volume (R-SV).
75796288|NCT03897114|Dietary Supplement|Cocoa group|Athletes perform the same training program and they take 5 g of cocoa (83 mg of flavonoids per gram of cocoa) mixed with low-fat milk for 10 weeks.
75796289|NCT03897114|Dietary Supplement|Placebo group|The athletes perform the same training program and they take for 10 weeks 5 g maltodextrin mixed with low-fat milk for 10 weeks
75796290|NCT03900078|Other|Incisional negative pressure wound therapy|A negative pressure dressing is applied to the skin incision.
75796291|NCT03900078|Other|Wound dressing with adhesive tapes|Regular adhesive wound tapes are applied over the closed skin.
75934114|NCT03237728|Drug|Placebos|Placebos,Q8h,Day1-Day7
75934115|NCT03241784|Biological|Autologous T-regulatory lymphocytes|intravenous administration of Autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth /kg.
75934116|NCT03241784|Biological|Interleukin-2|Subcutaneous Interleukin-2 at a dose of 2x10 to the fifth IU/m2, three times a week.
75934117|NCT03242096|Combination Product|Sirolimus coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
75934118|NCT03242096|Combination Product|Paclitaxel coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
75934119|NCT05211557|Biological|fhB7H3.CAR-Ts|"Three dose levels will be evaluated: Dose Level 1 (1×10^6/kg), dose Level 2 (3×10^6/kg) and dose Level 3 (5×10^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10^6/kg /infusion) will be evaluated.~Other Name: B7H3 targeting chimeric antigen receptor T cells Drug: Fludarabine 30 mg/m2 i.v. for 3 consecutive days (Day -5~Day -3) Other Name: FLUDARA Drug: Cyclophosphamide 750 mg/m2 i.v. for once (Day -5) Other Name: Cytoxan"
75934120|NCT03248336|Procedure|office-based vergence/accommodative therapy|one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
75934121|NCT04716803|Biological|Bone Marrow Aspirate Concentrate|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
75934122|NCT04716803|Device|Angel Concentrated Platelet Rich Plasma (cPRP) System|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
76086703|NCT03928418|Behavioral|In-person counseling session|Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
75796292|NCT03893604|Device|tDCS|20 minutes of anodal tDCS (C3/FP2) 2mA or sham
75934123|NCT03241472|Drug|Letrozole|oral tablets 5 mg
76086704|NCT03928418|Behavioral|Live phone call booster session|Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
76086705|NCT03928418|Behavioral|Technology (IVR or SMS) booster session|Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
76086706|NCT03926572|Other|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
76086707|NCT03924661|Device|Aortic Valve Replacement|SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
76086708|NCT03908567|Drug|Intranasal Drug|Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day
75796293|NCT02527824|Drug|Oxaliplatin, Irinotecan, S-1|"Treatment will be delivered every 2 weeks~Oxaliplatin 65 mg/m2 iv on day 1~Irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day on day1-7"
75796294|NCT02528058|Procedure|Vitrectomy with internal limiting membrane peeling|
75796295|NCT01149642|Dietary Supplement|Oral Impact|"The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.~This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes."
75796296|NCT01149642|Dietary Supplement|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
75934124|NCT03241472|Drug|Clomiphene Citrate plus N acetyl cystine|Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
75934125|NCT03241628|Device|Dressing Glove|Viscose dressing glove
75934126|NCT04313075|Drug|Leronlimab|Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
76086709|NCT03908567|Drug|Oral Tablet|Oral dosing with tablets 3 times a day
76086710|NCT03908567|Other|Intranasal Placebo|Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day
75648964|NCT00603824|Drug|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
75648965|NCT00677833|Drug|Azithromycin plus Chloroquine|Combination of Azithromycin plus Chloroquine Azithromycin (~30 mg/kg) + chloroquine (~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
75648966|NCT00677833|Drug|Artemether-lumefantrine|Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
75648967|NCT05086874|Other|butylphthalide|Observational only and no predesigned interventions in this study
75934127|NCT02551666|Other|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
75934128|NCT02551666|Other|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
75934129|NCT04306523|Other|Observation|4 months: observation of infant feeding behavior, behavior/temperament; bio-specimen collection; body composition, sucking intensity/frequency, activity intensity/frequency; maternal reports of feeding and behavior/temperament; maternal biospecimen. 6 month: behavior/temperament assessment, physical activity, and body composition. 12 month: Feeding behavior, behavior/temperament assessment, physical activity, and body composition. 24 month: maternal reports of children's eating behavior, behavior/temperament.
75934130|NCT03241550|Drug|isavuconazonium sulfate - intravenous|IV infusion
75934131|NCT03241550|Drug|isavuconazonium sulfate - oral|Oral
75934132|NCT05481580|Diagnostic Test|Periodontal probing|"The teeth involved will be probed to assess probing depth, presence of furcation, bleeding.~A radiograph will be taken to assess the length of the root trunk and the presence of root canal treatment"
76086711|NCT03898661|Drug|Collagenase histiolyticum|local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
76086712|NCT03884855|Other|Classical Cardiac Rehabilitation|Patients benefit from classical cardiac rehabilitation during 3 months.
76086713|NCT03884855|Other|Karate rehabilitation|Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
76086714|NCT03861273|Biological|PF-06838435/ fidanacogene elaparvovec|Gene Therapy
75796297|NCT01586208|Drug|valproic acid (VPA)|Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
76086715|NCT04208516|Procedure|Continuous Erector Spinae Plane Nerve Block|To be administered to subjects in the active comparator group receiving primary unilateral thoracic surgery.
76086716|NCT04208516|Procedure|Continuous Quadratus Lumborum Nerve Block|To be administered to subjects in the active comparator group receiving primary major abdominal surgery.
76086717|NCT04208516|Procedure|Single Erector Spinae Plane Nerve Block|To be administered to subjects in the experimental group receiving primary unilateral thoracic surgery.
75796298|NCT03893526|Drug|Entresto|Single dose administration of entresto
75796299|NCT03893526|Drug|Sitagliptin|Single dose administration of sitagliptin
75796300|NCT03893526|Drug|Valsartan|single doses administration of valsartan
75796301|NCT03893526|Drug|Placebo|placebo day
75796302|NCT01149720|Drug|Tivantinib (ARQ 197) Capsule|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
75934133|NCT05211167|Drug|Human Erythropoiesis Injection (CHO cell)|Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
75934134|NCT05211167|Drug|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
75473787|NCT01974947|Other|Blood sample, sperm sample and clinical examens|Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
75796303|NCT01149720|Drug|Tivantinib (ARQ 197) Tablet|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
75934135|NCT03241706|Drug|Fructose|IV fructose (1.3 mg/kg/min)
75934136|NCT03241706|Drug|Saline|Saline given as a comparison to fructose.
75338651|NCT00201734|Drug|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
75473788|NCT01974973|Procedure|Autologous bone marrow mononuclear cell transplantation|Intrathecal autologous bone marrow mononuclear cell transplantation
75473789|NCT01974986|Other|Water with flavoring and non-nutritive sweetener.|A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
75473790|NCT01974986|Other|High-Na low-CHO beverage|A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
75648968|NCT02586766|Behavioral|Project Sync|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
75648969|NCT04268108|Biological|liquid tumor infiltrating lymphocytes|Isolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.
75934137|NCT03241706|Drug|Somatostatin|IV infusion of somatostatin (60 ng/kg/min)
75934138|NCT03241706|Drug|Insulin|IV infusion of insulin between 20-60 mU/m2/min.
75934139|NCT03241706|Drug|Glucagon|IV glucagon (0.65 ng/kg/min).
75796304|NCT01149720|Drug|Tivantinib (ARQ 197) Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
75796305|NCT01149798|Drug|Abraxane and Cisplatin combination|"Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1."
75798987|NCT01182402|Device|Compliance monitoring with electronic device|Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
75798988|NCT03852420|Device|LUMINIZE RF Balloon Catheter|Ablation Therapy with the LUMINIZE RF Balloon Catheter
75798989|NCT01182558|Other|Hypothenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
75934140|NCT03241706|Drug|Dextrose solution|IV dextrose to clamp the plasma glucose at the desired level.
76086718|NCT04208516|Procedure|Single Quadratus Lumborum Nerve Block|To be administered to subjects in the experimental group receiving primary major abdominal surgery.
76086719|NCT04208516|Drug|Lidocaine IV|To be given postoperatively as a continuous infusion at a dose of 50 mg/hr in the experimental group.
76086720|NCT04208516|Drug|Ropivacaine 0.5% Injectable Solution|To be used in both treatment arms as nerve block initial bolus injection.
76086721|NCT04208516|Drug|Dexamethasone|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
76086722|NCT04208516|Drug|Dexmedetomidine|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
76086723|NCT04208516|Drug|Lidocaine|To be used perineurally as a 0.25% solution in the active comparator group at a rate of 10 ml/hr per perineural catheter.
76086724|NCT03860207|Biological|Humanized 3F8 Bispecific Antibody|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
76086725|NCT03860207|Other|Blood draw|In cycle 1, blood is drawn for PK studies.
76086726|NCT03860038|Drug|TJ202 and Dexamethasone|one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
76086727|NCT03851068|Device|Foldax Tria Aortic Valve|Aortic Valve Replacement
75934141|NCT03241706|Drug|High Fructose|IV-fructose (6.5 mg/kg/min)
75934142|NCT05477446|Biological|CD207 CAR-T cells|Single dose of CD207 CAR-T cells administered IV
75473791|NCT01974986|Other|Low-Na high-CHO beverage|A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
75473792|NCT01975012|Drug|Rilpivirine|"For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules [2.5 mg/g]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available."
75473793|NCT01975025|Procedure|Short daily dialysis for 2 weeks|
75473794|NCT01975051|Drug|Mitefosine|Tablet Miltefosine 100 mg in two devided doses for 12 weeks
75473795|NCT01975077|Drug|fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
75648970|NCT05466838|Drug|PERT at discharge|Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.
75648971|NCT05466838|Other|Standard of Care|Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.
75648972|NCT00764101|Behavioral|Attentional Bias Modification|computerized training to reduce attentional bias in posttraumatic stress disorder
75648973|NCT03930082|Other|Frailty Index Scale|We will evaluate the frailty with a Frailty Index Scale in elderly patients undergoing gastrointestinal surgery.
75648974|NCT00764179|Other|milk enriched in proteins (2.15 g/100ml)|"Neonates will drink the hyperproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
75648975|NCT00764179|Other|milk with normal protein concentration (1.45g/100ml)|"Neonates will drink the normoproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
75648976|NCT04048915|Behavioral|Long live drama|"The interactive live 90-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
75648977|NCT04048915|Behavioral|Short live drama|"The interactive live 60-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
75796306|NCT03896802|Procedure|Physiological assesment|"Arterial and mixed venous blood gas analysis.~Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~Urine flow in 1h and determination of the fractional excretion of sodium and creatinine."
75796307|NCT02527590|Other|pneumatic stimulations(allodynic area)|2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials
75936525|NCT03182348|Procedure|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
75338652|NCT01898468|Procedure|Pericostal Closure Technique|
75473796|NCT01975103|Procedure|Topcon Endpoint Management|
75473797|NCT01975116|Drug|azurin-derived cell-penetrating peptide p28|Given IV
75648978|NCT04652830|Behavioral|Naprapathy training|Active training aimed at strengthening the abdominal muscles
75338653|NCT01898468|Procedure|Intracostal Closure Technique|
75473798|NCT01975129|Drug|Vagitocin|
75473799|NCT01975142|Drug|Trastuzumab - Emtansine|
75473800|NCT01975155|Other|food questionnaire|
75473801|NCT01975155|Other|Urinary mycotoxin test|
75473802|NCT01975168|Device|Handylaser Trion laser acupuncture|intervention interval is 3 times per week for 12 weeks
75648979|NCT04652830|Other|Control group|No change of daily routines in regard to training
75648980|NCT00764257|Device|PREVELLE Shape|
75648981|NCT00764257|Device|Restylane|
75648982|NCT02585908|Biological|CIK|CIK cells will be used against tumor cells.
75648983|NCT02585908|Biological|γδ T|γδ T cells will be used against tumor cells.
75473803|NCT01975194|Drug|Rosuvastatin|Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
75473804|NCT01975207|Behavioral|Treatment as usual|Participants will be treated as per clinic's standard treatment for depression.
75648984|NCT02585908|Biological|CIK and γδ T|CIK and γδ T cells will be used against tumor cells.
75648985|NCT00764335|Procedure|total hip arthroplasty one side|unilateral total hip arthroplasty
75648986|NCT00764335|Procedure|total hip arthroplasty both sides|bilateral total hip arthroplasty
76086728|NCT03844061|Drug|Belimumab|Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.
76086729|NCT03844061|Drug|Rituximab|Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.
76086730|NCT03844061|Other|Placebo Subcutaneous Injection|Normal Saline
76086731|NCT03844061|Other|Placebo Infusion|Normal Saline
76086732|NCT03844061|Drug|MMF|MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
76086733|NCT03827967|Biological|PalloV-CC|The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
75648987|NCT00760825|Biological|killed bivalent (O1 and O139)whole cell oral cholera vaccine|1.5 ml given twice orally, 14 days apart
75648988|NCT02585752|Device|Noninvasive ventilation|Expiratory pressure modulation
75648989|NCT00764803|Device|Encore 3DKnee™ system|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.
75648990|NCT00764803|Device|Encore MJS™ Knee System|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
75648991|NCT02585674|Drug|Insulin glargine (U300)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75648992|NCT02585674|Device|MyStar DoseCoach|Glucose meter
75648993|NCT00942266|Drug|fluorouracil|Given IV
75648994|NCT00942266|Drug|leucovorin calcium|Given IV
75648995|NCT00942266|Drug|vorinostat|Given orally
75648996|NCT00942266|Other|pharmacological study|Correlative study
75648997|NCT05382182|Drug|androgen deprivation therapy|outcome of hormonal treatment as androgen deprivation therapy on prostate cancer patient on survival and relapse
75648998|NCT05382182|Radiation|external beam radiotherapy|outcome of radiotherapy as external beam radiotherapy on prostate cancer patient on survival and relapse
75648999|NCT04519294|Device|SURE|The SURE stone evacuation procedure is a technique intended to more easily and completely remove a kidney stone during a kidney stone treatment. The urologist first uses a laser to break the kidney stone into small pieces. Then with the SURE procedure, the pieces are gently vacuumed out of the kidney instead of retrieving the pieces one-by-one with a basket or leaving them to pass naturally in the urine. Basketing is allowed and might be used with the SURE procedure, if needed to remove some small stones.
75649000|NCT04519294|Device|Standard Ureteroscopy (Basketing)|This is a treatment in which the urologist uses a laser to break a kidney stone into small pieces and then uses a tool called a basket to retrieve the pieces one at a time.
75649001|NCT04079374|Drug|Etanercept|Subcutaneous injections
76086734|NCT03809715|Device|Coroflex® ISAR NEO coronary stent system|"treatment of coronary artery disease with Coroflex® ISAR NEO of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
75649002|NCT04079374|Drug|Enbrel|Subcutaneous injections
75649003|NCT00942188|Drug|LY2189102|Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
75649004|NCT00942188|Drug|Placebo|Participants received 2 SC injections weekly for 12 weeks.
75649005|NCT00673231|Drug|Dapagliflozin|tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
75649006|NCT00673231|Drug|Dapagliflozin|Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
75649007|NCT00673231|Drug|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
75796308|NCT02527590|Other|pneumatic stimulations (healthy area)|2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials
75649008|NCT00673231|Drug|Placebo|Placebo
75649009|NCT00673231|Drug|Dapagliflozin|tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
75649010|NCT00673231|Drug|Dapagliflozin|tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
75649011|NCT02583958|Device|Urgo 3103166|URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
75649012|NCT02583958|Device|Aquacel Extra|Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
75649013|NCT00604058|Biological|Inactivated Poliomyelitis vaccine (IMOVAX)|Fractional dose (1/5th) 0.1 mL, intradermally
75649014|NCT00604058|Biological|Inactivated Poliomyelitis vaccine (IMOVAX)|A full dose, 0.5 mL, intramuscular
75649015|NCT05674708|Other|Fat intake|Four different sources of dietary fat
76086735|NCT03807479|Drug|Ponatinib|2 film-coated tablets à 15mg for oral administration on a daily basis
76086736|NCT03784755|Radiation|Ablative Radiation Therapy|Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
75649016|NCT02852798|Drug|Apatinib Combined With Docetaxel|Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration
75796309|NCT02527590|Other|pneumatic stimulations no auditory masking|2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials
75934143|NCT05211089|Other|Optical Coherence Tomography imaging of choroid|A single expert retinal specialists used a Topcon DRI-1 SS-OCT to do the Choroidal Thickness measurements. A 12, 9-mm radial line scan procedure was performed. Each radial line was automatically scanned 32 times in the same spot, followed by the creation of 12 high-resolution average B-scan images. Each scan was double-checked to confirm that it was centred on the fovea. Only scans of good quality were included. The perpendicular distance between the outer border of the RPE and the junction of the choroid and sclera was used to calculate CT. It was calculated automatically using the mapping software incorporated into the device and displayed as a colourful topographic map with nine subfields defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) style grid.
75796310|NCT02527590|Other|no stimulation (control)|no stimulation (control condition): air jet directed beside the hand
75796311|NCT02527590|Other|pneumatic stimulations with audidory masking|2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
75796312|NCT01257360|Drug|Panitumumab|Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.
75934144|NCT03248102|Diagnostic Test|Blowing into the mouthpiece|Blowing into the mouthpiece of diagnostic device
75934145|NCT03903562|Biological|V503|0.5 mL 9vHPV VLP Vaccine
75934146|NCT03237416|Drug|Dabigatran etexilate|In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
75934147|NCT03237416|Drug|Midazolam|In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
75934148|NCT03237416|Drug|BAY1841788 (darolutamide)|In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
75934149|NCT05211011|Drug|Fosfomycin|Infectofos 5 g
75934150|NCT05481346|Procedure|Multidomain training|"The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training.~All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members."
75934151|NCT03247946|Behavioral|upright head position|Bottle feeding of infants with their head in upward and not supine head position
75934152|NCT05470894|Biological|Approved COVID-19 vaccine|Vaccination for COVI9-19
75934153|NCT04534049|Other|Intensive Strength Training (IST)|
75934154|NCT04534049|Other|Strength Endurance Training (SET)|
75934155|NCT04534049|Other|Flexibility Training (FT)|
75934156|NCT03237338|Procedure|ture acupuncture|"ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
76086737|NCT03784755|Other|Standard of care|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
76086738|NCT03782558|Procedure|Surgical transection of transverse ligament|Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
76086739|NCT03782545|Device|Cutera truSculpt Device|The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
75338654|NCT04752956|Other|"Total nasal symptom score (TNSS)"|TNSS contains 4 parameters in assessing the severity of allergic rhinitis: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored out of 4 points, from 0 to 3. 0, none- there are no complaints 1- mild- any symptom that exists but is not particularly annoying; 2, moderate, - any annoying symptom but does not interfere with daily activities or sleep; 3, severe - any symptom preventing daily activities or disturbing during sleeping. The total score is calculated by summing all the scores of 4 fields, which vary ranges from 0 to 15 .In our study, all patients will be instructed to record their TNSS symptom scores on their diary cards each morning before taking the drug. Patients will be graded on baseline TNSS parameters compared to 4 weeks before starting treatment.
75649017|NCT02586610|Drug|Pembrolizumab|Pembrolizumab 200 mg IV Days 1, 22 and 43
75649018|NCT02586610|Drug|Capecitabine|Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
75649019|NCT02586610|Radiation|Radiation Therapy|Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)
75649020|NCT03876535|Other|Nanomix eLab® System molecular diagnostic test (non-interventional)|This is not an interventional study. It involves performance equivalence demonstration of a point of care diagnostic system to FDA cleared predicate devices currently used in sepsis and SIRS diagnosis.
75649021|NCT05071040|Behavioral|Home-based physical activity|Participants will follow a strength exercise program
75649022|NCT00604682|Drug|CC10004|2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
75796313|NCT01257360|Radiation|Radiation of the pelvis|Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.
75796314|NCT01258452|Drug|CHF 5074|Drug is administered to subject in a fasting state
75796315|NCT01258452|Drug|CHF 5974|Drug is administered to subject after consumption of a high fat, high calorie meal
76086740|NCT03782415|Drug|MN-166|MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
76086741|NCT03782415|Drug|Temozolomide|Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
75649023|NCT00672841|Drug|Preemptive Therapy with Anidulafungin|Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.
76086742|NCT03782376|Drug|Ustekinumab approximately 6 mg/kg (IV)|Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.
76086743|NCT03782376|Drug|Placebo (SC)|Participants will receive SC injection of placebo at Week 0.
76086744|NCT03782376|Drug|Placebo (IV)|Participants will receive IV infusion of placebo at Week 0.
76086745|NCT03782376|Drug|Ustekinumab 90 mg (SC) Group 1|Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.
75934157|NCT03237338|Procedure|sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
75934158|NCT04243343|Device|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program for treatment of plantar fasciosis.
75934159|NCT04243343|Other|Standard of care|Standard of care prescribed home exercise program for treatment of plantar fasciosis.
76086746|NCT03782376|Drug|Ustekinumab 90 mg (SC) Group 2|Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
75473805|NCT01975207|Behavioral|Internet Intervention|"One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed MoodGYM (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice"
75649024|NCT00672841|Drug|Empiric antifungal therapy based on physician discretion.|Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
75649025|NCT00920296|Drug|GSK1265744|GSK drug
75649026|NCT04080388|Diagnostic Test|Lung Impedance Device|The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.
75796316|NCT01151202|Drug|AG NPP709syrup|
75649027|NCT04080388|Drug|Anti-congestive treatment|Continuation of in-hospital anti-congestive treatment
75649028|NCT00764959|Device|Encore Linear™ Hip System|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
75649029|NCT02585596|Drug|YH23537 1000mg/day|YH23537 500mg 2 tab
75796317|NCT05943054|Other|Temporal perception tasks|"A long temporal perception task in which the duration of the stimulus, around 2 min, is materialized by a video. For each trial, two videos are displayed to the participants, and then the task of the participant is to indicate the longest video and to give his level of confidence in his answer. A short temporal perception task which will take place in the same way as the long task except that the duration of the stimulus, around 2 seconds, is materialized by still frames from the videos used in the previous task."
75796318|NCT05943041|Drug|GB104(Level 1)|One capsule QD oral administration for 28 days
75934160|NCT03237104|Other|Immediate PT|Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
76086747|NCT03780842|Device|NAVA level|"A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV."
76086748|NCT03763032|Behavioral|Counseling|The patient navigator will provide educational materials, assessments, and counseling to the patients
75649030|NCT02585596|Drug|YH23537 2000mg/day|YH23537 500mg 4 tab
75649031|NCT02585596|Drug|YH23537 3000mg/day|YH23537 500mg 6 tab
75649032|NCT02585596|Drug|placebo|YH23537 500mg tab placebo
75649033|NCT00765115|Drug|LY450139|
75649034|NCT00765115|Drug|placebo|
75649035|NCT04080622|Drug|Selenium|Selenium 300 µg/day (IV infusion)
75649036|NCT04080622|Drug|Placebos|NaCl 0,9% (IV infusion)
75649037|NCT04079140|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
76086749|NCT03757130|Drug|AMG 598|AMG 598 administered by subcutaneous injection
76086750|NCT03757130|Drug|Placebo|Placebo matching to AMG 598 administered by subcutaneous injection
76086751|NCT03757130|Drug|Liraglutide|Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
76086752|NCT03743142|Procedure|endovascular repair of the AAA|The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
75934161|NCT04486820|Other|Analysis Immunohistochemical|Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
75338655|NCT04752956|Behavioral|"Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)"|"PRQLQ, is a self-administered, disease-specific questionnaire, evaluating physical, emotional, and social status of individuals with AR. It contains 23 items in 5 domains: nose symptoms (RS), eye symptoms (ES), practical problems (PF), activity limitation (RL) and other symptoms (OS). One score is given to each domain. 7-point scale (from 0, not problematic; to 6, very problematic). The overall score is derived from the average score of all items (20). In our study, the Turkish validated form of PRQLQ was used~Patients will be asked to answer PRQLQ questions at the end of each week during treatment. At the end of the treatment, an average of 4 weeks will be taken as the PRQLQ score. Basal PRQLQ questions will be evaluated by the participants based on 4 weeks prior to treatment."
76086753|NCT03719807|Other|Rehabilitation protocol|A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
75649038|NCT04079140|Drug|placebo|one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
76086754|NCT03719807|Other|Usual Care|No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
76086755|NCT03712202|Drug|Bleomycin|Given IV
75473806|NCT01975207|Behavioral|Depression Treatment Pathway|"There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes. A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family."
75649039|NCT00673465|Drug|SCH 497079|SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
75934162|NCT05210855|Diagnostic Test|CT scan|Scan with classic dose followed by ultra-low dose
75936526|NCT02429024|Device|OneTouch Reveal® Mobile APP|Diabetes management application for use on a mobile phone.
75649040|NCT00673465|Drug|Placebo|Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
75649041|NCT00673465|Drug|Metformin|Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
75649042|NCT00764413|Drug|methylprednisolone|1 gram intravenous a day for 3 days
75649043|NCT00764413|Drug|Sodium chlorid|Sodium chlorid 9mg/ml 500 ml per day in 3 days
75649044|NCT02583490|Device|spectrum 5000Q ECT device (RUL ECT)|
75649045|NCT02583490|Device|spectrum 5000Q ECT device (RUL LAP ECT)|
75649046|NCT04078984|Other|Experimental|"Daily measures of End Inspiratory Pressure with respiratory synchronisation optimised by use of EAdi~Daily spontaneous breathing trial using low levels of pressure support~Pplat, Respiratory System Compliance, Driving Pressure, PEEP, Tidal Volume will be monitored daily as well as clinical and other routine ventilatory data. Data concerning initial severity of ARDS, and duration of ARDS, controlled mechanical ventilation, sedation and neuromuscular blockade and date of first spontaneous breathing trial will be collected. A weaning test will be conducted daily."
76086756|NCT03712202|Drug|Brentuximab Vedotin|Given IV
75649047|NCT00941798|Drug|QMF149 Twisthaler®|Once daily via multi-dose dry-powder inhaler
75649048|NCT00941798|Drug|Mometasone Twisthaler®|Once daily via multi-dose dry-powder inhaler
75649049|NCT00604760|Drug|MEM 3454|Capsule 5 mg once a day
75649050|NCT00604760|Drug|MEM 3454|Capsule 15 mg once a day
75936527|NCT02429024|Device|OneTouch Verio® Flex BGMS|Blood Glucose Monitoring System (BGMS)
76086757|NCT03712202|Drug|Dacarbazine|Given IV
76086758|NCT03712202|Drug|Doxorubicin|Given IV
76086759|NCT03712202|Biological|Nivolumab|Given IV
75649051|NCT00604760|Drug|MEM 3454|Capsule 50 mg once a day
75649052|NCT00604760|Drug|Placebo for MEM 3454|Capsule once a day
75649053|NCT00583102|Drug|Cytarabine|Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7.
75796319|NCT05943041|Drug|GB104(Level 2)|Three capsules QD oral administration for 28 days
75796320|NCT05943041|Drug|GB104(Level 3)|Five capsules QD oral administration for 28 days
75796321|NCT05943028|Drug|Subanesthetic dose of esketamine|Both groups were given NI-guided propofol-refentanil dual-channel closed-loop target-controlled infusion under general anesthesia with a laryngeal mask/endotracheal intubation. The experimental group (EEG feedback index 36+N) and the control group (EEG feedback index 36) were intravenously injected esketamine 0.2mg∙kg-1 before anesthesia induction, followed by continuous 5μg∙kg-1∙min-1 infusion to maintain anesthesia for 30 minutes, and the maximum cumulative dose allowed was 100mg. In both groups, the infusion was stopped 30 minutes before the end of surgery.
75936528|NCT02421458|Radiation|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
75936529|NCT02421458|Radiation|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
76086760|NCT03712202|Other|Quality-of-Life Assessment|Ancillary studies
76086761|NCT03712202|Drug|Vinblastine|Given IV
76086762|NCT03708341|Drug|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
76086763|NCT03708341|Drug|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
76086764|NCT03692065|Drug|Apixaban 5 MG|Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
76086765|NCT03682068|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
76086766|NCT03682068|Drug|Tremelimumab|Tremelimumab IV (intravenous infusion)
76086767|NCT03682068|Drug|Cisplatin + Gemcitabine|Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
76086768|NCT03682068|Drug|Carboplatin + Gemcitabine|Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
76086769|NCT03674723|Other|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from Mung beans and 3 levels from Mung beans with rice or wheat.
76086770|NCT03667573|Device|tsDCS Dosage (A)|mild electrical stimulation delivered to lumbosacral spinal cord
75796322|NCT05943015|Procedure|Quadratus Lumborum Block II|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the psoas major and the transverse process adjacent to the quadratus lumborum muscle, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle negative aspiration into the middle layer of the thoracolumbar fascia posterior to the quadratus lumborum muscle, then 0.5-1 ml of saline 20 ml of 0.25% bupivacaine will be injected after hydrodissection is observed. The same will be done to the other side.
75649054|NCT00583102|Drug|Lovastatin|Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
76086771|NCT03667573|Device|tsDCS Dosage (B)|mild electrical stimulation delivered to lumbosacral spinal cord
75338656|NCT04752956|Diagnostic Test|Nasal cytology|In anterior rhinoscopy, nasal cytology will be scraped off the middle part of the lower turbinate with the help of a small sterile cotton swab. The cellular material obtained will be fixed by air drying on a glass slide and then stained by the May-Grünwald-Giemsa method. Preparations that do not contain respiratory epithelium or contain less than 10 epithelium at high magnification will be excluded from the study. A percentage of cells per 100 cells will be reported. NECs (nasal eosinophilic count) will be evaluated according to the quantitative classification of Gelardi et al. An experienced cytologist who is blind to the study groups will perform this test. Eosinophil percentages in nasal smears of all patients will be evaluated before and after the treatment.
75473807|NCT01975259|Drug|Oral Glucose Tolerance test (75g 2-hour)|A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution & have glucose levels recorded up to every 30 mins for 2hours
75473808|NCT01975259|Drug|Modified Oral Glucose Tolerance Test (50g 4-hours)|A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution & have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
75649055|NCT04267718|Other|Application of Padua and IMPROVE Bleeding scores|Eligible patients hospitalized in centres randomized to the Experimental group will be evaluated, within 48 hours from admission to hospital, by means of the Padua predictive score and the IMPROVE Bleeding score.
75649056|NCT02585440|Drug|CMX157|Oral tablet
75649057|NCT02585440|Drug|placebo|Oral tablet
75649058|NCT04266860|Other|Experimental - Test Results and Education|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the DxTerity test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the DxTerity test at the clinically-appropriate point in each case."
75796323|NCT05943015|Drug|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
75798990|NCT01182558|Other|Thenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
75936530|NCT04483310|Behavioral|MR therapy.|MR therapy is based on 4 steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
75936531|NCT04483310|Behavioral|breathing-distraction exercise|The control intervention is based on a breathing exercise, the patients should entail slow deep breaths, while repeatedly counting from 1-10
76086772|NCT03667573|Other|textured shoe insoles|textured shoe insoles
76086773|NCT03661528|Drug|andexanet alfa|Andexanet alfa is a recombinant version of human FXa
76086774|NCT03661528|Drug|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
76086775|NCT03660046|Drug|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
76086776|NCT03660046|Drug|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
76086777|NCT03660046|Drug|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
75649059|NCT05536726|Drug|608 Q2W|608 160 mg at week 0 + 80 mg Q2W ( 6 cycles) +80 mg Q4W during maintenance period
75649060|NCT05536726|Drug|608 Q4W|608 160 mg Q4W ( 3 cycles) +160 mg Q8W during maintenance period
75649061|NCT05536726|Drug|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
75936532|NCT02428946|Drug|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
75936533|NCT03182036|Device|Portable pulsed oxygen|Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
76086778|NCT03656601|Diagnostic Test|3D pelvic ultrasound|3D pelvic ultrasound by transperineal route
76086779|NCT03650673|Diagnostic Test|Identification of subgroups of patients with early AD with risk of progression|Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
75338657|NCT04752956|Diagnostic Test|anterior rhinomanometry|Children's right, left and total nasal airway resistance (NAR) and nasal airflow (NAF) will be measured with active anterior rhinomanometry ZAN 100 USB Rhinomanometry (Longmont, Colo., USA). In the evaluation, the NAR- pressure difference / air flow (R = P / V) formula will be used at a constant 150 Pascal prescribed by the European Rinomanometry Standardization Committee in 1984. After the patient is rested for 20 minutes, measurements will be made at 20-22 ° C and the nasal secretion will be cleared. NAR and NAF values of the participants will be measured before starting treatment and 4 weeks after treatment.
75649062|NCT00605852|Drug|GSK835726|GSK835726 will be available in single dose and repeat dose formulations.
75649063|NCT00605852|Drug|Placebo|Placebo will be given to subjects.
75649064|NCT00605930|Dietary Supplement|Pyruvate, creatine, niacinamide|A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.
75796324|NCT05943015|Procedure|Quadratus Lumborum Block III|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
75796325|NCT05943015|Drug|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
75796326|NCT05943015|Procedure|Paravertebral Block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. The linear ultrasound probe is placed longitudinally at the T6 level, 2-2.5 cm lateral to the spinous processes. Transverse process, superior costotransverse ligament and pleura are visualized, 22 gauge 80 mm peripheral block needle is passed with in-plane technique, superior costotransverse ligament is passed, negative aspiration into the paravertebral space under the ligament, followed by 0.5-1 ml of saline and hydrodissection of the pleura, followed by 20 ml of 0.25% bupivacaine is injected.The same is done to the opposite side.
76086780|NCT03643198|Drug|ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
75649065|NCT00605930|Dietary Supplement|Placebo|25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
75796327|NCT05943015|Drug|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
75796328|NCT05942989|Other|Reiki implementation|Reiki is implied by putting hands on the patient and it is believed that energy is transferred to patients by hands.
75796329|NCT05942963|Drug|Empagliflozin 10 MG|10-25 mg/day
75796330|NCT05942963|Drug|Pioglitazone 15mg|15-45 mg/day
75934163|NCT05481268|Other|Kinesiotaping Group|In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius. The tension of the tape was adjusted between 20 and 25% and the application was performed in the longest position of the muscle. The inhibition technique was applied from the insertion to the origin of the muscle. The tape was applied to cover the trigger points where pain was felt. For upper trapezius, the muscle was taped in the opposite direction on the cervical region in lateral flexion, slight flexion, shoulder depression and using the muscle technique with the I tape. For SCM muscle, the tape was applied on the muscle in the opposite direction on the cervical region with positioning in lateral flexion, extension and ipsilateral rotation using the muscle technique with I tape Taping was applied every 3 days and totally in 4 cycles.
75934164|NCT05481268|Other|Stretching Group|In our application, 3 cycles of 20 seconds of stretches were applied to upper trapezius and SCM muscle. The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching. For the SCM muscle, stretching was achieved in the positions of contralateral lateral flexion, ipsilateral rotation and extension. For upper trapezius, stretching was performed in flexion and lateral flexion. Stretching was performed every 3 days in 4 cycles in total.
75934165|NCT05481268|Other|Control Group|Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed. The assessment was performed before treatment, at the end of week 1 and at the end of week 2.
76086781|NCT03643198|Other|CONTROL|NO treatment
76086782|NCT03641469|Device|Green Sun Dynamic Brace|Change from standard-of-care TLSO to GSM brace
76086783|NCT03621956|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
75649066|NCT00602186|Drug|tamsolusin|0.4 mg /day
75649067|NCT00602186|Drug|prazosin|1 mg/day
75649068|NCT04204304|Drug|Isotretinoin|ISO
75649069|NCT02586688|Device|Active NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
75649070|NCT02586688|Device|Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
75649071|NCT02586688|Device|Open Label Active NeuroStar® TMS|Open label NeuroStar® coil.
75649072|NCT05380778|Drug|Deep anesthesia|"Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia~Other Names:~BIS lower than or equal to 45"
75649073|NCT05380778|Drug|Shallow anesthesia|"Drug: Low dose propofol, fentanyl and sevoflurane Shallow Anesthesia~Other Names:~BIS above 45"
75649074|NCT02585362|Behavioral|physical exercise|The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting
75649075|NCT02585362|Behavioral|nutrition counseling|At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake
75649076|NCT02585362|Dietary Supplement|whey protein supplement|On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
76086784|NCT03621956|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
75649077|NCT02852720|Drug|Levobupivacaine|After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.
75649078|NCT02852720|Procedure|Spinal anesthesia|Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.
75649079|NCT02852720|Procedure|Peripheral vein canulation|An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling
75649080|NCT02852720|Procedure|Ultrasonography|TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.
75649081|NCT02852720|Device|Holter|A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
75649082|NCT00604838|Device|AL-SENSE Diagnostic Absorbent Panty liner|worn for 12 hours
75649083|NCT00604838|Device|AL-SENSE Diagnostic Absorbent Panty liner|Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
75649084|NCT05857683|Procedure|cextension pin block|this is the technique for mallet finger where 2 pins are used, one for the extension block and other intramedullary for the extension posture
75649085|NCT05857683|Procedure|pin orthosis- extension block pin|this is the technique for mallet finger where only 1 pin is used for extension block and an orthosis is applied for the extension posture
75649086|NCT05857670|Behavioral|Genetic predisposition to breast cancer|Guilt feelings about procreating
75649087|NCT05857605|Other|Exercise for Knee Osteoarthritis|Standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
75649088|NCT05857605|Device|Compact seated elliptical exercise machine- Cubii JR-1|Compact seated elliptical machine exerice program in conjunction with standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
75649089|NCT05857579|Procedure|Microblepharoexfoliation|MBE was performed using the yokefellow instrument (Youke Electronic Corporation, Guangzhou, China), which contains a handpiece with a 1.80 mm diameter medical-grade diamond bur. Patients underwent MBE on the upper and lower lid margin of both eyes at 500 rpm until complete removal of accumulated biofilm debris, epithelial keratinization or capped meibomian glands. MBE was carried out only in the first combined treatment session.
75796331|NCT05942963|Drug|Metformin|1000mg-2850mg/ day
75796332|NCT05942937|Other|Education Intervention (The HepPEd Program)|"All healthcare providers, correctional officers, and people in prison (HepPEd Program target audience groups) at each participating site are anticipated to be exposed to the HepPEd Program over the course of the three-month education intervention phase.~The HepPEd Program involves a suite of multi-modal resources targeting each target audience group and a peer education program (for correctional officer and people in prison groups only). The HepPEd Program resources will be delivered in an informal, mass education-style, as well as in peer to peer format."
75796333|NCT05942924|Procedure|Repeated tactile stimulation|See arm
75934166|NCT04103333|Procedure|Lumbar Puncture|Administered as specified in the treatment arm.
75796334|NCT05942924|Procedure|Selective tactile stimulation|See arm
75796335|NCT05942872|Other|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
75934167|NCT04103333|Procedure|Blood Collection|Administered as specified in the treatment arm.
75934168|NCT04486664|Behavioral|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
75934169|NCT03247868|Combination Product|Botulinum Toxin+SPRInt|Botulinum toxin injections in association with rehabilitative approach to cervical dystonia (SPRInt)
75934170|NCT04207229|Device|CODMAN CERTAS Programmable Valves|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
75934171|NCT04487288|Diagnostic Test|SONAZOID|CEUS using SONAZOID with fusion technique
75934172|NCT04094519|Drug|enzalutamide|oral
75934173|NCT04094519|Drug|enzalutamide Placebo|oral
75934174|NCT04094519|Drug|digoxin|oral
75934175|NCT04094519|Drug|rosuvastatin|oral
75934176|NCT03241238|Other|Eating|Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
75934177|NCT03307564|Device|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.
75934178|NCT02454452|Procedure|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
75934179|NCT02454452|Procedure|Saphenous vein stripping|Saphenous vein stripping
76086785|NCT03598842|Dietary Supplement|Nutritional Supplementation Meal|Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.
76086786|NCT03598842|Dietary Supplement|Multivitamin|Study participants will be given a daily multivitamin to take for 6 months.
76086787|NCT03598842|Drug|Anti-parasitic medications|Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
75934180|NCT02454452|Procedure|CHIVA|conservative hemodynamic treatment venous insufficiency
75934181|NCT03061175|Other|Internet-Based Intervention|Receive web-based CPM-DA
75934182|NCT03061175|Other|Survey Administration|Ancillary studies
75934183|NCT02359838|Other|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
75934184|NCT02359838|Other|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
75796336|NCT05942768|Drug|regorafenib plus anti-PD-1 antibodies|The patients were treated orally with regorafenib (80 mg once daily for 21 days on/7 days off, over a 28-day cycle), combined with 1 of the 5 anti-PD-1 antibodies (i.e., nivolumab, pembrolizumab, camrelizumab, sintilimab, or toripalimab). The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks
75796337|NCT05942755|Other|Concurrent evaluation of blood and CSF ionograms to determine if there is a correlation between CSF change and the development of hyoponatremia between day 0 and day 14.|"Blood samples are taken as part of routine care on arrival of patients and then every 24 hours if an arterial catheter is in place; otherwise, every Monday, Wednesday and Friday. Samples from the EVD will be taken on Day 0 and then every 24 hours. A urine ionogram is also performed every 24 hours as part of the usual management to regulate water, sodium and potassium intake by enteral or parenteral routine.~The ionic composition of CSF from patients with SAH will be compared with a control population of patients hospitalized with normal pressure hydrocephalus. A lumbar puncture is performed in the operating room to evacuate the chronic CSF effusion in the ventricles (hydrocephalus), before performing an intrathecal perfusion test. 1ml of the CSF thus collected will be analyzed to determine its ionic composition"
75796338|NCT05942703|Other|saliva samples|Saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment
75338658|NCT00203216|Drug|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
75338659|NCT00203216|Procedure|Transcranial Magnetic Stimulation|
75649090|NCT05857579|Procedure|Intense pulse light|IPL treatment was carried out with Thermaeye Plus (MDS Medical Technologies SL, Barcelona, Spain). The procedure began by applying an ultrasound gel (Carmado SL, Alicante, Spain) to the patient's periocular areas and upper eyelids. In the periocular areas, 6 light pulses were applied; 4 light pulses on the skin below the lower eyelid (with handpiece placed horizontally in the first pass and vertically in the second pass) and 2 light pulses on the canthal area (with handpiece placed vertically in first and second pass). The parameters were as follows: (1) Filter: 650 nm; (2) fluence: 9 j/cm2; (3) pulses: 2; (4) duration: 3 ms; (5) Delay: 20 ms; and (6) Cooling: 70%. In the upper eyelids, 4 light pulses were applied; 2 light pulses in the first and second pass, respectively. The parameters were as follows: (1) Filter: 650 nm; (2) Fluence: 5 j/cm2; (3) pulses: 1; (4) duration: 3 ms and (5) Cooling: 70%.
75649091|NCT05857579|Procedure|Meibomian gland expression|Finally, the MGX was performed on both upper and lower eyelids of each eye with a Collins forceps (Medi Instrument Inc, New York, USA).
75649092|NCT05857579|Drug|Home-based therapy|Home-based therapy was based on Therapearl eye mask warming compress (Bausch & Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
75796339|NCT05942664|Behavioral|Sleep|Sleep will be restricted to 60% normal sleep duration
75796340|NCT05942651|Device|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
75796341|NCT05942651|Device|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 100 ms intervals|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
75796342|NCT05942573|Drug|Serplulimab+Paclitaxel+Apatinib|Immunotherapy+chemotherapy
75934187|NCT02189798|Device|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
75338660|NCT05156060|Drug|Gabapentin|Taken by mouth 3 times per day
75649093|NCT05857527|Combination Product|Custom EMG triggered Soterix taVNS stimulation with CIMT therapy|Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session.
75649094|NCT05857501|Device|abdominopelvic computerized tomography (CT) without contrast|scan combines a series of X-ray images taken from different angles around your body and uses computer processing to create cross-sectional images (slices) of the bones, blood vessels and soft tissues inside your body. CT scan images provide more-detailed information than plain X-rays do.
75934188|NCT02189798|Device|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
75934189|NCT03061097|Biological|Autologous fecal microbiota transplant (Auto-FMP Enema)|FMT is the process by which processed donor microbiota material is transplanted into recipients. The aim is to reconstitute the normal intestinal microbial flora in recipients. In this study, the fecal microbiota preparation will be made from the participant's own stool and processed into an auto-FMP enema formulation.
75934190|NCT03061097|Other|Placebo Enema Preparation|The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
75338661|NCT05156060|Drug|Ketamine|Administered intranasally 3 times per day
75338662|NCT00204932|Drug|conjugated linoleic acid|4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
75796343|NCT05942573|Drug|Paclitaxel±Ramucirumab|chemotherapy±Targeted therapy
75338663|NCT00206336|Drug|Topiramate (drug)|Topiramate 25 mg to 200 mg
75649095|NCT05857488|Device|Transnasal introduction tube|Imaging of the GI tract using the transnasal introduction tube and system. Optional gut microbiome sample collection using the microbiome brush and/or intestinal potential difference measurement using the intestinal potential difference probe.
75649096|NCT05857475|Device|CPAP therapy|Continous positive airway pressure therapy
75796344|NCT05942547|Drug|Diosmin|diosmin 600mg twice daily
75649097|NCT05857475|Other|Control|No CPAP
75649098|NCT05857462|Procedure|Post-admission FICB|Post-admission supra-inguinal FICB in hip fracture patient with 0.33% bupivacaine 30 ml
75649099|NCT05857449|Drug|LPM3480392|Intravenous infusion
75796345|NCT05942547|Drug|Placebo|twice daily
76086788|NCT03587701|Drug|Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
75338664|NCT00210470|Biological|IRX-2|IRX-2 for 10 days (2 s.c. injections of 1 mL each day) into bilateral mastoid insertion regions.
75649100|NCT05857436|Other|apical periodontitis|Of these patients, 60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
75649101|NCT05857423|Other|Gentle Human Touch|"Gentle Human Touch procedure has 3 step as follows:~Mother/nurse must wash their hands with antimicrobial soap for 3 minutes before starting Gentle Human Touch procedure.~Next, mother/nurse must warm their hands.~Mother/nurse must place their one hand on the infant's head and the other hand on the lower abdomen that covers the waist and hips of the preterm infant, for 15 minute."
75649102|NCT05857410|Drug|Dexmetomidine|Dexmetomidine (H20183219) 0.4μg / (kg·min)；
75649103|NCT05857410|Device|Lower limb heating blanket|Beijing Maikang Medical Device Co., Ltd., Model: Warm-1-1.
75649104|NCT05857319|Behavioral|Nutritional Psycho-Behavioral Reeducation Program|"The RNPC Program is based on a clinical protocol in three successive phases:~A weight loss phase during which food intake is restricted to 800-1000 kcal per day, with a nutrient distribution of 60% protein, 25% carbohydrates and 15% lipids. Patients eat two meals a day consisting of meat/fish/eggs/shellfish and vegetables, supplemented by products enriched in proteins, vitamins and minerals, and depleted in carbohydrates and lipids.~A stabilization phase specifically established for each patient according to their weight loss and their daily caloric needs, allowing them to gradually return to a balanced diet, with a nutrient distribution of 25% protein, 45% carbohydrates and 30% lipids. During this phase, the consumption of meal supplements gradually decreases.~A phase of return to dietary balance, unlimited in time, based on the precepts of the Mediterranean diet.~Each patient is followed every 14 days by a dietitian during the entire program."
75934191|NCT03107702|Diagnostic Test|melatonin|the relationship between melatonin level and analgesia requirement.
76086789|NCT03587701|Drug|Placebo injection (Period 1)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
75338665|NCT00210470|Drug|Cyclophosphamide|Single i.v. injection of low-dose (300 mg/m2) on Day 1
75649105|NCT05857306|Dietary Supplement|Olvanil|"Nutritional recommendation along with 4 mg Olvanil (1 capsule daily)~Subects within the Intervention group will be provided with a nutritional recommendation along with Olvanil capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 4 mg Olvanil and 255 mg soy lecithin as excipient"
75796346|NCT05942508|Drug|TQB2450 Injection + Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody
75796347|NCT05942469|Behavioral|FOREST|"The skill sessions will include didactic content defining the skill, rationale for including the skill in FOREST, and research demonstrating that practice of the skill increases positive emotion. In addition, the group will practice the skill together and will discuss ways to practice the skill at work as well as outside of work. Throughout the month, PEAs will implement the FOREST skill of the month in other existing meetings, check-ins, and team outings.~Concurrently, a module in READI's learning management system (LMS) will become available. The LMS modules will contain skill-related content similar to what is taught in the skill sessions, including a thorough definition of the skill, examples of ways to utilize the skill, a review or summary of the skill, and several knowledge questions to check for comprehension. The LMS content may include text, audio, images, and video components."
75796348|NCT05942456|Diagnostic Test|ELISA: enzyme-linked immunosorbent assay|enzyme-linked immunosorbent assay
75934192|NCT02554318|Drug|Rifampicin|
75649106|NCT05857306|Dietary Supplement|Placebo|"Nutritional recommendation along with 255 mg soy lecithin (1 capsule daily)~Subects within the placebo group will be provided with a nutritional recommendation along with placebo capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 255 mg soy lecithin"
75934193|NCT02554318|Drug|Isoniazid|
75934194|NCT02554318|Drug|Pyrazinamide|
75338666|NCT00210470|Drug|Indomethacin|21 days of oral indomethacin, 25 mg. 3 times daily
75338667|NCT00210470|Drug|Zinc|21 days of zinc gluconate (65 mg) as part of an oral multivitamin
75338668|NCT00210470|Drug|Omeprazole|21 days of 20 mg. orally
75338669|NCT00212264|Behavioral|Behavioral Therapy|Pelvic Floor Muscle Exercises and Bladder control strategies
75338670|NCT00212264|Device|Pelvic Floor Electrical Stimulation|Pelvic Floor Electrical Stimulation daily for 8 weeks
75649107|NCT05857293|Device|Catheter-guided PDA stent implantation|PDA stent is the primary treatment for patients with duct-dependent pulmonary circulation. It serves as a temporary bridge for later surgical repair by keeping the duct patent to improve oxygen saturation
75934195|NCT02554318|Drug|Ethambutol|
75934196|NCT02554318|Dietary Supplement|Fermented soybean|
75934197|NCT04487054|Other|Pro-active palliative care|Patient with high risk of mortality in ICU will be identified using our previously validated prognostic model. Intervention phase will employ pro-active palliative care on eligible patients after they survive 48 hours in ICU.
75338671|NCT00212264|Behavioral|Biofeedback|Pelvic Floor Muscle training via biofeedback
75934198|NCT03628157|Other|Geistlich Bio-Oss® bovine bone alone|Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
75936534|NCT02422004|Other|Range of motion|25 range of motion exercises of the ankle, 5 times per day.
75796349|NCT05942443|Procedure|Pre-treatment|The custom MCP blocking orthosis was made of a 1.6-mm-thick thermoplastic material that extends from the palm over the MCP joint and includes a ring around the proximal phalanx. It is designed to block the MCP joint in flexion of 10°-20° while allowing full range of motion of the proximal and distal interphalangeal joints.
75934199|NCT03241160|Other|Chewing evaluation|Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
75934200|NCT04487132|Behavioral|Active physical education lessons and physical education plan|Active physical education lessons and physical education plan Including importance of physical activity and health, and physical education plan; through lecture in classroom will be provided to the contyrolled group.
76086790|NCT03587701|Drug|Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
75649108|NCT05857280|Device|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms."
75649109|NCT05857267|Drug|Dorzolamide / Timolol Ophthalmic Solution|Dorzolamide-timolol fixed combination in a preservative-free multidose device
75649110|NCT05857267|Drug|dorzolamide/timolol|Dorzolamide-timolol BAK-preserved fixed combination
75649111|NCT05857215|Drug|amilo-5MER|amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
75649112|NCT05857202|Drug|Analgesics, Opioid|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
75649113|NCT05857202|Drug|Analgesics, Non-Narcotic|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
75649114|NCT05857189|Device|Digitalized printed paper|Patients will receive a newly formed digitalized printed paper inserted into eyeglasses
75649115|NCT05857189|Device|Traditional drawing image|Patients will receive eyeglasses that hold a traditional drawing image of the eye
75649116|NCT05857189|Other|Healthy controls|Patients will include volunteering participants with un defected eye
75649117|NCT05857137|Device|Active TMS|Continuous theta burst stimulation (cTBS) will be administered over the left inferior parietal lobule for approximately 3 minutes at 120% of the resting motor threshold.
75649118|NCT05857137|Device|Placebo TMS|Placebo TMS will be applied over the left inferior parietal lobule for approximately 3 minutes.
75649119|NCT05857124|Device|Vielight Neuro RX Gamma active device|The Vielight Neuro RX Gamma active device is a home-use photobiomodulation (PBM) device designed to deliver near-infrared (810 nm) light (or photons) to the brain/scalp and nasal tissues.
75649120|NCT05857124|Device|Vielight Neuro RX Gamma sham device|The Vielight Neuro RX Gamma sham device is a home-use device similar to the Vielight Neuro RX Gamma active device, but acting as a sham.
75796350|NCT05942443|Procedure|Post-treatment|The RME orthosis was fabricated from 3.2-mm-thick thermoplastic material with the affected finger positioned at an extension of approximately 10°-20° relative to the adjacent fingers.
75649121|NCT05857111|Device|Celbrea|The test with the CELBREA® device will be added to the routine screening according to the protocols of the health facility.
75649122|NCT05857098|Other|Local Field potential recording|Continuous recording of Local Field potentials in patients implanted with Deep brain stimulation
75796351|NCT05942417|Procedure|Echoguided percutaneous neuromodulation plus exercise|This group is taking the EPNM and the exercise program.
75796352|NCT05942417|Procedure|Strength program|This group is taking the exercise program
75934201|NCT04487132|Behavioral|Recess or lunch time activities|group intervention will be provided ti the experimental group which includes Preparing the playground by offering adequate spaces and games.Developing games and teaching children to play in recess time at-least 10-15 minutes daily(i.e.sport games, traditional games) Placing a sheet in the classroom with some reminders about being active in recess time (i.e. using a poster board encouraging playing one of the selected games )
76086791|NCT03587701|Drug|Placebo injection (Period 2)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
75649123|NCT05857085|Drug|Semaglutide Pen Injector [Ozempic]|GLP 1 agonist
75649124|NCT05857085|Drug|Empagliflozin 10 MG|SGLT 2 inhibitor
75649125|NCT05857046|Drug|Melatonin 10 MG|Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
75649126|NCT05857046|Other|Placebo|Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
75649127|NCT05857033|Other|Buccal and direct palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and direct palatal injection
75649128|NCT05857033|Other|Buccal and indirect palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and indirect palatal injection
76086792|NCT03587116|Drug|Standard of Care FIX Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
76086793|NCT03587116|Drug|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
75338672|NCT00212264|Other|No Treatment|No treatment
75338673|NCT01108445|Drug|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
75338674|NCT01108445|Drug|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
75649129|NCT05857033|Other|Buccal and direct palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and direct palatal injection
75649130|NCT05857033|Other|Buccal and indirect palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and indirect palatal injection
75649131|NCT05856968|Procedure|continuous subcutaneous tissue closure|The use of continuous subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
75649132|NCT05856968|Procedure|Interrupted subcutaneous tissue closure|The use of interrupted subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
75649133|NCT05856955|Behavioral|mHealth Coaching Intervention|The intervention uses a mHealth virtual tool that facilitates human-device interaction and is delivered by smartphone application. The program has coaching and education components that lead to chronic disease behavior change. It has been previously validated to improve self-management, medication adherence, and quality of life in individuals with CVD. The participant engages by selecting responses on the touch screen. In this manner, participants converse with the coach, develop a therapeutic alliance, and record responses. The investigators will institute behavior change methodology to enhance intervention efficacy.
75796353|NCT05942404|Procedure|mechanical bowel preparation|mechanical bowel preparation before surgery
75796354|NCT05942391|Behavioral|Cognitive behavioral therapy (CBT)|The intervention is brief-intensive, guided exposure therapy and consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks plus 4 follow-up sessions within 3 months.
75796355|NCT05942378|Drug|HRXG-K-1939|HRXG-K-1939
75934202|NCT03976973|Drug|Bromelain|Intratumoural injections of Bromelain 600ug/ml (maximum dose 90mg daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Acetylcysteine in 0.9% sodium chloride (normal saline).
75934203|NCT03976973|Drug|Acetylcysteine|Intratumoural injections of Acetylcysteine 20mg/ml (maximum dose 3g daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Bromelain.
75934204|NCT03976973|Procedure|Interventional radiology insertion of drain|Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour, then a pigtail drain (10Frg) will be secured into the tumour by an experienced, interventional radiologist, under standard procedures. This drain is utilised as access to the tumour for injections of the investigational drug product BromAc, and subsequent aspirations.
75934205|NCT03241316|Behavioral|Observational study of behaviour|As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
75934206|NCT05476978|Diagnostic Test|EUS-AI model|The test subset (approximately 20% of total patients) is reserved for the final evaluation of the EUS-AI model. Clinical parameters and EUS pictures of each patient in the test subset will be inputed into the trained EUS-AI model, and the most possible diagnosis will be given by the model.
75934207|NCT04066751|Drug|Ivacaftor|Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
75934208|NCT03241004|Other|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
75934209|NCT03240770|Device|VPro5 device|Use of the VPro5 device for 5 minutes a day
75934210|NCT03240770|Other|Deviation from Standard Tray Wear Time (14 Days)|Patients reduced Tray Wear Time Interval (14 Days)
75934211|NCT02550106|Drug|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
75934212|NCT05209919|Diagnostic Test|Transthoracic Echocardiography|All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)
75934213|NCT03237260|Drug|Vedolizumab|Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
75934214|NCT03237026|Other|No intervention required|No intervention required
75934215|NCT03247400|Drug|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb
75338675|NCT00212888|Biological|Remune and ALVAC|"Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);~Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or~Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."
75338676|NCT01607892|Drug|KPT-330|
75338677|NCT01108757|Drug|Bactrim|Bactrim DS BID for 3 days
75796356|NCT05942378|Drug|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody
75796357|NCT05942339|Device|Procedure/Surgery|The intervention involves the replacement of parts of the current implanted system with components of the ARC-IM Lumbar system.
75796358|NCT05942287|Other|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
75934216|NCT03247400|Drug|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb
75936535|NCT02422004|Other|Delayed weight-bearing|No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
75338678|NCT01108757|Other|Placebo|Corn starch capsules
75338679|NCT04352153|Drug|Febuxostat|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
75338680|NCT04352153|Drug|Uralyt-U|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
75338681|NCT05215067|Drug|AK104|IV infusion,Specified dose on specified days
75649134|NCT05856955|Behavioral|Enhanced Usual Care|Smart phone without health coach. A basic health application is installed on the smart phone provided to the participant.
75934217|NCT03060551|Procedure|SVF injection|SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
75934218|NCT03236948|Behavioral|Women for Women International Intervention|
75649135|NCT05856929|Other|no Intervention|no intervention
75649136|NCT05856825|Procedure|Robot-assisted radical cystectomy|Robot-assisted radical cystectomy
75796359|NCT05942274|Diagnostic Test|We propose to validate these smartwatch ECG functions to support FDA submissions|1) Obtain a simultaneous recording of a Lead I (RA-LA) ECG from the Smartwatch and a clinical standard device (GE Cardiosoft ECG). Subsequent recordings will be acquired from the other models of the Smartwatch as well as a recording utilizing the FDA-cleared KardiaMobile.
75796360|NCT05942248|Other|No Intervention|No Intervention
75796361|NCT05942235|Other|Education|Education
75796362|NCT05942222|Biological|dupilumab|Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.
75796363|NCT05942222|Biological|mepolizumab|Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.
75934219|NCT02453516|Procedure|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
75934220|NCT02453516|Procedure|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
75934221|NCT02453516|Drug|ropivacaine|Drug indicated for regional anesthesia
75934222|NCT02453516|Drug|epinephrine|Drug indicated to prolong the action of regional anesthesia
75796364|NCT05942209|Diagnostic Test|ECO-LEAK transvaginal ultrasound|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day an ultrasound - ecoenema is performed. First, the Foley catheter is inserted via the transanal route with instillation of 180cc of serum under ultrasound guidance with a probe in the vagina, using a sagittal and midline cut. In case there is the appearance of free pelvic fluid (previously absent) or an increase in free fluid compared to the baseline examination (fluid present at the beginning of the examination) around the anastomosis/pelvic area, the test will be considered positive.
75934223|NCT02453516|Other|sterile saline|Neutral injection (no drug involved)
75934224|NCT03716609|Dietary Supplement|Magnesium Citrate|Pure Magnesium citrate powder 2.07 gram from NOW FOODS (Bloomingdale, IL, USA)
75934225|NCT03716609|Other|Food grade citrate acid|Food grade citrate acid 0.1 gram from San Fu Chemical Co., Ltd (Taipei, Taiwan)
75934226|NCT03716609|Other|Splenda(Sucralose)|Splenda 1.0 gram from Splenda(Carmel, Indiana, USA)
75934227|NCT02453438|Other|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
75934228|NCT03709355|Drug|Elpida®|Elpida® capsules, 20mg
75934229|NCT03709355|Drug|Rifampin|Rifampin capsules, 150mg
75934230|NCT03709355|Drug|Rifabutin|Rifabutin capsules, 150mg
75934231|NCT03709355|Drug|Clarithromycin|Clarithromycin Film-coated tablets, 250mg
75934232|NCT03709355|Drug|Omeprazole|Omeprazole Film-coated tablets 20mg
75934233|NCT03709355|Drug|Atorvastatin|Atorvastatin Film-coated tablets, 80mg
75934234|NCT03709355|Drug|Levonorgestrel+Ethinylestradiol|Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
75934235|NCT03240848|Procedure|artificial intelligent clinic|Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
76086794|NCT03581136|Device|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
76086795|NCT03574103|Behavioral|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.
75934236|NCT03240848|Procedure|normal clinic|Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
75934237|NCT03240848|Procedure|experts diagnose|After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
76086796|NCT03574103|Behavioral|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.
75649137|NCT05856799|Device|Leadless Micra AV Transcatheter Pacing System|Patients are implanted with a leadless Micra AV TPS
75649138|NCT05856799|Device|Transvenous Azure XT DR dual chamber pacemaker|Patients are implanted with a transvenous Azure XT DR pacemaker
75934238|NCT05209217|Drug|Ketamine|Intranasal administration of their customary prescribed dose
75934239|NCT03240926|Device|Loop Band|Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
75934240|NCT03247244|Drug|Cannabis|THC 10%, CBD <0.5%
75934241|NCT03247244|Drug|Cannabis|THC 8.6%, CBD 8.6%
75934242|NCT03247244|Drug|Cannabis|THC 0.6%, CBD 14%
75934243|NCT03988829|Behavioral|Low-C|This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.
75934244|NCT03988829|Behavioral|High-C|In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.
75934245|NCT03988829|Behavioral|High-C+|A commercial video game will be used that requires a lot of demand on attentional control.
76086797|NCT03574103|Behavioral|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
76086798|NCT03570372|Behavioral|Internet-based treatment for adults with autism spectrum|Internet-based CBT. The intervention includes 18 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies and stress management
75649140|NCT05856734|Device|Weight and body composition change|1- Anthropometric Measurements: Body Weight (BW), Body Mass Index (BMI), Sitting Height Ratio (SHR), Waist to Hip Ratio (WHR), Finger Ratio (FR), Body Fat (BF%), and Growth Charts. (Single measure)
75934246|NCT03240458|Device|Optical Coherence Tomography|an objective non-invasive method for high-resolution cross-sectional imaging of the retina
75796365|NCT05942209|Diagnostic Test|ECO-LEAK with CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed, along with an ecoenema.
75796366|NCT05942209|Diagnostic Test|CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed
75796367|NCT05942170|Drug|ICG/ blue dye|The SLN mapping procedure was performed as previously described by using IGC or blue dye. The injection technique of the tracers was the same for both cervical and endometrial cancer. The cervical injection was done by insulin syringe(one ml) inserting full needle length (1 cm) and complete injection at 3, 9 o'clock, or 2,4,8,10 o'clock.
75796368|NCT05942144|Other|Exercise-snacks program|"Subjects in the exercise-snacks group will perform 4 exercise-snacks sessions per working day for 4 weeks. These sessions will consist of 80 one-to-one walks to be completed as quickly as possible. They will also receive information about their attitudes to physical activity."
75934247|NCT02453906|Other|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
75934248|NCT02453906|Other|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
75934249|NCT02453906|Other|Control 2|stimulation at 5 control points
75934250|NCT02453906|Other|Control 3|no stimulation at 5 control points
75934251|NCT01662310|Drug|Paliperidone|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
75934252|NCT01662310|Drug|Placebo|Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
75934253|NCT03973853|Behavioral|Virtual reality driving stimulation program|This group will benefit of 14 one hour sessions, using the driving simulator. The program is based on a progressive training, focused on the remediation of the cognitive functions specific to driving. The tool and the type of training aim to help transfer the abilities to daily life.
75934254|NCT03973853|Behavioral|TAU|This group will carry on their usual treatment during the whole length of the study. Patients will be randomized into the 2 groups. This TAU group will be the control group and will help assess the effectiveness of the stimulation program. The stimulation sessions will be proposed to the TAU group at the end of study.
75934255|NCT00700622|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
76086799|NCT03570372|Behavioral|Psychoeducation about autism spectum disorder|"Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö & Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half."
75649141|NCT05856734|Behavioral|Change in dietary intake|"24-hour recalls using Intake24 (online survey) over 3-day.~Self reported questionnaire. (Single measure)"
75649142|NCT05856734|Device|Change in physical activity|"ActiGraph GT9X Link accelerometer over 7-day.~Self reported questionnaire. (Single measure)"
76086800|NCT03569553|Drug|AIGIV|Anthrax Immune Globulin Intravenous (Human)
76086801|NCT03569514|Drug|AIGIV|Anthrax Immune Globulin Intravenous (Human)
75649143|NCT05856734|Behavioral|Change in stress|1- Self reported questionnaire. (Single measure)
75649144|NCT05856734|Behavioral|Change in socio-demographic characteristics|1- Self reported questionnaire. (Single measure)
75649145|NCT05856721|Diagnostic Test|stool analysis|"Detection of prevalence and pattern of intestinal parasitic infection in cirrhotic patients and the difference between cirrhotic patients and non-cirrhotic patients with no comorbidity.~To determine the most common risk factors of intestinal parasitic infection in cirrhotic patients."
75649146|NCT05856682|Procedure|Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block|Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee. • Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be anterior to the midaxillary line between the costal margin and iliac crest bilaterally.
75649147|NCT05856643|Drug|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10^6 cells, then increased to 1.0×10^8, 2.0×10^8and 5.0×10^8 cells. The infusion is given every 2 weeks.
75934256|NCT00700622|Drug|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
75934257|NCT00700622|Drug|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
75934258|NCT05480410|Device|Repetitive transcranial magnetic stimulation|rTMS is a minimal invasive technique which focus on the M1 cortex. It can stimulate the cortex by depolarizing superficial neurons. For this study we will use a MagVenture MagPro R20
75934259|NCT03236636|Drug|Icaritin|Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
75649148|NCT05856630|Drug|Goserelin Acetate Sustained-Release Microspheres for Injection|10.8mg, Single dose, subcutaneously（SC）
75338682|NCT05215067|Drug|Docetaxel|IV infusion,Specified dose on specified days
75649149|NCT05856630|Drug|Zoladex 10.8 MG Drug Implant|10.8mg, Single dose, subcutaneously（SC）
75649150|NCT05856604|Behavioral|Music Therapy|"Weekly individual (one2one) Music Therapy intervention lasting 4 months (n=16 sessions).~Behavioral: Music Therapy Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has been shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons & Koger, 2000; Hsu et al., 2015; Zhang et al., 2017)."
75649151|NCT05856604|Behavioral|Storytelling|"Weekly individual (one2one) Storytelling intervention lasting 4 months (n=16 sessions).~Behavioural: Storytelling is a non-pharmacological activity, in which a professional activity coordinator reads different stories (e.g., poems, novels) to the participants and used them to initiate a possible conversation."
75796369|NCT05942131|Other|Group-based laughter yoga|"A total of 8 sessions of laughter yoga will be applied to the students in the intervention group, 2 sessions per week. Each session will last 45 minutes on average. Each session will consist of groups of 7 people. An information meeting about the sessions will be held with the midwifery students who volunteered to participate in the study and assigned to the intervention group before starting laughter yoga. Midwifery students will be administered Secondary Traumatic Stress Scale for Social Media Users and Beck Depression Inventory before and after 4-6 weeks."
75796370|NCT05942118|Procedure|Breast conservative surgery|Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
75796371|NCT05942079|Other|REİKİ|Reiki is applied as an alternative and complementary treatment method.
75796372|NCT05942053|Drug|Placebo|Placebo match vitamin K2 capsules once per day.
75796373|NCT05942053|Drug|Vitamin K 2|Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
75796374|NCT05942027|Drug|Placebo|Placebo match Coenzyme Q10 capsules once per day .
75934260|NCT03236636|Drug|HUACHANSU PIAN|HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
75934261|NCT03628625|Drug|Letrozole 2.5mg|total dose 7.5 mg per day for 3 days
75934262|NCT03628625|Drug|Placebo|Folic acid for 3 days
75934263|NCT03628625|Drug|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
75934264|NCT03359993|Procedure|Premedication of intubation|The umbilical vein is punctured to inject drugs efficiently. The access is simple, the umbilical vein is clearly visible, and a blood reflux can be found easily. We used the same equipment required for a peripheral venous injection: 24 gauge cannula, antisepsis, compress, and a syringe with the prepared anesthetic drugs. We report 5 cases of intubations in the delivery room using this method to administer the premedication.
75934265|NCT04468594|Other|rigid tapping|Taping techniques We will use rigid tape and apply it bilaterally. In the rigid tape application, a combination pack of zinc oxide tape and the protective tape will be used. The protective tape will be applied first with no tension. To apply the rigid tape, subjects will be instructed to place their thoracic spine in a neutral position, the rigid tape will be applied bilaterally from the first to the twelfth thoracic vertebra. Subjects will be asked to retract and depress the scapula. The rigid tape will be applied diagonally from the middle of the scapular spine to the twelfth thoracic vertebra; this technique will be applied bilaterally. The rigid tape will be applied 3 times per week and will be applied for 6 weeks.
75934266|NCT04468594|Other|scapular stabilizing excercise|"consisted of:~wall slides with squat,~wall push-ups plus ipsilateral leg extension,~lawnmower with diagonal squat,~resisted scapular retraction with contralateral leg squat and robbery with squat.~Robbery with squat~Resisted shoulder internal rotation with step~Resisted shoulder external rotation with step~Resisted full can with step All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands The patient will perform 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly."
75649152|NCT05856578|Drug|Mulberry Twig Alkaloid Tablet|Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid
75649153|NCT05856578|Drug|Canagliflozin|Canagliflozin 100mg po qd
75338683|NCT05214833|Behavioral|Real Neurofeedback|During neurofeedback, the brain activity in response to a motor task is recorded in real-time and displayed back to the participants.
75338684|NCT05214833|Behavioral|Sham Neurofeedback|During sham neurofeedback, a signal which resembles the participant's brain activity is used instead of the actual brain activity.
75338685|NCT05176301|Radiation|computed tomography, Magnetic resonance image|Investigators measured the cervical cord and canal diameter by using CT and MRI that were previously taken.
75338686|NCT01162733|Drug|Vancomycin|15mg/kg
75649154|NCT05856565|Other|Photo|Photography intake
75649155|NCT05856474|Other|pancreatectomy|pancreaserving surgery, using end to side or end to end, pancreaticojejunostomy
75649156|NCT05856396|Biological|Boostrix® (Pertussis-containing vaccine)|"Boostrix® (Pertussis-containing vaccine) will be administered:~in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation~in Pregnant women between 16 and 29 weeks of gestation."
75796375|NCT05942027|Drug|Co-Enzyme Q10|Patients will be treated with Coenzyme Q10 capsules (CoQ10) 200 mg/day.
75796376|NCT05942014|Behavioral|dental anxiety|Evaluate dental anxiety in children and its relation with screen time exposure
75796377|NCT05942001|Drug|HRS-5041|HRS-5041 was given oral administration, qd, at a 28-day cycle. Patients may continue to use HRS-5041 until disease progression or unacceptable toxicity occurs.
75796378|NCT05941975|Device|Visual Evoked Potential (VEP)|To assess the integrity of visual pathways through the optic nerves to the visual cortex, latencies and amplitudes of P100 will be measured after pattern-reversal stimuli.
76086802|NCT03562273|Radiation|Quality Of Life Sizing Nomogram|"If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care."
75796379|NCT05941975|Device|Somatosensory evoked potential (SSEP)|To assess the integrity of sensitive pathways through the peripheral nerves and dorsal spinal cord to the somatosensory cortex. For the upper limbs, latencies and amplitudes of N9, N13, P14, N20 and P25 will be measured after median nerve stimulation. For the lower limbs, latency and amplitude of P40 will be measured after tibial nerve stimulation.
76086803|NCT03555565|Drug|Alogliptin and Metformin hydrochloride|Alogliptin and Metformin hydrochloride combination tablets
76086804|NCT03553836|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
75796380|NCT05941975|Device|Transcranial magnetic motor evoked potentials (TCmMEP)|To measure the integrity of motor pathways, the central conduction times will be measured for upper and lower limbs through magnetic stimulations of the primary motor cortex and the spinal cord, at cervical and lumbar levels.
76086805|NCT03553836|Other|Placebo|Administered as an IV infusion every 3 weeks (Q3W)
76086806|NCT03519386|Combination Product|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions.
75338687|NCT01162733|Drug|Vancomycin|30mg/kg
75338688|NCT02530242|Device|End-tidal Carbon Monoxide Subjects|ETCO monitor will be used to measure CO levels in subjects and controls.
75796381|NCT05941975|Device|Tesla Brain MRI|All patients will undergo a single brain MRI on a 3T scanner. The acquisition protocol will include high-resolution three-dimensional (3D) T2*-weighted echo-planar imaging and 3D T2-FLAIR images acquired, respectively, during or after intravenous injection of a single dose (0.1mmol/kg) of gadolinium-based contrast material.
75338689|NCT02530242|Device|End-tidal Carbon Monoxide Controls|ETCO monitor will be used to measure CO levels in subjects and controls.
75338690|NCT05121623|Other|Questionnaire|Online auto-administered Questionnaire
75649157|NCT05856396|Biological|Hexyon® (Pertussis-containing vaccine)|Hexyon ® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.
75649158|NCT05856383|Drug|Inetetamab Combined With Pyrotinib and Vinorelbine|Inetetamab Combined With Pyrotinib and Vinorelbine
75934267|NCT04468594|Other|therapeutic exercises|"Pectoralis minor stretching~Posterior shoulder stretching~Levator scapula stretching~Latissimus dorsi stretching ( stretching exercises will be 5 repetitions each session - 3 times per week)~Resisted shoulder internal rotation~Resisted shoulder external rotation~Resisted full can (strengthening exercises will be 510 repetitions each session - 3 times per week) All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands NOTE. All resisted exercises were progressed from starting 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly, supervising movement quality, presence of pain, and fatigue. If the subject achieves 20 repetitions 3 successfully, heavier resistance with resistance band color-coded loading prescribed from 10 repetitions 3 sets."
75934268|NCT03238235|Drug|givinostat|suspension of givinostat (10 mg/mL)
75934269|NCT03238235|Drug|placebo|suspension manufactured to mimic givinostat
75796382|NCT05941975|Diagnostic Test|Blood test - Neurofilament light chain (NfL)|- Neurofilament light chain (NfL) will be tested (Quanterix's Simoa® Technology) in the serum of patients. To evaluate their variation over time, 3 time-point tests will be obtained at 6 months apart (at baseline, at 6- and 12-month follow-up).
75796383|NCT05941975|Diagnostic Test|Blood test - EBV serology|EBV serology will be assessed (VCA IgG) in the serum of patients to evaluate the variation of antibody titers over time (at baseline, at 6- and 12-month follow-up), and compare to titers at the time of diagnosis (when available in their medical record).
75338691|NCT05444010|Behavioral|mandala painting|nurse painted mandala for relaksing
75796384|NCT05941936|Biological|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
75796385|NCT05941923|Other|respiratory critical care support|Patients in the intervention group will be received respiratory critical care support
75796386|NCT05941910|Drug|Q10|240mg of Q10 orally, every day
76086807|NCT03519386|Drug|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
76086808|NCT03508648|Drug|GTx-024|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
76086809|NCT03508648|Drug|Matching Placebo|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
76086810|NCT03487185|Device|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
75338692|NCT01131065|Drug|Hepatitis B immune globulin|Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
75338693|NCT00214526|Procedure|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
75338694|NCT00214526|Drug|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
75649159|NCT05856344|Device|Spherical tip noncompliant balloon|The main difference of this experimental balloon is the spherical tip, other parameters are consistent with regular noncompliant balloons.
75649160|NCT05856344|Device|Regular noncompliant balloon|The balloon is designed as tapered-tip.
75649161|NCT05856292|Other|Teach Back|Standard cancer pain educational intervention enhanced with teach-back method
75649162|NCT05856292|Other|Placebo|Standard cancer pain educational intervention without enhancement
75649163|NCT05856253|Procedure|Enhanced recovery program|Recvoery programs includes specific measures validated in multidisciplinary consultation, spread over the pre- intra- and postoperative period.
75934270|NCT03247166|Device|TOPS™ System|The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
76086811|NCT03487185|Other|Sleep Advice Control|Initial sleep advice counseling alone
76086812|NCT03474159|Device|Magnetic Resonance Imaging|Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
76086813|NCT03474159|Device|Transthoracic echocardiography|Aortic distensibility measured in TTE of the same segments in TM and in B mode
76086814|NCT03474159|Device|Echography UltraFast|Carotid pulse rate measured on carotid arteries by UF
76086815|NCT03463798|Device|Sonar|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
76086816|NCT03463798|Device|Structured light plethysmography (SLP)|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
76086817|NCT03460769|Other|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
76086818|NCT03456128|Other|CAPABLE|It involves up to 10 in-home tailored interventions of approximately 60 minutes duration each over a 5-month period. The assessment driven interventions are delivered by an Occupational Therapist (OT) (≤ 6 home visits for ≤ 1hour), a Registered Nurse (RN) (≤ 4 home visits for ≤ 1hour), and a handyman (HM) team.
76086819|NCT03456089|Diagnostic Test|Urodynamics Testing|Urodynamics utilizes a small catheter to fill the bladder and continuously measure pressure and volume giving information on bladder function and compliance
76086820|NCT03454204|Other|Pharmacokinetic|Analysis of blood samples
76086821|NCT03452332|Biological|Durvalumab|Given IV
76086822|NCT03452332|Other|Laboratory Biomarker Analysis|Correlative studies
75649164|NCT05856240|Behavioral|Managing Stress & Emotions Group (MSEG)|The intervention consists of 6, 90-minute weekly sessions and includes the following components: providing education about psychological and emotional reactions to stress, introducing and practicing coping skills (e.g., mindfulness, emotional awareness, flexible thinking, behavioral modification), decreasing psychological avoidance using emotional exposure, and facilitating group support and discussion (see De Paul & Caver, 2021 for original protocol description).
75649165|NCT05856214|Behavioral|Couple-Based Violence Prevention education(CBVPE)|Couples in the intervention group will receive training on violence against women including intimate partner violence, types, and consequences of intimate partner violence during pregnancy, managing triggers of intimate partner violence, healthy relationships, the role of male partners during pregnancy, and couples communication and problem-solving skills. Training will be provided every fourth week by trained health extension workers for consecutive six months.
75649166|NCT05856201|Procedure|Laparoscopic cervicosacropexy|The first step consists of a supracervical hysterectomy with morcellation. Anterior and posterior dissection of the vesicovaginal and rectovaginal space. Placing a flexible blade or a Breisky blade in the vagina which is manipulated by the assistant in order to improve exposure of the tissue planes. The retroperitoneum will then be opened from sacral promontory to cervix with the incision just medial to the uterosacral ligament. A low-weight preshaped Y-shaped polypropylene mesh will be secured to the anterior and posterior vagina with four to six separated absorbable 2.0 polyglactin sutures and two nonabsorbable 2.0 prolene sutures can be placed at the level of the remaining cervix. The mesh will be attached to the sacral promontory using two or three nonabsorbable monofilament 2.0 prolene suture. The retroperitoneal space will be closed with continuous 2.0 polyglactin suture or barbed 2.0 absorbable suture material.
75796387|NCT05941884|Diagnostic Test|Immunohistochemistry staining,|"Tissue samples:~Histopathological examination: Hematoxylin and Eosin slides will be prepared and examined.~The only dependable criterion for the diagnosis of bilharzial infestation is the microscopic detection of Bilharzia ova in pathological sections.~Pathology (cystitis- cancer and its grade staging will be reported in accordance with the 2022 World Health Organization Classification of Tumors of the Urinary System (17).~To quantify levels of Nuclear factor kappa B and protein kinase c α:~Immunohistochemistry according to the manufacturer's instructions."
75796388|NCT05941884|Diagnostic Test|microscopic examination of urine|"Urine samples:~Mic roscopic examination (detection of S. haematobium egg - egg counting)~Detection of HSP 70 Measurements: indirect ELISA will be used to quantify HSP concentrations in urine."
75338695|NCT02537574|Drug|NTX/BUP|Daily doses
75338696|NCT02537574|Drug|NTX/PBO-B|Daily doses
75934271|NCT05187923|Diagnostic Test|Artificial Intelligence Algorithm|Different machine learning and deep learning computer aided strategies for model construction and validation.
75934272|NCT02553928|Drug|Memantine (once daily)|
76086823|NCT03452332|Radiation|Stereotactic Radiosurgery|Undergo SABR
76086824|NCT03452332|Biological|Tremelimumab|Given IV
76086825|NCT03431090|Device|CliniMACS® TCRαβ/CD19 Combined Depletion System|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
75934273|NCT02553928|Drug|Memantine (twice daily)|
75934274|NCT04486976|Device|Cornea/Anterior Segment OCT CASIA2|Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.
76086826|NCT03424148|Device|Excel V™ Laser & Micro-Lens Array Attach|Subjects will receive laser treatments
76086827|NCT03405792|Drug|Temozolomide (TMZ)|Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.
75338697|NCT02537574|Drug|PBO-N/PBO-B|Daily doses
75338698|NCT05098925|Other|Biological testing|Blood sampling, microcapillary sampling, temperature monitoring, saliva testing, EHI questionnaire
75649167|NCT05856201|Procedure|Shull technique via V-NOTES|Using a cold-bladed scalpel, pericervical colpotomy and subsequent opening of the Douglas and vesico-uterine space is performed. The following step is forcipressure and section of uterosacral ligaments bilaterally with cold blade scissors and ligation in Polysorb 0. A v-PATH® wall retractor is placed, after insertion of three trocars. Total hysterectomy is then performed by standard V-NOTES technique. After transperitoneal visualization of the ureters bilaterally, the peritoneum is incised between the ureters and the uterosacral ligaments, which are thus bilaterally isolated, and three points in polydioxanone 2/0 are placed per side. The v-PATH wall retractor is then removed. Finally the suspension of the vaginal vault at the uterosacral ligaments is made according to Shull technique. Eventual fascial corrections of concomitant anterior or posterior defects will be associated if needed.
76086828|NCT03405792|Device|Optune System|Patients will undergo 24-months of planned treatment with Optune therapy.
75796389|NCT05941871|Other|Dietary intervention - intervention group|"Low-calorie diet for 4 months with a different daily energy distribution according to the chronotype:~Morning chronotype: 50% of kcal administered before lunch and 15% in the second part of the day (specifically: 40% at breakfast, 10% in the morning snack, 35% at lunch, 5% at afternoon snack and 10% at dinner)~Evening chronotype: 15% of kcal given before lunch and 50% in the second half of the day (specifically: 10% of kcal at breakfast, 5% in the morning snack, 35% at lunch, 10% at snack time and 40% at dinner)"
75796390|NCT05941871|Other|Dietary intervention - control group|Group that will follow a low-calorie diet with a standard daily energy distribution (20% of kcal at breakfast, 10% in the morning snack, 35% at lunch, 10% at afternoon snack and 25% at dinner) for 4 months
75796391|NCT05941845|Drug|Peginterferon Alfa-2A 180 MCG/ML Injectable Solution|"Injections will be carried out on the Nephrology day hospitalization ward. The injections follows a personalized administration schedule: all enrolled patients will receive an injection of Pegasys® at Week 0.~Patients with a persistent Th17 profile (cytokine profile showing IL-17A levels greater than 73 pg/ml) at Week 2 will receive a new dose of Pegasys®, followed by a monthly cytokine profile. In the case of a persistent Th17 profile, 2 injections will be given two weeks apart.~In patients with no Th17 profile at Week 2, no Pegasys® injections will be performed at this time. Cytokine profiles will be performed monthly, and in the case of a persistent Th17 profile, 1 injection will be performed.~In total, patients will receive a minimum of one injection and a maximum of 13 injections of 180 µg (1 injection every two weeks for 24 weeks)."
75796392|NCT05941806|Drug|pr Sandoz Tamsulosin|Sandoz Tamsulosin, the study drug, is an alpha1-adrenergic blocking agent approved by Health Canada for men with bladder outlet obstruction symptoms associated with benign prostatic hyperplasia.
76086829|NCT03405792|Drug|Pembrolizumab|Pembrolizumab will be given intravenously every 3 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. Treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
76086830|NCT03391973|Drug|Pembrolizumab Injection|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
76086831|NCT03385655|Drug|Adavosertib|250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1
76086832|NCT03385655|Drug|Savolitinib|600mg once daily, orally.
76086833|NCT03385655|Drug|Darolutamide|600mg twice daily, orally.
76086834|NCT03385655|Drug|CFI-400945|Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.
76086835|NCT03385655|Drug|Ipatasertib|400mg daily 3 weeks on, 1 week off
76086836|NCT03385655|Drug|Durvalumab and Tremelimumab|Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
75649168|NCT05856188|Dietary Supplement|Glutamine|Biologic
76086837|NCT03385655|Drug|Carboplatin|AUC 5 IV 60min Day 1 q 21 days
76086838|NCT03369665|Drug|Mavenclad®|Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
76086839|NCT03361436|Drug|Eribulin Mesylate|Given IV
76086840|NCT03361436|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
76086841|NCT03361436|Other|Laboratory Biomarker Analysis|Correlative studies
76086842|NCT03361436|Other|Quality-of-Life Assessment|Ancillary studies
76086843|NCT03361436|Other|Questionnaire Administration|Ancillary studies
76086844|NCT03361436|Procedure|Therapeutic Conventional Surgery|Undergo surgery
76086845|NCT03353870|Other|qualitative interview|individual qualitative interview
76086846|NCT03333590|Biological|rAAVrh74.MCK.GALGT2|Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
76086847|NCT03323112|Biological|influenza vaccine|Vaccine for prevention of influenza. Vaccines change by influenza season.
76086848|NCT03317405|Drug|Endoxifen Hydrochloride|Apply to the skin
76086849|NCT03317405|Other|Placebo Administration|Apply to the skin
75338699|NCT03011801|Behavioral|Interpersonal Therapy|reducing conflict in relationships, increasing social support in relationships, improving communication, reducing depressive symptoms
75338700|NCT03011801|Behavioral|Enhanced usual care|Treatment as Usual, including eclectic and supportive therapy, as well as psychiatric medication
75338701|NCT03010241|Drug|Tangbi (prescription)|A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
75338702|NCT03010241|Drug|Placebo|"Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
75338703|NCT01164137|Behavioral|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
75338704|NCT01165541|Drug|Mirtazapine|mirtazapine (7.5-45mg)
75338705|NCT01165541|Drug|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine fumarate extended release 50-400mg/d
75338706|NCT00284180|Drug|Vinflunine|Novel second generation vinca alkaloid
75338707|NCT00284180|Drug|Trastuzumab|Anti-HER2 monoclonal antibody
75934275|NCT04486976|Device|Optovue RTVue XR Avanti|Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
76086850|NCT03317405|Other|Questionnaire Administration|Ancillary studies
76086851|NCT03311503|Biological|autologous CD34+ cell transduced with G2SCID vector|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
75934276|NCT03247010|Other|Blood sampling|Blood samples are taken before each cycle of Radium 223
75649169|NCT05856149|Behavioral|Mobile Diabetes Prevention Program|The intervention is a mobile, web-based diabetes prevention program that participants will have access to for a total of 12 weeks. The intervention is a behavioral intervention aimed at increasing the knowledge and skills of participants to reduce type 2 diabetes risk behaviors.
75649170|NCT05856097|Other|kinesio taping with diaphragmatic breathing|.kinesio tape was applied on1st day of intervention with the 20 minutes session of diaphragmatic breathing 3 sessions were given
75649171|NCT05856097|Other|kinesio taping without diaphragmatic breathing|kinesio tape was applied day 1st of intervention. 3 sessions were given
75649172|NCT05856045|Other|PNF(proprioceptive neuromuscular facilitation exercises)|"PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session was given to patients. 45 mins session/each day for 6 days a week."
75649173|NCT05856045|Other|PBBT (pertubation based balance training)|"Perturbation-based balance training (PBT) is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Pertubations are given by therapist in unexpected directions to challenge patients reactive balance. In this study pertubations will be given manually and on treadmill by a harness system.~daily 45 mins of exercise session of pertuations divided into double leg foam roller, wobble board exercises and pertubations on treadmill were performed for total 8 weeks and 6 days a week."
75649174|NCT05856045|Other|PNF and PBBT intervention group|proprioceptive neuromuscular exercises, pertubation based balance training along with conventional physiotherapy exercises were given for 8 weeks and 6 days per week for around 45 mins.
75649175|NCT05856032|Device|Acapella device|Acapella is one of the Oscillatory Positive Expiratory Pressure (OPEP) device used in mobilization of peripheral secretions to the central trachea. It consists of a mouth piece and metal strip that is attached to a magnet which oscillates upon exhalation of the patient into the device results in oscillations. This helps in generating positive expiratory pressure (PEP) and oscillations of the magnetic ball assist in mucus collection and expectoration. Pulmonary functions are greatly reduced in patients undergone CABG surgery due to prolong effects of anaesthesia and muscle relaxants administered prior to surgery.
75649176|NCT05856032|Other|Conventional Treatment|Conventional chest physiotherapy techniques
75649177|NCT05856006|Other|upper trapezius stretching plus neck isometrics|upper trapezius stretching plus neck isometrics
75934277|NCT03240380|Behavioral|joint crisis plan|"Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare."
75936536|NCT02428634|Behavioral|PSIE13|The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
76086852|NCT03304249|Behavioral|iAmHealthy Healthy Lifestyles Program|iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
75338708|NCT01165775|Device|Dexcom Seven Plus Continuous Glucose Monitoring System|Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
75338709|NCT01899872|Behavioral|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
75649178|NCT05856006|Other|upper trapezius stretching with mid-lower trapezius strengthening exercises plus neck isometrics|"Mid-Lower Trapezius strengthening exercise includes:~Latissimus pull down~Prone V- raise~Modified Prone Cobra"
75796393|NCT05941806|Drug|Glucose|Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec
75796394|NCT05941754|Dietary Supplement|omega-3|supplement in the market
75796395|NCT05941754|Dietary Supplement|placebo|corn oil
75796396|NCT05941676|Diagnostic Test|Tumour immunoprofile evaluation|Tumour immunoprofile evaluation will be performed in patients with head and neck cancer.
75796397|NCT05941650|Dietary Supplement|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
75796398|NCT05941650|Other|Corn Starch|This group will receive 12 g of corn starch as a control group.
75796399|NCT05941637|Drug|Axitinib 5 MG|Patients will receive Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and c-Kit - 5mg daily
76086853|NCT03304249|Other|Newsletter|Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
76086854|NCT03279887|Diagnostic Test|Lung Ultrasound|
75338710|NCT01899872|Behavioral|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
76086855|NCT03278847|Dietary Supplement|Received enteral (milk) feeds during therapeutic hypothermia|"In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)"
76086856|NCT03278847|Dietary Supplement|Enteral (milk) feeds withheld during therapeutic hypothermia|Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
75649179|NCT05855993|Other|Nerve Glide Exercise with Ultra Sound|A brief demonstration will be given to perform the nerve glides exercises to both group. The duration of exercise programmed is 15 minutes every 3 to 5 times per day for 4 weeks. Group A will perform exercise with ultrasound
75796400|NCT05941624|Device|Ha-330 Hemoperfusion Filter Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
75796401|NCT05941624|Device|Conventional Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
75796402|NCT05941611|Device|Powered toothbrush|Oral-B powered toothbrush
75796403|NCT05941585|Drug|Mitoxantrone hydrochloride liposome injection|intravenous infusion on day 1 in a 4-week treatment cycle.
75796404|NCT05941585|Drug|Cytarabine|intravenous infusion
75796405|NCT05941585|Drug|Homoharringtonine|intravenous infusion
75796406|NCT05941585|Drug|Venetoclax|orally once a day
75796407|NCT05941559|Other|EMDR|Eye Movement Desensitization and Reprocessing
75796408|NCT05941481|Combination Product|neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)|"Immunotherapy combined with chemotherapy (2 cycles): Intravenous tislelizumab (200mg, d1, q21d) in combination with XELOX regimen (capecitabine 1000 mg/m2 bid*14d + oxaliplatin 130mg/m2, d1, q21d);~Concurrent radiotherapy: Within one week after the first initiation of chemo-immunotherapy, concurrent hypofractionated radiotherapy will be started: intensity modulated radiotherapy was given for tumors, total dose:30Gy/12f, 2.5Gy/f."
75934278|NCT03240380|Behavioral|crisis card|"Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office."
76086857|NCT03278847|Dietary Supplement|Received parenteral nutrition during therapeutic hypothermia|"In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater)."
76086858|NCT03278847|Dietary Supplement|Did not receive parenteral nutrition during therapeutic hypothermia|Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
76086859|NCT03259620|Drug|CLS006|Furosemide Topical Gel
76086860|NCT03259620|Drug|CLS006 Vehicle|Vehicle Topical Gel
75338711|NCT04087460|Biological|Protein based pneumococcal vaccine(Low dose)|0.2mL,Intramuscular other name:PBPV
75649180|NCT05855993|Other|Nerve Glide Exercise without Ultra Sound|Group B will perform exercise for 10 minutes every 3 to 5 times per day without ultrasound.
75649181|NCT05855980|Procedure|Wound closure|Wound is closed or left open to heal secondarily after amputation.
75649182|NCT05855954|Combination Product|controlled low central venous pressure technique (CLCVP)|20min after the end of cardiopulmonary bypass, on the basis of ensuring that the mean arterial pressure (MAP) ≥ 60mmHg, we maintain the patient's central venous pressure below 10 mmHg by adjusting the posture and pumping nitroglycerin.
75649183|NCT05855928|Diagnostic Test|Mime Therapy|electrical stimulation with the MIME therapy and protocol
75796409|NCT05941468|Device|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
75796410|NCT05941455|Device|Venus-Neo Surgical Aortic Valve|Implant of a Venus-Neo Surgical Aortic Valve
75796411|NCT05941429|Drug|Nano-Silver Fluoride|NSF is a varnish which has been introduced as experimental formulation . the laboratory synthesis of NSF was carried out in a nano techonolgy center .
75796412|NCT05941429|Drug|Silver diamine fluoride|38% silver diamine fluoride
75934279|NCT03908255|Drug|Branch Chain Amino Acid|Nutritional supplementation
75934280|NCT03908255|Other|maltodextrin|Placebo
75934281|NCT03246854|Drug|DBPR112|DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
75649184|NCT05855928|Diagnostic Test|PNF Technique|electrical stimulation with the PNF technique with the routine physical therapy
75796413|NCT05941403|Behavioral|Enhanced Produce Prescription Implementation|Practices make modifications to their usual produce prescription program based on an implementation blueprint. While the exact implementation strategies to be added will be defined based on qualitative data (data collection in progress), possible implementation strategies may include training or technical assistance.
75796414|NCT05941390|Device|VR without positive psychology|Using VR goggles showing relaxing short videos without sound
75796415|NCT05941390|Device|VR with positive psychology|Using VR goggles showing relaxing short videos with positive psychological messages
75796416|NCT05941377|Other|blood pressure lowering|For EBPL group, patients are required to keep blood pressure at 100-120 mmHg. For SBPL group, patients are required to keep blood pressure at 120-140 mmHg.
76086861|NCT03253341|Behavioral|Smart Aging Program|Comprehensive lifestyle and fitness program designed to improve the health of older adults. The Smart Aging Program represents a package consisting of a dedicated health coach, mobile monitoring, specialized curriculum, and exercise opportunities.
75473809|NCT01975259|Drug|Matched isoglycemic clamp|A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
75934282|NCT04527718|Drug|Placebo|placebo as a single SC injection on Day 1;
76086862|NCT03253341|Behavioral|Educational Materials|Current standard of care. Includes education materials covering benefits of a healthy lifestyle.
76086863|NCT03226522|Drug|AXS-05|AXS-05
76086864|NCT03226522|Drug|Bupropion|Bupropion
75649185|NCT05855915|Diagnostic Test|Kinesio taping|Kinesotaping will be applied with routine physical therapy
75649186|NCT05855915|Diagnostic Test|Sham taping|Sham taping will be applied with routine physical therapy
75649187|NCT05855902|Behavioral|group art therapy|Art therapy will be offered in a weekly 1.5 hour group. Clients are provided a prompt and then asked to express their feelings using art, such as drawing/painting/etc.
75796417|NCT05941351|Procedure|flap fixation|flap fixation using running or interrupted sutures
75796418|NCT05941338|Drug|Tirelizumab ,+Carboplatin+albumin-bound paclitaxel|Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel
75934283|NCT04527718|Drug|611|611 as a single SC injection on Day 1;
75934284|NCT03246776|Drug|Halometasone Triclosan|Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment
75649188|NCT05855824|Other|Applesauce Pouch|One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.
75649189|NCT05855824|Other|Fruit-vegetable puree blend|One 120 g pouch of fruit-vegetable puree blend provides 5 mg mixed carotenoids, 70 kcal, 4 mg vitamin C, and 2 g dietary fiber.
75796419|NCT05941325|Drug|fruquintinib|VEGF receptor tyrosine-kinase inhibitor：fruquintinib（4mg), Oral，qd, d1-d14, Q3w，Until disease progression or intolerable toxicity occurs.
75796420|NCT05941325|Drug|Envafolimab|anti-PD-1 immune checkpoint inhibitor：Envafolimab（400mg), subcutaneous injection, d1, Q3w，Until disease progression or intolerable toxicity occurs.
75796421|NCT05941312|Procedure|autologous products|After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.
75796422|NCT05941299|Device|REGENERA breast implant implantation|"Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:~Screening~Pre-surgery treatment~Surgery and study device implant~Post-surgery follow-up"
75934285|NCT03972826|Other|Provodine|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
76086865|NCT03226522|Drug|Placebo|Placebo
76086866|NCT03225677|Procedure|blood draw and muscle biopsy|One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
75934286|NCT03246542|Diagnostic Test|shistocytes percentage|
76086867|NCT03225508|Diagnostic Test|Linear Ultrasound to Measure Diaphragmatic Movement|A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
75338712|NCT04087460|Biological|Protein based pneumococcal vaccine placebo(Low dose)|0.2mL,Intramuscular other name:PBPV placebo
75338713|NCT04087460|Biological|Protein based pneumococcal vaccine(Middle dose)|0.5mL,Intramuscular other name:PBPV
75473810|NCT01975259|Drug|Hyperglycemic clamp with concurrent GLP-1 infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
75473811|NCT01975259|Drug|Hyperglycemic Clamp with concurrent GIP infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
75649190|NCT05853978|Drug|BSS Plus|BSS PLUS® Sterile Intraocular Irrigating Solution (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)
75649191|NCT05853978|Drug|BSS|BSS® Sterile Irrigating Solution (balanced salt solution)
75338714|NCT04087460|Biological|Protein based pneumococcal vaccine placebo(Middle dose)|0.5mL,Intramuscular other name:PBPV placebo
75338715|NCT04087460|Biological|Protein based pneumococcal vaccine(High dose)|1.0mL,Intramuscular other name:PBPV
75338716|NCT04087460|Biological|Protein based pneumococcal vaccine placebo(High dose)|1.0mL,Intramuscular other name:PBPV placebo
75338717|NCT02044172|Procedure|Radical prostatectomy|radical prostatectomy
75338718|NCT02044172|Radiation|Conformal radiation therapy|Conformal radiation therapy, external beam
75338719|NCT02044172|Other|Active monitoring|Active monitoring of Prostate specific antigen levels and disease surveillance
75934287|NCT05480332|Device|EndoPAT|"We will use the standard non-invasive EndoPAT finger probes to conduct the studies. A single finger on each hand will be placed into a probe equipped with pressure sensors. A baseline recording period will be obtained. After five minutes, an occlusion phase will start where a blood pressure cuff on the patient's non-dominant arm will be inflated to 60mmHg above the patient's systolic pressure, or 200mmHg, whichever is higher. This phase will be conducted in concert with the standard instructions provided with the EndoPAT system. The occlusion phase will last for five minutes, after which time the cuff will be deflated. There will then be a five minute post-occlusion recording period. The test will then be completed.~The baseline period, occlusion period, and post-occlusion period will then be analyzed. A reactive hyperemia index score will be the desired output from the EndoPAT computer software, and will become the primary data point."
75934288|NCT03240146|Device|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device
75934289|NCT03076775|Other|Maternal glycemic control|Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
75934290|NCT05480254|Other|clamped catheter|Q3 clamped catheter protocol is applied before urinary catheter removal
75934291|NCT03240224|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
75796423|NCT05941273|Device|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
75796424|NCT05941234|Other|Biological biomarker analysis|Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of AI-based prognostic markers
75796425|NCT05941221|Procedure|pericapsular nerve group (PENG) block|patients will receive PENG block through ultrasound. The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed . A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL bupivacaine 0.25%.
75934292|NCT03240224|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
75934293|NCT03240302|Device|ICSI petri dish|Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
75338720|NCT05031806|Drug|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.
75338721|NCT05031806|Drug|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
75934294|NCT03240302|Device|PICSI petri dish|Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
75934295|NCT05480176|Other|Comprehensive intervention and management Ⅰ|Mainly health advisory.
75934296|NCT05480176|Other|Comprehensive intervention and management Ⅱ|Health advisory and regular follow-ups.
75934297|NCT05480176|Other|Comprehensive intervention and management Ⅲ|Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
75934298|NCT03067493|Biological|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
75934299|NCT03239912|Device|Twin-block appliance|Functional treatment will be achieved using the Twin-block appliance
75934300|NCT03239912|Other|Low level laser|Functional treatment will be combined with low-level laser therapy on the TMG region
75338722|NCT05031806|Drug|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
75649192|NCT05853900|Device|ReMMi-D Digital Therapeutic|Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.
75649193|NCT05853328|Procedure|Epley Maneuver|"The patient is sitting with both feet on the table or bed with the head looking forward. Subsequently, they let themselves fall backwards with a pillow under the shoulder and the head is turned 45° to the right. They stay in this position for 30 seconds. Afterwards, they turn the head quickly 90° to the left side followed by a turn of the whole body to the left so that their nose is pointing at the floor. They stay in this position for another 30 seconds.~Subsequently, the patients sit themselves up with the head still turned 45° to the left. They can help themselves by using both arms. After a few seconds, they can turn the head slowly back to the neutral position facing forward."
75649194|NCT05853328|Procedure|SemontPLUS maneuver|The patients first turn head 45° to the left. Then they extend the right arm and subsequently move the whole body by 150°+ to the right side. This position is kept for 60 seconds. Subsequently, patients move their whole body by 240° towards the non-affected side. Finally, after another 60 seconds, the patient sits up for another 60 sec.
75338723|NCT05031806|Drug|Vehicle (eye drop formulation without aCT1)|"36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.~During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2)."
75338724|NCT01899404|Biological|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
75338725|NCT01898546|Procedure|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
75338726|NCT01898546|Procedure|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
75796426|NCT05941195|Other|Psychoeducation|"In the cognitive behavioral approach based psychoeducation given to the experimental group patients; Addiction and Its Effects, Increasing and Maintaining Motivation, The Cognitive Model and the Cognitive Model of Addiction, Automatic Thoughts That Increase Impulse to Substance Use, Dysfunctional Beliefs Regarding Substance Use, High Risk Situations and Coping Skills,  The topics of Prevention of Slippage and Recurrence and Problem Solving are included."
75338727|NCT04389008|Other|no interventions|no interventions
75338728|NCT00216320|Device|WalkAide|Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
75338729|NCT00216320|Device|AFO|Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
75338730|NCT00216320|Device|AFO|Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
75796427|NCT05941182|Other|online questionnaires|Before and after online questionnaires
75934301|NCT05476666|Procedure|Peripherial and central venous access|Passing a peripherial and a central venous catheter/cannula
75934302|NCT03875495|Drug|Temferon|Genetically modified autologous HSPCs
75934303|NCT03236558|Procedure|Blood collection|Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
75338731|NCT00217490|Behavioral|dietary counseling via computer|An interactive computer program that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
75338732|NCT00217490|Behavioral|dietary counseling via nutritionist|A one on one counseling sessions to addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
75338733|NCT00217490|Behavioral|combined computer and nutritionist|An interactive computer program plus one on one nutrition counseling that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
75338734|NCT00217490|Other|physical activity counseling via computer|An interactive computer program that addresses increase to physical activity, barriers to change and possible solution to barriers to develop an action plan
75338735|NCT00217724|Dietary Supplement|glutamine|Given orally
75936537|NCT02428634|Behavioral|PSIE46|The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
75936538|NCT02421302|Dietary Supplement|RUTF|This is ready-to-use-therapeutic-food
75936539|NCT02428868|Drug|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
75338736|NCT00217724|Other|placebo|Given orally
75338737|NCT00287222|Drug|Bevacizumab|15 mg/KG I.V. every 21 days
75338738|NCT00287222|Drug|Erlotinib|150 mg orally every day
75338739|NCT04751240|Behavioral|SIT and resistance training|Participants complete 30 sessions of sprints and resistance training. Outcomes are assessed acutely and at 6 months.
75338740|NCT00218426|Drug|naltrexone implant|naltrexone implant is 1000 mg naltrexone
75338741|NCT00218426|Drug|oral naltrexone|oral naltrexone 50 mg/day
75338742|NCT00218426|Drug|oral placebo naltrexone|oral placebo naltrexone resembles active medication
75338743|NCT00218426|Drug|placebo implant|placebo implant resembles active medication
75796428|NCT05941169|Procedure|Cytoreductive Nephrectomy|The experimental intervention consists of cytoreductive nephrectomy (CN) or any ablative local therapy within 6 months and 1 year after start of systemic treatment. All types of ablative local therapy are allowed as a substitute for CN
75936540|NCT02428868|Drug|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
75473812|NCT01975259|Drug|Hyperglycemic clamp with placebo infusion|"An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving."
75473813|NCT01975259|Other|Liquid Meal Test (Carbohydrate-rich)|A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
75649195|NCT05852678|Other|cohort|The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
75649196|NCT05852379|Device|active taVNS|Transcutaneous auricular vague nerve stimulation
75649197|NCT05852379|Device|sham taVNS|Scham transcutaneous auricular vague nerve stimulation
75649198|NCT05852132|Procedure|pars plana vitrectomy(PPV)|Vitrectomy was performed for severe non-proliferative diabetic retinopathy, but panretinal photocoagulation(PRP) was not performed
75649199|NCT05852132|Procedure|Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP)|PPV was performed for severe non-proliferative diabetic retinopathy with PRP.
75649200|NCT05852132|Procedure|Panretinal photocoagulation(PRP)|Only PRP was used for severe non-proliferative diabetic retinopathy.
76086868|NCT03225508|Diagnostic Test|Curvilinear Ultrasound to Measure Diaphragmatic Movement|A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
76086869|NCT03225508|Diagnostic Test|Pulmonary function tests|Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
76086870|NCT03224949|Other|Blood draw|Patients will have a one time blood draw
76086871|NCT03212976|Procedure|Phase contrast magnetic resonance imaging|Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
76086872|NCT03201757|Drug|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
75934304|NCT05160467|Diagnostic Test|Segmental multi-frequency bio electrical impedance analysis|"A segmental (eight-polar) multi-frequency bio electrical impedance analysis (Inbody S10, Seoul, Korea) is carried out at the initiation of the deresuscitation strategy, at day 1, 3 and 5, in lying posture with touch type electrodes. Raw and derived parameters are recorded. The measurement is performed 5 times for the first measurement and then one time at day 1, 3 and 5.~Measurement error is defined by the manufacturer as: reversed Impedance in different segment all between 5-500kHz; impedance over 50Ω in trunk, or over 700Ω in limb; sudden drop of impedance in trunk (more than 10Ω), or in limb (more than 50Ω). If it occurs, measurement is carried out three times maximum after solving potential technical issues to obtain a valid analysis."
76086873|NCT03189706|Drug|Irinotecan|50mg/m^2/day IV will be administered from day 1-5
76086874|NCT03189706|Drug|temozolomide|(given concurrently with Irinotecan) 150mg/m^2/day orally
76086875|NCT03189706|Biological|Hu3F8|2.25mg/kg IV will be administered on days 2, 4, 8 and 10
75338744|NCT01134575|Drug|CMC-544 (Inotuzumab Ozogamycin)|"First patients > 16 years and < 16 years receive CMC-544 at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2."
75338745|NCT01134575|Drug|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
75473814|NCT01975259|Other|Liquid Meal Test (Fat-rich)|A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
75473815|NCT01975259|Other|Liquid Meal Test (Mixed)|A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
75649201|NCT05851313|Combination Product|Vitamin-D|The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
75649202|NCT05850676|Diagnostic Test|Sleep study|Participants will spend two nights in the Penn Sleep Center
75649203|NCT05850065|Other|Hu-Friedy 212 clamp|Hu-Friedy 212 clamp is normally used for the retraction with rubber-dam
75649204|NCT05850065|Other|dental floss using the simple knot tie method|Dental floss using the simple knot tie method is normally used for the retraction with rubber-dam
75649205|NCT05850065|Other|Coltene B4 clamp|Coltene B4 clamp is normally used for the retraction with rubber-dam
75649206|NCT05848999|Biological|UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)|D0: 0.1×106/Kg ～ 2.0×106/Kg; Cells will be infused intravenously.
75649207|NCT05848882|Device|Elastodontic Device|Removable device that embraces two dental archs
75649208|NCT05847556|Other|video game hearing tests|Video game hearing tests (as a non-medical device) used to monitor ototoxicity
75649209|NCT05847556|Other|Audio-training|Audio-training (as a non-medical device) used to determine if it can improve spatial hearing perception.
75649210|NCT05847231|Behavioral|Perceived Stress, Mandala application|Mandala
75649211|NCT05844813|Drug|Doxorubicin+Ifosfamide+Anlotinib(AI+A)|Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks * 3 Circles
75649212|NCT05844813|Procedure|Radical Surgery|Radical sarcoma resectional surgery
75934305|NCT02453204|Behavioral|Sitting|
75934306|NCT02453204|Behavioral|Standing|
75934307|NCT02453204|Behavioral|Walking|
76086876|NCT03189706|Drug|GM-CSF|250mcg/m2/day SC will be administered on days 6-10
76086877|NCT03181893|Drug|PF-06823859 low|A humanized immunoglobulin neutralizing antibody
76086878|NCT03181893|Drug|Placebo Arm|Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
76086879|NCT03181893|Drug|PF-06823859 high|A humanized immunoglobulin neutralizing antibody
75934308|NCT05160389|Drug|PBI-200|Single dose of PBI-200
75934309|NCT03246386|Drug|Posaconazole Injection [Noxafil] 300mg|Single dose by intravenous infusion 300mg
76086880|NCT03180840|Biological|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg every 4 weeks
76086881|NCT03157804|Procedure|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
76086882|NCT03157804|Biological|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
76086883|NCT03157804|Other|Laboratory Biomarker Analysis|Correlative studies
76086884|NCT03157804|Biological|Filgrastim|Given subcutaneously (SC)
76086885|NCT03157804|Drug|Plerixafor|Given SC
76086886|NCT03157804|Procedure|Bone Marrow Aspiration|
76086887|NCT03139227|Procedure|Bio specimen Collection|Patients undergo collection of blood and urine
76086888|NCT03139227|Dietary Supplement|Dietary Intervention|Consume celery-banana bread
75934310|NCT03246386|Drug|Posaconazole Injection [Noxafil] 400mg|Single dose by intravenous infusion 400mg
76086889|NCT03139227|Other|Laboratory Biomarker Analysis|Correlative studies
76086890|NCT03135327|Dietary Supplement|Ocufolin|Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.
76086891|NCT03128879|Drug|Ibrutinib|Given PO
76086892|NCT03128879|Drug|Venetoclax|Given PO
76086893|NCT03128879|Drug|Acalabrutinib|Given BID
76086894|NCT03124160|Drug|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini
75649213|NCT05842928|Behavioral|PARTNER intervention|"The PARTNER intervention includes the following components:~Education for health care professionals~A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations;~B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions;~C) checklist for identification of drug-related problems for pharmacists;~D) tapering support tool to facilitate the selection of tapering schemes;~E) divisibility list for PSA-PIM to support the implementation of tapering schemes;~F) empowerment brochures for patients each focussing on one PSA-PIM subgroup~Interprofessional workshop and case conference for GPs and pharmacists~Pharmacy visit (brown bag/medication review) including patient empowerment~GP practice visit including shared decision making (SDM)"
75649214|NCT05842928|Behavioral|Control intervention|The control intervention only comprises a pharmacy visit with brown bag review.
75649215|NCT05842863|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a treatment program that helps teens reduce suicidal and self-harm behaviors by teaching them coping skills for managing negative emotions. DBT includes weekly individual therapy, weekly multifamily skills group, and 24/7 telephone-based skills coaching from the therapist.
76086895|NCT03124160|Drug|ParaGard® CuT380A|ParaGard® CuT380A
75649216|NCT05842863|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBTI) is a type of counseling that helps people improve sleep by changing their sleep behaviors and thinking about sleep. In CBTI, people learn about sleep regulation, factors that influence quantity and quality of sleep, and specific techniques to optimize sleep. In this study, CBTI will be delivered using a self-guided online program called Firefly.
75649217|NCT05837338|Drug|BXP154|BXP154 will be self-administered topically following wound induction
75796429|NCT05941156|Biological|Anti-CD56 CAR T|CAR T cells were pretreated at -5 days before retransfusion (FC regimen: fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day). Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.
76086896|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - deintensified|60 Gy at 2 Gy/fx
76086897|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - standard|70 Gy at 2 Gy/fx
76086898|NCT03077243|Drug|Cisplatin (or alternative) - deintensified|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses.
75338746|NCT01790672|Dietary Supplement|Ethanol|Vodka Absolut
75338747|NCT01790672|Other|Water|Lemon-flavored water
75338748|NCT01790672|Dietary Supplement|Alcoholized wine|Wine 13º or wine 8º
75338749|NCT01790672|Dietary Supplement|De-alcoholized wine|Wine 0º
75338750|NCT01134887|Other|Informational Guide for Patients|"Veterans received a copy of the NIA guide for Talking with Your Doctor. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
75649218|NCT05837338|Drug|Placebo|Placebo will be self-administered topically following wound induction
75796430|NCT05941143|Other|mindfulness-based intervention|8 weekly group 2-hour sessions program adapted from mindfulness-based stress reduction and mindfulness-based cognitive therapy protocols. It was specifically tailored to older adults.
75934311|NCT03851081|Biological|Inotuzumab Ozogamicin|Given IV
75934312|NCT03851081|Other|Quality-of-Life Assessment|Ancillary studies
75934313|NCT03851081|Drug|Vincristine Sulfate Liposome|Given IV
75934314|NCT03239756|Biological|TK006|Subcutaneous injection
75934315|NCT05156645|Drug|SCTA01 and SCTA01C|Diluted by 0.9% normal saline
75934316|NCT05156645|Drug|Placebo|Diluted by 0.9% normal saline
75936541|NCT02428868|Other|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
76086899|NCT03077243|Drug|Cisplatin (or alternative) - standard|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 7 total doses.
76086900|NCT03077243|Procedure|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
76086901|NCT03066596|Behavioral|PRAGMATIC|Provider educational seminar, EHR prompt, outreach-worker care coordination
76086902|NCT03064035|Drug|4-factor prothrombin complex concentrate (4FPCC)|4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
76086903|NCT03054181|Biological|HyQvia|
75934317|NCT03239834|Device|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.
76086904|NCT03028311|Procedure|Angiography|Undergo angiography
75649219|NCT05829681|Device|Repetitive Transcranial Magnetic Stimulation|Participants will receive a 5-day course of 10x daily rTMS, with sessions delivered hourly. Each session will deliver up to 1800 pulses of theta-burst stimulation per target.
76086905|NCT03028311|Procedure|Computed Tomography|Undergo SPECT-CT
76086906|NCT03028311|Procedure|Planar Imaging|Undergo planar imaging
76086907|NCT03028311|Radiation|Radioembolization|Undergo radioembolization
76086908|NCT03028311|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT-CT
76086909|NCT03028311|Radiation|Technetium Tc-99m Albumin Aggregated|Given via arterial catheter
76086910|NCT03028311|Other|Yttrium Y 90 Resin Microspheres|Given via arterial catheter
76086911|NCT03018730|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
76086912|NCT02971891|Drug|CLS006 (Furosemide) Topical Gel|
76086913|NCT02971891|Drug|Vehicle Topical Gel|
75338751|NCT01134887|Behavioral|Video-Assisted Coaching|Physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients, but before seeing them for follow-ups. The main goal of this video-assisted coaching session was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management.
75338752|NCT01134887|Other|Monograph for Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians. The Four Habits provided practical evidence-based advice for improving patient-physician communication."
75649220|NCT05820204|Behavioral|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain
75649221|NCT05820204|Behavioral|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|A psychotherapy for chronic pain that has 30+ years of research support.
75649222|NCT05820204|Other|Usual care|Participants will be asked to continue to do whatever they are currently doing to manager their pain
75649223|NCT05813574|Other|Observational patient reported outcomes|Of COVID-19 patients
75649224|NCT05812417|Drug|DA-8010|DA-8010 5mg single dose administration
75649225|NCT05800158|Diagnostic Test|Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit|A reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2.
75796431|NCT05941130|Drug|Combination of corticosteroid (methylprednisolone - Medrol, 16mg Pfizer Laboratories) therapy and non-steroidal anti-inflammatory (Ibuprofen 600mg Mylan) therapy|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative steroid anti-inflammatory"
75796432|NCT05941130|Drug|Non-steroidal anti-inflammatory therapy (Ibuprofen 600mg Mylan)|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative non-steroid anti-inflammatory"
75796433|NCT05941117|Combination Product|stretching exercises|stretching exercises for Hamstring, quadriceps and calf muscle for both lower limbs of the same patients. each exercise was repeated 5 times and each repetition hold for 30 seconds in the same session.
75796434|NCT05941117|Combination Product|Transcutaneous electrical nerve stimulation|it is one of the electrical stimulation modalities which is used to relief pain, each patient receive it on both knees every session.
75796435|NCT05941117|Combination Product|weight bearing strengthening exercises|strengthening exercises for quadriceps, gluteus maximus, gluteus Medius and calf muscle in the form of weight bearing from standing position each exercise was repeated for 10 times with 5 seconds hold in the same set and patient perform three sets in the same session for both lower limbs.
75934318|NCT05130671|Drug|Standard of care|Standard of care treatment as per the hospital guidelines
75934319|NCT05130671|Dietary Supplement|Investigational treatment|Combination of quercetin and curcumin as add-on to the standard of care
75934320|NCT05112419|Drug|Zibotentan|All participants will receive a single oral dose of zibotentan capsule under fasted conditions.
75934321|NCT03246308|Radiation|Phototherapy|Taking blood sample.
75934322|NCT03235388|Other|Audit filters|Institutional implementation of audit filters
76086914|NCT02953717|Radiation|Gamma Knife radiosurgery|GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.
76086915|NCT02953717|Radiation|Whole Brain Radiation Therapy|Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
76086916|NCT02940301|Drug|Ibrutinib|Given PO
76086917|NCT02940301|Other|Laboratory Biomarker Analysis|Correlative studies
76086918|NCT02940301|Biological|Nivolumab|Given IV
76086919|NCT02918474|Other|Decision Aid|Use decision making tool
76086920|NCT02918474|Other|Questionnaire Administration|Ancillary studies
76086921|NCT02881814|Diagnostic Test|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
76086922|NCT02881814|Diagnostic Test|Lung and diaphragm ultrasound in MV patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
76086923|NCT02872025|Drug|Pembrolizumab|Injected intralesionally
76086924|NCT02872025|Biological|Intralesional mRNA 2752|Injected intralesionally
75649226|NCT05770427|Behavioral|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by parents and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching parents to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
75649227|NCT05768555|Other|Whole body vibration intervention at 40 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 40 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
76086925|NCT02824029|Drug|Ibrutinib|Given PO
76086926|NCT02824029|Other|Laboratory Biomarker Analysis|Correlative studies
76086927|NCT02824029|Other|Pharmacological Study|Correlative studies
76086928|NCT02822573|Drug|Donepezil 5 mg|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
76086929|NCT02822573|Drug|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
76086930|NCT02795676|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
76086931|NCT02795676|Biological|agalsidase beta|agalsidase beta 1 mg/kg every 2 weeks
76086932|NCT02784535|Drug|Atomoxetine|norepinephrine transporter inhibitor
76086933|NCT02784535|Drug|Placebo|placebo
76086934|NCT02750072|Procedure|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
76086935|NCT02750072|Procedure|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
75649228|NCT05768555|Other|Whole body vibration intervention at 25 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 25 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
75649229|NCT05768555|Other|Whole body vibration intervention at 0 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 0 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
75649230|NCT05766540|Drug|Aripiprazole 10 MG|Aripiprazole hroup will receive Aripiprazole 10 mg/day along with Clozapine and Metformin
75796436|NCT05941117|Combination Product|Non-weight bearing strengthening exercises|strengthening exercises for quadriceps, gluteus maximus, gluteus Medius and calf muscle in the form of non-weight bearing from lying and setting positions each exercise was repeated for 10 times with 5 seconds hold in the same set and patient perform three sets in the same session for both lower limbs.
76086936|NCT02723409|Procedure|Round Procedure Umbilicoplasty|"Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure"
76086937|NCT02723409|Procedure|"Scarless round procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure"
76086938|NCT02723409|Procedure|"Inverted U Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure"
76086939|NCT02723409|Procedure|"Inverted VProcedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure"
76086940|NCT02723409|Procedure|"Y deepithelialized Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure"
76086941|NCT02708836|Procedure|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
76086942|NCT02708836|Device|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
76086943|NCT02708836|Device|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
76086944|NCT02708836|Procedure|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
76086945|NCT02708836|Procedure|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
76086946|NCT02708836|Procedure|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
76086947|NCT02708836|Procedure|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
76086948|NCT02708836|Procedure|Emergence from anesthesia|"At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand)."
76086949|NCT02699151|Drug|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
76086950|NCT02699151|Procedure|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
76086951|NCT02699151|Other|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
76086952|NCT02690545|Biological|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10^8 cells/m^2 and 2x10^8 cells/m^2. Phase II patients will receive the dose level decided upon in Phase I.
76086953|NCT02643069|Other|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
76086954|NCT02639026|Radiation|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
75649231|NCT05747131|Behavioral|Emotion Detectives In-Out|Emotion Detectives In-Out is a blended cognitive-behavioral intervention for children with emotional disorders aged between 7 to 12 years and their parents. It contains group sessions, online self-guided sessions and videoconference sessions. The groups will consist of about 5 to 7 children. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists with specific training in the program. The online sessions were developed by the research team and are completely self-guided. These sessions last approximately 45 minutes. Parents will be asked to participate in 2 face-to-face sessions, 4 videoconference sessions and 10 self-guided online sessions. It is a transdiagnostic and emotion-focused manualized cognitive-behavioral therapy designed to help children reduce the intensity and frequency of strong and aversive emotional experiences and to help parents reduce parental emotional behaviors.
75649232|NCT05747131|Behavioral|Coping Cat|Coping Cat is a cognitive behavioral therapy for children with anxiety aged between 7 to 13 years. Coping Cat consists of 16 weekly group sessions with the children (5 to 7 children per group) and 2 sessions with the parents. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists.
76086955|NCT02639026|Drug|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
75473816|NCT01975259|Device|Continuous Glucose Monitoring|Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid & every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
75649233|NCT05746806|Radiation|Ultrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy|Ultrahypofractioned radiotherapy for patients with isolated local recurrence after radical prostatectomy in 5 fractions
75649234|NCT05746806|Drug|Androgen deprivation therapy|"In combination to the radiotherapy a short term androgen deprivation drug for 6 months will be applied.~The drug concept used is:~- LHRH(Luteinizing hormone releasing hormone)-agonist with 3-month subcutaneous depot injection (e.g. Pamorelin® LA (Triptorelin) 11.25mg s.c.) in combination with nonsteroidal antiandrogen (e.g. Bicalutamide 50mg/day) as flare protection at least 5 days before and max. 15 days after first LHRH-injection"
75649235|NCT05743673|Device|Shape II|cardiopulmonary exercise testing apparatus
75649236|NCT05741229|Drug|Nebulized nitroglycerine as adjunctive therapy|Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy
75649237|NCT05741229|Drug|conventional therapy for PPHN|patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
75649238|NCT05740202|Drug|SHR-7367|The study was divided into three phases, the dose escalation phase and the dose extension phase and therapeutic effect extension of SHR-7367 in subjects with advanced malignant tumors.
75649239|NCT05736120|Other|No treatment given|No treatment given
75649240|NCT05734118|Device|Perfusion assessment by means of the SPY-PHI camera|Minutes after injection of ICG, the intestinal perfusion can and will be assessed using the SPY-PHI camera by Stryker Endoscopy. The operative plan will not be changed based on the results of the perfusion assessment. Images will be recorded and evaluated postoperatively.
75649241|NCT05733715|Drug|Pembrolizumab infusion|100 mg/ 4mL on Day 1 of each 3- or 6- week cycle (one 3 wk cycle; up to eight 6 wk cycles)
75649242|NCT05733715|Drug|Lenvatinib tablet|10mg and 4mg daily for 21 days
75796437|NCT05941104|Other|frailty|Frailty is a group of common clinical syndromes in the elderly, characterized by systematic, dynamic and reversible, the core of which is the decline of physiological reserves and the destruction of self-balance.
75796438|NCT05941091|Behavioral|HafifMod Programme|"MODULAR EDUCATION PROGRAMME: A training program consisting of five modules, shaped by the main headings of fluid and salt control in hemodialysis patients, was created. It is aimed that the patients receive training on a topic each week in a gradual manner. It will be ensured that HD patients can watch the modular training videos prepared in the computer environment on a tablet or computer.~MOBİLE APPLICATION: Through the mobile application to be developed, the maximum amount of fluid that HD patients should consume per day will be calculated automatically based on their dry weight. In addition, a system will be created where the user can manually enter the amount of fluid consumed daily and add it to the total amount of fluid consumed. In this way, people will be able to learn the amount of fluid they consume daily. In addition, the content of the application will include informative messages in the form of educational short tips and modular training videos."
76086956|NCT02639026|Drug|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
76086957|NCT02632448|Drug|LY2880070|Capsules
75649243|NCT05730179|Other|Mechanical Conditioning stimulus|Painful mechanical stimulus
76086958|NCT02632448|Drug|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
76086959|NCT02617511|Dietary Supplement|Omega-3 Supplementation|
76086960|NCT02617511|Dietary Supplement|Placebo|
76086961|NCT02587234|Device|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
76086962|NCT02561091|Other|Placebo|
75796439|NCT05941091|Behavioral|Distribution of printed material|In the study, a general dietary guideline including fluid and salt restriction, which is a printed educational material for the control group, will be used. Thus, it is planned that the participants in the control group will have a guide resource that will enable them to be informed about nutrition. In this way, an educational practice based on the distribution of printed material will be carried out for the control group. Except for the material distribution practice, the routine care procedures the unit will be maintained in the same way, and no different a practice will be made.
76086963|NCT02561091|Drug|AM-111 0.4 mg/ml|
76086964|NCT02561091|Drug|AM-111 0.8 mg/ml|
76086965|NCT02489604|Drug|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
76086966|NCT02489604|Drug|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
76086967|NCT02473276|Drug|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
76086968|NCT02473276|Drug|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
75796440|NCT05941078|Behavioral|ICF-based post-stroke rehabilitation program|Patients completed an intake interview with a case therapist for an initial assessment and setting of personal treatment goals. The therapist assisted the patient with setting goals that were related to their life roles and functional gaps in terms of body function and activity and participation. Patients' personalized treatment plans were composed in case conferences. The treatment program contents were organized as ICF-based body function and activity and participation intervention modules. Each of the occupational therapy, physiotherapy, and speech therapy disciplines set the aims and developed the training contents, intensities, durations, and upgrading and completion criteria.
76086969|NCT02451423|Drug|Atezolizumab|1200 mg Given IV
76086970|NCT02444442|Device|Renal Denervation|Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
75649244|NCT05730166|Other|Mechanical Conditioning stimulus|Mechanical stimulus on the upper trapezius of the non-dominant side.
75796441|NCT05941039|Device|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.
76086971|NCT02444442|Other|Sham control|Arterial access only. No delivery of radio frequency energy to renal arteries.
75796442|NCT05941039|Device|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
76086972|NCT02411773|Drug|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate > 30).
75796443|NCT05941026|Other|Structured education|"The educational content of the research was created by the researcher in line with the literature and expert opinions and covers the following topics.~Educational subjects~Culture and Concepts Related to Culture~Culture/Cultural Characteristics and Cultural Elements in Terms of Social Structure~Cultural Factors Affecting Health and Disease~Concepts and Practices Related to the Field of Study~The training is an online training and continued via video conference, and a session invitation was sent to the participants before each session. In addition, after the training, brochures containing the training topics of each week were prepared and delivered to the participants. The trainings were conducted by the researcher in a total of four sessions (each session 20 minutes) once a week during the training process. During the training, the questions of the participants were answered."
76086973|NCT02411773|Drug|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session.
75796444|NCT05940987|Behavioral|Phone-based smoking cessation intervention|Participants who allocate to the intervention group will receive regular phone-based smoking cessation intervention by professional team.
75798991|NCT01182558|Other|EDB muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
75798992|NCT01182558|Other|Relaxation of muscle|The muscle on the opposite side will be maintained at rest.
76086974|NCT02411773|Behavioral|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
76086975|NCT02411773|Behavioral|Control to Exercise (Stretching)|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
76086976|NCT02378428|Drug|MIBG|
76086977|NCT02328599|Procedure|Bariatric surgery involving Roux-en-Y gastric bypass|Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
75649245|NCT05730127|Other|Conditioning stimulus|Pain stimulus on non-dominant side
75473817|NCT01975311|Other|Lumbopelvic Manipulation|High-velocity low-amplitude non-specific lumbopelvic thrust manipulation
75649246|NCT05720663|Other|Standard of care|Participants will receive the standard of care for their condition
75649247|NCT05709691|Other|Oculomotor therapy|Visual exercise to improve oculomotor behavior.
75649248|NCT05709691|Other|Adapted yoga|Muscular Stretching Therapy, postural control, respiratory physiotherapy.
76086978|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic adjustable gastric banding|Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
75473818|NCT01975311|Other|Passive lumbar spine flexion and extension|Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
75649249|NCT05709145|Other|Written recommendation|"Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within1 year.~The colonoscopy report will included that an adequate intestinal cleansing has not been achieved and therefore it is an invalid exploration. Additionally, a written recommendation indicating that the colonoscopy should be repeated within1 year will be included in the colonoscopy report. This recommendation is addressed both to the clinician who requested the colonoscopy and to the patient himself."
76086979|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic sleeve gastrectomy|Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
76086980|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|single dose of 1 × 10(7) cells intrathecally
76086981|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart
75473819|NCT01975324|Drug|dalfampridine|dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
76086982|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|2 doses of 1 × 10(8) cells intrathecally each 1 month apart
76086983|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
76086984|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
76086985|NCT02297256|Procedure|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
76086986|NCT02297256|Procedure|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
76086987|NCT02278666|Procedure|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
76086988|NCT02278666|Device|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
76086989|NCT02278666|Device|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
76086990|NCT02189720|Drug|Amifampridine Phosphate|"Dosage form: tablets containing the equivalent of 10 mg amifampridine per tablet.~Amifampridine Phosphate given based on Investigator assessment of optimal neuromuscular benefit. In adult patients > 16 years of age, Doses ranged from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day and in pediatric patients age < 16 years the maximum daily dose was 60 mg/day. No single dose to exceed 20 mg."
76086991|NCT02184195|Drug|Olaparib|Tablet -100mg
76086992|NCT02184195|Drug|Olaparib|Tablet-150mg
76086993|NCT02184195|Drug|Placebo|Match Olaparib 100mg placebo
75796445|NCT05940519|Other|Dynamic taping technique|The dynamic taping method as specified in the literature will be applied to the right and left lumbar paravertebral muscles in the dynamic taping group. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
75798993|NCT02524470|Device|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
76086994|NCT02184195|Drug|Placebo|Match Olaparib 150mg placebo
76086995|NCT02181413|Drug|Ixazomib Citrate|Ixazomib citrate capsules
76086996|NCT02181413|Drug|Placebo|Ixazomib citrate placebo-matching capsules
75473820|NCT01975324|Drug|Placebo|placebo (sugar pill) twice a day for two weeks
76086997|NCT02152631|Drug|Abemaciclib|Administered orally
76086998|NCT02152631|Drug|Erlotinib|Administered orally
76086999|NCT02151981|Drug|Chemotherapy|Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
75473821|NCT01975337|Drug|Alisporivir|Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
75473822|NCT01975363|Dietary Supplement|curcumin|Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.
75473823|NCT01975363|Other|Biomarker analysis|Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.
75649250|NCT05702177|Drug|Daridorexant 25 mg|A single-dose of daridorexant 25 mg will be administered in the evening 30 minutes prior to bedtime.
75649251|NCT05702177|Drug|Daridorexant 50 mg|A single-dose of daridorexant 50 mg will be administered in the evening 30 minutes prior to bedtime.
75649252|NCT05702177|Drug|Placebo|A single-dose of placebo matching daridorexant will be administered in the evening 30 minutes prior to bedtime.
75649253|NCT05700305|Other|12-week, low threshold physical rehabilitation intervention with protein supplementation|12 week, low threshold, rolling exercise intervention with protein supplementation
75796446|NCT05940519|Other|Sham taping|Sham taping will be applied with a surgical patch while the patient is in a comfortable position without any technique or stretching.Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
75934323|NCT03239600|Drug|GSK2618960 2 mg/kg|GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
75934324|NCT03239600|Drug|Placebo|Placebo solution will be administered by IV infusion.
75934325|NCT03239600|Drug|Methotrexate|MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
76087000|NCT02151981|Drug|Cross-over to Osimertinib|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with Osimertinib 80mg, once daily. These subjects may continue treatment with Osimertinib even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to Osimertinib."
76087001|NCT02138617|Drug|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
76087002|NCT02138617|Drug|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
76087003|NCT02138617|Drug|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
76087004|NCT02138617|Drug|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
75796447|NCT05940116|Drug|HS-20117|"Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined.~Phase Ib: patients will receive HS-20117 at MED or MAD"
75338753|NCT01134887|Behavioral|Educational Coaching|an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management.
75796448|NCT05939921|Drug|Metformin|T2DM patients will be provided with metformin in a specified dose
75796449|NCT05939895|Device|Medtronic G3 sensor|A Sensor is fitted on the arm and abdomen of every patient and using a CGMS App. the patient's blood glucose level are monitored at regular intervals.
75796450|NCT05939869|Other|Medical and Clinical History|Retrospective and prospective analysis of patients data will be done.
75796451|NCT05939219|Biological|15-valent pneumococcal conjugate vaccine 202210001|Immunization program and dosage:3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
75934326|NCT03234998|Device|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.
75934327|NCT03234998|Device|cognitive dual-task training|Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
75936542|NCT02428400|Biological|TG1050|TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
75338754|NCT01134887|Other|Control|"The primary care providers randomly assigned to the Control-Physicians arm did not receive any additional coaching or resources and conducted their practice as usual."
75338755|NCT00223262|Drug|Lamotrigine (Drug)|
75936543|NCT02428400|Biological|Placebo|Placebo: adenovirus reference material (ARM) buffer
75936544|NCT02424890|Other|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
76087005|NCT02118584|Drug|Etrolizumab|Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
76087006|NCT02062827|Biological|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
76087007|NCT02040207|Drug|AM-101|AM-101 gel for intratympanic injection
76087008|NCT02040194|Drug|AM-101|AM-101 gel for intratympanic injection
76087009|NCT02040194|Drug|Placebo|Placebo gel for intratympanic injection
76087010|NCT02021019|Procedure|Renal Denervation|Renal Denervation
76087011|NCT01996605|Drug|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
76087012|NCT01996605|Drug|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
76087013|NCT01996605|Drug|Placebo|placebo will be administered spinally
76087014|NCT01981720|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
76087015|NCT01976182|Drug|Methotrexate|methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
75338756|NCT03011879|Other|clinical pathway|
75473824|NCT01975363|Other|Assessment of Dietary Intake|Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.
75338757|NCT00223652|Behavioral|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
75338758|NCT03012035|Other|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
75796452|NCT05939219|Biological|15-valent pneumococcal conjugate vaccineY202210002|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
75473825|NCT01975363|Other|Daily Log|All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
75934328|NCT03628547|Behavioral|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
75649254|NCT05691166|Behavioral|High-intensity progressive resistance training|Supervised high-intensity progressive resistance training twice per week for 12 months
75649255|NCT05691166|Other|General practitioner care|Referred to general practitioner (GP) for further follow-up. The GPs will be informed about participants sarcopenia status with results from assessments of muscle strength, muscle mass, and physical performance. The management of the sarcopenia is at the GPs own discretion.
75796453|NCT05939219|Biological|15-valent pneumococcal conjugate vaccineY202210003|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
75796454|NCT05939219|Biological|15-valent pneumococcal conjugate vaccineY202210004|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
75798994|NCT02524470|Device|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
76087016|NCT01976182|Drug|Cyclophosphamide|cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
76087017|NCT01974440|Drug|Bendamustine|90 milligram per meter square (mg/m^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
76087018|NCT01974440|Drug|Rituximab|375 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
75473826|NCT01975441|Drug|Diethylcarbamazine|Diethylcarbamazine 6mg/kg
75473827|NCT01975441|Drug|Albendazole|Albendazole 400mg
75473828|NCT01975441|Drug|Ivermectin|Ivermectin 200 mcg/kg
75473829|NCT01975454|Drug|Chemotherapy|Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
75473830|NCT01975454|Drug|Herbal therapy|TLBZT based herbal decoction administered orally twice a day
75473831|NCT01975480|Drug|Desvenlafaxine|
75473832|NCT01975545|Drug|Fluor varnish|Dental varnish will be applied to one anterior superior teeth in a random side.
75473833|NCT01975545|Drug|Fluor varnish with nanoparticles|Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
75473834|NCT01975558|Biological|Sampling at baseline, one week after baseline, two weeks after baseline|
75473835|NCT01975558|Biological|Sampling at baseline, during radiotherapy and after|
75473836|NCT01975584|Behavioral|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
75649256|NCT05691075|Procedure|Arthrodesis of the metatarsophalangeal joint|Isolated surgery of the first ray of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach
75649257|NCT05687955|Other|Hip Exercise Program|The exercise intervention is being implemented 3 times per week. Two sessions can be completed at home by the participant, and one session per week will be attended by a physiotherapist that will monitor exercise technique and progress the exercise program for each participant. The exercise protocol has been specifically designed to focus on hip rehabilitation appropriate for circus performance. The exercise program will involve hip strength exercises in the sagittal, coronal and transverse planes using weights and elastic bands (Theraband). It will also include trunk strength and postural correction exercises to address swayback posture which is a common clinical presentation in those with hip dysplasia.
75649258|NCT05683067|Other|Hand Held Capillary Microscopy|The investigator will visualize the blood vessel appearance, number, and size they have in their hands, feet, and under the tongue. This procedure is non-invasive and will not cause any pain.
76087019|NCT01974440|Drug|Cyclophosphamide|750 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
76087020|NCT01974440|Drug|Doxorubicin|50 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
76087021|NCT01974440|Drug|Vincristine|1.4 mg/m^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
76087022|NCT01974440|Drug|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
76087023|NCT01974440|Drug|PCI-32765 (Ibrutinib)|560 mg (4*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
76087024|NCT01974440|Drug|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
75338759|NCT03012035|Other|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
75649259|NCT05683067|Other|Mobile 'O' Graph|The aortic stiffness will be measured non-invasively using a special blood pressure monitor called Mobile 'O' Graph, which is about size of a pocket diary. 24 hour blood pressure monitoring is optional.
75796455|NCT05939219|Biological|13 valent pneumococcal polysaccharide conjugate vaccine|Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
75796456|NCT05938647|Other|Risk factor: group 3|Severe dengue, no shock. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
75934329|NCT02966093|Drug|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
75934330|NCT02966093|Drug|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
75934331|NCT03229616|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
75934332|NCT03229616|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
75934333|NCT03229616|Drug|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
75934334|NCT03058991|Behavioral|Distress Tolerance Intervention|See arm/group description.
75934335|NCT03058991|Behavioral|Working Memory Intervention|See arm/group description.
75934336|NCT03058991|Behavioral|Control Informational Intervention|See arm/group description.
75934337|NCT03234920|Dietary Supplement|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily
75934338|NCT03234920|Other|Placebo|The placebo will be 200 ml of fruit juice given twice daily
76087025|NCT01921166|Drug|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
76087026|NCT01921166|Drug|Leuprolide flare|Leuprolide flare ovulation induction
76087027|NCT01906970|Device|ClampArt|
76087028|NCT01855477|Procedure|Histological biopsy procedure|
76087029|NCT01836744|Device|Survival rate dental implant (OsseoSpeed™)|
76087030|NCT01805076|Procedure|Breast surgery|
75338760|NCT00289718|Biological|Twinrix™ adult|Intramuscular administration
75338761|NCT00290654|Drug|Tamoxifen|Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient
75338762|NCT00290654|Procedure|Lumpectomy|A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.
75649260|NCT05683067|Other|quality of life using questionnaires|The investigator will evaluate the quality of life using questionnaires such as EQ-5D-5L questionnaire and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
75649261|NCT05682560|Biological|RegeneCyte|HPC, Cord Blood
75649262|NCT05682560|Other|Placebo|Normal Saline
75649263|NCT05678647|Drug|Sucrosomial Iron|20 capsules of Sucrosomial Iron 30 mg is given after blood donation
75649264|NCT05678647|Drug|Iron Sulfate|20 tablets of oral iron sulphate (Duroferon®) 100 mg is given after blood donation
75796457|NCT05938647|Other|Risk factor: group 4|Dengue shock syndrome. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes
75796458|NCT05938517|Drug|Betahistine dihydrochloride|Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.
75798995|NCT01188252|Drug|Roniciclib (BAY1000394)|Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
75934339|NCT03236090|Dietary Supplement|Vivomixx|Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
75934340|NCT03229460|Other|standard low flow therapy|In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
75934341|NCT03229460|Device|high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 >92%.
76087031|NCT01805076|Procedure|Magnetic resonance imaging|
76087032|NCT01805076|Procedure|Mammography|
76087033|NCT01802281|Procedure|Uterosacral ligament suspension|The USLS procedure used in this protocol is a modification of the technique described by Shull.
76087034|NCT01802281|Procedure|Uphold® LITE|The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
76087035|NCT01796795|Drug|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
76087036|NCT01796795|Drug|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
76087037|NCT01796795|Drug|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
76087038|NCT01793831|Procedure|FMT|Standard FMT
76087039|NCT01790061|Procedure|Standardized FMT|Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut or whole colon
75338763|NCT00290654|Radiation|brachytherapy|Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
75338764|NCT00290810|Biological|bevacizumab|Given IV
75338765|NCT04042142|Other|glucagon|Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
75338766|NCT01137539|Device|Gynecare TVT-SECUR system|All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
75473837|NCT01975623|Device|HARMONIC ACE®+ Shears (HS)|We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
75473838|NCT01975636|Drug|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
75796459|NCT05938517|Drug|Selegiline-hydrochloride|In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.
75796460|NCT05937204|Other|Nursing Teaching|A nursing teaching scheme refers to a systematic and structured plan developed by nurses to provide teaching and instruction to patients. The components of a nursing teaching scheme typically include assessing learning needs, setting learning objectives, developing teaching materials, delivering information using various teaching methods, demonstrating skills, providing written instructions, assessing learning outcomes, and conducting follow-up
75796461|NCT05937022|Device|Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.
75796462|NCT05937022|Device|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to the sham control group will receive 30 seconds of active stimulation over brain regions identical to either the left DLPFC or the right VLPFC experimental tDCS group.
75338767|NCT01892930|Radiation|stereotactic body radiation therapy|Undergo SBRT
75338768|NCT01892930|Procedure|therapeutic conventional surgery|Undergo partial or radical nephrectomy
75338769|NCT01892930|Other|laboratory biomarker analysis|Correlative studies
75473839|NCT01975649|Drug|Tribulus Terrestris|patients will use 750 mg/day during 120 days
75473840|NCT01975649|Other|Placebo|patients will use placebo pills with the same shape of the drug
75649265|NCT05676008|Behavioral|Microdosing of mindfulness|The intervention consists of two parts: 1) four structured training sessions offered as online synchronous classes, and 2) self-microdosing of mindfulness activities in everyday life.
75649266|NCT05665101|Procedure|Coil embolization of aneurysm sac|Patients are treated with standard EVAR with additional coiling of the aneurysm sac. The distinct type of coils used is not predefined.
75649267|NCT05646888|Biological|Blood sampling|the blood sample will be taken during a planned blood sampling
75796463|NCT05936502|Other|Extranodal extension|Extranodal extension presence or absence on radiology and pathology assessment
75796464|NCT05935657|Drug|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.1~1.0 mg/kg/h continuous infusion
75796465|NCT05935657|Drug|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2~0.7 mcg/kg/h continuous infusion
76087040|NCT01790061|Drug|Traditional treatments|Medications
76087041|NCT01755650|Radiation|18F FPM|
76087042|NCT01696461|Drug|Plerixafor|
76087043|NCT01688492|Drug|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson & Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
76087044|NCT01678898|Drug|PRX-102|
76087045|NCT01606098|Procedure|Surgery of the primary tumour|Surgical resection of the colon tumour
76087046|NCT01606098|Drug|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
76087047|NCT01568307|Drug|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
76087048|NCT01508221|Drug|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
76087049|NCT01508221|Dietary Supplement|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
76087050|NCT01485861|Drug|Abiraterone|Orally once daily
76087051|NCT01485861|Drug|Apitolisib|Orally once daily
76087052|NCT01485861|Drug|Ipatasertib|Orally once daily
76087053|NCT01485861|Drug|Placebo|Orally once daily
75649268|NCT05639907|Device|K21 Cavity cleanser|K21 Cavity cleanser is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
75338770|NCT01138475|Drug|Paricalcitol|1 microgram by mouth daily for 6 weeks
75338771|NCT01138475|Drug|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
75649269|NCT05639907|Device|Ethanol control|Ethanol is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
75649270|NCT05626894|Combination Product|StrokeWear Motor and Behavioral Intervention|The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.
75649271|NCT05626894|Other|Usual Care|The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
75796466|NCT05935462|Combination Product|Digital Learning Aids|Recruitment is currently underway for special children undergoing outpatient early intervention. Among the recruited participants, five children between the ages of 6 and 9, who are receiving early intervention, were screened. After obtaining their consent to participate in this study, their basic information was recorded, including gender, age, education, diagnosis, Movement Assessment Battery for Children (MABC-2), Visual-Motor Integration (VMI) test, and Children's ABILHAND questionnaire for manual ability. Once the collection of basic information is completed, a trial of digital aids will be conducted, and a trial feedback questionnaire will be administered. The trial period will consist of a 20-minute session and 2-3 sessions (per week) of home (or therapy room) use.
75649272|NCT05625334|Drug|ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
75649273|NCT05625334|Drug|non-enteric-coated chewable aspirin|Orally administered
75649274|NCT05622344|Behavioral|Traditional Therapy|Exercises that teaches subjects to move their heads while viewing still or moving targets.
75649275|NCT05622344|Device|SWAN|The SWAN device uses video-oculography to monitor head motion while guiding participants to move their head in yaw, pitch, roll planes for 15 minutes. Feedback is provided regarding frequency and plane of head rotation
75798996|NCT03855072|Procedure|customized fixation plate|"All cases will undergo one surgery under general anesthesia.~Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~Amucoperiosteal flap was reflected to expose the lateral mandibular ramus to the posterior border and the sigmoid notch~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~The customized fixation plate is positioned to fix the proximal and distal segment together after setback"
75649276|NCT05619276|Device|Standard serving utensil toolkit|Serving a meal using standard kitchen utensils (100% of subjects experiment with these tools first)
75649277|NCT05619276|Device|Optimsed portion-control toolkit|Serving a meal using optimised, portion-control utensils (100% of subjects experiment with these tools second)
75934342|NCT03229460|Device|association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 >92% with the minimal FiO2.
75934343|NCT02744651|Device|EUS-FNA|"Please note the text in section Arm description"
75934344|NCT02744651|Device|EUS-Endodrill biopsy|"Please note the text in section Arm description"
75934345|NCT03229304|Other||
75934346|NCT03234764|Other|Immunotherapy|
75934347|NCT03234842|Radiation|Proton Beam Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
75934348|NCT03234842|Radiation|Photon Radiation Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
75934349|NCT03234842|Drug|Chemotherapy|Concurrent weekly chemotherapy at standard doses
75934350|NCT03229070|Other|Interval effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
75934351|NCT03229070|Other|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
75934352|NCT03229226|Other|Verbal versus procedural assessment|Faculty were assessed on both verbal and simulated performance of procedures.
75934353|NCT03229148|Procedure|General anaesthesia|Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
75649278|NCT05614115|Drug|Empagliflozin|is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
75934354|NCT03229148|Procedure|Conscious Sedation|A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
76087054|NCT01485861|Drug|Prednisone|Orally bid
75338772|NCT01138475|Drug|Placebo|Inactive substance, one capsule daily for 6 weeks
75338773|NCT01896830|Biological|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
75338774|NCT01896830|Biological|0.9% normal saline|0.5 mL, intramuscular
76087055|NCT01485861|Drug|Prednisolone|Orally bid
75649279|NCT05614115|Other|Placebo|Placebo comparator
76087056|NCT01452503|Device|Path Women's Condom|comparison between 3 types of female condoms
75649280|NCT05610930|Other|Front-of-pack label NutriScore 2.0|"Participants in the experimental arm can see, in case the product is ultra-processed, a black banner surrounding the Nutri-Score, with the word ultra-transformé, meaning ultra-processed, and no black banner otherwise. Participants in the control arm had no label at all. The intervention (the Nutri-Score 2.0) was added on the packaging on the products included in the 3 sets of images that participants recieved via the questionnaire."
75934355|NCT04485962|Biological|Fibroblasts and keratinocytes|"Autologous cultured fibroblasts and keratinocytes~For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
75934356|NCT03228992|Drug|Ibuprofen 400 mg|Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
75649281|NCT05604794|Combination Product|Ketamine-Assisted Psychotherapy (KAP)|KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.
75649282|NCT05602025|Biological|Depemokimab|Depemokimab will be administered via a SSD or autoinjector.
75649283|NCT05575310|Procedure|Total Knee Arthroplasty|Articular knee surface replacement
76087057|NCT01452503|Device|FC2 female condom|comparison between 3 types of female condoms
76087058|NCT01452503|Device|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
76087059|NCT01374984|Biological|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
76087060|NCT01241734|Drug|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
76087061|NCT01220674|Other|cognitive testing|computer-based cognitive assessment
76087062|NCT01101438|Drug|metformin hydrochloride|Given orally
76087063|NCT01101438|Other|placebo|Given orally
75649284|NCT05574699|Other|Social Risk Score and CDS Tool|A social risk score, which helps to identify patients with high social needs based on the risk score in the CDS tool and a closed loop referral, which helps to refer the patients to CBOs, if needed.
75649285|NCT05574699|Other|Standard of Care|Currently available process for screening, assessment, and addressing social needs in the clinic setting, which may include providing a sheet of various educational resources, or a list of organizations that can address the identified social need.
75649286|NCT05574452|Device|ACL reconstruction using the SONAR Femoral Aimer PSI|ACL reconstruction using the SONAR Femoral Aimer PSI
75649287|NCT05565404|Behavioral|mobile health|Scaling and root planing, interdental brushing demonstration and regular text messages in type 2 embrasure patients.
75649288|NCT05565404|Procedure|Scaling and root planing+Interdental aid|Scaling and root planing, interdental brushing demonstration in type 2 embrasure patients.
75796467|NCT05935072|Behavioral|Exercice and meal|The participants will carry out four experimental visits in a randomized order: CON_Calibré: control condition with a calibrated test meal; CON_AdLib: control condition with an ad libium test meal; EX_Calibré: exercise condition with a calibrated test meal; EX_AdLib: exercise condition with an ad libitm test meal. During each of the conditions, the participants will join the laboratory at 8:00 a.m. and will receive a calibrated breakfast. They will be asked at 11:00 a.m. either to rest in a semi-recumbent position for 30 minutes (CON conditions) or to perform a pedaling exercise on an ergocycle at 65% of their estimated aerobic capacity for 30 minutes. A test meal will be served to participants at 12:00 p.m., either ad libitum or calibrated. Appetite sensations will be assessed at regular intervals during each condition and their food reward preferences and ratio assessed 15 minutes before and 15 minutes after the test meals.
75796468|NCT05929846|Other|Back to Living Well Program|The Back to Living Well program (BLW), a sustainable community-based program for persons with persistent mild to moderate LBP. The goal of the intervention is to provide an opportunity for community dwelling persons with persistent mild to moderate LBP to learn how to safely engage in exercise and become active self-managers. The 12-week program will engage participants in weekly exercise sessions, education and self management sessions, and encourage independent exercise at least 1x per week. All participants will be encouraged to complete an action plan and watch online education videos weekly.
75934357|NCT03228992|Other|Placebo|Subjects will receive 4 doses of placebo over a 24 hour period.
75934358|NCT03234452|Dietary Supplement|Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
75934359|NCT03234452|Dietary Supplement|Placebo Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
76087064|NCT01094769|Drug|Moxonidine|Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
76087065|NCT01094769|Drug|Placebo|lactose capsule taken once daily
76087066|NCT01088633|Other|Exhaled particle analysis|"At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.~Visit 3:~After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2."
76087067|NCT01046825|Drug|COPAD|"Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
76087068|NCT01046825|Drug|COP, COPD M3, CYM|"GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
75649289|NCT05561088|Other|Scalp Acupuncture|mplementation plan of head needle: The middle frontal line (MS1), the middle parietal line (MS5) and the back parietal and temporal oblique line (MS7) in the International Standardization Program for the Name of the first needle Point in 1989 were selected, and the needles were inserted along the shape of each section. One needle was inserted into the middle frontal line and the middle parietal line, and two needles were inserted into the back parietal and temporal oblique line. The KWD-808I pulse electrotherapy instrument produced by Changzhou Wujin Great Wall Medical Equipment Co., Ltd. is used on the needle handle after lifting, inserting and twisting. The continuous waveform was used, the voltage was 2-4 V, the frequency was 60-80 times /min, the intensity was tolerated by the patient, the needle was kept for 30min, and the treatment was performed once a day.
75649290|NCT05561088|Other|The treatment recommended in the guidelines for acute ischemic stroke was administered|The treatment recommended in the guidelines for acute ischemic stroke was administered
75338775|NCT05076539|Other|Garmin GPS activity tracker|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery).
75796469|NCT05929222|Radiation|Radiotherapy|Involved-Site Radiation Therapy 24Gy
76087069|NCT01046825|Drug|COP, COPADM8, CYVE|"Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
76087070|NCT01007773|Drug|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
75796470|NCT05929222|Other|Radiotherapy plus Obinotuzumab|Involved-Site Radiation Therapy 24Gy followed by Obinotuzumab 1000mg flat dose 4 doses weekly plus addition 4 doses every 3 weeks
75796471|NCT05924477|Procedure|Sulcus tube placement|GDD implantation surgery with tube placement in the ciliary sulcus
75796472|NCT05924477|Procedure|Anterior chamber (AC) tube placement|GDD implantation surgery with tube placement in the anterior chamber
75796473|NCT05922982|Drug|norepinephrine weaning protocol|MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol
75796474|NCT05922982|Drug|norepinephrine weaning protocol and guided by the HPI|MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI<80) delivered by the Acumen IQ medical device.
75796475|NCT05922956|Other|Facial emotion recognition test|Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
75796476|NCT05915559|Procedure|Tonsillectomy|Tonsillectomy
75796477|NCT05915559|Other|daily follow-up|daily follow-up of clinical parameters (pain, feeding) and analgesia adapted to the pain
75796478|NCT05910840|Other|Support-t|Support-t plus usual diabetes care for 18 months
75934360|NCT00700310|Drug|perampanel|2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
75934361|NCT00700310|Drug|perampanel|4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
75934362|NCT00700310|Drug|perampanel|8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
75934363|NCT00700310|Drug|Placebo|Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
76087071|NCT01007773|Drug|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP < 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
75934364|NCT02452502|Device|atorvastatin|Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
75934365|NCT03228524|Drug|D-Aspartate|Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
75934366|NCT03228524|Behavioral|Therapeutic exercise|Standard physiotherapy
75934367|NCT03228524|Drug|Placebo Oral Tablet|Placebo
75934368|NCT03234296|Drug|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
75934369|NCT03234296|Other|Placebo|Intravenous placebo followed by per oral placebo
75934370|NCT03234140|Genetic|Genome Wide Association Studies|Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
75934371|NCT03234140|Genetic|Single-nucleotide polymorphisms's genotyping|Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
75934372|NCT02509325|Device|Parkinson's Kinetigraph|
75338776|NCT01894958|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
75338777|NCT01894958|Drug|Placebo|Strawberry flavored solution
75934373|NCT03228368|Drug|Atezolizumab (MPDL3280A)|anti-programmed death-ligand 1 (PD-L1) antibody
75934374|NCT05095805|Behavioral|additional weight-bearing exercise|Nintendo Wii Balance Board, real-time visual feedback, weight-bearing assessment by center of pressure
75934375|NCT05095805|Behavioral|standard weight-bearing exercise|conventional training for fitting of initial prosthesis
75934376|NCT03228758|Procedure|Per Oral Endoscopic Myotomy|The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
75934377|NCT03228446|Behavioral|filter training|one-week filter training on the computer: computerized visual change detection experiment (selective attention )
75934378|NCT03228446|Behavioral|memory training|one-week storage training on the computer: computerized visual change detection experiment (memory storage)
75934379|NCT03228446|Other|no training (control)|no training applied
75934380|NCT05042765|Other|self-reported entheogen use|self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
75934381|NCT03235466|Behavioral|Voice Therapy|See Arm 1 & 2
75934382|NCT03235466|Behavioral|Voice Therapy and Heart Rate Variability Biofeedback|See Arm 2 & 3
75934383|NCT03235466|Behavioral|Heart Rate Variability Biofeedback|See Arm 2 & 3
75796479|NCT05910762|Behavioral|Associative inference|Participants will engage in an associative inference paradigm. Memory will be assessed behaviorally and neural representations will be assessed using functional magnetic resonance imaging.
75796480|NCT05910762|Behavioral|Category learning|Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).
75796481|NCT05910762|Behavioral|Sleep|Participants will sleep after engaging in a category learning paradigm while electroencephalography data are collected, and memory will be assessed behaviorally after sleep.
75934384|NCT03665129|Biological|IPH5401 and Durvalumab|IPH5401 and durvalumab
75934385|NCT03235622|Diagnostic Test|Coronary CT angiography|Presence of coronary plaques Characteristic of coronary plaques
75934386|NCT03235700|Other|Maximal hyperemia with adenosine followed by nicorandil|IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
75934387|NCT03235700|Other|Maximal hyperemia with nicorandil followed by adenosine|IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
75934388|NCT03234062|Other|25% Cho diet|Subjects will consume meals containing 25% of the recommended intake of Choline (137.5 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
75934389|NCT03234062|Other|50% Cho diet|Subjects will consume meals containing 50% of the recommended intake of Choline (275 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
75934390|NCT03234062|Other|100% Cho diet|Subjects will consume meals containing 100% of the recommended intake of Choline (550 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
75934391|NCT03233984|Behavioral|"sensibilisation program Ma maison, mon environnement santé"|The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
75934392|NCT04882631|Drug|PBI-100 Topical Cream|A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.
75934393|NCT04882631|Drug|Positive Control - Sodium laurel sulfate (SLS)|Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.
75934394|NCT04882631|Other|PBI-100 Topical Cream, Vehicle|Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.
75473841|NCT01975662|Drug|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
75796482|NCT05907850|Drug|Riboflavin|Commercially available source of riboflavin capsules
75796483|NCT05907850|Drug|Placebo|Placebo capsule compounded to be similar in appearance to the active intervention
75796484|NCT05904730|Drug|Axitinib|The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)
75934395|NCT04882631|Other|Negative Control|A blank patch was applied daily (excluding weekends) as a negative control test site.
75934396|NCT03235778|Drug|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
75934397|NCT03235778|Drug|Placebo|Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
75934398|NCT04439513|Device|Hemostasis|Compression device to achieve hemostasis.
75934399|NCT03233906|Dietary Supplement|Chia Seeds- Salvia Hispanica|Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
75934400|NCT02452970|Drug|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
75934401|NCT02452970|Drug|Gemcitabine and cisplatin|RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
75934402|NCT04302077|Other|virtual doctor visit|interactive live-video feed at home through EPIC
75934403|NCT04302077|Other|Standard care doctor's visit|In person visit as per standard of care
75934404|NCT03233672|Radiation|Hypo-fractionated postoperative IMRT-SIB|intensity-modulated radiation treatment with simultaneous integrated boost
76087072|NCT01007773|Drug|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
75934405|NCT04854941|Other|Probiotics|Probiotics (10^9 CFU of each strain: Lactobacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301) 3 times per day in addition to standard treatment regimen for 2 weeks
75934406|NCT03227900|Drug|Lidocaine|Intragastric infusion of lidocain
76087073|NCT01007773|Drug|Propofol|Propofol will be titrated to an ICP < 20 mm Hg until achievement of sustained ICP control.
76087074|NCT01004640|Genetic|DNA analysis|
76087075|NCT01004640|Genetic|Southern blotting|
75796485|NCT05893173|Behavioral|Sleep Deprivation|Ten individuals (aged 25-50) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging and waking EEG prior to and following approximately 30 hours of total sleep deprivation.
76087076|NCT01004640|Genetic|cytogenetic analysis|Correlative studies
76087077|NCT01004640|Genetic|polymerase chain reaction|
76087078|NCT00966979|Device|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
75473842|NCT01975662|Drug|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
76087079|NCT00936663|Drug|Placebo|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
76087080|NCT00936663|Drug|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
75796486|NCT05860270|Drug|Cholecalciferol|Patients in the intervention group will receive oral cholecalciferol 4000U per day.
75796487|NCT05860270|Drug|Placebo|Patients in the control group will receive placebo 2 capsules per day.
75796488|NCT05855395|Drug|Glucocorticoid|standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)
75796489|NCT05855343|Other|BIDI Stick e-cigarette|The BIDI will be dispensed, and subjects will be instructed to use the BIDI as often as they like during the 12 week period, and to switch completely to the BIDI within 1 week. If, however, they do smoke any CC, they will also be instructed to use the BIDI immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The BIDI will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute BIDI for CCs by the end of the first week of use.
75796490|NCT05853354|Biological|Denosumab|Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
75796491|NCT05850260|Device|Macintosh laryngoscope|During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
75934407|NCT03227900|Drug|Placebos|Intragastric infusion of water for injections
75934408|NCT03227978|Combination Product|PCL mesh pleurodesis|Coverage of the lung surface by PCL mesh
75934409|NCT03227744|Behavioral|Group therapy|Twelve 1-hour group therapy sessions with a licensed psychologist for prostate-cancer related anxiety.
75934410|NCT03227744|Other|Surveys|MAX-PC, GAD and FACT-P
75934411|NCT03227822|Procedure|Short spot stenting|
75934412|NCT03227822|Procedure|Long lesion stenting|
75934413|NCT02452736|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|
75934414|NCT03120104|Other|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
75934415|NCT03120104|Other|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just two weeks after the stoma closure
76087081|NCT00931606|Biological|Sotatercept|up to 4 subcutaneous doses of sotatercept given once every 28 days
76087082|NCT00931606|Drug|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
76087083|NCT00912587|Drug|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
76087084|NCT00776035|Procedure|PET (positron Emission Tomography)|this is a diagnostic scan that requires the injection of radioactive tracers into an IV placed in the arm.
76087085|NCT00776035|Procedure|Echocardiogram|an ultrasound of the heart
76087086|NCT00776035|Procedure|VO2 peak test|walking on a treadmill during which you will breath in and out through a tube
76087087|NCT00776035|Procedure|Body composition Study|a scan of your entire body measuring Body Mass Index, fat percentage etc...
76087088|NCT00776035|Radiation|15O water|radioactive tracer used to study blood flow during the PET scan
75473843|NCT01975688|Drug|Sativex|"Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD."
75473844|NCT01975714|Drug|Preservative-free latanoprost|
75473845|NCT01975714|Drug|Preservative-free bimatoprost|
76087089|NCT00776035|Radiation|11C Acetate|radioactive tracer that helps study heart metabolism
76087090|NCT00776035|Radiation|11C Palmitate|radioactive tracer used to study fatty acid usage in the heart
76087091|NCT00776035|Radiation|11C Glucose|radioactive tracer usde to study glucose usage in the heart
76087092|NCT00681343|Drug|Thymoglobulin|Induction
76087093|NCT00681343|Drug|Campath-1H|Induction
76087094|NCT00681343|Drug|Daclizumab|Induction
76087095|NCT00665457|Biological|filgrastim|
76087096|NCT00665457|Drug|capecitabine|
76087097|NCT00665457|Drug|celecoxib|
76087098|NCT00665457|Drug|cyclophosphamide|
76087099|NCT00665457|Drug|docetaxel|
76087100|NCT00665457|Drug|doxorubicin hydrochloride|
76087101|NCT00665457|Genetic|gene expression analysis|
75934416|NCT03120182|Drug|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization
75338778|NCT05073497|Other|Finger puppets|In the experimental group, for distraction the researcher will put finger puppets consisting of various animal figures on his finger, and will ask the child to imitate these sounds by making animal-specific sounds that he moves with his finger. The researcher will also draw the child's attention to finger puppets by using methods such as making animals talk to each other and singing before and during venipuncture.
75338779|NCT05045807|Dietary Supplement|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.
75338780|NCT05045807|Dietary Supplement|Meat with added nitrate plus vegetables|"The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables."
75338781|NCT00293540|Procedure|oophorectomy|Excision of an ovary
75338782|NCT00293540|Drug|Tamoxifen|20 mg orally every day
75649295|NCT05548413|Behavioral|FamLit|The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide, including both spoken and printed materials written at a 4th-grade reading level for HF patients and their primary CPs.Three constructs guide the intervention, based on the Theory of Planned Behavior (TPB): 1) develop patient and CP positive attitudes through HF instruction and teach-back; 2) form positive subjective norms through coaching to improve patient and CP communication, support, and teamwork; and 3) increase perceived behavioral control through coaching and role-playing to empower patients and CPs to overcome individual barriers to adherence. This intervention also includes use of the SimpleMed+ electronic pillbox.
75649296|NCT05548413|Behavioral|Attention Control|Participants in this group will talk with an interventionist to discuss general health. This intervention also includes use of the SimpleMed+ electronic pillbox.
75796492|NCT05850260|Device|Videolaryngoscope|During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option.
75796493|NCT05830825|Procedure|Vertebral Body Tethering (VBT)|Vertebral Body Tethering surgery with the Tether™ in UK
75796494|NCT05818826|Drug|normal saline solution|Prepare 100 ml of normal saline solution, packed out in the same format, dose, and administration of the drug were exactly the same as in the conventional cessation group.
75796495|NCT05818826|Drug|Hydrocortisone and normal saline solution|Prepare hydrocortisone with normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min.
75796496|NCT05818293|Device|radiofrquency device|• The radiofrequency system has been used for treatment of subcutaneous fat layers.
75796497|NCT05808881|Drug|Nalmefene Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
75934417|NCT03120182|Drug|Placebo Oral Tablet|Patients will receive placebo medication 100mg daily for 12 days after randomization
75934418|NCT02074436|Drug|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
75934419|NCT02074436|Other|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
75934420|NCT01575548|Drug|Pazopanib|Given PO
75934421|NCT01575548|Other|Placebo Administration|Given PO
75934422|NCT03233282|Other|Electroencephalography (EEG) multi-sensor|Electrophysiological measurements of cerebral activity will be performed by multi-sensor electroencephalography (EEG), which is a non-invasive method.
75934423|NCT03233282|Other|Magnetoencephalography (MEG)|Electrophysiological measurements of brain activity will be performed by magnetoencephalography (MEG) which is a non-invasive method.
75934424|NCT03233282|Other|Behavioral Measures|The evaluation of cognitive performance will be carried out by means of behavioral measures, push-button type, handling of a mouse or a joystick.
75934425|NCT03233282|Other|Reaction time measurement|The assessment of cognitive performance will be carried out using standard behavioral measures, such as reaction time measurement.
75934426|NCT03233282|Other|Assessment of physical performance|The assessment of physical performance will be based both on bioenergetic measurements and on quantitative data collected in continuous and relative to the effort (eg instantaneous pedaling speed).
75934427|NCT03233282|Other|Electrooculogram (EOG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
75934428|NCT03233282|Other|Electromyogram (EMG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
75934429|NCT03233282|Other|Electrocardiogram with 3 leads|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
75934430|NCT03233282|Other|Electrodermogram (EDG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
75934431|NCT03233282|Other|Consumption of O2 (VO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
76087102|NCT00665457|Genetic|polymorphism analysis|
76087103|NCT00665457|Genetic|protein expression analysis|
76087104|NCT00665457|Genetic|reverse transcriptase-polymerase chain reaction|
75338783|NCT03012113|Drug|Mirabegron|
75338784|NCT03012113|Other|Short term mild cooling|
75338785|NCT03012113|Drug|Placebo Oral Capsule|
75338786|NCT05008133|Behavioral|Bicycle exercise|Stepwise increased exercise for 5 minutes at 0, 50, 100 and 150 Watts. One series lying flat in prone position, after 15 minutes of rest, series repeated at 70 degrees head up tilt.
76087105|NCT00665457|Other|imaging biomarker analysis|
76087106|NCT00665457|Other|immunohistochemistry staining method|
76087107|NCT00665457|Other|laboratory biomarker analysis|
76087108|NCT00665457|Other|pharmacogenomic studies|
76087109|NCT00665457|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
76087110|NCT00665457|Procedure|needle biopsy|
75338787|NCT01139411|Behavioral|Behavioral Weight Control with Enhanced Parent Involvement|
76087111|NCT00665457|Procedure|neoadjuvant therapy|
76087112|NCT00665457|Procedure|radiomammography|
75649297|NCT05542134|Diagnostic Test|P2Y12 Platelet Aggregation Inhibitor|Verify now PRU test
75338788|NCT01139411|Behavioral|Behavioral Weight Control with Minimal Parent Involvement|
75338789|NCT01139801|Drug|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
75649298|NCT05541939|Drug|Mizagliflozin|Encapsulated or Liquid Formulation
75796498|NCT05808881|Drug|Naloxone Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
75796499|NCT05802628|Drug|Cetylpyridinium Chloride Buccal Tablets|Subjects administrated single dose of Cetylpyridinium Chloride Buccal Tablet
75796500|NCT05792930|Behavioral|cognitive-behavioral therapy and biofeedback therapy|Complete eight sessions of cognitive-behavioral therapy and biofeedback therapy within three months.
75796501|NCT05792423|Device|GE ultrasound system with increased acoustic output settings|We will perform liver stiffness measurements with standard settings and an increased acoustic output enhanced ultrasound system. Pre and post ultrasound LFTs will be collected to monitor unexpected liver tissue damage.
75796502|NCT05775796|Drug|Serplulimab and Chemotherapy|Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin
75796503|NCT05775367|Device|Cochlear Implant|A cochlear implant is a surgically implanted device that provides access to sound in people cannot get enough access to sound for communication with traditional hearing aids.
75796504|NCT05767905|Drug|PF-06821497 Treatment A|A single dose of PF-06821497 administered under fasting conditions.
75934432|NCT03233282|Other|Production of CO2 (VCO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
75934433|NCT02451722|Device|Kyboot shoes|The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
75934434|NCT02451644|Device|pedometer|patient will cary pedometer
75934435|NCT03222908|Behavioral|Intervention1: Contract Agreement|Smoking Cessation Contract
75934436|NCT03222908|Behavioral|Intervention2: Implementation Intentions|Smoking Cessation Contract with worksheet for implementation intentions
75338790|NCT01139801|Drug|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
75338791|NCT01139879|Device|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
75338792|NCT05004467|Other|Mobilization With Movement Technique|The researcher explains cervical movements to the patient to be done while the technique is performed. This movements will be the painful and limited movements detected in goniometric intervention before the treatment and movements done actively and in all range of motion.
75338793|NCT00294632|Drug|Lenalidomide|Starting Dose 10 mg By Mouth Daily on Days 1-21
75338794|NCT00294632|Drug|Rituximab|375 mg/m^2 By Vein Weekly for 4 Weeks
75796505|NCT05767905|Drug|PF-06821497 Treatment B|A single dose of PF-06821497 administered under fasting conditions.
75796506|NCT05767905|Drug|PF-06821497 Treatment C|A single dose of PF-06821497 administered under fasting conditions.
75796507|NCT05767905|Drug|PF-06821497 Treatment D|A single dose of PF-06821497 administered under fasting conditions.
75934437|NCT03228056|Diagnostic Test|pain intensity measured in VAS scale|Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
75934438|NCT02452658|Other|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
75934439|NCT03227666|Behavioral|Exercise|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
75934440|NCT04486040|Procedure|Drainage|Use of the suction drainage after hip revision arthroplasty
75934441|NCT04486040|Procedure|No-drainage|Patients without drainage after surgery
75934442|NCT04485884|Drug|IN-C005 dose A|One time dose of IN-C005 dose A taken orally.
75934443|NCT04485884|Drug|IN-C005 dose B|One time dose of IN-C005 dose B taken orally.
75934444|NCT04485884|Drug|IN-C005 dose C|One time dose of IN-C005 dose C taken orally.
75934445|NCT04485884|Drug|IN-C005 dose D|Oral administration of IN-C005 dose D once daily for 7 days.
75934446|NCT04485884|Drug|IN-C005 dose E|Oral administration of IN-C005 dose E once daily for 7 days.
76087113|NCT00665457|Procedure|ultrasound imaging|
76087114|NCT00613041|Procedure|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
76087115|NCT00597870|Device|Endoluminal treament of thoracic lesions|Endoluminal treament of thoracic lesions with a thoracic stent-graft
75338795|NCT01898624|Drug|mirabegron|oral
75796508|NCT05767905|Drug|PF-06821497 Treatment E|A single dose of PF-06821497 administered after low fat meal
76087116|NCT00574730|Drug|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
76087117|NCT00574730|Drug|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
75796509|NCT05767905|Drug|PF-06821497 Treatment F|A single dose of PF-06821497 administered after high fat meal.
75338796|NCT01140191|Drug|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
75338797|NCT04752176|Device|ØREBLUE® Method|"The ØREBLUE® Method combines 2 inseparable therapeutic approaches that will be personalized, one dedicated to the auditory symptom (personalized sound therapy based on music and delivered through a helmet as part of the device), the other dedicated to the psychology of the subject.~Sound rehabilitation will be based on successive treatment sequences. The 1st sequence includes 30 hours of listening, at a rate of 2 hours / day, 5 days a week. A period of 4 to 6 weeks is necessary before carrying out a new sequence. The second sequence (and subsequent ones when necessary, respecting a 4-to-6-weeks window in between) of sound rehabilitation consists of 20 hours distributed as for the first sequence."
75796510|NCT05758727|Other|Exercise intervention|The exercise programme is progressive and has three levels. Each bout of exercise and Tai-chi snacking consists of 5 exercises. Each exercise is performed for one minute with one minute rest in between. For exercise snacking movements (including leg exercise, shoulder exercise, single leg exercise, arm exercise, and ankle exercise), participants are encouraged to complete as many repetitions as possible of that exercise in that minute. For Tai-chi snacking movements (including single leg squat, trunk rotation, single leg stand, hip and knee exercise, and ankle mobility exercise), participants are encouraged to complete repetitions of each exercise at a self-selected pace that is comfortable for them to maintain for the full minute, with the aim being to complete the movements as accurately and smoothly as possible (based on correct posture and proper alignment).
75934447|NCT04485884|Drug|IN-C005 dose F|Oral administration of IN-C005 dose F once daily for 7 days.
75934448|NCT03227432|Drug|Dexamethasone|Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.
75934449|NCT03227432|Drug|Pomalidomide|Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.
75934450|NCT03227432|Drug|Elotuzumab|Elotuzumab is an antibody, that stimulates the immune system to fight diseases
75934451|NCT03227432|Drug|Nivolumab|Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
75934452|NCT03222596|Behavioral|Exercise training|Exercise programme includes breathing and upper limbs exercises.
75934453|NCT03222674|Biological|Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells|Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
75934454|NCT04485572|Diagnostic Test|Straight Leg Raise test (SLR) and Bragard test (B)|The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)
75934455|NCT04485572|Diagnostic Test|Fajersztajn test (F) and Sicard test (S)|The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)
75934456|NCT04485572|Diagnostic Test|Passive Neck Flexion test (PNF)and Kernig test (K)|The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)
75934457|NCT04485572|Diagnostic Test|Slump test (ST) and Dejerine triad (DT)|The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)
75934458|NCT04485572|Diagnostic Test|MRI scan|All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
75934459|NCT03222518|Drug|Paracetamol|21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
75934460|NCT03222518|Drug|NSAID|14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
75934461|NCT03222518|Drug|paracetamol-NSAID|21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
75934462|NCT03222440|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
75934463|NCT03222206|Drug|Salsalate|"Medicate salsalate 2g/day after run-in period~Check side effect after 1 month and Control dosage (2g/day or 3g/day)~Check side effect after 2 month"
75934464|NCT03222206|Other|Placebo|"Medicate placebo 2g/day after run-in period~Check side effect after 1 month and Control dosage (2g/day or 3g/day)~Check side effect after 2 month"
75936545|NCT03181880|Drug|Aclidinium bromide/formoterol fumarate combination|"Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.~The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).~Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment."
76087118|NCT00518167|Behavioral|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at~weight reduction~dietary fibre 15 g /1000 kcal or more~energy proportion of dietary fat less than 30%~energy proportion of saturated fat less than 10%~moderate physical activity >30 minutes per day or 4 hours per week"
76087119|NCT00503269|Procedure|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
75338798|NCT01140815|Device|Total Knee Replacement|Smith and Nephew Total Knee Replacement
75649299|NCT05521776|Procedure|First-trimester preeclampsia screening (FMF triple test)|"An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations.~For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered."
75649300|NCT05514002|Biological|Fluzone Quadrivalent|Intramuscular
76087120|NCT00503269|Procedure|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
76087121|NCT00496756|Drug|Sorafenib|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
76087122|NCT00483561|Drug|Gefitinib plus etoposide|Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
75796511|NCT05753761|Behavioral|Behaviour- & Imaging-Guided Stepping Training Early Post-Stroke (BIG STEPS) intervention|Using baseline accelerometry data, personalized goals of replacing sedentary time with stepping time will be developed.
75796512|NCT05751187|Biological|Pembrolizumab|Pembrolizumab was given as 200 milligrams (mg) via intravenous (IV) infusion over 30 minutes on Day 1 of each 21-day cycle.
75796513|NCT05751187|Biological|Bevacizumab|Bevacizumab was given as 15 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle.
76087123|NCT00483366|Drug|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~500 mg/m2 bid~600 mg/m2 bid~600 mg/m2 bid~725 mg/m2 bid~725 mg/m2 bid~850 mg/m2 bid~850 mg/m2 bid"
75796514|NCT05751187|Drug|Pemetrexed|Pemetrexed was given as 500 mg/m^2 via intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle for 4-6 cycles.
76087124|NCT00483366|Drug|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~550 mg/m2~550 mg/m2~675 mg/m2~675 mg/m2~825 mg/m2~825 mg/m2~1000 mg/m2"
76087125|NCT00483366|Drug|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d"
75338799|NCT01140815|Device|Deuce|Smith and Nephew Bicompartmental Knee Replacement
75338800|NCT01141049|Drug|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
75338801|NCT01141049|Other|Placebo|Placebo, TID
75338802|NCT01141595|Drug|sapropterin dihydrochloride|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
75338803|NCT01141907|Behavioral|Heart Failure Self Care Support|The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.
75338804|NCT01141907|Other|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
75338805|NCT01142297|Device|dental implant and modified dental implant|standard SLA surface and chemically modified surface
75649301|NCT05514002|Biological|Flublok Quadrivalent|Intramuscular
75649302|NCT05510583|Other|Control group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
75649303|NCT05510583|Other|Treated group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
75649304|NCT05500066|Device|Aequalis Flex Revive Shoulder System|"The AEQUALIS FLEX REVIVE Shoulder System is intended for use as:~A replacement of shoulder joints in primary anatomic or in primary reverse~A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.~The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision."
75649305|NCT05498415|Behavioral|Education|Participants will receive standard of care education information on physical activity, sedentary behavior, and sleep via a mobile app for 8 weeks.
75796515|NCT05751187|Drug|Cisplatin|Cisplatin was given as 75 mg/m^2 via intravenous (IV) infusion (administered approximately 30 minutes after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
75936546|NCT03181880|Drug|Standard of Care|Brochodilators
75936547|NCT02428556|Other|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
75936548|NCT02428556|Other|promising language|"Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)"
75936549|NCT02428556|Other|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
75936550|NCT02428556|Other|"breakthrough with may warning"|"Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
75936551|NCT02428556|Other|"breakthrough with is warning"|"Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
75936552|NCT03178994|Drug|2% ketoconazole cream|2% ketoconazole cream applies twice daily
76087126|NCT00483366|Genetic|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
76087127|NCT00483366|Genetic|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
75338806|NCT03011723|Behavioral|Resource oriented music therapy|"10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.~The music therapy consists of one or more of the following activities:~Singing~Listening to live music~Listening to recorded music~Dancing~Conversations about memories/reminiscence~Exercising to music~Breathing exercises and relaxing exercises~The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)"
75796516|NCT05751187|Drug|Carboplatin|Carboplatin was given as Aare Under the Curve (AUC) 5 (5 mg/mL/min; over 15-60 min) via intravenous (IV) infusion (administered immediately after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
75796517|NCT05751187|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
75338807|NCT01143701|Other|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
75338808|NCT03012503|Drug|BioFreeze|The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
75338809|NCT03012503|Drug|Placebos|control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
75649306|NCT05498415|Behavioral|Health coaching|Participants will meet with a health coach weekly for 8 weeks
75649307|NCT05498415|Behavioral|Activity Monitor|Participants will receive a Fitbit activity monitor to support goal setting and self monitoring of behaviors.
75649308|NCT05495880|Procedure|Laryngoscopy with forearm-support|forearm-supported head extension during direct laryngoscopy
76087128|NCT00483366|Genetic|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
76087129|NCT00290368|Procedure|Skin Prick Test|
76087130|NCT00290368|Procedure|Nasal allergen challenge|
76087131|NCT00290368|Procedure|Nasal filter paper placement|
76087132|NCT00290368|Procedure|Nasal lavage|
76087133|NCT00290368|Procedure|Nasal scrape|
75338810|NCT01167569|Drug|Ascorbic Acid|Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
75338811|NCT01167569|Other|5 % Dextrose Water or Normal Saline|100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
75473846|NCT01975727|Drug|Placebo|Injection of placebo (saline 0.9%)
75649309|NCT05495880|Procedure|Laryngoscopy without forearm-support|without forearm-support for head extension during direct laryngoscopy
75649310|NCT05495789|Other|Virtual Reality|A relaxing video will be watched with virtual reality glasses.
75649311|NCT05495789|Other|Music|Relaxing music will be played by wearing headphones.
75649312|NCT05487534|Other|Observational|The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.
75649313|NCT05477407|Drug|Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine|Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)
75649314|NCT05466253|Procedure|Fixed Orthodontic treatment|All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group (EARLY)10 days after periodontal surgery whereas the control group will receive orthodontic intervention (DELAYED) 3 months after periodontal surgery.
75649315|NCT05457478|Other|Medical Device Qardio® smart scale Usage and Evaluation|Weight monitored using a Qardio® smart scale
75649316|NCT05457478|Other|Questionnaire Administration|Ancillary studies
75796518|NCT05751187|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed administration.
75796519|NCT05751187|Drug|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, the day of, and the day after pemetrexed administration.
75796520|NCT05733637|Other|No intervention|There will be no intervention apply to study participants.
75796521|NCT05731544|Drug|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
75796522|NCT05723484|Device|GIFT Device|The GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
76087134|NCT00290368|Procedure|Nasal symptoms score|
76087135|NCT00278083|Drug|Study drug administration|
76087136|NCT00278083|Procedure|Tuberculin intradermal skin test|
76087137|NCT00278083|Procedure|Lung function test for FEV1|
76087138|NCT00278083|Procedure|Asthma symptom scores diary|
76087139|NCT00278083|Procedure|Quality of life diary|
76087140|NCT00278083|Procedure|Breath nitric oxide|
76087141|NCT00278083|Procedure|Breath condensate|
76087142|NCT00278083|Procedure|Sputum induction|
76087143|NCT00278083|Procedure|Blood sampling|
75338812|NCT00296192|Drug|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
75338813|NCT00296192|Other|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
76087144|NCT00278083|Procedure|Urinalysis|
76087145|NCT00159341|Procedure|Nasal lavage|Nasal lavage was carried out at specified timepoints
76087146|NCT00159341|Procedure|Nasal filter paper|Nasal filter paper was placed at specified timepoints
75338814|NCT04312139|Diagnostic Test|Echocardiography|Baseline and prospective follow-up echocardiography
75338815|NCT04312139|Diagnostic Test|Computerized Tomography Aortic Valve Calcium Score|Baseline and prospective follow-up CT calcium score of aortic valve
75934465|NCT04484714|Behavioral|Exercise|Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises.
75338816|NCT04312139|Other|Untargeted LC/MS and LC-MS/MS|Serum samples untargeted proteomics and metabolomics
75338817|NCT04312139|Other|Targeted LC/MS and LC-MS/MS|Serum samples targeted proteomics and metabolomics
75338818|NCT04312139|Diagnostic Test|multiplex ELISA|Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.
75934466|NCT03227588|Diagnostic Test|Fractional Flow Reserve|This is a prospective data collection study for patients that have undergone FFR.
75934467|NCT03227276|Dietary Supplement|Litramine|2 tablets to be taken 3 times a day after meals
76087147|NCT00159341|Procedure|Blood sampling|Blood sampling was performed as a routine safety check
76087148|NCT00135642|Biological|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
76087149|NCT00135642|Procedure|Venepuncture: 20 ml blood sample taken on 2 separate visits|
76087150|NCT03338946|Device|CIED interrogation|CareLink Express interrogation
76087151|NCT03338868|Other|Body composition|evaluated by Bodystat®1500 Bio-impedance Analyzer
76087152|NCT03338868|Other|Physical activity level|assessed by the International Physical Activity Questionnaire-7
75338819|NCT04161950|Other|Assessment of the safety and validity of echoendoscope|"Ultrasonic and endoscopic image quality assessment~Device controllability assessment~System safety assessment~System stability assessment"
75338820|NCT00297596|Drug|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
75338821|NCT00297596|Drug|Oxaliplatin|"Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab"
75338822|NCT01144637|Biological|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
75338823|NCT01144637|Other|Placebo|0.5 ml TBS
75338824|NCT00298610|Drug|Artesunate|Intravenous Artesunate (2.4 mg/kg) once a day for three days
75338825|NCT00298610|Drug|Malarone|(proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
75473847|NCT01975727|Drug|Dexamethasone 3 mg|10 ml Seringue with Dexamethasone
75473848|NCT01975727|Drug|Dexamethasone 6 mg|10 ml Seringue with Dexamethasone
75473849|NCT01975727|Drug|Dexamethasone 12 mg|10 ml Seringue with Dexamethasone
75934468|NCT03227276|Dietary Supplement|Placebo tablet|2 tablets to be taken 3 times a day after meals
75934469|NCT03227354|Device|Vittamed 205|non-invasive Intracranial Pressure measurement
76087153|NCT03338868|Other|Musculoskeletal pain intensity|evaluated with Visual Analog Scale
76087154|NCT03338868|Other|Quality of life|assessed by the Nottingham Health Profile
76087155|NCT03338868|Other|Psychological Well-Being|assessed by the Hospital Anxiety and Depression Scale
76087156|NCT03338868|Diagnostic Test|Blood tests|Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
76087157|NCT04494204|Combination Product|Immunofree tablets and Reginmune capsule|2 Immunofree tablets thrice a day at an interval of 4-5 hours for 10 days and 1 Reginmune capsule twice a day for 10 days
76087158|NCT03330444|Procedure|Endometrial biopsy and endometrial fluid collection|On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
76087159|NCT03330366|Dietary Supplement|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
76087160|NCT03330366|Dietary Supplement|Placebo|take two capsules per day
76087161|NCT03334578|Drug|Gastrografin|Gastrografin group
76087162|NCT02493972|Procedure|GelPort|Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
76087163|NCT02493972|Procedure|laparotomy|laparotomy will be performed if indication confirmed by manual exploration
75649317|NCT05455190|Behavioral|Fit Together|Fit Together intervention follows a clinic and community partnership model for childhood obesity treatment. Children with obesity will receive standard of care obesity treatment from their usual provider and will also receive a referral to an activity program run out of the local community center. Each session delivers a combination of high-intensity individual exercises, sports and games, and unstructured playtime to help children reach the US Physical Activity guidelines of 60min moderate-to-vigorous physical activity daily. There will also be a nutrition activity session offered regularly.
75934470|NCT04485650|Other|music therapy|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group.
75649318|NCT05455190|Behavioral|Educational materials|Participants will receive a child-friendly cooking magazine mailed quarterly and a local Parks and Recreation program guide.
75796523|NCT05723393|Procedure|Erector spinae plane block|fascial plane injection guided by ultrasound
76087164|NCT03330210|Procedure|3D printing|Manufacturing and use of a model printed in 3D
76087165|NCT03338478|Diagnostic Test|Wii Balance Board|Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
76087166|NCT02492412|Drug|HE 10|
76087167|NCT02492412|Drug|Restasis|
76087168|NCT03330054|Device|fundoscope|Fundoscope for eye examination
75338826|NCT04236947|Behavioral|SCPP-YA|SCPP-YA includes two modules. In the first module of ten sessions, students will learn to employ a 6-step social information processing framework for solving a wide range of real-life problems. The six-step process consists of 1) stop, clam down, and think before you act; 2) say the problem and how you feel; 3) set a positive goal; 4) think of many solutions; 5) think ahead to the consequences and 6) go ahead and try the best plan. The second module offers 1) current and accurate information about the health, social, and legal consequences of substance use, 2) correct mistaken beliefs that students have about substance use, 3) enhances awareness of social and media influences; and 4) teachers assertiveness and critical thinking skills to resist peer pressure.
75338827|NCT00299000|Drug|Naglazyme|Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
75796524|NCT05719064|Behavioral|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
75796525|NCT05719064|Behavioral|Computer-Delivered Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
75796526|NCT05719064|Behavioral|Automated Text Reminders|Scheduled text reminder to take medication
75934471|NCT04485650|Other|sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
75934472|NCT04485650|Other|non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
76087169|NCT03329898|Procedure|dried biological amnion graft|dried biological amnion graft. The amnion grafts were spread on the balloon end of disposable balloon uterine stent .
76087170|NCT03329898|Device|disposable balloon uterine stent|the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.
76087171|NCT03329898|Drug|estradiol valerate tablets|oral estradiol valerate tablets, which can promote endometrial growth after operation.
76087172|NCT03329898|Drug|dydrogesterone Tablets|oral dydrogesterone Tablets
76087173|NCT03334110|Procedure|A method of operation: LIMA-GSV-SCVBG|On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
76087174|NCT03334110|Procedure|BIMA-SCVBG|On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
75796527|NCT05717803|Procedure|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
75796528|NCT05701241|Drug|Somatostatin analog|Somatostatin analog treatment every 4 weeks
75798997|NCT03855072|Procedure|maxillomandibular fixation|"All cases will undergo one surgery under general anesthesia.~incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint to assure accuracy of the mandibular position."
76087175|NCT03329742|Other|Low protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
75338828|NCT01144949|Drug|silodosin|one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
75338829|NCT01144949|Drug|placebo|one placebo capsule orally, once daily, with food for up to 4 weeks
75338830|NCT00215930|Drug|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
75473850|NCT01975740|Other|Sham manual diaphragm release technique|
75798998|NCT01588626|Drug|AZD6140|tablet
75934473|NCT03227120|Other|Prehabilitation exercise|"Three times weekly exercise program of strengthening, balance and functional activities.~Weekly evaluation and progression with daily use of the Borg Rating of Perceived Exertion (RPE) supplemented with Heart Rate (HR) and Blood Pressure as needed to target the moderate intensity training level (40-60% HR Max) or above as appropriate to each individual."
75338831|NCT00215930|Drug|Docetaxel|"RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days."
75649319|NCT05440812|Behavioral|Storytelling and Training to Advance Individual Recovery Skills (STAIRS)|STAIRS is a 8-week program, in which 8 different themes are addressed. Coverage of each theme starts with a group meeting guided by a professional and expert by experience. In these meetings different exercises are done (e.g., filling out an actual and desired week-schedule, role-playing a difficult situation), information is given and experiences are shared. Between meetings, participants can choose from a range of homework exercises to practice their desired skills in a tailored way. In addition, participants can share experiences with the other group members and exchange reactions using a private online community.
75934474|NCT03227198|Biological|Intramyocardial injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intramyocardial injection of the cells is performed in patients with Heart failure in open heart surgery (CABG)
75934475|NCT03227198|Biological|Placebo|Injection of Placebo in patients with Heart failure in open heart surgery (CABG)
75649320|NCT05436262|Device|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~Overt finger tapping in time with a flashing cue.~Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
75796529|NCT05698979|Drug|BOTOX INJECTION|"The patient will be treated with a single session with botulinum toxin A injections at the hospital, and the judgmental criteria will be assessed at 1, 3 and 6 months post injections.~The injections will be made in 4 injection points at the palmar or distal plantar fold, at the level of the neurovascular beams, 2h after topical anesthesia by lidocaine cream under occlusion, associated or not with nitrous oxide inhaled at the time of the injections (BOTOX® 100 U).~In the event of multiple lesions, a single limb is injected based on clinical severity (ulcer, gangrene) and ischemia parameters (lowest TCPO2)."
75796530|NCT05696483|Drug|OLX-07010 Active|25 and 75 mg capsules
75934476|NCT03222284|Device|Cornerstones4Care Powered by Glooko App|Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
76087176|NCT03329742|Other|Control protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
76087177|NCT03329664|Biological|Cytokine-induced killer cell|Immune-cell therapy with CIK cells
76087178|NCT03329664|Other|Chemotherapy AND/OR Radiation Therapy|Routine treatments for colon cancer patients according to their stage
76087179|NCT03338322|Device|Twisted file adaptive|Endodontic files that are used in preparation of root canals with adaptive motion
76087180|NCT03338322|Device|Reciproc|Endodontic files that are used in root canal preparation with reciprocation motion
76087181|NCT02493816|Drug|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
76087182|NCT02492568|Drug|pembrolizumab|
75338832|NCT00215930|Drug|Gemcitabine|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days."
75338833|NCT00215930|Drug|Carboplatin|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days."
75796531|NCT05696483|Drug|OLX-07010 Placebo|25 and 75 mg capsules
75796532|NCT05676216|Drug|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
75796533|NCT05676216|Drug|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
76087183|NCT02492568|Radiation|Stereotactic Body Radiation Therapy|
76087184|NCT03329586|Other|High-intensity training|6-month individualized home- and group-based training program with the goal to cycle the Mont Ventoux in France
76087185|NCT03334032|Other|Inpatient treatment for Anorexia nervosa|Nutritional rehabilitation in a clinic with specialized eating disorder service
76087186|NCT01722292|Drug|LY2940680|Administered orally
76087187|NCT01722292|Drug|Carboplatin|Administered IV
75796534|NCT05676216|Drug|Diphenhydramine + Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push when vertigo patients visit Emergency Department
75798999|NCT01290120|Drug|Chemotherapy-Rituximab combination|Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
75338834|NCT01145183|Drug|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
75796535|NCT05671380|Behavioral|Longitudinal Proactive Outreach (LPO).|All participants will receive personalized invitation materials (in their preferred language) with messages culturally and linguistically tailored to BIPOC communities, guided by the literature on culturally adapting evidence-based interventions. The study team will tailor these resources in collaboration with the CE core. The tailored mailed packet will include an invitation letter and a brochure describing the types of tobacco treatment services available from their health system and from Quit Partner. One week after the written materials are sent, participants assigned to this condition will receive LPO by a MI-trained coach. The MI outreach call protocol will consist of 6 contact attempts over two weeks.The MI outreach call protocol will be repeated at 3, 6, and 9 months for a total of four outreach cycles because participants may not have quit or may have relapsed.
76087188|NCT01722292|Drug|Etoposide|Administered IV
76087189|NCT01722292|Drug|Placebo|Administered orally
76087190|NCT03329430|Other|Foot orthoses|Customized foot orthoses
76087191|NCT02494050|Behavioral|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
76087192|NCT02494050|Behavioral|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
76087193|NCT02494050|Behavioral|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
75338835|NCT01145183|Drug|Placebo|Matched placebo daily dosing
75338836|NCT04183673|Procedure|Laser therapy-cryo thermal therapy|5 days per week, 3 weeks, sessions including laser therapy + cryo therapy followed by usual rehabilitation
75649321|NCT05436262|Behavioral|At-home therapy|"Participants are assigned to groups where the participants will practice each day for 3 weeks at-home.~Group 1: Imagery only.~Group 2: Overt finger tapping only.~Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that the participants are finger tapping in time with the flashing cue, using the imagery strategies identified during participants' previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
75934477|NCT03222362|Other|Surgery|
75934478|NCT02451566|Device|Ovation Prime Abdominal Stent Graft System|
75649322|NCT05433324|Other|MRI and PET Scans|All groups will undergo cognitive tests and brain imaging scans (MRI & PET)
75649323|NCT05432362|Other|Aronia Juice|The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially availabe juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
75649324|NCT05432362|Other|Placebo|A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.
75649325|NCT05422768|Behavioral|Warrior Renew|Warrior Renew is a program for military sexual trauma (MST).
75649326|NCT05422768|Behavioral|Warrior Renew + EAL|Warrior Renew and EAL are combined into one program for military sexual trauma (MST).
75934479|NCT03232970|Other|Full Plate Diet|12 weekly sessions on how to incorporate more fiber in the diet.
76087194|NCT02249494|Other|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
76087195|NCT02249494|Other|nutritional counseling|Performing routine nutritional counseling in their clinical practice
76087196|NCT02249494|Device|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
75338837|NCT04183673|Procedure|Usual care|5 days per week, 3 weeks, sessions of usual rehabilitation
75934480|NCT04484792|Other|green tea mouthwash|green tea bags in 100 ml warm water for 5 min
75934481|NCT04484792|Other|green tea mouthwash|, in Group B its prepared by soaking tea bags in 100 ml hot water followed by ice addition.
75338838|NCT00230126|Drug|erlotinib|Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
75338839|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
75934482|NCT04484792|Other|placebo|Plain water
75338840|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
75934483|NCT03222050|Other|Distraction technique|
75934484|NCT03221816|Drug|Tenavit®|The experimental group received one tablet of Tenavit® daily for a period of 4 months.
75934485|NCT03221816|Drug|Placebo Oral Tablet|Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
75936553|NCT03178994|Drug|Hydrophilic Cream|Hydrophilic cream (in-house preparation) applies twice daily
75936554|NCT03182114|Other|supine position|the patient will be placed in regular supine position after spinal anesthesia
75936555|NCT03182114|Other|left lateral tilted position|the patient will be placed in left lateral tilted position after spinal anesthesia
76087197|NCT02493894|Drug|PEG|PEG solution (80gr/1Litr) each 8 hours for 24 hours
76087198|NCT02493894|Drug|placebo|placebo each 8 hours for 24 hours
76087199|NCT02493894|Drug|Cefazolin|cefazolin 1gram, every 6hours for 2 days
76087200|NCT03338166|Other|LDH serum level|Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
75649327|NCT05419089|Procedure|Robotic surgery|Transoral robotic surgical resection of the tumor with negative intraoperative frozen section margins.
75649328|NCT05419089|Radiation|De-intensified XRT|Daily reduced-dose radiation treatment equal to 4600 cGy with either intensity-modulated radiotherapy (IMRT) or proton beam therapy
75649329|NCT05419089|Drug|Cisplatin|Dose: 40mg/M2/week Route: IV over approximately 30 minutes, mixed in 250ml normal saline Schedule: Weekly on Monday or Tuesday any time, or Wednesday prior to radiation for 5 weeks (total dose 200 mg/M2)
75649330|NCT05408143|Other|CC|To promote prompt effective care for medically complex children at all hours, we developed an outpatient comprehensive care (CC) program at the University of Texas Health Science Center at Houston (UTH) that now includes a hospital consultation service by the outpatient CC providers (the hospital component) and a conventional telemedicine (CTM) audio-visual program (the home component).
75649331|NCT05408143|Device|enhanced telemedicine (ETM)|"An enhanced telemedicine program (using HIPAA-compliant, mobile TytoCareTM devices) will be added to CC to allow providers to remotely visualize the skin, throat, & ears, auscultate the heart & lungs, and measure illnesses during clinic hours and chronic illnesses during the detailed patient evaluation to be conducted at least every 6 months by virtual patient rounds in the home. These visits will involve the parent(s), the PCP, and if needed any of 10 specialists, particularly pulmonology, gastroenterology, neurology, and physical medicine and rehabilitation. A social worker, nutritionist, or psychologist will be involved as needed. Each PCP will perform 2-3 virtual patient rounds per week to proactively identify medical problems, suboptimal adherence to treatment, dosing errors, or other problems and intervene before CMC develop a serious illness or require avoidable clinic visits, Emergency Department visits, or hospitalizations."
75649332|NCT05396105|Drug|deucrictibant low dose|deucrictibant soft capsules for oral use
75649333|NCT05396105|Drug|deucrictibant medium dose|deucrictibant soft capsules for oral use
75649334|NCT05396105|Drug|deucrictibant high dose|deucrictibant soft capsules for oral use
75649335|NCT05396105|Drug|deucrictibant selected dose|deucrictibant soft capsule for oral use
75649336|NCT05389371|Behavioral|Alberta Healthy Living Program|Weight management services
75649337|NCT05389371|Behavioral|Alberta Obesity Centre Program|Multi-disciplinary obesity management
75649338|NCT05389371|Behavioral|Osteoarthritis advice|Living Your Best Life with Osteoarthritis Handbook
75649339|NCT05389371|Behavioral|Physiotherapy|GLA:D physiotherapy programs.
75649340|NCT05368311|Other|Dietary recommendations including protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations and 2 protein enriched bars per day to be eaten 45 minutes before lunch and dinner.
75934486|NCT03221894|Dietary Supplement|GRAPE granules|GRAPE granules was mainly consisted of herbal medicines: Ren Shen (Ginseng, 10g/d), Di Huang (Rehmannia glutinosa, 30g/d), Shi Cangpu (Acorus tatarinowii, 10g/d), Yuan Zhi (Polygala tenuifolia, 10g/d), Yin Yanghuo (Epimedium brevicornu, 10g/d), Shan Zhuyu (Cornus officinalis, 10g/d), Rou Congrong (Cistanche deserticola, 10g/d), Yu Jin (Curcuma aromatica, 10g/d), Dan Shen (Salvia miltiorrhiza, 10g/d), Tian Ma (Angelica sinensis, 10g/d), Tian ma (Gastrodia elata, 10g/d), and Huang Lian (Berberine, 10g/d), which were supplied by Beijing Tcmages Pharmaceutical Co., LTD, Each bag of granules with 150ml warm water melt was taken orally twice a day.
75934487|NCT03226964|Device|high flow nasal oxygen|humidified high flow nasal oxygen
75934488|NCT03119870|Other|Train|Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).
75934489|NCT03119870|Other|MRI|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
76087201|NCT02493738|Drug|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
76087202|NCT02493738|Drug|Sporanox 100mg|Sporanox 100mg single dose under fed condition
75338841|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
75649341|NCT05368311|Other|Dietary recommendations without protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations.
75936556|NCT03182114|Drug|Bupivacaine|The patient will receive 10 mg Bupivacaine for spinal anesthesia
75936557|NCT03182270|Diagnostic Test|nCLE|Procedure: EUS-FNA Device: nCLE
76087203|NCT03875638|Drug|Levetiracetam|Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability
76087204|NCT03875638|Drug|Placebo oral capsule|The placebo is a capsule that is identical in appearance to the levetiracetam
75338842|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
76087205|NCT03333798|Behavioral|Cognitive-Behavioral Intervention|"A Cognitive-Behavioral intervention will be delivered by psychologists with LPCWs support. LPCWs who will be under the supervision and guidance of psychologists.~Volunteers will receive 11 weekly sessions of which six will be provided by psychologists and five by LPCWs.~The Cognitive-Behavioral component will be delivered through a set modules that will cover the following components:~The Cognitive-Behavioral model~Tackling traumatic events~Cognitive reprocessing~Relaxation techniques~Prevention of revictimization~Behavioral reactivation for the start of a new life The intervention will be given within the health system and volunteers will be seen if necessary by an interdisciplinary team including social workers, general physicians and psychiatrists."
75338843|NCT02103608|Device|Glide|6 facial hair reduction treatments with the Glide device, two weeks apart.
75338844|NCT04071977|Drug|Combined antioxidant therapy|It consists of a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1 mg), vitamin C (L-ascorbic acid 180 mg), vitamin E (DL-alpha tocopherol 30 mg), zinc (zinc oxide 20 mg), copper (copper sulfate 1 mg), taken once a day for 12 months
75649342|NCT05366829|Drug|Tislelizumab|Tislelizumab (also known as BGB A317) is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against programmed cell death protein-1 (PD-1) under clinical development for the treatment of several human malignancies. Tislelizumab consolidation therapy after radiation therapy can capitalize on the immunomodulatory effect of radiotherapy and improve tumor responses and patient outcomes.
75338845|NCT04071977|Other|Placebo|It consists in a capsule with 100 mg of magnesium oxide
75338846|NCT02101190|Drug|BIA 9-1067|Opicapone, OPC
75338847|NCT01170533|Drug|omeprazole and pantoprazole|The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
75338848|NCT01790906|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
75796536|NCT05671380|Behavioral|Ask-Advice-Connect (AAC)|Licensed Practical Nurses will be trained to ask all patients if they smoke, document smoking status in the EHR, advise patients to stop smoking, and complete an electronic referral to Quit Partner or the smoking cessation clinic. AAC will be designed to connect participants to Quit Partner Minnesota to receive tobacco cessation counseling. Quit Partner™ is a family of programs available to help Minnesota residents quit commercial tobacco, administered by the Minnesota Department of Health (MDH). Quit Partner programs are provided by National Jewish Health (NJH). Any Minnesota resident can access a free 2-week supply of Nicotine Replacement Therapy (NRT). Uninsured and underinsured residents can access the full Quit Partner programs, including free one-on- one coaching, more NRT, and additional supports. Quit Partner also offers four population- specific programs and calls are available in several languages.
75796537|NCT05657977|Other|nonpharmacologic intervention (swaddling)|Swaddling method;The newborn will be placed on a square fabric blanket in the flexion and abduction position and will be loosely swaddled with a blanket.
75934490|NCT03119870|Other|EEG|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
75934491|NCT03120026|Dietary Supplement|Experimental product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
75338849|NCT01790906|Other|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
75338850|NCT01147601|Drug|topical 0.5% Timolol|topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily
75338851|NCT01147601|Drug|Control (placebo) group|Control (placebo) group
75338852|NCT03011645|Drug|Ziprasidone|Given by mouth, single dose of 60 mg.
75338853|NCT03011645|Drug|Lorcaserin|Given by mouth, single dose of 20 mg.
75473851|NCT01975740|Other|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
75473852|NCT01975753|Drug|Morphine|
75473853|NCT01975753|Drug|Fentanyl|
75649343|NCT05348499|Other|Questionnaire/Interview|Questionnaire/Interview
75338854|NCT03011645|Drug|Placebo Oral Tablet|Given by mouth, single dose.
75338855|NCT03012269|Behavioral|Working memory training|
75338856|NCT01149785|Drug|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
75649344|NCT05342025|Other|PNF|PNF will be applied to the trunk and upper extremities combined with breathing, 3 times a week, 1 hour a day for 6 weeks. Breathing PNF patterns, pressure, and stretches will be applied inward and upwards into the rib cage so that they do not cause pain. Diaphragmatic stimulation will be performed on both sides with repeated contractions, hand contacts, and stabilization techniques. Facilitation techniques will be used to stimulate the intrinsic respiratory muscles. Again, with respect to inspiration, the patterns will be studied in neck extension, upper and lower trunk extension, and upper extremities flexion patterns. Neck flexion, upper and lower trunk flexion, and extension patterns of the upper extremities will be applied in relation to expiration. The physiotherapist will apply pressure and stretches to the chest wall and diaphragm for 20 seconds by giving verbal commands to the patient for the inspiration/expiratory phases.
75796538|NCT05650073|Other|Immersive soundscapes|Audio technology used to create a three-dimensional sound experience in which the user is immersed in a virtual soundscape
75649345|NCT05342025|Other|Breathing exercises|Breathing exercises: diaphragmatic breathing, thoracic expansion, pursed-lip breathing and respiratory control for 15 minutes a day, every day of the week.
75338857|NCT01149785|Drug|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
75338858|NCT01149785|Drug|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
75338859|NCT02182115|Drug|antiseptic bundle|"Chlorhexidine gluconate liquid soap for bathing daily.~Chlorhexidine gluconate mouthrinse to use twice daily.~Nasal mupirocin to apply twice daily."
75338860|NCT02182115|Drug|standard of care|Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
75649346|NCT05327504|Behavioral|Written Exposure Therapy|Written Exposure Therapy is a 5 session treatment in which individuals write about their trauma event in a specified manner.
75796539|NCT05643287|Procedure|Periodontal treatment|Non-surgical periodontal treatment
75338861|NCT01151189|Biological|MVA85A/AERAS-485|Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
75338862|NCT01151189|Biological|Placebo|Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
75338863|NCT01173029|Drug|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
75338864|NCT01174823|Drug|bepotastine besilate ophthalmic solution|sterile ophthalmic solution
75338865|NCT01174823|Drug|placebo comparator ophthalmic solution|sterile ophthalmic solution
75796540|NCT05636423|Other|Survey|Online survey via a questionnaire composed of 28 questions.
75796541|NCT05635435|Other|Detection of Immune and Inflammatory Indices in Peripheral Blood|We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.
75934492|NCT03120026|Dietary Supplement|Isocaloric placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
75338866|NCT03011489|Device|Vacuum formed aligners|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is a modified step in Figueroa's technique.
75338867|NCT03886649|Drug|Copanlisib|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.
75796542|NCT05633953|Drug|Osilodrostat|oral administration
75796543|NCT05630196|Drug|LY3857210|Administered orally
75796544|NCT05630196|Drug|Placebo|Administered orally
75936558|NCT02424812|Behavioral|Lifebuoy School of Five Handwashing Intervention|
75936559|NCT02428322|Dietary Supplement|Placebo|Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.
75936560|NCT02428322|Dietary Supplement|VItamin D3|Soft gel capsules will contain 2,000IU vitamin D.
75936561|NCT02428244|Behavioral|Motivational Interviewing|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
75338868|NCT03886649|Drug|Venetoclax|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
75338869|NCT01151813|Drug|Varenicline|Varenicline, oral target dose of 1.0 mg BID, one week titration.
75338870|NCT01151813|Drug|Placebo|Placebo
75338871|NCT01175369|Behavioral|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
75338872|NCT03877991|Drug|CBD-sesame oil capsule|A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
75338873|NCT03877991|Drug|CBD-LNL capsule|A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
75338874|NCT03877991|Drug|CBD powder form capsule|Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
75338875|NCT03835949|Drug|TJ004309|Antibody to CD73
75338876|NCT03835949|Drug|Atezolizumab|Humanized monoclonal antibody to PD-L1
75338877|NCT01176617|Device|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
75338878|NCT01177709|Drug|Metformin|metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.
75338879|NCT01179113|Drug|Esmolol|Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
75649347|NCT05327504|Behavioral|Neutral Topic Writing|Treatment as Usual augmented by 5 sessions of Neutral Topic Writing which involves writing about specific objects (e.g., what they have eaten over the past week) or events (e.g., what they did since yesterday) in detail without discussing thoughts or feelings.
75649348|NCT05321953|Other|Standard Physical Therapy Care|Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.
75338880|NCT01179113|Drug|Saline|Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
75338881|NCT01152359|Behavioral|Choice|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
75338882|NCT01152359|Behavioral|Control|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
75338883|NCT01152515|Drug|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
75473854|NCT01975766|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
75473855|NCT01975766|Device|External beam radiation therapy|
75473856|NCT01975779|Drug|Cohort A1: Lu AE58054 or placebo|One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
75649349|NCT05321953|Other|Aerobic and Inspiratory Muscle Training|The exercise-based 3 times per week for 8 weeks intervention will consist of aerobic interval training and inspiratory muscle training (IMT) for a total duration of 30 minutes. Aerobic-based intervals will be performed at a moderate intensity. Aerobic modes of exercise will include upper extremity ergometer, treadmill, bike, or elliptical.
75649350|NCT05319509|Device|gameChange|Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus. Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete. The participant will put on the Oculus headset, and go through a preliminary orientation game. The headset will be casted to an external monitor. Once they start gameChange, it will take the participants to the virtual therapist's room. They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario. Research staff will be taking event sampling-style observations of the participant. After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.
75649351|NCT05310292|Biological|Oral glucose tolerance test|Consumption of 75 grams of glucose, diluted in water, added 1,5 g of acetaminophen.
75649352|NCT05310292|Biological|Mixed meal test|Consumption of a standardized liquid meal, with caloric and dietary content equal to a standard meal.
75796545|NCT05620563|Drug|LY3857210|Administered orally
75796546|NCT05620563|Drug|Placebo|Administered orally
75796547|NCT05617027|Other|actual transcranial direct current stimulation (tDCS)|"tDCS is a non-invasive brain stimulation technique that would influence the brain's pain control mechanisms.~The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA."
75934493|NCT03107468|Other|Mokhuri intensive treatment|Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.
75338884|NCT03011255|Biological|peptide specific CTL|Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
76087206|NCT03333798|Behavioral|Standard psychosocial care|"The active control group will receive standard psychosocial care for intimate partner violence, provided by the participating health centers. Standard care is delivered by psychologists, social workers, general physicians and psychiatrists. Additionally, patients receive extramural support which includes telephone calls or domiciliary visits from a variety of health professionals (doctors, nurses, social workers and nursing assistants).~Psychology consultations typically occur every four weeks in each health center. Psychologists use a variety of approaches according to their personal preferences, including humanist, psychoanalytic, psychodynamic and cognitive-behavioral approaches. At the end of the intervention psychologists will be asked which approach or approaches they used."
75338885|NCT01153685|Biological|Fluviral®|Intramuscular injection, one dose
75338886|NCT03011177|Drug|Teneligliptin|teneligliptin 20mg qd
75338887|NCT03011177|Drug|Linagliptin|linagliptin 5mg qd
76087207|NCT02493582|Biological|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
76087208|NCT02493582|Drug|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
75338888|NCT01154699|Device|Bilevel PAP (4 weeks)|Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
75338889|NCT01154699|Other|Usual Care (4 weeks)|Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
75338890|NCT01154699|Other|Washout Period (4 weeks)|Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
75338891|NCT03465527|Drug|PrednisoLONE 50 MG|Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
75649353|NCT05305248|Drug|Remimazolam|After spinal anesthesia, 5 mg of remimazolam is injected by intravenous route for 1 minute to induce sedation. To maintain sedation, remimazolam is continuously infused at a rate within the range of 0.1 mg/kg/h to 1 mg/kg/h.
75649354|NCT05305248|Drug|Dexmedetomidine|After performing spinal anesthesia, dexmedetomidine is injected at a loading dose of 1 mcg/kg for 10 minutes to induce sedation. Thereafter, to maintain sedation, Dexmedetomidine is continuously infused at a rate within the range of 0.2 to 0.7 mcg/kg/h.
75338892|NCT03010943|Device|Virtual reality headset|Feasibility and tolerance
75338893|NCT01180127|Dietary Supplement|Flavanol containing food product|12 weeks, 2X/day, 20g serving
75338894|NCT01180127|Behavioral|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
75338895|NCT01180127|Dietary Supplement|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
75338896|NCT01180127|Behavioral|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
75338897|NCT03418805|Drug|Advil Ibuprofen table 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
75338898|NCT03418805|Drug|Motrin IB Ibuprofen Tablets 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
75473857|NCT01975779|Drug|Cohort A2: Lu AE58054 or placebo|One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
75649355|NCT05301400|Device|Bti Unit|Comparison with or without the device
75649356|NCT05291741|Dietary Supplement|VLCD|Advice regarding VLCD
75936562|NCT02428244|Behavioral|Motivational Interviewing + Follow-up|"Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.~In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months."
76087209|NCT05560360|Drug|SHR1459 tablet|100 mg/tablet; administered orally
76087210|NCT05560360|Drug|Efavirenz tablet|600 mg/tablet; administered orally
76087211|NCT03329118|Drug|SHR3824, Simvastatin|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
75338899|NCT03418805|Drug|Ibuprofen CR Tablets 600 mg|"Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively"
75338900|NCT01156571|Drug|cangrelor P2Y12 (platelet) inhibitor|
75338901|NCT01156571|Drug|Clopidogrel - 300 or 600 mg (study arm)|Over encapsulated tablets.
75338902|NCT01156571|Drug|Clopidogrel 600 mg post cangrelor|over-encapsulated clopidogrel (600 mg)
75338903|NCT01220687|Drug|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
75338904|NCT01220687|Other|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
75473858|NCT01975779|Drug|Cohort B1: Lu AE58054|Two single oral doses 60 mg with >=7 days washout.
75649357|NCT05291741|Dietary Supplement|Standard care|Standard dietary advice for weight loss before bariatric surgery
75473859|NCT01975805|Other|Chlorhexidine Gluconate|
75473860|NCT01975805|Other|Povidone Iodine|
75473861|NCT01975844|Other|Individualized Anemia Mangement Protocol|"Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
76087212|NCT03333720|Dietary Supplement|Phenylalanine-free protein substitute tablets|Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
76087213|NCT01723384|Drug|Intermittent Oral Naltrexone|
75338905|NCT03010865|Drug|Sodium Butyrate|Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
75338906|NCT03010865|Drug|Placebo Oral Capsule|Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
75338907|NCT01156805|Other|Educational program|The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
75338908|NCT02531802|Biological|ETVAX|"Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of:~Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg~E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I)~E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3)~E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5)~E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6)~The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid."
75338909|NCT02531802|Biological|dmLT|Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
75338910|NCT02531802|Other|Bicarbonate Buffer|Sodium bicarbonate buffer dissolved in 150 ml of potable water
75473862|NCT01975857|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
75338911|NCT01157429|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
75338912|NCT01157429|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
75338913|NCT01157429|Behavioral|CBT|12-session CBT protocol, called Youth PTSD Treatment.
75338914|NCT01158521|Drug|pazopanib hydrochloride|Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
75338915|NCT01158521|Procedure|therapeutic conventional surgery|Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
75649358|NCT05286996|Device|Iovera - Cryoneurolysis|Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.
75934494|NCT03107468|Other|Non-surgical conventional standard treatment|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
76087214|NCT01723384|Drug|Placebo|
75338916|NCT02246933|Other|PUFA Diet|The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
75338917|NCT02246933|Other|Control Diet|The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
75338918|NCT01221311|Device|Fully covered Metallic Stent|Covered Wallflex Biliary (TM)
75473863|NCT01975857|Behavioral|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
75473864|NCT01975870|Other|Application on smartphone|innovative application on smartphone which helps to increase the awareness of sedentary behavior of the user by messages, scoring system, ...
75649359|NCT05286996|Drug|Local anesthetic|Placebo - local anaesthesia
75799000|NCT01291758|Diagnostic Test|Submaximal bicycle exercise stress tests performed 24 hr apart|Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.
76087215|NCT03329040|Other|No Intervention.|No intervention.
76087216|NCT02492490|Other|SVFderived MSC transplantations|"infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab."
76087217|NCT02492490|Drug|Basiliximab|induction with Basiliximab before kidney transplantation and on POD 4
76087218|NCT03328962|Behavioral|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
76087219|NCT03333642|Procedure|Duodenal Ileal Interposition with Sleeve Gastrectomy|Laparoscopic or open Duodenal Ileal Interposition with Sleeve Gastrectomy
75338919|NCT01221311|Device|Plastic Stent|Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
76087220|NCT03333564|Dietary Supplement|VD3|50,000 IU VD3 / week for 8 weeks
76087221|NCT03333564|Dietary Supplement|Omega3-FA|300 mg of omega3-FA once daily for 8 weeks
76087222|NCT03333564|Dietary Supplement|VD3 and Omega-3FA|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
76087223|NCT03333564|Other|Control|No intervention was given
75338920|NCT04352075|Drug|Autologous biologic drug of innovative therapy /cell therapy drug|Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
75338921|NCT05410080|Diagnostic Test|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
75338922|NCT00234884|Biological|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
75338923|NCT01602666|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
75338924|NCT01602666|Drug|Carboplatin|Given IV
75338925|NCT01602666|Drug|Etoposide|Given IV
75338926|NCT01602666|Drug|Ifosfamide|Given IV
75649360|NCT05286710|Device|pharmacomechanical thrombectomy (PMT)|After randomization patients will be allocated to pharmacomechanical thrombectomy (PMT) via ipsilateral popliteal venous approach or to PMT via distal calf venous approach, bail-out contralateral femoral access can be used if puncture was failed in calf vein. After PMT treatment, residual thrombus was reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) was conducted if there was residual thrombus. Stenosis of iliac vein was assessed by multiangle venography and intravascular ultrasound (IVUS) was used if necessary. Percutaneous balloon angioplasty (PTA) was conducted if there was >50% stenosis of the diameter of the iliac vein. A stent was placed if the residual stenosis was >50% after PTA treatment.
75796548|NCT05617027|Other|placebo transcranial direct current stimulation (tDCS)|The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA for 30 secondes, and then 0 mA for the rest of the 20-minute session.
75338927|NCT01602666|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75338928|NCT04423380|Drug|SH3051 capsule treatment|Starting dose 20mg,oral administered twice daily.If tolerated subsequent cohorts will test increasing doses (40mg,60mg,80mg,100mg) of SH3051.
75934495|NCT03226574|Drug|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
76087224|NCT05464446|Device|Baseline Bubble Inclinometer, Baseline Digital İnclinometer and Hoggan microFET2 devices|Bubble inclinometer was used to measure lumbar lordosis angle, Digital inclinometer was used to measure pelvic inclination angle and Hoggan microFET2 was used for muscle strength measurement.
75934496|NCT03119636|Biological|NPC transplantation|The cells are stereotactically implanted in the striatum.
75934497|NCT03119636|Drug|Levodopa|Levodopa is used depending on the patient's condition
76087225|NCT02493504|Drug|Heparin|100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
76087226|NCT03333330|Drug|Visipaque 320 and SonoVue|"Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS"
75338929|NCT02531646|Radiation|Radiation|Radiation - Each human subject will receive one standard of care x-ray and one Duel Energy exposure or one standard of care x-ray and one Digital Tomosynthesis exposure. Phantoms were imaged using linear tomography and digital tomography.
75796549|NCT05584449|Other|Counseling|Attend online group facilitated by two oncology social workers
75338931|NCT05415618|Other|Manual lymphatic drainage|Manual lymphatic drainage will be applied 5 days a week for about 15 minutes every day for 4 weeks.
75338932|NCT05415618|Device|splint|In splint treatment, a volar-supported splint that keeps the wrist in a neutral position will be preferred and it will be recommended to both groups to be used only at night for 4 weeks.
75338933|NCT00300482|Drug|ABT-335|135 mg, daily, 12 weeks
75796550|NCT05584449|Procedure|Discussion|Discuss survivorship issues/concerns
75796551|NCT05584449|Other|Informational Intervention|Receive young adult cancer survivorship information
75796552|NCT05584449|Other|Medical Chart Review|Ancillary studies
75796553|NCT05584449|Other|Quality-of-Life Assessment|Ancillary studies
75934498|NCT03107234|Other|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
75934499|NCT03232814|Behavioral|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
75934500|NCT03226496|Behavioral|motivational interviewing|
75338934|NCT00300482|Drug|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
75649361|NCT05284123|Other|Self-compassion workshop|The self-compassion workshop instructs participants to reflect on a source of shame, connect with their suffering related to it, and then direct feelings of support and understanding towards their suffering via a few brief writing tasks. This workshop also provides participants with basic information about mental health resources.
75338935|NCT00300482|Drug|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
75796554|NCT05584449|Other|Questionnaire Administration|Ancillary studies
75649362|NCT05284123|Other|Mental health literacy workshop|The mental health literacy workshop provides participants with information about the symptoms and treatment of common mental disorders, and asks participants to reflect on what they learned through a couple brief writing tasks. This workshop also provides participants with basic information about mental health resources.
75338936|NCT01791062|Device|HYTOP®|HYTOP® will be implanted once during surgery.
75338937|NCT00301028|Biological|Cetuximab|Beginning weekly dose 400 mg/m^2 IV over 1-2 hours, and 250 mg/m^2 weeks 2-6.
75649363|NCT05284123|Other|Control workshop|The control workshop provides participants with basic information about mental health resources.
75796555|NCT05573737|Other|education|education about ubilical cord care
75796556|NCT05571592|Drug|Cannabidiol|Oral Capsule Formulation of CBD dissolved in a self-emulsifying drug technology called nanodomains, encapsulated within 1-ml softgel capsules, with a CBD purity ≥98%. Imported from Ananda Scientific
75796557|NCT05571592|Drug|Placebo|"Drug: Placebo~Placebo softgel capsule formulation."
75338938|NCT00301028|Drug|Carboplatin|AUC 2 weekly for 6 courses.
75796558|NCT05559905|Drug|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
75796559|NCT05559905|Drug|Placebo|Placebo capsule matched to molnupiravir taken twice daily by mouth.
75796560|NCT05559905|Biological|RSV A Memphis 37b|RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of ~4 Log10 plaque forming units (PFUs).
75934501|NCT03232502|Diagnostic Test|Pharmacogenetic testing|Basic pharmacogenetic panel
75934502|NCT03226262|Device|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
75934503|NCT03226340|Drug|S-amlodipine 2.5mg + Chlorthalidone 25mg|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
75338939|NCT00301028|Drug|Paclitaxel|135 mg/m^2 weekly for 6 courses.
75338940|NCT00301028|Procedure|Conventional Surgery|Following induction in second part of study.
75338941|NCT00301028|Radiation|Radiation Therapy|Following induction in second part of study.
75338942|NCT00301418|Drug|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
75338943|NCT00302042|Behavioral|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
75649364|NCT05273060|Procedure|3D Nasal Reconstruction Planning|3D molds or models to use in the reconstruction of nasal cartilage
75649365|NCT05269823|Other|Ice-therapy|Ice therapy will be provided prior to intravitreal injection provision
75649366|NCT05269823|Other|No Ice-therapy|No additional intervention (i.e.) ice therapy will be provided prior to intravitreal injection provision
75934504|NCT03226340|Drug|S-amlodipine 2.5mg + Telmisartan 40mg|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
75338944|NCT00302042|Behavioral|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
75338945|NCT01892228|Behavioral|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
75338946|NCT01898702|Behavioral|Diabetes expert patients programme|Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
75338947|NCT05414604|Diagnostic Test|3D spine CT|CT scan of the spine
75649367|NCT05269394|Drug|E2814|Administered intravenously in a blinded fashion
75649368|NCT05269394|Drug|Lecanemab|Administered intravenously
75649369|NCT05269394|Drug|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
75796561|NCT05556759|Procedure|control|patient will be operated under general anesthesia
75796562|NCT05556759|Procedure|IPS|patients will receive ultrasound-guided anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
75796563|NCT05556759|Procedure|Supra-iliac QL|patients will receive ultrasound-guided supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
75796564|NCT05538832|Device|BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Perception Training: Visual Sweeps; Mind's Eye; Hawk Eye; and Divided Attention. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
75338948|NCT01898780|Procedure|pancreaticojejunostomy with horizontal mattress suture|
76087227|NCT00706914|Drug|Once-daily aclidinium/formoterol|Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
75796565|NCT05538832|Device|BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Cognitive Control Training: Mind Bender; Divided Attention; Card Shark; and Freeze Frame. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
76087228|NCT00706914|Drug|Twice-daily formoterol fumarate|Inhaled formoterol fumarate 12 µg twice-daily (BID)
76087229|NCT00706914|Drug|Placebo to formoterol fumarate|Inhaled placebo to formoterol fumarate once-daily in the evening
76087230|NCT00706914|Drug|Once-daily formoterol fumarate|Inhaled formoterol fumarate 12 μg once-daily in the evening
76087231|NCT03337776|Other|WhatsApp message|WhatsApp message will be sent to invite subjects to participate in CRC screening
75934505|NCT03221504|Other|Longer therapy duration|Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
76087232|NCT03337776|Other|Telephone call|Telephone call will be made to invite subjects to participate in CRC screening
75338949|NCT01898780|Procedure|pancreaticojejunostomy with interrupted suture|
75338950|NCT05414214|Procedure|Thyromental Height Test|Thyromental Height Test (TMHT) : will be measured while a patient is lying supine with the head and neck are maintained in a neutral position using a pillow under the head. By using a digital depth gauge, the TMH is the vertical distance measured between the anterior border of the thyroid cartilage directly on the thyroid notch and the anterior border of the mentum.
75338951|NCT05414214|Procedure|Sternomental displacement|Sternomental displacement (SMDD): While the patient is sitting with the head in a neutral position, SMD-neutral will be measured using a tape as the distance between upper borders of the manubrium sterni and the mentum. The SMD-extension will then be measured in the same way with the head extended on the neck. The difference between SMD-extension and SMD-neutral will then be calculated as SMDD.
75338952|NCT05414214|Procedure|General anesthesia|patients will be pre-oxygenated with 100% oxygen for 3 minutes, anesthesia will be then induced intravenously using fentanyl 2 μg/kg, propofol 1 -1.5 mg/kg, and succinylcholine 1 mg/kg lean body weight. Mask ventilation will be maintained till complete muscle relaxation guided by a peripheral nerve stimulator. Using Macintosh laryngoscopy, an anesthetist who has at least three years experience and who will be blinded to the preoperative tests' results, determined the best laryngeal view by using Cormack-Lehane (CL) grading system from I-IV. External neck manipulation will be used when needed to obtain the best laryngoscopic view. Endotracheal intubation will then be accomplished. The number and duration of intubation attempts will be recorded.
75338953|NCT01898858|Device|Hypercapnia inhalation (Altitrainer NP 190)|Hypercapnia inhalation using an Altitrainer NP 190
75338954|NCT01898858|Device|Hypoxia and hypercapnia (Altitrainer NP 190)|Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
75338955|NCT01898858|Device|Hypoxia inhalation (Altitrainer NP 190)|Hypoxia inhalation using an Altitrainer NP 190
75649370|NCT05260723|Behavioral|Behavioral: Sit Less|The Sit Less arm uses habit formation, social cognitive theory, and motivational interviewing techniques to support behavior change and includes: 1) 7 health coaching sessions to set personalized goals and review progress; 2) wearing an activPAL (thigh worn accelerometer that measures sitting time); 3) intervention tools to support behavior change (e.g., standing desk, wrist worn monitor).
75649371|NCT05256394|Behavioral|Pain Manager + tailored implementation support|Individualized training, technical assistance, and workflow assessments.
76087233|NCT03328728|Device|Cellular Matrix / A-CP HA Kit|Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
75338956|NCT05014230|Dietary Supplement|Open Placebo|Zeebo
75649372|NCT05250830|Device|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
75649373|NCT05250830|Device|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
75796566|NCT05536791|Drug|Dabigatran Etexilate (DE)|Dabigatran Etexilate (DE)
75934506|NCT03221504|Other|Shorter therapy duration|Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
75934507|NCT03221582|Drug|EBR/GZR|Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
75934508|NCT03232268|Biological|HLA-mismatched microtransplantation|3 administrations of hematopoietic stem cells without immunosupression
75934509|NCT03221348|Biological|CHO-H01|Glyco-engineered anti-CD20 antibody
75338957|NCT05014230|Other|Opioid medication as part of standard care|Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
75338958|NCT00237770|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
76087234|NCT03328728|Device|Synvisc-One|Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
76087235|NCT03333174|Diagnostic Test|Cardiorespiratory monitoring|The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
75338959|NCT00237770|Procedure|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
75338960|NCT04228484|Other|Placebo|Placebo infusion
75338961|NCT04228484|Other|GIP receptor antagonization|GIP(3-30)NH2 infusion
75338962|NCT01895738|Behavioral|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
75649374|NCT05242952|Behavioral|Gaming in a virtual environment|To address the primary outcomes of feasibility and acceptability of the VE, we will capture process data using a computer-based virtual environment and self-report measures using an online survey.
75649375|NCT05232669|Dietary Supplement|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
75796567|NCT05529901|Device|GORE® CARDIOFORM Septal Occluder|Patients for whom the device is used (implanted or used by not implanted) during the enrollment period of this post-marketing surveillance will be considered eligible for the study
75934510|NCT03221114|Behavioral|Positive Psychological Intervention|Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
75338963|NCT01896284|Drug|0.5mg aflibercept|0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
75473865|NCT01975896|Behavioral|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
75649376|NCT05232669|Dietary Supplement|Cocoa extract placebo|Cocoa extract placebo
75649377|NCT05232669|Dietary Supplement|Multivitamin|Multivitamin
75796568|NCT05529264|Other|Memory Tasks|Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.
75934511|NCT03232034|Dietary Supplement|Calcium Citrate|1000 mg calcium as calcium citrate
75934512|NCT03232034|Dietary Supplement|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
76087236|NCT03328572|Other|E-max Endocrown|Endocrown preparation
76087237|NCT03328572|Other|Cerasmart Endocrown|Endocrown preparation
76087238|NCT03328494|Drug|BOS172722|Oral capsules
76087239|NCT03328494|Drug|Paclitaxel|IV infusion
76087240|NCT02491398|Drug|Bendamustine + Rituximab|
76087241|NCT03337464|Other|cycling exercise|5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
76087242|NCT03333096|Device|Ocusweep test battery|"Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)"
76087243|NCT03333096|Diagnostic Test|Neuropsychological test battery|Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
75338964|NCT02536404|Drug|Etrasimod|
75338965|NCT02536404|Drug|Placebo|
75473866|NCT01975961|Drug|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC|For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
75473867|NCT01975987|Device|Bonfils fiberscope|
75473868|NCT01976000|Procedure|multi-slice Computed Tomography angiography and three-dimensional reconstruction software|
75649378|NCT05232669|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
75649379|NCT05222815|Other|CGM|Continuous glucose monitor (CGM)-based glucose monitoring
75649380|NCT05222815|Other|SMBG|Self-monitoring of blood glucose (SMBG)-based glucose monitoring
75649381|NCT05210166|Device|Active tSCS and Lokomat|"A symmetrical biphasic 30 Hz current of 1 ms pulse-width with an electro-stimulator will be applied.~For the stimulation intensity, the maximum intensity tolerated by the patient will be selected. The intensity will be increased in case of habituation to the current."
75796569|NCT05529264|Other|Attention/arousal tasks|Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.
75934513|NCT03232034|Dietary Supplement|Whey Protein Hydrolysate|50 g whey protein hydrolysate
76087244|NCT02492256|Device|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
75796570|NCT05529264|Other|Language tasks|Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.
75338966|NCT04271618|Other|TheraTogs Orthotic Undergarment|Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs
75338967|NCT05438160|Device|Digital therapeutics app CT-155|Patients to be treated with digital therapeutics app CT-155 downloadable into personal smartphones
75473869|NCT01976013|Device|Coaguchek|The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
75473870|NCT01976026|Device|Flow Diversion|
75473871|NCT01976026|Device|Best Standard Therapy|
75649382|NCT05210166|Device|Sham tSCS and Lokomat|The protocol and device of sham tSCS combined with Lokomat will be the same as active tSCS except for the stimulus intensity, which will be set at the sensory threshold, maintained for 30 seconds and then slowly will be decreased to zero, being this intensity maintained for the remaining 20 minutes of stimulation.
75649383|NCT05208866|Drug|Lixivaptan|Oral vasopressin V2 receptor antagonist
75796571|NCT05529264|Other|Visuospatial tasks|Participants will be asked to copy 3 dimensional designs or make judgements of angle size.
75796572|NCT05529264|Other|Auditory Tasks|Participants will be presented with short, approximately 8-minute clips of music from various genres ( i.e. classical, country, rock, etc.) with an attention task (modified sustained attention to response task) nested within each trial. Participants will receive approximately 8 music stimuli and 1 control stimulus (pink noise) twice over the course of two testing sessions ( 90 mins each). Additionally, participants will be asked to answer questions about their hearing, music preferences/training, and certain demographic information (age, handedness, and language proficiency).
75796573|NCT05529264|Procedure|Brain Stimulation|A brain stimulator will be used to understand new functions of the brain. Participants will be presented with pictures on a computer screen and may be asked to tell researchers what is seen or remembered by participants. As pictures are viewed by the participants, the brain stimulator may be activated, which would not be something that would be felt by an individual participant.
75796574|NCT05529264|Other|Social Emotional Task|Participants will be asked to view presented pictures and videos of people engaged in social interaction. Additionally, participants will be presented with the standardized tasks that are designed to help the researchers with understanding the nature of emotions. Some of these images may be emotionally disturbing. If participants are not comfortable viewing such images, they will be asked to refrain from participation in this study.
75934514|NCT03225950|Other|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
76087245|NCT02492256|Device|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
75934515|NCT03225950|Diagnostic Test|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
75934516|NCT03225950|Genetic|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
76087246|NCT02492256|Device|ILR implantation|Implantation the ECG loop recorder according to standard procedure
76087247|NCT03337386|Diagnostic Test|inferior vena cava collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
75473872|NCT01976039|Other|rhinopharyngeal retrograde clearance (RRC)|The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
75473873|NCT01976078|Drug|Midazolam/Ranitidine/Esomeprazole|Each of the three drugs will be given at 10% of their usual doses for age/weight.
75649384|NCT05197530|Drug|Indocyanine green|A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.
75649385|NCT05197530|Device|MultiSpectral Imaging System|Once the ICG is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
75649386|NCT05196451|Behavioral|Rehabilitation based on CBT principles|Cf. arm description
75649387|NCT05190666|Behavioral|PACE Weight Loss program|12 month phone-based behavioral weight loss program
75649388|NCT05190666|Behavioral|Chronic Disease Self-Management|12 month phone-based chronic disease self-management program
76087248|NCT03337386|Diagnostic Test|subclavian vein collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
76087249|NCT03337386|Diagnostic Test|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
76087250|NCT03328416|Device|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
75338968|NCT05435820|Device|Near-infrared Transcranial Laser Therapy|The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
75338969|NCT01478581|Drug|PCI-32765|
75338970|NCT01478581|Drug|Dexamethasone|
75338971|NCT00239642|Drug|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
75796575|NCT05529264|Other|Recording of facial expressions|Some participants may be asked permission to record the video of their facial expressions during performance of a research task. Generally, this will include only research tasks investigating brain representation of social/emotional information. Automated analysis of facial expression may be used in certain experiments to provide information on experience of emotional states such as happiness and sadness related to the images being presented.
75796576|NCT05529264|Other|Judgement/Impulsivity Task|Certain study participants may be enrolled into research tasks designed to activate regions important for judgment and impulse control. These tasks will present participants with choices of varying monetary rewards and ask them to make judgements to measure one's tendency to prefer immediate over delayed rewards.
75796577|NCT05522231|Drug|fruquintinib+sintilimab|fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
75796578|NCT05522231|Drug|axitinib / everolimus|axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.
75796579|NCT05522231|Drug|fruquintinib|fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
75796580|NCT05513833|Other|Standard School Screening and Referral|Counties in the control condition will use standard hearing screening and standard referral by school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
75934517|NCT03225950|Diagnostic Test|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
75934518|NCT03119948|Drug|Placebo injection|"Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment"
76087251|NCT03333018|Drug|Aclidinium bromide|Administered as monotherapy, prescribed as recorded in the database.
76087252|NCT03333018|Drug|Aclidinium bromide/formoterol|Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
76087253|NCT03333018|Drug|Other COPD medication|"Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database."
76087254|NCT03328260|Device|HIFU|Transvaginal high intensity focused ultrasound to ablate uterine myoma
76087255|NCT03332940|Drug|Tc 99M Sulfur Colloid|Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.
76087256|NCT03332940|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
76087257|NCT03332862|Procedure|catheter ablation|catheter ablation for atrial fibrillation treatment
75473874|NCT01976117|Device|enose|
75473875|NCT01976130|Procedure|Bronchoscopy|
75473876|NCT01976143|Drug|NKTR-102|
75473877|NCT01976156|Dietary Supplement|PhosphoLean|PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
76087258|NCT03327948|Device|Axonics Sacral Neuromodulation System (SNM) System|Axonics Sacral Neuromodulation System (SNM) System
75338972|NCT00239642|Drug|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
75338973|NCT00239642|Drug|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
75338974|NCT04041830|Behavioral|Visit 1|the participants will fill in the LFPQ questionnaire before and after a lunch test meal
75473878|NCT01976156|Dietary Supplement|Placebo|Placebo consists of rice flour
75473879|NCT01976195|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
75473880|NCT01976195|Drug|Thalidomide|Thalidomide 150mg per day, 15 consecutive days
75473881|NCT01976208|Drug|Omalizumab|The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg~750mg，then dosing interval is every 2 weeks.
76087259|NCT03337230|Behavioral|Physical Activity|Fitbit Activity Monitor and IPAQ to give level of physical activity. Participants will be provided with education about physical activity recommendations and will be encouraged to set goals for improvement.
76087260|NCT03337230|Behavioral|Diet|National Cancer Institute's ASA24 web-based dietary assessment tool to determine intake. Participants will be provided with education about healthy diets and will be encouraged to set goals for making enduring changes to dietary intake.
76087261|NCT03337230|Behavioral|Social Support|Social support will be determined via self report scale measure and objective collection of social media communications. Each participant will be contacted through social media regularly with dietary and physical activity information and asked to support other participants via encouragement and sharing of information.
76087262|NCT02493348|Device|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
76087263|NCT03337074|Other|Questionnaire, semen sample, fasting blood sample|Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
75796581|NCT05513833|Other|Enhanced mHealth Screening|The enhanced screening protocol will consist of an mHealth-based hearing screen combined with tympanometry.
75796582|NCT05513833|Other|Specialty Telemedicine Referral|The specialty telemedicine referral will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the specialty telemedicine referral and send details asynchronously to an audiologist for consultation.
75796583|NCT05507918|Other|Oral water and clear liquids|Measured oral intake of fluids prior to tonsillectomy
75796584|NCT05506475|Procedure|Blood samples|venous blood collected in a 5 mL EDTA tube
76087264|NCT03337074|Other|Questionnaire|Participants are asked to complete a questionnaire.
75338975|NCT04041830|Behavioral|Visit 2|this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
75338976|NCT04271462|Other|Comparing two CO2 absorbers in the ventilator circuit|"General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):~I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow."
75338977|NCT01791218|Procedure|CABG, AVR or CABG+AVR and PVI|
75338978|NCT01791218|Procedure|CABG, AVR or CABG+AVR|
75338979|NCT00241904|Behavioral|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
75338980|NCT00241904|Drug|Antiplatelet Agents|Aspirin 81 mg q day
75338981|NCT00241904|Drug|Beta Blocker|Oral medication
75473882|NCT01976208|Drug|placebo|
75649389|NCT05178069|Drug|: Placebo for Probiotic|Capsule manufactured without active ingredients.
75649390|NCT05178069|Dietary Supplement|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus G
75649391|NCT05174910|Device|Obsidian ASG|Application of an autologous platelet-rich fibrin matrix
75796585|NCT05500339|Other|M-health App|Pregnant women receive the App designed for the support of the first 1000 days of life
75796586|NCT05500339|Other|Standard care|Pregnant women receive standard supportive and educational methods.
75796587|NCT05484154|Biological|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given at 100 mL IV infusion
75338982|NCT00241904|Drug|ACE Inhibitors|Oral medications, received 1-2 times per day
75338983|NCT01791296|Drug|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
75796588|NCT05484154|Other|Placebo|Matching placebo, 0.9% sodium chloride in water, given at 100 mL IV infusion
75338984|NCT01791296|Other|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
75338985|NCT01479127|Drug|ABT-SLV187|
75473883|NCT01976234|Other|Fresh RBC|Patients will receive fresh blood only
75473884|NCT01976234|Other|Old RBC|
75649392|NCT05173740|Other|Individually tailored rehabilitation intervention|Individually tailored rehabilitation intervention
75649393|NCT05173740|Other|Usual care|Usual care
75649394|NCT05169593|Drug|Biological Drug|Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence
75649395|NCT05161455|Biological|platelet rich fibrin|we would like to measure the effect of PRF on soft and hard tissue healing
75796589|NCT05467306|Behavioral|Nurse-Navigator Enhanced PrEP Support|Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
76087265|NCT03337074|Other|Questionnaire, fasting blood sample|Participants are asked to complete a questionnaire and provide a fasting blood sample.
76087266|NCT01723696|Dietary Supplement|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
76087267|NCT01723696|Dietary Supplement|Placebo tablet+prenatal vitamin|
76087268|NCT04494282|Procedure|Endoscopic retrograde pancreatography|Endoscopic cannulation of main pancreatic duct
75338986|NCT01479127|Drug|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
75473885|NCT01976325|Other|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
75473886|NCT01976403|Behavioral|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
75649396|NCT05158153|Other|ORKID Bundled Intervention|During the 90-day study period, participants will be prescribed outpatient hemodialysis with cooled dialysate (35-36°C), high sodium dialysate (145 mmol/L), a high ultrafiltration hold threshold (systolic blood pressure > 110 mmHg; ultrafiltration hold threshold will not be applied in participants with baseline systolic blood pressure < 120 mmHg), and high dose diuretics (160 mg oral furosemide twice daily) to be taken every day at home will also be prescribed. Dialysis will be weaned according to an active weaning protocol.
75649397|NCT05158153|Drug|Furosemide|160 mg oral furosemide twice daily to be taken every day at home
75649398|NCT05156840|Behavioral|Telehealth follow-up|A telehealth follow-up visit will be conducted via the Epic electronic medical record with a pediatric hospitalist following hospital discharge.
75649399|NCT05152992|Behavioral|Viewing visual stimuli and electrical stimulation of the brain|View emotionally evocative videos and undergo stimulation of brain regions involved in emotion. In a 20-minute block (5 total blocks), eighteen 30-second movie clips will be used to elicit different categories of emotions (sadness, fear, disgust, awe, affection, and amusement). Additionally, each hub of the emotion network will be stimulated to identify areas that generate similar emotional states as those elicited by the videos. Each stimulation trial consists of 3 minutes of 1-3 mA, 50 Hz, 100 us pulse-width stimulation.
75649400|NCT05149859|Other|Observational|(no intervention)
75796590|NCT05459077|Behavioral|Hypertension control through education and monitoring|Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..
75934519|NCT03119948|Drug|Botulinum toxin injection|"Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
75934520|NCT03119948|Drug|Placebo injection and botulinum toxin injection|"Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
76087269|NCT03332706|Other|observation|after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy
76087270|NCT01726036|Device|Gomco Circumcision Clamp|Neonatal male circumcision utilizing the Gomco Circumcision Clamp
76087271|NCT01726036|Device|Mogen Circumcision Clamp|Neonatal male circumcision utilizing the Mogen Circumcision Clamp
76087272|NCT03327558|Drug|Apriso 0.375G ER CAP|ER capsule
75338987|NCT01479127|Device|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
75338988|NCT01479127|Device|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
76087273|NCT03327558|Drug|APRISO 375 mg extended-release capsules|375 mg extended-release capsules
76087274|NCT02492646|Procedure|Saline group|After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
76087275|NCT02492646|Procedure|Dry group|After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
75338989|NCT01479127|Device|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
76087276|NCT01726504|Device|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
75338990|NCT03917966|Drug|SHR-1210+docetaxel+nedaplatin|neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
75338991|NCT03917966|Drug|SHR-1210+Apatinib|SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
75338992|NCT00243152|Drug|Lamotrigine|: 25mg and 50mg tablets
75338993|NCT00243152|Drug|Placebo (for Lamotrigine)|Sugar pill manufactured to mimic Lamotrigine tablets
75338994|NCT01453075|Drug|Valacyclovir|Valacyclovir 1.5 mg po bid
75338995|NCT01453075|Drug|Placebo|Matching placebo twice daily
75338996|NCT01899092|Drug|TT-034|The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
75649401|NCT05147558|Drug|Pembrolizumab|Pembrolizumab (200mg every 3 weeks, intravenously)
75649402|NCT05147558|Drug|Lenvatinib|Lenvatinib (20mg once daily orally)
75649403|NCT05144789|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
75649404|NCT05144789|Device|Active TBS-DMPFC|"Participants in the active stimulation group will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
75649405|NCT05144789|Device|Sham TBS-DLPFC or DMPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
75649406|NCT05133362|Device|Gait training with EksoNR|Participants will receive forward gait training with EksoNR
75649407|NCT05133362|Procedure|Backward gait training with EksoNR|Participants will receive backward gait training with EksoNR
75649408|NCT05118815|Other|Slim abutment|Use a narrower abutment to see if they present a better biological seal.
75649409|NCT05118815|Other|Standard abutment|Use a standard abutment
75649410|NCT05117073|Diagnostic Test|ASCITIC FLUID CULTURE|Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate
75799001|NCT03857022|Device|Enhanced External Counterpulsa|The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions. The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay. Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month. Plasma natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels will be checked at enrollment, day 35, and 6th month.
75934521|NCT03221270|Device|tACS treatment week|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 20 minutes twice for 5 consecutive days.
75934522|NCT03221270|Device|tACS sham week|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds twice a day for 5 consecutive days.
75934523|NCT03221270|Device|Maintenance tACS|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes once a weekly for 8 weeks.
75934524|NCT03221270|Device|Maintenance Sham tACS|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds once a week for 8 weeks.
75934525|NCT03232112|Drug|Exenatide 2 MG Injection|Subcutaneous injection once-weekly
75934526|NCT03232112|Drug|BD PosiFlush (saline)|Subcutaneous injection once-weekly
75338997|NCT05267210|Other|Questionnaire|"Back Pain and Body Posture Assessment Instrument for Adults (BackPDE-Y) This questionnaire assesses pain and risk factors associated with back pain. The questionnaire includes questions that include demographic, socio-economic, hereditary and behavioral risk factors. The questionarie consists of 20 questions in total.~Musculoskeletal Health Questionnaire (CIS-SS) The questionnaire included pain/stiffness (during the day and night), physical function (walking and dressing), physical activity level, involvement of symptom-related work/daily life and social activities/hobbies, difficulty sleeping, fatigue, emotional well-being, diagnosis and It consists of a total of 14 questions evaluating the understanding of the treatment and the overall effect of the disease."
75338998|NCT01891760|Device|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
75338999|NCT01891760|Device|Profore|Four-layer compression bandaging therapy.
75649411|NCT05114733|Behavioral|InVEST|Individualized vocational and educational support and training -- participant works with BA level school/ work coach for four months
75649412|NCT05098366|Drug|Furosemide|0.1mg/kg (max 5mg) of IV furosemide
75934527|NCT04485806|Other|GPS/LM|Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay
75796591|NCT05450848|Device|StrataXRT|StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
75339000|NCT01791374|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
75339001|NCT01791374|Drug|Rilotumumab|Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
75339002|NCT03783416|Drug|Ixazomib (NINLARO®) capsules / Matching placebo capsules|Participants will be treated for a maximum of 24 months
75339003|NCT00248534|Biological|rituximab|given IV days 1,8, 15 and 22
75339004|NCT00248534|Drug|methylprednisolone|2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)
75339005|NCT00248534|Drug|temozolomide|Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles
75339006|NCT00248612|Drug|Venlafaxine|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
75339007|NCT00248612|Behavioral|CBT|CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
75339008|NCT00248612|Other|Progressive muscle relaxation therapy (PMR)|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
75339009|NCT00248612|Other|Placebo medication|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
75339010|NCT03774992|Device|Orthokeratology lenses|Custom fit, form stable contact lenses
75649413|NCT05098366|Drug|Normal saline|20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
75649414|NCT05095363|Behavioral|PCplanner|A mobile app platform that will display participant survey results to clinicians to facilitate communication on specific needs as well as provide resources on advance care planning to participants.
75649415|NCT05090046|Other|Trauma exposure|Exposure to the Canterbury earthquake sequence and other relevant psychological trauma
75796592|NCT05450848|Other|Sorbolene|Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.
75934528|NCT04485806|Other|SPL/LM|Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay
75934529|NCT04485806|Other|GPS/PO|Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay
75934530|NCT04485806|Other|SPL/PO|Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
75934531|NCT03119558|Drug|18F-Florbetaben (Neuraceq®) PET/MRI|Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
75339011|NCT03951584|Other|ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset as primary outcome, to evaluate the damage and prognosis of vestibular function.
75934532|NCT03119480|Device|electronic alerts|electronic alerts for AKI
75934533|NCT03231956|Device|ClearSight™ / EV1000NI Clinical Platform|Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
75473887|NCT01976429|Other|flight/diving simulation|measurement of ET function during simulated flight/diving in pressure chamber
75473888|NCT01976429|Other|ET function testing at ambient pressure|ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence
75473889|NCT01976429|Other|nasal video-endoscopy|examination of nose, nasopharynx,and Eustachian tube orifice
75473890|NCT01976468|Other|SCC metastasis|occurrence of SCC metastasis
75473891|NCT01976481|Device|sunbed exposure|exposure to sunbed ultraviolet radiation
75649416|NCT05082480|Device|Hyaluronic acid (HA)|Hyaluronic acid (HA)
75649417|NCT05082480|Device|Saline|Saline
75649418|NCT05073302|Procedure|Implantation of Nylon catheter (Device-less sentinel unit)|"Implantation of the Device-Less sentinel units. Ultrasound monitoring will be performed after Device-Less implantation. Standard Islet cell Transplantation: Will occur simultaneously Portal islet transplantation and subcutaneous islet transplantation in the Device-Less sentinel spaces.~Islets are maintained for a minimum of 6 hours up to 72 hours in supplemented CMRL1066-based media until the time of transplant.~Concomitant to portal vein infusion, islet transplantation will occur in all four (4) DL sentinel spaces.~To explant a unit, the Surgeon will make an incision and then carefully dissect the tissue engrafted around the transplant. The entire transplant site and any adherent tissue capsule can then be removed entirely from the pocket."
75339012|NCT03924128|Device|Photobiomodulation|The Photobiomodulation device should cover the entire knee junction, with time of application from 6 to 8 minutes and device turned on.
75796593|NCT05441956|Drug|TGRX-326|Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
75796594|NCT05429112|Device|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
75796595|NCT05429112|Device|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
75796596|NCT05418894|Device|Device: Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
75796597|NCT05416489|Device|C-MAC videolayngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscopy.
75339013|NCT00249470|Behavioral|Abstinence & Work|Participants in the Abstinence & Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
75339014|NCT00249470|Behavioral|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
75339015|NCT05266820|Drug|Thalidomide|For the experimental group, the intervention was thalidomide（100mg PO Bid)
75339016|NCT05266820|Drug|TAS-102|TAS-102
75649419|NCT05073250|Drug|IBI376|IBI376 is administered orally once daily at a dose of 20 mg for 8 weeks, followed by an oral dose of 2.5 mg once daily. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of IBI376 at an oral dose of 2.5 mg once daily.
75649420|NCT05073250|Biological|Rituximab|Rituximab is administered at a dose of 375 mg/m^2 intravenously in the first 4 weeks, once a week. Subsequently, rituximab will be dosed once every 4 weeks. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of rituximab at a dose of 375 mg/m^2 intravenously once every 4 weeks.
75796598|NCT05416489|Device|Laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a laryngoscopy
75796599|NCT05404880|Device|EDWARDS INSPIRIS RESILIA Aortic Valve|Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve.
75796600|NCT05394714|Biological|Magicell-NK contains NK cells suspended in 100 mL normal saline|Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled
75796601|NCT05382936|Drug|SL-901|Patients will take study medication daily, with dosage based on their assigned cohort and regimen.
75796602|NCT05380414|Biological|Tumor samples (archival FFPE) and blood samples|Molecular screening
75796603|NCT05377424|Drug|Consume 20mg of istradefylline|Consume a single 20 mg istradefylline tablet
75796604|NCT05377424|Other|Low Oxygen therapy|Breathing short periods of low oxygen, consisting of 15 episodes of 1 minute of breathing 10% oxygen, with 2 minutes of breathing 21% oxygen. 45 minutes total.
75796605|NCT05377424|Drug|Placebo counterpart to the istradefylline drug|Consume a single microcrystalline cellulose
75796606|NCT05377424|Other|SHAM counterpart to low oxygen therapy.|Breathing short periods of sham low oxygen, consisting of 15 episodes of 1 minute of breathing 21% oxygen, separated by 2 minutes of breathing 21% oxygen. 45 minutes total.
75796607|NCT05372042|Behavioral|CBT Text Messages|CBT skills based text messages delivered 3x per week for four weeks
75796608|NCT05370833|Device|transcranial direct current stimulation|Anodal, 2mA, tDCS session applied on M1 for 20 minutes.
75934534|NCT02554786|Drug|Indacaterol acetate/Mometasone furoate|
75934535|NCT02554786|Drug|Mometasone furoate|
75934536|NCT02554786|Drug|Salmeterol xinafoate/fluticasone propionate|
75934537|NCT03232190|Other|Web Application|Parents receive a web application that offers information and support until the age of 2.
75339017|NCT05266742|Other|web based education|"An educative website was created for our study. The content of the website was accessible from www.diyabet.mumcu.net and the content of the website was brought together by scanning the literature. The content text was quoted from publicly available information and guides as ADA and IDF."
75934538|NCT05202314|Drug|Immunotherapy (Camrelizumab)|After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
75934539|NCT03225638|Combination Product|Intramuscular ZENEO® injection of nominal strength|Sodium Chloride (0.9%)
75934540|NCT03225638|Combination Product|Intramuscular ZENEO® injection of low strength (upper limit)|Sodium Chloride (0.9%)
75934541|NCT03225638|Combination Product|Intramuscular ZENEO® injection of low strength (lower limit)|Sodium Chloride (0.9%)
75934542|NCT03225326|Drug|Computer controlled 4% articaine delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
75339018|NCT01790204|Dietary Supplement|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
75649421|NCT05064579|Other|Questionnaires|Questionnaire in two parts: one part on the objectives related to taking the treatment and the objectives related to the treatment modality and a second part on the general characteristics of each participant and the characteristics of the child's asthma.
75339019|NCT00250484|Device|Transcranial Magnetic Stimulation|1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
75339020|NCT00250484|Device|Sham Transcranial Magnetic Stimulation|Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
75339021|NCT03549650|Drug|Pentosan Polysulfate Na 100Mg Cap|"Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
75649422|NCT05061810|Behavioral|Smartphone application self-management programme|The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.
75649423|NCT05043831|Device|DSLT|Direct-SLT is applied via the limbus to the trabecular meshwork
75339022|NCT03549650|Drug|Placebo oral capsule|"Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
75339023|NCT00252512|Behavioral|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
75339024|NCT00252512|Other|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
75339025|NCT00252590|Behavioral|Health Motivational Feedback|Personalized feedback on health status
75339026|NCT00252590|Behavioral|Health Education|Generalized health education related to alcohol use
75339027|NCT00252590|Behavioral|Control - treatment as usual|Control group with no additional intervention
75339028|NCT01453387|Drug|MSC2015103B|Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
75339029|NCT01453387|Drug|MSC2015103B|Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
75339030|NCT04751864|Device|Cranial Electrotherapy Stimulator (CES) Device|Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device
75339031|NCT03419702|Dietary Supplement|Almonds|During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
75339032|NCT02097992|Drug|Roflumilast Placebo|Placebo pill
75339033|NCT02097992|Drug|Roflumilast|500 Ug ORAL TABLET
75339034|NCT02098304|Device|Calcivis Caries Activity Imaging System|Teeth imaged with the Calcivis Caries Activity Imaging System
75339035|NCT01392625|Biological|Autologous hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
75339036|NCT01392625|Biological|Allogeneic hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
75339037|NCT02114294|Other|Isolated hip strengthening|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
75649424|NCT05041270|Drug|normal saline|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline)."
75934543|NCT03225326|Drug|Conventional 4% articaine delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
75934544|NCT03119792|Other|Education Intervention|The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles. The program will cover self care of the body and heart, emotional management, healthy diet, and physical activity.
75339038|NCT02114294|Other|Quadriceps based training|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.
75339039|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
75796609|NCT05364853|Behavioral|In-Person Testing|Participants will be randomly assigned to have either in-person testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
75796610|NCT05364853|Behavioral|Remote Testing|Participants will be randomly assigned to have either remote testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
76087277|NCT01726504|Device|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
75649425|NCT05041270|Drug|Dexmedetomidine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)."
76087278|NCT03332472|Other|Telemedicine group|
76087279|NCT03332472|Other|Conventional group|
76087280|NCT02242630|Drug|Methylprednisolone, 20 mg|Compared with intrabursal triamcinolone
76087281|NCT02242630|Drug|Methylprednisolone, 40 mg|Compared with intrabursal triamcinolone
76087282|NCT02242630|Drug|Triamcinolone, 20 mg|Compared with methylprednisolone
76087283|NCT02242630|Drug|Triamcinolone, 40 mg|Compared with methylprednisolone
76087284|NCT03327480|Other|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
76087285|NCT02980744|Behavioral|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
76087286|NCT03109158|Drug|NC-6004|NC-6004 provided by NanoCarrier
76087287|NCT03109158|Drug|Cetuximab|Commercially Available
76087288|NCT03109158|Drug|5-FU|Commercially Available
76087289|NCT03324906|Device|tDCS|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
76087290|NCT03324828|Drug|Hydroxyzine|Hydroxyzine solution
76087291|NCT03324828|Other|Clowns intervention|Clowns intervention
76087292|NCT03324594|Device|(1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator)|"WONDALEAF-ON-MEN (WLM) is a polyurethane pouch with outstretching adhesive shield. The pouch covers the penis in man user; while the adhesive shield covers the groin regions to provide extra protection for the couples. The pouch is equivalent to marketed polyurethane male; while the adhesive shield is equivalent to marketed polyurethane wound dressing. WLM integrally joined with an adhesive wound dressing, both made of the same polyurethane material.~WONDALEAF-CAP (WLC) is a miniature form of WLM: the pouch covers glans penis and the adhesive shield wraps around the shaft of the penis only, thereby emulating the configuration of a donned regular condom on the penis. Because of the adhesive coating, WLC overcomes the problems of slippage when the penis is flaccid.~The durex-TOGETHER serves as the active comparator in this study. It is a transparent natural rubber latex male condom which is commercially available."
76087293|NCT03327246|Device|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
76087294|NCT03327168|Drug|Adenosine|Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
76087295|NCT03327168|Other|Cold exposure|Controlled cold exposure is performed before and during PET/CT scan.
75796611|NCT05362747|Behavioral|Behavioral weight loss and produce vouchers|Participants will receive weekly 30-minute, individual, in-person lifestyle counseling delivered by trained interventionists (e.g., registered dietitians) that consists of behavioral, dietary, and physical activity counseling. ProduceRx vouchers will be in the form of Food Bucks and will be provided at each session.
75796612|NCT05349981|Device|Phonak Lyric self-replacement procedure|The self-replacement procedure is an experimental procedure in which the Lyric user replaces the Lyric devices independently at every other device replacement, using dedicated candidacy, training, and management procedures, conducted by and at the discretion of his/her hearing care provider (HCP).
75796613|NCT05338164|Procedure|cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
75796614|NCT05334264|Procedure|Cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
75796615|NCT05303311|Drug|Bupivacaine Hydrochloride|intrathecal injection of bupivacaine alone
75796616|NCT05303311|Drug|Pethidine plus Dexamethasone|Intrathecal injection of pethidine plus dexamethasone
76087296|NCT01726738|Drug|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
76087297|NCT02492178|Drug|Intrarectal artesunate|
75339040|NCT01454791|Drug|diclofenac sodium topical gel|diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
75339041|NCT01454791|Other|Placebo|a placebo gel is applied 1-4 times per day for two weeks.
75339042|NCT02099006|Drug|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
75339043|NCT02099006|Drug|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
75339044|NCT02099006|Drug|Ketoprofen|To be applied topically at a 10% concentration
75339045|NCT02099006|Drug|Ketamine|To be applied topically at a 10% concentration
75339046|NCT02099006|Drug|Loperamide|To be applied topically at a 5% concentration
75339047|NCT02099006|Drug|Gabapentin|To be applied topically at a 6% concentration
75796617|NCT05292118|Device|Navitian|Patients in whom treatment with (Navitian) has been attempted
75339048|NCT02099006|Drug|placebo|Compounding base to be used alone as a placebo
75339049|NCT01454947|Behavioral|Clinical Decision Support (CDS): Accountable Justifications|Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
75339050|NCT01454947|Behavioral|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
75339051|NCT01454947|Behavioral|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
75339052|NCT05266274|Drug|CD47 monoclonal antibody|patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation
75796618|NCT05286125|Procedure|erector spinae plane (ESP) block|Using the in plane technique, the needle will be advanced between the transverse process and erector spinae muscle. The correct location will be confirmed using 1ml of Local Anesthetic (LA) to view hydrodissection(12). 19ml of LA will be injected between the muscle and transverse process.
75796619|NCT05286125|Procedure|oblique subcostal transverse abdominis plane (TAP) block|An echogenic needle will be inserted in-plane until the needle tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles. Once the needle enters the TAP plane, a dynamic injection can be performed by advancing the needle under ultrasound guidance laterally in the pocket created by the initial injection of 5 - 10 mL of local anesthetic; as the needle is advanced, the remaining local anesthetic will be injected. This allows for a more lateral spread of the local anesthetic
75796620|NCT05282927|Other|Implementation Strategy: Foundational REP|The goal is to test implementation intensification approaches for group PT sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Group PT for context and provides tools for ongoing evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully implement group PT as a clinical service.
75934545|NCT03119792|Other|Control|"The control will not receive an education program relating to knowledge, attitudes, nor habits of healthy lifestyles. Instead, these sessions will occur twice a month, and will last an hour and forty-five minutes. The control program is titled Life's Challenges, which will focus on helping children develop skills necessary for day to day life, is divided into four modules: Person, Family, School, and Environment. There will be four different types of activities used throughout the program including: Lets Think, Lets Experiment, We will finish with...or synthesis, and Not here."
75936563|NCT03185078|Device|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system
76087298|NCT02492178|Drug|Intravenous artesunate|
76087299|NCT02492178|Drug|Intravenous quinine|
76087300|NCT03327090|Other|Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).|Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
76087301|NCT03699280|Other|Virtual Reality|Oculus Go VR device
76087302|NCT03324516|Procedure|Re-Suspension of the temporal muscle after a craniotomy.|The temporal muscle cuff will be used to re-suspend the temporal muscle after a traditional craniotomy.
76087303|NCT03324516|Procedure|Traditional re-suspension of the temporal muscle|The temporal muscle will be re-suspended to the bone plate that is used to fixate the temporal bone that is removed for the craniotomy.
75339053|NCT03225404|Other|Epte group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
75339054|NCT03225404|Other|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
75339055|NCT05265962|Drug|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
75339056|NCT01455181|Drug|NPSP558|50, 75, 100 μg
75339057|NCT00324896|Drug|eszopiclone|eszopiclone
75339058|NCT00324896|Other|placebo|matching placebo administered at night
75339059|NCT01479517|Drug|Kovacaine Mist 0.1 mL x 4 sprays|Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
76087304|NCT05542576|Drug|AMDX2011P|AMDX2011P single bolus injection intravenous for diagnostic review
76087305|NCT03332082|Procedure|Tooth positioner|Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
76087306|NCT03327012|Drug|Treatment of Panlongqi Tablet|Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
75339060|NCT01479517|Drug|Kovacaine Mist 0.2 mL x 2 sprays|Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
75796621|NCT05282927|Other|Implementation Strategy: Enhanced REP (enREP)|The goal is to test implementation intensification approaches for sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. EnREP. The investigators posit that monitoring sites' progress and adding, for sites with low adoption, higher intensity strategies (defined as EnREP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
75339061|NCT01479517|Drug|Kovacaine Mist 0.2 mL x 1 spray|Dose = 1 intranasal spray of study drug
75339062|NCT01480219|Drug|voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
75796622|NCT05273086|Behavioral|Sleep Intervention Group|"The intervention group will acquire skills to improve their quality of sleep such as:~Acquisition of notions of chronobiology.~Location of the nervous structures involved in biological rhythms.~Awareness of the existence of three times that direct our biological rhythms, and of the need for them to be synchronized.~Self-knowledge of the chronotype and the degree of adjustment of the three times.~Knowledge of the variables that determine a good quality of sleep.~Applications of chronobiology to the field of nursing. Recommendations for nurses and patients.~Self-knowledge of the quality of sleep and the health status of the circadian system."
75339063|NCT01480219|Other|no voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
75796623|NCT05263765|Procedure|utilization of AO in the acute resuscitation of trauma and acute care surgery patients in shock.|AO to facilitate the acute resuscitation of trauma and acute care surgery patients in shock.
75796624|NCT05262764|Drug|JARDIANCE®|JARDIANCE®
76087307|NCT03327012|Drug|Treatment of Panlongqi placebo|Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
76087308|NCT03683992|Device|Triathlon total knee system|Implantable
75339064|NCT01480297|Drug|Salsalate|Salsalate 3 grams daily (1 gram TID with meals)
75339065|NCT01480843|Drug|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
75339066|NCT01392703|Drug|Dasatinib as tablets|2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
75339067|NCT01392703|Drug|Dasatinib as liquid|100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
75796626|NCT05248737|Dietary Supplement|DHA/EPA bioenhanced chicken|Chicken fed on a high DHA/EPA diet
75936564|NCT03185078|Other|Placebo ESWT|In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.
75936565|NCT03184532|Diagnostic Test|ultrasound|ultrasound examination of pyloric antrum
75936566|NCT02424500|Device|d-Nav|Insulin dosage is adjusted as required
75936567|NCT02424500|Device|Blood Glucose Monitoring System|Insulin dosage is adjusted as required
75936568|NCT03106766|Drug|Acne cream 2X|Twice daily application of facial acne cream 2X after facial cleansing
75936569|NCT03106766|Drug|Acne cream 1X|Twice daily application of facial acne cream 1X after facial cleansing
76087309|NCT03326934|Dietary Supplement|Dark chocolate|Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
76087310|NCT03326934|Dietary Supplement|Milk Chocolate|Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
76087311|NCT03326778|Procedure|AVR and CABG|Combined AVR with CABG
76087312|NCT05530720|Other|Cross-sectional survey|No intervention.
76087313|NCT03332004|Drug|Indocyanine Green|0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
75339068|NCT01392703|Drug|Dasatinib as dispersed tablets|2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
75339069|NCT01392859|Drug|Levocetirizine 0.5 Mg/mL Oral Solution|Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.
75339070|NCT01457521|Drug|Ibuprofen|Ibuprofen
75339071|NCT00325442|Drug|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
75339072|NCT00325442|Drug|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
75339073|NCT01393717|Drug|brentuximab vedotin|Given IV
75339074|NCT01459705|Behavioral|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
75339075|NCT01459705|Behavioral|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
76087314|NCT03620500|Behavioral|Gross motor and developmental balance testing|Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
75339076|NCT01459705|Behavioral|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
75649426|NCT05041270|Drug|Nalbuphine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)."
75649427|NCT05039736|Drug|Cabozantinib|Given by PO
76087315|NCT03324204|Other|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis was placed on proper knee alignment during exercise. Most of the women exhibited excessive medial rotation and adduction of the femur, resulting in knee valgus, although knee varus was also observed. The women were instructed how to correct their abnormalities using mirrors as visual feedback. All exercises were completed without pain. If the exercises were too easy, the level of difficulty was increased individually in accordance with the rehabilitation protocol
76087316|NCT03324204|Other|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be applied to the iliotibial band and tensor fascia latae muscle with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session
76087317|NCT03331926|Drug|Xiapex|Follow-up of effect of treatment
75649428|NCT05039736|Drug|Nivolumab|Given by IV
75649429|NCT05033886|Drug|fezolinetant|oral
76087318|NCT02490618|Other|Probiotic tablet- Biogaia|
76087319|NCT02490618|Other|Placebo tablet|
75339077|NCT01460875|Biological|recombinant interferon alfa-2b|Given SC
75339078|NCT01460875|Other|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
75649430|NCT05033886|Drug|placebo|oral
75649431|NCT05030753|Behavioral|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
75796627|NCT05248737|Dietary Supplement|25(OH)D bioenhanced chicken|Chicken fed on a high 25(OH)D diet
75796628|NCT05234567|Biological|Asfotase Alfa|All participants will receive asfotase alfa subcutaneously per standard of care. Unless otherwise specified per the Physician's standard of care, participants aged < 2 years are recommended for a clinic visit approximately every 3 months after Enrollment until 2 years of age, after which they should have a clinic visit approximately every 6 months. Participants should be followed for 5 years, as possible.
75796629|NCT05233579|Dietary Supplement|Sulforaphane|Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.
75796630|NCT05227612|Drug|Psilocybin|Participants will receive two doses of psilocybin (10mg, 25mg) as well as 12 sessions of CBT.
75796631|NCT05222893|Diagnostic Test|Respiratory monitoring|Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation
76087320|NCT05464290|Procedure|NANOfat grafting|The nanofat in a 10 cc syringe connected with a 23 gauge needle is then used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels. During injection the area is massaged to achieve complete releasing of fibrous tissue that was feel under the fingers.
76087321|NCT03331848|Drug|Placebo oral capsule|BID
76087322|NCT03331848|Drug|PXT002331 - 20mg|Oral
75339079|NCT01481545|Radiation|Radiation therapy|Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
75649432|NCT05030753|Behavioral|Patient Education (PE)|he PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
75649433|NCT05014035|Behavioral|Resistance Exercise|This is an 8-week exercise program, delivered using a hybrid approach of in-person, in-home supervised exercise, and virtual delivery of exercise via zoom. Individuals will participate in resistance exercise 3 days per week for 8 weeks.
75649434|NCT05010590|Drug|Romosozumab|Monthly romosozumab
75649435|NCT05010590|Drug|Denosumab|Every 6 months denosumab
75649436|NCT04940637|Drug|niraparib and dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
75339080|NCT01481545|Drug|Oxaliplatin|100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
75339081|NCT01481545|Drug|Raltitrexed|2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
75339082|NCT01481545|Drug|levofolinic acid|250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
76087323|NCT01728844|Device|beta-tricalcium phosphate alone|
76087324|NCT01728844|Device|GFeBGS 0.1%|
76087325|NCT01728844|Device|GFeBGS 0.3%|
76087326|NCT01728844|Device|GFeBGS 0.4%|
76087327|NCT04494126|Drug|Tranexamic acid|Drug: Tranexamic Acid Injectable Solution the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia before incision.
75649437|NCT04939506|Behavioral|COVID-19 Vaccine Education at the Point of COVID-19 Testing|A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
75796632|NCT05222893|Diagnostic Test|Capnography|Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute
75339083|NCT01481545|Drug|5-fluorouracil|800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
75339084|NCT01481545|Drug|Bevacizumab|will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
76087328|NCT04494126|Drug|Placebo|Other: Placebo (normal saline 0.9%) An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
76087329|NCT05517694|Other|Pelvic floor exercises and behavioral therapy|Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.
76087330|NCT05517694|Other|Respiratory exercises|"Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.~Respiratory exercises will be given 6 breaths/minute with expiration and inspiration times of 7 seconds and 3 seconds, respectively. At least 10 diaphragmatic breaths will be given in each session, 2 times a day, 7 days a week, 8 weeks."
75649438|NCT04911660|Drug|Empagliflozin 25 MG|1 empagliflozin 25 mg capsule per day for 14 days
75649439|NCT04911660|Other|Placebo|1 placebo capsule per day for 14 days
75796633|NCT05222893|Diagnostic Test|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
75796634|NCT05222893|Device|Esophageal pressure|Measurement the pressure in the lower third of esophagus during inspiration and expiration
75934546|NCT03225014|Device|Accelerated Recovery Performance Wave Therapy|ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.
75936570|NCT04483154|Device|Coala Heart Monitor|The Coala Heart Monitor (Coala Life AB, Sweden) is a CE and FDA-cleared device for real-time, remote monitoring of 2-lead ECG as well as heart and lung sounds. The Coala Heart Monitor automatically detects for 9 of the most common arrhythmias and has an integrated stethoscope for remote auscultation. It is paired wirelessly with the patient's smartphone and results are provided instantly both to patient and to connected provider in the cloud-based Coala Care portal.
75339085|NCT01482091|Drug|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
75339086|NCT01482091|Drug|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
75339087|NCT00325598|Radiation|Partial Breast Irradiation (PBI)|
75649440|NCT04895644|Other|No Hard Collar|The patient in the intervention arm will not wear a Hard Collar for 12 weeks post injury
75649441|NCT04888988|Other|Exercise Intervention|Participate in the EXCAP exercise program (meeting with a counselor, receive follow-up meetings)
75649442|NCT04886544|Device|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
75649443|NCT04881682|Device|Immunoadsorption|see arm/group description
75649444|NCT04881682|Biological|Immunoglobulins|see arm/group description
75649445|NCT04877873|Behavioral|Gait analysis pre- and post- surgery|None (observational)
75796635|NCT05208892|Procedure|SZMN block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally
75796636|NCT05208892|Procedure|SZMN block with Dexmedetomidine|Suprazygomatic Maxillary Nerve (SZMN) Blocks with local anesthetic and Dexmedetomidine bilaterally
75796637|NCT05198089|Other|Internet-Based Intervention|Use MyInspiration website
75796638|NCT05163080|Biological|SurVaxM|Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).
75473892|NCT01976494|Device|The domestic PCA equipment 'Accufuser Omnibus®'|"Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
75339088|NCT05265884|Device|Kinesiotaping|The tape is waterproof, porous, and adhesive. The width is 5 cm and thickness of 0.5 mm will be used in this study. This tape is with elastic core wrapped within cotton and capable of stretching up to 140-150%, applies heat-sensitive acrylic adhesive to avoid risk of latex allergy .The tape without medicinal properties is water resistant and can remain on the skin for 3 to 5 days. It will be applied two times per week for one month
75339089|NCT05265884|Behavioral|traditional therapy intervention|traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
75339090|NCT03111758|Device|Flow augmentation|Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome
75649446|NCT04871035|Device|Immunoadsorption|1 cycle, consisting of 5 sessions on 5 consecutive days with processing of the 0.7-fold individual plasma volume (maximum 2.5 l) each days with tryptophan adsorbers.
75339091|NCT05261360|Drug|SF-MSC-EX|Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
75339092|NCT05261360|Drug|SF-MSC|Intra-articular administration of synovial fluid-derived mesenchymal stem cells
75339093|NCT05242094|Procedure|Pulmonary Rehabilitation Program|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
75649447|NCT04871035|Device|Plasma Exchange|1 cycle, consisting of 5 sessions on 5 consecutive days with exchange of 0.7-fold plasma volume (maximum 2.5 l) each day with albumin solution as volume replacement solution.
75796639|NCT05154955|Drug|10XB-101 Solution for Injection|One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
75796640|NCT05154955|Drug|10XB-101 Vehicle Solution for Injection|This is the placebo control
75934547|NCT03225014|Diagnostic Test|Physical therapy|PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.
75339094|NCT00326924|Biological|Transfusion|PRBC blood transfusions.
75339095|NCT00327392|Drug|AQUAVAN® (fospropofol disodium) Injection|
75339096|NCT00328016|Behavioral|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
75339097|NCT00328016|Device|RESPeRATE|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
75339098|NCT01791608|Dietary Supplement|Zinc sulfate as dietary supplementation|Zinc sulfate as dietary supplementation
75649448|NCT04857775|Behavioral|Attachment and Child Health (ATTACH) Parenting Program|ATTACH™ provides parent training to address Reflective Function (RF) of parents affected by a broad array of toxic stressors. RF, defined as the ability to have insight into one's own and one's child's mental states, feelings, thoughts and intentions, underpins parental sensitivity and responsiveness and is undermined by the experience of current or past stress. Parents require high RF to respond sensitively/appropriately to their children and thus promote secure parent-child attachments, essential for child MEB health. ATTACH™ consists of 10-12 ~45-minute clinic visits with dyadic (mother and infant) and triadic (mother, infant, and co-parent) elements, with a trained facilitator, who may be a nurse, social worker or other allied health professional.
75934548|NCT03225248|Drug|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
75339099|NCT01791608|Dietary Supplement|Zinc amino acid chelate as dietary supplementation|Zinc amino acid chelate as dietary supplementation
75339100|NCT01791608|Dietary Supplement|Milk without fortification without zinc|Milk without fortification
75339101|NCT04346030|Drug|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
75339102|NCT04346030|Drug|lidocaine hydrochloride|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
76087331|NCT03324048|Other|relaxation session|"During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y)."
76087332|NCT05503966|Behavioral|Attentional Bias Modification|The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
76087333|NCT02492022|Dietary Supplement|Probiotic L008-1|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
76087334|NCT02492022|Dietary Supplement|Probiotic L008-2|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
76087335|NCT02492022|Other|Placebo|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
76087336|NCT03323970|Other|semi-structured interviews|individual semi-structured interviews
76087337|NCT01730872|Drug|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
76087338|NCT01730872|Drug|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
76087339|NCT02491086|Drug|Nicotine replacement therapy (NRT) sampling|1-week free NRT
76087340|NCT02491086|Behavioral|Smoking cessation counseling|Smoking cessation counseling
76087341|NCT02491710|Device|Training on low-cost box trainer|
76087342|NCT02491710|Device|Training on standard box trainer|
75796641|NCT05153369|Behavioral|Enhanced Care|Enhanced care aims to educate participants about bipolar disorder using a didactic approach, in addition to teaching and practicing DBT skills in an applied and relevant manner based on the participant's needs. Participants will receive a total of four sessions (approx. 60 minutes in duration), to occur once a month, at a minimum. The content will be split up into psychoeducation (2 sessions) and selected DBT skills (2 sessions). Psychoeducation will be specific to youth bipolar disorder, covering topics such as symptoms of depression and hypo/mania, medications used to treat bipolar disorder, the role of biology and the environment in emotions, and vulnerability and protective factors to emotion dysregulation and mood episodes. The content of skills sessions will be individualized and based on participant needs and goals (e.g., learning and applying skills to optimize their overall functioning, address problem behaviors and/or stressors, and/or maintain commitment to treatment).
75796642|NCT05153369|Behavioral|DBT Skills Training|In DBT Skills Training, participants will only receive skills training and can choose to do this individually and/or with their individual family unit by including their parent(s) and/or sibling(s). Participants will receive 20-25 sessions (approx. 60 minutes in duration), to occur at least biweekly. Skills training will include the five standard youth DBT modules: psychoeducation about DBT and bipolar disorder, mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path. The primary focus of the skills training is to impart knowledge and acquire and strengthen pragmatic skills to replace dysfunctional behaviors. If participants choose to include their family members, they will be encouraged to coach one another in effective use of skills.
75799002|NCT01290198|Drug|Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)|At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
75934549|NCT03225248|Drug|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
75934550|NCT03225092|Biological|Ultrasound-guided platelet rich plasma injection|Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
75339103|NCT04346030|Drug|normal saline|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
75339104|NCT05095844|Biological|vaccinated|Pfizer-BioNTech COVID-19 Vaccine, Moderna or J&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)
75339105|NCT05087264|Drug|Indocyanine green|ICG retention test and clearance test: intravenous injection, 0.5mg/l. Liver blood flow measurement: intravenous drip, dissolve 25mg ICG in 100ml injection water, and drip at a constant speed for about 50min to make the ICG concentration reach equilibrium.
75339106|NCT05075330|Behavioral|Opioid Use Disorder Stigma Reduction|Billboards with destigmatizing language regarding opioid use disorder placed in the community.
75934551|NCT03224936|Device|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
75936571|NCT02424266|Device|None invasive imaging of the tear film (AdOM)|White light tomography imaging
75936572|NCT03053063|Drug|SEL|Tablets administered orally once daily
75936573|NCT03053063|Drug|Placebo to match SEL 6 mg|Tablets administered orally once daily
75936574|NCT03053063|Drug|Placebo to match SEL 18 mg|Tablets administered orally once daily
75936575|NCT03117218|Diagnostic Test|Coronary MR angiography|Quantitative analysis of coronary MR angiogram
75936576|NCT03116906|Drug|BI 685509|to be given for a total of up to 15 days
75936577|NCT03116906|Drug|Placebo|to be given for a total of up to 15 days
76087343|NCT03469492|Drug|Insulin|Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.
75339107|NCT05005286|Other|Past history of vaginal Infections|With or without vaginal infection during pregnancy
75339108|NCT01793558|Procedure|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
75339109|NCT02108288|Drug|OPC-1085EL ophthalmic solution|
75339110|NCT02108288|Drug|Carteolol long-acting ophthalmic solution|
75339111|NCT02108288|Drug|Latanoprost ophthalmic solution|
75339112|NCT02108522|Biological|Multivirus Specific T cells|
75339113|NCT02106494|Drug|APF530|
75339114|NCT02106494|Drug|Ondansetron|
76087344|NCT03469492|Behavioral|exercise|Exercise in accordance to the guidelines established by the American Diabetes Association.
75339115|NCT02106494|Drug|Ondansetron placebo|
75339116|NCT02106494|Drug|APF530 placebo|
75339117|NCT02106494|Drug|Fosaprepitant|
75339118|NCT02106494|Drug|Dexamethasone|
75339119|NCT01931852|Procedure|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
75649449|NCT04857060|Behavioral|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
75649450|NCT04854161|Behavioral|Empathic Attunement to Affect Training|"Empathic Attunement to Affect:~Empathy and neuroscience Therapeutic Presence~Opening receptivity channels Empathic reflections and landscapes (external, meaning and feeling)~Types of emotions: Primary (adaptive, maladaptive), Secondary. Emotion Scheme Types of experiential responses: conjectures, exploration.~Working with Core emotions Types of experiential responses: Evocation and Empathic affirmation,~Empathy and Emotion Productivity Types of experiential responses: Empathic formulation, process suggestion Difficult situations: working on assertive anger and self-soothing Types of experiential responses: Facilitative Congruence"
75649451|NCT04854161|Behavioral|Compassion Training|Compassion Training Introduction to Mindfulness Compassion toward a significant other Compassion toward a generic other Self-compassion Tonglen Compassion toward a difficult other
75649452|NCT04854161|Behavioral|Focusing Oriented Therapy Training|Focusing-Oriented Therapy training Introduction to focusing Acceptance and empathy as the main focusing attitudes Fels-sense markers Felt sense, handle and resonance Hakomi Therapy The Safe Place. Focusing with a challenging person
75649453|NCT04851886|Device|BURT|Robot-assisted upper-limb individual (i.e. one-on-one) rehabilitation will be delivered using the BURT system by Barrett Technology
76087345|NCT03469492|Dietary Supplement|Dietary counseling|Dietary counseling in accordance to the guidelines established by the American Diabetes Association.
75649454|NCT04851886|Device|BURT + PostureCheck|Robot-assisted upper-limb group (i.e. up to three subjects) rehabilitation will be delivered using the BURT system by Barrett Technology + PostureChek (a camera-based system to track the quality of the exercises)
75649455|NCT04839354|Drug|Arginine Hydrochloride|One-time L-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID)
75649456|NCT04839354|Other|Normal saline|Placebo (normal saline) loading dose (2ml/kg IV) + 1ml/kg IV TID
75799003|NCT01290276|Drug|Ond-PR1|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)
76087346|NCT02490696|Device|Miso PET scan|2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
75799004|NCT01290276|Drug|Ond-PR1 + MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
76087347|NCT02490696|Device|FAZA PET scan|2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
76087348|NCT03331770|Drug|Latanoprost Ophthalmic Product|Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use
76087349|NCT03323814|Device|Slow-wave optimization|employing sensory stimulation to enhance slow waves
76087350|NCT02491164|Other|BAC TWO|BAC TWO administration
75339120|NCT01931852|Other|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
75339121|NCT00333710|Behavioral|Individual psychotherapy|Individual face-to-face contact with educational and goal setting components
75339122|NCT00333710|Behavioral|Telehealth Intervention|Individual telephone contact with educational and goal setting components
75799005|NCT01290276|Drug|Ond-PR2|Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)
75799006|NCT01290276|Drug|Ond-PR2 +_ MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
75339123|NCT00335504|Drug|oligofructose-enriched inulin|Given orally
75339124|NCT00335504|Drug|sulindac|Given orally
75339125|NCT00335504|Drug|placebo|Given orally
75339126|NCT00335504|Drug|atorvastatin calcium|Given orally
75339127|NCT00335504|Other|laboratory biomarker analysis|Correlative studies
75339128|NCT01183169|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
75339129|NCT01183169|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
75339130|NCT01183169|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
75339131|NCT01183169|Drug|Placebo|ALV placebo soft gel capsules administered orally
75339132|NCT01183481|Drug|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
75339133|NCT01183481|Radiation|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
75339134|NCT01183481|Drug|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
75339135|NCT01183559|Drug|Vandetanib|Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy
76087351|NCT02491164|Device|FE and Cellvizio viewer software|Fibre based endomicroscopy to visualise fluorescent signal emitted by optical agents.
76087352|NCT03326700|Procedure|Inguinal Hernia Repair|Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
75649457|NCT04839185|Drug|Ferumoxytol infusion|"Ferumoxytol will be administered intravenously, by infusion, over 30 minutes. It will be used a contrast agent for MRI imaging to detect placental lesions in fetal growth restriction.~Dose will be 255 mg in 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Ferumoxytol/Feraheme will be administered only once, in one infusion of 255 mg to each subject."
75796643|NCT05153369|Behavioral|Dialectical Behavior Therapy Full Intervention|The DBT full intervention is based on Miller et al.'s DBT for suicidal youth, with modifications for youth with BD. DBT will be conducted over 1 year with approximately 40-50 sessions. Sessions will alternate between individual and skills training sessions. Family involvement in skills training will be strongly encouraged, however will be up to the participant to decide. Participants in Level 3 will complete diary cards tailored for this population, assessing daily mood, suicidality, sleep, and medication adherence. Participants will report use of specified DBT skills on the diary card, and individualized treatment goals will be incorporated into the diary card (e.g., alcohol use). In addition, Level 3 will include skills coaching by phone (via phone and/or text). These brief, structured calls and/or texts function to promote skills generalization by helping the participant and any participating family member(s) use skills to achieve goals and solve problems.
75796644|NCT05150210|Device|Robotic-Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
75339136|NCT01183559|Drug|5 Fluorouracil (FU)|5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
75339137|NCT01183559|Drug|Carboplatin|Carboplatin AUC=5 days 1 and 29 during radiation therapy
75339138|NCT01183559|Drug|Paclitaxel|Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy
75796645|NCT05142605|Behavioral|Meaning-Centered Grief Therapy|Meaning-centered grief therapy is a therapy that focuses on helping participants find a sense of meaning or purpose in their life after their loss. Parents will be provided (via mail or email) a workbook. This support program will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
75339139|NCT01183559|Radiation|External Beam Radiation Therapy (RT)|External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks
75339140|NCT01184417|Drug|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
75339141|NCT01184417|Drug|placebo|100 m l saline
75339142|NCT01159067|Drug|deferasirox|Given orally
75649458|NCT04839185|Procedure|MRI scan|The MRI scanning procedure will last for approximately 60 minutes.
75649459|NCT04838275|Behavioral|12-week mHealth home exercise prescription|3x/week home walking protocol, 2x/week resistance exercise program
75649460|NCT04822636|Behavioral|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
75796646|NCT05142605|Behavioral|Supportive Psychotherapy|Supportive psychotherapy will help participants cope with their loss by giving them a place to express their feelings and providing them with support during the sessions. Supportive counseling will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
75796647|NCT05142605|Behavioral|Enhanced Usual Care|Enhanced usual care includes any support or resources participants may receive as part of their standard care (for example, therapy sessions with a local therapist), enhanced with additional resources.
75799007|NCT01185912|Procedure|Ventricle muscle tissue samples|
75799008|NCT03852654|Drug|18F-DCFPyL|"Subjects with biopsy proven prostate cancer, no prior local therapy, and:~PSA ≥ 10 ng/dl, or Gleason Sum ≥ 4+3, or clinical stage ≥cT2c Staging by 99mTc-MDP or NaF PET bone scan, and Diagnostic CT (pelvis) or MRI will undergo 18F DCFPyL PET CT scan."
76087353|NCT03331692|Other|monitoring of the proper level of general anesthesia|The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
75339143|NCT01221857|Drug|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
75339144|NCT01159535|Behavioral|Mindfulness Based Relapse Prevention|The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
75339145|NCT01159535|Behavioral|Relapse Prevention|intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
75339146|NCT01159535|Behavioral|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
75339147|NCT02980055|Procedure|collagen matrix|Surgical procedure for root coverage using collagen matrix
75339148|NCT02980055|Procedure|connective tissue graft|Surgical procedure for root coverage using connective tissue graft
75339149|NCT01222091|Drug|Propranolol|Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
75339150|NCT01222091|Drug|Placebo to Match Propranolol|
75339151|NCT01222091|Drug|Remifentanil|Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
75339152|NCT01225055|Drug|Teriparatide|20 ug daily over 12 months
75339153|NCT01225055|Device|vibration|10 min/day for 12 months
75339154|NCT05412654|Dietary Supplement|High potassium water|High potassium water Potassium 6.2 mg/100ml
75339155|NCT05412654|Dietary Supplement|Control low potassium water|Control water Potassium 0.2 mg/100ml
75339156|NCT01160237|Biological|PandemrixTM|One dose intramuscular injection
75339157|NCT01160237|Biological|FluarixTM/ Influsplit SSW® 2010/2011|One dose intramuscular injection
75339158|NCT05379426|Other|Impact COVID-19 pandemic|Battery of screening tests and the semi-structured interview focusing on the difficulties experienced by the older adult during the pandemic period.
75339159|NCT03010787|Drug|V565|single ascending dose of V565
75649461|NCT04818047|Behavioral|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Videofeedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
75649462|NCT04809688|Dietary Supplement|Saskatoon berry|Freeze dried Saskatoon berry (30 g) will be orally administrated daily for 10 weeks.
75796648|NCT05138471|Device|transcranial direct current stimulation (tDCS)|tDCS intervention will consist in placing two electrodes, the cathode on the supraorbital surface on the same side as the painful knee, and the anode on the parietal area, corresponding to the area of the primary motor cortex, on the opposite side. The intensity will be 2 milli amperes (mA) and stimulation will be 20 minutes. The placebo will generate an initial sensation, and then descend until the stimulation is turned off.
75796649|NCT05138471|Device|TENS|TENS intervention will consist in placing two electrodes on the sides of the patella of the affected knee. The frequency will be 10Herzts and the intensity will remain at a sensitive threshold level, without reaching the motor. The placebo will generate a sensation of current to descend to the minimum value that the equipment allows. Stimulation will last for 20 minutes.
75934552|NCT04791137|Behavioral|Imagery cognitive bias modification|The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell & Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. It is hypothesised that via repeatedly practising imagining positive resolutions for ambiguous situations in the training sessions, a bias is trained to automatically imagine positive resolutions for ambiguous situations encountered in daily life.
75934553|NCT03220880|Drug|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
75934554|NCT02949479|Behavioral|Dissociation Investigation in Sex Offenders|prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
75339160|NCT03010787|Drug|V565|Multiple dose
75339161|NCT03010787|Drug|Placebo|Single and multiple dose
75339162|NCT03010787|Drug|V565|Open-label single dose
75339163|NCT03010787|Drug|V565|Open-label single ascending dose
75649463|NCT04806906|Drug|CC-486|Investigational product will be dispensed on Day 1 of each treatment cycle. 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
75339165|NCT01336140|Drug|Aminophylline|75 mg of intravenous aminophylline
75649464|NCT04804241|Drug|Senicapoc|10 mg oral tablet
75649465|NCT04804241|Other|Placebo Tablet|Placebo Oral Tablet
75649466|NCT04776954|Device|Forced Air Warming System|"The forced air warming system has a heater unit that blows air through a conduit to an air blanket that inflates with forced air that circulates throughout the blanket, and exits through tiny perforations on the patient-side of that blanket. The heat primarily warms the subject through convective means. As the warmed air escapes through the perforations in the blanket, it creates an environment of continuously circulating warm air that is in contact with the skin."
75339166|NCT01336140|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
75339167|NCT05398926|Biological|COVID-19 Vaccine (Vero cell), Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
75339168|NCT01184885|Drug|Hyper-CVAD|"Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are < 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses."
75649467|NCT04776954|Device|Resistive Blanket Warming System|This blanket is equivalent to an operating-room-safe electric blanket. Through a power cord, a separate power source powers a semiconductor layer within the resistive blanket to generate heat. The heat primarily warms the subject by conductive warming through direct skin contact, and, secondarily, by warming the air around the participant in areas where there is no direct skin contact.
75649468|NCT04752059|Drug|Trastuzumab deruxtecan|Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death
75649469|NCT04750473|Procedure|Computed Tomography|Undergo PET/CT scan
76087354|NCT05317156|Other|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th,12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
76087355|NCT03331614|Device|Flowaid FA-100 SCCD|The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
76087356|NCT03326622|Other|standard care|A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
76087357|NCT03326622|Other|moderate exercise|A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
76087358|NCT02491008|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
75339169|NCT01184885|Drug|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
76087359|NCT02491008|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
76087360|NCT05316844|Other|There will be no interventions.|Measurements and performance tests were conducted to investigate predictors of work-related performance
75339170|NCT02187887|Behavioral|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
75649470|NCT04750473|Drug|Fluciclovine F18|Given IV
75339171|NCT04346771|Behavioral|Working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
75339172|NCT04346771|Behavioral|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
75339173|NCT01187381|Drug|Trastuzumab|Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
75339174|NCT01187771|Procedure|Laparoscopic Gastric Banding|Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.
75649471|NCT04750473|Drug|Gallium Ga 68 Gozetotide|Given IV
75649472|NCT04750473|Procedure|Positron Emission Tomography|Undergo PET/CT scan
75649473|NCT04745351|Drug|Remdesivir|Administered as Intravenous (IV) infusion once daily
75649474|NCT04745351|Drug|RDV Placebo|Administered as IV saline once daily
75649475|NCT04745351|Drug|Standard of Care|Standard of Care Treatment for COVID-19 Infection
75649476|NCT04741568|Behavioral|Parental psychoeducational Intervention|"The psychoeducation intervention for parents will focus on providing skills, knowledge and support motivation for caregivers of children with diabetes.~A brief (one-day or two half days) workshop, and a website with downloadable content will be made available to review and refresh any skills and techniques."
75649477|NCT04710277|Other|Opioid-sparing multimodal pain management|Ice pack applied to abdominal incisions for 20 minutes every 2 to 3 hours for 24 hours after surgery and scheduled acetaminophen and NSAID for 96 hours after surgery. Narcotic pain medication for severe breakthrough pain.
75796650|NCT05138471|Behavioral|Exercise and General Education|The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.
75934555|NCT05700539|Behavioral|Internet-based cognitive behavioral therapy|A ten-week treatment based on cognitive behavioral therapy for ADHD, including two mandatory modules and at least four self-selected modules (out of ten available modules). The treatment consists of reading material and exercises to be completed each week.
75934556|NCT04787549|Device|Virtual reality exergames|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
75934557|NCT02929589|Drug|Ibuprofen|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
75339175|NCT01187771|Procedure|Continuous Positive Airway Pressure|Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
75339176|NCT01225289|Dietary Supplement|Vitamin A|25000 IU/day (one capsule per day) Vitamin A for 6 months
75339177|NCT01225289|Drug|Placebo|1 capsule per day for six months
75339178|NCT01161329|Other|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
75339179|NCT01227005|Biological|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
75649478|NCT04710277|Other|Usual care|Scheduled acetaminophen and NSAID for 24 hours after surgery. Narcotic pain medication for severe breakthrough pain.
75796651|NCT05138120|Behavioral|Common Elements Toolbox|An unguided online single-session intervention with four modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.
75796652|NCT05136339|Behavioral|Community-based mentoring and education sessions|Community-based mentoring and education sessions, group activities, and application of a community toolkit for healthy weight loss delivered by trained Health Promoters from Hispanic and Somali communities to their social networks.
75339180|NCT01161563|Drug|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
75339181|NCT01161563|Drug|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
75339182|NCT03010085|Procedure|Open left-sided hepatectomy|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
75339183|NCT03010085|Procedure|Laparoscopic left-sided hepatectomy|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
75339184|NCT01189409|Drug|PEG then Senna|Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
75339185|NCT01189409|Drug|Senna then PEG|Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
75796653|NCT05119920|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
75796654|NCT05119920|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
75934558|NCT02929589|Drug|Opioid Medication|1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
75339186|NCT01227551|Biological|Coxsackievirus A21 (CVA21)|CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.
75649479|NCT04705623|Behavioral|Iyengar Yoga|Weekly 90 minute Iyengar Yoga classes taught y a professional instructor. Twice weekly 45 minute self practice of Iyengar Yoga at home by the participants
75649480|NCT04704869|Biological|Cryoprecipitate|Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
75649481|NCT04704869|Biological|Red Blood Cells|RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
75796655|NCT05119920|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
75796656|NCT05119920|Drug|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
75339187|NCT03010475|Drug|Furosemide|Oral administration A total of three single doses.
75339188|NCT03010475|Drug|Rosuvastatin|Oral administration. A total of three single doses.
75339189|NCT03010475|Drug|SNAC|Oral administration. A total of five single doses.
75339190|NCT03010475|Drug|Semaglutide|Oral administration. Once daily.
75339191|NCT03010553|Procedure|Detection and resection of sentinel lymph node|
75339192|NCT01227785|Device|INCEPTA ICD or CRT-D|
75796657|NCT05107362|Diagnostic Test|untrained lay user performs investigational diagnostic test|Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
75796658|NCT05102656|Other|Best Practice|Physician conversations occur in-person
75796659|NCT05102656|Procedure|Discussion|Physician conversations occur via video call
75796660|NCT05102656|Other|Questionnaire Administration|Ancillary studies
75799009|NCT03854994|Biological|Anti-CD19 CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
75934559|NCT02929589|Drug|Placebo|800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
75934560|NCT02929589|Drug|Ibuprofen + Opioid medication|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
75934561|NCT02910635|Drug|Volanesorsen|ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial
75934562|NCT02910635|Drug|Moxifloxacin|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
75934563|NCT02910635|Drug|Placebo|
75934564|NCT04769531|Other|Hip Joint Mobilizations|i. Anterior-posterior glide ii. Posterior-anterior glide iii. Caudal glide iv. Posterior-anterior glide with Abduction, flexion, and lateral rotation
76087361|NCT03331536|Procedure|Roux en Y Gastric Bypass Pre-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
76087362|NCT03331536|Procedure|Roux en Y Gastric Bypass Post-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
76087363|NCT03331536|Procedure|Sleeve Gastrectomy Pre-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
76087364|NCT03331536|Procedure|Sleeve Gastrectomy Post-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
75339193|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
75649482|NCT04704869|Biological|Plasma|Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
75796661|NCT05096013|Other|individual nutritional therapy|Intervention arm: Usual care + individualized nutritional therapy. Patients at risk for malnutrition and sarcopenia will receive a counselling by the nutritional therapist twice a week. The therapists will assess the patient's energy and protein demand in order to develope appropriate individual measures (e.g additional meals or supplements) to increase patients' energy and protein intake. Individual nutritional therapy is already usual care in patients with high risk for malnutrition, but not for patients with only light to moderate risk of malnutrition and risk of sarcopenia.
75339194|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
75339195|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
75934565|NCT04769531|Other|Hip joint Muscle strength training|i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching
75934566|NCT04769531|Other|knee strengthening and flexibility exercises|"i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:"
75339196|NCT04352465|Drug|Methotrexate|Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
75649483|NCT04704869|Biological|Platelets|Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
75649484|NCT04704869|Biological|Whole Blood|Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
75796662|NCT05092191|Drug|Cannabis oil vs placebo|"Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being."
75339197|NCT04352465|Drug|Methotrexate|Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
75339198|NCT04352465|Drug|Methotrexate|Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
75339199|NCT01191749|Drug|Alemtuzumab|10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
75339200|NCT04934696|Drug|BMS-986166|Specified dose on specified days
75339201|NCT04934696|Drug|Oral contraceptive|Specified dose on specified days
75339202|NCT01192139|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
75339203|NCT01192139|Drug|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
75339204|NCT01192139|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
75796663|NCT05084638|Drug|Ofatumumab|20mg subcutaneous injection
75934567|NCT04721951|Procedure|Endovascular Aortic Repair using Carbon Dioxide Angiography|Endovascular Aortic Repair using Carbon Dioxide Angiography
75934568|NCT03628469|Behavioral|Proactive Health Support|Active listening, coaching and counselling
75936578|NCT00702338|Drug|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
75339205|NCT04924400|Behavioral|CHIP Program|"GHP members randomized to the intervention arm will participate in the following activities:~Attend 2 group meetings per week over 6 weeks, followed by one group meeting per week for 6 weeks (12 weeks total); each meeting will last about one hour. CHIP classes for weeks 1-4 and week 12 require in-person attendance, while week 5-11 classes can be attended either virtually or in-person.~Receive a copy of The Optimal Diet, The Official CHIP Cookbook.~The following data will be collected at weeks 1,12 and 26:~Biometrics: weight, BMI, waist circumference, systolic and diastolic blood pressure~Biomarkers (blood tests): HbA1c, LDL-C~Psychometrics: Wellbeing360 survey"
75339206|NCT04924400|Behavioral|Usual Care|"GHP members assigned to the control arm will receive the routine standard of care for GHP members. Members will receive a summary of diabetes-related benefits available to members with type 2 diabetes.~The following data will be collected at weeks 1,12 and 26:~Biometrics: Weight, BMI, waist circumference, systolic and diastolic blood pressure~Biomarkers (blood tests): HbA1c, LDL-C~Psychometrics: Wellbeing360 survey"
75339207|NCT04892186|Drug|Myo-inositol|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g twice daily for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
75339208|NCT04892186|Drug|Metformin|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin three times a day for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
75339209|NCT01684904|Radiation|Proton radiation|
75339210|NCT01229423|Drug|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
75649485|NCT04687293|Device|HUBER (LPG Systems, France)|The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.
75796664|NCT05064397|Drug|Eptinezumab|Eptinezumab will be administered per schedule specified in the arm description.
75796665|NCT05057676|Behavioral|Immediate Autoimmune Intervention Mastery Course (AIM)|Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
75796666|NCT05057676|Behavioral|Immediate Question and Answer sessions. (AIM Q and A sessions)|Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
75796667|NCT05057676|Behavioral|Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
75796668|NCT05057676|Behavioral|Delayed AIM Question and Answer sessions|Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
75796669|NCT05054868|Drug|Oxycodone|Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).
75934569|NCT01347645|Drug|FOLFIRI|Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
75934570|NCT01347645|Drug|E7820|"Test product: dose and mode of administration:~E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study.~The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle)."
75934571|NCT02614547|Drug|SAGE-547|Administered as intravenous infusion.
75934572|NCT02614547|Drug|Placebo|Administered as intravenous infusion.
75934573|NCT04472481|Drug|Ergocalciferol 1.25 mg tablet|weekly 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) given orally group II
75934574|NCT04472247|Diagnostic Test|Continuous EEG and EMG monitoring, with derived variables|All patients are monitored during their ICU stay by frontal EEG and EMG measuring devides, which are already in clinical use.
75339211|NCT01283321|Drug|Human fibrinogen concentrate|4 g IV once, within 30 minutes of ACT < 155 seconds, post CPB, with evidence of significant microvascular bleeding
75339212|NCT01283321|Other|apheresis platelets|A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT <155 seconds post CPB with evidence of significant microvascular bleeding.
75339213|NCT01229891|Dietary Supplement|plain yogurt drink|daily intake of two bottle of plain yogurt drink
75339214|NCT01229891|Dietary Supplement|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
75339215|NCT01229891|Dietary Supplement|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
75339216|NCT01283555|Drug|Tenofovir|Delivered using prefilled and user-filled applicator
75796670|NCT05054868|Drug|Ketorolac|Subjects randomized to the treatment group will receive oxycodone and ketorolac for postop pain management.
75796671|NCT05054036|Drug|MoviPrep|Split-dose MoviPrep bowel preparation
75796672|NCT05054036|Drug|Golytely|Split-dose GoLYTELY bowel preparation
75796673|NCT05048082|Drug|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
75339217|NCT00345176|Dietary Supplement|Lutein/zeaxanthin|10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
75473893|NCT01976494|Device|Imported PCA equipment 'Infusor SV®, Baxter, USA'|"Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
75473894|NCT01976520|Biological|Oncoquest-CLL vaccine|Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
75473895|NCT01976546|Device|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
75339218|NCT00345176|Dietary Supplement|DHA/EPA|Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
75339219|NCT00345176|Drug|Lutein/zeaxanthin and DHA/EPA|10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
75339220|NCT01194089|Drug|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
75339221|NCT01194089|Drug|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
75473896|NCT01976559|Device|Tympanic Membrane Displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration."
75649486|NCT04682223|Behavioral|Semantically-focused therapy tasks|1) Semantic feature analysis (SFA; Boyle & Coelho, 1995; Boyle, 2004). For each pictured stimulus the participant is prompted to name the picture. Then, s/he is encouraged to produce semantically related words that represent features similar to the target word. 2) Semantic barrier task. This approach includes features of the Promoting Aphasics' Communication Effectiveness (PACE; Davis & Wilcox,1985). The goal of the task is for one participant (e.g., person with aphasia) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. 3) Verb network strengthening therapy (VNeST; Edmonds et al., 2009; 2014) targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the participant to generate verb-noun associates with the purpose of strengthening the connections between the verb and its thematic roles.
75796674|NCT05046535|Behavioral|Sleep quality and physical activity|"Self-reported assessments will be used to measure the following: overall sleep quality, insomnia symptoms, Obstructive sleep apnea.~Physical activity will be measured objectively using the 6MWT, 9HPT, and cardiorespiratory fitness using the VO2 submaximal test on the recumbent stepper."
75796675|NCT05046535|Genetic|Nicotine dependence|DNA sequencing for 20-25 subjects out of the whole sample will be performed. Sanger sequencing to all subjects will also be performed to identify related genes
75796676|NCT05046535|Diagnostic Test|Nicotine and cotinine serum levels|Cotinine serum level which is a major metabolite of nicotine and the preferred biomarker for measuring tobacco use will be measured together with nicotine levels using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
75796677|NCT05046535|Behavioral|Smoking|Surveys that measure nicotine dependence and smoking behavior
75934575|NCT00581997|Drug|QAX576|
76087365|NCT03331458|Behavioral|exrecise intervention|Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
76087366|NCT04826692|Drug|Metformin|Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
76087367|NCT04826692|Drug|Placebo|425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
75339222|NCT00345254|Procedure|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
75339223|NCT00345332|Drug|Botox|Injected
75339224|NCT00345332|Drug|Placebo|Injected
75473897|NCT01976559|Device|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
75473898|NCT01976598|Other|Sub-Sensory Stimulation|Sub-Sensory Stimulation using Boston Scientific Spinal Cord Stimulation System in patients currently implanted with the system .
75473899|NCT01976611|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
75473900|NCT01976637|Other|no compression|no compression stockings worn during the study
75339225|NCT01650350|Drug|Naltrexone|"4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study."
75339226|NCT00505466|Behavioral|Genetic Counseling|Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
75339227|NCT00349388|Drug|Asacol|Asacol is given once a day versus twice or three times a day
75339228|NCT00349778|Drug|Cyclophosphamide|Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in ~250 mL of saline or D5W and infused IV over 2 hours
75339229|NCT00349778|Drug|Etoposide|100 mg etoposide as 5 mL solution in clear ampules for injection.
75339230|NCT00349778|Drug|Melphalan|Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
75649487|NCT04682223|Behavioral|Phonologically-focused therapy tasks|1) Phonological components analysis task (PCA; Leonard et al., 2008). The participant first attempts to name a given picture and then to identify the phonological features of the target words. 2) Phonological production task focuses on the identification of phonological features of targeted, imageable nouns and verbs. It requires the participant to sort picture stimuli based on the number of syllables and then to identify a hierarchy of phonological features. Once each targeted feature is identified for the pair of words, the participant is required to blend the syllables/sounds together. 3) Phonological judgment task relies on computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features (e.g. # of syllables, initial phonemes, final phonemes, rhyming).
75934576|NCT00581997|Drug|Placebo|
75934577|NCT02478983|Device|LMA Supreme|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
75339231|NCT00349778|Drug|Carmustine|Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
75339232|NCT00349778|Drug|Filgrastim|Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
75339233|NCT00305084|Drug|NGR-hTNF|0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks
75649488|NCT04736849|Device|Percutaneous epidural and dorsal root stimulation|"Abbott percutaneous trial lead for dorsal root ganglion neurostimulation (Model MN10350)~Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
76087368|NCT03326544|Other|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
75339234|NCT00305084|Drug|Doxorubicin|75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
75339235|NCT00305162|Drug|Cangrelor (P2Y12 inhibitor)|IV bolus (30 mcg/kg) & infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
75339236|NCT00305162|Drug|clopidogrel (oral P2Y12 inhibitor)|600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
75934578|NCT02478983|Device|LMA Proseal|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
76087369|NCT03326544|Other|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
75473901|NCT01976637|Device|compression|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
75934579|NCT04702763|Other|Eye-Tracker®T2 + e-VOG|"1st step: eyes movements assessed with standard video-oculography device~2° step: eyes movements assessed with e-VOG digital application~Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
75339237|NCT00305162|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
75339238|NCT00305162|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
75339239|NCT00305162|Drug|Placebo capsules - as soon as possible after randomization|Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
75339240|NCT01791686|Drug|CDX-1135|
75339241|NCT00351416|Drug|Letrozole|Letrozole 20 mg orally one time
75339242|NCT00351416|Drug|NAL-GLU GnRH antagonist|5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
75339243|NCT00305942|Drug|Topotecan|Topotecan 4mg/m2 IV on days 1, 8.
76087370|NCT02490930|Drug|Fingolimod|Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
76087371|NCT04825990|Drug|Pembrolizumab|200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
75339244|NCT00305942|Drug|carboplatin|Carboplatin AUC=5 IV day 1 only .
75339245|NCT04737668|Other|Intrathecal pump refill with Virtual Reality|VR game
75339246|NCT04737668|Other|Intrathecal pump refill with distraction|Video
75473902|NCT01976676|Dietary Supplement|5-methyltetrahydrofolate|
75339247|NCT04737668|Other|Intrathecal pump refill|daily routine care for pump refill
75473903|NCT01976676|Dietary Supplement|folic Acid|
75473904|NCT01976702|Behavioral|Enhanced Behavioral Skills Training|
75473905|NCT01976780|Drug|Artesunate|
75473906|NCT01976780|Drug|Artemether Lumefantrine|
75473907|NCT01976780|Drug|Mefloquine|
75473908|NCT01976832|Behavioral|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
75649489|NCT04665089|Drug|Erythromycin|"Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~Pro-inflammatory cytokine (TNF alpha)~Anti-inflammatory cytokine (IL-10)~Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)"
75934580|NCT04702763|Other|e-VOG + Eye-Tracker®T2|"1st step: eyes movements assessed with e-VOG digital application~2° step: eyes movements assessed with standard video-oculography device~Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
75339248|NCT00352976|Drug|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
75339249|NCT00352976|Drug|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m^2 intravenous (IV)
75339250|NCT00352976|Procedure|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
75339251|NCT00352976|Procedure|Bone Marrow Transplantation|A target of 5 * 10^6/kg and a minimum of 4 * 10^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
75339252|NCT00352976|Drug|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 * 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
75339253|NCT00352976|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
75649490|NCT04652531|Other|Autologous extracellular vesicles from serum|Peri-wound injection of the vesicles will be performed in a sterile environment. Sterile gauze and an elastic-compression bandage will be applied.
75649491|NCT04639024|Drug|ADCT-301|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
75649492|NCT04591002|Drug|Osimertinib 80 MG|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. Osimertinib will be administered orally as one 80 mg tablet once a day (1 cycle is 28 days). Cycles are repeated until disease progression, unacceptable toxicity, or until 1 year after the initiation of osimertinib administration.
75649493|NCT04585945|Diagnostic Test|Positive for SARS-CoV-2 infection|Patients that have a positive test for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
75649494|NCT04569773|Behavioral|Impact of Event Scale-Revised|The IES-R is a validated 22-item self-report scale measuring psychological stress reactions after a major life or traumatic event.1-3Items are rated with reference to the past 7 days on a 5-point scale, ranging from 0 to 4. Three subscale scores are calculated by taking the mean of the item responses: Intrustion (8 items), Avoidance (8 items), and Hyperarousal (6 items). The total score is similarly computed by taking the mean of all 22 items. All scores range from 0 to 4, with higher scores indicating higher event-related distress. Internal consistency estimates(Cronbach's alpha) for all scores range between 0.79 to 0.92.
75649495|NCT04569773|Behavioral|Reproductive Concerns Scale|The RCS is a 14-item, 5-point Likert-type self-report measure that assesses concern among cancer survivors whose reproductive ability may have been impaired or lost due to disease and/or treatment. Answers are rated on a 5-point scale (0 to 4), and a single total score is produced by summing responses to all 14 items (range, 0-56 points). A higher score represents more reproductive concerns, and a lower score represents fewer reproductive concerns. In the RCS validation study, internal consistency reliability was 0.91 among long-term female cancer survivors and 0.81 among control women.
75934581|NCT01233297|Drug|Azithromycin|10 mg/kg peroral for 3 consecutive days
75934582|NCT01233297|Other|Placebo mixture|Placebo mixture containing no active substance.
75934583|NCT04681079|Drug|albuterol sulfate (MDI)|albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer
75934584|NCT04681079|Drug|albuterol sulfate (nebulizer)|albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece
75934585|NCT00580125|Drug|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
75934586|NCT00580125|Other|Placebo|Placebo, oral capsule, once daily for 21 days
75934587|NCT00580125|Drug|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
75934588|NCT00580125|Drug|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
75934589|NCT00580125|Drug|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
75934590|NCT04423900|Diagnostic Test|smart phone application|Participants will be asked to provide information about their sociodemographic characteristics, chronic diseases, the history of the ankle injury, trauma, and surgery, the severity of the foot pain via using the mobile application.The app will be downloaded from the Google Play Store and available offline. Information from the patient will be stored in an SQLite database.The usability test will be carried out on the mobile application so that the latest releases contain clear, effective, loyal to the strategy, and easily understood messages by the intended audience and do not produce unwanted responses.Direct observation, individual interviews, and satisfaction surveys will be used to identify areas of improvement in a cross-sectional manner.Investigation of pes cavus, pes planus and ankle range of motion will be determined by image processing.All data can be analyzed and stored by Heel Analysis Systems established on an external server.The data will be transferred securely over HTTPS.
75934591|NCT00579189|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
76087372|NCT04816474|Behavioral|Online education and Phone Counseling Service|Online education total of 6 times for 6 weeks. Phone Counseling Service total of 6 times for 6 weeks
76087373|NCT03323424|Radiation|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|"According to the usual practice, patients will receive their systemic treatment, composed of :~Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.~In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis."
76087374|NCT03323424|Other|Systemic treatment|"According to the usual practice, patients will receive their systemic treatment, composed of :~Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice."
76087375|NCT03323268|Device|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
75649496|NCT04569773|Behavioral|Decision Regret Scale|"The DRS is a 5-item, 5-point Likert-type self-report measure that assesses distress or remorse after a health-care decision.5 Items are rated on a scale from 1 (strongly agree) to 5 (strongly disagree). Two of the statements (items 2 and 4) are phrased in the negative direction.~A single, total score is produced by first reversing the scores of the 2 negatively phrased items, then taking the mean of the 5 items. This mean is then rescaled to range from 0 to 100 by subtracting 1, then multiplying by 25. A score of 0 indicates no regret, whereas a score of 100 indicates high regret. Internal consistency reliability coefficients for the DRS range from 0.81 to 0.92."
75934592|NCT00579189|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
75934593|NCT00579189|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
75796678|NCT05024292|Procedure|rapid local ischemic postconditioning (RL-IPostC)|with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation
75649497|NCT04566510|Other|long lasting insecticidal nets with alpha-cypermethrin + pyriproxyfen (PPF LLIN, Royal Guard))|Next-generation bed net combining insecticides with different modes of action
75796679|NCT05015504|Behavioral|Time restricted feeding|In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
75796680|NCT05009342|Device|below-knee soft resin cast|Patients have soft resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
75796681|NCT05009342|Device|Below-knee rigid resin cast|Patients have rigid resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
75796682|NCT05007977|Drug|ZT-01 low dose|Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
76087376|NCT04809298|Device|Free-hand therapeutic CT-guided punction for lumbar pain|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
76087377|NCT04809298|Device|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
75934594|NCT00667953|Drug|Gleevec|Gleevec (600 mg) daily.
75649498|NCT04566510|Other|long lasting insecticidal nets with deltamethrin + piperonyl butoxide (PBO LLIN, PermaNet 3.0))|Next-generation bed net combining an insecticide with a synergist
75796683|NCT05007977|Drug|ZT-01 high dose|Single SC injection of ZT-01 20 mg during hypoglycemic clamp
76087378|NCT03331302|Drug|Hyperpolarized Xenon-129 MRI (Experimental)|MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
76087379|NCT03331302|Drug|Radioactive Xenon-133 scintigraphy (Active Comparator)|Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
76087380|NCT01738672|Drug|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
76087381|NCT02488512|Drug|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) [45-46], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
76087382|NCT03323190|Behavioral|Inpatient COPD education|
75796684|NCT05007977|Drug|Placebo|Single SC injection of placebo during hypoglycemic clamp
75796685|NCT05000359|Behavioral|text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
75796686|NCT04926805|Device|CPAP with Mask A|CPAP mask
75796687|NCT04926805|Device|CPAP with Mask B|CPAP mask
75796688|NCT04922827|Drug|Infliximab|single intravenous administration of 5 milligrams/kilogram
75796689|NCT04922827|Other|Standard of Care|Standard of Care
75934595|NCT00667953|Drug|Temodar|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
75934596|NCT00578955|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
75934597|NCT00578955|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
75934598|NCT00578955|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
75934599|NCT00576537|Biological|Dendritic Cell Immunotherapy|Patients will receive four vaccines.
75934600|NCT00575055|Drug|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
75934601|NCT00575055|Drug|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
76087383|NCT04790578|Device|ZoeInsights Application|ZI is designed to promote PA behavior change and maintenance via self-monitoring of PA, symptoms, and other health data. Additional information for using ZI will be provided via a PDF-based user guide on installing and using the application, a live instructional webinar hosted by ZI developer Hanalytics Solutions, and access to continued support via email/telephone communication with study staff as well as Hanalytics Solutions. Reminders to complete self-monitoring tasks will be provided using daily push notifications scheduled according to participant preferences. Automatic graphs will be generated and displayed within the app to allow participants to visualize trends in physical activity, symptoms, and other health data. ZI can be accessed via a web browser on any device that is connected to the internet (e.g. computer, laptop, tablet, smartphone), or via a native android or iOS mobile application on a smartphone or tablet.
76087384|NCT04790578|Behavioral|EXCEL Exercise Class|The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
76087385|NCT03326232|Device|Continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
76087386|NCT05316454|Behavioral|self-efficacy support|self-efficacy support
76087387|NCT01808651|Drug|Fluoxetine|Administered orally
75339254|NCT00306488|Drug|OT-551 antioxidant eye drop|0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
75473909|NCT01976832|Behavioral|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
75649499|NCT04566510|Behavioral|Social behaviour change communication|SBCC activities will use digital and other platforms, similar to those used for the COVID-19 response, including the following: (1) LLIN launch on television and radio; (2) regional advocacy meetings on Zoom; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about COVID-19, malaria, and use, care, repair and repurposing of LLINs.
75473910|NCT01976858|Drug|PEX168|A injection administered subcutaneously
75649500|NCT04535934|Other|Adenine 5+ (five stable-labeled nitrogens)|taggant coencapsulated with an excipient
76087388|NCT03326154|Other|No intervention, observational|Observation
75649501|NCT04526587|Other|Cytology Specimen Collection Procedure|Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples
75649502|NCT04526587|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
75649503|NCT04526587|Other|Medical Chart Review|Patient's electronic health records are reviewed
75649504|NCT04523012|Other|Seroprevalence of SARS-CoV-2 infection in patients with HIV infection|On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
75649505|NCT04498780|Drug|Sacubitril-Valsartan|Observational study during the clinically indicated treatment
75649506|NCT04493333|Drug|Vaginal Dehydroepiandrosterone|This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
75473911|NCT01976897|Other|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
75473912|NCT01976897|Other|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
75649507|NCT04493333|Combination Product|Vaginal Polycarbophil Moisturizer|This is an FDA cleared, over-the-counter personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. It is non-sterile, water-based, non-irritating, non-greasy, non-staining vaginal gel delivered as a long-lasting moisturizer for vaginal dryness.
75649508|NCT04489472|Dietary Supplement|Beet-it Juice|Patients will ingest 1 bottle (70ml) of beet-it juice (98% concentrated beet juice, 2% lemon juice containing 400 mg/6.5 mmol nitrate).
75649509|NCT04452591|Biological|CG0070|Engineered Oncolytic Adenovirus
75649510|NCT04452591|Other|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
75649511|NCT04427501|Drug|LY3819253|Administered IV
75649512|NCT04427501|Drug|LY3832479|Administered IV
75649513|NCT04427501|Drug|LY3853113|Administered IV
75649514|NCT04427501|Drug|Placebo|Administered IV
75649515|NCT04403165|Procedure|Nocturnal polysomnography (NPSG)|Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.
75473913|NCT01976897|Other|Heel - interface pressure measurements|"The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media."
75796690|NCT04922710|Behavioral|Home-based aerobic exercise|Guidelines for exercise programming (ACSM, 2018) will be followed including a warmup and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, three times a week, for 12 weeks. The prescribed intensity will be based on estimated heart rate reserve, calculated using resting heart rate and age-adjusted heart rate maximum (220-age in years). Participants will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
75796691|NCT04921930|Drug|Artesunate Oral Product|Dose escalation intake of artesunate
75649516|NCT04403165|Procedure|Lumbar Puncture (LP)|Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.
75473914|NCT01976910|Drug|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
75339255|NCT04751006|Other|Gaze Stabilization Exercises|Gaze group performed balance exercises with gaze stability exercise.Gaze stability exercises included two types of exercises vestibular adaptation and substitution exercises. In Adaptation exercises individual need to fixate on a visual target during horizontal and vertical head movement with a purpose of increasing gaze stability and a long term gain to vestibular system. Subsitution exercises are planned to use other eye movement stratigies to substitute vestibular function and sustained visual fixation. During Substitution exercises individual need to perfomed eye head movement between target with a purpose of clear sighting during these tasks. Balance exercises consist of both static and dynamic balance exercises with weekly progression making balance exercises more challenging.
75649517|NCT04403165|Other|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]O-methylreboxetine ([11C]MRB) to measure NET availability.
75796692|NCT04909684|Drug|Pembrolizumab|The approved doses of 400 mg every 6 weeks (Q6W) and 200 mg every 3 weeks (Q3W) will be decreased to a 300 mg Q6W dose. The approved dose of 150 mg Q3W will be decreased to a 100 mg Q3W dose.
75796693|NCT04893837|Device|Standard care plus infrascans|Hourly infrascans to detect expanding intracranial hematomas
75934602|NCT00575055|Drug|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
75649518|NCT04403165|Behavioral|Psychomotor Vigilance Task (PVT)|Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.
75649519|NCT04402294|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will create individualized TMS targets using deep learning methods on task and resting fMRI data to target working memory augmentation. The individualized target will be stimulated in a subsequent fMRI scan involving working memory task performance interleaved with repetitive TMS (rTMS) delivered at a variety of stimulation frequencies. Based on activation readouts in response to rTMS, an optimal and sub-optimal brain state frequency to impact working memory performance will be selected for each participant. Participants will receive rTMS at each frequency separately for three days (six days total), with the order of frequency randomly assigned and counterbalanced. Following each three day protocol, another fMRI working memory readout will be conducted to support the targeting and frequency selection algorithms.
75649520|NCT04401163|Diagnostic Test|Imaging of the lungs|After hospital admissions with COVID19 patients will come for two clinical visits to complete a number of questionnaires, pulmonary function testing, six-minute walk test, blood sampling and imaging of the lungs.
75649521|NCT04390347|Dietary Supplement|Yakult|A fermented milk product with live microorganisms.
75649522|NCT04390347|Dietary Supplement|Placebo|A milk product with no live microorganisms.
75649523|NCT05027789|Behavioral|Self-Guided|People in this arm will come to 15 information sessions. These sessions will provide training and education on memory support strategies and healthy lifestyles. You will decide how you want to implement this information into your daily life.
75934603|NCT02282241|Drug|Melatonin|
75796694|NCT04877457|Drug|Ocrelizumab|The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.
75796695|NCT04877457|Other|Placebo|Placebo will be administered at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given at Weeks 24 and 48.
75934604|NCT02282241|Other|Placebo|
75934605|NCT02424851|Drug|Bortezomib|"1.3 mg/m2 subcutaneously* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
75934606|NCT02424851|Drug|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
75934607|NCT02424851|Drug|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
75934608|NCT02424851|Drug|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
75934609|NCT02284035|Drug|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
75934610|NCT02284035|Drug|EFV/TDF/FTC|standard combination therapy
75934611|NCT02284035|Drug|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
75934612|NCT02284035|Drug|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
75934613|NCT02284035|Drug|EFV plus ABC/3TC or RPV/TDF/FTC|
75339256|NCT04751006|Other|Balance Training|Participants performed balance training with saccade eye exercises.balance exercises included both static and dynamic balance exercises with a purpose of increasing mobility and stability of a posture by weekly progression. These exercises included standing on firm and foam surface with eyes open or close, heel stand, toe stand, marching on firm surface, forward and backward walking with normal base of support with weekly progression. Each task was performed for 5 repetitions with weekly progression in each task.
75339257|NCT05378334|Drug|ICI|PD-1 inhibitors selected by clinicians based on patients' condition
75339258|NCT05378334|Drug|Chemotherapy|AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel 100mg/m2+carboplatin AUC=5,q3w）for Squamous cancer patients.
75339259|NCT05378334|Drug|Placebo|The particle size and color are similar to the HGXJT, and the smell and taste are close to the HGXJT, and the bacteria test is qualified
75339260|NCT05378334|Drug|Bone-protecting and Mass-dispersesing Decoction|Chinese Herbal Formula,also named as HGXJT
75339261|NCT01793636|Drug|AZD2014|AZD2014 vs Everolimus
75339262|NCT01793636|Drug|Everolimus|comparing PFS in patients treated with AZD2014 vs Everolimus
75473915|NCT01976923|Drug|Intravitreal bevacizumab|A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
75934614|NCT02284035|Drug|ATV/r plus ABC/3TC|
75934615|NCT02284035|Drug|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
75934616|NCT02284035|Drug|RAL plus ABC/3TC|
75934617|NCT02284035|Drug|Other ART regimens|
75934618|NCT00484419|Drug|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
75934619|NCT00484419|Drug|rosiglitazone maleate|rosiglitazone tablets 4mg
75934620|NCT00484419|Drug|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
75934621|NCT02422355|Device|FNS|Surgical intervention using the FNS
75934622|NCT02162615|Device|Restorelle Direct Fix A|
75934623|NCT02162615|Device|Restorelle Direct Fix P|
75934624|NCT02162615|Procedure|Native Tissue Repair Anterior|
75934625|NCT02162615|Procedure|Native Tissue Repair Posterior|
75934626|NCT03220724|Biological|CH505TF|Administered by intramuscular (IM) injection in the thigh
75934627|NCT03220724|Biological|CH505w53|Administered by IM injection in the thigh
75934628|NCT03220724|Biological|CH505w78|Administered by IM injection in the thigh
75934629|NCT03220724|Biological|CH505 M5|Administered by IM injection in the thigh
75934630|NCT03220724|Biological|GLA-SE adjuvant|Admixed with all CH505 gp120 proteins
75934631|NCT03220724|Biological|Placebo|Administered by IM injection in the thigh
75934632|NCT00484029|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
75934633|NCT00484029|Other|Air|Air (Medical Grade)
75934634|NCT00483171|Drug|CP-945,598|CP-945,598
75934635|NCT00483171|Behavioral|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
75934636|NCT00483171|Behavioral|Low Calorie Diet|Low calorie diet
75934637|NCT02273895|Drug|Scopolamine|0.3 mg/mL, intravenously, once
75934638|NCT00480831|Drug|bevacizumab|Intravenous repeating dose
75934639|NCT00480831|Drug|carboplatin|Intravenous repeating dose
75934640|NCT00480831|Drug|paclitaxel|Intravenous repeating dose
75934641|NCT00480831|Drug|placebo|Intravenous repeating dose
75934642|NCT00480831|Drug|PRO95780|Intravenous repeating dose
75934643|NCT03220568|Other|Fatty acids present in adipose tissue samples|
75934644|NCT00667173|Drug|IDP-115|Topical application for 12 weeks
75934645|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
75934646|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
75934647|NCT03220334|Drug|Platelet rich plasma|The experimental group was treated with PRP for artificial gastric ulcer after ESD.
75934648|NCT03220334|Drug|Normal saline|The control group was treated with normal saline for artificial gastric ulcer after ESD.
75934649|NCT03220256|Drug|Lamotrigine|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
75934650|NCT00479505|Drug|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
75934651|NCT00479505|Drug|Placebo|Placebo
76087389|NCT02488590|Drug|LABA + LAMA|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
75473916|NCT01976923|Procedure|Small-gauge pars plana vitrectomy|
75473917|NCT01976936|Drug|Low Dose Lovastatin|80 mg daily for 3 days
75473918|NCT01976936|Other|Placebo|Placebo for 3 days
75649524|NCT05027789|Behavioral|Structured Group|People in this group will come to 15 information sessions. The study will provide recommended behavior targets (like how much exercise you should have each week). Participants in this group will either receive an iPad or have a special application installed on their own personal device. They will receive training on how to use the application, and will be asked to use the application to record their activities and receive reminders.
75934652|NCT02451410|Other|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
75649525|NCT04359069|Other|Urinary catheter removal on postoperative day 1|Urinary catheter will be removed on day 1 (experimental) instead of day 3 (standard of care).
75649526|NCT04359069|Other|Urinary catheter removal on postoperative day 3|Urinary catheter will be removed on day 3 (standard of care)
75649527|NCT04343573|Radiation|Involved-field Photon Radiation Therapy|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions)
75649528|NCT04343573|Radiation|Proton Craniospinal Irradiation (CSI)|Proton CSI (30Gy [RBE] in 10 fractions)
75796696|NCT04859205|Behavioral|Intervention|"Participants will have access to the SUPPORT-Pro self-guided online training platform addressing many aspects of type 1 diabetes care. The SUPPORT-Pro content was developped by a team of health professionals specialized in type 1 diabetes as well as patient partners. It's content is regularly updated, evidence-based and divided into 6 categories (medication, blood glucose monitoring, diet, physical activity, hypo and hyperglycemia, health and other particularities). In each category, users can pick between 3 levels (beginner, intermediate and advanced) according to their level of confidence and knowledge.~Participants will be asked to fill out questionnaires at baseline, 3-month, and 12-month of the intervention which include the following: Eligibility assessment, identification, background, confidence, platform satisfaction."
75796697|NCT04820855|Behavioral|Treatment|This is the treatment program devised win conjunction with a pelvic floor physical therapist. It is a daily yoga series and mindfulness with a Smartphone app.
75649529|NCT04343573|Other|Neurocognitive Assessment|All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT. The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available. Patients will also complete self-report mood and fatigue scales at each of the same time points. This testing will only be done at MSKCC. Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments. Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
75649530|NCT04343573|Other|MDASI-BT and MDASI-SP|Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).
75796698|NCT04820855|Other|Usual Cares|This is standard treatment for Interstitial cystitis with your provider.
75934653|NCT02451332|Biological|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
75934654|NCT00566397|Drug|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
75934655|NCT00566397|Drug|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
75934656|NCT00566397|Drug|Placebo|Placebo
75934657|NCT03220490|Behavioral|5 minute interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
75934658|NCT03220490|Behavioral|no interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
76087390|NCT02488590|Drug|ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
75473919|NCT01976936|Drug|High Dose Lovastatin|640 mg daily for 3 days
75796699|NCT04820127|Behavioral|personalized care preceded by a standardized assessment|"personalized intervention plan (PIP) proposed to the patient/caregiver dyad to correct potentially reversible causes of psycho-behavioral symptoms. This PIP will be re-evaluated and adapted at each visit by the nurse in close collaboration with the GP;~PIP implementation will be based on a close follow-up during the 18 months follow-up coordinated by the nurse (3 memory consultation visits, 3 home visits (with the GP) and 6 phone calls). This follow up will be enhanced with the use of a web platform (allowing teleconsultation, tele-expertise and telemonitoring);~specific training on psycho-behavioral symptoms for caregivers at baseline and during follow-up will be performed. On line training on psycho-behavioral symptoms management for GP will be available;"
75339263|NCT05345418|Biological|Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency|Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
75339264|NCT00308282|Drug|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
75339265|NCT00308282|Drug|Placebo|IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
75339266|NCT00343460|Drug|APF530|Given subcutanously
75339267|NCT00343460|Drug|dexamethasone|Given IV and orally
75339268|NCT00343460|Drug|Palonosetron Hydrochloride|Given IV
75339269|NCT00343460|Other|placebo|Given subcutanously or IV
75339270|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
75339271|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
75649531|NCT04337372|Behavioral|Book reading|Parent and their infant will read a short book in the laboratory. Books will include three labeling conditions expected to elicit different levels of attention.
75649532|NCT04336553|Behavioral|Social prescribing in Sweden (SPiS)|Social prescribing in sweden (SPiS)
75649533|NCT04315571|Device|Gore® Viatorr® Endoprosthesis with controlled expansion|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is a minimally invasive procedure in which a new path is made through the liver to carry blood from the portal vein to the heart, thus helping to alleviate the problems associated with elevated portal vein pressure.
75649534|NCT04315571|Procedure|Large Volume Paracentesis with albumin infusion|For therapeutic (large-volume) paracentesis, a 14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid. Concurrent infusion of IV albumin is recommended during large-volume paracentesis to help avoid significant intravascular volume shift and postprocedural hypotension.
75649535|NCT04289779|Drug|Cabozantinib|Cabozantinib 40 mg orally daily for 3 cycles
75649536|NCT04289779|Drug|Atezolizumab|Atezolizumab 1200 mg IV every 3 weeks for 3 cycles
75649537|NCT04289779|Procedure|Cystectomy|Patients will receive three cycles of treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw consent.
75649538|NCT04281381|Diagnostic Test|Cross-sectional imaging|MRI with gadolinium contrast will be the imaging modality of choice. In patients with contraindications to MRI who instead undergo baseline evaluation by CT scan, tumor evaluation will be by serial CT scans with IV contrast throughout the study period.
75339272|NCT01659996|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
75339273|NCT00309140|Drug|enzastaurin|500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
75339274|NCT05395806|Other|Health App|The intervention will include training health teams and patients in accessing and using a gamified health App 2-3 times a week. The App is based on a gamified character that improves its health if a patient checks its App, complies with her therapy, does regular exercise, and introduces normal levels of blood pressure, lipids level, and HbA1c levels. On the other hand, the character gets sick if the patient does not comply with her therapy or does not achieve certain levels of physical activity (i.e. 30 min moderate exercise 5 times a week or 2.5 hs a week or more than 9000 steps/day).
75339275|NCT05395806|Other|Usual Care|In this group, participants will receive their usual cardiovascular care according to the national guidelines. All patients receive free care at the primary care clinics and also receive free medications prescribed according to the national guidelines at the clinics. In addition, participants in this group will receive specific written information to improve their medication compliance, level of physical activity, blood pressure, HbA1c, and lipids level control.
75339276|NCT00353522|Drug|Placebo|po daily for 24 weeks
75339277|NCT00353522|Drug|dalcetrapib|900mg po daily for 24 weeks
75339278|NCT05597046|Other|Interview|Interviews
75339279|NCT05376774|Other|Admitted to intensive care units|Admitted to intensive care units
75339280|NCT00310076|Drug|thalidomide|Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
75339281|NCT00310076|Procedure|surgery|Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
75339282|NCT00353834|Drug|Exenatide|Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
75339283|NCT00353834|Drug|Glargine Insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
75473920|NCT01976949|Behavioral|online social-networking intervention|
75473921|NCT01977001|Device|MigraineBoxTM|
75473922|NCT01977027|Other|Alternate Hand Training or Affected Hand Training|Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
75339284|NCT05344404|Dietary Supplement|Nicotinamide Riboside|3000mg total daily. Administered in capsule form in doses of 1500mg twice daily for the duration of the trial (4 weeks).
75934659|NCT03220490|Drug|IOP reduction of Brimonidine and Timolol with time interval|"In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop."
75339285|NCT05344404|Dietary Supplement|Placebo|Placebo drug. Administered in tablet form twice daily for the duration of the trial (4 weeks).
75339286|NCT00354224|Drug|capecitabine|
75339287|NCT00354224|Drug|oxaliplatin|
75649539|NCT04262648|Dietary Supplement|Lactobacillus Reuteri|Lactobacillus Reuteri NCIMB 30351
75649540|NCT04262648|Dietary Supplement|Placebo|Sunflower oil
75649541|NCT04241016|Procedure|Endoscopic sinus surgery (ESS)|Uncinectomy, middle meatal antrostomy by enlarging the natural maxillary ostium and partial ethmoidectomy or septoplasty according to clinical evaluation of the operator.
75339288|NCT05395260|Drug|FL-101|FL-101 200mg IV
75934660|NCT03220490|Drug|IOP reduction of Brimonidine and Timolol no time interval|"In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period."
75339289|NCT00310310|Behavioral|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
75339290|NCT00310310|Behavioral|Usual care|Usual sleep apnea and cpap care
75934661|NCT03056573|Device|Transaortic TAVR Implant|Transaortic TAVR implant
76087391|NCT02488590|Drug|LABA + LAMA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
76087392|NCT02488590|Drug|LABA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
75339291|NCT01792388|Dietary Supplement|Vitamin D|Capsule Form
75339292|NCT01792388|Dietary Supplement|Soya Bean oil|Capsule form
75339293|NCT01793870|Drug|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
75339294|NCT01793870|Drug|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
75339295|NCT01793870|Drug|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
75339296|NCT01793948|Drug|metformin hydrochloride|Given PO
75473923|NCT01977053|Other|Clinical and psychosocial phone calls|"The standard medical supervision is defined as follows:~Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.~Nominative notebook containing details of chemotherapy administered and medical contacts.~Consultations with psycho-oncologist or psychiatrist (if necessary).~The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported."
75473924|NCT01977066|Behavioral|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
75649542|NCT04240691|Behavioral|60-Minutes-For-Health|Refer to description under Groups
75649543|NCT04240691|Other|Time-and-Attention Control Session|Refer to description under Groups
75649544|NCT04226040|Behavioral|DOW and illness perception|Acutely ill patients are exposed to a survey regarding their degree of worry and illness perception
75649545|NCT04156802|Device|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded)
75649546|NCT04156802|Device|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
75649547|NCT04156802|Device|Real TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded).
75649548|NCT04156802|Device|Sham TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
75649549|NCT04154410|Other|Analgesia Nociception Index|Non invasive finger tip monitoring before during and 5 minutes after cannulation
75649550|NCT04154410|Other|algiscan|Portable videopupillometer to measure pupillary light reflex (PLR), variation coefficient of pupillary diameter (VCPD), pupillary diameter (PD) fluctuations before, during and 5 minutes after cannulation
75934662|NCT03056573|Device|Subclavian /Axillary TAVR implant|Subclavian /Axillary TAVR implant
75339297|NCT01793948|Other|placebo|Given PO
75339298|NCT01793948|Other|laboratory biomarker analysis|Correlative studies
75339299|NCT04623320|Diagnostic Test|euglycaemic clamp test|clamp test (golden standard) to determine insulin resistance
75339300|NCT04623320|Diagnostic Test|13C glucose breath test|13C glucose breath test to compare with the golden standard
75339301|NCT05342298|Other|prediction model|Data will be pre-processed prior to final analysis, including data cleaning, imputation of missing values, dimensionality reduction, and removal of outliers. Data will be utilized as Xi and Yi where Xi presents input (features) and Yi presents dependent variables (outcomes). Different classification algorithms will be tested for accuracy to build the final model including logistic regression, SVM, XGboost and random forest algorithms. Data will be split at 0.8:0.2 for model training and testing, respectively.
75339302|NCT05394402|Drug|SHR0410 Injection|SHR0410 Injection
75339303|NCT05394402|Drug|Placebo for SHR0410 Injection|SHR0410 Injection blank preparation
75339304|NCT05374434|Other|Conventional irrigation|The participant will be treated by manual irrigation with sodium hypochlorite NaOCl.
75339305|NCT05374434|Device|Inertial cavitation|The participant will be treated by inertial cavitation-generating device, that generates hydraulic cavitation to clean root canals deeper and more effectively than other existing systems.
75339306|NCT05374200|Other|Mind-body intervention with 1-1 support from study personnel|"The multicomponent intervention will consist of the following core components: (1) A choice between three different types of low-intensity, mindful movement videos - chair fitness, standing fitness, or standing tai chi (15-30 minutes/session); (2) Breathwork and theme-of-the-week based mindfulness meditations (5-10 minutes/session); (3) A once weekly positive psychology/behavior change activity presented as a point-and-click interactive storybook within the online site; (4) A once weekly disease management tip from a PBC physician.~Weekly brief (~10-minute) motivational interview style telephone check-ins taking place during the intervention period will be conducted by a member of the study team. During these check-ins, progress will be reviewed, motivation provided, and questions answered."
75339307|NCT05393310|Other|post isometric relaxation|The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks
75339308|NCT05393310|Other|MWM group|MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
75649551|NCT04141878|Behavioral|Aerobic Exercise|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise may vary, but will primarily focus on walking tutorials.
75649552|NCT04141878|Behavioral|Diet Skills|Participants will attend weekly classes focused on incorporating heart healthy foods into their existing diets. Calories will be restricted, and portion control will be taught with the goal of losing body weight. Hands-on skills will be taught for preparing healthy home-cooked meals by professional chefs.
75649553|NCT04136184|Drug|Eplontersen|Eplontersen by subcutaneous injection
75649554|NCT04136184|Drug|Inotersen|Inotersen by subcutaneous injection
75649555|NCT04130516|Drug|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
75649556|NCT04130516|Biological|Pembrolizumab - anti-PD-1 antibody|pembrolizumab- anti-PD-1 antibody
75649557|NCT04115085|Procedure|Hand therapy (18 treatments)|18 treatments (ea. 20 Min) within 9 weeks
75796700|NCT04815746|Behavioral|Cognitive Behavioral Therapy (CBT)-based skills|The CBT skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour.
75934663|NCT03220100|Other|Stepped Palliative Care|Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
75339309|NCT00310466|Biological|Sublingual immunotherapy|once daily intake of sublingual drops
75339310|NCT00310466|Biological|Placebo|once daily intake of sublingual drops
75649558|NCT04115085|Procedure|Therapeutic ultrasound (18 treatments)|18 treatments (ea. 10 Min) within 9 weeks
75649559|NCT04115085|Procedure|Combined hand therapy and therapeutic ultrasound (18 treatments)|18 treatments (ea. 30 Min) within 9 weeks
75649560|NCT04115085|Procedure|Sham ultrasound group (18 treatments)|Sham ultrasound group receive 18 treatments (ea. 10 Min) within 9 weeks
75649561|NCT04088435|Radiation|Intraoperative radiotherapy|The IORT component of this treatment is being delivered as per standard clinical practice. 20 Gy in one fraction will be delivered at the time of lumpectomy.
75649562|NCT04077567|Drug|TS-152|30mg,80mg
75649563|NCT04077021|Drug|CCW702|Investigational immunotherapy for prostate cancer
75796701|NCT04815746|Behavioral|Standard Education|Patients randomized to standard clinical care will receive standard education based on various resources (e.g., National Cancer Institute) relevant to pancreatic cancer.
75796702|NCT04791371|Behavioral|Cardiovascular exercise|15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
75934664|NCT02553772|Drug|Carboxymethylcellulose Based Eye Drop|Carboxymethylcellulose based eye drop (OM3 Tear) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
75796703|NCT04726423|Other|transcranial direct current stimulation|5 daily sessions of tDCS (2mA, 20 min) were recommended to all patients. Physical exercises were also done at the physiotherapy clinic. Physical exercises program was recommended to be continued at home after the week of physiotherapy visits.
75796704|NCT04725344|Other|ACTIV'DOS group|ACTIV'DOS group use ACTIV'DOS application (with smartphone) to do the self rehabilitation each day (15 minutes per day) during 6 weeks. There are 7 exercices.
75796705|NCT04725344|Other|Usual practise|Control group uses a standard sheet of paper to do the self-rehabilitation (15 minutes per day) during 6 weeks. There are 7 exercises.
75796706|NCT04720300|Other|MaaS app|The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app.
75796707|NCT04720300|Other|No app|students receive no app or housing information
75796708|NCT04719273|Drug|Extended-release Onapristone|Given PO
75796709|NCT04719273|Drug|Anastrozole|Given PO
75796710|NCT04719273|Other|Quality-of-Life Assessment|Ancillary studies
75796711|NCT04719273|Other|Questionnaire Administration|Ancillary studies
75934665|NCT02553772|Drug|Carboxymethylcellulose Sodium 0.5%|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
75934666|NCT00665145|Drug|SB-509|Active drug
75934667|NCT00665145|Drug|SB-509|Active drug
75934668|NCT00665145|Drug|Placebo|Placebo
75934669|NCT00665145|Drug|SB-509|Active drug
75934670|NCT03119714|Drug|Pemirolast|Treatment with pemirolast 200 mg bid for 14-16 days
75934671|NCT03119714|Drug|Placebo Oral Tablet|Treatment with placebo bid for 14-16 days
75339311|NCT00355394|Drug|Metoclopramide|Intravenous bolus administration.
75339312|NCT00355394|Other|Placebo|Standard care including intravenous fluid, but no metoclopramide.
75339313|NCT00355706|Procedure|Thoracic facet joint nerve blocks|Thoracic medial branch blocks
75339314|NCT00311246|Drug|Adalimumab|Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
75339315|NCT02105246|Behavioral|Referral to home-based cardiac rehab|Home-based cardiac rehab is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
75649564|NCT04056520|Device|Medtronic Infinity Occipitocervical-Upper Thoracic System using the O-arm Imaging System and StealthStation Navigation system|"The INFINITY™ OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7), and the thoracic spine from T1-T3:~Traumatic spinal fractures and/or traumatic dislocations.~Instability or deformity.~Failed previous fusions (e.g. pseudarthrosis).~Tumors involving the cervical spine.~Degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/ or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability."
75796712|NCT04719273|Diagnostic Test|Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)|Immunohistochemistry (IHC):Integral : Tissue
75339316|NCT02105246|Behavioral|Referral to center-based cardiac rehab|Center-based cardiac rehab is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
75339317|NCT01792466|Procedure|Transpancreatic sphincterotomy|A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
75796713|NCT04719273|Diagnostic Test|Progesterone Receptor Positive ( PGR Positive; PR Positive)|Immunohistochemistry (IHC)
75796714|NCT04703322|Drug|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
75339318|NCT02105324|Device|Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
75339319|NCT02105324|Other|Usual Care|As a comparator control, usual diabetes camp care with the participant's own insulin pump.
75339320|NCT02105558|Drug|Epidural anesthesia|"￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered."
75934672|NCT02274597|Device|metraux epitympanic thermometer|accuracy of epitympanic temperature measurement in different environmental settings
75934673|NCT04617977|Behavioral|I-BMS for families with children suffering from eczema|It is a strength-based, family system approach to aid empowerment of individuals. It focuses on the interplay between physical and emotional well-being, the spiritual transformation of adverse life experiences, and the acceptance of adversity through reflection on the philosophical concepts of forgiveness and letting go. It integrates Western therapeutic techniques and Eastern philosophies to develop spiritual transformation through suffering and pain under a meaning-oriented framework. It consists of six three-hour consecutive weekly sessions: (1) awareness of body-mind connection; (2) regulation of emotion; (3) acknowledgement of the gains and losses in the caregiving or illness experience; (4) appreciation of self and others; (5) cultivation of acceptance; and (6) meaning reconstruction of caregiving or illness experience.
75934674|NCT04617977|Behavioral|Health education for parents whose children have eczema|It focuses on practical eczema management. It serves as a control for group effect between conditions. It consists of six three-hour sessions: (1) information about the physiology of eczema and its health impact; (2) recognition and avoidance of trigger factors and daily skin care; (3) dealing with itching and scratching; (4) stage-related treatment of symptoms and unconventional therapies; (5) general child nutrition, food allergies in eczema, and different forms of diets; and (6) self-management plan and problems in integrating into daily routine.
75934675|NCT00562887|Biological|Placebo|every 4 weeks, IV
75934676|NCT00562887|Biological|ABT-874|400 mg IV every 4 weeks
75934677|NCT00562887|Biological|ABT-874|700 mg IV every 4 weeks
75796715|NCT04701515|Other|Chart review|Chart review
75339321|NCT02105558|Drug|Combined spinal and epidural anesthesia|"A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr."
75339322|NCT00312884|Device|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
75339323|NCT02106728|Behavioral|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
75796716|NCT04684537|Procedure|Extracorporeal shockwave therapy (ESWT)|The therapy will be performed with the focused piezoelectric shockwave (F10G4 Richard Wolf GmbH, Germany). The patient will be kept in the hip flexion, adduction and internal rotation position. After sonography-guided localization of the affected muscle and identification of the trigger point by the participant, ultrasound gel is applied to the skin and the applicator couple is placed with an impulse energy flux density of 0.456-0.882 mJ/mm2 for 3500 impulses.
75796717|NCT04684537|Procedure|Ultrasound-guided piriformis steroid injection|all the participants will receive ultrasound-guided piriformis injection with 10 mg triamcinolone and 1 c.c. 1% lidocaine for one time.
76087393|NCT02488590|Drug|other|An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
75339324|NCT02106728|Behavioral|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
76087394|NCT01738750|Other|Cost Information Included|
76087395|NCT02488668|Device|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
76087396|NCT05316376|Drug|albumin-bound paclitaxel|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)
76087397|NCT05316376|Drug|paclitaxel|paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
76087398|NCT03326076|Diagnostic Test|Donor-derived cell-free DNA (AlloSure®)|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
75339325|NCT02106962|Drug|Topical Tranexamic Acid 5% with bacitracin|Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
75649565|NCT04055311|Behavioral|Cancer Resource Information Support (CRIS)|Intervention support is patient initiated and accessed as needed
75649566|NCT04055311|Behavioral|Usual Care Enhanced|Usual care is enhanced with the addition of the NCI Facing Forward brochure
75649567|NCT04052230|Other|ultrasound measure|Admission to the intensive care unit, and setting up an ECMO Daily monitoring from D1 to D7, follow up at D60
75339326|NCT02106962|Other|Topical Tranexamic Acid 25% with bacitracin|Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
75649568|NCT04049643|Device|Audiologist-based fitting|Hearing aids will be fitted by audiologists using established procedures.
75649569|NCT04049643|Device|Service-only Fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. In this intervention group, audiological services plus hearing aids that provide minimum amplification will be provided. Specifically, patient participants in this group will receive audiological services (e.g., counselling and education), except that the hearing aids will be set to provide no amplification other than what is needed to overcome any sounds that are dampened by the earpieces.
75649570|NCT04049643|Device|Device-only fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. The patient participants in this intervention group will have minimum services regarding the pre-fitting, selection, and orientation of the hearing aids. The participants will have a hearing evaluation, including pure-tone audiometry. The audiologist will select the amplification characteristics and non-custom ear piece based on the audiogram. The audiologist will then briefly orient the participant on how to use the hearing aids and counsel on how to optimize their performance.
75339327|NCT00315146|Drug|Pioglitazone|
75339328|NCT00315146|Behavioral|Resistance exercise training to maximize muscle power|
76087399|NCT03326076|Other|Standard care|Current standard methods for monitoring of renal allograft recipients for rejection (e.g. donor-specific antibodies, serum creatinine, proteinuria, renal allograft biopsy)
76087400|NCT03326076|Diagnostic Test|Peripheral blood gene expression profiling (AlloMap Kidney)|Patients will receive peripheral blood gene expression profiling testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
76087401|NCT03326076|Diagnostic Test|Analytic platform (IBox)|Patients will receive IBox testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
76087402|NCT01743976|Drug|Donepezil|donepezil 5 mg once daily for 6 weeks
75339329|NCT00315146|Behavioral|Hypocaloric diet|
75339330|NCT00315146|Drug|Placebo|
75339331|NCT04462562|Diagnostic Test|Quantitative US (Samsung Medison, RS85A)|In each patients, measurements of tissue attenuation imagine (TAI), tissue scatter-distribution imaging (TSI) parameters, hepatorenal index (EzHRI) will be performed
75473925|NCT01977066|Behavioral|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
75473926|NCT01977079|Other|procalcitonin|
75649571|NCT04041583|Device|Cervical Interfacet Spacers|The use of Cervical Interfacet Spacers is a relatively novel technique shown to be useful for posterior fusion to address symptomatic pseudoarthrosis (fusion failure) after anterior cervical arthrodesis [2]. CIS have a relatively large osteoconductive surface area and are placed under tension in the interfacet space, which together favorably influence bony fusion [2].
75649572|NCT04030299|Device|Over-the-counter fitting|In this group, pre-configured hearing aids, which simulate over-the-counter hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
76087403|NCT01743976|Drug|Placebo|placebo or sugar pill will be taken once daily for 6 weeks
76087404|NCT05316064|Biological|probiotic|oral administration of probiotic at 9 log CFU/day for 12 weeks to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab.
76087405|NCT05316064|Other|placebo|oral administration of primarily carrier without the probiotic for 12 weeks
76087406|NCT05315986|Dietary Supplement|Saffr'Inside; 30mg|Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
76087407|NCT05315986|Behavioral|Enhanced Sleep Education|Psycho-education based multi-component sleep intervention
76087408|NCT05315986|Dietary Supplement|Placebo food supplement|Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
75339332|NCT04428164|Other|The Richards-Campbell Sleep Questionnaire (R-CSQ)|"Tool developed to assess patient satisfaction and comfort in the hospital setting.~The R-CSQ is a scale used to measure different aspects of sleep quality. This scale allows the patient to rate their quality and amount of sleep on a scale of 0-100. The R-CSQ allows the patient to rate six different components of their sleep, including sleep depth, sleep latency, awakenings, returning to sleep, sleep quality, and noise."
75339333|NCT04428164|Other|Revised American Pain Society Outcome Questionnaire (APS-POQ-R)|The APS-POQ-R can be utilized to measure perceived levels of pain in patients. The APS-POQ-R scale is a validated scale that is used in the hospital setting with reliable and consistent results. This scale measures five aspects of a patient's perception and experiences with pain and a sixth aspect including nonpharmacological interventions.
75339334|NCT01792544|Other|Statement|
75339335|NCT01792544|Other|No Statement|
75339336|NCT01792700|Drug|esomeprazole|
75339337|NCT01792700|Drug|tripotassium dicitrate bismuthate|
75339338|NCT01792700|Drug|metronidazole|
75339339|NCT01792700|Drug|tetracycline|
75339340|NCT01792700|Drug|moxifloxacin|
75649573|NCT04026867|Other|Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS), the most influential studies of HIV linkage-to-care to date.
75649574|NCT04026867|Other|Clinician Referral|"The Clinician Referral arm will serve as an active control and baseline standard of care."
75649575|NCT03989778|Drug|Vitamin D|Vitamin D supplementation
75649576|NCT03976063|Drug|Nifedipine|Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
75796718|NCT04682730|Behavioral|Deliberative Loop|"The investigators will give background information to the stakeholders before they engage in the Deliberative session.~Stakeholders from a given clinic will come together for a Deliberative session (i.e., facilitated conversation), enabling them to hear the full range of perspectives held by their fellow colleagues and to share their own perspective regarding how best to implement the guideline in small-group discussions.~Following the Deliberative session, each stakeholder will have the opportunity to record their opinions regarding possible implementation interventions. The investigators will share these opinions with the clinic's decision-makers to help guide their decision-making about which implementation interventions to deploy. If a stakeholder happens to be absent the day of their clinic's Deliberative session, they will still have the opportunity to complete the survey."
75796719|NCT04673370|Behavioral|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines techniques regulating body, breath and spirit. According to traditional Chinese theory, every movement of Ba Duan Jin has unique effect to different Zang-fu organs.
75339341|NCT01792700|Drug|amoxicillin|
75339342|NCT00315302|Drug|Atropine|Atropine 1% once each weekend day
75339343|NCT00315302|Device|Plano Lens|Plano lens for the sound eye
75339344|NCT00315614|Biological|Islet Transplantation and Bone Marrow|Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
75339345|NCT01792778|Device|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
75649577|NCT03976063|Drug|Placebo of Nifedipine|Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
75649578|NCT03964142|Other|Cardiac rehabilitation|"Integrated cardiac rehabilitation program that includes supervised exercise training*.~* Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise)."
75649579|NCT03959527|Drug|zoliflodacin|Dose: 3g, oral administration
75649580|NCT03959527|Drug|ceftriaxone|Dose: 500mg, Intra-Muscular (IM) administration
75649581|NCT03959527|Drug|azithromycin|Dose: 1g, oral administration
75796720|NCT04673370|Behavioral|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
75934678|NCT05468554|Drug|metformin|Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.
75934679|NCT05468554|Radiation|Radioactive iodine (I-131)|Patients qualified to receive 131I treatment
75339346|NCT01792778|Device|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
75339347|NCT01794026|Procedure|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
75339348|NCT00316862|Drug|cisplatin|Given IV
75339349|NCT00316862|Drug|irinotecan hydrochloride|Given IV
75339350|NCT00316862|Procedure|therapeutic conventional surgery|Undergo Surgery
75339351|NCT00316862|Radiation|radiation therapy|Undergo radiation
75339352|NCT00357032|Drug|belinostat|Given IV
75339353|NCT00357032|Other|laboratory biomarker analysis|Correlative studies
75339354|NCT00357734|Drug|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
75339355|NCT01791842|Drug|Tocilizumab|8 mg/kg/month
75339356|NCT01791842|Drug|Placebo|
75339357|NCT01791998|Procedure|magnetic resonance thermal imaging|Undergo MR-thermal image guided LITT
75339358|NCT01791998|Procedure|laser interstitial thermal therapy|Undergo MR-thermal image guided LITT
76087409|NCT05464212|Procedure|USG Guided Greater Occipital Nerve Block|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
75473927|NCT01977105|Behavioral|Grow Together peer group|"Participants in this intervention will:~Participate in Facebook group of 6-10 peers for about 8 weeks, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~1. View educational videos addressing topics related to healthy infant growth~2. Create photos/videos modeling healthy behaviors and post them to the group~3. Provide and receive feedback on posts~4. Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person.~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network.~Have basic program information provided to pediatrician to enhance conversation during office visits."
75473928|NCT01977118|Drug|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
75649582|NCT03955172|Drug|Everolimus|Patients will received everolimus (CERTICAN), oral form, at the necessary dose to obtain trough levels between 6 and 8 ng/ml, during 6 months. Everolimus will replace the anti-proliferative drug they have before (azathioprine or mycophenolic acid). Everolimus will be associated with corticosteroids (prednisolone) and a calcineurin inhibitor (tacrolimus or cyclosporin).
75649583|NCT03952208|Other|Neurocognitive Testing|A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
75473929|NCT01977118|Other|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
75649584|NCT03947216|Drug|Active drug: pimavanserin 17mg (2 strength tablets)|Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
75649585|NCT03947216|Drug|Placebo: 2 tablets containing same excipients except active compound|Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
75649586|NCT03947216|Behavioral|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
75796721|NCT04663646|Other|Optokinetic stimulation|"Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected.~The study will be carried out for 10 weeks with a frequency of two weekly sessions. During them, the participants will receive stimulation with OKS.~Stimulation will be performed at 1 cm/second, the vertical black bars will move to the left. The bars change color and the participants will be asked to detect the changes that will occur in the stimulus."
75796722|NCT04663646|Other|Placebo|Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected. In this group, stimulation consists of a video with static vertical bars that change their colour at a randon intervals, in the same way that in the intervention group. The difference between groups is that in control group, bars are not in movement, preventing from generating optokinetic stimulation.
75934680|NCT04617821|Drug|Nab paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine are given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycle.
75934681|NCT04617821|Drug|mFOLFIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
75934682|NCT03219632|Drug|Fimasartan|Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
75934683|NCT03219008|Drug|Fluoxetine|Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
75473930|NCT01977131|Other|Cells|
75473931|NCT01977157|Device|bioimpedance mesurements|Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
75473932|NCT01977170|Biological|Hib/PRP-T vaccine|Hib liquid vaccine
75473933|NCT01977196|Biological|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
75649587|NCT03947216|Behavioral|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
75649588|NCT03947216|Behavioral|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
75649589|NCT03947216|Behavioral|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)
75649590|NCT03947216|Behavioral|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.
75473934|NCT01977209|Drug|Gossypol|
75339359|NCT00318812|Drug|Heme Iron Polypeptide (Proferrin)|Heme iron polypeptide 11mg po tid for 6 months
75339360|NCT00318812|Drug|Iron sucrose (Venofer)|Iron sucrose infusion IV q month x 6 months
75339361|NCT02109458|Device|Navigation guided bronchoscopy|Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
75339362|NCT00319748|Drug|852A|0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
75339363|NCT01794260|Drug|Cream from Zingiber cassumunar Roxb. extract|
75796723|NCT04640688|Procedure|Bariatric procedures|510(k) summary K081853 dated June 26, 2008, Endoscopic Sleeve Gastroplasty lecture, Methodist Dallas Medical Center Endobariatric Pathway & Endoscopic Sleeve Gastroplasty Procedure Description
75796724|NCT04634253|Drug|Placebo|Given IV
75796725|NCT04634253|Drug|LY3462817|Given IV
75796726|NCT04631510|Drug|Gabapentin 300 mg PO at 8 PM|Administer gabapentin 300 mg PO at 8 PM for sleep
75934684|NCT03219008|Combination Product|fluoxetine + cognitive-behavioral treatment（CBT）|the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.
75934685|NCT03219008|Drug|fluoxetine + Amfebutamone|Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.
75339364|NCT01794260|Drug|Placebo cream|
75339365|NCT00361712|Procedure|Preemptive epidural analgesia|Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.
75339366|NCT00361712|Drug|Standard of care|Epidural analgesia with parturients with cervical dilatation and painful labor (VAS >5)
75339367|NCT04008056|Other|Patient Reported Outcome questionnaire|34 question form to assess patient symptoms
75473935|NCT01977209|Drug|Placebo|
75796727|NCT04629469|Diagnostic Test|Hyperfine MRI|• Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
75934686|NCT03219008|Combination Product|physical treatment+fluoxetine+amfebutamone|the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.
75934687|NCT03219008|Drug|Fluvoxamine|Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.
75934688|NCT03219008|Drug|Lithium+fluvoxamine|the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.
75339368|NCT03710096|Device|macGrath|in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube
75339369|NCT03710096|Device|Macintosh's|in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
75339370|NCT03993002|Other|Normoxia with Normocarbia|PaO2 < 100 (FiO2 >= 21%) PaCO2 of 30-40
75339371|NCT03993002|Other|Normoxia with Hypercarbia|PaO2 < 100 (FiO2 >= 21%) PaCO2 of 50-60
75339372|NCT03993002|Other|Hyperoxia with Normocarbia|PaO2 > 250 (FiO2 >= 70%) PaCO2 of 30-40
75339373|NCT03993002|Other|Hyperoxia with Hypercarbia|PaO2 > 250 (FiO2 >= 70%) PaCO2 of 50-60
75339374|NCT00362882|Drug|docetaxel|Given IV
75339375|NCT00362882|Drug|bortezomib|Given IV
75339376|NCT00362882|Other|laboratory biomarker analysis|correlative study
75339377|NCT00362882|Other|immunoenzyme technique|correlative study
75339378|NCT00362882|Other|immunohistochemistry staining method|correlative study
75339379|NCT00362882|Other|pharmacological study|correlative study
75339380|NCT05577312|Drug|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
75339381|NCT05532384|Behavioral|Early resumption of oral intake|as above
75339382|NCT05532384|Behavioral|Late resumption of oral intake|as above
75339383|NCT05339568|Other|Patients' whole process follow-up and management platform|Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
75473936|NCT01977248|Behavioral|Sensorimotor Affect Relationship-based Therapy (SMART)|The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
75473937|NCT01977261|Procedure|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu plate
75473938|NCT01977261|Procedure|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with two staples
75473939|NCT01977274|Other|gynecological cancer|blood and tumor samples
75473940|NCT01977287|Device|Functional Electrical Stimulation|
75473941|NCT01977287|Device|Ankle Foot Orthosis|
75934689|NCT03219008|Combination Product|fluvoxamine + lithium + physical therapy|the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.
75934690|NCT03219008|Combination Product|Cognitive behavior treatment +fluvoxamine|the investigators recommend behavioral therapy as well as drugs.
75339384|NCT00365144|Biological|bevacizumab|
75649591|NCT03947216|Behavioral|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
75339385|NCT00365144|Drug|erlotinib hydrochloride|
75796728|NCT04614441|Drug|OFEV®|nintedanib
75796729|NCT04612257|Other|Insulin-alone closed-loop|40-hour intervention period using the insulin-alone closed-loop system.
75796730|NCT04609956|Other|Virtual reality|Virtual reality consists of a headphones, a virtual reality headset and a smartphone.
75934691|NCT03219008|Drug|Mirtazapine/SNRIs|Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.
75796731|NCT04609956|Other|Standard|Standard arm is the habitual procedure. They use hydroxyzine and music with headphones
75796732|NCT04566003|Drug|[18F]GTP1|Participants will receive a bolus IV of approximately 7mCi of [18F]GTP1 radiotracer.
75339386|NCT00365144|Other|laboratory biomarker analysis|
75339387|NCT00365768|Drug|Glutamine|Administered orally twice daily for 21 days
75339388|NCT00365768|Other|Placebo|Administered orally twice daily for 21 days
75339389|NCT05336994|Dietary Supplement|Multivitamin/mineral supplement A|Oral administration of Supplement A
75339390|NCT05336994|Dietary Supplement|Multivitamin/mineral supplement B|Oral administration of Supplement B
75339391|NCT00366626|Drug|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
75339392|NCT00366626|Drug|Placebo|Placebo for 7 days matched to Naltrexone
75339393|NCT00367016|Drug|Omalizumab|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
75339394|NCT00367016|Drug|Placebo|Placebo, given by subcutaneous injection.
75339395|NCT05372250|Other|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
75339396|NCT04422678|Drug|Imatinib Mesylate|Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.
75339397|NCT04422678|Drug|Standard of Care|Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.
75339398|NCT01794416|Procedure|Thoracoscopic epicardial ablation|
75796733|NCT04566003|Drug|[18F]PI-2620|Participants will receive a bolus IV of approximately 5mCi of [18F]PI-2620 radiotracer.
75796734|NCT04566003|Drug|[18F]MK-6240|Participants will receive a bolus IV of approximately 5mCi of [18F]MK-6240 radiotracer.
75796735|NCT04559581|Drug|Nintedanib|Capsules
75649592|NCT03947216|Procedure|Blood analysis|Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56
75649593|NCT03947216|Procedure|Cardiac monitoring|Electrocardiogram will be realized at day 0, 28 and 56.
75649594|NCT03936335|Drug|dupilumab|No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
75796736|NCT04556734|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily
75796737|NCT04556734|Drug|Etrasimod|Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
75796738|NCT04556734|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily
75796739|NCT04553640|Other|Group A/Intervention Curriculum|Virtual patient cases and feedback
75796740|NCT04553640|Other|Group B/Control Curriculum|Online articles on dizziness and emergency department clinical experience
75796741|NCT04552119|Device|HEALICOIL Knotless PEEK|HEALICOIL Knotless PEEK Self-Tapping HEALICOIL Knotless Non-Self Tapping
75796742|NCT04552119|Device|HEALICOIL Knotless REGENESORB|HEALICOIL Knotless REGENESORB Self -Tapping HEALICOIL Knotless REGENSORB Non-Self Tapping
75796743|NCT04550715|Behavioral|Brief intervention (BI)|A remote brief intervention delivered by health coaches that uses Motivational Interviewing to address opioid misuse and risk factors. Remote health coaches use a web-based clinician support guide to maintain fidelity, while tailoring the session to unique participant factors.
75796744|NCT04550715|Behavioral|Portal|Remote health coaches will push tailored messages to participants over a 4-week period. The messages will use Motivational Interviewing strategies. The messages are designed to elicit a response from the participant. Health coaches will also respond to participant replies consistent with Motivational Interviewing over a course of 4 weeks.
75796745|NCT04550715|Behavioral|Enhanced Usual Care (EUC)|The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.
75934692|NCT03219008|Combination Product|mirtazapine+ Cognitive behavior treatment|the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .
75934693|NCT03219008|Drug|mirtazapine + SNRIs|the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.
75339399|NCT01794416|Procedure|Endocardial catheter ablation|
75339400|NCT01794416|Device|Implantable loop recorder|
75339401|NCT05371314|Diagnostic Test|P/FP ratio|PaO2/FiO2 X PEEP, SpO2/FiO2 X PEEP
75339402|NCT05370768|Behavioral|Parenting Mindfully Intervention|Includes meditation and using meditation and mindfulness in everyday life and in parenting interactions.
75473942|NCT01977300|Drug|Valproate|serum level of 50 to 125 ug/L
75473943|NCT01977300|Drug|Lithium|serum levels of 0.6 to 1.2 mmol/L
75473944|NCT01977300|Drug|Risperidone|1 to 6 mg/day
75473945|NCT01977300|Drug|Olanzapine|5 to 25 mg/day
75473946|NCT01977300|Other|Placebo|manufactured to mimic risperidone and olanzapine
75473947|NCT01977326|Behavioral|basic counselling by lay-health workers|6 sessions of manual based counselling by trained lay health workers
75473948|NCT01977326|Other|Enhanced usual care|3 monthly phone calls by trained lay health workers (without counselling)
75934694|NCT03219008|Combination Product|mirtazapine + SNRIs + physical therapy|the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.
75934695|NCT03219008|Other|TAU(treat as usual)|patients in this group would receive therapy strategies according to their symptoms and preference.
76087410|NCT05464212|Procedure|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
75649595|NCT03924167|Behavioral|Weaving Healthy Families Program|The Weaving Healthy Families program is created from integrating the widely disseminated, ecological, innovative, and culturally grounded Framework of Historical Oppression, Resilience, and Transcendence (FHORT) with the the Celebrating Families! evidenced-based program (EBP). The goal of this program is to reduce and postpone Alcohol and other Drug (AOD) use, decrease and prevent violence in families, and promote resilience and wellness (including mental health) among NA adults and youth. This intervention seeks to promote wellness by targeting key behavioral (AOD), mental/emotional (emotional regulation/anger management, cognitions, resilience), social and familial (healthy and safe relationships, the family environment, and parenting), cultural (values, traditions), and physical (nutrition) factors.
75473949|NCT01977339|Drug|Liposome Bupivacaine|10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
75473950|NCT01977339|Drug|Bupivacaine|20 cc of 0.25% bupivacaine
75796746|NCT04549259|Behavioral|Group-Based Social Support|This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 8 consecutive weeks. The calls will last approximately 90 minutes and will include 5-8 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Therapists will facilitate mutual support among group members, encourage greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy (Heckman et al., 2013).
75473951|NCT01977365|Behavioral|Growth promotion based on child centered approach|"- Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.~Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.~Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.~- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers."
75473952|NCT01977378|Drug|Sustained-Release Desvenlafaxine Hydrochloride|
75473953|NCT01977378|Drug|Sustained-Release Venlafaxine Hydrochloride|
75796747|NCT04549259|Behavioral|HIV Stigma Reduction|"This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 6 consecutive weeks. The calls will last approximately 60-90 minutes and will include 5-8 individuals per group. This intervention is grounded in minority stress theory and will use cognitive-behavioral strategies to help empower participants to cope with stressful and stigmatizing experiences. Intervention components may include minimizing self-stigmatizing attitudes, reducing engulfment, developing a sense of future and hope, and developing and pursuing meaningful life goals. This intervention is an adaptation of Ending Self Stigma (Lucksted et al., 2011)."
75796748|NCT04549259|Behavioral|Strengths-Based Case Management (SBCM)|The investigators have adapted an individually-tailored strengths-based case management (SBCM) intervention to help address the multiple structural barriers faced by rural older PLH. The adapted intervention, delivered by trained research staff, will include two 60-minute telephone-based SBCM counseling sessions with shorter follow-up phone calls to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
75934696|NCT02553538|Behavioral|Patient Navigation|Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
75934697|NCT03218930|Behavioral|Delayed antibiotic prescription|Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
75934698|NCT03218930|Behavioral|Antibiotic prescribing guidelines|Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.
75934699|NCT03218930|Behavioral|Education|General practitioners will receive a package of educational sessions tailored towards their specific needs.
75934700|NCT03218930|Behavioral|Educational materials|Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
75934701|NCT00562497|Drug|Prochymal®|Prochymal® intravenous infusion.
75934702|NCT00562497|Other|Placebo|Placebo-matching Prochymal® intravenous infusion.
76087411|NCT05315908|Other|Community outreach method|The method includes automated call and text messaging to increase testing for COVID-19
76087412|NCT05315830|Biological|HER2 Tumor Vaccine|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28
75339405|NCT00573378|Drug|PEG-IFN-a2b|Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.
75339406|NCT05334654|Drug|Enoxaparin Sodium|Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according
75339407|NCT05334654|Drug|Bivalirudin|Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
75649596|NCT03912870|Other|Value of Flow Cytometry in Infectious Point of Care|"To validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures. The results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity.~This study is the preliminary study, necessary to determine the detection characteristics of these biomarkers."
75649599|NCT03889249|Drug|Tenecteplase|Stroke Thrombolytic
75339408|NCT03561584|Drug|Sulfasalazine|Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.
75649600|NCT03889249|Drug|Alteplase|Stroke Thrombolytic
75339409|NCT03561584|Drug|Placebo|Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.
75339410|NCT00369512|Drug|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
75339411|NCT03459482|Other|Food Elimination Diet|Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
75339412|NCT05528484|Procedure|ERAS nursing|Patients were given education before surgery, fluid and anesthetic drug management during surgery, early ambulation, fluid management and early feeding after surgery, etc
75339413|NCT05528484|Procedure|non eras nursing|Patients were under the routine management without eras protocol
75473954|NCT01977430|Drug|Hydrochlorothiazide and furosemide|This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
75649601|NCT03841201|Drug|Lenvatinib|oral
75649602|NCT03841201|Drug|Nivolumab|iv infusion
75934703|NCT00562497|Other|Corticosteroid|Administration will be intravenously as prescribed by the caregiver.
75934704|NCT03218540|Procedure|Fluid management protocol|SVV protocol: keep SVV 10-13% and give fluid when SVV > 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP < 8 mmHg
75649603|NCT03814603|Procedure|PET-MR Scan|Participants will undergo PET-MR scans at baseline and two-year follow up to examine brain amyloid deposition longitudinally.
75934705|NCT02548156|Other|Test Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
75934706|NCT02548156|Other|Reference Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
75473955|NCT01977235|Drug|Irinotecan|
75473956|NCT01977235|Drug|Cisplatin|
75649604|NCT03814603|Drug|PiB|Subjects will receive a single dose of 555 MBq of PiB and perform a dynamic 30 min PiB PET-MR scan 60 min after injection.
75649605|NCT03809169|Procedure|Rapid on-site evaluation (ROSE)|Pathologist on site for direct evaluation of specimen adequacy
75649606|NCT03809169|Procedure|Slim bronchoscope without a guide sheath|peripheral endobronchial ultrasound performed with a slim bronchoscope (3.0 mm outer diameter with a 1.7mm channel) combined with a radial ultrasound probe but without the use of a guide sheath.
75649607|NCT03809169|Procedure|Standard pEBUS with guide sheath|Using a flexible bronchoscope with minimal outer diameter of 4.2mm.
75473957|NCT01977443|Drug|APD-209 Eye drops|
75649608|NCT03799276|Other|Opticare study|"Each patient will be evaluated by~An HIV physician~A nurse~A social worker~A psychological therapist~A cultural mediator/member of patients community if needed for migrants~Following these interviews and visits, a multisciplinary team will define for each patient an individualized OPTICARE program based on the following items: clinical, psychological/psychiatric, social status and follow up visits will be planned with the patient.~Regular (Day 15 and monthly) phone calls will be set up during the first six months of the OPTICARE program, to assess the clinical status and ART adherence.~Patients will have their medical, biological and social status assessed through visits at W4, W12, W24, W36 (medical and social status only) and W 48 with all members of the OPTICARE team."
75934707|NCT02548156|Other|Comparator Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
75934708|NCT02548156|Other|Orange Juice|Teeth will be rinsed with orange juice followed by rinsing with de-ionised water in test dentifrice and comparator dentifrice arms.
75934709|NCT02548156|Other|De-ionised water|Teeth will be rinsed with de-ionised water followed by reference dentifrice and followed by rinsing with orange juice in test dentifrice and comparator dentifrice arms.
75473958|NCT01977443|Drug|APD-209 Placebo Eye drops|
75934710|NCT03217994|Drug|gel HP|gel of hygrogen peroxide for teeth bleaching
75934711|NCT00468975|Drug|PF-610,355|
75934712|NCT00468975|Drug|Salmeterol|
75934713|NCT01503515|Drug|Caspofungin Acetate|Given IV
75934714|NCT01503515|Drug|Fluconazole|Given IV or PO
75934715|NCT01503515|Other|Laboratory Biomarker Analysis|Optional correlative studies
75934716|NCT01503515|Drug|Voriconazole|Given IV or PO
75934717|NCT03231566|Behavioral|Pain Neuroscience Education|See arm/group description
75339414|NCT05386134|Device|Adaptive Optics Retinal Camera|The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.
75339415|NCT00324272|Drug|Fibrin Sealant (Tisseel) used in the Experimental Arm.|"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."
75339416|NCT05332158|Behavioral|Questionnaires to report barriers to medication adherence|One questionnaire specific to DOACs and one specific to statins have been integrated within the medical records system and will be sent to eligible patients to respond to following written informed consent.
75339417|NCT00369590|Biological|ziv-aflibercept|Given IV
75339418|NCT00369590|Other|pharmacological study|correlative studies
75339419|NCT00369590|Other|laboratory biomarker analysis|correlative studies
75339420|NCT03367910|Drug|Fecal microbiota transplant|150mL of FMT product RBX2660 delivered via enema
75339421|NCT00324350|Drug|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
75649609|NCT03779841|Drug|AGN-151607|Injections will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
75934718|NCT00468273|Drug|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
75934719|NCT03217916|Diagnostic Test|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information."
75934720|NCT00468117|Procedure|Islet transplantation|
75934721|NCT00468117|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
75473959|NCT01977469|Behavioral|Low intensity resistance training|The LIRT group initiated the resistance training for UL with 30% of the 1RM, with 5% increases each nine sessions; therefore, the maximum load was 45% of the 1RM. The LL training initiated with 30% of the 1RM, increasing 7% each nine sessions, thus, the maximum load was 51% of the 1RM. Each exercise session consisted of three sets of 15 repetitions, with a 2 minutes interval between sets.
75649610|NCT03779841|Drug|Placebo|Injections of placebo will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
75649611|NCT03770273|Biological|sarilumab|sarilumab is a fully human anti-IL-6R(number sign) monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling
75934722|NCT00468117|Biological|Daclizumab or Basiliximab|Daclizumab or Basiliximab will be used for subsequent transplants.
75934723|NCT00468117|Biological|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
75934724|NCT00468117|Biological|Allogenic human purified pancreatic islets|200 ml suspension of allogenic human purified islets
75934725|NCT03231488|Other|Mindfulness intervention|A 10 minute mindfulness of breath exercise
75934726|NCT03231488|Other|Control intervention (unfocused attention)|A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
75473960|NCT01977469|Behavioral|High intensity resistance training|the initial load for HIRT group was 60% of 1RM for UL with 5% increases each nine sessions; therefore, the maximum load reached 75% of the 1RM. The LL training initiated with 60% of the 1RM with 7% increments each nine sessions, as a result, the maximum load after 36 sessions was 81% of the 1RM. These patients underwent three sets of eight repetitions, with two minutes intervals between sets.
75473961|NCT01977469|Behavioral|Aerobic training|Patients underwent an aerobic training in cycle ergometer, with load intensity determined as the same load the patient presented a VO2 value of 70-80% of the peak VO2 obtained in the symptom-limited CPET. Each session of aerobic training lasted 20-30min according to patient's tolerance.
75934727|NCT03217604|Drug|Placebo|Treatment with placebo
75649612|NCT03770273|Other|Placebo|Placebo
75649613|NCT03763552|Other|arthroscopic wrist arthrodesis|Cases of midcarpal wrist arthritis treated surgically with arthroscopic partial wrist fusion with cannulated screws
75649614|NCT03756454|Biological|Bezlotoxumab|Patients receiving Bezlotoxumab post-operatively.
75649615|NCT03756454|Other|Normal Saline|Placebo
75649616|NCT03733535|Drug|Benralizumab|Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
75934728|NCT03217604|Drug|PF-06852231|Treatment with PF-06852231
75934729|NCT03231254|Device|Remotely Controlled Mandibular Positioner (RCMP)|RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
75649617|NCT03733535|Drug|129 Xenon|1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
75339422|NCT00390182|Drug|Gemcitabine|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~**Radiation is the experimental part of the study."
75796749|NCT04549259|Behavioral|Personalized Technology Detailing|Participants will be called by a technology-fluent study staff member, who will assess the current state of their technology literacy, access, and use. Detailing will focus on advancing the participant along the technology use cascade (using the internet, possessing a device and service to access internet at home, using the internet to access their electronic health record and pharmacy services, seeking HIV-related information, and finding social support). Each participant will be provided with personalized assistance based on their local and personal circumstances. Because of the individualized advice provided, there will be a range of contacts between 1 and 5, at customized intervals. Detailing protocols include the option of providing the participant with a tablet including cellular service (for 3 months) when in-home internet service is not available or is cost prohibitive.
75796750|NCT04522050|Drug|Gemcitabine combined with cisplatin induction chemotherapy|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m², d1) every 3 weeks for 2 cycles before radiotherapy. And then intensity modulated radiotherapy (IMRT) is given a total dose of GTVnx 70Gy, GTVnd 66Gy, CTV1 60Gy and CTV2 54Gy for 33 times in total, concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. The patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
75796751|NCT04522050|Drug|concurrent chemoradiotherapy with gemcitabine|followed by concurrent gemcitabine chemoradiotherapy
75339423|NCT05366868|Drug|Imeglimin|Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
75934730|NCT02276079|Behavioral|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 - 0.7 × age).
75934731|NCT02276079|Behavioral|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
75934732|NCT03216824|Other|Dressing|A dressing is maintained on the CVAD exit site.
75339424|NCT05366868|Drug|Metformin|Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
75339425|NCT05366868|Drug|Vildagliptin|Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
75339426|NCT01793246|Device|probe based laser endomicroscopy (pCLE)|pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
75339427|NCT05610774|Drug|Dexmedetomidine|pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).
75339428|NCT05610774|Drug|Saline|pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
75339429|NCT00369746|Drug|citalopram|tablets, 60 mg maximum, daily, 12 weeks
75339430|NCT05366478|Drug|Autologous tumor infiltrating lymphocytes (TILs)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
75649618|NCT03728010|Diagnostic Test|Electrical impedance tomography. Pulmonary mechanics measurement.Arterial gas measurement. Esophageal pressure measurement|After general anesthesia, patients will be ventilated with three tidal volume level (4, 6 and 8 cc / Kg / IBW), in two levels of PEEP, 6 cm2 H20, and best PEEP, the latter obtained after a recruitment maneuver and decremental titration.
75649619|NCT03719092|Dietary Supplement|Vitamin A Compound|Given PO or enterally
75649620|NCT03661385|Drug|Nitric Oxide|Addition of nitric oxide 20ppm into bypass circuit
75649621|NCT03638453|Other|PediCARE|PediCARE provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through RideHealth).
75934733|NCT03216824|Other|No-Dressing|The CVAD exit site is not covered with a dressing.
75934734|NCT00468039|Drug|vildagliptin + metformin|
75339431|NCT00392054|Procedure|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
75934735|NCT02451254|Procedure|circumferential ablation|circumferential ablation of the pulmonary veins
75339432|NCT00392054|Drug|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
75339433|NCT02525874|Drug|dimethyl fumarate|Initial oral dose for 7 days with maintenance dose thereafter
75339434|NCT05288036|Other|Proprioceptive Neuromuscular Rehabilitation group|The PNF technique was performed in the supine position with the hip joints of the patients in 30° flexion and the lower extremities in semi-flexion. The application was performed in 2 different diagonal and 4 different patterns (flexion-abduction-external rotation/extension-abduction-internal rotation, and flexion-adduction-external rotation/extension-abduction-internal rotation) of the upper extremity. When starting the exercise, the muscles were first brought to their longest position and the patient was asked to move in the direction of the pattern with resistance (concentric contraction) and to maintain this position for 6 seconds at the end of the pattern (isometric contraction). Then, while the therapist was taking the patient's arm to the starting position, the patient was asked to prevent movement (eccentric contraction). All of these moves counted as one repetition. 3 sets of 8-12 repetitions were performed for each pattern.
75649622|NCT03638453|Other|Usual Care|Standard care per hospital guidelines.
75649623|NCT03630055|Drug|Rivaroxaban 15 MG Oral Tablet [Xarelto]|Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
75796752|NCT04481048|Drug|N-Acetyl cysteine|Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).
75796753|NCT04481048|Other|Placebo|Eight (8) weeks of treatment with placebo.
75796754|NCT04479787|Device|Spinal Cord Stimulation|Utilization of BURSTDR stimulation
75796755|NCT04479787|Other|Conventional Medical Management|Assessing type of CMM, location and frequency.
75649624|NCT03618667|Drug|GC1118|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
75796756|NCT04456569|Device|Geniculate Artery Embolization|All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.
75796757|NCT04428580|Other|Online FBT Training|Therapists will receive online training in Family-Based Treatment (FBT)
75473962|NCT01977495|Behavioral|Financial Incentive: Fixed Lottery|Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.
75796758|NCT04428580|Other|Webinar FBT Training|Therapists will receive webinar training in Family-Based Treatment (FBT)
75796759|NCT04421989|Behavioral|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
75473963|NCT01977508|Device|ePTFE vascular access grafts|
75649625|NCT03617731|Drug|Lenalidomide|25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
75473964|NCT01977521|Device|Eldith DC Stimulator stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.
75649626|NCT03617731|Drug|Bortezomib|all arms: 1,3 mg/m^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
75649627|NCT03617731|Drug|Dexamethasone|20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
75649628|NCT03617731|Drug|Isatuximab|10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
75796760|NCT04421989|Other|Support Group|Participants randomized to FBT + Support Group parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The support group will have a facilitator introduce each topic weekly and parents will discuss. The facilitator's role is to ensure the group remains on topic and on time. Weekly discussion topics include: co-morbid medical diagnoses, understanding levels of care in treatment, taking time off from work, and medications.
75796761|NCT04410133|Drug|18F fluciclovine|18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
75796762|NCT04392843|Other|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
75796763|NCT04392843|Other|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
75796764|NCT04377971|Behavioral|SOC education|Standard participant education from researcher
75796765|NCT04377971|Behavioral|Ask-tell-ask education|Participant education using the ask-tell-ask method. First the researcher will ask a question about participant understanding of wound care and after hearing the participant's answer, the researcher will then proceed to tell the patient how to best take care of their wound using a standardized script. After the educational portion, the researcher will then ask the patient to repeat the information that was shared. If the participant's answer is wrong or incomplete, the researcher will then explain the instructions again to ensure that the participant understands the steps needed.
75934736|NCT02451254|Device|SVT ablation|SVT ablation
75934737|NCT02451020|Other|Altitude exposure|Participants will stay for 3 weeks at an altitude of 3200 m
75934738|NCT03224702|Drug|M6495|Subjects will receive M6495 on Day 1
75934739|NCT03224702|Drug|Placebo|Subjects will receive placebo matched to M6495 on Day 1
75934740|NCT02742519|Drug|ivacaftor|
75934741|NCT02742519|Drug|Placebo|
75934742|NCT01375010|Drug|Vitamin D3|2000 mg QD
75339435|NCT05288036|Other|Progressive Resistance Exercise Group|"Strengthening exercises targeting the upper extremity main muscles were applied to the PRE group with progressive resistance. Dumbbells and sandbags were used as resistance equipment. resistance intensity; 50-80% of a repetition maximum (RM) was determined according to the patient's tolerance. The exercises were applied as 8-12 repetitions and 3 sets. A rest period of 60-90 seconds was allowed between each set. After the 4th week of the training, 1 RM was measured again and the resistance density was updated. The 8 strengthening exercises to be applied were created by taking examples from the literature and in accordance with the Guidelines for implementing exercise programs exercise programs for cancer patients. These exercises are: dumbbell fly, triceps extension, biceps curl up, one-arm bent over row, dumbbell sides rise, lifting the arm forward, wrist curl and side lying shoulder internal -external rotation."
75339436|NCT05288036|Other|Control Group|The patients in the control group were instructed to continue their usual daily lives (not changing their physical activity levels, diet, drug use, etc.) until the date of re-evaluation after the initial evaluation. Information was given about the upper extremity normal range of motion exercises that they could apply at home, and a brochure was given.
75339437|NCT05287880|Diagnostic Test|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
75339438|NCT05287880|Diagnostic Test|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
75339439|NCT05329662|Biological|Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency|"Patients in the two groups will receive two autologous AD-MSC administrations: the group A on day 0 and day 90 ± 7; the group B on day 180 ± 14 and day 270 ± 14.~Dose: 1.0 x 106 cells/kg patient bodyweight.~Route: intravenous infusion~ADSCs were collected after the third passage. On the day of transplantation, the ADSCs were harvested, washed twice with NaCl 0.9%, counted and resuspended in NaCl 0.9% in a total volume of 20 ml. Each participant received a dose of 1x10^6 cells/kg body weight infused through the intravenous route within 30 minutes before being discharged after 24 hours"
75339440|NCT05287802|Other|Balance and proprioception exercises|Balance and proprioception exercises using two different methods (classical balance training and Biodex) in addition to strengthening exercises
75339441|NCT05287802|Other|Home exercises program|Isometric exercises for the quadriceps and hamstrings at home
75339442|NCT05329428|Dietary Supplement|Vitamin D Supplementation 20 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week <15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 20 µg (800 IE), are taken daily throughout pregnancy.
75339443|NCT05329428|Dietary Supplement|Vitamin D Supplementation 40 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week <15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 40 µg (1600 IE), are taken daily throughout pregnancy.
75339444|NCT05329428|Other|Usual Antenatal Care|In early pregnancy (gestational week <15) women are advised by the regular midwife to take a daily supplement of Vitamin D throughout pregnancy, according to usual antenatal care routines.
75649629|NCT03614819|Procedure|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
75339445|NCT01794572|Drug|Melphalan|Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
75796766|NCT04377971|Other|Participant satisfaction survey|Participant satisfaction survey using components of the 16 item Skindex questionnaire and the 18 item version Patient Satisfaction Survey, adapted for treatment of skin cancer to characterize patient experience administered at two weeks post-operatively in person
75339446|NCT01794572|Biological|Autologous Hematopoietic Stem cell|"Autologous Peripheral Stem Cell Rescue : 2.5 10^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication."
75339447|NCT05385666|Other|collaborative cares|coordinate care between city medicine and specialized psychiatric care to improve the management of common mental disorders
75339448|NCT01794650|Dietary Supplement|Meal composition|
75339449|NCT00392444|Drug|sunitinib malate|Given orally
75339450|NCT02528214|Drug|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
75473965|NCT01977521|Device|Eldith DC Stimulator sham stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
75796767|NCT04377971|Other|Wound care adherence survey|Wound care adherence survey administered at one week over the phone and at two weeks in person
75796768|NCT04357587|Drug|Pembrolizumab|200 mg intravenously (IV) on days 1, 22, and 43
75796769|NCT04357587|Radiation|External beam radiation|Daily fractions of 200 cGy, 5 days a week for the first 5 weeks of the study, excluding weekends
75796770|NCT04357587|Drug|Capecitabine|825 mg/m2 orally twice a day on days where radiation therapy is given
75934743|NCT01375010|Other|Placebo|An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
75339451|NCT02528214|Drug|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
75796771|NCT04352244|Procedure|Fat biopsy|"The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep).~Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis."
75796772|NCT04352244|Diagnostic Test|Blood sampling|A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).
75796773|NCT04352244|Genetic|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.
75796774|NCT04315363|Behavioral|Motivational MRI and Behavioral Intervention|Motivational messaging delivered during a functional brain MRI scan and with daily messaging
75339452|NCT02528214|Drug|Oral corticosteroid therapy (prednisone/prednisolone)|Oral administration.
75339453|NCT02528214|Drug|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
75339454|NCT02528214|Drug|Albuterol/Salbutamol|Oral inhalation as needed.
75473966|NCT01977534|Device|Absorb BVS|The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating [formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating].
75796775|NCT04315363|Behavioral|Control MRI and Behavioral Intervention|Control messaging delivered during a functional brain MRI scan and with daily messaging
75796776|NCT04285658|Procedure|Ureteroscopy|An outpatient endoscopic surgery that accesses the ureters and kidneys per the urethra to fragment and remove the stones. Many patients who undergo ureteroscopy (URS), Shockwave lithotripsy (SWL), or percutaneous nephrolithotomy (PCNL) also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
75796777|NCT04285658|Procedure|Percutaneous Nephrolithotomy|A minimally invasive surgery in which a ~1cm flank incision is made, and a scope is passed through a tubular sheath into the kidney to fragment and remove the stone. There is typically a 1- to 2-day hospital stay. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
75796778|NCT04285658|Procedure|Shock Wave Lithotripsy|A non-invasive outpatient procedure that targets stones in the kidney or ureter with x-ray or ultrasound and uses shockwaves generated outside the body to fragment them; the fragments pass down the ureter and the patient expels them in the urine. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
75796779|NCT04269408|Drug|Nicardipine|10 NicaPlant® implants releasing 4 mg nicardipine each.
75473967|NCT01977586|Other|Magnetic Resonance Imaging (MRI)|
75934744|NCT01375010|Drug|Vitamin Supplements|Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
75934745|NCT03231332|Other|Microbiome Diversity detection|detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
75934746|NCT00548925|Drug|ABT-894|6 mg BID tablets, 8 weeks of treatment
75934747|NCT00548925|Drug|placebo|BID tablets, 8 weeks of treatment
75934748|NCT03231176|Drug|Varlitinib|oral tablets, twice daily
75934749|NCT03231176|Drug|Capecitabine|oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
75473968|NCT01977664|Other|no intervention|
75473969|NCT01977703|Other|Ultra Conservative ICD Programming|
75934750|NCT02276235|Device|Catgut embedding group|"An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
75339455|NCT02528214|Drug|Levalbuterol/Levosalbutamol|Oral inhalation as needed.
75339456|NCT00392678|Drug|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
75339457|NCT00392678|Drug|Placebo|Placebo to Salsalate
75339458|NCT05610540|Device|TECNIS Synergy IOL|Implanted in one eye
75339459|NCT05610540|Device|AcrySof PanOptix Trifocal IOL|Implanted in one eye
75339460|NCT05902299|Drug|Antibiotic|Evaluate the choice of antibiotic therapy prescribed for P. aeruginosa ou S. aureus infection
75473970|NCT01977703|Other|Traditional ICD Programming|
75473971|NCT01977742|Other|Supervised exercise program|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
75473972|NCT01977742|Other|Supervised exercise program together with a specific sudden rest-exercise training protocol|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
75473973|NCT01977755|Drug|danegaptide|
75473974|NCT01977755|Drug|Placebo|
75473975|NCT01977768|Biological|V7|One pill of V7 once daily for 30 days together with standard of care TB drugs
75473976|NCT01977768|Biological|Placebo|
75934751|NCT02276235|Device|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
75339461|NCT05902286|Behavioral|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
75934752|NCT02450942|Drug|18F-FDS|18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
75934753|NCT00467025|Drug|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
75339462|NCT05902286|Behavioral|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
75934754|NCT00467025|Drug|Sorafenib|400 mg PO BID
75934755|NCT00467025|Drug|AMG 386 placebo IV|AMG 386 placebo IV
75473977|NCT01977807|Device|Proscan, Zyoptix and Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
75473978|NCT01977833|Other|High Calorie Breakfast (BTdiet)|High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
75649630|NCT03614819|Procedure|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
75649631|NCT03580109|Other|Immediate spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
75649632|NCT03580109|Other|Late spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
75649633|NCT03579563|Other|Audiologist-based fitting|Hearing aids will be fitted by audiologists using established procedures.
75934756|NCT02276469|Behavioral|peer support|peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
75934757|NCT03231020|Other|Interview|"The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period."
75934758|NCT02277795|Device|AccuCirc|Circumcision with the use of the AccuCirc device.
75934759|NCT00546585|Biological|Influenza A/H7N7 Vaccine|Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
75934760|NCT00546585|Drug|Placebo|Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
75934761|NCT03230786|Drug|Daily injection of KBP/placebo for 12 weeks as add-on to metformin|Daily subcutaneous injection
75934762|NCT02282397|Device|Continuous Glucose Monitor|RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
75649634|NCT03579563|Other|Over-the-counter fitting|In this group, pre-configured Hearing aids will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
75649635|NCT03579563|Other|Hybrid fitting|Audiology professionals provide streamlined services to fit pre-configured amplification devices.
75796780|NCT04269408|Other|Standard of care|Both arms receive the usual standard of care.
75799010|NCT01588080|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
75934763|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
75339463|NCT05902273|Diagnostic Test|hemodynamic monitoring|Baxter Starling Monitor for measuring cardiac output and systemic vascular resistance (SVRI) which is using bioreactance technology. We need to place four electrodes on chest wall (upper left, upper right, down left, down right) and input monitor demographic parameters. Also enter mean arterial pressure (MAP) for calculating SVRI so we input MAP every minute.Patient bed set as 45 degree head elevated and legs 0 degree. Just after start measuring, monitor needs to synchronize itself for patient. After synchronisation we start fluid challenge with passive leg raising option. This test has two stages. First stage calculating baseline parameters which takes 3 minutes and second stage is measuring difference with fluid challenge which also takes 3 minutes. At the end of first stage monitor shows to perform passive leg raise and we perform trendelenburg maneuver till head comes to 0 degree. After second stage measurement has finished.
75934764|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
75934765|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
75934766|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
75934767|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
75934768|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
75649636|NCT03578510|Device|Hemocontrol hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
75934769|NCT00546273|Biological|RUTI|dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
75934770|NCT00546273|Biological|RUTI|dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
75934771|NCT00546273|Biological|RUTI|dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
75339464|NCT05902273|Diagnostic Test|resistive index|We use ultrasonography at the same time with cardiac output monitor in both stages. First we determine the location of radial artery at wrist snuffbox at 1.5 centimeters depth with linear probe and confirm pulsatile flow with color mode. In Starling's baseline stage we measure and calculate resistive index with doppler P-mode in triplex setting 3 times. When received 3 same result successively we noted as SBRI-1. Second measurement is initiated at last 30 seconds of passive leg raising as described before and we noted our measurement as SBRI-2
76087413|NCT05315830|Biological|HER2 Tumor Vaccine+ Standard of Care chemotherapy|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28 Standard of Care Chemotherapy cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle) or other standard of care chemotherapy
75339465|NCT05902273|Diagnostic Test|Pleth variability index|During all stages Masimo Rad-87 rainbow probe is placed patients index or middle finger and we note PVI-1 and PVI-2 at the same time with SBRI-1 and SBRI-2
75649637|NCT03578510|Device|Standard hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.
75649638|NCT03532828|Other|polysomnography|Patients will have a polygraphy, a postural evaluation including Vicon system, EOS imaging, ang a force platform
75649639|NCT03523325|Other|Exercise treatment|Treatment protocol is an exercise program consisting of four different phases (Silbernagel protocol). The progression consists of increasing number of repetitions, resistance, speed and range of motion of the exercises. A pain-monitoring model is used to adjust the exercise loads and progression through the four phases.
75649640|NCT03503123|Device|Monitoring physiology with Electrical Impedance Tomography, Electromyography and transcutaneous carbon dioxide measurements.|Both groups get the same exposures: with measure physiology in both groups by using non-invasive measurement techniques. The techniques we use are Electrical Impedance Tomography to determine degree of hyperinflation. We use Electromyography to analyse respiratory drive. We measure transcutaneous carbon dioxide to assess the effects of non-invasive ventilation. Thereby, we will perform lung function tests.
75339466|NCT05902260|Dietary Supplement|Nutritional intervention|Subjects should consume two 200 mL bottles of study product per day next to their cancer treatment (immunotherapy)
75649641|NCT03493789|Drug|Fludeoxyglucose F-18|Given IV
75934772|NCT00546273|Biological|RUTI|dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
75934773|NCT00546273|Biological|placebo of the vaccine RUTI|placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
75934774|NCT02452112|Drug|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
75934775|NCT02452112|Drug|Placebo|Placebo patch to be placed on the site of pain
75934776|NCT00659061|Dietary Supplement|SPRINKLES|"Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).~Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services."
75934777|NCT00659061|Behavioral|Nutrition education|Nutrition education will be provided by LHWs as per their regular routine monthly door to door community services
75934778|NCT02451956|Drug|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
75339467|NCT05902260|Drug|Immunotherapy|Pembrolizumab monotherapy with or without combination chemotherapy according to standard of care
76087414|NCT05464056|Behavioral|Be Unstoppable in Life Together (BUILT)|Participants will complete weekly sleep, food, and exercise home challenges focused on creating sustainable healthy eating, sleep, and exercise routines. Parents will participate in weekly support calls by UIC and Chicago Park District staff to provide support and accountability. Children will have the opportunity to win small prizes based on completing weekly challenges. The intervention will be co-facilitated by UIC students and Chicago Park District staff and will largely take place on-line. For additional details visit: https://built.ahs.uic.edu.
75339468|NCT05902247|Radiation|Radionuclide Therapy|To evaluate the tolerability and safety of 225Ac-PSMA I&T in patients with metastatic prostate cancer
75339469|NCT05902221|Drug|amoxicillin or moxifloxacin|Antibiotic treatment back bone during 12 weeks
75934779|NCT02451956|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
75934780|NCT02725372|Drug|Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
75934781|NCT02725372|Drug|Placebo|Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
75934782|NCT00542685|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
76087415|NCT03322956|Other|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
76087416|NCT04442568|Other|ERAS|early mobilisation, early oral intake, early discharge
76087417|NCT04716322|Behavioral|Adapted Physical Activity|A 16-week health-adapted physical activity program, individualized from baseline evaluation of participants including the specificities of their pathologies
76087418|NCT03109236|Drug|GCSF|5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.
75649642|NCT03493789|Procedure|Positron Emission Tomography (PET)|Undergo FDG-PET
75934783|NCT00542685|Drug|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
76087419|NCT03109236|Procedure|CD133 Cells Transplantation|Endothelial progenitor cells are harvested by CD133+ MACS (magnetic activated cell sorting) sort selection of bone marrow and a minimum of 1x 10^6 and up to 50-100 x 10^6 cells are transplanted to one lobe of the liver via a percutaneous catheter inserted into the portal venous system by percutaneous transhepatic approach for engraftment.
76087420|NCT05463822|Drug|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
75649643|NCT03493789|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
75339470|NCT05902221|Drug|amoxicillin or moxifloxacin + rifampicin|Antibiotic treatment back bone during 12 weeks + rifampicin
75339471|NCT05902195|Behavioral|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
75934784|NCT00542685|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
75934785|NCT00542685|Drug|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
75934786|NCT02450786|Drug|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
75339472|NCT05902195|Other|Usual care|Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
75339473|NCT05902182|Device|ConvaFoam|ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings are designed to provide a moist wound healing environment and removing dead-space between the wound and dressing interface. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. In addition, the dressings are designed to protect fragile skin from moisture, shear, and friction damage. These will be used in line with the patients pressure injury mitigation protocol for a 2 week period, with daily inspections of the skin area.
75339474|NCT05902169|Device|SonoCloud-9 (SC9)|Implantation of SC9 device and repeat activation at constant acoustic pressure
75473979|NCT01977833|Other|High Caloric Dinner (DTdiet)|High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
75473980|NCT01977859|Drug|Nesiritide|
75473981|NCT01977859|Drug|Saline|
75649644|NCT03479957|Behavioral|REMOTE-CR|The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link. Remotely monitored exercise training sessions will be offered monday-friday 13.00-16.00.
75934787|NCT03214718|Diagnostic Test|Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day|"For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
75934788|NCT03214718|Diagnostic Test|Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day|"For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
75934789|NCT00539721|Drug|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
75473982|NCT01977872|Behavioral|A worksite activity-diet intervention|
75473983|NCT01977885|Behavioral|High Protein Diet|All participants will be individually counseled by an RD for ~ 4 sessions (30 to 60 minutes)to meet weight loss goals. During the duration of the study, participants will be required to attend a 30 to 60 minute group educational/motivational meeting weekly (first 1 to 2 months) and then biweekly (for the remainder of the study). Diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). This combined with reducing energy from carbohydrates and fat from other sources will create an overall energy deficit of 500 kcal/day. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit
75649645|NCT03479957|Other|Control|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care)
75796781|NCT04247620|Behavioral|DiaBetter Together|Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult, including (a) teaching and modeling strengths-based skills for goal-setting, problem-solving, and stress management; (b) guiding participants in obtaining support from their social support network (e.g., family, friends); (c) developing a plan for accountability around diabetes management and follow-up in adult care; (d) sharing his/her transition experiences and strategies for successfully navigating the adult healthcare system; (e) discussing how to prioritize diabetes self-care; and (f) assisting them in accessing diabetes-related resources (e.g., local diabetes groups, apps, social media). Contact will be in-person, by phone, email, text message, and/or video, approximately weekly for first 3 mos, approximately biweekly for next 3 mos, and approximately monthly for last 6 mos (while COVID-19 safety recommendations are in place, in-person meetings will not occur).
75796782|NCT04247620|Behavioral|Peer Mentor Delivery|Peer Mentors deliver the intervention to multiple young adult participants, each for 12 months. Peer Mentors may take on one or more participants at a time, and Peer Mentors may stay in their role in the study (delivering the intervention) for 1-3 years.
75649646|NCT03439124|Drug|ceftobiprole medocaril|"Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole).~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment."
75934790|NCT00539721|Drug|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
75934791|NCT00539721|Drug|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
75934792|NCT00539721|Drug|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
75934793|NCT00539721|Drug|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
75934794|NCT00539721|Drug|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
76087421|NCT04639960|Drug|Risperdal|Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.
75796783|NCT04225624|Behavioral|Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based AR-ERT. This intervention aims to build attention regulation skills (i.e., the ability to flexibly shift and sustain attention) by teaching participants exercises for Orienting their attention and Allowing the presence of negative emotions. Participants are taught to apply these skills to counteract reactive perseverative thinking when negative emotions arise as well as proactively engage with emotion-laden situations that trigger repetitive negative thinking.
75934795|NCT03224780|Diagnostic Test|maternal serum creatine kinase|Biochemical marker
75934796|NCT03224780|Diagnostic Test|3D Doppler ultrasound|Doppler for placental vessels
75934797|NCT00464061|Drug|Volinanserin|oral administration
75796784|NCT04225624|Behavioral|Supportive Psychotherapy (SPT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based SPT. This intervention addresses factors that may affect participants' repetitive negative thinking symptoms (for example, relationships, work, stress), and teaches skills for managing challenges by improving self-esteem and positive coping skills.
76087422|NCT04639960|Drug|Placebo|Twelve weeks of placebo treatment.
75339475|NCT05902169|Drug|Carboplatin|"Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x [glomerular filtration rate (GFR) mL/minute + 25]."
75339476|NCT05902169|Drug|Lomustine|Dosed and administered per labelling.
75339477|NCT05902169|Drug|Temozolomide|Dosed and administered per labelling.
75796785|NCT04209634|Drug|Pozelimab|Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
75934798|NCT00464061|Drug|Placebo|oral administration
75934799|NCT03230630|Diagnostic Test|plasma melatonin levels|
75934800|NCT00460941|Drug|Placebo|sc weekly
75934801|NCT00460941|Drug|Taspoglutide 20mg|sc weekly
76087423|NCT03320616|Drug|EYP001a|Oral EYP001a capsules - 100 mg strength
76087424|NCT04597996|Other|web based education for students|"Web-based education will include modules on the following subjects;~Mental health literacy knowledge level~Improving help-seeking behavior~Avoiding self-stigmatization in seeking psychological help"
76087425|NCT03109314|Drug|Donepezil|Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.
76087426|NCT03109314|Behavioral|Single-letter training|Subjects will undergo training to identify single letters (10,000 trials, or 10 blocks per session for 10 sessions).
75339478|NCT05902091|Behavioral|Neurophysiology-based intervention|
75339479|NCT05902078|Drug|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
75339480|NCT05902078|Drug|Calcitriol capsules|Oral calcitriol 0.5μg daily
75796786|NCT04184401|Drug|Ascites replacement with albumin and hartmann's solution|"Combined strategy for ascites replacement~30% of ascites: replacement with 5% albumin~40% of ascites: replacement with Hartmann's solution"
76087427|NCT03109314|Behavioral|Uncrowd training|Subjects will undergo training to identify letters closely flanked by other letters (10,000 trials, or 10 blocks per session for 10 sessions).
75934802|NCT00460941|Drug|Taspoglutide 20mg-30mg|sc weekly
75934803|NCT00460941|Drug|Taspoglutide 20mg-40mg|sc weekly
76087428|NCT04566016|Procedure|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
75339481|NCT05902065|Device|AVR Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill with AVR applications. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. The patient will be supervised by a physical therapist and asked not to use lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance. Progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'; progression in difficulty: the protocol has 5 levels for each AVR application, and the transition among levels will be set at 80% success achievement.
75934804|NCT03224078|Other|data extraction|No Special interventions except from data extraction form the respective routine data sources are planned .
75473984|NCT01977885|Behavioral|Exercise|Participants will be prescribed a supervised exercise program with required attendance of 3 nonconsecutive days per week (75 minutes each session). A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. With specific regard to strength training, 50% of the resistance work will involve primary muscle groups of the lower body with the main focus being the gluteal and quadriceps groups (squats, lunges, etc.). The remaining 50% of work will dedicate 25% to the core stabilizers with the final 25% being the upper body. Transitions between segments of training will be used for recovery and social support enhancement. Note that all aspects of the exercise intervention will be progressive in intensity (i.e., starting at lower end of intensity or ~50% of maximal capacity), and duration (i.e., from 15 minutes to 35 minutes of exercise and adding a few minutes each session).
75649647|NCT03439124|Drug|IV standard-of-care cephalosporin|"Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days.~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.~At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
75934805|NCT03213782|Other|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
75934806|NCT00460317|Drug|AMG 706|125 mg QD orally every day
75934807|NCT00460317|Drug|placebo|125 mg QD orally every day
75934808|NCT00460317|Drug|paclitaxel|200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
76087429|NCT03320538|Other|Hou Gu Mi Xi|Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).
76087430|NCT03320538|Other|Placebo|The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
75649648|NCT03429803|Drug|DAY101|28 day cycle, oral, once per week
75649649|NCT03405025|Procedure|Endoscopic ultrasound guided radiofrequency ablation|To establish if radiofreuqency ablation of aldosterone producing adrenal adenomas can be carried out via the endoscopic route and to assess safety of the procedure.
75649650|NCT03405025|Device|ultrasound|ultrasound
76087431|NCT03320538|Drug|Rabeprazole|Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
76087432|NCT03322878|Drug|Magnesium SO4|The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
75649651|NCT03393741|Drug|Taxane|Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
75649652|NCT03393741|Drug|Vinorelbine|Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
75796787|NCT04184401|Drug|Ascites replacement with hartmann's solution|"Hartmann's solution only strategy for ascites replacement~- 70% of ascites: replacement with Hartmann's solution"
75796788|NCT04155749|Drug|CART-ddBCMA|Chimeric Antigen Receptor T cells
75796789|NCT04155749|Drug|ARC-T Plus Anti-BCMA SparX|Chimeric Antigen Receptor T cells plus SparX protein
75934809|NCT00460317|Drug|carboplatin|AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
75934810|NCT03230552|Other|Instructional surgical video|An instructional surgical video shown to residents before they perform LSO surgery.
76087433|NCT03322800|Drug|AK0529|Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
76087434|NCT03322800|Other|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
75796790|NCT04145843|Procedure|endoscopic retrograde cholangiopancreatography|ERCP is a procedure that enables the physician to examine the pancreatic and bile ducts and remove gallstones.
75796791|NCT04126486|Other|Zio®XT Monitor|A Zio® XT monitor will be affixed to the participant's chest
75796792|NCT04122170|Drug|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
76087435|NCT03325998|Device|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
75796793|NCT04122170|Drug|Aspirin (ASA) Oral Tablet - Pre-Treatment|Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
75796794|NCT04122170|Drug|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion."
75796795|NCT04122170|Drug|Placebo (0.9% Sodium chloride) infusion|0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
75796796|NCT04113499|Procedure|Direct Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes."
75339482|NCT05902065|Device|Conventional Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill without AVR applications, walking on the treadmill. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. All sessions will be supervised by a physical therapist, who will give guidance and standardized cues on walking patterns (e.g., step length). The patient will be asked not to use the lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance: progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'.
75649653|NCT03393741|Drug|Ixabepilone|Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
75936579|NCT00702338|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
75936580|NCT00702338|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
75936581|NCT00702338|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
75936582|NCT03184688|Procedure|platelet rich plasma|Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.
75649654|NCT03393741|Drug|Eribulin|Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
75649655|NCT03393741|Drug|Chemotherapy|Chemotherapy is used to treat various stages of breast cancer.
75649656|NCT03304093|Drug|Nivolumab Injection|Nivolumab 3mg/kg every 2 weeks
75649657|NCT03289052|Device|Restylane Volyme|Subcutis injection
75796797|NCT04113499|Procedure|Step-up Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention)."
75796798|NCT04074252|Device|Lofstrand Crutches|Device: Set of Lofstrand Crutches
75796799|NCT04074252|Device|Axillary Crutches|Device: Set of Axillary Crutches
75936583|NCT03184688|Drug|Normal saline|Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
75936584|NCT02428010|Device|TMVR Implant|Implantation of the Twelve TMVR System
75936585|NCT02427932|Drug|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
75936586|NCT02427932|Drug|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
75936587|NCT02427932|Drug|Gentamicin|Prescribed to non-pregnant participants
75936588|NCT04678193|Drug|Coromec Registry with ECL-19|Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
75936589|NCT03626519|Other|Test with Menthol|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
75796800|NCT04062396|Device|Eurosets REMOWELL 2 oxygenator|The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
76087436|NCT03325920|Device|DIABRUX|All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.
75934811|NCT03213548|Procedure|Alar facial groove incision|All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
76087437|NCT03320460|Drug|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
76087438|NCT03320460|Device|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
75796801|NCT04062396|Device|LivaNova INSPIRE oxygenator|INSPIRE oxygenator has no filtration system for extracavitary inlet
76087439|NCT03320460|Other|Placebo gel|Placebo gel for 30 consecutive days to mask the treatment
76087440|NCT03320460|Other|Placebo Photobiomodulation|Laser device will be positioned over the lesion but will be switched off to mask the treatment.
76087441|NCT03325764|Other|functional assessment|assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
76087442|NCT02488434|Device|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
75339483|NCT05902039|Other|MRI|All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2*-weighted gradient echo (T2*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
75339484|NCT05902013|Device|laryngoscopy|laryngoscopy for nasotracheal intubation
75339485|NCT05901948|Other|Classification|Novel Asherman Scoring Classification
75339486|NCT05901935|Drug|DP303c|DP303c injection, 3.0 mg/kg, Q3W.
75339487|NCT05901935|Drug|Trastuzumab|IV, 6 mg/kg, D1, Q3W
75339488|NCT05901935|Drug|Vinorelbine Tartrate|IV, 25 mg/m^2，D1、D8，Q3W
75796802|NCT04010214|Other|No intervention|No intervention
75339489|NCT05901935|Drug|Capecitabine tablets|PO 1000 mg/m^2, bid, D1-D14, Q3W
75339490|NCT05901922|Behavioral|Social skills training|In this training, role-playing will be done in groups of six. In these role playing, the importance and application of the social skill specified before the session will be studied.
75473985|NCT01977911|Other|Stem cell based tissue engineered partial laryngeal implants|Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
75649660|NCT03263117|Drug|Sedation|"The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist."
75796803|NCT03997266|Drug|Ampicillin|Intravenous ampicillin
75796804|NCT03997266|Drug|Gentamycin|Intravenous gentamycin
75796805|NCT03997266|Drug|Normal saline|Intravenous normal saline
75796806|NCT03959293|Drug|Durvalumab|1500 mg by 1-hour IV infusion - Every 4 weeks
75796807|NCT03959293|Drug|Tremelimumab|75 mg by 1-hour IV infusion - Every 4 weeks
75796808|NCT03959293|Drug|FOLFIRI Protocol|"Irinotecan: 180 mg/m² by 2-hour IV infusion,~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
75796809|NCT03952234|Drug|L-Citrulline|To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
75339491|NCT05901857|Diagnostic Test|convolutional neural network|A deep learning model for dental age classification from panoramic images
75796810|NCT03915951|Drug|encorafenib|self-administered orally
76087443|NCT01746784|Drug|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
75339492|NCT05901844|Diagnostic Test|Paraffin pathological diagnosis|Perform two diagnostic methods on the same sample
75339493|NCT05901805|Other|questionnaire application|"Participants will be asked to fill in the Occupational Sitting and Physical Activity Questionnaire adapted into Turkish. Correlation of the scale with the International Physical Activity Questionnaire-Short Form, VAS and YİBT-SF, Buss-Perry Aggression Scale will be tested. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
75473986|NCT01977924|Dietary Supplement|one month polyphenols supplementation (600mg)|
75473987|NCT01977924|Dietary Supplement|placebo (microcrystalline cellulose)|
75796811|NCT03915951|Drug|binimetinib|self-administered orally
76087444|NCT01746784|Drug|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
76087445|NCT04493970|Other|High School Students Survey|To assess retention, effectiveness and factors impacting comprehension of cardiopulmonary resuscitation (CPR) training among high school students.
76087446|NCT04513678|Behavioral|ImmunOncoTool Condition|Immunotherapy education + irAE monitoring + Facilitation of patient-provider communication
75473988|NCT01977976|Procedure|Endometrial aspiration by pipelle|Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
75473989|NCT01977989|Drug|Vancomycin Powder|For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
75473990|NCT01978002|Behavioral|Pain sensitivity testing|
75473991|NCT01978002|Behavioral|Urodynamic testing|
75796812|NCT03903705|Drug|Fruquintinib in Combination with Sintilimab|"Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2weeks on/1 weeks off + Sintilimab 200mg Q3W, intravenous dosing~Cohort E: Fruquintinib 3 mg QD, continuous, oral dosing, + Sintilimab 200mg Q3W, intravenous dosing~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
75796813|NCT03902873|Other|Real-time audiovisual feedback|During the chest compressions, doctors receive audiovisual feedback on the depth and speed of the appropriate chest compressions.
75796814|NCT03837392|Diagnostic Test|Baseline Assessment (18-26 weeks pregnant)|At baseline, participants will complete several interviews and questionnaires online and via phone to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables.
75796815|NCT03837392|Behavioral|Online Intervention and Phone Coaching Interventions|ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The active comparator is the Supportive Control. Two phone coaching sessions will occur 2- and 4-weeks post-intervention in both conditions.
75796816|NCT03837392|Diagnostic Test|Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum|The follow-up assessments at 34-36 weeks pregnancy and 4-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.
75796817|NCT03837392|Diagnostic Test|Follow Up Assessments: 8 weeks postpartum|The follow-up assessment at 8-weeks postpartum will be completed via phone.
75796818|NCT03793621|Drug|BI 730357|single rising oral dose
75796819|NCT03793621|Drug|Placebo|single rising oral dose
75796820|NCT03782987|Drug|BI 730357|0 mg BI 730357 tablet orally on Day 1
75934812|NCT03213548|Procedure|Alar facial groove spared|The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
75934813|NCT00534027|Drug|AMG 655|AMG 655 is a monoclonal antibody directed against TR-2.
75934814|NCT00534027|Other|AMG 655 placebo|Inactive dummy AMG 655 (to maintain blind)
75934815|NCT00459693|Drug|[11C]PBR28|
75934816|NCT02450864|Other|ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
75934817|NCT02451878|Behavioral|E-Couch|e-couch is an online CBT based intervention
75934818|NCT03230942|Other|Pre-operative education|Verbal and booklet about symptoms and physical conditions pos knee replacement
75934819|NCT03230942|Other|Pos-operative rehabilitation|Physical therapy treatment
75934820|NCT02284191|Radiation|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
75934821|NCT03212846|Other|Hippotherapy|Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
75934822|NCT02548078|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administered intramuscular
75934823|NCT02548078|Biological|Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine|A single dose administered intramuscular
75473992|NCT01978015|Drug|travoprost and timolol maleate fixed combination|travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
75473993|NCT01978015|Drug|latanoprost and maleate timolol fixed combination|Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
75934824|NCT00532311|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
76087447|NCT04507360|Behavioral|Engagement Strategies TBD|Engagement strategies that will be tested in Aim 3 in Y04 will be developed based on learnings from Aims 1 and 2 in Y01-Y03 of the project.
75934825|NCT00532311|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
76087448|NCT00706134|Drug|Placebo|Placebo tablet taken once daily in the morning with a light meal.
76087449|NCT00706134|Drug|Aliskiren 75 mg|Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
75934826|NCT03224156|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
75934827|NCT03230708|Other|Erythrocytes derived MPs containing MTX|General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX
76087450|NCT00706134|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
76087451|NCT00706134|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
76087452|NCT04471714|Drug|Baclofen|Participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other. During each visit the soleus H-reflex will be measured and conditioned by common peroneal nerve stimulation to assess presynaptic inhibition.
76087453|NCT03322644|Behavioral|Internet-based CBT intervention|The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
76087454|NCT05405790|Procedure|thoracic endovascular aortic repair|In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta.
76087455|NCT05315284|Procedure|the Use of Titanium Elastic Nail in The Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle|Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle
76087456|NCT02488278|Device|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
75796821|NCT03782987|Drug|Itraconazole|20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
75339494|NCT05901779|Drug|live combined Bifidobacteriun, Lactobacillus and Enterococcus capsules|Probiotics capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Each capsule contained>10,000,000 colony-forming units (CFUs). This drug can treat endoxemia caused by imbalance of intestinal flora.
75339495|NCT05901766|Dietary Supplement|UNIMAP Multiple Micronutrient Supplement|Iodine Containing Multiple Micronutrient Supplement once daily
75339496|NCT05901727|Other|No intervention|Observational data collection only.
75339497|NCT05901701|Radiation|Low Level LASER therapy|using semiconductor InGaAsp diode LASER type 940 nm with continuous mode of operation, with time of application 180 sec per session for 12 sessions.
75473994|NCT01978015|Drug|bimatoprost and timolol maleate fixed combination|bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
75796822|NCT03755791|Drug|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40 mg
75934828|NCT03230708|Drug|convention drugs|according to usage method of drugs
76087457|NCT02488356|Dietary Supplement|Litramine|
76087458|NCT03325686|Dietary Supplement|vitamin D supplement|D; received 50,000 IU of vitamin D supplement weekly
76087459|NCT03325686|Other|Placebo|placebo
76087460|NCT05315128|Drug|Methotrexate|A randomized comparative effectiveness clinical trial
76087461|NCT03322488|Procedure|Fistulodesis|"Fistulodesis comprises the following treatment steps:~Curettage and/or brushing of the fistula tract~Mini-excision of the inner (endoanal) fistula opening~Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline)."
75473995|NCT01978015|Drug|dextran and hypromellose|Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
75339498|NCT05901701|Device|Hard occlusal splint|2 mm thickness occlusal splint constructed over the maxillary arch using CAD/CAM technology.
75473996|NCT01978028|Drug|ferric carboxymaltose|
75473997|NCT01978028|Drug|placebo|
75473998|NCT01978041|Other|Meal prepared with non fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
75796823|NCT03755791|Drug|Cabozantinib|Supplied as 60-mg tablets; administered orally once daily at 60 mg
75796824|NCT03755791|Drug|Sorafenib|Supplied as 200-mg tablets; administered orally twice daily at 400 mg
75796825|NCT03755791|Drug|Atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
75796826|NCT03755102|Drug|Dacomitinib|"Cohort 1 Dacomitinib Dosing:~Dose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily~Cohort 2 Dacomitinib Dosing:~Dose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily"
75934829|NCT03230474|Drug|Morphine|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
75339499|NCT05901688|Other|Umbilical cord measurements & observations|"In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements:~Umbilical cord coiling index (UCI)~Transverse diameter of umbilical cord (UC)~Transverse diameter of umbilical vein (UV) and artery (UA)~Umbilical vein (UV) Doppler flow characteristics~Presence of nuchal cord"
75649661|NCT03263117|Drug|General Anesthesia (GA)|"The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)"
75649662|NCT03263117|Procedure|Intra-arterial Thrombectomy|The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
75796827|NCT03755102|Drug|Osimertinib|"In cohort 2, participants will begin on dacomitinib orally daily in combination with Osimertinib~Dose level Osimertinib Dosing:~Dose level 1: Osimertinib 80 mg daily Dose level -1: Osimertinib 40 mg daily"
75339500|NCT05901597|Device|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer
75339501|NCT05901571|Other|acupuncture|"The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation."
75339502|NCT05901571|Other|escitalopram|Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
75339503|NCT05901571|Other|sham-acupuncure|In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
75649663|NCT03232918|Drug|Half dose Oxytocin|Patients randomized to the half dose oxytocin group will have the oxytocin infusion reduced to 50 % prior to placement of combined spinal epidural for labor analgesia
75649664|NCT03231358|Behavioral|Our Family Our Future|Our Family Our Future is a 'selective' behavioral prevention program, designed to address HIV/STI acquisition, sexual risk behavior, and depression among adolescents (ages 14-16) in communities with high HIV prevalence and from families where adolescents and parents already exhibit mild, potentially troublesome, depressive symptoms but do not reach the threshold for further screening for a significant clinical depressive disorder. This intervention involves parent-child dyads who receive the intervention in a community setting, in a facilitated group format. The intervention is comprised of 3-hour sessions, held weekly for 3 consecutive weeks with an individual family meeting in the third or fourth week depending on family desires.
75339504|NCT05901571|Other|escitalopram placebo|Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
75339505|NCT05901454|Drug|Yellow Fever Vaccine|vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)
75649665|NCT03221075|Other|Registry|There is no intervention.
75649666|NCT03212989|Drug|Vorinostat|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
75796828|NCT03725982|Device|Laevo ®|A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).
75796829|NCT03725982|Device|No Laevo ®|The subjects will not wear any supporting device to perform the experiment, which serves as the control condition.
75796830|NCT03717727|Other|Exergame|16-week home-based exercise intervention with exergaming system and usual treatment.
75796831|NCT03717727|Other|Control|16-week home-based exercise by standard protocol and usual treatment.
75796832|NCT03708770|Device|everlinQ endoAVF System|
75796833|NCT03673774|Device|cardiac impedancemetry|The cardiac output is measured by impedance measurement at rest and during the walking test.
75796834|NCT03664011|Drug|BI 730357 mixed with [C-14]BI 730357 BS|Oral Solution
75934830|NCT03230474|Drug|Morphine-Naloxone|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
75934831|NCT00532233|Drug|QAX576|
75934832|NCT00532077|Drug|rhPTH(1-34)|
75934833|NCT00532077|Drug|SB-751689 100 mg|
75934834|NCT00532077|Drug|SB-751689 400 mg|
75936590|NCT03626519|Other|Test with placebo|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
75934835|NCT03212924|Behavioral|Pupillometry|Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
75934836|NCT03212924|Behavioral|Evaluation of speech comprehension in quiet|Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
75796835|NCT03630354|Behavioral|Exercise Intervention|Complete supervised exercise
75934837|NCT03212924|Behavioral|Evaluation of speech comprehension in noise|Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
75934838|NCT03212924|Behavioral|MOCA|The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
75339506|NCT05901441|Drug|Hydromorphone|For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
75339507|NCT05901441|Drug|Sufentanil|For those in SF group: they will be administered with 40 ug/ml sufentanil
75339508|NCT05901441|Drug|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
75339509|NCT05901402|Behavioral|aerobic and resistance exercise|The experimental group performed aerobic resistance exercise during pregnancy every day.
75339510|NCT05901389|Drug|Lidocaine|After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
75339511|NCT05901389|Drug|normal saline|After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
75339512|NCT05901376|Diagnostic Test|MicroRNA|MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
75649667|NCT03212989|Biological|HXTC|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
75339513|NCT05901363|Procedure|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones
75339514|NCT05901363|Procedure|aparoscopic common bile duct exploration and laparoscopic cholecystectomy|laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
75473999|NCT01978041|Other|Meal prepared with fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
75649668|NCT03203148|Diagnostic Test|Point-of-Care ACT|Comparison between two point-of-care devices for measurement of the activated clotting time
75796836|NCT03630354|Behavioral|Exercise Intervention|Complete unsupervised exercise
75796837|NCT03630354|Other|Informational Intervention|Receive instructional DVD
75796838|NCT03630354|Other|Questionnaire Administration|Ancillary studies
75796839|NCT03624023|Drug|TWB-103|TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
75796840|NCT03617562|Procedure|Superior Capsular Reconstruction|Residual rotator cuff defect is reconstructed with a dermal allograft secured to the glenoid and humeral head.
75796841|NCT03617562|Procedure|Partial Repair|Rotator cuff is repaired with residual defect remaining.
75796842|NCT03575403|Drug|Alcohol|In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
75796843|NCT03575403|Drug|Placebos|Subjects will receive placebo capsules.
75796844|NCT03575403|Drug|Duloxetine|Subjects will receive duloxetine capsules.
75796845|NCT03575403|Drug|Methylphenidate|Subjects will receive methylphenidate capsules.
75796846|NCT03539783|Diagnostic Test|Respiratory epithelial cell brushing|At specified time points, nasal brushings will be performed to obtain RNA.
75934839|NCT03212924|Behavioral|auto evaluation of listening effort in quiet|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
75934840|NCT03212924|Behavioral|auto evaluation of listening effort in noise|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
75936591|NCT02427776|Biological|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
75796847|NCT03513497|Other|Customized acrylic mouthguard|Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
75934841|NCT02282553|Device|Magnetically steerable pill camera (Microcam Navi, Intromedic Ltd, Seoul, Korea)|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet.
75934842|NCT02282553|Device|Flexible endoscope|The current standard for investigation of upper gastrointestinal disorders is flexible endoscopy; oesophagogastroduodenoscopy (OGD), also known as gastroscopy.
75934843|NCT05459896|Behavioral|Physical Activity Training|Participants who exhibit both physical and psychosocial distress will be recommended to receive physical activity intervention. An approach of adding game mechanics into an interactive environment that combines live action and an award system will be integrated into the intervention. The physical training involves 15-min resistance training and 30-min interactive cardio dancing each with beginner and advanced levels. Participants are recommended to start with the beginner level and do the exercises on regular intervals during the intervention period. The Light Detection and Ranging (LiDAR) motion sensor with tablet-based console and the full-body tracking sensor will be used to capture real-time data on participants' human body movements in order to enhance understanding of performance. Participants will get a commercial wearable sensor. Participants will be asked to wear the sensor at all times and sync the data with the Smart Health Platform to self-monitor daily condition.
76087462|NCT05315050|Other|Educational session and Information Pamphlet|"Each session will last for 50 minutes that will consist on lecturing, discussion about improving adolescent girls' menstrual knowledge, promoting a more positive attitude, encourage confidence, self-care behavior, physical activity and improve pain relief practice.~Exercise advice: The exercise protocol will include aerobic exercise such as jogging, which perform in the interventional group, three times a week, and for 10 to 30 min.~Stretching's advice: Piriformis stretching (5 repitition×20seconds), Cobra Pose. (5 repitition×20seconds), Adductor stretching. (5 repitition×20seconds), Sit up (10 repetition × 3 sets), Bridge exercise (10 repetition × 3 sets), Kegel exercise (10repetition × 3 sets), Pelvic eleva¬tion (10repetition × 3 sets), three times a week."
76087463|NCT05315050|Other|Information Pamphlet|Pamphlets consist of information about primary dysmenorrhea its causes, symptoms (onset, duration, location, prognosis) and treatment strategies (taking hot bath, heating pad, yoga, exercise, maintaining hygiene, modifying life style) Emphasized on that menstruation is a not a disease it's a natural life experience.
75474000|NCT01978041|Other|Non fluoridated water|Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
76087464|NCT02488200|Other|No intervention|No intervention
76087465|NCT05314504|Device|YVOIRE Y-Solution 360|Cross-linked sodium hyaluronate gel for injection with lidocaine
76087466|NCT03322410|Biological|modified Peritoneal Equilibration test|"Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~ High : D/P creatinine>0,8; D/D0 glucose<0,25~High average : 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38~Low average : 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48~Low  : D/P creatinine<0,5 ; D/D0 glucose>0,49."
76087467|NCT05300308|Other|usual care|The information about lymphoedema and its prevention is given during the hospital stay by the physical therapist of the department of urology. Skincare consists of daily skin moisturizer of feet and legs and prevention and care of wounds. Active exercises are performed to gain endurance and muscle strength after surgery and to stimulate the blood and lymph circulation. The exercises are supervised by the home physical therapist. Frequency of the supervised exercises is gradually decreased. If a patient develops lymphoedema, he/she receives compression stockings.
76087468|NCT03325530|Behavioral|Focus Group with Participants|Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
75474001|NCT01978041|Other|Fluoridated water|Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
75649669|NCT03200548|Behavioral|Relaxing acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
75649670|NCT03200548|Behavioral|Usual care|Negative control group. Participants are asked to carry on with their usual management practices and habits.
75649671|NCT03200548|Behavioral|Stimulating acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
75796848|NCT03476187|Device|µCor|Monitor with µCor
75796849|NCT03474029|Drug|Rifapentine daily for 6 weeks|600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
75339515|NCT05901337|Combination Product|Cupping therapy with convential medical treatment|"Device:Cupping therapy device~Group A participants received Dry cupping therapy one session per week for 8 weeks with 6 days intervals between sessions and with cups applied to the skin for around 8 minutes. (In addition to convential medical treatment for 8 weeks in the form of :~Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~Vitamine C: The recommended dietary dose 200 mg/day vitamin c~Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
75339516|NCT05901337|Drug|Convential medical treatment|"Group B participants received convential medical treatment for 8 weeks in the form of :~Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~Vitamine C: The recommended dietary dose 200 mg/day vitamin C~Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
76087469|NCT03320148|Behavioral|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
75649672|NCT03200548|Behavioral|Sham acupressure plus usual care|Positive control group. Chosen pressure points are not known to be effective.
75474002|NCT01978041|Other|Meal prepared to provide a fluoride dose of 60 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
75339517|NCT05901324|Radiation|intensity-modulated radiotherapy (IMRT)|1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.
75474003|NCT01978041|Other|Meal prepared to provide a fluoride dose of 120 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
76087470|NCT03320148|Other|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
75649673|NCT03169673|Diagnostic Test|Hyperpolarized Helium 3 Magnetic Resonance Imaging|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 3He gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
75649674|NCT03158688|Drug|Dexamethasone|Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants > 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
75649675|NCT03158688|Drug|Daratumumab|Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
75796850|NCT03474029|Drug|Rifapentine and Isoniazid weekly for 12 weeks|"Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).*~*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing > 50 kg. For persons weighing < 50 kg, the following doses will be given: weight > 25-32 kg - RPT 600 mg; weight > 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max)."
75796851|NCT03474029|Drug|Rifampin and Isoniazid daily for 12 weeks|"Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)*.~*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing > 50 kg. For persons weighing < 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max)."
75796852|NCT03474029|Drug|Rifampin daily for 16 weeks|"Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).*~*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing > 50 kg. For persons weighing < 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg."
75934844|NCT05459896|Other|Mindfulness-based Intervention|Participants who exhibit psychosocial distress will be recommended to receive mindfulness-based intervention which is designed based on the concept of validated Mindfulness-Based Stress Reduction (MBSR) combined with techniques from Mindfulness-Based Cognitive Therapy (MBCT). The intervention consists of 10 sessions, each session has different main themes and associated activities including body scan, mindful eating, abdominal breathing, chair yoga, awareness of breathing, mindful walking, breathing, body and emotions, yoga stretching, mindful listening and choiceless awreness. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week.
75934845|NCT05459896|Other|Energy Conservation Techniques|Participants who exhibit physiological symptoms will be recommended to receive energy savings intervention which is co-developed by the local Occupational Therapy Association. The intervention consists of six session, each session has different topics and associated energy savings techniques related to particular circumstances, such as the six principle of energy conservation, application of energy conservation in the domains of self-care, household tasks, outdoor activities and work. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week. Revision quiz will be given to understand the learning progress of participants.
76087471|NCT03325374|Other|Questionnaires and examination|Patients with in the BLB patients study will have interview and questionnaire carried out.
76087472|NCT03325296|Drug|LEO 124249|Ointment containing LEO 124249
76087473|NCT03325296|Other|Ointment vehicle|Ointment without active ingredients
76087474|NCT01808573|Drug|neratinib|
75796853|NCT03457402|Behavioral|Shaping Delay Tolerance|Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
75796854|NCT03448692|Drug|PF-06730512|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.
76087475|NCT01808573|Drug|capecitabine|
76087476|NCT01808573|Drug|lapatinib|
76087477|NCT01746940|Drug|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
76087478|NCT01746940|Drug|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
76087479|NCT01746940|Drug|Placebo Topical Solution|Placebo Topical Solution
76087480|NCT03322254|Other|respiratory pathogen panel|lab testing for respiratory pathogens
76087481|NCT03322176|Other|Genetic testing|LYNCH genetic testing
76087482|NCT01747330|Drug|Pancreatin|Doses of Pancreatin <2500 lipase u/kg/feed or <4000 lipase U/g fat/intake or <10000 lipase U/kg/day given orally are used
76087483|NCT03319992|Device|Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)|RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
76087484|NCT04493580|Behavioral|iDBT|Electronic DBT sessions designed to mirror in-person DBT.
76087485|NCT04493580|Behavioral|In-Person DBT|In-person DBT
76087486|NCT04769128|Other|Traditional physical therapy programe|thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.
76087487|NCT05253274|Device|Virtual Reality Glasses|In addition to the routine practice of the emergency service, the virtual reality (VR) group will watch a video with VR glasses during the emergency surgical intervention under local anesthesia. Before the emergency surgery, the patients will be asked to wear a VR glasses compatible with mobile phones with android operating system and a headset that minimizes sound loss. Patients will be shown their preferred 3D licensed video software with relaxing music in the background. VR glasses will be put on the patients before starting the emergency surgical procedure under local anesthesia and applied until the procedure was completed. Patients will be asked to refill the The State Anxiety Inventory at the end of the emergency surgical intervention. At the same time, blood pressure, heart rate, respiratory rate, SpO2 values will be monitored on a portable monitor.
76087488|NCT04442958|Other|Convalescent Immune Plasma|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
76087489|NCT02990962|Drug|5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
75474004|NCT01978054|Other|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
75649676|NCT03158688|Drug|Carfilzomib|"Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.~Dose could be modified based on a >20% change in body weight or toxicity."
75649677|NCT03152383|Behavioral|Training trials|"A highly preferred edible item will be selected to teach the contingencies for the assessment. Materials to engage in the work response (i.e., button press) will be placed within arm's reach of the child, and the edible item will be in sight. The therapist will deliver a vocal prompt for the child to engage in the work response (e.g., press the button and you can have some candy). If the child engages in the response, the therapist immediately delivers the edible item. The therapist will guide the child to engage in the instrumental response, and will then gradually begin to fade the prompt level. If the child makes an error at any level of prompting, the therapist will guide the participant to emit a correct response. The edible item will be delivered to the child each time that the child responds correctly at any prompt level."
75796855|NCT03419195|Other|Cardiovascular exercise training|Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.
75796856|NCT03395080|Drug|Paclitaxel|Administered by IV infusion
75796857|NCT03395080|Drug|300mg DKN-01|Administered by IV infusion
75796858|NCT03395080|Drug|600mg DKN-01|Administered by IV infusion
76087490|NCT02990962|Drug|1cc 2% Xylocaine+4cc Triamcinolone (40mg)|Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
76087491|NCT04443114|Other|Organ Donation Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators
76087492|NCT04443114|Other|End of Life Care Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
75649678|NCT03152383|Behavioral|Progressive Ratio Session|The child will be guided to engage in the instrumental response then the stimulus will be immediately delivered for 30 seconds. The leisure item or the individual who will provide attention will be directly outside of the session room. If the child emits the work response, they will be allowed access to either a leisure item or to attention (depending on the condition) for 30 seconds. The child is initially required to respond one time, then they will be required to respond two times to gain access to the item or attention (then 4, then 8, and so on) such that the response requirement progressively increases according to a pre-determined schedule. A minimum of 3 sessions will be conducted for each condition. The amount of time required for participation depends on the child's responding, and caregiver availability. Participation may take as little as a couple hours, or as long as 3-4 hours per day for approximately one week.
75796859|NCT03356860|Drug|Paclitaxel|80mg/m2 IV weekly from week 1 to week12
75796860|NCT03356860|Drug|Epirubicin|90 mg/m2 IV Q 2 weeks from week 14 to week 20
75796861|NCT03356860|Drug|Cyclophosphamide|600 mg/m2 IV Q 2 weeks from week 14 to week 20
76087493|NCT02246530|Procedure|PRP injection into PTRCT|"Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.~PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug."
76087494|NCT02246530|Drug|Subacromial steroid bursal injection|Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
76087495|NCT03319758|Procedure|buccal bone augmentation|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. At least 15 patients are recruited.
75474005|NCT01978067|Procedure|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
75649679|NCT03152383|Behavioral|Re-test|10 children with ASD will return to repeat the progressive ratio (PR) assessment one week after completing it the first time to examine the reliability of the measure.
75649680|NCT03152383|Behavioral|Pairing Protocol|15 children with ASD will receive an intervention designed to increase social approach after completing the PR assessment. Participants will attend 2 hour appointments 3-5 days per week in which a therapist will deliver highly preferred items, play with the child, work on teaching communication skills, and teach the child to comply with demands. After completing the intervention (once the child is willingly staying near and interacting with the therapist and complying with instructions), the PR assessment will be repeated to measure change due to the intervention.
75796862|NCT03356860|Drug|Durvalumab|Durvalumab 1500 mg IV at week 14 and 18
75796863|NCT03354273|Drug|PET MPI|Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.
75796864|NCT03354273|Drug|SPECT MPI|SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.
75796865|NCT03354273|Drug|Pharmacological stress agents|Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
75796866|NCT03319927|Behavioral|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
76087496|NCT03322098|Drug|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia
75796867|NCT03304912|Behavioral|PrEP Education and option to accept a PrEP prescription|Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
75796868|NCT03267251|Other|Vacteens Web app for mobile devices|The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
75796869|NCT03267251|Other|Standard Usual and Customary HPV Information - CDC pamphlet|The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
76087497|NCT03322098|Drug|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
75796870|NCT03245437|Drug|Oxytocin nasal spray|nasal spray
76087498|NCT04400578|Device|Trichloroacetic acid 85% (TCA)|Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
76087499|NCT03319680|Other|Citrate dialysate|Compare the effect of citrate dialysate with acetate dialysate
76087500|NCT03322020|Radiation|Cyberknife boost 18 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx
75474006|NCT01978080|Device|Kinesia HomeView|
75474007|NCT01978132|Procedure|forearm ischemia and reperfusion|both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
75474008|NCT01978158|Drug|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects
75339518|NCT05901298|Device|My Breastfeeding Guide|Development of the content of the mobile nursing application had began with a literature review on breastfeeding, Dennis' Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model and after content is created. The mobile nursing application can be download via the Google Play Store® and the Apple Store®. The application consist of three parts. In the first part includes mother and baby information which is asked with scales and forms, the second part includes literature knowledge and the third section includes the expert consultation and blog section. Mothers receive notifications consisting of sentences every two days to increase their breastfeeding self-efficacy. The application web page can allow the mothers' information to be kept in the system.
75796871|NCT03245437|Behavioral|Social Cognition Skills Training|Group based training in social cognition skills
75339519|NCT05901272|Other|Local clinical champion|A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.
75339520|NCT05901272|Other|Learning collaborative|Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.
75649681|NCT03137173|Drug|ceftobiprole medocaril|ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
75649682|NCT03137173|Drug|vancomycin+aztreonam|"Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was < 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit."
75796872|NCT03245437|Behavioral|Health Management|Group-based training in mental health management
75796873|NCT03245437|Drug|Placebo nasal spray|placebo condition
75796874|NCT03243396|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
75796875|NCT03217643|Drug|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
75796876|NCT03006432|Drug|Oxaliplatin|
75796877|NCT03006432|Drug|5Fluorouracil bolus|
75796878|NCT03006432|Drug|5Fluorouracil continu|
75796879|NCT03006432|Drug|Docetaxel|
75796880|NCT03006432|Drug|Folinic Acid|
75796881|NCT02917577|Biological|Avaxim Pediatric®|2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.
76087501|NCT03322020|Radiation|Cyberknife boost 21 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
76087502|NCT01808339|Drug|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
75796882|NCT02917577|Biological|Avaxim ® (adult)|2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.
75796883|NCT02802176|Device|INVOcell device|intra-vaginal culture of embryos using INVOcell device
75796884|NCT02802176|Other|Traditional IVF|traditional culture of embryos in-vitro
75796885|NCT02759185|Drug|High THC cannabis|Three weeks of smoking cannabis containing more THC than CBD with amount smoked limited to no more than 1.8 g per day.
75796886|NCT02759185|Drug|High CBD cannabis|Three weeks of smoking cannabis containing more CBD than THC with amount smoked limited to no more than 1.8 g per day.
75796887|NCT02759185|Drug|THC/CBD cannabis|Three weeks of smoking cannabis containing equal amounts of THC and CBD with smoking limited to no more than 1.8 g per day.
75796888|NCT02759185|Drug|Placebo cannabis|Three weeks of smoking cannabis with low levels of THC and CBD with smoking limited to no more than 1.8 per day.
75796889|NCT02685332|Radiation|Stereotactic Radiation|"Stereotactic Body Partial Breast irradiation Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1 26.5~1 30"
75796890|NCT02436993|Drug|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
75339521|NCT05901272|Other|External facilitation|. External facilitation will be provided by a trained external facilitator who is given the HITIDES Operations Guide and Consumer Voice tools for Veteran engagement in quality improvement. Facilitation is a process to enable sites to increase uptake of HITIDES through supportive relationships and strategies to navigate the implementation process. Virtual external facilitation is a recognized modality of facilitation delivery in VHA. The external facilitator will work with the clinical champion, site personnel, and Veterans-not conducting research activities but engaging in quality improvement processes with these individuals. The addition of a facilitator allows problem identification and problem-solving, using processes based on supportive relationships.
75339522|NCT05901233|Device|Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS)|tDCS is a type of non-invasive brain stimulation. 1.5 milliamp (mA) of current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. The stimulation will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
75339523|NCT05901233|Device|Remotely supervised sham tDCS (RS-sham-tDCS)|tDCS is a type of non-invasive brain stimulation. During sham stimulation 1.5 milliamp (mA) of current will be delivered for a brief period and then turned off. Current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. Sham will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
75339524|NCT05901233|Behavioral|Lexical Retrieval Training (LRT)|Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 3 times per week.
75339525|NCT05901233|Behavioral|Video Implemented Script Training in Aphasia (VISTA)|Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 3 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
75339526|NCT05901207|Diagnostic Test|blood test|blood test
75649683|NCT03126292|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
75649684|NCT03126292|Other|Child Safety Handout|Handout regarding early child safety
75796891|NCT02436993|Drug|Paclitaxel|80 mg/m^2 IV over 1-3 hours weekly for 12 doses
76087503|NCT01808339|Drug|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
76087504|NCT01749904|Drug|BOL-303259-X|Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
76087505|NCT01749904|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
75474009|NCT01978210|Device|Wireless Moisture Pager (WMP)|The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
75474010|NCT01978223|Procedure|Stool sample collection|Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
75474011|NCT01978249|Procedure|Systemic chemotherapy|
75474012|NCT01978249|Procedure|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
75474013|NCT01978275|Device|stimulong 100, pajunk, germany|simulating catheter
75474014|NCT01978275|Device|plexolong 100, pajunk, germany|nonstimulating catheter
75649685|NCT03072147|Drug|Teriparatide|20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
75649686|NCT03072147|Drug|Placebo|20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
75796892|NCT02436993|Drug|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
75796893|NCT02436993|Drug|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
75796894|NCT02436993|Drug|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
75796895|NCT02422147|Procedure|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
76087506|NCT01749904|Drug|BOL-303259-X|All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
76087507|NCT02484846|Behavioral|Time in bed|Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
75796896|NCT02360579|Biological|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
75339527|NCT05901194|Drug|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight < or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
75796897|NCT02244411|Behavioral|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
75339528|NCT05901181|Behavioral|Laughter Yoga|"Laughter yoga is a childlike practice where group members make eye contact with each other.~It is a breath yoga practiced by imitating games and fake laughing. Brain the effects of real laughter on the body, as it cannot distinguish between fake and real laughter.~showing positive effects. It consists of sessions lasting at least 20 minutes and an average of 45 minutes."
75339529|NCT05901142|Behavioral|Exercise-based multi-phasic, multi-modal intervention|"Pre-op: 2*60min supervised; 1*30min unsupervised walking sessions per week Supervised session: Aerobic: 8*60secs star jump, squat thrust, high knees with 90sec rest. Elastic resistance: 2*10-12reps of chest press, seated row, leg press, 'lat' pulldown, and either abdominal flexion or lumbar extension-alternated, with 60-90sec rest. Targeted physiotherapy: general breathing exercises, active-assisted range of motion (RoM) exercises, and active-resisted RoM exercises~Postop: 1*60min supervised exercise; unsupervised walking [2*30min weeks 1-2; 3*30min week 3; 4*30min weeks 4-6] session per week Supervised session: Aerobic: As above using full body extension, squat jump, static sprint in week 1-4. Progressed to those performed preoperatively from week 5. Elastic resistance: As above from week 4, performed 3*week. Targeted physiotherapy: As above, with active-assisted RoM progressing from 1*10reps in week 1, to 2*10reps in weeks 2-4, and 3*10reps in weeks 4-6"
75474015|NCT01978301|Drug|Triamcinolone acetonide|Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
75474016|NCT01978301|Drug|Placebo|Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
75796898|NCT02244411|Behavioral|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
75934846|NCT02279901|Behavioral|Telemedicine Education|"Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:~OSA program~CPAP program~Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor."
75934847|NCT02279901|Behavioral|IVR|"Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.~Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform."
75934848|NCT03230396|Dietary Supplement|Vitamingum Sport|Vitamin -supplemented chewing gum
75934849|NCT03230396|Dietary Supplement|Vitamingum Immunity|Vitamin -supplemented chewing gum
75934850|NCT03230396|Dietary Supplement|Placebo|Control chewing gum. No vitamin content.
76087508|NCT04585139|Device|Phase 1- Introduction to Dexcom G6 CGM|Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy
75649687|NCT03063372|Dietary Supplement|Pomella pomegranate extract|Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.
75649688|NCT03063372|Other|Placebo|Participants will take a gelatin placebo twice daily for 28 days.
75649689|NCT03052374|Behavioral|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
75649690|NCT03027869|Device|transcranial direct current stimulation|15 minute anodal stimulation 1.5mA
75649691|NCT02841527|Procedure|Gastric Band|Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
75649692|NCT02841527|Procedure|Gastric Bypass|Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
76087509|NCT02488044|Drug|AEB1102|modified human arginase I
75474017|NCT01978327|Drug|GSK2647544|repeat dose
75474018|NCT01978327|Drug|drug-drug interaction|drug-drug interaction
75796899|NCT02244411|Behavioral|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
75796900|NCT02244411|Other|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
75796901|NCT02205840|Drug|SI-614|1 drop in each eye
75796902|NCT02205840|Drug|Vehicle|1 drop in each eye
75934851|NCT03210194|Behavioral|Standard Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training
75934852|NCT03210194|Behavioral|MP-ICT Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
75796903|NCT02193841|Procedure|Curettage with puncture (C & P)|A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity
75934853|NCT00529503|Drug|SGN-40|2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
75339530|NCT05901129|Other|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
75934854|NCT00529503|Drug|placebo|Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
75339531|NCT05901116|Other|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
75474019|NCT01978353|Behavioral|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
75474020|NCT01978353|Behavioral|Psychoeducation|Participants receive information about memory functioning and aging
75474021|NCT01978392|Behavioral|Self-management group workshops|This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
75649693|NCT02841527|Procedure|Sleeve Gastrectomy|Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
75649694|NCT02798120|Drug|SB204 4%|Open label, topical SB204 4%
75649695|NCT02796534|Other|Diagnosis of sleep apnea by oxymetry|
75649696|NCT02723513|Other|Hyperpolarized Xenon-129|"Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
75649697|NCT02718690|Device|TENS|TENS transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
75934855|NCT00529503|Drug|rituximab|375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
75474022|NCT01978405|Drug|Alpha lipoic acid|
75474023|NCT01978418|Drug|salbutamol|Medication given once as a dose of 4 puffs at 30-60 minutes of age
75934856|NCT00529503|Drug|etoposide|100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
75934857|NCT00529503|Drug|carboplatin|AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
75934858|NCT00529503|Drug|ifosfamide|5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
75796904|NCT02193841|Device|Curette|A small surgical instrument with a rounded edge designed for scraping
75796905|NCT02193841|Device|Vitoss morsels|A bone substitute intended for use as a filler for voids or gaps in bones
75796906|NCT02011971|Drug|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
75934859|NCT05459350|Diagnostic Test|Safe Discharge Classification|Safe Discharge Classification
75934860|NCT05459194|Device|RP - TA|randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
75934861|NCT03230240|Drug|HIPEC|heated intraIP chemotherapy
75934862|NCT05476198|Procedure|Brachial plexus block|The effect of brachial plexus block method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
76087510|NCT04311268|Device|F2D armband|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
76087511|NCT02484768|Drug|Iron isomaltoside 1000|Intravenous treatment
76087512|NCT02484768|Drug|Sodium Chloride 0.9%|Intravenous treatment
75934863|NCT05476198|Procedure|General anesthesia|The effect of general anesthesia method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
76087513|NCT05190874|Device|Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
75339532|NCT05901103|Other|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
76087514|NCT02488122|Other|High Impact Exercise|In these workouts, both feet leave the ground at the same time.
76087515|NCT02488122|Other|Low Impact Exercise|A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
75796907|NCT01951339|Drug|Sitagliptin|100 mg sitagliptin
75796908|NCT01951339|Drug|Glimepiride|"Active Comparator~2mg glimepiride"
75796909|NCT01951339|Drug|Placebo|2 mg placebo once daily
76087516|NCT02240134|Behavioral|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
75796910|NCT01951339|Drug|Placebo|100 mg placebo once daily for three months
76087517|NCT02240134|Device|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency."
75339533|NCT05901090|Other|M-TAPA block|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose was applied to the contralateral side for each group of M-TAPA patients.
75796911|NCT01896479|Drug|Cabozantinib (XL184) 140 mg|
75796912|NCT01896479|Drug|Cabozantinib (XL184) 60 mg|
75796913|NCT01896479|Drug|Placebo tablet|
75796914|NCT01896479|Drug|Placebo capsule|
75796915|NCT01844518|Biological|Abatacept|
75796916|NCT01835041|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
75796917|NCT01835041|Drug|oxaliplatin|Given IV
75934864|NCT02280057|Drug|Metformin|Metformin 1500 mg (=2 pills) per day in six months
76087518|NCT02240134|Device|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
76087519|NCT03319602|Device|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
76087520|NCT02484612|Behavioral|acute exercise|
75796918|NCT01835041|Drug|leucovorin calcium|Given IV
75796919|NCT01835041|Drug|irinotecan hydrochloride|Given IV
75796920|NCT01835041|Drug|fluorouracil|Given IV
75796921|NCT01835041|Other|laboratory biomarker analysis|Correlative studies
75796922|NCT01833572|Drug|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
75796923|NCT01809002|Biological|Processed Nerve Allograft (human)|
75796924|NCT01809002|Device|Collagen Nerve Cuff|Bovine collagen based nerve cuff
75796925|NCT01793909|Other|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
75796926|NCT01713439|Biological|Injection of allogeneic neuroblastoma cells|Patients will receive a fixed dose of IL-2 gene modified tumor cells (10^7/kg, 10^8 max) already shown to be safe from a previous protocol, and an escalating dose of Lptn transduced tumor cells, beginning at 10^4/kg and rising to 10^7/kg (10^8 max). Patients will be assigned to an appropriate dose level for injection # 1. Injection #2 will contain 10 times more Lptn transduced cells than injection #1, until the max dose (10^8) has been reached in the first injection. The dose of injections 3 through 8 will be the same as the dose of injection #2. Initial injection volumes will be <1ml and should be injected in a single site. Only if these first patients show no undue local toxicity (including tumor cell growth) will multiple injection sites be used for subsequent high cell-dose studies.
75934865|NCT02280057|Drug|Placebo|2 pills per day in six months; pills look like metformin pills
75934866|NCT03209960|Diagnostic Test|Bedside Referral Tool|Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents. Each primary care provider will perform elements of a physical exam guided by the bedside referral tool to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
76087521|NCT03316326|Drug|Tegafur-gimeracil-oteracil potassium|40 mg bid, D1-14
76087522|NCT03316326|Drug|Oxaliplatin|85 mg/m2, D1
76087523|NCT03316326|Drug|Irinotecan|150 mg/m2, D8
76087524|NCT01751230|Behavioral|WIC E-Moms|Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
76087525|NCT03321942|Drug|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
75934867|NCT03209960|Other|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
76087526|NCT03321942|Drug|Control group|Conventional treatment were used to treat patients with chronic renal failure.
76087527|NCT05164432|Diagnostic Test|MRI scan|Women will have an MRI scan during pregnancy to evaluate the fetus and placenta
76087528|NCT02487732|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 5 weeks
75649698|NCT02718690|Device|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
75649699|NCT02706054|Other|saline|The patients received an IM injection of saline near the nerve root (periradicular)
76087529|NCT02487732|Drug|Prasugrel|Prasugrel 10mg once daily for 5 weeks
76087530|NCT03833362|Drug|Narlaprevir|yellow film-coated 100 mg. tablets
75796927|NCT01639690|Genetic|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10^6 untransduced CD34+ cells per kg will be preserved for every patient.
75934868|NCT05459116|Device|Placement of nasogastric balloon|A nasogastric balloon catheter will be inserted after inclusion. This will be a NutriVent (Sidam S.R.L., Mirandola, Italy) for patients >40kg, and a SmartCath Esophageal pressure catheter (Vyaire/Carefusion) for patients <40kg. This placement is similar to a standard nasogastric tube placement, which is a common procedure in an ICU. Potential minor side effects include a nosebleed, sore throat and erosion of the nose where the tube is anchored. All patients will receive this intervention. When the esophageal catheter becomes displaced or is accidentally removed during the study period, it will be replaced.
75934869|NCT02280135|Biological|Intravitreal injection of Autologous bone marrow Stem Cell|"We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.~After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
76087531|NCT03833362|Drug|Ritonavir|100 mg tablets encapsulates in gelatin capsules (for blinding purposes)
76087532|NCT03833362|Drug|Placebo Narlaprevir|yellow film-coated 100 mg. tablets identical to Narlaprevir tablets
75474024|NCT01978418|Drug|Placebo|Placebo given once as a dose of four puffs at 30-60 minutes of age
75474025|NCT01978444|Procedure|Laparoscopic D2 lymphadenectomy plus CME|
75474026|NCT01978444|Procedure|Laparoscopic D2 lymphadenectomy|
75474027|NCT01978457|Drug|cocaine hydrochloride|
75474028|NCT01978457|Drug|propranolol|
75474029|NCT01978457|Drug|placebo|
75474030|NCT01978470|Device|External Trigeminal Nerve Stimulation (eTNS)|External stimulation of the trigeminal nerve.
75474031|NCT01978483|Drug|Denosumab|
75649700|NCT02706054|Drug|Meloxicam|The patients received an IM injection of meloxicam near the nerve root (periradicular)
76087533|NCT03833362|Drug|Placebo Ritonavir|100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules
76087534|NCT03833362|Drug|Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b|180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials
76087535|NCT03833362|Drug|Ribavirin|"hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight <75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight <65 kg) - 1400 (patient weight >105 kg) mg/day with Peginterferon alfa-2b"
76087536|NCT03321864|Procedure|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
75474032|NCT01978483|Radiation|UVB exposure|
75649701|NCT02695875|Procedure|Aquatic therapy|"Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
75649702|NCT02695875|Procedure|Land-based therapy|"The material is contributed by Faculty of Physiotherapy at University of A Coruña.~The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
76087537|NCT05463588|Other|Exercising with virtual reality glasses|"GIVE PATIENTS EXERCISE WITH A 360 DEGREE EXERCISE VIDEO INSIDE VIRTUAL REALITY EYES.~Exercising with the training material taught at the beginning of the training"
76087538|NCT03316248|Other|visual feedback|in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
76087539|NCT03316248|Other|usual prosthetic rehabilitation|prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
75796928|NCT01591577|Other|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
75649703|NCT02630641|Drug|Gonadotropin-releasing Hormone (GnRH) agonist therapy|This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
75796929|NCT01521741|Other|Breast Cancer-Related Lymphedema Screening|All patients enrolled in the trial will receive prospective BCRL screening from their pre-operative baseline throughout their breast cancer treatment process. All participants will be measured with perometry, bioimpedance spectroscopy, and patient-reported outcome measures.
75934870|NCT02280135|Other|Subconjunctival injection of saline|"In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
75649704|NCT02600117|Drug|Tenofovir disoproxil fumarate|300 mg, oral, once a day
75649705|NCT02599714|Drug|AZD2014|The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
75934871|NCT02279589|Biological|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
75934872|NCT02279589|Biological|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
75934873|NCT02279589|Biological|Prevenar13® 0,5|"The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197)."
75649706|NCT02599714|Drug|Palbociclib|cyclin dependent kinase inhibitor
75796930|NCT01509586|Drug|Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product|The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
75934874|NCT03209804|Procedure|hybrid operating techniques|A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
75934875|NCT02282709|Drug|Daclatasvir|60 mg once daily
75796931|NCT01364584|Drug|Exenatide|Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
75796932|NCT01364584|Drug|Placebo|Subcutaneous injection 2.5 mcg-10 mcg BID
75649707|NCT02599714|Drug|Fulvestrant|Fulvestrant hormonal therapy as background
75796933|NCT01330121|Other|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
75796934|NCT01163383|Drug|131 I-Metaiodobenzylguanidine (131 I-MIBG)|131 I-MIBG 1-18mCi/kg given intravenously on day 1. Subjects may receive multiple courses every 4-8 weeks depending on the dose given.
75934876|NCT02282709|Drug|asunaprevir|100 mg BID
75934877|NCT03119402|Behavioral|Rhythmic Reading Training|RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
75339534|NCT05901090|Other|TAP block|After the necessary sterilization conditions were established, the linear ultrasound probe was sterilely coated and placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum were identified. As the tip of the 80 mm sonovisible needle passed through the muscular layers and fascia, a fascial click was felt and the needle was advanced with ultrasound in a controlled manner. After receiving the second click sensation (passage of the fascia of the internal oblique muscle), the location of the needle was fixed and frequently aspirated and applied to the plane so that 20 ml of 0.25% bupivacaine was applied to each side. (40 ml in total)
75649708|NCT02549937|Drug|surufatinib|orally once daily (QD) in patients with advanced solid tumor.
75649709|NCT02337634|Drug|Placebo|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
75649710|NCT02337634|Drug|Milk Thistle|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
75649711|NCT02288195|Drug|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
75796935|NCT01163383|Drug|131 I-MIBG|131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
75339535|NCT05901064|Procedure|Axillary clearance|Evaluating the use of Harmonic Focus in axillary clearance due to metastasis of breast cancer in axilla
75649712|NCT02288195|Drug|capecitabine|"825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.~1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B."
75796936|NCT01044264|Drug|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
75796937|NCT01044264|Drug|Placebo|Placebo
75649713|NCT02288195|Radiation|Radiation|The total dosage was 46Gy consisted of 23 fractions of 2 Gy to clinical target volume without a boost dose and with the boost 4 Gy consisted of 2 fractions of 2 Gy to gross tumor volume by IMRT or 3D-CRT.
75796938|NCT01039584|Drug|Butoconazole Nitrate Vaginal Cream|vaginal cream
75339536|NCT05901038|Device|Wearing heart rate monitors|Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.
75474033|NCT01978483|Drug|Diphenylcyclopropenone|
75474034|NCT01978483|Drug|Normal Saline|
75649714|NCT02285127|Procedure|Short versus long cephalomedullary Intramedullary nail|Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
75796939|NCT01039584|Drug|Placebo|vaginal cream
75796940|NCT01039584|Drug|Gynazole 1 vaginal cream|vaginal cream
75796941|NCT00920387|Drug|200 mcg LSD|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
75796942|NCT00920387|Drug|20 mcg LSD|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
75796943|NCT00920387|Behavioral|Therapy|Therapy provided by male and female co-therapists
75796944|NCT00786019|Behavioral|Exercise program|Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
75796945|NCT00786019|Drug|Ascorbic Acid (Vitamin C)|"During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute."
75796946|NCT00692484|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
75796947|NCT00692484|Drug|Povidone iodine|Povidone iodine scrub and paint. Administer topically.
75796948|NCT00679783|Drug|AZD2281|PARP inhibitor Olaparib tablets, oral
75934878|NCT03119402|Device|Transcranial direct current stimulation|tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
75339537|NCT05901012|Drug|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
75339538|NCT05901012|Drug|Placebo|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
75339539|NCT05900999|Behavioral|Feasibility of idle time exercise|The experiments in this proposal will assess the utility and subjective patient experience performing idle time exercise intervention designed to reduce learned non-use of the hemiparetic arm in the days, and weeks immediately following stroke. Exercise will be cued by wearable technology that provides vibrotactile cues similar to those provided by FitBit devices. Participants will be asked to perform simple exercises after receiving a vibration cue. In the first four sessions they will tap the more-involved wrist; in the second four sessions they will passively move the more-involved elbow through a range of motion; in the final four sessions they will actively move the more-involved elbow through a range of motion. Accelerometers in the wearable devices will monitor motion of the wrist during the exercise sessions. We will interview the participants two months later regarding how well they use the more-involved arm to perform daily activities.
75474035|NCT01978496|Drug|Placebo|matching placebo
75474036|NCT01978496|Drug|Eletriptan 20 mg|20mg oral
75474037|NCT01978496|Drug|Eletriptan 40 mg|40mg oral
75474038|NCT01978496|Drug|Eletriptan 80 mg|80mg oral
75474039|NCT01978522|Other|Randomisation of questionnaire receipt.|"The self-completion questionnaire will be delivered to the participants via post a week after completing the CAPI.~Self-completion questionnaire handed to participants immediately after completing the CAPI."
75474040|NCT01978548|Drug|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
75796949|NCT00490581|Other|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
75934879|NCT02282787|Drug|DEXMEDETOMIDINE|Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
75934880|NCT03223844|Drug|Dextroamphetamine Sulfate|Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
75934881|NCT00458601|Drug|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
75474041|NCT01978548|Drug|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
75474042|NCT01978548|Drug|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
75474043|NCT01978561|Biological|Post dosing with NT100|
75474044|NCT01978561|Other|Post dosing with Placebo|
75474045|NCT01978574|Behavioral|Intellectual Enrichment daily activities|A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
75474046|NCT01978574|Behavioral|Intellectual Enrichment documentary videos|Participants watch daily documentary videos.
75474047|NCT01978587|Drug|JTZ-951|
75796950|NCT00367003|Device|Deep Brain Stimulation|The deep brain stimulation system (consisting of a lead, extension wire, and implanted pulse generator) will be surgically implanted to stimulate the targeted area of the brain. Stimulation will be turned off for 4 weeks following implantation, then participants will use brain stimulation for 6 months. Participants will also take part in Behavioral Activation therapy during the 6 months of active stimulation. Participants will be followed for 10 years, or until the DBS device has been FDA approved, with adjustments made to the stimulator and medications as necessary.
75796951|NCT00152698|Drug|Irbesartan|
75934882|NCT00458601|Drug|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
75339540|NCT05900934|Other|Myofascial Releasing Group|Using a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort), the intensity of foam roller application can be determined. This intensity defines an application intensity that is mildly painful for the participant and appropriate according to previous literature.
75339541|NCT05900934|Other|Sham Myofascial Releasing Group|The severity of the application is not felt at all according to the numerical rating scale of 0/10.
75339542|NCT05900921|Drug|Trilaciclib|IV infusion, d1
75649715|NCT02279329|Other|Hyperpolarized Helium MRI|Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
75339543|NCT05900921|Drug|Carboplatin|IV infusion, d1
75649716|NCT02265874|Drug|Habitrol|Patch used daily for 28 weeks
75649717|NCT02265874|Drug|Placebo to Habitrol|
75796952|NCT00074698|Drug|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm description.
75796953|NCT01257516|Drug|Pregabalin immediate release, 300 mg|300 mg immediate release capsule administered twice daily for four days
75796954|NCT01257516|Drug|Pregabalin controlled release, 330 mg|Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
75796955|NCT01149954|Drug|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
75934883|NCT03223688|Behavioral|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
75339544|NCT05900921|Drug|Paclitaxel|IV infusion, d1
75339545|NCT05900921|Drug|Tislelizumab|IV infusion, d1
75339546|NCT05900869|Other|FSFI|Female Sexual Function Index questionnaire
75339547|NCT05900869|Other|BES|Body Esteem Scale questionnaire
75339548|NCT05900830|Other|play therapy|A combined program based on physical and occupational therapy techniques within a play context
75649718|NCT02263794|Procedure|Conventional Bronchial Thermoplasty|Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
75796956|NCT03900156|Other|goal-setting|The interviewer will have access to key information from the initial assessment such as details of identified risks. Areas where the participant would like to make changes or improvements will be identified and prioritized, and up to five specific, realistic and achievable goals will be identified.
75796957|NCT03893292|Procedure|Total knee replacement|Patients will undergo total knee replacement surgery.
75339549|NCT05900830|Other|common educational methods|the child will receive his education in a passive manner
75339550|NCT05900817|Other|antivet|A material used for micro abrasion of teeth
75339551|NCT05900817|Other|Oplsture|A material used for micro abrasion of teeth
75339552|NCT05900804|Other|Training Prepared in Line with the Fracture Liaison Service Model|The Effect of Education Prepared in Line with Fracture Liaison Service Model on Patients' Frailty Level, Care Dependency and Fear of Movement in Hip Surgery Patients
75796958|NCT03893292|Device|COOLIEF|The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
75796959|NCT03899766|Other|Animal Assisted Intervention|Operators of AAI and their dog meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
75796960|NCT03899766|Other|Clowns|Hospital clowns meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
75934884|NCT03223688|Behavioral|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
75934885|NCT03223688|Behavioral|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
75934886|NCT00658047|Drug|CH-1504|Comparison of different doses of CH-1504
75934887|NCT00658047|Drug|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
75934888|NCT03230162|Drug|Sildenafil|sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
75796961|NCT03899766|Other|Musicians|Musicians meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
75649719|NCT02263794|Procedure|Image Guided Bronchial Thermoplasty|Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
75649720|NCT02240251|Other|Prospective Chart Review|The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
76087540|NCT02487888|Other|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
75934889|NCT03230162|Drug|low molecular weight heparin|a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
75339553|NCT05900791|Procedure|Primary knee arthroplasty|All patients surveyed have undergone primary knee arthroplasty approximately 1 year prior to survey distribution
75339554|NCT05900739|Behavioral|Increase of fruit and vegetable consumption|"Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking"
75339555|NCT05900726|Diagnostic Test|High Resolution Anorectal Manometry|A test used to measure the strength of the muscles in the anal canal
75339556|NCT05900726|Diagnostic Test|Endoanal Ultrasound|An examination of the anal canal (back passage) that allows us to see the muscles involved in passing stool and the tissues that surround these.
75339557|NCT05900726|Other|Bowel diary|A daily diary to assess episodes of faecal incontinence
75339558|NCT05900726|Other|MYMOP2|Questionnaire to assess individual symptoms, general wellbeing and activity in faecal incontinence
75339559|NCT05900726|Other|FIQOL|Questionnaire to assess the quality of life with faecal incontinence
75649721|NCT02005861|Procedure|bone marrow cells transplantation on collagen scaffold|"120 ml of venous blood will be collected for the platelet gel production. The day of the surgery, 60 ml of bone marrow will be aspirate from the posterior iliac crest and concentrated. a standard ankle arthroscopy will be performed, with the patient in the supine position. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and cut into an appropriate shape to fit the lesion.~After the scaffold implantation 2 ml of platelet gel will be loaded on the top of implant, in order to provide growth factors and to improve the stability of the implant."
75649722|NCT01996436|Drug|Nicardipine|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
75649723|NCT01996436|Drug|Verapamil|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
75649724|NCT01996436|Drug|Nicardipine + Verapamil + Nitroglycerin|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
75934890|NCT03223532|Device|PrePex Day 7 FRP|Standard PrePex procedure, foreskin and device are removed 1 week after device application.
75934891|NCT03223532|Device|PrePex Day 0 FRP|Removal of the foreskin shortly after device application, the device is removed 1 week later
75934892|NCT00455559|Drug|Perifosine|
75934893|NCT00455559|Drug|Imatinib Mesylate|
76087541|NCT02487888|Other|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
75339560|NCT05900726|Other|FISI|Questionnaire to assess the severity of faecal incontinence
75339561|NCT05900726|Other|Follow up call|At 28 days and 3 months post final pelvipower or sham session to assess faecal incontience after study period
75339562|NCT05900726|Other|St Mark's incontinence score|A score of incontinence
75649725|NCT01892514|Procedure|core decompression|core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
75649726|NCT01845337|Drug|Teysuno|
75934894|NCT03230084|Device|Urine PDG test|Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
75934895|NCT02916433|Drug|Octreotide|
75934896|NCT02284269|Drug|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
75934897|NCT02451800|Other|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
75934898|NCT02451800|Other|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
75934899|NCT02451800|Other|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
75934900|NCT04059523|Drug|S6G5T-3|once daily
75934901|NCT04059523|Drug|Retin-A® 0.1% Cream|once daily
75934902|NCT02282943|Device|Laser|Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser
75934903|NCT02282943|Device|Harmonic scalpel|Excision of endometriosis using Harmonic scalpel
75936592|NCT03178760|Diagnostic Test|Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.|"Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified. Classifications will be done for;~Age~Gender~Weight~Length~Waist Circumference~Body mass index"
76087542|NCT03316092|Diagnostic Test|optical coherence tomography|screening and monitoring all patients who are to use or have been using oral Hydroxychloroquine
76087543|NCT02490774|Drug|BAY1007626|Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
76087544|NCT02490774|Drug|Jaydess|Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
76087545|NCT02490774|Drug|Mirena|Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
76087546|NCT02490852|Other|Investigational infant formula|fed ad libitum
76087547|NCT02490852|Other|Active Comparator: Commercially available Infant formula|fed ad libitum
76087548|NCT02490852|Other|Active Comparator: Human milk|fed ad libitum
75339563|NCT05900492|Procedure|cesarean section|caesarean delivery, is the surgical procedure by which one or more babies are delivered through an incision in the mother's abdomen
75339564|NCT05899725|Drug|Corticosteroids|Initial dosage of corticosteroids is more than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
75339565|NCT05899725|Drug|Corticosteroids and Ruxolitinib|Initial dosage of corticosteroids is more than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
75339566|NCT05899699|Drug|DAP-FLU ME|Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)
76087549|NCT03316014|Other|Adverse drug reaction|description of the adverse drug reactions (ADR) and the drugs involved in pediatrics
76087550|NCT02487654|Procedure|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
75339567|NCT05899699|Drug|Adapalene .1% gel|Adapalene .1% gel
76087551|NCT02487654|Procedure|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
76087552|NCT03315936|Drug|BI 894416|Oral solution
75339570|NCT05899530|Device|Invisalign|Expansion using Invisalign versus conventional expander
75339571|NCT05899530|Device|Conventional expander|conventional expander
75339572|NCT05899439|Other|blood draw|a peripheral blood draw
75339573|NCT05898854|Drug|68Ga-FAPi-46|Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging
75474048|NCT01978613|Drug|NNC0113-0987|Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.
75649727|NCT01845337|Drug|Capecitabine|
75474049|NCT01978613|Drug|placebo|Tablets for one-daily oral administration.
75649728|NCT01801384|Behavioral|Voucher-based incentives|
75649729|NCT01635569|Behavioral|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
75649730|NCT01635569|Other|Waitlist|Baseline and post-12 sessions
75649731|NCT01575808|Device|GP1101|Endovascular stent graft implantation
75796962|NCT03899610|Drug|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"Neoadjuvant treatment:~Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~Interval debulking surgery~Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
75339574|NCT05898516|Behavioral|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
75339575|NCT05897671|Other|retrospective data analysis|Macular hole closure rate, visual acuity and OCT
75339576|NCT05897151|Drug|Continuous spinal anesthesia|"Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics.~Norepinephrine starting. dose 0.01 micg/kg/min will be ready for both groups if needed (Mean arterial pressure < 70 or Mean arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics."
75339577|NCT05897151|Drug|General anesthesia|After establishing of ASA monitoring, a wide bore cannula (18 G) will be inserted. Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
75474050|NCT01978626|Behavioral|App modules|
75474051|NCT01978626|Behavioral|Traditional CBT-I|
75649732|NCT01563341|Device|Deep brain stimulation|Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
75649733|NCT01546753|Drug|Walnut Protein Powder|Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
75796963|NCT02527668|Dietary Supplement|Calcifediol|One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months
75796964|NCT02527668|Dietary Supplement|Vitamin D3|One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months
75796965|NCT02527668|Other|Placebo|One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
75796966|NCT03896412|Other|Detecton of circulating tumor DNA|7 blood samples to design a molecular probe
75796967|NCT03893214|Behavioral|virtual reality exposure for acrophobia|"The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase."
76087553|NCT03315936|Drug|Placebo|Oral solution
76087554|NCT03315936|Drug|BI 894416 (treatment X and Z)|Tablet
76087555|NCT03315936|Drug|BI 894416 (treatment Y)|Oral solution
75474052|NCT01978652|Biological|Peginterferon Beta-1a|As specified in the treatment arm
75474053|NCT01978665|Drug|prednisone|similar size tablets
75474054|NCT01978678|Drug|Pulmicort|ACQ and FeNO
75474055|NCT01978691|Dietary Supplement|Bifidobacterium animalis ssp. lactis 420|Studied as a probiotic bacteria
75474056|NCT01978691|Dietary Supplement|Polydextrose|Studied as a prebiotic
75474057|NCT01978691|Other|Placebo|Control
75339578|NCT05897138|Drug|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle|"Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle"
75934904|NCT03223454|Biological|hAECs|hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
75934905|NCT03223454|Biological|biological amnion|Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
75934906|NCT04059133|Device|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm|Sham treatment (shock wave probe w/o energy)
75934907|NCT04059133|Device|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm|Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
75934908|NCT00657501|Drug|testosterone gel|once daily transdermal gel, 300 mcg
75934909|NCT00657501|Drug|placebo gel|once daily transdermal placebo gel
75934910|NCT02452580|Other|Family Centered Care|Neonatal intensive care toward premature infants and their parents in a unit physically and culturally optimized for parent-infant interaction 24 hours a day 7 days a week from birth to discharge.
75474058|NCT01978704|Other|Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|
75649734|NCT01546753|Drug|Oat Powder (placebo)|Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
75796968|NCT03893214|Behavioral|movie|Participants will watch a movie without height content for the same amount of time as the virtual reality exposure will need.
75934911|NCT03675841|Drug|Pazufloxacin Mesilate ear drops|Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
75934912|NCT03229694|Drug|Tracleer 125Mg Tablet|Tracleer was administered orally at two hours before surgery and six hours after surgery.
76087556|NCT02484144|Other|modern information|information by video for coronarography
75474059|NCT01978704|Other|Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal|
75474060|NCT01978717|Procedure|epidural anesthesia|
75796969|NCT03896490|Behavioral|Attention Control Training|Infants watch interactive cartoons that respond to infants' direction of gaze. An eye-tracker records the infant's eye movements in real time, relaying this information to the computer. These presentations trigger motivating stimuli (cartoon animations with child-friendly sounds) every time the infant fulfills the demands of a task (e.g. when the infant looks at a character on the screen avoiding to be distracted by other objects moving across the screen). The length of training sessions varies depending on infants' engagement with stimuli and time criteria.
76087557|NCT02484144|Other|usual information|usual information for coronarography
75796970|NCT03896490|Behavioral|Control|The control procedure involves presentation of cartoons on a screen, while infants' gaze direction is recorded using the same eye-tracker and camera. The crucial difference is that the cartoons in this case are not interactive, thus do not change depending on infants' gaze direction. To ensure presentations in the control procedure are similar in length to those of the intervention group, infants in the control group are matched infant-by-infant and visit-by-visit with participants in the ACT treatment group: Infants in the control group see a replay of the session of the matched treated infant. Therefore, while the presentation is exactly the same (i.e. same length and same stimuli) for the treated and the control child, in the latter case the presentation is not interactive (i.e. not generated contingently on the infants' visual behaviour).
75796971|NCT03896256|Drug|ketamine infusion|Ketamine will be used in subanesthetic doses for patients with refractory chronic migraine to see if it improves pain after a 5-day continuous infusion.
75934913|NCT03229694|Drug|Placebo|Placebo was administered orally at two hour before surgery and six hours after surgery.
75934914|NCT03223142|Device|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
75474061|NCT01978717|Procedure|general anesthesia|Patients received general anesthesia for surgery
75474062|NCT01978730|Drug|high dose group of SaiLuoTong capsule|high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
75474063|NCT01978730|Drug|low dose group of SaiLuoTong|low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
75934915|NCT03675607|Other|Complementary feeding behaviours|Any kind of complementary feeding practice
75934916|NCT00452127|Drug|PRO131921|Escalating doses by IV infusion
75474064|NCT01978730|Drug|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
75796972|NCT03893136|Biological|Tocilizumab|The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
75649735|NCT01546753|Drug|Open-label Walnut Protein Powder|Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
75649736|NCT01528982|Behavioral|Mindfulness|Subjects receive mindfulness training
75796973|NCT03893136|Drug|Leflunomide|The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
75796974|NCT03899454|Drug|Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract|Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
75339579|NCT05896735|Procedure|Ultrasound-guided axillary vein catheterization|All axillary vein catheterizations were performed according to standard central venous catheterization procedures, which were performed under ultrasound guidance at the bedside. Before the operation, patients were placed in a supine position with the upper limb placed in a natural position, and the ultrasound probe and wires were wrapped with a sterile protective sheath. Ultrasound pre-scanning the axillary artery and axillary vein, and pay attention to using the minimum pressure to control the ultrasound probe to avoid crushing the blood vessels. The operator holds the ultrasound probe and puncture needle to puncture the axillary vein under the guidance of ultrasound. After drawing out of the dark red blood, the guide wire was inserted and the puncture needle was withdrawn. The three-lumen CVC catheter was then inserted using the Seldinger technique.
75339580|NCT05896501|Device|Fractional Flow Reserve|Functional assessement of anatomical stenosis of coronary artery
75649737|NCT01528982|Behavioral|Cognition|Subject receive cognitive training
75796975|NCT03899454|Drug|Placebo Control|Placebo Control
75796976|NCT01150032|Other|Bone quality complementary exams|"realisation of following exams to evaluate fracture risk in osteopenic women:~hip and wrist Dual energy X-ray Absorptiometry (DXA)~wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)~hip Quantitative Computed Tomography (QCT)~High Resolution Digital X-Ray of calcaneum using BMA(tm) system~low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)"
75796977|NCT01258530|Drug|over-encapsulated oseltamivir|75 mg once
75796978|NCT01258530|Drug|oseltamivir|75 mg once
75796979|NCT01255410|Biological|10^6 PFU rHMPV-Pa vaccine|Single dose of 10^6 PFU rHMPV-Pa vaccine delivered intranasally
75796980|NCT01255410|Biological|10^5 PFU rHMPV-Pa vaccine|Single dose of 10^5 PFU rHMPV-Pa vaccine delivered intranasally
75796981|NCT01255410|Biological|Placebo Vaccine|Single dose of placebo vaccine delivered intranasally
76087558|NCT02490540|Drug|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
75934917|NCT03223064|Diagnostic Test|Ferumoxtran-10 enhanced MRI; MRI contrast agent|Patient undergo MRI with an USPIO contrast agent
75934918|NCT03223064|Diagnostic Test|68Ga PSMA PET-CT|Patient undergo an 68Ga PSMA PET-CT scan
75339581|NCT05895903|Device|Screw expander|threadform screw expanders with special condensing burs for lateralization and compaction of bone
75339582|NCT05895903|Device|Osseodensification drills|special drills to expand narrow alveolar ridges.
75649738|NCT01334788|Other|sleep deprivation|Sleep restriction
75649739|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
75649740|NCT01291420|Biological|autologous dendritic cell vaccination|4 biweekly intradermal DC injections of 10*10E6 DCs (500 µL) at 5 sites (100 µL/site) in the ventromedial regions of the upper arm approximately 5-10 cm of the regional lymph nodes
75796982|NCT01150110|Device|resilient occlusal splints|"A resilient occlusal splints (silicone 2mm) was fabricated on the maxillary arch, using a vacuum pressing machine. The occlusal splints were adjusted to eliminate the gross interferences and to obtain occlusal stability with maximum posterior bilateral contacts.~Patients were instructed to use the occlusal splints for 24 hours during 30 days. The use was interrupted only during meals."
75796983|NCT01257672|Drug|Ondansetron|ondansetron syrup (0,15 mg/Kg of body weight)
75934919|NCT03675529|Behavioral|High Intensity Interval Training bout|Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
75339583|NCT05895253|Device|vibrotactile ground-contact feedback|Suralis®, Saphenus Medical Technology (Baden, Lower Austria, Austria)
75934920|NCT02280213|Device|MIL|Direct laryngoscopy 1
75339584|NCT05895162|Drug|JUVIA zinc containing vaginal gel treatment|Women receive a single oral dose of fluconazole (150mg) followed by treatment with JUVIA zinc containing vaginal gel (daily for 2 weeks and twice per week thereafter).
75796984|NCT01257672|Drug|Domperidone|domperidone syrup (0,5 mg/Kg of body weight)
75796985|NCT01257672|Drug|placebo|placebo
75796986|NCT01258686|Drug|Silymarin|700mg thrice daily
75934921|NCT02280213|Device|MAC|Direct laryngoscopy 2
75934922|NCT02280213|Device|WIS|Direct laryngoscopy 3
75934923|NCT02280213|Device|PHIL|Direct laryngoscopy 4
76087559|NCT02490540|Drug|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
75339585|NCT05895162|Drug|Fluconazole 150Mg Tab|Women receive oral fluconazole treatment with a single dose of oral fluconazole (150 mg).
75339586|NCT05891951|Other|Fluid therapy under the guide of Carotid ultrasound|Participants will use carotid ultrasound to assess volume status. If volume is insufficient, fluid therapy will be selected until volume is sufficient. If volume is sufficient, no fluid therapy will be given.
75339587|NCT05884125|Device|Checkpoint BEST System|Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair
75649741|NCT00836537|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
75649742|NCT00836537|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
75796987|NCT01258686|Drug|Placebo|Placebo 700mg thrice daily
75474065|NCT01978756|Other|Outpatient clinic|The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
75474066|NCT01978782|Drug|raltegravir|
75474067|NCT01978782|Drug|citalopram|
75474068|NCT01978795|Other|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).
75649743|NCT00832026|Device|Trans Nasal Insufflation (TNI) [nasal canula]|"Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing."
75649744|NCT00572169|Drug|Velcade|Will be given in central venous catheter
75649745|NCT00572169|Drug|Thalidomide|Capsule taken by mouth
75649746|NCT00572169|Drug|Dexamethasone|A pill taken by mouth
75649747|NCT00572169|Drug|Adriamycin|Given into the vein (IV) by a continuous infusion through a central catheter
75649748|NCT00572169|Drug|Cisplatin|Given into the vein (IV) by a continuous infusion through a central catheter
75649749|NCT00572169|Drug|Cyclophosphamide|Given into the vein (IV) by a continuous infusion through a central catheter
75649750|NCT00572169|Drug|Etoposide|Given into the vein (IV) by a continuous infusion through a central catheter
75796988|NCT03896178|Other|None, observational study|None, observational study
75796989|NCT03895944|Biological|ET190L1-ARTEMIS™ T cells -iv low dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10^6
75796990|NCT03895944|Biological|ET190L1-ARTEMIS™ T cells -iv middle dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10^6
75474069|NCT01978795|Other|Control|At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
75796991|NCT03895944|Biological|ET190L1-ARTEMIS™ T cells - iv high dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10^6
75934924|NCT03209648|Drug|Debio 1450|Debio 1450, 40 mg capsule.
75934925|NCT03209648|Drug|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
75934926|NCT04058899|Drug|Dexmedetomidine|sedative and might be analgesic drug
75934927|NCT04058899|Drug|Nalbuphine|agonist antagonist narcotic
75934928|NCT04058899|Device|infusion pump|infusion pump for titration of fluid containing drug infusion
75934929|NCT00657189|Drug|MEDI-545|100 mg once; SC Placebo × 12 doses on other weeks
75934930|NCT00657189|Drug|MEDI-545|100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
75934931|NCT00657189|Drug|MEDI-545|100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
75934932|NCT00657189|Drug|MEDI-545|100 mg every week × 13 doses
75934933|NCT00657189|Drug|Placebo|SC Placebo every week × 13 doses
75934934|NCT03670459|Other|Cawthorne Cooksey exercises|Eye movements and head movements
75934935|NCT03670459|Other|Vestibular habituation exercises|Move from a sitting position to flat on the back
75934936|NCT03670459|Other|Balance exercises|Weight Shift Forward and Back
75934937|NCT00656097|Biological|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
75649751|NCT00631280|Behavioral|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
75934938|NCT00656097|Biological|HRIG|HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
75934939|NCT00656097|Biological|Placebo matching CL184|Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
75649752|NCT00631280|Behavioral|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
75649753|NCT02585206|Behavioral|Personalization|"Phase I Factor~Personalized text messages using the participant's username and gender (Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!). Both data points will be pulled from BecomeAnEX registration data."
75934940|NCT03670381|Other|Psychiatric diagnosis|
75474070|NCT01978821|Procedure|Autologous bone marrow mononuclear cell transplantation|
75649754|NCT02585206|Behavioral|Integration|"Phase I Factor~Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:~Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community~Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online."
75649755|NCT02585206|Behavioral|Dynamic Tailoring|Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
75649756|NCT02585206|Behavioral|Message Intensity|"Phase I Factor~Varying levels of text message intensity over a 12-week period."
75649757|NCT02585206|Behavioral|Optimal-Adherence Text|Optimal-adherence text message intervention developed in Phase I
75649758|NCT04266626|Other|kinesiotaping therapy|Kinesiotaping is a new therapeutic technique that gives support to the lip and tongue base muscles without restricting range of motion or blood flow.
75796992|NCT03899298|Biological|Amniotic and Umbilical Cord Tissue Procedure|Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
75796993|NCT01258764|Drug|Lisinopril|Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle
75796994|NCT01258764|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle
75796995|NCT03895788|Drug|niraparib|Niraparib will be administered as a flat-fixed dose (100mg or 200 mg, daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
75796996|NCT03895788|Drug|Brivanib|Brivanib will be administered as a flat-fixed dose (200mg, 400 mg, or 600 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area.
75796997|NCT01258842|Dietary Supplement|Bifidobacterium lactis HN019|B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
75796998|NCT01258842|Dietary Supplement|Placebo|Placebo sachet, consumed once per day for 12 weeks
75934941|NCT03209180|Drug|CarVeDilol-SR (Slow Release)|patients will receive slow-release carvedilol (SR) once daily
75934942|NCT03209180|Drug|Carvedilol IR (Immediate Release)|patients will receive immediate release carvedilol (IR) twice daily
75934943|NCT02280369|Device|Automated abdominal binder|Inflatable abdominal binder
75934944|NCT03215017|Device|Transanal irrigation|Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
75934945|NCT03215017|Drug|Medication|Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
75474071|NCT01978860|Device|NovaCross, CTO|evaluate the safety and performance of the NovaCross™ micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.
75796999|NCT01257828|Drug|riluzole|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
75797000|NCT01257828|Drug|Placebo medication|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
75797001|NCT01150188|Dietary Supplement|Amino acids|11 g amino acids two times per day for eight weeks
75934946|NCT00447993|Drug|NT-501|High Dose
75934947|NCT00447993|Drug|NT-501|Low Dose
75934948|NCT03229928|Device|MOCHA|"MOCHA phone-based application~Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~Wrist based sensor (applicable only to sensor wearing participants)."
75934949|NCT03675373|Behavioral|Mobile chat-based instant messages|"Subjects in the active arm study will receive continuous interactive chat-based intervention as an extension of alcohol brief intervention at baseline. The interactive mobile chat will be carried out on Friday night and Saturday before and during the period of happy hour and ask for drinking and giving personalized advises on drinking reduction using behavioral change techniques."
75934950|NCT03675373|Behavioral|Alcohol brief intervention|Those in the control arm will be assigned to only receive the face-to-face ABI. The ABI consists of: (1) giving feedback and information about the screening result in phase I and hazard of drinking; (2) emphasizing the benefits of reduce drinking and informing about alcohol problems; (3) setting goal on reducing alcohol consumption; (4) reviewing advice and ;(5) giving encouragement.
75934951|NCT02283021|Other|A biopsy sample|Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
75934952|NCT03229772|Device|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
75339588|NCT05879731|Other|EEG-hd (high density electroencephalogram)|"Once in the operating room, the investigators will place a 128-channel Hd-EEG (high density electroencephalogram) saline net referenced to Cz on the patient's head. Impedances will be verified and maintained <50 kΩ for the duration of the study. The patient will be positioned supine and all routine monitors will be installed. A 5 minutes baseline resting-state Hd-EEG with eyes closed will be performed before induction. Once under general anesthesia and intubated, a no pain period of 5 minutes will take place. During this 5-min period, resting-state Hd-EEG recording will be recorded. A standardized tetanic stimulation to the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator (100 Hz, 70 mA) for a duration of 30 seconds will then be applied. Hd-EEG recording will take place during this 30 seconds and will continue during the 5 minutes after. Once this period will be over, the Hd-EEG net will be removed and the investigators will exit the operating room."
75339589|NCT05877326|Drug|General anesthesia with propofol or sevoflurane|General anesthesia
75339590|NCT05877326|Behavioral|CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative|The presence of mental confusion will be determined by CAM-ICU at J3 post intervention.
75339591|NCT05871489|Drug|Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)|Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
75339592|NCT05871489|Drug|Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)|Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
75797002|NCT01150188|Dietary Supplement|Placebo|Placebo of inert compounds, 11 g two times per day for eight weeks
75339593|NCT05871489|Drug|Bdq, Lzd, Lfx, Z, Dlm (9-12 months)|Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
75797003|NCT03899142|Biological|a human hepatitis B immunoglobulin solution for injection for intramuscular administration|intramuscular administration
75339594|NCT05871346|Behavioral|Complementary feeding counseling|Complementary Feeding Counseling to Improve Appropriate Complementary Feeding Practices and Reduce Child Undernutrition
75339595|NCT05868694|Diagnostic Test|polysomnography|Polysomnography is mainly used to diagnose sleep breathing disorders, including sleep apnea syndrome, snoring, upper airway resistance syndrome, and also used for the auxiliary diagnosis of other sleep disorders, such as: narcolepsy, restless legs syndrome, insomnia classification, etc.
75339596|NCT05855304|Other|manual therapy|The leg length was measured while the subjects were lying on their stomachs. Then, by grasping the lateral malleolus, the knees are bent 90 degrees and changes in leg length were observed, the positions of the SI joints were noted. Afterwards, the person
75474072|NCT01978873|Drug|Cabazitaxel + Androgen deprivation therapy|Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
75797004|NCT01255488|Behavioral|Access to EBN-Search (without full-text manuscripts)|Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
75797005|NCT03892902|Drug|ACT-541468|Film-coated tablet for oral use at a dose strength of 50 mg.
75797006|NCT03892902|Drug|Zopiclone 7.5 mg|Over-encapsulated to maintain blinding.
75797007|NCT03892902|Other|Placebo|Matching to maintain blinding.
75797008|NCT03895866|Other|The participants were assigned to different groups according to the results of HPV detection.|The participants were assigned to different groups according to the results of HPV detection
75797009|NCT03895554|Procedure|cardiac PET stress test|Volunteers will undergo cardiac PET stress testing
75797010|NCT03892668|Drug|Tranexamic Acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
75934953|NCT03670303|Behavioral|Educational intervention|"Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~Lectures on importance of spectacles use including visual materials such as pictures and videos.~An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~Posters~Brochures"
75934954|NCT03209336|Radiation|Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）|We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
75934955|NCT05208021|Behavioral|Intervention group (Motivational Interviewing)|The Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program were applied to the experimental group, which consisted of 6 sessions and lasted an average of 60-120 minutes. Sessions were held in the form of individual interviews due to the pandemic and social distance conditions.
75339597|NCT05855304|Other|Kinesiology taping|As part of the tape (kinesio tex brand) kinesio protocol used in this study, the starting position of the kinesio tape is the site of lumbar spine flexion. Kinesio tape was applied transversely to the bilateral sacroiliac joint area as a long I-shaped piece of tape with 80% tension and no tension was applied to the ends of the tape. Another short tape will be adhered to the SI joint with 80% tension at a right angle to the hip, and no tension is applied to the ends of the tape.
75339598|NCT05851326|Device|Active Sonodyn|Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.
75797011|NCT03892668|Drug|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
75339599|NCT05851326|Device|Sham|Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.
75339600|NCT05850793|Behavioral|Sensorimotor Exercise|Balance, perturbation , aging and strengthing exercise will be performed for knee
75339601|NCT05850793|Behavioral|Conventional Exercise|Range of motion, strengthing and stretching exercise will be performed for knee
75649759|NCT04266626|Other|oral motor manipulation therapy|Manipulation therapy include tapping and massage of oral motor muscles including orbicularis oris and base of tongue.
75797012|NCT03892668|Drug|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
75339602|NCT05850793|Behavioral|Progressive Motor Imagery Exercise|Different types of exercises will be applied targeting muscle strength, proprioceptive sense or brain neurons for knee
75649760|NCT02585128|Other|Delirium assessment|During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)
75649761|NCT02585128|Other|MMSE (Mini Mental State Examination)|
75934956|NCT03209102|Other|Clinical assessment|"Self-assessments based on questionnaires : Strengths and Difficulties Questionnaire - Development and Well-Being Assessment (SDQ-DAWBA) ; Pubertal Development Scale ; Life Events Questionnaire ; Childhood Trauma Questionnaire ; Abbreviated - Diagnostic Instrument for Borderline (Ab-DIB) ; Beck Depression Inventory ; Socio-demographic questionnaire)~and clinical evaluation by a psychiatrist : Mini-International Neuropsychiatric Interview (MINI); Global Assessment of Functioning"
75934957|NCT03209102|Behavioral|Stress elicitation experiment|"The stress elicitation experiment is based on a time-constrained mental arithmetic test in the presence of an observer. The task usually lasts about 30 minutes.~During the task, the investigators will monitor: neuro-vegetative parameters (skin conductance, temperature, respiratory and cardiac frequencies, and VNA) ; biological parameters : salivary Cortisol and Amylase before test (baseline), 15 min and 30 min after testing (respectively corresponding to Reactivity and Recovery) ; micro-behavioral cues extracted from 2D video and 3D sensors (Microsoft Kinect)."
75339603|NCT05837000|Drug|Dexmedetomidine|Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
75339604|NCT05837000|Drug|Ketamine|Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally
75474073|NCT01978873|Drug|Androgen deprivation therapy|LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
75649762|NCT02585128|Other|Barthel index|
75649763|NCT02585128|Other|HADS (Hospital Anxiety and Depression Scale)|
75649764|NCT02585128|Other|MNA-SF (Mini Nutritional Assessment - Short Form)|
75649765|NCT02585128|Device|NIRS (Near-Infrared Spectroscopy)|Regional cerebral oxygen saturation monitoring during TAVI procedure
75934958|NCT03209102|Other|Structural and Functional MRI|"Structural and Functional Magnetic Resonance Imaging (MRI). The functional acquisition will last 20 minutes and the structural acquisition 18 minutes. All MR image acquisition methodologies are already functioning on the 3 Tesla Prisma machine within the ICM(Brain and Spine Institute), Salpetriere. The fMRI session will provide three types of data: (1) task-related activity to probe the striato-limbic and prefrontal regions, (2) resting state connectivity to examine the integrity of canonical networks, and (3) MR structural images to measure regional volumes of key functional nodes.~For the task-related fMRI study, the investigators will use the monetary incentive delay task that reliably elicit an activation in known functional networks underlying reward anticipation/outcome."
75934959|NCT03209102|Biological|salivary collections of amylase and cortisol|Collection of saliva samples of cortisol and amylase repeated three times
75339605|NCT05837000|Drug|Magnesium sulphate|Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
75474074|NCT01978899|Behavioral|Immediate Weight Loss Program Group|Participation in 15-week Healthy Living Program.
75474075|NCT01978899|Behavioral|Delayed Weight Loss Program Group|Participation in 15-week Healthy Living Program following 15-week wait period.
75649766|NCT02585128|Other|CIRS (Cumulative Illness Rating Scale)|
75649767|NCT04266782|Other|Exercise program followed by long walk in group|The subjects will be included in a training exercise program for three months followed by a long-walk in group
75339606|NCT05833139|Drug|BI 1810631|BI 1810631
75339607|NCT05833139|Drug|Itraconazole|Itraconazole
75339608|NCT05821504|Behavioral|High-Intensity Interval Training|The training intervention is a popular exercise format that consist of alternating brief bouts of high-intensity efforts with bouts of light effort or complete rest.
75339609|NCT05821296|Device|Crystal Peel|3 applications performed by a dermatologist.
75649768|NCT04266782|Other|Exercise program followed by long walk in group (controls)|The controls matched for age will perform the same exercise program and long walk as the PD subjects
75649769|NCT00941720|Drug|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
75649770|NCT00941720|Drug|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
75649771|NCT00941720|Procedure|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
75649772|NCT02583568|Drug|Bevacizumab-800CW|three days prior to surgery bevacizumab-800CW will be administered
75649773|NCT02583802|Drug|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
75649774|NCT02583802|Drug|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
75649775|NCT02852564|Drug|Ethacrynic Acid|One oral dose at 50 mg prior to bladder tumor removal surgery
75339610|NCT05820321|Dietary Supplement|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (400mg) during 8-days. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will return to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
75797013|NCT01151982|Behavioral|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
75797014|NCT01258920|Drug|Paliperidone palmitate|Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
75934960|NCT02283099|Biological|rVSVΔ-ZEBOV-GP|single dose of rVSVΔ-ZEBOV-GP (3x10^6 pfu, 2x10^7 pfu or 3x10^5)
75339611|NCT05820321|Other|Beetroot juice NO3 depleted|The participant will intake beetroot juice depleted in NO3. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
75649776|NCT04481230|Drug|99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)
75339612|NCT05794880|Device|Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)|Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.
75339613|NCT05786287|Biological|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
75339614|NCT05786287|Biological|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
75649777|NCT04481230|Drug|99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)
75649778|NCT04481230|Drug|99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
75649779|NCT05593042|Biological|CoronaVac®|The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.
75649780|NCT05593042|Biological|Omicron Vaccine|"An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant."
75649781|NCT05593042|Biological|Trivalent Vaccine|"An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant)."
75649782|NCT02583412|Biological|Bexsero®|Multicomponent meningococcal B vaccine
75649783|NCT02583412|Biological|Havrix®|Hepatitis A vaccine
75649784|NCT05509816|Drug|Midazolam|Administered orally.
75649785|NCT05509816|Drug|Imlunestrant|Administered orally.
75649786|NCT02584972|Other|no intervention required|no intervention required
75797015|NCT03892590|Biological|Gut microbiota|Status of microbiota
75649787|NCT04078750|Behavioral|Tailored medication adherence plan|Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
75649788|NCT02581852|Other|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
75649789|NCT02583334|Device|Verum acupuncture (30# acupuncture needle)|Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)
75797016|NCT03898752|Dietary Supplement|Omega 3|Omega 3: 1g daily for 3 months CoQ10: 100 mg daily for 3 months Multivitamin: 1 normal multivitamin tablet daily for 3 months
75797017|NCT02527902|Device|Holter|measure of ANS in IgAN patients
75797018|NCT03898830|Device|eon™ FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
75934961|NCT03670225|Device|Invia Motion Endure|NPWT Invia Motion Endure
75934962|NCT03208400|Behavioral|virtual reality exposure|one-session exposure conveyed via virtual reality technology
75934963|NCT02280447|Biological|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
75934964|NCT02280447|Biological|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
75797019|NCT01255644|Drug|Valganciclovir|900 mg every 24 hours per os, day 1 through 90
75934965|NCT02280447|Biological|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
75339615|NCT05780450|Device|Transcranial Direct Current Therapy (tDCS)|"Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential.~Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA.~The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment."
75339616|NCT05763849|Behavioral|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance in Anorexia Nervosa. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Early sessions include using exposure to foods and counterconditioning to pair a positive stimulus with a food that would typically produce food avoidance. Parents are trained to model this at home. Sessions mid-way through address the use of non-judgmental description of appearance during mirror exposure. Sessions at the end of the 20 weeks are focused on recognizing change, planning for future obstacles, and developing a relapse prevention plan to continue practicing distress tolerance, counter-conditioning, and food/body exposure.
75339617|NCT05763849|Behavioral|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) includes parent-enforced contingencies to increase value of eating and decrease the value of food avoidance. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Sessions consist of checking in with the patient, discussion of the week's implementation of refeeding, and helping parents separate the illness from their child. In session 2, a family meal provides the therapist with an opportunity for direct observation of the familial interaction patterns around eating. The therapist makes careful and persistent requests for united parental action toward re-feeding and/or regulating eating habits, the primary concern at this point of the treatment, and the therapist tries to create and reinforce a strong parental alliance around efforts at feeding the child.
75649790|NCT02583334|Device|Sham acupuncture|Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
75339618|NCT05761561|Behavioral|Exercise and medical nutrition|"The study dietitian and exercise trainer will each conduct weekly counseling sessions via telephone or zoom throughout the course of chemotherapy (approximately 18 weeks) to assist the participants in achieving the diet and exercise study goals. Participants will be provided written informational material, exercise bands for strength training and a Fitbit to record activity.~Participant goals are to: 1) participate in 150 min/week of moderate-intensity physical activity 2) participate in two weekly strength training sessions; 3) eat a combination of 5 or more servings of vegetables and/or fruits per day 4) consume 25 grams or more of fiber/day; 5) consume adequate amounts of protein to prevent muscle wasting (1.2g/kg body weight)."
75339619|NCT05747430|Drug|IRX-101|IRX-101 is a novel ocular anti-septic
75339620|NCT05747430|Drug|Providone-Iodine|5% Providone-Iodine
75339621|NCT05747339|Biological|tumor treatment vaccine injection|Patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml / week, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml / week.The interval between injections can be shortened or extended depending on the patient's condition and response.The duration of treatment should be extended as long as possible, at least 6-12 months.
75339622|NCT05740475|Drug|9MW3811 injection|Single dose intravenously infused on day 1
75339623|NCT05740475|Drug|Placebo|Single dose of matching placebo intravenously infused on day 1
75797020|NCT01259076|Procedure|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
75649791|NCT04080310|Drug|Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin|"This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily."
75649792|NCT02584894|Device|rTMS 1Hz|trauma exposure + repeated transcranial magnetic stimulation at 1Hz
75649793|NCT02584894|Device|rTMS 10Hz|trauma exposure + repeated transcranial magnetic stimulation at 10Hz
75649794|NCT02584894|Behavioral|psychoneurological assessment|psychoneurological assessment
75649795|NCT02584894|Device|conductivity meter|electrodermal conductance measure
75797021|NCT01259076|Procedure|digital mammography|Undergo digital mammography at baseline and 1 year later.
75649796|NCT02584894|Device|electrocardiogram|heart rate measure
75797022|NCT01259076|Procedure|conventional surgery|Undergo gastric bypass surgery
75934966|NCT02280447|Biological|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
75934967|NCT03675295|Drug|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
75934968|NCT03675295|Drug|Saline|injection of 10 cc saline injection nearby median nerve as hydro-dissection
75934969|NCT00528333|Drug|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
76087560|NCT02490540|Drug|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
75339624|NCT05736861|Drug|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
75339625|NCT05736861|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
75339626|NCT05710965|Device|FRx-001|Wearable digital therapy
75339627|NCT05710965|Device|FRx-003|Wearable digital therapy
76087561|NCT02490462|Other|Education + Conventional PhysicalTherapy|The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.
75649797|NCT00933686|Drug|Saizen®|Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.
75649798|NCT00933686|Drug|Placebo and Saizen®|Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
75339628|NCT05710965|Device|FRx-004|Wearable digital therapy
75339629|NCT05708833|Device|Intraosseous venous access|Immediate placement of humeral intra-osseous venous access (after a first failed attempt of peripheral venous access)
75649799|NCT04078048|Dietary Supplement|Antioxidants (Vitamin C, E )|For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
75649800|NCT04079998|Device|Procellera®|Application of Procellera® dressing.
75649801|NCT04079998|Other|Standard of Care|Application of standard of care dressings as prescribed.
75934970|NCT00528333|Drug|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
75339630|NCT05708833|Device|Peripheral venous access|Looking for peripheral venous access, changing the site of puncture, the caliber of the catheter and/or the operator and/or assistance tools (ultrasound, infra-red guidance...) and/or using another route (oral, rectal, subcutaneous, intramuscular route and central venous access)
75339631|NCT05707273|Drug|Autologous Anti-CD19 CAR-expressing T Lymphocytes|Given IV
75339632|NCT05707273|Procedure|Biospecimen Collection|Undergo blood sample collection
75339633|NCT05707273|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate
75339634|NCT05707273|Drug|Cyclophosphamide|Given IV
75339635|NCT05707273|Drug|Fludarabine|Given IV
75339636|NCT05707273|Procedure|Leukapheresis|Undergo T-cell leukapheresis
75339637|NCT05707273|Other|Questionnaire Administration|Complete questionnaires
75339638|NCT05706649|Behavioral|Plant-based diet|21 day diet that excludes any form of meat and other animal products, including dairy products.
75339639|NCT05705856|Drug|Ustekinumab|Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.
75339640|NCT05699668|Device|OCT Angiography|"2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds."
75649802|NCT05379140|Behavioral|Three Weekly Therapeutic Chinese Massage Sessions|Participants in the therapeutic Chinese massage group received three weekly 25-minute therapeutic Chinese massage sessions. The intervention included acupressure to points along the distal lower extremity acupuncture points of the Gall Bladder Channel (GB 40 and then 34). Further Chinese Massage incorporates kneading, rolling, movement of the ankle, rotating, pulling, and scrubbing to the lower extremity.
75934971|NCT00528333|Drug|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
75934972|NCT03675217|Other|PE|Physical exercise program for familiy caregivers. 36 session physical exercise (3 sessions/week) performed by physioterapist. It incluided exercices to improve coordination, aerobic capacity, control motor and strenght
75934973|NCT03675217|Other|Usual Care|Usual Programe in primary care for family caregivers. 4 session (2 session/week). It incluides: ergonomy, postural hygiene, mobilitation of patients and self-care.
75934974|NCT00526227|Device|Secura ICD|Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
75934975|NCT02284425|Drug|REGN1193|
75934976|NCT02284425|Drug|Placebo|
76087562|NCT02490462|Other|Conventional Physical Therapy|The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
76087563|NCT03319290|Genetic|BRCA1 and BRCA2|Genetic breast and ovarian cancer testing
75649803|NCT05379140|Behavioral|Three Weekly Placebo Massage Sessions|The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
75649804|NCT04445896|Other|Qualitative Interview|Qualitative Interview to explore thoughts and feelings related to previous discussions around care at end of life
75649805|NCT02729974|Procedure|ROTEM|rapid testing of blood clot formation
75649806|NCT02729974|Procedure|standard treatment|visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
75649807|NCT00937040|Drug|OROS MPH|Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
75649808|NCT00937040|Drug|Placebo|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
75797023|NCT05119374|Device|SenseGuard Investigational Device|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
75797024|NCT01255800|Drug|IPI-926 and Cetuximab|"Patients will receive Cetuximab IV every week.~Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day."
75797025|NCT03898674|Drug|Intra venous fluid|Volume of intra venous fluid administered during GDT protocol
75649809|NCT00937040|Drug|OROS MPH Tablets|Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
75649810|NCT00937040|Drug|Placebo Tablets|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
75649811|NCT02583178|Device|Aegis Sierra Ligation System|The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
75934977|NCT03134157|Drug|oral drug and vaginal placebo|prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
75934978|NCT03134157|Drug|oral drug and oral placebo|prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
75934979|NCT03134157|Drug|Vaginal placebo+ oral placebo|prescription of Vaginal placebo + oral placebo every day for 3 months.
75934980|NCT02280603|Drug|DA-4001C|1ml by topical application twice a day
75934981|NCT02280603|Drug|5% minoxidil|1ml by topical application twice a day
75934982|NCT03134235|Other|Dietary Intervention|Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
75934983|NCT00524277|Biological|GP2 peptide + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
75934984|NCT00524277|Biological|GM-CSF (sargramostim)|GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
76087564|NCT02484300|Dietary Supplement|Melatonin|
76087565|NCT02484300|Other|Placebo|
75649812|NCT00673387|Drug|pramlintide acetate|subcutaneous injection, twice a day
75649813|NCT00673387|Drug|metreleptin|subcutaneous injection, twice a day
75649814|NCT00673387|Drug|placebo-P|subcutaneous injection, twice a day
75649815|NCT00673387|Drug|placebo-M|subcutaneous injection, twice a day
75649816|NCT00607490|Behavioral|Cognitive-Behavioral Therapy|Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
75649817|NCT00607490|Behavioral|Supportive Psychotherapy|Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
75649818|NCT03927430|Procedure|pars plana vitrectomy with membrane peeling|23-gauge pars plana vitrectomy with peeling of the epiretinal and internal limiting membrane as well as air- or gastamponade
75649819|NCT02583100|Behavioral|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
75797026|NCT01257906|Drug|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel applied in the evening for 84 days
75797027|NCT01257906|Drug|ZIANA®|Topical Gel applied in the evening for 84 days
75934985|NCT00524277|Biological|AE37 + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
75934986|NCT00524277|Biological|GM-CSF (sargramostim)|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
75934987|NCT02284503|Drug|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
75934988|NCT00650949|Drug|CYT997|Escalating doses (100mg/m^2 to 150mg/m^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
76087566|NCT02484066|Device|VBN|VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
76087567|NCT02484066|Device|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
76087568|NCT02484066|Device|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
76087569|NCT03319056|Other|Air purifier|active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design
75339641|NCT05698654|Behavioral|Fasting-mimicking diet (FMD)|"The subjects will be instructed to follow their usual diet plan, except for 5 days when they eat the foods in the FMD box.The fasting-mimicking diet consists of a blend of 100% plant based nutrients generally regarded as safe. The formulation of these products is based on studies carried out at the Longevity Institute of the University of Southern California and his collaborators over several decades of studies.~This food plan provides for the replacement of the normal diet with the organic plant products contained in the fasting-mimicking diet for five consecutive days."
75339642|NCT05698654|Behavioral|Longevity Diet (LD) + Fasting-mimicking Diet (FMD)|"The subjects will be instructed to follow their longevity diet plan, except for 5 days when they eat the foods in the FMD box, based on the following guidelines:~vegan based diet with the addition of low mercuryfish 2-3 times a week; protein content should be 0.7-0.8 grams per kilogram of ideal weight per day (most of the protein coming from whole cereals,vegetables, legumes and tree nuts only part from fish); monounsaturated and polyunsaturated fats are predominant and very low amounts of saturated and trans-fats are allowed; complex Carbohydrates from vegetables, whole grains and legumes; addition of vitamins, minerals and Omega3 fats; food selected between the traditional food consumed by ancestry; time-restricted feeding: all food must be consumed within 12 hours each day. for those who are overweight or are nearly overweight (BMI >25 kg/m2), either lunch or dinner will be substituted with a low calorie, low sugar snack (approximately 100 kcal: salad, nuts, fruit, etc.)."
75649820|NCT02583100|Behavioral|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
75649821|NCT00933608|Drug|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
75649822|NCT00933608|Drug|Placebo|participants will be asked to take 2 tablets per day to match active drug
75649823|NCT02582944|Device|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
75934989|NCT00650949|Drug|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
75934990|NCT00520923|Drug|LY2140023|80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
75649824|NCT02582944|Device|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
75649825|NCT02582944|Device|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
75797028|NCT01257906|Drug|Vehicle Control|Topical Gel applied in the evening for 84 days.
75934991|NCT00520923|Drug|LY2140023|40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
76087570|NCT02727660|Drug|BFF MDI (PT009) 320/9.6 μg|Blinded Treatment
76087571|NCT02727660|Drug|BFF MDI (PT009) 160/9.6 μg|Blinded Treatment
75649826|NCT02582944|Procedure|Biopsy|
75649827|NCT04264520|Behavioral|PTSD Psychoeducation + Skills Intervention|A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
75649828|NCT05380310|Device|"Active SMART ANGEL solution"|Nurse intervention according to the alert level + traditional monitoring
76087572|NCT02727660|Drug|FF MDI (PT005) 9.6 μg|Blinded Treatment
76087573|NCT03321474|Procedure|modified gull wing preparation|"preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
75649829|NCT05380310|Device|"Inactive SMART ANGEL solution"|No alert + traditional monitoring + alert in case of imminent life threat
75649830|NCT00764569|Device|Fluorescence/Elastic Scattering Spectroscopy|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
75649831|NCT04253054|Other|Cardiovascular risk factors|Different level of cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, smoke, alcohol drink, obesity and et al, associated with genetics, environments and lifestyles
75649832|NCT04253054|Other|Aging related health problems|Aging related health problems
76087574|NCT02490384|Procedure|Physical exam indicated cerclage|Cervical cerclage
75797029|NCT03892512|Drug|Esmolol Hydrochloride|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )
75797030|NCT03892512|Drug|Dexmedetomidine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )
75797031|NCT01257984|Drug|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
75797032|NCT01257984|Drug|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
75934992|NCT00520923|Drug|LY2140023|20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
75797033|NCT01152138|Device|Open cells stent|Cobalt Chromium Stent with open cell design
75934993|NCT00520923|Drug|LY2140023|5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
75934994|NCT00520923|Drug|Olanzapine|10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
75934995|NCT00520923|Drug|Placebo|Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
75934996|NCT00520923|Drug|Placebo|Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
75934997|NCT02547922|Biological|Anifrolumab|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
75934998|NCT02547922|Drug|Placebo|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
76087575|NCT02490072|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
75797034|NCT01152138|Device|Closed Cells Stent|Cobalt Chromium stent with closed cell design
75797035|NCT03895164|Behavioral|Enhanced NE|Standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
75797036|NCT03895164|Behavioral|Standard NE|Standard nutrition education package from primary health care
76087576|NCT02490072|Drug|normal saline(Saline 0.9%)|
76087577|NCT02490228|Procedure|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
75339644|NCT05689125|Device|Railroaded bougie|Residents expose the glottis by a video laryngoscope and place the tip of bougie through the vocal cords. Then, an assistant loads an endotracheal tube on the free end of the bougie. Residents advance the endotracheal tube over the bougie and withdraw the bougie.
75339645|NCT05689125|Device|Preloaded bougie|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation using a bougie with a preloaded endotracheal tube while an assistant secures the free end of the bougie. Residents withdraw the bougie when the endotracheal tube reaches an appropriate depth.
75339646|NCT05689125|Device|Stylet|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation with the assistance of a stylet. An assistant withdraws the stylet when the tip of the endotracheal tube passes through the vocal cords. Then residents place the endotracheal tube to an appropriate depth.
75339647|NCT05684939|Behavioral|Questionnaire (patient reported outcome)|Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies
75339648|NCT05672173|Procedure|Biopsy|Undergo tumor biopsy
75797037|NCT01258062|Drug|GelVac™ nasal powder H5N1 influenza vaccine.|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
75797038|NCT01258062|Drug|Placebo|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
75797039|NCT03895398|Other|nutrition and psychosocial intervention with community participatory|community participation to ensure the intervention is given to the study subject (underfive children)
75797040|NCT01255878|Device|occlusal stabilization splint|
75934999|NCT02286375|Behavioral|Intervention group|A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
75935000|NCT02283177|Drug|crenolanib|
75935001|NCT02283177|Drug|cytarabine|
75339649|NCT05672173|Procedure|Biospecimen Collection|Undergo blood specimen collection
75339650|NCT05672173|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
75339651|NCT05672173|Procedure|Computed Tomography|Undergo PET/CT
75339652|NCT05672173|Drug|Cyclophosphamide|Given IV
75339653|NCT05672173|Drug|Fludarabine|Given IV
75339654|NCT05672173|Drug|Ibrutinib|Given PO
75339655|NCT05672173|Biological|Lisocabtagene Maraleucel|Given IV
75339656|NCT05672173|Biological|Nivolumab|Given IV
75339657|NCT05672173|Procedure|Pheresis|Undergo apheresis
75797041|NCT01255878|Drug|Gabapentine|100 mg(1 capsule)three times per day for two months
75797042|NCT01255956|Device|Rapamycin eluting stent implantation|Rapamycin eluting stent implantation for in-stent restenosis treatment
75797043|NCT01255956|Device|Paclitaxel eluting balloon catheter|Paclitaxel eluting balloon catheter for in-stent restenosis treatment
75797044|NCT01258140|Radiation|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
75797045|NCT01258140|Radiation|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
76087578|NCT02483910|Behavioral|Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)|"DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons."
76087579|NCT02483910|Behavioral|Standard of care delivered via telehealth (e.g., Zoom or WebEx)|Usual care including speech therapy in school, community or both
75339658|NCT05672173|Procedure|Positron Emission Tomography|Undergo PET/CT
76087580|NCT03318822|Device|Q-Collar|An externally-worn medical device that applies mild jugular compression
76087581|NCT02490150|Drug|Corifollitropin alfa|
76087582|NCT02487576|Other|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
76087583|NCT02487576|Other|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
76087584|NCT02483598|Drug|Buspirone|The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
76087585|NCT02483598|Drug|Buspirone and Grapefruit Juice|Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
76087586|NCT02483832|Behavioral|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
75339659|NCT05661643|Drug|Temozolomide capsule|Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
75797046|NCT03892434|Drug|Intravitreal bevacizumab and dexamethasone implant Injection|Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.
75797047|NCT03892434|Device|Intravitreal dexamethasone implant|Dexamethasone implant insertion using approved kit
75339660|NCT05660096|Device|Cionic Neural Sleeve NS-100|Sleeve applies neuromuscular stimulation as patients walk to help contract appropriate muscles at appropriate times.
75339661|NCT05659056|Drug|Pyrotinib, trastuzumab, paclitaxel-albumin|pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
75339662|NCT05654649|Drug|0.9%sodium chloride|Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
75935002|NCT02283177|Drug|daunorubicin|
75935003|NCT02283177|Drug|idarubicin|
75339663|NCT05654649|Drug|Dexamethasone|Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
75649833|NCT02558023|Drug|Urapidil|"Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
75649834|NCT02558023|Drug|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
75797048|NCT01256112|Behavioral|Parent Supported Behavioral Intervention|Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
76087587|NCT03321318|Drug|AK-R215|Investigational product is prescribed to all ofrandomized subjects
76087588|NCT03321318|Drug|Bazedoxifene 20 mg|Investigational product is prescribed to all of randomized subjects
76087589|NCT03321318|Drug|Cholecalciferol 800IU|Investigational product is prescribed to all of randomized subjects
76087590|NCT01784861|Drug|X-82|
76087591|NCT01784861|Drug|Everolimus|
76087592|NCT03318744|Drug|Aspirin|Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.
76087593|NCT03318744|Drug|Placebo Oral Tablet|Placebo resembling aspirin tablet will be be given to participants in control arm.
75649835|NCT00607568|Drug|Atomoxetine|"atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II."
75649836|NCT00606164|Drug|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
75649837|NCT00606164|Drug|Placebo|A single one-hour intravenous infusion of placebo on Day 1
75797049|NCT01256112|Behavioral|Nutrition/Activity Education (NAE)|
75935004|NCT00514371|Drug|tanespimycin|High dose
75935005|NCT00514371|Drug|Bortezomib|Mid dose, and low dose
75935006|NCT04471077|Procedure|bariatric surgery|(Laparoscopic Sleeve Gastrectomy, laparoscopic Roux-en-Y gastric bypass)
75935007|NCT04470765|Device|Zida|Transcutaneous Tibial Nerve Stimulation
75935008|NCT02547766|Drug|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
75935009|NCT04470531|Drug|oral co-trimoxazole|oral co-trimoxazole + standard therapy
75935010|NCT02286453|Drug|Benjakul recipe|Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days
75935011|NCT02286453|Drug|diclofenac|diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
76087594|NCT02489994|Device|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
76087595|NCT02487342|Other|milk|small serving (217 mL) of british semi-skimmed milk
75935012|NCT02286531|Drug|O-(2[18F]FLUOROETHYL)-L-TYROSINE|Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
75935013|NCT04470999|Other|Leukapheresis|Blood collection and PBMC collection via apheresis machine will be conducted
75935014|NCT00385515|Drug|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
75935015|NCT00385515|Drug|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
75339664|NCT05654324|Other|pelvic floor muscle exercises|Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.
75649838|NCT04266548|Procedure|Superselective Intra-arterial Hepatic Injection of Indocyanine Green (ICG) for Fluorescence Image-guided Segmental Positive Staining|The patients with single HCC which is planned to received laparoscopic hepatectomy were involved. Procedures were performed in conventional angiography room. The celiac trunk was catheterized and a microcatheter was advanced into segmental hepatic artery branches which supplied the HCC. The 5cc 0.125 mg/cc ICG was injected from super-selective hepatic artery in operative room. A Near-Infrared laparoscope was used to detect the fluorescent signal to assess the correspondence between arterial-based fluorescence demarcation and ultrasound-based surgical demarcation.
75649839|NCT00604916|Other|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
75935016|NCT04471155|Procedure|Holep|laser enucleation of the gland versus open enucleation
75649840|NCT00604916|Other|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
75649841|NCT04610710|Procedure|Operation|Operation for deep infiltrating endometriosis
75649842|NCT04610710|Procedure|Fertility treatment|In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)
75935017|NCT00443391|Drug|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
75797050|NCT03895242|Behavioral|Group 1:Supine-Prone|After the infants were treated and fed, supine position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in supine position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the supine positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the prone position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the prone position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
75935018|NCT02286609|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
75935019|NCT00511485|Drug|Vintafolide|Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
76087596|NCT02487342|Other|orange fruit-juice|small serving (217 mL) of orange juice
76087597|NCT02489916|Drug|CM4307|CM4307 300mg bid, each 4 week cycle
76087598|NCT01751308|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Injection Route of administration: Intravenous
76087599|NCT02489682|Other|Long-form written Informed consent information|
75339665|NCT05608759|Behavioral|Multimodal prehabilitation|4 weeks of an supervised, pre-operative exercise prescription augmented by a wearable fitness device.
75339666|NCT05591820|Behavioral|Brief behavioral parent training with optional booster sessions|A brief and individually-tailored behavioral parent training program that combines stimulus control and contingency management techniques to treat children's disruptive behaviors in three (bi)weekly sessions and optional booster sessions.
75649843|NCT04323670|Device|"Selectra 3D guiding catheter"|His lead measurements
75649844|NCT00574951|Drug|motesanib diphosphate|
76087600|NCT02489682|Other|Short-form written Informed consent information|
76087601|NCT02489682|Other|Video Informed consent information|
76087602|NCT02483364|Other|HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)|A single application in the context of a single surgical intervention.
76087603|NCT02487186|Drug|Doxicicline|Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
75649845|NCT02584816|Biological|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
75935020|NCT00511485|Drug|Etarfolatide|
75339667|NCT05591820|Behavioral|Care as usual|The care that is usually provided by the clinical institutions to treat children's disruptive behaviors. There will be no restrictions regarding type or duration of CAU (only the brief parent training will not be allowed) which may for example include psychoeducation, (long) parent training, child treatment (e.g., pharmacotherapy, cognitive behavioral therapy) or family therapy.
75339668|NCT05589337|Behavioral|Baduanjin|The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
75339669|NCT05589337|Behavioral|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
75935021|NCT00508989|Drug|Niacin-ER|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
75935022|NCT00508989|Drug|Placebo|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
75339670|NCT05567237|Other|Microcurrent treatment with resistance exercise programme|This intervention will allow us to explore the effects of microcurrent added to resistance exercise.
76087604|NCT02487186|Procedure|Full-mouth debridment|"The patients will be treated by a single-session of periodontal debridement~during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de~Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed."
75339671|NCT05567237|Other|Resistance exercise programme|This intervention works as a control group for the participants undergoing the exercise programme.
75935023|NCT00508989|Drug|L-NMMA|
76087605|NCT03315624|Device|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
76087606|NCT01751386|Drug|Baclofen|
76087607|NCT01751386|Other|Placebo|
76087608|NCT02486874|Device|PoreSkin|a human acellular dermal matrix
76087609|NCT02489760|Biological|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
76087610|NCT02489760|Biological|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
76087611|NCT01752400|Drug|AUY922|
76087612|NCT03321240|Procedure|visual and quantitative SEEG signal analysis|signal SEEG analysis
76087613|NCT03321240|Procedure|Resective epilepsy surgery procedure|Surgical removal of the epileptogenic brain area
76087614|NCT01752712|Drug|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
76087615|NCT01752712|Drug|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
76087616|NCT03318510|Device|Laser Speckle Flowgraphy|A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
76087617|NCT02489370|Device|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
76087618|NCT05127928|Dietary Supplement|Dietary Supplement: Vitamin C and vitamin E|Antioxidant supplementation
76087619|NCT05127928|Dietary Supplement|Placebo|Placebo administration
76087620|NCT03315546|Radiation|radiotherapy delivery in deep-inspiration|Radiotherapy delivery i deep-inspiration versus free-breathing
76087621|NCT01754350|Dietary Supplement|calorie-restricted ketogenic diet and transient fasting|"On day 1-3 and day 7-9, restriction of carbohydrates to < 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by Tavarlin."
75649846|NCT02584816|Biological|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
75649847|NCT02584816|Biological|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
75649848|NCT02584816|Biological|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
75935024|NCT00508989|Drug|Acetylcholine|
75935025|NCT02742441|Drug|122-0551 Foam|Topical Foam containing active drug
75935026|NCT02742441|Drug|Vehicle Foam|Topical Foam containing no active drug
75935027|NCT05457166|Device|KASPARD system for fall prevention in nursing homes|"All subjects will be monitored for 2 periods of 100 nights each. Recordings will be made continuously at night for the duration of the study Period 0: set-up, adjustment, recording (without alarm); This is a preparatory phase which is part of the usual use of the device.~Duration: 10 days Before period: The BEFORE period runs for 100 nights during which the device alarm is not activated, but the device records events.~After period: The AFTER period is 100 nights during which the device alarm is activated: Monitoring with recording + alarm activated (usual care + action if alarm is triggered)"
76087622|NCT01754350|Dietary Supplement|standard nutrition|nutrition as recommended by the german society for nutrition, 30 kcal/kg per day
76087623|NCT02483130|Dietary Supplement|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
76087624|NCT02483130|Other|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
76087625|NCT03318354|Drug|Torrent's Olmesartan Medoxomil Tablets 40 mg|
76087626|NCT03318354|Drug|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
76087627|NCT02727192|Device|PAP (CPAP or ASV)|Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
76087628|NCT02252068|Behavioral|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
76087629|NCT02252068|Behavioral|IDC|Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
76087630|NCT05093140|Drug|Camrelizumab|"Induction therapy:~Camrelizumab 200mg, ivd, D1, Rituximab 375mg/m2, ivd, D1 every 3 weeks up to 2 cycles~Immunochemotherapy:~Rituximab: 375mg/m2, ivd, D1; Cyclophosphamide: 750mg/m2, iv or ivd, D1; Hydroxyldaunorubicin: 50mg/m2, iv or ivd, D1; Vincristine: 1.4 mg/m2 , iv(max：2mg), D1; Prednisone: 60mg/m2, po, d1-5 every 3 weeks up to 6 cycles Maintenance therapy: Camrelizumab 200mg, ivd, D1 every 4 weeks up to 6 cycles"
76087631|NCT05076214|Behavioral|Aerobic exercise in group|"The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions~Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
75797051|NCT03895242|Behavioral|Group 2:Prone-Supine|After the infants were treated and fed, prone position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in prone position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the supine position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the supine position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
75797052|NCT01151514|Other|Nephrologist referral|Nephrologist specialty, renal replacement therapy
75797053|NCT03895086|Other|Specific Physical Activity|An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)
76087632|NCT05076214|Behavioral|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together
76087633|NCT05021848|Other|partnered multicomponent exercises program|aerobic,strength, flexibility and balance exercises and game
75339672|NCT05567237|Other|Microcurrent treatment|This intervention will allow us to explore the effects of microcurrent alone.
75649849|NCT02584738|Drug|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
75797054|NCT03895086|Behavioral|Classic Physical Activity|"One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association"
75935028|NCT04470141|Drug|SHC014748M treatment|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
75797055|NCT03889626|Drug|Apatinib|Apatinib: 500mg qd po, q4w
75797056|NCT03889626|Drug|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-14, q3w
75797057|NCT03895008|Other|Cardia and Non-cardia gastric cancer|We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.
75935029|NCT03981328|Device|Dexcom G6 Continuous Glucose Monitoring System|Users insert a tiny sensor wire just under their skin using an automatic applicator. The sensor can measure glucose readings in interstitial fluid throughout the day and night.
75935030|NCT03981328|Device|self-monitored blood glucose|Each participant in the control group will be assigned a study blood glucose meter to measure and store their blood glucose values during the study. Therefore, the Contour® Next One system (or a comparable device) will be used. The meter has CE Mark clearance and is commercially available in Europe. Participants will receive an ample supply of meter test materials based on quantities routinely used.
75935031|NCT04470297|Drug|Ramelteon 8mg|Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
75935032|NCT03104842|Drug|Isatuximab|Antibody Intravenous
75935033|NCT03104842|Drug|Carfilzomib|Intravenous
75339673|NCT05567237|Other|No treatment|This intervention works as a control group for the participants who are not taking part into the exercise programme.
75935034|NCT03104842|Drug|Lenalidomide|Capsel
75339675|NCT05560100|Other|Nominal Group Technique - 2 to 3 hour virtual meeting|Participants will be invited to a 2-3 online virtual online meeting with the goal of constructing and defining elements for producing a risk statement for dry needling that can be used for informed consent.
75339676|NCT05525806|Other|Education Materials for MyProstateScore|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
75339677|NCT05519111|Drug|Dronabinol|Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)
75339678|NCT05519111|Drug|Placebo|placebo equivalent
75649850|NCT02584738|Drug|Nebulized isotonic saline|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
75649851|NCT02584738|Drug|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
75649852|NCT02584738|Drug|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
75649853|NCT02584738|Drug|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
75935035|NCT03104842|Drug|Dexamethasone|Capsel
75935036|NCT00436683|Drug|Fermagate|Film coated tablet 500mg
75935037|NCT00436683|Drug|Sevelamer HCl|tablet 800mg
75339679|NCT05517941|Other|active cycle breathing|The active cycle breathing technique will involve three steps: breathing control, thoracic expansion exercise, and forced expiration technique, In breathing control, the patient will sit comfortably in a chair and breathe at a normal rate and depth using the lower chest. In the thoracic expansion exercise, the physical therapist rested his/her hands on the patient's epigastrium and guided the patient's breathing so that they breathed at a slow and deep rate using the lower chest, then held their breath for 2 s and fully exhaled; this was repeated two or three times, then the patient returned to breathing control. For the forced expiration technique, the physical therapist asked the patient to inhale deeply while simultaneously contracting the abdominal muscle and keeping the mouth and throat open. They then held their breath for 2 s, followed by vigorous exhalation
75339680|NCT05517941|Other|incentive spirometer|Incentive spirometry is accomplished by using a device that provides feedback when the patient inhales at a predetermined flow and sustains the inflation for at least 5 seconds. The patient is instructed to hold the spirometer in an upright position, exhale normally, and then place the lips tightly around the mouthpiece. The next step is a slow inhalation to raise the ball (flow-oriented) or the piston/ plate (volume-oriented) in the chamber to the set target. At maximum inhalation, the mouthpiece is removed, followed by a breath-hold and normal exhalation.
75339681|NCT05503407|Procedure|Baseline V-RESOLVE score-guided PCI|"Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken.~Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB.~Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which usually stenting SB before MV stenting."
75935038|NCT02286999|Drug|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
75935039|NCT02286999|Drug|Placebo|
75339682|NCT05503407|Procedure|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
75935040|NCT00434811|Biological|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
75935041|NCT00434811|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
75339683|NCT05481710|Diagnostic Test|Nociplastic Pain Criteria|All participants will be assessed with the specific nociplastic pain criteria
75339684|NCT05465525|Procedure|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
75339685|NCT05465525|Procedure|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
75339686|NCT05465525|Other|No Block|The patients will receive general anesthesia.
75339687|NCT05460299|Combination Product|Telko plus conventional physical therapy (CPT)|All patients underwent about 15-minute CPT sessions 3 days a week for 4 weeks. The CPT intervention program consisted of closed kinetic chain exercises (squatting, hip bridge, lunge, and toe standing), 3 sets, 10 repetitions each and gait training (walking forward, backward, sidewalk, and between obstacles). Short breaks (1-5 minutes) were provided, depending on the patient tolerance. Before treatment, the skilled physical therapist was instructed about the duration, frequency, and content of therapy. The patients in the experimental group received additional lower extremities closed kinetic chain training using the Telko device. The participants train on Telko for 15 minutes using moderate resistance, 3 days a week for 4 weeks.
75339688|NCT05435482|Behavioral|Education|Participants will receive two small group meetings and two follow-up calls
75649854|NCT02559349|Other|Stool Collection|
75649855|NCT00764647|Behavioral|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
75935042|NCT00434811|Drug|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
75935043|NCT00434811|Drug|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
76087634|NCT00705666|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
75649856|NCT00765271|Drug|Abacavir|"Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study"
75935044|NCT00434811|Biological|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
75935045|NCT00434811|Procedure|Islet Transplantation|Transplantation of pancreatic islet cell
75935046|NCT00434811|Biological|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
75935047|NCT02284659|Device|Functional Electrical Stimulation (FES)|FES (50Hz / 500us)
75935048|NCT02284659|Device|FES- Sham|
75935049|NCT03133845|Procedure|Light sedation with propofol|Patients having lumbar spinal surgery and receiving spinal anesthesia will receive propofol for light sedation.
75935050|NCT03133845|Procedure|Induction with propofol|Patients having lumbar spinal surgery and receiving general anesthesia will receive propofol and their induction agent.
75935051|NCT03133845|Procedure|Maintenance anesthetic using a volatile anesthetic|Patients having lumbar spinal surgery and receiving general anesthesia will receive a volatile anesthetic for their maintenance anesthesia.
75649857|NCT00765271|Drug|Darunavir/ritonavir|"Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)"
76087635|NCT00705666|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
76087636|NCT04955236|Drug|Partial scalp block|"Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.)."
76087637|NCT04955236|Drug|Fentanyl|1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
76087638|NCT02489292|Biological|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
76087639|NCT04943770|Procedure|Spinal cord stimulator implant|"Patients will undergo spinal cord implant procedures as per standard of care and be implanted with the WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system.~Implant Procedures will be followed by a healing period (4-6 weeks) during which patients will be offered therapy (up to one 1Khz). Patients will then be randomised to receive therapy at four different rates (A, B, C, D) in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit."
76087640|NCT04943770|Diagnostic Test|Healing period|Acute opioid pain medications may be continued. No additional scheduled assessments will be completed during this period.
76087641|NCT04943770|Device|WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|Patients will then be randomised to receive therapy (up to 1KHz) at four different rates in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit.
76087642|NCT05463510|Diagnostic Test|Videodermoscopy|Patients who had records for at least twice with videodermoscopy every 3 months were included.
76087643|NCT04086862|Procedure|Therapeutic ultrasound|A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm^2 and 100% duty cycle sequentially to each masseter muscle.
75797058|NCT03892122|Drug|Propofol Fresenius|"Propofol will be infused with TCI (Target Controlled Infusion) pump. TCI system has been developed to provide improved convenience and control during intravenous anaesthesia. The basic principle is that the anesthetist sets and adjusts the target blood concentration- and depth of anesthesia-as required on clinical grounds.~Infusion rates are altered automatically according to a validated pharmacokinetic model. TCI technology uses different pharmacokinetic modeling to control the infusion rate of the pump, which allows for a direct control of the sedative agent brain concentration rather than its blood concentration. (de vito 2017) The development of target-controlled infusion (TCI) technology has increased the number of indications for propofol sedation in clinical practice. Furthermore, several studies have demonstrated that propofol-based TCI allows for the accurate control of sedation during DISE and results in an authentic reproduction of the sleep process."
75799011|NCT01588080|Device|SiPAP - placebo|The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
75935052|NCT03133845|Procedure|Muscle relaxant during maintenance anesthesia|Patients having lumbar spinal surgery and receiving general anesthesia with receive a muscle relaxant for muscle paralysis.
76087644|NCT02489136|Other|"laying of hands (Spiritist passe)"|In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
76087645|NCT04044274|Device|IOPstim|IOPstim (IMEDOS, Jena, Germany) is a device exerting defined pressure to the sclera and hence increasing IOP.
76087646|NCT04044274|Device|Suction Cup|Suction Cup is a device exerting defined suction to the clear and hence increasing IOP
75935053|NCT03133845|Procedure|Pain control with fentanyl|Patients having lumbar spinal surgery and receiving general anesthesia will receive fentanyl for their pain during surgery.
75935054|NCT03133845|Procedure|Bispectral Index (BIS) monitoring for depth of anesthesia|All patients will be monitored with Bispectral Index (BIS) to monitor the patient's depth of anesthesia.
75339689|NCT05435482|Other|COVID-19 testing kits|Participants will receive two COVID-19 at-home antigen test kits.
75649858|NCT00765271|Drug|Raltegravir|"Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)"
75935055|NCT03133845|Procedure|Spinal Anesthesia|Patients receiving spinal anesthesia will receive bupivacaine into the subarachnoid space.
75339690|NCT05435482|Other|Instruction|Participants will receive a written guide and a video clip guide to the test kit.
75339691|NCT05428202|Drug|GN037|GN-037 cream containing urea, salicylic acid, retinoic acid and clobetasol 17-propionate and matching placebo
75339692|NCT05428202|Drug|Placebo|Placebo cream containing base without active ingredients
75339693|NCT05427474|Drug|Propranolol , gabapentin|The combined therapy of propranolol and gabapentine can prevent the occurrence of paroxysmal sympathetic hyperactivity in traumatic brain injury patients and improve the clinical outcomes in emergency ICU.
75649859|NCT04411186|Procedure|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Subjects receive standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
75935056|NCT03133845|Procedure|Midazolam administered during spinal anesthesia|Midazolam may be administered during spinal needle insertion for patients receiving spinal anesthesia.
76087647|NCT04021030|Behavioral|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention consists of 8, one-hour individual therapy sessions delivered over the course of 2 to 4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both chronic pain and substance use.
75474076|NCT01978925|Other|Pharmaceutical care|"The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.~The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session."
75474077|NCT01978951|Behavioral|Integrated Chronic Kidney Disease care|Activities of integrated CKD care program, which will be provided during each hospital visit and quarterly home visits, are live demonstration about treatment and optimal diets for CKD patients, monitor drug compliance.
75474078|NCT01978951|Behavioral|Conventional CKD care|group counselling about optimal diets for CKD patients
75797059|NCT03892122|Drug|Dexmedetomidine|is a selective alpha-2 adrenergic receptor agonist, which seems to act on the locus coeruleus (LC) or to the preoptic hypothalamus to decrease wakefulness, with almost no effect on respiratory depression. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsyn¬aptic alpha2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique as¬pect that patients remain easily arousable and cooperative. Comparing with propofol, dexmedetomidine provides a state of sedation closer to natural sleep and lesser upper airways muscular relaxing effect, even at the increased anesthetic dosage Otherwise, Dexmedetomidine is characterized by a slightly longer onset of action (5-10 minutes), and patients take longer timing to recover..The sedative action of Dexmedetomidine can be reached by means of infusion technique (starting dose: 1 μg/kg over 10 minutes; maintenance infusion rate: 0,7 μg/kg/h).
75797060|NCT03892278|Behavioral|Water-based aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and <85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and <85% of HRat for 1 minute.
75474079|NCT01978964|Biological|ONT-10|ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
75799012|NCT03857100|Other|Audit and feedback - letter and report|letter describing project and report of participants' outlier status and how participants compare to peers
76087648|NCT03315234|Genetic|SNPs associated with CAD|Genotyping will be carried out by Real-Time PCR
76087649|NCT03957304|Drug|Dexmedetomidine|Intranasal dexmedetomidine
76087650|NCT02483286|Behavioral|ICG|"Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.~The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.~Subjects are encouraged to practice study home exercise program at least twice weekly."
75474080|NCT01979055|Behavioral|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
75339694|NCT05424211|Device|Music Therapy Mobile Application|The authorities determined by taking consultancy from TÜMATA (Turkish Music Research and Promotion Group) will be uploaded to the mobile application developed by the software specialist. The maqams (Rast, Nihavent and Neva) to be used in the application will be played to the patients 3 times in half an hour at different times of the day via the mobile application. Rast tonality will be played in the morning, nihavent tune will be played at noon and neva tune will be played in the afternoon.
75799013|NCT03856866|Drug|Hydroxychloroquine|Hydroxychloroquine: 4mg/kg/day, divided bid.
75339695|NCT05418647|Other|high dialysate Na|high dialysate sodium (Na = 141 mmol/L) for 8 weeks
75339696|NCT05418647|Other|low dialysate Na|low dialysate sodium (Na = 136 mmol/L) for 8 weeks
75799014|NCT03856866|Drug|Placebo|Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
75935057|NCT03133845|Procedure|Cerebrospinal fluid collection|8 ml of cerebrospinal fluid may be collected prior to the administration of intrathecal administration of morphine for pain control.
75935058|NCT03133845|Procedure|Administration of intrathecal morphine|Patient may receive intrathecal morphine for post-operative pain control.
75935059|NCT04441671|Drug|Disodium Pyrophosphate|Absorption trial
75935060|NCT03209024|Other|Handwritten logbook recording of home blood pressure readings|Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
75935061|NCT03209024|Device|Smartphone assisted wireless recording of home blood pressure readings|Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
75474081|NCT01979055|Behavioral|Telephone follow-up|Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
75474082|NCT01979081|Other|Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal|
75474083|NCT01979107|Behavioral|Proactive action by the general practitioner|"Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.~At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results."
75935062|NCT00120393|Drug|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
75797061|NCT03892278|Behavioral|Water-based aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and <85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and <85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
75935063|NCT00120393|Drug|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
75649860|NCT04411186|Procedure|ERAS and 5 Lung Protective Interventions|"Subjects will receive the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:~Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height) Positive end-expiratory pressure (PEEP) 7cm H2O5 Immediately post intubation recruitment breath (30cm water for 30 seconds) Every 1 hour recruitment breath (30cm water for 30 seconds) 40% FIO2 initially - titrate up as necessary to maintain SPO2 >94%"
75649861|NCT02583022|Drug|PAC-14028 cream 1.0%|Topical application
75649862|NCT02583022|Drug|PAC-14028 cream vehicle|Topical application
75649863|NCT02583022|Drug|Elidel cream 1%|Topical application
75649864|NCT00764725|Drug|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
75935064|NCT05476120|Behavioral|BATHE|The BATHE interview technique was applied 3 times, once every 3 months, for 6 months.
75339697|NCT05414396|Behavioral|Behavioral Intervention|Attend EML program sessions
75649865|NCT00764725|Biological|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
75649866|NCT05297266|Device|IscAlert|Insertion of a CO2- and temperature sensor in the distal part of the replanted extremity
75649867|NCT01557751|Genetic|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
75649868|NCT00775099|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
75649869|NCT00775099|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using Badimon Chamber
75649870|NCT02582710|Dietary Supplement|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
75935065|NCT03201224|Device|"After Group"|
75935066|NCT00117819|Drug|[123I]ß CIT and SPECT imaging|To assess [123I]ß CIT and SPECT imaging
75935067|NCT03208946|Other|High-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
75935068|NCT03208946|Other|Low-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
75935069|NCT05726019|Drug|Colchicine|Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
75339698|NCT05414396|Other|Questionnaire Administration|Ancillary studies
75339699|NCT05389189|Behavioral|Intervention Arm|"The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour)."
75649871|NCT02582710|Dietary Supplement|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
75797062|NCT03892278|Behavioral|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
75339700|NCT05377736|Genetic|Molecular analyses|Collect thyroid tissue for molecular analysis from the histological specimen collected by routine surgery
75797063|NCT01589562|Drug|Megace 800mg/20ml|Megestrol acetate 800mg/20ml, Suspension, Single dose
75339701|NCT05363345|Device|bile duct stone removal|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
75339702|NCT05355792|Device|OmniTaper EV implants|Partially edentulous subjects in need of one implant in the maxilla or mandible (2nd and 3rd molars excluded) will receive an OmniTaper EV implant system. The study will be done in accordance with standard dental practice using a one- or two-stage surgical protocol and immediate or delayed placement and/or loading.
75797064|NCT01589562|Drug|DW-ES(B) 625mg/5ml|Megestrol acetate 625mg/5ml, Nano suspension, Single dose
75339703|NCT05348681|Drug|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
75935070|NCT03208790|Drug|Nigella sativa buccal tablets 10mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
75339704|NCT05348681|Drug|Placebo|Matching placebo
75339705|NCT05340673|Drug|Agent Affecting Integumentary System|Apply Miaderm
75339706|NCT05340673|Other|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Apply to skin
75339707|NCT05340673|Other|Quality-of-Life Assessment|Ancillary studies
75339708|NCT05340673|Other|Questionnaire Administration|Ancillary studies
75339709|NCT05322837|Other|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires related to upper limb function and quality of life will be used
75474084|NCT01979146|Other|Provider Unrelieved Symptom Alert|The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
75474085|NCT01979224|Other|Educational intervention for parents|educational sessions once a week two hours for a month and later educational reinforcement and monitoring asthma control monthly for nine months
75649872|NCT00936884|Drug|Methylnaltrexone|"Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; 0.4 mL (8 mg) every other day if weight between 38 and < 62 kg; or 0.0075 mL/kg (0.15 mg/kg) every other day if weight between 27 and <38 kg.~Study duration: 2 weeks double-blind period (MNTX treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
75339710|NCT05320406|Radiation|Radiation therapy|Undergo radiation therapy
75339711|NCT05320406|Drug|Leuprolide|Given IM or SC
75474086|NCT01979237|Procedure|SPASO method and FARES method|SPASO method and FARES method as shoulder dislocation reduction methods
75474087|NCT01979250|Procedure|DSAEK surgery|"Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK)."
75649873|NCT00936884|Drug|Placebo|"Subjects received matching placebo injections.~Study duration: 2 weeks double-blind period (placebo treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
75649874|NCT04048135|Drug|BIO89-100|Subcutaneous injection
75797065|NCT01152372|Procedure|Insulin, glucose and staple isotopes|
75935071|NCT03208790|Drug|Nigella sativa buccal tablets 5mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
75935072|NCT03208790|Drug|Placebo buccal tablets|capsules with the same color and form as the active ones but without active ingredient will be given to the patients
75935073|NCT00116415|Drug|efavirenz; didanosine EC; lamivudine|
75935074|NCT03207698|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
75935075|NCT03207698|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
75339712|NCT05320406|Drug|Relugolix|Given PO
75339713|NCT05314218|Device|Electrophysiology catheters and cables|"The Xtrem electrophysiology catheter was developed for diagnosis of cardiac arrhythmias. Their function is to collect by contact, electrical signals generated by the heart muscle.~Xtrem are inserted via femoral vena cava or via artery and can be used in two occasions:~Exploration procedures for diagnosis alone~Diagnosis before ablation procedure An extension cable is used to connect the catheter to a stimulation/ recording device."
75339714|NCT05312151|Drug|Psilocybin|Open label
75474088|NCT01979263|Other|Attention Bias Modification Computer Task|Computer task aimed at actively modifying attention bias
75474089|NCT01979263|Other|Placebo Computer Task|Computer task that does not actively modify attention bias
75474090|NCT01979289|Other|computerized cognitive remediation|
75474091|NCT01979289|Other|computerized cognitive remediation:Control|
75797066|NCT01589640|Other|Blink Tears lubricating Eye Drops|2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
75797067|NCT01589640|Other|Blink Gel Tears Lubricating Eye Drops|2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
75797068|NCT01589640|Other|Systane Balance Lubricant Eye Drop|2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
75797069|NCT01259934|Drug|Interferon-alpha2b - 1 year|Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
75797070|NCT01259934|Drug|Interferon-alpha2b - 2 years|Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
75935076|NCT03207698|Procedure|OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
75935077|NCT02287077|Procedure|Umbilical Cord Milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
75935078|NCT03201302|Other|School physical education class|Children participated only in school physical education classes only.
75339715|NCT05300815|Other|Delphi Questionaire|"This study involves the use of questionnaires across 3 rounds as follows:~The objectives of round 1 are to collect participant demographic information and generate a list of adverse events. Round 1 will be open for 3 weeks with email reminders being provided at weeks 1 and 2.~The objectives of round 2 will be to share a list of adverse events generated from round 1 (with the addition of adverse events identified in literature if not generated in round 1) and allow participants to rate from 1-4 how important each item is for inclusion on informed consent. As per round 1, the round 2 questionnaire will remain active for 3 weeks with email reminders sent at weeks 1 and 2.~The objective of round 3 is to further gain consensus on adverse events from the results of round 2 where agreement was not reached. Round 3 remains active for 3 weeks with email reminders sent at weeks 1 and 2."
75339716|NCT05299073|Drug|MB09 (denosumab biosimilar)|Single dose of 35mg SC administered
75935079|NCT03201302|Other|Taekwondo|Children participated only in taekwondo training only.
76087651|NCT02483286|Behavioral|MTG|MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist
76087652|NCT02483286|Behavioral|XBG|XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
75339717|NCT05299073|Drug|US-sourced Xgeva|Single dose of 35mg SC administered
75649875|NCT04048135|Other|Placebo|Subcutaneous injection
75649876|NCT04077892|Drug|budesonide|SAR patients received treatment of a combination of budesonide and montelukast tablet or only intranasal budesonide randomly for 14 days
75649877|NCT02582788|Other|Bathing Additive|
75935080|NCT03201302|Other|Martial arts|Children participated only in martial arts training only.
75935081|NCT03201302|Other|Climbing|Children participated only in climbing training only.
75935082|NCT03201302|Other|Volleyball|Children participated only in volleyball training only.
75935083|NCT03201302|Other|Artistic gymnastics|Children participated only in artistic gymnastics training only.
75339718|NCT05299073|Drug|EU-sourced Xgeva|Single dose of 35mg SC administered
75339719|NCT05288764|Device|Bispectral Index|Comparing Bispectral index values (usually adopted during general anaesthesia monitoring) to Ketamine concenetration at the effector site calculated with Domino model pump (usually adopted for Ketamine infusion during general anaesthesia)
75935084|NCT03201302|Other|Swimming|Children participated only in swimming training only.
75935085|NCT03201302|Other|Dance|Children participated only in dance training only.
75935086|NCT03201302|Other|Basketball|Children participated only in basketball training only.
75935087|NCT03201302|Other|Wrestling|Children participated only in wrestling training only.
76087653|NCT03318276|Drug|SID142|SID142 is administrated to patients with PAD for 12 weeks
75339720|NCT05264194|Other|Suturing technique|The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.
75474092|NCT01979302|Other|Depression CAREPATH|Nurses receive training and agency support in depression assessment and depression care management
75474093|NCT01979302|Other|Usual Care|Nurses receive training in depression assessment and review of usual care procedures.
75474094|NCT01979328|Device|geko|
75474095|NCT01979328|Device|Plaster cast|
75474096|NCT01979341|Procedure|final oocyte maturation trigger|when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
76087654|NCT03318276|Drug|Rinexin® Tab|Rinexin® Tab is administrated to patients with PAD for 12 weeks
76087655|NCT02483208|Drug|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
76087656|NCT02483208|Drug|Advate|Advate infusion to analyze pharmacokinetics.
76087657|NCT03321162|Diagnostic Test|scan protocol|Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
75474097|NCT01979354|Drug|Spinal morphine|0.15 mg spinal morphine
75474098|NCT01979380|Drug|KD101|200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning
75474099|NCT01979380|Drug|placebo|PO, once in the morning
75474100|NCT01979406|Biological|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
75474101|NCT01979406|Biological|Ad4-PA-1|Ad4-PA will be given at 10^9, 10^10 and 10^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
75649878|NCT00606242|Drug|Fluticasone|Inhaled Fluticasone, either 100 or 1000 mcg per day
75649879|NCT04048369|Diagnostic Test|Rapid diagnosis of influenza in the emergency medical service|Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
75935088|NCT03201302|Other|Football (soccer)|Children participated only in football (soccer) training only.
75935089|NCT03201302|Other|Rhythmic gymnastics|Children participated only in rhythmic gymnastics training only.
75935090|NCT03201302|Other|Track and field|Children participated only in track and field training only.
75935091|NCT03201302|Other|Tennis|Children participated only in tennis training only.
75935092|NCT03201302|Other|Combination of activities 1|Children participated in two weight-bearing activities.
75935093|NCT03201302|Other|Combination of activities 2|Children participated in one weight-bearing activity and in one non weight-bearing activity.
75474102|NCT01979406|Biological|Ad4-PA-GPI-1|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
75935094|NCT02287155|Behavioral|occupation based health promotion|"The description of the intervention is provided in the detailed description of the study."
75649880|NCT04078438|Device|neurofeedback augmentation|"Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study."
75935095|NCT03208712|Drug|Atezolizumab|Atezolizumab 1200 mg IV once every 3 weeks
75935096|NCT03208712|Drug|Radium-223|Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
75935097|NCT00099879|Drug|BMS-275183|
75935098|NCT03201380|Other|TEP scanner with choline|
75339721|NCT05255536|Procedure|Serratus Anterior Plan Block with 20 ml|Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.
75339722|NCT05255536|Procedure|Serratus Anterior Plan Block with 30 ml|Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
75339723|NCT05247346|Device|SENSITIVE system|probe-based integrated Raman spectroscopy and scattering measurements of Barrett's and colorectal tissue during GI endoscopy
75339724|NCT05242146|Drug|GB5121|Capsule containing GB5121
75339725|NCT05236023|Behavioral|Zero separation and couplet care|"The essence of the intervention is that treatment-requiring mother-infant dyads are admitted together and receives couplet care provided by neonatal nurses.~The nurses will be educated for the intervention by participating in a two-day course about postpartum observations, treatment and care; and participate in education about family-centred care and family-focused nursing."
75474103|NCT01979432|Other|Cardiovascular evaluation|
75474104|NCT01979458|Device|PSE|
75649881|NCT04078438|Drug|treatment as usual|The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
75649882|NCT04078438|Other|psychotherapy placebo sessions|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
75797071|NCT01152528|Device|VA-SENSE|The VA-SENSE contains a strip of pH indicator (color indicator) that is sensitive to the acidity level. A change in the color of the strip due to changes in the acidity level of vaginal secretions absorbed in the panty liner clearly indicates high probability of bacterial or parasitic vaginal infection. Any color change that results from contact with urine will disappear 10 minutes of drying out, and then the color of the indicator strip will fade back to the original color (yellow).
75339726|NCT05221398|Drug|Immune Checkpoint Inhibitors Based Adjuvant therapy|Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy
75339727|NCT05213221|Drug|Envafolimab|300mg, subcutaneous injection, q3w
75339728|NCT05213221|Procedure|TACE|The first TACE will be started on d1, and the subsequent TACE will be performed on demand.
75339729|NCT05213221|Drug|Lenvatinib|8mg,QD (body weight <60kg); 12mg, QD (body weight ≥ 60kg)
75339730|NCT05212337|Drug|Denosumab|Subcutaneous injection with 60 mg Denosumab once
75649883|NCT00607646|Drug|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
75797072|NCT01153386|Drug|Treprostinil diethanolamine|Treprostinil diethanolamine sustained release oral tablets.
75797073|NCT01260012|Dietary Supplement|Praziquantel+antioxidant suppl|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.
75935099|NCT05725941|Device|TogRite stretch Strapping|it is a machine washable and highly durable elastic strap that maintains its recoil strength for a long-lasting period. It is made of latex-free materials. The TogRite Strapping can be used to support the weakened parts of the body and adjust or modify the position and posture of different body parts.
75935100|NCT05725941|Other|Traditional upper limb functional exercise training|The traditional upper limb functional exercise training will focus on the enhancement of muscle strength, joint range of motion, arm &hand activities, and daily living functions of the affected upper limbs.
75935101|NCT03208556|Biological|iPD1 CD19 eCAR T cells|"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.~CAR T cell dose escalation: 1×10^5 /kg，1×10^6 /kg，3×10^6 /kg，and 6×10^6 CAR T cells/kg"
75935102|NCT03208556|Drug|Fludarabine and cyclophosphamide|Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
75339731|NCT05212337|Drug|Sodium chloride|Subcutaneous injection with NaCl once
75339732|NCT05181228|Behavioral|Web-Based Education Based on Family-Centered Empowerment Model|Parents in the intervention group will receive care for ten weeks using the family-centered empowerment model (FCEM). The first step (two weeks) is to increase knowledge. For this purpose, they will receive web-based training on cancer. The second step (four weeks) is to develop parents' self-efficacy and problem-solving skills. A web-based training and group meeting will be held to share information and experiences on the evaluation and control of the side effects of the treatment and to increase their self-efficacy in care. The third step (three week) was to increase self-esteem through participation in the training. At this stage, each participant will be asked to teach one of the family members responsible for the child's care what they have learned in the last two sessions. In the fourth step (one week), all participants in the intervention group will be evaluated by asking questions about the topics discussed in the second and third sessions and the overall content taught.
75339733|NCT05157178|Biological|Covid-19 (recombinante) vaccine|Administration of the Covid-19 (recombinante) vaccine
75339734|NCT05131425|Behavioral|Facing Your Fears: ASD/ID|This cognitive behavioral therapy, entitled Facing Your Fears for Adolescents with Autism and Intellectual Disability, is focused on somatic management, helpful cognitive mantras, emotion regulation, and graduated exposure adapted for the cognitive and linguistic needs of an Intellectual Disability population.
75339735|NCT05131425|Other|Treatment as Usual|The treatment as usual condition is being used in this study as a control condition. The investigators will track what medication and intervention services families are currently receiving.
75339736|NCT05123040|Drug|Ruxolitinib 10 MG Oral Tablet|By mouth twice daily through day 56, then tapered
75339737|NCT05123040|Drug|hCG|2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
75339738|NCT05123040|Drug|Corticosteroids|"Dose level 1 (starting dose) = 1 mg/kg~Dose level 2 = 0.5 mg/kg~Dose level 3 = 0.25 mg/kg~Dose level 4 = 0.1 mg/kg~Dose level 5 = 0 mg/kg~• If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~Dose level -1 = 1.5 mg/kg~Dose level -2 = 2 mg/kg"
75339739|NCT05106569|Diagnostic Test|Spirometry|All study participants will undergo pulmonary function testing using conventional spirometry in clinic and portable spirometry in clinic and at home. In-clinic conventional laboratory spirometry is compared with portable spirometry and Slow vital capacity is obtained in upright and supine positions.
75649884|NCT00607646|Drug|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
75649885|NCT03875599|Other|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
75649886|NCT00606398|Procedure|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
75649887|NCT00770263|Drug|Erlotinib|
75649888|NCT00770263|Drug|Temsirolimus|
75649889|NCT02691026|Drug|Pembrolizumab|
75797074|NCT01260012|Other|Praziquantel + placebo 2mths then antioxidant for 10 mths|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
75797075|NCT01260012|Dietary Supplement|Praziquantel therapy and placebo as supplement|Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.
75797076|NCT01260012|Dietary Supplement|Praziquantel+antioxidant|Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
75797077|NCT03888924|Drug|Bacille Calmette-Guerin vaccine|"One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride."
75797078|NCT03888924|Drug|Placebo|isotonic solution of sodium chloride (2mL vials).
75935103|NCT00429429|Procedure|Sublingual immunotherapy|Drops of peanut protein placed and held under the tongue for a specific time before swallowed.
75935104|NCT03201146|Drug|Apatinib|Doses to be determined following the completion of Phase I of the study.
75935105|NCT03201146|Drug|AP or AC|Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
75935106|NCT03201146|Drug|Apatinib 250mg|250mg/d,q.d.,p.o.every 21 days.
75935107|NCT03201146|Drug|Apatinib 500mg|500mg/d,q.d.,p.o.every 21 days.
75797079|NCT03894930|Behavioral|Metta meditation|Administered 5 days per week for 8 weeks.
75935108|NCT03201146|Drug|Apatinib 750mg|750mg/d,q.d.,p.o.every 21 days.
75935109|NCT00370383|Drug|Erlotinib|erlotinib 150 mg/day once daily
75339740|NCT05096702|Drug|Tafenoquine|Tafenoquine 300 mg (2x150mg tablets)
75339741|NCT05096702|Drug|Primaquine|Daily primaquine adjusted by weight (0.5 mg/kg/day for 7 days)
75339742|NCT05096702|Drug|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
75339743|NCT05070533|Behavioral|Individual treatment|Participants will receive 7 home visits to implement the program.
75339744|NCT05070533|Behavioral|Groupal treatment|Subjects will participate in groups of about 8 - 12 to implement the program.
75339745|NCT05067543|Device|Tornier Perform Humeral - Stem|The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.
75339746|NCT05066724|Drug|Centanafadine|400 mg total daily dose Centanafadine Sustained Release, oral tablets
75339747|NCT05043103|Combination Product|Lecigon® based on European Medicines Agency (EMA) SmPC|There might be different brand names in other countries
75339748|NCT05041855|Behavioral|The Healthy Living Program/La Vida Saludable|A whole-family group childhood obesity intervention delivered at community recreation centers
75339749|NCT05041855|Behavioral|Recommended Treatment of Obesity in Primary Care|A healthy lifestyle counseling protocol that enhances usual primary care
75339750|NCT05040204|Dietary Supplement|Monosaccharide Powder|Monosaccharide powder dissolved in water.
75649890|NCT05400148|Drug|Bupivacaine Hydrochloride|Patients who were administered an analgesic PENG block with a dose of 2.5mg/kg with either lov (<20ml) or high volume (>20ml)
75649891|NCT00770419|Other|medical chart review|
75649892|NCT00770419|Other|questionnaire administration|
75649893|NCT00770419|Procedure|psychosocial assessment and care|
75649894|NCT04267484|Device|GPS and travel diary|WP1: GPS tracker for 2 weeks and a daily diary about activity (travel diary).
75649895|NCT04267484|Other|e-decision support platform|WP2 and WP3: An e-decision support platform that will foster shared decision making about options to stay safe at home for the older adult.
75339751|NCT05040204|Dietary Supplement|Placebo Comparator|Placebo (glucose powder)
75339752|NCT05017454|Drug|the optimized sodium valproate-loaded nanospanlastic dispersion|participants will apply the optimized sodium valproate-loaded nanospanlastic dispersion twice daily, on the affected areas of the scalp for 3 months
75339753|NCT05017454|Drug|mometasone furoate lotion|participants will apply marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
75339754|NCT05013424|Drug|OnabotulinumtoxinA|Intramuscular Injection
75649896|NCT04078360|Behavioral|AMBIT (Alcohol use disorders- mobile based Brief Intervention treatment) intervention|"The intervention will consist of participants receiving messages and/IVR calls not more than twice or thrice a week on their mobile phone for a duration of 8 weeks. Messages/IVR calls will be sent through VIAMO's technology platform. Each week messages will be focussed on specific content areas derived from the formative research of the study. Some of the components of the intervention include:~Self awareness messages~Self reflection messages~Motivational messages~Messages on safe drinking, alcohol reduction, drinking management, risk management, craving management and drinking alternatives.~Health education messages~Personalized feedback and information~Help-seeking resources~Goal setting messages"
75649897|NCT04078360|Behavioral|Face to face Brief Intervention|The intervention will consist of the participants receiving the BI based on the WHO Mental Health Gap Action Programme (mhGAP) intervention from a trained researcher. The BI will be conducted over a single session (5-10 mins).
75649898|NCT04078360|Behavioral|BI leaflet intervention|The intervention will consist of an educational BI leaflet consisting of health information on alcohol consumption, and tips to manage and reduce drinking.
75649899|NCT00765427|Drug|QLT091001|7-day repeated dose
75649900|NCT00605228|Drug|MOVIPREP|2L Drug
75649901|NCT00605228|Drug|COLOPEG|4L Drug
75649902|NCT00765505|Behavioral|Exercise Group|Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
75797080|NCT03894852|Diagnostic Test|PCR and cytogenetics|detection of SRSF2 gene mutation and cytogenetic studies
75797081|NCT01151592|Drug|Iron Sucrose|Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
75797082|NCT03891810|Behavioral|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
75935110|NCT00370383|Drug|Satraplatin|"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
75935111|NCT03107312|Procedure|Single blood sample collection|Collection of single blood sample of 10 ml volume by venepuncture
75935112|NCT02450630|Behavioral|Strenghtened referral of children|Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated & severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
75935113|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
75935114|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
75935115|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
75339755|NCT04999215|Drug|F-choline intravenous injection|Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
75339756|NCT04991025|Drug|Cisplatin|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
75339757|NCT04991025|Drug|Pemetrexed|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle
75339758|NCT04991025|Drug|Gemcitabine|Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
75339759|NCT04991025|Drug|Carboplatin|Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.
75339760|NCT04991025|Drug|Certolizumab|Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.
75339761|NCT04991025|Drug|Nivolumab|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.
75339762|NCT04989686|Other|Microsampling|Volumetric absorptive microsampling (VAMS) with Tasso-M20 devices allows for the accurate and precise collection of a fixed small volume of blood from a capillary needle without the need for phlebotomy.
75797083|NCT03894774|Behavioral|Intensive in-patient psychotherapy treatment|Intensive non-pharmaceutical in-patient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic setting where patients live during the whole treatment (approximately a 1:1-Ratio caregiver per patient is given) of 6 to 8 month treatment duration.
75797084|NCT03894774|Other|Treatment as usual|Combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy
75797085|NCT01151670|Drug|pioglitazone|Pioglitazone 22.5 mg daily before, during and after radiation therapy.
75797086|NCT01151670|Drug|Pioglitazone|Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
75649903|NCT00765505|Behavioral|Health Education Group|Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
75797087|NCT03888846|Drug|Pentoxifylline|Topical gel version of pentoxifylline to be administered intraorally.
75935116|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
75339763|NCT04985487|Other|brolucizumab|Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
75339764|NCT04979130|Drug|Semaglutide|Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
75339765|NCT04979130|Drug|Placebo|Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
75339766|NCT04957290|Drug|NOX66|NOX66 800 mg daily (400 mg suppository twice daily [BID]).
75339767|NCT04957290|Drug|NOX66|NOX66 1200 mg daily (600 mg suppository BID).
75935117|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
75649904|NCT02584582|Drug|Liraglutide|
75649905|NCT02584582|Drug|Exenatide|
75649906|NCT02584582|Procedure|Liquid meal test|
75649907|NCT02584582|Other|No drug (Baseline day)|
75649908|NCT05380232|Behavioral|Leisure-time physical activity|Self-reported leisure-time physical activity, categorized as; zero (reference), >0-7.49 MET-hrs/week, 7.5-14.9 MET-hrs/week, or ≥15 MET-hrs/week.
75649909|NCT00765583|Drug|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
75649910|NCT04299958|Other|Patient diary|In the first visit they will be examined by a neurologist with experience in headache disorders and NH diagnosis will be reviewed. Patients will be invited to participate into the study and they will provide and sign informed consent form. They will be instructed and trained to complete the prospective headache diary during 14 days. A follow up visit will be done within 15 to 30 days to review the data and analyze possible sources of bias.
75649911|NCT04266002|Other|Validation of Charter score for the CNS diffusion of antiretroviral drugs|IHFB001 (Neuroplustrois) is a pilot study, phase IV, open-label, multicenter in Ile-de-France region, trying to demonstrate the improvement of cognitive change after treatment characterized by its better diffusion in the central nervous system. The characteristics of the change in treatment are (Cn - Ci) ≥ 3 and Cn ≥ 9, where Cn is the Charter score of the new treatment and Ci the Charter score of the initial treatment.
75649912|NCT00765739|Other|Neuromuscular electrical stimulation|neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
75649913|NCT00765739|Other|voluntary strengthening exercise|contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
75649914|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
75797088|NCT03888846|Drug|Colchicine|Colchicine therapy is provided to patients with oral ulcers as part of supportive care routinely offered by Behcet's Clinic-Istanbul.
75935118|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
75649915|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
75935119|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
75339768|NCT04957290|Drug|NOX66|NOX66 1600 mg daily (800 mg suppository BID).
75935120|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
75339769|NCT04957290|Drug|NOX66|NOX66 2400 mg daily (1200 mg suppository BID).
75339770|NCT04957290|Drug|NOX66|NOX66 RP2D
75339771|NCT04957290|Radiation|EBRT|The dose levels of EBRT will be either 8 Gy as a single fraction, or 20/25 Gy as 5 fractions given over 5 to 10 days.
75339772|NCT04956952|Device|EECP|1 hour of treatment with EECP
75339773|NCT04955626|Biological|BNT162b2|Intramuscular Injection
75339774|NCT04955626|Other|Placebo|Intramuscular Injection
75339775|NCT04955626|Biological|BNT162b2 OMI|Intramuscular Injection
75339776|NCT04955626|Biological|Combination BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection"
75339777|NCT04955626|Biological|Combination (Bivalent) BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection"
75649916|NCT05378516|Other|no intervention|no intervention
75649917|NCT04077814|Device|Foot Drop Stimulatio - Neuro Orthosis|Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
75649918|NCT04077814|Device|Transcranial direct brain stimulation|Transcranial direct brain stimulation on motor cortex
75935121|NCT03207932|Procedure|Central vein catheterisation|ultrasound guided versus landmark central vein catheterisation
75935122|NCT02547220|Biological|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
75935123|NCT02547220|Drug|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
75935124|NCT03207308|Dietary Supplement|Vitamin A supplementation|200,000 IU of preformed vitamin A
75935125|NCT00366795|Drug|Satavaptan|oral administration once daily
75935126|NCT00366795|Drug|placebo|oral administration once daily
75935127|NCT04484870|Drug|oral Danshu capsule|Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
75649919|NCT00775177|Drug|Doxycycline monohydrate 100mg tablets|Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
75649920|NCT05378360|Biological|DWP708|Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days
76087658|NCT03321084|Other|MatPliates|The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.
76087659|NCT03321084|Other|Control|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
76087660|NCT03320928|Other|Photochemotherapy|Retrospective evaluation of treatment outcome and risk for pulmonary mortality and relapse incidence
76087661|NCT02488902|Drug|Placebo|Placebo
76087662|NCT02488902|Drug|Tafenoquine 25mg|Tafenoquine 25mg
76087663|NCT02488902|Drug|Tafenoquine 50mg|Tafenoquine 50mg
76087664|NCT02488902|Drug|Tafenoquine 100 mg|Tafenoquine 100 mg
75649921|NCT00766129|Device|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
75649922|NCT00766129|Device|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
75649923|NCT00607802|Biological|leukocyte therapy|
76087665|NCT02488902|Drug|Tafenoquine 200 mg|Tafenoquine 200 mg
76087666|NCT02488902|Drug|Mefloquine 250 mg|Mefloquine 250 mg
76087667|NCT05404776|Other|Placement of Foley balloon for cervical ripening with tension.|A Foley balloon will be placed for cervical ripening with tension.
75339778|NCT04946721|Diagnostic Test|The standard care exam and biological specimens' collection|During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
76087668|NCT05404776|Other|Placement of Foley balloon for cervical ripening without tension.|A Foley balloon will be placed for cervical ripening without tension.
76087669|NCT02253160|Device|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
76087670|NCT02253160|Device|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
76087671|NCT02253160|Drug|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
76087672|NCT05459766|Behavioral|Action observation and motor imagery|Observation and imagination of functional tasks that will be performed during the postoperative rehabilitation program.
76087673|NCT05459766|Behavioral|Usual care|Participants will be educated about the postoperative rehabilitation program
76087674|NCT02254252|Drug|Nicorandil|nicorandil (10mg tablets, two times a day)
75339779|NCT04935658|Device|Hypnotic relaxation induced by virtual reality (device)|A virtual reality device will be install on the patient 3-5 minutes before the beginning of the oocyte retrieval. The device will be wearing by the patient during the entire intervention and 2 minutes after the end of the ponction.
75339780|NCT04935658|Drug|local anesthesia|standard anesthesic procedure
75649924|NCT00607802|Genetic|polymerase chain reaction|
75649925|NCT00766207|Other|Clinical decision support|multi-faceted decision support
75339781|NCT04930315|Drug|Apatinib Mesylate|250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery
75339782|NCT04930315|Drug|Camrelizumab|200mg, iv, d1, q2w, both in two groups
75649926|NCT00766207|Other|stream-lined clinical alert|electronic notification that a medication is potentially teratogenic
75649927|NCT04299022|Other|Vivigen Cellular Bone Matrix|Allograft bone matrix
75649928|NCT00770497|Drug|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
75649929|NCT00770497|Drug|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
75935128|NCT00366327|Drug|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
75935129|NCT03207464|Drug|[C-11]Methylreboxetine|8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a [C-11]MRB PET scan and a MRI scan.
75935130|NCT03207230|Device|Cardea SOLO|Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
75935131|NCT03207230|Device|ActiGraph wGT3X-BT|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
76087675|NCT02254252|Drug|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
76087676|NCT03315156|Diagnostic Test|Electrogustometery|Taste assessment using EGM
76087677|NCT02483052|Device|RejuvenAir|RejuvenAir
76087678|NCT03318198|Other|Enhanged Attending Supervision|Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.
76087679|NCT03318198|Other|Standard of Care|Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
76087680|NCT02255032|Drug|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
76087681|NCT02255032|Drug|0.8 mg CLS-TA|8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
75339783|NCT04927494|Behavioral|Health is Wealth: A Cervical Health Program|Health is Wealth: A Cervical Health Program will be introduced in a one-time 2-hour educational session, participants will be given HPV self-sampling kits, and instructional sheet that visually depicts the steps for self-sampling. The program will be culturally tailored to increase self-efficacy and knowledge while simultaneously addressing perceived health beliefs associated with cervical cancer and barriers associated with cervical cancer screening and HPV self-sampling. Content will be delivered in a group format (about 10-15 participants) by lecture, demonstration, and interactive exercises.
75935132|NCT03207230|Device|Wavelet Wristband|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
75797089|NCT03889236|Other|Fasting mimicking diet Prolon|5-day fasting mimicking diet
75935133|NCT02542072|Device|comfilcon A|contact lens
75935134|NCT02542072|Device|samfilcon A|contact lens
75935135|NCT03207152|Biological|Influenza A/California/04/09|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
75339784|NCT04896801|Radiation|MR-guided RT|The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy < 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT
75339785|NCT04894929|Other|multi component exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
75474105|NCT01979471|Other|Advanced Care|"The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:~Patient assessment~Laboratory assessment of HbA1c and lipids~Individual assessment of CVD risk and education about this risk~Calculation of cardiovascular risk will be facilitated by an online tool~Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options~Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.~Regular communication with the patient's family physician after each contact with the patient~Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months."
75474106|NCT01979484|Drug|PPI-668 capsule|
75935136|NCT00422019|Drug|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
75935137|NCT00422019|Drug|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
75935138|NCT03207542|Drug|Daratumumab|16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
75935139|NCT00360867|Drug|AMG 706|The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
76087682|NCT03315078|Biological|CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT|Administered by intravenous (IV) infusion
75474107|NCT01979484|Drug|PPI-668 tablet|
76087683|NCT03315078|Drug|Palifermin|Administered by IV infusion at a dose of 60 mg/kg/day
76087684|NCT03315078|Drug|Busulfan|Administered by IV infusion at a dose of approximately 3 mg/kg per day
76087685|NCT03320772|Drug|TMVP1-ICG|Detection of SLN
76087686|NCT03320772|Drug|ICG|Detection of SLN
75474108|NCT01979497|Procedure|Suture with Adhesive Stripping|
75797090|NCT03889236|Dietary Supplement|Food supplement Endocalyx|Food supplement
75797091|NCT03889236|Dietary Supplement|Placebo|Placebo
75797092|NCT01153464|Behavioral|Recovery Support Counseling|Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
75797093|NCT03891420|Drug|Galidesivir|Galidesivir IV infusion
75797094|NCT03891420|Drug|Placebo|Placebo IV infusion
75797095|NCT01153542|Drug|VX-770|In period 1, subjects will receive a single oral dose of desipramine on Day 1.
75797096|NCT01153542|Drug|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
75797097|NCT01152606|Drug|trastuzumab [Herceptin]|There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
75935140|NCT03208634|Device|Robotic intervention|One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
76087687|NCT02255110|Drug|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
75935141|NCT03481114|Combination Product|PET-based, dose-painted, accelerated chemoradiotherapy|Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.
75935142|NCT03481114|Combination Product|Standard chemoradiotherapy|Patients in this arm will receive a standard radiotherapy course.
75339786|NCT04894929|Other|vestibular exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
75649930|NCT00770497|Drug|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
75797098|NCT03888690|Device|Virtual Reality Headset|Standardized procedures, with or without Virtual Reality Headset.
75339787|NCT04894929|Other|vestibular exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
75339788|NCT04894929|Other|multi component exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
75649931|NCT00606710|Device|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
75649932|NCT05285852|Other|Dry Needling|Dry needling technique is maneuvered by different skilled health practitioners aiming to reduce central sensitization, i.e., the hypersensitivity to pain of the central nervous system. It is also apprehended to reduce the local and referred pain, and improve the muscle activation patterns leading to improved range of motion.
75797099|NCT03888768|Drug|MonoFer|Administration of IV Monofer will be given according to body weight as recommended by the drug manufacturer.
75797100|NCT03894384|Diagnostic Test|Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)|Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
75935143|NCT02450474|Device|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
75339789|NCT04888507|Drug|Pozelimab|Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
75339790|NCT04888507|Drug|Cemdisiran|SC administration
75474109|NCT01979497|Procedure|Suture without Adhesive Stripping|
75649933|NCT05285852|Other|Placebo Dry Needling|Placebo Dry Needling only causes a pricking sensation
75649934|NCT04048291|Behavioral|Brisk walking and balance training|6 months of combined brisk walking and balance training
75649935|NCT04048291|Behavioral|Upper limb exercise|6 month of hand dexterity training
75797101|NCT01151748|Procedure|Intra-arterial infusion of chemotherapy|
75935144|NCT02450474|Device|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
75649936|NCT02581696|Drug|Lafutidine|Lafutidine 10mg, 1 tablet, bid
75649937|NCT02581696|Drug|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
75649938|NCT04265924|Other|fraction of inspired oxygen (FIO2)|The fraction of inspired oxygen (FIO2) is given accordingly (>0.85 for the >0.85 group, and <0.7 for the <0.7 group) to the patients during the surgery.
75649939|NCT00607958|Drug|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
75649940|NCT02582554|Behavioral|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
75649941|NCT00770575|Drug|Pioglitazone and atorvastatin|"Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
75649942|NCT00770575|Drug|Atorvastatin|"Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
75797102|NCT01155414|Other|Hydrolysate based infant formula|Infant formula ad lib
75797103|NCT01155414|Other|Investigational Infant Formula A|Investigational infant formula ad lib
75797104|NCT01155414|Other|Investigational Infant Formula B|Investigational infant formula ad lib
75797105|NCT01153776|Procedure|64-slice CT angiography|the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
75797106|NCT01153854|Drug|Racecadotril|oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
75797107|NCT01153854|Drug|Placebo groups|Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
75797108|NCT03891498|Drug|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
75797109|NCT03891342|Drug|Fluid bolus administration|"Fluid bolus administration either fast in 5 minutes or slow in 30minutes."
75797110|NCT01260246|Drug|sitagliptin|pill, 100mg/daily for 6 months
75797111|NCT01260246|Drug|placebo|placebo match for 6 months
75797112|NCT01262040|Other|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
75797113|NCT03886116|Other|Exercise|3 sets of 10 forearm exercises performed twice in the Morning and Evening for 6 weeks.
75797114|NCT03891108|Drug|BMS-986231 Formulation A|Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.
75935145|NCT00074997|Other|Placebo|Single intravenous infusion of placebo.
75935146|NCT00074997|Genetic|OZ1|Single intravenous infusion of OZ1.
75935147|NCT00074997|Genetic|CD34+ cells|Autologous CD34+ cells.
76087688|NCT02255110|Drug|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
75649943|NCT00606788|Device|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
76087689|NCT03320694|Drug|Metformin|metformin 500mg twice daily & increased until 2500mg till normoglycemia was achieved and was continued till delivery
76087690|NCT03320694|Drug|Insulin|The insulin group was given 3 S/C injections of regular insulin & one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
76087691|NCT03318042|Other|Walnuts|The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
76087692|NCT03318042|Other|Pomegranate juice|Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
75339791|NCT04886999|Behavioral|Exploratory study on patient's perception of Asthma symptoms|To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
75649944|NCT00606788|Procedure|Conventional weaning|Patients received physician-directed non-protocolized weaning
75339792|NCT04855266|Drug|Sucrose|5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted
75649945|NCT04108078|Behavioral|Health Policy Plus (HP+)|HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility.
75649946|NCT04108078|Behavioral|Many Men Many Voices (3MV)|3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana.
75649947|NCT04108078|Behavioral|HIV Education, Empathy and Empowerment (HIVE3)|The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana.
75649948|NCT00770731|Drug|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
75649949|NCT00770731|Drug|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
75797115|NCT03891108|Drug|BMS-986231 Formulation B|Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.
75797116|NCT03891108|Drug|BMS-986231 Formulation C|Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.
75797117|NCT03891108|Drug|BMS-986231 Formulation D|Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.
75935148|NCT03200990|Device|iVAC2L pVAD|To determine the effects of the new PFLVAD PulseCath® iVAC2L on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
75935149|NCT02287389|Device|balloon dilation|
75935150|NCT02287389|Procedure|cryotherapy|
75935151|NCT02287389|Procedure|spiculiform electrosurgery|
76087693|NCT02482740|Drug|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
76087694|NCT02482740|Drug|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
76087695|NCT03317886|Procedure|pancreaticoduodenectomy|pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
75339793|NCT04855266|Drug|Placebo|Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)
75935152|NCT02287389|Drug|mitomycin C|
75935153|NCT00057993|Biological|trastuzumab|
75935154|NCT00057993|Drug|exemestane|
75935155|NCT03200756|Behavioral|Sedentary Group|The sedentary group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
75935156|NCT03200756|Behavioral|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
75935157|NCT02284737|Procedure|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
76087696|NCT03315000|Drug|Vilanterol and Fluticasone Furoate|Same as vilanterol arm description
76087697|NCT03315000|Drug|Fluticasone Furoate|Same as fluticasone arm description
76087698|NCT03315000|Drug|Placebos|Same as placebo arm description
75339794|NCT04855266|Diagnostic Test|Tilt Table Test|A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.
75797118|NCT03885882|Drug|E0302 SR1|E0302 SR1, oral tablet.
75797119|NCT03885882|Drug|E0302 SR3|E0302 SR3, oral tablet.
75797120|NCT03885882|Drug|E0302 SR2|E0302 SR2, oral tablet.
75797121|NCT03885882|Drug|E0302 IR|E0302 IR, oral tablet.
75797122|NCT03888534|Drug|Ixazomib|Ixazomib intravenous injection in combination with reduction chemotherapy.
75797123|NCT02527278|Procedure|Laparoscopic tubal ligation|Female permanent birth control method performed via a surgical procedure
75797124|NCT02527278|Procedure|Hysteroscopic sterilization|Female permanent birth control method performed via placement of a device
75339795|NCT04827394|Device|Neonatal warming mattress|Babies will be warmed with a standard neonatal transport warming mattress immediately after birth.
75339796|NCT04827394|Device|Sterile polyethylene wrap|Babies will be wrapped in a sterile polyethylene wrap prior to arrival at the warmer.
76087699|NCT04892602|Diagnostic Test|Serum vitaminDlevel|Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level
76087700|NCT02482818|Drug|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
75339797|NCT04826939|Device|PFDx device and leva device|Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
75339798|NCT04824066|Device|Device: Wearable Device|A Wearable Device will be placed on the wrist of the patient ~30 days prior to the patient's scheduled surgery, removed during the operation, and replaced for ~180 days post-operatively. The device will record activity in terms of steps, sleep quality, heart rate, etc.
75649950|NCT00770731|Drug|Velcade (Bortezomib)|Starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
75649951|NCT05379764|Other|Embodiment|Embodiment of a real human in a virtual human (avatar) means that the real human feels incarnated in the avatar. This happens when the real human sees the VRscenario from first person perspective, that the real human can make the avatar move (=agency over the avatar), multi-sensorial integration (=there is a link between the brain of the real human and the avatar. Example, when the avatar sits on a chair, the real human will too and he feels that he is sitting on a chair. Or when the avatar is moving the real human is doing the same movement (and of course the brain of the real human is aware of this movement)) and co-location (= avatar and real human have the sane posture).
75649952|NCT05379764|Other|Observation|The person is looking at the VR scenario as if s/he was looking at a TV
75649953|NCT04287478|Biological|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
75649954|NCT04264598|Biological|sIPV|The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
75649955|NCT04264598|Biological|Commercialized sIPV|The commercialized sIPV was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.The antigen contents of type I, type II and type III polioviruses in the commercialized sIPV were 30 DU, 32 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
75649956|NCT04264598|Biological|Commercialized IPV|The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.The antigen contents of type I, type II and type III polioviruses in the commercialized IPV were 40 DU, 8 DU and 32 DU. The vaccine was in liquid form, 0.5 ml per dose.
75649957|NCT00770887|Procedure|Self administration|Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
75649958|NCT04076722|Behavioral|Stress reactivity stimuli|An evaluated speech task delivered to participants after baseline testing.
75797125|NCT01260480|Other|[18F]-ML-10 in conjunction with PET imaging|Subjects will receive two to three intravenous (IV) doses of [18F]-ML-10. The dose for each [18F]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
75797126|NCT03891186|Behavioral|Metacognitive Training in Schizophrenia (MCT)|"MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual Metacognitive Training for Psychosis (MCT) that is currently available in 35 languages (available in www.uke.de/mkt)."
75935158|NCT02284737|Procedure|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
75935159|NCT02284737|Drug|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
75935160|NCT02448290|Drug|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
75339799|NCT04822584|Drug|Baricitinib Oral Product|Baricitinib 4 mg/day orally for 36 weeks
75935161|NCT00357279|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
75339800|NCT04822584|Drug|Placebo|Placebo once a day orally for 36 weeks
75474110|NCT01979510|Drug|MK-0663B|MK-0663B once daily for 8 days.
75474111|NCT01979510|Drug|DOLOCAM PLUS®|DOLOCAM PLUS® once daily for 8 days.
75935162|NCT00357279|Drug|Placebo - 0.9% w/v sodium chloride solution|4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
76087701|NCT02482818|Drug|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
76087702|NCT02989870|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Participants will receive 3-5 fractions of radiation as determined by the dose level at time of enrollment. The starting dose level will be Dose Level 1: 8 Gy x 3 fractions for a total of 24 Gy. If sufficient treatment related toxicity is observed at the initial starting dose, then the dose will be reduced to 16 Gy in 2 fractions of 8 Gy. The dose per fraction for each participant will be provided at the time of registration based on the toxicity experience of the previous participants on study. This will be escalated to 40 Gy in 5 fractions of 8 Gy."
76087703|NCT02989870|Drug|Sorafenib|Sorafenib by mouth (PO): 200 mg twice a day (BID) then 400 mg BID.
75474112|NCT01979510|Drug|Acetaminophen 500 mg|Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
75474113|NCT01979588|Other|What's Going Around tool|Provider has access to the What's Going Around tool
75797127|NCT03891186|Other|Treatment As Usual (TAU)|In both groups will be maintained the TAU.
76087704|NCT02989870|Drug|Bavituximab|Bavituximab intravenously (IV): 3 mg/kg every week (q wk).
76087705|NCT02488746|Device|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
75935163|NCT02448134|Behavioral|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
76087706|NCT02480088|Drug|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
76087707|NCT02480088|Drug|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
76087708|NCT01807624|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
76087709|NCT02482506|Behavioral|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
76087710|NCT02482506|Behavioral|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
76087711|NCT03317808|Diagnostic Test|Different exercise|Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
76087712|NCT02480244|Behavioral|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
76087713|NCT02480244|Other|Control|Control arm receives no health-related behavioral intervention
75339801|NCT04822194|Behavioral|Cognitive Emotion Regulation Training|Cognitive emotion regulation training via cognitive reappraisal involves the ability to modify the trajectory of an emotional response by thinking about and appraising emotional information in an alternative, more adaptive way. Reappraisal to down-regulate negative emotion can be operationalized via two tactics: psychological distancing and reinterpretation. The current study will randomly assign participants to receive a brief course of reappraisal training using either psychological distancing or reinterpretation.
75649959|NCT04265690|Behavioral|Cooking classes|Participants will receive 2 cooking classes (each 1-hour long) during their Centering group-care visit at the BMC teaching kitchen, taught by a Registered Dietitian. The recipes taught during the cooking classes will follow the Special Supplemental Nutrition Program for Women, Infants, and Children, the 2015-2020 Dietary Guidelines for Americans, and recommendations from The American College of Obstetricians and Gynecologists.
75649960|NCT04265690|Behavioral|Text messages|Participants will receive text messages, through a password secured phone, based on their content and frequency preferences.
76087714|NCT01808326|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
76087715|NCT05714358|Behavioral|Education|"The patients were given face-to-face training on nutrition, physical activity and drug use in chronic renal failure .~After the training, the biochemical parameters of the patients were followed for 6 months.~In this process, the questions asked by the patients in order not to hinder their right to receive information were answered."
75649961|NCT00775255|Drug|clarithromycin 250 mg/5 mL powder for oral suspension|
75649962|NCT02582398|Other|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
75649963|NCT02582398|Other|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
75935164|NCT02284815|Dietary Supplement|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
75935165|NCT04484558|Drug|Actilyse|Infusion
75935166|NCT00055575|Drug|Scopolamine Nasal Spray|
75649964|NCT00766285|Biological|Trivalent inactivated influenza vaccine|Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.
75649965|NCT00766285|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
75936593|NCT04576247|Behavioral|Combined aerobic and resistance exercise|"The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.~The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program."
75797128|NCT01153932|Drug|GSK2402968|Subcutaneous injection
76087716|NCT03317730|Drug|Xtampza ER|Xtampza ER is a wax microsphere formulation of oxycodone that results in a nearly identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube as opposed to by mouth.
76087717|NCT02486484|Drug|ziv-aflibercept|zaltrap injection
76087718|NCT01808560|Device|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
76087719|NCT01808560|Device|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
76087720|NCT03317652|Other|Hyperventilation|The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
75339802|NCT04786847|Biological|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)
75649966|NCT05367700|Drug|HS-10382(Part 1: Dose escalation)|Single or multiple dose(s) of HS-10382 once daily.
75649967|NCT05367700|Drug|HS-10382(Part 2: Dose expansion)|HS-10382 is administered orally once daily.
75649968|NCT00775333|Procedure|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
75649969|NCT02581774|Other|normal delivery tracking|normal delivery tracking
75649970|NCT04265456|Drug|Pregabalin 100mg|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
75649971|NCT04265456|Drug|Acetaminophen 1300mg|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
75649972|NCT04379518|Other|Best Practice|Receive standard of care
75935167|NCT03206996|Behavioral|Exposure therapy|"The therapist, child and family collaborate to set short and long term goals, develop the exposure hierarchy and Subjective Units of Distress (SUD) scale and design their challenge activities (i.e., exposures). The exposure hierarchy lists activities in ascending order from minimal exposure/minimally difficult (e.g, toilet is not flushed and bathroom door is closed while child walks by) to maximum exposure/maximally difficult (e.g., toilet is flushed repeatedly while child is inside the stall with the door closed). Treatment begins with exposure to activities on the lower end of the hierarchy, with adjustments as indicated, to present stimuli that provide a just-right level of difficulty as indicated by the participant's SUD level and therapists clinical judgment. Participants communicate the level of difficulty using their individualized SUD scale. Additionally, the child and family complete home exercises with exposures."
75936594|NCT03184610|Device|OCT-scanning|All participants will be scanned with a OCT-device
75936595|NCT03184766|Drug|Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules|2 x 200 mg ibuprofen & 30 mg pseudoephedrine
75936596|NCT03184766|Drug|Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets|2 x 200 mg ibuprofen & 30 mg pseudoephedrine
76087721|NCT03317652|Other|6% CO2 breathing|The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
76087722|NCT03317652|Drug|Infusion of sodium nitroprusside|Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
76087723|NCT02479854|Drug|Asmakast|1 chewable tablet contains 5 mg montelukast
76087724|NCT02479854|Drug|Singulair|1 chewable tablet contains 5 mg montelukast
76087725|NCT02486172|Behavioral|Peer support program|Peer support program as an additional service to the routine clinical service
76087726|NCT01809106|Drug|Morphine|60 mg /24 ore
75339803|NCT04772209|Drug|Sodium bicarbonate|Dialysis catheter lumen will be filled (locked) by sodium bicarbonate solution. The amount of solution depends on the diameter and length and will be in accordance with the manufacturer's specifications.
75339804|NCT04772209|Drug|Heparin|Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.
75339805|NCT04762368|Device|Active anodal tDCS|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
75339806|NCT04762368|Device|Sham anodal tDCS|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
75339807|NCT04757662|Drug|Tadalafil|Tadalafil is commercially available and will be purchased by the Siteman Cancer Center and distributed to participants free of charge.
75649973|NCT04379518|Biological|Recombinant Interferon Alfa-2b|Given IV
75649974|NCT04379518|Drug|Rintatolimod|Given IV
75649975|NCT04264364|Procedure|Laparoscopic sleeve gastrectomy|Bariatric surgical intervention
75649976|NCT04264364|Procedure|Endoscopic sleeve gastroplasty|Endoscopic bariatric procedure
75797129|NCT01153932|Drug|matched placebo|Subcutaneous injection
75797130|NCT03886194|Procedure|interventional treatment in pulmonary|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
76087727|NCT01809106|Drug|Fentanyl|25 microg/h
75797131|NCT03888456|Other|osteopathic treatment|the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified
75797132|NCT03888456|Other|sham|the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique
76087728|NCT01809106|Drug|Buprenorphine|35 microg/h
76087729|NCT01809106|Drug|Oxycodone|40 mg /24 ore
76087730|NCT02479932|Other|Transperitoneal cesarean technique|Pfannenstiel-Kerr technique for laparatomy and uterine entry
75797133|NCT03891030|Other|Checklist Based Box system intervention|The intervention has both behavioural change and service utilization drop out tracing mechanism. Special type of boxes designed to schedule health educations and continued service utilization monitoring boxes will be placed at health posts and health centers respectively. Community level survey will be conducted to identify suspected pregnant mothers using stanback et al, 1999 checklist, and mothers are linked to health centers. Then, they will be followed for their subsequent attendance of consecutive maternal health services (ANC 2nd-third PNC). Mothers who fail to utilize the service will be traced; will get person-centered health education to continue the service.
75339808|NCT04756050|Drug|Bupivacaine HCl 0.5% Injectable Solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
75797134|NCT05095584|Diagnostic Test|3 meter backward walk test|validity and reliability of 3-meter backward walk test in lower limb amputation group
75339809|NCT04756050|Drug|Prilocaine HCl % 2 injectable solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
75339810|NCT04756050|Drug|adrenaline amp 0.5mg|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
75339811|NCT04756050|Procedure|Ultrasound Guided Supraclavicular Block Corner pocket approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance. Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
75339812|NCT04756050|Procedure|Ultrasound Guided Supraclavicular Block Corner pocket + intracluster approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance .10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
75339813|NCT04756050|Procedure|Ultrasound Guided Supraclavicular Block multi approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
75339814|NCT04756050|Procedure|diagraphma muscle evaluation with ultrasound|"All patients will be evaluated with USG in a head-up position facing the side to be operated before and 30 minutes after the block is performed.~The probe will be placed perpendicular to the chest wall, in the eighth or ninth intercostal space, between the anterior axillary and midaxillary lines, 0.5 to 2 cm below the costophrenic sinus."
75339815|NCT04748107|Diagnostic Test|Impendence Cardiography|ICG is a noninvasive method of determining the amount of blood flow using the Non-Invasive Cardiac System - Cardiac Surveyor (NICaS) system, which provides an assessment of the cardiovascular system, respiratory system, and fluid retention.
75649977|NCT04378426|Drug|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50% nitrous oxide and 50% oxygen plus intravenous saline
75339816|NCT04732143|Other|Inspiratory muscle training|At least 2 weeks prior to surgery, participants will be given a Vyaire incentive spirometer device and provided with formal training on proper inspiratory muscle breathing exercise using the device. They will be instructed to perform 4 sets of these exercises per day for 14 days prior to surgery.
75339817|NCT04731103|Drug|Abacavir (ABC)|Tablets or oral solution
75339818|NCT04731103|Drug|Lamivudine (3TC)|Tablet or oral solution
75339819|NCT04731103|Drug|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Tablet or oral solution
75339820|NCT04716712|Drug|Azithromycin|Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
75339821|NCT04716712|Drug|Placebo|Matching identical placebo in packaging, appearance, and taste.
75339822|NCT04710420|Device|Endovascular therapy|Endovascular treatment for critical limb threatening Ischemia
75339823|NCT04709562|Device|High Velocity Nasal Insufflation (HVNI)|The purpose of this intervention is to evaluate the efficacy of HVNI in clinically stabilizing patients presenting with hypercapnic respiratory distress.
75339824|NCT04709562|Device|Noninvasive Positive Pressure Ventilation (NIPPV)|The purpose of this intervention is to evaluate the efficacy of NIPPV in clinically stabilizing patients presenting with hypercapnic respiratory distress.
75339825|NCT04700553|Device|Localized muscle vibration|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
75474114|NCT01979588|Other|Control|Provider does not have access to the What's Going Around tool but received information regarding the tool prior to study initiation
75649978|NCT04378426|Drug|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
75649979|NCT04378426|Drug|Nitrogen|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
75797135|NCT03885570|Procedure|Mitral valve replacement|Blood transfusion
75936597|NCT03184766|Drug|Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules|2 x 200 mg solubilised ibuprofen
75936598|NCT03184376|Dietary Supplement|Prebiotic oligofructose|Powder format
75936599|NCT03184376|Dietary Supplement|Placebo maltodextrin|Powder format
75474115|NCT01979601|Drug|LGT209|150 mg lyophilized powder in glass vial
75474116|NCT01979601|Drug|Placebo|Placebo comparator
75474117|NCT01979627|Procedure|transulnar approach interventional procedure|
75649980|NCT04378426|Drug|Oxygen|inhaled gas
75649981|NCT04378426|Drug|Saline|Placebo infusion
75649982|NCT04094506|Drug|ASP1948|Intravenous
75797136|NCT03890640|Procedure|Ultrasound-guided TECI|When performing an ultrasound-guided thoracic epidural catheter insertion (TECI), an 18-gauge Tuohy needle will be used for interlaminar epidural access. All procedures will be performed with a paramedian approach under ultrasound-guidance and using the loss of resistance technique with saline. If the needle is deemed to be in the epidural space when the loss of resistance occurred, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
75797137|NCT03885804|Drug|Quadratus lamborum dexmedetomidine intravenous|Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
75649983|NCT00605618|Drug|BMS-777607|Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
75339826|NCT04700553|Other|Conventional physiotherapy intervention|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
75339827|NCT04699539|Radiation|SBRT|SBRT: in 5-6fractions with Cyberknife.
75649984|NCT00608192|Behavioral|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
75339828|NCT04699539|Drug|Chemotherapy|Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) or single-agent oral S-1 (60-120 mg/ daily, d1-14) , repeat every 3 weeks.
75474118|NCT01979627|Procedure|transradial approach interventional procedure|
75797138|NCT03885804|Drug|Quadratus lamborum dexmedetomidine perineural group(|Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
75797139|NCT03885258|Drug|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
75797140|NCT01262196|Drug|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
75797141|NCT01262196|Drug|Saline|Normal saline (0.9%) solution
75797142|NCT03885180|Drug|Warfarin Sodium|Extending warfarin anticoagulation
75797143|NCT01154244|Other|HOMA-IR|Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
75797144|NCT03888300|Other|Physiotherapy|Chest Physiotherapy, physical exercises
75797145|NCT03885414|Behavioral|In-session Virtual Reality exposure therapy|A series of exposure exercises (speech exercises) in front of a virtual audience, focusing on promoting inhibitory learning, with audio-feedback.
75935168|NCT03206996|Behavioral|Psycho-education|Child and caregiver receive education and training will be provided to improve the participant's self-awareness of his/her behavioral and emotional response to auditory stimuli, his/her ability to self-report anxiety/emotional response levels, as well as his/her ability to identify useful arousal level modulation/coping strategies. During this phase, the child, caregiver and therapist will collaborate to identify the participant's Subjective Units of Distress Scale (SUD) from 0-10 with each level defined, particularly for what levels are tolerable or intolerable.
75797146|NCT03885414|Behavioral|Internet-administered transition program|Four-module internet program with weekly therapist guidance, focusing on transitioning to in-vivo exposure in everyday settings.
76087731|NCT02479932|Other|Extraperitoneal cesarean technique|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
76087732|NCT03852394|Other|Respiratory mechanics assessment|The study protocol consisted of two consecutive phases; in the first step measurements of static respiratory mechanics and end expiratory lung volume (EELV) were performed after 30 minutes of MV in volume control mode. In the second step transdiaphragmatic pressure (Pdi) was calculated by means of a sniff maneuver (Maximal Pdi) after 30 minutes of spontaneous breathing trial. Linear regression analysis and Pearson's correlation coefficient was used to asses the association between Maximal Pdi values and static and dynamic mechanical features and the association between Maximal Pdi and Pdi/Maximal Pdi.
75474119|NCT01979640|Procedure|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
75474120|NCT01979640|Procedure|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
75474121|NCT01979640|Procedure|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
75797147|NCT01152762|Procedure|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy during 6 months
75797148|NCT03890562|Other|Auricular acupressure|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
75474122|NCT01979653|Drug|dexmedetomidine alone or dexmedetomidine + midazolam|
75474123|NCT01979666|Drug|nitrate patch|patients in the study group will get a nitrate patch
75474124|NCT01979666|Drug|placebo patch|control group patients will get a placebo patch
75797149|NCT03888144|Drug|Oxycodone|5 mg of oxycodone taken by mouth every 6 hours for 5 days
76087733|NCT02482662|Procedure|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
76087734|NCT03828136|Device|Novum Vitrium® Cervical Interbody Device|For spinal fusion procedure at one level (C3 to T1) of the cervical spine.
76087735|NCT03828136|Device|Allograft Ring or Block|Standard of Care
75797150|NCT03888144|Drug|Ketorolac|10 mg of ketorolac taken by mouth every 6 hours for 5 days
75649985|NCT00608192|Behavioral|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
75339829|NCT04697849|Behavioral|Cognitive Rehabilitation and Exposure/Sorting Therapy|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
75649986|NCT02581462|Drug|FLOT alone|"Pre-operative therapy:~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43"
75339830|NCT04697849|Behavioral|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
75339831|NCT04690777|Procedure|Experimental: VESTIBULAR EXERCISE|OCULAR AND MOVEMENT EXERCISES
75339832|NCT04690777|Procedure|MULTICOMPONENT EXERCISE|exercises includes strengthening, cardiovascular training, flexibility and balance
75474125|NCT01979666|Device|MRI scan|MRI scan after 6 weeks of treatment
75474126|NCT01979679|Drug|Lurasidone 80 mg|
75797151|NCT03890406|Drug|Rocuronium: PTC(Post-tetanic count) 1~2|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
75797152|NCT03890406|Drug|Rocuronium: TOF(Train-of-four) 1~2|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
75797153|NCT03887832|Other|SMBI digital app|Digital platform on the smartphone for the media package
75797154|NCT03887832|Behavioral|media package|The SMBI app contains a <1 minute video of a mother and baby or just mother, a reflection question about the video, a few questions about their mood and stress, and some prompts and suggestions on what to do if they have problems.
75797155|NCT03887832|Other|standard newborn and infant care|Recommended standard pediatric primary care will be provided for infants up to 6 months.
75797156|NCT01154400|Dietary Supplement|Casein protein hydrolysates|15 g casein protein hydrolysates + 15 g maltodextrin
75935169|NCT03206996|Behavioral|Caregiver education/home program development|Parents will be provided with education on home programs to facilitate treatment gains. Home programs will be designed specifically for each participant. Parent education and home programs are provided either concurrently or after the exposure phase for the family to apply these methods to other settings. Home programs can continue as a maintenance program after treatment has ended. At the end of the treatment phase, the study team will conduct the following assessments for a third time: (1) the Sensory Profile, a clinical tool commonly used in OT to assess parent reports of sensory processing difficulties in children, (2) Parent Stress Index - 4 to evaluate stress related to parent-child interactions, and (3) the Modified Khalfa Hyper-acusis Questionnaire to assess the level of hyper-sensitivity to sound.
75935170|NCT00051129|Drug|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
75935171|NCT00051129|Other|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
75935172|NCT03200600|Drug|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
75935173|NCT03200600|Drug|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
75339833|NCT04683640|Dietary Supplement|GABA|Daily oral GABA for 4 weeks
75339834|NCT04683640|Drug|Placebo|Daily oral Placebo for 4 weeks
75797157|NCT01154400|Dietary Supplement|Whey protein hydrolysates|15 g whey protein isolate + 15 g maltodextrin
75797158|NCT01154400|Dietary Supplement|Casein protein hydrolysates + LEU|15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
76087736|NCT03314610|Other|Gait speed|No intervention, only propose water and wait for need to void
75474127|NCT01979679|Drug|Lurasidone 120 mg|
75474128|NCT01979679|Drug|Lurasidone 160 mg|
75474129|NCT01979692|Procedure|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
75797159|NCT01154400|Dietary Supplement|Whey protein hydrolysates + LEU|15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
75797160|NCT03884868|Other|Iconographies to communicate risks|Use of iconographies to communicate the risks of the different possible diagnosis after a positive FIT during the screening program nurse visit.
75797161|NCT01152840|Drug|RAD001|"RAD001 10 mg po daily medication~Treatments will be continued until any of the following events occur:~progression of disease,~the subject develops unacceptable toxicity,~consent to participate in the study is withdrawn."
76087737|NCT03804580|Drug|osimertinib|Non-randomized trial, all patients receive therapy
76087738|NCT02482584|Device|CPAP|CPAP intervention
75474130|NCT01979692|Device|CT guided trans thoracic needle biopsy|
76087739|NCT02482584|Other|Control|Control
76087740|NCT03317574|Drug|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
76087741|NCT03317574|Drug|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
76087742|NCT01765972|Device|etafilcon A with Lacreon|contact lens with Lacreon
75797162|NCT01262274|Drug|Anastrozole|ANA is given 1mg daily for 24 weeks.
75649987|NCT02581462|Biological|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:~Herceptin 8/6 mg/kg, d1, d22, d43~Pertuzumab 840 mg, d1, d22, d43~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~Herceptin 8/6 mg/kg, d1, d22, d43~Pertuzumab 840 mg, d1, d22, d43~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43."
75797163|NCT01262274|Drug|Anastrozole plus tegafur-uracil|ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
75797164|NCT03890796|Behavioral|Activity Scheduling|AS is strategy for behavioral activation that has also been used with success in people with dementia, after the training of their caregivers. A certified occupational therapist will train up the caregivers of dementia in conducting AS activities for participants in experimental group
75797165|NCT03890796|Behavioral|Educational|A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
75797166|NCT01155648|Device|Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.|
75797167|NCT01155648|Device|Chest wall compression for ten minutes in chest|
75797168|NCT03890328|Procedure|radiofrequency ablation|apply RF therapy to the treatment of splenic trauma
75797169|NCT01154478|Other|Diet rich in omega-3 fatty acids|fish at least 3 times per week, large leaf vegetables
75797170|NCT01154478|Other|Diet rich in polyphenols|extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
75797171|NCT01154478|Other|Control diet|low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)
75797172|NCT01154478|Other|diet rich in omega-3 and polyphenols|Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
75935174|NCT03200600|Drug|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
75339835|NCT04680221|Drug|Liposomal bupivacaine|Deposition of liposomal bupivacaine
75649988|NCT00668863|Drug|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
75797173|NCT01260558|Device|Sirolimus-Permanent-Polymer Eluting Stent|due randomization sirolimus-permanent-polymer eluting stent was implanted
75935175|NCT03200600|Drug|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
75935176|NCT02547454|Drug|Methoxy polyethylene glycol-epoetin beta|
75935177|NCT05725785|Behavioral|FOCUS participants|Participants using FOCUS will be given access to the FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
75935178|NCT00049959|Drug|verteporfin PDT|
75935179|NCT00040677|Drug|Low Dose ICA-17043|Low dose arm
75935180|NCT00040677|Drug|High dose ICA-17043|150 mg Loading Dose; 10 mg daily dose
75797174|NCT01260558|Device|Sirolimus-Polymer-free Eluting Stent|due randomization sirolimus-polymer-free eluting stent was implanted
75797175|NCT01152918|Behavioral|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
75935181|NCT00040677|Drug|Placebo|Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
76087743|NCT01765972|Device|etafilcon A with Lacreon with print|contact lens with Lacreon and cosmetic print
75339836|NCT04680221|Procedure|TAP block|Transversus abdominis plane block performed to deposit anesthetic
75339837|NCT04680221|Drug|Deposition of saline|Deposition of saline
75339838|NCT04676607|Drug|SHR7390|SHR7390
75339839|NCT04668144|Drug|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.
75339840|NCT04668144|Drug|Prasugrel|Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration
75339841|NCT04662060|Drug|Acebilustat|100 mg capsule administered orally once daily
75339842|NCT04662060|Drug|Placebo|Placebo to match acebilustat administered orally once daily
75339843|NCT04649190|Device|TAVI|Coronary access for PCI after TAVI
75797176|NCT01152918|Behavioral|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
75797177|NCT01152918|Behavioral|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
75797178|NCT01152918|Behavioral|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
75797179|NCT01152918|Behavioral|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
75339844|NCT04644796|Drug|saline 0.9%|Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
75339845|NCT04644796|Drug|Liposomal bupivacaine|Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
75935182|NCT03206840|Behavioral|"control, meditation, hypnosis."|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
75339846|NCT04643340|Other|real-time fMRI|Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).
75339847|NCT04621929|Drug|Phentermine / Topiramate Oral Product|All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)
75797180|NCT01152918|Behavioral|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
75339848|NCT04621929|Combination Product|Citrate Salts, Allopurinol, Diet|Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.
75935183|NCT05725707|Behavioral|Friendship Group|Whether face-to-face or online delivery, each FG session followed the same broad format - (1) Group meditative exercise and reminder of group agreement (10 mins); (2) Check in with support group members and main session (50mins); (3) Summary of group discussion and homework activity planning (10mins); (4) Final group meditative exercise and closing of group (10mins). Session length was up to 80 minutes (see table 2) and each facilitator was provided with a manual describing each section as well as some hints and tips to promote discussion and engagement. While all FG's would follow this structure, group members would drive the content (particularly during Step 2).
75474131|NCT01979718|Device|Mirrored Virtual reality|Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
75797181|NCT01260636|Drug|Gadobenate Dimeglumine|0.1 mmol/kg, single dose
75797182|NCT01260636|Drug|Gadopentetate Dimeglumine|Double dose of 0.2 mmol/kg
75797183|NCT01260714|Drug|Azacitidine|Given SC
75797184|NCT01260714|Drug|Etoposide|Given IV
75797185|NCT01260714|Other|Laboratory Biomarker Analysis|Correlative studies
75474132|NCT01979731|Other|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
75797186|NCT01260714|Drug|Mitoxantrone Hydrochloride|Given IV
75797187|NCT03890094|Drug|Sufentanil|Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
75935184|NCT03206684|Drug|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
75339849|NCT04612491|Behavioral|Pre-operative Consultation|Pre-operative consultation will be given before Mohs surgery
75339850|NCT04596553|Dietary Supplement|Essential Amino Acid|Immediately following the exercise intervention participants will consume their assigned essential amino acid supplement
75339851|NCT04596553|Dietary Supplement|Collagen Peptide|Immediately following the exercise intervention participants will consume their assigned collagen peptide supplement
75935185|NCT03206684|Drug|rhG-CSF|rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
75935186|NCT05219123|Other|ERCP with no PD cannulation|ERCP with no PD cannulation
75935187|NCT05219123|Other|ERCP with single PD cannulation|ERCP with single PD cannulation
75935188|NCT00036621|Drug|BMS-275291|
75935189|NCT03200444|Other|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy products
75935190|NCT03200444|Other|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy products
75935191|NCT03200444|Other|Standard adhesive 3|This strip consists of a standard hydrocolloid adhesive found in ostomy products
75935192|NCT03200444|Other|P-4|Newly developed adhesive P-4
75339852|NCT04596553|Dietary Supplement|Maltodextrin Placebo|Immediately following the exercise intervention participants will consume their assigned maltodextrin supplement
75474133|NCT01979731|Other|Guidelines ergonomics|Orientation about manual material handling, posture, furniture, rest break and others in general.
75649989|NCT00668863|Drug|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
75649990|NCT04077736|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82). Then all patients were followed up for 3 months
75649991|NCT00608348|Procedure|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
75649992|NCT00608348|Procedure|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
75649993|NCT00766441|Drug|Sitagliptin|tablet, 100mg, once daily, 4 weeks
75649994|NCT00766441|Drug|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
75649995|NCT00766519|Other|volume optimization|"Fluid management:~basal fluid administration = 5 ml/kg/h lactated Ringer's solution~+ systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is > 10%"
75649996|NCT00766519|Other|standard volume administration|"Fluid management:~basal fluid administration = 5 ml/kg/h lactated Ringer's solution~hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV"
75339853|NCT04582279|Diagnostic Test|Lung ultrasound|The lung ultrasound will be performed by a trained pulmonologist by gently pressing a probe to various areas of your chest. This is a non-invasive procedure and you should not feel any pain. The ultrasound will take less than 10 minutes.
75649997|NCT00771043|Drug|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
75339854|NCT04572763|Drug|Copanlisib|Intravenous infusion
75935193|NCT03200444|Other|P-15|Newly developed adhesive P-14
75339855|NCT04572763|Drug|Venetoclax|Tablet taken orally
75797188|NCT03887754|Drug|Risperidone|It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.
75339856|NCT04556981|Biological|M72/AS01E Mycobacterium tuberculosis vaccine|Participants will receive an intramuscular dose of M72 (10 micrograms of recombinant fusion protein) reconstituted with AS01E (an adjuvant system), on Day 1 and Day 29
75935194|NCT03200444|Other|P-16|Newly developed adhesive P-8
75339857|NCT04556981|Biological|Placebo|Participants will receive an intramuscular dose of saline (0.9% NaCl), on Day 1 and Day 29
75339858|NCT04556370|Drug|Normal saline|Normal saline infusion simultaneous with subarachnoid block
75339859|NCT04556370|Drug|Norepinephrine|Different infusion dose of norepinephrine simultaneous with subarachnoid block
75797189|NCT03887754|Device|hyperbaric oxygen therapy|Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.
75797190|NCT03887754|Drug|Non specific Multivitamin|control group received non specific multivitamins as placebo for 8 months.
75797191|NCT01262430|Procedure|OtisMed|OtisMed Custom-fit Shapematching Guides
75797192|NCT01262430|Procedure|Computer Assisted Surgery (CAS)|Stryker Navigation System
75797193|NCT01259622|Drug|saline|intravenous infusion
75797194|NCT01259622|Drug|K201|intravenous infusion
75797195|NCT03890016|Diagnostic Test|20'Whole Blood ClottingTest (WBCT)|"1ml of blood drawn from snake bite victims in clean glass test tubes of 1 cm diameter Kept undisturbed for a period of 20 minutes (measured by a stop watch). At the end of 20 minutes the tube is tilted to see if the blood has clotted or not.~If a well formed clot is not formed, the test is recorded as 'abnormal'.~If the clot seems well formed, it is further observed for a period of 30 minutes to look for dissolution of the formed clot and would be termed clot lysis. Clot lysis indicates an unstable clot."
75797196|NCT03890016|Diagnostic Test|Modified Lee and White (MLW) Method Clotting Time|"The blood collected in three additional test tubes would be utilised for MLW.~The three test tubes would be kept on a rack at ambient temperature.~The blood sample would be drawn in a 5cc syringe and 1 ml would be added in the three test tubes consecutively.~The test tube would be left undisturbed for 5 minutes, after that the first tube would be tilted approximately to check for clot formation every 30 seconds while the other tubes are left undisturbed.~After the blood in the first tube has clotted, the time would be noted and the second tube would be tilted every 30 seconds and examined.~Following its clotting, the third tube would be examined. The time at which the third tube is recorded as the CT value.~Once clotted, then the sample in the all three test tube would be assessed at 20 minute and 30 min to look for breakup or lysis of the clot."
75935195|NCT04588337|Drug|rhTNK-tPA|Thrombolysis
75935196|NCT03119324|Device|B-Cure® diode laser|B-Cure laser® (Good Energies, Haifa, Israel) 808nm diode laser application in contact mode over painful area twice a day for 7 consecutive days
75935197|NCT03119324|Device|B-Cure® diode laser sham device|B-Cure laser® (Good Energies, Haifa, Israel) application by sham device twice a day for 7 consecutive days
75339860|NCT04535882|Diagnostic Test|serum leucine-rich alpha-2 glycoprotein (LRG) levels|Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.
75339861|NCT04535687|Drug|Fluzoparib|Fluzoparib
75339862|NCT04527887|Drug|Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.
75339863|NCT04527887|Other|ProLong™ collagen plugs|The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.
75339864|NCT04526145|Behavioral|Stress and emotion management|Group intervention led by a nurse and dietitian to address stress, emotion management and healthy lifestyle for African American women with hypertension. The weekly sessions will include:how to manage stress during Covid-19, taking blood pressure, interpersonal relationships skills, mindful awareness, restful sleep, physical activity, and healthy eating.
75339865|NCT04484285|Device|Transcutaneous Vagal Nerve Stimulation (tVNS)|vagal nerve stimulation
75649998|NCT00771121|Drug|urea/lactic acid|new emulsion type
75649999|NCT00771121|Drug|Placebo|only emulsion base
75650000|NCT04267250|Drug|PF-06700841|60 mg by mouth (PO) once daily (QD).
75650001|NCT04267250|Drug|Ethinyl estradiol (EE) and levonorgestrel (LN)|Oral tablet containing 30 mcg EE and 150 mcg LN.
75650002|NCT00775489|Drug|Nasal steroid Beclomethasone|Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.
75935198|NCT03119324|Drug|Nimesulide Ratiopharm® and Flexiban®|Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
75935199|NCT00415623|Drug|Amlodipine|Amlodipine 5mg/ day
75935200|NCT00415623|Drug|Amlodipine|Amlodipine 10mg/ day
75935201|NCT05219045|Other|Ohio RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an active comparator that is not.
75650003|NCT00775489|Drug|Saline|control group will receive normal saline inhaler
75797197|NCT01155804|Behavioral|preparation of the delivery|Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
75797198|NCT01155882|Procedure|Whipple at the Splenic Artery (WATSA)|
75935202|NCT03206606|Device|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
75935203|NCT02287545|Procedure|trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
75935204|NCT03195608|Device|Lane change assistance system|This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
76087744|NCT01765972|Device|etafilcon A with print|contact lens with print
76087745|NCT01765972|Device|Spectacles (habitual)|Spectacles
76087746|NCT02486250|Other|Validation Study|
76087747|NCT01810666|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
75339866|NCT04480099|Drug|CHOP|Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
75339867|NCT04480099|Drug|CHOP+X|X: X(i.e. targeted drug) will decided by NGS results as following. Decitabine 10mg/m2 ivgtt D-5 to-1 if with TP53 gene muation. Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation. Chidamide 20mg/day po D1,4,8,11 if with CREBBP/EP300 gene mutation. Lenalidomide 25mg/day po D1-10 if without gene mutation above. X will be added from the second cycle CHOP:Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
75650004|NCT00771199|Drug|Transdermal Therapeutic System (TTS)-Fentanyl|Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
75474134|NCT01979744|Procedure|IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
75474135|NCT01979744|Device|Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
75650005|NCT04264130|Drug|Artesunate-Pyronaridine|Subjects received artesunate-pyronaridine according to their body weight once per day for three days.
75474136|NCT01979744|Device|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
75650006|NCT04264130|Drug|Artemether-Lumefantrine|subjects received artemether-lumefantrine according to their body weight twice per day for three days.
75650007|NCT04264130|Drug|Artefenomel-Ferroquine|Subject received a single dose of artefenomel-ferroquine according to their body weight
75650008|NCT00775567|Dietary Supplement|Fructose powder|30g in 250ml water twice a day
75650009|NCT04267016|Diagnostic Test|TruGraf Testing - Peripheral blood gene expression profiling|5 mL collection PAXgene blood sample
75650010|NCT02557867|Drug|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
75650011|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
75650012|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
75650013|NCT04264286|Drug|Prophylactic esmolol|Patients will receive prophylactic esmolol after the end of the surgery
75650014|NCT04264286|Drug|Placebo|Patients will prophylactic placebo after the end of the surgery
75650015|NCT04356976|Device|Ventralex|Repair of hernia using Ventralex patch in sublay position
75797199|NCT03887598|Device|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
75650016|NCT04356976|Other|Stratafix|Repair of hernia without mesh. Defect closed with Stratafix suture.
75650017|NCT04077502|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
75935205|NCT03195608|Behavioral|Active Control|Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
75935206|NCT03134001|Device|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
75339870|NCT04438460|Biological|Blood test|"For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery."
75935207|NCT03118544|Device|DyeVert System|The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
75935208|NCT01969409|Drug|Rituximab|i.v. rituximab given on two occasions 14 days apart.
76087748|NCT02482272|Drug|Lamivudine|Lamivudine 100mg/day orally
76087749|NCT02482272|Drug|Adefovir|Adefovir 10mg/day orally
75339871|NCT04436926|Behavioral|opioid approach bias modification|The investigators will use a training version of the Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different opioid and 20 different non-medication alternative pain managing activities. Training effect is achieved by presenting opioid pictures in push format only and non-opioid pictures in pull format only. Two hundred training trials are presented per session.
75339872|NCT04436926|Behavioral|sham training|Sham training is identical to opioid approach bias training, except pictures are presented randomly in both formats.
75339873|NCT04423757|Drug|BI 1358894|125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
75339874|NCT04423757|Drug|Placebo|Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
75339875|NCT04423055|Drug|Etonogestrel contraceptive implant|Place etonogestrel contraceptive implant.
75650018|NCT02582476|Drug|Bumetanide|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
75650019|NCT02582476|Drug|Placebo|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
75650020|NCT02582320|Drug|Ibrutinib|A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
75650021|NCT02582086|Other|BOR15001L7|Active cream with 5% 15019L0
75650022|NCT02582086|Other|Placebo|Placebo Cream with 0% 15019L0
75650023|NCT04078204|Drug|Butylphthalide Soft Capsules|The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
75797200|NCT01260792|Other|questionnaire|The teachers or the professors complete questionnaires on the child on their behavior in classes
75797201|NCT01260792|Other|Questionnaire|The parents complete a questionnaire on the behavior of their child and on their own behavior
75797202|NCT01153074|Device|Closure of bronchopleural fistula with Occlutech Figulla|Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
75797203|NCT03884322|Other|Prepod|the prepod is either a 4 way stretch polyester blend fleece with 8 to 10% lycra, or a 95%cotton5% lycra blend knit. It comes in 4 different sizes to assure a pod that has a conforming but not restricting fit so that the infant is free to stretch in any direction at any time but is loosely held in a position of physiological flexion (the fetal position) when not stretching.
75797204|NCT03884322|Procedure|Joint compression exercises|Each premature infant enrolled as a control subject received approximately 10 minutes of joint compression exercises provided by a NICU trained physical or occupational therapist 5x a week. The exercises consisted of waking the infant slowly, gently if necessary just before feeding with a simple range of motion stretching program then stabilizing an extremity and applying force distally to proximally for 6 repetitions with a brief pause between each compression.
75935209|NCT01969409|Drug|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
75935210|NCT00413205|Drug|Placebo|po daily
75935211|NCT00413205|Drug|RAR Gamma|5mg po daily
75935212|NCT03118856|Diagnostic Test|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
75935213|NCT02448212|Drug|TS-121|Oral
76087750|NCT02482272|Drug|Entecavir|Entecavir 1mg/day orally
76087751|NCT01766440|Drug|Calcitriol 3 mcg/g ointment|Topical ointment; twice daily application
76087752|NCT03317340|Other|Background Sounds|Background music or sound of running water
76087753|NCT05714124|Procedure|Embolization|Endovascular treatment for patients with primary and secondary liver tumors
76087754|NCT02482116|Other|malaria or pneumonia diagnosis|Diagnostic approaches for malaria (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, rapid diagnostic tests, Giemsa microscopy); Diagnostic approaches for pneumonia (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, chest x-ray)
75935214|NCT02448212|Drug|[11C]TASP0410699|Intravenous radiotracer
75339876|NCT04418401|Drug|Donafenib and anti-PD-1 antibody|Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
75797205|NCT03890172|Other|20-100 ml venous blood will be drawn the from patient into sterilized centrifuge tube ,following centrifuge to separate PRP and at the bed side and tricked onto the ulcer twice weekly|topical application of platelets rich plasma after Centrifugation at diabetic foot ulcer to study group ,history taking . Ankle brachial index (ABI) measuring and laboratory testes including hemoglobin A1c ( HgA1)c,cbc and prothrombin time( pt) and prothrombin concentration ( pc)
75339877|NCT04404400|Drug|Investigational products administration|"Investigational products include:~Hydrocortisone hemisuccinate 50 mg: one intravenous injection every 6 hours, and~9 alpha fludrocortisone 50 μg: one tablet per day via a nasogastric tube.~All treatments will be stopped after 7 days or until the patient has left the intensive care unit (whichever occurs first) without tapering off."
75339878|NCT04404400|Drug|Placebo administration|Placebos for hydrocortisone and for fludrocortisone, administered in same manner as the active drugs in the interventional arm, for 7 days.
75339879|NCT04385602|Drug|Intratracheal dexmedetomidine|Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
75339880|NCT04385602|Drug|Saline Solution|Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
75339881|NCT04379713|Biological|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
75339882|NCT04379713|Biological|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
75339883|NCT04359108|Device|Navigation System for Users of a Visual Prosthesis|We use common psychophysical judgments such as the following: discriminating between two alternatives by saying which is present in the field of view, touching a tablet computer to indicate the apparent location of a target in the frontal plane, and looking for targets by rotating the head and pointing when one is found. We will compare user performance using the Basic system with user performance using the Augmented and Augmented + Modal systems where contextual information associated with the task is conveyed to users via enhanced visual, auditory, and haptic modalities.
75339884|NCT04346615|Drug|Zavegepant (BHV-3500)|10 mg intranasal (IN) for 14 days
75339885|NCT04346615|Drug|Placebo|Placebo Q8h for 14 days
75339886|NCT04323397|Device|Non-invasive ventilation|Intervention nasal high frequency oscillatory ventilation (nHFOV) and nasal synchronized intermittent positive pressure ventilation (nSIPPV) were generated by neonatal ventilators (SLE6000 infant ventilators, United Kingdom) using bi-nasal prongs (RAM cannula, NEOTECH®, USA) or the nasal mask of the same type for both ventilation modes. The size of the prongs was determined by the infant's weight. The largest possible prongs were used, with a snug fit to avoid leakage. Pacifier for preterm and term neonate (Jollypop™, USA) was taken to avoid leakage from the mouth. The disposable ventilator circuit (Fisher & Paykel RT268™, Evaqua Dual Limb Infant Breathing Circuit Kit with Evaqua 2 Technology and Pressure Line, Flow > 4L/min, New Zealand) was used. The initial NIV setting was (7) described in arm description. (above)
75474137|NCT01979744|Procedure|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
75474138|NCT01979757|Other|Puregraft|
75474139|NCT01979757|Other|Centrifugation|
75650024|NCT04078204|Drug|placebo Soft Capsules|The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
75650025|NCT04249414|Device|PulmoVista 500|"Monitoring of Ventilation and Perfusion with the PulmoVista 500 during clinical routine.~No medical interventions required"
75650026|NCT04076488|Other|Dividat Fit|tablet based, remote assisted home-training
75797206|NCT03890172|Other|standard treatment|Subjects in the control group will receive Standard Wound Care treatment for chronic ulcers according to accepted medical practices.
75797207|NCT03884244|Other|chewing gum|The group who take chewing gum after operation
75797208|NCT03889470|Drug|NTG 1 MG/ML Injectable Solution|administered after sheath placement
75797209|NCT01259700|Behavioral|High-risk patient standardized management package|A primary-care based high cardiovascular risk management package delivered by village doctors
75935215|NCT02448212|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
76087755|NCT01811212|Drug|Cabozantinib S-malate|Given PO
76087756|NCT01811212|Other|Laboratory Biomarker Analysis|Correlative studies
76087757|NCT03314532|Procedure|TILA-TACE|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
76087758|NCT02482194|Biological|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
76087759|NCT01767064|Other|Posted commitment letter|
76087760|NCT03317184|Procedure|Periumbilical incision|A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.
75797210|NCT01259700|Behavioral|Community based salt reduction program|A community-based salt reduction program delivered mainly by community health educators
75797211|NCT01153308|Other|Observational Study|This is an Observational study
75797212|NCT01262586|Drug|Vildagliptin|
75935216|NCT05218577|Other|high selenium functional food|HSFF was made from the liver of the cow, that participant could eat HSFF direcly.
75935217|NCT05218577|Dietary Supplement|selenium supplement|20 microgram/day selenium suppplement powder.
75935218|NCT05218577|Other|Placebo|the placebo mocaf powder
75797213|NCT01262586|Drug|Glimepiride|
75935219|NCT03134079|Other|apple crisp|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
76087761|NCT03317184|Procedure|Pfannenstiel incision|Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
75339887|NCT04317937|Other|Jaw opening-closing movements|"Jaw opening-closing movements Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Active jaw movements The patient will then perform maximal Jaw opening-closing movements at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active neck exercises While performing the above movements of jaws, the patient will actively perform active neck exercise (head-neck movements in sagittal plane- Extension- Flexion).~Head-Neck extension on jaw opening (Mandible moves vertically downward); and then from Head-Neck extension to natural flexion movement on jaw closing (Mandible moves vertically upward)."
75339888|NCT04317937|Other|Specific Active exercises|"Active neck exercises:~Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Note: For Active neck exercise (flexion and extension movements of neck), firstly the patient will perform maximal Jaw opening-closing movements at a pace convenient for his/her for 5 times in order to observe (eyeball observation) the neck extension and flexion as reference point for each individual.~Using this reference points, the patient will ask perform below mentioned active neck exercise.~Active neck exercises: The patient will then perform active neck exercise (flexion and extension of neck) at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active jaw movement: While performing the above movements of neck, the patient will not perform any jaws movements."
75339889|NCT04317937|Other|Exercise Therapy|"Isometric strengthening exercises For flexion the starting position will be upright head and neck. The patient will be asked to hold this position.~For extension the starting position will be upright head and neck. The patient will be asked to hold this position.~For rotation the starting position will be upright head and neck. The patient will be asked to hold this position.~• In all above movements ( flexion, extension & rotation) following method will be followed: Manual resistance will then be applied by the investigator by placing the hand on the patient's forehead, posterior part of the head and lateral part of the head with 6 second hold. 15 repetitions of this exercise will be performed. Three sets with one minute rest in between will be ensured."
75474140|NCT01979809|Behavioral|MENU GenY|Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
75650027|NCT05325658|Other|FEES, treatment with modified diet, electrical swallowing muscle stimulation.|Endoscopic swallowing assessment (FEES) consists of three parts:1) assessment of mouth, throat anatomy and more; 2) the patient is given to swallow a certain amount and consistency of liquids and solid food. 3) evaluated: preparation of the bolus for swallowing, aspiration. An 8-point Penetration-Aspiration scale is described.Swallowing exercises. Swallowing exercises are also used in practice, which can help coordinate the swallowing muscles or stimulate the nerves involved in the swallowing reflex.Transcutaneous electrical stimulation is a method of treating dysphagia in which weak electrical impulses stimulate the muscles in the neck area associated with swallowing. In patients with oropharyngeal dysphagia, patients have great difficulty swallowing water of normal consistency or other non-thick liquids, so they should be thickened with special thickeners to such an extent that the patient does not experience discomfort and be able to swallow.
75650028|NCT00935012|Drug|tafamidis|Once daily 20 mg oral tafamidis (soft gelatin capsule)
75797214|NCT03887364|Other|Group A-Diaphragmatic breathing|Patient was in casual and agreeable position in which gravity helped the stomach, for example, a semi fowler's position. Hand was put on the rectus abdominis just beneath the foremost costal edge and requested that the patient take in gradually and profoundly through the nose. Persistent was told to keep the shoulder casual and upper chest very, enabling the belly to rise marginally. At that point persistent was guided to remain loose and breathed out gradually through the mouth. The patient rehearsed this 3 to 4 times and the rest time frame was given so patient couldn't hyperventilate.This group was given 10 reps of 3 sets with 4 weeks of follow up
75935220|NCT03134079|Other|tea|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
75650029|NCT05373914|Drug|Cudetaxestat (BLD-0409)|Cudetaxestat - 250mg tablets (orally)
76087762|NCT04350814|Behavioral|Self-Compassion Step by Step|This is a 6-lesson self-guided audio program by Dr. Kristen Neff (2013)
76087763|NCT04350814|Behavioral|Self-Reflection Active Control|Participants randomized to this active control condition will be asked to complete study measures at the same intervals as those assigned to the intervention condition. In addition to completing study questionnaires, participants in this arm will also be invited to reflect on their weekly reported symptoms, whether they experienced changed, what they believe these changes are attributed to, etc.
76087764|NCT01811680|Device|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
75650030|NCT05373914|Drug|Control: Matching Placebo|Placebo - 250mg tablets (orally)
75650031|NCT00932360|Device|TENS|Active TENS, Placebo TENS and No Treatment TENS
75650032|NCT00668707|Dietary Supplement|melatonin|20 mgs ingested nightly
75797215|NCT03887364|Other|Group B-Icing and Airflow Stimulation|"Patient was lying comfortable in semi fowler position. Facial muscle icing was given using ice pack wrapped in cloth over cheeks and nose in butterfly pattern and over forehead for 5 minutes. Ice pack was applied on the patients face (around the cheek & nose) and accessory muscles (sternocleidomastoid muscles, upper trapezius) for single session of 5 to 10 minutes.~After that airflow stimulation was given with the help of table fan. Table fan was placed on the central area of face. Duration of the fan for the patient was at least 5 minutes to relive dyspnea and distance kept approximate of 60 centimeter (2 rulers)."
75935221|NCT03134079|Other|oatmeal|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
75935222|NCT02447978|Biological|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
75339890|NCT04317937|Other|Supportive Treatment|"Postural Advice and Home Exercise Program with Dairy Postural advice and home exercise program. Postural Advise Maintain upright posture while sitting.~Avoid prolonged neck bending.~Avoid twisting movement of the neck.~Use a suitable pillow to maintain cervical spine.~Adjust computer screen at eye level.~Avoid constant use of mobile or similar device to prevent excessive strain over neck joints and muscles.~Carry light and even weight in both hands while shopping and other chores.•Stay hydrated.~Home Exercise Program (unsupervised) (3 times a day)~Forward flexion (Self Resisted), 6 sec hold, number of repetitions 15~Right side flexion (Self Resisted ), 6 sec hold, number of repetitions 15~Left side flexion (Self Resisted) x 6 sec hold,number of repetitions 15~Backward flexion (Self Resisted) x 6 sec hold, number of repetitions 15~Home Dairy A home dairy will be provided to maintain home exercise program record."
75339891|NCT04300998|Behavioral|Activities of Daily Living/ADLs|7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14
75339892|NCT04300998|Behavioral|Instrumental Activity of Daily Living|8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.
75474141|NCT01979822|Other|PH patients with LenusPro pump|Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
75474142|NCT01979861|Device|AEGEA Vapor System(TM)|vapor endometrial ablation
75474143|NCT01979874|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months
75474144|NCT01979874|Other|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
75650033|NCT00668707|Dietary Supplement|placebo|similar to experimental in all ways except for lack of active ingredient
75474145|NCT01979887|Procedure|Meibum Expression|Meibum expression as per protocol. No investigational drug is administered in this study.
75474146|NCT01979900|Drug|Vaccae|One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
75797216|NCT03889392|Procedure|Kidney transplantation and nephrectomy|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
75935223|NCT02447978|Biological|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
75935224|NCT02447978|Biological|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
75935225|NCT03962231|Other|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid reeducation exercises, assisted arm elevation and scapular control exercises.
75935226|NCT03962231|Other|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises focusing on lateral rotation, medial rotation and arm elevation.
75935227|NCT01909895|Other|Anger Induction|The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.
75935228|NCT01909895|Other|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
75935229|NCT01909895|Other|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
75474147|NCT01979900|Drug|placebo|One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
75797217|NCT01262664|Drug|Prohibitin-TP01|Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
75797218|NCT01261182|Other|In School Feeding|The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
75797219|NCT01261182|Other|Take Home Rations|The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
75339893|NCT04300998|Behavioral|Timed Up and Go|Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (<10 seconds, 10-20 seconds, >20 seconds)
75339894|NCT04300998|Behavioral|Cognition|Mini-Cognition test: CDT and 3-word recall
75339895|NCT04300998|Behavioral|Geriatric Depression Scale|Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of >/=1 is usually indicative of depression.
75339896|NCT04300998|Behavioral|Social Support|Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.
75339897|NCT04300998|Behavioral|Brief Test of Attention|assess selective auditory attention.
75797220|NCT01157052|Other|(supplement) Calcium and Magnesium|"FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.~XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.~Ca2+/Mg2: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1 (Arm A) or cycle 2 (Arm B)"
75797221|NCT03887130|Drug|oral vinorelbine|Oral vinorelbine 60 mg/m² on day 1 & day 8, for cycle 1, and then 80 mg/m² on day 1 & day 8, every 3 weeks for subsequent cycles
75797222|NCT03887130|Drug|Capecitabine|Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14
75797223|NCT03887130|Drug|Gemcitabine 1250 mg/m²|Gemcitabine 1250 mg/m² on day 1 & day 8
75797224|NCT03887130|Drug|Gemcitabine 1000 mg/m²|Gemcitabine: 1000 mg/m² on day 1 & 8
75797225|NCT03887130|Drug|Paclitaxel|Paclitaxel 175 mg/m² on day 1
75797226|NCT03887130|Drug|Docetaxel|Docetaxel 75 mg/m² on day 1
75339898|NCT04300998|Behavioral|Trail Making Test|Assesses visual scanning, graphomotor speed, and set shifting.
75339899|NCT04300998|Behavioral|Controlled Oral Word Association Test|A timed test of verbal fluency
75339900|NCT04300998|Behavioral|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.
75339901|NCT04300998|Other|Blood draw|collection of blood tests
75339902|NCT04293146|Procedure|pre-pectoral IBBR|The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.
75339903|NCT04293146|Procedure|sub-pectoral IBBR|The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.
75339904|NCT04292288|Diagnostic Test|Biochemical observational|no intervention - observational
75339905|NCT04270942|Biological|teplizumab|anti-CD3 humanized monoclonal antibody
75339906|NCT04253015|Other|Data-collection|Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.
75339907|NCT04222322|Device|Epitomee Capsule|Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.
75339908|NCT04222322|Other|Control-Placebo|Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.
75474148|NCT01979913|Drug|Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis|
75474149|NCT01979926|Drug|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
75474150|NCT01979965|Drug|Ranolazine (Active drug)|Ranolazine therapy for three months
75797227|NCT01154712|Device|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
75797228|NCT01154712|Device|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
75797229|NCT01155960|Drug|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
75797230|NCT03883932|Behavioral|Fatherhood Focused FVEP (F3)|F3 is designed to focus specifically on the importance of fathering within a cognitive-behavioral intervention.
75797231|NCT03883932|Behavioral|Family Violence Education Program (FVEP)|FVEP is a court-mandated program intended to treat those arrested for intimate partner violence (IPV).
75339909|NCT04222231|Other|Blood-flow restriction resistance training|Training program: After 10 minutes of warm-up the participant performs three exercises with BFRT for the lower extremities. The intensity is about 15-30% of 1-RM.
75339910|NCT04222231|Other|Classical resistance training|Training program: After warm-up the participant performs three exercises for lower body. The intensity is about 60-80% of 1-RM.
75339911|NCT04218773|Drug|Phenylephrine|Patients will receive intravenous phenylephrine at a rate of 60 µg/min. The infusion rate will be adjusted at 30 µg/min increments (maximum 180 µg/min) at 3-minute intervals to maintain an increase in SBP to the target SBP of 160 - 220 mmHg or a 20% increase above baseline SBP values.
75474151|NCT01979965|Drug|Placebo|Placebo therapy for three months
75474152|NCT01979978|Other|Healthy Buddies Curriculum|"Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors (Buddies), teaching a 30-minute lesson to their younger students. The Physical activity (i.e.Go Move!) component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary (Go Fuel!) component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image (Go Feel Good!) component, the students are taught to value classmates based on individual traits rather than peer influence."
75797232|NCT03883776|Drug|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
75797233|NCT03883776|Device|PET/CT|"Part 1: Healthy volunteers will undergo consecutive whole-body PET scans, including one low-dose CT, for the first 90 minutes. At 150 ± 15 min and 300 ± 30 min post injection two additional static whole-body PET/CT scans will be acquired.~Part 2: Neuroendocrine tumor patients will undergo a dynamic PET scan for the first 45 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection."
75935230|NCT01909895|Other|Neutral emotion task|This is a neutral control task that each of the negation emotion induction tasks will be compared to.
75650034|NCT05064514|Device|Transcatheter Tricuspid Valved Stent Graft|All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.
75935231|NCT00150813|Drug|Levetiracetam|Pharmaceutical form: oral tablets Route of administration: Oral use
75797234|NCT03883776|Other|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, venous blood samples will be obtained for metabolite analysis and activity measurements (only for patients) at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min, 120 ± 60 min).
75935232|NCT02712788|Drug|Milrinone|
76087765|NCT02479776|Biological|stem cell injection|Injection of autologous bone marrow derived stem cells
75650035|NCT00766909|Drug|cyclosporine|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days."
75339912|NCT04218773|Drug|Norepinephrine|As an alternative to intravenous phenylephrine, intravenous norepinephrine can be used with an initial infusion rate of 3 mcg/min. The initial infusion rate of norepinephrine will be adjusted at 1 mcg/min increments at 3-minute intervals to achieve and maintain the target blood pressure. Maximum dose is 25 mcg/min. Combination therapy with both agents (phenylephrine and norepinephrine) to achieve and maintain blood pressure targets is not permitted.
75339913|NCT04207892|Procedure|Conservative (non-surgical) treatment|Cast Sling Splint Collar
75650036|NCT00766909|Drug|tacrolimus|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days."
75797235|NCT01157130|Other|Exercise Regimen|Exercise instruction
75797236|NCT01157208|Other|Diet A|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
75650037|NCT00766909|Other|Capsules and isotonic saline|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days."
75339914|NCT04207892|Procedure|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) K-Wire External fixation
76087766|NCT02479620|Drug|Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL|Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
75339915|NCT04175340|Device|BL-300-PFM04|Preservative Free Lubricating and Rewetting Drops for use during contact lens wear
75650038|NCT02581228|Device|ML-PrediCare|
75650039|NCT04059952|Procedure|Electroconvulsive Therapy|Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.
75797237|NCT01157208|Other|Diet B|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
75797238|NCT03886896|Drug|Lidocaine|Lidocaine infusion during surgery
75797239|NCT03881826|Other|collection of clinical data and biological samples|"nutritional assessement~cachexia symptoms~urine, feces and blood samples"
75797240|NCT03881904|Drug|0.075mg gestodene/0.03mg ethinylestradiol|OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
75935233|NCT02712788|Drug|Placebo|
75935234|NCT05218421|Diagnostic Test|Carotid ultrasound|Carotid ultrasound with flow and elastography (strain and shear wave) measurements will be performed maximally 2 weeks prior to the CEA. Ultrasound-based flow imaging will be repeated six weeks after the CEA to assess the hemodynamic consequences of the CEA procedure.
75935235|NCT05218421|Other|Biospecimen collection and examination|The plaque excised during CEA will be histologically examined to assess the plaque composition, and therefore plaque vulnerability.
75935236|NCT05218421|Other|Blood sample collection|In the first 20 included patients in the Radboudumc, a 10 mL blood sample will be collected during surgery via the arterial line that is applied for regular care.
75935237|NCT00035529|Drug|Placebo|Solution, i.v infusion, 0 mg, Days 1 & 15 then monthly, 10 months.
75935238|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 2mg/kg, Days 1 & 15 then monthly, 10 months.
75935239|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 10 mg/kg, Days 1 & 15 then monthly, 10 months.
76087767|NCT02482038|Device|geko|neuromuscular electrostimulator
76087768|NCT03552562|Device|Fourier Domain Color Doppler Optical Coherence Tomography (FDOCT)|Fourier domain OCT is based on a local phase analysis of the backscattered signal and allows for bidirectional Doppler flow imaging.(Leitgeb et al. 2003a; Leitgeb et al. 2003b) It does not need reference arm scanning and records one full depth and Doppler profile in parallel. The system operates with an equivalent A-scan rate of 25 kHz and allows real time imaging of the color encoded Doppler information together with the tissue morphology at a rate of 2-4 tomograms (40 x 512 pixel) per second. Despite the high detection speed we achieve a system sensitivity of 86dB using a beam power of 500μW at the cornea. The fundus camera allows simultaneous view for selection of the region of interest. We observe bi-directional blood flow and pulsatility of blood velocity in retinal vessels with a Doppler detection bandwidth of 12.5 kHz and a longitudinal velocity sensitivity in tissue of 200μm/s. Diffuse luminance flicker will be applied during the measurements for 60 seconds.
76087769|NCT02481960|Procedure|CM-BC2 Irinotecan drug-eluting bead|
75339916|NCT04175340|Device|OPTI-FREE|Replenish Rewetting Drops
75650040|NCT00775801|Device|FLD|Artificial lumbar disc
75935240|NCT03195686|Device|PLE100(Inbody®)|PLE100(Inbody®) monitoring in children to be operated under the total intravenous anesthesia (Propofol)
75935241|NCT03206528|Device|Vital Signs Monitoring System|The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
75650041|NCT00775801|Device|Control|Artificial lumbar disc
75650042|NCT00767065|Radiation|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate <70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
75797241|NCT01263678|Behavioral|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
76087770|NCT01767688|Drug|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
75797242|NCT01263678|Other|Usual Care|Patient views DA and completes post DA survey.
75797243|NCT05666934|Device|Augmented Reality Storybook|The AR system was developed using a Vuforia Engine Package for Unity (PTC Inc, San Diego, CA), which enabled to create an application for children to view a storybook in their own homes. The children and caregivers could view eight scenarios (receiving a praise, broken toys, waiting in line at the playground, getting a vaccination, waiting for watching a video, hitting someone in an accident, grabbing a toy, understanding another person's feelings) and learn strategies for emotional events reflected in the tablet (Figure 1). This AR application supports a tablet size of 10.4 inches and is equipped with a Samsung Galaxy Tab A7.
76087771|NCT03317028|Drug|CS02 tablet and placebo tablet|Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
75797244|NCT03883308|Behavioral|Multi-domain cognitive training|The cognitive exercises are designed to train executive functions and memory.
76087772|NCT04492176|Device|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times
75935242|NCT02449928|Drug|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
75650043|NCT00767065|Other|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
75650044|NCT04229836|Drug|Tildrakizumab 100 mg Solution for Injection|Participants will be treated with tildrakizumab 100 mg.
75650045|NCT00771433|Biological|filgrastim|Given subcutaneously
75650046|NCT04053790|Drug|lactobacillus LB|administration of different doses of Lactobacillus LB according to the treatment groups described previously
75650047|NCT04053790|Other|placebo|a tablet of placebo every 12 hours given by mouth
75650048|NCT00668395|Drug|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
75650049|NCT00668317|Drug|Omeprazole|20 mg BD tablet 8 weeks duration
75650050|NCT00668317|Drug|Ranitidine|300 mg od nocte tablet 8weeks duration
75650051|NCT00775879|Drug|Induction with Sevoflurane|
75650052|NCT00767221|Drug|Budesonide|8 mg PL-56 once daily for six months
75650053|NCT04024072|Drug|Brinzolamide 1% ophthalmic suspension|Test product
75650054|NCT04024072|Drug|Azopt 1% Ophthalmic Suspension|Reference product
75797245|NCT03883308|Behavioral|Cross-word puzzle training|The active control group will be asked to complete a variety of crossword puzzles using the same curriculum assigned to the TG group.
75797246|NCT01156038|Device|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
75935243|NCT02449928|Drug|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
75935244|NCT00356109|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
75935245|NCT00356109|Drug|Injectable insulin|patient specific dose, injected, before meals, 6 months
75935246|NCT00356109|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 6 months
75935247|NCT02308111|Drug|Obeticholic Acid (OCA)|"Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants).~Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study."
75935248|NCT02308111|Drug|Placebo|One tablet daily (or a lower frequency depending on CP score) for the remainder of the study
76087773|NCT04769752|Other|collection of the allocated treatment|collection of the allocated treatment
76087774|NCT04769752|Other|collection of medical complications|collection of medical complications
76087775|NCT05713968|Other|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
76087776|NCT05713968|Other|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2 examined by HRIM
75650055|NCT00771511|Drug|capsaicin|capsaicin cream 0.1% 10 ml applied to cervix
76087777|NCT03314376|Device|Prehabilitation program|"The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
75474153|NCT01979991|Procedure|CT Imaging and Reconstruction|"Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.~Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used."
75474154|NCT01980004|Dietary Supplement|Potassium Citrate Supplementation|20 mEq taken twice daily
75474155|NCT01980004|Other|Dietary Education|Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.
75650056|NCT00771511|Drug|Placebo|Only lidocaine gel will be appled to the cervix
75650057|NCT04021576|Other|preventative training program|complementary training of leg-, hip- and core-strength/stability
75797247|NCT05482776|Other|High intensity functional training|"HIFT is an exercise modality that emphasizes functional movements through exercises that involve a large amount of muscle mass and that can be adapted to the level of physical condition of each subject. Although it has similarities and is compared to HIIT, they are different.~In this discipline, functional exercises with an external load such as squats, pull-ups, or functional exercises with our own weight, are mixed with other aerobics such as running, rowing or cycling. This mix results in a high-intensity training that improves parameters of physical condition in general and performance."
75797248|NCT05482776|Other|classic training group|This intervention consists of carrying out their conventional weekly physiotherapy training sessions where strength, coordination and balance are trained.
75474156|NCT01980030|Drug|Romiplostim|
75797249|NCT01261260|Drug|Uridine|1 gram tablets BID for 7 days
75797250|NCT01262742|Drug|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75797251|NCT01262742|Drug|Carbetocin|90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75650058|NCT00775957|Procedure|FLT-PET scan|imaging scan
75797252|NCT01262742|Drug|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75797253|NCT01262742|Drug|Carbetocin|110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75650059|NCT00775957|Procedure|FDG-PET scan|imaging scan
75474157|NCT01980043|Procedure|endoluminal rectal prolapse repair under sedation|endoluminal rectal prolapse repair under sedation
75797254|NCT01262742|Drug|Carbetocin|120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
75797255|NCT03883464|Other|Diet|Restriction in postoperative fat diet
75797256|NCT03883620|Biological|Dengushield 1 mg/kg (Cohort 1) intravenous|Participants will be administered Dengushield 1 mg/kg as slow intravenous injection.
75474158|NCT01980069|Drug|Sugammadex|In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
75474159|NCT01980069|Drug|Neostigmine|In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
75474160|NCT01980082|Drug|Cefazolin|Antibiotic
75797257|NCT03883620|Biological|Dengushield 3 mg/kg (Cohort 2) intravenous|Participants will be administered Dengushield 3 mg/kg as slow intravenous infusion.
75797258|NCT03883620|Biological|Placebo 3 mg/kg (Cohort 2) intravenous|Participants will be administered Placebo 3 mg/kg as slow intravenous infusion.
75797259|NCT03883620|Biological|Dengushield 7 mg/kg (Cohort 3) intravenous|Participants will be administered Dengushield 7 mg/kg as slow intravenous infusion.
75797260|NCT03883620|Biological|Placebo 7 mg/kg (Cohort 3) intravenous|Participants will be administered Placebo 7 mg/kg as slow intravenous infusion.
75797261|NCT03883620|Biological|Dengushield 12 mg/kg (Cohort 4) intravenous|Participants will be administered Dengushield 12 mg/kg as slow intravenous infusion.
75797262|NCT03883620|Biological|Placebo 12 mg/kg (Cohort 4) intravenous|Participants will be administered Placebo 12 mg/kg as slow intravenous infusion.
75797263|NCT01261416|Drug|levetiracetam|Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
75797264|NCT03617172|Drug|Misoprostol 100Mcg Tab|Two 100mcg capsules twice per day
75797265|NCT03617172|Other|Placebo|Two capsules twice per day
75797266|NCT01154790|Drug|CG100649|6 subjects: study drug 2 subjects: placebo
75797267|NCT01154790|Drug|Placebo|6 subjects: study drug 2 subjects: placebo
75797268|NCT01154790|Drug|Naproxen|6 subjects: study drug 2 subjects: placebo
75797269|NCT01261494|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
75797270|NCT01261494|Drug|Placebo|hard gelatin capsules,oral administration,4 capsules per day before breakfast
75797271|NCT01157442|Behavioral|cell phone sms text messaging|At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
75650060|NCT03828214|Device|Robotic exoskeleton for walking assist|Participants will have two testing sessions in this within-subject design experiment. The conditions under which walking will be evaluated are control (normal) walking, walking with the exoskeleton assistance and walking immediately following exoskeleton walking. The conditions under which stair walking (ascending and descending) will be evaluated include control (normal) stairs and exoskeleton assisted stairs. Assistance is provided by The Honda Walking Assist (HWA) System is a robotic device developed by Honda R&D Corporation ®, Japan. The devices computer-activated motors use hip angle information to guide assistance delivered through the thigh straps to the legs in time with the walking cycle. The maximum torque delivered is 4 Newton-meters.
75474161|NCT01980082|Drug|Placebo|Placebo
75797272|NCT01261572|Drug|degarelix|periodic injection
75797273|NCT01261650|Device|transcranial direct current stimulation|
76087778|NCT01768000|Behavioral|Family Cognitive Adaptation Training|Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
76087779|NCT04492878|Drug|IKERVIS®1mg/mL|One drop of study medication once daily in each eye at bedtime during 90 days.
76087780|NCT02725866|Drug|Paritaprevir/ritonavir/ombitasvir|Co-formulated tablet
75650061|NCT00776113|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol fasting
75650062|NCT04076332|Other|Decision aid|Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
75797274|NCT01261650|Device|sham treatment|
75797275|NCT01156194|Drug|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
76087781|NCT02725866|Drug|Dasabuvir|Tablet
76087782|NCT02725866|Drug|Ribavirin|Tablet
76087783|NCT05713812|Procedure|Kinesiotaping|Kinesiotape will be applied
75474162|NCT01980108|Other|water|water
75797276|NCT01156194|Drug|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
75650063|NCT04075786|Other|Survey|Each participant will be shown 40 (forty) 3D ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3D ultrasound and associated infertility (T, Y or I shaped).
76087784|NCT05713812|Procedure|Control Treatment|IFC + Hot pack for 20 minutes MDT (prone positioning) for 10 minutes. Lumbar SNAGs + lumbar rotation mobilization. Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.
75650064|NCT00670111|Device|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
75650065|NCT04077658|Behavioral|HeartMath|HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.
75797277|NCT01156194|Drug|Placebo|globule identical to true homeopathy comparators
75935249|NCT03206138|Biological|GX-188E, GX-I7|Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.
75935250|NCT03206138|Biological|GX-188E, Imiquimod|1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.
75935251|NCT03195842|Other|Recordable card|
75935252|NCT00006225|Biological|filgrastim|
75935253|NCT00006225|Biological|recombinant flt3 ligand|
75935254|NCT00006225|Biological|recombinant human thrombopoietin|
75935255|NCT00006225|Biological|recombinant interleukin-3|
75935256|NCT00006225|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75474163|NCT01980121|Device|Ultrasound|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
75650066|NCT04077658|Behavioral|Waitlist Control|Standard of Care Migraine Treatment
75650067|NCT00771589|Device|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
75935257|NCT02447900|Device|BioXmark|
75935258|NCT00005595|Drug|arsenic trioxide|
75935259|NCT02447822|Drug|Thymoglobulin|6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
75935260|NCT04481945|Drug|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
75935261|NCT00411801|Biological|Uniplas|Uniplas will be provided frozen in sterile plastic bags.
75935262|NCT00411801|Biological|Cryosupernatant plasma|Cryosupernatant plasma will be provided frozen in sterile plastic bags.
75935263|NCT03200522|Other|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
75935264|NCT03200522|Other|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
75935265|NCT04477265|Drug|Solifenacin Succinate 5mg/tab daily|participants will be taking oral medication for 3 months
75339917|NCT04175119|Device|Visual attention/perception tasks in healthy participants|The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2, 3) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
75797278|NCT03883698|Drug|Sofosbuvir|Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
75339918|NCT04138823|Drug|BI 891065|Tablets
75650068|NCT05244148|Device|IP1 - Stérimar BLOCKED NOSE Baby nasal spray|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
75339919|NCT04138823|Drug|BI 754091|Solution for infusion
75339920|NCT04126031|Drug|Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Single intravenous infusion of ceftazidime-avibactam over 2 hours
75339921|NCT04126031|Drug|Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3|Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
75339922|NCT04100824|Procedure|stellate ganglion block by transcranial doppler|stellate ganglion block is a block of sympathetic ganglion
75339923|NCT04100824|Drug|Nimodipine|Nimodipine 60mg every 4h
75650069|NCT05244148|Device|IP2 - Stérimar Stop & Protect Cold Baby + standard of care|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
75650070|NCT05244148|Behavioral|Standard of Care|hydration + rest at home + if needed paracetamol
75650071|NCT00767377|Drug|EOF5|epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
75935266|NCT04477265|Behavioral|biofeedback-assisted pelvic floor muscle training|participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months
75650072|NCT02580448|Drug|Seviteronel|Seviteronel given daily with evening meal in 28 day cycles
75935267|NCT00353457|Drug|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
75935268|NCT00353457|Radiation|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
75935269|NCT03206294|Other|pharmacist assessment|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
75650073|NCT00776191|Drug|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
75650074|NCT00776191|Drug|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
75797279|NCT03883698|Drug|Daclatasvir 60 mg|Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
75797280|NCT01263210|Biological|Prevenar|
75797281|NCT01263288|Dietary Supplement|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
75797282|NCT01263288|Dietary Supplement|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
75797283|NCT01263288|Dietary Supplement|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
75935270|NCT02287701|Procedure|PET/MRI|Simultaneous PET/MRI (3T system)
75650075|NCT04008238|Drug|Trabectedin|- Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period
75650076|NCT04077034|Dietary Supplement|Probiotic Formula Bacillus subtilis DE111®|Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
75650077|NCT04077034|Dietary Supplement|Placebo comparator|Placebo comparator, once a day for 8 weeks
75650078|NCT04223674|Diagnostic Test|Serological screen and treat|Multi-antigen sero-diagnostic test for measurement of P. vivax antibodies in plasma from finger stick as a means to detect hypnozoite carriers for treatment
75797284|NCT01261806|Behavioral|Attachment and Biobehavioral Catch-up|Enhances nurturance, following the lead, and calming behaviors
75797285|NCT01261806|Behavioral|Developmental Education for Families|Attention control: Enhances parents understanding of developmental milestones
75797286|NCT01154868|Procedure|Alveolar ridge augmentation|Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
75797287|NCT01261884|Behavioral|Exercise support|Group B (exercise support) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, and a pedometer. This group will be asked to wear the pedometer for 7 consecutive days between Visits 1 and 2, and record daily activities.
75935271|NCT02449850|Other|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
75935272|NCT02449850|Other|Skin care|Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
75935273|NCT01346189|Behavioral|Behavioral Economic Intervention|Various combinations of financial incentives to patients and providers.
75935274|NCT00411099|Drug|agomelatine|
75935275|NCT00411099|Drug|placebo|
75339924|NCT04088851|Drug|On Metformin|Oral intake of Metformin (1 g / day) for 2 weeks
75650079|NCT02580682|Drug|Sanfu herbal patch|The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
75650080|NCT02580682|Drug|Sanfu moxibustion|Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
75650081|NCT02580682|Drug|Sanfu herbal patch and moxibustion|use Sanfu moxibustion followed by Sanfu herbal patch
75650082|NCT03776890|Behavioral|DeStress for Health Program|The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
75650083|NCT00672139|Drug|Methylnaltrexone bromide|
75650084|NCT00776269|Procedure|argon laser and radiofrequency|
75650085|NCT02557789|Drug|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
75650086|NCT00771823|Drug|Maraviroc|Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
75650087|NCT00771823|Drug|Maraviroc|"Placebo twice daily for the first 14 days of the study.~Maraviroc 300 mg twice daily for the last 14 days of the study."
75650088|NCT05224648|Device|TOF scan train of four ratio monitoring|Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
75650089|NCT05224648|Device|ITF device tetanus stimulation monitoring|Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
75650092|NCT05674084|Diagnostic Test|Capillary refill time|CRT will be measured by applying firm pressure to the ventral surface of the index finger distal phalanx with a glass microscope slide. The pressure will be increased until the skin is blank and then maintained for 10 seconds. The time for return of the normal skin color will be registered with a chronometer, and > 3 seconds is defined as abnormal. Light and ambient temperature will be the same for all individuals.
75650093|NCT04077112|Behavioral|Parent Child Interaction Therapy|Behavioral parent training program targeting parent-child relationship
75797288|NCT01261884|Behavioral|Exercise intervention|Group C (exercise intervention) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, a pedometer, a resistance band, and a handout on specific exercises (type and frequency) to be performed. The study coordinator will demonstrate each exercise and then observe the participant perform each exercise to assure full understanding. In addition to wearing the pedometer for 7 days and completing the activity log, this group will also record compliance with the exercise regimen.
75797289|NCT03886428|Other|100% portion size|Entree portion size 100% of baseline
75935276|NCT03206372|Other|Case group|Questionnaire to be completed, blood sample and possibly echo-doppler
75935277|NCT03206372|Other|Control group|Questionnaire to be completed, blood sample and possibly echo-doppler
75339925|NCT04088851|Drug|Off Metformin|No oral intake of Metformin (1 g / day) for 2 weeks
75339926|NCT04085328|Device|LID015385 soft contact lenses|Investigational silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
75339927|NCT04085328|Device|Comfilcon A soft contact lenses|Silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
75339928|NCT04082611|Behavioral|Data-Driven Clinical Recommendations|Data-driven clinical recommendations. Participants will receive routine care with data-driven, personalized, multi-modal clinical recommendations by a study physician based on study assessments and clinical lab values and be monitored and re-assessed for a period of 12 months.
76087785|NCT05454072|Procedure|Sinonasal Microbiota Transfer|Pre-screened donor mucus, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
76087786|NCT05454072|Procedure|Sham Sinonasal Microbiota Transfer|Saline, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
75339929|NCT04082611|Behavioral|Coached Data-Driven Clinical Recommendations|Data-driven multi-modal lifestyle intervention with coaching. Participants will receive coached routine care with data-driven, personalized, multimodal recommendations. MMIC participants will receive an intensive multi-modal intervention with health coaching, support and resources to carry out these recommendations. This additional intervention services include: 13 personal, data-driven brain health coaching sessions (with an RDN), 7 personal dietary counseling sessions (with an RDN), 33 group-based cognitive and physical exercise classes (CogFit) with a certified personal trainer and a computer-based neurocognitive program at home and be monitored and re-assessed for a period of 12 months.
75339930|NCT04074265|Drug|Ropivacaine injection|Injection containing a mix of the above medications will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
75339931|NCT04074265|Drug|normal saline|Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
75339932|NCT04070144|Device|IQ-Tip(tm) system|Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system
75650094|NCT02581150|Procedure|Treatment of Occlusive Arterial Disease|Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
75650095|NCT02581072|Drug|SB204 4%|Applied topically once
75650096|NCT02581072|Drug|SB204 8% or 12%|Applied once topically
75650097|NCT02581072|Drug|Vehicle|Applied topically once
75650098|NCT03955900|Other|No intervention|Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
75650099|NCT03955042|Drug|Pemetrexed|Pemetrexed 900 mg/m^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
75650100|NCT02580526|Procedure|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
75797290|NCT03886428|Other|125% portion size|Entree portion size 125% of baseline
75797291|NCT03886428|Other|150% portion size|Entree portion size 150% of baseline
75797292|NCT03886428|Other|175% portion size|Entree portion size 175% of baseline
75935278|NCT05218031|Behavioral|Acceptance and Commitment Therapy|A 90-120 minute 5-week group intervention for unaccompanied minors. Each week there will be a different focus. Week 1: Grounding, Week 2: Unhooking, Week 3: Values, Week 4: Self-compassion, Week 5: Making room for unwanted thoughts and feelings.
75935279|NCT03195530|Drug|Propofol|Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
75935280|NCT03195452|Drug|Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)|All virologically suppressed
76087787|NCT04492644|Other|No intervention|No intervention
75935281|NCT00406809|Drug|ABT-263|"Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose."
75797293|NCT03881280|Behavioral|Parenting education program|"Parenting education program through the app Fammeal. It includes educational content, tailored to parents and centered on positive parenting child-feeding practices. The app will also include a virtual-pet game for children, in order to help them self-regulate their intake.~Through the app, parents will:~Fill in a registration questionnaire, which will tailor recommendations.~Receive information and video content recommendations.~Set goals related to their child's lifestyle and tracking progress.~Earn points by watching the contents.~Invite children to play a serious game.~Exchange messages with other users.~The investigators created a support website that connects to the main server to get data gathered from the mobile app and game."
75797294|NCT01156272|Device|ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm|Replacement aortic heart valve
75797295|NCT01263834|Drug|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
76087788|NCT03316794|Drug|SC-005|intravenous
76087789|NCT02481726|Radiation|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
76087790|NCT02481882|Device|Magnetic Resonance Imaging|All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.
75935282|NCT02449772|Other|No intervention|No intervention
75935283|NCT00004911|Procedure|bowel obstruction management|
75935284|NCT00004911|Procedure|quality-of-life assessment|
75935285|NCT03200210|Drug|Febuxostat|Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.
76087791|NCT02481882|Drug|Prohance (Gadoteridol)|A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
76087792|NCT02481804|Other|Dietary intervention|"Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.~Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts."
76087793|NCT02481804|Other|Standard treatment|Standard treatment will be continued
75474164|NCT01980160|Device|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
75474165|NCT01980160|Device|Unactivated Nometex Device|
75650101|NCT02580526|Procedure|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
75650102|NCT03717922|Device|Low Intensity Focused Ultrasound Pulsation|BOLD fMRI will be collected during two conditions (given that the timecourse of LIFUP related changes is unknown, sham will always precede the LIFUP condition). LIFUP (previously used in primary sensory cortices will be administered in 75 sonifications at 210 KHz frequency with pulse repetition frequency of 500Hz, 35mW/cm2, sonification duration 0.5s with 7s inter-stimulation intervals. Sham LIFUP will involve the same procedures (e.g. participant provided the same instructions) except the sonification will not occur.
75339933|NCT04058067|Drug|Brolucizumab|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
75650103|NCT03717922|Device|SHAM Ultrasound|BOLD fMRI will be collected while the ultrasound trandsducer is not turned on. Participants are unable to tell whether the transducer is on or off.
75797296|NCT01263834|Drug|Mitomycin C|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
75797297|NCT01263366|Drug|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
75339934|NCT04058067|Drug|Aflibercept|5 x every 4 weeks loading then every 8 weeks maintenance
75339935|NCT03983057|Drug|Anti-PD-1 monoclonal antibody|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly.
75650104|NCT00570739|Drug|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
75797298|NCT03886506|Biological|PLX-PAD|PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval.
75797299|NCT01263912|Dietary Supplement|LCPUFA Supplement|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
75797300|NCT01263912|Dietary Supplement|Placebo|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
75339936|NCT03960619|Behavioral|coping skills training|We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
75797301|NCT01155102|Drug|Anastrozole|1 mg tablet
75797302|NCT03882606|Device|Scharioth Macula Lens (SML, Medicontur)|magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient
75797303|NCT01263990|Device|NexFin|noninvasive finger cuff system
75797304|NCT02527356|Behavioral|Ride-On Cars with Standing Posture (ROC-Stand)|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
75935286|NCT03200210|Drug|Placebo|Pills manufactured to mimic Febuxostat tablets
75339937|NCT03947437|Biological|LEP-F1 + GLA-SE|Leprosy antigen formulated with an adjuvant.
75474166|NCT01980173|Procedure|Routine care|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.
75474167|NCT01980173|Device|Bakri balloon|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
75474168|NCT01980186|Device|TUS transcranial 2D ultrasound|
75474169|NCT01980199|Drug|Fexinidazole|"600 mg tablets given orally, after the main daily meal~at the daily dose of 1800 mg (3 tablets) once a day for 4 days~continued by 1200mg (2 tablets)once a day for 6 days"
75797305|NCT02527356|Behavioral|Ride-On Cars with Standing Postures (ROC-Sit)|Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
75935287|NCT00004899|Biological|filgrastim|
75935288|NCT00004899|Drug|busulfan|
75935289|NCT00004899|Drug|etoposide|
75935290|NCT00004899|Procedure|autologous bone marrow transplantation|
75935291|NCT00333411|Drug|BIRT 2584 XX|
75935292|NCT00333411|Drug|Placebo|
76087794|NCT03314298|Drug|testosterone anastrozole|subcutaneous testosterone and anastrozole
75339938|NCT03947437|Biological|Placebo|Sterile normal saline for injection.
75339939|NCT03898310|Dietary Supplement|Cranberry extract capsules|Participants in the treatment arm will receive cranberry extract capsules.
75339940|NCT03898310|Dietary Supplement|Placebo capsule|Participants in the placebo arm will receive placebo capsules.
75797306|NCT02527356|Behavioral|Regular Therapy Program|The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. In addition, they will receive training program in a hospital for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention. The participants will also experience the two 30-minute car driving sessions during the whole 2-hour training. The difference between the regular therapy group and the two ROC groups is the experience of car driving is controlled by the therapist, i.e. passive locomotion. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
75935293|NCT03199976|Drug|Tiotropium Bromide|Tiotropium Bromide 2.5 µg/dose inhaled aerosol
75339941|NCT03852030|Behavioral|Text or email message|Text or email messages sent to research participants
75339942|NCT03775915|Other|Neurofeedback|A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.
75339943|NCT03775915|Other|Sham Neurofeedback|A visual representation of brain activity pre-recorded from a previous participant
75339944|NCT03775759|Procedure|Tricuspid valve repair or replacement|Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.
75339945|NCT03775759|Other|Medical management of tricuspid regurgitation|The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
75339946|NCT03759028|Drug|Ibuprofen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
75339947|NCT03759028|Drug|Oxycodone|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
75339948|NCT03759028|Drug|Acetaminophen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
75650105|NCT00570739|Drug|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
75650106|NCT00570739|Drug|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
75650107|NCT00570739|Drug|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
75797307|NCT01156350|Drug|Busulfan - Fludarabine - TBI|This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained < 2.5 x 104 CD3+ cells/kg
75339949|NCT03716921|Other|Short antibiotics treatment|Patients randomized in this arm will pursue antibiotic administration until visit 3 weeks after D0
75339950|NCT03693560|Drug|Vildagliptin 50 mg Oral Tablet|Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.
75339951|NCT03693560|Drug|Metformin 1000 mg Oral Tablet|Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.
75339952|NCT03693560|Drug|Glimepiride upto 4 mg Oral Tablet|Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
75339953|NCT03675893|Drug|Letrozole|Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.
75339954|NCT03675893|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.
75474170|NCT01980225|Procedure|Collapse|inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
75797308|NCT03882762|Drug|Cebranopadol 200 μg tablet|200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.
75797309|NCT01261962|Dietary Supplement|zinc|zinc sulfate, 35 mg twice daily for 4 months
75797310|NCT01261962|Other|Placebo|Placebo, One capsule, twice daily for 4 months
75935294|NCT03199976|Drug|Fluticasone Propionate|Fluticasone Propionate 125 µg/dose inhaled aerosol
75935295|NCT03199976|Drug|Salbutamol|Salbutamol 0.1 mg/dose inhaled aerosol
75935296|NCT03675061|Other|Current care|Tocolysis and a complete corticosteroid treatment.
75935297|NCT03675061|Device|PartoSure Test negative|Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
75935298|NCT03675061|Device|PartoSure Test positive|Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
75935299|NCT00369317|Drug|asparaginase|Given IM
75935300|NCT00369317|Drug|daunorubicin hydrochloride|Given IV
75935301|NCT00369317|Drug|cytarabine|Given IV or IT
75339955|NCT03675893|Drug|LY3023414|LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.
75339956|NCT03675893|Drug|Metformin|Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.
75339957|NCT03664791|Procedure|Vanguard Rocc|Patient operated with the Vanguard Rocc knee prosthesis
75474171|NCT01980238|Device|cannula ileostomy|
75474172|NCT01980238|Device|loop ileostomy|
75474173|NCT01980238|Device|LAR|
75474174|NCT01980277|Drug|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
75474175|NCT01980303|Drug|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
75935302|NCT00369317|Drug|thioguanine|Given orally
75650108|NCT03689530|Behavioral|Peer Support|"Participants will be paired with a peer supporter. They will meet in person one time and then be in contact by phone or texting on a weekly basis for the first 6 months of a year.~During the final six months of the year, the peer supporter and participant will be in touch at least monthly. The peer supporter will help link participants to existing health system and community diabetes prevention programs, support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes.~The 95 peer supporters who consented to participate in the study are included in this arm, along with the participants who were randomized to this arm, in the participant flow. The peer supporters were not randomized to the arm; rather, they consented to deliver the intervention. Although 95 consented, only 68 met with at least one peer, the first step in intervention delivery."
75650109|NCT03689530|Behavioral|Enhanced Usual Care|Participants will receive brief education and folder of information and resources.
75935303|NCT00369317|Drug|etoposide|Given IV
75650110|NCT02580214|Dietary Supplement|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
75339958|NCT03627988|Other|Patients with invasive breast cancer will receive:|"Mastectomy with Immediate prosthetic breast reconstruction~Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy)."
75339959|NCT03594760|Diagnostic Test|18F-DCFPyL IV injection|Patient will receive one injection of 18F-DCFPyL and undergo PET-CT imaging
75935304|NCT00369317|Other|laboratory biomarker analysis|Correlative studies
75935305|NCT03205670|Procedure|Urethroplasty with a tissue-engineered construct|The investigators will perform urethroplasty with the tissue-engineered construct - epithelial cells isolated from patient's buccal mucosa and seeded on a collagen-polylactoglycolide matrix.
76087795|NCT02479542|Other|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
76087796|NCT02479542|Device|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
76087797|NCT02479308|Drug|Moxifloxacin|Single administration
75339960|NCT03574090|Drug|Amoxicillin Clavulanate|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
75339961|NCT03574090|Drug|Physiological Saline|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
75339962|NCT03510117|Behavioral|Mindfulness|Mindfulness
75339963|NCT03427047|Device|MyKnee with single use Efficiency Instrument|Total Knee Arthroplasty utilizing a CT scan for customization of cutting blocks with single use instrumentation
75339964|NCT03427047|Device|Stryker Navigational with conventional metal instruments|Total Knee Arthroplasty without customization of cutting blocks using conventional metal instruments.
75339965|NCT03417544|Drug|ATEZOLIZUMAB|(IV) every 3 weeks
75339966|NCT03417544|Drug|PERTUZUMAB|Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV
75650111|NCT03649204|Behavioral|HY-PAD|Hybrid intervention that includes supervised on-site and home-based components in people with PAD
75935306|NCT05725551|Device|ShotBlocker|"Before the procedure, the protruding surface of the vehicle was placed on the injection site in contact with the skin and used by holding it during injection. The level of pain and fear experienced by the child during and 5 minutes after the injection was evaluated with the Facial Expressions Pain Scale and Visual Comparison Scale, and the level of fear was evaluated with the Child Fear Scale by the child, the parent accompanying the child, and the observer."
75935307|NCT05725551|Other|Finger Puppet group|"During the interaction between the finger puppet and the child, an intramuscular injection was made. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
76087798|NCT02479308|Drug|ALKS 5461|Daily administration for a total of 12 dosing days
76087799|NCT02479308|Drug|Placebo|Placebo will be matched to Moxifloxacin or ALKS 5461
76087800|NCT02485782|Device|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
76087801|NCT02485782|Device|BCM- Body Composition Monitor, Fresenius Medical Care|Information about the individual fluid status and the nutritional status.
76087802|NCT02485782|Device|SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 15 min during hemodialysis
75339967|NCT03417544|Drug|TRASTUZUMAB|Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks
75339968|NCT03363464|Drug|Empagliflozin|Empagliflozin
75339969|NCT03363464|Drug|DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor
75339970|NCT03363464|Drug|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist
75935308|NCT05725551|Other|Balloon group|"An intramuscular injection was given when the child began to inflate the balloon. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
76087803|NCT02479386|Other|No intervention|No intervention was administered in this study.
75339971|NCT03314714|Procedure|Acute bout of endurance exercise|Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
75650112|NCT04076098|Drug|Minocycline Hydrochloride|Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
75797311|NCT03886662|Drug|LB-100|"Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes."
75935309|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
75650113|NCT04076254|Drug|Albumins|albumin 5%
75935310|NCT04470219|Other|Cognitive support by RemindMe|
75935311|NCT02447666|Drug|Azacitidine|
75339972|NCT03314454|Drug|Beer|Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)
75339973|NCT03314454|Device|Videotaped drinking session|Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder
75339974|NCT03294863|Device|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.
75474176|NCT01980316|Drug|Argatroban|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
75797312|NCT01264068|Drug|Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San|Take medicine every day 3 times, each time 4 grams.
75339975|NCT03294863|Other|Standard of Care|Without the embrace Scar Therapy Device
75339976|NCT03275584|Drug|N-13 ammonia intravenous injection|"Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging"
75474177|NCT01980316|Drug|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
75650114|NCT04076254|Drug|Fluid|Ringer Lactate
75935312|NCT04469751|Diagnostic Test|invasive blood pressure monitoring|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
75935313|NCT03193021|Device|Cardiva Mid-Bore VVCS|The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.
75935314|NCT03193021|Other|Manual compression|Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
75935315|NCT04469829|Drug|Secukinumab|standard doses of secukinumab for psoriasis
75935316|NCT04469829|Drug|Methotrexate|Methotrexate 15 mg/week
75935317|NCT05217719|Drug|recombinant human thrombopoietin|The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.
75935318|NCT05217719|Drug|normal saline|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
75339977|NCT03241459|Device|Surmodics SurVeil DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
75339978|NCT03241459|Device|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
75339979|NCT03229863|Other|Sweet Potatos|Plum Organics, Just Sweet Potato
75339980|NCT03229863|Other|Pears|Earth's Best, First Pears
75797313|NCT01155258|Drug|temsirolimus|Given IV
75935319|NCT04469673|Biological|Biological：JS002|Administered by subcutaneous injection
75339981|NCT03113851|Radiation|Radiotherapy|One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.
75339982|NCT03113851|Drug|rhGM-CSF|Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
75339983|NCT03101891|Procedure|Serial amnioinfusions with isotonic fluid|Amnioinfusions will be performed by an expert in fetal procedures with a 20 or 22 gauge needle using sterile technique and ultrasound guidance. Local anesthetic will be employed. The fluid will consist of warmed isotonic fluid. Infusions may take up to 1 hour.
75339984|NCT03101891|Device|Spinal needle|A 20 or 22 gauge spinal needle will be used with sterile technique to access the uterus under ultrasound guidance and to infuse isotonic fluid.
75474178|NCT01980329|Drug|Maraviroc|
75474179|NCT01980368|Other|Educational Intervention|Receive readings and attend book club
75474180|NCT01980368|Behavioral|Exercise Intervention|Receive Tai Chi Easy class, DVD, and exercise manual
75474181|NCT01980368|Other|Questionnaire Administration|Ancillary studies
75474182|NCT01980394|Procedure|Esophageal Stump Washout|a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
75797314|NCT01155258|Drug|vinorelbine ditartrate|Given IV
75797315|NCT01157598|Device|bispectral index monitoring|parameter monitoring of bispectral index
75797316|NCT01156584|Biological|Toca 511 vector|Single, stereotactic, transcranial, intratumoral injection or intravenous injection
75797317|NCT01156584|Drug|Toca FC|4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
75797318|NCT01264146|Procedure|HBOT|Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)
75797319|NCT01264146|Procedure|Placebo (Sham)|open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
75797320|NCT01265316|Device|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
75935320|NCT04469673|Biological|Placebo|Administered by subcutaneous injection
75935321|NCT03195296|Other|No intervention|No intervention related to the study is foreseen
75935322|NCT03674905|Procedure|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
75935323|NCT03674905|Procedure|Peripheral nerve block|Pre-operative peripheral nerve block.
75339985|NCT03101891|Drug|Isotonic fluid|Isotonic fluids, including normal saline or lactated ringers solution, will be infused into the uterus through a spinal needle under ultrasound guidance using sterile technique. This fluid will act as replacement amniotic fluid.
75339986|NCT03074474|Device|OviTex 1S Permanent|OviTex 1S Permanent is a reinforced tissue matrix consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
75339987|NCT03064503|Biological|Blood sampling|Blood sampling will be performed at inclusion to investigate some biological eligibility criteria, and the day of MRI in order to analyse fibrosis biomarkers and collagen synthesis biomarkers
75339988|NCT03064503|Device|MRI|MRI will be performed to measure interstitial fibrosis
75339989|NCT03064503|Biological|Skin auto-fluorescence|Skin auto-fluorescence measures will be performed to measure advanced glycation end-products (AGE) produced by collagen degradation
75339990|NCT03017118|Dietary Supplement|Turmeric|Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
75339991|NCT03017118|Other|Placebo|Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
75474183|NCT01980407|Drug|S-1, leucovorin, oxaliplatin|S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
75474184|NCT01980420|Procedure|Laparoscopic sleeve gastrectomy|Conventional laparoscopic sleeve gastrectomy using EndoFLIP® probe to provide measures on the distensibility of gastro-esophageal junction (GEJ) and gastric tube.
75474185|NCT01980433|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Inhibitory 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
75650115|NCT03938116|Other|Healing Hearts Together|Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
75650116|NCT00771979|Drug|AZD0530|of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
75935324|NCT05217485|Device|Zio 14-day cardiac patch|A wearble adhesive cardiac patch (14-day) called Zio
76087804|NCT02481492|Device|No flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
75474186|NCT01980433|Other|pre and post-rTMS electroencephalogram|to verify the absence of infraclinical seizures
75474187|NCT01980433|Other|WCRS|Writer's cramp rating scale
75474188|NCT01980433|Other|handwriting scale DPRE|handwriting in development and being evaluated by the NRC Wilson
75474189|NCT01980433|Other|visual analog scale of discomfort writing and parameters collected on touchpad|
75650117|NCT00771979|Drug|AZD0530|Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
75650118|NCT00767689|Drug|Vitamin B 6|vitamin b6 100 mg po daily
75650119|NCT00767689|Drug|placebo|placebo is given in the placebo arm
75650120|NCT04076956|Device|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw
75650121|NCT00772057|Drug|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
75935325|NCT00405951|Drug|Obatoclax mesylate 250 ml|
75935326|NCT00405951|Drug|Docetaxel|
75935327|NCT03194984|Drug|Hydrogen peroxide 35%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
75935328|NCT03194984|Drug|Hydrogen peroxide 38%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
75935329|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
76087805|NCT02481492|Device|Flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
75474190|NCT01980446|Procedure|Auditory-evoked potentials|cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
75474191|NCT01980459|Dietary Supplement|magnesium lactate|Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.
75474192|NCT01980472|Biological|bevacizumab, carboplatin and paclitaxel|4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity
75474193|NCT01980498|Drug|Fentanyl pectin nasal spray (FPNS)|The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.
75339992|NCT02990299|Behavioral|mHealth for Diabetes Adherence Support|Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
75339993|NCT02968732|Procedure|Radical Cystectomy|
75650122|NCT00772057|Drug|Placebo|Placebo tablets given two times daily.
75935330|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
75339994|NCT02963558|Device|cycle ergometry|The cycler will provide 3 different possible modes of cycling-passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
75339995|NCT02903381|Drug|Nivolumab|Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
75339996|NCT02903381|Drug|Lenalidomide|Oral, predetermined dosage, Days 1-21 of cycle 1-12
75474194|NCT01980498|Drug|Physician choice-Usual care (PC-UC)|"The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.~If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice."
75474195|NCT01980537|Procedure|Magnetic wire navigation|
75474196|NCT01980537|Procedure|Conventional wire navigation|
75650123|NCT00776347|Drug|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
75650124|NCT00776347|Drug|Donepezil|
75650125|NCT00776425|Drug|Epoetin beta|Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
75650126|NCT03913702|Drug|Ketorolac Tromethamine|2ml of injectable Ketorolac (30mg/ml) will be mixed with 8ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 60mg of active substance in 10ml).
75935331|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
75935332|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
75935333|NCT03669757|Drug|LEO 134310 vehicle|Active substance: none
76087806|NCT05461560|Dietary Supplement|Sucrose solution|50 g of sucrose dissolved in 500 ml of tap water
76087807|NCT05461560|Dietary Supplement|Seaweed extract in sucrose solution|1 g of seaweed extract in solution of 50 g of sucrose in 500 ml of tap water
76087808|NCT03314220|Behavioral|preoperative preparation|Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
76087809|NCT02481570|Other|pharmacokinetic simulation|The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
76087810|NCT02479464|Genetic|Genotyping results|Genotyping results provided in Phase II
75339997|NCT02903381|Drug|Dexamethasone|Oral, Days 1, 8, 15 of cycle 1-6
75339998|NCT02850991|Radiation|High-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
75474197|NCT01980550|Drug|sublingual nicotine|The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
75474198|NCT01980563|Procedure|ultrasound|
75474199|NCT01980563|Procedure|combined monitoring|
75650127|NCT03913702|Drug|Methylprednisolone Acetate|1ml of injectable Methylprednisolone (80mg/ml) will be mixed with 9ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 80mg of active substance in 10ml)
75650128|NCT00772135|Drug|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
75650129|NCT00776503|Drug|VORINOSTAT|vorinostat; 400mg once daily; increasing duration (7-10-14 days)
75935334|NCT03669757|Drug|0.1% betamethasone valerate ointment (class III steroid)|Active substance: betamethasone valerate
75935335|NCT00405327|Biological|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
75935336|NCT00405327|Other|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
76087811|NCT05713578|Drug|apantamide+docetaxel+ADT|Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
76087812|NCT05713578|Drug|apantamide+ADT treatment|apantamide+ADT treatment
75339999|NCT02850991|Radiation|Standard-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
75474200|NCT01980602|Procedure|Supervised Exercise program|
75474201|NCT01980615|Drug|Inhaled BGF (PT010) Dose 1|
75474202|NCT01980615|Drug|Inhaled BGF (PT010) Dose 2|
75935337|NCT03199898|Diagnostic Test|Silverman-Andersen Retraction Score|The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
75340000|NCT02744391|Drug|Levodopa|
75650130|NCT04075006|Drug|Ketamine|standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
75340001|NCT02634645|Procedure|Endoscopic eradication therapies (EET)|Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.
75340002|NCT02634645|Procedure|Esophagectomy|The esophagus is surgically removed
75650131|NCT00772213|Procedure|MIGTS treatment|treatment of multiple trauma patients in the MIGTS
75340003|NCT02634645|Drug|Chemotherapy|Chemical substances are used to treat cancer
75340004|NCT02634645|Radiation|Radiation|Cancer cells are destroyed by radiation therapy.
75650132|NCT04188106|Drug|Varenicline Pill|FDA approved starter kit of varenicline (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) followed by FDA-approved dose of varenicline (1 mg twice daily) for the remaining 11 weeks
75340005|NCT02594813|Procedure|Biopsy or cold snare polypectomy|
75340006|NCT02555072|Biological|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
75340007|NCT02462837|Drug|Mirabegron|
75340008|NCT02462837|Drug|Placebo|
75340009|NCT02437500|Biological|SER-109|SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
75650133|NCT04188106|Drug|Hydroxyzine Pill|For the first week, participants will receive 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night for the remaining 12 weeks.
75935338|NCT03913091|Drug|Liposomal Bupivacaine|Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
75935339|NCT03913091|Drug|0.5% Bupivacaine HCL|0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
76087813|NCT02485548|Drug|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
75340010|NCT02420977|Drug|Pelvic DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
75340011|NCT02366221|Other|60-minute visit to the outpatient clinic|An interview, an injury-specific physical exam and/or a set of xrays.
75650134|NCT00669955|Drug|Omeprazole, amoxicillin, clarithromycin|Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
75799015|NCT01587768|Drug|Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009|Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides &amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
75935340|NCT00330369|Drug|Darusentan|Darusentan administered orally once daily
75935341|NCT00330369|Drug|Darusentan Placebo|Placebo to match darusentan administered orally once daily
75935342|NCT03199664|Radiation|NB-UVB|NB-UVB given twice weekly for 6 months
75935343|NCT03199664|Combination Product|NB-UVB & Tacrolimus 0.03%|NB-UVB given twice weekly for 6 months and tacrolimus 0.03 % ointment given for twice daily for the first month of treatment and once daily for the rest 5 months of treatment
75935344|NCT02447588|Other|IAD at 36 hours|Intrauterine insemination with sperm donor at 36 hours post-hCG
75935345|NCT02447588|Other|IAD at 24 hours|Intrauterine insemination with sperm donor at 24 hours post-hCG
75935346|NCT02447510|Procedure|group 1 bio-oss bone xenograft|bone substitute (bio-oss)
76087814|NCT02485548|Drug|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
75340012|NCT02366221|Other|Phone Interview|If subject cannot return to office in Boston, researcher may conduct interview over the phone.
75340013|NCT02346201|Drug|Methylphenidate|Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
75340014|NCT02346201|Drug|Placebo|Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
75340015|NCT02326207|Device|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
75340016|NCT02318732|Behavioral|APPS intervention|Contact with and recovery of firearms from individuals who are prohibited from possessing them
75340017|NCT02042378|Drug|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
75340018|NCT01956942|Device|Micropulse Laser Trabeculoplasty|
75340019|NCT01956942|Device|Selective Laser Trabeculoplasty|
75340020|NCT01866930|Biological|Pegylated Interferon Lambda-1a|
75340021|NCT01866930|Drug|Daclatasvir (DCV)|
75340022|NCT01866930|Drug|Ribasphere (RBV)|
75340023|NCT01807819|Other|Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
75474203|NCT01980615|Drug|Inhaled BGF (PT010) Dose 3|
75474204|NCT01980615|Drug|Inhaled GFF (PT003)|
75474205|NCT01980615|Drug|Inhaled Symbicort Dose 1|
75650135|NCT00669955|Drug|Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole|Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
75935347|NCT02447510|Procedure|group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)|platelet rich in growth factor (autogenous platelet rich in growth factor)
76087815|NCT02485548|Drug|Cisplatin|All patients will receive concurrent cisplatin.
75797321|NCT03879174|Drug|Pembrolizumab + Tamoxifen|"The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe.~A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and to reduce potential for dosing errors. A fixed dosing scheme will also reduce complexity in the logistical chain at treatment facilities and reduce wastage."
75340024|NCT01693094|Behavioral|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
75935348|NCT02447510|Procedure|group 3 platelet rich fibrin (autogenous platelet rich fibrin)|platelet rich fibrin (autogenous platelet rich fibrin)
75650136|NCT04176874|Procedure|Robotic-assisted diastasis of the rectus abdominis muscles repair|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
75340025|NCT01682187|Drug|LY2157299|Administered orally
75340026|NCT01682187|Drug|Lomustine|Administered orally
75340027|NCT01621568|Drug|Sunitinib|50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)
75650137|NCT00772291|Drug|pregabalin|pregabalin 150-600mg/day during 8 weeks
75935349|NCT03205592|Diagnostic Test|Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later
75340028|NCT01621568|Drug|Sunitinib|50mg/day for 2 weeks daily, by mouth with 1 week off (3 week cycle)
75474206|NCT01980615|Drug|Inhaled Symbicort Dose 2|
75474207|NCT01980641|Behavioral|Educational intervention|All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
75474208|NCT01980641|Device|Smartphone-based application|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
75474209|NCT01980667|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
75474210|NCT01980667|Drug|Cisplatin|vials containing 1 mg/ml concentrate for solution for infusion
75650138|NCT00772291|Drug|placebo|placebo drug during 8 weeks
75797322|NCT03882450|Procedure|Flexible fiberoptic laryngoscopy|Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.
75935350|NCT05216471|Radiation|chest X-ray|Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory
75935351|NCT02149537|Drug|hydroxyurea|
75935352|NCT03205982|Device|Wise app with medication adherence reminders|The Intervention group will receive the Wise app that delivers medication adherence reminders.
75935353|NCT03205982|Device|Wise app with fitness reminders|The control group will receive the Wise app with fitness reminders
75935354|NCT05216237|Drug|Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)|for 2-6 cycles followed by Sindilizumab plus Tegafur gimeracil oteracil potassium capsules.
75935355|NCT03205904|Dietary Supplement|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
76087816|NCT02485548|Radiation|IMRT|All patients will receive IMRT
75340029|NCT01574170|Other|Construction of a prognostic score (non-drug intervention types)|Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression
75340030|NCT01511393|Other|No treatment given|None. Non-interventional study.
75340031|NCT01472328|Procedure|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
75340032|NCT01472328|Procedure|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
75340033|NCT01366612|Drug|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1"
75340034|NCT01366612|Drug|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
75340035|NCT00813293|Drug|Sorafenib|
75340036|NCT00813293|Procedure|radiofrequency ablation|
75340037|NCT00481091|Drug|ABT-263|Tablet; Oral
75340038|NCT00085982|Drug|Metreleptin|Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
75474211|NCT01980680|Drug|hCG|
75474212|NCT01980680|Drug|Progesterone and Estradiol|
75650139|NCT00767845|Other|questionnaire/survey administration|
75650140|NCT04048525|Procedure|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
75340039|NCT00067821|Drug|2-Flourodeoxyglucose|
75340040|NCT00003641|Biological|interferon alfa-2b|Given IV
75340041|NCT00003641|Other|observation|Patients undergo observation for 4 weeks.
75935356|NCT04058977|Other|Power training|Progressive exercise protocol with focus on velocity of movement
75935357|NCT03205514|Diagnostic Test|NSTE-ACS with intermediate stenosis and negative FFR|Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
75340042|NCT05327400|Other|Pathological|The pancreatic cancer cohort and the healthy cancer-free patient cohort were divided according to pathology reports
75650141|NCT04048525|Procedure|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
75650142|NCT03595150|Drug|Diclofenac|Diclofenac rectally given before the ERCP to prevent pancreatitis
75797323|NCT03882450|Procedure|Laryngeal ultrasonography|Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.
75935358|NCT03674749|Other|Meditation and Hyperbaric Oxygen Treament|Meditation sessions will be combined with hyperbaric oxygen treatment
75935359|NCT02284971|Biological|CDX1127|
76087817|NCT02478840|Drug|Lamazym|recombinant human alpha-mannosidase
75650143|NCT00776581|Procedure|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
75650144|NCT00776581|Procedure|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
75650145|NCT00776581|Procedure|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
75650146|NCT00776581|Procedure|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
75797324|NCT03881202|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
75797325|NCT01263522|Other|different training programs|two different endurance programs and one strength endurance program
75797326|NCT01263522|Other|control condition|unchanged lifestyle
75935360|NCT02284971|Radiation|SBRT|
75935361|NCT05217329|Other|smart phone App rehabilitation|stroke subjects use smart phone to complete therapeutic tasks 5 min/session total 8 sessions/day with affected arm or bilateral arm movement for 6 weeks
75935362|NCT05217329|Other|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program for 6 weeks(30min/day)
75935363|NCT03205202|Dietary Supplement|Cocoa extract|
75340043|NCT05326542|Procedure|ESWL and ERCP|First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.
75340044|NCT05326542|Procedure|LL and ERCP|After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.
75340045|NCT00392834|Biological|filgrastim|given subcutaneously
75340046|NCT00392834|Biological|pegfilgrastim|given subcutaneously
75340047|NCT00392834|Biological|rituximab|given IV
75340048|NCT00392834|Drug|cyclophosphamide|given IV
75340049|NCT00392834|Drug|cytarabine|given intrathecally
75340050|NCT00392834|Drug|doxorubicin hydrochloride|given IV
75340051|NCT00392834|Drug|etoposide|given IV
75340052|NCT00392834|Drug|ifosfamide|given IV
75340053|NCT00392834|Drug|leucovorin calcium|given IV
75340054|NCT00392834|Drug|liposomal cytarabine|given intrathecally
75340055|NCT00392834|Drug|methotrexate|given intrathecally
75340056|NCT00392834|Drug|therapeutic hydrocortisone|given intrathecally
75340057|NCT00392834|Drug|vincristine sulfate|given IV
75340058|NCT02982980|Procedure|Physiotherapy Guidance|Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.
75340059|NCT02982980|Procedure|Physiotherapy Muscle strengthening|The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
75797327|NCT01156662|Device|Endeavor resolute or Resolute integrity (Medtronic)|PCI without thrombus aspiration
75797328|NCT01156662|Device|Export Aspiration Catheter, Endeavor resolute or Resolute integrity (Medtronic)|PCI after thrombus aspiration
75797329|NCT01159548|Drug|Promethazine|
75797330|NCT01159548|Drug|Promethazine|
75935364|NCT03205202|Dietary Supplement|Multivitamin|
75935365|NCT03205202|Dietary Supplement|Cocoa extract placebo|
75935366|NCT03205202|Dietary Supplement|Multivitamin placebo|
75935367|NCT00322257|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
75935368|NCT00322257|Drug|insulin detemir|Injection s.c., 50% of daily dose
75935369|NCT00322257|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
76087818|NCT02479152|Device|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
75340060|NCT00393380|Drug|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC>2000/microL: PTH 100 mcg
75340061|NCT05362422|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3-5 times per week for 4 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
75340062|NCT05362422|Device|sham long-term paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
75340063|NCT05361642|Drug|Bupivacaine HCl 0.5% Injectable Solution|using nasal block including sphenopalatine ganglion block with general anesthesia to optimize surgical field
75340064|NCT05361642|Drug|Dexmedetomidine|using dexmedetomidine with induction of general anesthesia to optimize surgical field
75340065|NCT05359770|Device|Active HD-tDCS|Experimental group: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
75650147|NCT03565744|Behavioral|B'N Fit POWER|Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
75340066|NCT05359770|Device|Control group|Sham Control: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
75340067|NCT04422834|Other|Questionnaire|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
75340068|NCT00395876|Drug|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
75340069|NCT00395876|Drug|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
75340070|NCT05324514|Procedure|Split-thickness skin grafting|Harvesting for split-thickness skin grafting will be performed at the specified donor site using a pneumatically powered dermatome with a setting of 10 /1000th inch and meshed 2:1.
75650148|NCT04047667|Procedure|cone beam CT guided transbronchial cryobiopsy|CBCT images are acquried and reviewed in axial, coronal and sagittal planes to most accurately assess the cryoprobe position within the lung parenchyma and relative to other thoracic structures. The minimum probe-to-pleura distance will be measured. If the position of cryoprobe is proper, TBCB will be perfomed.
75340071|NCT05324514|Device|High density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at high density (300-360 columns/50cm2).
75340072|NCT05324514|Device|Low density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at low density (150-180 columns/50cm2).
75340073|NCT05323578|Other|Survey|Prevalence of safe caffeine consumption among anesthetists
75650149|NCT03922828|Diagnostic Test|CT scans|CT surveillance, Lung biopsy, Lung resection
75650150|NCT02580916|Other|SCQOLIT questionnaire|"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires [Appendices C & D) at:~baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"
75650151|NCT00768157|Drug|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
75650152|NCT00768157|Procedure|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
75340074|NCT02662634|Biological|AGS-003-LNG|autologous dendritic cell immunotherapy
75340075|NCT02662634|Drug|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
75340076|NCT02662634|Drug|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
76087819|NCT02478918|Other|Phone call|Automated phone call reminder
75340077|NCT02662634|Drug|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
75340078|NCT02662634|Drug|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
75340079|NCT02662634|Drug|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
75797331|NCT03881358|Device|ortho-k lenses and thinner spectacles|Conventinally designed (Emerald) ortho-k lenses (target for -4.00D) and thinner specs during day time
75797332|NCT03881358|Device|newly designed ortho-k lenses|Newly designed (Topaz) ortho-k lenses for high myopia (target for full correction)
75340080|NCT02662634|Radiation|Radiation Therapy|Causes DNA strand breaks.
75474213|NCT01980693|Device|SonicBone ultrasound|The device measure BA using ultrasound technology by measurement of speed of sound in three different sites : wrist bones, Phalanx III, Metacarpal bones.The device sends a short US pulse and measures the distance between a transmitter probe and a receiver probe, located at the bone measured area.The US probe converts electrical pulse to US pulse and US wave via tested bone arrives from transmitter to Receiver. Simultaneously with US pulse, controller start timer to calculate time between US pulse and the moment that US wave arrives to receiver. The accepted US signal of selected probe via amplifiers arrives to comparators that read timer value. The microcontroller calculates SOS using distance between probes and US time of flight.
76087820|NCT02478996|Other|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
76087821|NCT02479074|Drug|Montelukast (High FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days
76087822|NCT02479074|Drug|Prednisolon, Montelukast (High FeNO)|Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.
76087823|NCT02479074|Drug|Montelukast (Low FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
76087824|NCT02478762|Procedure|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
75474214|NCT01980732|Drug|68Ga-DOTA TATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.
75474215|NCT01980745|Drug|Chloroquine diphosphate 250mg|Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
75474216|NCT01980745|Drug|Placebo|
75474217|NCT01980758|Procedure|Laparoscopic Gastric Plication|The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
76087825|NCT02478762|Procedure|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
76087826|NCT02478684|Other|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
76087827|NCT02478684|Other|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
76087828|NCT05715060|Procedure|Median sternotomy closure (sternal closure)|Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire & Polydioxanone (PDS)
76087829|NCT02481180|Drug|T0001|injection (SC) T0001 15mg weekly for 12 weeks
75474218|NCT01980810|Drug|albumin-bounded paclitaxel|200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
75474219|NCT01980810|Drug|S-1|40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
76087830|NCT02481180|Drug|T0001|injection (SC) T0001 30mg weekly for 12 weeks
76087831|NCT02481180|Drug|T0001|injection (SC) T0001 30mg every two weeks for 12 weeks
76087832|NCT02481180|Drug|T0001|injection (SC) T0001 50mg every two weeks for 12 weeks
76087833|NCT02481180|Drug|Enbrel|injection (SC) enbrel 50mg twice a week for 12 weeks
76087834|NCT02480946|Drug|MBS2320|As described in the arm descriptions
76087835|NCT02480946|Drug|Placebo|As described in the arm descriptions
76087836|NCT02480946|Drug|Methotrexate|Background therapy as described in the arm descriptions
75474220|NCT01980836|Biological|Seasonal influenza vaccine|
75474221|NCT01980849|Drug|Nadroparin, long term|
75474222|NCT01980849|Drug|Nadroparin: short-term|
75474223|NCT01980901|Device|Ovation™/Ovation Prime™ Abdominal Stent Graft System|Single occurence permanent implant of AAA device.
75474224|NCT01980927|Procedure|NUCCA atlas correction|"A chiropractic procedure involving correcting a misalignment of the atlas or top vertebra in the spine."
75474225|NCT01980953|Drug|GDC-0032 Phase III Tablet|Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
75474226|NCT01980953|Drug|GDC-0032 Tablet|Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
75935370|NCT03199742|Behavioral|Personalized App Coaching|All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress & use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
75935371|NCT03199742|Behavioral|Active Comparator|Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
76087837|NCT02480868|Device|ARTEBONE|4,3 g Bone Void Filler
76087838|NCT02478528|Device|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
76087839|NCT02478528|Device|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
76087840|NCT02478528|Other|control condition|No exposure of the subject to any light sources (control condition)
75340081|NCT02524158|Behavioral|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
75340082|NCT05323500|Other|Senobi breathing exercises|The study participants will be screened first, then trained to perform SBE (1-minute maneuver). Participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. Then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. After this, instruct them to exhale by using their whole body for pushing air out of the lungs. Participants will also guided to tighten all their body muscles while pushing air out. Exhale should last for seven seconds.
75650153|NCT04076878|Device|Mollii|The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
75650154|NCT00671749|Drug|adapalene gel, 0.3%|Applied once daily at bedtime
75650155|NCT00671749|Drug|clindamycin/benzoyl peroxide gel|Applied once daily in the morning
75650156|NCT04149106|Drug|Sulfadoxine pyrimethamine + Amodiaquin|Monthly dose of SPAQ over three days for SMC
76087841|NCT03316716|Procedure|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
76087842|NCT02478606|Other|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
75474227|NCT01980953|Drug|GDC-0032 Capsule|Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
75474228|NCT01980966|Drug|MHAA549A|IV dose
75650157|NCT04149106|Drug|Dihydroartemisinin piperaquin|Monthly dose of DHAPQ for SMC
75650158|NCT03889600|Other|REDD-CAT|After obtaining informed consent from a participant and gathering baseline data, the study RA will send a flag in the EMR to notify the nurse care manager that a patient has enrolled in the REDD-CAT pilot. The nurse care manager will then incorporate the administration of the REDD-CAT to the patient as part of standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
75650159|NCT00768235|Other|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
75650160|NCT00768313|Device|titanium rod|comparison of rods of varying yield strengths and their ability to hold correction of scoliosis.
75650161|NCT00768313|Device|ultra strength stainless steel rod|interventions involving rods of various strength to treat scoliosis
76087843|NCT01769170|Drug|Brincidofovir|
76087844|NCT01769170|Other|Placebo|
76087845|NCT05714904|Drug|ZVS101e|ZVS101e is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene.
76087846|NCT04350970|Other|High flow nasal therapy|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The high flow nasal therapy was used during all exercise test.
76087847|NCT04350970|Other|Non-invasive ventilation|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The NIV was used during all exercise test.
76087848|NCT04350970|Other|Control|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The control test was performed with no additional therapy.
76087849|NCT02480634|Drug|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
75474229|NCT01980966|Drug|Placebo|IV dose
75474230|NCT01980966|Drug|oseltamivir [Tamiflu]|Orally b.i.d, 5 days
76087850|NCT02480634|Radiation|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/5f
75340083|NCT00396032|Drug|placebo|For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
75340084|NCT00396032|Drug|tenecteplase|For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
75340085|NCT02277782|Drug|Hydromorphone|
75340086|NCT02277782|Drug|Hyperbaric bupivacaine|
75650162|NCT00768391|Biological|IMC-3G3|Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
75797333|NCT03882684|Diagnostic Test|In-situ imprinting detection|The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.
76087851|NCT01815502|Diagnostic Test|Cardiac catheterization|All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.
76087852|NCT01769248|Device|Fine needle aspiration|Fine needle aspiration
75340087|NCT02277782|Drug|Fentanyl|
75474231|NCT01980979|Drug|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
75474232|NCT01981005|Drug|RO5424802|Single oral doses followed by IV or oral administration of a 14C-labeled tracer
75650163|NCT00669877|Drug|Rituximab|375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
75650164|NCT00669877|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
75340088|NCT02525094|Biological|MEDI9929|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
75340089|NCT02525094|Biological|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
75340090|NCT04255914|Procedure|Periodontal plastic surgery procedure and orthodontic treatment|subepithelial connective tissue graft and orthodontic tooth levelling and alignment
75474233|NCT01981018|Other|Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)|"ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:~Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.~Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.~Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a video blue print."
76087853|NCT01769248|Device|Fine needle biopsy|FNB
75474234|NCT01981031|Drug|BioChaperone® Combo|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
75340091|NCT04255914|Procedure|Periodontal plastic surgery procedure|subepithelial connective tissue graft procedure
75340092|NCT02271230|Drug|Vitamin D and fish oil|2000 IU vitamin D and 1g/d fish oil
75340093|NCT02271230|Dietary Supplement|Fish oil (EPA/DHA) alone|1 g/d fish oil
75340094|NCT02271230|Drug|Vitamin D alone|2000 IU vitamin D
75474235|NCT01981031|Drug|Humalog® Mix25|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
75474236|NCT01981070|Behavioral|Mindfulness Intervention for Parents|See Study Arms
75474237|NCT01981070|Behavioral|Support and Information for Parents|See Study Arms
75474238|NCT01981083|Dietary Supplement|Egg albumin-based protein supplement|
75474239|NCT01981083|Dietary Supplement|Renal-specific oral supplement|
75474240|NCT01981135|Other|Clean Air|Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
75650165|NCT00669877|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
76087854|NCT03316560|Biological|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
75474241|NCT01981135|Other|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
76087855|NCT03399292|Drug|Cationorm MD sine eye drops|studyparticipants receive lipidbased eye drops once only in the study eye
75474242|NCT01981161|Procedure|biological samples and clinical data|
76087856|NCT02726022|Drug|Peginterferon alfa-2a|As per treating physician discretion and according to summary of product characteristics.
76087857|NCT02726022|Drug|Ribavirin|As per treating physician discretion and according to summary of product characteristics.
75474243|NCT01981200|Other|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
75650166|NCT00669877|Drug|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
75650167|NCT00669877|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
75650168|NCT00669877|Drug|G-CSF|10 mcg/kg
75650169|NCT00669877|Drug|Cytarabine|100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
75650170|NCT00669877|Drug|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
75650171|NCT04047901|Other|exercise training|Patients undergo 16 weeks of physical training
75340095|NCT02271230|Other|Placebo|Vitamin D placebo and fish oil placebo
75340096|NCT00396266|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
75340097|NCT05381142|Drug|Elinzanetant (BAY3427080)|Elinzanetant will be administered as a single dose on Study Day 1 and a multiple dose once daily for another 6 consecutive days on Study Day 8 to Study Day 13.
75650172|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|
75650173|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|Placebo
76087858|NCT05714748|Biological|EBV mRNA vaccine|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval
76087859|NCT02258152|Drug|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
76087860|NCT02258152|Drug|Placebo|Placebo QD
75340098|NCT05381142|Drug|Placebo|Matching placebo will be administered the same as Elinzanetant (BAY3427080)
75340099|NCT05610384|Drug|Ketorolac Injectable Solution|ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively
75650174|NCT00772681|Drug|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
75340100|NCT05610384|Drug|Ibuprofen 800 mg|ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
75340101|NCT05353296|Behavioral|Digital cognitive behavioral therapy for insomnia (CBT-I) program|A self-guided digital program of CBT-I (Somryst) that has been culturally adapted for Spanish-language speakers. Somryst is an interactive and tailored mobile-based program modeled on the primary tenets of face-to-face CBT-I. Patients will be asked to complete six cores (main intervention content) during the 9-week intervention period. The cores provide key content across six domains including behavioral (sleep restriction, stimulus control), cognitive (cognitive restricting), educational (sleep hygiene), overview, and consolidation/relapse prevention.
75797334|NCT03880890|Procedure|sphenoidotomy versus sphenoid nasalisation|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
75474244|NCT01981226|Device|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
75650175|NCT02557633|Biological|Grass MATA MPL 10200|
75650176|NCT02557633|Biological|Grass MATA MPL 18200|
75650177|NCT02557633|Biological|Placebo|
75650178|NCT04143646|Behavioral|Web-based prevention program|"Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk."
75474245|NCT01981239|Device|VFSS|VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
75474246|NCT01981252|Device|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
75474247|NCT01981278|Drug|Tapentadol ER 250-mg TRF tablet|Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
75797335|NCT01156740|Drug|Penicillin G, Benzathine|IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg)
75797336|NCT01156740|Drug|Amoxicillin|750 mg/QD
75797337|NCT03882138|Procedure|open flap debridement|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
75797338|NCT01265628|Procedure|perimetry|automated static perimetry with adapted GATE strategy
75797339|NCT03880812|Other|Societal cost|Annual societal cost information to the US for carpal tunnel release surgery was displayed.
75340102|NCT05353296|Behavioral|Minimally Enhanced Usual Care (mEUC)|A minimally enhanced usual care, which will include usual care by patients' Primary Care Provider and a sleep hygiene brochure.
75340103|NCT05353296|Device|Somryst (culturally adapted)|FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) trains your brain for better sleep.
75340104|NCT05286944|Other|Mobile phone alarm reminder|Patients are reminded to take their INCS using a mobile phone alarm set to ring daily
75340105|NCT05319132|Other|Adult subjects with ROSAH syndrome|The main objective is to evaluate the ex vivo inhibitory potential of DF-003 on alpha-1 kinase activity.
75340106|NCT00397904|Biological|cetuximab|
75340107|NCT00397904|Drug|cisplatin|
75340108|NCT00397904|Drug|irinotecan hydrochloride|
75650179|NCT02557711|Device|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
75650180|NCT00772759|Drug|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
75650181|NCT00772759|Drug|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
75650182|NCT03866668|Drug|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
75650183|NCT00772837|Drug|Omeprazole + Clarithromycin + Amoxycillin|Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
75650184|NCT00772837|Drug|Omeprazole + placebo antibiotics|omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
75650185|NCT03863704|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
75650186|NCT00776971|Other|Sugar-sweetened soft drink|500mL as a preload drink
75650187|NCT00776971|Other|Aspartame-sweetened soft drink|500mL as a preload drink
75650188|NCT00776971|Other|Semi-skimmed milk|500mL as a preload drink
75650189|NCT00776971|Other|Water|500mL as a preload drink
75650190|NCT03850288|Other|Neuropsychological assessment : Stroop task|"Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive."
75650191|NCT03850288|Other|Neuropsychological assessment : Go No Go task|"Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive."
75797340|NCT01159626|Drug|PF-03463275|Oral single 20 mg dose as two 10mg controlled release tablets
75650192|NCT00773071|Device|SPECT/CT guided LM/SL|Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
75340109|NCT00397904|Other|immunohistochemistry staining method|
75340110|NCT00397904|Other|laboratory biomarker analysis|
76087861|NCT02725788|Device|New PIV Dressing|A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
76087862|NCT02725788|Device|Standard PIV Dressing|A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
76087863|NCT02485626|Procedure|2D tissue doppler echocardiography|
76087864|NCT01817374|Diagnostic Test|2D US grayscale plus quantitative VCEUS|This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
76087865|NCT04492332|Diagnostic Test|standard lumbar puncture|Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.
75797341|NCT01159626|Drug|PF-03463275|Oral single 40 mg dose as four 10mg controlled release tablets
75935372|NCT05216939|Other|Flannel mask with ear loops|Participants will have a mask fit test and will wear a flannel mask with ear loops. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort and fit of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
75340111|NCT00397904|Procedure|biopsy|
75935373|NCT05216939|Other|Flannel mask with ties|Participants will have a mask fit test and will wear a flannel mask with ties. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
75474248|NCT01981278|Drug|Tapentadol ER 250-mg PR2 tablet|Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
75474249|NCT01981291|Procedure|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
75474250|NCT01981291|Procedure|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
75474251|NCT01981291|Procedure|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
75340112|NCT05610228|Other|NO intervention|No intervention
75340113|NCT05610150|Device|Myobrace Functional Appliance|An Appliance for treating growing Class II patients with mandibular deficiency
75340114|NCT05610150|Device|Twin Block|An Appliance for treating growing Class II patients with mandibular deficiency
75340115|NCT00398918|Drug|zonisamide|zonisamide (100 mg)one time
75340116|NCT00398918|Drug|Placebo|Placebo Comparator
75474252|NCT01981291|Procedure|Patient-controlled postoperative analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
75650193|NCT03492424|Device|cryotherapy|Subjects will receive focal cryotherapy for treatment of prostate cancer
75797342|NCT01159626|Drug|PF-03463275|Oral single 60 mg dose as six 10mg controlled release tablets
75797343|NCT01159626|Drug|Placebo|Oral single dose as matching placebo
75797344|NCT01159626|Drug|PF-03463275|Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
75797345|NCT01159626|Drug|Placebo|Oral multiple doses as matching placebo for 7 days
75340117|NCT05380752|Drug|TPOXX IV (Tecovirimat Injection, 10 mg/mL)|IV solution (10 mg/mL) must be diluted with 2 parts 0.9% normal saline or 5% dextrose solution prior to dosing. Once diluted, the drug product should be stored at 2-8°C (36-46°F) and used as soon as possible (i.e., not more than 24 hours after dilution). Given via an IV infusion pump over a 6 hour period, twice daily, and for up to 7 days, or until the physician determines oral TPOXX may be given
75797346|NCT03880968|Drug|tapering or discontinuation of etanercept|Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).
75340118|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four biweekly applications of Celaderm plus compression therapy
75340119|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four weekly applications of Celaderm plus compression therapy
75935374|NCT05216939|Other|Twill mask with ear loops|Participants will have a mask fit test and will wear a twill mask with ear loops. While wearing the twill mask with ear loops, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
75340120|NCT00399308|Device|Control (compression bandaging)|Multi-layer compression bandaging
75340121|NCT05599776|Other|Smart ring assisted physiotherapeutic intervention|the effect of a smart ring (Oura), a wearable activity tracker assisted physiotherapeutic intervention on the risk of poor outcome measured on patient reported post-operative outcome (Oxford Knee Score) 12 months after a primary total knee replacement.
75340122|NCT05286476|Combination Product|Whole Body Vibration|vibration was administered for 1min, with a rest interval of 1min between each vibration set repeating 10 vibrations, with a frequency of 30 Hz and an amplitude of 0-2 mm and a speed of 50 m /s,18 and these sessions lasted for 6 weeks 3 days a week. whole-body vibration was induced by a noninvasive oscillation platform
75340123|NCT05286476|Other|pelvic floor exercises and static abdominal exercises in addition to diet instructions|"During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times."
75340124|NCT05599074|Device|extrusion arch|A stainless steel pre-formed arch wire custom made by placing V-bends 3-5 mm mesial to the molar tubes, placed into the auxiliary molar tubes after leveling phase and tied over the main arch wire distal to the lateral incisors
75340125|NCT00401102|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
75340126|NCT05350722|Radiation|Single dose ablative radiotherapy|Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation
75474253|NCT01981291|Drug|Mepivacaine|Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
75650194|NCT00773149|Drug|Alemtuzumab (CAMPATH 1H) associated to G-CSF|"All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
76087866|NCT02485470|Other|MPACT|Maintaining Physical Activity during Cancer Treatment
76087867|NCT02478294|Procedure|Thoracoscopic LAA Excision plus AF Ablation|In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
75650195|NCT00768703|Device|Percutaneous endoscopic fetal tracheal occlusion/unocclusion|Between 26-28 wks' gestation, percutaneous endoscopic placement of the tracheal balloon. Between 32-34 wks' gestation, percutaneous endoscopic removal of the balloon.
75797347|NCT01159704|Behavioral|Peer Education Model|The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.
75797348|NCT01159704|Behavioral|HIV Counseling and Education Model|"The C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
75797349|NCT03880734|Drug|Cholecalciferol|ingredients-Cholecalciferol (40,000 IU),Microcrystalline Cellulose (58.1 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
75797350|NCT03880734|Other|Placebo oral capsule|ingredients- Microcrystalline Cellulose (303.8 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
75936600|NCT03181568|Device|MolecuLight i:X™ Imaging Device|Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
76087868|NCT02478294|Drug|Warfarin or Novel Oral Anticoagulants|In this group, patients receive warfarin or novel oral anticoagulants
76087869|NCT02485392|Device|Da Vinci Single Site Robot-Assisted Cholecystectomy|
76087870|NCT02485392|Device|Single Incision Laparoscopic Cholecystectomy|
75340127|NCT04750694|Behavioral|Resistance training|A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
75340128|NCT05317104|Other|Aerobic exercise|For 6 weeks, 3 times a week, aerobic exercise will be performed with a treadmill at 55-74% of the maximal heart rate.
75340129|NCT01794884|Drug|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
75340130|NCT01794884|Drug|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
75340131|NCT05315934|Other|Upper body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.
75340132|NCT05315934|Other|Lower body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
75340133|NCT00401414|Drug|Warfarin|2 mg tablets take as directed by study staff (based on INR)
75340134|NCT05513196|Procedure|Erector spinae plane block (ESPB)|Bilateral erector spinae plane block will be performed with 20 mL, 0.25% bupivacaine at T9 level preoperatively.
75474254|NCT01981317|Behavioral|Stepped Care Cognitive Behavioral Therapy|
75474255|NCT01981317|Behavioral|Cognitive Behavioral Therapy|
75650196|NCT00768781|Behavioral|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
75650197|NCT00768781|Behavioral|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
75797351|NCT01159782|Other|Rhinovirus infection|All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
76087871|NCT01770652|Drug|Deferiprone|Oral iron chelator
76087872|NCT02485314|Other|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
76087873|NCT01820416|Radiation|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
75474256|NCT01981330|Biological|aMSC|aMSC injected into the vocal fold of the patient
75797352|NCT01157754|Drug|levonorgestrel and ethynilestradiol|
76087874|NCT01820416|Other|Placebo Comparator: Disabled Laser|Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
75797353|NCT03879252|Device|Toothbrush|Brushing teeth three times a day (extra-soft toothbrush) with a 1.4% baking mouthwash solution.
75797354|NCT03879252|Drug|Mouthwashes|Mouthwashes three times a day with a 1.4% baking mouthwash solution.
75797355|NCT01265862|Procedure|Tracheal intubation through LMA-Fastrach®|Tracheal intubation through a supraglottic airway device (LMA-Fastrach®) using a GlideRite® endotracheal tube
75936601|NCT03181568|Procedure|Wound care|Standard wound care of chronic wounds e.g. sampling, debridement, infection control
76087875|NCT03316482|Drug|Leuplin DPS 11.25mg|Leuplin DPS 11.25mg s.c. every 12 weeks
76087876|NCT03143218|Biological|RABIPUR®|Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
76087877|NCT03143218|Biological|RTS,S/AS01|Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
76087878|NCT03143218|Drug|SMC with SP+AQ|Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
76087879|NCT03143218|Drug|SMC placebo|Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
75650198|NCT00768781|Behavioral|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
76087880|NCT02480556|Procedure|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction & cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
75650199|NCT00777361|Drug|AZD3480|Iv single dose, 4-hour infusion of 25 mg
75340135|NCT00370838|Drug|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
75340136|NCT00370838|Drug|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
75340137|NCT00370994|Procedure|Caudal epidural injection|Caudal epidural injection with catheterization
75474257|NCT01981330|Biological|aMSC+hyaluronan gel|aMSC+ hyaluronan gel is injected into the patients vocal fold
75474258|NCT01981343|Dietary Supplement|A-F Betafood|
75474259|NCT01981343|Other|Placebo|
75650200|NCT00777361|Drug|AZD3480|Oral solution single dose of 50 mg
75797356|NCT01265862|Procedure|Tracheal intubation through I-gel®|Tracheal intubation through a supraglottic airway device (I-gel®) using a GlideRite® endotracheal tube
75797357|NCT03881982|Other|PIMPERNEL Novel Electronic Log: Pain display can be seen|Pain scores are displayed on the screen when the participant presses the corresponding button
75797358|NCT03881982|Other|PIMPERNEL Novel Electronic Log: Pain display is hidden|Participants press the buttons to record their pain score but the score is not on display (the screen is turned backwards).
75797359|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose in the fasting state.
75797360|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
75797361|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
75797362|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
75797363|NCT01264224|Drug|PAC-14028|tablets, oral administration, single/multiple dosing, dose escalation
75797364|NCT01156974|Behavioral|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
75935375|NCT05216939|Other|Twill mask with ties|Participants will have a mask fit test and will wear a twill mask with ties. While wearing the twill mask with ties, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
75936602|NCT03181646|Drug|citicoline|intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
76087881|NCT02480556|Procedure|Conservative separation of placenta|"Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu & uterus is massaged awaiting spontaneous placental separation"
75340138|NCT00370994|Procedure|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
75340139|NCT01795430|Drug|etoposide|Given IV
75340140|NCT01795430|Drug|ifosfamide|Given IV
75474260|NCT01981369|Drug|Dexmedetomidine|Intravenous sedation with dexmedetomidine
75474261|NCT01981369|Drug|Propofol|Intravenous sedation with propofol
75474262|NCT01981369|Procedure|Infraclavicular block|All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
75474263|NCT01981395|Drug|Fenobam|Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
75474264|NCT01981395|Drug|Placebo|A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
75474265|NCT01981408|Drug|[^14C]-LY2801653|Administered orally
75797365|NCT01156974|Behavioral|education only|patients receive education about care goals
75797366|NCT03882216|Procedure|soft tissue augmentation using pouch technique|crestal incision with split thickness flap without vertical releasing incision till the mucogingival line then apply the harvested connective tissue graft through it.
75797367|NCT03882216|Procedure|soft tissue augmentation using modified pouch technique|tunneling will be done at the pontic site till the mucogingival line then a distant vertical incision near the tunnel at the lining mucosa where the harvested connective tissue graft wll be applied .
75797368|NCT01265940|Drug|Pazopanib as add-on to vinflunine|"Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose."
75797369|NCT01159860|Procedure|cryosurgery|freezing of lesion with liquid nitrogen
75935376|NCT03195218|Device|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
75935377|NCT05216783|Behavioral|Motivational Interviews|The qualitative research studies performed on the traumatic childbirth experiences indicated that the pregnant women's interaction and communication with the midwives were more effective than the medical intervention methods that were applied.
75935379|NCT03627845|Drug|PHP-303|Investigational drug
75340141|NCT01795430|Radiation|intensity-modulated radiation therapy|Undergo WB-MRI-guided IMRT
75935380|NCT03627845|Other|Placebo|Matching placebo
75650201|NCT02556853|Device|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
75935381|NCT03199586|Drug|NP-G2-044|capsule
75340142|NCT01795430|Drug|topotecan hydrochloride|Given IV
75340143|NCT01795430|Drug|busulfan|Given IV
75650202|NCT02556853|Other|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
75650203|NCT00768859|Drug|paclitaxel, trastuzumab and carboplatin|paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
75797370|NCT01159860|Procedure|Curettage|the lesion will be anesthetized and destroyed with a curette.
75797371|NCT01264302|Drug|Finasteride|Finasteride Tablets 5 mg
75935382|NCT01918345|Behavioral|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
75797372|NCT03760146|Biological|20vPnC|20vPnC
75936603|NCT04482998|Other|No intervention - retrospective study|No intervention - retrospective study
75936604|NCT02420834|Other|Hypromellose 0.15%|Tear supplement to be taken as required to relieve symptoms
75936605|NCT02420834|Other|Hypromellose 0.4%|Tear supplement to be taken as required to relieve symptoms
75340144|NCT01795430|Drug|melphalan|Given IV
75340145|NCT01795430|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell or bone marrow transplant
75340146|NCT01795430|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
75797373|NCT03760146|Biological|13vPnC|Pneumococcal conjugate vaccine
75797374|NCT03760146|Biological|PPSV23|Pneumococcal polysaccharide vaccine
75797375|NCT03760146|Other|Saline|Placebo
75797376|NCT03877068|Device|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay up to 10 days using the Dexcom Studio software to download the Dexcom receiver data.
75936606|NCT02420834|Other|Carboxymethylcellulose|Tear supplement to be taken as required to relieve symptoms
75936607|NCT02420834|Other|Liposomal Spray|Tear supplement o be taken as required to relieve symptoms
75340147|NCT01795430|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow transplant
75340148|NCT04750382|Drug|HX008+Cisplatin+Gemcitabine|Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m^2, Day 1, Day 8, Q3W for up to 6 cycles
75340149|NCT04271150|Device|Self-etch|Universal adhesive with self-etch mode
75340150|NCT04271150|Device|Total-etch|Universal adhesive with total-etch mode
75474266|NCT01981434|Other|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
75474267|NCT01981447|Drug|IV Lacosamide|Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
75650204|NCT00768937|Drug|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
75797377|NCT03877068|Diagnostic Test|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.
76087882|NCT01771666|Device|SPY Elite Imaging|A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes
75340151|NCT00401882|Drug|Epinephrine|Epinephrine (1 mg) IV additional doses
75340152|NCT00401882|Drug|Metoprolol|Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
75340153|NCT01794962|Other|Cognitive functional therapy|The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
75340154|NCT01794962|Other|manual therapy and exercises|Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
75340155|NCT00371540|Other|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
75340156|NCT04248738|Behavioral|NEEDS|NEEDS intervention includes assessing patients' social needs and resources (SocNSuppR) and communicating those SocNSuppR to discharge teams
75340157|NCT05345886|Behavioral|Hippotherapy|Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
75650205|NCT00768937|Procedure|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
75797378|NCT01161654|Drug|naratriptan hydrochoride|2.5 mg tablet
75650206|NCT04047745|Drug|Liposomal bupivacaine|interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine
75474268|NCT01981460|Procedure|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
75650207|NCT04047745|Drug|Ropivacaine injection|interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
75797379|NCT01266174|Drug|Eltoprazine|Comparison of eltoprazine, dosed orally, for 8 weeks
75797380|NCT01266174|Drug|Placebo|Placebo to match eltoprazine
75797381|NCT01266252|Drug|Dexmedetomidine|"Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
75797382|NCT03878940|Diagnostic Test|Abdominal ´yes-no´ pathway|A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
75797383|NCT01266330|Dietary Supplement|Low Dairy|Less than 0.5 standard servings of dairy products per day
75797384|NCT01266330|Dietary Supplement|Adequate Dairy|3.5 standard servings of dairy foods per day
75797385|NCT01161732|Procedure|Early surgery|Early surgery is performed within 2 months of randomization.
75935383|NCT01918345|Behavioral|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
75935384|NCT05234138|Other|Blood Sample|Blood Sample
76087883|NCT01771666|Drug|Indocyanine Green|"started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
76087884|NCT01771666|Drug|Isosulfan blue|"3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
76087885|NCT01771666|Drug|99technetium-sulfur colloid radiolabel|
75340158|NCT05555394|Other|Basic Body Awareness Therapy|The intervention will be twice a week during 12 weeks. It lasts 90 min of movements of daily life, massage and self-reflections.
75340159|NCT05555394|Other|Stretching Exercise|It consists in stretching movements of whole body
75340160|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
75340161|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
75340162|NCT00373334|Drug|placebo|placebo
75340163|NCT05507346|Device|Cross over Device (PCD or Dayspring - alternate to first group)|Cross over after three month of use and a month of washout period
75340164|NCT04749914|Drug|Lasmiditan|Administered orally.
75340165|NCT04749914|Drug|Dabigatran Etexilate|Administered orally.
75340166|NCT04749914|Drug|Rosuvastatin|Administered orally.
75797386|NCT01266486|Drug|Metformin|Extended release Metformin 1500mg once daily for 14-21 days
75797387|NCT03879954|Device|Catetherization approach|Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization
75797388|NCT01267968|Drug|GSK2251052|1500 mg (dosing detailed in Arm description)
75797389|NCT01161888|Drug|Imiquimod|250mg sachets to be applied at a start dose of 5 days a week. Dose will be adjusted using an algorithm according to tolerability.
75797390|NCT01160094|Drug|Treatment|patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
75797391|NCT01157988|Drug|ibritumomab tiuxetan (Zevalin)|During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count > 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
75797392|NCT03760068|Drug|MYL-1601D Product|(100 U/mL)
76087886|NCT05713188|Device|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream. Healthy volunteers will undergo filtration for 5 hours.
75340167|NCT00402194|Drug|Losartan|Tablet, 100mg, once per day for 3 months
75340168|NCT05286086|Behavioral|prehabilitation|Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
75340169|NCT05305404|Drug|Dexamethasone Oral|1.5mg oral dexamethasone to be administered once at 11:00PM
75650208|NCT00773227|Procedure|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
75340170|NCT05305404|Drug|Placebo|oral placebo to be administered once at 11:00PM
75340171|NCT00402896|Drug|ZD6474|300 mg/day orally for 10 weeks.
75650209|NCT00777439|Drug|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
75797393|NCT03760068|Drug|FlexPen NovoLog®|(100 U/mL)
75797394|NCT03759600|Drug|Niraparib|Niraparib capsule
76087887|NCT02485236|Device|Low flow oxygen via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
75340172|NCT05303610|Other|Observational|This is a cross sectional study. The aim of the study is to evaluate the myofascial chain lines in addition to the general evaluation parameters in patients with patellofemoral pain syndrome (PFPS) and to determine whether deviations from normal in the myofascial structure have an effect on the development of PFPS.
75797395|NCT01158066|Procedure|CT Cardiac|the patient will undergo cardiac CT
75797396|NCT03876912|Drug|GnRH antagonist|18F-PSMA 1007 PET/CT before, 3 weeks after ADT, at 1 year and at CRPC in 35 patients. 18F-FDG PET/CT in a subgroup of 20 patients before ADT.
75935385|NCT02285049|Other|Urticaria Control Test|"The patients get the 1st UAS28 form and four-week appointment to follow up.~Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~Then patients fill the 1st UCT and DLQI questionnaire by themselves.~The patients get the 2nd UAS28 form and four-week appointment to follow up.~At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves."
75935386|NCT03674515|Device|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
75935387|NCT03674515|Device|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
75340173|NCT00405704|Drug|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
75474269|NCT01981486|Drug|Placebo Tablets|BID modified-release tablets
75935388|NCT03205436|Other|Affinity human amniotic membrane|fresh hypothermically stored human amniotic membrane
75474270|NCT01981486|Drug|PF-05180999 Tablets|BID modified-release tablets (20 to 240 mg BID)
75474271|NCT01981499|Drug|PF-05180999|Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
75474272|NCT01981499|Drug|Placebo|Placebo tablets
75650210|NCT00882999|Drug|LY2127399|Administered via Injection
75650211|NCT00882999|Drug|Placebo|Administered via Injection
75650212|NCT00769093|Drug|Ferumoxytol|2 mg/kg
75650213|NCT00671437|Procedure|FDG-PET/CT|
75797397|NCT01268124|Drug|HTC-867|
75797398|NCT01161966|Drug|Zonisamide|Zonisamide capsules 100 mg
75797399|NCT01161966|Drug|Zonegran|Zonegran Capsules 100 mg of EISAI INC
75935389|NCT03674359|Diagnostic Test|BDG analysis|BDG analysis
75935390|NCT00312975|Drug|CP-675,206|Given intravenously every 3 months
75935391|NCT00312975|Drug|best supportive care|As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
76087888|NCT02485236|Device|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
76087889|NCT01821352|Device|Erchonia Obesity Laser|10 independent 17 milliwatts 532 nm green diode lasers
76087890|NCT01821352|Device|Placebo Laser|Emits light that has no therapeutic effect
76087891|NCT02485002|Device|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
76087892|NCT02485002|Device|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
76087893|NCT05713032|Procedure|Pulsed radiofrequency on lumbar dorsal root ganglion|voltage of pulsed radiofrequency on DRG
76087894|NCT01772758|Drug|BH4 5mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
75650214|NCT00671437|Drug|Cetuximab|
75650215|NCT02556697|Device|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
75797400|NCT01158144|Drug|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
75797401|NCT01158144|Drug|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
75340174|NCT00405704|Drug|Placebo|Cherry flavored liquid suspension matched to active comparator.
75340175|NCT01657266|Drug|PRO-155|Pre-medication (before surgery) and maintenance treatment.
76087895|NCT01772758|Drug|BH4 20mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
75797402|NCT01162044|Other|Computer game|Playing with specially designed computer game while in emergency room
76087896|NCT01772758|Dietary Supplement|Antioxidant Cocktail|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
76087897|NCT05712954|Other|music group|music
75797403|NCT01264536|Dietary Supplement|lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
75935392|NCT03425435|Other|QoL and developed questionnaires for healthcare research|Questionnaires
76087898|NCT05712954|Other|video group|video
75340176|NCT01657266|Drug|Nevanac|Pre-medication (before surgery) and maintenance treatment.
75650216|NCT04162353|Biological|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
75935393|NCT03199508|Diagnostic Test|the 3-day voiding diary|The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
75650217|NCT00777517|Drug|Lipitor|A single dose of 10 mg Lipitor tablet
75935394|NCT03199508|Diagnostic Test|the 7-day voiding diary|The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights.
75935395|NCT05215301|Diagnostic Test|Multidimensional Voice Program|"MDVP (Multidimensional Voice Program) is a computerized acoustic analysis used to analyze sound quality using various parameters. Multidimensional Voice Program (MDVP) 4500 produced by Kay Elemetric Corp was used for voice evaluation.~Research subjects were asked to make a vowel sound /a/ using the same tone and intensity as the subject's daily speech. The researcher will give an example before letting the research subject tries. Voice recording was done using a microphone connected to a computer with the MDVP program. Voice recording was done in a quiet room for at least 3 seconds with a microphone distance of 10 cm from the mouth of the research subject. The recorded sound will be directly analyzed with the MDVP program. Sound recording was done 3 - 5 times, and the best sound acoustic analysis results were used for the study."
76087899|NCT01775410|Device|Wolverine System to perform atherectomy|
76087900|NCT02485080|Drug|Simeprevir|
76087901|NCT02485080|Drug|Sofosbuvir|
76087902|NCT02480322|Procedure|bariatric surgery (sleeve resection, proximal RYGB, distal RYGB)|
76087903|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
76087904|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
76087905|NCT05029830|Combination Product|investigations like MRI..|• Multiple Sclerosis Quality of Life-54 (MSQOL-54) Can be considered as the most known disease-specific instrument for the evaluation of quality of life in patients with multiple sclerosis (MS). It was developed to combine generic quality of life aspects of the SF-36 with MS-targeted dimensions and ratings for the overall quality of life. Therefore, 18 disease-specific items were added to the original 36 items of the SF-36. The 54 items are divided into 12 multi-item and 2 single-item scales. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales
75340177|NCT05217264|Other|Assesment|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
75340179|NCT05302440|Device|remote real-time health monitoring system with ring-like sensor|The remote monitoring system will constantly record the temperature, pulse and SpO2 of the residents wearing the equipment. When the staff find abnormal vital signs, they will provide further medical assistance. All care staff who manage the system will be complete a very brief survey (1-minute) after each work shift for 14 days.
75474273|NCT01981499|Drug|120 mg MR PF-05180999|Single 120 mg dose administered as modified release formulation
75650218|NCT00777517|Drug|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
75650219|NCT00769171|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
75650220|NCT00769171|Drug|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
75340180|NCT05286008|Drug|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
75340181|NCT05286008|Drug|Ropivacaine at high concentration|Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
75340182|NCT05286008|Drug|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
75340183|NCT05302284|Drug|RC48-ADC|2.0 mg/kg IV every 2 weeks
75340184|NCT05302284|Drug|Toripalimab|3.0 mg/kg IV every 2 weeks
75650221|NCT02579980|Procedure|DCE and DWI MRI|Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.
75650222|NCT02579980|Procedure|Surgery|Standard of care procedure for sarcoma patients
75650223|NCT00769249|Other|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
75650224|NCT00769249|Other|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
75797404|NCT01264536|Dietary Supplement|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
75797405|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392103A|intramuscular vaccination according to protocol schedule
75797406|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392105A|intramuscular vaccination according to protocol schedule
75797407|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392106A|intramuscular vaccination according to protocol schedule
75797408|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392019A|intramuscular vaccination according to protocol schedule
75797409|NCT01160172|Drug|Saline placebo|intramuscular vaccination according to protocol schedule
75935396|NCT02285205|Drug|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
75935397|NCT03199820|Device|Cook cervical balloon|trans-cervical balloon catheter for out-patient labour induction
75797410|NCT02527122|Diagnostic Test|Allergen extracts|
75797411|NCT03878784|Drug|Imigran|All patients will undergo this intervention on one of two study days
75797412|NCT03878784|Other|Isotonic Saline|All patients will undergo this intervention on one of two study days
75797413|NCT01266720|Biological|VEGFR1, VEGFR2|One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22
75797414|NCT01266720|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
75797415|NCT01162200|Radiation|Stereotactic Body Radiation Therapy|3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
75935398|NCT03199820|Drug|Prostin E2 Vaginal Suppository|Propess Vaginal suppository for out-patient Labour induction
75340185|NCT05302284|Drug|Gemcitabine|1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
75797416|NCT03876756|Other|postpartum acute urinary retention|Collection of risk factors
75340186|NCT05302284|Drug|Cisplatin|70mg/m2 IV infusion on Day 1 of every 3 week cycle
75340187|NCT05302284|Drug|Carboplatin|AUC=4.5, IV infusion on Day 1 of every 3 week cycle
75340188|NCT05213442|Diagnostic Test|To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.|"Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.~Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires)."
75797417|NCT03876756|Other|no postpartum acute urinary retention|Collection of risk factors
75797418|NCT01162278|Radiation|SBRT|Single fraction SBRT
75935399|NCT03532659|Other|Active video game|Among the 20 municipal schools, two will be selected between those with 298 or more students (corresponding to the third quartile of the number of students per school). Next will be selected the school in which the adolescents will be submitted to intervention, and the students from the other school will be control. The intervention will aim to promote physical exercise through active video game XBOX 360 with Kinect. The game selected will be Just Dance, to allow the participation of up to four students at the same time. In addition, a gamification protocol will be performed to increase the adolescents engagement in the exercise.
75936608|NCT03184298|Other|Surveys|The purpose of the surveys is to collect quantitative data to determine the relative impact of the intervention program on participants' sexual behaviors and alcohol use.
76087906|NCT01824082|Drug|Perineural infusion [continuous peripheral nerve block(s)]|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
75340189|NCT05300802|Drug|Placebo|50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
75650225|NCT00769249|Procedure|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
75650226|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
75650227|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
75650228|NCT00777595|Drug|Placebo|Inhaled solution, single dose of placebo
75650229|NCT00777595|Drug|Moxifloxacin|Tablet, oral, 400mg, single dose
75650230|NCT02579746|Behavioral|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
75650231|NCT02579746|Behavioral|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
75650232|NCT02581618|Other|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
75797419|NCT01589952|Drug|Pegalyted interferon, Entecavir|Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
75799016|NCT01188330|Behavioral|WITH Comprehensive Geriatric assessment|"Each month after randomization, a nurse practitioner will systematically review the intervention plan.~In case of hospitalisation, the nurse will go and meet the patient and his care giver to check each point of the intervention plan. If an action has not been done, a new proposal will be made to the patient. If the patient is at home or in institution, the nurse practitioner will call the patient and /or his care giver for the same purpose"
75799017|NCT01188330|Behavioral|Conventional|no Comprehensive Geriatric assessment
75935400|NCT03243071|Behavioral|Tailored Website|Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.
75935401|NCT03243071|Behavioral|Standard Website|Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
75935402|NCT03199430|Dietary Supplement|Epigallocatechin gallate|
75935403|NCT03199430|Dietary Supplement|Placebo|1450mg Corn Flour
75935404|NCT05725473|Device|Eso-Flip|Dilatation with Eso-FLIP
75935405|NCT03195062|Other|Test meal|Liquid test meal (fructose+glucose)
75935406|NCT03532503|Device|Foley catheter|Transcervical foley catheter will be applied
75340190|NCT05300802|Drug|Dexmedetomidine Hcl 100 Mcg/mL Inj|1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
75340191|NCT05300802|Drug|Dexmedetomidine Hcl 100 Mcg/mL Inj|0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
75474274|NCT01981499|Drug|360 mg MR PF-05180999|Single 360 mg dose administered as modified release formulation
75474275|NCT01981499|Drug|10 mg cetirizine|Single 10 mg dose of cetirizine
75474276|NCT01981499|Drug|Placebo|Placebo tablets
75650233|NCT00769405|Drug|fluorouracil|Given IV
75650234|NCT00769405|Drug|leucovorin calcium|Given IV
75650235|NCT00769405|Drug|oxaliplatin|Given during surgery
75650236|NCT00769405|Procedure|hyperthermia treatment|Given intraperitoneally during surgery
75650237|NCT00882921|Biological|Idursulfase|Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
75650238|NCT02829502|Drug|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
75650239|NCT02829502|Drug|Normosaline|Single dose of subcutaneous injection of 20 μL normosaline (placebo).
75650240|NCT02635191|Drug|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
75650241|NCT02635191|Drug|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
75650242|NCT00773539|Procedure|PVI using an open irrigated tip catheter|transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
75650243|NCT00773539|Procedure|PVI using a closed irrigated tip catheter|transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
75650244|NCT00773539|Procedure|PVI using a cryoballoon|transseptal PVI using the cryoballoon from CRYOCATH
75936609|NCT03184298|Other|Interviews|These Motivational Interviews aim to promote change in behavior through open-ended questions, affirmations, and reflections.
76087907|NCT02725710|Drug|Gabapentin|600mg Gabapentin administered orally 1-2 hours prior to procedure
76087908|NCT02725710|Drug|Placebo|Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
75650245|NCT00773617|Behavioral|ICAT|ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.
76087909|NCT02256358|Drug|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
76087910|NCT02256358|Drug|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
75650246|NCT00773617|Behavioral|CBT|CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
75650247|NCT02579824|Drug|DS-3032b|Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
75650248|NCT02635113|Device|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
75650249|NCT02557165|Procedure|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
75650250|NCT05673850|Drug|NET or NCT|In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
75650251|NCT00777673|Drug|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|"Eligible patients will receive:~nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
75797420|NCT01266798|Behavioral|Portal|"The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.~A checklist for critical assessment of health information~Access to research databases for health information and an introduction to research methods and principles of science~A checklist to the consultation"
75797421|NCT01585896|Other|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, & Steketee, 2007).
75797422|NCT01158300|Drug|VEGF inhibitor PTC299|This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
75797423|NCT01160250|Drug|vismodegib (GDC-0449)|Oral repeating dose
75935407|NCT03118388|Behavioral|Social Enterprise Intervention|The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).
75935408|NCT03118388|Behavioral|IPS|To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
75935409|NCT02287857|Drug|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
75935410|NCT02287857|Drug|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
75935411|NCT05214677|Drug|DW1809|pelubiprofen 30mg
75935412|NCT05214677|Drug|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
75935413|NCT03532347|Device|EUS-FNA needle (Beacon)|Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
75935414|NCT03204968|Device|Vagus nerve stimulation|transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
76087911|NCT05521542|Device|SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter|SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable coronary artery disease
76087912|NCT04999098|Drug|Echinaforce Forte tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients"
75799018|NCT01186068|Drug|V-101|Cream QD
75799019|NCT01186068|Other|vehicle|Cream QD
75650252|NCT00656721|Device|Flutter Valve|"Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done."
75650253|NCT02556619|Behavioral|Early Palliative Care/Symptom Control|"Establish palliative care goals~Determination of Medical Power of Attorney~Discuss/plan code status/advance directives~Document palliative care goals~Symptom Assessment and Control~Pain-treatment with opioid and non-opioid medications~Itching-H2 blockers, steroids~Nutrition-appetite stimulated with Megace, review low sodium diet~Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed~Nausea- treated with anti-emetics~Jaundice and Body Image- counselling regarding symptoms~End-of-Life Care~Discuss religious preferences~Assess for distress- ensure interaction with Cancer Resource Center~Hospice- charity Hospice options for select patients."
75650254|NCT04162119|Biological|BCMA-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.
75650255|NCT02579902|Dietary Supplement|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
75650256|NCT02579902|Dietary Supplement|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
75650257|NCT02557087|Drug|Hyoscine|
75650258|NCT02557087|Drug|Pethidine|
75797424|NCT03876600|Procedure|Replacement of permanent pacemakers for elective wear.|"START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day."
75797425|NCT03876444|Drug|Intravenous Methylprednisolone|Intravenous Methylprednisolone will be used in the intervention group
75797426|NCT03876444|Drug|Oral Pednisolone|Oral Prednisolone will be used in the Control Group
75797427|NCT01162512|Behavioral|physical activity|physical activity counseling sessions will occur by telephone weekly for 2 months
75797428|NCT01264692|Drug|ACT-280778|10 mg once daily for 28 ± 2 days
75797429|NCT01264692|Drug|Placebo|Placebo oral capsules matching ACT-280778
75797430|NCT01264692|Drug|Amlodipine|10 mg once daily for 28 ± 2 days
75650259|NCT02634879|Behavioral|Incentive Change|
75650260|NCT02579590|Drug|Depot Medroxyprogesterone Acetate 150 mg|"the DMPA user where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month"
75797431|NCT01162590|Biological|Rotarix ™|Oral, single dose
75797432|NCT01162590|Biological|Placebo|Oral, single dose
75797433|NCT01266954|Drug|GSK2141795|GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
75650261|NCT02579590|Drug|Implanon( 68 mg etonogestrel implant)|where they are using etonogestrel 68 mg implant (Implanon; Organon)
75650262|NCT02579590|Drug|Cerazette pills (75 micrograms desogestrel)|where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
75797434|NCT01160328|Drug|Leuprolide|7.5 mg - 1 month depot, 2 doses over 7 weeks
75797435|NCT01160328|Drug|Testosterone|7.5g - 1% testosterone gel, daily x 7 weeks
75797436|NCT03878238|Dietary Supplement|Probiotic Bths-003|Probiotic with maltodextrin as a carrier.
75797437|NCT03878238|Other|Placebo|Placebo with maltodextrin base.
75797438|NCT01162746|Drug|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
75936610|NCT03184298|Other|Group Discussions|The purpose of the group workshop is to create discussions surrounding perceived and collective social norms found among male soldiers that have been connected to sexual aggression. These discussions are used to promote bystander intervention among participants and help identify the prosocial attitudes that may be more common than previously perceived.
75936611|NCT03184142|Behavioral|Simulation|Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
75797439|NCT01162746|Drug|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
75797440|NCT01268202|Drug|Pravastatin|Pravastatin 40mg/day during 12 months
76087913|NCT04999098|Drug|Echinaforce Chewable tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients"
75340192|NCT05299476|Drug|CAPOX combined with bevacizumab and Tislelizumab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 4-8 cycles; Capecitabine: oral administration, 2g/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Bevacizumab was administered intravenously (without prophylaxis) at 7.5mg/kg. The first infusion was 90min, the second infusion was 60min, and each infusion was 30 min. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~Tislelizumab is administered intravenously (without prophylaxis) at a fixed dose of 200mg. Each infusion was 30 min (no less than 20 min, no more than 60 min), and the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
75340193|NCT00405938|Drug|Bevacizumab|Bevacizumab 10mg/kg IV every 2 weeks
75340194|NCT00405938|Drug|Anastrozole|anastrozole (1 mg orally daily)
75340195|NCT00405938|Drug|Fulvestrant|fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
75474277|NCT01981525|Drug|Metformin|Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
75474278|NCT01981603|Other|navigator|
75474279|NCT01981629|Device|USCOM|The USCOM device will be used in addition to cardiac ultrasound in patients with shock.
75474280|NCT01981655|Drug|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
75474281|NCT01981655|Drug|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
75474282|NCT01981668|Drug|cabazitaxel|Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
75474283|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
75474284|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
75474285|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
75797441|NCT01264848|Procedure|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins
75797442|NCT01264848|Procedure|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
75797443|NCT01268358|Drug|Lamazym|Lamazym, ERT, infusion weekly
75474286|NCT01981681|Drug|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
75474287|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
75797444|NCT01162824|Drug|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
75799020|NCT01182636|Drug|Adapalene|0.1% Topical Gel
75799021|NCT01182636|Drug|Differin®|0.1% Topical Gel
76087914|NCT04999098|Drug|Echinaforce tincture|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)"
75474288|NCT01981681|Drug|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
75474289|NCT01981694|Drug|PF-06649751|Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
75650263|NCT02634957|Behavioral|absolute voice rest|absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or whispering)
75650264|NCT03846544|Drug|CFA-double pick up|In the study group, 225 IU of rFSH will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with hCG 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
75650265|NCT02634723|Biological|Octocog alfa (recombinant human coagulation factor VIII)|
75799022|NCT01182636|Drug|Placebo|Gel Base
75799023|NCT01290354|Drug|Lapatinib|Unlabelled, administered orally
75799024|NCT01290354|Drug|[11C] lapatinib|Radiolabelled, administered intravenously
75340196|NCT04239534|Device|Convergence Of Epicardial And Endocardial RF Ablation|The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
75340197|NCT05299398|Drug|Trazodone|Trazodone capsule once daily
75340198|NCT05299398|Drug|Placebo|Placebo capsule once daily
75797445|NCT01162824|Drug|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
75797446|NCT01267032|Behavioral|Integrated Care|A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
75340199|NCT01793480|Drug|Methadone|
75797447|NCT01267032|Behavioral|Cognitive-Behavioral Treatment for Insomnia|A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
75935415|NCT03532269|Device|Nightly App|The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.
75936612|NCT03184142|Behavioral|Video|Student watch a 15-minute intimidation video (see arm description).
75340200|NCT05285930|Combination Product|Bee venom phonophoresis|phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care. The performance of the ultrasound applicator was tested regularly before and after each patient exposure; each test included all relevant acoustic field parameters (pressure amplitude, frequency) and uniformity of the field distribution. This type of test of the acoustic output of the applicators was important to eliminate the possibility of any malfunctioning of the devices.
75340201|NCT05285930|Device|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
75340202|NCT00407420|Device|Mandometer|A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
75340203|NCT00407420|Behavioral|Lifestyle|Typical dietary and activity advice as normally provided in clinic (control).
75340205|NCT05258526|Other|Home based exercise training|The intervention will be based on a remote approach, lasting 12 weeks. The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week. The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.
75340206|NCT05258292|Device|Continuous glucose monitoring|Glucose levels will be measured using continuous glucose monitoring
75340207|NCT05258292|Drug|Insulin|Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
75340208|NCT05258292|Other|Premenstrual symptoms|Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool
75340209|NCT05258292|Other|Ovulation kits|Ovulation testing will be done using ovulation kits
75797448|NCT01267032|Behavioral|Desensitization Treatment for Insomnia|A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
75797449|NCT03877848|Device|Percutaneous Coronary Intervention (PCI)|Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.
75797450|NCT01265004|Procedure|Stitches|Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching
75797451|NCT01265004|Procedure|Fibrin-glue|Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
75797452|NCT01265004|Procedure|Stitches and Fibrin-glue|Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
75797453|NCT01586598|Behavioral|sensory retraining protocol|"within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day~one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day~three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day"
75797454|NCT01162902|Drug|Diltiazem treated group|Diltiazem 180mg for 9 months
75797455|NCT01162902|Drug|Bisoprolol treated group|Bisoprolol 5mg for 9 months
75797456|NCT01162902|Drug|Candesartan treated group|Candesartan 32mg for 9 months
75799025|NCT01188408|Drug|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
75799026|NCT01182714|Procedure|immediate removal of in-dwelling catheter|
75799027|NCT01182714|Procedure|24 hours delayed removal of catheter|
75799028|NCT01186146|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
75797457|NCT05666856|Behavioral|Community Reinforcement And Family Training|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
75340210|NCT05258292|Device|Fitbit Inspire 2|Physical activity will be assessed using the Fitbit Inspire 2
75799029|NCT01186146|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
75935416|NCT03204890|Other|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
75340211|NCT05258292|Other|Keenoa|Food intake will be assessed using the Keenoa phone application
75340212|NCT05258292|Other|Menstrual cycle|The application My Calendar will be used to record information on the menstrual cycle
75340213|NCT05256264|Drug|Ketamine|Ketamine infusion at different dose to observe EEG DSA changes
75340214|NCT00379574|Drug|Bortezomib|"Bortezomib:~For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.~For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks."
75935417|NCT00399789|Drug|Perifosine|Perifosine will be tested in 3 dose forms
75340215|NCT00379574|Drug|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
75340216|NCT00379574|Drug|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
75340217|NCT00379574|Drug|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
75650266|NCT00769717|Behavioral|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
75935418|NCT03118310|Behavioral|5:2 diet|Dietary intervention according to 5:2 diet during three months.
75935419|NCT03118310|Behavioral|LCHF|Dietary intervention according to LCHF diet during three months.
75935420|NCT03118310|Behavioral|Placebo diet|Placebo diet: normal dietary advice
75340218|NCT00379574|Drug|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
75340219|NCT00379574|Drug|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
75340220|NCT05256108|Drug|Oxycodone 40 mg|Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
75340221|NCT05256108|Drug|Tramadol 600 mg|Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
75935421|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
75935422|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
75935423|NCT01318499|Other|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
75935424|NCT00397293|Drug|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
75935425|NCT00397293|Drug|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
75935426|NCT03628079|Drug|ReposMBZ|Capsules 50mg, 100mg, 200mg
75474290|NCT01981694|Drug|PF-06649751|It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
75936613|NCT03184142|Behavioral|Control group|No intervention. The students suture for 70 minutes
75936614|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams once daily
76087915|NCT01824160|Device|Repair of RV-PA Conduit Disruption|Repair of RV-PA Conduit Disruption
75340222|NCT05256108|Drug|Placebo|Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
75340223|NCT05256108|Drug|Cebranopadol 600 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
75340224|NCT05256108|Drug|Cebranopadol 1000 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
75474291|NCT01981707|Device|F-Choline-PET|
75797458|NCT05666856|Behavioral|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
75797459|NCT03876834|Other|respiratory training|Respiratory training was done by using threshold inspiratory muscle trainer(Respironics, New Jersey , USA, No.8373-0730)
75797460|NCT03877536|Drug|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Participants will receive 1 tablet per day throughout study duration (96 weeks).
75935427|NCT03118154|Other|Manual Physical Therapy|Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
76087916|NCT02478216|Procedure|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
75340225|NCT05209776|Biological|Peripheral immunological assessment on venous blood|Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube
75340226|NCT05209776|Biological|Immunological assessment carried out on intracardiac material|Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube
75340227|NCT00407654|Drug|aflibercept|Given intravenously
75340228|NCT05484492|Biological|demineralized and mineralized combination putty bone allograft|Subjects in this group will receive an intrasocket demineralized and mineralized combination putty bone allograft following tooth extraction
75650267|NCT00769717|Behavioral|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
75650268|NCT04075942|Procedure|Atrophic Anterior Maxillary Ridges|Use of modified cortical shell technique grafted with customized Xenograft bone shell
75340229|NCT05484492|Biological|calcium phosphosilicate putty alloplast graft|Subjects in this group will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft following tooth extraction
75340230|NCT05261048|Other|Pelvic Proprioceptive neuromuscular facilitation in addition to Conventional Physical Therapy|"The experimental group received both conventional and Pelvic PNF for 30 minutes each, once in a day, 4 days per week. The experimental group will be given anterior elevation-Posterior depression pattern with the techniques of Rhythmic initiation, Slow reversal and Stabilizing reversal. These techniques will be given on affected side for total 30 minutes with 15 minutes of pelvic PNF in one session with rest periods in between. Participants will be positioned into side lying with both hip flexion 1000 and knee flexion 450, neck supported by a pillow with flexion of 300. Hand placement for anterior elevation over the crest of the ilium one hand overlaps other for posterior depression heel of the one hand hold with other hand on the ischial tuberosity.~Pull up and Push down command will be given along with the techniques of rhythmic initiation, slow reversal and stabilizing reversal."
75650269|NCT02634567|Behavioral|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
75650270|NCT03843424|Behavioral|eSOC program|American Medical Association (AMA) recommended staged approach to childhood obesity screening and counseling
75797461|NCT02526888|Drug|ACT-541468|Oral capsule (25 mg) as single dose
75797462|NCT02526888|Drug|Diltiazem|Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
75797463|NCT05436600|Other|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
75797464|NCT01158612|Drug|Growth Hormone|infusion of Growth hormone in the patella tendon.
75797465|NCT01267110|Other|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
75474292|NCT01981733|Device|geko|The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
75935428|NCT03204734|Drug|Capecitabine|Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
75935429|NCT03204734|Drug|endocrine therapy|endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
75936615|NCT01316939|Drug|Placebo|Placebo
76087917|NCT04977726|Behavioral|STRIVE curriculum|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session.
75935430|NCT02287935|Procedure|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
76087918|NCT01775800|Other|Treatment modification|
76087919|NCT02478060|Biological|Birch-SPIRE|
76087920|NCT02478060|Biological|Placebo|
76087921|NCT02724462|Behavioral|Smartphone-delivered Intervention (SmartQuit)|The experimental arm includes an intervention using a novel smartphone smoking cessation app.
75650271|NCT03843424|Behavioral|FBT program|An intensive,comprehensive, behavioral intervention aligned with the US Preventive Services Task Force recommendations for childhood obesity screening and counseling.
75935431|NCT02287935|Procedure|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
75935432|NCT03627689|Other|Active air purifier in respiratory allergies/asthma|Continuous use of air purifier to improve allergies and asthma control
75935433|NCT03627689|Other|Sham air purifier|control arm
75340231|NCT05261048|Other|Conventional Physical Therapy|"Conventional physiotherapy will be asked to perform truncal exercises in spine and sitting position for total 30 minutes including rest periods in between, once in a day for 4 days per week.~Exercises in supine position included (pelvic bridging, unilateral pelvic bridging, upper trunk rotation (clasped hand), lower trunk rotation (crook lying) with 3 repetitions for each exercise.~In sitting position, exercises included flexion and extension of lower trunk, rotation of upper and lower trunk, forward and lateral reach with 3 repetitions for each exercise."
75340232|NCT05260580|Other|No Intervention: Routine care|
76087922|NCT02724462|Behavioral|: Smartphone-delivered Intervention (Standard of care app)|The control intervention uses a standard of care smartphone smoking cessation app.
75340233|NCT00407888|Drug|doxorubicin hydrochloride|Given IV
75474293|NCT01981746|Procedure|Adductor canal block with ropivacaine 0.1%|US-guided adductor canal block
75474294|NCT01981798|Behavioral|Physiotherapy and occupational therapy|Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
75474295|NCT01981811|Drug|Aripiprazole|
75474296|NCT01981811|Device|Ingestible Event Marker (IEM)|
75935434|NCT00300027|Drug|BMS-582664|
75935435|NCT00396357|Drug|Vildagliptin|
75935436|NCT00396357|Drug|metformin|
76087923|NCT01825408|Drug|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
76087924|NCT01825408|Drug|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
76087925|NCT01825408|Drug|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
75340234|NCT00407888|Drug|cyclophosphamide|Given orally
75340235|NCT00407888|Biological|filgrastim|Given SC
75340236|NCT00407888|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
75474297|NCT01981889|Drug|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
75474298|NCT01981915|Procedure|IPPB|Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
75650272|NCT02634489|Drug|Tamsulosin HCl|Oral
75650273|NCT02634489|Drug|Solifenacin Succinate|Oral
75650274|NCT02634489|Drug|EC905|Oral
75650275|NCT02579512|Other|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
75650276|NCT00582712|Drug|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
75935437|NCT03627611|Drug|Levothyroxin|3 months
75935438|NCT03627611|Drug|Liothyronine|3 months
75935439|NCT02447042|Procedure|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
75935440|NCT02447042|Device|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
75935441|NCT00394563|Drug|RN624 (PF-04383119)|10 mcg/kg
75474299|NCT01981915|Procedure|LIAM|Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
75340237|NCT00407888|Biological|trastuzumab|Given IV
75797466|NCT01267110|Other|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
75797467|NCT02526966|Biological|blood sample|dosage of anti-hinge region antibodies
75340238|NCT00407888|Other|laboratory biomarker analysis|Correlative studies
75340239|NCT00407888|Procedure|quality-of-life assessment|Ancillary studies
75935442|NCT00394563|Drug|RN624 (PF-04383119)|25 mcg/kg
75474300|NCT01981928|Drug|ASP7962|Oral
75474301|NCT01981928|Drug|Placebo|Oral
75474302|NCT01981941|Drug|Gabapentin enacarbil|Oral
75935443|NCT00394563|Drug|RN624 (PF-04383119)|50 mcg/kg
75340240|NCT05208684|Other|Breast stimulation|Breast stimulation by the Elvie Pump to trigger prolactin release.
75340241|NCT00407966|Drug|alvocidib|Given IV
75340242|NCT00407966|Drug|cytarabine|Given IV
75474303|NCT01981980|Other|Carboxytherapy|Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
75474304|NCT01981980|Other|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
75474305|NCT01982006|Procedure|Cataract surgery with Phacoemulsification|"Each patients randomized in the phaco arm will undergo a conventional cataract surgery.~Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.~Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center."
75650277|NCT04161963|Device|SD-OCT|Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
75797468|NCT01267188|Drug|NBI-98854|powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
75797469|NCT01158690|Other|resource card|the intervention group receives an envelop with resource card
75340243|NCT00407966|Drug|mitoxantrone hydrochloride|Given IV
75340244|NCT00408200|Drug|propafenone; flecainide; sotalol; dofetilide|Above drugs prescribed per established guidelines for treatment of AF
75340245|NCT00408200|Device|Radiofrequency catheter ablation|A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
75935444|NCT00394563|Drug|RN624 (PF-04383119)|100 mcg/kg
75935445|NCT00394563|Drug|RN624 (PF-04383119)|200 mcg/kg
75935446|NCT00394563|Drug|placebo|
75340246|NCT05255406|Drug|Furmonertinib (160mg)|160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).
75340247|NCT05250050|Drug|Esomeprazole|20mg bid
75340248|NCT05250050|Drug|Bismuth potassium citrate|0.6g bid
75340249|NCT05250050|Drug|Metronidazole|0.4g qid
75340250|NCT05250050|Drug|Clarithromycin|0.5g bid
75340251|NCT05250050|Drug|Levofloxacin|0.5g qd
75340252|NCT05250050|Drug|Amoxicillin|1g bid
75340253|NCT05250050|Drug|Tetracycline|0.5g qid
75340254|NCT05294328|Drug|Aceclidine+Brimonidine combination ophthalmic solution|Ophthalmic Solution
75340255|NCT05294328|Drug|Aceclidine ophthalmic solution|Ophthalmic Solution
75340256|NCT05294328|Drug|Vehicle Proprietary Ophthalmic Solution|Ophthalmic Solution
75474306|NCT01982006|Device|Femtosecond laser-assisted cataract surgery|"Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.~Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.~Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm"
75474307|NCT01982019|Behavioral|Meal test taking and hormones measure including 26RFa|Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
75474308|NCT01982032|Procedure|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
75474309|NCT01982032|Device|Medtronic CoreValve system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
75474310|NCT01982032|Device|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
75650278|NCT04161963|Device|OCT-A|swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
75650279|NCT02754778|Behavioral|conditional workout|6 month of regular conditional workout 1-3 times a weak
75650280|NCT02579668|Other|Language Therapy|
75650281|NCT03920566|Other|Anti-Xa level|Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment
75650282|NCT02578498|Dietary Supplement|High carbohydrate intake|Carbohydrate intake < 50 gram
75650283|NCT02578498|Dietary Supplement|Low carbohydrate intake|Carbohydrate intake > 250 gram
75650284|NCT00582790|Drug|IL2|Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
75936616|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams twice daily
75936617|NCT03183986|Device|Phototherapy|Phototherapy for 24 hours.
75797470|NCT01158690|Other|no resource card|the control group receives an envelop without resource card
75650285|NCT00582790|Drug|Zoledronic acid|Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
75935447|NCT05194319|Other|All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)|The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .
75797471|NCT03877692|Drug|Experimental dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
75797472|NCT03877692|Other|Standard dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive either the standard of care dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
75797473|NCT03879720|Procedure|Endoscope assisted endotracheal intubation [EAEI]|Endoscope assisted endotracheal intubation [EAEI] performed by anesthesiologist with endoscopist assistance.
75797474|NCT03877614|Other|ASCVD risk score|ASCVD score< 10% will be in the control or low-risk group
75797475|NCT03878004|Biological|GamTBvac vaccine|introduction of GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose) twice into a shoulder with an 8-week interval.
75797476|NCT03878004|Biological|placebo|introduction of placebo twice into a shoulder with an 8-week interval.
75797477|NCT01268592|Procedure|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
75797478|NCT01158846|Drug|prasugrel/bivalirudin|60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)
75797479|NCT01158846|Drug|clopidogrel/abciximab|600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.
75797480|NCT01268670|Drug|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
75797481|NCT01268670|Drug|Oxycodone|Subjects will receive topical LET and oral oxycodone.
76087926|NCT03108612|Diagnostic Test|Análisis de carga de trabajo (ACT)|Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
75797482|NCT01268670|Other|Placebo|Subjects will receive topical LET and oral placebo.
75797483|NCT01160718|Drug|fulvestrant|Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
75797484|NCT01160718|Drug|selumetinib|AZD6244 75 mg p.o. bid
75797485|NCT01160796|Drug|placebo|1x14-day course of treatment during 4 cycles
75797486|NCT01160796|Drug|Lcr35®|1x14-day course of treatment during 4 cycles
75797487|NCT01160874|Other|Polysomnography|Sleep study monitoring
75935448|NCT02449538|Drug|everolimus|everolimus 10 mg qd daily one cycle is 28days.
75797488|NCT01160874|Other|Maintenance Wakefulness Test|Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
75797489|NCT01160874|Behavioral|Neuropsychological evaluation|Neuropsychological evaluation for cognitive functions study
76087927|NCT01776268|Other|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
76087928|NCT02477904|Other|Ketogenic Diet|Dietary
76087929|NCT04945824|Drug|Dexamethasone Ophthalmic|Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
75797490|NCT01160874|Other|Driving test on a simulator|Driving simulator test during wich a camera register different parameters as the position of the vehicle.
75797491|NCT01159002|Device|SmartPill|Qualifying patients were assigned to the study within four days of hospital admission. They all received a gastro-duodenal tube and capsule. The motility capsule (SmartPill®) was placed into the capsule delivery device (AdvanCE™, US Endoscopy) and advanced blindly into the stomach and released
76087930|NCT04945824|Device|Dilator|Intracanalicular Dilator Device
75650286|NCT00773929|Drug|TAK-593|"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"
75650287|NCT00777907|Device|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
75650288|NCT00777907|Device|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
75935449|NCT04469361|Other|Navicular drop measurement|The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.
75650289|NCT00774007|Drug|mesalazine|
75650290|NCT00774007|Drug|placebo|
75797492|NCT01159080|Drug|routine dose tacrolimus and less myfortic|oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day
75797493|NCT01159080|Drug|reduced dose tacrolimus and conventional myfortic|low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
75797494|NCT01160952|Drug|itraconazole|the two groups are defined by different treatment duration
75797495|NCT01161030|Dietary Supplement|Almonds|
75797496|NCT01163370|Dietary Supplement|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
75650291|NCT00774085|Other|No intervention was given|Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
75797497|NCT01163370|Other|exercise training|resistance training twice a week for 24 weeks
75797498|NCT01163370|Other|placebo (dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
75474311|NCT01982045|Device|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
75650292|NCT00769873|Drug|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days
75650293|NCT00777985|Drug|bosentan|62.5 mg b.i.d for 4 weeks
75797499|NCT01163448|Radiation|High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy|A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
75797500|NCT01163526|Procedure|CT perfusion|
75797501|NCT01159158|Drug|Nateglinide|Nateglinide Tablets 120 mg
75797502|NCT01161108|Drug|Fast Release Melatonin (FR MLT)|3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
75797503|NCT01161108|Drug|Fast Release Placebo|"A matching FR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
75797504|NCT01161108|Drug|Timed Release Melatonin (TR MLT)|"3 mg capsules will be used.~The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
75935450|NCT04469361|Other|Measurement of venous return parameters in supine|Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position
75650294|NCT00777985|Device|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
75650295|NCT00769951|Other|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
75650296|NCT00769951|Other|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
75797505|NCT01161108|Drug|Timed Release Placebo|"A matching TR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
75797506|NCT01161186|Drug|nab-paclitaxel, gemcitabine, capecitabine|{nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
75797507|NCT01159236|Drug|Paclitaxel|80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
75935451|NCT04469361|Other|Measurement of venous return parameters in standing|In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.
75474312|NCT01982045|Other|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
75650297|NCT00769951|Procedure|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
75797508|NCT01159236|Drug|Fluorouracil|500 mg/m2 for 4 courses (once every 7 days)
75797509|NCT01159236|Drug|Doxorubicin|50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
75935452|NCT04469361|Other|measurement of midfoot pressure distrubition|In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
75797510|NCT01159236|Drug|Epirubicin|100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
75797511|NCT01159236|Drug|Cyclophosphamide|500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
76087931|NCT01777126|Other|Oral Nutrition Protocol (ONP) group|For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
76087932|NCT01777126|Other|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
76087933|NCT04937634|Drug|Melphalan|The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m^2/day. Infuse Melphalan over 30 minutes.
76087934|NCT01826812|Other|30 minutes sustained reading|The participants will be given a text to read silently in 30 minutes.
76087935|NCT01826812|Other|Dry eye exam|Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
76087936|NCT02725476|Biological|XmAb5871|
76087937|NCT04931628|Drug|Salvianolic Acid|salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days
75340257|NCT05204238|Diagnostic Test|Transthoracic Echocardiography|LV dimensions, LV mass and indices of LV function LA area and volume Indices of diastolic function (E/A ratio, E/e' ratio) Heart valve assessment according to GL RV dimensions and indices of RV function PAPs (RV-RA gradient and vena cava dimensions and collapsibility) B-lines at lung ultrasounds (comet lung score) Speckle Tracking analysis of LV (GLS), LA (PALS) and RV (LS of free wall) Optional 3D analysis of left and right ventricle
75650298|NCT00769951|Procedure|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
75340258|NCT01657032|Dietary Supplement|Smectite|Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
75340259|NCT01657032|Dietary Supplement|Placebo|Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
75340260|NCT01657032|Dietary Supplement|Lactobacillus GG|All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
75340261|NCT05202912|Drug|IDX-1197(After a meal)|randomized, open-label, single-dose, 2-period, 2-sequence crossover study in healthy male Korean and Caucasian volunteers
75650299|NCT00769951|Procedure|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
75650300|NCT00770107|Drug|Thiamine|Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
75650301|NCT00770107|Drug|Placebo|Placebo, once daily, for a duration of 4 weeks
75650302|NCT00774241|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
75935453|NCT02446652|Drug|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
75340262|NCT05202912|Drug|IDX-1197(fasting)|open-label, single-dose study in Chinese male volunteers
75340263|NCT05292690|Device|Powered Wheelchair Obstacle Alerting System|Evaluation of an Obstacle Alerting System
75474313|NCT01982071|Drug|Micafungin|Intravenous (IV)
75650303|NCT00774241|Drug|docetaxel|75mg/m2 every 3 weeks for 18 weeks
75650304|NCT00774319|Radiation|conventional radiotherapy with 'high' dose cisplatin|"radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43"
75650305|NCT00774319|Radiation|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
75650306|NCT00881751|Biological|bevacizumab|Given IV
75935454|NCT02446652|Drug|Placebo|Placebo (orally) starting 1 week before the first day of the QT
75650307|NCT00881751|Drug|erlotinib hydrochloride|Given orally
75650308|NCT00881751|Drug|sorafenib tosylate|Given orally
75650309|NCT02634255|Drug|Rocuronium elective surgery|Rocuronium onset time in patients undergoing inguinal herniorrhaphy
75935455|NCT02446652|Drug|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
75935456|NCT02446652|Drug|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
75650310|NCT02634255|Drug|Rocuronium emergency surgery|Rocuronium onset time in patients undergoing appendectomy
75650311|NCT02634255|Drug|Propofol|
75935457|NCT05068427|Drug|Chidamide|20mg or 30mg orally twice per week(BIW)
76087938|NCT04931628|Drug|0.9% NaCl|0.9% NaCl
76087939|NCT02262130|Drug|Omalizumab|
75650312|NCT02634255|Drug|Fentanyl|
75797512|NCT01159236|Drug|Bevacizumab|10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
75797513|NCT01267344|Drug|gemcitabine, oxaliplatin|GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
76087940|NCT02578342|Device|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
76087941|NCT02476188|Procedure|Sample of Blood|
76087942|NCT01778296|Device|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
76087943|NCT04887870|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
75797514|NCT01267344|Drug|cetuximab, gemcitabine, oxaliplatin|E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
75797515|NCT01159314|Procedure|Baerveldt Device surgical Procedure|Implant surgery
75797516|NCT03877302|Other|reflexology|foot reflexology
75340264|NCT05250648|Drug|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
76087944|NCT04887870|Drug|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
76087945|NCT04887870|Drug|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
75340265|NCT05250648|Procedure|complete cytoreductive surgery without HIPEC|in the arm without HIPEC, only complete cytoreductive surgery will be performed
75340266|NCT00382148|Drug|omalizumab|SC repeating dose
75650313|NCT02634255|Other|Ringer Lactate|
75650314|NCT02634255|Device|Acceleromyography device|
75650315|NCT04161651|Device|eversense|eversense CGM
75340267|NCT02111252|Drug|TAK-850|TAK-850 injection
75340268|NCT05292066|Drug|Duloxetine Tablets,|"Duloxetine is an FDA-approved medication used to treat the major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. It is taken by mouth. It is a serotonin-norepinephrine reuptake inhibitor.~Pregabalin is an FDA approved, sold under the brand name Lyrica. it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,"
75797517|NCT03875976|Procedure|Fast Track Protocol|Fast Track Care consists in educational preoperative preparation for patients, particular strategies for controlling pain and intensive early rehabilitation protocol
75650316|NCT02634021|Drug|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
75650317|NCT02634021|Drug|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
75650318|NCT02634099|Device|blood measurement|Hemoglobin measurement
75650319|NCT02634099|Device|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
75797518|NCT03875976|Procedure|Standard Care Protocol|Standard Care Protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol
75797519|NCT04997226|Device|tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 1 and 3.
75797520|NCT04997226|Device|Sham tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 2 and 4.
75340269|NCT05292066|Drug|Pregabalin Tablets|Pregabalin is an FDA approved, it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
75650320|NCT02634099|Device|hemoCue|non invasive method of hemoglobin measurement
75650321|NCT04161729|Drug|Magnesium Sulfate|Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
75797521|NCT03879564|Drug|Ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
75797522|NCT03879564|Drug|Normal saline|NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
75935458|NCT05068427|Drug|Envafolimab|400mg subcutaneous infusions every 4 weeks
75935459|NCT00299715|Drug|Paliperidone extended-release|
75935460|NCT05193695|Other|Treadmill exercise|the patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002)
75935461|NCT00299325|Drug|Rimonabant|Tablet, oral administration
75935462|NCT00299325|Drug|Placebo (for Rimonabant)|Tablet, oral administration
75340270|NCT04270994|Drug|Misoprostol|
75474314|NCT01982097|Drug|Sorafenib (Nexavar, BAY 43-9006)|The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
75650322|NCT04161729|Drug|Isotonic saline 0.9%|Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
75650323|NCT04161573|Behavioral|Watching ironic stories|All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
75650324|NCT04161339|Drug|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
75650325|NCT04161339|Drug|Placebo oral tablet|Amido pills/daily for 8 weeks
75650326|NCT00934856|Drug|Docetaxel|Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics [SmPC]).
75650327|NCT00934856|Drug|Pertuzumab|Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
75650328|NCT00934856|Drug|Trastuzumab emtansine|T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
75650329|NCT00934700|Other|Xenon gas|30% Xenon gas inhaled for 24 hours
75797523|NCT01581840|Drug|radiochemotherapy|Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
75797524|NCT01581840|Drug|Panitumumab|3 or 6 mg/kg (according to dose level)
75797525|NCT01161264|Biological|Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011|Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
75935463|NCT00299325|Other|Mild hypocaloric diet|Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
76087946|NCT04887870|Drug|Enfortumab Vedotin-Ejfv|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
76087947|NCT04887870|Drug|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
75340271|NCT05495490|Procedure|Osseodensification Internal Sinus Lift|"The osteotomy for the Osseodensification internal sinus lift begins with the advancement of a twist drill at 800 rpm and saline irrigation to within 1-2 mm of the sinus floor. The osteotomy is then widened by employing a series of osteotomy drills rotating at 800 rpm. Infracture of the sinus has occurred when the final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation (haptic feedback) occurs. After infracture, the graft material will be injected into the osteotomy site. Using the final osteotomy drill, the graft is guided apically. This procedure is repeated incrementally to raise the membrane. Once sufficient space has been created beneath the antral membrane, the implant will be inserted followed by suturing."
75797526|NCT03879486|Other|Intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy|The examiner will use a gauze soaked and saturated with iodopovidone and perform a mechanical friction motion on the anterior wall of the rectum, at least 5 times from one margin to another of the prostate laterally-laterally. A period of two (2) minutes shall be waited from the prophylactic cleaning of the rectum to the beginning of the biopsy. The examiner will use a technique of disinfecting the 10% formaldehyde biopsy needle without manual contact by soaking the distal 3 cm of the needle directly into a vial containing the bactericidal solution between obtaining the different fragments. An individual bottle will be used for each patient
75797527|NCT01163838|Biological|Placebo|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
75797528|NCT01163838|Biological|1 mg/kg every 2 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
75797529|NCT01163838|Biological|2 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
75340272|NCT05495490|Procedure|Osteotome Internal Sinus Lift|"The osteotomy for the Osteotome internal sinus lift will begin with standard drills and saline irrigation to prepare the implant socket with a working length that is 1-2 mm shorter than the residual bone height as determined by radiographic examination. After preparation, a series of osteotomes of varying diameters will be sequentially utilized to widen the osteotomy and elevate the Schneiderian membrane by vertical tapping to create a greenstick fracture. The Valsalva maneuver (nasal blowing test) will be performed to determine the integrity of the Schneiderian membrane. During the osteotomy, the graft material will be injected and slowly placed into the elevated space using osteotomes until the desired depth is reached. Implant placement and suturing will conclude the procedure."
75340273|NCT05291832|Other|Brain.fm Music|Experimental arm
75650330|NCT05369624|Other|Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)|"The strength training program included upper and lower limb exercises, initially with no weights but progressively adding weights once a week depending on symptoms, in 2 sets with 6-8 repetitions, for at least 5 days a week. The exercises recommended were the 'hanger' (which exercises the latissimus dorsi muscle), 'butterfly' (pectoralis major muscle), 'neck press' (triceps brachii and deltoids), leg flexion (biceps femoris and gastrocnemius) and leg extension (quadriceps femoris).~As resistance training, patients could choose between walking or cycling 3 to 5 days per week, for at least 20 minutes, increasing the duration of the exercise weekly, depending on their symptoms"
75650331|NCT00930176|Biological|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
75650332|NCT04263116|Procedure|Balloon Assisted Maturation|Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
75650333|NCT05171270|Other|Questionnaire|PsAID questionnaire
75650334|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
75340274|NCT05291832|Other|Spectrally-matched Noise|Active control arm
75340275|NCT02111798|Drug|Placebo|Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.
75340276|NCT02111798|Drug|Bupropion XL|Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.
75474315|NCT01982110|Behavioral|Mindfulness based smoking cessation|Mindfulness based interventions are provided via a mobile phone application.
75650335|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
75797530|NCT01163838|Biological|4 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
75797531|NCT01163838|Biological|4 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
75797532|NCT01163838|Biological|8 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
75474316|NCT01982110|Behavioral|Behavioral Smoking Cessation intervention|Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
75474317|NCT01982136|Procedure|end-to-end urethroplasty|
75474318|NCT01982136|Procedure|substitution urethroplasty (buccal mucosa)|
75474319|NCT01982136|Procedure|substitution urethroplasty (pedicled skin flap)|
75474320|NCT01982149|Genetic|Group 1|Perform gene expression studies of airway epithelium to correlate findings in the gene expression of nasal bronchial epithelium
75650336|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
75650337|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
75650338|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
75650339|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of Placebo IV
75650340|NCT00778141|Drug|metformin HC1 750 mg extended-release tablets|
75650341|NCT00778219|Device|devices for tracheal intubation|tracheal intubation by laryngoscope or lightwand
75650342|NCT00774475|Drug|comparison of different dosage of clopidogrel|clopidogrel 75 mg/day versus clopidogrel 150 mg/day
75650343|NCT00774475|Drug|doubled therapy|clopidogrel 150 mg/day
75650344|NCT00669331|Drug|Inhaled mannitol|400mg dose of Mannitol BD (twice a day) for 52 weeks
75340277|NCT02111798|Behavioral|Abstinence Initiation|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.
75797533|NCT01163838|Biological|12 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
75797534|NCT01269294|Drug|TMC435|2 capsules of 75 mg once daily for 7 days in Treatment A
75797535|NCT01269294|Drug|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment C
75474321|NCT01982149|Genetic|Group 2|Correlate gene expression data from nasal and bronchial epithelium
75474322|NCT01982149|Genetic|Group 3|Correlated nasal epithelial gene expression with the ultimate diagnosis (by biopsy or surgery)
75474323|NCT01982201|Drug|Lesinurad 400 mg|
75340278|NCT02111798|Behavioral|Relapse Prevention|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.
75474324|NCT01982201|Drug|Tums 500 mg and 750 mg|
75650345|NCT00669331|Drug|Matched control|50mg dose of Mannitol BD (twice a day) for 52 weeks
75650346|NCT00932126|Drug|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
75650347|NCT00778297|Biological|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
75650348|NCT00778297|Biological|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
75650349|NCT05156216|Other|Patient education|Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
75797536|NCT01269294|Drug|TMC435|2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
75797537|NCT01269294|Drug|Placebo for TMC435|2 placebo capsules once daily for 7 days in Treatment A
75797538|NCT01269294|Drug|Moxifloxacin|1 tablet of 400 mg on Day 7 of Treatment C
75797539|NCT01269294|Drug|Placebo for moxifloxacin|1 placebo tablet on Day 7 of Treatments A, B and D
75797540|NCT01269294|Drug|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment D
75474325|NCT01982201|Drug|MINTOX 10 mL|
75797541|NCT03876210|Combination Product|PK101|PK101-001 + PK101-002 (combination)
75797542|NCT03876210|Drug|PK101-001, PK101-002|coadministration
75797543|NCT03875898|Other|150 g bread fortified (15 g mix fibre)|Daily consumption of 150g of a bread fortified in fibre mix (15g) during eight weeks.
75340279|NCT05145140|Drug|Standardized Western Medicine Treatment|Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
75474326|NCT01982214|Device|sedentary|No intervention
75650350|NCT00779233|Drug|Zidovudine tablets 300 mg|
75474327|NCT01982214|Device|Vibration|Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
75474328|NCT01982227|Drug|indocyanine green|intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
75474329|NCT01982266|Device|GRADION™ Hip Total Cartilage Replacement (TCR)™|
75474330|NCT01982305|Procedure|Simulator|Axillary nerve anatomy lecture plus training with the simulator.
75474331|NCT01982305|Procedure|Cadaver|Axillary nerve anatomy lecture plus training with the cadaver model.
75474332|NCT01982318|Drug|VitroGro® ECM|
75474333|NCT01982318|Drug|Dulbecco's Phosphate Buffered Saline|
75474334|NCT01982344|Device|mini-exchange-room|
75474335|NCT01982396|Drug|ABC Twice Daily|
75474336|NCT01982396|Drug|ABC Once Daily|
75474337|NCT01982396|Drug|3TC Once Daily|
75474338|NCT01982396|Drug|3TC Twice Daily|
75474339|NCT01982409|Biological|Live Attenuated Varicella Vaccine|
75474340|NCT01982422|Behavioral|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
75474341|NCT01982422|Behavioral|Standard of Care|Normal standard-of-care for pregnancy.
75474342|NCT01982461|Drug|Rosuvastatin|10mg,once daily
75474343|NCT01982461|Drug|Crestor®|10mg,once daily
75650351|NCT04265300|Dietary Supplement|Creative Roots|The Creative Roots beverage is a coconut water-based drink with three flavors Mixed Berry, Watermelon Lemonade, and Peach Mango. The ingredients are as follows and are the same for all three flavors: water, coconut water concentrate, citric acid, stevia leaf extract, natural flavor, rosemary extract (to preserve flavor). Contains: coconut
75797544|NCT03875898|Other|150 g unfortified bread|Daily consumption of 150g of an usual bread in fibre-unfortified bread during eight weeks
75797545|NCT01163994|Drug|ceftriaxone|intravenously, 2 g, qd, 15 days
75797546|NCT01163994|Drug|doxycycline|orally, 100 mg, bid, 15 days
75797547|NCT01163994|Other|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
75797548|NCT01267578|Biological|vaccination|Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
75797549|NCT03874728|Other|Minimal shoes|A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.
75797550|NCT03874728|Other|Standardised conventional shoes|The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.
75797551|NCT03874728|Other|Barefoot|Participants will conduct the assessments barefoot.
75797552|NCT03874728|Other|"Smart shoe insoles"|Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.
75797553|NCT01161576|Biological|AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies|The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.
75797554|NCT01161576|Biological|AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies|The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
75340280|NCT05145140|Drug|Tangningtongluo tablet and cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.There are two dosage forms: tablet and cream.
75340281|NCT05145140|Drug|Tangningtongluo tablet|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use tablet.
75935464|NCT02446808|Device|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
75340282|NCT05145140|Drug|Tangningtongluo cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use cream.
75935465|NCT00391209|Drug|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
75935466|NCT00391209|Drug|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
75340283|NCT05290662|Drug|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
75340284|NCT05290662|Drug|Cyclophosphamide/Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
75650352|NCT00607178|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
75650353|NCT00607178|Biological|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
75340285|NCT05143502|Drug|Montelukast|"Montelukast is a leukotrienes antagonist which has proven efficacious in chronic inflammatory conditions of the airways, including allergic rhinitis, asthma, and aspirin-exacerbated respiratory disease (AERD), all diseases that often coexist with CRSwNP.~We will use oral Montelukast (montelukast 10 mg, once a day) for 3 monthes"
75340286|NCT05143502|Drug|Prednisolone|Oral Prednisolone 40 mg/day for two weeks.
75340287|NCT05143502|Drug|Fluticasone Furoate|fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily
75650354|NCT00778453|Other|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
75650355|NCT00778453|Other|Hospital-based BIT|bilateral symmetric, repetitive arm training
75650356|NCT00778453|Other|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
75797555|NCT01267734|Device|Everolimus-eluting coronary stenting system (EECSS, Promus Element)|Everolimus-eluting stent
75797556|NCT01267734|Device|Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)|Zotarolimus-eluting stent
75797557|NCT01267734|Drug|Triple anti-platelet therapy (TAT)|100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
75935467|NCT02446574|Drug|Paclitaxel|starting dose 20mg/m2 qw
75935468|NCT02446574|Drug|Cisplatin|dose 25mg/m2 qw
75935469|NCT02446574|Radiation|Radiation|60Gy/2Gy/30f
76087948|NCT02476344|Other|experiment protocol|"each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~sack carrying exercise.~crawling exercise.~combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously."
75474344|NCT01982474|Biological|Grass pollen extract|Grass pollen extract injected intralymphatically q 4 weeks x 3
75474345|NCT01982474|Other|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
75474346|NCT01982487|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
75474347|NCT01982487|Drug|IDO1 inhibitor INCB024360|Given PO
75474348|NCT01982487|Other|laboratory biomarker analysis|Correlative studies
75474349|NCT01982487|Other|pharmacological study|Correlative studies
75650357|NCT00778453|Other|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
75650358|NCT00778453|Other|Home-based BAT|bilateral symmetric, repetitive arm training
75650359|NCT00778453|Other|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
75650360|NCT02556463|Drug|MEDI9197|Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
75650361|NCT02556463|Biological|durvalumab|Subjects will receive durvalumab every 4 weeks
75340288|NCT05247840|Diagnostic Test|uroflowmetry|Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.
75797558|NCT01267734|Drug|Double-dose clopidogrel anti-platelet therapy (DDAT)|100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
75340289|NCT05247840|Diagnostic Test|Cardiovascular autonomic dysfunction test proposed by Ewing et al.|CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.
75340290|NCT05247840|Diagnostic Test|peripheral nerve conduction test|Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.
75650362|NCT00779389|Drug|Erlotinib|Erlotinib 150mg will be taken once a day for 14-21days.
75650363|NCT00779389|Drug|Dasatinib + Placebo|Dasatinib (100 mg) once a day for 14-21 days.
75650364|NCT00779389|Drug|Erlotinib plus Dasatinib|Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
75650365|NCT00779389|Drug|Placebo|Placebo for 14-21 days.
75650366|NCT00779389|Drug|Erlotinib|Erlotinib 150 mg for 14-21 days.
75797559|NCT01268748|Procedure|Conventional laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports
75797560|NCT01268748|Procedure|Experimental laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
75797561|NCT01164306|Behavioral|LifeSkills Training|"LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.~Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions."
75797562|NCT01164306|Behavioral|Healthy Lifestyle Behavior Choices|"The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.~Parents will also be given health related information by mail to parallel the information students receive in school health classes."
75797563|NCT01164306|Behavioral|NRT and Motivational Interviewing (MI)|For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
75797564|NCT01269450|Drug|micronized progesterone 200 mg (Utrogestan)|micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
75935470|NCT01775813|Drug|Metformin|After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
75935471|NCT01775813|Drug|Placebo|Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
75935472|NCT00287547|Drug|CTLA4Ig / Abatacept|
75650367|NCT00778609|Drug|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
75650368|NCT00778609|Drug|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
75650369|NCT05357534|Other|Physical activity|Physical activity: 10 km run on a treadmill
75650370|NCT00774553|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
75650371|NCT00774553|Drug|Placebo|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
75797565|NCT01269450|Drug|placebo|placebo 200mg vaginal tablets
75936618|NCT03184220|Procedure|Physiotherapy treatment|"The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~Suboccipital induction~Posterior elongation of the cervical fascia in Supine position~Assisted cervical fascia~Myofascial induction of sternocleidomastoid"
75340291|NCT00382928|Device|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
75340292|NCT05290116|Drug|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD."
75797566|NCT01269528|Other|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
75650372|NCT00774631|Procedure|Mild induced hypothermia (32-34°C)|"Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 [6, 48]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods."
75650373|NCT00774631|Procedure|local recommendations and guidelines|"Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours."
75935473|NCT03204344|Dietary Supplement|Oral carbohydrate (Outfast)|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above."
75340293|NCT00409292|Drug|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
75650374|NCT00778765|Drug|400 mg Gabapentin Capsules|
75797567|NCT01269528|Other|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
75797568|NCT01269528|Other|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
75935474|NCT03204344|Other|Routine fasting|"For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary."
75935475|NCT02285517|Procedure|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
75340294|NCT05246046|Drug|Tiotropium Bromide Monohydrate|In each period, subjects receive single dose of tiotropium consisting of 2 inhaled doses via Easyhaler or 2 Spiriva capsules inhaled via HandiHaler
75340295|NCT00383942|Drug|Misoprostol|Misoprostol,25 micrograms every 4 hours.
75650375|NCT00774865|Procedure|MIBI and CTA|Rest and Stress MIBI and CT Angiography
75650376|NCT00774943|Drug|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
75650377|NCT02556151|Procedure|Repetitive lumbosacral magnetic stimulation (rTLSMS)|Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
75650378|NCT00779935|Biological|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
75797569|NCT01269528|Other|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
75340296|NCT00383942|Device|Catheter|A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
75340297|NCT05482308|Drug|Tafamidis free acid tablet (Test)|Variant 12.2 mg tafamidis free acid tablet (Test)
75650379|NCT03873181|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.
75650380|NCT00780013|Drug|metformin hydrochloride liquid 500 mg per 5 mL|
76087949|NCT05665452|Procedure|Patellar mobilization, retinacula release, deep friction message, stretch and strength|"All exercises will be performed for 30 to 45 minutes per session, 3 times per week for 4 weeks (12 sessions). Group (1): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise).~Group (2): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise). manual therapy consists from iliotibial band release, deep friction message for lateral retinacula and medial patella mobilization."
75797570|NCT01269528|Other|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
75797571|NCT01164384|Drug|Baminercept|
75797572|NCT03877146|Behavioral|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).
75797573|NCT01164930|Behavioral|Acceptance and Commitment Therapy|8-week ACT group
75797574|NCT01167036|Device|FascialEdge instrument|Stroking massage to patient tolerance over the muscle
76087950|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
76087951|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
76087952|NCT01828216|Device|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
76087953|NCT01828216|Device|conventional polysomnography|conventional type I sleep study according to international guidelines
75650381|NCT00778843|Dietary Supplement|Viusid|Viusid, three oral sachets daily during 24 weeks
75797575|NCT01167036|Other|Placebo electric point stimulation|Detuned electric point stimulation over the involved muscle
75935476|NCT02285517|Procedure|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
75935477|NCT03204578|Drug|AB (Midazolam OD formulation/Dormicum)|Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
75935478|NCT03204578|Drug|BA (Dormicum/Midazolam OD formulation)|Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
75935479|NCT02285595|Device|Sonendo GentleWave™ System|
75935480|NCT01694069|Drug|Piperacillin-tazobactam combination product|400 mg/kg/day as either intermittent or continuous infusion
76087954|NCT01780324|Drug|Lidocaine|Intervention - intraurethral lidocaine
75340298|NCT05482308|Drug|Tafamidis free acid tablet (Reference)|Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)
75935481|NCT03204500|Combination Product|Active treatment with dual therapy|Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
75340299|NCT05196672|Behavioral|Virtual reality and eye mask|Adults will receive a virtual reality program 30 min before bedtime and then be placed on an eye mask during their sleep for consecutive 2 nights of ICU stay.
75340300|NCT05288400|Combination Product|Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg|1 capsule/day Oral administration
75340301|NCT05288400|Drug|Norvasc 5mg tablet|Norvasc (amlodipine) 5mg, 1 tablet/day
75340302|NCT05288400|Drug|Concor 5mg tablet|Concor (bisoprolol fumarate) 5mg, 1 tablet/day
75340303|NCT05288400|Drug|Coversyl 5mg tablet|Coversyl (perindopril arginine) 5mg, 1 tablet/day
75797576|NCT01268904|Drug|Valproate|Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
75650382|NCT00778843|Other|Placebo|Placebo three oral sachets daily during 24 weeks
75650383|NCT00780091|Other|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
75650384|NCT00780091|Other|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
75650385|NCT00667225|Drug|cantharidin's vehicle|Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
75650386|NCT00667225|Drug|Cantharidin 0.7%|Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
75797577|NCT01269606|Drug|insulin aspart|At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
75935482|NCT03204500|Drug|Placebos|Administered orally under the same conditions
75935483|NCT02449616|Drug|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
75797578|NCT01269606|Drug|insulin human|At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
75797579|NCT01269606|Drug|insulin aspart|At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
75935484|NCT02285673|Biological|Umbilical Cord Mesenchymal Stem Cell|
75935485|NCT03204032|Drug|Tegafur|Tegafur 40-60mg po bid(d1-d14);
75935486|NCT03204032|Drug|Temozolomide|200mg po qd(d10-d14)
75935487|NCT03204032|Drug|Thalidomide|Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
75935488|NCT01445327|Other|Specimen collection|
75650387|NCT00784381|Device|computer-assisted counselling about target drugs|implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
75935489|NCT02285751|Drug|acetylsalicylic acid|
76087955|NCT02989792|Genetic|Blood sampling for genotyping|Venous punction of maximum 10 millilitres
75650388|NCT02556541|Procedure|IV puncture guided by ultrasound|
75650389|NCT00784537|Drug|ABVD|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)"
75650390|NCT00784537|Drug|ABVD and Radiotherapy|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk)."
75650391|NCT00780169|Drug|sorafenib + FOLFIRI|"escalating doses of sorafenib and irinotecan~sorafenib starting dose 400 mg/day~irinotecan starting dose 80 mg/m2 on day 1"
75935490|NCT02285751|Drug|clopidogrel|
76087956|NCT02989792|Other|Personality Questionnaires completion|Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
76087957|NCT02476266|Other|Resistance Training|Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
76087958|NCT01780870|Dietary Supplement|Weight loss group (Full meal replacement products)|In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
76087959|NCT02472600|Drug|Colistin|
76087960|NCT02472600|Drug|Neomycin|
76087961|NCT02472600|Drug|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
76087962|NCT02472600|Drug|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
76087963|NCT01781806|Drug|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to <50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl <30 mL/min, Truvada will be discontinued.
76087964|NCT05315076|Other|thoracic Manipulation Posterior anterior and conventional therapy|A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.
76087965|NCT05315076|Other|Muscle Energy Technique (PIR) and conventional treatment|sustain the Isometric contraction for 7-10 and hold the breath. Then the patient will be asked to breathe out and relax while the therapist stretches further up to the neck barrier and hold this for 30 seconds.3 to 5 repetition
75935491|NCT02285751|Drug|prasugrel|
75935492|NCT02285751|Drug|ticagrelor|
75935493|NCT02446184|Procedure|Fetal Cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
76087966|NCT04769284|Other|Mental health student|"An ad-hoc questionnaire was designed that included sociodemographic variables related to the characteristics of the students. The variables sex, age, degree, employment situation, coexistence situation, economic situation, origin environment, country of origin, time of residence in the Spanish State were collected.~Personal variables:~Gender stereotypes: Short version of the Bem Sex Rol Inventory (BRSI).~International Physical Activity Questionnaire (IPAQ)~Abbreviated Goldberg Anxiety Scale EADG~Modified version of EPP-10 related to COVID-19 (EPP-10-C)"
76087967|NCT04844892|Device|Lungpacer PROTECT Diaphragm Pacing Therapy|PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
76087968|NCT02477592|Procedure|individualized substrate modification|CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.
75797580|NCT01269606|Drug|insulin human|At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
75797581|NCT03875430|Dietary Supplement|Humulus lupulus L|Patients with this intervention will receive a dietary supplement to relieve the symptoms of menopause
75935494|NCT02446184|Procedure|Fetal vesicoamniotic shunt|Fetal vesicoamniotic shunt will be performed under ultrasound guidance
75935495|NCT03532113|Behavioral|Updating|Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.
75340304|NCT05193864|Device|Device: JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
75650392|NCT00789841|Device|Magnetic Tracking System (MTS) and radio-opaque markers|MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
75340305|NCT00454532|Drug|BZL101|Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.
75474350|NCT01982513|Device|Ultrasound|The IVC will be visualized and images obtained using the intercostal window in both longitudinal and transverse planes.
75340306|NCT05193630|Dietary Supplement|Milnutri Sure™|"Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water."
75650393|NCT00780325|Drug|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
75650394|NCT00780325|Drug|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
75650395|NCT00780325|Drug|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
75650396|NCT00780325|Drug|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
75340307|NCT01796600|Device|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner|
75340308|NCT05474040|Drug|Morphine versus multimodal analgesia for post elective craniotomy pain|To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
75474351|NCT01982565|Device|NOx dressing|The NOx dressing should be changed at least every 2 days.
75650397|NCT00780325|Drug|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
75650398|NCT00780325|Drug|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
75650399|NCT02556229|Drug|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
75474352|NCT01982565|Other|Standard of Care|The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
75650400|NCT00929864|Drug|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
75797582|NCT03875742|Device|Ultraplex 360(Braun)|"This group will use as first needle the ultraplex 360 (Braun)"
75797583|NCT03875742|Device|STIMUPLEX D SH, 30°(Braun)|"This group will use as first needle the  STIMUPLEX D SH, 30° (Braun)"
75935496|NCT03532113|Behavioral|Inhibition|Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.
75474353|NCT01982578|Dietary Supplement|Genistein|Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.
75474354|NCT01982578|Other|Placebo|360 days of double blind treatment of placebo.
75474355|NCT01982591|Other|laboratory biomarker analysis|Correlative studies
75650401|NCT00929864|Drug|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
75797584|NCT01268982|Procedure|socket preservation|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket
75797585|NCT03875352|Procedure|CHG technique|The CHG technique includes treatment using dressing with chlorhexidine.
75797586|NCT03875352|Procedure|HMG technique|The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.
75797587|NCT03872232|Drug|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
75650402|NCT00597753|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
75797588|NCT03872232|Drug|Telmisartan|PO, Once daily(QD), 8weeks
75935497|NCT03532113|Behavioral|General knowledge|General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
75935498|NCT02449694|Device|OCS Liver|OCS Liver will be used to preserve the donor liver
75935499|NCT02446730|Device|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
75935500|NCT02446730|Drug|Prasugel|
75935501|NCT02446730|Drug|Clopidogrel|
75935502|NCT03198806|Other|Treadmill aerobic exercise in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
75935503|NCT03198806|Other|Treadmill aerobic exercise and water intake in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
75935504|NCT03198806|Other|Treadmill aerobic exercise in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
75340309|NCT05245422|Other|Infant Formula - Partially hydrolyzed protein|Partially hydrolyzed cow's milk protein
75340310|NCT05245422|Other|Infant Formula - Intact protein|Intact cow's milk protein
75935505|NCT03198806|Other|Treadmill aerobic exercise and water intake in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
75797589|NCT03872076|Other|Experimental|"The Drom Jump technique with the legs flexed will be performed with the patient standing in front of a bench 30 cm high by 100 cm wide. The physiotherapist will be placed lateral to the athlete. The subject will be asked to jump up from the box or bench, with the hip and knees in semi-reflexion, with his hands on his hip and he will be asked for an explosive jump, followed by a jump downwards falling the floor of the same way.~The technique of lateral jumps on cones will be carried out by means of unipodal jumps, achieving a distance of 50 cm between cones. The physiotherapist will stand in front of the athlete. The subject will be asked to perform a lateral unipodal explosive jump by flexing the hip and knee."
75797590|NCT03872076|Other|Control|"Elastic bands will be combined with isometric exercises in 3 sets of 10 repetitions each. The exercises they will perform are front squat. On the one hand, separating the legs at the height of the shoulders with hip and knee flexion, with the elastic band above the knees, maintaining the position 20 seconds.~In the following exercise, with the elastic band on the ankle, in unipodal support at the same time that the contralateral limb is free of support, the hip will be flexed at 45º with full knee extension, requesting the athlete to keep the tension 20 seconds, performing 3 sets of 10 repetitions."
75797591|NCT01280214|Drug|Triamcinolone|Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
75797592|NCT01165008|Drug|Anakinra|
75797593|NCT01280292|Drug|Eltroxin|Eltroxin dosage titration according to free T4 measurement every 3 months
75797594|NCT03871842|Device|active tDCS|Considering that the daily outpatient use of tDCS equipment is not feasible for most patients, the Pain and Neuromodulation group of the Hospital de Clínicas de Porto Alegre developed a portable tDCS device for home use that has a safe protocol, in addition of being easy to use so that the patient can use it at home without help. The safety protocol embedded in the device does not, for example, allow the appliance to be used for more than 20 minutes per day. The device can also provide the assisting staff with data such as the time the patient used the equipment, providing an accurate picture of the patient's adherence to this type of equipment. This tDCS equipment for home use has already been validated in a pilot study and will be used in this work.
75935506|NCT03194828|Behavioral|Medication reminder|Using the real-time data capture of the electronic device, an automated voice call or text message will be sent to active arm participants only when a missed dose is determined
75935507|NCT03194828|Behavioral|Medication monitoring only|Patients will use an electronic medication monitoring device to record their actual medication use
75935508|NCT05114915|Drug|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion
75935509|NCT03532035|Drug|Brincidofovir|Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
76087969|NCT02477592|Procedure|stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
76087970|NCT02477514|Drug|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
76087971|NCT02477514|Drug|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
76087972|NCT02477514|Drug|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
75340311|NCT00410150|Drug|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
75340312|NCT00410150|Drug|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
75340313|NCT01796678|Drug|Arginine|
75340314|NCT01796678|Drug|Placebo|Saline or Sugar pill was given as placebo
75474356|NCT01982591|Other|questionnaire administration|Ancillary studies
75474357|NCT01982604|Drug|TI-Inhalation Powder A|Inhaled Insulin
75474358|NCT01982604|Drug|TI-Inhalation Powder B|Inhaled Insulin
75474359|NCT01982617|Other|Motivational Interviewing|
75650403|NCT00597753|Drug|Epoetin Alfa|Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
75797595|NCT03871842|Device|sham tDCS|The sham intervention will be applied exactly equal to active intervention, but the electric stimulus will last just for 30 seconds.
75650404|NCT04262804|Drug|Margetuximab|Margetuximab IV
75650405|NCT04262804|Drug|Trastuzumab|Trastuzumab IV
75340315|NCT05288322|Procedure|Mostafa Maged maneuver|"The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery . The Mostafa Maged technique is applied by :- (Description of the new Mostafa Maged technique) :-~First , placing our right hand to the posterior fornix of vaginal canal trying to cuddle the lower part of uterus compressing the anterior and posterior walls of the uterus .~Second , placing our left hand over the fundus of the uterus and the posterior wall of uterus from the abdominal part.~Third , by our two hands , trying to grasp the whole uterus by our two hands abdominally and vaginally against the symphysis pubis as if the uterus is cuddling the symphysis pubis bone and in this way , we try to get the anterior and posterior walls against each other and reducing the intra-cavitary space so we prevent the expansion of the uterus ."
75340316|NCT01796756|Other|Handover program|
75340317|NCT00385268|Drug|acamprosate|1998 mg/dau fpr 8 weeks
75650406|NCT04262804|Drug|Chosen Chemotherapy (Capecitabine)|Capecitabine tablet
75797596|NCT01164462|Biological|blood test: rapid finger-stick blood specimen test|
75797597|NCT01164462|Biological|blood test: conventional test|
75650407|NCT04262804|Drug|Chosen Chemotherapy (Vinorelbine )|Vinorelbine IV
75650408|NCT04262804|Drug|Chosen Chemotherapy (Gemcitabine )|Gemcitabine IV
75797598|NCT01164540|Drug|Rosuvastatin (AZD4522)|Oral dose (od) 20 mg
76087973|NCT01784848|Procedure|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
75340318|NCT00385268|Drug|placebo|placebo pills
75340319|NCT05287932|Behavioral|Brief physical activity intervention|See arm/group descriptions
75340320|NCT01657500|Other|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
75340321|NCT01657500|Other|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
75340322|NCT00411086|Biological|Rituximab|375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22.
75797599|NCT01164540|Drug|Placebo|Oral dose (od)
75340323|NCT00411086|Biological|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
75797600|NCT01269684|Drug|Everolimus|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
75797601|NCT01164618|Procedure|Remote ischemic preconditioning (RIPC)|RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
75797602|NCT01164618|Other|Exercise|Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
75340324|NCT05191524|Other|Constrained induced movement|Practice in two sessions per day (supervised) for 3 days per week, for six consecutive weeks. The unaffected limb will be constraint using a knee immobilizer only during practice sessions. We will perform the interventions under the supervision of a trained physiotherapist.
75797603|NCT01280370|Procedure|Abdominal surgery|intraoperative mesh implantation
75797604|NCT01165086|Other|Incorporating vegetables into the diet to reduce energy density|The entree portion of breakfast, lunch, and dinner meals will be manipulated to be a standard energy density, a 15% reduction in energy density, or a 25% reduction in energy density.
76087974|NCT01784848|Other|Clinical treatment|Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
76087975|NCT01753648|Device|Dynamic Vessel Analyzer|Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation
75340325|NCT05191524|Other|Proprioceptive Neuromuscular facilitation|Group B will receive PNF intervention given for 30 minutes to the lower limb 3 times a week for 6 weeks
75340326|NCT05190900|Other|neural mobilization|neural mobilisation of the posterior tibial, deep peroneal and lateral, intermediate and medial dorsocutaneous nerves.
75340327|NCT05190354|Device|Xtremity Polymer Prosthetic Socket|Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
75474360|NCT01982617|Other|Psychoeducation|
75650409|NCT00665431|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
75650410|NCT00665431|Drug|celebrex|200 mg celecoxib qd
75650411|NCT00665431|Other|Placebo|sugar pill bid
75650412|NCT00665431|Drug|Rescue Antacid|Antacid Tablets
75650413|NCT02633709|Drug|Itraconazole|Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
75650414|NCT02633709|Other|Placebo|In Part 1 of the study matching oral placebo will be administered once on Day 1.
75650415|NCT02633709|Drug|Risdiplam|Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
76087976|NCT01753648|Other|FDOCT|total retinal blood flow (together with DVA), retinal blood velocities
75340328|NCT05190198|Other|Proprioceptive neuromuscular facilitation|"Weight shifting in each direction (anteriorly, posteriorly, and lateral side) combined with side-to-side head movements (5 times for each direction).~One-legged stance with slight knee flexion of another leg for 15 seconds (5 times for each leg).~One-legged stance with increasing knee flexion of the other leg for 15 seconds (5 times for each leg).~Standing on a balance pad with shifting weight (anteriorly, posteriorly, and lateral side) 10 times in each direction.~In standing position, moving the weight left and right maximally.~In standing position, moving the weight forward and backward maximally.~In standing position, moving both heels of feet up and down.~In standing position, bending and stretching both knees by squatting as much as possible."
75340329|NCT05190198|Other|conventional therapy|"(Dorsiflexion, planter flexion, eversion and inversion) 10 repetitions for each movement.~(A) Sit to stand (5 times). (B) Standing with shifting Weight anteriorly, posteriorly, and sideway (5 times for each direction). (C) Functional reach sideway and anterior for touching targets set by the therapist (5 times for each direction). (D) Standing on heels for 20 seconds (5 times). (E) Standing on toes for 20 seconds (5 times).~(A) Spot marching (2 min). (B) Walking over the heels, toes, lateral border of feet with the preferred speed (6 min). (C) Tandem walking in a straight line (2 min)."
75340330|NCT01658904|Drug|Carfilzomib|
75340331|NCT01658904|Drug|Melphalan|
75340332|NCT01658904|Drug|Filgrastim|
75340333|NCT04235400|Diagnostic Test|No Dye BreakUp Time|Measurement without dye of the tear meniscus height (TMH) which give an rapid hint on the quantity of tears present on the ocular surface, the measure in real time of the tear osmolarity and, at last, the analysis of the thickness of the tear's layer by interferometry (measurement of the light fringes reflected by the tears when illuminated with polarized light, whereby the complete layer or the lipid layer alone can be evaluated separately depending on the machines used) and of the assessment of the quality of the Meibomian glands (non-contact imaging by infrared illumination).
75340334|NCT05238948|Drug|Midazolam|Substrate of CYP3A4
75474361|NCT01982656|Other|Massage|twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
75650416|NCT04265066|Diagnostic Test|microcirculation|measurement of microcirculation
75650417|NCT04264988|Procedure|Stopping of pelvic bleeding via several surgical methods|Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those
75650418|NCT00657033|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
75650419|NCT00657033|Drug|Placebo|Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
75797605|NCT03875196|Device|Pelvic Floor Muscle Training With Biofeedback|Biyofeedback: The Biyofeedback allows the patient to see the results of her behavior immediately By a perineometer device or electromyelography that is placed in the vagina, the patient sees how she hears the pelvic floor muscles, hears the sound or hears her voice, and detects how much she needs to contract.
75797606|NCT03875196|Device|Extracorporeal Magnetic Innervation|Extracorporeal Magnetic Innervation: The patients are seated in a special chair connected to an external power unit and a magnetic field generator inside with their clothes on. In order to coincide the spreading magnetic field with pelvic floor muscles, the urethral and anal sphincters, the perineum of the patients should be placed in the center of the chair. In this way, the perineum tissues are stimulated by emitted magnetic field waves. Thus no electrical current passes through the device to the patient's body and the patient is exposed to only the magnetic current.
75797607|NCT01165164|Other|FID 115958D (lubricant eye drop)|1 drop in each eye at bedtime
75797608|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
75935510|NCT03532035|Drug|Standard of Care|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin."
76087977|NCT01753648|Other|Ocular perfusion pressure|Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
75340335|NCT05238948|Drug|CKD-506|Perpetrator of CYP3A4
75340336|NCT05284578|Other|Self-compassionate writing intervention|Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
75474362|NCT01982669|Other|No Intervention|
75474363|NCT01982721|Device|Locking mechanism for prosthetic knee|
75474364|NCT01982734|Dietary Supplement|curcumin|80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals
75474365|NCT01982747|Drug|MGN-Placebo|
75474366|NCT01982747|Drug|Placebo-MGN|
75474367|NCT01982760|Drug|DDAVP|Patients Receiving DDAVP prior to operation
75474368|NCT01982799|Drug|Oral placebo|placebo
75474369|NCT01982799|Drug|Oral ibuprofen|Ibuprofen
75650420|NCT00784615|Procedure|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
75797609|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
75650421|NCT04263740|Procedure|Kinesio Taping|Taping for 3 days every week and two sessions of PT twice a week. The PI also instructed the patient to inform him if the tape gets off or become loose. KT was removed after 72 hours, and then reapplied after a few days rest to allow the skin to recover and to avoid skin irritation. The patient was instructed to refrain from getting the tape wet for 30 to 45 minutes after application to allow for better adherence. Patients were also instructed to be careful during dressing and undressing so the tape does not get caught with their clothes if the edges of the tape get slightly loose. No physical therapy treatment or taping was provided during the rest period except for the prescribed home exercise program. Patients in both groups received the same traditional physical therapy treatment two times a week.
75797610|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
76087978|NCT02472288|Device|Electroacupuncture (EA)|The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
76087979|NCT02472288|Device|Sham electroacupuncture|The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
76087980|NCT01746238|Drug|Bevacizumab|Intravenous infusion, every 2 weeks, 3 doses total
75474370|NCT01982799|Drug|oral naproxen|naproxen
75797611|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
75797612|NCT01164696|Drug|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Zevalin was administered according to the directives in the approved package leaflet.
75935511|NCT04950257|Device|digital CBT self-help including specific intervention elements to target worry and rumination.|The self-help app includes self-monitoring, psychoeducation and active self-help exercises. The self-monitoring includes daily mood ratings and an ecological momentary assessment option (MoodTracker) for more detailed analysis of mood, worry, activity and situational context. The digital self-help provides psychoeducation, tips, advice, exercises and training for each individual focused on reducing worry and rumination, using strategies from the proven rumination-focused CBT intervention. The app includes text, pictures, audio-recordings, animations, audio-exercises to practice (e.g., self-compassion, relaxation, concreteness exercises), and questionnaires with tailored feedback. The app is designed for iOS and Android use.
75797613|NCT03874650|Behavioral|Activity Planning Group|Participants in this group will receive 8 1-hour sessions of Behavioural Activation combined with select Goal Management Training strategies over the course of 8 weeks.
75797614|NCT03874650|Behavioral|Activity Engagement Group|Participants in this group will attend 8 1-hour sessions of various social activities such as board games and puzzles.
75797615|NCT03874650|Behavioral|Waitlist Group|Participants in this group will continue on their care as usual before being re-randomised into either the Activity Planning Group or Activity Engagement Group after 8 weeks.
75935512|NCT03531801|Other|Pressure algometry and mapping referred pain areas|The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
75935513|NCT03198182|Drug|Placebo|Specified dose on specified days
75935514|NCT03198182|Drug|BMS-986036|Specified dose on specified days
75797616|NCT01269060|Procedure|Single Incision Laparoscopic Surgery|Single Incision Laparoscopic Sigmoidectomy
75797617|NCT03874962|Other|Routine oral cleaning and professional oral care group|Besides routine oral cleaning was conducted by caregivers, professional oral care intervention was conducted by dental hygienists, and it included muscle massage, oral cleaning, and oral health education once a week.
75797618|NCT01164774|Drug|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
75797619|NCT01164774|Drug|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
76087981|NCT01746238|Drug|Doxorubicin|Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
75797620|NCT01269138|Drug|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
75797621|NCT01269138|Drug|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
75797622|NCT01269138|Drug|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
76087982|NCT01746238|Radiation|Radiation Therapy|Daily, Monday-Friday, for 6 weeks
76087983|NCT02476110|Dietary Supplement|Oral nutritive supplements|
76087984|NCT02472054|Drug|Alemtuzumab|
76087985|NCT02472054|Drug|Methyl Prednisolone (MP)|
76087986|NCT02472054|Drug|Cyclosporin A (CSA)|
75474371|NCT01982799|Drug|oral acetaminophen/hydrocodone + ibuprofen|vicodin/ibuprofen
75474372|NCT01982825|Behavioral|Online intervention arm|See online intervention arm
75474373|NCT01982825|Behavioral|Online control arm|See online control arm
75474374|NCT01982838|Procedure|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
75935515|NCT03531723|Other|Measuring the size of the 3rd ventricle by ultrasound|The surveillance of the clamping test is essentially clinical. No cerebral imaging is performed systematically in our service protocol.The study consisted of including ultrasound measurements during the usual weaning protocol of the service.All patients receiving a SEV withdrawal test will be included. Inclusion begins when the clinician in charge of the patient initiates the withdrawal test. The measurements will be performed blindly by a trained physician who does not participate in the patient's care. Four measurements will be made, with recording of ultrasound loops
75797623|NCT01269138|Drug|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
75935516|NCT05037071|Device|Upper body graduated compression sleeve|An over the counter light compression sleeve will be worn during game training
75650422|NCT04263740|Procedure|Traditional Physical therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
75935517|NCT03203798|Procedure|Training of pelvic floor muscles|The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
76087987|NCT01782898|Drug|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
75474375|NCT01982838|Procedure|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
75474376|NCT01982851|Procedure|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
75797624|NCT01269138|Drug|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
75797625|NCT03871920|Other|physical therapy treatment|any treatment chosen by treating physiotherapist
75797626|NCT03874572|Biological|Allogeneic adipose derived stem/stromal cells|Culture expanded allogeneic adipose derived stem/stromal cells
75474377|NCT01982851|Procedure|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
75650423|NCT02633319|Behavioral|Skilful Parenting|Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.
75797627|NCT02526810|Drug|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
76087988|NCT01782898|Drug|Placebo Comparator: .9 normal saline|Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
76087989|NCT02472132|Device|POC US|Use of point of care ultrasound in insertion of CVC
76087990|NCT02475876|Drug|Clindamycin|"Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose =12 mg/kg;~Cohort 3; No. Subjects = 5; Age >1-2 years; Dose =12 mg/kg.~Cohort 4; No. Subjects = 4; Age >2-6 years; Dose =12 mg/kg.~Cohort 5; No. Subjects = 4; Age >6-12 years; Dose =10 mg/kg.~Cohort 6; No. Subjects = 4; Age >12-16 years; Dose =10 mg/kg."
76087991|NCT02475876|Drug|trimethoprim-sulfamethoxazole|"Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:~Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.~Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose = 6 mg/kg.~Cohort 3; No. Subjects = 5; Age >1-2 years; Dose = 6 mg/kg.~Cohort 4; No. Subjects = 4; Age >2-6 years; Dose = 6 mg/kg.~Cohort 5; No. Subjects = 4; Age >6-12 years; Dose = 6 mg/kg.~Cohort 6; No. Subjects = 4; Age >12-16 years; Dose = 4 mg/kg."
76087992|NCT02472210|Drug|Botulinum Toxin|An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
76087993|NCT01831960|Drug|cortexolone 17α-propionate|
75340337|NCT05284578|Other|Expressive writing intervention|Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
75340338|NCT05284578|Other|Control writing task|Participants assigned to this condition were asked to engage in a neutral time management writing task.
75340339|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
75650424|NCT02633319|Other|Agrics|Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.
75935518|NCT03203798|Procedure|Hipopressive abdominal gymnastics|The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
75650425|NCT04262570|Device|Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)|Non-invasive transcutaneous imaging of molecular muscle components
76087994|NCT04825236|Other|MyVoice:CF|"Participants will be given access to MyVoice:CF, a web-based decision aid (DA). This tool includes information about fertility, genetics, parenting, pregnancy, and breastfeeding within the context of cystic fibrosis (CF). The tool includes interactive elements designed to give users the ability to assess and reflect on their own reproductive goals and experiences and promote self-efficacy to engage in shared decision-making with their CF and women's health providers.~Upon completion of use of the decision aid, a summary sheet is generated based on the user's interaction with the tool. This summary is supplied to the provider prior to the next appointment."
76087995|NCT04802148|Procedure|membrane guided regeneration|after tooth extraction, the socket was filled with membrane and graft (FDBA)
76087996|NCT04802148|Procedure|collagen plug|after tooth extraction, the socket was filled with collagen plug
75340340|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
75340341|NCT05489640|Other|No Intervention|No Intervention will be administered in this study.
75340342|NCT05185674|Other|Exposure: Coronavirus disease 2019 (COVID-19)|Having presented Coronavirus disease 2019 (COVID-19) and stay in the Intensive Care Unit
75340343|NCT05236530|Drug|Midazolam|Midazolam 2 mg (1 mL of 2 mg/mL oral solution) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
75340344|NCT05236530|Drug|Repaglinide|Repaglinide 0.5 mg (1 x 0.5 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
75340345|NCT05236530|Drug|Dextromethorphan|Dextromethorphan 15 mg (10 mL of 7.5 mg/5 mL syrup) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
75340346|NCT05236530|Drug|Metformin|Metformin 500 mg (1 x 500 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
75650426|NCT00784771|Behavioral|Hypnotherapeutic Olfactory Conditioning (HOC)|
75935519|NCT05724927|Behavioral|Animal assisted activity|The interviews consist of a total of six interviews, including an introduction, four studies, and a termination. Interviews will be held individually in each person's own room in the nursing home. Materials such as plastic aquarium, fish, fish food, fish food scales that will be given to the individuals during the interviews will be taken to the institution by the researchers before and will be given to the elderly individuals in the second interview.
75935520|NCT02446340|Drug|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
75935521|NCT02446340|Drug|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
76087997|NCT02475798|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
75340347|NCT05236530|Drug|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 4-probe cocktail co administered on the morning of Day 3.
75340348|NCT05236530|Combination Product|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
75340349|NCT05236530|Drug|Rosuvastatin|Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
75650427|NCT04161261|Procedure|Electrical Stimulation|To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
75650428|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
75650429|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
75650430|NCT00789919|Procedure|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
75650431|NCT04161105|Procedure|Dry needling|Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.
75650432|NCT00934622|Device|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
75650433|NCT00657111|Drug|CS-8958 formulated as dry powder|CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
75340350|NCT05236530|Drug|Dolutegravir|Dolutegravir 50 mg (1 x 50 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
75340351|NCT05236530|Drug|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 2-probe cocktail co administered on the morning of Day 3.
75935522|NCT04669379|Behavioral|EXPECT: Preoperative optimization of patient's expectations|Patients work through an online-tool (around 30 minutes). This preoperative intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the surgery-benefits and recovery process, giving information, and giving advice for coping resources.
75340352|NCT05236530|Combination Product|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
75650434|NCT00657111|Other|Placebo|placebo capsules containing 25 mg lactose
75650435|NCT04160871|Behavioral|Family Connections|Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.
75340353|NCT00455702|Drug|d-cycloserine|50mg dose d-cycloserine v placebo
75340354|NCT04388306|Other|Shoulder Performance Test- Functional Impairment Test-Head and Neck, Shoulder, Arm (FIT-HaNSA)|Participants were evaluated with all tests, respectively. To eliminate the fatigue factor, 5 minutes breaks were given after each test.
75650436|NCT04160871|Behavioral|Treatment As Usual|"The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation."
75650437|NCT02633475|Genetic|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
75935523|NCT03531567|Behavioral|Virtual Reality Mystic Isle Game|8 week virtual reality based exercise program
75935524|NCT03531567|Behavioral|Standard Home Exercise Program|8 week standard occupational therapy home exercise program
76087998|NCT01783054|Procedure|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
76087999|NCT01783054|Genetic|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
75650438|NCT04032405|Procedure|CAF+CTG+i-prf|combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
75650439|NCT04160637|Diagnostic Test|Immediate postoperative PTH serum sampling and cut-off value identification|The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.
75650440|NCT04160949|Other|No Intervention|There is no intervention for this study.
75650441|NCT04160403|Other|physical therapy intervention|NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
75650442|NCT02633007|Drug|CVT-301 (levodopa inhalation powder)|Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
76088000|NCT01783054|Drug|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
75650443|NCT02633007|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
75650444|NCT02633007|Other|Placebo|Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
75935525|NCT04797065|Procedure|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 2 minutes then in 3 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 2 minutes, then reentered the cecum and withdrawn to the splenic curvature in 3 minutes."
76088001|NCT02475642|Other|PVI-ADT|Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm
76088002|NCT02475642|Other|PVI+ADT|Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
75935526|NCT04797065|Procedure|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 3 minutes then in 2 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 3 minutes, then reentered the cecum and withdrawn to the splenic curvature in 2 minutes."
75935527|NCT03531489|Device|AIR-AD|Non-significant risk medical device as decided by institutional review board
75797628|NCT02526810|Drug|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
75650445|NCT04160793|Device|Genital Nerve Stimulation|Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
75650446|NCT00881361|Drug|systemic chemotherapy|
75797629|NCT01269762|Drug|LipoCol Forte|Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
75797630|NCT01280760|Other|Device: Neurally Adjusted Ventilatory Assistance|"Device: Neurally Adjusted Ventilatory Assistance~In ICU following extubation NIV was performed as follows:~facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode"
75797631|NCT01280838|Behavioral|Hombre Seguro|A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.
75935528|NCT02712398|Device|Phasix™ ST|Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
75935529|NCT05222945|Other|Biopsies and bloood samplings|blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample
75797632|NCT01280838|Behavioral|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
76088003|NCT05405088|Other|Questionnaires|Pain Sensitive Questionnaire (PSQ) Corah's Dental Anxiety Scale (CDAS) Pain Catastrophizing Scale (PCS) Gender Eye color Hair color Blood group
75340355|NCT00456014|Drug|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
76088004|NCT04784520|Drug|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
75650447|NCT00881361|Procedure|axillary lymph node dissection|
75650448|NCT00881361|Procedure|neoadjuvant therapy|
75650449|NCT00881361|Procedure|sentinel lymph node biopsy|
75650450|NCT00881361|Procedure|therapeutic conventional surgery|
75650451|NCT00881361|Procedure|ultrasound imaging|
75650452|NCT01000727|Drug|Darapladib 160 mg|Lp-PLA2 inhibitor
75797633|NCT01164852|Procedure|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
75797634|NCT01269216|Drug|5-FU with leucovorin|5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29
75797635|NCT01269216|Drug|TS-1 with Irinotecan|Irinotecan 40mg/m2/day IV on day 1,8,15,22 and 29 with TS-1 70mg/m2/day PO for 25 days
76088005|NCT02725008|Drug|Dexamethasone|
76088006|NCT02725008|Drug|placebo|to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
76088007|NCT02475486|Device|VistaO2|ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
75797636|NCT03874806|Drug|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|0.25% ropivacaine administered through a nerve catheter
75797637|NCT03874806|Drug|Ropivacaine 0.2%-NaCl 0.9% Injectable Solution|0.2% ropivacaine administered through a nerve catheter
75797638|NCT01280916|Behavioral|Mindful Awareness in Body-oriented Therapy|8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
76088008|NCT02471976|Other|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
75340356|NCT00456014|Drug|Desipramine|Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
75340357|NCT05235516|Drug|AK104|q3w iv
75340358|NCT05235516|Radiation|EBRT|45-50.4Gy
75340359|NCT05235516|Radiation|BT|≥80Gy
75340360|NCT05235516|Drug|cisplatin|qw iv
75340361|NCT05235516|Drug|Placebo|q3w iv
75650453|NCT01000727|Drug|Placebo|Placebo administered
75650454|NCT01000727|Other|Standard Therapy|Guideline mandated therapy for individual's condition
75650455|NCT04160247|Procedure|Immediate implant placement|Implants are placed in fresh socket
75650456|NCT04160247|Procedure|Angulated screw-retained crowns placement|To insert the restorations by angulated screw systems
75650457|NCT04160247|Procedure|Cemented crowns placement|To cement the restorations onto the implant abutment
75650458|NCT04160559|Other|green tea|The investigators require patients to regularly drink green tea during the trial period.
75650459|NCT04160481|Dietary Supplement|FruitFlow|300mg tomato extract
75650460|NCT04160481|Dietary Supplement|Placebo|Maltodextrin
75797639|NCT01165476|Drug|Treprostinil diethanolamine|sustained release tablets. One 1mg tablet per period. Two total doses.
75797640|NCT03871686|Behavioral|Brief Internet-based Behavioral Activation Intervention|A brief Internet-based behavioral activation intervention consisting of 4 sessions.
75797641|NCT01281072|Other|vaccine|
75935530|NCT02288013|Procedure|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
76088009|NCT01832506|Drug|MSC2156119J|Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
76088010|NCT02477748|Drug|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
76088011|NCT02477748|Drug|Placebo|Tablet PO, taken once daily for 10 weeks.
76088012|NCT02477436|Drug|Avanafil|"One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~Investigational products were administered prior to the sexual intercourse for total 8 weeks."
76088013|NCT02477436|Drug|Placebo|"One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.~Placebos were administered prior to the sexual intercourse for total 8 weeks."
76088014|NCT01783522|Drug|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
75797642|NCT01167348|Procedure|auricular acupressure|Investigator will put a tape with a 0.5mmx0.5mm seed on the specific positions on the ear of participants of intervention group, and participants will be asked to press these specific positions 3 times a day.
75797643|NCT01283100|Drug|GSK1349572|50mg once every 24 hours for 7 days
75797644|NCT01283100|Drug|GSK2248761|200 mg once every 24 hours for 7 days
75935531|NCT05222867|Procedure|lower back massage|Lower back massage performance: In the study, Linda Kimber's massage protocol was used. First, the researcher ensured that the patient was holding the bed, squatting, or bent over on the bed, which is suitable for the massage, between two contractions. The pregnant woman was instructed to breathe deeply and exhale audibly when her contractions began. Gloves were worn during the massage and liquid Vaseline, which does not contain any active substance, was used to provide lubricity. The circular hip massage was applied at the beginning of the contraction, and lower lateral area and sacral pressure massage was applied towards the end of the contraction as per the massage protocol, and simultaneously with the inhaling sound of the pregnant woman
76088015|NCT01783522|Other|quality-of-life assessment|Ancillary studies
76088016|NCT01783522|Other|placebo|Given PO
76088017|NCT04734366|Procedure|"Uterine closure with Baseball suture technique"|"A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision."
76088018|NCT04734366|Procedure|Single Layer Continuous Locked|Suturing is continued by passing through the previous stitch.
76088019|NCT02471820|Drug|Lenalidomide|Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
76088020|NCT02471820|Drug|Adriamycin|Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
75650461|NCT00881205|Drug|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
75935532|NCT00282867|Drug|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
75935533|NCT00282867|Other|standard care|usual care
75935534|NCT03203720|Behavioral|Brief Motivational Intervention|A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
75935535|NCT05222711|Device|Use of the PICO(TM) monitoring device|The aim is to record if the outcome (referral or not) is influenced by the results of the parameters and/or the ECG.
75935536|NCT03198338|Drug|0.25% Bupivacaine, 0.5mL/kg|Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
76088021|NCT02471820|Drug|Dexamethasone|Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
76088022|NCT01833130|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
76088023|NCT01833130|Drug|Normal saline (placebo)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
76088024|NCT02475408|Device|Amplatzer vascular plug|
76088025|NCT02471664|Device|Mitral Loop Cerclage Annuloplasty|
76088026|NCT01783912|Behavioral|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
76088027|NCT01783912|Behavioral|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
75650462|NCT00881205|Drug|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
75650463|NCT00879879|Drug|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
76088028|NCT01783912|Drug|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
76088029|NCT01783912|Behavioral|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
76088030|NCT02475330|Dietary Supplement|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
76088031|NCT02475174|Other|Without upper limb elevation|Lymphatic drainage without elevation of the upper limb.
76088032|NCT02475174|Other|Upper limb elevation to 30º|Lymphatic drainage with elevation of the upper limb to 30º.
75340362|NCT00411398|Drug|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
75797645|NCT01269996|Drug|Janumet, Lantus|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
75935537|NCT03198338|Drug|Normal Saline|0.9% Normal Saline
75797646|NCT01269996|Drug|metformin, gliclazide, protaphane|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
76088033|NCT01783990|Drug|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
76088034|NCT05582382|Other|logistic regression of known prognostic markers of severity of COVID19|"An observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . The risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA & ALKA and compared with the currently proposed clinical risk assessment scoring system~The utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:~Hospital admission on the first encounter to ED~Admission to ICU for the duration of the COVID-19 hospitalization~In hospital and out of hospital mortality~Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)"
75935538|NCT03198338|Device|Ultrasound|Ultrasound guided TAP block
75935539|NCT05724771|Drug|Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)|OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL
76088035|NCT01733056|Biological|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
76088036|NCT04672824|Biological|ChAdOx1 RVF|Single dose ChAdOx1 vectored vaccine
75340363|NCT05234268|Other|Manual Cervical Traction|"Time: 20 minutes Duration: thrice a week for 4 weeks.~Position:~The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion."
76088037|NCT04672824|Other|Saline|0.5ml saline placebo
76088038|NCT01833988|Device|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
76088039|NCT01833988|Other|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
76088040|NCT02471742|Procedure|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
76088041|NCT02471742|Procedure|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
75340364|NCT05234268|Other|Passive Accessory Intervertebral Movements|"Time: 20 minutes Duration: thrice a week for 4 weeks~Position:~Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension.~Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra."
75340365|NCT05234268|Other|Active Strength Training|"Time: 20 minutes Duration: thrice a week for 4 weeks. The progression of exercises will be done using different colors of Thera-band indicating varied resistance. (A) Resistive lateral flexion of uninvolved side.~Position:~The patient is in sitting position. By the help of thera-band patient will actively flex the neck against resistance on the uninvolved side."
75340366|NCT05231694|Drug|Nerver growth factor (NGF) injection|The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
75340367|NCT05231694|Drug|Placebo injection|The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
75474378|NCT01982864|Drug|Gentamicin|"The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.~Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance…).~The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD)."
75797647|NCT01283178|Radiation|intensity-modulated radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
75797648|NCT01283178|Drug|cisplatin|Given IV
75797649|NCT01283178|Radiation|image-guided adaptive radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
75935540|NCT05222633|Drug|Ranibizumab|Ranibizumab 0.5mg/0.05ml intravitreal injection
75935541|NCT05222633|Drug|Aflibercept|Aflibercept 2.0mg/0.05ml intravitreal injection
75935542|NCT05222633|Drug|Conbercept|Conbercept 0.5mg/0.05ml intravitreal injection
75935543|NCT03198260|Other|Fascial manipulation|Deep frictional massage
75935544|NCT05724693|Drug|Bemnifosbuvir (BEM)|Day 1: A single dose of BEM will be administered
75935545|NCT03198104|Device|MRI|
75935546|NCT05222243|Drug|Direct pulp capping with calcium hydroxide|Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
75935547|NCT05222243|Drug|Direct pulp capping with MTA|Capping exposed dental pulps during cavity preparation in primary teeth with MTA
75935548|NCT05222243|Drug|Direct pulp capping with Formocresol|Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
75935549|NCT03203252|Other|Reconstruction BREAST-Q|Validated Patient reported outcome measure specifically designed to assess Quality of life domains and satisfaction following breast reconstruction.
76088042|NCT02477046|Biological|tOPV|administered per protocol
76088043|NCT02477046|Biological|bOPV|administered per protocol
76088044|NCT02477046|Biological|IPV|administered per protocol
76088045|NCT02475096|Behavioral|Internet-delivered CBT|"The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.~Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire."
75650464|NCT04157283|Diagnostic Test|MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)|"Neurophysiological Evaluation:~Visual Evoked Potential (VEP).~Imaging Evaluation:~Conventional MRI.~Cerebrospinal Fluid (CSF):~Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54)."
75935550|NCT03203252|Other|3-dimensional Surface Image|Non-invasive 3-dimensional photograph using VECTRA® XT 3D imaging system.
76088046|NCT02475018|Dietary Supplement|Milk fortified with plant sterol esters|250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
76088047|NCT02475018|Dietary Supplement|Plain milk|250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
76088048|NCT05363436|Drug|Oxycodone|Providers had to prescribe 15 oxycodone pills to each patient discharge
76088049|NCT04641078|Drug|Darolutamide|600 mg BID
75650465|NCT00661999|Biological|darbepoetin alfa|Given by injection
75650466|NCT00661999|Dietary Supplement|ferrous sulfate|Given by mouth
75650467|NCT00661999|Drug|sodium ferric gluconate complex in sucrose|Given by IV
75650468|NCT00661999|Other|placebo|Given by mouth
75650469|NCT00661167|Drug|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
76088050|NCT04641078|Radiation|metastasis-directed treatment|stereotactic body radiotherapy
76088051|NCT04575870|Other|waiting period|amount of time between clinical procedure and modified functional endoscopic exam of swallowing
76088052|NCT02474940|Behavioral|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
75650470|NCT04156737|Device|TECNIS Symfony plus IOL Model ZHR00V|IOL replaces the natural lens removed during cataract surgery
75650471|NCT04156737|Device|Trifocal Intraocular lens|IOL replaces the natural lens removed during cataract surgery
75650472|NCT00661245|Device|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
75650473|NCT00661245|Device|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
75650474|NCT04156815|Radiation|1,565nm NAFL|1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
75797650|NCT01283178|Other|3'-deoxy-3'-[18F]fluorothymidine|Undergo FLT-PET scans for IMRT/IGART
75797651|NCT01283178|Procedure|positron emission tomography/computed tomography|Undergo FDG/FLT-PET scans for IMRT/IGARTT
75797652|NCT01283178|Radiation|fludeoxyglucose F 18|Undergo FDG-PET scans for IMRT/IGART
75797653|NCT01281150|Drug|Carboplatin|Given IV
75797654|NCT01281150|Other|Laboratory Biomarker Analysis|Correlative studies
75797655|NCT01281150|Drug|Paclitaxel|Given IV
75797656|NCT01281150|Other|Pharmacological Study|Correlative studies
75797657|NCT01281150|Drug|Veliparib|Given PO
75797658|NCT03871218|Biological|Hyaluronic acid group|Applicaton of topical Hyaluronic acid
75797659|NCT01281228|Drug|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
75797660|NCT01281228|Drug|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
75797661|NCT01281228|Drug|placebo|saline infusion
75935551|NCT03203252|Other|Treatment Questionnaire|Online questionnaire pertaining to treatment received pertaining to breast cancer or risk reduction for breast cancer.
75935552|NCT04469283|Other|caffeine and movement disorders|Caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
75797662|NCT01283256|Drug|zonisamide|zonisamide 100mg tablets
75935553|NCT02285829|Drug|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
75797663|NCT01270776|Drug|2% aqueous chlorhexidine|A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
76088053|NCT02474940|Behavioral|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
75340368|NCT05231694|Device|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
75797664|NCT01270776|Drug|2% Chlorhexidine 70% isopropyl alcohol|single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
75935554|NCT03203408|Device|OSTENIL PLUS|Injection into the joint cavity of the most painful knee
75340369|NCT05231694|Device|sham EA intervention|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
75340370|NCT00457730|Drug|Duloxetine|Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
75474379|NCT01982877|Behavioral|Four Supports Intervention|The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.
75650475|NCT04156815|Drug|Oral isotretinoin|Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
75650476|NCT04156815|Other|Pricking blood therapy|Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
75650477|NCT04156425|Drug|Escitalopram+golimumab|Escitalopram will be administered at 10-20 mg/d during the acute phase. Golimumab will be administered at the dose of 50mg every month during the acute phase.
75650478|NCT04156425|Dietary Supplement|Escitalopram+Calcium Tablet|Escitalopram will be administered at 10-20 mg/d during the acute phase. Calcium tablet will be administered at 2000mg/d during the acute phase.
75797665|NCT03874260|Drug|Fenofibrate|statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
75797666|NCT03869424|Other|Active Placebo labelled as antidepessant|Participants receive an active nasal spray that is in fact a placebo.
75797667|NCT01271322|Radiation|neoadjuvant radiochemotherapy in metabolic non responders|Metabolic non-responders, with a SUV decrease of less than 35%, discontinue induction chemotherapy and proceed to an intensified radiochemotherapy treatment
75797668|NCT01281384|Other|Advanced Imaging|
75797669|NCT01281384|Other|Standard Imaging|
75797670|NCT01281540|Drug|Cisapride|one 10 mg tablet 4 times a day for 8 weeks
75797671|NCT01281540|Drug|Placebo|one placebo tablet 4 times a day for 8 weeks
75340371|NCT00457730|Drug|Placebo|Subjects are randomized to either Duloxetine or Placebo
75340372|NCT05183802|Drug|Setmelanotide, administered subcutaneously [SC], once daily.|Dosing based on age, and titrated from starting dose to target dose.
75340373|NCT01965470|Other|Combination Prevention|
75340374|NCT01965470|Other|Enhanced Care|
75935555|NCT03203408|Device|SYNVISC-ONE|Injection into the joint cavity of the most painful knee
75935556|NCT02285985|Drug|Saxagliptin|Tablets: 5 mg
75935557|NCT02285985|Drug|Placebo|Tablets: 5mg
75935558|NCT02445950|Behavioral|Technology-aided phone wellness counselling|The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
75935559|NCT02445950|Behavioral|Phone wellness counselling|The intervention provides phone wellness counseling in occupational health.
75935560|NCT05222009|Drug|PEG-rhG-CSF|PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
76088054|NCT02474940|Behavioral|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
76088055|NCT01784614|Drug|LY2624803 - Solution|Administered orally as reconstituted solution
75935561|NCT05222009|Drug|PEG-rhG-CSF|PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
75340375|NCT05181384|Other|isolated pelvic floor muscles training|isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.
75340376|NCT05181384|Other|comprehensive stabilization exercise program|incorporated the contraction of PFMs with other spinal or extremity muscles
75340377|NCT05181384|Other|education of pelvic girdle|educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
75340378|NCT00458822|Drug|bortezomib|Given IV
75650479|NCT04156425|Drug|Escitalopram|Escitalopram will be administered at 10-20 mg/d during the acute phase.
75650480|NCT02555059|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Treatment parameters following the physician's decision based on the summary of product characteristics.
75650481|NCT00790075|Drug|risperidone|liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was >30 minutes.
75797672|NCT03874026|Drug|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
75797673|NCT01283412|Drug|Placebo|Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
75935562|NCT02445872|Drug|Aprepitant|Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
75935563|NCT02445872|Drug|Palonosetron|
75935564|NCT02445872|Drug|Dexamethasone|
75935565|NCT02286063|Drug|Ambulatory Oxygen|"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."
75935566|NCT02446106|Dietary Supplement|Soup with MSG|0.5% MSG + 0.48% salt
75935567|NCT02446106|Dietary Supplement|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
75935568|NCT02288169|Behavioral|COPE|We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
75935569|NCT02288169|Behavioral|Support/Attention Control|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
76088056|NCT01784614|Drug|LY2624803 - Capsule|Administered orally as a capsule
76088057|NCT01784614|Drug|Placebo - Solution|Administered orally as solution
75340379|NCT00458822|Drug|dexamethasone|Given orally
75340380|NCT05229744|Device|sequence MRI 3D FLAIR|"Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®):~- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product"
75650482|NCT04156503|Other|Palm olein vs Lard|A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.
75650483|NCT00785083|Drug|FTY720|
75650484|NCT00785083|Drug|Placebo|
76088058|NCT01784614|Drug|Placebo - Capsule|Administered orally as a capsule
76088059|NCT05314686|Other|Five exercise sessions of forty-five minutes within the pulmonary rehabilitation centre and ten days of using a physical activity tracker.|"Five exercise sessions of forty-five minutes within the centre on a cycle ergometer using a pulse oximetry device connected to the telerehabilitation system through Bluetooth. Data recorded in the internal memory of the pulse oximeter will be compared with those transmitted through the telerehabilitation system.~Ten days of use of a physical activity tracker connected to the telerehabilitation system. Self-reported daily step count by the participants (using a standardized data sheet) will be compared with the daily step count transmitted through the telerehabilitation system."
75935570|NCT03203486|Other|Mediterranean Diet|Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
75340381|NCT00459368|Behavioral|Feedback of patient adherence information|Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
75340382|NCT00459368|Behavioral|Active control group|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
75650485|NCT02631681|Behavioral|Group based exercise|Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
75797674|NCT01283412|Drug|Dexmedetomidine|Dexmedetomidine 0.1~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
75340383|NCT01795040|Dietary Supplement|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
75650486|NCT00780637|Drug|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
75650487|NCT00785161|Device|Penumbra System|Mechanical Thrombectomy in acute stroke
75650488|NCT00661401|Biological|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
75340384|NCT05278572|Behavioral|Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST)|Cognitive-behavioral stress management/expressive supportive therapy (CBSM+) group targeting depression
75474380|NCT01982877|Behavioral|Educational Control Intervention|In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
75650489|NCT00790153|Drug|Insulin|Insulin infusion given during 3 hours at one occasion.
75650490|NCT00790153|Drug|AZD1656|Single dose oral suspension given at one occasion.
75650491|NCT00911391|Device|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
75650492|NCT00911391|Procedure|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
75650493|NCT00785317|Drug|Angemin vs Activelle|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
75797675|NCT01271478|Drug|captopril plus placebo|This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
75797676|NCT01271478|Drug|telmisartan plus placebo|Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
75797677|NCT01271478|Drug|Telmisartan plus Captopril|Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
75650494|NCT05017831|Behavioral|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
75935571|NCT05724537|Procedure|Quadrangular resection and annular plication|Mitral regurgitation is treated removing the redundant tissue of the posterior leaflet, which is then reconstructed by sutures and plicating the posterior annulus
75474381|NCT01982916|Drug|AGR tablet|
75474382|NCT01982916|Drug|Placebo (for AGR tablet and/or Active Comparator)|
75797678|NCT01271478|Drug|Placebo|Patients in this group will receive 2 tablets of placebo (starch) twice a day.
75797679|NCT03871452|Procedure|Ankaferd Blood Stopper in theTraumatic Bleeding|"ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses"
75797680|NCT01281618|Procedure|24 hour pH study and upper endoscopy (EGD)|All subjects enrolled will undergo 24 hour pH followed by EGD.
75797681|NCT03871062|Procedure|Two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
75797682|NCT03871062|Procedure|topical anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
75797683|NCT01281696|Drug|Bevacizumab, etoposide, cisplatin|Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles
75797684|NCT01281696|Drug|Intrathecal methotrexate|Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
75797685|NCT05835947|Other|Dual Pathology|Women with both genital HSIL/SCC and Anal HSIL/SCC
75797686|NCT05835934|Drug|[14C]HSK21542|A single intravenous dose of 2 μg/0.212 μCi/kg [14C]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
75797687|NCT05835817|Other|Magnetoencephalography|40 minutes of Magnetoencephalography with Optical Pump Magnetometer
76088060|NCT05314686|Other|Telerehabilitation|"An eight-week program including:~Endurance training on a cycle ergometer (performed independently with remote monitoring or through video conference, according to the participant's preference), three times per week. Training prescription is progressively adjusted using an automated algorithm (aimed to first increase the training duration and then workload intensity).~Peripheral muscle strengthening using the app (the patient will be requested to reproduce different exercises after watching a video) or through video conference, three times per week (thirty minutes).~Daily walking with automated coaching.~Self management education (one to nine sessions according to each individual needs, scheduled through videoconference).~A self evaluation of symptoms through daily or weekly questionnaires. Different types of alert will be triggered at the center according to remote monitoring: non-adherence, clinical issue during endurance exercise sessions and change in symptoms."
76088061|NCT01733212|Drug|Ginger|Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
75797688|NCT05835765|Device|Dynamic Elastometric Body in Preterm Newborns|The study group made up of 12 newborns will use Flexa bodysuits made to the measurements of newborns.The bodysuit will be worn for a minimum of 4 hours and a maximum of 6 hours each day for a week (depending on any signs of discomfort). After 6 hours, the body will be removed and reapplied the next day for 4-6 hours. The child will use the same leotard for the entire study period (1 week) and changed only if dirty.
75797689|NCT05835713|Drug|Remimazolam besylate|Remimazolam group is induced general anesthesia using remimazolam besylate injection (0.2mg/kg bolus). General anesthesia is maintained using remimazolam infusion at a rate of 1mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min. After recovering spontaneous respiration during emergence, remimazolam group receive flumazenil injection (0.5 mg)
75935572|NCT05221775|Drug|Lenvatinib|XELOX regimen combined with GLS-010 and different doses of Lenvatinib
75474383|NCT01982916|Drug|Active Comparator|
75650495|NCT05017831|Behavioral|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition. CRT is a behavioral treatment that presents tasks to participants in a standardized order within each session. Each task has a number of levels. Participants stay at the same task-based level until mastered. They then move up a level on that task. participants can be at different levels on different tasks within each session. After completion of tasks, participants are asked to reflect on their thought processes in solving the tasks. Standard prompts are used to guide the discussion.
75935573|NCT02288403|Behavioral|Aerobic interval training|
75474384|NCT01982929|Procedure|TAP block (Bupivacaine 0.25% with epinephrine)|Ultrasound guided TAP blocks
75474385|NCT01982929|Procedure|Sham block control|A blunt needleless syringe was firmly pressed on either side of the abdomen.
75474386|NCT01982981|Other|water provision|perception behavioral change at the beginning and at the end of the intervention
75650496|NCT00661791|Behavioral|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
75650497|NCT00661791|Behavioral|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
75650498|NCT04156269|Biological|BCMA-CS1 cCAR T cells|BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
75650499|NCT00790231|Device|urodynamic procedure|introduction of the urodynamic catheter into the bladder and assessment of the bladder function
75650500|NCT00661869|Other|Wellness Program|36 weeks of educational and supportive interventions
75935574|NCT02288403|Behavioral|Continuous training|
75474387|NCT01982981|Other|Water provision|After participants are recruited, drink 2L of water for 8 weeks.
75650501|NCT05001217|Drug|Conventional medication|Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
75650502|NCT05001217|Drug|Chinese herbal medicine treatment|"Huanglian Wendan Decoction~Jin Gui Shen Qi Pill~Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~Bu Yang Huan Wu Decoction"
75650503|NCT02631603|Drug|Placebo|Administer Placebo as anti-inflammatory
75650504|NCT02631603|Drug|Prednisolone|Administer Prednisolone as anti-inflammatory
75650505|NCT00790309|Procedure|Weight loss surgery|Weight loss surgery
75650506|NCT00790309|Procedure|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
75650507|NCT04156113|Other|Yo-Yo intermittent recovery test (level 1)|The Yo-Yo intermittent recovery test (level 1) will be administered once.
75650508|NCT00790387|Drug|Enoxaparin|Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
75797690|NCT05835713|Drug|Propofol|Propofol group is induced general anesthesia using propofol injection (2 mg/kg bolus). General anesthesia is maintained using propofol infusion at a rate of 4-8 mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min.
75797691|NCT05835700|Other|Gasdermin-d|Maternal serum Gasdermin-D levels in preterm labor and healthy pregnant women.
75935575|NCT03197792|Other|All patients|"TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death."
75935576|NCT05221541|Procedure|vibration|whole-body vibration and soleus tendon vibration will be applied to participants
75935577|NCT05724459|Other|Peer education|Training on stem cell transplantation for a total of 12 hours, two days a week for three weeks, two lesson hours a day (60 min. + 60 min.)
75650509|NCT00790387|Drug|Tirofiban|
75650510|NCT00790387|Drug|unfractionated heparin|
75650511|NCT00661947|Other|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
75340385|NCT00413582|Drug|Epidural Analgesia|Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
75474388|NCT01982994|Behavioral|Education/Daily Planning|"In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)"
75474389|NCT01983007|Procedure|High-intensity exercise|Performance of high-intensity exercise
75650512|NCT00662103|Behavioral|exercise intervention|"Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.~Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months."
75650513|NCT00662103|Other|laboratory biomarker analysis|All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health & Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
75935578|NCT02445560|Dietary Supplement|Probiotic capsule and Fiber Sachet|"A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
75935579|NCT02445560|Dietary Supplement|Probiotic capsule and Placebo sachet|"A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
75935580|NCT02445560|Dietary Supplement|Placebo capsule and Fiber Sachet|"A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
75935581|NCT02445560|Dietary Supplement|Placebo capsule and Placebo sachet|"A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
75935582|NCT02445638|Other|Whole egg|Subjects will be provided with the equivalent of 2 whole eggs daily.
75935583|NCT02445638|Other|Yolk-free egg|Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
75935584|NCT04700423|Drug|moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
75935585|NCT04700423|Drug|ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
75650514|NCT00662103|Other|questionnaire administration|Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
75650515|NCT00662103|Other|survey administration|Administered at measured at baseline, 3, 6, 12, and 18 months
76088062|NCT01733212|Drug|Placebo Oral Tablet|Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
75650516|NCT00662103|Procedure|assessment of therapy complications|Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
75797692|NCT05835674|Diagnostic Test|Early intervention program|"At enrollment visit: History and examination, MRI, evaluation of comorbidities, medication and genomic testing. HINE, GMA (if below 5 mo), AIMS, SHAI, PSS and DASS-21 questionnaire.~At 6 mo visit: Examination and evaluation of comorbidities, medication and HINE and AIMS~At 12 mo visit: Examination and evaluation of comorbidities, medication and HINE, AIMS, HAI, PSS and DASS-21 questionnaire.~At 18 mo visit: Examination and evaluation of comorbidities, medication and HINE~At 24 mo visit: Examination and evaluation of comorbidities, medication and HINE, PDMS-2, GMFM-66, BSID-IV-cog, MPOC-20 ,PSS, and DASS-21 questionnaire. GMFCS and Mini MACS if CP."
76088063|NCT02474706|Drug|Cefoxitin|
76088064|NCT02474706|Drug|imipenem|
75797693|NCT05835648|Dietary Supplement|Nutrasumma|On the basis of daily diet, dietary fiber supplement (Nutrasumma) was given once a day, 1 strip each time, before meals, and the intervention lasted for 3 months.
75797694|NCT05835622|Device|Keeogo|Keeogo is exoskeleton for walking assistance
75797695|NCT05835622|Other|adviced home practice|health tips for regular and appropriate physical activity
76088065|NCT01784770|Drug|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
76088066|NCT02471274|Drug|sotagliflozin|single 400 mg dose
75797696|NCT05835609|Drug|PM534|PM534 drug product is provided as a powder for concentrate for solution for infusion, is a sterile, preservative-free, lyophilized white cake in a single-dose vial for reconstitution prior to intravenous infusion.
75935586|NCT04700423|Drug|ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]|Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
76088067|NCT01784926|Procedure|Intraocular lens repositioning by scleral suturing|
76088068|NCT01784926|Procedure|Intraocular lens exchange with retropupillary iris-claw lens|
75340386|NCT00413582|Drug|Patient-Controlled IV Analgesia|In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are > 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of > 4/10 throughout the duration of PCA use.
75340387|NCT00389168|Drug|Irbesartan|Titrated to 300 mg od, 48 weeks.
76088069|NCT02471196|Drug|ORM-12741|ORM-12741 low dose twice a day
76088070|NCT02471196|Drug|ORM-12741|ORM-12741 high dose twice a day
75340388|NCT00389168|Drug|Atenolol|Titrated to 100 mg od, 48 weeks.
75340389|NCT00462020|Drug|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
75340390|NCT00462020|Drug|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
75340391|NCT05178576|Drug|Gevokizumab|120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)
75340392|NCT05178576|Diagnostic Test|Signatera test|ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.
75650517|NCT00662103|Procedure|fatigue assessment and management|The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
75797697|NCT05835596|Device|Access to MumCare app|Education, push warning to book cardiovascular health follow-up at own general practitioner , registration of BP and lipids, HbAc
75797698|NCT05835583|Behavioral|The theory based integrated program|The theory-based integrated program is administered by a nurse trained in motivational interviewing.In the 12-hour intervention, this program uses motivational interviewing skills to increase the patient's attitude towards medication, enhance the support of significant others around them, and increase the patient's control over their own behavior.
75797699|NCT05835557|Other|BFR-ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Blood flow restriction will be applied for 2 mins during the passive rest at 80% of limb occlusion pressure.
75935587|NCT04700423|Drug|ivermectin (200 µg/kg)|Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
75935588|NCT04700423|Drug|moxidectin (8 mg)|Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
75935589|NCT02286219|Drug|FS102|Experimental
75935590|NCT03197948|Other|Internet-Based Intervention|Complete questionnaire via a smartphone application
75935591|NCT04653467|Drug|GLPG4399 oral suspension|GLPG4399 for oral administration
75935592|NCT04653467|Drug|GLPG4399 capsules|GLPG4399 for oral administration
75935593|NCT04653467|Drug|Placebo|Placebo oral suspension
75340393|NCT05177718|Drug|Natalizumab 300 MG in 15 ML Injection|Disease modifying agent
75340394|NCT05177250|Device|HPLC|taking urine samples from participants and analyze these samples to detect bisphenol A and paraben
75340395|NCT00414206|Drug|Mecamylamine|
75340396|NCT00414206|Drug|Placebo|
75340397|NCT04241874|Other|Mechanical Ventilation|Respiratory support through mechanical ventilator
75340398|NCT04241640|Drug|Nefopam 20 MG/ML|Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative
75340399|NCT04241640|Drug|Placebo|Placebo
75340400|NCT00462332|Drug|Fludarabine|Induction therapy
75340401|NCT00462332|Drug|Campath|Induction therapy
75340402|NCT00462332|Procedure|Transplant|Post-induction therapy
75340403|NCT00462332|Drug|Campath|Post-induction therapy
75340404|NCT00462332|Drug|Fludarabine|Induction therapy
75340405|NCT00462332|Drug|Campath|Induction therapy
75340406|NCT00462332|Drug|Campath|Post-induction therapy
75340407|NCT04241094|Behavioral|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
75474390|NCT01983007|Procedure|Low-intensity exercise|Performance of low-intensity exercise
76088071|NCT02471196|Drug|Placebo|Placebo twice a day
76088072|NCT02471508|Device|Body-mapping Tank-top Embedded with Biofeedback System|In this study, the eligible subjects will be given tailor-made tank-top embedded with biofeedback system to wear it 8 hours daily. Monitor, observation and additional posture training sessions will be provided during the 6 months wearing period. The effectiveness of the biofeedback tank-top will be evaluated by pre-and post- treatment ultrasonic imaging device (measuring the angle of the spine) and electromyography muscle signal
75340408|NCT05226312|Other|Local Warm Compress|The warm application will be made by the researcher for 15 minutes three times a day according to the local warm application process steps.
75474391|NCT01983033|Behavioral|Drop It training session|8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month
75797700|NCT05835557|Other|ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Cycling will be conducted in an environmental chamber and participants informed that the altitude is set to 2500m - actual altitude will be sea level.
75340409|NCT00462644|Drug|RSI sedation with etomidate/succinylcholine|etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
75340410|NCT00462644|Drug|RSI sedation with fentanyl/midazolam/succinylcholine|100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
75650518|NCT00662103|Procedure|management of therapy complications|An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
75650519|NCT00662103|Procedure|psychosocial assessment and care|We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
75650520|NCT04156035|Drug|Lamotrigine|Orally; 300 mg
75797701|NCT05835531|Device|Catheters comparation|Assessment of incidence of complications associated with midline catheters
75797702|NCT05835479|Drug|Co-Trimoxazole|Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
75474392|NCT01983033|Behavioral|treatment as usual|12 weeks of no intervention other than treatment as usual
75797703|NCT05835479|Drug|Rezafungin Acetate / Co Trimoxazole|"Rezafungin for infusion. Intravenous anti fungal therapy~Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication"
75797704|NCT05835401|Dietary Supplement|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (800mg). Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
75340411|NCT00462722|Drug|Ibuprofen|400 mg with each exercise session (up to 5 days per week) for 9 months
75340412|NCT00462722|Drug|Placebo|with each exercise session (up to 5 days per week) for 9 months
75797705|NCT05835401|Dietary Supplement|Beetroot juice depleted in nitrate|The participant will intake beetroot juice depleted in NO3. Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
75340413|NCT00462722|Behavioral|musculoskeletal-loading exercise|Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
75797706|NCT05835362|Behavioral|Question prompt list|A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.
75474393|NCT01983046|Drug|Three different mixture of acetate, butyrate and propionate and palcebo|
75474394|NCT01983072|Dietary Supplement|Infant formula|
75340414|NCT05224830|Other|Nijmegen questionnaire score|We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
75340415|NCT00528398|Drug|cytarabine|
75340416|NCT00528398|Drug|idarubicin|
75340417|NCT05223348|Other|Meditation practice|Our intervention will involve two meditation exercises. 1) the experimental condition (body scan meditation). 2) the active comparator condition (listening task)
75340418|NCT00528788|Drug|doxercalciferol|
75340419|NCT05174520|Other|Routine Physical Therapy|Routine physical therapy will be provided to group A for 25 minutes thrice a week for 4 weeks.
75340420|NCT05174520|Other|Muscle Energy Technique|Muscle Energy technique along with Routine physical therapy will be provided to group B for40 minutes thrice a week for 4 weeks.
75474395|NCT01983072|Other|Breastfeeding|Breastfeeding
75474396|NCT01983085|Device|NOx dressing|The NOx dressing should be changed at least every 2 days.
75474397|NCT01983085|Device|Standard of Care|Dressing changed as per normal clinical practice
75650521|NCT04156035|Drug|Ketamine|Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min
75650522|NCT04156035|Drug|Placebo Pretreatment|Lamotrigine Placebo
75474398|NCT01983124|Drug|Fotemustine + Vemurafenib|"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."
75474399|NCT01983137|Drug|Targinact® (oxycodone/naloxone)|
75650523|NCT04156035|Drug|Placebo Infusion|Ketamine Placebo
75650524|NCT00662337|Drug|Diphenhydramine hydrochloride|After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
75474400|NCT01983150|Behavioral|Crush the Crave Application|Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.
75340421|NCT05173974|Device|Super Poligrip Free|A single application of 1 gram of Super Poligrip Free will be applied topically to oral tissues via the upper denture.
75340422|NCT05173974|Device|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
75340423|NCT05173974|Device|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
75340424|NCT00414518|Drug|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
75340425|NCT00414518|Drug|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
75935594|NCT00273351|Drug|[123I]B-CIT|Subjects will receive up to 6 mCi of [123I] B-CIT injected intravenously
75340426|NCT01795664|Radiation|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
75340427|NCT01795664|Drug|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
75340428|NCT01795664|Drug|Seretide Evohaler|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
75340429|NCT01795664|Drug|Placebo of Test product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
75474401|NCT01983150|Behavioral|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
75797707|NCT05835362|Behavioral|Pre-visit video|The 11-minute video has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD.
75340430|NCT01795664|Drug|Placebo of Reference product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
75797708|NCT05835362|Behavioral|Combined question prompt list/video|"A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.~And the video is an 11-minute video that has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD."
75797709|NCT05835349|Device|transcatheter pulmonary valve implantation (TPVI)|A stent-mounted valve is introduced over a guidewire and positioned in the RVOT, followed by balloon inflation to deploy the valve.
75340431|NCT05271084|Drug|Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg|Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
75340432|NCT05271084|Drug|Citalopram (tablet) 20 mg + Placebo (tablet)|Selective serotonin reuptake inhibitor (SSRI) + placebo
75340433|NCT00531518|Drug|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
75340434|NCT00531518|Behavioral|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
75340435|NCT00531518|Behavioral|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
75340436|NCT01658514|Drug|Met DR|metformin delayed-release tablets
75340437|NCT01658514|Drug|Met XR|metformin extended-release tablets
75340438|NCT01658514|Drug|Placebo|
75340439|NCT00533546|Drug|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
75340440|NCT00534794|Drug|Elestat|Elestat BID for 2 days
75340441|NCT00534794|Drug|Pataday|Pataday QD for 2 days
75340442|NCT01658436|Drug|BEZ235 (Stage 1)|The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
75340443|NCT04244604|Other|Acute Salt (sodium chloride)|Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure
75340444|NCT05170776|Other|Pilates and postural correction exercise|"ten exercises will be performed:~Hip Twist Level 1~Double leg stretch Level 1~Double leg stretch Level 2~One leg stretch Level 1~Clam Level 1~Scissors Level 1~Arm openings Level 1~Breast stroke prep Level 1t~Hip Twist Level 1.~Breast stroke prep Level 2 as for level 1 postural correction exercise~1-Strengthening deep cervical flexors 2-Stretching cervical extensors 3- Strengthen shoulder retractors 4-Unilateral and bilateral pectoralis stretch"
75650525|NCT00662415|Device|mirror-box treatment|15 minutes daily for 4 weeks
75650526|NCT00662415|Behavioral|observation|observation
75935595|NCT02445716|Drug|Testosterone|"It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit."
76088073|NCT01835626|Drug|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
75797710|NCT05835336|Device|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
75650527|NCT00665353|Drug|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
76088074|NCT01835626|Radiation|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
76088075|NCT04491786|Drug|Gabapentin|Gabapentin plus nefopam
76088076|NCT04749784|Dietary Supplement|High Dose Arterin Cholesterol|240mg active ingredient daily
76088077|NCT04749784|Dietary Supplement|Low Dose Arterin Cholesterol|120mg active ingredient daily
76088078|NCT04749784|Dietary Supplement|Placebo|Placebo tablet
76088079|NCT01786252|Drug|human chorionic gonadotropin (hCG)|"500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)"
76088080|NCT01786252|Drug|Placebo Comparator (for hCG)|"50ul of IVF medium (Global-trademark) to mimic hCG infusion"
75650528|NCT00665353|Drug|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
75650529|NCT00665353|Drug|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
75797711|NCT05835310|Biological|Anifrolumab|Participants will receive a single dose of Anifrolumab via IV infusion.
75797712|NCT05835310|Drug|Placebo|Participants will receive matching placebo via IV infusion
75797713|NCT05835232|Other|Survey|Each participant completed an anonymous 62-item online survey.
75935596|NCT02445716|Drug|Placebo|It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
75935597|NCT04607369|Device|EyeCTester|Smartphone app that allows vision testing
76088081|NCT02470026|Drug|yohimbine|single low dose treatment
75650530|NCT00597207|Device|AutoPulse|Mechanical device that provides chest compression
75650531|NCT00597207|Other|Manual|Manual chest compression
75650532|NCT00662493|Behavioral|Motor control retraining program|Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated
75797714|NCT05835167|Procedure|Inferior part-sternotomy|A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.
75797715|NCT05835167|Procedure|Full median sternotomy|A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.
75797716|NCT05835141|Other|OCT Imaging|Each participant will receive imaging of the inferior sectors of the iridocorneal angle at 150°, and 180°, and 210° with the swept-source ANTERION AS-OCT system under standardized light and dark lighting conditions by a trained research technician
75797717|NCT05835115|Diagnostic Test|A deep learning-based myopia and myopic maculopathy detection and prediction system|This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.
75797718|NCT05835089|Diagnostic Test|serum kisspeptin levels|Evaluation of the serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels
76088082|NCT02470026|Drug|placebo|single control treatment
76088083|NCT04749316|Procedure|AcuTENS|Stimulation of acupuncture points with TENS machine
76088084|NCT03238794|Procedure|Roux-En-Y Gastric Bypass|Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
75650533|NCT00662493|Behavioral|Quadriceps strengthening program|4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
75650534|NCT00785395|Drug|Oxytocin infusion|Up-down dosing determination
75650535|NCT00662571|Drug|acamprosate|acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
75797719|NCT05835076|Diagnostic Test|Stool antigen test|Antigen test in the stool analysis
76088085|NCT03238794|Other|Low-calorie Diet|Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
75650536|NCT00780793|Drug|progressive spacing of TNF-blocker injections|"Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~if DAS28 > 2.6 and DAS28 change ≤ 0.6: continue at step N~if DAS28 > 2.6 and DAS28 change > 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~Adalimumab 40 mg / 14 days~Etanercept 50 mg / 7 days~Step 1 :~Adalimumab 40 mg / 21 days~Etanercept 50 mg / 10 days~Step 2 :~Adalimumab 40 mg / 28 days~Etanercept 50 mg / 14 days~Step 3 :~Adalimumab 40 mg / 42 days~Etanercept 50 mg / 21 days~Step 4 :~TNF-blocker stop"
75935598|NCT02286297|Device|McGRATH® MAC|video-laryngoscopy-1
75650537|NCT00780793|Drug|DMARD maintenance|DMARD maintenance
75650538|NCT00662727|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
75650539|NCT00662727|Device|Placebo|Placebo
75935599|NCT02286297|Device|AirTraq|video-laryngoscopy-2
75935600|NCT02286297|Device|GlideScope|video-laryngoscopy-3
75935601|NCT02286297|Device|Miller|Direct laryngoscopy
75935602|NCT03197636|Drug|Pembrolizumab|Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
76088086|NCT03208296|Biological|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
76088087|NCT02989480|Radiation|PET CT|PET CT scans
76088088|NCT02989480|Other|Cardiac MRI|Cardiac MRI
76088089|NCT01786876|Drug|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
75340445|NCT05170776|Other|Pilates exercises|"ten exercises will be performed:~Hip Twist Level 1~Double leg stretch Level 1~Double leg stretch Level 2~One leg stretch Level 1~Clam Level 1~Scissors Level 1~Arm openings Level 1~Breast stroke prep Level 1t~Hip Twist Level 1.~Breast stroke prep Level 2 as for level 1"
75340446|NCT05170776|Other|postural correction exercises|"postural correction exercise in the form of :~Strengthening deep cervical flexors through chin tucks,~Stretching cervical extensors through a chin drop~Strengthen shoulder retractors~Unilateral and bilateral pectoralis stretch alternating each two-week period."
75340447|NCT05219838|Drug|Lu AG06466|Lu AG06466 will be administered per dose and schedule specified in the arm description.
75935603|NCT04597151|Dietary Supplement|Dietary Intervention|Attend diet education sessions
75935604|NCT03194438|Behavioral|Urban Zen Integrative Therapy (UZIT)|Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
75935605|NCT05724381|Diagnostic Test|auramine phenol staining|The samples will be divided into 2 parts. The 1st part will be subjected to a direct wet saline smear, iodine smear, and concentration techniques. The 2nd part will be used to perform thin smears of the fecal concentrates and air-dried on 2 different slides. The first slide will be stained with Kinyoun's acid-fast stain and examined with the conventional light microscope and the second will be stained with auramine-phenol stain and examined with the fluorescent microscope.
75935606|NCT03194594|Drug|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
75935607|NCT04469049|Behavioral|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
75935608|NCT03133533|Procedure|laparoscopic repair|Surgical inguinal hernia repair using laparoscopic approach.
75935609|NCT03133533|Procedure|robot-assisted repair|Surgical inguinal hernia repair using robot-assisted approach.
75935610|NCT02450240|Behavioral|standardized diagnostic assessment|
75935611|NCT02450240|Behavioral|self-report questionnaires|
75935612|NCT02450240|Behavioral|behavioral tasks|
75935613|NCT02450240|Other|physiological measurements|
75340448|NCT05168280|Drug|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.
75650540|NCT00661635|Drug|placebo|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
75650541|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
75650542|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
75650543|NCT00790465|Dietary Supplement|dark chocolate|21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.
75935614|NCT02450240|Other|structural and functional magnetic resonance imaging and EEG|
75935615|NCT02450240|Other|biomarker and microbiome assessments|
75935616|NCT02450240|Other|blood to derive induced pluripotent stem cells|
75935617|NCT02450240|Other|genetic and epigenetic assessments|
76088090|NCT05230290|Biological|KD6001 Injection|Solution for intravenous injection
76088091|NCT01786954|Device|Icare rebound tonometry|
76088092|NCT01786954|Device|Tonopen applanation|
76088093|NCT01786954|Device|Goldmann applanation|
76088094|NCT05217810|Other|Atectura inhalation capsule (150/80ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
75474402|NCT01983163|Other|Ketogenic diet (2.5 to 4:1)|Minimum ratio (2.5 to4:1) ketogenic diet causing ketosis will be given
75797720|NCT05835050|Diagnostic Test|serum interleukin 10 level|b. Serum levels of IL-10 were measured using a quantitative enzyme-linked immunosorbent assay (ELISA)
75797721|NCT05834985|Procedure|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
75340449|NCT05168280|Drug|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
75797722|NCT05834933|Behavioral|Individualized breast cancer risk assessment|Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.
75797723|NCT05834933|Behavioral|Individualized breast cancer risk counselling|Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The
75797724|NCT05834868|Drug|THDB0206 Injection|Drug: THDB0206 Injection Injected subcutaneously three times a day. Dose was individually adjusted.
75797725|NCT05834868|Drug|Insulin Lispro Injection|Drug:Insulin Lispro Injection Injected subcutaneously three times a day. Dose was individually adjusted.
75340450|NCT05219370|Drug|Cannabis oil|administration of different cannabis oil types as compared with placebo
75650544|NCT00790465|Dietary Supplement|placebo chocolate with crossover to dark chocolate|Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
75650545|NCT04155957|Other|Rapid Recovery Rehabilitation Programme|"Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises."
75797726|NCT05834855|Drug|Rituximab|Treatment with rituximab
75474403|NCT01983163|Other|Modified Atkin's diet|1:1 fixed ketogenic ratio Modified atkins diet will be given
75797727|NCT05834764|Drug|Pyrotinib|Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）
75797728|NCT05834751|Drug|PEG-rhG-CSF|48-72 hours after chemotherapy,9 mg of PEG-rhG-CSF was injected subcutaneously for mobilization
75797729|NCT05834751|Drug|RhG-CSF|After clinical evaluation, rhG-CSF was given 10μ g/kg/d for mobilization until the stem cell collection was completed.
75797730|NCT05834712|Device|mobile platform or not mobile platform|Intervention using WeChat
75797731|NCT05834699|Biological|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-low ABC
75935618|NCT03133455|Other|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
75935619|NCT04407377|Drug|Tolperisone Hydrochloride|Study Drug
75935620|NCT04407377|Drug|Cyclobenzaprine Hydrochloride 10 MG|Active Comparator
75935621|NCT04407377|Other|Placebo|Placebo Comparator
75935622|NCT00272649|Biological|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
75340451|NCT05170308|Device|CO2 fractional laser|The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) to treat dyspigmentation in lichen planus pigmentosus
75340452|NCT05170152|Procedure|ultrasonography-guided injection|ultrasonography-guided injection
75340453|NCT05170152|Procedure|pullae A1 release|ultrasonography-guided pullae A1 release
75474404|NCT01983189|Procedure|transcranial magnetic stimulation|1 hz transcranial magnetic stimulation
75474405|NCT01983215|Device|Prevena vac|
75474406|NCT01983267|Drug|cannabis|use of cannabis oil or cigarets
75474407|NCT01983280|Other|Healing Touch|
75474408|NCT01983319|Device|active anodal transcranial Direct Current Stimulation (tDCS)|Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
75474409|NCT01983319|Device|sham transcranial Direct Current Stimulation|sham transcranial Direct Current Stimulation 30 min with CIMT
75474410|NCT01983319|Behavioral|Constraint Induced Movement Therapy (CIMT)|2 weeks of CIMT
75474411|NCT01983345|Procedure|prenatal surgical repair of fetal myelomeningocele|open surgical repair of myelomeningocele before 26 weeks gestational age
75797732|NCT05834686|Biological|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-positive ABC
75797733|NCT05834647|Drug|Prilocaine 2%|50 mg prilocaine 2% (2.5 mL volume) before undergoing cystoscopy procedure
75797734|NCT05834647|Drug|Hyperbaric Lidocaine 5%|50 mg Hyperbaric Lidocaine 5% (1.0 mL volume) before undergoing cystoscopy procedure
75935623|NCT04375085|Device|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
75935624|NCT03203174|Device|Microneedle|Microneedles are small needles used to create holes in the stratum corneum (top layer of skin) with relatively low amount of pain.
75935625|NCT03203174|Device|Sham Microneedle|Flat roller with no needles on the roller
75935626|NCT03203174|Drug|Botulinum Toxin Type A|Botulinum toxin type A will be applied to the palm
75935627|NCT03203174|Other|Saline|Saline applied to the palm
75935628|NCT03531333|Procedure|ultrasound guided surgery.|during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
76088095|NCT05217810|Other|Atectura inhalation capsule (150/160ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
76088096|NCT05217810|Other|Atectura inhalation capsule (150/320ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
75797735|NCT05834634|Device|Ultrasound|The patients and controls will be scanned at the Neurophysiology unit of the Department of Neurology, Neurology, psychiatry and Neurosurgery hospital, Assiut university hospital. The acquisition of ultrasound images was performed using a Philips HD11XE imaging system with an L12-8 linear array probe. Cross-sectional area (CSA) of the right and left Vagus nerves in each subject, perimeter, echogenicity, and fascicular structure will be assessed and measured by tracing the nerve just inside its hyperechoic rim. The nerve will be seen on ultrasound B-mode near the bifurcation of the carotid artery, dorsal to the internal and common carotid arteries, as a structure that is hypoechogenic in the centre and more hyperechogenic on the periphery (24, 25). Both the carotid artery and the internal jugular vein served as anatomical landmarks (25). Two separate CSA measurements, with the probe repositioned for each measurement, will be taken and they will be averaged.
75935629|NCT04484480|Procedure|Balance training|Proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
75935630|NCT02450162|Procedure|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
75650546|NCT04155957|Device|ReHub|"Participants use a telerehabilitation platform, ReHub, as a guide to perform the TKA rehabilitation exercises of the Rapid Recovery Rehabilitation Programme intervention.~The exercise plan in ReHub is carried out by a site physiotherapist on the first day after discharge by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor that transmits data to the platform.~The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. At the end of each exercise, participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
75650547|NCT02555761|Drug|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
75935631|NCT04612283|Other|NGA-01 gel|NGA-01 is a gel formulation with mostly herbal active ingredients
75650548|NCT04155879|Drug|Colchicine Tablets|Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
76088097|NCT04517838|Procedure|Biospecimen Collection|Undergo collection of blood and tumor tissue samples
75935632|NCT04612283|Other|Placebo|A Placebo with no active ingredients
75650549|NCT04155879|Procedure|Cardioversion|Electrical or pharmacologic restoration of sinus rhythm
75935633|NCT04484402|Biological|mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution
75935634|NCT04484402|Biological|limbal stem cells|Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution
75935635|NCT04484402|Other|standard treatment|Standard treatment according to the Clinical protocols
75935636|NCT05220995|Genetic|protocol|ovarian stimulation protocols on euploid rates were compared.
75935637|NCT00257205|Drug|dacarbazine|decarbazine 1000 mg/m2 IV Q 21 days x 12
75935638|NCT00257205|Drug|CP-675,206|CP-675,206 15 mg/kg IV Q 90 days x 4
76088098|NCT01837654|Behavioral|Plantarflexion 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
76088099|NCT01837654|Behavioral|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
75474412|NCT01983358|Drug|JPI-289|PARP-1 inhibitor
75474413|NCT01983358|Other|Placebo|Placebo
75935639|NCT00257205|Drug|temozolomide|temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
75474414|NCT01983371|Drug|Ferumoxytol|All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
75474415|NCT01983371|Other|Magnetic Resonance Imaging|All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
75474416|NCT01983384|Other|Processed EEG-guided anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
75650550|NCT00662805|Drug|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
75935640|NCT05052749|Other|High Intensity Resistance Training (HIRT)|High Intensity Resistance Exercises Supervised High Intensity Resistance Training with 15 minutes of cycling as a warm-up activity then HIRT through Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
75474417|NCT01983397|Other|Multicomponent training|The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.
76088100|NCT02474862|Behavioral|Prenatal Walking Program|PWP is a gentle walking intervention tailored for pregnant women.
76088101|NCT02474862|Behavioral|Postpartum Prep Program|PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
76088102|NCT02261428|Device|Catheter Tiemann|We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
76088103|NCT02261428|Device|Suction catheter|We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
76088104|NCT01838980|Device|Motus GI Clean-Up Device|
75797736|NCT05834582|Drug|Fluzoparib+Paclitaxel|Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy
75797737|NCT05834582|Drug|Epirubicin+Cyclophosphamide|Epirubicin+Cyclophosphamide
75797738|NCT05834556|Behavioral|Prehabilitation|Everyone will participate in a home-based prehab program with individual video sessions with a physiotherapist at 4 time points over a period of 3 weeks. The initial session will take an hour and consist of a subjective and physical assessment followed by an individualized exercise program demonstration and education. Patients will be instructed to complete the exercises independently 3x/week. The second and third sessions will be 30 minutes in duration and will check in on activity progress, the presence of abnormal responses to exercise, review exercise technique, address barriers and facilitators to activity completion as well as provide support and encouragement for the current level of activity. The final session will take 30 minutes and will review exercise progress, presence of abnormal responses to exercise followed by a reassessment of physical function.
75650551|NCT02555137|Other|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
75650552|NCT00662883|Drug|PMI-150 (intranasal ketamine HCl); mometasone furoate|"1 dose PMI-150 (intranasal ketamine HCl); day 1~mometasone furoate, daily; days 2-15~1 dose PMI-150 (intranasal ketamine HCl); day 15"
76088105|NCT01839058|Other|Esophageal Manometry|Both cohorts will undergo standard high resolution esophageal manometry testing. This entails a catheter passed through the nose into the esophagus and measures pressure changes with a series of wet swallows. As part of the study, we will also be instilling both weak acid and saline into the esophagus.
76088106|NCT01839604|Drug|AZD9150|Intravenous infusion over 3 hours.
75474418|NCT01983397|Other|Resistance training|The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
75650553|NCT00662961|Procedure|Periosteum|Periosteum fixation
75650554|NCT00662961|Procedure|Bone|Bone tunnel fixation
75650555|NCT00785473|Dietary Supplement|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
75935641|NCT05052749|Other|Low-moderate Resistance Exercise Training|Supervised Low-moderate Resistance Training with 15 minutes of cycling as a warm-up activity then Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
76088107|NCT02261818|Behavioral|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
75650556|NCT00785473|Dietary Supplement|calcium carbonate|calcium carbonate 500 mg daily for 2 years
75650557|NCT02631291|Behavioral|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
76088108|NCT01840072|Other|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
75650558|NCT02631291|Behavioral|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
75797739|NCT05834543|Drug|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin|"TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
75797740|NCT05834543|Drug|Penpulimab injection, Paclitaxel, Cisplatin|"Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
75797741|NCT05834543|Drug|TQB2618 injection, Penpulimab injection, TQB3617capsules|TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).
75935642|NCT03194516|Other|Surveillance|The investigators propose an 8-week ketogenic diet intervention with pre-/post-intervention assessment of serum and tissue metabolic and inflammatory biomarkers, including metabolomics analysis, among a sample of 12 overweight or obese prostate cancer patients on active surveillance. There will be no randomization; all patients will receive the diet intervention.
75935643|NCT03627533|Procedure|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
75935644|NCT03197714|Drug|OPB-111077|"Two dose schemas will be employed:~Level 1: 200 mg daily~Level 2: 250 mg daily"
76088109|NCT01789138|Behavioral|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
75797742|NCT05834530|Other|3D Printed Complete Dentures|Denture bases printed from a pre-polymerized block via additive technique, using photon S desktop 3D printer* that relies on SLA technology and post cured by post curing unit.
75797743|NCT05834517|Drug|Hyaluronic acid|Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts
75797744|NCT05834517|Procedure|non surgical periodontal therapy|NSPT, with or without adjunctive therapies, is an effective treatment for periodontitis. It reduces PD and results in formation of some new attachment; however, it also has several limitations, and surgical therapy might be required to control inflammation and optimize outcomes. When used for non-surgical scaling and root planing, periodontal curettes can reach a mean PD of up to approximately 5.5 mm. The mean PD in which a plaque-free and calculus-free surface can be established is <4 mm
76088110|NCT01841632|Drug|MultiStem|
75797745|NCT05834504|Other|Short distributed training (1-2 days)|"The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved."
76088111|NCT01807949|Drug|Placebo|Matching placebo tablet
76088112|NCT01807949|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
76088113|NCT01807949|Drug|Ivacaftor|Film-coated tablet
76088114|NCT02989558|Drug|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
75650559|NCT00785551|Drug|quinine sulfate|2 x 324mg given in one dose to healthy subjects
75935645|NCT05220761|Diagnostic Test|Cornell Assessment of Pediatric Delirium|Cornell Assessment of Pediatric Delirium is a diagnostic test for PICU delirium State Behavioral Scale and Richmond Agitation and Sedation Scale are diagnostic tests for sedation and agitation in children
75474419|NCT01983423|Device|Endometrial Biopsy|An endometrial biopsy is performed using a sampling device known as a pipelle catheter which is introduced into the uterine cavity. The inner core is withdrawn creating suctional pressure into the hollow bore of the cavity, which allows acquisition of endometrial tissue upon rotation in the cavity. This is removed and the tissue sent for pathologic examination.
75935646|NCT05220683|Device|digital marking system|Verion or Callisto, digital marking system
75935647|NCT03194282|Other|insole|The subjects are randomly assigned to assess balance capacity either with or without insole.
75935648|NCT04089527|Drug|CC-95775|CC-95775
76088115|NCT02989558|Drug|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
76088116|NCT01806779|Drug|Chantix|
75650560|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
75650561|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
75650562|NCT04031937|Other|Psychomotor assessment|the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
75650563|NCT00780949|Other|intestinal biopsies|intestinal biopsies during routine endoscopy
75935649|NCT05724303|Other|8-week neuromuscular training program|Training program consisting of two neuromuscular training sessions per week
75935650|NCT03194204|Drug|Doxycycline Tablets|MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
75935651|NCT04441359|Other|Supplemented formula|standard infant formula supplemented with 8 g/L prebiotic inulin-type fructans
75650564|NCT02631369|Device|Heidelberg Spectralis OCT device|
75650565|NCT00790777|Drug|Paliperidone ER|
75650566|NCT00663195|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
75650567|NCT00791011|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
75650568|NCT00791011|Other|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
75650569|NCT00791011|Other|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
75650570|NCT00663273|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
75935652|NCT04441359|Other|Standard formula|standard infant formula not supplemented with prebiotic inulin-type fructans
75935653|NCT05052047|Other|Brisk Walking Group|Brisk Walk: 20 min/day (The researchers found, for most people, brisk walking could be defined as moving at a pace of 2.7 miles per hour or 100 steps per minute for adults under about age 60 or guidelines define brisk walking as occurring when individuals move at a pace that increases their heart rate to about 70% of their heart rate maximum) Patient will also perform breathing exercises as given to Control group, Positioning (lean forward when needed) Percussion coughing when needed
76088117|NCT01806779|Drug|Zyban|
76088118|NCT01806779|Drug|Nicotine patches|All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
76088119|NCT01789840|Device|Embosphere Microspheres|
75650571|NCT00663429|Drug|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
75797746|NCT05834452|Procedure|The Epley Maneuver|"5 step procedure where the patient:~Sits upright in a neutral position~Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~Rotated 90° towards the unaffected side around the yaw axis~Rotate a further 90° toward the unaffected side around the yaw axis~Rotates back to an upright position with a 135° backward rotation around the pitch axis."
75935654|NCT05052047|Other|Conventional Breathing Exercise Group|"Breathing exercises: 20 min/day~Breathing Ex includes:~• Pursed lip breathing: Sit with your back straight, inhale through your nose for 2 seconds. Purse your lips like you rae blowing on hot food and then breath out slowly, take twice as long to exhale as you took to breath in 4-5 times a day~• Diaphragmatic breathing: Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs . breathe in slowly through your nose tighten your stomach, letting them fall inward as you exhale through your pursed lips. Practice these exercises 5-10 minutes about 3-4 times a day.~Positioning (lean forward when needed) Percussion coughing when needed"
75935655|NCT03203018|Behavioral|Interactive workshop based on community specific needs|"Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results."
75935656|NCT05013359|Other|No treatment given|No treatment given
75935657|NCT03197480|Drug|Aflibercept Injection [Eylea]|All subjects will receive 4 monthly intravitreal injections of aflibercept
76088120|NCT01789840|Procedure|TURP|
75474420|NCT01983436|Other|Manual Lymphatic drainage|Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
75650572|NCT00781027|Procedure|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
75650573|NCT02555917|Procedure|anterior cruciate ligament reconstruction|Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
75650574|NCT00781105|Drug|Telbivudine|600 mg/day, oral tablets, once daily, 52 weeks
75650575|NCT00785863|Other|Placebo|Placebo IV before placebo infusion
75650576|NCT00785863|Drug|Remifentanil|placebo IV and remifentanil infusion
75650577|NCT00785863|Drug|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
75650578|NCT00785863|Drug|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
75797747|NCT05834452|Procedure|The 360 Degree Maneuver|"5 step procedure where the patient:~Sits upright in a neutral position~Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~Rotate a further 90° backward around the pitch axis (total 225°)~Rotate a further 90° backward around the pitch axis (total 315°)~Rotate back to an upright position with an additional 45° backward rota-tion around the pitch axis (total 360°)."
75935658|NCT00151281|Drug|PEPC|"Induction phase (month 1-3)~• PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC < 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.~Maintenance phase (month 4-12) • PEPC QOD or fractionated weekly basis.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• PEPC QOD or fractionated weekly basis"
75935659|NCT00151281|Drug|Thalidomide|"Induction phase (month 1-3)~• Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.~Maintenance phase (month 4-12) • Daily low dose thalidomide (50-100 mg/d)~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Daily low dose thalidomide (50-100mg/d)"
76088121|NCT01878526|Drug|Alginic acid|Algycon 1 tab chew tid after meal
76088122|NCT01878526|Drug|placebo (for domperidone)|placebo (for domperidone) 1 tab oral tid before meal
76088123|NCT01878526|Drug|Domperidone|domperidone (10 mg) 1 tab oral tid before meal
76088124|NCT01878526|Drug|placebo (of alginic acid)|placebo (for alginic acid) 1 tab chew tid after meal
76088125|NCT01878604|Genetic|Gene analysis|Gene analysis
75650579|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
75650580|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
75650581|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
75650582|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
75650583|NCT00664105|Drug|Carboplatin|"Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment."
75650584|NCT00664105|Drug|Docetaxel|"Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks)."
75650585|NCT00664105|Radiation|radiation therapy|Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
75797748|NCT05834452|Device|Mechanical rotational chair|TRV chair
76088126|NCT01878604|Other|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
76088127|NCT01878604|Other|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
76088128|NCT01792024|Device|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
76088129|NCT01792024|Procedure|magnetic resonance imaging|Undergo MR-guided LITT
75935660|NCT00151281|Drug|Rituximab|"Induction phase (month 1-3)~• Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.~Maintenance phase (month 4-12) • Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months"
75935661|NCT03202862|Drug|Fulvestrant|Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
75340454|NCT05168514|Other|Massage|"Patient Identification Form, Pittsburgh Sleep Quality Index and McGill Pain Scale Short Form will be applied to patients with written and verbal consent. Scales and massage application will be done before the pharmacological agent is administered to the patients.~Back massage will be applied to the experimental group for 10 minutes every day for 10 days. Routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the experimental group before and after each massage and scores will be recorded for 10 days.~The control group will not be interfered with, and the routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the control group simultaneously with the experimental group and scores will be recorded for 10 days."
75340455|NCT05108376|Device|Visensia Safety Index (VSI)|Enrolled patients will undergo continuous vital sign monitoring, to be used by the Visensia Safety Index (VSI) to identify early deterioration. If early deterioration is identified, the VSI will produce an alert to notify the RACE team.
75797749|NCT05834413|Drug|chemotherapy plus TCM 1&ICIs plusTCM2 placebo|"In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
75797750|NCT05834413|Drug|chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo|"Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
75797751|NCT05834374|Other|Contextual variation|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
75935662|NCT03627455|Other|Percutaneous coronary intervention|Percutaneous coronary intervention
75935663|NCT03202940|Drug|Alectinib|Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow
75340456|NCT00464204|Drug|"6 % Hydroxyethylstarch 130/0.4 = Voluven®"|Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.
75340457|NCT00464204|Drug|0.9 % NaCl|NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
75340458|NCT05107206|Device|Mechanical Thrombectomy using the Envi™-SR Thrombectomy device|Clot removal using the Envi™-SR Thrombectomy device
75935664|NCT03202940|Drug|Cobimetinib|Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow
75935665|NCT00255099|Drug|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
75935666|NCT00255099|Drug|Placebo|2 tablets b.i.d. / 96 weeks
75935667|NCT02445482|Procedure|Biopsy|archival tissue or fresh biospsy
75935668|NCT02288481|Drug|TBA-354|TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
75935669|NCT02288481|Other|Placebo|Placebo Suspension
75935670|NCT03197246|Device|IVECG|Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
75935671|NCT03197246|Device|Chest X-ray|Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
75935672|NCT05724147|Behavioral|Mandala Activity|Three sessions of mandala activity, once a week, will be applied to the participants from the elderly people in the nursing home included in the study. The mandala activity planned to be done with the group will be done in addition to the standard monitoring applied in the institution, so it will be held at an appropriate time according to the flow in the institution. Before leaving the individuals, the most appropriate time for the next mandala session will be determined by taking into account the preferences of the individuals. Individuals to be included in the study will be grouped in groups of 10. Mandala activity application time is planned to last approximately 2 hours. If individuals have any physical symptoms, the time of the mandala activity is rescheduled, and each individual is expected to attend five sessions during the total study period.
75935673|NCT03203096|Dietary Supplement|Magnesium|Magnesium citrate / Magnesium oxide
75935674|NCT03203096|Dietary Supplement|Placebo|
75935675|NCT00231153|Drug|Omiganan 1% gel|Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
75935676|NCT00231153|Drug|Povidone-Iodine 10%|All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
75650586|NCT04155645|Drug|AZD8233 subcutaneous injection|Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
76088130|NCT02266576|Behavioral|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.
75650587|NCT04155645|Drug|Placebo|Randomized subjects will receive SC dose of placebo injection.
75650588|NCT04155801|Dietary Supplement|Salix Probiotic Blend|Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus [NCFM]® and Lactobacillus paracasei [Lpc-37]®).
76088131|NCT02266576|Behavioral|Enhanced DPP|Enhanced DPP components consist of access to a mental health counselor, active referrals to mental health services, and traditional healing workshops such as the use of talking circles, a modified photo voice and digital storytelling to address specific psychosocial issues that are a result of historical trauma, stress, and grief.
76088132|NCT02266810|Device|PROPEL Mini Sinus Implant.|Placement of sinus implant following frontal sinus surgery
75797752|NCT05834374|Other|Maximum affordances|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
75797753|NCT05834361|Drug|early vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is 20 minutes before the surgery.
75797754|NCT05834361|Drug|delayed vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is usually 110-120 minutes before the surgery.
75797755|NCT05834283|Other|aerobic exercises|"This group will be received aerobic exercises 3 sessions per week for 8 weeks. Warm up phase: in which each participant will walk at 80 m/min at 0.0% grade for 5 mint.~Active phase: treadmill speed will be increased to 147 m/min and grade will be increased gradually untill reached 25% grade for 20 mint.~Cool down phase: in which the treadmil speed and grade will be decreased to 2.0miles/h and 0.0% grade during a cool down period consisted of 5 mint."
76088133|NCT02266810|Procedure|Sinus Surgery alone|Sinus surgery only, without implant placement
75797756|NCT05834283|Other|core stability exercises|"This group will be received core stability exercises 3 sessions per week for 8 weeks.~All participants in both groups will be evaluated before and after the treatment programs.~Lie on your back and place your feet on a wall so that your knees and hips are bent at 90 degrees angles. Tighten your abdominal muscles.~Raise your head and shoulders off the floor. Return to the start position and repeat."
75797757|NCT05834270|Drug|Single dose tamsulosin 0.4mg|Single dose tamsulosin 0.4mg
75935677|NCT03202784|Drug|BCX7353|BCX7353
75935678|NCT05220527|Drug|Triamcinolone plus hyruan|triamcinolone plus hyruan injections, one time per week, for 3 weeks
75935679|NCT05220527|Drug|vitagen plus hyruan|vitagen plus hyruan injections, one time per week, for 3 weeks
75935680|NCT05220527|Drug|normal saline plus hyruan|normal saline plus hyruan injections, one time per week, for 3 weeks
75340459|NCT05107206|Device|Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device|Clot removal using the Solitaire or Trevo Revascularization Device
75340460|NCT05106816|Other|skin surface vibration|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.
75650589|NCT00785941|Biological|IMC-A12|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
75650590|NCT00785941|Biological|IMC-A12|"Cohort 2~10 mg/kg I.V., once every other week for 4 weeks"
75650591|NCT00785941|Biological|IMC-A12|"Cohort 3~15 mg/kg I.V., once every other week for 4 weeks"
75650592|NCT00785941|Biological|IMC-A12|"Cohort 4~21 mg/kg I.V., once every other week for 4 weeks"
75650593|NCT00785941|Biological|IMC-A12|"Cohort 5~27 mg/kg I.V., once every other week for 4 weeks"
75650594|NCT00663585|Behavioral|Vipassana Meditation|12 day retreat where participants learn to meditate
75650595|NCT02555605|Drug|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
75797758|NCT05834270|Drug|Double dose tamsulosin 0.4mg|Double dose tamsulosin 0.4mg
76088134|NCT02266810|Device|Propel Nova Sinus Implant|Placement of sinus implant following frontal sinus surgery
76088135|NCT01879540|Biological|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
75797759|NCT05834257|Other|Crystalloid fluid infusion|Cardiac surgery patients admitted to the intensive care units will either receive, following consent and randomisation, Normal Saline, PlasmaLyte or Ringer's Lactate as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient enrolled in the study.
75340461|NCT05106816|Other|light skin surface vibration- SHAM|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones. Worn at the lowest frequency will simulate the active arms with no potential change in symptoms.
75340462|NCT00464438|Drug|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
75935681|NCT03197402|Dietary Supplement|Leucine-enriched protein gel delivery system|Leucine enriched
75935682|NCT03197402|Dietary Supplement|Milk protein gel delivery system|Non-leucine enriched
75474421|NCT01983449|Drug|Dexamethasone Sodium Phosphate Injection, USP|Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
75650596|NCT00663663|Behavioral|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
75650597|NCT00663663|Behavioral|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
75650598|NCT00791167|Drug|Paliperidone ER|
75650599|NCT04155255|Other|MyBFF@school|
76088136|NCT01842646|Drug|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
76088137|NCT04350736|Drug|TD-0903|Study drug to be administered by inhalation
76088138|NCT04350736|Drug|Placebo|Placebo to be administered by inhalation
76088139|NCT01607957|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
76088140|NCT01607957|Drug|Placebo|Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
76088141|NCT01845220|Drug|Broccoli Sprout Extract|150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
75650600|NCT00781183|Other|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
75650601|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle
75797760|NCT05834231|Drug|Memantine|oral
75797761|NCT05834231|Drug|Placebo|oral
75935683|NCT05220449|Other|Cross-frequency dual-site tACS|Dual site transcranial alternating current stimulation over the primary visual cortex (V1) and the mediotemporal cortex (MT/V5) using two different stimulation frequencies (Alpha and Gamma)
75935684|NCT05724069|Drug|Velusetrag|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
75935685|NCT05724069|Drug|Placebo|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
76088142|NCT01845220|Drug|Placebo|80% acetone
76088143|NCT01795534|Dietary Supplement|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
76088144|NCT01795534|Dietary Supplement|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
76088145|NCT01806623|Drug|Fluconazole|Single oral dose of 150mg Fluconazole
76088146|NCT01806545|Biological|SRM003|One time implant (2 SRM003 pieces) on surgery day.
76088147|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
76088148|NCT01846702|Drug|Placebo|Given as a SC injection.
76088149|NCT01846702|Drug|LY3084077|Given as a SC injection.
75340463|NCT00464438|Drug|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
75340464|NCT00465530|Drug|Saline|Intranasal Saline
75340465|NCT00465530|Drug|Gentamycin|Intranasal irrigation
75474422|NCT01983475|Drug|Denosumab|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
75935686|NCT05723991|Drug|Disitamab Vedotin and Gemcitabine|Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every two weeks. After completing 3 cycles of neoadjuvant combined therapy, imaging evaluation was performed. If the tumor is T0, radical surgery for bladder cancer was performed; Otherwise, perform radical surgery for bladder cancer after completing 1-3 cycles of treatment (total cystectomy+standard/extended lymph node dissection)
76088150|NCT01847014|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
76088151|NCT01847638|Drug|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
75797762|NCT05834192|Other|Backward treadmill walking|Backward Treadmill walking will be given to this group. Speed settings of treadmill will be established based on the previous motor function of participants. All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down.
75935687|NCT05220215|Other|Nordic Hamstring Exercise|To perform Nordic Hamstring Exercise, the subject was in kneeling position on the mat, arms by the side or in front of the chest, knee in 90-degree flexion and ankles well stabilized with the help of a therapist which is positioned behind the subject. Then subject was asked to lean forward by using the hamstring muscles by extending while trying to resist the forward fall, he should lean forward from the knee and not from the hip. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and them repeat the procedure again.
75340466|NCT04421430|Other|Distraction cards|The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.
75340467|NCT04421430|Other|Virtual reality|The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.
75474423|NCT01983475|Drug|Placebo (identical Denosumab volume of normal saline)|The placebo group will receive the identical volume of normal saline at parallel time points.
75474424|NCT01983501|Drug|Tucatinib (ONT-380)|Given twice per day, orally
75650602|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle
75935688|NCT05220215|Other|Hamstring Curl with Resistance band|"Traditional Hamstring Curl by using Resistance band.~Resistance Band: Thera-band Green, 4.6 kg resistance at 100% elongation"
75650603|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
75650604|NCT00661687|Device|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
75650605|NCT00661687|Device|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
75650606|NCT04155177|Procedure|training for french ambulatory caesarean section|"The participant will be first invited to consult a theoretical support and a video treating on FAUCS.~After that, he will be asked to be the first assistant, in a FAUCS procedure with one of the two senior surgeons assigned for the study.~In a second step, the trainee will have to perform all the steps of the FAUCS, assisted by one of the two senior surgeons . During each surgery, Operative time will be measured, while an evaluation on four stages according to the Zwisch model of supervision will performed by the senior surgeons .~Once, the two seniors agree on the highest level assessment for the resident, he will be allowed to operate alone FAUCS procedures and will be evaluated by the measurement of operating times, the neonatal outcomes and the occurrence or not of complications.~finally, total number of FAUCS procedures required for each resident in order to master the technique will be determined."
75650607|NCT00791245|Biological|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
75650608|NCT00663897|Drug|lansoprazole|lansoprazole, 30 mg, once daily for 14 days
75650609|NCT00663897|Drug|mosapride|mosapride, 5 mg, thrice daily for 14 days
75650610|NCT00663975|Drug|DCI 1020|capsules (4,000 units of lipase) will be administered with meals and snacks
75650611|NCT00664053|Dietary Supplement|DHEA|50mg daily for 6 months
76088152|NCT01847638|Drug|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
76088153|NCT05328778|Drug|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
76088154|NCT01796236|Device|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
76088155|NCT01796236|Device|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
76088156|NCT02470962|Other|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
76088157|NCT02474628|Dietary Supplement|sodium bicarbonate|
76088158|NCT02474628|Dietary Supplement|calcium carbonate|
75474425|NCT01983501|Drug|T-DM1|Given intravenously once every 21 days
75474426|NCT01983514|Drug|8IU intranasal oxytocin|
75650612|NCT00664053|Behavioral|Yoga|2 sessions per week for 6 months
75650613|NCT00664053|Dietary Supplement|Placebo|Placebo supplement every day for 6 months
75650614|NCT00664053|Behavioral|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
75340468|NCT04421430|Other|Buzzy|Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
75340469|NCT05052762|Other|Group A: Elastic resisted training for Gluteus Maximus strength|"Subjects attended physical therapy two times per week for a total of 10 visits. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) are added. Each exercise was performed for 10 repetitions. Elastic resistance was Added to the fire hydrant, hip extension in prone and deadlift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
75340470|NCT05052762|Other|Group B: Weight resisted training for Gluteus Maximus strength|Subjects attended p two times per week for a total of 10 visits. The participants performed PHEKF in 90° knee flexion with 30° hip abduction and 10° hip extension to increase the muscle activity of the gluteus maximus. In the prone position, the participant performed 10° hip extension until the posterior knee reached the horizontal bar. The participants maintained 90° knee flexion with 30° hip abduction and 10° hip extension in the prone position against the resistance. Sandbags (3 kg) will be used to provide resistance on the ankle through a rope and pulley. Each subject performed three sets with three repetitions of five seconds each. 1-minute break is allowed between each set.
75340471|NCT00466310|Drug|Aripiprazole|Aripiprazole for 4 weeks
75340472|NCT00466310|Drug|Risperidone|Subjects will be randomized to risperidone for 4 weeks
75340473|NCT00466310|Other|Healthy volunteers|Healthy volunteers
75340474|NCT05106270|Diagnostic Test|Atrial pressure measurement using transseptal puncture sheath|both left and right atrial pressure was measured using transseptal puncture sheath before and after combined procedure
75340475|NCT02116322|Procedure|EUS-FNA with Corkscrew technique|
75340476|NCT02116322|Device|Expect 19 G Flex needle|
75340477|NCT03463460|Other|Laboratory Biomarker Analysis|Correlative studies
75650615|NCT00664131|Other|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
75650616|NCT04031859|Drug|acetylsalicylic acid|It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
75797763|NCT05834192|Other|Lower extremity cross training|"For cross-training, a strong resistance will be applied by the therapist until a response will be achieved on the contralateral lower extremity at the end range of motion. Resistance will be consistently applied for 10 seconds once a response will be achieved.~All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down."
75797764|NCT05834179|Other|cold endotracheal tube|patients who were intubated with an ETT which kept in the fridge.
75340478|NCT03463460|Biological|Pembrolizumab|Given IV
75797765|NCT05834140|Other|Traditional Physical Therapy|"TENS (transcutaneous electrical nerve stimulation) on continuous mode at 80-120 Hz for 15-20 min and Heating pads for 10-15 min~Total 4 sessions will be given in 2 days"
75340479|NCT03463460|Drug|Sunitinib Malate|Given PO
75340480|NCT00535652|Drug|Ertapenem|powder for infusion, 1 gram I.V., single dose over 30 min.
75650617|NCT00664287|Drug|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
75797766|NCT05834140|Other|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) along with TENS and Heating pads.~MET of the scaleni~MET of Sternocleidomastoid~MET of Levator Scapulae~MET of Upper fibers of Trapezius~Total 4 sessions will be given in 2 days"
75935689|NCT03531177|Behavioral|HEAL-D|HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.
75340481|NCT00418028|Drug|Capecitabine|
75340482|NCT05160246|Other|kinesiology tape|The tape will be fixed without any tension 10 cm below the origin of the rectus femoris muscle. Then 35-50% tension will be applied to the band and descended to the patella. After this point, the Y-shaped band will be terminated to wrap the patella medially and laterally without any tension.
75340483|NCT05160246|Other|Placebo tape|The tape will attach to the rectus femoris without any tension.
75650618|NCT00664287|Drug|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
75650619|NCT00664365|Drug|GSK958108|GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
75935690|NCT03531177|Behavioral|Control|Participants receive usual care from their healthcare team.
75935691|NCT05682599|Drug|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
75935692|NCT05682599|Drug|Placebo|Placebo
75340484|NCT05049954|Other|Calorie-Restricted Healthy Ketogenic Diet|Participants in the experimental group will be advised on a Calorie-restricted Healthy Ketogenic Diet via 7 workshops. Participants will also be advised to monitor their urinary ketones to track compliance.
75474427|NCT01983514|Drug|24 IU intranasal oxytocin|
75650620|NCT00664365|Drug|Placebo|Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
75935693|NCT03531021|Behavioral|Heart healthy intervention|Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
76088159|NCT03108768|Device|Hearing Aid (Successor of Phonak Virto V)|The successor of Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
75340485|NCT05049954|Other|Calorie-Restricted Low Fat Diet|Participants will be advised on Calorie-restricted Low Fat diet via 7 workshops.
75340486|NCT00537290|Drug|Rituximab|Rituximab 1000mg IV on Days 0 and 15
75340487|NCT05049720|Device|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
75340488|NCT05158842|Device|Adult bubble CPAP oxygen therapy device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the patient. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the patient. Oxygen is delivered by a successfully tested, silicon-based, ergonomically designed adaptive version of nasal canula (nasal seal) inserted into the nostril of a patient.~The components are:~Adaptive version of nasal canula (nasal seal)~A nasal canula with connecting circuit system~Water-filled bottle with marking water pressure from10 to15 L/min.~Oxygen cylinder, central distribution through pipelines or by oxygen concentrator will be used as an oxygen source."
75340489|NCT00538304|Drug|bimatoprost eye drops|1 drop in each eye daily for 1 month
75340490|NCT00538304|Drug|placebo|1 drop in each eye daily for 1 month
75340491|NCT00538616|Drug|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
75340492|NCT00538616|Drug|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
75340493|NCT00469274|Drug|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
75340494|NCT00469274|Drug|Antibiotic PEP|TMP-SMX DS po BID for 14 days
75650621|NCT00664443|Behavioral|Dispatch-assisted CPR Instructions|Pre and post assessment of bystander CPR frequency and impact on victim survival related to Dispatch-assisted CPR Instructions given since 2004
75650622|NCT00664599|Drug|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
75797767|NCT05834101|Other|Myofacial Release|Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs
75935694|NCT03530553|Other|Hunt Motivational Scale|The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
75935695|NCT05673551|Other|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
75935696|NCT05722509|Procedure|"Distal Flap Reduction Group"|A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.
76088160|NCT03108768|Device|Hearing Aid (Phonak Virto V)|Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
76088161|NCT03099564|Drug|Pembrolizumab|pembrolizumab 200mg IV every three weeks
75340495|NCT05158296|Drug|Ultevursen|RNA antisense oligonucleotide for intravitreal injection
75340496|NCT05158296|Other|Sham-procedure|Sham-procedure (no experimental drug administered)
75340497|NCT05099094|Genetic|BD311|Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody
75340498|NCT05099016|Other|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and 14) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
75340499|NCT05099016|Other|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use use. Participants will also be offered basic reliable non personalized information on lower-risk cannabis use in the form of official public websites.
75340500|NCT00469508|Drug|Modafinil|400mg pills taken orally daily for 12 wks.
75340501|NCT00469508|Drug|Placebo|400mg pills taken orally daily for 12 wks
75474428|NCT01983514|Drug|1 IU intravenous oxytocin|
75474429|NCT01983514|Drug|Placebo|
75474430|NCT01983527|Procedure|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
75650623|NCT00664599|Drug|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
75650624|NCT02631135|Drug|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
75650625|NCT02631135|Drug|Propofol|BIS values were arranged 40-60 until the end of operation
75650626|NCT02631135|Drug|Dexmedetomidine|0.5 microgram/kg infusion, no changes
75650627|NCT02631135|Drug|Rocuronium|0.5 mg/kg iv for intubation, no change
75650628|NCT00664677|Drug|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
75474431|NCT01983527|Drug|Intra-articular corticosteroid Depo Medrol|Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
75650629|NCT00596817|Drug|Placebo|capsules, daily, orally
76088162|NCT03099564|Device|Y90 radioembolization|The first Y90 radioembolization treatment will be administered one week after the first dose of pembrolizumab. If a second Y90 radioembolization treatment is required for bilobar disease, this should occur within 4 weeks of the initial procedure (between Cycles 2 and 3 of pembrolizumab).
76088163|NCT02469948|Drug|Botulinum toxin type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
76088164|NCT02469792|Procedure|Liposuction|
76088165|NCT02469792|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
76088166|NCT02469792|Procedure|Arthroscopic surgery|
75650630|NCT00596817|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
75650631|NCT01000649|Drug|FE 202158 1.25|FE 202158 at dose 1.25 ng/kg/min infused.
75650632|NCT01000649|Drug|FE 202158 2.5|FE 202158 at dose 2.5 ng/kg/min infused.
75650633|NCT01000649|Drug|FE 202158 3.75|FE 202158 at dose 3.75 ng/kg/min infused.
75650634|NCT01000649|Other|Placebo|Isotonic saline infused.
75650635|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Primary Care Physician (PCP) received the educational intervention
75797768|NCT05834101|Other|Dynamic streching|The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
75797769|NCT05833243|Other|modified diaphragmatic training|Modified diaphragmatic strength training prescriptions will be given based on the result of baseline assessment. The intensity is 60% from the maximum respiratory muscle strength from baseline and weekly remeasurement. Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist.
75935697|NCT05722509|Procedure|"Only Exodontia Group"|Third molar exodontia without associated surgery.
75935698|NCT05219747|Other|Mucoadhesive film containing Acmella oleracea extract|Participants will apply a mucoadhesive film containing Acmella oleracea extract on labial mucosa of lower lip by themselves at least for 2 hours
75935699|NCT05219747|Other|Mucoadhesive film without Acmella oleracea extract|Participants will apply a mucoadhesive film on labial mucosa of lower lip by themselves at least for 2 hours
75935700|NCT02288715|Other|no interventions|
75935701|NCT05219357|Other|Ayu-Care|Ayurveda treatment modalities includes three parts to manage mental health Satwawajay Chikitsa, Yuktivyapashray and Daivyapashray Chikitsa. It is based on personalised whole person approach.
75935702|NCT05219357|Drug|Usual-Care|Management strategies includes restraints, emergency medications, behavioral interventions, with a special focus on the pharmacological interventions.
75650636|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Subject received the educational intervention
75650637|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|Both the Primary Care Physician (PCP) and the subject received the educational intervention
75650638|NCT00664833|Other|No Education|No education provided to either the Primary Care Physician (PCP) or the subject.
75650639|NCT00664911|Other|chemotherapy|
75650640|NCT02870777|Combination Product|MRD-directed therapy|The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
75650641|NCT04352231|Dietary Supplement|High Fiber Diet Intervention|Plant-based diet with a targeted quantity of 35 g of dietary fiber per day, from a variety of fiber types. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
75650642|NCT04352231|Dietary Supplement|Low Fiber Diet Intervention|Animal based diet (meat, dairy) with a targeted quantity of 10 g of dietary fiber per day. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
75650643|NCT00911469|Drug|AS902330|3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
75650644|NCT00911469|Drug|Placebo|Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
75935703|NCT04873739|Diagnostic Test|Anterior Segment OCT|AS-OCT for SLE patients with dry eye, SLE patients without dry eye and compare them with normal subjects.
75935704|NCT05723757|Diagnostic Test|blood sampling|Draw a 8.5mL blood sample for detection of SNPs of genomic origin
76088167|NCT02469792|Other|Intraarticular administration of autologous ADRC|
76088168|NCT02869932|Radiation|Lung CT scan|Lung CT scan without injection
76088169|NCT04362228|Behavioral|Whole-body exercise|10-week one-on-one, virtual, whole-body exercise class, 3x/week, focused on increasing respiratory rate through moderate-intensity aerobic exercises.
75340502|NCT05096832|Biological|Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|"Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).~Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily"
75340503|NCT05096832|Biological|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
75650645|NCT00665379|Other|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
75650646|NCT00665379|Other|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
75650647|NCT00879411|Drug|Micardis|
75650648|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
75650649|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
75650650|NCT01000493|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
75650651|NCT01000493|Other|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
75650652|NCT00671151|Drug|Theophylline|Theophylline 100 mg bid for 3 months
75797770|NCT05833243|Other|standard diaphragmatic training|"standard diaphragmatic strength training prescriptions will be given as daily routine, 3 times a day.~Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist."
75797771|NCT05833191|Device|Auricular vagus stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
75797772|NCT05833191|Device|Tibial Nerve Stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
75797773|NCT05831306|Other|Diet A|Modified Diet A
75797774|NCT05831306|Other|Diet B|Modified Diet B
75797775|NCT05830890|Procedure|Sentinel lymph node biopsy|After the total mesorectal excision, the indocyanine green was injected around the tumor via the anus. The fluorescence laparoscope was used to visualize and locate the sentinel lymph node, which was then removed and sent for rapid frozen pathological examination. Subsequently, a lateral lymph node dissection was performed.
75797776|NCT05830890|Drug|Indocyanine green solution|Indocyanine green was injected around the tumor via the anus to visualize the sentinel lymph nodes under the fluorescence laparoscope.
75650653|NCT04153461|Procedure|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
75650654|NCT04153461|Procedure|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
75650655|NCT00671307|Drug|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
75797777|NCT05830890|Device|fluorescence laparoscope|The fluorescence laparoscope was used to visualize and locate the sentinel lymph node.
75797778|NCT05830890|Diagnostic Test|pathological examination|The surgical specimens and sentinel lymph nodes were routinely examined for pathology.
75797779|NCT05830890|Diagnostic Test|rapid frozen pathological examination|The lateral green fluorescence imaging sentinel lymph nodes found during surgery was sent to make cryosections. And then a pathologist makes a rapid diagnosis under a microscope。
75935705|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
75650656|NCT00671307|Drug|Placebo|Vehicle control given as IV infusion over 1 hour
75650657|NCT00666757|Drug|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
75650658|NCT00666757|Drug|fluoxetine|20-80 mgs orally daily for 12 weeks
75650659|NCT00666757|Drug|citalopram|20-40 mgs orally daily for 12 weeks
75650660|NCT00666757|Drug|paroxetine|20-50 mgs orally daily for 12 weeks
75650661|NCT00666757|Drug|sertraline|50-200 mgs orally daily for 12 weeks
75650662|NCT01000337|Drug|Sevoflurane|Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
75935706|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
75340504|NCT00470600|Drug|Caldolor|800 milligrams intravenous
75340505|NCT00470600|Other|Normal Saline|Placebo comparator
75340506|NCT00471068|Drug|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
75340507|NCT00471068|Drug|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
75650663|NCT01000337|Drug|Propofol|Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
75650664|NCT02869763|Dietary Supplement|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
75935707|NCT01318109|Drug|Metformin|Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
75650665|NCT02869763|Dietary Supplement|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
75935708|NCT05722197|Behavioral|Crisis Response Planning and Lethal Means Safety Counseling|Crisis Response Planning is an efficacious, one-session intervention that increases positive affect, decreases negative affect and psychiatric hospitalizations, and reduces suicide attempts by 76% among Servicemembers
75935709|NCT03530475|Diagnostic Test|ultrasound and doppler|"• Ultrasound examination (2D gray scale and color doppler )~1. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion."
75935710|NCT05720871|Device|rTMS + capsaicin 150μM (natural TRPV1 agonist)|"Repetitive transcranial magnetic stimulation (non-invasive brain stimulation) + Capsaicin.~5 consecutive days of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere. A total of 500 pulses/session are delivered consisting of 10 5Hz-trains of 10s of 50 pulses each (total 2500 pulses), with a 1min interval between trains at an intensity of 90% of the resting motor threshold (RMT).~The intervention has its respective sham rTMS+placebo group that is also applied over 5 consecutive days."
75650666|NCT02869763|Dietary Supplement|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
75797780|NCT05830890|Procedure|total mesorectal excision|"Sharply dissect the vascular interface between the pelvic fascia parietal layer and the visceral layer around the mesentery under direct vision to ensure that the rectal mesentery of the resected specimen is intact and tearless.~For medium and low rectal cancer: the distal intestinal tube of the tumor should be resected ≥ 2 cm.~TME or mesenteric distal resection margin ≥ 5 cm away from the tumor."
75797781|NCT05830162|Drug|Placebo|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
75797782|NCT05830162|Drug|Bioclavid (Amoxicillin and Clavulanic acid)|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
75935711|NCT05720871|Device|tDCS + capsaicin 150μM (natural TRPV1 agonist)|"Transcranial direct current stimulation (non-invasive brain stimulation) + Capsaicin.~Treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.~The intervention has its respective sham tDCS+placebo group that is also applied over 5 consecutive days."
76088170|NCT05328544|Procedure|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) with the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw with the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
76088171|NCT05328544|Procedure|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) without the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw without the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
76088172|NCT05328310|Drug|Nebivolol|Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.
75650667|NCT00671463|Procedure|Pancreatic duct stenting|In the treatment arm, patients will have a pancreatic duct stent placed prior to having their distal pancreatectomy.
75650668|NCT00671619|Drug|ESBA105|eye drops
75650669|NCT04153227|Diagnostic Test|Bone mineral density (BMD)|Bone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA).
75935712|NCT05198453|Biological|vaccination|patients who received COVID-19 vaccine
75935713|NCT02288793|Other|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
75650670|NCT02629653|Device|endovascular cooling (Zoll system)|The Zoll IVTM is an endovascular cooling system that consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585).
75650671|NCT00671697|Drug|Arsenic Trioxide|
75935714|NCT05720481|Other|Full mouth Scaling and root planing|patients were treated with full mouth Scaling and root planing
75935715|NCT05720481|Other|Quadrant Scaling and root planing|patients were treated with quadrant Scaling and root planing
75935716|NCT05636267|Drug|AK119|AK119 IV every 3 weeks.
76088173|NCT01848184|Device|PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for ventral hernia repair
76088174|NCT01797328|Procedure|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
76088175|NCT01797328|Procedure|warm arm|To the best of ability avoid feeling cold during 6 weeks
75650672|NCT00671697|Drug|Decitabine|
75650673|NCT00666679|Drug|Comparator: mometasone|mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
75650674|NCT00666679|Drug|Comparator: montelukast|montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
75650675|NCT00666679|Drug|Comparator: placebo (unspecified)|Placebo (Placebo once-daily, for approximately 2 weeks)
75935717|NCT05636267|Drug|AK112|AK112 IV every 3 weeks.
75650676|NCT04031781|Device|repetitive transcranial magnetic stimulation (rTMS) 100% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
75935718|NCT05636267|Drug|Pemetrexed|Pemetrexed IV every 3 weeks.
75935719|NCT05636267|Drug|Carboplatin|Carboplatin IV every 3 weeks.
75935720|NCT02288871|Radiation|Cardiac CT-scan|"ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves."
75340508|NCT00471068|Drug|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
75340509|NCT00471380|Drug|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
75650677|NCT04031781|Device|repetitive transcranial magnetic stimulation (rTMS) 50% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
75650678|NCT00786097|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
75650679|NCT00791401|Drug|ER OROS Paliperidone|
75650680|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg on demand use
75650681|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil daily dosing 10 mg
75650682|NCT02556073|Other|Smartphone action|Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
75650683|NCT02556073|Drug|usual care|fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
75650684|NCT00595413|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
75340510|NCT00471380|Drug|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
75340511|NCT00538850|Drug|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
75340512|NCT00538850|Drug|Placebo|Matching placebo to fentanyl sublingual spray.
75340513|NCT00418262|Drug|Atomoxetine|Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
75340514|NCT00418574|Biological|Abagovomab|2 mg/ml SC (subcutaneously)
75340515|NCT00418574|Biological|Placebo|2 mg/ml SC (subcutaneously)
75650685|NCT00595413|Drug|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
75650686|NCT00595413|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
75935721|NCT05635175|Other|hip abductors physiotherapy self training|hip abductors self training program during 7 to 10 weeks associate with a PFMT
75340516|NCT00473642|Drug|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
75340517|NCT00473642|Drug|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
75340518|NCT00473642|Drug|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
75797783|NCT05830149|Other|Cryoinsufflation|In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
75935722|NCT05635175|Other|Standard pelvic floor muscle training|Standard pelvic floor muscle training
75935723|NCT05635175|Other|Standard pelvic floor muscle training self training|Standard pelvic floor muscle training self training
75650687|NCT00595413|Biological|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
75650688|NCT00781261|Drug|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
75650689|NCT00781261|Drug|Placebo|Subjects in the control group will receive a placebo drug for a similar period
75650690|NCT02629497|Dietary Supplement|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
75650691|NCT02629497|Dietary Supplement|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
75797784|NCT05830149|Other|Deroofing|Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
75935724|NCT02288949|Other|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
75935725|NCT05194709|Biological|Anti-CAR-NK Cells|The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10^9 cells.
76088176|NCT01849822|Device|Neural Prosthetic System|The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
75340519|NCT00418964|Procedure|Single bundle hamstring|Single bundle hamstring
75340520|NCT00418964|Procedure|Double bundle hamstring|Double bundle hamstring
75340521|NCT00418964|Procedure|Bone patellar tendon bone|Bone patellar tendon bone
75340522|NCT00539942|Drug|Arixtra (fondaparinux sodium)|Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
75650692|NCT02554825|Behavioral|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels-individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
75650693|NCT02554825|Behavioral|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
75650694|NCT00786331|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
75650695|NCT00786331|Drug|Pemetrexed plus carboplatin|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
75650696|NCT01000025|Drug|PF-00299804|PF-804 45 mg PO, daily
75650697|NCT01000025|Drug|Placebo|Placebo 45 mg PO, daily
75650698|NCT00791713|Drug|Paliperidone ER|
75650699|NCT00595335|Drug|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
75650700|NCT00595335|Drug|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
75650701|NCT00595335|Drug|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
75650702|NCT00781417|Dietary Supplement|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
75340523|NCT00539942|Device|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
75340524|NCT00419666|Drug|Calcitriol 3mcg/g|Calcitriol 3mcg/g ointment applied twice daily for 56 weeks.
75340525|NCT00540722|Drug|R-(-)-gossypol acetic acid|Given PO
75650703|NCT00781417|Other|Placebo|Matching Placebo
75650704|NCT00781495|Device|Sensewear Bodymedia armband|To assess physical activity levels patients will wear Sensewear bodymedia armband
75340526|NCT00540722|Other|laboratory biomarker analysis|Correlative studies
75797785|NCT05829941|Behavioral|Smartwatch app to deliver binge-eating CBT strategies|Participants will receive a smartwatch with a pre-loaded app that will alert the participant to relevant binge-eating strategies based on their previous detected behavior.
75797786|NCT05829941|Behavioral|Reminder control condition|Participants will receive a smartwatch that vibrates randomly, and will be instructed the vibration is a cue not to binge eat.
75797787|NCT05829707|Drug|Diclofenac Sodium|"A group of patients with breast cancer who were randomized to the diclofenac group by drawing random numbers was given 2 x 75 mg of drug IV on the first PO day and then 3 x 50 mg tablets orally for postoperative analgesia.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain >4 on the VAS, meperidine 20-30 mg for VAS >or = 4"
75340527|NCT00541190|Other|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
75474432|NCT01983540|Biological|DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine|DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study
75650705|NCT00672087|Genetic|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
76088177|NCT05328232|Other|Olive oil|The parents of the babies included in the experimental group were asked to fill in the questionnaires. The infant's skin condition was assessed using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants. Each time the diaper was changed, the diaper area was cleaned with water and cotton wool and dried, 1-2 cc of natural extra virgin olive oil was applied, and the new diaper was fastened. At the end of each day, the diaper area was evaluated by the researcher and a nurse by using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants.
76088178|NCT01797484|Drug|Ranolazine|Improvement of myocardial microcirculation
75797788|NCT05829707|Drug|Levobupivacaine bolus analgesia|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. A first dose of local anesthetic was delivered at the end of the surgical procedure to test catheter placement. Bolus doses of local anesthetics based on the patients' body weight were thereafter delivered by the nurse in 8 hours intervals.~All patients were assessed before the surgical procedure and hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain >4 on the VAS, meperidine 20-30 mg for VAS >or = 4."
75650706|NCT00672165|Biological|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
75935726|NCT03530943|Behavioral|Animal Assisted Activities|Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation
75935727|NCT03530943|Behavioral|Academic Stress Management tools|Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
76088179|NCT01798186|Drug|Cannabis|Participants will be exposed to cannabis smoke present in ambient air
75650707|NCT00661609|Drug|AZD4877|Intravenous (IV)25mg/weekly
75935728|NCT03530787|Other|Acetyl Zingerone Topical Cream|Topical cream with an active acetyl zingerone component.
75935729|NCT03530787|Other|Topical cream|Topical cream without an active acetyl zingerone component and just the carrier cream.
75935730|NCT03873311|Drug|Azacytidine, HAG Regimen|Azacytidine（75mg/m2 QD for 7 days）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) for 14 days), Cytarabine 10mg/(m2.d) for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d) for 14 days until absolute neutrophil count(ANC) ≥ 10X109／L)
76088180|NCT01851772|Device|Treatment with Electronic Brachytherapy|
75340528|NCT00542750|Drug|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
75474433|NCT01983540|Biological|DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine|DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age) and a booster dose of Infanrix hexa vaccine with Prevnar at 12 to 24 months of age in a previous study.
76088181|NCT01852084|Device|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
76088182|NCT01852084|Device|enVista control lens|Spherical Control lens
75650710|NCT00672321|Genetic|gene expression analysis|
75935731|NCT03873311|Drug|Azacytidine|Azacytidine 75mg/m2 QD for 7 days.
75650711|NCT00672321|Genetic|mutation analysis|
75650712|NCT00672321|Genetic|polymorphism analysis|
75935732|NCT05717283|Diagnostic Test|Nasal swab|We will take nasal swabs from anterior and middle nostril, once a week for each newborn included.
75935733|NCT00162279|Drug|Abatacept|
76088183|NCT01798264|Drug|ITCA 650 (exenatide in DUROS)|
76088184|NCT01798966|Device|SENSIMED Triggerfish|
76088185|NCT05326984|Drug|Metformin|Metformin will be administered orally to the experimental group by randomization at a dose of 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.
76088186|NCT01799278|Drug|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
75474434|NCT01983540|Biological|Infanrix hexa + Prevenar + Rotarix vaccine|Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster dose of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar vaccine concomitantly with Prevenar at 12 to 24 months of age in a previous study.
75340529|NCT00475904|Drug|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
75797789|NCT05829707|Drug|Levobupivacaine PCA group|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. Levobupivacaine was delivered by PCA pump (CADD - Legacy® PCA Pump, Model 6300, Smiths Medical MD, Inc., St. Paul, USA). A drug delivery was started at the end of the surgical procedure.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for persisting pain >4 on the VAS, and meperidine 20-30 mg for VAS >or = 4."
75340530|NCT00475904|Drug|Gabapentin Capsules|1800mg/day capsules for 4 weeks
75650713|NCT00672321|Other|laboratory biomarker analysis|
75650714|NCT00672321|Other|questionnaire administration|
75935734|NCT02712554|Drug|CL-108|7.5 mg/325 mg/12.5 mg tablet
76088187|NCT01800838|Drug|silicon phthalocyanine 4|Given topically
76088188|NCT01800838|Drug|photodynamic therapy|Undergo PDT
76088189|NCT01800838|Other|pharmacological study|Correlative studies
76088190|NCT01800838|Other|laboratory biomarker analysis|Correlative studies
75340531|NCT00475904|Drug|placebo|placebo cream and caps
75340532|NCT00420992|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|capsules, up to 80 mg bid
75340533|NCT00420992|Drug|Placebo|capsules, bid
75340534|NCT00423878|Drug|Risperidone|Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
75340535|NCT00423878|Drug|Olanzapine|Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
75340536|NCT00423878|Drug|Quetiapine|Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
75474435|NCT01983579|Procedure|Intraocular anti-VEGF injection|
75474436|NCT01983579|Device|SENSIMED Triggerfish|
75474437|NCT01983592|Other|Homeopathic medicine|Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
75935735|NCT02712554|Drug|M366|7.5 mg/325 mg tablet
75474438|NCT01983592|Other|Unmedicated lactose/sucrose globule|
75340537|NCT00423878|Drug|Aripiprazole|Switching medication to aripiprazole for schizophrenia for up to 6 months in study
75340538|NCT00478556|Drug|Omnipaque|Oral CT contrast
75340539|NCT00478556|Drug|Gastroview|Oral CT contrast
75340540|NCT00480740|Drug|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
75340541|NCT00424268|Drug|Roflumilast|500 µg, once daily, oral administration in the morning
75340542|NCT00424268|Drug|Placebo|once daily
75340543|NCT00424502|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
75340544|NCT00424502|Drug|Methotrexate|10-25mg po/week
75340545|NCT00425672|Biological|ONTAK|Given IV
75340546|NCT00425672|Other|flow cytometry|Correlative studies
75340547|NCT00425672|Other|immunohistochemistry staining method|Correlative studies
75340548|NCT00425672|Other|enzyme-linked immunosorbent assay|Correlative studies
75474439|NCT01983605|Device|LARIAT Suture Delivery Device|LAA exclusion procedure
75474440|NCT01983618|Procedure|Interscalene nerve block and catheter|
75474441|NCT01983618|Procedure|Interscalene catheter|
75474442|NCT01983631|Other|Whole body vibration training|
75650715|NCT04153071|Device|OPUS system|Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
75340549|NCT00425672|Other|laboratory biomarker analysis|Correlative studies
75340550|NCT00425672|Genetic|protein expression analysis|Correlative studies
75340551|NCT00543764|Other|pathway|Comparison of pre and post pathway
75340552|NCT00544076|Drug|sildenafil citrate|Given orally
75650716|NCT00672399|Drug|exenatide|Subcutaneously injected, 10 mcg, single doses
75650717|NCT00672399|Drug|Moxifloxacin|oral, 400 mg tablet, single doses
75650718|NCT00672399|Drug|Placebo|Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
75650719|NCT00661531|Drug|Estrace|Estrace 10 mg three times daily will be administered for 3 months.
75935736|NCT02712554|Drug|Placebo|
75935737|NCT03527901|Diagnostic Test|GCF collection with aMMP-8 chair side test|
75935738|NCT03527901|Other|Saliva collection|
75935739|NCT00145431|Drug|torcetrapib/atorvastatin|
75935740|NCT00145431|Drug|atorvastatin|
75935741|NCT00145431|Drug|fenofibrate|
75935742|NCT05370261|Dietary Supplement|Berberine LipoMicel|Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine
75935743|NCT05370261|Dietary Supplement|Regular Berberine hard-gels|Total dose of 500 mg of berberine
75935744|NCT00135369|Drug|stavudine extended-release, lamivudine, efavirenz|
75935745|NCT03530319|Drug|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
75340553|NCT00544076|Drug|alprostadil|Given intraurethrally
75340554|NCT00544076|Procedure|robotic-assisted laparoscopic surgery|Undergo prostatectomy
75650720|NCT00661531|Drug|Anastrozole|After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
75340555|NCT00544076|Procedure|quality-of-life assessment|Ancillary studies
75935746|NCT03530319|Drug|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
75650721|NCT00998309|Drug|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
76088191|NCT01854034|Drug|AUY922|AUY922 administered intravenously once a week at 70mg/m2
76088192|NCT01802554|Behavioral|Pleasant Events Program (PEP)|Behavioral Activation Therapy
75340556|NCT00544076|Other|questionnaire administration|Ancillary studies
75797790|NCT05828290|Behavioral|Child Yoga|The children's yoga consists of compositions such as playing, stories, postures, breathing exercises, imitations things in nature, memory games, music, dance and daydreaming.
75340557|NCT00544778|Biological|filgrastim|
75797791|NCT05826938|Device|Virtual reality technology|Participants who are randomized to group 1 will receive the Virtual Reality glasses on the day of oocyte retrieval in the recovery room. The participant chooses which animation she wants to experience.
75797792|NCT05826756|Other|There are no interventions in this study. All participants complete online surveys.|There are no interventions in this study. All participants complete online surveys.
75935747|NCT05234372|Behavioral|mivacunaLA|Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites & resources.
75340558|NCT00544778|Drug|dexrazoxane hydrochloride|
75340559|NCT00544778|Drug|doxorubicin hydrochloride|
76088193|NCT01802554|Behavioral|Information Support (IS)|Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
76088194|NCT01781975|Drug|Imatinib Mesylate|
76088195|NCT01781975|Drug|Placebo (For imatinib mesylate)|
76088196|NCT01855360|Drug|Tauroursodeoxycholic Acid and Doxycycline|
75340560|NCT00544778|Drug|ifosfamide|
75340561|NCT00544778|Drug|irinotecan hydrochloride|
75340562|NCT00544778|Genetic|protein expression analysis|
75340563|NCT00544778|Other|immunoenzyme technique|
76088197|NCT01802710|Behavioral|Psychological support|
76088198|NCT01802710|Other|No intervention|
75340564|NCT00544778|Procedure|adjuvant therapy|
75340565|NCT00544778|Procedure|conventional surgery|
75340566|NCT00544778|Procedure|neoadjuvant therapy|
75340567|NCT00544778|Radiation|radiation therapy|
75340568|NCT02122796|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
75340569|NCT00484874|Drug|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
75340570|NCT01795742|Device|Human-Powered Nebulizer|
75340571|NCT00486824|Drug|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
75340572|NCT00486824|Drug|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
75340573|NCT00489086|Drug|tazarotene|Tazarotene is a member of the acetylenic class of retinoids.
75340574|NCT02119442|Device|Transcather Valve Implantation|Transcather Valve Implantation
75340575|NCT00489866|Drug|Aripiprazole|Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
75340576|NCT00489866|Drug|Placebo|Same as active drug.
75340577|NCT00546104|Drug|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
75340578|NCT00546728|Drug|Exenatide|exenatide 10 mcg twice daily
75340579|NCT00546728|Drug|Metformin|metformin 500 twice daily
75650722|NCT02629575|Device|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
75650723|NCT00791791|Procedure|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
75650724|NCT00781573|Drug|Clopidogrel|Clopidogrel, 75 mg QD, for one year
75650725|NCT04293965|Drug|Single ascending dose of X842|A total of 7 dose groups will be set for the ascending dose: 5.6 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg. In the 5.6 mg dose group, 4 subjects will receive X842; in the 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg dose groups, 8 subjects in each group will receive X842. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
75650726|NCT04293965|Drug|Multiple ascending dose of X842|Two dose groups will be set, including the groups receiving the recommended phase II dose and a higher dose; Eight subjects will be enrolled in each group, with half male and half female, who will receive X842 once daily for 5 consecutive days. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
75797793|NCT05819918|Drug|Calcifediol|Subjects hospitalized with COVID-19 treated with calcifediol
75797794|NCT05819918|Drug|Best available therapy|Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.
75797795|NCT05818228|Behavioral|Video|A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
76088199|NCT04351126|Drug|Fludrocortisone 0.1 Milligrams (mg)|0.2-0.6 mg/day of fludrocortisone is prescribed
76088200|NCT04351126|Drug|Bromocriptine|2.5 mg prescribed Vaginally twice daily
75340580|NCT00546884|Behavioral|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
75340581|NCT00546884|Behavioral|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
75340582|NCT00547586|Drug|N-methylnaltrexone bromide (MOA-728)|Oral
75340583|NCT00547586|Other|placebo|placebo
76088201|NCT01804673|Drug|Fentanyl-ITS|Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
75474443|NCT01983644|Device|RECO flow restoration device|RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
75474444|NCT01983644|Device|Solitaire FR flow restoration device|Solitaire FR flow restoration device has been approved by the FDA and CFDA.
75650727|NCT04293965|Other|Food Effect|Twelve subjects (appropriate ratio of male to female) screened for eligibility will be randomized into Group A and B. The 6 subjects in Group A will take the study drug (X842) in fasted condition and subject in Group B will take the study drug in fed condition in the 1st cycle. In the 2nd Cycle, subjects in Group A will take the study drug in fed condition, and subjects in Group B will take the study drug in fasted condition. The interval between the two cycles is at least 7 days.
75650728|NCT00672789|Behavioral|Blood smear education|education at baseline and three month follow-up
75650729|NCT00672789|Other|standard education|standard education
75650730|NCT00791947|Drug|CHOEP + G-CSF followed by BEAM|"CHOEP:~Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5~BEAM:~Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6"
75935748|NCT03530241|Diagnostic Test|Presence of bile duct stones|MRCP verified gall stones in the bile ducts
75935749|NCT03530241|Diagnostic Test|Non-presence of bile duct stones|MRCP without bile duct stones
75935750|NCT05726253|Drug|Supportive Care + Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (7 days)
75935751|NCT05726253|Drug|Supportive Care + Placebo (no antibiotics)|Participants will be randomized to receive oral placebo for a standard course (7 days)
75935752|NCT03202706|Procedure|Samples of adipose tissue|Samples of visceral and subcutaneous adipose tissue collected during hernia surgery
75935753|NCT00133497|Biological|MF-59|Microfluoridized adjuvant 59 (MF59).
75935754|NCT00133497|Drug|Placebo|0.5 mL of saline placebo.
75935755|NCT00133497|Biological|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
75935756|NCT02445170|Procedure|Amputation|Transmetatarsal or below-knee amputation
76088202|NCT01856218|Drug|UX003|
75340584|NCT00547898|Drug|Crofelemer 125 mg|Crofelemer 125 mg
75340585|NCT00547898|Drug|Crofelemer 250 mg|Crofelemer 250 mg
75340586|NCT00547898|Drug|Crofelemer 500 mg|Crofelemer 500 mg
75340587|NCT00547898|Drug|Placebo|Placebo
76088203|NCT01774097|Biological|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
75340588|NCT00548132|Device|Chlorhexidine-impregnated foam dressing|Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
75340589|NCT00490100|Drug|Increlex|
75340590|NCT00490256|Procedure|Modified Selective Cerebral Perfusion|Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
75340591|NCT00490802|Drug|Oxytocin|Intranasal Oxytocin
75474445|NCT01983657|Drug|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
75474446|NCT01983657|Procedure|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
75474447|NCT01983670|Other|Temporal electrical stimulation|
75474448|NCT01983696|Other|5% oxygen concentration|the oocytes and embryos are cultured in the incubator with concentrations of 6% CO2,5%O2, and 89% N2
75474449|NCT01983709|Biological|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV 4 days prior to undergoing a planned prostatectomy.~The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy."
75474450|NCT01983722|Drug|Stiripentol|
75474451|NCT01983735|Drug|TELMINUVO Tab. (80/2.5mg)|"Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~With the others investigation product placebo 1 tab QD 2 weeks."
75474452|NCT01983735|Drug|TELMINUVO Tab. (80/5mg)|"Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~With the others investigation product placebo 1 tab QD 6 weeks."
75650731|NCT02629263|Dietary Supplement|Viscous Fiber|Meta- analysis of Randomized Controlled Trials
75650732|NCT00671541|Drug|Merogel Nasal Stent and Nasopore Stent|Merogel Nasal Stent and Nasopore Stent
75935757|NCT02445404|Drug|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
75935758|NCT02445404|Drug|fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
76088204|NCT01774097|Biological|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
76088205|NCT01856530|Drug|Oxytocin|Liquid metered-dose nasal spray, 24 IU, administered once
76088206|NCT01856530|Drug|Placebo|Matched placebo nasal spray
75340592|NCT00490802|Drug|Placebo|Placebo Comparator
75650733|NCT00671541|Drug|Nasopore Stent and either Gentamycin or Bacitracin|Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
75650734|NCT00781729|Behavioral|Yoga, one hour class, 3 times per week, for 24 weeks|Yoga, one hour class, 3 times per week, for 24 weeks
75935759|NCT05346315|Other|RDN Medical Nutrition Therapy|The RDNs will provide bi-monthly nutrition care, counseling, and dietary recommendations for a 6-month intervention, delivered either in-person or via telehealth, to the grocery store patrons during the study intervention. The RDN will provided care to the participant based upon the participant's unique dietary and nutritional needs. The RDN will provide nutrition recommendations and create meal plans via NutriStyle for the participants to follow. The meal plans will be uploaded into the grocery store's E-commerce shopping platform, which the participant can utilize to purchase foods that are needed to follow the RDNs nutrition recommendations for an individual person.
76088207|NCT05302336|Drug|Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide|"All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide)."
76088208|NCT01804036|Drug|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
75650735|NCT00781729|Behavioral|Luncheon Seminar Series, once per month, for 24 weeks|Luncheon Seminar Series, once per month, for 24 weeks
76088209|NCT01804036|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
76088210|NCT01856764|Drug|0.5% Roflumilast Cream|Roflumilast 0.5% cream
75340593|NCT00550394|Drug|quetiapine and placebo|"Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
75340594|NCT00550394|Drug|Quetiapine and Topiramate|"Dosing Schedule and Titration of Quetiapine:~open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
75340595|NCT00550862|Drug|INT-747|Once a day (QD) by mouth (PO)
75474453|NCT01983735|Drug|S-amlodipine 2.5mg|"S-amlodipine 2.5mg QD 2 weeks~With the others investigation product placebo 1 tab QD 2 weeks."
75650736|NCT04152681|Drug|Apatinib|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
75797796|NCT05810883|Diagnostic Test|Blood Tests; Serum Fasting Insulin and Glucose|"Laboratory results of blood samples, for high-density lipoprotein (HDL), low-density protein (LDL), triglycerides, and total cholesterol (TC) will be evaluated for this study. Fasting Insulin and fasting glucose levels will be used to calculate IR.~Insulin Resistance will be calculated using Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (FPG (mmol/L) × FPI (mU/L)/22.5) [21] and defined as HOMA-IR ≥ 3.4"
75650737|NCT00999713|Drug|Calfactant|Endotracheal calfactant, up to 3 doses if subject qualifies
75340596|NCT00550862|Drug|Ursodeoxycholic Acid (URSO)|Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
75474454|NCT01983735|Drug|S-amlodipine 5mg|"S-amlodipine 5mg QD 6weeks~With the others investigation product placebo 1 tab QD 6 weeks."
75474455|NCT01983761|Drug|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|
75650738|NCT00999713|Other|Air placebo|Endotracheal air administration
75474456|NCT01983761|Drug|Fludarabine, Melphalan, ATG (Reduced Intensity)|
75650739|NCT00781807|Other|multi-module rehabilitation program|"The multi-module rehabilitation program includes:~Nutrition management~Home-based ergometer training program~Psychosocial support"
75650740|NCT00672867|Drug|Clevudine|30mg
75650741|NCT00672867|Drug|Adefovir dipivoxil|10mg
75650742|NCT00786721|Device|Diffuse Optical Spectroscopy|muscle properties scanning
75474457|NCT01983800|Drug|Isoflurane|
75474458|NCT01983800|Drug|Propofol/midazolam|
75650743|NCT00997373|Drug|Letrozole|2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
75650744|NCT04152759|Drug|Drug: BAT2506 injection Other Names: Simponi(EU-licensed)|"Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)"
75650745|NCT04047043|Diagnostic Test|serum taurine|blood sample for serum taurine level
75650746|NCT00672945|Drug|PRX-03140|
75650747|NCT00672945|Drug|Placebo|
75650748|NCT02869607|Other|Data collection|
75650749|NCT00792025|Drug|sunitinib malate|
75650750|NCT00786877|Other|Improved biomass cookstove with exterior ventilation|Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
75650751|NCT00786877|Other|Phase 2 intervention arm (LPG stove)|LPG two burner stove with a 12 month supply of LP gas.
75650752|NCT04293731|Dietary Supplement|Symbiter-Smectite|Symbiter-Smectite contains biomass of alive probiotic microorganism symbiosis, colony forming units - CFU/g: Lactobacillus - 1.0х109, Bifidobacterium - 1.0х109, Lactococcus - 1.0х108, Propionibacterium - 1.0х108 and Acetobacter - 1.0х105; and smectite gel (250 mg)
75797797|NCT05807074|Drug|Tranexamic Acid|Applied intraoperatively
75797798|NCT05807074|Other|Saline|Applied intraoperatively
75797799|NCT05805202|Other|Blood sampling and urine analysis|A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
75797800|NCT05780645|Drug|ALXN2050 MR Prototype Tablet|Participants will receive various doses of the MR Prototype Tablet orally.
75340597|NCT00550862|Drug|Placebo|Placebo
75474459|NCT01983813|Other|PHCVRS Intervention|"A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:~Contact via email, phone or text every 2-4 weeks~Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.~Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.~Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk."
75650753|NCT04293731|Dietary Supplement|Placebo|Placebo
75650754|NCT00673023|Other|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
75650755|NCT02870231|Drug|NNC9204-0530|Once-daily subcutaneous (s.c., under the skin) administration.
75650756|NCT02870231|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration.
75935760|NCT04468269|Other|Task oriented balance training with sensory integration group|"Sitting position:~Sit in a chair without backrest while keeping the feet on floor.~Sit on a ball while keeping the feet on the floor.~Sit to stand:~Sit in a chair without a backrest~Sit in a chair without a backrest with and perform the sit-to-stand motion repeatedly.~Sit on a ball and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing Control Of Weight Shifting. Perform a semi-tandem stance. One Foot Standing.~Walking:~Walk forward~Walk forward cross an obstacle, and then continue to walk.~Walk Lateral~Walk Backward~Tandem walk"
76088211|NCT01856764|Drug|Vehicle Cream|Roflumilast formulation vehicle
76088212|NCT01857232|Drug|Ondansetron|5HT3-antagonist
75650757|NCT02870231|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration
75650758|NCT02554747|Device|Navigated laser|Aflibercept, Navilas®
75650759|NCT02554747|Device|Conventional laser|Aflibercept, Pascal
75650760|NCT00911781|Other|No intervention|We are only asking for photographs from parents.
75650761|NCT02869685|Radiation|radiotherapy|
75650762|NCT00663871|Dietary Supplement|Fish Oil|Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
75650763|NCT00663871|Dietary Supplement|Soybean Oil (Placebo)|Participants will take 2 grams of soybean oil supplements on a daily basis.
75650764|NCT02869919|Other|AKI|Vitamin D levels
75650765|NCT04152447|Device|VR device|Patients use a VR device
75650766|NCT00628979|Behavioral|CBT|cognitive- behavioral treatment for panic disorder.
75650767|NCT02629029|Procedure|Pre-op CTA with IV contrast|Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
75650768|NCT02629029|Device|Computed tomography angiography (CTA)|
75650769|NCT02870075|Behavioral|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
75650770|NCT02870075|Behavioral|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
76088213|NCT01857232|Drug|Placebo|Comparator
76088214|NCT01857232|Drug|Dexamethasone|Corticosteroid
76088215|NCT01857232|Drug|Fosaprepitant|NK1 antagonist
75797801|NCT05780645|Drug|ALXN2050 Immediate Release (IR) Tablet|Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
75797802|NCT05780645|Drug|ALXN2050 MR Prototype Mini-Tablet|Participants will receive various doses of the MR Prototype Mini-Tablet orally.
75797803|NCT05776576|Behavioral|Evaluation|Within the scope of the evaluation, first of all, physical activity levels of children and adolescents with physical disabilities, barriers that prevent them from participating in physical activity, and motivators that can increase their participation will be determined, accompanied by an interactive roundtable meeting. Afterwards, posture analyzes of children and adolescents with special needs with physical disabilities will be performed by physiotherapists.
75797804|NCT05776576|Behavioral|Education|"In the education part, interactive informative seminars titled Physical Activity in Individuals with Special Needs will be given and after the objective posture assessments, postural disorders of children and adolescents with special needs will be determined and accordingly, posture and ergonomics training will be given to the participants individually."
76088216|NCT01857232|Drug|APD403 IV|Amisulpride IV 20 mg
75340598|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
75340599|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
75340600|NCT03430076|Procedure|revascularization|open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
75340601|NCT03430076|Device|Propaten®|Propaten®
75340602|NCT03430076|Device|Crude PTFE|Crude PTFE
75650771|NCT02629341|Dietary Supplement|Functional yogurt powder|"Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10"
75650772|NCT02629341|Dietary Supplement|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
76088217|NCT01857232|Drug|APD403 oral|Amisulpride oral 10, 20 or 40 mg
76088218|NCT01804114|Procedure|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
76088219|NCT01804114|Procedure|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
76088220|NCT05275036|Device|early detection test|Blood collection and early detection testing
75340603|NCT00492206|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
75340604|NCT00431132|Drug|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
75650773|NCT02869997|Device|Aspect BIS XP (A-2000) Bispectral Index Patient Monitor|
75797805|NCT05776576|Other|Experimentation|In the experimentation part, group exercises, dance therapy programs and technology-supported exercise educations with various technological equipment will be implemented in the company of physiotherapists, taking into account the posture assessments.
75650774|NCT00782041|Drug|Oxaliplatin|85 mg/m²
75340605|NCT00493064|Drug|Nicotinic acid|topical eye drops
75797806|NCT05775601|Drug|18F-LY3950321|3 millicuries (±1 mCi)
75797807|NCT05775601|Procedure|PET Scan|positron emission tomography (PET) scan
75935761|NCT04468269|Other|Task oriented balance training without sensory integration group|"Sitting position:~Sit in a chair without a backrest while keeping the feet on a firm surface.~Sit on a ball while keeping the feet on the firm surface~Sit to stand:~Sit in a chair without a backrest with the feet on a firm surface and perform the sit-to-stand motion repeatedly.~Sit on a ball with the feet on the firm surface and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing on a firm surface.~Perform a semi-tandem stance on the firm surface~Walking:~Walk forward on a firm surface.~Walk forward on the firm surface, cross an obstacle, and then continue to walk.~Walk sideways~Walk Backward~Tandem walk"
75935762|NCT02445092|Other|washing the insemination catheter with sperm washing media|"Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter."
75935763|NCT05726175|Drug|Disitamab Vedotin|Disitamab Vedotin(RC48)：2.0mg/kg, iv, day1, q3weeks, 6 cycles in total;
76088221|NCT01766128|Drug|Zonisamide|The first arm will be treated by zonisamide
76088222|NCT01766128|Drug|Placebo|The second arm will receive placebo
75340606|NCT00493064|Drug|Prednisolone acetate|topical eye drops
75340607|NCT00552422|Drug|domperidone|10mg orally four times per day
75474460|NCT01983813|Other|Personal Health Record|Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
75340608|NCT00552812|Device|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
75474461|NCT01983865|Other|Exposure to birch pollen|
75797808|NCT05772273|Drug|Azacitidine|Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
75340609|NCT00432458|Drug|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
75340610|NCT00432458|Drug|zoledronic acid|4 mg^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
75340611|NCT01656408|Drug|MK-8150|
75340612|NCT01656408|Drug|Placebo for MK-8150|
75340613|NCT05046600|Device|Products listed in cohort description|Depending on approved indication per product
75340614|NCT00433550|Drug|capecitabine|given orally
75340615|NCT00433550|Drug|irinotecan hydrochloride|given IV
75340616|NCT00433550|Drug|oxaliplatin|given IV
75340617|NCT02208037|Drug|Tacrolimus (ARM with Methotrexate)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
75474462|NCT01983891|Other|Cooking course|6-week nutrition education and cooking course
75474463|NCT01983904|Device|deep brain stimulation with short & long pulse width|surgical implantation for bilateral electrodes and stimulation using short and long pulse width
75474464|NCT01983917|Behavioral|Diabetes Mobile Application|
75474465|NCT01983943|Dietary Supplement|Hydroxytyrosol, the active ingredient in olive oil.|A 40mg capsule will be taken once daily for 6 months.
75474466|NCT01983943|Dietary Supplement|Placebo|A 40mg placebo will be taken once per day for 6 months.
75474467|NCT01983943|Behavioral|Nutrition counseling|Nutrition counseling on eating a healthy diet will be offered once at baseline.
75650775|NCT00782041|Drug|5-FluoroUracil|2,000 mg/m²
75650776|NCT00782041|Drug|Folinic acid|20 mg/m²
75650777|NCT00673491|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
75650778|NCT00673569|Drug|erlotinib hydrochloride|
75797809|NCT05772273|Biological|Donor lymphocyte infusion|The 4 DLI doses (dose range: ±10%) of sib-matched donor HSCT patients were 1×10^6/kg, 5×10^6/kg, 1×10^7/kg, 5×10^7/kg; The 4 DLI doses (dose range: ±10%) of haploidentical or unrelated donor HSCT patients were 1×10^5/kg, 5×10^5/kg, 1×10^6/kg, 5×10^6/kg.
75797810|NCT05772273|Drug|Camrelizumab|Camrelizumab 200mg Q2W for sib-matched donor HSCT patients, 100mg Q2W for haploidentical or unrelated donor HSCT patients.
75935764|NCT05726175|Drug|Penpulimab|Penpulimab(AK105)：200mg, iv, day1, q3weeks, 6 cycles in total;
75935765|NCT02444858|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10^5/kg) ，once a day,a total of three times.
75650779|NCT00673569|Genetic|gene expression analysis|
75935766|NCT02444858|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
75474468|NCT01983943|Device|Endopat|An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
75340618|NCT02208037|Drug|Tacrolimus (ARM with MMF and Cyclophosphamide)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
75340619|NCT02208037|Drug|Methotrexate (ARM with Maraviroc)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
75340620|NCT02208037|Drug|Methotrexate (ARM with Bortezomib)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
75474469|NCT01983956|Behavioral|SENS model|Palliative care with a structured approach (SENS model) based on the bio-psycho-social-spiritual model of care, the WHO definitions of palliative care as well as the National Comprehensive Cancer Networks (NCCN) Practice Guidelines for Palliative Care. The approach supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
75474470|NCT01984008|Drug|Picosulfate sodium, magnesium oxide, citric acid|
75474471|NCT01984021|Device|Acupuncture|
75474472|NCT01984021|Device|Sham acupuncture|
75935767|NCT02444780|Procedure|no intervention, blood is sampled for routine|no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
75650780|NCT00673569|Genetic|protein expression analysis|
75650781|NCT00673569|Other|immunoenzyme technique|
75650782|NCT00673569|Other|immunologic technique|
75650783|NCT00673569|Other|laboratory biomarker analysis|
75650784|NCT00673569|Procedure|needle biopsy|
75650785|NCT00787033|Drug|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
75650786|NCT00792181|Drug|Midazolam|Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
75650787|NCT00792181|Other|Course intervention - a professional development course for caregivers.|The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
75650788|NCT00673647|Behavioral|Cognitive-behavioral treatment|10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
75650789|NCT00792337|Drug|simvastatin|10 mg per oral once daily for 8 weeks
75650790|NCT00792337|Drug|B1-6-12|1 table per day for 8 weeks
75650791|NCT00673725|Drug|Locobase® REPAIR|emollient
75650792|NCT00787111|Drug|Fluoxetine (prozac)|Formulation: ODT
75650793|NCT00673803|Procedure|cataract surgery|cataract surgery with implantation of an IOL
75650794|NCT04152525|Other|Psychoeducation|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
75650795|NCT00782197|Device|PRGF Intraarticular injection|Three consecutive PRGF injections each one week apart.
75650796|NCT00782197|Device|Hyaluronic Acid Intraarticular injection|Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
75650797|NCT04152291|Dietary Supplement|Ethyl-Eicosapentaenoic Acid (E-EPA)|3,9 grams of EPA is added to participants' normal diet.
75935768|NCT04484246|Other|Prevalence of sarcopenia in older patient with prostate cancer|All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.
75650798|NCT00782353|Drug|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
75650799|NCT00782353|Drug|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
75650800|NCT00782353|Drug|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
76088223|NCT02859558|Drug|elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy|Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.
75474473|NCT01984034|Behavioral|Educational Outreach Visits|The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
75474474|NCT01984034|Other|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
75340621|NCT02208037|Drug|Maraviroc|Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
75340622|NCT02208037|Drug|Bortezomib|Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
75340623|NCT02208037|Drug|Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
75935769|NCT05319327|Other|Nutritional intervention|"A nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.~Total intervention will last 6 months for both groups. During the intervention phase, a monthly interview with nutritionist/dietitian is scheduled. Face-to-face interviews will be carried out in months 2 and 4. Phone interviews will be carried out in months 1, 3 and 5. In the baseline and final visits (months 0 and 6) a sample and data collection will be performed."
75650801|NCT00996593|Biological|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
75650802|NCT00570661|Drug|ITF2357|ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.
75340624|NCT02208037|Drug|Cyclophosphamide|"Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide [50 mg/kg ideal body weight (IBW); if ABW < IBW, use ABW] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
75474475|NCT01984047|Drug|GSK3050002|GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
75650803|NCT00787345|Other|simulation based training|simulation based training in aseptic techniques that included specified AT categories
75650804|NCT02870153|Drug|SOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
76088224|NCT02830542|Drug|SER-262|SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
75650805|NCT02870153|Drug|XELOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
75340625|NCT05043402|Drug|navicixizumab|navicixizumab IV
75474476|NCT01984047|Drug|Placebo|Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
76088225|NCT02830542|Drug|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
75650806|NCT00934544|Drug|Ruxolitinib|5 mg tablets packaged as 60-count in high-density polyethylene bottles
75650807|NCT00934544|Drug|Best Available Therapy (BAT)|Prescribing and usage per respective package inserts
75650808|NCT02554669|Behavioral|postprandial and postabsorptive physical activity on treadmill|
75340626|NCT05043402|Device|Xerna™ TME Panel|RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).
75340627|NCT03008161|Drug|NPT088|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
75340628|NCT03008161|Drug|Placebo|Placebo
75340629|NCT00496262|Biological|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
75340630|NCT05043246|Biological|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
75340631|NCT03007927|Drug|Bupivacaine-Dexamethasone|Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
75935770|NCT05319327|Other|Control|General counseling to adhere to a healthy Mediterranean diet
75935771|NCT03197168|Behavioral|Intervention to reduce self-stigma among people with mental illness|"This is a 10-session group intervention (held once a week), each lasting approximately 90 minutes, taking place where the participants receive mental health treatment.~The intervention is informed by the following key areas: (1) recovery perspective of mental health and severe mental disorders; (2) constructivist epistemology approach to learning, using cases and users' experiences; and (3) psychotherapeutic and collective narrative practices, to address internalized problems and challenges shared among the group members, respectively."
75935772|NCT03197168|Behavioral|Control|Generally, each community mental health center in Chile includes two full-time psychologists, a full-time social worker and half-time occupational therapist, nurse, and psychiatrist. This team mainly offers psychiatric medication, psychotherapy, and psycho-education for users and relatives. They do not offer any specific intervention to tackle stigma among providers.
75935773|NCT04441515|Device|Ipod with music|music of patient's preference provided 2 hours daily
75935774|NCT04441515|Device|ipod with books to listen|2 hours of daily listening to books
75340632|NCT03007927|Drug|Bupivacaine- physiological solution|Bupivacaine 1,5 mg/kg- physiological solution
75935775|NCT04441515|Device|ipod only with usual care|participants given device only
75935776|NCT03107156|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their NSCLC patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
75340633|NCT05151900|Behavioral|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
75340634|NCT01483807|Behavioral|Sound Production Treatment - Blocked|Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.
75340635|NCT01483807|Behavioral|Sound Production Treatment - Random|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
75340636|NCT00434018|Behavioral|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
75340637|NCT00434018|Behavioral|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
75340638|NCT05150496|Biological|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
75650809|NCT00787501|Drug|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI < 2) and tolerability is adequate. Nonresponse at week 10 (CGI < 2) will be cause for medication switch or augmentation.
75650810|NCT00787501|Behavioral|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
75797811|NCT05771376|Other|Qigong exercise program|"The intervention group will perform a qigong exercise program online (via Zoom video conference) for 12 weeks under the supervision of two physiotherapists. The qigong exercise program had previously been videotaped by the researchers.~qigong exercise program includes: Preparation posture Prop up the sky by two improve trijiao Draw a bow on both sides like shooting a vulture Raise single arm up to regulate spleen Look back to treat five strains and seven impairments Shake the head and wag to expel Heart (Xin)-fire Pull toes with both hands to reinforce the kidney Clench one's fist and glare to increase strength Rise and fall on tiptoe sevan times to treat all diseases Ending posture. Qigong exercises will be performed 45 minutes twice in a week for 12 weeks."
75797812|NCT05771376|Other|Home exercise program|"The home exercise program will include stretching for cervical, thoracic and lumbar flexibility, shoulder girdle, hamstring and erector spinal muscles, and strengthening exercises for abdominal, back, and proximal muscles.~Home exercises will be performed 45 minutes twice in a week for 12 weeks."
75797813|NCT05769127|Other|Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)|DPP lifestyle intervention program DSMT education on diabetes and lifestyle changes
76088226|NCT02267356|Drug|VT-1161|
76088227|NCT02267356|Drug|Placebo|
76088228|NCT05229250|Other|Cycling test|RAMP and MULTI-STAGE test
75340639|NCT05150496|Biological|High-dose COVID-19 Vaccine(Vero Cell),Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
75650811|NCT00792493|Drug|ORM-12741|Alternating panel multiple dose escalation
75340640|NCT05090514|Behavioral|Reading and Growth Mindset|Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
75650812|NCT05325320|Behavioral|SMI/SIA Stigma Reduction Intervention|Online course designed to reduce stigma behaviors towards serious mental illness and suicide ideation and attempt among medical students. It aims to improve medical students' healthcare delivery skills.
75474477|NCT01984060|Other|HOME-EX|"Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.~Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise"
75474478|NCT01984073|Drug|ER Niacin Oral Fat Challenge|Extended release niacin 2000 mg at hour 0, followed by oral fat challenge at hour 1.
75797814|NCT05763719|Behavioral|Rabbits for Resilience (RFR) + HIKA|Economic empowerment program using animal husbandry for young adolescents and healthy relationship program for parents/couples in same household
75474479|NCT01984073|Drug|IR Niacin Oral Fat Challenge|Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6. Oral fat challenge at hour 1 (one hour after first dose of immediate-release niacin)
75650813|NCT05325320|Other|Disaster Preparedness Course|Online course designed to improve professionals' skills and competencies for engaging in disaster preparedness.
75650814|NCT00787579|Device|Bifocal spectacles|+1.50D bifocal spectacles
75650815|NCT00787579|Device|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
75650816|NCT04264832|Other|Clinical data collection|"Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life ."
75650817|NCT00787657|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
75650818|NCT04263662|Other|Analgesia-Sedation algorithm|The analgesia-sedation algorithm is a suggested protocol for approach to providing analgesia and sedation to patients admitted to the pediatric ICU who are newly intubated. The approach focuses on using dexmedetomidine as the primary sedative, non-opioids as the primary analgesia, then stepwise approach to adding in adjunctives (e.g. opioids, non-benzodiazepines) with the intention of minimizing benzodiazepine exposure and utilizing minimal-dose effective analgesia/sedative dosing.
75797815|NCT05763719|Behavioral|Rabbits for Resilience (RFR) only|Economic empowerment program using animal husbandry with young adolescents
75797816|NCT05763719|Behavioral|HIKA Healthy Relationship Program|Healthy relationship program for parents/couples
75797817|NCT05753917|Device|Piezo-surgery insert OR Conventional Drills|piezo-surgery: Group A (piezoelectric device with IM1, IM2, IM2-3, or IM3 piezo-inserts according to the manufacturer's protocol (Piezosurgery, Mectron Medical Technology, Carasco, Italy) Conventional drill: Group B (conventional drills according to the manufacturer's protocol (Premium, Sweden & Martina, Due Carrare, Padova, Italy)
75650819|NCT00999167|Drug|HPN-100|Part B: 6 mL BID for 16 weeks.
75650820|NCT00999167|Drug|Placebo|Part B: same as experimental arm
75797818|NCT05753098|Drug|estrogen therapy|oral estradiol valerate
75797819|NCT05753098|Drug|Sildenafil|PDE5 inhibitor
75797820|NCT05753098|Drug|Clomiphene Citrate 50mg|used for ovulation induction
75797821|NCT05726292|Drug|Relacorilant|Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is being used in this study as an experimental drug combined with other treatments for prostate cancer.
75935777|NCT03530085|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -9 to -7.
75935778|NCT03530085|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
75797822|NCT05726292|Drug|Enzalutamide|Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.
75797823|NCT05726292|Other|Placebo (Sugar Pill)|This would be a sugar pill consisting of 2 softgels. This is not an experimental drug or treatment.
75935779|NCT03530085|Drug|Fludarabine(Flu)|Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.
75935780|NCT03107390|Other|Evaluate the blood level of NTproBNP|Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.
76088229|NCT05229250|Other|Occlusion tests|Occlusion test before and after exercise
76088230|NCT05229250|Device|NIRS during cycling|NIRS devices measuring oxygenation during exercise
75935781|NCT03525639|Diagnostic Test|Cardiac Magnetic Resonance|Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
75935782|NCT03196934|Drug|Cannabidiol oral solution|Cannabidiol; Pharmacological class of drug
75935783|NCT02712320|Drug|LMIS 50 mg|Subcutaneous injection of 50 mg Leuprolide Mesylate
75797824|NCT05726292|Other|Androgen Deprivation Therapy|"All participants in this study, who meet the requirements to participate, will get Androgen Deprivation Therapy (ADT; a form of hormone therapy) continuously before their radical prostatectomy surgery. As part of this study, ADT consists of one injection every 1-3 months. In this study, ADT is a gonadotropin releasing hormone (GnRH) agonists or antagonist; the choice of which brand of ADT to use is up to your treating physician. GnRH agonists and antagonists are drugs that lower the production of androgens (male hormones) in your body. Prostate cancer cells usually require androgens, such as testosterone, to grow.~Androgen Deprivation Therapy (ADT) has been approved by United Stated Food and Drug Administration (US FDA) to treat patients with prostate cancer but is not approved to treat patients prior to prostatectomy."
75650821|NCT00787735|Behavioral|Counseling compliance|Rates of attendance to call counseling session over specific time points
75650822|NCT04264754|Procedure|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
75650823|NCT00782587|Drug|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
75797825|NCT05726292|Procedure|Radical Prostatectomy|Radical prostatectomy is surgery to remove the entire prostate gland and surrounding lymph nodes to treat men with localized prostate cancer.
75935784|NCT03527667|Behavioral|Financial incentives|Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
75935785|NCT04620915|Behavioral|High-level construal|"In the high-level construal condition, participants will be sent messages asking them to consider why they are quitting (What are your main reasons for quitting?) and to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014). The corpus for this condition is 100 messages composed by a large independent sample of mTurk workers who are smokers and validated by a team of RAs trained to 0.8 reliability on ratings of high-level construal. To meet criteria for inclusion, a message must be rated as significantly closer to high-level (vs. low-level) on a rating scale of construal level.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
75935786|NCT04620915|Behavioral|Down-regulation of craving for cigarettes|"In the down-regulation of craving condition, participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences). The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability on ratings of plausibility AND effortful cognitive inhibition or control.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
76088231|NCT05229250|Device|CPET|Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise
75340641|NCT05090514|Behavioral|Wait-list Control|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
75650824|NCT04293497|Diagnostic Test|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained using endoscopic ultrasound-guided fine needle aspiration. Three types of slides (direct smear, thinprep, surepath) are prepared for staining.~conventional cytology staining method~new cytology staining method using antibody of methionyl-tRNA synthetase 1"
76088232|NCT05229250|Device|Echo-Doppler examination|Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract
76088233|NCT01860586|Drug|Bevacizumab|Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
76088234|NCT05166382|Behavioral|Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.
75797826|NCT05699811|Biological|MSC-IFNα|MSC-IFNα form a dose of 2×10^6 cells/kg, intravenous infusion every 4-6 weeks
75797827|NCT05699811|Drug|Nab paclitaxel|125mg/m2, intravenous infusion every 4-6 weeks
76088235|NCT05166382|Behavioral|Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.
76088236|NCT02273206|Behavioral|Prevention Care Management for Depression and Cancer Screening|
76088237|NCT02273206|Behavioral|Prevention Care Management for Cancer Screening|
76088238|NCT00705432|Biological|Peginterferon alfa-2b (PEG)|Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
76088239|NCT00705432|Drug|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
75340642|NCT00496340|Drug|Pentostatin|"Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.~Participant will receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3."
75340643|NCT00496340|Drug|Busulfan|"Pre-conditioning therapy:~Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600."
75340644|NCT00496340|Drug|Rituximab|"Pre-conditioning therapy:~Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines."
75797828|NCT05699811|Drug|Cyclophosphamide|200mg/m2, intravenous infusion every 4-6 weeks
75797829|NCT05699811|Drug|Anti-PD-1 monoclonal antibody|200mg, intravenous infusion every 4-6 weeks
76088240|NCT00705432|Drug|Placebo|Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
76088241|NCT00705432|Drug|Boceprevir|Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
76088242|NCT04491708|Other|Pilates exercises|The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.
75340645|NCT00496340|Procedure|Allogeneic Hematopoietic Cell Transplant|Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
75797830|NCT05692908|Biological|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
75650825|NCT04264676|Drug|Metronidazole Oral Tablet|Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
75650826|NCT04264676|Drug|Placebo oral tablet|Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
75650827|NCT02869373|Behavioral|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
75650828|NCT00608660|Other|acupuncture|staging acupuncture
75797831|NCT05692843|Drug|Cyclosporin A|"Once the patient is included in the clinical trial their therapeutic management will be carried out according to usual clinical practice, but additional procedures will be performed:~The frequency of follow-up visits will be increased in order to collect data related to clinical efficacy, safety and quality of life;~Biological samples will be obtained (blood and urine) for biochemical, kinetic, pharmacogenetic and immunological biomarker analysis to identify variables associated to CsA treatment."
75340646|NCT00496808|Drug|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
75340647|NCT05089812|Procedure|Third-molar extraction using platelet-rich fibrin as a filling of the alveolus|see above
75340648|NCT05040672|Behavioral|questionare online application|questionare online application
75340649|NCT05039268|Drug|3K3A-APC Protein|3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
75340650|NCT05038878|Drug|Elagolix|Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months
75340651|NCT05038566|Device|Pointdexter|i-Digits partial hand prosthesis modified with the investigational pointdexter finger in place of the usual index finger.
75340652|NCT00554372|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
75340653|NCT01795820|Drug|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
75340654|NCT01795820|Drug|no loading with Ticagrelor|"Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor."
75340655|NCT00554996|Device|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
75797832|NCT05692843|Other|Follow-up of Cyclospoin treatment already started|"If the patient is receiving cyclosporine therapy, a blood sample for pharmacogenetic analysis will be obtained at screening; also, at discretion of the treating physician, biological samples will be obtained (blood and urine) in this visit and in the follow-up visits to assess biochemical and kinetic variables. Clinical data (scales) will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.~If the patient received cyclosporine previously but is no longer under CsA therapy, a blood sample will be extracted at screening for pharmacogenetic analysis. Clinical data (scales) will be collected from clinical records."
75797833|NCT05679544|Biological|Characterization of early biological effects following exposure to PAHs|Biological samples collected in period of exposure and after holidays
76088243|NCT00704964|Biological|PegIntron|PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany
76088244|NCT00704964|Drug|Rebetol|Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
76088245|NCT02474238|Device|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
75340656|NCT05087238|Behavioral|CBT|Cognitive Behavior Therapy for PVC-specific anxiety education, in-vivo exposure, interoceptive exposure, behavioral activation, relapse prevention
75340657|NCT01483963|Biological|AA4500 0.29 mg/1 mL|treatment of adhesive capsulitis
75340658|NCT01483963|Biological|AA4500 0.58 mg/2 mL|treatment of adhesive capsulitis
75340659|NCT01483963|Biological|AA4500 0.58 mg/1 mL|treatment of adhesive capsulitis
75340660|NCT01483963|Biological|AA4500 0.58 mg/0.5 mL|treatment of adhesive capsulitis
75474480|NCT01984073|Other|Placebo Oral Fat Challenge|Placebo at hour 0. Oral fat challenge at hour 1, followed by placebo at hours 2,4,and 6
75650829|NCT00608660|Other|acupuncture and moxibustion|staging acupuncture and moxibustion
75340661|NCT01483963|Other|Shoulder exercises|Home shoulder exercises, minimum of 3 times per day
75650830|NCT00608660|Other|electroacupuncture|staging electroacupuncture
75650831|NCT00608660|Other|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
75650832|NCT00608660|Other|acupuncture|non-staging acupuncture
75650833|NCT00782665|Procedure|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
75340662|NCT05145660|Radiation|intensity-modulated radiotherapy (IMRT) with reduced-volume|PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f
75340663|NCT05145660|Drug|Chemotherapy|Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
75340664|NCT05085132|Behavioral|MindFi app: Standard content|Digital wellness training in this study will be delivered via the MindFi app, designed by Jaedye Labs. Content includes learning, assesesment, and practice tracks A core component of the exercises in this app is mindfulness training; however, the app also incorporates other exercises drawn from positive psychology such as journaling and diaphragmatic breathing. The app goes beyond traditional guided meditation through content that reinforces the principles and attitudes taught during in-person training, and also seeks to maximize user experience by using interactive tasks and progress charts.
75340665|NCT05085132|Behavioral|Mindfi app: Standard content without practice|In this condition, participants will receive a version of the MindFi app that does NOT contain the practice tracks, only the learning and assessment tracks.
75650834|NCT00607412|Behavioral|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
75650835|NCT00607412|Behavioral|12-step based supportive therapy|supportive psychotherapy based on 12-step model
76088246|NCT02474238|Device|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
75340666|NCT05034900|Other|Chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, postural drainage and coughing techniques.
75340667|NCT05034900|Device|Oscillatory Positive Expiratory Pressure (OPEP) device|Shaker® device will be used.
75340668|NCT01484041|Drug|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
75340669|NCT01484041|Drug|Aromatase Inhibitors|Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
75340670|NCT00555152|Other|Laboratory Biomarker Analysis|Correlative studies
75340671|NCT00555152|Drug|Lapatinib Ditosylate|Given PO
75340672|NCT00555152|Other|Placebo|Given PO
75340673|NCT01461499|Drug|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
75340674|NCT01461499|Drug|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
75340675|NCT00555464|Drug|Vincristine|Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
75797835|NCT05669248|Diagnostic Test|mid covid-19 patients|Collect the patient's whole blood for testing
75340676|NCT00555464|Drug|Prednisone|Prednisolone given at 3 mg/kg/day by mouth for 12 week
75340677|NCT05082948|Other|Suture fixation of stent|Esophageal stent will be placed in the standard of care fashion by the endoscopists using standard gastroscopes. Covered self-expanding metal stent will be placed as per endoscopist preference. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
75797836|NCT05660616|Drug|Gemcitabine|"The study includes patients with unresectable malignant pleural mesothelioma who received at least 4 cycles of first line platinum (Cisplatin or Carboplatin) and pemetrexed combination chemotherapy~Response after first line treatment will be assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 for pleural mesothelioma.~Patients will be randomized according to a (1:1) ratio to either Arm 1: Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care Arm 2 (control arm): best supportive care alone.~Cases will be evaluated every cycle clinically and every three cycles radiologically with CTs."
75340678|NCT05082948|Other|Non suture|Standard placement of stent without suture fixation
75340679|NCT01795976|Genetic|NY-ESO-1 T cells|
75340680|NCT01795976|Drug|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
75797837|NCT05660616|Other|supportive care|supportive care
76088247|NCT02474394|Device|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
76088248|NCT02474394|Device|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
76088249|NCT01861054|Drug|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
76088250|NCT00704808|Procedure|Primary surgical treatment|Primary surgery for tumor resection.
76088251|NCT00704808|Radiation|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
76088252|NCT00704808|Drug|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
75340681|NCT01795976|Drug|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
75340682|NCT01795976|Biological|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
75650836|NCT00609440|Other|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
75650837|NCT00637637|Drug|indinavir sulfate|
75650838|NCT00637637|Drug|ritonavir|
75797838|NCT05660291|Behavioral|Early time-restricted eating|Subjects can eat whatever they want between the hours of 8:00 AM and 4:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 4:00 PM to 8:00 AM).
75650839|NCT00637637|Radiation|radiation therapy|
76088253|NCT04241718|Device|Aquadex FlexFlow System and BVA-100|Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100
75650840|NCT00570505|Device|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
76088254|NCT05323032|Device|Multifocal electroretinogram (mf-ERG) by electroretinogram device|Measurement of mf-ERG parameters with 61 stimulus elements to asses amplitude of waves in nano volt/degree square (nv/deg2) and latency in millisecond (msec) as measured by electroretinogram device.
75650841|NCT05136482|Device|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a constant pressure of 25 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). Depending on the condition, the temperature of the water being pumped through the device will be either 6, 8, 10, or 12℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
76088255|NCT01861756|Other|Diabetes Medication Choice decision aid|The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.
76088256|NCT05301582|Diagnostic Test|Tidal volume challenge test|The purpose of our study is to verify the predictability of TVC test during laparoscopic abdominal surgery for early postoperative AKI and intra-operative hypotension.
76088257|NCT02474316|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
76088258|NCT02474316|Drug|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
76088259|NCT01862536|Drug|Tadalafil|Daily use of study drug to treat pulmonary hypertension.
75340683|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
75340684|NCT01461655|Drug|marketed topical NSAID|once daily application, 4 weeks
75474481|NCT01984086|Drug|Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
75650842|NCT02869529|Other|Data collection|
75650843|NCT02555995|Device|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
75650844|NCT00931892|Dietary Supplement|Gluten|3g
75650845|NCT00931892|Dietary Supplement|Gluten|10g
75650846|NCT00666211|Other|educational intervention|Participants will be educated on pain management.
76088260|NCT01862536|Drug|placebo|Daily use in double blind study.
76088261|NCT03108378|Procedure|Surgery|hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
76088262|NCT01862614|Drug|Articaine Hydrochloride + Epinephrine|
76088263|NCT01862614|Drug|Buffered Articaine Hydrochloride + Epinephrine|
76088264|NCT00558688|Procedure|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
76088265|NCT02470650|Drug|elvitegravir/cobicistat/emtricitabine/tenofovir|1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
76088266|NCT02470650|Drug|Darunavir|Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
76088267|NCT02470650|Drug|abacavir/lamivudine|Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
76088268|NCT02470650|Drug|Ritonavir|Ritonavir 100 mg recovered tablet once a day
76088269|NCT02470650|Drug|Lamivudine|lamivudine 300mg (Epivir) 1 recovered tablet
75340685|NCT01461655|Drug|vehicle gel|once daily application, 4 weeks
75340686|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
75340687|NCT01461733|Drug|amiodarone|standard dose amiodarone
75340688|NCT01461733|Drug|Placebo|placebo delivered blinded
75340689|NCT01462279|Drug|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
75650847|NCT00666211|Other|Titrated pain management|Pain will be Monitored and Medication Titrated
75650848|NCT00666211|Other|questionnaire administration|Participants will be given questionnaires to complete.
75650849|NCT05331326|Drug|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
75650850|NCT00878709|Drug|neratinib|
75650851|NCT00878709|Other|placebo|
75650852|NCT00927758|Drug|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
75797839|NCT05660291|Behavioral|Late time-restricted eating|Subjects can eat whatever they want between the hours of 12:00 PM and 8:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 8:00 PM to noon).
75797840|NCT05659810|Drug|Gabapentin 300mg|Preoperative gabapentin before spinal anesthesia
75797841|NCT05658497|Drug|Diroximel Fumarate|Administered as specified in the treatment arm.
75797842|NCT05658497|Drug|Avonex|Administered as specified in the treatment arm.
76088270|NCT02470650|Drug|rilpivirine|rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
76088271|NCT01866592|Drug|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
76088272|NCT01375608|Drug|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
75797843|NCT05658497|Biological|Tysabri|Administered as specified in the treatment arm.
75797844|NCT05658497|Drug|Dimethyl Fumarate|Administered as specified in the treatment arm.
75340690|NCT03839472|Procedure|CBI|CBI with 5 liters normal saline in 1 liter increments up to 2 hours after TURBT procedure.
75340691|NCT02207803|Behavioral|Transition Assistance Program|
75935787|NCT04620915|Behavioral|Up-regulation of goal energization|"In the up-regulation of goal energization condition, participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking. These messages will name a specific core value that the participant rated in the top three (of 19) during the baseline session, and will draw a connection between quitting and the core value. For example, a message for a person who nominated family as one of her top three core values might read, Quitting will help you model a healthy lifestyle for your family. This intervention is grounded in robust theory and evidence supporting Self-Affirmation Theory. The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability in correctly identifying to which core value the message is tied.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics."
75935788|NCT03197012|Drug|90Y-DOTA-TOC|Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
75340692|NCT00435812|Biological|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24
75340693|NCT00435812|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4, and Week 24
75340694|NCT05081466|Other|Dietary pattern|(regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan)
75340695|NCT05081466|Other|Fruit and vegetable intake|Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire
75340696|NCT05081466|Other|Meat intake|Red meat, poultry, processed meat from food frequency questionnaire
75340697|NCT05081466|Other|Fish intake|Intake of fish from food frequency questionnaire
75650853|NCT00782977|Other|Nasal oxygen therapy|Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
75650854|NCT00783055|Other|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
75650855|NCT00608738|Other|informational intervention|
75650856|NCT00608738|Other|medical chart review|
75650857|NCT00608738|Other|questionnaire administration|
75650858|NCT00608738|Procedure|assessment of therapy complications|
75650859|NCT00608738|Procedure|management of therapy complications|
75650860|NCT00783445|Behavioral|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
75650861|NCT00783445|Behavioral|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
75650862|NCT00783523|Drug|Doxycycline or Placebo|Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
75797845|NCT05650619|Other|Biospecimen collection|Specimens that may be collected include urine, blood, saliva, kidney tissue, etc. Biospecimens will be collected to establish the RESOLVE biobank.
75797846|NCT05650619|Other|Data collection|Data collection for all groups
75797847|NCT05639699|Other|motivational interview|Quitting smoking with motivational interviewing
75797848|NCT05635240|Other|Interview / questionnaires|At each of the 4 visits, the participant will have to answer several questions regarding trauma-related data, employment and sport practice.
75935789|NCT03197012|Drug|68Ga-DOTA-TOC|In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
75935790|NCT02449304|Device|Endometrial ablation (4th gen)|Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining
75935791|NCT03196856|Behavioral|Resistance and Plyometric Exercise|12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
75935792|NCT03196856|Dietary Supplement|Greek Yogurt (0% Plain)|200g 3x/day for 12 weeks.
75340698|NCT05081466|Other|Egg intake|Intake of eggs from food frequency questionnaire
75340699|NCT05081466|Other|Dairy intake|Intake of dairy products from food frequency questionnaire
75340700|NCT05081466|Other|Tea intake|Intake of tea (drink) from food frequency questionnaire
75340701|NCT05081466|Other|Coffee intake|Intake of coffee (caffeinated or decaffeinated) from food frequency questionnaire
75340702|NCT05081466|Other|Tea and coffee intake|Combined intake of tea and coffee from food frequency questionnaire
75340703|NCT05081466|Other|Protein intake|Estimated intake of protein, derived from food frequency questionnaire
75340704|NCT05081466|Other|Calcium intake|Estimated intake of calcium, derived from food frequency questionnaire
75340705|NCT05081466|Other|Vitamin D intake|Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake
75340706|NCT01464229|Drug|Iloperidone|Iloperidone 1-8 mg for 4 weeks
75340707|NCT01464229|Drug|Placebo|Placebo
75340708|NCT05030688|Other|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
75797849|NCT05625347|Drug|single dose (100 mg) of ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
75797850|NCT05625347|Drug|single dose (162 mg) of non-enteric-coated chewable aspirin tablets|orally administered
75935793|NCT03196856|Dietary Supplement|Placebo - Study Designed Supplement|Iso-energetic to yogurt. 3x/day for 12 weeks.
75797851|NCT05622422|Behavioral|EMPOWER-BKP|The intervention aims to activate patients' inherent resources and by this, facilitate empowerment, patient activation, and self-care management of their chronic disease. The participants will include people 18 years and older that have been diagnosed with a chronic disease. This pilot study will use a pre-post design. Some of the data will be collected initially at the first session and then again at the seventh session. The intervention will be provided in seven sessions the first three will be face-to-face at a community center and then the last four sessions will be through video conferencing and will be facilitated by three researchers. The participants will be invited to a focus group interview in week nine in order to collect quantitative data. Once the sessions are finished both qualitative and quantitative data will be collected and then analyzed.
75935794|NCT03530007|Drug|Normal saline|normal saline used for prevention of spinal shivering
75935795|NCT03530007|Drug|Ondansetron 4 MG|ondansetron 4 MG used for prevention of spinal shivering
75935796|NCT03530007|Drug|Ondansetron 8mg|ondansetron 8 MG used for prevention of spinal shivering
75935797|NCT03194048|Other|Functional Chewing Training|"FuCT;~Family training~Providing optimal sitting posture for children to support oral sensorimotor functions~Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~Massage of the upper and lower gums through the front teeth to molar area~Chewing training to stimulate lateral and rotational tongue movements~Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
75935798|NCT03194048|Other|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;~Family training~passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
75935799|NCT04608045|Drug|CPX-POM|CPX-POM
76088273|NCT02474004|Procedure|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis & knee scores 6 mo after the procedures
76088274|NCT02473848|Drug|ingenol mebutate 500 ucg|Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
75340709|NCT00556478|Drug|PSD502, contains a mixture of lidocaine and prilocaine|"PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
75650863|NCT00927368|Procedure|ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
75650864|NCT00927368|Procedure|ultrasound guidance and needle stimulation|For the ultrasound guidance and needle stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation.
76088275|NCT01868776|Drug|buffered lidocaine|
75474482|NCT01984086|Drug|Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
75650865|NCT00927368|Procedure|ultrasound guidance and catheter stimulation|The Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
75650866|NCT00783601|Drug|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
75650867|NCT00783601|Drug|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
75935800|NCT03202238|Other|Conventional|Conventional venepuncture without use of any venepuncture assistive device.
75935801|NCT03202238|Device|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
75935802|NCT03202238|Device|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
75935803|NCT03529929|Drug|Methylprednisolone|6 day dosing as dictated by Medrol 6 Day Dose Pack
76088276|NCT01868776|Drug|nonbuffered lidocaine|
76088277|NCT02469558|Dietary Supplement|Winclove 851 and 110|prebiotic and probiotic mixture
75474483|NCT01984086|Drug|Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
75650868|NCT00783601|Drug|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
75935804|NCT03202394|Drug|BIO-11006|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
75935805|NCT03202394|Drug|Placebo|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
75474484|NCT01984086|Drug|Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
75474485|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister|Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
75340710|NCT00556478|Drug|Placebo|"The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
75340711|NCT01467037|Other|No intervention done|Not applicable because no intervention was done.
75340712|NCT05080998|Diagnostic Test|CxBladder Monitor|CxBladder Monitor (CxbM) is a high sensitivity and negative predictive value (NPV) urinary biomarker test to rule-out subjects at low risk of bladder cancer monitoring for recurrence of disease.
75340713|NCT01912040|Drug|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
75340714|NCT01468675|Other|Intervention|risk assessment survey; decision support for providers for prevention based on risk
75474486|NCT01984086|Drug|Salbutamol MDI 100mcg|Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
75474487|NCT01984086|Drug|Salbutamol Sulphate UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
75474488|NCT01984086|Drug|Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
75650869|NCT00783601|Drug|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
75650870|NCT00783679|Device|NICO device|"Measurement of cardiac output and simultaneous blood sampling.~The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy."
75650871|NCT04259840|Other|Observation|Soft tissue implant measurements
75797852|NCT05611138|Dietary Supplement|Protein supplementation|Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.
75797853|NCT05602090|Drug|4 IU of recombinant GH (Somatotropin )|4 IU of recombinant GH
75935806|NCT03052751|Drug|UCB7665|UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)
75935807|NCT03052751|Other|Placebo|Placebo will be administered in period 1 of dosage regimen 2.
75935808|NCT03525561|Drug|Acetazolamide Pill|Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude.
76088278|NCT02469558|Dietary Supplement|Placebo|white powder without pro/probiotic
75340715|NCT00500240|Drug|Insulin Glargine|Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
75340716|NCT00500240|Drug|Insulin Aspart|Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
75340717|NCT01469767|Drug|Fluocinonide cream|Fluocinonide cream 0.1% applied twice daily for 5 days.
75340718|NCT03246620|Drug|Olanzapine oro-dispersible 5Mg Tab|Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
75474489|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister without activated charcoal|Formulation will be determined depending on the outcome of Part A.
75474490|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister with activated charcoal|Formulation will be determined depending on the outcome of Part A.
75474491|NCT01984086|Drug|Salbutamol MDI 100mcg without activated charcoal|Formulation will be determined depending on the outcome of Part A.
75474492|NCT01984086|Drug|Salbutamol MDI 100mcg with activated charcoal|Formulation will be determined depending on the outcome of Part A.
75650872|NCT00783757|Device|Optical Imaging|TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
75650873|NCT05331092|Other|Cryotherapy|20 minutes of cryotherapy on the dominant ankle with ice bags
75650874|NCT00783913|Other|Visumotor Upper Extremity Training|Control
75935809|NCT03525561|Drug|Placebo pill|Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.
75935810|NCT03202004|Drug|GSK2894512 1% cream|1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
75650875|NCT00783913|Other|Anodal/Sham tDCS|Condition
75650876|NCT04261868|Device|Virtual Reality|New treatment for amblyopia therapy using playing games
75650877|NCT04261868|Other|Patching|Patching
75650878|NCT00787813|Drug|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
75650879|NCT00787813|Drug|Placebo|
75797854|NCT05599308|Device|OMRON blood pressure monitor with AFib screening feature|Blood pressure measurement by an oscillometric blood pressure monitor
75797855|NCT05599308|Device|Microlife WatchBP Home A|Blood pressure measurement by an oscillometric blood pressure monitor
75797856|NCT05594680|Drug|Cilostazol|Cilostazol 50 MG
76088279|NCT05748340|Procedure|Unilateral cleft lip repair|Surgical repair unilateral cleft lip
76088280|NCT00704418|Drug|Bromfenac|sterile ophthalmic solution
76088281|NCT00704418|Drug|Placebo|sterile ophthalmic solution
76088282|NCT01869634|Drug|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
76088283|NCT02047578|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
76088284|NCT05232552|Drug|Anlotinib hydrochloride|anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
76088285|NCT05232552|Drug|induction chemotherapy|docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
76088286|NCT05232552|Radiation|concurrent chemoradiation|definitive IMRT (GTV>66Gy) concurrent with 2 cycles of DDP (100mg/m2 d1) and anlotinib (12mg d1-14) every 21 days
76088287|NCT02470572|Other|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
76088288|NCT02470572|Other|Conventional light microscope|Conventional light microscope
75340719|NCT03246620|Drug|Haloperidol 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
75340720|NCT03246620|Drug|Diazepam 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
75650880|NCT04261634|Procedure|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
75650881|NCT04261634|Procedure|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
75797857|NCT05594680|Drug|Methotrexate|Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.
75797858|NCT05594680|Drug|Placebo|Placebo
75797859|NCT05591885|Dietary Supplement|Study product group (Nutrilite Memory Builder)|During study intervention, subjects are required to take the randomly assigned study product following the instructions.Take one tablet twice daily with meals.
75935811|NCT03202004|Drug|Vehicle cream|Vehicle cream will be provided in tubes labeled in compliance with country requirements.
75935812|NCT05270265|Biological|Pvs25-IMX313/Matrix-M1|Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
75935813|NCT03118700|Other|Aerobic Interval Exercise|Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time
76088289|NCT02266108|Behavioral|ESTIMA Intervention|This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
76088290|NCT01515462|Genetic|OTL-103|OTL-103 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
76088291|NCT01201590|Dietary Supplement|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
76088292|NCT01201590|Dietary Supplement|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
76088293|NCT00916656|Biological|Fibrinogen Concentrate, Human (FCH)|"Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually."
75340721|NCT05141058|Biological|Coronavirus-specific T cell (CST)|Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and <4 months after hematopoietic stem cell transplantation (HSCT).
75474493|NCT01984099|Drug|Methotrexate|Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
75650882|NCT00787969|Biological|rituximab|Give IV
75650883|NCT00787969|Drug|cladribine|Give IV
75650884|NCT00787969|Drug|temsirolimus|Give IV
75650885|NCT00787969|Biological|Filgrastim|Give SC
75650886|NCT00787969|Biological|Pegfilgrastim|
75797860|NCT05591885|Dietary Supplement|Placebo group|During study intervention, subjects are required to take the randomly assigned placebo following the instructions.Take one tablet twice daily with meals.
75797861|NCT05567029|Drug|Risankizumab Dose A|Prefilled Syringe
75797862|NCT05567029|Drug|Risankizumab Dose B|Prefilled Syringe
75797863|NCT05564702|Other|traditional drug treatment|The patients in this arm will be given doctor specified dosage.
75797864|NCT05564702|Other|Opt-IVF predicted dosage|The patients in this arm will be given dosage predicted by Opt-IVF.
75474494|NCT01984099|Drug|Vitamin B Complex|Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
75797865|NCT05562700|Other|On-line questionnaire|"It is a self-administered questionnaire (20 minutes) with several subparts:~Socio-demographic questions: age, height, weight, smoking status, etc.~Care: date of accident, initial treatment, duration of symptoms, complications, return to work, return to sport, recovery of skills, etc.~Functional results"
75797866|NCT05557643|Drug|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the issues that arise in this participant population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
75474495|NCT01984112|Device|Locked plate|Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
75650887|NCT00609596|Drug|GI198745|
75650888|NCT05007470|Drug|VSL #3 112.5 Capsule|VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
75650889|NCT05007470|Other|Placebo|100 mg sugar
75650890|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
75650891|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
75650892|NCT02535273|Drug|Dexmedetomidine|load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
75650893|NCT02535273|Drug|Lidocaine|local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
75935814|NCT03118700|Other|Continuous exercise|Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
75935815|NCT04782947|Device|Exoskeletal assisted walking|Exoskeletal assisted walking includes the use of robotic suit to train participant to walk with different level of assistance.
75935816|NCT04782947|Device|Epidural Stimulation|lumbo-sacral epidural simulation at the beginning of the study.
75935817|NCT04782947|Procedure|Resistance Training|Using two forms of resistance training to increase muscle size. The first form includes seated leg extension exercise for 12 weeks followed by a second form that includes sit-to-stand exercise using participant's body weight.
76088294|NCT00916656|Biological|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
76088295|NCT01871506|Behavioral|Standard Care (SC)|"Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."
76088296|NCT01871506|Behavioral|Intensive Counseling (IC)|"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."
76088297|NCT05351892|Drug|Elinzanetant (BAY3427080)|Soft gel capsule, oral
76088298|NCT00555646|Drug|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
76088299|NCT00555646|Drug|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 2: PH-10 with ambient light illumination.
76088300|NCT00555646|Drug|Control|No treatment control.
76088301|NCT01873846|Device|Silicone Hydrogel Contact Lens|
76088302|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
76088303|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
75474496|NCT01984112|Device|Intramedullary locked nail|Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
75474497|NCT01984125|Other|Point-of-Care Prompt|
75650894|NCT02535273|Drug|Low-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
75650895|NCT02535273|Drug|Moderate-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
75650896|NCT02535273|Drug|High-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
75650897|NCT02535273|Drug|normal saline|Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
75650898|NCT05006066|Other|Temporal Summation|4 type of stimulations applied on the right arm
75650899|NCT00788047|Drug|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
75340722|NCT01470781|Behavioral|BrainWorks|"13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as directors for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training."
76088304|NCT01874392|Drug|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
76088305|NCT01874392|Device|Artificial Pancreas (AP) device (APS©)|"Device includes:~OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~Dexcom® G4® CGM System (CGM) from Dexcom® Corp~Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)"
75474498|NCT01984177|Drug|Corticotropin-Releasing Hormone|Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. ~15 minutes after Corticorelin/saline injection, [11C]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure ([11C]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
75340723|NCT01470781|Behavioral|Computer Control|"Sessions will involve generic computer games administered via the game interface Sporcle. Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session."
75474499|NCT01984203|Other|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
75474500|NCT01984203|Other|Progressive Heavy Strength Exercises|"All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.~Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
75650900|NCT00788047|Drug|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
75650901|NCT04152369|Procedure|Anti-microbial prophylaxis for an endourological procedure or ESWL|anti-microbial prophylaxis according to urine culture results
75650902|NCT00674037|Other|monetary incentive|75 euros for each patient included
75650903|NCT05331014|Drug|LivaloVA|For 8 weeks(PO, QD)
75340724|NCT01470859|Drug|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
75797867|NCT05557643|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) is a well-established evidence-based mindfulness training program initially developed by Jon Kabat-Zinn that has been shown to reduce symptoms of depression, anxiety, and burnout. The 8-week MBSR curriculum provides training in formal meditation practices including body scan techniques, mindfulness meditation, and yoga. Mindfulness can be understood as the non-judgmental acceptance and investigation of present experience, including body sensations, internal mental states, thoughts, emotions, impulses and memories, in order to reduce suffering or distress and to increase well-being.
75650904|NCT05331014|Drug|LivaloV|For 8 weeks(PO, QD)
75797868|NCT05553795|Procedure|Early removal of chest drain|Chest drains are removed 3 hours after the end of surgery in absence of contraindications in arm A.
75650905|NCT05331014|Drug|VA|For 8 weeks(PO, QD)
75797869|NCT05553795|Procedure|Chest drain|The chest drains in arm B are removed during the further postoperative course according to standard algorithm.
75340725|NCT01470859|Drug|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
75650906|NCT00788281|Procedure|laparoscopic surgery|surgery would be performed by laparoscope
75650907|NCT00788281|Procedure|open surgery|surgery would be performed by traditional surgery.
75650908|NCT04259684|Drug|gases Nitric Oxide (gNO)|Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
75797870|NCT05542641|Device|repetitive transcranial magnetic stimulation (rTMS)|real versus sham rTMS
75935818|NCT04782947|Device|delayed-ES|lumbo-sacral epidural simulation starting 6 months after the beginning of the study.
75935819|NCT04782947|Procedure|no-Resistance training|The participants will perform 24 weeks of passive movement or passive stretching from seated position.
75935820|NCT03527511|Other|Measure of etecalcetide on osteoclastic biology|In vitro evaluation of osteoclastic biology after blood sampling of patients.
76088306|NCT04064346|Drug|Lixivaptan|Oral vasopressin V2 receptor antagonist
76088307|NCT04064346|Drug|Placebo|Matching placebo
75340726|NCT00436046|Biological|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
75474501|NCT01984216|Procedure|Roux-en-Y for the gastrojejunostomy reconstruction|
75650909|NCT00788515|Drug|Volinanserin (M100907)|2 mg tablets QD
75340727|NCT00436046|Biological|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
75340728|NCT01471639|Drug|intranasal ketorolac|15 mg
75340729|NCT05622656|Drug|Dexmedetomidine|Dexmedetomidine 0.0005%
75340730|NCT05622656|Drug|Placebo|0.9% Sodium Chloride Solution
75340731|NCT05079126|Drug|Trans Sodium Crocetinate|Single IV Bolus
75935821|NCT05696691|Drug|Ketamine Hydrochloride|100mg IM ketamine to be administered in conjunction with CRP. The ketamine injection will be administered first. Participants will be observed and have vital signs monitored for the first 45 minutes after administering medication in the ED, observing for immediate reactions. Afterwards, participants will continue to be monitored for potential late-term side effects on the inpatient unit. Ketamine will be given only after initial standard of care (SOC) treatment and screening studies have been initiated.
75650910|NCT00788515|Drug|Lormetazepam|1 mg tablets (overencapsulated) QD
75797871|NCT05531370|Other|Breathing Retraining|"Conforming the real-world setting, all participants will continue standard asthma care, i.e., acute and planned visits at GP or pulmonologist.~BR aims to normalize the inhaled volume, nasal inhalation, exhalation to the resting position of the chest (functional residual capacity, FRC), use of the diaphragm muscle, and to move lower parts of the chest in a frequency of 12-16 per minute. This pattern is initially trained in rest (e.g., side lying or sitting), then during physical activity (e.g., walking). Uncontrolled coughing, frequent yawning or sighing is handled by a suppression technique. Relaxation technique is introduced as a separate activity but to be combined with the breathing pattern method to be used in both resting and as possible during physical activity."
75650911|NCT04259606|Dietary Supplement|Cassia Cinnamon|Reddish - brown to light brown, typical sweet and aromatic free flowing powder.
75797872|NCT05530473|Device|capsular tension ring|To insert a capsular tension ring during the cataract surgery
75797873|NCT05526443|Drug|all approved chemotherapeutic agents from second line|all approved chemotherapeutic agents from second line
75797874|NCT05518604|Behavioral|Counseling with goal of modifying eating behaviors|Dietary counseling will occur virtually a minimum of 4x and as desired by participant in the first year postpartum according to a standard protocol
75935822|NCT05696691|Behavioral|Crisis Response Plan|"Crisis Response Plan is a brief, empirically-validated, Cognitive-Behavioral Therapy-based one-time therapy, and its administration typically takes 30-60 minutes. It begins with a narrative assessment (allowing patients to tell their story) and concludes with collaboratively constructed plan that outlines strategies for the patient's self-management of future acute suicidal crises. Patients who engage in CRP are given an index card to keep with them that summarizes the emotional management strategies that they collaboratively generate with the CRP provider."
75935823|NCT04525131|Drug|CPX-POM|CPX-POM
75935824|NCT04760483|Device|SoracteLite(TM) TPLA for BPH|see prior section
75340732|NCT05079126|Drug|Placebo|Single IV Bolus
75340733|NCT05149872|Other|Muscle relaxation|Rocuronium will be used to induce partial paralysis
75340734|NCT05149872|Other|Reversal|Sugamamdex will be used to reverse muscle relaxation
75650912|NCT04259606|Other|Calcined magnesia|White, odor, color and flavorless thin powder.
75650913|NCT00788749|Drug|Prednisolone|tablets 25 mg/day
75650914|NCT00788749|Drug|Placebo|tablets once daily
75797875|NCT05507905|Behavioral|Music|Music associated with dance forms in dance classes.
75797876|NCT05507905|Behavioral|Dance Classes|Four Different dance forms taught for 6 weeks each
75474502|NCT01984216|Procedure|Billroth II for the gastrojejunostomy reconstruction|
75474503|NCT01984255|Drug|Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV|Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.
75474504|NCT01984255|Drug|Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.|Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
75650915|NCT00788749|Other|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
75650916|NCT00788749|Other|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
75340735|NCT05140278|Drug|Argesun 60mg (1 step parenteral artesunate)|Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.
75340736|NCT05140278|Drug|Artesun 60mg (2-step parenteral artesunate)|Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
75340737|NCT00436904|Drug|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
75650917|NCT00609752|Drug|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
75935825|NCT03525483|Diagnostic Test|Ultrasound for renal resistivity index measurement|"Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ..."
75340738|NCT00436904|Drug|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
75650918|NCT00609752|Dietary Supplement|Alicalm (polymeric liquid formula)|"Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks."
75340739|NCT05139654|Other|Arm elevation in the scapular plane|Lift the arm up in the scapular plane
75340740|NCT05139654|Other|Pull up with gymbar|Grasp the gymbar with both hands and pull up as high as the subject can
75340741|NCT05139654|Other|Pull up with fingerboard|The width of the fingerboar is 20 mm. Pull up with fingers on the fingerboard.
75340742|NCT00438854|Drug|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
75650919|NCT00662857|Drug|Technosphere® Insulin Inhalation Powder|TI Inhalation Powder, two 15 U cartridges
75650920|NCT00662857|Drug|Technosphere Insulin® Inhalation Powder|TI Inhalation Powder, one 30 U cartridge
75650921|NCT00662857|Drug|RAA Population|RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
75650922|NCT04261400|Behavioral|MAMAACT|Improved communication regarding warning signs of pregnancy complications
75650923|NCT00788905|Device|Allient System|The Allient System uses a different type of blood pump and a lower volume of dialysate.
75935826|NCT03529851|Other|Weekly questionnaires|In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
75935827|NCT03527355|Biological|Vi-DT|Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
75650924|NCT00878553|Drug|placebo|tablet at bedtime
75650925|NCT00878553|Drug|SKP-1041 (experimental formulation of zaleplon)|tablet at bedtime
75650926|NCT05220020|Procedure|TACE(Transcatheter arterial chemoembolization)|Hepatic arterial chemoembolization treatment
75340743|NCT01485055|Drug|Infliximab and Basiliximab|"Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
75340744|NCT05028348|Drug|Selinexor|Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.
75340745|NCT05028348|Drug|Elotuzumab|Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.
75650927|NCT05220020|Drug|Lenvatinib|Experimental group(Synchronous treatment group): the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.Control group:(Sequential treatment group)patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
75650928|NCT00789061|Drug|Proton pump inhibitor|One dosage/day/year
75650929|NCT00996437|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
75650930|NCT00996437|Drug|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
75650931|NCT00789139|Device|ICM Implantation|Sub cutaneous implantation of the ICM
75650932|NCT04985396|Drug|Platelet Rich Plasma (PRP) group|Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
75650933|NCT00789217|Procedure|Immediate skin test|Intradermal test with immediate reading
75340746|NCT05028348|Drug|Pomalidomide|Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
75650934|NCT04248842|Device|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor (Meditech Blue BP-05), Nonin WristOx 3150 as well as departments standard monitors
75650935|NCT00609830|Behavioral|Tailored Materials|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
75340747|NCT05028348|Drug|Dexamethasone Oral|Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for >75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.
75340748|NCT01486615|Drug|meloset (melatonin)|3 mg melatonin tablet 1-2 hour prior surgery
76088308|NCT05747872|Behavioral|Buerger Allen Exercises|"These exercises are specific exercises aimed at improving circulation in the feet and legs.~While doing the exercises, first of all;~The legs are raised at an angle of 45 degrees and supported in this position for 1-3 minutes until the skin turns white.~Sit on the edge of the bed and let your legs hang down (make sure there is no pressure behind the knees). In this position, move your foot left and right and up and down for 3 minutes.~Lie on your back for 5 minutes keeping your legs warm with a blanket.~Performing all three of these exercises in sequence means 1 session. Exercises are done 2 times a day, at least 3 sessions each time."
76088309|NCT05575648|Other|10 meter walk test|To assess the dual task performance of children 10 meter walk test will be used.
76088310|NCT00576654|Drug|Irinotecan Hydrochloride|Given IV
76088311|NCT00576654|Other|Laboratory Biomarker Analysis|Correlative studies
76088312|NCT00576654|Other|Pharmacological Study|Correlative studies
75650936|NCT00609830|Behavioral|Tailored Materials Plus Physician Feedback|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
75650937|NCT00609830|Behavioral|Generic Materials|Participants received generic written educational materials about osteoporosis prevention.
75340749|NCT01486615|Drug|stresnil ( melatonin and alprazolam)|3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
75935828|NCT03527355|Biological|FluQuadri™|"Manufacturer: Sanofi Pasteur Dose: 0.25 ml~*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding."
75935829|NCT03527355|Other|0.9% sodium chloride isotonic solution|Manufacture: Euro-Med Inc. Dose: 0.5 mL
75935830|NCT01317797|Drug|namilumab (MT203)|administered three times, subcutaneous in the abdomen
75340750|NCT01486615|Drug|(alprax) alprazolam|0.5 mg alprazolam
75340751|NCT01486615|Drug|placebo|similar looking placebo tablet
75340752|NCT01797068|Behavioral|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
75650938|NCT00609830|Behavioral|No Information|Participants received no informational materials.
75650939|NCT00674193|Other|pharmacological study|Correlative studies
75340753|NCT01797068|Other|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
75935831|NCT01317797|Drug|Placebo|administered three times, subcutaneous in the abdomen
75935832|NCT05595395|Drug|Enteral Dose Form|"In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be Elomel isoton."
75340754|NCT00503750|Drug|Pre operativeTrastuzumab|"Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.~As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52."
75650940|NCT00674193|Other|laboratory biomarker analysis|Correlative studies
75650941|NCT04968379|Drug|Ferric carboxymaltose|Intravenous
75650942|NCT04263506|Other|Vignette with emphasis on supervisor's opinion|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
75650943|NCT00784069|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
75935833|NCT05595395|Drug|Intravenous Infusion|"In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be Elomel isoton."
75935834|NCT03529617|Other|Sample collection|Plasma, urine, BAL and ascitic fluid sample collection.
75935835|NCT05707169|Procedure|Saphenous Ablation|Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture.
75935836|NCT05707169|Device|Endogenous Laser Ablation (EVLA)|Endogenous Laser Ablation (EVLA)
75935837|NCT05707169|Drug|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
76088313|NCT00576654|Drug|Veliparib|Given PO
76088314|NCT05747716|Drug|SBRT, Fruquintinib, Cadonilimab|Radiation: Stereotactic body radiationtherapy (SBRT) for metastatic sites (less than 5) Fruquintinib: 5mg, po, everyday; Cadonilimab: 10mg/kg, iv, q3w
76088315|NCT03314142|Other|Glucose as reference food|Ten subjects (male: 7, female: 3) consumed 50g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
76088316|NCT03314142|Other|White bread as reference food|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from white bread along with 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
76088317|NCT03314142|Other|Bread enriched with coarse wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
76088318|NCT03314142|Other|Bread enriched with fine wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
76088319|NCT03314142|Other|Bread enriched with fine wheat bran and carob seed flour|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
75340755|NCT00503750|Drug|ABI-007 (Abraxane)|ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
75340756|NCT00503750|Drug|Vinorelbine|Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
76088320|NCT05747482|Other|Surgery procedure|Omentectomy vs omental preservations during gastric surgery
76088321|NCT00704340|Device|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
75935838|NCT05707091|Other|Low level laser therapy and conventional therapy|One group treated with low level laser therapy along with conventional therapy
75650944|NCT02628951|Drug|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
75935839|NCT05707091|Procedure|Conventional therapy|Group B treated with ems and exercises
75650945|NCT02628951|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
75650946|NCT00662311|Drug|vorinostat|Given PO
75935840|NCT03525249|Dietary Supplement|nutraceutical|Subjects will consume a capsule for eight weeks
75935841|NCT03529539|Drug|PSV|
75935842|NCT03627221|Behavioral|music listening and social network|The 12-week combination of music care and social network program consists of three parts: sleep related variables assessment and monitoring, sleep management education and outcome evaluation. Participants in the intervention group will receive weekly online (social network) education and music listening interventions for 12 weeks provided by the PI.
75935843|NCT02712008|Drug|REGN910-3|Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
75935844|NCT02712008|Drug|Intravitreal Aflibercept Injection (IAI)|
75935845|NCT03527121|Other|ESP physiotherapy|A single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
75935846|NCT03527121|Other|Usual care|A single session with advice and instructions from a physician in rest, ice, compression and elevation (usual care group).
75935847|NCT05130515|Drug|Niraparib|Niraparib 200mg po QD, day1~21
76088322|NCT00704340|Other|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
76088323|NCT03314064|Drug|Dolutegravir 50 mg|DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
76088324|NCT00552058|Biological|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
75340757|NCT05078112|Device|Sleep sensor technology|Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output based on historical sleep data.
75340758|NCT00438932|Drug|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
75340759|NCT00438932|Dietary Supplement|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
75340760|NCT00438932|Dietary Supplement|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
76088325|NCT00552058|Other|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
76088326|NCT02473692|Other|Online Migraine Treatment Optimization|"The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:~Introduction to the series~Getting to know migraine~Making the most of your medical care~Partnering with your doctor~Best use of migraine medication~Keeping tabs on your migraine~Take home message (summary)"
75650947|NCT00662311|Drug|paclitaxel|Given IV
75650948|NCT00662311|Radiation|radiation therapy|Undergo radiation therapy
75650949|NCT00674349|Procedure|surgery|staging surgery
75650950|NCT00929708|Drug|AZD3199|Dry powder for inhalation, o.d., 4 weeks
75650951|NCT00929708|Drug|formoterol|Dry powder for inhalation, b.i.d., 4 weeks
75650952|NCT00929708|Drug|Placebo|Dry powder for inhalation, b.i.d., 4 weeks
75650953|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
75650954|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
75650955|NCT00789295|Other|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
75650956|NCT00674505|Device|Lumen Biomedical FiberNet Embolic Protection System|to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
75935848|NCT05130515|Drug|Anlotinib|Anlotinib 10mg po QD, day1~14, 3 weeks/cycle
76088327|NCT02473302|Other|ham|160g per day during 4 days
76088328|NCT02473302|Other|ham + pomegranate extract|160g per day during 4 days
76088329|NCT02473302|Other|ham + tocopherol|160g per day during 4 days
76088330|NCT02473302|Other|rare sirloin steak|110g per day during 4 days
75650957|NCT02628795|Behavioral|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
75650958|NCT02628795|Other|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
75650959|NCT04261322|Radiation|x ray exposure|exposure of whole body to x ray
75650960|NCT00674895|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
75340761|NCT00438932|Drug|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
75650961|NCT00609908|Procedure|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
75650962|NCT00609908|Procedure|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
75650963|NCT00609908|Procedure|serial excision|as much scar as possible is excised, whereafter the wound is closed
75650964|NCT00609908|Procedure|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
75650965|NCT00789451|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
75650966|NCT00996281|Drug|Azilsartan medoxomil and chlorthalidone|Combination tablet.
75650967|NCT00996281|Drug|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
75650968|NCT04259528|Device|Pediatric endoscopic ultrasound|endoscopic ultrasound at the esophageal stricture site to assess echo texture and esophageal layers
76088331|NCT02473302|Other|marinated rare sirloin steak|110g per day during 4 days
75650969|NCT04046653|Dietary Supplement|Allin|Dietary supplement
75650970|NCT04046653|Dietary Supplement|Sulforaphane|Dietary supplement
75650971|NCT04046653|Dietary Supplement|Placebo|Dietary supplement
75650972|NCT00675129|Behavioral|Dialectical behavioral therapy for adolescents (DBT-A)|"Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
75650973|NCT00675129|Behavioral|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
75650974|NCT04259294|Behavioral|Caspar Telerehabilitation|"The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists."
75650975|NCT04293887|Drug|Recombinant human interferon α1β|Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
75650976|NCT04259216|Behavioral|IMPACT Intervention|Brief remote session + tailored, daily 8-week mobile application facilitated messaging secondary prevention intervention.
75650977|NCT04259216|Other|Control: Enhanced Online Resources (EOR)|EOR group participants will receive standardized information on cyberbullying.
75650978|NCT00675207|Drug|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
76088332|NCT02473302|Other|marinated cooked sirloin steak|110g per day during 4 days
76088333|NCT02473458|Drug|Licorice whole extract|"Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~Starch-filled capsules (as placebo)~450 mg whole licorice extract capsules~900 mg whole licorice extract capsules"
76088334|NCT02473458|Drug|Placebo|
76088335|NCT02473380|Device|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
76088336|NCT05747326|Drug|oral vinorelbine and capecitabine|The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
76088337|NCT03108300|Drug|Propranolol Hydrochloride|propranolol hydrochloride is a beta-adrenergic receptor blocker
75340762|NCT04421274|Biological|Bone marrow mesenchymal stem cells transfer|Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 ~ 8 times
75340763|NCT04421274|Drug|Best medical treatment|Refer to the latest medication guidelines and give the best medication to the patients
75340764|NCT04421274|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
76088338|NCT03108300|Drug|Doxorubicin|Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
76088339|NCT02473224|Biological|Norovirus GII.2 Challenge|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10^2 GEC or 1.2 x10^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, or 1.2 x 10^6 GEC, or 1.2 GEC x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
75797877|NCT05467787|Behavioral|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
75797878|NCT05467787|Behavioral|Video-chat Psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
75340765|NCT05022498|Behavioral|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
76088340|NCT02473224|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
75650979|NCT00675207|Drug|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
75650980|NCT00675207|Drug|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
75340766|NCT00506714|Device|single point cane|Adjustable single point cane with SureGrip handle
75474505|NCT01984281|Behavioral|Pedometer-based physical activity prescription|After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.
75650981|NCT00795223|Drug|morphine and bupivacaine|0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block
75340767|NCT00508118|Drug|Nicardipine|on bypass
75650982|NCT00795223|Drug|spinal morphine and marcaine|0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block
75650983|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block
75650984|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
75650985|NCT00795301|Drug|Capecitabine, Cetuximab, Oxaliplatin|
75797879|NCT05446389|Device|Pacifier Activated Lullaby ®|Pacifier Activated Lullaby (PAL®) is a medical device that encourages and reinforces the development of non-nutritive sucking (NNS) of premature infants. This is accomplished by giving positive feedback in the form of music/mother's voice as an auditory input in direct response to effective sucking.
75650986|NCT00675285|Drug|montelukast sodium|one tablet 5 mg once/day for 4 weeks
75650987|NCT00675285|Drug|placebo|one tablet 5 mg once/day for 4 weeks
75650988|NCT04258982|Other|no intervention|no intervention
75650989|NCT00792961|Device|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
75650990|NCT00675363|Procedure|Protocolized Sedation|Nurse-directed protocol for administering sedation and/or analgesia.
75650991|NCT00675363|Procedure|Protocolized sedation, with daily interruption|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
75797880|NCT05441111|Behavioral|Common Elements Toolbox|"COMET consists of the following modules: cognitive restructuring (labeled flexible thinking), behavioral activation (labeled positive activities), gratitude, and self-compassion. Participants complete these COMET modules by themselves. The format is reading psychoeducational along with completing specific activities"
75935849|NCT03525171|Diagnostic Test|euglycemic hyperinsulinemic clamp|In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
75935850|NCT04484324|Other|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
75935851|NCT04483934|Biological|Dermal fibroblasts|"Cultured autologous dermal fibroblasts.~For PR: The name dermal fibroblasts is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
75340768|NCT00508118|Drug|0.9% saline|on bypass
75340769|NCT00508196|Other|RVP-min|DDD pacing with long AV delay
75340770|NCT00508196|Other|RVP-max|DDD pacing with short AV delay
75340771|NCT05622266|Procedure|Pulpotomy|The patients who are randomly assigned to the experimental group receive pulpotomy.
75340772|NCT05622266|Procedure|Root Canal Therapy|The patients who are randomly assigned to the Active Comparator group receive root canal therapy.
75935852|NCT04483934|Device|LED phototherapy|LED phototherapy
75935853|NCT03626987|Diagnostic Test|mass spectrometry (MALDI-TOF)|The determination of the protein composition of the bacterial spectrum
75340773|NCT05139030|Drug|bupivacaine liposome injectable suspension|Adductor canal block with EXPAREL
75340774|NCT05139030|Drug|Bupivacaine Hydrochloride|Adductor Canal Block with bupivacaine HCl
75340775|NCT00440180|Drug|Anastrozole|1 mg qd for 4 months
75340776|NCT00440180|Drug|Placebo|Placebo Comparator
75340777|NCT05021094|Drug|Kuntai Capsule|The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.
75340778|NCT05021094|Drug|Femoston|The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
75340779|NCT02114216|Procedure|endoscopic mucosal biopsy|endoscopic mucosal biopsy was undertaken for every participant.
75474506|NCT01984320|Procedure|ICSI|Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
75474507|NCT01984333|Behavioral|Online cognitive training|Online cognitive training is a web-based video game that offers systematic training of response inhibition capabilities. Participants will be guided to make progress in an individually-tailored fashion to master increasingly difficult game levels.
75935854|NCT03201926|Dietary Supplement|mealworms|10g , 3 times a day , po, 2 months
75935855|NCT03201926|Dietary Supplement|grain powder|grain powder, 10g ,3times one day,2months
75935856|NCT03626909|Other|Primary visit and assessment|"At the initial visit on entry into the program CHW will collect information and the application will guide initial treatment and referral recommendations. At this visit:~Collection of demographic information and relevant past medical history Medication history, adherence and side effects Glycemic testing, vital signs, and other anthropometric data. Screening for possible complications of diabetes Recommendations for referrals Medication recommendations and counseling"
75474508|NCT01984359|Other|Obtaining Human tissue|
75474509|NCT01984372|Drug|insulin degludec|Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
75474510|NCT01984411|Procedure|Radial Technical|Vascular Access for cardiac catheterization
75474511|NCT01984411|Procedure|Femoral Technical|Vascular Access for cardiac catheterization
75474512|NCT01984411|Drug|Omnipaque|
75650992|NCT05211908|Procedure|Composite resin restoration with Self Etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
75935857|NCT03626909|Other|Follow up visits|CHWs will meet with patients once per month to follow up on adherence and tolerance to medications, assess glycemic control, assess for complications of diabetes, refill medications (with dosing adjustments as needed for side effects, non-adherence or poor glycemic control), and provide diabetic education. These monthly visits will be facilitated by the smartphone application monthly protocol
75797881|NCT05441111|Behavioral|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
75797882|NCT05441111|Behavioral|Guided self-help|"Participants in the guided self-help condition are assigned an eCoach who provides emotional support as well as who promote adherence to the intervention"
75935858|NCT03626909|Other|3 month visits|At every 3rd monthly visit, starting with the visit 3 months after enrollment, A1c will be assessed. When A1c is checked, the month 3 medication titration algorithm, is used rather than the monthly titration algorithm, which uses blood glucose. Other than checking A1c and using the A1c-based algorithm as indicated, the procedures performed at the month 3 visit are identical to those of the monthly visit.
76088341|NCT03313908|Procedure|detection of the tumor lesion|non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
76088342|NCT02274688|Behavioral|Stepped Care Management|Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
76088343|NCT02470338|Procedure|MBP plus arthroscopy (Group A)|
76088344|NCT02470338|Procedure|MBP alone (Group B)|
76088345|NCT03313830|Dietary Supplement|Whey Protein Hydrolysate (WPH)|Subjects will ingest WPH on one occasion.
75340780|NCT02982746|Other|gPCC (Gothenburg Person Centred Care)|
75340781|NCT01364298|Drug|Gabapentin/B-complex|Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram [mg] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
75340782|NCT01364298|Drug|Pregabalin|Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
75340783|NCT04421742|Drug|Beclomethasone Dipropionate/Formoterol Fumarate|BDP/FF NEXThaler® 100/6 μg b.i.d.
75340784|NCT00441350|Drug|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
75340785|NCT00441350|Drug|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
75340786|NCT05072652|Other|Neuromuscular Electrical Stimulation|Participants in this group will perform twice daily neuromuscular electrical stimulation training sessions of the quadriceps muscles (specifically, the vastus lateralis and rectus femoris) or the immobilized left leg.
75340787|NCT05072652|Other|Action Observation + Mental Imagery|Participants in this group will perform daily action observation + mental imagery training via video and audio recordings.
75340788|NCT01488019|Drug|Perforomist-Placebo|Placebo vehicle, 2mL, twice daily for 52 weeks
75340789|NCT01488019|Drug|Perforomist, nebulization, COPD|Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
75474513|NCT01984450|Procedure|ACIC|"Autologous Collagen Induced Chondrogenesis (ACIC):~ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation."
75474514|NCT01984450|Procedure|MCIC|"Mesenchymal Cell Induced Chondrogenesis (MCIC):~MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation."
75474515|NCT01984450|Device|implant with a collagen + fibrin gel mixture|
75474516|NCT01984463|Drug|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
75340790|NCT05138796|Drug|TP-05 (lotilaner oral capsules)|TP-05 (lotilaner oral capsules)
75474517|NCT01984463|Drug|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
75340791|NCT05138796|Drug|Placebo|Placebo to match TP-05 (lotilaner oral capsules)
75340792|NCT04351321|Procedure|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
75474518|NCT01984489|Drug|Placebo|
75474519|NCT01984489|Drug|SHR117887|
75474520|NCT01984528|Biological|four differente concentrations of Alternaria alternata allergen extract, positive control and negative control|This concentrations will be tested in every patient in duplicate on the volar surface of the forearm.
75474521|NCT01984541|Biological|Artemisia vulgaris|Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
75474522|NCT01984567|Dietary Supplement|Vitamin E|Daily consumption of vitamin E capsules, 3 capsules of 268 mg daily, in total daily consumption of 804 mg
75474523|NCT01984567|Dietary Supplement|Lipoic acid|Daily consumption of lipoic acid capsules, 3 capsules of 200 mg daily, in total daily consumption of 600 mg
75474524|NCT01984567|Dietary Supplement|Control|Daily consumption of 3 placebo capsules
75935859|NCT03626909|Other|Unscheduled visits|The CHWs live in the same communities as the patients they will be serving. As such, the investigators recognize that patients may come to them with concerns outside of the structure of monthly visits as described above. The investigators have designed an additional module for the smartphone application that guides the CHWs through an assessment for hypoglycemia or severe hyperglycemia and possible complications of diabetes. If a patient or CHW has a concern outside of the scope of these protocols, the CHW will contact a CHW coordinator and/or the medical director for guidance
75935860|NCT03202082|Behavioral|Neuropsychological testing|Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.
75935861|NCT03201692|Device|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
75935862|NCT03201692|Device|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
75340793|NCT04351321|Procedure|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-Assisted Total Gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
75474525|NCT01984580|Drug|zinc gluconate|26.6 mg zinc BID (as zinc gluconate)
75474526|NCT01984593|Other|Yoga|"The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.~The two yoga exercises were:~Left nostril breathing - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and~Spinal flex - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes)."
75474527|NCT01984606|Drug|Empagliflozin|Empagliflozin once daily
75474528|NCT01984606|Drug|Placebo|Placebo matching empagliflozin
75474529|NCT01984606|Drug|Sitagliptin|Sitagliptin once daily
75797883|NCT05428904|Other|Virtual Reality Simulation|Virtual reality applications are a type of three-dimensional computer-based simulation that gives a sense of being anywhere and provides various data to the sense organs for this. However, virtual reality applications are a simulation model that creates a sense of reality for the participants and allows mutual communication with a computer-based dynamic environment.
75797884|NCT05413642|Drug|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
75797885|NCT05413642|Drug|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
75650993|NCT05211908|Procedure|Composite resin restoration with Seletive enamel etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
75797886|NCT05396599|Device|Model DIU|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
76088346|NCT03313830|Dietary Supplement|Intact Whey Protein (WHEY)|Subject will ingest WHEY on another occasion.
75797887|NCT05396599|Device|Model DFW|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
75797888|NCT05396599|Device|Model ZCT|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
75797889|NCT05378126|Other|Neurological assessment|"No specific procedure is planned for the study other than the neurological examination by a neurologist of all patients. The patient will be taken care according to current recommendations.~In addition, a study-specific, non-injected brain CT scan will be performed systematically in patients undergoing cardiac surgery to evaluate postoperative hemorrhagic transformation."
75340794|NCT05071248|Device|VEMO (Reactive Robotics GmbH)|The robot used for early mobilization is able to verticalize the patients in their bed without transfer and to generate a movement of the legs that measures and supports the patients' own movement. The device meets the requirements for mobilizing critically ill patients in an intensive care unit, maintaining hygiene standards and providing the best possible support for the patient's own movement.
75340795|NCT01797146|Procedure|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~Type and duration of urinary catheter use.~Indication of urinary catheter _________~Type and duration of central venous catheter use~Indication of urinary catheter _________~Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
75340796|NCT01488409|Drug|Acipimox|250 mg by mouth (PO) three times daily
75340797|NCT01488409|Drug|Placebo|0 mg by mouth (PO) three times daily
75340798|NCT01488877|Drug|PF-03882845|3 mg tablet once daily
75935863|NCT02450084|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
75935864|NCT02450084|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
75935865|NCT02450084|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
75935866|NCT02450084|Drug|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
75935867|NCT04467177|Other|30% glucose|Male neonates will receive 2 ml of 30% glucose two minutes prior to circumcision
75340799|NCT01488877|Drug|PF-03882845|up to 10 mg tablet once daily
75935868|NCT04467177|Other|Placebo|Male neonates will receive 2 ml of sterile water two minutes prior to circumcision
75935869|NCT03196622|Device|Handgrip test|Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
75340800|NCT01488877|Drug|PF-03882845|up to 30 mg once daily
76088347|NCT03313752|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
75340801|NCT01488877|Drug|Spironolactone|spironolactone 25 mg once daily
75340802|NCT01488877|Other|placebo|placebo once daily
75474530|NCT01984606|Drug|Placebo|Placebo matching sitagliptin
75474531|NCT01984619|Device|Cryotherapy for the utilization of wrinkle reduction (iovera)|
75474532|NCT01984632|Procedure|Single-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture (control group) in terms of operative time (esp. suturing time).
75474533|NCT01984632|Procedure|Multi-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture(control group) in terms of operative time (esp. suturing time).
75474534|NCT01984645|Other|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
76088348|NCT03313752|Other|Placebo|placebo
76088349|NCT02473068|Device|CPAP|
76088350|NCT02473146|Drug|Gemtuzumab ozogamicin (GO)|
75340803|NCT01364922|Drug|hydrocodone/acetaminophen extended release|
75340804|NCT01364922|Drug|Placebo|
76088351|NCT05747170|Other|Olfactory sstimulation|"The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be randomized according to a computer-generated sequence."
76088352|NCT03313674|Device|Bright Light Therapy|Light box that emits light at 10,000 lux or higher and has been demonstrated to regulate circadian rhythm that is aberrant in the SAD population
76088353|NCT05747092|Procedure|gingival graft|"investigators:~Donor site:~tissue graft harvesting from the palate behind the palatal rugae .~placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope"
76088354|NCT02470104|Dietary Supplement|Breastmilk|"A registered dietician will supervise milk provision.~If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
75650994|NCT05211908|Procedure|Composite resin restoration with Self Etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
75650995|NCT05211908|Procedure|Composite resin restoration with Seletive enamel etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
75650996|NCT00795379|Behavioral|Interoceptive Exposure|Exposure to internal stimuli.
75650997|NCT00996203|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for 24 weeks
75935870|NCT05706467|Device|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
75935871|NCT05706467|Device|Non-invasive continuous positive airway pressure ventilation|Non-invasive positive airway pressure ventilation is carried out through non-invasive ventilator.
75935872|NCT03201770|Drug|pyronaridine artesunate|Antimalarial treatment
75935873|NCT03529305|Device|rTMS|Receive rTMS treatment to the primary motor cortex (M1)
75935874|NCT03529305|Other|Physical therapy|Receive physical therapy
75935875|NCT02444468|Device|Flowtron ACS800|Flowtron ACS800 and bandage
75935876|NCT02444468|Other|Bandage|Bandage only
75935877|NCT03196700|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
75935878|NCT03196544|Behavioral|Social Approach Training (5 sessions)|5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
75340805|NCT01489579|Behavioral|Telephone Counseling for Tobacco Cessation|"The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)"
75340806|NCT01489579|Behavioral|Usual Care|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
75340807|NCT01489969|Drug|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
75650998|NCT00996203|Drug|DMARDs (disease-modifying antirheumatic drugs)|stable doses at investigator's prescription
75797890|NCT05367804|Dietary Supplement|Isolated pea protein|The subjects eligible to take part in this study will consume an isolated plant protein for 4 weeks (week 4 to 8), in each week the amount of protein supplementation will increase (0.25 to 1.0 g of protein per kg of body weight). The protein will be provided as a powder in opaque bags and participants will be instructed to dissolve the contained powder in liquids (as water) or on their food (e.g., yogurt, oat porridge). The baseline will consist of 4 visits (1 to 4) to see how stable are the baseline results.
75935879|NCT03196544|Behavioral|Social Approach Training (10 sessions)|10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
75935880|NCT04205799|Drug|Cabozantinib|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
75340808|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor|"Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10^8 cells will be given up to 3x10^11 anti-MART-1 F5 TCR engineered TIL or PBL."
75474535|NCT01984658|Biological|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
75650999|NCT04258748|Behavioral|Motivational Interviewing (MI)|In each of the four MI counseling sessions that were delivered, the researcher approached mothers in small groups of 5 via three phases, in 15-30 minutes, to establish rapport/ alliance in the first phase, to identify health needs in the second phase and finally to reinforce dental needs in the third phase.
75340809|NCT00509288|Drug|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
75340810|NCT00509288|Drug|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
75474536|NCT01984723|Drug|Experimental: EVP-6124|
75474537|NCT01984736|Drug|Experimental: EVP-6124|
75474538|NCT01984749|Drug|Febuxostat|"Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.~The starting dose of the investigational product (febuxostat) will be 10 mg/day.~The dose will be increased to 20 mg/day at Week 4.~The aim is to increase the dose to 40 mg/day at Week 8."
75651000|NCT04258748|Behavioral|Gaming and MI|In each of the four MI counseling sessions, the researcher approached mothers via three phases, in 15-30 minutes, to establish rapport/ alliance, to identify and finally reinforce dental needs in the same pattern as MI group. In addition, the children were engaged in 'Happy Teeth, Healthy Kids' which is an android tablet game that was included in the MI session scheduled for the mothers. Children were told to follow correct steps of brushing in order to obtain happy bright teeth. This helped the children realize that brushing teeth will give them a bright smile.
75474539|NCT01984775|Drug|GSK2894512 cream|GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% [5 milligram (mg)/gram (g)], 1% [10 mg/g], and 2% [20 mg/g]).
75474540|NCT01984775|Drug|Vehicle cream|Vehicle cream does not contain any active pharmaceutical ingredient.
75651001|NCT04258748|Behavioral|Conventional dental health education|It was delivered through a 15-minutes oral health session given to mothers of preschoolers. Mothers were given brief information about causes of dental caries and role of plaque, toothbrush size, diet / frequency of sweet snacks, brushing technique, toothpaste and fluoride use as well as regular dental visits. Participants were then shown a short educational video about prevention of dental caries among children coupled with oral hygiene instructions. At the end of the session, participants were given a leaflet reinforcing the information to take home.
75651002|NCT00675519|Behavioral|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
75797891|NCT05354414|Device|Virtual reality|Administered as specified in the treatment arm.
75797892|NCT05354414|Procedure|Standard of Care|Administered as specified in the treatment arm.
75935881|NCT03201614|Device|A-CP HA Kit|Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2
75935882|NCT03201614|Device|ArthroVisc 40|Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2
75797893|NCT05353218|Procedure|Intermediate cervical plexus block|Intermediate cervical plexus block will be applied in transverse plane using posterior approach at C4.
75935883|NCT03201614|Drug|Placebo|Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
75935884|NCT04188405|Drug|Decitabine|Given IV
75474541|NCT01984775|Drug|Positive control|Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).
75474542|NCT01984775|Drug|Negative control|Negative control contains petrolatum.
75474543|NCT01984801|Drug|0.3% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
75474544|NCT01984801|Drug|1% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
75797894|NCT05353218|Procedure|Deep cervical plexus block|Deep cervical plexus block will be appliedin transverse plane using anterior approach at C2-3-4.
75935885|NCT04188405|Drug|Ponatinib|Given PO
75935886|NCT04188405|Drug|Venetoclax|Given PO
75935887|NCT03201536|Device|conventional Suture|Sutures
75935888|NCT03201536|Device|Zip3|wound closure device
76088355|NCT03313596|Drug|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
76088356|NCT03313596|Procedure|LT|Orthotopic LT and subsequent immunosuppression therapy
76088357|NCT05746936|Procedure|Roux en-Y gastric bypass|gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
75340811|NCT00509288|Biological|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e^11 (with a minimum of 5x10e^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
75651003|NCT00789763|Drug|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
75651004|NCT00789763|Radiation|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
75651005|NCT00789763|Drug|Sorafenib|200-800 mg/day p.o. during 5 weeks
75797895|NCT05345925|Device|Moderato|Several algorithms comprising CNT will be delivered by the Moderato Implantable Pulse Generator. Each application will last approximately 3 min with 2 minutes baseline (regular pacing) between them. Hence, each subject will serve as its own control (during pacing) and test (during CNT application). Furthermore, the average control value for the whole group will be compared with the average test values of CNT algorithms at the different ventricular lead locations for efficacy assessments. Stratification of subjects by initial hemodynamic parameters (such as Ejection Fraction, for example) would be possible depending on the total number of subjects in each group.
75797896|NCT05344950|Behavioral|Audio + Radio (AURA)|Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from interacting with our voice assistant device, connected to a system that integrating the PRO (e.g., fatigue) and objective data from passive RF sensing to provide continuous monitoring of patients' symptoms and complications after they are discharged home. AURA will triage patient care based on the monitoring data that indicate the severity of their symptoms and complications. Patients and caregivers will self-monitor and manage at home for mild and moderate symptoms but be referred to professionals (e.g., wound and stoma nurse) when the patient experiences severe symptoms or significantly worsened symptoms.
75935889|NCT03856190|Other|Fasting and plant-based nutrition|The experimental intervention is divided into an initial part with periodic fasting for 7-10 days on an outpatient basis, which is followed by a build-up phase. This group part then receives a diet change with a specific normocaloric nutrition including the concept of time restricted eating (TRE, 16/8h) and according to the following criteria: 1) plant-based, 2) rich in prebiotics, 3) enriched with kitchen spices and kitchen herbs known for their anti-mycotic and anti-inflammatory potential.
75935890|NCT03856190|Other|Standard Nutrition Counselling|The control group receives a diet considered to be fundamentally beneficial to health in the sense of the recommendations of the German Association for Nutrition (DGE), which contain a reduced intake of arachidonic acid and, as a result, modulate an anti-inflammatory effect.
75935891|NCT04176393|Drug|ivosidenib|subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
76088358|NCT05746858|Other|no intervention (observational study)|No intervention (observational study)
76088359|NCT05454124|Behavioral|Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
76088360|NCT05454124|Behavioral|Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision, this condition combines elements of training visual sensitivity, spatial integration, and spatial attention.
76088361|NCT03313518|Device|tDCS|15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.
76088362|NCT03313518|Device|Sham tDCS|15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
75474545|NCT01984801|Drug|0.3%/1% vehicle gel only|200 mg of the gel will be applied to individual patches by using a spatula
75474546|NCT01984801|Other|Sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
75340812|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
75474547|NCT01984801|Other|0.5% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
75474548|NCT01984801|Other|0.1% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
75474549|NCT01984801|Other|Patch only|Only patch will be applied
75474550|NCT01984814|Biological|Stem cell|Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
75651006|NCT05211752|Other|eVOG (Mobile VideoOculoGraphy)|"Eyes movements assessed with e-VOG (mobile application, that uses the face detection features of the front camera to detect and record eye movements).~Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
75651007|NCT00675675|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.
75651008|NCT00675675|Behavioral|Minimal Contact Waitlist|Bimonthly phone check-in to assess clinical status and enhance subject retention
75651009|NCT00793117|Procedure|packing|packing in middle meatus for duration of 5 day
75651010|NCT00609050|Behavioral|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
75651011|NCT00609050|Behavioral|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
75340813|NCT01490359|Behavioral|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
75651012|NCT00609050|Behavioral|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
75651013|NCT02873741|Procedure|Perianal and Digital Anorectal Exam|The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.
75651014|NCT02873741|Procedure|Cervical Swabs|A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.
75651015|NCT02873741|Procedure|Anal Swabs|The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.
75935892|NCT03525093|Behavioral|Hypnosis|"5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress."
75340814|NCT01490359|Behavioral|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
75935893|NCT03525093|Behavioral|Health education|Participants receive a health education booklet on improving coping with stress.
75340815|NCT00442364|Drug|Polidocanol (1%) Microfoam (Varisolve)|Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
75935894|NCT03193658|Procedure|Thoracolumbar Interfascial Plane (TLIP) block|"A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.~The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally."
75935895|NCT03193658|Drug|I.V drug based multimodal approach|A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
75935896|NCT03119246|Other|CAPIT-HD beta|New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
75935897|NCT03525015|Other|A decision aid booklet about cataract surgery choice|Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
75340816|NCT00442364|Procedure|Endovenous Microfoam Occlusion|Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
75340817|NCT01492309|Device|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
75340818|NCT01492309|Device|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
75340819|NCT00444080|Procedure|Trabeculectomy|"Standard trabeculectomy procedure~Creation of a fornix or limbal based conjunctival flap in upper quadrants~Creation of a limbal-based scleral flap extending into clear cornea~Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~Creation of fistula 1mm x 2mm in size~Iridectomy~Suturing the scleral flap~Repositioning of conjunctiva with sutures After procedure, antibiotics & steroids are administered topically; eye is covered with a pad - patient is discharged."
75340820|NCT00444080|Device|Ex-PRESS mini shunt|"Ex-PRESS implantation procedure:~Creation of a fornix or limbal based conjunctival flap in upper quadrants~Creation of limbal-based scleral flap extending into clear cornea~Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus~Prior to implantation, a thorough mobility check should be performed~Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision~Withdrawal of introducer~Tucking plate under the scleral flap, and verification of its position~Suturing scleral flap After implantation procedure, antibiotics & steroids administered topically; eye is covered with a pad - patient is discharged."
75935898|NCT03525015|Other|An usual booklet about cataract and cataract surgery|Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
75935899|NCT02449070|Drug|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
75340821|NCT01493167|Other|limb casting/splinting|ankle and arm cast
75340822|NCT05136300|Behavioral|Pulmonary rehabilitation|"Patients in the intervention group will receive physical therapy, scheduled pain monitoring and coaching by a social worker.~The intensity of the rehabilitation training program will be determined separately for each patient by a steepramp and 1-repetition test within 3 weeks post-operative. The intervention group will be trained and educated in 2 sessions of 2 hours per week, for a period of 3 months."
75340823|NCT00510224|Drug|Sandostatin|Sandostatin 30mg intramuscular every 28 days
75340824|NCT00511706|Drug|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
75340825|NCT00511706|Biological|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
75340826|NCT00511706|Other|sham|Sham needle-less injection administered in the study eye at Day 1.
75651016|NCT02873741|Procedure|High Resolution Anoscopy (HRA)|High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
75651017|NCT04258670|Other|No intervention|Patients in these cohorts will not be given anti-filariasis therapies because these drugs are not approved for use in patients with high worm burdens (>20,000 Mf/mL)
75651018|NCT02554357|Drug|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
75651019|NCT02554357|Drug|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
75935900|NCT03529149|Combination Product|Urapidil Hydrochloride Injection|"Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV>37cm/s of （middle cerebral artery)MCA, PI < 1.34cm/s, aMFV>40cm/s of (basilar artery)BA, PI < 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure."
75651020|NCT00877929|Drug|Telmisartan 80|Telmisartan 80 mg
75651021|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
75935901|NCT03618056|Biological|AIDSVAX® B/E|Administered by intramuscular injection
75935902|NCT03526809|Diagnostic Test|MRI scan and FDG-PET scan|Scanning with MRI and FDG-PET
75935903|NCT04101045|Diagnostic Test|Oral Glucose Tolerance Test|Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
75340827|NCT05015244|Procedure|3T (Tesla) Magnetic Resonance Imaging (MRI)|Neurological evaluation using MRI and neuropsychological tests
75340828|NCT00511862|Device|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
75340829|NCT05067894|Biological|SARS-CoV-2 Protein Subunit Recombinant Vaccine|intramuscular injection
75340830|NCT05067894|Biological|SARS-CoV-2 Inactivated Vaccine|intramuscular injection
75651022|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
75651023|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
75651024|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
75651025|NCT00931268|Device|Macrolane VRF 30|One administration
75651026|NCT00793195|Drug|Intralipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
75651027|NCT00793195|Drug|SMOFlipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
75797897|NCT05328648|Behavioral|Community Score Card|In Community Score Card intervention, all communities associated with the targeted facilities will assess the primary barriers to quality family planning service delivery and develop indicators. The communities will then each complete the score card and generate ideas for quality improvement. Family planning providers in the target facilities will meet and determine the barriers to high quality family planning service delivery. Providers will decide on priority areas and make suggestions for improving service delivery. Study facilitators will bring these two groups together to share their respective score cards and jointly develop an action. Within the action plan, agreed upon responsibilities will be assigned and a timeline will be communicated.
75935904|NCT02449382|Procedure|continuous venovenous hemofiltration|If the serum sodium concentration >150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment
75935905|NCT02449382|Drug|Control group|If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
75935906|NCT03193268|Other|Single-blind RTC of PD patients|The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
75935907|NCT03193268|Other|cycling|Patients must undergo a daily exercise cycle of 1 hour during the intervention
76088363|NCT04491630|Behavioral|Self-Hypnosis (SH)|"Participants assigned to this condition will listen to a 20-minute recording with instructions of SH adapted from one of our team member's proposed model. First, the audio recording will introduce and orient the participant to SH. Then instruction in SH will be provided, including: (a) how to self-induce a hypnotic induction; (b) specific self-suggestions for comfort and ability to manage intense sensations; and (c) post-hypnotic suggestions that the participant will be easily able to use these hypnotic strategies on their own at a later time (i.e., in this case, during the Cold Pressor Arm Wrap procedures that will follow).~A second 5-minute audio recording with instructions to guide the participant in SH will be provided during the second cycle of Cold Pressor Arm Wrap (CPAW)."
76088364|NCT04491630|Behavioral|Mindfulness Meditation (MM)|"Participants in the MM condition will listen to a 20-minutes recording with instructions in the use and application of Vipassana MM, adapted from the manual developed by one of our team members. First, the audio recording will focus on introducing the idea of attention to their breath, and of non-judgmental monitoring and acceptance of the all events and stimuli. Then a guided MM (body scan) experience will be provided.~A second 5-minute audio recording with instructions to facilitate the MM (body scan) experience taught in the first audio recording will be provided during the second cycle of CPAW."
76088365|NCT04491630|Behavioral|Christian Prayer (CP)|"Participants in this condition will listen to a 20-minute recording with CP instructions. These instructions will be adapted from the existing on-line biblical meditations from the Society of Jesus (www.passo-a-rezar.net). First, the recording will introduce and orient the participant to CP. Then, a text of the Bible will be read twice, followed by a brief suggestion of prayer.~A second 5-minute audio recording with instructions to facilitate the CP experience taught in the first audio recording, including the recording of a text of the Bible followed by a brief suggestion of meditation and relaxing music, will be provided during the second cycle of CPAW."
75340831|NCT05621798|Other|Hearing Aid Manufacturer's Software|"When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software."
75474551|NCT01984827|Drug|Moxifloxacin|"a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~a single oral dose of 400mg Moxifloxacin plus C-peptide~a single oral dose of 400mg Moxifloxacin~placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m."
75474552|NCT01984827|Other|hyper-glycaemic clamp|a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
75474553|NCT01984840|Device|Telemedicine|
75474554|NCT01984853|Other|OBSERVATIONAL REGISTRY|
75935908|NCT03196388|Drug|Enzalutamide|"Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is >95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy"
76088366|NCT02989012|Drug|GanMaoKangNing Granules|3 times a day, 2 bags each time.
75340832|NCT05621798|Other|REM (Real Ear Measurements)|Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.
75340833|NCT01493947|Drug|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
75340834|NCT01493947|Drug|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
75797898|NCT05328648|Behavioral|Citizen Report Card|Citizen Report Card (CRC): The data from the CRC questionnaire will be analyzed and translated into a report card. Extensive dissemination activities will ensure the CRC is widely shared with members of the community. The goal is to create a public record of service quality.
75340835|NCT05621720|Other|Case management|On enrolment, the nurse case manager will perform the initial comprehensive assessment based on the Omaha domains of environment, psychosocial, physiological and health-related behavior. The nurse case manager will execute the intervention scheme of teaching, guidance & counseling, treatments & procedure, case management, and/or surveillance, with the mutual goal set with clients to promote health and self-efficacy. Home visits and telephone calls will be employed. The referral network to health and social service will be activated as appropriate.
75340836|NCT05621720|Other|Social control call and usual are|Subjects in the control group will receive usual community service. in addition, a monthly social control call from trained community workers will be given to rule out the possible social effects of the intervention. These social calls will not be related the participants' health condition nor delivery of any health information.
75340837|NCT05013372|Drug|CD147- CAR T cells|CAR T cells targeting CD147
75340838|NCT00445484|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
75340839|NCT00445484|Drug|lenalidomide|Given orally
75797899|NCT05325593|Drug|romiplostim plus dexamethasone|Patients will be reviewed weekly for 8 weeks (56 days). After Week 8, patients will be reviewed every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
75797900|NCT05325593|Drug|Dexamethasone|Patients will be reviewed weekly until the completion of dexamethasone cycles and for a minimum of 8 weeks (56 days). After that, every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
75797901|NCT05325372|Procedure|axillary block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
75936619|NCT03184220|Procedure|Physiotherapy treatment|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
75340840|NCT01495585|Drug|Lonafarnib|Commercially approved products used to test the research hypothesis
75474555|NCT01984918|Other|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
75474556|NCT01984918|Other|Non-SMS reminder|No Stext message reminder via Short Message Service (SMS) will be sent
76088367|NCT02989012|Drug|Analogous Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
76088368|NCT02989012|Drug|Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
76088369|NCT02989012|Drug|Analogous GanMaoKangNing Granules|3 times a day, 2 bags each time.
76088370|NCT03313440|Other|High wheat fiber|Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
75340841|NCT01495585|Other|Placebo|Placebo control
75474557|NCT01984931|Drug|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
75797902|NCT05325372|Procedure|infraclavicular block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
75797903|NCT05322967|Other|Time of ordinary antihypertensive medication intake|Time of ordinary antihypertensive medication intake
75797904|NCT05321121|Drug|Dexmedetomidine|Dexmedotomidine for Acute Pain Control in Patients with Multiple Rib Fractures
75797905|NCT05321121|Other|Placebo|The control arm will receive an infusion of normal saline
75797906|NCT05302141|Behavioral|Wear 3D printing assistive device|"Wear 3D printing aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
75797907|NCT05302141|Behavioral|Wear universal cuff device|"Wear universal cuff aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
75797908|NCT05281614|Drug|Etanercept|Etanercept is a fully humanized monoclonal antibody that targets TNFα.
75797909|NCT05281614|Drug|Vedolizumab|Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.
75797910|NCT05264636|Other|Sucrose|Sucrose Beverage
75797911|NCT05264636|Other|Steviol Glycosides|Steviol Glycoside Beverage
76088371|NCT03313440|Other|Low fiber|Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
76088372|NCT02276638|Device|Specular Microscope Nidek CEM-530|Nidek CEM-530
76088373|NCT02276638|Device|Specular Microscope Konan CELLCHEK XL|Konan CELLCHEK XL
75651028|NCT00996125|Biological|CervarixTM|Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
75651029|NCT00996125|Other|Control|Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
75651030|NCT00793273|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
75651031|NCT04301141|Other|Virtual Reality Assisted Cognitive Behavioural Therapy|The intervention will be delivered in NHS services and will involve using VR to assist the delivery of conventional CBT for the treatment of social anxiety in autistic adolescents. Social situations that are commonly anxiety-evoking for this patient group will be simulated in VR and used for exposure (a typical component of CBT for social anxiety). Therapists will use a modular approach involving optional modules such as psychoeducation on anxiety in the context of ASD, managing expectations of outcome and emotional literacy training. Essential modules include rapport building, introducing the use and purpose of VR, and exposure (incorporating VR). Because CBT is delivered in routine clinical practice, the VR exposure sessions will be the main subject of interest.
75651032|NCT04045951|Other|Myopia prediction algorithm|Candidate predictors included age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
76088374|NCT03313362|Device|SPEAC System|Seizure Monitoring and Alerting System
76088375|NCT03313362|Device|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
75651033|NCT05330624|Biological|plague vaccine(F1+rV)|plague vaccine(F1+rV) (Lanzhou Institute of Biological Products Co.,Ltd) of 1.0ml, three doses
75797912|NCT05256680|Other|Gardening Activities|"In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.~No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home."
75935909|NCT05056545|Behavioral|C4 Intervention|"C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.~The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW."
75797913|NCT05251805|Procedure|Blood, bone marrow and lung tumor tissue collection|"Blood sampling: 12ml of blood will be collected during the routine pre-operative blood collection~Bone marrow aspiration during thoracic surgery: following the surgical intervention, bone marrow aspiration will be performed through the incisions made for the thoracic procedure. The ribs lying directly above and below the trocar incision will be exposed. A bone marrow needle will be advanced into the periost until the needle tip reaches the bone marrow. After removing the stylet a 2ml syringe will be attached to the aspiration needle and 0.5ml to 2ml of bone marrow will be aspirated before removing the needle. This procedure will be repeated twice for every trocar site, for a maximum of 3 trocar sites, or until 5ml of bone marrow aspirate is obtained.~Lung tumor collection: all surgical samples will be analyzed by our anatomopathological department. Viable and fresh material, not used for the diagnostic purposes, will be sent to the LMCT."
75340842|NCT04421976|Procedure|PEEP|"Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
75474558|NCT01984931|Drug|Metoclopramide hydrochloride monohydrate|
75340843|NCT00446264|Procedure|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
75797914|NCT05238194|Other|The Psychological Effects of The Covid-19 Pandemic Process|Investigation of The Psychological Effects of The Covid-19 Pandemic Process on The Health Staff Workıng in The Filation Team
75797915|NCT05233774|Drug|Allogeneic MSC|An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation
75797916|NCT05233774|Other|Placebo|Placebo
75797917|NCT05228288|Procedure|Conventional direct laryngoscopy (CDL)|This procedure is considered the gold standard for endotracheal intubation and is routinely used in the peri-operative setting as well as in intensive care and emergency medicine.
75797918|NCT05228288|Procedure|Video assisted laryngoscopy with Macintosh-shaped blade (M-VAL)|This device is implemented in most german hospitals and used when conventional direct laryngoscopy is not sufficient. By positioning the camera at the tip of the blade, the achievable field of view onto the glottic plane is improved.
75935910|NCT03526731|Other|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
75935911|NCT03193502|Drug|rivaroxaban|rivaroxaban
75935912|NCT03526965|Other|Yoga Chikitsa|Intervention consisted of combination of static movements, yoga style exercise, yoga postures, breathing practices, relaxation and yoga counselling.
75935913|NCT03526965|Drug|Usual care|Intervention included pain medications and exercise movements for neck.
76088376|NCT03108534|Drug|CHF1535 NEXThaler|Rescue treatment
76088377|NCT03108534|Drug|CHF1535 pMDI|Rescue treatment
76088378|NCT03108534|Drug|Placebo|Rescue treatment
75340844|NCT00446264|Drug|daclizumab - sirolimus - tacrolimus|Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
75651034|NCT00793351|Procedure|Reduced-intensity allogeneic hematopoietic stem cell transplantation|"Treatment Scheme~Enrollment - Pre-RIST treatment - RIST~4 cycles of conventional chemotherapy will be given prior to RIST.~Surgery will be done whenever possible prior to RIST.~Local radiotherapy will be applied whenever possible prior to RIST.~topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.~Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT."
76088379|NCT05746780|Procedure|Elective bilateral neck dissection in cN0 patients|Radical modified type 3 selective bilaterale elective neck dissection
75340845|NCT01495819|Drug|Saline|5cc's of saline give at least once.
75651035|NCT02628639|Device|high-density electroencephalography|
75651036|NCT00610064|Radiation|Baseline neuroimaging|Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
75651037|NCT00610064|Radiation|Neuroimaging during sacral neuromodulation|Neuroimaging during sacral neuromodulation using PET
75651038|NCT04292951|Procedure|Fluid and inotropic/vasoactive management protocol|GDT protocol: keep SVV 10-13% and give fluid when SVV > 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP < 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate
75797919|NCT05228288|Procedure|Video assisted laryngoscopy with hyper-angulated blade (H-VAL)|The hyper-angulated blades are often used as a backup instrument when a view of the glottic plane cannot be achieved with the Macintosh blade due to anatomic abnormalities, even with a video-assisted laryngoscope.
75797920|NCT05216861|Other|Demand and ability protocol|"The intervention consists of a structured conversation between the patient and his immediate manager under the guidance of licensed medical staff (in this case REKO) with knowledge of the requirements of the patient's work and his/her current functional ability. The intervention takes about 90 minutes excluding preparation time for REKO.~DAP consider the following domains; 1) mental and cognitive ability, 2) basic skills and social ability, 3) tolerance for physical conditions, 4) ability to work dynamically, 5) ability to work statically and 6) to be able to work certain times.~Based on the above domains, a structured review is made of the balance between requirements and function in current work in order to identify possible adaptations and measures at the workplace. During the intervention, the work requirements and the patient's function/ability are identified on a three-point scale and in domains where there is thus an imbalance adjustments or changed tasks are identified."
75797921|NCT05216861|Other|Collaborative interventions as usual|The rehabilitation coordinator conduct collaborative interventions as usual with patient and employer. This might be through phone calls are unstructured meetings.
75797922|NCT05215574|Drug|NGM831|Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
75935914|NCT03193580|Device|Anodal Conventional tDCS|tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
75935915|NCT03193580|Device|Anodal High Definition tDCS|HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
75651039|NCT00795613|Drug|ESCALATED BEACOPP|Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
75651040|NCT00795613|Drug|CONVENTIONAL ABVD|ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
75935916|NCT03193580|Device|Sham tDCS|tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
75797923|NCT05215574|Drug|NGM831 plus pembrolizumab|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
75935917|NCT05616429|Dietary Supplement|Alcat based personal diet|Alcat based personalized diet with dietician supervision and follow-up + usual care
75935918|NCT05616429|Dietary Supplement|Standard balanced diet|"Sham standard balanced diet with dietician supervision and follow up + usual care."
75935919|NCT05616429|Other|usual care|usual care
76088380|NCT02472834|Dietary Supplement|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing ~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
76088381|NCT03832894|Drug|Estradiol Valerate|Oestradiol supplementation starting from day of trigger through out the luteal phase
75340846|NCT01495819|Drug|Nicotine|(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
75340847|NCT04214886|Drug|Fludarabine|Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
75340848|NCT04214886|Drug|Cyclophosphamide|Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
75340849|NCT04214886|Biological|CD19-CD34 CAR transduced T cells|CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
75340850|NCT05621642|Other|Breathing exercises|In the sitting position, the patient does 15 diaphragm breathing and 15 huffing exercises.
76088382|NCT02472990|Other|No drug and no placebo were used in this study|measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
76088383|NCT02989324|Drug|MisoprostoL|Vaginal MisoprostoL
76088384|NCT02989324|Device|Foley Catheter|Misoprostol Plus Foley Catheter
75340851|NCT05621642|Other|Core stabilization exercises|This intervention includes bridging exercise and abdominal exercises.
75340852|NCT05621642|Other|Balance and strengthening exercises|It includes sitting and standing on the chair 15 times and turning around the chair.
75797924|NCT05215574|Drug|NGM831|Drug: NGM831 Preliminary recommended phase 2 dose (RP2D) of NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle.
75651041|NCT00675753|Genetic|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
75935920|NCT04013217|Combination Product|Eribulin ORA|Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
75935921|NCT03193034|Device|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
75935922|NCT05603949|Device|3D deep learning neural network system|With the consent of the patient, we will assist in the production of images of 3D defect blocks for free (3D deep learning neural network system (3D DNN) system process planning), complete the repair and reconstruction under the clinical routine surgery, and track the repair results after surgery. meet medical needs.
75935923|NCT02711306|Dietary Supplement|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
76088385|NCT02472678|Other|Web-based tailored information and support system|Access to the web-based tailored information and support system (with a username/password)
75935924|NCT02711306|Dietary Supplement|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
75935925|NCT03528993|Other|exercise by hippotherapy device|Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
75935926|NCT03528993|Other|conventional rehabilitation|Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
75935927|NCT03528993|Other|postural control exercises|perturbation on four directions, weight bearing exercises on standing positions
75935928|NCT03193112|Drug|Agomelatine 25 MG Oral Tablet|We will treat our patients with Agomelatine tablet of 25 mg.
75935929|NCT03196154|Diagnostic Test|Fasting insulin level|Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
75340853|NCT00512876|Drug|Bevacizumab (Avastin)|Bevacizumab 10mg/mL 1 drop BID x 3 weeks
75340854|NCT00513344|Dietary Supplement|Dark Chocolate|1 portion
75340855|NCT00513344|Dietary Supplement|Milk Chocolate|1 portion
75935930|NCT03196154|Diagnostic Test|Plasma drug level|Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
76088386|NCT02472678|Other|Standard care|The control group will receive standard care.
76088387|NCT00550732|Drug|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
75340856|NCT00513344|Dietary Supplement|"Control (polyphenol-free) Chocolate"|one portion
75340857|NCT00514592|Other|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
75340858|NCT04422054|Procedure|Open Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent open surgical repair.
75340859|NCT04422054|Procedure|Endovascular Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent endovascular repair.
75340860|NCT05127876|Drug|Ondansetron 4 MG|Ondansetron 4mg was given over 1 min, 5 min before spinal anesthesia
75340861|NCT05127876|Drug|Ondansetron 8mg|Ondansetron 8mg was given over 1 min, 5 min before spinal anesthesia
75474559|NCT01984944|Other|Autistic functional exploration|"50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~25 childs with urinary sample, Circadian rhythms assessed with actometer"
75651042|NCT04293263|Combination Product|2gether app used by trained personal|"each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.~Musical partner - A person trained in the program's work plan, which includes contact with empathic listening and the use of a dedicated application developed for it. A musical partner will meet with the same elderly person throughout the study period.~Empathetic listening - a situation in which a person listens to music with another person, while the music enables contact and deepening the connection between people."
75651043|NCT00675831|Device|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
75651044|NCT04263428|Behavioral|Irregular sleep|Experimental-induced sleep variability
75936620|NCT02424110|Procedure|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
76088388|NCT03311100|Other|immunohistochemistry assay|biomarkers expression
76088389|NCT03311022|Drug|Nefopam Hydrochloride 30mg Tablets|
76088390|NCT03311022|Drug|Acupan® 30mg Tablets|
76088391|NCT03310866|Device|fiberoptic, airway|classic fiberoptic bronchoscope, fenstrated airway
76088392|NCT03310866|Device|fiberoptic, Machintosh|oral fiberoptic brochoscopic, Machintosh laryngoscope
76088393|NCT02469480|Drug|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
76088394|NCT02469480|Drug|Ferro sanol|200 mg ferro sanol per day over 12 weeks
76088395|NCT03313284|Procedure|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
75797925|NCT05214898|Behavioral|24/7 Dad|"The 24/7 Dad curriculum is an evidence-based, skills driven curriculum (12 group sessions). The following topics are included: Family History, What it Means to Be a Man, Showing and Handling Feelings, Men's Health, Communication, The Father's Role, Discipline, Children's Growth, Getting Involved, Working with & Co-Parenting, Dads and Work, and the My 24/7Dad Checklist. Healthy Relationship topics include: Communication Skills, including expression, discussion, and negotiation skills; Conflict Resolution and Anger Management; Problem-Solving; and Knowledge of the Benefits of Marriage. Responsible Parenting areas of focus include: children's growth/development; non-violent discipline; co-parenting; building conflict resolutions skills (for the child and the family); and, enhancing family relationships."
75797926|NCT05211492|Other|Questionnaire|Patients are asked to fill in an online questionnaire concerning their postoperative pain.
75797927|NCT05193955|Other|Laughter Yoga|Laughter yoga is one of the methods that is among the complementary therapy and supportive care practices in the world and is used increasingly. Laughter yoga is a non-invasive and non-pharmacological method that combines unconditional laughter with yoga breathing techniques. In laughter yoga, one can laugh without being humorous, joking, or funny. Laughter is simulated by starting out as a physical exercise and making eye contact with other members of the group and playing games with them. The body cannot distinguish between real and unreal laughter and laughter begins.
75340862|NCT05127876|Drug|EPHEDrine 10 Mg/mL-NaCl 0.9% Intravenous Solution|Ephedrine 10mg was given over 1 min, 5 min before spinal anesthesia
75340863|NCT05127876|Other|10 mL normal saline|10 mL normal salinwe 0.9% was given over 1 min, 5 min before spinal anesthesia
75340864|NCT02522286|Behavioral|Ask 3 Questions|"Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare."
75797928|NCT05185323|Other|Breastfeeding usual known aids and osteopathic treatment|Breastfeeding usual known aids and osteopathic treatment
75340865|NCT02522286|Behavioral|Open Communication|"Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow."
75474560|NCT01984944|Other|Control functional exploration|"50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~25 childs with urinary sample, Circadian rhythms assessed with actometer"
75935931|NCT03996525|Device|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
75935932|NCT03996525|Device|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
75935933|NCT03994497|Other|Blood samples|Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
76088396|NCT03313284|Procedure|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
76088397|NCT03313284|Procedure|Control|No intervention
76088398|NCT02469402|Dietary Supplement|Standard infant formula|
76088399|NCT02469402|Dietary Supplement|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
76088400|NCT02274844|Behavioral|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
76088401|NCT05736094|Device|SURF|Dual-frequency ultrasound
76088402|NCT03656016|Device|Magnetic Resonance Imaging|Phase contrast magnetic resonance imaging technique
75340866|NCT01496131|Radiation|Radiation therapy|Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
75340867|NCT01496131|Drug|Goserelin|ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
75474561|NCT01984957|Procedure|Muscle biopsy|open muscular biopsy of the deltoid under local anaesthesia
75474562|NCT01984970|Device|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
75474563|NCT01984983|Biological|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate|
75474564|NCT01984983|Other|0.9% saline placebo|
75474565|NCT01984996|Device|Freedom ProFlor Inguinal Hernia Implant|
75797929|NCT05185323|Other|Breastfeeding usual known aids|Breastfeeding usual known aids
75797930|NCT05181345|Other|Sleep recording (at home)|Before both heat exposures, the sleep-wake rhythm will be measured at home for 7 days using actigraphy and a sleep diary that will have been given to him/her during the inclusion visit.
75935934|NCT03193424|Drug|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
75474566|NCT01985009|Device|FibroScan® examination.|The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
75651045|NCT00800761|Drug|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
75651046|NCT00800761|Drug|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
75935935|NCT03526653|Other|exercise without visual stimuli|exercise on an ergometer or motomed in an environment without other visual stimuli
76088403|NCT03304938|Drug|Lavender Oil|The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
76088404|NCT03304938|Drug|Placebos|The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
75474567|NCT01985022|Behavioral|Group-ESI|The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.
75474568|NCT01985022|Behavioral|Individual-ESI|The Individual-ESI intervention consists of twice-weekly home-based individualized coaching sessions. Parents learn how to support their child's communication, social, and play skills in everyday routines, activities, and places. Individual-ESI begins with an initial home visit, followed by a month of program planning, 6 months of intervention implementation, and 2 months of generalization. During generalization, the clinician meets with the family in a variety of community settings to teach the parent how to implement strategies in new settings.
76088405|NCT03310554|Procedure|26cm suspended overlength biliary stents|The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP
76088406|NCT03310554|Procedure|30cm suspended overlength biliary stents|The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
75474569|NCT01985035|Behavioral|Diet|Reduction of energy intake in order to weight loss
75474570|NCT01985061|Drug|BX2|
75474571|NCT01985061|Drug|BX3|
75651047|NCT04220645|Other|Opportunstic treatment|opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
75651048|NCT04220645|Other|Standard of care|Referral at discharge
75651049|NCT00676221|Drug|Myfortic|"Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.~Cellcept 1000mg bid = Myfortic 720mg bid"
76088407|NCT03310554|Procedure|ordinary plastic biliary stents|The control group will be placed ordinary plastic biliary stents in bile duct in ERCP
75651050|NCT05206136|Device|Ultrasonography|Neck and Low back muscles will be evaluated by ultrasound.
75651051|NCT00800917|Drug|Temsirolimus|25 mg weekly IV
75651052|NCT00800917|Drug|Bevacizumab|10 mg/kg every 2 weeks
75651053|NCT04276337|Diagnostic Test|LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)|LiquidSCAN : detection of circulating DNA CancerSCAN : detection of somatic mutation using tumor tissue
75797931|NCT05181345|Other|Heat exposure|"The subjects will be exposed twice (2 different visits) to heat (45°C; 60-70% humidity rate) for 3 hours in a climate chamber.~The subjects will be equipped with various external sensors allowing the continuous recording of core temperature, mean skin temperature (9 skin measurement points), heart rate, cerebral electrical activity, cerebral oxygenation, skin vascular conductance (blood flow by laser-doppler), blood pressure and skin conductance.~Neurophysiological and cognitive exploration (NPCE) includes the Stroop test, the Psychomotor Vigilance Task (PVT) and the odd-ball test."
75797932|NCT05181345|Other|Normal sleep|"The night before one of the two heat exposures (first visit for the Normal sleep first group and second visit for the Reduced sleep first group), the participants will have a normal night at home. The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
75935936|NCT03526653|Other|excercise with National Geografics|exercise on an ergometer or motomed while watching the National Geografics channel on television
75935937|NCT03526653|Other|Exercise with MemoRide|excercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
75935938|NCT03193346|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
75935939|NCT03193346|Drug|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® [Sodium chloride 0.9 mg] IM injections in head/neck areas.
75651054|NCT00676299|Drug|JNJ-26483327|
75651055|NCT05003102|Drug|Dexmedetomidine Hydrochloride - Cycling|Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.
75651056|NCT05003102|Drug|Fentanyl - PICU Standard|fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
75651057|NCT05003102|Drug|Dexmedetomidine Hydrochloride - PICU Standard|Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr
75651058|NCT00676377|Drug|Neostigmine|2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
75935940|NCT03118622|Device|Pentax|Intubation using Pentax video laryngoscope in Pentax group
76088408|NCT03310476|Other|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
76088409|NCT03310398|Behavioral|NeuroImaging|standard anatomical and functional imaging
76088410|NCT03310398|Behavioral|Psychophysiological|Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
76088411|NCT00550420|Drug|Rosiglitazone XR|experimental drug
75797933|NCT05181345|Other|Sleep restriction|"The night before one of the two heat exposures (first visit for the Reduced sleep first group and second visit for the Normal sleep first group), the participants' sleep will be restricted. The sleep restriction will correspond to a reduced sleep period with a bedtime of 3 hours (04:00 - 07:00). This night of sleep restriction will be carried out in a sleep apartment (at the lab). The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
75797934|NCT05180526|Drug|QLETLI|80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
75935941|NCT02448836|Device|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
75935942|NCT02448836|Device|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
75935943|NCT03118076|Drug|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
75935944|NCT03118076|Drug|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
76088412|NCT03312972|Radiation|HDR Brachytherapy|HDR Brachytherapy implant, deliver 1 to 2 fractions, Up to 30 Gray (Gy) to target lesion
75340868|NCT01496131|Drug|Cyclophosphamide|Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
75340869|NCT01496131|Drug|Tecemotide (L-BLP25)|Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
75340870|NCT02520726|Drug|Sertraline|< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
75651059|NCT00676377|Drug|Saline|Saline Placebo
75340871|NCT02520726|Drug|Placebo oral capsule|Matched encapsulated placebo from 1-4 capsules daily
75651060|NCT00795691|Behavioral|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
75651061|NCT00795691|Behavioral|low-fat diet|low-fat diet in patients with type 2 diabetes
75340872|NCT05062434|Other|Academic detailing and audit and feedback intervention|An academic detailing and audit and feedback intervention will be presented to VA cardiac electrophysiologists, and will include quantitative data about the individual physician's facilities cardiovascular implantable electronic device lead implants and national data on lead implants over the past year.
75797935|NCT05173844|Other|SleepFix mobile application|Digital behavioural therapy (dBTi) mobile application SleepFix® is specifically designed to treat insomnia and has been shown to be engaging and clinically efficacious.
75797936|NCT05165706|Behavioral|Dietary Intervention Mediterranean Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
75797937|NCT05165706|Behavioral|Dietary Intervention Standard Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
75935945|NCT03117764|Device|Microfet Dynamometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
75936621|NCT02424110|Procedure|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
75936622|NCT02424110|Device|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
76088413|NCT03312894|Drug|TAK-653|TAK-653 tablets
76088414|NCT03312894|Drug|Placebo|Placebo-matching tablets
76088415|NCT00559936|Drug|Topical Avastin 1%|Avastin (bevacizumab) 1%
76088416|NCT03304860|Other|Survey|Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
75340873|NCT01497613|Behavioral|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
75340874|NCT01497613|Behavioral|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
75474572|NCT01985061|Drug|BX4-Suspended|Suspended
75651062|NCT00676533|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
75651063|NCT04261244|Radiation|preoperative radiotherapy|preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
75651064|NCT04261244|Radiation|postoperative radiotherapy|postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
75651065|NCT04211363|Drug|Roflumilast 0.3% cream|Roflumilast 0.3% cream for topical application.
75651066|NCT04211363|Drug|Vehicle Cream|Vehicle cream for topical application.
75340875|NCT05126550|Biological|SARS-CoV-2 vaccine (Vero cell) inactivated|"Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)"
75474573|NCT01985074|Behavioral|Case-management intervention|The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
75935946|NCT03117764|Behavioral|1 minute sit to stand test|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
75651067|NCT04052295|Procedure|surgical diaphragmatic plication|The plication was done by the same surgeon either via a 7-8 cm long lateral thoracotomy and entrance to the pleural cavity through the eighth intercostals space on the affected side or using VATS (video-assisted thoracoscopic surgery) procedure. It was performed under single lumen intubation general anaesthesia. The diaphragm with the abdominal content was pushed caudally till the normal position of the copula achieved. At this position a fold of about 5 cm is made using traction forceps of the reluctant diaphragm. Polypropylene sutures (zero or 1) were used to perform the plication of the diaphragm. in making a fold on itself. The plication was performed using interrupted polypropylene U-stitches; usually, it started from posterior part to the anterior part of the diaphragm. We merged every two rows with continuous polypropylene sutures. The diaphragm became tough and firm and returned to its normal position. An intercostal tube was inserted, and the thoracotomy was closed in layers.
75935947|NCT03117764|Device|Accelerometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
75340876|NCT02115542|Drug|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (<30% fat) breakfast.
75651068|NCT00676767|Dietary Supplement|Resistant Starch Type 4|
75651069|NCT00676767|Dietary Supplement|Dextrose|
75651070|NCT00676767|Dietary Supplement|Puffed wheat|
75651071|NCT04263272|Other|Upper Body Circuit Training Program|16 week seated upper body exercise for persons with Spinal Cord Injuries. Participants will attend 2-3 exercise sessions a week, sessions have a mix of SCI community members and inpatients.
75651072|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
75935948|NCT03528915|Other|Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
75797938|NCT05165706|Behavioral|Dietary Intervention Standard Low Fat Diet|Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
75340877|NCT01540513|Drug|NM404|"injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging~Other Names:~PET imaging with I-124 NM404"
75340878|NCT01540513|Drug|NM404|injection of an experimental imaging agent, 5mCi I-124NM404
75340879|NCT02519712|Drug|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
75797939|NCT05159947|Drug|SPT-07A injection|20mg (2), dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.
75797940|NCT05159947|Other|placebo|2 Injection simulants, dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.
75797941|NCT05145075|Other|Survey|Patients are asked to fill in a survey concerning teleconsultations
75340880|NCT02519712|Procedure|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
75797942|NCT05141318|Other|FROM-16 Questionnaire|A 16-item questionnaire to provide information about the impact of a patient's disease/condition the participants (family member of patient) quality of life
75797943|NCT05141318|Other|Semi-structured two-part interview|A telephone/video interview to provide additional context to the FROM-16 responses
75935949|NCT03528915|Other|whithout Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
75935950|NCT03192878|Drug|Infliximab|infliximab biosimilar
75935951|NCT03524703|Other|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
76088417|NCT03304782|Other|Fitbit activity tracker|Wearable device that records the number of steps a person takes throughout the day
75651073|NCT00676845|Drug|placebo|dosage form: tablet; frequency: daily; duration: 3 weeks
75651074|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
75651075|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
75651076|NCT04946708|Other|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.
75651077|NCT04152057|Drug|Pyrotinib Maleate Tablets|400mg/d,po qd,q3w, 4 cycles
75651078|NCT04152057|Drug|Albumin Paclitaxel|125mg/m2,ivggt,d1,q3w,4 cycles.
75651079|NCT04152057|Drug|Trastuzumab|The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
75651080|NCT00610142|Drug|pimecrolimus 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
75651081|NCT00610142|Drug|hydrocortison 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
76088418|NCT04768738|Device|Auricular Vagus Nerve Stimulation Level Of Above Threshold|Biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
76088419|NCT04768738|Device|Auricular Vagus Nerve Stimulation Level Of Subthreshold|biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
75340881|NCT00450242|Drug|5% topical lidocaine ointment|Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
76088420|NCT04768738|Device|Auricular Vagus Nerve Stimulation Sham Method|Participants were shown that the device was working, but no current was given.
75935952|NCT03195920|Device|Enhanced Lithotripsy System|The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
75935953|NCT04467099|Other|Foot Exam Follow-Up|All participants will have a clinical assessment of their surgery foot by the study doctor.
76088421|NCT04768738|Diagnostic Test|5 Minutes Bicycle Exercise|Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.
75935954|NCT04467099|Radiation|X-ray|Standard x-ray of the foot.
76088422|NCT03312816|Other|cookies enriched with POP|Cookies
76088423|NCT03310320|Drug|AZD0284 oral solution 2.5 mg/mL|AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
75651082|NCT04151823|Drug|Vitamin D3|2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.
76088424|NCT03310320|Drug|Placebo|Placebo for AZD0284 oral solution, twice daily for 4 weeks
76088425|NCT05721118|Diagnostic Test|CBCT and DXA exams performed in current practice in Nantes University Hospital|40 patients will be enrolled in order to study DXA/CBCT acquisitions of 16 osteoporotic women vs 34 osteopenic/healthy women (Estimated osteoporotic rate = 20%)
76088426|NCT03304548|Other|Telephone concept elicitation interview|All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
76088427|NCT05353192|Drug|Recombinant human growth hormone|Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
76088428|NCT03310242|Behavioral|Sunlight Exposure|"Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks~Completing a Sun Diary after sunlight exposure"
76088429|NCT03310242|Dietary Supplement|Vitamin D Supplementation|- Supplementation of vitamin D3 500 IU/day for 8 weeks
75651083|NCT04151823|Drug|Immunofos|Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).
75651084|NCT04151823|Other|Promotion of physical activity|Promotion of physical activity will be encouraged at t0, t1, t2
76088430|NCT03310242|Other|Placebo|- Intake of placebo for 8 weeks
76088431|NCT00557128|Drug|COREG CR and lisinopril (FDC)|
76088432|NCT05341492|Biological|EGFR/B7H3 CAR-T|2 × 10^6/kg CAR-T cells,For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
76088433|NCT03312660|Dietary Supplement|Prebiotic group|Fermented dairy product with galacto-oligosaccharides (GOS), kefiran and other metabolites resulting from the fermentation with kefir granules.
76088434|NCT03312660|Dietary Supplement|Placebo group|Beverage with color, flavor and nutritional composition similar to the fermented dairy product but not containing the prebiotic components.
75340882|NCT00450242|Drug|Placebo cream|hydrophilic petrolatum, dime-sized amount, applied nightly.
75340883|NCT05009238|Other|lumbar stabilization exercises|selected exercises will taught to participant and practiced 3 times per week for 6 weeks
75340884|NCT05124132|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction
75651085|NCT04151823|Other|Healthy food habits promotion|Promotion of healthy food habits will be encouraged at t0, t1, t2
75651086|NCT00995345|Drug|KRP-104|Tablet
75651087|NCT00995345|Drug|Placebo|Tablet
75651088|NCT05199038|Drug|Octreotide|Octreotide infusion for 2 days in patients with bleeding esophageal varices.
75651089|NCT04262960|Device|Device: active CPAP|auto-PAP with pressure between 4 and 20 cm H2O will be administered to randomized patients
75935955|NCT04467099|Other|Questionnaire|All participants will complete a questionnaire.
75935956|NCT00294320|Drug|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
75935957|NCT00294320|Other|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
75935958|NCT03526575|Drug|Zolpidem|
75935959|NCT00189254|Drug|Imiquimod|No defined treatments were given during this study.
75935960|NCT03526419|Drug|Bupivacaine liposome|blood and milk samples will be obtained from those subjects after TAP block
75935961|NCT04978857|Other|autobiographic movie|viewing an autobiographic film through a virtual reality headset
75935962|NCT02448524|Device|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
76088435|NCT03312582|Drug|1% local metformin gel|After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
76088436|NCT03312582|Procedure|Placebo|
75340885|NCT05124132|Behavioral|Exercise|Exercise
76088437|NCT05704582|Other|Avatar Intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
75340886|NCT05124132|Behavioral|Mindfulness-Based Stress Reduction + Exercise|Mindfulness-Based Stress Reduction + Exercise
75340887|NCT05124132|Behavioral|Health Education|Health Education
75340888|NCT00515528|Biological|4-peptide melanoma vaccine|Experimental cancer vaccine given as a shot under the skin once every two weeks
75340889|NCT00515528|Drug|Ontak|A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
75340890|NCT05007444|Drug|P2Et (Caesalpinia spinosa extract)|Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
75651090|NCT04262960|Device|Device: sham-CPAP|The sham-CPAP will be fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al, with pressure that no greater than 1cm H2O.
75651091|NCT00660907|Drug|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
75651092|NCT00660907|Drug|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
75474574|NCT01985087|Radiation|Hypofractionated radiotherapy|Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.
75935963|NCT02448524|Device|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
75935964|NCT02710292|Device|Delefilcon A contact lenses|
75474575|NCT01985087|Drug|Temozolomide|During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
75651093|NCT00660907|Drug|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
75474576|NCT01985100|Other|hyperbaric oxygen chamber|
76088438|NCT05704582|Other|Addiction supportive intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
75474577|NCT01985139|Behavioral|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities
75474578|NCT01985139|Biological|Blood sampling|Blood drawn for the measurement of circulating endocannabinoids concentrations
75474579|NCT01985152|Drug|Azilsartan Trimethylethanolamine|
75474580|NCT01985152|Drug|Placebo|
75474581|NCT01985165|Drug|Imrecoxib|
75474582|NCT01985178|Dietary Supplement|Omega-3 Fatty Acid Supplement|
75651094|NCT04992572|Drug|Propofol Injection|25mg Propofol administered by injection
75797944|NCT05132686|Behavioral|IER+MED|Over a 6 month period follow a euenergetic Mediterranean diet 5 days per week and a 20% energy restriction over 2 contiguous days as a 70% energy restriction using the same macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
75797945|NCT05132686|Behavioral|MED/DER|Over a 6 month period follow a Mediterranean diet 7 days per week with a 20% energy restriction 7 days a week using the macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
75474583|NCT01985191|Drug|SAR405838|"Pharmaceutical form:capsule~Route of administration: oral"
75474584|NCT01985191|Drug|Pimasertib|"Pharmaceutical form: capsule~Route of administration: oral"
75474585|NCT01985204|Dietary Supplement|Iodine tablet|Iodine tablets containing 200 ug iodine as potassium iodate
75474586|NCT01985204|Dietary Supplement|Placebo tablet|Placebo tablet without iodine
75474587|NCT01985243|Behavioral|Nutrition and agriculture|The intervention includes two components: (1) nutrition education on infant and young child nutrition, and (2) agriculture and small animal husbandry intervention to increase women's income and the accessibility of animal source foods for infants and young children.
75651095|NCT04992572|Drug|Lidocaine Hydrochloride, Injectable|Licocaine administered locally via injection.
75651096|NCT05083052|Other|Propolis 15%|oothpaste formulation with 15% propolis.
75651097|NCT05083052|Other|Propolis 10%|Toothpaste formulation with 10% propolis.
75651098|NCT05083052|Other|Placebo|Formulation of toothpaste without active ingredient.
75797946|NCT05109351|Behavioral|Participating to Boost Meal Participation|The Participating to Boost Meal Participation intervention consists of utilizing marketing and communication strategies to promote school meal participation in elementary school students.
75797947|NCT05109208|Diagnostic Test|Ulrasound Vibroelastography (UVE)|Ultrasound technique to quantitatively assess tissue stiffness (elasticity and viscosity) by applying vibration through a specialized probe (indenter).
75797948|NCT05060692|Diagnostic Test|Bloot testing|NFL measruments in serum
75935965|NCT02710292|Device|Narafilcon A contact lenses|
75935966|NCT03192644|Procedure|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
75935967|NCT03192644|Procedure|TACE|transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
75935968|NCT03192644|Drug|epidoxorubicin and cisplatin and lipiodol|epidoxorubicin and cisplatin and lipiodol
75935969|NCT03192644|Drug|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
75935970|NCT03110055|Drug|Grazoprevir/Elbasvir|anti-viral treatment for HCV
76088439|NCT03304470|Drug|ATx201 2% Cream|Anhydrous Cream
76088440|NCT03304470|Drug|ATx201 Cream Vehicle|Anhydrous Cream
76088441|NCT04350580|Drug|Human immunoglobulin|Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)
75340891|NCT05007444|Drug|Placebo|After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
75797949|NCT05051475|Procedure|Endoscopic radiofrequency ablation|Endoscopic ablation technique for Barrett's epithelium
75474588|NCT01985243|Behavioral|Iron-rich food & business literacy|The intervention includes two components: (1) a behavioural change intervention to improve school meals and increase the available iron in adolescents' diets, (2) savings & business literacy program for young female adolescents to encourage them to stay in school.
75797950|NCT05051475|Procedure|Endoscopic hybrid argon plasma coagulation|Endoscopic ablation technique for Barrett's epithelium
76088442|NCT04350580|Drug|Placebo|Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin
75474589|NCT01985256|Biological|Toca 511|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.
75474590|NCT01985256|Drug|Toca FC|
75651099|NCT04031703|Drug|Paclitaxel|Paclitaxel chemotherapy (injection)
75474591|NCT01985269|Other|Home visits|The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
75651100|NCT04031703|Drug|Carboplatin|Carboplatin chemotherapy (injection)
75651101|NCT04031703|Drug|Epirubicin|Epirubicin chemotherapy (injection)
75651102|NCT04031703|Drug|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
75651103|NCT04031703|Drug|5-fluorouracil|5-fluorouracil chemotherapy (injection)
75651104|NCT04031703|Drug|Docetaxel|Docetaxel chemotherapy (injection)
75651105|NCT05081258|Procedure|passive Alveolar Molding|A passive palate plate (passive Alveolar Molding) will be inserted within the first week after birth. The pAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and the treatment with the pAM appliance will continue until palate closure (10-12 months of life).
75797951|NCT05030831|Drug|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
76088443|NCT03312504|Other|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
76088444|NCT03312504|Other|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
75340892|NCT00517010|Drug|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
75340893|NCT00517556|Drug|CCOCP|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
75340894|NCT00517556|Drug|Traditional OCP|(traditional OCP) (21 active days/7 inactive days) treatment regimen
75651106|NCT05081258|Procedure|Nasoalveolar Molding|A passive palate plate will be inserted within the first week after birth. A nasal stent will be added to the palate plate after one week (NAM appliance). The NAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and will be treated with a passive palate plate without nasal stent until palate closure (10-12 months of life).
75651107|NCT00795847|Drug|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
75651108|NCT00877773|Drug|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
75797952|NCT05025631|Drug|Fruquintinib|Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.
76088445|NCT02469324|Behavioral|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
76088446|NCT02469324|Behavioral|Compassionate Mind Training|see above
76088447|NCT03310086|Device|Traditional fixed appliance|aligning and leveling of lower anterior teeth using traditional fixed appliance.
75651109|NCT00610220|Device|Fiberglass short arm cast|Cast will be applied for a 4-week period
75651110|NCT00610220|Device|Prefabricated wrist splint|Splint will be applied for a 4-week period
75340895|NCT05057988|Behavioral|Empowered Relief class|The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
75340896|NCT00519584|Drug|Ropivacaine|30 ml 0.5%
75340897|NCT00519584|Drug|dex|8 mg (2 ml)
75340898|NCT00519584|Drug|Bupivacaine|30 ml 0.5%
75340899|NCT00519584|Drug|Saline|0.9% saline; systemic and local
75340900|NCT05057910|Diagnostic Test|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: < 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
75340901|NCT05122884|Drug|Milrinone|Prepare milrinone 20 mg with NSS 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours.
75340902|NCT00520286|Drug|Modafinil|200 mg or 400 mg /daily
75651111|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
76088448|NCT03310086|Procedure|Corticision|Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
75935971|NCT03110055|Other|Medical records|Medical records of patients who underwent Transarterial Chemoembolization only, in the past.
75935972|NCT03110055|Procedure|Transarterial Chemoembolization|A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
75935973|NCT02448602|Other|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
75935974|NCT02448602|Other|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
75935975|NCT02448602|Other|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
75936623|NCT02424110|Device|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
76088449|NCT03310008|Biological|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
75340903|NCT00520286|Drug|Placebo|Placebo / daily
75340904|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
75340905|NCT01540825|Drug|BI 113608|High dose powder for oral solution
75340906|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
75340907|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
75651112|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
75651113|NCT00994643|Biological|Rituximab|Given IV
75651114|NCT00994643|Biological|Interleukin-2|Given SC
75651115|NCT00912171|Drug|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
75651116|NCT00912171|Drug|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
75651117|NCT00800995|Dietary Supplement|SOD|
75651118|NCT00800995|Dietary Supplement|Sham|
75797958|NCT04987047|Biological|Blood collection|A blood sample will be collected at enrollment to perform pharmacogenetics analyses.
76088450|NCT03304392|Behavioral|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
75797959|NCT04987047|Other|Questionnaires|Several questionnaires will be filled by the participants or by the clinicians at every study visits: Hospital anxiety depression scale (HAD), Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), Quick inventory of depressive symptomatology - self rated (QiDS), Beck's Anxiety Inventory (BAI), World Health Organization Quality Of Life (WHOQOL-BREF), EuroQol Group questionnaire (EQ5D), Frequency, intensity, burden of side effects rating (FIBSER), Udvalg for Kliniske Undersøgelser - Side Effects Rating Scale - for Patients (UKU-SERS-PAT), Clinical Global impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS).
76088451|NCT03304392|Behavioral|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
76088452|NCT00558064|Drug|telmisartan+amlodipine|
76088453|NCT00558064|Drug|amlodipine|
76088454|NCT03309930|Behavioral|Comprehension Acquired Brain Injury|For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
76088455|NCT03312426|Drug|BMS-986205|Single dose, 100 mg administered at Day 1 and at Day 15.
76088456|NCT03309774|Diagnostic Test|questionnaires|"Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child~There will be:~Questionnaire KIDSCREEN 52~Visual Analogue Scale (EVA)~Neuropathic Pain 4 (DN4)~Pain of the child Gustave Roussy (DEGR)"
76088457|NCT03309774|Diagnostic Test|holter electrocardiogram|Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.
76088458|NCT03309774|Diagnostic Test|blood pressure|Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.
76088459|NCT03309774|Other|relaxation sessions|"Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.~During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.~After every relaxation sessions children evaluate pain according to Eland Color Scale."
75340908|NCT01540825|Drug|Placebo|Powder for oral solution
75340909|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
75340910|NCT01540825|Drug|BI 113608|High dose powder for oral solution
75340911|NCT01540825|Drug|BI 113608|High dose powder for oral solution
75340912|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
75340913|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
75340914|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
75340915|NCT05122416|Device|FibroScan examination (S)|A FibroScan examination with the Exploratory S probe.
75340916|NCT05122416|Device|FibroScan examination (M)|A FibroScan examination with the Optimized M probe.
75340917|NCT05122416|Device|FibroScan examination (XL)|A FibroScan examination with the Exploratory XL probe.
75474592|NCT01985282|Behavioral|Nutrition Status Questionnaires and Physicial Function Test|Nutrition status questionnaires will be administered, Physical functional status will be tested
75651119|NCT04293575|Device|MitraClip|transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)
75651120|NCT00677391|Drug|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
75651121|NCT00677391|Drug|Placebo|Capsules, once daily
75651122|NCT00629057|Biological|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
75651123|NCT00629057|Biological|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
75651124|NCT00629057|Biological|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
75340918|NCT05122416|Device|FibroScan examination (Standard M)|A FibroScan examination with the Standard M probe.
75651125|NCT00660829|Drug|Placebo|Placebo
75340919|NCT01796288|Radiation|simultaneous radiotherapy|
75340920|NCT01796288|Drug|Erlotinib|
75340921|NCT01395043|Procedure|Placing bilateral TAP-catheters preoperatively|Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
75340922|NCT01395043|Drug|Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters|Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
75340923|NCT05573750|Behavioral|Singing group|Intervention involves singing groups with person with dementia and carer. Please see earlier descriptions.
75651126|NCT00660829|Drug|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
75651127|NCT00677469|Drug|Cholestyramine|2 grams BID
75651128|NCT00677469|Drug|Cholestyramine|1 gram BID
75651129|NCT00677469|Drug|Placebo powder|1 gram BID
75797960|NCT04987047|Other|Cognitive test battery (optional)|"For patients participating in the ELAN ancillary study : the participants will undergo a battery of neurocognitive tests assessing motivation (élan vital in French)."
75797961|NCT05246774|Biological|Biological sample collection|"The following biological samples will be collected on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~fecal sample~urinary sample~blood sample (22 ml at each occasion)"
76088460|NCT03304158|Behavioral|FCHV visit|FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
75651130|NCT00629135|Drug|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
75935976|NCT03195998|Diagnostic Test|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
76088461|NCT03312192|Device|Interbody Cage|Anterior cervical discectomy and fusion with interbody cage placement
76088462|NCT03312192|Device|Interbody Cage and Anterior Plating|Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
76088463|NCT03304002|Other|Breast Cancer Surgery Decision Aid|We use a standard decision aid collaboratively developed by Health Dialog and the Informed Medical Decisions Foundation
76088464|NCT03312036|Device|Coupled plasma filtration and adsorption (CPFA)|"Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a bridge to liver transplantation"
76088465|NCT02468622|Other|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
75340924|NCT01542229|Behavioral|Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
75340925|NCT01542229|Behavioral|Treatment As Usual (TAU)|Treatment as usual (TAU) will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
75935977|NCT03528759|Diagnostic Test||phenotypic and genotypic Method
75935978|NCT01190852|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
76088466|NCT03309618|Drug|low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)|
75935979|NCT01190852|Drug|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
75935980|NCT01190852|Drug|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
76088467|NCT03309618|Drug|placebo|
76088468|NCT03303924|Drug|ETX2514 and sulbactam|Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
76088469|NCT03309540|Other|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
76088470|NCT03309462|Device|Miseq sequencer|The sequencer will be used to detect the gene mutations of the re-biopsy tissue samples and peripheral blood samples obtained from patients.
76088471|NCT03311880|Behavioral|Cognitive remediation|Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
76088472|NCT03303768|Diagnostic Test|Ultrasound|Investigation of relevant ultrasound signs to improve the antenatal diagnosis of coarctation of the aorta by calculating the sensitivity and specificity of these different signs
76088473|NCT03311568|Device|ultrasound for microcirculatory assessment|"Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface."
75340926|NCT00520910|Drug|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
75935981|NCT02444312|Behavioral|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
75935982|NCT02444312|Behavioral|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
75935983|NCT02444156|Other|Indoor rowing|
75936624|NCT02424032|Behavioral|"Exercise and connective tissue massage"|Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
75340927|NCT00521456|Drug|ketorolac eye drops|"1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo"
75651131|NCT00795925|Drug|propiverine hydrochloride|"coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."
75651132|NCT04293419|Drug|Durvalumab (MEDI4736)|6 cycles of mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) followed by long course chemoradiotherapy (50.4 Gy together with capecitabine) followed by surgery. Patients will receive durvalumab 1500 mg every 4 weeks during induction chemotherapy, chemoradiotherapy and waiting period until surgery.
75651133|NCT00801073|Procedure|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
75340928|NCT01542307|Biological|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
76088474|NCT03311490|Device|Spraino|"Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period."
76088475|NCT00557830|Drug|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
75474593|NCT01985295|Drug|pazopanib|A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
76088476|NCT00557830|Drug|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
76088477|NCT05207202|Device|electrical impedance tomography|PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to zero every 2min.
75651134|NCT02873663|Procedure|Plasma and head hair collection|Plasma and head hair collection
75797962|NCT05246774|Other|Questionnaires|"The following questionnaires will be filled by the patients on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~CTCAE Radiation Adverse Event Questionnaire~Lower Urinary Tract Disorders Questionnaire (IPSS Score)~Quality of Life Questionnaire (FACT-P)~Physical Activity Questionnaire (IPAQ)"
75340929|NCT01542307|Biological|Room air|Placebo
75340930|NCT01796366|Drug|insulin 338 (GIPET I)|Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
75340931|NCT01796366|Drug|placebo|S.c placebo administered in combination with insulin 338
75340932|NCT01796366|Drug|insulin glargine|Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
75340933|NCT01796366|Drug|placebo|Oral placebo administered in combination with s.c. insulin glargine
75340934|NCT03326180|Drug|Liposomal bupivacaine|266mg/20ml vial of EXPAREL
75340935|NCT03326180|Drug|Bupivacaine hydrochloride|100mg/20ml 0.5% bupivacaine hydrochloride. Branded or generic, must be plain (cannot contain adrenaline/epinephrine)
75340936|NCT01498549|Drug|Atomoxetine|Atomoxetine 40mg and 80mg compared to the sugar pill
75340937|NCT01498549|Drug|Sugar Pill|Sugar pill compared to Atomoxetine 40mg and 80mg.
75797963|NCT04983329|Other|Telemedicine intervention|Following education, the telemedicine center will subsequently monitor operating rooms included in this trial for protocol adherence for three-months. The telemedicine center is staffed by attending anesthesiologists, resident anesthesiologists, certified registered nurse anesthetists (CRNAs) and student registered nurse anesthetists (SRNAs) and is currently providing evidence-based support to clinicians in a subset of operating rooms and post-anesthesia care unit (PACU) beds at Barnes-Jewish Hospital.
75474594|NCT01985308|Device|MRT-Active|
75474595|NCT01985308|Device|MRT-SHAM|
75474596|NCT01985347|Device|CPAP|Continuous positive airway pressure( CPAP)
75797964|NCT04955938|Drug|Ivosidenib|A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).
75797965|NCT04955938|Drug|Enasidenib|A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.
75797966|NCT04955938|Drug|Fedratinib|This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
75797967|NCT04927650|Diagnostic Test|HPV testing|Undergo collection of cervical samples for HPV testing
75797968|NCT04927650|Other|Questionnaire Administration|Complete questionnaires
75797969|NCT04923347|Drug|FF/UMEC/VI|FF/UMEC/VI will be administered
75474597|NCT01985373|Drug|Intravenous immunoglobulin infusion|Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
75474598|NCT01985386|Dietary Supplement|GDS capsule with meal|GDS capsule with meal
75651135|NCT00793429|Drug|Prucalopride|
75651136|NCT00793429|Other|Placebo|
75651137|NCT00801151|Drug|Zolinza (vorinostat), vinorelbine|"Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication."
75797970|NCT04923347|Device|ELLIPTA|Participants will receive FF/UMEC/VI using ELLIPTA inhaler.
75935984|NCT04917159|Behavioral|ACT (Acceptance and Commitment Therapy) plus brief CHF education|The participants will identify their values and clarify their alternative behavior, exploring their thoughts and feelings, and finding ways to meet their own and their family member's needs. The rational bond between the patient and his/her family caregiver will be emphasized. In addtion, the contents of brief CHF education are based on the latest national clinical practice guideline for CHF, including symptoms monitoring, medication adherence, fluid and salt restriction, smoking cessation, alcohol consumption, and physical activity maintenance.
76088478|NCT02468466|Behavioral|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
76088479|NCT02468466|Behavioral|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
76088480|NCT03304236|Device|Myelopathy Hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists)
75340939|NCT05549102|Behavioral|Cognitive Behavioural Therapy|In the Cognitive Behavioural Therapy group (N=87), patients will undergo CBT as part of their routine care in Step 3 of the IAPT programme. This will be administered by suitably trained clinicians. The specification of CBT is as recommended by the National Institute for Health and Care Excellence (NICE) guidelines (CG113 - Generalised anxiety disorder and panic disorder in adults: management). In these guidelines, patients are offered on average, 12-15 hourly, weekly sessions of CBT with a trained and competent practitioners. Therapy sessions involve discussions that identify patterns in thinking or behaviours which may be problematic, and therapists and patients work to set goals to reduce these using cognitive techniques. The principle is to teach the patient how to use CBT techniques in their day-to-day life to promote a lasting effect on mental health. We will test patients before (T1) and after (T2) a course of treatment.
75340940|NCT05549102|Other|Waiting List|In the control group (N=87), we will test patients who are currently seeking (but not undergoing) treatment before (T1) and after a wait (T2) of equivalent time (i.e. waiting list controls)
75474599|NCT01985386|Dietary Supplement|Ferrous sulfate with meal|Ferrous sulfate with meal
75935985|NCT04917159|Behavioral|HE (Health Education)|The educational contents are based on the latest national clinical practice guideline for CHF. Besides the basic information on CHF education provided in intervention group, the contents of CHF education also include definition of CHF, epidemiology, diagnosis, comorbidity, and CHF treatment. ACT components are not covered.
75935986|NCT04915677|Procedure|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Subepithelial connective tissue graft will be harvested and inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
76088481|NCT05080686|Device|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
76088482|NCT03303690|Procedure|Ankle Spacer (AS)|All included patients will be treated by means of surgical implantation of the Ankle Spacer prosthesis in an open manner replacing the talar side of the tibiotalar joint.
75651138|NCT00796081|Drug|ER OROS paliperidone, paliperidone ER|
76088483|NCT03309228|Other|individual interviews|Semi-structured individual interviews with patients, relatives and general practitioners.
76088484|NCT00557440|Drug|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
76088485|NCT00557440|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
75797971|NCT04905745|Procedure|Korean integrative medicine|"Any kind of Korean integrative medicine will be applicable and the treatment will be entirely determined by experienced clinicians. On the premise of the above, the following examples are the treatments applicable to the subject of this observational study.~Chuna: Chuna therapy is performed on the face and cervical spine to induce decompression of the captured facial nerve. In addition, SJS Non-Resistance Technique-Facial palsy (SJS NRT-F), a technique of Chuna, can be performed to stimulate the intrinsic receptive sensation of the facial muscles to promote the neuromuscular response.~Acupuncture: acupuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~Pharmacopuncture: pharmacopuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~Herbal medicine: It is prescribed according to clinical judgment according to the patient's symptoms and disease status."
75797972|NCT04901091|Other|Not Provided|Not Provided
75797973|NCT04894006|Behavioral|Community Health Worker (CHW) Home Visit Intervention|The on-site intervention will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions. The education of dementia caregiving skills will include (1) understanding about Alzheimer's and dementias, (2) appropriate communication skills with PWD, (3) daily activities for or with PWD together (e.g., puzzles, writing, reading, singing, taking a walk, etc), and (4) care resources including support groups, adult day centers, or other dementia related social services (legal and financial matters). For stress reduction techniques to be effective, the investigators have installed an app on the smartwatch to remind them to practice mindful breathing exercises two times a day and when needed.
75797974|NCT04894006|Behavioral|Attention Control Group with WIoT Technology|The caregivers randomly assigned to the AC group will be asked to wear the smartwatch during the day time and the smartring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, and sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months answering general questions from participants. CHW will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
75935987|NCT04915677|Procedure|Soft tissue augmentation with xenogenic volume stable collagen matrix|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Xenogenic volume stable collagen matrix will be inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
75935988|NCT02710214|Drug|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
76088486|NCT00557440|Drug|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
76088487|NCT00557440|Drug|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
75340941|NCT01499173|Behavioral|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
75340942|NCT01796444|Procedure|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
75474600|NCT01985399|Behavioral|Neuropsychological testing|Neuropsychological testing
75651139|NCT00793507|Other|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
75651140|NCT00877383|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
75651141|NCT00877383|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
75797975|NCT04894006|Behavioral|Usual Care|The caregivers randomly assigned to UC group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. CHWs will contact them monthly for 6 months by phone asking general questions from participants. CHWs will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
75797976|NCT04880200|Diagnostic Test|POC NAT & Adherence Intervention|The POC NAT test will be the SAMBA Semi-Q HIV test. The adherence intervention will be developed by study staff and tailored for delivery along with the POC NAT results.
75797977|NCT04879589|Drug|Abiraterone Acetate|ATRS-2002
75935989|NCT02710214|Drug|Placebo|Once-daily dosing of placebo for 8 weeks
75797978|NCT04872608|Drug|Letrozole|Letrozole will be given daily on days 1-28.
75935990|NCT03524547|Device|J shaped stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
76088488|NCT03303534|Dietary Supplement|ScandiShake|weight gain supplement low in protein
76088489|NCT03308994|Other|Delay between MS onset and introduction of first line DMT|Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)
75474601|NCT01985438|Procedure|percutaneous endoscopic gastrostomy tube placement|A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.
75474602|NCT01985438|Procedure|nasogastric tube placement|All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
75651142|NCT00877383|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
75651143|NCT00796159|Drug|Olmesartan medoxomil|olmesartan medoxomil 20 mg and HCTZ 12.5 mg
75797979|NCT04872608|Drug|Palbociclib|Palbociclib will be given daily on days 1-21 and held on days 22-28, as per standard FDA-approved dosing guidelines.
75935991|NCT03524547|Device|60-degrees stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
75340943|NCT01796444|Procedure|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
75340944|NCT01796444|Procedure|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
75340945|NCT01796444|Procedure|Pathological Evaluation|H&E and IHC
76088490|NCT03308994|Other|EDI|For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
75797980|NCT04872608|Drug|Onapristone ER|Onapristone will be given daily on days 1-28.
75651144|NCT00993473|Drug|Insulin glargine (HOE901)|"100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~HbA1c <7.5%."
75651145|NCT00993473|Drug|Neutral Protamine Hagedorn (NPH) insulin|"NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine"
76088491|NCT03311178|Drug|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
75651146|NCT00993473|Drug|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
75651147|NCT00660595|Drug|Quetiapine|Oral administration
75651148|NCT00660595|Drug|Risperidone|Oral administration
75651149|NCT00929240|Drug|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
75651150|NCT00929240|Drug|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
75797981|NCT04869501|Drug|TJ004309|Antibody to CD73
75797982|NCT04869501|Drug|Atezolizumab|Humanized monoclonal antibody to PD-L1
75935992|NCT05189990|Diagnostic Test|Electrical impedance tomography|Fatty liver patients will be recruited from the Department of Medicine at Queen Mary Hospital. Gender- and age- matched control subjects will be publicly recruited. Subjects will undergo the EIT-liver scan and FibroScan®. Selected subgroups will also undergo MRI-PDFF scan. The performance characteristics of the device and with respect to Fibroscan/ MRI-PDFF for liver fat quantification will be assessed.
76088492|NCT02469012|Drug|Combination #1|Sofosbuvir + Ribavirin
75340946|NCT01796444|Drug|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
76088493|NCT02469012|Drug|Combination #2|Sofosbuvir + Daclatasvir
76088494|NCT02469012|Drug|Combination #3|Sofosbuvir + Daclatasvir + Ribavirin
76088495|NCT02469012|Drug|Combination #4|Sofosbuvir + Ledipasvir
76088496|NCT02469012|Drug|Combination #5|Sofosbuvir + Ledipasvir + Ribavirin
75935993|NCT05561205|Device|rTMS|repetitive transcranial magnetic stimulation
75935994|NCT05561205|Drug|methylphenidate|methylphenidate
75935995|NCT03052517|Drug|QAW039 150 mg|One tablet of QAW039 150 mg once daily
75935996|NCT03052517|Drug|QAW039 450 mg|One tablet of QAW039 450 mg once daily
75935997|NCT03052517|Drug|Placebo|One tablet of Placebo once daily
75936625|NCT02424032|Behavioral|"Exercise"|Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
75936626|NCT02420756|Device|PET Scan|
76088497|NCT02468856|Drug|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
76088498|NCT02468856|Drug|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
76088499|NCT03303456|Other|Mobile health application - Ginger.io|the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data
76088500|NCT05202106|Behavioral|Home visits|Home visits entail a visit a children's home every two weeks. During this visit, trained child development agents will engage parents in activities with the child and provide basic toys and learning materials.
75340947|NCT01796444|Radiation|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
75651151|NCT00796237|Device|Whole body vibration therapy|In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.
75651152|NCT00796237|Other|standing on the vibration platform but no vibration will be applied|The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
75797989|NCT04853641|Procedure|Cadaveric|Cadaveric Organ Transplant
75797990|NCT04853641|Procedure|Living Donor|Living Donor Organ Transplant
75936627|NCT02423954|Drug|Temsirolimus|
75936628|NCT02423954|Drug|Irinotecan|
75936629|NCT02423954|Drug|Irinotecan + capecitabine|
75936630|NCT02423954|Drug|nivolumab|
76088501|NCT05202106|Other|Afini App|Afini is an app designed to help parents provide nurturing environments and stimulation to their young children. Most caregivers currently connect to the platform via Facebook Messenger; once they sign up, the platforms start engaging the caregiver by recommending age-specific health- and development-promoting activities. Rather than just hoping that caregivers will later engage in these activities, the virtual assistant directly observes whether caregivers access the materials for the recommended activity, and asks caregivers to provide feedback on each task.
76088502|NCT03308760|Other|Questionnaire|Interview concerning the post-operative rehabilitation programme and a functional analysis using the American Orthopaedic Foot and Ankle Society questionnaire
75340948|NCT01542541|Drug|Rifaximin|550mg BID for 2 days
75340949|NCT05054946|Procedure|Laparoscopic cystectomy|All surgeries will be performed under general anesthesia by laparoscopically.
75340950|NCT00524264|Drug|ketorolac|"Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo"
75474603|NCT01985451|Drug|Pemetrexe|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m²).
75474604|NCT01985451|Drug|Temozolomide|Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m² day 1-5,28).
75651153|NCT04292249|Other|Blood sampling|Analysis will be performed using commercially available analyses (suPARnostic® kit (validated to measure suPAR concentrations between 0.6 and 22 ng/mL) (ViroGates)). HsCRP will be measured by high sensitivity CRP assays (Tina-quant hs-CRP latex assay (validated to measure CRP concentrations between 0.3 - 20 mg/L) (Roche/Hitachi)). In patients with CRP>20 mg/L a regular CRP-measurement will be performed.
75651154|NCT00801307|Device|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
75651155|NCT02869139|Other|Mentholated lip moisturizer and ice popsicle|Mentholated package of measures
75797991|NCT04836624|Device|Co-designing of personalised aids of daily living|"In the initial session the researcher will work with the participants to identify challenges in daily living for the device to overcome.~In between sessions the researcher will design and manufacture different solutions which will then be sent out for the participant to trial. The participant will then meet with the researcher to and feedback on the device provided. Feedback from the user is used to alter and improve the design of the device; new device(s) are then , enabling the design to be adapted to the participants needs. The process of design changes and feedback forms an iterative loop. This is expected to continue for 4-5 appointments over a period of serveral months until a final design is agreed upon.~After the device is issue, both qualitative and quantitative outcome measures are provided to participants to complete, including questionnaires and semi-structured interviews. ."
75797992|NCT04831398|Dietary Supplement|melatonin|A 5mg dose of melatonin spay will be delivered sublingually.
75797993|NCT04831398|Other|Placebo|10 sprays of diluted mint extract. This mimics the sensation and taste of the melatonin spray
75935998|NCT02708498|Behavioral|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
75797994|NCT04801849|Drug|Vitamin E|Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks
75797995|NCT04801849|Drug|Placebo|Participants will take a placebo vitamin E capsule daily for 24 weeks
75797996|NCT04791488|Procedure|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy protocol
75935999|NCT03766659|Diagnostic Test|MOSE|EUS-FNB with MOSE
75936000|NCT03766659|Diagnostic Test|ROSE|EUS-FNA with ROSE
75936001|NCT03524391|Behavioral|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
76088503|NCT03308760|Other|Static stabilometry|on a force plate, in a double- then single-foot stance, with the eyes open and then closed
76088504|NCT03308760|Other|Isokinetic test|Isokinetic test of the flexors/extensors and invertors/evertors of the ankle
75340951|NCT05119218|Other|No Intervention|No Intervention
75340952|NCT05505110|Procedure|Vaginal Seeding|Following delivery by C-section, participating infants randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.
75340953|NCT05505110|Procedure|Sterile Swab|Following delivery by C-section, participating infants randomized to the control group will have their nasal cavity swabbed with a sterile swab.
75474605|NCT01985464|Biological|Umbilical cord mesenchymal stem cells|
75474606|NCT01985477|Drug|Lenalidomide|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.~Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.~Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment."
75474607|NCT01985477|Drug|Dexamethasone|"Phase I All Patients - Induction: Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22.~Phase II Group A: Dexamethasone starting dose: Dose previously on when progressing prior to study entry.~Maintenance Therapy: Phase I and Phase II Group A: Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22."
75651156|NCT02869139|Other|Non-mentholated lip moisturizer and ice popsicle|Non-mentholated package of measures
75340954|NCT01395277|Dietary Supplement|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
75651157|NCT00677703|Other|Daily Text Messages|"Text message reminders to take oral contraception daily:~Each text message will be a short educational message listing the benefits of contraceptive use and providing instructions for avoiding common medication errors."
75340955|NCT01395277|Dietary Supplement|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
75936002|NCT03524391|Drug|Chemotherapy|Usual Care group had standard chemotherapy regimens
75936003|NCT02710136|Biological|Glycerinated German Cockroach Allergenic Extract|"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."
75936631|NCT04221503|Drug|Niraparib|Niraparib ([3S]-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl] piperidine [tosylate monohydrate salt]) is an orally available, potent, highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
75340956|NCT00452426|Device|Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|propofol sedation per device instructions for use
75340957|NCT00452426|Other|benzodiazepines and opioid sedation|per site's current standard of care
75340958|NCT01396837|Device|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
75340959|NCT05117814|Drug|Zanubrutinib|as long as 24 months or consolidated with ASCT or WBRT after achieving PR or CR
75474608|NCT01985477|Drug|All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: ATRA starting dose: MTD from Phase I.~Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.~Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days."
75651158|NCT00793663|Drug|Xenon|Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.
76088505|NCT03303378|Drug|melatonin (Helsinn Chemical Co, Biasca, Switzerland)|"Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention)."
76088506|NCT03303378|Drug|Placebos|The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
76088507|NCT04491474|Drug|Lidocaine Hydrochloride|While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
75651159|NCT00793663|Drug|Sevoflurane|Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time
75651160|NCT00793663|Drug|Dexamethasone|Intravenous use, 4 mg, single shot
75651161|NCT00793663|Drug|NaCl|Intravenous use; single shot
75651162|NCT00793663|Drug|Ondansetron|Intravenous use; 4 mg; single shot
75651163|NCT00793663|Drug|NaCl|Intravenous use; single shot
75797997|NCT04791488|Procedure|Diving simulation|Hyperbaric chamber diving simulation protocol
75797998|NCT04784533|Drug|CTP-543|Oral dosing
75797999|NCT04784533|Drug|Placebo|Oral dosing
76088508|NCT04491474|Drug|Placebo|There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
75798000|NCT04784416|Device|Active tPBM-2.0|The NIR continuous wave (average irradiance = 300 mW/cm2) will be used. The duration or irradiation will be for ~11 minutes (666 seconds).
75798001|NCT04784416|Device|Sham tPBM-2.0|"The sham mode (0 mW/cm2) will be used. The duration or sham irradiation will be for ~11 minutes (666 seconds)."
75798002|NCT04784416|Drug|18F-MK-6240|PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
75798003|NCT04770935|Drug|efanesoctocog alfa (BIVV001)|Pharmaceutical form:solution for injection Route of administration: intravenous injection
75798004|NCT04764448|Drug|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
75798005|NCT04764448|Other|Placebo|Comparator: Placebo Cohort 1 Administered sterile normal saline (0.9% NaCl) matching volume of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
75798006|NCT04764448|Drug|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
76088509|NCT00556894|Drug|CF101|orally q12h
75798007|NCT04764448|Other|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
75798008|NCT04764448|Drug|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.
75798009|NCT04764448|Other|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 96 weeks.
75651164|NCT00610298|Device|whole body vibration using a Galileo vibrating platform|whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
75936004|NCT04441437|Behavioral|Task-oriented training with a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
76088510|NCT00556894|Drug|Placebo|orally q12h
75340960|NCT04999254|Other|Medical treatment|"Medical treatment will be based on functional treatment and the doctor will prescribe the RICE protocol. For this, the patient will have to :~place an ice pack on the sprain~apply sports rest for three weeks~compress the sprain with a compression stocking when standing in order to prevent phlebitis. In addition, to avoid this complication, the doctor will prescribe an anticoagulant.~raise the foot with crutches during the day~elevate the foot at night or when doing an activity in a sitting position, using a cushion for example.~In addition, the doctor will prescribe anti-inflammatory drugs to ease the pain and physiotherapy to establish proprioception, muscle strength, joint range and dynamic postural balance of the sprain."
76088511|NCT03308682|Drug|177Lu-DOTA-EB-TATE|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
75651165|NCT02628561|Device|Transcranial direct current stimulation|
75340961|NCT04999254|Other|osteopathic treatment|Each patient will be treated as a whole and within a time limit of 45 minutes. The consultation will start with a medical history followed by medical tests. Then, the osteopath will perform osteopathic tests and manual treatment.
75340962|NCT00524342|Drug|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
75651166|NCT02628561|Behavioral|Constraint-Induced Movement Therapy|
76088512|NCT03303222|Diagnostic Test|breath|measurement of volatile compounds, such as TMAO in exhaled breath and blood
75798010|NCT04746690|Other|Slider, tensioner neurodynamic mobilization techniques and stretching exercises of back, hamstrings and gastrocnemius|neurodynamic mobilization techniques of sciatic nerve and stretching exercises of back extensors, hamstrings and lower limbs for patients with chronic discogenic sciatica.
75798011|NCT04731688|Behavioral|Weight Maintenance Group|The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.
75798012|NCT04726397|Radiation|Reduced margin adaptive radiotherapy|Reduced (5 mm) clinical target volume margin with weekly contrast-enhanced adaptive radiation on the MR-Linac treatment machine
75798013|NCT04724733|Behavioral|Smoke Sense|Smoke Sense is a smartphone application (app). Smoke Sense participants will be asked to establish a profile which includes demographics, baseline health information and current beliefs about smoke and air pollution. In the Symptoms & Smoke Observations tab, participants are asked to report their weekly observations of smoke, health symptoms, and exposure reduction behaviors. In the Fire & Smoke Near Me tab, participants review the most recent AQ data measured at an AQ monitoring sites. Participants are asked to complete the AQ 101 module which test knowledge of AQ facts and provides correct answers. Badges are awarded for accomplishments within the app to promote certain desired behaviors: completing a user profile, launching the app weekly to check local AQ, reporting smoke and symptom observations, expanding AQ knowledge with AQ lessons, and exploring the map. Finally, participants can engage with other users by viewing cumulative statistics of symptoms and smoke observations.
76088513|NCT05182372|Behavioral|Enhanced dCBT-I|Telehealth Coaching
75651167|NCT04258202|Other|Alveolar recruitment maneuver|The two methods for performing an alveolar recruitment maneuver. Alveolar recruitment maneuvers consisted of a stepwise increase in tidal volume to a plateau pressure of 30 cm H2O versus a stepwise increase in PEEP H2O to a plateau pressure of 30 cm H2O.
75651168|NCT04151745|Procedure|external pacemaker switched off|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
76088514|NCT03308604|Drug|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|"Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later.~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg."
75651169|NCT02553811|Diagnostic Test|accuracy diagnostic|effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
75651170|NCT02554045|Drug|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
75340963|NCT01545193|Other|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
75340964|NCT05117658|Drug|HA121-28 tablet|HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
75340965|NCT00524576|Biological|Engerix™-B|One dose (10µg Hepatitis B surface antigen (HBsAg))
75651171|NCT02554045|Drug|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
75651172|NCT05330390|Drug|Levetiracetam|Epilepsy, treatment with levetiracetam
75651173|NCT00677859|Biological|MultiStem®|Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
75651174|NCT00677859|Biological|MultiStem®|Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
75651175|NCT00993317|Drug|Placebo of CDP870|Given every 2 weeks until Week22 (SC)
75798014|NCT04724733|Behavioral|Smoke Sense Plus|Participants randomized to the Smoke Sense Plus intervention will be asked to do everything that the Smoke Sense intervention group does on a weekly basis, as well as: 1) Receive weekly push notifications that remind them to, for example, review their asthma action plan, refill any expired medications, take their daily controller medication, identify a clean air space in their home and community, 2) Monitor their lung function weekly via mobile spirometry, and 3) Subscribe to a social network to share strategies to minimize exposure.
75798015|NCT04709796|Drug|EmbryoGlue®, Vitrolife|The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.
75798016|NCT04709796|Drug|Conventional Transfer|The control arm is the conventional embryo transfer without Embryo glue medium
75936005|NCT04441437|Behavioral|Task-oriented training without a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
75651176|NCT00993317|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
75651177|NCT00993317|Drug|Methotrexate|"Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly."
75798017|NCT04705038|Behavioral|Patient Education|Brief educational session on surgical castration as an alternative to lifelong ADT for prostate cancer.
75798018|NCT04703413|Device|LoFric® OrigoTM and LoFric® SenseTM|The investigational device is either a CE-marked LoFric® OrigoTM , 40 cm, CH12/CH14 or LoFric® SenseTM, 15 cm, CH12. They are all intermittent urinary catheters with a Nelaton tip from a more sustainable manufacturing process. All subjects will use the investigational device for 30 days each.
76088515|NCT03308604|Radiation|External beam radiotherapy (EBRT)|to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases
76088516|NCT03308604|Radiation|Uterovaginal brachytherapy|15 Gy (maximal interval between EBRT and brachytherapy: 14 days).
75936006|NCT03526341|Device|ReliaTack™ Articulating Reloadable Fixation Device|ReliaTack™ Articulating Reloadable Fixation Device with Deep Purchase Tacks
75936007|NCT04467645|Other|reflexology|Reflexology is the stimulation of the reflex points in the hands and feet by massage, designed to provide relaxation and relief in the body.
75936008|NCT02443844|Procedure|Transurethral Resection|Endoscopic treatment of bladder cancer
75936009|NCT02443844|Drug|Tamsulosin|Medical treatment for benign prostate hyperplasia
76088517|NCT03308604|Drug|Chemotherapy (cisplatin)|Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
76088518|NCT05168956|Other|Collect data of medical record|"Collect data of medical record:~Genealogy characteristics~Family characteristics: Number of members in the sibling, rank in the sibling / incestuous relationships or not~Graphic representation: age / gender / age at time of sexual assault / whether or not a victim of sexual violence / education / family dynamics / living environment during childhood / Criminal category"
76088519|NCT00553306|Biological|therapeutic autologous lymphocytes|Given IV
76088520|NCT00553306|Biological|aldesleukin|Given subcutaneously
75340966|NCT02516202|Drug|Vagifem|One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
75340967|NCT02516202|Device|Replens|2.5 gm to be applied vaginally every 3 days over 12 weeks.
75340968|NCT02516202|Other|Placebo tablet|Dispensed in visually identical bottle and tablet form to Vagifem.
75651178|NCT00801385|Drug|erlotinib hydrochloride|
76088521|NCT00553306|Drug|cyclophosphamide|Given IV
76088522|NCT00553306|Procedure|biopsy|Optional correlative studies
76088523|NCT00553306|Other|immunohistochemistry staining method|Optional correlative studies
76088524|NCT00553306|Other|flow cytometry|Correlative studies
76088525|NCT00553306|Genetic|polymerase chain reaction|Correlative studies
75651179|NCT00801385|Drug|sorafenib tosylate|
75651180|NCT00801385|Genetic|DNA analysis|
75651181|NCT00801385|Genetic|mutation analysis|
75651182|NCT00801385|Genetic|polymerase chain reaction|
75651183|NCT00801385|Genetic|protein analysis|
75651184|NCT00801385|Genetic|protein expression analysis|
75651185|NCT00801385|Other|immunohistochemistry staining method|
75651186|NCT00801385|Other|laboratory biomarker analysis|
75340969|NCT02516202|Other|Placebo gel|Dispensed in visually identical tube and gel form to Replens.
75340970|NCT00526058|Device|Secura then Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
75340971|NCT00526058|Device|Futura then Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
75340972|NCT00526292|Biological|natural killer cell therapy|The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
75340973|NCT00526292|Drug|cyclophosphamide|Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
75651187|NCT04258124|Other|Control motor intervention|The intervention through motor control will consist in the application of the protocol described by Hidalgo-Peréz et al. The objective of the application of the technique is to produce an increase in the strength of the deep cervical musculature. The exercises will be performed with the subject in different positions: supine, quadrupedic and standing position. The physiotherapist will be placed in standing position in front of the subject. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
75474609|NCT01985490|Procedure|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
75651188|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (325mg EPA + 225mg DHA)
75651189|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (300mg EPA + 200mg DHA)
75651190|NCT04045873|Device|extracorporeal membrane oxygenation|The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
75474610|NCT01985516|Other|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
75474611|NCT01985516|Other|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
75474612|NCT01985529|Other|Exercise|
75651191|NCT05330156|Procedure|Transurethral resection of the prostate|- After an initial cysto-urethroscopy assessment done, Transurethral resection of the prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
75651192|NCT05330156|Procedure|transurethral enucleation of prostate|After an initial cysto-urethroscopy assessment done, transurethral enucleation of prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
75651193|NCT00677001|Drug|R306465|
75474613|NCT01985555|Drug|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
75651194|NCT02628249|Dietary Supplement|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
75798019|NCT04693936|Combination Product|Nutraceutical Combination Plan|"Multivitamin (My Total Health) 1 tablet per day Vitamin C (My Immuno) 1 scoop per day Calcium-Magnesium combination (My Calmag) 1 scoop per day Omega 3-6-9 My Omega Krill. 1 capsule per day Glutamine (L-Glutamin &Chios Mastiha) 1 tablet per day Probiotics 40 billion 1 capsule per day~Nutraceuticals will be received daily along with the patient's customary psoriasis/Hashimoto's disease treatment."
75651195|NCT02628249|Dietary Supplement|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
75651196|NCT02628249|Dietary Supplement|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
75798020|NCT04692480|Behavioral|Breastfeeding Video Education|"Video entitled Breastfeeding in the First Hour, It's in Your Hands"
75936010|NCT03754335|Procedure|Lumbar puncture|"Patient will be managed according to the current international recommendations in the Toulouse acute stroke center.~In the absence of clear recommendation in the literature headache will be treated according to our local predefined analgesic protocol: paracetamol 1g/6 h, and if the numerical scale ≥ 4 : continuous intravenous morphine starting at 1mg/h and increased per 0.5 mg/h every hour if numerical scale remains ≥ 4.~Lumbar puncture will be performed between day 3 and day 5 after subarachnoid hemorrhage onset by an independent scientist from our clinical investigator center. 30-mL CSF will be removed by LP.~Sham LP consisting in superficial skin puncture by a subcutaneous needle (27 gauge needle) during the usual procedure will be performed at the same time point."
75936011|NCT02440100|Drug|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
75936012|NCT02440100|Drug|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
75936013|NCT02440100|Drug|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
75474614|NCT01985594|Drug|utrogestan|Oral Tablet Utrogestan 400 mg daily for 2 days
75474615|NCT01985594|Drug|Nifedipine|Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
75651197|NCT02628249|Dietary Supplement|Essential amino acids|Essential amino acids modeled after egg protein.
75651198|NCT02628249|Dietary Supplement|Non essential amino acids|Non essential amino acids modeled after egg protein.
75798021|NCT04692480|Behavioral|Breastfeeding PDF education|PDF of standard breastfeeding education handouts
75340974|NCT00526292|Drug|fludarabine|Day -5 fludarabine 25mg/m2 CIV for 5 days
75651199|NCT01030133|Device|Operator Role Real TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
75651200|NCT01030133|Device|Receiver Role Real TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
75340975|NCT05115396|Other|Mirror therapy|The patient shall be seated in a chair with a table in front of him/her. On the table there is a mirror in the sagittal plane between the two upper extremities. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the procedure, patients will be instructed to concentrate on the hand reflected in the mirror.
75798022|NCT04654260|Behavioral|Behavioral Therapy for Irritability in Autism|The child-focused components of BTIA are organized in modules dedicated to emotion regulation, problem solving and practice of planned steps to prevent or resolve conflicts. Each session contains a set of six to seven goals, and each goal contains a menu of techniques and activities that can be used to attain this goal. In order to administer the treatment in a flexible yet reliable manner, the therapist works collaboratively with the child and his or her parents to select activities that are perceived as relevant for attaining the session's goal. The parent-focused components of BTIA include include education about the effects of antecedents and consequences on disruptive behavior, developing strategies for reducing or altering antecedent events that may lead to disruptive reactions and helping parents to use reinforcement of competent and calm responses in potentially frustrating situations.
75340976|NCT05115396|Other|Cross-education treatment|Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
75340977|NCT04949490|Biological|BNT162b2s01|intramuscular (IM) injection
75798023|NCT04654260|Behavioral|Psychoeducation and Supportive Therapy (PST)|Each PST session will start with a review of events of the past week and include queries of topics such as school, interests, hobbies, and family with an overarching goal of enhancing subjective well-being. A major objective is to enables the participant to discuss his or her concerns with a therapist toward a goal of enhancing overall psychological wellbeing. Education about autism diagnosis and services is also provided to families as part of PST.
75798024|NCT04635839|Drug|Standard Dose of Unfractionated Heparin|5,000 units subcutaneous unfractionated heparin every 12 hours
75340978|NCT04949490|Biological|BNT162b2|IM injection
75340979|NCT02121860|Drug|IDN-6556|
75340980|NCT04203810|Device|Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
75340981|NCT04203810|Device|EMSER® Hals-und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
75340982|NCT02122406|Other|Hospital Anxiety and Depression Scale (HADS) questionnaire|Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
75340983|NCT05113446|Diagnostic Test|Delirium assessment using S-CAM|Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM
75340984|NCT04420806|Other|HIT-exercise|13 months of high intensity endurance and resistance exercise, 3x 45 min/week - 3 months of COVID-19 induced exercise break
75340985|NCT04420806|Other|Sham intervention|Types of exercise (flexibility, relaxation) that did not affect the present outcomes
75474616|NCT01985607|Dietary Supplement|new extensively hydrolysed formula|
75474617|NCT01985607|Dietary Supplement|Extensively hydrolysed formula|
75474618|NCT01985620|Behavioral|Educational intervention|
75340986|NCT05298332|Drug|ATI-2173 50 mg|ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
75340987|NCT04211220|Other|A decision support software|Insulin pump Continuous glucose monitoring
75340988|NCT01545583|Drug|LY3016859 intravenous|Administered intravenously
75340989|NCT01545583|Drug|Placebo intravenous|Administered intravenously
75340990|NCT01545583|Drug|LY3016859 subcutaneous|Administered subcutaneously
75340991|NCT01545583|Drug|Placebo subcutaneous|Administered subcutaneously
75340992|NCT04210362|Behavioral|Workshops on responsive caregiving|Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
75340993|NCT02124044|Drug|Asunaprevir and Daclatasvir|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
75340994|NCT02124044|Drug|Asunaprevir and Daclatasvir with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
75340995|NCT01502761|Drug|Magnesium Sulfate|Intra-arterial
75340996|NCT05112276|Other|Diet|A review has been undertaken to both identify specific bacteria associated with cardiometabolic risk factors and food items that have been shown to affect such bacteria in a beneficial direction. The intervention diet will include a variety of food items e.g. vegetables, fermented vegetables, fermented dairy products and cereal products. The control diet is based on a Swedish Average Diet
75340997|NCT02124122|Biological|Lactobacillus reuteri|Probiotic
75340998|NCT02124122|Biological|Placebo|Placebo
75340999|NCT01504477|Drug|Panitumumab and bortezomib|"Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle."
75341000|NCT02124512|Drug|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
75341001|NCT02124512|Other|Placebo|80 mg placebo once daily
75341002|NCT01504711|Drug|fosaprepitant dimeglumine|Given IV
75651201|NCT01030133|Device|Operator Role Sham TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
75798025|NCT04635839|Drug|Gestational Age-Based Dose of Unfractionated Heparin|"First trimester (< 14 weeks of gestation): 5,000 units subcutaneous unfractionated heparin every 12 hours~Second trimester (14-28 weeks of gestation): 7,500 units subcutaneous unfractionated heparin every 12 hours~Third trimester (> 28 weeks of gestation): 10,000 units subcutaneous unfractionated heparin every 12 hours"
75651202|NCT01030133|Device|Receiver Role Sham TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
75341003|NCT05148260|Behavioral|Learning Through Play plus (LTP+)|Group-1: Experimental (n=40 participants) will receive the LTP+ which consist of a total of 12-group integrated treatment sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother/child pair per sub-group.
75341004|NCT05148260|Behavioral|Psychoeducation|Group-2: Controlled (n=40 participants) will receive 'psychoeducation' which consist of a total of 12-group sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother-child pair per sub-group.
75341005|NCT05131880|Other|GAIT RE-EDUCATION PROGRAM ON A SEQUENTIAL MAT IN SUBJECTS WITH PARKINSON'S DISEASE|"Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition."
75341006|NCT04993950|Other|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
75341007|NCT04993950|Other|SNAGS with thoracic postural correction techniques|thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
75651203|NCT01030133|Device|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
75651204|NCT00677937|Behavioral|Modified DESMOND education and ongoing support|6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
75651205|NCT04291781|Biological|RC18 160mg|subcutaneous injection RC18 160mg on the upper arm, abdomen, or upper thigh outside;
75651206|NCT04291781|Biological|RC18 240mg|subcutaneous injection RC18 240mg on the upper arm, abdomen, or upper thigh outside;
75651207|NCT04291781|Biological|placebo|subcutaneous injection placebo on the upper arm, abdomen, or upper thigh outside;
75651208|NCT04257968|Diagnostic Test|Ultrasonography|carotid ultrasonography (IMT and elastography)
75651209|NCT04257968|Diagnostic Test|MRI|MRI of carotid artery and brain
75651210|NCT04257968|Diagnostic Test|Neuro Psychological Assessment Battery|Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV
75798026|NCT04599270|Other|PREVENTURE Program|Adolescents will be follow PREVENTURE program (2 session of 90 min).
75798027|NCT04599270|Other|Routine care|Adolescents will be follow routine care
75341008|NCT02208349|Device|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
75341009|NCT02208349|Device|traditional direct laryngoscopy (DL)|
75341010|NCT04993716|Other|observational|Collect from a bank of biological samples, identification of prognostic factors associated with survival without serious neurological heavy sequelae
75341011|NCT02209519|Drug|Metronidazole (male partner)|500 mg PO BID for 7 days
75651211|NCT04257968|Diagnostic Test|Questionaires|Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
75798028|NCT04591275|Drug|CMAB807 Injection|mAb targeting RANKL, human monoclonal antibody targeting RANKL
75798029|NCT04591275|Drug|Prolia®|mAb targeting RANKL, human monoclonal antibody targeting RANKL
75798030|NCT04590365|Device|Carrageenan nasal and throat spray|Iota-carrageenan nasal and throat spray (verum Coldamaris plus i.e. Iota-Carrageenan 0.12% plus 0.04% Kappa-Carrageenan in 0.5% saline)
75798031|NCT04590365|Device|Saline nasal and throat spray|Saline nasal and throat spray (placebo Coldamaris sine i.e. 0.5% saline)
75341012|NCT02209519|Other|Placeob (male partner)|matching placebo capsules PO BID for 7 days
75341013|NCT01546285|Device|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
75341014|NCT01397071|Other|Avocado|Fresh Avocado
75341015|NCT01546675|Other|Skeletal Stabilization|Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
75341016|NCT01397617|Device|NobelActive Internal implant|Dental implant
75341017|NCT01397617|Device|NobelActive External implant|Dental implant
75651212|NCT00877071|Drug|LC Bead loaded with doxorubicin|LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
75341018|NCT01397617|Device|NobelReplace Tapered Groovy implant|Dental implant
75474619|NCT01985633|Biological|Mesenchymal stem cell suspension|About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
75651213|NCT04292795|Device|Therapeutic Ultrasound|The Intervention will be provided according to the set protocols used in previous literature.
75474620|NCT01985633|Biological|PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
75474621|NCT01985646|Procedure|surgery treatment|one staged pull-through left-colectomy
75474622|NCT01985646|Behavioral|anal dilation|anal dilation
75474623|NCT01985646|Behavioral|colonic lavage|colonic lavage
75474624|NCT01985646|Drug|oral probiotic|oral probiotic
75651214|NCT04292795|Device|Short wave diathermy|The Intervention will be provided according to the set protocols used in previous literature.
75798032|NCT04584801|Diagnostic Test|Structured Light Plethysmography|"Part A: Subjects will have two 5-minute SLP measurements (Pre and Post bronchodilator).~Part B: Subjects will be seen in the clinics and have three 5-minute SLP measurements (pre-bronchodilator, post-bronchodilator and post spirometry testing)."
75651215|NCT00678093|Other|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
75651216|NCT02868905|Procedure|Blood sample|
75798033|NCT04560179|Drug|Tobramycin solution for inhalation 78mg dose|Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
75798034|NCT04560179|Drug|Tobramycin solution for inhalation 150mg dose|Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
75798035|NCT04560179|Drug|Tobramycin solution for inhalation 216mg dose|Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
75798036|NCT04560179|Drug|Tobramycin solution for inhalation 300mg dose|Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
75798037|NCT04555174|Device|Orsiro Mission DES|Percutaneous Coronary Intervention (PCI)
75936014|NCT03524313|Diagnostic Test|End tidal carbon monoxide|"Evaluation of cardiac output estimated by transthoracic echocardiography and end tidal carbon monoxide~Evaluation of cardiac output estimated by transthoracic echocardiography and portal veinous velocity~Evaluation of femoral veinous velocity"
75936015|NCT02439944|Drug|Nicotine patch|
75936016|NCT02439944|Drug|Nicotine mouthspray|
75341019|NCT02518620|Biological|ALX-0061|Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
75651217|NCT02628171|Other|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
75936632|NCT04221503|Device|Optune|"Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells."
75341020|NCT02129660|Drug|Dose 1 of glycopyrrolate, 2.0% QD|Dose 1 of glycopyrrolate Topical Wipes
75341021|NCT02129660|Drug|Dose 2 of glycopyrrolate, 3.0% QD|Dose 2 of glycopyrrolate Topical Wipes
75341022|NCT02129660|Drug|Dose 1 of glycopyrronium, 2.5% QD|Dose 1 of glycopyrronium Topical Wipes
75341023|NCT02129660|Drug|Dose 2 of glycopyrronium, 3.75% QD|Dose 2 of glycopyrronium Topical Wipes
75341024|NCT02129660|Other|Vehicle|Vehicle Topical Wipes
75341025|NCT01398475|Drug|LY3009104|Administered orally
75341026|NCT04946136|Other|Gait modification|Individualized gait modifications guided by real-time visual feedback of knee load
75474625|NCT01985672|Procedure|Frozen embryo transfer|Embryo transfer of frozen/thawed embryos after IVF/ICSI
75474626|NCT01985698|Procedure|Robotic-assisted resection.|Robotic-assisted abdominoperineal resection.
75474627|NCT01985698|Procedure|Laparoscopic resection|Laparoscopic abdominoperineal resection
75474628|NCT01985711|Device|web-based collaborative care|"Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months."
75651218|NCT02628171|Other|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
75474629|NCT01985711|Other|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
75798038|NCT04547062|Drug|Tocilizumab|Administration of tocilizumab at day 8 of induction following a classical induction
75798039|NCT04543799|Device|polysomnography, actigraphy, questionnaires|sleep quality recording
75798040|NCT04536337|Drug|ALG-000184|Single or multiple doses of ALG-000184
75936633|NCT04221503|Procedure|Planned surgical resection|Surgery of supratentorial glioblastoma (GBM).
76088526|NCT05110612|Behavioral|Episodic Future Thinking|Episodic Future Thinking involves generating positive, autobiographical events that could realistically occur following each of five delays in the subsequent DD task: 1 day, 1 week, 1 month, 3 months, and 1 year. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
76088527|NCT05110612|Behavioral|Control Episodic Thinking|Control Episodic Thinking will report three real, positive events that occurred earlier in the session while playing mobile video games. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
76088528|NCT02722044|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
76088529|NCT02722044|Device|Autoinjector|Subcutaneous administration
76088530|NCT05728008|Drug|Ustekinumab|a human monoclonal antibody to interleukin IL 12/23 p40. It is indicated in the treatment of adult patients with moderately to severely active UC. The induction phase consists of approximately 6 mg/kg intravenous dose administration. After the induction, the maintenance phase consists of a 90mg subcutaneous dose every 8 weeks.
76088531|NCT05728008|Drug|Tofacitinib|Jak inhibitor. It is indicated in the treatment of adult patients with moderately to severely active UC who have experienced inadequate response or have lost the response or who are intolerant to conventional therapy or to a biological agent. The induction phase consists of 10mg twice daily for 8 to 16 weeks. After the induction, the maintenance phase consists of 5mg x twice daily.
75341027|NCT04235582|Behavioral|App + Inputs Contingency Management|The app has programmed contingencies whereby incentives can be earned for behaviors that are inputs to abstaining from drug use (e.g., attending psychotherapy or taking SUD psychopharmacology).
75341028|NCT04235582|Behavioral|App + Outcomes Contingency Management|The app has programmed contingencies whereby incentives can be earned for outcomes of abstaining from drug use (e.g., drug-negative saliva samples on saliva opioid tests).
75341029|NCT01549405|Other|İntercostal nerve block|Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
75651219|NCT00610376|Behavioral|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
75651220|NCT00610376|Behavioral|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
75651221|NCT02868827|Drug|Cholecalciferol|400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
75651222|NCT02868827|Other|Milk (Nestle)|45 ml of Nestle milk will given to patients assigned as placebo
75651223|NCT02869061|Procedure|Liposuction|
75798041|NCT04536337|Drug|Placebo|Single or multiple doses of Placebo
75798042|NCT04536337|Drug|Entecavir|multiple doses of Entecavir
75798043|NCT04530214|Other|Blood collection|Blood collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
75798044|NCT04530214|Other|Saliva collection|Saliva collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
75798045|NCT04530214|Other|Electrocardiography (ECG)|Electrocardiography (ECG) at enrollment (24-72h following surgery) and at Visit 1 (45-60 days following surgery) to assess heart rate variability
75936017|NCT03133065|Drug|treatment of HCV with oral direct acting antiviral therapy|A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
75936018|NCT02434250|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
75651224|NCT02869061|Procedure|Transurethral bladder neck resection.|
75341030|NCT04945044|Device|Computed adenoma detection system (CADe)|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps
75341031|NCT04945044|Behavioral|Control group (regular colonoscopy)|It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)
75341032|NCT01797770|Drug|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
75341033|NCT01797770|Other|No Preparation|No laxatives or bowel preparation
75474630|NCT01985711|Behavioral|usual diabetes outpatient care|
75651225|NCT02869061|Biological|ADRC|Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
75651226|NCT02869061|Other|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
75651227|NCT04151589|Behavioral|ANGEL Intervention Package and Toolbox|The interventional measures include emergency work flow management app on smartphone, specialized training, assessment of quality improvement outcomes and feedback on a regular basis, patient-centred management frame based lean six-sigma, and other specialised approach.
75651228|NCT02867657|Behavioral|Mindfulness|Five days MBSR curriculum with meditation and yoga
75798046|NCT04530214|Behavioral|Questionnaires|Mental health assessment through questionnaires at enrollment (24-72h following surgery), at Visit 1 (45-60 days following surgery), at Visit 2 (7 months following surgery) and at Visit 3 (12 months following surgery)
75651229|NCT02627859|Device|Durolane SJ|1ml single intra-articular injection in ankle
75798047|NCT04518644|Drug|Nilotinib|The recommended dosing of nilotinib is 400 mg orally twice daily
75798048|NCT04518267|Behavioral|Structured clinical interview|A structured clinical interview will be performed at enrollment.
75798049|NCT04518267|Behavioral|Psychological questionnaires|Several psychological questionnaires will be performed at enrollment.
75798050|NCT04515836|Drug|Olaparib|Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
75651230|NCT02867579|Behavioral|"evaluation of the child quality attachment (Strange situation)"|
75798051|NCT04514744|Procedure|Knee bracing|Participants will have one leg immobilized, by means of a removable Don Joy Knee Brace. Participants will be expected to keep the knee brace on for 14 days, completely prevent weight bearing on the immobilized leg, and use crutches.
75798052|NCT04514744|Other|Unilateral Resistance Exercise Training|Participants will perform resistance training on 4 occasions throughout an 8 day time period.
75798053|NCT04493502|Drug|Placebo|Administered IV
75798054|NCT04493502|Drug|LY3041658|Administered IV
75474631|NCT01985724|Drug|Docetaxel|ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
75474632|NCT01985724|Drug|Epirubicin|ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
75474633|NCT01985724|Drug|Cyclophosphamide|ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
75474634|NCT01985724|Drug|5-fluoruracil|ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
75651231|NCT02868593|Other|Pharyngeal swab|
75651232|NCT00678405|Behavioral|Breathlessness Intervention Service|Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer & non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
75651233|NCT00678405|Behavioral|Best supportive care (Standard Care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
75798055|NCT04489342|Device|IMU sensor test|Measurement of maximum range of movement in the spine; Ambulatory observational data while performing standardised functional tests
75798056|NCT04453293|Biological|BCG (Tokyo 172) vaccine|Freeze-Dried Glutamate Bacillus Calmette-Guérin BCG Vaccine (Japan BCG Laboratory), 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
75798057|NCT04453293|Drug|Placebo|Placebo vaccine diluent, 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
75798058|NCT04441034|Drug|Anti-convulsant medications|Anti-convulsants are very commonly used to treat patients with chronic pain.
75798059|NCT04441034|Drug|Anti-depressant medications|Anti-depressants are very commonly used to treat patients with chronic pain.
75798060|NCT04438369|Procedure|Erector Spinae Plane Block|Cathether based Erector Spinae Plane Block for postoperative pain management.
75798061|NCT04408001|Other|Clinical interview|At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.
75798062|NCT04408001|Biological|Blood collection|"At each study visit,~1 EDTA tube for complete blood count~3 dry tubes with gel for serology, serum neutralisation test and serum library~1 cell preparation tube for the separation of immune cells within the circulating blood will be collected."
76088532|NCT03302988|Other|Everted closure|Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion
75474635|NCT01985724|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
75798063|NCT04408001|Biological|Saliva collection|At each study visit, a saliva sample will be collected for the determination of IgA antibodies.
75798064|NCT04390672|Device|SUPRAFLEX Cruz|Percutaneous Coronary Intervention for multivessel disease
75798065|NCT04390672|Device|SYNERGY|Percutaneous Coronary Intervention for multivessel disease
76088533|NCT03302988|Other|Planar closure|The planar side will be closed with traditional buried simple closure and running cuticular sutures
75798066|NCT04380337|Drug|FOLFOXIRI|Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil
75798067|NCT04380337|Drug|FOLFOX regimen|Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2
75798068|NCT04380337|Drug|XELOX|Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2
75798069|NCT04380337|Radiation|IMRT|Radiotherapy (5 Gy x 5 fractions) with an additional boost fraction (5 Gy x 1 fraction) delivered sequentially
75936019|NCT03803111|Behavioral|Initial exercise training|Initial exercise training program
75936020|NCT03803111|Drug|Initial FCM|Initial intravenous iron supplementation (FCM)
76088534|NCT04490382|Device|32 channel external stimulator|Patients will be stimulated by the 32 channel external stimulator via leads placed as part of standard care neuromodulation. Then patients will undergo various tasks.
75798070|NCT04373551|Behavioral|Cultural adaptation of a patient-provider communication tool|Adaptation of a patient-provider communication tool for PrEP uptake utilized among AA women and their providers in a pilot pre/post-intervention design.
76088535|NCT02988700|Drug|Intrathecal hyperbaric bupivacaine 0.25mg/kg 0.5%|The lumber puncture will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
75474636|NCT01985737|Other|Sample collection|
76088536|NCT02988700|Drug|caudal plain bupivacaine 2.5mg/kg 0.25%|"The sacral hiatus between the sacral conru will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
76088537|NCT03308370|Biological|Platelet rich plasma|10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
76088538|NCT03308292|Other|Exercise|Aerobic exercise program
76088539|NCT03302832|Other|Physical Therapy|Physical therapy includes both the in-person and home-based interventions prescribed for each individual participant in order to maximize overall patient outcomes including: ambulation, range of motion, strength, functional activities, pain, swelling, balance, patient safety, and other items within the scope of physical therapy practice.
76088540|NCT03302832|Other|In-home Exercise Equipment|The in-home exercise component of the study will supplement physical therapy services. This exercise equipment will be utilized daily for up to 90 minutes as guided by the healthcare team
76088541|NCT03308214|Drug|Imipenem|Imipenem 1.0 q 8h
75341034|NCT05109780|Device|My EMI, Emotional Well-being + self-applied online transdiagnostic treatment|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMI. In terms of monitoring, the My EMI, Emotional Well-being is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
75651234|NCT00987389|Procedure|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
75341035|NCT01505179|Drug|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
75651235|NCT00987389|Other|No Plasma Exchange|No plasma exchange.
75798071|NCT04354909|Other|s-CD95-L|levels of s-CD95-L (ELISA test)
75798072|NCT04348006|Drug|Bortezomib 3.5 MG|"VCD protocol~V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)~D, Dexamethasone oral: 40mg (days 1 to 4)~VRD protocol:~V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~R, Lenalid® cap 25 mg po (day 1 to 21)~D, Dexamethasone oral: 40mg (days 1 to 4)"
75798073|NCT04313972|Drug|low-dose naltrexone|2mg of low-dose naltrexone nightly for 2 weeks, then 4mg of low-dose naltrexone nightly for 4 weeks
75798074|NCT04313972|Drug|Placebo oral tablet|1 capsule nighty for 2 weeks, then 2 capsules nightly for 4 weeks
75798075|NCT04306237|Drug|IMB-1018972|IMB-1018972 200 mg tablet for oral administration
75798076|NCT04306237|Drug|Placebo oral tablet|Matched placebo tablet for oral administration
75936021|NCT03803111|Drug|Subsequent FCM|Subsequent intravenous iron Supplementation (FCM) after 2 months
75936022|NCT03803111|Behavioral|Subsequent exercise training|Subsequent exercise training program after 2 months
75474637|NCT01985750|Drug|d-cycloserine|250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
75474638|NCT01985750|Drug|placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
75474639|NCT01985776|Procedure|Exercise intervention|Functional stabilisation exercise for the trunk.
75474640|NCT01985776|Procedure|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
75474641|NCT01985789|Drug|Diphenhydramine|
75651236|NCT00987389|Drug|Glucocorticoids [Standard Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
75936023|NCT03190616|Drug|apatinib|apatinib 500mg/qd, 28d/cycle
75936024|NCT03190538|Other|No intervention|There will be no specific intervention to these paediatric NASH patient
75936025|NCT03702231|Biological|Zoster Vaccine Recombinant, Adjuvanted|A series of 2 doses of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) will be given on a 0- and 3-month schedule by intramuscular injection.
75936026|NCT04484090|Device|Vertica RF device|The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction
75936027|NCT02443922|Drug|Glimepiride|Glimepiride 2mg qam
75936028|NCT02443922|Drug|Sitagliptin|Sitagliptin 100mg qam
75936029|NCT02443922|Drug|Metformin|Metformin as prescribed
75651237|NCT00987389|Drug|Glucocorticoids [Reduced Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
76088542|NCT03308136|Procedure|1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.|1) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
76088543|NCT03308136|Procedure|1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.|2) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.
75341036|NCT01505179|Drug|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
76088544|NCT03308136|Drug|1% Lidocaine|1% Lidocaine
75341037|NCT01797848|Drug|Peginterferon alfa 2a|
75474642|NCT01985789|Drug|cetirizine|
75651238|NCT00929162|Drug|ZD4054 Zibotentan|10 mg oral tablets once daily
75651239|NCT00929162|Drug|Paclitaxel|175mg/m2 IV on day 1 every 3 weeks
76088545|NCT02466906|Drug|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC>20.0X109/L.
75341038|NCT01797848|Drug|Ribavirin|
75341039|NCT01797848|Drug|Placebo matching Daclatasvir|
75341040|NCT01797848|Drug|Daclatasvir|
75341041|NCT04944576|Device|Total Ankle Prosthesis, EasyMove®|Patients who will be implanted with a total ankle prosthesis, EasyMove.
75341042|NCT04740632|Behavioral|Personalized Nutritional Counseling by a multidisciplinary team|Active diet therapy, instructions on reading labels, cross-contamination, allergen-free, foods recipes
75341043|NCT04580810|Behavioral|CBT4CBT in the Black Church|Use of Computer Based Treatment for Cognitive Behavioral Therapy for alcohol use disorder offered in a Black church setting
75341044|NCT01398943|Drug|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
75341045|NCT01398943|Dietary Supplement|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
75341046|NCT04372862|Procedure|Plane block|Two different plane blocks to control post-mastectomy pain
75341047|NCT01550341|Drug|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
75341048|NCT01550341|Drug|Placebo Oral Tablet|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
75341049|NCT02125292|Drug|Mesalamine|
75341050|NCT01401517|Drug|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
75651240|NCT00929162|Drug|Carboplatin|Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
75651241|NCT00929162|Drug|Placebo|matching placebo for ZD4054 10 mg
75798077|NCT04304599|Device|LoFric Elle|The study device is commercially available (CE-marked). It is a device for female intermittent catheterization. Treatment Period will last for 2 weeks. The angulated handle available with the device must be used by each subject at least 10 times.
75798078|NCT04295863|Drug|Nivolumab Standard|For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks
75341051|NCT05038436|Device|Polyglucosamine L112|Two tablets once daily per os
75341052|NCT02214277|Device|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
75341053|NCT02214277|Device|TAVR|
75474643|NCT01985789|Drug|desloratadine|
75474644|NCT01985789|Drug|placebo|
75474645|NCT01985802|Other|Pacing|
75474646|NCT01985815|Device|VC/VS stimulation|
75474647|NCT01985828|Radiation|CyberKnife|
75474648|NCT01985828|Other|Androgen Deprivation Therapy (ADT)|
75474649|NCT01985828|Radiation|Intensity Modulated radiation therapy (IMRT)|Per current standard of care
75798079|NCT04295863|Drug|Pembrolizumab Standard|For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks
75798080|NCT04295863|Drug|Nivolumab Extended|For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks
75798081|NCT04295863|Drug|Pembrolizumab Extended|For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
75936030|NCT04799847|Drug|Catumaxomab|This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
75474650|NCT01985841|Drug|Bevacizumb|Avastin
75474651|NCT01985841|Drug|5-Fluorouracil|5-FU
75474652|NCT01985841|Drug|Epirubicin|Farmorubicin
75936031|NCT02434562|Other|Serum (with or without urine) samples|
75936032|NCT02439866|Drug|placebo|gelatinous capsules filled with sugar as placebo
75474653|NCT01985841|Drug|Cyclophosphamide|Endoxan
75936033|NCT02439866|Drug|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
75936034|NCT02439866|Drug|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
76088546|NCT02466906|Drug|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
75651242|NCT02627625|Drug|Tiotropium|4 inhalations
75651243|NCT00678483|Drug|rimonabant (SR141716)|once daily
75651244|NCT00610454|Drug|Levetiracetam|
75651245|NCT04292015|Diagnostic Test|Optos ultra-widefield retinal imaging (Optos California)|retinal imaging device
75651246|NCT04151355|Drug|Atorvastatin 20mg|atorvastatin (20 mg once daily)
76088547|NCT02467140|Device|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
75651247|NCT04291625|Procedure|Levator muscle resection|"Surgery was performed under general anaesthesia. Two milliliters of 2% lidocaine with 1:100 000 epinephrine is injected subcutaneously. After the upper eyelid incision at the desired crease line, the orbital septum was opened and the preaponeurotic fat was identified and dissected off the levator aponeurosis. The aponeurosis was disinserted from the tarsus, and the complex of levator aponeurosis and Muller muscle was dissected free from the conjunctiva. The desired eyelid height was determined from the proposed formula.~Satisfactory Intraoperative lagophthalmos was defined as a difference of less than 1 mm between recommended by the formula and actual intraoperative lagophthalmos.~After permanent fixation, a caliper was used for precise measurement of lagophthalmos in a supine position. Additional sutures were placed on the medial and lateral sides for satisfactory eyelid contour. The redundant levator complex was excised. Eyelid crease was made by placing three interrupted sutures"
75798082|NCT04287608|Drug|dupilumab|No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.
75798083|NCT04281537|Drug|Agalsidase Beta|Enzyme Replacement Therapy - Infusion every other week
75798084|NCT04281537|Drug|Agalsidase Alpha|Enzyme Replacement Therapy - Infusion every other week
75936035|NCT02439788|Drug|cyclophosphamide|500 mg/m2/day x 2 days; for patients <12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
75936036|NCT02439788|Drug|Fludarabine|30 mg/m2/day x 3 days; for patients <12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
76088548|NCT02467140|Device|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
76088549|NCT02467062|Device|MRI|MRI measurement to evualuate for 4D blood flow pattern
76088550|NCT02466984|Drug|metoclopramide intravenous|Administration route
76088551|NCT00556426|Device|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
76088552|NCT05727852|Diagnostic Test|Breath test using the Compact PTR-TOF-MS|Breath samples will be analyzed with a proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria) to obtain eVOCs profiles listed as ions at various mass-to-charge ratios (m/z).
75474654|NCT01985841|Drug|Docetaxel|Taxotere
75474655|NCT01985854|Drug|Propofol|
75474656|NCT01985854|Drug|Desflurane|
75798085|NCT04276805|Device|Transcutaneous vagal nerve stimulation (tVNS)|a non-invasive and safe technique that transiently enhances brain GABA and noradrenaline levels.
76088553|NCT05727852|Diagnostic Test|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
75798086|NCT04276805|Behavioral|cognitive training|A program of regular mental activities purported to maintain or improve one's cognitive abilities.
75798087|NCT04262544|Behavioral|iCardia4HF|Participants in the intervention group will receive the following main components in addition to usual care: 1) the Heart Failure Health Storylines mobile app which supports daily self-monitoring and management of vital signs and symptoms; 2) three connected health devices (Fitbit activity tracker, Withings Cardio Body weight scale and blood pressure monitor), and 3) a program of tailored text-messages targeting health beliefs, self-efficacy, and HF-knowledge.
75936037|NCT02439788|Genetic|GINAKIT Cells|"Dose Level 1 = 3 x 10^6~Dose Level 2 = 1 x 10^7~Dose Level 3 = 3 x 10^7~Dose Level 4 = 1 x 10^8~After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future."
76088554|NCT05727852|Diagnostic Test|Assessment of arterial stiffness using the VaSera VS-1500N|Assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, PCG and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.
75474657|NCT01985893|Drug|Lapatinib plus trastuzumab|Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
75474658|NCT01985906|Procedure|Multiple overlapping uncovered stents|Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
75474659|NCT01985906|Device|Uncovered stents|The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
75936634|NCT03626441|Dietary Supplement|Ginger|Capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger
75936635|NCT03626441|Dietary Supplement|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
75936636|NCT02427542|Other|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
75936637|NCT02427542|Other|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
76088555|NCT03302754|Drug|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. Single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
75474660|NCT01985945|Other|Yoga|
76088556|NCT00555568|Behavioral|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
75474661|NCT01986023|Behavioral|SMS- Short Messaging Service|
75474662|NCT01986036|Dietary Supplement|Protein|Milk-Protein
75474663|NCT01986036|Dietary Supplement|Calcium|Soluble calcium powder.
75651248|NCT00678717|Procedure|Autonomic Evaluation|Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.
75651249|NCT00609284|Drug|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
75651250|NCT00609284|Drug|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
75651251|NCT00609284|Radiation|Radiotherapy|70 Gy in 7 weeks
75936038|NCT02434796|Behavioral|Male Peer Groups|In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
75936039|NCT02434796|Behavioral|Male Peer Groups and Community Dialogues|Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
75474664|NCT01986036|Dietary Supplement|Porridge-based breakfast.|Oats and water.
75651252|NCT04291937|Drug|Lurbinectedin|Powder for concentrate for solution for infusion in 4 mg vials
75651253|NCT00678873|Procedure|Single Incision Laparoscopic Cholecystectomy|A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
75651254|NCT04257890|Behavioral|Cognitive behavioral therapy|The CBT focuses on cognitive restructuring to reduce the specific key maladaptive beliefs on Internet gaming suggested by King's model, and develop useful coping skills (self-regulation/control, emotion regulation, problem-solving coping) that are adapted from previous CBT for adolescent IGD. In addition, it provides training on relapse-prevention and maintenance techniques.
75936040|NCT04483388|Other|Training with Virtual Reality|Computed virtual reality therapy was performed using the Nintendo Wii® console equipment. This system allows interaction with the player by means of a movement detection system and the representation of his avatar graphical representation of a user in virtual reality. It has a remote control with a wireless system, responsible for capturing the speed, direction , acceleration and deceleration of movement. The movements performed by the player are captured and reproduced on a screen via an infrared light sensor, positioned above the TV. The feedback given by the TV provides the movement itself observing opportunity in real time, generating positive reinforcement and facilitating training and improved task. The software used in this study was the Nintendo Wii Sports.
76088557|NCT00555568|Behavioral|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
76088558|NCT03302676|Dietary Supplement|Chewing gum|
76088559|NCT02988778|Drug|Budesonid 50mcg (Noex)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
76088560|NCT02988778|Drug|Budesonid 50mcg (Busonid)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
76088561|NCT04490460|Dietary Supplement|WBF-0031|Medical food formulation WBF-0031
76088562|NCT03302598|Diagnostic Test|serum C-reactive protein|
76088563|NCT04998682|Procedure|Axillary Dissection|A surgical procedure that opens the armpit (axilla) to identify, examine, or remove lymph nodes. Axillary dissection will be performed during SoC breast cancer surgery.
75474665|NCT01986049|Drug|Bupivicaine|
75474666|NCT01986088|Drug|Placebo|matching placebo
75474667|NCT01986088|Drug|Eletriptan 40 mg|40mg oral
75474668|NCT01986088|Drug|Eletriptan 80 mg|80mg oral
75474669|NCT01986088|Drug|Sumatriptan 50 mg|50mg oral
75474670|NCT01986088|Drug|Sumatriptan 100 mg|100mg oral
75474671|NCT01986127|Drug|Adalimumab|single intralesional administration during endoscopy process
75474672|NCT01986127|Drug|placebo|single intralesional administration during endoscopy
75474673|NCT01986166|Drug|Cobimetinib|In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.
75474674|NCT01986166|Drug|MEHD7945A|MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
75474675|NCT01986179|Other|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
75651255|NCT04257890|Other|Education material about IGD|Printed education material introducing IGD will be distributed.
75651256|NCT04257890|Other|Education material about CBT|Printed education material introducing CBT will be distributed.
75936041|NCT04483388|Other|Conventional Training|"It was done five types of exercises following to the protocol:~Exercise 1 (shoulder abduction); Exercise 2 (external rotation of the shoulder); Exercise 3 (elbow extension); Exercise 4 (weight transfer in upper limbs: a sitting position); Exercise 5 (function: task-oriented training)."
76088564|NCT04883112|Device|Magnetic Tape®|Magnetic tape® is applied without creating any tension over low back
75474676|NCT01986179|Other|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
75651257|NCT04151511|Procedure|Continuous Erector Spinae Plane Block|"Continuous Thoracic Epidural Thoracic Epidural Analgesia~Continuous Erector Spinae Plane Block"
75474677|NCT01986192|Drug|rivaroxaban|
75474678|NCT01986192|Drug|Warfarin|
75474679|NCT01986218|Drug|BMS-986115|
75474680|NCT01986257|Behavioral|Emotion Regulation Group Therapy (ERGT).|
75651258|NCT00992459|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
75651259|NCT00992459|Drug|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
75651260|NCT00930722|Drug|quinapril|per label as non interventional study
75651261|NCT00679107|Device|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
75651262|NCT00679185|Behavioral|expressive writing|four non-emotional writing assignments
75651263|NCT04990622|Dietary Supplement|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
75651264|NCT00912249|Behavioral|Horticulture Therapy|We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
75936042|NCT02443532|Behavioral|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
75651265|NCT00610610|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
75651266|NCT00610610|Drug|Placebo|Same shape Placebo
75651267|NCT00912327|Biological|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
75651268|NCT04257812|Drug|Ceftolozane/tazobactam|"The dose will be 1g ceftolozane + 0,5 g tazobactam every 8 hours or 2 g ceftolozane + 1 g tazobactam, it´s recommended to use this last dose regimen in patients with pneumonia or septic shock of any focus.~The patients will be followed as it´s done habitually. There will be done infection focus cultures and others according to usual clinical practice. It´ll be determined the clinical response and mortality in the days 14 and 30 after the beginning of the medicine, respectively.~The Ceftolozane-Tazobactam levels determination will always be made in state of equilibrium (after the third dose). Four samples will be collected:~Just before the antibiotic infusion.~One hour after the antibiotic infusion.~Three hours after the antibiotic infusion.~Six hours after the antibiotic infusion."
75936043|NCT02443532|Behavioral|Individual education|Usual care (individual consultations as routinely performed)
75474681|NCT01986270|Drug|Placebo|Matching Placebo
75936044|NCT02443454|Device|Device: Complior Analyse System|Monitoring of Arterial Stiffness and Central Aortic Pressure
75936045|NCT02443454|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
75936046|NCT03188198|Drug|rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim|
76088565|NCT04883112|Device|Kinesiology Tape|Kinesiology tape is applied without creating any tension over low back
76088566|NCT03307902|Biological|Imiquimod + ID HBVv|Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
76088567|NCT03307902|Biological|Aqueous + ID HBVv|Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
76088568|NCT03307902|Biological|Imiquimod + IM HBVv|Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
75474682|NCT01986270|Drug|Eletriptan 40 mg|40mg oral
75474683|NCT01986270|Drug|Eletriptan 80 mg|80mg oral
75474684|NCT01986270|Drug|Sumatriptan 25 mg|25mg oral
75474685|NCT01986270|Drug|Sumatriptan 50 mg|50mg oral
75474686|NCT01986283|Drug|Capsule|Taken once
75474687|NCT01986283|Drug|PF-00345439|40 mg capsule swallowed whole, taken once
76088569|NCT04490772|Diagnostic Test|Laboratory tests|Laboratory tests such as CBC, Liver function and CRP
76088570|NCT03302442|Other|Non interventional study|Not applicable - Non interventional Study
76088571|NCT05120310|Behavioral|The Calm App|Participants will be asked to use the Calm app for at least 10 minutes per day for eight weeks. They will also be asked to schedule one live 20-minute coaching session with a Calm Coach within the first week of the eight-week intervention to help identify areas for health behavior improvements (i.e., Calm Concierge). Participants will be asked to download the Calm app to their mobile phone. The Calm Coaching for sleep program is administered by Calm for six weeks. Participants are asked to complete weekly modules and interact with a coach to help them improve their sleep. Participants also complete a sleep diary throughout the program.
76088572|NCT05117346|Drug|CARDIX-101A, CARDIX-101B, CARDIX-101C|Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.
76088573|NCT05116410|Drug|HS-20094|Administrated SC
75474688|NCT01986283|Drug|PF-00345439|40 mg capsule chewed, taken once
75474689|NCT01986283|Drug|oxycodone|40 mg solution, taken once
75474690|NCT01986296|Device|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
75474691|NCT01986309|Drug|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
75474692|NCT01986309|Drug|Normal saline|Sodium Chloride 0.9% infusion
76088574|NCT05116410|Drug|Placebo|Administrated SC
75474693|NCT01986322|Biological|DTP/HB/Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
75936047|NCT03188276|Drug|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
76088575|NCT05727618|Drug|Pituitrin|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
76088576|NCT05727618|Drug|normal saline|Intravenous infusion of normal saline at the same dose and speed
76088577|NCT03302364|Drug|Risperidone|patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
75474694|NCT01986322|Biological|DTP/HB and Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
75474695|NCT01986335|Biological|DTP/HB/Hib Vaccine|DPT/HB/Hib vaccine (Bio Farma)
75474696|NCT01986374|Drug|HCG is introduced|must have good blastocysts
75651269|NCT00992225|Drug|LY573636-sodium|Dose is adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
75651270|NCT02627703|Other|Oncotype DX|The Oncotype DX® assay is a multi-gene reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test that analyzes the expression of 21 genes, and quantifies the 10 year distant breast cancer recurrence risk in patients with stage I and II, lymph node negative, estrogen receptor positive disease who plan to be treated with tamoxifen for 5 years.
75651271|NCT04257734|Other|observation|different serum antibodies status
75651272|NCT02868749|Device|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
75651273|NCT02868749|Device|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
75651274|NCT00659581|Drug|Telmisartan|Oral administration
75651275|NCT02627547|Behavioral|Normal training|5-10 hours of endurance training each week
75651276|NCT02627547|Behavioral|De-training|No training
75651277|NCT00679497|Biological|MVA-B|"Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml~3 immunisations at week 0, 4 and 16"
75651278|NCT00679497|Biological|Placebo|-3 immunisations at week 0, 4 and 16
75341054|NCT02126306|Drug|Beta Glucosylceramide|Beta Glucosylceramide
75341055|NCT02126306|Drug|Placebo|normal saline
75651279|NCT00796393|Dietary Supplement|Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033|1 pill per day for 12 weeks
75651280|NCT00796393|Dietary Supplement|Starch of potato|1 pill per day for 12 weeks
75936048|NCT03188276|Drug|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
75341056|NCT01550731|Behavioral|PREPARE website|Advance care planning website and materials plus an advance directive.
75651281|NCT00793741|Drug|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
75651282|NCT00796471|Drug|Paliperidone ER|
75651283|NCT00991289|Drug|Nitazoxanide (NTZ)|500 mg twice daily, taken orally with food
75936049|NCT03192410|Behavioral|Dietary intake|Intake of nutrients, foods, food groups, beverages; dietary patterns.
75936050|NCT03192410|Behavioral|Lifestyle factors|Physical activity; smoking; alcohol use; educational level.
75341057|NCT01550731|Behavioral|Advance directive|The control group will only receive an advance directive.
75341058|NCT02127632|Device|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
75341059|NCT02127632|Device|Laryngeal Mask Airway-Supreme|"Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson & Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.~Other Names:~LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7"
75341060|NCT01550809|Other|iBolus|Insulin bolus calculated from data obtained through CGM
75936051|NCT03192410|Biological|Blood biomarkers|Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
75341061|NCT01550809|Other|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
75341062|NCT01551199|Behavioral|Multiple Channel Exposure Therapy- Veterans|Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
75651284|NCT00991289|Drug|Pegylated interferon alfa-2a (PEG)|180 micrograms via subcutaneous injection once weekly
75651285|NCT00991289|Drug|Ribavirin (RBV)|Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
75651286|NCT00801463|Drug|tripterygium wilfordii (TW)|Pre 30mg/d +TW 120 mg/d, po for 12 weeks
75936052|NCT03192410|Biological|Health|Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
75936053|NCT03192410|Genetic|DNA|SNPs (GWAS)
75936054|NCT03192410|Biological|Mental well-being|Cognitive function; dispositional optimism; depression.
75936055|NCT03187964|Diagnostic Test|PLHIV Point of Care Xpert Ultra|Sputum-based TB diagnostic test that takes 80 min to run. Test performed on the same day as the patient visit.
75936056|NCT03187964|Diagnostic Test|PLHIV Point of Care Xpert VL|Blood-based HIV-1 VL diagnostic and monitoring test that takes 60 min to run. Test performed on the same day as the patient visit.
76088578|NCT00702702|Drug|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
76088579|NCT00702702|Drug|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
76088580|NCT00702702|Drug|Placebo|Placebo, 2 capsules daily for 3 months
76088581|NCT03307668|Device|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
75936057|NCT02443376|Device|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
75341063|NCT01653912|Drug|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
75936058|NCT02443376|Device|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
75936059|NCT03190304|Drug|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
75936060|NCT03190304|Drug|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
75936061|NCT03190148|Other|OGTT|A standardized 75g oral Glucose tolerance test was accomplished.
75341064|NCT01551979|Device|Repetitive Transcranial Magnetic Stimulation|"intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group."
75341065|NCT03833258|Behavioral|Rehabilitation with no precautions|Patients will recover from total hip replacement surgery being guided by pain only and not by the precautions imposed upon them by clinicians.
75936062|NCT03190148|Other|IVGTT|For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
75341066|NCT04132388|Other|Electronic Reporting|"The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
75341067|NCT04132388|Drug|Adalimumab|Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks
75341068|NCT04944030|Procedure|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
75474697|NCT01986387|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
75651287|NCT04150809|Other|No intervention|There is no intervention for this study
75651288|NCT04046029|Drug|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
75651289|NCT04046029|Drug|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
75651290|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 10 mg, capsules, once daily
75651291|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 15 mg, capsules, once daily
75936063|NCT03190148|Other|1H-magnetic resonance spectroscopy|For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
75936064|NCT03189992|Drug|Bushen-Jianpi Dedoction|A traditional chinese medicine prescription
75936065|NCT03189992|Drug|cinobufotalin injection|an effective Chinese preparation to treat malignant tumor.
75936066|NCT02439632|Drug|prulifloxacin|
75936067|NCT02439632|Drug|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
75936068|NCT02439632|Drug|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
75936069|NCT02439632|Drug|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
75936070|NCT02434172|Other|Pre-emptive screening and treatment for cryptococcal disease|Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
75936071|NCT02434874|Device|StimGuard Sacral Nerve Stimulator System|The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
75341069|NCT01552213|Other|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
75341070|NCT01552213|Other|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
75341071|NCT02982824|Dietary Supplement|Magnesium|Oral magnesium
75341072|NCT02982824|Drug|Placebo - Concentrate|Placebo will be given
75341073|NCT04991688|Drug|BOTOX-A|10 injections of 20 U of toxin will be made into the rectum 5, 10 and 15 cm above the pectinate line. At each level, 3 injections of 20 U will be performed in the submucosa, circumferentially.The last injection is made 20 cm above the pectinate line. Total does not exceed 200U of Botox-A
75651292|NCT00679653|Drug|verapamil/trandolapril|2 wk Run-in phase, antihypertensive therapy only
75341074|NCT02483520|Behavioral|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
75341075|NCT01797692|Other|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
75474698|NCT01986400|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
75474699|NCT01986413|Device|pressure controlled ventilation BIPAP ST|spontaneous timed pressure controled bilevel ventilation
75474700|NCT01986413|Device|volume assured pressure support IVAPS|intelligent volume assured Pressure Support
75474701|NCT01986413|Device|NIV|Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
75651293|NCT00679653|Drug|metoprolol/HCT|2 wk Run-in phase, antihypertensive therapy only
75651294|NCT00679653|Drug|felodipine/ramipril|2 wk Run-in phase, antihypertensive therapy only
75651295|NCT02868983|Other|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
75651296|NCT00793897|Drug|BMS-754807|Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
76088582|NCT03307668|Device|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
75651297|NCT00793897|Drug|Paclitaxel|Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
75651298|NCT00793897|Drug|Carboplatin|Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
75936072|NCT02434094|Behavioral|eDAPT on-line training program|A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
75936073|NCT03133611|Other|Speech assessment|Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.
75936074|NCT03133611|Other|Routine clinical assessment|Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
76088583|NCT02467920|Drug|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
76088584|NCT02467920|Drug|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
75651299|NCT00679887|Procedure|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
75651300|NCT00793975|Biological|IMC-1121B|"Cohort 1~2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
75651301|NCT00793975|Biological|1121B|"Cohort 2~4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
75651302|NCT00793975|Biological|1121B|"Cohort 3~6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
75651303|NCT00793975|Biological|1121B|"Cohort 4~8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
75651304|NCT00793975|Biological|1121B|"Cohort 5~10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
75651305|NCT00793975|Biological|1121B|"Cohort 6~13 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
75651306|NCT00793975|Biological|1121B|"Cohort 7~16 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
75651307|NCT00679965|Drug|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
76088585|NCT04927312|Drug|PF-06947386|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
76088586|NCT04927312|Drug|Metronidazole|Metronidazole 0.5 g solution for injection.
76088587|NCT02467218|Other|Hyperbaric Oxygen Treatment|Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
76088588|NCT03307590|Drug|Dexmedetomidine|Caudal block by dexmedetomidine and bupivavaine
76088589|NCT03307590|Drug|Bupivacaine|Caudal block by bupivavaine alone
76088590|NCT03302208|Drug|Pregabalin|Pregabalin capsule 150 mg oral
76088591|NCT03302208|Drug|Placebo|Placebo
76088592|NCT03307512|Drug|inhaled human insulin|Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
76088593|NCT03307512|Drug|Insulin Lispro (Humalog U-100)|Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
75798088|NCT04262544|Other|Usual Care|Participants assigned to the control group will receive usual care and the same connected health devices (Fitbit activity tracker, Withings weight scale and blood pressure monitor) as patients in the intervention group, but without the heart failure health storylines mobile app and text-messaging program. Usual care includes patient education before hospital discharge, and follow-up visits at the outpatient HF clinic a week after discharge and monthly thereafter depending on the patient's condition. Patient education includes literacy-sensitive, education material about HF self-care developed by the Sheps Center for Health Services Research,and a 40-minute education session with an APN and a dietician to review and discuss the education material provided to the patient.
76088594|NCT02466828|Drug|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
75341076|NCT04989738|Behavioral|THRIVE intervention|Parents learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
75341077|NCT04989738|Behavioral|Active Control|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
75341078|NCT01798160|Procedure|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
75341079|NCT01798160|Procedure|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
75936075|NCT02439398|Biological|Allogeneic human cardiac stem cells (CSCs)|Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
75798089|NCT04244162|Diagnostic Test|Brain Imaging|Magnetic resonance imaging (MRI) using diffusion tensor imaging (DTI)-based mean diffusivity (MD) measures.
75936076|NCT02439398|Other|Human Serum Albumin-HSA 5%|Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
75474702|NCT01986426|Drug|LTX-315 consecutive lesions|"Dose escalation:~Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)"
75936077|NCT03187808|Other|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
76088595|NCT02467998|Device|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
76088596|NCT03307434|Other|Athletics Injury Prevention Program|The Athletics Injury Prevention Program (AIPP) will be performed by experimental group twice a week. The AIPP is composed of 8 exercises including core stability, balance, pelvic stabilization, stretching and strengthening of the Achilles tendon and hamstrings.
76088597|NCT03307434|Other|regular training|The regular training will be performed by control group according to the standard practice.
76088598|NCT02721966|Biological|Secukinumab|Anti IL-17a monoclonal antibody
75341080|NCT02514174|Drug|Afatinib|afatinib starting at 30 mg daily dose
75341081|NCT02132468|Drug|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
75341082|NCT01507987|Device|Implanted with one or more of the following SJM leads: Riata leads, RiataST leads, Durata leads, and QuickSite/QuickFlex leads|"Riata leads implanted between 2002-2009 Riata ST leads implanted between 2006-2009 Quicksite or QuickFlex leads implanted between 2006-2010 Durata leads implanted between 2008-2010~Subjects were followed for three years and cinefluoroscopy imaging was done annually to determine prevalence of externalized conductors or other visual lead anomalies"
75341083|NCT03906578|Dietary Supplement|Vivomixx®|Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus
76088599|NCT02721966|Drug|Secukinumab and Placebo|Placebo matching AIN457
76088600|NCT00553462|Drug|carboplatin|
75341084|NCT03906578|Other|Placebo|Placebo with similar appearance to probiotic
75341085|NCT03265808|Drug|allogeneic human mesenchymal stem cells (allo-hMSCs)|Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
75651308|NCT00679965|Drug|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
75651309|NCT00679965|Drug|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
75651310|NCT00679965|Drug|AN2690 Solution Vehicle|Once daily application for 90 days and 3x weekly for 90 days
75651311|NCT00930644|Drug|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
75651312|NCT05251051|Behavioral|pediatric physical therapy|Pediatric physical therapists will provide weekly home therapy using standard of care/best evidence procedures
75651313|NCT05251051|Other|Care Coordination|A navigator will be assigned who will assist families in obtaining Early Intervention services and other therapy services if needed
75651314|NCT02627469|Behavioral|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
76088601|NCT00553462|Drug|erlotinib hydrochloride|
76088602|NCT00553462|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
76088603|NCT00553462|Radiation|radiation therapy|
76088604|NCT03307278|Biological|House dust mite|As a stimulant to induce inflammasome activation
75341086|NCT03265808|Drug|Placebo|Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
75341087|NCT03195764|Drug|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
75341088|NCT01508455|Drug|Dexmedetomidine|
75651315|NCT02627469|Device|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
75651316|NCT02627469|Device|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
75651317|NCT00796783|Drug|Cushing's syndrome confirmation|
75651318|NCT00680277|Dietary Supplement|spirulina ß-carotene|an acute dose of spirulina up to 5 g
75651319|NCT00680277|Dietary Supplement|spirulina ß-carotene|vitamin A value of spirulina ß-carotene
75651320|NCT00794053|Procedure|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
75651321|NCT00680355|Dietary Supplement|golden rice|An acute dose of cooked golden rice containing ~ 1 mg of ß-carotene
76088605|NCT02989090|Other|Receive Detailed ICD Information-electronic|Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control
75651322|NCT00680355|Dietary Supplement|corn oil 0g|0 g of corn oil in the golden rice meal
76088606|NCT02989090|Other|Receive Detailed ICD Information-paper|Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
75341089|NCT01508455|Drug|Midazolam|
75341090|NCT01508455|Drug|Fentanyl|
75341091|NCT01508455|Drug|Morphine|
75341092|NCT03127982|Behavioral|Unified Protocol|The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
75341093|NCT03114254|Drug|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days."
75651323|NCT00680355|Dietary Supplement|corn oil 10g|10g corn oil in the golden rice meal
75341094|NCT01509625|Drug|Fulvestrant|It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.
75341095|NCT04081922|Procedure|Erector spinae plane block|Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.
75341096|NCT02482428|Drug|Investigational Treatment|Applied twice daily for up to 12 weeks
75341097|NCT02482428|Drug|Aldara|Applied 3 times a week for 16 weeks
75341098|NCT04054076|Device|Prefabricated insoles|The participants received prefabricated insoles
75341099|NCT04054076|Device|Soft custom-made insoles|The participants received soft custom-made insoles
75341100|NCT04054076|Device|Hard custom-made insoles|The participants received hard custom-made insoles
75651324|NCT00680355|Dietary Supplement|coren oil 5 g|golden rice meal with 5 g corn oil
75651325|NCT00801697|Biological|DNA Vaccine|4 mg VRC-HIVDNA044-00-VP administered as 1 mL
75651326|NCT00801697|Biological|DNA Vaccine placebo|1 mL VRC-PBSPLA043-00-VP
75474703|NCT01986426|Drug|LTX-315|"Dose escalation:~Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection"
75474704|NCT01986426|Drug|LTX-315 + ipilimumab|Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
75474705|NCT01986426|Drug|LTX-315 + pembrolizumab|Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
75474706|NCT01986452|Device|CPAP therapy|
75474707|NCT01986452|Other|Support|
75474708|NCT01986465|Drug|Depomedrol|
75651327|NCT00801697|Biological|rAd35|VRC-HIVADV027-00-VP 1 x 10^10 PU administered as 1 mL
75651328|NCT00801697|Biological|rAd35 placebo|1 mL VRC-PBSPLA043-00-0VP
75651329|NCT00801697|Biological|rAd5|4 mg VRC-HIVADV038-00-VP administered as 1 mL
75651330|NCT00801697|Biological|rAd5 placebo|1 mL VRC-DILUENT013-DIL-VP
75651331|NCT02626299|Drug|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
75651332|NCT02626299|Drug|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
75651333|NCT02626299|Other|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
75651334|NCT00794131|Biological|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
75798090|NCT04244162|Diagnostic Test|Cognitive testing|Wide Range Assessment of Memory and Learning (WRAML2), Montreal Cognitive Assessment (MoCA), and Confusion Assessment Method for the ICU -severity (CAM-ICU S) tests.
75798091|NCT04244162|Diagnostic Test|Blood Biomarkers|Inflammatory markers
75798092|NCT04231526|Drug|Pembrolizumab|2 cycles of neoadjuvant pembrolizumab (200mg IV every 21 days)
75798093|NCT04231526|Procedure|Surgery|Standard of care surgery
75798094|NCT04201873|Biological|Dendritic Cell Tumor Cell Lysate Vaccine|Given ID
75798095|NCT04201873|Biological|Pembrolizumab|Given IV
75798096|NCT04201873|Other|Placebo Administration|Given IV
75798097|NCT04201873|Drug|Poly ICLC|Given IM
75798098|NCT04173117|Dietary Supplement|Low energy meal replacement plan (12 weeks)|Low energy meal replacement plan (12 weeks)
76088607|NCT05727228|Other|cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,|p16/Ki67 dual stain cytology, extended genotyping and DNA methylation will be performed from the residual cell-pellet from the HPV-positive screening samples. If no cytology-triage testing is performed as a part of the screening algorithm, a cytology will be performed at inclusion. If any residual material is left after DS, extended genotyping and DNA methylation, it will be stores at -80 degrees for future purposes.
76088608|NCT05727150|Procedure|Reconstruction of Soft tissue defects of head and neck by Supraclavicular artery flap|Supraclavicular artery flap will be used in the reconstruction of traumatic and non-traumatic defects of head and neck.Flap harvesting and reconstruction will be performed under general anesthesia. The defect dimensions are measured and the superficial landmarks for the supraclavicular artery are drawn .The flap will be used as island flap, transposed or interpolated flap depending on the arc of rotation needed to achieve flap inset without tension and flap elevation proceeds from lateral to medial.The flap is rotated and inset into the defect
75798099|NCT04158492|Diagnostic Test|real-time multiplex PCR|Patients will be randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to routine microbiological testing) AND standard diagnosis microbiological procedures
75798100|NCT04158492|Diagnostic Test|Standard diagnostic procedures|Patients who will undergo only the standard microbiological diagnostic procedures: blood cultures, Gram stain and culture sputum when possible, Gram and pleural fluid culture when appropriate, urine determination of the pneumococcal and Legionella pneumophila serogroup antigens type 1. A serological study will be carried out for the etiological agents of atypical pneumonia in the acute and convalescent phases of the infection.
75651335|NCT00684489|Drug|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
75341101|NCT03796754|Behavioral|YoBEKA|The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
75798101|NCT04147858|Drug|NYX-2925|NYX-2925 administered orally
75341102|NCT02319824|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
75936078|NCT03187808|Other|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
76088609|NCT02988388|Procedure|Lung biopsy/lobectomy|Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
75341103|NCT02319824|Other|Laboratory Biomarker Analysis|Correlative studies
75341104|NCT02319824|Radiation|Palliative Radiation Therapy|Undergo palliative radiation therapy
75341105|NCT01510327|Device|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
76088610|NCT03307122|Other|Routine Infant Formula 1|Routine infant formula with probiotic
76088611|NCT03307122|Other|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
75798102|NCT04147858|Drug|Placebo|Placebo administered orally
76088612|NCT03306966|Device|Endoscopic Linear Cutter Stapler and Reloads (Frankenman)|The Single Use Endoscopic Linear Cutter Stapler and Reloads from Frankenman received CE-mark in April 2013. It is used to staple and simultaneously divide tissue from the central line.
75798103|NCT04146896|Drug|NYX-2925 50 mg|NYX-2925 administered orally
75341106|NCT01510327|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
75341107|NCT01510327|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
75474709|NCT01986465|Drug|Placebo|
75474710|NCT01986491|Drug|JNJ 39393406 30 mg solid X|Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
75798104|NCT04146896|Drug|Placebo|Placebo administered orally
75936638|NCT03178682|Diagnostic Test|ultrasound parameters|ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss.
75341108|NCT01401595|Drug|escitalopram oxalate|The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
75936079|NCT02443064|Drug|Vancomycin|"Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.~Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on."
76088613|NCT03301974|Procedure|conjunctival autograft with fibrin glue|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
76088614|NCT03301974|Procedure|sutured conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
75341109|NCT01511809|Drug|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
75341110|NCT02480712|Drug|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
75341111|NCT02678156|Device|Lyoplant Onlay|
76088615|NCT03301974|Procedure|sutureless and glue-free conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
76088616|NCT03306888|Other|Physical Activity Coaching|Physical activity coaching over 4 months
76088617|NCT03306810|Other|AG service|The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
76088618|NCT02468388|Other|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
75341112|NCT01512667|Drug|MK-0822|A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
75341113|NCT03916094|Drug|HLX22|Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
75341114|NCT03628976|Other|tVNS|Intervention
75341115|NCT03628976|Other|Motor training|Same finger training for both arms
75341116|NCT00115700|Drug|Cyclophosphamide|1000 mg/m2 I.V. on day 1
75341117|NCT00115700|Radiation|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
75341118|NCT00115700|Drug|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
75798105|NCT04146285|Drug|BAT4406F|"Open-label dose escalation starting from 20mg.~Route of administration: intravenous infusion."
75798106|NCT04142398|Other|Cytology Specimen Collection Procedure|Undergo penile skin cell and anal swab collection
75798107|NCT04142398|Procedure|High Resolution Anoscopy with Biopsy|Undergo HRA with biopsy
76088619|NCT02468388|Other|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
76088620|NCT02468388|Other|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
75341119|NCT00115700|Drug|Prednisolone|50 mg/m2 orally daily for days 1 - 5
75341120|NCT00115700|Drug|Rituximab|375 mg/m2 IV Infusion day 1
75798108|NCT04142398|Other|Laboratory Biomarker Analysis|Correlative studies
75798109|NCT04142398|Procedure|Medical Examination|Undergo anal and penile clinical exam
75798110|NCT04142398|Procedure|Physical Examination|Undergo targeted physical exam
75798111|NCT04142398|Other|Questionnaire Administration|Ancillary studies
75798112|NCT04120480|Diagnostic Test|Pharmacogenomic test|The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.
76088621|NCT03306732|Drug|Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline|"After anesthesia induction~After separation from CPB~On the evening of the day of surgery (22:00)~On POD 1 twice a day at 8:00 and 22:00~On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
76088622|NCT03306732|Drug|Normal saline (100ml)|"After anesthesia induction~After separation from CPB~On the evening of the day of surgery (22:00)~On POD 1 twice a day at 8:00 and 22:00~On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
75936080|NCT02433938|Procedure|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
76088623|NCT03306654|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
75936081|NCT02433938|Procedure|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
75341121|NCT01553539|Drug|therapeutic angiotensin-(1-7)|Given SC
75341122|NCT01553539|Other|laboratory biomarker analysis|Correlative study
75341123|NCT05566171|Dietary Supplement|Activia Probiotic Yogurt|Activia probiotic Yogurt will be consumed by participants in this group
75474711|NCT01986491|Drug|JNJ 39393406 30 mg solid Y|Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
75651336|NCT00684489|Drug|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
75651337|NCT00684801|Other|questionnaire administration|Patients complete questionnaires.
75798115|NCT04092504|Other|gero-erat|"The intervention is a standardize Care Plan which will be developed based on the evidence of caring for eldery patients in a trauma setting. The Care Plan will have its base in, the concept of ERAS and CGA. Also, patient experience will be taken in consideration and complement the care pathway.~Patients admitted to the trauma unit will be given the care and asked to be a part of the study witch include to fill out surveys at baseline, six months and 1 year."
75936082|NCT02741271|Drug|MF MDI 100 mcg BID (Open Label)|Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.
75936083|NCT02741271|Drug|MF/F MDI 100/10 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.
75936084|NCT02741271|Drug|MF MDI 100 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.
75936085|NCT02741271|Drug|Albuterol/Salbutamol PRN|Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
75936086|NCT02741271|Drug|Prednisone/Prednisolone|Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
76088624|NCT03306498|Drug|Aminoleban (8% amino acids infusion)|Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
76088625|NCT02468310|Other|Maternal and neonatal emergency protocols|Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
76088626|NCT02809014|Other|Dentifrice F-Complex|Use of few of dentifrice on brushing for one week, twice day.
76088627|NCT02809014|Other|Dentifrice F-Complex + NaF|Use of few of dentifrice on brushing for one week, twice day.
75651338|NCT00684801|Procedure|quality-of-life assessment|Patients undergo quality-of-life assessments.
75798116|NCT04080232|Device|lung MRI|lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.
75798117|NCT04072887|Drug|QBW251|QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks
75798118|NCT04072887|Drug|Placebo|Placebo oral capsules administered twice a day for 24 weeks
75798119|NCT04072887|Drug|COPD maintenance background therapy|Combination of fluticasone furoate, vilanterol and umeclidinium bromide
76088628|NCT02809014|Other|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
75341124|NCT00557882|Device|synthetic polypropylene mesh|Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
75936087|NCT02443142|Drug|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
75936088|NCT02443142|Drug|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
75936089|NCT02442908|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
75936090|NCT02442908|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
75936091|NCT02439242|Drug|fluid challenge of saline|250 ml of saline
75936092|NCT02439008|Procedure|Blood samples collection before radiotherapy|"Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.~Before radiotherapy:~Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy"
76088629|NCT02809014|Other|Dentifrice with tara gum|Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
75474712|NCT01986491|Drug|JNJ 39393406 120 mg solid X|Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
75651339|NCT00990821|Drug|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
75651340|NCT00990821|Drug|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
75651341|NCT00990821|Drug|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
75651342|NCT00990821|Drug|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
75651343|NCT00990821|Drug|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
75651344|NCT00990821|Drug|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
75651345|NCT00990821|Drug|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
75651346|NCT00990821|Drug|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
75936093|NCT02439008|Procedure|Blood samples collection during radiotherapy|"Sample T1: within 15 minutes after the administration of the first fraction,~Sample T2: within 15 minutes after the administration of the second fraction,~Sample T3: within 15 minutes after the administration of the third fraction"
75936094|NCT02439008|Procedure|Blood samples collection after radiotherapy|"Sample T4: one week after the end of the radiotherapy,~Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy."
75341125|NCT03848000|Other|Exercise Programme|Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.
75341126|NCT03848000|Behavioral|NHS Standard Care|Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
75341127|NCT01555567|Device|Electrical Stimulation|Electrical stimulation will be delivered 2 times per week
75341128|NCT01555567|Other|Eccentric Exercise|Eccentric Exercise will be delivered 2 times per week
75341129|NCT01555957|Drug|intravenous lipid|intravenous given daily for 6 weeks
75341130|NCT03243890|Dietary Supplement|Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).|Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
75341131|NCT03243890|Dietary Supplement|Placebo|Half of the patients are randomized to placebo treatment (no active treatment).
75341132|NCT03750500|Device|Biofeedback device|12-week exercise program performed through the device
75651347|NCT00990821|Drug|Placebo|Placebo matching MK-0517
75651348|NCT00990821|Drug|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
75651349|NCT00990821|Drug|125 mg Aprepitant|Aprepitant oral tablet, single dose
75341133|NCT03750500|Behavioral|Education on falls risk|Education on falls risk factors and how to minimize them
75474713|NCT01986491|Drug|JNJ 39393406 120 mg solid Y|Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
75936095|NCT02439008|Radiation|Radiotherapy|
75341134|NCT03750500|Other|Medication review|Medication will be reviewed to reduce sedative drugs and minimize interactions
75341135|NCT03750500|Diagnostic Test|Visual and auditory screening|Patients will go through visual and auditory screening as part of their regular care
75651350|NCT00990821|Drug|2 mg Midazolam|Midazolam oral tablet, single dose
75651351|NCT00801853|Drug|Aerovant|Aerovant 1mg bid (dry powder)
75651352|NCT00801853|Drug|Aerovant|Aerovant 3mg bid (dry powder)
75651353|NCT00801853|Drug|Aerovant|Aerovant 10mg bid (dry powder)
75798120|NCT04028609|Behavioral|Healthy at Home|In addition to receiving medical services as usual, subjects receive services from Community Healthy Workers during the transition from the hospital to their community residence.
75798121|NCT04028609|Other|Services as Usual|Routine medical services
75936096|NCT03524079|Drug|Ajmaline 17-(Chloroacetate) Monohydrochloride|Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
75936097|NCT03528525|Other||observation
75341136|NCT00560612|Drug|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
75341137|NCT00560612|Drug|Placebo|Placebo: same as paroxetine (active comparator)
75341138|NCT01556347|Drug|Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis|
75341139|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
75341140|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
75341141|NCT03236792|Drug|Ixazomib|3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle
75341142|NCT03236792|Drug|Cyclophosphamide|300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
75341143|NCT03236792|Drug|Dexamethasone|20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
75341144|NCT03725384|Drug|Ferrous Sulfate 300Mg Tablet|oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
75341145|NCT03725384|Drug|Vitamin C 500Mg tablet|Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
75474714|NCT01986491|Drug|JNJ 39393406 30 mg solution|Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
75474715|NCT01986517|Behavioral|No feedback|Therapists will receive no feedback.
75474716|NCT01986517|Behavioral|Feedback after every fourth session|
75474717|NCT01986530|Dietary Supplement|Boost|After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion
75651354|NCT00801853|Other|placebo|placebo control (dry powder)
75651355|NCT00990665|Device|CRT-D and LV lead (Quartet™ lead and Promote Q® device system)|Promote Q CRT-D and Quartet LV lead
75651356|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, for six weeks
75651357|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|20 mg, tablet, once daily by mouth, for six weeks
75651358|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|Placebo, tablet, once daily by mouth, for six weeks
75651359|NCT00875433|Drug|BIBW 2992|patients to receive continuous oral daily dosing of BIBW 2992
75798122|NCT03972813|Behavioral|Broadened information about cancers|Caregivers receive information that HPV causes more than just cervical cancer.
75798123|NCT03972813|Behavioral|Information about STDs|Caregivers learn that HPV is an STD.
75798124|NCT03972813|Behavioral|Information about infectious disease|Caregivers learn that HPV is infectious (but information that it is an STD is omitted).
75798125|NCT03972813|Behavioral|Recommendation for children 12 years old|Caregivers are prompted to get their child vaccinated when the child is 12 years old.
75798126|NCT03972813|Behavioral|Recommendation for children 18 years old|Caregivers are prompted to get their child vaccinated when the child is 18 years old.
75341146|NCT01556425|Drug|Vivitrol|Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
75341147|NCT01556425|Behavioral|Employment-based opiate abstinence reinforcement|This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
75341148|NCT01556425|Other|Usual Care Control|Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
75341149|NCT01798628|Drug|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
75341150|NCT01798628|Drug|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
75341151|NCT01798628|Drug|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
75341152|NCT01513447|Drug|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
75341153|NCT00562328|Biological|Alemtuzumab|"Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week."
75651360|NCT04292093|Behavioral|Home rehabilitation training|The rehabilitation training will be provided via Lumosity platform. Participants will be asked to play computer video-games aimed at strengthening specific sub-functions pertaining to the macro area of executive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. Specifically, 20 games out of a total of 64 available games provided by the platform have been selected. The selected games are aimed at training 4 cognitive skills: memory, attention, cognitive flexibility and problem solving. In particular, 5 different games were chosen for each cognitive ability.
75651361|NCT04292093|Behavioral|Home control activity|The control group will watch a series of animated / TV shows suitable for the sample age, again for 30 minutes a day, 5 days a week, for 8 weeks. The videos will be provided by the experimenter and participants will watch them on their personal computer. At the end of each videos, participants will answer a series of multiple-choice questions aimed at evaluating the attention deployed to the content of the videos.
75651362|NCT04291235|Procedure|Airway Management Pathway|Patients in this group will receive several components that comprise airway management pathway: (1) daily spontaneous breathing trials (SBTs); (2) prompt extubation following successful extubation readiness criteria; (3) high-flow nasal oxygen for at least 24 hours following extubation.
75651363|NCT04291235|Procedure|Usual Care|Patients in this group will be treated according to usual care, which may include extubation or tracheostomy timed according to treating physicians' discretion.
75798127|NCT03972813|Behavioral|Standard age information|Caregivers are given information about when the HPV vaccination can be given in China, but no additional recommendations.
75936098|NCT02439086|Device|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
75936099|NCT04694547|Other|There is no intervention, as this is a survey study|Survey
75936100|NCT02438774|Behavioral|post-harvest intervention package|The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
75936101|NCT02438774|Behavioral|Routine agriculture extension services|This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
75936102|NCT02438930|Behavioral|Motivational interviewing intervention during HIV testing|
75341154|NCT00562328|Biological|Rituximab|"Weeks 2-5:~375 mg/m^2 by IV once weekly"
75341155|NCT00562328|Biological|Sargramostim|"Week 1-6:~250 mcg subcutaneously three time as week"
75341156|NCT01514149|Drug|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
75341157|NCT01514149|Drug|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
75341158|NCT03131492|Diagnostic Test|Blood test|C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
75341159|NCT01514383|Device|Cyanoacrylate (Octylseal )|surgical adhesive
75474718|NCT01986530|Other|Aerobic exercise|After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
75474719|NCT01986543|Drug|drug administration|
75651364|NCT00684957|Drug|Recombinant Human Growth Hormone|300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
75651365|NCT00684957|Drug|Recombinant human IGF-1|30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
75651366|NCT02868515|Other|Hot cereal contain 3 g dietary fiber|Intervention involves consumption of a hot cereal over 14 day period
75798128|NCT03972813|Behavioral|Cervical cancer|Caregivers are told that HPV causes cervical cancer.
75798129|NCT03972813|Behavioral|Blank information about communicability|Caregivers are not given any information on how HPV is spread.
75474720|NCT01986556|Drug|Lesinurad 400 mg (Site 1)|
75798130|NCT03947697|Device|Neuromuscular Electrical Stimulation (Sensory)|Group will receive Electrical Stimulation up to sensory level
75798131|NCT03947697|Device|Neuromuscular Electrical Stimulation|Group will receive Electrical Stimulation up to maximum tolerable level
75798132|NCT03947697|Other|Resistance Training|Group will receive exercise training.
75936103|NCT02438930|Behavioral|Standard-of-care counseling during HIV testing|
75474721|NCT01986556|Drug|Lesinurad 400 mg (Site 2, Lot A)|
75936104|NCT03526263|Procedure|Gastric mucosal devitalization|During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
75341160|NCT01556581|Procedure|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
75651367|NCT04898491|Other|Pain assessment using a behavioral scale|"The pain of the subjects will be evaluated by two independent observers and with a blind result between them, coinciding with the application of two painful procedures used in routine practice: suction of tracheal secretions and the pressure in the nail bed by means of a pressure algometer. In addition, a painless procedure will also be performed to establish an element of control with the procedures painful. This will consist of the application of gentle friction with a cloth gauze, on a part of healthy skin tissue of the patient. The measurement will be performed twice for each patient and procedure depending on the level of sedation, so that the first measurement will be performed with a deeper sedation level and the second with a change in sedation level to moderate-mild.~In turn, the pain assessment will be carried out in three moments: first or baseline measurement, during the application of the painless and 15 minutes after finishing the procedures."
75474722|NCT01986556|Drug|Lesinurad 400 mg (Site 2, Lot B)|
75474723|NCT01986569|Drug|[18F]fluoroestradiol (FES)|[18F]FES PET/CT will be performed 90 min (± 10 min) after administration of [18F]FES. Patients will undergo core needle biopsy or surgery within 15 days after [18F]FES PET; or patients will undergo core needle biopsy within 30 days before [18F]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
75474724|NCT01986582|Drug|Oxymetazoline|Intranasal application
75474725|NCT01986582|Other|Hydroxyl-propyl-methyl cellulose powder|Intranasal application
75474726|NCT01986582|Other|Placebo (lactose powder)|Intranasal application
75651368|NCT00685191|Drug|Salvage antiretroviral therapy including raltegravir|Initiation of raltegravir-including salvage antiretroviral therapy
75651369|NCT02626143|Other|Investigational nutrient-rich whey protein formula|
75651370|NCT02626143|Other|Cow's milk based formula|
75936105|NCT02438852|Other|Placebo|Given IV
75936106|NCT02438852|Other|Questionnaire Administration|Ancillary studies
75936107|NCT02438852|Drug|Ropivacaine Hydrochloride|Given IV
75936108|NCT03523845|Other|Observational intervention to diagnose an early apical peri-implantitis|diagnose an early apical peri-implantitis
75936109|NCT02438618|Procedure|Surgery for Ponto bone anchored hearing aids|
75936110|NCT02438696|Drug|BI 1060469, iFF, Test|
75474727|NCT01986608|Drug|Lacosamide infusion|"Strength: 10 mg/mL for infusion~Form: solution for infusion~Dosage: 200 mg, single dose~Duration: 30-minute infusion or 60-minute infusion"
75474728|NCT01986608|Drug|Lacosamide oral|"Strength: 200 mg~Form: film-coated tablet~Dosage: 200 mg, single dose~Duration: single oral intake"
75474729|NCT01986660|Drug|Ibuprofen Cream (SST-0225)|
75474730|NCT01986673|Drug|5% Sildenafil Cream (SST-6006)|5 % Sildenafil Cream
75341161|NCT01556581|Procedure|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
75474731|NCT01986673|Drug|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
75474732|NCT01986699|Procedure|Laparoscopic Assisted Polypectomy|
75651371|NCT00685269|Drug|Eszopiclone|Eszopiclone 3 mg QD
75651372|NCT00685269|Drug|Placebo|Placebo tablet
75651373|NCT00794209|Drug|i.v fentanyl, AeroLEF|"i.v fentanyl~5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas)~5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois)~5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario)~3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device."
75651374|NCT00985985|Drug|Nicotine|2 mg or 4 mg nicotine lozenge
75651375|NCT00985985|Drug|Placebo|placebo lozenge
75798133|NCT03930342|Behavioral|Native-CHOICES|Native CHOICES is a behavioral intervention for prevention of prenatal alcohol exposure in women at high risk for alcohol-exposed pregnancies. The intervention uses motivational interviewing and cognitive-behavioral strategies, and targets adoption of effective contraception and reduction of alcohol use.
75798134|NCT03914794|Drug|Pemigatinib|Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.
75798135|NCT03880513|Diagnostic Test|Cardiovascular status and quality of life|Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment
75798136|NCT03865667|Device|PROFEMUR® Preserve Femoral Stem|Total Hip Total Hip Arthroscopy
75798137|NCT03861195|Procedure|laparoscopic surgery|patients affected by uterine diseases that undergo treatment
75798138|NCT03836300|Behavioral|Parent-Infant Inter(X)action Intervention (PIXI)|Psychoeducation around the diagnosed disorder, early development, and service navigation along with parent-child interaction activities, parent coaching, and family/parent well-being support.
75936111|NCT02438696|Drug|BI 1060469, iFF, Test|
75341162|NCT05566093|Procedure|EUS-guided ethanol ablation|After puncturing with the needle, 95% ethanol under the guidance of EUS was injected into the tumor. The injection volume of ethanol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
75341163|NCT05566093|Procedure|EUS-guided lauromacrogol ablation|After puncturing with the needle, lauromacrogol under the guidance of EUS was injected into the tumor. The injection volume of lauromacrogol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
75341164|NCT05565859|Behavioral|Planetary Health Plate signage|A Planetary Health Plate graphic was developed based on the healthy reference diet proposed by the Eat Lancet Commission. The graphic was designed to capture the food groups and proportions of food groups promoted by the Planetary Health diet.
75474733|NCT01986725|Behavioral|standardized care (Intervention I)|During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
75474734|NCT01986725|Behavioral|Standardized care + WOMAN-PRO II program (Intervention II)|This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
76088630|NCT02466594|Device|Hilotherm Clinic®|Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
76088631|NCT05726760|Behavioral|Seeking informed consent for participation in the study.|The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. The Anaesthetist or researcher will conduct this process. A patient information leaflet will be provided for the parturients.
76088632|NCT05726760|Device|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
75474735|NCT01986738|Radiation|Standard Radiation Therapy|Radiotherapy will be planned and delivered according to institutional standard of care.
75651376|NCT00685347|Drug|Levalbuterol HFA MDI|"levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~Arm #A~Xopenex HFA MDI"
75474736|NCT01986738|Device|Active Breathing Control Device (ABC)|
75474737|NCT01986738|Device|Computed Tomography Scan (CT)|
75474738|NCT01986764|Drug|Lisdexamfetamine|
75474739|NCT01986764|Drug|Estradiol|
75474740|NCT01986764|Drug|Placebo|Placebo capsules will be filled with lactose powder.
75936112|NCT02438696|Drug|BI 1060469, TF1, Reference|
75936113|NCT02438696|Drug|BI 1060469, TF2, Test|
75936114|NCT02438696|Drug|BI 1060469, TF2, Test|
75936115|NCT02438696|Drug|BI 1060469, iFF, Test|
75936116|NCT02438696|Drug|BI 1060469, TF1, Reference|
75936117|NCT02438696|Drug|BI 1060469, iFF, Test|
75936118|NCT02438696|Drug|BI 1060469, iFF, Test|
75936119|NCT02438696|Drug|BI 1060469, TF1, Reference|
75474741|NCT01986777|Drug|lisdexamfetamine|
75474742|NCT01986777|Drug|Placebo|The placebo capsules will be filled with lactose.
75474743|NCT01986803|Device|Percutaneous Coronary Intervention|"Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point."
75651377|NCT00685347|Drug|Racemic Albuterol|"racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~Arm #B~Proventil HFA MDI"
75651378|NCT00796939|Device|Green light mask|Participants will receive approximately 10,000 lux from green light-emitting diodes.
75651379|NCT00796939|Device|Red Light Mask|Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
75936120|NCT02438696|Drug|BI 1060469, TF2, Test|
75936121|NCT02438696|Drug|BI 1060469, TF1, Reference|
75936122|NCT02438696|Drug|BI 1060469, TF1, Reference|
75936123|NCT02438696|Drug|BI 1060469, TF2, Test|
75936124|NCT02438696|Drug|BI 1060469, TF2, Test|
75936125|NCT02438696|Drug|BI 1060469, iFF, Test|
75936126|NCT02438696|Drug|BI 1060469, TF2, Test|
75936127|NCT02438696|Drug|BI 1060469, TF1, Reference|
75936128|NCT03523767|Biological|S.typhi Injection|0.5 ml of S.typhi injection
75936129|NCT03523767|Biological|Normal Saline Injection|0.5 ml of normal saline injection
75936130|NCT05509803|Behavioral|PE Audit and Feedback Tool|The intervention consists of a Physical Education (PE) Audit and Feedback tool, which was adapted from work done through the PE Works program in the New York City Department of Education. A district-level PE program leader in Oakland Unified School District will deliver the tool, which consists of auditing the current status of PE in intervention schools, providing feedback on the status to help improve PE, and providing technical assistance to bring schools up to code and ensure support for PE programming.
76088633|NCT05726760|Device|Covidien Mon-a-Therm skin temperature probes will be applied to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher will conduct the intervention in theatre. The probes will be removed in the recovery ward.
76088634|NCT05726760|Device|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the ear.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
76088635|NCT03301818|Device|Vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
76088636|NCT02468544|Other|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
75474744|NCT01986842|Dietary Supplement|Protein diet|Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
76088637|NCT04491162|Other|Body weight support treadmill training + conventional therapy|"Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.~Patients in intervention arm were additionally trained with a 40% body weight support and a comfortable walking speed on treadmill for twenty minutes. The training, which was conducted three times a week, for period of two weeks."
75651380|NCT00685425|Drug|Levalbuterol HFA MDI|"levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~Arm #A~Xopenex HFA MDI"
75474745|NCT01986868|Other|Coronary MR Angiography (CMRA)|Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.
75651381|NCT00685425|Drug|Racemic Albuterol|"racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~Arm #B~Proventil HFA MDI"
75798139|NCT03785678|Biological|Tenecteplase|The investigational medicinal product (IMP) for this study is tenecteplase. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose should be administered over 5 seconds based on patient weight.
75798140|NCT03785678|Other|Placebo|Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard of care guidelines support use out to 4.5 hours.
75798141|NCT03774719|Device|Hand-carried ultrasound|Hand-carried ultrasound of both kidneys to detect the presence or absence of hydronephrosis. Device used will be the lumify portable ultrasound equipped with the C5-2 curved array transducer (Philips, USA).
75936131|NCT02442674|Drug|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days"
76088638|NCT04491162|Other|Conventional therapy|Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.
75798142|NCT03748420|Other|Adherence-enhanced clinical decision support|Clinical decision support system integrating electronic medication data with claims data on prescription fills
75936132|NCT02442674|Other|Placebo|Placebo tablet matching active drug
75936133|NCT02442752|Drug|Dexlansoprazole|Dexlansoprazole capsules
76088639|NCT02467764|Other|Retrospective study|
76088640|NCT04491318|Other|Observational|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
76088641|NCT05726526|Device|VIEWER virtual care platform|VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
76088642|NCT00553150|Drug|everolimus|
75936134|NCT03523689|Procedure|Bronchoscopy|Undergo bronchoscopy
75936135|NCT03523689|Procedure|Radial Probe Endobronchial Ultrasound|Undergo RP-EBUS
75936136|NCT02442518|Procedure|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
76088643|NCT00553150|Drug|temozolomide|
76088644|NCT00553150|Radiation|radiation|
75474746|NCT01986894|Drug|Placebo|Single oral dose of Placebo
75474747|NCT01986894|Drug|Pomalidomide|Single oral dose of 4 mg pomalidomide
75474748|NCT01986894|Drug|Pomalidomide|Single oral dose of 20 mg pomalidomide
75474749|NCT01986894|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
75474750|NCT01986959|Procedure|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
75474751|NCT01986959|Procedure|Without Periodontal dressing|The dressing was not inserted.
75651382|NCT04290455|Device|Microblepharoexfoliative procedure with BlephEx™|The device will be used to clean both upper and lower eyelid in the office visit.
75651383|NCT04290455|Procedure|Eyelid cleansing with eyelid wipes (Optase)|Eyelid cleansing will be done with eyelid wipes (Optase) by one clinician
75651384|NCT04290455|Procedure|Daily eyelid cleansing with eyelid wipes (Optase)|Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
75651385|NCT00794287|Other|Taking blood samples|No intervention is done. Only blood samples are taken.
75936137|NCT03523611|Procedure|Lung Resection|Lung resection surgery
76088645|NCT03301662|Diagnostic Test|chest and thumb- ECG|chest and thumb- ECG using the Coala Heart Monitor
75651386|NCT00685503|Drug|Ranibizumab|
76088646|NCT03301584|Other|Enhanced collaboration to promote patient participation|"Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
76088647|NCT03301584|Other|Usual Care treatment|The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
75474752|NCT01986972|Other|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
75341165|NCT01557595|Device|Polarized glasses designed to filter out blue light|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so."
75474753|NCT01986972|Other|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
76088648|NCT03306186|Device|HemoSpec|Blood sampling for analysis
75651387|NCT00802009|Drug|Dexamethasone|Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
75936138|NCT02442362|Drug|paclitaxel+oxaliplatin+fluorouracil|"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."
75936139|NCT02442362|Drug|oxaliplatin+S1|"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area < 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"
75936140|NCT04440488|Biological|ARALAST NP|Partcipants will be randomized to receive ARALAST NP 60 or 120 mg/kg BW/week IV infusion for a total of 104 weeks.
75936141|NCT03523533|Procedure|Angiocatheter|Placement of angiocatheter in internal jugular vein
76088649|NCT03301428|Other|Retrain pain educational website|Patients in this group will be invited to consult an educational website developped for patients with chronic pain
75936142|NCT03187574|Device|Elevate Ant™|Surgery with Elevate Ant™
75936143|NCT03187574|Device|Perigee™|Surgery with Perigee™
75936144|NCT04468581|Behavioral|Use of mobile application|Use of the TraceTogether mobile application during the COVID-19 period
75936639|NCT03181334|Behavioral|Branch I|FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
76088650|NCT03301428|Other|Booklet|Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
75651388|NCT00802009|Drug|Mepivicaine|Standard anesthetic solution administered during routine brachial plexus nerve blockade.
75651389|NCT02868437|Device|intrauterine self-cross-linked hyaluronic acid gel|intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
75651390|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
75341166|NCT02127710|Drug|AZD6094|AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
75651391|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
75798143|NCT03748420|Behavioral|ReachOut Adherence intervention|The pharmacist outreach intervention is based on the theoretically grounded and evidence-based Information-Motivation-Behavioral framework endorsed by the World Health Organization to improve adherence
75798144|NCT03729804|Drug|Carfilzomib|"Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.~Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24."
75798145|NCT03729804|Drug|Lenalidomide|"Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24."
76088651|NCT03026218|Other|GlucoseMama application with blood sugar monitoring and carb monitoring.|We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.
75341167|NCT01558063|Drug|Ketamine|Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.
75341168|NCT01558063|Drug|Saline|Single infusion of saline given intravenously over 40 minutes.
75341169|NCT01558063|Procedure|Magnetic Resonance Imaging (MRI)|90-minute scan during the 40-minute infusion.
75341170|NCT01515943|Other|Active home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed 15 minutes/day of active home-based computer therapy for 5 days/week during the 12 week treatment phase. Active home-based computer therapy will be provided the Home Therapy System (HTS) computer software and will include both fusional vergence and accommodative therapy. Subjects will perform the computer therapy while wearing red/blue glasses and accommodative therapy will be performed using the HTS accommodative flippers. Please refer to the procedures manual for further details.
75341171|NCT01515943|Procedure|Near target push-ups|At enrollment, subjects will be prescribed 15 minutes/day (3 sessions of 5 minutes each) of near target push-ups (NTP) for 5 days/week during the 12-week treatment phase. An alphabet pencil will be used as the target and an index card placed in the background will provide physiological diplopia control. With the pencil positioned at arm's length directly between the subject's eyes, the subject will slowly bring the pencil toward his/her nose while focusing on the small letter on the pencil. When the subject is no longer able to maintain a single image of the pencil, he/she will slowly move the target away from the nose until the pencil becomes single again. This procedure will be repeated several times. Please refer to the procedures manual for further details.
75341172|NCT01515943|Other|Placebo home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed either 5 minutes/day (NTP group) or 15 minutes/day (Placebo group) of placebo home-based computer therapy for 5 days/week during the 12 week treatment phase. Placebo computer-based therapy will be provided by the Home Therapy System (HTS) computer software. The vergence procedures are similar to the active version, however, the tasks will be modified to ensure no demand on the vergence system and no accommodative therapy is included in the placebo version. Please refer to the procedures manual for further details.
75341173|NCT01515943|Procedure|Placebo yoked prism flippers|"Subjects will be prescribed 5 minutes/day of placebo yoked prism flipper therapy for 5 days/week during the 12 week treatment phase. This procedure utilizes a 4 pd base right/4 pd base left prism flipper and Accommodative Hopping Cards. Subjects view the text on the card through the prisms at 40 cm, perform the appropriate task and then flip the prism flipper to the other side after each word before proceeding to the next line. Please refer to the procedures manual for further details. The task remains constant, but the nature of the procedure changes with time:~Weeks 1-4: View the target through prism flippers~Weeks 5-8: Wear red-blue filter glasses while viewing the text through prism flippers~Weeks 9-12: Wear polaroid glasses while viewing the text through prism flippers"
75341174|NCT03670784|Other|No intervention|No intervention, epidemiological investigation
75341175|NCT01798238|Drug|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
75651392|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
75651393|NCT00802087|Drug|hydrocodone|Extended Release tablet
75651394|NCT00802087|Drug|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
75936640|NCT03181334|Behavioral|Branch II|"FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week."
75651395|NCT04291157|Other|CVD risk estimation incorporating the PRS and guideline based preventive interventions.|Total CVD risk estimation using SCORE plus PRS and European Society of Cardiology (ESC) CVD prevention guideline based interventions.
75651396|NCT04291157|Other|Standard GP care|Usual GP care (opportunistic CVD prevention)
75936641|NCT03181334|Behavioral|Branch III|"FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks."
76088652|NCT03026218|Other|Group prenatal care for GDM.|group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
76088653|NCT03306108|Device|NRT|NRTratio is based on each individual electrode's ECAP threshold and can identify the intracochlear electrode array position in perimodiolar electrodes. The NRT-ratio showed a good reliability for the determination of the intracochlear electrode array position compared to the radiologic control intraoperatively Calculation of the NRT-ratio is done by dividing the arithmetic average of the t-NRT values from the apical electrodes 16 to 18 divided by the arithmetic average of the basal t-NRT from electrodes 5 to 7. With a NRT-ratio above 1.05, a high chance of a scalar change was rather likely, and a NRT-ratio below 1.05 was associated with a high chance of an electrode array position within the scala tympani.
75651397|NCT04139811|Other|Pars Plana Vitrectomy|vitrectomy with and without ILM peeling
75651398|NCT00923936|Drug|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles.
75651399|NCT00923936|Drug|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
75798146|NCT03729804|Drug|Dexamethasone|"Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24."
75798147|NCT03729804|Drug|Bortezomib|Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.
75341176|NCT01798238|Drug|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
76088654|NCT03306030|Drug|Split dose of 4L PEG|All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
75341177|NCT02857400|Other|current standard of care|connection documentation faxed to GP (General practitioner) on the day of patient's discharge
75341178|NCT02857400|Other|CREDO standard of care|"organized consultation return home between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP"
75798151|NCT03705000|Device|Slit Stent II|The Slit-Stent II device is created by modifying the BIKA for DCR lacrimal stent through the addition of a center slit, 12 ± 1.5 mm in length, and two lateral slits 32 ± 4.5 mm in length, each having identical depth measurements to facilitate the drainage of tears. The BIKA for DCR is a sterile, single-use device that is FDA cleared as part of the BIKA family of devices under K911109..There are no changes to the raw materials used in making the modifications to the BIKA for DCR during the manufacturing of the Slit Stent II.
75341179|NCT05565781|Device|ECG smartwatch|Testing ECG smartwatch
75651400|NCT04121351|Other|Singing participation|Participants will follow a 15 minute protocol consisting of the components of a Singing for Lung Health class, and a short period walking on a treadmill.
75651401|NCT00797017|Drug|fentanyl|Infection, starting with 12mcg/h (flexible dose)
75651402|NCT00797017|Drug|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
75651403|NCT00797017|Drug|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
75651404|NCT00797017|Drug|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
75651405|NCT00797017|Drug|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
75798152|NCT03705000|Device|BIKA for DCR|The BIKA for DCR lacrimal stent is a bicanalicular intubation device used for intubation of the lacrimal drainage apparatus, especially in cases of dacryocystorhinostomy (conventional or laser). The silicone tube acts as a conformer during the healing process while facilitating drainage of tears through capillary action around the stent. In cases of canalicular lacerations, the silicone tube guides wound healing and prevents the onset of synechia. The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device
75936145|NCT02433860|Behavioral|pharmacist nicotine cessation counseling using SCRIPT protocol|"Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately > 36 weeks gestation or at delivery."
75936146|NCT04468503|Other|Two differnt protien prescription (ig per kg per day and 2g per kg /day )will be assigned to each group interventional|In this study intervention will be the dose of protein, one group will be prescribed with the protein dose (1 g/kg/day) and other group will be on prescribed higher dose (2gm/kg/day) of protein according to the ASPEN guideline for critically ill and the energy requirements (other than proteins) will be 25 kcal/kg of adjusted body weight (Picolo et al.,). Each subject in the trail will provide remaining medical nutrition therapy according to the therapeutic guidelines in the field. The medical nutrition management other than protein will be adjust according to need of each patient.
75341180|NCT05565781|Device|Insertable Cardiac Monitor (ICM)|Gold-standard cardiac monitor for comparison of testing device (ECG smartwatch)
75341181|NCT05565781|Device|External ECG Monitoring|Regular cardiac monitor for diagnosis of atrial fibrillation
75341182|NCT03641846|Other|DornierAries2 LiST device + 5 mg Tadalafil|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
75341183|NCT03641846|Other|DornierAries2 LiST device + Placebo Pill|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
75341184|NCT05560724|Device|Transcranial direct current stimulation (tDCS)|Anodal stimulation or sham
75341185|NCT02490722|Other|Patient education|Four times two hours group based patient education
75341186|NCT02241980|Other|Patient survey|
75651406|NCT00797017|Drug|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
75651407|NCT00797017|Drug|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
75651408|NCT02626221|Other|Non Interventional Study|Non Interventional Study
75651409|NCT02868359|Other|No Intervention|The study is observational.
75651410|NCT05330000|Drug|4 mg/kg Voriconazole|Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
75341187|NCT02241980|Other|Physician survey|
75651411|NCT05330000|Drug|6 mg/kg Voriconazole|High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
75651412|NCT00794443|Drug|YM529 / ONO-5920|Oral
75798153|NCT03697564|Drug|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 Q4W
75798154|NCT03697564|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV on Day 1 Q4W
75798155|NCT03697564|Drug|Cabiralizumab|4mg/kg IV on day 1 and 15 Q4W
76088655|NCT03306030|Drug|Three times dose of 4L PEG|The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
76088656|NCT03193996|Device|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
76088657|NCT02495610|Other|Gait analysis and MRI:|"Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.~MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
76088658|NCT05726448|Behavioral|Telehealth solution|Mobile-friendly nutrition education platform
76088659|NCT04754152|Other|θ burst transcranial magnetic stimulation|In addition to drug therapy, TBS supplementary therapy was given every 3 months.The TBS parameters were as follows: 3 pulses, 50 Hz bursts given every 200 ms (at 5 Hz), and an intensity of 70% of the resting motor threshold, as measured from the right first dorsal interosseous muscle using a handheld 70 mm figure-of-eight coil. Take a course every 10 weeks .
76088660|NCT04754152|Drug|Pharmacotherapy|Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
75651413|NCT04139889|Diagnostic Test|Confocal Laser Endomicroscopy|"Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm."
75651414|NCT00924950|Drug|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
75936147|NCT03523455|Dietary Supplement|Iron Aid IPS (Iron Protein Succinylate)|Taken orally in capsule form
76088661|NCT03141346|Behavioral|Sugar reduction health education program|A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
75651415|NCT00924950|Drug|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
75651416|NCT00685737|Drug|1-MNA|Capsule
75651417|NCT00685737|Drug|Placebo|Capsule
75936148|NCT03523455|Other|Sugar Pill|Taken orally in capsule form
75936149|NCT03189836|Biological|ACTR707|autologous T cell product
76088662|NCT03141346|Behavioral|Control health education program|Control health education program provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
76088663|NCT03141346|Other|Home water delivery|Home delivery of bottled water administered over 24 months
75651418|NCT04291547|Device|BALM|An online Behavioural Activation programme for young people with mild to moderate low mood/depression. The programme comprises 10 treatment sessions lasting 30 to 45 minutes
75651419|NCT00797251|Procedure|Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.|The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
75651420|NCT02868203|Device|OCT|OCT after stent implantation
75651421|NCT02868203|Device|eLuting stent|
75936150|NCT03189836|Biological|rituximab|CD20-directed cytolytic antibody
75936151|NCT03523299|Procedure|Cryoablation|Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
76088664|NCT04630834|Drug|Ibuprofen|Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
76088665|NCT04630834|Drug|Acetaminophen|patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg
75651422|NCT00685815|Drug|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc NS IV over one hour, once on Day 3, once on Day 4
75936152|NCT03190226|Procedure|L-PRF membranes|split-mouth design, randomized L-PRF membranes vs. free gingival graft
75936153|NCT03190226|Procedure|Free Gingival Graft|split-mouth design, randomized L-PRF membranes vs. free gingival graft
76088666|NCT04630834|Drug|Placebo|patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
76088667|NCT03301350|Drug|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
76088668|NCT03301350|Drug|Paclitaxel|Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
75651423|NCT00685815|Drug|Placebo|250cc NS IV over one hour, once on Day 3, once on Day 4
75651424|NCT00802165|Device|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
75651425|NCT00802165|Device|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
75651426|NCT04881188|Diagnostic Test|Survey|Patients with chronic low back pain in in-patient multimodal pain therapy. Three survey times, questionnaires
75341188|NCT02118662|Other|Energy Expenditure during seated in an office chair|You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
75474754|NCT01986998|Drug|Methylprednisolone 1250 mg/24h x3 days|Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
75651427|NCT02553889|Drug|ISIS 416858|subcutaneous injection
75798156|NCT03690011|Genetic|CD7.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10^7 cells/m^2~Dose level two: 3×10^7 cells/m^2~Dose level three: 1×10^8 cells/m^2"
75798157|NCT03662126|Drug|KRT-232|KRT-232, administered by mouth
75798158|NCT03662126|Drug|Best Available Therapy (BAT)|"Best available therapy options include:~hydroxyurea~chemotherapy or~supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed)."
75798159|NCT03658616|Drug|WO3970|Application of cream to each axilla
75474755|NCT01986998|Drug|Oral Methylprednisolone 625 mg/24h x3 days|Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
75798160|NCT03658616|Drug|Placebo (WO3988)|Application of cream to each axilla
76088669|NCT03301350|Drug|Doxorubicin|Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
75798163|NCT03565445|Drug|ASP1948|Intravenously (IV)
75798164|NCT03565445|Drug|nivolumab|Intravenously (IV)
75798165|NCT03565445|Drug|pembrolizumab|Intravenously (IV)
75936154|NCT05490927|Behavioral|Microaggression Recall and Relapse Analogue Task|Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task
75936155|NCT03525717|Dietary Supplement|Routine Dinner|Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
75936156|NCT03525717|Dietary Supplement|Late dinner|Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
75341189|NCT02118662|Other|Energy Expenditure during seated and typing|You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
75341190|NCT02118662|Other|Energy Expenditure during Treadmill walking work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
75474756|NCT01987011|Biological|MG1109|
75474757|NCT01987011|Biological|Placebo|
75474758|NCT01987024|Device|Actim Partus® test|
75474759|NCT01987024|Other|usual procedure|
75651428|NCT02553889|Drug|Placebo|subcutaneous injection
75651429|NCT00685893|Behavioral|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
75651430|NCT00685893|Behavioral|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
75651431|NCT00685893|Behavioral|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
75798166|NCT03516812|Other|Laboratory Biomarker Analysis|Correlative studies
75798167|NCT03516812|Drug|Olaparib|Given PO
75798168|NCT03516812|Other|Quality-of-Life Assessment|Ancillary studies
75798169|NCT03516812|Other|Survey Administration|Ancillary studies
75798170|NCT03516812|Drug|Testosterone Enanthate|Given IM
75798171|NCT03516812|Drug|Testosterone Cypionate|Given IM
75798172|NCT03500445|Drug|Daratumumab|"Daratumumab (16 mg/kg) will be administered as an IV infusion:~Cycle 1-2: 16 mg/kg weekly~Cycles 3-8: 16 mg/kg IV infusion every 2 weeks~Cycles 9-24: 16 mg/kg IV infusion Day 1"
75798173|NCT03500445|Drug|Carfilzomib|"Carfilzomib will be given as an IV infusion over 30 minutes:~Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.~Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16~Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16"
75474760|NCT01987037|Behavioral|neuropsychomotor assessment|Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
75474761|NCT01987076|Drug|Prednisone|"Prednisone:~Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days."
75474762|NCT01987076|Drug|Clobetasol|Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
75651432|NCT00685893|Behavioral|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
75651433|NCT00685893|Behavioral|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
75651434|NCT04880174|Diagnostic Test|serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
75651435|NCT04256564|Procedure|Central venous catheterization|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance
75651436|NCT02626065|Biological|blood sampling|Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
75651437|NCT02626065|Drug|Nivolumab|injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
75651438|NCT00794755|Dietary Supplement|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
75936157|NCT03187184|Device|OneOme RightMed®|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
75936158|NCT04466943|Device|Neuromuscular transmission monitoring (NMT)|NMT is to monitor the depth of neuromuscular blockade intensity
75936159|NCT02438462|Other|Soluble Fibrin|Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
75651439|NCT00794755|Dietary Supplement|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
75651440|NCT00685971|Dietary Supplement|5000 IU of cholecalciferol|5 drops taken once daily for 12 weeks
75651441|NCT00685971|Dietary Supplement|placebo|5 drops once daily for 12 weeks
75651442|NCT00802243|Drug|leflunomide|
75651443|NCT00988637|Drug|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
75936160|NCT04466397|Device|3D printed individualized porous implants|Use 3D printed individualized porous implants to reconstruct the large bone defects caused by tumor, infection or trauma.
75936161|NCT02438150|Behavioral|Hospital fire video training|Participants will watch a video about hospital fire training which last for 30 minutes
75936162|NCT02438150|Behavioral|Non hospital fire video training|Participants will watch a video about volcanic eruption which last for 30 minutes
75936163|NCT03212469|Drug|Durvalumab|"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~SBRT at C1D15, then~Durvalumab Q4W alone for up to 9 additional doses"
76088670|NCT03301350|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
75651444|NCT00988637|Drug|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
75936164|NCT03212469|Drug|Tremelimumab|"Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~SBRT at C1D15, then~Durvalumab Q4W alone for up to 9 additional doses"
76088671|NCT03301350|Drug|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
76088672|NCT03301350|Drug|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
76088673|NCT04737304|Drug|BEN2293 (0.25% or 1.0% w/w) or matching placebo|BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
76088674|NCT02466750|Biological|Western Equine Encephalitis (WEE) Vaccine|Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92
76088675|NCT03301194|Other|RAMP-HT|RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
76088676|NCT04735432|Biological|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
76088677|NCT04735432|Biological|efgartigimod IV|Intravenous infusion of efgartigimod
75651445|NCT00802321|Drug|Dutasteride|Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
75651446|NCT00686283|Behavioral|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
75651447|NCT00802399|Procedure|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
75798174|NCT03500445|Drug|Lenalidomide|"Lenalidomide will be taken orally as follows:~• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21"
76088678|NCT04717492|Other|Observational|Observational
76088679|NCT02994160|Other|Fast electrode|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
76088680|NCT02722278|Drug|Oral Testosterone Undecanoate|Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg < 350 ng/dL, decreased if > 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
76088681|NCT02722278|Drug|Axiron Testosterone Topical Solution|"Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg < 350 ng/dL, decreased if > 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL."
76088682|NCT03024034|Drug|TP-271|single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
75341191|NCT02118662|Other|Energy Expenditure during cycling work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
76088683|NCT03305952|Behavioral|CBCT|
76088684|NCT03305952|Other|TAU|
76088685|NCT03305796|Radiation|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
76088686|NCT03305718|Other|Meal sequence: 3C1A2B4D|Participants receive test meals in the sequence 3C1A2B4D
76088687|NCT03305718|Other|Meal sequence: 2A3D4C1B|Participants receive test meals in the sequence 2A3D4C1B
76088688|NCT03305718|Other|Meal sequence: 2D4B3A1C|Participants receive test meals in the sequence 2D4B3A1C
76088689|NCT03305718|Other|Meal sequence: 3B2C1D4A|Participants receive test meals in the sequence 3B2C1D4A
76088690|NCT03305718|Other|Meal sequence: 4C2B1A3D|Participants receive test meals in the sequence 4C2B1A3D
76088691|NCT03305718|Other|Meal sequence:1B4D3C2A|Participants receive test meals in the sequence 1B4D3C2A
76088692|NCT03305718|Other|Meal sequence:4A1C2D3B|Participants receive test meals in the sequence 4A1C2D3B
75798175|NCT03500445|Drug|Dexamethasone|"Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:~Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week~Cycles 9-24: 20 mg PO per week~During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after~During weeks with no daratumumab, single dose of 20 mg on day 1"
75798176|NCT03494530|Drug|Edoxaban 60 MG|Anticoagulant used to treat atrial fibrillation
76088693|NCT03305718|Other|Meal sequence:1D3A4B2C|Participants receive test meals in the sequence 1D3A4B2C
76088694|NCT03305718|Other|Meal sequence: 4D3B2C1A|Participants receive test meals in the sequence 4D3B2C1A
76088695|NCT03305718|Other|Meal sequence: 3A4C1B2D|Participants receive test meals in the sequence 3A4C1B2D
76088696|NCT03305718|Other|Meal sequence: 1C2A3D4B|Participants receive test meals in the sequence 1C2A3D4B
76088697|NCT03305718|Other|Meal sequence: 2B1D4A3C|Participants receive test meals in the sequence 2B1D4A3C
76088698|NCT03300960|Drug|Provera 10 mg.|One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
76088699|NCT03300960|Drug|Ganirelix (GnRH antagonist)|One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
76088700|NCT04583254|Radiation|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental|40 Gy / 15 Fractions EBRT + HDR-Brachytherapy
76088701|NCT04583254|Radiation|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care|45 Gy / 25 Fractions EBRT + HDR-Brachytherapy
75936165|NCT03212469|Radiation|SBRT|"Preliminary steps : Safety Runs~Safety run of the dual combination:~SBRT at C1D15.~Safety run of the triple combination:~SBRT at C1D15.~Efficacy step~Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~SBRT at C1D15, then~Durvalumab Q4W alone for up to 9 additional doses"
76088702|NCT04583254|Drug|Concurrent Chemotherapy|Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
76088703|NCT03305640|Procedure|acetabular fracture surgery|acetabular fracture surgery
76088704|NCT02993146|Other|Laboratory Biomarker Analysis|Correlative studies
75341192|NCT03545282|Behavioral|Amigas Latinas Motivando el Alma (ALMA)|"In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions."
75651448|NCT00686361|Drug|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
75651449|NCT04162925|Behavioral|Cancer screening education for breast, colon and oral cancers|Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening
75651450|NCT00802477|Procedure|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
75651451|NCT00802477|Procedure|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
75651452|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg on alternate weeks
75798177|NCT03494530|Drug|Edoxaban 30 mg|Anticoagulant used to treat atrial fibrillation
75798178|NCT03484208|Other|osteoporotic fracture liaison service|a specific nurse calls patient and propose them to follow the osteoporotic fracture liaison service
75798179|NCT03466736|Diagnostic Test|[18F]flutemetamol PET scan|Each subject will receive an amyloid PET scan with [18F]flutemetamol
75936166|NCT02438228|Other|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
75341193|NCT05560334|Drug|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
75341194|NCT05560256|Other|Diary/Journal|Participants will be given a diary to record their blood glucose measurements, and other pertinent information (diet and activities).
75341195|NCT05560178|Other|SEXUAL HEALTH EDUCATION|Women in the intervention group will be given sexual health education once a week for 4 weeks
75341196|NCT01516957|Drug|AMG 827 140|140 mg AMG 827 SC (subcutaneous)
75341197|NCT01516957|Drug|Placebo|Placebo SC (subcutaneous)
75341198|NCT01516957|Drug|AMG 827 280|280 mg AMG 827 SC (subcutaneous)
75341199|NCT01516957|Drug|AMG 827 210|210 mg AMG 827 SC (subcutaneous)
75341200|NCT03448250|Behavioral|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
75798180|NCT03441100|Drug|IMA202 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
75341201|NCT03448250|Other|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
75341202|NCT01519063|Drug|Naltrexone and memantine first|Naltrexone 50mg memantine 20mg
75341203|NCT01519063|Drug|Naltrexone and Placebo first|Naltrexone 50 mg Placebo
75798181|NCT03441100|Device|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.
76088705|NCT02993146|Other|Pharmacological Study|Correlative studies
76088706|NCT02993146|Other|Quality-of-Life Assessment|Ancillary studies
76088707|NCT02993146|Drug|Ropidoxuridine|Given PO
76088708|NCT02993146|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
76088709|NCT02964442|Other|Capsinoids|12 mg of Gel capsules
76088710|NCT02964442|Other|Cold Stimulus|Cooling vest maintain at 14 degree Celsius
76088711|NCT04768582|Diagnostic Test|P2Y12-reaction-units (PRU) by VerifyNow-P2Y12 assay|The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).
76088712|NCT03300882|Other|Procedure|Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
76088713|NCT02485444|Drug|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
76088714|NCT03300726|Diagnostic Test|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
76088715|NCT03300726|Radiation|Functional MRI|Functional MRI during resting state and semantic memory task activation
76088716|NCT04490538|Diagnostic Test|Transthoracic echocardiography|Conventional transthoracic echocardiographic examination at the intensive care unit.
76088717|NCT04490304|Other|durability of posterior soft tissue repair|how durable is the posterior soft tissue repair after total hip arthroplasty in primary osteoarthiritis patients?
76088718|NCT03305484|Other|No intervention|No intervention, observation only
76088719|NCT02468076|Device|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
76088720|NCT04428346|Behavioral|Incentive payment|Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.
76088721|NCT04490694|Drug|Lenvatinib|Intervention Description：lenvatinib will be administered daily (for patients <60kg, lenvatinib 8mg bid po for patients ≥60kg, lenvatinib 12mg bid po) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
76088722|NCT04490694|Procedure|TACE|Patients will be treated with TACE 2-4 weeks after randomization: the blood supply of the tumor will be evaluated by transradial / femoral artery approach, microcatheter will be inserted into the tumor feeding artery, and lipiodol plus epirubicin emulsifier will be injected (40mg epirubicin will be added to each 10ml lipiodol, the total amount should less than 20ml, epirubicin 40-60mg). Gelatin sponge particles / microspheres are used to strengthen embolization. Blood biochemical examination will be performed within 1 week before TACE, 3 days after operation and 1 month after operation.
76088723|NCT04601584|Biological|Cohort 1, GNR-084|0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
76088724|NCT04601584|Biological|Cohort 2, GNR-084|0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
76088725|NCT04601584|Biological|Cohort 3, GNR-084|1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
76088726|NCT04601584|Biological|Cohort 4, GNR-084|4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
75474763|NCT01987115|Procedure|Fascial manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
75651453|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg every other week
75936167|NCT02442440|Drug|anisodamine|Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
75936168|NCT03187496|Drug|Midazolam|Each subject will receive midazolam on Days 1 and 12.
75936169|NCT03187496|Drug|Caffeine|Each subject will receive caffeine on Days 1 and 12.
76088727|NCT04601584|Biological|Cohort 5, GNR-084|10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
76088728|NCT04601584|Biological|Cohort 6, GNR-084|20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
76088729|NCT02988310|Other|No intervention|
75341204|NCT01559857|Drug|Pioglitazone|30mg once daily for 12 weeks
75651454|NCT00797329|Other|chart review|"cholesterol~cognitive profiles~violent behavior"
75651455|NCT04031235|Behavioral|Sleep Baby, Safe and Snug|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommended safe sleep practices. AAP safe sleep recommendations listed on the back cover.
75651456|NCT04031235|Behavioral|Read Baby, Every Day|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommendations regarding the importance of reading and talking to infants. Recommendations and benefits of reading with infants are listed on the back cover as well.
75651457|NCT00797407|Dietary Supplement|Creatine|Creatine 5 gm orally twice a day for 5 days, followed by 5 gm once a day
75651458|NCT02625987|Procedure|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
75936170|NCT03187496|Drug|Rosuvastatin|Each subject will receive rosuvastatin on Days 2 and 13.
76088730|NCT02988076|Device|PEER Interactive Report|A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
75341205|NCT01559857|Drug|Sugar Pill|Placebo
75341206|NCT01814540|Dietary Supplement|Bovine Milk Oligosaccharide|The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
75341207|NCT01814540|Dietary Supplement|Placebo Glucose Polymer|
75651459|NCT02625987|Procedure|Separated stitches|Appendectomy wound closure with a separated stitches.
75651460|NCT00797485|Biological|bevacizumab|Given IV
75651461|NCT00797485|Drug|capecitabine|Given orally
75651462|NCT00797485|Drug|fluorouracil|Given IV
75651463|NCT00797485|Drug|irinotecan hydrochloride|Given IV
75651464|NCT00797485|Drug|leucovorin calcium|Given IV
75936171|NCT03187496|Drug|EDP-305|Each subject will receive EDP-305 on Days 5 through 15.
76088731|NCT02359474|Drug|Trabectedin|
75651465|NCT00686673|Behavioral|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
75651466|NCT00686673|Behavioral|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
75651467|NCT00686751|Drug|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
75651468|NCT00686985|Drug|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
75651469|NCT00802555|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
75651470|NCT00687141|Drug|AZD0328|Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
75798182|NCT03440047|Device|Fuji Flim Processor VP-7000, Light Source BL-7000|Fujifilm's Digital Video Processor VP-7000 and LED Light Source BL-7000 is a class II Endoscopic Video Imaging System under 21 C.F.R. 876.1500. It is the next generation of Fujifilm's VP-4440HD Digital Video Processor with Flexible-spectral Imaging Color Enhancement (FICE) and Light Source (K140149).
75936172|NCT04440969|Behavioral|Multi-domain intervention|"Participants will undergo dual-task physical exercises and small group activities comprising of quizzes, puzzles and simulate daily living activities that have been gamified (Mindfun and MindGym, ProAge,Singapore). They will also play games on a touch screen device (computerised cognitive training) that aims to improve cognition in the domains of attention, memory, spatial ability, decision making and cognitive flexibility (Memorie, Neeuro, Singapore) while wearing the Senzeband, which emits low frequency signals on the forehead picked up by four individual sensors, allowing participant to play certain games without touching the device but by attention and focus (https://www.neeuro.com/senzeband).~Dietary guidance will be delivered via a dietary app (Glycoleap). Participants are expected to take photos of their meals daily and upload them onto the app. Certified dieticians will give advice and tips on their choice of food and how to make healthier choices through the app."
75936173|NCT03186950|Procedure|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
75936174|NCT03186950|Procedure|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
75936175|NCT02438072|Drug|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
75936176|NCT03184311|Other|High-intensity interval training (HIT)|Supervised 12-week HIT 3 times per week on a bicycle ergometer.
75936177|NCT03184311|Other|Moderate-intensity contiuous training (MCT)|Supervised 12-week MCT 3 times per week on a bicycle ergometer.
75936178|NCT02437994|Behavioral|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
75936179|NCT02437838|Other|No Intervention|No Intervention
75341208|NCT01562041|Drug|Ranolazine 500 mg|Ranolazine 500 mg, oral tablet, b.i.d.
75798184|NCT03397134|Drug|Placebo Oral Tablet|Placebo administered as a single dose once daily
75798185|NCT03397134|Drug|Roluperidone 32 mg|Roluperidone administered as a single dose once daily
75341209|NCT01519453|Behavioral|Home Based Asthma Education|4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
75341210|NCT02210065|Biological|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
75341211|NCT05565547|Device|META|The META device is used for a comprehensive ophthalmic examination.
75798186|NCT03397134|Drug|Roluperidone 64 mg|Roluperidone administered as a single dose once daily
75341212|NCT05565547|Device|Commercial devices|Commercial devices (including near and far eye charts, refractometer, optical biometry, slit lamp microscopy, fundus camera and OCT) are used for a comprehensive ophthalmic examination.
75341213|NCT00634166|Drug|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
75936180|NCT03522987|Drug|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
75651471|NCT00687141|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
75651472|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
75651473|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
75651474|NCT05192083|Behavioral|Self-management and Support|A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
75651475|NCT02866955|Drug|Estramustine|140mg/4 caps/day
75651476|NCT02866955|Drug|Tamoxifen|20mg/day
75798187|NCT03357562|Device|lung MRI|lung MRI without contrast injection
75798188|NCT03324672|Procedure|TRIGGER|only TRIGGER point will be included for the manual therapy
75798189|NCT03324672|Procedure|TRIGGER+CURETAPE|TRIGGER point will be included for the manual therapy with kinesio-taping
75651477|NCT00794911|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
75651478|NCT00794911|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
75474764|NCT01987115|Procedure|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
75798190|NCT03275194|Procedure|HIPEC|Following complete cytoreductive surgery without any evidence of residual disease, the patient will be randomized either HIPEC (intervention) or no-HIPEC (control) in the operative Room. If the arm HIPEC is obtained, then a HIPEC procedure with cisplatin and doxorubicin will be performed. If no-HIPEC (control arm) is assigned then the surgical procedure will be finished.
75936181|NCT02437760|Other|serum and pleural effusion CA-125 level|"serum and pleural effusion(if exist) CA-125 are collected:~at time of diagnosis~every 3 month during treatment~stop at the progression or after 12 months"
75936182|NCT03186872|Behavioral|Digital behavioral program app|mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
75936183|NCT03522909|Other|Seen in clinic|"We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~Primary outcome variable.~- Hospital length of stay~Secondary outcome variables.~Number of admissions from outside hospitals~Adverse outcomes~Intensive Care Unit admissions~Opioid use~NICU admissions~Patient satisfaction~Cost of inpatient admission~Cost of outpatient care~Hospital readmissions rate"
76088732|NCT02359474|Genetic|DNA double-strand breaks|"The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018)."
76088733|NCT02467686|Behavioral|WHOQOL questionnaire|WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
76088734|NCT02467686|Behavioral|FSFI questionnaire|FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
75651479|NCT02625753|Drug|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
75474765|NCT01987128|Procedure|Intraneural injection|BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
75474766|NCT01987128|Procedure|Extraneural injection|BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
75651480|NCT02625753|Drug|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
75651481|NCT02625753|Drug|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
75651482|NCT04907006|Drug|SY-004 capsule|After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule（80mg） orally with 240ml warm water. The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
75798191|NCT03238976|Other|Nature sounds|Nature sounds will be played for patients in the nature sounds exposure group.
75474767|NCT01987128|Drug|Ropivacaine|
75936184|NCT02433626|Drug|COTI2|COTI-2 is a third generation thiosemicarbazone.
75936185|NCT02433626|Drug|Cisplatin|Cisplatin is approved to treat a range of solid tumors and lymphomas.
75936186|NCT03392415|Procedure|CTO PCI|attempted percutaneous coronary intervention of the chronic total coronary occlusion
75474768|NCT01987128|Device|PAJUNK SonoPlex 22G needle.|
75474769|NCT01987141|Other|EMR Intervention|Electronic medical record flag/notification in the patient's chart
75474770|NCT01987154|Other|Marketed cow milk-based premature infant formula|
75798192|NCT03225547|Drug|Pembrolizumab|Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.
75798193|NCT03225547|Drug|Mifepristone|Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.
75936187|NCT04466709|Other|none intervention type|This is an observational study, no intervention
75936188|NCT02437448|Other|No intervention|
75474771|NCT01987154|Other|Marketed extensively hydrolyzed casein infant formula|
75474772|NCT01987167|Drug|ACTHAR|Injectable Gel
75474773|NCT01987206|Device|MPC control algorithm|
75474774|NCT01987206|Device|PID control algorithm|
75474775|NCT01987258|Behavioral|Interval Walking|
75474776|NCT01987258|Behavioral|Continuous walking|
75474777|NCT01987271|Device|Noninvasive Ventilation|A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
75474778|NCT01987284|Drug|SER100|
75474779|NCT01987284|Drug|Placebo|
75651483|NCT02625675|Other|Ultrasound scan|
75651484|NCT04257422|Other|Intentional Rounding|"A new method of nursing care named Intentional Rounding. The intentional roundings are planned rounds, conducted at regular intervals by nursing staff to anticipate care, comfort, hospitality and psychological needs of hospitalized users."
75651485|NCT04139421|Behavioral|Shinrin-Yoku|Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
75651486|NCT04257656|Drug|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
75651487|NCT04257656|Drug|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
75341214|NCT00634166|Drug|Topical Antimicrobial/Antifungal Medications|'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
75936189|NCT02290041|Drug|Infusion of MSC|Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).
75936190|NCT02290041|Drug|Infusion of placebo|Infusion of placebo (weeks 0-4-8-20)
75936191|NCT02442128|Drug|propofol /Fentanyl|fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
75936192|NCT02442128|Drug|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
75936193|NCT04465773|Procedure|general anesthesia for scheduled gynecological surgery|
75936194|NCT04465773|Drug|Propofol|continuous infusion, target concentration adjusted to maintain bispectral index between 45 and 55
75936195|NCT04465773|Drug|Remifentanil, Ultiva®|continuous infusion, target concentration 1 ng/ml
75341215|NCT02981251|Behavioral|Health education with support by trained female health volunteer|Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
75798194|NCT03122119|Drug|Platelet Rich Plasma Joint Injection|30 to 50 milliliters of venous blood will be drawn from the patients arm with a 19 gauge ¾ inch needle using universal precautions. The venous blood will be mixed with 8 milliliters of anticoagulant citrate dextrose solution-A (ACD-A). The anti-coagulated blood will then be centrifuged for 15 minutes at 3200 revolutions per minute in the office centrifuge. This will allow plasma to separate from blood cells. The portion of centrifuged blood deficient in platelets will be extracted and discarded. Once the needle is visualized entering the joint capsule via ultrasound guidance and the physician feels resistance provided by the capsule and ligaments, 3 milliliters of PRP extract will be injected (3 inch, 22 gauge needle) into the sacroiliac joint. The needles will be properly disposed.
75798195|NCT02990533|Drug|Testosterone|
75474780|NCT01987297|Drug|ATRA+Arsenic|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients."
75651488|NCT04139031|Device|Ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure < 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
75651489|NCT05329844|Drug|Vildagliptin 50 MG|50 mg Vildagliptin as single-dose per study period
75936196|NCT04465773|Procedure|tetanic stimulations|10-20-30-40-50-60 milliamps, 5 seconds, 100 Hertz 2 minutes between stimulations delivered via the standard neuromuscular blocking agents monitor
75936197|NCT04465773|Device|VideoAlgesiGraph|non invasive infrared camera placed in front of the left eye of the patients during the study period, connected to a laptop. No part of the device touches the eye.
75936198|NCT02441972|Drug|18F-Al-NOTA-PRGD2 PET/CT|18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
75936199|NCT04468191|Device|Experimental expiratory muscle strength training (EMST)|The experimental EMST will involve blowing into a device with a spring-loaded valve set to 50% of the patient with ALS' maximum expiratory pressure.
75936200|NCT04468191|Device|Sham expiratory muscle strength training (EMST)|The sham EMST will involve blowing into a device without a spring-loaded valve (0% resistance).
75936201|NCT02290197|Procedure|Surgery|Surgical reconstruction of all injured ligaments.
75936202|NCT02290197|Device|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
75936203|NCT02290197|Device|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
75341219|NCT00565370|Drug|Capecitabine, Cisplatin, Sorafenib|Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
75341220|NCT05559632|Procedure|osteotomy for implant placement|preparing the bone for implant placement
75651490|NCT00687999|Drug|pegylated interferon alpha and ribavirin|standard pegylated interferon alpha and ribavirin
75651491|NCT00688077|Drug|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
75651492|NCT00688077|Drug|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
76088735|NCT02467686|Behavioral|kupperman scale|Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
75936204|NCT02290275|Dietary Supplement|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
75936205|NCT02290275|Other|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
75798196|NCT02990533|Dietary Supplement|Protein Supplement|
76088736|NCT02467686|Drug|Cimicifuga racemosa|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
76088737|NCT02467686|Drug|tamoxifen|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
76088738|NCT02467686|Drug|exemestane|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
75341221|NCT03315182|Biological|rAAV9.CMV.hNAGLU|Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
75341222|NCT03303950|Drug|Busulfan|Given IV
75341223|NCT03303950|Drug|Cyclophosphamide|Given IV
75936206|NCT02290275|Dietary Supplement|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
75936207|NCT02709746|Drug|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
75341224|NCT03303950|Drug|Fludarabine|Given IV
75651493|NCT00688233|Device|Seifi's Functional|Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
75798197|NCT02990533|Other|Placebo Injection|
75798198|NCT02990533|Other|Placebo supplement|
75798199|NCT02969837|Drug|Elotuzumab|Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15
75798200|NCT02969837|Drug|Carfilzomib|Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond
76088739|NCT02987608|Device|Power Up|Smartphone phone app
76088740|NCT05707962|Drug|Magnesium sulfate|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
76088741|NCT02218840|Other|Smoking topography|Evaluation of cigar smoking topography
75798201|NCT02969837|Drug|Lenalidomide|Lenalidomide will be given on days 1-21 for all cycles.
75341225|NCT03303950|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
75341226|NCT03303950|Other|Laboratory Biomarker Analysis|Correlative studies
75341227|NCT01563055|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
75651494|NCT00923156|Drug|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
75651495|NCT00923156|Drug|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
75651496|NCT00923156|Drug|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
75651497|NCT00923156|Drug|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
75798202|NCT02969837|Drug|Dexamethasone|"Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22"
75798203|NCT02815462|Other|FAMFACESG|- PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.
75798204|NCT02815462|Other|Control|- Usual hospital Care
75798205|NCT02815462|Other|FAMFACESG|- PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.
75798206|NCT02815462|Other|FAMFACESG|"For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up.~For high and moderate risk patients & have complex nursing and / or high functional needs, PNs will refer these patients for THC.~For mild risk patients, PNs will refer them to care coordinator."
75798207|NCT02815462|Other|FAMFACESG|- For low risk patients, PNs will continue usual hospital care.
75798208|NCT02776917|Drug|Cirmtuzumab + Paclitaxel|Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
75936208|NCT02709746|Drug|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
75936209|NCT02709746|Drug|Fluoxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
75936210|NCT02709746|Other|Placebo|Encapsulated tablet
75936211|NCT02441894|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
76088742|NCT05698680|Drug|Prednisolone 30 mg Tablet|"See treatment arm Prednisolone"
75341228|NCT01563055|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
75341229|NCT00565916|Drug|Estrogen|"Estrogen only plus placebo: estradiol topical patch 0.3 mg placed on the lower abdomen for 3 days plus an oral placebo.~Other procedures: heart metabolism tests which includes a positron-emission tomography (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO)."
75474781|NCT01987297|Drug|ATRA+Chemo|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients."
75936212|NCT02441894|Drug|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
75936213|NCT02441894|Drug|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
75936214|NCT02441894|Drug|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
75936215|NCT02441894|Drug|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
75936216|NCT02441894|Drug|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
75936217|NCT02441894|Drug|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
75936218|NCT01317641|Drug|ODM-201|ODM-201 administered orally daily
75936219|NCT02433548|Procedure|Fascia iliaca block|injection of 30 mLs below the fascia iliaca
76088743|NCT05698680|Drug|Colchicine 0.5 mg Oral Tablet|"See treatment arm Colchicine"
76088744|NCT03305328|Device|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
76088745|NCT04350346|Drug|Motilitone|"Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~Pharmacological action:~It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor."
76088746|NCT04350346|Drug|Gasmotin|"Ingredient and content: mosapride citrate dihydrate 5.29mg (5mg as active ingredient)~Dosage method: Usually, an adult is orally administered 1 tablet 3 times a day before meals.~Pharmacological action: mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle"
76088747|NCT00703092|Drug|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
76088748|NCT03305172|Behavioral|Financial Incentive|Giving different structures of long term (36 weeks) financial incentives to increase physical activity
76088749|NCT05697822|Other|Mobile Phone and Cloud-based Electronic Contact and Recording System|A mobile phone application has been developed which is intended to be used by pregnant women and their healthcare workers. A pregnant woman can get registered in this app and enter information and data related to their health and current pregnancy. Their health worker at their health post can access this information on their mobile phone too. The pregnant woman can also input her daily symptom on this app. She can also input and/or access information on examination and tests that have been carried out. If a concerning symptom or event has been entered by a user in the app, the health worker will be notified through this app. The health worker can also track the pregnant women under their care through this application. A cloud-based database of pregnant women will have the details of all the pregnant women in a given ward or rural municipality. Health coordinators in the municipality will be able to access the database for their municipality and track the pregnant women, if needed.
76088750|NCT01968538|Radiation|Radiation Therapy|
75936220|NCT02433548|Procedure|Sham injection|subcutaneous of 5 cc of normal saline
75936221|NCT02433704|Device|New Intraosseous|Intraosseous administration of prophylactic antibiotics
76088751|NCT03300414|Other|One time blood draw|Same as part 1
76088752|NCT04058470|Drug|Toripalimab, Rituximab|Toripalimab in combination with Rituximab will be administered every 3 weeks up to 4 cycles.
76088753|NCT04058470|Drug|R-CHOP Protocol|After toripalimab plus rituximab treatment, R-CHOP regimen will be administered every 3 weeks in combination with R-CHOP up to 6 cycles.
75341230|NCT00565916|Drug|Progesterone|Estrogen plus progesterone: estradiol with oral progesterone (Prometrium, 200 mg/day) for 3 days, instead of placebo. Progesterone therapy involves taking a daily oral pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.
75341231|NCT00565916|Drug|Placebo|Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
75474782|NCT01987310|Drug|atorvastatin|atorvastatin 20 mg per day for 6 months
75474783|NCT01987310|Behavioral|lifestyle counseling|lifestyle modification by dietician counseling and follow up
75474784|NCT01987323|Drug|Subconjunctival injection of liposomal latanoprost|
75474785|NCT01987362|Drug|RO6870810|Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.
75798209|NCT02751255|Drug|all-trans retinoic acid (ATRA)|Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
75936222|NCT02433704|Drug|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
75936223|NCT02437292|Other|Ischemic compression with stretching|
75651498|NCT00688311|Dietary Supplement|Synbiotic 2000|A preparation consisting of 4 species of probiotic bacteria (10^10 each) combined with 4 types of dietary fiber (2.5g each).
75651499|NCT00688311|Dietary Supplement|Placebo|Placebo
75651500|NCT00688389|Other|case/control|case: infected dengue fever people control:healthy people
75651501|NCT04257266|Device|Ice Pack Cooling|5 ice packs (Cryo cooling pack or commercial ice pack) will be placed on the subject for 30 mins after exercise-induced hyperthermia
75651502|NCT02625831|Other|Biological analysis|"Biological analysis :~ficolin-3~anti-ficolin 3 antibodies~anti-C1q antibodies"
75651503|NCT04203602|Procedure|telepresence discharge|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
75651504|NCT04203602|Other|Conventional discharge|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
75651505|NCT00688779|Drug|AZD8848|Concentrate for nasal spray,solution 60 mg/g
75651506|NCT00688779|Drug|Placebo|
75798210|NCT02748941|Device|HITS quantification, Ultrasound examinations, High Resolution MRI|"Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque~Description of different modalities:~HITS quantification~Ultrasound examinations:~Ulceration >2 mm~Plaque thickness~GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop~CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)~High Resolution MRI:~Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated~Quantification of shear stresses (Pa) on the surface of the plaque~mi-RNA identification and quantification"
75798211|NCT02747303|Procedure|Stereotactic Radiosurgery|The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
75936224|NCT02433470|Device|Transcranial direct current stimulation|Transcranial direct current stimulation over the motor cortex
75936225|NCT05453825|Biological|navicixizumab+paclitaxel|navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly
75936226|NCT05453825|Biological|navicixizumab+irinotecan|navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W
75936227|NCT05453825|Biological|navicixizumab monotherapy|navicixizumab 3 mg/kg Q2W
75936228|NCT03186794|Other|Treadmill exercise training|30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
75936229|NCT02437058|Other|preidictive model|
75651507|NCT04203992|Behavioral|Videogame|"True Champion is an educational, values-based game that aims to empower young athletes to make informed decisions to avoid doping.~Participants engaging in the videogame sessions will encounter a series of thought-provoking situations and knowledge tests. Players will help their assigned character navigate through these curriculum-rich scenarios in order to reach their performance goals in a healthy and ethical way."
75936230|NCT03189680|Other|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
75936231|NCT05024279|Device|Left bundle branch area pacing|"Left bundle branch area pacing will be applied as established in the literature using commercially available equipment.~In case of unsuccessful application of left bundle branch area pacing, cross-over to right ventricular pacing is allowed."
75651508|NCT04203992|Behavioral|Control|Participants will be given an anti-doping booklet prepared by UNESCO. This booklet is considered standard educational material, i.e. what might be presented to young athletes as part of their regular sports curriculum.
75651509|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
75651510|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
75798212|NCT02707666|Drug|Pembrolizumab|Neoadjuvant pembrolizumab every 21 days for three cycles
75798213|NCT02707666|Drug|Cisplatin and Pemetrexed|Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
75798214|NCT02678273|Other|Intervention group|"The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents~."
75936232|NCT05024279|Device|Right ventricular pacing|Right ventricular pacing as the standard, established form of pacing will be applied in the control group. No cross-over to the intervention arm is anticipated.
75651511|NCT00689013|Other|Personalized letter|On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
75651512|NCT00689013|Other|Flyer advertisement|Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
76088754|NCT05696808|Dietary Supplement|IHPD|The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.
75798215|NCT02659293|Drug|Lenalidomide|"Cycle 1: 15 mg days 1-21~Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~Cycles 5 and beyond: best tolerated dose days 1-21"
76088755|NCT05696808|Dietary Supplement|Western Diet|The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
75474786|NCT01987375|Drug|Cetuximab-IRDye800|a single dose of the study drug following a single loading dose of unlabeled cetuximab
75474787|NCT01987388|Other|High Intensity Exercise|While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.
76088756|NCT04465708|Behavioral|Homework, Organization, and Planning Skills|HOPS is a 16-session, skills training program, provided individually to students in grades 6 through 8 who have OTMP skills deficits that contribute to academic difficulties. HOPS includes two parent consultations and one teacher consultation to promote generalization and maintenance of effects.
75341232|NCT03258320|Drug|Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin|As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
75798216|NCT02659293|Drug|Carfilzomib|"Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16"
76088757|NCT02467530|Other|AGE|
75474788|NCT01987388|Other|Low Intensity Exercise|While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.
75798217|NCT02659293|Drug|Dexamethasone|"Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22"
75798218|NCT02659293|Drug|Lenalidomide (Control)|"Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~Cycles 5 and beyond: best tolerated dose days 1-28"
75474789|NCT01987388|Other|High Carbohydrate Beverage|Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.
75474790|NCT01987388|Other|High Fat Beverage|Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
75798219|NCT02656511|Drug|Dolutegravir|Dolutegravir 50 mg PO daily
75474791|NCT01987440|Drug|lubricating gel|
75798220|NCT02656511|Drug|Emtricitabine/Tenofovir|Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
75474792|NCT01987466|Biological|Serum NGAL level|Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
75474793|NCT01987492|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.
75474794|NCT01987492|Drug|Placebo|Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
75474795|NCT01987518|Other|Procedure surgery behavioral and genetic diagnosis|Observational Study
75474796|NCT01987518|Procedure|quality of life after different type of surgery|
75474797|NCT01987531|Other|left ventricular epicardial pacing lead|
75474798|NCT01987544|Other|Ergometer Training|
75474799|NCT01987544|Other|Motivation|
75474800|NCT01987570|Drug|Allopurinol|
75798221|NCT02613169|Drug|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
75936233|NCT02441738|Procedure|Hybrid Ablation|The procedure will be performed following standard of care guidelines.
75936234|NCT02441738|Procedure|Catheter Ablation|The procedure will be performed following standard of care guidelines.
75936235|NCT02441504|Other|Low intensity Exercise|aerobic exercise training using walking and running
75936236|NCT02290353|Device|FEATHERS|"FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer [2]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants."
75936237|NCT02441816|Drug|Aflibercept|
76088758|NCT02467296|Other|Dietary plan with controlled amount of Sodium|Dietary plan with 1.5 gr vs 3 gr of Sodium
76088759|NCT03300102|Other|Questionnaires, interviews and or tissue donation|Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
76088760|NCT02720484|Other|Laboratory Biomarker Analysis|Correlative studies
76088761|NCT02720484|Drug|Nivolumab|Given IV
75936238|NCT02441816|Other|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
76088762|NCT05447520|Drug|Montelukast|Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
76088763|NCT05447520|Drug|Placebo|Oral tablet once daily
76088764|NCT05447520|Drug|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
76088765|NCT05438550|Drug|14-day high-dose Tegoprazan Dual Therapy (HDDT)|14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
75936239|NCT02433392|Procedure|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
75936240|NCT02441582|Other|Telemetry|
76088766|NCT03299868|Device|peripherally inserted central catheter (PICC)|comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
75651513|NCT00689013|Other|Newspaper press release|During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
76088767|NCT02466672|Other|none - observational only|
75474801|NCT01987570|Drug|Placebo|
75798222|NCT02611102|Dietary Supplement|MCT oil + Butter in Coffee|2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
76088768|NCT05403684|Other|High-volume breastmilk|Preterm infants will be given high-volume breastmilk
76088769|NCT02466282|Device|Angiography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
75798223|NCT02572323|Drug|Tesamorelin|Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
76088770|NCT02466282|Device|optical coherence tomography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
76088771|NCT05639946|Drug|brivaracetam|Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.
76088772|NCT05639946|Drug|Placebo|Participants will receive placebo drug
76088773|NCT03299790|Other|high-intensity interval exercise training (HIIT)|This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).
75651514|NCT04203758|Other|Cereal products based on rye|Participants will receive a fixed amount of rye based cereals products, corresponding to approx 650 kcal/day.
75651515|NCT04203758|Other|Cereal products based on wheat|Participants will receive a fixed amount of wheat based cereals products, corresponding to approx 650 kcal/day.
75651516|NCT04256798|Drug|Chlorhexidine mouthwash|0.2% Chlorhexidine digluconate
75651517|NCT04256798|Drug|Oxygen|Oxygen 80-100%
75651518|NCT04256798|Drug|Oxygen|Oxygen 21-30 %
75651519|NCT00687843|Drug|Tegafur-gimeracil-oteracil potassium (TS-1)|80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
75798224|NCT02441491|Drug|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster."
75936241|NCT02441582|Other|Non-telemetry|
75936242|NCT02433782|Other|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
75936243|NCT02433314|Drug|SAGE-547|
75341233|NCT05565469|Other|Adjustment of neurostimulator settings|"This is an interventional prospective study. After obtaining informed consent, only necessary information will be extracted through the electronic patient record. Through post-operative imaging, a level determination of the neurostimulator tip will be done. During general consultations, patients will be asked if they experienced abdominal wall stimulation after the procedure and when (YES/NO, NRS). This will include looking at the settings of the neurostimulator. And its adjustments. Furthermore, general epidemiological characteristics such as age, gender, height, weight will be extracted from the electronic patient record.~At the consultation, another active programming will take place (in accordance with clinical programming) on the tip of the electrode to check whether it provokes abdominal wall stimulation. This will also be scored YES/NO + NRS. Then the settings will be returned as they were pre-consultation."
75341234|NCT05559554|Drug|AK104 (before the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
75341235|NCT05559554|Drug|AK104 (after the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
75341236|NCT01797926|Drug|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
75341237|NCT01797926|Drug|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
75651520|NCT00687843|Drug|Krestin (PSK)|3 g, PO from day 1 to day 336
75651521|NCT04139187|Other|Combined training with power and strength exercises|"The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks)."
75341238|NCT01797926|Drug|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
75651522|NCT00689169|Drug|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
75798225|NCT02437526|Other|Analytic treatment interruption|
75341239|NCT01797926|Drug|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
75798226|NCT02431988|Procedure|Leukapheresis|Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
75936244|NCT02290431|Drug|LBH589 (panobinostat)|Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)
75798227|NCT02431988|Drug|Cyclophosphamide|Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
75936245|NCT02290431|Drug|bortezomib|Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) & treatment phase 2 (42 days).
75798228|NCT02431988|Drug|Fludarabine|Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
75936246|NCT02290431|Drug|dexamethasone|Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days & treatment phase 2 (42 days)
75798229|NCT02431988|Biological|CAR19 T-Cells|"The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.~Three dose cohorts are planned:~Dose Level 1: 2x105 CAR19 T-cells/kg~Dose Level 2: 1x106 CAR19 T-cells/kg~Dose Level 3: 5x106 CAR19 T-cells/kg"
75798230|NCT02399371|Biological|Pembrolizumab|Given IV
75798231|NCT02399371|Other|Laboratory Biomarker Analysis|Correlative studies
75798232|NCT02399371|Other|Pharmacogenomic Study|Correlative studies
75798233|NCT02389517|Drug|Ixazomib Citrate|Given PO
75798234|NCT02389517|Drug|Lenalidomide|Given PO
75798235|NCT02389517|Drug|Dexamethasone|Given PO
75798236|NCT02366819|Drug|Oxaliplatin|Given IV
75798237|NCT02366819|Drug|Leucovorin Calcium|Given IV
75798238|NCT02366819|Drug|Irinotecan Hydrochloride|Given IV
75798239|NCT02366819|Drug|Fluorouracil|Given IV
75936247|NCT03189758|Other|Observational Control Diet|Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
75936248|NCT03189758|Other|Controlled Dietary Sodium Restriction|Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
75798240|NCT02366819|Procedure|Conventional Surgery|Undergo surgery
75936249|NCT02433236|Drug|Fostamatinib Disodium tablet 100 mg|
75936250|NCT02433236|Drug|Fostamatinib Disodium tablet 150 mg|
75936251|NCT02290587|Other|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :~Questionnaire for depression and anxiety~Evaluation of executive functions~Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~morphological MRI~functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
75936252|NCT02290587|Device|MRI|
76088774|NCT03299790|Other|moderate-intensity exercise training (MIT)|This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.
76088775|NCT03299712|Device|ArteFill|soft tissue filler
76088776|NCT05391906|Other|Diffusion-weighted magnetic resonance imaging|Diffusion-weighted magnetic resonance imaging
76088777|NCT05388396|Other|PIMS-TS diagnostic a treatment|PIMS-TS diagnostic a treatment
76088778|NCT03299634|Other|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
76088779|NCT05382858|Device|Deep brain stimulation|active DBS with optimal stimulating parameters
75936253|NCT02432924|Behavioral|Instant + Multidimensional Physical Activity Feedback|
75341240|NCT03008083|Drug|3 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
75341241|NCT03008083|Drug|12 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
75474802|NCT01987622|Procedure|Acupuncture|The patients in this group will receive individualized acupuncture prescribed by a certified Korean Medicine Doctor (KMD) with at least three years of clinical experience. The acupuncture formulas will be determined based on the individual patient's symptoms and at the KMD's discretion. The acupuncture treatment will be applied one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). Acupuncture will be manually stimulated at first, and then electrical stimulation will be allowed at the KMD's discretion. Retention time will be equal to or less than 20 minutes. Examples of acupuncture points to be used might include LI4, LI11, TE5, SI3, TE3, ST36, SP6, SP9, LR3, GB34, Gb39, BL40, BL57, EX-B2, and BL23.
75474803|NCT01987622|Procedure|Usual care|Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.
75651523|NCT00689169|Procedure|ASCT|ASCT : D0
75651524|NCT00689169|Drug|Rituximab|Rituximab 250 mg/m² :D-21 D-14
75651525|NCT00610844|Procedure|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
75651526|NCT00610922|Dietary Supplement|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
75651527|NCT04203914|Drug|Empagliflozin Tablets|Add-on 25mg once daily
75651528|NCT04260620|Device|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
75798251|NCT02281838|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
75798252|NCT02213913|Drug|lenalidomide|Given PO
75798253|NCT02213913|Drug|etoposide|Given IV
75936254|NCT02888535|Other|Internal Medicine consultation|
75936255|NCT02441270|Drug|Cyclophosphamide|
75936256|NCT02441270|Radiation|Stereotactic body radiotherapy|
75798254|NCT02213913|Drug|prednisone|Given PO
75936257|NCT03528135|Behavioral|Project PRIDE|See arms section.
75936258|NCT02441192|Other|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
76088780|NCT03299556|Other|WHT|Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
75474804|NCT01987661|Device|BIPAP ST|non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
75651529|NCT00874731|Drug|Ridaforolimus 100 mg|Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
75651530|NCT00874731|Drug|Ridaforolimus 40 mg|Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
75651531|NCT00874731|Drug|Placebo|Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
75798255|NCT02213913|Drug|vincristine sulfate|Given IV
75798256|NCT02213913|Drug|doxorubicin hydrochloride|Given IV
75798257|NCT02213913|Drug|cyclophosphamide|Given IV
76088781|NCT05352204|Procedure|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization after liver resection
76088782|NCT05327556|Drug|Epinephrine 0.5 mcg/kg|Syringe with 5 mcg/mL epinephrine
75651532|NCT02625519|Drug|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
75651533|NCT02625519|Drug|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
75651534|NCT00912483|Biological|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
75651535|NCT00912483|Biological|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
75651536|NCT00689247|Drug|AZD1305|oral solution, single dose
75651537|NCT00689247|Drug|AZD1305|iv infusion, single dose
75651538|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
75651539|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
75798258|NCT02213913|Biological|rituximab|Given IV
75798259|NCT02213913|Other|quality-of-life assessment|Ancillary studies
75798260|NCT02213913|Other|laboratory biomarker analysis|Correlative studies
75798261|NCT01974765|Drug|Enzalutamide|All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
75798262|NCT01953159|Other|Blood Collection|
75936259|NCT02441192|Other|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
75936260|NCT02441192|Other|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
75936261|NCT02441348|Behavioral|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
75341242|NCT05559398|Drug|Glenzocimab|"Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.~It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL.~Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g.~Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion."
75341243|NCT05559398|Drug|Placebo|Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
75341244|NCT04388462|Other|Finite element analysis|Biomechanical study to describe micromotion
75341245|NCT01521871|Procedure|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
75341246|NCT01521871|Procedure|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
75474805|NCT01987661|Device|Airtrap|"Addional to the individally titrated BiPAP ventilation parameters the function AirTrap Control is added.~AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time."
75474806|NCT01987674|Dietary Supplement|Pre-meal protein drink|
75341247|NCT00566150|Drug|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
75474807|NCT01987674|Other|Water drink|
75798263|NCT01953159|Other|Patient Questionnaires|
75936262|NCT02290665|Other|Thermosensitive gel rectal formulation|
75651540|NCT00924638|Device|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
75798264|NCT01914094|Behavioral|Prehab|
76088783|NCT05327556|Drug|Epinephrine 1 mcg/kg|Syringe with 10 mcg/mL epinephrine
76088784|NCT02466438|Drug|Piperacillin-tazobactam|"Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~Acute Kidney injury : Dosing as prescribed by treating physician"
76088785|NCT05587062|Biological|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) by intravitreal injection
75341248|NCT00566150|Drug|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
75341249|NCT05565157|Procedure|Zygomatic implants|A robotic assisted new strategy for positioning zygomatic implants will be performed and its efficacy and accuracy will be assess
75341250|NCT01521949|Drug|Acai Juice Product|2 ounces of Acai Juice Product twice daily.
76088786|NCT05587062|Biological|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) by intravitreal injection
75341251|NCT05559242|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor
75341252|NCT01522339|Device|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan(s) for no longer than 60 minutes
75798273|NCT01725217|Biological|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
75936263|NCT02290665|Other|Saline enema|
75936264|NCT02436980|Drug|Tramadol|GROUP T
75936265|NCT02436980|Drug|Midazolam|GROUP M
75341253|NCT00566540|Drug|Cisplatin|Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
75341254|NCT00566540|Drug|Paclitaxel|Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
75341255|NCT00566540|Radiation|Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation|Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.
75474808|NCT01987687|Behavioral|Exercise|Exercise at 55% of maximum power output for 30 min.
75474809|NCT01987687|Behavioral|Rest|Rest for 30 min
75474810|NCT01987687|Behavioral|Delay|Delay between exercise and OGTT
75474811|NCT01987700|Device|FLEX-HD|
75474812|NCT01987700|Device|Strattice|
75651541|NCT04257032|Drug|Rosuvastatin|Tablet
75651542|NCT04257032|Drug|Rosuvastatin + BI 1323495|Tablets
75651543|NCT04257032|Drug|Dabigatran etexilate|Capsule
75651544|NCT04257032|Drug|Dabigatran etexilate + BI 1323495|Capsule and tablets
75651545|NCT04256720|Behavioral|No intervention|No intervention - questionnaire study
75651546|NCT00874497|Drug|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
75651547|NCT00874497|Drug|placebo|Placebo for 104 weeks (2 years)
75651548|NCT00924560|Drug|91-day Levonorgestrel Oral Contraceptive|"Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.~Take 1 tablet daily"
75798274|NCT01706432|Radiation|hyperfractionated radiation therapy|Undergo hypofractionated radiation therapy
75798275|NCT01706432|Other|laboratory biomarker analysis|Correlative studies
75798276|NCT01706432|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
75798277|NCT01665794|Drug|Pomalidomide|Pomalidomide taken orally at assigned dose.
75798278|NCT01665794|Drug|Carfilzomib|Carfilzomib given by intravenous (IV) infusion at assigned dose.
75798279|NCT01665794|Drug|dexamethasone|Dexamethasone taken orally of given by IV infusion.
75798280|NCT01665794|Drug|Daratumumab|Daratumumab given by intravenous (IV) infusion at assigned dose.
75936266|NCT02436902|Procedure|TACE|TACE is performed one month after resection.
75936267|NCT02436902|Drug|Sorafenib|Sorafenib is submitted one month after resection.
75936268|NCT02436902|Drug|TACE plus sorafenib|TACE plus sorafenib will be submitted one month after resection.
75936269|NCT02436902|Other|empty control|This group will not receive adjuvant therapy.
76088787|NCT05575128|Behavioral|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
75341256|NCT00566540|Procedure|Triple endoscopy and biopsy|Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
75341257|NCT00566930|Other|spinal manipulation|Monthly cervical spinal manipulation
75341258|NCT00566930|Other|Spinal manipulation + exercises|Monthly cervical spine manipulation and daily home exercises
75341259|NCT00567008|Drug|varenicline|1.0 mg BID for 8 weeks
75474813|NCT01987713|Behavioral|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
75474814|NCT01987726|Other|cytology specimen collection procedure|Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
75651549|NCT00924560|Drug|28-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
75651550|NCT00689559|Drug|AZD3480|AZD3480 capsules qd, oral, 22 days
75651551|NCT00689559|Drug|Placebo|Placebo qd, 12 days
75936270|NCT04009863|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
75936271|NCT04009863|Radiation|Radioactive iodine (Radioidine i131)|Radioactive iodine (RAI) is a radioactive form of iodine that for ablation in thyroid disease (i.e. Graves' disease or few thyroid cancer)
75936272|NCT02436590|Device|Orthofix Physio-Stim Model 3315OA|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
75936273|NCT02290743|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
75936274|NCT02436512|Drug|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~(Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~(Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
75936275|NCT02432768|Drug|Triheptanoin|Anaplerotic dietary oil
76088788|NCT05575128|Other|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
76088789|NCT05575128|Other|Care as usual|Care as usual, with written resources provided
75341260|NCT00567008|Drug|placebo|placebo BID for 8 weeks
75341261|NCT00567242|Behavioral|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
75341262|NCT00567242|Behavioral|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
75341263|NCT00567320|Drug|Varenicline|Varenicline up to 2 mg a day
75936276|NCT02432768|Other|Placebo oil|Safflower oil
75936277|NCT03186716|Dietary Supplement|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
76088790|NCT05322876|Behavioral|Healthy Hearts Family Program|Participants will participate in a baseline health and knowledge screening, followed by a 6-week once-weekly class series, and 3- and 6-month follow-up health and knowledge screenings.
75341264|NCT00567320|Drug|Sugar pill or Placebo|Placebo
75651552|NCT00689559|Drug|Aripiprazole|single dose on day 5
75651553|NCT00689637|Drug|AZD3480|AZD3480 capsules qd, 12 days
75651554|NCT00689637|Drug|Placebo|Placebo capsules qd, 12 days
75651555|NCT00689637|Drug|Warfarin|Warfarin: single dose on day 6
75651556|NCT00689715|Procedure|Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection|A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
75651557|NCT00689949|Dietary Supplement|folic acid|0.4 mg of folic acid per day
75651558|NCT04256642|Procedure|Erector Spinae Plane Block|A nerve block that injects local anesthetic in the Erector Spinae Plane
76088791|NCT03299400|Device|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
75341265|NCT01522417|Drug|Short Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
75341266|NCT01522417|Drug|Eptifibatide|180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
75341267|NCT01522417|Drug|Long Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.
75341268|NCT00568022|Drug|Ixabepilone|Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m^2, once every 3 weeks, up to 6 cycles
76088792|NCT02464566|Behavioral|Intensive lifestyle intervention|
75936278|NCT03186716|Dietary Supplement|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
75936279|NCT02436434|Device|pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
75936280|NCT04466241|Drug|Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|2 tablets morning and evening from Day 1 to Day 10
75936281|NCT04466241|Drug|Telmisartan 40Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
75474815|NCT01987726|Other|laboratory biomarker analysis|2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
75474816|NCT01987739|Drug|200 mg almorexant|
75651559|NCT04256642|Drug|Intrathecal morphine|Intrathecal morphine at the time of spinal anesthesia
75651560|NCT00611000|Dietary Supplement|folic acid|
75651561|NCT00611000|Genetic|DNA methylation analysis|
76088793|NCT02464566|Other|Health Education|
76088794|NCT05516004|Device|PXL Platinum 330 system|to determine the efficacy of riboflavin solution and UV light to treat cornea thinning conditions
76088795|NCT05257512|Drug|SY-3505|The third-generation ALK TKI
75936282|NCT04466241|Drug|Atorvastatin 20 Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
75936283|NCT02440880|Drug|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
75341269|NCT00568022|Drug|Capecitabine|Capecitabine: Tablets, Oral, 1650(2000)mg/m^2, twice daily for 2 weeks, one week off, up to 6 cycles
75651562|NCT00611000|Genetic|gene expression analysis|
75651563|NCT00611000|Genetic|microarray analysis|
75651564|NCT00611000|Genetic|polymorphism analysis|
75651565|NCT00611000|Other|laboratory biomarker analysis|
75651566|NCT04031157|Device|Predictix Antidepressant|Predictix Antidepressant guided treatment
76088796|NCT04489680|Other|Educational|Teaching session
76088797|NCT02463006|Drug|Porous variant of Bioactive Glass.|Flap surgery with Porous variant of Bioactive Glass.
76088798|NCT02463006|Drug|Non porous variant of Bioactive Glass.|Flap surgery with non-Porous variant of Bioactive Glass.
75798288|NCT01369212|Drug|Tenofovir|300 mg daily for 192 weeks (4 years)
75798289|NCT01369212|Drug|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
75798290|NCT01344057|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
75798291|NCT01017055|Other|Voice and Swallowing evaluations|Fiberoptic exam to evaluate vocal cord and swallowing function
75936284|NCT02440880|Drug|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
75936285|NCT02440880|Drug|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
75936286|NCT02440880|Drug|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
75936287|NCT02440880|Other|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
76088799|NCT02463084|Other|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
76088800|NCT02463084|Other|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
76088801|NCT04756908|Device|Cataract Surgery|The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.
76088802|NCT02466204|Drug|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
75341270|NCT05554562|Other|Adductor strength assessment|Adductor strength will be evaluated with HHD (handheld dynamometer) and forceplates (Forceframe), both injured leg and healthy will be assess in order to compare both limbs
75341271|NCT01522963|Drug|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
75474817|NCT01987739|Drug|400 mg almorexant|
75474818|NCT01987739|Drug|1000 mg almorexant|
75474819|NCT01987739|Drug|20 mg zolpidem|
75474820|NCT01987739|Drug|40 mg zolpidem|
75474821|NCT01987739|Drug|placebo|
76088803|NCT02466204|Drug|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
76088804|NCT02462694|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
75474822|NCT01987778|Other|Resistance training|Resistance training supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
76088805|NCT02462694|Behavioral|Treatment As Usual|TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
75474823|NCT01987804|Drug|Oxytocin 100 i.u.|
75474824|NCT01987804|Drug|Oxytocin 400 i.u.|
75651567|NCT04260386|Other|Non-Interventional|"During the cardiac arrest scenario, the delegates observing will be asked to refer to the maternal cardiac arrest proforma and record those details of events that they are able to see/hear from the video link. In addition, the proforma will be provided to the team taking part in the simulation. One or more team members would routinely be given the role of 'scribe', recording events as they occur. The proforma is accompanied by explanatory notes on how to use it.~Delegates (observers plus scribes) will then be asked to complete a questionnaire, seeking their opinions on the usefulness of the proforma. Questionnaires will be linked to the written consent forms by a participant ID number."
75651568|NCT00690027|Procedure|Emergency portacaval shunt|
75651569|NCT00690027|Procedure|Emergency and long-term endoscopic sclerotherapy|
75651570|NCT00690105|Drug|tacrolimus 0.1%|ointment
75798292|NCT00977119|Other|Side-effect questionnaires|Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
75936288|NCT04466319|Other|Rocking Chair|Patients in the experimental group were sat rocking chair three times a day in a rocking wooden chair in addition to their postoperative routine care by their nurses. After providing the rocking chair to the patients' room, the researcher gave the data collection form to be filled by the patient himself. It was the researcher's supervision that the patient sat in the rocking chair for the first time. The rocking chair movement continued to intervene until the patient released gas. After emitting gas, he continued to swing in the rocking chair until he made his first stools. The patient was visited every day until he was discharged. No special clothing or materials were required for the patients to sit in the rocking chair.
75651571|NCT00690105|Drug|fluticasone 0.005 %|ointment
75798293|NCT00977119|Other|research blood samples|Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
75798294|NCT00886782|Drug|Cdc7-inhibitor|Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
75936289|NCT03192098|Device|Savary bougie dilation|Patients will be dilated with the use of the Savary bougienage device
75341272|NCT03094286|Drug|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
75798295|NCT00800215|Drug|iv SPM 927 and oral placebo tablet|60-minute infusion iv SPM 927 and oral placebo tablet
75798296|NCT00800215|Drug|oral SPM 927 tablet and iv placebo|60-minute infusion placebo and oral SPM 927 tablet
75341273|NCT03071666|Dietary Supplement|cobalamin|Vitamin supplment tablet containing 50µg cobalamin
75341274|NCT03071666|Dietary Supplement|placebo|A tablet identical to the vitamin supplement but containing no vitamin B12
75341275|NCT01865162|Other|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
75474825|NCT01987804|Drug|Placebo|
75474826|NCT01987843|Drug|MT-1303-Low|
75474827|NCT01987843|Drug|MT-1303-Middle|
75474828|NCT01987843|Drug|MT-1303-High|
75474829|NCT01987843|Drug|Placebo|
75474830|NCT01987856|Procedure|Blastocyst morphology|microscopic examination only
75651572|NCT00923078|Behavioral|Auditory Cognitive Training|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.
75798297|NCT00800215|Drug|iv SPM 927 and oral placebo tablet|30-minute infusion iv SPM 927 and oral placebo tablet
75798298|NCT00800215|Drug|oral SPM 927 tablet and iv placebo|30-minute infusion placebo and oral SPM 927 tablet
75474831|NCT01987947|Drug|Placebo|Two administrations by subcutaneous injection
75474832|NCT01987947|Drug|Quilizumab|Two administrations by subcutaneous injection
75474833|NCT01987999|Dietary Supplement|Acetogenins|
75474834|NCT01988064|Other|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.
75798299|NCT00795028|Other|Standard Care for people after hip fracture|
75798300|NCT00795028|Other|Standard Care + exercise intervention|
75798301|NCT00583024|Biological|ADENOVIRUS/PSA VACCINE|1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60
75936290|NCT02290977|Radiation|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
75936291|NCT03186482|Drug|Descovy® (TAF/FTC)|25/200 mg once daily for 28 days (DAYS 1-28).
75936292|NCT03186482|Drug|Viread® (TDF)|245 mg once daily for 28 days (DAYS 57-84).
75936293|NCT03186482|Drug|Rifadin® (Rifampicin)|600 mg once daily for 28 days (DAYS 29-56).
75936294|NCT03522363|Other|Streptococcus dentisani CECT7746|Treatment will be applied topically as an adhesive gel with a dental splint
75936642|NCT03181334|Behavioral|Branch IV|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive."
75651573|NCT00923078|Behavioral|Visual Cognitive Training|The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.
76088806|NCT02715804|Other|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
76088807|NCT02715804|Drug|Placebo|Matching placebo for PEGPH20
75341276|NCT05363306|Procedure|implant insertion|"4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component."
75474835|NCT01988064|Other|Group training|Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
75651574|NCT04139265|Diagnostic Test|biologic analysis (ferritinemia, transferrin saturation coefficient)|Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis
75651575|NCT00694317|Drug|Zaleplon|Short term treatment of insomnia
75651576|NCT04260152|Device|Geistlich Fibro-Gide|Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide
75651577|NCT04260152|Procedure|Connective Tissue Graft (CTG|Surgical recession root coverage with coronally advanced flap in combination with CTG
75651578|NCT04136613|Device|Copper Intra uterine contarceptive device ( Cu-T 380A)|Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.
75651579|NCT00978731|Drug|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~5 days on, 2 days off~6 days on, 1 day off~Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
75798302|NCT00337649|Drug|Epothilone D|≤100 mg/m^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks
75936643|NCT03181334|Behavioral|Branch V|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive."
76088808|NCT02715804|Drug|nab-Paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
75474836|NCT01988077|Biological|Adoptive cell transfer|Adoptive cell transfer
75474837|NCT01988077|Drug|Ipilimumab 5 MG/ML Injection [Yervoy]|2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
75798303|NCT00337649|Drug|Herceptin|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
76088809|NCT02715804|Drug|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
76088810|NCT04749264|Behavioral|Mindfulness meditation retreat|6 to 7-days mindfulness retreat (Vipassana/insight meditation). The retreats are held in silence and led by senior teachers with many years of experience in teaching meditation. The focus of the retreat is the practice of mindfulness meditation while sitting and walking. Retreats include focused attention and open monitoring mindfulness meditation practices. Each retreat has a similar practice schedule thus the amount and nature of formal practice is mostly the same.
76088811|NCT02466360|Behavioral|Back Belief questionnaire|
76088812|NCT02466360|Behavioral|QUEBEC scale|
75651580|NCT04136535|Drug|Pemetrexed|Pemetrexed，500mg/m²，ivgtt ，d1，q3w
75651581|NCT04136535|Drug|Carboplatin|Carboplatin，AUC 5.0，ivgtt，d1，q3w，
76088813|NCT02466360|Behavioral|Fear Avoidance beliefs questionnaire|
76088814|NCT02466360|Behavioral|Visual analog scale|
75651582|NCT04136535|Drug|Anlotinib|Anlotinib ，12 mg，po，qd，d1-14，q3w；
75651583|NCT00694629|Drug|rifampin|tablet, 10 mg/kg, daily, 8 weeks
76088815|NCT02466360|Behavioral|individual interviews|
75474838|NCT01988116|Drug|Oral Calcitriol 0.5 mcg once daily for 6 weeks|
75474839|NCT01988116|Drug|Placebo|
75474840|NCT01988142|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
75651584|NCT00694629|Drug|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
75798304|NCT00071084|Drug|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 16 weeks.
75798305|NCT00071084|Drug|HuMax-CD4|HuMax-CD4 980 mg was administered as a SC infusion OD up to 16 weeks.
75798306|NCT00057304|Drug|RO 205-2349|
75798307|NCT00042406|Drug|HuMax-CD4|HuMax-CD4 80 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
75798308|NCT00042406|Drug|Placebo|Placebo was administered as a subcutaneous infusion twice (BID) with 2 weeks interval followed by administration every 4 weeks up to Week 22.
75798309|NCT00042406|Drug|Humax-CD4|HuMax-CD4 160 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
75798310|NCT01281774|Biological|CSL112|reconstituted high density lipoprotein
76088816|NCT02466360|Behavioral|Focus groups|
76088817|NCT04745130|Drug|Sintilimab，regofinib，cetuximab|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
76088923|NCT04553835|Behavioral|Rhythmic auditory stimulation (RAS) for schizophrenia patients|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday."
76088924|NCT04553835|Behavioral|No RAS for schizophrenia patients|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
76117185|NCT04353141|Diagnostic Test|standardized Lung Ultrasound (LUS) examination|14 areas (three posterior, two lateral and two anterior) will be assigned a COVID-LUS score: Score 0 (Normal pattern), Score 1 (Pattern of mild disease), Score 2 (Pattern of moderate disease), Score 3 (Pattern of severe disease). Classification of LUS result: LUS NEGATIVE: Group A = Score 0 in all 14 areas OR score =1 in areas of one site (right or left). It means that score 1 is pathological only when present bilaterally; LUS POSITIVE: both group B and C have to be considered positive: Group B (MILD DISEASE) = Score 1 in at least two areas localized bilaterally and no areas with score >1; Group C (MODERATE/SEVERE DISEASE)= Score >2 in at least two areas localized bilaterally
75474841|NCT01988155|Other|Eccentric Exercise|Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.
75672223|NCT02660502|Drug|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
75799030|NCT01186224|Drug|Plerixafor and G-CSF|"G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.~The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily."
75799031|NCT01182792|Dietary Supplement|Vitamin C and E|1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)
75799032|NCT01182792|Dietary Supplement|Placebo|1 month Placebo
75799033|NCT01188486|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Standard of care diagnostic radiotherapy procedure
75799034|NCT01188486|Radiation|Computed Tomography (CT)|For each participant, 3 chest CT scans will be obtained, 1 before and 2 after interstitial injection of the water-soluble contrast
75672224|NCT02660502|Drug|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
75799035|NCT01188486|Device|Cyberknife|Linear accelerator for producing high energy x-rays for radiation therapy.
75799036|NCT01188486|Device|Trilogy|Linear accelerator for producing high energy x-rays for radiation therapy.
75936680|NCT03181022|Behavioral|Motivational Interviewing|HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
75936681|NCT03181490|Diagnostic Test|Circulating Tumor DNA Methylation Test|Methylation profiling by high-throughput bisulfite DNA sequencing in blood sample to differentiate benign and malignant pulmonary nodules
75672225|NCT02660502|Drug|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
75672226|NCT02660502|Drug|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
75672227|NCT04203524|Diagnostic Test|Procalcitonin Levels|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first. A PCT-guided algorithm will be available to guide the management of patients in the PCT group.
75799037|NCT01188486|Device|True Beam|Linear accelerator for producing high energy x-rays for radiation therapy.
75799038|NCT01188486|Drug|Iohexol|Aqueous solution of a nonionic, water-soluble radiographic contrast medium in prefilled cartridges with a molecular weight of 821.14 (iodine content 46.36%), available at 140, 180, 240, 300, and 350 mgI/mL.
75341463|NCT05094986|Behavioral|Initial Medication Adherence (IMA) Intervention|The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.
75474842|NCT01988155|Other|Astym|In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
75799039|NCT01188486|Drug|Iodixanol|Aqueous solution of a nonionic, water-soluble, dimeric, isosmolar, radiographic contrast medium with a molecular weight of 1550.20 (iodine content 49.1%), available in 2 concentrations, (270 mgI/mL and 320 mgI/mL.
75799040|NCT01186302|Other|Type of provider|Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.
75799041|NCT01186380|Device|PET-512MC|Transesophageal Transducer
75799042|NCT03856554|Procedure|Unilateral Transforaminal Interbody fusion|TLIF via unilateral factectomy and insertion of one cage
75799043|NCT03856554|Procedure|Bilateral Transforaminal Interbody fusion|TLIF via bilateral factectomy and insertion of two cages
75799044|NCT03852186|Behavioral|Cognitive behavioral therapy|Group based psychotherapy
75936682|NCT04440839|Other|Telemedicine specialty consultation|Patients with lower extremity wounds due to peripheral artery disease and diabetes mellitus will undergo a specialty consultation with a provider through telemedicine
75936683|NCT03180944|Drug|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
75936684|NCT03180944|Drug|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
75936685|NCT03180944|Drug|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
75936686|NCT03180944|Drug|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
75341464|NCT05094986|Other|Usual Care|Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.
75936687|NCT03180944|Drug|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
75936688|NCT03184064|Dietary Supplement|Blackcurrant extract (low dose)|Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
75936689|NCT03184064|Dietary Supplement|Placebo|Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
75474843|NCT01988168|Procedure|Suture closure|A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
75511099|NCT00937638|Dietary Supplement|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
75799045|NCT03852186|Behavioral|Acceptance and commitment therapy|Group based psychotherapy
75799046|NCT01182870|Drug|choleclaciferol|800-6000 IU cholecalciferol per day
75936690|NCT03184064|Dietary Supplement|Citrus extract (low dose)|Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
75936691|NCT03184064|Dietary Supplement|Blackcurrant extract (high dose)|Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
75936692|NCT03184064|Dietary Supplement|Blackcurrant and citrus extracts (low dose / low dose)|Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
75936693|NCT02420288|Behavioral|Exercise Group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
75936694|NCT03975491|Behavioral|Moderate-Intensity Aerobic Exercise|The exercise intervention will consist of moderate-intensity (50-70% age-predicted maximum heart rate) treadmill walking. All exercise sessions will begin with a five-minute warm up of slow walking, 30-60 minutes of moderate-intensity walking, and a five-minute cool down of slow walking.
75341465|NCT04257188|Procedure|minimally invasive vitrectomy under subtenon anaesthesia|The safety and feasibility in terms of tolerance and pain sensation during the surgery as well as the possible perception of light and colour sensations in minimally invasive vitrectomy under sub-tenon anesthesia shall be investigated.
75799047|NCT01182948|Behavioral|Aerobic Training|The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
75799048|NCT01182948|Behavioral|Resistance Training|The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
75799049|NCT01183182|Device|ActiSight Needle Guidance System|Three different groups of patients defined per lesion size
75799050|NCT03854760|Behavioral|anesthesiologist with limited experiment|Using the simulate device, the trainees are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
75799051|NCT04979286|Other|Kinesiotaping|"Y strip kinesiotaping will be applied to both the gastrocnemius muscles while keeping the participant's ankle in full dorsiflexion. The tape will start from the plantar surface of the toe and continue proximally. The medial Y tail will be applied along the medial border of the gastrocnemius and the lateral Y tail along the lateral border of the gastrocnemius, at approximately 20% tension from the resting length. End points will end just below the popliteal crease."
75799052|NCT04979286|Other|Placebo Kinesiotaping|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
75799053|NCT03854292|Procedure|Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.
75799054|NCT03854448|Device|holter monitoring|"Transthoracic Echocardiography (TTE) Left atrial ( LA) volume will be measured using standard apical two- and four-chamber views on the frame just prior to mitral valve opening and as specified by current American Society of Echocardiography guidelines (10) LA volume is indexed to body surface area. Mitral inflow velocity is obtained in the apical four-chamber view by placing a pulsed-Doppler sample volume between the tips of the mitral leaflets. Mitral annular velocity is assessed during the early phase of diastole(e=) using pulsed-wave Doppler sampling of septal mitral annular motion from the four chamber view.~24 to 48 hours Holter monitoring after 1 month after PCI"
75936695|NCT03975491|Behavioral|Wait-List Control|Participants randomized into the wait-list control group are asked to maintain their pre-study levels of physical activity and follow the recommendations provided by their physician.
75936696|NCT03180710|Drug|BioChaperone® Combo 75/25 at 0.6 U/kg|Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
75936697|NCT03180710|Drug|BioChaperone® Combo 75/25 at 0.8 U/kg|Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
75799055|NCT01186536|Dietary Supplement|Whey Protein supplement|40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
75799056|NCT01186536|Dietary Supplement|Soy Protein Supplement|40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
75799057|NCT01186536|Dietary Supplement|Carbohydrate supplement|40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
75799058|NCT05202678|Device|AGN1 LOEP|Subjects with osteoporosis are treated with AGN1 local osteo-enhancement procedure in the proximal femur
75799059|NCT01188642|Behavioral|obesity lifestyle intervention|physical activity 5 times per week + nutrition education
75799060|NCT01188720|Behavioral|Physical activity|30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
75936698|NCT03180710|Drug|BioChaperone® Combo 75/25 at 1.0 U/kg|Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
75936699|NCT03180710|Drug|Humalog® Mix25 at 0.8 U/kg|Injection of Humalog® Mix25 at 0.8 U/kg
75936700|NCT04322669|Drug|Pidotimod|Participants will be randomized in ratio of 1:1 to receive Pidotimod 400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
75936701|NCT04322669|Drug|Placebo|Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
75341466|NCT01579669|Behavioral|Use of toolkit|Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
75341467|NCT05039996|Behavioral|education and relaxation program|randomized controlled trial
75672228|NCT04203524|Other|Control|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first.The results of the PCT levels obtained will be blinded and all clinical team members will not be able to access the results.
75672229|NCT02830763|Dietary Supplement|CNT-02|Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
75672230|NCT02655900|Other|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
75936702|NCT03180476|Drug|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
75936703|NCT03180632|Drug|Lorazepam|Patient receives one or two tablet of 0,5mg Lorazepam according to body weight
75799061|NCT01183494|Drug|FOLFIRI, Avastin, Irinotecan|Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1*1/*1 and UGT1A1*1/*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
75936704|NCT03180632|Other|Placebo|Patient receive one of two tablet of Placebo according to body weight
75474844|NCT01988168|Procedure|Staples closure|Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
75799062|NCT01183572|Dietary Supplement|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
75799063|NCT01183572|Dietary Supplement|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
75799064|NCT01183572|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid
75799065|NCT02524548|Other|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
75799066|NCT01291446|Dietary Supplement|High flatulogenic diet|During 3-days subjects will consume a diet with high content of fermentable residues
75799067|NCT01186614|Device|Automated CPR|Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
75799068|NCT01186614|Device|ECMO|Insertion of peripheral VA ECMO
75799069|NCT01186614|Procedure|Coronary angiography|Coronary angiography and intervention where necessary will be performed following ECMO insertion
75672231|NCT04247321|Device|Licox® Brain Tissue Oxygen Monitoring System|Invasive brain tissue oxygenation monitoring
75799070|NCT01186614|Procedure|Therapeutic Hypothermia|Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
75936705|NCT03943277|Other|No intervention, observational study|No intervention observational study
75936706|NCT04483232|Biological|Ear canal swab|Ear canal swab
75799071|NCT03854136|Procedure|Excision of tumor|Wide margin excision of tumors +/- limb preservation
75799072|NCT02524236|Drug|Botox injection in the prostate|transrectal access of prostatic injection
75799073|NCT03856008|Other|Exercises focused on flexor muscles|Exercises emphasis flexor muscles.
75799074|NCT03856008|Other|Exercises focused on extensor muscles|Exercises emphasis extensor muscles.
75799075|NCT03855930|Diagnostic Test|functional MRI|During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
75799076|NCT03856242|Drug|Tamsulosin Oral Capsule|Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg
75799077|NCT03856242|Procedure|TURP|Routine transurethral prostatic resection
75799078|NCT01186926|Device|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
75799079|NCT03851874|Procedure|Bariatric surgery|Bariatric surgery
75799080|NCT01187082|Behavioral|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
75799081|NCT01187082|Behavioral|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
75799082|NCT01291524|Drug|Pregabalin controlled release, 330 mg, 400 to 500 calorie|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
75799083|NCT01291524|Drug|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
75799084|NCT01291524|Drug|Pregabalin controlled release, 330 mg, bedtime|A single oral dose of 330 mg controlled release tablet administered at bedtime
75799085|NCT01291524|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
75936707|NCT04295057|Other|Non-intervention|Non-intervention
75936708|NCT02420132|Other|Ranibizumab|Ranibizumab administered as part of standard-of-care
75936709|NCT03183752|Drug|Metformin|500 mg metformin three times daily
75936710|NCT03183752|Drug|Placebo|500 mg placebo three times daily
75936711|NCT02420054|Behavioral|Intermittent fasting|Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
75936712|NCT02420054|Other|Time control|Time control period with no change in eating habits.
75936713|NCT04287179|Drug|Semaglutide|Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.
75936714|NCT03183674|Drug|Oxytocin|Single dose oxytocin 45 minutes before the test
75936715|NCT03183674|Other|placebo|saline solution 0,9% spray nasal
75672232|NCT04247321|Device|Near-infrared spectroscopy (NIRS)|Non-invasive approach to monitoring brain tissue oxygenation which uses two wavelengths of near infrared light and takes measurements of the ratio of oxyhemoglobin to total hemoglobin
75672233|NCT02660346|Drug|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
75672234|NCT02660346|Drug|Vancomycin|Control Arm Treatment
75672235|NCT02660346|Drug|Ceftaroline|Study Arm Treatment
75965916|NCT04385966|Procedure|Interscalene brachial plexus block|Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
75474845|NCT01988181|Device|BVM-UF biofeedback|The Fresenius 5008 uses an ultrasound and temperature monitor incorporated into the machine to detect ultrasonic velocity and temperature changes to derive the total protein concentration, which is a sum of total plasma proteins and hemoglobin. The relative blood volume is calculated at by dividing the initial concentration of total protein by the total protein concentration at any given time, multiplied by 100. The HD software is based on the critical blood volume entered at the beginning of the dialysis session for each individual patient. The UF rate is adjusted based on the changes in the relative blood volume to the patient's critical relative blood volume.
75799086|NCT03855852|Procedure|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
75799087|NCT03855852|Procedure|Xenograft and APRF|Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
75799088|NCT01183806|Drug|Rivastigmine|All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
75799089|NCT01183806|Other|Exercise training program|Exercise training program
75799090|NCT01188954|Drug|doxycycline|50 ml/mg
75936716|NCT03117530|Drug|Minocycline|Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
75936717|NCT03180320|Behavioral|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:~Baduanjin exercise;~evaluations of exercise capacity and clinical conditions;~consultations on exercise prescription and management of symptoms/signs during exercise;~education covering topics related to the CHF and exercise; and~a series of adherence strategies."
75936718|NCT03180320|Drug|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
75936719|NCT03889925|Drug|Hyaluronan|Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.
75936720|NCT03889925|Biological|Autologous conditioned plasma|Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.
75936721|NCT05103254|Drug|Bempedoic Acid|Bempedoic Acid 180 MG
75936722|NCT05103254|Drug|Bempedoic Acid / Ezetimibe|Bempedoic Acid 180 MG / Ezetimibe 10 MG
75936723|NCT02426840|Dietary Supplement|High dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
75936724|NCT02426840|Dietary Supplement|Normal dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
75936725|NCT02427074|Procedure|Balloon Compression Rhizotomy|The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
75936726|NCT02427074|Procedure|Radiofrequency Thermal Coagulation Rhizotomy|The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
75936727|NCT03178526|Drug|Lovastatin gel|Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
75936728|NCT03178526|Drug|Placebo|placebo gel
75936729|NCT02426996|Procedure|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
75936730|NCT02423486|Device|Electromagnetic stimulation therapy (BIOCON-2000)|
75936731|NCT02423486|Device|Electromagnetic stimulation therapy with biofeedback|
75799091|NCT01188954|Other|No intervention|Normal Saline/Water
75936732|NCT04256369|Combination Product|Parenteral Nutrition (PN) Premixed Olimel N9E|Parenteral nutrition
75936733|NCT02423564|Dietary Supplement|Digesta Lac|
75936734|NCT02423564|Other|Placebo|
75936735|NCT03180164|Other|hospital anxiety and depression scale|self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
75936736|NCT02423642|Procedure|Continuous renal replacement therapy with regional citrate anticoagulation|"CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)"
75936737|NCT02423642|Procedure|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
75936738|NCT03180242|Biological|EG12014|EG12014, single-dose IV infusion over 90 min at 6 mg/kg
75799092|NCT01183962|Dietary Supplement|Vitamin D|Vitamin D 3000 IU daily
75799093|NCT01183962|Other|No medication|No intervention
75799094|NCT01184040|Behavioral|VIP CM|Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
75936739|NCT03180242|Biological|EU-sourced Herceptin|EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
75936740|NCT03180242|Biological|US-sourced Herceptin|US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
75936741|NCT00709904|Drug|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
75936742|NCT00709904|Drug|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"
75799095|NCT01187160|Procedure|Transoral robotic surgery (TORS)|The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
75936743|NCT00709904|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"
75936744|NCT02426606|Other|Various lentil varieties (varying in slow digested starch content)|"Randomized, cross-over block design.~Comparison of glycemic and insulinemic responses following meals composed of:~white rice or white rice combined with 1 of 3 different lentil varieties or~white potato or white potato combined with 1 of 3 different lentil varieties~Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.~Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit)."
75936745|NCT03183596|Drug|Bupivacaine|20-60cc of 0.25% Bupivacaine
75936746|NCT03183596|Drug|Dexamethasone|2-4mg of Dexamethasone
75936747|NCT03178214|Drug|Infacort|Immediate-release multiparticulate formulation of hydrocortisone.
75936748|NCT03626051|Device|Rigid tape|This taping method used an anchor, two stirrups, three figure-six's (two preventing inversion and one preventing eversion), heel lock and a lock off. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
75799096|NCT03851718|Device|Acupuncture Procedure|Each session will run about 30~40 minutes at the Family Medicine Clinic and performed by a licensed acupuncturist. The expense of all three sessions will be reimbursed by the project, not billed to the participant. The following points CV17, ST18 (bilateral), ST36 (bilateral), SI1(bilateral) and LR3(bilateral) , adopted from TCM classic text and previous studies done in China, will be used for all three sessions .
75799097|NCT03851718|Behavioral|Power pumping|It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days. During this one hour, the moms will be advised to pump for 20 minutes, rest for 10 minutes, pump for 10 minutes, then rest for 10 minutes and pump for 10 minutes. Alternatively they can also opt to pump and rest for every 10 minutes during the hour.
75936749|NCT03626051|Device|Fibular tape|This taping method used a rigid strapping tape to reinforce a posterior-superior mobilisation of the distal fibula. Tension was applied on the tape in a posterior and superior direction. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
75936750|NCT03183362|Device|Barbed suture ( STRATAFIX™ )|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.
75936751|NCT03183362|Device|Conventional suture (VICRYL™)|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures .
75936752|NCT03117062|Other|occlusal reduction|relief of occlusion following endodontic treatment
75936753|NCT02704130|Device|Transarterial embolization|In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
75936754|NCT02704130|Procedure|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
75936755|NCT03180008|Behavioral|Fit and Strong!|Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
75936756|NCT03180008|Behavioral|Fit and Strong! Plus|The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
75936757|NCT03594305|Behavioral|Educational seminar|Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
75936758|NCT02426762|Procedure|Laparoscopic surgery|"Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:~4-5 trocar-produced incisions (5/10mm, minor incision)~1 sample-retrieval incision (4-5cm, small incision)"
75936759|NCT02426762|Device|Skin sealant|After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
75936760|NCT04325243|Drug|Sildenafil 50 mg|50 mg oral Sildenafil tablet
75936761|NCT04325243|Drug|Placebo oral tablet|placebo tablets of the same shape, color and size of Sildenafil tablets manufactured in the Department of Pharmaceuticals, Faculty of Pharmacy
76027217|NCT05061641|Drug|Progesterone|The delivery outcomes of the three groups were compared, including the rate of premature delivery (<37 weeks of gestation), the rate of early premature delivery (<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (<37 weeks), neonatal perinatal mortality and morbidity.
75799098|NCT01187238|Drug|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
75799099|NCT01588314|Drug|Gabapentin|gabapentin 100 mg capsules
75799100|NCT01588314|Drug|placebo|compounded placebo capsules
75799101|NCT03853980|Device|Focal Contouring System|Single treatment of skin resection (removal of loose skin)
75799102|NCT04970550|Other|Non intervention|Non intervention
75799103|NCT01290432|Dietary Supplement|Inofolic Plus|Inofolic Plus contains folic acid and myoinositol and melatonin
75799104|NCT01290510|Device|hyaluronic acid sodium salt|Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
75799105|NCT01184196|Drug|Swab area with Betadine|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
75799106|NCT01184196|Drug|Swab area with ChloraPrep|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
75672236|NCT02833649|Device|Toric Implantable collamer Lens|The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
75672237|NCT02828735|Device|respiration assessment|Respiration Breathing Exercise
75799107|NCT01292382|Device|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
75799108|NCT01292382|Device|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
75799109|NCT01292460|Drug|Timolol/ FDC/ Placebo/ Tafluprost|"Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00)."
75799110|NCT03851952|Device|Optilume Drug Coated Balloon|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
75799111|NCT03855540|Diagnostic Test|ECHOcardiography|"ECHO parameters~LA diameter~LVEDD~LVEF~Diastolic dysfunction~Valvular disease"
75799112|NCT03855540|Diagnostic Test|Peripheral blood samples for plasmatic biomarkers|"Coagulation~D - dimer~Fibrinogen~Inflammation and fibrosis~Hs - CRP~AGEs~Soluble RAGE~Hemodynamics (LA stretch)~Apelin~NT - proBNP~Hs - troponin~MiRNA~miRNA - 1~miRNA - 133~miRNA - 29b~miRNA - 208a~miRNA - 208b~miRNA - 499"
75799113|NCT03855540|Diagnostic Test|Athens insomnia scale questionnaire|Athens insomnia scale questionnaire
75799114|NCT03855540|Diagnostic Test|ECG Holter monitor|Patient receives ECG Holter monitor if included to the control group
75799115|NCT03855540|Diagnostic Test|ECG event recorder|Patient receives ECG event recorder for twice daily (or if symptoms), 90 seconds duration ECG monitoring if included to the control group
75799116|NCT01292616|Drug|therapy with disease-modifying anti rheumatic drugs (DMARD)|DMARD drug and dosage is chosen by the treating physician without restriction by the study
75341468|NCT04224428|Drug|Fexofenadine Pill|fexofenadine tablets 60 mg once daily will be taken for six months
75341469|NCT04224428|Drug|Placebo oral tablet|lactose oral tablet
75341470|NCT01579747|Procedure|Ultrasound|Using ultrasound for nerve localization when performing a sciatic nerve block via the lateral popliteal approach
75672238|NCT02660190|Drug|hexaminoavolunate|
75672239|NCT02660190|Procedure|WL cystoscopy|
75672240|NCT04211324|Device|TENS|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
75799117|NCT01184352|Device|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
75799118|NCT03855462|Device|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with MCT oil :~Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~MCT ablation after 4 to 6 weeks (after effective retinopexy)~after MCT ablation, total follow-up duration by patient is 6 months."
75799119|NCT01187316|Device|Transcutaneous electrical nerve stimulation|Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.
75799120|NCT01187316|Other|Physiotherapy|Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
75799121|NCT01292694|Drug|Losartan|Oral, single-dose, 50 mg tablet
75799122|NCT01292694|Drug|Captopril|Oral, single-dose, 50 mg tablet
75799123|NCT01292694|Drug|Placebo|Oral, single administration, gelatin capsule filled with microcrystalline cellulose
75799124|NCT01184430|Device|Pulse contour cardiac output device|Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
75799125|NCT03853668|Behavioral|exercise|control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks
75799126|NCT03855774|Genetic|Polymorphisms|Classification of sleep disorders using 22 genetic polymorphisms
75799127|NCT03851562|Drug|Alprostadil 20 micrograms|Intravenous infusion of PGE1 (Days 0, +1 and +2)
75799128|NCT03851562|Drug|Placebo|Intravenous infusion of physiological saline solution
75799129|NCT02524704|Device|CT scan|Applied only when part of the patient's standard care
75799130|NCT01293630|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
75799131|NCT01293630|Drug|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
75799132|NCT01293630|Drug|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
76027218|NCT02367625|Device|CryoPop|The new CryoPop device will be compared to standard cryotherapy
75936762|NCT03179774|Device|Endovascular revascularization|All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
75936763|NCT02419586|Other|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
75936764|NCT02419820|Drug|APD791|Temanogrel
75936765|NCT02419820|Drug|Clopidogrel|Clopidogrel
75936766|NCT02419820|Drug|Aspirin|Aspirin
75936767|NCT02419820|Drug|Placebo for APD791|Placebo for APD791
75651925|NCT04624139|Behavioral|Internet-based cognitive behavioral therapy + physiotherapy|"Combined intervention of stress reducing I-CBT and physiotherapy. The intervention consists of two components; I-CBT and physiotherapy aiming to reduce symptoms of stress.~I-CBT: Designed to reduce stress, during 8 weeks. Physiotherapy: A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
75936768|NCT05464511|Other|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
75936769|NCT03179852|Behavioral|nutrition education|nutrition education
75936770|NCT02419430|Behavioral|MBRT ClassRoom and Phone Application|2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
75936771|NCT02419430|Behavioral|Phone application only|"Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:~Joys of Life~Count your blessings~Think differenc, feel better~Exercising --> Happier~+ Exercising --> Sleep~Pre-Sleep routine~Eat that frog~Mindful Meditation"
75672241|NCT04211324|Device|electro-acupuncture|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
75936772|NCT02419430|Behavioral|Questionnaires|At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
75936773|NCT05692739|Drug|Insulin|see arm description
75936774|NCT05692739|Drug|Cyclosporins|see arm description
75936775|NCT05692739|Drug|Artificial tears|see arm description
75936776|NCT03116984|Procedure|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
75936777|NCT03116984|Radiation|External- beam radiotherapy|We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
75936778|NCT02426528|Other|Cultural and Social exposure|"The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase)."
75672242|NCT00620360|Dietary Supplement|fructose|acute administration of 4 times 0.3g fructose/kg lean body mass
75936779|NCT03380351|Behavioral|SCDIC interventions|The research team will characterize the intervention components and their implementation strategies.
75936780|NCT03380351|Behavioral|SCDIC control groups|The research team will characterize the control settings, including patients, providers and organization.
75936781|NCT02419352|Drug|Sugammadex|
75936782|NCT02419352|Drug|Neostigmine/atropine|
75936783|NCT02423720|Behavioral|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
75936784|NCT03365687|Dietary Supplement|Vitamin D|2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
75672243|NCT00620360|Dietary Supplement|Fructose|acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
75672244|NCT04669418|Diagnostic Test|RNA expression signature|Whole transcriptome profiling using RNA sequencing
75799133|NCT01191060|Drug|Lenalidomide, Bortezomib|"Lenalidomide/Bortézomib/Dexamethasone cycles:~Number of cycles: 8 cycles for arm A~Cycle length~Dosage:~Lenalidomide: 25 mg/day on days 1-14 of each cycle~Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
75799134|NCT01191060|Drug|Lenalidomide, Bortezomib|"Lenalidomide Bortezomib Dexamethasone cycles:~Number of cycles: 5 cycles for arm B~Cycle length~Dosage:~Lenalidomide: 25 mg/day on days 1-14 of each cycle~Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
75799135|NCT03853824|Other|Increased postoperative surveillance|Increased postoperative surveillance can include either of the following; i) admission to a higher care ward than had been planned at the time of surgery, ii) an increase in the frequency of nursing observations in the postoperative period, iii) ensuring that the patient is placed in view of the nursing station, and not in a remote location in the postoperative ward, or iv) allowing family members to stay with the patient in the ward in the postoperative period.
75936785|NCT03365687|Dietary Supplement|Placebo|2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
75936786|NCT02419118|Drug|Daratumumab|Treatment of myeloma patients with Daratumumab
75936787|NCT02419118|Drug|Lenalidomide|Treatment of myeloma patients
75936788|NCT02419118|Drug|Dexamethasone|Treatment of myeloma patients
75936789|NCT05515289|Drug|SHR6390|SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.
75936790|NCT02426294|Drug|Pioglitazone|
75936791|NCT02426294|Drug|Glimepiride|
75936792|NCT05692661|Radiation|proton plus carbon ion radiotherapy|CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels [10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx ].
75936793|NCT02426450|Procedure|RFA|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics)."
75799136|NCT03853824|Other|Usual postoperative care|Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers.
75799137|NCT02524392|Other|Independent medical evaluation|The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
75799138|NCT01291602|Drug|NXL104|IV Solution
75936794|NCT02426450|Drug|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
75936795|NCT02426450|Drug|5-Fluorouracil/Leucovorin|"4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
75936796|NCT02423330|Device|Strattice-LIFT|Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
75936797|NCT02419196|Other|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
75936798|NCT02426372|Biological|QBECO SSI|QBECO Site Specific Immunomodulators
75936799|NCT02426060|Drug|Imrecoxib|
75936800|NCT02426060|Drug|Warfarin|
76117186|NCT04348565|Other|Diabetes Care Programme|20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
75341471|NCT01579747|Procedure|Nerve stimulation|Using nerve stimulation for nerve localization in sciatic nerve blocks via the lateral popliteal approach
75341472|NCT00584480|Other|Hyperbaric Oxygen Treatment (HBOT)|1.5 ATA at 100% Oxygen of HBOT
75341473|NCT03007693|Drug|JNJ-61393215|Participants will receive JNJ-61393215 for 7 days.
75799139|NCT01291602|Drug|CAZ104|IV Solution
75799140|NCT01291602|Drug|Placebo|IV saline
75936801|NCT03761069|Drug|PTC299|PTC299 will be administered per the treatment arm description
75936802|NCT02423174|Procedure|Total Mesorectal Excision|Surgical intervention with the FMwand Surgical System
75936803|NCT02423174|Device|FMwand Surgical System|
75936804|NCT02423252|Behavioral|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
75936805|NCT02423252|Other|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
75936806|NCT05692583|Diagnostic Test|ultrasound examination of wrist|musculoskeletal ultrasound examination of affected wrist
75965917|NCT04385966|Drug|Levobupivacaine Hydrochloride 2.5 MG/ML|"Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999)."
75965918|NCT04869800|Drug|CKD-398|Test Drug
75965919|NCT04869800|Drug|CKD-501, D745|Reference Drug
75799141|NCT03853590|Procedure|Roux-en-Y gastric bypass|Creation of a small pouch from the stomach and connection of the newly created pouch directly to the small intestine so that swallowed food bypasses most of the stomach and the first section of the small intestine.
75936807|NCT04051697|Behavioral|SEA CHANGE intervention|The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.
75936808|NCT02425982|Procedure|Operative treatment|The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
75936809|NCT02425982|Procedure|Conservative treatment|The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
75936810|NCT03749135|Drug|Dupilumab|anti-IL4-Receptor alpha
75936811|NCT03749135|Drug|Placebo|Placebo
75936812|NCT02418962|Biological|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
75936813|NCT02418962|Other|Normal Saline|0.9% Sodium chloride solution for injection
75936814|NCT02422784|Dietary Supplement|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
75936815|NCT02422784|Dietary Supplement|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
75936816|NCT02422784|Dietary Supplement|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
75936817|NCT03740009|Drug|Bazedoxifene/Conjugated Estrogen|20 mg bazedoxifene/0.45mg conjugated estrogens tablets
75936818|NCT02418806|Behavioral|Psychotherapy groups|
75936819|NCT02418806|Behavioral|Self-help groups|
75341474|NCT03007693|Drug|Placebo|Participants will receive JNJ- 61393215 matching placebo for 7 days.
76117187|NCT04443192|Drug|ZF874|ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.
75341475|NCT00584558|Procedure|Catheter Ablation|Catheter Ablation of arrhythmias
75341476|NCT04224194|Combination Product|Adalimumab|Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.
75799142|NCT03853590|Procedure|Laparoscopic adjustable gastric banding|Placement of a soft silicone ring with an expandable balloon in the center, around the top part of the stomach to create a two-compartment stomach, with a much smaller top part above the band. The subject will eat enough food only to fill the top part of the stomach decreasing caloric consumption.
75799143|NCT01187628|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
75799144|NCT03851172|Drug|Ketorolac Ophthalmic|Preoperative administration of Ketorolac 0.5% eye drops
75799145|NCT03851172|Drug|Nepafenac Ophthalmic|Preoperative administration of Nepafenac 1 mg eye drops
75799146|NCT03851172|Drug|Cyclopentolate Ophthalmic|Preoperative administration of Cyclopentolate eye drops
75936820|NCT03183440|Dietary Supplement|PREBIOTICS|women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery
75936821|NCT03183440|Other|PLACEBO|women will daily take placebo (maltodextrin) from inclusion to delivery
75936822|NCT05692505|Diagnostic Test|QuadQuik|Invitro diagnostic device
75936823|NCT02425670|Other|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
75936824|NCT03710525|Other|Own-Price Elasticity|The price of vegetables will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
75936825|NCT03710525|Other|Cross-Price Elasticity|The price of vegetables will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
75936826|NCT05692427|Device|Cryopen - Cryotherapy|Cryotherapy with N20
75341477|NCT02215369|Device|VenaCure EVLT 400 µm fiber Procedure Kit|The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit.
75936827|NCT03183206|Procedure|Cryosurgery , IRE surgery ,surgery|surgery will be used in local tumor
75936828|NCT03183206|Biological|γδ T cells|γδ T cells will be used against
75936829|NCT03183206|Other|γδ T cells/ Surgery|Combination γδ T cell and Cryosurgery, IRE surgery or surgery will be used in Breast Cancer
75936830|NCT05692349|Device|MRI|MRI will be employed to assess muscle composition, evidence of degeneration or replacement by fat
75936831|NCT03179696|Behavioral|Mobile-assisted CBT|mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
75936832|NCT03179618|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
75936833|NCT03179618|Drug|Lipid Regulating Drugs|Mainly including statins
76117188|NCT04443192|Drug|Placebo|Placebo to ZF874
75799147|NCT05671458|Other|intraoperative navigation and creation of tumor resection maps|TRM are based on intraoperative navigation data and yield anatomically accurate marks of the tumor resection margin and potential residual tumor areas on clinical imaging. These marks will be annotated with histopathological information. Subsequently, the resulting 3-dimensional TRM will be imported into the radiotherapy planning system as part of a multidisciplinary workflow.
75799148|NCT03853512|Drug|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
75936834|NCT03179618|Drug|Coronary Vasodilator|Mainly including nitrates
75936835|NCT03179618|Drug|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
75936836|NCT03182894|Drug|Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
75936837|NCT03649217|Device|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
75936838|NCT02418650|Drug|ODM-201 300 mg tablet|
75936839|NCT02418650|Drug|intravenous14C-ODM-201|
75936840|NCT02418650|Drug|300 mg 14C-ODM-201 oral solution|
75936841|NCT02418728|Other|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
75936842|NCT02418884|Drug|rosuvastatin|CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
75936843|NCT05511935|Other|professional development training for CHWs on dental health (GRIN)|multi module online training
75936844|NCT03106922|Drug|PMF104|"Powder for oral solution:~Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water"
75936845|NCT03106922|Drug|Klean-prep|"Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water"
75936846|NCT05692193|Behavioral|pain education|Pain education was given to the experimental group for 20-30 minutes on the day of hospitalization.
75936847|NCT02423096|Drug|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
75936848|NCT03629951|Drug|Oral Antipsychotics (OAP)|This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
75799149|NCT03853512|Other|Semisolid vaseline|Product is applied to the other side of the inguinal region.
75936849|NCT02423018|Drug|Pregabalin|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
75936850|NCT02423018|Drug|Placebo|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
75341478|NCT04986176|Drug|HC-1119|oral
75799150|NCT03849924|Behavioral|Self-affirmation|Self-affirmation implementation intentions in the form of a questionnaire.
75341479|NCT04986176|Drug|Placebo|oral
75799151|NCT01189188|Procedure|Artery puncture with ultrasound guidance|Ultrasound device will be used to locate artery for puncture.
75799152|NCT01189188|Procedure|Artery puncture without ultrasound guidance|Blood drawn from radial artery according to conventional procedure, without ultrasound guidance.
75936851|NCT03622385|Other|DNA Methylation|No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
75341480|NCT00584948|Drug|Memantine|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
75341481|NCT00584948|Drug|Placebo|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
75341482|NCT00605072|Drug|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
75936852|NCT04483076|Drug|Chemotherapy drug|The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA < 1.25 m2; 50mg BID for 1.25 m2 < BSA <1.5 m2; 60mg BID for BSA > 1.5 m2. Day 15 to day 21 is the rest period.
75936853|NCT04483076|Procedure|Gastrectomy|Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.
76027219|NCT02367625|Device|MedGyn MGC 200|Standard cryotherapy
76027220|NCT03055403|Drug|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
76027221|NCT03055403|Drug|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
76027222|NCT02367703|Procedure|laparoscopic hysterectomy|
75936854|NCT04483076|Procedure|Laparoscopic exploration|Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.
75651926|NCT04624139|Behavioral|Physiotherapy only|"A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
75651927|NCT04614363|Drug|68Ga-PSMA|All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
75799153|NCT03849846|Other|Focus groups|Participants will also complete a sociodemographic questionnaire. The moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioural control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data.
75341483|NCT00605072|Drug|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
75799154|NCT01292772|Procedure|contract-enhanced MRI|Patients will have contrast-enhanced MRI of the breasts.
75799155|NCT01292772|Radiation|Unilateral Adjuvant Radiation Therapy|The study group will consist breasts receiving post-operative radiation, and the control group will consist of the patient's breasts on the non-radiated side. In this way, patients will act as their own control.
75341484|NCT00605072|Drug|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
75936855|NCT05692115|Diagnostic Test|stress ECG|stress ECG to patients suspected to be ischemic patients .
75936856|NCT02422862|Other|UC-TSM|"Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization."
75936857|NCT03564353|Device|tDCS|tDCS
75936858|NCT05691959|Drug|Placebo|Patients randomized to placebo group will receive Normal Saline 50ml IV.
75936859|NCT05691959|Drug|Calcium|Patients randomized to the study group will receive Calcium 2gm in Normal Saline 50ml IV.
75936860|NCT02418338|Other|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
75936861|NCT02422706|Drug|Nitazoxanide|Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
75936862|NCT02422706|Drug|Metronidazole(MTZ)|Metronidazole 500 mg twice daily
75936863|NCT02422706|Drug|Omeprazole|Omeprazole 20 twice daily
75936864|NCT02422706|Drug|Clarithromycin|KLacid twice daily
75936865|NCT02422706|Drug|Levofloxacin|Tavanic. Tavacin
75799156|NCT03849612|Device|AID System|AID system
75341485|NCT00605072|Drug|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
75341486|NCT00605072|Drug|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
75651928|NCT04555967|Device|SAPIEN 3 Ultra System|Transcatheter aortic valve implantation
75651929|NCT04544904|Device|PAARx|Prescription Physical Activity Programming Application
75651930|NCT04544904|Device|JM|Joint Management (JM) web-based joint management resource.
75799157|NCT03849612|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
75936866|NCT02422706|Drug|Doxicycline|Vibramycin 100 mg twice daily
75936867|NCT03058757|Drug|intravesical mitomycin-C 40mg/20ml instillation|"neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation~one day before surgery~four hours before surgery"
75936868|NCT02418260|Procedure|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
75936869|NCT02418260|Procedure|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
75936870|NCT02418260|Procedure|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
75936871|NCT03138889|Drug|NKTR-214|NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
75936872|NCT03138889|Drug|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
75936873|NCT03138889|Drug|NKTR-214|NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
75936874|NCT03138889|Drug|NKTR-214|NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
75651931|NCT04539002|Behavioral|Aerobic exercise|Aerobic exercise performed on a stationary ergometer for 30 minutes, thrice weekly, with graded supervision. Participants will participate in the intervention over 24 weeks.
75799158|NCT03853278|Behavioral|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
75936875|NCT03138889|Drug|Cisplatin|Cisplatin will be dosed per the pharmacy manual
75799159|NCT01189344|Drug|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
75799160|NCT01191138|Procedure|Infracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
75799161|NCT01191138|Procedure|Supracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
75799162|NCT03853200|Drug|QMix Root Canal Irrigant|Endodontic irrigant recommended for final irrigation
75799163|NCT03853200|Drug|17%EDTA+2%Chlorhexidine|two endodontic irrigants will be used in this group in a sequential manner
75799164|NCT03853200|Other|EDTA|17% EDTA irrigation solution
75799165|NCT01187784|Behavioral|Coping Cat cognitive-behavioral therapy for anxious youth|Manualized, empirically supported CBT treatment for anxious youth
75799166|NCT01293942|Drug|irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab|IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
75936876|NCT03138889|Drug|Carboplatin|Carboplatin will be dosed per the pharmacy manual
75799167|NCT01189656|Biological|HBV DNA Vaccine|HBV DNA Vaccine, 1mg/ml/syringe, formulation
75651932|NCT04539002|Behavioral|Education Group Control|A monthly, hour-long, class over various MS topics and symptoms, led by a trained facilitator.
76088925|NCT04553835|Behavioral|RAS for at-risk individuals|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day."
76088926|NCT04553835|Behavioral|No RAS for at-risk individuals|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
75651933|NCT04525274|Drug|normal saline|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of 40 ml bupivacaine 0.25% + 5 ml normal saline will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
75651934|NCT04525274|Drug|dexmedetomidine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
75651935|NCT04525274|Drug|Ketamine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
75651936|NCT04513483|Device|continuous positive airway pressure|CPAP treatment at night. Treat AF as cardiologist's discretion.
75651937|NCT04513483|Device|Placebo|Observation. Treat AF as cardiologist's discretion.
75651938|NCT04502446|Biological|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
75672245|NCT00620438|Drug|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
75799168|NCT01581138|Drug|VX-222|400 mg tablets twice daily for oral administration
75799169|NCT01581138|Drug|telaprevir|1125 mg tablets twice daily for oral administration
75936877|NCT03138889|Drug|Nab paclitaxel|Nab-paclitaxel will be dosed per local practice and label
75936878|NCT03138889|Drug|Paclitaxel|Paclitaxel will be dosed per local practice and label
75936879|NCT03138889|Drug|Pemetrexed|Pemetrexed will be dosed per the pharmacy manual
75936880|NCT03138889|Drug|Atezolizumab|Atezolizumab will be dosed per current label indication
75936881|NCT02422472|Device|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
75936882|NCT02425514|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
75936883|NCT02425514|Device|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
75936884|NCT02425748|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
75936885|NCT02425748|Biological|γδ T Cell|γδ T cells will be used against non small lung tumor.
75936886|NCT02425748|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against lung tumor.
75936887|NCT03669679|Procedure|Breast reduction|breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique
75936888|NCT02422394|Drug|Eltrombopag|
75651939|NCT04501445|Behavioral|Written Summary of Rounds|The summary was organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
75936889|NCT02418494|Other|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
75936890|NCT02418494|Other|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
75651940|NCT04493606|Other|SCI ProACTIVE Coaching (objective 1)|Peer coaches will conduct an assessment to understand patient's readiness, goals, barriers, preferences, and access to physical activity resources and mutually select tailored physical activity-enhancing strategies based on the assessment. These strategies include education (SCI exercise guidelines, safety, benefits, basics of physical activity, behaviour change techniques) and referral to appropriate peers, programs, and organizations. Goals will be based on the SCI Fitness Guidelines (targeting a goal of 20min of moderate to vigorous intensity aerobic exercise + 3 sets of strength training exercises for each major functioning muscle group at a moderate to vigorous intensity each 2x/week) and if ready, the Canadian SCI Physical Activity Guidelines (30 min 3x/week of moderate to vigorous intensity aerobic exercise + strength training 2x/ week). Ten 15-minute, video-conference or telephone sessions will be scheduled in accordance with patient needs and readiness with the peer coaches.
75799170|NCT01581138|Drug|ribavirin|1000 mg per day for subjects weighing <75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
75799171|NCT01191216|Drug|1-methyl-d-tryptophan|
75936891|NCT01881763|Drug|Ketamine|Ketamine 1-2 mgr/ kg IV
75936892|NCT01881763|Drug|Methohexital|Methohexital 0.5-1mg/kg IV
75936893|NCT03178058|Other|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
75936894|NCT03137095|Other|Cognitive testing|computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3, 4.5 & 5.
75936895|NCT03137095|Other|Research Brain MRI|Optional sub-study participation includes undergoing research brain MRI to obtain structural and functional brain images at Assessment 4.5 and 6.
75936896|NCT02418416|Other|Oocyte double chemical activation|Oocyte double chemical activation
75936897|NCT02422316|Other|Non-contrast Cardiac CT scan|
75936898|NCT03674203|Biological|Platelet-Rich Plasma|1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
75936899|NCT03674125|Biological|GLS-6150|Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)
75936900|NCT03669601|Drug|AZD6738|A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
75799172|NCT01191216|Drug|docetaxel|
75799173|NCT01191216|Other|diagnostic laboratory biomarker analysis|
75341487|NCT00585104|Drug|levosimendan|10-minute infusion
75341488|NCT00585182|Drug|Enoxaparin 0.5 mg/kg once daily|Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
75799174|NCT01191216|Other|pharmacological study|
75341489|NCT04856228|Diagnostic Test|diagnostic posterior interosseous nerve lidocaine injection|ultrasound guided posterior interosseous nerve and lateral epicondyle 1 ml 2% lidocaine injection
75799175|NCT01580358|Drug|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
75799176|NCT01580358|Drug|Starch|It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
75799177|NCT01193946|Dietary Supplement|dietary control|Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
75799178|NCT01194024|Other|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
75799179|NCT01191294|Other|Simulation teaching session|Simulation-based, mastery learning educational intervention in visual screening for melanoma
75799180|NCT01294176|Drug|Lipoic Acid|Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
75799181|NCT01191372|Drug|placebo control|sterile saline for injection
75799182|NCT01191372|Drug|ARC19499|Anti-tissue factor pathway inhibitor (TFPI) aptamer
75936901|NCT03669601|Drug|Gemcitabine|Nucleoside metabolic inhibitor.
75936902|NCT03541499|Biological|BPZE1|Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10^7 colony forming units (CFU) or 10^9 CFU.
75936903|NCT03541499|Other|Placebo|The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
75936904|NCT05691881|Drug|68Ga-NY105|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105
75936905|NCT05457569|Other|Focus group (FC) - WP1|"3 group meetings for each group of parents:~Parents only~Parents and representatives of patient support groups~Parents and health professionals specialized in the care of these children at risk"
75936906|NCT05457569|Other|Child Neurodevelopment Questionnaires - WP2|during the 4th month of corrected infant age
75651941|NCT04493606|Behavioral|Implementation Intervention (objective 2)|"A training on how to deliver the ProACTIVE intervention will be delivered. Day 1 training will include an overview of the intervention, demonstration of the delivery of the intervention, and behavioural practice. Interventionists will practice delivering the intervention and record issues or questions to bring to the day 2 training. Day 2 training will include a refresher on intervention content, barriers identified during in-clinic/community practice will be addressed, and further behavioural practice with volunteer clients with additional feedback provided.~The trainer (Dr. Jasmin Ma) will provide monitoring and feedback during the first two months of implementation. Community of practice meetings will be held as needed to discuss challenges and facilitators to implementation. Feedback provided during community of practice meetings will be collected and used for iterative quality improvement of the intervention approaches."
75936907|NCT05457569|Other|Evaluation of compliance for the acquired skills in terms of development support - WP2|during the 4th month of corrected infant age
75474846|NCT01988181|Device|Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)|For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
75651942|NCT04491071|Diagnostic Test|Generalized Anxiety Disorder-7 (GAD 7)|test that will evaluate persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry.
75651943|NCT04491071|Diagnostic Test|Background questionnaire|questionnaire on the living conditions, socio-professional contexts and environmental conditions of the participants
75651944|NCT04491071|Diagnostic Test|Impact of COVID-19 questionnaire|status of the patient with regard to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus)
75799183|NCT01189734|Procedure|laparoscopic common bile duct exploration|
75936908|NCT05457569|Other|Evaluation of physiotherapist satisfaction with the follow-up and the time spent at the consultation - WP2|at the end of the study
75936909|NCT05457569|Other|4 Focus Group (FC) - WP2|"Parents who accepted the follow-up~Parents who refused at least part of the follow-up~Maternal and Child Protection & CAMSP professionals~Physiotherapists in a private practice"
75799184|NCT01189734|Procedure|laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy|
75936910|NCT02706392|Other|Laboratory Biomarker Analysis|Correlative studies
75936911|NCT02706392|Biological|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
75936912|NCT02416388|Drug|Idarubicin|"Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
75936913|NCT02416388|Drug|Daunorubicin|"Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
75936914|NCT02416388|Drug|HD Cytarabine|"Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
75474847|NCT01988194|Procedure|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
75651945|NCT04491071|Diagnostic Test|Confinement and Communication During the COVID-19 Pandemic|know the experience of containment and isolation during the pandemic
75936915|NCT02416388|Drug|Cyclosporine|"GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100"
75936916|NCT02416388|Drug|Methotrexate|"GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11"
75936917|NCT02416388|Drug|Mycophenolic acid (MPA)|"GvHD prophylaxis post allogeneic SCT :~720 mg BID from D0 to D+28 for HLA-identical siblings~720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors"
75936918|NCT02416388|Drug|vosaroxin|"Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4"
75936919|NCT02416388|Drug|ID cytarabine|"Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
75651946|NCT04491071|Diagnostic Test|Mental Health questionnaire|welfare effect
75799185|NCT01294254|Drug|Oleogel-S10|Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
75799186|NCT01294254|Procedure|Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site|wound is covered conventionally by applying one half of the Mepilex cut
75799187|NCT03847818|Drug|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|"Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles"
75936920|NCT02416388|Drug|Dexamethasone|"Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5"
76027223|NCT05060861|Other|ChAdOx1 nCoV-19 vaccine|covid-19 vaccine
76027224|NCT03100019|Dietary Supplement|Resveratrol|
76027225|NCT03100019|Drug|Placebo|
76027226|NCT02363725|Drug|Colchimax®|
76027227|NCT02363725|Drug|Conventional treatment|
76027228|NCT05060393|Behavioral|Mindfulness-based cognitive therapy|Mobile application, mindfulness-based therapy
76027229|NCT02367235|Procedure|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
76027230|NCT02367235|Procedure|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
75651947|NCT04491071|Diagnostic Test|Patient Health Questionnaire (PHQ-9)|assess depression during the pandemic
76088927|NCT05608785|Drug|IBI315|IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
75936921|NCT02416388|Drug|Venetoclax|"Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~100 mg/d on D1 to D8 (selection phase dose level 1)~or 200 mg/d on D1 to D8 (selection phase dose level 2)~or 400 mg/d on D1 to D8 (selection phase dose level 3)~or 400 mg/d on D1 to D14 (selection phase dose level 4)"
75799188|NCT03847584|Other|Survey|The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.
75799189|NCT01194102|Behavioral|Community Based Exercise Program|Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.
75936922|NCT02417948|Other|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
75936923|NCT02417948|Other|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
75936924|NCT02418104|Drug|CHS-1701|
75936925|NCT02418104|Drug|Pegfilgrastim (Neulasta)|
75936926|NCT02886065|Drug|Hiltonol|Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
75936927|NCT02886065|Drug|Citarinostat|Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
76088928|NCT05608785|Drug|Oxaliplatin|Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
76088929|NCT05608785|Drug|Capecitabine|Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
75341490|NCT04817696|Other|Patients without chronic pain symptoms|Verbal score < 3 at 3 months
75651948|NCT04491071|Diagnostic Test|Post Traumatic Stress Disorder questionnaire (PTSD-8)|Assessing the trauma of subjects during the pandemic
75651949|NCT04491071|Diagnostic Test|Experiences in Close Relationship Scale questionnaire (ECR-S)|Measuring social ties and attachment of subjects
75799190|NCT01194102|Other|Living with Stroke Education program|Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.
75799191|NCT01194102|Other|YMCA membership|Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
75936928|NCT02886065|Drug|Lenalidomide|Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.
75936929|NCT02886065|Biological|PVX-410|PVX-410 Biweekly (0.8 mg) via subcutaneous injection
75936930|NCT02416466|Biological|anti-CEA CAR-T cells|Gene modified patient T cells.
75936931|NCT02416466|Device|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
75936932|NCT03496259|Device|On-Q pump|Type of pain control device used
75936933|NCT03496259|Device|Epidural catheter|Type of pain control device used
75936934|NCT05454215|Device|Mechanical insufflation/exsufflation conventional|Conventional settings in a commercially available chest physiotherapy device
75936935|NCT05454215|Device|Mechanical insufflation/exsufflation modified|Modified settings in a commercially available chest physiotherapy device
75936936|NCT02416310|Device|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
75936937|NCT03392441|Other|Insulin Deprivation in Type 1 Diabetic Patients|Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
75936938|NCT03177824|Drug|Sildenafil Citrate 25Mg Tab|Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
75936939|NCT03177824|Drug|Placebo Oral Tablet|Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
75651950|NCT04488822|Drug|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
75672246|NCT00620438|Drug|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
75672247|NCT00620438|Drug|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
75799192|NCT03850938|Device|Conventional Kyphoplasty|The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.
75936940|NCT02416544|Other|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
76088930|NCT05608785|Drug|TST001|TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
75651951|NCT04488484|Other|Serology test follow-up|"The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken.~In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.)."
75936941|NCT02416232|Drug|Trametinib|Trametinib will be provided as tablets containing 0.5 milligram (mg) or 2.0 mg of trametinib parent (present as the DMSO solvate). The starting dose of trametinib will be administered orally 2.0 mg, once daily (QD)
75651952|NCT04472611|Drug|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
76088931|NCT05608785|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
76088932|NCT05608785|Drug|Anrotinib|Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
76088933|NCT04394013|Behavioral|Mindfulness intervention|Gentle body stretching with the incorporation of breathing technique
76088934|NCT04394013|Behavioral|Non-Mindfulness intervention|Gentle body stretching without the incorporation of breathing technique
75799193|NCT03850938|Device|Kyphoplasty with Rotary Cutter|The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.
76088935|NCT04552509|Radiation|Stereotactic Body Radiotherapy|Treatment of prostate cancer with stereotactic body radiation therapy (SBRT)
75651953|NCT04472598|Drug|Navitoclax|Tablet; Oral
75651954|NCT04472598|Drug|Ruxolitinib|Tablet; Oral
75651955|NCT04472598|Drug|Placebo for Navitoclax|Tablet; Oral
75651956|NCT04450550|Device|VeNS device|VeNS treatment
75651957|NCT04450550|Device|Sham VeNS device|Sham treatment of VeNS
75651958|NCT04437446|Diagnostic Test|Case Group|The additional examination corresponds to an OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.
75651959|NCT04437446|Diagnostic Test|Control Group|"The additional examinations correspond to:~OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.~OCT: non-invasive examination, without potential risks, without radiation, using infrared light. The patient must sit in front of a screen and a contact is taken without contact in about ten seconds.~Visual field"
75651960|NCT04428489|Other|Observation and necessary supportive care|For patients with ICUS and CCUS, necessary supportive care could be given. No addtitional treatment is administrated.
75799194|NCT01294410|Drug|Placebo|Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
76088936|NCT05608551|Behavioral|Animal-assisted trauma-focused therapy|Animal-assisted trauma-focused therapy (AA TF-CBT) is a specific form of trauma treatment, in which one or more animals are integrated into the therapy. AA TF-CBT follows a structured, standardized therapy manual.
75799195|NCT01294410|Drug|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
75799196|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
75799197|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
75936942|NCT02416232|Drug|Dabrafenib|Dabrafenib is commercially available as capsules containing 50 mg or 75 mg as free base (present as the mesylate salt). Dabrafenib will be administered orally 150 mg, twice daily (BID).
75936943|NCT04482842|Device|Gene detection (CYP2C9*3, VKORC1)|Warfarin is administered at the recommended dose by detecting CYP2C9*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.
75936944|NCT04482842|Drug|Warfarin Sodium|Warfarin is administered at a gene-guided dose or at a regular dose.
75936945|NCT02767661|Drug|Capecitabine|Capecitabine, 625mg/m2, orally twice daily (continuously)
75936946|NCT02767661|Drug|Aromatase Inhibitor|Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
76088937|NCT05608551|Behavioral|Standard trauma-focused therapy|Standard trauma-focused therapy (AA TF-CBT) is a standardized trauma therapy following a structured manual.
75651961|NCT04417842|Diagnostic Test|Respimetrix flow-volume monitoring device|The Respimetrix flow-volume monitoring device is being tested to validate its ability to measure Inspiratory Capacity
75651962|NCT04391790|Procedure|Cystectomy and modified urinary conduit|The modified retrosigmoid conduit is extended aorund 5 cm, so the left ureter does not have to cross under the mesentery wheras the presumed more robust ileal segment does.
75341491|NCT04817696|Other|Patients with chronic pain symptoms|Verbal score ≥ 3 at 3 months
75651963|NCT04391790|Procedure|Cystectomy and standard urinary conduit ad modum Bricker|The conduit is constructed using approximately 15 cm of terminal ileum and placed in the right side of the abdomen. In order for the left ureter to reach the conduit, it is mobilized behind the sigmoideum to the conduit.
75651964|NCT04373811|Diagnostic Test|Lung ultrasound|"Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax.~Lung Ultrasound Score (lung aeration) will be recorded using a convex probe with a transverse view. Presence of pleural thickening and subpleural consolidations will be recorded."
75799198|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
75799199|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
75799200|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
75799201|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
75799202|NCT01191450|Drug|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
75936947|NCT02415920|Drug|Oxytocin|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
75651965|NCT04373811|Diagnostic Test|Muscle ultrasound|"Diaphragm ultrasound will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness and thickening and subcostal anterior view with convex probe to assess diaphragm excursion.~Thickness of vastus intermedius, rectus femori and tibialis anterior will be measured using ultrasound linear probe. Cross-sectionnal area and echogeneicity of rectus femori and tibialis anterior will be measured using ultrasound linear probe. Penation angle of rectus femori will be assessed using ultrasound linear probe."
75672248|NCT05004506|Drug|Adductor Canal Block|The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
75936948|NCT02415920|Drug|Placebo|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
75936949|NCT02415764|Behavioral|Behavioral/Attitudinal OnTrack Role-Playing Game|"The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys."
75936950|NCT02422082|Dietary Supplement|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
75936951|NCT02422082|Dietary Supplement|Placebo|Dietary supplementation with placebo twice daily for 12 months
75936952|NCT03389243|Drug|Metamizol|in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
75672249|NCT05004506|Drug|Intra-articular Injection|receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
75936953|NCT03389243|Drug|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
75936954|NCT03389243|Drug|paracetamol and metamizole|in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
75936955|NCT03179150|Diagnostic Test|Computed Tomography|CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
75936956|NCT03179228|Device|Prostate Embolization|Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
75936957|NCT03042767|Biological|IMM-124E|IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
75474848|NCT01988207|Behavioral|Vocal Hygiene Training|Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
75474849|NCT01988207|Behavioral|Flow Phonation Exercises|Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
75799203|NCT01191450|Drug|Higroton® Laboratório Novartis|Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
75799204|NCT01194180|Biological|BCG: 100 microlitres ~ 2-8 x 105 pfu|BCG vaccination at day C (challenge day) then punch biopsy at day C+14
75799205|NCT01194180|Biological|MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu|MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
75799206|NCT01294488|Behavioral|Parent-Child Interaction Therapy|Therapists receive training in Parent-Child Interaction Therapy (PCIT) and receive supervision in their implementation of PCIT skills via phone consultation and polycommunication technology, each for 6 months.
75341492|NCT03830528|Drug|KW-6356 Low Dose|KW-6356 will be administered as single doses.
75936958|NCT03042767|Other|Placebo|Matched Placebo
75936959|NCT02421770|Other|Chamaemelum nobile 2%|"Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are"
75936960|NCT02421770|Other|placebo|
75936961|NCT02421692|Other|Progressive Rehabilitation|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
75936962|NCT02421926|Drug|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
75936963|NCT02421614|Other|high-protein low-carbohydrate diet with high olive oil|
75341493|NCT03830528|Drug|KW-6356 Middle Dose|KW-6356 will be administered as single doses.
75474850|NCT01988220|Other|sensory retraining|
75474851|NCT01988220|Other|repeated sensory input|sensory stimulation without attentive learning focus
75799207|NCT01189968|Drug|Demcizumab|The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.
75936964|NCT02421614|Other|high-protein low-carbohydrate diet with high sunflower oil|
75936965|NCT03312881|Diagnostic Test|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
75936966|NCT03312881|Diagnostic Test|neuroimaging|magnetic resonance imaging (MRI)
75936967|NCT03312881|Other|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
75474852|NCT01988259|Procedure|Bilateral approach for Laminoplasty|Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
75936968|NCT02410616|Behavioral|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
75474853|NCT01988259|Procedure|Unilateral approach for laminoplasty|Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
75936969|NCT02410616|Behavioral|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
75936970|NCT05691257|Drug|Roxadustat|"The initial dose of roxadustat was given according to body weight, which was more than 60kg: 100mg (three times a week); Weight less than 60kg: 70mg (three times a week); 2 weeks later, the corresponding indexes were rechecked and medication was adjusted according to hemoglobin. The target is hemoglobin 100-120g/L.~Reference for medication Method: The use of roxadustat is the same as the RCT study of roxadustat in the treatment of anemia and the drug instructions of roxadustat published by N Engl J Med in 2019."
75936971|NCT05691257|Drug|Recombinant human eythropoietin and/or Iron agents|Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
75799208|NCT01294566|Drug|GSK1322888|1 mg, 5 mg or 25 mg capsule
75799209|NCT01294566|Drug|Placebo|matching placebo capsules
75936972|NCT02410460|Drug|clonidine|
75936973|NCT02410460|Drug|glycopyrrolate|
75936974|NCT02410460|Drug|propofol|
75936975|NCT02410460|Drug|ketamine|
75936976|NCT02410460|Drug|marcaine|
75474854|NCT01988259|Procedure|Subperiosteal approach for foraminotomy|Unilateral subperiostal approach for single level foraminotomy
75474855|NCT01988259|Procedure|Transmuscular approach for foraminotomy|Unilateral transmuscular approach for single level foraminotomy
75799210|NCT01194336|Drug|Huperzine A|dosage form: tablet dose frequency: once only
75799211|NCT01194336|Drug|Donepezil|dosage form: tablet dosage frequency: once only
75936977|NCT02410460|Drug|scopolamine|
75936978|NCT02410460|Drug|midazolam|
75936979|NCT02410460|Device|ondansetron|
75936980|NCT02410460|Drug|metoclopramide|
75936981|NCT02410460|Drug|glycopyrrolate|
75936982|NCT02410460|Drug|lidocaine|
75936983|NCT02410460|Drug|famotidine|
75936984|NCT02410460|Drug|desflurane|
75936985|NCT02410460|Drug|sevoflurane|
75936986|NCT02410226|Procedure|Double-space combined spinal-epidural anesthesia|Epidural space identification in Lumbar 2-3 or 3-4 space using loss of resistance to air technique with 18-gauge Tuohy needle, then threading a 20-gauge multi-orifice epidural catheter 4-5 cm into the epidural space. Spinal anesthesia administration in an appropriate lower intervertebral space with intrathecal bupivacaine 12.5 mg and fentanyl 10 mcg through a 27-gauge spinal needle.
75474856|NCT01988272|Device|SPECT/CT imaging|Patients will undergo scanning on the above system.
75474857|NCT01988298|Drug|Ibuprofen|Ibuprofen 400 mg each 8 hours
75474858|NCT01988298|Drug|Acetaminophen|Control group
75474859|NCT01988311|Drug|psilocybin|dose manipulation as described in the protocol
75474860|NCT01988324|Other|FDHT-PET scan|
75474861|NCT01988324|Other|FES-PET scan|
75474862|NCT01988324|Other|CT-scan|
75474863|NCT01988324|Other|Bone scintigraphy|
75474864|NCT01988324|Other|Tumor biopsy|
75511100|NCT00937638|Dietary Supplement|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
75799212|NCT01194336|Drug|Galantamine|dosage form: tablet dosage frequency: once only
75799213|NCT01194336|Other|Placebo|dosage form: tablet dosage frequency: once only
75799214|NCT01194492|Radiation|Albumin transcapillary escape rate (125I-albumin)|Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
75799215|NCT03850470|Diagnostic Test|clinical examination|Thorough examination including history, screening, motion testing, strength testing, special testing
75936987|NCT02410226|Radiation|Preprocedure spinal ultrasound|Lumbar spinal ultrasound using the 2-5 MHz curved probe, performed in both the longitudinal and transverse planes for identification of the appropriate intervertebral spce, estimation of the depth to the epidural space, and noting the proper angle for subsequent needle insertion. Then skin markings relying on the ultrasound procedure are made identifying 2 intervertebral spaces.
75936988|NCT02410226|Radiation|Sham ultrasound procedure|Applying the ultrasound probe on the patient's back while the ultrasound machine is on the freeze position.Then skin markings relying on landmark palpation are made identifying 2 intervertebral spaces.
75799216|NCT03850470|Other|MRI|Low field MRI .25 Tesla
75799217|NCT03849222|Procedure|Apexification|
75799218|NCT03849222|Drug|MTA|
75799219|NCT03849222|Drug|Ca(OH)2|
75936989|NCT02410070|Procedure|Incision|The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
75936990|NCT03116672|Drug|one dose ketorolac 10 mg|Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
75936991|NCT03116672|Drug|One dose Diclofenac|Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
75799220|NCT03849222|Drug|Apical matrix|collagen membrane (Biocollagen; Bioteck:Turin, Italy)
75799221|NCT01190046|Behavioral|Resistance exercise training|Lower extremity resistance exercise training 3x/wk
75799222|NCT01190202|Procedure|Blood sampling|Capillary blood samples collected by finger/heel prick
75799223|NCT01190202|Procedure|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
75936992|NCT03116672|Drug|Placebo oral capsule|Administration of Placebo, 15 minutes before the clinical procedure.
75799224|NCT02849626|Drug|Perampanel|E2007
75936993|NCT02417636|Other|Task Shifting|Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
75936994|NCT03175094|Behavioral|Holistic Health Recovery Program for HIV+|Holistic Health Recovery Program for HIV+ (HHRP+) is a CDC-recommended, evidence based behavioral (psychoeducational) group intervention focused on harm reduction principles. The investigators systematically adapted HHRP+ using findings from qualitative interviews with the target population of adult women living with and at-risk for HIV who are justice-involved (on probation, parole, or recently released from prison or jail).
75936995|NCT03174860|Drug|Diclofenac Potassium 50mg Tab|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
75799225|NCT03849144|Behavioral|Therapy dog activity|Visiting therapy dogs and their owners, evaluated and registered as therapy dog teams with Pet Partners will be spread around a large room on the Aetna campus. Employees will arrive at scheduled times to visit with the dogs for 15 minutes, talking to the dogs and owners and petting the dogs
75799226|NCT03849144|Behavioral|Low impact exercise|The low impact exercise will consist of stretching exercises conducted by a member of Aetna's wellness team in the same room for 15 minutes.
75799227|NCT02833792|Drug|Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Intravenous administration
75936996|NCT03174860|Drug|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
75936997|NCT02417480|Behavioral|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
75936998|NCT02417480|Behavioral|Follow habitual, usual diet|Participants will be asked to consume their habitual, usual diet.
75799228|NCT02833792|Other|Placebo|Intravenous administration
75799229|NCT02660710|Drug|R-CHOP|maximum of 6-8 cycles of R-CHOP over 18-24 weeks
75799230|NCT01294878|Drug|omalizumab|The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
75799231|NCT01296438|Drug|Faster-acting insulin aspart|Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
75799232|NCT01296438|Drug|insulin aspart|Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
75799233|NCT01190280|Procedure|Cholecystectomy operation|Cholecystectomy after randomization
75799234|NCT03850548|Other|Prosthetic joint infection with Cutibacterium acnes|patients having a prosthesis infection with C.acnes identified by specific PCR
75799235|NCT03850626|Biological|Immunotherapy|subcutaneous injection
75799236|NCT01296516|Behavioral|Non-intervention group|A pedometer and written material on a healthy lifestyle.
75799237|NCT01296516|Behavioral|Face to face|Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
75799238|NCT01296516|Behavioral|Telehelath Group|Participants will speak to Trestletree personnel once a week via phone.
75799239|NCT01294956|Other|Lubricant Eye Drop|1 drop in each eye, four times a day for 42 days
75799240|NCT01294956|Other|Refresh Liquigel|1 drop in each eye, four times a day for 42 days
75936999|NCT03174548|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
75799241|NCT01190358|Dietary Supplement|Placebo|Sugar pill containing maltodextrin.
75799242|NCT01190358|Dietary Supplement|Grape seed extract|Meganatural Gold® contains 300mg of grape seed extract.
75341494|NCT03830528|Drug|KW-6356 High Dose|KW-6356 will be administered as single doses.
75341495|NCT03830528|Drug|KW-6356 X Dose|KW-6356 will be administered as multiple doses.
75341496|NCT03830528|Drug|KW-6356 Y Dose|KW-6356 will be administered for Japanese healthy men as multiple doses.
75341497|NCT03830528|Drug|Placebo|All study cohorts (except Part C) are placebo controlled.
75799243|NCT01191528|Device|capnostream 20, Oridian Medical 1987 ltd, Needham MA|"Oxygen blood saturation measured by a s sensor that reflects infrared light on oxygenated and deoxygenated arterial blood via a noninvasive, clip on digit sensor connected to a combination capnometer and pulse oximeter monitor.~End-tidal Carbon dioxide (EtCO2) is measured with a noninvasive nasal cannula sampling line which calculates the EtCO2 from exhaled air. Measurements recorded at 5 second intervals."
75799244|NCT01296594|Other|Usual Care|Usual Care
75937000|NCT03174548|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: solution~Route of administration: oral"
75651966|NCT04316663|Behavioral|Well-Being Intervention|The main aim of the well-being intervention is to reduce levels of distress through the promotion of psychological well-being. Key components of the intervention are self-monitoring of instances of well-being and what leads to their interruption (i.e., thoughts and behaviors), cognitive restructuring of interfering thoughts, and homework assignments to address dysfunctional behaviors and increase exposure to optimal experiences. Participants will become aware of their functioning based on six different dimensions of psychological well-being (i.e., self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth), and will be guided in finding a balance within each dimension.
75937001|NCT02417558|Behavioral|Alterniity Augmented Reality (AAR)|AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
75937002|NCT02417558|Behavioral|VideoGrade|Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
75937003|NCT02410148|Device|Non-invasive ICP measurement (Vittamed 305)|The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
75937004|NCT03174470|Device|TENS Stimulator|Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
75937005|NCT02417402|Other|Control|The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
75937006|NCT02417402|Other|Trained|The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
75937007|NCT02409992|Behavioral|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
75937008|NCT02409992|Behavioral|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
75937009|NCT02417090|Drug|Insulin|Pregnant women who used insulin to treat gestational diabetes
75937010|NCT02417090|Drug|Metformin|Pregnant women who used metformin to treat gestational diabetes
75937011|NCT00703820|Drug|Cytarabine|See Detailed Description
75937012|NCT00703820|Drug|Daunorubicin|See Detailed Description
75799245|NCT01296594|Behavioral|Contingency Management|This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
75799246|NCT01293162|Drug|Armolipid Prev|Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
75937013|NCT00703820|Drug|Etoposide|See Detailed Description
75937014|NCT00703820|Drug|Clofarabine|See Detailed Description
75651967|NCT04316663|Behavioral|Sleep Hygiene|The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
75965920|NCT04875572|Device|Analgesia Nociception Index (ANI) Monitor|The ANI monitor produces an objective measure of parasympathetic tone through non-invasive electrodes placed on the patient's chest. The patient's standard of care is not affected, and the anesthetist is blinded to the monitor, so as not to affect their anesthetic practice.
75651968|NCT04254939|Drug|CS3007 (BLU-285)|"A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days."
75651969|NCT04242186|Other|Injury Liaison Service|The Injury Liaison Service nurse will coordinate deprescribing of fall-related medications, osteoporosis management, staff support of behavior management using video case conferencing, and shared decision making with residents and/or families.
75799247|NCT01296750|Other|Early Physiotherapy start|Physiotherapy starting at one day post op
76088938|NCT04556097|Behavioral|Care Ecosystem|"The Care Ecosystem model uses a telephone-based intervention to support persons with dementia and their care partners, screening for common dementia-related problems and providing modular standardized support protocols and caregiver education. Specially trained health care navigators systematically identify needs and address health status, advance care planning, medication management and management of challenging behaviors. Health care navigators receive backup support from a nurse, social worker, dementia specialist, and pharmacist, and maintain close communication with the primary care provider of the persons with dementia.~This Care Ecosystem model will be adapted to augment the dementia care provided by experienced Integrated Care Management Program nurse care managers engaged in the care of high-risk, high-cost patients in a large health system."
75937015|NCT00703820|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
75937016|NCT03177980|Drug|Fentanyl|The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
75937017|NCT03177980|Drug|Fentanyl and clonidine|In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
75341498|NCT00605384|Drug|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
75474865|NCT01988363|Procedure|GON injection at C2 location|GON will be identified at the novel, proximal C2 location on the symptomatic side via ultrasound guidance. Prior to injection, an independent examiner will perform a sensory exam of the involved dermatome. A 25 gauge spinal needle will be inserted into the symptomatic side after locating the GON via ultrasound at the C2 level. Subjects will be injected with treatment medication. Thirty minutes after injection, an independent examiner will test for anesthesia over the desired dermatome. VAS will be assessed pre-injection, 30 post-injection, 2 weeks post-injection and 1 month post-injection. The 2 week and 1 month assessments will be conducted by telephone.
75474866|NCT01988389|Dietary Supplement|whole apples (WA)|
75651970|NCT04218448|Other|Hypnorelaxation|"Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes.~The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of adapted suggestions and metaphors, adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. Using the elements previously supplied by the patient, the investigator tells a story which allows the patient to focus his attention on something other than the performance of the somatosensory evoked potentials examination. The investigator, thanks to hypnosis, allows the development"
75799248|NCT01296906|Behavioral|Recall conducted by private practices|All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.
75799249|NCT01296906|Behavioral|Recall conducted centrally by local health department|A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
75651971|NCT04213261|Biological|FCX-007 (dabocemagene autoficel; see below for FCX-007 description)|FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
75651972|NCT04183894|Behavioral|Personalized Intervention|Participants will receive a personalized intervention based on their personalized network.
75937018|NCT02409836|Drug|Marketed Dentifrice|Marketed Dentifrice
75937019|NCT02409836|Drug|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
75937020|NCT02409836|Drug|Marketed Flavored Dentifrice|Bubble Gum Flavored
75937021|NCT03174626|Behavioral|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
75937022|NCT03174626|Other|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
75341499|NCT00605384|Drug|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
75341500|NCT00586196|Drug|donepezil|5 mg each day for 30 days
75341501|NCT00586196|Drug|Placebo|Encapsulated cornstarch One capsule daily for 30 days
75341502|NCT00605696|Drug|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
75341503|NCT04745312|Device|Visible light|Ambient room lighting will be supplemented with additional light from a task lamp.
75341504|NCT00606554|Device|Computer-assisted weaning program|Closed-loop, knowledge-based, computer-assisted wean program initiated at the start of ventilator weaning.
75474867|NCT01988389|Dietary Supplement|apple juice (AJ)|
75474868|NCT01988428|Drug|Ceftriaxone 2000 mg|Ceftriaxone 2000 mg
75474869|NCT01988467|Other|exposure to second hand smoking|The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
75474870|NCT01988480|Procedure|Image-guided surgery|Placement on residual bone around the implant
75474871|NCT01988480|Procedure|Sinus lift surgery|Allograft bone
75937023|NCT02417012|Behavioral|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
75937024|NCT02417012|Behavioral|Standard care|Standard individual diabetes support
75651973|NCT04171440|Procedure|robotic pancreaticoduodenectomy|The robotic pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
75937025|NCT02409758|Behavioral|Voice therapy|Voice therapy applied during 6 weeks.
75937026|NCT02409602|Other|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
75937027|NCT03177668|Drug|YS110|Intravenous administration
75937028|NCT03177902|Drug|Chemotherapy|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
75937029|NCT03177590|Other|Recordings of facial and vocal emotional productions|"Children are asked to perform three tasks:~an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)~an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation~Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context."
75937030|NCT03177434|Drug|polyethylene glycols (PEG) 3350|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
75937031|NCT03177434|Drug|Lactulose Oral Product|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
75937032|NCT02415530|Behavioral|Combined home visiting and group intervention|home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3~6 months
75937033|NCT02415530|Other|No intervention|No intervention
75937034|NCT03045887|Drug|GSK2292767 50 μg|GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
75937035|NCT03045887|Drug|GSK2292767 500 μg|GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
75937036|NCT03045887|Drug|Placebo|Lactose as powder for inhalation
75937037|NCT02415374|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
75937038|NCT02415296|Other|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
75799250|NCT01191606|Procedure|the change of ventilatory mode|One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
76088939|NCT03828760|Behavioral|Music listening|Patients will be asked to either use their personal phones to listen to preferred music which is already on their device, or if they do not have a phone or other personal device capable of playing music of their choice, we will use a device (e.g. iPod) to load music of their choice. While in the waiting room, participants will listen to music through headphones/earphones, however they will need to remove their headphones/earphones during the initial consultation with the family physician (explaining risks, etc.), and resume listening to music through the phone speakers once in the examination room as patients will need to be able to hear instructions from the physician during the procedure.
76088940|NCT01775501|Drug|Leucovorin|200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
75937039|NCT02415296|Other|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
75937040|NCT02415296|Other|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
75651974|NCT04146870|Other|not have|not have
75341505|NCT00606554|Behavioral|Standard of Care weaning|Evidence-based standard of care weaning process.
75341506|NCT00587132|Drug|Synthetic Human Secretin|0.2mcg/kg one time dose.
75341507|NCT00606944|Behavioral|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
75341508|NCT00587678|Drug|Simvastatin|40mg each night
75651975|NCT04142385|Other|Cytology Specimen Collection Procedure|Undergo blood, urethral swab, penile skin cell, and anal swab collection
75651976|NCT04142385|Other|Laboratory Biomarker Analysis|Correlative studies
75651977|NCT04142385|Procedure|Medical Examination|Undergo anal and penile clinical exam
75651978|NCT04142385|Procedure|Physical Examination|Undergo targeted physical exam
75651979|NCT04142385|Procedure|Proctoscopy with Biopsy|Undergo HRA
75651980|NCT04142385|Other|Questionnaire Administration|Ancillary studies
75799251|NCT01191606|Procedure|the change of ventilatory mode|One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
75937041|NCT02415452|Procedure|drug-eluting stent implantation|The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
75341509|NCT00587678|Drug|Ezetimibe|10mg daily
75799252|NCT05671536|Behavioral|motivational interview|Intervention arm will receive motivational interview by the researcher, once a month for 4 times at least 20 minutes. The researcher received education about motivational interview.
75937042|NCT02409524|Biological|AlloVax|Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)
75341510|NCT00587678|Drug|Simvastatin/Ezetimibe|40mg/10mg each night
75937043|NCT02409524|Biological|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
75937044|NCT02409524|Biological|CRCL|Autologous tumor-derived chaperone protein mixture
75341511|NCT02138006|Drug|Intensive insulin treatment|Mealtime insulin (Actrapid) Basal insulin (Monotard)
75341512|NCT02138006|Drug|Standard insulin treatment|Insulin Mixtard
75341513|NCT00587834|Device|Gintuit|Application of Gintuit at Day 0 to the gingival bed
75651981|NCT04125563|Drug|Capsicum Oleoresin|The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).
75937045|NCT03177278|Drug|[14C]-plazomicin|single intravenous dose
75937046|NCT02587325|Drug|nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)|ABI-009
75937047|NCT02409446|Dietary Supplement|Anthocyanin|Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
75937048|NCT02409056|Behavioral|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
76088941|NCT01775501|Drug|Fluorouracil|5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
76088942|NCT01775501|Drug|Oxaliplatin|85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
76088943|NCT01775501|Drug|Sorafenib|400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
76088944|NCT03786640|Radiation|3T MRI scan|A clinically indicated 3T MRI scan will be performed per standard procedures for the radiology department. Cardiac monitoring during the MRI scan is recommended to include Pulse Oximetry and/or ECG.
75651982|NCT04125563|Drug|Placebos|Soft gel capsules filled with placebo - sorbitol and colorant.
75341514|NCT00587834|Other|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
75341515|NCT05247476|Drug|L-T4|Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
75651983|NCT04113161|Other|Standard Care|Standard care will consist of 1) community-based screening and referral conducted by HomeGrown St. Louis (HomeGrown StL) network members and supported by HomeGrown StL coordinator; and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
75672250|NCT00891839|Drug|Bendamustine|Bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
75341516|NCT05247476|Drug|L-T4+T3 (thyroid tablet)|Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
75937049|NCT02409056|Behavioral|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
75937050|NCT02415218|Biological|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
75937051|NCT02415140|Other|Rate of depression|
75937052|NCT02414906|Other|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
75341517|NCT04565210|Other|Music exposure|Participants will be offered individual sessions of music. They will be exposed for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
75937053|NCT03177356|Procedure|extraction,implant placement,PRF|Surgical extraction of mandibular molar using periotome and forceps followed by implant placement in inter-septal bone. Then a blood sample is withdrawn from patient and placed in the centrifuge. Then Platelet-Rich fibrin is placed in the extraction socket as space filling material
75937054|NCT03177356|Procedure|Exctraction,Implant placement,Bone graft|Surgical extraction of mandibular molar using extraction forceps and periotome followed by implant placement in interseptal bone. De-proteinized bovine bone graft material is placed as space filling material
75937055|NCT02414984|Biological|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
75937056|NCT02415062|Drug|Donepezil|23mg/day for 24 weeks versus 10mg/day for 24 weeks
75651984|NCT04113161|Other|Child Behavioral Health Navigator (cbhN)|CbhNs will engage in a series of contacts in person and by phone/text to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
75651985|NCT04106232|Other|No change in procedure except for specimen collection throughout procedure|Stool specimens will be taken before and during the HyGIeaCare procedure. Microbiome comparisons will be made across all specimens
75341518|NCT04565210|Other|Silence|Participants in this group will be offered individual silence session for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
75341519|NCT04545008|Drug|Famotidine|Oral Famotidine
75341520|NCT04545008|Drug|N-Acetyl cysteine|Oral N-Acetyl Cysteine
75799253|NCT01190592|Other|Resistance Training with Milk Supplementation in Adolescents|"On resistance training days, the RT+ milk group will receive milk (280kcals) immediately following exercise and milk at another time during the day. The RT+ juice group will receive fruit juice immediately following resistance exercise and juice again another time during the day. The RT+ water group will receive water following resistance exercise and water at another time during the day.~On non training days, students in the RT+ milk group will receive milk. Students in the RT+ juice group will receive juice. The RT+ water group will receive water during the school day. On non-RT days, the total volume of milk, juice, or water will be split into two administration times during the school day."
75937057|NCT02409212|Behavioral|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
75937058|NCT02409212|Behavioral|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
75937059|NCT02416700|Procedure|immediate implant surgery|Surgery of dental implants in one side of the mouth.
75937060|NCT02416700|Device|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
75474872|NCT01988506|Drug|Interleukin 2|Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
75651986|NCT04078295|Drug|E7389-LF|E7389-LF Intravenous infusion.
75651987|NCT04078295|Drug|Nivolumab|Nivolumab Intravenous infusion.
75937061|NCT02408978|Drug|OXP005|
75937062|NCT02408978|Drug|Naproxen|
75937063|NCT02408822|Device|PTA Balloon dilatation catheter Advance® (Cook® Medical)|2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
76088945|NCT04124835|Other|Swiss Ball|"Top narrow (DeLee Plan -5 to -1 or Hodge Plan 1-3) Retroversion, lateralization and pelvic circumference exercises with abducted hips and external rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and external rotation.~Lower Narrow (DeLee Plan +1 to +5 or Hodge Plan 3-4) Pelvic anteversion, tilt, and circumference exercises with abducted hips and internal rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and internal rotation."
75341521|NCT04527770|Drug|Dexamethasone|Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam
75341522|NCT04527770|Drug|Midazolam injection|intracarpal injection of midazolam and bupivacaine 0.5%
75341523|NCT02138240|Behavioral|Social network intervention|The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
75341524|NCT05247086|Device|Negative pressure therapy|After surgical wound closure we will apply negative pressure therapy
75341525|NCT05247008|Other|Thyme honey|"Thyme honey will topically be applied to the oral mucosa as oral rinse based on the Biswal et al. (2003) administration protocol.~Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day."
75341526|NCT02139176|Behavioral|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
75937064|NCT02408822|Device|Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®|2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
75937065|NCT02414672|Behavioral|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
75937066|NCT03176576|Behavioral|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
75341527|NCT02139176|Behavioral|patient referral|A patient agrees to recruit their partner using the invitation.
75341528|NCT01798784|Behavioral|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
75341529|NCT01798784|Behavioral|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
75474873|NCT01988519|Procedure|Closed gravity drain|passive tube drains (PFM Medical, Köln, Germany)
75474874|NCT01988519|Procedure|closed suction drain|BLAKE Silicon drains (Ethicon, USA)
75474875|NCT01988532|Other|No treatment given|Subject will only fill out a questionnaire
75341530|NCT01798784|Behavioral|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
75799254|NCT01211418|Behavioral|Integrative Meditation|"Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.~Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB & IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.~Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study."
75474876|NCT01988545|Other|1,5 nmol/kg,GLP-1 sc injection|
75799255|NCT01211418|Behavioral|Supportive Counseling|"NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.~The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion."
75799256|NCT03735498|Other|Psychological Intervention|Promote effective coping and reduce caregiving burden
75799257|NCT01194648|Other|questionnaire administration|
75799258|NCT01194648|Procedure|assessment of therapy complications|
75799259|NCT01194648|Procedure|high-intensity focused ultrasound ablation|
75799260|NCT01194648|Procedure|multiparametric magnetic resonance imaging|
75799261|NCT01194648|Procedure|quality-of-life assessment|
75937067|NCT03176576|Other|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
75937068|NCT03176576|Other|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
76088946|NCT04124835|Other|Control Grup|Habitual Care of the Service.
75341531|NCT04492436|Drug|thrombomodulin alfa|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
75341532|NCT04492436|Drug|Placebo|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
75474877|NCT01988545|Other|1,5 nmol/kg GLP-1 9-36amide, sc injection|
75474878|NCT01988545|Other|Exendin-4 ;10 ug,sc injection|
75651988|NCT04072367|Device|NeVa Stent Retrievers|thrombus removal
75651989|NCT04072367|Device|Solitaire Stent Retrievers|thrombus removal
75651990|NCT04038021|Behavioral|Phosphatidylethanol-based Contingency Management|In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.
75651991|NCT04038021|Behavioral|Non-Contingent Control|In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
75651992|NCT04020471|Other|Pain Scale/Medication Log|Daily recording of pain level after surgery and recording of medication taken for pain relief.
75651993|NCT03974828|Device|Anesthesia Control Tower Notification|Real-time data will be monitored through the AlertWatch system as well as the electronic health record. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.
75799262|NCT01194648|Procedure|transperineal prostate biopsy|
75799263|NCT01194648|Procedure|transrectal prostate biopsy|
75799264|NCT01293318|Other|No intervention|No intervention
75799265|NCT01190670|Drug|Tacrolimus|Oral and Intravenous
75799266|NCT01190670|Drug|ASP015K|Oral
75799267|NCT01194882|Drug|HUMAN INSULIN (BIOSYNTHETIC)|Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml
75799268|NCT01194882|Drug|Insuplant|"Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:"
75799269|NCT03848598|Diagnostic Test|Evaluation of local tendon deformation|Ultrasound-based speckle tracking to evaluate the local tendon tissue displacement during isometric exercise.
75799270|NCT01191684|Other|laboratory biomarker analysis|Correlative studies
75937069|NCT03176576|Other|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
75341533|NCT01798940|Drug|Torrent's Pioglitazone|
75341534|NCT00609128|Drug|olopatadine|olopatadine one drop in one eye for one week
75474879|NCT01988545|Other|saline|
75474880|NCT01988558|Drug|DL - Lactic Acid|Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
75474881|NCT01988558|Dietary Supplement|Raspberry flavored syrup|Placebo group to receive Raspberry flavored Syrup
75474882|NCT01988597|Other|Dry eyes|
75474883|NCT01988610|Drug|28 days treatment with Mifepristone.|
75474884|NCT01988623|Behavioral|Pivotal Response Treatment (PRT)|
75799271|NCT01191684|Other|enzyme-linked immunosorbent assay|Correlative studies
75799272|NCT01191684|Other|flow cytometry|Correlative studies
75799273|NCT01191684|Other|immunoenzyme technique|Correlative studies
75341535|NCT04409054|Other|Cough and Valsalva effort|Three increasingly cough effort and three Valsalva type effort at four different volumes of rectal distension (empty rectum, volume for a first sensation of filling, volume for desire to defecate and maximal tolerable volume) while recording the external anal sphincter activity
75937070|NCT02408744|Drug|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
75937071|NCT03176888|Behavioral|Reduced-exertion, high-intensity interval training (REHIT)|As in arm/group description
75651994|NCT03973580|Behavioral|Attentional Bias Modification (ABM) task|Participants will be presented with a fixation cross (500ms) followed by a pair of identity-matched, angry-neutral faces (1000ms). The pair presentation is replaced by a single arrow-probe (1000ms) in the position of the neural face. Inter-trial intervals (ITI) are 500ms. Participants indicate arrow direction (left or right) by pressing one of two buttons as quickly as possible. By responding to the probe that always replaces the neutral face, participants learn to attend to the non-threat cues and away from threat cues. There are 120 trials of angry-neutral faces in total, and 40 other catch trials with neutral-neutral faces.
75937072|NCT03176888|Behavioral|Cognitive behavioral therapy (CBT)|Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey & Greer (2012)
75474885|NCT01988636|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
75474886|NCT01988636|Drug|Placebo|Placebo
75651995|NCT03973580|Behavioral|Control task|The control task is identical with the ABM task, except that in the 120 angry-neutral trials, the arrow-probe replaces the angry face and the neutral face with equal probabilities (60 trials each).
75651996|NCT03953677|Drug|Dexmedetomidine 100 Mcg/mL Intravenous Solution|Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
75799274|NCT01191684|Biological|modified vaccinia virus ankara vaccine expressing p53|Given SC
75799275|NCT02659540|Drug|Nivolumab|Nivolumab was administered as an intravenous (IV) infusion over approximately 30 or 90 minutes, with dosing calculated using body weight.
75937073|NCT02414594|Drug|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
76088947|NCT03721042|Device|olfactory measuring device|Patients blowing into bags then analysis by olfadiag system
76088948|NCT04553445|Behavioral|Chronotype|Participants screened using the Morningness/Eveningness Questionnaire. Chronotype categorized as either Definite Morning/Morning, or Evening/Definite Evening. Participant will exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) either in sync or not in sync with chronotype for one month in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in the alternate chronotype for one month.
76088949|NCT04553445|Behavioral|Green exercise|Participants will be randomly assigned to four weeks of moderate intensity aerobic exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) in either natural or indoor environments in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in alternate environment for one month.
75474887|NCT01988649|Drug|Intranasal Oxytocin|Administration of intranasal Oxytocin
75474888|NCT01988649|Drug|Placebo (saline)|Administration of normal saline intranasally.
75651997|NCT03953677|Drug|5% glucose Infusion solution|Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
75651998|NCT03936478|Radiation|MRIdian Radiation Treatment Unit|partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
75799276|NCT02659540|Drug|Ipilimumab|Ipilimumab was administered as an IV infusion over approximately 30 or 90 minutes, with dosing calculated using body weight. The ipilimumab infusion was initiated approximately 30 minutes after the end of the nivolumab infusion on applicable dosing days.
75799277|NCT02659540|Radiation|Radiotherapy|RT was delivered in accordance with cohort assignment and institutional practices.
75799278|NCT01295268|Other|Emu Oil|Subjects will apply a specified amount of emu oil daily to area.
75341536|NCT00668564|Procedure|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
75341537|NCT00668564|Drug|Cyclophosphamide|"Days before Transplant Drug Frequency~4 Cyclophosphamide Once, given over 2 hours~3 Cyclophosphamide Once, given over 2 hours~2 Cyclophosphamide Once, given over 2 hours~1 Cyclophosphamide Once, given over 2 hours"
75799279|NCT01295268|Other|Inert oil|A specified amount of inert oil will be applied daily to area.
75799280|NCT03850392|Device|cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)|cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval
75937074|NCT02414594|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
75937075|NCT03176810|Device|OCT|OCT is used to guide PCI.
75937076|NCT03176810|Device|Angiography|Angiography is used to guide PCI.
75937077|NCT02416778|Drug|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
75474889|NCT01988675|Radiation|Whole Brain Irradiation|
75474890|NCT01988675|Radiation|Partial Brain Irradiation|
75474891|NCT01988675|Behavioral|Neuropsychological Testing|
75474892|NCT01988675|Behavioral|Quality of Life Questionnaire|
75937078|NCT02408666|Other|Interview|
75651999|NCT03934216|Drug|BMS-986165|Specified Dose on Specified Days
75652000|NCT03934216|Other|Placebo|Specified Dose on Specified Days
75937079|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
75937080|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
75937081|NCT02414516|Drug|OBP-801|OBP-801 will be administered IV
75937082|NCT03176342|Other|patch test|Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
75341538|NCT00668564|Drug|Campath-1H|"Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours"
75652001|NCT03925480|Drug|Azithromycin 500 mg Oral Tablet x 4|A single prophylactic dose of antibiotic given during labour
75652002|NCT03925480|Drug|Matching Placebo|Matching Placebo
75652003|NCT03891160|Other|3D model of heart|To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
75652004|NCT03889561|Behavioral|Drink Tap|The Drink Tap intervention consists of increased access to safe and appealing drinking water, multicultural water promotion, and soda taxes.
75652005|NCT03878069|Biological|elapegademase-lvlr|"Patients transitioning from Adagen: For patients currently receiving Adagen at ≤ 30 U/kg/wk or an unknown Adagen dose, the suggested dosage of Revcovi is 0.2 mg/kg/wk IM. For patients currently receiving Adagen at > 30 U/kg/wk the suggested equivalent Revcovi dosage (mg/kg/wk) is the Adagen dosage in U/kg/wk divided by 150.~At the investigator's discretion, the total weekly dose may be divided and administered in multiple IM injections, increased by 0.033 mg/kg/wk if trough ADA activity is < 30 mmol/hr/L, dAXP is > 0.02 mmol/L, and/or the immune reconstitution is inadequate.~Adagen-naïve patients: The suggested starting Revcovi dosage is 0.2 mg/kg twice weekly IM based on ideal body weight, for a minimum of 12 to 24 weeks until immune reconstitution is achieved. At the investigator's discretion, the dosage may be gradually increased to maintain trough ADA activity > 30 mmol/hr/L, dAXP < 0.02 mmol/L, and/or to maintain adequate immune reconstitution."
75652006|NCT03876873|Procedure|Head Rotation During Face Mask Ventilation|Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).
75652007|NCT03876873|Device|Medline Top Valve Anesthesia Mask|Face mask used per standard of care to provide oxygen to subjects before surgical procedures.
75652008|NCT03875885|Behavioral|CONNECT|A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.
75652009|NCT03875885|Behavioral|CONTROL|This group will receive a generic resource list. The generic resource list will be printed for participants and emailed to them, if participants have an email address.
75652010|NCT03867214|Drug|Glutamine|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
75652011|NCT03867214|Drug|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
75652012|NCT03815266|Diagnostic Test|transcranial Direct Current Stimulation (tDCS)|"transcranial Direct Current Stimulation (tDCS) is device which consist in setting up an electrode on the skull of the patient to deliver the low intensity current.~Patient will have transcranial Direct Current Stimulation (tDCS) at each session and at the same time of Computerized Mirror Therapy (CMT)."
75652013|NCT03815266|Diagnostic Test|Computerized Mirror Therapy (CMT)|Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3). Patient will have Computerized Mirror Therapy (CMT) at each session and at the same time of transcranial Direct Current Stimulation (tDCS).
75652014|NCT03815266|Diagnostic Test|Tolerance Assessment Questionnaire|The Tolerance Assessment Questionnaire will be completed at the end of each session.
75652015|NCT03815266|Diagnostic Test|Ashworth's scale|Ashworth's scale evaluates the resistance to stretching. This test will be completed before the start of the program, at the end of the program and one month after.
75937083|NCT03174080|Radiation|FDG (glucose labeled isotope of fluorine)|Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI
75937084|NCT02414360|Other|Shortened Format|Shortened format of a systematic review
75799281|NCT01383694|Drug|Piperine|
75799282|NCT03850158|Drug|Indocyanine Green|Indocyanine green is administered intra-venous after dilution with water in a peripheral vein at a dosage of 0.3mg/kg body weight as a bolus injection. The injection will take place during surgery. By using NIR fluorescence imaging ICG is made visible.
75799283|NCT01295346|Other|Head CT scan and blood draw|
75799284|NCT02558764|Device|portable (pocket) negative pressure wound treatment device|PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.
75799285|NCT01191918|Drug|Donepezil and Lithium|Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
75937085|NCT02414360|Other|Full Length|Full length systematic review
75937086|NCT03171896|Other|clown|A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
75937087|NCT03171896|Other|Sham|No clown will be present in the room during labor
75937088|NCT04482452|Procedure|Colonoscopy|Diagnostic colonoscopy will be performed
75965921|NCT04875182|Diagnostic Test|Evaluation of Delirium development|Postoperative pain scores of the patients will recorded by using a numerical rating scale.
75965922|NCT04875494|Behavioral|Counseling/support group therapy|6 weeks of counseling group therapy; 2 sessions of 30 min each week, with a psychologist and two former victims
75341539|NCT00668564|Drug|Busulfan|"Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day"
75937089|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~st period: Spontaneous breathing for 10 minutes~nd period: CPAP for 10 minutes~rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~oesogastric pressures~air flow~gas exchange~right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale"
75341540|NCT00610688|Drug|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
75937090|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~st period: Spontaneous breathing for 10 minutes~nd period: CPAP for 10 minutes~rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~oesogastric pressures~air flow~gas exchange~right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale"
75652016|NCT03815266|Diagnostic Test|Frenchay arm test|"Frenchay arm test evaluates your abilities with the affected hand to perform several actions.~This test will be completed before the start of the program, at the end of the program and one month after."
75652017|NCT03815266|Diagnostic Test|Abilhand questionnaire|"Abilhand questionnaire evaluates your abilities to perform several activities in the daily life with your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
75652018|NCT03815266|Diagnostic Test|Fugl-Meyer test|"Fugl-Meyer test evaluates your ability to perform different movements with all the joints of your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
75937091|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~st period: Spontaneous breathing for 10 minutes~nd period: CPAP for 10 minutes~rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~oesogastric pressures~air flow~gas exchange~right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale"
75937092|NCT02414126|Device|CPAP|
75937093|NCT02414282|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
75937094|NCT03116204|Other|Assessment of score SAS|Assessment of a score assessing physical and cognitive activities of patients in follow-up care and rehabilitation departments
75937095|NCT03116516|Drug|Temisartan/Amlodipine+Rosuvastatin|All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
75937096|NCT03116516|Drug|YHP1604|All subjects will receive a single oral dose of YHP1604 administered in the morning.
75937097|NCT01564537|Drug|Ixazomib|Ixazomib capsules
75937098|NCT01564537|Drug|Lenalidomide|Lenalidomide capsules
75937099|NCT01564537|Drug|Dexamethasone|Dexamethasone tablets
75937100|NCT01564537|Drug|Placebo|Ixazomib placebo-matching capsules
75937101|NCT03116360|Diagnostic Test|Diagnostic Ultrasound|The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
75965923|NCT04875494|Behavioral|Physical Exercise|6 weeks of physical exercise training; 2 sessions of 30 min each week, with an instructor
75341541|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
75341542|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
75652019|NCT03815266|Diagnostic Test|Goal Attainment Scaling (GAS)|"Goal Attainment Scaling (GAS) sets therapeutic goals with the patient before the start of the program.~These goals will be checked at the end of the program and one month after."
75652020|NCT03736941|Other|Patients with venous leg|The medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. It will be dispensed in town pharmacies. After inclusion, follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
75341543|NCT00669578|Drug|CC-4047|CC-4047: taken orally each day in a 28 day cycle.
75341544|NCT02135900|Drug|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
75341545|NCT02137382|Drug|Creon®|active comparator
75341546|NCT02137382|Drug|Creon N|experimental drug
75341547|NCT00611468|Drug|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
75652021|NCT03736668|Diagnostic Test|echocardiography|One year after patient's inclusion, an echocardiography / doppler will be performed to evaluate any changes.Two years after the patient's inclusion, an investigating cardiologist will contact the physician, cardiologist and / or diabetologist treating the patient by telephone to find out if any cardiovascular events have occurred.
75652022|NCT03663530|Behavioral|Meal times|Meal times vary based on the arm: aligned or misaligned
75341548|NCT00611468|Drug|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
75341549|NCT00670202|Drug|Fasudil Hydrochloride|Fasudil 40 mg three times a day x 14 days
75652023|NCT03642808|Other|rehabilitation program|Availibility of patients to complete a rehabilitation program during 8 weeks and to come back 4 times for a careful medical examination
75652024|NCT03642782|Device|Electroretinogram Pattern (Diopsys® NOVA System)|it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
75799286|NCT01191918|Drug|Placebo plus Lithium|
75652025|NCT03641300|Device|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
75937102|NCT03174236|Drug|Ceftriaxone|Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
75937103|NCT03174236|Drug|Benzyl penicillin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
75799287|NCT02544802|Drug|Adipose-Derived Mesenchymal Stem Cells|
75799288|NCT03850314|Dietary Supplement|Glycine|Glycine powder to be dissolved in water.
75937104|NCT03174236|Drug|Metronidazole|"The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials."
75937105|NCT03174236|Other|Placebo|Suspension manufactured to match metronidazole
75799289|NCT03850080|Drug|Autologous Conditioned Serum|"Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. 50mL of whole blood were taken using a special syringe containing CrSO4-coated grade glass beads in order to promote IL-1ra synthesis and aggregation.The incubation period lasted 7 hours after which, the blood-filled syringes were centrifuged and the serum supernatant was filtered and aliquoted into four 3mL portions. The aliquots were stored at -20oC until their use was necessary.~Patients received 1 intra-articular injection for 4 consecutive weeks at the site of OA."
75799290|NCT01097746|Biological|Bevacizumab|Given IV
75799291|NCT01097746|Drug|Carboplatin|Given IV
75799292|NCT01097746|Drug|Paclitaxel|Given IV
75799293|NCT01191996|Biological|MIS416|MIS416 intravenously every week
75937106|NCT03174236|Drug|Gentamicin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
75937107|NCT03202043|Other|High dose vegetable juice|High dose (13 fl oz) vegetable juice
75937108|NCT03202043|Other|Medium dose vegetable juice|Medium dose (10 fl oz) vegetable juice
75937109|NCT03202043|Other|Low dose vegetable juice|Low dose (5.5 fl oz) vegetable juice
75937110|NCT03202043|Other|Control bottled water|Control (12 fl oz) bottled water
75937111|NCT03172052|Drug|streptokinase|• Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
75937112|NCT03172052|Drug|MESNA (2-mercaptoethane sulfonate Na)|• Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
75937113|NCT03172052|Device|Medical thoracoscopy|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
75937114|NCT03172052|Device|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
75937115|NCT03673969|Procedure|Gastric bypass|Surgical method of gastric bypass
75937116|NCT03673891|Device|Life Flow|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
75937117|NCT03174392|Other|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
75965924|NCT05258006|Procedure|Autogenous demineralized dentin nanoparticles|Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
75965925|NCT02613884|Drug|Treatment|
75341550|NCT00670202|Drug|Placebo Oral Tablet|Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
75341551|NCT00670982|Drug|bevacizumab|Given intravenously every 2 weeks
75341552|NCT00670982|Drug|vinorelbine|Given intravenously once a week
75341553|NCT00670982|Drug|trastuzumab|Given intravenously once a week
75799294|NCT01190748|Drug|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions
75799295|NCT01190748|Drug|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions
75937118|NCT03174392|Other|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
75652026|NCT03641300|Device|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
75799296|NCT01383538|Drug|FOLFIRINOX, IPI-926|"Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle."
75652027|NCT03623139|Behavioral|Standard nutritional education|Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.
75937119|NCT02414048|Drug|Pimonidazole|Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
75937120|NCT03171662|Other|Evaluation of Pediatric Appendicitis Score|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
75937121|NCT03064217|Procedure|CLP and 12 weeks waiting|Restorative treatments will be initiated 12 weeks after clinical crown lengthenings (CLPs).
75937122|NCT03064217|Procedure|Digital impression taken at surgery|The final impression will be made at surgery.
75937123|NCT02413814|Behavioral|Anger Reduction Treatment|Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
75937124|NCT02413814|Behavioral|Control Condition|Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
75937125|NCT02408354|Drug|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
75937126|NCT02408354|Drug|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
76117189|NCT03724487|Behavioral|Coachman|Coachman is comprised of: TBI and nurse counseling. TBI is comprised of: 1) web-based education modules on hypertension knowledge and skills as well as behavioral lifestyle guidance, (2) Medisafe, a smartphone medication management app to support medication adherence to antihypertensives, and (3) self-monitoring blood pressure. Participants will be exposed to nurse counseling, by registered nurses from the community, affiliated with a local nurse organization that will serve as community health workers (CHWs). The CHWs will provide informal counseling, social support, as well as follow-up phone sessions on medication adherence and monitoring blood pressure.
75474893|NCT01988675|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).
75474894|NCT01988688|Device|Deep Brain Stimulation (DBS)|Deep Brain Stimulation (DBS) bilaterally in area LC.
75652028|NCT03623139|Behavioral|Basic carbohydrate counting|The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
75799297|NCT01192074|Device|Ultrasound|Preprocedure ultrasound examination of the spine
75799298|NCT01383460|Drug|Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)|G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
75799299|NCT01383460|Drug|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
75799300|NCT01192230|Drug|Endostatins|7.5mg/m2 qd *14d,q3w
75799301|NCT01192230|Drug|Docetaxel|75mg/m2 D1, q3w,4-6cycles
75937127|NCT02406404|Behavioral|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
75937128|NCT03176264|Drug|PDR001|400 mg every 4 weeks
75937129|NCT03176264|Drug|bevacizumab|5 mg/kg every 2 weeks
75937130|NCT03176264|Drug|mFOLFOX6|Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
75937131|NCT02406170|Drug|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
75937132|NCT02406170|Drug|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
75799302|NCT05420116|Behavioral|Cerdanya on Fitness|The intervention lasts 9 months. The participants will carry out group activities and will be followed individually by the different interdisciplinary professionals. Goals will be set for each visit. Before and after the training there will be an assessment of physical exercise, nutritional and positive mental health habits.
75799303|NCT01195038|Biological|Recombinant Influenza HA Vaccine (H5N1)|one booster dose of 45 μg rHA derived from A/Indonesia/05/2005 strain
75799304|NCT05419492|Drug|ETX101|ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
75799305|NCT01190826|Drug|ASM-024|Target dose of 10 mg ASM-024 administered once by inhalation
75799306|NCT01190826|Drug|ASM-024 100 mg|Target dose of 100 mg ASM-024 administered once by inhalation
75799307|NCT01190826|Drug|Placebo|Placebo administered once by inhalation
75937133|NCT03173768|Procedure|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
75937134|NCT02413658|Drug|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
75937135|NCT02413658|Drug|Sugar solution|
75937136|NCT02406014|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
75474895|NCT01988701|Other|Ancillary-Correlative|Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
75937137|NCT02406014|Drug|Diclofenac sodium gel 3%|Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
75937138|NCT02406092|Drug|Rituximab|Rituximab SC 1400 mg
75937139|NCT02406092|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice.
75937140|NCT02406092|Drug|Doxorubicin|Doxorubicin will be administered as per standard local practice.
75937141|NCT02406092|Drug|Vincristine|Vincristine will be administered as per standard local practice.
75937142|NCT02406092|Drug|Prednisone|Prednisone will be administered as per standard local practice.
75799308|NCT05419414|Device|Shear wave elastography|Both groups were examined with shear wave elastography.
75937143|NCT02406092|Drug|Fludarabine|Fludarabine will be administered as per standard local practice.
75937144|NCT02413268|Drug|Nitroglycerin|
75937145|NCT03173690|Other|Medication reconciliation at the ICU|Medication reconciliation performed according to Integrated Medicines Management model
76117190|NCT03724487|Behavioral|Enhanced Usual Care (EUC)|Standard printed education materials on hypertension management, including content on lifestyle modification and medication-taking will be provided; plus access to one web-based education (video) with information on how to self-monitoring blood pressure.
75474896|NCT01988714|Other|(TCT) plus evidence-based SE|Targeted cognitive computer training (TCT) plus evidence-based SE in a community setting
75652029|NCT03582956|Procedure|Euglycemic hyperinsulinemic clamp with tracer enhancement|To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
75652030|NCT03582956|Procedure|Euglycemic hyperinsulinemic clamp with tracer enhancement|A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
75652031|NCT03564132|Drug|Yigansan|Yigansan granules
75652032|NCT03564132|Drug|Placebo|One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
75799309|NCT01195194|Drug|PRE-TRANSPLANT (PRE=before)|"All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL)."
75672251|NCT00891839|Drug|Rituximab|Patients receive 375 mg/m^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
75672252|NCT00600756|Drug|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
75937146|NCT03173690|Other|Medication Reconciliation at the Ward|Medication reconciliation performed according to Integrated Medicines Management model
75937147|NCT02405936|Procedure|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
75937148|NCT02413502|Biological|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10^8 CFUs.
75937149|NCT02405858|Drug|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
75937150|NCT02405858|Drug|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
75937151|NCT03171740|Drug|Dexmedetomidine|Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)
75937152|NCT03171740|Drug|Midazolam oral solution|Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)
75937153|NCT03171740|Drug|Oral saline|Oral saline, 0.25ml/kg
75937154|NCT03171740|Drug|Nasal saline|Nasal saline 0.01ml/kg
76117191|NCT00979017|Drug|Avastin|Avastin, by intravenous infusion, 10 mg/kg every 14 days
76117192|NCT00979017|Drug|Temozolomide|Oral temozolomide at 200 mg/m2 daily for 5 days
75937155|NCT03176186|Combination Product|Xenon|50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
75474897|NCT01988714|Other|(CG) plus evidence-based SE|(CG) plus evidence-based SE
75474898|NCT01988792|Dietary Supplement|Human milk fortifiers|
75937156|NCT03175952|Diagnostic Test|virtual histology intravascular ultrasound|Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
75937157|NCT02413424|Dietary Supplement|Sucralose|60 ml of 2mM sucralose
75937158|NCT02413424|Other|Water|60 ml of water
75937159|NCT02413424|Dietary Supplement|glucose load|
75937160|NCT02413112|Behavioral|Resistance training|"Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week."
75937161|NCT04482764|Drug|Valproic Acid|Treatment of children with frequent cyanotic breath holding spells (at least 4 spells per week) with 5 mg/kg/day for 6 months.
75799310|NCT05419102|Procedure|peri-implantitis surgery with enamel matrix derivative|surgical procedures around dental implants with peri-implantits to remove infectious material and apply enamel matrix derivative to the implant.
75799311|NCT05416840|Drug|Clonidine controlled-release patch|"Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
75799312|NCT05416840|Drug|Amlodipine|"Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
75799313|NCT01192308|Drug|Tamoxifen 40mg QD|Tamoxifen 40mg QD during 4 weeks
75799314|NCT01190982|Drug|LEP-ETU|275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
75799315|NCT03631186|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
75799316|NCT03631108|Diagnostic Test|OCTA (ZEISS)|All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens.
75799317|NCT00176436|Behavioral|Diet support group|Diet support group weekly and exercise sessions 3 times/week, placebo medication
75799318|NCT00176436|Behavioral|Group counseling and exercise|Support group weekly and exercise sessions 3 times/week for 24 weeks
75799319|NCT05282784|Other|Hyperthermia|"Patients will be treated with hyperthermia 2 or 3 times a week. Treatment will be performed for 1 hours per each visit.~Patients will be treated with radiotherapy 5 times a week."
75799320|NCT05282784|Radiation|Radiotherapy|Patients will be treated with radiotherapy 5 times a week.
75937162|NCT03173378|Other|Questionnaires|Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
75937163|NCT02408042|Drug|Pembrolizumab|
75937164|NCT02408042|Drug|Etoposide|
75937165|NCT02408042|Drug|Ifosfamide|
75799321|NCT03846960|Device|using specially adapted VNscope|surfactant administration via thin catheter using a specially adapted VNscope
75937166|NCT02408042|Drug|Mesna|
75799322|NCT03846960|Drug|surfactant administration|surfactant administration via thin catheter using a specially adapted VNscope
75799323|NCT05410756|Diagnostic Test|Assessment of Voice Quality and Function|An acoustic voice analysis (fundamental frequency (F0), jitter, shimmer, noise to harmonic ratio (NHR), harmonic to noise ratio (HNR)) and an aerodynamic analysis (maximal phonation time (MPT)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. These analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.
75937167|NCT02408042|Drug|Carboplatin|
75937168|NCT02408042|Drug|Brentuximab vedotin|
75937169|NCT02408042|Drug|Rituximab|
75937170|NCT03173222|Procedure|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
75937171|NCT03172988|Drug|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
75937172|NCT03172988|Drug|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
75937173|NCT03172988|Drug|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
75937174|NCT03172988|Drug|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
75937175|NCT03042611|Drug|Rivoceranib|Oral tablet
75937176|NCT03042611|Drug|Placebo|Oral tablet
75474899|NCT01988805|Other|Blood Draw|
75474900|NCT01988818|Device|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
75937177|NCT03171350|Diagnostic Test|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
75937178|NCT03171584|Drug|Terbinafine|oral antifungal drugs
75652033|NCT03563339|Behavioral|P-POD|. P-POD will include seven 30-minute online, educational, interactive modules that teach at-risk pregnant women skills derived from the gold standard, empirically supported cognitive-behavioral treatment for anxiety disorders and OCD. Additionally, P-POD will include three modules for fathers, to help them support their partners during the postpartum period. We will modify P-POD from an already existing in-person prevention program for postpartum OCD (developed by Co-Investigator Kiara Timpano). The m-health foundation of P-POD will be an already existing Internet-delivered treatment infrastructure (OurRelationship.com, developed by Co-Investigator Brian Doss).
75652034|NCT03562728|Device|MRP and NMES(neuromuscular electric stimulation)|nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
75652035|NCT03562728|Other|Standard of Care|Patients in the control group are going to receive standard of care
76117193|NCT00979017|Drug|Irinotecan|Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
75474901|NCT01988818|Device|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
75799324|NCT01293474|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the choroidal thickness with Spectralis® SD-OCT
75799325|NCT05409508|Other|mindfulness meditation care|mindfulness meditation care
75652036|NCT03550066|Behavioral|Values affirmation|A health message with a prompt asking participants to reflect on important personal values
75652037|NCT03550066|Behavioral|No affirmation|A health message alone
75799326|NCT05409508|Other|no mindfulness meditation care|no mindfulness meditation care
75652038|NCT03549091|Diagnostic Test|transthoracic echocardiography|This involves the acquisition of 1 additional sequence: a 10-minute sequence for transthoracic echocardiography.
75474902|NCT01988831|Drug|Propranolol hydrochloride|This intervention apply to Propranolol group
75652039|NCT03549091|Diagnostic Test|Cardiovascular Magnetic Resonance Imaging|This involves the acquisition of 1 additional sequence: a 10-minute sequence for Cardiovascular Magnetic Resonance Imaging 4D Flow.
75652040|NCT03533855|Diagnostic Test|CS plus FRFSE|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
75652041|NCT03420859|Diagnostic Test|qPCR for abnormal vaginal microbiota|qPCR for A.vaginae and/or G.vaginalis as developed in the pilot study (Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.)
75652042|NCT03341052|Other|Normal Diet|The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
75652043|NCT03341052|Other|High Fat Diet|The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
75652044|NCT03341052|Other|Low Fat Diet|The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
75652045|NCT03295994|Procedure|Operative|Arthroscopic rotator cuff surgery followed by physical therapy.
75652046|NCT03295994|Procedure|Non-Operative|Physical therapy (without surgery).
75652047|NCT03243097|Device|Phase I - Standard Microphone Cros Input|Subject will be fit with the research processor plus CROS microphone and wear for a 4 week period
75652048|NCT03243097|Device|Phase II - Automatic directional microphone Cros Input|Automatic directional microphone technology will be activated in the research processor. Subjects will wear the CI+CROS configuration with directionality activated exclusively for 4-weeks.
75652049|NCT03243097|Device|Phase III - No Cros Input|Subjects will return the research processor and CROS device and wear their own processor for a 2-week period
75652050|NCT03222752|Device|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
75652051|NCT03222752|Device|Sham Cranial Electrotherapy Stimulation|The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
75652052|NCT03200353|Device|system NATROX (device name)|system NATROX (device name) application on the wounds of lower limbs
75652053|NCT03183128|Biological|SER-109|"SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors~Other Names:~Eubacterial Spores, Purified Suspension, Encapsulated"
75652054|NCT03183128|Drug|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).
75652055|NCT03149484|Device|Personal remote microphone (RM) system|Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
75652056|NCT03149484|Other|Subjective Questionnaire|These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
75672253|NCT00600756|Drug|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
75799327|NCT05344690|Genetic|SLMAP and EPO genetic polymorphism|Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
75799328|NCT01196754|Other|sevoflurane|
75799329|NCT05208580|Behavioral|Virtual education|Participants undergo virtual education activities on an on-line platform 10-14 days before the surgery
75799330|NCT05208580|Behavioral|Contact education|Participants attend live educational classes 10-14 days before the surgery
75799331|NCT01295424|Other|No intervention|Observational study, no interventions
75799332|NCT01383226|Procedure|Thoracic endosonography|Thoracic endosonography is a minimal invasive diagnostic intervention
75799333|NCT01295502|Drug|Carboplatin|Given IV
75937179|NCT02988245|Drug|Geneticure Panel for HTN therapy|Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
75937180|NCT02988245|Drug|JNC-8|Using JNC-8 guidelines to guide therapy
75937185|NCT02388659|Device|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
75937186|NCT02879825|Device|Cardiac MRI|"Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)"
75937187|NCT02349815|Drug|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
75937188|NCT03171506|Other|Ketogenic diet|Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that ~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.
75937189|NCT03171506|Other|AND diet|Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
75937190|NCT02818517|Other|ACE inhibitors|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
75937191|NCT02818517|Other|beta blockers|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
75937192|NCT02405702|Other|restrospective study|
75474903|NCT01988831|Drug|Placebo pill|We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
75474904|NCT01988844|Other|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
75937193|NCT02699957|Procedure|Left Atrial Appendage Occlusion|Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
75937194|NCT02405546|Other|Pre-Rotated (Group R)|In group R, placement of ETT over the FOS was done with 90° CCR from the beginning so that the bevel of the ETT faced posteriorly before it was advanced through the larynx.
75937195|NCT02405546|Other|No pre-rotation|ETT was not pre-rotated but rotated only if necessary
75937196|NCT02407652|Behavioral|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
75474905|NCT01988870|Radiation|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
75652057|NCT03127423|Procedure|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
75652058|NCT03127423|Procedure|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
75937197|NCT02407652|Behavioral|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
75652059|NCT03118375|Device|super-power BAHA processor|The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
75652060|NCT03097796|Drug|PUL-042|PUL-042 Inhalation Solution
75672254|NCT04246931|Other|No intervention (survey)|No intervention -> survey at 1 timepoint
75799334|NCT01295502|Drug|Cisplatin|Given IV
75799335|NCT01295502|Radiation|External Beam Radiation Therapy|Undergo EBRT
75937198|NCT02407574|Device|External Pacing Box|Atrial pacing using an external pacing box
75937199|NCT02407496|Other|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
75937200|NCT02407418|Other|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
75474906|NCT01988896|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose as specified via IV infusion.
75799336|NCT01295502|Radiation|Internal Radiation Therapy|Undergo brachytherapy
75799337|NCT01295502|Drug|Paclitaxel|Given IV
75799338|NCT05207644|Drug|30 mg letrozole followed by 800 mcg misoprostol|30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
75799339|NCT03631030|Device|Cooled radiofrequency ablation|Cooled Radiofrequency ablation (CRFA) is a well-established method for delivering lesions into nervous tissue to accomplish neurotomy procedures
75799340|NCT03846102|Drug|Levobupivacaine|Levobupivacaïne for injection 7.5 mg/kg diluted with Sodium Chloride 0,9%
75799341|NCT03846102|Drug|Placebo|Sodium Chloride 0,9% for injection/infusion.
75799342|NCT03846102|Drug|Acetaminophen|Acetaminophen 500 milligram tablet
75937201|NCT02407418|Other|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
75937202|NCT02412410|Behavioral|Fatigue avoidance education|Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
76027231|NCT02373631|Other|Dry Needling, Conventional PT|Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
76027232|NCT02373631|Other|Conventional PT|Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
76027233|NCT02363413|Other|IniVAH|Initiation of the NIV during a 3 days hospitalization as usual.
75937203|NCT04481984|Other|Home-based Hand exercise|"Isometric exercise; patients squeezed a hand exercise ball for 60 seconds. This exercise repeated 15-times/3 set per day.~Stretching exercises; self-administered stretching exercises were as follows; i) forearm supination and pronation, ii) wrist flexion and extension, iii) finger flexion, extension, and abduction iv) thumb flexion, extension, and abduction. These exercises repeated 10-times/2 set per day."
75937204|NCT04481984|Other|Care advice|Patients received care advice including avoiding cold exposure and trauma.
75937205|NCT02405624|Procedure|continuous positive airway pressure|CPAP training for muscle strength
75937206|NCT02407340|Drug|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
75937207|NCT02407340|Drug|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
75937208|NCT02701634|Drug|ENTO|Tablets administered orally
75937209|NCT02701634|Drug|Placebo|Tablets administered orally
75937210|NCT02407262|Dietary Supplement|Black seed oil|
75937211|NCT02407262|Other|Placebo|vegetable oil
75937212|NCT02407184|Other|Newborn exposure to mother vaginal microbiota|Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
75652061|NCT03084627|Behavioral|Tailored dietary advice|The nutrient adequacy of the diet of each patient will be evaluated, at baseline, by a diet quality index: the PANDiet. Then, tailored dietary advice aiming at improving the nutrient adequacy of the diet will be generated for each patient in the arm #2. Patients will choose 3 tailored dietary advices among 3 options during three appointments with a research project team member (the first in person and the second and the third by phone). Each appointment will be spaced of 2 weeks. In total, each patient in the arm #2 will choose nine tailored dietary advice. Tailored dietary advices are of two kinds: substitution of a consumed food item by a food item in the same food subgroup or modification of the consumed amount (increase or decrease) of a food item. Tailored dietary advices cannot generate an increase of more than 190 kcal or a decrease as compared to the observed energy intake.
75652062|NCT03067051|Drug|Verteporfin|In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
75652063|NCT03067051|Device|SpectraCure P18 System|Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
75652064|NCT03013998|Biological|Samalizumab (BAML-16-001-S1)|300 mg/m2, IV, on days 1, 3, and 24; followed by 300 mg/m2, IV, every 21 days for 2 years in the absence of toxicity or disease progression. Dose may be de-escalated to 150 mg/m2 or escalated to 600 mg/m2 based on occurrence of dose-limiting toxicity.
75652065|NCT03013998|Biological|BI 836858 (BAML-16-001-S2)|20 mg/m2, IV, on days 9, 16, and 23 of a 28-day cycle; followed 20 by mg/m2, IV, on days 1, 8, 15 and 22 of each 28-day cycle for 2 years in the absence of toxicity or disease progression (reduced to monthly administration in event of complete response or complete response with incomplete blood count recovery). Dose may be escalated to a maximum dose of 320 mg/m2 or de-escalated to 10 mg/m2 based on occurrence of dose-limiting toxicity.
75652066|NCT03013998|Other|Laboratory Biomarker Analysis|Molecular genomic assessment to assign patients to targeted therapy (sub-study) based on their specific subtype of acute myeloid leukemia
75652067|NCT03013998|Drug|Daunorubicin (BAML-16-001-S1)|60 mg/m2, IV, on days 4, 5, and 6 of the induction cycle
75652068|NCT03013998|Drug|Cytarabine (BAML-16-001-S1)|100 mg/m2, IV, on days 4 through 10 of the 24-day induction cycle; 1000 mg/m2, IV, on days 2, 4, and 6 of the consolidation cycle 1 and days 1, 3, and 5 of consolidation cycles 2 through 4
75652069|NCT03013998|Drug|Azacitidine (BAML-16-001-S2)|75 mg/m2, IV, on days 1 through 7 of each 28-day cycle for 2 years in the absence of toxicity or disease progression
75652070|NCT03013998|Drug|AG-221 (BAML-16-001-S3)|100 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 50 mg based on occurrence of dose-limiting toxicity.
75652071|NCT03013998|Drug|Azacitidine (BAML-16-001-S3)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle starting with cycle 6 and ending after 12 cycles for patients not attaining complete remission or complete remission with incomplete blood count recovery after 5 cycles of monotherapy with AG-221
75652072|NCT03013998|Drug|Entospletinib (BAML-16-001-S4)|200 mg, oral, twice daily for 5 years until time of intolerance or disease progression. Dose may be escalated to 400 mg.
75652073|NCT03013998|Drug|Azacitidine (BAML-16-001-S4)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle and continuing for 12 cycles. Treatment starts after 1 cycle of monotherapy with entospletinib for patients not attaining complete remission or complete remission with incomplete blood count recovery or after later cycles of monotherapy with entospletinib for patients with disease progression.
75652074|NCT03013998|Drug|Entospletinib (BAML-16-001-S5)|400 mg, oral, twice daily for 2 years on study until time of intolerance or disease progression. Dose may be de-escalated to 200 mg twice daily or 200 mg once daily based on occurrence of dose-limiting toxicity.
75799343|NCT03846102|Drug|Morphine|Morphine 1 mg/ml solution for infusion.
75799344|NCT03846102|Procedure|Fascia Iliaca Compartment Block with Levobupivacaine|Ultrasound guided Fascia Iliaca Compartment Block with levobupivacaine placed in the emergency department by an emergency physician.
75799345|NCT03846102|Procedure|Fascia Iliaca Compartment Block with placebo|Ultrasound guided Fascia Iliaca Compartment Block with placebo placed in the emergency department by an emergency physician.
75937213|NCT02412332|Procedure|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
75937214|NCT02412332|Procedure|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
75937215|NCT02405156|Drug|Letrozole|
75937216|NCT02405156|Drug|Placebo|
75937217|NCT02405156|Drug|Misoprostol|
75937218|NCT02412254|Other|Best practices hearing rehabilitative treatment|Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
75937219|NCT02412254|Other|Successful aging intervention|One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
75937220|NCT02407106|Dietary Supplement|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
75341554|NCT00611624|Radiation|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
75341555|NCT00612560|Drug|Anastrozole|1 mg per day
75341556|NCT00612560|Dietary Supplement|flaxseed|25 g per day ground
75652075|NCT03013998|Drug|Decitabine (BAML-16-001-S5)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 11 cycles. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During subsequent consolidation, decitabine is administered on days 1 through 5 of each 28-day cycle and continuing for up to 11 cycles. Duration may be reduced by 1 day based on occurrence of dose-limiting toxicity, and patients may switch to entospletinib monotherapy maintenance at any time if they develop toxicity or are unwilling to continue decitabine during consolidation therapy.
75652076|NCT03013998|Drug|Entospletinib (BAML-16-001-S6)|400 mg, oral, twice daily for 2 years until time of intolerance or disease progression.
75652077|NCT03013998|Drug|Daunorubicin (BAML-16-001-S6)|60 mg/m2, IV, on days 1-3 or 1-2 of each 28-day cycle for the first and second induction cycle, respectively
75652078|NCT03013998|Drug|Cytarabine (BAML-16-001-S6)|100 mg/m2, IV, on days 1 through 7 or 1 through 5 of each 28-day cycle for the first and second induction cycle, respectively; then 1000 mg/m2 (patients ≥60 years) or 3000 mg/m2 (younger patients with creatinine clearance >30 mL/min and <50 mL/min), IV, every 12 hours on days 1, 3, and 5 of each 28-day cycle for up to 4 consolidation cycles
75652079|NCT03013998|Drug|Pevonedistat (BAML-16-001-S9)|20 mg/m2, IV, on days 1, 3, and 5 of each 28-day cycle and continuing for 24 cycles in the absence of toxicity or disease progression
75652080|NCT03013998|Drug|Azacitidine (BAML-16-001-S9)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
75652081|NCT03013998|Drug|AG-120 (BAML-16-001-S16)|500 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 250 mg based on occurrence of dose-limiting toxicity.
75652082|NCT03013998|Drug|Azacitidine (BAML-16-001-S16)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
75652083|NCT03013998|Drug|Gilteritinib (BAML-16-001-S8 Group 1)|"120 mg, oral, daily, with treatment continuing based on bone marrow results at 28 and 56 days. Patients with partial response at 28 days continue treatment for an additional 28 days. Patients with complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) at 28 or 56 days continue treatment for 5 years until time of intolerance or disease progression. Patients with less than partial response at 28 days or partial response at 28 days followed by less than CR or CRi at 56 days proceed to combination treatment with decitabine or non-study alternative.~The combination dose is 80 mg, oral, daily, for 5 years until time of intolerance or disease progression (patients who do not achieve CR or CRi after 3 cycles will discontinue study treatment). The combination dose may be escalated to 120 mg daily or de-escalated to 80 mg daily given after decitabine rather than in combination with decitabine based on absence or occurrence of dose-limiting toxicity."
75652084|NCT03013998|Drug|Decitabine (BAML-16-001-S8 Group 1)|20 mg/m2, IV, on days 1 through 10 of each 28-day cycle and continuing for up to 3 cycles. Treatment starts after 1-2 cycles of monotherapy with gilteritinib if patients do not attain complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with monotherapy. Patients who do not achieve CR/CRi after 3 cycles of combination therapy will discontinue study treatment. If CR or CRi is obtained with combination therapy after 3 cycles, decitabine will be administered on days 1-5 of each subsequent 28-day cycle until progression, intolerance, or patient desire to discontinue therapy.
75652085|NCT03013998|Drug|AZD5153 (BAML-16-001-S10)|20 mg, oral, once daily during 7-day lead-in and then on days 1 through 21 of each 28-day cycle for up to 2 years or until allogeneic stem cell transplantation, time of intolerance, or disease progression [if the continuous administration AZD5153 on Days 1-21 of a 28-day cycle is not tolerated, an alternative schedule of 2 weeks on and 2 weeks off (i.e. AZD5153 will be administered on Days 1-14 of a 28-day cycle) will be explored]. Dose may be de-escalated to 10 mg or escalated to 30 mg based on occurrence of dose-limiting toxicity during phase 1 dose escalation. Starting with Cycle 2, patients may receive concomitant fluconazole, isavuconazole, or posaconazole and doses adjusted to 2, 5, or 8 mg daily. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with AZD5153 dose adjusted from 10, 20, or 30 mg daily to 2, 5, or 8 mg daily. Phase 2 dose will be based on Phase 1 results.
75937221|NCT02405312|Behavioral|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
75937222|NCT02412020|Drug|PA101|
75341557|NCT00612560|Drug|Placebo|Placebo pill 1 per day
75341558|NCT00671918|Drug|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
75341559|NCT00612716|Drug|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
75341560|NCT00612716|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
75937223|NCT02412020|Drug|Placebo|
75652086|NCT03013998|Drug|Venetoclax (BAML-16-001-S10)|400 mg, oral, on days 1 through 21 of each 28-day cycle and continuing for up to 12 cycles (for Cycle 1, day 1 dose will be 100 mg, day 2 dose 200 mg, and days 3 onward 400 mg). Starting with Cycle 2, patients may receive concomitant fluconazole or isavuconazole and daily doses adjusted to 200 mg, or posaconazole and daily doses adjusted to 70 mg. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with Venetoclax dose adjusted to 10 mg on day 1, 20 mg on day 2, 50 mg on day 3, and 70 mg on day 4 onward).
75799346|NCT01383148|Biological|TG4010|"TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.~Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.~First line therapy:~Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab~Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin~Maintenance therapy:~• Pemetrexed or erlotinib for eligible patients and according to labeling."
75799347|NCT01383148|Drug|placebo|"Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~First line therapy: as in Arm 1~Maintenance therapy: as in Arm 1"
75799348|NCT05123716|Drug|MDMA|Participants will be given 100 mg of MDMA
75799349|NCT05123716|Drug|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
75799350|NCT03845868|Other|Dietary and environmental exposure (Observational study)|
75799351|NCT01383070|Behavioral|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
75799352|NCT01196910|Device|treatment by HLPFC coil|"DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase."
75799353|NCT04945174|Behavioral|Cardiorespiratory exercise combined with patient education and individual follow-up sessions|6 weeks of cardiorespiratory exercise combined with patient education at the hospital, followed by 6 weeks of cardiorespiratory exercise in the local municipality. Subsequently individual follow-up sessions with the aim to facilitate the patients to stay physically active in their everyday life
75799354|NCT01382914|Other|chlorhexidine 0.12%|twice daily, 10 ml, topical
75341561|NCT00612716|Biological|Stem cell infusion|Infused on Day 0
75474907|NCT01988896|Drug|Cobimetinib|Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
75799355|NCT03997318|Biological|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
75937224|NCT03171428|Procedure|Hepatectomy|Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
75341562|NCT00612716|Radiation|Total body irradiation|165 cGy morning and evening on days -4 through -1.
75341563|NCT04242602|Device|Transcranial Doppler|Record flow velocity tracing of middle cerebral artery using a transcranial doppler.
75341564|NCT00613028|Drug|Temo + Avastin|Patients have progressed/had gr3/> toxicity related to etoposide, with no had progression/gr 3/> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
75474908|NCT01988909|Drug|WR 279,396|Paromomycin + Gentamicin Topical Cream
75474909|NCT01988935|Behavioral|Prolonged Exposure|Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
75474910|NCT01988935|Behavioral|Smoking Cessation|Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
75474911|NCT01988948|Other|Various biological sampling|
75474912|NCT01988961|Biological|Golimumab|SC injections
75511101|NCT00924521|Dietary Supplement|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
75799356|NCT03997318|Other|Placebo|Placebo control is the vehicle solution used for the study product.
75799357|NCT03992092|Device|C-MAC VS|C-MAC Video Stylet
75799358|NCT03992092|Device|Flexible Bronchoscopy|Flexible Bronchoscopy
75799359|NCT01195428|Drug|Simvastatin|Simvastatin 40 mg daily
75799360|NCT01195428|Drug|Placebo|Placebo
75799361|NCT03718780|Other|simultaneous determination of PaCO2 and PtCO2|"Patients in intensive care, equipped, for their routine clinical management, with an arterial catheter blood line, will have a simultaneous determination of PaCO2 and PtCO2:~1) at rest; 2 arterial CO2/PtCO2 determinations will be carried out, 10 minutes apart~2) During the muscular exercise part of their routine rehabilitation program (whatever it might be, limbs active mobilization, walking, etc...) : several arterial /PtCO2 samples will be collected during the first minutes of their muscular routine: 30 sec, 1 minute, 1 ½ minute, 2, 2 ½ , 3, 4, 5 minutes, 10 minutes (end of exercise). This will generate several couples of blood/transcutaneous CO2 determinations"
75799362|NCT03718780|Other|Hyperventilation test|Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest (0), then 30 sec post beginning of hyperventilation (breathing with accelerated frequency e.g. 30/min), 1 minute, 1 ½ minute 2, 2 ½ , 3, , 4, 5 minutes; recovery of this hyperventilation will be followed, for 5 minutes, with the PtCO2, during 3 minutes
75937225|NCT02412176|Procedure|Pacing site - the implantation in the right ventricular (RV) apex|Pacing site - RV apex. The lead will be implanted in the RV apex.
75937226|NCT02412176|Procedure|Pacing site - the implantation in the septum|Pacing site - septum. The lead will be implanted in the septum.
75937227|NCT02411942|Drug|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
75937228|NCT02411942|Drug|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
75937229|NCT02411942|Drug|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
75937230|NCT02406950|Drug|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
75937231|NCT02406872|Drug|Remimazolam Tosilate|IV pumping for anesthesia
75937232|NCT02406872|Drug|Propofol|IV bolus for anesthesia
76088950|NCT04129827|Other|Clinical, self-reported psychological and biomechanical assessments|"medical check up~active and passive Range Of Motion (ROM)~anterior drawer test~knee's alignment~modified cincinnati rating system questionnaire (mCRSQ)~tegner lysholm knee scoring scale (TLKS)~Tegner Activity Level Score (TALS)~self-reported psychological questionnaires~Tampa Scale of Kinesiophobia (TSK)~ACL Return to Sport after Injury (ACL-RSI) score~biomechanical tests~Stability test: to balance on one/two legs on a free to move disc for 30s~Jump test: i) a maximize jump with both legs; ii) a maximize jump with only one leg; three consecutive jumps; iv) jump coordination path where the patient had to perform a forward-backward-forward jump and a sideway jump on one leg~Coordination test: a square hurdle was used for the quick test, where the patient had to step in and out with both feet for a total of 15-rep as quickly as possible~fatigue test: to rise and sit from a chair for 30-rep as quickly and safely as possible"
75341565|NCT00613028|Drug|VP-16 + Avastin|Patients have progressed/had gr3/> toxicity related to temozolomide, but have not progressed/gr3/> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
75341566|NCT01799798|Drug|Denosumab|Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
75341567|NCT00614198|Other|Gluten- and casein-free diet|Removal of foods containing gluten (cereal produce) and casein (dairy produce)
75341568|NCT00616772|Drug|ABT-335|Capsule
75341569|NCT00616772|Drug|Placebo|Capsule
75511102|NCT00924521|Dietary Supplement|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
75652087|NCT03013998|Drug|TP-0903 (BAML-16-001-S14)|37 mg, oral, once daily on days 1 through 21 of each 28-day cycle for up to 2 years to time of intolerance or disease progression. Dose may be de-escalated to as low as 12 mg or escalated to 50 mg based on occurrence of dose-limiting toxicity during Phase 1 dose escalation. Phase 2 dose will be based on Phase 1 results.
75799363|NCT03718780|Other|Exercise test|an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes
75799364|NCT03846648|Drug|Cypep-1|"Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~CyPep-1 topical formulation 1% (w/w)~Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest."
75799365|NCT03496168|Drug|mavacamten|mavacamten capsules
75341570|NCT00616772|Other|Atorvastatin|Capsule
75799366|NCT04903392|Other|Backward Walking Training|"The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. The training, which will take 30 minutes, will be as follows: 5 minutes forward walking (warm-up phase), 20 minutes backward walking (intervention phase) and 5 minutes forward (cooling phase).~-three times a week for six weeks"
75799367|NCT04903392|Other|Forward Walking Training|"The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. It will be in the form of walking forward for 30 minutes.~-three times a week for six weeks"
75799368|NCT05283174|Other|Blood sampling to test drug level|To collect blood sample during acute stroke and measure NOAC concentration.
75341571|NCT00672854|Drug|ClinOleic 20% Intravenous Emulsion|ClinOleic 20% is a lipid emulsion containing a mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to an essential fatty acid intake of approximately 20% of the total fatty acids intake.
75511103|NCT00898456|Genetic|gene expression analysis|
75511104|NCT00898456|Genetic|molecular genetic technique|
75937233|NCT03171272|Other|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
75937234|NCT02404922|Drug|CTP-730|
75937235|NCT02404922|Drug|Placebo for CTP-730|
75511105|NCT00898456|Genetic|polymorphism analysis|
75511106|NCT00898456|Genetic|protein expression analysis|
75511107|NCT00898456|Other|diagnostic laboratory biomarker analysis|
76088951|NCT04347525|Other|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
76088952|NCT01880320|Drug|CD0271 0.3% / CD1579 2.5%|
76088953|NCT01880320|Drug|CD0271 0.1% / CD1579 2.5%|
76088954|NCT01880320|Drug|Topical Gel Vehicle|
76088955|NCT04346667|Drug|Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
76088956|NCT04346667|Drug|Hydroxychloroquine Sulfate Loading Dose|Hydroxychloroquine administered as a loading dose only
75341572|NCT00672854|Drug|Intralipid, 20% Intravenous Emulsion|It is made up of 20% Soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection
75652088|NCT03013998|Drug|Decitabine (BAML-16-001-S14)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 2 years to time of intolerance or disease progression. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During maintenance, decitabine is administered on days 1 through 5 of each 28-day cycle. Patients may switch to TP-0903 monotherapy maintenance if they develop toxicity or are unwilling to continue decitabine during maintenance therapy.
75799369|NCT01192932|Radiation|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~90 quality ref mAs with care-dose ON~120 kV~Pitch 1.4~Rotation time 0.33 s~Acquired images 64 x 0.6 mm"
75341573|NCT00672932|Drug|raltegravir|400 mg two times daily for three months
75474913|NCT01988974|Behavioral|Alert for Atrial Fibrillation Program|Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.
75652089|NCT03013998|Drug|Decitabine (BAML-16-001-S8 Group 2)|20 mg/m2, IV, on days 8 through 12 of the first 35-day induction cycle, then on days 1 through 5 of subsequent 28-day cycles and continuing for up to 60 cycles, disease progression, intolerance, or patient desire to discontinue therapy.
75799370|NCT01193166|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
75799371|NCT01193166|Drug|risperidone|flexible dosing as prescribed by the study doctor for 12 months
75799372|NCT01193166|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
75799373|NCT01193166|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
75799374|NCT01193166|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
76088957|NCT04346667|Drug|Chloroquine|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
76088958|NCT04346667|Drug|Placebo|Standard of Care plus placebo
76088959|NCT04129983|Combination Product|Drugs and Stimulation|60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
75341574|NCT02513550|Drug|Ixekizumab|Administered SQ
75799375|NCT01193166|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
75341575|NCT02513550|Drug|Placebo|Administered SQ
75341576|NCT00673400|Procedure|Stapled transanal rectum resection|Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
75341577|NCT00673712|Device|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
75341578|NCT00673712|Drug|Opioid based analgesia|"Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
75341579|NCT04062032|Drug|Aspirin 81 mg|ASA 81mg taken daily
75341580|NCT04062032|Drug|Aspirin 325mg|ASA 325mg taken daily
75799376|NCT01193166|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
76088960|NCT05608239|Device|Sculptra aesthetic|The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
76088961|NCT03426358|Device|LSM assessed by Elastographic Techniques|Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
75341581|NCT03981380|Drug|11C-PIB|Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of [11C]PiB (over 5-10 seconds).
76117194|NCT03723005|Device|Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
75341582|NCT00617396|Drug|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
75474914|NCT01988974|Behavioral|Healthy Sleep|Participants will receive a 45 minute face to face instruction about sleep hygiene
75799377|NCT01193166|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
75799378|NCT03848520|Procedure|TKA|TKA performed in the past
75341583|NCT03722966|Drug|Varenicline|All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.
75341584|NCT03722966|Drug|Oral Nicotine Replacement Therapy (NRT)|Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
75652090|NCT03013998|Drug|Venetoclax (BAML-16-001-S8 Group 2)|Oral dosing based on concurrent antifungal use. Dose without use of concomitant antifungal is 400mg, dose if on posaconazole is 70mg, dose if on voriconazole is 100mg, and dose if on moderate CYP3A inhibitors (ie fluconazole, isavuconazole) is 200mg continuing for up to 12 total cycles. For the 35-day induction cycle 1, dosing is days 2 through 28. For the 28-day induction cycle 2, if needed, dosing is days 1 through 21. For the 28-day consolidation cycles, dosing is days 1-15.
75652091|NCT03013998|Drug|AZD5991 (BAML-16-001-S18)|150 mg, IV, on days 1, 4, 8, 11, 15, and 18 of three 28-day cycles; followed by 150 mg/m2, IV, on days 1, 4, 8, and 11 of twenty-one 28-day cycles; followed by 150 mg/m2 on days 1 and 4 of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment. Dose may be escalated to a maximum dose of 400 mg or de-escalated to 100 mg based on occurrence of dose-limiting toxicity.
76117195|NCT03723005|Device|Standard-of-Care|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
75341585|NCT03722966|Behavioral|Medication Reminders|Half of study participants will be randomly assigned to receive automated medication reminders via their smartphones.
75341586|NCT03722966|Behavioral|Tobacco Cessation Counseling|All participants will be offered 6 weekly tobacco cessation counseling sessions with a Tobacco Treatment Specialist.
75341587|NCT01581541|Drug|PU-H71|PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
75341588|NCT02142608|Drug|BR55|Ultrasound contrast agent
75341589|NCT02143310|Device|EVP|
75341590|NCT01582477|Drug|EXPAREL 20 mL|EXPAREL 266 mg (undiluted)
75652092|NCT03013998|Drug|Azacitidine (BAML-16-001-S18)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment
75799379|NCT01197144|Drug|adalimumab|Subcutaneous, 40 mg every other week for 4 weeks
75799380|NCT01197144|Drug|Placebo|Subcutaneous, every other week for 4 weeks
75799381|NCT01193400|Drug|Clofarabine|
75799382|NCT01193400|Drug|Cytarabine|
75799383|NCT03904888|Procedure|r-TAPP|Robot-assisted repair
75799384|NCT03904888|Procedure|l-TAPP|Laporoscopic repair
75799385|NCT03904888|Procedure|local anesthetics|local anesthetics will be administred
75341591|NCT01582477|Drug|EXPAREL 40 mL|EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
75341592|NCT03001687|Dietary Supplement|enteral supplementation with vitamin D|"Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)"
75799386|NCT05670834|Genetic|genotyping assay by real-time PCR|genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
75799387|NCT05670834|Diagnostic Test|ELISA|. IL-6 level in serum will be analyzed by ELISA assay kit.
75799388|NCT01197222|Device|EndoClear Lens Cleaning Device|EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
75799389|NCT03846258|Drug|Low bicarbonate solution (22 mmol/L)|Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.
75937236|NCT02406716|Other|Biospecimen retention|
75341593|NCT03001687|Other|blood collection 3mL|all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
75341594|NCT03001765|Other|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
75341595|NCT03007771|Device|Magnetic Resonance-guided High-Intensity Focused Ultrasound|-Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
75341596|NCT01583101|Other|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
75937237|NCT03172832|Procedure|PTBD|Percutaneous access and tube placement into the bile duct
75937238|NCT03172832|Procedure|ERC|Endoscopic access and stent placement in the bile duct
75937239|NCT03173144|Other|Primary exposure variable|"Upper tertile (33.3% of the total sample) based on the ratio: fibre/meat intake is associated with better treatment outcome~Low intake of red and processed meat (defined as below the lower tertile [33.3% of the total sample]) and high intake of dietary fibres (defined as those above the upper tertile [33.3% of the total sample]) are independently associated with better treatment outcome, and their synergy (interaction between the factors meat and fibres) gives the best treatment outcome"
75341597|NCT01583101|Other|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
75341598|NCT03001609|Drug|AC0010|Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi[14C]
75799390|NCT03846258|Drug|High Bicarbonate solution (32 mmol/L)|Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.
75799391|NCT03763318|Biological|EQ001|Itolizumab [Bmab 600])
75799392|NCT03763318|Biological|EQ001 Placebo|EQ001 Placebo
75799393|NCT01193478|Drug|GS-5885|tablet, oral, 3 mg once daily for 3 days
75799394|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
75799395|NCT01193478|Drug|GS-5885|tablet, oral, 10 mg once daily for 3 days
76117196|NCT01670526|Drug|Rivastigmine Transdermal Patch|Cholinesterase Inhibitor
75937240|NCT03173144|Other|Other (exploratory) exposure variables|"Lifestyle factors independently or combined (red and processed meat, vegetable, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/ fat, protein/ fat from red and processed meat, glucemic index)~Pretreatment lifestyle-associated biomarkers~Combinations of lifestyle factors and lifestyle-associated biomarkers~Gene-environment interaction analyses~Pretreatment levels of inflammatory molecules"
75799396|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
75799397|NCT01193478|Drug|GS-5885|tablet, oral, 30 mg once daily for 3 days
75799398|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
75799399|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
75799400|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
75799401|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
75799402|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
75799403|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
76117197|NCT03721913|Other|participation-based intervention|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
76117198|NCT03018795|Procedure|Decontamination of implant surfaces|Decontamination of implant surfaces in combination with regenerative surgery
75652093|NCT03013998|Drug|SNDX-5613 (BAML-16-001-S17)|113 mg, oral, every 12 hours on Day 1-28 of each 28-day cycle, until time of progression, unacceptable toxicity, or death. Dose may be escalated to a maximum dose of 163 mg on days 1-28 or de-escalated to 113 mg on days 1-21 based on occurrence of dose-limiting toxicity. Other possible dose escalation and de-escalation would be 163 mg on days 1-21, 75 mg on days 1-21 and 75 mg on days 1-28. Following completion of induction, patients who do not require strong CYP3A4 inhibitor antifungals will have daily doses increased for doses in range of 113-226 mg (days 1-21 or days 1-28).
75652094|NCT03013998|Drug|Azacitidine (BAML-16-001-S17)|75 mg/m2, IV or SC, on days 1-7 (during induction cycle/cycles) or can use alternative scheduled on days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) during continued therapy cycles of each 28-day cycle until time of progression, unacceptable toxicity, or death.
75799404|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
75799405|NCT01193634|Device|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
75341599|NCT03007381|Drug|Ketorolac Tromethamine|Intravenous analgesic
75341600|NCT03007381|Drug|Normal Saline|Sham comparator
75341601|NCT03001921|Other|No intervention|Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
75474915|NCT01988987|Other|Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
75799406|NCT02930590|Other|Alternating low pressure mattress with air loss function|IsoAir, Stryker, USA
75799407|NCT02930590|Other|Gel mattress|IsoGel, Stryker, USA
75799408|NCT02930590|Other|Basic foam|Standard hospital mattress
75799409|NCT03848442|Other|'Uptime' participation|The intervention are designed for each individual and are consistent with the model for participation-based interventions. The interventions are goal-oriented (meaningful and family/client-selected goals), family/client-centered (promoted self-determination and decision making), collaborative (partnership between caregivers), strength-based (built on participant and caregiver strengths) and ecological (natural environment and real-life experiences). Design of the intervention comprised three steps: 1) Preparation period (6 weeks); 2) Intervention period (12 weeks); 3) Follow-up period (12 weeks)
75341602|NCT01585129|Drug|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
75341603|NCT01585129|Drug|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
75341604|NCT01585207|Drug|vigabatrin|3 tablets, bid for 8 weeks
75341605|NCT03007303|Drug|Atypical Antipsychotic|Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
75474916|NCT01989000|Drug|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
75474917|NCT01989000|Drug|[F-18]HX4|400 MBq [F-18]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
75474918|NCT01989000|Drug|Gemcitabine|1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.
75474919|NCT01989000|Radiation|Radiotherapy|A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.
75474920|NCT01989000|Procedure|Pancreaticoduodenectomy|
75474921|NCT01989026|Biological|BCG|
75799410|NCT01295736|Drug|Sildenafil|Sildenafil 20 mg TID per os during 90 days
75799411|NCT01295736|Drug|placebo|Placebo pills TID per os during 90 days
75819612|NCT02170714|Other|Clinical and laboratory assessment|Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
75937241|NCT03172676|Drug|Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.
75341606|NCT03007303|Other|atypical antipsychotic combined with MECT|The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
75652095|NCT03013998|Drug|Venetoclax (BAML-16-001-S17)|For Cycle 1 induction, day 1 dose is 10 mg, day 2 dose 20 mg, day 3 dose is 50 mg, and day 4 onward dose is 100 mg or 70 mg depending on concomitant antifungal treatment. For Cycles 2 and 3 inductions, daily doses are 100 or 70 mg depending on concomitant antifungal treatment. During continued therapy cycles, if not on concomitant strong CYP3A4 inhibitor antifungals, 400 mg, oral, on days 1 through 28 of each 28-day cycle until time of progression, unacceptable toxicity, or death (patients on moderate CYP3A4 inhibitor antifungals should receive 200 mg/day).
75672255|NCT02830685|Device|DTI with Acellular Dermal Matrix (CELLIS® Breast)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using an ADM (CELLIS® Breast), either completely covering the implant or simply covering the anterior surface of it. The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
75799412|NCT01195740|Behavioral|Attachment Based Family Therapy|ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
75341607|NCT01585441|Drug|Finasteride|Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
75937242|NCT03172676|Drug|Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
75937243|NCT03172676|Drug|Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.
76027234|NCT02363413|Other|IniVAD|Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
75341608|NCT01585441|Drug|Placebo|Capsule with no active ingredients to mimic finasteride
75474922|NCT01989052|Drug|CTO|
75799413|NCT01195740|Behavioral|Enhanced Usual Care|"Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a bridge between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team."
75341609|NCT04345315|Other|serological test|serological test assessing IgM and IgG directed against SARS-CoV-2
75341610|NCT04345315|Other|Rapid molecular test|Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab
75341611|NCT04345315|Genetic|Next generation Sequencing (NGS) analysis|analysis of genetic variability of virus and host
75341612|NCT04345315|Other|serum chemistry analysis|Analysis of serum chemistry factors and coagulation panel in blood samples
75474923|NCT01989052|Drug|Lomustine|
75474924|NCT01989065|Behavioral|Lifestyle counseling|see arm description
75474925|NCT01989065|Behavioral|Text Messaging|See Arm Description
75511108|NCT00871013|Drug|Melphalan|"Given by vein, Day 3~First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2~Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days~Years 2 & 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days"
75511109|NCT00871013|Drug|Velcade|Given by vein, Days 1, 5, 8, 11
75511110|NCT00871013|Drug|Thalidomide|Given by mouth at bedtime, Days 5-8
75511111|NCT00871013|Drug|Dexamethasone|Given by mouth, once per day Days 5-8
75511112|NCT00871013|Drug|Cisplatin|Given by vein, Days 5-8 continuous infusion
75511113|NCT00871013|Drug|Adriamycin|Given by vein, days 5-8 continuous infusion
75511114|NCT00871013|Drug|Cyclophosphamide|Given by vein days 5-8 continuous infusion
75511115|NCT00871013|Drug|Etoposide|Given by vein days 5-8 continuous infusion
75511116|NCT00847574|Behavioral|Moderate-fat|35% of calories from fat
75511117|NCT00847574|Behavioral|Lower-fat|20% of calories from fat
75511118|NCT00585650|Biological|Etanercept|Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.
75511119|NCT00585650|Other|Placebo injections|Placebo injections twice weekly for 12 weeks.
75511120|NCT00539643|Device|Bead Block microspheres|Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
75937244|NCT03176030|Dietary Supplement|Fortified Foods|The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
75937245|NCT02404844|Drug|BKM120|daily oral
75937246|NCT02404844|Drug|Tamoxifen|daily oral
75937247|NCT02404766|Other|C0-C1 dorsal glide manual mobilization|
75937248|NCT02404766|Other|C7-T1 ventral cranial glide manual mobilization|
75937249|NCT03116594|Biological|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
75937250|NCT03116594|Biological|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
75937251|NCT03175640|Behavioral|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
75937252|NCT03175406|Diagnostic Test|Manipal cervical scoring system|
75937253|NCT04482296|Drug|SSRI with Zinc Sulfate|Zinc sulfate (30 mg) once daily for 8 weeks SSRI
75937254|NCT03116282|Behavioral|E-alcohol therapy|Conversational therapy sessions provided via video conference by a professional alcohol therapist.
75937255|NCT04481906|Procedure|Vaginal mesh for female cystocele|Vaginal mesh procedures (e.g. Perigee) were susgested for women with POP-Q stage III or more cystocele
76088962|NCT05608161|Diagnostic Test|speech in noise test|The noise masker was a stream of steady-state speech-spectrum noise, whose spectrum was representative of the average spectrum of target sentences. The speech masker was a 47-s loop of digitally combined continuous recordings for Chinese nonsense sentences. Patients from the idiopathic sudden sensorineural hearing loss (ISSNHL) group and control group were tested bilateral (left, right) speech-in-noise (SIN) perception of various signal-to-noise ratios (SNRs) under speech and noise masking conditions. Each participant has to complete four consequent levels of SNRs (-12, -8, -4, 0 decibel (dB) for most of control group, -8, -4, 0, 4 dB for ISSNHL group). In addition, the benefits of spatial separation cues under these two types of masking were analyzed.
76088963|NCT02983929|Procedure|Rehabilitation after total knee arthroplasty|All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
76088964|NCT03024489|Drug|Palbociclib|Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
76088965|NCT03024489|Drug|Palbociclib|Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
75474926|NCT01989078|Drug|Losartan|"Adults and Children >50 kg:~Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.~Those with SBP <100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.~Children <50 kg weight:~Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved."
75474927|NCT01989091|Device|B-Lock|Antimicrobial Catheter Lock Solution
75474928|NCT01989091|Drug|Heparin 5,000 U/mL|Standard of Care Catheter Lock Solution
75474929|NCT01989182|Device|Spiration Valve System|
75474930|NCT01989182|Other|Medical Management|
75474931|NCT01989247|Behavioral|Self-management programme|Seven weekly group-based sessions for people with anxiety and depressive symptoms
75474932|NCT01989260|Device|Anti-adhesive gel|4mls of anti-adhesive gel coated to the randomized ovary
75474933|NCT01989273|Device|Ultrasound of inferior vena cava|
75672256|NCT02830685|Device|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using a TCPM (TiLOOOP® Bra), either completely covering the implant or simply covering the anterior surface of it.The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
75672257|NCT02656914|Drug|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
75937256|NCT02405000|Other|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
75937257|NCT02406482|Behavioral|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
75937258|NCT02406482|Behavioral|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
75937259|NCT03171194|Drug|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
75937260|NCT02442765|Drug|AVP-786|
75937261|NCT02442765|Drug|Placebo|
75652096|NCT03013998|Drug|Gilteritinib (BAML-16-001-S8 Group 2)|Phase 1b induction: 80-120 mg, oral, daily for day 1 up to day 28 of the 35-day induction cycle 1; then 80-120 mg, oral, daily for day 1 up to day 28 of the 28-day induction cycle 2 (induction cycle 2 administered if needed after cycle 1 based on results bone marrow evaluation). Phase 1b consolidation: 80-120 mg, oral, daily for day 1 up to day 21 of the 28-day cycles, for a total of 12 total induction and consolidation cycles. Phase 1b induction and consolidation dose and duration may be escalated or de-escalated based on occurrence of dose-limiting toxicity. Phase 2 induction and consolidation dosage to be based on results of Phase 1b. Phase 1b and 2 maintenance: 120 mg, oral, daily for 28 days of the 28-day cycles until patient is minimal residual disease negative for FLT3 based on scheduled bone marrow biopsy, progression of disease, unacceptable toxicities, or desire to discontinue therapy.
75474934|NCT01989286|Other|Assessment|The posture, motor development and balance are going to be assessed.
75937262|NCT02404454|Procedure|Hysteroscopic metroplasty|
76088966|NCT03024489|Drug|Palbociclib|Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
76088967|NCT03024489|Drug|Palbociclib|Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
75652097|NCT03013998|Drug|Venetoclax (BAML-16-001-S12 Arm A)|400 mg, oral, on days 1 through 28 of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
75652098|NCT03013998|Drug|Azacitidine (BAML-16-001-S12 Arm A)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death.
75799414|NCT01195818|Drug|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
75652099|NCT03013998|Drug|Venetoclax (BAML-16-001-S12 Arm B)|400 mg, oral, on days 1 through 14 of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
75652100|NCT03013998|Drug|Azacitidine (BAML-16-001-S12 Arm B)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death.
75652101|NCT03006328|Behavioral|GEM|Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.
75652102|NCT03006328|Behavioral|Enhanced Usual Care|Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
76088968|NCT03024489|Drug|Cetuximab|All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
75652103|NCT02901067|Drug|Aspirin and Rosuvastatin|Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
75652104|NCT02901067|Drug|Placebo (for Aspirin and Rosuvastatin)|Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.
75652105|NCT02889926|Biological|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
75799415|NCT03733470|Drug|Sildenafil study group|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
75799416|NCT03058276|Behavioral|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
75937263|NCT02404454|Device|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
75937264|NCT02404454|Procedure|Office second look hysteroscopy|Second-look hysteroscopy after three months
75474935|NCT01989312|Procedure|intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
75474936|NCT01989312|Procedure|Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.|Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.
75937265|NCT04964258|Drug|TAK-105-a|TAK-105-a subcutaneous solution.
75937266|NCT04964258|Drug|TAK-105-a Placebo|TAK-105-a placebo-matching solution.
75937267|NCT04964258|Drug|TAK-105-b|TAK-105-b subcutaneous solution.
75474937|NCT01989312|Device|Intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
75474938|NCT01989312|Device|Routine ASA monitoring|Monitorization with ECG, noninvasive blood pressure and spO2.
75474939|NCT01989312|Drug|Premedication midazolam|Premedication with 0.03 mg/kg midazolam iv
75937268|NCT04964258|Drug|TAK-105-b Placebo|TAK-105-b placebo-matching solution.
75937269|NCT03115892|Drug|Green Tea With Aloe Vera mouthwash|measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score
76088969|NCT03024489|Radiation|Intensity Modulated Radiation Therapy|5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
76088970|NCT04129749|Procedure|Real-Time Analysis Interactive Lab|The Real-Time Analysis Interactive Lab uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment.
75799417|NCT03058276|Other|rTMS|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
75799418|NCT03058276|Other|SAM|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
75341613|NCT03007459|Other|Psychological health|Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
75341614|NCT03007459|Other|Physiological health|Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
75937270|NCT03115892|Drug|Chlorhexidine mouthwash|chlorohexidine mouthwash take two times per day for one week
75341615|NCT02980861|Procedure|Laparoscopic total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.
75341616|NCT02980861|Procedure|Open total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
75937271|NCT03116048|Other|Chronic pain evaluation|Chronic pain assessment with study questionnaire
75341617|NCT03007615|Other|Intimate Lubricant Gel|
75799419|NCT03845478|Behavioral|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of achieving 10,000 steps a day in weight loss and improved body composition.
75937272|NCT02406794|Drug|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
75937273|NCT02411786|Biological|pTVG-AR|Given ID
75341618|NCT03006913|Behavioral|In-person|At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
75341619|NCT03006913|Behavioral|By phone|Patients in the phone arm will receive a scheduled call at their home.
75937274|NCT02411786|Biological|gm-csf|Given ID
75937275|NCT02411708|Drug|SANGUINATE|Single two-hour infusion of SANGUINATE
76088971|NCT02268994|Drug|ferric citrate|1 g ferric citrate containing approximately 210 mg of ferric iron
75474940|NCT01989312|Drug|Lidocaine|
75474941|NCT01989312|Drug|Epinephrine|
75799420|NCT03845478|Behavioral|Intervention Group (IG)|This group in addition to fulfilling a hypocaloric diet identical to the control group, and receive identical information about physical activity that the control group, it has a system of prescription, monitoring and establishing an objective to achieve 10,000 steps a day.
75937276|NCT02411708|Drug|Placebo|Single two-hour infusion of placebo
75937277|NCT02411864|Other|different low b-values distribution|
76088972|NCT02268994|Drug|Placebo|Matching placebo
75474942|NCT01989312|Drug|Levobupivacaine|
75474943|NCT01989403|Other|herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation|
75937278|NCT02411552|Behavioral|physical activity|4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
75937279|NCT03172442|Device|Vacuum plate|Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
75937280|NCT03172442|Device|Rapid maxillary expander|Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
75937281|NCT03172442|Device|Class III elastics|Class III elastic traction from upper first molar to the hook in both side will be applied.
75474944|NCT01989416|Drug|2% chlorhexidine wipe|The ICU patients will be bathing with 2% chlorhexidine wipe
76088973|NCT04129593|Behavioral|Self Awakening - Natural Waking|subjects in this arm will be assigned to natural waking and self awaking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: natural waking, Sunday: self awakening and Saturday: self awakening, Sunday: natural waking.
76088974|NCT04129593|Behavioral|Snooze - Natural waking|subjects in this arm will be assigned to snooze and natural waking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: snooze, Sunday: natural waking and Saturday: natural waking, Sunday: snooze.
75341620|NCT03006913|Behavioral|By video|Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
75341621|NCT04345237|Dietary Supplement|dietary supplement consumption|"Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training"
75341622|NCT03001531|Device|HydroSun|a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp
75341623|NCT03001531|Device|Hilotherm|a skin area of the lower limb will be treated three times with heat applied by a sleeve
75474945|NCT01989416|Drug|Soap|The ICU patients will be bathing with Soap
75474946|NCT01989442|Device|binasal prongs|patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
75474947|NCT01989442|Device|nasal mask|patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
75474948|NCT01989494|Device|Pedometer|All groups will receive a pedometer to measure their daily steps
75474949|NCT01989507|Drug|Nicotine|
75474950|NCT01989507|Behavioral|behavioral counseling for smoking cessation|Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
75937282|NCT03524001|Device|Compare VVi mode versus DDD bifocal stimulation through crossover randomization|All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.
75937283|NCT02404376|Drug|Exenatide|Intravenous administration of Exenatide
75937284|NCT02404376|Other|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
75937285|NCT02404376|Drug|Placebo|Intrevenous administration of Placebo
75937286|NCT02406560|Drug|tafamidis|fasted
75341624|NCT00617942|Drug|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
75652106|NCT02889926|Biological|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
75937287|NCT02406560|Drug|tafamidis|high fat meal
75937288|NCT02406560|Drug|tafamidis|
75341625|NCT00617942|Drug|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
75652107|NCT02859896|Drug|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule~Route of administration: oral"
75799421|NCT05351710|Behavioral|Exposure-Based Treatment for Perfectionism|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
76088975|NCT04768894|Procedure|Second transurehral resection of bladder tumour|Remove of the bladder tumour as endoscopically
75799422|NCT05351710|Behavioral|Stress Management|Videos focused on education about healthy habits and relaxation. Each session is approximately twenty minutes.
75341626|NCT00617942|Drug|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
75341627|NCT00617942|Drug|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
75341628|NCT03001375|Procedure|Laparoscopic high anterior resection splenic flexure mobilization|
75341629|NCT03001375|Procedure|Laparoscopic high anterior resection without splenic flexure mobilization|
75341630|NCT03001297|Biological|Placebo|Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1
75341631|NCT03001297|Biological|MEDI5884 Dose 1|Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.
75474951|NCT01989520|Drug|Phase IIb formulation|Single oral dose 45mg AZD5069
75474952|NCT01989520|Drug|Putative phase III formulation|Single oral dose 45mg AZD5069
75474953|NCT01989520|Drug|Slow dissolution variant 1|Single oral dose 45mg AZD5069
75474954|NCT01989520|Drug|Slow dissolution variant 2|Single oral dose 45mg AZD 5069
75652108|NCT02859896|Drug|Calcitriol|"Pharmaceutical form: capsule~Route of administration: oral"
75652109|NCT02846298|Biological|Drug Monitoring|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
75672258|NCT02656914|Drug|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
75799423|NCT01195896|Device|New NPWT system|According clinical routine (Instruction for Use)
75474955|NCT01989520|Drug|Test treatment E|Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
75799424|NCT01195974|Drug|YASMIN|YASMIN for 21 days
75799425|NCT01195974|Drug|GSK2248761|200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
75474956|NCT01989533|Biological|Ad4-mgag|Ad4 live virus vaccine with an HIV insert
75474957|NCT01989533|Biological|Ad4-EnvC150|Ad4 live virus vaccine with an HIV insert
75799426|NCT01195974|Other|Placebo|Placebo taken on Days 1 - 10 or Days 12 - 21
75937289|NCT04466085|Biological|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
75937290|NCT04466085|Biological|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
75937291|NCT04466085|Biological|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
75937292|NCT02404298|Drug|IVIg|
75937293|NCT02217891|Behavioral|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, & qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits & harms of tumor genomic profiling; 2) interest in & perceived benefits & harms of incidental findings arising from tumor genomic profiling; 3) anticipated process & needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, & those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; & 6) implications of & concerns about incidental findings for family.
75937294|NCT02406638|Other|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
75474958|NCT01989533|Biological|gp 120 Protein Boost|HIV protein boost
75341632|NCT03001297|Biological|MEDI5884 Dose 2|Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1
75474959|NCT01989559|Biological|gp100:209-217(210M) Peptide Vaccine|Given SC
75652110|NCT02845479|Other|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
75652111|NCT02830958|Device|Kinesiotaping|The Kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting. Latex-free and wearable for days at a time, Kinesio® Tex Tape is safe for populations ranging from pediatric to geriatric, and successfully treats a variety of orthopedic, neuromuscular, neurological and other medical conditions.
75799427|NCT03268356|Device|AGN1 Femoral Local Osteo-Enhancement Procedure Kit|A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.
75799428|NCT04731376|Other|Best Practice|Receive standard peri-operative care
75937295|NCT03517995|Drug|Sulforaphane Administration|1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
75937296|NCT03517995|Other|Placebo Administration|1 capsule (placebo) taken two times per day (2 capsules total).
75937297|NCT03517995|Procedure|Standard of Care Surgery|The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
75937298|NCT03115658|Behavioral|Physical Activity|12 week print based intervention
75341633|NCT03001297|Biological|MEDI5884 Dose 3|Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1
75341634|NCT03001297|Biological|MEDI5884 Dose 4|Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1
75799429|NCT04731376|Procedure|Quality-of-Life Assessment|Ancillary studies
75799430|NCT04731376|Other|Questionnaire Administration|Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
75799431|NCT04731376|Drug|Testosterone Cypionate|Given IM
75799432|NCT05281354|Other|Multimodal intervention|Treatment to normalise resting energy expenditure according to the observed abnormalities such as anti-inflammatory treatment with Omega 3 in the case of systemic inflammation, treatment with a non-specific beta-blocker such as propanolol in the case of activation of the beta-adrenergic system, appropriate physical activity in the case of sarcopenia, or nutritional support aimed at re-establishing the balance of calorie and protein intake and expenditure, or a combination of these actions
75799433|NCT01196208|Drug|brentuximab vedotin|Every 21 days by intravenous infusion (1.8 mg/kg)
75937299|NCT02411240|Device|Air filtering|The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
75341635|NCT03000985|Behavioral|Psychoeducation|6 session psychoeducation program with the family caregiver of schizophrenics patients.
75341636|NCT00618332|Drug|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
75341637|NCT00618332|Drug|placebo|2 puffs in each nostril once a day for 2 weeks
75474960|NCT01989559|Biological|HPV 16 E7:12-20 Peptide Vaccine|Given SC
75474961|NCT01989559|Other|Laboratory Biomarker Analysis|Correlative studies
75652112|NCT02830958|Other|No intervention|No intervention. Uses of an ordinary tape
75652113|NCT02828488|Other|No intervention|It is a descriptive study. No intervention
75341638|NCT03001141|Other|Observational|Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
75341639|NCT03000907|Other|Intervention|Diet and physical exercises
75341640|NCT01585597|Device|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
75341641|NCT01588561|Drug|Intravenous Nicotine|Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
75474962|NCT01989611|Drug|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
75474963|NCT01989637|Dietary Supplement|Strawberry Meal|High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder
75474964|NCT01989637|Dietary Supplement|Control Meal|High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
75672259|NCT02657148|Drug|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
75799434|NCT01295892|Drug|Estrogen|transdermal 17-β-estradiol 1mg/day during three months
75799435|NCT05257720|Diagnostic Test|GFAP, S100B|It is planned to measure serum GFAP and S100 B protein levels by ELISA method.
76027235|NCT03099239|Biological|hCT-MSC infusion|hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
75341642|NCT01588561|Other|Saline - placebo|Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
75474965|NCT01989650|Other|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
75474966|NCT01989650|Other|No break|No break will be provided
75474967|NCT01989663|Drug|1% vaginally applied tenofovir gel|
75474968|NCT01989663|Drug|Tenofovir film- 10mg|
75474969|NCT01989663|Drug|Tenofovir Film-40 mg|
75474970|NCT01989663|Other|HEC Placebo Gel|
75474971|NCT01989663|Other|Placebo Vaginal Film|
76027236|NCT02373475|Other|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
75799436|NCT01295970|Procedure|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
75341643|NCT00619190|Drug|aripiprazole|aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
75652114|NCT02775630|Procedure|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
75799437|NCT01295970|Procedure|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
75341644|NCT01589263|Drug|onaBoNT-A + placebo|"200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo"
75799438|NCT01193712|Procedure|temporary left ventricular endocardial pacing|a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.
75474972|NCT01989676|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
75799439|NCT03848130|Other|Mulligan Knee Taping with Home Exercises|Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings & ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).
75341645|NCT01589263|Drug|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
75474973|NCT01989676|Drug|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m^2 and then 60 mg/m^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
75511121|NCT00539643|Other|Bead + Dox Arm|Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
75511122|NCT00455065|Behavioral|Whole Grain Foods|
75511123|NCT00195052|Diagnostic Test|Intrinsic signal imaging of human cortex|Light is shined on the brain at 540 nm and 610 nm and images are acquired at 10 frames per second.
75652115|NCT02750358|Drug|Enzalutamide|
75799440|NCT03848130|Other|Lateral wedge insoles with Home Exercises|Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)
75819613|NCT02174770|Other|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
75937300|NCT03132987|Other|Progressive strengthening program|The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
76027237|NCT02373475|Other|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
76027238|NCT05059613|Other|probiotics|one times a day during the whole treatment
76088976|NCT01775189|Drug|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
76088977|NCT01775189|Drug|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
75341646|NCT01590979|Drug|Ranolazine|1000mg, two times a day, 12 hour intervals
75341647|NCT01590979|Drug|Placebo|two times a day, 12 hour intervals
75511124|NCT00172029|Drug|Zoledronic acid|
75511125|NCT00080912|Radiation|radiation therapy|Given in a single fraction or multiple fractions
75652116|NCT02750358|Behavioral|assessment|
75652117|NCT02718170|Procedure|Buried Intramedullary K-wire Fixation|
75652118|NCT02718170|Procedure|Plate and Screw Fixation|
75341648|NCT00619970|Procedure|Lactulose Breath Test|Healthy controls will receive one lactulose breath test to assess for SIBO
75341649|NCT00619970|Drug|xifaxan|xifaxan 550mg TID x10days
75341650|NCT00619970|Drug|placebo|placebo TID x 10days
75341651|NCT00619970|Procedure|Lactulose Breath Test|Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
75799441|NCT03848130|Other|Traditional Physiotherapy with Home Exercises|Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors & abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
75937301|NCT02411630|Drug|Emtricitabine/tenofovir disoproxil|"ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed."
75799442|NCT03631576|Biological|CD123/CLL1 CAR-T Cells|CD123/CLL1 CAR-T Cell Therapy
75937302|NCT02411318|Behavioral|Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.
75937303|NCT02411318|Drug|ProLab 200mg caffeine capsule|Participants will swallow one ProLab caffeine 200mg tablet.
76088978|NCT01775189|Drug|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
75341652|NCT01591837|Biological|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
75341653|NCT01592071|Other|Replace reactive foods with non-reactive foods|Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
75341654|NCT03531788|Device|Armon Ayura (Kinova)|Actively assisted mechanical arm support (electric powered to balance arm)
75341655|NCT03531788|Device|JAECO Wrex|Passive mechanical arm support (elastic bands to balance arm)
75341656|NCT03445130|Other|Lavandula Angustifolia oil (LO)|two drops on the inside of an oxygen face mask for 15 minutes.
75341657|NCT03445130|Other|Michelia Alba Leaf oil (MA)|two drops on the inside of an oxygen face mask for 15 minutes.
75474974|NCT01989676|Biological|Herceptin®|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
75511126|NCT00039130|Biological|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC>5000/ul courses II-VII
75341658|NCT03445130|Other|Almond oil (AO)|two drops on the inside of an oxygen face mask for 15 minutes.
75341659|NCT03445130|Other|Water|two drops on the inside of an oxygen face mask for 15 minutes.
75341660|NCT03006991|Other|therapeutic drug monitoring|dose of methotrexate can be adjusted by therapeutic drug monitoring.
75799443|NCT01296048|Device|Comparison test|Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
75799444|NCT05136118|Procedure|TAPB|TAPB will be given to parturients whether by the modified surgeon assisted approach or by the ultra-sound guided approach.
75799445|NCT01196286|Behavioral|Multifamily Group Psychoeducation (MFG)|Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
75937304|NCT02411318|Other|Ethanol ingestion|Participants will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.
75937305|NCT02411318|Drug|Glucose Tolerance Drink|Participants will consume 100 grams of glucose
76088979|NCT01775189|Drug|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
75341661|NCT01592851|Drug|Stannous Fluoride|dentifrice containing stannous fluoride
75341662|NCT01592851|Drug|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
75511127|NCT00039130|Biological|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV & VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
75511128|NCT00039130|Drug|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
75511129|NCT00039130|Drug|cytarabine|1 g/sq m/day IV infusion Days 4 & 5, courses II, IV, VI
75511130|NCT00039130|Drug|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
75511131|NCT00039130|Drug|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 & 5 courses III,V, VII
75652119|NCT02711670|Drug|chlorthalidone|
75652120|NCT02711670|Drug|Hydrochlorothiazide|
75652121|NCT02658097|Drug|Pembrolizumab|200mg Pembrolizumab by IV infusion
75652122|NCT02658097|Radiation|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
75652123|NCT02649270|Biological|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
75652124|NCT02581527|Drug|Rifampicin|Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
75652125|NCT02581527|Drug|Isoniazid|Isoniazid 75mg - all arms
75652126|NCT02581527|Drug|Ethambutol|Ethambutol 275mg - all arms
75652127|NCT02581527|Drug|Pyrazinamide|Pyrazinamide 400mg - all arms
75937306|NCT03133299|Drug|Glucocorticoids|Oral prednisolone for four months
75937307|NCT03133299|Drug|Vitamin D|Oral vitamin D for two months
75937308|NCT03172598|Drug|MT-8554 low dose|Capsule
75799446|NCT01196286|Behavioral|Cognitive Remediation (CR)|Computer exercises designed to improve cognitive functioning (3hr/wk).
75799447|NCT01196364|Other|Dietary Supplement: water with noncalorie sweetener|
75799448|NCT01196364|Other|Activity: With noncalorie sweetener or glucose|
75937309|NCT03172598|Drug|MT-8554 middle dose|Capsule
75937310|NCT03172598|Drug|MT-8554 high dose|Capsule
76088980|NCT03832582|Drug|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
75341663|NCT00675584|Drug|Budesonide|Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
75341664|NCT00675584|Drug|Placebo Budesonide|Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
75341665|NCT03007069|Other|Mineralized plasmatic matrix (MPM).|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
75341666|NCT03007069|Other|Autogenous bone graft (gold standard).|Exposed implant threads are to be covered with autogenous bone and collagen membrane.
75341667|NCT00620126|Other|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
75341668|NCT00620126|Other|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
75474975|NCT01989676|Drug|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m^2 and then 60 mg/m^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
75474976|NCT01989702|Other|Fermented blueberry drink|
75799449|NCT01197768|Behavioral|Nutrition Intervention|Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
75799450|NCT03732534|Drug|NBI-98854|vesicular monoamine transporter 2 (VMAT2) inhibitor
75799451|NCT04983472|Other|Observational|Respiratory muscle electromyographic activations of individuals will be taken during supine, normal sitting and dyspnea reduction positions. Individuals with chronic obstructive pulmonary disease will be asked to perform normal breathing, pursed lip breathing, and breathing control during these positions. Respiratory muscle activation measurement of individuals will be taken during different breathing patterns in each position. Respiratory functions will be evaluated with pulmonary function test, respiratory muscle strength, intraoral pressure measurement device, respiratory muscle activation with surface electromyographic device, health status disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
75799452|NCT02998450|Drug|IMR-687|1 of 6 possible single doses administered orally following overnight fast
75799453|NCT02998450|Drug|Placebo Oral Capsule|Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
75799454|NCT01296204|Drug|BB4 antibody-Iodine 131|Injection of an antibody after labelling with Iodine 131
75799455|NCT03846336|Other|Upper extremity function|Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.
75819614|NCT02174770|Other|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
75819615|NCT02170792|Drug|BIBR 1048 MS|Low, medium or high dose
75819616|NCT02170792|Drug|Ranitidine|150mg
75819617|NCT02174926|Procedure|Elective laparoscopic sigmoid resection|
75937311|NCT03172598|Drug|Placebo|Capsule
75937312|NCT04465695|Drug|Interferon beta-1b|Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days
75937313|NCT04465695|Drug|Clofazimine|Oral 100mg twice daily on day 1, then 100mg daily for 2 days
75937314|NCT03115736|Drug|Tenofovir Alafenamide|Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
75937315|NCT03172286|Device|Radiofrequencer|Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
76088981|NCT04768816|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
75474977|NCT01989702|Other|Placebo drink|
75474978|NCT01989702|Other|Sachets with probiotic bacterial powder|
75937316|NCT04465851|Dietary Supplement|Ferrous Sulphate 65 mg|"Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
75937317|NCT04465851|Dietary Supplement|Curcumin|"HydroCurc™ 500 mg formulated curcumin~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
75937318|NCT04465851|Other|Placebo (Ferrous Sulphate)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
75799456|NCT03846336|Other|Shoulder position sense|Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.
75937319|NCT04465851|Other|Placebo (Curcumin)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
76088982|NCT04768816|Biological|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Autism Spectrum Disorder for safety and effect evaluation.
75341669|NCT03376646|Device|Cohort A: Dissolve™|Dissolve™ are to be used in the trial
75341670|NCT03376646|Device|Cohort A: Resolute™ Integrity|Resolute™ Integrity are to be used in the trial
75341671|NCT03376646|Device|Cohort B: Dissolve™-2.00mm|Dissolve™ are to be used in the trial
75341672|NCT00620828|Other|Placebo saline injection|20 cc of sterile, injectable saline
75341673|NCT00620828|Drug|Ropivicaine 0.5%|Ropivicaine
75341674|NCT01596283|Procedure|Standard fluid management|The patient will receive standard fluid management
75474979|NCT01989702|Other|Sachets with placebo powder|
75474980|NCT01989715|Other|analyzing the position of the body, muscle activity|
75799457|NCT01197846|Drug|Quetiapine|quetiapine 300 mg or 600 mg
75474981|NCT01989728|Procedure|psychiatric examination and feedback|
75799458|NCT01197846|Drug|Placebo|Placebo
75799459|NCT03847740|Device|Isometric Trumb Force handle|Compare the pattern of neuromuscular blocking drug between two devices applied on the same patient during general anesthesia.
75799460|NCT01193790|Procedure|Coblation channeling|"The combination of the energy and the fluid creates a plasma field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation."
75474982|NCT01989741|Other|Sleep restriction|4 hours sleep by night during one week
75799461|NCT03087058|Drug|Patiromer|4.2 g/day, 8.4 g/day and 16.8 g/day
75799462|NCT03087058|Drug|Patiromer|2 g/day, 4 g/day and 8 g/day
75799463|NCT03087058|Drug|Patiromer|1 g/day, 2 g/day and 4 g/day
75799464|NCT01296282|Device|Medronics CRT Optivol Impedance Measurement|Pacemaker
75937320|NCT04465851|Dietary Supplement|Ferrous Sulphate 18mg|"Oral ferrous salt supplement~Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
75341675|NCT01596283|Device|Goal directed fluid therapy with the Edwards EV1000 system|This arm will have fluid therapy guided by the Edwards EV1000 system.
75341676|NCT00676364|Drug|4% lidocaine topical anesthetic cream|A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
75341677|NCT00676364|Drug|Placebo cream|A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
75341678|NCT00676676|Drug|Testosterone|Testosterone atch delivering 300mcg daily for 8-weeks
75474983|NCT01989767|Behavioral|control Rehabilitation as usual|Rehabilitation as usual
75474984|NCT01989767|Behavioral|education|Education as add on to to rehabilitation as usual
75474985|NCT01989806|Device|Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)|
75474986|NCT01989806|Device|Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)|
75474987|NCT01989819|Other|skin biopsy|
75474988|NCT01989845|Drug|Rivaroxaban|Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
75474989|NCT01989858|Other|peri-operative cht|"CHT treatment have to be chosen between the following associations:~Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or~Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line."
75799465|NCT01296282|Device|External Thoracic Impedance Measurement|
75799466|NCT01192854|Drug|Clevudine|Clevudine flexible dosages of 30 mg/day
75799467|NCT01192854|Drug|Adefovir|Adefovir flexible dosages of 10 mg/day
75799468|NCT04183660|Device|MOBYBOX System|extracorporeal cardiopulmonary support
75819618|NCT02174926|Dietary Supplement|Conservative treatment|Written lifestyle guidance and fiber supplements
75819619|NCT02172976|Drug|Gemcitabine|
75341679|NCT00677690|Other|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
75341680|NCT00677690|Other|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
75474990|NCT01989858|Other|post-operative CHT|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line."
75511132|NCT00039130|Drug|etoposide|80 mg/sq m/day IV infusion Days 4 & 5 courses II, IV, VI
76088983|NCT02988154|Other|Simulation training|Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
75474991|NCT01989858|Other|peri-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~5FU 225 mg/m² given as a continuous iv infusion or~capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
75799469|NCT05670678|Dietary Supplement|a2 growing up stage 3 formula puls lactoferrin supplement|The participants in this group will consume 4-5 scoops (8.5g/scoop) of the assigned formula each time, and 4 times per day
75937321|NCT04465539|Drug|Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]|Hydroxyethyl starch dose is 500 cc in 6 hours
75937322|NCT04465539|Drug|Hydrocortisone|Hydrocortisone dose is 200-300 mg /day intravenously
75937323|NCT04465539|Drug|Placebo|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
75799470|NCT05670678|Dietary Supplement|Enfinitas growing up stage 3 formula|The participants in this group will consume 4 scoops (10g/scoop) of the assigned formula each time, and 3 times per day
75937324|NCT02404142|Drug|Curare (Atracurium)|Curare (Atracurium) versus saline isotonic solution for tracheal intubation
76088984|NCT02988154|Other|''See one, do one'' approach|The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
75341681|NCT00621530|Drug|ketorolac tromethamine opthalmic solution|ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
75341682|NCT00621530|Drug|placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
75341683|NCT02513472|Drug|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
75511133|NCT00039130|Drug|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
75799471|NCT02914366|Drug|Ambroxol|
75799472|NCT02914366|Other|Placebo|
75937325|NCT02404142|Drug|saline isotonic solution|
76088985|NCT04129203|Device|Versi Retriever thrombectomy|Mechanical thrombectomy using Versi Retriever
76088986|NCT04128813|Device|Vertical whole body vibration|A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.
76088987|NCT01881412|Drug|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
76117199|NCT05212038|Procedure|iliopsoas plane block group|Ultrasound-guided iliopsoas plane block with 0.75% ropivacaine 10 ml and epinephrine 0.05 ml (1:200,000) 10 ml
75799473|NCT03846180|Drug|Terlipressin|Continuous or intermittent intravenous infusion of terlipressin was given.
75799474|NCT03846180|Drug|Somatostatin|Continuous or intermittent intravenous infusion of somatostatin was given.
75799475|NCT03846180|Drug|Octreotide|Continuous or intermittent intravenous infusion of octreotide was given.
75799476|NCT05487690|Other|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries. to help to reduce intra-operative radiation.
75799477|NCT05487690|Other|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
75799478|NCT01199406|Drug|Levobupivacaine|0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally
75937326|NCT03172208|Biological|Caplacizumab Dose 1 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 1
75937327|NCT03172208|Biological|Caplacizumab Dose 2 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 2
75937328|NCT03172208|Biological|Caplacizumab Dose 2 sc (single-dose)|Single subcutaneous (sc) administration of Caplacizumab Dose 2
76117200|NCT05212038|Procedure|sham block group|Ultrasound-guided iliopsoas plane block with normal saline 10 ml
75341684|NCT02513472|Drug|Pembrolizumab|Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
75341685|NCT03109028|Behavioral|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
76088988|NCT01881412|Other|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
76088989|NCT03378609|Other|Vocal Fatigue Index (VFI)|collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
76088990|NCT03832816|Drug|Placebo|Placebo vapor (distilled water)
76088991|NCT03832816|Drug|Vaporized THC alone|Acute exposure to vaporized THC
76088992|NCT03832816|Drug|Vaporized CBD alone|Acute exposure to vaporized CBD
76088993|NCT03832816|Drug|Vaporized CBD with THC|Acute exposure to vaporized CBD with THC
75341686|NCT03109028|Behavioral|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
75354653|NCT04816006|Other|Health Education (Active comparator)|Breast cancer survivors in the Health Education group will participate in education sessions with a health educator and receive monthly newsletters/webinars (N=20 total contacts) across 24 weeks. The program will include cancer support and discussion of cancer-related wellness topics (e.g., stress management, coping). Control group participants will be offered a 6-month fitness center membership upon study completion.
75799479|NCT01197924|Other|IRMf Bold|IRMf BOLD of the working memory
75799480|NCT03846414|Drug|PEG-rhG-CSF|PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
75511134|NCT00039130|Drug|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX <10nM, courses II-VII
75799481|NCT01196598|Other|Exercises|"Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist."
75799482|NCT02729116|Drug|Sitafloxacin|Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.
75511135|NCT00039130|Drug|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
75799483|NCT02729116|Drug|Ertapenem|Patients are given IV ertapenem for 14 days
75799484|NCT05668260|Device|Biodegradable Stent|A trans-anastomotic biodegradable internal stent (ARCHIMEDES™) will be placed between the main pancreatic duct (MPD) and the enterotomy in the jejunum just after the completion of the posterior suture of duct-to-mucosa. The biodegradable stent will then be shaped according to the angle of the jejunal loop in order to minimise the risk of displacement. The adequate length of the stent will be chosen according to the length of the jejunal loop.
75937329|NCT03172208|Biological|Caplacizumab Dose 2 sc (multiple-dose)|Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
75937330|NCT03172208|Other|Placebo iv (single-dose)|Single intravenous (iv) administration of Placebo
75937331|NCT03172208|Other|Placebo sc (single-dose)|Single subcutaneous (sc) administration of Placebo
76088994|NCT04129047|Drug|Omnichroma (one shade universal) composite by Tokuyama|Omnichroma is a single shade composite that is intended to have a color blending potential. It eliminates the shade matching procedures and makes it easier to avoid individual errors in shade matching in composite restorations.
76088995|NCT04129047|Drug|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA|a multiple shade universal composite that needs prior shade selection procedure
76088996|NCT02987764|Other|cord milking|For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
76088997|NCT04231084|Drug|Vasodilator testing (Inhaled Nitric Oxide)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
75354654|NCT04816006|Procedure|Magnetic Resonance Imaging|Undergo MRI
75511136|NCT00039130|Drug|prednisone|60 mg/sq m PO/day Days 1-7 course I
75511137|NCT00039130|Drug|vincristine sulfate|2 mg IV push Day 1 courses II-VII
75511138|NCT00039130|Drug|Allopurinol|300 mg/day PO Days 1-14, course I
75511139|NCT00005957|Radiation|Standard Breast Irradiation|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
75652128|NCT02471040|Drug|Beta-hydroxybutyrate|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
75652129|NCT02471040|Other|Normal Saline|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
75652130|NCT02466074|Drug|Acetazolamide|see arm description
75652131|NCT02466074|Drug|Placebo|Placebo arm
75652132|NCT02393794|Drug|Romidepsin|Histone deacetylase inhibitor
75937332|NCT03172208|Other|Placebo sc (multiple-dose)|Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
75937333|NCT02294565|Drug|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
75799485|NCT01196676|Drug|AZD4451|1 mg capsules, 5 mg capsules, and 25 mg capsules
75474992|NCT01989858|Other|post-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~5FU 225 mg/m² given as a continuous iv infusion or~capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
75652133|NCT02393794|Drug|Cisplatin|Platinum compound
75799486|NCT01196676|Drug|Placebo|1 mg capsules, 5 mg capsules, and 25 mg capsules
75799487|NCT03844230|Other|Control - Inhibition|Taste and spit up water 10 minutes before drinking a glucose load
75799488|NCT03844230|Other|Experimental I- Inhibition|Taste and spit up water 10 minutes before drinking a glucose load mixed with lactisole
75937334|NCT02294565|Drug|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
75937335|NCT02410928|Device|direct laringoscopy|the vocal cords will be visualized after extubation with direct laringoscopy
76088998|NCT04231084|Drug|Vasodilator testing (Inhaled Epoprostenol)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
75341687|NCT03109028|Behavioral|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
75341688|NCT03109028|Behavioral|Empowerment-Groupintervention|"Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
75474993|NCT01989871|Behavioral|Adjusted individual feeding|Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
75474994|NCT01989884|Drug|Ortataxel|75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
75474995|NCT01989897|Drug|saline with 1mg/ml Histamine base|
75652134|NCT02393794|Drug|Nivolumab|Monoclonal antibody, checkpoint inhibitor
75652135|NCT02308488|Radiation|Intensity-modulated radiation therapy (IMRT)|Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
75652136|NCT02159950|Other|Laboratory Biomarker Analysis|Correlative studies
75799489|NCT03844230|Other|Experimental II- Inhibition|Taste and spit up sucralose 10 minutes before drinking a glucose load mixed with lactisole
75799490|NCT03844230|Other|Control- Stimulation|Taste and spit up water 10 minutes before drinking a glucose load
75799491|NCT03844230|Other|Experimental I- Stimulation|Taste and spit up sucralose 10 minutes before drinking a glucose load
75799492|NCT03844230|Other|Experimental II- Stimulation|Drink sucralose 10 minutes before drinking a glucose load
75799493|NCT03844230|Other|Sensory Evaluation|Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold
75799494|NCT05467410|Behavioral|COG-AM|Participants who are randomized to the COG-AM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during morning hours (between 09:00-12:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
75937336|NCT02410928|Device|fiberoptic nasal laringoscopy|the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
75937337|NCT02410928|Device|ultrasonograph|the vocal cords will be visualized after extubation with fiberoptic ultrasonography
75652137|NCT02159950|Biological|Sipuleucel-T|Given IV
75652138|NCT02159950|Drug|Tasquinimod|Given PO
75652139|NCT02152137|Drug|efatutazone|Given PO
75652140|NCT02152137|Drug|paclitaxel|Given IV
75672260|NCT02657148|Drug|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
75819620|NCT02172976|Drug|Oxaliplatin|
75819621|NCT02172976|Drug|5-Fluorouracil|
75819622|NCT02172976|Drug|Irinotecan|
75819623|NCT02172976|Drug|Natriumfolinate|
75819624|NCT02178202|Behavioral|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
76117201|NCT00945035|Drug|etoricoxib|Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.
76088999|NCT04551105|Diagnostic Test|Reader Group X - Session 1|"Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
75341689|NCT03109028|Behavioral|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
75474996|NCT01989897|Drug|diluent, saline with HSA--phenol|
75799495|NCT05467410|Behavioral|COG-PM|Participants who are randomized to the COG-PM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during late afternoon/early evening hours (between 15:00-18:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
75474997|NCT01989923|Other|Nicotine Replacement Therapy|Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
75474998|NCT01989923|Device|Electronic Cigarettes|The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
75511140|NCT00005957|Radiation|Breast Radiation plus Regional Radiation|Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
75341690|NCT03109028|Other|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
75341691|NCT00621686|Biological|bevacizumab|
75652141|NCT02098538|Drug|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
75799496|NCT05668338|Device|Implantable or non-implantable MED-EL hearing solution|Receipt of an implantable or non-implantable MED-EL hearing solution
75341692|NCT00621686|Drug|sorafenib tosylate|
75799497|NCT05289648|Drug|Niraparib oral capsule|Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
75799498|NCT05457270|Drug|AZD4831|Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
76089000|NCT04551105|Diagnostic Test|Reader Group Y - Session 1|"Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
75341693|NCT02924714|Other|Discontinuation of imatinib|
75341694|NCT00678470|Drug|Intralesional Alefacept|Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
75341695|NCT00679952|Procedure|closed suction drainage of pancreatic duct|A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.
75341696|NCT00679952|Procedure|natural drainage of pancreatic duct|Natural drainage group
76089001|NCT04551105|Diagnostic Test|Reader Group X - Session 2|"Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
75341697|NCT00623012|Drug|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
75354655|NCT04816006|Other|Medical Device Usage and Evaluation|Wear accelerometer
75511141|NCT00003692|Procedure|therapeutic thoracoscopy|
75511142|NCT00003692|Procedure|video-assisted surgery|
75511143|NCT00002889|Drug|flutamide|
75511144|NCT00002889|Drug|goserelin|
75511145|NCT00002889|Drug|leuprolide acetate|
75511146|NCT00002889|Radiation|low-LET photon therapy|
75511147|NCT00122577|Drug|Tenofovir|
75652142|NCT02007512|Drug|Enzalutamide|160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
75511148|NCT00122577|Drug|Atazanavir|
75341698|NCT00623012|Drug|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
75652143|NCT02007512|Drug|exemestane|25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
75819625|NCT02178202|Device|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
75819626|NCT04588480|Biological|BNT162b2|BNT162b2 (intramuscular injection)
75819627|NCT04588480|Other|Placebo|Placebo (intramuscular injection)
75819628|NCT02178280|Other|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
75937338|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
75937339|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
75937340|NCT02411162|Drug|Combination therapy GSK2894512 Cream A + GSK2894512 Cream B|GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm^2 of skin.
75937341|NCT02411162|Drug|Combination therapy Vehicle Cream A + Vehicle Cream B|Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
75937342|NCT03522051|Other|calcium silicate based material,|Its a dental pulp capping material which is biocompatable and induces hard tissue barrier formation
75937343|NCT02411006|Behavioral|Prediction mailing|Ask people to predict their upcoming medication adherence
75937344|NCT02411006|Behavioral|Commitment mailing|Ask people to commit to their upcoming medication adherence
75937345|NCT02411006|Behavioral|Reminder|Remind people to take their medicine
75937346|NCT02411006|Behavioral|Anonymity|Keep patient predictions and commitment anonymous
75937347|NCT02411006|Behavioral|Identification|Ask patients to report their predictions and commitments
75937348|NCT03521973|Biological|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
75937349|NCT03521973|Other|Normal Saline|0.9% Sodium chloride
75937350|NCT03171974|Drug|Dexamethasone|dexamethasone will be injected intracapsular under US
75937351|NCT03171974|Device|US|dexamethasone will be injected intracapsular under US
75937352|NCT02292069|Drug|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
75937353|NCT02404064|Drug|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
75937354|NCT02404064|Drug|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
75937355|NCT02404064|Drug|Placebo|No perioperative antibiotics
75937356|NCT03171038|Other|Telemonitoring|
75341699|NCT02699060|Procedure|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.
75341700|NCT02699060|Procedure|Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring|we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was <4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.
75511149|NCT00122577|Drug|Ritonavir|
75511150|NCT00313261|Drug|Clevudine|
75511151|NCT00419029|Behavioral|telephone-administered motivational interviewing|telephone motivational interviewing
75652144|NCT02007512|Drug|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
75652145|NCT02007512|Drug|exemestane|50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
75511152|NCT00419029|Behavioral|control|brief telephone check-in (no motivational interviewing)
75511153|NCT00425074|Drug|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
75511154|NCT00425074|Drug|ASA|normal release acetylsalicylic acid
75652146|NCT01971489|Drug|Buparlisib|Given PO
75819629|NCT02178514|Other|Formula fed with BabyNes Nutrition System|
75819630|NCT02173132|Drug|Acetyl-L-carnitine|
75819631|NCT02173132|Other|Placebo|
75819632|NCT02175082|Other|Cycling at Forced rate|
75819633|NCT02175082|Other|Cycling at self-selected rate|
75819634|NCT03538366|Other|Donor FMT|Fecal transplant from unrelated, healthy donors using enemas
75819635|NCT02175160|Other|Braking and functionality|
75819636|NCT03538288|Device|rTMS|rTMS will be applied at 10 Hz to the DLPFC
75819637|NCT02756650|Drug|Canakinumab|150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)
75819638|NCT02173288|Drug|Standard medical therapy|
75511155|NCT00425074|Drug|SR-ASA|slow release acetylsalicylic acid 150 mg
75511156|NCT00425152|Drug|fluorouracil|
75511157|NCT00425152|Drug|leucovorin calcium|
75819639|NCT02173288|Drug|Tolvaptan|
75819640|NCT02173288|Drug|Midodrine|
75819641|NCT02173366|Behavioral|Change Club Intervention|
75819642|NCT02173444|Other|Blood test|
75819643|NCT02178670|Biological|CSC-DC|
75819644|NCT02178748|Biological|MVA85A|Single dose of 1x10^8pfu MVA85A intramuscular vaccination
75937357|NCT02294643|Drug|Sarpogrelate|
75937358|NCT02294643|Drug|Aspirin|
75937359|NCT02294643|Drug|Clopidogrel|
75937360|NCT02294643|Drug|Placebo (for Sarpogrelate)|
75652147|NCT01971489|Drug|Cisplatin|Given IV
75799499|NCT03844152|Dietary Supplement|Fermented whey concentrate|The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability. The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose. The research team will provide non-descriptive bottles of drink to all volunteers. The flavour of the FWC will be masked by the flavoured water. In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers. At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study. The daily energy content of the FWC is 4kcal.
75799500|NCT01199484|Other|Cow's milk|
75799501|NCT01199562|Procedure|infection prophylaxis and management|Undergo infection prophylaxis and management
75799502|NCT01199562|Other|laboratory biomarker analysis|Correlative studies
75799503|NCT01199562|Other|flow cytometry|Correlative studies
75937361|NCT02401958|Other|Resistance training|17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
75937362|NCT03520803|Other|Enhanced recovery after surgery protocol|Experimental enhanced recovery protocol for pre-surgery and post surgery
75937363|NCT02410694|Drug|Ixazomib|
75937364|NCT02410694|Drug|Thalidomide|
75937365|NCT02410694|Drug|Dexamethasone|
75937366|NCT02410538|Other|"list of FAQ"|
75937367|NCT03521895|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Patients observed with regular and irregular treatment course
75937368|NCT03171116|Other|none intervention|it is not an interventional study; it is an observational study
75652148|NCT01971489|Drug|Gemcitabine Hydrochloride|Given IV
75652149|NCT01971489|Other|Laboratory Biomarker Analysis|Correlative studies
75652150|NCT01971489|Other|Pharmacological Study|Correlative studies
75652151|NCT01971489|Other|Questionnaire Administration|Ancillary studies
75937369|NCT02401880|Drug|Linagliptin|22 subjects will receive Linagliptin for 30 days
75937370|NCT02401880|Other|Placebo|22 subjects will receive Placebo for 30 days
75937371|NCT02401880|Drug|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
75937372|NCT03517839|Other|Inspiratory muscle trainig|Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
75937373|NCT03170726|Drug|arveles|Intraoperative and postoperative pain values between these three groups will be compared.
75341701|NCT00623636|Drug|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
75341702|NCT00623636|Drug|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
75341703|NCT02549222|Other|Standard of Care|
75341704|NCT01799876|Procedure|Autologous Cell|
75341705|NCT01799876|Procedure|Standard microfracture arthroscopic surgery|
75652152|NCT01942135|Drug|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
75652153|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
75652154|NCT01942135|Drug|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
75652155|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
75652156|NCT01889238|Drug|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
75799504|NCT01199562|Genetic|DNA analysis|Correlative studies
75799505|NCT01199562|Genetic|RNA analysis|Correlative studies
75799506|NCT01199562|Procedure|management of therapy complications|undergo infection prophylaxis and management
75799507|NCT01199562|Drug|ganciclovir|Given IV
75799508|NCT01199562|Drug|valganciclovir|Given orally
75799509|NCT01199562|Drug|foscarnet sodium|Given orally
75799510|NCT01199562|Procedure|antiviral therapy|undergo infection prophylaxis and management
75799511|NCT01199562|Genetic|polymerase chain reaction|Correlative studies
75799512|NCT01199562|Genetic|protein expression analysis|Correlative studies
75819645|NCT02178826|Device|Rapid Maxillary Expansion|The Rapid Maxillary Expander will over 10-14 days create a palatal expansion of about 5mm.
75937374|NCT03170726|Drug|intrafen 800 mg|ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
75937375|NCT03170726|Other|plasebos|normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
75937376|NCT03520725|Other|No Intervention|This gruop did not have an intervention
75937377|NCT03520725|Dietary Supplement|Pineapple snack bar|30 g daily of pineapple snack bar
75937378|NCT03520725|Dietary Supplement|Mango snack bar|30 g daily of mango snack bar
75937379|NCT02401802|Dietary Supplement|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
75937380|NCT02401802|Dietary Supplement|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
75937381|NCT02401724|Other|Transcranial direct current stimulation|
76089002|NCT04551105|Diagnostic Test|Reader Group Y - Session 2|"Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
76089003|NCT04128345|Device|Use of navigation system|Feasibility assessment of using an integrated navigation system incorporating advanced diffusion MRI, volumentric tumour representation and intraoperative ultrasound
76089004|NCT01883440|Drug|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
75652157|NCT01838174|Drug|ACTHAR Gel (ACTH)|15 days of daily injections
75937382|NCT02401724|Other|Action Training|
75474999|NCT01989936|Drug|Placebo|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
76089005|NCT01883440|Drug|Saline+glucose|Placebo arm
76089006|NCT01770743|Biological|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
75341706|NCT01799954|Biological|DNA-HIV-PT123|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
75341707|NCT01799954|Biological|NYVAC-HIV-PT1|(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
75341708|NCT01799954|Biological|NYVAC-HIV-PT4|(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
75341709|NCT01799954|Biological|AIDSVAX® B/E|300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
75937383|NCT02401490|Drug|Human albumin|1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
75937384|NCT02401490|Drug|Placebo|
75937385|NCT02401646|Dietary Supplement|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
75937386|NCT02401646|Dietary Supplement|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
75937387|NCT04481438|Other|Acupunch Exercises|The acupunch exercise program was developed based on Jing-Luo theory of tranditional Chinese Medicine. The experiment group will receive Acupunch exercise for 40 minute sessions, 3 times a week, for 24 weeks
75937388|NCT02294721|Device|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
76089007|NCT01770743|Biological|BioThrax|
76089008|NCT04124211|Biological|Fecal Microbiota Transplantation (FMT)|FMT will be performed through transendoscopic enteral tubing (TET) within one week during treatment period
76089009|NCT04128657|Diagnostic Test|MA_LARS|Validation of the MA_LARS and MA_Wexner
75341710|NCT01799954|Biological|Placebo for DNA/NYVAC|Sodium Chloride for injection, 0.9% administered IM
75341711|NCT01799954|Biological|Placebo for AIDSVAX(R) B/E|600 mcg of aluminum hydroxide adjuvant, administered IM
75475000|NCT01989936|Drug|Eletriptan 40 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
75511158|NCT00425152|Drug|levamisole hydrochloride|
75511159|NCT00090714|Genetic|pVGI.1(VEGF2)|
75511160|NCT00314314|Drug|Intranasal Insulin|Intranasal spray; 40 IU qid; 8 weeks
75511161|NCT00314314|Drug|Diluent|Intranasal spray; 8 weeks
75511162|NCT00314392|Behavioral|Information (behavior)|
75511163|NCT00314431|Procedure|Care coordination by telephone contacts with a nurse|
75511164|NCT00122616|Biological|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
75652158|NCT01838174|Drug|IV methylprednisolone (steroids)|3 days of intravenous methylprednisolone followed by 11 days of oral taper
76089010|NCT04124289|Other|Pain measurement using 3 scales|Patients will assess their pain after surgery using three different pain scales.
75341712|NCT00623714|Drug|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
75937389|NCT02294721|Device|The CPREazy|feedback device-1
75937390|NCT02294721|Device|TrueCPR|feedback device -2
75937391|NCT02294721|Device|The CPR PRO APP|feedback device -3
75937392|NCT02294721|Device|The CardioPump|feedback device- 4
75937393|NCT03175016|Procedure|TACE|Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
76089011|NCT03305146|Genetic|Molecular biology analysis of pancreatic intra-cyst fluid|"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( <50ng) DNA."
76117202|NCT00945035|Drug|Comparator: etoricoxib|Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.
75652159|NCT01753414|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
75799513|NCT05289258|Behavioral|Neuropsychological treatment|combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying difficulty. These exercises automatically adjust your difficulty to maintain an 85% rate of return. Treatment is carried out in groups of 10 cancer survivors. It consists of 10 weekly sessions of 2 hours each (the first hour for memory training and the second for processing speed exercises). In order to improve the adherence to treatment of the participants, emails and telephone text messages will be sent with reminders of appointments and tasks to be performed.
76089012|NCT04127799|Other|Hospital-Community-Family-Care Management Platform Online|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
75341713|NCT00623714|Drug|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
75341714|NCT02174822|Drug|AVP-786|
75341715|NCT02174822|Drug|Paroxetine|
75341716|NCT02174822|Drug|Duloxetine|
75652160|NCT01753414|Procedure|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
75799514|NCT05289258|Behavioral|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used (Barlow et al., 2015). All patients receive the workbook to help them read the contents of each session, do the recommended exercises between sessions, and to help them once the treatment is finished. The treatment lasts 10 weeks (one session a week). As in the previous intervention group, emails and telephone text messages will be used with reminders of appointments and tasks to be carried out.
75799515|NCT05289258|Behavioral|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
75799516|NCT03845322|Drug|Curcumin Pill|Curcumin (turmeric extract), over the counter supplement (1 capsule/three times a day). According to the Company, each capsule contains: 270 mg of pure curcuminoids (curcumin) and 3 mg of black pepper extract. Recommended serving size is 3 capsules per day in total, the patients will receive 810 mg of pure curcumin and 9 mg of black pepper extract (peperine/BioPerine) per day.
75799517|NCT03845322|Drug|Placebo pills|The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
75819646|NCT02178826|Device|Placebo Appliance|The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
75819647|NCT02175238|Drug|BI 691751 fasted|single dose BI 691751 in fasted state
75819648|NCT02175238|Drug|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
75819649|NCT02175316|Device|Enhanced External Counterpulsation|Enhanced External Counterpulsation
75341717|NCT02139800|Procedure|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
75511165|NCT00122616|Drug|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
75511166|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
75652161|NCT01743131|Drug|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
75652162|NCT01743131|Drug|placebo|
75652163|NCT01685814|Drug|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
75652164|NCT01685814|Biological|autologous stem cell transplant|
75652165|NCT01685814|Biological|allogeneic stem cell transplant|
75652166|NCT01603849|Radiation|Prophylactic Cranial Irradiation|Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
75819650|NCT02175394|Drug|Microgynon®|
75819651|NCT02175394|Drug|BI 1356|
75511167|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
75652167|NCT01495533|Device|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
75652168|NCT01495533|Combination Product|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
75341718|NCT02139800|Procedure|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
75511168|NCT04984070|Drug|Oral Contraceptives, Combined|One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
75652169|NCT01363596|Other|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
75652170|NCT01260090|Device|Vagus nerve stimulation;|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
75799518|NCT04889976|Device|Double Active: Active portable transcranial stimulation (ptES) and active internet-based behavioral therapy (iBT)|ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). Active iBT consists of a smartphone app with an electronic therapist-avatar. The iBT sessions are delivered concomitantly to the tDCS sessions (the tDCS device connects via bluetooth to the participant's smartphone app).
75799519|NCT04889976|Device|ptES-only: Active portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)|ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). The sham iBT sessions are delivered concomitantly to the active ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).
75937394|NCT03175016|Drug|Irinotecan|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
75341719|NCT02139878|Other|Wild blueberry juice|
75341720|NCT02139878|Other|Placebo wild blueberry juice|
75937395|NCT03175016|Device|eluting-bead|The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
75937396|NCT03175250|Behavioral|Health Education|Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
75937397|NCT03175250|Behavioral|Action Plan|Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
75937398|NCT03175250|Behavioral|Memory Practice|Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
76027239|NCT02373553|Other|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
76027240|NCT02373553|Other|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
76027241|NCT03098849|Other|Buteyko Breathing Technique|Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
76027242|NCT02373397|Device|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
76027243|NCT02373397|Device|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
76027244|NCT05059847|Other|Training|Training routine assigned by randomized chart
76027245|NCT03098927|Behavioral|Motor imagery training|Motor imagery training
76027246|NCT05060159|Other|Hemofiltration|Postdilutional Hemofiltration
75341721|NCT00624416|Drug|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
75511169|NCT04984070|Drug|Metformin Pill|Metformin is used to lower insulin resistance or to modulate hyperinsulinism.
76027247|NCT03098771|Procedure|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
75341722|NCT01894646|Radiation|Positron Emission Tomography (PET) Imaging|
75341723|NCT00682838|Behavioral|Self-management|Self-management
75341724|NCT00682838|Behavioral|Telemonitored care|Telemonitored care
75341725|NCT00624806|Behavioral|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
75341726|NCT00624806|Behavioral|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
75341727|NCT00626210|Drug|modafinil|100-400 mg daily for 4 weeks
75511170|NCT04984070|Other|lifestyle intervention|Weight control including calorie restriction and moderate exercise will be recommended to obese PCOS patients
75511171|NCT00314509|Drug|Ciclesonide/Formoterol Combination|
75341728|NCT00653276|Drug|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
75819652|NCT02173600|Behavioral|Group-level Intensive dietary Counselling|
75819653|NCT02173600|Behavioral|Individual-level Intensive Dietary Counselling|
76027248|NCT03098771|Drug|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
76027249|NCT03098537|Drug|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
75341729|NCT00653276|Drug|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
76027250|NCT03098537|Other|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
75341730|NCT00683852|Drug|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
75475001|NCT01989936|Drug|Eletriptan 80 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
75819654|NCT02178904|Procedure|CT and stress test|Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
76027251|NCT05046665|Drug|89Zr-Girentuximab|Administration of 89Zr-girentuximab as per protocol.
76089013|NCT04127799|Other|Subjects with AF conventional treatment|Subjects with standardized treatment according to latest guidelines via conventional visit.
75341731|NCT00683852|Drug|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
75341732|NCT00683852|Drug|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
75341733|NCT01596751|Drug|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
75341734|NCT01596751|Drug|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
75341735|NCT03000751|Other|Simple Audit Report|The simple audit provides comparison and feedback on radiation doses.
75341736|NCT03000751|Other|Multi-Component Intervention|The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
75341737|NCT03000751|Other|In-Person Meeting|Collaborator meeting with an emphasis on quality improvement.
75341738|NCT03000595|Drug|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
75341739|NCT03000595|Drug|Placebo|The vehicle cream
75341740|NCT03006835|Drug|Clopidogrel|
75475002|NCT01989962|Other|E4E intervention|The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
75475003|NCT01989988|Procedure|LMGB|
75475004|NCT01989988|Procedure|LRYGB|
75475005|NCT01989988|Procedure|SADJB|
75475006|NCT01990001|Other|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
75511172|NCT00314548|Drug|PGE1 (prostacyclin)|alprostadil nebulization
75511173|NCT00314548|Drug|normal saline|nebulize for 30 mins
75511174|NCT00314587|Procedure|1 or 2 elastic stable intramedullary nails|
75511175|NCT00314626|Drug|efavirenz|Efavirenz
75511176|NCT00314626|Drug|Abacavir+lamivudine|Abacavir+lamivudine
75511177|NCT02960074|Biological|Fecal Microbiota Capsule|We will treat patients with oral encapsulated frozen FMT over 2 days.
75511178|NCT00314665|Drug|Thalidomide|
75511179|NCT00314704|Drug|dopamine versus norepinephrine|
75511180|NCT00090909|Drug|cisplatin|
75511181|NCT00090909|Drug|dexamethasone|
75511182|NCT00090909|Drug|gemcitabine hydrochloride|
75652171|NCT01260090|Device|No stimulation|Vagus nerve stimulation
75652172|NCT01147016|Biological|HER2Bi-armed activated T cells|Total of 4 of the T cell infusions intravenously over a period of 1 month.
75652173|NCT01147016|Drug|cyclophosphamide|As prescribed by physician, standard of care.
75652174|NCT01147016|Drug|doxorubicin hydrochloride|As prescribed by physician, standard of care.
75652175|NCT01147016|Drug|paclitaxel|As prescribed by physician, standard of care.
75819655|NCT02173678|Drug|COMBIVENT® HFA-MDI|
75819656|NCT02173678|Drug|COMBIVENT® CFC-MDI|
75819657|NCT02173678|Drug|Placebo HFA-MDI|
75819658|NCT02256124|Drug|Lamotrigine|
75819659|NCT02256124|Drug|Placebo|
75819660|NCT02173756|Drug|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
75819661|NCT02173756|Drug|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
75819662|NCT00102466|Drug|vildagliptin|
75819663|NCT00102466|Drug|Gliclazide|
75819664|NCT00102466|Drug|Metformin|
76089014|NCT04127877|Device|NICAS|Electric regional bio impedance device
75937399|NCT03520257|Drug|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.
75341741|NCT03006757|Other|titanium dioxide denture base|
75652176|NCT01147016|Other|laboratory biomarker analysis|Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
75937400|NCT03520257|Device|Radiotherapy|Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities.
75937401|NCT02292303|Dietary Supplement|zinc-enriched yeast|
75937402|NCT02292303|Dietary Supplement|Zinc references|
75341742|NCT02247271|Behavioral|Diabetes health coach support|Receives support from a trained peer health coach for a six month period
75341743|NCT05566405|Procedure|General Anaesthesia|All patients in the general anaesthesia group will be premedicated with intravenously administered (iv) midazolam (2mg) and fentanyl (100 mcg). Induction will be performed using intravenous propofol (2.5-3mg/kg) and lidocaine (40mg); dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg will also be administered. After successful tracheal intubation, total intravenous anaesthesia will be maintained by administering propofol (0.05 mg/kg/sec iv) and remifentanil (0.2 mcg/kg/sec iv). Pain management will be achieved by paracetamol (1g iv) and tramadol (100mg iv) whereas muscle relaxation by vecuronium (0.6 mg/kg iv).
75341744|NCT05566405|Procedure|Combined (Epidural and Spinal) Anaesthesia|Combined (epidural and spinal) anaesthesia will be performed using an epidural 18G needle and a spinal 27G needle, in the L2-L3 or L3-L4 interspace. Induction will be carried out by spinal intrathecal administration of levobupivacaine (2.6-3ml of 0.5%) and mild sedation by midazolam (5mg iv in bolus). All patients will be administered dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg iv. Maintenance will be performed 75 minutes after induction and obtained using an epidural administration of levobupivacaine (4-5ml of 0.5%).
75341745|NCT05566405|Procedure|Open Retropubic Radical Prostatectomy|All patients will undergo a nerve-sparing open retropubic radical prostatectomy
75341746|NCT03000361|Procedure|Motorized Spiral Colonoscopy|For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
75652177|NCT01147016|Procedure|neoadjuvant therapy|As prescribed by physician, standard of care.
75652178|NCT01147016|Procedure|therapeutic conventional surgery|As recommended by physician, post immunotherapy.
75652179|NCT01140204|Device|Implantation of a bare metal stent|Bare Metal Stent
75652180|NCT01124890|Device|early percutaneous coronary intervention|
75799520|NCT04889976|Device|Double-sham: Sham portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)|Sham ptES for this trial is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all transcranial direct current stimulation (tDCS) headset, with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining 28 1/2 minutes. The sham iBT sessions are delivered concomitantly to the sham ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).
75799521|NCT01199640|Drug|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
75937403|NCT02397044|Procedure|Implant surgery|Compare surgical protocols
75937404|NCT03170570|Device|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
76089015|NCT04768660|Other|gum|Other: Chewing gum ChiczaTM organic chewing gum 6 pieces a day Other: Glucose 12ml glucose solution (13,6g) per day
75652181|NCT01124890|Device|late percutaneous coronary intervention|
76089016|NCT04128033|Other|Puncture of the RP6 point|"Puncture of RP6 San Yin Jiao point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus."
75341747|NCT03000127|Drug|AndroGel 1 % Topical Gel|testosterone gel
75341748|NCT03000127|Drug|Placebos|Placebo gel
75341749|NCT03000049|Other|bedside blood culture|
75341750|NCT02999815|Procedure|Human tetanus immunoglobulin|Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.
75511183|NCT04943627|Drug|Balstilimab (BAL)|Anti-PD-1 Monoclonal antibody
75511184|NCT04943627|Drug|Topotecan|Chemotherapy
75511185|NCT04943627|Drug|Vinorelbine|Chemotherapy
75511186|NCT04943627|Drug|Gemcitabine|Chemotherapy
75511187|NCT04943627|Drug|Irinotecan|Chemotherapy
75511188|NCT04943627|Drug|Pemetrexed|Chemotherapy
75511189|NCT00314743|Drug|Ondansetron|
75511190|NCT00314743|Drug|Dexamethasone|
75511191|NCT00314743|Drug|Aprepitant|
75511192|NCT00314782|Drug|ZD4054 (Zibotentan)|oral tablet
75511193|NCT00314782|Drug|Docetaxel|intravenous infusion
75511194|NCT00314782|Drug|Placebo|
75652182|NCT00773019|Device|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
75652183|NCT00756509|Drug|Nilotinib|800 mg/d orally
75652184|NCT00634998|Dietary Supplement|Vitamin C|1000mg Vitamin C capsules orally twice daily
75652185|NCT00634998|Dietary Supplement|Placebo|1000mg Placebo capsules orally twice daily for 90 days
75799522|NCT01198080|Biological|CD133+ cells|bone marrow derived CD133+ cells injection with core compression
75799523|NCT03844932|Drug|ST-0529|ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
75799524|NCT03726996|Drug|Desipramine|Study drug (desipramine) provided in tablet form to be taken daily.
75937405|NCT02294955|Device|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
75799525|NCT01202058|Device|NEVO™ Sirolimus-eluting Coronary Stent System|"Design Original Protocol~Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting."
75799526|NCT01202058|Device|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
75799527|NCT04136418|Device|COPDPredict mobile App|An App on a mobile device is used by the patient to track the status of their COPD and inform the patient's care team
75799528|NCT04136418|Other|Usual care|Patients self-manage their COPD using prescribed medication in accordance with basic guidance information
75819665|NCT02173834|Other|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
75937406|NCT02294955|Drug|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
75937407|NCT02294955|Drug|Sotalol|Dosage orally 80-160 mg twice daily
75937408|NCT02294955|Drug|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
75937409|NCT02294955|Drug|Propafenone|Dosage orally 300 mg twice daily
75937410|NCT02294955|Drug|Disopyramide|Dosage orally 250-375 mg twice Daily
75937411|NCT02294955|Drug|Dronedarone|Dosage orally 400 mg twice daily
75341751|NCT02999815|Procedure|Intramuscular antitoxin|First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
75341752|NCT02999659|Device|Pupilometer|Device to measure change in pupil diameter due to a defined light stimulus.
75937412|NCT03619733|Other|no intervention|this is an observational study. no intervention is planned
75937413|NCT04481594|Drug|HPN-01|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
75937414|NCT04481594|Drug|Placebo|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
75937415|NCT05416697|Drug|CBD oil|The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.
75937416|NCT05416697|Drug|Placebo|The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
75937417|NCT02396888|Drug|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
75937418|NCT02396888|Drug|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
75937419|NCT02295033|Radiation|Boost irradiation|
75937420|NCT04480580|Diagnostic Test|SARS-CoV-2 Ab|Patient test for specific antibodies for SARS-CoV-2
75937421|NCT03517683|Other|Low speed|Speed of intrathecal injection will be 1ml in 15 seconds
75937422|NCT03517683|Other|High speed|speed of intrathecal injection will be 1ml in 5 seconds
75652186|NCT00200200|Drug|Bevacizumab HAI plus systemic chemotherapy|Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
75652187|NCT00200200|Drug|HAI plus systemic chemotherapy|Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
75652188|NCT00106587|Device|PTCA|
75652189|NCT00106587|Combination Product|paclitaxel coated balloon catheter (device with drug)|
75652190|NCT02866331|Drug|G-CSF (Leucostim)|
75652191|NCT02866331|Biological|CB (autologous cord blood)|
75652192|NCT02866331|Drug|Placebo (Normal saline)|
75652193|NCT00694863|Drug|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
75937423|NCT02401334|Device|Cook® Antimicrobial Hernia Repair Device|Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
75937424|NCT02401568|Device|Dynamic CT|Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
75937425|NCT02401568|Procedure|Arthrography|percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
75937426|NCT02245763|Device|Leaflet Clip|
75341753|NCT03006523|Procedure|Intrauterine insemination|IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
75799529|NCT03844308|Behavioral|Isha Kriya Meditation|Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
75799530|NCT05670054|Drug|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
75652194|NCT02868047|Procedure|Endoscopic Ultrasound|Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
75652195|NCT04136301|Other|Informative Video group|Informative Video group before labor in nulliparous women
75652196|NCT04290143|Other|Colored healing water|Patients will be treated with colored healing water for 20 minutes.
75652197|NCT04290143|Other|Placebo treatment (colored tap water)|Patients will be treated with colored tap water for 20 minutes.
75652198|NCT00694941|Drug|ONO-2506PO|1200mg QD / 5 years
75799531|NCT04777656|Dietary Supplement|Phase1 : CDED/Modulen™IBD® + Maintenance therapy|from D0 until M2: Phase 1 (2 months run-in phase with CDED protocol + maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped until M2.)
75799532|NCT04777656|Dietary Supplement|Phase2 and 3 :|from M2 until M4 CDED phase 2 (introduction of a selected number of additional food). From M4 until end of the study CDED phase 3 (enlargement of number of additional foods and allowance of some initially excluded foods).
75937427|NCT02396498|Drug|HIPEC|Using cisplatin in HIPEC plus oral S-1
75937428|NCT02164643|Drug|Flutemetamol (18F)|
75341754|NCT02247817|Device|Hybrid CRT-D/P implantation|
75341755|NCT05096299|Device|OCS Heart|Transplanted with OCS preserved heart.
75652199|NCT00629213|Drug|acarbose|
75652200|NCT00629213|Drug|placebo|
75652201|NCT00978341|Drug|Pregabalin|Pregabalin 150mg capsules BID for 7.5 days
75799533|NCT05670600|Other|foot and ankle exercise|"Foot and Ankle Exercise Phase~Pulling the foot upwards from the ankle~Bending the foot down from the ankle~Spreading the feet like a fan, moving the toes in and out to the right and left~Circle drawing exercise with ankle~Towel folding exercise~Bottle rolling exercise under the feet (The water in the bottle will be warm tap water)"
75799534|NCT04776564|Other|Participation in the couple enhancement program|Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)
75799535|NCT03844854|Other|Stabilization occlusal splint and manual therapy|Providing stabilization occlusal splint and manual therapy
75799536|NCT03842046|Procedure|phenylephrine infusion|In parturients allocated to the phenylephrine group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
75819666|NCT02175550|Device|NR CC|
75937429|NCT02164643|Drug|Florbetapir (18F)|
75937430|NCT02403908|Device|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery <2 mm proximal from both ostia of right and left pulmonary arteries.
75652202|NCT00978341|Drug|Placebo for pregabalin|Placebo capsules BID for 7.5 days
75652203|NCT00695331|Drug|Misoprostol|Titrated Misoprostol Solution
75652204|NCT00695331|Drug|Oxytocin|Titrated Intravenous Oxytocin
75652205|NCT00695487|Drug|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
75652206|NCT00695643|Drug|Mesalazine|3 g per day
75652207|NCT00695643|Drug|Placebo|0 g per day
75652208|NCT02624349|Drug|Quadravalent human papillomavirus vaccine|Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
75937431|NCT02292459|Drug|Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|
75937432|NCT02292459|Drug|Polyethylene Glycol 4000 Powder for Solution (PEG 4000)|
76089017|NCT04128033|Other|Puncture of the placebo point|"Puncture of a placebo point outside the meridian, with no effect"
75341756|NCT03006679|Drug|Meropenem-Vaborbactam|meropenem 2 g and vaborbactam 2 g
75341757|NCT03006679|Drug|Piperacillin/Tazobactam|piperacillin 4 g and tazobactam 0.5 g
75341758|NCT02998333|Procedure|Surgical stabilization|Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
75341759|NCT03006601|Other|Office-based accommodative/vergence therapy|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks)
75341760|NCT03006445|Drug|FYU-981|
75341761|NCT02247895|Device|Sham Treatment|Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
75341762|NCT02247895|Device|Electrical stimulation|Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
75652209|NCT00695877|Biological|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
75652210|NCT00978029|Drug|Placebo|Placebo sublingual tablet, once daily
75652211|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
75652212|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
75652213|NCT02624193|Behavioral|MBSR Program|Mindfulness-based stress reduction, as described previously.
75652214|NCT02624193|Behavioral|HT Program|Health education curriculum, as described previously
75652215|NCT02624037|Other|Individualized Dosage Precision IFX Dashboard|Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
75652216|NCT02623881|Device|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
75799537|NCT03842046|Procedure|norepinephrine infusion|In parturients allocated to the norepinephrine group group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
75799538|NCT01198236|Drug|Itraconazole|"Itraconazole will be administered intravenously 2×200 mg/d(200mg twice a day, with 12 hours interval, and should be completed in no less than 60 minutes each time) in the first two days of treatment as a loading dose, then 200mg/d intravenously (200mg once a day with 24 hours interval and completed in no less than 60 minutes) until the end of the at-risk period.~In transplant patients, the end of at-risk period is defined as a stable engraftment of 1*109/L neutrophil cells; in patients who have undergone chemotherapy, it is defined as the resolution of neutropenia (neutrophil cells> 0.5*109/L).~If needed, the patients will take itraconazole solution orally after intravenous administration."
75799539|NCT01198314|Procedure|immunosuppression withdrawal|tapering off immunosuppressant
75799540|NCT01198314|Procedure|continue of taking immunosuppressant|maintain immunosuppression
75799541|NCT01199718|Drug|CX-4945|CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
75799542|NCT01202214|Drug|1440115|
75799543|NCT01202214|Drug|Placebo|matching placebo
75799544|NCT03841734|Drug|treatment|8 patients will be treat with bosentan at 145 mg per day during 14 days
75799545|NCT01202292|Behavioral|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
75799546|NCT05212740|Drug|Corticosteroid|The treatment will initiate with a dose of 0.5 mg/kg/day prednisolone for two weeks and the dose will halve in the next two weeks.
75799547|NCT05212740|Other|Exercise|The exercise program will be performed two times per week for six weeks for 12 sessions.
75937433|NCT02396576|Behavioral|Telehealth Intervention|The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
75799548|NCT03841968|Procedure|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
75799549|NCT03841968|Procedure|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
75799550|NCT04103502|Device|MicroPort Medial Pivot TKA|Subjects will have been implanted with the MicroPort Medial Pivot TKA
75799551|NCT04103502|Device|DePuy Attune PCR TKA|Subjects will have been implanted with the DePuy Attune PCR TKA
75799552|NCT04707300|Drug|Human T Lymphoid Progenitor (HTLP) injection|The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
75511195|NCT00122655|Drug|non-nucleoside reverse transcriptase inhibitors|
75511196|NCT00122655|Drug|nucleoside reverse transcriptase inhibitors|
75511197|NCT00122655|Drug|protease inhibitors|
75511198|NCT00314821|Drug|ropinirole|
75511199|NCT00314860|Drug|ropinirole Extended Release (XR)|
75511200|NCT00091104|Biological|MART-1:27-35 peptide vaccine|
75652217|NCT02623881|Drug|Vaginal progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
75652218|NCT04135833|Drug|BPI-7711|BPI-7711 60 mg
75652219|NCT04135833|Drug|BPI-7711|BPI-7711 180 mg
75511201|NCT00091104|Biological|aldesleukin|
75511202|NCT00091104|Biological|filgrastim|
75511203|NCT00091104|Biological|incomplete Freund's adjuvant|
75511204|NCT00091104|Biological|therapeutic autologous lymphocytes|
75652220|NCT04135833|Drug|Itraconazole|Itraconazole 200 mg
75652221|NCT04135833|Drug|Rifampicin|Rifampicin 600 mg
75652222|NCT00696033|Drug|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
75652223|NCT00696033|Drug|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
75652224|NCT00696033|Drug|placebo|lorazépam placebo or Diazépam placebo
75652225|NCT02623647|Radiation|stereotactic body radiotherapy SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
75652226|NCT00871377|Drug|Placebo|corn oil (n-6 fatty acids)
75652227|NCT00871377|Drug|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
75799553|NCT03843996|Device|Treatment - Stratamed|To determine if Stratamed is more effective than standard of care therapy in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure.
75799554|NCT03843918|Drug|LAE001|LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
75799555|NCT03843918|Drug|Placebo|Placebo BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The placebo dose adopted for the phase II study will be same as LAE001 (RP2D dose).
75799556|NCT04084392|Other|Bridge Clinic|Referral to the Bridge Clinic for temporary outpatient addiction treatment while the bridge clinic identifies an outpatient addiction treatment provider to accept the patient for long term treatment.
75799557|NCT04084392|Other|Usual Care|Referral to an outpatient provider for addiction treatment.
75799558|NCT05174754|Behavioral|Physician-prescribed Exercise Programme|A 20-week structured exercise programme derived and supervised by a Sports Medicine Physician following the FITT Principles
75799559|NCT05174754|Drug|Best Medical Therapy|Best medical therapy with biologic agent or small-molecule therapy
75799560|NCT03841890|Device|the Clarus Video System as a video stylet|video-guided intubation
75937434|NCT03520023|Other|Palliative Care Consult|Consult of hospital palliative care service for those meeting study inclusion criteria
75937435|NCT02396654|Other|2D and 5D LB ultrasound comparison for fetal weight estimation|2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
75937436|NCT03170336|Drug|Amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
75799561|NCT03841890|Device|the Clarus Video System as a lightwand|The endotracheal tube will be initially guided into larynx in the dimly lit operating room by a bright glow moving in the anterior soft tissue of the neck and finally by the image of the trachea rings on the video screen.
75475007|NCT01990066|Behavioral|Home Based Exercise|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
75652228|NCT00871377|Drug|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
75799562|NCT03841890|Device|direct laryngoscope|Macintosh laryngoscope size 3
75799563|NCT03052218|Device|Pupillometry|Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
75799564|NCT01199874|Biological|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
75799565|NCT05670444|Drug|kelavit|The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
75799566|NCT01200108|Drug|Budesonide|
75799567|NCT01200108|Drug|Budesonide|
75799568|NCT01200108|Drug|Budesonide|
75799569|NCT01200186|Drug|EV/DNG (Qlaira, BAY86-5027)|At the discretion of the attending physician
75799570|NCT01200186|Drug|Progestin Only Pills|At the discretion of the attending physician
75799571|NCT03841578|Dietary Supplement|Healthy|25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat
75799572|NCT03841812|Drug|5mg/kg/h Propofol|5mg/kg/h Propofol continuously infused during intre-operation
75799573|NCT03841812|Drug|Sevoflurane|1% Sevoflurane continuously using during intre-operation.
75937437|NCT03170336|Drug|Hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
76089018|NCT01883986|Behavioral|Palliative Care|Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
76089019|NCT01884064|Device|rTMS|rTMS
75799574|NCT03841812|Drug|2 mg/kg/h Propofol|2mg/kg/h Propofol continuously infused during intre-operation
75511205|NCT00091104|Biological|therapeutic tumor infiltrating lymphocytes|
75511206|NCT00091104|Drug|cyclophosphamide|
75511207|NCT00091104|Drug|fludarabine phosphate|
75511208|NCT00091104|Procedure|autologous hematopoietic stem cell transplantation|
75511209|NCT00091104|Procedure|in vitro-treated peripheral blood stem cell transplantation|
75511210|NCT00091104|Radiation|total-body irradiation|
75511211|NCT00314938|Drug|PHA-794428|
75511212|NCT00313339|Drug|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
75511213|NCT00313378|Drug|Hypothetica|
75511214|NCT00122694|Drug|carbon monoxide|
75652229|NCT02623569|Drug|Ivabradine|Not Provided
75652230|NCT02623569|Drug|Atenolol|Not Provided
75652231|NCT02623491|Drug|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
75652232|NCT02623491|Drug|Placebo|Participants will receive matching placebo.
75652233|NCT00977561|Drug|figitumumab|Figitumumab (20 mg/kg)
75652234|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
75652235|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
75652236|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
75652237|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
75652238|NCT04291313|Dietary Supplement|Vitamin D3 (90µg)|The intervention is a higher dose of vitamin D than what is currently recommended to Danish pregnant women
75799575|NCT03882970|Drug|Tirzepatide|Administered SC
75799576|NCT03882970|Drug|Insulin Degludec|Administered SC
75799577|NCT05111808|Device|Methylene blue fluorescence|IV administration of methylene blue, detection with deep infrared camera and light source
75799578|NCT01566786|Drug|activated recombinant human factor VII|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
75799579|NCT01566786|Drug|placebo|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
75799580|NCT01198392|Drug|s-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
75819667|NCT04620928|Behavioral|Concepts|Images and sounds that are characteristic of various common objects.
75937438|NCT02295111|Device|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
75937439|NCT02295111|Behavioral|TCM health consult|Traditional Chinese Medicine Health Consult without needling
75937440|NCT02295111|Other|Usual Care|Standard NHS care
75937441|NCT03170102|Other|Building capacity through education|Participants engaged in 2 webinars and 3 online discussions following reading selected material.
75937442|NCT04465305|Procedure|entraped treatment|patients with tarlov cysts treated by entraped and plasty nerve root
75937443|NCT04465305|Procedure|plasty treatment|patients with tarlov cysts treated by plasty nerve root
76089020|NCT01884064|Device|Sham rTMS|Sham rTMS
76089021|NCT04123899|Drug|IGAD→GSTD|"Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
75652239|NCT04291313|Dietary Supplement|Vitamin D3 (10µg)|This intervention serves as a control as they get the current recommended vitamin D dose
75799581|NCT01198392|Drug|5-Fu plus cisplatin|"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.~Number of Cycles: until progression or unacceptable toxicity develops."
75937444|NCT03169946|Procedure|RCT with CHX-MTZ,OFD|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
75937445|NCT03169946|Procedure|RCT with CHX,OFD|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
75937446|NCT02396186|Device|PTCA Balloon Angioplasty|
75937447|NCT03517605|Other|Exercise for cardiac rehabilitation|An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.
75937448|NCT03517527|Behavioral|Exercise|
75937449|NCT02699684|Device|Lotrafilcon B contact lenses with EOBO-41|Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
75937450|NCT02699684|Device|Lotrafilcon B contact lenses|Lotrafilcon B contact lenses packaged with copolymer 845
75937451|NCT02699684|Device|Hydrogen peroxide-based lens care solution|Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
75937452|NCT02699684|Device|Saline solution for rinsing contact lenses|Commercially-available saline solution used as needed
75937453|NCT02699684|Device|Saline solution for rinsing contact lens case|Commercially-available solution used as needed
75937454|NCT03169868|Diagnostic Test|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
75937455|NCT03169400|Device|Theranova dialyzer|Hemoadialysis
75937456|NCT02292615|Other|Medical Imaging|
75937457|NCT03169478|Procedure|multiple myoma IUB dilatation group|A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
75937458|NCT02295189|Drug|Ketorolac Tromethamine|anti-inflammatory injection
75937459|NCT02295189|Drug|Triamcinolone Acetonide|corticosteroid injection
75475008|NCT01990079|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
75652240|NCT02866253|Drug|DHEA|Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
75652241|NCT04080479|Diagnostic Test|Quadriceps Muscle Layer Fitness|The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
75799582|NCT03844542|Device|Therapeutic plasma exchange|Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure
75799583|NCT03843684|Device|3D-printed foot orthoses|3D printed foot orthoses with arch support
75799584|NCT03843684|Device|5 degrees lateral wedge insoles|Insoles with a lateral inclination set at 5 degrees
75937460|NCT03169322|Procedure|SRP|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing
75937461|NCT02292693|Device|MIL|Direct laryngoscopy. Laryngoscopy with Miller blade
75475009|NCT01990079|Drug|nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
75511215|NCT00313417|Dietary Supplement|Creatine monohydrate|Up to 10 grams
75511216|NCT00313417|Other|Placebo|Placebo will be given in the same way and appearance as the active treatment
75511217|NCT00313456|Drug|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
75652242|NCT04080479|Diagnostic Test|Muscle Strength|All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
75652243|NCT04080479|Diagnostic Test|Acute Physiology and Chronic Health Evaluation|All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
75937462|NCT02292693|Device|MAC|Direct laryngoscopy. Laryngoscopy with Macintosh blade
75937463|NCT02292693|Device|McCoy|Direct laryngoscopy. Laryngoscopy with McCoy blade
75937464|NCT03169556|Device|Video-laryngoscope guided lightwand|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
75937465|NCT03169556|Device|lightwand alone|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
75937466|NCT02295267|Other|walnut allergy provocation|double blind placebo controlled food challenge
75937467|NCT02396264|Other|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
75937468|NCT02396264|Other|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
75937469|NCT03519633|Drug|Sugammadex|Reversal of deep NMB
75341763|NCT05007847|Device|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF Catheter Ablation (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
75652244|NCT04080479|Diagnostic Test|Sequential Organ Failure Assessment|All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
75652245|NCT04080479|Diagnostic Test|Nutritional Risk Screening|All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
75652246|NCT04080479|Diagnostic Test|Energy and Protein Intake|The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
75652247|NCT04074629|Diagnostic Test|Diagnosis, skin volatile organic compounds (VOCs)|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\or GC-MS analysis"
75652248|NCT02867423|Device|CK Boost radiation|single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
75652249|NCT04290767|Diagnostic Test|Sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy)|Enhanced-contrast brain ultrasound with intravenously sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy) injection and using the time-intensity curve profile to evaluate brain microcirculation.
75652250|NCT02865941|Dietary Supplement|Fortification with modular protein|Modular product supplementation is based on most recent breast analysis done for the participant.
75652251|NCT02865941|Dietary Supplement|Fortification with modular carbohydrate|Modular product supplementation is based on most recent breast analysis done for the participant.
75652252|NCT02865941|Dietary Supplement|Fortification with modular fat|Modular product supplementation is based on most recent breast analysis done for the participant.
75799585|NCT05759650|Other|Execution of different motor tasks typical of daily life and work|Patients with obesity will carry out different motor tasks typical of daily life and work and, using optoelectronic systems based on passive markers, force platforms and electromyographic systems, kinematic and kinetic parameters of movement will be recorded and analysed for the implementation of an integrated protocol for the clinical evaluation of subjects with obesity.
75799586|NCT01200264|Drug|apremilast|apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
75799587|NCT04818970|Device|Narrow Band ultraviolet B-Band Light|Daily doses of NB-UVB for 8 consecutive days.
75937470|NCT03519633|Drug|Neostigmine|Reversal of moderate NMB
75937471|NCT02289027|Biological|cAd3-EBOZ vaccine|
76089022|NCT04123899|Drug|GSTD→IGAD|"Drug: GSTD First Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)~Other: Washout period 7 days~Drug: IGAD Second Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)"
75652253|NCT02865785|Drug|Intralipid 20%|intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
75652254|NCT02865785|Drug|Placebo|saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
75799588|NCT04818970|Device|non Narrow Band ultraviolet B-Band Light|Daily doses of non-NB-UVB for 8 consecutive days.
75799589|NCT03841344|Device|MRI|Evaluation of the utility of candidate endpoints in PAH trials
75937472|NCT02289027|Biological|Placebo (for cAd3-EBOZ vaccine)|Diluent
75937473|NCT02396030|Drug|Magnesium sulfate 50% - 1g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
75937474|NCT02396030|Drug|Magnesium sulfate 50% - 2g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
76089023|NCT04124055|Diagnostic Test|Therapeutic drug monitoring (TDM)|Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
75652255|NCT00594165|Drug|Rotigotine|"Rotigotine trans-dermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year:~The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
75652256|NCT00975923|Behavioral|Collaborative Group|"In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these virtual learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams."
75672261|NCT04247087|Drug|phytomenadione|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
75937475|NCT02289183|Procedure|Totally laparoscopic distal gastrectomy|Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
75937476|NCT02289183|Procedure|Laparoscopy-assisted distal gastrectomy|Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
75937477|NCT03168152|Radiation|Microwave Ablation (MWA)|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
75937478|NCT03168152|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
76089024|NCT01884844|Drug|Vitamin D3, Cholecalciferol|
75799590|NCT04811872|Biological|Intact umbilical cord milking (I-UCM)|Umblical cord milking will be performed by holding the newborn at or ∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team.
75799591|NCT04811872|Biological|Cut-umbilical cord milking(C-UCM)|This technique involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM.
75799592|NCT04811872|Biological|Delayed Cord Clamping (DCC)|Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60 seconds before clamping the cord.
75799593|NCT03841500|Device|Biocomposite intereference screw femoral tunnel fixation|ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation
75937479|NCT03168230|Procedure|Portal vein embolization (PVE)|"Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx"
75652257|NCT00975923|Behavioral|Tool Kit|Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
75937480|NCT02289261|Drug|Morphine|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
75937481|NCT02289261|Drug|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
75341764|NCT05237479|Procedure|Suprainguinal fascia ilica block|Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory & motor distribution of the LFCN, FN, & ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory & motor distribution of LFCN, FN, & ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory & motor distribution of LFCN, FN, & ON & adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
75937482|NCT03168074|Drug|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
75937483|NCT02295345|Other|Cognitive Behavioural Therapy for Insomnia|
76089025|NCT01884844|Drug|Placebo|
75341765|NCT05237479|Other|Placebo|The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
76089026|NCT04123431|Device|Total Hip Replacement|Primary elective total hip replacement
75341766|NCT03006367|Drug|NFC-1 100 mg|
75341767|NCT03006367|Drug|NFC-1 200 mg|
75341768|NCT03006367|Drug|NFC-1 400 mg|
75341769|NCT03006367|Drug|NFC-1 800 mg|
75652258|NCT00928070|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg
76089027|NCT04123587|Drug|discontinuation of Sulfonylureas|"Discontinuation of sulfonylurea, alternative drug administration.~If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent"
76089028|NCT01890226|Behavioral|Mobile Personal Health Record App.|
75652259|NCT00928070|Drug|Placebo|Placebo sham 4 mg and 8 mg
75652260|NCT02623257|Other|mutation detection|
75652261|NCT02623257|Other|ARMS|
75652262|NCT02623257|Genetic|ctDNA analysis|
75341770|NCT02980939|Other|iv fluid infusion|Intravenous isotonic saline infusion
75341771|NCT04987723|Other|Holter monitoring|Assessment of HRV shall be performed in all enrolled patients. Ventricular HRV will be derived from a continuous 24-hour period of a 48-hour ambulatory Holter recording during AF. Participants will be requested to avoid alcohol and caffeine from 24-hours prior to fitting and any activity more strenuous than walking for the recording duration. After initial fitting, a 20-minute high-resolution ECG recording will be performed lying supine at rest.
75341772|NCT04987723|Other|stress echocardiography|Echocardiography will be performed using a GE Vivid 9 echocardiography machine (Vingmed-General Electric, Horten, Norway) equipped with a phased-array 3.5 MHz transducer. All measurements will be made according to the guidelines set by the British Society of Echocardiography.
75652263|NCT04135755|Other|no drug intervention|no drug or treatment intervention
75341773|NCT04987723|Other|Cardiac MRI|Contraindications to MRI will be excluded using the appropriate departmental screening forms. A trained scanner operator or radiographer will co-ordinate and supervise the scan. Cardiac MRI will be performed at 1.5T (Aera, Siemens Healthineers, Erlangen, Germany) with a protocol consisting of cine imaging, stress and rest perfusion, and late gadolinium enhancement (LGE).
75341774|NCT04987723|Other|Patient questionnaires|Two validated Health Related Quality of Life (HRQoL) surveys designed for patients with AF will be used; the AF Effect on Quality of Life (AFEQT) and Barts AF Patient reported objective measure (PROM).
75475010|NCT01990079|Other|Smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
75475011|NCT01990079|Behavioral|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
75475012|NCT01990079|Other|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
75475013|NCT01990092|Other|Metanx|Metanx is a prescription medical food.
75475014|NCT01990092|Other|Placebo|
75937484|NCT02403752|Behavioral|Paired PLIE Program|Integrative exercise as described above
75799594|NCT03841500|Device|Endobutton (Tightrope) femoral tunnel fixation|ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
75937485|NCT03517215|Behavioral|Enhanced CB-ASP|The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.
75937486|NCT03517215|Behavioral|Standard CB-ASP|A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
75937487|NCT02396108|Drug|Paclitaxel + Carboplatin + ASLAN001|"Phase I~IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
75937488|NCT02293083|Drug|trigger point injection|
75937489|NCT03519477|Diagnostic Test|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
75937490|NCT03521661|Procedure|Kyphoplasty|Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
75341775|NCT05673031|Diagnostic Test|68Ga-HA-DOTATATE PET/CT imaging|"Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients.~After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans.~The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results."
75341776|NCT03006211|Other|Nitrogen protoxide|
75475015|NCT01990118|Drug|Neoral|Neoral® capsule containing 25mg or 100mg cyclosporine
75475016|NCT01990118|Drug|Gengraf® capsule containing 25mg or 100mg cyclosporine|Transplant patients who were stable on Neoral were converted to Gengraf
75475017|NCT01990131|Other|Cognitive Anxiety Sensitivity Treatment|
75475018|NCT01990131|Other|Physical Health Education Training|
75652264|NCT04289909|Other|Adaptive Optics Ophthalmoscopy (AOO)|AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)
75652265|NCT04135599|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
75652266|NCT00629369|Device|Extra 3 mouth guard, Shock doctor mouth guard v3.0|Dental mouthguard, molded for each individual patient when in labor. The device is put in the water then in microwave for one minute to soften the device. The device is then applied to the patient's mouth for over 10 seconds to mold it.
75799595|NCT01200420|Drug|miravirsen|SC injection
75799596|NCT01200420|Drug|saline|SC injection
75799597|NCT04799236|Drug|Group 1: Miltefosine|Miltefosine 50 mg pill will be administered po every 8 hours with food, during 28 days
75799598|NCT04799236|Drug|Group 2: Pentavalent Antimony|will be administered by IV infusion diluted in 150 ml of DWD5% over 20 minutes
75799599|NCT04799236|Drug|Group 3: Liposomal amphotericin B|3 amps (150 mg) will be administered by IV infusion iver 2 hours every other day for a total of 15 doses.
75799600|NCT01198704|Other|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
75799601|NCT01202370|Drug|7-t-butyldimethylsilyl-10-hydroxycamptothecin|IV Over 1 hour Days 1, 4, 8, 12 & 15 of a 21 day cycle (7.5 mg/m^2).
75799602|NCT04720378|Biological|ST266|1X ST266
75799603|NCT04614402|Device|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
75341777|NCT03006211|Other|Oxygen|
75341778|NCT05672719|Diagnostic Test|Right Heart Catheterization|Procedure
75341779|NCT02248051|Drug|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
75475019|NCT01990144|Drug|Bendamustine+Rituximab|"Patients will receive :~Rituximab 375 mg/m2 intravenously on day 1*~Bendamustine 90 mg/m2 intravenously on days 2 and 3** Treatment will be administered on a 28-day cycle basis.~Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.~After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice."
75475020|NCT01990157|Drug|TAB08|Weekly intravenous administration in escalating doses.
75475021|NCT01990183|Device|CareToy|Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home - session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
75652267|NCT04290221|Other|Ultrasound-guided percutaneous electrolysis in the lumbar nerve root|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3 (one times per week / 3 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
75652268|NCT04290221|Other|Electrical Dry Needling in trigger points|It consists in apply the ultrasound-guided percutaneous electrolysis on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 6 weeks).
75672262|NCT04247087|Drug|placebo solution|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
75937491|NCT02395718|Other|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
75937492|NCT02395718|Other|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
75937493|NCT02289339|Device|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
75937494|NCT02403518|Device|Freedom Spinal Cord Stimulator System|
75937495|NCT03519399|Device|Monica AN24|Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
75937496|NCT02403596|Drug|Exacyl®|
75937497|NCT02403596|Other|Placebo of Exacyl®|
75937498|NCT02293161|Drug|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
75937499|NCT02293161|Drug|Placebo|It is Sodium Chloride Intravenous Infusion
75937500|NCT04480112|Behavioral|Technology based social interactions|Participants will be socially interacting using any available technology with members of the research team.
75937501|NCT04480112|Other|No research related technology based social interactions|No technology based social interactions with the research team.
75937502|NCT03167762|Device|Fluorescence and thermal imaging|Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
75937503|NCT03519321|Device|MID-C|The MID-C system is being connected to the spine via standard unilateral posterior approach. Pedicle screws above and below the main curve are being used to attach the device to the selected vertebra.
75937504|NCT03169088|Other|Coaching procedure|"In this study, the volunteers will be followed during one year.~The wellbeing will be followed with :~survey like FFQ, IPAQ, SF36, dietary habits.~actimetry measurement~one year follow-up of weight, waist measurement~nutritional biomarkers"
75937505|NCT04464681|Drug|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
75937506|NCT04464681|Drug|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
75937507|NCT02289495|Drug|GSK2838232|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
75937508|NCT02289495|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
75937509|NCT02289495|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
75937510|NCT03168776|Device|BuMA Supreme DES|Implant BuMA Supreme stent only
75937511|NCT03168776|Device|Xience or Promus DES|Implant XIENCE family or Promus family only
75937512|NCT03519165|Device|EV1000(FloTrac System 4.0)|
75937513|NCT01774721|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
75937514|NCT01774721|Drug|Gefitinib|Gefitinib 250 mg tablets, continuous oral daily dosing.
75937515|NCT02293239|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
76027252|NCT05046041|Drug|Mifepristone + Misoprostol|A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.
75475022|NCT01990183|Other|Standard Care|Current care advices in the management of preterm infants in the first months of life
75799604|NCT04614402|Device|Edwards PASCAL Precision Transcatheter Valve Repair System|The Edwards PASCAL Precision Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
75937516|NCT02395796|Procedure|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
75937517|NCT02289573|Device|NAVA and PSV|change ventilation modes(NAVA and PSV) with different support levels
75937518|NCT03170492|Other|RehaCom Computerized Cognitive Training for 480 minutes|Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
76089029|NCT04127721|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
76089030|NCT04127721|Drug|Busulfan|Given IV
75341780|NCT05672641|Other|Inertial training|Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
75475023|NCT01990235|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
75475024|NCT01990274|Procedure|GeneXpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
75475025|NCT01990274|Procedure|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
75475026|NCT01990287|Device|SCS and PNfS|Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.
75475027|NCT01990287|Device|SCS Alone|Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.
75475028|NCT01990326|Drug|XAF5 Gel|
75652269|NCT04135287|Drug|GLP-1 receptor agonist|The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
75799605|NCT01382680|Device|Guidewire|Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
75799606|NCT04703140|Diagnostic Test|Rapid Diagnostic Test vs PCR|2 nasopharyngeal swabs taken for PCR and COVIDISC
75799607|NCT03843606|Other|Modified ketogenic diets|Different diet composition
75799608|NCT03630952|Biological|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
75475029|NCT01990326|Drug|Placebo Gel|
75475030|NCT01990378|Drug|Rabeprazole sodium 20 mg Delayed Release tablet|
75475031|NCT01990391|Dietary Supplement|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months.
75652270|NCT04135521|Drug|Intraperitoneal chemotherapy|Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy
75652271|NCT04001621|Drug|Pyrotinib combined with capecitabine|pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
75672263|NCT00367406|Device|Gamma 3 nail versus ACE trochanteric nail|Comparing Gamma 3 nail versus ACE trochanteric nail
75799609|NCT03630952|Biological|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
76089031|NCT04127721|Drug|Fludarabine|Given IV
76089032|NCT04127721|Drug|Itacitinib|Given PO
76089033|NCT04127721|Drug|Methotrexate|Given IV
76089034|NCT04127721|Drug|Tacrolimus|Given IV and PO
75475032|NCT01990391|Dietary Supplement|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
75475033|NCT01990404|Drug|Premixed 50% nitrous oxide and oxygen|Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
75799610|NCT03630952|Biological|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
75799611|NCT01198782|Other|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
75937519|NCT03170492|Other|Pencil-and-Paper Cognitive Training for 480 minutes|Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
75652272|NCT02623179|Other|culture versus Molecular diagnostics|Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
75652273|NCT02623101|Device|Reflectance confocal microscopy|Non-invasive imaging of the lesion
75341781|NCT05672641|Other|Body building training|Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
75937520|NCT03518931|Diagnostic Test|Fitness testing|The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
75652274|NCT02623101|Procedure|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
75937521|NCT02395952|Drug|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
75937522|NCT02395952|Device|Acuvue Oasys Bandage Contact Lens|
75937523|NCT02395952|Device|Ambiodisk|
75937524|NCT02395952|Device|Prokera|
75937525|NCT03516903|Drug|Methotrexate|ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
75475034|NCT01990404|Drug|Medical Air|Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
75652275|NCT02623101|Procedure|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
75652276|NCT00924404|Drug|Xylitol|5% solution for sinus rinse
75652277|NCT00924404|Drug|Saline|saline for sinus rinse
75652278|NCT00976937|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
75937526|NCT03516903|Drug|Placebo|Placebo-LDE (Lipid nanoemulsion)
75652279|NCT00976937|Drug|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
75652280|NCT00976937|Device|Pen auto-injector|
75937527|NCT03516903|Drug|Folic Acid|Folic acid pill
75937528|NCT05693285|Other|No intervention|No intervention
75937529|NCT02292381|Other|Isometric exercise|
75937530|NCT05693207|Device|EMG|wearables EMG
75937531|NCT02289651|Device|Venner|Video-laryngoscopy
75937532|NCT02289651|Device|Miller|Direct-Laryngoscopy
75652281|NCT00976937|Drug|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
75652282|NCT00976937|Drug|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
75652283|NCT00976937|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
75652284|NCT02623023|Drug|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
75652285|NCT02623023|Other|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
75652286|NCT02622945|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
75672264|NCT00649116|Drug|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
75937533|NCT02293317|Biological|M-001|A recombinant epitope based universal vaccine against seasonal and pandemic influenza
75937534|NCT02293317|Drug|TIV|HA based seasonal influenza vaccine, for 2014/15 seson
75937535|NCT02293317|Other|Saline|Placebo
75937536|NCT03516825|Other|Musical Neglect Training|MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field.
75937537|NCT02295501|Biological|INTERCEPT Plasma|Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
75937538|NCT02295579|Other|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
75937539|NCT02295657|Device|standard double-lumen tube|intubation using standard double-lumen tube
75937540|NCT02295657|Device|VivaSight Double Lumen Tube|intubation using VivaSight Double Lumen Tube
75937541|NCT03516747|Diagnostic Test|pre operative parathyroid hormone level measurement|At the clinic, the participants will undergo ultrasound examination with fine needle aspiration. The aspirated material will be sent for parathyroid hormone level measurement.
76089035|NCT04123743|Drug|Trigonella foenum-graceum extract topical cream|Topical cream containing Trigonella foenum-graceum extract
76089036|NCT04123743|Other|Facial Wash|Wardah brand facial wash
76089037|NCT04123743|Other|Sunscreen Cream|Parasol sunscreen cream SPF 33
75341782|NCT05672563|Drug|Saline infusion sonography for evaluation of cesarean scar|The intervention included the usage of balloon-less GIS catheter with a soft tapered tip inserted into the endocervical canal, with no use of a tenaculum or a cervical dilatator. Normal saline is slowly introduced into the uterine cavity via the catheter until achieving satisfactory distension and visualization of the uterine cavity using trans-vaginal ultra-sonographic imaging.
75937542|NCT03516747|Diagnostic Test|pre operative parathyroid cytology|At the clinic, the participants will undergo neck ultrasound examination with fine needle aspiration. The aspirated material will be sent for cytology examination.
75341783|NCT03005821|Other|Chinese pediatric massage therapy + usual care|
75341784|NCT03005821|Other|Sham massage therapy + usual care|
75475035|NCT01990417|Other|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
75652287|NCT02622945|Device|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
75652288|NCT02622867|Other|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
75652289|NCT02622867|Dietary Supplement|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
75799612|NCT05282160|Device|Epino|The pregnant women will perform 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device (pressure gauge connected to an inflatable soda that simulates the baby's head the vaginal canal). After the introduction of the deflated probe (only the first half of the device), it is minimally inflated until the perception in the vaginal canal. The first 5 minutes will be for perception of the pelvic floor with contraction and relaxation with the purpose of toning and maintaining muscular strength, followed by 15 minutes of perineal elongation respecting the tolerance of the pregnant woman. After 20 minutes in total, the pregnant woman relaxes so that the inflated device leaves gently of her vaginal cavity and the physiotherapist helps at that moment. After the device is removed, note the circumference reached on the day.
75799613|NCT05032638|Behavioral|Therapist guided training|Therapist guided period delivered virtually (WebEx/Zoom). Participants will be patients associated with NYULH and will have access to Zoom. Each session will last 45 min, and will completed 3x/week by research therapists, who are part of the study.
75799614|NCT05032638|Behavioral|Upper extremity (UE) Training|The 4-week UE training is completed in the participants home on their own and communication with study staff is virtual. Participants will receive daily communication through the Expiwell app to answer survey questions related to adherence, and safety/adverse events. Participants will also complete weekly check-ins with their research therapist over Zoom to answer questions about difficulties related to UE training activities, refinement of training goals, and to receive feedback on their training performance. Each weekly check-in will be approximately 45 minutes.
75799615|NCT03763240|Dietary Supplement|BSE|"BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract."
75799616|NCT03763240|Dietary Supplement|Placebo|Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
75937543|NCT03516747|Diagnostic Test|parathyroid hormone level measurement|At surgery, after the pathologic gland is excised , the gland will be aspirated. The material will be sent for parathyroid hormone level measurement.
75937544|NCT03516747|Diagnostic Test|parathyroid cytology|At surgery, after the pathologic gland is excised , it will be aspirated again for cytologic examination.
75937545|NCT03516669|Drug|Clarithromycin|Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
75937546|NCT03516669|Drug|Amoxicillin, Clarithromycin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
76089038|NCT04123743|Other|Placebo|Placebo topical cream
76089039|NCT04123119|Biological|Rotavirus vaccine|An exploratory and observational cohort study following infants receiving two standard doses of live, attenuated, oral Rotarix™ administered at 6 & 10 weeks.
76117203|NCT03018639|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
75652290|NCT04256252|Drug|Rituximab|A scheduled therapeutic regimen with low-dose rituximab was performed.
75652291|NCT04256096|Device|Thrombectomy|Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
75341785|NCT02247505|Drug|Harnal-D Cap. 0.2mg|
75341786|NCT02247505|Drug|Cialis Tab. 5mg|
75652292|NCT02622633|Device|Epidural Electrode|Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.
75652293|NCT02865239|Procedure|Position for the 3.0 Tesla in Magnetic Resonance Imaging|"Eligible patients will have a standard MRI in prone position. At the end of this examination, all patients will have an other standard MRI in supine position.~This examination is then extended by 10 minutes without additional injection of contrast medium"
75652294|NCT02622555|Drug|Mirabegron|Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
75672265|NCT00649116|Drug|Lopressor® Tablets 100 mg|100mg, single dose fed
75341787|NCT02996929|Device|LC System|Subjects will undergo CIED lead extraction with the LC system
75475036|NCT01990430|Behavioral|Exercise Intervention|"Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer."
75819668|NCT02256046|Device|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
75937547|NCT03521427|Other|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
75937548|NCT03521427|Other|Intensive neurodevelopmental therapy|Ninety hours of intensive neurodevelopmental therapy
75937549|NCT02289807|Drug|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
75937550|NCT02289807|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
75937551|NCT03521349|Other|Whole Egg Intervention|Participants will consume an isocaloric muffin containing important bioactives from whole eggs.
75937552|NCT03521349|Other|Egg White Control|Participants will consume an isocaloric muffin containing egg white, lacking important bioactives from whole eggs.
75937553|NCT02289885|Device|SonoScape|Ultrasonography device
76089040|NCT04059016|Other|MBC4OUD|This computer software program consists of patient-completed self reports for screening and diagnosis of opioid use disorder among primary care patients and provides web-based clinical decision support to primary care providers for provision of pharmacotherapy for opioid use disorder.
75341788|NCT02248129|Drug|Telmisartan and hydrochlorothiazide|
75341789|NCT04627675|Drug|CORVax|DNA-encodable coronaviral vaccine
75475037|NCT01990443|Drug|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
75652295|NCT02866019|Device|CLS2702C/CLS2702D|CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month [4 weeks]; cell sheet culture period, 0.5 month [16 days]; transplantation period, assessment/follow-up period, 6 months [24 weeks])
75652296|NCT05329454|Drug|Ibuprofen Tablets|"Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing)."
75819669|NCT02175706|Device|Resolute Integrity®|Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
75937554|NCT02298153|Drug|atezolizumab|atezolizumab: administered intravenously (IV) every three weeks (q3w)
75937555|NCT02298153|Drug|epacadostat|epacadostat: Oral daily dosing
75475038|NCT01990443|Drug|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
75937556|NCT03514797|Drug|Bleaching Agents|In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.
75937557|NCT03514797|Drug|Bleaching Agents|At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
75652297|NCT02622789|Other|Pilates Exercises|Pilates method based stability exercise intervention
75937558|NCT02298231|Other|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
75937559|NCT02298231|Other|Mystic Isle Balance Intervention|Balance therapy using virtual reality
75937560|NCT02298231|Other|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
75937561|NCT03518775|Device|Biometry|Measurement of Cornea
75937562|NCT03518697|Behavioral|exercise program|"The exercise program is planned as a low-threshold exercise program with low barriers to participate. Patients will be asked about their interests and preferences of sports activities to conceive the exercise program together with the patients."
75937563|NCT02293473|Device|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
75937564|NCT02293473|Device|BIS-Bispectral Index Monitor|Depth of anaesthesia
75937565|NCT02293473|Device|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
75937566|NCT02293473|Other|Standard of care|Using standard of care
75937567|NCT02298309|Other|Test-and-Treat TB|
75937568|NCT02298387|Drug|OMP-305B83|intravenous (in the vein) infusions
75937569|NCT02295813|Biological|FBF001|
75937570|NCT02295813|Drug|Placebo|
75937571|NCT02293551|Drug|Lispro|Administered SC
76027253|NCT01970878|Drug|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
76027254|NCT01970878|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
76027255|NCT01970878|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
75341790|NCT04627675|Drug|IL-12 plasmid|cytokine
75341791|NCT04627675|Device|Cliniporator|electroporation system
75341792|NCT02248207|Drug|Pramipexole|
75341793|NCT03006055|Device|Circulating tumor cells|
76027256|NCT01970878|Drug|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
76089041|NCT04393077|Behavioral|Emotional Freedom Technique|EFT application was started by showing the meridian points to the participants through the picture. It was advised that these points should be clicked with the index finger and middle finger without hurting, but with certain strokes, and it was ensured that they understood the regions by showing and applying them. Then, the following basic steps, which should be followed by the EFT session (four in total lasting 20 minutes), were carried out in succession with the researcher.
75652298|NCT02865863|Dietary Supplement|Eurycomalongifoliawater extract (Physta®)|
75652299|NCT02865863|Dietary Supplement|Placebo|
75799617|NCT03840954|Other|Neuromuscular Electrical Stimulation|"The application of NMES will be performed with the patient positioned in the supine position in the bed. Self-adhesive electrodes will be positioned at the motor points of the quadriceps and anterior tibial muscles respectively. A symmetrical biphasic pulsed current with a frequency of 80 Hz, a pulse width of 500 μs and an intensity at the motor threshold will be applied up to the maximum tolerated by the patient. ON and OFF time and total session time will be used according to protocol with progressive increase of the total intervention time and reduction of OFF time of the NMES. The device used will be the Neurodyn II model, manufactured by IBRAMED.~Patients will receive NMES for as long as they remain hospitalized or for up to 3 weeks."
75799618|NCT03752866|Device|Portico™ Valve, Portico Delivery System(s) and Loading Systems(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system
75799619|NCT03752866|Device|Portico™ Valve, FlexNav Delivery System(s) and Loading Systems(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems
75937572|NCT03518541|Procedure|Femoral Derotation Osteotomy (FDO)|Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
75937573|NCT02298543|Other|coronary spasm|
75937574|NCT03518463|Combination Product|Enhanced recovery after surgery (ERAS)|The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
75937575|NCT02298621|Other|pomegranate juice|Randomized clinical trial or RCT
76089042|NCT02996799|Other|Umbilical cord milking|Milking of the umbilical cord at delivery
76089043|NCT02996721|Biological|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
75799620|NCT03841188|Other|Nutritional orientation|Nutritional orientation with emphasis in rich calcium food
76089044|NCT02705404|Genetic|Multifocal Tissue Banking|
76089045|NCT02666326|Procedure|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is <9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is <14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
75652300|NCT02865863|Dietary Supplement|Multivitamin|
75652301|NCT05331560|Device|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
75652302|NCT02622711|Behavioral|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
75937576|NCT02298621|Other|placebo|Randomized clinical trial or RCT
75937577|NCT02293629|Drug|BMS-986147|
75652303|NCT02622711|Behavioral|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
75937578|NCT02293629|Drug|Placebo matching BMS-986147|
75937579|NCT04465149|Procedure|Third Molar Germectomy|Surgical extraction of Third Molars that exhibits at least a third of its root in formation, with a periodontal ligament discernible on panoramic x-ray (defined as germectomy).
75937580|NCT02295969|Drug|Oralair|Observational study, Oralair is used as prescribed by the prescriber phycisian.
75937581|NCT03516435|Device|Parasacral transcutaneous electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.
75937582|NCT03516435|Device|Intravaginal electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
75652304|NCT02622711|Behavioral|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
76089046|NCT04122963|Procedure|High power CLOSE-guided PVI ablation|CLOSE-guided PVI ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds)
75652305|NCT02622711|Behavioral|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
75652306|NCT00629447|Drug|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
75341794|NCT03005743|Radiation|Magnetic Resonance Image based Brachytherapy|MRI based BT prescription will be in accordance to the GEC-ESTRO guidelines [Intention will be to treat the whole cervix and the remaining residual tumour tissue at the primary site at the time of BT (high risk-clinical target volume) to a dose level analogue to the dose level previously prescribed for point-A]
75341795|NCT03005743|Radiation|Conventional Radiograph based Brachytherapy|The standard conventional radiography based prescription will be according to Manchester system Point A and bladder & rectum ICRU point dose constraints
75937583|NCT02298855|Behavioral|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
75475039|NCT01990456|Device|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
75652307|NCT04289831|Procedure|Preoperative Biliary Drainage (PBD)|Endoscopic retrograde biliary drainage (ERBD) and stent placement was the first choice for PBD while ultrasound-guided percutaneous transhepatic biliary drainage (PTBD) was done if ERBD was not feasible. Biliary drainage was considered successful if the serum bilirubin level decreased by 50% or more within 2 weeks after the procedure. Patients with failed PBD were referred directly to surgery, while those with successful PBD were referred to surgery 4 to 6 weeks after first drainage procedure according to the latest guidelines
75937584|NCT04464837|Device|Cold Snare Polypectomy of intermediate sized polyps (10-15 mm)|If an eligible polyp (10-15mm) is found, cold snare polypectomy is performed with the Olympus SnareMaster® Plus Snare
75937585|NCT03518385|Diagnostic Test|ultrasound,transvaginal scan|The presence of fluid in the uterine cavity during hormonal stimulation.
75937586|NCT02299011|Device|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
75937587|NCT02299011|Drug|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
75652308|NCT04289831|Procedure|Surgery|The standard surgical procedure for operable tumors Whipple procedure with triple reconstruction, namely pancreatogastrostomy or pancreatojejunostomy,hepaticojejunostomy and gastrojejunostomy
75652309|NCT02622477|Drug|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
75799621|NCT05759494|Diagnostic Test|rapid diagnostic test (multiplex PCR filmArray)|"novel diagnostic platform, the FilmArray®, which combines automated sample preparation, nucleic acid extraction and PCR-based detection of 31 separate targets from a single unprocessed sample in one hour. It combines nesting and multiplexing of the PCR (referred to here as nested multiplex or nmPCR) together with DNA melting curve analysis."
75799622|NCT01202448|Procedure|CSF analysis|The cerebrospinal fluid will be evaluated via lumbar puncture.
75799623|NCT03730480|Device|Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes|Using the first blood glucose monitoring system (BGMS), which is either Contour Next or Contour TV3, subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Using the second BGMS, the palm, self test and staff tests are performed. Subjects with diabetes get a venipuncture and staff tests using both BGMS using the venous blood.
75937588|NCT02296047|Drug|Placebo|physiological saline
75937589|NCT02296047|Drug|ipratropium bromide|80 µg inhalation once
75937590|NCT02296047|Drug|salbutamol|400 µg inhalation once
75937591|NCT02293707|Biological|GX301|"GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG."
75937592|NCT03514407|Drug|INCB059872|Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
75937593|NCT02293785|Drug|Oxycodone-Naloxone|
75937594|NCT01162109|Dietary Supplement|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
75937595|NCT02296203|Drug|cetuximab|
75937596|NCT02296203|Drug|irinotecan|
75937597|NCT03514251|Procedure|The suture marks the location of the parathyroid gland|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
75937598|NCT03518229|Device|Microsoft Band 2 + UV messaging|wearable device (wrist) and associated mobile application; UV sensor and messaging activated
75937599|NCT03518229|Device|Microsoft Band 2|wearable device (wrist) and associated mobile application; UV messaging not activated
75965926|NCT05257616|Other|Traction Mobilization technique|Traction Mobilization was given by Researcher at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again. Participant sits comfortably or leans against a chair backrest. Palms of the hands are placed on the mastoid processes of the patient's skull while pressing the elbows in a caudal direction. It was held for 5 seconds then relaxed.
75341796|NCT00683930|Drug|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
75341797|NCT00683930|Drug|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
75341798|NCT00683930|Drug|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
75341799|NCT02248363|Other|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
75341800|NCT03005509|Other|TQIM checklist|"The intervention phase will include an intense training period covering:~Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.~Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist."
75341801|NCT00684242|Drug|Lenalidomide|10 mg by mouth daily
75475040|NCT01990456|Device|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
75475041|NCT01990469|Drug|Gemigliptin|DPP-4 inhibitor
75475042|NCT01990469|Drug|Gemigliptin placebo|Placebo of Gemigliptin
75799624|NCT05282628|Behavioral|Building Better Brains and Behavior program (B4 Preterm)|The program couples online learning modules with video conferencing sessions with a trained therapist to review skills and practice implementing the skills with live coaching. Online modules include didactic content, video clips of parents modeling the skills, and exercises. Parents will complete intervention modules sequentially in conjunction with scheduled 1:1 videoconference sessions with a trained therapist. Videoconference sessions with the therapist will be scheduled weekly, once parents have completed their modules. During these sessions, the therapist will review the online materials and provide active coaching to the parent on how to use the skills with their child (e.g., labeled praise, reflective responses). Each session follows a manualized therapy protocol to optimize content fidelity. Parents will be instructed to practice the parenting skills for 5 minutes each day to promote mastery in the home environment.
75799625|NCT01200654|Drug|Linezolid|Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
75799626|NCT05008380|Procedure|prone positioning|3-6 hours of prone-positioning twice a day
75799627|NCT01200732|Drug|Tadalafil, placebo|20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
75799628|NCT01198860|Drug|CTH Chronic Hepatitis B|"Drug:~Tenofovir/ 300mg daily~Phyllanthus Urinaria/300mg daily~Adenosma Glutinosum/150mg daily~Eclipta Prostrata/150mg daily~Ascorbic Acid / 500mg daily"
75799629|NCT01198938|Other|Melatonin|Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
75799630|NCT01566708|Behavioral|Neuro-Music Therapy immediately|20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
75799631|NCT01566708|Behavioral|Neuro-Music Therapy after waiting time|20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
75799632|NCT01566708|Behavioral|Music-therapeutical stress management coaching|20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
76027257|NCT05045651|Procedure|Gender Solution®posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA and standard posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA|gender specific knee prosthesis:design for female to restore Q-angle, reduce anteroposterior (AP)/mediolateral(ML) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. The standard TKA or unisex knee prosthesis was design for female and male.
75475043|NCT01990482|Dietary Supplement|caffe|
75475044|NCT01990482|Dietary Supplement|Water|
75475045|NCT01990508|Behavioral|Targeted beverage education and financial incentives|
75475046|NCT01990508|Behavioral|Traffic-light labeling of all beverages in store|All beverages in the supermarket will be labeled as red, yellow, or green
75475047|NCT01990586|Drug|Rabeprazole sodium 20 mg Delayed Release tablet|
75652310|NCT04290065|Other|Manual therapy|The patient will be lying supine, relaxed. The physiotherapist, located at the patient's head, will cover the occipital bone with one hand while the palm of the hand will rest on the lambdoid suture, and the fingers will be introduced into the suboccipital space. The other hand, with a glove, will be inserted into the patient's oral cavity, resting respectively the index and middle fingers, each in an upper dental hemiarchy, on the chewing face of the tooth. An axial traction will be carried out until the three tension barriers of equal size between them are overcome, in an estimated time between 1.50 and 3 minutes. All manual therapy sessions will be performed by the same physiotherapist, following the same protocol and under the same conditions.
75652311|NCT02622243|Drug|Tiotropium|long acting muscarinic antagonist
75652312|NCT02622243|Drug|glycopyrronium|long acting muscarinic antagonist
75799633|NCT03841032|Drug|Coppertone, BAY1183345|Lotion, for 4 weeks
75799634|NCT01201044|Drug|Gemcitabine, Nedaplatin, iV|Gemcitabine, Injection, 1000mg/m2, D1 & D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
75475048|NCT01990599|Other|Nasopharyngeal Tube|
75475049|NCT01990625|Device|Antenatal Ultrasound Scan|Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
75475050|NCT01990638|Other|exercise capacity test|
75937600|NCT05504525|Procedure|Fascia Iliaca block|Ultrasound guided fascia iliaca block done by palpation of anterior superior iliac spine to identify the inguinal crease, then place the ultrasound probe on it to identify the sartorius muscle. Sonographic anatomy will be identified, from superficial to deep, consisting of subcutaneous fat, the internal oblique muscle, the transverse abdominis muscle, the fascia iliaca covering the iliacus muscle and the iliacus muscle itself. The block needle will be advanced in out-of plane to puncture the fascia iliaca. With the needle tip just below the fascia iliaca, 2 ml of a local anesthetic will be injected to confirm the tip location. Once the proper position is confirmed, 40 ml of bupivacaine 0.25% will be injected superficial to the iliacus muscle and deep to the fascia iliaca.
75341802|NCT00684320|Behavioral|Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
75937601|NCT05504525|Procedure|Quadratus lumborum block|The patients will receive anterior ultrasound guided quadratus lumborum block QLB in the lateral position. The transducer will be first placed in a parasagittal orientation 3-4 cm lateral to the midline and over the sacrum to identify the L5 transverse process. The probe will then rotated into a transverse orientation with slight medial and caudal angulation to obtain a transverse oblique view at L5 transverse process .The ultrasound probe will be tilted , so the lateral end of the probe will be more cranial than the medial side of the probe to avoid the acoustic shadow of the iliac crest. Identify the quadratus lumborum and psoas major and inject the local anesthetic above the QL
75937602|NCT03518151|Other|Product placement intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
76089047|NCT04122963|Procedure|Standard CLOSE-guided PVI ablation|Standard AF ablation according to the CLOSE-protocol
75475051|NCT01990690|Drug|anti oxidant omega 3|"Soft gelatineous capsule (Sedico medical company) each capsule contains:~Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks."
75475052|NCT01990716|Other|Colonic Biopsy|"Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.~The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.~Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.~For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time."
75475053|NCT01990729|Dietary Supplement|ARTRA|ARTRA (glucosamine and chondroitin sulfate)
75475054|NCT01990755|Behavioral|CBT (Cognitive Behavioral Therapy)|It is a worldwide known form of psychotherapy for eating disorders
75937603|NCT03518151|Other|Sham comparator|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
75652313|NCT02622243|Device|Respimat|inhaler device used to deliver active tiotropium or placebo
75652314|NCT02622243|Device|Breezehaler|inhaler device used to deliver active glycopyrronium or placebo
75652315|NCT04289675|Drug|Interferon-Beta|Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.
75799635|NCT01201044|Radiation|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
75799636|NCT01201044|Radiation|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
75652316|NCT02622165|Behavioral|The REWARD serious game intervention|The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
75799637|NCT01201044|Drug|Gemcitabine，Nedaplatin, BAI|"Drug: Gemcitabine, Nedaplatin, iV~Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI"
75799638|NCT04525872|Other|Full parenteral nutrition light protection of the bag, tubing and lipids|Each infant enrolled in this study will receive full PN light protection including the PN bag, lipids and tubing.
75799639|NCT03843060|Drug|AZD9977|Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.
76027258|NCT05045417|Diagnostic Test|Serum level of IL-17|"Measurement of serum level of IL-17 :~To explore the role of IL-17 in systemic lupus erythematosus~To determine the relation between IL-17 and lupus disease activity~To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)"
76027259|NCT05045339|Procedure|Ball Exercises|Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed. Exercises were performed with 55 and 65 inch gym ball and a small regular plastic ball.
76027260|NCT05059145|Drug|Chlorhexidine Gluconate|Vaginal cream 1%
76027261|NCT05059145|Drug|Fluconazole|150 mg oral capsule
76089048|NCT04122885|Combination Product|PIPAC with oxaliplatin|Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure
75937604|NCT03514095|Other|Individual Cognitive Stimulation Therapy Program|"This program unfolds in 3 weekly sessions of 30 minutes, for 12 weeks, thus completing a total of 36 sessions.~Over the 3 months, the dyad will need to be monitored for orientation / monitoring of intervention by an element of the research team. This monitoring will be bi-weekly, in person or by phone - here according to the choice of the dyad). After each session the caregiver has a questionnaire to complete (intervention monitoring strategy), with the objective of evaluating the acceptability and applicability of the program."
76089049|NCT04122885|Procedure|Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy|If complete cytoreduction possible (CC-0). Application time 60 min, T 41-43 °C
76089050|NCT04122651|Procedure|'Off the shelf' toric lens|'Off the shelf' toric lens (either 2.00D or 4.00D) and combined limbal relaxing incisions and/or off-axis inttaocular lens rotation
76089051|NCT04122651|Procedure|Tailored Toric lens|Fully targeted toric intraocular lens correction for corneal astigmatism
76089052|NCT03022851|Device|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
75341803|NCT00684320|Behavioral|Placebo Condition|The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
75341804|NCT00651560|Drug|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
75341805|NCT04492111|Procedure|post-extraction dental implant|Insertion of a dental implant immediately after tooth extraction.
75475055|NCT01990755|Other|IBPP (individual psychology brief psychotherapy)|It is a worldwide known form of psychotherapy for eating disorders
75341806|NCT00684554|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
75341807|NCT04490395|Behavioral|Engage PA|Engage PA will consist of a 2-session intervention delivered to participants at the medical center or virtual visit by their study therapist, and includes a wearable personal fitness monitor for tracking their daily activity levels throughout.
75652317|NCT02622399|Behavioral|Project NOW|This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
75799640|NCT03843060|Drug|Itraconazole|Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
76089053|NCT03926338|Drug|Neoadjuvant therapy with PD-1 inhibitor plus COX inhibitor|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months or 6 months) and Celecoxib (oral 200mg twice daily for 3 months or 6 months) followed by colectomy. The choice of treatment duration of 3 months or 6 months was made by the treating physician and patient before randomization.
75341808|NCT04490395|Other|Treatment as Usual plus (TAU+)|The comparison condition will receive treatment as usual throughout the study, and are given a wearable personal fitness monitor for tracking their daily activity levels throughout the study.
75341809|NCT00626912|Procedure|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
75799641|NCT03842904|Drug|Trimbow pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
75937605|NCT02294097|Procedure|Surveillance protocol kidney allograft biopsy|Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
76089054|NCT03926338|Drug|Neoadjuvant therapy with PD-1 inhibitor|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months or 6 months) followed by colectomy. The choice of treatment duration of 3 months or 6 months was made by the treating physician and patient before randomization.
75341810|NCT02248441|Other|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
75341811|NCT00551876|Drug|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
75475056|NCT01990755|Drug|CBT + OLANZAPINE|It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
75475057|NCT01990755|Dietary Supplement|nutritional rehabilitation|all patients were followed-up monthly with nutritionist and dietitian visits
75475058|NCT01990755|Drug|delorazepam|all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
75475059|NCT01990781|Drug|LD: Lidocaine and dexamethasone|LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
75799642|NCT03842904|Drug|Fostair pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
75799643|NCT04427904|Drug|Bupivacaine 0.5% with 1:200 000 epinephrine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
75799644|NCT04427904|Drug|Lidocaine 2% with 1:100 000 epinephrine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
75799645|NCT03769038|Device|chronic total occlusion|chronic total occlusion of coronary atery was opened and then stents were placed
75799646|NCT03744156|Behavioral|Cognitive Behavioral Treatment-Insomnia|8 session Cognitive Behavioral Therapy for Insomnia. Individualized sessions with a therapist.
75799647|NCT03744156|Behavioral|Sleep Hygiene Education|8 Session Sleep Hygiene Education. Individualized sessions with a therapist.
75937606|NCT02302443|Biological|HM12470|Single dose subcutaneous administration ranging from a very low dose to high dose
75937607|NCT02302443|Biological|Active comparator|Single dose subcutaneous administration of active comparator
75937608|NCT03516123|Drug|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
75937609|NCT03132597|Behavioral|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
76089055|NCT04122417|Other|The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby|The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
76089056|NCT04122573|Diagnostic Test|Coronary angiography|Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.
75652318|NCT00976703|Other|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
76089057|NCT04122573|Diagnostic Test|CT angiography of aorta|Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.
76089058|NCT04122573|Diagnostic Test|CT angiography of pulmonary arteries.|Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.
75799648|NCT01202838|Device|Composite Implant|Subjects receiving composite implants
76089059|NCT04122573|Diagnostic Test|Electrocardiogram|All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.
75475060|NCT01990781|Drug|L:Lidocaine|Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
75652319|NCT00976703|Other|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
75937610|NCT02296281|Drug|Pirfenidone|
75937611|NCT03513861|Other|FASTER Assessment tool|The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.
75937612|NCT02299245|Drug|rosuvastatin|different dose of rosuvastatin treatment
76089060|NCT04122573|Diagnostic Test|Cardiac Troponin|Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
76089061|NCT04122807|Procedure|Cardiac catheter ablation|Cryoablation
76089062|NCT03875716|Radiation|Radiation therapy|Radiation therapy
76089063|NCT04126941|Other|Serum calcium concentrations results|To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
75475061|NCT01990781|Drug|D: Dexamethasone|D:intravenous dexamethasone 8 mg before induction of anesthesia
75475062|NCT01990781|Drug|N: Normal saline (placebo)|Normal saline: 2ml
75475063|NCT01990807|Drug|Idarubicin(IDA)|6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
75475064|NCT01990846|Drug|Flufirvitide 3|
75799649|NCT03840798|Other|Child Abuse Clinical Decision Support system|"The investigators are implementing the following aspects of the Electronic Health Record (EHR) based child abuse- clinical decision support (CA-CDS) system.~a universal child abuse screen (CAS)~an embedded child abuse alert system~alerts to physicians and advanced practice providers~physical abuse order sets"
75799650|NCT03840876|Device|WEI NASAL JET (WNJ)|Jet ventilation was achieved with WEI NASAL JET (WNJ) connected to a manual jet ventilator (Driving pressure: 40 psi, fraction of inspired oxygen: 100% O2, Respiratory rate: 25/min, I/E ratio: 40%)
75819670|NCT02175706|Device|Promus Element®|fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
75819671|NCT02173912|Drug|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
76089064|NCT04122027|Other|Cerebral oximeter|Near infra-red spectroscopy, NIRS
76089065|NCT04122105|Drug|Sildenafil|The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
76089066|NCT02385214|Procedure|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
76089067|NCT02385214|Procedure|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
76089068|NCT03202641|Procedure|PEEP ARDSnet|PEEP settings based on the low PEEP/high FiO2 table
76089069|NCT03202641|Procedure|PEEP LRM|A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
75475065|NCT01990846|Drug|Placebo for Flufirvitide-3|
75475066|NCT01990872|Dietary Supplement|Vitamin D3 (20 micrograms/day)|Vitamin D3 (20 micrograms/day)
75475067|NCT01990872|Dietary Supplement|Placebo|Placebo (0 micrograms vitamin D3/day)
75475068|NCT01990885|Drug|BL-7010|
75475069|NCT01990885|Drug|Placebo|
75475070|NCT01990924|Radiation|15 FPS|X-ray pictures
75475071|NCT01990924|Radiation|7.5 FPS|X-ray pictures
75819672|NCT02173912|Drug|CJ-30059 (Test)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
75937613|NCT02302521|Device|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
75937614|NCT02299323|Device|INDEPENDENCE|Lumbar Integrated plate and spacer, with percutaneous screws and rods.
75937615|NCT02296359|Biological|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
75937616|NCT02302599|Biological|Umbilical cord mesenchymal stem cells|Infusion treatment
75937617|NCT02302599|Biological|Controlled suspension liquid|Infusion treatment
75937618|NCT03513627|Procedure|Post-occlusive reactive hyperemia test (PORH test)|Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
75937619|NCT03513549|Drug|Loxapine 10 MG|
75937620|NCT03513471|Biological|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
75937621|NCT03513471|Other|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
75937622|NCT03513471|Drug|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
75937623|NCT02296437|Other|Transcranial direct current stimulation combined with cognitive training|
75937624|NCT03516045|Drug|18F-AlF-NOTA-neurotensin|One injection of the radioligand 18F-AlF-NOTA-neurotensin
75475072|NCT01990937|Drug|Oral midazolam|5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
75937625|NCT03515967|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
75652320|NCT02622087|Behavioral|One-Session-Treatment|There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
75652321|NCT00696579|Drug|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
75937626|NCT02302755|Drug|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
75937627|NCT03513393|Drug|velpatasvir|Test 1
75937628|NCT03513393|Drug|velpatasvir|Test 2
75937629|NCT03513393|Drug|velpatasvir|Reference
76089070|NCT04121793|Device|Kinesia 360 and Smartphone sensors|Data will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.
75475073|NCT01990976|Device|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
75819673|NCT02173990|Drug|Aflibercept-FOLFIRI|"Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²"
76089071|NCT04127019|Drug|Paclitaxel|Paclitaxel chemotherapy (injection)
76089072|NCT04127019|Drug|Docetaxel|Docetaxel chemotherapy (injection)
76089073|NCT04127019|Drug|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
75341812|NCT00551876|Drug|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
75341813|NCT00628394|Drug|Atomoxetine|40mg 2po qam
75341814|NCT00628394|Drug|Placebo|40mg 2po qam
75475074|NCT01990976|Procedure|Biopsy|biopsy of the vastus lateralis muscle
75819674|NCT02255812|Dietary Supplement|Single intragastric instillation of 200 mL tap water via nasogastric tube|
75819675|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
75819676|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
75819677|NCT02255812|Dietary Supplement|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
75819678|NCT02255812|Dietary Supplement|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
75819679|NCT02255812|Dietary Supplement|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
75341815|NCT04449835|Procedure|Intracept Procedure|radio frequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
75341816|NCT00251576|Drug|A-Phase: tirofiban; Z-Phase simvastatin|
75341817|NCT00251576|Drug|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
75341818|NCT00251576|Drug|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
75819680|NCT02179138|Drug|TFV 1% gel|
75819681|NCT02175784|Drug|ipragliflozin|oral
75819682|NCT02175784|Drug|placebo|oral
75341819|NCT00251576|Drug|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
75341820|NCT00251576|Drug|Duration of Treatment: Z-Phase, 2 years.|
75475075|NCT01991002|Behavioral|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
75475076|NCT01991028|Drug|Radiolabelled OligoG CF-5/20 DPI|Inhalation with dry powder by Mia Monodose Inhaler
75652322|NCT00696579|Drug|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
75652323|NCT02866097|Other|mHealth inventory management|Improved stock management of iCCM commodities using the DHIS2 mHealth platform
75652324|NCT02866097|Other|Supportive supervision|Strengthening of supportive supervision using DHIS2
75937630|NCT02302911|Behavioral|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
75652325|NCT02866097|Other|ICCM current standard of care|ICCM implementation as per current practice without mHealth interventions
75799651|NCT01201122|Drug|Mesalamine|"Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- <30 kg, 30-40kg, >40kg.~For body wt. 15- <20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- <30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- <40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening)."
75799652|NCT05670366|Device|Activity tracker and chest strap|During the study, the participants will be asked to wear a commercially-available activity tracker during day and night, and a chest strap during sport activities to collect data on physical activity (type, intensity and duration of activity).
75799653|NCT05670366|Device|Diary app|During the study, the participants will be asked to log the ingestion of carbohydrates, periods and type of physical activity, feelings (e.g. sick, stress, ...) in a diary app.
75799654|NCT03668808|Drug|Insulin Degludec|Subjects will use Insulin Degludec (Tresiba) with TRESIBA® FLEXTOUCH® pens as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
75937631|NCT02302911|Behavioral|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
75937632|NCT02302911|Other|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
75937633|NCT02299401|Drug|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
75937634|NCT02299401|Device|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
75937635|NCT03513315|Behavioral|Implementation of Community-based Home Heat Bundle|This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
75937636|NCT03513315|Behavioral|Regular Community Healthcare provision|The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
76089074|NCT04127019|Drug|Epirubicin|Epirubicin chemotherapy (injection)
76089075|NCT04127019|Drug|5-fluorouracil|5-fluorouracil chemotherapy (injection)
76089076|NCT02244034|Procedure|hypothermia|
76089077|NCT04127175|Device|Volpara|This tool represents a physics-based model which extract pixel-wise information from the FFDM or DBT images, and combine it with metadata information from the DICOM header and appropriate linear attenuation coefficients of both adipose and glandular tissue.
75475077|NCT01991028|Drug|Radiolabelled OligoG CF-5/20 6% Solution|Inhalation with aerosolised solution by nebuliser
75799655|NCT03668808|Drug|Insulin Glargine|Subjects will use Insulin Glargine (Lantus) with LANTUS® SOLOSTAR® INSULIN PEN as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
75799656|NCT03668808|Device|TRESIBA® FLEXTOUCH®|Subjects will use Tresiba FlexTouch pens when using Tresiba as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
76089078|NCT02076646|Drug|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
76089079|NCT02076646|Drug|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
76089080|NCT02076646|Drug|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
75475078|NCT01991054|Dietary Supplement|vitamin D3|
75475079|NCT01991080|Behavioral|biofeedback|Patients will go through biofeedback sessions
75475080|NCT01991080|Drug|Wheatgerm juice|Patient will drink wheatgerm juice
75475081|NCT01991106|Behavioral|High intensity interval training|Twelve weeks of 2-3 supervised training sessions each week.
76089081|NCT04127097|Other|cartoon group|The children in the groups were distracted by watching cartoon 2 minutes before treatment, until the process was over
76089082|NCT04121481|Dietary Supplement|Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement|Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample
76089083|NCT04121481|Dietary Supplement|Broad Spectrum Safety|Benefits in Sports Nutrition
76089084|NCT04121715|Device|Fastigial Nucleus Stimulation|Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
76089085|NCT04121715|Drug|Standard treatment|"Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition"
75341821|NCT02996617|Drug|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
75475082|NCT01991106|Behavioral|Moderate intensity continuous training|Twelve weeks of 2-3 supervised training sessions each week.
75937637|NCT02296515|Procedure|Intrathecal pump refill:|Two different experienced clinicians will perform one time the blind technique andTwo different experienced clinicians will perform one time the blind technique andtwo times the ultrasound-guided technique on all patients.
75937638|NCT02296593|Device|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
75937639|NCT02699450|Drug|Faricimab|Faricimab will be administered by IVT injection in the study eye.
75799657|NCT03668808|Device|LANTUS® SOLOSTAR® INSULIN PEN|Subjects will use Lantus SoloStar insulin pens when using Lantus as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
75937640|NCT02699450|Drug|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
75475083|NCT01991106|Dietary Supplement|Nutritional advice|healthy food choices, portion sizes and regular mealtimes
75475084|NCT01991119|Drug|Propafenone|
75652326|NCT04929938|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This is a combination of cognitive-behavioural techniques oriented to improve the emotional regulation. The Unified Protocol is comprised of 8 modules and it is applied following The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders Manual (Barlow, 2017).
75652327|NCT02622009|Procedure|BRONCHOSCOPIC PROCEDURE|After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina
75672266|NCT04115228|Device|Implantation and neuromodulation therapy|The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.
75799658|NCT05281926|Drug|Poly ICLC|IT Poly-ICLC injection (1.0 mg) at Day 1 of weeks 0, 1 and 2. IM Poly-ICLC (20 μg/Kg) at Day 1 and Day 3 of weeks 3, 4, 5 and 6.
75799659|NCT03641118|Diagnostic Test|Cardiopulmonary exercise test|The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
75799660|NCT03840330|Other|Experimental: High-intensity interval training group|16 weeks of High-intensity interval training
75799661|NCT03840330|Other|Experimental: Moderate-intensity interval training group|16 weeks of Moderate-intensity interval training
75799662|NCT01199172|Behavioral|voice hygiene|subjects will receive voice hygiene training
75799663|NCT01199172|Behavioral|VH + VP|subjects will be trained in voice hygiene and voice production training
75937641|NCT02299557|Drug|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
75937642|NCT02299557|Drug|Placebo gel|Placebo gel applied intra-anally once daily
75937643|NCT02302989|Drug|Ranibizumab 0.5mg|
75937644|NCT02299713|Device|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
75937645|NCT02296671|Drug|Pemetrexed|
75937646|NCT02296671|Drug|Oxaliplatin|
75937647|NCT02296671|Drug|Leucovorin|
75937648|NCT02296671|Drug|Fluorouracil|
75937649|NCT02296671|Genetic|Germline genotyping analyses for TSER|
75937650|NCT02296749|Drug|Sirolimus|Sirolimus tablets 2 mg
75475085|NCT01991119|Drug|Dronedarone|
75475086|NCT01991132|Other|MediView 2.0 software|
75475087|NCT01991145|Procedure|Umbilical Cord Blood therapy|HLA (Human Leukocyte Antigen) typing
75475088|NCT01991145|Biological|Erythropoietin alfa|
75475089|NCT01991145|Other|Rehabilitation|Active rehabilitation
75475090|NCT01991145|Procedure|Placebo UCB|
75475091|NCT01991145|Biological|Placebo EPO|
75475092|NCT01991158|Drug|High dose of methotrexate|Methotrexate 3.0g/Kg, intravenous drip D1
75475093|NCT01991158|Drug|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
75475094|NCT01991158|Drug|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
75475095|NCT01991158|Drug|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
75475096|NCT01991171|Other|Kinesio Taping|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
75475097|NCT01991223|Drug|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
75475098|NCT01991223|Drug|NS infusion|Normal saline will be infused during surgery
75937651|NCT04481750|Drug|MT-1186|Solution or suspension
75475099|NCT01991236|Behavioral|Video|Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
75937652|NCT04481750|Drug|MT-1186-matching placebo|Solution or suspension
75937653|NCT02303223|Drug|Propofol|
75475100|NCT01991236|Behavioral|Standard Script|Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
75475101|NCT01991275|Drug|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
75937654|NCT03168620|Procedure|Restoration|
75937655|NCT03515889|Behavioral|Ideal Protein Weight Loss Method|"An initial visit will take place in which each participant assigned to the experimental group will complete a health profile questionnaire.The Ideal Protein method will be explained and the participant will be weighed, measured and given diet related informational materials. A staff member will assist the participant with the selection of foods and snacks to ensure adequate quantity for the week. Weekly follow-up visits of 15 minutes duration will be implemented with a telephone follow-up occurring during the first 4 days after the initial appointment.~For 12 weeks Ideal Protein foods that are of the appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
75937656|NCT03515889|Behavioral|Standard Weight Loss|"This arm utilizes evidence-based strategies that have been shown to be effective for long-term weight loss and weight loss maintenance (including behavioral techniques, diet modification, and social support) consistent with the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Participants in this arm will have an initial one hour consultation with a trained interventionist, where the fat goal and calorie restriction goal are explained.~For 12 weeks low-fat reduced calorie foods that are of appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
75475102|NCT01991275|Drug|The intrathecal morphine injection|A single injection of morphine intrathecally
75937657|NCT02395874|Procedure|tDCS + speech therapy|Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
75937658|NCT02299947|Drug|Haemocomplettan P|
75937659|NCT02299947|Drug|Placebo|
75937660|NCT05692817|Device|Low-Intensity Pulsed Ultrasound|"The total sample will be randomly divided into two equal groups (according to method of application of the lipus on the intervention side)as follows: ■ Group I: will include 8 patients who will receive lipus with maxillary canine retraction that will be performed every (3 weeks) on intervention 6 sides according to a standardized protocol.~▪ Group II: will include 8 patients who will receive lipus that will be performed every (1 week) on intervention sides according to a standardized protocol."
75937661|NCT03510585|Other|saline and sniffing|This technique is a combination of positioning (laying down), saline instilation (5 ml in each side), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
75937662|NCT03510585|Other|sniffing|This technique is a combination of positioning (laying down), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
75937663|NCT05364983|Device|Juvene IOL|Cataract extraction and implantation of a posterior chamber IOL
75475103|NCT01991288|Procedure|SNB Saphenous Nerve Block|Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
75799664|NCT05282472|Diagnostic Test|CPET without mask|Regular cardiopulmonary exercise tests were applied to all participants in phase 1.
75799665|NCT05282472|Diagnostic Test|CPET with mask|A 3-layer surgical mask was placed on CPET device's mask and was fixed with a CPET tribune. In phase 2, as using this combined (surgical mask and device's mask) masks, CPETs were performed in all participants again, after 48 hours.
75652328|NCT02865629|Drug|N-acetyl cysteine|N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
75652329|NCT04253210|Other|psychological|Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
75799666|NCT03844776|Drug|Co-Amoxiclav|amoxicillin + clavulanic acid orally
75799667|NCT03844776|Drug|Paracetamol|paracetamol orally
75799668|NCT03844776|Drug|Chlorhexidine mouthwash|0.2% chlorhexidine mouthwash
75799669|NCT03844776|Drug|Normal saline|0.9% normal saline irrigation
75799670|NCT03844776|Drug|Amoxicillin 500 Mg|Amoxicillin 500 orally
75799671|NCT03844776|Drug|Metronidazole|metronidazole 500 mg orally
75799672|NCT04358328|Other|Comprehensive geriatric assessment (CGA) and care|Comprehensive geriatric assessment and care including geriatric-, nursing-, physiotherapist-, and dietician assessments followed by appropriate interventions.
75937664|NCT05364983|Device|Tecnis® Monofocal (ZCB00, PCB00 or DCB00)|Cataract extraction and implantation of a posterior chamber IOL
76089086|NCT01894906|Drug|Soluble Ferric Pyrophosphate|
76089087|NCT01894906|Other|Placebo|
75341822|NCT02996617|Drug|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
75799673|NCT04358328|Other|Standard care|Standard pre-, peri- and post operative care.
75475104|NCT01991288|Procedure|NSNB Non Saphenous Nerve Block|All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
75799674|NCT01566864|Behavioral|Improve clinic based measurement of blood pressure|This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.
75937665|NCT03168854|Biological|Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
75937666|NCT03168854|Other|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
75475105|NCT01991301|Drug|carfilzumib|carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
75937667|NCT02300181|Dietary Supplement|Placebo|
75937668|NCT02300181|Dietary Supplement|Bacillus subtilis var natto DC-15|
75475106|NCT01991327|Drug|Androxal|
75475107|NCT01991327|Drug|Placebo|
75475108|NCT01991353|Procedure|With PRP|Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.
75475109|NCT01991353|Procedure|Without PRP|Standard of care meniscal repair without augmentation.
75475110|NCT01991392|Device|Nasogastric tube|For nasogastric decompression.
75652330|NCT00696735|Procedure|chemotherapy|injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
75652331|NCT00696735|Procedure|high dose therapy and autologous stem cell transplantation|VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
75652332|NCT02867345|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
75652333|NCT02867345|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
75652334|NCT02867345|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
75652335|NCT04260230|Device|Lifetemp/Lifetouch sensors|Wearing the devices for six weeks. Data only reviewed retrospectively.
75937669|NCT02699996|Other|Questionnaire Administration|Complete interview
75937670|NCT02699996|Behavioral|Telephone-Based Intervention|Complete the self management + peer mentoring intervention with videoconferencing
75937671|NCT03510429|Dietary Supplement|Postoperative Nutritional Supplement|Postoperative Nutritional Supplement (newly developed ketogenic drink: NDKD)
75937672|NCT03510429|Other|Routine post-op care|Routine post-operative care
75937673|NCT02403362|Drug|EPO-018B|
75937674|NCT03513159|Behavioral|Pathfinder support|A pathfinder will support the patient with structured activities.
76089088|NCT04121247|Other|nonpharmacological approaches to parents of children with sickle cell disease training program|use of non-pharmacological approaches in children with sickle cell disease, parent education
75475111|NCT01991392|Device|No nasogastric tube|For nasogastric decompression.
75475112|NCT01991405|Device|Computerized Working Memory Training.|"Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an adaptive level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a sham program that is fixed (non-adaptive in difficulty level), but otherwise identical."
75475113|NCT01991444|Other|TAVI|no Intervention planned, Observation only
75937675|NCT03168698|Drug|Carbetocin|Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
75937676|NCT03168698|Drug|Oxytocin|Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
75937677|NCT02303301|Dietary Supplement|Probiotics|Cultures from the oropharynx
76089089|NCT04121091|Drug|Pramipexole Pill|Add-on pramipexole
76089090|NCT04127253|Device|Sooma transcranial direct current stimulation device plus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the stimulation of the transcranial direct current.
75652336|NCT02621853|Device|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
75652337|NCT02867189|Other|atlas of micro-instrument|Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
75652338|NCT02621775|Behavioral|Computer-based stress management program|The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.
75672267|NCT04245527|Device|Joovv Infrared Light Device|Joovv is the leading manufacturer of personal, in-home red light therapy devices
75799675|NCT01566864|Behavioral|Provider education system to promote patient-centered care|The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.
75799676|NCT01566864|Behavioral|Introduce care management system in clinics|The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
75799677|NCT03840564|Other|Point of care (POC)|All the analyzes will be done in delocalized
75799678|NCT01566942|Drug|Oxaliplatin|In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
75799679|NCT01566942|Drug|Irinotecan|In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
75799680|NCT01201278|Drug|Insulin|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
75799681|NCT01201278|Drug|Insulin|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
75799682|NCT01201278|Drug|Insulin LISPRO|Subcutaneous insulin lispro 8 U
75799683|NCT05668182|Procedure|TRUMATCH Graft Cage|TRUMATCH Graft Cage for surgical repair of segmental long bone defect
75799684|NCT05667948|Drug|Chemotherapy|different treatments based on the molecular analysis
75799685|NCT01201434|Dietary Supplement|Bio-25 probiotic|2 tablets per day for 6 months
75937678|NCT02303301|Dietary Supplement|Placebo|Cultures from the oropharynx
75937679|NCT02395406|Device|Orotracheal intubation with Totaltrack|
75937680|NCT02395406|Device|Orotracheal intubation with Airtraq|
75937681|NCT02296905|Drug|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
75937682|NCT02296905|Drug|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
75937683|NCT04464447|Behavioral|Acceptance and Commitment Therapy|"The treatment ACT for Health in Adolescents (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module. Six to eight patients participate in each treatment Group. An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module."
75937684|NCT04464135|Other|acetic acid staining|The water exchange colonoscopy is used during insertion procedure, in which the water contains 1% acetic acid, and the liquid is absorbed during the withdrawal process for observation.
75937685|NCT04464135|Other|Water exchange colonoscopy|The water exchange colonoscopy is used during insertion procedure, and the liquid is absorbed during the withdrawal process for observation.
75937686|NCT02403440|Drug|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
75937687|NCT02395328|Behavioral|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
75937688|NCT03513003|Device|Functional Pacifier|Children swap from their habitual pacifier to the functional pacifier and stop baby bottle
75937689|NCT03513003|Behavioral|Stop habit|Children stop the use of their pacifier and/or baby bottle
75937690|NCT03510351|Drug|Ceftolozane-Tazobactam|Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
75937691|NCT02400632|Device|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
75937692|NCT03512925|Other|Standardized debriefing session of coercive measures|Debriefing session following the developed guidelines including setting and themes.
75937693|NCT02395250|Biological|anti-GPC3 CAR T|
75937694|NCT02296983|Biological|VSV-ZEBOV|VSV-ZEBOV
75937695|NCT02403284|Drug|Liraglutide|Subcutaneous injection by patient
75937696|NCT02403284|Drug|Sugar Pill|Subcutaneous injection daily
75937697|NCT02400866|Drug|Olanzapine|
75937698|NCT03132909|Other|Feelings Determination|Determine the feelings of doctors caring for their colleagues
75341823|NCT04387604|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|"PRN regimen. Treatment Schedule Repeat injections at every 4-week visit if eye improves or worsens (defined as ≥5 letter change from last injection or ≥10% CST change on OCT from last injection or CSF>300 μm at any timepoint).~Defer injections if either BCVA of 85 letters and OCT CSF normal (CSF≤300 μm and non-existent intra- or sub-retinal fluid); or OCT CSF normal (CSF≤300 μm) and stable BCVA (defined as < 5 letters change from last injection) after two consecutive injections during the first 24 weeks, or after one injection if the initial stability period has already been achieved (OCT CSF normal and stable BCVA).~Resume injections if BCVA or OCT worsens."
75341824|NCT03005665|Drug|Acetazolamide|
75341825|NCT03005665|Drug|Normal Saline|
75341826|NCT04429945|Device|Virtual Reality|Virtual Reality Headset with Virtual Reality Applications
75341827|NCT00684788|Combination Product|employment-based reinforcement|"Participants in the Work Plus Naltrexone Contingency condition were required to take scheduled doses of depot naltrexone to work and earn wages."
75475114|NCT01991509|Biological|LBR-101 IV|LBR-101 Administered Intravenously
75475115|NCT01991509|Biological|LBR-101 SC|LBR-101 Administered Subcutaneously
75652339|NCT02621775|Behavioral|Stress management in face-to-face|The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.
75341828|NCT04351165|Drug|IMP4297|IMP4297 10mg/capsule; IMP4297 20mg/capsule;
75341829|NCT00628628|Drug|As Needed Rasburicase|.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
75652340|NCT02621775|Other|Waiting list|The patients are followed by their General Practitioners without change in treatment .
75341830|NCT00628628|Drug|Fixed Dose Rasburicase|.15 mg/kg IV Over 30 Minutes Daily
75652341|NCT04259918|Procedure|Alveolar recruitment maneuver|Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery
75672268|NCT00620048|Biological|Intramyocardial injection of autologous CD34-positive cells (stem cells)|Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
75799686|NCT03549624|Other|Standardised protocol for the perioperative management in patients in need of an acute laparotomy|A standardised protocol for the perioperative management of patients including early start of antibiotics and swift surgical intervention as well as an emphasis on repeated monitoring of physiological parameters pre- and post-operatively.
75799687|NCT01199250|Other|Laboratory Biomarker Analysis|Correlative studies
75799688|NCT01199328|Drug|Aspirin|81mg Tablet oral, once daily
75799689|NCT01199328|Drug|Esomeprazole|20 mg Tablet oral, once daily
75341831|NCT04386811|Drug|Calcitriol|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
75475116|NCT01991535|Device|Spontaneous Ventilation Mode|"Respiratory rate and duration of inspiration are controlled by the patient.~Device model: Stellar 150® (ResMed, Australia)."
75475117|NCT01991535|Device|Controlled Ventilation Mode|"Ventilator maintains the positive end-expiratory pressure until the patient inspires. At that point, the ventilator reaches the support pressure in a predetermined time. The patient fixes the respiratory rate and the duration of inspiration, triggering all the cycles.~Device model: Stellar 150® (ResMed, Australia)."
75475118|NCT01991535|Device|Simulator Ventilation Mode|"Ventilator maintains a continuous positive airway pressure during the entire cycle.~Device model: Stellar 150® (ResMed, Australia)."
75475119|NCT01991561|Biological|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
75475120|NCT01991561|Biological|Med dose of H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
75475121|NCT01991561|Biological|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
75475122|NCT01991561|Biological|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
75475123|NCT01991561|Biological|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
75475124|NCT01991561|Biological|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
75475125|NCT01991574|Drug|Calcium acetate|
75475126|NCT01991574|Dietary Supplement|Iron Hydroxide Adipate|
75475127|NCT01991574|Drug|Placebo|methylcellulose capsules
75799690|NCT03842514|Dietary Supplement|Soya lecithin|The lecithin supplement will be soya lecithin granules given as 7.5 g twice daily, incorporated into juices
75799691|NCT03428490|Behavioral|Fully integrated treatment|Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).
75799692|NCT03428490|Behavioral|Stand-alone Intensive Outpatient Program|Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
75937699|NCT02400788|Drug|Resminostat|
76089091|NCT04127253|Device|Placebo Sooma transcranial direct current stimulation deviceplus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the placebo stimulation of the transcranial direct current, where it will be acrtivo during 15 seconds and then it will be turned off during the rest of the intervention.
75799693|NCT03134742|Other|Control Group|No interventions this is the control group-no additional scans
75937700|NCT02400788|Drug|Sorafenib|
75937701|NCT02297061|Biological|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
75652342|NCT02867111|Device|Sperm Selection Assay|Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.
75937702|NCT02403128|Drug|aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
75799694|NCT03134742|Diagnostic Test|CT Scan|CT Scan of affected and contralateral limb
75475128|NCT01991587|Biological|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
75475129|NCT01991587|Biological|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
75475130|NCT01991587|Biological|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
75475131|NCT01991587|Biological|Placebo|A single dose of placebo
75799695|NCT03134742|Diagnostic Test|DEXA Scans|DEXA Scan of affected and contralateral limb
75799696|NCT03134742|Diagnostic Test|CT and DEXA Scans|CT Scan and DEXA Scan of affected and contralateral limb
75937703|NCT02297217|Drug|Carboplatin and Taxol (paclitaxel)|Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
75937704|NCT02297217|Radiation|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
76027262|NCT05045105|Other|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
75475132|NCT01991600|Dietary Supplement|ferrous sulphate|
75672269|NCT02828501|Procedure|Spinal Manipulation|A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.
75799697|NCT05281848|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal treatment includes periodontal prophylaxis and root planning. No other methods or any of drugs will be used.
75799698|NCT03842592|Diagnostic Test|Treadmill Stress test|Ventricular arrhythmia will be assessed by ECG Holter and during treadmill stress test, both being performed 3 months and 1 year after acute myocarditis
75799699|NCT03134586|Other|Diagnostic imaging|
75799700|NCT02982954|Drug|Nivolumab|Specified dose on specified day
75799701|NCT02982954|Drug|Ipilimumab|Specified Dose on Specified Day
75799702|NCT03840408|Other|Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation|Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
76027263|NCT05059067|Device|Direct laryngoscopy for endotracheal intubation|Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
76027264|NCT05058599|Diagnostic Test|DM|A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
76027265|NCT01970488|Biological|Adalimumab|Administered by subcutaneous injection
76027266|NCT01970488|Biological|ABP 501|Administered by subcutaneous injection
75799703|NCT03840408|Procedure|Surgery|Patients will be treated with surgery
75799704|NCT01203150|Other|Exercise|CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
75799705|NCT02970864|Device|Polynerve|Polymer biomaterial nerve conduit
75799706|NCT01203228|Other|Reduced Intensity Conditioning|"Busilvex®:~6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available)~Busulfan:~8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Fludarabine:~5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS"
75475133|NCT01991600|Dietary Supplement|ferric iron oxide-organic acid (Fe-OA)|
75475134|NCT01991613|Dietary Supplement|liquid protein supplement|The liquid protein supplement is already in use. The purpose of this study is to determine whether using the supplement earlier will lead to improved growth.
75475135|NCT01991626|Dietary Supplement|micronutrient powder|
75475136|NCT01991626|Dietary Supplement|micronutrient powder (containing FeSO4), phytase|
75475137|NCT01991626|Dietary Supplement|Iron pyrophosphate (FePP)|
75475138|NCT01991626|Dietary Supplement|Iron sulphate|
75475139|NCT01991639|Other|Nutritional and physical activity intervention|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
75475140|NCT01991665|Other|Digital examination|
75475141|NCT01991665|Other|Sonography evaluation|
75475142|NCT01991678|Drug|145 mg/m2 NKTR 102|
75475143|NCT01991678|Drug|120 mg/m2 NKTR 102|
75475144|NCT01991678|Drug|50 mg/m2 NKTR 102|
75475145|NCT01991691|Device|Tablet-based questionnaire|tablet-based patient reported outcomes (TabPRO)
75475146|NCT01991717|Device|Victus|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
75475147|NCT01991717|Device|Conventional Phaco|The capsulotomy as well as the lens fragmentation is performed manually.
75799707|NCT01203228|Other|Myeloablative conditioning|"Busilvex®:~12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available):~Busulfan:~16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Cyclophosphamide:~120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW"
75799708|NCT01203696|Drug|Amlodipine|For patient with suboptimal angina control: oral 2.5-10mg daily
75799709|NCT01203696|Drug|Amlodipine|For patient with suboptimal BP control: 2.5-10mg daily po
75799710|NCT01204008|Procedure|conservative discectomy|a smaller incision with removal of the disc fragment with little invasion of the disc
75799711|NCT01204008|Procedure|aggressive discectomy|a large open incision with aggressive removal of the disc fragments and curettage of the disc space
75799712|NCT01203306|Drug|bevacizumab + octreotide LAR + capecitabine|long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
75937705|NCT03512769|Device|Restful Jaw Device|The Restful Jaw device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. If needed, the dental assistant also holds the jaw in a slightly forward position to maintain an open airway. This device replicates the dental assistant in holding the jaw during dental procedures.
75937706|NCT03512691|Behavioral|Information on CVD Risk|Respondents will be provided three types of information on CVD risks: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent's age and sex only. After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI.
75475148|NCT01991756|Device|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
75672270|NCT00621608|Procedure|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
76027267|NCT03097835|Drug|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
76027268|NCT03097835|Drug|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
76027269|NCT03097835|Other|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
75341832|NCT04386811|Other|Placebo|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
75341833|NCT04366999|Procedure|LSG|The operation was started by replacing the 12-mm bladed trocar, and two additional trocars were inserted. LigaSure was used to dissect the omental pieces of the great curvature and any adhesions of the pancreas and stomach. A 36-French orogastric tube was then placed in the stomach. Gastric transection was started at a distance of approximately 4cm from the pylorus using a stapler (EndoGIA™; Covidien). All stapling was performed with yellow/green/black/blue cartridges. The staple line was reinforced with continuous barbed prolene sutures, and any sites of bleeding were closed with the LigaSure device. The portion of the stomach that had been transected from the pylorus was extracted through the 12-mm trocar site.
75475149|NCT01991769|Behavioral|47 min moderate intensity training|
75475150|NCT01991769|Behavioral|exercise healthy volunteers|
75799713|NCT03840018|Other|Letter by post to patients|Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
75799714|NCT03839316|Device|tDCS|A constant current stimulator (ZMI Electronics LTD.,Taiwan,2012) will be used through 2 saline-soaked surface gel-sponge electrodes (22 cm2 active area). Real stimulation consisting of thirty minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex (C3 and C4 of the international 10-20 EEG electrode system).
75475151|NCT01991769|Behavioral|control; no exercise training|
75475152|NCT01991782|Other|Telemedicine|Patients in the telemedicine cohort will have two follow-up visits (at 6 weeks and 6 months) through video calls.
75475153|NCT01991834|Procedure|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
75475154|NCT01991834|Drug|Cefazolin|Intravenous administration of 1 g of cefazolin
75799715|NCT03839316|Device|sham tDCS|For sham tDCS, the same electrode positions were used. The current was ramped up to 2 mA and slowly decreased over 30 seconds to ensure the typical initial tingling sensation
75799716|NCT01203384|Drug|CHF5074 1x|oral tablet, 1x, once a day in the morning for 14 days
75799717|NCT01203384|Drug|CHF5074 2x|oral tablet, 2x, once a day in the morning for 14 days
75799718|NCT01203384|Drug|CHF5074 3x|oral tablet, 3x, once a day in the morning for 14 days
75799719|NCT01203384|Drug|Placebo|oral tablet, placebo, once a day in the morning for 14 days
75799720|NCT05669508|Device|RISES-T System|Non-invasive closed-loop electrical stimulation of the spinal cord through the skin
75799721|NCT05669508|Other|Occupational/Physical Therapy|Exercise therapy to improve function of upper and/or lower limbs
75475155|NCT01991834|Drug|Placebo|Intravenous administration of saline sterile solution
75937707|NCT03512691|Behavioral|Lottery Incentive|Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
76089092|NCT04127253|Behavioral|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
76089093|NCT03029338|Biological|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
76089094|NCT03283605|Radiation|SBRT|SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
75937708|NCT02300337|Device|Reduce Cuff pressure|We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
75937709|NCT02300415|Biological|blood sample|Dosage of presepsine
75475156|NCT01991847|Behavioral|Physical activity|The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
75475157|NCT01991886|Device|Vapotherm Precision Flow|Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
75799722|NCT03724968|Drug|Nivolumab|Nivolumab will be given by vein on day 1 of each cycle.
75799723|NCT03724968|Drug|Relatlimab|Relatlimab will be given by vein on day 1 of each 28-day cycle
76089095|NCT03283605|Drug|Durvalumab|Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
75475158|NCT01991899|Biological|MMR Bio-Manguinhos|1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline
75475159|NCT01991899|Biological|MMR GlaxoSmithKline|390 children will receive 0,5 ml MMR GlaxoSmithKline
75475160|NCT01991912|Procedure|open lumbar decompression|A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
75475161|NCT01991938|Drug|VS-5584|
75475162|NCT01991951|Drug|warfarin|
75475163|NCT01991964|Other|laryngeal ultrasound|
75475164|NCT01992029|Other|Clinical evaluation|Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12
75475165|NCT01992029|Procedure|Muscular biopsy|Muscular biopsy at M0
75475166|NCT01992029|Procedure|Lumbar puncture|Lumbar puncture at M0 and M12
75652343|NCT02867111|Other|Attractant Substance|Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa
75799724|NCT03724968|Drug|Ipilimumab|Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).
75799725|NCT03724812|Device|Portico Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach
75799726|NCT01204086|Drug|Venlafaxine|The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
75799727|NCT01204086|Drug|Fluoxetine|The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
75799728|NCT03840096|Device|Breg Flex|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation using Breg Flex device on the affected leg to guide and monitor of knee HEP during the 6 weeks prior to surgery and 12 weeks following surgery.
75799729|NCT03840252|Diagnostic Test|3D gait analysis|Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics
75799730|NCT03840252|Diagnostic Test|rsfMRI|MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).
75799731|NCT03840252|Diagnostic Test|Montreal Cognitive assesment (MoCA)|Standard clinical questionnaire
75937710|NCT03510039|Behavioral|Early device / Follow up|"Early device:~Standardized Nursing Interview (30 minutes) with the Third Party Person Measure and follow the anxiety of the Third Party by rating the AMDP-AT scale, on D0 and D7~Telephone follow-up by nurses:~Interviews built and standardized, to M2, M4 and M6 Quantification of the AMDP-AT anxiety scale on each call"
75937711|NCT03510039|Other|Usual care|"Group Before : usual care by nurses"
75937712|NCT03515577|Procedure|Computed Tomography|Undergo PET/CT
75937713|NCT03515577|Drug|Fluciclovine F18|Given fluciclovine F18
75937714|NCT03515577|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
75475167|NCT01992029|Procedure|Blood sampling|Blood sampling at M0, M4, M4, M8 and M12
75475168|NCT01992029|Other|Neurological assessments|Neurological assessments (MRC score and cognitive scales: MMS and BREF)
75475169|NCT01992029|Procedure|Neuro-muscular biopsy and lumbar puncture|Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy
75475170|NCT01992029|Procedure|Muscular biopsy|Muscular biopsy for patient explored for myopathy
75652344|NCT02867111|Procedure|ICSI|An in vitro fertilization procedure in which a single sperm is injected directly into an egg
75937715|NCT03515577|Other|Laboratory Biomarker Analysis|Correlative studies
75341834|NCT04366999|Procedure|LRYGB|LRYGB is performed as described as standard. In brief, smaller stomach pouch of 10 to 20 ml or larger stomach pouch of 25 to 35 ml were created according to the metabolic status of the patients. The jejunum at approximately 150 cm distal site was dragged up and connected (anastomosed) to the remnant stomach.
75341835|NCT04366999|Procedure|OAGB-MGB|"Four ports are placed generally. Thepaddleretractor is used to retract the liver. The GIA stapler divides the stomach at the junction of the body and antrum, at a location where the jejunal loop can be brought up comfortably. With 4-6 lines of staples that seal the gastric pouch. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 150 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to anastomose the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel. The inside of the anastomosis is inspected for bleeding before final closure. The stapler then closes the anatomosis."
75341836|NCT00629018|Biological|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
75799732|NCT01567176|Biological|Blood sample|It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
75799733|NCT03842280|Device|Diaphragm ultrasound assessment & Esophageal pressure measurement|Diaphragm ultrasound assessment and/or Esophageal pressure measurement before, during and after spontaneous breathing trial
75799734|NCT03842202|Drug|Semaglutide|Participants will receive gradually increasing doses of semaglutide (subcutaneous [s.c.], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
75937716|NCT03515577|Procedure|Positron Emission Tomography|Undergo PET/CT
75937717|NCT02303379|Other|Continuous Endurance Training|Endurance training with constant work load 31min at 65-75% Hrmax
75937718|NCT02303379|Other|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
75937719|NCT02303379|Other|High-intensity interval training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
75341837|NCT00629018|Drug|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
75937720|NCT03509961|Diagnostic Test|NGS-MRD|Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.
75475171|NCT01992029|Procedure|Blood sample|Blood sample for qRT PCR, detection and quantification for miRNA
75475172|NCT01992029|Device|Cervical spinal cord and brain MRI|ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
75672271|NCT00621608|Procedure|Placebo Hyperbaric Oxygen Chamber|Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
75672272|NCT02652546|Drug|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
75799735|NCT03842202|Drug|Placebo|Participants will receive once weekly injections of semaglutide matched placebo.
75937721|NCT03509961|Drug|Myeloablative allogeneic HCT with a non-TBI conditioning regimen|"Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant"
75937722|NCT03515499|Behavioral|Incentives|Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
75799736|NCT01201746|Procedure|Delayed treatment|Scaling, Root Planing and oral hygiene instruction
75937723|NCT03515499|Behavioral|Medication device monitoring and reminders|Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
76027270|NCT03097601|Diagnostic Test|ELR+CXCL cytokines levels are of sunitinib response|Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
76027271|NCT05058755|Drug|tislelizumab, azacytidine, lenalidomide|"tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days."
76027272|NCT05058755|Drug|tislelizumab, etoposide, pegaspargase|"tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days"
76027273|NCT05044247|Procedure|ESP blocks|ultrasound and fluoroscopy to identify the spread of drug
76027274|NCT05044169|Drug|Broncho-Vaxom|administration for 6 months after remmission
75475173|NCT01992042|Drug|Fluvastatin|HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
75475174|NCT01992042|Drug|Pimonidazole|
75937724|NCT03512613|Device|c-FLOW 3310-P|"c-FLOW 3310-P is a continuous, non-invasive monitor of cerebral deep tissue blood flow used to measure relative changes in blood flow.~The device monitors regional micro circulatory blood flow in tissues, by using sensors placed near the area of interest."
75799737|NCT01201746|Procedure|Periodontal therapy|Scaling, root planning and oral hygiene instructions
76089096|NCT03283605|Drug|Tremelimumab|Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
75475175|NCT01992055|Behavioral|Goal Management Training|Participants will be randomly assigned to the GMT Treatment. The GMT cognitive rehabilitation intervention program will be administered in group format, consisting of 8 sessions, including structured psychoeducation, relaxation training, and stepwise learning of GMT.
75799738|NCT01201824|Procedure|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
75799739|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
75799740|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
75799741|NCT01201902|Biological|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
75799742|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
75799743|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
75799744|NCT01204164|Drug|TG02 citrate|TG02 citrate capsules given orally.
75799745|NCT01204164|Drug|Carfilzomib|Carfilzomib per PI
75799746|NCT01204164|Drug|Dexamethasone|Dexamethasone (Oral or IV)
75799747|NCT01203462|Other|Probiotic strain of Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
75799748|NCT01203462|Other|No Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
75799749|NCT03837912|Behavioral|Patient reported safety experiences fed back to PC providers|The intervention will involve three key stages: a) Measurement: Patients will be invited to complete the Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC) questionnaire using a tablet-computer. b) Feedback: Using a bespoke online tool, the information will be processed and presented to each centre in the form of a Feedback Report, which will offer comparisons with other centres along with a set of recommendations for addressing the problems identified. c) Action planning and change: centres will form an Action Planning Team, which will be responsible for analyzing the report, considering which area(s) should be improved, and developing, implementing and monitoring an action plan to address the safety problems identified.
75799750|NCT01206036|Drug|Docetaxel|DL 1: Docetaxel 60mg/m^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
75799751|NCT01206036|Drug|Temsirolimus|DL 1: Docetaxel 60mg/m^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
75799752|NCT01206114|Other|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
75799753|NCT01206114|Other|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
75799754|NCT03722784|Device|Invigor A (test)|silicone hydrogel lens
75799755|NCT03722784|Device|Invigor B (control)|silicone hydrogel lens
75799756|NCT01204320|Procedure|Paclitaxel-coated Balloon|POBA
75937725|NCT03509805|Diagnostic Test|polysomnography|
75937726|NCT02297295|Other|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
75937727|NCT02303457|Procedure|CO2 Laser surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
75937728|NCT02303457|Procedure|Open Surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
76117204|NCT04432740|Procedure|Conservative Treatment of Distal Radius Fracture|The purpose of this prospective randomized study was to compare a new reverse sugar tong splint technique that does not immobilize the elbow with a below-arm cast, in terms of patient radiological and clinical outcomes and the ability to maintain fracture reduction.
75475176|NCT01992055|Behavioral|Education & relaxation training|The Education & Relaxation Training Control Group program will also be administered in group format, consisting of two sessions, including structured psychoeducation and relaxation training. Participants assigned to the Control condition will be offered the opportunity to complete the full GMT program following the completion of the study.
75475177|NCT01992081|Device|Automated telehealth system|The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
75475178|NCT01992081|Other|Usual care|Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
75799757|NCT01204320|Device|Paclitaxel-eluting Stent|Stenting
75799758|NCT01298154|Other|Dietary intervention|Dietary treatments with beverages
75799759|NCT03722238|Drug|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
75819683|NCT02256280|Drug|Sugammadex|"Sugammadex will be diluted in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~If Post tetanic count = 1-15: 4 mg/kg~If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg"
75937729|NCT02300649|Drug|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
75937730|NCT02300649|Drug|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
75937731|NCT03512379|Device|TIANJI Robot|A robotic system for spinal surgery
75937732|NCT03512379|Device|Fluoroscopy|For fluoroscopy-based free hand surgery
75937733|NCT03512379|Device|Navigation|For navigation-assisted spinal surgery
75937734|NCT02297451|Procedure|Proximal radial/ulnar artery as inflow|Proximal radial/ulnar artery used as inflow
75652345|NCT04253366|Device|Clinical investigation device class IIa not marked CE|Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients will be ready for the MammoWave exam. The exam will be composed of two phases: the data acquisition and the data processing. During the acquisition that should takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
75799760|NCT02725554|Device|StimRelieve Halo System|The StimRelieve Halo System is intended as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic migraine as defined by the Third edition of the International Classification of headache disorders (ICDH-3). The system provides treatment by delivering small controlled electrical pulses to the occipital and supraorbital nerves, as it has been shown that for chronic migraine headaches the response to combined systems appears to be substantially better than occipital nerves stimulation alone.
75937735|NCT02303535|Procedure|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
75341838|NCT00629018|Biological|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
75341839|NCT04357873|Drug|pembrolizumab; vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
75475179|NCT01992120|Other|Debriefing of high-fidelity sepsis simulation scenarios|Educational intervention
75475180|NCT01992120|Other|Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios|
75475181|NCT01992133|Dietary Supplement|Vitamin D3|
75799761|NCT01203540|Drug|NAABAK eyedrops|
75475182|NCT01992133|Dietary Supplement|Placebo|
75475183|NCT01992146|Drug|Target-controlled naloxone-infusion|
75652346|NCT04134975|Procedure|Spine surgery|surgery with pedicle screw placement between L1 and S1
75799762|NCT01203540|Drug|Saline eyedrops|
75799763|NCT01203618|Drug|Farletuzumab|Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
75799764|NCT03819036|Other|Questionnaires|Day 0 : Satisfaction questionnaire immediately after consultation Day 1, Day 3 and Day 7 : Telephone follow-up
75799765|NCT05622786|Other|HIGT - physical rehab|High Intensity Gait Training using treadmill and overhead harness for fall prevention
75799766|NCT05622786|Other|Low intensity physical therapy|Low Intensity Gait Activities
75799767|NCT01298232|Other|Cardiophonogram|Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure
75799768|NCT01206270|Drug|Testosterone undecanoate|Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
75799769|NCT01206270|Drug|Castor Oil|4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
75799770|NCT01298310|Drug|Xylocaine|1 mg/mL solution for injection
75799771|NCT01298310|Drug|Xylocaine|10 mg/mL solution for injection
75937736|NCT02303535|Procedure|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
75937737|NCT02303613|Other|Mapping|Mapping of current triage situation regarding 30 days mortality
75475184|NCT01992146|Drug|Placebo|
75475185|NCT01992198|Drug|cefoperazone + metronidazole|"1.Clinical parameters (2 of 3):~1)temperature<37.8℃ or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h"
75475186|NCT01992198|Procedure|oral care by chlorhexidine gluconate|oral care by 0.2% chlorhexidine gluconate twice daily
75475187|NCT01992198|Procedure|enteral nutrition|
75475188|NCT01992198|Drug|Somatostatin|
75475189|NCT01992198|Drug|Meropenem|"All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.~1.Clinical parameters (2 of 3):~1)temperature<37.8℃ or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h"
75475190|NCT01992211|Drug|Rosuvastatin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
75475191|NCT01992211|Drug|Metformin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
75799772|NCT01298310|Drug|Placebo|solution for injection
75937738|NCT02739321|Device|Sound to Sleep System|Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
75341840|NCT00199238|Drug|Rupatadine Fumarate|
75341841|NCT05670067|Procedure|maxillary tuberosity bone graft (autogenous graft)|the usage of maxillary tuberosity as source of autogenous graft supplying the needed cells for bone regeneration
75937739|NCT02449161|Drug|MPA|
75937740|NCT02449161|Drug|placebo|
75937741|NCT02303691|Behavioral|Attention Bias Modification|Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
75937742|NCT02303691|Behavioral|Neutral Training|A control version of computerized attention training.
75937743|NCT03515421|Device|Frazier 3 Verio|In vitro diagnostic device (IVDD)
75341842|NCT05670067|Procedure|Bone graft (xenograft)|xenograft is bone graft material that is obtained from porcine, bovine or equine source
75341843|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 1-4
75672273|NCT02652546|Drug|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
75341844|NCT00630734|Drug|Darunavir|Darunavir 600mg by mouth twice daily on days 12-18
75341845|NCT00630734|Drug|Ritonavir|Ritonavir 100mg by mouth twice daily on days 12-18
75341846|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 15-18
75341847|NCT00630734|Other|Washout|Washout (no medication) on days 5-11.
75672274|NCT02652546|Drug|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
75672275|NCT02652546|Drug|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
75672276|NCT02830373|Device|LVIS stents|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
75799773|NCT01298388|Other|medical chart review|
75799774|NCT01298388|Other|questionnaire administration|
75799775|NCT01298388|Other|study of socioeconomic and demographic variables|
75937744|NCT03515421|Device|Frazier 3 UltraPlus|In vitro diagnostic device (IVDD)
75341848|NCT05666323|Behavioral|Single Text Messaging (TM1)|Receives single text message
75341849|NCT05666323|Behavioral|Patient Navigation (PN)|Receive phone calls from trained MAPS counselors
75341850|NCT05666323|Behavioral|Multiple Text Messaging (TM+)|Receives multiple scheduled text messages
75341851|NCT05665933|Behavioral|ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION|Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
75341852|NCT01799096|Dietary Supplement|Sucrose|Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
75341853|NCT01799096|Dietary Supplement|Aspartame|Intensely sweetened soft drink (no energy content)
75341854|NCT03005431|Behavioral|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
75341855|NCT05516017|Device|Vestibular Electrical Stimulator and Pinhole Glasses|"It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.~The pinhole glasses are made of 2 pieces of opaque black plastic material with a total of 113 holes on each side. The opaque black plastic is 1.7 mm thick, 4.5 cm wide, and 5.5 cm long.~The holes in the opaque black material are arranged horizontally in 11 rows from top to bottom. The diameter of each hole is 1.1 mm, the horizontal distance of the holes from each other is 4.5 mm, and the vertical distance is 3.5 mm."
75341856|NCT05516017|Device|Vestibular Electrical Stimulator|It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.
75341857|NCT01799174|Procedure|UVA-1 Phototherapy|
75341858|NCT01799174|Procedure|Placebo|
75341859|NCT05644249|Drug|Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy|Each course of combined treatment will start with PIPAC (a pressurized aerosol containing cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 diluted in NaCl 0.9% applied through the nebulizer inside the abdominal cavity during laparoscopy). Fourteen days afterward 2 cycles of systemic FOLFOX chemotherapy will be applied within 28 days. The interval between combined treatment courses will be 14 days.
75341860|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
75341861|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
75341862|NCT00686582|Procedure|Blood Draw Only|
75799776|NCT01298466|Drug|Pregabalin|The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
75799777|NCT03837990|Drug|Helicobacter Pylori eradication therapy|Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
75799778|NCT01206348|Drug|Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide|Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
75799779|NCT03818958|Other|blood sampling|blood sampling
75937745|NCT02297529|Drug|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
75937746|NCT02303769|Drug|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
75937747|NCT02303769|Drug|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
75937748|NCT04464525|Drug|Omecamtiv mecarbil|Film-coated tablet administered orally.
75341863|NCT02223637|Biological|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
75341864|NCT00631358|Drug|Maxidex|Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
75937749|NCT03509649|Procedure|Cervical spine manipulation|High-velocity low-amplitude thrust joint manipulation to the cervical spine
75937750|NCT02303847|Drug|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
75937751|NCT03509493|Diagnostic Test|FibriCheck|Digital health application
75937752|NCT03512145|Device|VIPUN Balloon Catheter|Gastric motility is recorded continuously with the VIPUN Balloon Catheter for 10 hours.
75937753|NCT02297607|Dietary Supplement|Tube Feeding|
75937754|NCT03509415|Diagnostic Test|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
75341865|NCT00631358|Other|No treatment|Healthy normal control group receiving no treatment
75341866|NCT02248753|Drug|Pharmacological cardioversion - Flecainide|
75652347|NCT04290533|Device|Active High Definition transcranial Direct Current Stimulation (HD-tDCS)|TDCS is a non-invasive neuromodulation technique that modulates membrane potentials by means of small electrical currents. Electrical currents induced by tDCS electrodes produce an electrical field that modulates the excitability of brain areas. In the present HD-tDCS montage, one anodal electrode and four return electrodes are applied. Hereby, the anodal electrode modulates the excitability of the targeted area, whereas the other 4 electrodes return electrical currents that flow away from that area. Direct currents will be transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2) with a current intensity of 1.5 mA. The HD-tDCS session will last for 20 minutes in total, with a 60 sec ramp at the beginning and end of the session. The electrodes will be filled with conductive gel and plugged into an EEG cap, with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system).
75799780|NCT03836820|Other|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
75799781|NCT03836820|Other|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
75475192|NCT01992211|Drug|BCWP_C003|Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
75799782|NCT03836820|Other|Clinical Pilates and Aerobic Exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
75799783|NCT05622240|Drug|99mTc-MIRC213|99mTc-MIRC213 were intravenous injected into the patients before the wholebody and SPECT/CT scans
75937755|NCT02297685|Device|Sham Transcutaneous nerve stimulation|The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
75937756|NCT02297685|Device|Transcutaneous nerve stimulation|The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.
75937757|NCT02297685|Device|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
76089097|NCT03814564|Device|NIRS monitoring|Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
76089098|NCT01895062|Device|Airway Management System (AMS)|"The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway."
76089099|NCT04121013|Other|mothership|Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence
76089100|NCT04126707|Drug|[14C] HQP1351|Orally, single dose of 30mg
75341867|NCT02248753|Procedure|Electrical cardioversion|
75341868|NCT02248753|Drug|Metoprolol|
75341869|NCT02248753|Drug|Verapamil|
75475193|NCT01992224|Other|early mechanical Ventilation|"Fulfillment of three or more criteria below:~respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation"
75475194|NCT01992224|Other|Conventional Mechanical Ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
75475195|NCT01992250|Device|Visica 2 Treatment System|Cryoablation
75475196|NCT01992263|Dietary Supplement|Vitamin D (600 IU)|Daily oral dose for 12 months
75341870|NCT02248753|Drug|Digoxin|
75341871|NCT02248753|Drug|Pharmacological cardioversion - Amiodarone|
75475197|NCT01992263|Dietary Supplement|Vitamin D (2000 IU)|Daily oral dose for 12 months
75475198|NCT01992263|Dietary Supplement|Vitamin D (4000 IU)|Daily oral dose for 12 months
75475199|NCT01992263|Other|Placebo|Daily oral dose for 12 months
75475200|NCT01992276|Biological|CR8020|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
75475201|NCT01992276|Biological|CR6261|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
75475202|NCT01992276|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1
75475203|NCT01992289|Drug|EDI200|Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
75341872|NCT00687674|Drug|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
75341873|NCT00687674|Drug|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM & 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
75341874|NCT00687674|Drug|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
75341875|NCT03005197|Device|Laser Doppler Flowmetry|
75799784|NCT03818568|Dietary Supplement|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
75799785|NCT01204476|Biological|Cixutumumab|Given IV
75937758|NCT02297763|Drug|quetiapine|"patient body weight <50kg : quetiapine 12.5mg patient body weight >=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water)."
75937759|NCT02297763|Drug|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
75937760|NCT03511989|Device|Bone borne distractor|Bone borne distraction device
75937761|NCT03511989|Device|Tooth borne distractor|Tooth borne distraction device
75937762|NCT03511989|Procedure|Segmental LF1 Osteotomy group 1|
75937763|NCT03511989|Procedure|Segmental LF1 Osteotomy group 2|
75937764|NCT03511989|Procedure|Segmental LF1 Osteotomy group 3|
75937765|NCT03511911|Diagnostic Test|evaluation of pelvic floor muscle function through the PHENIX instrument|the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.
75937766|NCT03511911|Diagnostic Test|vaginal palpation|vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength
75937767|NCT02303925|Device|NESTER COILS|
75652348|NCT04290533|Device|Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)|For the sham-condition, the placement of the electrodes was identical to active HD-tDCS stimulation with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system). The direct current, also transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2), was increased in a ramp-like fashion over 60 seconds until it reached 1.5 mA. Directly after ramp-up, the current intensity was gradually switched off over 60 seconds, followed by 20 minutes without active stimulation. Sham procedures for tDCS mimic the transient skin sensation at the beginning of active HD-tDCS, without producing any conditioning effects on the brain. Consequently, participants are reliably blinded for sham tDCS.
75799786|NCT01204476|Drug|Everolimus|Given PO
75799787|NCT01204476|Other|Laboratory Biomarker Analysis|Correlative studies
75799788|NCT01204476|Drug|Octreotide Acetate|Given IM
75937768|NCT02304003|Other|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
75937769|NCT02304003|Other|Standard Care|Standard follow up in primary care.
75937770|NCT03511833|Drug|Morphine|IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----> 0.1 ml/kg
75937771|NCT03511833|Drug|Ketamine|IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---> 0.02ml/kg
75937772|NCT03515343|Diagnostic Test|Screening colonoscopy according to resect-and-discard strategy|This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).
75937773|NCT03509337|Diagnostic Test|shear-wave elastography|Measurement by shear-wave elastography of the nerve, muscle and ulnar tendon before and after the tension of the ulnar nerve
75937774|NCT03511755|Device|Transdermal Electrical Neuromodulator (TEN)|Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7).
75799789|NCT01204476|Other|Pharmacological Study|Correlative studies
75799790|NCT02927080|Drug|ACE-083|Recombinant fusion protein.
75937775|NCT02696798|Drug|Ixekizumab|Administered SC
75937776|NCT02696798|Drug|Placebo|Administered SC
75937777|NCT02304081|Drug|Saxagliptin|competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
76089101|NCT01896544|Dietary Supplement|Cholecalciferol|7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
75799791|NCT02927080|Drug|ACE-083 or placebo|Recombinant fusion protein or normal saline.
75799792|NCT03633292|Drug|Antiseptic clorhexidine gel (Lacer, Barcelona, Spain)|"Together with the dispensing container, the dosing and dosage of the gel in research will be attached, with the description of the pharmaceutical form, packaging and labeling of the product. Packages with 8 ml of the gel under investigation, sufficient treatment for 1 month of applications. Posology: After tooth brushing, apply a small amount of gel on the fingertip of a freshly washed finger and spread it over the gum, doing a gentle massage, for 15 , 2 times a day after proper oral hygiene and it is recommended not to ingest no liquid or food until after half an hour of use."
75799793|NCT03633292|Drug|Master formula of aloe vera gel 80%|Blindly and in the same container as chlorhexidine, patients will be instructed to apply aloe vera gel on the gums and mucous membranes once the orthodontic appliances have been cemented
75799794|NCT03688672|Device|Apioc Contact Lens Design|Novel soft contact lens design.
75799795|NCT04630210|Drug|Letrozole|Letrozole 2.5 mg/day oral until surgery
75799796|NCT04630210|Drug|Atezolizumab|Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
75799797|NCT04613752|Device|diaphragmatic function measurements and diaphragmatic ultrasound|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
75799798|NCT02051374|Procedure|Decompression alone|
75937778|NCT02304081|Drug|Placebo for Saxagliptin|
75341876|NCT00687830|Drug|Polyethylene Glycol afternoon|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
75937779|NCT03511677|Device|Insole|Customized insole
75937780|NCT03511677|Device|Placebo Insole|Placebo flat insole
75937781|NCT03515265|Other|Fiber reinforced resin composite restoration|a type of resin composite with improved strength due to the fiber's action
76089102|NCT01896544|Dietary Supplement|Placebo|7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
76089103|NCT04120623|Drug|Dapagliflozin 10 MG|Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).
76089104|NCT04120623|Drug|Insulin Aspart|Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)
76089105|NCT01767467|Biological|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
75652349|NCT04914260|Other|Questionnaire|The participants will have to fill in an on-line questionnaire regarding quality of life, their level of knowledge of the rehabilitation through sport program and their level of satisfaction toward this program.
75652350|NCT04135053|Biological|Lyophilised Neisseria lactamica|Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
75799799|NCT02051374|Procedure|Decompression followed by fusion with instrumentation|
75799800|NCT01382368|Drug|Sildenafil|Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
75799801|NCT04563442|Other|complication|complication co morbidities
75799802|NCT04546828|Drug|Gemcitabine, Cisplatin, and Nab-Paclitaxe|"Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days ."
75799803|NCT01382290|Procedure|MRI|
75937782|NCT03515265|Other|Microhybrid resin composite restoration|a type of conventional resin composite
75937783|NCT02304237|Drug|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
75937784|NCT02304237|Drug|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
75937785|NCT03515187|Drug|0.3% sodium hyaluronate ophthalmic solution|one to two drops in eye, four times per day
75937786|NCT03515187|Drug|0.1% sodium bromide solution|one to two drops in eye, twice per day
75937787|NCT03515187|Other|Meibomian gland massage|Physiotherapy
75937788|NCT03515187|Other|Placebo|Vehicle
75937789|NCT02301117|Drug|TAS-102|
75937790|NCT02394938|Other|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
75937791|NCT02301195|Other|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
75937792|NCT02301195|Other|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
76089106|NCT01767467|Drug|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
76089107|NCT02988232|Drug|Sogyeonghwalhyeol-tang|herbal extract
76089108|NCT02988232|Drug|Placebo|extract powder with same appearance, odor and color as SGHH
76089109|NCT04758897|Drug|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
76089110|NCT01931878|Drug|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
76089111|NCT01931878|Drug|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
76089112|NCT01932112|Drug|Adenosine arm|After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
76089113|NCT02987452|Other|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
76089114|NCT02987452|Other|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
76089115|NCT02987452|Other|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
75652351|NCT04252976|Behavioral|Ethical Living|Ethical principles based on Yoga philosophy, including contents of Yamas and Niyamas.
75652352|NCT04252976|Behavioral|Yoga Exercises|Ujjaii breathing and simple yoga asanas
75652353|NCT04252976|Behavioral|Mantra Meditation|Meditation with mantras
75652354|NCT02621697|Other|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
75652355|NCT02621697|Other|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
75937793|NCT02395094|Behavioral|Child Life|"Child Life preparation in surgical daycare can include:~role-play using dolls and medical equipment (either toy doctor kits or true medical materials)~the use of books/storyboards that show pictures of operating room and daycare routines~teaching & rehearsing coping and relaxation skills such as deep breathing and guided imagery~age-appropriate explanation of what to expect throughout the day in SDCU"
75652356|NCT02621541|Device|PET/CT|
75652357|NCT04862624|Behavioral|Catalina Story-Based Web-App|"Latinas in the experimental group will view a story-based web-app featuring a character named Catalina and psycho-therapeutic modules to motivate them to take action and get help for their symptoms of depression and/or anxiety."
75652358|NCT04862624|Behavioral|Attention Control Web-App|Latinas in the attention control group will view non-story based media that is informational.
75652359|NCT00975689|Drug|N-Acetyl Cysteine|900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).
75799804|NCT01382134|Drug|Aspirin, desmopressin|Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
75652360|NCT05329298|Drug|BPI-361175|Subjects will receive BPI-361175 until disease progression
75652361|NCT02621385|Drug|tradipitant|test agent
75652362|NCT02621385|Drug|Midazolam|substrate for drug-drug interaction assessment
75672277|NCT04210856|Other|Contemplative landscape exposure|landscapes classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to non-contemplative ones.
75672278|NCT02652234|Drug|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
75672279|NCT02652234|Drug|Chemotherapy|
75799805|NCT01382134|Drug|Placebo, desmopressin|Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
75799806|NCT01298856|Procedure|hydrotherapy|hydrotherapy and ankle taping and land-based
75799807|NCT03829176|Genetic|Whole Genome Sequencing|Participants in this arm will have their sample analyzed by whole genome sequencing (WGS), and a report will be included in their medical record. Analysis will be phenotype-driven (gene list will be curated based on primary indication for testing and other available medical history information), and may include genes on ACMG 59 list if participant elects for these results. This report will include pathogenic, likely pathogenic, and suspicious VUS results identified in the genes analyzed.
75799808|NCT05077488|Device|Juvéderm® VOLIFT™ with Lidocaine|Sterile gel in disposable syringe
75799809|NCT05668572|Biological|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30mcg, 40mcg, 60mcg, 40mcg, 20mcg, 20mcg, 20mcg, 20mcg and 20mcg, respectively, totaling 270mcg of antigens. A 3-dose regimen administered at months 0, 2 and 6.
75799810|NCT05668572|Biological|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）|0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens
75937794|NCT02304315|Biological|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
75937795|NCT02304315|Biological|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
75937796|NCT02400320|Drug|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
75937797|NCT02400320|Drug|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
75937798|NCT02400320|Other|Saline|Saline
75937799|NCT03511443|Diagnostic Test|hsRDT|Testing highly sensitive RDT detection for low parasitemia
75937800|NCT03511365|Biological|Probiotic Formulation VSL#3|Probiotic VSL#3 administration.
75937801|NCT02297919|Behavioral|Effectiveness of Internet Based Obesity Control Programme|
75937802|NCT02297997|Drug|cetylpyridinium chloride|Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
75937803|NCT02297997|Drug|Placebo|Control group takes the placebo for the same period.
75937804|NCT03511287|Other|Inspiratory Muscle Training|Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
75341877|NCT00687830|Drug|Polyethylene Glycol morning|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
75937805|NCT03509103|Other|Electronic Partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
75937806|NCT02301273|Other|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
76089116|NCT04120389|Device|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)|wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.
76089117|NCT04120389|Procedure|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
75672280|NCT02830607|Device|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
75341878|NCT02248831|Device|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
75341879|NCT00687908|Drug|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
75341880|NCT00687908|Drug|Vehicle Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
75341881|NCT04028011|Diagnostic Test|Novel Wearable device|patient will wear novel wearable device overnight along with normal standard of care
75341882|NCT04002583|Diagnostic Test|Computer assisted ambulatory electroencephalogram|A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
75475204|NCT01992315|Device|Adipose-derived ECM|Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
75652363|NCT04135131|Other|pilates mat exercises and home exercises|Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
75652364|NCT00922766|Drug|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention [PCI] or coronary artery bypass graft [CABG] within 48 hours).
75652365|NCT04134897|Drug|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
75652366|NCT04134897|Drug|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
75652367|NCT04134897|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
75652368|NCT04134897|Radiation|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
75652369|NCT04134897|Procedure|Rectal cancer surgery|Laparoscopic or open total mesorectal excision
75799811|NCT03818646|Diagnostic Test|Functional Respiratory Imaging|Functional Respiratory Imaging (FRI) is a novel image based functional diagnostic tool that combines high-resolution CT scans (HRCT) at TLC and FRC with flow simulations (computational fluid dynamics - CFD) providing a 3D visualization and quantification of lung structure and function.
75799812|NCT03828240|Other|HIP fracture REhabilitation Programme for the elderly with hip fractures|Eight-week activity-based intervention for elderly with hip fractures; one intervention during the hospital stay, four interventions at the elderly's municipality.
75799813|NCT01206504|Biological|MGAWN1|Humanized monoclonal to West Nile virus. Dose=30mg/kg
75799814|NCT02410980|Drug|Tretinoin cream 0.1%|Assessment of the skin change
75799815|NCT03818490|Other|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes.
75799816|NCT01298934|Drug|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
75799817|NCT02374476|Device|Bipolar Ablation|Patients will undergo bipolar ablation if unipolar ablation unsuccessful
75799818|NCT02340468|Device|diffuse optical spectroscopy|diffuse optical spectroscopy
75799819|NCT02169726|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
75799820|NCT03818022|Procedure|Cryoneurolysis (Iovera)|Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
75799821|NCT01299012|Drug|Liraglutide|Liraglutide s/c 0.6mg once daily.
75799822|NCT02155920|Drug|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
75799823|NCT01204554|Drug|Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
75799824|NCT01981902|Device|Non-Invasive Optical Spectroscopic|Non-Invasive Optical Spectroscopic
75799825|NCT01206894|Procedure|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
75799826|NCT03818100|Radiation|Intensity modulated radiotherapy (IMRT)|Simultaneous integrated boost technique using IMRT: 48 Gray (Gy) and 40 Gy will treat tumour and breast tissue respectively, in 15 fractions over 3 weeks.
75799827|NCT03818100|Drug|Endocrine therapy|Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.
75799828|NCT03818100|Procedure|Breast conserving surgery|Surgery carried out using local protocol following completion of endocrine therapy.
75799829|NCT01301040|Drug|epirubicin, cyclophosphamide, docetaxel|"Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles."
75341883|NCT05626231|Behavioral|Gender-Affirming Psychotherapy (GAP) Training|"The GAP training is a modular online asynchronous training intervention designed to increase mental health providers' use of gender-affirming practices with GMY (ages 12-25). It was developed using community-engaged and human-centered design methods with key stakeholders (GMY, their caregivers, mental health providers). In this open trial, GAP training will be offered to mental health providers at a multisite mental health clinic in the U.S. (referred to as pilot site herein)."
75341884|NCT00689078|Drug|Prednisolone Acetate 1%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
76089118|NCT04120077|Dietary Supplement|EyePromise DVS, EyePromise DVS plus EyePromise EZTears|Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements
75652370|NCT04134897|Radiation|Radiotherapy|Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
76089119|NCT01897402|Biological|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
76089120|NCT01897402|Biological|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
76089121|NCT04126239|Other|Online survey - questionnaire|Online survey - questionnaire
76089122|NCT04122339|Drug|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
76089123|NCT02280226|Device|magnetic resonance imaging (MRI)|
76089124|NCT01897792|Dietary Supplement|Vitamin C|
75475205|NCT01992328|Drug|Immune Globulin|6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
75652371|NCT02621307|Dietary Supplement|Salba|
75652372|NCT02621307|Dietary Supplement|Flax|
75799830|NCT03818334|Drug|Cyclophosphamide|Cyclophosphamide 1000 mg/flask
76089125|NCT01897792|Dietary Supplement|Vitamin E|
76089126|NCT01897792|Dietary Supplement|Saline (for Vitamin C)|0.9% saline administered to mimic Vitamin C
75799831|NCT03818334|Drug|ATG|Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
75799832|NCT03817788|Drug|polyethylene glycol|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.
75799833|NCT03817788|Drug|sodium phosphate|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
76089127|NCT01897792|Drug|Placebo (for Vitamin E)|Sugar pill administered to mimic Vitamin E
76089128|NCT02982915|Biological|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
76089129|NCT02982915|Biological|Fluzone High Dose Vaccine|Intramuscular injection
76089130|NCT01933984|Drug|Bronchodilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
75475206|NCT01992341|Drug|AMG 386|Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
75475207|NCT01992341|Drug|Paclitaxel|Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
75652373|NCT02621307|Dietary Supplement|Control|
75652374|NCT04255472|Behavioral|WHO Caregiver skills training (CST) program|Caregivers are provided with tangible strategies to appropriately respond to their children's emotional regulation, engagement, and communication. Further, the program focuses on helping caregivers to develop their children's communication and adaptive skills while reducing challenging behavior by focusing on identifying the function of the behavior and learning to teach developmentally appropriate replacement skills. The WHO CST program includes nine group sessions delivered at a community venue (e.g., BHU, school, home) and three home visits: the first at entry prior to session 1, the second after session 4, and the third after the final group session. Training for program facilitators will be included prior to the delivery of the intervention.
75672281|NCT04167852|Behavioral|Daily text message|Patients will receive a daily text message stating how many days they have until or since their surgery.
75672282|NCT04167852|Behavioral|Mindfulness intervention|Patients will receive a link to mindfulness meditation intervention for ten minutes.
75799834|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
75799835|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
75799836|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
75799837|NCT01206972|Drug|Enoxaparin|daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
75799838|NCT03833232|Device|omentopexy with cyanoacrilate glue|apposition of omentum with cyanoacrilate glue on gastric section
76089131|NCT04126083|Drug|Lofexidine Oral Tablet|lofexidine 0.54 mg 4 times daily
76089132|NCT02282722|Other|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
76089133|NCT02282722|Other|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
76089134|NCT04393545|Device|hallux valgus night splint|The HV night splint holds the hallux in abduction in order to provide a correct position. The SP group was given splints consisting of a rigid polyethylene bar along the medial of the hallux, and soft polyform and Velcro fastener parts.
76089135|NCT04393545|Other|exercise|The exercises involved strengthening the AbdH (abductor hallucis) and plantar fascia muscles, and stretching the hallux
75937807|NCT02301273|Other|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
75652375|NCT04255472|Behavioral|Treatment as usual|WHO CST will be compared with TAU. TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets. Evidence-based mental health care is currently not available in primary healthcare centers. A complete record of services availed by the trial participants at tertiary mental healthcare center will be maintained by using an adapted Client Services Receipt Inventory (CSRI) for children with developmental disorders and delays at baseline and end point.
75652376|NCT02620995|Drug|sildenafil citrate|the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
75652377|NCT02620995|Other|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
75652378|NCT05313074|Biological|CoronaVac vaccine|An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
75652379|NCT04135209|Diagnostic Test|Optical coherence tomography angiography OCTA|Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
75652380|NCT04252898|Behavioral|Front-of-pack nutrition label Nutri-Score|The intervention consists of displaying the Nutri-Score on dishes and pre-packed foods.
75799839|NCT01299246|Procedure|Michigan Neuropathy Screening Instrument|Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
75799840|NCT01301196|Behavioral|Educational workshop|3h attendance at educational workshop plus self-monitoring
75799841|NCT03833076|Device|Medical device Procto|Medical device Procto presents itself as a translucent green gel with a typical smell.
75799842|NCT03833076|Device|Matching placebo|IP placebo presents itself as a translucent green gel with a typical smell.
75799843|NCT03817476|Drug|BI 425809 (Treatment T1)|Intended commercial formulation tablet from batch 1 (iCF1)
75799844|NCT03817476|Drug|BI 425809 (Treatment T2)|Intended commercial formulation tablet from batch 2 (iCF2)
75799845|NCT03817476|Drug|BI 425809 (Treatment R)|Trial formulation 2 tablet (TF2)
75475208|NCT01992367|Drug|ASLAN003 ACTIVE|This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
75652381|NCT02620839|Drug|Alpelisib|Given PO
75799846|NCT01299324|Device|BMAC infusion|Infusion of 60 mL of Bone Marrow Aspirate Concentrate
75799847|NCT01299402|Dietary Supplement|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
75799848|NCT01299402|Dietary Supplement|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
75799849|NCT02918292|Drug|Antithymocyte Globulin (ATG)|Administration of ATG will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.
75799850|NCT02918292|Drug|Fludarabine|Fludarabine dose will be 30 mg/m^2 IV daily for 5 days from Day -6 to Day -2.
75799851|NCT02918292|Drug|Cyclophosphamide|Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.
75799852|NCT02918292|Radiation|Total Body Irradiation (TBI)|TBI is to be delivered in a single dose of 200 cGy on Day -1.
75799853|NCT02918292|Procedure|Haplo HSCT|Eligible patients without a fully matched related or unrelated donor available will undergo haploidentical bone marrow transplant.
75652382|NCT02620839|Drug|Cisplatin|Given IV
75799854|NCT02918292|Drug|Tacrolimus|Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.
75799855|NCT02918292|Drug|Mycophenolate mofetil (MMF)|MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5.
75652383|NCT02620605|Drug|Late Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
75652384|NCT02620605|Drug|Early Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
75652385|NCT00696891|Biological|HBV-MPL vaccine|3-dose intramuscular injection
75652386|NCT00696891|Biological|Engerix™-B|3-dose intramuscular injection
75799856|NCT02918292|Drug|G-CSF|G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is > 1500 for 3 days.
75799857|NCT01207128|Drug|Voriconazole, micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
75937808|NCT02395016|Drug|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
75937809|NCT02395016|Drug|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
75652387|NCT00917852|Device|Gore Conformable TAG Thoracic Endoprosthesis|Endovascular stent graft
75799858|NCT01204866|Biological|Valortim and selected Components|"Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.~Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.~Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1~Histamine (1 mg/mL), positive control~Saline (0.9%), negative control"
75937810|NCT02395016|Other|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
75937811|NCT02298075|Drug|Eltrombopag|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
75341885|NCT00689078|Drug|Prednisolone Acetate 0.12%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
75475209|NCT01992471|Behavioral|Pre-test Assessment|Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
75652388|NCT02620449|Other|Diet|Participants will be fed a low-additive diet as the primary intervention
75652389|NCT00976391|Biological|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
75937812|NCT02298075|Drug|Romiplostin|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
75937813|NCT03515109|Procedure|Altis tape|placement of Altis tape through transobturator foramen bilaterally under epidural anesthesia
75937814|NCT03515109|Procedure|TVTO|placement of TVTO tape through transobturator foarmen bilaterally under epidural anesthesia
75937815|NCT02403050|Device|Fiducial markers|2 fiducial markers (Visicoils) to be placed in the tumor area
75937816|NCT03508947|Drug|WVE-210201|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
75799859|NCT01204866|Drug|Valortim and Selected Components|"• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~Only one subject will be skin tested in a single day.~The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively"
75799860|NCT01299558|Drug|fluticasone furoate//GW642444|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
75799861|NCT01299558|Drug|fluticasone furoate|Single IV dose of FF (250mcg)
75937817|NCT03508947|Drug|Placebo|Sodium Chloride
75937818|NCT02394782|Device|RebiSmart®2.0|Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
75937819|NCT02394782|Device|MSdialog™|Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
75937820|NCT04480268|Drug|PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy|"The PAXG regimen includes:~nab-paclitaxel 150 mg/m2 on day 1 and 15 of each cycle;~cisplatin 30 mg/m2 on day 1 and 15 of each cycle;~capecitabine 1250 mg/m2 on 1 day to 28 of each cycle;~gemcitabine 800 mg/m2 on day 1 and 15 of each cycle. Each cycle lasts 28 days. Patients are treated until maximal response, disease progression or unacceptable toxicity."
75937821|NCT03515031|Device|High Flow Nasal Cannula Oxygenation|Delivery of humidified and heated (37ºC) high flow oxygen
75937822|NCT03515031|Device|Venturi Mask Oxygenation|delivery of high flow oxygen
75937823|NCT03514953|Behavioral|Reduced Physical Activity|"Preliminary Phase (Baseline to Day 7): Subjects will begin wearing an accelerometer for 7 days to track physical activity and sleep patterns.~Experimental Phase 1 (Day 7 to Day 21): Participants will be required to reduce their step count by 5,000 steps per day and engage in no moderate-vigorous physical activity during this timeframe. Every 7 days subjects undergo the blood draw, vascular health measures and questionnaire assessments.~Experimental Phase 2 (Day 21 to 28): During the week of assessment, subjects will be asked to return to their normal physical activity patterns."
75937824|NCT02400398|Other|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
75341886|NCT00689078|Drug|Loteprednol Etabonate 0.2%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
75341887|NCT00689078|Drug|Placebo|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
75341888|NCT05590819|Device|repetitive transcranial magnetic stimulation(rTMS)|5 hertz(Hz), 1000 pulses, 90% RMT stimulation; 15 minutes per session; for a total of 10 sessions
75652390|NCT00976391|Drug|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
75672283|NCT02830529|Behavioral|MAD DASH|Participants were taught mindfulness meditation including body scan, loving kindness meditation and breathing exercises. The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
75672284|NCT02830529|Behavioral|DASH diet education|The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
75937825|NCT02301351|Other|Graphic Warning Label|All packs provided will include FDA-approved graphic warning labels
75937826|NCT02301351|Other|Text Warning Label|All packs provided will include standard text warning labels
75937827|NCT02400164|Device|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
75799862|NCT01299558|Drug|GW642444|Single IV dose of GW642444 (55mcg)
75799863|NCT03826758|Other|E-DYNAMIC Clinical Decision Support|Clinical decision support system
75937828|NCT03510975|Drug|desmopressin melt form 120 μg|desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
75937829|NCT03510975|Behavioral|Verbal behavioral therapy|Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary
75937830|NCT03510975|Behavioral|Behavioral therapy with written check-list|Behavioral therapy with written check-list includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary, ensuring optimal posture to facilitate good bladder function and bowel movements, avoding holding urine, encouring healthy diet
75937831|NCT02301507|Behavioral|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
75937832|NCT03169790|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
75341889|NCT05590819|Device|Intermittent Theta-burst Stimulation(iTBS)|3 pulses of stimulation delivered at 50 Hz and repeated at 5 Hz; 2s train of TBS with repetitive interval of every 10s, 70% RMT; 600 pulses in total; 15 minutes per session; for a total of 10 sessions
75341890|NCT05590819|Device|Sham stimulation|Set-up the coil without true stimulation; 15 minutes per session; for a total of 10 sessions
75937833|NCT03169790|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
75341891|NCT01795508|Behavioral|PMTO|Parent Management Training, Oregon
75341892|NCT01795508|Behavioral|TAU|Other kinds of family training
75652391|NCT02620371|Procedure|modified pectoral block|"Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line."
75652392|NCT04252664|Drug|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
75652393|NCT04252664|Drug|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
75652394|NCT00696969|Drug|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
75652395|NCT00696969|Drug|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
75652396|NCT00696969|Drug|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
75652397|NCT00696969|Drug|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
75652398|NCT04203680|Drug|HTK cardioplegic solution|30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
75799864|NCT01207206|Drug|oral ketamine|"The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).~The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception"
75799865|NCT03826680|Procedure|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia
75652399|NCT04203680|Drug|blood cardioplegia|one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
75937834|NCT03169790|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75937835|NCT03169790|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75937836|NCT03169790|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
75937837|NCT03169790|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
75341893|NCT05568979|Biological|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
75341894|NCT05568979|Biological|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
75341895|NCT00588380|Drug|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
75652400|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
75799866|NCT03826680|Procedure|Direct laryngoscopy|Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
75799867|NCT01301352|Other|Route of feeding (nasogastric vs. nasojejunal)|Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
75341896|NCT03991429|Diagnostic Test|Simultaneous functional MRI and urodynamic studies|"Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure."
75341897|NCT03991429|Behavioral|Questionnaires|Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
75341898|NCT03991429|Other|Post Void Residual (PVR), Uroflow and Bladder Diary|Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.
75341899|NCT03991429|Diagnostic Test|Urinalysis|Urine sample
75341900|NCT03005353|Drug|Cumin seed extract|patients will receive the drug in suppository form
75341901|NCT03005353|Drug|clotrimazole|patients will receive the drug in suppository form
75341902|NCT00588536|Drug|Methotrexate|MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
75341903|NCT00588536|Drug|6-Thioguanine|6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
75341904|NCT00588536|Drug|Leucovorin Calcium|5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
75341905|NCT03977233|Drug|Oxaliplatin|85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
75341906|NCT03977233|Drug|Leucovorin|400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
75341907|NCT03977233|Drug|Irinotecan Hydrochloride|180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
75652401|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
75652402|NCT04255862|Drug|Bimekizumab|Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
75341908|NCT03977233|Drug|5-FU|400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
75341909|NCT00590018|Drug|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --> 25mg/m2/day) over 5 days intravenously.
75341910|NCT00590018|Drug|Placebo|Placebo for 5 days intravenously.
75341911|NCT02219503|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
75341912|NCT02219503|Drug|Dasabuvir|Tablet
75341913|NCT02219815|Behavioral|Prehab Intervention|Pre-operative, structured exercise intervention.
75652403|NCT02620215|Device|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
75341914|NCT00592124|Drug|Tenofovir disoproxil fumarate|300 mg tablet daily
75341915|NCT00592124|Drug|Tenofovir gel|1 gm/100 ml of 1% gel vaginally daily
75341916|NCT03005119|Drug|PTL201|Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
75341917|NCT03005119|Drug|Placebo Oral Capsule|Placebo seamless gelatin matrix green beads containing excipients only
75652404|NCT02620215|Drug|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
75652405|NCT04252820|Device|WarmTouch total body blanket, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room
75652406|NCT02620059|Behavioral|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
75652407|NCT04252352|Device|Ablative fractional CO2 laser resurfacing/Radio-frequency microneedling|Intra-person split-face trial
75799868|NCT01207284|Other|Physical Therapy|strengthening passive and active stretching balance training gait training
75799869|NCT01299636|Drug|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
75799870|NCT03826290|Other|EHR-integrated diabetes dashboard|The diabetes dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface.
75799871|NCT03817242|Procedure|Tympanoplasty using tragal cartilage graft|tympanoplasty type I is performed using tragal cartilage in arm 1
75799872|NCT03817242|Procedure|Tympanoplasty using temporalis fascia graft|tympanoplasty type I is performed using temporalis fascia in arm 2
75799873|NCT03817164|Device|Autonomic Nerve Modulation - Active|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
75937838|NCT03169790|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
75937839|NCT03169790|Drug|Lovaza|Omega-3-acid ethyl esters
75937840|NCT03169790|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
75937841|NCT03169790|Drug|rituximab|Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
75937842|NCT03169790|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
75937843|NCT03169790|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
75511218|NCT04861727|Other|MRPA procedure|The patient will receive the device for BP measurement at home for a week and two daily measurements will be taken, one in the morning (between 6 and 10 am) and one in the afternoon / evening (between 6 pm and 10 pm), for seven days. At the end of the procedure, it is expected to record 14 measurements (representing a total of 42 in seven days), but it is considered feasible when at least 10 results are recorded, respecting the number of two measurements per day, in the periods oriented. Participants who do not reach the satisfactory number of measures or do not check between the times mentioned above, will be invited to repeat the procedure
75652408|NCT02620293|Device|Eczema Repair Emollient|An Emollient
75799874|NCT03817164|Device|Autonomic Nerve Modulation - Control|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
75799875|NCT03816930|Procedure|mechanical cord usage|Due to the retraction procedures, same preparation conditions will be obtained.
75799876|NCT05604144|Device|Cryoanalgesia (iovera°®)|iovera°® treatment will be administered via ultrasound guidance to 1-2 branches of the dorsal/digital/proper nerve/s that innervate the Morton's neuroma. The treatment will be completed one time per subject.
75799877|NCT03720210|Device|RFA|Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis
75799878|NCT03719586|Drug|ZMapp|Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
75799879|NCT03719586|Drug|Remdesivir|Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight >= 40 kg and for pediatric patients weighing < 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight >= 40 kg and for pediatric patients weighing < 40 kg remdesivir 2.5 mg/kg)
75799880|NCT03719586|Drug|MAb114|50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
75799881|NCT03719586|Drug|REGN-EB3|150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
75937844|NCT03169790|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
75937845|NCT03169790|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
75937846|NCT02301585|Procedure|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
75937847|NCT02301585|Procedure|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
75652409|NCT04288973|Diagnostic Test|Microsoft Kinect Detection during mother child interaction|methodology based on RGB-D sensors applied to the setting of free parent-infant interaction
75652410|NCT04252508|Other|Animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
75652411|NCT02619981|Procedure|Restorative procedure|A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
75652412|NCT02619981|Drug|Maxillary infiltration anesthesia with 2%Lidocaine|1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
75799882|NCT05624034|Device|Electrogastrography|Electrogastrography is used to study abnormalities in healthy subjects and in patients with Diabetic and Idiopathic Gastroparesis
75799883|NCT03817008|Procedure|Ascending aorta replacement with graft|Patient with planned Ascending aorta replacement with graft
75799884|NCT01297140|Behavioral|questioning|Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
75799885|NCT03816540|Device|HRV and respiratory coherence biofeedback|Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.
75799886|NCT03830502|Procedure|Surgical sterilization|Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
75799887|NCT01299792|Other|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
75799888|NCT03825276|Dietary Supplement|Mango consumption|Daily consumption of 280 g of frozen mangos during 8 weeks. The daily dose in equivalent to a 2-cups serving.
75799889|NCT01205022|Drug|irinotecan hydrochloride|Given IV
75799890|NCT01205022|Drug|leucovorin calcium|Given IV
75799891|NCT01205022|Drug|fluorouracil|Given IV
75799892|NCT01205022|Biological|bevacizumab|Given IV
75799893|NCT01205022|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
75799894|NCT01205022|Other|laboratory biomarker analysis|Correlative studies
75799895|NCT01297218|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
75799896|NCT03824574|Device|Clear Mandibular Advancement Appliance|Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
75341918|NCT00593372|Behavioral|Spaced Retrieval Training|Increasing time to remember important information.
75341919|NCT02221219|Drug|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
75341920|NCT02221219|Procedure|delay in umbilical cord clamp at birth|provision of a ~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
75341921|NCT02221219|Drug|placebo infusion|saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
75341922|NCT02221219|Procedure|immediate cord clamp at birth|no delay in umbilical cord clamp; <10sec (recorded in delivery note)
75341923|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later). Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU. Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
75511219|NCT04861727|Other|Pharmaceutical intervention|The suggestion procedure, for this research, is defined as the pharmaceutical act of forwarding a letter of suggestion to the prescriber, previously agreed with the patient, based on clinical evaluation, review of pharmacotherapy, adherence to treatment and result of the MRPA procedure.
75937848|NCT02304393|Drug|Atezolizumab|Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
75937849|NCT02304393|Drug|Selicrelumab|Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
75341924|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred"
75937850|NCT02402972|Drug|FUDR +oxaliplatin|IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein
75652413|NCT03872297|Dietary Supplement|Placebo supplement|"Consumption of a non active food complement during 3 months.~Tests performed :~2 blood tests :~2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
75652414|NCT03872297|Dietary Supplement|Naticol supplement|"Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~2 blood tests :~2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
75652415|NCT04252430|Drug|MD1003|Single oral dose administration of MD1003 at Day 1
75937851|NCT02402972|Drug|oxaliplatin+Leucovorin+5-FU|Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
75937852|NCT04464369|Drug|itopride|itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide
75937853|NCT04464369|Drug|Placebo|placebo pills matching the look and weight of the itopride tablets
75937854|NCT02402816|Device|MultiPoint Pacing ON|MultiPoint Pacing ON
75937855|NCT02402816|Device|Implantable cardioverter-defibrillator (ICD)|Implantable cardioverter-defibrillator (ICD)
75937856|NCT02394470|Other|Deuterium oxide dilution|Reference standard for total body water: deuterium oxide dilution by mass spectrometry
75937857|NCT02394470|Other|Bioimpedentiometry|Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance
75937858|NCT02394470|Other|Lung and subcutaneous ultrasound|Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)
75937859|NCT02394236|Other|Aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
75937860|NCT02304627|Drug|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
75937861|NCT02402738|Behavioral|Interpersonal and Social Rhythm Therapy|
76089136|NCT04393545|Other|Electrotherapy|Two self-adhesive electrodes were used. One was placed over the medial distal end of the first metatarsal and the other was attached to the motor point of the AbdH (inferior and posterior to the navicular tuberosity).21 The stimulation intensity was increased until a contraction was observed without causing discomfort and pain. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks.
75341925|NCT00593450|Drug|ranibizumab|• 0.5 mg (0.05 mL)intravitreal injection
75341926|NCT00593450|Drug|bevacizumab|• 1.25 mg (0.05 mL)intravitreal injection
75341927|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|15 Gy in one treatment
75341928|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|Dose: 70 Gy at 2.8 Gy/treatment
75511220|NCT00313534|Drug|masoprocol|
75511221|NCT00313573|Procedure|management of therapy complications|
75937862|NCT02402738|Behavioral|Enhanced Treatment as Usual|
75937863|NCT02301741|Behavioral|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
75511222|NCT00313573|Procedure|pain therapy|
75511223|NCT00313573|Procedure|psychosocial assessment and care|
75511224|NCT00313573|Procedure|quality-of-life assessment|
75511225|NCT00313690|Drug|Bortezomib, Docetaxel and Cisplatin|
75511226|NCT00402402|Procedure|Tuberculin skin test|
75341929|NCT00631748|Drug|quetiapine fumarate|At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
75937864|NCT02399930|Other|Respiratory & Heart Rate Data Collection|"This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.~Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.~If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns."
75341930|NCT00631748|Drug|Matched Placebo|Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
75341931|NCT00631748|Behavioral|Cognitive-behavioral Therapy|During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
75475210|NCT01992471|Behavioral|Pre test Counseling|Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
75475211|NCT01992471|Other|Blood draw|After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
75672285|NCT02657070|Behavioral|Reinforcement-Induced Movement Therapy (RIMT)|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
75799897|NCT01205100|Behavioral|Bio-feedback|By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.
75475212|NCT01992471|Behavioral|Post-test counseling, and post-test assessment|When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
75475213|NCT01992471|Behavioral|Follow-up assessments (6 and 12 months)|At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
75475214|NCT01992497|Dietary Supplement|Probiotic|
75475215|NCT01992562|Drug|Ziconotide|
75799898|NCT01205100|Drug|Placebo|
75937865|NCT03508791|Other|Arterial carbon dioxide monitoring|Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
75937866|NCT03508791|Other|End-tidal carbon dioxide monitoring|End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
75937867|NCT03508791|Other|Transcutaneous carbon dioxide monitoring|Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
76089137|NCT04393155|Other|COVID-19+ observational|This is observational -- there is no intervention
76089138|NCT01935622|Drug|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
75475216|NCT01992562|Drug|placebo|
75475217|NCT01992588|Drug|Faster-acting insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
75511227|NCT00402402|Procedure|Quantiferon-TB Gold assay|
75511228|NCT00313807|Drug|Amino Acid|7% amino acid infusion
75511229|NCT00313807|Drug|Placebo|0.9% Saline Infusion
75511230|NCT00313885|Drug|eplivanserin (SR46349)|oral administration
75511231|NCT00313885|Drug|placebo|oral administration
75511232|NCT00091143|Biological|gp100 antigen|
75511233|NCT00091143|Biological|incomplete Freund's adjuvant|
75511234|NCT00091143|Biological|keyhole limpet hemocyanin|
75511235|NCT00091143|Drug|fludarabine phosphate|
75511236|NCT00091143|Procedure|peripheral blood stem cell transplantation|
75799899|NCT03823560|Device|Celegyn®|Medical device Celegyn® presents itself as a cream.
75799900|NCT03823560|Device|Matching placebo|IP placebo presents itself as a cream.
75799901|NCT05623566|Device|Picterus Jaundice Pro|In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
76089139|NCT01935622|Drug|placebo|Placebo 1 tablet every 12 hours for 14 days
76089140|NCT03010917|Drug|Fish Oil with ethanol and placebo ethanol infusions|Fish Oil with ethanol and placebo ethanol infusions
76027275|NCT05058365|Behavioral|dots Curriculum|"dots is a mindfulness curriculum developed by Mindfulness in Schools Project (MiSP) for children aged 3-6 in pre-school settings. The program consists of 15-minute twice weekly lessons that span for fifteen weeks. dots has various suggestions for Have A Go after each session - both in the classroom and at home."
76089141|NCT03010917|Drug|Placebo with ethanol and placebo ethanol infusions|Placebo with ethanol and placebo ethanol infusions
75652416|NCT02864225|Device|Scalp electrode,|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
75475218|NCT01992588|Drug|insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
75475219|NCT01992601|Drug|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)|"For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period."
75475220|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
75475221|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
75475222|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
75652417|NCT02864225|Device|Fetal doppler|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
75652418|NCT02864225|Device|EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
75652419|NCT00697047|Behavioral|Automated Mailing|Usual Care plus Automated mailing
75652420|NCT00697047|Behavioral|Automated Mailing Plus Assisted|If not screened after automated mailing, MA assists with screening.
75652421|NCT00697047|Behavioral|Auto Plus Assisted Plus Navigation|If not screened after automated mailing and assistance by MA, RN begins navigation.
75799902|NCT05583396|Diagnostic Test|Acute exercise|The measurement will be repeated within one to seven days.
75799903|NCT01205178|Drug|Chloroquine|The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
75799904|NCT01205178|Drug|Primaquine|Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
76089142|NCT03008187|Drug|SEL24/MEN1703|SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
76089143|NCT01936324|Drug|Olumacostat Glasaretil Gel, 7.5%|Gel containing Olumacostat Glasaretil
75475223|NCT01992627|Device|HILTERAPIA HIRO 3.0|High-intensity laser therapy (HILT), which involves higher-intensity laser radiation and which causes minor and slow light absorption by chromophores. This absorption is obtained not with concentrated light but with diffuse light in all directions (the scattering phenomenon), increasing the mitochondrial oxidative reaction and adenosine triphosphate, RNA, or DNA production (photochemistry effects) and resulting in the phenomenon of tissue stimulation called photobiology.
75475224|NCT01992666|Genetic|Blood sampling|Immunologic and genetic analysis from a single blood sample.
75652422|NCT04252196|Device|usability evaluation of medical device|participants interact with medical device and rate it for usability
75799905|NCT01205178|Drug|Tafenoquine|Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
75799906|NCT01205256|Drug|methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
75799907|NCT03816384|Device|Standard of Care|Standard of care urinary drainage system.
75799908|NCT03816384|Device|DLC Group|Urinary drainage system with active drain line clearance and plain silicone catheter.
75799909|NCT03816384|Device|DLCS Group|Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
75799910|NCT03823170|Radiation|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
76027276|NCT05044559|Other|Continuous Positive Air Way Group|CPAP between 10 and 12 cmH2O
76089144|NCT01936324|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
76089145|NCT04274673|Device|measuring cotinine level|Measuring of the cotinine levels
75652423|NCT04287881|Genetic|Methylenetetrahydrofolate reductase (MTHFR) deficiency|To investigate the incidence of MTHFR deficiency in patients with adult-onset epileptic seizures and diagnosed ischemic stroke
75799911|NCT03823170|Procedure|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish, with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
75799912|NCT03823170|Combination Product|Laser therapy and Fluorotherapy|This group will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
75799913|NCT03823482|Drug|Lidocaine|Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
75799914|NCT01299870|Drug|AED treatment plus placebo|Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.
75937868|NCT02306421|Procedure|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
76027277|NCT05044559|Other|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
76089146|NCT02979561|Drug|Dabigatran Etexilate|All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
75652424|NCT04255706|Device|biometric measurement IOLMaster 700|Three biometric measurements will be performed with 3 devices for all the patients included
75652425|NCT04255706|Device|biometric measurement Lenstar LS 700|Three biometric measurements will be performed with 3 devices for all the patients included
75475225|NCT01992679|Behavioral|Exercise group|The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.
75652426|NCT04255706|Device|biometric measurement Anterion Heildelberg|Three biometric measurements will be performed with 3 devices for all the patients included
75652427|NCT04204889|Drug|Oxaloacetic Acid|The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.
75652428|NCT02619903|Procedure|Dental cleaning|Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
75652429|NCT04287725|Device|exercise + photobiomodulation therapy|Treatment sessions will be provided twice a week for 6 weeks (totaling 12 sessions) with participants receiving either placebo or active PBMT + exercise protocol.
75672286|NCT02657070|Behavioral|VR-based motor rehabilitation in RGS without augmented feedback|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
76027278|NCT05058053|Other|Cold application|Cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals.
76027279|NCT03097679|Device|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
76027280|NCT03097679|Device|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
76027281|NCT05058209|Drug|Triamcinolone acetonide extended-release injectable suspension|Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
76027282|NCT05058209|Drug|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension|Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
75652430|NCT02619669|Drug|TAK-228|Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
76089147|NCT02979561|Drug|Warfarin|all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
75799915|NCT01299870|Drug|Keishibukuryogan|Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
76089148|NCT01766921|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
76089149|NCT01937026|Drug|Baricitinib|Administered orally
76089150|NCT01937026|Drug|Probenecid|Administered orally
76089151|NCT04759053|Procedure|FNB|Fine needle aspiration from the nodules
76089152|NCT04759053|Procedure|Core biopsy|Core biopsy from thyroid nodules
75937869|NCT02306421|Procedure|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
76089153|NCT04393467|Device|tSMS|tSMS delivered on bilateral motor cortex
76089154|NCT04393467|Device|sham tSMS|sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
75652431|NCT02619669|Drug|Letrozole|An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
75652432|NCT02866799|Other|Multi-PAP|Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.
75652433|NCT02866799|Other|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
75799916|NCT01567254|Behavioral|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
75799917|NCT01567254|Behavioral|music ONLY|music. It will be equal in length to the auditory guided imagery disk
75799918|NCT03816306|Drug|LCZ 696|LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
75341932|NCT04387682|Dietary Supplement|β-glucan|β-glucan, a biological response regulator, derived from yeast has been known for more than 45 years, and has anti-infective and anti-tumor activities. β-glucan is a molecule with a β-1,3-linked D-glucose backbone and β-1,6-linked side chains. Thus far, at least 4 receptors for β-glucan have been discovered in humans, which are surface antigens associated with macrophages or myeloid precursor cells as complement receptor 3 (CR3; CD11b/CD18, Mac-1, αMβ2 integrin) (Vetvicka et al. 1996; Xia et al. 1999), lactosylceramide (Zimmerman et al. 1998), scavenger receptor (Rice et al. 2002) and dectin-1 (Brown et al. 2003; Taylor et al. 2007; Saijo et al. 2007).
75475226|NCT01992705|Other|Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable|Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
75652434|NCT02619825|Device|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
75799919|NCT03816072|Drug|Phenylephrine infusion|Correction of anesthesia induced hypotension with phenylephrine to obtain sCA and dCA measurements at 60, 70, 80, 90 and 100 mmHg mean blood pressure. This is achieved by stepwise increases in phenylephrine infusion dose.
76089155|NCT01774799|Behavioral|Advance care planning intervention|
75652435|NCT02619825|Device|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
75799920|NCT03816072|Other|Mechanical ventilation|Patientes are mechanically ventilated at 6 bpm to obtain low frequency blood pressure oscillations (~0.1 Hz).
75799921|NCT03816072|Drug|Propofol|Propofol
75799922|NCT03816072|Drug|Sevoflurane|Sevoflurane
76089156|NCT01774799|Other|Control group|
75475227|NCT01992705|Drug|-Oxaliplatin 85 mg/m2 IV on Day 1|Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
75475228|NCT01992705|Drug|-Irinotecan 180 mg/m2 IV on Day 1|Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
75475229|NCT01992705|Drug|-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours|5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
76089157|NCT03825783|Biological|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
76089158|NCT03824223|Diagnostic Test|Hypoxic challenge test|Physiological response to 15% ambient oxygen monitored.
75799923|NCT05560698|Other|Motivation-enhancing intervention|The web app is designed as an efficient and easy-to-use app configurable to personal preferences. Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. The questionnaire addresses the same questions as the questionnaire in the standard intervention, but the format is different, and some shortcuts makes it easier to answer. When the questionnaire is answered, the web app gives access to different features. The following features distinct the motivation-enhancing intervention from the standard intervention (1) only complete the entire questionnaire on days with symptoms, (2) integration of grass pollen counts and forecasts, (3) showing personal response rate, (4) access to own data via a graph, (5) advice against grass pollen allergy, (6) status of the study, (7) individually choosing the time of response, (8) option to download an icon for the home screen and (9) contact information. The development is an ongoing iterative process
75937870|NCT02306421|Procedure|RPH|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
75937871|NCT02306421|Procedure|PPH|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
75937872|NCT02306421|Procedure|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
75652436|NCT03965117|Drug|Norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is > 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
75799924|NCT05560698|Other|Standard intervention|Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. When the questionnaire is answered, the tab needs to be closed.
75799925|NCT01207050|Drug|Ramelteon|8mg capsule taken within one half hour of bedtime each night over the three night study period.
75937873|NCT02400008|Procedure|Surgery for bilateral laryngeal reinnervation|Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
76117205|NCT03720431|Drug|TTAC-0001 and pembrolizumab combination|"Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~Treatment groups: 3 dose levels~Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Cycle: 3 weeks (21 days per cycle)"
76117206|NCT05389605|Other|No intervention was undertaken|This was an observational study, no intervention was done.
75475230|NCT01992718|Procedure|Evaluation of MRI, US for pelvic and uterine conditions|"Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).~A patient survey will be included."
75652437|NCT00917462|Drug|Sorafenib, administered orally|Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
75799926|NCT01207050|Dietary Supplement|Placebo|Control treatment
75799927|NCT01299948|Drug|Prednisolone|5 mg prednisolone orally per day
75799928|NCT01300026|Drug|AMG 319|AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
75799929|NCT01300104|Behavioral|Exercise|"Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.~Restrictions: None."
75799930|NCT01300104|Behavioral|Whole grain rye|Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
75799931|NCT01300104|Behavioral|Recommendations|Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
75799932|NCT01297374|Behavioral|physical activities, dietician counseling and behavioral changes|One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
75799933|NCT03815760|Device|Blood Flow Restriction|Subjects will perform sidelying external rotation exercise
75937874|NCT02394314|Drug|MEDI0382|MEDI0382 administered subcutaneously
75937875|NCT02394314|Drug|Placebo|Placebo administered subcutaneously
75937876|NCT03508713|Drug|disease modified antirheumatic drugs or biological agents|Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
75475231|NCT01992718|Procedure|Patient preference between MRI and Ultrasound|"Subjects may take part in this arm because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.~Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete."
75475232|NCT01992731|Other|Drug: Follitropine Bèta|
75937877|NCT04481828|Procedure|gastrectomy|gastric resection with lymph node dissection(D1+,D2) for stomach cancer.
76089159|NCT03828903|Device|Cryoprobe|"The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~The frozen tissue is going to be extracted by gently pulling of the probe.~Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~The biopsy sample will be released from the probe by thawing in the saline.~The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding."
76089160|NCT01937260|Drug|Brodalumab|Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
75475233|NCT01992770|Behavioral|Hierarchical graded exposure|"Individual Behavioural goal identification, depending on risk profile~(1a). Catastrophising and/or fear-avoidance (2); hierarchical graded exposure, organized with individual coaching in connection to the physical training sessions, based on activities that each participant fear and/or avoid."
75652438|NCT00917462|Procedure|CT/MRI|A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
75475234|NCT01992770|Behavioral|Graded activity|"Individual Behavioural goal identification, depending on risk profile~(1b) Graded activity;(2) self-monitoring of everyday life activities (3) functional behavioural analyses to describe, predict, and verify factors controlling patient's current and future activity performance (4) training of motor skills, cognitive skills, and strategies to organise everyday life including social support. (5) gradual application of acquired skills in everyday life situations as formulated by Specific, Measureable, Activity-related, Realistic, and Time- specified (SMART) goal setting (6) generalisation of skills to additional activities and challenging situations, and (7) strategies for maintenance and relapse prevention."
75799934|NCT01297452|Drug|BKM120 days 1 - 21 plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
75937878|NCT03510897|Drug|teprasiran|IV injection
75937879|NCT03510897|Drug|Placebo|isotonic saline
76089161|NCT04125381|Other|Exposure to Arsenic by drinking water|People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
76117207|NCT05187156|Behavioral|Behavioral Activation and Social Engagement|brief, PCMHI-based psychotherapy using behavioral activation principles and focused attention on enhancement of social support
76117208|NCT05187156|Behavioral|Treatment as usual|treatment as usual in PCMHI includes participation in any other skills-based groups or brief individual psychotherapy and medication management offered in PCMHI
75799935|NCT01297452|Drug|BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
75937880|NCT02394158|Drug|Metformin|
75937881|NCT02394158|Drug|placebo|
76117209|NCT05386953|Drug|Normal saline|Patients received normal saline as a maintenance crystalloid during liver transplantation surgery.
75937882|NCT02698826|Other|Protocol for rapid FiO2 optimization|"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas [ABG] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value <100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."
75937883|NCT03508635|Drug|CORT125134|Oral capsules
75475235|NCT01992770|Behavioral|Physical exercises|Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8
75475236|NCT01992783|Dietary Supplement|Hi-maize resistant starch|13.5 g/day
75475237|NCT01992783|Dietary Supplement|Maltodextrin|13.5 g/day
75475238|NCT01992796|Drug|Irbesartan|75 mg/per os/for 15 days
75652439|NCT02619513|Drug|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
75799936|NCT01297452|Drug|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
75799937|NCT01297452|Drug|BKM120, Paclitaxel + Carboplatin|BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
75799938|NCT01301586|Drug|Doxycycline and S-equol|Oral doxycycline and s-equol twice a day
75799939|NCT01301586|Drug|Doxycycline|ORAL DOXYCYCLINE TWICE A DAY
75799940|NCT01297530|Drug|BAY87-2243|Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
75799941|NCT01297608|Drug|caoted suppository|coated suppository with active drug
75799942|NCT01297608|Drug|coated suppository|coated suppository with placebo
75937884|NCT03508635|Drug|Matching Placebo of CORT125134|Placebo
75652440|NCT02619513|Drug|Ropivacaine|Group GE\GT\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
75652441|NCT02619513|Device|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
75799943|NCT03815994|Device|Neuromuscular Electrical Stimulation|This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
75799944|NCT03815838|Diagnostic Test|PET imaging|Positron emission tomography imaging using 18F-Fallypride and 18F-FDOPA
75799945|NCT01300182|Other|Whole body vibration therapy|The WBVT will be carried out in a vibration plates operated in vertical direction. The frequency of that vibration can be adjusted step of 5Hz with vibration frequency ranges from 20Hz to 60Hz. The amplitude can be set as 4mm.
75937885|NCT03508635|Drug|Mifepristone|Active comparator
75937886|NCT03508635|Drug|Prednisone|Challenge agent
75799946|NCT01300182|Other|Control|Conventional post-operative physical therapy exercises and rehabilitation.
75799947|NCT01205412|Procedure|Endocervical samples|Endocervical samples collection during routine gynaecological examinations
75937887|NCT03508635|Drug|Glucose|
75937888|NCT02399852|Drug|Lomitapide|
75937889|NCT02399774|Device|Leboride|"Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control~Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
75937890|NCT04481282|Drug|Terbutaline|2.5mg po tid for 12 weeks
75937891|NCT04481282|Drug|Danazol|200mg po bid for 12 weeks
75937892|NCT02541604|Drug|Atezolizumab|Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
75937893|NCT02302053|Dietary Supplement|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
75937894|NCT02302053|Dietary Supplement|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
75937895|NCT02399540|Device|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
75937896|NCT02399540|Device|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
75652442|NCT02619747|Drug|Compound Sodium Alginate Oral Suspension sachet|
75799948|NCT03819972|Dietary Supplement|Dose response of Capolac®|Capolac® (milk minerals high in calcium) dose is manipulated
75475239|NCT01992809|Dietary Supplement|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
75475240|NCT01992822|Other|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm.
75652443|NCT02619747|Drug|Matched placebo|
75652444|NCT02866877|Other|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
75799949|NCT03815526|Other|Dynamic tape|Dynamic tape apply 1 time
75799950|NCT03815526|Other|Kinesio tape|Dynamic tape apply 1 time
75799951|NCT03815526|Other|Sport tape|Dynamic tape apply 1 time
75475241|NCT01992835|Other|Grass pollen allergen extract|Each subject will be challenged with a grass pollen allergen extract and with placebo.
75652445|NCT00697125|Biological|Engerix™-B|Intramuscular injection, 3 doses
75652446|NCT00697125|Biological|HBV-MPL vaccine (208129)|
75652447|NCT00697125|Biological|Hepatitis B vaccine, experimental formulation|Intramuscular injection, 3 doses
75652448|NCT04287491|Other|Oculus Go Virtual Reality System|The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.
75652449|NCT04134351|Other|Bronchial challenge test|Bronchial challenge test with sphingosine-1-phosphate
75819684|NCT02256280|Drug|Neostigmine|"Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~If Post tetanic count = 1-15: 0.07 mg/kg~If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage."
75819685|NCT02174068|Drug|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
75475242|NCT01992835|Other|placebo|
75937897|NCT02399540|Device|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
75937898|NCT02399540|Device|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
75937899|NCT02304861|Procedure|Viscoat|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision 3% Sodium Hyaluronate, 4% Chondroitin Sulfate (Viscoat, Alcon, Greece) was injected in the anterior chamber
75475243|NCT01992848|Other|Venous blood sampling|40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
75475244|NCT01992848|Other|4-day food diary|
75475245|NCT01992848|Other|1 week UV dosimeter|To be worn on outerwear for one week week prior to attendance for pQCT
75937900|NCT02304861|Procedure|Visthesia|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision sodium hyaluronate 1.5% and lidocaine hydrochloride 1% ophthalmic viscosurgical device (OVD) (Visthesia, Carl Zeiss, Germany) was injected in the anterior chamber
75475246|NCT01992848|Radiation|Peripheral Quantitative Computed Tomography of the radius|To be performed within one month of attendance for CT coronary angiography
75475247|NCT01992900|Drug|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
75652450|NCT04134273|Drug|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
75652451|NCT04134273|Drug|Clindamycin|Clindamycin Phosphate topical gel 1%
75652452|NCT04134273|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
75937901|NCT02302131|Other|SAPIEN XT|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
75652453|NCT05326659|Drug|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
75652454|NCT05326659|Drug|Placebo|Placebo, applied twice daily for 12 weeks after enrolment.
75652455|NCT04134117|Biological|Tisagenlecleucel|One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
75652456|NCT03853187|Radiation|Zr-89 labelled durvalumab PET/CT|Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine or in-vivo [89zr]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
75652457|NCT03853187|Drug|Durvalumab (MEDI4736)|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
75652458|NCT02619357|Device|SenseWear Armband Gecko|Subjects will wear SenseWear Armband Gecko up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
75937902|NCT02393846|Drug|Ketoprofen gel|Topical ketoprofen as used in gel form.
75937903|NCT02393846|Drug|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
75937904|NCT02302209|Drug|Oxytocin|
75937905|NCT02302209|Other|Placebo Comparator|
75937906|NCT02302287|Dietary Supplement|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
75937907|NCT02302287|Other|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
75937908|NCT02302287|Other|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
75652459|NCT02619357|Device|SenseWear Armband MF|Subjects will wear SenseWear Armband MF up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
75652460|NCT02619357|Device|Actigraph GT9x wristband and waistband|Subjects will wear Actigraph GT9x wristband and waistband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
75652461|NCT02619357|Device|Garmin Vivofit 2 wristband|Subjects will wear Garmin Vivofit 2 wristband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
75652462|NCT02619357|Device|SOMNOwatch plus EEG 6 sleep monitor|In a subset of subjects, this device will be worn as a comparator for monitoring sleep quality and duration.
75652463|NCT02619357|Other|Strength exercises|Subjects will perform strength exercises using elastic bands of varying resistance
75652464|NCT02619357|Other|Field-based exercise tests|Subjects will perform an Incremental Shuttle Walk Test (ISWT) and each individual component of a Short Physical Performance Battery (SPPB).
75652465|NCT02619357|Other|Laboratory-based exercise tests|Subjects will perform an incremental, symptom-limited cardiopulmonary exercise test on a cycle ergometer and will walk at various speeds on a treadmill
75652466|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 1"
75652467|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 2"
75652468|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 3"
75652469|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 4"
75652470|NCT00697281|Drug|Placebo|"Tablets twice daily for 8 days~Dose level 5"
75652471|NCT00979901|Drug|Comparator: montelukast|10 mg montelukast tablet given once daily at bedtime for 2 weeks
75937909|NCT04481360|Device|CT of the chest|Degree of affection on the lung infected by COVID19
75937910|NCT02399618|Drug|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
75937911|NCT02306499|Procedure|ICSI|Intracytoplasmic Sperm Injection
75937912|NCT02394002|Drug|Propofol|
75937913|NCT02306577|Drug|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
75341933|NCT00594230|Drug|Panobinostat|Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
75475248|NCT01992900|Drug|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
75475249|NCT01992913|Behavioral|integrated Cognitive Behavioral Therapy|Novel CBT paradigm for schizophrenia/schizoaffective disorder
75475250|NCT01992913|Other|Usual Care|The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)
75475251|NCT01992913|Behavioral|Computerized cognitive remediation (CCR)|Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
75799952|NCT01205490|Other|head positions and spinal manipulation|Each subject will then undergo a baseline MRI in a head neutral position (0 degrees rotation). They will then be placed in head rotation (45 degrees) to the non-dominant and undergo a MRI. Maximum rotation to the side with MRI will follow. Finally, each subject will receive an upper cervical rotary manipulation to the non-dominant side with MRI immediately after. A total of 4 test conditions will be evaluated (rest, 45 degree, maximal, post-manipulation). The manipulation will be performed by an experience practitioner on a bed just outside the MRI room in supine position. A controlled impulse load will be applied and the head/neck returned to neutral position. Prior to each maneuver, the subject will be queried on their comfort, condition and willingness to continue
75799953|NCT01205724|Drug|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
75799954|NCT01205724|Drug|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
75799955|NCT01205724|Drug|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
75799956|NCT01301664|Other|total knee / hip replacement|Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.
75799957|NCT03819894|Diagnostic Test|Introduction of a lower female hs-cTn threshold|The new female hs-cTn threshold will be baed on current recommendations for each of the assays used (hs-cTn T and I). The hospitals are the unit of randomization. At 5-month intervals, randomly selected hospitals will be advised that they are to transition to the intervention phase. For all men, the standard of care, overall population threshold will be used throughout the entire study.
75799958|NCT01205802|Procedure|MHV reconstruction|MHV reconstruction with PTFE or homograft
75799959|NCT05623332|Diagnostic Test|Maraciclatide|Imaging marker that binds to AVB3/5 lesions
75799960|NCT01301820|Drug|azacitidine|azacitidine sc 75 mg/m²/d (d1- d7)
75799961|NCT01301820|Drug|Lenalidomide|lenalidomide 10mg/d (d1- d21)
75799962|NCT01560000|Dietary Supplement|Dietary fiber|Wheat, barley, oat and bran fibers added to a breakfast product
75799963|NCT01297686|Other|Karaoke Exercise|lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
75652472|NCT00979901|Drug|Comparator: loratadine|10 mg loratadine tablet given once daily at bedtime for 2 weeks
75652473|NCT00979901|Drug|Comparator: placebo|placebo tablet given once daily at bedtime for 2 weeks
75652474|NCT00979901|Drug|Comparator: montelukast/loratadine|montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
75799964|NCT01297686|Other|Balance walking exercise|Walking along a straight line on the ground, for 5 sets of 30 strides
75799965|NCT01297686|Other|Forefoot extension exercise|The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended. The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
75341934|NCT00594308|Drug|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
75341935|NCT00594308|Drug|Fludarabine|25mg/m2/day for 5 consecutive days
75341936|NCT00594308|Drug|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
75341937|NCT00594308|Drug|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
75475252|NCT01992926|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
75475253|NCT01992939|Other|Specialized pulse oximetry probe with external heat pack|Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
75475254|NCT01992939|Other|Standard of Care Pulse Oximetry Probe|Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
75475255|NCT01992965|Other|Different methods of blood glucose monitoring between groups|Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
75475256|NCT01992978|Procedure|Radiofrequency-assisted Hepatectomy|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
75652475|NCT02619201|Drug|Ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
75652476|NCT02619201|Drug|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
75799966|NCT01297686|Other|Standing one-legged balance exercise:|This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
75799967|NCT01297686|Other|Ankle inversion/eversion exercise|The foot is placed sideways at the edge of a step. After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
75341938|NCT00594308|Drug|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
76117210|NCT05386953|Drug|Balanced crystalloid solution|Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
75341939|NCT00595088|Biological|BC-819/PEI|Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
75341940|NCT02137538|Drug|Letrozole|
75341941|NCT02137538|Drug|Anastrozole|
75341942|NCT01799330|Procedure|Transcutaneous Electrical Muscle Stimulation (TCEMS)|
75341943|NCT01799330|Other|Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response
75341944|NCT00595556|Drug|zonisamide|flexible dosages of 100-500mg/day
75341945|NCT00595556|Drug|Placebo|Placebo
75341946|NCT00595790|Biological|IC51|
75341947|NCT00595946|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
75475257|NCT01992978|Procedure|Conventional Hepatectomy|Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
75652477|NCT04134741|Other|Kinetic Control|"The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes."
75475258|NCT01992991|Device|Transcranial direct current stimulation|Transcranial direct current stimulation of motor cortex
75652478|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine tablets 100 mg. BID for 4 weeks
75799968|NCT01297686|Other|Gastrocnemius and soleus stretching|This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
75819686|NCT00101608|Drug|vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
75341948|NCT00595946|Drug|Placebo|0 mcg capsules twice daily (BID)
75341949|NCT00596102|Biological|Japanese Encephalitis purified inactivated vaccine|Japanese Encephalitis purified inactivated vaccine
75341950|NCT00638924|Other|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
75341951|NCT00597038|Drug|Dasatinib and Dacarbazine (DTIC)|"Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m^2."
75475259|NCT01993056|Behavioral|"FIFA 11+"|
75341952|NCT00597272|Biological|KLH conjugates with GD2L and GD3L|6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
75341953|NCT00597428|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
75341954|NCT00597428|Drug|Placebo|0 mcg capsules twice daily (BID)
75475260|NCT01993056|Behavioral|"no FIFA 11+"|
75475261|NCT01993069|Behavioral|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
75475262|NCT01993095|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.
75475263|NCT01993095|Behavioral|Behavioral: Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
75475264|NCT01993121|Other|Supervised Exercise Training|All subjects will perform three months of supervised exercise training.
75475265|NCT01993134|Procedure|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
75475266|NCT01993134|Procedure|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
75652479|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine 200 mg. tablets BID for 4 weeks
75652480|NCT00975611|Drug|Placebo|tablets BID, for 4 weeks
75475267|NCT01993147|Behavioral|Dual task paradigm pilot|
75475268|NCT01993160|Drug|Fluorocholine (18F-FCH) Injection|Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
75475269|NCT01993160|Radiation|PET scan|A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
75799969|NCT01297686|Other|Tissue-specific plantar fascia self massage|This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot. The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch. Same procedure is then repeated for the left foot.
75652481|NCT02619279|Other|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
75799970|NCT01297686|Drug|Dexamethasone|"A 22-gauge, 1.5 needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area."
75799971|NCT01205880|Drug|Calcitriol ointment|twice daily
75799972|NCT01205880|Drug|Clobetasol spray|twice daily
75799973|NCT05652114|Behavioral|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children.
75799974|NCT03819738|Diagnostic Test|fMRI|Functional MRI will be performed in 1 scan, which will take 1.5 h. (scanning time = 30 min)
75799975|NCT01205958|Procedure|acupuncture|Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
75799976|NCT05623098|Dietary Supplement|dietary fiber nutrients|Whether to add nutrients containing dietary fiber
75799977|NCT03830268|Dietary Supplement|No MCT intake with breakfast, no lunch|Water given with a regular standardize breakfast and water given at noon without lunch.
75799978|NCT03830268|Dietary Supplement|No MCT intake with lunch, no breakfast|Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
75799979|NCT03830268|Dietary Supplement|10g of Betaquik|BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
75799980|NCT03830268|Dietary Supplement|10g of Betaquik with low-carbs breakfast|BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
75799981|NCT03830268|Dietary Supplement|20g of Betaquik|BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
75475270|NCT01993160|Radiation|Whole body MRI|A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
75475271|NCT01993173|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)|0.5 mL, Intramuscular
75475272|NCT01993173|Biological|DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)|0.5 mL, Intramuscular
75475273|NCT01993173|Biological|Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)|0.5 mL, Intramuscular
75475274|NCT01993199|Procedure|deep biopsy via ESD technique|
75799982|NCT03830268|Dietary Supplement|10g of Betaquik with lunch, no breakfast|BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
75799983|NCT01297842|Drug|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
76117211|NCT03719573|Other|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
75475275|NCT01993212|Drug|Androxal 12.5 mg or 25 mg|
75475276|NCT01993212|Drug|AndroGel 1.62%|
75652482|NCT05298189|Behavioral|MindBreaks - Audio-visual|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain visual and auditory stimuli."
75652483|NCT05298189|Behavioral|MindBreaks - Auditory-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only auditory stimuli."
75799984|NCT01297842|Drug|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
75799985|NCT01297998|Drug|gemcitabine , cisplatin|Dose of gemcitabine and cisplatin and treatment schedule
75799986|NCT03819582|Device|EyeCee One intraocular lens|Hydrophobic aspheric monofocal intraocular lens
75819687|NCT02174146|Procedure|non-surgical periodontal therapy|supra and subgingival debridement
75475277|NCT01993212|Drug|Placebo Capsules|
75475278|NCT01993212|Drug|Placebo Gel|
75475279|NCT01993225|Drug|Androxal 12.5 mg/25 mg|
75475280|NCT01993225|Drug|Placebo Capsules|
75475281|NCT01993225|Drug|AndroGel 1.62%|
75475282|NCT01993225|Drug|Placebo Gel|
75475283|NCT01993251|Drug|melatonin|one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
75475284|NCT01993251|Drug|Melatonin|one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
75475285|NCT01993251|Drug|Melatonin|one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
75475286|NCT01993251|Drug|placebo|one capsule, placebo, oral, once a day, 30 minutes before bedtime
75475287|NCT01993277|Device|Nexalin Brain Stimulator|
75475288|NCT01993277|Device|Fischer Wallace Stimulator|
75475289|NCT01993277|Device|David Delight Stimulator|
75475290|NCT01993277|Behavioral|Relaxation Therapy|
75475291|NCT01993290|Drug|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
75475292|NCT01993316|Device|Mitsar 201 neurofeedback|
75475293|NCT01993342|Other|arthrocentesis|The made a diagnostic arthrocentesis to all patient we included
75475294|NCT01993342|Other|ultrasonography of the knee|We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
75819688|NCT02179216|Other|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
75819689|NCT02179216|Other|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
75475295|NCT01993355|Other|Physiotherapy|Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
75652484|NCT05298189|Behavioral|MindBreaks - Visual-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only visual stimuli."
75475296|NCT01993355|Other|Intervention 1|Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
75799987|NCT05458206|Other|mulligan snag mobilization and diaphragmatic release|"The patients will be in the supine position. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ). During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally. During exhalation, the therapist will deepen hand contact toward the inner coastal margins.~mulligan snag, Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement"
75799988|NCT01298076|Drug|bevacizumab|Anti-VEGF drug for intravitreal injection
75341955|NCT00597818|Drug|Cobiprostone|18 mcg cobiprostone capsules for oral administration
75799989|NCT01298076|Drug|dexamethasone|Slow-release steroid formulation for intravitreal injection
75799990|NCT03814902|Device|Electronic Tracking Device|This commercially-available electronic tracking device uses Global Positioning System (GPS) technology to display the wearer's location on a mobile phone, tablet, or computer. The device may be securely attached to clothing and is designed to be worn by children with developmental disabilities. Parents may use the associated application to view the child's location when the device is turned on and active.
75799991|NCT03819504|Procedure|4-D navigated stereotactic radio surgical ablation|4-D navigated stereotactic radio surgical ablation will be performed in patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias
75799992|NCT03814824|Diagnostic Test|IRIS (Intelligent real-time image segmentation)|IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.
75799993|NCT03814824|Diagnostic Test|VLE (Volumetric laser endomicroscopy)|VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
75799994|NCT03821298|Other|Standard of Care Hand Therapy|8 sessions 2 times a week for 4 weeks
75799995|NCT03819270|Drug|LY3372689|Administered orally
75799996|NCT03819270|Drug|Placebo|Administered orally
75937914|NCT05454982|Device|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
75937915|NCT02402348|Drug|Metformin|
75937916|NCT02304939|Procedure|changeover|
75937917|NCT02304939|Device|use of automatic infusion pump|
75341956|NCT00597818|Drug|Placebo|Matching placebo capsules for oral administration
75475297|NCT01993355|Behavioral|Intervention 2|Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
75475298|NCT01993368|Other|flow cytometry|"These populations will be identified by different combinations of antibodies to identify:~T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)"
75475299|NCT01993394|Other|hypergravity|1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)
75341957|NCT00597818|Drug|Non-steroidal anti-inflammatory drug|Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.
75341958|NCT00597896|Drug|pramipexole|po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
75799997|NCT03814980|Behavioral|mindful breathing application|Participants will use a mindful breathing application on a computer tablet.
75799998|NCT03814980|Device|application on a computer tablet|a computer tablet
75799999|NCT03814668|Dietary Supplement|Probiotic|Intake of probiotic
75800000|NCT03814668|Dietary Supplement|Lactase|Intake of lactase
75800001|NCT03814668|Other|Placebo|Intake of placebo
75937918|NCT02304939|Behavioral|datas collection|
75341959|NCT00600080|Device|etafilcon A|contact lens worn daily for one week (first or second week depending on arm)
75341960|NCT00600080|Device|nelfilcon A|Contact lens worn daily for one week (first or second week depending on arm)
75341961|NCT00600704|Procedure|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
75652485|NCT04287335|Diagnostic Test|Multitarget stool FIT-DNA test - ColoClear|Multitarget stool FIT-DNA test
75652486|NCT04287335|Diagnostic Test|FIT|fecal immunochemical test
75652487|NCT04287335|Procedure|Colonoscopy|diagnostic colonoscopy
75937919|NCT04423666|Behavioral|Walking using a wireless pedometer|See arm/group
75937920|NCT02399696|Behavioral|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
75937921|NCT02399696|Behavioral|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
76117212|NCT05176548|Diagnostic Test|Bone-cardiac scintigraphy|Patients with confirmed ATTR type CA will undergo a study of mutations in the TTR gene
76117213|NCT00979875|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
76117214|NCT00979875|Drug|Insulin lispro|
75475300|NCT01993394|Other|gas mixture|breathing air, 44.5%O2 or 100%O2
75937922|NCT02399462|Drug|Acthar|"Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly* Weeks 27 through 28~*Injections are to be spaced 72-96 hours apart (+/-6 hours)."
75475301|NCT01993407|Behavioral|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
75937923|NCT04852328|Drug|CUE-101|CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
75652488|NCT04134039|Device|Polyurethane (PU) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
75652489|NCT04134039|Device|Natural Rubber Latex (NRL) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
75937924|NCT03505047|Device|Copper Intrauterine device|Immediate insertion of the copper intrauterine device after completion of abortion
75475302|NCT01993407|Behavioral|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
75475303|NCT01993420|Drug|DRM02|
75475304|NCT01993420|Other|Vehicle|
75652490|NCT02865161|Drug|NISELAT|NISELAT 600MG BD
75800002|NCT03819348|Other|the multiple programs of antifungal therapy for HIV-negative host|the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators.
75800003|NCT03819426|Behavioral|Low Intensity Exercise Intervention|Those in the walking intervention will be instructed to take walks below a brisk pace (low intensity) to improve mood
75800004|NCT03819426|Behavioral|High Intensity Intervention|Instructed in high intensity interval training techniques and will be provided videos to follow for implementation of intervention at home that will include short bursts of high energy
75937925|NCT02402114|Drug|Hydrocortisone|120 mg Hydrocortisone given orally one time.
75937926|NCT02311413|Drug|Cat-PAD|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
75937927|NCT02311413|Drug|Placebo|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
75937928|NCT02311491|Device|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
75937929|NCT05745896|Other|Telemedicine appointment|Three online appointments for pregnancy monitoring at prenatal care.
75475305|NCT01993433|Drug|DRM02|
75475306|NCT01993433|Other|Vehicle|
75475307|NCT01993446|Drug|DRM02|
75475308|NCT01993446|Other|Vehicle|
75652491|NCT02619123|Other|Tailored screening according to breast density|Different interval of mammography screening according to breast density
75937930|NCT05745896|Other|Face-to-face appointment|Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.
75937931|NCT02394080|Device|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
75937932|NCT02546674|Drug|Nilotinib|A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.
75937933|NCT02305251|Other|Survey|Standard Gamble Survey
76117215|NCT00979875|Drug|Insulin glulisine|
75475309|NCT01993459|Drug|Midazolam|We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
75475310|NCT01993459|Drug|NaCl (sodium chloride) 0,9%|We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
75475311|NCT01993472|Drug|Andrographolides|comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer
75475312|NCT01993472|Drug|Capecitabine|
75475313|NCT01993524|Dietary Supplement|probiotic|antibiotic plus probiotic
75475314|NCT01993524|Other|placebo|antibiotic plus placebo
75475315|NCT01993537|Drug|Vitamin D|
75475316|NCT01993550|Behavioral|Telephone counseling|
75475317|NCT01993550|Behavioral|Education|
75511237|NCT04898452|Other|A new model of interaction across health services with use of welfare technology and telemedicine|Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
75511238|NCT04767919|Procedure|Standard Percutaneous Nephrolithotomy (sPCNL)|Endoscopic stone procedure using a laser placed in the kidney through an 30 Fr access sheath following balloon dilation.
75511239|NCT04767919|Procedure|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|Endoscopic stone procedure using a laser placed in the kidney through an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
75511240|NCT00091182|Drug|oxaliplatin|Given IV
75511241|NCT04635280|Device|any closed-loop automatic insulin delivery system (or artificial pancreas) CE-marking|A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and a dedicated terminal.
75511242|NCT04729790|Drug|PRIM-DJ2727|oral FMT capsules
75652492|NCT02619123|Other|Annual invitation to mammography|Annual interval mammography screening according to international guidelines for women younger than 50 years old
76117216|NCT00979875|Drug|Insulin aspart|
75475318|NCT01993563|Other|Graded Motor Imagery|"GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).~IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.~EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.~MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror."
75937934|NCT02393534|Other|Telephone Visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
75937935|NCT04463355|Behavioral|Video discharge instructions|Short video (2 minutes) including information about clinical features, management and follow up of pediatric patients with acute gastroenteritis
75937936|NCT02399150|Other|No intervention as observational study|
75652493|NCT04289129|Diagnostic Test|Myotonometric evaluation|Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.
75937937|NCT02305407|Procedure|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
75475319|NCT01993563|Other|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
75475320|NCT01993576|Drug|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
75475321|NCT01993589|Drug|comparison of pain relievers during curattage|
75475322|NCT01993589|Drug|comparison of pain relievers|
75475323|NCT01993589|Drug|comparison of pain relievers during curattage|
76089162|NCT04125615|Behavioral|Protected Time Intervention|Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
76089163|NCT01902004|Drug|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
76089164|NCT01902004|Drug|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
75652494|NCT02865005|Drug|Dapsone 5.0% Gel (SEEGPharm)|Topical Gel
75475324|NCT01993589|Drug|comparison of pain relievers during curattage|
75475325|NCT01993589|Drug|comparison of pain relievers during curattage|
75475326|NCT01993602|Procedure|Breathing exercises|"The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.~The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.~The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.~Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise."
75475327|NCT01993628|Other|Rey figure test|
75475328|NCT01993628|Other|MRI|
75475329|NCT01993654|Procedure|HRT III with Non-Contact Cornea Rostock Module|Confocal imaging of the conjunctival lesion
75652495|NCT02865005|Other|Placebo|Topical Gel
75652496|NCT02865005|Drug|Dapsone 5.0% Gel (Allergan)|Topical Gel
75652497|NCT02619045|Other|Telephone follow-up nursing device|"Telephone follow-up nursing device involving:~telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);"
75652498|NCT03835403|Other|Activation of HeartRunners|Activation of volunteer citizen first-responders to respond to nearby cardiac arrests
75475330|NCT01993680|Drug|Pyridostigmine bromide|"Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days"
75475331|NCT01993680|Drug|fludrocortisone|drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
75937938|NCT02305407|Other|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
75937939|NCT03507543|Drug|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
75937940|NCT04487782|Other|Focus Groups|The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
75937941|NCT03167684|Device|Oral appliance therapy|Fitted oral appliance
75652499|NCT02618889|Behavioral|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
75652500|NCT04287257|Device|Fracture Healing Patch (FHP)|The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.
76089165|NCT01902004|Drug|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
76089166|NCT04125303|Behavioral|brief motivational psychoeducational therapy|The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
76089167|NCT03829995|Other|Drug counseling|Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
76089168|NCT01938040|Drug|ibuprofen|single preoperative dose prior to surgery
76089169|NCT01938040|Other|sugar water/placebo|single preoperative dose prior to surgery
76089170|NCT04125849|Procedure|Thoraco-laparoscopic esophagectomy|Thoraco-laparoscopic esophagectomy surgery
76089171|NCT04125849|Procedure|Mediastinoscopy-assisted transhiatal esophagectomy|Mediastinoscopy-assisted transhiatal esophagectomy surgery
75341962|NCT00600704|Procedure|Free fluid infusion|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
75341963|NCT01790282|Drug|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
75341964|NCT01790282|Drug|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
75341965|NCT00691808|Drug|LX6171 High Dose|A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
75652501|NCT02862977|Drug|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
75475332|NCT01993693|Device|Ultrasonic Diathermy Device|The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.
75475333|NCT01993693|Device|Sham Ultrasonic Diathermy Device|Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound
75475334|NCT01993706|Drug|VRC-HIVMAB060-00-AB|
75652502|NCT02862977|Drug|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
75800005|NCT03814512|Behavioral|Extended Sleep Intervention|Participants will receive an Extended Sleep Intervention (ES). Participants will be prescribed a sleep schedule that allows them to obtain approximately 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively through discussion with participants and parents.
75800006|NCT01560312|Device|Renal denervation (Symplicity® Catheter System™)|4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)
75800007|NCT01560390|Drug|Rémifentamil + KETAMINE|All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.
75800008|NCT01560390|Drug|ketamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
75800009|NCT05400798|Device|Adipose Derived Regenerative Cells|single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
75800010|NCT05400798|Device|Corticosteroid|a single corticosteroid injection into the associated subacromial space
75800011|NCT01301898|Drug|GC1111_0.5mg/kg|
75800012|NCT01301898|Drug|GC1111_1.0mg/kg|
76089172|NCT01765751|Procedure|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
76089173|NCT03829839|Drug|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin
75652503|NCT02618655|Other|diagnostic methods|explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
75652504|NCT02864927|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
75341966|NCT00691808|Drug|LX6171 Low Dose|A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
75341967|NCT00691808|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
75341968|NCT03843541|Drug|N-acetylcysteine (NAC) 600 mg|NAC will be administered twice a day, morning and evening, during treatment period.
75475335|NCT01993732|Procedure|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
76089174|NCT03829839|Drug|Lorazepam 1 mg|Oral administration of 1mg lorazepam
76089175|NCT03829839|Drug|Placebo nasalspray|The placebo nasalspray contain identical ingredients except for the active agent itself.
76089176|NCT03829839|Drug|Placebo Oral Tablet|The placebo pill contain identical ingredients except for the active agent itself.
75341969|NCT03843541|Drug|Ambroxol hydrochloride 30 mg|Ambroxol hydrochloride will be administered twice a day, morning and evening, during treatment period.
75341970|NCT03843541|Other|placebo|Placebo will be administered twice a day, morning and evening, during treatment period.
75341971|NCT00692198|Drug|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
75341972|NCT00639158|Drug|ABT-335|135 mg capsule, daily, 12 weeks
76089177|NCT01938664|Drug|Candesartan with CBT|8 mg, po (by mouth)
76089178|NCT01938664|Other|Placebo with CBT|
76089179|NCT03829917|Drug|Miltefosine and Paromomycin|28 days of miltefosine plus 28 days of Paromomycin cream
76089180|NCT03829917|Drug|miltefosine|28 days of miltefosine
75341973|NCT00639158|Drug|placebo|placebo capsule, daily, 12 weeks
75341974|NCT00639158|Drug|atorvastatin|40 mg, tablet, daily, 12 weeks
75341975|NCT00639158|Drug|ezetimibe|10 mg capsule, daily, 12 weeks
75475336|NCT01993758|Procedure|Low tourniquet pressure|Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation
76089181|NCT03829917|Drug|paromomycin|28 days of paromomycin creaam
76117217|NCT03716531|Radiation|IORT|IORT works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy
75341976|NCT03004885|Device|PrismaLung|Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
75341977|NCT02994589|Other|Tegaderm™(Absorbant, 3M)|3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
75341978|NCT02994589|Device|OASIS® wound matrix|OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
75341979|NCT02994589|Other|Xeroform™|Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
75341980|NCT03498859|Other|Physiotherapist-supervised training|The intervention is physiotherapist-supervised training once per week during 10 weeks.
75475337|NCT01993758|Procedure|Conventional tourniquet pressure|Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
75652505|NCT02864927|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
75652506|NCT00697359|Device|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
75652507|NCT02618499|Drug|Timing of administration of post partum Oxytocin|10 IU of oxytocin given IV at different times after birth
75652508|NCT04133961|Drug|Phenylephrine|Phenylephrine infusion 0.3ml/kg/hour (equivalent to 0.5mcg/kg/min, phenylephrine dilution is 100mcg/ml in 20ml syringe)
75652509|NCT04133961|Drug|Normal saline|Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
75800013|NCT01301898|Drug|Elaprase_0.5mg/kg|
75800014|NCT03815136|Other|Chewing Gum|Patients of CG group chewed one piece of sugarless gum for approximately 15 min every 30 min at the first hour of the examination.
75800015|NCT03815136|Other|Control|The control group will not chew chewing gum while undergoing capsule endoscopy
75800016|NCT03808194|Other|Conditional lottery incentive|Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
75800017|NCT03808194|Other|Optimized ART linkage package|Optimized ART linkage package
75800018|NCT03807882|Other|Bilateral M-ECT|Following acute treatment with bilateral ECT of 6 sessions over a period of two weeks, Bilateral M-ECT will be administered at a frequency of 1 session/week for one month, then 1 session / 2 weeks for 2 months and then 1 session/month for next 3 months.
75800019|NCT03807882|Drug|Clozapine|Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
75341981|NCT03498859|Other|Home-based training|The intervention is home-based training during 10 weeks
75341982|NCT05424133|Other|High frequency chest wall oscillation|High frequency chest wall oscillations at 13-15Hz oscillating frequency for 20 minutes twice a day for 4 weeks.
75475338|NCT01993771|Procedure|Surgery with general anaesthesia.|
75341983|NCT05424133|Other|Active cycle of breathing|Active cycle of breathing technique and it will performed twice a day for 4 week intervention period for 20 minutes
75652510|NCT02618265|Procedure|Mobile terminal|multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
75800020|NCT03814434|Procedure|Non-Surgical treatment|Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation
75937942|NCT05454904|Behavioral|Low fat diet|The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the following criteria: 1) <3 teaspoons/day of olive or Canola oil and <3 units/week of avocado, 2) removal of visible fat from meats before cooking or from cooked dishes before intake, 3) ≤1 serving per week fat-rich meats, hamburger, commercial ground meat, sausage, cured ham, bacon and salami, 4) daily consumption of low fat dairy products, 5) ≤1 serving/week of butter, margarine, lard, mayonnaise, milk cream, or milk- based ice cream, 6) ≤1 time/week intake of fatty fish or seafood, 7) ≤1 serving per week of commercial sweets or industrial bakery products (not homemade), and 8) ≤1 time/week consumption of nuts (including peanuts), potato chips, French fries, or commercial snacks. This intervention arm will be supplemented with powdered low fat milk (3 kgs/month) for daily use.
75937943|NCT05454904|Behavioral|Mediterranean diet|The Mediterranean diet group will receive dietary recommendations as follows: 1) use of olive oil (>3 teaspoons/day), 2) Canola oil as second fat source for cooking and dressing or >3 units/week of avocado; 3) ≥3 daily servings of vegetables (at least one of them as fresh vegetables in a salad), 4) ≥2 daily servings of fresh fruits; 5) ≥2 weekly servings of legumes; 6) >2 weekly servings of fresh, canned or frozen fish (at least one serving of oily fish)/seafood; 7) ≥2 weekly servings of nuts/seeds; 8) 4-8 servings/week of white meats (poultry or turkey without skin) instead of 9) fatty or processed meats (<1 serving/week), 10) ≥2 daily servings of whole grains, 11) ≥1 daily/serving of low fat and fermented dairy products, 12) <1 daily/serving of whole fat dairy products, 13) ≤1 daily/serving of sugary snacks, drinks or juices and <4 teaspoons/daily of sugar, and 14) moderate (1-2 drinks/day) wine consumption with meals.
76089182|NCT03829449|Drug|rVA576 (Coversin)|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).
76089183|NCT01736657|Device|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
75341986|NCT00692276|Device|Superion™ Interspinous Spacer|Implantation of interspinous process spacer to treat lumbar spinal stenosis
75341987|NCT00692276|Device|X-STOP® IPD® Device|Implantation of interspinous process spacer to treat lumbar spinal stenosis
75341988|NCT02248987|Other|patients treated with antipsychotics|
75475339|NCT01993771|Procedure|Raw EEG|
75475340|NCT01993784|Drug|nimotuzumab|
75475341|NCT01993797|Other|Lung US|
75800021|NCT03814434|Procedure|Surgical Treatment|Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
75800022|NCT05647434|Procedure|sustained inflations|Sustained inflation will be applied at a pressure of 30 cmH2O and will be held for a period of 30 secs. After each SI the standard ventilatory settings will be resumed with a PEEP setting of 8 cmH2O to prevent lung derecruitment. Lung recruitment will be stopped immediately if mean arterial pressure and/or heart rate change by at least 25% from baseline values.
75341989|NCT03004963|Device|Body composition monitor|Both body composition monitor (BCM) is used to evaluate the volume status of patients.
75341990|NCT03004963|Device|clinical indexes|The investigators evaluate the volume status of patients according to clinical indexes.
75341991|NCT00639860|Device|OSSIX-Plus|resorbable collagen membrane
75341992|NCT05392309|Other|Manual ankle rocking training|Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk
75475342|NCT01993862|Other|Same Day Discharge|Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
75475343|NCT01993901|Other|CSRT led telephone follow up|Patients in the intervention group will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms. A second follow up telephone call will be made at 12 weeks post treatment if required in order to address treatment related side effects that were identified during the first call and any interventions that were recommended
75652511|NCT02618265|Procedure|traditional management|aspirin or clopidogrel monotherapy or double treatment for
75652512|NCT02618265|Procedure|website platform management|second prevention based on website platform management
75652513|NCT02618733|Drug|Ticagrelor|90mg, twice a day
75652514|NCT02618733|Drug|Clopidogrel|75mg, once a day
75652515|NCT04134195|Device|Transcranial direct current stimulation|2mA stimulation for 20 minutes
75800023|NCT01303146|Drug|rhARSA|intravenous infusion 100U/kg every other week for 18 months
75800024|NCT03806946|Diagnostic Test|electroencephalography|diagnosis epileptic discharge
75800025|NCT03806946|Diagnostic Test|psychometric scales to diagnosis psychiatric disorders|to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.
75800026|NCT03806946|Other|psychometric scales for assesment socioeconomic and behaviour problems|to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden
75800027|NCT03806322|Other|Intermittent Pneumatic Compression|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression.
76089184|NCT04124679|Other|Transcutaneous Electrical Acupoint Stimulation|patients received Transcutaneous Electrical Acupoint Stimulation for 30 mins on the acupoints
76089185|NCT02284126|Drug|Vancomycin|Topically applied powder and paste to surgical site at time of closure.
76089186|NCT01736579|Drug|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)|
76089187|NCT02974335|Behavioral|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
76089188|NCT01939288|Device|Neuromuscular stimulation, followed by intermittent pneumatic compression|
76089189|NCT01939288|Device|Intermittent pneumatic compression, followed by neuromuscular stimulation|
76089190|NCT01940146|Drug|SPARC Placebo|Placebo
76089191|NCT01940146|Drug|SPARC1310 I|SPARC1310 I
76089192|NCT01940146|Drug|SPARC1310 II|SPARC1310 II
76089193|NCT01940146|Drug|SPARC1310 III|SPARC1310 III
75341993|NCT05392309|Other|Conventional|Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
75475344|NCT01993953|Other|BodyPump|Participants will be offered BP sessions at fitness centers in Oslo/Akershus. They will exercise three times a week. The instructors at all centers have a BP license from Les Mills, and the same program will be conducted at all centers at all times. The project manager has been in contact with Les Mills Scandinavia and has been given permission to use the training concept for research.
75475345|NCT01993953|Other|Personal training|Participants in this group will be offered training with a PT at the Norwegian School of Sports Sciences. They will exercise with their PT three times per week. The training program for this group will be based on the exercises in the BP class, but repetitions will vary between 3-15, and series between 2-4.
75475346|NCT01993953|Other|Resistance training with instructor|Participants in this group will be invited to train on their own, three times a week, at the Norwegian School of Sports Science. Prior to the intervention period they will receive a training manual, instructions of the exercises and advice about progression during the intervention period. They will also have a follow-up with the same instructor after six weeks. The training program for this group will be the same as for group B. The PT's from group B will also serve as training instructors.
75475347|NCT01993979|Drug|Chemotherapy|
75652516|NCT02617953|Device|Active rTMS(A)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
75800028|NCT03806322|Other|Cold-pack|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs.
75937944|NCT05454904|Behavioral|Mediterranean diet plus psychological well-being support|This group will be subjected to the same Mediterranean diet pattern indicated previously as well as to a psychological well-being intervention that will include a variety of components/activities, embracing values, purpose, self-acceptance, character strengths, emotional regulation, dealing with negativity, goal-setting, mindfulness, savoring, gratitude, autonomy, relationships, social interactions, and prosocial behavior.
75937945|NCT02305485|Device|NeoVas BCS|Subjects receiving NeoVas BCS
76089194|NCT01765673|Device|Vibrotactile stimulation|Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
76089195|NCT04124913|Drug|Dydrogesterone 10 MG Oral Tablet|Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
75341994|NCT00692978|Drug|Fluticasone Propionate_1.5|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
75341995|NCT00692978|Drug|Fluticasone Propionate_3|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
75341996|NCT00692978|Drug|Fluticasone Propionate_6|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
75341997|NCT00692978|Drug|FP From Active 250 ug MDI Inhaler|Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
75475348|NCT01993979|Other|Surveillance|Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
75475349|NCT01994005|Behavioral|Facebook|Facebook page with contraception information used for counseling
75475350|NCT01994005|Behavioral|Pamphlet|Contraceptive knowledge pamphlets
75475351|NCT01994031|Drug|Paclitaxel liposome injection|
75937946|NCT02305485|Device|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
75937947|NCT02399072|Other|No intervention|No intervention administered in this study
75937948|NCT04480762|Drug|SHR-1703|SHR-1703
75937949|NCT04480762|Drug|Placebo|Placebo of the SHR-1703
75937950|NCT02311569|Drug|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
76089196|NCT04124913|Drug|Progesterone Vaginal Gel [Crinone]|Vaginal progesterone gel 90 mg once a day for luteal phase support
76089197|NCT03828279|Diagnostic Test|functional and antigenic C1 inhibitor|Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
76089198|NCT02987920|Drug|Dextromethorphan|Additional medication to perioperative analgesic regimen in Group B
76089199|NCT02987920|Drug|Placebo - Concentrate|Additional medication to perioperative analgesic regimen to Group A
76089200|NCT02987920|Drug|Acetaminophen|Multimodal analgesic regimen to Group A and Group B
76089201|NCT02987920|Drug|Oxycodone|Multimodal analgesic regimen to Group A and Group B
76089202|NCT02987920|Drug|Celecoxib|Multimodal analgesic regimen to Group A and Group B
76089203|NCT02987920|Drug|Pantoprazole|Multimodal analgesic regimen to Group A and Group B
75937951|NCT02399306|Drug|Enteral nutrition|Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.
75937952|NCT02399306|Radiation|radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f."
75937953|NCT02393456|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
75937954|NCT02393456|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
75937955|NCT02393612|Drug|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
75937956|NCT02393612|Drug|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
75475352|NCT01994031|Drug|Paclitaxel injection|
75475353|NCT01994044|Procedure|Cervical fusion|
75652517|NCT02617953|Device|Active rTMS(B)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
75652518|NCT02617953|Device|Sham condition(C)|"The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
75937957|NCT02311803|Procedure|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
75937958|NCT02311803|Procedure|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
75341998|NCT03004807|Dietary Supplement|Centrum Silver Mens' Formula|Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.
75475354|NCT01994070|Drug|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
75652519|NCT02618109|Biological|Collection of blood samples|Collection of blood samples
75652520|NCT00970307|Biological|GSK2202083A vaccine|Intramuscular, three doses
75800029|NCT03805854|Device|10 Hz tACS of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
75800030|NCT03805854|Device|10 Hz tACS of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
75800031|NCT03805854|Device|80 Hz tACS of the bilateral somatosensory cortex|80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
75937959|NCT02546362|Device|Cefaly|
75937960|NCT03167840|Behavioral|Physical and Cognitive Training|Physical Exercise and Cognitive Training
75937961|NCT03167840|Behavioral|Physical Training|Physical training alone
75341999|NCT03004807|Other|Control|A matching tablet to the dietary supplement, but without any active ingredients
75342000|NCT00601718|Drug|vorinostat|Given PO
75342001|NCT00601718|Biological|rituximab|Given IV
75342002|NCT00601718|Drug|ifosfamide|Given IV
75342003|NCT00601718|Drug|carboplatin|Given IV
75342004|NCT00601718|Drug|etoposide|Given IV
75342005|NCT00601718|Other|pharmacological study|Correlative studies
75342006|NCT00601718|Other|laboratory biomarker analysis|Correlative studies
75342007|NCT00601718|Genetic|gene expression analysis|Correlative studies
75342008|NCT03004729|Other|CoMiSS questionnaire|
75937962|NCT03167840|Behavioral|Cognitive training|Cognitive training alone
75937963|NCT03504891|Diagnostic Test|MRI prior to CRT Upgrade|We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
75937964|NCT03504891|Diagnostic Test|MRI prior to de novo CRT|We will perform MRI prior to de novo CRT implants as the comparison group.
75937965|NCT02306733|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
75937966|NCT02306733|Drug|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
75937967|NCT05454436|Procedure|sinus tract healing in single or multi visit with single cone technique with bioceramic sealer|Investigators will see the healing rate between single visit and multi visit with single cone technique with bioceramic sealer .
75937968|NCT02698436|Device|Acne Mask|The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes
76089204|NCT02987920|Drug|Ketorolac|Multimodal analgesic regimen to Group A and Group B
75342009|NCT03275779|Behavioral|Low Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
75937969|NCT02698436|Drug|2.5% Benzoyl Peroxide Treatment|The BPO treatment is applied twice daily, once in the morning and once in the evening
75342010|NCT03275779|Behavioral|High Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
75652521|NCT00970307|Biological|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
75800032|NCT03805854|Device|80 Hz tACS of the prefrontal cortex|80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
75937970|NCT03507465|Drug|Letrozole Plus Low-Dose Metronomic Capecitabine|Letrozole Plus Low-Dose Metronomic Capecitabine
75475355|NCT01994070|Drug|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
75937971|NCT03507465|Drug|EC-T|Epirubicin/Cyclophosphamide Followed by Docetaxel
75937972|NCT05476042|Drug|Prescription of placebo|Normal saline
75937973|NCT05476042|Drug|Erythropoietin prescription|Erythropoietin 3000 units in normal saline
75475356|NCT01994083|Drug|Placebo|Administered orally
75475357|NCT01994083|Drug|IX-01|Administered orally
75652522|NCT00970307|Biological|Infanrix hexa™|Intramuscular, three doses
75652523|NCT00970307|Biological|Menjugate®|Intramuscular, two doses
75800033|NCT03805854|Device|Sham stimulation of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
75937974|NCT05476042|Drug|Erythropoietin prescription|Erythropoietin 6000 units in normal saline
75937975|NCT03507387|Drug|Phenylephrine|5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .
75937976|NCT03507387|Drug|Normal saline|1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
75937977|NCT03507387|Drug|Bupivacaine|All patients will receive spinal anesthesia with bupivacaine.
75342011|NCT03004651|Other|Power Doppler ultrasound|Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)
75342012|NCT03004651|Other|Clinical evaluation|swollen joint count (SJC) as componant of SDAI
75475358|NCT01994096|Drug|Caspofungin|
75475359|NCT01994135|Other|Reference food|Reference food will be used to which test food samples will be compared to.
75475360|NCT01994135|Other|Test food dose 1|Will contain low dose of a mixture of polyphenols in addition to the reference food
75475361|NCT01994135|Other|Test food dose 2|Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
75475362|NCT01994148|Procedure|Laparoscopy|In this study, laparoscopic intervention will be performed under carbon dioxide pneumoperitoneum (pressure, 10-12 mm Hg; flow volume, 8-10 L/min). A 12-mm trocar will be placed in the umbilicus with use of an open technique and to establish pneumoperitoneum.A 10-mm and a 5-mm trocar will be inserted in the right and left flanks,respectively.
75475363|NCT01994161|Procedure|intracranial stenting|"all the participants in this group will be performed with intracranial stenting~--------------------------------------------------------------------------------"
75475364|NCT01994187|Procedure|Carotid endarterectomy|
75475365|NCT01994187|Procedure|carotid angioplasty|
75475366|NCT01994200|Other|Interdisciplinary Team-Based Approach|Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
75937978|NCT03508401|Other|Passive leg raising (PLR)|"PLR is a test that predicts whether cardiac output will increase with volume expansion. By transferring a volume of around 300 mL of venous blood from the lower body toward the right heart, PLR mimics a fluid challenge. However, no fluid is infused and the hemodynamic effects are rapidly reversible, thereby avoiding the risks of fluid overload.~PLR starts from the semi-recumbent and not the supine position. PLR is performed by adjusting the bed and not by manually raising the patient's legs"
75937979|NCT03508401|Device|Echo-Doppler measurements|"Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). All measurements are recorded at the end of expiration. Echo-Doppler measurements are performed in the upper part of the SVC, approximately 1 to 2 cm below the brachiocephalic vein. From this view, pulse Doppler is performed. Pulse Doppler waves obtained in the SVC are used to obtain velocity time integrals (VTI). Expiratory VTI is named VTImax and inspiratory VTI is named VTImin. These values will allow the calculation of Respiratory variations of the superior vena cava flow (ΔSVCf).~ΔSVCf is calculated as (VTImax- VTImin )/(1/2(VTImax+ VTImin))."
76089205|NCT02987920|Drug|Gabapentin|Multimodal analgesic regimen to Group A and Group B
75475367|NCT01994200|Other|Usual Care Control|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
75475368|NCT01994213|Drug|Famitinib|Famitinib 25 mg p.o. qd
75475369|NCT01994265|Drug|Warfarin|Warfarin once daily, at fast, targeting INR between 2 and 3
75342013|NCT03004573|Other|Neuropsychological detailed tests with focus on social cognition|MATTIS, MOCA, BREF, Light points test, PDQ39
75342014|NCT00640250|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
75652524|NCT02617875|Other|conventional EMS physician|A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.
75800034|NCT03805854|Device|Sham stimulation of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
75937980|NCT03504813|Other|Physical activities program|To implement this line, the protocol of the VIVIFRAIL Project will be used as a reference. That protocol has different physical exercises, divided into itineraries, in order to adapt it to a person's capability. Several sessions of this research line will employ the use of videogames so that the elderly can explore new forms of physical activity and thus establish contact and expertise with new technologies. It is estimated that two sessions per week over two months are needed for each person to continue doing physical activity independently and with autonomy.
75937981|NCT03504813|Other|Relaxation training|Will take place with those participants who are included in the research lines of insomnia and risk of falls. It is estimated that two sessions per week for one month are needed.
75937982|NCT03504813|Other|Training of the pelvic floor|the intervention will apply to participants enrolled in the research line dealing with urinary incontinence during the six months of intervention, with a frequency of two sessions per week
75475370|NCT01994265|Drug|Dabigatran|
75475371|NCT01994278|Device|Peri Clean|
75652525|NCT02617875|Other|tele-EMS physician|The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
75475372|NCT01994304|Behavioral|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
75937983|NCT03504813|Behavioral|Counseling about occupational performance|After the physical activity and relaxation programs, the counselling will start. With each participant, routines and daily activities will be planned that will be adequate according to different recommendations about urinary incontinence, insomnia and risk of falls. Different performance guidelines will be established in order to establish a good balance between activities. The guidelines can include the recommendations about adjustments to the environment. It is estimated that three sessions per week for two months are needed to incorporate advice and routines into the daily lives of participants.
75475373|NCT01994317|Other|Algorithm|IV sedation dosing calculated by algorithm
75475374|NCT01994317|Other|Standard care|IV sedation dosing calculated by standard care.
75652526|NCT00917384|Biological|ramucirumab|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
75652527|NCT00917384|Drug|Placebo|Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
75652528|NCT00917384|Other|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
75800035|NCT03796494|Procedure|Straight abutment|This is the classic abutment, straight and anti-rotational for dental implants which have been tested before
75800036|NCT03796494|Procedure|Slim abutment|This is the new concept of the prostheses abutment, slim and anti-rotational to improve the width of biologic space
75937984|NCT02694536|Drug|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
75937985|NCT02694536|Drug|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
75937986|NCT01661686|Device|Partially covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
75937987|NCT01661686|Device|Fully covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
75937988|NCT02312037|Biological|Antibody Drug Conjugate Chemotherapeutic|"Three Treatment Regimens:~Mylotarg <=9 mg/m2 as a single agent on Day 1 & 14 of a 28-day cycle for a total of two cycles~Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen~Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL"
75937989|NCT03167918|Drug|Calcium Dobesilate|gave each patient 0.5 g bid，
75937990|NCT03167918|Drug|Xuefuzhuyu Decoction|gave each patient100 ml bid，po
75937991|NCT03167918|Drug|Xuefuzhuyu Decoction & Calcium dobesilate|gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
75475375|NCT01994330|Drug|desmopressin|0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
75475376|NCT01994343|Other|Global posture reeducation|An assessment of the women is performed using global posture reeducation.
75475377|NCT01994356|Behavioral|Physician self-disclosure of personal IUC use|Physicians self-disclosed personal intrauterine contraceptive use to subjects in intervention arm of study during contraceptive counseling
75937992|NCT03167918|Drug|metformin|gave each patient 1000 mg, bid, PO
76089206|NCT02987920|Drug|Hydromorphone|Multimodal analgesic regimen to Group A and Group B
76089207|NCT03902301|Dietary Supplement|Lactobacillus group|Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).
76089208|NCT03902301|Dietary Supplement|Dietary group|Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
76089209|NCT01764659|Other|Contrast-enhanced 4D computed tomography|All enrolled patients each underwent three CT scans: a 4DCT immediately following a contrast-enhanced 3DCT and an individually optimized contrast-enhanced 4DCT.
76089210|NCT03828123|Biological|Suspension of human autologous MSC 3P in 1.5 ml|Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
76089211|NCT02974257|Drug|Thiamine|Thiamine 500mg IV twice daily for 2 days
76089212|NCT02974257|Other|placebo|100mL normal saline IV every 12 hours for 2 days
76089213|NCT01736189|Drug|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
75342015|NCT00601796|Biological|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
75342016|NCT00601796|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
75475378|NCT01994356|Behavioral|Usual contraceptive counseling|all subjects recieved usual contraceptive counseling
75475379|NCT01994369|Drug|EC17|
75652529|NCT04133571|Drug|0.05% Lidocaine|0.05% lidocaine with normal saline as a bladder irrigation solution after transurethral surgery intravenous pethidine to decrease CRBD if needed
75652530|NCT03749837|Device|C- MAC VS|The C-MAC VS is a new device on the airway management aid market. It will be used according to the instructions of the distributor. Before the study starts on humans, each study participants will do at least 5 intubations on an airway manikin or more until he or she feels confident to use the device.
75652531|NCT03749837|Device|Video Endoscope|Fiberoptic video endoscopic devices are standard aids to facilitate intubation on all study sites and are used according to the instructions to use. To facilitate fiberoptic intubation a macintosh blade to raise the root of tongue will be used. Also with these devices the study participants need at least 5 trials to intubate a manikin (or more to feel confident) before they are going to use the study device in patients.
75475380|NCT01994408|Other|default intensification|The investigators will determine which blood pressure medications to use. No specific drug will be tested but rather the automatic intensification of medications is the intervention. Examples of drugs used in this study are calcium channel blockers (e.g., amlodipine 2.5 mg to 10 mg) or ACE-inhibitors (e.g., lisinopril 5 mg to 40 mg) or diuretics (HCTZ 25 mg).
75800037|NCT03814278|Behavioral|complete bed rest|Patients in this group received standard care for PPROM according to the institution protocol, including antepartum confinement to bed.
75937993|NCT03167918|Drug|Mecobalamin Tablets|gave each patient 0.5 mg bid, PO
75800038|NCT03814278|Behavioral|activity restriction|Patients in this group received standard care for PPROM according to the institution protocol but to had bathroom privileges and walks to the ward canteen four times per day.
75937995|NCT05745818|Drug|Colchicine Pill|oral pills
75937996|NCT05475964|Device|Endoscopic ultrasound|Endoscopic ultrasound and biopsy intake of suspected lesions
75800039|NCT04368858|Diagnostic Test|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.|In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.
75937997|NCT02393300|Drug|normal saline|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
75937998|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
76089214|NCT01903564|Device|magnetocardiography|recording of magnetic heart activity
76089215|NCT01903564|Device|postnatal ECG|postnatal ECG
76089216|NCT01903564|Device|fetal echocardiography|fetal echocardiography
76089217|NCT02970981|Biological|Nivolumab|
76089218|NCT02970981|Biological|Ipilimumab|
76089219|NCT02987842|Device|TruScan Neurofeedback|Neurofeedback and quantitative EEG system
76089220|NCT04169711|Drug|ARO-HIF2|Multiple doses of ARO-HIF2 by intravenous infusion
75342017|NCT00601796|Drug|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
75475381|NCT01994421|Other|Kinesiotape|
75475382|NCT01994434|Procedure|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
76089221|NCT03829137|Device|Verum laser acupuncture|The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.
76089222|NCT03829137|Device|Sham laser acupuncture|The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
75342018|NCT00601952|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
75475383|NCT01994447|Other|Student Enrollment|The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
75342019|NCT00601952|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
75342020|NCT00693992|Other|Laboratory Biomarker Analysis|Correlative studies
75342021|NCT00693992|Other|Placebo|Given PO
75342022|NCT00693992|Other|Quality-of-Life Assessment|Ancillary studies
75342023|NCT00693992|Drug|Sunitinib Malate|Given PO
75342024|NCT00645710|Drug|gemcitabine hydrochloride|Given IV
75342025|NCT00645710|Drug|floxuridine|Given via hepatic arterial infusion
75342026|NCT00645710|Genetic|proteomic profiling|Correlative studies
75342027|NCT00645710|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
75342028|NCT00645710|Other|liquid chromatography|Correlative studies
75342029|NCT00645710|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
75342030|NCT00645710|Other|laboratory biomarker analysis|Correlative studies
75475384|NCT01994460|Drug|Linezolid|
75475385|NCT01994460|Drug|Ethambutol|
75937999|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
75938000|NCT02305875|Other|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
75938001|NCT03106610|Drug|Nivolumab|3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.
75938002|NCT03106610|Behavioral|Questionnaires|2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
75938003|NCT02678884|Drug|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
75938004|NCT03504735|Behavioral|Therapeutic Lifestyle Change|Monthly consult with a dietitian and fitness instructor.
75342031|NCT00645710|Other|mass spectrometry|Correlative studies
75342032|NCT00645710|Other|pharmacological study|Correlative studies
75342033|NCT00603044|Drug|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
75475386|NCT01994473|Drug|SEP-363856|SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg
75475387|NCT01994473|Drug|Placebo|single oral dose placebo
75475388|NCT01994473|Drug|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
75475389|NCT01994512|Procedure|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
75475390|NCT01994512|Procedure|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
75475391|NCT01994525|Biological|PfRAS|Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes
75475392|NCT01994525|Biological|Placebo|Administered by the bite of noninfected Anopheles stephensi mosquitoes
75475393|NCT01994525|Other|Challenge|5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
75475394|NCT01994603|Behavioral|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
75475395|NCT01994603|Behavioral|Focus Group|Study participants will be invited to participate in a focus group discussion.
75475396|NCT01994616|Procedure|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
75475397|NCT01994642|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension|
75938005|NCT03504735|Drug|Caduet Pill|Take once daily.
75938006|NCT03504735|Drug|Placebo|Take once daily.
75938007|NCT05475886|Drug|Hydroxyethyl starch 130/0.4|An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
75938008|NCT02312115|Drug|Furosemide|Diuretic
75938009|NCT02312115|Drug|Placebo|Saline
75938010|NCT03106532|Drug|PHP-201 0.25% ophthalmic solution|3 drops daily, 28 days
75938011|NCT03106532|Drug|PHP-201 0.5% ophthalmic solution|3 drops daily, 28 days
75938012|NCT03106532|Drug|Placebo ophthalmic solution|3 drops daily, 28 days
75938013|NCT03504657|Device|Drug-coated balloon angioplasty|Angioplasty with a drug-coated angioplasty
75938014|NCT03504657|Device|stenting angioplasty|Angioplasty with a stenting
75938015|NCT03026140|Drug|Nivolumab|Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
75938016|NCT03026140|Drug|Ipilimumab|Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
75938017|NCT03026140|Drug|Celecoxib 200mg|celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
75342034|NCT00603902|Drug|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
75800040|NCT03813810|Other|Non|There would be no interventions. Only measurements will be performed.
75938018|NCT03026140|Drug|BMS-986253|BMS-986253 2400mg IV will be administered on day 1 and 15 (only applicable for patients with MSS tumors)
75938019|NCT03026140|Drug|BMS-986016|Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29
75938020|NCT02398994|Drug|Intravenous Methylprednisolone|
75475398|NCT01994642|Drug|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)|
75800041|NCT03814122|Behavioral|Action-based cognitive remediation|Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.
75938021|NCT02398994|Drug|Intravenous Immunoglobulin|
75938022|NCT02306889|Drug|Fenofibrate|130mg Capsules
75938023|NCT02306889|Drug|ANTARA® (fenofibrate)|130mg Capsules
75938024|NCT02393144|Device|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
75342035|NCT00603902|Drug|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
75342036|NCT00603902|Drug|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
75475399|NCT01994642|Drug|Placebo Sterile Otic Suspension|
75800042|NCT03814122|Other|Waitlist Control Group|Receive treatment-as-usual through regular early psychosis programming.
75475400|NCT01994655|Other|Doing exercise|We want to investigate the effects of exercise on climacteric symptoms
75475401|NCT01994655|Other|Doing exercise|Doing exercise at least 6 months including walking, running, yoga etc.
75475402|NCT01994668|Drug|Lorazepam|A single intravenous administration of 2 mg lorazepam over 1 minute
75800043|NCT01303302|Device|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
75800044|NCT01303302|Device|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
75800045|NCT01303458|Behavioral|Basic Needs Surveillance (BNS) protocol|The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
75938025|NCT02393144|Device|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
75938026|NCT02393144|Other|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
75938027|NCT02393144|Drug|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
75342037|NCT00646646|Drug|propofol|sedative
75342038|NCT00646646|Drug|dexmedetomidine|Sedative
75342039|NCT00646646|Drug|Midazolam|sedative
75342040|NCT00646646|Drug|saline placebo|saline placebo
75342041|NCT02998658|Device|Vaginal cuff closure using barbed sutures|Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
75342042|NCT02998658|Device|Vaginal cuff closure using conventional sutures|Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
75342043|NCT02998424|Drug|Propofol|Continuous infusion
75342044|NCT02998424|Device|Pupillary diameter measurement|Instantaneous measure
75475403|NCT01994668|Drug|Placebo|A single intravenous administration of 0.9% saline over 1 minute
75475404|NCT01994707|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation
75475405|NCT01994707|Procedure|Placebo|Deflated cuff on arm for 30 minutes.
75938028|NCT02393144|Drug|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
75938029|NCT02393144|Drug|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
75938030|NCT02393144|Drug|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
75938031|NCT05465200|Procedure|Structured treatment of cardiogenic shock patients|"Creation of hub&spoke structure which covers all Lower Silesian Voivodeship (Poland) for treatment of cardiogenic shock patients. Based on shared protocol patients are reported to hub by spoke and decision is made as for patient transfer or further treatment in the spoke facility. If decision on transfer is made, patient is further treated according to hub on site shock team protocol"
75938032|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected.
75938033|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected
75938034|NCT02393222|Other|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
75938035|NCT02306031|Drug|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
75938036|NCT02306031|Drug|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
75342045|NCT00696488|Drug|Fluorouracil 0.5%|Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
76089223|NCT03829293|Device|High-flow nasal cannula oxygenation group|usual care + High-flow nasal oxygenation (HFNO) therapy during GI endoscopy under sedation (with a flow at 70L/min and FiO2 50%) through a dedicated system, the THRIVETM (Fisher&Paykel, New-Zealand)
76089224|NCT03828435|Device|rTMS|Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
76089225|NCT02983773|Drug|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
76089226|NCT02983773|Drug|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
76089227|NCT02983773|Drug|Placebo|1 smoked placebo marijuana cigarette
76089228|NCT03828591|Procedure|Intensive psychological support|Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)
76089229|NCT03828591|Procedure|Standard psychological support|Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery
75342046|NCT00648908|Drug|Fampridine-SR|Tablets, 10 mg, BID
75342047|NCT00697190|Device|senofilcon A toric|silicone hydrogel contact lens for patients with astigmatism
75342048|NCT00697190|Device|galyfilcon A toric|silicone hydrogel contact lens for patients with astigmatism
75652532|NCT02617641|Behavioral|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
75938037|NCT02392910|Drug|Iron Sucrose|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
75938038|NCT02392910|Drug|Placebo|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
75342049|NCT02998112|Drug|fecal microbiota transplantation|Fecal microbiota which was purified from fresh stool defecated by a healthy donor
75938039|NCT02307045|Drug|Varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
75938040|NCT02307045|Drug|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
75938041|NCT02398604|Drug|Allo-hMSCs|Allogeneic Human Mesenchymal Stem Cells
75342050|NCT02998112|Drug|Saline|
75342051|NCT00650078|Drug|MR prednisone|1 x 5 mg daily
75342052|NCT00650078|Drug|Placebo|1x daily
75342053|NCT00699140|Biological|IGIV3I Grifols|Immune Globulin Intravenous (Human)
75342054|NCT01799486|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
75342055|NCT01799486|Drug|Enecavir|0.5 mg monotherapy supplied in tablets.
75342056|NCT01799486|Drug|Adefovir|10 mg monotherapy supplied in tablets.
75342057|NCT02320838|Device|5 KHz|5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
75342058|NCT02320838|Device|TENS|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
75342059|NCT02320838|Device|Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
75342060|NCT00650546|Drug|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
75938042|NCT02398604|Drug|Placebo|Placebo
75938043|NCT04464291|Other|Detection of Streptococcus pneumoniae strains|There will be detection of Streptococcus pneumoniae, serotype identification, susceptibility tests for penicillin, erythromycin, azithromycin, tetracycline, ciprofloxacin, levofloxacin, moxifloxacin and vancomycin
76089230|NCT01941472|Other|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
76089231|NCT04274205|Other|Intervention group|Brief supportive psychotherapy
76117218|NCT03714425|Device|Quell|Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
75342061|NCT02998190|Drug|Single Ascending Doses of EB8018|
75342062|NCT02998190|Drug|Single Ascending Doses of placebo|
75342063|NCT02998190|Drug|Multiple Ascending Doses of EB8018|
75342064|NCT02998190|Drug|Multiple Ascending Doses of placebo|
75342065|NCT00699218|Device|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
75342066|NCT00650858|Drug|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
75342067|NCT00650936|Device|AMPLATZER Septal Occluder|AMPLATZER Septal Occluder
75342068|NCT00651482|Drug|Everolimus|
75342069|NCT00651482|Drug|Bevacizumab|
75652533|NCT02617641|Behavioral|Publicly available websites|"Le Programme de marche (Institut de Cardiologie de Montréal)~L'activité physique (Institut de Cardiologie de Montréal)~L'activité physique (Fondation des maladies du cœur et de l'AVC)~Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)"
75652534|NCT02862899|Device|Thermowire|
75938044|NCT03167372|Other|Litebook® Advantage|Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.
75938045|NCT03167372|Other|Fitbit Flex2 TM|Standard system activity and sleep tracker
75938046|NCT02312271|Other|enteral formula|standard tube feeding formulas
75475406|NCT01994733|Drug|Calcium carbonate ( Intensive phosphate control)|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice
75475407|NCT01994733|Drug|Calcium carbonate (Liberalized phosphate control)|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
75652535|NCT04287023|Other|individual physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - individual
75652536|NCT04287023|Other|group physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - groups of 10 patients
75652537|NCT00629681|Drug|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
75652538|NCT05308394|Other|No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.|Each participant will provide a blood and fecal sample.
75800046|NCT03795948|Other|PROMs|"Introduction and assessment of the ICHOM standard set consisting of demographic and medical data as well as questionnaires filled in by patients, shortly after admission to the stroke unit, at discharge, and at 90 and 360 days after stroke.~Specifically the intervention includes an assembly of clinical records, in particular records of complications, recurrence of disease and mortality. Further patients will be required to complete a questionnaire assessing their situation in terms of housing and symptom burden as well as their self-perceived autonomy and quality of life.~Telephone assessments will be administered to support patients if necessary and validate their responses."
75800047|NCT01304472|Drug|Prasugrel|Prasugrel 10mg per day
75800048|NCT01304472|Drug|Clopidogrel|Clopidogrel 150mg per day
75800049|NCT03447210|Behavioral|Assisted Partner Services|Contact tracing for sexual and drug-sharing partners to notify about exposure to HIV and offer HIV and hepatitis C testing with linkage to care and partner services for those who test positive.
75800050|NCT03795792|Dietary Supplement|Curcumin|Will be provided in capsules
75800051|NCT03795792|Dietary Supplement|Hydrolyzed collagen|Will be provided in capsules.
75800052|NCT03813888|Other|Arsha Vidya chldren's Group|Yoga, Vedic chants, Vedant sessions, Gita sessions and group activities within the Gurukulam (centre)
75800053|NCT03813888|Other|Usual Activity group|Usual after school activities at home.
75800054|NCT03795636|Other|Garlic extract|A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water
75800055|NCT03795636|Other|NaOCl (COLTENE®)|Sodium hypochlorite
75800056|NCT01303536|Drug|Ondansetron|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
75938047|NCT02306109|Procedure|Standard motor rehabilitation treatment|Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
75938048|NCT02306109|Procedure|Intensive motor rehabilitation treatment|Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
75938049|NCT03167294|Device|AquaBeam System|Aquablation
75938050|NCT03504345|Drug|Prometrium|The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
76089232|NCT03828669|Behavioral|Recovery Toolkits|"Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)"
75342070|NCT02998034|Device|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
75342071|NCT02998034|Device|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
75342072|NCT00651794|Behavioral|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
75342073|NCT00651794|Behavioral|Standard NRP curriculum|The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
75475408|NCT01994759|Other|Training|Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly
75475409|NCT01994759|Drug|Glucocorticosteroid injection|"Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections)."
75475410|NCT01994759|Behavioral|Reduction in impact|advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.
75475411|NCT01994772|Procedure|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
75652539|NCT04289207|Drug|Romiplostim and danazol|Treatment with romiplostim and danazol
75652540|NCT04928378|Other|Descriptive retrospective study|characterization of the diagnosis, management and outcome of patients with osteoarticular infection due to MDR M. tuberculosis in France (MDR IOATB).
75652541|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
75652542|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
75652543|NCT04252118|Biological|MSCs|3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
75938051|NCT02398760|Other|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
75652544|NCT02863835|Other|EIT|All participants will have continuous monitoring of EIT whilst self venting
75652545|NCT02863835|Other|Salbutamol nebulisation and with CPAP|All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
75652546|NCT00697437|Drug|Docetaxel|70mg q3wx 1 dose
75652547|NCT00697437|Drug|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
75800057|NCT01303614|Drug|Lidocaine-Prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
75800058|NCT01303614|Drug|placebo|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
75938052|NCT02392988|Other|acupuncture treatment|acupuncture treatment
75938053|NCT02392988|Other|Placebo Comparator|Placebo Comparator
75800059|NCT03795714|Diagnostic Test|IVUS or OCT and Invasive physiologic indices|IVUS or OCT measurement in order to evaluate the lesion morphology and stent optimization, and invasive physiologic measurement in order to functional significance of epicardial stenosis
75938054|NCT02307201|Drug|Magnesium Sulfate|The patient will receive magnesium sulfate for 24 hours postpartum
75938055|NCT03167528|Behavioral|Relaxation|Relaxation
75938056|NCT03167528|Behavioral|Hypnosis|Hypnosis
75938057|NCT03167528|Behavioral|Holistic gymnastics|holistic gymnastics
75938058|NCT03167528|Device|Transcutaneous electrical nerve stimulation (TENS)|TENS
75938059|NCT03167528|Behavioral|Sophrology|Sophrology
75938060|NCT02306187|Drug|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
75938061|NCT03167216|Drug|Cromolyn Sodium|Mast cell stabilizer
75938062|NCT03167216|Drug|Cetirizine Hydrochloride|Histamine receptor antagonist
76089233|NCT01941628|Drug|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
75342074|NCT00651794|Behavioral|Skills practice with low-fidelity mannequin|
75342075|NCT00651794|Behavioral|Skills practice with high-fidelity mannequin|SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
75342076|NCT02997956|Drug|Tocilizumab|Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
75342077|NCT02997956|Procedure|Transcatheter Arterial Chemoembolization|Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
75342078|NCT00654836|Biological|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
75342079|NCT00654836|Drug|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
75342080|NCT00654836|Drug|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
75342081|NCT02997800|Drug|Esmolol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP >20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
75342082|NCT02997800|Drug|Labetalol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
75652548|NCT04252274|Drug|Darunavir and Cobicistat|Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments
75652549|NCT04133727|Behavioral|Use of an ageing suit|The simulation suit consists of a pair glasses which simulates narrowing of visual field; a pair of gloves ; a vest ; elbow and knee wraps and sand bags worn on the wrists and ankles
75652550|NCT04133727|Other|Polypharmacy workshop|Participants will conduct a full medication review for older adults within 1 hour and develop a medication list which can be used for counselling of older adults
75652551|NCT04133649|Drug|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
75652552|NCT05251844|Other|receiving an email|The email informed that the employee has had been identified as having accessed a patient's electronic medical record without a known work-related purpose and that unauthorized access is a privacy violation.
75652553|NCT02617173|Device|Micro 400 Matrix Therapy Products|Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
75800060|NCT03342378|Radiation|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) will be delivered over 6.5 weeks in 33 daily fractions. Treatments will be initiated on Monday or Tuesday. Missed treatments will be compensated for by delivering an additional BID treatment during the week given at least 6 hours apart OR treating on the Saturday of that week, OR adding to the end of treatment. Gross disease will receive 70 Gy in 2.12 Gy fractions, areas at high-risk for subclinical disease will receive 60 Gy in 1.82 Gy fractions, and areas at low-risk for harboring subclinical disease will receive 56 Gy in 1.70 Gy fractions.
75800061|NCT03342378|Diagnostic Test|PET-MRI|All imaging data will be acquired using a 3.0T PET-MRI scanner with a standard bore size of 60 cm. Patients will be placed in standard non-ferrous head and neck immobilization devices during PET-MRI to simulate their anticipated positioning during subsequent CT simulation and treatment. A head and neck PET-MRI study will be performed with scan sequences tailored for the site of interest. The PET-MRI exam will take approximately 90 minutes to complete.
75800062|NCT03813732|Procedure|orbital fracture|using the trans-conjunctival approach alone in restoring the esthetics compared with using it along in addition to lateral canthotomy which is important in providing wider surgical area
75800063|NCT03795480|Behavioral|MOOD|MOOD is an online self-help program targeted on depressive symptoms. The program consists of nine modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention. All modules are based on principles of cognitive behavioral therapy (CBT) and include elements of mindfulness-based and metacognitive techniques. The modules contain interactive exercises which are aimed at incorporating the participant's experiences into the program and increasing identification of the participant with the presented material. Participants are free to work through the different modules in their own speed and way, however, it is recommended to work on one to two modules per week.
75938063|NCT03508167|Device|Thermal Band|Thermal Band used 8 hours per day
75938064|NCT03508167|Drug|Dorilax®|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
75938065|NCT03508167|Drug|Placebo|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
75938066|NCT03507231|Behavioral|Email Message|Participants will randomly receive an e-mail message about the availability of free flu vaccines.
75938067|NCT03507231|Behavioral|Incentive for Vaccination|$5 gift card offered for vaccination
75938068|NCT03507231|Behavioral|Incentive for completing a short survey|$5 gift card offered for completing s short survey after one gets vaccinated
76025768|NCT05898880|Other|Acupressure by therapists|In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.
75652554|NCT05296226|Procedure|dry needling and ischemic compression|dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Ischemic compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points.
75800064|NCT03795090|Combination Product|Regular Patient privacy curtain|Laundered curtains, used in the hospital, coming from the hospital inventory.
75800065|NCT03795090|Combination Product|Antimicrobial Coated curtains|Antimicrobial coating consist of active polymers that are approved by USFDA and USEPA.
75800066|NCT03802578|Behavioral|HAND EXERCISE|
75800067|NCT03802422|Drug|Vitamin B12|Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.
75800068|NCT03802422|Drug|Normal saline|Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
75800069|NCT03813576|Diagnostic Test|Self-collected HPV vaginal swab|Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
75800070|NCT03813498|Behavioral|HCV articles|The intervention group receive a targeted short article on HCV from WeChat weekly.
75800071|NCT03813498|Behavioral|general health articles|The control group receive a general health article with no mention of HCV from WeChat weekly.
76025769|NCT05898880|Other|Control group|No intervention will be made in the control group.
76089234|NCT01941628|Drug|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
76089235|NCT02987218|Drug|Propofol|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
75652555|NCT04255316|Procedure|Modified method of eversion carotid endarterectomy|Mini approach for CCA bifurcation - Clamping ICA, ECA and CCA - ICA is cut off with a scalpel at the mouth itself - Dissection of the ICA and ECA in the distal direction to the distal border of the atherosclerotic plaque - Endarterectomy - Performing of a new bifurcation of the CCA with prolene 7/0
75652556|NCT04255316|Procedure|Standard method of eversion carotid endarterectomy|standard eversion technic
75652557|NCT04130607|Other|Conceptual teaching|"The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group."
75652558|NCT04130373|Procedure|Autologous fat grafting procedure|Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.
75652559|NCT04130373|Procedure|Breast reconstruction|Breast reconstructive procedures after oncological radical or conservative breast surgery
75652560|NCT04130451|Drug|PYODINE AND TALC SLURRY|"pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate"
75800072|NCT03813264|Other|Routine outcome measures (ROM)|The proposed study consists of two complementary processes: the first is the routine collection of clinical data using ROM; The second process is MATRIX-based intervention that is expected to improve the course of treatment.
75800073|NCT03801564|Device|Platelet Rich Plasma Treatment Group (PRP)|EASY PRP is in category IIa and manufactured by Neotec Biotechnology Industry and Foreign Trade Company. (Item No. 8680976403603; UNSPSC 42295470; GMDN 46923; certificate no: M.2016.106.7294).
75800074|NCT03801564|Device|Hyaluronic Acid Treatment Group (HA)|REGENFLEX STARTER is a class III intraarticular viscosupplementation device (Art. No. 8681065100076; UNSPSC 42295509). Sodium hyaluronate is obtained by bacterial fermentation (STREPTOCOCCUS EQUI) method. The product is in disposable packages, sterile and contained in a 2 ml pyrogen-free syringe.
75800075|NCT03795324|Other|Redlove Apple intervention|The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.
76025770|NCT05898867|Other|Saline|Open label intra-articular injection of isotonic saline.
75800076|NCT03795324|Other|Green Apple intervention|It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.
75800077|NCT03795324|Other|Aronia drink intervention|The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
75800078|NCT03795402|Device|Microneedle Device|Microneedle device will be used for collecting skin samples as a non-invasive method.
75800079|NCT03813186|Drug|ASTX727 + Day 2 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
75800080|NCT03813186|Drug|ASTX727 + Day 4 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 4.
75800081|NCT01304628|Drug|PL-3994|subcutaneous PL-3994, single dose, 4 escalating dose groups
76025771|NCT05898815|Diagnostic Test|Medical record collection|Medical record collection
76025772|NCT05898802|Dietary Supplement|Kimchi|Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated.
76025773|NCT05898802|Dietary Supplement|Placebo|Lactose with kimchi flavor
76089236|NCT02987218|Drug|Desflurane|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
76089237|NCT03822429|Drug|Controlled ovarian stimulation|Hormonal therapy to induce ovulation by multiple ovarian follicles
76089238|NCT01735175|Drug|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
75342083|NCT02997800|Drug|Fentanyl|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
75652561|NCT04130295|Other|Wearable intensive nerve stimulator|The wearable device consists of 2 leads that provide biphasic, with alternating lead phase, asymmetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
75342084|NCT02997800|Other|saline infusion|An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
75652562|NCT04031079|Device|Wearable tech with feedback|an armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone
75800082|NCT03795012|Drug|Eribulin|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
75800083|NCT03353350|Drug|efpeglenatide (SAR439977)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75800084|NCT03353350|Drug|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
75800085|NCT03800238|Behavioral|Telehealth Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered via telehealth.
75800086|NCT03800238|Behavioral|Standard Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered in the traditional in-person format.
75800087|NCT03799848|Drug|Vadadustat|Oral tablet
75652563|NCT04031079|Device|Wearable tech without feedback|an armwrist device measuring physical activity level, no reporting back to the user
75652564|NCT04031079|Behavioral|Rehabilitation program|traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)
75800088|NCT01382056|Other|control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
75800089|NCT01382056|Other|Mixed bean (higher amount)|0.6 cup of mixed beans consumed 5 days per week for 8 weeks
75800090|NCT01382056|Other|Mixed beans (lower amount)|0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
75800091|NCT03799692|Drug|Chemotherapy|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15.~Drug: Carboplatin AUC=2 iv, d1, 8, 15."
75800092|NCT03281824|Biological|ALT-P7 (HM2-MMAE)|Antibody-Drug Conjugate
75800093|NCT01302132|Drug|ASP1941|Oral solution
75800094|NCT03799536|Drug|Sotalol|Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
75800095|NCT03799536|Drug|Sotalex|Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH & Co. KGaA, Germany
75800096|NCT03812796|Drug|Domatinostat|"Domatinostat is an oral tablet which will be given at a variable dose during the Phase IIA safety run in phase of the trial.~During the Phase IIB efficacy phase of the trial patients will be treated with domatinostat at the safe and tolerated combination dose identified during the Phase IIA safety run in phase."
75800097|NCT03812796|Drug|Avelumab|Avelumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 10mg/kg every two weeks on the first day of a two week cycle. (Day 1 q 14d) from Cycle 2 onwards.
75800098|NCT03633214|Other|Online training module|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later; as well as to the control group.
75800099|NCT01381822|Drug|TH-302|TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.
75800100|NCT03794934|Behavioral|Structured Education for new glucose management devices|Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus
75800101|NCT05759104|Drug|Infliximab|Drug
75800102|NCT05759104|Procedure|Stomy|Surgery
75800103|NCT01381744|Biological|Flagellin/F1/V|Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.
75800104|NCT01381744|Other|Placebo|Phosphate buffered saline (PBS) used as diluent and placebo.
75800105|NCT04403464|Behavioral|HABIT-ILE with REAtouch®|65h HABIT-ILE including 30h REAtouch®
75800106|NCT04403464|Behavioral|HABIT-ILE without REAtouch®|65h HABIT-ILE
75800108|NCT01384318|Other|Manometer|Measuring cuff pressure
75800109|NCT01384240|Drug|Proflavine Hemisulfate|3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
75342085|NCT02997800|Other|1 ml saline infusion|Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
75652565|NCT00864513|Drug|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
75652566|NCT04130139|Other|oocyte pick up simulator|oocyte pick up simulation
76025774|NCT05898685|Behavioral|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
75652567|NCT02614443|Other|Space from Depression|Delivered through the online SilverCloud platform, the program for the treatment of depression employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
76025775|NCT05898685|Behavioral|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
75342086|NCT02997644|Behavioral|Video Education|"The content of the education focuses on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage.~The consent, enrollment, and video education will take about 20-30 minutes for patients in this group, and occur at the end of their preoperative visit. The patient will watch the video on a portable Tablet computer."
75342087|NCT02997644|Behavioral|Usual Care Group|Patients that are randomized to usual care will only receive the regular instructions about opioid usage they typically receive from their surgeon.
75342088|NCT00701636|Drug|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
75800110|NCT04357600|Biological|Allogeneic Umbilical Cord Mesenchymal Stem Cell|All research samples will be treated by Intravenous injection of allogeneic mesenchymal stem cells and hemodynamic observation will be done for 24 hours after treated. Periodic post-treatment observation will be done on 1st month, 3rd month, and 6th month after therapy. The Independent variable in this research is Child-Pugh B Cirrhosis caused by Hepatitis B, while the dependent variable is the degree of liver function damage consisting of an examination of liver function, Child-Pugh score, and MELD score.
75652568|NCT02614443|Other|Space from Anxiety|Delivered through the online SilverCloud platform, the program for the treatment of anxiety employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
75652569|NCT02614443|Other|Space from Stress|Delivered through the online SilverCloud platform, the program for the treatment of stress employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
75652570|NCT02614521|Other|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
75342089|NCT00701714|Drug|HX575 recombinant human erythropoietin alfa|Solution for injection (s.c.)
75800111|NCT04332640|Device|VERITAS Vision System|The investigators or designees will perform routine small-incision cataract surgery via phacoemulsification and use the VERITAS Vision system. The Investigator or designee will then complete a questionnaire regarding the clinical use of the VERITAS Vision system. The system log files automatically generated by the VERITAS Vision system after completion of each surgery will be collected.
75800112|NCT01381588|Other|Fracture evaluation|DEXA(Dual-energy X-ray absorptiometry), X-ray
75652571|NCT02614365|Behavioral|Aerobic exercise|Cardiovascular fitness
75652572|NCT02614365|Behavioral|Stretch exercise|Muscle stretch
75652573|NCT04130217|Procedure|addition of positive end expiratory pressure in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
75652574|NCT04130217|Procedure|addition of positive end expiratory pressure and recruitment maneuver in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
75800113|NCT03032068|Other|At-Home Monitoring|Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
75938069|NCT02392832|Biological|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|"In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, a total of 34 clusters in the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs."
75938070|NCT03507153|Procedure|Bre-flex maxillary partial denture|Partial denture fabricated from Bre.flex material.
75938071|NCT03507153|Procedure|PEEK maxillary partial denture|Partial denture fabricated from PEEK material.
75938072|NCT02393066|Drug|Propofol|Sedation
75938073|NCT02393066|Drug|Dexmedetomidine|Sedation
75938074|NCT03504267|Other|Physical Activity Education and Resources|The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
75652575|NCT02614209|Device|In Vitro diagnostic tests|Prospective blood collection
75652576|NCT04130061|Biological|Human Amniotic Membrane|Epicardial application of human amniotic membrane during cardiac surgery
75342090|NCT00701714|Drug|ERYPO|Solution for injection (s.c.)
75342091|NCT00655538|Drug|Placebo|po daily for 36 weeks
75342092|NCT00655538|Drug|dalcetrapib|600mg po daily for 36 weeks
75342093|NCT00656630|Drug|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
75342094|NCT00656630|Drug|Naltrexone|50mg capsule, Once daily, 1 week duration
75342095|NCT00656630|Drug|Placebo|Matched placebo capsule, 1 week duration
75652577|NCT04129671|Genetic|No intervention was applied|No intervention was administered
75652578|NCT04128891|Drug|Sacubitril-Valsartan|Cardiomagnetic Resonance Imaging
75652579|NCT00698529|Behavioral|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
75652580|NCT00698529|Behavioral|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
75342096|NCT02994914|Other|Onco Geriatric Evaluation|"Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy."
75800114|NCT04293796|Procedure|Vacuum-assisted biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, after neoadjuvant systemic treatment on patients with clinical complete response on primary breast cancer management we recommend to take at least 12 biopsies with 7-10G needle sizes with sentinel lymph node biopsy.
75652581|NCT00698529|Behavioral|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
75800115|NCT01381510|Drug|5-alpha Reductase Inhibitor (5ARI)|A 5ARI: Either dutasteride or finisteride
75342097|NCT01362998|Drug|Preservative free morphine|3mg given epidurally during the Cesarean section.
75342098|NCT01362998|Drug|Fentanyl|An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
75342099|NCT04387526|Drug|(SOF and DCV)|
75800116|NCT04258072|Drug|Vactosertib|Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight
75800117|NCT03923452|Behavioral|Mindfulness-based Stress Reduction|"Mindfulness-based stress reduction is a manualized mindfulness training protocol that has been researched for over 20 years. The original protocol will be used, with the exception of the prescribed home practice duration (i.e. 30 mins of practice). Rather, the program will be modified to set up participants for success by providing them with instruction to build on their meditation practice, beginning with 8 minutes a day."
75342100|NCT04387526|Drug|(SOF, DCV, and RBV)|
75342101|NCT02997566|Other|Autonomic evaluation|
75475412|NCT01994772|Procedure|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
75800118|NCT03631342|Other|VCV20|controlled volume ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
75800119|NCT03631342|Other|VCV40|volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
75800120|NCT03631342|Other|PCV|controlled ventilation mode, 1 second inspiratory time. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
75938075|NCT02392754|Device|Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
75938076|NCT03504111|Procedure|Percutaneous Needle Tenotomy|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided needle tenontomy with be performed at the common extensor tendon at the area of tendinosis. There will be approximately 25 passes through the tendon with an 18 gauge needle. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia
75938077|NCT03504111|Procedure|PRP|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided injection of the PRP will be performed at the common extensor tendon at the area of tendinosis. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia to the local skin
75938078|NCT02398838|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone.
75938079|NCT02398838|Drug|Home or clinic administration of 400 mcg buccal misoprostol|Home or clinic administration of 400 mcg buccal misoprostol
75938080|NCT02398682|Other|Rapid diagnosis of AKI cause|"The Outreach team will advise on an evidence-based package of care:~1) Rapidly establish a credible diagnosis of the cause of AKI including:~Improved assessment of volume status~Standardised use of urine dipstick .~Appropriate sepsis investigations.~Urgent ultrasound with suspected obstruction."
75342102|NCT02997488|Device|Pentax Airwayscope|intubation using Pentax Airwayscope
75342103|NCT02997488|Device|McGrath Videolaryngoscope|intubation using McGrath Videolaryngoscope
75342104|NCT00658112|Drug|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
75342105|NCT02997332|Drug|Durvalumab|Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.
75342106|NCT02997332|Drug|Docetaxel|Docetaxel 75mg/m² on D2, IV in 1 hour
75342107|NCT02997332|Drug|Cisplatin|Cisplatin 75mg/m² on D2, IV in 3 hours
75342108|NCT02997332|Drug|5 Fluorouracil|5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
75342109|NCT04345094|Other|Hexylresourcinol|Emulsion containing hexylresorcinol as an active
75342110|NCT04345094|Other|Hydroquinone|Emulsions containing hydroquinone as an active
75342111|NCT00702884|Drug|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
75342112|NCT00703508|Drug|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
75342113|NCT01284335|Drug|Gemcitabine|1000 mg/m2 administered intravenously on Days 1 and 15 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
75652582|NCT04127955|Other|Theory of Planned Behavior based Physical Activity Intervention|"Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial."
75652583|NCT02613975|Device|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
75800121|NCT03631342|Other|PCV+Tins|controlled ventilation and inspiratory pressure was increased every 5 cmH2O until the maximum pressure was 40 cmH2O. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
75800122|NCT03631342|Other|PSV|ventilatory mode with pressure support, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
75800123|NCT02984800|Other|Anesthesia induction|All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.
75800124|NCT02984800|Other|PVB injection at L1-L2|Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.
75800125|NCT02984800|Other|PVB injections at T12-L1, L1-L2 and L2-L3.|Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
75800126|NCT04210414|Other|Embryo transfer|Transfer of only one embryo
75800127|NCT04188730|Drug|Lofexidine (granules for reconstitution)|All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.
75800128|NCT04188730|Drug|LUCEMYRA (lofexidine) tablets|All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.
75800129|NCT01381432|Drug|Azathioprine|At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
75800130|NCT01381354|Other|Progressive exercise|Progressive strengthening exercises designed to improve core muscles and muscles of ambulation.
75800131|NCT01381354|Device|Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Neuromuscular electrical stimulation to train core muscles and ambulation muscles. Device is Empi 300 manufactured by DJO Inc.
75800132|NCT01381354|Other|Modified paleolithic diet|Diet based upon a Paleolithic diet and structured to increase the consumption of greens, sulfur rich vegetables, bright colors, seaweed and omega 3 fatty acid rich foods.
75800133|NCT01381354|Dietary Supplement|Omega 3 fatty acids|4 grams daily by mouth.
75800134|NCT01381354|Dietary Supplement|Full Spectrum vitamin|Two capsules daily.
75800135|NCT01381354|Dietary Supplement|Essential - hydroxytyrosol|Two capsules twice daily.
75800136|NCT01381354|Dietary Supplement|Maltodextrin fiber supplement|One scoop daily.
75800137|NCT01381354|Dietary Supplement|Mineral boost (magnesium)|Two capsules daily
75800138|NCT01381354|Dietary Supplement|Niacinamide|500 mg daily
75938081|NCT02398682|Other|Rapid treatment of AKI cause|Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
75800139|NCT01381354|Dietary Supplement|Methyl B12|Methyl B12 1000 mcg daily
75800140|NCT01381354|Dietary Supplement|Taurine|one gram daily
75800141|NCT01381354|Dietary Supplement|creatine|one teaspoon daily
75800142|NCT01381354|Dietary Supplement|thiamine|100 mg daily
75800143|NCT01381354|Dietary Supplement|riboflavin|200 mg daily
75800144|NCT01381354|Dietary Supplement|N acetylcysteine|1 gram daily
75800145|NCT01381354|Dietary Supplement|alpha lipoic acid|300 mg twice daily
75800146|NCT01381354|Dietary Supplement|L acetyl carnitine|500 mg twice daily
75800147|NCT01381354|Dietary Supplement|methyl folate|1000 mcg one pill four times a week
75800148|NCT01381354|Dietary Supplement|coenzyme Q|100 mg daily
75800149|NCT01381354|Behavioral|meditation|meditation 15 minutes daily
75800150|NCT01381354|Behavioral|self massage|self massage of hands, feet, ears 15 minutes daily
75800151|NCT01381354|Behavioral|learning|completing puzzles or learning 15 minutes daily
75800152|NCT01381354|Dietary Supplement|Coconut oil|If excessive weight loss occurs, the subject will add 1-2 tablespoons of coconut oil daily to smoothies or foods eaten.
75800153|NCT01381276|Other|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
75800154|NCT01381276|Other|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
75800155|NCT01381276|Other|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
75800156|NCT03852472|Drug|Avacopan|Active treatment
75800157|NCT03852472|Other|Placebo|Placebo
75938082|NCT02398682|Other|Stopping 'nephrotoxic' drugs|Cessation of all potentially nephrotoxic drugs.
75938083|NCT02398682|Other|Early nephrology followup for stage 3 AKI|A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
75938084|NCT02398682|Other|Preventing recurrent AKI|Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
76025776|NCT05898568|Device|virtual reality|In addition to the routine hand rehabilitation programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days a week, 20 minutes) virtual reality based movement therapy program will be applied.
75342114|NCT01284335|Drug|Docetaxel|60 mg/m2 administered intravenously over 60 minutes on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
75938085|NCT02398682|Other|Good standard care|Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
75475413|NCT01994915|Other|Occupational therapy|Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
75475414|NCT01994928|Device|Nose-mouth mask|Preoxygenation using a nose-mouth mask.
75652584|NCT04126785|Other|High Intensity Interval Exercise in Heated Water-Based|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
75800158|NCT01569178|Procedure|Bone Marrow aspiration and intracoronary reinfusion|Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
75800159|NCT02674516|Device|Transcranial direct current stimulation|
75938086|NCT03508089|Other|Ocular fundus on patient with Multiple Sclerosis|Ocular fundus on patient with Multiple Sclerosis
75652585|NCT04126785|Other|Continuous Moderate Exercise in Heated Water-Based|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.
75652586|NCT04126785|Other|Control Group|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
75652587|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 12.5mg OPC-6535, once daily for 24months
75652588|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 25mg OPC-6535, once daily for 24months
75652589|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 50 mg OPC-6535, once daily for 24months
75652590|NCT00917150|Drug|placebo|oral administration of placebo, once daily for 24months
75652591|NCT04251962|Drug|Bupivacaine|epidural solution containing bupivacaine 0.1% in normal saline
75652592|NCT04251962|Drug|Fentanyl|Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
75800160|NCT02674516|Device|Sham transcranial direct current stimulation|
75800161|NCT01569334|Biological|blood samples|
75800162|NCT01381198|Procedure|Distal rectus femoris transfer|Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
75800163|NCT05758870|Procedure|surgical stabilization of low rib fratures|surgical stabiliazation of rib fractures by internal fixation
75800164|NCT05758870|Other|converstive treatment of low rib fratures|chest wall fixation band
75800165|NCT03633136|Behavioral|electronic video education|Solid Organ Transplantation: An Educational Mini-Series for Patients consists of 6 videos ranging in length between 3 and 23 minutes, and has been developed according to best practice for designing education for patients with end-stage renal disease pursuing transplant. Each video outlines a subsequent stage of the transplant process, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives keep the content relevant and culturally inclusive. The educational intervention was developed with experts in medication adherence, video education, motivational psychology, cultural education (First Nations perspective), healthcare providers, and most importantly patients.
75938087|NCT03508089|Other|Ocular Fundus on voluntary person|Ocular Fundus on voluntary person
75938088|NCT02312427|Drug|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
75938089|NCT02312427|Drug|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
75938090|NCT02312427|Drug|Suspending DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
75938091|NCT02398916|Behavioral|Music listening|
75938092|NCT02312505|Device|COPFX|cardiac Output by semi-invasive pulse contour analysis
75342115|NCT01284335|Drug|Temozolomide|200 mg/m2 administered orally on days 1-5 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
75342116|NCT01284335|Drug|Cisplatin|75 mg/m2 administered intravenously on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
75475415|NCT01994928|Device|High flow nasal cannula oxygen|Preoxygenation using high flow nasal cannula oxygen.
75475416|NCT01994928|Procedure|Intubation|Intubation
75475417|NCT01994941|Drug|Clopidogrel|"A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients."
75342117|NCT01284335|Drug|Erlotinib|150 mg administered orally days 1-28 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
75652593|NCT04251650|Other|subgingival plaque sample|for subgingival plaque sample, on three affected sites (PD>3mm) and three healthy sites (PD≤3mm), after supra-gingival plaque removal, sterile endodontic paper points were inserted in selects pockets for 30s to collect the subgingival plaque. The material was transferred into eppendorf tube, one for affected samples and one for healthy samples.
75800166|NCT02463448|Biological|Autologous Muscle Derived Cells|A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the sample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
75342118|NCT01284335|Drug|LY573636|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.
75342119|NCT01230125|Drug|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
75800167|NCT01569256|Drug|Cabergoline|Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
75800168|NCT01384162|Drug|sNN0029|ICV infusion
75800169|NCT01384084|Procedure|POP repair plus mini-sling|"For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh."
75800170|NCT01384084|Procedure|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
75800171|NCT01380886|Other|experimental infant formula with alternate protein source|experimental infant formula to be fed ad libitum
75800172|NCT01380886|Other|Infant formula powder|powdered infant formula to be fed ad libitum
75800173|NCT03794544|Drug|Durvalumab|Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
75800174|NCT03794544|Combination Product|Oleclumab|Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
75800175|NCT03794544|Combination Product|Monalizumab|Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
75800176|NCT03794544|Combination Product|Danvatirsen|Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
75800177|NCT01380808|Drug|capecitabine and pseudomonas aeruginosa combination|capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
75800178|NCT01380652|Procedure|whole body vibration training|pulmonary rehabilitation with strength and endurance training and additionally vibration training
75800179|NCT03799224|Drug|Decitabine|Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11
75800180|NCT03799224|Drug|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
75938093|NCT03115346|Other|Decision aid|Decision aid for repair type for aortic abdominal aneurysms
75938094|NCT03504033|Drug|Xenon|inhalation to maintain anesthesia
75342120|NCT01230125|Drug|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
75342121|NCT01194479|Drug|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
75342122|NCT01194479|Other|Placebo|Participants in both arms received placebo on 1 of the 2 visits.
75475418|NCT01994941|Drug|Ticagrelor|"A platelet aggregation inhibitor.~Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.~A loading dose of 180mg will be used."
75652594|NCT04251650|Other|CGF sample|each site was sampled with a PerioPaper Strip® (Oraflow), and the volumes collected were measured with a Periotron® (Oraflow). Then samples of affected sites were stowed in an eppendorf tube with 120µL of PBS Tween. The same procedure was performed for the healthy sites
75652595|NCT04251728|Device|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
75475419|NCT01994967|Drug|Levobupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
75475420|NCT01994967|Drug|Bupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
75342123|NCT01230593|Drug|Hot Compress plus Tobramycin Drops and Ointment|In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
75342124|NCT01230593|Drug|Hot compress plus Tobramycin/Dexamethasone Drops and Ointment|In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
75342125|NCT01230593|Other|Hot Compresses|Hot compresses 3x/day to eyelids
75342126|NCT01195025|Drug|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
75475421|NCT01995006|Drug|metamizole|metamizol tablets (500mg): 1000mg TID during 7 days
75800181|NCT03799224|Drug|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3
75800182|NCT03737734|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
75938095|NCT03504033|Drug|Desflurane|inhalation to maintain anesthesia
75800183|NCT03794622|Other|intramedullary nail fixation with bone marrow concentration|intramedullary nail fixation with bone marrow concentration
75800184|NCT03794622|Other|intramedullary nail fixation|intramedullary nail fixation only
75800185|NCT03799068|Other|suprazygomatic maxillary nerve block|bilateral Suprazygomatic maxillary nerve block is performed before surgery in anaesthetized children, after aseptic preparation of the skin. The patient is in supine position with the head in neutral position. The puncture site is at the frontozygomatic angle, at the junction of the upper edge of the zygomatic arch and the frontal process. A 24G needle is attached to a syringe containing the local anaesthetic. It is advanced to reach the greater wing of sphenoid at approximately 20 mm depth, then withdrawn a few millimetres and redirected toward the nasolabial fold in a 20° forward and 10° downward direction. The progression in the pterygopalatine fossa is 35 to 45 mm. Loss of resistance after passing through the temporalis muscle assisted in determining the puncture depth. After a negative blood aspiration test, the calculated dose of the local anaesthetic is injected on each side.
75800186|NCT03799068|Other|surgical site infiltration|peri-incisional infiltration of bupivacaine around the incision site given by the surgeon on an anesthetized patient before the incision is done.
75800187|NCT03812406|Procedure|French Abulatory Cesrean Section|A cesarean section performed according to the FAUCS technique
75800188|NCT03812406|Procedure|Misgav-Ladach|A cesarean section performed according to the Misgav Ladach technique
75475422|NCT01995006|Drug|Naproxen|Naproxen tablets (500mg): 500 mg BID during 7 days
75938096|NCT03132519|Drug|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
75938097|NCT03115970|Procedure|capillary and venous lactate level measurement|capillary and venous lactate level measurement
75800189|NCT03631264|Device|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants to improve sucking and swallowing.
75938098|NCT02306343|Device|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
75938099|NCT02398448|Drug|Zyloprim® 300 mg|
75342127|NCT01195025|Drug|colloid|Infusion of starch 10 ml/kg over 30 min
75342128|NCT01195025|Drug|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
75800190|NCT01383850|Other|NCPAP + standard air|NCAP (SiPAP, Vyasis) was used to administer standard air
75800191|NCT01383850|Other|NCPAP + Heliox|Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
75342129|NCT01195025|Device|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
75475423|NCT01995019|Drug|Methylprednisolone|1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
75475424|NCT01995019|Drug|Physiologic saline|1 ml intra-articular placebo
75475425|NCT01995032|Drug|750 mg metformin and 7.5 g L-citrulline daily p.o.|
75475426|NCT01995032|Drug|Placebo|
75475427|NCT01995058|Drug|cabozantinib|Tablets taken orally
75800192|NCT03798912|Combination Product|RaniPill capsule containing octreotide|Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
75938100|NCT02398448|Drug|Allopurinol 300 mg; undergranulated, high hardness condition|There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
75938101|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 2|There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
75938102|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 3|
75475428|NCT01995058|Drug|abiraterone|Tablets taken orally daily
75475429|NCT01995058|Drug|prednisone|Tablets taken orally twice daily
75475430|NCT01995084|Drug|[F-18]HX4|400 MBq [F-18]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
75475431|NCT01995097|Behavioral|Scheduled Gradual Reduction Text Messages|
75475432|NCT01995097|Behavioral|Support Text Messages|
75475433|NCT01995110|Other|high-fat meal A|
75475434|NCT01995110|Other|high-fat meal B|
75475435|NCT01995110|Other|high-fat meal C|
75475436|NCT01995149|Behavioral|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
75800193|NCT03666832|Drug|TEW-7197|"TEW-7197 1cycle 14days~-intake 5days, rest 2days"
75342130|NCT03009695|Device|High frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
75652596|NCT04251728|Other|Physical Exercise|The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.
75652597|NCT04251728|Device|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
75652598|NCT04255238|Drug|Gemigliptin 50mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
75800194|NCT03812640|Device|Vicryl suture|Corneal suture with Vicryl suture
75800195|NCT03812640|Device|Nylon suture|Corneal suture with Nylon suture
75800196|NCT01804270|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
75800197|NCT01560468|Drug|ITX 5061|300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
75800198|NCT03798834|Drug|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
75800199|NCT03798834|Other|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
75800200|NCT03812562|Biological|Nivolumab|Given IV
75800201|NCT03812562|Radiation|Yttrium Y 90 Glass Microspheres|Given IV
75800202|NCT01304784|Drug|Cisplatin, Capecitabine, Trastuzumab and MM-111|Conventional chemotherapy
75800203|NCT01304784|Drug|Lapatinib +/- Trastuzumab and MM-111|Conventional chemotherapy
75800204|NCT01304784|Drug|Paclitaxel, Trastuzumab and MM-111|Conventional chemotherapy
75800205|NCT01304784|Drug|Lapatinib, trastuzumab, paclitaxel, and MM-111|Conventional chemo
75800206|NCT01304784|Drug|Docetaxel, trastuzumab and MM-111|Conventional chemotherapy
75800207|NCT03107026|Drug|dasotraline 4mg|dasotraline 4mg tablet once daily
75800208|NCT03107026|Drug|dasotraline 6mg|dasotraline 6mg tablet once daily
75800209|NCT03107026|Drug|Placebo|Placebo tablet once daily
75342131|NCT03009695|Device|Low frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.
75800210|NCT05574972|Device|Timing Carotid Stent|all the participants in this group will be performed with Timing Carotid Stent
75800211|NCT05574972|Device|Carotid Wallstent|all the participants in this group will be performed with Carotid Wallstent
75800212|NCT01302288|Procedure|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
75800213|NCT03798600|Drug|Caspofungin|In accordance with routine clinical practice, Caspofungin will be given at the loading dose of 70 mg followed by 50 mg daily (for people < 80 kg body weight). No dose reduction will be performed in Child-Pugh score A or B. Duration of therapy will be performed in accordance with ESCMID guidelines and clinical conditions.
75800214|NCT03798522|Procedure|bilateral ultrasound guided erector spinae plane block|ESPB on both sides at T7 before GA
75800215|NCT03798522|Drug|Nalbuphine|in nalbuphine for analgesia after GA
75800216|NCT01379404|Device|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
75800217|NCT03812484|Behavioral|SCF Supervision|SCF Supervision entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). SCF Supervision includes regular random drug testing.
75800218|NCT03812484|Behavioral|Parole-as-Usual|Parolees are supervised under standard parole supervision practice in New Jersey
75938103|NCT03508011|Drug|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
75938104|NCT02398370|Biological|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
75800219|NCT01308034|Drug|sunitinib|"All patients will be treated with sunitinib (2 dose levels) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.~Dose level 1 : 25 mg once daily Dose level 2 : 37.5 mg once daily Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring."
75800220|NCT03798444|Radiation|dual energy X-ray absorptiometry|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry. The lumbar spine, left femoral neck, or total hip of T-score ≤-2.5 as the osteoporosis
75800221|NCT03798444|Radiation|lateral spine imaging from T4 to L4 on X-ray|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray .A visual semi-quantitative method was used, with fractures defined as a vertebral Vertebral fractures should be diagnose if height ratio <0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra
75342132|NCT03009695|Device|Sham|Sham stimulation will be performed by an H-sham-coil. The H-sham-coil is designed to mimic the auditory artifacts and the scalp sensation evoked by the real coil, without stimulating the brain itself. As in the other groups, in each patient the rMT will be determined before each repetitive dTMS session. The sham stimulation will be performed either at high frequency (50% of subjects) or at low-frequency (50% of subjects), according to the previously described methodologies. All obese people in this group will be submitted at the sight of food preferred (cue).
75342133|NCT03009851|Behavioral|OBCHI|Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
75800222|NCT01302210|Drug|Decolonization|5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
75800223|NCT01303770|Behavioral|Self-management cognitive rehabilitation group intervention|8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
75800224|NCT01303770|Behavioral|Control intervention|8-week group program that is not specifically directed to management of cognitive impairments.
75800225|NCT03717480|Device|ClinicMACs|The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to participants
75800226|NCT03798210|Dietary Supplement|Lactobacillus reuteri|Study group split in two arms for experimental treatment with Lactobacillus reuteri or placebo.
75800227|NCT03798210|Dietary Supplement|Placebo|Placebo
75342134|NCT01286441|Drug|10% EISO|During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
75800228|NCT00005044|Drug|Casodex|Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
75800229|NCT00005044|Drug|Eulexin|Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
75800230|NCT00005044|Drug|LHRH agonist|LHRH agonist of choice. The manufacturer's instructions should be followed.
75800231|NCT00005044|Radiation|radiation therapy|[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)] OR [regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin]
75800232|NCT03800082|Behavioral|at heart (changed from HEARTPA♀N during usability testing)|An integrated smartphone and web-based intervention (at heart) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease. The intervention for participants randomized to the treatment group will consist of regular use of a progressive WebApp that is managed by a Chatbot named 'Holly', in addition to usual care, for a period of 3 months.
75800233|NCT01302522|Behavioral|Mental practice|All patients in the study will be administered a regimen of locomotor therapy (rehabilitative therapy working on walking). Half of the patients will also be administered a regimen in which they mentally rehearse the exercises that they have just physically performed.
75800234|NCT01303848|Other|Blood Sampling|Blood Sampling over 24 hours
75800235|NCT03811938|Procedure|Low voltage ablation|Catheter ablation of low voltage areas in the left atrium and catheter ablation aiming for the electrical isolation of the pulmonary veins.
75800236|NCT03811938|Procedure|Pulmonary Vein Isolation|Catheter ablation aiming for the electrical isolation of the pulmonary veins.
75800237|NCT03798132|Diagnostic Test|laparoscopy|evaluation of peritoneal carcinomatosis by laparoscopy
75800238|NCT03794232|Dietary Supplement|NIUCHANG|
75800239|NCT03794232|Dietary Supplement|Placebo|
75800240|NCT03794154|Drug|Cymbalta capsule|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
75800241|NCT03794154|Drug|Duloxetine hydrochloride capsule|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
75800242|NCT05090202|Diagnostic Test|hbA1C|hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic
75800243|NCT01305018|Dietary Supplement|BCAA|7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
75800244|NCT01305018|Dietary Supplement|Leucine|7 g of leucine + 7 g of alanine per day during 9 days
75800245|NCT01305018|Dietary Supplement|Placebo|14 g of alanine per day during 9 days
75800246|NCT03811860|Diagnostic Test|Lithium level|The level of lithium in the serum
75800247|NCT03811860|Diagnostic Test|Serum Creatinine|The level of creatinine (as an indicator of kidney function, to approximate GFR) in the serum
75800248|NCT03811782|Behavioral|Single-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).
75938105|NCT03503955|Other|Leap-Motion virtual reality games|Games that Fizyosoft has prepared on Leap Motion equipment to improve hand and grip activities will be played individually and will focus on running hand, wrist and grip movements
75652599|NCT04255238|Drug|Dapagliflozin 10mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
75652600|NCT04251572|Other|Blood sampling|Blood sampling
75652601|NCT04251572|Other|questionaires|Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.
75652602|NCT04251494|Diagnostic Test|Carotid intima media thickness measurement (CIMT)|CIMT is a measurement of the thickness of the two inner layers of the common carotid artery wall. Using ultrasound, a linear array transducer is placed on the surface of the skin at the neck. Electrocardiogram(ECG) electrodes are placed on each wrist and one on the ankle. An image of the common carotid artery (CCA) is then produced in anterior, posterior and lateral views, and saved along with the ECG recording. The wall thickness can then be measured at the same point in the cardiac cycle using semi-automated detection software (Philips QLAB), which can reduce observer variability. The CIMT will be averaged across left and right CIMTs, as the control reference values use an average of both sides.
75800249|NCT03811782|Behavioral|Dual-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).
75800250|NCT03811782|Behavioral|Analogy Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
75800251|NCT02722668|Drug|Fludarabine|Both Arms: 30 mg/m^2 IV over 1 hour Day -6 to Day -2
75800252|NCT02722668|Drug|Cyclophosphamide|Arm 1: 50 mg/kg IV over 2 hours Day -6
75800253|NCT02722668|Drug|MMF|"Both Arms:~Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, do not stop MMF."
75800254|NCT02722668|Drug|Sirolimus|"Both Arms:~Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation.~Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines."
75800255|NCT02722668|Radiation|TBI|Both Arms: 200 cGy on Day -1
75800256|NCT02722668|Biological|Umbilical cord blood cell infusion|Both Arms: Day 0
75800257|NCT02722668|Biological|ATG|Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
75800258|NCT03799926|Drug|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
75800259|NCT03799926|Drug|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
75800260|NCT03799926|Drug|placebo|Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
75800261|NCT03799926|Drug|placebo|Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
75800262|NCT03799926|Drug|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
75800263|NCT03799926|Drug|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
75800264|NCT03799926|Drug|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
75938106|NCT03503955|Other|fine motor skills activities|activities that stimulate finger movements such as holding, reaching, catching, writing, and strengthening muscles
75475437|NCT01995162|Device|Energy expenditure estimation|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
75938107|NCT02392520|Drug|cetrorelix (cetrotide)|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
75938108|NCT02392520|Drug|Placebo|intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
75475438|NCT01995188|Drug|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
75652603|NCT04251494|Diagnostic Test|Pulse Wave Velocity measurement|The PWV measures the speed of a pulse wave travelling between two points in the vascular systems of known distance between them. PWV will be measured by the gold standard carotid-femoral PWV method which is a direct measurement of aortic stiffness. A 3-Lead ECG is connected alongside measurements of the blood velocity trace for the left CCA 2cm proximal to the bifurcation, and for the left common femoral artery origin.
75938109|NCT02312583|Behavioral|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
75938110|NCT02312583|Behavioral|iFightDepression online programme|"iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression"
75652604|NCT04251494|Diagnostic Test|Ankle-brachial pressure index (ABPI)|A blood pressure cuff is placed around the ankle and upper arm of the participant. A continuous wave Doppler probe is used over the surface of the skin to locate the artery distal to the cuff (such as the brachial artery in the arm, or the anterior tibial and posterior tibial arteries in the ankle). The cuff is then inflated, and the systolic pressure identified by listening cessation of the sounds produced by the probe corresponding to blood flow in the artery. The ABPI is then the ratio of the highest systolic ankle pressure divided by the highest systolic brachial pressure for the left and right sides of the body.
75938111|NCT02316249|Drug|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
75475439|NCT01995188|Drug|Carboplatin|Carboplatin fixed dose of AUC=6 mg/mL*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
75938112|NCT02316249|Other|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
76025777|NCT05898568|Behavioral|routine treatment|20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be applied.
75342135|NCT01286441|Drug|Placebo|During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
75342136|NCT01286441|Drug|20% EISO|During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
75342137|NCT01286441|Drug|30% EISO|During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
75475440|NCT01995188|Drug|DNIB0600A|DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
75475441|NCT01995214|Drug|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
75475442|NCT01995214|Drug|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
75475443|NCT01995227|Biological|AlloVax|Personalized anti-cancer vaccine
75475444|NCT01995227|Biological|CRCL|Personalized anti-cancer vaccine
75475445|NCT01995227|Biological|AlloStim|ID injections IV infusion
75475446|NCT01995240|Drug|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
76025778|NCT05898542|Procedure|Nature-based therapy|Therapy sessions conducted outdoors
76025779|NCT05898503|Behavioral|Walking exercise + resistance training|Walking exercise and resistance training for 12 weeks
76025780|NCT05898503|Behavioral|Resistance training|Resistance training for 12 weeks
76025781|NCT05898503|Behavioral|Walking exercise|Walking exercise for 12 weeks
76025782|NCT05898503|Behavioral|Health promotion|Health promotion for 12 weeks
76025783|NCT05898490|Behavioral|Animation Therapy|The process of shooting a stop-motion animation film, is designed according to the interests and leading of the participant.
76025784|NCT05898451|Drug|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)|has a direct antitumor effect in vitro and in vivo on various tumor cell lines
76025785|NCT05898451|Drug|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy|Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
76025786|NCT05898373|Drug|vedicitumomab (Edisil, RC48）|intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
76025787|NCT05898373|Drug|vedicitumomab in combination with pyrrolizidine|vedicitumomab in combination with pyrrolizidine
76025788|NCT05898373|Drug|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 in combination with a platinum-based chemotherapeutic agent
76025789|NCT05898373|Drug|RC48 in combination with teraplizumab|RC48 in combination with teraplizumab
76025790|NCT05898360|Combination Product|Time Restricted Eating|time restricted eating
76025791|NCT05898360|Other|normal diet|normal diet
75475447|NCT01995253|Device|Energy expenditure estimation in controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
75652605|NCT04251494|Other|Diet questionnaire and diet diary|Dietary information will be collected in two formats. One will be a 14-item questionnaire (Martínez-González et al., 2012), which is a simplified version of a comprehensive food frequency questionnaire. This provides a quick measure of compliance to a Mediterranean dietary pattern and a rough measure of protective and adverse dietary factors that could affect individual CVD risk. The second will be a 3-day diet diary (3DDD). This will consist of participants recording the foods that they consume and the quantities, which will then be analysed for macro- and micronutrient composition once completed.
75342138|NCT01195883|Drug|Crystalloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
75342139|NCT01195883|Drug|Colloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
75342140|NCT01196117|Device|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
75342141|NCT01196117|Device|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
75652606|NCT04251494|Other|Routine blood samples|Blood samples will be taken from participants during their outpatient appointment. Patients routinely have blood samples taken during this clinic. The study will use the results from the routine blood tests, and also extra blood samples to collect data on other biomarkers. The laboratory facilities at Guy's and St Thomas Hospitals will be used to conduct analysis, no other laboratories will be used. Data will be collected on Phenylalanine levels, lipids, vitamin B12 and related biomarkers.
75652607|NCT05286164|Drug|Eltrombopag|Eltrombopag 150 mg QD for 8 weeks
75938113|NCT03115268|Behavioral|Social support groups delivered in EVA Park|Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
75800265|NCT03799926|Drug|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
75800266|NCT03797976|Device|MIP and MEP|Pre-op, Post-op of, 1 month after surgery, 3 months after surgery
75800267|NCT01303926|Drug|cisplatin pemetrexed|Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
75800268|NCT01303926|Drug|carboplatin paclitaxel bevacizumab|Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
75800269|NCT01304004|Other|Satiety|"Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~Experimental drinkable yogurt enriched in proteins and fibres~Placebo drinkable yogurt (isocaloric and isovolumetric)"
75800270|NCT03797820|Other|Our study type is observational|Our study type is observational
75800271|NCT01305096|Other|Yoga intervention|6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
75938114|NCT02307357|Behavioral|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
75938115|NCT02307435|Biological|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
75800272|NCT01305174|Device|PROTEGE GPS stent vs. VISI-PRO stent|Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
75800273|NCT05069844|Dietary Supplement|Gum chewing for 2 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
75800274|NCT05069844|Dietary Supplement|Gum chewing for 4 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
75938116|NCT02696096|Other|FMRI|all participants will complete 2 FMRIs
75938117|NCT02696096|Drug|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
75938118|NCT02316327|Drug|gemcitabine, cisplatin and bevacizumab|Therapeutic
75938119|NCT04480346|Behavioral|Challenging Horizons Program|Intervention delivered in high schools provided by school mental health professional over the course of an academic year with twice-weekly meetings with students and 10 evening group meetings with students and 10 group sessions with parents.
76089239|NCT01735175|Drug|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
75342142|NCT00703664|Drug|Bortezomib|Bortezomib: 1.3 mg/m^2/d IV days 1, 4, 8, and 11.
75342143|NCT00703664|Other|Laboratory Biomarker Analysis|Correlative studies
75342144|NCT00703664|Drug|Vorinostat|Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.
75342145|NCT03009929|Other|Observational study|No intervention, observational only
75342146|NCT00658736|Drug|Triamcinolone|Injection of bupivacaine and triamcinolone
75342147|NCT00658736|Drug|Bupivicaine alone|Injection of bupivacaine
75938120|NCT03132441|Other|Strength Training for Frailty|Cardiac Rehabilitation, abbreviated course
75475448|NCT01995253|Device|Energy expenditure estimation in free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
75475449|NCT01995279|Device|French ear acupuncture|Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
75475450|NCT01995279|Other|Sham Ultrasound|Ultrasound turned off.
75475451|NCT01995292|Device|bronchoscope|
75475452|NCT01995292|Device|Enk Fiberoptic Atomizer|
75652608|NCT04251104|Other|Images' personal relevance effectiveness in objective and subjective mood recovery|"After completing the PANAS, the negative mood induction phase (viewing a film clip) phase will begin. Before this phase, the participants will be encouraged to experience the feelings generated by the clip as intensely as possible. After viewing the film clip, participants will be asked to complete the PANAS again in order to assess the effectiveness of the negative mood induction procedure.~Following the negative mood induction phase, the emotional recovery phase will be initiated, in which the participants will look at a total of six pictures previously selected according to their experimental condition in order to generate specific positive autobiographical memories. At the end of this phase, participants will once more complete the PANAS in order to assess the effectiveness of the emotional recovery."
75800275|NCT01302600|Drug|Olesoxime|Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
75800276|NCT01302600|Drug|Placebo|0.1ml/kg once a day with food at dinner.
75800277|NCT03793764|Procedure|TAP block|USG guided TAP block
75800278|NCT03793764|Procedure|QL block|USG guided QL block
75800279|NCT01304160|Radiation|stereotactic body radiotherapy|30Gray in 5 fractions
75938121|NCT02695628|Drug|18F-Fluoromisonidazole|Undergo [18F] FMISO PET/CT
75938122|NCT02695628|Procedure|Arterial Embolization|Undergo transcatheter arterial embolization
75938123|NCT02695628|Diagnostic Test|Computed Tomography|Undergo [18F] FMISO PET/CT
75938124|NCT02695628|Diagnostic Test|Positron Emission Tomography|Undergo [18F] FMISO PET/CT
75938125|NCT03503721|Procedure|BipolEP|the prostate will be transurethrally enucleated using a bipolar current
75938126|NCT03503721|Procedure|bipolarTURP|the prostate will transurethrally resected using a bipolar current
75342148|NCT01196819|Device|Firehawk|Implantation of Firehawk drug eluting stent
75342149|NCT01196819|Device|Xience V|Implantation of Xience V drug eluting stent
75342150|NCT04387058|Device|TIPS|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is an interventional radiology method that creates an anastomosis between the portal venous network and the hepatic venous network.
75342151|NCT01799564|Procedure|Micropulse|Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
75342152|NCT00659360|Drug|saracatinib|Given orally
75342153|NCT01197833|Drug|endovenous ablation+polidocanol injectable microfoam 0.125%|All components except API
75342154|NCT01197833|Drug|Endovenous ablation+polidocanol injectable microfoam 1.0%|endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
75475453|NCT01995305|Genetic|human whole exome|he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
75475454|NCT01995305|Genetic|whole genomic|This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.
75475455|NCT01995318|Other|Kinesiotaping|Application of anti-edema type kinesiotaping to injured ankle.
75800280|NCT03811704|Device|Laparoscopic surgical navigation system|We will use this navigation system to guide de liver resection.
75800281|NCT03811704|Drug|Indocyanine Green|ICG was administered 24 hours before the operation or intravenously after clamping the Glissonian sheaths flowing in the cancer-bearing hepatic segment, or directly into the portal branches supplying blood flow to the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
75800282|NCT03084796|Drug|CHF 5259|Dose Response: Test one of four different doses of CHF 5259
75938127|NCT02316405|Other|Arm and Leg Cycling Exercise for Walking after Stroke|
75938128|NCT02392364|Drug|Intravitreal Aflibercept Injection|
75938129|NCT02392676|Drug|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
75938130|NCT02392676|Drug|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
75938131|NCT03503487|Other|3D informed consent|Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
75938132|NCT03167996|Behavioral|Use of HealthPals (Telemedicine supported by digital health platform)|"HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.~The HealthPals app was developed by HealthPals, Inc."
75938133|NCT03507075|Behavioral|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
75342155|NCT01197833|Drug|Endovenous ablation+polidocanol injectable foam 2.0%|Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
75342156|NCT04270448|Behavioral|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
75342157|NCT04270370|Drug|LY3478045|Administered orally.
75342158|NCT04270370|Drug|Placebo|Administered orally.
75342159|NCT04270370|Drug|Atorvastatin|Administered orally.
75342160|NCT01288781|Drug|Acetazolamide|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
75342161|NCT01288781|Drug|Lactose monohydrate|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
75475456|NCT01995331|Drug|cyclophosphamide,cyclosporine A|"Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.~Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was >1×109/L."
75652609|NCT04255004|Device|Pall Celeris System, point of care device for human cell therapy|Concentration of PB-MNCs autologous cell therapy was produced by a filtration-based point-of-care device. All the procedures were performed in operatory room with anaesthesiologic support (propofol and/or peripheral block). Blood withdrawal (120 ml) was collected through a peripheral venous access. Blood was loaded, and gravity filtration was allowed to proceed until the upstream side of the filter had no remaining blood; filtration last about 10 minutes. During filtration, MNCs were captured in the filter while plasma, platelets (PLTs) and red blood cells (RBCs) were not retained. Immediately concentrate solution is injected in the perilesional area and intramuscular in the foot and the leg (0.2-0.3cc in boluses) below the knee, at intervals of 1-2 cm and to a mean depth of 1.5-2 cm, using a 21G needle. This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
75800283|NCT03084796|Drug|Placebo|Placebo Control
75800284|NCT03084796|Drug|Tiotropium Bromide 18 µg Inhalation Capsule|Active Control
75800285|NCT03717012|Drug|Nintedanib|stable dose
75800286|NCT03717012|Other|Pulmonary rehabilitation program|12 weeks
75800287|NCT01302756|Other|Placebo|Group 1: Placebo plus standard of care pre-natal vitamins (which include 1 milligram of folic acid) a day for the duration of pregnancy
75800288|NCT01302756|Dietary Supplement|Folic Acid|Group 2: 4-milligrams of folic acid a day for the duration of pregnancy plus standard of care pre-natal vitamins (which include 1 milligram of folic acid)
75800289|NCT03793686|Drug|PBCLN-003|Investigational drug
75800290|NCT03793686|Drug|Placebo|Placebo
75800291|NCT02501148|Device|carotid artery stenting|Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
75800292|NCT03793530|Other|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
75938134|NCT03507075|Behavioral|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
75938135|NCT03106298|Drug|Iron Sucrose|All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
75800293|NCT03793530|Other|Transforaminal lumbar interbody fusion with local bone graft|Transforaminal lumbar interbody fusion with local bone graft
75800294|NCT01848912|Device|Zephyr Biopatch Device|
75938136|NCT02316561|Radiation|Single dose ablative radiotherapy|A single dose ablative radiotherapy will be delivered prior to surgery
75800295|NCT04893252|Drug|durvalumab and vactosertib|durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)
75938137|NCT02398292|Other|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
75938138|NCT02398292|Other|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
75938139|NCT02307591|Drug|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
75938140|NCT02307591|Drug|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~Children < 29 kg: 5 mg/kg 3 times a day"
75800296|NCT04863300|Behavioral|Collaborative stepped care and peer support|"Case identification will be done through open referral and outreach activities such as street booth, talks, and home visits.~For older adults with mild depressive symptoms (PHQ-9 score 5-9), 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided by the project social workers in DECC. For participants with moderate depressive symptoms (PHQ-9 score 10-14), 6-8 weeks high-intensity clinical intervention, mainly group cognitive behavioral therapy (CBT), would be provided by project social workers from DECC and ICCMW. For those with moderately severe depressive symptoms (PHQ-9 score 15-19), 8-10 weeks individual CBT or group CBT at higher frequency would be provided by the project social workers from ICCMW.~In the progress review when a client is assessed to meet the discharge criteria, a 2-month exit plan involving a Peer Supporter follow-up is invoked."
75938141|NCT02316639|Other|Neuromuscular Training|The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
75938142|NCT02397980|Behavioral|Behavioral intervention|"What the dementia is~How to deal with behavioral problems in patients with dementia~How to manage caregiver's stress~How to care dementic patients as well as caregivers themselves"
75938143|NCT03506997|Drug|Pembrolizumab|Pembrolizumab 200mg given as a 30 minute intravenous (IV) infusion, on day 1 of each 3 week cycle. Patients may continue with pembrolizumab treatment as long as they remain free from intolerable toxicity for a maximum of two years, if in the Investigator's opinion they are receiving clinical benefit, and/or they do not meet any discontinuation criteria.
75938144|NCT02398136|Drug|Ketamine|
75938145|NCT02398136|Drug|Midazolam|
75342162|NCT02990078|Drug|Sildenafil citrate|Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
75342163|NCT02990078|Device|Functional Near Infared Spectroscopy|Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
75342164|NCT02990078|Other|Hypercapnia Challenge|The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
75342165|NCT01288859|Other|free curcumin|free curcumin in bread, dosage 1g/100g, 200g/day per 1 day
75342166|NCT01288859|Other|encapsulated curcumin|encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day
75475457|NCT01995370|Drug|aspirin|Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
75475458|NCT01995370|Drug|clopidogrel|Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
75342167|NCT01288859|Other|encapsulated curcumin + PQG|bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day
75475459|NCT01995370|Drug|cilostazol|Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
75475460|NCT01995383|Other|LS followed by NS diet condition|LS diet period followed by NS diet period
75475461|NCT01995383|Other|NS followed by LS diet condition|NS diet period followed by LS diet period
75938146|NCT03503253|Device|Interlock-35 Fibered IDC Occlusion System|Use of detachable coil for LAA leak closure
75938147|NCT03503253|Device|Concerto Helix Detachable Coil System|Use of detachable coil for LAA leak closure
75938148|NCT03503253|Device|Azur Peripheral Coil System|Use of detachable coil for LAA leak closure
75475462|NCT01995383|Drug|Placebo|Single oral administrations
75475463|NCT01995383|Drug|Placebo|2 single oral administrations
75475464|NCT01995383|Drug|RO6836191|Orally administered, single ascending doses
75475465|NCT01995383|Drug|RO6836191|2 single oral doses
75475466|NCT01995383|Drug|RO6836191|Intravenous administration
75475467|NCT01995409|Behavioral|No smoking material provided in households with newborn infants|
75475468|NCT01995422|Other|Physical activity program|One hour sessions of active walking occurring three times a week during three months
75475469|NCT01995435|Device|Telemedicine refraction|
75475470|NCT01995435|Device|Traditional refraction|
75475471|NCT01995448|Biological|Blood test|Residue of blood further to NFS.
75475472|NCT01995474|Other|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
75475473|NCT01995474|Other|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
75475474|NCT01995500|Device|BioNIR|drug-eluting stent
75342168|NCT01288859|Other|free cocoa polyphenol|nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
75342169|NCT01288859|Other|encapsulated cocoa polyphenols|nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
75652610|NCT05251766|Drug|Nab paclitaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
75800297|NCT03797664|Drug|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 7.5, 15.0 and 22.5g
75800298|NCT03797664|Drug|Placebo|Phosphate Buffer Diluent oral solution
75800299|NCT03811314|Device|Strength training|Using dumbbells, butterfly machine and vertical leg press machine for strength training, 12 repetition maximum weight for 12 repetition, three times a day, five days a week, for a total of four weeks
75800300|NCT03811314|Device|Aerobic training|Using stationary bicycle to perform cardiopulmonary endurance training in 50-70 heart rate reserve for 20 minutes, five days per week, for a total of four weeks
75800301|NCT03797508|Diagnostic Test|ultrasound|To evaluate the accuracy of ultrasound findings in comparison to serum CA125and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage.
75800302|NCT03797118|Device|FFR|Fractional flow reserve measured during cardiac catheterization
75800303|NCT03797352|Other|Multicomponent exercise|To identify frailty and other potential health issues, and determine if Multicomponent exercise helps at-risk elderly to have better health outcomes.
75800304|NCT03811548|Drug|Janagliflozin 25mg|Tablets, Oral, 25 mg, Tablets, Oral, 50 mg
75800305|NCT03811548|Drug|Janagliflozin 50mg|Tablets, Oral, 25 mg, Once daily, 52 weeks
75800306|NCT03811548|Drug|Placebo/Janagliflozin|Tablets, Oral, 25 mg, Once daily, 52 weeks
75800307|NCT03793296|Device|Percutaneous Device Closure: Vascular plug|percutaneous transcatheter approach into cardiac valve
75800308|NCT05634096|Diagnostic Test|Oximetry|Children underwent oximetry simultaneously with video-polygraphy or video-polysomnography in routine clinical practice. The data are retrospectively collected from the patient's recording.
75800309|NCT03811626|Procedure|cognitive-behavioral rehabilitation|Combination of clinical examination and neuropsychological and psychological tests
75800310|NCT01380496|Drug|doxycycline monohydrate|tablet, 100 mg, single, oral dose
75800311|NCT01380496|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
75800312|NCT01380496|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
75800313|NCT03793374|Other|Subcutaneous apocrine glands shaving|A 0.5-cm long incision was made in the identified elliptical surgical area at each axilla for the access of arthroscopy to remove the apocrine glands. A suction-assisted cartilage shaver (E9005 System, Linvatec Corporation, Largo, Florida, USA) was introduced through the incisions to remove of the subcutaneous apocrine glands radially. After defatting, the incisions were closed primarily with 4-0 polyglactin. We anchored the defatting skin to the axillary fascia by 4-0 nylon sutures instead of the tie-over dressing or tissue glues, and we also made several drainage holes by inserting an 18G needle obliquely into the defatting skin. Therefore, draining tubes were no longer needed. We will remove the stiches at the 8th day after the operation.
75800314|NCT05752708|Diagnostic Test|Diagnostic Test|Evaluation of perioperative anxiety in parents of children undergoing thoracic surgery using standardized tests: The Amsterdam Preoperative Anxiety and Information Scale (APAIS), the State-Trait Anxiety Inventory (STAI).
75800315|NCT03797040|Biological|Cell therapy|PLX-R18: Allogeneic ex vivo expanded placental stromal cells
75800316|NCT01304316|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
75800317|NCT01301430|Drug|H-1PV|H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
75800318|NCT03792828|Drug|Duloxetine HCl 30mg|In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation. In the control group, the patients can take painkillers except duloxetine.
75800319|NCT01302912|Procedure|Lymphoma-Biopsy|Patients after biopsy of orbital lymphoma
75800320|NCT01304394|Drug|Ped3CB|The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
75342170|NCT01288859|Other|control nut cream|nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
75800321|NCT01379326|Drug|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
75800322|NCT00791466|Dietary Supplement|Placebo|Daily placebo supplementation from enrolment <14 wk of gestation until delivery
75800323|NCT00791466|Dietary Supplement|Iodine|Daily supplementation with 200 µg iodine from enrolment <14 wk of gestation until delivery
75800324|NCT05748574|Dietary Supplement|Sleep Well Sachet|Individuals will take 1 Sleep Well sachet daily over 2 weeks Exception: Two sachets are taken on days 4 and 17 upon acute assessment
75800325|NCT01560546|Drug|Testosterone|50 mg/dose/day for 24 weeks
75800326|NCT01560546|Drug|Placebo|placebo on the skin for 24 weeks
75800327|NCT01380340|Other|Seniors Early Intervention Planning and Discussion.|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
75800328|NCT03811392|Procedure|Hernioraphy/Caudal block|30 patients will receive a caudal block after induction of general anaesthesia
75800329|NCT03811392|Procedure|Hernioraphy/Quadratus Lumborum block|30 patients will receive ultrasound guided quadrates lumborum block
75475475|NCT01995500|Device|Resolute|drug-eluting stent
75652611|NCT05251766|Drug|Docetaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
75800330|NCT04921254|Drug|BSG005 or placebo|"SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level."
75800331|NCT03630874|Other|Evaluate the impact of a prescription support tool|"From a systematic review of international guidelines (2012-2018), we developed a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy.~In the experimental group, the tool will be provided with an explanatory guide. Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (thanks to the tool) the right prescription of ATs by answering a multiple-choice question, with the number, type, duration and dosage of AT provided."
75800332|NCT03792984|Dietary Supplement|Vitamin D3|Vitamin D3 (Cholecalciferol) (6000 IU/daily). PO for 8 weeks.
75800333|NCT03792984|Dietary Supplement|Calcium Carbonate|Calcium carbonate (1000 mg/daily). PO for 8 weeks.
75800334|NCT03792984|Drug|Metformin|Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
75800335|NCT03792984|Drug|Placebo|PO for 8 weeks.
75800336|NCT04914546|Drug|LY3819469|Administered SC.
75800337|NCT04914546|Drug|Placebo|Administered SC.
75800338|NCT05200234|Drug|Nattokinase|Nattokinase + standard treatment
75800339|NCT05200234|Drug|Placebo|Placebo+ standard treatment
75800340|NCT03792906|Drug|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
75800341|NCT03792906|Drug|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
75800342|NCT03792906|Drug|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block.
75475476|NCT01995565|Other|PLR|
75475477|NCT01995604|Other|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
75475478|NCT01995604|Other|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
75800343|NCT03792906|Drug|Bupivacaine hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
75475479|NCT01995617|Biological|Placebo|normal saline, 0.5 mL per dose
75475480|NCT01995617|Biological|GEN-004 Low Dose|The GEN-004 Low Dose contains 10µg of each of the three antigens.
75475481|NCT01995617|Biological|GEN-004 Low Dose + Adjuvant|The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
75652612|NCT04254848|Other|oral stereognostic test|Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
75800344|NCT05483166|Behavioral|ImPACT|"During the ImPACT program, the childhood cancer survivor and at least one parent collaborates on:~Becoming aware of the child's core strengths and difficulties~Helping the child to be optimally responsive to the guidance of the parent(s), and~Creating compensatory strategies to respond to real-world manifestations of the child's difficulties and helping the child implement these strategies at home."
75800345|NCT04884126|Procedure|dental implant placement|The time of dental implant surgery
75800346|NCT02613286|Procedure|Extrafascial Hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
75800347|NCT02613286|Procedure|Modified radical hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
75800348|NCT03792594|Other|arthroscopic repair with bone marrow concentration|arthroscopic repair with bone marrow concentration
75800349|NCT03792594|Other|arthroscopic repair|arthroscopic repair only
75800350|NCT05200078|Device|Deep inspiration breath-hold technique|Selective application of deep inspiration breath-hold technique
75938149|NCT05745584|Drug|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
75475482|NCT01995617|Biological|GEN-004 Mid Dose|The GEN-004 Mid Dose contains 30µg of each of the three antigens.
75475483|NCT01995617|Biological|GEN-004 Mid Dose + Adjuvant|The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
75475484|NCT01995617|Biological|GEN-004 High Dose|The GEN-004 High Dose contains 100µg of each of the three antigens.
75938150|NCT02312661|Drug|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
75938151|NCT02312661|Drug|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
75938152|NCT02312661|Drug|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
75938153|NCT05745506|Other||Not applicable, there is no intervention description in this study.
75475485|NCT01995617|Biological|GEN-004 High Dose + Adjuvant|The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
75475486|NCT01995630|Device|AMO Tecnis ZA9003|
75475487|NCT01995630|Device|AMO Sensar AR40e|
75475488|NCT01995643|Dietary Supplement|Active Capsule|GSE Capsule
75475489|NCT01995643|Dietary Supplement|Placebo Capsule|Placebo Capsule
75475490|NCT01995656|Drug|Placebo - Capsule|Administered orally
75475491|NCT01995656|Drug|LY3108743 - Capsule|Administered orally
75652613|NCT05253170|Radiation|Hypofractionation|Radiation regimen of 2.5-3.0Gy x 13-17 fractions +/- sequential boost 0-7 fractions
75652614|NCT05253170|Radiation|Conventional Fractionation|Radiation regimen of 1.8-2.0Gy x 23-28 fractions +/- sequential boost 0-5 fractions
75652615|NCT04719338|Diagnostic Test|presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .|samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
75800351|NCT03810846|Behavioral|Walking football exercise program|Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
75800352|NCT05625048|Other|Transperinal ultrasound guided instruction in pelvic floor muscle training|The physiotherapists uses transperinal ultrasound as a biofeedback or pedagogical tool to improve the muscle contractions and visualize the muscle work.
75800353|NCT04152382|Drug|LY3462817 - IV|Administered IV
75800354|NCT04152382|Drug|LY3462817 - SC|Administered SC
75800355|NCT04152382|Drug|Placebo - IV|Administered IV
75800356|NCT04152382|Drug|Placebo - SC|Administered SC
75800357|NCT04152382|Drug|LY3509754|Administered orally.
75800358|NCT04152382|Drug|Placebo|Administered orally.
75800359|NCT03792204|Diagnostic Test|Wearing-off 9 questionnaire|The participants would receive appropriate anti-PD medical treatments according to the patients' need during the investigation.The anti -PD treatment would not be changed in the population of the participants.
75475492|NCT01995656|Drug|Placebo - Solution|Administered orally
75652616|NCT04254380|Biological|Gan & Lee Insulin Lispro Injection|Route of administration: subcutaneous injection
75652617|NCT04254380|Biological|Humalog|Route of administration: subcutaneous injection
75800360|NCT01379248|Device|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
75800361|NCT03078556|Drug|Dolutegravir|Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.
75800362|NCT03078556|Drug|Lamivudine|"Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.<br>3TC will be gray, diamond shaped tablet, engraved GX EJ7 on one side and plain on the other side."
75800363|NCT03078556|Drug|Dolutegravir + Lamivudine FDC Formulation 1|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. &lt;br&gt;FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.
75800364|NCT03078556|Drug|Dolutegravir + Lamivudine FDC Formulation 2|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. &lt;br&gt;FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.
75800365|NCT03949894|Drug|Tolvaptan|30mg and 15mg of Tolvaptan Tablet
75800366|NCT02299648|Other|Molecular profiling|molecular profiling, patient derived cells, fresh or FFPE
75800367|NCT03714672|Drug|Tramadol/Diclofenac 50/50|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
75800368|NCT03714672|Drug|Tramadol/Diclofenac 25/25|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
75938154|NCT03501771|Other|Acupuncture|Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
75938155|NCT02397902|Dietary Supplement|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
75938156|NCT02397902|Dietary Supplement|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
75938157|NCT02307669|Behavioral|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
76089240|NCT03822273|Procedure|Traditional acupuncture (TA)|"Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min."
75342171|NCT02994134|Behavioral|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
75342172|NCT02994134|Behavioral|High intensity exercise.|High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
75342173|NCT00659828|Drug|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
75342174|NCT01235195|Drug|sertraline hydrochloride|50 mg capsule, single-dose
75342175|NCT01235195|Drug|sertraline hydrochloride|50 mg tablet, single-dose
75342176|NCT04387214|Other|survey|online survey
75938158|NCT02307669|Behavioral|Usual Care|"The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines."
76089241|NCT03822273|Procedure|Laser acupuncture (LA)|"Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies [B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz]; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2)."
75342177|NCT01198691|Device|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
75342178|NCT01198691|Device|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
75652618|NCT00631514|Drug|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
75800369|NCT03714672|Drug|Tramadol 50|Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.
75800370|NCT03714672|Drug|Diclofenac 50|Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
75342179|NCT00660530|Drug|Lanthanum Carbonate Chewable Product|Lanthanum carbonate 1 g to be chewed, three times daily with meals
75342180|NCT00660530|Drug|Lanthanum carbonate crushed powder|Lanthanum carbonate (Fosrenol) 1 g crushed into a fine powder, three times daily with meal
75342181|NCT01198769|Biological|Rotarix TM|Oral, 2 doses
75342182|NCT02996942|Biological|Factor VIII replacement|Patients receive their usual treatment
75342183|NCT02998580|Device|LFR followed by HFL|Magventure Cool B70 Coil with RX100 Stimulator
75342184|NCT02998580|Device|cTBS followed by iTBS|Magventure Cool B70 Coil with RX100 Stimulator
75342185|NCT01199237|Drug|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
75475493|NCT01995656|Drug|LY3108743 - Solution|Administered orally
75652619|NCT00631514|Drug|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
75652620|NCT00631514|Drug|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
75652621|NCT05253014|Procedure|sphenopalatine ganglion block|block of the sphenopalatine ganglion using either lidocaine or bupivacaine to relief postdural puncture headache
75652622|NCT05253014|Drug|paracetamol|intravenous paracetamol every 8 hours
75800371|NCT03083470|Drug|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
75800372|NCT03083470|Other|SOR007 Ointment Vehicle|SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
75938159|NCT02398058|Drug|trabectedin|trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
75938160|NCT02398058|Drug|olaparib|olaparib will be administered in a continuous daily dose every 12 hours
75342186|NCT01199237|Drug|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
75342187|NCT01199237|Drug|Rocuronium|
75342188|NCT01199237|Drug|Neostigmine|
75342189|NCT01199237|Drug|Glycopyrrolate|
75342190|NCT01235897|Drug|MK-2206|Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
75342191|NCT01235897|Drug|Paclitaxel|80 mg/m2 weekly - paclitaxel
75342192|NCT01235897|Drug|Trastuzumab|2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
75342193|NCT01236053|Drug|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
75800373|NCT01306188|Biological|Breast cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~The analysis of TCR and BCR repertoire diversity,~The phenotypic analysis of immune subpopulations,~The analysis of the global lymphopenia or subpopulations T,~The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
75342194|NCT00703976|Drug|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
75342195|NCT00703976|Drug|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
75800374|NCT01306188|Biological|Lung cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~The analysis of TCR and BCR repertoire diversity,~The phenotypic analysis of immune subpopulations,~The analysis of the global lymphopenia or subpopulations T,~The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
75800375|NCT01377610|Drug|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
75800376|NCT01377610|Drug|Buprenorphine|Following detoxification with buprenorphine [8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
75800377|NCT01377610|Drug|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
75800378|NCT04121572|Device|Nasal cannula capnography|Capnography: a continuous wave form of the CO2 level with the digital reading of CO2 level at end of expiration
75342196|NCT00703976|Drug|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
75342197|NCT00703976|Radiation|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
75800379|NCT05669118|Procedure|Tooth Autotransplantation|Place another tooth in the place of the newly extracted tooth in the same patient.
75800380|NCT03811080|Drug|DWP14012 A mg|The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
75800381|NCT03811080|Drug|DWP14012 B mg|The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
75800382|NCT03811080|Drug|Placebo|The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
75342198|NCT02320214|Device|Miami w/ frag Personal lubricant|
75475494|NCT01995695|Biological|Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
75800383|NCT01302990|Biological|Dose given at Day 0|Dose given by intramuscular administration (0.5 mL)
75342199|NCT02994368|Other|Observation|
75342200|NCT00661544|Drug|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
75475495|NCT01995695|Biological|Inactivated subvirion H7N9 influenza vaccine|Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
75800384|NCT05624970|Behavioral|aerobic training , tobacco cessation and nutritional advices|"Aerobic training program according to Taheri et al 2017:~Mode: recruits large groups of muscles and includes brisk walking on treadmill, cycling, swimming, and jogging~Intensity: submaximal aerobic exercise program (50-60% of maximal heart rate reserve) on treadmill~Frequency: 3 sessions a week for 2 months.~Duration: 60 min/session The training protocol was divided into three phases: the warm up period (10 minutes), the main program (aerobic exercise; 40 minutes), and a cool down period (10 minutes).~Tobacco Cessation Programs for 3 months~Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months"
75800385|NCT05624970|Behavioral|tobacco cessation and nutritional advices|Tobacco Cessation Programs for 3 months Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months
75342201|NCT00661544|Drug|Melphalan|Dose Levels 1, 2, & 3: 100 mg/m2 IV Days -4, -3.
75652623|NCT05278442|Other|LaserArc|LaserArcs.com is an online arcuate incision nomogram calculator initially developed on the basis of 12 months of data tabulation of patients undergoing femtosecond surgery with arcuate incisions
75652624|NCT05252780|Behavioral|My Body, My Rhythm, My Voice|My Body was a behavioral intervention informed by the social cognitive and self-determination theories. Based on the discussions and a systematic review of the literature, we designed the 8-week, 3 times/week rumba physical activity intervention. The goal of the intervention was to gradually increase all participants' physical activity levels to achieve significant health benefits. As part of the physical activity intervention, participants were also taught by their instructor during each class how to utilize behavioral and cognitive self-regulatory skills to increase and maintain their physical activity participation. Examples of such skills were action planning, coping planning, counter conditioning, self-evaluation, among others.
75342202|NCT00661544|Drug|Ascorbic Acid|Dose Levels 1, 2, & 3: 1000 mg IV Days -9 to -3.
75342203|NCT02996552|Procedure|M & T Repair Group|After the mitral valve repair a device for tricuspid annuloplasty will be implanted.
75342204|NCT02996552|Procedure|Mitral-Only Group|Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
75342205|NCT00706394|Device|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
75475496|NCT01995721|Biological|4-valent HPV vaccine|Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
76089242|NCT03822273|Procedure|Sham laser acupuncture (SLA)|"Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group."
75800386|NCT01377532|Drug|131 I-Metaiodobenzylguanidine (131 I-MIBG)|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions. A radiation safety officer will instruct the patient, family, and caretakers about specific UCSF radiation safety guidelines for both hospitalization and discharge.
76089243|NCT01942720|Device|Capsule endoscopy and Ileocolonoscopy tests|
75342206|NCT00706550|Biological|(PV) 23-valent pneumococcal polysaccharide vaccine|Currently commercially available pneumococcal polysaccharide vaccine
76089244|NCT03827577|Procedure|Surgical removal of primary and/or of all oligometastases|Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).
76089245|NCT03827577|Radiation|Non-surgical LAT|Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.
76089246|NCT03827577|Drug|Standard medical therapy|platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
75342207|NCT00706550|Biological|Placebo|Placebo
76089247|NCT01762943|Drug|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
75342208|NCT02997878|Biological|Orbcel-C|Selected Mesenchymal Stromal Cells derived from human umbilical cord
75342209|NCT02979392|Drug|TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)|TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
75342210|NCT01237301|Device|CGM Group|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
76089248|NCT01762943|Drug|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
76089249|NCT01762943|Drug|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
75475497|NCT01995734|Drug|Pasireotide long acting release formulation|Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
76089250|NCT01943110|Device|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
75652625|NCT04254458|Diagnostic Test|Corneal densitometry|Corneal density values were measured by densitometry software of Pentacam HR-Scheimpflug corneal topography
75652626|NCT04254614|Device|Personalised mobile application for IBD patients|"Patients will use a mobile application for ±6months (exact period depends on interval of biologic treatment) with the following functionalities:~Personal interactive timeline to prepare for biologic treatment with reminders for blood tests, a questionnaire to exclude contra-indications for biologic treatment (e.g. current infection) and a message from the gastroenterology nurse when blood tests results and the questionnaire have been checked. Only in case of abnormal results or answers patients will be contacted by telephone by their gastroenterology nurse, which is currently standard care.~Information about the patients' diagnosis and biologic treatment.~General information on e.g. IBD treatment, vaccinations, frequently used medical terms, preparing for outpatient visits, what to do in case of disease symptoms.~Patients will fill in a questionnaire to measure study outcomes at baseline and at the end of the study period."
76089251|NCT01943110|Device|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
76089252|NCT03331354|Behavioral|Distant vocational learning|use of hybrid distance learning to facilitate successful employment outcomes
76089253|NCT03331354|Other|Basic vocational services|self-help manual
76089254|NCT01943344|Device|VIVASURE CLOSURE DEVICE™|implantation of VIVASURE CLOSURE DEVICE™
75342211|NCT01237301|Device|SMBG Group|Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
75342212|NCT02999906|Drug|Oral Treprostinil|Sustained release oral tablets for three times daily administration
75342213|NCT02999906|Drug|Placebo|Placebo (sugar pill) for three times daily oral administration
75342214|NCT01200875|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
75342215|NCT01200875|Procedure|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
75342216|NCT02999750|Other|individual therapy|Patient will be treated with individual therapy.
75342217|NCT01238471|Drug|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
75342218|NCT01238471|Drug|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
75342219|NCT00706784|Drug|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
75342220|NCT02996786|Dietary Supplement|Danggui Buxue Tang|Danggui Buxue Tang purchased from Kaiser Pharmaceutical
75475498|NCT01995786|Device|Goal Directed Fluid Therapy FloTrac/Vigileo|
75475499|NCT01995799|Device|Ferumoxytol enhanced MRI|Ferumoxytol enhanced MRI scan
75475500|NCT01995812|Behavioral|Hula and heart health education|
75800387|NCT05624892|Diagnostic Test|Mirror Therapy with Virtual Reality Application|Researchers will apply Mirror Therapy with Virtual Reality Application to increase individuals' quality of life and motor sense gains.
75475501|NCT01995864|Behavioral|CTI-TS|"The following briefly describes the three phases of CTI-TS:~Phase 1: Initiation: The client and CTI-TS team formulate a treatment plan that focuses on selected areas identified as crucial for strengthening stability and facilitating the assimilation of the individual into community living.~Phase 2: The Try-Out phase is devoted to testing and adjusting the support systems that have been established in the community.~Phase 3: The final phase, Transfer of Care, is devoted to making any necessary improvements in the network of supports of the individual."
75475502|NCT01995877|Procedure|Subjects scheduled for IVC filter placement|"Subjects will have an intra vascular ultrasound (IVUS) performed while lying down on the exam table; this will be performed before and after the IVC (inferior vena cava) filter is placed. During the ultrasound, measurements of the diameter of different areas of the IVC will be taken. The table will then be moved so that you are in a standing position and the measurements will be taken again.~The ultrasound will be done by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS (intra vascular ultrasound) catheter will be inserted through the sheath and used to measure the size of the IVC at various places.~The IVUS procedure will add about 30-45 minutes to the filter placement procedure."
75800388|NCT03788772|Other|Multiple blood sampling|ICU septic and non-septic patients will be subjected to repeated blood samples at the following time-points: ICU admission, day 4/5, ICU and hospital discharge, 3 months. Patients exhibiting ICU-acquired infection will also be sampled at the time of diagnosis (up to 6 additional blood samples of 20 mL within 3 months = 120mL)
75800389|NCT03788772|Other|Simple blood sampling|Healthy controls (blood donors and patients undergoing elective cataract surgery) will be subjected to one single blood sample of 20 mL.
75475503|NCT01995890|Drug|nepafenac|
75800390|NCT03810976|Drug|Eribulin, gemcitabine|Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1& Day 8 every 3 weeks
75800391|NCT05405244|Drug|Placebo|2 capsules, orally administered once
75800392|NCT05405244|Drug|Bromocriptine-QR|1.6mg (2 0.8mg capsules), orally administered once
75800393|NCT05420974|Procedure|NIR fluorescence imaging of the vascular perfusion of the meniscus using ICG|NIR fluorescence imaging of vascular perfusion using the Arthrex NIR fluorescence scope and Indocyanin Green
75800394|NCT01379872|Other|Non-Interventional Study|This is a non-interventional study
75800395|NCT03810690|Biological|mRNA-3704|mRNA-3704 dispersion for intravenous (IV) infusion
75800396|NCT03762460|Other|Online eHealth tool|Mobile-optimized online eHealth tool to support MBC.
75800397|NCT03762460|Other|Informational website|Participants randomized to this group will receive information about online resources for mental health
75938161|NCT03503175|Device|Novel urinary access system (CystoSureTM)|CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).
75938162|NCT03503175|Device|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
75938163|NCT03501615|Drug|Moxetumomab Pasudotox|A recombinant conjugated immunotoxin composed of a disulfide-stabilized anti-CD22 Ig Fv genetically fused to a truncated form of Pseudomonas exotoxin, PE38
76089255|NCT04392063|Drug|Melatonin 3 mg|The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
75475504|NCT01995903|Diagnostic Test|MRI(magnetic resonance imaging)|Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
75475505|NCT01995916|Behavioral|Mindfulness Intervention|The Mindfulness Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
75475506|NCT01995916|Behavioral|Social Support Group|The Social Support Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
75800398|NCT03789006|Drug|Antithymocyte Immunoglobulin (Rabbit)|Induction agent for living donor kidney transplantation
75800399|NCT03789006|Drug|Interleukin 2 Receptor Antagonist|Induction agent for living donor kidney transplantation
75800400|NCT01379170|Drug|Euthyrox (levothyroxine)|A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
75800401|NCT01306266|Drug|Rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache
75800402|NCT01306266|Drug|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
75800403|NCT03516214|Drug|EGF816|Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
75800404|NCT03516214|Drug|Trametinib|Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
75800405|NCT05624814|Device|Spinal Cord Stimulation|Spinal Cord Stimulation consists of the transcutaneous or surgical implantation of different types of electrodes in the epidural space; electrodes are then connected to an Implanted Pulse Generator that generates stimulating currents.
75800406|NCT05624814|Other|Standard therapies|Standard therapies for chronic low back pain are pharmacological, psychological, physical and occupational therapies or surgery.
75800407|NCT05624736|Diagnostic Test|multi-parametric magnetic resonance imaging scan|Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.
75800408|NCT05624736|Diagnostic Test|Pathology examination|The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
75342221|NCT02996786|Other|Placebo|Consisting of corn starch and carboxymethyl cellulose
75475507|NCT01995955|Procedure|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
75475508|NCT01995968|Other|Antenatal identification of fetal growth restriction|"FGR is considered as identified if:~FGR was mentioned in medical charts~OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~OR utero-placental Doppler ultrasound indicated for suspicion of growth failure"
75652627|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
75652628|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
75800409|NCT03630796|Drug|Sevoflurane|Use of sevoflurane (compared to total intravenous anesthesia) in congenital heart deffects surgeries.
75800410|NCT03630796|Drug|TIVA|Total intravenous anesthesia
75475509|NCT01995981|Drug|Pazopanib|
75800411|NCT03630718|Behavioral|Psychoeducational Intervention|"The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest.~The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient."
75800412|NCT03630718|Behavioral|Hypnosis intervention|"The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being.~Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue."
75475510|NCT01996059|Procedure|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
75800413|NCT05388162|Device|Mobile colposcope|It is a comparison trial - Comparing a standard colposcpoe with a smart-phone based colpsocpe.
75800414|NCT01379092|Device|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
75800415|NCT01379092|Device|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
75800416|NCT03810300|Other|Cash transfer|1500 taka ($18.75) per household distributed monthly
75800417|NCT03810300|Other|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
76089256|NCT01903798|Drug|Mycophenolate mofetil|Immunosuppressive agent
76089257|NCT01903798|Drug|Prednisolone|Corticosteroid
76089258|NCT01903798|Drug|Rilonacept|
75475511|NCT01996059|Procedure|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
75475512|NCT01996072|Drug|EC17|
76089259|NCT03821961|Procedure|Metabolic Surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
76089260|NCT01909180|Device|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
76089261|NCT04273815|Drug|TQ-A3334|TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
75342222|NCT00664430|Drug|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
75342223|NCT00664430|Drug|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
75475513|NCT01996085|Drug|lisinopril|"Angiotensin converting enzyme inhibitor recommended in case of:~hyperconstrictive profile (SVRI > 2500-2800 dyn•s•cm-5•m2)~hyperdynamic profile (CI > 4.2 l/min/m2 and/or HR > 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~hypervolemic profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~balanced profile"
75342224|NCT02996162|Device|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
75342225|NCT02996162|Device|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
75342226|NCT01292135|Drug|PCI-32765|420 mg daily
75800418|NCT03810300|Other|Food and cash transfer|15 kg of rice, 1 kg of lentils, and 1 kg of micronutrient-fortified cooking oil, and 750 taka cash per household, distributed monthly
75800419|NCT03810300|Behavioral|Nutrition behavior Communication Change (BCC)|Weekly, group-based, one-hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings
75800420|NCT03810300|Other|Control|No transfer, no behavior change communication
75800421|NCT05202964|Other|Tolerance and adherence to oral antibiotics in patients managed for BJI|"Adherence and tolerance will be measured 6 weeks (S6) and 3 months (M3) after the surgery.~The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire) Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse.~Patients will respond to a questionnaire about the tolerance on the consultation at S6 and M3."
75800422|NCT01567332|Device|SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
75800423|NCT01567332|Device|SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
75800424|NCT01346722|Other|Diet-ZnBfR|zinc biofortified rice-based diet
75800425|NCT01346722|Other|Diet- CR|conventional rice-based diet
75800426|NCT01346722|Other|Diet-ZnBfR|zinc biofortified rice-based diet
75800427|NCT01346722|Other|CR + Zn|conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
75800428|NCT01096966|Drug|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
75800429|NCT01096966|Drug|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
75800430|NCT01379716|Other|skin biopsy|Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
75800431|NCT01379560|Drug|unoprostone isopropyl|"unoprostone isopropyl (2 drops)~placebo (2 drops)"
75938164|NCT02312817|Other|Mailed Outreach Invitation|"Individuals randomized to Group 2 will receive:~Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
75475514|NCT01996085|Drug|Telmisartan|Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
75652629|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
75652630|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
75652631|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
75800432|NCT01379560|Drug|unoprostone isopropyl|"unoprostone isopropyl (3 drops)~placebo (3 drops)"
75652632|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
75938165|NCT02312817|Other|Mailed Outreach Invitation and Patient Navigation|"Individuals randomized to Group 3 will receive:~Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
75938166|NCT02693834|Device|Posterior Leaf spring AFO|Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.
75938167|NCT02693834|Device|Double adjustable AFO|Double adjustable AFO is a custom AFO with double action metal upright joints
75938168|NCT02312895|Other|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
75342227|NCT01241435|Drug|LY2216684|Administered orally
75652633|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
75342228|NCT01292447|Drug|2% lidocaine gel|120mg lidocaine x 1
75475515|NCT01996085|Drug|Nebivolol|"Beta-blocker recommended in case of:~1.hyperdynamic profile (CI > 4.2 l/min/m2 and/or HR > 80/min)"
75938169|NCT02312895|Other|Dry needling|Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.
75938170|NCT02312895|Other|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
75938171|NCT02312973|Drug|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
75652634|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
75652635|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
75652636|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
75938172|NCT02312973|Drug|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
75938173|NCT03506919|Drug|Allopurinol|Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
75800433|NCT01379482|Drug|Multimodal treatment|"3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)"
75938174|NCT04871048|Device|Transcranial direct current stimulation (tDCS) active|Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.
75938175|NCT04871048|Device|Transcranial direct current stimulation (tDCS) non active|The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures.
75938176|NCT02545504|Drug|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
75938177|NCT02545504|Drug|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
75938178|NCT02545504|Drug|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
75938179|NCT02545504|Drug|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
75938180|NCT02545504|Drug|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
75652637|NCT00794989|Dietary Supplement|Ground Flaxseed|Given orally
75652638|NCT00794989|Other|No Intervention|Participants randomized to Arm 2 do not receive any intervention
75342229|NCT01292447|Drug|Placebo gel|Inert gel x 1
75342230|NCT00704912|Drug|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
75342231|NCT00704912|Drug|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
75342232|NCT00704912|Drug|Combination of treatments|Medications will be administered as described for the other 2 arms.
75800434|NCT03791892|Other|Shoulder mobilization Group|Suprascapular nerve block administered every week to both groups. Joint mobilization (3 sets / 40 seconds hold / 30 seconds interval) Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Strengthening exercises ( 3 sets / 15 reps)
75938181|NCT03506841|Drug|Cerebrolysin|Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
75652639|NCT00805753|Drug|ACTH|comparison of different dosages of drug
75938182|NCT02316795|Procedure|Sentinel lymph node biopsy|
75938183|NCT02316795|Device|Goggle-based device with light-emitting diodes (LED)|
75938184|NCT02316795|Drug|Indocynanine Green|This is a infrared fluorescence imaging contrast agent
75938185|NCT02397512|Drug|application of lactulose|Subjects will ingest 50g of lactulose once
75938186|NCT02397512|Other|application of sucrose|Subjects will ingest 50g of sucrose once
75800435|NCT03791892|Other|Conventional Treatment Group|Suprascapular nerve block administered every week to both groups. Daily Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Daily Strengthening exercises ( 3 sets / 15 reps)
75938187|NCT02313051|Drug|Everolimus|mTOR inhibitor
75342233|NCT02195921|Other|single point Zhongwan(CV12) plus antiemetic drug|"All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
75652640|NCT00797875|Procedure|PNF stretching|PNF stretching x 5 repetitions and continue 3 days
75800436|NCT05624424|Drug|Rematazolam Besylate|Anesthesia was induced with Rematazolam Besylate 0.3~0.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS<60, followed by remimazolam 1-3 mg/kg/h until the end of surgery.
75800437|NCT05624424|Drug|Propofol|Anesthesia was induced with Propofol 2~2.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS<60, followed by remimazolam 5~12 mg/kg/h until the end of surgery.
75800438|NCT05624424|Drug|Sevoflurane|Anesthesia was induced with etomidate 0.03 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS<60, followed by 2 %-3 % Sevoflorane until the end of surgery.
75800439|NCT05624424|Drug|Sufentanil|Anesthesia was induced with Sufentanil 0.3~0.5 ug/kg by intravenous injection after the LoC and BIS<60.
75938188|NCT02313051|Drug|Goserelin|
75938189|NCT02313051|Drug|Letrozole|
75938190|NCT03501537|Procedure|Free gingival graft obtained from the palate and debridement of the peri-implant lesion|granulation tissue debridement and grafting of a free gingival strip obtained from the palate
75938191|NCT02397590|Drug|Fimasartan|
75938192|NCT02397590|Drug|Atorvastatin|
75938193|NCT05745116|Device|Notal Vision Home OCT|Optical Coherence Tomography (OCT) was originally developed in 1991 as a non-invasive imaging technology to generate cross-sectional imagery of ocular tissues in vivo1. Cross-sectional visualization of the retina has proven to be a valuable tool in the identification and assessment of structural abnormalities that are not visible with ophthalmoscopic or biomicroscopic examination. OCT has become eye care professionals' leading diagnostic tool in the detection, diagnosis and treatment of retinal diseases and conditions, including age-related macular degeneration (AMD), Diabetic Macular Edema (DME), and Retina Vein Occlusion (RVO). Notal Vision, Inc. (Manassas, VA) is developing a Home Optical Coherence Tomography (OCT) System to allow OCT images to be captured on an OCT device placed in the patients' homes for daily scanning of eyes diagnosed with DME. This Home OCT allows visualization of retinal fluid in the central 10 degrees and is currently for investigational use only.
75938194|NCT02545270|Procedure|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
75938195|NCT02545270|Procedure|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
75938196|NCT02545270|Procedure|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
75938197|NCT02397356|Drug|Ketamine first AB|Nebulised ketamine 1mg/kg
75938198|NCT02397356|Drug|Placebo first BA|Nebulised saline 1-2ml
75652641|NCT00797875|Procedure|passive stretching|passive stretching x 5 repetitions continue 3 days
75652642|NCT00805831|Device|HDH|sutureless vascular anastomosis
75475516|NCT01996085|Drug|Indapamide/hydrochlorothiazide|"hypervolemic profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm)~hyperconstrictive profile (SVRI > 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)"
75475517|NCT01996085|Drug|Amlodipine|1/ SVRI > 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
75475518|NCT01996085|Drug|lisinopril|Drug choice at the discretion of physician (blinded to ICG)
75475519|NCT01996085|Drug|Telmisartan|Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
75475520|NCT01996085|Drug|Nebivolol|Drug choice at the discretion of physician (blinded to ICG)
75475521|NCT01996085|Drug|Indapamide/hydrochlorothiazide|Drug choice at the discretion of physician (blinded to ICG)
75475522|NCT01996085|Drug|Amlodipine|Drug choice at the discretion of physician (blinded to ICG)
75652643|NCT05179915|Other|Therapeutic Touch|In the latent phase of labor, the field energy of the sacral region will be cleared for an average of 15 minutes.
75652644|NCT00656851|Drug|Pioglitazone|30mg/day for 16 weeks
75652645|NCT00656851|Behavioral|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
75800440|NCT05624424|Drug|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
75938199|NCT02316873|Behavioral|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
75652646|NCT00803257|Other|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
75938200|NCT02316873|Behavioral|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
75938201|NCT05453344|Device|DexCom one|Provision of DexCom One for glucose monitoring
75800441|NCT05624424|Drug|Remifentanil|After the LoC, remifentanil 0.1~0.3 ug/kg/min inject intravenously until the end of surgery.
75800442|NCT05461846|Other|integrated neuromuscular inhibition technique|is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
75938202|NCT02317029|Device|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
75938203|NCT02317029|Procedure|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
75938204|NCT02317029|Device|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
75475523|NCT01996098|Drug|6-month Icotinib|125 mg three times daily (375 mg per day) by mouth for 6 months
75475524|NCT01996098|Drug|12-month icotinib|125 mg three times daily (375 mg per day) by mouth for 12 months
75652647|NCT00803335|Drug|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
75652648|NCT00803335|Drug|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
75652649|NCT00797953|Drug|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
75652650|NCT00798031|Device|A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.|A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
75652651|NCT00798031|Device|Placement of dental implant|"Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.~A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis."
75652652|NCT00798031|Device|dental implant|Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
75652653|NCT00798109|Behavioral|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
75652654|NCT00798109|Behavioral|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
75652655|NCT00656617|Drug|Idarubicin|12 mg/m^2 IV over 1 hour daily for 3 days (days 4 to 6)
75652656|NCT00656617|Drug|Cytarabine|1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
75652657|NCT00656617|Drug|Vorinostat|Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
75652658|NCT00798187|Behavioral|Group Meetings|10 weekly group meetings lasting 2 hours.
75652659|NCT00798187|Behavioral|Questionnaire|Surveys
75652660|NCT00805909|Drug|NI-0401|5 daily infusions with escalating doses of NI-0401
75800443|NCT05461690|Drug|Niraparib|200mg once a day for patients with body weight <77kg or baseline platelet count <150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.
75652661|NCT00798343|Biological|Seasonal vaccine|Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
75652662|NCT00798343|Biological|H5 vaccine|MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
75800444|NCT05461612|Device|Spatial Resynchronization Therapy delivered by the MAX-SRS, external recording and stimulation device|Delivery of algorithmically defined pacing stimuli over a multitude of electrodes placed on the left atrium.
75938205|NCT02317029|Procedure|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
75938206|NCT05453110|Behavioral|Deadlift Form Education|The education will include information about the lumbar spine as it relates to a deadlift. The researchers will administer this education shortly prior to participants taking a strength test.
75938207|NCT02307825|Drug|Azithromycin|The drug will be taken three times a week for four months.
75938208|NCT02307825|Drug|Placebo|The placebo will be taken three times a week for four months.
75938209|NCT02540668|Drug|Lanabecestat|Administered orally
75938210|NCT02540668|Drug|Warfarin|Administered orally
75938211|NCT03506763|Drug|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
75938212|NCT03506763|Drug|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
75938213|NCT03506763|Drug|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
75938214|NCT02441439|Dietary Supplement|Iron sucrose 200 mg|I.V Iron sucrose 200 mg 2-3 times per week. Each time for 20-30 minutes
75938215|NCT02441439|Dietary Supplement|Iron sucrose 500 mg|I.V Iron sucrose 500 mg once per week. Each time for 3.5 hours
75938216|NCT02669992|Procedure|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
75938217|NCT02669992|Procedure|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
75938218|NCT05475652|Other|Manual therapy|The manual therapy intervention is performed twice on the experimental group, once on day 0 (D0) and the second time on day 7 (D7). This intervention consists of a manual therapy protocol (base on myofascial release) applied to the cervical spine. Protocol consists of succession of techniques: suboccipital decompression, disengagement of Cervical 0-1-2,vibratory stimulation at C4 level and myofascial release technique of the cervical aponeuroses. Outcomes are evaluated before and after intervention.The same schedule will be reproduced on D7. On D21, only one assessment will be done at the beginning of the session.
75342234|NCT02195921|Other|single point Zusanli(ST36) plus antiemetic drug|"A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
75342235|NCT02195921|Other|Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug|Stimulating both Zusanli(ST36)and Zhongwan(CV12)
75475525|NCT01996111|Procedure|Injection of 1.0 cc of 0.9% Saline|Injection of 1.0 cc of 0.9% Saline into affected area
75475526|NCT01996111|Procedure|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
75475527|NCT01996111|Procedure|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area
75800445|NCT05461534|Behavioral|mindfulness yoga|Each mindfulness yoga session will last for 90 minutes and will be conducted in a group format once a week. Each session includes breathing exercise (10 min), mindfulness meditation and body scan (20 min) and yoga practice (60 min).
75938219|NCT05475652|Other|Placebo intervention|"The Sham group receives placebo treatment twice (D0 and D7). This placebo treatment also called light touch treatment consists of applying light pressure with broad support from both hands on either side of the joint, in contact with the skin, without equal bone pressure or therapeutic intention, for a duration comparable to that of manual therapy. Outcomes are evaluation before and after placebo intervention. The same schedule will be reproduced at D7. On D21, only one assessment will be done at the beginning of the session and a manual therapy treatment on the cervical spine is provided to balance access to care in the two group"
75475528|NCT01996111|Procedure|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
75475529|NCT01996124|Drug|Indacaterol Fumarate|150 mcg inhalation powder, hard capsules, once daily
75652663|NCT00803491|Other|Problem based learning|Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.
75652664|NCT00803491|Other|Traditional rheumatology care.|Individually base.
75652665|NCT02553187|Drug|Kanglaite Injection|"200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks)."
75652666|NCT00803725|Drug|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
75652667|NCT00803725|Drug|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
75800446|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
75800447|NCT01306422|Other|Placebo yogurt drink|Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
75475530|NCT01996124|Drug|Placebo|Fructose, dry inhalation powder, hard capsules via breezhaler
75475531|NCT01996137|Device|VASST II treadmill|Supervised treadmill training under physiotherapist
76089262|NCT04273815|Drug|Anlotinib|Anlotinib is a multi-target receptor tyrosine kinase inhibitor.
76089263|NCT01945138|Device|Closed Loop Insulin|The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
75342236|NCT02195921|Drug|only antiemetic drug|received routine antiemetic treatment
75475532|NCT01996150|Drug|bleach bath (sodium hypochlorite)|Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
75475533|NCT01996176|Behavioral|Intervention group|"The intervention consists of four components, which as described below:~Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.~Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.~Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.~Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project."
75475534|NCT01996176|Behavioral|Control group|The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
75475535|NCT01996189|Device|Standard needle BBraun Sterican® 23G and 25mm in length|Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
75652668|NCT00803803|Drug|Pilocarpine Concentration|Varying concentration 0.5 to 8%
75652669|NCT00803803|Drug|Pilocarpine Frequency|1 to 4 times daily
75652670|NCT04775329|Drug|Rifaximin|Rifaximin 1000mg OM
75800448|NCT01306422|Other|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
75475536|NCT01996189|Device|Insulin|Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
75800449|NCT01306422|Other|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
75475537|NCT01996202|Drug|Ipilumimab|
75652671|NCT00803881|Other|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
75938220|NCT04463199|Other|Craniocervical flexion training|"PBU airbag was clipped together and folded in, fastened, and placed suboccipital. Uninflated pressure sensor was kept below the neck, so that it touched the occiput then inflated to a stable baseline pressure of 20 mmHg to just fill the space below the neck but not to push it into lordosis. Subjects were demonstrated the correct action of the deep cervical flexors that is gentle nodding of head as if saying yes."
75938221|NCT02307981|Other|Training with vision teacher (visual rehabilitation)|Individually adapted training With vision teacher
75652672|NCT00798499|Other|Laboratory variables|1 visit
75652673|NCT00659269|Dietary Supplement|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
75652674|NCT00659269|Dietary Supplement|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
75342237|NCT04387292|Procedure|Ophthalmologic exam|"Visual acuity (ETDRS exam)~Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test~Lipiview~Eye pressure measurement (air tonometer)~Wide field retinophotography~Multicolor and auto-fluorescence retinophotography~Indocyanine green retinal angiography~Optical coherence tomography (OCT) B posterior pole scan~OCT Angiography (OCT-A) of the optic nerve and posterior pole~Adaptive optics~Visual field (Humphrey)"
75652675|NCT00659269|Drug|Chemotherapy|"Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800"
75342238|NCT02189213|Drug|Sertraline|Sertraline will be administered to treat anxiety disorders in children and adolescents.
75342239|NCT02999828|Biological|inactivated EV71 vaccine (KMB-17)|3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
75342240|NCT01241513|Drug|NAC|NAC provided to determine if beneficial at altitude
75652676|NCT00806143|Device|repetitive transcranial stimulation (rTMS)|"Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.~In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days."
75800450|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
75938222|NCT02317185|Device|genex bone graft with bone graft|
75938223|NCT02317185|Other|autogenous bone graft|
75938224|NCT02308059|Other|Ultrasonographic evaluation of nerves in diabetic patients|Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy
75938225|NCT02308059|Other|Ultrasonographic evaluation of nerves of healthy volunteers|evaluation of peripheral nerves and correlated with group I
75938226|NCT02308137|Drug|Domperidone|Simon-2-stage design for domperidone futility
75938227|NCT02313363|Device|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
75342241|NCT01241513|Drug|Placebo|Placebo
75342242|NCT00665132|Device|StimRouter System|Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
75475538|NCT01996202|Radiation|Radiation|
75475539|NCT01996228|Device|Stem Cell Educator|
75475540|NCT01996280|Behavioral|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
75800451|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
75800452|NCT03630094|Drug|FEP-ZID|A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
75800453|NCT01305642|Dietary Supplement|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
75938228|NCT03502863|Device|Digital refraction|A web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone.
75938229|NCT03502863|Other|Manual Refraction|Manual refraction and ETDRS chart
75938230|NCT02397824|Other|Salivary and blood samples|
75938231|NCT03294759|Other|Bio ACL|Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
75938232|NCT03294759|Other|Control|Normal ACL reconstruction technique with either patella or hamstring autograft
75938233|NCT03501459|Drug|Rituximab|
75938234|NCT02308293|Behavioral|High intensity exercise|3x30 seconds 'all out' sprints
75938235|NCT02308293|Behavioral|Lay down comfortably|rest
75938236|NCT02317263|Drug|testosterone|
75938237|NCT02317263|Drug|placebo gel|
75938238|NCT03506685|Other|Dry needling and STM|dry needling and soft tissue mobilization
75938239|NCT03502629|Biological|GB226|3mg/kg treat every 2 weeks
75938240|NCT02317341|Drug|Ketamine|Single intravenous dose
75938241|NCT02317341|Drug|Placebo (saline)|Given intravenously over 40 minutes
75652677|NCT00806143|Device|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
75475541|NCT01996280|Behavioral|Culturally Tailored MI|CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
75475542|NCT01996306|Biological|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
75475543|NCT01996306|Drug|CPT-11 (Irinotecan)|150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
75475544|NCT01996306|Drug|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
75652678|NCT00922129|Drug|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
75475545|NCT01996306|Drug|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
75475546|NCT01996306|Drug|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
75475547|NCT01996306|Biological|bevacizumab|7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
75475548|NCT01996306|Drug|CPT-11 (Irinotecan)|150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
75938242|NCT02317341|Drug|Ketamine|Single intravenous dose given over 40 minutes
75938243|NCT02317341|Drug|Midazolam|Given intravenously over 40 minutes
75938244|NCT02317341|Drug|Midazolam(placebo)|Given intravenously over 40 minutes
75475549|NCT01996306|Drug|Capecitabine|1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
75938245|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
75475550|NCT01996345|Procedure|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
75652679|NCT00922129|Drug|Cyclosporin (Neoral) or Tacrolimus (Prograf)|"Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months"
75652680|NCT02553655|Procedure|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
75938246|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
75938247|NCT02317419|Drug|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
75938248|NCT02317419|Drug|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
75938249|NCT02313441|Other|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
75938250|NCT02313519|Dietary Supplement|Probiotics|Probiotics are prepared in capsule form
75938251|NCT02313519|Dietary Supplement|Placebo|Glucose powder
75938252|NCT02308605|Device|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
75938253|NCT03501225|Procedure|ozone|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with ozonated water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with ozonated water according to randomization. The suture was then performed.
75938254|NCT03501225|Procedure|water|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with redistilled water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with redistilled water according to randomization. The suture was then performed.
75938255|NCT02313753|Behavioral|CLASP|
75938256|NCT02313753|Behavioral|SAFE|
75938257|NCT05452330|Other|Connective tissue massage|Connective tissue massage will be applied with short and long pulling strokes to create a reflex effect for 2 days a week, a total of 8 weeks.
75938258|NCT05452330|Other|Classical massage|Classical massage will be applied with the techniques of stroking, kneading, and friction for 2 days a week, a total of 8 weeks.
76089264|NCT03810339|Drug|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
76089265|NCT01734785|Drug|Linagliptin|tablet
76089266|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
76089267|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
76089268|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
75938259|NCT02317497|Other|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
75938260|NCT02317497|Drug|Vasopressors to maintain normal blood pressure values, if needed|
75938261|NCT02317497|Drug|Osmotherapeutics to lowr intracranial pressure, if needed|
75938262|NCT02317497|Procedure|Endovascular stroke care to treat brain vessel occlusions, if needed|
75475551|NCT01996358|Drug|Succinylcholine|Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.
75475552|NCT01996358|Drug|Rocuronium 0,3|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
75342243|NCT01241903|Drug|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
75342244|NCT01241903|Drug|placebo|frequency and duration
75652681|NCT02553655|Procedure|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
75938263|NCT02317497|Procedure|Decompressive neurosurgery, if needed|
75938264|NCT02313831|Other|Interval training|Patients of this group will be submitted to an interval training program
75342245|NCT00666848|Drug|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
75938265|NCT03501147|Other|Resistance training|15 minutes of resistance training during work every day
75652682|NCT02553655|Procedure|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
75652683|NCT00804037|Procedure|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
75652684|NCT00806299|Drug|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
75652685|NCT00806299|Drug|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
75652686|NCT00806299|Drug|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
75652687|NCT00804115|Drug|Latanoprost with Pilocarpine vs Timolol or Cosopt|Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
75342246|NCT00666848|Drug|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
75652688|NCT04758247|Device|TheraNova Neuromodulation System|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
75938266|NCT02314065|Behavioral|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
75938267|NCT02314065|Behavioral|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
75938268|NCT02314221|Device|Exoskeletal-assisted walking (ReWalk, Ekso)|The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
75938269|NCT02308683|Dietary Supplement|Moringa oleifera|12 weeks supplementation
75342247|NCT00666848|Drug|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
75342248|NCT00666848|Drug|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
75938270|NCT03943888|Drug|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
75938271|NCT03943888|Drug|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
75938272|NCT03943888|Drug|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
75938273|NCT03943888|Drug|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
75938274|NCT02308761|Drug|RO6870810|Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
75475553|NCT01996358|Drug|Rocuronium 0,6|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
75652689|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery -> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
75938275|NCT03506607|Other|Exercise in hypoxia 1500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
75652690|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
75938276|NCT03506607|Other|Exercise in hypoxia 2500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
75938277|NCT03506607|Other|Exercise in normoxia|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
75938278|NCT03942718|Other|Exercise|Participants will obtain an individualized exercise program based on entrance examination on treadmill.
75938279|NCT03506529|Other|questionnary|questionnary on predictif factors about physiological hypermetabolism of anal canal
75938280|NCT02317731|Other|Straw|Bowel preparation ingestion with a straw
75652691|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|(Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
75652692|NCT02554123|Drug|Vitamin E ointment application|Vitamin E ointment application. Every 12 hours during 7 days.
75800454|NCT04101916|Device|Paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 12 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
75938281|NCT03502551|Drug|Ketamine|Ketamine infusion (0.5 mg/kg) over 40 minutes.
75938282|NCT02314377|Drug|Bevacizumab|Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
75938283|NCT03502473|Device|UltraShape Power device|"UltraShape Power is a non-invasive focused ultrasound device, approved by the FDA (160896K;170370K); CE; Israeli Ministry of Health. The UltraShape Power system works by emitting acoustic waves of focused ultrasonic energy (200 ± 30 KHz frequency) that converge into a confined focal volume underneath the skin, thereby, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape Power's energy transmits pulsed ultrasound, allowing control over temperature elevation. The system comprised of two main parts:~The Main console~Transducer"
76089269|NCT01734785|Drug|Empaglifozin placebo + Linagliptin placebo|Matching Empaglifozin + Linagliptin low dose
76089270|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
75342249|NCT01287377|Behavioral|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
75475554|NCT01996384|Procedure|Classical Acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
75652693|NCT02554123|Drug|Vaseline ointment application|Vaseline ointment application. Every 12 hours during 7 days.
75652694|NCT00799045|Drug|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
75652695|NCT04713085|Device|Invasive Sacral Neuromodulation|Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)
75800455|NCT04101916|Device|Sham paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
75800456|NCT01569490|Behavioral|Incentives for abstinence and treatment engagement|Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
75800457|NCT01569490|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
75342250|NCT01287377|Drug|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
75342251|NCT01511042|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
75800458|NCT01308216|Procedure|low level laser therapy procedure|Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
75342252|NCT01511042|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
75342253|NCT01511042|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
75342254|NCT02996240|Dietary Supplement|Omega-3 FFA|Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
75342255|NCT02996006|Procedure|stepwise vascular control|"Before liver parenchymal resection, we performed total hepatic vascular preparation for occlusion with portal triad (PT), infra-hepatic inferior vena cava (IIVC), and supra-hepatic inferior vena cava (SIVC) preparation in order. Then we performed step-by-step vascular occlusion according to the individual bleeding situation."
75652696|NCT04713085|Device|Non-invasive Sacral Neuromodulation|External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).
75652697|NCT00658333|Drug|Enteric-coated Mycophenolate Acid (EC-MPA)|
75652698|NCT00658333|Drug|Mycophenolate Mofetil (MMF)|
75652699|NCT00658333|Drug|Placebo MMF|
75652700|NCT00658333|Drug|Placebo EC-MPA|
75652701|NCT00804271|Drug|memantine|memantine tablets, OD, 12 weeks
75652702|NCT00806533|Drug|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
75800459|NCT05456230|Drug|Midazolam|Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
75800460|NCT03792048|Procedure|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
75800461|NCT05764174|Behavioral|Factual messages|Messages with descriptive data on COVID-19 vaccines
75800462|NCT05764174|Behavioral|Narrative message|Messages with emotional descriptions on COVID-19 vaccines
75938284|NCT02398214|Behavioral|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to < 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
75938285|NCT02314455|Other|D-xylose|There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
75938286|NCT02535364|Biological|JCAR015 (CD19-targeted CAR T cells)|"Part A: Following leukapheresis and concurrent with generation of JCAR015, participants received, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.~Part B: Participants who were eligible for treatment in Part B received two IV doses of JCAR015 CAR T cells separated by 14 to 28 days. JCAR015 infusion was preceded by lymphodepleting chemotherapy with cyclophosphamide alone or cyclophosphamide + fludarabine."
75938287|NCT05464576|Diagnostic Test|MRI|Using the MRI in the diagnosis of the bladder cancer (invasive or not)
75342256|NCT01242527|Drug|placebo|4 capsules (1g) daily for 12 weeks
75342257|NCT01242527|Drug|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
75342258|NCT01242527|Drug|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
75342259|NCT01242527|Drug|omefas|4 capsules (1g)daily for 12 weeks
75342260|NCT00667004|Drug|ecabet ophthalmic solution|sterile ophthalmic solution
75342261|NCT00667004|Drug|placebo|sterile ophthalmic solution
75652703|NCT00804505|Device|SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens|Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
75652704|NCT00804505|Device|SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens|Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
75652705|NCT00799201|Drug|Naloxone and Docusate|Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
75800463|NCT05764174|Behavioral|Mixed message|Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
75800464|NCT03791814|Drug|Zepatier|Patients screened as HCV positive will receive Zepatier for 12 weeks.
75800465|NCT05426122|Other|Barley rice protein concentrate shake|At one out of three test days barley rice protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
75800466|NCT05426122|Other|Pea protein concentrate shake|At one out of three test days pea protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
75800467|NCT05426122|Other|Whey protein concentrate shake|At one out of three test days whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
75800468|NCT03792126|Other|Implicit Learning Approach|"All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA."
75342262|NCT02991014|Behavioral|researcher-selected frequency-modulated music|Music pieces have been selected in advance by the researchers. Furthermore, musical frequencies have been artificially modulated.
75342263|NCT02991014|Behavioral|researcher-selected non-modulated music|The same music pieces as in the active comparator arm have been selected in advance by the researchers, but no artificial frequency modulation.
75652706|NCT00799279|Behavioral|Smoking cessation training, support, and telephone follow-up|The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
75652707|NCT00799279|Behavioral|smoking cessation intervention|Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
75800469|NCT01306500|Procedure|Gastric lavage|8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
75800470|NCT01379014|Behavioral|Decision Aid Tool|A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
75938288|NCT02942290|Drug|Azacitidine|Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 & Days 1-2 of Week 2 of 28 day cycle.
75938289|NCT02942290|Drug|Venetoclax|Oral; Tablet
75938290|NCT02540356|Biological|BAX69 Single-Route Arm|Intraperitoneal (IP) only
75938291|NCT02540356|Biological|BAX69 Double-Route Arm|Intravenous (IV) infusion + intraperitoneal (IP) infusion
75800471|NCT01379014|Other|Treatment as Usual|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
75938292|NCT05433064|Device|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
75938293|NCT05431816|Dietary Supplement|Dietary intervention|dietary fiber （Inulin 4g，Resistant Starch 4g，β-glucan 2g）
75938294|NCT05463094|Drug|Test Glucophage® XR|Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.
75938295|NCT05463094|Drug|Reference Glucophage® XR|Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.
75938296|NCT05463016|Device|Experimental Group 1: Color Correcting Lenses|Color Correcting Lenses
75938297|NCT05463016|Device|Placebo Group 1: Placebo Lenses|Placebo Lenses
75938298|NCT05463016|Device|Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses|Color Correcting Lenses
75938299|NCT05463016|Device|Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses|Placebo Lenses
75938300|NCT05463016|Device|Color Correcting Lenses in Subjects with Normal Color Vision|Color Correcting Lenses
75938301|NCT05431660|Other|education and exercise protocol about diabetic foot|In diabetic foot school education, foot anatomy and functions, biomechanics, diabetic foot causes, epidemiology, causes of pain will be explained and treatment methods, ergonomic information, exercises to be done, sensory education, appropriate positions in daily life activities, risky situations, points to be considered and foot care. information will be given.
75938302|NCT05431660|Other|control group|diabetic foot school information booklet and weekly video conference meeting
75938303|NCT05431348|Device|Smartwatch|Patients will wear the smartwatch during treatment which measures, activity, steps, sleep and heartrate
75938304|NCT05431348|Diagnostic Test|Serum Cortisol|Level of cortisol in serum will be determined
75938305|NCT05431348|Other|Questionnaires|Patients are asked to fill in patient reported outcomes (PROMS) and specific questions on stress, exercise and fatigue (QSC-R23, IPAQ-SF, MVI-20)
75938306|NCT05450068|Other|Mulligan's Mobilization with movement|The Mulligan's technique will be performed as described by Brian Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets.
75938307|NCT05450068|Other|Spencer's muscle energy technique|Muscle energy technique that is composed of 7 stages repeated on after the other will be performed. Each movement will be repeated 10 times with 1 minute rest between each set.
75938308|NCT05450068|Other|Conventional Therapy|Electrotherapy-Ultrasound (5-10 mins), Exercise therapy program (isometric, capsular stretching, pectoral stretch and scapular stabilization exercises)
75938309|NCT05449678|Behavioral|Low-carb diet|A close nutritional follow-up will take place with a qualified nutritionist to adapt the participants' usual diet to their assignment diet. This is not a strict diet to follow or a ketogenic diet. Nutritional modifications will be based on the participants' usual diet to improve adherence (personalized follow-up).
75938310|NCT05449600|Device|Thermotape|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
76089271|NCT03821805|Other|Foot reflexology massage|Foot reflexology technique of Father Josef was used as massage intervention
76089272|NCT03008031|Procedure|CESM with a reduced dose of contrast agent|
75342264|NCT02991014|Behavioral|participant-selected non-modulated music|Participants bring their own choice of personally preferred music pieces and listen to them during the intervention sessions. There is no frequency modulation in this condition.
75342265|NCT02995616|Device|Regular therapy settings|Patients will walk in the Lokomat according to their regular therapy settings for a minimum of 20 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)
75342266|NCT02995616|Device|100% guidance force|Patients will walk in the Lokomat with 100% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
75342267|NCT02995616|Device|60% guidance force|Patients will walk in the Lokomat with 60% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
75342268|NCT01204853|Drug|Sitaxentan|sitaxentan sodium 100 mg
75342269|NCT01028846|Drug|Diazoxide|1-2 mg/kg total dose given intravenously
75342270|NCT01028846|Drug|Placebo|Intravenous normal saline
75342271|NCT02998814|Other|acid-etch|acid-etch
75342272|NCT02998814|Other|self-etch adhesive|Self etch (7th generation ) bonding agent
75342273|NCT02998814|Other|etch-and-rinse adhesive|Total etch bonding agent (5th generation)
75800472|NCT05273034|Procedure|1-hour sepsis bundle|"The sepsis management will be delivered in a timely manner within 60 minutes of ED triage including~usual test and treatment~blood culture~lactate measurement~broad spectrum antibiotics~In case of hypotension or lactate > 4, rapid administration of 30ml/kg crystalloid fluid resuscitation will be mandated~In case of initial elevated lactate (> 2 mmol/l), a second lactate measurement should be done after initial fluid resuscitation."
75800473|NCT01377376|Drug|ARQ 197 and Erlotinib|Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
75342274|NCT02998814|Other|self-etch adhesive after acid-etch|acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
75342275|NCT00714272|Device|Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1|6 treatments. One per week during the first six consecutive weeks.
75342276|NCT00714272|Device|Treatment with a sham device, EXcorLab box 1.2|6 sham treatments. One treatment per week during the first six consecutive weeks.
75652708|NCT02554201|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
75800474|NCT01377376|Drug|Placebo and Erlotinib|Oral twice daily administration of placebo and oral once daily administration of erlotinib
75800475|NCT03788538|Drug|dexmedetomidine|10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.
75800476|NCT03494920|Other|Direct endovascular clot retrieval|Direct endovascular clot retrieval within 4.5 hours of stroke onset
75938311|NCT05449600|Device|Tegaderm|Tegaderm™will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
75342277|NCT04386122|Drug|FABALOFEN 60|Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
75342278|NCT04386122|Drug|JAPROLOX TABLET|Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
75652709|NCT02554201|Device|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
75652710|NCT00806611|Procedure|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
75652711|NCT00806689|Procedure|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
75800477|NCT03494920|Other|Bridging thrombolysis followed by ECR|Bridging thrombolysis followed by ECR within 4.5 hours of stroke onset
75800478|NCT01306578|Drug|IVIG|Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
75800479|NCT01306578|Procedure|Plasma Exchange|Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
75938312|NCT05449600|Device|Kind|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
75342279|NCT03009461|Procedure|HAIC|Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
75342280|NCT03009461|Drug|Sorafenib|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
75342281|NCT02995460|Behavioral|interval training|4x4 high intensity interval training
75342282|NCT02990702|Other|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
75342283|NCT02990702|Other|Ultrasound guided coracoid infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
75342284|NCT02990702|Drug|Bupivacaine|
75342285|NCT02990702|Device|Ultrasound|
75342286|NCT01243619|Drug|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
75938313|NCT05430724|Procedure|Controlled hypotention|"The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg)."
75342287|NCT02995304|Drug|Morphine premedication|30 children will 0.1 mg/kg morphine as a premedication 20 to 30 min before surgical incision.
75342288|NCT02995304|Drug|Midazolam premedication|All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.
75475555|NCT01996384|Procedure|Non-classical acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
75652712|NCT00806689|Device|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
75652713|NCT00799513|Drug|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
75652714|NCT00570037|Biological|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
75938314|NCT02534896|Drug|Treatment I|Sunpharma1505 and Placebo
75652715|NCT00804661|Device|SENTEC device|Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
75938315|NCT02534896|Drug|Treatment II|Sunpharma1505 and Placebo
75938316|NCT02534896|Drug|Treatment III|Reference1505 and Placebo
75652716|NCT00806767|Biological|therapeutic immune globulin|
75652717|NCT00806767|Drug|busulfan|
75938317|NCT02697734|Drug|osilodrostat|In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
75938318|NCT02697734|Drug|osilodrostat Placebo|Matching Placebo in the form of filmcoated tablets for oral administration
75938319|NCT05447494|Drug|Low-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
75938320|NCT05447494|Drug|High-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
75652718|NCT00806767|Drug|fludarabine phosphate|
75652719|NCT00806767|Procedure|allogeneic hematopoietic stem cell transplantation|
75652720|NCT00804739|Other|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
75938321|NCT05411536|Other|Walking trials|"All participants will complete a series of walking trials. They will first be requested to perform three practice walks followed by three walking trials on a 7.4m straight level-ground firm walkway (GW) and the other three walking trials on a 7.4m straight foam walkway (FW) in a randomised order. The dimension of the foam walkway in the FW will be 8m (length), 0.8m (width), and 0.3m (height). The starting and finishing lines of the FW will be positioned at 0.3m from each side of the FW's edges. Thus, the lengths of the FW and the GW will be identical (i.e., 7.4m). Participants will be asked to walk 7.4m and stop for each walking trial.~After a 10-minute rest break, participants will perform nine walking trials on the GW and the other nine walking trials on the FW, including three repetitions of three different attentional focus instructions (external focus [EF], internal focus [IF], and no specific focus [NF]) in the GW and FW in a randomised order."
75938322|NCT02392130|Drug|Clobetasol propionate 0.05% ointment|
75938323|NCT02392130|Drug|LEO 130852A gel 1%|
75938324|NCT02392130|Drug|LEO 130852A placebo gel|
75938325|NCT02392052|Behavioral|Reinvention Protocol Participants|A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.
76089273|NCT03821415|Drug|RP101|17β-oestradiol-3-phosphate ophthalmic sterile solution
75342289|NCT02995304|Drug|Saline premedication (placebo)|30 children in midazolam only group will receive saline after midazolam
75342290|NCT02990858|Drug|PRO 140 SC injections|
75342291|NCT02995148|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-104)
75342292|NCT02995148|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75342293|NCT00725504|Drug|Intravenous lidocaine|Intravenous lidocaine administered up to 5 µg/ml.
75652721|NCT00804817|Behavioral|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
75800480|NCT05343754|Drug|Hyperbaric oxygen|Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
75652722|NCT00804817|Behavioral|SCION-HSCT program|"Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
75342294|NCT02990624|Radiation|PUVA|36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
75800481|NCT05343754|Other|Control group|In order to compare efficacy, patients that do not wish to undergo hyperbaric treatment, will serve as a control group. At baseline they will be asked for the reason they do not wish to undergo hyperbaric treatment. All patients and controls will be asked to report pain scores using a numeric pain rating scale (NRS) and quality of life (Wound-Q) questionnaires. They will continue to receive standard care as deemed necessary by their primary physician.
75652723|NCT00799669|Behavioral|smoking cessation intervention|Standard quit-smoking counseling to help decrease their risk of cancer.
75800482|NCT03788304|Device|non-invasive ventilation|conventional NIV
75800483|NCT03788304|Device|high flow nasal cannula|HFNC ventilation
75800484|NCT03785886|Behavioral|Walking group|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β-blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
75800485|NCT03785886|Behavioral|Chinese square dancing group|"Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study.~Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13."
75800486|NCT03785886|Behavioral|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
75800487|NCT03297190|Behavioral|SMS|Receipt of SMS messages on nutrition and health topics
75938326|NCT02392052|Behavioral|Wait List|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
75342295|NCT01275872|Other|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
75342296|NCT01275950|Behavioral|Health Education|"Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the shop-owners.~Administering the questionnaire to objectively asses the impact of direct/ surrogate tobacco advertisements influencing student behavior and perception about tobacco and tobacco products.~Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the students through interactive sessions with students in their respective educational institute."
75342297|NCT02995226|Other|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
75475556|NCT01996384|Drug|Lidocaine|Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
75652724|NCT00799669|Other|counseling intervention|Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
75652725|NCT00799669|Other|preventive intervention|
75652726|NCT00799669|Other|questionnaire administration|
75938327|NCT02391974|Device|PERIOSYAL FILL|"Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks."
75800488|NCT03297190|Behavioral|Interpersonal Counselling|Interpersonal counselling on health and nutrition topics
75938328|NCT02692586|Device|FlowTriever System|
75938329|NCT02391896|Device|Dual energy and tomosynthesis xray|
75938330|NCT05744882|Procedure|coronectony|root canal treatment
75652727|NCT00799747|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
75652728|NCT00799747|Drug|Placebo|placebo
75652729|NCT00863655|Drug|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
75652730|NCT00863655|Drug|Exemestane|Exemestane 25 mg orally daily.
75938331|NCT05744882|Procedure|root canal treatment|root canal treatment
75938332|NCT02534350|Drug|Presatovir|Tablets administered orally or via nasogastric (NG) tube once daily
75800489|NCT05320120|Drug|56mg esketamine (2x Spravato® 28 mg nasal spray)|56mg esketamine (2x Spravato® 28 mg nasal spray)
75938333|NCT02534350|Drug|Placebo|Tablets administered orally or via NG tube once daily
75938334|NCT03165422|Other|Non-Interventional|Non-Interventional
75342298|NCT02995226|Other|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
75342299|NCT02995070|Procedure|CTG|Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
75342300|NCT02995070|Device|LLLT|Low Level Laser Therapy on the buccal recipient site of connective tissue graft.
75342301|NCT02995070|Device|SHAM|Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
75342302|NCT01276028|Procedure|Acupuncture|"For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.~Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments."
75342303|NCT03830684|Drug|Baicalein Tablets 400mg|4 Baicalein Tablets and 2 placebo per time, three times a day
75475557|NCT01996397|Procedure|Cardiac resynchronization therapy device implantation|
75475558|NCT01996423|Dietary Supplement|Vitamin D3|
75342304|NCT03830684|Drug|Baicalein Tablets 600mg|6 Baicalein Tablets per time, three times a day
75475559|NCT01996423|Dietary Supplement|Placebo|
75475560|NCT01996462|Drug|Escitalopram Oxalate Tablets|
75800490|NCT05320120|Drug|0.9% saline solution nasal spray|0.9% saline solution nasal spray
75475561|NCT01996475|Drug|Escitalopram Oxalate Tablets|
75475562|NCT01996488|Drug|Olanzapine Orally Disintegrating Tablets 5mg|
75475563|NCT01996501|Drug|Olanzapine Orally Disintegrating 5mg Tablets|
75475564|NCT01996514|Dietary Supplement|Glucose with water|Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
75652731|NCT00863655|Drug|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
75938335|NCT03166904|Drug|Vistusertib(AZD2014)|Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
75938336|NCT05385497|Other|Aerobic Exercise|Participants will perform a 30-minute exercise protocol (5 minutes warm-up and cool-down each and 20 minutes moderate intensity exercise) on a StepOne™ recumbent stepper
75938337|NCT05385497|Device|Virtual Reality|Participants will interact with the virtual environment and view the gaming environment on a flat-screen TV placed in front of them at a suitable distance. The participants will play four games (50 repetitions/game divided into three blocks with 1-2 minutes rest between blocks), with the order of the games randomized in every session.
75938338|NCT05356091|Drug|Sevoflurane|Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
75652732|NCT00806923|Drug|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
75652733|NCT00806923|Drug|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
75652734|NCT00806923|Drug|Placebo|iv on day 1 of each 3 week cycle until disease progression
75652735|NCT00806923|Drug|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
75652736|NCT00806923|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
75652737|NCT00698607|Device|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
75652738|NCT00698607|Device|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
75652739|NCT00698607|Drug|6-month clopidogrel therapy|Use clopidogrel for 6 months
75652740|NCT00698607|Drug|12-month clopidogrel therapy|Use clopidogrel for 12 months
75652742|NCT04123041|Other|JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum|JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum
75800491|NCT01567410|Other|e-learning|Braden scale and pressure ulcer classification
75342305|NCT03830684|Drug|blank control 0mg|6 placebo per time, three times a day
75342306|NCT00727064|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
75475565|NCT01996514|Dietary Supplement|non-caloric sweetener with water|0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
75800492|NCT01567410|Other|traditional classroom training|Braden scale and pressure ulcer classification
75800493|NCT03074500|Device|Kinesiotaping|Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
75475566|NCT01996514|Behavioral|TV program with non-food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
75475567|NCT01996514|Behavioral|TV program with food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
75475568|NCT01996527|Device|3-Tesla magnetic resonance imaging|3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI
75475569|NCT01996527|Device|CEST-MRI|Undergo CEST-MRI
75475570|NCT01996527|Device|DW-MRI|Undergo DWI-MRI
75475571|NCT01996527|Device|DCE-MRI|Undergo DCE-MRI
75475572|NCT01996527|Device|DSC-MRI|Undergo DSC-MRI
75800494|NCT03074500|Other|Sham taping|Sham taping will be performed without using any technique
75938339|NCT05356091|Drug|Remimazolam|Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
76089274|NCT03821181|Device|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
75342307|NCT00727064|Drug|Venlafaxine Extended Release (VEN ER)|
75342308|NCT01294163|Drug|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
75342309|NCT01294163|Drug|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
75342310|NCT01294163|Drug|Propofol|Hourly dose of 2-4 mg/kg
75342311|NCT01294241|Drug|Oleogel-S10|1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
75342312|NCT01294241|Device|Mepilex® soft silicone faced polyurethane foam dressing|Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
75342313|NCT01244243|Device|Hand & Wrist Assisting Robotic Device|Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
75342314|NCT01294319|Drug|Mifepristone|
75342315|NCT01294319|Drug|Placebo|
75342316|NCT01294319|Drug|Spironolactone|
75652743|NCT04122495|Dietary Supplement|Probiotic|Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks
75800495|NCT03074500|Other|Exercise|Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
75800496|NCT03791502|Other|Pilates Method Exercises|Pilates Method exercises performed on the apparatus, on the ground and with accessories. They will always be performed by a physiotherapist with teaching certification in the Pilates methodology and will be supervised by two properly trained physiotherapy trainees. Participants will start the exercise program in small groups of up to 8 people, twice a week for 60 minutes, for 12 weeks, totaling 24 sessions. The first day of intervention for both groups will be devoted to explaining the six principles described by Joseph Pilates: centralization, concentration, control, precision, fluidity and breathing, and some fundamentals such as the neutral position of the spine. And in all sessions, these principles will be remembered by the physiotherapist.
75342317|NCT01294319|Drug|Combined|
75938340|NCT05196971|Drug|HS-10345 84mg|6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
75938341|NCT05196971|Drug|Placebo|6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
75938342|NCT05351021|Drug|Metformin|cidophage 850 gm twice daily
75475573|NCT01996527|Drug|IV administration of gadolinium-containing contrast agent|Gadolinium-containing paramagnetic contrast agent (Magnevist®; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast
75475574|NCT01996540|Other|Interventional arm: Early best palliative care|Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
75652744|NCT04122495|Dietary Supplement|Placebo|Oral administration of maltodextrin daily for 4-weeks
75938343|NCT05351021|Drug|Placebo|placebo twice daily for treatment period
75938344|NCT05309291|Device|Theranova 400 Dialyzer|Dialysis performed in HD mode.
75938345|NCT05309291|Device|FX 800 Dialyzer|Dialysis performed in HDF mode.
75342318|NCT01294319|Drug|Dexamethasone|
75652745|NCT00698763|Drug|Levosimendan|from 0.125 mg to 2 mg in escalating doses
75652746|NCT00698763|Drug|Placebo|Placebo capsules are identical in appearance to active capsules
75652747|NCT00658723|Drug|Fibrin Pad|Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
75652748|NCT00658723|Device|SURGICEL™|Absorbable hemostat
76089275|NCT03821181|Device|Sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
75652749|NCT00800059|Radiation|Total Marrow Irradiation|Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
75652750|NCT00804895|Drug|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
75652751|NCT00804895|Drug|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
76089276|NCT03821025|Device|Biliary stent|Palliation of malignant biliary obstruction
76089277|NCT01734395|Drug|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
76089278|NCT03820869|Other|Family Training|Family Training
76089279|NCT03820869|Other|Occupational Therapy|Occupational Therapy
75800497|NCT05621070|Drug|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.
75938346|NCT03625817|Behavioral|Mountainous setting|The mountainous setting is characterized by lower temperatures (about 8-10C ambient air temp.) than those in urban setting, also having >800m altitude.Each period will last for 1 week with a wash out period of minimum 2 days. Continuous skin temperature and ambient temperature monitoring will take place in the last day of each period, towards the end. During the 2 sampling days, 24-hour urine voids will be collected in different vials. Participants will be required to fulfill a diary with their daily activities, meal times, collection of urine times, sleep/wake times and times of leaving/entering a closed environment.
75938347|NCT02688764|Drug|PA21 (Velphoro®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
75938348|NCT02688764|Drug|Calcium Acetate (Phoslyra®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
75938349|NCT05182307|Device|DurAVR™ THV System|Transcatheter Aortic Valve Implantation (TAVI) Procedure
75938350|NCT02688608|Drug|Pembrolizumab|200 mg IV once every 3 weeks
75938351|NCT02688530|Drug|IV Saline|
75938352|NCT02688530|Drug|IV Dexamethasone 4mg|
75475575|NCT01996579|Dietary Supplement|Lactoferrin|Lactoferrin is an 80 kilodalton (kD) naturally occurring multifunctional glycoprotein of the transferrin family which is an important component of the human innate immune system. Lactoferrin is distributed widely in humans with the main sources of production being exocrine glands and specific granules of neutrophils. It is present in virtually all human secretions. The highest concentrations are found in milk and colostrum. Lactoferrin has multiple biological functions which make it of interest as a therapeutic agent in the critically ill. These include the ability to bind iron, antimicrobial activity including antibacterial, antifungal, antiviral properties, the ability to bind endotoxin, promotion of beneficial bacteria in the gastro-intestinal tract and immunomodulatory activity.
75652752|NCT00804895|Drug|Verapamil|standard prophylactic treatment
75672287|NCT04211012|Drug|Toripalimab plus Nab-Paclitaxel +/- cisplatin|"Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin"
75800498|NCT05621070|Drug|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.
75800499|NCT05621070|Drug|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.
75800500|NCT05621070|Drug|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
75800501|NCT03715530|Device|PAMG-1 immunoassay|The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
75800502|NCT01378936|Behavioral|MI plus IOC group intervention|45 minute Motivational Interview plus 16 session IOC intervention
75800503|NCT01378936|Behavioral|Motivational Interview only|45 minute Motivational Interview session
75800504|NCT03077698|Drug|Sodium Cridanimod|The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
75938353|NCT02688530|Drug|IV Dexamethasone 6mg|
75938354|NCT02688530|Drug|IV Dexamethasone 8mg|
75938355|NCT03167060|Device|Active RhinoChill|"Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
75938356|NCT03167060|Device|Control Rhinochill|"Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
75938357|NCT03166826|Other|Modified Apgar Scoring System|Modified APGAR scoring system
76089280|NCT03820713|Procedure|Concentrate of plasma coagulation factors|The plasma concentrate of coagulation factors is applied to the surgical site.
76089281|NCT03820713|Procedure|0.9% saline|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
76089282|NCT01945294|Drug|Boceprevir|800 mg three times daily orally
75342319|NCT00727298|Biological|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
75342320|NCT02994992|Drug|BAY 987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-100)
75652753|NCT00800137|Drug|low molecular weight heparin or unfractionated heparin|"For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.~Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.~Last dose given in the morning(ie. > 24 hours)of the day prior to the procedure.~Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.~Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery."
75652754|NCT00800137|Drug|Warfarin or coumadin|Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be < 3.0
75800505|NCT03077698|Drug|progestin therapy|The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
75652755|NCT00807079|Drug|carboplatin|
75652756|NCT00807079|Drug|topotecan hydrochloride|
75652757|NCT00800293|Drug|Betamethasone Dipropionate 0.05% Cream|Small amount applied and evaluated over the course of several hours
75652758|NCT00800371|Procedure|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
75652759|NCT00593385|Device|iCAST covered stent|Iliac stent implantation
75652760|NCT00658021|Drug|Placebo|Subcutaneous injection, twice a day
75652761|NCT00658021|Drug|Exenatide|Subcutaneous injection, 5 µg, twice a day
75652762|NCT00658021|Drug|Exenatide|Subcutaneous injection,10 µg, twice a day
75652763|NCT00698919|Other|Observational study|"This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision."
75652764|NCT04121637|Other|Aerobic Exercise|"Each exercise session;~5 min warm-up = 30% of VO2 max~20 min exercise = 50-60% of VO2 max~5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS."
75652765|NCT04121637|Other|Frenkel coordination exercises|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
75800506|NCT05764096|Other|No intervention|No intervention
76089283|NCT01945294|Biological|Peg-interferon alfa-2b|1.5 mcg/kg weekly subcutaneously
76089284|NCT01945294|Drug|Ribavirin|800-1400 mg twice-daily divided orally based on body weight
75800507|NCT01377298|Drug|Pazopanib|200mg/tablet, 800mg/day PO.
75800508|NCT01377220|Drug|11C-Choline|11C-Choline : 6MBq/kg on direct intravenous on one minute.
75800509|NCT03788460|Other|no intervention|no intervention
76089285|NCT01947946|Biological|Benralizumab|"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
75652766|NCT00920816|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
75652767|NCT00920816|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
75652768|NCT04254224|Procedure|colon resection, stoma|oral or intravenous antibiotics treatment with or without percutanous or transrectal or transvaginal drainage
75652769|NCT04254146|Other|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
75800510|NCT05059366|Device|Manual Ventilation Grip Device|Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.
75800511|NCT05059366|Other|2VE|the standard 2VE technique for ventilation
76089286|NCT01947946|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
75672288|NCT02655978|Other|Magnetic Resonance Imaging|
75672289|NCT00649974|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fasting
75672290|NCT00649974|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fasting
76089287|NCT02954055|Drug|Paclitaxel|Arm A
76089288|NCT02954055|Drug|Cyclophosphamide|Arm B
76089289|NCT02954055|Drug|Capecitabine|Arm B
76089290|NCT02954055|Drug|Vinorelbine|Arm B
76089291|NCT03820635|Diagnostic Test|Osteopontin (OPN)|the serum level of Osteopontin (OPN) will be measured in the subject's blood sample
76089292|NCT03313180|Drug|Nintedanib|Administered twice daily
76089293|NCT03820401|Device|choice of dialyzer|Fiber blocking is calculated in different commercially available dialyzers
76089294|NCT03820401|Other|choice of dialysis mode|Fiber blocking is calculated in different commercially available dialyzers used in different dialysis stategies
76089295|NCT03820401|Other|choice of anticoagulation strategy|Fiber blocking is calculated in different commercially available dialyzers using different anticoagulation strategies
75938358|NCT05744804|Drug|-group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg|receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally)
75938359|NCT05744804|Drug|(acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)|control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
75938360|NCT03166748|Combination Product|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
75342321|NCT02994992|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
75652770|NCT05251688|Other|Cryoanalgesia|"On the first day of the study, the PI met the participants and assessed their level of consciousness using the Modified Glasgow Coma Scale to ensure that they were unconscious and reviewed the medical records to collect their sociodemographic data. After that, the participants received routine care before the arterial puncture. The PI assessed their pain scores during the puncture.~In the second meeting (on the same day or the following day), the PI prepared the ice packs by crushing small pieces of ice and wrapping them in smooth gauze to avoid skin damage and moisture in the puncture area. Before the arterial puncture, the ice pack was applied over the selected puncture site (radial, brachial, or femoral artery) for 5 minutes in addition to the routine care. After removing the ice pack, the nurse palpated the artery, wiped of the residue of ice vapor present on the skin, and took the arterial blood sample. During the puncture, the PI assessed the participants' pain scores."
75652771|NCT04253990|Procedure|Precut EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
75652772|NCT04253990|Procedure|Conventional MER|EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current.
75652773|NCT00631592|Drug|GSK1349572|
75652774|NCT05251610|Drug|20mg oral propranolol and oxytocin|Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin
75938361|NCT05744726|Biological|A-PRF|0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.
75938362|NCT05744726|Combination Product|Bone-wax|0.5 to 1g of Bone-wax for each dental socket
75938363|NCT02467270|Drug|Ponatinib|Tablet, taken orally once daily.
75938364|NCT03166670|Diagnostic Test|stool examination|collection of stool specimen and microscopic examination for parasites
75938365|NCT03166670|Diagnostic Test|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
75938366|NCT05083559|Device|MPC AP algorithm|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
75938367|NCT05083559|Device|Robust R-AP algorithm|The R-AP is a modified MPC algorithm. A new feature in the algorithm includes a model for missed meal insulin detection. The model includes estimations for carbohydrate consumption based glucose patterns to determine if that person has consumed a meal without announcing it to the system.
75938368|NCT03166982|Procedure|transvaginal approach|
75938369|NCT03166982|Procedure|laparoscopic approach|
75938370|NCT05150795|Drug|Pregabalin 150mg|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
76089296|NCT03820401|Other|preparation of dialyzer|Fiber blocking is calculated in different commercially available dialyzers either preprimed with Albumin or not
75475576|NCT01996579|Other|Placebo|Sterile water will be utilized as the placebo control in this double blind randomized-controlled trial.
75652775|NCT05251610|Drug|Oxytocin only|Participants will have outright augmentation or induction of labor with oxytocin
75652776|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
75652777|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
75652778|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
75652779|NCT00657709|Biological|Infanrix Hexa|Routine vaccination
75652780|NCT00657709|Biological|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
75652781|NCT00657709|Biological|Prevenar|Routine vaccination
75652782|NCT00915356|Drug|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
75652783|NCT00915356|Drug|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
75342322|NCT02990312|Drug|Sirolimus + Maraviroc|Patients will be placed on the combination of Sirolimus and Maraviroc starting on Day 0 and followed for 96 weeks during which they will have regular monitoring of both clinical safety labs, Sirolimus levels, and research labs to look at the HIV reservoir, CCR5 density, and immune activation
75342323|NCT01244477|Behavioral|Group CPT-C|Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
75342324|NCT02994524|Procedure|Rerouting technique for transsphincteric perianal fistula|
75342325|NCT01294709|Drug|telcagepant|
75342326|NCT01294709|Drug|Placebo to telcagepant|
75342327|NCT01295879|Drug|Ergocalciferol|Ergocalciferol 50,000 IU's orally per week, for 8 weeks
75938371|NCT05150795|Drug|Fentanyl 100 micrograms ampoule|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
76089297|NCT03820245|Dietary Supplement|Bixin|Volunteers consumed bixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
75342328|NCT01244633|Drug|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
75342329|NCT01296191|Drug|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
75652784|NCT05218070|Drug|EgyVax Vaccine Candidate|EgyVax Inactivated SARS-CoV-2 vaccine candidate, equivalent to 70 mcg inactivated SARS-CoV-2 total protein. Alum adjuvant 2% 50 µl (equivalent to 0.5 mg AlOH). Equivalent volume of Saline 0.9% to each vaccine dose. Each vial contains 0.5 ml representing one dose 70 mcg of inactivated SARS-CoV-2 virus with alum adjuvant or two doses of 35 mcg of inactivated SARS-CoV-2 virus with alum adjuvant
75652785|NCT05218070|Drug|Placebo|0.5ml Saline (0.9%)
75652786|NCT00657553|Drug|Bortezomib|Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks
75652787|NCT04675970|Other|Observational|Product in a Institute of Bio-Stem Cell rehabilitation UAB - sponsored clinical trial who agree to participate in this study
75652788|NCT05150977|Other|Polysomnography|Reviewing collected data
75342330|NCT01296191|Drug|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
75342331|NCT01244711|Drug|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
75652789|NCT04254068|Behavioral|Parent-based prevention|Parent-based prevention is a 12 session program for parents with eating disorders and their partners. Most sessions occur on a weekly basis, most of the sessions involve both partners.
75652790|NCT00807157|Dietary Supplement|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
75800512|NCT03791580|Behavioral|Commitment nudge|"The commitment nudge will ask clinicians to commit to discussing high-risk polypharmacy at the next office visit with patients who have high-risk polypharmacy. Clinicians who commit will receive a reminder just before the next office visit begins. The patient will also receive notification of the commitment via EHR patient portal.~This nudge will be operationalized via two sequential clinician-facing EHR best practice alerts (BPAs): the first at time of opening any encounter (including encounters other than a face-to-face office visit, e.g., medication refills), and the second (contingent on making a commitment to discuss high-risk polypharmacy) at time of opening the subsequent encounter for a face-to-face office visit. Each of these BPAs will describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies."
75342332|NCT01245413|Device|SenSura|Adhesive to stoma bag
75342333|NCT01245413|Device|Athena|Adhesive to stoma bag
75342334|NCT01210079|Drug|Gabapentin;|Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
75342335|NCT01210079|Drug|Placebo|Placebo titrated over 1 week with established dose taken daily for 5 weeks.
75342336|NCT01245647|Drug|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
75342337|NCT01245647|Other|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
75652791|NCT00807157|Dietary Supplement|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
75652792|NCT04253912|Drug|VBP-245|2% Povidone-Iodine Gel
75652793|NCT04253912|Drug|Placebo Gel (no Povidone-Iodine)|Placebo Gel (no Povidone-Iodine)
75652794|NCT02552797|Behavioral|Shared Decision Making tool|
75938372|NCT04475393|Device|Carmat Total Artificial Heart|Heart Replacement Therapy
75342338|NCT00708110|Drug|GSK1349572|GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
75342339|NCT00708110|Drug|Placebo|Placebo is a tablet with no drug in it.
75342340|NCT01296815|Drug|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
75342341|NCT01246349|Behavioral|Motivational Interviewing (Treatment Group)|Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.
75342342|NCT01246349|Behavioral|Social Skills Training (Control Group)|Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
75342343|NCT01276262|Drug|fostamatinib|Oral tablets, repeated doses for 21 days (2 x 50mg BID)
75342344|NCT01276262|Drug|Microgynon® 30 (Oral contraceptive)|Oral tablets, repeated doses
75342345|NCT01276262|Drug|Placebo|Oral tablets BID, repeated doses for 21 days
75342346|NCT01276340|Device|KEAT stimulator|electrical stimulation with KEAT stimulator : 4 times per week during 2 months
75475577|NCT01996618|Drug|Ranolazine|After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
75475578|NCT01996683|Drug|desferal, ferriprox, blood transfusion|"Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation"
75800513|NCT03791580|Behavioral|Justification nudge|The justification nudge will ask clinicians who prescribe or renew a drug that meets high-risk polypharmacy criteria (in the context of the patient's other medications) to write a brief justification for prescribing this high-risk medication. This written justification will be recorded in the patient's medical record. The best practice alert requesting the justification will also describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies.
75938373|NCT02400658|Device|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
75652795|NCT04253600|Behavioral|Risk profile screening questionnaire|Families will be asked to complete a LimeSurvey questionnaire that aims at evaluating general risk profiles associated with DLD (e.g., no elevated risk, behavioral risk, environmental risk, familial risk), as well as our exclusion criteria (e.g., hearing deficit).
75800514|NCT01305720|Device|near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, the investigators applied NIRS probes to the forehead and abdomen for cerebral (rSO2C) and abdominal (rSO2P) regional oxygen saturation measurements.
75800515|NCT03791658|Other|The 12-question TAI|The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).
75938374|NCT03167138|Biological|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
75938375|NCT03167138|Device|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
75938376|NCT05027087|Dietary Supplement|Blueberry gummy|Gummy bear containing blueberry powder
75938377|NCT05027087|Dietary Supplement|Placebo gummy|Gummy bear with no active ingredients
75938378|NCT05446636|Device|Huawei bracelet|Huawei bracelet was used to continuously record maternal respiration, heart rate, temperature and sleep data, and then calculate maternal circadian rhythm state
75938379|NCT03166280|Drug|Sofosbuvir 400 mg|treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
75938380|NCT03166280|Drug|Daclatasvir 60 mg/day|treatment for hepatitis c by Daclatasvir 60 mg/day
75938381|NCT05427994|Other|National Eye Institute Visual Function Questionnaire|National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) measures the quality of life related to vision. This questionnaire has been validated for use on low vision patients.
75938382|NCT04440254|Diagnostic Test|Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device|Subcutaneously implanted under local anesthesia of the device on the presternal or subclavicular region
75938383|NCT03037307|Other|Test Product|Five strips of test adhesive cream for upper denture, as per application instructions.
75938384|NCT03037307|Other|Positive Contol|Three dabs of positive control adhesive cream for upper denture, as per application instructions.
75938385|NCT03037307|Other|Negative Control|No adhesive
75938386|NCT05746052|Procedure|Punch insturment|surgical and dermatological tool used mainly for skin biopsy and therapeutic skin disorders
75938387|NCT02428049|Radiation|Stereotactic or conventional radiotherapy and chemotherapy in curative intent|
75938388|NCT05427526|Procedure|intraocular lens implantation|Lens surgery during or before vitrectomy surgery.
75938389|NCT05410054|Other|no intervention|observational research
76089298|NCT03820245|Dietary Supplement|Norbixin|Volunteers consumed norbixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
76089299|NCT03820245|Dietary Supplement|Lycopene|Volunteers consumed lycopene capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
75342347|NCT01276418|Device|CO2 laser|Ablation and coagulation of soft tissue
75342348|NCT01297283|Other|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
75342349|NCT01297283|Other|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
75342350|NCT02995382|Procedure|Anterior Intramuscular Transposition|Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
75342351|NCT02998502|Device|Freespira Breathing System|Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
75342352|NCT04351997|Procedure|Cord clamping|Umbilical cord clamping after delivery.
75342353|NCT01276496|Drug|Cilengitide|Given IV
75342354|NCT01276496|Other|Laboratory Biomarker Analysis|Correlative studies
75475581|NCT01996735|Drug|Ticagrelor 180 mg single dose|
75475582|NCT01996735|Drug|Placebo|
75475583|NCT01996761|Drug|porcine brain peptide (Cerebrolysin)|
75475584|NCT01996761|Drug|Placebo|
75938390|NCT03669887|Behavioral|Lifestyle Modification Program|The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
75652796|NCT04253600|Procedure|Investigation of the neural correlates of DLD using Magnetic Resonance Imagery (MRI)|MRI data acquisition will take place during natural sleep in infants aged from 6 to 12 months. First, families will have to complete a security questionnaire to make sure that neither the children nor the accompanying parent have any known contraindication preventing the MRI session and that none of them is wearing any ferro-magnetic elements. Then, families will be welcomed in a calm and child-friendly environment where we will propose them some preparatory games known to facilitate sleep in children. MRI protocol will comprise structural and functional images and won't exceed 30 minutes.
75342355|NCT01276496|Drug|Paclitaxel|Given IV
75652797|NCT04253600|Behavioral|Online investigation of predictive factors associated with DLD and LANCOM app development|Parents will be asked to complete a series of online questionnaires every six months. Questionnaires will be created on LimeSurvey and will include different questionnaires, scales, and observations that aim at evaluating children's development, and especially language development, as well as parental and environmental characteristics.
75652798|NCT04253600|Behavioral|Individual behavioral and cognitive assessment|Individual cognitive and behavioral assessment will be scheduled once a year, around the child's birth date, and will comprise an extensive battery of standardized evaluation appropriate for the child's age. This individual evaluation will focus on several developmental aspects including language, psychomotor, behavioral and cognitive development, as well as executive and socio-emotional functioning, depending on the age of the children. Evaluations will be adapted to each child's specific profile, while respecting the following administration rules: (1) we will prioritize language development testing, (2) testing sessions will be adapted to each child's pace and possibilities, (3) if a child does not want to take part in the assessment, feels tired, or does not seem to be comfortable with the investigator, tests won't be administered.
75938391|NCT02538094|Device|Sham Transcranial direct current stimulation|Delivery of sham stimulation for 30 minutes using Neuro-Conn Direct Current (DC) Stimulator Plus.
75938392|NCT02538094|Device|Anodal Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes.
75938393|NCT02686034|Device|gammaCore-S|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
75938394|NCT02686034|Device|gammaCore-S Sham|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
75938395|NCT02685488|Device|Transcranial Ultrasound Power|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
75938396|NCT02685488|Device|Transcranial Ultrasound Sham|"Transcranial ultrasound will be used without power for a sham condition."
75938397|NCT03166592|Device|Magnetic resonance imaging with contrast|injection of gadolinium contrast then acquisition of images with magnetic resonance imaging then spectroscopy
75342356|NCT01276496|Other|Pharmacological Study|Correlative studies
75342357|NCT01297595|Drug|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
75938398|NCT03166514|Dietary Supplement|Commercially Available Food Bar|
75938399|NCT03166514|Dietary Supplement|Placebo|
75938400|NCT04479800|Drug|ASTX660|Form: capsule; Route of administration: oral
75938401|NCT02533570|Drug|Brentuximab vedotin|
75938402|NCT02533570|Drug|Placebo|
75938403|NCT03106220|Behavioral|exercise|home exercise program
75342358|NCT01297985|Behavioral|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a week course to an 8-week course, meeting for 2 1/2 hours once a week.
75938404|NCT03106220|Other|placebo|encourage walking and physical therapy per standard care.
75938405|NCT02268448|Drug|Clonidine|
75938406|NCT02268448|Drug|Naltrexone|
75938407|NCT05744570|Procedure|Epidural anesthesia|Regional anesthesia for labor pain
75938408|NCT03106064|Behavioral|Promoting independence in self-care|The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.
75342359|NCT02992418|Biological|CYD Dengue Vaccine|0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively
75342360|NCT02992418|Biological|Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed|0.5 mL, intramuscularly (IM) at Month 1.
75342361|NCT02992418|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Day 0.
75475585|NCT01996787|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
75938409|NCT03106064|Other|Usual Care|Usual hospital care
75938410|NCT03106142|Procedure|Academic detailing visit arm|General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
75475586|NCT01996787|Device|Clariti with Handling Tint|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
75652799|NCT04253600|Behavioral|Automated analysis of language development and environment|"Following the individual assessment, families will be asked to record their child's language environment over a 2-days' timeframe using the LENA® device, a small wearable device allowing for large-scale all-day audio recording and automated vocal analyses of speech segments. An automatic analysis of the recordings, performed by the LENA pro software algorithms, will provide amongst others, a direct and natural measure of the child's number of vocalizations, adult word counts, conversational turns, duration of exposure to electronic media versus to meaningful language. Data acquisition will take place once a year following our sample selection, with a required recording time per day ranging from 12 to 16 hours."
75652800|NCT00800527|Drug|Gabapentin|Gabapentin 800 mg one a day up to 30 day
75652801|NCT00800527|Drug|Diclofenac|Diclofenac 75 mg one a day up to 30 day
75938411|NCT03105908|Behavioral|Internet delivered Acceptance and Commitment therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
75938412|NCT03105908|Behavioral|Waiting list control condition|After a ten week wait list period, the control condition receive same treatment as the intervention group, but without therapist support.
75938413|NCT03036839|Drug|LDV/SOF|90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
75938414|NCT04977791|Drug|Anti-PD-1/PD-L1 monoclonal antibody|Observe a situation before and after immunotherapy
75938415|NCT03619421|Dietary Supplement|Zinc supplement|25 mg
75800516|NCT03791658|Other|Information from patients file|Depending on which arm or group specific information will be gathered from the patients file after informed consent.
75938416|NCT03625739|Drug|anti-tuberculosis drug|The intervention drugs are prescribed by treating caregiver
75938417|NCT05123885|Other|Study on Data|Study on Data
75938418|NCT04030871|Device|Capsule Dome G-Tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
75652802|NCT00809263|Drug|homeopathic remedy|Homeopathic remedy 12C potency, 10 drops TID X 7 days
75652803|NCT00862719|Drug|Sitagliptin|600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.
75652804|NCT04120779|Device|The EMPOWER-SUSTAIN e-Health Self-Management Intervention|Multifaceted chronic disease management strategies involving web-based self-management intervention mobile apps based on chronic care model and persuasive technology theory to improve patient activation and self-management behaviours among patients with metabolic syndrome.
75800517|NCT03791658|Other|The Asthma Control Test (ACT)|An international validated questionnaire on the symptoms an asthmatic experiences and the disease control in the patient. Only for the Asthmatics arm of the study
75800518|NCT03791658|Other|The COPD Assessment Test (CAT)|An international validated questionnaire on the symptoms a COPD-patient experiences and the disease control in the patient. Only for the COPD arm of the study
75800519|NCT03079102|Drug|Nitric Oxide|An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
75800520|NCT03079102|Drug|Nitrogen|Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
75800521|NCT03791424|Drug|Midazolam|Administering premedication with sedative drug to relieve anxiety
75938419|NCT04030871|Device|Balloon Bolus feeding tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
75938420|NCT03904199|Drug|Insulin|Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
75938421|NCT03902951|Drug|Abiraterone Acetate|Given PO
75938422|NCT03902951|Drug|Apalutamide|Given PO
75938423|NCT03902951|Drug|Leuprolide Acetate|Given SC
75938424|NCT03902951|Other|Quality-of-Life Assessment|Ancillary studies
75938425|NCT03902951|Other|Questionnaire Administration|Ancillary studies
75938426|NCT03902951|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75938427|NCT05022173|Device|Helmet Non-Invasive Ventilation|The helmet interface is a modality which is used to deliver NIV to patients with respiratory failure. A transparent hood is placed over the entire head of the patient with a seal at the neck using a soft collar.
75938428|NCT05022173|Device|Facemask Non-Invasive Ventilation|The facemask interface is a modality which is also used to deliver NIV to patients with respiratory failure. A large mask covering the mouth and nose is strapped to the patient's face to create a seal.
75938429|NCT01286207|Drug|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
75938430|NCT01286207|Drug|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
75938431|NCT01286207|Drug|Standard Care|Active standard care
75938432|NCT02236000|Drug|Neratinib|"Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy"
75342362|NCT01276730|Drug|Interferon, Retinoic Acid and radiation|Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
75800522|NCT03788226|Drug|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
75938433|NCT02236000|Drug|T-DM1|"Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
76089300|NCT03820245|Dietary Supplement|Placebo|Volunteers consumed placebo capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
76089301|NCT01597505|Drug|Surotomycin|250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days
76089302|NCT01597505|Drug|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
75342363|NCT01276730|Drug|Cisplatin and radiation|Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
75342364|NCT02994212|Dietary Supplement|Monthly distribution of RUTF|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.
75342365|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
75938434|NCT04460014|Behavioral|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
75652805|NCT00862641|Drug|Regadenoson|IV
75652806|NCT00862641|Drug|Placebo|IV
75652807|NCT04120857|Behavioral|Gentle Stretching|60 minutes fo gentle stretching twice weekly for 8 weeks
75652808|NCT02614053|Device|Masimo Radical-7™ Pulse CO-Oximeter|a device collecting data regarding PVI, PI & spHB
75652809|NCT04119921|Drug|prescription topical ketorolac in group 1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
75938435|NCT04460014|Behavioral|Attention Placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
75938436|NCT05408026|Drug|Daratumumab|"Daratumumab (and hyaluronidase) will be given over 3-5 minutes subcutaneously (under the skin) in the clinic at alternating left/right abdominal sites. Patient will take dexamethasone orally (by mouth) either before coming to clinic or in clinic, before other medications.~Only for the first cycle, patient will receive on Day 1 daratumumab (which is mixed with a compound called hyaluronidase) and dexamethasone, 1 day before patient start the other 2 medications."
75938437|NCT05408026|Drug|Pomalidomide|On day 2 of cycle 1, patient will start the other medications and will therefore receive bortezomib administered subcutaneously (SC) over 3-5 minutes and dexamethasone given orally (by mouth), either before coming to clinic or in clinic, before bortezomib. Patient will also start pomalidomide on the same day, which patient will take that evening at home and every evening for 21 days.
75938438|NCT04423510|Procedure|Crystallized phenol treatment|
76089303|NCT01597505|Drug|Placebo|Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
76089304|NCT03821571|Diagnostic Test|Brain MRI|Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
76089305|NCT03821103|Behavioral|Training|The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department (ED) administration within 3 month study period
76089306|NCT03821103|Behavioral|Behavioral economic enhanced arm|Behavioral economic enhancement includes an opt-out invitation, loss-framed incentivization, weekly tailored text based reminders
75342366|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
75342367|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
75342368|NCT04386356|Device|Orotracheal intubation with either Macintosh laryngoscope versus Airtraq video laryngoscope|Tracheal intubation will be performed by first year anaesthesia trainee using either Macintosh laryngoscope or Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
75342369|NCT02999594|Drug|Tramadol Hydrochloride|50mg intramuscularly
75342370|NCT02999594|Drug|Distilled Water|2ml intramuscularly
75342371|NCT01298219|Drug|Lubiprostone|24 mcg administered orally twice daily (BID)
75652810|NCT04119921|Drug|prescription artificial tear in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
75652811|NCT04119921|Drug|prescription topical ketorolac in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
75652812|NCT04119921|Drug|prescription artificial tear in group1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
75938439|NCT00968201|Drug|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
75342372|NCT01298219|Drug|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
75938440|NCT00968201|Drug|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
75652813|NCT02613663|Procedure|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
75938441|NCT00967577|Drug|177Lu-J591|70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
75938442|NCT00943397|Drug|montelukast sodium|Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
75342373|NCT01276808|Procedure|Magnetic navigation PCI|Magnetically navigated angioplasty wire technique
75342374|NCT01276808|Procedure|Conventional PCI|Conventional manual angioplasty wire percutaneous coronary intervention
75342375|NCT01276886|Drug|antibiotic|
75938443|NCT00943397|Drug|Comparator: Usual Care|Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
75938444|NCT00935519|Device|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
75938445|NCT00817817|Device|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
75475587|NCT01996800|Procedure|Spinal Manipulative Therapy (SMT)|Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
75475588|NCT01996800|Procedure|SMT and Neuromuscular Reeducation|Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
75652814|NCT02613663|Procedure|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
75652815|NCT00861471|Drug|Docetaxel|"One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m^2 (60 mg/m^2 was tested in Phase I as well), Intravenous, every 21 days."
75652816|NCT00861471|Drug|Imatinib Mesylate|"One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."
75652817|NCT00699231|Biological|HBV-MPL vaccine 208129|IM injection
75938446|NCT00817817|Device|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
75938447|NCT05303675|Other|exercise and training|"Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
75938448|NCT03628859|Biological|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, everolimus, axitinib or cabozantinib [in France only], as per product SmPC or 1st line treatment with sunitinib or pazopanib or receiving 2nd or 3rd line of treatment with nivolumab)
75938449|NCT00702845|Drug|corifollitropin alfa (Org 36286)|100 µg corifollitropin alfa subcutaneous (SC) injection
75342376|NCT01276886|Procedure|Colonic resection with or without stoma|
75342377|NCT02322242|Drug|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
75652818|NCT00699231|Biological|Engerix™-B|IM injection
75652819|NCT02613585|Other|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
75938450|NCT00702845|Drug|recFSH (follitropin beta)|150 IU recFSH SC injection
75938451|NCT00702845|Drug|gonadatropin releasing hormone (GnRH) antagonist (ganirelix)|GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
75938452|NCT00702845|Drug|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC
75342378|NCT02322242|Drug|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
75342379|NCT02993666|Device|Bair Hugger|forced air warming with Bair Hugger air warmer
75342380|NCT02993354|Device|The EUM300 (electrical uterine myography)|External monitor intended for the evaluation of electrical signals originating in the uterus, thus providing a tool for measuring uterine activity as well as fetal heart rate.
75342381|NCT01211873|Drug|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
75342382|NCT01211873|Drug|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
75342383|NCT02993588|Drug|Melatonin|Melatonin 6 mg tablet once daily
75342384|NCT02993588|Other|Placebo|one tablet once daily
75342385|NCT02991092|Procedure|fluid administration|"After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
75342386|NCT01270022|Other|Implementation|
75475589|NCT01996891|Other|Anti-Inflammatory Diet|The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
75475590|NCT01996930|Drug|Haelan tape (steroid impregnated tape)|Medicated plaster applied daily. Max daily dose = 0.1mg (25cm squared per day)Maximum duration of treatment = 28 days
75652820|NCT04119297|Other|Routine care|"Routine care was applied to the periorbital area by clinical nurses.~Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara & Gokalan's Scale"
75652821|NCT04119297|Other|Cold gel pack|"Cold application was applied to the periorbital area for 20 minutes per hour beginning 3rd hour following craniotomy, except from 10pm-7 am, and for three days using gel pack cooled to -14ºC.~Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara & Gokalan's Scale"
75342387|NCT01270022|Other|dissemination|
75342388|NCT01277276|Device|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
75342389|NCT04386824|Other|Erectil dysfunction|A complete ophthalmological examination including best-corrected visual acuity using the decimal system (BCVA), measurement of intraocular pressure (IOP) and axial length (AL), slit-lamp examination and dilated fundus examination
75342390|NCT01270100|Behavioral|Recovery management|
75342391|NCT01277432|Other|Psychiatrist Interview|"Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~MINI~SSI-28 (somatization)"
75652822|NCT04119297|Drug|Heparinoids Topical Cream|"Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara & Gokalan's Scale"
75652823|NCT00860067|Biological|Q/LAIV (MEDI3250)|0.2 mL dose at Day 0
75652824|NCT00860067|Biological|FluMist/B/Yamagata|0.2 mL dose at Day 0
75652825|NCT00860067|Biological|FluMist/B/Victoria|0.2 mL dose at Day 0
75652826|NCT00699387|Drug|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
75800523|NCT03788226|Drug|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
75938453|NCT00702845|Biological|progesterone|Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
75672291|NCT02830295|Other|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
75819690|NCT02174224|Behavioral|Brief Intervention|Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
75342392|NCT01277432|Other|Depression screening - control|"All study participants will undergo;~a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal~a detailed psychological and behavioral assessments using validated questionnaires~several specialist questionnaires on depression, self care and quality of life"
75342393|NCT01270178|Drug|Entecavir|film coated tablets / 0.5mg / once daily / 3 years
75342394|NCT02993276|Device|Neurocap®|NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
75342395|NCT02993042|Device|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
75342396|NCT01270334|Other|PH meassurment|meassuring ph USING PROBE
75938454|NCT00702845|Drug|placebo-recFSH (follitropin alfa)|Placebo-recFSH administered at the equivalent volume of 150 IU/day.
75938455|NCT00702845|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
75342397|NCT01277900|Procedure|Laparoscopic Roux en Y gastric Bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
75342398|NCT02992730|Behavioral|No Intervention|No Intervention
75342399|NCT01270412|Biological|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
75342400|NCT01270412|Drug|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
75475591|NCT01996930|Drug|Silver Nitrate|Cautery with silver nitrate cutaneous stick undertaken twice weekly for a maximum duration of treatment = 28 days
75475592|NCT01996956|Other|volume expansion|fluid loading of 10 ml/kg colloid or blood product
75819691|NCT02174224|Behavioral|Case Management|Case management based on needs-assessment. Resource connection and mentoring.
75342401|NCT02992496|Drug|Ketamine|1mg/kg, 6 applications over 2 weeks
75342402|NCT02992496|Drug|Midazolam Hydrochloride|0.03mg/kg, 6 applications over 2 weeks
75938456|NCT00702845|Biological|open-label recFSH|Open-label recFSH administered up to a maximum dose of 200 IU/day.
75938457|NCT00647933|Drug|Org 36286|Subcutaneous Org 36286
75938458|NCT00647933|Drug|Lyndiol®|Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
75938459|NCT00641771|Drug|alendronate sodium (+) cholecalciferol|MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
75342403|NCT00729482|Drug|RAD001|RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
75342404|NCT01270490|Drug|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
75342405|NCT01278056|Drug|Exjade|Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
75342406|NCT02992652|Drug|Allopurinol|600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
75819692|NCT02174224|Behavioral|Standard Medical Care|This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
75342407|NCT01270646|Device|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|"Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping."
75342408|NCT01270724|Drug|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
75938460|NCT00641771|Drug|Comparator: Placebo (unspecified)|MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
75938461|NCT05008445|Biological|LM-102 Injection|LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.
75938462|NCT05008445|Combination Product|LM-102 Injection combined with SOC|LM-102 Injection with appropriate dose level(s), combined with SOC.
75938463|NCT03821831|Device|Continuous Positive Airway Pressure|CPAP machine
75938464|NCT03821831|Device|Orthodontic intervention|Mandibular advancement or Rapid maxillary expansion devices
75342409|NCT00709826|Drug|gemcitabine|Gemcitabine: per package insert.
75938465|NCT05096585|Behavioral|Delayed bedtime sleep restriction|bedtime 2 hr later than their normal bedtime
75938466|NCT05096585|Behavioral|Early wake sleep restriction|wake time 2 hr earlier than their normal wake time
75342410|NCT00709826|Drug|placebo|placebo: 100 mg tablets, 400 mg/day
75342411|NCT00709826|Drug|Erlotinib|Erlotinib - per package insert.
75342412|NCT00709826|Drug|apricoxib|apricoxib: 100mg tablets, given orally
75672292|NCT00350714|Other|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
75672293|NCT02536638|Other|Exposure to pyelonephritis|Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
75819693|NCT03537430|Procedure|TNT uniportal VATS mediastinal tumor resection|TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.
75475593|NCT01996969|Drug|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
75475594|NCT01996995|Device|Nd:YAG laser pulse therapy|
75475595|NCT01996995|Device|Sham procedure|Sham procedure
75475596|NCT01997008|Behavioral|Intervention|Positive Affect Skills Training
75938467|NCT00519857|Drug|Tibolone|1.25 mg p.o, once daily for 3 years
75938468|NCT00519857|Drug|Placebo|Tablet p.o, once daily for 3 years
75938469|NCT00431093|Drug|tibolone|uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
75342413|NCT01271114|Drug|Hypertonic Saline and Terlipressin|Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
75342414|NCT01271114|Drug|Normal saline and norepinephrine|Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
75672294|NCT04246775|Device|Peristeen|rectal irrigation
75819694|NCT03537430|Procedure|Traditional uniportal VATS mediastinal tumor resection|The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
75342415|NCT00710840|Procedure|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
75342416|NCT00710840|Procedure|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
75342417|NCT02992340|Drug|Varlitinib|Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
76089307|NCT05735860|Behavioral|Virtual Reality Exposure Therapy (VRET)|Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.
75342418|NCT02992340|Drug|Cisplatin|On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
75342419|NCT02992340|Drug|Gemcitabine|On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
75800524|NCT01378780|Behavioral|Educational intervention for diet and physical activity|The proposed project, SHARE, is a culturally-tailored, primary stroke prevention intervention for MAs and EAs that targets a number of health-related behaviors related to stroke risk. Using a combination of self-help materials, social support, peer counseling based on Motivational interviewing, tailored newsletters, and social environmental changes in Catholic Churches, the SHARE intervention will lead to increases in moderate and vigorous intensity physical activity, decreases in salt intake, and increases in fruit and vegetable intake. Additional targets include decreases in BMI for those overweight or obese, reduction of dietary fat (trans, saturated and total fat), and increases in low-fat dairy products, changes that will serve to reduce blood pressure and stroke risk. Additionally, SHARE will seek to improve hypertension medication adherence in participants with previously diagnosed high blood pressure at baseline screening.
75819695|NCT02176096|Dietary Supplement|Glycosade|
75938470|NCT00431093|Drug|low-dose estradiol/noresterone|"Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time)."
75938471|NCT04051385|Other|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
75342420|NCT00711464|Drug|modafinil (M1, M2, M4)|modafinil 100, 200, and 400 mg oral dose
75342421|NCT01278290|Diagnostic Test|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate test, using aqueous 0.1 mg/m2 subcutaneous. Gonadorelin test using 100 ug intravenous.
75938472|NCT04051385|Other|Gingival crevicular fluid and serum collection|GCF with filter paper using the intracrevicular method and serum collection
75938473|NCT05283941|Dietary Supplement|Pistachio Group|Consumption of 2-ounce packs of pistachio nuts, daily, for 12 weeks.
75342422|NCT01278290|Diagnostic Test|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
75938474|NCT01302847|Drug|DTG film-coated tablets|DTG film-coated tablets initial starting dose at ~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
75342423|NCT00575432|Radiation|diffusion MRI|diffusion MRI
75342424|NCT00575432|Radiation|BOLD MRI|BOLD MRI
75342425|NCT00575432|Other|Clinical Outcome|Clinical outcome
75342426|NCT01278368|Procedure|Pancreatic resection after preoperative chemotherapy|Pancreatic resection after preoperative chemotherapy
75475597|NCT01997021|Other|US|US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
75475598|NCT01997021|Other|IW|IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
75475599|NCT01997021|Other|CW|CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
75938475|NCT01302847|Drug|DTG granules for suspension|DTG granules for suspension initial starting dose at ~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
75342427|NCT01278368|Procedure|Pancreatic resection|Pancreatic resection
75342428|NCT01278446|Other|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
75342429|NCT01278446|Other|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
75342430|NCT01271192|Procedure|surgical resection and adjuvant therapy|"Postoperative:~Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks"
75342431|NCT01271192|Procedure|Neoadjuvant followed by operation|"Preoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks~Postoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV"
75342432|NCT02339558|Other|Laboratory Biomarker Analysis|Correlative studies
75342433|NCT02339558|Biological|Nivolumab|Given IV
75342434|NCT01271270|Drug|Palomid 529|
75475600|NCT01997034|Behavioral|Intensive Lifestyle Intervention|The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
75475601|NCT01997060|Behavioral|Intensive Lifestyle Intervention|
75342435|NCT00730730|Device|Complete SE Iliac Stent|Iliac stenting
75342436|NCT00730730|Device|Complete SE Iliac Stent|Self-expanding stent
76089308|NCT05735860|Behavioral|Progressive Muscle Relaxation (PMR)|Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
76089309|NCT03826485|Drug|PRIC|Pranlukast hydrate 50mg
76089310|NCT03826485|Drug|Pranlukast hydrate|Pranlukast hydrate 225mg/2.25g
76089311|NCT03029572|Drug|Diet supplementation|Micronutriment supplementation therapy
76089312|NCT03029572|Procedure|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
75342437|NCT00730964|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)|"The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.~The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .~The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study."
75652827|NCT04030923|Device|repetitive transcranial magnetic stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
75652828|NCT00699465|Drug|enoxaparin|20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
75800525|NCT01378780|Behavioral|Educational message on skin cancer awareness|Control group will get the diet and physical activity intervention after the crossover but no outcomes will be measured after the crossover
75800526|NCT03787992|Drug|Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo|"The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
75342438|NCT00731198|Drug|Drotaverine hydrochloride|Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
75342439|NCT00731198|Drug|Hyoscine-N-butylbromide|Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
75652829|NCT00699465|Drug|enoxaparin placebo|Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
75800527|NCT03787992|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
75800528|NCT03787992|Drug|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
75819696|NCT02179294|Drug|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
75819697|NCT02179294|Drug|Remifentanil|"Dedicated intravenous cannula for remifentanil administration PCA protocol~PCA bolus remifentanil 40 μg~Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes."
75819698|NCT02179372|Dietary Supplement|Eicosapentaenoic acid|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.
75819699|NCT02179372|Dietary Supplement|Medium chain fatty acid (placebo)|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
75342440|NCT01278602|Drug|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
75342441|NCT00712244|Device|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
75342442|NCT00712244|Device|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
75819700|NCT02174380|Other|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
75819701|NCT02176252|Drug|AZD1722|
75819702|NCT02176252|Drug|Placebo|
75819703|NCT02174458|Procedure|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
75819704|NCT02174536|Biological|Decidual stromal cells|Decidual stromal cells (approximately 1x10^6 cells/kg) will be infused intravenously.
75819705|NCT02174536|Biological|Placebo|
75938476|NCT01302847|Drug|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of ~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to <6 kg: 5 mg DTG dispersible tablets; Weight band 6 to <10 kg: 15 mg DTG dispersible tablets; Weight band 10 to <14 kg: 20 mg DTG dispersible tablets; Weight band 14 to <20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
76089313|NCT03126747|Drug|BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
75938477|NCT01302847|Drug|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of ~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to <6 kg: 5 mg DTG dispersible tablets; Weight band 6 to <10 kg: 15 mg DTG dispersible tablets; Weight band 10 to <14 kg: 20 mg DTG dispersible tablets; Weight band 14 to <20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
75938478|NCT01302847|Drug|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of ~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to <6 kg: 5 mg DTG dispersible tablets; Weight band 6 to <10 kg: 15 mg DTG dispersible tablets."
76089314|NCT03117777|Behavioral|group cognitive behavioral therapy for insomnia|cognitive behavioral therapy for insomnia delivered in group setting for older adults
75475602|NCT01997086|Procedure|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
75342443|NCT00712244|Device|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
75342444|NCT00712244|Device|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
75475603|NCT01997086|Procedure|Microendoscopic discectomy (MED)|Microendoscopic discectomy
75475604|NCT01997099|Device|CADD®-Solis VIP Pump|
75475605|NCT01997099|Device|CADD™ Solis Medication Safety Software Administrator|
75475606|NCT01997112|Drug|Paracetamol|
75475607|NCT01997112|Drug|Placebo oral capsule|
75475608|NCT01997138|Drug|Anakinra 100 mg in 2 ml saline IA|
75475609|NCT01997151|Behavioral|Healthy Pregnancy: Step by Step|
75652830|NCT00858117|Biological|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
75652831|NCT00858117|Biological|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
75800529|NCT03787992|Drug|Placebo AST2818 80mg//40 mg|The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
75800530|NCT04913194|Behavioral|ARFID-PTP|ARFID-PTP is a two-session virtual protocol using psychoeducation, parent training skills, and exposure to decrease picky eating symptoms consistent with an ARFID diagnosis.
75800531|NCT04755426|Behavioral|AVITA--Aortic Valve Improved Treatment Approaches|AVITA is an interactive shared decision making tool that helps patients clarify their treatment goals and preferences and communicate those preferences to their valve specialist.
75800532|NCT03785808|Behavioral|Special Diet Therapy (low-carb)|Receive dietary guidelines and recipes and consume a low-carbohydrate diet
75800533|NCT03785808|Behavioral|Special Diet Therapy (low-fat)|Receive dietary guidelines and recipes and consume a low-fat diet
75800534|NCT03785808|Behavioral|Special Diet Therapy (USDA control)|Receive dietary guidelines and recipes and consume USDA control diet
75800535|NCT04804306|Device|Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
75475610|NCT01997164|Drug|REGN910-3|
75475611|NCT01997164|Drug|REGN910|
75475612|NCT01997164|Drug|Intravitreal Aflibercept Injection (IAI)|
75475613|NCT01997203|Drug|Vitamin D|vitamin D was given to 50 patients (HCV under treatment)
75475614|NCT01997255|Drug|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
75475615|NCT01997268|Drug|Placebo|Corn Oil
75475616|NCT01997268|Drug|SC401B 2 capsules|
75475617|NCT01997268|Drug|SC401B 4 capsules|
75475618|NCT01997268|Drug|SC401B 6 capsules|
75652832|NCT04119141|Diagnostic Test|X ray imaging|"Acquisition:~140 kVp,~1/2 mAs/kg,~Pitch: 1.35,~Rotation time: 0.5 sec.~Reconstruction:~I70f filter, 3 iteration loops,~Cutting thickness 1 mm/0.7 mm~Fenestration: C -600/W 1600~Field of view (Size, x & y coordinates) identical on both acquisitions."
75652833|NCT04030689|Other|data collected from patient file|socio-demographics, previous HIV testing history, history of HIV contamination, clinics HIV related data will be collected for each patient who notified his non-objection to participate to this non interventional study.
75819706|NCT02174614|Behavioral|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
75819707|NCT02174614|Behavioral|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
75475619|NCT01997294|Drug|Sequential therapy of atorvastatin|80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
75475620|NCT01997320|Other|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.
75938479|NCT03619577|Behavioral|Sequential training|For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
75938480|NCT00092963|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
75938481|NCT00092963|Drug|Comparator: placebo / Duration of Treatment: 1 day|
75938482|NCT00092885|Drug|MK0476, montelukast sodium|
75938483|NCT00092885|Drug|Comparator: placebo|
75938484|NCT03039569|Behavioral|Text messaging|"The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages"
75938485|NCT03673735|Drug|Durvalumab|Durvalumab (one dose) before CRT and for 6 months Q4W after CRT
75938486|NCT03673735|Radiation|radiotherapy|radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
75938487|NCT03673735|Drug|Placebo|placebo (one dose) before CRT and for 6 months Q4W after CRT
75938488|NCT03673735|Drug|Cisplatin|Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
75938489|NCT02738775|Biological|Ublituximab|Administered as an IV infusion.
75342445|NCT02992106|Other|Parental questionnaires|"We will provide parents with questionnaires depending on the age of their children:~Children aged 0-6 years old:~Questionnaire on socio-demographic characteristics~Dutch Eating Behaviour Questionnaire~Food Frequency Questionnaire~Ages and Stages Questionnaire~Strengths and Difficulties Questionnaire~Questionnaire on developmental milestones~Questionnaire on behaviour~Children older than 6 years:~Questionnaire on socio-demographic characteristics~Dutch Eating Behaviour Questionnaire~Food Frequency Questionnaire~Pediatric Quality of Life Questionnaire~Children's Behaviour Questionnaire in Dutch~Questionnaire on developmental milestones~Developmental Coordination Disorder Questionnaire~Strengths and Difficulties Questionnaire"
75475621|NCT01997320|Other|Nutrition supplement|Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
75475622|NCT01997372|Drug|ATG|Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) >1×109/L.
75475623|NCT01997385|Procedure|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
75475624|NCT01997385|Procedure|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
75475625|NCT01997424|Device|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
75475626|NCT01997424|Device|FibroScan, Echosens, Paris, France|
75652834|NCT00700947|Drug|Beta-blocker therapy (TOPROL-XL® )|Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
75652835|NCT04116333|Device|Endotracheal tube introducer|Use of endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
75652836|NCT04116333|Device|Macintosh laryngoscope|Use of the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
75652837|NCT04116177|Device|Deep brain stimulation|Stimulation using VerciseTM system
75800536|NCT01305798|Other|Scheduling and Active Choice for Biometric Participation|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
75800537|NCT02434354|Drug|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
75938490|NCT02738775|Drug|Placebo|
75938491|NCT00092105|Drug|MK0476, montelukast sodium|
75938492|NCT00092105|Drug|Comparator: placebo|
75938493|NCT00092027|Drug|MK0217, alendronate sodium/Duration of Treatment: 6 months|
75938494|NCT00092027|Drug|Comparator: placebo / Duration of Treatment: 6 months|
75938495|NCT00076973|Drug|montelukast sodium|Duration of Treatment: 6 months
75938496|NCT00076973|Drug|Comparator: placebo|Duration of Treatment: 6 months
75938497|NCT02314533|Drug|fenofibrate|Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
75938498|NCT02317965|Other|Maternal Blood Draw|Maternal Blood Draw
75938499|NCT03502395|Drug|Lidocaine|): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
75938500|NCT03502395|Drug|Normal saline|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
75938501|NCT02308995|Procedure|Cystectomy using barbed sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
75342446|NCT02992106|Other|Blood sample|We will determine the following biochemical parameters: glucose, insulin, total cholesterol, LDL, HDL, triglycerides, uric acid, IGF-1, adiponectin, leptin, hs-CRP, IL-6, TNF-α and ICAM-1.
75342447|NCT02992106|Other|Urine sample|We will take a urine sample to evaluate the albumin to creatinin ratio.
75342448|NCT02992106|Other|Anthropometric measurements|We will measure weight, Height, hip, waist and neck circumference, blood pressure, 4-site skinfold measurements and BIA.
75342449|NCT02992106|Other|Ultrasound|We will do an abdominal ultrasound to measure the abdominal fat accumulation
75938502|NCT02308995|Procedure|Cystectomy using conventional sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
75342450|NCT02992106|Other|EndoPAT|We will use the EndoPAT device to measure endothelial function, which is a non-invasive and innovative technique (peripheral pulse wave amplitude measurement).
75342451|NCT02992106|Other|Faces Pain Scale|After performing the measurements with the EndoPAT device, Harpender kalliper and ultrasound, the children will be asked to fill out a Faces Pain Scale, validated for children aged 4-16 years old and obtained for use from the International Association for the Study of Pain
75342452|NCT02991950|Drug|Parnaparin Sodium|Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
75342453|NCT02991872|Procedure|Blood draw|Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
75342454|NCT02992262|Device|Point of care ocular ultrasound|
75342455|NCT01271582|Drug|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks [irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)]
75342456|NCT02991638|Drug|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
75342457|NCT01271660|Drug|Pregabalin|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
75342458|NCT01271660|Drug|Placebo|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
75938503|NCT02308995|Device|V-Loc (Covidien, Mansfield, MA)|
75342459|NCT02991794|Device|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
75342460|NCT02991560|Other|Strengthening exercises|The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
75342461|NCT02991560|Other|Intensive Physioytherapy|The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
75342462|NCT02991560|Device|Kinesio taping|Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
75342463|NCT02991560|Device|Athletic taping|By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
75342464|NCT00731588|Biological|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns ~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
75475627|NCT01997476|Procedure|Combined EUS, e-PFT and sEUS Testing|"advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
75800538|NCT05553210|Behavioral|FOREST+|The intervention will be delivered as an internet-based stress recovery intervention consisting of six weekly modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. Each module consists of a psychoeducational and an exercise component. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.
75800539|NCT01377142|Device|Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
75800540|NCT01377142|Device|Vaginal mesh hysteropexy|Uphold device used which includes sacrospinous ligament fixation
75800541|NCT01377064|Behavioral|Physical Activity Group|9 months of home based physical activity meeting HHS recommendations for physical activity for all americans
75800542|NCT01377064|Other|Standard Care Group|No intervention, the group will be followed under their standard medical care.
75938504|NCT02308995|Device|polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)|
75938505|NCT02318043|Drug|inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)|Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
75652838|NCT00652951|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
75938506|NCT05277545|Behavioral|Technology addiction education|Technology addiction personal development training was applied by the researcher to the students in the experimental group for 10 weeks.
75938507|NCT03502317|Behavioral|Physical Prehabilitation|Physical prehabilitation will comprise a personalized, home-based exercise program designed to meet the Cancer Care Ontario Exercise Guidelines for Cancer Survivors. A Registered Kinesiologist (RKin) will complete a baseline physical assessment and prescribe an individualized multi-modal exercise program consisting of 4-5 days of 30+ minutes of aerobic exercise (brisk walking or equivalent to target heart rate of 40-60% of max) and 2-3 days of moderate intensity resistance training of major muscle groups (8-10 repetitions). Participants will be provided with a Fitbit with a heart rate monitor, resistance bands, and a stability ball. Patients will be required to wear their Fitbit and record the number of steps at the end of each day from randomization to 90 days post-surgery.
75342465|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
75342466|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
75342467|NCT01271738|Procedure|Remove tumor only|No additional margins (tissue) removed at the initial surgery
75342468|NCT01271738|Procedure|Removal of tumor and tissue|5 additional margins (tissue) removed at the time of surgery
75475628|NCT01997489|Drug|Enzyme replacement|Observational study of current treatment and with no comparative groups
75475629|NCT01997528|Device|Change of blood flow or sweep gas flow ( ILA Activve)|
75475630|NCT01997554|Other|Blood sample|An extra blood sample of 10 ml is collected
75475631|NCT01997580|Drug|escitalopram|SSRI antidepressant
75652839|NCT00652951|Biological|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
75938508|NCT03502317|Behavioral|Psychological Prehabilitation|Psychological prehabilitation will consist of one in-person coaching session of a 'mindfulness' informed intervention conducted by a specially trained RKin. The 40 minute coaching session will include a guided mindfulness session and debriefing. Participants will be asked to practice for 20 minutes twice a day. The patients will be given access to an audio file that will walk them through the 20 minute sessions.
75938509|NCT03433313|Drug|EG12014|EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
75475632|NCT01997593|Drug|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
75475633|NCT01997606|Other|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
75475634|NCT01997606|Other|placebo|
75475635|NCT01997632|Biological|a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)|a single dose m-IPV2 HD (study vaccine), 0,5ml
75475636|NCT01997632|Biological|a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).|a single 0.5 ml dose Imovax Polio (control vaccine)
75475637|NCT01997645|Procedure|LIFT|
75475638|NCT01997645|Procedure|RAF|
75652840|NCT00652951|Biological|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
75652841|NCT00652951|Biological|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
75652842|NCT00848211|Other|Placebo|Subcutaneous injection on Day 0, Day 28, and Day 84
75652843|NCT00848211|Biological|TUTI-16 (0.03mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
75652844|NCT00848211|Biological|TUTI-16 (0.1mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
75652845|NCT00848211|Biological|TUTI-16 (0.6mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
75800543|NCT05549700|Other|Neuromodulation|Ultrasound-guided percutaneous neuromodulation will be applied. The protocol used was 5 seconds of stimulation, 55 seconds of rest for 5 minutes at a frequency of 100 Hz and a phase duration of 350 microseconds
75800544|NCT04783480|Other|Birthly|Women will receive a code to sign up for 3 free interactive childbirth education classes through the Birthly platform. They will be enrolled in 3 courses: Prenatal Education, Childcare and Breastfeeding. They will be encouraged to complete all courses prior to 36 weeks gestational age.
75800545|NCT04783480|Other|Standard of care|Subjects will participate in childbirth education at their own discretion.
75800546|NCT03791268|Procedure|Gastric cancer surgery|Gastric cancer surgery is performed according to the Japanese Guidelines. Patients will intraoperative evaluate the edema, fibrosis and exudation.
75342469|NCT01278680|Behavioral|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
75475639|NCT01997658|Drug|Methylprednisolone|Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.
75475640|NCT01997658|Drug|Placebo|Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
75652846|NCT04116255|Other|Mandibular oral occlusal splint|The panoramic open-mouth and close-mouth radiographs of the first group(splint group) were taken, and intraoral and extraoral examinations were performed by an experienced dentist that also examined the radiographs. The upper jaw of the patients was measured with an alginate impression material, to obtain a hard plaster model. Then, using these models, a vacuum plate machine made a customized mandibular oral occlusal splint suitable for each patient's teeth. The suitability of the splints was checked and confirmed by the dentist on the first and seventh days of use. The patients were asked to use these splints at night (for at least six hours) throughout the study.
75652847|NCT04116255|Other|Temporomandibular joint Exercises|This program was created by combining patient training and a home exercise program. The exercise program consisted of slow passive and active mouth opening and closing exercises, isometric masseter exercises, mouth stretching exercises, and resistant mouth opening and closing exercises. Each exercise set was administered twice a day, and each movement was undertaken for 10 seconds and repeated 15 times. The training was given by an experienced physical medicine and rehabilitation expert over approximately 45 minutes. The exercise program was demonstrated for the patients in front of a mirror, and each exercise was performed by a set of patients under the supervision of a doctor. A training document including the written exercise program was to the patients in the exercises group.
75652848|NCT02553031|Device|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
75652849|NCT00809419|Device|NeoVista Ophthalmic System|A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
75938510|NCT03433313|Drug|Herceptin|Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
75652850|NCT00805519|Drug|Glucosamine and chondroitin sulfate|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
75800547|NCT05764018|Dietary Supplement|Caffeine|Negligible amount of maltodextrin in flavoured drink solution containing 6 mg/kg body mass caffeine provided 45 minutes before exercise
75800548|NCT05764018|Other|Hypoxia|Participants will be breathing from a hypoxic gas mixture (13% O2) for the duration of the exercise bout. This will simulate an altitude of approximately 3500 m.
75800549|NCT05764018|Other|Placebo|Negligible amount of maltodextrin in flavoured drink solution provided 45 minutes before exercise.
75800550|NCT05764018|Other|Normoxia|Participants will be breathing from ambient air (~21% O2) for the duration of the exercise bout. This will provide no hypoxic stimulus as the laboratory is located relatively near sea level (295 m)
75800551|NCT01308528|Drug|Sodium enoxaparin|40 mg/mL
75938511|NCT02314767|Behavioral|Interpersonal Psychotherapy|Patients were treated with IPT method, which was an active comparator vs treatment as usual
75938512|NCT02314767|Behavioral|Psychoeducational Group Therapy|Patients were treated with PeGt method which was an active comparatos vs treatment as usual
75938513|NCT02318121|Procedure|Amniotomy first|rupture of membranes to augment labor
75938514|NCT02318121|Procedure|Oxytocin first|Administration of oxytocin to augment labor
75342470|NCT01271894|Drug|Efavirenz|600 mg once daily; given as 3 x 200 mg once
75342471|NCT01271894|Drug|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
75800552|NCT01308528|Drug|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
75800553|NCT03785652|Drug|LY03005 extended-release tablets 40 mg|LY03005 extended-release tablets 40 mg group :40mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfas
75800554|NCT03785652|Drug|LY03005 extended-release tablets 80 mg group|"LY03005 extended-release tablets 80 mg group :~80mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
75938515|NCT02318121|Procedure|Amniotomy and oxytocin|Rupture of membranes and administration of oxytocin to augment labor
75938516|NCT02318121|Drug|Oxytocin|
75938517|NCT02318199|Procedure|Anesthesia recovery after intracranial surgery|Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
76025792|NCT05898347|Other|Active surveillance|"Skin lesions clinically compatible with nevoid basal cell carcinomas are documented with measurements, clinical description, clinical photos and dermatoscopy photos every eight months for two years. Three representative skin lesions are selected at the first visit to be removed by skin biopsy at the end of the observation period (two years) for histopathological analyses.~If a nevoid basal cell carcinoma shows a certain increases in size (according to pre-specified criteria of the study protocol), ulcerates, gets unevenly demarcated or give functional complaints during the observation period, the skin lesion will be excised."
76025793|NCT05898334|Device|Active Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the strong biophoton field so her/his entire body will be energized to promote self-healing.
75342472|NCT01271972|Drug|nesvacumab (REGN910/ SAR307746)|
75342473|NCT01278758|Drug|ASA404, DMXAA or DXAA|
75342474|NCT02991716|Other|recorded patients|No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
75342475|NCT00717626|Drug|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is < 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
75342476|NCT04386668|Other|Let It Out (LIO)-C|Participants complete three online 20-minute writing sessions in response to prompts asking them to write about their experiences during the COVID19 pandemic from a self-compassionate perspective
76025794|NCT05898334|Device|Inactive Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the normal hotel bed and the participant will not receive any biophotons.
76025795|NCT05898321|Drug|Zoladex|Patients with fibroid remained will be enrolled and divided into three groups. one group wii be administrated with Zoladex (3.60mg/28 days) for three to six months.
76025796|NCT05898321|Drug|Mifepristone Oral Tablet|Patients with fibroid remained will be enrolled and divided into three groups. one group will be administrated with mifepristone(10.0mg/d) for three to six months.
75342477|NCT04386668|Other|Neutral writing control|Participants complete three online 20-minute writing sessions in response to neutral writing prompts
75342478|NCT00718094|Drug|Polyphenon E®|Oral capsules
75342479|NCT00718094|Drug|Placebo Oral Tablet|Oral tablet: placebo
75342480|NCT01272128|Drug|Interferon beta-1a|Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
75475641|NCT01997671|Other|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
75652851|NCT00805519|Drug|glucosamine and chondroitin sulfate plus Prednisolone|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
75652852|NCT00805519|Drug|Glucosamine and Chondroitin sulfate plus Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
75652853|NCT00805519|Drug|Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
75652854|NCT00592683|Drug|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
75800555|NCT03785652|Drug|LY03005 extended-release tablets 120 mg group|"LY03005 extended-release tablets 120 mg group :~120mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
75800556|NCT03785652|Drug|LY03005 extended-release tablets 160 mg group|"LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
75800557|NCT03785652|Drug|Placebo group|"Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast"
75800558|NCT03076996|Behavioral|Online support group|"Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.~The m/eHealth intervention components include:~Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis~Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis~Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
75800559|NCT03785496|Drug|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
75342481|NCT02991326|Other|Osteopathic Manipulative Treatment|"The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~Compression of the fourth ventricle;~inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~inhibition of the inferior head of the lateral pterygoid muscle;~intra-oral inhibition of the masseter muscle;~Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~BLT of the accessory ligaments - pterygomandibular raphe;~sphenopalatine ganglion technique;~Craniosacral rebalancing;"
75342482|NCT02991326|Other|Sham intervention|The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
75652855|NCT00592683|Dietary Supplement|fish oil|1600mg (4 capsules) daily for 12 weeks
75652856|NCT00592683|Drug|Placebo|Placebo
75652857|NCT00805597|Radiation|radiation|radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
75800560|NCT01307124|Drug|kaletra|"The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW >35-50 kg 400/100 mg 300/75 mg"
75800561|NCT03078868|Device|Magnetic Resonance Scanner|MRI
75800562|NCT01378702|Drug|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
75800563|NCT03785418|Behavioral|Multicomponent Risk Factor Modification|Healthy eating, regular exercise and behavioural therapy.
75800564|NCT01376986|Behavioral|physical, psychological and social activation|
75800565|NCT01307202|Drug|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
75800566|NCT01307202|Drug|Placebo|Placebo will match the the gabapentin pill and will be given orally.
75800567|NCT03791190|Other|Regional citrate anticoagulation|Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
75342483|NCT02991170|Procedure|unipolar or bipolar radiofrequency ablation+CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
75342484|NCT02991170|Procedure|CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
75652858|NCT00805597|Radiation|no radiation|no radiotherapy
75652859|NCT02613039|Drug|Combined Estrogen-Progestin Oral Contraceptives|All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
75652860|NCT02612961|Other|3mL of normal saline from the pink sodium chloride bullet|
75652861|NCT02612961|Other|Sham Comparator of 3mL normal saline|
75652862|NCT00813475|Drug|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
75652863|NCT00813475|Drug|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
75652864|NCT04115943|Other|Treatment protocol for neck pain|The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
75652865|NCT04115943|Other|Protocol for release of tongue muscles|. The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
75800568|NCT03791190|Other|No-anticoagulation|Patients accepted CRRT without anticoagulant.
75800569|NCT01307280|Behavioral|RCT1|the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
75800570|NCT01307280|Behavioral|RCT2|bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments
75800571|NCT01307280|Behavioral|RCT3|bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
75800572|NCT03790722|Other|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
75938518|NCT05225597|Procedure|Intracameral administration of epinephrine and carbachol during cataract surgery|All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.
75652866|NCT00809497|Drug|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
75652867|NCT04016857|Procedure|RIPC|4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff
75652868|NCT04016857|Procedure|Control|deflated cuff placed on the left arm for 40 min
75652869|NCT00809575|Other|questionnaire administration|
75652870|NCT00809575|Other|fatigue assessment and management|
75652871|NCT00809575|Other|observation|
75652872|NCT00809575|Other|quality-of-life assessment|
75652873|NCT00847665|Other|repositioning|Turning every 4 or 2 hours
75938519|NCT02314845|Other|Optimal PEEP|"Optimal PEEP determined by EIT during a PEEP titration procedure."
75938520|NCT02314845|Other|Low PEEP|Use of PEEP of 4 cmH2O during intraoperative period
75938521|NCT05225519|Device|long-sleeved white shirt impregnated with a long-infrared irradiation|Usage of an experimental shirt for a period of 12 weeks.
75652874|NCT00809653|Device|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
75938522|NCT05225519|Device|long-sleeved white shirt|Usage of an experimental shirt for a period of 12 weeks.
75938523|NCT04051307|Drug|PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL|Peptide vaccination
75938524|NCT04051307|Drug|Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL|Peptide vaccination
75938525|NCT05225285|Biological|Inactivated Coronavac/Butantan vaccine|Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
75342485|NCT01278836|Procedure|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
75342486|NCT00719186|Drug|Clomiphene citrate|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
75342487|NCT00719186|Drug|Letrozole|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
75342488|NCT02991404|Procedure|Multimodal Peripheral Nerve Block Injection|After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.
75475642|NCT01997684|Procedure|Colonic Stenting with Elective Surgery|"After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.~If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.~Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.~Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis."
75475643|NCT01997684|Procedure|Emergency Surgery|Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
75475644|NCT01997736|Device|Ablation|
75475645|NCT01997749|Dietary Supplement|Ketocal 4:1 (Nutricia)|
75475646|NCT01997749|Dietary Supplement|Control diet: Regular diet offered at the hospitals|
75652875|NCT00809653|Device|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
75800573|NCT03790722|Other|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
75800574|NCT03787914|Procedure|Mobile Outreach Approach|TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
75800575|NCT01308606|Drug|TMC435 HPMC capsule|Single intake of one 150-mg capsule without food
75475647|NCT01997749|Dietary Supplement|Ketogenic meals|
75475648|NCT01997762|Dietary Supplement|Resveratrol|gel-coated capsules to be taken twice a day; one with breakfast and dinner
75652876|NCT00701259|Drug|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
75652877|NCT00701259|Drug|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
75652878|NCT00701259|Drug|placebo|
75800576|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after high-fat breakfast
75800577|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule without food
75800578|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after standardized breakfast
75800579|NCT01308606|Drug|TMC435 gelatin capsule|Single intake of one 150-mg capsule without food
75800580|NCT04637386|Procedure|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
75800581|NCT04637386|Procedure|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
75475649|NCT01997762|Dietary Supplement|Placebo|
75652879|NCT00807391|Procedure|TBCA, TBNA|One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
75652880|NCT00701337|Drug|oestradiol|oestradiol 2 mg oral route 30 days
75652881|NCT00701337|Drug|oestradiol|oestradio transdermal patch 60ug by 24 hours 30 days
75652882|NCT00916370|Device|Core size Xience Prime|Core size includes a range of stent sizes.
75652883|NCT00916370|Device|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
75652884|NCT04116021|Other|PECS block|Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
75652885|NCT04116021|Other|Local infiltration|Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
75800582|NCT01307358|Other|Sonicare Interproximal (IP) Cleaning Prototype|Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
75800583|NCT03629938|Other|evaluation|evaluation and classification of medial longitudinal arch height of foot in adults
75800584|NCT01308684|Drug|RO5323441 + bevacizumab [Avastin]|Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
75800585|NCT01308684|Drug|bevacizumab [Avastin]|Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
75800586|NCT03629860|Procedure|Atrophic maxillary alveolar ridge augmentation|Autogenous bone blocks from chin and ascending ramus are obtained and used for reconstruction of atrophic maxillary ridges
75800587|NCT05613114|Drug|Dalfampridine 10 MG|The participants in the experimental group received dalfampridine administered as 10 mg extended-release tablets every twelve hours for 8 weeks.
75800588|NCT05613114|Drug|Placebo|Control group received a placebo drug with the same administration method (2 times per week for the total duration of 8 weeks).
75938526|NCT05225285|Biological|BNT162b2 (Pfizer)|BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart
75938527|NCT03673579|Device|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
75938528|NCT03070327|Biological|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10^6, 3x10^6, and 1x10^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
75938529|NCT03070327|Drug|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
75938530|NCT03070327|Drug|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
75342489|NCT02991404|Procedure|Single Shot Adductor Canal Block|A total of 20 ml of solution containing a combination of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, 150 micrograms of buprenorphine, 2 mg of dexamethasone, and 1:400,000 epinephrine will be administered underneath the Sartorius muscle. A sham catheter will then be placed subcutaneously into the Sartorius muscle, secured in typical fashion, and connected to a pump containing saline to provide similar shape and weight with an opaque bag covering the pump. The pump will be run at the lowest possible ml/hour rate, which is currently 0.1 ml/hour with the current pump used in our hospital.
75652886|NCT00847197|Drug|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
75652887|NCT00847197|Drug|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
75938531|NCT00543127|Drug|Fulvestrant|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
75938532|NCT00543127|Drug|Anastrozole|1 mg oral Anastrozole per day during 5 years.
75938533|NCT02314923|Biological|V920 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^3, 3x10^4, 3x10^5, 3x10^6, 9x10^6, 2x10^7, or 1x10^8 pfu.
75342490|NCT02991404|Drug|Initial Bolus|20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine
75342491|NCT02991404|Drug|Continuous infusion|Continuous infusion of 0.125% bupivacaine
75652888|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)|0.5 mL, Intramuscular
75652889|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)|0.5 mL, Intramuscular
75342492|NCT00719576|Biological|autologous cultured chondrocytes on porcine collagen membrane|Implantation via mini-arthrotomy
75800589|NCT05613114|Behavioral|Physiotherapy|Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.
75342493|NCT00719576|Procedure|Microfracture|Microfracture performed by arthroscopic surgery
75342494|NCT00721136|Drug|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
75652890|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)|0.5 mL, Intramuscular
75652891|NCT00654901|Biological|Infanrix Hexa™|0.5 mL, Intramuscular
75652892|NCT00701493|Drug|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
75652893|NCT00813553|Dietary Supplement|placebo|daily
75652894|NCT00813553|Dietary Supplement|beta-alanine|daily
75652895|NCT00813553|Dietary Supplement|beta-alanine|daily
75800590|NCT01378624|Other|Bronchoscopy|"In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies."
75652896|NCT04253678|Drug|Vortioxetine|Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
75652897|NCT02551939|Procedure|Autologous Fat Grafting|Autologous Fat Grafting
75652898|NCT00813631|Other|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
75652899|NCT02551861|Drug|Daclatasvir|
75652900|NCT02551861|Drug|Sofosbuvir|
75652901|NCT02551861|Drug|Ribavirin|
75800591|NCT03630406|Diagnostic Test|Vaginal Tactile Imaging|Vaginal Tactile Imaging
75800592|NCT03790566|Drug|Bupivacaine|0.5 ml/kg 0.25% bupivacaine
75800593|NCT05763940|Dietary Supplement|OmegaBoost|"An ultra-pure omega-3 fish oil supplement with no fishy aftertaste and no fish burps.~10x more omega-3 from fish oil than the leading omega-3 gummies. Gel bites have better absorption than ordinary, hard-to-swallow fish oil pills."
75938534|NCT02314923|Other|Placebo|0.9% Saline
75938535|NCT00409435|Drug|pyridostigmine|one 180 mg capsule per day for 3 days
75938536|NCT00409435|Drug|Placebo|one capsule per day for 3 days
75938537|NCT02309307|Device|Tissue Repair Device (VergenixTM STR)|Administration of Soft Tissue Repair Device
75938538|NCT03500601|Other|Nut components|nut components consumed daily for a period of 28 days
75342495|NCT00721136|Drug|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
75342496|NCT00721136|Drug|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
75342497|NCT01278992|Dietary Supplement|Rhodiola rosea|1 capsule = 182 mg Rhodiola rosea extract standardized to 2.8% total rosavins. Take 2 capsules at start of wakeful period each day. Participants will self-determine need for second dose, of 1 capsule, within 4 hours of the initial dose.
75342498|NCT00736580|Other|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
75938539|NCT03500601|Other|Placebo|Placebo consumed daily for a period of 28 days
75938540|NCT02309385|Drug|8% Dexamethasone Sodium Phosphate - Visulex|
75342499|NCT00736580|Other|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
75342500|NCT01272206|Drug|NNC 0128-0000-2011|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
75652902|NCT00701571|Procedure|Virtual Reality distraction|"Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is Snow World. In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities."
75652903|NCT00701649|Biological|CYT006-AngQb|s.c.
75652904|NCT00701649|Biological|Placebo|s.c.
75652905|NCT00846495|Drug|topiramate|topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
75800594|NCT05763940|Dietary Supplement|Nature Made (soft gel)|A commercially-available omega-3 soft gel formula
75800595|NCT05763940|Dietary Supplement|Nature Made (gummy)|A commercially-available omega-3 formula in gummy form
75800596|NCT05694780|Behavioral|Sleep intervention|Standard obstetric care plus the sleep intervention which is a 8-week program based on sleep hygiene education and cognitive-behavioral training.
75800597|NCT04436224|Drug|Hydromorphone|Intravenous analgesia using hydromorphone in ICU patients with non-mechanical ventilation(NS 40ML+ hydromorphone 10mg ，IV-Pump)
75652906|NCT00846495|Drug|frovatriptan|frovatriptan 5mg tab during premonitory phase of migraine
75652907|NCT02612805|Other|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
75652908|NCT02612805|Other|Combined training|"Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed."
75652909|NCT02612805|Other|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
75800598|NCT04436224|Drug|Fentanyl|Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)
75938541|NCT02309385|Drug|15% Dexamethasone Sodium Phosphate - Visulex|
75938542|NCT02309385|Drug|Prednisolone Acetate (1%) Eye Drops|
75938543|NCT03463785|Other|cone beam computed tomography|The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.
75938544|NCT03023137|Behavioral|Walking & dietary modification|"Daily walking at a moderate pace (4 km/h) > 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding >12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.~At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention"
75938545|NCT03502239|Other|Mega Team - video game|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 15 minutes a day, 5 days a week for a minimum of 21 days and a maximum of 25 days.
75938546|NCT02315001|Drug|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
75938547|NCT02315001|Other|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
75938548|NCT03049813|Behavioral|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
75342501|NCT01272206|Drug|NNC 0128-0000-2021|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
75652910|NCT02612493|Other|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
75800599|NCT04436224|Drug|Butorphanol|Intravenous analgesia using butorphanol in ICU patients with non-mechanical ventilation(NS 40ML+ butorphanol 10mg，IV-Pump)
75800600|NCT01307436|Biological|Epaxal|0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)
75800601|NCT01307436|Biological|Havrix 720|0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide
75800602|NCT04255108|Device|Cova Patch|CoVa Patch will measure quasi-continuously, approximately every 5 minutes for a period between 6 to 48 hours
75800603|NCT03785184|Drug|venetoclax|tablet; oral
75800604|NCT03785184|Drug|lenalidomide|capsule; oral
75800605|NCT03785184|Drug|dexamethasone|tablet; oral
75800606|NCT03790176|Drug|Intravenous Infusion|see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
75652911|NCT00654745|Drug|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
75800607|NCT04524598|Device|Limbix Spark|The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.
75800608|NCT04524598|Other|Psychoeducation|The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.
75800609|NCT01305876|Behavioral|yoga intervention|yoga session 2 x week over 3-1/2 months
75800610|NCT03784950|Behavioral|Rating tool|eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
75938549|NCT03049813|Other|Supported Employment (Services as Usual)|Standard supported employment services.
75938550|NCT03502161|Device|QuantiFERON CMV Assay|Assay to measure cell-mediated immune function using QuantiFERON CMV assay.
75938551|NCT02445885|Procedure|PCI|Guideline directed Percutaneous Coronary Intervention
75938552|NCT03673267|Behavioral|Nutricity|Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
75342502|NCT00737204|Drug|Armodafinil|Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
75938553|NCT03669913|Other|Lessons on comprehensive sexuality education|Provision of 11 standardized lessons on comprehensive sexuality education based on international guidance on sexuality education by UNESCO
75938554|NCT02315079|Other|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
75938555|NCT02315079|Other|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
75938556|NCT03500523|Diagnostic Test|corneal biomechanical properties|We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
75938557|NCT03673111|Drug|Y14|Gut hormone analogue
75938558|NCT03673111|Drug|Placebo|0.9% saline
75938559|NCT02315157|Drug|Bendamustine|Given IV
75938560|NCT03673033|Procedure|liver transplantation|calculation of hot and cold ischemia durations from donor artery cut-off time in liver transplantation
75938561|NCT04463277|Behavioral|Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day.
75938562|NCT04463277|Behavioral|Time Restricted Feeding|Participants assigned to this arm to consume food at maintenance calories (calories required per day to maintain weight, calculated based on height, weight and physical activity using the MyFitnessPal application) within an 8-hour window during daylight hours.
75938563|NCT04463277|Behavioral|Time Restricted Feeding with Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day within an 8-hour window during daylight hours.
75342503|NCT00737204|Drug|Placebo|Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
75342504|NCT04385810|Procedure|Ophthalmologic exam|Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital
75652912|NCT00654745|Drug|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
75652913|NCT00654745|Drug|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
75652914|NCT00809887|Drug|Micafungin lock therapy|
75652915|NCT00807547|Biological|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
75652916|NCT00846027|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
75938564|NCT03506217|Device|Vigileo Flo-trac device|A Vigileo Flotrac pulse counter invasive arterial cardiac output meter was used for cardiac output measurement. Heart rate, blood pressure, cardiac output, stroke volume variance (SVV), systemic vascular resistance (SVR) values were recorded.
75938565|NCT02309463|Drug|Endothelin receptor antagonist therapy|
75938566|NCT03502083|Drug|GLP-1 (7-36)Amide|IV infusion
75938567|NCT03500367|Drug|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
75938568|NCT02318433|Drug|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
75652917|NCT00846027|Drug|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
75938569|NCT02318433|Drug|Saline|
75938570|NCT02315235|Biological|Normal saline|Normal saline is injected in one leg of patient.
75938571|NCT02315235|Biological|stem-cell|"Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient."
75938572|NCT03506139|Radiation|External beam radiation therapy|Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
75652918|NCT00846027|Drug|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
75652919|NCT00807625|Drug|Depo Provera|Depo Provera administered by injection at randomization visit and the 12-week study visit.
75652920|NCT00807625|Device|Copper T Intrauterine contraception device|IUCD inserted upon randomization to this study arm
75652921|NCT00807703|Procedure|Select Stim|Select Stim: see summary
76089315|NCT01911910|Behavioral|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
76089316|NCT03820791|Device|Placement of a poster in patients' rooms|Patients and their caregivers will be exposed to the poster for one month
76089317|NCT03823989|Drug|Promitil|The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
75652922|NCT02551549|Drug|CD101 IV|antifungal
75652923|NCT02551549|Drug|Placebo|Normal saline
75652924|NCT00646399|Drug|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
75652925|NCT00646399|Drug|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
75800611|NCT03784950|Behavioral|Feedback|eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
75800612|NCT03784794|Diagnostic Test|Thromboelastometry|devices generate output by transducing changes in the viscoelastic strength of a small sample of clotting blood (300 µl) to which a constant rotational force is applied. These point of care devices allow visual assessment of blood coagulation from clot formation, through propagation, and stabilization, until clot dissolution. Computer analysis of the output allows sophisticated clot formation/dissolution kinetics and clot strength data to be generated
75800613|NCT03784794|Diagnostic Test|Standard Coagulation Test|coagulation tests, such as the prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT), to assess blood clotting function in patients. Clauss Fibrinogen.
75800614|NCT03784794|Drug|Fibrinogen Concentrate Human|To treat acquired fribinogen deficiency investigators will treat with the following doses FIBTEM A5 = 9-11 MM a 2 G FIBRINOGEN CONC. (25 MG/KG); FIBTEM A5 = 4-8 MM a 4 G FIBRINOGEN CONC. (50 MG/KG); FIBTEM A5 < 4 MM a 6 G FIBRINOGEN CONC. (75 MG/KG)
75800615|NCT03784794|Drug|Prothrombin Complex Concentrates|to treat acquired factor deficiency investigators will treat as follows PROTROMBIN COMPLEX CONCENTRATE EXTEM CT > 80 SEC AND FIBTEM A5 ≥ 8 MM 4F-PCC 20 IU/KG (F II, VII, IX and X) GOAL: EXTEM CT ≤ 80 SEC
75800616|NCT03784794|Other|Platelets|PLATELETS EXTEM A5 < 40 MM AND FIBTEM A5 ≥ 12 MM EXTEM A5 < 40 MM → 1 PLATELET POOL OR APHERESIS; EXTEM A5 < 30 MM → 2 PLATELET POOL OR APHERESIS GOAL: EXTEM A5: 40-50 MM or PLATELET COUNT < 100/µL PLT < 100/µL → 1 PLATELET POOL OR APHERESIS; PLT > 50/µL → 2 PLATELET POOL OR APHERESIS GOAL: PLT COUNT > 100/µL
75938573|NCT02318511|Procedure|Knee injection|Injection into knee for the treatment of Osteoarthritis
75938574|NCT02318511|Other|ReNu amniotic allograft|
75938575|NCT02318511|Device|placebo saline|
75938576|NCT02318511|Device|Hyaluronic Acid|
75652926|NCT00807781|Biological|Mammaglobin-A DNA vaccine|
75652927|NCT00810121|Drug|ketoprofen 100 mg|100 mg b.i.d. for 5 days
75652928|NCT00810121|Drug|ketoprofen|150 mg b.i.d. for 5 days
75800617|NCT03784794|Other|Red Blood Cells|"Transfuce Red Blood Cells if Hemoglobine levels < 7 G/DL;~1 unit of FFP for every unit of RBC Transfused GOAL: Hb > 7.5 G/DL"
75800618|NCT03784794|Other|Fresh Frozen Plasma|FRESH FROZEN PLASMA TP AND/OR TTP PATHOLOGICAL INR, 2.0-4.0 → FFP 20 ML/KG GOAL: TP AND TTP NORMAL AND INR < 2.0
75938577|NCT02315391|Dietary Supplement|isolated whey protein|isolated whey protein
75652929|NCT02552875|Other|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
75652930|NCT02552875|Other|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
75652931|NCT00652327|Drug|Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)|ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
75652932|NCT00652327|Drug|Double Statin (simvastatin, atorvastatin, or pravastatin)|simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
75652933|NCT00814021|Drug|sunitinib malate|
75652934|NCT02551627|Dietary Supplement|Test Product|MMN fortified beverage powder.
75652935|NCT02551627|Dietary Supplement|Control|Isocaloric beverage powder without micronutrient fortification.
75652936|NCT00814099|Behavioral|Team approach to sedation management|"The team approach to sedation management includes the following:~Team education and consensus on the use of sedatives~Team identification of the patient's trajectory of illness and daily prescription of a sedation goal~A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines~Team feedback on sedation management performance"
75938578|NCT02315391|Dietary Supplement|micellar whey protein|micellar whey protein
75938579|NCT02315391|Dietary Supplement|glycine|glycine
75938580|NCT02315391|Dietary Supplement|citrulline|citrulline
75938581|NCT02318745|Behavioral|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
75938582|NCT02318745|Behavioral|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
75938583|NCT03022981|Drug|SOF/VEL|SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
75938584|NCT03022981|Drug|SOF/VEL|SOF/VEL FDC 200/50 mg oral granules
75938585|NCT03164967|Biological|Bivigam|
75652937|NCT00814099|Behavioral|Usual approach to sedation management|The pediatric ICU will continue its usual approach to sedation management.
75652938|NCT00808093|Drug|GSK256073|GSK256073 100 mg study drug
75652939|NCT00645853|Drug|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
75652940|NCT00645853|Drug|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
75652941|NCT02551783|Procedure|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
75342505|NCT00722072|Drug|fulvestrant|Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
75342506|NCT00722072|Drug|sorafenib tosylate|Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
75652942|NCT02551783|Procedure|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
75652943|NCT00652093|Drug|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
75652944|NCT00652093|Drug|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
75652945|NCT00652093|Drug|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
75652946|NCT00652093|Drug|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
75652947|NCT00652093|Drug|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
75652948|NCT00652093|Drug|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
75652949|NCT00651937|Drug|Melphalan|100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
75652950|NCT00651937|Procedure|Stem Cell Infusion|"Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0."
75652951|NCT00651937|Behavioral|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
75652952|NCT00651937|Drug|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
75652953|NCT00651937|Procedure|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
75652954|NCT00654355|Drug|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
75652955|NCT00651313|Drug|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
75652956|NCT00651313|Drug|Placebo|Placebo vaginal gel administered once daily for 4 days
75652957|NCT02551705|Other|functional Imaging|Brain responses associated with emotional memory will be investigated
75800619|NCT03784794|Other|cryoprecipitates|FIBRINOGEN (CLAUSS) < 250 MG/DL FIB 200-250 MG/DL → CRYOS, PACK OF 10 (25 MG/KG); FIB 100-200 MG/DL → CRYOS, PACK OF 20 (50 MG/KG); FIB < 100 MG/DL → CRYOS, PACK OF 30 (75 MG/KG) GOAL: FIB > 250 MG/DL
75938586|NCT03502005|Drug|bictegravir/emtricitabine/tenofovir alafenamide|Discontinue ATRIPLA® and initiate BIKTARVY®
76089318|NCT03823989|Radiation|EBR|A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
76089319|NCT03826719|Biological|NBP607QIV|Purified inactivated influenza virus surface antigens of four strains(quadrivalent)
76089320|NCT03826719|Biological|Agrippal|Influenza virus surface antigens of three strains(trivalent)
75819708|NCT02174614|Behavioral|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
75819709|NCT02179528|Drug|Etoposide|
75938587|NCT03501927|Diagnostic Test|FOCUS (focused cardiac ultrasound)|"A ultrasound of the heart and pleura will be performed. This provide information on~Left ventricular systolic function~Left ventricular diastolic function~Right ventricular systolic function~Right ventricular pressure overload~Biventricular sizes~Pathology of the mitral- and aortic valves~Pericardial fluid~Gross fluid status~Pleural effusion"
75938588|NCT04058821|Diagnostic Test|Novel MRI scan - 7 days post injury|"A turbo spin-echo localiser (20 seconds)~Single-shot echo planar diffusion tensor imaging (7 minutes)~3D constructive interference in steady state (CISS, 6 minutes)~Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
76089321|NCT03823677|Procedure|Hypoxia|hypoxia
76089322|NCT01951066|Drug|Dexamethasone Implant|Patients will receive a single injection of a dexmethasone implant
75800620|NCT05074446|Other|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/she belongs.~Stereotype threat manipulation will be performed on the intensivist and non-intensivist participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare the cardiopulmonary resuscitation performance between intensive care units and other branches. The other participants (Control Group) will not be given any prior information."
75342507|NCT04385186|Drug|Inactivated convalescent plasma|"Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol~Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma"
75342508|NCT04385186|Drug|Support treatment|Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
75342509|NCT04385420|Drug|ATR-002 MEK Inhibitor|Drug ATR-002 administered as film-coated tablet via oral route
75342510|NCT04385420|Drug|Placebo oral tablet|Placebo film-coated tablet administered via oral route
75342511|NCT00737360|Drug|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
75342512|NCT01279226|Device|Auralevée device|Single treatment with Auralevée device.
75342513|NCT01276106|Drug|AC-201, 25mg|Capsule, 25mg BID
75342514|NCT01276106|Drug|AC-201, 50mg|Capsule, 50mg BID
75342515|NCT01276106|Drug|AC-201, 75mg|Capsule, 75mg BID
75652958|NCT00808171|Drug|Livopan|Inhalation of oxygen and nitrous oxide 50%
75652959|NCT00808171|Drug|Livopan|equimolar mixture of N2O/O2
75800621|NCT01378546|Drug|3,4-diaminopyridine|Treatment will begin with 5mg three times a day or less.
75938589|NCT04058821|Diagnostic Test|Novel MRI scan - 14 days post injury|"A turbo spin-echo localiser (20 seconds)~Single-shot echo planar diffusion tensor imaging (7 minutes)~3D constructive interference in steady state (CISS, 6 minutes)~Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
75652960|NCT00808171|Drug|EMLA|Lidocaine-prilocain cream
75652961|NCT00814411|Behavioral|group family planning counseling|group family planning counseling for gynecological patients with unmet need
75652962|NCT00814411|Behavioral|Individual family planning counseling|Individual family planning counseling with gynecological patients - the current standard of care
75652963|NCT04703257|Drug|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days. .
75652964|NCT04703257|Drug|Placebo|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
75652965|NCT00808327|Drug|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
75652966|NCT00808327|Drug|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
75652967|NCT00814567|Radiation|radiation therapy|Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
75652968|NCT00814645|Drug|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
75938590|NCT04058821|Diagnostic Test|Functional MRI scan - 6 months post brachial plexus exploration|"Continuous whole brain echo-planar imaging~High-resolution T1-weighted imaging of the brain~Bilateral magnetic resonance spectroscopy (12 minutes)"
75342516|NCT01276106|Drug|Placebo|Placebo BID
75342517|NCT01275170|Drug|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
75938591|NCT04058821|Diagnostic Test|Functional MRI scan - 12 months post brachial plexus exploration|"Continuous whole brain echo-planar imaging~High-resolution T1-weighted imaging of the brain~Bilateral magnetic resonance spectroscopy (12 minutes)"
76025797|NCT05898308|Drug|RiTUXimab Injection|"Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels."
76025798|NCT05898295|Other|no intervention|No intervention: only observation of the child behavior
76025799|NCT05898282|Other|observation|since this is a cross sectional observational study any form of intervention was not applicable
75342518|NCT01275170|Drug|Imipenem + Cilastatin|250 mg IV over 30 minutes as a single dose
75342519|NCT01275170|Drug|Caffeine|Caffeine caplet, single 200 mg dose, orally
75342520|NCT01275170|Drug|Midazolam|Midazolam hcl syrup single 2.0 mg dose by mouth.
75342521|NCT01275170|Drug|Omeprazole|Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
75342522|NCT04385654|Drug|Toripalimab|Toripalimab (240 mg,ivgtt,q3w) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
75652969|NCT00814645|Drug|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
75652970|NCT00814723|Drug|fluvastatin|80 mg MR, 12 weeks
75652971|NCT00814723|Drug|Fluvastatin plus ezetimibe|fluvastatin 80 mg MR plus ezetimibe 10 mg
76025800|NCT05898256|Drug|Cadonilimab|10mg/kg administered intravenously (IV)
75342523|NCT04385654|Drug|Axitinib|Axitinib (5 mg,po,qd) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
75342524|NCT01272674|Other|exercise training|4 weeks supervised physical exercise training
75342525|NCT00400634|Drug|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10^11 vg
75342526|NCT00400634|Procedure|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
75800622|NCT05690412|Procedure|Endoscopic Papillectomy|Endoscopic resection of ampullary neoplasm
75800623|NCT04247308|Other|Sensory Stimulation|Auditory, tactile, visual, vestibular and oro motor stimulation
75800624|NCT04247308|Other|Movement therapy|Passive range of movements, antigravity movements in prone and supine
75938592|NCT02315547|Drug|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
76089323|NCT01951066|Drug|Anti-VEGF injection|Patients will receive PRN injections of an anti-VEGF agent
75652972|NCT00810433|Procedure|GO-LIF - Guided Oblique Lumbar Interbody Fusion|"All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.~Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.~Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused."
75652973|NCT00969761|Drug|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
75652974|NCT00969761|Drug|BI 6727|low to high dose
75652975|NCT00845871|Drug|deferasirox:|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
75652976|NCT02864849|Drug|Oxaliplatin|
75938593|NCT02309541|Device|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
75652977|NCT02864849|Drug|Capecitabine|
75652978|NCT02864849|Radiation|Intensity modulated radiotherapy|
75652979|NCT02864849|Procedure|Total mesorectal excision|
75652980|NCT00915278|Drug|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
75938594|NCT03669445|Drug|Ixazomib|21-day cycles induction and 28-day cycles consolidation
75938595|NCT03669445|Drug|Lenalidomide|21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
75938596|NCT03669445|Drug|Dexamethasone|21-day cycles induction and 28-day cycles consolidation
75938597|NCT03669445|Drug|Daratumumab|21-day cycles induction and 28-day cycles consolidation
75938598|NCT02309619|Procedure|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
75938599|NCT03669835|Dietary Supplement|Mare milk supplement|Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
75938600|NCT03669835|Drug|Standard therapy|For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
75938601|NCT03501849|Device|Polypectomy using a cold snare|Polypectomy by cold-snare technique
75938602|NCT03500133|Radiation|No radiotherapy if CR at the end of chemotherapy.|Adapted chemotherapy without radiotherapy
75938603|NCT03500133|Drug|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
75342527|NCT01273064|Drug|CTS-1027|Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
75652981|NCT00701961|Drug|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
75800625|NCT04247308|Other|Routine hospital care|Maintaining the vitals
75800626|NCT05688384|Drug|Propofol + Alfentanil|In addition to LA, patients in the study group are able to self-administer a combination of propofol and alfentanil using a patient-controlled sedation pump. The pump enables the patient via a hand-held button to trigger the release of a single bolus of 0.5ml containing 4.5mg propofol and 25µg alfentanil under an 10second period. This results in a maximal possible amount of 6 bolus doses per minute.
75800627|NCT03075904|Drug|ALXN1830|Administered via IV infusion.
75800628|NCT01307592|Biological|rituximab|
75938604|NCT03500133|Drug|Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
76025801|NCT05898256|Drug|Gemcitabine|1 g/m2, administered as an IV infusion within 30 minutes
75800629|NCT01307592|Drug|gemcitabine hydrochloride|
75800630|NCT01307592|Drug|lenalidomide|
76025802|NCT05898256|Drug|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
76025803|NCT05898204|Other|Ketogenic diet|Prescription of a ketogenic diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
76025804|NCT05898204|Other|Balanced diet|Prescription of a balanced diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
75938605|NCT03500133|Radiation|IN 30Gy RT in case of PR at the end of chemotherapy|Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT
75938606|NCT03500133|Drug|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
75938607|NCT03500133|Drug|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
75938608|NCT03500133|Drug|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
75938609|NCT03500133|Drug|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
75652982|NCT04286711|Drug|Albumin-paclitaxel, Apatinib, Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8, Repeat the therapeutic schedule every 3 weeks; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day, Q3W;
75800631|NCT01307592|Drug|oxaliplatin|
75800632|NCT03790410|Other|Complex pulmonary rehabilitation|Complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.
75800633|NCT03790410|Other|Inspiratory muscle training|The training program contains strengthening exercises on the diaphragm muscle.
75800634|NCT03630250|Biological|N. lactamica|Genetically modified N. lactamica
75800635|NCT01378468|Other|"oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)"|see Ebinger et al., IJS, 2010
75800636|NCT01378390|Drug|Expanded autologous adipose-derived adult stem cells (eASCs)|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
75800637|NCT01378390|Drug|Placebo|Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
75800638|NCT03790020|Drug|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
75800639|NCT05763784|Device|Tightrope|Tightrope use special fiber and a set of metal buttons to fix diastasis of a joint.
75938610|NCT03500133|Drug|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
75938611|NCT02315781|Device|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
76089324|NCT05735626|Combination Product|Piperine 150μM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 150μM + tDCS 2mA (cross-over randomized study).
76089325|NCT05735626|Combination Product|Piperine 1mM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 1mM + tDCS 2mA (cross-over randomized study).
76089326|NCT05735626|Combination Product|Capsaicin 10μM + tDCS 2mA|2 days treatment with either sham + placebo or capsaicin 10μM + tDCS 2mA (cross-over randomized study).
76089327|NCT03826329|Other|observational study|this is an observational study, there is no intervention in this study
76089328|NCT03826017|Dietary Supplement|Catechin high contain greentea extract|Catechin high contain greentea extract 260 mg/day for 12 weeks.
75342528|NCT01273064|Drug|pegylated interferon|180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
75652983|NCT04115709|Device|Beacon Caresystem device with advice|Beacon Caresystem device provides ventilator settings advice to Doctors
75800640|NCT05685654|Device|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
75800641|NCT01308996|Device|INFUSE® Bone Graft|Implantation of INFUSE® Bone Graft [recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device
75938612|NCT02315781|Device|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
75938613|NCT02315937|Procedure|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
75938614|NCT02316015|Dietary Supplement|Infatrini® or Infatrini Peptisorb®|
76089329|NCT03826017|Dietary Supplement|Placebo|Placebo for 12 weeks.
76089330|NCT01913314|Drug|[^14C]-LY2835219|Administered as oral solution
75652984|NCT04115709|Device|Beacon Caresystem device without advice activated|Beacon Caresystem device does not give ventilator settings advice
75652985|NCT02863913|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
75652986|NCT02863913|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
75938615|NCT02316093|Other|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
75342529|NCT01273064|Drug|Ribavirin|200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
76089331|NCT04768192|Procedure|Physical Rehabilitation without lokomat|"Conventional physiotherapy is performed in 10 weekly sessions (45 minutes each) over 4 weeks(total 40 sessions).~Specific exercises are administered to improve gait, balance and functional abilities focusing on:~strengthening the gluteus and quadriceps muscles stretching the hip flexor and hamstrings muscles increasing static balance increasing dynamic balance increasing functional abilities improving ground gait going up and down the stairs.~Physiotherapists can choose from a list of 25 standard exercises, according to some constraints:~strengthening exercises had to involve all the lower limb joints (no segmental intervention)~during each session, at least 4 out of the 7 categories above had to be delivered~the impossibility to perform any of the categories above during any session had to be recorded in the patient's treatment diary.~Physiotherapists of the treatments group discuss patients' diaries during weekly meetings."
75342530|NCT01273064|Drug|Placebo|"Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo)."
75342531|NCT01279382|Behavioral|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
75938616|NCT04462653|Device|Wearable Dynamic ECG Recorder|use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation
75342532|NCT01279382|Behavioral|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
75342533|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
75652987|NCT02863913|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
75652988|NCT02612649|Drug|Ramosetron|Oral
75652989|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula|A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
75800642|NCT01308996|Procedure|Autogenous bone graft from tibia or iliac crest|Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
75938617|NCT04462653|Device|12-lead ECG recordings|use a 12-lead ECG recordings to record heart rate and atrial fibrillation
75938618|NCT04462809|Drug|Talazoparib|"Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment."
75938619|NCT04462575|Procedure|Onlay bone block covered using collagen membrane|The ratio is 40% of xenogenic bone particles (low resorption rate) to 60% of autogenous bone particles (contains viable cells) to be placed in recipient decorticated site and covered by onlay bone block..
75938620|NCT04462575|Procedure|Onlay bone block without collagen membrane|Onlay bone block without collagen membrane
75938621|NCT02320773|Drug|Betmiga®|Oral
75938622|NCT03498651|Behavioral|Cognitive Bias Modification - Interpretation training|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.
75938623|NCT03498651|Behavioral|Coaching|Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.
75342534|NCT01272986|Device|ALOA IgG-Elisa|measurement of IgG Level in blood
75342535|NCT01272986|Device|ALOA IgG-AtheroAbzyme|measurement of IgG in blood
75342536|NCT01272908|Drug|rituximab|1000 mg intravenously on Days 1 and 15
75652990|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure|CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
75652991|NCT00702039|Other|No Music|No music will be played in patients in arm 2 of the study.
75652992|NCT00702039|Other|Music Therapy|Classical music being played during intravitreal injection.
75800643|NCT01378312|Biological|AERAS 402|0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
75938624|NCT03498651|Behavioral|Online psychoeducation about anxiety|Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.
75342537|NCT01271504|Drug|Sorafenib|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
75342538|NCT01271504|Drug|Sorafenib|"E7050 given orally at 200, 300 or 400 mg once daily.~Sorafenib given orally, 400 mg twice daily."
75342539|NCT02144714|Biological|SB5|
75342540|NCT02144714|Biological|EU sourced Humira®|
75342541|NCT02144714|Biological|US sourced Humira®|
75342542|NCT01279538|Drug|bleselumab|Intravenous (IV) infusion
75342543|NCT01279538|Drug|Placebo|Intravenous (IV) infusion
75342544|NCT00741026|Drug|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
75342545|NCT00741026|Drug|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
75800644|NCT01378312|Biological|Placebo|0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
75938625|NCT02320851|Behavioral|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
75800645|NCT04409470|Diagnostic Test|Blood gas sampling from artery and vein|Patients included in this study are treated according to clinical routine. After inclusion, sampling of an arterial blood gas and a venous blood gas is performed simultaneously or as close in time as possible. Because the venous blood gas analysis sample can be taken directly from the patient's peripheral venous catheter, no additional venous puncture is usually required and the additional amount of blood that may be required is approx. 1 ml (the assay requires about 500 µl). In the very rare cases where it is not possible to establish a peripheral venous catheter within a reasonable time, the sample will be acquired from a new venous puncture together with other venous routine samples.
75938626|NCT02320851|Behavioral|Self-help group (SHG)|(see description of corresponding study arm)
75938627|NCT02309775|Other|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
75938628|NCT03377699|Drug|Insulin degludec|Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months
75800646|NCT03789942|Procedure|Oral surgery|Oral surgery procedures
75938629|NCT03377699|Drug|Insulin Aspart|Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months
75938630|NCT03377699|Drug|Insulin detemir|Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily. The total trial duration for subjects will be maximum 25 months
75938631|NCT04463901|Procedure|Pterygium excision|Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
75938632|NCT04463901|Procedure|Intraoperative mitomycin C|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
75938633|NCT04463901|Procedure|Conjunctival autograft|A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
75938634|NCT04463901|Procedure|Limbal conjunctival autograft|A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
75938635|NCT02309853|Other|Visual and tactile scanning training|"20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~Visual or tactile scanning in the personal space~Visual or tactile scanning and trunk rotation in the peripersonal space~Visual scanning and trunk rotation in the extrapersonal space"
75938636|NCT02309853|Other|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
75938637|NCT03505827|Diagnostic Test|24-2 SITA Standard Humphrey Visual Field Test|Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
75938638|NCT03500055|Procedure|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
75938639|NCT04752449|Behavioral|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
75938640|NCT02318823|Other|Beer (alcoholic)|Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
75938641|NCT02318823|Other|Placebo (non-alcoholic beer)|Non-alcoholic beer serves as Placebo.
75938642|NCT05224817|Other|Necrotizing soft tissue infections (NSTIs)|There will be no direct interaction with subjects and involves no interventions; study is conducted completely via review of electronic health records. Our site will only collect data from the Methodist Dallas Medical Center.
75938643|NCT02319057|Drug|ORM-12741 MR A|Modified release formulation of ORM-12741
75938644|NCT02319057|Drug|ORM-12741 IR|Immediate release formulation of ORM-12741
75938645|NCT02319057|Drug|ORM-12741 MR B|Modified release formulation of ORM-12741
75342546|NCT00741104|Drug|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
75938646|NCT01314443|Other|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
75938647|NCT01314443|Dietary Supplement|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
75938648|NCT01314443|Other|Placebo|Participants will take placebo for 7 days
75938649|NCT01314443|Behavioral|Smoking cessation|Participants will quit smoking without any pharmacological aids
75938650|NCT02310009|Drug|Anakinra (AN)|
75342547|NCT01273298|Drug|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
75938651|NCT02310009|Behavioral|Exercise (EX)|
75938652|NCT02310009|Behavioral|Control (CON)|
75938653|NCT03498573|Other|tunneling surgical technique|sticky bone prepared by centrifuge patient blood and mixing with xinograft
75938654|NCT05655065|Procedure|increase of mean arterial pressure at 65-70 mmHg|Increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion at the discretion of the clinician)
75938655|NCT05655065|Procedure|increase of mean arterial pressure at 80-85 mmHg|Increase of mean arterial pressure at 80-85mmHg (with catecholamines or volemic expansion at the discretion of the clinician).
75652993|NCT05237102|Procedure|Cerebrospinal fluid shunt|"The procedure is designed to reduce the amount of cerebrospinal fluid in a patient's brain by draining it through a shunt tube:~①V-P shunt is suitable for most types of hydrocephalus; ②L-P shunt is suitable for traffic hydrocephalus and positive pressure hydrocephalus, and patients with lower cerebellar tonsil hernia are contraindications; ③ Common terms of ventriculoatrial (V-A) shunt are not suitable for V-P shunt (abdominal infection, serious respiratory and circulatory diseases are contraindications); ④ The third ventriculostomy is suitable for patients with non-traffic and partial traffic hydrocephalus （infants and patients with severe ventricular enlargement should be cautious, and patients with shunt tube cannot be placed due to ventricular conditions）; ⑤Other shunt methods include septum pellucidum fistula and Torshunt （ventriculo-occipital cistern shunt after tumor resection）"
75938656|NCT03498417|Diagnostic Test|Serum antibodies against the IGF-1R|Measurement of antibodies against the IGF-1R in serum samples by ELISA
75938657|NCT03212651|Drug|Pembrolizumab|Pembrolizumab 200mg IV infusion
75938658|NCT03499977|Behavioral|Sitting|10 min bouts
75938659|NCT03499977|Behavioral|Light-Intensity Cycling|10min bout
75938660|NCT03499977|Behavioral|Moderate-Intensity Cycling|10 min bout
75938661|NCT03499977|Behavioral|High-Intensity Cycling|10 min bout
75938662|NCT02319135|Drug|Azacitadine|
75938663|NCT02319135|Drug|Fludarabine|
75938664|NCT02319135|Drug|Cytarabine|
75938665|NCT02319135|Drug|Lenograstim|
75938666|NCT02319135|Drug|Filgastrim|
75342548|NCT01273298|Drug|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
75342549|NCT01273376|Drug|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
75938667|NCT05242991|Device|Photobiomodulation therapy|Light therapy for the management of oral side effects related to radiotherapy, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief.
75342550|NCT01270958|Drug|Avamys aqueous nasal spray 110mcg|"At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken."
75938668|NCT02319213|Other|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
75342551|NCT01270880|Drug|Hsp90 inhibitor STA-9090|Given IV
75342552|NCT01270880|Other|laboratory biomarker analysis|Correlative studies
75342553|NCT01270880|Genetic|polymerase chain reaction|Correlative studies
75342554|NCT01270880|Other|enzyme-linked immunosorbent assay|Correlative studies
75652994|NCT00844857|Drug|Olanzapine Fluoxetine Combination (OFC)|OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
75652995|NCT00844857|Drug|Placebo|Orally, once daily in the evening for 8 weeks.
75652996|NCT05158088|Device|Borescope|Endotracheal intubation using borescope
75652997|NCT05158088|Device|Video laryngoscope|Endotracheal intubation using video laryngoscope
75652998|NCT04712240|Device|Respiration rate monitor|A portable continuously monitoring respiration rate monitor will be fitted to each participant. The respiration rate monitor is housed within a comfortable chest strap that be secured to the participant for the duration of the surgical procedure
75652999|NCT00702117|Drug|flecainide|2 mg/kg iv in 10 minutes
75938669|NCT02319213|Other|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
75938670|NCT02319213|Other|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
75938671|NCT03498183|Drug|MIBI-Tc99m/Iodine-123|Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
75938672|NCT03499743|Drug|hyoscine butyl bromide|intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion
75938673|NCT03499743|Drug|Celecoxib 200mg|Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
75938674|NCT03499743|Drug|Placebo Oral Tablet|a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
75938675|NCT03498027|Device|TaqMan Bacillus anthracis Detection Kit|The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
75938676|NCT02310087|Dietary Supplement|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
75938677|NCT02310087|Other|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
75938678|NCT02310165|Procedure|Z-tract Insertion Technique|
75938679|NCT02310165|Procedure|Coaxial Insertion Technique|
75938680|NCT02923921|Biological|Pegilodecakin|Pegilodecakin plus FOLFOX
75938681|NCT02923921|Drug|FOLFOX|FOLFOX Alone
75938682|NCT02310243|Drug|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
75342555|NCT01270880|Genetic|RNA analysis|Correlative studies
75342556|NCT01270880|Other|spectrophotometry|Correlative studies
75342557|NCT01270880|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
75938683|NCT05223569|Device|Home OCT monitoring model|A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester
75342558|NCT01270880|Genetic|gene expression analysis|Correlative studies
75342559|NCT01270802|Drug|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
75342560|NCT01270802|Drug|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
75342561|NCT01270802|Drug|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
75653000|NCT00702117|Drug|ajmaline|1 mg/kg iv in 10 minutes
75653001|NCT00702117|Drug|procainamide|10 mg/kg iv in 10 minutes
75653002|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
75653003|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
75800647|NCT03784872|Procedure|Laparoscopic guided Ventrosuspension|Laparoscopy was done. Under vision the skin overlying the attachment of the round ligament to the anterior abdominal wall was incised followed by introduction of 30 curved needle attached to absorpable Vicryl 2/0 suture through the incision and withdrawn through grasper under laparoscopi vision. The needle was turned around the round ligament all through its length to plicate it then the needle was pushed again beside its entry side to appear at the skin incision. The same was repeated on the other side and both sutures were tied at the subcutaneous tissue simultaneously. then the laparoscopy was withdrawn followed by closure of the skin incision.
75938684|NCT05223569|Device|Hospital-based monitoring with a staff-administrated OCT|Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
75938685|NCT02989571|Drug|Intravenous normal saline administered at 250ml/hr|Intravenous normal saline administered at 250ml/hr
76117219|NCT03710603|Drug|Daratumumab|Daratumumab will be given at a dose of 1800 mg SC weekly in Cycles 1 and 2, then every 2 weeks in Cycles 3-6. In maintenance Cycles 7+, subjects will receive daratumumab once every 4 weeks until disease progression or unacceptable toxicity. MRD-negative subjects will stop daratumumab after sustained MRD negativity for 12 months & after a min. of 24 months of maintenance. Daratumumab should be restarted at recurrence of MRD or confirmed loss of CR without disease progression.
75653004|NCT00913107|Drug|Lamictal®|"The regime of prescription for Lamictal® during the clinical trials was as follows:~50 mg twice daily for 10days, followed by,~100 mg twice daily for the next 10days, followed by,~100 mg thrice daily for the next10 days, followed by,~100 mg four times daily for the final 10 days."
75938686|NCT02989571|Drug|Intravenous normal saline administered at 125ml/hr|Intravenous normal saline administered at 125ml/hr
75342562|NCT01273454|Drug|OROS Hydromorphone|8,16, 32 mg once a day for 4 weeks
75342563|NCT01270256|Drug|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
75342564|NCT01270256|Drug|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
75653005|NCT00913107|Drug|Tegretol®|"The regime of prescription for Tegretol® during the clinical trials was as follows:~150 mg twice daily for 10days, followed by,~200 mg thrice daily for the next 10days, followed by,~300 mg thrice daily for the next 10 days, followed by,~300 mg four times daily for the final 10 days."
75653006|NCT00569803|Drug|belatacept|single dose, 116 days
75653007|NCT00569803|Drug|Placebo|Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
75653008|NCT00913185|Drug|Acne Free, Proactiv|
75342565|NCT01279694|Drug|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
75342566|NCT01279694|Drug|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
75342567|NCT01279694|Drug|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
75342568|NCT01273532|Drug|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
75342569|NCT01273532|Drug|tapentadol (CG5503) ER 50-mg TRF|100 mg TRF single oral dose
75342570|NCT04386434|Behavioral|Active for Life: Assisted Living|"Each intervention session will take place within the assisted living facility twice a week for 12 weeks.~Sessions will begin with 5-10 minutes of walking in the hallway. Participants will be encouraged to walk at their own pace and allowed to take breaks if needed.~Next, behavioral strategies based on the construct of self-efficacy from social cognitive theory and education about physical activity will be delivered. This component is scheduled between the walking and circuit training, lasts 15-20 minutes, and serves as a rest period.~Circuit training will focus on strength and balance. Approximately 8 exercise stations will be set up, and the exercises performed at each station will be changed approximately every 4 weeks. The circuit training will last ~30-40 minutes, with participants moving from one station to the next at their own pace and taking breaks in between."
75342571|NCT00744380|Drug|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
75653009|NCT00920426|Drug|GSK1265744 30mg|GSK1265744 30 mg
75653010|NCT00920426|Drug|Placebo|Placebo to match GSK1265744
75653011|NCT00920426|Drug|GSK1265744 5mg|GSK1265744 5mg
75653012|NCT04046185|Drug|PD-1 inhibitor combined progesterone|Toripalimab combine with progesterone
75653013|NCT04046185|Drug|progesterone|progesterone
75653014|NCT00810589|Drug|Levemir|0,4 IE per kg bodyweight
75800648|NCT03789708|Dietary Supplement|Gum Arabic|Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
75800649|NCT03789708|Other|Placebo|Maltodextrin powder, easily soluble
75938687|NCT03497793|Other|SNUBY|Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
75938688|NCT02319447|Behavioral|Additional education|"Our Intervention includes a 60-90 minute educational seminar, entitled Destination: Transplant, featuring live speakers, delivered to small groups of Black kidney transplant candidates and their family and friends. Topics include: 1) basic facts about Chronic Kidney Disease (CKD), transplant, and the waiting list; 2) the experience of receiving a LDKT transplant (by a Black LDKT recipient); 3) the experience of serving as a living kidney donor (by a Black living kidney donor); and 4) strategies to increase the chances of getting a transplant sooner. Participants receive monthly mailed, written information for 9 months and a follow-up phone call from a transplant educator, 3 months after attending the seminar."
75342572|NCT00744380|Drug|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
75653015|NCT00810589|Drug|Humalog NPL Insulin|0,4 IE per kg bodyweight
75653016|NCT00810667|Drug|Lu AE58054|twice daily oral dose (60 mg BID: total dose 120 mg/day)
75653017|NCT00810667|Drug|Placebo|twice daily oral dose
75653018|NCT00810745|Procedure|starr|stapled transanal rectal resection
75800650|NCT03073798|Drug|Roflumilast|500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
75800651|NCT03073798|Drug|Placebo|500 mcg of placebo is used
75800652|NCT04083274|Other|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
75938689|NCT02321085|Procedure|Sinus Rhythm control|
75938690|NCT02321085|Procedure|Pulse Rate control|
75938691|NCT03625661|Drug|Ferinject|Ferinject 50mg/ml, one injection
76089332|NCT04768192|Procedure|Physical Rehabilitation with Lokomat|"The rehabilitation protocol consists of 20 sessions of robotic training alternated with 20 sessions of conventional physiotherapy (CP). Each treatment is performed in 5 weekly sessions (45 minutes each) over 4 weeks.~Robotic training aimed to recovery/improve walking capacity from the initial Gross Motor Function Classification System (GMFCS) level. It is performed using the Lokomat® (Hocoma AG, Volketswil, Switzerland) gait orthosis. Initial set ups includes 50% body weight unload, gait velocity adjusted on the patient individual capability (1.5 km/h on average) and 100% guidance force. Both weight unload and guidance force are gradually reduced across sessions according to patient recovery of muscle strength and allowing patients to work harden and move more freely.~Children engagement, active participation and motivation were reinforced through frequent encouragement by therapists and performance feedback implemented in the exercise video-games."
76089333|NCT03826251|Procedure|Nasogastric tube removal|Nasogastric tube was removed immediately after surgery
76089334|NCT01951768|Drug|Garamycin Sponge (Gentamicin-Collagen sponge)|Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
76089335|NCT01951768|Drug|Systemic Antibiotic|"Antibiotics options per protocol:~Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h"
76089336|NCT04758585|Procedure|Arthroscopy|Shoulder Arthroscopy
76089337|NCT02987140|Behavioral|Clinical evaluations|Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
76089338|NCT04273659|Dietary Supplement|Pulses and cereals|Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.
75938692|NCT03497715|Drug|Ibuprofen lysine|Test 1
75938693|NCT03497715|Drug|Ibuprofen Sodium|Test 2
75342573|NCT00744692|Biological|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
75342574|NCT00744692|Drug|Reduced Intensity Conditioning|
75938694|NCT03497715|Drug|Ibuprofen|Test 3
75938695|NCT03497715|Drug|Ibuprofen (Nurofen)|Reference 1
75938696|NCT03497715|Drug|Ibuprofen (Wockhardt)|Reference 2
75342575|NCT00744848|Drug|Bupivacaine HCl|100 mg Bupivacaine HCl
75342576|NCT00744848|Drug|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
75653019|NCT04240340|Other|semi-structured interview|Semi-structured, face-to-face interviews will be carried out with participants.
75653020|NCT02552485|Other|No intervention was applied, because it is an observational study|
75653021|NCT04253132|Drug|Tolfenamic Acid|Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
75653022|NCT04253132|Drug|Placebos|oral placebo
75653023|NCT00814957|Drug|GSK618334|D3 receptor antagonist
75653024|NCT05136404|Drug|Selpercatinib|Administered orally
75653025|NCT05054816|Device|Investigational adaptive directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the investigational adaptive directional microphone strategy that is expected to improve sound quality of speech in a car.
75342577|NCT00745940|Behavioral|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
75342578|NCT03830606|Drug|Nab-paclitaxel,S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-14, q3w)
75342579|NCT04385342|Drug|FSH|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
75653026|NCT05054816|Device|Comparator omnidirectional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator omnidirectional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
75653027|NCT05054816|Device|Comparator fixed directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator fixed directional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
75653028|NCT00644995|Behavioral|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
75653029|NCT00644995|Behavioral|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
75800653|NCT04083274|Other|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded"
75800654|NCT03787056|Other|Blood draws|"Blood draws are realized at each steps of patient disease management. The volume of each blood drawn is 25 mL for progastrin measurements and 5 mL for the dosage of the other tumor markers. The frequency depend to the cancer and treatment administered :~Baseline at diagnosis : Local radical treatment : within 24h before surgery, within 24h after surgery and at the post-surgery follow up visit~Chemotherapy treatment : every 3 or 4 weeks~Radiotherapy : start day and at the end of radiation (end of treatment visit)~Palliative systemic treatment (only palliative cohorts) : every 3 to 12 weeks. Follow until the third progression or change of treatment line, or alternatively up to 5 years after inclusion~In case of PD or TOX~Follow up: at each visit scheduled (every 3 months) for the first 2 years, then every 6 months for 3 years~Relapse : withdrawn from the study and last progastrin measurement. Patient could be enrolled in the non-curative intent cohort"
75800655|NCT03786978|Behavioral|Structured pharmaceutical care|Patients receive a structured pharmaceutical care from one year after basal hospital discharge
75800656|NCT03786978|Behavioral|Comparator|Patient received a single phone call 30 days after basal hospital discharge.
75342580|NCT04385342|Drug|HP-hMG|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
75342581|NCT01272752|Dietary Supplement|IHBG-10|500 mg IHBG-10
75800657|NCT03784638|Procedure|lingually-based triangle flap design|A mucoperiosteal lingually-based triangle flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
75938697|NCT02321163|Device|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
75938698|NCT02321163|Device|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
75938699|NCT02321163|Device|NMES no stimulation|Placebo, electrode pad on, no stimulation
75342582|NCT01272752|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
75342583|NCT00751634|Device|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
75342584|NCT01278134|Drug|Copegus placebo|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
75342585|NCT01278134|Drug|RO5024048|1000 mg bid orally, up to 24 weeks
75342586|NCT01278134|Drug|danoprevir|100 mg bid orally, up to 24 weeks
75475650|NCT01997775|Drug|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 > 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
75475651|NCT01997788|Drug|The intrathecal morphine injection|A single injection of morphine intrathecally
75342587|NCT01278134|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
75342588|NCT01278134|Drug|ribavirin [Copegus]|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
75342589|NCT01278134|Drug|ritonavir|100 mg bid orally, up to 24 weeks
75342590|NCT01273844|Drug|Bortezomib|Bortezomib
75342591|NCT01270568|Other|Positive Psychology|Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states
75938700|NCT04462887|Behavioral|Nursing intervention program|The intervention consisted of structured information (SI) provided in a booklet, nursing telephone support (NTS) and access to a nurse pager 24h/day. The SI booklet, Sudden Cardiac Arrest: A Survivor's Experience, contains 2 components: a descriptive component including individual verbatim statements about experiences of others during the first year of recovery and a management component outlining successful strategies used by others in dealing with issues in recovery. The NTS telephone calls included: check-in about current concerns, assessment of the topic for the week, review of common recovery experiences, discussion of behavioral strategies for dealing with the topic for the week, provision of positive feedback for strategies already working well, anxiety reduction statements, practice of new behaviors using role-playing and problem solving techniques, summarization, setting specific goals for the upcoming week, and collaborating on a learning assignment for the subsequent week.
75938701|NCT02321241|Drug|Aflibercept (EYLEA, BAY-86-5321)|"st year: 3 monthly injections followed by 1 injection every two months~nd year and following: injection according the visual and anatomical results observed the 1st year"
75938702|NCT03583307|Drug|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
75342592|NCT01270568|Behavioral|Relaxation Response|Daily practice of relaxation response, reviewed on a weekly basis
75342593|NCT01270568|Behavioral|Recollection|Subjects record daily events on a weekly basis for 8 weeks
75938703|NCT02310477|Drug|regorafenib|regorafenib for all groups
75938704|NCT02449551|Drug|Volitinib|Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
75342594|NCT01271348|Drug|Etoricoxib|Etoricoxib film tablet, 90 mg, q.d.
75342595|NCT01271348|Drug|placebo|Placebo tablet, q.d.
75342596|NCT04385264|Drug|Hydroxychloroquine|Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
75653030|NCT04045327|Drug|Normal saline + Standard Treatment|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
75653031|NCT04045327|Drug|Centhaquine + Standard Treatment|Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
75653032|NCT00914966|Biological|C1 inhibitor (human) [C1 INH]|
75653033|NCT02551471|Other|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|"This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries."
75653034|NCT02551471|Other|MDT (Multidisciplinary team) meeting observation|"3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading)."
75800658|NCT03784638|Other|buccally based triangular flap design|A mucoperiosteal buccally based triangular flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
75800659|NCT04243642|Device|IntelliSpace Cognition|Philips IntelliSpace Cognition (ISC) is a digital assessment platform that supports Healthcare Professionals (HCP) in assessing the cognition of individuals. It consists of two interfaces connected to the DCDx-module in the cloud. ISC is hosted on the Philips Health Suite Digital Platform (HSDP). The first interface is the patient's interface and is presented via a tablet to collect data on how the patient performs a series of tests. The second interface is the clinician's interface and can be used on any PC or tablet. It allows for assessments to be selected and administered, observations made, data analytics performed and the generation of a report.
75938705|NCT03499665|Behavioral|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.
76089339|NCT05735470|Device|antibacterial bone traction needles|Whether to use bone traction needles containing antibacterial coatings
75342597|NCT04385264|Drug|Mannitol|Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD
75342598|NCT00746954|Drug|Acetazolamide|Cabonic Anhydrase inhibitor
75342599|NCT00746954|Drug|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
75342600|NCT00752102|Drug|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
75342601|NCT00752102|Drug|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
75342602|NCT01273922|Biological|NDV-3 investigational vaccine|Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
75342603|NCT01279928|Procedure|Video Nailfold Capillaroscopy|Single session of video Nailfold Capillaroscopy wit KKK technology
75342604|NCT01279928|Device|Ambulatory 24 hr Blood Pressure Monitoring|24 hr upper arm cuff measurement of Blood Pressure
75342605|NCT01279928|Procedure|Fundoscopy of eyes|examination of microvascular health of eye with the use of opthalmoscope
75342606|NCT01279928|Procedure|Laser Doppler Flowmetry|Examination of vascular flow
75342607|NCT00723632|Biological|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
75342608|NCT00723632|Drug|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants <65 kg, 1000 mg/day for participants >65 to <85 kg, and 1200 mg/day for participants >=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
75938706|NCT03499665|Behavioral|Myofascial Releasing Maneuvers and Home Exercises Group|In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.
75938707|NCT03499665|Behavioral|Control Group|In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
75938708|NCT03039023|Dietary Supplement|Choline Bitartrate|500mg choline bitartrate tablets
75938709|NCT03039023|Other|Pre-cooked, pre-peeled whole hardboiled eggs|Obtained from a commercial source.
75938710|NCT03039023|Other|Egg whites from pre-cooked, pre-peeled hardboiled eggs|Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.
75938711|NCT03039023|Dietary Supplement|Phosphatidylcholine capsules|420 mg phosphatidylcholine capsules obtained from a commercial source.
75938712|NCT02310555|Procedure|Gastric bypass|
75342609|NCT00723788|Device|MRI of the abdomen|Multiple MRI pulse sequences of the abdomen
75475652|NCT01997788|Drug|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
75342610|NCT01279304|Radiation|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
75653035|NCT02551471|Other|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
75653036|NCT00815269|Drug|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
75653037|NCT00815269|Drug|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
75653038|NCT00815269|Drug|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
75653039|NCT00815269|Drug|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
75938713|NCT02310555|Procedure|Modified gastric bypass.|
75938714|NCT02310555|Procedure|Slevee Gastrectomy|
75342611|NCT01279304|Radiation|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
75342612|NCT01279304|Radiation|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
75342613|NCT01279616|Drug|Fludarabine monophosphate|180 mg/m2 over 6 days.
75342614|NCT01279616|Drug|Rituximab|375 mg/m2 on day -13 and day -3
75800660|NCT03786822|Procedure|Cryoballoon Pulmonary Vein Isolation - PVI|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12 French steerable sheath (FlexCath, Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
75800661|NCT03789552|Drug|T89 capsule|T89 capsules (75mg)
75342615|NCT01279616|Drug|Busulfan|AUC 1000-1200 microM.mt
75342616|NCT01279616|Drug|ATG|2.5 mg/kg for 3 days
75342617|NCT01279616|Drug|Cyclophosphamide|50 mg/kg on day +3
75342618|NCT01279616|Drug|Mycophenolate mofetil|15 mg/kg q 8 hours
75342619|NCT01279616|Drug|Tacrolimus|0.03 mg/kg /d
75475653|NCT01997788|Drug|Demerol on demand|Demerol 25 mg intravenously when pain scores more than 5.
75475654|NCT01997801|Drug|Ketamine infusion|Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
75653040|NCT00815269|Drug|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
75800662|NCT03789552|Drug|Placebo capsule|Placebo capsules (0mg)
75475655|NCT01997801|Drug|NS infusion|Normal saline will be infused intraoperatively.
75475656|NCT01997814|Drug|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
75653041|NCT00914810|Dietary Supplement|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
75653042|NCT00914810|Dietary Supplement|Placebo|Placebo (sugar pill) daily for 6 weeks
75938715|NCT03499431|Device|Endovascular Thoracoabdominal Aneurysm Repair|Standard of care, treatment of thoracoabdominal aneurysms using endovascular techiniques.
75938716|NCT03708263|Device|Excel V 532nm (KTP) green Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
75938717|NCT03708263|Device|PHOTOLASE PLV 585 nm yellow laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
75938718|NCT02310711|Other|Standard of Care|"Standard of care for early stage breast cancer is breast conserving therapy at this center.~Other concomitant standard of care treatment • Radiation therapy to the whole breast~o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions"
75938719|NCT03022045|Drug|risankizumab|risankizumab administered by subcutaneous injection
75938720|NCT02736695|Drug|F-18 AV 1451|Tau binding agent
75938721|NCT04462263|Drug|HTL0014242|Solid suspension capsule
75938722|NCT04462341|Device|Water Flosser|Device that uses water under pressure to clean around teeth and under the gums
75938723|NCT04462341|Device|Manual Toothbrush|Plastic handle with nylon bristles to clean teeth
75938724|NCT02321397|Drug|Oxycodone|
75938725|NCT02321397|Drug|Naloxone|Prolonged Release Tablets
75342620|NCT01275638|Drug|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
75938726|NCT02319603|Drug|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
75938727|NCT02319603|Drug|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
75475657|NCT01997814|Drug|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
75653043|NCT00922285|Other|psychosocial support for caregiver|6 weekly 60 minute sessions
75653044|NCT00922285|Other|questionnaire administration|Evaluated at baseline, week 1 and week 6 of art therapy
75938728|NCT02673671|Device|G-Tech Myoelectric recording device|A minimum of three patches are placed on the abdomen of the patient to record myoelectric activity.
75342621|NCT00724568|Drug|Lenalidomide|Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
75653045|NCT00922285|Procedure|quality-of-life assessment|Evaluated at baseline, week 1 and week 6 of art therapy
75653046|NCT00922285|Procedure|stress management therapy|6 weekly 60 minute sessions
75653047|NCT00808561|Other|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
75653048|NCT00808561|Other|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
75653049|NCT00808717|Drug|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
75342622|NCT00724568|Drug|Bortezomib|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
75342623|NCT00724568|Drug|Dexamethasone|Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
75653050|NCT00644917|Drug|Xenaderm|20mg under Finn chambers
75653051|NCT00644917|Drug|Placebo|20mg under Finn chambers
75653052|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
75653053|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose [2x10^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose] by intradermal (ID) route on Days 0 and 28.
75800663|NCT03784560|Other|The Psychomotor Vigilance Task (PVT)|PVT has emerged as one of the most widely used tools to assess vigilant attention. Vigilance can be defined as sustained attention and tonic alertness. In sleep deprived individuals, vigilance is the component of cognition that is most consistently and dramatically affected. The PVT is a reaction-time test that allows the collection of a large amount of data in a relatively short period of time. These characteristics increase the sensitivity of the test to detect even small changes in vigilant attention, which can wax and wane within seconds.
75800664|NCT03784560|Other|Epworth Sleepiness Scale|"Epworth Sleepiness Scale a set of questions that assess excessive daytime sleepiness during professional activities and vacations.~This scale was designed to assess the efficiency of sleep apnea treatments. It is also used for the subjective sleepiness assessment based on the likelihood of falling asleep in different everyday life situations. This results in an overall score."
75938729|NCT03499275|Device|Active NMES|Neuromuscular electrical stimulation to the quadriceps muscle
75342624|NCT00724568|Drug|Doxil|Patients will be treated with Doxil on day 4.
75653054|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
75938730|NCT03499275|Device|Sham NMES|Sham neuromuscular electrical stimulation to the quadriceps muscle
75475658|NCT01997827|Device|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
75475659|NCT01997827|Device|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
75475660|NCT01997853|Drug|Omega 3 fatty acid|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
75475661|NCT01997853|Drug|Placebo|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
75938731|NCT03499275|Other|Home exercise programme|Home exercise programme. Both arms of the trial receive this intervention.
75938732|NCT03499275|Other|Breathlessness advice|Breathlessness advice. Both arms of the trial receive this intervention.
75938733|NCT03497559|Other|Music|Classical music
75938734|NCT02310945|Other|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
76089340|NCT03825861|Drug|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
76089341|NCT01760447|Drug|Sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.
75342625|NCT01279070|Behavioral|Repyflec cognitive remediation training|Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
75342626|NCT01274000|Drug|YM060|oral
75653055|NCT00844545|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
75653056|NCT00815503|Drug|Ropivacaine|Approved by the Danish Medicines Agency
75653057|NCT00815503|Drug|Placebo|Saline
75938735|NCT05209451|Behavioral|Digital, evidence-based behavioral health program for smoking cessation|Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.
75938736|NCT05209451|Other|Bluetooth enabled iPad|Bluetooth enabled iPad with data plan coverage that provides a personal Wi-Fi (Internet) hot spot for all home devices and allows for up to 64 GB of cellular data.
76089342|NCT01760447|Drug|Placebo to metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.
75653058|NCT02552407|Device|Manual Aspiration Thrombectomy|Thrombus aspiration
75800665|NCT03784560|Other|Karolinska sleeping scale|"The KSS is assumed to be an ordinal scale with a unitary structure. KSS scores may require standardization to control for differences between subjects. The changes observed in the EEG/EOG with drowsiness do not usually appear until KSS scores reach 7 and higher. Lower KSS scores (<5) may reflect differences in the subjective awareness of fatigue as much, or more than, levels of drowsiness.~Higher KSS scores (7+) may refer more specifically to the state of drowsiness because the subject may then have experienced involuntary dozing behavior, with lapsing episodes and brief loss of awareness of the here-and-now, followed by arousal and the return of awareness, including some awareness of recently having dozed off"
75653059|NCT04708262|Other|Cognitive Analytic Therapy for Containing Self-Harm in Young People|The intervention will run over five sessions, each lasting around 30 - 40 minutes. Researchers will follow the CATCH-Y manualised treatment guide. CATCH-Y is a brief, five session psychological intervention based upon CAT principles and designed to help young people who have self-injured.
76089343|NCT01760447|Drug|Metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.
76089344|NCT01760447|Drug|Placebo to sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.
75342627|NCT01274000|Drug|placebo|oral
75342628|NCT04270526|Drug|Bicarbonate protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
75653060|NCT00702819|Drug|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
75653061|NCT00651157|Biological|wild-type reovirus|Given IV: Administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
75938737|NCT05209451|Behavioral|Coaching Support|Six coaching calls, 15-20 minutes each in duration. The research coach will use motivational interviewing and goal setting to enhance the participant's technology access and use and digital literacy.
75938738|NCT02319681|Behavioral|Simple Reminiscence (SR)|SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.
76089345|NCT01760447|Drug|Sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.
76089346|NCT01760447|Drug|Placebo to metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.
76089347|NCT01760447|Drug|Insulin|"Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the Sitagliptin/Metformin and Metformin arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the Sitagliptin/Metformin XR and Metformin XR arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine."
76089348|NCT01760447|Drug|Placebo to sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.
75342629|NCT04270526|Drug|Standard protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline
75342630|NCT04274738|Drug|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
75342631|NCT04274738|Drug|Ibrutinib|Ibrutinib capsules will be administered per dose and schedule specified in the arm.
75653062|NCT02691182|Drug|SPN-810|
75653063|NCT00843843|Device|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
75653064|NCT00650845|Drug|Dotarem®-enhanced MRI|Single IV administration before MRI exam
75653065|NCT00650845|Other|non-enhanced MRI|non injected MRI
75653066|NCT00842985|Drug|drug condition|Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
75342632|NCT04272320|Drug|Bupivacaine Hydrochloride|Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
75342633|NCT01274078|Biological|Blueberries|150 grams of frozen blueberries on the same day as exercise
75342634|NCT01277744|Procedure|Hyperthermic Peritoneal Perfusion (HIPEC)|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
75653067|NCT04017091|Diagnostic Test|Virtual Reality Cognitive Training|Bimodal VR-Stroop (ClinicaVR: Apartment Stroop) Patient find themselves seated with a virtual apartment, where they see a living room, in front of a flat-screen TV set, a kitchen and a window. This intervention consisted of two Stroop conditions across all 8 sessions. In Condition 1 (Inhibition), Patients indicated when the color named (audio stimulus) matched the color shown (visual stimulus). Participants were to withhold their response in mismatched trials. In Condition 2 (Interference), Participants clicked the mouse when the color heard was the same as the ink color; not the word printed.
75938739|NCT02319681|Behavioral|Attention Control (AC)|AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
75653068|NCT00808795|Drug|N-acetylcysteine|NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
75342635|NCT01277744|Drug|Cisplatin|100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
75342636|NCT04386200|Other|web-based thecnologies|"Integration of traditional face-to-face educational approach with web-based technologies."
75342637|NCT04386200|Behavioral|traditional approach|"traditional face-to-face educational approach"
75342638|NCT01274156|Device|"MEDISPEC treatment probe"|300 shocks in 5 different anatomical locations of the penis.
75342639|NCT01274156|Device|"MEDISPEC Sham Probe"|Sham probe applied same as treatment probe without energy
76089349|NCT01760447|Drug|Metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
75800666|NCT03784560|Other|Trail making test|Most variants of this test, which was apparently introduced in 1938 by Partington (Partington & Leiter, 1949), have at least two conditions. In condition A the participant is to draw lines to connect circled numbers in a numerical sequence (i.e., 1-2-3, etc.) as rapidly as possible. In condition B the participant is to draw lines to connect circled numbers and letters in an alternating numeric and alphabetic sequence (i.e., 1-A-2-B, etc.) as rapidly as possible.
76089350|NCT01952470|Drug|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
75342640|NCT01274156|Device|"MEDISPEC Low intensity shock waves"|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
75800667|NCT03789396|Other|Targeted Normoxia (oxygen saturation 90-96%)|The intervention (post-implementation) group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation
75800668|NCT03789396|Other|Usual Care Oxygenation|The control (pre-implementation) group will be trauma patients admitted to the ICU during the 12 months prior to the targeted normoxia implementation
75800669|NCT03784404|Procedure|Transvaginal aspiration|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
76089351|NCT01952470|Drug|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
75800670|NCT03784404|Procedure|transvaginal aspiration and surgicel injection|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
75800671|NCT03784404|Drug|Intracytoplasmic sperm injection|"Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance."
75938740|NCT02321475|Drug|EGb761®|
75938741|NCT02321553|Other|Brown rice|brown rice cake
75938742|NCT02321553|Other|White rice|white rice cake
75938743|NCT05155631|Behavioral|COGNITIVE BEHAVIORAL THERAPY|8-10 week self directed on line CBT program approved by FDA
75342641|NCT01274156|Device|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
75342642|NCT01274234|Device|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
75342643|NCT04385576|Device|Aerosol Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
75938744|NCT02321631|Dietary Supplement|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
76089352|NCT03820011|Other|PEM+|PEM+ is a five-step recursive process (i.e., the caregiver can repeat the five-step process to create as many intervention plans for their child as needed, relative to the number of activities in which change is desired based on the YC-PEM e-PRO, and it offers tiered support to the user during completion (tier 1: frequently asked questions available in the application, tier 2: support provided by email, tier 3: support provided by phone).
76089353|NCT01915108|Drug|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
76089354|NCT03825471|Procedure|electrotherapy|Cranial electrotherapy stimulation
76089355|NCT03825471|Drug|Opioid Anesthetics|consumption of opioids during general anesthesia
76089356|NCT03825471|Procedure|colon cancer surgery|laparoscopic colon cancer surgery
76089357|NCT05735392|Other|Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.|Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.
75342644|NCT04385576|Device|Intubation Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
75342645|NCT01274312|Procedure|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
75342646|NCT01277822|Drug|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
75342647|NCT01277822|Drug|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
75342648|NCT01277822|Drug|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
75342649|NCT01277822|Drug|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
75800672|NCT03075826|Drug|SGI-110|subcutaneously at a dose of 60 mg/m2
75800673|NCT04116970|Procedure|Bronchoscopy|Undergo bronchoscopy with EBUS-TBNA
75938745|NCT02321631|Dietary Supplement|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
75938746|NCT03499197|Diagnostic Test|cardiac magnetic resonance imaging|Detailed and regular CMR examination (LGE, stress perfusion, T1, T2 mapping)
75938747|NCT02321709|Drug|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75938748|NCT02321709|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
75938749|NCT03037619|Behavioral|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months
75938750|NCT03037619|Behavioral|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
75938751|NCT03497403|Procedure|Socket preservation control|After a tooth was extracted, the adjacent gum tissue was fully reflected, bone graft (FDBA) and non-cross-linked barrier membrane (Bio-Gide) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
75342650|NCT01277666|Drug|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
75342651|NCT01277666|Drug|GSK1605786A|500 mg once daily, administered orally for 12 weeks
75342652|NCT01277666|Drug|Placebo|Placebo capsules, administered orally for 12 weeks
75342653|NCT00249002|Drug|ABI-007|
75342654|NCT04386278|Device|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
75342655|NCT04386278|Device|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
75342656|NCT04386278|Device|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
75342657|NCT04386278|Device|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
75342658|NCT04386278|Device|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
75342659|NCT04386278|Device|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
75342660|NCT04386278|Device|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
75342661|NCT04386278|Device|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RBP) for five minutes
75342662|NCT01277042|Biological|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
75342663|NCT01277042|Biological|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
75800674|NCT04116970|Procedure|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo bronchoscopy with EBUS-TBNA
75800675|NCT03630484|Other|Expiratory Rib Cage Compression|Compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
75938752|NCT03497403|Procedure|Socket preservation experimental|After a tooth was extracted, the adjacent gum tissue was minimally reflected, bone graft (FDBA) and cross-linked barrier membrane (OssixPlus) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
76089358|NCT03825705|Drug|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
76089359|NCT03825705|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
76089360|NCT03096639|Device|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
75342664|NCT01274546|Device|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
75938753|NCT04463433|Behavioral|Cognitive and behavioral intervention.|Two hours group sessions including mindfulness and emotion regulation. The practice of mindfulness is taught to parents to become aware of their thoughts and emotion on the present moment. The behavioral intervention has parents develop an Positive Time-out for dealing with conflict and negativity, using strategies to down-regulate their own negative emotions.
75938754|NCT04463433|Behavioral|Problem-solving and relationship improvement intervention.|Two hours group sessions including problem-solving and improving marital relationship . In the problem-solving part, the knowledge and techniques of problem-solving are taught to couple. relationship improvement part which promote the couple relationship by being aware of their own and their partner's deep-seated needs and communicating in a congruent way.
76089361|NCT01917136|Drug|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
76089362|NCT01917136|Drug|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
75342665|NCT00748826|Biological|Infliximab|"Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of~Infliximab therapy with additional infusions of 5 mg/kg at week 2"
75342666|NCT00754130|Drug|Placebo|Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
75475662|NCT01997866|Other|STOP-BANG Scoring Model|Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
75653069|NCT00808795|Drug|Placebo|Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
75800676|NCT03630484|Other|Compression + Ventilator Hyperinflation|Mechanical ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same. In Expiratory Rib Cage Compression associated with ventilator hyperinflation, thoracic compression maneuver was performed at the end of inspiration, at the exact moment of cycling.
75938755|NCT02319915|Drug|Tranexamic Acid|
75938756|NCT02319915|Drug|Adrenalin|
75938757|NCT04898309|Drug|GNR-038, 50 МЕ/ kg|A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
75938758|NCT04898309|Drug|GNR-038, 100 МЕ/ kg|A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
75938759|NCT04898309|Drug|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
76089363|NCT01917136|Other|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
76089364|NCT05735236|Device|BFR Cuff|The BFR cuff will be applied to the proximal thigh of the surgical leg while the patient completes specified physical therapy exercises.80% occlusion pressure will be determined by PT's in clinic through the use of a Delphi unit. Subjects will then be able to use the Saga Fitness app to adjust this pressure if it differs from the automatic calibrated pressure.
76089365|NCT03825549|Behavioral|Individual audit feedback|Practice sites randomly assigned to have individual audit feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. The email will inform the clinician that the health system is doing monthly audits and provide them the number of patients in the last month for whom they prescribed 30 opioid pills per prescription or higher.
76089366|NCT03825549|Behavioral|Peer comparison feedback|"Practice sites randomly assigned to have peer comparison feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. Data on the mean number of opioid pills per prescription and the proportion of visits with an opioid prescription will be delivered using a 3-month rolling average as follows: a) If clinician is above median: informed how their data compares to the median; b) If clinician is below median but above 10th percentile: informed how their data compares to the 10th percentile; c) If clinician is 10th percentile or below: informed of their data and commended for being a low prescriber."
76089367|NCT01450215|Drug|Revlimid|Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .
75342667|NCT00754130|Drug|MK-0941|MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
75342668|NCT00246740|Drug|Periostat|In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
75342669|NCT00246740|Drug|Placebo Oral Tablet|In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
75342670|NCT01274624|Biological|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
75475663|NCT01997866|Other|Polysomnogram Sleep Study|Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
75653070|NCT00815581|Device|photorefraction,cycloautorefraction,cycloretinoscopy|
75653071|NCT00808873|Other|socio-educational intervention|brief mental health education and 6 follow-up visits
75653072|NCT00811213|Device|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
75653073|NCT00811213|Device|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
75938760|NCT04898309|Drug|Placebo|A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
75938761|NCT04898309|Drug|GNR-038. The dose will be selected according to results of stage 1 clinical trial.|A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
75800677|NCT01378234|Behavioral|Enhanced Discharge Planning Program transitional care|"Enhanced Discharge Planning Program (EDPP) provides telephonic short-term post-discharge social work services that assess and intervene from a biopsychosocial perspective for at-risk older adults returning home after an inpatient hospitalization. EDPP follows a four-step process to with three guiding tasks to reach the goal of preventing avoidable adverse events post-discharge:~Ensure patients understand the discharge plan of care and receive recommended services while screening for unidentified medical or social needs~Connect patients to outpatient health services (ex: home health, in-home services, dialysis, radiology, laboratory services, specialty care) with particular emphasis on the first physician follow-up appointment~Supporting caregivers to reduce stress and burden"
75938762|NCT04898309|Drug|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
75938763|NCT02311023|Other|Intermittent fasting|
75938764|NCT03694457|Procedure|Reversed total shoulder arthroplasty|Replacement of the proximal humeral head by a reversed prosthesis through an anterior approach
75653074|NCT00808951|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
75653075|NCT00808951|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
75475664|NCT01997931|Device|Bispectral Index Sedation monitor|
75938765|NCT03694457|Procedure|lateral approach|Replacement of the proximal humeral head by a reversed prosthesis through a lateral approach
76089368|NCT01450293|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|1x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
76089369|NCT01450293|Biological|AdCH63 ME-TRAP, MVA ME-TRAP|5x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
76089370|NCT01953874|Device|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
76089371|NCT01953874|Drug|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
75653076|NCT00815737|Drug|rhubarb|14 days of rhubarb
75653077|NCT00815737|Drug|Placebo|14 days of Placebo
75653078|NCT00809029|Other|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
75938766|NCT03505437|Other|Cold water condition|Cold water condition of the SECPT. Participants immerse their hand into ice-cold water (0-3°C). During the SECPT, participants are videotyped and monitored. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders
75938767|NCT03505437|Other|Warm water condition|Warm water condition of the SECPT. Participants immerse their hand into warm water (36-37°C). Participants are neither videotyped nor monitored during the whole procedure. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders.
75938768|NCT03497325|Drug|autologus platelet rich plasma|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
75938769|NCT03497325|Drug|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
75938770|NCT02321787|Procedure|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
75938771|NCT03497247|Behavioral|Mindfulness-Based Cognitive-Behavioral Therapy|Both arms have the same intervention techniques (relative intervention, stimulus control and others) except relapse prevention sessions. In the experimental arm, these sessions are carried out from Mindfulness, and in the active comparator is the usual relapse prevention.
75938772|NCT03499041|Drug|LY3314814|Administered orally
76089372|NCT01450371|Device|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
76089373|NCT01450371|Device|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
76089374|NCT04391829|Diagnostic Test|Ejaculated semen sample|SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.
76089375|NCT01954264|Procedure|Capillary blood sample|Capillary blood sample (up to 200µL) for determination of PP (blood slides).
76089376|NCT01954264|Other|Data collection|Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
75475665|NCT01997944|Biological|Human Serum ALbumin/interferon alpha2a|600,750 or 900 mcg dosing every 2 weeks
75475666|NCT01997944|Biological|Pegasys|180 mcg dosing every week
75475667|NCT01997957|Drug|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
75475668|NCT01997970|Behavioral|Treadmill workstation|The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.
75653079|NCT04045483|Other|Virtual reality based cognitive training|The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
75342671|NCT01274624|Drug|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
75342672|NCT01274624|Drug|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
75938773|NCT03498963|Procedure|bronchoalveolar lavage|Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
75800678|NCT05694390|Other|Use of sterile transparent film dressing|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed. The infiltration scale for infants, , the criteria of extravasation (Redness accompanied by a vesicle, tissue necrosis, and ulcer), and The Phlebitis Scale were used to evaluate the catheter site.
75938774|NCT02321865|Drug|NPC-02|
76089377|NCT03825159|Device|Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing|The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.
76089378|NCT03825159|Device|spinal orthosis|The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
75653080|NCT02551393|Behavioral|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
75342673|NCT01274624|Drug|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
75342674|NCT01274624|Drug|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
75653081|NCT00842829|Drug|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
75653082|NCT04045249|Dietary Supplement|Home based food|Home based food is compare able to RUTF
75653083|NCT04045093|Drug|Dabigatran etexilate|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
75653084|NCT04045093|Drug|Warfarin|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
75800679|NCT01569412|Biological|Ertumaxomab|trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
75800680|NCT03786588|Other|Observation|The patients with the negative results of HPV infection, and assigned to different group according to the CPP manifestation.
75800681|NCT01378156|Biological|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
75800682|NCT03786510|Behavioral|Active control|Control group received a personalized advice on lifestyle modification to prevent dementia and usual care of Community Center for Dementia.
75800683|NCT03786510|Behavioral|Intensive + Maintenance program|"Both intensive and maintenance program~Intensive program The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.~Maintenance program The allocated study assistants monthly check-up whether participants adhere to the altered habits or not, based on the workbook"
75342675|NCT00748982|Drug|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
75342676|NCT00748982|Drug|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
75342677|NCT00749606|Behavioral|Individual telephone intervention|"Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
75342678|NCT00749606|Behavioral|Group telephone intervention|"Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
75342679|NCT01274936|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
76089379|NCT01917214|Other|Sutent: Observational Study|Sutent oral therapy
75342680|NCT01274936|Drug|Qishe Placebo|Pill, 3.75 g, twice per day, four weeks
75938775|NCT03505359|Other|partial knee immobilization protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength with a 0-60 degrees articulated knee brace in the first 6 weeks in the experimental group.
75938776|NCT03505359|Other|standard ACL reconstruction rehabilitation protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength.
75938777|NCT03498885|Procedure|Low ligation|Left colic artery (LCA) is identified, Tie the sigmoid artery and superior rectal artery, Apical lymph node dissection with the left colic artery preservation is performed.
75938778|NCT03498885|Procedure|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apicallymph nodes dissection is performed.
76089380|NCT03825237|Diagnostic Test|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
75653085|NCT00811291|Dietary Supplement|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
75653086|NCT00811291|Dietary Supplement|calcium|according to protocol
75653087|NCT00811369|Drug|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
75653088|NCT00811369|Drug|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
75800684|NCT03786510|Behavioral|Intensive program only|"Only the intensive program was conducted.~The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching."
75800685|NCT01378078|Device|eldith DC-stimulator (neuroconn, Ilmenau, Germany)|daily tDCS treatment over left DLPFC, 20 min, 2 mA
75800686|NCT01378078|Device|eldith DC-stimulator (Neuroconn, Ilmenau, Germany)|same as sham stimulation
76089381|NCT01450605|Drug|No Intervention|Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
76089382|NCT01955434|Drug|Cyclophosphamide|Given PO
76089383|NCT01955434|Other|Laboratory Biomarker Analysis|Correlative studies
76089384|NCT01955434|Other|Pharmacological Study|Correlative studies
76089385|NCT01955434|Other|Quality-of-Life Assessment|Ancillary studies
76089386|NCT01955434|Drug|Smac Mimetic LCL161|Given PO
76089387|NCT04758429|Device|Machine-learning Algorithm|System technology/Software
75800687|NCT03784092|Other|feedback|feedback by electronic pedometers regarding patient mobility while undergoing labor induction
75938779|NCT05027399|Behavioral|Nursing teleconsultation for lifestyle changes|Guidance on better medication adherence, monitoring of signs and symptoms of exacerbation of heart failure, guidance on the need for fluid restriction.
75938780|NCT02311101|Drug|Mitomycin C|Given intravesically
75938781|NCT03619499|Device|non invasive ventilation|patients who will fulfill the criteria of severe bronchiolitis will be connected to non invasive ventilation including continuous positive airway pressure via nasal prongs or nasal mask. Mode of ventilation, inspired oxygen levels, oxygen saturation, respiratory rate, and blood gas values from arterial samples prior to and after 2 and 4 hrs of ventilation or nearest time, will be documented.
75938782|NCT04058119|Behavioral|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
76117220|NCT03710603|Drug|velcade|Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.
75475669|NCT01997970|Behavioral|Health talk|Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
75475670|NCT01997983|Device|TC-3 Gel mixed with Botox (BTX)|TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
75475671|NCT01998009|Other|fecal occult blood tests|
75475672|NCT01998048|Procedure|Latarjet|A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.
75653089|NCT00842361|Drug|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
75653090|NCT00842361|Drug|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
75653091|NCT00811447|Drug|5-fluorouracil|600 mg/m²/day intravenous
75938783|NCT04925765|Device|Flowly (TMC-CP01)|The Flowly (TMC-CP01) treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain/anxiety/depression.
75938784|NCT04058275|Other|Draw blood (phlebotomy, 83 ml)|Draw 83 ml of blood
75938785|NCT03498807|Device|Ventiltor P/V Loop|determine the Optimal PEEP and keep 48hr on ARDS patients
75342681|NCT00761930|Drug|Fluoride|Brush twice daily
75342682|NCT00761930|Drug|Triclosan and fluoride|Brush twice daily
75342683|NCT00761930|Drug|Herbal Ingredient and fluoride|Brush twice daily
75800688|NCT04108234|Drug|HR071603|HR071603 monotherapy ,nasal spray
75653092|NCT00811447|Drug|Cisplatin|60 mg/m² or 75 mg/m² intravenous
75800689|NCT04108234|Drug|placebo|placebo,nasal spray
75800690|NCT01307826|Other|massage|"session - 20 minutes.~Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:~latissimus muscle of the back~major pectoral muscle~supraspinous and infraspinous muscles~teres minor muscle~serratus anterior muscle~deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.~A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation."
75800691|NCT01307826|Other|massage|classical massage (Swedish massage)
75800692|NCT01307904|Other|Glucose|Each healthy and Diabetic volunteers received 50 grams of glucose
75342684|NCT00245102|Drug|sorafenib tosylate|Given orally
75342685|NCT01275014|Drug|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
75800693|NCT01307904|Other|Dates|Each healthy and diabetic volunteers received 50 grams equivalent of carbohydrates of each of the five selected dates, on five separate days.
75800694|NCT01310634|Behavioral|Comprehensive intervention|Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
75800695|NCT03821896|Behavioral|Conversation Cards for Adolescents and Goal-Setting|The intervention includes using an adolescent-tailored tool (a deck of cards) created by researchers at the University of Alberta and adolescents with obesity seeking weight management care. It contains a list of factors that make it easy or hard for teens to make and maintain healthy lifestyle changes. Its use will be paired with a S.M.A.R.T. goal-setting activity using principles of shared decision-making.
75938786|NCT03498807|Device|Electrical Impedance Tomography|determine Optimal PEEP and keep 48hr on ARDS patients
75800696|NCT03821896|Behavioral|Goal-Setting|Collaborative setting of S.M.A.R.T. goals using principles of shared decision-making.
75938787|NCT03668899|Procedure|irrigation|irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
75938788|NCT02319993|Drug|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
75938789|NCT02319993|Drug|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
75342686|NCT01275014|Drug|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
75800697|NCT01310790|Procedure|lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group|"Patients assigned to lactate group started with the resuscitation to achieve a CVP of 8 to 12 mmHg and MAP 65 to 90 mmHg. Then if ScvO2 was less than 70 percent, red cells were transfused to achieve a hematocrit of at least 30 percent. After the CVP, MAP, and hematocrit achieved the goals, dobutamine was given until the ScvO2 was 70 percent or higher. Arterial blood lactate concentration was obtained at 6 hours and try to achieve lactate clearance was >30%.~Patients in the ScvO2 group received the treatment as ScvO2 directed therapy protocol for at least 6 hours and maintained for 72 hours. The protocol was the same as that of lactated directed therapy with the exception of blood lactate concentration testing.~Patients in the control group received the treatment as the same protocol for maintaining CVP and MAP in that of lactated directed therapy. ScvO2 and arterial blood lactated concentration were not necessary to obtain."
75938790|NCT02319993|Drug|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
75938791|NCT03669211|Diagnostic Test|Cardiac stress test|In order to assess the evolution of their cardiorespiratory function, patients will benefit from two cardiac stress test combined with VO2 study, one at inclusion in the study, and the other one 6 months later.
75653093|NCT00811447|Drug|Docetaxel|60 mg/m² intravenous
75653094|NCT00702975|Drug|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
75653095|NCT02552251|Biological|Hormonal balance measurements|
75653096|NCT02552251|Biological|metabolic balance measurements|
75653097|NCT02552251|Biological|bone balance measurements|
75653098|NCT02552251|Behavioral|quality of life assessment|
75653099|NCT05603403|Drug|Probiatop|1 sachet orally, 2 times a day, for 42 days
75653100|NCT05603403|Other|Placebo|1 sachet orally, 2 times a day, for 42 days
75653101|NCT00809107|Drug|HCG|5000IU
75342687|NCT00754832|Drug|American ginseng extract HT-1001|Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
75342688|NCT00754832|Drug|placebo|Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
75342689|NCT01275248|Drug|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
75938792|NCT04771013|Biological|Thymic peptides|250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.
75653102|NCT00811525|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement. CPG was available in sizes 120 cc-775 cc and 5 styles with various projection and height options.~With approval of MemoryShape™ (CPG 321) Breast Implants, the study converted to a post approval study for this style."
75342690|NCT01275248|Drug|Placebo|Oral tablet to match the experimental interventions
75342691|NCT00756236|Drug|Metoprolol|60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
75342692|NCT00756236|Drug|Esmolol|60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
75342693|NCT00756236|Drug|P-Group|0.9%NaCl dispensed in 60ml & 5ml syringes
75342694|NCT00762320|Drug|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
75342695|NCT03807830|Procedure|Electrocochlography|Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
75342696|NCT03807752|Dietary Supplement|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
75938793|NCT02320071|Other|Examination of abdominal wall strength changes over time|
75342697|NCT03807752|Dietary Supplement|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
75475673|NCT01998048|Procedure|Bankart|An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
75475674|NCT01998061|Drug|EGFR tyrosine kinase inhibitor|Arm A
75475675|NCT01998061|Drug|EGFR tyrosine kinase inhibitor with chemotherapy|Arm B
75653103|NCT02612181|Drug|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
75475676|NCT01998074|Dietary Supplement|extensively hydrolyzed rice protein formula|
75475677|NCT01998087|Behavioral|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
75475678|NCT01998100|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
75653104|NCT02612259|Dietary Supplement|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
75653105|NCT02612259|Other|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
75653106|NCT00841035|Drug|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
75653107|NCT00703131|Device|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
75800698|NCT03687814|Other|Low FODMAP diet/PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
75800699|NCT03687814|Other|sham diet/PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
75800700|NCT03782220|Other|Kinesio tape|The Kinesio taping ( Kinesio Tex Gold, 2in x103.3 ft) was applied to sternocleidomastoid, upper trapezium and levator scapulae muscles by the muscle inhibition technique ( from insertion to origin of a muscle) for experimental group.
75938794|NCT03623191|Other|Clinical examination|
76025805|NCT05898178|Other|Experimental intervention: 8-5-2% oxygen gradient concentration in the incubator|After oocyte retrieval and insemination, half of a given patient's embryos will be randomly allocated in an incubator set at a gradient of oxygen tension (8-5-2%). The embryos will remain in the incubator until their developmental assessments on day 5.
75342698|NCT03807674|Procedure|Coronal pulpotomy|Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.
75342699|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|"Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patients success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2)."
75342700|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
75938795|NCT04760561|Procedure|prone position group|Patients randomized to this arm will receive self-prone positioning. Each patient in the intervention group will be helped into the prone position and encouraged to stay in the prone position as long as tolerated (at least 1 hour). The prone positioning consists of placing the patient on his or her stomach with the head on the side. Self-prone position will be performed 45 minutes up to 1 hour after meals to avoid gastrointestinal side effects. The patient will be maintained in prone position until the patient becomes too tired and uncomfortable to keep that position. If patients will asked to regain the supine position before the 1 hour period was complete, patient's prone position will be considered unfeasible and the reason will be reported. Patients who required invasive mechanical ventilation at any time point will be intubated and excluded from the study.
76089388|NCT01450839|Drug|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
76089389|NCT01450839|Drug|Placebo|Matching Placebo tablets and tape
76089390|NCT01917682|Procedure|CorPath-assisted Percutaneous Coronary Intervention|Robotic-assisted Percutaneous Coronary Intervention
76089391|NCT01732913|Drug|Placebo|Tablets administered orally twice daily
75342701|NCT03807206|Behavioral|Questionnaire|Patient questionnaire
75342702|NCT00244712|Drug|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
75342703|NCT00244712|Drug|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
75342704|NCT00725270|Drug|Mifepristone|600 mg of mifepristone
75475679|NCT01998100|Behavioral|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
75653108|NCT00703209|Procedure|Nerve Decompression|"Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is blinded to which leg received the decompression."
75653109|NCT00642811|Drug|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
75653110|NCT00642811|Drug|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
75800701|NCT03782220|Other|Shame tape|For the Shame taping group, a placebo taping method considered to be ineffective ( not from insertion to origin of muscles) with the same material without tension and with the neck in neutral position was used.
75938796|NCT04620187|Drug|Ado-trastuzumab (T) emtansine (T-DM1)|Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)
76089392|NCT01732913|Drug|Rituximab|375 mg/m^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
75800702|NCT03785626|Procedure|CEA surgery|patients with carotid artery severe (70-99%) stenosis or occlusion received CEA surgery
75800703|NCT03786276|Behavioral|VR-WMR-Only|Participants will spend up to 30 minutes in a VR-WMR environment during each training session.
75800704|NCT03786276|Behavioral|Exercise-only|Participants will ride a stationary recumbent bicycle for up to 30 minutes during each training session.
76089393|NCT01732913|Drug|Idelalisib|150 mg tablets administered orally twice daily
76089394|NCT03824925|Drug|Placebo oral Zinc capsule|Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
76089395|NCT03824925|Drug|Zinc Sulfate 220 MG|Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
76089396|NCT03825081|Drug|Brimonidine, pilocarpine|"1 drop of pilocarpine (0.5%)~1 drop of brimonidine (0.2%)"
76089397|NCT01918072|Other|Clinical innovation|Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
75342705|NCT00725270|Drug|Placebo Oral Tablet|Placebo comparator
75342706|NCT00243932|Drug|coenzyme Q10|antioxidant and mitochondrial cofactor, given in capsules three times daily
75342707|NCT00243932|Drug|Placebo|Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
75342708|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue. During the massage, we can caused isolated contractions from the fiber muscles containing the latent trigger points.
75342709|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.
75475680|NCT01998113|Drug|Glyburide vs Insulin trials|Affecting groups 1 and 2
75475681|NCT01998113|Drug|Metformin vs Insulin trials|Affecting groups 3 and 4
75475682|NCT01998113|Drug|Metformin vs Glyburide trials|Affecting groups 5 and 6
75475683|NCT01998126|Drug|Ipilimumab|Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
75653111|NCT00642811|Drug|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
75653112|NCT00838929|Drug|Vorinostat|"All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd"
75800705|NCT03786276|Behavioral|Active VR-WMR|Participants will spend up to 30 minutes in a VR-WMR environment while riding a stationary, recumbent bicycle during each training session.
75938797|NCT04620187|Radiation|Standard of Care Radiotherapy|Radiotherapy to shrink or kill tumors
76089398|NCT04273971|Other|Plyometric exercises|Plyometric exercises will be composed of vertical jumps, box jumps, half squat jumps, high straight jumps, bounding jumps, drop jumps and 10-m sprint.
75342710|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
75342711|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
75342712|NCT03807284|Behavioral|A group psychosocial course|A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
75475684|NCT01998126|Drug|Erlotinib|Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
75475685|NCT01998126|Drug|Crizotinib|Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
75653113|NCT00838929|Radiation|Radiation Therapy|Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
75475686|NCT01998126|Drug|Nivolumab|
75653114|NCT02612025|Behavioral|Exercise Training|Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
75653115|NCT00811603|Drug|Cefazolin (Timing of Antibiotic Prophylaxis)|Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
75653116|NCT00811681|Drug|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
75653117|NCT00811681|Drug|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
75800706|NCT03784248|Other|blood donation and isolation of leuco-platelet layers|patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice
75800707|NCT03266068|Genetic|DNA Analysis of Blood Sample|DNA analysis of the genes possibly involved in IBS.
75800708|NCT03266068|Procedure|Flexible sigmoidoscopy with colonic biopsies|Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.
75800709|NCT03266068|Procedure|Small bowel and colonic gastrointestinal permeability|A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.
75800710|NCT03266068|Diagnostic Test|Stool sample analysis|Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
75938798|NCT04620187|Drug|Standard of Care Chemotherapy|Intravenous injection
75653118|NCT00811759|Drug|sorafenib tosylate|
75653119|NCT00811759|Drug|temozolomide|
75653120|NCT00811759|Genetic|gene expression analysis|
75653121|NCT00811759|Genetic|mutation analysis|
75938799|NCT04637321|Procedure|Solid organ transplant|Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018
75342713|NCT03807362|Drug|CC-11050|CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
75342714|NCT01275560|Drug|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
75342715|NCT01275560|Drug|CArbosylane|
75475687|NCT01998152|Procedure|Nutritional counseling|Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
75653122|NCT00811759|Other|laboratory biomarker analysis|
75653123|NCT00811759|Other|pharmacological study|
75653124|NCT00811759|Procedure|biopsy|
75653125|NCT00815893|Drug|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
75938800|NCT02320305|Biological|MART-1 Antigen|Given IM
75938801|NCT02320305|Drug|TLR4 Agonist GLA-SE|Given IM
75938802|NCT02320305|Other|Laboratory Biomarker Analysis|Correlative studies
75938803|NCT04599725|Drug|medical abortion|medical abortion
76025806|NCT05898152|Other|Data collection|A collection about patient's data demographic, neurologic and gynecologic follow-up and satisfaction will be review by questionnaire. And a calendar of epileptic seizures will be completed by patients on 4 months
76025807|NCT05898087|Drug|Marcaine 0.25 % Injectable Solution|Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
76025808|NCT05898087|Drug|Saline|Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
76025809|NCT05898074|Device|Non-Absorbable Packing (Silastic Splint)|Participant will have silastic splint applied to nasoseptal flap harvest site
76025810|NCT05898074|Device|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site
76027522|NCT02362243|Other|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
76027523|NCT05038007|Drug|Liposomal bupivacaine|As prior described
75342716|NCT00762710|Drug|Prazosin medication|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
75342717|NCT00762710|Drug|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
75342718|NCT03807518|Behavioral|Standard Exercise Program|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
75342719|NCT04384640|Other|Change of posture after Intra Tympanic injection|Seating position after Intra Tympanic injection
75342720|NCT03807128|Other|No interventional study|No interventional study
75342721|NCT03807050|Dietary Supplement|Astaxanthin|Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
75342722|NCT00756548|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
75342723|NCT00756548|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
75342724|NCT00243230|Drug|Vicriviroc 30 mg|Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).
75342725|NCT00243230|Drug|Vicriviroc 20 mg|Two tablets of vicriviroc 10 mg once daily for 48 weeks.
75342726|NCT00243230|Drug|Placebo|Three tablets of placebo once daily for 48 weeks.
75342727|NCT00243230|Drug|Placebo|Two tablets of placebo once daily for 48 weeks.
75342728|NCT00243230|Drug|Background ART Regimen|"An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor [PI]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir."
75342729|NCT00243074|Drug|cediranib maleate|Given orally
75342730|NCT00243074|Other|laboratory biomarker analysis|Correlative studies
75342731|NCT00241358|Drug|AMD3100|
75342732|NCT00241358|Procedure|Stem Cell Transplant|
76027524|NCT05038007|Drug|Bupivacaine Hydrochloride|As prior described
75475688|NCT01998165|Drug|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
75475689|NCT01998217|Drug|Remifentanil|Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.
75653126|NCT00815893|Drug|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
75653127|NCT00815893|Drug|propofol 1%|"Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion."
75342733|NCT00241280|Device|etafilcon A|
75342734|NCT00241280|Device|galyfilcon A|
75342735|NCT00240500|Biological|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
75342736|NCT00778310|Drug|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
75342737|NCT00778310|Drug|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
75342738|NCT03806426|Drug|Eicosapentaenoic acid free fatty acid (EPA-FFA)|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
75342739|NCT03806426|Drug|Placebo|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
75342740|NCT03805646|Other|Mobile Phone-based Triage Tool|The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
75342741|NCT03809390|Procedure|Vaginal seeding|The same as that stated in arm descriptions.
75342742|NCT01212107|Drug|FGF Receptor|LY2874455 administered orally.
75342743|NCT01212107|Drug|Phosphate Binders|
75342744|NCT03801278|Drug|FPA144|Bemarituzumab administration every two weeks
75342745|NCT03808064|Behavioral|FCHV home visit|Behavioral: FCHV visit Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages Other Name: FCHV Home Visit
75342746|NCT04271306|Biological|Pfs25-IMX313 (10ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
75342747|NCT04271306|Biological|Pfs25-IMX313 (50ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)
75653128|NCT00816049|Drug|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
75653129|NCT00816049|Drug|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
75938804|NCT03625271|Device|The PEER Report|PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
75938805|NCT03497091|Other|Enteral Formula|Enteral Feeding with an amino acid-based formula
75938806|NCT03668665|Drug|Ready Medical Post Treatment|"Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed"
75938807|NCT03668665|Device|Conventionell Treatment|Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively
75938808|NCT02322489|Device|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
76089399|NCT01451073|Biological|Autologous cultured dermal and epidermal cells|Two pieces of occipital scalp are taken from the subject, three weeks apart. The dermal and epidermal cells from these tissues are expanded in culture. The cells are then harvested and, for certain types of product, combined. On the day the cells are harvested after manufacture, they are then injected into the balding area of the scalp of the original subject within a certain time period.
75475690|NCT01998217|Drug|Flurbiprofen and remifentanil|Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
75475691|NCT01998230|Dietary Supplement|early oral feeding|In the early oral feeding group, the patients are encouraged to intake liquid food on post operative day 1.
75475692|NCT01998256|Device|AV optimization|Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
75475693|NCT01998295|Drug|Artemether/lumefantrine|Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
75475694|NCT01998308|Drug|Crespine gel|50 Knees will have single injection of Crespine gel
75475695|NCT01998308|Drug|Intragel|50 Knees will have single injection of 2 ampules of Intragel
75653130|NCT02550925|Behavioral|Acceptance and Commitment Therapy (ACT) Group|A 7-session Acceptance and Commitment Therapy (ACT) group intervention
75653131|NCT02550925|Behavioral|Usual Care|Check in with clinical social worker at oncology care site and obtain list of supportive resources
75653132|NCT04648891|Drug|Lidocaine|Subcutaneous lidocaine injection prior to laryngeal injection
75653133|NCT04648891|Device|Vibrating wand|Concomitant use of vibrating wand during laryngeal injection
75653134|NCT04648891|Other|Control|Laryngeal injection without additional anesthesia
75653135|NCT04045015|Dietary Supplement|Liqourice|Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
75800711|NCT01307982|Procedure|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
75800712|NCT01307982|Procedure|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
75800713|NCT03784170|Device|FemPulse System|Device therapy with the FemPulse System
75800714|NCT05763472|Genetic|Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).|Next-generation sequencing (NGS) analysis with TruSight Oncology 500 (TSO 500) is performed on tumor samples from breast and ovarian cancer of the enrolled patients.
75800715|NCT05763394|Other|Polarized workout program|Polarized workout lasting approximately 40 minutes (two sessions/day, 5 days a week), characterized by a 5-minute warm-up performed at 50% of the peak V'O2, followed by 3 sets of 2 minutes at 95% of peak V'O2, interspersed with 1 minute of recovery at 40% of peak V'O2, followed by 30 minutes of moderate activity at 60% of V'O2 peak. Total of 24 sessions in 12 days.
75938809|NCT02322489|Device|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
76089400|NCT05735002|Diagnostic Test|13C-butyrate breath test|breath test
76089401|NCT04758663|Behavioral|Nap/wake conditions on memory|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities.
75475696|NCT01998308|Drug|Crespine plus gel|50 Knees will have single injection of Crespine Plus Gel
75475697|NCT01998308|Drug|Monovisc|50 Knees will have single injection of Monovisc
75475698|NCT01998321|Other|Patient specific instrument|A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation & PSI designing and PSI production
75475699|NCT01998321|Other|conventional technique for TKA|
75475700|NCT01998334|Other|CVVH 6h|CVVH 6h for first three days
75475701|NCT01998334|Other|CVVH 10h|CVVH 10h for first three days
75475702|NCT01998334|Other|CVVHDF 6h|CVVHDF 6h for first three days
75475703|NCT01998347|Drug|Paclitaxel liposome|
75475704|NCT01998347|Drug|Cisplatin|
75475705|NCT01998347|Drug|5-fluorouracil|
75653136|NCT00811837|Drug|Midazolam|Intravenous infusion
75653137|NCT00811837|Drug|Remifentanil|Intravenous infusion
75653138|NCT00817609|Drug|Angongniuhuang Pill|7 days of Angongniuhuang Pill
75653139|NCT00817609|Drug|placebo|7 days of placebo
75938810|NCT04058509|Combination Product|Focused shockwave therapy|3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.
75938811|NCT02320383|Biological|GA101 (Obinutuzumab)|"Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days"
75475706|NCT01998373|Behavioral|training leaflet and oral training|The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
75475707|NCT01998386|Other|Placebo gel without hydrogen peroxide|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
75653140|NCT00811915|Drug|Sirolimus|"Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
76089402|NCT04758663|Behavioral|Nap/wake conditions on overnight physiology|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities. On the nights of the nap and wake conditions, physiology will be recorded in habitual and non-habitual nappers.
75938812|NCT02320383|Drug|Bendamustine|"Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d"
75938813|NCT03668509|Drug|SHR1459|oral adminstration, single dose
76089403|NCT01920802|Drug|olanzapine|5mg BID up to 4 weeks
75938814|NCT03494595|Procedure|Pediatric Liver transplantation|Pediatric Liver transplantation
75938815|NCT03021265|Drug|T80/A5/H12.5 FDC|Drug
75938816|NCT02322567|Other|medical records|review of medical records
76089404|NCT01920802|Drug|iloperidone|6 mg BID up to 4 weeks
76089405|NCT01920802|Drug|Placebo|BID up to 4 weeks
75938817|NCT03704987|Diagnostic Test|dual-energy X-ray absorptiometry|dual-energy X-ray absorptiometry
75938818|NCT03669289|Other|enhanced model of primary care|The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
75938819|NCT04461951|Other|Lifestyles (exposure)|no intervention
75938820|NCT03668353|Biological|Recombinant SeV-hFGF2/dF Injection|intramuscular injection of investigator drugs
75938821|NCT03704909|Drug|Adrenaline|i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
76089406|NCT01451151|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
76089407|NCT01732835|Device|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
76089408|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
75342748|NCT04271306|Biological|Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)|2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)
75342749|NCT01246895|Device|Microfracture with BST-CarGel|
75342750|NCT01246895|Device|Microfracture without BST-CarGel|
75342751|NCT03800420|Drug|BBT-401-1S first and then Placebo|Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
75653141|NCT00816127|Drug|Desmopressin|intranasal desmopressin (300μg)
75653142|NCT00816127|Biological|blood transfusion|fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
75653143|NCT00916058|Drug|Bendamustine|30 mg/m^2 given on day 2 of melphalan
75653144|NCT00916058|Drug|Melphalan|100 mg/m^2 for 2 days (70 mg/m^2 for patients with Creatinine Clearance <70 ml/min)
75653145|NCT00916058|Drug|Bendamustine|60 mg/m^2 given on the 2nd day of melphalan
75653146|NCT00916058|Drug|Bendamustine|90 mg/m^2 given on the 2nd day of melphalan
75653147|NCT00916058|Drug|Bendamustine|60 mg/m^2 given on the 1st and 2nd day of melphalan
75938822|NCT03704909|Drug|Ephedrine|i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
76089409|NCT05734924|Device|low Frequency High Intensity magnetic therapy|low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
76089410|NCT03824613|Diagnostic Test|Urinary miRNA|MiRNA detection in urine
76089411|NCT01451229|Drug|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
75342752|NCT03800420|Drug|Placebo first and then BBT-401-1S|Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
75800716|NCT05763394|Other|High intensity workout program|High intensity workout (HIIT) (two sessions/day, 5 days a week), characterized by a 10-minute warm-up performed at 50% of peak V'O2 , followed by 6 series of 40 s of high-intensity walking corresponding to 95% of peak V'O2, interspersed with 5 minutes of walking at 40% of peak V'O2, ending with 5' of cool-down at 50% of the peak V'O2. Total of 24 sessions in 12 days.
75938823|NCT03704831|Other|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block (Interspace between the Popliteal Artery and the Capsule of the posterior Knee)
75938824|NCT03704831|Other|Injection of local anesthetics during total knee arthroplasty by surgical infiltration|Injection of local anesthetics during total knee arthroplasty by surgical infiltration.
75938825|NCT04462029|Drug|BR4002|"Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours"
75938826|NCT04462029|Drug|BR4002-1|Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
75938827|NCT03669055|Other|Magnetic Resonance Imaging|Realization of a MRI before and after the endovascular treatment of the aortic dissection. Use of the 4D phase-contrast sequence during the MRI.
75938828|NCT03704675|Drug|TEW-7197|Administered orally
75938829|NCT03494517|Drug|Magnesium Sulfate|Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
75938830|NCT04461873|Other|Reiki|Reiki by touching
75938831|NCT04461873|Other|Sham Reiki|Sham reiki by gesturing and mimic imitation through touching
75938832|NCT04177901|Device|Near infrared spectroscopy|It is used for detection of tissue oxygenation
75938833|NCT02320617|Procedure|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
75938834|NCT03491865|Behavioral|REAL media Plus curriculum|REAL media Plus is a 7-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth smoking and vaping use.
75653148|NCT00916058|Drug|Bendamustine|90 mg/m^2 given on the 1st day of melphalan and 60 mg/m^2 given on the 2nd day of melphalan
75938835|NCT04912427|Drug|Isatuximab|Isatuximab is supplied by Sanofi.
76089412|NCT01957384|Device|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
76089413|NCT01957384|Device|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
75653149|NCT00916058|Drug|Bendamustine|125 mg/m^2 given on the 1st day of melphalan and 100mg/m^2 given on the 2nd day of melphalan
75653150|NCT05228678|Diagnostic Test|cardiopulmonary exercise tests|"Spirometry~forced expiratory volume in 1 second (FEV1) % predicted,~forced vital capacity (FVC)% predicted,~forced expiratory volume in 1 second /forced vital capacity FEV1 /FVC"
75938836|NCT04912427|Drug|Bortezomib|Bortezomib is commercially available.
75938837|NCT04912427|Drug|Dexamethasone|Dexamethasone is commercially available.
75938838|NCT03496935|Device|Tunneled versus non-tunneled dialysis catheter insertion|The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
76089414|NCT01957384|Device|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|"Standard Care was the subject usual ostomy appliance and had to be one of the following:~Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,~Dansac: Nova 1 & Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate~Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate~ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate~B. Braun: Flexima Active & Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate"
76089415|NCT01451619|Drug|Laropiprant|One 100-mg tablet orally once daily for 4 weeks
76089416|NCT01451619|Drug|Placebo for Laropiprant|One tablet orally once daily for 4 weeks
76089417|NCT03054519|Drug|Metformin|Participants will be prescribed up to 2,000 mgs daily of metformin
75653151|NCT04253288|Other|Morbidity Mortality Review (MMR)|"Standardization of Morbidity Mortality Review (MMR) in radiotherapy centers~National database from MMR board meetings which include clinical , radiation technique and biological parameters of intrinsic radiosensitivity of patients"
75800717|NCT01569724|Other|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
75800718|NCT03781908|Drug|Silver Nitrate|First, pleural fluid drainage will be done after administration of 5 cc of local anesthetic lidocain1% either by insertion of chest tube (26F or 28F ) or by using ultrasonography. Pleural fluid drainage will be terminated when the patient want to cough to make sure that the pleural cavity is empty, then the sclerosant material will be injected, patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%.
75938839|NCT04050839|Other|Pain neuroscience education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
75342753|NCT03802760|Device|Transcranial Doppler (TCD) ultrasound measurement|Non-invasive measurement of cerebral embolic load and blood flow using TCD
75938840|NCT04050839|Drug|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
75938841|NCT02322645|Drug|Eszopiclone Tablets 3 mg|
75938842|NCT04050761|Biological|Nivolumab|Specified dose on Specific Days
75475708|NCT01998386|Other|6.0% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
75342754|NCT04345484|Behavioral|Goal-management training|9-week goal-management program
75475709|NCT01998386|Other|7.5% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
75475710|NCT01998386|Other|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
75800719|NCT03781908|Device|Indwelling Pleural Catheter|"First , insert the wire into the pleural effusion at approximately the anterior axillary line. A 1-2 cm incision is made over the wire. A chest wall tunnel (5-8 cm in length) is created with a counter incision. The catheter is pulled through the tunnel and out next to the wire. After dilation of the wire tract with a Teflon peel-away sheath, the indwelling catheter is inserted into the chest. The counter incision is closed primarily, and the catheter is secured to the skin medially with a suture."
75800720|NCT03781830|Other|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
75800721|NCT05764486|Device|Hitachi's Heavy Ion Beam Therapy System HyBEAT|treating patients with solid tumor
75800722|NCT05694078|Other|Hand Therapy Splinting Protocol|Relative motion splinting protocol
75938843|NCT03496857|Device|Light emitting diode|Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.
75938844|NCT03496857|Other|Bath Therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
75938845|NCT05130021|Drug|MAX-40279-01|MAX-40279-01 50mg/70mg
75938846|NCT05130021|Drug|regorafenib|regorafenib
75938847|NCT02324595|Procedure|Laparoscopic interval debulking surgery|"Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered"
75938848|NCT03491787|Device|Ultrasound guidance|The ultrasound guidance was used to obtain intraosseous access
75342755|NCT04345484|Behavioral|Control|Healthy Lifestyle Program
75342756|NCT01247285|Drug|Fluoxetine Hydrochloride|90 mg Capsules
75342757|NCT01247285|Drug|PROZAC WEEKLY®|90 mg Capsules
75342758|NCT03806582|Drug|Norepinephrine|intervention with norepinephrine to reach a MAP of 85 mmHg
75342759|NCT00779558|Drug|Heparin sulfate infusion at 10 units/kg/hour|Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
75342760|NCT00779558|Drug|Placebo infusion|Infusion of normal saline
75342761|NCT01300559|Device|Tissuelink device|Tissuelink device plus Unipolar electrocautery
75342762|NCT03806894|Diagnostic Test|Quantification of platelet aggregation|Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay
75342763|NCT01300949|Diagnostic Test|Spaeth/Richman Contrast Sensitivity Test|internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.
75475711|NCT01998451|Drug|Tauroursodeoxycholic acid|patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
75475712|NCT01998490|Other|Animal-assisted activity|
75475713|NCT01998490|Other|Robot-assisted activity|
75475714|NCT01998503|Drug|Bortezomib|
75475715|NCT01998503|Drug|dexamethasone|Given orally
75475716|NCT01998503|Biological|filgrastim|Given subcutaneous
75938849|NCT05099757|Biological|20 µg dose hepatitis B vaccine|one-dose, two-dose or three-dose, 20 µg per dose
75938850|NCT03494283|Behavioral|Practice Behaviour|Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
75938851|NCT02322957|Drug|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
76089418|NCT03054519|Drug|Placebo|Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
76089419|NCT01921894|Dietary Supplement|Cholecalciferol|vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
75475717|NCT01998503|Procedure|autologous hematopoietic stem cell transplantation (ASCT)|Given on day 0
75653152|NCT04559906|Other|Spray and Stretch technique (Ethyl chloride)|"Group A receive spray and stretch technique (Ethyl chloride) with conventional treatment.~The upper trapezius muscle stretches on the basis of the Technique originally described by Simons. The subject is seated in a relaxed position on their homolateral hand for anchoring the distal end of the studied muscle. Initially, 3 to 5 parallel sweeps of ethyl chloride spray is applied covering the Upper trapezius muscle. Then, the muscle are positioned in a maximal but tolerable stretch and lengthened until the Physical Therapist felt the muscle tension barrier. This procedure repeated 2 or 3 times."
76089420|NCT03047577|Behavioral|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
75342764|NCT01300949|Diagnostic Test|Pelli-Robson Contrast Sensitivity Chart|wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.
75342765|NCT01301183|Drug|RhIGF-1 with transdermal 17-beta estradiol|"RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D."
75342766|NCT01301183|Drug|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
75800723|NCT03427528|Behavioral|Fathers and Babies (FAB)|The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session.
75938852|NCT04785261|Drug|Methylhydroxypropylcellulose|1-2 drips each time, every 4 hours, for 12 weeks.
76089421|NCT01452009|Drug|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
76089422|NCT01452009|Drug|TRAVATAN®|TRAVATAN® administered one drop once daily
75342767|NCT00758420|Drug|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
75342768|NCT00758420|Drug|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
76089423|NCT03824379|Dietary Supplement|Magnesium citrate|magnesium citrate equivalent 20-30 mmol elemental magnesium
75342769|NCT00779870|Other|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
75342770|NCT01213043|Biological|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks
75475718|NCT01998503|Drug|Melphalan|
75475719|NCT01998542|Biological|AlloVax|Personalized anti-cancer vaccine with AlloStim(TM) and CRCL
75475720|NCT01998542|Biological|CRCL|autologous tumor-derived chaperone protein mixture
75475721|NCT01998542|Biological|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
75800724|NCT03427528|Behavioral|MB 1-on-1 plus TXT|Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT). After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
75800725|NCT05694000|Device|On-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is on."
75800726|NCT05694000|Device|Off-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is off."
75938853|NCT04785261|Drug|Carbomer|1 drip each time, at bedtime, for 12 weeks.
75938854|NCT04785261|Drug|TCM Formula|6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
75938855|NCT04611789|Drug|LY3832479|Administered subcutaneously
75938856|NCT04611789|Drug|Placebo|Administered subcutaneously
75938857|NCT03496389|Drug|Gabapentin|Gabapentin 300mg daily
75938858|NCT03496389|Drug|Tramadol|Tramadol 50mg QID
75938859|NCT03496389|Drug|Panadol|Panadol 500mg QID
75938860|NCT03496311|Diagnostic Test|Acid - Base characterization|Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels
76089424|NCT03824379|Drug|Antidiabetic|insulin or oral hypoglycemics
76089425|NCT01957930|Drug|Intensified insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
76089426|NCT01957930|Drug|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
75342771|NCT01213043|Biological|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks
75342772|NCT00758576|Device|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
75475722|NCT01998555|Other|CBT|
75475723|NCT01998568|Other|Intraocular pressure measurement|Using different tonometers for intraocular pressure measurement
75342773|NCT01213199|Drug|Adapalene|Adapalene Gel 0.3%
75800727|NCT05622396|Procedure|Mindfulness Based Stress Reduction|Inspired by the standard Mindfulness Based Stress Reductio program, the study MAdaPARK is a 8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews carried out as part of the M-PARK study,as well as the reflections of the working group specially set up for this purpose. Several areas of adaptation have been identified: shorter mediations, a break time during the sessions, more times for exchanges, a more developed practice in movement, and finally, more important work based on self-esteem and self-compassion.
75938861|NCT02323035|Device|Headgear|Investigative Headgear with CPAP Mask.
75938862|NCT03496155|Behavioral|Build and Support Your Teen's Strengths|"This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach."
75938863|NCT04414527|Behavioral|Standard counselling|"The control cohort will receive national standard counseling during four ante-natal care visits.~Women in the control group will receive additionally~national nutrition and health care including IFA supplementation,~treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
75938864|NCT04414527|Behavioral|Health-Video|"The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education.~Women in this group will receive additionally:~National nutrition and health care including IFA supplementation~treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
75938865|NCT03491709|Drug|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
75938866|NCT03491709|Drug|Cetuximab injection|Cetuximab injection
75938867|NCT02325063|Drug|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
75800728|NCT03781596|Diagnostic Test|Retrospective evaluation of endoscopy prior to study drug|Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.
75342774|NCT03809702|Drug|Pregabalin|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
75342775|NCT03809702|Drug|Placebo|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
75342776|NCT03806036|Drug|Vitamin D|300.000 I.U single dose of VIT D IM injection
75342777|NCT03806036|Drug|Clomiphene Citrate|100mg daily for 5 days starting from third day of menstruation
75342778|NCT03806504|Other|PEEP|performing 35 cm/H2O PEEP and 2-3 ml/kg tidal volume
75342779|NCT03806504|Other|control group|performing 6 cm/H2O PEEP and 6-8 ml/kg tidal volume
75342780|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
75653153|NCT04559906|Other|Sustain pressure release|"Group B receive sustain pressure release with conventional treatment. Progressive pressure release are considered in two stages. The initial step is to recognize and find the trigger in upper fiber of trapezius, utilizing trigger point palpation. Trigger point felt as firm and restricted hyperirritable knots with in gut of the muscle.~The second step is to applying pressure release ranging from eight to twelve second for each pressure, then it increases gradually for maximum of twenty seconds. The total duration of pressure is five minutes or more until the discharge is felt by the fingers."
75653154|NCT04633694|Dietary Supplement|insect, pea or whey protein|The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.
75653155|NCT04624334|Other|Elektro-Entero-Graphy procedure|Fasting, after which pre- and postprandial EEnG measurements are performed.
75653156|NCT04624334|Other|EEnG Questionnaire|Filling out questionnaire about EEnG procedure.
75653157|NCT04624334|Other|Gold Standard Questionnaire|Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.
75800729|NCT03781596|Other|Symptom Survey|Patient will complete symptom survey prior to starting the study drugs.
75800730|NCT03781596|Other|Medication Compliance Phone Call|The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.
75800731|NCT03781596|Diagnostic Test|Endoscopy while on study drug|Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.
75938868|NCT02325063|Drug|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
75938869|NCT02325063|Drug|Corticoid injection|Patients will be treated with an injection of Corticoids.
75938870|NCT04086693|Device|Standard IV dressing|Polyurethane and clear tape dressing used to secure peripheral IV
75938871|NCT04086693|Device|Standard IV dressing plus a tissue adhesive peripheral IV securement device|Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
75938872|NCT02325141|Procedure|laparoscopic sleeve gastrectomy|creation of a gastric tube of 100cc using a stapler.
75938873|NCT03495999|Diagnostic Test|hyperuricemia|serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
75938874|NCT02323191|Drug|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
75938875|NCT02323191|Drug|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
75938876|NCT02323269|Drug|dimethyl fumarate|administered according to the local product label (i.e., Canadian Product Monograph).
75938877|NCT02323347|Other|Progesterone|Progesterone level
75938878|NCT03495843|Diagnostic Test|Spinal stiffness|Spinal stiffness will be assessed with a device, which measures tissue compliance according to the concept of impulse-response
75938879|NCT04070313|Drug|S-1|Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
75938880|NCT03763149|Biological|IBI188|"The study is composed of two stages: Part 1 Accelerated Titration Phase and Part 2 Dose Escalation Phase with initial fixed priming dose.~The starting dose for part 1 is 0.1 mg/kg QW, followed by 2 dose cohorts (0.3 mg/kg QW and 1 mg/kg QW). Duration of dose limiting toxicity (DLT) observation is 28 days.~Part 2 will have 4 dose cohorts(3mg/kg QW、10mg/kg QW、20mg/kg QW and 30mg/kg QW). Conventional 3+3 Dose Escalation will be adopted. DLT observation period is 28 days."
75938881|NCT03495765|Drug|Ranibizumab|Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
75938882|NCT03495531|Device|Virtual Reality|Virtual Reality headset with calming scenery
75938883|NCT02325297|Other|Letter of condolence|
75938884|NCT02325375|Procedure|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
75938885|NCT03491475|Drug|Ajmaline test|Administration of Ajmaline
75938886|NCT02325453|Procedure|Robotic Surgery|Surgical procedure performed with a robotic system.
75800732|NCT03781596|Other|Symptom Survey|The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.
75938887|NCT02325453|Procedure|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
76089427|NCT01759511|Drug|Simtuzumab|200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
76089428|NCT03824457|Drug|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
76089429|NCT03824457|Drug|Ringer lactate|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
75653158|NCT04619498|Device|PediAppRREST|PediAppRREST is a new audiovisual interactive app for tablets developed to support the management of pediatric cardiac arrest. It sequentially displays directions on recommended management interventions. It was specifically designed to guide the team leader to perform resuscitation interventions in the sequence/timing and modality reported by the American Heart Association Pediatric Advanced Life Support (AHA-PALS) guidelines.
75653159|NCT04619498|Other|AHA-PALS pocket reference card|It is a 10 cm x 16.5 cm, full-color, 2-sided, 6-panel card that shows the American Heart Association Pediatric Advanced Life Support (AHA-PALS) treatment algorithms. By providing a quick reference tool, it serves as a cognitive aid for healthcare providers who either direct or participate in the management of pediatric respiratory and/or cardiovascular emergencies, including cardiac arrest.
75800733|NCT03781596|Drug|Fluticasone|Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.
75800734|NCT03781596|Drug|Omeprazole|The participants in the experimental arm will be given oral omprazole capsules for an 8 week period (along with the swallowed fluticasone). Doses determined by age and weight.
75938888|NCT02325453|Procedure|Open Surgery|Traditional approach for gastric cancer.
75938889|NCT03561597|Behavioral|Mobile health intervention|The Kurbo program is a multifunctional mobile application that aid adolescents and their families to learn healthy eating habits and weight management through the use of a mobile application with dietary self-monitoring and weekly interactive coaching sessions. Using the Kurbo app, adolescents track their food and exercise, as well as learn about healthy behaviours through games and videos. The Kurbo coaches check in with adolescents for 15 minutes once a week via video, phone or text over a 12 weeks period.
75938890|NCT02323425|Device|Remote ischemic postconditioning|Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
75938891|NCT02323503|Device|CRT-D device replacement|
76089430|NCT01958320|Other|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
75342781|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
75342782|NCT00780026|Drug|insulin|bolus or infusion 80 to 110 mg/dl
75653160|NCT04422314|Diagnostic Test|T-Detect Lyme|T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.
75653161|NCT04599920|Dietary Supplement|Partial replacement of red meat with legume-based foods|560 g of cooked and boneless red meat is replaced with legume-based foods providing the equal amount of protein.
75653162|NCT04443842|Behavioral|Financial and social incentives|"Participants will be credited with HK$1000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, participants will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.~The social incentives are peer comparison and social support. Participants receive feedback of their physical activity performance by assessing whether they met or exceeded their step count target, followed by positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support."
75653163|NCT00912782|Drug|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
75653164|NCT00912782|Drug|Placebo|Placebo one time per week for 3 weeks
75938892|NCT03499119|Drug|AMG 334 Dose 1|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2"
75938893|NCT03499119|Drug|AMG 334 Dose 2|Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
75653165|NCT00632060|Procedure|Manual / Manipulative Therapy (M/MT)|Subjects will receive M/MT twice a week for 4 weeks
75653166|NCT04205396|Behavioral|Written emotional disclosure|Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
75342783|NCT01214057|Drug|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
75938894|NCT03499119|Drug|AMG 334 Dose 3|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
75475724|NCT01998594|Procedure|Arthroplasty|A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
75800735|NCT03781596|Drug|Placebo oral capsule|The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
75475725|NCT01998607|Other|Physician Survey|Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
75475726|NCT01998620|Drug|Ademetionine 2|Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
75475727|NCT01998620|Drug|Ademetionine 1|Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
75475728|NCT01998620|Drug|Ademetionine 3|no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
75475729|NCT01998646|Drug|ASP4058|Oral tablet
75475730|NCT01998646|Drug|Placebo|Oral tablet
75475731|NCT01998659|Drug|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
75653167|NCT04205396|Behavioral|Resilience training|Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
75800736|NCT04074148|Behavioral|Diabetes Prevention Education Program|An educational lifestyle modification program, offering 4 sessions of 30 minutes theory and 30 minutes practice each, total duration 6 months
75475732|NCT01998659|Drug|Placebo|Oral drinking solution
75475733|NCT01998672|Drug|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
75475734|NCT01998672|Drug|Placebo|Drinking solution
75800737|NCT04074148|Behavioral|Diabetes Prevention Education brochure|An educational lifestyle modification brochure
75938895|NCT03132207|Other|Non interventionel study|Only one questionnaire will be done for women and professional
75938896|NCT03328845|Drug|Toujeo SoloStar|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
75475735|NCT01998685|Drug|Propofol|
75475736|NCT01998685|Drug|remifentanyl|
75475737|NCT01998685|Drug|Midazolam|
75475738|NCT01998685|Drug|Fentanyl|
75475739|NCT01998685|Drug|Sevoflurane|
75653168|NCT04205396|Other|No treatment|Participants will complete baseline and outcome assessments and no intervention will be conducted.
75475740|NCT01998698|Procedure|Phacoemulsification surgery|Phacoemulsification surgery with intraocular lens implantation and monovision correction
75475741|NCT01998698|Procedure|Phacoemulsification surgery|Phacoemulsification surgery with multifocal intraocular lens implantation
75475742|NCT01998711|Behavioral|Memory group|Five 1-1.5 hour weekly session of memory training
75475743|NCT01998724|Behavioral|Tai Chi|24 week tai chi intervention designed for individuals with COPD
75475744|NCT01998724|Behavioral|Group Walking|24 week group walking intervention
75475745|NCT01998763|Dietary Supplement|Placebo|placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
75653169|NCT04730804|Drug|ALXN1830|ALXN1830 will be administered as SC infusion(s).
75653170|NCT04730804|Drug|Placebo|Placebo will be administered as SC infusion(s).
75653171|NCT04202978|Drug|Camrelizumab|Camrelizumab ：200mg intravenous injection d1 q3w
75653172|NCT04202978|Drug|Apatinib Mesylate|Apatinib：250mg/d P.O ,qd ,3weeks
75475746|NCT01998763|Dietary Supplement|Vitamin D3|Vitamin D3 2000 IU per day
75653173|NCT04202978|Drug|Capecitabine|capecitabine:850mg/m2 P.O ,bid ,d1-d14
75800738|NCT03781674|Drug|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age
75800739|NCT03781674|Drug|progesterone 200mg|Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
75938897|NCT03328845|Drug|Tresiba|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
75938898|NCT03328845|Drug|Humalog Kwikpen|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels < 150 mg/dl
75938899|NCT03328845|Drug|NovoRapid|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels < 150 mg/dl
75475747|NCT01998776|Drug|Misoprostol|Misoprostol 200ug four times daily
75475748|NCT01998776|Drug|Placebo|Placebo Starch four times daily
75800740|NCT03781674|Drug|placebo to progesterone 200mg|Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
75938900|NCT03328845|Drug|Apidra|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels < 150 mg/dl
75938901|NCT03495297|Procedure|ommitence of defibrillation testing|Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted
75938902|NCT03291171|Behavioral|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
75938903|NCT02323737|Drug|Irinotecan and cisplatin|
75938904|NCT02323737|Drug|Etoposide and cisplatin|
75938905|NCT03491319|Procedure|Group X - head low tilt|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal anaesthesia
76089431|NCT01958320|Other|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
76089432|NCT01958320|Drug|NSAID|Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
76089433|NCT04414007|Behavioral|Internet+ home-based cardiac rehabilitation|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
76089434|NCT04414007|Behavioral|Conventional rehabilitation|We provide patients with cardiac rehabilitation manuals and exercise logs. 4 weeks after ablation，Patients have CPET.Their exercise prescription was made according to CPET .The patients have rehabilitation training at home and recorded their exercise data including exercise time、type、frequency and average heart rate.
76089435|NCT01452087|Other|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
75475749|NCT01998789|Drug|Everolimus|Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).
75475750|NCT01998789|Drug|Standard Tacrolimus|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
75800741|NCT03781674|Drug|placebo to progesterone 400mg|Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age
76089436|NCT01452321|Procedure|repetitive transcranial magnetic stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
76089437|NCT01732757|Drug|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
76089438|NCT01732757|Drug|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
76089439|NCT01732757|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
76089440|NCT03824301|Device|Volume controlled ventilation|Changing modes of ventilation during cardiopulmonary bypass
75475751|NCT01998802|Drug|Active Comparator EBI-005|
75475752|NCT01998802|Drug|Placebo Comparator|
75475753|NCT01998854|Device|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
75475754|NCT01998945|Behavioral|Exposure-based Cognitive Behavioral Therapy|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
75475755|NCT01998945|Behavioral|Relaxation Training|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
75800742|NCT03166930|Behavioral|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
75800743|NCT03166930|Behavioral|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management from the manual.
75938906|NCT03491319|Procedure|Group Y - head low tilt|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
75475756|NCT01998997|Behavioral|Family educational intervention|The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
75475757|NCT01999010|Device|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
75475758|NCT01999023|Dietary Supplement|Low protein formula group|Low protein formula formula (28.5 g) twice a day
75475759|NCT01999075|Device|Lung Volume Recruitment (LVR)|LVR will be used twice per day
75938907|NCT03491319|Procedure|Group C - neutral|spinal anaesthesia was given with table in neutral positon. Patient was maintained in supine position for 10 minutes following spinal anaesthesia
75938908|NCT03037359|Biological|Bivigam|Human immune globulin
75938909|NCT03037359|Biological|Other|Human immune globulin
75938910|NCT03491241|Dietary Supplement|hypocaloric diet therapy|all patients will receive an hypocaloric diet, with low carboidrates (<50%) overload.
75938911|NCT03495219|Procedure|Esophageal Manometry|A catheter inserted through the nares, post appropriate anesthetization. The subject is then given 8 - 10 sips of water or semi viscous fluid during the routine study. At the conclusion of the clinical portion of the examination the manometer catheter is typically removed by the technician at that point. For the purposes of this research study the catheter will remain in place to examine pressures specifically at the lower end of the esophagus during various breathing patterns and training activities to see if pressures can be increased with instruction.
75938912|NCT03491163|Diagnostic Test|Syndecan-1 concentration evaluation|Blood sample will be taken and analysed using ELISA method.
75938913|NCT02323815|Dietary Supplement|Small-Quantity Lipid-based nutrient supplement|A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
75938914|NCT02323815|Behavioral|Child's health and nutrition topics|Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
75938915|NCT03491085|Drug|Amoxicillin/clavulanate|after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.
76089441|NCT03824301|Device|Pressure controlled ventilation|Applying pressure controlled ventilation during cardiopulmonary bypass Period
76089442|NCT01452399|Procedure|Shave margins|Partial mastectomy with shave margins.
75475760|NCT01999075|Other|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
75800744|NCT03786120|Drug|Zolpidem|PO sleep aid in various doses
75800745|NCT03783858|Device|P200TE|OCT images
75800746|NCT01308138|Behavioral|Exercise training|exercise training
75800747|NCT01308138|Procedure|remote ischemic preconditioning|remote ischemic preconditioning
75800748|NCT03781518|Procedure|ridge splitting in group and khoury shell technique in the other group|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
75938916|NCT02323893|Drug|[18F]F-AraG|
75938917|NCT02323971|Drug|Ticagrelor|
75475761|NCT01999088|Other|Functional Meet|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
75475762|NCT01999088|Other|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
75938918|NCT03490851|Other|Oatmeal + OatWell28CF Int 1|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
75938919|NCT03490851|Other|Oatmeal + OatWell28CF Int 2|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
75938920|NCT03490851|Other|Oatmeal + OatWell28CF Int 3|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
75938921|NCT03490851|Other|Cream of Rice|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
75475763|NCT01999101|Drug|Px-104|28 days treatment
75475764|NCT01999153|Drug|20 mL topically used during alginate dressing NAROPEINE|20 mL topically used during alginate dressing
75475765|NCT01999153|Drug|20 mL topically used during alginate dressing NaCl|20 mL topically used during alginate dressing
75653174|NCT04202978|Drug|Oxaliplatin|oxaliplatin:130mg/m2 intravenous injection d1 q3w
75653175|NCT04202978|Radiation|radiofrequency ablation|radiofrequency ablation:between first cycle and second cycle percutaneous
75653176|NCT04186442|Drug|Botulinum toxin type A injection|Experimental
75653177|NCT04186442|Drug|Botulinum Toxin Type A Injection [Botox]|Active Comparator
75653178|NCT00631982|Procedure|in vitro matuartion of oocytes|in vitro maturation of (immature) oocytes
75653179|NCT04203368|Drug|adenosine|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
75800749|NCT01561014|Drug|erlotinib hydrochloride|Given PO
76089443|NCT01452399|Procedure|No Shave Margins|Partial mastectomy without shave margins.
76089444|NCT03824067|Diagnostic Test|Point of Care Early Infant Diagnosis|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
76089445|NCT03824067|Diagnostic Test|Standard of Care Early Infant Diagnosis|Conventional laboratory based EID testing
76089446|NCT01758731|Drug|Olaparib|Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.
76089447|NCT01758731|Drug|Cetuximab|Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.
75475766|NCT01999166|Radiation|radiography (X-ray)|
75475767|NCT01999166|Genetic|DNA sampling|
75475768|NCT01999205|Behavioral|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
75800750|NCT01561014|Drug|oxaliplatin|Given IV
75800751|NCT01561014|Drug|fluorouracil|Given IV
75800752|NCT01561014|Radiation|radiation therapy|Undergo radiotherapy
75938922|NCT04461717|Device|MicroNet covered stent implantation in the increased risk arterial lesions beyond the carotid bifurcation|Implantation of the MicroNet covered stent in the increased risk arterial lesions beyond the carotid bifurcation as per Vascular Team recommendation
75342784|NCT01214057|Drug|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
75938923|NCT03148899|Drug|Oxytocin Intranasal Spray|In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
75800753|NCT01561014|Procedure|conventional surgery|Undergo surgical resection
75342785|NCT03009149|Other|Aerobic exercise|Aerobic exercise will perform 3 days per week
75342786|NCT00780338|Other|Assets Getting To Outcomes|Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
75938924|NCT03148899|Drug|Placebo Intranasal Spray|The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
75938925|NCT03493893|Device|Intermedullary nail|investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
75938926|NCT03495141|Behavioral|Supervision/Coaching|Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
75938927|NCT03495063|Dietary Supplement|Natural Caffeine|Consumption of 400mg of natural caffeine
75342787|NCT03805958|Procedure|realtime ultrasonography|Applying realtime ultrasound during the combined anesthesia
75342788|NCT03805958|Procedure|prescan ultrasonography|Applying realtime ultrasound before the combined anesthesia
76089448|NCT01758731|Radiation|Radiation Therapy|RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
75342789|NCT03809546|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
75342790|NCT03809546|Drug|dextrose|We are administering dextrose to health volunteers for our placebo group
75342791|NCT03809312|Drug|Amoxicillin / Clavulanic acid 875mg / 125mg|Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
75342792|NCT03809312|Drug|Placebos|Placebos BID x 10 days
75342793|NCT03807986|Procedure|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
75342794|NCT03807986|Procedure|Microfat grafting|Microfat grafting will be applied once every three months for 2 times.
75342795|NCT03807986|Procedure|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
75938928|NCT03495063|Dietary Supplement|Synthetic Caffeine|Consumption of 400mg of synthetic caffeine
75342796|NCT03805802|Other|active product|Once daily consumption over the period of the study
75475769|NCT01999244|Behavioral|Self-monitoring skills|
76089449|NCT01452477|Drug|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
75342797|NCT03805802|Other|reference product|Once daily consumption over the period of the study
75938929|NCT02324127|Device|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
75938930|NCT03036267|Behavioral|BREATHE|Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.
75938931|NCT03036267|Other|Attention Control Condition|PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
75938932|NCT03132285|Device|PrePex|Prepex is a non surgical male circumcision device
75938933|NCT02325843|Other|human bone marrow MSC|The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
76089450|NCT01452477|Drug|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
76089451|NCT04168775|Device|Home PIFR monitoring with InCheck Dial|The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
75342798|NCT01247363|Drug|LY2608204|Administered orally.
75342799|NCT00780494|Drug|bevacizumab|Intravenous 15 mg/kg
75342800|NCT00780494|Drug|carboplatin|AUC 6, Intravenously Day 1 every 21 days
75342801|NCT00780494|Drug|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
75342802|NCT03806348|Procedure|Resuturing|Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
75342803|NCT00763412|Drug|placebo|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
75475770|NCT01999244|Behavioral|Technology|
75475771|NCT01999244|Behavioral|Interventionist Contact|
75475772|NCT01999257|Other|Online pre-test genetic education tool|See Arm Descriptions above.
75800754|NCT01561014|Other|immunohistochemistry staining method|Correlative study
75800755|NCT01561014|Procedure|positron emission tomography|Correlative study
75800756|NCT01561014|Procedure|computed tomography|Correlative study
75800757|NCT01561014|Procedure|laboratory biomarker analysis|Correlative study
75800758|NCT01561014|Genetic|gene expression analysis|Correlative study
75800759|NCT01561014|Radiation|fludeoxyglucose F 18|Undergo F18 PET and CT scan
75800760|NCT01561092|Drug|Escitalopram|5 or 10 mg escitalopram tablets administered orally once daily
75800761|NCT01561092|Drug|Placebo|Tablets
75938934|NCT02325921|Device|Magnetic Resonance Imaging|One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences, but without contrast enhancement.
76089452|NCT01452555|Behavioral|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
75938935|NCT03490617|Drug|Vaginal misoprostol|To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
76089453|NCT01452633|Drug|0.25% bupivicaine will be injected at the study port site prior to incision|Injection will precede the incision
75342804|NCT00763412|Drug|repaglinide|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
75342805|NCT01302743|Drug|Group 1: Metformin|Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
75342806|NCT01302743|Dietary Supplement|Group 2: Cinnamon Bark|Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days
75653180|NCT04203368|Drug|verapamil|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
75800762|NCT05494866|Drug|Cobicistat Oral Tablet|Cobicistat Oral Tablet
75800763|NCT05494866|Drug|Gemcitabin|Gemcitabin
75342807|NCT01302743|Dietary Supplement|Group 3: Cinnulin PF|Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
75938936|NCT03494907|Drug|Seltorexant|Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.
75938937|NCT03494907|Other|Placebo Matched to Seltorexant|Participants will be administered matching placebo to seltorexant tablets on Day 1.
75938938|NCT03494907|Other|Placebo Matched to Moxifloxacin|Participants will be administered oral dose of moxifloxacin placebo tablet on Day 1.
75475773|NCT01999270|Drug|Irinotecan|"Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)~Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider."
75342808|NCT01248221|Drug|[13C]-Spirulina platensis and 99mTc sulfur colloid|The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
75342809|NCT00763490|Procedure|Full intensity, double umbilical cord, stem cell transplant|stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
75475774|NCT01999270|Drug|Bevacizumab|Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
75475775|NCT01999270|Device|FDOPA-PET/MRI imaging|FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
75475776|NCT01999283|Other|Yoga Group Exercise|Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.
75475777|NCT01999283|Other|Pilates Group Mat Exercise|The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
75475778|NCT01999296|Device|Use of Thunderbeat (TM) in laparoscopic surgery|
75653181|NCT03444038|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
75938939|NCT03494907|Drug|Moxifloxacin Dose 1|Participants will be administered oral dose 1 of moxifloxacin on Day 1.
75938940|NCT03490539|Drug|Mycophenolate Mofetil|oral tablets
75938941|NCT03490539|Drug|Azathioprine|oral tablet
75938942|NCT03494751|Device|Heart monitor|Use of heart monitor device in the patients after acute myocardium infarct.
75653182|NCT00911534|Drug|rabeprazole sodium|One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
75653183|NCT00911534|Drug|Placebo|One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
75653184|NCT04319042|Procedure|Immediate Loading|The implant receives an artificial tooth the same day as it is placed.
75653185|NCT04319042|Procedure|Early Loading|The implant receives an artificial tooth 4 weeks after placement.
75653186|NCT00632138|Behavioral|exercise intervention|
75800764|NCT05494866|Drug|Nab paclitaxel|nab-Paclitaxel
75800765|NCT01561326|Behavioral|Cognitive-affective barriers counseling|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
75938943|NCT03494751|Device|No heart monitor|Standard monitoring by nurses.
75938944|NCT03494673|Diagnostic Test|BOLD MRI|"Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~BOLD MR images will be obtained by using a T2*-weighted two-dimensional gradient-echo sequence with echoplanar readout."
75938945|NCT03490461|Drug|Statin|Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
75938946|NCT03489135|Device|ReVene Thrombectomy Catheter|Endovascular treatment of an acute iliofemoral DVT
75938947|NCT03493737|Behavioral|Quality of life surveys|Quality of life surveys by EQ-5D and QLQ-C30
75938948|NCT03490305|Procedure|Exploratory laparotomy|Findings and procedures done at exploratory laparotomy
75653187|NCT00632138|Other|questionnaire administration|
76089454|NCT01452633|Drug|Saline will be injected at the study port site prior to incision|Injection will precede incision
75342810|NCT00763490|Drug|Flu/Bu4 conditioning regimen|"Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2"
75342811|NCT00763490|Radiation|Total Lymphoid Irradiation (TLI)|one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
75653188|NCT00632138|Procedure|biofeedback|
75653189|NCT00632138|Procedure|management of therapy complications|
75653190|NCT00632138|Procedure|psychosocial assessment and care|
75653191|NCT00632138|Procedure|quality-of-life assessment|
75653192|NCT04571840|Diagnostic Test|Multiparametric MRI +/- prostate biopsy|MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings
75653193|NCT04571840|Diagnostic Test|Biparametric MRI +/- prostate biopsy|MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings
75653194|NCT04302974|Procedure|Different structures and processes of primary care management strategies|Different structures and processes of primary care management strategies includes: Multi-morbidity, continuity-of-care, different service delivery models and management strategies (i.e. investigation frequency and specific drug regimens)
75653195|NCT04302974|Procedure|Multi-disciplinary Risk Factor Assessment and Management Programmes for diabetes (RAMP-DM)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for diabetes (RAMP-DM), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All DM patients are eligible to enrol into the DM RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
75475779|NCT01999309|Drug|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
75653196|NCT04302974|Procedure|Multi-disciplinary Risk Factor Assessment and Management Programmes for hypertension (RAMP-HT)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for hypertension (RAMP-HT), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All HT patients are eligible to enrol into the HT RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
75800766|NCT01561326|Behavioral|Cognitive-affective barriers counseling via brochure|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence via brochure, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
75800767|NCT01561326|Behavioral|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
75800768|NCT01316874|Drug|Valrubicin, 800 mg|Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
75800769|NCT01309542|Drug|Desvenlafaxine Succinate|Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
75938949|NCT03493659|Behavioral|Standing during Concept Test|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test.
75938950|NCT03493659|Behavioral|Standing during regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during their regular tutorial sessions.
76089455|NCT01452633|Drug|Saline will be in injected into the port site prior to closure|Saline will be injected into the port site prior to the closure without any preincisional intervention
75342812|NCT00763490|Drug|Graft versus Host Disease prevention (GVHD prophylaxis)|Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
75342813|NCT00763490|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) < 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.~MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued."
75342814|NCT01214759|Drug|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
75342815|NCT01214759|Drug|Raltegravir|Raltegravir 400mg twice a day
75938951|NCT03493659|Behavioral|Standing during Concept Test and regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test and during their regular tutorial sessions.
75938952|NCT03496077|Other|Flavored and unflavored little cigars/cigarillos (LCCs)|Flavored and unflavored LCCs that are currently available for purchase
76089456|NCT01452633|Drug|0.25% bupivicaine will be injected into the port site prior to closure|0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
76089457|NCT01606319|Drug|Acetaminophen|15 mg/kg every 6 hours as needed
76089458|NCT01606319|Drug|Ibuprofen|9.4 mg/kg every 6 hours as needed
76089459|NCT01452711|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
75653197|NCT04302974|Procedure|Patient Support Call Centre (PSCC)|RAMP Patients can also be referred to the Patient Empowerment Programme(PEP) - a structured self-care education programme delivered by non-governmental organisations(NGOs). If the DM control is suboptimal but the patient is unable to attend the PEP, they may be referred to the Patient Support Call Centre(PSCC) service. PSCC provides individualized telephone counselling by trained nurses. PSCC empowers high-risk DM patients to engage in self-care behaviours by providing regular protocol-led telephone support to advise and reinforce healthy behaviours. Targeted self-care behaviours include self-monitoring, medication management, balanced diet, exercise, risk factor reduction, problem solving and healthy coping. Enrolled patients receive weekly to bi-weekly calls in the first 3 months and additional calls as required for a maximum of 9 months. Subsequent follow-up calls are undertaken to assess self-care behaviours related to the selected goals and to develop a care plan with the patient.
75342816|NCT03805724|Other|Plaque Samples|After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.
75653198|NCT00911300|Drug|fondaparinux|Comparison of different drugs
75342817|NCT03806192|Behavioral|Telephone-Based Intervention|Attend psychoeducational counseling sessions via telephone
75653199|NCT00911300|Drug|unfractionated heparin|Comparison of different drugs
75653200|NCT00911300|Drug|Vitamin-K-Antagonist|Comparison of different drugs
75342818|NCT03806192|Other|Behavioral, Psychological or Informational Intervention|Attend psychoeducational counseling sessions via video teleconference
75800770|NCT03777150|Other|Postoperative care in Intensive care unit (ICU)|Postoperative care in Intensive care unit (ICU)
75800771|NCT03777150|Other|Postoperative care in standard ward|Postoperative care in standard ward
75800772|NCT01309620|Dietary Supplement|Zinc gluconate|Zinc gluconate (GNC, USA), 100 mg twice daily
75938953|NCT02586519|Device|SurroSense Rx System|"The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur."
75475780|NCT01999309|Drug|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
75938954|NCT02516553|Drug|BI 894999|day 1 to day 21 in 3-week cycles
76089460|NCT01452711|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
75475781|NCT01999387|Dietary Supplement|Allergenic food|
75475782|NCT01999413|Drug|OMEGAVEN|AML Study treatment induction phase
75475783|NCT01999413|Drug|Daunorubicin|AML Study treatment induction phase
75475784|NCT01999413|Drug|Cytarabine|AML Study treatment induction phase
75653201|NCT00632294|Procedure|Tissue Sample|A leftover sample of the removed allograft bone will be collected.
75653202|NCT04202822|Other|Oral soft tissues biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) will be harvested by the examiner at the time of the surgery (immediately before to start the surgical procedure -T0) and 24 hours after surgery (T24) at the level of the vertical released incisions (VRIs) with a biopsy punch with plunger of 2.0 mm diameter.
75342819|NCT03806192|Other|Questionnaire Administration|Ancillary studies
75342820|NCT01249625|Device|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
75342821|NCT01249625|Device|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
75342822|NCT03809468|Other|phone call follow up|instead of a clinic visit, patients will be randomized to a phone call
75475785|NCT01999426|Other|Airway clearance intervention|Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
75653203|NCT00911144|Biological|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
75800773|NCT01309620|Dietary Supplement|Placebo|Placebo, Twice Daily
75800774|NCT01312740|Other|LC-P-LGI diet|a hypocaloric diet low in lipids (25%) which is compensated by proteins (35%) with no change in carbohydrate content.
75800775|NCT01312740|Other|LC-CONV|4-week CONV period consisted in the subjects' consumption of 1200 Kcal/ day (25% protein, 31% lipids, 44% carbohydrates).
75800776|NCT05351658|Device|KronoSafe® System|All patients included in the study will have a temporary pacemaker with active fixation leads, held by the KronoSafe® fixation system.
75800777|NCT03783312|Drug|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
75800778|NCT03783312|Drug|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
75800779|NCT03783312|Drug|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
75800780|NCT01317108|Drug|CMF Chemotherapy|
75800781|NCT03776916|Other|Simethicone administration 20-30 min before the procedure|Patients intake simethicone 20-30 min before the procedure
75800782|NCT03776916|Other|Simethicone administration 31-60 min before the procedure|Patients intake simethicone administration 31-60 min before the procedure.
75938955|NCT02516553|Drug|BI 894999|day 1 to day 14 followed by a week off in 3-week cycles in schedule B
75938956|NCT02516553|Drug|BI 894999|one week on followed by one week off treatment, repeated every two weeks in 4-week cycles
76089461|NCT01452711|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
76089462|NCT01452711|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
76089463|NCT02630121|Drug|Oxymetazoline Hydrochloride|Proportion of the subjects with 50% reduction in AHI.
76089464|NCT02630121|Drug|Placebo|Proportion of the subjects with 50% reduction in AHI.
75653204|NCT00911144|Biological|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
75653205|NCT00911144|Biological|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
75475786|NCT01999439|Procedure|Eosinophilic Esophagitis with Dysphagia|"An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.~Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete."
75653206|NCT04561622|Behavioral|Emotional Stroop Task|"Classic Stroop task The subject names one of the 3 colors of the crosses on a sheet.Then, the subject must read the words written on the sheet for 45 seconds.These are the words: RED, BLUE and GREEN, written in black color. The subject must name the color of the word.~Emotional Stroop task This is a computed task in which the patient is asked to answer both as accurately and as quickly as possible.~The target stimulus is an emotional face of joy or anger, surmounted by the word joy or anger.The subject must respond using the arrow corresponding to the face he sees.~A training phase is offered to the subject.~3 / Categorization task For each trial the participant will visualize a short emotional film or not. Then, the participant will have to choose, the emotion corresponding to what he just saw. A training period is offered too."
75653207|NCT04395248|Procedure|Exploring potential risk factors of difficult intubation using ultrasound|Before surgery, ultrasound will be used to assess pretracheal soft tissue depth and height and width of tongue base. The distance from the skin to the anterior aspect of the trachea will be measured at three levels: vocal cords, thyroid isthmus, and suprasternal notch. With the patient in a seated position, the convex transducer of a portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be introduced to the skin of the neck in the submental region coronally, immediately cephalad to the body of the hyoid bone, and then in the area between the hyoid bone and the symphysis of the mandible. Maximal width of tongue base, tongue base height, and maximal height of mid-tongue will be measured. The laryngoscopy intubation will be performed using a size-3 or -4 Macintosh (Rüsch Inc., Duluth, GA, USA) blade and a styletted endotracheal tube. The laryngoscopic view will be graded according to Cormack and Lehane's classification with external laryngeal pressure applied.
75800783|NCT03776916|Other|Simethicone administration > 60 min before the procedure|Patients intake simethicone administration > 60 min before the procedure.
75800784|NCT03783390|Behavioral|Exercise Intervention|Youth randomized to the active condition will participate in an organized exercise program. During the exercise program, adolescents will participate in a supervised structured exercise (treadmill walking/cycling on stationary bike) on 3 days equivalent to approximately 180 min/week of moderate-intensity exercise. The rationale for this dose of structured exercise is based on national (ADA) and international physical activity recommendations for youth of 60 minutes/day.
75672295|NCT05662670|Drug|WJ13404 tablets|"Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied."
75672296|NCT02828345|Other|Specimen Collection|
75672297|NCT02536482|Dietary Supplement|Amix|Treat the children with cow's milk allergy for 5 months.
75800785|NCT03783390|Behavioral|Newsletter|"Families will receive a monthly newsletter with parenting tips, sample praise statements, and child-appropriate activities and recipes identical to what has been used in the work of leaders in the field of pediatric obesity. Previous research suggests that newsletter/mail interventions are well received by participants and are frequently included in federally funded health intervention studies."
75800786|NCT01317342|Device|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure < 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
75800787|NCT01317576|Behavioral|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
75800788|NCT01560702|Drug|Epinephrine|10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
75342823|NCT00759668|Device|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
75800789|NCT01560702|Biological|Blood|5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
75938957|NCT03034967|Drug|Danirixin|Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
75938958|NCT03034967|Drug|Danirixin matching placebo|Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
75938959|NCT03034967|Drug|Standard of care|Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
75342824|NCT00759668|Device|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
75342825|NCT00780572|Behavioral|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
75342826|NCT00780962|Drug|N-Acetylcysteine (NAC)|"Experimental:~Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."
75342827|NCT00780962|Drug|0.9% Sodium-chloride|"Placebo:~Before CT: 500 cc 0.9% Sodium-chloride~After CT: NS at 67 cc/hour for up to 24 hours."
75342828|NCT04384874|Other|Exercise therapy|A 12 week multi-stage exercise rehabilitation program
76089465|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
75342829|NCT00764738|Device|OCT, Multifocal ERG, Microperimetry|"OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry."
75342830|NCT00764738|Drug|Ranibizumab Ophthalmic|0.5 mg ranibizumab vs 2.0 mg ranibizumab
75653208|NCT04395248|Procedure|Radial artery catheterization using ultrasound guidance or blind palpation|For all patients, the wrist will be extended and taped to a board to maintain wrist extension. All patients will receive local skin anesthesia at the anticipated puncture site. All radial artery catheterizations will be performed by anesthesiology residents with similar levels of experience in both blind-palpation and ultrasound-guided radial arterial catheterization. In the ultrasound group, a linear vascular probe of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image. In the palpation group, the radial artery will be identified by palpation, and the cannula will be directed by continuous or intermittent palpation of arterial pulsation. An attempt is defined as a new penetration of the skin with the needle, followed by an unlimited number of subcutaneous needle redirections.
75800790|NCT03776838|Drug|Intravenous Fentanyl guided by SoC+NOL|Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
75800791|NCT03776838|Drug|Intravenous Fentanyl guided by SoC|Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
75800792|NCT03781206|Device|PICO™ 7|PICO™ system (Smith&Nephew Healthcare, Hull, UK) is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips.
75800793|NCT05542836|Behavioral|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
75800794|NCT05542836|Behavioral|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
75800795|NCT03781284|Diagnostic Test|[18F]-FDG PET/MRI|
75800796|NCT03781284|Diagnostic Test|Colonoscopy|
76089466|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
76089467|NCT02956785|Drug|10 mg Dinoprostone; CTS, UK|
76089468|NCT02956785|Drug|3 mg Dinoprostone vaginal tablet; Pfizer, UK|
76089469|NCT02956785|Drug|Aquacryl hydrogel rod; HPSRx Enterprises, USA|
76089470|NCT01452867|Device|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
75342831|NCT00781508|Drug|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
75475787|NCT01999439|Procedure|Eosinophilic Esophagitis with Dysphagia|Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
75475788|NCT01999452|Behavioral|Paleolithic diet|
75800797|NCT03781050|Drug|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
75800798|NCT01561170|Device|Active Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive active devices. Both patients and investigator are blinded.
75800799|NCT01561170|Device|Placebo Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive placebo devices. Both patients and investigator are blinded.
75800800|NCT01317654|Other|Observation|Collection of mortality data at 5 years post trial
75800801|NCT02865850|Drug|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
76089471|NCT01452867|Device|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
75342832|NCT00781508|Other|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
75342833|NCT03805568|Drug|dexmedetomidine infusion group|dexmedetomidine as anaesthetic adjuvant
75342834|NCT03805568|Drug|remifentanil infusion group|remifentanil as anaesthetic adjuvant
75938960|NCT03034967|Drug|Rescue medication|Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
75938961|NCT03021187|Drug|semaglutide|Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
75938962|NCT03021187|Drug|semaglutide|Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
75938963|NCT03021187|Drug|semaglutide|Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
75938964|NCT03021187|Drug|placebo|Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
75938965|NCT03493503|Drug|Salbutamol|Intravenous Salbutamol loading dose
75938966|NCT03493503|Drug|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
75938967|NCT03490149|Device|Electroconvulsive Therapy|Series of electroconvulsive therapy for major depressive disorder
76089472|NCT01452867|Device|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
76089473|NCT04273503|Behavioral|Mentoring/educational session|12 mentoring/educational sessions focused on physical activity and healthy nutrition by Mayo Clinic experts.
75342835|NCT00781898|Drug|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
75342836|NCT00781898|Other|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
75800802|NCT02865850|Drug|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
75938968|NCT03490149|Drug|Medication - Treatment as usual|Medication only sample - Treatment as usual
75800803|NCT03711162|Drug|GLPG1690|GLPG1690, film-coated tablets for oral use.
75938969|NCT02366559|Device|Hyfrecator|
75938970|NCT02366559|Device|532 nm Q-switched Nd:YAG laser|
75938971|NCT05150145|Radiation|Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.|Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .
75938972|NCT05150067|Other|A Blended Learning Programme|A blended learning programme with face-to-face training and an online module on handover practice
76089474|NCT02947581|Drug|Albendazole and praziquantel|Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
75342837|NCT03800732|Other|With Meal during night work|Two nights of work with a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
75342838|NCT03800732|Other|Without Meal during night work|Two nights of work without a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
75475789|NCT01999452|Behavioral|Diabetes diet|
75800804|NCT03711162|Drug|Placebo|Matching placebo, film-coated tablets for oral use.
75800805|NCT02347618|Radiation|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
75800806|NCT01309698|Drug|Vildagliptin (LAF237)|
75800807|NCT01309698|Drug|Voglibose|
75800808|NCT01309698|Drug|Vildagliptin and Voglibose|
75938973|NCT05150067|Other|Waitlist control group|The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed
75938974|NCT03493347|Behavioral|Equine-assisted Occupational Therapy|Occupational therapy provided in an equine environment that includes activities such as groundwork, grooming, tacking, mounting, and riding horses
75938975|NCT03668275|Procedure|(partial) oncological home-hospitalization|Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
75938976|NCT03489915|Device|OCT|Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity
75938977|NCT03667963|Other|Glucose|50g glucose dissolved in 250ml water
75938978|NCT03667963|Other|Glucose plus lactulose|50g glucose plus 10g lactulose dissolved in 250ml water
75938979|NCT03667963|Other|Hot Rice|Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.
75938980|NCT03667963|Other|Cold Rice|Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.
75938981|NCT03488901|Other|chemoresistance signature|to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy
75938982|NCT03667885|Diagnostic Test|Blood sample|basic blood sample
75938983|NCT03667885|Diagnostic Test|urine sample|basic urine sample
75938984|NCT03667885|Diagnostic Test|Multi planar MRI|T1 (with reduced affinity for fatty tissue) +/- contrast, diffusion weighted sequences and wash in/wash out
75938985|NCT03704597|Other|cryotherapy|Cooling of oral mucosa
75938986|NCT05149521|Other|None - this is a consensus group study to develop an intervention|None - this is a consensus group study to develop an intervention
75938987|NCT03489837|Drug|Levotuss|oral taken
75938988|NCT03488823|Dietary Supplement|with Flavanol|Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
75938989|NCT03488823|Dietary Supplement|without Flavanol|Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
76089475|NCT02947581|Drug|Albendazole and praziquantel placebo|PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
75475790|NCT01999504|Other|PAL-2|meal
75475791|NCT01999504|Other|TFH-1|Meal
75653209|NCT04395248|Device|Comparing the effectiveness of preoxygenation between high-flow nasal cannula and facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher & Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs. After tracheal intubation, correct placement of the endotracheal tube will be confirmed by capnography and the nasal prongs of the HFNC group will be removed.
76089476|NCT01453257|Drug|Tailored Chemotherapy|"Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU"
75342839|NCT03800732|Other|Sleep night|Two sleep nights and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
75938990|NCT03488745|Behavioral|IntelliCare + Phone Coaching|IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
75342840|NCT00765128|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
75672298|NCT04209452|Behavioral|Rehearsal strategy|Teaching children to cumulatively rehearse numbers as they are being said.
75342841|NCT00765128|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
75342842|NCT00765206|Drug|Omeprazole/sodium bicarbonate|Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
75342843|NCT00765206|Drug|omeprazole magnesium (20 mg equivalent)|Single dose of omeprazole magnesium per day for either 1 or 7 days.
75342844|NCT05316896|Other|Internal Perturbation|"Raising and lowering arms 90 degrees forward and sideways with eyes open and closed.~In tandem stance with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~While standing on one leg with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~Step forward and backward with right and left foot alternately~Take a step back and step back alternately with right and left foot~Put the right foot on the step and take it back, then do the same with the left foot and ask the patient to do it quickly.~First step on the step with the right foot and put the left foot next to it, then step down with the right foot and take the left foot with it, repeat the same with the left foot and ask the patient to do this. rapidly.~Normal gait, sideways gait, tandem gait, backward gait, raising and lowering the arms forward and sideways 90 degrees, respectively, during back-to-back tandem gait."
75342845|NCT05316896|Other|Eksternal Perturbation|"Front, side, and rear loading and release, pushing and pulling while standing with eyes open and closed~Front, side and rear loading and release, pushing and pulling while standing in tandem with eyes open and closed~Loading and releasing from the front, sides and back, pushing and pulling while turning the head left and right while standing~Front, side and rear loading and release, pushing and pulling while standing up and down with eyes open and closed~Front, side, and rear loading and release, pushing and pulling while standing on one leg with eyes open and closed~Holding the ball thrown by physiotherapist~Kicking a ball thrown by physiotherapist~Holding the ball thrown by the physiotherapist while standing in tandem, walking, walking sideways, walking in tandem, walking backwards."
75342846|NCT03809156|Drug|Riociguat Oral Product|Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
75342847|NCT03808844|Drug|HSK3486|Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
75475792|NCT01999504|Other|Reference|Meal
75475793|NCT01999543|Dietary Supplement|plant-based dietary supplement|
75475794|NCT01999543|Other|Placebo|
75475795|NCT01999582|Biological|Sotatercept|Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
75475796|NCT01999582|Biological|Sotatercept|Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
75475797|NCT01999634|Device|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
75938991|NCT03625505|Drug|Venetoclax|tablet, oral
75938992|NCT03625505|Drug|Gilteritinib|tablet, oral
75475798|NCT01999647|Procedure|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
75672299|NCT04209452|Behavioral|Reinforcement|Providing reinforcement for correct recall after a delay.
75938993|NCT03493269|Drug|BAY1834845|Orally administered.
75938994|NCT03493269|Other|Matching Placebo|Orally administered.
75938995|NCT03493269|Drug|Midazolam|Part 1: Orally administered 1mg as a single dose.
75938996|NCT04257682|Drug|Bupivacaine|Bupivacaine is a long-lasting dense sensory-motor block that can last up to four hours. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 6.75 mg to 8.25 mg for the knee, and 7.5 mg to 9 mg for the hip.
75938997|NCT04257682|Drug|Ropivacaine|Ropivacaine is a long-acting local anesthetic that is known for its differential sensory-motor block. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 9 mg to 11 mg for the knee, and 10 mg to 12 mg for the hip.
75342848|NCT03808844|Drug|Propofol|Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
75653210|NCT04395248|Drug|Type of volatile anesthetics and M-Entropy guidance of anesthesia depth|"At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge."
75938998|NCT04257682|Drug|Mepivacaine|Mepivacaine is an intermediate-acting local anesthetic producing shorting and motor-sparing blocks. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 40 mg to 50 mg for the knee, and 45 mg to 55 mg for the hip.
75653211|NCT04247048|Other|infusion of tracer [5,5,5-2H3] -L-leucine|A bolus of 6ml of [5,5,5-2H3] -L-leucine tracers will be performed followed by an infusion of 90 ml of [5,5,5-2H3] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.
75938999|NCT03704519|Drug|Darolutamide (BAY1841788)|300 mg tablet darolutamide, once orally
75939000|NCT03704519|Drug|Enzalutamide|4 x 40 mg capsules, once orally
75939001|NCT03704519|Other|Placebo|4 placebo tablets, once orally
75939002|NCT01735929|Procedure|Neck Liposuction and Ultrasound Treatment|
75939003|NCT01735929|Procedure|Sham Treatment|
75939004|NCT03489759|Device|ViE15-A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
75939005|NCT03489759|Device|REXEED-15A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
75342849|NCT05316428|Drug|TPN171H tablet plus alcohol|10 mg TPN171H tablet QD plus 0.5 g/kg alcohol
75653212|NCT00632216|Drug|Risedronate Sodium|
75653213|NCT04276298|Drug|Metronidazole cream|10% metronidazole applied rectally
75653214|NCT04276298|Drug|Metronidazole and Diltiazem cream|Combination Metronidazole and Diltiazem applied rectally
75653215|NCT04276298|Drug|Metronidazole and Lidocaine cream|Combination metronidazole and lignocaine applied rectally
75653216|NCT04276298|Drug|Metronidazole, Diltiazem and Lidocaine cream|Combination of all active agents tested applied rectally
75800809|NCT01142284|Drug|Cilostazol, Probucol|"Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID"
75800810|NCT03783156|Procedure|hot snare|polypectomy with hot snare
75653217|NCT04273880|Drug|Methylphenidate|10mg of MPH taken an hour and a half before one of the testing sessions.
75653218|NCT04273880|Drug|Vitamin C|90 mg of Vitamin C taken an hour and a half before the other testing session
75800811|NCT03783156|Procedure|cold snare|polypectomy with cold snare
75800812|NCT05762848|Device|Mobile Phone Head Circumference App|Measurement of Head circumference of Babies/Infants with a mobile phone application.
75800813|NCT01309776|Drug|Tianeptine|week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
75939006|NCT03667183|Other|Pilates|Specific postures in movement according to Pilates guidelines.
75939007|NCT05424952|Other|Conversational AI Service (Chatbot)|WhatsApp or Messenger Chatbot for COVID-19 vaccines
75939008|NCT04766333|Behavioral|Healthcare Worker Focused Outreach|This a focused outreach intervention strategy specifically designed for healthcare workers.
75939009|NCT04766333|Behavioral|Community Organization Led Outreach|This is a standard community engaged outreach approach that has traditionally been used in previous research. Analogous to the standard of care for outreach.
75939010|NCT05405530|Device|nasal mask oxygen kit|Using the nasal mask oxygen kit for oxygenation.
75939011|NCT05405530|Device|regular nasal cannula|Using nasal cannula for oxygenation.
75342850|NCT05316428|Other|alcohol|0.5 g/kg alcohol
75342851|NCT05316428|Drug|TPN171H tablet|10 mg TPN171H tablet QD
75800814|NCT01309776|Drug|Escitalopram|week1 : 5mg/day q.d., week2: 10mg/day q.d.
75800815|NCT00498160|Biological|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
75800816|NCT03782766|Procedure|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
75800817|NCT02772328|Behavioral|Peer Mentor|comparison of communication training to equal attention control
75800818|NCT03780582|Behavioral|AI-human interaction|Exploring what kinds of AI-human interaction improve radiologists detection accuracy.
75939012|NCT03020641|Procedure|Low pressure pneumoperitoneum|Low pressure pneumoperitoneum
75939013|NCT03020641|Procedure|standard pneumoperitoneum pressure|standard pneumoperitoneum pressure
75939014|NCT05405140|Other|Shock wave therapy with multiphasic neuroplasticity based training protocol|Interventions program will be based on Activity dependent neuroplasticity targeting relevant impairments included: task specific practice, motor learning, strengthening, postural awareness, Balance training, aerobic and conditioning exercises, range of movement with Shock wave therapy for most of time of the day .
75939015|NCT05405140|Other|Conventional physical therapy|The CP program focused on the facilitation of movements on the paretic side, range of motion, stretching exercises, upper and lower limb strengthening exercises, and improving balance, standing, sitting, transferring, patients received a program for at least 30 sessions, 5 times per week for 6 or more weeks.
75939016|NCT05404906|Drug|Azacitidine|Given SC
75939017|NCT05404906|Drug|Venetoclax|Given PO
75939018|NCT05404906|Other|Supportive care|Patients will receive disease monitoring and supportive care for any complication.
75939019|NCT03020407|Procedure|IVC Ultrasound-guided|IVC is identified in longitudinal section in the subcostal area of a patient using the curvilinear probe of standard ultrasound. The selected area of IVC diameter measurement is set at 2 centimeters distal to the confluence of hepatic vein by M-mode coupled by two-dimensional mode on frozen screen images using the Sonosite® X-porte.
75939020|NCT03020407|Drug|Antibiotics|Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
75939021|NCT03020407|Drug|Vasopressor|The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
75939022|NCT03667729|Behavioral|progressive muscle relaxation|intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
75939023|NCT03624959|Drug|Ozanimod|ozanimod
75939024|NCT03624959|Drug|Gemfibrozil|Gemfibrozil
76089477|NCT01453491|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
75653219|NCT03316742|Combination Product|Intervention 1|Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
75653220|NCT03316742|Combination Product|Intervention 2|Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
75653223|NCT04099628|Diagnostic Test|Rapid diagnostic test (RDT); Serological and molecular tests on DBS|"The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.~Other Names:~rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)"
75653224|NCT00910988|Drug|Olanzapine|olanzapine/Zyprexa
75653225|NCT00910988|Drug|Ziprasidone|ziprasidone/Geodon
75653226|NCT00644059|Biological|Adjuvanted trivalent inactivated subunit influenza vaccine|Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
75800819|NCT02684422|Other|Intervention N/A. Observational study|There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
75800820|NCT03783000|Drug|BI 425809|Treatment T
75800821|NCT03783000|Drug|BI 425809 mixed with [C-14]-BI 425809|Treatment R
75800822|NCT02344420|Procedure|Echocardiography|"The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.~Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization."
75939025|NCT03624959|Drug|Itraconazole|Itraconazole
75939026|NCT03624959|Drug|Rifampin|Rifampin
76089478|NCT03823599|Behavioral|Mobile chat-based instant messages|Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline
76089479|NCT03823599|Behavioral|Alcohol brief intervention|The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
75939027|NCT03667105|Procedure|CAF|Periodontal surgical technique to treat gingival recessions.
75939028|NCT03667105|Other|MC|Xenogenous graft placed in the surgical site.
75939029|NCT03667105|Other|XDM|Xenogenous dermal collagen graft placed in the surgical site.
75939030|NCT04888637|Diagnostic Test|Baseline MEG Test|Each subject will have one MEG session with the recordings of baseline resting state, language and memory protocols. Subjects will have a break period between the language and memory tasks. MEG recordings will be acquired for approximately 35 minutes. The subject will be allowed to practice the language and memory tasks before the MEG recording to feel familiar with them. This practice phase will be a short version of the task administered by a computer and will take approximately 6 minutes.
75939031|NCT04888637|Behavioral|Receptive Language Task|"The subject will perform a practice session where they will be instructed to try to remember a set of ﬁve audibly spoken English words, deemed targets (jump, little, please, drink, and good). Depending on the subject's overall verbal memory capacity, the target words will be presented once or twice during the practice phase. Subsequently, during the MEG recording, the ﬁve target words will repeat in a different random order, mixed with a different set of 40 distractors (non-repeating words) in each of three blocks of stimuli. The subject's task will be to listen to the words and lift their index finger of the dominant hand whenever they hear a repeated target word (one of the five). After the language task, the subject will be given a break."
76089480|NCT01453647|Other|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
75939032|NCT04888637|Behavioral|Memory Task|"The subject will be tasked with indicating whether the encoding stimulus matched the retrieval stimulus using two buttons; one for congruent and the other for incongruent response. Button type will be counterbalanced among subjects. The task will take around 16 minutes. The visual stimuli will be projected through an LCD projector onto a white screen located about 0.5 m in front of the subject and subtending 1.0-4.0 and 0.5 degrees of horizontal and vertical visual angle, respectively. A MEG compatible keyboard will be used to measure the subject's responses for congruent and incongruent. The subject will practice the memory task before going to the MEG system using a computer from MEG laboratory. This practice phase will consist of a short version of the memory task with duration of approximately 4 minutes."
75939033|NCT04579315|Other|Intervention group; NNRD group|The intervention is a whole food approach, meaning that the participants in the intervention group receives all daily food elements that they should consume
75939034|NCT02536846|Drug|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
75342852|NCT03805178|Drug|Belatacept|"Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen."
75342853|NCT03805178|Drug|Carfilzomib|20mg/m2 Plasmapheresis
75653227|NCT00644059|Biological|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine|For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
75939035|NCT03554057|Diagnostic Test|Coronary Computed Tomographic Angiography|All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
75939036|NCT03014011|Other|Hypoglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.
75939037|NCT03014011|Other|Euglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
75939038|NCT03012841|Device|Arctic Front Advance Cardiac CryoAblation Catheter|Cryoablation
75939039|NCT03704129|Other|Tutor|The participants will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself.
75653228|NCT00644059|Biological|Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine|"Meningococcal vaccine: two IM injections~Tick-borne encephalitis vaccine: two IM injections"
75653229|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
75653230|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
75653231|NCT00811993|Drug|RG1507|Starting dose of >=3mg/kg iv escalating to a maximum dose of <=16mg/kg iv, depending on dosing schedule in each combination treatment arm
75653232|NCT00811993|Drug|RO1507|27mg/kg iv, monotherapy
75653233|NCT00811993|Drug|bevacizumab [Avastin]|as prescribed
75653234|NCT00811993|Drug|capecitabine [Xeloda]|as prescribed
75653235|NCT00811993|Drug|carboplatin|as prescribed
75653236|NCT00811993|Drug|cetuximab|as prescribed
75800823|NCT02344420|Behavioral|Minnesota Living Heart Failure Questionnaire (MLHF)|MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
75800824|NCT02344420|Procedure|Six minute walk test|The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
75800825|NCT02344420|Behavioral|Self assessment score|patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
75939040|NCT02359864|Radiation|5 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
75653237|NCT00811993|Drug|docetaxel|as prescribed
75342854|NCT05318378|Diagnostic Test|BIXAM|Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
75342855|NCT01303835|Drug|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
75653238|NCT00811993|Drug|erlotinib [Tarceva]|as prescribed
75653239|NCT00811993|Drug|etoposide|as prescribed
75653240|NCT00811993|Drug|gemcitabine|as prescribed
75653241|NCT00811993|Drug|irinotecan|as prescribed
75653242|NCT00811993|Drug|mFOLFOX6|as prescribed
75653243|NCT00811993|Drug|paclitaxel|as prescribed
75653244|NCT00811993|Drug|pemetrexel|as prescribed
75653245|NCT00811993|Drug|sorafenib|as prescribed
75653246|NCT00811993|Drug|temozolomide|as prescribed
75653247|NCT00811993|Drug|trastuzumab [Herceptin]|as prescribed
75800826|NCT02235142|Other|Blood sample|
75939041|NCT02359864|Radiation|10 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
75939042|NCT03703973|Diagnostic Test|Neuropsychology test|We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
75939043|NCT01764191|Other|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
75939044|NCT03703739|Dietary Supplement|Reference meal 1|1 ml Ferrous sulfate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g mixed vegetable Sauce and 300 ml nanopure water
75939045|NCT03703739|Dietary Supplement|Reference 2|1 ml Ferrous sulphate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g bean Sauce and 300 ml nanopure water
75939046|NCT03703739|Dietary Supplement|Test meal A|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc oxide and ethylenediaminetetraacetic acid"
75653248|NCT00817765|Drug|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
75939047|NCT03703739|Dietary Supplement|Test meal B|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and ethylenediaminetetraacetic acid"
75939048|NCT03703739|Dietary Supplement|Test meal C|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
75939049|NCT03703739|Dietary Supplement|Test meal D|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and sodium pyrophosphate."
75475799|NCT01999647|Procedure|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
75653249|NCT00817765|Drug|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
75653250|NCT00817765|Drug|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
75653251|NCT02552329|Other|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
75653252|NCT00812071|Biological|RiVax|vaccine
75653253|NCT00816205|Drug|Coated Nifedipine Suppositories|"Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine."
75653254|NCT00816283|Drug|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
75800827|NCT02171884|Other|Sample of cord blood|
75800828|NCT02171884|Other|Sample of placenta|
75800829|NCT01309854|Drug|fostamatinib|oral tablets, 100mg (2 X 50mg) twice daily for 8 days
75939050|NCT03703739|Dietary Supplement|Test meal E|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g bean Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
75939051|NCT05441176|Other|Questionnaires|Scoring of the DASH is performed according to references.
75939052|NCT05402254|Other|Pharmacovigilance Program|Knowledge of the risks in the use of the drug, identification and notification of ADE
75342856|NCT01303835|Drug|Placebo|Randomized patients received placebo to be taken every night before bed.
75939053|NCT04423042|Biological|Tocilizumab|Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.
75939054|NCT05440006|Drug|Fuzuloparib|Fuzuloparib Capsules; 150mg; single dose per cycle.
75939055|NCT05439460|Drug|Phenylephrine|5 subjects will get Phenylephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
75939056|NCT05439460|Drug|Epinephrine|5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
75800830|NCT01309854|Drug|pioglitazone|oral tablets, 30mg single dose per period
75800831|NCT03776604|Drug|PEG-rhG-CSF|"Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were <45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
75800832|NCT03776526|Behavioral|Fitbit® Alta HR Sleep monitoring|Patients will be fitted with a Fitbit® Alta HR after surgery, which will monitor sleep quality (sleep duration and number of awakenings) for the duration of hospitalization.
75800833|NCT05097534|Other|iDSMES|Intensive Diabetes Self-Management Education and Support combined with Addressing Social Determinants of Health
75800834|NCT05097534|Other|Standard of Care|Standard of Care for patients with type 2 diabetes
75342857|NCT03805334|Other|Touchpoints|Touchpoints are worn on either the wrists or ankles. They deliver a low level vibration in an alternating fashion to the skin.
75342858|NCT01250717|Drug|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
75342859|NCT01250717|Drug|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
75653255|NCT00816283|Drug|vorinostat|100 mg orally 2 times per day
75653256|NCT00816283|Genetic|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
75653257|NCT00816283|Genetic|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
76089481|NCT01453803|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
76089482|NCT04273893|Radiation|SBRT with additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
75939057|NCT05439460|Drug|Arginine Vasopressin|5 subjects will get Arginine Vasopressin during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
75939058|NCT03019627|Drug|NGF|Eye Drop 20 μg/mL
75939059|NCT03019627|Other|Vehicle|Vehicle Eye Drop
76089483|NCT04273893|Radiation|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
76089484|NCT04273893|Diagnostic Test|Blood Draws|CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.
76089485|NCT01453881|Device|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
76089486|NCT01453881|Device|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
76089487|NCT05608473|Other|Posture Exercises|A 10-minute video consisted of 14 cervical and thoracal postural exercises was uploaded to the computers of the participants. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
75342860|NCT01250717|Drug|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
75939060|NCT01661140|Drug|Methotrexate (stable dose)|Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
75939061|NCT01661140|Drug|Tocilizumab|8 mg/kg intravenously every 4 weeks for 72 weeks
75342861|NCT01250717|Drug|Zoladex|Given subcutaneously for 4 doses every three months
75342862|NCT01250717|Drug|Casodex|Taken orally once a day for 6 months
75342863|NCT01250717|Procedure|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
75342864|NCT03808532|Other|Cura+ Moisturizing Cream|Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily for six months.
75342865|NCT03808376|Device|Continuous Glucose Monitoring System|The Eversense® 180 CGM System
75342866|NCT03009305|Other|Lower body negative pressure|Model of hypovolemia: Lower body negative pressure down to -80 mmHg (maximum).
75342867|NCT03009305|Device|Continuous positive airway pressure|CPAP of 0, 5 and 10 cm water (H2O).
75342868|NCT03009305|Device|Positive expiratory pressure|PEP of 0, 5 and 10 cm H2O.
75342869|NCT05744258|Device|Bio-electrical impedance analysis|"Bio-electrical Impedance Analysis will be performed by trained personnel. BIA will be performed after fasting for at least 6 hours. Subjects should refrain from intensive physical activity the day be-fore the measurement. For women, measurements will be performed outside menstruating periods. Subjects will lay down on an examination couch with bare feet. Any jewelry will be removed.~Reactance and resistance will be obtained. Phase angle will be calculated according to the formula:~PhA (°) = (reactance/ resistance° x (180°/π). Body composition, including muscle mass and percentage body fat will be calculated."
75342870|NCT02189915|Drug|Creatine monohydrate|
75342871|NCT04385030|Device|TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY|The study will consist of 12 sessions, carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
75342872|NCT03804866|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
75653258|NCT00816283|Genetic|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
75800835|NCT05074212|Other|Factorial Assignment|At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
75800836|NCT03776994|Biological|Vaccinations on Day 0, Day 28, and Day 140|The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 [Day 28], and Week 20 [Day 140]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)
75800837|NCT05073510|Device|BVE|Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
75800838|NCT03780192|Device|Inspiron Sirolimus Eluting Stent|Bifurcation treatment using provisional stent technique
75939062|NCT01661140|Drug|Methotrexate (tapering dose)|Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
75939063|NCT03019549|Drug|Lanabecestat|Administered orally
75939064|NCT03019549|Drug|Rosuvastatin|Administered orally
75342873|NCT03804866|Drug|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
75653259|NCT00816283|Genetic|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
75653260|NCT00816283|Other|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
75653261|NCT00816283|Other|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
75653262|NCT00910910|Drug|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to < 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
75653263|NCT00910910|Drug|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
75672300|NCT04209452|Behavioral|Rehearsal strategy and reinforcement|Teaching children to cumulatively rehearse numbers as they are being said, AND providing reinforcement for correct recall after a delay.
75800839|NCT05305560|Drug|Ivermectin Tablets|Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
75800840|NCT05305560|Drug|Matching placebo tablets|Daily placebo tablets intake for 28 days
75800841|NCT03780348|Diagnostic Test|New Method|A 'new' WHZ tool will be used to assess children.
75800842|NCT03780348|Diagnostic Test|Existing Method|'Existing' WHZ tools will be used to assess children
75939065|NCT05400850|Other|YOGA|Five different YOGA Asana's will made randomly
75939066|NCT05423314|Procedure|knee brace cold therapy|"receiving a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase."
75342874|NCT03804866|Drug|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
75342875|NCT01251575|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
75342876|NCT01251575|Drug|Cyclosporine|Given PO or IV
75342877|NCT01251575|Drug|Fludarabine Phosphate|Given IV
75342878|NCT01251575|Other|Laboratory Biomarker Analysis|Correlative studies
75342879|NCT01251575|Drug|Mycophenolate Mofetil|Given PO
75342880|NCT01251575|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
75475800|NCT01999647|Procedure|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
75672301|NCT02536872|Other|None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied|
75342881|NCT01251575|Drug|Sirolimus|Given PO
75342882|NCT01251575|Radiation|Total-Body Irradiation|Undergo total-body irradiation
75342883|NCT00782756|Other|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
75342884|NCT01215695|Device|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
75342885|NCT01215695|Device|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
75475801|NCT01999647|Procedure|Patient-Controlled Postoperative Analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
75800843|NCT03782922|Other|Exercise Training Program|10min of coordination and strength training (2-3x per week) during 2-6 weeks
75800844|NCT03782844|Device|Simple CPAP+Conventional fixed CPAP|Patients used simple CPAP and conventional fixed CPAP during overnight polysomnography.
75800845|NCT03782844|Device|Simple CPAP + Auto CPAP|Patients used simple CPAP and Auto CPAP during overnight polysomnography.
75800846|NCT01310088|Behavioral|Lifestyle intervention|Treatment protocol. The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
75800847|NCT01319058|Procedure|Tonsillectomy, laser tonsillotomy, debrider tonsillotomy|Each arm will be treated by one of the three methods in addition to adenoidectomy
75939067|NCT01661062|Other|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
75939068|NCT04260958|Other|Exercise-based cardiac rehabilitation|The exercise program (remote/centre-based) will be standardized. An exCR-program is defined as at least 24 supervised sessions, with a total session length of 60 minutes, for at least 3 months, with possibility to complete missed sessions the 4th month. Each exercise session includes at least 20 min of aerobic exercise, intensity 13-17 on Borg´s rating of perceived exertion (RPE)-scale ≈ 60% - 85% of VO2max or 70 - 95% of maximal heart rate. In addition, each exercise session includes 1-3 sets of 8-10 upper and/or lower limb exercises in 10-15 repetitions, 40-80% of 1 repetition maximum. Attending ≥75% of the 24 sessions over a 4-month period will be considered as successful.
75653264|NCT04267172|Behavioral|Surgical simulation training in primary Total Hip Arthroplasty|The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.
75939069|NCT05436886|Drug|Neurogabin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
75939070|NCT05436886|Drug|Parketin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
75939071|NCT01373151|Drug|BMS-945429 Placebo|Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
75653265|NCT04267172|Other|No intervention: Surgical Resident Control Group|Control Group
75342886|NCT05744102|Diagnostic Test|MRI Image|MRI sequences
75342887|NCT03808142|Other|myBETAapp|Patients choosing to use the myBETAapp were required to insert the Mixject number from their prescribed Betaferon box, which serves as an opening key for the app. Obtaining a new Betaferon box and obtaining a new Mixject number was not interfere with the process of continuously allocating data to a single patient; each patient had a unique personal identifier in the database. All data recorded in the myBETAapp including demographic and injection-related data were stored in the database once the mobile device was connected to the internet.
75342888|NCT03808142|Other|PEAK|Peak is an application that aims at helping its users to challenge their brains and keep them sharp.
75342889|NCT03808142|Drug|Betaferon, BAY86-5046|Injection
75342890|NCT03808142|Device|BETACONNECT|BETACONNECT automatically records and stores injection-related details including injection time, speed, and depth upon every injection.
75653266|NCT04267172|Other|No Intervention: Consultant and Fellow Comparator Group|Comparator Group
75800848|NCT03776448|Dietary Supplement|Sativa Nigra oil Softgels|Nigella sativa, a flowering plant native to southwest Asia, is considered one of the most important healing medicinal plants in Islamic culture. The use of its richly colored black seeds has been recommended in the prophetic medicine. It's also known by various other names amongst different cultures. Importantly, its seed is known in Arabic as 'habat al Baraka' which translates literally to 'the seed of blessing'.The active ingredient is believed to be thymoquinone richly present in the oil extract of its seeds. Apart from mild occasional gastrointestinal disturbance, black seed oil has no side effects and is considered very safe. .
75800849|NCT03776448|Dietary Supplement|Activated Charcoal Softgels|This supplement is manufactured by [Arkopharma Pharmaceutical Laboratories] and is available commercially. The use of activated charcoal softgels as a placebo is documented in several other clinical trials. The single most relevant characteristic of charcoal is its minimal if any gastrointestinal absorption. As a result, it does not undergo any metabolism and is excreted completely in feces. This makes charcoal an attractive placebo choice for small trials or when manufacturing a specific placebo is not feasible. Charcoal softgels are black in color and resemble black seed oil softgels to a great extent.
75939072|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
75939073|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
75939074|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
75800850|NCT03780270|Device|Fluoride Varnish|Fluor Protector S (Ivoclar, 7'700 ppm F-)
75800851|NCT03780270|Device|Curodont Repair|P11-4 (monomeric peptide) - for professional use
75800852|NCT03780270|Device|Curodont Protect|Tooth gel (containing P11-4 assembled to a fibrillary matrix) - for home use (OTC)
75800853|NCT05669040|Other|Pharmacological education|Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.
75800854|NCT05669040|Other|Training in the use of MyPlan Aplication|Review of the use of the aplication
75939075|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
75342891|NCT00760526|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor
75342892|NCT00760526|Device|Home blood glucose monitor|Home monitoring 3 or more times a day
75653267|NCT04232462|Diagnostic Test|Endoscopists refer to AI for diagnosis|The AI will provide a clinical diagnosis during endoscopy.
75653268|NCT04384562|Drug|Methylphenidate|A 20 mg methylphenidate (Ritalin®) is administered only once for the dopamine reuptake inhibitor group.
75653269|NCT04384562|Drug|Reboxetine|A 4 mg reboxetine (Edronax®) is administered only once for the noradrenaline reuptake inhibitor group.
75939076|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
75939077|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, 48 weeks
75939078|NCT01373151|Drug|Methotrexate Placebo|Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
75939079|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
75939080|NCT01373151|Drug|Adalimumab Placebo|Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
75939081|NCT01373151|Drug|Adalimumab|Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
75342893|NCT01306175|Drug|Digoxin plus BI 10773|Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
75342894|NCT01306175|Drug|Digoxin|Digoxin 0.5 mg as single dose
75342895|NCT03804476|Drug|AER-271|AER-271, the test article for this study.
75939082|NCT05435716|Device|C-wave™ peripheral seismic waveguide system|In the experimental group, if the target lesions did not show flow-limiting dissection or severe elastic retraction, drug-coated balloon was subsequently performed after lumen preparation by peripheral seismic catheterization system (IVL). If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
75939083|NCT05435716|Device|Peripheral vascular balloon dilatation catheter (PTA)|Subjects in the control group received balloon dilatation catheter in peripheral blood for lumen preparation, and if the target lesions did not show flow-limiting interlayer or severe elastic retraction, drug-coated balloon therapy was subsequently performed. If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
75653270|NCT04384562|Drug|Nicotine gum|A 2 mg nicotine (Nicorette®) gum is administered only once for the cholinergic receptor agonist group.
75653271|NCT04384562|Drug|Placebo pill|A placebo pill is administered only once.
75800855|NCT05669040|Other|Patient Experience|"How do you feel?~Sad feelings and frustration.~Achievements day by day, think positive.~Importance of interpersonal relationships.~Explain activities to relax the mind"
75342896|NCT03804476|Drug|Placebo|Placebo control for this study.
75342897|NCT01215929|Drug|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
75342898|NCT01215929|Drug|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
75342899|NCT03804398|Device|compliance guided an optimal Positive End-Expiratory Pressure|The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
75475802|NCT01999647|Drug|Ropivacaine|Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
75475803|NCT01999660|Device|SpaceOAR™ implantation|
75653272|NCT04384562|Drug|Placebo gum|A placebo gum is administered only once.
75653273|NCT04519892|Other|PDRC|Personalized depression risk communication.
75475804|NCT01999673|Biological|bavituximab|
75475805|NCT01999673|Drug|Docetaxel|
75800856|NCT03780036|Device|Megaprosthetic Implants the Next Generation (MING)|Use of either porous of porous+hydroxyapathite collars.
75800857|NCT03782454|Diagnostic Test|Blood sampling|Blood samples taken every third hour during the first 48 hours of intensive care
75939084|NCT05148897|Other|Questionnaire|a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to GDM were included.
75939085|NCT03488589|Diagnostic Test|serum samples for HEV RNA PCR|serum samples HEV RNA PCR
75939086|NCT03488511|Other|FoodforCare at home|Six small protein rich meals that will be delivered twice a week for 3 weeks.
75475806|NCT01999673|Other|Placebo (for bavituximab)|
75475807|NCT01999686|Drug|DLBS3233|
75475808|NCT01999686|Drug|Metformin XR|
75653274|NCT04519892|Other|Coach guidance|Coaching service to guide the understanding of PDRC and answer questions.
75653275|NCT04243304|Other|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
75653276|NCT04243304|Other|18F-PE2I PET-MR|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
75475809|NCT01999686|Drug|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
75653277|NCT04515134|Diagnostic Test|assessment of follicular level of coenzyme Q10 in the ovaries in females undergoing ICSI|human coenzyme Q10 (CoQ10) ELISA kit
75653278|NCT04238390|Drug|Ceftolozane-Tazobactam|Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.
75653279|NCT04238390|Drug|Meropenem|Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.
75653280|NCT04237220|Diagnostic Test|stomach biopsies|To determine the diagnostic performance in the detection of Helicobacter pylori in biopsies taken only from the gastric antrum for the determination of the positive predictive value, the negative predictive value, and sensitivity and specificity.
75653281|NCT04236830|Drug|Silver diamine fluoride/ potassium iodide|Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.
75939087|NCT01660906|Drug|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
75939088|NCT03488979|Other|educational interventional group|• Patient Education Tool (Appendix 3) and the patient's own IVC images will be shared with each patient in the intervention group in real time. If feasible, each intervention patient will also receive a printed copy of his or her IVC image.
75475810|NCT01999686|Drug|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
75475811|NCT01999699|Biological|HEPLISAV|
75475812|NCT01999712|Procedure|Echocardiography|Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
75475813|NCT01999725|Drug|EDP-788|EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
75475814|NCT01999725|Drug|Placebo|Matching placebo capsules or matching suspension
75800858|NCT03779802|Other|Device programming of ABBOTT CRT pacemaker or defibrillator|Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session.
75939089|NCT01285947|Device|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
75653282|NCT04236830|Drug|Silver diamine fluoride|Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.
75653283|NCT04236830|Drug|Resin modified glass ionomer cement|Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
75653284|NCT04203212|Drug|Goserelin Acetate|Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months
75342900|NCT03804398|Device|PEEP level of 5 cmH2O|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
75342901|NCT05744024|Device|Virtual Reality system|The intervention group 1 will be wearing the 'SyncVR' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, a controller, and a headphone. The SyncVR Relax & Distract Application (SyncVR R&D) will be used.
75342902|NCT05744024|Other|Headphones|Headphones with audio. The patients will be hearing their preferred audio, chosen by patient to relaxing and to offer distraction, through headphones during wound care.
75342903|NCT01252277|Drug|Lovaza™|4 capsules daily for 6 months
75475815|NCT01999738|Drug|EC1456 and EC20|"EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging."
75475816|NCT01999751|Device|MRI Scan|Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
75653285|NCT04187066|Behavioral|mindset induction|induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
75653286|NCT04163042|Behavioral|12-week videoconferencing behavioural support intervention to promote physical activity behaviour|Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
75653287|NCT04789538|Other|monofocal lens|not applicable as patients are already implanted with the monofocal intraocular lens
75653288|NCT04484168|Procedure|Terminal Interruption of the Reflux Source|Foam Sclerotherapy of veins in the immediate vicinity of the venous ulcer
75653289|NCT04484168|Procedure|Axial Ablation|Endovenous ablation of venous reflux in the main superficial veins of the leg
75653290|NCT00637910|Drug|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
75653291|NCT00637910|Drug|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops
75653292|NCT03408236|Drug|Botulinum toxin type A|Experimental
75653293|NCT03408236|Drug|Botulinum toxin type A|Active Comparator
75800859|NCT04531254|Behavioral|Wearing a face mask at all times|Children in this group will be asked to wear a face mask in the classroom and common areas during the simulation
75800860|NCT03072160|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks.
75800861|NCT05517486|Drug|GTX-101|Bupivacaine HCl metered spray
75939090|NCT01285947|Other|Needle Application|30-gauge needle insertion into skin
75939091|NCT01285947|Device|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
75939092|NCT01285947|Device|Ulthera|"Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm"
75939093|NCT03015181|Biological|VRC-HIVMAB075-00-AB|VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
75939094|NCT03493191|Drug|0.5μg/kg SHR0410|a single dose of 0.5μg/kg SHR0410
75939095|NCT03493191|Drug|1μg/kg SHR0410|a single dose of 2μg/kg SHR0410
75939096|NCT03493191|Drug|2μg/kg SHR0410|a single dose of 2μg/kg SHR0410
75939097|NCT03493191|Drug|5μg/kg SHR0410|a single dose of 5μg/kg SHR0410
75939098|NCT03493191|Drug|10μg/kg SHR0410|a single dose of 10μg/kg SHR0410
75939099|NCT03493191|Drug|20μg/kg SHR0410|a single dose of 20μg/kg SHR0410
75939100|NCT05435014|Drug|T-ACE Oil|TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
75342904|NCT00767624|Drug|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
75342905|NCT00767624|Behavioral|Desensitization Therapy for Insomnia|
75342906|NCT00767624|Behavioral|Cognitive Behavioral Therapy for Insomnia|
75342907|NCT01216241|Drug|Daptomycin|8 MG/KG IV
75342908|NCT01216241|Other|Saline Placebo|50 ml normal saline once daily
75475817|NCT01999790|Procedure|blepharotomy|upper eyelid surgery by blepharotomy
75475818|NCT01999790|Procedure|posterior approach|upper eyelid surgery by posterior approach
75475819|NCT01999803|Drug|sNN0029|
75475820|NCT01999803|Drug|Placebo|
75475821|NCT01999816|Behavioral|Lifestyle Redesign|Individualized program for lifestyle redesign aimed at decreasing the risk of medically serious pressure ulcers led by licensed occupational therapists trained in the implementation of the lifestyle redesign program
75342909|NCT01216241|Drug|Daptomycin|8 mg/kg once daily
75800862|NCT05517486|Drug|Bupivacaine HCl subcutaneous injection|Bupivacaine HCl, 50 mg/10 mL
75939101|NCT05435014|Drug|Lipiodol|TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
75939102|NCT03666949|Drug|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
75939103|NCT03666949|Drug|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
75939104|NCT00886691|Biological|Bevacizumab|Given IV
75342910|NCT03807908|Other|Tape|"The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
75653294|NCT04155320|Behavioral|IMPART|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
75672302|NCT04829006|Device|Understand Me For Life|The aim of the current investigation is to test the efficacy of an app to measure sentence intelligibility in noise in speakers with Parkinson's disease and in healthy controls.
75800863|NCT01019356|Drug|Rosiglitazone|4 mg twice daily for 8 weeks orally
75939105|NCT00886691|Drug|Everolimus|Given PO
75939106|NCT00886691|Other|Laboratory Biomarker Analysis|Correlative studies
75800864|NCT01019356|Drug|Acarbose|100 mg three times daily for 8 weeks orally
76117221|NCT03710603|Drug|Lenalidomide|Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
75342911|NCT03807908|Other|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
75342912|NCT01216397|Drug|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
75342913|NCT01216397|Drug|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
75800865|NCT03776292|Other|monitoring|Primary outcome; composite 1ry outcome [1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.
75800866|NCT01314066|Drug|Bevacizumab|Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
75939107|NCT00886691|Other|Placebo|Given PO
75939108|NCT03667417|Other|Questionnaires|standardized data collection and 10-year prospective follow-up
75939109|NCT00960297|Drug|Carboplatin|Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
75939110|NCT00960297|Drug|Paclitaxel|Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
75939111|NCT00960297|Drug|Bevacizumab|Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
75939112|NCT03488433|Device|Abduction brace|Donjoy Ultrasling IV
75939113|NCT03488433|Device|Antirotation sling|Donjoy shoulder immobilizer
75342914|NCT04345406|Drug|ACEIs|Captopril or enalapril
75342915|NCT04345406|Drug|Conventional treatment|alexoquine
75342916|NCT01216943|Drug|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
75475822|NCT01999829|Drug|citrate of caffeine|
75939114|NCT00518037|Behavioral|surveys|anxiety surveys
75939115|NCT04423354|Procedure|Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy by the fixed surgical group.The same model surgical instruments will be provided by the same instrument company.
75939116|NCT03018691|Drug|OPA-15406|
75939117|NCT03018691|Drug|Placebos|
75939118|NCT03493113|Diagnostic Test|EEG|
75939119|NCT05112861|Biological|bevacizumab|1.25 mg, intravitreal injection
75800867|NCT01314066|Drug|Placebo|Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
76089488|NCT04391751|Procedure|Carpal tunnel release and basal joint arthroplasty through single incision|Group I: experimental - single incision The surgical technique chosen for thumb basal join was trapeziectomy with ligamentous reconstruction and tendon interposition (LRTI), using flexor carpi radialis (FCR). Through a dorsal approach over trapeziometacarpal joint, the entire trapezium was excised. Volar traction of FCR allowed us to longitudinally incise the deep leaflet of FCR tendon until flexor pollicis longus (FPL) tendon was clearly visualized. Then, ulnar half of FCR tendon was harvested proximally through a second transverse incision in middle third of the forearm and split all the way to its insertion on the index metacarpal. A hole was placed in the base of the first metacarpal and FCR tendon was routed through the bone canal and then fixed with non-reabsorbable sutures. Finally, the tendon remanent was rolled up and placed into the trapezial void to act as a spacer.
75653295|NCT04155320|Behavioral|Standard Care|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
75653296|NCT04202744|Other|Shoulder and core evaluations|Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated.
75653297|NCT04202510|Procedure|Glaucoma and Cataract Surgery|Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
75342917|NCT00783614|Drug|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
75342918|NCT00783614|Drug|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
75800868|NCT00407602|Device|Implant of Argus II Retinal Prosthesis|epiretinal implantation of device
75939120|NCT04052035|Procedure|measuring the size of the follicle at time of follicle aspiration|While for an OPU out of the study the follicles are aspirated without measuring their sizes, now the follicles will be measured before they are aspirated. The measurement of the follicles is a non- invasive measurement: as the OPU is always performed under vaginal echo-guidance, the follicles are visible on the screen connected to the vaginal echo probe. By measuring two dimensions of the follicle, an average follicle diameter is registered for that follicle
75342919|NCT01252745|Drug|10.0 mg of Testosterone, 4.0% TID|
75800869|NCT01314300|Drug|Lidocaine|Lidocaine 5% plaster
75342920|NCT01252745|Drug|13.5 mg of Testosterone, 4.5% B.I.D|
75342921|NCT01252745|Drug|11.25 mg of Testosterone, 4.5% T.I.D|
75342922|NCT04278872|Drug|SJX-653|administered orally once daily
75342923|NCT04278872|Drug|Placebo|administered orally once daily
75475823|NCT01999829|Drug|placebo|
75342924|NCT03807596|Procedure|Periodontal treatment with Hyaluronic acid associated with SRP|In addition to SRP, patients in the test group received adjunct subgingival application of hyaluronic acid in all selected periodontal pockets.
75342925|NCT03807596|Procedure|Scaling & root planning alone|Patients received full-mouth supra- & sub-gingival SRP with the use of ultrasonic device & periodontal universal & Gracey curettes under local anesthesia.
75475824|NCT01999842|Biological|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
75475825|NCT01999842|Biological|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
75800870|NCT05202652|Dietary Supplement|HealthSpan|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the oral capsule containing the active ingredients, for three consecutive months.
75800871|NCT05202652|Dietary Supplement|Placebo|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the placebo, for three consecutive months.
75939121|NCT04423198|Behavioral|Cognitive Assessment|Self administered cognitive battery
75800872|NCT03773640|Device|Radio frequency currents|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
75342926|NCT02147522|Behavioral|Self-care management|AHH behavioral intervention is provided by promotoras
75342927|NCT01217411|Drug|Gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
75800873|NCT03773640|Drug|Sonophoresis|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
75800874|NCT03779958|Other|Mobile App|a mobile app that demonstrates hand therapy exercises
75800875|NCT01314690|Other|Caloric transition|6 week low calorie diet followed by 6 week stabilization period
75800876|NCT03629704|Diagnostic Test|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
75939122|NCT04423198|Behavioral|Patient Reported Neurological Outcome Assessments|Standard neurocognitive and neuropsychological tests
75939123|NCT04423198|Procedure|Blood Draw|Specimen collection of whole blood, serum, RNA
75800877|NCT01314768|Behavioral|Brief intervention|Structured behavioural Brief intervention given by trained GPs
75653298|NCT04202666|Device|convex skin barrier|Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)
75939124|NCT03667261|Device|Sealing Socket Abutment|Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions
75939125|NCT03667261|Device|cover screw|immediate implant placement in mandibular molar area will be covered with conventional cover screw
75939126|NCT03493035|Diagnostic Test|Computed tomography angiography (3D CTA)|CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.
75342928|NCT01217411|Radiation|Whole-brain radiation therapy (WBRT)|Undergo WBRT
75939127|NCT03493035|Diagnostic Test|Transcranial color-coded sonography (TCCS)|TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
75939128|NCT05418400|Other|sonic fill 3 & PALFIQUE bulk flow & Neo spectra & Clear fill AP-X|dental filling materials
75939129|NCT01790776|Radiation|Urografin 30%|"Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).~The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled."
75939130|NCT01790776|Radiation|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
75342929|NCT01217411|Radiation|Stereotactic radiosurgery (SRS)|Undergo SRS
75342930|NCT01217411|Procedure|Cognitive assessment|Ancillary studies
75672303|NCT02536716|Procedure|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
75672304|NCT02536716|Procedure|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
75672305|NCT00620594|Drug|BEZ235|
75672306|NCT02652000|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
75800878|NCT01314768|Other|Business as usual|GPs to treat patient as they have until now based on best established practice
75800879|NCT01314768|Other|Screening and outcome evaluation only|No additional intervention
75800880|NCT01314768|Other|Screening and outcome evaluation only|No additional intervention
75939131|NCT05148585|Other|physiotherapy|Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.
75939132|NCT05148585|Other|activity-based therapy|patients get from the seventh week to the twelfth week an activity-based therapy. Activities are diverse according to the patient's needs. activities have therapeutic efficacy for improving range of motion, tendon gliding and strength.
75939133|NCT05130333|Other|No intervention|No intervention
75939134|NCT04746911|Drug|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
75939135|NCT04460859|Other|Specific lung recruitment maneuvers|Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.
75939136|NCT03012061|Drug|Placebo|Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.
75939137|NCT03012061|Drug|UMEC|UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.
76089489|NCT04391751|Procedure|Carpal tunnel release and basal joint arthroplasty through double incision|Group II: active comparator - double incision Trapezial excision and ligament reconstruction were performed in the same way as in group I, except that FCR deep leaflet was not incised. After radial incision wound closure, carpal tunnel release was performed through a second separate longitudinal palmar incision.
75342931|NCT01217411|Other|Laboratory biomarker analysis|Correlative studies
75800881|NCT03776058|Drug|Cinacalcet|Tablets for oral administration
75475826|NCT01999842|Biological|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
75475827|NCT01999855|Other|Phoniatric tests|
75475828|NCT01999881|Behavioral|exercise intervention|Receive aerobic and exercise intervention
75475829|NCT01999881|Procedure|standard follow-up care|Receive usual care
75800882|NCT03776058|Drug|Placebo|Tablets for oral administration
75800883|NCT05202574|Drug|Intravenous drug|intravenous drug injection
75800884|NCT03773874|Other|Assessment|Evaluation
75800885|NCT05202496|Drug|Calcitriol 0.25Mcg Cap|After orthodontic levelling and alignment, experimental group subjects are administered one capsule of calcitriol 0.25 mcg on a daily basis during the study period. Also, serum vitamin D levels are monitored at monthly intervals and rate of canine retraction is measured at monthly intervals
75800886|NCT05202496|Procedure|orthodontic treatment|experimental group subjects undergo orthodontic treatment after extraction of premolars
75800887|NCT03779568|Other|Dose adjustment of bupivacaine|Spinal bupivacaine dose will be adjusted according to previous patient experience.
76089490|NCT02983851|Procedure|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
75939138|NCT03012061|Drug|Fluticasone Furoate|FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
76089491|NCT02983851|Procedure|Invasive mechanical ventilation|Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
76089492|NCT02884401|Device|Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)|A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
76089493|NCT04391361|Drug|Scopolamine, atropine, edaravone and dexmedetomidine|The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.
75342932|NCT05595356|Device|transcranial direct current stimulation|"Session description: An electric current of 2mA will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
75342933|NCT05595356|Device|sham transcranial direct current stimulation|"Session description: Three ramps of 30 seconds of current will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
75342934|NCT05595356|Device|run-in sham transcranial direct current stimulation|In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.
75342935|NCT05595356|Behavioral|Psychoeducation video|Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.
75342936|NCT05595356|Behavioral|Tutorial video|Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
75475830|NCT01999881|Procedure|quality-of-life assessment|Ancillary studies
75475831|NCT01999881|Other|laboratory biomarker analysis|Correlative studies
75475832|NCT01999907|Dietary Supplement|Vitamin D|100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
75475833|NCT01999907|Dietary Supplement|daily vitamin D supplement|Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
75475834|NCT01999907|Other|Placebo|placebo given in a 2ml dose by mouth at baseline.
75800888|NCT05201560|Drug|Butorphanol Tartrate Injection|Patients of this group will receive Butorphanol Tartrate Injection
75800889|NCT05201560|Drug|Fentanyl|Patients of this group will receive Fentanyl
75800890|NCT05201326|Drug|Bevacizumab，Irinotecan and Re-radiotherapy|All patients with recurrent glioblastoma will accept irinotecan and bevacizumab combined with re-radiotherapy .
75800891|NCT05762458|Drug|Ammoxetine|Ammoxetine hydrochloride enteric-coated tablets
76089494|NCT04391361|Drug|Edaravone|The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.
75800892|NCT05762458|Drug|Placebo|placebo to Ammoxetine.
75800893|NCT03779256|Procedure|2D transvaginal ultrasound|"Transvaginal ultrasound is part of routine pre-operative examination of the women before surgery is scheduled. Described surgical treatment interventions is standard practice used to alleviate patient symptoms.~Women recruited at Oslo university hospital, Norway will also have an MRI performed pre-operatively."
75800894|NCT03775668|Drug|1 µCi of 14C-AAI101 + 500 mg AAI101|Single dose open label
75800895|NCT05762380|Dietary Supplement|Ferrous sulfate|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
75800896|NCT05762380|Dietary Supplement|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
75800897|NCT04928430|Drug|XAV-19|150 mg of XAV-19 single IV perfusion
75800898|NCT04928430|Drug|Placebo|Single IV infusion
75800899|NCT05200780|Device|ultrasound|All subjects will undergo the tests with the same machine. Transverse ultrasound images were obtained using the Philips HD with a 4-12 MHz probe. in neurosonology unit in neurology department.
75800900|NCT01561404|Drug|Everolimus|In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
75939139|NCT03012061|Drug|Albuterol/salbutamol|Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
75475835|NCT01999933|Radiation|Radiation|Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
75475836|NCT01999933|Drug|cisplatin（DDP） weekly|concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
75939140|NCT05106231|Behavioral|PICC Program|Participants will attend the PICC program which consists of 4 sessions that involve Visualization in Participatory Programmes (VIPP) and quizzes to evaluate retention in diabetes knowledge.
75939141|NCT05106231|Behavioral|Control|The control arm received four sessions one-on-one education program by a pharmacist. It is a Malaysian national education pharmacy-led program to instil knowledge and inculcate medication adherence.
75653299|NCT04473014|Behavioral|Heat Pain Paradigm|A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.
75800901|NCT01320774|Drug|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
75939142|NCT04953065|Other|COVID-19 vaccine hesitancy and acceptance survey|Participants will be provided with a COVID-19 vaccine hesitancy and acceptance survey developed by the study team.
75800902|NCT03775824|Drug|MTX start|Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
75939143|NCT00408863|Drug|tibolone|tibolone 2.5 mg/day
75939144|NCT00408863|Drug|placebo|
75939145|NCT05085327|Drug|ChapStick Lip Moisturizer Original|Sunscreen lip balm.
75939146|NCT05085327|Drug|ChapStick Lip Moisturizer Mint Flavour|Sunscreen lip balm.
75939147|NCT05085327|Drug|ChapStick Lip Moisturizer Black Cherry Flavour|Sunscreen lip balm.
75939148|NCT05085327|Drug|SPF Standard Sunscreen|SPF Standard (7 percent [%] Padimate-O and 3% Oxybenzone)
75939149|NCT05378074|Drug|Maxipost|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
75475837|NCT01999933|Drug|docetaxel plus cisplatin|concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
75342937|NCT03804086|Procedure|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement|"will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze."
75475838|NCT01999933|Drug|docetaxel plus cisplatin|adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
75475839|NCT01999959|Procedure|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
75475840|NCT01999998|Radiation|Radiotherapy|
75800903|NCT03775824|Drug|TNF start|Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
75653300|NCT04031690|Other|Caregiver Quality of Life Questionnaires|Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
75800904|NCT03775590|Procedure|Water|To evaluate using water in the treatment of atopic dermatitis
75800905|NCT03775590|Procedure|Bleach|To evaluate using water + dilute bleach in the treatment of atopic dermatitis
75800906|NCT03775590|Procedure|Acetic acid|To evaluate using water + vinegar in the treatment of atopic dermatitis
75800907|NCT04661566|Behavioral|"Basic Education (Education)"|All participants will receive the basic educational component in the Mission Wellness app. This component will contain text and media (e.g., images, videos) to teach basic SRH topics. The exact information in this component will be determined by an assessment of baseline SRH knowledge at the start of the intervention.
75800908|NCT04661566|Behavioral|"Narrative Videos (Narratives)"|The narrative video component is a motivation-based component that includes stories of individuals engaging in positive and negative SRH behaviors that lead to either positive or negative outcomes, respectively, in a video format.
75800909|NCT04661566|Behavioral|"Skills Building Videos (Skills)"|The skills-building videos component is a component rooted in behavioral skills that involves the provision of information on how to perform or engage positive SRH behaviors (e.g., correctly using a condom, what to expect when having a Pap smear) via instructional videos.
75800910|NCT04661566|Behavioral|"Interactive Scenarios (Scenarios)"|The interactive scenarios are a behavioral skills-building component that walks through conversations surrounding SRH with select individuals (e.g., partner, healthcare provider), providing suggestions on how to have these conversations and why these conversations are important to have.
75939150|NCT05378074|Drug|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
75939151|NCT05113719|Other|Exercise|Both groups will perform bridge exercise
75939152|NCT03666793|Other|global care|Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
75653301|NCT04031690|Other|Patient Quality of Life Questionnaires|Quality of life measurement at D0, M6 and M12 via the SF-36
75653302|NCT04354220|Diagnostic Test|capnography monitoring|routinely used capnography monitoring
75653303|NCT04354220|Diagnostic Test|arterial blood gas|Routinely taken arterial blood gas values
75939153|NCT03488277|Other|leg elevation|intra operative position that consists in leg elevation with a 30 cm height pillow under the patient's heels
75939154|NCT03665389|Device|iFR / FFR measurement|At the time of pre-TAVR coronary angiogram, iFR (iFR before TAVR) will be measured. The cCTA data collected from patients whose consent is obtained following TAVR will be anonymized and sent to HeartFlow, Inc., where the FFRct （FFRct before TAVR） values will be calculated using their cardiovascular dynamics analysis program. With the FFRct values blinded, FFR (FFR after TAVR) and iFR (iFR after TAVR) will be measured using a guide wire that is capable of sensing pressure after TAVR is performed. Furthermore, FFRct(FFRct after TAVR) is calculated from cCTA taken after TAVR.
75939155|NCT03703661|Procedure|Needle-Aspirated Negative Pressure Dressing|dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
75939156|NCT03703661|Procedure|Control|dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
75939157|NCT04941339|Drug|MRG002|Administrated intravenously
75653304|NCT04449536|Drug|Mesna|Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
75800911|NCT04661566|Behavioral|"Future Life Planning Tool (Future)"|The future life planning tool is a motivation-based component contains a series of questions to help users plan future goals to put current decision making related to SRH into perspective and provide suggestions on how to stay healthy now to be able to achieve those goals later.
75800912|NCT04661566|Behavioral|"Epidemiological Risk Scenario (Risk)"|The risk component is an information- and motivation-based component with tailored epidemiological risk information about relative risk of contracting a specific STI and/or having an unintended pregnancy. Relative risk information will be determined by adjusting variables within the component (e.g., number of partners within the last month, percent of time using condoms).
75800913|NCT03775746|Drug|Clopidogrel 75Mg Tablet|Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
75800914|NCT03775746|Drug|Rivaroxaban 2.5Mg Tablet|Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)
75800915|NCT03775746|Drug|Ticagrelor 90Mg Tablet|Prevention of atherothrombotic events in patients with acute coronary syndrome [in combination with aspirin]
75800916|NCT03779412|Behavioral|The Happiness Trap|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
75800917|NCT03779412|Behavioral|A Mindfulness-Based Stress Reduction Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
75939158|NCT03666715|Drug|Oral Antipsychotics (OAPs)|No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
75342938|NCT03804086|Procedure|Open flap debridement|a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
75653305|NCT03960554|Drug|Denosumab Inj 60 mg/ml|Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
75653306|NCT03960554|Other|Placebo|Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
75342939|NCT03804242|Behavioral|Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience|This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
75653307|NCT00911768|Dietary Supplement|Korean Red Ginseng Powder Capsule|Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study
75653308|NCT00911768|Dietary Supplement|Corn-starch powder with ginseng flavor|"There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.~The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).~Main contents: corn-starch with Panax ginseng flavor"
75653309|NCT04131374|Behavioral|Reminiscence Therapy|Virtual reality scenarios will be used to delivered reminiscence therapy with each caregiving dyad (i.e. person living with dementia; family member).
75653310|NCT02377622|Device|THERANOVA 400 dialyzer prototype AA|
75653311|NCT02377622|Device|THERANOVA 400 dialyzer prototype BB|
75653312|NCT02377622|Device|FX CorDiax 80 Dialyzer|
75653313|NCT02377622|Device|FX CorDiax 800 Dialyzer|
75653314|NCT03038984|Behavioral|At Home Screening procedure On demand|Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
75800918|NCT01561248|Drug|polyethylene glycol solution for daily bowel lavage.|At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
75800919|NCT05171218|Behavioral|Music & Auditory Beat Stimulation|Listening to calm music and auditory beat stimulation Participants listened to calm music with theta auditory beat stimulation for 24 minutes
75939159|NCT03666715|Drug|Paliperidone Palmitate 1-Month Formulation (PP1M)|No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
75939160|NCT03665311|Biological|25% Albumin fluid|25% Albumin fluid (100 mL)
75939161|NCT03665311|Other|Normal Saline|0.9% Normal Saline (100 mL)
75800920|NCT05171218|Behavioral|Music Alone|Listening to calm music Participants listened to calm music for 24 minutes
75800921|NCT05171218|Behavioral|Auditory Beat Stimulation|Listening to theta auditory beat stimulation Participants listened to theta auditory beat stimulation for 24 minutes
75939162|NCT04830033|Other|ENO Breathe group|Six weekly group online workshop sessions, led by an ENO vocal specialist. Workshops will encourage participants to take part in exercises and activities especially designed to support breathing control, providing tools for self-management of breath and anxiety. They will also have access to bespoke online digital resources, designed to support participants between sessions. These will include exercises, song sheets and audio and video materials, especially recorded by the ENO for participants on the programme.
75939163|NCT03666637|Procedure|dynamic hip screw (DHS) and cannulated screw (CS)|A preformed case report form was used to collect the data which included the demographic profile of the patients (age, gender), comorbidities, smoking history, mode of injury (high or low energy), presence of multiple trauma, garden classification, side of injury, time to fixation (in hours), type of reduction, type of implant used, RUSH score (healing), start of weight bearing, development of AVN, and final outcome (whether varus, valgus, displaced or healed).
75939164|NCT03488199|Device|Stent Acculink ™|Carotid Artery Revascularization using Stents
75939165|NCT03488199|Device|CGuardTM™|Carotid Artery Revascularization using Stents
75939166|NCT03010501|Other|Food Energy Density|Food Energy density manipulated
75800922|NCT05171218|Behavioral|Pink Noise|Listening to pink noise Participants listened to pink noise for 24 minutes
75939167|NCT03489681|Device|acupuncture|"Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62)."
76089495|NCT05603325|Other|Person Centered Practice|"Staff will be asked to:~Complete two surveys on two occasions, once before the intervention sessions and once following the last session. The first survey is views on patient feedback and the other is about the workplace culture and how person-centred it is.~Attend 6 x 2 hour facilitated workshops which will involve getting ready to work with patient feedback, establishing values and visions for the intervention group, critically reviewing the ways patients are offered the opportunity to give feedback~Engage in changes in practice (e.g. how staff offer patients the opportunity to provide feedback and the way staff make changes in response to this feedback);~Attend a final focus group to evaluate the workshop programme."
75342940|NCT01253525|Biological|Ramucirumab (IMC-1121B )|8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
75342941|NCT01253525|Drug|Paclitaxel|80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
75342942|NCT05743712|Other|SMART-Wrap|This intervention, SMS (short message system)-based augmentation, seeks to improve the impact and approach of the Wraparound service model by utilizing SMS, which has been shown to increase treatment adherence and sustained engagement. This intervention will facilitate regular, repeated evaluation of intermediate outcomes through self-report assessments.
75800923|NCT03773172|Drug|MEDI6012|MEDI6012 is recombinant human lecithin-cholesterol acyltransferase (rhLCAT), an approximately 60 kilodalton, glycosylated, single-chain protein consisting of 416 amino acids produced via Chinese hamster ovary cell culture. It is being explored as an acute treatment to reduce the risk of recurrent cardiovascular events as an adjunct to the standard of care in patients with acute myocardial infarction (MI). MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.
75800924|NCT03773172|Drug|Placebo|The placebo will mimic the active treatment.
75800925|NCT05162560|Other|patients with acute diverticulitis|registry and hospital charts of patients with acute diverticulitis
75800926|NCT03779178|Drug|Landiolol|Landiolol perfusion over 120 minutes in incremental doses : 0.5, 1, 2, 5 and 10 µg/kg/min. Doses are modified every 20 minutes
75939168|NCT03666481|Behavioral|Motivational Physical Activity Intervention (MPAI)|"MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions."
75939169|NCT03131973|Drug|BMS-986195|Specified dose on specified days
75939170|NCT03131973|Drug|Methotrexate|Specified dose on specified days
75939171|NCT03131973|Drug|Leucovorin|Specified dose on specified days
75939172|NCT03131973|Drug|Caffeine|Specified dose on specified days
75939173|NCT03131973|Drug|Montelukast|Specified dose on specified days
75939174|NCT03131973|Drug|Flurbiprofen|Specified dose on specified days
76089496|NCT05603325|Other|Interview|Interviews will be used to gather views about how easy or difficult it is to give feedback and how it feels to consider and/or give feedback
76089497|NCT01454037|Procedure|Prostate cryotherapy|cryoablate the prostate
75342943|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
75800927|NCT03779178|Drug|Placebo|Placebo perfusion is sodium chloride NaCl 0.9% over 120 minutes in incremental doses : 0.03, 0.06, 0.12, 0.3 and 0.6 mL/kg/h. Doses are modified every 20 minutes. Perfusion are similar in landiolol group to preserve blind.
75800928|NCT05096338|Other|Social Determinants of Health|We will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
75800929|NCT05091892|Other|Hydrotherapy programm|Treatment
75939175|NCT03131973|Drug|Omeprazole|Specified dose on specified days
75342944|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
75342945|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
75342946|NCT01247675|Drug|Omnitrope|s.c., daily injection
75342947|NCT05310968|Drug|Tirofiban hydrochloride sodium chloride injection|Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.
75342948|NCT05310968|Drug|Tirofiban hydrochloride sodium chloride injection placebo|Day 1: Tirofiban placebo will be injected at the same rate with experimental group.
75342949|NCT05310968|Drug|Aspirin|Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
75939176|NCT03131973|Drug|Midazolam|Specified dose on specified days
75939177|NCT03131973|Drug|Digoxin|Specified dose on specified days
75939178|NCT03131973|Drug|Pravastatin|Specified dose on specified days
75939179|NCT03665233|Device|VR|People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
75939180|NCT05078931|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles
75939181|NCT05078931|Drug|Lenvatinib|Lenvatinib 20mg will be administered orally daily.
75939182|NCT05579873|Procedure|Clavicle plating|VariAx 2.0mm + 2.4 or 2.7mm vs any other single plate
75939183|NCT03492957|Other|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
75939184|NCT03002623|Drug|CUDC-907|60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
75939185|NCT04825197|Drug|Poractant Alfa Intratracheal Suspension [Curosurf]|up to 4 doses (100 mg Kg) of Poractant alfa every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV.
75939186|NCT04728191|Other|Physiotherapy|physiotherapeutical instructions and training as described.
75800930|NCT05084326|Procedure|Engagement of fetal head as a predictor of a successful vaginal delivery|"In addition to the fetal lie, presentation, and position, the level or station of the presenting part in the maternal pelvis is an important factors in the labor process.~In primigravida, Delayed engagement of fetal head has been theorized that it is more likely in women with a possible cephalo-pelvic disproportion, so far they are associated with higher risk of cervical dystocia, which led to increased rate of caesarean section."
75800931|NCT05070286|Behavioral|Observational Study.|Semi-structured interviews.
75939187|NCT04728191|Other|standard care|Standard care as described.
75939188|NCT04737135|Other|Non intervention|Patients without intervention
75939189|NCT03665857|Behavioral|a multicomponent intervention|"School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~Monitoring of students' weight and height Students will be monitored their weight and height monthly.~Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors."
75939190|NCT04703361|Biological|Placebo NaCl|Placebo
75939191|NCT04703361|Biological|Niacin|B3 vitamin, Niacin
76089498|NCT01454037|Procedure|Radical prostatectomy|Remove prostate
75342950|NCT03804164|Other|Educational Intervention|Attend Emerging from the Haze psychoeducational sessions
75342951|NCT03804164|Other|Quality-of-Life Assessment|Ancillary studies
75342952|NCT03804164|Other|Survey Administration|Ancillary studies
75342953|NCT01254851|Behavioral|goal-augmented post-operative care|Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
75342954|NCT00768716|Drug|Acetaminophen|2 x 500 mg by mouth once
75800932|NCT04440384|Other|Functional evaluation|"Patients will complete these forms and tests :~Box and block test, Purdue peg board, Percival, Nine hole peg, T-GAP, EGF, MAHVIE, DASH, RAND36, CHQ-PF28, CHQ-CF45, CGI-S"
75939192|NCT04703361|Biological|Na-3-OHB|Na-3-OHB
75939193|NCT03010423|Drug|Nicorandil|Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
75939194|NCT05576597|Drug|Sodium Butyrate|2 capsules butyrate supplement once a day for 12 weeks
76089499|NCT01454037|Procedure|Radiation|Radiate prostate
76089500|NCT04272957|Drug|HMPL-306|HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
75342955|NCT05743634|Biological|YY001|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
75342956|NCT05743634|Biological|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
75342957|NCT05743634|Biological|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
75342958|NCT05583188|Device|Aliya Pulsed Electric Fields (PEF) ablation|Patients will undergo PEF ablation
75342959|NCT05583188|Drug|Nivolumab plus Platinum Doublet Chemotherapy|If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
75342960|NCT05583188|Drug|Standard of care neoadjuvant therapy|Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
75342961|NCT05583188|Other|Surgical Resection|Patients not eligible for systemic therapy will receive definitive surgery without neoadjuvant therapy as per institutional standard of care post-PEF ablation.
75342962|NCT05743322|Device|Left atrial appendage closure|Left atrial appendage will be occluded using commercially available device
75342963|NCT01218971|Drug|Medisorb naltrexone 190 mg|naltrexone for extended-release injectable suspension
75800933|NCT05762224|Other|Effect of kinesio taping on upper limb lymphedema|Group A received Kinesio taping 2 times a week for 3 weeks to reduce lymphedema and Group B received pressure garments(20-60 mm Hg) for at least 15 to 18 hours per day for 3 weeks
75800934|NCT04976452|Other|Multi-component teaching content|The students assigned to Group 1 will undergo interactive module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines. Following completion of the module, students will be presented with a powerpoint lecture by the Primary Investigator on Blood Pressure. Students will then undergo a competency examination that assesses their ability to measure blood pressure following the guidelines of the American Heart Association.
76089501|NCT04273191|Drug|Brexanolone|Brexanolone will be initiated and administered per the USPI and the associated REMS.
76089502|NCT04391985|Drug|SOF plus (OBV/PTV/r) plus RBV|They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
75800935|NCT04889508|Behavioral|Socio-emotional mental training|Core practice: Affect Dyad. In the Affect Dyad (AD), participants perform a 12-minute partner-based exercise which involves contemplating over one difficult situation and one situation which incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation. The goal of the exercise is to enhance coping with difficult emotions, empathic listening, social sharing, acceptance, and gratitude.
75342964|NCT01218971|Drug|Medisorb naltrexone 380 mg|naltrexone for extended-release injectable suspension
75342965|NCT01337687|Drug|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
75939195|NCT04727099|Device|PicoWay Laser System|The PicoWay® laser system is an alexandrite laser pumped, solid-state Neodymium:Yttruium Aluminum Garnet (Nd:YAG) laser emitting energy at user selectable wavelengths of 1064 nm, 532 nm, 785 nm or 730 nm, designed for the treatment of tattoo, benign pigmented lesions, acne scars, and wrinkles.
75939196|NCT03492879|Device|EIT Technology|Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage
75939197|NCT03002311|Device|Epharmix/CareSignal eHealth|The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
75939198|NCT05034471|Device|Mi-Chord™ Device Technologies|Mi-Chord™ System consists of LS-5™ ePTFE suture, the Mi-STITCH™ suturing device, the Mi-KNOT™ device and the Mi-KNOT™ titanium fastener. Mi-Chord™ system is designed to replace the chordae tendineae in order to enable mitral valve repair. These sub-devices (ePTFE suture, Mi-STITCH™, Mi-KNOT™ device, Mi-KNOT™ titanium fastener) can be considered as one system and refer to different aspects of the overall technology.
75342966|NCT01337687|Drug|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
75342967|NCT04351919|Drug|Hydroxychloroquine|400mg per day during 10 days
75342968|NCT04351919|Drug|Azithromycin|500 mg per day during 5 days
75342969|NCT05743088|Behavioral|questionnaire|The questionnaire consists of the following parts: socio-demographic data of participants, student perception and attitude towards the COVID-19 pandemic and its consequences, as well as practices of preventive measures in the community.
75342970|NCT00769808|Device|Bausch & Lomb 217z Excimer Laser|LASIK correction of myopia and myopic astigmatism
75653315|NCT03038984|Behavioral|At Home Screening procedure every 3 months|Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
75800936|NCT04889508|Behavioral|Mindfulness-based mental training|Core practice: Breathing Meditation. In this intervention, participants will practice 12-minute basic attention-based mindfulness meditation such as the Breathing Meditation (BM). BM is a 12-minute individual exercise that requires participants to focus their attention on the sensations of breathing. Participants have to sustain their attention to breath for long stretches of time, and have to return their attention to their breath when their mind wanders. The key focus is on training attention and interoceptive body awareness. Other practices participants will be taught is mindfulness on sounds (here the object of attention is not the breath but sounds in the environment).
75800937|NCT05214508|Diagnostic Test|interleukin 6|assessment of serum IL-6 by ELISA
75800938|NCT01320852|Other|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
75342971|NCT00769886|Drug|Ketotifen/naphazoline|One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
75342972|NCT00769886|Drug|Ketotifen|One drop of Ketotifen in study eye at visit 3 and visit 4.
75939199|NCT03488043|Procedure|Needle lung biopsy|Needle lung biopsy
75939200|NCT03002077|Drug|Rapastinel|Rapastinel pre-filled syringes for IV injections.
75342973|NCT00769886|Drug|Naphazoline|One drop of naphazoline in study eye at vist 3 and visit 4.
75342974|NCT00769886|Drug|Vehicle|One drop of vehicle in study eye at visit 3 and visit 4.
75342975|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|one spray in each nostril twice daily for 2 weeks
75342976|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray Vehicle|one spray in each nostril twice daily for 2 weeks
75342977|NCT01309451|Drug|Bevacizumab|intravitreal, 1.25mg., monthly
75342978|NCT01309451|Drug|dexamethasone intravitreal implant|0.7mg, intravitreal every 4 months
75342979|NCT04351841|Other|arabinogalactan|A beverage will be prepared by thoroughly mixing the 15 g of arabinogalactan with water and Crystal Light flavoring
75342980|NCT04351841|Other|maltodextrin|A beverage will be prepared by thoroughly mixing the 15 g of maltodextrin with water and Crystal Light flavoring
75342981|NCT04383704|Other|New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))|A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.
75342982|NCT03803384|Other|Oxygen therapy|Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.
75653316|NCT03753932|Device|Fixed prosthodontics|The intervention takes place six months after finishing radiotherapy.
75653317|NCT04084106|Drug|Phenoxymethylpenicillin|Oral administration
75653318|NCT04084106|Drug|Amoxicillin|Oral administration
75653319|NCT04084106|Drug|Amoxicillin-clavulanic acid|Oral administration
75653320|NCT04229654|Other|Questionnaire|A written questionnaire was used to capture demographic data, obstetric history, knowledge, expectations, and perception of anomaly scans.
75653321|NCT04227080|Drug|BH4|oral administration of 20 mg/kg KUVAN (BH4)
75800939|NCT01320930|Behavioral|Pulmonary rehabilitation|
75342983|NCT03803306|Combination Product|Vedic Medical Astrology|Individualised astrological based interventions were given including vedic counselling, diet, colors, gems, mantras and the worship deities as an adjuvent to ongoing conventional treatments
75342984|NCT03803306|Other|Placebo vedic medical astrology (PMA)|Conventional treatments were followed with counselling and diet suggestions. astrological interventions were not incorporated during the study phase.
75939201|NCT03487965|Dietary Supplement|Low dose Polyphenol|botanical supplement with 25 mg polyphenol
75939202|NCT03487965|Dietary Supplement|High dose Polyphenol|botanical supplement with 13 mg polyphenol
75939203|NCT03487965|Dietary Supplement|Placebo Control|inert tablet made to mimic the experimental tablets
75939204|NCT04209153|Other|Transcranial Direct Current Stimulation|tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics
75939205|NCT03665779|Drug|isosorbide mononitrate|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times
75939206|NCT03665779|Drug|Placebo|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
75939207|NCT03664999|Diagnostic Test|Blood sampling|differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
75475841|NCT02000024|Behavioral|Weight Watchers|"The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk."
75475842|NCT02000024|Behavioral|National Diabetes Education Program|
75939208|NCT03703505|Drug|AG-348|120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled [14C]AG-348.
75939209|NCT03703505|Drug|[13C6]AG-348|IV microdose of approximately 100 micrograms (mcg), single dose.
75939210|NCT04947293|Other|Physical activity|Both groups will practice a physical activity adapted to their motor skills. They will have two group sessions (maximum 5 people per group) in a face-to-face setting, and one independent session at home supported by a video, each week. These programs last 12 weeks, and will be supervised by the same person, a physiotherapist.
75939211|NCT04946435|Combination Product|Antibiotic Irrigation|The first 30 patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group. The following 30 patients will be assigned to the experimental group. Immediately following surgery, the control group will receive nasal packing alone and the experimental group will receive nasal packing with antibiotic irrigation
75939212|NCT03666403|Procedure|NIV rate: 0/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
75939213|NCT03666403|Procedure|NIV rate: 10-20/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
76089503|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
76089504|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
75342985|NCT00771056|Drug|Hydroxychloroquine|400mg by mouth daily x 1 year
75342986|NCT00795002|Drug|alvocidib|Given IV
75342987|NCT00795002|Drug|mitoxantrone hydrochloride|Given IV
75342988|NCT00795002|Drug|cytarabine|Given IV
75342989|NCT00795002|Other|pharmacological study|Correlative studies
75342990|NCT00795002|Other|laboratory biomarker analysis|Correlative studies
75800940|NCT01320930|Behavioral|conventional care|
75800941|NCT05214352|Other|co-design in the intervention manual elaboration to increase the participation in the community|"It will co-design an intervention manual between all participants (families, young people with cerebral palsy and therapists) and researchers, using the involvement matrix to increase the participation of young people in the community.~Different focus grous will be created to work together and various online meetings, masterclass, workshops to increase the knowlodge in all groups."
75800942|NCT03775434|Drug|Experimental: B244|B244 suspension in 30ml/bottle
76089505|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
76089506|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
75342991|NCT03802838|Device|acupuncture|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
75800943|NCT03779100|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
75800944|NCT03779100|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
75939214|NCT03666403|Procedure|NIV rate: 5-10/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
75939215|NCT04944017|Drug|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
75939216|NCT04944017|Other|Placebo - Saline Infusion|Participants will receive 6 infusions of saline administered over 40 minutes while on continuous cardiac monitoring and oximetry
75939217|NCT03686891|Other|Skin prick tests with four native legumes|Skin prick tests with four native legumes
75939218|NCT03703427|Drug|Capecitabine, Oral, 500 Mg|1250mg/m2，d1-d14，q3w
75342992|NCT03802838|Drug|Amisulpride|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
75653322|NCT03750110|Other|Intervention|"In addition to usual care, personalised feedback from the participants screening appointment will be provided;~For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided."
75653323|NCT03750110|Other|Usual Care|Smoking cessation support in line with NICE PH48 guidelines
75653324|NCT03746210|Diagnostic Test|Standard diagnostic procedures|B-Mode ultrasound, Duplex sonography, contrast-enhanced ultrasound, elastography, CT, MRI, anthropometrics
75800945|NCT05224440|Behavioral|TSMV Sponsorship Initiative|Consistent with preventive, universal and public health approaches to suicide, the VA's TSMV Sponsorship Initiative establishes public-private partnerships with federal and community organizations to provide TSMVs with one-on-one, certified and volunteer sponsors in their post-military hometowns. Sponsors are assigned approximately six months prior to discharge and help TSMVs to accomplish reintegration tasks pre-and post-discharge. After certification, sponsors are assigned to and managed by a community integration coordinator (CIC), which is a local organization. CICs recruit sponsors, manage sponsors and match sponsors with TSMVs moving to the local region. After being matched with a TSMV, sponsors then integrate their skills during regular contact with matched TSMVs and monthly video or in-person sessions and help TSMVs identify SMART goals and develop reintegration action plans and ensure TSMVs attend VA healthcare appointments.
75800946|NCT05213494|Other|Inulin|Inulin, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
75800947|NCT05213494|Other|soluble corn fiber|soluble corn fiber, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
75800948|NCT01321086|Behavioral|Motivational Interviewing|9 sessions of MI from baseline to six months
75800949|NCT01321086|Behavioral|PACE|9 sessions of PACE delivered from baseline to six months
75800950|NCT03778866|Other|Bicarbonate-buffered handling medium|The investigators will evaluate whether the usual bicarbonate culture medium can replace the HEPES buffered medium effectively.
75800951|NCT05711212|Dietary Supplement|micellar solubilized Xanthohumol|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
75800952|NCT05711212|Dietary Supplement|Placebo|single administration of 4 soft gelatine capsules containing only micelles
75800953|NCT01320228|Dietary Supplement|Control|Alli treatment plus placebo (rice flour)
75800954|NCT01320228|Dietary Supplement|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
75800955|NCT01320228|Dietary Supplement|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
75800956|NCT01320228|Dietary Supplement|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
75800957|NCT05212636|Device|Repetitive transcranial magnetic stimulation (rTMS)|A total of 12 sessions of rTMS (5 sessions per week for 2 weeks, follow by 1 session per week for next 2 weeks) .
75800958|NCT03775278|Drug|PHP-303|Investigational drug
75800959|NCT03775278|Other|Placebo|Matching placebo
75800960|NCT05212558|Other|Placebo respiratory muscle training|Unloaded respiratory muscle training plus conventional respiratory exercises
75800961|NCT05212558|Other|Inspiratory muscle training|Inspiratory muscle training plus conventional respiratory exercises
75800962|NCT05212558|Other|Combined inspiratory and expiratory muscle training|Combined inspiratory and expiratory muscle training in the same respiratory cycle plus conventional respiratory exercises.
75800963|NCT03775122|Device|TAES|TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity
75939219|NCT03703427|Drug|Vinorelbine Tartrate Oral|60mg/m2，d1；d8；q3w
75939220|NCT03703349|Drug|Magnesium Sulfate|Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery
75939221|NCT03703349|Drug|Placebo Oral Tablet|Placebo for Magnesium
75939222|NCT03008005|Drug|Placebo Oral Capsule|Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
75939223|NCT03008005|Drug|Dronabinol Cap 5 milligrams (MG)|Dronabinol (5mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
76089507|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
75800964|NCT05212324|Procedure|widening of first web space|widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
75939224|NCT03008005|Drug|Dronabinol Cap 10 milligrams (MG)|Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
75939225|NCT03666325|Drug|Pembrolizumab|Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
75939226|NCT03666325|Drug|Cetuximab|In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
75939227|NCT03394781|Drug|DUR-928|oral suspension daily for 28 days
75939228|NCT03666247|Behavioral|HealthMindr Application|From baseline to 3-month post-test, participants in the intervention arm are granted access and instructed to interact regularly with the HealthMindr messaging platform. The HealthMindr messaging platform delivers messages relevant to both general audiences of sexually-active MSM, as well as messages relevant only to specific subgroups of HIV-positive men, and currently higher and lower risk HIV-negative men. Answers provided during the assessments determine which subset of messages are delivered to app users, with information such as HIV status, changes in self-reported risk behaviors, or other factors that influence the relevance of any given message. The HealthMindr application also offers free condoms, lube, and a HIV and STI testing kits.
75939229|NCT03666247|Behavioral|Waitlist|Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States (AIDSVu) and resources to locate HIV testing services and prevention information in their area. No information recommending frequency of testing will be given in the welcome greeting.
75653325|NCT05580302|Other|Transcranial Magnetic Stimulation (TMS)|An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.
75653326|NCT02973542|Drug|Ethosuximide|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
75653327|NCT02973542|Other|Placebo|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
75939230|NCT03703193|Other|Dry Needling|A single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
75939231|NCT03703193|Other|Physical Therapy|A single session of modulatory interventions targeting modulation of central nervous system.
75939232|NCT03665701|Procedure|Blood Sampling|Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
75939233|NCT03255863|Other|Questionnaire|Patient Self reported questionnaire filled in.
75939234|NCT02440425|Drug|Pembrolizumab|Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
75475843|NCT02000076|Behavioral|Partial sleep deprivation allowing 3 h sleep at night|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
75653328|NCT04228874|Device|coronary artery stents|"Coronary angiography was done for all the patients according to the Judkins technique. All images were evaluated by an experienced operator, significant coronary artery disease was defined as > 70 % luminar diameter stenos. The following data was obtained:~Site of stent implantation within LAD. The first Diagonal branch serves as the boundary between the proximal and mid portion of the LAD. Thus, the portion of the artery prior to the origin of the 1st diagonal is known as the proximal LAD, while the segment just below the1st diagonal branch is the mid LAD. The distal segment of the LAD is the terminal third of the artery (Cao et al., 2017).~Length, diameter and number of stents.~TIMI flow after stent deployment."
75653329|NCT02973386|Drug|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
75800965|NCT03773094|Drug|Guava leaves extract|"Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•"
75800966|NCT03773094|Drug|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
75939235|NCT02440425|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
75939236|NCT04054141|Device|Mag Stim|rTMS
75939237|NCT03199079|Other|Measurement|Measurement of cervix elasticity and length measurements is not an intervention
75342993|NCT03802682|Drug|Apalutamide|Participants will receive apalutamide 240 mg as a whole tablets administered orally (Treatment A) or as a dispersed mixture in applesauce (Treatment B) under fasted condition.
75342994|NCT00772304|Drug|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
75342995|NCT01310231|Drug|Metformin|"metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: Until progression or unacceptable toxicity develops."
75939238|NCT04050917|Device|real stimulation|The smartwatch generates imperceptible vibratory stimulation.
75939239|NCT04050917|Device|no stimulation|The smartwatch generates no stimulation.
75939240|NCT03109743|Behavioral|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
75939241|NCT03109743|Behavioral|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
75939242|NCT04182321|Drug|Metformin & Entecavir|Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
75939243|NCT04182321|Drug|Placebo & Entecavir|Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
75939244|NCT03703037|Diagnostic Test|Ultrasound and Doppler ultrasound|Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
75939245|NCT04461405|Behavioral|INTEGRATE-D|INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
75939246|NCT03702959|Drug|Betamethasone|Corticosteroids
75939247|NCT03702881|Device|Bonded Spurs associated with posterior build-ups|Twenty-five patients will be treated with bonded spurs associated with posterior build-ups. The cervical portion of the palatal surfaces of the maxillary incisors and the incisal portion of the lingual surfaces of the mandibular incisors will be pumiced, rinsed, dried, and acid etched with 37% phosphoric acid. The etched surfaces will be subsequently rinsed and carefully dried. Then, the spurs will be bonded using Transbond primer/adhesive. The positions for the spurs will be chose to prevent possible future occlusal interferences The spurs will be sharpened with a carborundum disk before bonding. In addition, posterior build-ups (resin blocks) will be cemented on the functional cusps of all maxillary posterior teeth. The treatment time will be 12 months. After this time, the posterior build ups will be removed and the bonded spurs will be maintained for 12 months more, as active retention.
76089508|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
75342996|NCT01310231|Drug|Placebo|"Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops."
76089509|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
76089510|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
76089511|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
76089512|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
76089513|NCT01454115|Drug|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
76089514|NCT01454115|Drug|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
75342997|NCT00789074|Drug|Varenicline|Varenicline 1mg twice daily
75342998|NCT00789074|Drug|Placebo|Placebo 1mg BD
76089515|NCT01455597|Drug|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
76089516|NCT01454271|Procedure|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
76089517|NCT01453101|Drug|Fludarabine monophosphate, melphalan, Bortezomib|"Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.~Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2~Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan."
76089518|NCT01454349|Drug|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
76089519|NCT01454349|Drug|Placebo|Single intraprostatic injection of matching placebo
76089520|NCT02935257|Biological|CD19CAT-41BBZ CAR T-cells|Infusion with CD19CAT-41BBZ CAR T-cells
75342999|NCT01338857|Drug|Sorafenib (Nexavar)|"Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.~Children/adolescents (< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily~Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily~NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily"
76089521|NCT01454661|Dietary Supplement|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
76089522|NCT01454661|Dietary Supplement|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
76089523|NCT01454661|Dietary Supplement|Placebo|Microcrystalline cellulose is used as placebo.
76089524|NCT02085447|Behavioral|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
76089525|NCT04847193|Other|Dietary Intervention 1: Placebo|Participants receive a study drink supplemented with a placebo for 5 days
75939248|NCT03702881|Device|Conventional bonded spurs|Twenty-five patients will be treated only with bonded spurs. The bonding of the spurs will follow the same protocol described for the experimental group. The treatment time will be 12 months. After this time, the bonded spurs will be maintained for 12 months more, as active retention.
75939249|NCT03001219|Drug|Anti-TNF-alpha|Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
75939250|NCT03001219|Drug|Methotrexate|Participants will continue their pre-trial methotrexate therapy at a stable dose.
75939251|NCT03001219|Drug|Placebo|Participants will receive intravenous infusion of placebo.
75653330|NCT02973386|Drug|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
75653331|NCT04228718|Behavioral|Zarit Burden Interview Scale|It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.
75939252|NCT03001219|Drug|RO7123520|Participants will receive intravenous infusion of RO7123520.
75939253|NCT03492723|Dietary Supplement|Aged Garlic Extract|NR
75939254|NCT05477849|Drug|Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection|"Dose level 1~Dose level 2~Dose level 3~Dose level 4~Dose level 5"
75653332|NCT04228718|Behavioral|Family Needs Survey (FNS)|It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.
75939255|NCT04461093|Other|Acupressure wristband and Palanosetron|"Group 1 Patients with odd numbers labelled form will be Group I patients. They will receive intravenous dexamethasone 8mg during induction. Acupressure P6 wristband is applied after induction and removed prior to emergence to maintain blinding. Intravenous ondansetron 4mg is given prior to skin closure.~Group 11 Patients with even numbers labelled form will be Group II patients who will receive intravenous palonosetron 0.075mg during induction."
76089526|NCT04847193|Other|Dietary Intervention 2: Xanthohumol and Iso-alpha acids|Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
75653333|NCT04228718|Other|Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)|CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.
75653334|NCT04228718|Other|Hammersmith Functional Motor Scale Expanded (HMFSE)|It is an extended version of the 20-item HFMS. Based on another scale known as GMFM, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.
75653335|NCT04228328|Diagnostic Test|The 6-minutes Walk Test|To walk for 6 minutes
75939256|NCT03702803|Dietary Supplement|Galphimia glauca standardized extract|Each patient will be administered with a capsule once a day (in the morning), for 10 weeks. A capsule contains the standardized extract of Galphimia glauca corresponding to 0.374 mg of Galphimine-B
75939257|NCT03702803|Drug|alprazolam 1mg|Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
75939258|NCT03543943|Procedure|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon [1]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively.
76117222|NCT03710603|Drug|dexamethasone|Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.
75939259|NCT03543943|Procedure|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
75939260|NCT03543943|Procedure|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
75939261|NCT03702647|Drug|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
75939262|NCT03702647|Drug|Normal saline|30mL of normal saline placed in the POEM tunnel
75939263|NCT03489447|Other|ICU care|exposure to ICU treatment with or without diagnosed sepsis
75939264|NCT04583787|Diagnostic Test|99mTc-sestamibi myocardial perfusion SPECT|82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
75939265|NCT04583787|Diagnostic Test|82Rb-Chloride myocardial perfusion PET with CCTA|stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
75939266|NCT03000673|Drug|Enoxaparin|Specified dose of Enoxaparin on specified days
75939267|NCT03000673|Drug|unfractionated heparin (UFH)|Specified dose of UFH on specified days
75939268|NCT03000673|Drug|BMS-986177|Specified dose of BMS-986177 on specified day
75939269|NCT03487731|Biological|Allogeneic Human Mesenchymal Stem Cells (hMSCs)|A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.
75475844|NCT02000076|Behavioral|Full sleep|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
75475845|NCT02000102|Drug|Intravitreal Injection of Aflibercept|
75475846|NCT02000128|Device|bioimpedance monitoring|To assess the body composition using Multi-frequency bioelectrical impedance analysis
75939270|NCT03487731|Drug|Placebo|A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
75939271|NCT03487653|Biological|microbiology:Blood culture and sensitvity test .Serology|Gram stain ,Blood culture ,sensitivity test ,biochemical reactions and serological study will be done
75939272|NCT05423249|Drug|Ferrous sulfate|Oral ferrous sulfate 325 mg once daily, containing 65 mg of elemental iron to treat non-anemic iron deficiency
75939273|NCT05423249|Drug|Prenatal|Oral prenatal vitamin once daily for both groups
75939274|NCT05423249|Drug|Docusate Sodium|Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation
75939275|NCT05423249|Drug|Ascorbic Acid 500Mg Tab|Oral ascorbic acid 500 mg daily, to improve absorption of oral iron
75939276|NCT05423249|Drug|Placebo|Oral placebo pill once daily
75939277|NCT04334577|Biological|live attenuated zoster vaccine|subcutaneous injection
75939278|NCT04334577|Biological|placebo|subcutaneous injection
75939279|NCT02912455|Drug|canagliflozin|encapsulated (gelatin capsule).
75939280|NCT02912455|Drug|Placebo (for canagliflozin)|encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
75939281|NCT03492645|Behavioral|Telephone-and technology-facilitated treatment protocol|"8 video or telephone counseling sessions targeting PTSD symptoms related to smoking lapse. The first of these sessions will last approximately 45-60 minutes, and the remaining 7 sessions will last 20-30 minutes.~Use of the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed by our co-investigators at the National Center for PTSD to complement the IC protocol with evidence-based tools to support smoking cessation, such as motivational messaging and coping tools for managing PTSD symptoms associated with smoking lapse.~Use of the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor, compatible with iOS and Android smartphones, that provides CO readings to the user at any time in order to self-monitor progress in quitting. The Covita iCO mobile app is used with the iCO Smoerlyzer to display CO readings."
75800967|NCT03057496|Device|Collision warning device|The collision warning device is a pocket-sized, electronic system that includes a micro-computer, a clip-on miniature camera, a gyro-sensor, an accelerometer, and a rechargeable battery, all contained within a shoulder bag. It is about the size of a smart phone. When a potential collision is detected by the device it emits a warning to the user, either in the form of an audible beep or a tactile warning through bracelets worn on the wrist. The time to collision will be coded in both the auditory and tactile domains. The device is designed to only give warnings about high risk collisions, so the users will not be continually bombarded by warnings for every potential collision object in the environment.
75939282|NCT03492645|Behavioral|Office-based treatment protocol|Weekly face-to-face sessions using the unmodified treatment manual developed by McFall and Saxon, a protocol combining office-based therapy plus evidence-based pharmacotherapies for smoking cessation that doubled quit rates in veteran smokers with PTSD.
75653336|NCT05576714|Other|delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis|We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.
76117223|NCT02630706|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral tablet taken once daily
75343000|NCT05742620|Drug|anlotinib+CAPEOX/SOX|"Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1."
75475847|NCT02000128|Other|clinical monitoring|clinical symptom and examination,such as edema, body weight, blood pressure, cardial function
75475848|NCT02000193|Drug|fulvestrant|"Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.~The treatment will continue until disease progression or intolerable AE."
75475849|NCT02000206|Drug|Propofol|
75475850|NCT02000206|Drug|Ketamine|
75653337|NCT00632528|Drug|MEOPA|Administration of MEOPA gaz during postoperative physical therapy
75653338|NCT00632528|Drug|Medicinal air|Administration of medical air during postoperative physical therapy
75800968|NCT03775356|Other|Treatment of hypotension and/or reduction of anesthetics|The treatment of hypotension can be done by the responsible anesthetist according to the clinical standard operations including any accepted drug typically used in this hospital. The reduction of anesthetics can be done either by reducing the volatile end tidal anesthetics concentration (ETAC) or the infusion rate of propofol.
75800969|NCT05211934|Other|No intervention|No intervention
75800970|NCT05211778|Behavioral|Digital Education Group|Multimedia education provided to the intervention group via a digital tablet
75939283|NCT03492567|Biological|Blood test|Blood draw (max 15 ml)
75939284|NCT03666169|Other|Survey|Survey
76117224|NCT02630706|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily
75475851|NCT02000206|Drug|Alfentanil|
75939285|NCT03702491|Drug|Apatinib|Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
75475852|NCT02000245|Behavioral|verbal expression for compassion|The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
75343001|NCT03802448|Combination Product|Study group|"Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
75939286|NCT03702491|Drug|Tegafur|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
75343002|NCT03802448|Device|Control group|A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
75939287|NCT04056481|Drug|Givosiran|givosiran (ALN-AS1) administered as a subcutaneous (SC) injection
75475853|NCT02000245|Behavioral|touch|The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
75800971|NCT03779022|Genetic|microRNA|The level of microRNA in plasma will be detected by TaqMan in screening phase and by quantitative Real-time PCR (qRT-PCR) in validation phase.
75800972|NCT05211622|Drug|1. alpha acid lipoic - tables|600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days
75800973|NCT05211622|Drug|2. ozonated oil - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks
75800974|NCT05211622|Drug|3. chlorhexidine 0,2% - mouthwash|1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks
75939288|NCT03663751|Drug|Decitabine|low-dose decitabine: 5mg/m2 daily for 5 days
75939289|NCT04054687|Drug|Tranexamic Acid|Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
75939290|NCT04054687|Other|Placebo|This group will receive pledget soaked in saline. Protocol will continue as with TXA group.
75939291|NCT04524507|Biological|High-titer Convalescent COVID-19 Plasma (CCP1)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
75939292|NCT04524507|Biological|Standard-titer Convalescent COVID-19 plasma (CCP2)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
75475854|NCT02000258|Procedure|Double-bundle ACL reconstruction|
75475855|NCT02000258|Device|Magnetic resonance imaging (MRI)|MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
75475856|NCT02000271|Procedure|Vaginal packing|
75653339|NCT04019132|Diagnostic Test|Muscle function test|Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)
75653340|NCT00632372|Device|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
75343003|NCT01339013|Device|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
75653341|NCT00632372|Device|HeartPOD™ System|Left atrial pressure monitoring.
75653342|NCT00909428|Drug|Solifenacin Succinate|Participants take 10mg daily solifenacin succinate for 30 days
75653343|NCT03718130|Combination Product|Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
75800975|NCT05211622|Drug|4. sodium bicarbonate 5% solution - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 3 weeks
75800976|NCT01321164|Device|Full Body UV Therapy System UV 7002 plus fumaric acid esters|"Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.~Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months"
75800977|NCT01321164|Drug|Fumaric acid esters|Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
75939293|NCT02999191|Drug|BI 1467335 (Treatment A)|
75939294|NCT02999191|Drug|BI 1467335 (Treatment B)|
75939295|NCT02999191|Drug|BI 1467335 (Treatment C)|
76117225|NCT02630706|Drug|Placebo matching ertugliflozin|Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
76117226|NCT02630706|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
75343004|NCT01339091|Drug|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
75343005|NCT01339091|Drug|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
75475857|NCT02000271|Procedure|No vaginal packing|
75475858|NCT02000297|Procedure|Allogenic bone graft|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
75653344|NCT03718130|Combination Product|Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The HTNV vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
76089527|NCT03473847|Device|ArcScan Insight 100 very high-frequency digital ultrasound|The ArcScan Insight 100 VHF digital ultrasound scanner can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris. The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
75800978|NCT03778788|Other|App group|Intervention group the participants will receive a Lifestyle Intervention Program (LIP) with the support of MetS mobile application (MetS app). The MetS app support include app installment and briefing by a research assistant after the educational talk. The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.
75475859|NCT02000297|Procedure|Synthetic bone substitute (geneX®)|Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
75475860|NCT02000323|Other|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day.~nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day"
75653345|NCT03718130|Combination Product|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The PUUV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
75653346|NCT03718130|Combination Product|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The PUUV DNA vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
75653347|NCT03718130|Combination Product|Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV and PUUV vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
75653348|NCT03718130|Combination Product|Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)|The HTNV and PUUV vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
75653349|NCT04756856|Other|Muscle-target oral nutritional supplementation|Patients will receive daily for 12 weeks two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D. Patients will be also followed for 12 weeks after the suspension of supplementation.
75653350|NCT04756076|Diagnostic Test|Metal level measurements|Measure multiple metal levels
75653351|NCT05579834|Procedure|posterior correction surgery|Cases of hemothorax developing after posterior correction surgery for spinal deformities
75800979|NCT03778788|Other|Booklet group|The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
75800980|NCT03778788|Other|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 24 weeks.
75800981|NCT05211544|Other|physical therapy modalities and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
75800982|NCT05211544|Other|kinesio taping and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
75475861|NCT02000323|Other|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
75475862|NCT02000336|Drug|Prednisolone|To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
75475863|NCT02000336|Drug|Placebo|
75475864|NCT02000349|Other|PGD|PGD using Next generation sequencing
75800983|NCT05211544|Other|exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
75939296|NCT03837639|Other|Arm ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard
75939297|NCT03837639|Other|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
76089528|NCT03473847|Device|Carl Zeiss Meditec Cirrus HD OCT 5000|The Cirrus HD OCT 5000 uses high definition spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
76089529|NCT03473847|Device|Optovue RTVue OCT|The Optovue RTVue OCT uses high definition Fourier/spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
76117227|NCT02630706|Drug|Glimepiride|Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
75800984|NCT03778632|Behavioral|individualized desensitization exercises|implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
75800985|NCT05210686|Other|subgingival re-instrumentation|subgingival re-instrumentation (control)
76117228|NCT04763057|Drug|NeoPUTTY MTA|NeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing
76117229|NCT04763057|Drug|calcium hydroxide|Calcium hydroxide the gold standard for IPT
75653352|NCT02801084|Behavioral|Reduced environmental stimulation|"Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 & 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart."
75653353|NCT00908960|Drug|Enoxaparin|
75653354|NCT03933020|Device|VR active video game intervention|The Microsoft VR active game program will consist of 3 weekly sessions of 45 minutes each combining 3 different types of exercise
75653355|NCT03933020|Behavioral|Educational session|This consists of two education discussion sessions on the benefits of exercise for people with MS. The investigator MS specialists will conduct these sessions either by phone or at the time of a clinic visit and will also discuss difficulties encountered by participants with adherence.
75475865|NCT02000362|Biological|Stem cells|
75475866|NCT02000375|Drug|DHEA|DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
75475867|NCT02000388|Drug|Ketorolac Tromethamine|
75653356|NCT03933020|Behavioral|Standard Management of Physical Activity|Routine discussion of lifestyle factors including physical activity during clinic visits
75653357|NCT03682796|Drug|TRPH-222|administered by IV, 21-day Cycle
75653358|NCT03680066|Other|Oral food challenge to foods with traces|"Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~cookies, max 30 g;~chocolate, max 30 g;~breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end."
75653359|NCT03449732|Device|PDR measurement|"PDR measurement at two standardized times perioperatively:~Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth"
75653360|NCT05332106|Drug|Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet|Investigational Medicinal Product
75653361|NCT05332106|Drug|Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet|Climodien (Bayer plc.)
75800986|NCT05210452|Biological|Follicular stem cells|Cultured autologous follicular stem cells
75800987|NCT05210452|Other|Standard treatment according to the clinical protocols|Standard treatment of alopecia according to the clinical protocols
75475868|NCT02000388|Other|Standard of Care|
75939298|NCT03837639|Other|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
75475869|NCT02000401|Drug|Ketorolac Tromethamine|
75475870|NCT02000414|Drug|intraperitoneal daptomycin|intraperitoneal daptomycin administartion and study of daptomycin kinetics
75939299|NCT03492489|Drug|cemiplimab|Intravenous (IV) administration
75939300|NCT04050397|Other|Progressive supervised weight training|12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.
75939301|NCT04050397|Other|Lecture|Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
75653362|NCT05333198|Other|Traditional physical therapy using Epley's maneuver|Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.
75800988|NCT05210218|Dietary Supplement|Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively)|The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK)
75800989|NCT05210218|Dietary Supplement|placebo|cellulose
75800990|NCT05499312|Drug|HKIIM-KU formula|Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
75800991|NCT05499312|Drug|Placebo|Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
75800992|NCT03772860|Other|Pain stimulation|Pain will be simulated with an electric shock 25 mlAMP over the median nerve
75939302|NCT03492411|Other|eHealth Breastfeeding Co-parenting Resource|The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
75939303|NCT02531698|Biological|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
75939304|NCT02531698|Biological|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
75939305|NCT02531698|Other|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
75939306|NCT04308837|Drug|Paclitaxel|50 mg/m2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
75475871|NCT02000453|Drug|GSK2586184 400mg|White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
75653363|NCT05333198|Other|Oculomotor and Vestibular Ocular Reflex (VOR) exercises|oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
75653364|NCT05332028|Drug|bupivacaine|Block applications
75800993|NCT03772860|Other|Visual stimulation|Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds
75800994|NCT03772860|Other|Auditory stimulation|Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds
75800995|NCT03772860|Other|Mental stress|A mathematical challenge will be displayed on a computer screen that must be quickly solved
75800996|NCT05705518|Drug|Systane Complete PF|3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product
75800997|NCT05705518|Drug|Refresh Relieva PF|3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product
75939307|NCT04308837|Drug|Carboplatin|Carboplatin AUC = 2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
75939308|NCT04308837|Drug|Dexamethasone|All patients receiving Paclitaxel will receive institutional standard premedications, which include Dexamethasone (10 mg IVPB)
75939309|NCT04308837|Drug|Diphenhydramine|All patients receiving Paclitaxel will receive institutional standard premedications, which include diphenhydramine (50mg IVP)
75939310|NCT04308837|Drug|Famotidine|All patients receiving Paclitaxel will receive institutional standard premedications, which include Famotidine (20mg IVPB)
75475872|NCT02000466|Other|Data collection|Initial and follow-up data will be collected using questionnaires
75475873|NCT02000479|Other|training|
75475874|NCT02000492|Behavioral|Football|
75475875|NCT02000492|Behavioral|Running|
75475876|NCT02000492|Behavioral|Circuit training|
75475877|NCT02000505|Device|PocketCPR|5 minutes chest-compression-only CPR, using Zoll PocketCPR
75475878|NCT02000505|Device|Metronome|5 minutes chest-compression-only CPR, using a metronome
75475879|NCT02000505|Device|110bpm Song|5 minutes chest-compression-only CPR, using a song with 110bpm for support
75475880|NCT02000518|Radiation|external beam radiotherapy|
75939311|NCT04308837|Drug|Palonosetron|All patients receiving Paclitaxel will receive institutional standard premedications, which include Palonosetron (0.25mg IVP)
75653365|NCT05332028|Device|22 gauge 100 mm needle|Block applications
75343006|NCT01257347|Behavioral|Disclosure of adherence report to clinician|During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (<10 minutes) in the interpretation and use of the report at the time of enrollment.
75343007|NCT01257347|Device|MedSignals pillbox|(Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
75653366|NCT05332028|Drug|Propofol|Routine general anesthesia protocol
75800998|NCT05705518|Drug|Refresh Optive Mega-3 PF|3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
75800999|NCT05705518|Drug|CVS Health Lubricant Eye Drop (PG 0.6%)|3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product
75801000|NCT03778398|Other|Neurologic music therapy|Customized piano training
75939312|NCT04308837|Radiation|3D conformal or intensity modulated radiotherapy|Treatment will be given 5 days per week. Photon beams >6 MV are required. Treatment may be delivered either by a 3D conformal technique or IMRT. IMRT via dynamically moving MLCs, step-and-shoot with a multileaf collimator, Rapid Arc, binary multileaf collimator, and tomotherapy are allowed. Proton therapy is not allowed.
75939313|NCT04308837|Procedure|Surgical resection|Surgical resection will constitute subtotal or total gastrectomy (depending on tumor size and location) and D2 lymphadenectomy.
76117230|NCT03702179|Drug|Durvalumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
75343008|NCT05742542|Other|Exercise training|Two weeks of high intensity interval training with high or low time spent near VO2max.
75653367|NCT05332028|Drug|fentanyl|patient-controlled analgesia
75653368|NCT00650767|Drug|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
75653369|NCT00650767|Drug|Placebo; oral|matching placebo
75343009|NCT04383236|Other|Probiotics|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
75343010|NCT04383236|Drug|Oracure oral gel|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
75653370|NCT02552095|Device|Triathlon PKR|
75653371|NCT02552173|Radiation|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
75801001|NCT03778476|Other|Isometric Exercise|Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
75801002|NCT03778320|Drug|CTP-692|Single oral dose
75653372|NCT00818077|Other|Continuous Glucose Monitoring of Carbohydrate Intake|Subjects eat standard breakfast and lunch and keep food records.
75653373|NCT00812227|Behavioral|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
75653374|NCT00816517|Biological|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
75653375|NCT00973349|Biological|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
75801003|NCT03778320|Drug|D-Serine|Single oral dose
75801004|NCT05191264|Other|EQ5D (EuroQol 5 Dimensions)|The evaluation of the quality of life was conducted with the EQ5D (EuroQol 5 Dimensions) score (min 0: bad health and max:100 good health).
75653376|NCT00629603|Genetic|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
75801005|NCT05191264|Other|Numerical Rating Scale (NRS)|the type and intensity of pain will be evaluated by Numerical Rating Scale (NRS) from 0 to 10 in different positions and in different activities (e.g. background pain, general maximum/minimum pain, pain of the site treated by the procedure, pain at rest, in lying position, in sitting position, in standing position, at bearing weight, in walking, description of painful irradiations, nocturnal awakenings).
75939314|NCT04308837|Radiation|Adjuvant Chemotherapy|The patient will begin adjuvant chemotherapy 4-12 weeks after surgery. The adjuvant chemotherapy will consist of FOLFOX every 2 weeks for 6 cycles (i.e. 3 months)
75801006|NCT05191264|Other|evaluated the consumption of analgesics|the consumption of analgesics by step and by dosage will be evaluated.
75801007|NCT04872348|Device|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
75653377|NCT00629603|Genetic|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
75475881|NCT02000544|Device|Modular Cardiopulmonary Bypass Circuit|Open heart surgery with a novel hybrid modular extracorporeal circulation circuit which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
75653378|NCT00629603|Genetic|cytokine polymorphism|fibrosis-relating cytokine polymorphism
75343011|NCT01339247|Drug|Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
75343012|NCT01339247|Drug|Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
75343013|NCT00772772|Drug|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
75343014|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
75343015|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
75343016|NCT05742464|Behavioral|RUBI|"RUBI teaches caregivers a range of skills to support the building of a behavioral management toolbox. The intervention emphasizes: 1) tailoring the intervention to the child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice (i.e., targeting what is driving the behavior, instead of the behavior itself); 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g. use of visual supports), reinforcement, and functional communication strategies as the means to modify behaviors. RUBI uses a behavioral skills training approach, which includes direct instruction, modeling, role-play and practice with feedback in order to train caregivers in the various RUBI skills. Sessions also have accompanying video vignettes that are used to illustrate skills or test parental understanding of session materials."
75653379|NCT04288739|Diagnostic Test|flow cytometric immunophenotyping|Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).
75343017|NCT03802526|Drug|NVP-1805-R1|1 tablet, multiple oral dosing
75343018|NCT03802526|Drug|NVP-1805-R2|1 tablet, multiple oral dosing
75343019|NCT03802526|Drug|NVP-1805-R1 and NVP-1805-R2|NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing
75343020|NCT02197481|Procedure|Clamp-Crushing technique|Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps
75653380|NCT04288739|Genetic|Xist gene by fluorescence insitu hybridization|"Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes."
75653381|NCT04286945|Procedure|LATERAL RECTUS MUSCLE AUGMENTED RECESSION BY ELONGATION OF THE TENDON WITH AUTOGRAFT FROM RESECTED MEDIAL RECTUS MUSCLE|After resection of the medial rectus muscle, the resected segment is sutured to the lateral rectus muscle after dissection and marking to elongate and slaken the muscle then the elongated muscle is sutured to the sclera at the desired amount of conventional recession.
75653382|NCT00643201|Drug|Enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
75653383|NCT00643201|Drug|warfarin|tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
75653384|NCT00643201|Drug|Placebo for apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
75653385|NCT00643201|Drug|Placebo for enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
75653386|NCT00643201|Drug|Placebo for warfarin|tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
75653387|NCT00643201|Drug|apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
75475882|NCT02000570|Procedure|Sitting position (neurosurgery)|
75475883|NCT02000609|Drug|CHF 1535 NEXThaler 800/48|
75343021|NCT02197481|Device|BiClamp forceps|liver transection during hepatectomy by BiClamp forceps
75343022|NCT00773474|Drug|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
75343023|NCT01310855|Drug|cediranib maleate|
75343024|NCT01310855|Drug|gefitinib|
75343025|NCT01310855|Drug|Placebo|
75343026|NCT00773786|Drug|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
75343027|NCT00773786|Drug|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
75343028|NCT03802370|Procedure|connective tissue grafting by Dome Technique|The dome technique addresses the placement of the CT, as it is layered over the implant and takes the shape of an inverted dome
75475884|NCT02000609|Drug|CHF 1535 NEXThaler 200/12|
75475885|NCT02000609|Drug|CHF 1535 NEXThaler PLACEBO|
75475886|NCT02000609|Drug|CHF 1535 pMDI 200/12|
75475887|NCT02000609|Drug|CHF1535 pMDI 800/48|
75475888|NCT02000661|Device|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
75475889|NCT02000674|Drug|Succinylcholine : 1mg/kg|
75475890|NCT02000674|Drug|Rocuronium : 1.2 mg/kg|
75343029|NCT01312181|Behavioral|HealthCall and Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
75475891|NCT02000700|Drug|Canagliflozin 100 mg|One 100-mg tablet of canagliflozin orally administered daily for 14 days.
76089530|NCT03473847|Device|CSO MS-39 OCT|"The CSO MS-39 OCT uses high definition Fourier domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. The MS-39 also includes a Placido topographer within the device to simultaneously obtain a measurement of the shape (curvature) of the front surface of the cornea, which is then combined with the OCT thickness measurement to generate the shape of the back surface of the cornea.~An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them."
76089531|NCT04273035|Drug|Midazolam oral solution|Oral Buccolam
76089532|NCT04273035|Device|IPAD|Playing any game, film, clip or puzzle on a tablet till after induction of anesthesia
75343030|NCT01312181|Behavioral|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
75653388|NCT00643123|Drug|Allopurinol|300-600 mg/day over a 6 week period
75653389|NCT00643123|Other|Placebo|Inactive substance
75653390|NCT00816673|Drug|placebo Circadin|Placebo tabs of Prolonged release melatonin
75653391|NCT00816673|Drug|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
75653392|NCT00818155|Drug|desvenlafaxine succinate SR|desvenlafaxine succinate SR
75653393|NCT00818155|Other|Placebo|
75653394|NCT00968981|Drug|GDC-0449|Daily oral repeating dose
75653395|NCT00968981|Drug|GDC-0449|Three times weekly oral repeating dose
75653396|NCT00968981|Drug|GDC-0449|Once weekly oral repeating dose
75653397|NCT04288817|Biological|Tuberculin purified protein derivative|Intralesional injection of tuberculin PPD in treatment of multiple common warts
75653398|NCT02863133|Device|Liquid Embolic|The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
75653399|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 40 mg QD, PO, 1 year
75653400|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 60 mg QD, PO, 1 year
75653401|NCT02863367|Drug|Apatinib|Apatinib：500 mg，po，qd, d1-14, every 3 week
75653402|NCT02863367|Drug|Gemcitabine|Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
75653403|NCT00922363|Biological|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
75653404|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
75475892|NCT02000700|Drug|Canagliflozin 50 mg|One 50-mg tablet of canagliflozin orally administered daily for 14 days.
75653405|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
75653406|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
75801008|NCT05190406|Procedure|Pulpotomy|After achieving hemostasis, in pulpotomy group bioceramic material will be placed and then permanent restoration will be done.
75343031|NCT01312181|Behavioral|HIV/AIDS health education|The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
75801009|NCT05190406|Procedure|root canal treatment|Single visit root canal treatment will be done according to standard protocol.
75653407|NCT00648895|Drug|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
75653408|NCT00648895|Drug|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
75801010|NCT03774966|Procedure|Adductor Canal Block + Catheter & IPACK block|Adductor Canal Block + Catheter & IPACK block
75801011|NCT03774966|Procedure|Adductor canal block + catheter|Adductor canal block + catheter
75801012|NCT01320384|Other|O2 conventional|standard low flow therapy
75801013|NCT01320384|Device|O2-HFN : high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 >92%.
75801014|NCT01320384|Device|O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 >92% with the minimal FiO2.
75343032|NCT03802292|Biological|YQ23|Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated
75343033|NCT03802292|Biological|Matching Placebo|Single dose of the matching placebo delivered via intravenous route.
75343034|NCT01258049|Drug|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
75939315|NCT02998021|Device|Vibrating Dumbbell|Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
75475893|NCT02000700|Drug|Canagliflozin 300 mg|One 300-mg tablet of canagliflozin orally administered daily for 14 days.
75343035|NCT01258049|Drug|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
75343036|NCT03802214|Drug|Vedolizumab|standard vedolizumab induction (300mg IV at week 0, 2, 6)
75343037|NCT03801980|Drug|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
75343038|NCT03801980|Drug|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
75343039|NCT03801746|Drug|vadadustat|Oral dose 300 mg
75475894|NCT02000700|Drug|Placebo|One matching placebo tablet orally administered at baseline phase.
75475895|NCT02000713|Other|MRI|Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
75653409|NCT00812539|Other|"Subject/Provider Portal Diabetes Connected Health tool - Deluxe"|"Subjects enrolled into the Deluxeintervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal (Diabetes Connected Health tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading."
75653410|NCT00812539|Other|"Subject only Portal Diabetes Connected Health Tool Basic"|"Patients enrolled in the Diabetes Connect Basic intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the Diabetes Connected Health tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system."
75653411|NCT00818233|Device|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
75653412|NCT00812617|Dietary Supplement|Mineral water (Hita, Oita, Japan)|
75653413|NCT00812617|Dietary Supplement|Mineral water (Aso-gun, Kumamoto, Japan)|
75653414|NCT00975221|Drug|Cinacalcet|Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
75653415|NCT00975221|Drug|Placebo|Administered orally following the same tiitration regimen as the experimental arm.
75653416|NCT02864693|Device|Kinnex|The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).
75653417|NCT02864693|Device|Pacifica LP|The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
75343040|NCT03801746|Drug|Rifampin|IV Rifampin
75343041|NCT03801746|Drug|Probenecid|Oral Probenecid
75343042|NCT03801746|Drug|Cyclosporins|Oral Cyclosporine
75475896|NCT02000713|Other|Clinical Exam|Brief neurological exam will be performed.
75475897|NCT02000726|Drug|Placebo|
75475898|NCT02000726|Drug|Citalopram|
75475899|NCT02000726|Drug|Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session|Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
75475900|NCT02000739|Genetic|Genetically Informed Therapy|If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
75475901|NCT02000765|Drug|GSK2140944 for Injection|GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing [14C] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
75475902|NCT02000765|Drug|GSK2140944 Capsule|GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing [14C] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
75475903|NCT02000778|Drug|EC17|
75475904|NCT02000791|Other|Comparison of fibreoptic view|
75475905|NCT02000804|Drug|darapladib 160mg|drug
75475906|NCT02000830|Drug|Stannsoporfin|Stannsoporfin administered by intramuscular (IM) injection
75475907|NCT02000830|Drug|Placebo|Matching placebo administered by IM injection
75653418|NCT04204421|Other|Experience Sampling Method (ESM)|Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
75653419|NCT02863679|Drug|Tetracaine hydrochloride gel|Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
75653420|NCT00972179|Drug|Placebo|Administered by subcutaneous or intravenous injection.
75653421|NCT00972179|Drug|Tezepelumab|Administered by subcutaneous or intravenous injection
75653422|NCT04288505|Diagnostic Test|VIRTUAL REALITY application|application on virtual reality headset
75343043|NCT03801668|Drug|Albumin-bound Paclitaxel plus S-1|Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
75939316|NCT02998021|Device|Standard Dumbbell|"Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks.~The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.~To obtain as much data as possible on resistance training with vibration within study timeline, a modification was recently approved by the Institutional Review Board (IRB) to cease enrolling subjects into standard dumbbell training."
75939317|NCT03487497|Procedure|Lateral column lengthening osteotomy|Lengthening osteotomy of the lateral column of the foot
75939318|NCT03664375|Other|Botulinum toxin type A|All patients in the experimental group received a BoNT-A injection. The injected total dose for individual patient in the experimental group was 100 units which is equivalent to approximately 300-500 Units of Dysport (the other type of BoNT-A available). The Botox was injected by the neurophysician intramuscularly using insulin U100 syringe and determination of muscles for injection was assessed clinically.
75939319|NCT03664375|Other|Task Specific Training|Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression
75939320|NCT03731247|Device|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
75475908|NCT02000843|Procedure|tympanoplasty -- conchal cavum approach|Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
75475909|NCT02000856|Dietary Supplement|Beetroot juice|
75475910|NCT02000947|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
75475911|NCT02000947|Drug|Tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
75939321|NCT03731247|Device|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
75343044|NCT03801668|Drug|Oxaliplatin plus S-1|Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
75343045|NCT05414006|Drug|S-ketamine|S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
75343046|NCT02199041|Drug|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
75939322|NCT03434301|Device|ReliaTack™|Absorbable tack (ReliaTack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
75939323|NCT03434301|Device|Protack™|Non-absorbable tack (Protack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
75939324|NCT03492333|Other|Gluten free diet|Gluten-free diet- Instructions provided by a dietitian
75939325|NCT00403793|Drug|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
75939326|NCT00403793|Drug|Placebo|42 or 44 weeks with placebo implant and placebo injections
75343047|NCT02199041|Drug|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
75343048|NCT02199041|Drug|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
75343049|NCT02199041|Drug|Melphalan|Given by intravenous infusion as part of the preparative regimen.
75343050|NCT02199041|Drug|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
75343051|NCT02199041|Biological|G-CSF|Given either by intravenous infusion or subcutaneously daily until absolute neutrophil count (ANC) >2000 for 3 consecutive days.
75343052|NCT02199041|Drug|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
75343053|NCT02199041|Drug|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
75343054|NCT02199041|Drug|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
75343055|NCT02199041|Radiation|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
75343056|NCT02199041|Biological|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
75343057|NCT02199041|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
75343058|NCT00789776|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
75475912|NCT02000947|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
75653423|NCT00906698|Drug|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
75653424|NCT00906698|Drug|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
75343059|NCT00789776|Drug|Cyclophosphamide|Given IV
75343060|NCT00789776|Drug|Fludarabine Phosphate|Given IV
75343061|NCT00789776|Other|Laboratory Biomarker Analysis|Correlative studies
75343062|NCT00789776|Drug|Mycophenolate Mofetil|Given PO
75343063|NCT00789776|Biological|Natural Killer Cell Therapy|Given IV
75343064|NCT00789776|Drug|Tacrolimus|Given IV or PO
75801015|NCT03773016|Behavioral|Art apps|Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
75939327|NCT03419871|Other|Monitoring Sleep|An accelerometer will be placed on the wrist or ankle of the child while the child sleeps in their home. Caregivers will be instructed to keep the accelerometer on their toddler's ankle to measure sleep duration, latency and sleep efficiency. Seven nights of data will be obtained because actigraphy is most reliably measured in young children over this time frame.
75939328|NCT03419871|Other|stress biomarkers|"Salivary and hair cortisol measurements were used to obtain a change in baseline from 12 to 24 months. Data on the timing of the saliva collection will be collected using a Medical Electronic Monitoring System (MEMScapTM) - a digital memory cap that records the timing and frequency of opening.~Cortisol will be measure in the morning and bedtime samples. A small amount of hair (30mg) will be cut from the posterior vertex of the child's head. Due to the expected variability in hair length of toddlers, documentation of hair length will be completed. Each centimeter represents 1 month history of stress and ideally 3 cm of hair length will be collected to provide a three month history of stress."
76089533|NCT02836899|Drug|Nitric Oxide|Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
76089534|NCT02836899|Other|Placebo|This is the placebo group. Nitrogen will be added instead of nitric oxide.
76089535|NCT01454817|Behavioral|Quality of life|Improving Quality of Life
75343065|NCT00789776|Radiation|Total-Body Irradiation|Undergo total-body irradiation
75343066|NCT04384094|Device|Esthesiometer measurement|Measuring the corneal sensitivity using rebound technology.
75343067|NCT03801590|Device|Crosslinking with Riboflavin and UV-A|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.
75343068|NCT03801512|Other|Steroid|Triamcinolone 1pc + lidocaine 1% 1cc inject at neuritis nerve roots
75343069|NCT03801512|Other|Acupuncture|1.5 inch acupuncture needles insert at acupoints BL23, BL24, BL25 and BL26
75343070|NCT03801512|Other|Platelet Rich Plasma|Inject investigators Platelet Rich Plasma at neuritis nerve roots
75343071|NCT03800966|Other|Leaflet|Leaflets for both groups will be printed in colour. Leaflet in each group contains 8 pictures and 8 statement, whose sequences will be scrambled. Primary school students need to do the matching, to ensure they read the statements.
75343072|NCT00775658|Drug|olopatadine|olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
75343073|NCT00775658|Drug|placebo|placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
75653425|NCT00906698|Drug|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
75653426|NCT00906698|Drug|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
75653427|NCT00906698|Drug|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
75653428|NCT00906698|Drug|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
75653429|NCT00972023|Drug|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
75653430|NCT00972023|Procedure|Surgical resection|Surgical procedure of the invasive breast cancer
75475913|NCT02000960|Drug|Triheptanoin|Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid heptonate.
75475914|NCT02000986|Behavioral|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy|Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
75343074|NCT02199197|Drug|Radium Ra 223 Dichloride|Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.
75343075|NCT02199197|Drug|Enzalutamide|Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.
75343076|NCT01258985|Behavioral|Tai Chi|12 weeks of Tai Chi
75343077|NCT01258985|Behavioral|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
75343078|NCT00799604|Drug|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
75343079|NCT03009383|Device|A bedside portable endoscopy|
75343080|NCT05721638|Diagnostic Test|Neutrophil gelatinase-associated lipocalin|Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 KDa, neutrophil-derived molecule from the lipocalin family. It is also secreted in small amounts from kidney, prostate, and respiratory tract epithelial cells. After ischemic and nephrotoxic acute tubular necrosis, NGAL levels peak at the 3rd hour and remain elevated for approximately 24 hours. In patients who do not progress to AKI, NGAL levels begin to decrease as of the 1st hour after injury.
75475915|NCT02000999|Other|brushing of bile duct strictures for cytology|
75475916|NCT02001012|Drug|Artemether-lumefantrine combination|
75475917|NCT02001012|Drug|Chloroquine|
76089536|NCT01454895|Behavioral|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
76089537|NCT01454895|Behavioral|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
76089538|NCT01454895|Behavioral|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
76089539|NCT02902029|Drug|Vemurafenib|960 mg vemurafenib BID until progression or unacceptable toxicity develops
76089540|NCT02902029|Drug|Cobimetinib|60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
75653431|NCT04223414|Device|Analgesia Nociception Index (ANI)|"ANI will be used to analyse the autonomic nervous system's response to volume expansion.~ANI will be assessed during surgery, before during and after the volume expansion"
75343081|NCT05721482|Behavioral|Caregiver Training|"A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth. Participants will receive session materials so they can follow along. Each MIM session consists of material related to mindfulness-the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Group interaction centers on sharing ideas toward effective practice and practical daily challenges to being mindful. Each class begins with a prompt for participant contemplation during the next hour that reference a unique weekly theme which will be reiterated in the session materials.~The DASH portion, led by the Registered Dietitian, focuses on education to increase vegetables, fruits, whole grains and decrease intakes of fat and sodium, sugar sweetened beverages and sweets. Education includes adapting traditional Soul food dishes to meet the DASH dietary guidelines."
75343082|NCT00791102|Drug|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
75343083|NCT00791102|Drug|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
75475918|NCT02001025|Device|Absorb scaffold|
76089541|NCT02902029|Drug|Atezolizumab|1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
75475919|NCT02001025|Device|Xience stent|
76089542|NCT02933697|Drug|Apixaban|Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
75475920|NCT02001038|Other|Survey|
75653432|NCT03396926|Biological|Bevacizumab|Given IV
75653433|NCT03396926|Drug|Capecitabine|Given PO
75475921|NCT02001077|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
75475922|NCT02001077|Behavioral|Cognitive Behavioral Therapy for Pain (CBT-P)|
75475923|NCT02001103|Drug|Memantine|"Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3."
75653434|NCT03396926|Other|Laboratory Biomarker Analysis|Correlative studies
75653435|NCT03396926|Biological|Pembrolizumab|Given IV
75653436|NCT00971945|Drug|Paclitaxel|Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
75653437|NCT03672500|Drug|Bupivacaine 0.5%+Epinephrine 50mc|Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
75653438|NCT03672500|Other|Sham injection|Sham injection of the perineum
75653439|NCT00971867|Drug|Paclitaxel|Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
75653440|NCT04744376|Other|QoR15|Quality of Recovery 15 questionnaire (QoR-15) is a measurement tool that evaluates the recovery quality of patients after surgery and anesthesia by the patient himself.
75653441|NCT04744376|Other|ACS risk calculator|American College of Surgeons risk calculator is a risk prediction tool for abdominal surgery. It calculates the risk of possible postoperative complications according to the type of surgery, ASA score, and patients' preoperative co-morbidities.
75653442|NCT04744376|Other|Clavien - Dindo classification|It is a classification for postoperative complications.
75653443|NCT04202432|Diagnostic Test|Mean systemic filling pressure|"Peri- and postoperative measurement of continuous cardiac output with thermodilution derived pulse contour calculated device (PiCCO).~Estimation of mean systemic filling pressure using a computerized algorithm and by creating venous return curves with inspiratory hold maneuvers, thereby extrapolating the VR-curve until mean systemic filling pressure is calculated."
75653444|NCT03336164|Behavioral|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
75653445|NCT05331872|Biological|Human umbilical cord-derived mesenchymal stem cell infusion|Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis
75653446|NCT00971321|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
75653447|NCT03200054|Other|Adherence Clubs|Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last ~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
76089543|NCT02933697|Drug|Phenprocoumon|Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
76089544|NCT04848285|Other|Early Mobilization|Additional 2 or more sessions of out-of-bed activity to the standard stroke care, focused in active sitting, standing and walking assisted by physiotherapists
76089545|NCT04848285|Other|Standard care|Standard protocol of mobilization in acute stroke patients admitted to the Stroke Unit at the discretion of the nursing and physiotherapy staff
75343084|NCT01259063|Drug|Everolimus and Intravesical Gemcitabine|Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
75343085|NCT05317052|Behavioral|Massage group|Massage and music therapy
75653448|NCT00648739|Drug|Samalizumab|Samalizumab is a humanized anti-CD200 monoclonal antibody.
75653449|NCT00812695|Device|CPAP|Gold standard treatment for Obstructive sleep apnea
75653450|NCT00812773|Drug|GSK2190915|Investigational Product
75653451|NCT02552017|Device|Endocuff Vision|Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
75653452|NCT00816985|Procedure|Liposuction|Liposuction is a procedure that involves the removal of fat from deposits beneath the skin using a hollow stainless steel tube with the assistance of a powerful vacuum. Liposuction can be accomplished either with the use of local or general anesthesia.
75939329|NCT03702335|Behavioral|Dietary Counselling|Intervention group will be given a comprehensive dietary guidance on how to choose healthier options when eating out, as well as how to personally prepare a healthy meals.
75939330|NCT03489213|Other|Dietary Intervention|Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
75343086|NCT01312805|Other|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
75343087|NCT01312805|Other|CHICA Control|This is CHICA without the asthma module, and was used as a control
75939331|NCT03489213|Behavioral|Exercise Intervention|Participants will wear a FitBit every day and monitor daily physical activity.
75475924|NCT02001103|Drug|Placebo|Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
75653453|NCT00816985|Other|Quality of Life Questionnaires|Ratings of 0 to 4, with 0 being Not at ll and 4 being Very Much, regarding how true each statement has been. Statements are in the following categories: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns.
75653454|NCT00817141|Other|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
75653455|NCT00818311|Device|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
75653456|NCT00812851|Drug|Dronabinol|
75939332|NCT03489213|Other|Laboratory Biomarker Analysis|Correlative studies
75939333|NCT03489213|Dietary Supplement|Nutritional Intervention|Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
76089546|NCT01455129|Drug|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
76089547|NCT01455129|Drug|placebo|placebo, once daily, inhaled by HandiHaler
76089548|NCT02790411|Device|Imaging devices|technological adjustment tests
76089549|NCT02790411|Device|New Non Invasive Devices|Tests with REX BIONICS Exoskeleton
76089550|NCT01455207|Behavioral|Neuropsychological testing|assessment of memory, executive functions and ataxia
76089551|NCT01455207|Biological|blood draw|hepatic markers, red blood markers and vitamin markers
76089552|NCT01455207|Genetic|genetic testing|genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
76089553|NCT01455207|Other|Brain imaging examination|MRI, DTI and PET examinations
75653457|NCT00818467|Other|Tanning spray|using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
76089554|NCT01455363|Procedure|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
76089555|NCT01455363|Other|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
75343088|NCT04383548|Other|hyper immunoglobulins containing anti-Corona VS2 immunoglobulin|Prospective randomized clinical study for efficacy of anti-SARS-CoV-2 hyper immunoglobulins prepared from COVID19 convalescent plasma using VIPS Mini-Pool IVIG medical device
75343089|NCT04383392|Device|Rate adaptive pacing|Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
75801016|NCT05087524|Diagnostic Test|BinaxNOW Ag Card|A nasal swab specimen is collected from the participant, 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The participant sample is inserted into the test card through the bottom hole of the swab well, and firmly pushed upwards until the swab tip is visible through the top hole. The swab is rotated 3 times clockwise and the card is closed, bringing the extracted sample into contact with the test strip. Test results are interpreted visually at 15 minutes based on the presence or absence of visually detectable pink/purple colored lines.
75343090|NCT01313507|Biological|NewGam|The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
75343091|NCT01313897|Drug|Bortezomib|bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
75801017|NCT05032144|Drug|STSA-1002 injection|Intravenous injection
75801018|NCT05032144|Drug|Placebo|Intravenous injection
75801019|NCT05032144|Drug|STSA-1002 injection|Intravenous injection
75801020|NCT05032144|Drug|Placebo|Intravenous injection
75801021|NCT05032144|Drug|STSA-1002 injection|Intravenous injection
75653458|NCT00818467|Other|UVB|receiving 40mJ UV-B phototherapy three times a week for four weeks
75653459|NCT00648037|Drug|Rituximab|Rituximab 375 mg/m^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is > 200 cells/ul or a maximum of 6 doses have been given.
75653460|NCT00813007|Behavioral|Questionnaires|5 Questionnaires at differing times before and after surgery.
75801022|NCT05032144|Drug|Placebo|Intravenous injection
75801023|NCT05032144|Drug|STSA-1002 injection|Intravenous injection
75801024|NCT05032144|Drug|Placebo|Intravenous injection
75343092|NCT01341977|Device|Alcon MPDS|Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses
75653461|NCT00817297|Device|noninvasive ventilator|Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
75653462|NCT00817375|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
75801025|NCT05032144|Drug|STSA-1002 injection|Intravenous injection
75801026|NCT05032144|Drug|Placebo|Intravenous injection
75801027|NCT04908436|Drug|Finerenone (BAY94-8862)|10 mg BAY94-8862 immediate release (IR) tablet, administered orally
75801028|NCT04906330|Diagnostic Test|Onco-liq: kit for breast cancer diagnosis.|Onco-liq is a novel diagnosis kit for early breast cancer diagnosis in blood, based on liquid biopsies and miRNAs. The main advantage of this kit is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.
75801029|NCT03774498|Drug|Sensodyne repair and protect|NovaMin & fluoride toothpaste
75801030|NCT04877392|Dietary Supplement|Lavender essential oil|Use of inhaled lavender essential oil
75801031|NCT03778008|Drug|Recombinant bovine basic fibroblast growth factor|Recombinant bovine basic fibroblast growth factor is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of recombinant bovine basic fibroblast growth factor at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
75939334|NCT03489213|Other|Questionnaire Administration|Ancillary studies
76089556|NCT01455363|Other|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
76089557|NCT02865447|Device|total hip arthroplasty implant|PROFEMUR PRESERVE total hip arthroplasty femoral stem
76089558|NCT04846959|Drug|Risankizumab|Subcutaneous Injection
76089559|NCT04846959|Drug|Comparator|Subcutaneous or Intravenous Injection
76089560|NCT01455441|Other|Training and liraglutide|
76089561|NCT01455441|Other|Training and placebo|
76089562|NCT01455675|Drug|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
76089563|NCT01455675|Drug|Placebo|Placebo, 70 ml gargling solution, once daily
76089564|NCT02858583|Procedure|CC+SI|chest compression will be delivered during sustained inflation (CC+SI). The duration of each sustain inflation is 20sec. After 20sec a pause of 1sec id done before the next sustained inflation is delivered for another 20sec. Chest compressions are given continuously. This approach is continued until return of spontaneous circulation.
75343093|NCT01341977|Device|ReNu Fresh MPS|ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
75475925|NCT02001116|Other|Quality Improvement intervention|"Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.~Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care"
75475926|NCT02001129|Behavioral|Automated Telephone System|Participants receive automated reminder phone calls.
75343094|NCT02192879|Device|thoracic epidural|Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
75343095|NCT02192879|Device|continuous paravertebral catheter|Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
75343096|NCT02192879|Drug|Patient-Controlled Analgesia|Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
75343097|NCT04351763|Drug|Amiodarone|Ion channel blocker
75343098|NCT04351763|Drug|Verapamil|Ion channel blocker
75475927|NCT02001129|Behavioral|Personalized Telephone Call|Participants receive reminder phone calls by study staff.
75475928|NCT02001129|Behavioral|Usual Care|Participants receive a standard reminder letter in the mail.
75475929|NCT02001155|Procedure|Water Drinking Test|The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
75475930|NCT02001168|Drug|Pemetrexed|Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
75653463|NCT00817375|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
75653464|NCT00818545|Drug|ER4017 (hydroxypropyltetrahydropyrantriol)|Cream, 10%, each day during 3 months
75801032|NCT03778008|Combination Product|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
75801033|NCT04864678|Other|Referral to the Young People's Health Service immunisation nurse|Young people who have been referred to an immunisation nurse at the Young People's Health Service.
75343099|NCT00801398|Drug|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
75343100|NCT01342523|Other|CIS - telephone cessation quitline counseling|Up to 5 total tobacco cessation counseling calls
75343101|NCT01342523|Other|Lozenge - nicotine mini-lozenges|2-week starter pack of nicotine mini-lozenges
75343102|NCT01342523|Other|Emails - Brief smoking prevention messages|Brief email messages that could be accessed by any computer or mobile device that allowed email receipt
75343103|NCT01342523|Other|Full website - standard smokefree.gov website content|Over 50 web pages of resources for quitting smoking, including interactive features and referral links
75343104|NCT01342523|Other|Lite website - lite version of smokefree.gov|Reduced version of the smokefree.gov website developed for the research; reduced number of web pages and external links (considered a placebo intervention)
75343105|NCT01342523|Other|Full mailed booklet - NCI's detailed 36-page quit guide|NCI's Clearing the Air brochure for preparing to quit, quitting and preventing relapse
75343106|NCT01342523|Other|brief mailed booklet - smaller version of NCI's booklet|12-page booklet developed by the investigators for the research (considered to be placebo intervention)
75475931|NCT02001168|Drug|Docetaxel|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
75653465|NCT00818545|Drug|placebo|
75653466|NCT00818701|Drug|low dose Nesiritide|Nesiritide infusion 0.005ug/kg/min
75653467|NCT00818701|Drug|nesiritide, Sildenafil|Nesiritide 0.005ug/kg/min Sildenafil 50 mg
75653468|NCT00813085|Other|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
75653469|NCT00813241|Drug|celecoxib reference formulation|200 mg single oral dose of celecoxib tablets
75653470|NCT00813241|Drug|celecoxib test formulation A1|150 mg single oral dose of celecoxib A1 formulation tablets
75475932|NCT02001168|Drug|rh-Endostatin|rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
75475933|NCT02001168|Drug|Cis-platinum|Cis-platinum 60mg/m2, d1, 21 d as a cycle.
75475934|NCT02001207|Other|Salivary cortisol test|
75475935|NCT02001220|Procedure|Once daily screening|"In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.~The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre."
76089565|NCT02858583|Procedure|3:1 C:V|During 3:1 C:V. 3 chest compressions are given, then stopped and then 1 inflation is given. This approach is continued until return of spontaneous circulation.
75343107|NCT01261559|Device|Chrysalis breast displacement device|Chrysalis is a cloth device secured with velcro and buckles around the upper abdomen and chest following manual cephalad breast displacement.
75343108|NCT01342757|Drug|vorinostat|Given orally
75343109|NCT01342757|Drug|temozolomide|Given orally
75653471|NCT00813241|Drug|celecoxib test formulation B2|150 mg single oral dose of celecoxib B2 formulation tablets
75653472|NCT00813241|Drug|celecoxib test formulation C1|150 mg single oral dose of celecoxib Cl formulation tablets
75653473|NCT00818857|Behavioral|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
75653474|NCT00818857|Behavioral|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
75653475|NCT00813397|Device|Sepraspray|Max. 10g of Sepraspray
75653476|NCT00627523|Drug|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
75653477|NCT00627523|Drug|Control-no treatment|Control-no treatment
75653478|NCT00640393|Drug|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
75653479|NCT00640393|Device|nbUVB|
75801034|NCT04801576|Other|Flouride in mouthrinses|Custom made toothpastes and mouthrinses that do or do not contain flouride as sodium fluoride in different concentrations.
75801035|NCT04801576|Other|Placebo mouthrinse|Mouthrinses without flouride
75801036|NCT03778086|Procedure|gonioscopy|gonioscopic observation and grading of iridocorneal angle
75801037|NCT03777852|Diagnostic Test|First Questionnaire application|Women with breast cancer will respond to the First Breast Q questionnaire before treatment with breast cancer reconstruction surgery.
75801038|NCT03777852|Diagnostic Test|Second Questionnaire application|Women with breast cancer will respond to the Second Breast Q questionnaire after treatment with breast cancer reconstruction surgery.
76089566|NCT01455753|Other|Functional Proximity|Using each employee's building entry/exit swipe card data, we test whether functional proximity-the likelihood that the employee walks by the clinic for reasons other than vaccination-predicts whether the employee gets vaccinated at the clinic.
75343110|NCT01342757|Procedure|magnetic resonance spectroscopic imaging|Undergo MRI
75475936|NCT02001220|Procedure|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
75343111|NCT01342757|Other|survey administration|Ancillary studies
75343112|NCT02199743|Drug|Lurasidone|Compare to haloperidol and perphenazine
75343113|NCT02199743|Drug|Haloperidol|Compare to lurasidone
75343114|NCT02199743|Drug|Perphenazine|Compare to lurasidone
75343115|NCT01315145|Procedure|Percutaneous Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
75343116|NCT01315145|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
75343117|NCT01316315|Drug|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
75653480|NCT00821353|Procedure|RF catheter ablation|RF catheter ablation
75653481|NCT00821353|Drug|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
75653482|NCT02550847|Device|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
75343118|NCT01316315|Drug|Placebo|Same as active
75343119|NCT00776594|Drug|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
75343120|NCT00776594|Drug|bicalutamide|50mg orally daily for 6 months
75653483|NCT02550535|Genetic|Autologous WT1 TCR transduced T cells|Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
75653484|NCT00907478|Biological|romiplostim|Romiplostim administered by subcutaneous injection
75653485|NCT05315024|Drug|Fluarix Tetra|Fluarix Tetra
75653486|NCT05315024|Drug|Imiquimod cream|Imiquimod cream
75653487|NCT00627445|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
75653488|NCT00627445|Drug|metformin|Tablets, 500 - 2000 mg, once, twice or three times daily
75653489|NCT00627445|Drug|biphasic insulin aspart 50|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
75653490|NCT00905840|Device|Titanium Zircon implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
75653491|NCT00905840|Device|Titanium Grade IV implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
75653492|NCT00821665|Dietary Supplement|Sucrose consumption|Sucrose
75653493|NCT00821665|Dietary Supplement|water consumption|water
75653494|NCT02030990|Drug|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
75343121|NCT00776594|Drug|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
76089567|NCT01455753|Other|Base Proximity|We also test whether base proximity-the inverse of walking distance from the employee's desk to the clinic-predicts vaccination probability.
76089568|NCT03823053|Other|Home Based Traditional Scoliosis Exercise|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.
75653495|NCT02030990|Drug|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
75343122|NCT01262105|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
75939335|NCT04387773|Drug|GOCOVRI|"Participants will have gait and balance baseline assessment and then repeat assessment after being on full-dose of GOCOVRI for two weeks. The assessments will include measures of gait, balance and dyskinesia. Participants will also wear body-worn sensors (on wrist, feet and lumbar area) during daily-life for seven days to quantify mobility.~GOCOVRI will be started at 137mg/day for two weeks and then increased to 274mg/day for two weeks. Participants will repeat baseline assessments and then decrease to a dose of 137mg/day of GOCOVRI for one week, before stopping the medication completely.~All participants will receive GOCOVRI and they will know that they are on study drug. No placebo group."
75939336|NCT03034577|Drug|Sugammadex|Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
76089569|NCT03823053|Other|Home Based Core Stabilization Training|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. In addition, the training group received core stabilization exercises for multifidus, transversus abdominis, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and pelvic floor muscles.Exercises will be applied 1 sets of 10 repetitions and once a day.
75475937|NCT02001246|Behavioral|Real Deal program for Anger Management|Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
76089570|NCT01455831|Drug|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
75475938|NCT02001246|Behavioral|Mind-body Bridging (MBB) program|MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
76089571|NCT01455831|Drug|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
75801039|NCT05697328|Drug|Pseudoephedrine Pill|One-time 60mg dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
75343123|NCT00777062|Drug|VIVITROL (Naltrexone extended-release injectable suspension)|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
75343124|NCT00777062|Drug|Placebo|Placebo injection at the start of weeks 2 and 6.
75343125|NCT01264601|Biological|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
75475939|NCT02001259|Drug|epidural triamsinolone|add drugs into catheter at 48 hr after surgery
75801040|NCT05697328|Drug|Placebo|One time dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
75343126|NCT01317095|Device|Sternalock Rigid Fixation|Patients will have their sternum closed by rigid fixation using Sternalock plates.
75475940|NCT02001259|Drug|epidural lidocaine|add into catheter at 48 hr after surgery
75343127|NCT01345721|Biological|MenACWY-CRM|
75343128|NCT01346267|Procedure|Real Acupressure Band|Acupressure wristband
75475941|NCT02001272|Drug|Paclitaxel + Carboplatin every 3 weeks|Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.
75475942|NCT02001272|Drug|Carboplatin monotherapy every 3 weeks|A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.
75653496|NCT00821743|Device|Deep brain stimulation electrode|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
75653497|NCT00821899|Biological|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
75653498|NCT03861572|Other|Isokinetic eccentric training|Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
75653499|NCT03861572|Other|Traditional eccentric training|Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
75801041|NCT05160948|Other|Informational Report|All EcoMAPPE participants and their caregivers will be invited to complete a questionnaire to assess their understanding of air pollution and attitudes and beliefs about science and research before and after receiving their individual study air pollution monitoring results collected as part of their participation in EcoMAPPE.
75801042|NCT01316796|Drug|Sodium Nitrite Cream|
75801043|NCT05691634|Procedure|MRI|Patient with a tatoo will perform an MRI. The possible symptoms during the MRI or after MRI will then be described (duration, type,...).
75801044|NCT05691634|Other|Likert scale questionnaire|The patient will appreciate his feeling after MRI on a Likert scale (from 1 to 5)
75801045|NCT03628378|Device|Verasense|Ligamentous balancing device
76089572|NCT04840641|Drug|Flucloxacillin|Healthy volunteers will take 2x500 mg flucloxacillin 3 times a day for 31 days. The investigators will measure the baseline concentration of the 6-cocktaildrugs and flucloxacillin before start of 31 days of flucloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of flucloxacillin. On day 10 and 28 the investigators will measure the concentration of the 6 cocktaildrugs
75939337|NCT03034577|Drug|Neostigmine|Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
76089573|NCT01455909|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
76089574|NCT01455909|Drug|sitagliptin|sitagliptin oral 100 mg/day
76089575|NCT04844619|Drug|4mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
75653500|NCT03859999|Diagnostic Test|Analysis of primary radiograph and available demographics|Multivariate analysis of the fracture x-ray features measured by computer, together with the database demographic and outcome data will be used to develop the best model /decision rule to predict likelihood of MUA success
76089576|NCT04844619|Drug|16mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
76089577|NCT01757171|Drug|Cabazitaxel|20mg IV over 1 hour every 3 weeks
75475943|NCT02001272|Drug|Weekly Paclitaxel and Carboplatin|A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.
75475944|NCT02001285|Drug|Remifentanil|During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
75475945|NCT02001298|Drug|remifentanil|
75475946|NCT02001298|Drug|nitroprusside|
75939338|NCT03487341|Other|Cord drainage|Cord drainage
75939339|NCT03487341|Other|Cord clamping|Cord clamping
75939340|NCT05377060|Behavioral|Plasma p-tau risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, MMSE score, and plasma p-tau results.
75939341|NCT05377060|Behavioral|Standard risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, and MMSE score.
75939342|NCT04384497|Biological|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
75939343|NCT03705455|Behavioral|ISAP SMS|ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
75939344|NCT03092427|Dietary Supplement|VSL#3|Dietary Supplement
75939345|NCT03092427|Other|Placebo|Placebo
75939346|NCT04364997|Drug|Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
76089578|NCT04847349|Dietary Supplement|OL-1, standard dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
76089579|NCT04847349|Dietary Supplement|OL-1, high dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
76089580|NCT04847349|Dietary Supplement|Placebo|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.
76089581|NCT01456065|Biological|Procure|The IMP (Investigational Medical Product) consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
76089582|NCT01456065|Biological|Procure|The IMP consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
76089583|NCT04842123|Diagnostic Test|Electrocardiogram|Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device. All participants will record three simultaneous 12-lead and single-lead ECGs.
75475947|NCT02001311|Drug|Chlorhexidine gluconate|
76089584|NCT02555787|Drug|Tacrolimus|oral
76089585|NCT04847583|Drug|Telacebec|Telacebec 100 mg tablet
76089586|NCT04847583|Drug|COVID-19 Standard of care|The Standard of Care treatment and administration thereof will be determined by the Investigator
76089587|NCT01730729|Drug|cabergoline|Given orally
75475948|NCT02001324|Other|Web-based data collection|
75475949|NCT02001324|Other|Paper-based data collection|
75475950|NCT02001337|Other|medical chart review|baseline, quarterly follow-up for 24 months
75475951|NCT02001337|Other|survey administration|baseline
75475952|NCT02001337|Other|Specimen collection|baseline
75653501|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
75653502|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
75653503|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
75653504|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
75653505|NCT00822133|Drug|lidocaine|lidocaine 5%
75653506|NCT00822133|Drug|ketamine|ketamine cream
76089588|NCT03822819|Dietary Supplement|probiotic cocktail capsules|Daily uptake of probiotic cocktail for three weeks
76089589|NCT03822819|Dietary Supplement|placebo capsules|Daily uptake of placebo capsule for three weeks
76089590|NCT01756157|Biological|CINRYZE with rHuPH20|
76089591|NCT02931513|Other|Blood samples|
76089592|NCT02931513|Device|Fibroscan|
75475953|NCT02001350|Other|Ultrasonography|
75475954|NCT02001363|Drug|liraglutide (Novo Nordisk, Bagsværd, Denmark)|once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
75475955|NCT02001363|Drug|liraglutide placebo (Novo Nordisk)|once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
75475956|NCT02001376|Other|Intensive exercise|The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.
75653507|NCT00822133|Drug|non-active drug cream|will be put on the skin
75653508|NCT00822211|Drug|Vildagliptin 50 mg bid|
75653509|NCT00822211|Drug|Vildagliptin 50 mg qd|
75653510|NCT00822211|Drug|Placebo|
75653511|NCT04614805|Behavioral|Mobilizing clinical leaders|Clinical leaders and clinical personnel will regularly receive feedback regarding performance of their own hospital as well as other providers in the regional health trust of North Norway.
75653512|NCT00822367|Dietary Supplement|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
75939347|NCT04364997|Drug|Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule|Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
75939348|NCT04364997|Drug|Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
75939349|NCT04364997|Drug|Duloxetine Hydrochloride Enteric-coated Capsule|Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
75939350|NCT05376982|Diagnostic Test|Neurodevelopmental Treatment|Using Neurodevelopmental Treatment Method
75939351|NCT05376982|Diagnostic Test|Body weight supported treadmill training along with conventional therapy|Using Body weight supported treadmill training along with conventional therapy Method
76089593|NCT02931513|Other|Questionnaires|
75939352|NCT04820075|Behavioral|improvement of preoperative shower|Process about preoperative shower
76089594|NCT02931513|Biological|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
76089595|NCT04847505|Diagnostic Test|68Ga-DOTA-TATE|The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.
76089596|NCT01756079|Drug|boceprevir|
76089597|NCT01756079|Biological|PegIFN-2b|
76089598|NCT01756079|Drug|RBV|
75343129|NCT01346267|Procedure|Placebo Acupressure Band|Sham wristband
75343130|NCT01318577|Device|Investigational Cleaning & Disinfecting Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
75343131|NCT01318577|Device|Clear Care Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
75475957|NCT02001376|Other|Home exercise|The home-based exercise group will receive exercise instruction biweekly for three months
75475958|NCT02001376|Other|Control group live as usual|Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.
75653513|NCT05295602|Radiation|CT scan|CT of lower leg
75653514|NCT01977560|Behavioral|Intensive Lifestyle Intervention|Participants will be instructed to consume ~500 kcal/day less than their calculated estimated total daily energy requirements. The supervised exercise program will include both endurance and resistance exercise training sessions. The doses of diabetes medications will be adjusted by study physicians every 1-2 weeks, as needed to avoid hypoglycemia.
75939353|NCT03034629|Behavioral|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
75939354|NCT01717924|Procedure|peri-operative chemotherapy|Usual treatment strategy for gastric adenocarcinoma
75939355|NCT01717924|Procedure|Surgery first|strategy with a surgical procedure first, without the usual peri-operative chemotherapy
76089599|NCT05587101|Diagnostic Test|Urodynamic Study (Filling cystometry and pressure-flow study)|Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped. While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded.
75343132|NCT01318733|Drug|CD07805/47 gel 0.5%|In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
75343133|NCT01318967|Drug|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
75343134|NCT01318967|Other|Placebo|
75343135|NCT01319045|Drug|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
75475959|NCT02001389|Drug|EVP-6308|Arms 1, 2, 3, 4
75475960|NCT02001415|Other|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
75939356|NCT04289493|Other|Language and functional communication therapy|17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.
75939357|NCT03701867|Other|Metabolic Flexibility Tests|Energy Metabolism, Oxygenation, Body Composition, Blood Samples
75343136|NCT01267019|Behavioral|social cognitive training with in vivo augmentation|24 sessions of social cognitive training plus 6 sessions of in vivo exercises
75343137|NCT01267019|Behavioral|social cognitive training|30 sessions of social cognitive training without in vivo exercises
75343138|NCT01267019|Behavioral|non-social skills training|30 sessions of skills training that has no specific social content
75939358|NCT05594758|Drug|Olverembatinib|Oral Olverembatinib
75653515|NCT01977560|Behavioral|Standard Care|After receiving dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines participants will meet approximately every month for about 7 months with a study team member to record body weight, review diet and physical activity behaviors, and document medication use. Participants will continue their routine medical management, including regular clinic visits with their personal physician and/or diabetes educator during their participation in this study. Any changes medications will made by the participants' personal physician(s).
75653516|NCT00626821|Device|SenSura|Real life assessment of SenSura
75343139|NCT01348607|Drug|methylphenidate hydrochloride|Given orally
75343140|NCT01348607|Drug|modafinil|Given orally
75343141|NCT01348607|Drug|placebo|Given orally
75653517|NCT03609866|Procedure|rapid thoracic compression technique|in the expiratory time of the ventilation set, it will be applied a rapid thoracic compression
75939359|NCT03750279|Other|Exercise therapy|"5 min. warm up with light exercises for the lower limb prior to strength/endurance exercise therapy.~Strength/endurance exercise therapy including level 1 or 2 per session:~Level 1: Pelvic lifts (2x15 rep.), one-legged knee bends (2x10 rep. per leg), hip abductions (2x10 rep. per leg). The participants may progress from level 1 to level 2.~Level 2: Pelvic lifts (3x15 rep.), one-legged knee bends (3x10 rep. per leg), hip abductions (2x10 rep. per leg), sideways slide (2x10 rep. per leg), and backwards slide (2x10 rep. per leg). The participants may regress from level 2 to level 1."
75343142|NCT06214689|Other|biomarkers analysis|IDH1 and OCT4 markers analysis of surgical specimens of high grade astrocytoma
75343143|NCT06214676|Device|OCT angiography|Detection of microvascular changes in patients with primary open angle glaucoma by using Optical Coherence Tomography Angiography
75653518|NCT03609866|Procedure|metatarsophalangeal joint passive mobilization|it will be performed a metatarsophalangeal joint passive mobilization technique on the patient
75653519|NCT05332886|Behavioral|MetaHealth Group|Three metaverse rooms will be created via metaverse technology that aims to develop healthy nutrition, physical activity, and psychological resilience skills to reduce the risk of of NCDs in youth.
75653520|NCT05332886|Behavioral|MobileHealth Group|The intervention aims to develop healthy nutrition, physical activity, and psychological resilience skills using mobile application materials to reduce the risk of NCDs in youth.
75939360|NCT03750279|Other|LLLT|- LLLT (60 mW mean output per probe, 904 nm wavelength) applied to the knee in adherence with the recommendations by World Association for Laser Therapy, in terms of dosage per treatment spot.
75939361|NCT03750279|Other|Sham LLLT|- Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
75939362|NCT03701789|Drug|Baricitinib|Effect of Baricitinib on vBMD measured by HR-pQCT
75939363|NCT05417386|Drug|FOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
75343144|NCT06214663|Other|0.9 NaCl solution|Saline injections will be administered over the sacral area (both posterior iliac spines and 2 cm downward and medial), and this technique was described by Lytzen et al in 1989 and later standardized. The results will be compared between the three groups.
75343145|NCT06214650|Other|Radiofrequency|"Experimental group will receive the common exercise program associated with a radiofrequency treatment using INDIBA® (INDIBA Activ 7, Barcelona, INDIBA S.A.) at a frequency of 448 hertz. It will use the capacitive electrode as a method of preparation and vascularization of the superficial tissues and immediately, within the same session, the resistive electrode to stimulate deep tissues. This treatment is based on the protocols established by INDIBA® S.A.~It will consist of one weekly diathermy session of thirty minutes during ten weeks. The use of diathermy will not be interrupted throughout the session.~The common exercise program consist in a ten abdominal exercises (including recti abdominis, transversus and obliques). It will practised at home only just three days at week."
75343146|NCT06214650|Other|Control|Control group will receive a weekly INDIBA® session in the abdominal area with the same protocol as the experimental group in athermic mode (placebo treatment) and the common exercise program. The session will last thirty minutes and will be carried out by the research physiotherapist during ten weeks.
75343147|NCT06214637|Drug|Melissa|The test solutions will be administered once a day through administration in drops for children between 5 and 10 years old and for adolescents between 11 and 16 years old. As participants will be between 5 and 16 years old, children will be given a minimum of 5 and a maximum of 10 drops of the solutions per individual (Tavares-Silva, Holandino et al. 2019) as well as a maximum of 10 drops for adolescents of solutions per individual (Taylor, Lancaster et al. 2000). Highlighting that the prescription of Melissa officinalis will be at night, around 20/30 minutes before bedtime, respecting the indications for the medications described in the Hahnemannian Materia Medica (Vijnovsky, 2003). All medications must be taken away from meals and they will be instructed not to use mentholated substances, respecting a minimum time of 30 minutes.
75653521|NCT03842930|Procedure|Endovascular embolization|Endovascular embolization of the Lumbar Arteries
75653522|NCT04018417|Drug|Amphotericin B|Drug concentration: 0.255 μg/mL
75653523|NCT03808220|Behavioral|postoperative pain intensity|estimate the postoperative pain intensity by using a scaling system via questionnaire
75653524|NCT03808220|Behavioral|preoperative pain frequency|estimate the preoperative pain intensity by using a scaling system via questionnaire
75653525|NCT03808220|Behavioral|Side effect|investigate the presence of any side effect
75939364|NCT05417386|Drug|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
75939365|NCT05417386|Drug|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
75939366|NCT05417386|Drug|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
75939367|NCT05417386|Drug|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
75939368|NCT05417386|Drug|NIS793|Given by intravenous infusion
75343148|NCT06214637|Drug|Placebo|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
75939369|NCT05417386|Radiation|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
75343149|NCT06214624|Behavioral|Two types of exercise interventions|"HIIT. 3 times/week. This consists of a 4x4 HIIT (preferably in treadmill), 4 intervals of 4min at high intensity (85-95% HRmax) and 3 intervals of 3min of active resting at ~70% HRmax in between. All sessions including 10 min of warming-up and 10min of cooling down, resulting in 45min sessions. The first 2 weeks will progress from moderate-intensity training to HIIT for a better adaptation and acceptability of the program.~HIIT + resistance. 3 times/week. The aerobic part consists of a 3x4 HIIT (preferably in treadmill), 3 intervals of 4min at high intensity (85-95% HRmax) and 2 intervals of 3min of active resting (~70% HRmax) in between. The resistance part consists of 2 series of an 8-exercise circuit (combination of upper and lower body exercises using elastic bands and body weight) with a ratio of 20sec of effort - 40sec of resting. Sessions will have 5min of warming up in the treadmill and 5min of cooling down walking in the gym, comprising a total of 45min sessions."
75343150|NCT06214585|Procedure|Intermittent heat and cold versus heat-only therapy|for the experimental group, a cyclical method of alternating heat and cold application will be used on the lumbosacral and lower abdominal area of the laboring women. The process involves applying a hot pack with a temperature range of 38-40°C on their lower abdomen and low back for 30 minutes during contractions and a relaxing period using a 2-litre rubber hot water bag. Subsequently, reusable ice packs typically contain water, covered with a towel and with a temperature range of 0-5°C will be applied to the same areas for 10 minutes. After a 30-minute interval, the heat application will be reapplied, and this alternating heat and cold cycle will be repeated throughout the first stage of the laboring process.
75343151|NCT06214585|Procedure|Heat- only Therapy|hot water bag will be used to provide heat to the lower back of primigravida women during the first stage of labor. The water in the bag will be maintained at a temperature of 40-42ºC. The application of heat will last for 20 minutes, and it will be repeated every hour until the cervix is fully dilated.
75653526|NCT00826345|Other|Acupuncture / Moxibustion|"Acupuncture/Moxibustion points will be administered per point prescription.~- Active"
75653527|NCT00826345|Other|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
75653528|NCT01791920|Drug|Botulinum toxin type A(Botulax®)|Single administration, Day 0, 20 units
75653529|NCT01791920|Drug|Botulinum toxin type A(Botox®)|Single administration, Day 0, 20units
75653530|NCT00826501|Procedure|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
75653531|NCT00826501|Procedure|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
75653532|NCT00826579|Procedure|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
75653533|NCT00826579|Procedure|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
75653534|NCT03014024|Other|Low-Level Laser Therapy|The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
75653535|NCT03014024|Other|Placebo Low Level Laser therapy|This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
75653536|NCT00826657|Dietary Supplement|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
75939370|NCT05417386|Drug|Capecitabine|Taken Orally as part of Chemoradiation
75653537|NCT00826657|Dietary Supplement|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
75653538|NCT03597776|Drug|Lidocaine|Bolus of lidocaine will be given over 5 minutes before skin incision
75939371|NCT05417386|Radiation|Radiation Therapy|Radiation Therapy as part of Chemoradiation
75939372|NCT05417386|Procedure|Surgery|Surgical removal of tumor
75939373|NCT03487263|Biological|IC14|chimeric monoclonal antibody against human IC14
75939374|NCT03702101|Device|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
75939375|NCT04005729|Drug|Cangrelor 50 MG|30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
75939376|NCT03486015|Drug|Sterile water|2 ml of sterile water
75939377|NCT03486015|Drug|30% glucose|2 ml of 30% glucose
75939378|NCT04599023|Device|MSPT|The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
75939379|NCT01659736|Device|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
75939380|NCT03487107|Drug|SOF|400 mg tablet administered orally once daily
75939381|NCT03487107|Drug|DAG181|100 mg capsule administered orally once daily
75939382|NCT03705299|Device|Non-Invasive CVP vs Standard CVP|
75939383|NCT03705221|Behavioral|Healthy Parent Carers group programme|Peer-led group-based weekly programme.
75939384|NCT03705221|Behavioral|Healthy Parent Carers online resources|Online resources related to health and wellbeing
76089600|NCT05587101|Diagnostic Test|Questionnaires|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance.
76089601|NCT05587101|Diagnostic Test|Uroflowmetry|Uroflowmetry test consists measuring the maximum urine flow rate, the average urine flow rate, the micturiated volume and postmictional urine volume. The maximum flow rate below 12 ml/sec in males and 18 ml/sec in females will be recorded as emptying phase disorder. Postvoid residual urine volume above 150 ml is a sign of incomplete emptying of bladder.
76089602|NCT04272645|Drug|Abemaciclib 200 MG|200 MG orally BID Days 1-21
75343152|NCT06214572|Drug|Systemic therapy (Gemcitabine plus Cisplatin)|"Participants will receive one of the following Gemcitabine-based systemic therapy alone:~Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~Duration: 3 months (in addition to 3 months previously received)"
75939385|NCT03485937|Behavioral|Pre-Operative Videos|Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions. The videos will be split into two modules: 1) preparing for Mohs Surgery 2) Mohs Surgery Walk through. The intervention, in the form of a video walk through, will be provided to the patient via email prior to their surgical procedure once they schedule an appointment with the Mohs clinic for their surgery day.
75939386|NCT03485937|Behavioral|verbal instructions|As part of the standard of care for patients receiving Mohs surgery, patients are told about the day of their surgery and what to expect
75939387|NCT03485937|Behavioral|written instructions|As part of the standard of care for patients receiving Mohs surgery, patients receive written material about the day of their surgery and what to expect
75939388|NCT05591716|Procedure|Bilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis.The ureteroscope was extracted together with the case with the ureteral revision: there was no damage to the ureter.Next, this procedure is performed from the other side. Urine was excreted from the bladder using a Nelaton catheter.
75653539|NCT03597776|Drug|Saline|Bolus of saline will be given over 5 minutes before skin incision
75939389|NCT05591716|Procedure|Unilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis. The ureteroscope was extracted together with the body with revision of the ureter: there was no damage to the ureter. Urine was excreted from the bladder using a Nelaton catheter.
76089603|NCT04272645|Drug|Atezolizumab 1200 MG in 20 ML Injection|1200 mg IV on Day 1 of 21-day cycle
76089604|NCT04272645|Drug|Abemaciclib 150 MG|150 MG orally BID Days 1-21
75343153|NCT06214572|Radiation|RT|"Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.~This is followed by systemic therapy as in the Systemic therapy alone arm."
75653540|NCT00625183|Dietary Supplement|selenomethionine|
75801046|NCT04476576|Behavioral|Aerobic exercise (experimental)|3 times per week, 30 minutes each time. Entrance in heat: 8-10 min of joint mobility and / or the aerobic exercise in the main part at light intensity (OMNI 3-4) Main part: minimum 30 minutes, maximun 60 minutes. Intensity: moderate, guided by Talk Test and effort perception scale 5-6 OMNI. Type: aerobic, cycling or walking at home using a treadmill or exercise bike and / or cycling and walking outdoors according to the patient's possibilities and preferences. Return to calm: 5 min of aerobic physical activity of main part at mild intensity (OMNI 3-4), then static stretching. Pictures with each type of exercise will be offered and detailed explained.
75801047|NCT04476576|Behavioral|Flexibility exercise (active comparator)|Entrance in heat: 10 min of joint mobility. Main part: Minimum 30 minutes. Frequency: 3 times por week Intensity: The patient should be able to slowly stretch the muscle to a position of mild discomfort. Type: Static Stretch Time: 15-30 seconds 2 repetitions of each stretch Number of exercises: 12 . Pictures with each muscle group to exercise will be offered and detailed explained.
75801048|NCT04668586|Device|Holmium:YAG laser machine|Ureteroscopy with Holmium:YAG laser lithotripsy
75801049|NCT04668586|Device|Thulium Fiber laser machine|Ureteroscopy with Thulium Fiber laser lithotripsy
75801050|NCT03777930|Drug|Chemotherapy drugs|According to the NCCN Guidelines
75801051|NCT03777930|Drug|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
75343154|NCT06214572|Drug|Systemic therapy (Gemcitabine plus oxaliplatin)|"Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~Duration: 3 months"
75653541|NCT00625183|Drug|capecitabine|
75653542|NCT00625183|Drug|oxaliplatin|
75653543|NCT00625183|Other|laboratory biomarker analysis|
75653544|NCT00625183|Other|pharmacological study|
75653545|NCT00625183|Procedure|adjuvant therapy|
75653546|NCT00625183|Procedure|neoadjuvant therapy|
75653547|NCT00625183|Procedure|therapeutic conventional surgery|
75653548|NCT00625183|Radiation|radiation therapy|
75653549|NCT05332808|Other|questionnare|collecting data about treatment and quality of life
75653550|NCT00826735|Behavioral|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
75653551|NCT03569072|Radiation|Functionally adapted, dose escalated VMAT radiotherapy|Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
75343155|NCT06214572|Drug|Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)|"Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~Duration 3 months Durvalumab (12 months)"
75343156|NCT06214572|Drug|Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)|Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w Duration: 3 months
75939390|NCT03485859|Device|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
75653552|NCT00826813|Device|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
75939391|NCT03485859|Device|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
75653553|NCT00826891|Drug|Cisplatin Combined With Topotecan|"Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).~Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.~Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2~Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2"
75653554|NCT02549443|Dietary Supplement|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
76089605|NCT03822585|Diagnostic Test|CBC, Iron Study, Serum Ferrittin, HPLC,Genitic Study|"high performance liquid chromatography (HPLC) has become the preferred technique, as it can detect most of the clinically significant variants. polymerase chain reaction (PCR)-based procedures detect Commonly occurring mutations of the HBB gene .~If targeted mutation analysis fails to detect the mutation, scanning or sequence analysis can be used. Sensitivity of both mutation scanning and sequence analysis is 99%."
76089606|NCT04390815|Drug|Insulin|Adding insulin to conventional wound treatment
76089607|NCT01456611|Drug|Diclofenac|Diclofenac Sodium Gel 1%
76089608|NCT01456611|Drug|Placebo|Placebo Topical Gel
75653555|NCT00904982|Behavioral|Financial Incentive and Med-eMonitor|"Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server."
75939392|NCT03705143|Behavioral|Treatment as usual|Treatment as Usual participants will receive the treatment typically provided to patients at the MMT clinic in Wuhan, China.
76089609|NCT01456689|Drug|LGH447|
76089610|NCT01456689|Drug|midazolam|
76089611|NCT05827185|Biological|Ergonomic modifications|A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains (7 items related to office chair, 9 items related to office desk, 8 items related to keyboard and mouse, 5 items related to computer screen, 3 items related to telephone and 5 items related to the office environment -) and it has a good reliability and validity. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
75343157|NCT06214559|Device|Sérum VERRUPRO|To be applied twice a day
75343158|NCT06214546|Other|Regular walking|Participants perform 6 overground walking trials (12.5 m) without support system. Participants perform all measurements (regular walking, Myosuit, ZeroG) on one single measurement day.
75343159|NCT06214546|Device|Myosuit|Participants perform 6 overground walking trials (12.5 m) while wearing the Myosuit. ZeroG and Myosuit intervention will be performed in random order.
75343160|NCT06214546|Device|ZeroG|Participants perform 6 overground walking trials (12.5 m) while walking in the ZeroG. ZeroG and Myosuit intervention will be performed in random order.
75475961|NCT02001415|Other|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
75475962|NCT02001415|Other|Orthokeratology|Orthokeratology lenses.
75653556|NCT00904982|Device|2Med-eMonitor|Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
75653557|NCT00826969|Drug|Ciclesonide|320µg Ciclesonide versus Placebo
75653558|NCT00826969|Drug|Placebo|Placebo
75343161|NCT06214533|Drug|Ropivacaine 0.5%|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.
75343162|NCT06214533|Drug|Normal Saline|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.
75343163|NCT06214520|Behavioral|App-based Motivational Interviewing & Human health coaching|"Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.~App-based Motivational Interviewing & Human health coaching:~The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call."
75343164|NCT06214520|Behavioral|Empower+ App & Smartwatch wearable tracker|Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.
75343165|NCT06214507|Other|No intervention|No intervention
75343166|NCT06214494|Other|Blood Flow Restricted High Intensity Treadmill Training|Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion (on hemiparetic limb only) 2x weekly for 16 Sessions totaling minimum of 75 minutes weekly.
75343167|NCT06214494|Other|HITT|High Intensity Treadmill Training 2x weekly for 16 Sessions totaling minimum of 75minutes weekly.
75343168|NCT06214481|Drug|Rocatinlimab|Administered SC.
75343169|NCT06214468|Combination Product|Acetaminophen and Nicotinamide Riboside|Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside
75343170|NCT06214468|Drug|Acetaminophen|Collection of urine at different time intervals following ingestion of Tylenol only
75801052|NCT03777930|Other|optimal support treatment|Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
75801053|NCT03777930|Drug|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
75343171|NCT06214455|Other|Low sugar diet and 10-12 hour eating window|Low sugar diet and 10-12 hour eating window for four weeks
75653559|NCT04222166|Biological|CAM|Cryopreserved Amniotic Membrane
75343172|NCT06214455|Other|Low sugar diet, 8 hour eating window and fasting|Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.
75801054|NCT03777774|Procedure|Passive Redon subgaleal drains|Passive non-vacuum subgaleal drains will be placed during closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
75653560|NCT00822601|Device|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
75653561|NCT00822601|Device|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
75653562|NCT03560882|Drug|Atorvastatin|Atorvastatin tablet, 80mg
75801055|NCT03777774|Procedure|Vacuum Redon subgaleal drains|Active vacuum subgaleal drains will be placed during the closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
75939393|NCT03705143|Behavioral|Chinese translated LETS ACT|The Chinese translated Behavioral Activation (C-BA) will be provided in Mandarin. C-BA treatment includes psychoeducation regarding the link between mood and behavior, identification of values/goals/activities across life areas, planning and tracking of daily value driven activities.
75939394|NCT05375890|Other|no intervention|Narcolepsy patients in Russia gathered according to criteria.
75939395|NCT02997163|Drug|Talazoparib|Daily oral doses of talazoparib 0.5 mg
75939396|NCT03705065|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
75939397|NCT03702023|Drug|Acetaminophen|Intervention group will receive 1000 mg of acetaminophen
75653563|NCT04044547|Drug|Rotigotine, extended-release microspheres|"Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
75939398|NCT03702023|Drug|Placebo Oral Tablet|Control group will be given a placebo capsule.
75939399|NCT05391880|Drug|BEBT-503 20mg|BEBT-503 capsule
75939400|NCT05391880|Drug|BEBT-503 40mg|BEBT-503 capsule
75939401|NCT05391880|Drug|BEBT-503 80mg|BEBT-503 capsule
76089612|NCT05827185|Biological|Physiotherapy|First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. To perform the C1-C2 cervical spine manipulation (CSM) the participant was instructed to lie in a face-up position with upper and lower extremities kept aside relaxed. The head was kept in a neutral position and the treating therapist stands at the patient's head side and holds the chin of the patient with the right side hand. The therapist left hand holds the posterior aspect of the head and does two to three free rotatory movements. Afterwards, the therapist did HVLAT technique in either the right or left direction based upon the symptoms informed by the patient.
76089613|NCT05827185|Biological|Ergonomic modifications and Physiotherapy|"A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given."
76117231|NCT03702179|Drug|Tremelimumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
75343173|NCT06214442|Other|Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle|Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.
75801056|NCT03777774|Procedure|No Redon subgaleal drains|A subgaleal drain will be placed during the closing stage of craniectomy but it will be clamped. The drain will be unclamped if necessary. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
75801057|NCT04630054|Device|Face mask|Intervention individuals will be given cloth or surgical face masks.
75939402|NCT05391880|Drug|BEBT-503 120mg|BEBT-503 capsule
75939403|NCT05391880|Drug|BEBT-503 180mg|BEBT-503 capsule
75939404|NCT05391880|Drug|placebo 20mg|placebo capsule
75343174|NCT06214429|Diagnostic Test|Vascular Ultrasound|Complete vascular ultrasound routine in B mode, color mode and Doppler.
75343175|NCT06214429|Diagnostic Test|Shear Wave Elastography|Vascular ultrasound assisted shear wave elastography of the atherosclerotic plaque.
75343176|NCT06214429|Diagnostic Test|Greyscale Median|Vascular ultrasound assisted assessment of the plaque in B mode. The plaque image will be post-processed for the histogram median value for the plaque area.
75653564|NCT04044547|Drug|Placebo, extended-release microspheres|"Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
75801058|NCT04630054|Behavioral|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
75801059|NCT03777696|Drug|Misoprostol|400 μg of buccal misoprostol
75801060|NCT03777696|Drug|TA|1 gm of tranexamic acid in 100 ml saline iv
75801061|NCT03777696|Drug|placebo to misoprostol|placebo tablets to misoprostol buccal
75801062|NCT03777696|Drug|placebo to TA|110 ml saline iv
75801063|NCT04627714|Other|Adapted Physical Activity|Intervention consists in 1h30/week of adapted fencing
75939405|NCT05391880|Drug|placebo 40mg|placebo capsule
75343177|NCT06214429|Diagnostic Test|Magnetic Resonance Imaging|Assessment of the plaque and carotid residual lumen by magnetic resonance.
75475963|NCT02001428|Drug|dihydroartemisinin-piperaquine|Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
75475964|NCT02001467|Other|Simulation-based training|
75939406|NCT05391880|Drug|placebo 80mg|placebo capsule
75939407|NCT05391880|Drug|placebo 120mg|placebo capsule
75939408|NCT05391880|Drug|placebo 180mg|placebo capsule
75939409|NCT04649255|Device|Liquid Embolic|Lava Liquid Embolic System (LES)
76025901|NCT05583110|Drug|Tucatinib|"Run-in Phase:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity [DLT] is seen) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg BID on a continuous dosing schedule."
75343178|NCT06214429|Diagnostic Test|Histopathology|Histopathology findings for patients that undergo carotid endarterectomy.
75475965|NCT02001480|Device|12 lead Holter|12 lead Holter measurements will be performed for 7 days
75475966|NCT02001480|Device|CGM Continuous Glucose Monitoring|CGM will be performed continously for 7 days
75475967|NCT02001506|Drug|FEC3-D3|"Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
76117232|NCT03702179|Radiation|Radiotherapy|Radiotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder.
75343179|NCT06214416|Behavioral|Abstention|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote abstention.
75343180|NCT06214416|Behavioral|Mediterranean alcohol-drinking pattern|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote the Mediterranean alcohol-drinking pattern.
75343181|NCT06214403|Drug|MET-2|Microbial Ecosystem Therapeutics (MET) is a defined microbial community derived from healthy donor stool. MET capsules are orally administered mixtures of pure cultures of human-derived bacterial strains.
75801064|NCT03777540|Procedure|Gastric resection|"Partial gastrectomy with jejunal anastomosis, total gastrectomy, gastroenterostomy without gastrectomy or other (palliative surgery)."
75939410|NCT04532827|Behavioral|Case formulation with web-program|"The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing.~WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB."
75939411|NCT05390086|Other|Standard of care|The study is being implemented among children who are seeking care at collaborating hospitals for signs and symptoms suggestive of TDD. All children will be treated by the hospital physicians following the usual hospital procedures. The study will not interfere in any with the administration of required treatments and interventions.
75939412|NCT03698513|Drug|BMS-986177|BMS-986177 capsule
75343182|NCT06214403|Drug|Placebo|Microcrystalline Cellulose
75475968|NCT02001519|Drug|AC4-CDDP4|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
75653565|NCT05332652|Device|trancranial magnetic stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
75653566|NCT05064787|Behavioral|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
75653567|NCT00827047|Procedure|Total hemihepatic vascular exclusion|A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.
75653568|NCT00827047|Procedure|Hemihepatic vascular Clamping|Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.
75653569|NCT00827047|Procedure|Pringle's Maneuver|Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
75653570|NCT05332184|Procedure|aortic valve surgery|
75653571|NCT02768948|Drug|telmisartan during 6 months|telmisartan during 6 months
75653572|NCT02768948|Drug|Losartan during 6 months|Losartan during 6 months
75653573|NCT02768948|Procedure|blood sample|blood sample
75939413|NCT03698513|Other|Placebo (for BMS-986177)|BMS-986177 placebo match capsule
76117233|NCT03065166|Other|Raisin Treatment|Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
76117234|NCT03065166|Other|Bagel Control|Subjects will consume 95g of whole wheat bagel during a single intervention time point.
75653574|NCT02761382|Other|Mindfulness-based psychological treatment|
75801065|NCT04611880|Drug|Crizanlizumab|Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. It is administered intravenously.
75801066|NCT03769740|Device|Cerebral Oximetry|Non invasive, near infrared spectroscopy cerebral oximetry
75801067|NCT03774342|Procedure|Coronary Artery Bypass Grafting|Patients undergoing coronary artery bypass grafting
75343183|NCT06214390|Procedure|Single strategy|In the single strategy, RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use
75343184|NCT06214390|Procedure|Combined strategy|In the combined strategy, when urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine > 5.2mmol/day [5] and 3) urinary urea > 1.35mmol/kg/day (using the patient's body weight at ICU admission) [6], RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume.
75475969|NCT02001571|Drug|Abiraterone acetate|On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
75475970|NCT02001584|Drug|Baclofen|
76089614|NCT05827185|Biological|Patient education|Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
76089615|NCT05827172|Procedure|AF ablation|The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.
75801068|NCT04581148|Diagnostic Test|Blood test antibodies against SARS-CoV-2|Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2
75939414|NCT03698513|Drug|Clopidogrel|Clopidogrel tablet
76089616|NCT05827172|Other|medical therapy|The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. The aim of the treatment was a ventricular rate of 60 to 80 beats per minute at rest.
76117235|NCT03700931|Behavioral|Eating recall condition|Recall of eating episodes would increase subsequent intake of fruit or vegetable items
76117236|NCT03700931|Behavioral|Non-eating recall condition|Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
75653575|NCT02761382|Other|Non-specific psychological treatment|
75653576|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
75653577|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
75653578|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
75653579|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
75653580|NCT00904748|Drug|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
75653581|NCT02721758|Behavioral|Brief Motivational Intervention|
75653582|NCT00574405|Drug|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
75939415|NCT03698513|Drug|Aspirin|Aspirin tablet
75653583|NCT00574405|Device|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
75343185|NCT06214377|Device|Active Transcranial Direct Current Stimulation|The Starstim tCS® equipment will be used, with 35 cm2 sponge electrodes. The tDCS over M1 will be performed by placing the active anode on the C3 point (10/20 EEG system) and the cathode on the contralateral supraorbital area (Fp2). Regarding the stimulated hemisphere, in cases of asymmetric pain, it will be applied to the contralateral M1, and in cases of bilateral pain, it will be applied to the M1 of the dominant hemisphere. A constant current of 2 mA (subthreshold intensity) will be applied for 20 minutes, with the first 30 seconds used as a ramp-up and the last 30 seconds as a ramp-down. Number of sessions: 1.
75653584|NCT00827125|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
75801069|NCT03942094|Drug|Nilotinib|"Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily"
75801070|NCT04478812|Diagnostic Test|Single Group Assignment|Tbit™ System will detect S100B and GFAP concentrations with the blood specimen collected
75653585|NCT03859609|Procedure|Spinal Fusion|Spinal alignment was evaluated according to two different score-systems
75801071|NCT03708744|Drug|A: M207 3.8mg, 30 min, upper arm|A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
75939416|NCT05416294|Device|Primary Relief|The group will receive PENS treatment using Primary Relief in addition to the multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline) including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
75939417|NCT05416294|Device|Inactive Primary Relief|The group will receive a sham device with multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline), including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
76117237|NCT03696953|Biological|Florajen3|Probiotic combination product One capsule daily by mouth.
75475971|NCT02001584|Drug|Memantine|
75653586|NCT00818935|Dietary Supplement|Low-Intermediate-Glycemic Index diets|
75653587|NCT00818935|Dietary Supplement|High GI diet|
75653588|NCT00971243|Drug|MP-513 Lowest Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
75653589|NCT00971243|Drug|MP-513 Low Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
75939418|NCT03698435|Drug|Ganciclovir|Intravenous ganciclovir + TDM
75653590|NCT00971243|Drug|MP-513 Medium Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
75653591|NCT00971243|Drug|MP-513 High Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
75653592|NCT00971243|Drug|Placebo and Metformin|Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
75653593|NCT04017169|Other|No intervention as observational study|
75801072|NCT03708744|Drug|B: M207 3.8 mg, 30 min, thigh|B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
75939419|NCT03698435|Drug|Valganciclovir|Oral valganciclovir + TDM
75939420|NCT05416216|Behavioral|WELL|The WELL intervention is a multi-level, three-strategy program to promote the wellbeing of the ECE workforce.
75475972|NCT02001584|Drug|Placebo|
76089617|NCT05827094|Other|Mobile app|The main mobile intervention features. Tracking and immediate feedback: Pressing the icon launches a short series of questions with multiple-choice response options focusing on recent meals . The survey items are modeled after the 14-item Mediterranean Adherence Screener using simplified language and intuitive visuals to lower cognitive load. Based on responses to the survey, the app provides an intuitive visualization of the survey results, personalized feedback, and recipes on how to improve the person's diet. On-demand resources: individuals are able to access on-demand resources about the MedD diet, its benefits, and best dietary practices. The recipe page includes a personalized list of simple breakfast, lunch, dinner, and snack recipes based on the survey results with step by step instructions on how to prepare Mediterranean foods. In-app messaging: Individuals are able to receive notifications and send and receive messages.
76089618|NCT05827094|Other|Usual Care|Participants randomly allocated to the control group will receive educational materials on healthy eating, as provided on the NIA web page (https://www.nia.nih.gov/health/healthy-eating).
76089619|NCT05827029|Procedure|Preopertive drink|"Group C: will receive a carbohydrate drink of 400 ml (50 g of glucose prepared by nutrition division, same appearance and containing bottles of water)~Group W: will receive water 400 ml (prepared by nutrition division, Songklanagarind hospital, same appearance and containing bottles of carbohydrate drink) In both groups, the received 400-mL drink was consumed within 5 minutes.~Before drinking, baseline data (gastric residual volume, POCT glucose, degree of hunger, and thirst) will be evaluated.~Gastric ultrasound will be performed by the same Radiologist on each participant at 0, 30, 60, 90, 120 minutes~after drinking to evaluate the gastric residual volume and time to empty gastric antrum.~POCT glucose and degree of hunger and thirst are also assessed again at 120 minutes after drinking.~After completing one type of drinking, participants will be appointed again after 1 week later for doing the same protocol with another drinking."
76089620|NCT05826977|Behavioral|CASI-Plus|See arm description
75939421|NCT03698357|Behavioral|interactive video balance-based exercise|Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.
76089621|NCT05826925|Other|Decision aid|A decision aid will be developed based on qualitative data from Aim 1 and iterative refinement with input from stakeholders from Aim 2. Anticipated content includes: 1) information about cardiovascular risk following hypertensive disorders of pregnancy; 2) goal-setting exercises for blood pressure, weight management, glucose control, physical activity, and smoking cessation; 3) self-care steps to achieve management targets; 4) values clarification exercises to identify values related to cardiovascular risk management and identify priority areas for focus and improvement; and 5) discussion of how to communicate questions and goals of treatment to their provider.
75343186|NCT06214377|Device|Sham Transcranial Direct Current Stimulation|The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes. The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol. However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method. Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.
75343187|NCT06214377|Drug|Dopaminergic medication|After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
75343188|NCT06214364|Device|Active Transcranial Direct Current Stimulation|"Active Anodal Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex of the affected or most affected hemisphere during 10 20 minute-sessions at 2 miliamps.~The tDCS stimulator device will be used by an experienced physical therapist by a saline-soak pair of surface electrodes. The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1.~While the tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
75475973|NCT02001610|Dietary Supplement|Acidophilus pearls|"Acidophilus pearls are encapsulated using patented process~Subjects take one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
75475974|NCT02001610|Dietary Supplement|Hard shell gelatin capsules|"Hard-shelled gelatin capsule with same microbial formulation as pearl supplement~Subjects consume one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
76089622|NCT05826821|Drug|Pirfenidone|Intervention drug
75475975|NCT02001636|Drug|Resource Instant Protein 88|Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
75475976|NCT02001636|Drug|Resource Maltodextrin|Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
75475977|NCT02001649|Genetic|SNP Genotyping|Individuals were genotyped at a total 96 SNP from 15 candidate gene
75475978|NCT02001649|Genetic|SNP genotyping|
75653594|NCT00822835|Biological|ILV-095|
75653595|NCT00822835|Biological|Placebo|
75653596|NCT00822913|Drug|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
75939422|NCT03698357|Behavioral|Conventional physiotherapy|conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
75939423|NCT05389072|Device|control contact lens|control CRT lens
75475979|NCT02001662|Procedure|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
75475980|NCT02001662|Procedure|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
75653597|NCT00827203|Drug|Elesclomol Sodium|Chemotherapy agent
75653598|NCT04400383|Drug|AB011 Injection|"Stage 1 Single treatment: AB011 Injection with dose escalation of 1mg/kg up to 40mg/kg, as well as dose expansion with recommended dose level from dose escalation.~Stage 2 Combo Treatment: AB011 combine XELOX( GC) or Gem/nab-P (PC) Injection with dose escalation of 10mg/kg up to 30mg/kg, as well as dose expansion with recommended dose level from dose escalation."
75653599|NCT04381429|Drug|A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
75939424|NCT03701633|Diagnostic Test|Postpartum ultrasound|Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
75653600|NCT04381429|Drug|F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
75653601|NCT00568555|Drug|Low Dose Naltrexone|3-4.5mg Naltrexone once daily
75939425|NCT04641065|Other|Music listening|An expert on the particular type of music will do the selection of the playlist of Traditional Turkish Military music, and this playlist will be listened to the patients by the researchers.
76089623|NCT05826795|Procedure|Early goal-directed therapy (EGDT)|The principle of hemodynamic optimization to achieve the defined goals.
76089624|NCT05826769|Dietary Supplement|Energy- Protein Enriched Nutritional Formula|EN volume will start at 1 mL/kg/h and then increase by 1 mL/kg every 6 hours if tolerated, until reaching 130 mL/kg/d.
76089625|NCT05826730|Other|Eccentric Exercises|Eccentric Exercises for neck muscles.
76089626|NCT05826717|Other|Apple|20g fructose in [x] g of apple
76089627|NCT05826717|Other|Mashed apple|20g fructose in [x] g of mashed apple
76089628|NCT05826717|Other|Apple juice|20g fructose in [x] ml apple juice
76089629|NCT05826717|Other|Fructose powder in water|20g fructose in [x] ml water
76089630|NCT05826704|Dietary Supplement|Probiotics|Participants will be taking 2 capsule a day for 6 weeks
75653602|NCT00568555|Drug|Placebo - sugar pill|Placebo pill once daily
75653603|NCT00819325|Drug|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
75653604|NCT00819325|Drug|oral hypoglycemic agents|sulfonylurea or metformin
75653605|NCT00904670|Drug|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
75653606|NCT00904670|Drug|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
75801073|NCT03708744|Drug|C: M207 3.8 mg, 1 hr, upper arm|C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
75343189|NCT06214364|Device|Sham Transcranial Direct Current Stimulation|"The electrodes will be placed in the same position as for the Primary Motor Cortex stimulation, as in the experimental group. Current will be applied for 30 seconds in the beginning and at the end for securing the blinding.~While the sham tDCS stimulation is administered virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
75343190|NCT06214351|Other|Use of mobile midwifery application|Pregnant women in the experimental group will have a mobile midwifery application installed on their smartphones. The pregnant woman will be able to reach the research midwife 24/7. With the informative content and algorithm mechanism in the application, she will be able to provide individual care and detect early signs of danger, enabling her to seek medical attention.
76089631|NCT05826691|Procedure|Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).|Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction
75653607|NCT00904670|Drug|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
75653608|NCT00827281|Drug|D-cycloserine|Single dosage prior to sessions 3, 4 & 5
75653609|NCT00827281|Drug|Placebo|Single dosage prior to sessions 3, 4 & 5
75653610|NCT00827437|Other|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
75939426|NCT03701945|Other|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
75939427|NCT05415982|Other|Ketogenic Diet|The intervention is a ketogenic diet based on high-fat ketogenic meals prepared by the study participants, complemented with ketogenic food products from Natural Ketosis and Vitaflo. Exogenous ketones are provided by Audacious Nutrition. The macronutrient composition of the ketogenic diet given approx.: Fat 87 E%, Carbohydrate 3 E%, Protein 10 E%,
75653611|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
75653612|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
75653613|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
75939428|NCT03698045|Drug|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
75653614|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
75653615|NCT02708654|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
75801074|NCT03708744|Drug|D:zolmitriptan nasal spray|D: 2.5 mg/0.1 mL intranasal zolmitriptan
75801075|NCT03747328|Drug|ABI-009|nanoparticle albumin bound sirolimus
75801076|NCT01320462|Drug|Smoking cessation counselling group|The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
75801077|NCT01320462|Other|Control group:|Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
75801078|NCT03774030|Procedure|several virtual 3-D complex audio environments|The focus is a comparison of 3 hearing aid algorithms in a virtual 3-D complex audio Environment.
75801079|NCT03774108|Drug|Metformin Hydrochloride 850 MG|8 weeks tratment with oral metformin
75801080|NCT03774108|Other|Placebo|8 weeks tratment with oral placebo
75801081|NCT03769662|Biological|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
75343191|NCT06214338|Dietary Supplement|Experimental dose 1|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 2.5, separated by 1 hour and 15 min.
75343192|NCT06214338|Dietary Supplement|Experimental dose 2|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 5 separated by 1 hour and 15 min.
75939429|NCT04547075|Other|Turkish validity and reliability|"Contact with developers and formation of steering committee~Translation from English to Turkish~Back translation from Turkish to English~Comparison of translation~Review of translated versions.~Reaching consensus and development of pilot version~Testing in clinical setting~Revision of pilot version~Testing of final version"
75939430|NCT03701477|Behavioral|Trans-diagnostic cognitive-behavioral therapy|10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
75939431|NCT03701477|Behavioral|General relaxation/stress management therapeutic session|Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
75939432|NCT03697889|Drug|Naproxen sodium (test product)|Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
75939433|NCT03697889|Drug|Naproxen sodium (reference product)|Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
75939434|NCT03692819|Drug|Placebo Oral Tablet|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.
75939435|NCT03692819|Drug|Amoxicillin 500 Mg|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
75939436|NCT03692819|Drug|Lactobacillus reuteri Oral Drops|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
75939437|NCT00458536|Biological|Dendritic Cell Tumor Fusion Vaccine|3 vaccinations at three week intervals
75343193|NCT06214312|Diagnostic Test|Lung Ultrasounds|An ultrasound exam of the lungs to identify possible areas of atelectasis.
75343194|NCT06214286|Device|Shockwave|Shockwave therapy
75343195|NCT06214286|Other|Kinesio taping|Kinesio taping application
75475981|NCT02001675|Device|magnetic resonance imaging (MRI)|
75475982|NCT02001675|Device|31-phosphorous magnetic resonance spectroscopy (MRS-P31)|
75475983|NCT02001701|Procedure|Intravitreal Injection of sulfahexafluoride gas|After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
75475984|NCT02001727|Other|13C-Urea breath test for Helicobacter Pylori|
75653616|NCT02708654|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
75653617|NCT02708654|Behavioral|Support Partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
75939438|NCT00458536|Drug|Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|Combined with the vaccine in the remaining subjects after the first 6 are enrolled.
75653618|NCT02708654|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
75939439|NCT03697733|Procedure|fractional curettage|Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
75939440|NCT05373394|Other|Test battery|motor and neuropsychological test battery
75939441|NCT03697655|Drug|Daratumumab 20 MG/ML [Darzalex]|Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
75939442|NCT05373160|Other|Assessment study|Assessment of functional tests with and without dual tasks
75939443|NCT02526550|Biological|Live attenuated chimeric Japanese Encephalitis vaccine|0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh
75939444|NCT02526550|Biological|Inactivated Hepatitis A vaccine|0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
75343196|NCT06214286|Other|conventional physical therapy|conventional physical therapy
75653619|NCT00822991|Device|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
75343197|NCT06214247|Device|Wedge NC Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Wedge NC Scoring Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure.
75343198|NCT06214247|Device|Scoreflex Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using a similar product on the market in the control group, subsequently completing the remaining procedure.
75343199|NCT06214234|Procedure|Band ligation|Band ligation in variceal bleeding
75475985|NCT02001727|Other|Questionaire|
75475986|NCT02001740|Drug|Triamcinalone (steroid) and lidocaine|receive once
75475987|NCT02001740|Other|Lidocaine|receive once
75475988|NCT02001753|Device|CMR|
75475989|NCT02001766|Behavioral|Exercise training|
75343200|NCT06214208|Other|Transcutaneous Spinal Stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic pulses. A single cathode electrode will be placed over the skin of the back spine at the T11/T12 spinous interspace. Two reference electrodes will be placed over the stomach. Stimulation intensity will be set to 0.8x reflex threshold, as determined by posterior root muscle reflex testing before the intervention. Treatments will be a minimum of 72 hours apart.
75939445|NCT05565352|Drug|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
75939446|NCT04423276|Drug|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
75939447|NCT04423276|Drug|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
75343201|NCT06214195|Drug|Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)|Ginseng 6g , Ophiopogon japonicus 12g ,Schisandra chinensis 5g , other secondary Chinese medicines can be added according to the doctor's judgment and the patient's condition，decoction in water, one dose and two decoctions, taken twice a day, continuously for 7 days from the start of each chemotherapy cycle (± 3 days), including anthracyclines and taxanes (the frequency and dosage of medication can be adjusted according to adverse reactions in the later stage); The total duration of medication interventionis 7 days per cycle, with a total of 8 cycles. If the chemotherapy is less than 8 cycles, continue taking for 7 consecutive days from the start of each subsequent trastuzumab cycle (the frequency and dosage can be adjusted based on adverse reactions) until a total of 8 cycles are reached.
75653620|NCT00822991|Device|B-mode US|screening by conventional B-mode US every 3-5 months
75939448|NCT03701243|Procedure|mNT-BBAVF|Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.
75653621|NCT05213156|Drug|Oxatrex|0.3% ofloxacin eye drops in single doses
75343202|NCT06214169|Drug|Cisatracurium Besylate|Addition of cisatracurium to plain lignocaine for IVRA.
75653622|NCT00823147|Behavioral|Pain Catastrophizing Induction|Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
75653623|NCT00823225|Procedure|standard therapy|wound debridement, moist wound dressing
75653624|NCT00823225|Drug|Urokinase|"Daily infusion up to 21 applications, dose dependent on fibrinogen level:~> 2,5g/l 1 000 000 IU, < 2,5g/l 500 000 IU"
75653625|NCT00823381|Dietary Supplement|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
75653626|NCT00823381|Other|placebo|one placebo pill taken once a day with breakfast
75653627|NCT00823381|Behavioral|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
75653628|NCT02850380|Other|"FLIP SWITCHES DOWN IN WEIGHTLESSNESS"|"The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below)."
75653629|NCT02850224|Behavioral|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
75653630|NCT00638443|Drug|Pregabalin|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
75653631|NCT00638443|Drug|Diphenhydramine|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
75343203|NCT06214169|Drug|Lignocaine|Plain Lignocaine for IVRA
75343204|NCT06214117|Drug|Remimazolam|Anesthesia induction:intravenous Fentanyl 2-3 μg/kg, remimazolam 0.3-0.5 mg/kg and Rocuronium 0.6mg/kg; Maintenance of anesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h), and remifentanil will administer at an initial infusion rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
75653632|NCT00632684|Behavioral|Interviews with a single treatment planning session|Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
75653633|NCT00632684|Behavioral|Adaptive treatment model|The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
75653634|NCT05184218|Drug|IGM-6268|Active Comparator
75475990|NCT02001779|Device|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
75653635|NCT05184218|Drug|Placebo|Placebo Comparator
75653636|NCT00636181|Device|Auto AFlex|Positive pressure therapy treatment
75653637|NCT00636181|Device|Auto CPAP|Positive pressure therapy treatment
75653638|NCT00636181|Device|CPAP|Positive pressure therapy treatment
75653639|NCT00968669|Biological|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
75653640|NCT00968669|Biological|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
75653641|NCT00968669|Biological|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
75653642|NCT00968669|Other|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
75801082|NCT03547726|Other|Physical Therapy|These patients will receive a formal physical therapy protocol by seeing a physical therapist in clinic.
75939449|NCT03701243|Procedure|RCAVF|Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
75343205|NCT06214117|Drug|Sevoflurane|Anesthesia induction: Anesthesia will induce with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min, and then intravenous fentanyl (2-3 μg/kg) and rocuronium (0.6 mg/kg); Maintenance of anaesthesia: Anesthesia depth will maintain at 1-1.5 minimum alveolar concentration (MAC), and remifentanil was infuse at an initial rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
75653643|NCT00568399|Drug|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
75653644|NCT00827593|Behavioral|Standard behavioral weight loss treatment|Participants will receive 12 months of university-based behavioral weight loss treatment
75653645|NCT00827593|Behavioral|Weight Watchers|Participants will receive 12 months of Weight Watchers
75801083|NCT03547726|Other|Self-Rehab|These patients will be provided with a list of actions NOT to perform and allowed to self rehabilitate. They will not see a physical therapist.
75939450|NCT03697499|Combination Product|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
75801084|NCT03772938|Biological|Stem/progenitor cells transplantation|Human autologous bone marrow-derived stem/progenitor cell transplantation administered as an intravitreal injection in patients with degenerative disease of retina.
75801085|NCT03438526|Drug|Melatonin (Circadin ®)|4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
75801086|NCT03438526|Drug|Placebo|Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
75939451|NCT03697499|Combination Product|fish oil and sham exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
75939452|NCT03697499|Combination Product|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
75939453|NCT03697499|Combination Product|soy oil and sham exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
75939454|NCT05371210|Other|SAIF|Participants interacted with SAIF system at least 2-3 times per week; each session took up to 20 minutes.
75939455|NCT04423432|Other|Lower Extremity Resistance Exercise Training|3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)
75939456|NCT04423432|Other|Home Exercise Plan|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion~Isometric isolated knee extension and knee flexion~Isometric terminal knee extension~Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)"
75939457|NCT04423432|Device|Electrotherapy + Heating|Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes
75939458|NCT04423432|Procedure|Joint Mobilization|"Tibio-femoral Anterior Glide~Tibio-femoral Posterior Glide~Patellofemoral Joint Mobilization"
75939459|NCT04423432|Dietary Supplement|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
75939460|NCT04423432|Dietary Supplement|Glucoseamine/ Chondritin Sulfate Supplementation|Glucoseamine/ Chondritin Sulfate Supplementation (500mg+400mg/day)
75939461|NCT05370586|Other|Pericapsular nerve Group Block|Patients of study group will receive PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone
75939462|NCT05370586|Other|Infrainguinal Fascia Iliaca Block|Patients of control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone
75939463|NCT04255966|Device|Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
75939464|NCT03701087|Drug|Vitamin D|2800 IU daily till 26 weeks of pregnancy
75939465|NCT03701009|Procedure|CBD stone removal via lithotripsy|Hold saline irrigation just after X-ray demonstrated no stone residue, a Spyglass explored.
75939466|NCT03701009|Procedure|Saline 50ml|If not clean, intermittent saline irrigation 50ml, and Spyglass explored second time.
75343206|NCT06214104|Behavioral|Acupressur|Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
75475991|NCT02001779|Device|Conventional biliary SEMS|A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
75475992|NCT02001792|Procedure|Position the patient during colonoscopy|Position the patient either in a left lateral position during colonoscopy
75653646|NCT00827593|Behavioral|Combined Treatment|Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
75653647|NCT00975143|Drug|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
75653648|NCT00975143|Drug|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
75801087|NCT03361696|Other|Help to use the Interface System of Communication and Control of the Environment|the occupational therapist and the ergonomics engineers at the rate of 4 sessions per patient for periods of 2 to 3 hours help patient to use use the Interface System of Communication and Control of the Environment
75939467|NCT03701009|Procedure|Saline +50ml|If still have some stone fragments, intermittent saline irrigation another 50ml after the second Spyglass detection, Spyglass explored third time to evaluate stone clearance.
75939468|NCT03697265|Drug|Sepranolone (UC1010) low dose|Subcutaneous (SC) administration
75939469|NCT03697265|Drug|Sepranolone (UC1010) high dose|Subcutaneous (SC) administration
75939470|NCT03697265|Drug|Placebo|Subcutaneous (SC) adminstration
75939471|NCT05415046|Procedure|Sacral ESPB|Erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
75939472|NCT03697187|Drug|rhC1INH|Recombinant human C1 inhibitor
75939473|NCT03692507|Dietary Supplement|HMB|Patients in the first group (HMB only) will take 3 capsules of HMB by VitaMonk™ (1000mg/capsule) daily (morning, noon, and night) for 5 days prior to surgery.
75939474|NCT03692507|Dietary Supplement|Protein and HMB|Patients in the second group (HMB + protein) will drink 2- 8oz bottles of Ensure Enlive daily (morning and night) for 5 days prior to surgery. Each bottle contains 1500mg of HMB and 20 g of protein.
75939475|NCT03692507|Dietary Supplement|ERAS|Patients in the third group (High protein) will drink 2- 8oz bottles of Ensure surgery daily (morning and night) for 5 days prior to surgery. Each bottle contains 18g of protein. and a clear 50g Pre-surgery drink on the day of surgery
75939476|NCT05610748|Procedure|Sub-Periosteal Peri-implant Augmented Layer technique|In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
75939477|NCT05610748|Procedure|Soft tissue augmentation|In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.
75801088|NCT01561638|Procedure|Conventional Radiofrequency|pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
75801089|NCT01561638|Procedure|Pulsed Dose Radiofrequency|pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
75939478|NCT05369338|Device|Low Level Light Therapy|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
75801090|NCT01561638|Procedure|Sham|will receive puncture for 4 minutes
75939479|NCT05369338|Device|Sham Controll|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
75653649|NCT04288349|Procedure|perineal block with usage of one of solutions|Perineal block using solution of ropivocaine and epinephrine for the first group was performed. Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus. Ten ml of the solution is injected in ischiorectal fat on each side. The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve. In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial. The total amount of the injected solution is 50 ml.
75939480|NCT03696875|Other|Multilevel Guided Discharge Planning|Clinical recommendations and resources activations + scheduling of early visit with the specialist + communication with primary care + written instruction sheet to the patient
76089632|NCT05826678|Device|Continuous Glucose Monitor|The Clinical Diabetes Educator (CDE) will follow up with the participants at Month 1 after the baseline study visit, at the study midpoint (Month 3), and at the end of the study (Month 6) to check CGM usage, including timely calibration and change adherence. At the end of the study, participants will be invited to complete a survey and participate in virtual interviews to assess changes in their health behaviors and the acceptability of CGM devices.
76089633|NCT05826678|Behavioral|Finger stick glucose monitoring|Participants will adhere to the standard care protocol and continue self-monitoring of blood glucose through fingersticks as per usual practice[46]. The Clinical Diabetes Educator (CDE) will monitor and provide follow-up to the control group participants as per the same schedule followed for the intervention group.
76089634|NCT05826652|Other|Single injection subcostal transversus abdominis plane block|Single injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 20 ml between tranvers and rectus abdominis muscle immediately next to the linea semilunaris.
75475993|NCT02001792|Device|pulse oximeter|
75653650|NCT04288349|Drug|epinephrine + ropivacaine +saline|epinephrine + ropivacaine +saline
75653651|NCT04288349|Drug|epinephrine + saline|epinephrine + saline
75653652|NCT03667313|Combination Product|sirolimus-eluting balloon (SEB) MagicTouch|Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
75801091|NCT03322384|Drug|epacadostat|Epacadostat will be administered orally, in pill form, twice daily until disease progression.
75801092|NCT03322384|Drug|SD-101|Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
75801093|NCT03322384|Radiation|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
75343207|NCT06214078|Dietary Supplement|nicotinamide mononucleotide|Nicotinamide mononucleotide (NMN), a bioactive substance found in a variety of foods, is a precursor for the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ plays a crucial role in a variety of biological processes including cell death, senescence, gene expression, neuroinflammation, and DNA repair.
75343208|NCT06214078|Other|placebo|The placebo mimicked the appearance and properties of nicotinamide mononucleotide(NMN) enteric-coated capsules. The specifications, usage and dosage of placebo were the same as those of NMN.
75475994|NCT02001831|Dietary Supplement|Supplement|
75653653|NCT03667313|Combination Product|paclitaxel-eluting balloon (PEB) Sequent Please|Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
75475995|NCT02001831|Dietary Supplement|Placebo|
75653654|NCT03796091|Behavioral|Educational Brochure|Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.
75653655|NCT03796091|Behavioral|Body Project Traditional|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice & Shaw, 2001).
75475996|NCT02001844|Device|Trial Foot Orthoses (FOs)|"Trial Group:~The children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
75653656|NCT03796091|Behavioral|Body Project Expanded|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
75939481|NCT03696875|Other|Standard of care|Standard of care
75939482|NCT03692429|Drug|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
75939483|NCT03692429|Drug|FOLFOX|5-FU, leucovorin and oxaliplatin
75939484|NCT03692429|Drug|FOLFIRI|5-FU, leucovorin and irinotecan
76089635|NCT05826652|Other|Multiple injection subcostal transversus abdominis plane block|Multiple injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 5 ml between transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volume lateral to this point near the subcostal margin.
75653657|NCT00629759|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
75653658|NCT00974675|Biological|CAT-354 1mg/kg|CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
75653659|NCT00974675|Biological|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
75653660|NCT00974675|Biological|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
75343209|NCT06214065|Diagnostic Test|fMRI|fMRI will be performed pre- and post-rTMS
75343210|NCT06214065|Device|rTMS|TMS procedures are scheduled during study sessions 2-4 between the two MRI scans on those days. Because rTMS induces neural changes that last about 1 hour, rTMS will be applied immediately before the second MRI scan on each day. Prior to the TMS visits, target coordinates and orientation vectors will be generated from the MRI data and the e-field models and loaded into Localite along with the participant's reconstructed T1 image. During the visits, the participant's head will be co-registered to the T1 using fiducial points at the Nasion and Tragi. TMS pulses will be delivered, using the Localite software to target and track the optimal orientation calculated with e-field modeling.
75653661|NCT00974675|Other|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
75939485|NCT03700853|Diagnostic Test|Dysphagia Trained Nurse Assessment (DTNAx)|Bedside swallowing assessment carried out by trained nurses
76089636|NCT05826626|Device|MindLenses Professional|MindLenses professional's device combines the prismatic adaptation procedure with the administration of serious games for cognitive training using a tablet
76089637|NCT05826626|Behavioral|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
75653662|NCT04925531|Drug|Antibiotics|to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
75653663|NCT04288037|Diagnostic Test|fetal heart rate variability|observational study. no intervention
75653664|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
75653665|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
75653666|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
75653667|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
75653668|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
75653669|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
75653670|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
75653671|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
75939486|NCT04523129|Drug|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
75939487|NCT04523129|Drug|Vehicle topical ocular, eye drops|Vehicle
75653672|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
76089638|NCT05826548|Behavioral|Telerehabilitation group|Patients will undergo the experimental intervention for 1 hour/day, for 5 days, for 4 weeks.
76089639|NCT05826548|Behavioral|Conventioanl treatment group|Patients will undergo the control intervention for 1 hour/day, for 5 days, for 4 weeks.
75939488|NCT03700775|Other|Remote Telemonitoring|Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal <130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
75939489|NCT03692351|Device|Uncemented acetabular cup with screw holes|
75939490|NCT03692351|Device|Uncemented acetabular cup without screw holes|
76089640|NCT05826522|Other|observationnal|cohort of blood collection and severals exams
75343211|NCT06214052|Drug|VH4524184|VH4524184 will be administered.
75343212|NCT06214052|Drug|Placebo|Placebo will be administered.
75343213|NCT06214039|Behavioral|Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety|A 3-hour one session exposure therapy for public speaking anxiety
75801094|NCT03772470|Other|1X airtime incentive|An incentive given in the form of airtime
75939491|NCT03700697|Behavioral|Family Stress Module Intervention|as above
76089641|NCT05826483|Drug|Almonertinib|Almonertinib Mesilate Tablets
76089642|NCT05826444|Diagnostic Test|Echocardiography|Echocardiography with afterload change
75343216|NCT06213987|Drug|0.025% Tretinoin|Total duration of 8 weeks.
75343217|NCT06213974|Other|No Intervention|This is non-interventional study.
75343218|NCT06213948|Drug|Mirtazapine 15 MG|"Mirtazapine~Commercial name: Remeron® SolTab~Pharmaceutical form: film-coated tablets (15 mg)"
75939492|NCT03700619|Other|BRIEF parental survey|estimate incidence of executive functions disorders in preterm children in 11 to 12 year old, born less than 34 weeks of gestation, with the BRIEF parental questionnaire. Effects are potentially important because this study could objectify an increase of risk of executive functions disorders f in preterm children in 11 to 12 year old, and identify associated risk factors. This work could eventually alert pediatrician to be careful at the executive functions and to propose adapted supportive cares.
75343219|NCT06213935|Drug|Norepinephrine|after spinal anesthesia, norepinephrine will be injected intravenous as bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min to prevent post spinal hypotension
75343220|NCT06213935|Drug|Midodrine|10 mg tablets of midodrine 1 hour before spinal anesthesia to prevent post spinal anesthesia hypotension
75343221|NCT06213922|Behavioral|Food intake|Fast food
75343222|NCT06213909|Other|This is a retrospective analysis of health data from inpatient record, no intervention was designed|This is a retrospective analysis of health data from inpatient record, no intervention was designed
76089643|NCT05826444|Diagnostic Test|Magnetic resonance imaging|Stress-MRI
75343223|NCT06213870|Diagnostic Test|Surgical criteria|"In the MRI group, patients with FVH-DWI mismatch underwent EVT surgery or were otherwise treated with medication.~In the perfusion group, patients who meet the criteria of DEFUSE3 will receive EVT surgery, otherwise receive medication."
75343224|NCT06213857|Dietary Supplement|Silymarin|Silymarin (milk thistle), an extract obtained from Silybum marianum seeds containing a complex of flavonolignans with a potent intracellular antioxidant property. The first usage of Milk thistle was for its hepatoprotective and antioxidant activities, but in the recent years it has been used to control of immune based murine colitis by healing of bowel histology and reduction of bowel inflammatory cytokines especially TNF-α, interleukin-1β (IL-1β), and nuclear factor κB (NF-κB). Silymarin has anti-viral, immunomodulation, anti-inflammatory effects as well as antioxidant properties by scavenging free radicals and increasing the glutathione concentrations, protective and wound healing effects. It increases the gene expression of antioxidant enzymes and the number of the most important protection mechanisms against free-radicals damage containing superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase.
75343225|NCT06213844|Drug|IBI3002|Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1
75653673|NCT00967499|Drug|Ondansetron|"Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting."
75801095|NCT03772470|Other|2X airtime incentive|An incentive given in the form of airtime
75801096|NCT03772470|Other|Lottery airtime incentive|An incentive given in the form of airtime
76089644|NCT05826444|Diagnostic Test|Magnetocardiography|Magnetocardiography
76089645|NCT05826444|Diagnostic Test|Histology|Histological analysis
76089646|NCT05826444|Diagnostic Test|Genetics|miRNA sequencing
76089647|NCT05826444|Diagnostic Test|calcium signaling|cardiomyocyte calcium signaling
76089648|NCT05826444|Diagnostic Test|IMR|Index of microvascular resistance measurement
76089649|NCT05826444|Diagnostic Test|Angio-IMR|Angiography derived post-processing index if microvascular resistance
75343226|NCT06213844|Drug|Placebo|Single dose of Placebo, administered subcutaneously on Day 1
75801097|NCT02977624|Behavioral|The Cognitive Orientation to daily Occupational Performance|
76089650|NCT05826431|Device|Cubii elliptical|Low impact, portable, and compact elliptical for seated use.
75939493|NCT04519229|Behavioral|Child-Parent Psychotherapy|Relationship-based trauma focused psychotherapy for Children 0-6 years old and their caregivers. The objective is to decrease symptoms of post-traumatic tress and re-establish a secure attachment for the child and good caregiving from the caregiver/s.
76089651|NCT05826405|Other|No intervention|No intervention, it's an observational study
76089652|NCT05826340|Behavioral|Tailored progressive loading and return to sport|Participants will undergo a 5-stage progressive return to sport tool.
76089653|NCT05826340|Behavioral|Pain guided activity|Participants will be provided on information on how to guide activity based on pain response.
76089654|NCT05826262|Procedure|diagnostic laparoscopy|diagnosis and management of patients with penetrating anterior abdominal wall injuries
76089655|NCT05826249|Drug|SIM0417/Ritonavir|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
76089656|NCT05826236|Device|Periarticular compression|Periarticular knee compression using a sphygmomanometer.
76089657|NCT05826210|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was performed in all patients with or without SO.
76089658|NCT05826158|Diagnostic Test|18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)|18F-mFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
76089659|NCT05826145|Behavioral|Vocal Expression|There will be a total of 8 sessions. At baseline (week 0), only questionnaires will be completed. There will be 7 treatment sessions beginning at week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration where the vocal expression sessions will be provided.
76089660|NCT05826145|Behavioral|Cognitive Behavioral|There will be 8 treatment sessions where part of the baseline session of session 1 (week 0) will include some instruction, session 2 will occur in week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration. Sessions will include various cognitive-behavioral techniques including completing a grief monitoring diary, imaginal revisiting, cognitive restructuring, describing positive memories of the deceased, and identifying future goals.
75343227|NCT06213831|Drug|Ruxolitinib Cream 1.5%|Ruxolitinib Cream 1.5%
75343228|NCT06213818|Drug|INCB160058|Oral; Tablet
75343229|NCT06213818|Drug|Placebo|Oral; Tablet
75343230|NCT06213818|Drug|Esomeprazole|Oral; Capsule
75801098|NCT03769428|Procedure|erector spinae plane block|The ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Local anesthetic (LA) is injected between the erector spinae muscle and transverse process. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid. Then 40cc of Ropivacaine (3.75mg/cc) will be injected .The distribution will be observed in both cranial and caudal directions.
75939494|NCT04346849|Procedure|Pulpotomy|Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
75939495|NCT03696719|Device|BIS bispectral index monitoring device|In addition to the standard monitoring prescribed by the American society of Anesthesiologists, all study participants will be monitored with the BIS, a noninvasive monitoring device which measures the depth of anesthesia. The monitoring is performed using noninvasive electrodes placed on the forehead.
75343231|NCT06213805|Procedure|Minimally invasive microsclerostomy|"MIMS is a filtering glaucoma surgery, which consists of creating a sclero-corneal drainage channel, to allow the flow of aqueous humor and therefore the reduction of intraocular pressure.~This surgery is extremely quick, lasting 3 to 5 minutes, according to recent MIMS studies, in contrast to the duration of a trabeculectomy, the classic glaucoma surgery, which varies between 20 and 60 minutes."
75343232|NCT06213792|Other|Adaptation of the VOR|Subjects will undergo adaptation of their VOR in virtual reality in two different conditions. The side on which the adaptation will take place and the type of condition with which the patients will start will be randomized. Subject will undergo passive rapid head movements done by an experienced examinator whilst fixing a target in front of them. The movement of the target relative to the movement of the head will increase every 90 seconds by 10% until the movement of the visual scene is twice that of the head movement. In one condition the visual scene will be only a target in a grey void. In the other condition the visual scene will be more complex and represent a target in the room in which the subject is seated. Subjects will undergo both conditions at least 7 days apart.
76089661|NCT05826106|Procedure|R anastomosis|Modifying the surgical technique of totally laparoscopic Billroth-II reconstruction with Braun anastomosis and to name it as the R anastomosis.
76089662|NCT05826093|Procedure|Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)|US-TAP is a peripheral nerve block applied for postoperative pain relief. Subcostal refers to the approach which can also be lateral or posterior. In this trial the subcostal approach was used.
76089663|NCT05826041|Behavioral|(INSPIRE) INtervention Support groups: Peers Inspiring Resilience and Empowerment.|The support group contains both structured components, which are psychoeducational and focused on skill-building, and an unstructured component where discussion is open and determined by the needs and interests of the clients present (e.g., support and process-oriented.)
76089664|NCT05826041|Behavioral|Traditional Domestic Violence Support Group|The activities of the group are determined by agency staff from week to week and may be open group discussion, psychoeducation, or a combination of both.
76089665|NCT05825976|Dietary Supplement|Omega-3 Fatty ACids|Intervention consists of two different doses of omega-3: high concentration (Intervention group 1) and low concentration (Intervention group 2).
76089666|NCT05825976|Other|Control|Supplementation with extra virgin olive oil as a for of positive placebo control.
76117238|NCT03065088|Behavioral|aLIFE|The aLiFE programme is taught by an instructor during six home visits and 3 phone calls during the 6-month intervention period. The programme will be personalised by use of an initial balance and strength assessment (aLiFE assessment tool). The participants assigns activities to his or her daily activities, and during subsequent home visits, the number of activities and task demands are upgraded. Participants will be taught how to select opportunities themselves to embed activities into their individual daily routine, and how to progress over time.
76089667|NCT05825872|Procedure|internal superior laryngeal nerve block|"A linear 4- to 12-MHz ultrasound probe will be placed in the oblique parasagittal plane to obtain an image of the hyoid bone and the thyroid cartilage. The probe will be kept parasagitally, and the following structures will be identified anteriorly to posteriorly: omohyoid muscle, sternohyoid muscle, thyrohyoid muscle, thyrohyoid membrane, superior laryngeal artery, and pre-epiglottis space.~After identifying the local anatomic structure, a needle will be inserted out-plane from anterior to posterior. The muscles above the thyrohyoid membrane will be penetrated and hydrodissected; local anesthetic will be injected into the superior laryngeal nerve space. The superior laryngeal nerve space will be located between the hyoid bone (cephalad) and the thyroid cartilage (caudal) and delimited between the thyrohyoid muscle, anteriorly, and the thyrohyoid membrane and the pre-epiglottis space, posteriorly"
76089668|NCT05825872|Drug|Lidocaine 2% Injectable Solution|0.5 ml will be injected
75653674|NCT00967499|Drug|Palonosetron|"Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery."
76089669|NCT05825872|Drug|Bupivacaine 0.5% Injectable Solution|1.5 ml will be injected
76089670|NCT05825820|Behavioral|Enhanced Outreach Intervention (EOI) plus Care as Usual|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~A phone call (or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if you have suicidal thoughts, and (c) discuss participants' plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals give for individuals who present to the ED with suicidal thoughts."
75801099|NCT03769428|Procedure|sham erector spinae plane block|The sham ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid a total of 40 mL of fluid will be injected next between the erector spinae muscle and transverse process. Then 40cc of normal saline will be injected.The distribution will be observed in both cranial and caudal directions.
75653675|NCT04286399|Drug|Renin-angiotensin-aldosterone system inhibitors|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
75801100|NCT02575144|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle
75801101|NCT02575144|Drug|Lenalidomide|25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min
75939496|NCT03696719|Biological|NSE cerebral biomarker testing|Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.
75939497|NCT04336943|Biological|Durvalumab|Given IV
75939498|NCT04336943|Drug|Olaparib|Given PO
75939499|NCT04336943|Other|Quality-of-Life Assessment|Ancillary studies
75939500|NCT04336943|Other|Questionnaire Administration|Ancillary studies
75801102|NCT02575144|Drug|Dexamethasone|40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
75653676|NCT04286399|Drug|Beta blocker|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
75653677|NCT04286399|Drug|SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
75801103|NCT03769272|Procedure|Measurement of electrical delay during LV lead placement|Measurement of electrical signal in the heart during implantation of CRT, by positioning the lead in different places in the heart.
75801104|NCT04092114|Other|Control|Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered
75801105|NCT04092114|Behavioral|CHARISMA Intervention|"SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable:~Module A: General Partner Communication and Relationship Skills~Module B: Partner Disclosure and Communication around PrEP Use~Module C: Responding to Intimate Partner Violence and Safety Planning"
75801106|NCT03768882|Drug|paracetamol|1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients
75939501|NCT03030989|Drug|Chlorhexidine Gluconate 2% Wipe|
75939502|NCT03030989|Drug|Placebo Wipe|
76089671|NCT05825690|Other|Retrospective evaluation of specific brain MRI features|"Initial brain MRI and subsequent follow-up studies will be reviewed to document the presence of specific MRI features, and their association with greater disease severity in the acute phase and/or neurological sequelae after encephalitis resolution will be investigated. More specifically, we will analyze the presence of:~Brain MRI changes in the acute stage, i.e. < 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~Brain MRI changes after acute phase resolution (> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
76089672|NCT05825677|Device|tDCS actif|Active brain stimulation
75939503|NCT03030599|Drug|JZP-258|JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate
76089673|NCT05825677|Device|tDCS Sham|Sham brain stimulation
75801107|NCT03768882|Drug|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay -Menarini,Turkey) intravenous (IV) was given 98 patients
75653678|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 [13mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
75653679|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 [22mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
75653680|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 [13mg of liposomes/kg]
75801108|NCT02574286|Drug|Velaglucerase alfa|Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.
75653681|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 [22mg of liposomes/kg]
75801109|NCT02574286|Dietary Supplement|Vitamin D|Participants will receive 800 IU vitamin D orally daily.
75801110|NCT01321944|Other|Direct to Smoker Outreach Program|"Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs."
75801111|NCT03771846|Drug|irinotecan, oxaliplatin , fluorouracil, and leucovorin|administration of irinotecan, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
75801112|NCT03771846|Drug|gemcitabine and oxaliplatin|administration of gemcitabine and oxaliplatin via vein
76089674|NCT05825664|Procedure|Endoscopic resection|Group 1: Polyps are resected by UEMR Group 2: Polyps are resected by CEMR
76089675|NCT05825638|Other|Continuous training session|Continuous training consists of a 5 minute warm up, 5 minute cool down and 20 minutes of moderate intensity work. The workload is set at 60% of the patient's maximum power
76089676|NCT05825638|Other|Interval training session|Interval training consists of a 5-minute warm-up, a 5-minute cool-down and 20 minutes of alternating 60 seconds of high-intensity work (100% of the maximum power recorded in the incremental test that was carried out when the patient was admitted to the pulmonary rehabilitation department) and 60 seconds of unloaded pedalling or rest.
76089677|NCT05825599|Device|Hydroxypropyl methylcellulose eye drops|Hydroxypropyl methylcellulose (HPMC)-based eyedrops
76089678|NCT05825586|Device|Distilled waters based eye drops|Distilled Waters (DW)-based eyedrops
76089679|NCT05825560|Drug|OFA multimodal analgesia|Multimodal opioid free analgesia
76089680|NCT05825560|Drug|Standard multimodal analgesia|Standard remifentanil analgesia
75801113|NCT03768804|Other|SyncAV algorithm on|"Cardiac Resynchronisation Device will be set to have the SyncAV algorithm on for the duration of the cardiopulmonary exercise test (CPET), before being reset to pre-existing settings"
75801114|NCT03768804|Other|SyncAV algorithm off|ardiac Resynchronisation Device will be set to have the SyncAV algorithm off and a fixed AV delay, for the duration of the CPET, before being reset to pre-existing settings
75939504|NCT03030599|Other|Placebo|Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial [United States Pharmacopeia/ National Formulary])
75939505|NCT04512521|Drug|Mepolizumab|Mepolizumab therapy
75939506|NCT03692195|Device|WHOOP Strap 2.0|The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.
75939507|NCT03692195|Other|No Device|The WHOOP Strap 2.0 is not worn on the wrist for a seven day period.
75939508|NCT04499807|Other|AFib detection with wearable smart watch|Patients will transmit two rhythm strips every day through both the devices and additional transmission whenever they have symptoms (palpitations, skipped beats, shortness of breath and chest pain). The transmitted rhythm strips are de-identified and analyzed after assigning a unique ID for research purposes.
75939509|NCT03700463|Other|BRIEF parental survey|Estimate incidence of executive functions disorders in preterm children in 3 to 4 year old, born less than 34 weeks of gestation
75939510|NCT03696641|Other|glazed lithium disilicate crowns|glazing of IPS e.max crowns
75939511|NCT03696641|Other|polished lithium disilicate crowns|polishing of IPS e.max crowns
76089681|NCT05825547|Procedure|Cryotherapy treatment|Cryotherapy treatment administered by an interventional radiologist: the cryotherapy needle is placed under local anesthesia, ultrasound monitoring in real time. A complete cryotherapy cycle is performed with: freezing until the entire tumor is frozen as judged by ultrasound, then thawing for the same duration and refreezing according to the same principle.
76089682|NCT05825508|Device|ankle robot|home ankle robot and video game
76089683|NCT05825482|Procedure|Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 1 randomization, the surgeons will be instructed to perform a partial mastectomy with routine cavity shave margins using Savi Scout® localization. The lesion will be removed in the routine fashion. The surgeons will use the Savi Scout® to perform routine cavity shave margins by extracting superior, lateral, inferior, medial, anterior, and posterior margins.
76089684|NCT05825482|Procedure|Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 2 randomization, the surgeons will be instructed to perform a partial mastectomy with selective margins shave margins using Savi Scout®. The lesion will be removed in the routine fashion. The Savi Scout® localizer will be utilized to determine selective shave margins by examining the same margins on the excised tissue specimen. The surgeon will obtain selective margins if the margin of the tissue specimen is within 1mm of invasive cancer and 2mm within DCIS.
75653682|NCT00827671|Drug|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
76089685|NCT05825456|Procedure|endoprosthetic reconstruction|This is a type of surgery in which the affected part of the bone and joint is removed, and replaced by a prosthesis.
75939512|NCT03696563|Device|Automated oxygen administration - FreeO2|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.
75801115|NCT03763344|Behavioral|Perceptual Cognitive Training (PCT)|Perceptual Cognitive Training (PCT) will be performed by having individuals work with a visual perceptual training software program called NeuroTracker. This device uses Multiple Object Tracking at increasing difficulties to develop high-level brain functions critical to recovery & cognitive health. By increasing in difficulty with each correct response and decreasing in difficulty when mistakes are made, brain function is constantly challenged. Each session (6 mins) delivers a series of mini-tests where the patient needs to remember key targets, then track them moving among distractors for several seconds and then identify them. Simple to do, but always challenging, NeuroTracker adaptively optimizes difficulty to each patient's level, maximizing cognitive stimulation every step of the way.
75939513|NCT03696563|Other|Standard administration of oxygen flow|The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
75475997|NCT02001844|Device|placebo foot orthoses (FOs)|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
75801116|NCT03763266|Other|1 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
75653683|NCT00827671|Radiation|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
75653684|NCT03909971|Drug|Lorlatinib|ALK inhibitor-treated ALK-positive NSCL treatment
75653685|NCT00823537|Procedure|therapeutic electrical stimulation|
75653686|NCT03473483|Other|SREC|"The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices.~Tank:~Sealed and disposable~Minimum 350 puffs per tank~Volume of e-liquid per tank ~ 3ml~E-Liquid Characteristics:~Tobacco flavored~Nicotine concentration: 15 mg/ml~Propylene Glycol:~ 50% (wt / wt)~Glycerin: ~ 50% (wt / wt)~Cotinine: <1 μg/g~Nornicotine: 5 μg/g~Myosmine : 3 μg/g~Anabasine: <1 μg/g~Anatabine: <1 μg/g~Beta:nicotyrine: <1 μg/g~Diacetyl: <2 μg/g~2,3:Pentanedione: <1 μg/g~Arsenic: <0.1 μg/g~Cadmium: <0.1 μg/g~Chromium: <0.1 μg/g~Lead: <0.1 μg/g~Nickel: <0.1 μg/g~Mercury: <0.05 μg/g"
75653687|NCT00819481|Device|3DKnee™ System|Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
75801117|NCT03763266|Other|3 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
75801118|NCT03763188|Other|Use of daily urinary urea excretion|Weaning dialysis catheter
75801119|NCT03771690|Behavioral|Standardised meal|A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
75801120|NCT03763110|Device|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye [named photosensitizer PS] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
75801121|NCT03763110|Drug|antibiotic paste|"An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996"
75801122|NCT03772002|Diagnostic Test|HCV screening|HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
75801123|NCT03771924|Dietary Supplement|inorganic phosphate|Sodium phosphate
75939514|NCT03624647|Device|Power toothbrush|Experimental power toothbrush
75939515|NCT03624647|Device|Manual toothbrush|Marketed manual toothbrush
75939516|NCT03624257|Device|Laser treatment|The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
75939517|NCT03624257|Procedure|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
75801124|NCT03771924|Dietary Supplement|placebo|Sodium chlorid
75801125|NCT03771768|Radiation|Diode laser 980nm&100 mWatt|Diode laser 980 nm &100 milli Watt.
75801126|NCT03771768|Drug|Triamcinolone Acetonide|0.1 &5gm paste 4 times/day
75343237|NCT06213727|Drug|lowe-dose ZKY001 eye drops|eye drops
75653688|NCT02550145|Drug|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
75653689|NCT02550145|Other|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
75653690|NCT00823693|Drug|Bimosiamose Cream|
75801127|NCT01567566|Other|exercise rehabilitation program|6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
75801128|NCT03772080|Other|Early counseling of prematurity in high-risk pregnancies.|Standardized information regarding prematurity, including associated complications and ways to decrease chances of preterm birth using web-based educational platform.
75801129|NCT03771456|Procedure|Colorectal resections|Colorectal resections
75343238|NCT06213727|Drug|Medium-dose ZKY001 eye drops|eye drops
75343239|NCT06213727|Drug|ZKY001 simulated eye drops|eye drops
75475998|NCT02001857|Drug|1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.|at the end of surgery
75653691|NCT00823693|Drug|Placebo Cream|
75653692|NCT03643133|Drug|Mifamurtide|48 doses overall over 36 weeks
75653693|NCT03643133|Combination Product|EI or M-API regimen depending on patient age|"M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days"
75653694|NCT00827749|Device|respiratory plethysmography by inductance|contribution of respiratory plethysmography by inductance and informatic tool
75801130|NCT03771378|Drug|rhTPO|After enrollment, all subjects receive TPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
75801131|NCT03771378|Drug|eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd. blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
75801132|NCT04379700|Procedure|Transcatheter arterial embolization|Transcatheter arterial embolization of one or more genicular artery(ies) using Embozene™ Color-Advanced Microspheres. Embozene™ Color-Advanced Microspheres are spherical, tightly calibrated, biocompatible, non-resorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer used for embolization.
75653695|NCT00967343|Biological|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
75653696|NCT00973973|Drug|Placebo|Matching placebo tablets taken orally once a day
75653697|NCT00973973|Drug|Elagolix|Immediate release (IR) tablets taken orally once a day
75801133|NCT04379700|Device|Embozene™ Microspheres|Embozene™ Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer (Polyzene™-F). The microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue. They are available in prefilled syringes in a range of sizes suitable for embolic therapy. The microspheres are compressible to enable smooth delivery through the indicated delivery catheter and color-coded by size to allow for easy identification. 250 μm microsphere will be used and are supplied in prefilled yellow syringes.
75801134|NCT03771534|Drug|Oxygen gas|Brief maternal administration of 65-70% O2 via a face mask during the last trimester
75801135|NCT03762798|Device|The Bridge|The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
75801136|NCT03762720|Device|Physium treatment|patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for one month in muscle injury and diagnosed by ultrasound and Shear Wave Elastography.
75801137|NCT03762642|Procedure|Mastectomy|Removal of the whole breast
75801138|NCT03762642|Procedure|Breast-Conserving Surgery|Removal of the cancerous tissue only
75801139|NCT03771300|Behavioral|Mindfulness|This program is structured around two central elements, mindfulness and compassion. The sessions combine theory and practice components, using a methodology which priorities the reflection and debate among the students. Regarding theory component, mindfulness and compassion concepts will be set out over the length of the program, in addition to others related to time management, stress, anxiety and the balance between personal life and academic/work life. The practical component of the program consists of mindfulness and self-compassion formal and informal practices under the guidance of a specialized instructor.
75939518|NCT03624569|Other|Bagel|A bagel will be consumed daily for 2 weeks.
75939519|NCT03624569|Other|Potato|A potato will be consumed daily for 2 weeks.
75939520|NCT03700307|Procedure|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.
75939521|NCT03696329|Drug|Tetrabenazine Tablets 25 mg|
75939522|NCT03696173|Other|Non-Interventional|Non-Interventional
75939523|NCT03696173|Other|Non-Interventional|Non-Interventional
75939524|NCT03696095|Drug|Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)|programmed intermittent bolus 5ml each one hour.
75939525|NCT03696095|Drug|Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)|continuous infusion 6ml/h
75939526|NCT03700229|Drug|Bortezomib|Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses
75801140|NCT03771300|Behavioral|Mindfulness condition complemented by VR|"The VR is comprised of a Samsung VR goggles, a Samsung Galaxy S6 phone and optional headphones.~In this condition, the instructor is the same as previously but the implementation of VR will be carried out by a psychologist specially trained for the application of these VR scenarios. Prior to the VR use, the psychologist will make sure about the participants´ health."
75343240|NCT06213714|Device|5G Tele-Robotic-Assisted PCI|The 5G Tele-Robotic-Assisted VRS100 system is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
75343241|NCT06213701|Device|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
75343242|NCT06213701|Other|Psychoeducation app|Psychoeducation app
75343243|NCT06213688|Other|blood sampling|blood sampling at inclusion
75343244|NCT06213688|Other|urine sampling|urine sampling at inclusion
75653698|NCT00633139|Biological|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
75653699|NCT04044235|Behavioral|PrEP Cohort|AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
75653700|NCT00827905|Device|RSpot Non-Contact Respiratory Rate Spot Check|The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
75801141|NCT03771300|Behavioral|Relaxation|This condition is based on the Progressive Muscle Relaxation.The relaxation program include training 16 muscle groups during the initial sessions, 7 muscle groups during the intermediate sessions, 4 muscle groups later and a only recall relaxation in the final session.This program is complemented with visualizations, as it was originally proposed by Jacobson (1938).
75801142|NCT03768258|Drug|Testosterone Implant|Testosterone implants or combination testosterone + anstrozole implants used to treat symptoms of hormone/androgen deficiency
75801143|NCT03771222|Biological|Prophylactic DLI|The G-CSF-mobilized PBSCs from cryopreserved cells of the graft were infused to the recipient at a dose of 2X10^7 CD3+ cells/kg recipient body weight. Decitabine (10 mg/m2, days 1 to 5) followed by prophylactic DLI would be given to those patients carrying TET2, DNMT3a or TP53 gene mutations.
75801144|NCT03770988|Drug|Treatment with Poziotinib|Treatment with Poziotinib
75801145|NCT04018248|Drug|BR101801 (Phase Ia)|Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
75801146|NCT04018248|Drug|BR101801 (Phase Ib)|Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
75801147|NCT03762486|Other|TENS|4 electrodes were placed 2-3 cm lateral to the incision of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
75801148|NCT03762486|Other|TAES|4 electrodes were placed at the ST25, P6, ST36, and LI4 acupuncture points of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
75801149|NCT03762408|Device|ENKO 1|50 mg of HA/ 50 mg of CS in 5 ml
75801150|NCT03762408|Device|Durolane|60 mg HA crosslinked in 3 ml
75801151|NCT03770910|Other|GIP receptor antagonist|GIP receptor antagonist
75801152|NCT03770910|Other|GIP receptor agonist|GIP(1-42)
75801153|NCT03770910|Other|Saline|Placebo (vehicle for infusions)
75801154|NCT03771066|Behavioral|bisphenol A|Vanilla wafer cookie with bisphenol A administered
75801155|NCT03771066|Behavioral|Placebo|Vanilla wafer cookie with no bisphenol A
75801156|NCT03627754|Drug|Glasdegib 100 mg single oral dose|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.
75801157|NCT03762330|Behavioral|COPD structured self-management plan.|Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations
75801158|NCT03762252|Other|Dry needling|A solid filiform needle will be inserted over active trigger points in the scalene muscles for 30 seconds. The aim will be to elicit local twitch responses or the referred pain pattern of the scalene muscles.
75801159|NCT03762252|Other|Manual Therapy|The therapist will apply manual compression over active trigger points in the scalene muscles for 30 seconds
75939527|NCT03700229|Drug|Rituximab|rituximab intravenously 500 mg for one dose
76089686|NCT05825456|Procedure|Intramedullary nailing|This is a type of surgery in which the affected bone is stabilized by a nail. The affected part could be removed or retained. If removed, the defect is filled with bone cement.
75343247|NCT06213662|Drug|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
75801160|NCT03627676|Procedure|Cryoablation|Two percutaneous cryoprobes would be used for all patients. The 17-Gauge cryoprobes is introduced into the masses under US guidance. Mean distance to the skin has to be 5mm at least. Although US guidance is used, a non-enhanced CT scan may be used to assess the position of the cryoprobes before ablation, and to obtain a baseline examination in order to avoid thermal injuries to adjacent tissues such as the bowel during the ice growth. No ice extension to the skin has to be observed during cycles assessed by real-time US monitoring. Each cryoablation procedure involves 3 successive cycles: 10 minutes freeze with Argon gas, followed by 9 minutes passive and 1 minute active thawing with Helium gas, followed by a second 7 minutes freeze. The ice covered the entire targeted lesion on the short axes is visualize by US or CT-scan performed at the end of the three cycles or after repositioning. At the end of the cryoablation procedures, the probes are removed through active thawing.
75343248|NCT06213610|Drug|Perindopril tablet|Perindopril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril tert-butylamine.
75343249|NCT06213610|Drug|Prestarium® A tablet|Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.
75343250|NCT06213584|Other|conservative rehabilitation|Hotpack + TENS + streching exercises
75343251|NCT06213584|Other|mullgan mobilization techniques|Passive mobilization techniques during active movements
75653701|NCT02549521|Dietary Supplement|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
75653702|NCT02549521|Dietary Supplement|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
75653703|NCT02864615|Radiation|SBRT|Dose and schedule will be depended on metastases location.
75653704|NCT00823849|Drug|Cilostazol|From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
75801161|NCT03761940|Other|EQ5D questionnaire and a demographic questionnaire|questionnaires
75801162|NCT03768024|Drug|GRT0151Y 50 mg capsule|GRT0151Y 50 mg capsule
75801163|NCT03768024|Drug|Hydromorphone IR 4 mg|Hydromorphone IR 4 mg tablet (encapsulated)
75343252|NCT06213584|Other|pnf|hold relax active movements
75801164|NCT03768024|Drug|Matching placebo|Matching placebo
75939528|NCT03700151|Behavioral|Treatment for Children with Severe Speech Sound Disorders|The intervention has two tasks, including syllable repetition tasks which requires participants to repeat nonsense syllables, and training of vocabulary or phrase with the application of Principle of Motor Learning.
75939529|NCT03619343|Procedure|ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
75939530|NCT03692117|Device|Extracorporeal Carbon Dioxide Removal|Place a double lumen catheter in jugular vein, drainage the venous blood in vitro tube, after blood-gas exchange and remove CO2, then return back to the Superior vena cava
75939531|NCT03700073|Other|Experimental group (GTVR)|Gait training with a robotic system (CL1Walker) combined with immersion in a Virtual Reality program
75939532|NCT03700073|Other|Control group (GT)|Gait training with a robotic system (CL1Walker) alone.
75939533|NCT03692039|Procedure|M-pro files in rotating motion|An endodontic file that has controlled memory properties
75653705|NCT00823849|Drug|Probucol|250 mg Bid, PO after breakfast and dinner.
75653706|NCT00823849|Drug|Cilostazol+Probucol|
75801165|NCT01567644|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
75939534|NCT03692039|Procedure|ProTaper Next files in rotating motion|An endodontic file that has an off center mass of rotation
75343253|NCT06213571|Other|Exercise Counseling|Participate in exercise coaching sessions
75343254|NCT06213571|Other|Exercise Intervention|Participate in home-based exercise program
75939535|NCT03695861|Diagnostic Test|Whole-body 18F-FDG PET-CT scan|A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
75939536|NCT04311749|Genetic|Expanded panel cell free DNA testing (non-invasive prenatal testing)|Maternal blood sampling
75343255|NCT06213571|Other|Health Promotion and Education|Receive resistance band and exercise booklets
75343256|NCT06213571|Other|Interview|Ancillary studies
75343257|NCT06213571|Other|Physical Performance Testing|Ancillary studies
75653707|NCT00823849|Other|Control Group|Routine treatment
75653708|NCT02864459|Other|Muscular ultrasound|Muscular ultrasound is done before extubation
75653709|NCT04284683|Other|DRINK - Water, Protein, Fat, Carbohydrate|Following exercise participants will consume a drink (with different composition in each visit) and than RMR will be evaluated.
75653710|NCT02550067|Drug|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
75653711|NCT02550067|Drug|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
75653712|NCT02550067|Drug|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
75801166|NCT03767790|Device|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
75801167|NCT03999684|Drug|Tretinoin|ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
75939537|NCT04311749|Genetic|Placental biopsy|Post-delivery placental sampling
75653713|NCT03873935|Other|Evaluation of periodontal status|Clinical examination
75939538|NCT04311749|Genetic|Umbilical cord blood|Post-delivery umbilical cord blood sampling
75653714|NCT02862509|Drug|Budesonide nasal instillation|
75801168|NCT02083354|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
75801169|NCT02083354|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
75801170|NCT03761862|Procedure|Neural Therapy|Neural therapy is a form of alternative medicine in which local anesthetic is injected into certain locations of the body in an attempt to treat chronic pain and illness.
75343258|NCT06213571|Other|Questionnaire Administration|Ancillary studies
75939539|NCT03695705|Drug|Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day|Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
75939540|NCT03695627|Behavioral|Meditation|10 minute a day, 8 week digital meditation
75653715|NCT02862509|Drug|Normal saline nasal instillation|
75653716|NCT02550379|Behavioral|Intervention|Emotion Recognition Training
75343259|NCT06213571|Other|Telemedicine|Participate in sessions remotely
75343260|NCT06213558|Device|Rectangular and square striaght archwire technique|The Effect of Rectangular Versus Square Archwire on Maxillary Canine Retraction
75343261|NCT06213545|Diagnostic Test|In-clinic interpretation|Reading patch test result at clinic
75343262|NCT06213545|Diagnostic Test|Photo interpretation|Reading patch test result by sending photo to clinic
75343263|NCT06213532|Behavioral|Smoking Cessation Intervention|Multimedia program administered either remotely or in person
75653717|NCT02550379|Other|Placebo|Placebo Training
75653718|NCT04285775|Device|Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)|A stand-alone disc-shaped device (approximately 5 cm in diameter and <1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.
75801171|NCT04230486|Device|Cross-model Visual Auditory Rehabilitation|Subjects will put on a virtual reality rehabilitation system which will present sights and sounds.
75801172|NCT01399918|Drug|everolimus and bevacizumab|Cycle length will be defined as 28 days. Treatment will include everolimus 10mg, self administered orally once daily on a continuous schedule (days 1-28), and bevacizumab 10mg/kg, administered intravenously on days 1 and 15 of each cycle. Treatment will be continued until disease progression, major toxicity, or withdrawal from the study for any reason. Dose modification will be permitted based on toxicity. Patients that come off study before 6 months before documented progression/death will be treated as events for the 6 month PFS endpoint.
75801173|NCT03770754|Procedure|Clean and shape Control group|"For the control group the root canals were prepared manually with K-files and step back technique up to size #35. For this group were administered Tylenol"
75801174|NCT03770754|Procedure|Cleand and shape Group 1|For the Group 1, LightSpeed LSX rotary instruments (Discus Dental, Culver City, CA, USA) were used to complete the canal preparation to a size #50 for the anteriors and molars to size #40. After procedures were administered Tylenol
75801175|NCT03770754|Procedure|Clean and shape Group 2|"For the group 2 the root canals were instrumented with ProTaper ﬁles using X1, X2 (21mm) to X3 (21mm). 0.5% NaOCl was used for irrigation, the original protocol suggested by ProTaper for permanent teeth was simplified for this study.~After clinical procedures Tylenol were administered"
75801176|NCT03761628|Device|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of VVC
75801177|NCT01034254|Biological|influenza vaccine|Pregnant women will receive FDA approved influenza vaccine.
75801178|NCT01034254|Biological|saline placebo|Vaccination of pregnant women with saline placebo.
75343264|NCT06213532|Other|Saliva Collection|Saliva samples will be collected from each participant
75343265|NCT06213532|Other|Survey Administration|Ancillary studies
75343266|NCT06213519|Drug|S-1, Oxaliplatin sintilimab HIPEC|"Exploratory laparoscopy or laparotomy~SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA < 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~Another 3-cycle SOX regimen of systemic chemotherapy.~After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity."
75653719|NCT02864537|Other|Training|Patients were trained to measure INR and dose warfarin
75801179|NCT03761472|Biological|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2.4 ml solution
75801180|NCT03761472|Biological|Platelet-rich plasma injection|Platelet-rich plasma injection 5ml
75801181|NCT03767556|Procedure|Inspiratory muscle training|Powerbreathe® K5
75801182|NCT03767400|Device|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.
75801183|NCT03767400|Other|Facial Cleanser|Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
75801184|NCT03767322|Drug|Allopurinol|Eligible patients will receive allopurinol 300 mg before and after coronary intervention
75801185|NCT03767322|Drug|Febuxostat|Eligible patients will receive febuxostat 80 mg before and after coronary intervention
75653720|NCT04285619|Other|Positive expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the investigator will induce the positive expectation through a standardized phrase for all subjects"
75801186|NCT03767322|Drug|Placebo|Eligible patients will receive before and after coronary intervention
75801187|NCT01321320|Other|Active muscle stimulation|Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).
75801188|NCT03770520|Procedure|QFR-guided CABG|CABG surgery based on CAG and QFR
75801189|NCT03770520|Procedure|Angio-guided CABG|CABG surgery based on heart team discussion of CAG
75801190|NCT03767088|Device|WB-EMS|whole body electromyostimulation
75801191|NCT03767088|Other|(synchronized) Training program without WB-EMS|20 min of pronounced eccentric movement patterns
75475999|NCT02001870|Procedure|In Vitro Fecundation (IVF)|In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
75801192|NCT03761316|Other|interview regarding goals|interview regarding goals
75801193|NCT03761238|Device|Molecular Adsorbent Recirculating System|MARS therapy will start within 24-48 h after randomization and be given on 3 consecutive days in sessions of 8-12 h. The patients are observed for 2 days following the last session, with focus on bilirubin INR and signs of encephalopathy, and can thereafter receive 3 additional sessions in case of no or partial response to treatment.
75801194|NCT03761238|Other|Standard medical treatment (SMT)|Patient management and standard medical treatment (SMT) as specified in the study protocol.
75801195|NCT03570996|Procedure|Esophagectomy|"Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal"
75939541|NCT03699839|Biological|High-dose influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
75939542|NCT03699839|Biological|MF59-adjuvanted influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
75939543|NCT03699839|Biological|Standard intramuscular influenza vaccine|The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
75939544|NCT04050215|Procedure|Computed Tomography|Undergo PET/CT
75939545|NCT04050215|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
75939546|NCT04050215|Procedure|Positron Emission Tomography|Undergo PET/CT
75939547|NCT04050215|Other|Questionnaire Administration|Ancillary studies
75939548|NCT03699683|Other|Combined aerobic and resistance training program|
75939549|NCT03691805|Device|tDCS|The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
75939550|NCT03691805|Device|Sham tDCS|The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
75939551|NCT03699605|Other|VESMP|. The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.
75939552|NCT03699605|Other|Traditional Therapy|, All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
75939553|NCT03695549|Procedure|CAF + (A-PRF)|advanced platelet rich fibrin prepared by low speed centrfugation concept(LSCC) together with coronally advanced flap .
75939554|NCT03695549|Procedure|CAF+SCTG|cornally advanced flap plus subepithilial connective tissue graft harvested from the palate
75939555|NCT03699527|Behavioral|Multiple questionnaires administered|This is an observational trial
75939556|NCT04478123|Drug|Romiplostim|Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is >50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
75939557|NCT03699449|Drug|olaparib+cediranib combination therapy|Cediranib (30mg p.o. qd) + Olaparib (200mg p.o. bid) until disease progression
75939558|NCT03699449|Drug|durvalumab + olaparib combination therapy|Durvalumab (1500mg i.v. every 4 weeks starting on week 5 day1 for up to 12 months) + Olaparib (300mg p.o. bid) until disease progression
75476000|NCT02001870|Procedure|Intra Uterine Insemination (IUI)|Intra-uterine insemination will be performed according to the usual procedure of each ART center
75476001|NCT02001883|Drug|Association low-dose statin and nutraceuticals|
75476002|NCT02001896|Drug|gemcitabine; cisplatin or carboplatin; erlotinib|
75476003|NCT02001896|Drug|erlotinib|
75939559|NCT03699449|Drug|durvalumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 6 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
75939560|NCT03699449|Drug|durvalumab + tremelimumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (75mg i.v. every 4 weeks for up to 4 doses) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin (PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
75343267|NCT06213506|Biological|Measles and Rubella vaccine|Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
75653721|NCT04285619|Other|Neutral expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the researcher will not induce any expectations to the athletes."
75801196|NCT03570996|Procedure|Transversus abdominis plane catheter|TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine
75801197|NCT03570996|Procedure|Epidural|Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
75653722|NCT00965081|Drug|Duloxetine|30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
75653723|NCT00965081|Drug|Placebo|QD po at the same time each day for 12 weeks
75801198|NCT03770442|Device|Cycling with FES|As described already
75801199|NCT03770442|Other|Routine physiotherapy|As described already
75801200|NCT03519048|Procedure|Nasofibroscopy|every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter
76089687|NCT05825456|Procedure|Open reduction internal fixation with plate and screws|This is a type of surgery in which the affected part of the bone is visualized completely, after the reduction is achieved, the fixation is provided with appropriate plates and screws. Again the affected part could be removed or retained. If removed, the defect is filled with bone cement.
76089688|NCT05825378|Drug|Dexamethasone 8mg+0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml of a mixture of 0.375% ropivacaine and 8 mg dexamethasone was injected at each point
76089689|NCT05825378|Drug|0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml 0.375% ropivacaine was injected at each point
76089690|NCT05825339|Diagnostic Test|Coronary Flow Reserve|Diagnostic of Microvascular Coronary Dysfunction using continuous thermodilution flow reserve
75939561|NCT03699449|Drug|durvalumab + tremelimumab + paclitaxel treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (300mg i.v. once) + non-platinum-based standard of care chemotherapy (weekly paclitaxel up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 60mg/m2 (day 1,8,15 every 4 weeks)"
76089691|NCT05825313|Behavioral|Podcast Using|Students in the experimental group listened to podcast episodes any time they desired following the course every week during the semester from February 2021 to June 2021.
76089692|NCT05825287|Other|Trained by teaching back method|in chemotherapy symptom management training, 2 groups will be created and a group will be given normal symptom management training, and the other group will be trained by teaching back method to assess the symptom control and quality of life after the chemotherapy training that patients have received and evaluate the effect of the teaching back method
76089693|NCT05825287|Other|Management training|Management training
76089694|NCT05825274|Device|Cathodal tDCS|We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
76089695|NCT05825248|Other|Fine and gross motor treatment only|occupational therapy intervention involving general fine and gross motor activities
76089696|NCT05825248|Other|Reflex integration + fine and gross motor treatment|occupational therapy intervention involving general fine and gross motor activities as well as targeted reflex integration exercises
76089697|NCT05825196|Diagnostic Test|tumor tissue and blood tests|In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
75653724|NCT00961649|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
75653725|NCT00961649|Drug|Brinzolamide ophthalmic suspension, 1%|
75653726|NCT00961649|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
75653727|NCT00961649|Other|Vehicle|Inactive ingredients used as placebo
75653728|NCT04267601|Drug|Anagliptin|Anagliptin treatment for 24weeks
75939562|NCT03699449|Drug|durvalumab +chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
75343268|NCT06213506|Biological|Yellow Fever vaccine|Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
75801201|NCT03519048|Other|Low Dose Chest CTscan|every year in patients with tobacco consumption history of > 20 pack-year
75343269|NCT06213506|Biological|Pentavalent vaccine|Pentavalent vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
75343270|NCT06213506|Biological|Pneumococcal vaccine|Pneumococcal vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
75801202|NCT03519048|Other|injected CT-scan|the first performed 12 months after inclusion
75653729|NCT04284917|Drug|Carglumic Acid (Carbaglu®)|"A. Study period: 24 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12. (Check Plasma Amino Acid Analysis, Ammonia, acylcarnitine profile, Urinary organic acid analysis.)~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis will be recorded during treatment period."
75653730|NCT02861261|Drug|1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder|"0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~4g (2 strips) of ProMetS probiotics powder administered orally every night"
75653731|NCT02861261|Drug|1. Berberine placebo tablets ; 2. ProMetS probiotics powder|"6 pills of Berberine placebo tablets administered twice a day orally before meal;~4g (2 strips) of ProMetS probiotics powder administered orally every night"
75653732|NCT02861261|Drug|1. Berberine hydrochloride tablets; 2. Probiotics placebo powder|"0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2 strips of probiotics placebo powder administered orally every night"
75653733|NCT02861261|Drug|1. Berberine placebo tablets; 2. Probiotics placebo powder|"6 pills of Berberine placebo tablets administered twice a day orally before meal;~2 strips of probiotics placebo powder administered orally every night"
75653734|NCT04283435|Drug|Sildenafil Citrate|Sildenafil Citrate 50 mg tablets taken from the first day of the cycle till the day we start progesterone (we stop 3 days before embryo transfer)
75801203|NCT03519048|Other|whole body PET-CT|annual whole body PET-CT (the first at 6 months after inclusion)
75939563|NCT03028415|Device|AMPLEX|A bone graft substitute
75939564|NCT03028415|Procedure|Autogenous Bone Graft (ABG)|Control material administered by surgical implant
75476004|NCT02001909|Drug|Regorafenib (Stivarga, BAY73-4506)|single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
75476005|NCT02001909|Drug|Neomycin|1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
75653735|NCT04283435|Other|Placebo|Placebo tablet (multivitamins),Pregnacare vitamins (Vitabiotics,UK)
75653736|NCT04283435|Drug|Estradiol Valerate|Estradiol valerate tablets 2mg every 8 hours daily starting from the fist day of the cycle till 12th day of the menstrual cycle.
75939565|NCT04477577|Behavioral|New Parent Intervention|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional active and targeted engagement of new parents by a health coach.
75653737|NCT04265885|Other|collection of testimonies from transgender people|guided interview
75653738|NCT00632125|Drug|HX575 recombinant human erythropoietin alfa|HX575 epoetin alfa i.v. will be administered according to the SmPC
75801204|NCT03519048|Procedure|Lugol upper gastrointestinal endoscopy|the first performed 12 months after inclusion
75801205|NCT03519048|Procedure|Biopsy|In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
75801206|NCT03761004|Drug|carbidopa-levodopa|single dose of WD-1603, BID dose of WD-1603 and Sinemet IR
75801207|NCT03770208|Drug|Intervention: Lidocaine|IV Lidocaine bolus plus infusion. Weight based.
75801208|NCT03770208|Drug|Control: Standard Care + Placebo|Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
75801209|NCT03766854|Drug|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks
75801210|NCT03766854|Drug|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
75801211|NCT03766776|Drug|Anlotinib|Anlotinib capsules: dosage of 12 mg PO qd, 14 days, 7 days, 21 days for a cycle. The dosage was adjusted according to the adverse reactions of patients.
75939566|NCT04477577|Behavioral|Safety Control|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional infant safety education materials.
76089698|NCT05825157|Device|BioBridge|Fibralign BioBridge is a thread-like, multi-lumen scaffold consisting of highly aligned collagen fibrils, optimized to encourage the endothelial cell attachment,alignment and migration that are prerequisites to new vessel formation. BioBridge is a device made from highly purified, medical-grade porcine collagen.
76089699|NCT05825144|Device|Robotic exoskeleton-assisted gait rehabilitation|Use a robotic exoskeleton for gait rehabilitation in addition to conventional rehabilitation
75939567|NCT03699371|Procedure|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU. Central venous catheter placement would not be assessed as a part of intervention due to the fact that it is a part of routine medical activities performed during admission to ICU.
75939568|NCT04475939|Drug|Niraparib|Niraparib will be administered
76089700|NCT05825144|Other|Conventional rehabilitation|Regular post-stroke rehabilitation
76089701|NCT05825118|Diagnostic Test|Neutrophil/Lymphocyte ratio and lactate/ albumin ratio will be measured in all patients.|Blood will be drawn from peripheral vein, arterial or a central catheter for evaluation of whole blood count, serum lactate and serum albumin.
76089702|NCT05825053|Behavioral|Gait adaptability training|Over a span of 1 year participants will receive 3 one hour, single sessions at 3, 6 and 9 months following baseline assessment, of gait adaptability training, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be trained.
76089703|NCT05825053|Behavioral|Home-based exercise training|Participants will receive tailored exercise through an online platform targeting gait adaptability. Participants are instructed to train at a minimum of 60 minutes per week, with a frequency of 2 sessions per week. Participants will be supported through tele-consultations on a monthly basis for the first 3 months and bi-monthly for the remaining time of the study. These consultations are focused on technical support, on ways to ensure training progression and to encourage adherence to the program.
76089704|NCT05824949|Procedure|osseodensification drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the osseodensification protocol.
75343271|NCT06213506|Biological|Inactivated polio vaccine|Inactivated polio vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
75343272|NCT06213506|Biological|iNTS-GMMA Dose C|-2 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1 and Day 57 to adults and children in the Adults_Dose C and Children_Dose C groups; -3 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants_9M_Dose C group, and at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants_6W_Dose C and Infants_6W_Dose C_2 groups.
75476006|NCT02001922|Other|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
75653739|NCT00819559|Radiation|PCRT|Preoperative chemoradiotherapy
75653740|NCT00903968|Drug|Plerixafor|
75653741|NCT00903968|Drug|bortezomib|
75653742|NCT00903968|Drug|Dexamethasone|
75653743|NCT04220450|Diagnostic Test|T1 mapping on Cardiovascular Magnetic Resonance Studies|On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined
75653744|NCT00632606|Drug|magnesium sulfate|magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
75801212|NCT01322100|Device|The Electroporation System|The Electroporation System comprises of 3 parts: 1.Switch Box, 2. Driver, 3. Brain Probe
75801213|NCT01322100|Drug|Bleomycin|Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.
75939569|NCT04475939|Drug|Pembrolizumab|Pembrolizumab will be administered
75653745|NCT00632606|Drug|metoclopramide|metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
75653746|NCT02602574|Other|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
75653747|NCT02849834|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
75653748|NCT02849912|Other|questionnaire|
75653749|NCT02849756|Other|older in intensive care unit|It is an observational study with no intervention.
75653750|NCT00903344|Drug|Vitamin D3|4000IU vitamin D3 tablet taken daily
75801214|NCT03760848|Drug|Aramchol|Aramchol 600 mg
75801215|NCT03760848|Drug|Midazolam|Midazolam 2 mg
75801216|NCT03760848|Drug|Atorvastatin|atorvastatin 40 mg
75801217|NCT01567488|Drug|Everolimus|Everolimus 10mg/day
75801218|NCT01567488|Drug|octreotide LAR|30 mg each 28 days
75939570|NCT04475939|Drug|Placebo|Matching placebo will be administered
75939571|NCT04475081|Biological|MMR vaccine|Merck MMR-II vaccine
75939572|NCT03699293|Drug|celecoxib 200mg capsule|celecoxib 200mg twice a day for 4 weeks
75939573|NCT03699293|Drug|naproxen sodium 550mg tablet|naproxen sodium 550mg twice a day for 4 weeks
75939574|NCT03699293|Drug|Aspirin 81mg tablet|81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
75939575|NCT03695003|Dietary Supplement|Cognivia|Cognivia is a trademarked sage/polyphenol combination dietary supplement from Nexira
75939576|NCT03695003|Dietary Supplement|Placebo|Placebo control capsules were prepared by Nexira also and are aesthetically identical to the Cognivia capsules
76089705|NCT05824949|Procedure|conventional drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the conventional drilling protocol.
76089706|NCT05824897|Other|Serum levels of vitamin D|Subjects in this study are grouped according to baseline serum levels of 25(OH)D. The serum level of total 25(OH)D ≥30ng/ml (75nM) is sufficient, 20-30ng/ml (50-75 nm) is insufficient, and less than 20ng/ml (50nM) is deficient.
76089707|NCT05824793|Combination Product|A-PRF+|A-PRF+ contributes to accelerating the healing process, more rapid revascularization, and reducing the risk of inflammation at the graft site. It leads to a decrease in the severity of postoperative complications. Many authors have mentioned platelet concentrates as an effective adjunction that improves the healing of hard and soft tissue and decreases pain, swelling, and trismus. However, there are still some controversial results in the literature. Recently, it has been demonstrated that the production of PRF with lower centrifugal force and lower centrifugal time has more potential to release several growth factors and facilitate more favorable healing at the site of the application when compared to standard PRF. Promoting the healing process after tooth extraction using A-PRF+ aims to manage patient discomfort as well as postoperation complications.
76089708|NCT05823844|Drug|Suvorexant|Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.
75939577|NCT02692040|Drug|G3215|Gut hormone analogue
76089709|NCT05823844|Drug|Placebo|The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
76089710|NCT05823831|Diagnostic Test|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire was used to assess children's social-emotional development.
75653751|NCT00903344|Dietary Supplement|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
75653752|NCT02847416|Device|BreatheMAX breathing device|
76089711|NCT05823831|Diagnostic Test|Brief Infant Sleep Questionnaire (BISQ) questionnaire|A brief Infant Sleep Questionnaire (BISQ) was used to assess children's sleep.
75653753|NCT02849444|Other|Anti-myeloma treatment at physician discretion|non Interventional Study
75801219|NCT03760770|Procedure|corneal collagen crosslinking|Crosslinking in patients with progressive keratoconus.
75801220|NCT01561794|Drug|Ciprofloxacin (Cipro, BAYQ3939)|"(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.~2) Hospital-acquired pneumonia (HAP): For the patient with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days."
75801221|NCT01322178|Drug|Cetuximab; mFOLFOX6|"Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1~Oxaliplatin: 85 mg/m2 iv gtt over 2 hours, D1; leucovorin: 400 mg/m2 iv gtt , D1; 5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h~repeated every two weeks for 4.5 months(9 cycles)"
75939578|NCT02692040|Drug|Placebo|0.9% saline
75939579|NCT05610670|Other|Questionnaire|The questionnaire will allow us to complete the information and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
75939580|NCT03029819|Behavioral|Mindfulness-based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).
76089712|NCT05823831|Diagnostic Test|Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire|A Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire was used to evaluate maternal social support.
75476007|NCT02001935|Drug|theophylline|After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
75653754|NCT02385812|Procedure|Low-dose computed tomography Annual scan x3|Annual scan x3
75653755|NCT02385812|Procedure|Low-dose computed tomography Baseline scan only|Baseline scan only
75653756|NCT02383160|Device|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
75653757|NCT02383160|Device|Sham device|Placebo device with no active therapy
75653758|NCT04466072|Diagnostic Test|Stool test for microbial analysis|Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.
75653759|NCT02847338|Drug|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
75653760|NCT02847338|Drug|Lisinopril|"Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm."
75653761|NCT02847338|Drug|Amiloride|Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
75939581|NCT03029819|Behavioral|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
76089713|NCT05823831|Diagnostic Test|Brief Symptom Inventory (BSI) questionnaire|A brief Symptom Inventory (BSI) questionnaire was used to evaluate psychological distress.
76089714|NCT05823662|Procedure|DJ stent|A 5 Fr DJ stent will be inserted and then removed after three weeks.
76089715|NCT05823662|Drug|Silodosin|Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
76089716|NCT05823363|Drug|Exparel with Bubivacaine|10ml Exparel mixed with10ml bupivicaine in vaginal cuff
76089717|NCT05823363|Drug|Bupivacaine only|20ml of Bubivacaine in the vaginal cugg
75476008|NCT02001948|Drug|intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg|
76089718|NCT05822076|Procedure|Paravertebral block (ropivacaine) left|Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
76089719|NCT05822076|Procedure|Paravertebral block (ropivacaine) right|Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
75939582|NCT03029819|Behavioral|Self-Help guide|Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).
76089720|NCT05821816|Device|tDCS|Use of Transcranial direct current stimulation for 20 minutes per day, 5 days a week, at 2mA
76089721|NCT05821816|Other|Conventional rehabilitative treatment|Physiotherapy treatment consisting in two treatments per day of 40 minutes each
76089722|NCT05821608|Other|Message variation 1|Message before call letting member know they will be called (variation 1)
75343273|NCT06213506|Biological|iNTS-GMMA Dose B|-2 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1 and Day 57 to children in the Children_Dose B group; -3 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants_9M_Dose B group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants_6W_Dose B and Infants_6W_Dose B_2 groups.
75343274|NCT06213506|Biological|iNTS-GMMA Dose A|3 doses of iNTS-GMMA Dose A vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants_9M_Dose A group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants_6W_Dose A and Infants_6W_Dose A_2 groups.
75343275|NCT06213506|Biological|MenACWY|-1 dose of MenACWY vaccine administered intramuscularly at Day 1 to adults in the Adults_Control group; -2 doses of MenACWY vaccine administered intramuscularly at Day 1 and Day 57 to children in the Children_Control B and Children_Control C groups, and at Day 1 and Day 85 to infants in the Infants_9M_Control A, Infants_9M_Control B and Infants_9M_Control C groups; -3 doses of MenACWY vaccine administered intramuscularly at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants_6W_Control A, Infants_6W_Control B, Infants_6W_Control C and Infants_6W_Control_2 groups. A 4th dose of MenACWY vaccine is administered after the trial ends, to infants in the aforementioned study groups, as per the licensed indication and in private vaccination settings.
75343276|NCT06213506|Combination Product|DTPa-HBV-IPV+Hib|1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants_9M_Control A, Infants_9M_Control B and Infants_9M_Control C groups.
75653762|NCT02847338|Drug|Chlortalidone|Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
75939583|NCT03029819|Drug|Nicotine Patch|Patch therapy (beginning the week before quit day) for participants who smoke >10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
75939584|NCT03105830|Drug|iv paracetamol|iv paracetamol
75939585|NCT03694769|Other|Semi-structured interview|One-hour interview with researcher
75939586|NCT03694769|Other|Drop attack diary|Diary of any drop attacks experienced within an 8 week period
75343277|NCT06213506|Drug|Placebo|1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults_Control group.
75653763|NCT02847104|Other|dynamic insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
75653764|NCT02847104|Other|static insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
75653765|NCT02849522|Procedure|Prostatic Artery Embolisation|"The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.~The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.~NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation."
75801222|NCT03766542|Device|Bi-level positive airway pressure with ventilatory support|Positive airway pressure will be applied in the experimental group through a oronasal interface, in ventilatory support mode (Bi-level) with a fixed backup rate.
75801223|NCT03766542|Device|continuous positive airway pressure without ventilatory support|Continuous positive airway pressure (CPAP) will be applied in the active comparator group through a oronasal interface.
75801224|NCT01321398|Other|Esophageal Pressure Monitoring|An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
75939587|NCT03162380|Other|Date collection|Date collection
76089723|NCT05821608|Other|Message variation 2|Message before call letting member know they will be called (variation 2)
76089724|NCT05821543|Drug|metformin+sibutramine|1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)
76089725|NCT05821543|Drug|sibutramine+ microcrystalline cellulose|1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
75343278|NCT06213493|Diagnostic Test|measurement of RNAs|RNAs will be measured in heart tissues and in peripheral blood mononuclear cells
75653766|NCT02849522|Procedure|TURP|Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.
75939588|NCT04465409|Device|Intrastromal implantation of CorVision bioengineered corneal inlay for correction of presbyopia.|Presbyopia is an age-related progressive loss of crystalline lens accommodation power resulting in the decreased ability to see near objects. CorVision® is a tissue-mimetic device primarily intended to be used as a corneal inlay in the management of presbyopia and low hypermetropia. The inlay is inserted into the patient's cornea via a minimally invasive laser pocket procedure to modify corneal surface topography and corneal optical performance.
75939589|NCT04440020|Other|Beverage of Olive Oil Leaves|Beverage of Olive Oil Leaves,Oleuropein
75939590|NCT04440020|Other|Mediterranean Diet|Mediterranean Diet ,for a personal nutrition with the same dietary habits
75939591|NCT03691415|Drug|BELKYRA Inj.|Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.
75343279|NCT06213480|Dietary Supplement|Synbiotic Group|"WBF-038: Noninfectious and nonhazardous lyophilized commensal bacteria (probiotics). Contains no genetically modified organisms (GMOs) and contains no animal ingredients or by-products, and were originally isolated from human sources. The (probiotic) strains are grown in a FDA registered food facility, adhering to Good Manufacturing Practice (GMP) conditions.~Probiotic Ingredients:~Clostridium butyricum WBSTR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WBSTR-0001, and Bifidobacterium infantis~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit & vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
75343280|NCT06213480|Other|Placebo Group|Ingredients: Chicory inulin and oligofructose (prebiotic fiber, hypromellose (vegetarian capsule), fruit & vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation).
75343281|NCT06213467|Device|diode laser 940nm|Exposure for the two implants was done at the same visit, with one implant being exposed using diode laser and the other implant using traditional method
75476009|NCT02001948|Drug|intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg|
75476010|NCT02001948|Device|standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland|electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure
75653767|NCT02849522|Procedure|Open prostatectomy|In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).
75653768|NCT02849522|Procedure|Laser prostate surgery|"This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses."
75653769|NCT02849366|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
75653770|NCT02849366|Biological|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
75653771|NCT02849288|Device|Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)|Automated Insulin Delivery System
75653772|NCT02846948|Other|Focused assessed echocardiography|Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
75653773|NCT02848976|Other|Re-training to effort (RE)|The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
75653774|NCT02847026|Biological|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
75801225|NCT03760614|Drug|Entinostat|Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
75801226|NCT03760614|Drug|FOLFOX regimen|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.
75801227|NCT03760536|Behavioral|16-week Exercise Rehabilitation Program for Breast Cancer Survivors|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
75801228|NCT03769974|Behavioral|Motor imagery|Two series of 30 seconds training of motor imagery in each manual engine gesture
75801229|NCT03769974|Behavioral|Action observation|Two series of 30 seconds training of action observation training in video format in each manual engine gesture
75801230|NCT03769974|Behavioral|Placebo intervention|Two series of 30 seconds of observation and imagination of a landscape during for each manual motor sequence
76089726|NCT05821101|Device|Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.|Bilateral implantation of IOLs such that dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters).
75343284|NCT06213428|Biological|Progressive Perfect Probiotic|Participants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing.
75343285|NCT06213428|Other|Placebo|Participants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing.
75939592|NCT03699215|Drug|Levosimendan|Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension <90 mmHg.
75343286|NCT06213415|Drug|Corticosteroid|Oral steroids plus intratympanic injection
75343287|NCT06213402|Other|Data collection from EHR.|Collection of clinical and laboratory data. Reviwe of the electronic health record
75653775|NCT02847026|Biological|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
75653776|NCT02847026|Biological|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
75653777|NCT02847026|Biological|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
75801231|NCT05436210|Other|foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test|Patients will be evaluated only observationally without intervention by foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test
75653778|NCT02847026|Biological|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
75653779|NCT02847026|Biological|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
75801232|NCT00112840|Drug|CCI-779|CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
75801233|NCT00112840|Drug|Bevacizumab|Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
75801234|NCT03766308|Dietary Supplement|Highland Barley Diet|Highland Barley Diet
75801235|NCT03766308|Dietary Supplement|ADA diet|ADA diet
75801236|NCT03769818|Drug|bupivacaine|Bilateral TAP block with 20 ml of 0.25% bupivacaine
75939593|NCT03699215|Drug|Placebos|continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
75801237|NCT03769818|Drug|dexamethasone|Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
75801238|NCT03769818|Drug|placebo to dexamethasone|Bilateral TAP block with placebo to dexamethasone.
75801239|NCT03769818|Drug|placebo to bupivacaine|Bilateral TAP block with placebo to bupivacaine.
75801240|NCT05223244|Drug|bupivacaine, triamcinolone, and heparin (BTH)|30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
75801241|NCT05223244|Drug|dimethyl sulfoxide (DMSO)|50mL of DMSO and 1mL of triamcinolone (10mg/mL)
75801242|NCT03627598|Device|HFNC|patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions
75939594|NCT03166436|Procedure|Radiofrequency ablation|radiofrequency ablation
75939595|NCT03166436|Procedure|Biliary stenting|biliary stenting
75939596|NCT03699137|Other|No interventions|No interventions
75939597|NCT03166358|Behavioral|Hatha yoga|8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
75939598|NCT04479956|Procedure|Varicose vein surgery|sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee
76089727|NCT05820971|Other|C-short plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (6a)~Sample size (7a)~Sequence generation (8a)~Allocation concealment (9)~Blinding (11a)~Outcomes and estimation (17a/b)~Harms (19)~Registration (23)~Protocol (24)~Funding (25)"
75343288|NCT06213389|Device|EzVision® videolaryngoscopy|Patient will be intubated with EzVision® videolaryngoscopy
75343289|NCT06213389|Device|Macintosh Blade|Patient will be intubated with Macintosh Blade
75343290|NCT06213376|Behavioral|Melodic Intonation Therapy|Melodic Intonation Therapy uses intonation and melody to aid individuals with aphasia with producing words.
75343291|NCT06213376|Behavioral|Video Feedback Performance Review|Participant will view recording to judge correct and incorrect productions of trained words and to identify motor techniques increasing intelligibility
75476011|NCT02001948|Drug|intravenous cannulation and premedication|18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
75476012|NCT02001974|Drug|Paclitaxel+Reparixin|Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
76089728|NCT05820724|Diagnostic Test|PSMA PET scan|Subjects will undergo DCFPyL PET/CT imaging and mpMRI imaging prior to the prostate biopsy. The decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. The intervention includes a mpMRI, a PSMA PET scan, and a prostate biopsy.
75343292|NCT06213363|Drug|TCR1672 tablet|All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three oral doses of three times a day TCR1672 (20mg, 40mg, 60mg). Then patients will further be randomized to two treatment sequences, Dosing Sequence 1 and Dosing Sequence 2. Participants in Dosing Sequence 1 will be given TCR1672 Tablets for 1 weeks, followed by a 1-week washout period, and then crossover to 1-week placebo treatment. Participants in Dosing Sequence 2 will be firstly administered 1-week placebo treatment, followed by a 1-week washout period, and then crossover to TCR1672 tablets for 1-week treatment.
75653780|NCT02847026|Biological|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
75653781|NCT02847026|Biological|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
75653782|NCT02849054|Device|Measurement of PTPdi|Insertion of pressure transducer catheter to measure gastic and oesophadgeal pressures for calculation of PTPdi
75653783|NCT02849054|Device|TTV at 4ml/kg|Provision of targetted tidal volume of 4ml/kg
75801243|NCT03627598|Device|standard|patients will receive low flow oxygen therapy at 1 to 4 liters per minute
75801244|NCT01321632|Drug|Zingiber officinalis|To start with subjects will be prescribed Zingiber officinalis in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
75653784|NCT02849054|Device|TTV at 5ml/kg|Provision of targetted tidal volume of 5ml/kg
75653785|NCT02849054|Device|TTV at 6ml/kg|Provision of targetted tidal volume of 6ml/kg
75653786|NCT02849210|Biological|Allergovac depot with Olea europaea pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
75653787|NCT02849132|Drug|Entecavir|oral entecavir 0.5mg daily for 8 years
75801245|NCT03766152|Device|Adhesive bone conduction hearing aid (ADHEAR - Med El)|Patients are asked to wear an adhesive bone conduction hearing device which is attached to the mastoid with an adhesive adapter
75653788|NCT02846870|Other|Visually enhanced prostate cancer educational presentation|Receive visually enhanced prostate cancer educational presentation
75653789|NCT02846870|Other|Standard prostate cancer education presentation|Receive standard prostate cancer education presentation
75801246|NCT05222698|Procedure|Facial reanimation surgery by free muscle trasfer.|Muscle flap harvesting from the back or from the thigh to be insetted to the paralyzed side of the face with microvascular anastomosis of the muscle pedicle to facial artery and vein.
75801247|NCT05222074|Other|Venous congestion|Venous congestion exposures were quantified as area under the curve (AUC) of central venous pressure ≥12, 16 or 20 mmHg
75801248|NCT05222074|Other|Introperation hypotension|Introperation hypotension exposures were quantified as area under the curve (AUC) of mean arterial pressure ≤55, 65, 75 mmHg
75939599|NCT04457843|Other|usual medical care|Prospective monitoring of clinical Outcomes and digital collected outcomes via the mobile COPD staus test app.
75939600|NCT03699059|Other|ExeRTiOn|REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
75939601|NCT03694535|Drug|bladder wall thermotherapy with Mitomycin-c|application of intravesical mitomycin-C with hyperthermia
75939602|NCT03694379|Other|Apneic oxygenation during endotracheal intubation|Providing oxygenation through nasal cannula during the apneic phase of endotracheal intubation.
75939603|NCT03115034|Drug|Melatonin|Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
75939604|NCT03115034|Drug|placebo|Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
75939605|NCT03115034|Other|blank|Patients under CEA without taking melatonin or placebo
75939606|NCT03161990|Procedure|Transgluteal approach to the hip joint|Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
75939607|NCT03161990|Procedure|Posterior approach to the hip joint|Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
75939608|NCT03694223|Other|Health education delivery methods|
76089729|NCT05820724|Other|No PSMA PET|Subjects will undergo mpMRI imaging prior to the prostate biopsy. These subjects do not undergo a PSMA PET scan prior to the prostate biopsy. The decision for biopsy targets will be made based on the findings of mpMRI. The intervention includes a mpMRI and a prostate biopsy.
75653790|NCT05116826|Drug|Nitazoxanide|500 mg Twice Daily for 7 days
75801249|NCT03760380|Device|Sole 1 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.
75939609|NCT03691259|Other|Ballet Classes|Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
75939610|NCT02678390|Dietary Supplement|MCT|A 5 day consecutive MCT intake of 30 g/day.
75939611|NCT02678390|Dietary Supplement|MCT+ aerobic exercise|A 5 day consecutive MCT intake of 30 g/day in combinaison with 30 minutes of aerobic exercise (70% to 80% HRR) per day for the five days.
75939612|NCT02678390|Dietary Supplement|Aerobic exercise|A single period of 30 minutes of aerobic exercise (70% to 80% HRR).
75939613|NCT02678390|Dietary Supplement|Control day|No MCT or aerobic exercise
75939614|NCT03694067|Other|Punch skin biopsy|One 1 mm punch biopsy will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand.
75939615|NCT05553236|Diagnostic Test|Targeted next-generation sequencing|During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.
75939616|NCT03698981|Behavioral|Mothers Moving towards Empowerment (MME)|"MME integrates 3 components: 1) psychoeducation regarding causes, transmission, and treatment of HIV re how adherence to ART and antenatal care acts to promote health for HIV+ women and PMTCT82,83. We will emphasize ART adherence spanning into PP as a maternal duty to raise a healthy child; 2) challenging stereotypes of HIV+ women, such as promiscuity, that threaten core aspects of being a good woman and hinder treatment adherence; 3) coping skills for HIV-related discrimination, i.e., rejection or abandonment by male partners leading to discontinuing treatment adherence and impacts on raising children."
75939617|NCT03027557|Drug|Cinacalcet 30 mg Tablet|Participants in one arm will receive 30 mg cinacalcet each day.
75939618|NCT03027557|Drug|Denosumab Inj 60 mg/ml|Participants in two arms will receive 60 mg Denosumab biannually.
75653791|NCT04268264|Procedure|Incremental haemodialysis|twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
75653792|NCT04268264|Procedure|Conventional haemodialysis|three times weekly 4-hour long haemodialysis sessions from the start
75939619|NCT03027557|Other|Placebo tablets|Participants in two arms will receive one placebo-tablet each day.
75476013|NCT02002000|Drug|vitamin D (cholecalciferol)|Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
75476014|NCT02002000|Drug|Placebo, similar in appearance and taste to cholecalciferol|Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
75653793|NCT04862078|Diagnostic Test|Shared decision making|"Shared decision making and decide surveillance strategy between standard follow-up according to the institutional practice and decide what to do advanced imagings for surveillance and guideline-based surveillance"
75653794|NCT04862078|Diagnostic Test|Usual care|standard follow-up according to the institutional practice
75939620|NCT03027557|Other|Saline Injection (Placebo)|Participants in one arm will receive saline injections as placebo for denosumab.
75939621|NCT03162068|Other|Osteodensitometry and pQCT|The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
75939622|NCT03162146|Other|Deaths in intensive care unit|Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
75939623|NCT03698903|Behavioral|Take a STAND 4 Health|The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.
75939624|NCT04175327|Device|CardioCel implantation|treatment of intracardiac defects; treatment of septal defects; valve and annulus repair; great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
75939625|NCT03698825|Drug|TEW-7197|TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
75939626|NCT03691181|Device|Ventilation|monitoring with the use of the Life2000 Ventilation System for a period of six months
75939627|NCT03029585|Drug|NanoPac® 100 mg/m2|Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
75939628|NCT03029585|Drug|NanoPac® 200 mg/m2|Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
75476015|NCT02002026|Procedure|Uterine artery ligation|Uterine artery ligation during cesarean section before delivery of the baby
75476016|NCT02002039|Drug|Erythropoietin|500 units /kg /day every other day for 5 doses
75653795|NCT02848898|Device|Equistasi|
75653796|NCT02848898|Other|Placebo|
75653797|NCT02848742|Device|Dermal Cooling System|Dermal cryotherapy
75653798|NCT04202198|Biological|A-PRF|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
75343293|NCT06213337|Other|Foot care training with virtual classroom|Providing foot care training once every two weeks in virtual classes created via the Google meet application.
75343294|NCT06213337|Other|Foot care training with SMS support|Total of 60 SMS messages containing foot care information will be sent, one every day.
75343295|NCT06213337|Other|Foot care training with virtual classroom and SMS support|Providing foot care training once every two weeks in virtual classes created via the Google meet application. Furthermore, total of 60 SMS messages containing foot care information will be sent, one every day.
75343296|NCT06213324|Drug|Ketamine|0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously
75343297|NCT06213324|Drug|Placebo|Normal saline delivered intravenously
75343298|NCT06213311|Drug|Glofitamab|Given by IV
75343299|NCT06213311|Drug|Obinutuzumab|Given by IV
75343300|NCT06213311|Drug|Axi-cel|Given by IV
75343301|NCT06213298|Drug|Kava|75 mg kavalactones
75343302|NCT06213298|Dietary Supplement|Placebo|Placebo capsule
75343303|NCT06213285|Device|Watchman FLX left atrial appendage occlusion|Early (30-120 days) CT follow-up after Watchman FLX LAAO
75653799|NCT04202198|Procedure|pinhole surgical technique only|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
75653800|NCT02848508|Drug|Metformin|
75801250|NCT03760380|Device|Sole 1 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
75939629|NCT03029585|Drug|NanoPac® 300 mg/m2|Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
75343304|NCT06213272|Behavioral|Phono-Motor Therapy|The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) & vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
75653801|NCT00903032|Behavioral|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
75653802|NCT00903032|Behavioral|Usual care|Usual care following ACS hospital discharge.
75653803|NCT02113592|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
75801251|NCT03760380|Device|Sole 2 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.
75939630|NCT03029585|Drug|NanoPac® 400 mg/m2|Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
75939631|NCT03029585|Drug|Standard of Care Intravenous Chemotherapy|Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
75343305|NCT06213272|Behavioral|Aerobic Exercise Training (AET)|Stationary ergometer cycling at 60% heart rate range for 20 minutes, plus 5 minutes of warm up and cool down.
75343306|NCT06213272|Behavioral|Stretching|Light stretching activities targeting the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
75343307|NCT06213259|Drug|KD6005|Biological: KD6005, SQ
75343308|NCT06213259|Drug|Placebo|Placebo, SQ
75343309|NCT06213246|Behavioral|Sleep Hygiene Strategies|"The sleep hygiene strategies will be applied for all seven days of Week 3 and will involve the following guidelines recommended by the National Sleep Foundation~Maintain a consistent wake-up and bedtime schedule during workdays.~Do not delay/advance excessively (no more than 2 hours) the wake-up and bedtime - schedule during weekends.~Keep the bedroom temperature below 22°C.~Avoid sources of light and noise in the bedroom.~Use the bed only for sleeping, avoiding other activities before bedtime.~Avoid daytime naps during workdays.~Refrain from using electronic devices (PC, laptop, cellphone, television) at least 30 minutes before bedtime.~Expose yourself to natural light in the morning and reduce artificial lights in the evening.~Avoid consuming alcoholic beverages and caffeine in the afternoon.~Have a moderately sized dinner at least 3 hours before bedtime."
75343310|NCT06213194|Other|MindZone|The name of the online training will be MindZone. It consists of combined game-based social cognitive and executive functions skills, and it will be presented on the training website. There is no consensus about the length of time for the training in the literature, so the average time for the training process will be used. This means that the training will last 6 weeks, 7.5 hours in total. To satisfy the training requirement, 1.15 hours (75 mins) of play will be expected from participants each week. Before each game, a brief introduction about the game will be presented and participants will get feedback about their progress. Each participant will conduct the tasks in a different random order. After 6 weeks, a post-test will be completed, and follow-up scores will be obtained after a month. All tasks were designed according to the five intervention areas: working memory, cognitive flexibility, inhibition, cognitive empathy and affective empathy based on the literature.
75343311|NCT06213168|Other|HFNC|Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization
75343312|NCT06213168|Other|CPAP and HFNC|Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
75653804|NCT00902564|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
75653805|NCT05055362|Other|Honey Spice Group|Consume baked good daily for 10 days and provide samples of saliva, urine and dietary habits and spice intake.
75653806|NCT00626197|Drug|Corticosteroids|Intravenous and oral repeating dose
75653807|NCT00626197|Drug|Cyclophosphamide|Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.
75343313|NCT06213142|Other|CBToolkit|CB Toolkit Mindful Awareness module to increase awareness and tolerance of physical sensations and emotional experiences using mindfulness practices. The module involves videos with motion graphics, video demos, voiceover, music, and sound effects intermixed throughout with a variety of interactive exercises tailored to specific core components. The module aims to establish understanding of the intervention concept (psychoeducation), increase self-efficacy in mindfulness skills via active practice and personalized feedback, and facilitate self-reflection and understanding of strengths and improvement areas related to mindfulness. CBToolkit Flexible Problem Solving module to promote cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies. Videos and activities will be tailored to provide examples of effective problem-solving techniques and provide personalized reinforcing and/or scaffolded feedback.
75801252|NCT03760380|Device|Sole 2 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
75801253|NCT03760302|Other|analgesics|analgesics given to a patient treated from HEMS
75801254|NCT03760302|Other|hypnotics|hypnotics given to a patient treated from HEMS
75801255|NCT03323892|Other|second masturbation|Husbands will be asked to produce a second sperm sample in the masturbatorium
75801256|NCT05221684|Procedure|Lymph node harvesting|Lymph node harvesting after radical resection for rectal cancer with curative intent
75801257|NCT01322256|Procedure|Bone scintigraphy|Bone scintigraphy of the affected area
75343314|NCT06213129|Device|Na and ultrafiltration profiling|Sodium and ultrafiltration profiling are method of dialysis in which dialysate sodium concentration and ultrafiltration rate are altered during the course of the dialysis session
75343315|NCT06213116|Device|MADgic Atomizer|Device to deliver directly lignocaine
75343316|NCT06213116|Device|Lignocaine pump spray|Lignocaine 30 mg (3 puffs) given via 10mg Lignocain Pump Spray prior to endotracheal intubation
75343317|NCT06213103|Procedure|Patient cohort|Collection of 6 blood tubes at the inclusion visit.
75343318|NCT06213103|Procedure|Control cohort|Collection of 6 blood tubes at the inclusion visit.
75476017|NCT02002052|Drug|Concurrent platinum-based chemotherapy|Platinum-based concurrent chemotherapy in both arms
75476018|NCT02002052|Radiation|Standard Radiotherapy, 60 Gy in 30 fractions.|
75476019|NCT02002052|Radiation|Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions|
75653808|NCT00626197|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.
75653809|NCT00626197|Drug|Ocrelizumab|Ocrelizumab was administed at a dose and as per schedule in arm description
75653810|NCT00626197|Drug|Placebo|Placebo was administered as per schedule in arm description
75653811|NCT00626197|Drug|Azathioprine|Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
75653812|NCT05054894|Other|Therapeutic Plasma Exchange (TPE)|"Following all necessary screening and consenting protocol, patients will be scheduled for the plasmapheresis procedure.~Plasmapheresis~On the days of the scheduled procedure, patients will undergo up to 1.5 hours of plasmapheresis treatment. Patients will be awake and situated in a relaxed position in a reclined chair. The plasmapheresis device to be used is the Fresenius Kabi 'Amicus', which is currently FDA approved for a variety of clinical conditions. In one treatment, roughly 60-70% of a patient's plasma can safely be replaced; by using six consecutive treatments, more of the patient's plasma (approaching 100%) will be replaced in an exponential fashion."
75653813|NCT01940822|Other|Energy Drink|
75653814|NCT01940822|Other|Placebo Drink|
75653815|NCT02848430|Dietary Supplement|Humulus lupulus|Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
75653816|NCT00828217|Other|adapted physical activity|one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
75653817|NCT02848352|Other|Placebo nasal spray|
75653818|NCT02848352|Other|Film Sequence|
75653819|NCT00626275|Drug|ADL5859|
75653820|NCT00626275|Drug|Naproxen|
75653821|NCT00626275|Drug|Placebo|
75653822|NCT00626275|Drug|ADL5859|
75653823|NCT00626275|Drug|Placebo|
75801258|NCT01322256|Procedure|Leukoscan|Scintigraphy with labeled neutrophils
75801259|NCT01322256|Procedure|PET / CT|PET / CT of the affected area
75801260|NCT01322256|Procedure|Bone biopsy|A bone biopsy is performed during pre-inclusion work up.
75801261|NCT01322256|Biological|Bloodwork|CRP and procalcitonin are measured in the pre-inclusion work up.
75801262|NCT05221528|Diagnostic Test|Measurement of lipid profiles|Measured: total cholesterol, high-density lipoprotein cholesterol, and triglyceride Calculated: low-density lipoprotein
75801263|NCT02301858|Genetic|Genome analysis of tissue samples.|Genome analysis of tissue samples.
75801264|NCT03766074|Dietary Supplement|vitamin D supplement|The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.
75801265|NCT03766074|Dietary Supplement|Placebo|placebo
75939632|NCT04295135|Behavioral|Chronic Pain OneSheet|The Chronic Pain OneSheet (OneSheet) is an EHR decision support tool that uses behavioral economics to increase adoption of chronic pain guideline recommendations. The OneSheet works by aggregating and structuring information that is already collected, that providers often need while caring for patients with chronic pain conditions. By aggregating and structuring this information in a more convenient manner, the goal of the OneSheet is to make the information that is important in clinical decisionmaking more readily available, and to reduce the amount of time that providers need to spend locating this information.
76089730|NCT05820724|Drug|18F- DCFPyl Injection|DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
76089731|NCT05811949|Drug|Dimethyl Fumarate 240 MG [Tecfidera]|DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
76089732|NCT05806684|Other|ROP|Correlation between neonatal indirect bilirubin jaundice and ROP.
76089733|NCT05805670|Other|Yoga and Mindfulness|"Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to and 1 post-operative visit (24 hours after surgery)~The 5 sessions will be carried out 1 session/week from inclusion to the day before surgery"
75343319|NCT06213077|Dietary Supplement|Nitric Oxide|Naturally produced and found in many different kinds of cells and organ systems, NO is an integral molecule in regulating blood pressure and maintaining a healthy cardiovascular system. NO produced or generated in the vasculature then diffuses into the underlying smooth muscle causing these muscles to relax. This results in vasodilation, causing a reduction in systemic blood pressure and an increase in blood flow and oxygen delivery to specific vascular beds.
75801266|NCT05221216|Other|Collect data of medical record|Collect data of medical record: plasma concentrations of cotrimoxazole, demographic data (age, weight, height), data on the use of an extra renal replacement therapy (RRT) (date, type, number of sessions and duration of extra renal replacement therapy (RRT))
75801267|NCT05221138|Drug|VV116|VV116 oral tablets, 400mg
75343320|NCT06213077|Drug|Tadalafil|Vasodilator which treats erectile dysfunction and enlarged prostate (benign prostatic hyperplasia). It can also treat high blood pressure in the lungs (pulmonary arterial hypertension).
75343321|NCT06213077|Other|Placebo|Nitric Oxide Placebo Compound
75476020|NCT02002065|Biological|Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
75476021|NCT02002065|Biological|Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
75653824|NCT02848118|Device|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
75653825|NCT02848118|Other|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
75653826|NCT02847884|Biological|Infliximab|Patients will be prescribed Infliximab as a standard of care regardless of study participation.
75653827|NCT00623935|Drug|Fludarabine|Fludarabine (40 mg/m2/day x 4 days)
75653828|NCT00623935|Drug|Busulfan|Busulfan (3.2 mg/m2/day x 2 days or x 4 days).
75653829|NCT00623935|Radiation|Total Body Irradiation|Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.
75653830|NCT00623935|Procedure|Stem Cell Transplant|Allogeneic stem cell transplant from related or unrelated donor
75476022|NCT02002078|Drug|methylprednisolon|
75653831|NCT03782246|Behavioral|MBCT|Mindfulness- based Cognitive Therapy
75653832|NCT03782246|Behavioral|CBT|Cognitive Behavioral Therapy
75653833|NCT00623779|Drug|AZD0837|ER formulation
75801268|NCT03758820|Behavioral|Behavorial Cognitive Therapy (BCT)|"Check-in : review of the homewok Talk : Presentation of the aim of the session Group Activity : Relaxation and Execises Refreshment break Homework : exercises to practice at home and explanation about the forms to fill in.~Passout : session handbook and supports for exercises."
75653834|NCT00623779|Drug|Aspirin|Oral form
76089734|NCT05800639|Procedure|Ophthalmic surgery|Ophthalmic surgery will be performed as standard practice of our institution.
76089735|NCT05800639|Procedure|General anesthesia|General anesthesia will be performed as standard practice of our institution.
76089736|NCT05797454|Procedure|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the lesion
76089737|NCT05797454|Procedure|Wire-guided localization|Positioning guide wire in the center of the lesion
76089738|NCT05788757|Device|Optetrak Total Knee System|Total Knee Arthroplasty using Exactech's Optetrak branded components.
75653835|NCT04202042|Other|Psychological first aid|PFA responders (peer support workers) are trained to deliver 8 core actions: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services
75653836|NCT04202042|Other|Usual organisational intervention|Emergency intervention by workplace psychologist and limited therapeutic sessions with employee aid program
75653837|NCT04043845|Drug|Ibrutinib|Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
75653838|NCT04043845|Drug|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
75801269|NCT03765606|Dietary Supplement|Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
75801270|NCT03765606|Dietary Supplement|De-xanthinated Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
75939633|NCT03698747|Device|McDESPOT|myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
75476023|NCT02002117|Other|DNA mass|DNA mass spectrometry
75653839|NCT00828373|Drug|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
75653840|NCT00828373|Drug|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
75343322|NCT06213064|Behavioral|Study Product, THC Product, Placebo|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 21-day product use period with a total of 9 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
75653841|NCT03573518|Drug|BTX 1503|BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
75653842|NCT03573518|Drug|Vehicle|Placebo
75653843|NCT02550301|Other|Mean Platelet Volume|Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
75653844|NCT00819949|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
75653845|NCT00824239|Procedure|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
75343323|NCT06213051|Device|• COPAN Self-collection FLOQSwabs® (COPAN, Italy)|COPAN swabs evaluated on Roche COBAS and Cepheid Xpert PCRs
75343324|NCT06213025|Behavioral|web-based Educational program promoting response and willingness to handle elderly|promote the response and willingness of gerontological nurses in handling elderly abuse cases. By employing a rigorous experimental design, this research seeks to contribute evidence-based insights that can inform educational strategies to empower nurses in safeguarding the well-being of elderly individuals.
75801271|NCT05220592|Behavioral|Internet-based recovery training program|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention, and inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week. Each module contained psycho education, worksheets, images, cases, audio and video files, and homework assignments.
75653846|NCT00824239|Procedure|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
75653847|NCT04777760|Drug|one dose of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
75653848|NCT04777760|Drug|two and more doses of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
75801272|NCT03759990|Device|lean|Videolaryngoscope used in intubation
75801273|NCT03759990|Device|obese|Videolaryngoscope used in intubation
75343325|NCT06212999|Drug|Povorcitinib|Oral; Tablet
75343326|NCT06212986|Device|Promotion of mental training through mobile application Perform-UP Tennis|"Perform-UP Tennis is a sport specific mental training app that integrates breathing, relaxation and na-ture-based guided imagery exercises and aims to promote emotional well-being and the enhancement of mental skills. The app techniques are integrated into a single gradual path that involves increasingly complex breathing and relaxation exercises with increasing duration.~The intervention consists of eight weekly modules over a period of 8 weeks with progressive exercises."
75653849|NCT02548975|Drug|Statin, beta blocker|Patients receiving either statin or beta blockers prior to cardiac surgery.
75653850|NCT02548975|Other|Cardiopulmonary bypass|Patients exposed to cardiopulmonary bypass during cardiac surgery.
75653851|NCT02847962|Other|Corn Soy Blend Plus (CSB+)|
75476024|NCT02002143|Behavioral|Group Appointments|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
75653852|NCT02847962|Other|Corn Soy Blend 14 (CSB14)|
75653853|NCT02847962|Other|White Sorghum Cowpea Blend Variety 1|
75939634|NCT02678000|Drug|LHW090|LHW090 is orally administered
75343327|NCT06212973|Drug|Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln|Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
76089739|NCT05788120|Other|Follow up by phone call|Centralized review of ECGs by the Pitié-Salpêtrière rhythmology department and collection of vital status at 12 months (if information not available, telephone call to the patient)
75343328|NCT06212973|Drug|Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln|Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
75801274|NCT05220436|Other|DISCOVER workshop programme|See arm description. The manualised group workshop day is informed by Cognitive Behaviour Therapy and Acceptance & Commitment Therapy principles.
75343329|NCT06212960|Biological|DWP712|Clostridium botulinum Toxin
75939635|NCT02678000|Drug|Placebo|Matching placebo of LHW090
75653854|NCT02847962|Other|White Sorghum Cowpea Blend Variety 2|
75801275|NCT05220124|Drug|Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)|420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 4 treatment cycles.
75939636|NCT05495438|Other|Hypothetical AI|n/a - There is no intervention. Clinicians will review the suggestions of a hypothetical AI
75939637|NCT02691572|Procedure|Spinal anesthesia|Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
75939638|NCT02691572|Drug|Intrathecal bupivacaine|Bupivacaine 12.5 mg will be administered in the subarachnoid space.
76089740|NCT05783635|Behavioral|Enhanced Usual Care (pre-operative)|The enhanced usual care will receive standard surgical care, and a resource brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources. The resource brochure will be e-mailed to patients or sent via postal mail.
75343330|NCT06212960|Biological|BOTOX®|Clostridium botulinum Toxin
75343331|NCT06212934|Other|Acupuncture|"Chou's Tiaoshen acupoints includes Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1), Sanyinjiao (SP-6), Shenmen (HT-7) . Using stainless steel needles (0.32×40)mm, HuaTuo, China). Then some other points like, Danzhong(CV-17), Daling(PC-7), Taixi (KI-3), Qihai (CV-6), Taichong (LR3), and Qiuxu(GB-40) are chosen. Operation: Patients in supine position. Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1) are punctured at a depth of 20-25mm obliquely. Sanyinjiao (SP-6) and Shenmen (HT-7) are inserted 15mm perpendicularly. Until feeling tactile sensation then manually manipulated by rotation methods to produce a characteristic sensation known as De Qi; Technique: Mild reinforcing and attenuating, retaining the needle for 30minutes. The treatment will be givenonce a day and 5 times a week in weekdays, the course will last two weeks."
75343332|NCT06212934|Drug|Estazolam|Participants will take estazolam 1mg 30min prior to bedtime everyday. The course of treatment is two weeks.
75343333|NCT06212921|Diagnostic Test|Sequential blood samples|Sequential blood samples for diagnostic tests is the only intervention in thei study
75653855|NCT02847962|Other|Red Sorghum Cowpea Blend|
75653856|NCT02847962|Other|White Sorghum Soy Blend|
75801276|NCT05219656|Drug|Cyclosporine A|Rescue therapy in acute severe ulcerative colitis
75801277|NCT05197660|Procedure|surgical procedures|number of hospital stays
75939639|NCT02691572|Drug|Intrathecal fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space.
75653857|NCT04044703|Drug|Vancomycin - model-based dosing regimen|A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
75653858|NCT02848040|Other|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
75653859|NCT00824317|Drug|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
75939640|NCT02691572|Procedure|Cesarean delivery|Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
75939641|NCT02691572|Procedure|Wound infiltration|30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.
75939642|NCT02691572|Procedure|Sham procedure|Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients' abdomen.
75653860|NCT00824317|Drug|Placebo|
75653861|NCT02847806|Biological|Estradiol (Insulin sensitivity)|
75653862|NCT02847806|Biological|Testosterone (Insulin sensitivity)|
75653863|NCT00820105|Drug|ADX10059|oral administration
75653864|NCT00820105|Drug|ADX10059|Oral administration
75801278|NCT03849274|Combination Product|Smart Scar Care Pad=Pressure Garment|Smart Scar Care Pad (SSCP) + conventional Pressure Garment in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
75801279|NCT03849274|Device|Pressure Garment|Conventional Pressure Garment (PG) alone in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
75939643|NCT02691572|Procedure|Transversus abdominis plane block|Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.
75939644|NCT02691572|Drug|Ketorolac|IV ketorolac 30 mg/8 h starting at the end of surgery.
75939645|NCT02691572|Drug|Paracetamol|Oral paracetamol 1 gm/8 h starting 4 h after surgery.
75939646|NCT02691572|Procedure|Fentanyl patient-controlled analgesia|Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
75343334|NCT06212908|Other|Basic Periodontal Therapy|All patients received oral hygiene instructions (interproximal cleaning with floss and interdental brushes, brushing instructions on the Bass technique). The patients were also encouraged to brush the back of the tongue once a day. Subsequently, all patients underwent supragingival scaling, prophylaxis, and polishing. Supragingival scaling was performed using manual instruments (Gracey curettes) and an ultrasonic device.
75801280|NCT05173636|Other|cervical lateral glide|A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
75801281|NCT05173636|Other|thoracic mobilization technique|Participants in group B will be given cervical lateral glide along with thoracic mobilization technique in prone position.
75653865|NCT00820105|Drug|ADX10059|Oral administration
75343335|NCT06212895|Other|Survey|"A survey is handled out at the patient registration. Patients can fill it out during waiting for their appointment. The physician, who treats the patients is not aware aout the filling status or content. The Survy will not influence the treatment.~The Survey consists of 3 parts: patients attidude and expectations, and questionnaire about their usual physical activity and the validated Expectation Treatment Score."
75653866|NCT00820105|Drug|ADX10059 Matching Placebo|Oral administration
75653867|NCT02847572|Procedure|Cataract Surgery|All patients wil be having intraocular lens surgery
75653868|NCT01780220|Drug|Abiraterone|Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
75653869|NCT02549053|Procedure|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
75653870|NCT02549053|Procedure|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
75653871|NCT01461278|Device|iStent supra|Cataract surgery and implantation of one iStent supra
75653872|NCT01461278|Procedure|Cataract surgery|Cataract surgery alone
75653873|NCT00828529|Drug|TMC207|
75801282|NCT05168644|Drug|Niclosamide Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 0.25 mg or 1 mg of Niclosamide Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
75801283|NCT05168644|Drug|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
75653874|NCT02846402|Other|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
75653875|NCT00824551|Procedure|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
75653876|NCT00824551|Other|Standard care|Patient will undergo standard care
75653877|NCT00632762|Drug|mantadix|dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
75653878|NCT00820183|Other|Quality Improvement plan for Hypertension Control|"Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation"
75653879|NCT02846480|Other|physical therapy|"Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises."
75653880|NCT02846480|Other|surgical treatment|Surgical correction of POP.
75653881|NCT02846480|Other|behavior therapy|At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
75653882|NCT00824629|Procedure|Afterloading embryo transfer procedure|Afterloading embryo transfer procedure
75653883|NCT00824629|Procedure|Direct embryo transfer procedure|Direct embryo transfer procedure
75653884|NCT01351766|Drug|Transdermal Nicotine Patch|Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
75653885|NCT02548897|Device|Deep brain stimulation|The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.
75653886|NCT02548897|Other|Electroencephalography|An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
75653887|NCT01179932|Other|No Intervention Used|Our study is observational; therefore, there is no type of intervention being used.
75653888|NCT04044391|Diagnostic Test|CardioFlux Magnetocardiograph|CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
75653889|NCT02845934|Other|blood sample|additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
75939647|NCT03688217|Behavioral|Philani Intervention Model+MOVIE (PIM+M)|The PIM+M intervention will involve the integration of the mobile video intervention into the standard perinatal counseling program offered by the intervention mentor-mothers. MOVIE intervention videos are narrated in English and isiXhosa, the languages spoken most widely among the study participants. Teaching videos are short (2-5 min.) and use simple language, avoiding medical jargon. The modularity of the videos facilitates delivery in any order and thus, they can be deployed at the discretion of each skilled mentor-mother, such that the health messages delivered are aligned with the individual needs of each participant at each perinatal stage. All videos will be administered at least once to each participant in the intervention group during the study period.
75939648|NCT03688217|Behavioral|Philani Intervention Model (PIM)|The Philani Intervention Model (PIM) describes a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
75939649|NCT05320172|Drug|Autologous platelet rich plasma eye drops|Fifty milliliters of patient's own whole blood will be placed in five 10-ml vacutainer tubes containing anticoagulant-citrate-dextrose solution (1.4 ml) and centrifuged at 200g for 11 min. The upper two layers of the centrifuged blood, the plasma and buffy coat layer will be separated in a sterile manner and diluted to 20 % (v/v) with a sterile saline solution. The final preparation is divided into 5-ml bottles wrapped in aluminum foil for protection from ultraviolet light. The patients are instructed to store these bottles at -20 °C until required. The bottles being used will be maintained under refrigerated conditions at 4 °C.
75939650|NCT03693911|Behavioral|Acceptance and Commitment Therapy|6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
76089741|NCT05783635|Behavioral|Preoperative Virtual Health Coaching|"Preoperative Virtual Coaching is based on principles of health coaching, collaborative care, and motivational interviewing. Health and educational content is framed using the Health Belief Model. During two sessions, that take place approximately 3 and 5 weeks prior to surgery, the health coach presents alcohol use reduction/abstinence as important for surgical health (rather than addiction or chronic health reasons) and engages participants in discussion and patient-centered goal-setting.~Participants will also receive a brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources."
76089742|NCT05783635|Behavioral|Usual surgical care (post-operative)|This group will receive standard post-operative care.
76089743|NCT05783635|Behavioral|Postoperative Virtual Health Coaching|Postoperative Virtual Coaching uses the same framework and structure as Preoperative Virtual Coaching. These sessions will be delivered by a health coach using a collaborative, and motivational interviewing-based approach. The goal of these sessions is to promote well-being and help participants maintain alcohol abstinence or reduction long-term (or initiate change in alcohol use if they have not already). These sessions promote low-risk alcohol use, provide education on chronic health effects of heavy alcohol use, and teach skills for coping with or avoiding triggers for alcohol use including coping with stress and mood challenges. These sessions introduce skills to help participants manage alcohol, stress, and mood as they recover from surgery.
75343336|NCT06212882|Diagnostic Test|Lower concentration and lower volume contrast agent group|CT images using lower concentration and lower volume contrast material
75343337|NCT06212869|Device|Transcranial direct current stimulation|tDCS group will give active tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
75653890|NCT00820261|Other|oral rehydration therapy for diarrhea cases|Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
75801284|NCT03627520|Drug|[14C]Sulfatinib|300 mg Sulfatinib with 100 µCi [14C]
75801285|NCT02197572|Drug|Sapanisertib|Sapanisertib capsules.
75801286|NCT05139862|Device|Repetitive Transcranial Magnetic Stimulation|This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.
75939651|NCT03693833|Drug|Cannabidiol|Cannabidiol (CBD) tablets of 10mg each
75939652|NCT03693833|Drug|Placebo Oral Tablet|Oral Placebo tablets of 10mg each
75939653|NCT03693755|Procedure|In-plane Group|Placement of femoral nerve catheter under ultrasound control
75939654|NCT03693755|Procedure|Out-of-plane Group|Placement of femoral nerve catheter under ultrasound control
75939655|NCT03693599|Drug|carbetocin|single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
75343338|NCT06212869|Device|Sham transcranial direct current stimulation|Sham tDCS group will give sham tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
75343339|NCT06212869|Device|Green light|Green light group will give green light exposure with the prescribed medications for 1-2 hour. The intervention will conduct 5 days in a week.
75653891|NCT02844608|Other|Quality of Life Questionnaires|Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
75653892|NCT00820339|Procedure|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
75653893|NCT00820339|Procedure|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
75801287|NCT05119738|Biological|Three doses of BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine)
75801288|NCT05119738|Biological|Two doses of Coronavac and one dose BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)
75801289|NCT05088694|Behavioral|Peaceful Coexistence|"The Peaceful Coexistence intervention seeks to target important risk and protective factors related to tolerance and acceptance.~The Anti-Extremism intervention seeks to take the same risk and protective factors covered in the Peaceful Coexistence intervention and have students' psychosocial factors shift their skills and behavior."
75801290|NCT02174406|Procedure|breast ultrasound|
75801291|NCT02174406|Procedure|DBT (Full field digital mammography + tomosynthesis)|
75939656|NCT03693599|Drug|Syntometrine|one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
76089744|NCT05783635|Behavioral|On-Track (Post-operative)|"On-Track is a mobile and web-accessible health tool that uses self-monitoring and provision of feedback on progress towards goals to engage participants in self-management of alcohol use and motivate behavior change through increased self-awareness and accountability for health.~The On-Track application includes a) daily tracking of alcohol and other substance use; b) daily tracking of stress, mood, and pain; c) personalized health goals; and d) visual displays of alcohol use, stress, mood, pain, and goal achievement including graphs of trends over time.~On-Track also uses novel monetary and non-monetary incentives to encourage utilization including an escalating monetary incentive schedule for self-monitoring."
76089745|NCT05776329|Behavioral|AIA-D|"The total energy contribution (1800 kcal/d) is 20% from protein, 25% from lipids, and 55% from carbohydrates. The recommendations include increasing protein intake primarily from plant sources, limiting the intake of red and processed meat, reducing refined sugar, and moderating dairy consumption. It also includes a list of locally produced and seasonal fruits and vegetables and a list of selected ingredients with anti-inflammatory properties to elaborate their foods. Participants will attend 3 motivational sessions of 1 h every two weeks. Besides nutrition and health, the motivational talks focused on the environmental impact of sustainability. Session 1: Planetary healthy diet. The inflammatory potential of diet. Explanation of the program. Session 2. Effect of ultra-processed food on health. Session 3. Healthy diets.~Follow-up information, recipes, and pictures of dishes that meet the given recommendations will be sent once a week through closed social media groups."
75801292|NCT05077384|Drug|Surufatinib|Surufatinib 300 mg oral once daily
75801293|NCT05059990|Other|Low Intensity Aerobic Exercises Group|Intervention Low Intensity Aerobic Exercises i.e. stationary cycle(supervised) Intensity 55-65% of HRmax Frequency 3 times a week Duration 30 min each session
75653894|NCT02844686|Other|Cardiac SPECT|3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
75939657|NCT04277663|Drug|IBI310+IBI308|In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
75343340|NCT06212856|Other|Plyometric training|"The group will receive plyometric exercises in a controlled environment. Following, Plyometrics would be performed.~Leg hops~Tuck jumps~Vertical jumps~Explosive push-ups~Jumping spider~Lateral/ diagonal and broad jumps~Clapping push-ups~Medicine ball presses~Rotational throws~Vertical and obstacle jumps~Box shuffles~Chest passes~Box jumps~Drop jumps~Overarm throws"
75343341|NCT06212856|Other|Conventional|"The group will receive conventional exercises in a controlled environment. Following, conventional exercises would be performed.~Pushups.~Situps.~Lunges~Squats~500m running"
75343342|NCT06212843|Other|plyometric training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~Plyo Pushup.~Chest Pass.~Overhead Throw.~Squat jump.~Plyo Step-up.~Cone jumps.~Med Ball drop.~Kneeling Squat jump.~Lateral jump over hurdle.~Overhead throw.~Under hand throws.~Dynamic Rotational Chest pass.~Overhead throw with step."
75343343|NCT06212843|Other|conventional exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~Pushups.~Situps.~Lunges 4.500m running.~5.Squats"
75343344|NCT06212830|Drug|Gabapentin|Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
75343345|NCT06212830|Drug|Targin|Targin 5 mg twice a day after the procedure for 48 hours
75343346|NCT06212830|Drug|NSAID|Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
75653895|NCT00828685|Procedure|CRPP|Closed reduction, percutaneous pinning
75653896|NCT00828685|Procedure|ORIF|Open reduction, internal fixation
75653897|NCT00629707|Other|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
75653898|NCT02846090|Drug|Dexmedetomidine to reduce the IOP|Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
75653899|NCT02550613|Device|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
75653900|NCT04323098|Biological|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
75801294|NCT05059990|Other|Active Exercises Group|Intervention Upper and lower limb ROM & stretching exercises Intensity As per tolerance Frequency 12 repetition/4sets per exercise 3 times/week Duration 30 minutes each session
75801295|NCT05412888|Dietary Supplement|CoQ10 supplementation|Young men training endurance running will be supplemented with CoQ10
75939658|NCT04277663|Drug|IBI308|In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
75343347|NCT06212830|Drug|Paracetamol|Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
75343348|NCT06212817|Other|Dietary intervention|Increase dietary fiber intake
75343349|NCT06212804|Biological|VIS954|A humanized IgG4 monoclonal antibody.
75343350|NCT06212804|Other|Placebo|VIS954 Placebo
75343351|NCT06212791|Behavioral|Self- Report Evaluation-Duke Activity Status Index|Complete the Self- Report Evaluation-Duke Activity Status Index
75653901|NCT00828763|Drug|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
76089746|NCT05776329|Behavioral|CONV-D|"CONV-D is based on general healthy diet recommendations. The total energy contribution (1800 kcal/d) was 20% from protein, 25% from lipids, and 55% from carbohydrates.~Among the recommended food groups are fruits (5 times a day), vegetables (5 times a day), cereals (3 times a day), legumes (3 times a day), dairy products (2 times a day), food of animal origin (3 times per day).~Participants in the CONV-D group will attend one motivational and nutritional orientation session on day 1 of the intervention.~Session 1. Food and nutrition. Obesity and diet. General healthy diet recommendations. Delivery of material (table of food equivalents).~Follow-up information will be sent once a week through closed social media groups."
76089747|NCT05769075|Drug|TY-2136b|"Drug: TY-2136b PO, QD or BID~Escalation stage: 7 increased dose cohorts from low dose to MTD (from 40mg QD to 420mg QD)"
76089748|NCT05769075|Drug|TY-2136b|"Expansion stage: 4 distinct cohorts~The dose for the Expansion stage will be determined based on results from the Escalation stage"
75653902|NCT00824707|Drug|Entecavir|Entecavir 0.5mg per day
76089749|NCT05758428|Drug|Ensifentrine|14 Subjects enrolled will use one 3 mg/2.5 mL ampule for the 3 mg dose, subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID). On the dosing day (Day 1), subjects will receive a single dose of 3 mg ensifentrine. On Day 4, subjects will receive multiple doses of 3 mg ensifentrine BID for 3 days (Day 4 to Day 6), and a morning dose will be administered on Day 7.
76089750|NCT05758428|Drug|Ensifentrine|14 subjects will be enrolled in this cohort, then randomly assigned to one of 2 treatment sequences (6mg and 1.5mg single dose). Subjects will 2 different dose levels of study drug. Two 3 mg/2.5 mL ampules will be needed for the 6 mg dose (5 mL total volume) and the 1.5 mg dose will be achieved using an appropriate dilution protocol described in the pharmacy manual.
76089751|NCT05753618|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
75343352|NCT06212791|Behavioral|Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire|Complete the Self- Report Evaluation, Atrial Fibrillation Effect on Quality of Life Questionnaire
75653903|NCT00824707|Drug|conventional therapy|conventional therapy including protecting the liver function, anti-tumor and so on
75653904|NCT00824785|Drug|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
75801296|NCT05412888|Procedure|Ischemic preconditioning training|Young men training endurance running will undergo IPC training
75653905|NCT00824785|Drug|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
75653906|NCT02550457|Other|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
75801297|NCT05412888|Dietary Supplement|IPC training combined with CoQ10 supplementation|Young men training endurance running will undergo IPC training combined with CoQ10 supplementation
75801298|NCT05412888|Dietary Supplement|Sham IPC combined with placebo|Young men training endurance running will undergo sham IPC training combined with placebo supplementation
75801299|NCT03759756|Other|AI presentation|AI presentation means the automatic diagnosis information of AI and AI presentation means it is visible in the group.
75939659|NCT04277663|Drug|High-dose recombinant interferon a-2B|In this group, subjects will be given 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
75653907|NCT02550457|Other|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
75653908|NCT02550457|Other|Rigid Tape|Application of Micropore tape in the erector spine muscles.
75939660|NCT03693443|Behavioral|early childhood caries|a questionnaire evaluates the oral health beliefs, knowledge, and behaviors of a sample representing Egyptian mothers toward early childhood caries
75939661|NCT03693209|Behavioral|Volitional Help Sheet (VHS)|VHS with a general anger trigger and 10 anger management strategies
75939662|NCT03693209|Behavioral|Volitional Help Sheet (VHS)|VHS with 10 specific anger triggers and 10 anger management strategies
75939663|NCT04270643|Dietary Supplement|Vitamin D3|ATC code A11CC05 (cholecalciferol)
75939664|NCT04270643|Dietary Supplement|Placebo|Ethyl oleate
75343353|NCT06212791|Diagnostic Test|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise test (CPET)
75343354|NCT06212791|Diagnostic Test|Transthoracic echocardiogram|Transthoracic echocardiogram at rest and immediately following peak exercise during CPET
75653909|NCT00902330|Procedure|energy-based therapy|Given once a day for 18 weeks
75653910|NCT00902330|Procedure|sham intervention|Given once a day for 18 weeks
75653911|NCT04016701|Device|Floreo Joint Attention Module|Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long
75801300|NCT03759756|Other|no AI presentation|AI presentation means the automatic diagnosis information of AI and no AI presentation means it is invisible in the group.
75801301|NCT03765294|Drug|ACT-541468|Film-coated tablet for oral use
75801302|NCT03765294|Drug|Placebo|Film-coated tablet for oral use
75801303|NCT05133388|Genetic|ARMS PCR|ARMS PCR using primer pairs that only amplify individual alleles
75939665|NCT03693131|Drug|Icosapent (MND-2119)|Icosapent (MND-2119) capsules.
75939666|NCT03693131|Drug|Icosapent (EPADEL CAPSULES 300)|Icosapent (EPADEL CAPSULES 300) capsules.
75939667|NCT03687983|Device|GoldenFlow Peripheral Stent System|Performing anaesthetic and pathological angiography according to the standard method, and select appropriate stent specifications according to the contrast results. After 1:1 pre-expansion, the stent system will be imparted into the lesion location, the stent will be distally positioned and released. The Tip head will be reset and the conveyor will be removed. If necessary, local re-expansion can be carried out. Remove the catheter and suture the wound. Postoperative treatment and anticoagulation.
75939668|NCT02677844|Drug|Abemaciclib|Administered orally
75653912|NCT04016701|Behavioral|Regularly Scheduled Therapy|therapy as regularly scheduled at therapy center
75653913|NCT00824863|Drug|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
76089752|NCT05753618|Drug|Omission of Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
76089753|NCT05752461|Drug|SHR-2004 injection|low dose subcutaneous injection once
76089754|NCT05752461|Drug|SHR-2004 injection|medium dose subcutaneous injection once
76089755|NCT05752461|Drug|SHR-2004 injection|high dose subcutaneous injection once
76089756|NCT05752461|Drug|Enoxaparin sodium injection|40 mg administered as subcutaneous injection once daily
76089757|NCT05750277|Other|Evening Time-Restricted Eating|Eating between 8am-6pm.
76089758|NCT05733546|Drug|Psilocybin|COMP360 Psilocybin administered under supportive conditions
75343355|NCT06212791|Diagnostic Test|Ambulatory cardiac rhythm assessment|Ambulatory cardiac rhythm assessment
75343356|NCT06212791|Diagnostic Test|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) study at rest and during two stages of submaximal exercise (ExeCMR)
75939669|NCT02677844|Drug|Placebo|Administered orally
76089759|NCT05724550|Drug|Sugammadex|"Sugammadex(100mg/mL), 2mg/kg~After confirming Train-of-four counts 4, patients allocated to sugammadex group receive sugammadex 2mg/kg for reversal of rocuronium at the end of the surgery."
75939670|NCT02677844|Drug|Loperamide|Administered orally
76089760|NCT05724550|Drug|Neostigmine|"Neostigmine methylsulfate(0.5mg/mL) 0.02mg/kg~After confirming Train-of-four counts 4, patients allocated to neostigmine group receive neostigmine 0.02mg/kg (maximum 5mg) combined with atropine 0.02mg/kg for reversal of rocuronium at the end of the surgery."
76089761|NCT05708274|Drug|CPH + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
76089762|NCT05708274|Drug|CD-LD + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
76089763|NCT05708274|Drug|ATX + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
76089764|NCT05708274|Drug|Placebo + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
75343357|NCT06212765|Drug|L-citrulline|to take 1 pod a day for 45 days
75653914|NCT02548819|Other|MRI|MR imaging of patients with implanted cardiac devices
75653915|NCT02844530|Drug|90Y-epratuzumab tetraxetan|"The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients"
75653916|NCT02844530|Drug|chemotherapy/ immunotherapy|
75653917|NCT00820417|Drug|Cetuximab/Gefitinib combination and/or monotherapy|
75653918|NCT00820495|Behavioral|Web + Phone|Web + Phone
75653919|NCT00820495|Behavioral|Web Only|Web Only
75653920|NCT00820495|Behavioral|Phone Only|Phone Only
75653921|NCT00820495|Behavioral|Usual Care|Usual Care
75653922|NCT04923854|Other|No intervention|No intervention
75653923|NCT04923620|Drug|cetuximab+mFOLFOX6|cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
75939671|NCT03687905|Drug|Chloroquine|group1 received chloroquine .
75939672|NCT03687905|Drug|Hydroxychloroquine|Group 2 received hydroxychloroquine
75939673|NCT03687515|Drug|budesonide|1mg/2ml Pulmicort Respules BIS twice daily
75939674|NCT03687515|Drug|budesonide|nasal spray 256μg BID
75939675|NCT03687515|Drug|Prednisone|oral prednisone 24mg QD
75939676|NCT03164876|Drug|AUT00206|4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
75939677|NCT03164876|Drug|Placebo|4 capsules of placebo, twice daily, to take orally with food for 4 weeks
75343358|NCT06212752|Biological|Pembrolizumab coformulated with hyaluronidase|MK3475A SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
75343359|NCT06212752|Drug|Pemetrexed|Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
75343360|NCT06212752|Drug|Cisplatin|Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
75801304|NCT03765216|Drug|2L Polyethylene Glycol (PEG)|Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
76089765|NCT05699954|Diagnostic Test|Presence of Blink impression features for cancer in colorectal polyps|"20 LNPCPs will be collected from the UZ Ghent database (all LNPCPs, ICF present).~A survey will be made where participant endoscopist will be informed about the study. They will here be asked for electronic consent.~The survey asks for demographics of the participant endosopists (experience, country where they work).~The last part of the survey is where the 20 images of the LNPCPs are shown. After evere image 4 questions are asked. Is this a colorectal polyp? (Yes/No)~Is your Blink (first) Impression that this polyp contains cancer? (Yes/No)~If yes, why do you think that? (Free comment box)~What treatment would you recommend for this polyp? (piecemeal endoscopic mucosal resection/endoscopic submucosal disection/surgery)~Study will be closed after 2 weeks.~Data analysis"
76089766|NCT05659329|Device|Simplex HV|Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.
76089767|NCT05653232|Other|Prophylaxis (P2W)|For participants enrolled in P2W arm, the initial dose of SOF/VEL will be administered to the recipient when called to the operating room for transplant (typically 1-3 hours prior to the start of surgery). Post-transplant, SOF/VEL will be continued daily for 13 days post-KT (a total of 14 doses administered).
75343361|NCT06212752|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
75343362|NCT06212752|Drug|Paclitaxel|Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
75653924|NCT04923620|Radiation|short-course radiotherapy|25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6
75939678|NCT03690713|Diagnostic Test|Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance|The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × ([1.35 × Pd/Pa] - 0.32).
75939679|NCT03687437|Diagnostic Test|Blood sample|Complete blood count
75939680|NCT03687281|Other|Survey|"The questionnaire consists of three parts:~knowledge assessment;~socio-demographic, medical and lifestyle data;~use of Chemsex."
75939681|NCT03687203|Diagnostic Test|Functional Activities Questionnaire|The FAQ is an economic and easy to apply activity of daily living scale. We aim to validate the prognostic value of novel FAQ scores, which differentiate cognitive- from motor-driven activity of daily living function.
75939682|NCT03682913|Behavioral|P-CIT protocol|Personalized inhibitory control training for one week.
75801305|NCT03765216|Drug|4L Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
75343363|NCT06212752|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
75343364|NCT06212752|Biological|Pembrolizumab|Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
75343365|NCT06212739|Procedure|Laser|Diode laser used to effect closure of the anal fistula tract
75343366|NCT06212739|Procedure|LIFT|The intersphincteric portion of the fistula is excised and ligated.
75653925|NCT00828997|Biological|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
75653926|NCT03454334|Device|multifocal intraocular lens IOLs|clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts
75653927|NCT00829075|Drug|r-FSH|
75653928|NCT00829075|Drug|HP-hMG|
75653929|NCT00829075|Drug|r-FSH plus HP-hMG|
75801306|NCT03626896|Device|NaviFUS System|BBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system
75801307|NCT01322334|Behavioral|Singing exercises|A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
75801308|NCT05087212|Drug|plerixafor + G-CSF|subcutaneous (SC) injection
75801309|NCT05086510|Procedure|Radiofrequency ablation|Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.
75801310|NCT03765060|Procedure|Monomax® 2/0 HR26|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle.~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
75939683|NCT03682913|Behavioral|Placebo|without personalized inhibitory control training for one week.
75939684|NCT03682835|Dietary Supplement|FDGard|capsule containing peppermint oil and caraway oil
75939685|NCT03682835|Other|Placebo|Placebo capsule containing cellulose
75939686|NCT02691494|Drug|Elagolix|Film-coated tablets
75939687|NCT02691494|Drug|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
75939688|NCT02691494|Drug|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
75939689|NCT02691494|Drug|Placebo for Elagolix|Film-coated placebo tablets
75343367|NCT06212726|Behavioral|InjureFree|The InjureFree software is a commercialized injury incident management platform for organizations working in sports and athlete care and is focused on providing administrators and caregivers' technology to enhance coordination of care. InjureFree will be utilized to track concussion management and communication following SRRC at Buchholz and Gainesville High Schools. This will not modify the current standard of practice for healthcare delivery, it will only modify the communication between members of the concussion management team
75343368|NCT06212713|Other|Questionnaire administration|Questionnaire administration - version older adults and informal caregivers
75343369|NCT06212700|Behavioral|Preoperative Exercise|Aerobic (HIIT) Endurance Respiratory Muscle Strength Education
75653930|NCT04849676|Other|visual neurofeedback|"Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity."
75653931|NCT02550223|Procedure|radial artery Catheterization|Insertion of radial artery catheter for sampling and blood pressure measurement
75343370|NCT06212700|Behavioral|Postoperative Exercise|Aerobic Muscle Strength Walking Program Education
75653932|NCT02844140|Procedure|DE-CT's and SE-CT|Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
75653933|NCT02548741|Drug|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy & David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
75801311|NCT03765060|Procedure|Monomax® 1 HR48|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle.~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
75801312|NCT01532310|Drug|belimumab|Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
75801313|NCT05070910|Behavioral|Therapy|The intervention performed in the practicum will not be able to be influenced by the study investigators and the intervention may be different for each child based on their needs
75801314|NCT01423734|Other|magnetic resonance imaging (MRI)|"Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.~During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center."
75939690|NCT03682679|Diagnostic Test|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
75939691|NCT03164798|Procedure|Conventional inpatient rehabilitation|comprehensive inpatient rehabilitation for 2 weeks
75939692|NCT03624335|Procedure|ECC|Early clamping of the umbilical cord
76089768|NCT05653232|Other|Transmit and Treat (T&T)|For participants enrolled in T&T arm, SOF/VEL will begin between post-KT day 0 and post-KT day 14. Participants will be clinically-prescribed DAAs once viremia is detected, and participant's insurance will be petitioned to obtain treatment as soon as possible. If insurance-provided DAAs are approved before post-KT day 14, participant will begin 12 weeks of study-provided SOF/VEL on date of insurance-provided DAAs approval. If insurance-provided DAAs are not approved by post-KT day 14, study-provided SOF/VEL will begin on post-KT day 14 and continue for 12 weeks.
75939693|NCT03624335|Procedure|DCC|Delayed clamping of the umbilical cord
75939694|NCT03624335|Procedure|Blood Test 6hours|Blood Test 6hours
75343371|NCT06212700|Dietary Supplement|Preoperative Nutrition|Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
75939695|NCT03624335|Procedure|Blood Test 24hours|Blood Test 24hours
75939696|NCT03624335|Procedure|Blood Test 48hours|Blood Test 48hours
75939697|NCT03624335|Procedure|Blood Test 28days|Blood Test 28days
75939698|NCT02677220|Device|CI532 cochlear implant|
75939699|NCT05277116|Other|Genome Informed Risk Assessment (GIRA) report|A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.
76089769|NCT05653102|Device|Truliant Total Knee System|Total Knee Arthroplasty using Exactech's Truliant® branded components are compatible with Optetrak branded components.
76089770|NCT05646498|Procedure|Closed sinus lift procedure|The closed sinus lift is the elevation of the sinus membrane through the osteotomy
75939700|NCT03972449|Behavioral|BEAT-Speech|BEAT-Speech integrates beatboxing techniques within speech-therapy services for individuals with speech sound disorders.
75939701|NCT03972449|Behavioral|Traditional Articulation Approach|The traditional approach to treating speech sound disorders focus on one or two sounds at a time until they are mastered by the client. Perceptual and production training are used with target starting at simple (isolation) and moving to more complex (sentences). A variety of cues such as shaping and phonetic placement cues are used.
75653934|NCT02548741|Drug|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
76089771|NCT05646498|Device|Crestal sinus lift|The crestal approach is the elevation of the sinus membrane by osteotomes, piezosurgery, or Densah burs.
75653935|NCT02548741|Other|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
75939702|NCT03962309|Other|Health self-assessment questionnaire|The health self-assessment questionnaire includes questions covering anthropometric, sociodemographics, personal and family health history, life style habits and aspects of the behavioral domain. The questionnaire will be administered as paper format or web-based electronic format according to participants' preferences.
76089772|NCT05639556|Diagnostic Test|BMI and lean mass index from DXA|Estimate and compare correlation between lean mass index from DXA and BMI
75939703|NCT02682602|Device|DePuy Synthes total hip arthroplasty|
75939704|NCT02682602|Radiation|Computer tomography|Computer tomography (CT) scan of the hip for creation of bone models.
75939705|NCT02682602|Radiation|Fluoroscopy surveillance|Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
75939706|NCT03959111|Other|Stimulation at Location 1|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
75939707|NCT03959111|Other|Stimulation at Location 2|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
75653936|NCT02548741|Other|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
75801315|NCT03758586|Other|Computerized spatial skill training|The spatial skills training session consisted of six practice trials that were run in a sequence. The objective of each practice was to manipulate the simulated robotic arm to grab the cubes and move them to a desired location using keyboard keys. The participant was required to reach a decision based on the visual-spatial information, before initiating subsequent movements of the simulated robotic arm. Each practice trial presented an initial state of the cubes in front of the robotic arm, and a target position of the cubes.
75801316|NCT03758586|Other|Watching a presentation regarding robotic surgery|Watching a 20-35 minute long power-point presentation regarding the history of robotic surgery.
75801317|NCT03764826|Device|CAABT|The sound generators with CAABT will be used 15 min each session, three times a day
75801318|NCT03764826|Device|TMT|The sound generators with TMT will be used 15 min each session, three times a day
75801319|NCT03764748|Drug|mini-FMT|200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) will be delivered daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.
75939708|NCT05736536|Behavioral|Chance2Act|A Health education package that has been developed based on Transtheoretical Model to encourage behaviour change for weight loss among overweight/obese type 2 diabetes adults.
75939709|NCT03803657|Device|Monitoring of energy expenditure|Continuous monitoring of energy expenditure.
75939710|NCT03690635|Procedure|VISTA (vestibular incision subperiosteal tunnel acess)|"A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity."
76089773|NCT05639556|Diagnostic Test|skinfold and circumference|Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.
76089774|NCT05639556|Diagnostic Test|Hand-grip strength|A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.
76089775|NCT05639556|Diagnostic Test|6-minute walk|This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.
75343372|NCT06212700|Dietary Supplement|Postoperative Nutrition|Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
75343373|NCT06212700|Behavioral|Preoperative Psychology|CBT skills Skills training Emotional validation Behavioural activation Psycho-education
75343374|NCT06212700|Behavioral|Postoperative Psychology|CBT skills Skills training Emotional validation Behavioural activation Psycho-education
75653937|NCT02844374|Other|Functional stereotaxic exploration|Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
75653938|NCT02845856|Drug|Cetuximab|400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
75653939|NCT02845856|Biological|NK immunotherapy|For each procedure, 10 billion cells will be infused in 4 times
75653940|NCT00825019|Drug|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
75653941|NCT00825019|Drug|placebo|oral administration in 12h intervals
75653942|NCT00825019|Drug|paroxetine|oral administration of 20 mg/day
75653943|NCT05337956|Procedure|Erector spinae plane block catheter|All ESP blocks will be performed in lateral position after general anesthesia induction. ESPB will be performed under ultrasonographic guidance using a linear 6- to 10-MHz ultrasound probe. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T6-10 spinous process. The erector spinae muscles will be identiﬁed superﬁcial to the tip of the transverse process. A 21-gauge 10-cm needle will be inserted using an in-plane superior-to-inferior approach or an out of plane approach. The tip of the needle will be placed into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be conﬁrmed by visible ﬂuid spread lifting erector spinae muscle oﬀ the bony shadow of the transverse process on Ultrasonographic imaging. A total of 10-15 ml of 0.2% ropivacaine will be injected each side. A catheter will then be placed leaving 5 cm in place.
75801320|NCT05065450|Device|Intracranial Stimulation|Electrodes localized to the BLA will be stimulated with either active-BLAES (0.5-3.5 mA, theta-modulated gamma burst) electrical stimulation for a 1-sec duration immediately following item image presentation or sham-BLAES (zero-amplitude). At later stages of the project, stimulation parameters and timing will be varied and triggered not at random, but by real-time closed-loop analysis of memory biomarkers in the medial temporal lobe.
75801321|NCT01321788|Drug|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
75801322|NCT01321788|Drug|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
75801323|NCT05053828|Drug|Antiplatelet Drug|Antiplatelet drugs and agents
75801324|NCT05038306|Drug|Chinese medicine WT|The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
75939711|NCT03691337|Drug|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.11 mL x subject height
75939712|NCT03691337|Drug|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.22 mL x subject height
75939713|NCT03691337|Drug|Sodium chloride|Fascia iliaca block with volume 0.11 mL x subject height
75939714|NCT03682445|Other|exercise|Aerobic tyep of exercise will be made at different intensities in 2 groups.
75939715|NCT03164642|Behavioral|LENA with Feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.
75939716|NCT03164642|Behavioral|LENA no feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
75939717|NCT03690479|Device|Florida Probe Straight Tip Probe|Twenty (20) consecutive adult patients with a diagnosis of periodontal disease (varying degrees, from slight to severe) will be selected to undergo full-mouth periodontal probing. . One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip.
75939718|NCT03690479|Device|Ball Tip Probe|Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. The opposing jaw will be probed using the new trial tip. At a second visit, prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.
75939719|NCT02681510|Drug|Varenicline|Standard FDA approved 12 weeks of treatment with Varenicline
75939720|NCT02681510|Drug|Nicotine Transdermal Patch|Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
75939721|NCT02681510|Drug|Nicotine Mini|Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
75939722|NCT03690323|Procedure|Radiofrequency ablation (RFA)|RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
75343375|NCT06212700|Other|Preoperative Nursing|Comorbidities Managing pain Wound care Complications Surgical education ERAS
75343376|NCT06212700|Other|Postoperative Nursing|Managing pain Cardiovascular stability Wound care Bowel function/Stoma Complications Education
75801325|NCT03759444|Other|Questionnaires|The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
75801326|NCT03759132|Procedure|Transcranial direct current stimulation|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
75801327|NCT05019040|Drug|PA1010|TDF as control
76089776|NCT05639556|Diagnostic Test|1-minute site to stand|This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.
75801328|NCT03764436|Behavioral|LEAPS-NCHD Program|The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.
75801329|NCT05552482|Other|Identification of predictive factors|Evaluation of the following variables : age, sex, body mass index, Diabetes mellitus, vascular disease, hematologic disease, venous thromboembolic disease, antiplatelet or anticoagulant treatments, haemodialysis Catheter Insertion, number of comorbid conditions, Venous diameter, Arterial diameter, AVF type, AVF limb, Anasthesia group
75801330|NCT03764358|Device|Arteriovenous Fistula|Surgical implantation of an arteriovenous fistula for hemodialysis
75801331|NCT03764358|Device|Tunneled Cuffed Catheter|Placement of a tunneled cuffed catheter in surgical theatre
75939723|NCT03690323|Drug|FOLFIRINOX|Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
75939724|NCT03690323|Drug|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
75939725|NCT03690323|Drug|Gemcitabine|Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
76089777|NCT05639556|Diagnostic Test|Short physical performance battery (SPPB)|This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).
76089778|NCT05639556|Diagnostic Test|BIA Sub-study|A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).
75343377|NCT06212700|Other|Preoperative Peer Support Group|"Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education"
75476025|NCT02002143|Behavioral|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
75801332|NCT04920838|Drug|Nitazoxanide and Ciclésonide|Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.
75801333|NCT04920838|Drug|Telmisartan 20Mg Oral Tablet|20 mg tablet daily
75801334|NCT04920838|Drug|Paracetamol|"Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses.~Duration of treatment: up to 14 days"
75801335|NCT04920838|Drug|Fluoxétine and Budésonide|Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.
75939726|NCT03682211|Drug|Fentanyl Citrate|50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
75939727|NCT03682211|Drug|Morphine sulphate|10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
75939728|NCT03161834|Other|Observational|
75343378|NCT06212700|Other|Postoperative Peer Support Group|"Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education"
75343379|NCT06212700|Other|Usual Care|Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
75939729|NCT03161600|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at a surgical visit, enabling providers to deliver evidence-based and personalized treatment care plans to their breast cancer patients. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
75939730|NCT03690245|Procedure|Initiation of Resuscitation While Attached to the Cord|Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
76089779|NCT05639556|Diagnostic Test|Accelerometry to assess physical activity|Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (at least two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.
75476026|NCT02002156|Biological|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at birth and all routine vaccinations.
75653944|NCT02844218|Other|Age of patient|"Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.~Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.~Improvement of Treatments Over Time~Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)"
75476027|NCT02002156|Biological|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at three months old and all routine vaccinations.
75653945|NCT02550691|Procedure|blood sampling|A blood sample will be taken on subject carrying specific genotype
75653946|NCT02844452|Device|Acupuncture|Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.
75801336|NCT03764280|Other|Multiple Daily Injections: Slow acting insulin and Rapid acting insulin|Multiple daily injections (MDI) therapy involves four or more daily insulin injections. Once or twice daily, a long acting insulin is injected as a basal dose. These long acting insulins are designed to dissipate slowly and evenly into the bloodstream for 24 to 36 hours following injection. This basal injection aims to mimic the physiological healthy basal insulin released from a healthy pancreas all day. Furthermore, multiple insulin bolus doses are injected at every meal each day using rapid or short acting insulin. These injections are administered before meals and are calculated using patients' ICRs and meal carbohydrate quantities.
75801337|NCT02666586|Other|Faba bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder (300g).
75801338|NCT02666586|Other|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
75801339|NCT02666586|Other|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
75801340|NCT02666586|Other|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
75801341|NCT02666586|Other|Non-pulse smoothie smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
75801342|NCT02654964|Drug|Combination Drug Therapy|"Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
75801343|NCT03764202|Other|Detection of sufentanil concentration|"Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~The volume of human breast milk was detected at each fixed time point"
75801344|NCT02627196|Device|BAROSTIM NEO® System|
75939731|NCT03686735|Other|5 anchors and numbers|"How helpful was this visit? 0 This visit was not helpful at all~1 2-3 There were many ways it could have been better 4 5 Neither useless nor helpful visit 6 7-8 Exceptionally helpful visit 9 10 One of the most helpful doctor visits I have ever had"
75939732|NCT03686735|Other|5 anchors and no numbers|How helpful was this visit? This visit was not helpful at all There were many ways it could have been better Neither useless nor helpful visit Exceptionally helpful visit One of the most helpful doctor visits I have ever had
75939733|NCT03686735|Other|Visual analog scale with 3 anchors and numbers|How helpful was this visit? 0 neutral/50 100 Least helpful visit Most helpful visit
75801345|NCT02627196|Drug|Medical Management|
75801346|NCT03626740|Other|TheraCal|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with TheraCal
75801347|NCT03626740|Other|MTA|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with MTA
75801348|NCT05123196|Drug|MT-8554|Oral Capsule
75939734|NCT03686735|Other|Visual analog scale with 3 anchors and no numbers|"How helpful was this visit?~This visit was not Neither useless nor One of the most helpful doctor helpful at all helpful visit visits I have ever had"
75965927|NCT05257616|Other|Traction Mobilization technique with SNAGS|Traction Mobilization with SNAGS were given at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again The position of the therapist is behind him or her, medial border of therapist's right thumb is used to contact the spinous process of C6 vertebrae i.e. level above the suspected painful or hypo mobile region. Therapist's left thumb reinforces his/her (right) contact thumb. Therapist fingers are gently placed along the patient's mandible or thorax. Following the treatment plane towards the eye, lift comes from the mobilizing thumb not the contact thumb. While the glide is maintained, the patient is asked to rotate his/her head towards the side of pain or hypo mobility.
75965928|NCT03049436|Other|Program of adapted physical activity|
75965929|NCT03046550|Drug|NTM-1634|NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
75965930|NCT03046550|Drug|Placebo|placebo
75965931|NCT03046394|Device|C-SACH|Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
75965932|NCT03046394|Device|B-DER|Dynamic Motion by Otto Bock, advertised for activity category 2-3
75476028|NCT02002156|Biological|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive no BCG but will receive all routine vaccinations.
75343380|NCT06212687|Behavioral|Digital pre-therapy patient education program (StartHjelp)|After randomization the intervention group receives access to a pre-therapy informational app, presenting information about the treatment process, options, patient rights, user organizations, and self-help while on waiting list before mental health outpatient treatment. The information is presented stepwise through video and text, while also providing links to additional information if needed. The videos are made available to the patients gradually, with more general information about the treatment process first, and more specific information as the first session approaches. The patient has the opportunity to rewatch the videos as they please.
75343381|NCT06212687|Behavioral|Comparator intervention|After randomization, while on waiting list, the control group gets sent all the same information as the intervention group in written form, by mail.
75343382|NCT06212661|Drug|Ubrogepant|Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
75343383|NCT06212661|Drug|Rimegepant|Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
75343384|NCT06212661|Drug|Atogepant|Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
75343385|NCT06212661|Drug|Eptinezumab|Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
75343386|NCT06212661|Drug|Fremanezumab|Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
75343387|NCT06212661|Drug|Galcanezumab|Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
75343388|NCT06212661|Drug|Erenumab|Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
75653947|NCT02844452|Device|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders. In an ideal controlled study, subjects would not know whether they were getting true or sham acupuncture. We are going to use Park Sham Acupuncture, which is composed of sham acupuncture needle not penetrating the skin of subjects and Park sham acupuncture device attacted on the subject's skin in order to block the seeing whether the acupuncture needle penetrates skin or not.
75653948|NCT05337878|Drug|Placebo|Pelacarsen-matching placebo administered by SC injection.
75939735|NCT03681899|Other|Questionnaires|"Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));~Medical and surgical history (Charlson Comorbidity Scale);~Assessment of oral/dental condition~Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);~Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);~Autonomy evaluation (Lawton and Katz scales);~Mobility assessment (anamnestic evaluation);~Evaluation of Thyme (GDS 4 items);~Psycho-behavioral disorders,~Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data)."
75939736|NCT02690714|Biological|Plasminogen (Human) intravenous|Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
75343389|NCT06212661|Drug|Botulinum toxin A|Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
75653949|NCT05337878|Drug|Pelacarsen|Pelacarsen administered by SC injection.
75653950|NCT00929006|Drug|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
75653951|NCT00929006|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
75801349|NCT05123196|Drug|Placebo|Oral Capsule
75801350|NCT04678492|Drug|Esomeprazole|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID
75939737|NCT04769726|Dietary Supplement|almonds|almond intervention (20 g) before three major meals (60g per day) for 3 days in subacute phase, before OGTT in the acute phase ad for 3 months in chronic phase
75965933|NCT03046394|Device|A-DER|Triton by Otto Bock, advertised for activity category 3-4
75965934|NCT05257226|Behavioral|frailty|questionaire
75965935|NCT03046316|Other|local consolidative treatment|local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy
76089780|NCT05639556|Other|Gastrointestinal (GI) and nutrition questionnaires|Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).
75343390|NCT06212648|Drug|SPC1001 High|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
75343391|NCT06212648|Drug|SPC1001 Mid1|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
75343392|NCT06212648|Drug|SPC1001 Mid2|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
75343393|NCT06212648|Drug|SPC1001 Low|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
75343394|NCT06212648|Drug|SPC3001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
75801351|NCT04678492|Drug|Amoxicillin|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID
75801352|NCT04678492|Drug|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
75801353|NCT04678492|Drug|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
75801354|NCT04678492|Drug|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
75939738|NCT03165812|Procedure|SADJB-SG group|Patients will undergo bariatric surgery. A clear liquid high protein diet will be started in the first two postoperative days. If no complications were detected by physical examination, patients will be stimulated to walk and will be dismissed from the hospital on postoperative day 3. Patients will be subjected to a strict adherence to diet and close monitoring of their blood glucose and HbA1c levels during the study period. Standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Glycaemic control at home will be maintained as in the preoperative period and patients will need to inform the results of their blood glucose levels to the doctor during each follow-up visits.
75939739|NCT03165812|Procedure|IMT group|Patients will be subjected to strict adherence to their diet, optimisation of their diabetic medications and close monitoring of their blood glucose and HbA1c levels at 0, 6, 12, 24 months. The endocrinologist will be monitoring the patients in this group. Detailed individualized lifestyle and dietary counseling will be given by a dietitian emphasizing on nutrition knowledge, the timing of meal with medication, portion control, and increasing daily physical activity level.
75939740|NCT03690167|Other|Concentrated Growth Factor (CGF)|CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)
76089781|NCT05639556|Other|Psychosocial questionnaire: PHQ-8|This is an 8-item scale that measures depressive symptoms over the past two weeks.
75343395|NCT06212648|Drug|SPC4001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
75653952|NCT00877214|Drug|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
75653953|NCT00877214|Drug|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
75653954|NCT00667238|Behavioral|Questionnaire|
75653955|NCT00474032|Drug|Botulinum Toxin (Type A) injection (10 U/Kg)|See Detailed Description.
75653956|NCT02845622|Dietary Supplement|Hazelnut|This dietary supplement contains 30 g of hazelnut.
75653957|NCT02845622|Dietary Supplement|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
75653958|NCT02845622|Dietary Supplement|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
75653959|NCT02845622|Dietary Supplement|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
75801355|NCT04678492|Drug|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
75801356|NCT03758430|Other|Meal-Tagging App|Meal tagging app to capture frequently eaten meals and test meals for 16 weeks.
75801357|NCT03758430|Device|Fitness Tracker|Fitness tracker will be worn around the clock for 16 weeks.
75801358|NCT04266366|Other|Face-to-Face Rehabilitation program|In each hospital, two trained therapists will carry out a face-to-face rehabilitation program consisting of electroanalgesia and an exercise program that follows the Mckenzie method. The physiotherapists place the electrodes in the patients, for this they use 5x9 cm electrodes, which they place at the bilateral paravertebral level, in the patients who present with radicular pain, the electrodes will be placed in the path of the affected nerve. The duration will be sufficient to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal periarticular components of the spine.
75343396|NCT06212648|Drug|SPC4002|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
75343397|NCT06212648|Drug|Placebo|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
75343398|NCT06212635|Diagnostic Test|T-TAS|Blood test, laboratory assays
75653960|NCT02845622|Dietary Supplement|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
75653961|NCT04887350|Behavioral|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.
75653962|NCT04887350|Behavioral|Problem Solving Therapy (PST).|Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.
75653963|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
75653964|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
75653965|NCT05337800|Behavioral|stress managment program|A four-session stress management program will be applied to the experimental group students.
75653966|NCT05242796|Device|Low frequency magnetic therapy|
75653967|NCT05242718|Dietary Supplement|N-Acetyl-L-cysteine (NAC)|Health Canada Natural Product Number (NPN) 80056946
75653968|NCT05242718|Dietary Supplement|Echinacea purpurea|Health Canada Natural Product Number (NPN) 80093896
75653969|NCT05242718|Dietary Supplement|Curcumin|Health Canada Natural Product Number (NPN) 80043455
75939741|NCT03690167|Other|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)
75653970|NCT05242718|Dietary Supplement|Palmitoylethanolamide|Health Canada Natural Product Number (NPN) 80097472
75939742|NCT03690167|Other|Control|Nothing applied after extraction
75939743|NCT03686579|Radiation|chest trauma|clinical and radiological study
75653971|NCT04202120|Other|Age-related stereotyping priming|The priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
75653972|NCT04202120|Other|Non age-related stereotype priming|he priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
75653973|NCT02846012|Other|CSCM2|
75653974|NCT05242328|Procedure|Ultrasound-guided erector spinae plane block|Ultrasound-guided erector spinae plane block
75653975|NCT05242328|Procedure|surgical thoracoscopic intercostal nerve block|surgical thoracoscopic intercostal nerve block
75653976|NCT05337644|Drug|Indocyanine green solution|"5 ml of ICG were then injected intravenously to identify the stomach, carefully assessing the angle of His (preoperative written informed consent was obtained from the patient).~Adequate perfusion was defined as the direct and clear visualization of the fluorescence around the gastric tube, after an estimated time of 150-180 s followingi.v. administration."
75801359|NCT04266366|Other|Telemedicine program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
75801360|NCT03176784|Drug|Varenicline|0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
75801361|NCT03176784|Drug|Nicotine patch|14 mg and 7 mg nicotine patches used. See arms for specific durations.
75801362|NCT03176784|Other|Placebo Patch|Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
75801363|NCT03176784|Other|Placebo Pill|Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
75801364|NCT03049852|Drug|CBT-001 single dose|One drop in the study administered one time
75801365|NCT03049852|Drug|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
75939744|NCT03164954|Diagnostic Test|automatic risk detection|automatic alert of the risk for CPSP, triggered by one of the following entries in the hospital information system: psychological risk factors (depression, anxiety, PTSD, catastrophizing, high pain anticipation), chronic use of benzodiazepines or opioids, intense postoperative pain or need of large opioid doses in the recovery room
75939745|NCT03686501|Drug|PF-06412562|Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two [18F]MNI-968 injections
75939746|NCT03165968|Device|Neuro Kinetics, Inc, i-PAS|This is a test of i-PAS device reliability only.
75939747|NCT03681821|Behavioral|Transtheoretical Model (TTM)-based Intervention|Patients in the intervention group had access to conventional care, in addition to receiving the follow-up TTM-based intervention sessions. The intervention was provided by trained nurses, including one researcher and one ET nurse. Sessions were held in the meeting room in the unit four times: at baseline (T0), 2 days before discharge (T1), and at 1-month (T2) and 3-months (T3) after discharge, according to the assessment of their current stage of change delivered by filling the Stages of Change Subscale. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
75939748|NCT03164408|Procedure|Orthopaedic Implant Removal|
75939749|NCT03164330|Behavioral|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
75939750|NCT03164330|Behavioral|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
76089782|NCT05639556|Other|Psychosocial questionnaire: GAD-7|This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.
76089783|NCT05639556|Other|Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)|This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.
75343399|NCT06212622|Drug|Alfentanil|Subcutaneous injection
75343400|NCT06212622|Drug|Oxycodone|Oral solution
75939751|NCT03164330|Behavioral|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, & waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); & (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
75343401|NCT06212609|Other|transcranial electrical stimulation therapy|new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies
75939752|NCT03164330|Behavioral|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
75939753|NCT03164330|Behavioral|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
75939754|NCT03164330|Behavioral|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
75939755|NCT03681743|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
75939756|NCT03681665|Other|ultralow dose abdominopelvic CT|In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80~90% reduced radiation dose compared to standard dose CT.
75939757|NCT03165890|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
75939758|NCT03165890|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
75801366|NCT03049852|Drug|CBT-001 Multi-dose|One drop in the study administered three times daily (TID) for 4 weeks
75801367|NCT05091528|Drug|SBT6050|Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles
76089784|NCT05639556|Other|Psychosocial questionnaire: CF Fatalism Scale|The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.
76089785|NCT05639556|Other|Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)|The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.
75801368|NCT05091528|Drug|trastuzumab deruxtecan|5.4 mg/kg by intravenous (IV) infusion in 21-day cycles
75801369|NCT05091528|Drug|tucatinib|300 mg by mouth (PO) twice daily (BID)
75801370|NCT05091528|Drug|trastuzumab|8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles
75801371|NCT05091528|Drug|capecitabine|1000 mg/m2 PO BID for 14 days of each 21-day cycle
75653977|NCT05242172|Diagnostic Test|CRP/Albumin ratio|it is aimed to investigate prognosis and severity of covid-19 infection with using CRP/Albumin ratio in pregnant patient
75653978|NCT00045968|Drug|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
75653979|NCT02845778|Drug|Melatonin|Each sachet contains 0.5 g
75653980|NCT05242016|Other|structured individual reminiscence|reminiscence therapy
75653981|NCT05242016|Other|unstructured social interview|placebo
75343402|NCT06212596|Drug|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumour suppressor proteins (TSPs). Selinexor is an oral, first-in-class, potent, slowly reversible, covalent-binding Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks the karyopherin protein Exportin 1 (XPO1), also called chromosome region maintenance 1.
75343403|NCT06212596|Drug|Cyclophosphamide|Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
75801372|NCT05091528|Drug|trastuzumab deruxtecan|6.4 mg/kg by IV infusion in 21-day cycles
75801373|NCT04236258|Drug|NIFEdipine ER|Postpartum women with high blood pressure will be randomized to receive nifedipine extended release 30mg daily as their starting antihypertensive.
75939759|NCT03689933|Device|Root analog implant|a custom made root analogue implant made from milled titanium
75653982|NCT05241938|Procedure|PSLT|PSLT will be performed under topical anesthesia (proxymetacaine hydrochloride 5mg/ml eye drops) using a mirrored gonioscopy lens (Latina Ocular Instruments). A α2 agonist hypotensive eye drops (0.2% brimonidine tartrate) and 2% pilocarpine eye drops are applied 40 minutes before the procedure. After laser treatment, the patient will be instructed to use non-steroidal anti-inflammatory eye drops (thrice daily for 7 days).
75343404|NCT06212596|Drug|Prednisone|Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
75343405|NCT06212583|Drug|niraparib/abiraterone acetate|Patients on Arm 2 to receive drug for 6 months
75343406|NCT06212583|Radiation|Stereotactic ablative radiation therapy (SABR)|Both arms will receive SABR
75653983|NCT05241938|Drug|Prostaglandin analogue eye drops|Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
75653984|NCT02845544|Other|Pilates-based exercises|
75653985|NCT05241782|Other|auricular acupressure|"Auricular therapy, as defined by Oleson, refers to a healthcare modality by stimulating the external surface of the ear to alleviate pathological conditions in other parts of the bodyExperimental group will receive acupressure treatment by the second week, trice daily, 3~5minutes each session for a course of four weeks"
75653986|NCT05337332|Drug|Triamcinolone Acetonide|Suprachoroidal injection of triamcinolone acetonide
75653987|NCT02850302|Other|PET with FDG|A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
75801374|NCT04236258|Drug|Enalapril|Postpartum women with high blood pressure will be randomized to receive enalapril 10 mg daily as their starting antihypertensive.
75801375|NCT01317004|Drug|Fingolimod|0.5 mg/day oral capsule
75801376|NCT01317004|Drug|Standard MS DMT|Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
75939760|NCT05228990|Device|warm acupunctrue|"The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes."
75343407|NCT06212583|Drug|Androgen deprivation therapy (ADT)|All ADT is provided as best prescribed for patient per their medical oncologist.
75343408|NCT06212570|Device|KeySuite|KeyScope and KeyLoop will be used to perform biopsies of intra-abdominal masses and cancers.
75343409|NCT06212557|Device|KIOS App|KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)
75476029|NCT02002169|Other|Shower Technique Protocol|Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
75476030|NCT02002169|Other|Standard CVC Care|Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
75801377|NCT03758976|Diagnostic Test|Biopsies, blood|We will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer
76089786|NCT05639556|Other|STRONG Participant Experience Survey|A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.
75343410|NCT06212557|Behavioral|KIOS App education|Educational tools provided to participants with opioid use disorder
75343411|NCT06212557|Behavioral|Treatment as usual|Behavioral counseling in clinic
75343412|NCT06212531|Procedure|Medical male circumcision using standard surgical technique.|Medical male circumcision using the WHO standard technique followed by examination of wound healing and behavioral risk assessment.
75343413|NCT06212518|Other|GENPOP ad libitum fluid intake|Unrestricted fluid intake.
75476031|NCT02002195|Drug|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
75476032|NCT02002195|Drug|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
75476033|NCT02002234|Procedure|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
75653988|NCT02850302|Other|Tumor exome analysis|A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
75653989|NCT02845232|Other|Transfusion|The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.
75653990|NCT02850458|Device|implant-retained overdentures|patients treated with an implant-retained overdenture in the mandible
75653991|NCT04793204|Drug|fezolinetant|oral
75653992|NCT00901394|Drug|B12-Folic Acid, nitrous oxide|"IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline."
75343414|NCT06212518|Other|GENPOP fluid restriction|In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).
75343415|NCT06212518|Other|ATHLETE ad libitum fluid intake|No restriction on fluid intake
75343416|NCT06212518|Other|ATHLETE restricted fluid intake|Not permitted to drink during training session.
75476034|NCT02002234|Procedure|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
75476035|NCT02002247|Drug|sodium selenite|All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
75476036|NCT02002247|Drug|Placebo|All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
75476037|NCT02002260|Device|Levonorgestrel intrauterine system|
75653993|NCT00901394|Drug|Nitrous oxide (NO) and placebo|60% nitrous oxide anesthesia plus saline
75653994|NCT00901394|Other|Placebo|Saline
75939761|NCT03115190|Diagnostic Test|General Practitioner diagnosis with Heart score|All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
75939762|NCT03114800|Device|E-Scale|The E-Scale is comprised of a series of weight monitoring 'pods' and a set of software modules that facilitate data transfer and analysis.
75939763|NCT03114956|Procedure|Gauze|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
75939764|NCT03114956|Procedure|Titanium brush|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
75653995|NCT00901394|Other|oxygen nitrogen|60% air and oxygen mix.
75653996|NCT05241704|Procedure|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the ulcer under complete aseptic operative setting
75939765|NCT03114956|Procedure|Air powder abrasion|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
75939766|NCT03114956|Procedure|Comprehensive|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
75939767|NCT03166046|Device|Pulsed Shortwave Therapy|Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
75343417|NCT06212505|Other|blood test|blood test at the inclusion 10 tubes of 2.7mL blood
75343418|NCT06212492|Drug|NMBAs|Early and systematic use of NMBAs
75343419|NCT06212492|Other|Prone positioning|Early and systematic use of prone positioning
75343420|NCT06212427|Dietary Supplement|HMO supplement|Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.
75343421|NCT06212115|Diagnostic Test|mNGS|metagenomics next generation sequencing
75343422|NCT06212076|Drug|IPG1094|IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg
75343423|NCT06211738|Other|no intervention|no intervention
75343424|NCT06211660|Behavioral|AI-based AR training system|Participants will use the AI-empowered AR training system to get individualized assessments of their hand wash performance. They will not be informed about the hand scanner results.
75476038|NCT02002260|Drug|Combined oral contraceptives|
75476039|NCT02002273|Procedure|Switching level of suction|
75653997|NCT05241704|Procedure|Endovenous ablation of superficial venous reflux|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
75653998|NCT05241626|Diagnostic Test|AS-OCT|Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
75653999|NCT05337254|Drug|Dihydroergotamine|Dihydroergotamine intranasal powder
75654000|NCT05337254|Drug|Dihydroergotamine|Dihydroergotamine intramuscular injection
75939768|NCT03166046|Device|Placebo Pulsed Shortwave therapy|Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
75939769|NCT03681587|Other|Control situation|"Standard breakfast usually offered monotonous control condition at the retirement home: the time of distribution, the duration of ingestion and the composition will be habitual. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone in the room or with others in the dining room."
75939770|NCT03681587|Other|Experimental situation|"Salty/sweet breakfast varied experimental situation: the time of distribution and the duration of mealtime will be open and the composition will be varied with sweet/savory foods. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone or in the room or with others in the dining room."
75939771|NCT03161366|Biological|rVSVΔG-ZEBOV-GP|Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
75939772|NCT03161288|Drug|KY1005|A human anti-OX40 ligand monoclonal antibody
75939773|NCT03161288|Drug|Placebo|Matched placebo
75939774|NCT03681509|Drug|Pramipexole|Pramipexole
75654001|NCT05337254|Drug|Dihydroergotamine|Dihydroergotamine intranasal spray
75939775|NCT03681509|Drug|Placebo|Lactose placebo capsule
75939776|NCT03686267|Other|opaqued titanium abutments|masking metallic color of titanium abutments by opaque porcelain
75343425|NCT06211660|Behavioral|Hand scanner and Video training|Participants will use an existing education program that has been demonstrated effective in our previous study (unpublished). In brief, the participants will be informed about their hand scanner results during the first HW attempt. They will also watch a training video about the 7 steps of hand washing.
75343426|NCT06211517|Other|Semi-structured interviews with visual mediations|Semi-structured interviews with visual mediations / An hour-long interview
75343427|NCT06211517|Other|Semi-structured interviews|Semi-structured interviews
75343428|NCT06211374|Behavioral|Communication Bridge|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
75343429|NCT06211296|Device|Shortcut|Splitting bioprosthetic aortic valve leaflets
75476040|NCT02002286|Drug|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
75939777|NCT03686267|Other|lithium disilicate coping (high opacity)|masking metallic color of titanium abutments using lithium disilicate copings
75939778|NCT03686267|Other|titanium abutment with no color masking|color masking methods are avoided in this arm
75939779|NCT03686189|Device|Iliac Bifurcation Stent Graft System|Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
75939780|NCT03686111|Diagnostic Test|oocytes collect|After stimulation, an echo-guided oocyte puncture is performed under anesthesia
75939781|NCT03685955|Biological|Amniotic membranes|Amniotic membranes will be employed during participant's genitourinary reconstruction
75939782|NCT03164252|Radiation|Grupo I- Lower laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
75343430|NCT06210815|Drug|HLX42|HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
75476041|NCT02002286|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
75476042|NCT02002312|Drug|Lu-177-DOTA-girentuximab|"Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.~Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments."
75343431|NCT06210776|Drug|Trastuzumab deruxtecan|Intravenous infusion
75343432|NCT06210633|Other|medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
75343433|NCT06210633|Other|endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
75343434|NCT06210555|Procedure|Renal transplantation|Operative procedure - receipt of a kidney
75476043|NCT02002325|Drug|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
75476044|NCT02002325|Other|Standard care|Standard treatment for acute stroke without intravenous alteplase.
75654002|NCT00896532|Drug|Placebo to Romosozumab|Administered by subcutaneous injection QM or Q3M.
75654003|NCT00896532|Drug|Alendronate|Administered orally once a week
75654004|NCT00896532|Drug|Teriparatide|Teriparatide 20 μg administered by subcutaneous injection once a day
75939783|NCT03164252|Radiation|Grupo II- Greater laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
75939784|NCT03164252|Radiation|Grupo III- Laser sham|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
75939785|NCT03161210|Other|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
75939786|NCT03161210|Other|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
75939787|NCT03161210|Other|Saline|Saline is a control group
76089787|NCT05639556|Other|Oral glucose tolerance testing (OGTT)|For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.
76089788|NCT05639556|Device|Continuous glucose monitoring (CGM)|Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.
76089789|NCT05639556|Diagnostic Test|Chest CT scans (When available within the past 6 months in medical records)|Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.
75939788|NCT03160976|Other|Cryolipolysis|First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
75939789|NCT03164096|Drug|Bupivacaine Hydrochloride|intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
76089790|NCT05639556|Diagnostic Test|Hologic Dual X-Ray Absorptiometry (DXA)|DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.
75939790|NCT04480034|Procedure|Bariatric procedures|All standard, laparoscopic bariatric procedures endorsed by SICOB (Società Italiana della Chirurgia dell'Obesità, Italian Society of Obesity Surgery) and by IFSO (International Federation of the Societies of Obesity Surgery), will be considered: sleeve gastrectomy, R-en-Y gastric bypass, one anastomosis gastric bypass, single anastomosis duodeno-ileal bypass with sleeve. The selection criteria for the surgery candidates will comply to the latest guidelines for bariatric surgery endorsed by SICOB, IFSO and EAES (European Association of Endoscopic Surgery). All the participating centers will follow the usual recruitment protocol. Restart of the bariatric elective surgery is based on the guidelines of SICOB for the bariatric surgery restart in Italy during the COVID-19 phase 2-3 of endemics.
76089791|NCT05639556|Diagnostic Test|Ultrasound Sub-study of assessment of appendage muscles using ultrasound|A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.
76089792|NCT05639556|Diagnostic Test|Hunger Vital Sign questionnaire|Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.
76089793|NCT05639556|Other|Respiratory symptom questionnaire: CRISS|Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.
76089794|NCT05639556|Diagnostic Test|Spirometry|Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.
76089795|NCT05639556|Other|Food logging|Subjects will be requested to complete an electronic food diary for at least 3 days and a maximum of 10 days (2 weekdays, 1 weekend day) to document dietary intake pre-specified days during the study period.
76089796|NCT05612750|Behavioral|Education|Participants will receive one of two educational programs.
76089797|NCT05600543|Device|Lumbar belt|"All subjects (LBP group and healthy group) wear the belt during the two visits to perform differents tests.~The invistigator will ask the LBP patients to wear the lumbar belt between the two visits (for 4 weeks, for 4 to 8 hours per day)"
76089798|NCT05580419|Behavioral|4PCP Course|4PCP is a training framework for the management of chronic pain and gives practitioners lasting knowledge on how to better care for chronic pain patients.
76089799|NCT05565833|Behavioral|SHUTi OASIS|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6-9 weeks in a fully automated, interactive, tailored web-based program
76089800|NCT05565833|Other|Patient Education|An educational website containing information on insomnia
76089801|NCT05525403|Other|Knee Extension Exercise|Participants will be seated in a Steel Flex machine with weight equal to 50% of their 1 repetition maximum added to the machine. Participants will extend the dominant knee until the assigned fatigue level.
75343435|NCT06210555|Procedure|Living kidney donation|Operative procedure - donation of a kidney
75343436|NCT06210516|Device|PowerBreathe|"Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~Chest circumference measurements~Diaphragm movements and thickness (ultrasound)~Hand grip strength (with a Jamar hand dynamometer)~Motor Activity Log~6 Minute Walk Test (6MWT)~Canadian Occupational Performance Measure~Charlson Comorbidity Index"
75476045|NCT02002364|Procedure|tracheal intubation|
75476046|NCT02002377|Drug|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
75476047|NCT02002390|Drug|Fingolimod|A sphingosine-1-phosphate receptor regulator
75476048|NCT02002403|Drug|Danazol|
75476049|NCT02002429|Procedure|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
75801378|NCT01343056|Behavioral|Office Staff Support|The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
75801379|NCT01343056|Behavioral|Peer Support|Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
75801380|NCT01343056|Behavioral|Usual Care Support|Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
76089802|NCT05525403|Other|Quiet Rest|Participants will sit quietly for two minutes, three times.
75801381|NCT01343056|Behavioral|Educator Support|Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
75939791|NCT03164018|Drug|Fampridine|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments and management of the disease will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behavior.
76089803|NCT05500833|Other|Multidimentional observation scale (MDP)|Upon arriving to the hospital (for an hospitalization or a consultation), a trained and declared investigator will inform the patients and their parents of the study, orally and using a written information note. Participation to the study will also be proposed to under aged children in an adequate language and a specific information note will be handed to them. If they wish, they will have a 20 min reflexion time before deciding on participating to the study.One the patient is included, the study will unfold as follows. First, Evaluation of acute dyspnea: general data and dyspnea scores will be collected upon inclusion, and dyspnea score will be collected once again 30 min later, and subsequently one a day until the end of hospitalization (test-retest). Data from clinical examination and treatment modifications will also be collected daily. Second, Evaluation of chronic dyspnea: general data and dyspnea scores will be collected upon inclusion and 1 to 1.5h later
75476050|NCT02002429|Procedure|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
75654005|NCT00896532|Drug|Romosozumab|Administered by subcutaneous injection
76089804|NCT05499013|Drug|SLN124|SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
75801382|NCT04558138|Other|Discharge timing|Patients will be discharged home on the day of surgery as opposed to POD #1
75939792|NCT03689777|Procedure|sleeve gastrectomy|sleeve gastrectomy
75939793|NCT03689777|Procedure|gastric bypass|gastric bypass
75939794|NCT03163784|Biological|Fecal Inoculum Capsule|Sieved fecal matter prepared in glycerol/saline solution
76089805|NCT05499013|Drug|Placebo|sodium chloride, solution for injection
76089806|NCT05496036|Drug|Pembrolizumab|400mg IV
76089807|NCT05493176|Other|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
75939795|NCT03163784|Biological|Placebo (for Fecal Inoculum Capsule)|Placebo capsule manufactured to mimic Fecal Inoculum Capsules
75939796|NCT03163784|Drug|Antibiotic|Antibiotic pre-treatment
75939797|NCT03163784|Drug|Antibiotic Placebo|Placebo tablets manufactured to mimic antibiotics
75939798|NCT01791543|Device|Intramural Needle Ablation Catheter|
76089808|NCT05488496|Behavioral|Nature-based social intervention (NBSI)|"The nature-based social prescribing is a multicomponent complex intervention applied by health or social care professionals as facilitators after a specific training.~It comprises: a psychosocial component and nature-based activities.~The psychosocial component is adapted from the group dynamic of Circle of Friends methodology focused on loneliness (Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Barcelona and the target population of adults living in urban socio-economic vulnerable areas.~Nature-based activities are chosen by group participants through a co-created menu comprising all local resources in the area related to nature.~Specifically, participants start with an individual one-to-one session and then they meet once a week for two hours 10 weeks. Each week, participants decide the nature-based activity they wish to conduct."
75343437|NCT06210516|Other|Conventional Physiotherapy|"Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~Chest circumference measurements~Diaphragm movements and thickness (ultrasound)~Hand grip strength (with a Jamar hand dynamometer)~Motor Activity Log~6 Minute Walk Test (6MWT)~Canadian Occupational Performance Measure~Charlson Comorbidity Index"
75343438|NCT06210191|Procedure|Intramedullary headless screw fixation|fixation of fractures of metacarpals and phalanges by intramedullary headless screws
75343439|NCT06210126|Other|local anesthetic injection|Ultrasound-guided pectointercostal fascial plane block group using 20 mL of 0.25% bupivacaine
75343440|NCT06210126|Other|Standard perioperative and postoperative analgesia protocol|postoperative IV morphine PCA and paracetamol will be given. If VAS is 3 or above, 75 mg dexketoprofen trometamol will be administered.
75476051|NCT02002429|Procedure|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
75939799|NCT03681431|Drug|Ceftriaxone 4g/ 24h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
75654006|NCT00896532|Drug|Denosumab|Denosumab 60 mg administered by subcutaneous injection Q6M
75654007|NCT00896532|Drug|Placebo to Denosumab|Administered by subcutaneous injection Q6M
75654008|NCT00896532|Drug|Zoledronic acid|Zoledronic acid 5 mg administered intravenously
75654009|NCT00574873|Drug|Bosutinib|500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
75801383|NCT03049618|Other|Laboratory Biomarker Analysis|Correlative studies
75801384|NCT03049618|Biological|Pembrolizumab|Given IV
75801385|NCT03049618|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
75801386|NCT01316692|Other|laboratory biomarker identification and analysis|Correlative studies
75801387|NCT01316692|Procedure|biopsy|Correlative studies
75801388|NCT01316692|Other|immunohistochemistry/tissue microarrays|Correlative studies
75801389|NCT01316692|Genetic|TdT-mediated dUTP nick end labeling assay|Correlative studies
75939800|NCT03681431|Drug|Ceftriaxone 2g/ 12h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
76089809|NCT05488496|Behavioral|Usual care + menu with nature-based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
75476052|NCT02002442|Other|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
76089810|NCT05393999|Biological|BMS-986414|Broadly neutralising antibodies BMS-986414
76089811|NCT05393999|Biological|BMS-986413|Broadly neutralising antibodies BMS-986413
76089812|NCT05364918|Drug|Jeksung combined with anti-radiation spray|Treat radiation stomatitis with Jeksung combined with anti-radiation spray
76089813|NCT05363215|Drug|S-217622|Tablet for oral administration
76089814|NCT05359380|Other|ADL performance|"ADL performance~All study groups address the following 10 ADL tasks in 9 different combinations of light temperature and light intensity in order possible differences to be revealed among the study groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc / 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc / 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
75343441|NCT06210100|Device|Active iTBS|Mag-TD stimulator
75343442|NCT06210100|Device|Sham iTBS|Mag-TD stimulator
75343443|NCT06209788|Procedure|experimental group|The music intervention consists of two parts. The first part occurs during the surgical procedure, starting from the induction of anesthesia and continuing until the surgery over. The second part spans from the first day post-surgery to the fifth day (or until discharge), with the patient listening to music twice a day, each session lasting for 30 minutes. The planned times for the music sessions are expected to be at 11 a.m. and 8 p.m. Each day post-surgery, the music intervention must be completed, and measurements of respiratory rate, pulse rate, blood pressure, and pain score should be taken both before and after listening to the music. Other are routine post-operative care.
75476053|NCT02002455|Device|PET/CT, PET/MRI, mpMRI|FACBC dose 370 megabecquerel (MBq)
75476054|NCT02002468|Other|Test result sent by letter|
75343444|NCT06209606|Drug|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
75343445|NCT06209606|Drug|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
75939801|NCT03744741|Diagnostic Test|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
75939802|NCT02925455|Device|Contralaterally-controlled functional electrical stimulation|Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
75939803|NCT02925455|Device|Hand therapy video games|Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
75343446|NCT06209606|Drug|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
75343447|NCT06209060|Behavioral|Hammock Position|Researchers will make a hammock by using a soft rectangular cotton cloth with ropes that pass through the circular openings of the incubator and are tied on the upper part of it. Babies will be placed in this hammock in a supine position with their extremities in the midline. The spine of the preterm neonate will support while arms and knees are flexed. Additionally, a small rectangular roller will be placed between the cervical and scapular region of the newborn in the hammock position to ensure that no hyperflexion or hyperextension position of the head occurs, which may impair respiratory function.
75343448|NCT06209060|Behavioral|Nesting|In the nesting group, a nest will be made using rolls prepared with materials such as towels and blankets, and the baby will be placed in this nest. The baby's head and body will be positioned on the same axis, its extremities will be positioned in the midline, and its hands will be positioned close to its face.
75476055|NCT02002468|Other|Test result conveyed by general practitioners|
75476056|NCT02002481|Other|transport|The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
75476057|NCT02002585|Procedure|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
75476058|NCT02002598|Drug|Bendamustine|"Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.~Dose escalation is as follows:~-1 | 60 mg/m2~| 70 mg/m2~| 70 mg/m2~| 90 mg/m2~| 90mg/m2~| 90 mg/m2"
75476059|NCT02002598|Drug|Carfilzomib|"Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.~Dose Escalation is as follows:~-1 | 27 mg/m2~| 27 mg/m2~| 36 mg/m2~| 36 mg/m2~| 45 mg/m2~| 56 mg/m2"
75476060|NCT02002598|Drug|Dexamethasone|Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
75476061|NCT02002611|Drug|Lobeglitazone|
75476062|NCT02002611|Drug|Warfarin|
75476063|NCT02002624|Device|PSI|
75476064|NCT02002624|Device|Conventional instrumentation|
75476065|NCT02002637|Device|Latella Knee Implant System|
75476066|NCT02002663|Drug|ropivacaine 0.2%|PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
75476067|NCT02002663|Drug|Methylprednisolone 1mg/kg|
75476068|NCT02002663|Drug|saline 0.9%|
75801390|NCT01316692|Other|mass spectrometry|Correlative studies
75801391|NCT05536102|Drug|PLD|20mg/m2, day 1, q3w
75801392|NCT05536102|Drug|Oxaliplatin|130 mg/m2, day 1, q3w
75801393|NCT05536102|Drug|Capecitabine|1000 mg/m2, days 1-14, q3w
75801394|NCT05536102|Drug|Tislelizumab|200 mg, day 1, q3w
75801395|NCT04452916|Other|Buchinger fasting|Caloric intake of < 250 kcal/d for 5 days
75939804|NCT01563783|Procedure|Global Fibroid Ablation (GFA)|GFA is being used for the treatment of symptomatic uterine fibroids
76089815|NCT05336747|Behavioral|Voice lessons|12 x 60 minute one-on-one vocal training lessons, once weekly in person or over videoconferencing, and additional 60 min per week home training of vocal pitch control using an internet based vocal pitch app.
76089816|NCT05320068|Drug|Oral Vancomycin|A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
76089817|NCT05320068|Drug|Placebo|A blinded capsule that contains no vancomycin every 6 hours during 10 days.
76089818|NCT05296551|Other|Motor Task|A visuomotor task is presented where an individual must match their knee to an ellipse that moves up and down on a screen, resulting in a marching-in-place motion at a specified frequency.
75343449|NCT06208670|Behavioral|Progressive muscle relaxation exercises|PMI is among the non-pharmacological methods nurses can offer caregivers (Yılmaz et al., 2019). Health professionals, especially nurses, should evaluate all women of reproductive age in terms of PMS, plan educational interventions that will increase their awareness of the issue and enable them to develop appropriate coping strategies, support the planned educational interventions through written or visual materials, provide effective and quality counseling services, and aim to improve women's decreased quality of life (Abay & Kaplan 2019; Aksoy Derya et al. 2019; Akmalı et al. 2020). Women can be advised to do relaxation exercises such as walking, running, swimming, and yoga regularly (at least 30 minutes a day) as they reduce stress by increasing endorphin levels and improve heart rate, lung capacity, and general health (Penedo & Dahn, 2005; ACOG, 2015; Khajehei 2015).
75654010|NCT00574873|Drug|imatinib|400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
75654011|NCT02843334|Biological|Dried blood spot (DBS) sampling|DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
76089819|NCT05296551|Other|Cognitive-motor dual-task|"While performing the Motor Task intervention, letters of different colors and orientation randomly appear one at a time on the screen. During the Cognitive-motor dual-task, individuals are instructed to count the number of times that either 1 (simple cognitive task), or 2 (complex cognitive task) characters appear on the screen during the motor task."
76089820|NCT05296135|Diagnostic Test|OncoPrism-HNSCC™|OncoPrism-HNSCC™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
76089821|NCT05291377|Other||
76117239|NCT03065088|Behavioral|eLIFE|The eLIFE includes a personalised ICT-administered training schedule using the activities developed in aLiFE, delivered in the form of video clips, pictures and text/verbal instructions on a smartphone and smartwatch application. Personalisation of activity content will be decided based on a phenotype tool and initial difficulty level is decided through the aLiFE assessment tool. In addition, a virtual instructor teaches the participants how to carry out the eLiFE programme. The user receives motivational messages and feedback, and there will be a possibility for social interaction between the participants. The instructors teach the eLiFE participants the programme during 4 home visits and 3 phone calls during the 6 month intervention period.
75654012|NCT05335746|Diagnostic Test|Optical coherence tomography angiography (OCT-A)|Optical coherence tomography angiography scanning will be done for all subjects in the study.
75801396|NCT03626584|Other|18F-NaF PET|Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes
75343450|NCT06208670|Behavioral|Violent tendency Scale|Violent tendency Scale
75939805|NCT01563783|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
75939806|NCT01563783|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
75343451|NCT06208371|Procedure|Surgical resection and/or ablation therapy and/or SBRT|Participants may receive surgical resection and/or ablation therapy and/or stereotactic body radiotherapy
75476069|NCT02002715|Drug|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
75476070|NCT02002741|Drug|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
75476071|NCT02002741|Drug|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
75801397|NCT05524714|Dietary Supplement|solubilized Xanthohumol low dose|single administration of 2 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol and 2 soft gelatine capsules containing only micelles
75801398|NCT05524714|Dietary Supplement|solubilized Xanthohumol high dose|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
75801399|NCT05524714|Dietary Supplement|native Xanthohumol low dose|single administration of 2 hard gelatine capsules each containing 43 mg native Xanthohumol and 2 hard gelatine capsules containing silicon dioxide
75939807|NCT03689621|Device|Transcutaneous vagus nerve stimulation (tVNS)|
75939808|NCT03681197|Drug|Metformin|Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
75939809|NCT03681197|Drug|Placebo|In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
75939810|NCT03681197|Drug|Clomiphene Citrate|50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
75939811|NCT03485703|Drug|Azithromycin|the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
75939812|NCT03485703|Drug|Placebo|the group of newborns will receive 0.9% saline once daily for 5 days
75939813|NCT03165344|Other|Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)|the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
75939814|NCT03165344|Other|Triamcinolone Acetonide (route of administration)|The control group will get local injection of triamcinolone acetonide in wound during the operation.
75939815|NCT03165344|Other|Prednisone (route of administration)|The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
75939816|NCT03487029|Other|Short duration|exercise Short duration high intensity training
75939817|NCT03487029|Other|Long duration|exercise Long duration high intensity training
75343452|NCT06208371|Drug|Palliative Chemotherapy|Participants in this group may continue the original systemic chemotherapy regimen. Patients with tumor control after 10-12 cycles can either transition to maintenance treatment or temporarily suspend treatment until disease progression, at which point they switch to a second-line treatment regimen.The selection of second-line and subsequent treatment regimens follows CSCO guidelines and clinical practices.
75343453|NCT06208189|Behavioral|High-effort session|Participants will perform 3 sets per exercise (total of 21 sets) with as many repetitions they can each set. We anticipate participants will perform ~10 repetitions per set in this session, with a total tempo of ~2.5 seconds per rep, averaging ~25 seconds per set. Resting period between exercises and sets will be 120 seconds. This will lead to a total session time of ~50 min. Their glycemic control will be evaluated during the following ~48 hours.
75476072|NCT02002754|Drug|Bambuterol Hydrochloride tablets|Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
75476073|NCT02002780|Behavioral|Day Camp|"The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project."
75476074|NCT02002793|Other|Early stage abdominal drainage|Ultrasound/CT/GUS guided abdominocentesis and drainage with single-chamber deep venous catheters shoule be implemented and the catheter should be removed when abdominal drainage flow≤100ml in two successive days;
75801400|NCT05524714|Dietary Supplement|native Xanthohumol high dose|single administration of 4 hard gelatine capsules each containing 43 mg native Xanthohumol
75476075|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT scan:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
75801401|NCT05692804|Diagnostic Test|Mini Mental State Examination(MMSE),Montreal Cognitive Assessment ( MoCA),S100B ( protein S100 subunit beta) ,GFAP ( glial fibrillary acidic protein ),NSE ( neuron-specific enolase )|MMSE and MoCA will be applied preoperative,postoperative first day and fourth day S100B,GFAP and NSE will be measured in blood tests preoperative,postoperative second hour,postoperative 24. hour and postoperative 96. hour
75476076|NCT02002806|Other|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
75654013|NCT02843490|Drug|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
75654014|NCT00902174|Drug|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
75801402|NCT01316380|Drug|placebo|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
75801403|NCT01316380|Drug|tiotropium 2.5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
75801404|NCT01316380|Drug|tiotropium 5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
75801405|NCT05692648|Behavioral|Supine position group|These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.
75939818|NCT03165578|Other|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
75939819|NCT03165578|Other|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
75939820|NCT03486951|Procedure|Orthognathic Surgery:|maxillary/mandibular osteotomies for orthognathic purposes for the treatment of a dento-maxillary dysharmony The choice between outpatient procedure or hospitalization is decided by the surgeon on a case-by-case basis according to data relating to the general state of the patient, the type of surgery, the social context, the distance from the patient's home. a medical center in accordance with the usual and legal standards of outpatient surgery
75939821|NCT03114878|Other|TRT / EMDR|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Eye Movement Desensitization and Reprocessing:~This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere."
75939822|NCT03114878|Behavioral|TRT / CBT|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Cognitive Behavioral Therapy:~CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions."
76117240|NCT03065088|Behavioral|control|The control group follows the World Health Organization's recommendations of physical activity. The control participants will receive one home visit and be given a written letter with the activity recommendations.
75654015|NCT00902174|Drug|Placebo|Placebo to imatinib 100 mg film coated tablets
75343454|NCT06208189|Behavioral|Low-effort session|Participants will perform 6 sets per exercise (total of 42 sets) but perform half of the anticipated number of repetitions of the HIGH session (i.e., 5 reps). Repetition tempo at ~2.5 seconds will result in ~12.5 seconds per set. Resting period between exercises and sets will be 60 seconds. This prescription will also lead to a total session time of ~50 min. Thus, both the HIGH and LOW session will have similar total volume-load and session density, but differ in perceived effort after each set. Their glycemic control will be evaluated during the following ~48 hours.
75343455|NCT06208189|Behavioral|Control|The control session all procedures will be identical to the HIGH session, with the exception of performing the resistance exercises. However, to simulate all other procedures participants will follow all instructions, be positioned on the equipment for the same amount of time as the HIGH session, but will not perform any repetition. Interval between fake sets and exercises will be 120 seconds. Their glycemic control will be evaluated during the following ~48 hours.
75343456|NCT06208020|Other|Functional near-infrared spectroscopy (fNIRS) detection|fNIRS( NirScan Danyang Huichuang Medical Equipment Co. Ltd., China) will be used to detect changes in HbO and HbR during rest and voluntary swallowing. The swallowing procedure will be used consisted of three phases of manipulations: 30-s resting state periods, 30-s swallowing periods and 30-s resting state periods. A pre-collection will be conducted before the formal collection so that the subjects could understand the test process. After the pre-collection, the subjects will take a rest for 5 minutes before the formal collection.
75343457|NCT06207942|Device|Feed back controlled temperature device|If core temperature exceeds 37.7 degrees celsius a feedback controlled-device will be used at set to 37.5 degrees celsius
75343458|NCT06207942|Other|High MAP|A mean arterial blood pressure (MAP) of >85mmHg will be used. Vasopressors will be titrated to this target during 36 hours
76117241|NCT01677143|Drug|Bupivacaine 5mg/ml|5 ml in trocar area
76117242|NCT03693365|Procedure|PEEP trial|Positive end-expiratory pressure (PEEP) is increased from 5 to 10 cmH2O during one minute.
76117243|NCT03692663|Drug|TABP EIC|A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
75343459|NCT06207942|Other|Deep sedation|Deep sedation for at least 36 hours
75343460|NCT06207942|Other|Fever control without a device|Management of fever in the intensive care unit without a device
75343461|NCT06207942|Other|Low MAP|A mean arterial blood pressure (MAP) of >65mmHG will be used. Vasopressors will be titrated to this target during 36 hours
75343462|NCT06207942|Other|Minimal sedation|A strategy of minimal sedation in the intensive care unit, used only as needed to facilitate transport, imaging and invasive procedures
75343463|NCT06207851|Device|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
75476077|NCT02002806|Other|Placebo Injection|
75654016|NCT05337176|Other|app-coo application|"The Montreal Cognitive Assessment (MoCA) is a measure designed specifically for detecting mental cognitive impairment(MCI) APP-Coo-Balance-Test can assess the oscillation of the trunk in different static positions: Feet Together, On a Broad Base (medial malleoli 30 cm apart) , and during the gait Dynamic(Arcuria et al., 2020)."
75654017|NCT04201808|Drug|Tenofovir Alafenamide 25 MG|All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
75801406|NCT05692648|Behavioral|Hourly position change group|"Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours."
75801407|NCT05692648|Behavioral|Control Group (2-hour position change)|Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation. Phototherapy was started with neonates in supine position. In the second period, the neonate was placed in the prone position after routine feeding was performed.
75801408|NCT05692570|Drug|PBI-200 Tablet|PBI-200 is a TRK inhibitor
75801409|NCT05692570|Drug|Ritonavir Oral Tablet|Ritonavir is a potent CYP3A inhibitor
75801410|NCT05692570|Drug|Cobicistat Oral Tablet|Cobicistat is a potent CYP3A inhibitor
75801411|NCT05692414|Dietary Supplement|Preoperative carbohydrate drink|Allocation will be performed using an alternating weeks scheme. Patients undergoing surgery in the first week will be included in the control group and follow a conventional fasting protocol. However, patients undergoing surgery the following week will be included in the intervention group and take 800 ml of CHO drink on the day before surgery and 400 ml on the surgery day no later than 6 hours before the procedure.
75801412|NCT05692336|Other|vestibular training|balance training in the form of vestibular training
75801413|NCT05692336|Other|dual task training|balance training in the form of dual task training
75801414|NCT05692258|Other|Acupuncture|"Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint).~Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011."
75939823|NCT03689465|Drug|ATG|In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
75939824|NCT03689465|Drug|CTX|In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
75939825|NCT03689465|Drug|Mycophenolate Mofetil|In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
75939826|NCT03689465|Drug|Ciclosporin A (CsA)|In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
75939827|NCT03689465|Drug|methotrexate (MTX)|In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
75476078|NCT02002845|Device|robotic surgery using the da Vinci Surgical System|
75476079|NCT02002858|Drug|Nicotine Patch|
75476080|NCT02002858|Behavioral|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
75939828|NCT03485625|Drug|Lidocaine|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
75654020|NCT04201886|Other|serum calprotectin|serum calcium binding leucocyte protein
75654021|NCT02845388|Drug|Sildenafil citrate|
75801415|NCT05692102|Other|Evaluate quality of life after gynaecological malignancies diagnosis and treatment|diagnosis and treatment
75801416|NCT05691946|Procedure|Kinesiology Taping|The experimental group was applied 'Y shaped' kinesiology taping on gastro-soleus muscle group, based on facilitation technique with 25-50% stretching.
75939829|NCT03485625|Drug|Ketorolac|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
75939830|NCT03485625|Drug|paracetamol|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
75939831|NCT03685799|Diagnostic Test|Pathological revision|Pathological revision
75939832|NCT03114332|Procedure|Subcutaneous Drain|A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
75939833|NCT03680885|Drug|Lidocaine gel|Lidocaine gel 5%, PEG with FD&C Blue No.1 (Brilliant Blue FCF)
75939834|NCT03680885|Drug|Placebo|PEG with FD&C Blue No.1 (Brilliant Blue FCF)
75939835|NCT03680885|Drug|Injected lidocaine|Standard FDA-approved dental injectable lidocaine
75939836|NCT03114566|Other|Leukapheresis|Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
75939837|NCT03689309|Procedure|High Flow Oxygen SBT|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
75939838|NCT03680807|Diagnostic Test|Muscle function test|Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests
75939839|NCT03163862|Procedure|Endometrial scratch|the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
75939840|NCT03163862|Drug|G-CSF administration|1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
76117244|NCT03692663|Biological|Cyclophosphamide|Cyclophosphamide will be iv administered with 250 mg/m^2 at D-3, D-2, and D-1 before TABP EIC infusion.
76117245|NCT03692663|Biological|fludarabine|Fludarabine will be iv administered with 25 mg/m^2 at D-3, D-2, and D-1 before TABP EIC infusion.
75476081|NCT02002858|Behavioral|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
75654022|NCT02845388|Drug|estradiol valerate|
75654023|NCT02843412|Procedure|choose two tumor tissue paraffin blocks|
75654024|NCT04357184|Other|Blood flow restriction training|BFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum
75654025|NCT02840760|Device|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
75654026|NCT02845466|Biological|Becaplermin|0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
75476082|NCT02002897|Device|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
75801417|NCT05691946|Procedure|Placebo Taping|The placebo group was applied kinesiology taping on gastro-soleus muscle group without any stretching.
75801418|NCT05691556|Procedure|HABIT ILE rehabilitation course|"The HABIT-ILE course, created by the Belgian team of Prof. Yannick Bleyenheuft, is a rehabilitation of the upper and lower limbs, following the concepts of structured motor learning and intensive therapy. The internships last 2 weeks and are performed on a multi-year basis since 2018 at the SSR pediatric, Fondation Ildys, Site de Ty Yann in Brest.~In this group, upper limb assessments are performed the week before and the week after the HABIT ILE training course"
75801419|NCT05691556|Procedure|botulinum toxin injections|"Toxin injections are used for their effect on the local reduction of spasticity after intramuscular injection. This treatment is usually offered to these children every 6 months or so for functional improvement.~These botulinum toxin injections are organized on a weekly basis in a pediatric day hospital (CHU Morvan in Brest).~In this group, upper limb assessments were performed 0-2 weeks before and then 4 to 6 weeks after the botulinum toxin injections (see table below), at the peak of the toxin's efficacy."
75801420|NCT05691322|Diagnostic Test|transvaginal ultrasound|Transvaginal ultrasound for endometriosis diagnosis (UBESS)
76089822|NCT05286359|Diagnostic Test|NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device|"NxTekTM Malaria Pf/Pv Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum(P.f.) on one test line and of pLDH of Plasmodium vivax (P.v.) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~NxTekTM Malaria Pf Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Plasmodium falciparum(P.f.) malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
75801421|NCT05691322|Diagnostic Test|MRI|MRI for endometriosis diagnosis (Enzian classification)
75801422|NCT05421364|Biological|Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)|Approximately 9 ml blood from each patient will be collected on the day of the LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. PBMCs (1x106cells/ml) suspended in RPMI 1640 supplemented with 10% HSA will be incubated in the presence of 10 IU/ml hHCG for 48 h. On day 2 after LH peak, fresh PBMCs (1x107 cells) will be also obtained from the same patients, these fresh PBMCs will be immediately combined with the 2-day cultured PBMC and suspended in PBS (2x107 cells/200µl). This cell suspension will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak.
75801423|NCT05689450|Other|Data collection: Amikacin concentration|Blood samples for the measurement of the concentration and calculation of the AUC of amikacin are collected 60 min (+/-30 min) and 8 h (+/-1 h) after the beginning of amikacin infusion. The blood collection after the start of the amikacin infusion will be repeated during every subsequent amikacin administration, but max. during 3 consecutive days.
75801424|NCT05688826|Dietary Supplement|Sugar|75 g sugar dissolved in 0.8 dl water and flavored with lemon. Ingested during 5 minutes
75801425|NCT03619720|Other|Records|Respiratory records, Vocal records Video records Questionnaires
75939841|NCT03163862|Drug|Saline Solution|saline infusion every day from the day of embryo transfer through the day of beta HCG test
75939842|NCT03685565|Procedure|Dermabond and steristrips|Laceration repaired with Dermabond with underlying steristrips
75939843|NCT03685565|Procedure|Dermabond|Laceration repaired with Dermabond
75939844|NCT03163706|Behavioral|Modified Stroop effect|to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
75939845|NCT03033069|Drug|Brexpiprazole|Brexpiprazole oral tablets.
75939846|NCT03033069|Drug|Sertraline|Sertraline oral capsules.
75939847|NCT03033069|Drug|Brexpiprazole Matching Placebo|Brexpiprazole matching placebo oral tablets.
76089823|NCT05284565|Device|Reading of the skin prick allergy test|"A double reading of the forearm will be performed with the Nexkin DSPT device. Also, two healthcare professionals will perform, consecutively, the manual reading according to their usual practice. Nexkin DSPT device provides a semi-automatic wheal detection, presenting the user an initial set of potential wheals and information about them (as their measure).~Healthcare professional can then discard, add and/or confirm wheals by visual validation, and add/edit wheal information. The device automates the test reading process, digitises the results, and quantifies."
76089824|NCT05277402|Drug|ADG116|IV infusion
76089825|NCT05397132|Genetic|Blood draw|Patients will provide a blood draw for research and repository
76089826|NCT05225168|Procedure|laparoscopic burch colposuspension operation|By pushing the urethra medially, two sutures are placed on the bladder at trigon level and midurethral and suspended on the bilateral iliopectineal ligament and colposuspension is supplied.
76117246|NCT02084069|Drug|Atorvastatin|
76117247|NCT03691961|Other|Hair sampling|After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.
75939848|NCT03033069|Drug|Sertraline Matching Placebo|Sertraline matching placebo oral capsules.
75939849|NCT03689231|Other|Volumetric measurements of liver metastases|"Depending on the available data and to be reproducible, patients will be divided into 2 sub-groups of follow-up imaging: CT only or MRI only, combined evaluation being not reliable for tumor detection~Patient follow-up at CT or MRI will be analyzed at baseline (date of discovery of hepatic metastatic disease), then 3-6 months after the start of the study, then annually.~At each assessment, a radiologist will analyze: the total volume of liver metastases (mm3), the estimated volume of the two target lesions chosen for RECIST follow-up (mm3), the number of liver lesions, and the evolution according to the RECIST criteria based on uni-dimensional measurements.~We will then correlate the following clinical data collected for patients: age, sex, presence of a carcinoid syndrome, Ki67 (%) and chromogranin A blood level (%) at diagnosis, number and location of other metastases, Octreoscan or Stereotactic Radio Surgery data if available."
75965936|NCT04874090|Other|Acupuncture|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program
75965937|NCT04874090|Other|Exercises|Patient will perform neck exercises
75965938|NCT03046082|Drug|Antibiotics|Observation of antibiotic types given to patients with pneumonia.
75939850|NCT03163628|Biological|Diagnostic performances of a combination of biomarkers|"3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.~The calculation of positive and negative likelihood ratios will be performed.~The targeted performances are:~A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.~A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3."
75939851|NCT03685409|Drug|Metformin Hydrochloride 500 MG|Metformin hydrochloride tablets 500 mg given orally once daily.
75939852|NCT03685409|Drug|Placebo Oral Tablet|Starch Placebo oral tablets will be given once daily to the control group
75343464|NCT06206265|Drug|TRYP-0082|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
75965939|NCT04869722|Behavioral|Liquid Model|Whey protein beverages will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
76089827|NCT05225168|Procedure|minisling suburethral sling|A vertical vaginal incision is made 1 cm below the external urethral meatus. It is followed by minimal vaginal dissection from the inferior portion of the ascending ramus of the ischiopubic bone to the obturator muscle. The arms of the mesh are fixed on both sides of the obturator internus muscle with the help of a trocar. After leaving a 1-2 mm gap between the mesh and the urethra, the vaginal wall is closed by suturing.
76089828|NCT01456377|Drug|predinose oral|1 mg for kg for 3 wekees
75343465|NCT06206265|Behavioral|Psychotherapy|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
75343466|NCT06205862|Procedure|fecal microbiota transplantation|We will use fecal suspensions and capsules prepared from the feces of healthy donors for fecal microbiota transplantation. Participants are required to complete one colonoscopy and infuse 125ml of fecal suspension into the terminal ileum under endoscopy, performing the first fecal microbiota transplantation (FMT) on day 0. Subsequently, for 5 days continuously (day 1-5), the participants will undergo microbiota transplantation in the form of oral capsules, taking 40 FMT capsules within one day (20 capsules bid). Subsequently, participants will receive a maintenance treatment with oral FMT capsules once a month (approximately every 25 to 30 days, for a total of 6 maintenance treatments). Participants will continue maintenance treatment until 6 months after their initial FMT treatment and undergo their first follow-up colonoscopy between 6 to 12 months.
76089829|NCT01456377|Drug|placebo group|use a oral placebo
75343467|NCT06205602|Drug|3BNC117-LS|30 mg/kg to be administered via IV at Step 1 (Day 1)
75343468|NCT06205602|Drug|10-1074-LS|10 mg/kg to be administered intravenously at Step 1 (Day 1)
75343469|NCT06205602|Drug|Placebo for 3BNC117-LS|0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
75343470|NCT06205602|Drug|Placebo for 10-1074-LS|0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
75476083|NCT02002897|Device|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
75654027|NCT02845466|Device|Promagran Dressing|44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
75654028|NCT02845466|Device|Placebo Dressing|Inactive wound dressing.
75801426|NCT05663554|Behavioral|WW Intervention|The core of the WW food program is the SmartPoints® system. Briefly, the SmartPoints® system assigns each food and beverage a SmartPoints® value per volume based on four components: calories, sugar, saturated fat, and protein. Certain foods have a SmartPoints® value of zero (ZeroPoint foods). These foods (e.g., lean sources of protein such as skinless chicken breast and vegetables) form the basis of a healthy eating pattern, are at low risk for overconsumption and do not have to be weighed, measured or tracked. Participants were assigned a personalized SmartPoints® Budget, based on reported food and lifestyle preferences, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure.
75801427|NCT05663554|Other|Usual Care|The Usual Care group will continue to receive routine medical care by their provider, in addition to receiving one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments.
75654029|NCT00623623|Procedure|primary PCI|Standard primary PCI
75654030|NCT00623623|Drug|enoxaparin|Adjunctive treatment
75654031|NCT00623623|Procedure|catheterisation|Routine or rescue coronary intervention
75654032|NCT00623623|Drug|tenecteplase|Single, weight-adjusted i.v. bolus of tenecteplase
75654033|NCT00623623|Drug|clopidogrel|Adjunctive treatment
75654034|NCT04281134|Device|Summit RC+S System|"Summit RC+S System consists of:~(i) One Model B35300R Olympus RC+S neurostimulator; (ii) One Model 4NR009 Patient Therapy Manager; (iii) One Model 4NR011 Clinician Telemetry Module; (iv) Two Model 3387 DBS leads; (v) Two Model 37087-60 DBS extensions; and (vi) One Model 97755 Recharger."
75801428|NCT05417308|Drug|Minoxidil|Applied topically
75801429|NCT05417308|Drug|Minoxidil|Given PO
75801430|NCT05417308|Other|Quality-of-Life Assessment|Ancillary studies
75801431|NCT05417308|Other|Questionnaire Administration|Ancillary studies
75939853|NCT05147948|Behavioral|iACT for PTSD and Chronic Pain|The participants will go through internet-based Acceptance and Commitment Therapy which mainly involves: 1) Exercises focused on developing acceptance, defusion, and mindfulness skills; 2) Identification of personal values as well as valued steps and feared situations to approach during the program 3) Written exposure exercises focusing on the traumatic memory adapted from Written exposure therapy (WET) using an ACT-based framework. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
75801432|NCT05606848|Other|Nutrition Emulsion (TPF-T)|"All patients will be randomized to receive the FSMP or control product.~Before the surgery: Patients daily intake control product with recommended energy.~1-8 days after surgery: Patients gradually increase control product intake to reach the recommended energy."
75939854|NCT05146544|Other|Heart Rate Recording|During the APA session, HR was digitized at 1Hz (using custo guard, Custo Med GmbH). The ratio between the APA session HR and exercise test HRpeak was used to assess the intensity of effort.
75801433|NCT05606848|Other|Foods for special medical purposes [FSMP] for patients with tumors|"All patients will be randomized to receive the FSMP or control product.~Before the surgery: Patients daily intake FSMP with recommended energy.~1-8 days after surgery: Patients gradually increase FSMP intake to reach the recommended energy."
75801434|NCT05578846|Drug|Treatment A|Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.
75939855|NCT03486795|Device|M1 stimulation|stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
75939856|NCT03486795|Device|PMC stimulation|stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
75939857|NCT03486795|Device|Sham stimulation|sham stimulation over both primary motor cortex and premotor cortex
75939858|NCT02917265|Device|TENS for vagus stimulation|TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.
75939859|NCT02917265|Device|TENS for sham stimulation|TENS electrodes are applied on an area of the external ear devoid of vagus innervation.
75939860|NCT03486717|Device|Virtual reality goggles|Patients will act as their own control over two different dental appointments. One appointment will consist of wearing the virtual reality googles, the other appointment will be conducted without them. The goggles have a small screen inside of them along with headphones. This device will play an a movie or cartoon that will immerse the patient during treatment.
75939861|NCT03163940|Behavioral|Laughter Yoga|A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
75939862|NCT03486639|Other|IPSS questionnaire|IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
75939863|NCT03165500|Drug|Diazepam|"Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
75654035|NCT04281134|Other|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
75654036|NCT02845310|Procedure|Restricted fluid therapy group|Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV < 10% - MAP >65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP > 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
75801435|NCT05578846|Drug|Treatment B|Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.
76089830|NCT05214950|Device|ORI monitoring|Oxygen reserve index monitoring during the surgery
75654037|NCT02845310|Procedure|Standard fluid management|Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
75654038|NCT02845154|Other|bolus purge|complete and uninterrupted purge
75801436|NCT05578846|Drug|Treatment C|Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.
75801437|NCT03619642|Other|Robotic assessment of finger proprioception|The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .
76089831|NCT05204160|Biological|Pembrolizumab|Given IV
75654039|NCT02845154|Other|Intermittent purge|intermittent portal purge
75654040|NCT02845076|Other|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
75343471|NCT06203639|Other|UR Caregiver|The UR Caregiver app was informed by previous research and developed in collaboration with caregiver partners. The app utilizes cognitive behavioural principles and is consistent with models of stress and coping. The app consists of seven modules. The app is available on IOS and Googe Play store. In addition to the didactic information provided in the app, worksheets are available in each module to practice the strategy/skill provided.
75343472|NCT06203639|Other|CLEAR Dementia Care|A subset of participants will be randomly assigned to use the CLEAR Dementia Care app as part of an active control group. The app consists of features that primarily address care-related needs (as opposed to stress management strategies) allowing for a comparison with the UR Caregiver app. The app was developed by the Northern Health and Social Care Trust (Northern Ireland) and is freely available on both IOS and Google Play stores. The CLEAR Dementia Care app provides users with information about dementia (e.g., the different types of dementia, how dementia affects the brain, and symptoms associated with dementia). The app offers suggestions and alternative approaches to various care-related situations through illustrations/images that caregivers may experience.
75343473|NCT06202092|Device|Phonophoresis|Ultrasound using honey as a media over the knee joint
75343474|NCT06202092|Device|Ultrasound|ultrasound using gel as a media over the knee joint
75343475|NCT06202092|Procedure|conventional physiotherapy|TENS, Strengthening, and stretching exercises
75654041|NCT00896454|Drug|denosumab|120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
75654042|NCT04224584|Drug|Duloxetine|Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.
75801438|NCT05393362|Procedure|Cardiac Rehabilitation Program (CR)|"Strength exercises: strengthe exercise will be performed twice a week for 12 weeks, 4-6 series at 60% RM at the beginning of the program, with a progression towards 85% RM in each functional movement at the end of the intervention. The patients will rest for 90 seconds between series and 3 minutes between exercises. Each session has an estimated duration of between 45-60 min.~Aerobic exercise: aerobic exercise it will be performed twice a week for twelve weeks, between 45-60 min each session of aerobic exercise. It will be developed on a treadmill or cycle ergometer at 50% of HR max at the beginning of the program with a progression towards 80% of HR max at the end, continuously or internally. The Borg scale will prevail over the objective data to adjust the intensity of each patient, Borg = 10/20 or mBorg = 5/10 at the beginning, with progression to Borg = 14/20 or mBorg = 8/10 at the end."
75801439|NCT05393362|Behavioral|Control Group (CG)|The control group will receive two education sessions per week for twelve weeks on the complications derived from Heart Failure (HF), functional deterioration, and healthy lifestyle habits.
75801440|NCT05391022|Drug|Pelabresib|Pelabresib monohydrate tablets
75801441|NCT04315298|Drug|Sarilumab|Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
75801442|NCT04315298|Drug|Placebo|Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
75939864|NCT03165500|Drug|Midazolam|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
75939865|NCT03165500|Drug|Nitrous Oxide + Oxygen Gas|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971)."
75939866|NCT03165500|Procedure|Third molar extraction|Anxious patients in need of third molar extraction
75939867|NCT03163238|Drug|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
75939868|NCT03163238|Drug|Normal saline|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
76089832|NCT05169151|Other|Smartphone Application|Utilize smartphone application
75654043|NCT04224584|Drug|Placebo oral tablet|Placebo will act as a control for duloxetine.
75654044|NCT04168892|Drug|150 IU of HMG in patients with age ≤ 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
75654045|NCT04168892|Drug|225 IU of HMG in patients with age > 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
75654046|NCT02789670|Other|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
75654047|NCT04044157|Other|non-invasive measurement of cardiac output|cardiac output will be non-invasivaly measured by means of electrical cardiometry
75654048|NCT00820651|Dietary Supplement|Diamel|Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks
75939869|NCT05150379|Other|Different exercises with their shoulders|"Y Balance Test~Shoulder rotator muscle isometric maximum strength~One handed medicine ball throw~Modified Closed Kinetic Chain Upper Extremity Stability Test"
75939870|NCT05150379|Behavioral|SI-RSI questionnaire|French version of Shoulder Instability Return-to-Sport after Injury
75965940|NCT04869722|Behavioral|Solid Model|Protein fortified scones will be used, with the amount of fat varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
76089833|NCT05161637|Drug|TLC590|TLC590 490mg or 588mg
75654049|NCT00820651|Other|Placebo and lifestyle counseling|Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with <10% of saturated fatty acids and protein 14%, and exercise)
75654050|NCT02993198|Drug|Carvedilol|
75801443|NCT04650542|Drug|HBI-3000|small molecule, multi-ion channel blocker
75801444|NCT04650542|Drug|Paroxetine|serotonin uptake inhibitor, CYP2D6 inhibitor
75801445|NCT03747224|Drug|ARO-ANG3|single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections
75939871|NCT04461561|Genetic|end-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
75939872|NCT04059341|Device|Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)|Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
75939873|NCT03486561|Drug|Ranolazine|Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
75939874|NCT03689153|Drug|JNJ-63733657|Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.
75801446|NCT03747224|Drug|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
75939875|NCT03689153|Drug|Placebo|Participants will receive matching placebo intravenously.
75939876|NCT05123144|Behavioral|BHS+ORCHID|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
75801447|NCT04621058|Drug|Vitamin D|In case of Vitamin D levels <30 or 40ng/ml patients will take vitamin D supplements.
75939877|NCT03685097|Diagnostic Test|Quantra System with the QPlus Cartridge|Point-of-care viscoelastic testing
75965941|NCT03048110|Drug|BAY1841788 (ODM-201)|In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5, In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8.
75965942|NCT03048110|Drug|Itraconazole|200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1, 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7.
75801448|NCT04621058|Drug|PLACEBO|Placebo capsules exactly the same as the above, but without the active component.
75801449|NCT04308668|Drug|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
76089834|NCT05161637|Drug|Bupivacain|Bupivacaine 75mg
75654051|NCT02843256|Device|Isomark Canary|The Isomark Canary will analyze the exhaled air and generate a breath delta value.
75654052|NCT01012596|Behavioral|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
76089835|NCT05161637|Drug|Ropivacaine|Ropivacaine 150mg
76089836|NCT05161637|Drug|Normal saline|Normal saline 20mL or 24mL
75654053|NCT04981808|Device|Telemonitoring|Telemonitoring of CGM and insulin pen data
75654054|NCT00629239|Drug|AZD4818|Dry Powder, inhalation, b.i.d., 4 weeks
75654055|NCT00629239|Drug|Placebo|
75654056|NCT04208100|Device|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery. The 595nm and 660nm wavelengths of the Lutronic PicoPlus Laser system are used for the treatment of benign pigmented lesions.
75654057|NCT03797378|Other|eM2M|The eM2M intervention involves three 60-minute sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
75654058|NCT02842944|Device|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
75654059|NCT02842944|Other|Routine care|Standardized routine care
75801450|NCT04308668|Other|Placebo|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
75801451|NCT04451330|Drug|Trifarotene cream|Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.
75801452|NCT04451330|Drug|Doxycycline hyclate|Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.
75801453|NCT04451330|Drug|Trifarotene Vehicle|Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.
75801454|NCT04451330|Drug|Doxycycline Placebo|Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
75801455|NCT02493426|Drug|Intranasal Oxytocin|
75801456|NCT02493426|Drug|Placebo|
75801457|NCT03747068|Drug|Anti-TNF Drug|
76089837|NCT05148559|Behavioral|Reminder Sent Via Preferred Method of Communication|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
75343476|NCT06202014|Radiation|concurrent radiotherapy with envafolimab and capecitabine|Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.Concurrent and sequential dose of envafolimab is 200mg subcutaneous injection weekly.Capecitabine is with a concurrent and sequential dose of 500-800 mg/m2 bid po , taken orally for 2 weeks and stopped for 1 week (standard concurrent dose is 800 mg/m2 bid po , but for patients ≥70 years of age, 500 mg/m2 bid po depending on physical status ) until progression or intolerance.
75343477|NCT06200194|Device|MiyoSmart Spectacles|No power in the central optic zone of DIMS lens for premyopic children with normal vision. Before entering elementary school, eligible preschoolers are asked to wear the DIMS spectacles after kindergarten hours and during weekends and holidays. After entering elementary school, full-time mode wearing of DIMS spectacles is required.
75939878|NCT03165266|Diagnostic Test|Two dimensional Echocardiography|"I- Routine transthoracic assessment for Left Atrium and Left Ventricle dimensions :~II- transthoracic assessment of the Right ventricular systolic function by:~. Right Ventricle fractional area change.~. Tricuspid annular plane systolic excursion .~. Tissue Doppler derived tricuspid annular systolic velocity.~. Right ventricle myocardial performance index . III- Assessment of Right ventricular diastolic function: is carried out by pulsed Doppler of the tricuspid inflow, or tissue Doppler of the lateral tricuspid annulus.~IV Assessment of Right Ventricle chamber quantification:~Right ventricular basal, mid ,and longitudinal dimensions.~Right ventricular Outflow Tract, and wall thickness V- Assessment of right atrial major ,and minor dimensions ,and right atrial End- systolic area IV- Assessment of longitudinal Right ventricular strain and strain rate by speckle tracking"
75939879|NCT02533713|Device|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
75343478|NCT06200194|Drug|0.01% atropine|daily use of non-preservative 0.01% atropine eye drop for each eye over the study period.
75343479|NCT06199934|Biological|Vaccination|BNT162b2 vaccination
75939880|NCT03680573|Drug|Control: Lacated Ringers|This site will serve as the control site
75939881|NCT03680573|Drug|Apocynin|This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.
75939882|NCT03680573|Drug|Allopurinol|This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.
75939883|NCT03680573|Drug|BH4|This site will be use to locally supplement BH4.
75939884|NCT03680573|Drug|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
75939885|NCT03680573|Drug|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
75939886|NCT03680573|Drug|Acetyl-ß-methylcholine chloride|Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
75343480|NCT06199206|Other|Theraputic Play|Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
75343481|NCT06198556|Drug|HRS-1167 tablets; rifampicin|HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.
75476084|NCT02002923|Procedure|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
75654060|NCT00625807|Behavioral|RR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing relaxation
75654061|NCT00625807|Behavioral|MBSR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing mindfulness
75654062|NCT02907242|Other|Revealment|Cerebroplacental ratio revealment
75654063|NCT04251000|Device|Joovv Mini|the smallest photomodulation device in the Joovv infrared light product line.
75939887|NCT05130645|Diagnostic Test|Mental Angle|In order to standardize and measure the mental angle, the projection of the mental will be accepted as the midline, the jaw structure will be transferred to the paper using the profile contour meter, and the angle between the angulus mandible and the mental will be measured and recorded with a digital protractor.
75939888|NCT03689075|Drug|Envarsus Oral Product|Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
76089838|NCT05148559|Behavioral|Reminder Sent Via Mailed Letter|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
76089839|NCT05147116|Other|Sleeping in a tent|Participants will spend 10 consecutive nights of sleeping in a tent
76089840|NCT05138666|Biological|respiratory sample|tracheal aspirate or sputum if the patient is not intubated
75654064|NCT02520908|Procedure|HSCT|Hematopoietic stem cell transplantation
75654065|NCT02520908|Other|Standard Care|
75939889|NCT05015127|Drug|HBM9161 680 mg qw by q2w from week 13|HBM9161 680 mg qw by q2w from week 13
75939890|NCT05015127|Drug|Placebo|Placebo
75939891|NCT05015127|Drug|HBM9161 680 mg qw by q2w from week 7|HBM9161 680 mg qw by q2w from week 7
75801458|NCT03758898|Other|Treatment|Chest physiotherapy and mobilization were applied twice a day, 8 times in total.
75343482|NCT06198335|Other|Modified Perichondral Approach Thoracoabdominal Nerve block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
75343483|NCT06198335|Other|Transversus Abdominal Plane block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
75343484|NCT06195878|Device|CPAP Therapy|Continuous positive airway pressure (CPAP) therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs)/sleep apnea.
75654066|NCT00829153|Device|U Clip|Interuppted nitional clips
75939892|NCT05015127|Drug|Placebo|Placebo qw by HBM9161 680mg qw from week 12
75939893|NCT03680495|Drug|Methylprednisolone|1. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.
75476085|NCT02002923|Drug|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
75654067|NCT00829153|Procedure|Conventional prolene anastomosis|Continuous prolene anastomosis
75654068|NCT02843022|Behavioral|standardized electronic messages|supportive and educational short messages
75654069|NCT02843022|Behavioral|nurse phone call if requested|"If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response"
75654070|NCT02843022|Behavioral|Staff nurse phone follow-up|Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
75801459|NCT03758898|Other|Group 2|Only mobilization was applied twice a day, 8 times in total.
75801460|NCT03758352|Procedure|remote ischemic preconditioning (rIC)|Short intermittent peripheral occlusions and reperfusions of the blood flow in the right lower extremity with the help of a tourniquet.
75801461|NCT03758352|Other|non remote ischemic preconditioning (non-rIC)|Retrospective group who have not undergone intervention.
75801462|NCT03756636|Procedure|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
75801463|NCT03756558|Device|Cross-Seal System|Use of the Cross-Seal system to close the femoral arteriotomy
75801464|NCT01321866|Procedure|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
75939894|NCT02328885|Drug|DLI of the 20 fraction of the UCBT|Administration of 20 fraction of the UCBT
75939895|NCT02178345|Procedure|diffusion weighted (DW) MRI|
75939896|NCT02178345|Procedure|dynamic contrast agent (DCE) MRI|
75939897|NCT03685019|Radiation|Valgus Stress|Valgus stress radiograph
75939898|NCT03685019|Radiation|Varus stress|Varus stress radiograph
75939899|NCT03685019|Radiation|0 degree flexion radiograph|0 degree flexion radiograph
75939900|NCT03685019|Radiation|20 degree flexion radiograph|20 degree flexion radiograph
75939901|NCT03685019|Radiation|45 degree flexion radiograph|45 degree flexion radiograph
75939902|NCT01997697|Other|behavior change program|behavior change program among patients with obesity
75939903|NCT03688997|Other|Simulator training|bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
75801465|NCT01321866|Procedure|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
75801466|NCT03763812|Procedure|Endovascular Aneurysm Repair (EVAR)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~Before induction of anesthesia~At wound closure~24 hours after surgery~48 hours after surgery~1 month after surgery~6 months after surgery~12 months after surgery"
75939904|NCT03492255|Drug|Cyclophosphamide|Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
75939905|NCT03492255|Drug|Methylprednisolone|"Patients in EUROLUPUS group will receive Methylprednisolone [750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone [500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)."
75939906|NCT03492255|Drug|Prednisone|Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.
75939907|NCT03492255|Drug|Mycophenolate Mofetil|From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
75343485|NCT06194227|Behavioral|High-speed, Cognitive Challenge Yoga|Participants in this group will receive in-person high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
75343486|NCT06194227|Behavioral|Traditional Yoga|Participants will perform in-person controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
75343487|NCT06193499|Procedure|Platelet rich plasma (PRP)|Intra-articular injection of platelet rich plasma (PRP)
75939908|NCT03684941|Device|Treatment Period One|LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
75939909|NCT03684941|Device|Treatment Period Two|CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
75343488|NCT06193499|Other|Placebo|Intra-articular Saline injection (0,6-1ml)
75343489|NCT06193174|Drug|C134 Re-Administration|Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).
75654071|NCT04024280|Other|Physical exercise program|Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
75654072|NCT04910438|Other|STIs screening and care|"Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).~Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM."
75654073|NCT00629083|Device|Bulkamid|Bulking injection with Bulkamid injection device
75654074|NCT00629083|Device|Contigen|Transurethral bulking injection
75939910|NCT03684863|Drug|Capecitabine|observation
75939911|NCT04715997|Drug|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
75939912|NCT04715997|Drug|Placebo|Normal saline
75343490|NCT06191198|Behavioral|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
75343491|NCT06191198|Behavioral|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
75343492|NCT06191042|Drug|si-544|Subcutaneous injection in the abdomen
75343493|NCT06191042|Drug|Placebo|Subcutaneous injection in the abdomen
75343494|NCT06191016|Device|Vagal nerve stimulation|Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
75343495|NCT06191016|Device|Sham vagal nerve stimulation|control will receive sham stimulation to vagal nerve along with prescribed medications
75654075|NCT02640690|Behavioral|Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)|(10) 1-hour sessions of trauma sensitive yoga
75965943|NCT03048110|Drug|Rifampicin|600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10.
76089841|NCT05138666|Biological|blood sample|Blood sampling drawn from an existing arterial line twice a week
75343496|NCT06190249|Biological|LN-144|LN-144 is composed of autologous TIL, which are obtained from an individual participant's tumor and expanded ex vivo through cell culture in the presence of the cytokine IL-2 and muromonab CD3, a monoclonal antibody (mAb) to human CD3 (OKT3). Participants will be given LN-144 on day 0 of the study.
75343497|NCT06190249|Drug|Cyclophosphamide|60 mg/kg of cyclophosphamide will be given intravenously to participants on days -5 and -4 of the study as a part of the NMA-LD regimen
75343498|NCT06190249|Drug|Mesna|a total of 78 mg/kg Mesna will be given to participants on days -5 and -4 of the study to prevent hemorrhagic cystitis that can be caused by the cyclophosphamide used in the NMA-LD regimen
75343499|NCT06190249|Drug|Fludarabine|25 mg/m2 of fludarabine will be given intravenously to participants on days -5 through -1 of the study as a part of the NMA-LD regimen
75343500|NCT06190249|Biological|Interleukin-2 (IL-2)|IL-2 IV administrations at a dose of 600,000 IU/kg may begin as soon as 3 hours after, but no later than 24 hours after, completion of the LN-144 infusion on Day 0. Additional IL-2 doses will be given approximately every 8 to 12 hours for up to 6 total doses
75343501|NCT06190249|Drug|Pembrolizumab|Up to 17 cycles of Pembrolizumab 200mg every 3 weeks starting at Week 12 will occur for up to 1 year during the post-treatment efficacy follow-up
75476086|NCT02002949|Procedure|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
75654076|NCT02640690|Behavioral|Cognitive Processing Therapy|(12) 1.5 hour sessions of cognitive processing therapy
75654077|NCT02840058|Other|Biological samples|blood and tumor tissue samples
75654078|NCT02840058|Drug|Anti PD1/PDL1 treatment|
75654079|NCT04841564|Procedure|ultrasound approach of serratus anterior block|After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.
76089842|NCT05103722|Other|Combined Aerobic and Resistance Exercise Training|Participants receive personalized exercise plan for home-based two days of aerobic exercises (20-30-minutes) and two days of resistance exercises per week for 12 weeks. After completion of study intervention, participants will be assessed at the of study visit at Week 24.
76089843|NCT05102773|Procedure|Biospecimen Collection|Undergo collection of blood and stool
76089844|NCT05102773|Procedure|Computed Tomography|Undergo CT
76089845|NCT05102773|Other|Laboratory Biomarker Analysis|Correlative studies
75939913|NCT03680417|Biological|Measles-Rubella (MR) Vaccine|Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
75939914|NCT05388513|Procedure|Surgical Resection|Surgically treated patients included
75939915|NCT03680339|Procedure|cesarean section|CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers
75939916|NCT03680339|Drug|Misoprostol|The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
75939917|NCT03680339|Drug|Oxytocin|10 IU of oxytocin with fetal delivery
75343502|NCT06189508|Drug|NXT007|In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
75654080|NCT04841564|Procedure|open approach of serratus anterior block|After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
75476087|NCT02002949|Procedure|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
75654081|NCT02842710|Device|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
75654082|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
75654083|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
75654084|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
75654085|NCT02839824|Procedure|Bowel preparation|Bowel preparation for bowel cleansing in a real clinical practice
75801467|NCT03763812|Procedure|Endovascular Aneurysm Sealing (EVAS)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~Before induction of anesthesia~At wound closure~24 hours after surgery~48 hours after surgery~1 month after surgery~6 months after surgery~12 months after surgery"
75939918|NCT04100057|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
75965944|NCT03047876|Procedure|aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
75476088|NCT02002962|Procedure|radiofrequency ablation|
75801468|NCT04448756|Drug|M5049|Participants received M5049 50 milligram (mg) orally twice daily for 14 days.
75654086|NCT00901628|Drug|ropivacaine|300mg (0.75%, 40cc) intraoperative periarticular injection
75654087|NCT00901628|Drug|morphine sulfate|10mg intraoperative periarticular injection
75654088|NCT00901628|Drug|ketorolac|30 mg intraoperative periarticular injection
75654089|NCT00901628|Drug|epinephrine|300 microgram (1:1000) intraoperative periarticular injection
75654090|NCT00901628|Drug|cefuroxime|750mg intraoperative periarticular injection
75654091|NCT00623545|Drug|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
75801469|NCT04448756|Drug|M5049|Participants received M5049 100 mg orally twice daily for 14 days.
75801470|NCT04448756|Drug|Placebo|Participants received placebo tablets matched to M5049 daily for 14 days.
75654092|NCT02840214|Device|transcranial direct current stimulation|Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
75654093|NCT02840214|Device|sham tDCS|Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
75654094|NCT00825097|Procedure|Selective tibial neurotomy|Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
75654095|NCT00825097|Drug|Botulinum toxin injection|Botulinum toxin type A
75654096|NCT02844764|Biological|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 [StroMed + platelet rich plasma (PRP)], Day 7, 14 and 30 [PRP]
75654097|NCT02839668|Drug|Lidocaine|Continuous infusion of lidocaine
75801471|NCT03763734|Drug|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
75801472|NCT05063136|Drug|Capecitabine+endocrine therapy|Capecitabine (500mg, tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
75801473|NCT05063136|Drug|Placebo+endocrine therapy|Placebo (tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
75801474|NCT04601090|Other|ICU treatment|This is an observational study, so all patients will undergo a variation of ICU treatment, and we will record that information (e.g., time on ventilator, time in ICU, SAPS score at admission)
75801475|NCT05053932|Other|blood collection|blood collection
75801476|NCT04276220|Diagnostic Test|Tenosynovial biopsy|Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.
75654098|NCT02839668|Drug|Sevoflurane|maintenance of hypnosis during anaesthesia with sevoflurane
75654099|NCT02839668|Drug|TIVA-TCI|maintenance of hypnosis during anaesthesia with sevoflurane
75654100|NCT02839668|Drug|Acetaminophen|administration of 1 g acetaminophen for postoperative analgesia
75654101|NCT02839668|Drug|Tramadol|administration of tramadol for postoperative analgesia
75654102|NCT02839668|Drug|Neostigmine|A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
75654103|NCT02839668|Drug|Atropine|A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
75801477|NCT03763500|Other|Internet-based education|A six-step Internet-based patient education.
75939919|NCT04100057|Behavioral|Desensitization Therapy for insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
75939920|NCT03680261|Radiation|chemoradiotherapy|CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
75939921|NCT03680261|Drug|chemotherapy|CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
75939922|NCT03680183|Drug|Entecavir 1Mg Oral Tablet|The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
75939923|NCT02136069|Drug|Etrolizumab|105 mg administered by subcutaneous (SC) injection once every 4 weeks (Q4W) until Week 52.
75939924|NCT02136069|Drug|Infliximab|5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
75939925|NCT02136069|Other|Placebo (IV)|Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
75939926|NCT02136069|Other|Placebo (Injection)|Administered by SC injection Q4W until Week 52
75654104|NCT02839668|Device|BIS|For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
75654105|NCT04701788|Biological|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.
75654106|NCT04700618|Biological|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
75654107|NCT02842632|Other|theoretical test|The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
75654108|NCT02842632|Other|practical test|The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
75654109|NCT03855709|Diagnostic Test|microbiological culture and sensetivity|microbioloical culture will be used to detect microbiological profile in hepatic patients with infections, drug sensitivity to detect resistent bacteria which will be confirmed using PCR detection of resistent gene
75654110|NCT04698122|Other|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
75654111|NCT04698122|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
75654112|NCT04698122|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
75654113|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
75801478|NCT03749486|Procedure|Cataract surgery|Cataract surgery will be done following ArcScan measurement
75801479|NCT04274192|Other|Synchronized HFNC at 6 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 6 LPM
75801480|NCT04274192|Other|Continuous HFNC at 6 liters per minute (LPM)|Standard HFNC therapy at 6 LPM
75801481|NCT04274192|Other|Synchronized HFNC at 8 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 8 LPM
75801482|NCT04274192|Other|Continuous HFNC at 8 liters per minute (LPM)|Standard HFNC therapy at 8 LPM
75801483|NCT03753594|Device|tissue oxygenation saturation|tissue oxygenation saturation
75939927|NCT02917031|Drug|Saxagliptin|5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
75939928|NCT02917031|Drug|Sitagliptin|50 mg or 100 mg, gray capsule
75939929|NCT02917031|Drug|Placebo to match saxagliptin|2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
75939930|NCT02917031|Drug|Placebo to match sitagliptin|50 mg or 100 mg, gray capsule
75939931|NCT03485235|Procedure|D&C|Dilatation and curettage
75939932|NCT03485235|Procedure|ICSI|Intra Cytoplasmic Sperm Injection
75939933|NCT04654455|Other|Describe the evolution of dry eye between 1 month and 3 months post-LASIK|Dry eye will be assessed through the OSDI (Ocular Surface Disease Index) questionnaire. The questionnaire will be dispensed during consultations by an orthoptist or an intern/junior doctor, at 1 month and at 3 months post-LASIK.
75939934|NCT04460547|Drug|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion to COVID-19 infected patients.
75939935|NCT04460547|Drug|Hydroxychloroquine|Hydroxychloroquine administration to COVID-19 infected patients.
75939936|NCT04460547|Drug|DAS181|DAS181 administration to COVID-19 infected patients.
75939937|NCT04460547|Drug|Ivermectin|Ivermectin administration to COVID-19 infected patients.
75654114|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
75801484|NCT03756324|Drug|CHPM (Chinese Herbal Patent Medicine )|Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
75939938|NCT04460547|Drug|Interferon Beta-1A|Interferon Beta-1A administration to COVID-19 infected patients.
75801485|NCT03756324|Drug|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
75801486|NCT03756324|Behavioral|Education|Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.
75801487|NCT03756324|Drug|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
75939939|NCT03132051|Drug|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
75939940|NCT03684707|Drug|Metformin Hcl 500Mg 24Hr Sa Tab|Glucophage 500 mg once daily
75939941|NCT03684707|Other|starch tablet|starch tablets
75939942|NCT03688841|Device|Bridged V.A.C.® with compression therapy|Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
75939943|NCT03688841|Device|Conventional Compression Therapy|Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
75939944|NCT03684551|Other|The CHW-led health system|During the study period, all CHWs, regardless of treatment arm, performed proactive case detection, the process of conducting at least two hours per day of door-to-door home visits to proactively identify - through health history inquiry and/or disease diagnostics - patients who need care. For all patients identified, CHWs provided doorstep counselling, evaluation, diagnostics, treatment, referral to appropriate health facilities, and follow-up. CHWs provided care in the community without user fees, and were able to refer patients to the reinforced government primary health centres for care without user fees as well. CHWs were residents of the communities they served, and they were required to be available at home or by phone for consultation at any time.
75939945|NCT03684551|Other|The CHW Supervision model|CHWs in both study arms received monthly individual supervisory sessions and weekly group supervisory sessions from their dedicated CHW supervisor. An individual monthly session of 360 Supervision included: (i) solicitation of patient perspectives of CHW care; (ii) direct observation of CHW doorstep care; and (iii) a one-on-one feedback discussion with or without the CHW Performance Dashboard depending on treatment arm.
75939946|NCT03684551|Other|The CHW Performance Dashboard|"The CHW Performance Dashboard was a graphic display of a CHW's performance along three indicators defined as follows: (i) Quantity of care: the number of homes visited during the month; (ii) Timeliness of care: the percentage of sick children under five treated within 24 hours of symptom onset during the month; (iii) Quality of care: the percentage of sick children under five treated without protocol error among 23 potential errors during the month. The Dashboard displayed an individual CHW's quantity, timeliness, and quality of care indicators from the previous month, using absolute numbers, percentages, and visual graphics, alongside those of the highest performing CHW. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month."
75939947|NCT03680027|Dietary Supplement|Walnut-enriched Group|All subjects supplemented with 40 g/day of walnuts for 6 weeks.
75939948|NCT01018563|Drug|MORAb-003|Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
75939949|NCT03679871|Other|Questionnaire validation|"Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)"
75801488|NCT03751202|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg|2 inhalations of Test and Reference product in each study period
75801489|NCT03751202|Drug|ADVAIR DISKUS|2 inhalations of Test and Reference product in each study period
75939950|NCT02528188|Drug|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
75939951|NCT02528188|Biological|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
75939952|NCT02528188|Biological|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
75654115|NCT00820807|Other|Placebo|oral consumption in beverage
75801490|NCT03749408|Drug|bupivacaine plus mannitol|local anesthesia
75801491|NCT03749408|Drug|bupivacaine alone|local anesthesia
75801492|NCT04387136|Drug|Sublingual Sufentanil|15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
75801493|NCT04252586|Drug|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
75801494|NCT03753516|Procedure|Laparoscopic - Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close laparoscopically using an 0-Barbed suture.
75939953|NCT03684395|Drug|DOACs: Rivaroxaban, Dabigatran, Apixaban|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
75343503|NCT06188117|Other|'Digital Game Addiction Awareness Training'|"Experimental Group The 'Digital Game Addiction Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.~The training program will be implemented in line with the headings 'Digital Game Addiction Definition, Diagnostic Criteria, Frequency, Symptoms, Physical, Psychological and Social Problems Caused by Excessive Digital Game Playing, Recommendations for Parents to Prevent Digital Game Addiction'."
75654116|NCT04688918|Procedure|Retrolaminar block|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. A 50 mm 22-gauge needle will be inserted in an in-plane technique from cranial to caudal direction and will be advanced till hitting the laminae of fourth thoracic vertebrae and then we will try to inject the local anesthetic, if the resistance to injection is very high, hence we will withdraw the needle slowly and its tip will be kept in its position immediately after disappearance this high resistance. Bupivacaine 0.25%, 0.4mL/kg will be injected.
75654117|NCT04688918|Procedure|paravertebral group|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The transverse process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vcostotransverse ligament, 0.4mL/kg will be injected
75654118|NCT02839590|Device|HiFU|Ciliary Ablation Treatment ( HiFu ultrasound treatment)
75654119|NCT02839590|Device|Baerveldt implant|External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
75939954|NCT03684395|Drug|Standard of care (Warfarin)|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
75939955|NCT04050137|Other|Therapeutic Exercise|"Patients who meet the inclusion criteria and who want to carry out the workshops, fill out an informed consent explaining the procedure to be followed and accepting the cessation of data to carry out the study.~Patients will be divided into 2 working groups (approximately 10 patients in total, in a Gaucher disease group and in another Fabry disease). The workshops will be held at the foundation twice a month in sessions of 45 minutes of work for 3 months (May, June, July 2019). In these sessions the physiotherapists will show the new exercises to the patients. The exercises that are taught in that session should be done at home 3 times a week. In addition, a document will be delivered with the exercises to be carried out and the frequency and intensity of execution. The workshops will be guided at all times by a physiotherapist specialized in therapeutic exercise and EDL."
75939956|NCT04460391|Behavioral|Intensive rehabilitation|Early standing training and routine rehabilitation
76089846|NCT05102773|Other|Questionnaire Administration|Complete questionnaire
76089847|NCT04981782|Other|No study specific intervention, regular care.|Chiropractic care (regular care)
76089848|NCT04967885|Behavioral|Ecological Momentary Implementation Intentions Intervention (EMI-II)|To reduce smoking, this text messaging intervention will use a self-regulatory strategy, Implementation Intentions (II) to deliver appropriate alternative responses to cigarette smoking. Participants will create personalized II messages before starting the two-week intervention period. Then during the intervention period, after receiving Ecological Momentary Assessments (EMAs), participants will be micro-randomized to receive the EMI-II. During the EMA + EMI-II period, participants will complete five daily EMAs. After approximately 40% of these EMAs, participants will also receive the personalized EMI-II by text messaging.
76089849|NCT04967599|Behavioral|Phenotype Feedback Intervention|Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.
76089850|NCT04967599|Behavioral|Genotype Feedback Intervention|Online session providing personalized feedback on alcohol metabolism genotypes and associated health-related risks.
76089851|NCT04962477|Other|Nasal brush sampling|Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.
76089852|NCT04947410|Device|CPAP or nasal dilators|CPAP = active comparator nasal dilators = placebo comparator
76089853|NCT04932148|Other|Incremental HD|Starting haemodialysis at twice weekly frequency
76089854|NCT04932148|Other|Conventional HD|Starting haemodialysis at thrice weekly frequency
75343504|NCT06184126|Device|Virtual Reality Headset and Hand-Held Controllers|Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.
75343505|NCT06184126|Other|Blindfolding and Noise Cancelling|Control group-Blindfold and noise cancelling headphones will be a placebo comparator group to the experimental interventions of virtual reality devices.
75476089|NCT02002962|Drug|Botulinum Toxin Type A injection|
75476090|NCT02002988|Procedure|endomyocardial BT injection|
75476091|NCT02003001|Drug|Botulinum Toxin|
75801495|NCT03753516|Procedure|Vaginal- Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close vaginally using an 0-Vicryl suture in a vertical fashion.
75965945|NCT05256758|Drug|Fenofibrate Capsules|49 patients randomised to receive fenofibrate for 6 months.
75965946|NCT05256758|Drug|Placental Lactogen|13 patients randomised to receive placebo for 6 months.
75939957|NCT04059497|Behavioral|Exercise condition|Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire
75939958|NCT04059497|Behavioral|Healthy diet condition|The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
75939959|NCT04460001|Drug|Ranibizumab|Intravitreal
75939960|NCT04460001|Drug|Ranibizumab|Intravitreal
75939961|NCT04460001|Drug|triamcinolone acetate|intravitreal
75939962|NCT03486483|Other|Exercise|Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
75939963|NCT03896165|Other|Reiki|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the parent how to perform a simple 15-minute Reiki session. Parents will complete a return demonstration using light touch with their adolescent. Parents will be asked to complete a minimum of 15 minutes of Reiki with their adolescent at least five days per week for the four-week intervention period.
75654120|NCT02839590|Device|Ahmed implant|External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
75654121|NCT02839590|Device|STARflo|Suprachoroidal Shunt Surgery (STARflo)
75654122|NCT02839590|Device|Hydrus Microstent implant|Trans-trabecular meshwork implants (Hydrus Microstent implant).
75654123|NCT02839590|Device|iStent implant|Trans-trabecular meshwork implants (iStent implant).
75654124|NCT02839590|Device|Kahook Dual Blade|It removes part of the trabecular meshwork
75654125|NCT00829465|Drug|Licartin|Licartin
75801496|NCT04985370|Other|Pain neuroscience education|Three sessions of pain neuroscience education based on explaining patients: characteristics of acute versus chronic pain, function of acute pain, how acute pain is originated within the nervous system, how acute pain progress to chronic pain, and factors that contribute to central sensitization (e.g., emotions, stress, disease and pain beliefs, behaviors regarding pain...). All the explanations will be conducted using easy-understandable examples and metaphors.
75801497|NCT04985370|Other|Exercise|Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.
75801498|NCT05359536|Behavioral|Training Early Childhood educators in PA|The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
75801499|NCT04247828|Device|Experimental AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with an adaptive and individualized keyboard to test communication performance.
75654126|NCT00829465|Procedure|Transcatheter arterial chemoembolization|TACE
75654127|NCT05336708|Other|Acupressure Group|In the acupressure group, acupressure will be applied to the heart meridian 7th point (HT7), large intestine meridian 4th point (LI4), stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6). After pressing each point for a certain period of time, a total of two minutes of rest periods will be applied by the researcher.
75654128|NCT05336708|Other|Sham Acupressure Group|In the sham acupressure group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
75801500|NCT04247828|Device|Generic AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with a generic QWERTY keyboard to test communication performance.
75801501|NCT04507776|Drug|Etanercept|Patients with spondyloarthrosis as provided in real world practice
75939964|NCT04459923|Procedure|ultrasound-guided erector spinae plane block catheter|for postoperative pain management ultrasound-guided erector spine plane block catheter placement
75476092|NCT02003027|Drug|BT injection|
75476093|NCT02003040|Device|Mespere Venus 1000 CVP System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
75939965|NCT04459923|Procedure|thoracic epidural catheter|for postoperative pain management thoracic epidural catheter placement
75939966|NCT03679793|Procedure|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger
75939967|NCT03679793|Procedure|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
75939968|NCT03679715|Other|participatory art-based activity|"The intervention is a participatory art-based activity which consists in making art in group, involving the participants directly in the creative process, allowing them to become co-authors of the work.~In Montreal, Canada, participants will meet once per week for a 2h workshop from 2.00 PM to 4.00 PM at the MMFA in a dedicated room during a three month-period defining a session. Two successive sessions will be setup; a winter and a spring sessions. Each session will be composed of 12 consecutive workshops.~In Tokyo, Japan, participants will meet once per week for a 2h workshop at the Tokyo Fuji Museum in a dedicated room during a three month-period defining a session. The session will be composed of 12 consecutive workshops."
76089855|NCT04922333|Drug|Risedronate|150mg over-encapsulated risedronate
76089856|NCT04922333|Drug|Placebo|Capsules containing placebo tablets
75654129|NCT02839356|Drug|epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
75654130|NCT02839356|Drug|normal saline|20-mL irrigation with physiological saline over the entire papilla
75939969|NCT03486405|Other|Control group|Control group runners will receive the same graduated return to run intervals and 4-week home exercise program. However, they will receive no video education during the initial 10 weeks.
75939970|NCT03486405|Other|Intervention group|Runners randomized to the intervention group will receive additional video tele-health instruction on how to transition to a non-rearfoot strike (NRFS) running pattern. Runners in the intervention group will have additional tele-health follow-ups at weeks 1, 2, 4,6, 8, and 10 using a tele-conferencing program and the Hudl Technique application. At each tele-health video follow-up participants will be emailed a questionnaire assessing their progress and function. At month 6 a final data collection session to include video analysis will be performed.
75939971|NCT03679637|Behavioral|Tablet-based aphasia therapy|patients will independently practice with a speech app during hospitalisation
75654131|NCT03860701|Procedure|Remote ischemic conditioning|An appropriately sized blood pressure cuff will be inflated around a limb (systolic blood pressure + 15 mmHg) for different periods of time (1 to up to 4 minutes), times (1 to up to 4 times) and consecutive days (1 to up to 2).
76089857|NCT04911166|Combination Product|Atezolizumab and Interleukin-12 Gene Therapy|To determine the safety and tolerability of the atezolizumab and ADV/IL-12 gene therapy combination in patients with metastatic NSCLC who have disease progression after a prior line of either single agent immunotherapy or a regimen of chemoimmunotherapy.
76089858|NCT04903353|Drug|Comparison of Risperidone and Aripiprazole|Comparing two FDA approved medications for treatment of irritability in autism
76089859|NCT04903028|Device|Sham rTMS|Two electrodes on the scalp will be connected to transcutaneous electrical nerve stimulation.
76089860|NCT04903028|Device|Active rTMS 10 Hz DLPFC|10 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left dorsolateral prefrontal cortex (DLPFC).
76089861|NCT04903028|Device|Active rTMS 1 Hz mOFC|1 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left medial orbitofrontal cortex (mOFC).
76089862|NCT04902508|Behavioral|Implicit-only|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment.
75343506|NCT06183125|Behavioral|Traditional Chinese Medicine-based program|"Week1-2: one health talk session(60 mins); three workshops (each workshop will last for 60-90mins) to provide hands-on training in Baduanjin, acupressure techniques, mindful stretching, and effective strategies to combat sedentary behavior in the workplace.~Week 3-4: group practice sessions will take place for one hour every other day throughout the workweek; website support."
75343507|NCT06181357|Procedure|Endoscopic lung volume reduction in 2 stages|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the experimental group, patients will be treated according to Limoges' treatment algorithm (2 stages)
75654132|NCT04674410|Drug|Antibiotic|Empiric antibiotic therapy, subdivided according to Community Acquired Pneumonia coverage vs Hospital Acquired Pneumonia coverage
75654133|NCT00829543|Procedure|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
75654134|NCT02840526|Procedure|Paravertebral blockade (PVB)|preoperative ThPVB performed unilaterally at Th10 level
75654135|NCT02840526|Drug|Sopodorm|midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
75939972|NCT03485001|Other|Sham|This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.
75939973|NCT03485001|Procedure|Argon Laser Treatment|This group will receive argon laser medical treatment to the body and head of pterygium
75654136|NCT02840526|Drug|Propofol WZF|propofol 2 mgkg-1intravenously (anesthesia induction)
75654137|NCT02840526|Drug|Nimbex|cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
75654138|NCT02840526|Drug|Fentanyl WZF|fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
75654139|NCT02840526|Drug|Sevorane|sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
75654140|NCT02840526|Device|Intubation|Intratracheal intubation with a single lumen endotracheal tube
75654141|NCT02840526|Drug|Oxynorm|1 mgml-1 concentration oxycodone solution intravenously
75654142|NCT02840526|Drug|Paracetamol Kabi|1g paracetamol intravenously every 6 hours
75654143|NCT02840526|Drug|Ketonal|100 mg ketoprofen intravenously every 12 hours
75801502|NCT04386902|Device|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface.
75654144|NCT02840526|Drug|Bupivacaine WZF|0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
75965947|NCT04869332|Device|three cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Three screws for internal fixation in the three-screw group, and three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
76089863|NCT04902508|Behavioral|Explicit-added|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment. Interventionists will also present the rule/pattern guiding the target form.
75654145|NCT00825253|Drug|biphasic insulin aspart 30|
75654146|NCT00825253|Drug|biphasic human insulin 30|
75654147|NCT02840370|Device|transcranial direct current stimulation|In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.
75654148|NCT02840370|Device|Sham tDCS|S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
75654149|NCT00820885|Drug|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
75939974|NCT03484845|Drug|Lactoferrin and ferrous fumarate|"Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily ."
75939975|NCT03688607|Procedure|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.
75939976|NCT03679481|Drug|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
75939977|NCT03679481|Drug|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
75939978|NCT03679403|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
75939979|NCT05151783|Other|conventional physiotherapy|"Control group receivewill routine physical therapy including modalities like ultrasound (3 MHz continuous type; duration 10 minutes), heat modalities (apply to the involved region of shoulder joint shoulder for 10 minutes), shoulder ROM exercises, capsular stretching, and joint mobilization 5 times per week for four weeks. Duration of session will be 40 minutes.~All Maitland mobilization will be given in supine position. After giving glenohumeral (GH) joint distraction, GH caudal glide, GH dorsal glide, and GH ventral glide were given at a rate of 2-3/second oscillations for 1-2 minutes to patients. Grade I or II rhythmic oscillations will be applied in pain free movement."
75965948|NCT04869332|Device|four cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Four screws for internal fixation in the four-screw group, and the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
75343508|NCT06181357|Procedure|Endoscopic lung volume reduction in 1 stage|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the control group, the entire lobe will be treated during one procedure
75654150|NCT00820885|Drug|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
75654151|NCT00820885|Drug|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
75343509|NCT06181266|Drug|ZH9|ZH9 is a live attenuated S. enterica serovar Typhi ZH9 [Ty2 ΔaroC ΔssaV]), a differentiated novel microbial immunotherapy.
75476094|NCT02003066|Procedure|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
75343510|NCT06181240|Device|Intravascular lithotripsy|Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.
75343511|NCT06174688|Drug|BOTOX|Intramuscular Injections
75343512|NCT06174688|Drug|Placebo|Intramuscular Injections
75476095|NCT02003066|Procedure|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
75343513|NCT06174558|Device|Sleep Tracking Devices|Observational Study, Smartwatches and home sleep device for sleep and respiratory monitoring
75476096|NCT02003079|Behavioral|Cystic Fibrosis Questionnaire (Revised) for Teens/Adults|
75476097|NCT02003092|Drug|RX-5902|escalating doses (mg)
75476098|NCT02001818|Drug|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
75476099|NCT02003118|Drug|AKR 202|
75476100|NCT02003118|Drug|Placebo|
75654154|NCT00633048|Drug|NSA-789|
75654155|NCT00633048|Drug|placebo|
75654156|NCT02844842|Biological|Allergovac Poliplus|
75801503|NCT04357262|Other|StreaMD|Patients who are randomized to the intervention arm will be signed up for the automated text messaging program. Patients will receive automated text messages related to their surgery during the study period and can also ask questions through the text messages program, where automated messages will be sent based on the questions asked.
75801504|NCT04232540|Device|MedViewer report|Results from the analysis of hair samples performed using the MedViewer
75654157|NCT04533464|Biological|MultiStem|Intravenous Infusion
75654158|NCT04533464|Biological|Placebo|Intravenous Infusion
75654159|NCT02839434|Procedure|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
75801505|NCT04504032|Drug|Rivaroxaban|Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.
75476101|NCT02003131|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
75476102|NCT02003157|Procedure|hypnosis during embryo transfer or usual transfer procedure|
75476103|NCT02003235|Device|Daily watching videos using Reviview™, a dichoptic video display device, for 60 min|
75654160|NCT00820963|Drug|temozolomide|Given orally
75654161|NCT00820963|Radiation|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
75654162|NCT00820963|Radiation|radiation therapy|Patients undergo standard radiotherapy
75654163|NCT02834676|Drug|Gelified Ethanol|Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
75801506|NCT04504032|Drug|Placebo|Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
75801507|NCT03746912|Drug|Quizartinib Dihydrochloride|Tablets for once daily oral administration at doctor-recommended dose in continuous 28-day cycles
75939980|NCT05151783|Other|PNF technique|Group will receive scapular PNF techniques with routine physical therapy explained above For PNF techniques, patients will be lying on unaffected shoulder. In this group, 20 repetitions of diagonal scapular Pattern (Anterior Elevation and Posterior Depression and Posterior Elevation and Anterior Depression) with 20 sec rest period will be given to patients. Preparatory instructions for the desired movement will be given to patients at the start of procedure. PNF facilitation techniques of RI (Rhythmic initiation) & repeated contractions will be used in all patterns
75939981|NCT03484689|Behavioral|Mindfulness-based cognitive therapy MBCT|8-week mindfulness-based cognitive therapy
75939982|NCT05151705|Drug|HR17031 injection|Treatment group A:HR17031 injection; 10U/0.024mg
75939983|NCT05151705|Drug|HR17031 injection|Treatment group B: HR17031 injection; 10U/0.024mg
75939984|NCT05151705|Drug|HR17031 injection|Treatment group C: HR17031 injection; 10U/0.024mg
75343514|NCT06171893|Behavioral|Wavy stress application|"The intervention consists of the application named Wavy. Wavy uses artificial intelligence and the user's feedback to detect stress increasingly more efficient over time. This provides not only real-time feedback on an individual's stress level but also helps the patient to calm down using music guided relaxation. It does so with a music filter, allowing the participant to listen to music where the stress level determines the quality of the music.~Thus, relaxing is rewarded by improving the experience. In this process, implicit learning is used to establish a habit of getting better at recognising increased stress levels and getting familiar with reducing stress levels more and more effectively."
75801508|NCT03746834|Device|NASHA/Dx (Solesta®)|Perianal submucosal injection of 3-4 ml of NASHA/Dx
75654164|NCT00632840|Drug|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
75939985|NCT05151627|Procedure|KINESIO TAPING|Kinesio taping The patient is in a supine position with full knee flexion. Prior to application, the skin surface was cleaned. This technique involved the use of two Y-cut strips and two I-cut strips.
75801509|NCT03756246|Biological|Influenza Vaccine|The appropriate quadrivalent influenza vaccine for the give year will be given to subjects.
75343517|NCT06169735|Drug|Indocyanine green|ICG Administration: All enrolled patients with scheduled thyroidectomy or parathyroidectomy will receive a standard cervical incision that afford access to either side of neck. Following sufficient exposure of thyroid, 25 mg of indocyanine green (ICG), reconstituted in 10 ml of sterile water, will be administered intravenously. A dosage of 1 ml of this solution will be injected into a peripheral IV line, followed by a 5 ml flush of normal saline to ensure the propagation of the dye within the vascular compartment.
75343518|NCT06169735|Device|SPY Portable Handheld Imaging|Fluorescent Imaging: Approximately 30 seconds post-administration, the parathyroid glands are expected to exhibit fluorescence under near-infrared imaging. The emitted fluorescence is anticipated to persist for approximately 20 minutes, allowing ample time for intraoperative evaluation of parathyroid viability and perfusion
75343519|NCT06168253|Behavioral|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
75343520|NCT06168253|Behavioral|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
75343521|NCT06164951|Drug|Infigratinib 0.25 mg/kg/day|Daily doses of oral Infigratinib (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
75343522|NCT06164951|Drug|Placebo Comparator 0.25 mg/kg/day|Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
75343523|NCT06164028|Other|cognitive interview|Participants will take part in a semi-structured qualitative interview (~1 hour).
75654165|NCT02834598|Device|high-density electroencephalography|Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
75654166|NCT00829699|Procedure|euinsulinemic euglycemic glucose clamp|euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
75654167|NCT00829699|Procedure|euinsulinemic hyperglycemic glucose clamp|euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
75654168|NCT00829699|Procedure|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
75801510|NCT03758196|Device|Radiofrequency ablation instruments|Renal Sympathetic Denervation from the adventitia of renal artery
75654169|NCT00829699|Procedure|Hyperinsulinemic hyperglycemic glucose clamp|Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
75801511|NCT04439240|Drug|FGFR Inhibitor AZD4547|Given PO
75801512|NCT05460858|Drug|N-acetyl cysteine|One hundred and forty participants randomize in the intervention and placebo groups, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction. They will be received 1200 (2×600) mg of effervescent tablets of NAC or placebo daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles.
75801513|NCT05460858|Drug|placebo|placebo
75939986|NCT05151627|Device|CONVENTIONAL PHYSICAL THERAPY|"Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions."
75939987|NCT04461249|Drug|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
75939988|NCT04461249|Drug|Travoprost 0.004% ophthalmic solution|Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
76117248|NCT03691961|Diagnostic Test|Hair's drug concentrations|The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.
76089864|NCT04889417|Behavioral|Comprehensive training program|The COPE-iOS program is a pragmatic comprehensive training program that combines computerized cognitive training and progressive supervised video conference physical exercise sessions performed 2-4 weeks prior to surgery and for 3 months after discharge.
76089865|NCT04889417|Behavioral|Active control|The active attention control will include control computer games and supervised video conference stretching exercises performed 2-4 weeks prior to surgery and for 3 months after discharge.
76089866|NCT04850807|Behavioral|Music & Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences at times when behaviors are likely
76089867|NCT04848883|Behavioral|Advanced AMS program|"- Telephone acces to infectious disease experts to discuss patients' therpies during working days.~- Biweeckly meetings with infectious diseases experts and antimicrobial stewardship group."
76089868|NCT04848883|Behavioral|Standard AMS program|"- Educational materials.~- Updated local antibiotic guidelines.~- Promotion of delayed antibiotic prescription.~- Promotion of Streptococcus pyogenes antigen test (Streptotest) if bacterial tonsillitis is suspected.~- Daily report to GP of multiresistant bacteria isolates in urinary samples.~- Quarterly reports to prescribers of AMS outcomes at the centre-level."
76089869|NCT04844021|Behavioral|Nudge|"EHR-based nudge"
76089870|NCT04844021|Behavioral|Nudge+|"EHR-based nudge plus facilitation"
76089871|NCT04831047|Drug|Oxymetazoline hydrochloride 0.1% ophthalmic solution|One drop of Upneeq (Oxymetazoline hydrochloride 0.1% ophthalmic solution) will be applied to the ocular surface of each eye.
76089872|NCT04831047|Drug|Placebo|One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.
76089873|NCT04792268|Other|Access to eCDSS on wards|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm.~An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~The key digital tool to be used for eCDSS in this study is CogStack. This eCDSS has been developed to alert clinicians automatically regarding patients admitted under their care, triggered by the presence of new, old or absent HbA1c pathology reports on the electronic health record (EHR)."
76089874|NCT04775680|Biological|ADG106 injection|ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
75654170|NCT05334030|Device|High Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~Sitting program - Min lean;~Standing program - Auto lean;~Step initiation program - ProStep+,~Training mode - Off,~SmartAssist option - 2Free;~Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
75801514|NCT04660032|Behavioral|Nudge|An electronic prompt (nudge) will be sent to the participant's obstetric care provider. The provider will receive a staff message in Epic (Penn Chart) that his/her patient has an upcoming postpartum visit. The message will be sent 1 week before the scheduled visit. The message will have patient-specific information including hypertensive diagnosis, blood pressure medication(s), gestational diabetes diagnosis, and primary care provider as listed in the Epic banner. The message will also have dot phrases for recommended counseling and contact information for UPHS primary care and cardiology providers. There will be example text recommending follow-up with primary care or cardiology; counseling on risk of future CVD; and recommending aspirin in a future pregnancy.
75801515|NCT03753438|Procedure|Intragstric Ballooning|Intragstric Ballooning will be put.
75801516|NCT05359224|Drug|Prasugrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given prasugrel 5mg once. And aspirin 100mg and prasugrel 5mg will be maintained for 30 days.
75939989|NCT04461249|Drug|Tafluprost Ophthalmic 0.0015% Ophthalmic Solution|Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
75939990|NCT04611633|Combination Product|Trimbow|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
75939991|NCT05151549|Drug|Camrelizumab|200mg/3weeks
75939992|NCT05151549|Drug|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
75939993|NCT05151393|Diagnostic Test|Measuring vitamin D3 level|Measuring vitamin D3 in both groups
76089875|NCT04775680|Biological|PD-1 antibody injection|PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle
76089876|NCT04747314|Drug|Antidepressant|"The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes.~The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change."
76089877|NCT04747314|Other|Enhanced Fear Avoidance Rehabilitation|The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
76089878|NCT04743154|Other|In-hospital nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure during index admission.
76089879|NCT04743154|Other|After-discharge nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure after hospital discharge.
76089880|NCT04736576|Device|Wearable device|As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
75654171|NCT05334030|Device|Neutral Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~Sitting program - Min lean;~Standing program - Auto lean;~Step initiation program - ProStep+,~Training mode - Off,~SmartAssist option - 2Free;~Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
75654172|NCT05334030|Device|High Swing Resistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~Sitting program - Min lean;~Standing program - Auto lean;~Step initiation program - ProStep+,~Training mode - Off,~SmartAssist option - 2Free;~Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
75801517|NCT05359224|Drug|Clopidogrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given pletaal 100mg once. And aspirin 100mg and clopidogrel 75mg mg will be maintained for 30 days.
75939994|NCT03484611|Drug|GnRH antagonist|0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
75939995|NCT03484611|Drug|Gonadotropins|started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
75939996|NCT03484611|Drug|Human chorionic gonadotropin|10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more
75939997|NCT03484611|Procedure|Embryo transfer|0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)
75939998|NCT03484611|Drug|Progesterone|vaginal prontogest 400 mg twice daily
75939999|NCT05151081|Other|basicly|Do not repeat information already included in arm/group descriptions.
75940000|NCT03486249|Other|Repetition of medical examinations performed as part of the care|Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
75940001|NCT03491943|Procedure|ultrasound-assisted midline approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.
75940002|NCT03491943|Procedure|ultrasound-assisted paramedian approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
75940003|NCT02447133|Device|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
75940004|NCT03679325|Dietary Supplement|vitamine D|a dose once a week
75940005|NCT03679325|Other|whole body vibration (WBV)|03 months of WBV training three times per week
75801518|NCT03753282|Other|questionnaires for patient reported outcome|"questionnaires with respect to outcomes:~Reoperations~Short term complications~Long term complications~EQ-5D (current)~HOOS (current)~disease related change of occupation~use of walking aids~comorbidities~medication"
75801519|NCT03753282|Other|questionnaire for course of the disease|"questionnaires to assess course of the disease:~from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA)~therapeutic interventions"
75940006|NCT03684239|Behavioral|G-CBT|CBT is based on the model that there is a interaction between cognition, emotion and behavior. The way people think affects the way they feel and the behavior they do. And then the feelings in turn affect how they think,So it is valid for AN patient.
75940007|NCT03684239|Other|Conventional treatment|Conventional treatment including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
75940008|NCT03684161|Diagnostic Test|Cardiopulmonary function|Body composition measurements; Pulmonary function tests; Cardiopulmonary exercise test; Force frequency releationship, ultrasound
75940009|NCT03684083|Procedure|bronchial biopsies|bronchial fibroscopy with bronchial biopsies
75940010|NCT03878927|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.
75940011|NCT03878927|Drug|Gemtuzumab Ozogamicin|Gemtuzumab ozogamicin is a CD-33 directed antibody drug conjugated to calicheamicin. CD 33 is expressed on myeloid leukemic blast cells and on normal hematopoietic cells. The drug is approved for the treatment of newly diagnosed CD 33 positive AML in adults and the treatment of relapsed and refractory CD 33 positive AML in adults. The drug is available for injection 4.5 mg as a lyophilized cake or powder in a single use vial for reconstitution and dilution.
75940012|NCT03684005|Other|MyPatientPal smartphone app|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
75940013|NCT03867539|Other|Differing pain management strategy|"The investigators aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated."
75940014|NCT03679169|Procedure|pancreatosplenectomy|standard or radical anterograde modularpancreatosplenectomy
76089881|NCT04733950|Other|Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm)|"Description:~3-interval, 3-alternative forced choice amplitude modulation detection task using a target sinusoidal carrier and a spectrally distant, interfering (distracting), sinusoidal carrier that may or not be modulated at the same rate as the target."
76117249|NCT05117112|Dietary Supplement|XS Muscle Multiplier|Distributed by Amway; this product is a powder, sold in a 6.8 ounce (192g) container.
75940015|NCT03623555|Behavioral|Trier Social Stress Test|"The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback."
75940016|NCT03623555|Biological|Salivary cortisol|Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
75940017|NCT03842267|Drug|Gemigliptin 50mg|"The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~Dapagliflozin 10 mg / day~Metformin ≥ 1,000 mg / day"
75940018|NCT03842267|Drug|Gemigliptin Placebo|"The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~- The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~Dapagliflozin 10 mg / day~Metformin ≥ 1,000 mg / day"
75343524|NCT06160193|Behavioral|Brief behavioral parent training with optional care as usual|A brief behavioral parent training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of 120 minutes, and a third session of 60 minutes, in which the training will be evaluated and maintenance training will be provided.
76089882|NCT04733950|Other|Measurement of the pupil diameter for the evaluation of listening effort during speech perception|Pupil diameter is recorded using an eye-tracker device (Tobii Pro TX300) while the subject performs a 16-alternative consonant identification task both in silence and in the presence of interfering speech.
75343525|NCT06160193|Other|Care as usual|Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
75343526|NCT06159543|Behavioral|Mango|1.5 cups/day of mango for 12 weeks
75343527|NCT06156462|Device|ResAppDx v.20|Software device measuring cough sounds to aid diagnosis of respiratory diseases
75343528|NCT06156436|Device|ResAppDx v.20|Software application used to aid diagnosis of respiratory disorders
75654173|NCT05334030|Device|Max Trajectory Control|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~Sitting program - Min lean;~Standing program - Auto lean;~Step initiation program - ProStep+,~Training mode - Off,~SmartAssist option - Bilateral;~Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
75654174|NCT00821197|Procedure|long-limb gastric bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
75654175|NCT00821197|Procedure|distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
75654176|NCT00829777|Drug|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|"Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:~Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo."
75801521|NCT04919928|Device|Cochlear Implant and Hearing aid in bimodal solution|"Sixty adult participants with bilateral hearing aids (HA) referred for cochlear implantation (CI) will be included in the study. It will be patients who report limited benefit with appropriately fitted HAs in daily speech communication in quiet and in noise. The patients are depending on visual cues for successful communication.~All the referred patients have potential optimal fitted HAs that are no longer sufficient to treat their hearing loss and to improve the daily communication. All the patients will then receive new replacement HAs with the ability to corporate with a CI for one month trial period. One month is considered as a sufficient adaptation period to new replacement HAs according to current clinical practice.~Thirty individuals randomised to receive the intervention with CI to the poorest hearing ear."
76089883|NCT04725565|Behavioral|Genetics ADvISER Decision Aid Plus Standard Genetic Counselling|The decision aid will educate patients about the types of incidental finding they can learn from genomic sequencing and will give them opportunity select what types of results they would like to receive.
76089884|NCT04725565|Behavioral|Standard Genetic Counseling|Standard Genetic counseling to learn about and select incidental results from genomic sequencing.
76089885|NCT04719936|Procedure|inferior capsulotomy|inferior capsulotomy will be conducted during posterior approach.
75343530|NCT06155071|Other|Plyometric Training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~Plyo Pushup.~Chest Pass.~Overhead Throw.~Squat jump.~Plyo Step-up.~Cone jumps.~Med Ball drop.~Kneeling Squat jump.~Lateral jump over hurdle.~Overhead throw.~Under hand throws.~Dynamic Rotational Chest pass.~Overhead throw with step."
75343531|NCT06155071|Other|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~Pushups.~Situps.~Lunges 4.500m running.~5.Squats"
75801522|NCT04919928|Device|Bilateral hearing aids|Thirty individuals randomised to the control group will continue use of the new replacement HAs another three months, thus in total of four months of use.
75343535|NCT06150183|Biological|BNT314|Intravenous infusion
75343536|NCT06150183|Biological|Pembrolizumab|Intravenous infusion
75654177|NCT05318586|Procedure|individual rTMS based on fNIRS|The rTMS parameters will be set according to fNIRS results.
75654178|NCT05318586|Procedure|Traditional rTMS strategy|The low-frequency rTMS to contralesional M1 will always be used.
75654179|NCT00825487|Drug|ARQ 621|Treatment will be initiated at a dose level of 10 mg/m^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m^2 and higher (cohort 8 and above).
75654180|NCT00821275|Procedure|Interventional radiological or surgical management|Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
75654181|NCT00830011|Behavioral|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
75654182|NCT00830011|Other|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
75654183|NCT02834832|Device|PECVD coating|SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
75654184|NCT04250610|Other|Survey|On-line survey.
75654185|NCT00623467|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
75801523|NCT03756090|Drug|Palbociclib|Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week [28 days] cycle.
75801524|NCT03756090|Drug|Placebo oral capsule|Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week [28 days] cycle.
75801525|NCT03756090|Drug|Epirubicin|Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
75801526|NCT03756090|Drug|Cyclophosphamide|Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
75801527|NCT03756090|Drug|Paclitaxel|Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
75801528|NCT03753126|Radiation|4-dimensional volume-rendered computed tomography|
75940019|NCT03688373|Behavioral|Cognitive Behavioral Therapy|Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.
75940020|NCT04060511|Drug|HS-10342|HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
75940021|NCT03623711|Drug|Escitalopram|participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
75940022|NCT03623711|Drug|Duloxetine|participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.
75940023|NCT03623711|Drug|Bupropion|participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.
75940024|NCT03623711|Other|Healthy control|Healthy control take placebo tablets
75940025|NCT03677609|Behavioral|Mindset & Communication Training|The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
75940026|NCT03683927|Combination Product|Bacillus clausii|The probiotic (Bacillus clausii) will be administered 4 times a week to the infant
75940027|NCT03683927|Other|Sterile water|The placebo group will receive sterile water 4 times a week
75819710|NCT02176330|Other|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
75940028|NCT03683849|Other|Training|One hour of training, twice a week, for six months.
75940029|NCT03563261|Dietary Supplement|Collagen supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
76089886|NCT04719936|Procedure|superior capsulotomy|superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
75343537|NCT06147037|Drug|FPI-2053|FPI-2053 is a bispecific antibody that targets EGFR and cMET
75343538|NCT06147037|Drug|[111In]-FPI-2107|"[111In]-FPI-2107 is an imaging agent in which indium-111 is conjugated to FPI-2053.~Participants will have a fixed dose of [111In]-FPI-2107 followed by imaging scans (with or without pre-administration of FPI-2053)."
75343539|NCT06147037|Drug|[225Ac]-FPI-2068|"[225Ac]-FPI-2068 is a radiopharmaceutical therapy in which an alpha emitter, actinium-225, is conjugated to FPI-2053.~Participants will be dosed through IV administration every 56 days for up to 3 cycles of the Treatment Period."
75343540|NCT06141850|Behavioral|COVID-19 Test Reporting|Participants will use a simple text-based data reporting tool which they will be asked to use to report any COVID-19 testing during the 12-month long tudy.
75343541|NCT06141850|Behavioral|Personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages, personalized to participants' diabetes status, race/ethnicity, age group, sex, and/or vaccine/testing history, will be sent in weeks 1-16 of the intervention to encourage adherence to COVID-19 testing and preventive behaviors as well as other behaviors important for diabetes management, prevention, or care.
75343542|NCT06141850|Behavioral|Non-personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages will be sent in weeks 1-16 of the intervention sharing tips lifestyle behaviors important for diabetes management and prevention (e.g., exercise, eating a healthy diet, etc.).
75343543|NCT06140836|Drug|Repotrectinib|Specified dose on specified days
75343544|NCT06140836|Drug|Crizotinib|Specified dose on specified days
75476104|NCT02003248|Device|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
75940030|NCT03563261|Dietary Supplement|Placebo supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
75801529|NCT03753048|Procedure|Y-Graft|Y-Graft Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, the left internal thoracic artery is cut off distally and the right internal thoracic artery is cut off proximally and distally. Then they anastomose the following way. Left internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, distal part of the right internal thoracic artery should be anastomosed to the obtuse marginal artery. Finally, proximal part of the right internal thoracic artery is anastomosed to the left internal thoracic artery as Y-graft in the end to side fashion. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
75940031|NCT03677531|Other|Quality-of-Life Assessment|Ancillary studies
75940032|NCT03677531|Other|Questionnaire Administration|Ancillary studies
75940033|NCT03677531|Radiation|Radiation Therapy|Undergo RT
75940034|NCT03677531|Other|Video|Watch video of choice during RT
75940035|NCT05610592|Procedure|total mesorectal exicision|
75940036|NCT03678857|Dietary Supplement|Creatine|"Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes)."
75940037|NCT03683771|Diagnostic Test|Transvaginal US with Doppler study|Transvaginal Ultrasound with doppler study on endometrium will be made
75940038|NCT03683693|Diagnostic Test|Procalcitonin group|"The ICU physician gets on regular base (day 0, d4, d7, d11, d15, d19, d23, d27) a PCT value and the according non-binding recommendation:~PCT < 0.5 microgram/L of 80% drop of the peak value : antibiotic stop recommended.~PCT < 0.25 microgram/L: antibiotic stop strongly recommended. The recommendation is not-binding and can be overruled by the ICU physician. The intervention is only set up for stopping antibiotics, not for initiating. PCT measurements only happens in case of still ongoing antibiotic course. In case of a second course of antibiotics, after interruption of the initial course, new PCT measurement will take place at this point followed by the continuation of the initial schedule of PCT measurement.~Intervention ends 28 days after inclusion."
75940039|NCT04994080|Drug|Paricalcitol|Paricalcitol QD Treatment
75940040|NCT04994080|Drug|Placebo|Placebo QD or TIW
75940041|NCT05412316|Other|Intervention: Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
75940042|NCT05382442|Drug|AK112|AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity
75940043|NCT05382442|Drug|AK117|AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity
75940044|NCT05382442|Drug|Oxaliplatin|Oxaliplatin via IV infusion
75940045|NCT05382442|Drug|Capecitabine|Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
75940046|NCT05382442|Drug|Irinotecan|Irinotecan via IV infusion
75940047|NCT05382442|Drug|Leucovorin|Leucovorin via IV infusion
75343545|NCT06139614|Behavioral|PERSIST|PERSIST is adapted from empirically validated treatment of negative affect and low positive emotion. Skills Training 1 includes content across 4 sessions on 1) understanding emotions, 2) present-moment emotional awareness, 3) cognitive flexibility, and 4) countering avoidant and emotion-driven responses. Skills Training 2 includes content across 4 sessions on a) translating values to action, b) lower barriers to action, c) countering avoidance, and d) maintaining actions that support personal resilience. The classes will occur every other Wednesday, resulting in a 16-week intervention period.
75343546|NCT06135701|Diagnostic Test|One-legged knee-extensor exercise with Doppler measurements|Doppler ultrasound is used while participants exercise according to the one-legged knee-extensor exercise model
75343547|NCT06133348|Behavioral|Promoting Resilience in Stress Management Intervention|"PRISM is a manualized, brief, skills-based intervention targeting four resilience resources; PRISM is delivered by trained intervention staff (called coaches within the PRISM program). Session 1, Stress-Management. Session 2, Goal setting. Session 3, Cognitive Restructuring. Session 4, Meaning-Making. Session 5 (optional), Coming Together. Session 6 (optional) involved advance care planning to discuss."
75343548|NCT06132958|Biological|MK-2870|4 mg/kg of MK-2870 by IV infusion
75343549|NCT06132958|Drug|Doxorubicin|60 mg/m^2 of doxorubicin by IV Infusion
75343550|NCT06132958|Drug|Paclitaxel|80 mg/m^2 of paclitaxel by IV infusion
75476105|NCT02003261|Behavioral|Unified Protocol with Treatment As Usual|"Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.~UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure."
75476106|NCT02003261|Other|Treatment As Usual|Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
75940048|NCT05382442|Drug|5-fluorouracil|5-fluorouracil via IV infusion
75940049|NCT05382442|Drug|Bevacizumab|Bevacizumab via IV infusion
75476107|NCT02003274|Other|Clamp-Mixed Meal|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
75654186|NCT00633204|Biological|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
75654187|NCT02834754|Drug|Vedolizumab|Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
75940050|NCT05363878|Behavioral|Native HEALTH|This application proposes the development and initial test of a culturally grounded, trauma informed intervention for alcohol use.
75343551|NCT06129825|Other|Prospective|Single arm, healthy adult volunteers for blood donation.
75654188|NCT02834754|Drug|placebo|Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
75343552|NCT06128382|Biological|OVX033|One single administration intramuscularly on Day 1
75940051|NCT05363800|Drug|HRS-3738|HRS-3738 will be administrated per dose level in which the patients are assigned.
75940052|NCT05550220|Diagnostic Test|Cuff Leak Test|Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
75940053|NCT05362474|Drug|Montelukast|10mg orally once a day
75940054|NCT05542342|Drug|Tislelizumab|200 mg IV once every 3 weeks
75940055|NCT05542342|Drug|Sitravatinib Malate|100 mg orally once daily
75343553|NCT06128382|Biological|Saline solution|One single administration intramuscularly on Day 1
75343554|NCT06120972|Drug|Olaparib tablet|Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
75343555|NCT06116422|Behavioral|Grocery intervention - unrestricted|Receives financial support in an unrestricted fashion (i.e., can use the money for whatever they need).
76089887|NCT04715087|Other|Blood sample (Day -42 to Day -28, Day 3),Skin swab sampling (Day -42 to Day -28, Day 0, Day 13) , patch test application (Day 0) , skin biopsies (Day 13)|A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at screening and Day 3. Bacteriological samples from AD patients will be performed by swabbing the skin at screening visit (Day -42 to Day -28). Each sample will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be re-applied (via patchtest) to AD patient. A well-characterized S. epidermidis lab strain will be also applied to AD patients. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healed or improved area as defined by a lesional score ≤ 1 or a 2-point change from the baseline lesional score. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application.
75343556|NCT06116422|Behavioral|Grocery intervention - restricted|Receives financial support restricted to the purchase of items at a grocery store, and with monthly grocery shopping coaching from a trained nutrition expert.
75801530|NCT03753048|Procedure|In-Situ|In-Situ Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, both internal thoracic arteries are cut off distally. Then they anastomose the following way. Right internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, left internal thoracic artery should be anastomosed to the obtuse marginal artery. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
75654189|NCT02839512|Device|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
75654190|NCT02839122|Drug|Tadalafil|
75343559|NCT06108830|Drug|Esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
75476108|NCT02003274|Other|IVGTT-Mixed Meal Arm|"Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
75476109|NCT02003287|Other|VFSS|Videofluoroscopic Swallow Study
75343560|NCT06108830|Drug|Remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
75654191|NCT02839122|Drug|Dutasteride|
75654192|NCT02838810|Drug|peginterferon alfa|peginterferon alfa-2b or peginterferon alfa-2a
75940056|NCT05362396|Other|Inspiratory Muscle Training with Powerbreath IMT device.|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 repetitions, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP
75940057|NCT05610202|Drug|TQB3702 tablets|TQB3702 tablets are selective BTK inhibitors.
75343561|NCT06108830|Drug|Esketamine and remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
75940058|NCT05361304|Device|senofilcon A contact lenses made with a novel manufacturing technology|TEST Lens
75940059|NCT05361304|Device|senofilcon A contact lenses made with the current manufacturing technology|CONTROL Lens
75940060|NCT05344456|Device|Change in the device PVC algorithm to ''Off''|PVC algorithm change from Atrial Pace mode to Off
75343562|NCT06108830|Drug|normal saline|Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
75654193|NCT02838810|Drug|Nucleoside analogues|Nucleoside analogues
75343563|NCT06106828|Drug|Satralizumab|Satralizumab will be administered by SC injection.
75343564|NCT06106828|Other|Placebo|Placebo will be administered by SC injection
75476110|NCT02003287|Other|FEES|Fiberoptic Endoscopic Swallow Study
75476111|NCT02003313|Biological|Group T|0.5ml, Intramuscular
75476112|NCT02003313|Biological|Group C|0.5ml, Intramuscular
75654194|NCT02838888|Device|Automatic polyp detection software|A computer program for the detection of colonic polyps will be used during colonoscopy
75654195|NCT00830635|Other|educational intervention|
75654196|NCT00830635|Other|informational intervention|
75654197|NCT00830635|Other|internet-based intervention|
75654198|NCT00830635|Other|questionnaire administration|
75343565|NCT06105307|Behavioral|RN-SLEEP|RN-SLEEP is a training program delivered via mobile application and designed to help improve the sleep of nurses who engage in shift work. RN-SLEEP aims to include training on strategies for sleeping while working shift work, basics of sleep science and physiology, behavior change components (i.e., goal setting), and components of cognitive behavioral therapy for insomnia (i.e., relaxation).
75343566|NCT06105307|Behavioral|Healthy Habit - Educational Control|Healthy habit app (i.e., exercise tracking) to act as a control arm for the RN-SLEEP intervention
75343567|NCT06099782|Biological|Pembrolizumab co-formulated with hyaluronidase|Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.
75343568|NCT06099782|Biological|Pembrolizumab|Administered via IV infusion
75801531|NCT04605588|Drug|Nitazoxanide|Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
75940061|NCT05540002|Device|High Intensity Quell|Participants will receive 1 hour of continuous stimulation during each therapy session. Subjects are asked to complete a minimum of 3 sessions per day.
76089888|NCT04715087|Other|Blood sample (Day 0 ,Day 3),Skin swab sampling (Day 0,Day 13), patch test application (Day 1), skin biopsies (Day 13)|"A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at Day 0 and Day 3.~Each bacteriological sample from AD patients performed by swabbing the skin at screening visit will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. A well-characterized S. epidermidis lab strain will be also applied to healthy volunteers. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healthy skin. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application"
75940062|NCT05540002|Device|Low Intensity Quell|Participants will receive only three 2-minute periods of stimulation (at 0, 28, 58 minutes) during each 60-minute therapeutic session. Subjects are asked to complete a minimum of 3 sessions per day.
75940063|NCT05359510|Procedure|prophylactic mesh repair at different sites for prevention of incisional hernia after various abdominal incision versus primary abdominal suturing|before closure of the abdominal layers prophylactic mesh will be used for prevention of incisional hernia. another patient with abdominal incision , primary closure of abdominal layer will occur.
75476113|NCT02003326|Other|Inflammatory markers|
75940064|NCT05601622|Procedure|Fluid loading|Intravenous administration of 10ml/kg of crystalloids over 10 minutes
76089889|NCT04704973|Behavioral|Transdiagnostic short-term psychotherapy|Focused clinical functional analysis, formulation of a valued life direction includings strategies to handle obstacles, and a summarizing exercise including relapse prevention.
76089890|NCT04700514|Drug|Dexmedetomidine|Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia
76089891|NCT04669145|Drug|Ropivacaine|Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.
75476114|NCT02003339|Other|Additional RMIs|
75940065|NCT05601622|Diagnostic Test|Transthoracic echocardiography|Transthoracic echocardiographic measurement of stroke volume index
75940066|NCT05601622|Diagnostic Test|PVI, RPVI|Continuous measurement of pleth variability index and Rainbow pleth variability index
75940067|NCT05601622|Procedure|Tidal volume change|Changing tidal volume for mechanical ventilation as 6, 8, 10 ml/kg
75654199|NCT00830635|Other|study of socioeconomic and demographic variables|
76089892|NCT04667364|Device|Transcutaneous electrical nerve stimulation (TENS)|Conventional TENS will be performed using two electrodes placed on the involved extremity and with the following stimulation parameters; a frequency of 100 Hz, pulse duration 50-100 ms, and at an intensity gradually increased until the patient feels a strong, tolerable and non-painful sensation (18, 19). The intensity is incrementally increased based on patient feedback. Patients will receive guidelines on how to use the TENS device at home and will over a period of 30 days self-administer TENS as needed. Patients is to fill out a predefined schedule on paper each day to monitor dose.
76089893|NCT04652050|Drug|Tolsura|Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
75476115|NCT02003378|Device|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
75654200|NCT00830635|Other|survey administration|
75654201|NCT00830635|Procedure|psychosocial assessment and care|
75654202|NCT00830635|Procedure|quality-of-life assessment|
75654203|NCT00633282|Behavioral|Life style intervention|"calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate"
75343569|NCT06092996|Other|Time of Sling Use|Standard sling worn for only three days post operatively
75343570|NCT06089577|Drug|Cangrelor 50 MG|Cangrelor will be administered during PCI
75343571|NCT06089395|Drug|Jiajian Guishen granules|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
75343572|NCT06089395|Drug|coenzyme Q10|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
75343573|NCT06085924|Drug|SoC|COVID-19 treatment as per government guidance
75343574|NCT06085924|Other|Disease description|No intervention
75654204|NCT00633282|Drug|pioglitazone|pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
75654205|NCT00633282|Drug|berberine|berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
75654206|NCT00830089|Drug|Levobupivicaine 0.25%|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
75343578|NCT06079775|Drug|Xeruborbactam Oral Prodrug|Experimental
75343579|NCT06079775|Drug|Ceftibuten|Experimental
75343580|NCT06079775|Drug|Xeruborbactam Oral Prodrug Placebo|Placebo Comparator
75343581|NCT06079775|Drug|Ceftibuten Placebo|Placebo Comparator
75476116|NCT02003378|Device|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
75476117|NCT02003456|Drug|Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82|Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
75476118|NCT02003469|Device|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
75476119|NCT02003482|Radiation|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
76089894|NCT04651634|Drug|MIT-001 plus CCRT|MIT-001 IV-infusion plus CCRT
76089895|NCT04650074|Drug|LIDOCAINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
75343582|NCT06077721|Drug|Milrinone|giving intravenous milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/ min infusion
75343583|NCT06074588|Biological|MK-2870|4 mg/kg of MK-2870 by IV infusion
75343584|NCT06074588|Drug|Docetaxel|75 mg/m^2 of docetaxel by IV Infusion
75343585|NCT06074588|Drug|Pemetrexed|500 mg/m^2 of pemetrexed by IV infusion
75343586|NCT06074198|Behavioral|SuCCESs|strengthening and endurance exercises
75343587|NCT06073457|Device|MagGJ System|Anastomoses achieved by magnetic compression.
75654207|NCT02838966|Dietary Supplement|Nestle IMPACT Advanced Recovery|
75654208|NCT02838966|Dietary Supplement|Nestle Boost High Protein Drink|
75940068|NCT05599516|Biological|LIBP-Rec-Vaccine|Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
75940069|NCT05599516|Biological|BIBP-Rec-Vaccine|Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
75343588|NCT06068673|Drug|Clindamycin 600 mg|Clindamycin 900 - 1200 mg TWICE per day during 2 weeks period.
75343589|NCT06068673|Drug|standard regimen|standard regimen
75476120|NCT02003482|Device|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
75476121|NCT02003495|Biological|MCV-ACYW135 Vaccine Group|0.5ml, intramuscular
75654209|NCT00830245|Drug|Erlotinib|Erlotinib 150mg/day
75801532|NCT04605588|Drug|Placebo Nitazoxanide|Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
75801533|NCT04605588|Drug|Ribavirin|Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
75801534|NCT04605588|Drug|Placebo Ribavirin|Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
75940070|NCT05599516|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
75965949|NCT03047798|Drug|Mouthrinse|"A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen."
75343590|NCT06065280|Drug|Empagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
75343591|NCT06065280|Drug|Dapagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
75343592|NCT06060860|Behavioral|Cognitive-Behavioral Therapy (CBT)|"The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules:~emotion awareness,~cognitive appraisal & reappraisal,~emotion avoidance & emotion-driven behaviors,~awareness and tolerance of emotion-related physical sensations, &~interoceptive and situational emotion-focused exposures.~There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth."
75476122|NCT02003495|Biological|MPV-ACYW135 Vaccine Group|0.5ml, intramuscular
75476123|NCT02003495|Biological|MPV-A Vaccine Group|0.5ml, intramuscular
75476124|NCT02003495|Biological|MCV-AC Vaccine Group|0.5ml, intramuscular
75476125|NCT02003495|Biological|Hib Vaccine Group|0.5ml, intramuscular
75476126|NCT02003521|Device|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
75654210|NCT02837874|Procedure|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
75654211|NCT02837874|Procedure|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
75801535|NCT04605588|Drug|Hydroxychloroquine|Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
75801536|NCT04605588|Drug|Placebo Hydroxychloroquine|Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
75801537|NCT04885296|Device|TRP-200|JJVC Investigational Contact Lens
75801538|NCT04885296|Device|JJVC Marketed Contact Lens|ACUVUE Oasys 1-Day
75801539|NCT04602000|Biological|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
75801540|NCT04602000|Biological|CT-P59|CT-P59 (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
75940071|NCT05598970|Other|Digital application supported CHW Parenting Intervention|"All pregnant women served by the trained CHW will be invited to participate in the Parenting program, from when the mother is at least 20 weeks pregnant and less than 32 weeks pregnant with the target child for a period of 15 months. CHWs will visit pregnant women at least 3 times during their pregnancy and at least 16 times following delivery. In addition to the individual home visits, the CHWs will organise bi-weekly in-community group sessions for children aged 6-12 months and their primary caregivers, focusing on caregiver-child interaction and stimulation activities.~The immediate supervisors Health Care Workers (HCWs) of the CHWs will be trained to closely monitor CHWs activities and progress made. HCWs and CHWs will in turn be supervised and supported by district level Council Health Management Team (CHMT).~Parenting services will be provided to all target children of these eligible caregivers, irrespective of their learning or physical abilities."
76089896|NCT04650074|Drug|LIDOCAINE 20 mg + KETAMINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
75801541|NCT04602000|Biological|Placebo|Placebo (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
75654212|NCT02549911|Other|HIPEC,Chemotherapy AND surgery|"HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
75654213|NCT02838030|Drug|L-arginine|3 gr per day
75343593|NCT06060860|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.
75343594|NCT06058156|Drug|SAR444656 (KT-474)|Oral Tablet
75343595|NCT06058156|Drug|Placebo|Oral Tablet
75343596|NCT06055920|Device|FlowTriever System|Mechanical Thrombectomy for pulmonary embolism
75343597|NCT06055920|Drug|Anticoagulation Agents|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
75476127|NCT02003547|Drug|AMA0076|
75476128|NCT02003547|Drug|Placebo|
75654214|NCT02838030|Drug|Placebo (for L-arginine)|3 gr per day
75801542|NCT04602000|Biological|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
75801543|NCT04602000|Biological|Placebo|Placebo (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
75801544|NCT05053230|Behavioral|IM@Home|"Participants will be enrolled into either IM@Home or enhanced usual care for the study duration of 12 weeks.~IM@Home is an online mind-body program consisted of a series of virtual, synchronous classes that offer a variety of rigorously tested mind-body therapies led by an Integrative Medicine Service (IMS) clinical therapist. The virtual mind-body group therapy sessions will be conducted using Zoom video conferencing platform."
75801545|NCT05053230|Behavioral|Enhanced usual care|Patients in the enhanced usual care will receive usual care. In addition, once enrolling into the trial, they will be given a handout to encourage them to visit the MSK's multimedia page on the Integrative Medicine website to access pre-recorded, on-demand meditation videos/audios
75801546|NCT05361018|Other|Whole Body Vibration exercise - WBV|participants will be randomised to two different training interventions
75801547|NCT03755856|Other|Questionnaire|Health-related quality of life
75940072|NCT05598970|Other|Unconditional Cash Transfer only Intervention fixed amount|The fixed cost for delivering the Parenting only Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer fixed amount' treatment arm, the transfer will be 109,000 TZS (32,000 TZS + 77,000 TZS).
75343598|NCT06052059|Drug|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
75343599|NCT06052059|Drug|IV Placebo|Placebo matching IV tulisokibart
75343600|NCT06052059|Drug|SC Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
75801548|NCT03757962|Other|Dietary intervention|Limiting dietary exposure to benzoic acid, sorbic acid, polysorbates and related food additives; limiting eating out to a maximum of 2 days per week.
75476129|NCT02003560|Radiation|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
75476130|NCT02003586|Dietary Supplement|plant-based ingredient|
75476131|NCT02003586|Dietary Supplement|No plant-based ingredient|
75476132|NCT02003599|Device|Laser therapy|The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
75343601|NCT06052059|Drug|SC Placebo|Placebo matching SC tulisokibart
75801549|NCT03752736|Behavioral|"I wear sunscreen everyday song-based video"|"All four classes (arms) will be shown (sitting on carpet, not participating) a 2-3 minute song-based video titled I wear sunscreen everyday in which they observe elementary age children applying sunscreen in a systematic fashion. Following the viewing, classes will be administered this video guided, song- based intervention while their teacher documents their independent participation using our classroom map data collection sheet."
76089897|NCT04650074|Drug|LIDOCAINE 20 mg + KETAMINE 40 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute"
76089898|NCT04631445|Other|Ketogenic Diet|Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to < 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).
75654215|NCT02838030|Drug|acetylsalicylic acid|3 gr per day
75654216|NCT00825643|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
75476133|NCT02003599|Device|Placebo|In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
75476134|NCT02003651|Dietary Supplement|Quick Defense|Echinacea product from Gaia Herbs.
75476135|NCT02003651|Dietary Supplement|Placebo|Placebo
75476136|NCT02003664|Drug|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
75654217|NCT04250298|Dietary Supplement|sucrosomal iron|oral intake of iron as sachets or capsules
75654218|NCT04044079|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
75801550|NCT03041116|Drug|Fosmetpantotenate|Daily dosing
75801551|NCT03041116|Drug|Placebo|Daily dosing
75940073|NCT05598970|Other|Unconditional Cash Transfer Intervention|Families will receive from 5-7 months pregnancy over a period of 15 months a bi-monthly unconditional cash transfer, which equals the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under Tanzania Social Action Fund (TASAF), i.e., Tanzania's National Cash Transfer program.
75654219|NCT04044079|Drug|Misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
75654220|NCT04044079|Drug|Placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
75940074|NCT05598970|Other|Unconditional Cash Transfer only Intervention vary amount|The rationale for the levels of the varying UCT amounts is to keep them comparable with i) the bi-monthly cost of the parenting program per family, ii) the bi-monthly cash transfers disbursed under TASAF, and iii) the sum of the bi-monthly cost of the parenting program and the bi-monthly cash transfer disbursed under TASAF. The fixed cost for delivering the Parenting Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer only vary amount' group, each of the amounts vary individually (32,000 TZS; 77,000 TZS; 109,000 TZS).
75654221|NCT02837484|Other|NuTech Affinity™ Membrane|NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
75654222|NCT00830323|Drug|oseltamivir + zanamivir|oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
75654223|NCT00830323|Drug|oseltamivir+ amantadine|oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
75654224|NCT00830323|Drug|oseltamivir|oseltamivir (75mg bd for 5 days, oral)
75654225|NCT05333562|Other|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
75940075|NCT05380024|Drug|Ensartinib|Ensartinib 225mg QD 8 weeks
76089899|NCT04620304|Biological|UB-421 SC(dB4C7C22-6 mAb)|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
76089900|NCT04620278|Genetic|DNA or RNA Sequencing|Samples will be used for whole exome (DNA) or RNA sequencing
75801552|NCT04860258|Biological|CVnCoV Vaccine|Intramuscular (IM) injection in the deltoid area, preferably in the non-dominant arm.
75940076|NCT05343598|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses."
75343604|NCT06049342|Biological|NCR100 injection|Subjects will receive a one-dose intra-articular NCR100 injection.
75343605|NCT06047548|Drug|Tirzepatide|Administered SC
75343606|NCT06047548|Drug|Placebo|Administered SC
75343607|NCT06044610|Other|GENPOP Passive dehydration (75% reduction in fluid intake|Over 24-hours
75343608|NCT06044610|Other|GENPOP Ad lib fluid intake|Over 24 hours
75476137|NCT02003664|Drug|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
75476138|NCT02003677|Drug|Faster-acting insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
75476139|NCT02003677|Drug|insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
75476140|NCT02003703|Biological|Recombinant Hepatitis B Virus Vaccine|
75476141|NCT02003729|Device|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
75343609|NCT06044610|Other|EXERCISE without fluid replacement|90-min standard cycling exercise trial in heat chamber
75940077|NCT05343598|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
75343610|NCT06044610|Other|EXERCISE with fluid replacement|90-min standard cycling exercise trial in heat chamber
75654226|NCT05333562|Other|Motor control exercise with mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
75654227|NCT00830401|Procedure|Treatment of predefined abnormality by hysteroscopic surgery|"Polyp resection with Hysteroscopic scissors or Versapoint~Resection of myoma with Resectoscope Storz or Versapoint~Septum resection with Resectoscope Storz or Versapoint~Resection of adhesions with Hysteroscopic scissors or Versapoint"
75654228|NCT00830401|Drug|Ofloxacinum/Doxycycline|Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
75343611|NCT06038188|Behavioral|SIT LESS Booster|"Patients allocated to the SIT LESS Booster group receive usual care in combination with the SIT LESS Booster program.~The SIT LESS Booster program consists of: 1) The use of the pocket-worn activity tracker (Activ8sit). The activity tracker can be connected to an app to track the daily sitting time. Besides, the device buzzes when a person sits more than 30 consective minutes a s a reminder to stand up and move; 2) Telephone consultation (TC1) during which the researcher and patients will reactivate knowledge on the detrimental health effects of SB, discuss patients' personal goals and motivation, and collaboratively set action plans for reducing SB in the upcoming week (±20 minutes); and 3) Weekly telephone calls (TC2 and TC3) to evaluate sedentery behaviour of the preceding week (±10 minutes).~The SIT LESS Booster will be delivered completely remote"
75343612|NCT06034002|Drug|INCA033989|INCA033989 will be administered at protocol defined dose.
75476142|NCT02003755|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
75654229|NCT04249908|Drug|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d.
75801553|NCT05374798|Device|Heart Rate Variability-Biofeedback (HRV-B) via Smartwatch Device Intervention|"Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed. HRV-B will guide participants in an evidence-based paced breathing technique (about 6 breaths per minutes) using visualization on thier mobile device of thier real-time respiratory and cardiac parameters.~During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed."
75654230|NCT00830713|Procedure|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
75654231|NCT02837796|Procedure|transobturator tape|
75654232|NCT00825721|Drug|LiquiTears|4 drops applied daily for 360 days
75654233|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
75654234|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
75801554|NCT03752658|Drug|Tenofovir Alafenamide|The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
75801555|NCT03752580|Device|User Instructions of novel nasal mask|User Unstructions interpretation of novel nasal mask for the treatment of obstructive sleep apnea (OSA).
75801556|NCT03041038|Drug|Secukinumab|Anti IL-17A antibody
75801557|NCT03041038|Drug|Placebo|
75801558|NCT05460546|Drug|Jincaopian Tablets high dose|Jincaopian Tablets 0.2g tid p.o.
75940078|NCT05342740|Other|collect whole blood, urine and stool samples|collect whole blood, urine and stool samples
76089901|NCT04606173|Other|Team Education for Adopting Changes in Healthcare (TEACH)|TEACH, an educational strategy which includes evidence-based strategies to improve task-specific teamwork will occur across 4 brief (20-30 minutes) team meetings over a 12-week period.
76089902|NCT04601571|Device|CORTRAK Stylet|The stylet is a component of the CORTRAK feeding tube system used to confirm the correct placement of the feeding tube
75343613|NCT06029972|Drug|Tilpisertib Fosmecarbil|Tablets administered orally
75476143|NCT02003768|Drug|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
75476144|NCT02003768|Drug|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
75476145|NCT02003794|Drug|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
75654235|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
75654236|NCT02837640|Drug|levodopa-carbidopa|sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
75654237|NCT02548663|Other|Sport therapy|"Frequency: 60 min three times/week~20 min: aerobic training on bicycle ergometer.~20 min: strength training at 60% of maximal load.~20 min: proprioception and stretching exercises."
75654238|NCT02548663|Other|Osteopathic treatment|Frequency: 60 min weekly
75801559|NCT05460546|Drug|Jincaopian Tablets low dose|Jincaopian Tablets 0.1g tid p.o.
75801560|NCT05460546|Other|Placebo|Placebo tid p.o.
75940079|NCT05342194|Drug|Toripalimab|240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
75940080|NCT05342194|Drug|Lenvatinib mesylate capsules|8 mg orally (po) once daily (QD)
75801561|NCT04382066|Drug|Plitidepsin 1.5 mg/day|"Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~Diphenhydramine hydrochloride 25 mg iv or equivalent.~Ranitidine 50 mg iv or equivalent.~Dexamethasone 8 mg iv.~Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
75940081|NCT05342194|Drug|Placebo IV|Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
75940082|NCT05342194|Drug|Oral placebo|Oral placebo po QD continuously
75940083|NCT05342194|Drug|Oxaliplatin for injection|85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles
75940084|NCT05342194|Drug|Gemcitabine hydrochloride|1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
75940085|NCT05342194|Drug|Cisplatin|25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
75940086|NCT04422496|Drug|HEC96719|"single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study."
75940087|NCT05341804|Behavioral|cognitive and balance dual task training|a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software
75343614|NCT06029972|Drug|Placebo|Tablets administered orally
75343615|NCT06028230|Drug|SAR444656 (KT-474)|Oral Tablet
75654239|NCT02837718|Procedure|bupivakain % 0,5|Bupivacaine 0,5% The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
75654240|NCT02834442|Drug|MT-7117|
75654241|NCT02834442|Drug|Placebo|
75801562|NCT04382066|Drug|Plitidepsin 2.0 mg/day|"Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~Diphenhydramine hydrochloride 25 mg iv or equivalent.~Ranitidine 50 mg iv or equivalent.~Dexamethasone 8 mg iv.~Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
75801563|NCT04382066|Drug|Plitidepsin 2.5 mg/day|"Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~Diphenhydramine hydrochloride 25 mg iv or equivalent.~Ranitidine 50 mg iv or equivalent.~Dexamethasone 8 mg iv.~Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
75940088|NCT05341804|Behavioral|balance training|Includes static balance, dynamic balance and strength training
75940089|NCT05341258|Diagnostic Test|EtCO2|EtCO2
75940090|NCT05341258|Diagnostic Test|PaCO2|PaCO2
75940091|NCT03623789|Drug|intravenous application of tranexamic acid|intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.
75940092|NCT03623789|Drug|Floseal hemostatic matrix|application of Floseal® on potential bleeding sites after prosthesis implantation
75940093|NCT03623789|Drug|Normal saline|Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
75940094|NCT05307406|Biological|Experimental|Participants will receive a single IV infusion in a double blind manner
75940095|NCT05341024|Other|Pelvic Floor Muscle Training in female CrossFit and functional fitness exercisers|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the participants in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (clinical exams of pelvic floor muscle function by observation and vaginal digital palpation) and instructions on how to perform the training program. The program consists of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The participants will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 16 weeks and the exercises will take approximately 10 minutes per day to perform.
75654242|NCT02834208|Other|MRI (Magnetic resonance imaging)|
75940096|NCT05306470|Procedure|Ethyl chloride|Application of ethyl chloride for a cooling effect to numb the area for oral infiltration anesthetic
76089903|NCT04589598|Device|Femoral Neck System|femoral neck system using bolt and antirotation screw with one/two hole plate
75343616|NCT06028230|Drug|Placebo|Oral Tablet
75654243|NCT02834208|Genetic|Polymorphism (SNP in DNA)|
75654244|NCT02834208|Genetic|quantitative measures of mRNA|
75654245|NCT02834208|Other|Neuropsychological assessment|
75654246|NCT02834286|Drug|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
75654247|NCT02834286|Drug|Eltrombopag|Eltrombopag 50 mg PO days 1-28
75343617|NCT06025578|Drug|BMS-986278|Specified dose on specified days
75343618|NCT06025578|Drug|BMS-986278 Placebo|Specified dose on specified days
75343619|NCT06017570|Diagnostic Test|Radiologic examination on orthopantomogram|Caries examination on the distal side of the adjacent second molar in the orthopantomogram of patients with an appointment for the extraction of mesioangular or horizontal partially impacted third molars
75343620|NCT06017570|Diagnostic Test|Clinical examination after surgery|İnspectional caries examination on the distal side of the adjacent second molar after surgery of patients with mesioangular or horizontal partially impacted third molars
75940097|NCT05306470|Procedure|5% lidocaine gel|Application of 5% lidocaine gel to numb the area for oral infiltration anesthetic
75940098|NCT05340010|Drug|Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU|From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
75940099|NCT05339386|Drug|Hyperpolarized Xe129|Lung MRI using gaseous contrast agent hyperpolarized 129Xe.
75940100|NCT05339074|Drug|Ketamine Hydrochloride|60 patients will receive ketamine hydrochloride over 12 weeks, flexible dosed between 0.5 mg/kg to 1.0 mg/kg
75940101|NCT05338996|Behavioral|iENGAGE for PrEP|This intervention originally developed for people living with HIV (PLWH), is designed to promote engagement, retention, and adherence to treatment by addressing the social determinants of health that often act as barrier to remaining in care and achieving viral suppression. Based on our experience with this intervention we believe that it is well suited to similarly promote engagement, retention, and utilization of PrEP care among our proposed target population of WOC by a) removing barriers to care and b) addressing unmet needs by providing c) point-to-point linkage to care services delivered by multi-disciplinary teams of individuals within or outside of the health facility, and d) the use of telehealth visits to facilitate engagement in care and improve health visit attendance. The original iENGAGE is a 4-session, in-clinic behavioral intervention.
75940102|NCT05352490|Diagnostic Test|calculate LUS score|calculate LUS score
75940103|NCT05560282|Drug|Fenfluramine|"FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt. The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl) phenethylamine hydrochloride.~Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2. FINTEPLA is a clear, colorless solution, pH 5."
75343621|NCT06015282|Biological|Investigational aQIVc|Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
75343622|NCT06015282|Biological|licensed QIV1|Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
75654248|NCT02834286|Drug|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
75654249|NCT02837562|Other|Slit lamp eye examination|All participants in the trial will undergo a slit lamp eye examination
75654250|NCT02834130|Behavioral|Evaluation of psychological and psychopathological|
75654251|NCT04248270|Drug|18F-PM-PBB3|All scans will be acquired in pairs of 18F-florbetapir(18F-AV45) and/or18F-PM-PBB3 PET scans (if patient select), performed on separate days, and at least 2 days apart, with either scan performed first. The 18F-florbetapir and 18F-PM-PBB3 protocol will entail the inon of 5±2mCi of tracer followed by an uptake phase of 50 min during which time the state of the subject is not important. After 40 minutes, subjects will be positioned and 4 x 5 min frames of emission data will be collected right at 50 min after tracer injection. PET/MRI scans will precede this acquisition with a MRI scan for attenuation correction; PET-only scanners will perform a transmission scan following the emission scan.
75801564|NCT03757884|Behavioral|Mindfulness breathing exercise|Spire monitor instructed mindfulness breathing
76089904|NCT04589598|Device|Multiple Cannulated Screw|multiple cannulated screw using 3 or 4 cannulated screw
76089905|NCT04578886|Drug|Guanfacine|Guanfacine 2 mg administered at 21:00 for up to 14 days or otherwise indicated by study protocol.
75801565|NCT03757884|Behavioral|Diagnostic Checklist|Checklist reminder for diagnosis
75801566|NCT03757884|Behavioral|Noise cancelling headphones|Noise cancelling headphones
75801567|NCT03757884|Behavioral|Privacy tablescreen|Privacy Tablescreen
75801568|NCT03757884|Behavioral|Diagnostic assistance application|Diagnostic assistance application
75801569|NCT03752502|Procedure|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
75940104|NCT03683615|Procedure|repair of orbital floor fractures using resorbable plates|
76089906|NCT04578886|Drug|Placebo|Placebo, administered at 2100 for up to 14 days or otherwise indicated by study protocol.
76089907|NCT04571060|Drug|Zavegepant|One dose of zavegepant
75654252|NCT02837016|Device|Wearable biofeedback|
75654253|NCT02837016|Behavioral|Relaxation Treatment|group-based relaxation treatment based on mindfulness meditation principles
75654254|NCT02833896|Genetic|surgery|
75654255|NCT02833818|Dietary Supplement|CAKE-intervention|Increased protein and energy supplementation and conversations
75654256|NCT02833818|Dietary Supplement|CAKE-control|nutrition according to established procedures
75654257|NCT02837172|Other|Diffusion Weighted Imaging (DWI)|"MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.~Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS"
75654258|NCT04250532|Other|Drowning|Measurement of pulse oximetry, after lifeguard immersion during their morning training
75654259|NCT02839044|Dietary Supplement|Menaquinone-7|
75801570|NCT03752502|Procedure|Peripheral electrical stimulation (PES)|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia.
75801571|NCT03752502|Procedure|Sham tDCS|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
75801572|NCT03757728|Procedure|Haemorrhoidectomy operations|for treatment of symptomatic 2 to 3 degree haemorrhoids
75801573|NCT03752424|Drug|Silver nanoparticles|The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
75801574|NCT03752424|Drug|Topical approved anti-microbial gel|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
75940105|NCT03678779|Behavioral|Incentive|$5 grocery gift card
76089908|NCT04571060|Drug|Placebo|One dose of matching placebo
76089909|NCT04550585|Other|Education: Session 1 - Basics of type 1 management|"In a group education session, a diabetes educator provides educational session 1 - Basics of type 1 management.~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
76089910|NCT04550585|Other|Session 2 - Carbohydrate counting|"In a group education session, a diabetes educator provides educational session 2 - Carbohydrate counting~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
76089911|NCT04550585|Other|Education: Session 3 - Insulin self- adjustment|"In a group education session, a diabetes educator provides educational session 3 - Insulin self- adjustment~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
76089912|NCT04550585|Other|Education: Session 4 - Sick day rules and physical activity dose adjustments|"In a group education session, a diabetes educator provides educational session 4 - Sick day rules and physical activity dose adjustments~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
76089913|NCT04550585|Other|Education: Session 5 - Starting the insulin pen (for pen users) or pump (for pump users)|"In a group education session, a diabetes educator provides educational session 5 - Starting the insulin pen (for pen users) or pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump? Is the Insulin Pen Right for Me?"
75654260|NCT02839044|Dietary Supplement|Placebo|
75654261|NCT02833740|Device|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
75654262|NCT02833662|Other|Measure of ODI and heart rhythm|Record nocturnal respiratory and cardiac parameters before and after surgery.
75654263|NCT05285592|Other|Fecal Transplantation|Fecal Transplantation
75801575|NCT03755778|Drug|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)
75801576|NCT03755778|Drug|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)
75801577|NCT03755778|Drug|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)
75801578|NCT03755778|Drug|Itraconazole|Subjects will receive itraconazole once daily from Day 5 to Day 18
75940106|NCT03678779|Behavioral|Education|Video-based brief nutrition education
75940107|NCT03678779|Behavioral|Combined|Both Incentive and Education interventions received
76089914|NCT04550585|Other|Education: Session 6 - Trouble shooting the pump (for pump users)|"In a group education session, a diabetes educator provides educational session 6 - Trouble shooting the pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump?"
75343623|NCT06015282|Biological|licensed QIV2|Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
75654264|NCT05285592|Drug|Standard Medical Treatment|Standard Medical Treatment
76089915|NCT04548713|Device|4% EDTA|Sterile Catheter Lock Solution
76089916|NCT04548713|Device|Saline|Saline Lock Solution
76089917|NCT04545515|Drug|ELX/TEZ/IVA|Fixed dose combination (FDC) tablet for oral administration.
76089918|NCT04545515|Drug|IVA|Tablet for oral administration.
76089919|NCT04512066|Drug|RO6889450|Participants will receive oral RO6889450 QD.
76089920|NCT04512066|Drug|Placebo|Participants will receive oral placebo QD.
75343624|NCT06015256|Biological|blood sample|Blood sample (56mL) taken in a heparin tube
75654265|NCT04249440|Procedure|Preoperative systemic treatment|neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment
75654266|NCT04249518|Behavioral|Videoeducation|No drugs used. The only difference in the to arms is the way the extradition is.
75654267|NCT04249206|Procedure|Root Canal Treatment|
75654268|NCT02833506|Other|Laboratory Biomarker Analysis|Correlative studies
75654269|NCT02833506|Biological|Recombinant NY-ESO-1 Protein|Given recombinant NY-ESO-1 protein SC
75654270|NCT02833506|Drug|Sirolimus|Given PO
75654271|NCT02838498|Device|ERCP Mechanical Simulator (EMS)|Hands on EMS training
75654272|NCT02833272|Behavioral|EMPOWER Educational Brochure|The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
75654273|NCT02838576|Drug|Conjugated Equine Estrogen|Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
75654274|NCT02838576|Drug|Placebo|Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
75801579|NCT03755778|Drug|Rifampin|Subjects will receive rifampin once daily from Day 5 to Day 16
75801580|NCT03755778|Drug|Quinidine|Subjects will receive quinidine once daily from Day 5 to Day 12
75801581|NCT05266378|Procedure|PECs block|The PECs block is performed immediately after induction of anesthesia, and 0.375% concentration of ropivacaine (carbiropivacaine injection, Fresinius Kavi Korea Co., Ltd.) is used with a 25 G 5 cm (or 8 cm) needle to induce ultrasound-guided pectoralis major (pectoralis major). 10mL (PECs I block) into the fascia between the pectoralis minor muscle) and the pectoralis minor muscle, and 20mL (PECs II block) between the pectoralis minor and serratus anterior muscle.
75801582|NCT05266378|Other|Not receiving PECs Block|In this group, the PECs block was not implemented.
76089921|NCT04512066|Drug|Risperidone|Participants will receive oral risperidone QD.
76089922|NCT04506892|Behavioral|Meditation|meditation
76089923|NCT04448847|Dietary Supplement|Bif195|Active trial product with minimum 100 billion CFU daily dose
76089924|NCT04448847|Other|Placebo|Placebo similar to trial product but without Bif195
75343625|NCT06014762|Biological|P-CD19CD20-ALLO1|Single weight-based IV administration
75343626|NCT06014762|Drug|Rimiducid|Single weight-based IV administration
75940108|NCT03677453|Other|Interactive Perioperative Teaching Platform|An active video format will be used to provide instructions for navigating the hospital; describe induction of anesthesia and the surgical procedure; and provide post-surgery and post-discharge instructions for pain management.
75801583|NCT04435184|Drug|Crizanlizumab|Crizanlizumab 5.0 mg/kg in 100 ml IV once.
75940109|NCT03678701|Dietary Supplement|Pre-meal 100% whey protein intake|Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
75940110|NCT05338450|Drug|Clemastine Fumarate|4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)
75940111|NCT05338450|Drug|Placebo|Placebo equivalent to experimental arm
75940112|NCT03683537|Diagnostic Test|Glial fibrillary acidic protein|3 samples of serum are drawn from patients. The 1st Sample of patient serum is drawn before induction into anesthesia. The 2nd is drawn 24 hours after the 1st one. The 3rd sample is drawn on 3 or 4 postoperative day. All samples collected and preserved in the same temperature as required for ELISA.
75654275|NCT02836860|Other|Tactile stimuli|Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
75654276|NCT00838539|Drug|Neratinib|
75940113|NCT03677297|Drug|Rosuvastatin|Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
75940114|NCT03683459|Device|FemFlow Drug-Eluting Peripheral Balloon Catheter|Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.
76089925|NCT04426318|Behavioral|Healthy Minds Program Foundations Training|The HMP is a novel, smartphone-based app that provides a series of guided meditation practices on four primary constituents of well-being: Awareness, Connection, Insight, and Purpose. The program is unique in several ways. First, all program elements are introduced with a summary of the scientific evidence supporting its constituent elements (e.g., Awareness and well-being). Second, in addition to standard sitting meditation practices found in many meditation-based behavioral interventions, the HMP offers active practices in which participants can develop the same skills but while embedding practice into activities they already do in their normal daily routine.
76089926|NCT04421092|Procedure|Superior laryngeal nerve block|Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
75801584|NCT04435184|Other|0.9% saline|0.9% saline 100 ml IV once.
75343627|NCT06013748|Behavioral|VR-VOICES|7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.
75343628|NCT06013748|Other|Treatment as usual|Treatment as usual as provided by the mental health centers
75343629|NCT06013241|Drug|Brensocatib|Film-coated tablet.
75343630|NCT06013241|Drug|Placebo|Film-coated tablet.
75476146|NCT02003820|Behavioral|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
75476147|NCT02003833|Device|Poly-L-lactic acid|Sculptra injections
75343631|NCT06013241|Drug|Mometasone furoate nasal spray (MFNS)|Nasal spray suspension.
75343632|NCT06005220|Other|SBD121|Medical Food
75343633|NCT06005220|Other|Placebo|Placebo
75343634|NCT06003426|Drug|BMS-986278|Specified dose on specified days
75476148|NCT02003833|Device|Placebo comparator|saline injections
75654277|NCT00838539|Drug|Temsirolimus|
75801585|NCT03755700|Drug|Vitamin E|As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention
75801586|NCT03755700|Drug|N-acetyl cysteine|As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention
75801587|NCT03755700|Drug|Placebo oral capsule|The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
75801588|NCT03755700|Drug|Placebos|The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group
75801589|NCT03755700|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
75801590|NCT03755622|Device|Conventional Transpalatal Arch (TPA)|In Group C, upper molar bands selection will be carried out by direct intra oral procedure. The conventional TPA is made on the stone working models.
75343635|NCT06003426|Drug|BMS-986278 Placebo|Specified dose on specified days
75343636|NCT06001541|Behavioral|Web-SUCCEED|web-SUCCEED (Web-based Self-management Using Collaborative Coping EnhancEment in Diseases), a theoretically-derived, dyadic, self-management program.20,21 Web-SUCCEED is designed to improve self-management by improving dyadic stress coping and strengthening collaboration and communication.21 Web-SUCCEED comprises: 1) a three-module, self-paced behavioral intervention that Veterans and caregivers complete individually (one audio/video module per week) on the web-SUCCEED website; 2) brief, staff-led telephone calls in which dyads participate simultaneously after each module; and 3) peer support via a study-specific discussion board. Dyads learn and practice cognitive behavioral skills to reduce individual and relationship stress; improve positive emotions; improve communication and collaboration; increase pleasant activities; and maintain behavior change.
75343637|NCT05997771|Other|Personal Nutrition Advisor|The study intervention will be the use of the PNA data analysis tool during remote nutritional counselling sessions delivered by certified dietitians, also referred to as PNA-assisted remote nutritional counselling.
75476149|NCT02003872|Device|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
75801591|NCT03755622|Device|Transpalatal Arch (TPA) fabricated from 3D reconstructed model|In Group 3D, upper molar bands selection will be carried out on the 3D printed model instead of direct intra oral procedure. The 3D TPA will be fabricated on the 3D reconstructed model while the conventional TPA is made on the stone models.
75343638|NCT05990439|Behavioral|Baby-Feed|The Baby-Feed web application was developed by the researchers of this application at Florida International University. It was designed based on a validated infant food frequency questionnaire (FFQ) developed by our group. The Social Cognitive Theory (SCT) and the Health Self-Empowerment Theory (HSET) were used in the development of the different components. The main intervention component is showing automatic results on how well parents are feeding their infants, upon completion of the infant FFQ, showing results on which food groups are consumed at the recommended level, which are consumed above and which are consumed below. It also shows a growth chart showing how the baby is progressing when they add their baby's weight and length. The website also includes a tracking system with short questions asking about their weekly progress and the recommendations to review frequently, if needed.
75343639|NCT05990439|Behavioral|Limited access to the Baby-Feed web application|Limited access to the Baby-Feed web application, with only the options of completing the FFQ and inputing their baby's weight and length.
75343640|NCT05987852|Device|Hyperbaric Oxygen Therapy|"Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute air breaks (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days."
75343641|NCT05987852|Other|Sham Hyperbaric Air|"This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute air breaks to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days."
75654278|NCT02836626|Procedure|deep fascial mobilization|Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
76089927|NCT04421092|Procedure|Injection of placebo (saline)|Superior laryngeal nerve block using 1mL of saline as the injection.
76089928|NCT04421092|Procedure|Injection of steroid-lidocaine mixture|Superior laryngeal nerve block using 1mg 1:1 triamcinolone 40mg: 1% lidocaine with 1:200000 epinephrine as the injection.
76089929|NCT04412083|Behavioral|PPA Tele-Savvy Pilot Intervention|We will engage PPA caregivers in the process of adapting the existing Tele-Savvy program to fit their needs and then pilot test the adapted PPA Tele-Savvy program.
75343642|NCT05987423|Drug|Satralizumab|Satralizumab will be administered by SC injection.
76089930|NCT04406727|Biological|UB-421|UB-421 in combination with their ARV
75343643|NCT05987423|Other|Placebo|Placebo will be administered by SC injection
75343644|NCT05983250|Drug|TNX-103|levosimendan 1 mg
75343645|NCT05983250|Drug|Placebo|Placebo
75343646|NCT05979571|Other|Mobile health app|Breastfeeding knowledge and promotion information will be delivered through the AmiBreastfeed app platform
75343647|NCT05967195|Behavioral|Financial Incentive and Text-Messages|"Patient-participants will receive modest financial incentive for attending therapy or medication management appointments combined with text messages to encourage attendance at these appointments. Text messages will be informed by principles of behavioral economics. Maximum incentive = $50/month if all appointments attended. Incentives will be pro-rated by percentage of appointments attended. Pro-rating strategies (e.g., uniform amount per appointment, escalating [aka, 'back-loaded'], or decreasing [aka 'frontloaded'] will be sequentially changed based on acceptability and other intervention-related data gathered from participants during the trial.~Clinician-participants will not receive any intervention, but will receive surveys and interviews to assess their perceptions about the optimization, acceptability, scalability, and other implementation barriers/facilitators for the intervention."
75343648|NCT05961839|Drug|SGR-2921|SGR-2921 will be administered orally.
75343649|NCT05961592|Drug|R-2487|Probiotic
75343650|NCT05961566|Device|Use of collagen matrix after subepithelial connective tissue graft harvest|A collagen matrix is placed under the overlying flap after the subepithelial connective tissue graft harvesting.
75343651|NCT05959096|Drug|LY3437943|Administered SC
75343652|NCT05959096|Drug|LY3437943|Administered IV
75343653|NCT05957185|Dietary Supplement|OPTIZIOME® P³ HYDROLYZER® - WHEY|One dose of P3 - WHEY will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
75801592|NCT05280990|Diagnostic Test|mHBS|Preoperative FLRF assessment using 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS).
75801593|NCT05280990|Diagnostic Test|CT/MRI volumetry|Preoperative FLRF assessment using CT/MRI volumetry
75343654|NCT05957185|Other|Placebo|One dose of placebo maltodextrain will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
76089931|NCT04406727|Other|Antiretroviral (ARV)|Antiretroviral (ARV)
76089932|NCT04401891|Behavioral|Formal pre-operative education|One group of patients will receive formal pre-operative education prior to surgery from an occupational or physical therapists while the other group of patients will only receive routine education in the MD office.
76089933|NCT04397614|Other|mHealth Assessments|Daily symptom tracker
76089934|NCT04385732|Device|2D or 3D Melanoma Surveillance Photography|Total body imaging using 2D or 3D Melanoma Surveillance Photography plus digital dermoscopy.
76089935|NCT04364945|Drug|dexmedetomidine|administration of dexmedetomidine 1 mcg/kg/hr
76089936|NCT04364945|Drug|remifentanil|administration of remifentanil 0.1-0.2 mcg/kg/min
75343657|NCT05952453|Drug|Carboplatin|neoadjuvant treatment , followed by surgery, then maintenance chemotherapy
75343658|NCT05952453|Drug|olaparibp, embro|maintenance chemotherapy : olaparib, pembro
76089937|NCT04364945|Drug|Sevoflurane|Anesthesia is maintained using sevoflurane.
76089938|NCT04356963|Behavioral|Virtual Reality Session (VR Blu)|20-30 minute session of virtual reality immersive content.
76089939|NCT04356963|Behavioral|Tablet-based Session (Tablet Blu)|20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.
76089940|NCT04356963|Behavioral|Use of Virtual Reality Head Mounted Display without Content (VR Blank)|20-30 minutes session using head mounted display to reduce light and sound.
76089941|NCT04319731|Biological|Human Amniotic Fluid|Administration of amniotic fluid in SARS-CoV-2 positive patients
75343659|NCT05947266|Behavioral|an adaptation of the iENGAGE|Haitian immigrant iENGAGE (H-iENGAGE) is an adaptation of the iENGAGE intervention culturally adapted for Haitian immigrants with HIV that will be tested in a quasi-experimental pilot for preliminary efficacy among recently diagnosed or nonvirally suppressed adults across two Federally Qualified Health Centers (FQHCs) in Miami.
75343660|NCT05942300|Drug|CPI-0209|A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
75343661|NCT05942300|Drug|carboplatin|Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
75476150|NCT02003885|Drug|increment of desflurane|"After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion"
75476151|NCT02003937|Behavioral|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
75476152|NCT02003989|Other|ophthalmologic examination and MRI|thorough investigation of patients, not included in usual care.
75476153|NCT02004002|Behavioral|Weight maintenance with normal protein intake|Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.
75801594|NCT03619486|Device|Low energy shock wave|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 4 weeks
75801595|NCT03619486|Device|Placebo|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second but no energy once a week for 4 weeks
75801596|NCT03757650|Drug|Bismuth Subsalicylate|omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
75801597|NCT05190718|Device|Pharyngeal electrostimulation|"Routine treatment:~Pharyngeal stimulation is performed via a nasogastric probe (Phagenyx) for a duration of 10 minutes daily and for at least 3 consecutive days. The number of stimulation repeats until max 2x3 repeats, depends on therapy progress and an interdisciplinary re-evaluation of the patient's rehabilitation potential."
75801598|NCT03752346|Other|exercise group|"A step aerobics exercise lasted a total 30 minutes, including:~a warm-up with 10 minutes of stretching exercises.~A step aerobics exercise (step aerobics for 30 minutes; step by step, step exercise, or stepping the ground repetitively)23,24 a total of 30 minutes then cool down (5 minutes).~Resistance training (10 minutes), stretching and relaxation for 10-15 minutes."
75801599|NCT03751046|Behavioral|Trial-Based Cognitive Therapy|Participants in the TBCT intervention arm will have 14 (fourteen) psychotherapy sessions over a period of 7 (seven) months. The frequency of the intervention is biweekly with a duration of approximately 90 minutes per session. We will have10 groups with 5 participants each. All participants will practice the learned techniques during the meetings, have a manual with a description summary of the sessions and the activities to practice at home. The main TBCT techniques that will be used are case conceptualization, intrapersonal thought record, consensual role-play, action plan, trial-based thought record and trial-based metacognitive awareness.
75801600|NCT03751046|Other|Control group. Standard healthcare.|"Participants with therapeutic failure, receiving the standard healthcare in the HIV / AIDS Program, which includes at least a half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each).~The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV"
75801601|NCT03693404|Drug|Marcaine, Duramorph , ketorolac|Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
75801602|NCT03693404|Drug|Bupivacaine (Marcaine)|0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
75801603|NCT03693404|Drug|General Anesthetics|Placebo group will only receive standard of care general anesthesia
75965950|NCT02791763|Drug|1 to 4 mg tablets of GSK1278863|7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
75965951|NCT02791763|Drug|6 mg GSK1278863 tablet|9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
75965952|NCT02791763|Drug|Epoetin beta pegol|An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
75965953|NCT02086409|Dietary Supplement|Yogurt supplemented with vitamin D and calcium|The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
76089942|NCT04263948|Device|Picado system internet platform and connected objects|The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.
75343662|NCT05935527|Drug|POLAT-001|Subjects will be randomized to receive three injections per under eyebag, either 1 mg/mL or 2 mg/mL and 120 microliter volume, at each of three treatment visits.
75343663|NCT05935527|Drug|Placebo|Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
75343664|NCT05933889|Genetic|Molecular Analysis|Germline and circulating tumour DNA analysis of buccal/ blood samples and molecular analysis of primary and recurrent tumour tissue samples
75343665|NCT05933889|Other|Radiomic/ Morphological analysis|Radiomic analysis and assessment of morphological features of pre-operative CT/ MRI imaging in patients who have undergone TORS for primary oropharyngeal cancer.
76089943|NCT04235608|Drug|Inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden).
75343666|NCT05931653|Other|Multimodal Physical therapy|• Multimodal Physical therapy: Hot pack for 15 mins, TENS for 15 mins, Ultrasound at 1.5 W/cm2 intensity for 5 mins, Soft tissue release for <5-15 mins as per need, HVLA, PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets, Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets). 03 days/week for 06 weeks.
76089944|NCT04235608|Drug|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs.
76089945|NCT04233554|Behavioral|Patient Priorities Care|Patients will participate in a structured conversation in which the facilitator (i.e. social worker) helps patients identify their health goals, measurable, actionable, realistic outcomes (e.g. walk ½ mile daily). Both practice and patient level data will be collected.
76089946|NCT04231097|Other|MBCT intervention for ACS patients|The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants involved in the intervention will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
75343667|NCT05931653|Other|Proprioceptive training along with and Multimodal Physical therapy|"Multimodal Physical Therapy: Hot pack-5 mins, TENS-5 mins, U.S (1.5 W/cm2)-5 mins, Soft tissue release-<5-15 mins, HVLA, PA Glides (Central and Transverse)-10 sec each 5 sets, Lumbar facet gapping-10 sec 3 sets and Lumbar rotational facet gapping-10 sec 3 sets. 3 days/week for 6 weeks.~Proprioceptive Training:1. Trunk Balance (15 mins). In sitting, kneeling, quadruped, and supine positions for 30 seconds to 2 minutes. Progression to more challenging. Each will be performed for 2-3 mins. In case of pain exercise will be interrupted and substituted with another one.~2. PNF Training (10-12 mins). Each PNF training-1 set of 15 reps with 30s rest between and 60s after 15 reps. Week 1-2 alternate full isometrics of trunk flexors and extensors for 10s in sitting. Week 3-4, 5s resisted concentric, 5s eccentric and 5s isometrics contractions in forward and backward bending. Week 5-6, alternate chop and lift movement patterns of upper extremities in diagonal and spiral directions for 10s."
75343668|NCT05927142|Biological|Durvalumab|Human anti-PD-L1 antibody
75476154|NCT02004002|Behavioral|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
75476155|NCT02004015|Drug|injection of placebo|0.5 mg/kg milligram(s)/kilogram
75654279|NCT02836626|Procedure|superficial fascial mobilization|This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
75654280|NCT02836548|Drug|Vorinostat|vorinostat 360 milligram once daily
75654281|NCT04249128|Dietary Supplement|Vegetarian Collagen|Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.
75654282|NCT04249128|Dietary Supplement|Keratin|Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.
75654283|NCT04249128|Dietary Supplement|Ceramides|Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.
75654284|NCT04249128|Dietary Supplement|Astaxanthin|is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.
75801604|NCT03746678|Other|C-Care Mobile Application|C-care is a mobile application developed based on previous research at the IWK Health Centre. It contains topics relevant to Cesarean delivery and the recovery process, which the patient could access at anytime. Patient engagement with the application will be monitored anonymously for 30 days after delivery. On days one to five after delivery, patients will receive a short self-monitoring questionnaire (approximately 1 minute). At the end of two weeks (14 days), patients will complete an online survey regarding overall satisfaction, potential impact on care, usability and feasibility problems. At any point during the study, patients can email us to report any problems with the application.
75801605|NCT03696108|Drug|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID
75801606|NCT03696108|Drug|Placebo|Placebo matched to gefapixant 15 mg or 45 mg administered orally BID
75940115|NCT05303584|Biological|Ad5-nCoV-IH|The orally aerosolized Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. The Ad5-nCoV vaccine was supplied in 1.5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. 0.1 ml of Ad5-nCoV vaccine will be aerosolized by using Continuous Vapouring System. Then, the aerosolized droplets will be poured into a disposable suction cup and be inhaled by participants through mouth.
75940116|NCT05303584|Biological|Ad5-nCoV-IM|The Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. It was supplied in 1·5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. Participants will be administrated 0.5ml（5×1010VP）of Ad5-nCoV vaccine intramuscularly.
75940117|NCT05303584|Biological|CoronaVac|CoronaVac is an inactivated whole-virion vaccine with aluminium hydroxide as the adjuvant, prepared with a novel coronavirus (CZ02 strain) inoculated in African green monkey kidney cells (Vero cells). One dose of CoronaVac contains 3 μg of SARS-CoV-2 virion in a 0.5 mL aqueous suspension for injection with 0.45 mg/mL of aluminium.
75940118|NCT03677219|Other|Educational Video|The educational video is a 2 minute video depicting a live lumbar puncture on an infant interwoven with animations of the relevant anatomy.
75940119|NCT03683303|Behavioral|mobile applications (APP)|"the experimental group receiving education using Mobile Application (APP), collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3). The SPSS 22.0 for Windows was used for statistics analyses."
75343669|NCT05927142|Drug|Rintatolimod|TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)
75343670|NCT05916690|Drug|Electrochemotherapy with bleomycin or cisplatin|Combination of drug delivery platform (electroporation) and drug (bleomycin)
76089947|NCT04180020|Other|ID/LAB|ID/LAB is the new model in which OUD is managed by Infectious Disease (ID) specialists and/or Hospitalists concurrent with management of the infectious diseases, using long-acting injectable buprenorphine (LAB).
75343671|NCT05912777|Radiation|Scanner|Scanner to be performed by patients
75476156|NCT02004015|Drug|injection of NMBA|
75476157|NCT02004028|Drug|VS-6063|
75801607|NCT04219358|Drug|Vehicle Gel Base|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and water."
75801608|NCT04219358|Drug|Imiquimod 5% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and free form imiquimod 5%."
75801609|NCT04219358|Drug|Imiquimod 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquimod 0.05% free form."
75343672|NCT05909384|Other|Survey|Multiple rounds of surveys collecting information on sepsis diagnosis and management in resource-limited settings.
75343673|NCT05906628|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
75940120|NCT03683303|Behavioral|oral education|"the control group receiving the oral education, collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
75343674|NCT05906628|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
75343675|NCT05906095|Behavioral|LOCK Falls Program|The LOCK Falls Program helps multi-disciplinary frontline staff teams (nursing, physician, housekeeping, physical therapy, etc.) work together to identify and discuss risk factors for falling and use rapid-cycle QI techniques to pilot and monitor their actions to reduce resident falls.
75476158|NCT02004041|Drug|VLY-686|capsules containing 50 mg VLY-686
75476159|NCT02004041|Drug|Placebo|Sugar capsule to mimic VLY-686 50 mg capsule
75476160|NCT02004054|Other|measure of pupil diameter|The measure will use infra-red cameras
75476161|NCT02004067|Drug|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
75476162|NCT02004067|Drug|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
75476163|NCT02004106|Drug|RO6895882|Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
75476164|NCT02004119|Drug|KHK4577|
75476165|NCT02004119|Drug|Placebo|
75476166|NCT02004145|Behavioral|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
75476167|NCT02004145|Behavioral|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
75476168|NCT02004171|Other|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
75476169|NCT02004171|Drug|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
75654285|NCT02836938|Other|Collection of exhaled breath volatile organic compounds|
75654286|NCT05333484|Other|Programed Pilates|The 60 min Pilates sessions were held twice a week for 12 weeks. Each session included three stages: 10 min of warm-up exercises, 40 min of floor-based Pilates training, and 10 min of cool-down exercises. Each stage was adjusted according to the participants' physical capacity. Only participants with an attendance rate of > 80% were included in the final sample. The content of the exercise program was determined according to their muscular strength, flexibility, and fitness levels. The training course was divided into three levels: elementary, intermediate, and advanced. Each motion was performed in conjunction with a specific breathing pattern for effective muscle activations of each exercise.
75654287|NCT04030767|Drug|Botox Injectable Product|Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
75654288|NCT02836704|Drug|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous injection"
75940121|NCT03676985|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
75940122|NCT03676985|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
75476170|NCT02004184|Drug|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
75476171|NCT02004184|Drug|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
75476172|NCT02004197|Drug|Quadruple Allopathic therapy|
75476173|NCT02004197|Drug|Pylorex plus|
75476174|NCT02004210|Procedure|transarterial radioembolization (TARE)|transarterial radioembolization
75476175|NCT02004210|Procedure|transarterial chemoembolization (TACE)|transarterial chemoembolization
75343676|NCT05901168|Other|Active Video Games Intervention|Participants will complete active video games in the same order until they fill 20 minutes after the first 5 minutes of warm-up. In addition, during the change between games (lasting approximately 20 seconds), patients will be instructed by a therapist to perform combined exercises to minimize immobility time. These exercises are: elbow flexion and foot flexion, shoulder flexion and unilateral hip extension, and arm abduction and squat exercises that will prevent the patient from cooling down.
75343677|NCT05901168|Other|Traditional Exercise Intervention|"Active exercises for the upper extremities (without support): Shoulder flexion, Shoulder abduction, Elbow flexion at shoulder 90° flexion.~Active exercises for the lower extremities: Ankle-foot movements (ankle pumping exercise), heel raise, Knee extension in sitting high, Hip-knee flexion while lying supine~Body: Bridging, Trunk rotations in sitting~These exercises will be done in 1 set of 8-10 repetitions.~It will take about 20 minutes."
75476176|NCT02004223|Radiation|Dose escalation using stereotactic boost|"This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.~The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.~Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes."
75476177|NCT02004301|Drug|Radiolabelled T4 Tablet|
75654289|NCT02836704|Drug|metformin|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
75654290|NCT02836704|Drug|acarbose|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
75476178|NCT02004301|Drug|Radiolabelled T6 Tablet|
75476179|NCT02004314|Drug|Chloroquine|
75476180|NCT02004327|Drug|DW1029M300mg|DW1029M300mg PO Once
75476181|NCT02004327|Drug|DW1029M600mg|DW1029M300mg 2 tablets Once
75476182|NCT02004327|Drug|DW1029M1200mg|DW1029M300mg 4 tablets PO Once
75654291|NCT02611947|Radiation|Low-dose chest CT scans|"Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm"
75654292|NCT04478604|Other|applied forms to pregnant women|
75476183|NCT02004340|Device|ear vagus nerve stimulator|
75476184|NCT02004392|Drug|EVP-6124|
75476185|NCT02004405|Other|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
75654293|NCT02833584|Drug|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
75654294|NCT02833584|Drug|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
75654295|NCT00837759|Drug|Insulin|
75654296|NCT00837759|Drug|Lansoprazole|
75654297|NCT00837759|Drug|Sitagliptin|
75654298|NCT00837759|Biological|Diamyd|
75654299|NCT00837759|Drug|GAD65 (Diamyd)|
75654300|NCT02832960|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
75654301|NCT02832960|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
75654302|NCT00703287|Other|Physiotherapy|Specialized physiotherapy programme developed by Jean-Pierre Bleton
75654303|NCT00703287|Other|Physiotherapy|Generic physiotherapy
75654304|NCT02836782|Procedure|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
75654305|NCT02836314|Other|Anorganic Bovine Bone Mineral (ABBM)|In the control group, periodontal intrabony defects were treated with ABBM alone.
75654306|NCT02836314|Other|Anorganic Bovine Bone Mineral and Platelet Rich Fibrin (PRF)|In the test group, periodontal intrabony defects were treated with ABBM and PRF combination.
75654307|NCT00703365|Drug|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
75654308|NCT00891774|Device|EVOLENCE®|Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
75654309|NCT00703521|Biological|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
75654310|NCT05878899|Drug|Enoxaparin|Prophylactic dose of enoxaparin once daily for 10 days after delivery.
75801610|NCT04219358|Drug|Imiquimod nanoencapsulated 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquomod in a nanoencapsulated suspension at concentration of 0,05%"
75801611|NCT04219358|Drug|Lip sunscreen 30 Sun Protector Factor (SPF)|Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
75940123|NCT03676985|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
75940124|NCT05348824|Dietary Supplement|Moringa oleifera leaf|Leaf extract preparation
75940125|NCT05348824|Drug|Sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
75476186|NCT02004405|Other|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
75476187|NCT02004418|Radiation|11C-Choline|
76089948|NCT04180020|Other|TAU|TAU is designed to systematize what is the current practice at the participating hospitals and in most U.S. hospitals while offering a minimum standard of care. TAU will constitute recommendation for MOUD initiation and consultation for addiction medicine when available; in practice, it is typically detoxification from opioids and referral to community-based addiction treatment after hospital discharge.
75343678|NCT05900037|Device|GATT-Patch|"GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
76089949|NCT04161027|Drug|Pregabalin 75mg|Pregabalin 75 mg capsule
75654311|NCT05878886|Dietary Supplement|Emergency Food Product|Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.
76089950|NCT04161027|Drug|Placebos|Placebo capsule
76089951|NCT04144842|Biological|ATOR-1017|ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)
75476188|NCT02004457|Behavioral|ABBT|
75343679|NCT05900037|Device|SURGICEL® Original|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is indicated for use in surgical procedures to assist in the control of capillary, venous and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective.
75476189|NCT02004457|Other|TAU|
76089952|NCT04043104|Drug|AAV2hAQP1: 1 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10^11 vg/gland
75801612|NCT04219358|Drug|Dexpanthenol|"Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon.~Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair."
76089953|NCT04043104|Drug|AAV2hAQP1: 3 x 10^10 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10^10 vg/gland
76089954|NCT04043104|Drug|AAV2hAQP1: 3 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10^11 vg/gland
75343680|NCT05899465|Drug|Tranexamic acid|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
75343681|NCT05899465|Drug|Saline|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
75801613|NCT05159206|Procedure|CT group|This group will do a preoperative CT scan for templating. The same scan is then used for per-operative navigation. After surgery, a postoperative CT will validate the templating/navigation, and then subsequent CT scans (postoperative, 3 months, 1 and 2 years) will be done to measure prosthetic migration over time.
75654312|NCT05878847|Dietary Supplement|Q-actin|idoBR1 is an iminosugar amino acid isolated from fruits of certain cucumbers, Cucumis sativus (Cucurbitaceae), which has been shown to have anti-inflammatory activity. IminoTech Inc in the USA has produced a quality-controlled cucumber extract containing measured idoBR1 (Q-actin™) that has given good results in osteo-arthritis from oral use.
75654313|NCT05878847|Dietary Supplement|Placebo|Placebo
75476190|NCT02004470|Procedure|Active lavage and suction|Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
75654314|NCT05878808|Diagnostic Test|Psychometric assessment|Eighty subjects diagnosed with bipolar I disorder were enrolled in this study, subjects were divided according to the presence or absence of OCD to Group A: Bipolar disorder patients with OCD (n = 26), Group B: Bipolar disorder patients without OCD (n = 54). The following scales were applied: Dimensional Yale-Brown obsessive compulsive scale (DYBOCS)- Beck scale for Suicidal ideations (BSSI) - Hamilton depression rating scale (HDRS) and Young mania rating scale (YMRS).
75940126|NCT03678155|Other|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
75940127|NCT03678077|Other|Mild traumatic brain injury|This is a register based observational study and does not include interventions. Exposure is mild traumatic brain injury.
75940128|NCT05301088|Other|Chocolate Scent|"Chocolate Scent:Children in this group will be given chocolate scent sniffing as a non-pharmacological distraction method.~Stress Ball:Stress ball squeezing will be used as a non-pharmacological distraction method for children in this group."
75940129|NCT05299762|Device|INFUSE™ Bone Graft|Ministry of Food and Drug Safety (MFDS) has approved the INFUSE™ Bone Graft for anterior (ALIF) or oblique (OLIF) lumbar interbody spine fusion as a substitute for autogenous bone graft for patients with degenerative disc disease (DDD) who have had at least 6 months of non-operative treatment for this condition.
75940130|NCT02988401|Drug|Insulin|All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.
75940131|NCT02988401|Drug|Placebo (Sterile diluent)|All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
75940132|NCT05299060|Procedure|cyanoacrylate adhesive (SecurePortIV®)|Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
76089955|NCT04043104|Drug|AAV2hAQP1: 1 x 10^11 vg/gland (both glands)|intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10^11 vg/gland
76089956|NCT04043104|Drug|AAV2hAQP1: 1 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10^12 vg/gland
75801614|NCT03757572|Other|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Alginate dressings with silver and high-G cellulose will be applied to the wound. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials, will be also placed.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
75801615|NCT03757572|Other|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Simple gauze dressings will be applied to the wound.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
75801616|NCT04218110|Drug|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
76089957|NCT04043104|Drug|AAV2hAQP1: 3 x 10^11 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10^11 vg/gland
76089958|NCT04043104|Drug|AAV2hAQP1: 3 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10^12 vg/gland
75801617|NCT04218110|Drug|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
75801618|NCT04218110|Drug|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
75940133|NCT05299060|Procedure|standard cure|"The standard cure consists of:~Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus)."
75654315|NCT05878782|Other|MCRO+Occupational therapy|Experimental group A will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.
75654316|NCT05878782|Other|MCRO without intervention|Experimental group B will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
75654317|NCT05878743|Behavioral|Safety Planning a recovery-orientated mental health risk management intervention|Developing the skills to manage risks associated with mental health difficulties in ways which increase personal recovery for individuals.
75940134|NCT05268874|Other|Clavipectoral block|Clavipectoral block will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third (or on the proximal or distal end, according to the localization of the fracture) of the clavicle. A 22-gauge, 50 mm block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 30 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
75965954|NCT02086409|Dietary Supplement|Yogurt not supplemented with vitamin D and calcium|The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
76089959|NCT04043104|Drug|AAV2hAQP1: 1 x 10^12 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10^12 vg/gland
75343689|NCT05889195|Diagnostic Test|Cxbladder urine test|Cxbladder tests uses mRNA and DNA biomarkers in the urine to direct the management of UC from diagnosis to surveillance for disease recurrence.
75343690|NCT05885074|Drug|Empagliflozin Arm|The subject will be randomized, in a double-blind manner to Empagliflozin 25mg once daily for a period of 12 months
75343691|NCT05885074|Other|Control Arm|The subject will be randomized, in a double-blind manner to receive placebo once daily for a period of 12 months
75343692|NCT05885074|Other|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
75343693|NCT05885074|Other|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
75343694|NCT05884528|Biological|CC BoNT/A|Complex-containing BotulinumtoxinA (BoNT/A) formulations
75476191|NCT02004483|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
75654318|NCT05878678|Device|Fixed positions of arm down and arm up|In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.
75654319|NCT05878652|Device|3D printed knee extender device|Participants will receive the standard of prehabilitation education at Sanford as well as a 3D printed knee extension device with sealed water bottles and a home prehabilitation program designed to be used with the 3D printed knee extension device.
75654320|NCT05878652|Other|Standard Prehabilitation Education|Participants in the control group will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
75343695|NCT05884528|Biological|CF BoNT/A|Complex-free BotulinumtoxinA (BoNT/A) formulation
75343696|NCT05884528|Biological|CF to CC BoNT/A|Switch from complex-free to complex-containing BoNT/A formulations
75343697|NCT05884528|Biological|CC to CF BoNT/A|Switch from complex-containing to complex-free BoNT/A formulations
75343698|NCT05878626|Other|Transcranial Direct Current Stimulation|The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
75940135|NCT04246528|Behavioral|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
75940136|NCT05330962|Other|Framingham study cardiovascular disease 10-years risk assessment score|A personal interview questionnaire
75801619|NCT04218110|Drug|Prevantics 3.15 % / 70 % Swabstick|Application of antiseptic drug to the inguinal area of the subjects
75476192|NCT02004496|Device|Consilium|Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
75654321|NCT05878613|Device|treadmill training with KT group (TTKT group)|The area to be taped will be cleaned with an alcohol swab, and the I-shaped elastic KT was applied to the four trunk muscles from their insertion to their origin. Patients will then undergo treadmill walking with easy speed control for 20 minutes. The training will be immediately stopped if the subject complain of fatigue during treadmill training; training will be resumed after sufficient rest.
75654322|NCT05878613|Device|treadmill training without KT group (TT group)|General treadmill training without taping will be carried out for the same time as the gait training of the experimental group, and the treadmill speed will also be a comfortable speed in the same manner as in the experimental group.
75343700|NCT05869591|Drug|Apixaban 5 MG [Eliquis]|Pharmacokinetics and pharmacodynamics assessment of apixaban in patients with Child A or B liver cirrhosis
75343701|NCT05869591|Drug|Edoxaban 60 MG [Lixiana]|Pharmacokinetics and pharmacodynamics assessment of edoxaban in patients with Child A or B liver cirrhosis
75476193|NCT02004509|Drug|Anticoagulant|Anticoagulant treatment will be started in case of subclinical atrial fibrillation (>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
75476194|NCT02004535|Procedure|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
75476195|NCT02004548|Drug|Metatinib Tromethamine|
75801620|NCT03752268|Behavioral|Enhancing Cancer Pain Management|Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
75801621|NCT03752190|Drug|Cosyntropin|intramuscular and intravenous administration
75801622|NCT04214600|Behavioral|Cognitive Behavioral Therapy (CBT)|"Patients in the CBT intervention group will receive four educational sessions for 30-45 minutes on one to one basis every two weeks during patients' regular follow up visits. The visits will be scheduled depending on the patient's availability. The sessions will be delivered by a trained physician. The sessions will include:~Session 1: Dealing with thoughts of sadness and depression Session 2: Dealing with thoughts of anxiety and stress Session 3: Dealing with anger Session 4: Enhancement of coping and problem-solving skills"
75801623|NCT04210310|Drug|Oxytocin|The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
75801624|NCT04210310|Other|Placebo nasal spray|A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.
75801625|NCT03755466|Drug|"Baricitinib, olumiant®"|To examine the effects of baricitinib in RA patients
75801626|NCT03755466|Drug|"Biologics"|To examine the effects of biologics in RA patients
75654323|NCT05878574|Drug|Low molecular weight heparin|Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
75801627|NCT03755466|Drug|Tofacitinib 5 MG [Xeljanz]|To examine the effects of tofacitinib in RA patients
75801628|NCT04209530|Drug|EN3835|Collagenase Clostridium Histolyticum (CCH)
75801629|NCT04349098|Drug|Selinexor|Participants will receive 20 mg of selinexor.
75940137|NCT05329246|Device|AI-assisted Clinical Assistant PMcardio|PMcardio is an AI-powered clinical assistant in the form of a mobile application empowering non-cardiologist healthcare workers with advanced cardiovascular diagnostic capabilities, recommending patient-specific suggestions for referral and facilitating remote consultations with specialized cardiologists.
75343702|NCT05867121|Drug|RO7496353|RO7496353 will be administered as per the schedules specified in the respective arms.
75343703|NCT05867121|Drug|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
75343704|NCT05867121|Drug|Capecitabine|Capecitabine will be administered as per the schedules specified in the respective arms
75654324|NCT05878561|Drug|Fimasartan + Indapamide|a fixed dose combination
75654325|NCT05878561|Drug|Fimasartan + Indapamide placebo|a fixed dose combination
75654326|NCT05878548|Procedure|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
75654327|NCT05878496|Procedure|fixation by plate and screws|reduction and fixation of pediatric fracture neck femur by plate and screws
75940138|NCT05501470|Drug|VSL#3|"VSL#3 (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center on a weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm."
75940139|NCT05501470|Device|CapScan®|"The only non-standard sample collection instrument is the CapScan® device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
75654328|NCT05878470|Behavioral|video|A brief (119 seconds) social contact-based video. The video presented a young Black man in his early twenties, a professional actor, sharing his scripted personal story of struggles with psychotic illness and raising themes of recovery and hope.
75801630|NCT04349098|Other|Placebo|Participants will receive 20 mg of placebo matched to selinexor.
75801631|NCT04208750|Device|Vision R-800 Phoropter|Refraction utilizing the Vision R-800 Phoropter with resulting glasses
75801632|NCT04208750|Device|Standard Phoropter|Refraction utilizing the standard phoropter with resulting glasses
75801633|NCT03755310|Drug|Suvorexant|First week: 10 mg tabs; Second week: 10-20 mg tabs
75801634|NCT03755310|Drug|Placebo|Equivalent dosage, route of administration and dose regimen
75940140|NCT05501470|Drug|Placebo|The placebo for the experimental drug VSL#3 (Vivomixx) is microcrystalline cellulose. It is similar in appearance to VSL#3.
75940141|NCT05266456|Biological|24 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
75654329|NCT05878444|Dietary Supplement|Probiotic|Resistant gastrointestinal capsules will be provided daily to the participants.
75801635|NCT03755232|Dietary Supplement|scFOS|Fossence™ (short chain Fructo-oligosaccharides (scFOS)
75801636|NCT03755232|Other|Control|water or dextrose or white bread
75940142|NCT05266456|Biological|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
75940143|NCT05329012|Device|DUL- Distal Ulna Locking PLate (I.T.S)|The patients are surgical treated with the Distal Ulna locking plate according to standard surgical procedures to treat the unstable distal ulna fractures.
75940144|NCT05328466|Device|The engineer-built system, video-game based Kinect sensor|The games were developed by the researcher team.
75940145|NCT05295550|Other|Realibility|measurement of the thoracic kyphosis with flexicurve and Smartphone inclinometer app
75940146|NCT02269917|Drug|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
75940147|NCT02269917|Drug|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) as per current treatment regimen.
75940148|NCT02269917|Drug|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
75940149|NCT02522494|Behavioral|Pamphlet|An educational intervention delivered prior to patients' visits with primary care physicians.
75940150|NCT02522494|Behavioral|Video|An educational intervention delivered prior to patients' visits with primary care providers.
75940151|NCT05263570|Drug|Standard Therapy|Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
75343705|NCT05867121|Drug|S-1|S-1 will be administered as per the schedules specified in the respective arms.
75801637|NCT04381988|Drug|Hydroxychloroquine|400mg daily
75801638|NCT04381988|Other|Placebo|400mg daily
75940152|NCT05326828|Device|CONFIRM Rx implantable cardiac rhythm monitor (Abbott)|Implantation of CONFIRM Rx ICM
75940153|NCT05326828|Diagnostic Test|Systematic etiologic work-up for underlying causes of MINOCA|Intracoronary optical coherence tomography, cardiac magnetic resonance imaging, transesophageal echocardiography, vasospasm testing, thrombophilia screening, Holter ECG (only non-ICM group)
75940154|NCT03484377|Device|Anodal tDCS|The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
75940155|NCT03484377|Device|Sham tDCS|The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
75343706|NCT05867121|Drug|Nivolumab|Nivolumab will be administered as per the schedules specified in the respective arms.
75343707|NCT05867121|Drug|Oxaliplatin|Oxaliplatin will be administered as per the schedules specified in the respective arms.
75801639|NCT04381988|Radiation|Radiation therapy|Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.
75801640|NCT04333498|Behavioral|Feedback on DBS Concentrations|The study team will examine the feasibility and acceptability of a feedback system based on DBS concentration amounts.
75801641|NCT03355664|Drug|ACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24
75801642|NCT03355664|Drug|TACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24
75801643|NCT03668392|Drug|Asparaginase|Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
75801644|NCT04216576|Other|Paper Drug Diary|Participants will receive and use a paper Drug Diary and a paper medication calendar.
75801645|NCT04216576|Other|OhMD APP|Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication
76089960|NCT04031170|Behavioral|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies for themselves; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, they learn how to be more positive and nurturing through academic, social and emotional coaching.
76089961|NCT04031170|Other|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
76089962|NCT04019964|Drug|Nivolumab|Nivolumab 480mg intravenously every 4 weeks
76089963|NCT04007432|Other|pulse oxymeter|Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
76089964|NCT03996291|Drug|Tolebrutinib|Pharmaceutical form: Film coated tablet Route of administration: Oral
76089965|NCT03977584|Drug|Crenezumab|Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
76089966|NCT03977584|Drug|Placebo|Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
75343708|NCT05867121|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as per the schedules specified in the respective arms.
75343709|NCT05867121|Drug|Gemcitabine|Gemcitabine will be administered as per the schedules specified in the respective arms.
75940156|NCT05261308|Other|new prosthesis|Operation to fix the new prosthesis
75654330|NCT05878431|Other|Foot Reflexology|"The patients in the experimental group underwent 12 sessions of foot reflexology in a quiet room, twice a week, for 6 weeks. No application was made to the patients in the control group.~FOOT REFLEXOLOGY APPLICATION STAGES~Application of heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts about 3 minutes,~Pressure on the brain, cervical region, solar plexus (the projection of the central nervous system on the sole of the foot), lymph system, adrenal glands, urinary system, digestive system, sciatic nerve, hips, knees and reflex points on the soles of the legs for about 10-15 minutes. implementation (Figure 3.4),~Ending the application by applying heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts approximately 3 minutes after the application."
75343710|NCT05857644|Drug|PF-07923568|One time dose of 4 capsules taken orally.
75343711|NCT05855044|Other|Rosemary oil application|Application of Rosemary oil (10%) to both hands and both feet once a day for 24 weeks
75801646|NCT04170686|Behavioral|Zemedy App for Irritable Bowel Syndrome|The Zemedy App for irritable bowel syndrome is designed to be an engaging, self-help app for people with irritable bowel syndrome. It is based on empirically supported cognitive-behavioral, and GI focused hypnotherapy interventions for IBS.
75801647|NCT03661372|Other|Robot|Use of a telesimulation robot using contextual interview format.
75801648|NCT03661372|Other|Face-to-face|Use of face-to-face patient interview using contextual interview format.
75801649|NCT04176016|Drug|OTSA101-DTPA-111In|single IV injection, 185MBq/body
75801650|NCT04176016|Drug|OTSA101-DTPA-90Y|IV injection (max. 3 injections per patient), 1110MBq/body
75801651|NCT05668832|Dietary Supplement|UVB-exposed button mushrooms|Healthy subjects will be randomized into two groups and received either UVB-exposed button mushrooms or non-UVB-exposed button mushrooms for 7 days. Blood samples from each subject will be taken at baseline (before the intake of the mushrooms, 3 h and 6 h thereafter, and at day 8. Three months later, another blood sample was taken.
75801652|NCT03695094|Drug|Padsevonil|Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed
75801653|NCT03695094|Drug|Oxcarbazepine|Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
75801654|NCT03695094|Drug|Levetiracetam|Concomitant administration of levetiracetam (LEV) at therapeutic dosage
75801655|NCT03695094|Drug|Lamotrigine|Concomitant administration of lamotrigine (LTG) at therapeutic dosage
75940157|NCT05259514|Device|CytoSorb|The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
75965955|NCT02086487|Drug|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript > 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at > 12 months; i.e (BCR-ABL1 0.1 -1%)"
76089967|NCT03977584|Other|[^18F]GTP1|IV [^18F]GTP1 will be administered up to three times. The first primary [^18F]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second [^18F]GTP1 tau PET scan from Week 248 to Week 260. The third and optional [^18F]GTP1 tau PET scan will supplement the two primary scans.
76089968|NCT03949881|Biological|FEMJA transplatation|The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.
76089969|NCT03941483|Drug|ASP1128|Intravenous Infusion
76089970|NCT03941483|Drug|Placebo|Intravenous Infusion
76089971|NCT03927521|Procedure|Focal HIFU using PET-MRI/68Ga-PSMA imaging guidance|Focal HIFU treatment will be conducted with the Focal One® device using the PET-MRI/68Ga-PSMA imaging. The treatment area will be defined using PET-MRI/68Ga-PSMA imaging data and 3D biopsies.
76089972|NCT03914716|Diagnostic Test|Study group|Subjects will have physical, imaging examinations and provide samples for biological markers
76089973|NCT03889756|Drug|Ketamine infusion|The dose of ketamine established in prior research (0.5 mg/kg over 40 minutes) will be used in this study to minimize risks. The maximum total single dose allowed in this study will be 40mg, corresponding to a weight of 80kg.
75343712|NCT05853887|Behavioral|iNUDGE|Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.
75801656|NCT03695094|Drug|Brivaracetam|Concomitant administration of brivaracetam (BRV) at therapeutic dosage
75801657|NCT04101526|Behavioral|Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference|Six sessions of Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference. Sessions address topics such as sleep education, sleep hygiene, sleep restriction, stimulus control, relapse prevention, and cognitive restructuring.
75801658|NCT04497948|Drug|Acalabrutinib|Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
75801659|NCT04495374|Drug|Pregabalin 300mg|Group P1 will receive a 300 mg tablet of pregabalin, 02h before the surgical procedure
75343717|NCT05834738|Drug|Atrasentan|Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - Placebo
75343718|NCT05834738|Drug|Atrasentan|Period B (12 Weeks) - Placebo, Washout Period: 12 weeks, Period A (24 Weeks) - Film-coated tablet
75476196|NCT02004574|Drug|Calcipotriol/betamethasone dipropionate gel|"All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be Responder by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks."
75476197|NCT02004587|Drug|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
75476198|NCT02004600|Procedure|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
75654331|NCT05878392|Other|bone filling materials|the buccal jumping gap was packed using PRF in group 1 the buccal jumping gap was packed using xenograft in group 2 the buccal jumping gap was packed using Alloplastic β-tricalcium phosphate in group 3
75801660|NCT04495374|Other|Placebo|Group P0 will receive a placebo tablet, 02h before the surgical procedure
75801661|NCT04805008|Other|Lactation cookies|1 serving of 2 OZ of cookies per day for 30 consecutive days. These cookies will contain ingredients thought to increase breast milk production.
75801662|NCT04805008|Other|Control cookies|"1 serving of 2 OZ of cookies per day for 30 consecutive days.~The cookies will not contain ingredients thought to increase breast milk production."
75801663|NCT03752112|Drug|Cefixime|Cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection
75801664|NCT03752112|Drug|Benzathine penicillin 2.4 million units|Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
75801665|NCT04650646|Other|Exercise-related hypoglycaemia|Hypoglycaemia induced by intravenous insulin and exercise on a vertical cycle ergometer.
75801666|NCT04650646|Other|Hypoglycaemia under resting conditions|Hypoglycaemia induced by intravenous insulin during bed rest.
75801667|NCT04800666|Procedure|Stellate Ganglion Block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
75965956|NCT02088827|Other|Inactivity|Subjects will remain inactive (lying on a bed) for 4 hours.
75965957|NCT02088827|Other|Activity|Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
75965958|NCT02603471|Other|Informational group|A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
75343719|NCT05834738|Drug|Placebo|Placebo
75343720|NCT05833906|Drug|CKR-051 Dose 1|Subjects will be administered 5 g of CKR-051.
75343721|NCT05833906|Drug|CKR-051 Dose 2|Subjects will be administered 10 g of CKR-051.
75343722|NCT05833906|Drug|CKR-051 Dose 3|Subjects will be administered 10 g of CKR-051.
75343723|NCT05833906|Drug|CKR-051 Dose 4|Subjects will be administered 10 g of CKR-051.
75343724|NCT05833906|Drug|Placebo|Placebo comparator.
75343725|NCT05830838|Procedure|Computed Tomography|Undergo PET/CT
75343726|NCT05830838|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo daily adaptive online replanning for SBRT
75343727|NCT05830838|Procedure|Magnetic Resonance Imaging|Undergo MRI
75343728|NCT05830838|Procedure|Positron Emission Tomography|Undergo PET/CT
75343729|NCT05830838|Other|Questionnaire Administration|Ancillary studies
75343730|NCT05830838|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
75343731|NCT05826379|Behavioral|Adaptive Daily Goal Setting|Daily step goals displayed by the study application
75343732|NCT05826379|Behavioral|Interim Goal Prompt|Short-term step goals
75343733|NCT05816954|Diagnostic Test|Chest Computed Tomography Scan per normal clinical practice|Normal Clinical practice
75343734|NCT05815342|Device|Omnipod 5 Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
75343735|NCT05805501|Drug|Tobemstomig|Participants will receive IV tobemstomig Q3W.
75343736|NCT05805501|Drug|Tiragolumab|Participants will receive IV tiragolumab Q3W.
75343737|NCT05805501|Drug|Pembrolizumab|Participants will receive IV pembrolizumab Q3W.
75343738|NCT05805501|Drug|Axitinib|Participants will receive axitinib PO BID.
75654332|NCT05878379|Behavioral|Dietary Iron Program|"Teachers Lesson 1: Discuss about causes, prevention and effects of anemia and ID, dietary iron, dietary enhancers and inhibitors of iron absorption, and school lunch menu Lesson 2: Participate in and observe how to teach children in an iron curriculum~Caregivers Lesson 1: Presentation and group talk about causes, prevention, and effects of anemia and ID, dietary iron, and dietary enhancers and inhibitors of iron absorption Lesson 2: Discuss benefits and barriers of changing to an iron-rich meal at home Lesson 3: Cooking class for preparing an iron-rich meal at home (2 times) Lesson 4: Home visit~Children Lesson 1: Group talk about causes and effects of anemia and ID Games: Where are you from? Lesson 2: Presentation and group talk about dietary iron, and dietary enhancers and inhibitors of iron absorption, and iron-rich food Games: What is the winner? Assignment: Market assignment Lesson 3: Cooking class (2 times)"
75654333|NCT05878366|Other|Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT|Standard approach for SMC strategy used by the Ministry of Health (without directly-observed therapy) and without any interference of the study team. Implemented over 4 rounds, carried out in June-October 2023 with ~30 days between rounds.
75654334|NCT05878366|Other|Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT|SMC will be implemented with the same number of rounds and the same timing as in active comparator arm but village health workers will visit the participants at home to administer each dose of study treatment (with DOT-directly-observed therapy)
75801668|NCT04800666|Procedure|Facial Nerve Block|Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )
75801669|NCT04800666|Drug|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
75801670|NCT04595734|Other|No intervention due to observational methods of study|No intervention due to observational methods of study
75801671|NCT04794270|Device|ACUVUE OASYS® 1-Day for Astigmatism - TAM 24|TEST
75940158|NCT03486093|Device|"Training and retraining to GAVECELT bundle recommendations plus port protector"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced."
75940159|NCT03486093|Behavioral|"Training and retraining to GAVECELT bundle recommendations"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed."
75940160|NCT03484221|Drug|FOLFOXIRI|IRINOTECAN 150 mg/m^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
75940161|NCT03484221|Radiation|Short-Course Radiation Therapy(5Gy*5)|Patients received a short-course radiation therapy(5Gy*5) after 4 cycles of FOLFOXIRI.
75940162|NCT03484221|Drug|XELOX|OXALIPLATIN 130 mg/m^2 IV over 2-h, day 1 Capecitabine 1000 mg/m^2 twice daily days 1-14 every 3 weeks for 4 cycles.
75940163|NCT03481491|Other|transcranial magnetic stimulation of the cerebellum|The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.
75940164|NCT03857139|Drug|Nicotine patch|Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
75940165|NCT03481335|Other|CHAP-P Sessions|Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
75940166|NCT01658020|Drug|Zabofloxacin|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
75940167|NCT01658020|Drug|Moxifloxacin|Moxifloxacin 400mg tablet P.O. once daily for 7days
75801672|NCT04794270|Device|ACUVUE OASYS® 1-Day for Astigmatism|CONTROL
75801673|NCT04567186|Device|Investigational senofilcon A C3 Multifocal Lens|TEST
75801674|NCT04567186|Device|delefilcon A Multifocal Lens|Dailies Total 1® Multifocal Contact Lens
75801675|NCT05460156|Behavioral|Bridges Self-management Support|Self-management support intervention tailored for people with neuromuscular diseases
75343739|NCT05804500|Behavioral|Cardiac Telerehabilitation (CTR) via the RecoveryPlus platform|RecoveryPlus has developed an innovative CTR platform for patients with CVD that leverages: (1) video conferencing functionality (Zoom) for synchronous telehealth sessions of CR instruction for patients and licensed exercise physiologists (EPs), (2) a patient-facing mobile application delivering asynchronous exercise videos, and (3) a health care provider web portal for clinicians and EPs. The RecoveryPlus platform includes the ability for EPs and clinicians to monitor patient clinical data (e.g., heart rate) and input (e.g., rating of difficulty for individual exercises) and tailor individual patient regimens regularly for increased safety and optimal outcomes.
75940168|NCT03481179|Device|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
75343742|NCT05799950|Device|AcrySof single-piece IOL|Acrylic single-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
75940169|NCT03481179|Other|Physical therapy|The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM & JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
75940170|NCT05257876|Other|Breathing exercise|Participants will receive breathing exercise training, and a 4-week self exercise
75940171|NCT03477201|Procedure|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Laparoscopic inguinal hernia repair using a robotic assisted laparoscopic procedure.
75940172|NCT03477201|Procedure|Standard laparoscopic inguinal hernia repair|Laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia.
75940173|NCT05485948|Drug|Ropeginterferon alfa-2b|Initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg until Week 52.
75343743|NCT05799950|Device|AcrySof multi-piece IOL|Acrylic multi-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
75343744|NCT05795855|Behavioral|ADEPT|Prenatal providers will participate in trainings that will lay the foundation for an effective vaccination recommendation. After the completion of training, prenatal care providers will begin making recommendations promoting the importance of maternal and childhood vaccinations to pregnant individuals, as part of routine prenatal care. The core component of ADEPT is prenatal provider training to enable a vaccination recommendation, encouraging pregnant individuals to receive vaccines during pregnancy and for their child after birth. Pregnant individuals who remain vaccine hesitant despite the provider recommendation, will be eligible to receive the adaptive components of ADEPT in the form of evidence-based educational materials on vaccinations and phone consultations with a vaccine navigator to discuss residual concerns.
75476199|NCT02004626|Drug|Collagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
75654335|NCT05878366|Other|Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT|SMC will be implemented as in arm 2 but age of participants is extended up to 10 years: each dose of study treatment (with DOT-directly-observed therapy) distributed at home by village health workers.
75654336|NCT05878340|Behavioral|Miffy|A method to stimulate children to try different fruits and vegetables using reward and role modelling
75801676|NCT04561102|Diagnostic Test|Diagnostic test for detection of SARS-CoV-2|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
75940174|NCT03477123|Device|Walking therapy with Exo-H2 exoskeleton|
76089974|NCT03889756|Drug|Midazolam infusion|The weight-based midazolam dosing established in prior ketamine trials in adults (0.045mg/kg) will be used to minimize risks, as this is considered a very low dose compared to the sedation literature. The maximum total dose allowed in this study will be 3.6mg per infusion, corresponding to a weight of 80kg.
76089975|NCT03887559|Behavioral|Group-based stabilization and skill training in addition to individual treatment|"Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'."
76089976|NCT03887559|Other|Treatment as usual|Treatment as usual: conventional individual treatment (outpatient). Not standardized.
75343745|NCT05795361|Drug|Idursulfase-IT|Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 [NCT01506141] or SHP609-302 [NCT02412787] study [10mg or 30mg] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
75654337|NCT05878340|Behavioral|Reward|Reference method to stimulate children to try fruits and vegetables using reward alone
75654338|NCT05878327|Other|Thrombophilia screening|No intervention. Blood is drawn for analysis.
75654339|NCT05878262|Drug|ibuprofen suppository|After the induction of anesthesia was performed, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg for the pre-emptive analgesia group children.
75801677|NCT03757494|Device|Alpha Stim|Use of Alpha Stim Device
75801678|NCT03751956|Drug|HSK3486|The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of [14C]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
75801679|NCT03757416|Other|Data collection|If it has been determined that the patient will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome, the patient will be asked to participate in this data collection study.
75801680|NCT04391920|Device|CytoSorb 300 mL device|CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.
75940175|NCT05291494|Behavioral|follow the WeChat public platform to watch the education videos|In addition to the regular preoperative visits, the WeChat education group will watch science videos through WeChat before the surgical procedures.
75940176|NCT05291494|Behavioral|regular preoperative visits and education by ward nurses.|received oral instruction from the ward nurse covering the same contents as above instead of the education video.
75940177|NCT03476967|Procedure|Panretinal photocoagulation|In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
75801681|NCT03751878|Behavioral|Evaluation of reporting inconsistencies|"The completed CONSORT checklist submitted by authors of manuscripts randomised to the intervention group will be assessed by the lead investigator (DB) as to whether it is consistent with the information that was actually reported in the manuscript. This evaluation will be focused on 8 core CONSORT items.~DB will produce a standardised report containing precise requests for authors in order to improve the completeness of reporting of the items where reporting inconsistencies were found. This report will consist of a brief introduction followed by a point by point description of the inconsistencies found together with precise requests related to the information missing and examples extracted from CONSORT. DB will upload this report to the submission on the managing system of the journal (Scholar One) to make it accessible to the handling editor of the manuscript.~This editor will include the report in the letter to authors alongside the standard peer review reports."
76089977|NCT03882580|Drug|Anti-Cancer Agents|Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects
76089978|NCT03856177|Behavioral|Emotion Induction|Described in arm
76089979|NCT03845114|Other|Continous exercise|60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
76089980|NCT03845114|Other|Interval exercise|Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
76089981|NCT03845114|Other|Reduction of basal insulin by 40%|Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.
76089982|NCT03845114|Other|Reduction of basal insulin by 80%|Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.
76089983|NCT03778502|Drug|Direct Oral Anticoagulants|Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
75343746|NCT05789485|Behavioral|structured treadmill walking|Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered from chemotherapy initiation until surgery (~32 weeks).
75801682|NCT03751878|Behavioral|Standard Peer Review.|Manuscripts will undergo the usual peer review process.
75801683|NCT03757338|Drug|Fingolimod Reference Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.
75801684|NCT03757338|Drug|Fingolimod Test Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.
75801685|NCT04305262|Device|Wireless continuous vital parameter monitoring|The patients included in this study will have continuous, wireless monitoring of vital parameters during the first four days of acute admission
75801686|NCT03629548|Procedure|early amniotomy|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
75801687|NCT03629548|Device|foley catheter balloon placement|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg PGE2 vaginal ovul will be inserted to the posterior fornix
75801688|NCT03757260|Device|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is methylene blue. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is illuminated for 60 seconds to activate the agent using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
75940178|NCT03476889|Other|Infant formula|Infants are randomized to one of two infant formulas from <14 days of age to 17 weeks of age.
75965959|NCT02603471|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
76089984|NCT03775200|Drug|Psilocybin|Dose-finding
76089985|NCT03774121|Device|Cryoneurolysis|A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve & anterior femoral cutaneous nerve) guided by ultrasound visualization.
76089986|NCT03774121|Other|Neuromuscular exercise (GLA:D)|The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
76089987|NCT03774121|Device|Sham|The sham intervention includes a similar procedure but without freezing temperatures.
76089988|NCT03761498|Other|Caloric Requirement|Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.
75343747|NCT05787847|Behavioral|Incentives for Abstinence|Participants in the incentives for abstinence condition will have the opportunity to earn financial incentives for abstaining from stimulant use.
75801689|NCT03757260|Device|Placebo of photodynamic therapy|The placebo of the antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is saline solution. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is not illuminated (falsely activated) for 60 seconds using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
75819711|NCT02176330|Other|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
75940179|NCT04968028|Procedure|ACAF|(1)A standard right-side Smith-Robinson approach is performed. (2) The involved disc tissues are removed. The posterior longitudinal ligament is cut down at the levels cephalic and caudal to OPLL. (3) The anterior portion of the middle vertebral bodies is removed according to the thickness of ossification. Suitable cages are placed into each intervertebral space. (4) On the left side of the vertebra, a 2-mm-wide groove is created at the medial border of the transverse foramina. After that, an curved plated is fixed with screws. (5) On the right side of the vertebrae, a similar groove was also created. (6) Finally, tightening the screws to achieve a gradual evaluation of the vertebrae with OPLL.
75940180|NCT04968028|Procedure|Laminoplasty|(1) In the prone position, the skin and nuchal ligament were cut through the posterior median incision, and the paravertebral muscles were stripped layer by layer to expose the bilateral vertebral lamina, lateral mass and articular process.（2) Part of spinous process were removed with bone biting forceps. The side with more severe symptoms was selected as the open side, bone groove was performed at 2-3 mm of the medial edge of bilateral facet joints with the medial cortex was reserved at the shaft side.（3) Slowly lift the lamina and maintained.（4)Determining the opening width of each segment by trial, and selecting the appropriate size Arch miniplate, and fixed with screws.
75940181|NCT03476733|Other|Detection of drug related problem in inpatient|Detection of drug related problem in inpatient
75940182|NCT04713267|Device|ISABel Bed 1|During the intervention nights (2 out of 3 experiment nights), positional therapy by means of the automated bed will be applied in order to induce a change in the sleeping position.
75940183|NCT05255770|Device|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
76089989|NCT03737864|Behavioral|Patient navigation|The patient navigator will provide support to patients upon discharge and will maintain regular contact either in person or by phone at a minimum of once per week for 30 days, or until the patient successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
75343748|NCT05787847|Behavioral|Health Education|The Health Education condition is based on a previous intervention used as a control in a number of other studies. Sessions consist of an educational program addressing a variety of health, wellness, and lifestyle topics adapted from a previously implemented wellness manual.
75343749|NCT05786573|Drug|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
75343750|NCT05786573|Drug|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
75343751|NCT05786573|Other|Placebo|Placebo
75343752|NCT05782608|Drug|IV ibuprofen|Group 1 will receive IV ibuprofen 400mg \ 6 hours the first dose will be administrated immediately post operative.
75343753|NCT05782608|Drug|IV ketorolac|Group 2 will receive 20 mg IV ketorolac\ 6 hours the first dose will be administrated immediately post operative
75343754|NCT05776875|Drug|Atezolizumab Injection|Atezolizumab is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma It is a fully humanized, engineered monoclonal antibody of Immunoglobulin G1 (IgG1) isotype against the protein programmed cell death-ligand 1 (PD-L1).
75819712|NCT02179606|Device|Dermalax Implant Plus|Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
75940184|NCT05255770|Device|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
75343755|NCT05776875|Drug|Bevacizumab|Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
75940185|NCT05255770|Device|Control NRL condom|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
75940186|NCT04635579|Device|Blood flow restriction|Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure
75940187|NCT05322538|Diagnostic Test|vitamin D plasma levels baseline|Measuring vitamin D plasma levels at baseline
76089990|NCT03737864|Behavioral|Motivational interviewing (MI)|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
75343756|NCT05776875|Combination Product|Transarterial chemoembolization|Transarterial chemoembolization (TACE) is a local therapy for HCC which induces tumor necrosis.
75343757|NCT05776524|Drug|Nab paclitaxel|125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
75343758|NCT05776524|Drug|Gemcitabine|1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
76089991|NCT03729596|Biological|vobramitamab duocarmazine|Anti-B7H3 antibody drug conjugate
76089992|NCT03689855|Drug|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
76089993|NCT03689855|Drug|Atezolizumab|The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).
75343759|NCT05776524|Device|TheraBionic|This treatment consists of delivering low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
75940188|NCT05322538|Diagnostic Test|Dual-energy X-ray absorptiometry at baseline|Measuring T-score and Z-score of the femur and lumbar spine at baseline
75343760|NCT05772234|Drug|Lactated ringers solution|Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
75343761|NCT05772234|Drug|normal saline|Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
75801690|NCT03754998|Behavioral|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
75801691|NCT05761990|Other|POST ISOMTERIC RELAXATION TECHNIQUE|"POST ISOMETRIC RELAXATION TECHNIQUES~Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~Starting with this new barrier, the procedure is carried out two or three more times."
75940189|NCT05322538|Diagnostic Test|cervical Vestibular evoked myogenic potentials at baseline|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured.
75940190|NCT05322538|Diagnostic Test|Audiogram at baseline|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score.
75343766|NCT05762055|Device|Titan nanoLOCK interbody cage|Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology
75476200|NCT02004626|Drug|Kollagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
75654340|NCT05878197|Behavioral|Straw phonation|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, straw phonation on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, straw phonation on word and sentence level, pitch variations Day 4: straw phonation in spontaneous speech, combination exercises"
76089994|NCT03689855|Procedure|Peripheral blood draw|-Baseline and Cycle 2 Day 1
76089995|NCT03689855|Procedure|Biopsy|"If archival biopsy tissue not available, participant will undergo biopsy at baseline~When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan."
76089996|NCT03673800|Other|Experimental Group|Cognitive web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
76089997|NCT03673800|Other|Control Group|Sensorial web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
75476201|NCT02004639|Radiation|Masticators sparing techniques|
75476202|NCT02004639|Other|electro-acupunture treatment|electro-acupunture treatment and sham-EA
75476203|NCT02004652|Drug|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
75476204|NCT02004652|Drug|Placebo|Vitamin, 50mg, tablet.
75476205|NCT02004678|Drug|DS-1150b|
75476206|NCT02004678|Other|Placebo|
75343767|NCT05762055|Device|ACDF interbody cage|Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology
75343768|NCT05761171|Procedure|Biospecimen Collection|Undergo collection of blood and CSF samples
75343769|NCT05761171|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
75343770|NCT05761171|Drug|Calaspargase Pegol|Given IV
75476207|NCT02004717|Drug|DS-8895a|
75476208|NCT02004730|Device|ABSORB implantation|ABSORB implantation for long (> 24mm) single vessel disease
75940191|NCT05322538|Diagnostic Test|Measuring Orthostatic Blood Pressure at baseline|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test
76089998|NCT03636568|Other|Fluid Restricted Group|"Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients < 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients >100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh <=100 kg and 1200 cc/24 hours for patients who weigh > 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~Serum Na level must be < 145 mEq/l~Patient should be taking fluids by mouth~Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated."
76089999|NCT03635996|Drug|Etripamil NS 70 mg|All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
76090000|NCT03635996|Device|Aptar Pharma Nasal Spray Bidose System|Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
76090001|NCT03613181|Drug|ANG1005|Investigational drug
76090002|NCT03613181|Drug|Physician's Best Choice|Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.
76090003|NCT03598439|Biological|Standard IIV4|Standard inactivated influenza vaccine
75343771|NCT05761171|Drug|Cytarabine|Given IV and IT
75343772|NCT05761171|Procedure|Echocardiography|Undergo ECHO
75476209|NCT02004743|Behavioral|Intervention|"Psychological guidelines and PET~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD."
75476210|NCT02004743|Other|Treatment as usual|"Participants will experience treatment as usual.~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD"
75476211|NCT02004756|Other|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
75801692|NCT05761990|Other|NOVEL STRETCHING|"NOVEL STRETCHING The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained."
75801693|NCT04483908|Diagnostic Test|blood draw|2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)
75801694|NCT04483908|Diagnostic Test|fingertip tests for POC assays|performing POC test by taking two blood drops from the fingertip
75801695|NCT04483908|Diagnostic Test|saliva collection|saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.
75801696|NCT04483908|Diagnostic Test|collection of swabs|collection of nasopharyngeal and oropharyngeal swabs for PCR testing on the control group (eg negative subpopulation)
75819713|NCT02179606|Device|Restylane Sub-Q|Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
75940192|NCT05322538|Diagnostic Test|cold pressor test at baseline|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function.
75940193|NCT05322538|Diagnostic Test|vitamin D plasma levels one year after recruitment|Measuring vitamin D plasma levels one year after recruitment
75940194|NCT05322538|Diagnostic Test|vitamin D plasma levels two years after recruitment|Measuring vitamin D plasma levels two years after recruitment
75940195|NCT05322538|Diagnostic Test|Dual-energy X-ray absorptiometry one year after recruitment|Measuring T-score and Z-score of the femur and lumbar spine one year after recruitment
76090004|NCT03598439|Biological|Recombinant|Influenza vaccine that uses a hemagglutinin protein manufactured in insect cells with a baculovirus vector
76090005|NCT03598439|Biological|Cell-culture|inactivated influenza vaccine manufactured using mammalian cell lines; current vaccine uses a cell-propagated H3N2 strain.
75343773|NCT05761171|Drug|Fludarabine Phosphate|Given IV
75343774|NCT05761171|Drug|Hydrocortisone Sodium Succinate|Given IT
75343775|NCT05761171|Procedure|Lumbar Puncture|Undergo lumbar puncture
75343776|NCT05761171|Drug|Methotrexate|Given IT
75343777|NCT05761171|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
75343778|NCT05761171|Drug|Prednisolone|Given PO or via NG, NJ, ND or G-tube
75343779|NCT05761171|Drug|Prednisone|Given PO or via NG, NJ, ND or G-tube
75343780|NCT05761171|Drug|Revumenib|Given PO or via NG, NJ, ND or G-tube
75343781|NCT05761171|Drug|Vincristine Sulfate|Given IV
75343782|NCT05757700|Biological|19(T2)28z1xx TRAC T cell|"Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10^6 Dose level 1: 10 x 10^6 Dose level 2: 30 x 10^6 Dose level 3: 100 x 10^6"
76090006|NCT03595878|Radiation|Parotid sparing WBRT|Whole Brain Radiation Therapy with avoidance of the parotid glands
75940196|NCT05322538|Diagnostic Test|Dual-energy X-ray absorptiometry two years after recruitment|Measuring T-score and Z-score of the femur and lumbar spine two years after recruitment
75940197|NCT05322538|Diagnostic Test|cervical Vestibular evoked myogenic potentials one year after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured one year after recruitment
75654341|NCT05878197|Behavioral|Resonant voice therapy|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, resonant voice therapy on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, resonant voice therapy on word and sentence level, pitch variations Day 4: resonant voice therapy in spontaneous speech, combination exercises"
76090007|NCT03595878|Radiation|Standard WBRT|Standard Whole Brain Radiation Therapy
76090008|NCT03558945|Biological|Personalized neoantigen vaccine|Patients will have complete resection of primary tumor without preoperative chemotherapy. Patients will receive postoperative chemotherapy and subsequently personalized vaccines on days 1, 4, 8, 15, 22 (priming phase) and weeks 12, 20 (boosting phase). Personalized vaccines will consist of several distinct peptides (the dose is 0.3 mg/peptide) that are grouped into 2-4 pools and 0.5 mg of poly-ICLC as the adjuvant for each pool. Injection sites will be 2-4 separate sites of the subject's thighs.
75654342|NCT05878197|Behavioral|Vocal Hygiene|"Participants of the control group will receive a sham treatment, including the exact same games, drawing assignments, etc. as in the experimental groups. However, no SOVT or other active vocal techniques will be practiced. Vocal hygiene guidelines (e.g. avoid screaming, imitating voices, sufficient hydration etc.) will be kept equally in the four groups. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations Day 3: breathing exercises, vocal hygiene recommendations Day 4: combination exercises"
75940198|NCT05322538|Diagnostic Test|cervical Vestibular evoked myogenic potentials two years after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured two years after recruitment
75654343|NCT05878158|Drug|Simvastatin|pulpotomy of immature permanent teeth
76090009|NCT03552120|Behavioral|MORE|MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
75654344|NCT05878145|Behavioral|Structured rehabilitation exercise program|Stretching (10 mins): neck, shoulder, wrist, back; Aerobic exercise (20 mins): cycle ergometer, wheelchair run; Strengthening exercise (15 mins): shoulder press, chest press, front raise, biceps curl, lateral raise, bent over rowing or rowing, bent over lateral raise, triceps extension; Balance training (5 mins); Stretching exercise (10 mins)
75801697|NCT04168190|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
75801698|NCT04168190|Biological|Pneumovax™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
75801699|NCT01322724|Procedure|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
75801700|NCT03649672|Device|TOF Watch SX|Neuromuscular monitoring via the TOF Watch SX device
75801701|NCT05460000|Drug|3 cycles chemotherapy instead of 6 cycles chemotherapy|We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.
75801702|NCT05460000|Drug|6 cycles chemotherapy|Standard chemotherapy as comparator
75801703|NCT03754920|Behavioral|prolonged fasting|"Fasting for 5 days: Fasting with some fitness regimen, such as meditation and mild physical exercise;~Feeding for 3 days: Gradually distribute participants with rice flour, porridge and juice."
75801704|NCT05668962|Drug|Selpercatinib|Selpercatinib Oral, twice daily during initial treatment period (28 Days). A second course of selpercatinib if the participant is demonstrating clinical benefit to the initial course selpercatinib and deemed clinically appropriate by the treating investigator
75801705|NCT05668962|Drug|Sodium Iodine I-131|I-131, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer
75801706|NCT05668962|Drug|rhTSH|"RhTSH injection, dosage per protocol, timing per protocol during the initial treatment period per standard of care.~Participants may receive a second course of rhTSH if the participant is demonstrating clinical benefit to the initial course rhTSH and deemed clinically appropriate by the treating investigator."
75819714|NCT02176564|Drug|inhaled bronchodilator|
75819715|NCT02182102|Drug|BIBF 1120|
75819716|NCT02182102|Drug|Pemetrexed|
75343783|NCT05747794|Biological|eftilagimod alpha|APC activator, MHC II agonist
75654345|NCT05878132|Device|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 30-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
76090010|NCT03552120|Behavioral|Supportive Psychotherapy|Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
76090011|NCT03490045|Other|Diaper Incentive|A diaper incentive will be distributed to participants in the Intervention condition at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final distribution of diapers.
75654346|NCT05878132|Other|Conventional therapy|The participants in the control group received similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They were instructed to perform the exercises for the recommended therapy dose and received a weekly therapy consultation as well. To monitor the participant's exercise compliance, they were instructed to record their daily exercise progress in the exercise log.
75476212|NCT02004769|Drug|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
75476213|NCT02004769|Drug|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
75476214|NCT02004769|Drug|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
75343784|NCT05747794|Drug|Paclitaxel|paclitaxel will be given as standard of care (chemotherapy)
75343785|NCT05747794|Other|placebo|placebo matching eftilagimod alpha
75801707|NCT04732338|Other|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic practitioners use a wide variety of therapeutic manual techniques to improve physiological function and help restore homeostasis in the body. There is a structural assessment is to identify possible abnormalities of tissue texture. Areas of asymmetry and misalignment of bony landmarks are also evaluated, along with the quality of motion, balance, and organization. These asymmetries, also known as somatic dysfunctions, are then treated by a variety of manual treatments, administered by osteopaths.
75801708|NCT03501940|Procedure|Computed Tomography|Undergo 18F-DCFPyL PET/CT
75801709|NCT03501940|Radiation|Fluorine F 18 DCFPyL|Given IV
75801710|NCT03501940|Other|Laboratory Biomarker Analysis|Correlative studies
75801711|NCT03501940|Procedure|Positron Emission Tomography|Undergo 18F-DCFPyL PET/CT
76090012|NCT03490045|Other|Conditional Cash Transfer Condition|Participants in the control condition will receive the cash equivalent value of the diapers distributed to the Experimental Condition for their participation at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final conditional cash transfer.
76090013|NCT03484078|Device|Vibration Platform|The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.
76090014|NCT03484078|Device|Placebo Platform|The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
76090015|NCT03468478|Drug|Sirolimus|sirolimus combined to reduced dose of tacrolimus
75343786|NCT05747287|Device|microcatheter|supports the insertion of the guide wire，exchange of the guide wire and the delivery of contrast media
75476215|NCT02004795|Radiation|BNCT + IG-IMRT|Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
75343787|NCT05741476|Drug|DBV712|DBV712 250 mcg epicutaneous system.
75343788|NCT05741476|Other|Placebo|DBV712 matching placebo epicutaneous system.
75801712|NCT03754842|Other|Placebo (twice daily)|Matching placebo
75801713|NCT03754842|Other|Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)|Elysium Basis TM, Elysium Health, Inc., NY, USA
75801714|NCT04194008|Device|Nerivio|A remote electrical neuromodulation (REN) device for the acute treatment of migraines.The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
75343789|NCT05737693|Drug|Ketamine|Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy
75343790|NCT05737693|Drug|Midazolam|Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
75476216|NCT02004821|Dietary Supplement|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.|
75343796|NCT05732779|Other|DOT intervention|A mobile health application developed by eMocha Health Inc. facilitates asynchronous mobile video directly observed therapy (DOT) intervention, empowering users to track dose-by-dose medication adherence
75343797|NCT05732428|Drug|ARV-471|ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles
75343798|NCT05726331|Other|Chiropractic Care|Chiropractic care will be delivered by community-based chiropractors that meet pre-set qualifications. Chiropractic treatment protocol will be multimodal and will follow predefined standard operating procedures including the following 6 components: 1) Posture correction and spinal stabilization exercises; 2) Soft tissue release techniques; 3) Manual spinal manipulation; 4) Condition-specific education; 5) Myofascial strengthening and motor control training; 6) Ergonomic and lifestyle modifications/advice. Subjects randomized to chiropractic treatment groups will receive up to 10 chiropractic sessions over 16 weeks.
75801715|NCT03463330|Behavioral|Qigong exercise|The Qigong exercise is a series of mild exercise movements.
75940199|NCT05322538|Diagnostic Test|Audiogram one year after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed one year after recruitment
75940200|NCT05322538|Diagnostic Test|Audiogram two years after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed two years after recruitment
75476217|NCT02004860|Drug|Protopic (R)|Protopic® 0.1% ointment - 2 applications per week for 6 months
75801716|NCT03463330|Behavioral|Mild body exercise|Participants will be taught of series of similar movements to the Qigong exercise.
75343799|NCT05726331|Other|Tai Chi|Tai Chi (TC) will be delivered by community based Tai Chi schools that meet pre-set qualifications. TC programs will emphasize core principles including biomechanically efficient alignment, relaxed integrated movements, deep breathing, and heightened body awareness. Subjects randomized to TC treatment group will attend at least one TC class per week for 16 weeks.
75343800|NCT05726331|Other|Enhanced Usual Care|Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).
75940201|NCT05322538|Diagnostic Test|Measuring Orthostatic Blood Pressure one year after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed one year after recruitment
75940202|NCT05322538|Diagnostic Test|Measuring Orthostatic Blood Pressure two years after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed two year after recruitment.
75343801|NCT05723601|Drug|Estradiol vaginal cream|Participants will use vaginal estradiol cream for 3 months
75343802|NCT05723601|Drug|Estradiol Vaginal Tablet|Participants will use vaginal estradiol tablet for 3 months
75476218|NCT02004860|Drug|Mycoster (R)|Mycoster 1% - 2 applications per week for 6 months
75940203|NCT05322538|Diagnostic Test|cold pressor test one year after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed one year after recruitment.
75476219|NCT02004899|Drug|Fentanyl|After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
75476220|NCT02004912|Other|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
75476221|NCT02004938|Device|Sonosite Titan Ultrasound Machine|
75476222|NCT02004951|Device|Misago RX|
75654347|NCT05878054|Other|Proactive, integrated and personalised care|During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.
75654348|NCT05878028|Combination Product|L-TIL, Tislelizumab, Docetaxel|PD1 positive lymphocytes were collect, isolated, and expanded from peripheral blood, then infused back into the patient's body. Besides this, Tislelizumab and Docetaxel were used as combination therapy.
75654349|NCT05878002|Device|polysomnography|Sleep study through polysomnographic examination
75940204|NCT05322538|Diagnostic Test|cold pressor test two years after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed two years after recruitment.
76090016|NCT03468478|Drug|Everolimus|everolimus combined to reduced dose of tacrolimus
76090017|NCT03468478|Drug|Mycophenolic acid|Control arm: mycophenolate combined to regular tacrolimus
75476223|NCT02004951|Device|Zilver PTX|
75476224|NCT02005003|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
75801717|NCT03751644|Other|Electrical stimulation|Patients with systemic autoimmune myopathies will receive peripheral electrical stimulation in thigh muscles
75801718|NCT03751566|Other|Acupuncture|"Schedule of the acupuncture:~Acupuncture may be done ambulant or during hospitalisation . Acupuncture will be administered 1-3 times a week ( in case of severe toxicity and problems caused by the radiotherapy, it may continue also after the termination of the radiotherapy.) Acupuncture needles will be left for 5- 30 minutes, as per individual need of the patients.~Acupuncture will be performed by a physician trained in acupuncture."
75801719|NCT03751566|Drug|Standard supportive therapy|Standard supportive therapy
75654350|NCT05877989|Drug|Amino Acid|Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
75476225|NCT02005003|Procedure|Blood samples|Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
75476226|NCT02005003|Biological|Feces collection|Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
75940205|NCT03476655|Drug|Ibrutinib|No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
75940206|NCT04593537|Other|No intervention|This is an observational study, no intervention is involved
75940207|NCT03484065|Other|Questionnaire quality of life|
75940208|NCT04376385|Behavioral|GROw: An Internet based Self Applied Treatment Program for Prolonged Grief Disorder (PGD)|"It is a self-applied treatment through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is 8-10 weeks. A support call will be made a week (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided.~Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
75940209|NCT04459767|Drug|Vupanorsen|80 mg subcutaneous injection
75940210|NCT04459767|Drug|Placebo|Subcutaneous injection
75940211|NCT03481101|Device|PET/CT|3 extra scans with FDG-PET/CT and 4 blood samples
75940212|NCT04245670|Radiation|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
75654351|NCT05877989|Procedure|Physical exercise|The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
75654352|NCT05877950|Device|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
75654353|NCT05877950|Other|Home-based speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
75940213|NCT02523573|Procedure|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
75940214|NCT04965220|Drug|HLX 208|take orally
75940215|NCT03483987|Drug|Sof+Ledi+R arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
75940216|NCT03483987|Drug|Sof+Ledi+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
75476227|NCT02005003|Procedure|Caloric preload|A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
75654354|NCT05877937|Other|Supportive care (Watching a comedy movie)|A 10.1 inch Android tablet (2 pieces) and disposable earplugs for each patient were used in the study. A comic film archive was created in line with the recommendation and consultancy of department of state conservatory and performing arts. In this regard, the officials of the Conservatory stated that they had no standardized comedy films specific to society and emphasized that the standardization of art limits art activities. Therefore, there should be no limitations for art. In the film archive cre-ated according to their suggestions, there were a total of five comedy movies, including three Turkish comedies, one foreign romantic comedy, and one foreign Turkish-dubbed family comedy. The original/licensed versions of the movies in this archive were ob-tained and uploaded to the tablet. The movies lasted 90-120 minutes (as long as the av-erage duration of IV treatment). The patients selected the movie that they would watch during the treatment.
75654355|NCT05877911|Drug|Sodium Sulfate|Sodium thiosulfate has previously been reported to reduce the incidence of acute kidney injury after HIPEC with cisplatin, but this finding has not been confirmed in a high-level study.
75654356|NCT05877911|Other|Hydration|On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters.
75654357|NCT05877911|Drug|Cisplatin|Infuse cisplatin (75mg/m^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 60-90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC should be performed within 24-48 hours after cytoreductive surgery. The second HIPEC should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as dexmedetomidine or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.
75476228|NCT02005003|Behavioral|Food selection task|Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
75476229|NCT02005003|Behavioral|Memory task|Participants perform short memory tasks on each visit
76090018|NCT03451708|Device|OKS|Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.
75476230|NCT02005003|Behavioral|Food consumption task|Participants are given a selection of food items to consume on each visit
75476231|NCT02005042|Behavioral|Feedback on smartphone|Receive personalized feedback (EMI) on smartphone regarding physical activity
75343803|NCT05716893|Behavioral|Adaptive Aerobic Training/AT Dosing|o In Phase A (~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ<3.50 ml O2 .kg-1.min-1 from baseline to ~32 weeks, or unsupervised AT in patients with a CRF Δ>3.50 ml O2 .kg-1.min-1 from baseline to ~32 weeks. Supervised AT will be monitored using TeleEx.
76090019|NCT03409367|Other|Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream|Lipid-rich emollient serving as skin barrier
75654358|NCT05877872|Procedure|Reduced-target resection|Patients receive surgery according to pSTV-post-IC.
75654359|NCT05877872|Procedure|Full-target resection|Patients receive surgery according to pSTV-pre-IC.
75940217|NCT03483987|Drug|Sof+Dacla+R arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
75940218|NCT03483987|Drug|Sof+Dacla+R+Peg-IFN arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
76090020|NCT03381729|Biological|Onasemnogene Abeparvovec-xioi|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
75654360|NCT05877872|Drug|Adjuvant immunotherapy|Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
76090021|NCT03381105|Diagnostic Test|PSA and Stockholm3|The new Stockholm3 test and traditional PSA test
75654361|NCT05877794|Device|central venous catheter insertion|All patients were under trendlenburg position (10 degrees) and disinfected for CVC catheterization. After attaching 2 suture wings of 18G single catheter set to the insertion needle in the 7 Fr or 8 Fr central catheter set, check the IJV to be punctured with an ultrasonic probe. The IJV is punctured using a cross sectional image confirmed at the cricoid cartilage level. After confirming the needle tip on the ultrasound image and blood coming out, the guide wire is mounted on the IJV and then a CVC catheter (arrow international INC) ., USA) is inserted. All actions are performed by a specialist who has more than 30 CVC catheterization experiences using ultrasound, and the occurrence of side effects and the time from puncture to guide wire entry are recorded by another researcher. After the procedure, the researcher who directly performed the procedure records the difficulty or difference compared to when using a conventional needle that does not have a suture wing installed.
75654362|NCT05877781|Dietary Supplement|Palmitoylethanolamide|8-week treatment 3x400 mg per day
75654363|NCT05877768|Diagnostic Test|Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Photon Counting Detector Coronary Computed Tomography Angiography for the suspicion of coronary artery disease or the progression thereof.
75801720|NCT05761834|Other|Sample blood and 2D-echocardiography with Doppler|Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.
76090022|NCT03318692|Procedure|spondylodesis|Dorsal instrumentation with transpedicular screws (spondylodesis)
76090023|NCT03318692|Procedure|CT|CT of operated area is performed within 7 days of surgery
76090024|NCT03240237|Device|Optimizer SMART|Cardiac Contractility Modulation
75801721|NCT03757104|Behavioral|micro-incentive|Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test
75940219|NCT03483987|Drug|Sof+Velpa+R arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
76090025|NCT03234114|Drug|Triple antithrombotic therapy|Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)
76090026|NCT03234114|Drug|Dual antithrombotc therapy-1|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)
76090027|NCT03234114|Drug|Dual antithrombotc therapy-2|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)
76090028|NCT03229031|Drug|ES135|ES135 will be administered via intrathecal
76090029|NCT03176836|Diagnostic Test|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
76090030|NCT03176836|Diagnostic Test|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
76090031|NCT03176836|Diagnostic Test|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
75343804|NCT05716893|Behavioral|Standard (fixed) Aerobic Training/AT dosing|In Phase A (~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ<3.50 ml O2 .kg-1.min-1 from baseline to ~32 weeks, or unsupervised AT in patients with a CRF Δ>3.50 ml O2 .kg-1.min-1 from baseline to ~32 weeks. Supervised AT will be monitored using TeleEx.
75343805|NCT05710640|Device|Active tcVNS or Sham tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
75819717|NCT02176720|Drug|FDOPA PET|[18F]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
76090032|NCT03168464|Drug|Ipilimumab|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
76090033|NCT03168464|Drug|Nivolumab|On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
76090034|NCT03168464|Radiation|Radiation therapy|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
76090035|NCT03164447|Biological|UB-421|Monoclonal antibody by IV infusion
76090036|NCT03164447|Drug|Optimized background therapy (OBT)|The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
75343806|NCT05710640|Device|Active tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
76090037|NCT03136094|Behavioral|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
76090038|NCT03136094|Behavioral|SBIRT+Usual Care|Patients receive usual SBIRT care
75343807|NCT05709119|Diagnostic Test|Quantification of human DNA retrieved and DNA fragmentation profile.|The sample will be analysed for material quality and have no impact on the patient's future care.
76090039|NCT03113136|Behavioral|Low wattage E cigarette device|The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
76090040|NCT03113136|Behavioral|HIgh wattage E cigarette device|The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
75343808|NCT05696392|Drug|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
75343809|NCT05695963|Other|Clinical assessment|RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
75343810|NCT05695963|Behavioral|auto-questionnaires|To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
75343811|NCT05695963|Device|Ecological Momentary Assessment (EMA)|4 electronic interviews administred per day during 14 days by a study-dedicated Android OS smartphone
75343812|NCT05695963|Device|activity-rest cycle|To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
75343813|NCT05695521|Biological|CK0803|CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously
75654364|NCT05877755|Device|Cardiac MRI acquisition|All patients will have additional images collected during the magnetic resonance imaging (MRI) examination. These are high-resolution multi-contrast cardiac MRI sequences in gradient echo or in balanced steady state free precession with synchronization on the electrocardiogram. The acquisitions last between 1 minute and 10 minutes. This duration depends on the patient's heart rate and breathing rate. The imaging protocol will last approximately 50 minutes. MRI examinations will be performed on a 1.5 Tesla clinical system with specific cardiac imaging coils.
75654365|NCT05877742|Other|AA group|Participants will individually receive a 5-minute AA education delivered verbally at his/her respective clinic by a trained nursing student interventionist in addition to the usual scheduled follow-ups and activities at clinics.
76090041|NCT03113136|Behavioral|Usual brand cigarette|The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.
76090042|NCT03054792|Drug|18F-FAZA (F18-Fluoroazomycin Arabinoside)|Intravenous administration of a hypoxia marker, 18F- Fluoroazomycin arabinoside (FAZA), before a PET-MR imaging in order to identify areas of lower oxygen content on samples of a tumour.
75343814|NCT05695521|Other|Excipient|Excipient
75343815|NCT05692518|Device|MAGNET System, DI Bio-fragmentable|Anastomoses achieved by magnetic compression.
75343816|NCT05691712|Drug|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
75343817|NCT05691712|Drug|Placebo|Administered SC as add-on to the pre-trial background medication.
75343818|NCT05691530|Drug|rDENdelta30/31-7164|The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.
75654366|NCT05877742|Other|Control group|To mimic the time and attention spent, the control group will individually receive a 5-minute seminar delivered by an RA.
75654367|NCT05877703|Other|close kinetic chain exercises|CKC include mini squats, leg press, step-up and step-down, wall slides etc along with their respective modality as quadriceps drill and static cycle ergometer respectively on grade-3 knee OA patients
75654368|NCT05877703|Other|open kinetic chain exercises|The distal segment of the body components can move freely during OKC exercise.OKC exercises include quadriceps setting, knee extension in sitting and straight leg raise in lying position; it also includes quadriceps drills as part of OKC exercises
75654369|NCT05877690|Drug|Bupivacaine 0.5% Injectable Solution|Patient will be received the drug intrathecal
75654370|NCT05877690|Drug|Prilocaine Hydrochloride 2% Injection|Patient will be received the drug intrathecal
75654371|NCT05878509|Other|conducting questionnaires|The patients were administered TSK, Pain Catastrophizing Scale (PCS), Beck Anxiety Inventory (BAI) by face to face interview technique.
75654372|NCT05878509|Other|assesment of the severity and pain|The Modified Hand Injury Scoring System (MHISS) to determine the severity of the injury, and Visual Analog Scale (VAS) to evaluate perceived pain levels were used.
75654373|NCT05877638|Device|SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel|(FDA) 510(k) cleared wound care medical devices formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn serves as a protective gel dressing.
75654374|NCT05877638|Drug|SILVADENE Cream 1% (silver sulfadiazine)|SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
75940220|NCT03483987|Drug|Sof+Velpa+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
75801722|NCT03757104|Behavioral|EPIC-HIV|Men in these communities are eligible to receive a tablet-based male-sensitive HIV decision support app (EPIC-HIV 1)to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
75801723|NCT03757104|Behavioral|micro-incentive and EPIC-HIV|"micro-incentives: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test.~EPIC-HIV 1:~Men in these communities are eligible to receive a tablet-based male-sensitive HIV specific decision support app (EPIC-HIV 1) to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care."
75940221|NCT02523729|Dietary Supplement|Anke Malz|non-alcoholic malt drink
76090043|NCT03054792|Diagnostic Test|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
76090044|NCT03054792|Diagnostic Test|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
75343819|NCT05689073|Device|Conversational AI system|The conversational AI system based on LLM processes user queries with a sophisticated generation, decision, action, and safety framework to provide optimal feedback. The system has several key features. Firstly, it utilizes retrieval-augmented in-context learning to enhance responses generated by the LLM, sourcing information from trustworthy websites. Secondly, it includes Guardrail module that addresses potential harmful content in the LLM-generated responses by clarifying and validating the content before delivery. Furthermore, the AI system is equipped with Self-checking memory module that retains essential clinical characteristics across multi-turn dialogues, ensuring the continuity and consistency of its interactions with users. The educational content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
75343820|NCT05689073|Other|Printed educational Brochure|A printed brochure whose content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
75654375|NCT05877521|Behavioral|MORE treatments|MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time
75654376|NCT05877521|Other|Standard of Care for Pain Management|Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers.
75654377|NCT05877495|Behavioral|Nutritional Education Intervention|A 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. The content of the intervention will be loaded soon.
75654378|NCT05877482|Other|Short foot exercises|A total of 26 participants with pes planus were assigned to the short-foot exercises group (n = 13) and the control group (n = 13). Both groups will be informed about pes planus, usual foot care, and appropriate footwear with foot insoles. In experimental group Short foot exercises (SFE) and internal shoe modification will be performed by placing a medial longitudinal arch support insoles inside the shoe. Exercises will be performed daily for six weeks.
75654379|NCT05877482|Other|Insoles|In control group only internal shoe modification will be performed by placing medial longitudinal arch support insoles inside the shoe. Group assignment and SFE training will be conducted by the second physical therapist to provide blindness.
75801724|NCT01562210|Drug|Olaparib|"Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.~The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID."
75801725|NCT01562210|Drug|Cisplatin|6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
75801726|NCT01562210|Radiation|Radiation|A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.
75801727|NCT02650414|Biological|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB|
75940222|NCT03476499|Device|Near Infrared Imaging (NIR) device|Handheld near infrared multispectral imaging device with custom software.
75965960|NCT03557723|Other|Art activities program|"The intervention will be the MMFA art activities program Les Beaux Jeudis. Three activities will be examined:~Cultural mediation workshop~Supervised visit and tour of the museum~Cultural mediation workshop combined with supervised visit and tour of the museum~The duration of the MMFA art activities program Les Beaux Jeudis will be 3 months. Each participatory-based art activity is a weekly activity."
75965961|NCT02613572|Drug|alpha lipoic acid|
75965962|NCT02613572|Drug|Placebo|
76090045|NCT03054792|Diagnostic Test|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
76090046|NCT03047694|Other|tablet therapy|stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
76090047|NCT03047694|Other|usual care|speech therapy
76090048|NCT02875262|Drug|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
76090049|NCT02875262|Other|placebo|placebo (NaCl 0.9%) in equal dose to treatment
75940223|NCT04459533|Device|TOF protocol|"To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~If 0 response and no respiratory asynchrony: no change in flow rate~If >=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1."
75343824|NCT05681715|Drug|Rozanolixizumab|Rozanolixizumab self-administration via Syringe Driver or Manual Push.
75343825|NCT05678959|Drug|Ligelizumab 120 mg|1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo
75940224|NCT03483909|Device|left IFG iTBS|15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4
75343826|NCT05678959|Drug|Ligelizumab 240 mg|2 injections of 1.0 mL ligelizumab
75343827|NCT05675774|Diagnostic Test|Dual Energy CT|Patients with acute stroke who receive intervention will undergo dual-energy CT in lieu of single-energy CT at 24 hours post-intervention.
75343828|NCT05674643|Diagnostic Test|Gastric Ultrasound Baseline Scans|The patient's abdomen will be scanned using the ultrasound device by an expert scanner and novice scanner for baseline assessment of the antral CSA and gastric volume using Perlas US qualitative grading assessment.
75343829|NCT05674643|Diagnostic Test|Acetaminophen Absorption Test (AAT)|"Prior to starting the AAT, a baseline plasma acetaminophen level (250 microliters) will be obtained from the intravenous catheter. The subject will then be given 12.5 mg/kg or max 650mg of single batch 32mg/mL acetaminophen followed by 6oz of water PO. Up to 3 additional small volume blood samples will be drawn for acetaminophen levels.~These additional blood samples (250 microliters each) will be obtained to measure acetaminophen plasma levels at the following goal intervals after acetaminophen administration.T1:10-20 mins, T2:35-45 mins, T3: 60mins. At the time of each lab draw gastric ultrasound will be assessed by the expert scanner to correlate gastric ultrasound with the acetaminophen absorption test as a gold-standard of gastric emptying."
75343830|NCT05674643|Diagnostic Test|Gastric Ultrasound Serial Scans|Cohort 1 will have multiple scans as part of assessing gastric emptying. These sequential scans after the baseline assessment will be done in line with the Acetaminophen Absorption Test timeline (T1:10-20 mins, T2:35-45 mins, T3: 60mins) and will be performed by an expert scanner only.
75654380|NCT05877417|Dietary Supplement|Creatine Monohydrate|Creatine supplementation for 8 weeks, 5g daily. A 5 day loading phase will be implemented with 20g daily for 5 days.
75654381|NCT05877417|Device|Blood Flow Restriction|Blood Flow Restriction Cuffs applied during exercise
75654382|NCT05877417|Other|Exercise|Participants will exercise
75654383|NCT05877378|Device|Single-use negative pressure therapy (PICO)|PICO system will be applied to patients in the intervention group with diabetic foot ulcers, venous leg ulcers or pressure ulcers. This device will be changed every 7 days, until the wound is closed, or until a set period of study duration, approximately 12 weeks.
75801728|NCT02341534|Device|BioMonitor|Patients will be implanted with the BioMonitor + Home Monitoring feature
75801729|NCT04189952|Drug|Acalabrutinib|Acalabrutinib 100 mg capsules taken by mouth every 12 hours (PO BID), for a total of 2 daily doses on Days 1 to 21 of each cycle.
75801730|NCT04189952|Drug|Rituximab|Rituximab 375 mg/m2 administered intravenously (IV) on Day 1 of each cycle.
75801731|NCT04189952|Drug|Ifosfamide|Ifosfamide 5g/m2 administered intravenously (IV) over 24 hours on Day 2 of each cycle.
75801732|NCT04189952|Drug|Carboplatin|Carboplatin Area Under the Concentration time Curve (AUC) 5 IV administered intravenously (IV) on Day 2 of each cycle.
75801733|NCT04189952|Drug|Etoposide|Etoposide 100 mg/m2 administered intravenously (IV) on Days 1, 2 and 3 of each cycle.
75801734|NCT04716426|Drug|Tetracycline hydrochloride 3%|Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.
75801735|NCT04716426|Drug|Placebo|Formulation composed of FDA approved inactive ingredients.
75801736|NCT03694548|Behavioral|Part A Survey|Survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
75801737|NCT03694548|Behavioral|Part B Yoga Program|Eight in-person instructor-led group yoga sessions.
75801738|NCT01747096|Drug|68-Ga-DOTANOC|
75801739|NCT04166630|Device|Clinical Electrical Stimulator|Conductive electrodes will be on the skin at each end of the tested muscle(s). Each subject will have two target muscle groups tested (extensor carpi radialis longus, and tibialis anterior). Each muscle will be stimulated at three separate stimulation frequencies (2 Hz, 4 Hz, and 6Hz) over 3 minutes each, for a total of 9 minutes of stimulation per muscle. The clinical electrical stimulator will deliver mild electrical stimulations to the muscle (20-100 mA).
75801740|NCT05234736|Drug|CBL-514|CBL-514 800 mg (unit dose: 2.0 mg/cm^2)
75801741|NCT03754764|Biological|Specificity CD38 CAR-T Cells|1) Biological: Specificity CD38 CAR-T Cells 2) Day 0: 1-5x10e6/kg total dose .3) Other: Laboratory Biomarker Analysis
75801742|NCT04164758|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
75801743|NCT04164758|Other|Placebo|Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily
75801744|NCT04164758|Drug|Quetiapine|Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
75801745|NCT03754686|Drug|Oseltamivir|Best medical care and oral oseltamivir 75 mg twice daily for five days. Dose adjustments of oseltamivir will be made according to manufacturer's instructions.
75801746|NCT03754686|Drug|Paracetamol|Best medical care and oral paracetamol twice daily for five days
75940225|NCT03483909|Device|right IPL cTBS|15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4
75940226|NCT03483909|Device|Placebo|rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL
75940227|NCT04459455|Behavioral|Contain COVID Anxiety SSI|Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people around the world who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
75654384|NCT05877365|Dietary Supplement|Standard Process 21-Day Purification Program|Purification, also known as detoxification, may help remove natural toxins from the body, while maintaining a healthy weight. The toxin load humans are exposed to daily may take a toll on physical and emotional well-being. Internally, human bodies produce waste byproducts because of normal metabolic function. Although the body is designed to rid itself of these toxins naturally, it can become overburdened. Purification may offer the body additional support to expel these toxins and manage weight, which is important to maintaining health and vitality.
76090050|NCT02823444|Other|Magnetic Resonance Angiography|"Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational."
76090051|NCT02818920|Drug|Pembrolizumab|"Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 & 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications"
76090052|NCT02811510|Drug|Placebo|Placebo pill (no active cannabinoids)
75654385|NCT05877352|Radiation|Intraoperative Electron Radiotherapy (IOERT)|IOERT can be defined as the direct application of high-energy electron beam irradiation to a tumour bed during an operative procedure. This approach permits precise delivery of a single large fraction of radiation directly and specifically to high recurrence risk anatomical target areas, which the treating clinicians (surgeon and attending clinical oncologist) predict will be a close or involved margin, while simultaneously displacing and shielding dose-limiting radiosensitive structures such as the small bowel or ureter or any anastomoses, if not involved by tumour.
76090053|NCT02811510|Drug|Dronabinol|10 mg capsule of Dronabinol will be administered orally.
76090054|NCT02786264|Drug|Dexmedetomidine with propofol|A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start. This group was subsequently modified in light of retrospective data collection to specify a group receiving dexmedetomidine in combination with propofol.
75801747|NCT05200884|Drug|Lidocaine 2%|The child will be injected with lidocaine 2% and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker FACES pain rating scale
75801748|NCT05200884|Drug|Articaine 4%|The child will be injected with 4% Articaine and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and face scale
75801749|NCT04178720|Device|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
75801750|NCT04178720|Device|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
75801751|NCT04178720|Device|CLEAR CARE|Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
75343831|NCT05673720|Device|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session for 5 times via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session for 5 times by a recorded meditation.
75654386|NCT05877352|Procedure|Extended Margin Surgery|Surgery intended to remove both a tumour and any metastases
75965963|NCT02088983|Dietary Supplement|CDP-Choline|Capsule
75965964|NCT02088983|Dietary Supplement|Cellulose|Capsule
76090055|NCT02786264|Drug|Propofol|A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start. This definition was subsequently modified to include patients who received propofol infusion but not dexmedetomidine.
76090056|NCT02778971|Drug|[18F]Flutemetamol|amyloid PET imaging with [18F]Flutemetamol and subsequent modification of diagnosis and management
75654387|NCT05877261|Device|Cementless Total Knee Replacement|Artificial knee implant inserted by cementless fixation.
75654388|NCT05877235|Dietary Supplement|Quercetin|Trans-quercetin, 1000 mg daily for 60 days
75654389|NCT05877235|Dietary Supplement|Placebo|Starch, 1000 mg daily for 60 days
75819718|NCT04373434|Behavioral|Health Homes/Healthy Families (HH/HF) Intervention|The HH/HF Intervention involves coaching calls, text messages and intervention materials that are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention. The intervention is delivered over a 12 week period.
75965965|NCT02089061|Drug|BMS-919373|
75965966|NCT02089061|Drug|Rosuvastatin|
75343832|NCT05673720|Device|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
75940228|NCT04459455|Behavioral|Remain COVID Free SSI|This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
75940229|NCT03476421|Procedure|Hepatic resection|Surgery of the liver; removal of a part of the liver
75940230|NCT03483831|Behavioral|Intervention group|Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
75940231|NCT03476265|Device|Electrical Stimulation of the Lower Esophageal Sphincter|Laparoscopic implantation of an electrical stimulation device to perform an electrical sphincter augmentation for the treatment of GERD.
75940232|NCT03389477|Drug|Palbociclib|Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
75940233|NCT03389477|Drug|Cetuximab|-Cetuximab must not be administered as an IV push or bolus
75940234|NCT03389477|Drug|Cisplatin|-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
75940235|NCT03389477|Radiation|Intensity-Modulated Radiation Therapy|-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
75343833|NCT05671510|Drug|Gotistobart|Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
75343834|NCT05671510|Drug|Docetaxel|Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
75343835|NCT05670236|Drug|Lidocaine Hydrochloride|10 mL of 1% lidocaine hydrochloride for each intraarticular knee injection
76090057|NCT02756533|Other|Telemonitoring of daily parameters recorded by NIV|"Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. When an alert is received, a nurse will evaluate the symptoms of the patient by a standardized phone call questionnaire. The results will be transmitted to a referent practitioner who will decide what the patient should do.~Recommendations will be transferred to the patient within 36 hours."
75654390|NCT05877196|Behavioral|Moderate Intensity Continuous Training (MICT)|Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
75940236|NCT03389477|Procedure|Tumor biopsy|"Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline."
75654391|NCT05877196|Behavioral|Chair-based Stretch|Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
75654392|NCT05877196|Behavioral|High-Intensity Interval Training (HIIT)|Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
75654393|NCT05877196|Behavioral|Combined Aerobic Resistance Exercise (CARE)|6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
75343838|NCT05660980|Drug|Once daily CAB tablet + RPV tablet|Tablet
75343839|NCT05660980|Drug|Long acting CAB injectable + long acting RPV injectable|Injectable
75343840|NCT05660980|Drug|Long acting CAB injectable + long acting RPV injectable|Injectable
75343841|NCT05643651|Drug|Rivaroxaban Oral Tablet [Xarelto]|Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model- and clinical evidence-informed precision dosing
75343842|NCT05643651|Drug|Aspirin or Clopidogrel|Aspirin [3 ~5mg/(kg·d) once daily] or Clopidogrel [0.2~1.0 mg/kg(<2 years old),1 mg/kg(≥2 years old); once daily]
75343843|NCT05643651|Drug|Warfarin|Warfarin 0.05~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5
75654394|NCT05877170|Dietary Supplement|Palmitoyletinolamide|Taking a once-daily supplement containing PEA in an oral formulation (tablets), to be taken away from meals
75654395|NCT05877170|Drug|Placebo|Taking a placebo in an oral formulation (tablets), to be taken away from meals
75940237|NCT03389477|Procedure|Peripheral blood draw|Baseline and post-treatment
75940238|NCT05153577|Other|Group A: $5 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
76090058|NCT02756533|Other|Placebo|Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. Alerts will only be collected, the patient will not be contacted by phone during the alert.
75801752|NCT03757026|Other|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
75940239|NCT05153577|Other|Group B: $10 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
75965967|NCT02089061|Drug|Atorvastatin|
75343844|NCT05642936|Behavioral|didactic health education control|didactic classroom-based comparison group that follows standard guidelines for diet, exercise and substance use with no stress reduction component
75654396|NCT05877144|Procedure|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
75654397|NCT05877144|Other|Medical Device Usage and Evaluation|Receive LiSWT
75940240|NCT03672617|Other|No treatment given|"No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion."
75940241|NCT03677921|Dietary Supplement|Investigational Product (Bio-Germanium)|"Ingredient: Bio-Germanium~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~Storage: Room temperature (below 25℃)~Duration of use: 8 weeks"
75940242|NCT03677921|Dietary Supplement|Control Group - Placebo Product|"Ingredient: Corn starch~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day~Storage: Room temperature (below 25℃)~Duration of use: 8 weeks"
75940243|NCT05153031|Other|lithiasic|Cholelithiasis is the presence of one or more calculi (gallstones) in the gallbladder.
75940244|NCT05153031|Procedure|Emergency surgery|Emergency cholecystectomy
75940245|NCT05153031|Procedure|cholecystectomy|cholecystectomy
75476232|NCT02005055|Procedure|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
75476233|NCT02005068|Drug|Ceftaroline|The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
75476234|NCT02005081|Device|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
75654398|NCT05877144|Procedure|Duplex Ultrasound|Undergo DDUS
75654399|NCT05877144|Other|Survey Administration|Ancillary studies
75940246|NCT03677765|Procedure|Supra- vs Infraclavicular approach using ultrasonography|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle. Meanwhile, in the infraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
75654400|NCT05877144|Procedure|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
75654401|NCT05877144|Procedure|Sham Intervention|Receive sham LiSWT
75940247|NCT03623477|Behavioral|Cognitive Remediation (CRT)|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The cognitive remediation therapy group will complete computerized training activities in attention, memory, processing speed, problem solving, and executive functions.
75940248|NCT03623477|Behavioral|CRT+ Social Cognition Training|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The combined cognitive remediation and social cognition training group will complete computerized training that target neurocognitive functions, facial affect emotion recognition and mentalizing tasks.
75476235|NCT02005081|Device|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
75476236|NCT02005107|Drug|Venlafaxine IR and Venlafaxine XR|
75476237|NCT02005120|Drug|Bevacizumab|Intrapleural administration of bevacizumab
75476238|NCT02005120|Drug|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
75654402|NCT05877144|Procedure|Duplex Ultrasound|Undergo DDUS
75654403|NCT05877144|Other|Survey Administration|Ancillary studies
75476239|NCT02005159|Other|Microbiological studies|
75801753|NCT03757026|Other|Slip Training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine interventional sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
75940249|NCT05152797|Biological|Autologous tumor-infiltrating lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
75940250|NCT03677687|Behavioral|Mindfulness for Physical Activity|The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
75476240|NCT02005198|Other|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
75654404|NCT05877131|Drug|Levobupivacaine|To evaluate the efficacy of low-dose levobupivacaine (0.125%) (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
75654405|NCT05877131|Drug|Ropivacaine|To evaluate the efficacy of low-dose ropivacaine (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
75654406|NCT05877118|Behavioral|Enhanced Overdose Education (EOE)|"EOE was adapted by Co-I Dr. Monique Miley at HHC's premier addiction hospital-The Rushford Center. It follows the guidelines set by Co-PI Jonathan Craig Allen when working with opioid patients reluctant to obtain naloxone:~Express confidence in naloxone~Provide a clear statement about suitability (You are an excellent candidate for naloxone)~Begin discussion using presumptive language (You must be ready for an overdose)"
75940251|NCT03481023|Device|EnsoETM|Use of esophageal thermal regulation device during radiofrequency ablation.
75476241|NCT02005224|Other|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
75654407|NCT05877118|Behavioral|Standard education|Written instructions that accompany a kit prescription in many EDs throughout the country.
75801754|NCT03757026|Other|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
75801755|NCT03746444|Other|General Anesthesia|The patients in general anesthesia group will undergo general anesthesia
75940252|NCT03481023|Procedure|Conventional Care|Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
75940253|NCT03476031|Diagnostic Test|renal biopsy|needle biopsy will be taken from the kidney tissue then, diagnosed
75654408|NCT05877092|Device|implants with overdentures|two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.
75940254|NCT03483519|Other|Rehabilitation|Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
75940255|NCT03483519|Other|Standard of Care|Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
75940256|NCT03672383|Device|BAY987534|Form: cream; Route of Administration: topical; Frequency of Administration: twice daily ; Duration of Treatment: 4 weeks .
75940257|NCT04154163|Diagnostic Test|Dried blood Spot (DBS)|Dried Blood Spot filter paper and sponges
75940258|NCT04154163|Diagnostic Test|Venous blood sampling|Venous blood
75940259|NCT03672305|Biological|c-Met/PD-L1 CAR-T cell injection|injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes
75940260|NCT02680574|Drug|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
75940261|NCT02680574|Drug|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
75940262|NCT03676829|Device|Arterial Embolization of the Shoulder|Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
75940263|NCT02523963|Other|family work shop|"The family work shop has 5 courses, with 6 families in one course.~One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods"
75940264|NCT03672149|Drug|Cefazolin|Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion
75940265|NCT05152719|Behavioral|Cognitive Performance|Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.
75940266|NCT03672071|Other|Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)|If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups
75801756|NCT03746444|Other|Regional Anesthesia|The patients in Group R will be given combined spinoepidural anesthesia
75801757|NCT03749096|Drug|Intravenous Immunoglobulins, Human|Immunoglobulins are fractionated blood products made from pooled human plasma.
75801758|NCT03749096|Drug|Placebos|Normal Saline
75801759|NCT03748940|Drug|LY3074828|Administered SC
75476242|NCT02005237|Behavioral|Aerobic Exercise|3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
75476243|NCT02005263|Procedure|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
75476244|NCT02005302|Drug|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
75801760|NCT03748940|Drug|Placebo|Administered SC
75801761|NCT03748940|Drug|LY900021|Administered SC
75801762|NCT04177862|Drug|Sublingual Sufentanil|30 mcg of sublingual sufentanil
75801763|NCT04177862|Drug|IV Fentanyl|50 mcg of IV fentanyl
76090059|NCT02726061|Behavioral|Internet-based psychological support|A behavioral therapy called Problem Solving Therapy, conflict management training, and stress management training will be administered via an interactive multimedia program (PATH) to participants referred from their Employee Assistance Program and the general public for the management of depression, stress, and conflict.
75654409|NCT05877079|Drug|Menthol|Patients will wear hand and foot wraps with 8% w/w menthol lotion (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
75801764|NCT03748862|Other|Taper Plan|Occurrence of a taper plan defined by a primary care provider during the follow-up period. Evidence of a taper plan will be obtained by searching prescriptions (SIGs) and medical encounter notes using natural language processing (NLP).
75654410|NCT05877079|Drug|Placebo|Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
75654411|NCT05877053|Drug|CK-4021586|CK-4021586
75801765|NCT04173572|Behavioral|PACE-Life|PACE-Life Groups will occur twice per week for 15 minutes in the first two weeks, progressing to 30-minute walking sessions over the course of the intervention without changes in frequency. The intensity of virtual walks will increase throughout this intervention in a stepwise fashion to create an exercise dose response to maximize impact on CRF.
75801766|NCT04173572|Behavioral|Exercise Intervention|Data from Fitbit devices will be synced and accessed through Fitbit.com. Participants will be provided account information to view data but will be asked not to change any of the settings as the investigators will be using data for tracking steps/day and minutes spent walking.
75801767|NCT03746366|Radiation|[C-11]|Radiolabel
75801768|NCT03746366|Drug|Pittsburgh Compound B|Tracer
75940267|NCT04010565|Dietary Supplement|Aged black garlic extract|"Participants will intake a tablet with 250 mg of a aged black garlic extract with higher concentration of bioactive compounds S-allyl cysteine and alliin, and minor unwanted compounds such as simple sugars and furfural derivatives.~In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias."
76090060|NCT02444546|Other|Laboratory Biomarker Analysis|Correlative studies
76090061|NCT02444546|Biological|Sargramostim|Given SC
76090062|NCT02444546|Biological|Wild-type Reovirus|Given IV
76090063|NCT02436941|Radiation|Proton or Photon|
76090064|NCT01993498|Procedure|blood sampling|blood samples collection
76090065|NCT01965912|Drug|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
75654412|NCT05877053|Drug|Placebo for CK-4021586|Placebo for CK-4021586
75654413|NCT05877040|Drug|Rituximab|Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
75801769|NCT04157738|Drug|Rapid-Acting Insulin|Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
75801770|NCT04157738|Drug|Long acting insulin|Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
75801771|NCT04156646|Drug|Balovaptan|Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
75801772|NCT04156646|Drug|Esomeprazole|Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
75801773|NCT03751488|Drug|LY03010|Single Dose of LY03010 at 351 mg or 156 mg or 117mg
75940268|NCT04010565|Dietary Supplement|Placebo|Participants will intake a tablet with 250 mg of microcrystalline cellulose. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias.
75654414|NCT05877001|Drug|Tislelizumab|200mg, IV, Q3W
75654415|NCT05877001|Drug|Regorafenib|80 mg once daily for the first 3 weeks of each 4-week cycle
75654416|NCT05877001|Other|HAIC|OXA 85mg/m2 IA 0-4h +5-Fu 2000mg/m2 IA 4-48h，CF 200mg/m2 IV 2-4h， Q3W
75801774|NCT03751488|Drug|Invega Sustenna 156 MG in 1 ML Prefilled Syringe|Single Dose at 156mg
76090066|NCT01948505|Drug|Intravenous acetaminophen|
76090067|NCT01948505|Drug|Placebo for IV acetaminophen|
76090068|NCT01934296|Device|Activa PC+S|Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
76090069|NCT01916005|Device|18F-FDG PET/CT|
75476245|NCT02005302|Drug|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
75801775|NCT01562288|Genetic|DNA analysis|
75801776|NCT01562288|Genetic|gene expression analysis|
75801777|NCT01562288|Genetic|polymerase chain reaction|
75801778|NCT01562288|Other|enzyme-linked immunosorbent assay|
75801779|NCT01562288|Other|laboratory biomarker analysis|
76090070|NCT01454401|Device|LeucoPatch treatment|weekly
76090071|NCT01344018|Procedure|therapeutic conventional surgery|
76090072|NCT01344018|Radiation|3-dimensional conformal radiation therapy|
76090073|NCT01160926|Drug|AZD6244|"Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd~Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy"
76090074|NCT01160926|Drug|Cediranib (AZD2171)|"10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od~Oral tablets"
75476246|NCT02005302|Dietary Supplement|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
75654417|NCT05876975|Procedure|laparoscopic pectopexy|Women with pelvic organ prolapse and suitable indications underwent laparoscopic pectopexy.
75801780|NCT03746288|Drug|CAN008|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
75801781|NCT05070702|Drug|CT-1500|Hard Capsule
75654418|NCT05876936|Device|contact lens sensor (CLS) SENSIMED Triggerfish®|contact lens sensor CLS placing and fitting evaluation, 24h recording
75801782|NCT05070702|Drug|Placebo|Hard Capsule
75940269|NCT03671993|Procedure|Electrical pudendal nerve stimulation|Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.
76090075|NCT01126957|Drug|Ketamine|Ketamine was given as a 0.5mg / Kg bolus.
76090076|NCT01126957|Drug|Placebo|Placebo given as an bolus to control group.
76090077|NCT01126957|Drug|Fentanyl|Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
75654419|NCT05876845|Other|Combined pre-, pro-, and post-biotic supplement|Participants will take 2 capsules daily with water, with their first meal of the day.
75940270|NCT03671993|Procedure|Intravesical instillation|The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
75940271|NCT03475797|Device|Occipital nerve stimulation|Occipital nerve stimulation with percutaneous or surgical lead
76090078|NCT01126957|Drug|Propofol|Propofol given to both arms to maintain sedation throughout procedure.
75654420|NCT05876832|Drug|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.
75654421|NCT05876832|Drug|Salvage Chemotherapy|Low-dose Cytarabine (LoDAC) or azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide, cytarabine (MEC)will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
75940272|NCT03475797|Other|Optimal Medical Management|Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
75940273|NCT03483285|Device|airtraq|airtraq videolaryngoscope
75940274|NCT03483285|Device|storz|storz videolaryngoscope
75940275|NCT03475719|Drug|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
75940276|NCT03475719|Drug|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
75940277|NCT03475563|Procedure|Coronary angioplasty with stent implantation|Coronary angioplasty with BiOSS LIM C stent implantation
75940278|NCT03480945|Diagnostic Test|serotonin|Endothelium-dependent dilatation
75940279|NCT05151237|Diagnostic Test|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
76090079|NCT00811122|Radiation|11C-PIB PET Scan|Participants will receive an 11C-PIB PET scan of the brain.
76090080|NCT00811122|Radiation|FDG-PET Scan|Participants will receive an FDG-PET scan of the brain.
76090081|NCT00651885|Drug|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
75654422|NCT05875805|Behavioral|Telehealth Serious Illness Care Program|The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
75654423|NCT05875805|Other|Education Control|"Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version"
75654424|NCT05873855|Behavioral|Para ti, para mi, para nosotros (P3)|From day 1 to day 180 (i.e., entire 6-month duration, post baseline) of the pilot trial, participants randomized to the intervention arm will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
75654425|NCT05873855|Behavioral|Waitlist Control Para ti, para mi, para nosotros (P3)|From day 91 to day 180 (i.e., starting after 3-month assessment) of the pilot trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
75654426|NCT05873829|Other|Hand-foot exercises|Hand-foot exercise program consists of 5 hand and 5 foot exercises, and a total of 15 minutes of simple hand-foot exercises. The exercise program is applied 3 times a day, 3 days a week. The tennis ball and the towel that used in the exercise program, the booklet which containing the exercise explanations and the video link showing the implementation of the exercises were provided by the researcher.
75801783|NCT04150250|Drug|iOWH032|Anti-secretory synthetically manufactured small molecule designed to inhibit the cystic fibrosis transmembrane conductance regulator chloride channel.
75801784|NCT04150250|Drug|Placebo|Oral tablets matching iOWH032 on taste, appearance, dissolution time with the same excipients but no active ingredients.
75801785|NCT04150250|Other|V. cholerae Challenge|Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.
76090082|NCT00651885|Drug|Placebo|Placebo
76090083|NCT00247377|Procedure|Gastric bypass surgery|in order to meet health requirements for patient, gastric bypass surgery was undergone
76090084|NCT00247377|Procedure|Lap-Band|in order to meet health requirements for patient, gastric band surgery was undergone
75940280|NCT03483207|Drug|Warfarin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
75940281|NCT03483207|Procedure|MVT with failure of anticoagulation therapy|"patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded."
75940282|NCT03483207|Drug|Heparin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
75940283|NCT05132985|Drug|Icotinib|125mg 1tt(Take 1 tablet 3 times a day) orally.
75940284|NCT05132985|Drug|Cisplatin|75 mg/m2 (IV，Q3W)
76090085|NCT01456767|Dietary Supplement|Probiotics|"Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells."
75801786|NCT04150250|Drug|Antibiotics|"Antibiotic therapy may include:~Ciprofloxacin 500 mg, twice daily;~Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)"
75801787|NCT04537806|Drug|Brexanolone|Administered as IV infusion.
75476247|NCT02005302|Dietary Supplement|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
75801788|NCT04537806|Drug|Placebo|Administered as IV infusion.
75654427|NCT05873777|Diagnostic Test|18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-LM3, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
75654428|NCT05872802|Other|eccentric exercises and electrical stimulation|Eccentric exercises and strengthening currents to improve ankle dorsiflexion in professional padel players.
75654429|NCT05872802|Other|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation to improve ankle dorsiflexion in professional padel players.
75654430|NCT05859958|Other|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups
75654431|NCT05859737|Behavioral|Disaster Preparedness Education Program|The SIMAH Program includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages will apply.
75801789|NCT03756948|Other|Usual Care|Treatment of Coagulation Disorders Using Standard Coagulation Tests and Blood Components
75801790|NCT03756948|Other|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates|Thromboelastometry-Guided Treatment of Coagulation Disorders Using Synthetic Factor Concentrates
75801791|NCT04015232|Combination Product|INTP5|INTP5, a pegfilgrastim biosimilar to US Neulasta.
75801792|NCT04015232|Combination Product|US Neulasta|US Neulasta: FDA approved pegfilgrastim innovator product.
75801793|NCT04533204|Behavioral|mnemonic strategy training|training using mnemonic strategies
75801794|NCT04533204|Behavioral|spaced retrieval training|training using spaced retrieval
75801795|NCT03744884|Behavioral|Force efforts with haptic feedback in virtual reality.|A virtual reality game-based intervention incorporating fully-automated robotic haptic feedback. The study consists of face-to-face assessments of movement before, after, and one-month following the completion of the six-session game-based intervention. Children with spastic/dystonic cerebral palsy between the ages of 7 and 17 will be recruited for this study along with a group of typically developing children in the same age range. Both groups of children will be randomly allocated into an intervention or control group using a blocked randomization method.
75940285|NCT05132985|Drug|Carboplatin|AUC 5 (IV, Q3W)
75940286|NCT05132985|Drug|Pemetrexed|500 mg/m2 (IV, Q3W)
75940287|NCT03483129|Behavioral|Consultation|15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
75940288|NCT05676320|Device|V-Flex|Bone cement including Inossia Cement Softener. Treatment for vertebral compression fracture
76090086|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
76090087|NCT01890369|Dietary Supplement|3g Leucine|Dissolved in 250ml water.
76090088|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
75476248|NCT02005315|Drug|Vantictumab|Administered intravenous (IV) infusion.
75476249|NCT02005315|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
75654432|NCT05859737|Other|Disaster and Emergency Management Presidency Education|Public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will give.
75940289|NCT05676320|Device|V-Steady|Bone Cement alone
75940290|NCT05091723|Drug|Nezulcitinib (TD-0903) Dose A|TD-0903 Dose A
75940291|NCT05091723|Drug|Nezulcitinib (TD-0903) Dose B|TD-0903 Dose B
75801796|NCT04465422|Behavioral|Occupational therapy based on the MOHO theory|"We selected two acute wards in the Songde hospital as the intervention group and the control group. At the same time, the demographic data of the participants were collected, including gender, age, age of onset, marital status, education level, work experience, etc., and the clinical records, including assessment of mental symptoms and medication records, etc. Continuity or categorical information on Occupational performance, personal and social performance, instrumental activities daily living, and clinical performance.~OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model."
75476250|NCT02005315|Drug|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
75654433|NCT05850585|Drug|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
75940292|NCT03163316|Other|Unenhanced magnetic resonance imaging.|"The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.~The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.~Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination."
75940293|NCT05079633|Biological|Homologous boost schedule|1st dose mRNA 1273 , 2nd dose mRNA 1273
75476251|NCT02005328|Device|Tested product : DC161-DP0291|Application of product in the mouth twice daily
76090089|NCT01890447|Other|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
75476252|NCT02005328|Device|Tested product : DC161-DP0292|Application of product in the mouth twice daily
76090090|NCT01456923|Other|Treatment with chemotherapy|
75476253|NCT02005328|Device|Tested product : DC161-DP0293|Application of product in the mouth twice daily
75940294|NCT05079633|Biological|Heterologous boost schedule|1st dose mRNA 1273 , 2nd dose MVC COV1901
75940295|NCT02522884|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
75476254|NCT02005328|Device|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
75476255|NCT02005341|Device|nanOSS|
75940296|NCT05087966|Behavioral|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
75940297|NCT05518630|Behavioral|Nomothetic Versus Idiographic Assessment in Chronic Pain|Participants with either endometriosis, vulvodynia, and/or fibromyalgia will answer a twice-daily diary for 42 days and a short weekly diary six times in total. In addition, they will answer two longer surveys at the start and at the end of the 42 days. These questionnaires ask about psychological flexibility, depression, catastrophizing, and pain interference. The data collected is only observational and does not include any intervention.
75940298|NCT03739593|Drug|AR-1105-CF1|AR-1105 clinical formulation 1 (AR-1105-CF1)
75940299|NCT03739593|Drug|AR-1105-CF2|AR-1105 clinical formulation 2 (AR-1105-CF2)
75940300|NCT03475485|Device|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
75940301|NCT03475485|Device|Wearable Sensor|Subjects will wear an ID-Reader
75940302|NCT03475485|Device|Placebo|A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
75940303|NCT05676164|Device|KANG XIAN|This product is a liquid composed of silica, stabilizer, xylitol, flavoring agent and water. The pH value of the product is 5.0 ~ 8.0, and the total heavy metal content (measured by Pb2+) is less than 10µg/ml.
75940304|NCT05676164|Device|TIAN XIA|The products are dark yellow granules made from rice, soybean, lotus root powder, orange peel, coix seed and yam.
75940305|NCT03480867|Drug|Temozolomide|Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
75940306|NCT03480867|Radiation|Pre-Operative Radiation|Radiation is given with Temozolomide for 7 days before surgery
75940307|NCT05254912|Drug|6% Bemotrizinol in sunscreen formulation|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)
75940308|NCT05254912|Drug|6% Bemotrizinol in petrolatum|6% Bemotrizinol (BEMT) as a dispersion in petrolatum (SU-E-101413-82)
75940309|NCT05254912|Other|Vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91)
75940310|NCT03482895|Biological|Blood sampling|Quantitative analysis of enterohormones, citrulline and ApoB48
75940311|NCT03482895|Biological|Feces sampling|Intestinal absorption assessment
76090091|NCT01456923|Other|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
76090092|NCT01456923|Procedure|surgery|
75654434|NCT05850585|Other|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
75476256|NCT02005341|Device|Autograft|
75801797|NCT04465422|Behavioral|Occupational therapy|The original Occupational therapy. OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model.
75343845|NCT05642936|Behavioral|Transcendental Meditation technique|a mental technique derived from the Vedic tradition of ancient India and practiced by anyone for 20 minutes twice a day sitting
75801798|NCT01322802|Biological|pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine|Given ID
75343846|NCT05640895|Procedure|Intravitreal injection site|Intravitreal injections will be made at varying sites; patients will report on pain perception
75801799|NCT01322802|Other|laboratory biomarker analysis|Correlative studies
75801800|NCT04676256|Procedure|Early vitrectomy|Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
75801801|NCT04014062|Combination Product|INTP5|INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
76090093|NCT01890603|Other|Data collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
76090094|NCT01890603|Other|Data Collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
75654435|NCT05849623|Procedure|Endoscopic Mucosal Resection (EMR)|EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
75654436|NCT05849623|Procedure|Cold Endoscopic Mucosal Resection (C-EMR)|C-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
75801802|NCT04014062|Combination Product|US Neulasta|US Neulasta: FDA-approved pegfilgrastim innovator product.
75801803|NCT03744806|Drug|Bevacizumab Injection|
75940312|NCT03480789|Drug|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
75940313|NCT03480789|Device|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
76090095|NCT04845321|Drug|VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
76090096|NCT04845321|Drug|Placebo for VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
76090097|NCT01457001|Drug|25-OH-D vitamin|
76090098|NCT02846883|Biological|MSCs|Intravenous infusion of 1 million allogeneic MSCs/kg.
76090099|NCT02846883|Biological|MSCs|Intravenous infusion of 3 million allogeneic MSCs/kg
76090100|NCT02846883|Drug|Placebo|Intravenous infusion of Plasmalyte A (placebo)
76090101|NCT01457235|Other|Cognitive Remediation|All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
75654437|NCT05849623|Procedure|Underwater Endoscopic Mucosal Resection (U-EMR)|U-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
75654438|NCT05834842|Behavioral|Unisalud|"The UNISALUD intervention will be made up of 42 videos, made using the visual collage technique, where illustration, video fragments and visual interactions are mixed and in some there will be a presenter to achieve captivating visual material. to the participant. Likewise, it will be accompanied by digital infographics that will help reinforce the information proposed by the intervention."
75801804|NCT01562366|Device|Topaz|Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure
76090102|NCT01457391|Behavioral|Cognitive Behavioral Therapy|Individual CBT, approx. 12 sessions, one session per week
76090103|NCT01457391|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
76090104|NCT01457391|Behavioral|Treatment-as-usual|Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
75343847|NCT05629741|Drug|CMTX-101|Administered as specified in the treatment arm
75801805|NCT01562366|Procedure|Iliotibial band release and trochanteric bursectomy|Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
75343848|NCT05629741|Drug|Placebo|Administered as specified in the treatment arm
75801806|NCT04531098|Biological|Sci-B-Vac-Lot B|Sci-B-Vac Lot B -10 μg of HBsAg, intramuscular injection of 10 μg/ml
75940314|NCT03480711|Procedure|SST in group (A)|group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
75343849|NCT05625815|Device|Prototypes (816-v1 001) to (816-v1 050)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75801807|NCT04531098|Biological|Sci-B-Vac-Lot A|Sci-B-Vac Lot A - 10 μg of HBsAg, intramuscular injection of 10 μg/ml
75801808|NCT04531098|Biological|Engerix-B|Engerix-B (hepatitis B vaccine (recombinant)) is indicated for active immunization against hepatitis B virus infection
75940315|NCT03480711|Procedure|trabeculectomy with ESST in group (B)|group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
75940316|NCT03475407|Drug|Ozurdex intravitreal injection|"Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~AC paracentesis at 6 wk~intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk"
75801809|NCT03744650|Behavioral|"Care4Heart programme"|"A 4-week mHealth programme in the form of a smartphone app, named Care4Heart, has been developed. The content and scope of the design are developed by a thorough literature review and an extensive analysis of existing education leaflets and brochures used to prevent CHD. The contents are specified and tailored to the working population.~The app is developed by a team of software engineers from Computing School of NUS. Several functions include: (1) app using instructional video; (2) easy-to-read information on healthy lifestyle toward heart health, including information about the disease, CHD risk factors (e.g. diet, smoking cessation), stress, physical exercises and relaxation techniques; and (3) scheduled reminders for doing exercise and relaxation"
75940317|NCT05286424|Procedure|fat grafting|Fat will be removed from abdomen or legs, processed and re-injected into grafting sites.
75654439|NCT05832918|Other|exercise therapy|Exercise therapy is one of the rehabilitation methods that is defined as a regimen or plan of physical activities designed and prescribed to facilitate the patient's recovery from diseases and any conditions which disturb their movement and activity of daily life or maintain a state of well-being through neuro re-education, gait training, and therapeutic exercises.
75801810|NCT04144166|Device|capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
75801811|NCT04142450|Device|CoolSculpting® System|Each participant underwent a single treatment session that was comprised of timed segments of cooling followed by 2 minutes of manual massage.
75940318|NCT03475329|Other|adenotonsillectomy|adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
75940319|NCT05285956|Behavioral|Calm app|Calm is a popular, subscription-based, meditation app accessible across web-based and smartphone platforms (iOS and Android) with over 100 million downloads and four million subscribers. The app offers a range of content rooted in mindfulness principles to help users incorporate mindfulness into their lives and generally promote wellbeing (e.g., a large library of guided meditations including the 10-minute Daily Calm, Sleep Stories, educational courses, mindful movement, music, and nature scenes and sounds). Calm also teaches users the basics of mindfulness, includes components to remind users to meditate, track user activity, and allow users to share their status with others. The feasibility of the app and its efficacy for improving mental health outcomes (i.e., stress, anxiety, and depressive symptoms), mindfulness, and sleep have been previously tested in various populations providing evidence that using Calm may improve wellbeing.
76090105|NCT02816775|Device|Macintosh Laryngoscope|After induction of anesthesia, tracheal intubation will made by Macintosh Laryngoscope
75654440|NCT05831670|Drug|KSP-0243|Oral administration
76090106|NCT02816775|Device|McGRATH Videolaryngoscope|After induction of anesthesia, tracheal intubation will made by McGRATH Videolaryngoscope
75801812|NCT04529850|Drug|Drug: GC4419|GC4419 60 Minute Infusion
75801813|NCT04529850|Radiation|Intensity-modulated radiation therapy (IMRT)|2.0 to 2.2 Gy daily over 7 weeks
75801814|NCT04529850|Drug|Cisplatin|100mg/m2 once every 3 weeks or 40mg/m2 once weekly for 6-7 doses
76090107|NCT01457469|Other|questionnaire administration|Ancillary studies
76090108|NCT01457469|Procedure|quality-of-life assessment|Ancillary studies
76090109|NCT01457469|Other|counseling intervention|Undergo counseling session
76090110|NCT01457469|Other|internet-based intervention|Receive enhanced quitline intervention
76090111|NCT01457469|Behavioral|telephone-based intervention|Receive enhanced quitline intervention
76090112|NCT01457469|Other|educational intervention|Receive usual care plus
76090113|NCT01457469|Drug|nicotine replacement therapy|Receive nicotine replacement patches
76090114|NCT01457469|Other|educational intervention|Receive enhanced quitline intervention
76090115|NCT01457547|Biological|DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)|Three doses administered intramuscularly
75343850|NCT05625815|Device|Prototype (816-v1 051) to (816-v1 100)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75476257|NCT02005367|Behavioral|Natural Recovery-Horticulture|"Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.~Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures."
75654441|NCT05831670|Drug|Placebo|Oral administration
75654442|NCT05796427|Behavioral|SupporT for ADHD and Related Treatment|Intervention will include 6 modules typically taught over 6-7 weeks. Participants will have up to 3 months to complete the intervention. Modules will provide more knowledge on ADHD, discuss stigma around ADHD, address barriers in receiving care, encourage communication with physician and child, and empower caregivers. Overall, the goal being to improve engagement in ADHD treatment for newly diagnosed or unengaged families. This intervention is mostly targeted towards primary caregivers. However, the last module explicitly includes the child.
75654443|NCT05791253|Other|Pain management|Check whether pain management was carried out according to the recommendations of the French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Emergency Medicine (SFMU)
76090116|NCT01457547|Biological|DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)|Three doses administered intramuscularly
76090117|NCT01457859|Drug|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
75654444|NCT05790707|Procedure|Atrial fibrillation ablation + antiarrhythmic drugs|"Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation.~Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed."
75654445|NCT05790707|Drug|Antiarrhythmic drug|Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
75654446|NCT05790460|Other|Telehealth|Enhanced synchronous telehealth nurse navigation, compared to usual care nurse navigation, to increase timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.
75801815|NCT04225676|Biological|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients > 50 kg body weight."
75654447|NCT05789420|Other|P1R stick|Regular flavor tobacco stick
75801816|NCT04142216|Dietary Supplement|Chewing Gum|The patients will chew one piece of regular chewing gum six times in a day and feeling of thirst for ten minutes for three months.
75940320|NCT03482817|Drug|Ze 117|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
75940321|NCT03482817|Drug|Probe drug cocktail|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
75940322|NCT03655197|Drug|Doxycycline|For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
75654448|NCT05789420|Other|P1M stick|Mentholated flavor tobacco stick
75654449|NCT05789420|Other|CIG|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
75654450|NCT05764629|Diagnostic Test|blood test|Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.
75801817|NCT04140890|Behavioral|Habit Formation|Treatment sessions consist of 12 weekly health coaching sessions at participants' home. During the intervention period, an occupational therapist will help the participant to commit to developing new simple habits (dietary habits or physical activity habits) in each 60-minute session.
75801818|NCT04140890|Behavioral|Education|In the education group, participants will receive newsletters containing general healthy aging materials over 12 weeks. A trained research assistant will call participants to verify receipt of the newsletter, and answer their questions about the materials. Each phone call will last ~15 minutes.
75801819|NCT03700320|Drug|Standard of Care (SOC) Migraine Preventive Medication|Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
75801820|NCT03700320|Drug|Atogepant|Atogepant tablets taken orally, once daily for 52 weeks.
76090118|NCT01457859|Other|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
76090119|NCT01890993|Drug|liraglutide|Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
75940323|NCT05317624|Combination Product|Platelet rich plasma|platelet rich plasma will be obtained from the particepants own blood mixed with activator and bupivacaine
75940324|NCT05317624|Combination Product|Methylprednisolone|1ml methyl prednisolone 40mg\ml mixed with normal saline and bupivacaine
75940325|NCT03482661|Other|magnetic steering|The capsule was controlled to pass through the pylorus by magnet steering.
75940326|NCT05283772|Behavioral|Development of eye tracker for simulation training in nursing|"Purpose: To develop a cost-effective and effective eye tracker for simulation training in nursing in Turkey.~The wearable eye tracker consists of a front camera that will detect the pupil and determine the gaze region of the eye, and glasses or an alternative headband to which these cameras will be connected. A portable mini-computer will be used to process the obtained images. While recording and monitoring the eye movement with the pupil detection camera, real-world images in the user's field of view will be recorded by the front camera and the focal points will be determined. By establishing a linear connection between these found points, temperature (heat) maps will be created at the points where the eye looks."
75940327|NCT03475095|Other|Tuina|Patients will receive Tuina therapies tiwce per week in one month.each time lasts about 20 minutes,a total of 4 weeks.
76090120|NCT02979483|Procedure|Integrative supportive care|"At the inclusion, the investigator determine a personalized program of supportive care procedures for each patient (for instance : treatment of pain and nutritional support,stenting of bile duct and/or duodenum, tumor biopsy for pathologic diagnosis ,..)~At the end on the integrative supportive care, according to the ECOG-PS of patients , they will be classified into two groups:~Group 1 :Good prognosis - ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~- Group 2 : Poor prognosis - ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patients will be treated by: FOLFOX7lightened"
75476258|NCT02005367|Behavioral|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
75476259|NCT02005380|Other|Text-based task|Participants are required to take text-based exercise.
75476260|NCT02005380|Other|Graphic-based Task|Participants are required to take the graphic-based exercise.
75476261|NCT02005406|Device|Experimental group and control groupl|JET
75654451|NCT05764629|Drug|pharmacologic approaches to glycemic treatment|documenting the change of glycemic treatment during the follow-up period
75654452|NCT05757141|Drug|ABBV-CLS-7262|ABBV-CLS-7262 is an eIF2B activator
75654453|NCT05737121|Drug|VNX001|VNX001 (alkalinized lidocaine HCl and heparin sodium)
75965968|NCT02086643|Procedure|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
75654454|NCT05737121|Drug|Placebo|Inactive placebo for VNX001
75654455|NCT05737121|Drug|Lidocaine|Alkalinized lidocaine hydrochloride
75819719|NCT04373434|Behavioral|Control|"Participants in the control condition will receive two mailings on healthy eating, the first from the Dietary Guidelines For Americans 2015-2020, 8th Edition and the second from Choose MyPlate. Additionally, both mailings will include a food diary from the Centers for Disease Control and Prevention. Mailings will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes being targeted in the HH/HF intervention, but without the home environment emphasis. Control group participants will receive their home environment profile with a list of healthy actions upon completion of the study."
75654456|NCT05737121|Drug|Heparin|Alkalinized heparin sodium
75940328|NCT04422340|Other|Group1|"Comorbidities (CIRS-G scale),~Functional status of the patient with~Clinical frailty scale (1 month before infection)~ADL score (1 month before infection)~Biological data~Blood group~TP, D-dimers, CRP, creatinine level at the patient's entry, triglyceridemia, fibrinogen, ferritin~Parameters derived from the platelet formula count on D1 of the start of intensive care (lymphocytes, neutrophils, platelets, average platelet volume, red blood cell distribution index), SYSMEX data (IG: Immature granulocytes; HFLC: high fluorescent lymphocyte count)~Resuscitation outcomes~LDH rate at the start of intensive care~PaO2 / FiO2 ratio at the start of intensive care~IGSII / SASPII score (simplified acute physiology score) on D1 of the start of intensive care~SOFA score (sepsis-related organ failure assessment): a posteriori estimate based on IGSII / SASPII~Delay between the appearance of the first signs of infection and admission to intensive care"
75940329|NCT03475017|Dietary Supplement|Active Comparator: Supplement A|The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
75940330|NCT03475017|Dietary Supplement|Placebo Comparator: Supplement B|The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
75940331|NCT03480555|Dietary Supplement|Replenish Protein|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
75940332|NCT03480555|Dietary Supplement|Standard protein|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
75940333|NCT02674568|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
75940334|NCT05490784|Other|Lee Silverman Voice Treatment BIG|Patients assigned to experimental group will get Lee Silverman Voice Treatment BIG along with conventional treatment.
75940335|NCT05490784|Other|conventional treatment|patients in this group will get conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
75801821|NCT03744416|Other|Counseling based on Epstein's active decision making|"Birth information leaflet. Based on the best evidence practice. Midwives' training on share decision making based on Epstein model. Pregnant intervention. The pregnant women will receive from the midwives the birth plan (BP) in the prenatal check at the health center, between the 24-28 weeks, to be completed at home. Later, on the visit between 29-33 weeks, the midwives will provide the birth information leaflet and carry out the counseling intervention based on shared decision making to the pregnant women. As well, midwives will deliver a second BP that pregnant woman will fill at home. On the prenatal check between 34 to 40 weeks, the midwife will save a copy of the latest BP. The midwife will instruct the woman to deliver the BP when she arrives to the hospital for birth."
75940336|NCT03474939|Drug|Midazolam Oral Tablet|Midazolam Oral tablet
75940337|NCT03474939|Other|Placebo Oral Tablet|Glucose 1000mg tablet night before surgery and 60 minutes before surgery
75940338|NCT03131271|Other|cold application|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
75940339|NCT03163160|Procedure|Pelvic floor manual therapy group|Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
75940340|NCT03163160|Procedure|Pelvic floor electrolysis group|"An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks."
75940341|NCT03474861|Biological|anticancer medication A01; immune cells IC01|"The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded."
75940342|NCT05251480|Procedure|Standard of Care|debridement, wound dressings, offloading
75940343|NCT05251480|Other|DermGEN™|Decellularized human dermal matrix created from donated human skin
75940344|NCT03163550|Drug|ACHN-383|Oral dose
75940345|NCT03163550|Drug|ACHN-789|Oral dose
75940346|NCT03163550|Drug|Placebo|Oral dose
75940347|NCT03131583|Drug|Colchicine|Day-14~Day16 qd
75476262|NCT02005419|Drug|Gemcitabine|Patients receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
75940348|NCT03131583|Drug|Febuxostat|Day1 and Day8 qd
75940349|NCT03131583|Drug|SHR4640|Day3~Day8 qd
75940350|NCT05250622|Other|Japanese-translated evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to Japanese-translated version of evidence summaries.
75654457|NCT05725044|Dietary Supplement|Ginsengberry concentrate|Ginsengberry concentrate
75940351|NCT05250622|Other|English evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to English version of evidence summaries.
75940352|NCT03131349|Diagnostic Test|serum zinc and iron|history ,examination,investigations
75940353|NCT04672928|Drug|paclitaxel|80mg/m^2,iv,Q4W
75940354|NCT04672928|Drug|IBI318|300mg,iv,Q4W
75940355|NCT05249842|Diagnostic Test|Spirometric evaluation|Evaluation of: forced vital capacity (FVC),, FEV1', FEV 1/FVC, FEF 25-75
75654458|NCT05725044|Dietary Supplement|Placebo|Placebo
75654459|NCT05703256|Behavioral|Amygdala real-time fMRI neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
75654460|NCT05703256|Behavioral|Sham feedback|Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
75940356|NCT05249842|Diagnostic Test|Physical component summary|Evaluation of the physical component summary of SF-36 quality of life
75940357|NCT05249842|Diagnostic Test|6MWT|6 minute walk test
75940358|NCT03480477|Other|ACE questionnaire|No intervention is performed, patients will complete BRFSS Adverse Childhood experiences questionnaire
75940359|NCT03162926|Combination Product|VC-02 Combination Product (aka PEC-Direct)|PEC-01 cells loaded into a Delivery Device
75940360|NCT03162848|Behavioral|SystemCHANGE|At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
75343851|NCT05625815|Device|Prototypes (816-v1 101) to (816-v1 150)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75654461|NCT05702983|Drug|STSA-1002 subcutaneous injection|Subjects will receive a single low dose on day 1 following protocol requirements.
75654462|NCT05702983|Drug|STSA-1002 subcutaneous injection|Subjects will receive a single high dose on day 1 following protocol requirements.
75654463|NCT05695599|Device|Whole body vibration training|3 times per week of 20 to 30 minute sessions during 16 weeks of training
75940361|NCT03482427|Behavioral|Healthy Heart Score|Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.
75940362|NCT05317390|Diagnostic Test|DystoniaNet-based diagnosis of isolated dystonia|DystoniaNet will be used for the diagnosis of dystonia and its differential diagnosis from other neurological and non-neurological disorders mimicking symptoms of dystonia
75940363|NCT04805385|Dietary Supplement|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
75343852|NCT05625815|Device|Prototypes (816-v1 151) to (816-v1 200)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
75654464|NCT05695222|Other|This is not an interventional study|This is not an interventional study
75654465|NCT05694494|Behavioral|internet-based Lifestyle-integrated Functional Exercise (iLiFE)|receiving internet-based LiFE training and home safety assessment
75801822|NCT03744338|Other|questionnaire|"The questionnaire is composed of two parts:~The first part let know the characteristics of the patients as age, the BMI, the socio-professional category, the current treatments, the medical-surgical antecedents of interest."
75801823|NCT04223258|Device|Automatic Oxygen control|The CLiO device is integral to the Avea infant ventilator and allows automated OXYGEN adjustment aiming to maintain SpO2 within assigned target range using neonatal pulse oximeter. When first started it adopts the FiO2 previously set by the clinician as the initial 'Baseline FiO2' level. Thereafter, the changes to the FiO2 and their frequency depend on whether SpO2 is below, above or within the target range, the trend in SpO2 and all changes are proportionate to the 'Baseline FiO2' level.
76090121|NCT01457937|Drug|Pegylated Interferon, Ribavirin, Boceprevir|"PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)"
76090122|NCT05023629|Other|Intracoronary balloon inflation|Patients with a significant coronary artery lesion in a proximal coronary segment will undergo intracoronary balloon inflation for 90s prior to PCI.
76090123|NCT05026671|Procedure|Endotracheal Tube Alone|Intubating the trachea with an endotracheal tube alone ( without stylet).
75654466|NCT05694494|Behavioral|upper limb exercise training|upper limb exercise training
75801824|NCT04223258|Other|Manual Oxygen Control|In the manual arm the oxygen is adjusted manually by the clinical team.
75801825|NCT01561950|Drug|eptacog alfa (activated)|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
75801826|NCT01561950|Drug|clopidogrel|Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
75801827|NCT01561950|Drug|placebo|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
75801828|NCT04139018|Drug|Timolol Gel|Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.
75343853|NCT05623319|Drug|Pembrolizumab/Olaparib|Patients will receive pembrolizumab 200 mg 1q21 and chemotherapy -platinum compound (cisplatin 75 mg/m2 or carboplatin area under the curve of 5 mg per milliliter per minute) 1q21 plus etoposide 100 mg/m2 1-3q21- for 4 cycles (Induction Phase). In case of responsive or stable disease, patients will receive pembrolizumab 200 mg 1q21 plus olaparib 300 mg twice daily until progression (Maintenance Phase) or up to a maximum of 35 cycles.
75654467|NCT05689541|Other|Mobile app intervention|"A mobile-based application will be developed to provide parents with a supplemental curriculum that will include games and activities focusing on motor outcomes. The focus of these games and activities will correspond with the adapted horseback riding program's weekly lesson plan. The mobile app will be created with Glide, which allows us to create a mobile application with basic spreadsheet skills.~The mobile app will aim to incorporate 10-12 games and activities designed to improve specific motor outcomes. Parents will be instructed to partake in the app-delivered activities with their children daily for at least 30-45 minutes."
75654468|NCT05688917|Dietary Supplement|Green coffee been extract|supportive treatment
75801829|NCT04139018|Drug|Placebo Gel|Placebo gel is prepared with poloxamers and no active ingredients.
75801830|NCT03748628|Drug|EDP-305|[14C]EDP-305
75940364|NCT05676086|Behavioral|indoor light intervention|"Persons allocated to the indoor light intervention arm will be given a lamp to be placed at home with specific instructions to install it in a room where they spend most of their time, in order to supplement the existing indoor lighting. Thus, all people of the intervention arm will be equipped with the LUMIE Halo lamp. Utilizing both warm-white and cool-white LEDs, Lumie Halo delivers 10,000 lux at 20 cm at maximum brightness in Day Mode. The touch slider allows the user to adjust the brightness while mixing the color temperature of the light."
76090124|NCT05026671|Procedure|Endotracheal Tube+ Stylet|Intubating the trachea with an endotracheal tube + stylet.
75343854|NCT05623189|Drug|HTD1801|HTD1801,1250 mg, BID
75343855|NCT05623189|Drug|Placebo|Placebo, BID
75343856|NCT05615220|Drug|Ecopipam Hydrochloride|Selective dopamine D1 and D5 receptor antagonist
75801831|NCT05206318|Drug|Topical Cysteamine|Topical cysteamine cream applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
75801832|NCT05206318|Drug|Topical Vehicle Control|Topical vehicle control cream without cysteamine active ingredients applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
75343859|NCT05604521|Biological|PfSPZ Vaccine|PfSPZ vaccine consists of radiation-attenuated, aseptic, purified Plasmodium falciparum (NF54) sporozoites (SPZ) cryopreserved in liquid nitrogen vapor phase (LNVP) at -150C to - 196C. PfSPZ Vaccine is composed of PfSPZ derived from the NF54 strain of Pf, which is thought to be from West Africa. PfSPZ Vaccine is diluted in phosphate buffered saline (PBS) with human serum albumin (HSA) to achieve the correct dosage and is administered by DVI.
75654469|NCT05688917|Other|Placebo|Placebo capsule
75801833|NCT04527978|Device|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
75801834|NCT04527978|Device|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
75801835|NCT04136444|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
75801836|NCT05206006|Other|routine care|The choice of the initial antibiotic regimen will be let to the discretion of the emergency physician
75819720|NCT04494568|Device|HIFU treatment|HIFU Treatment of rectal endometriosis
75819721|NCT02176876|Drug|GS-5745|GS-5745 400 mg administered intravenously
75819722|NCT02176876|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
75819723|NCT02179684|Procedure|Baby-sitter surgery N. fascialis|
75819724|NCT02179684|Other|Conventional treatment and follow-up|Patient´s with Bells´palasy are treated with conventional treatment and follow-up
75819725|NCT02179762|Behavioral|moderate exercise intervention|Perform moderate exercise therapy
75819726|NCT02179762|Behavioral|vigorous exercise intervention - standard|Perform HIIT exercise therapy on a standard stationary bike
75819727|NCT02179762|Other|questionnaire administration|Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)
75819728|NCT02179762|Other|laboratory biomarker analysis|Correlative studies
75819729|NCT02179762|Behavioral|vigorous exercise intervention - cybercycling|perform HIIT exercise on cybercycles aided by electronic racing and other games
75819730|NCT02179762|Behavioral|Exercise Logs|The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.
75819731|NCT02179762|Behavioral|Adherence|We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
75819732|NCT02179762|Behavioral|Exercise and body composition test|Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
75819733|NCT02179840|Procedure|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
75819734|NCT02182258|Drug|BIBF 1120 soft gelatine capsule|
75819735|NCT02182258|Drug|BIBF 1120 intravenous solution|
75819736|NCT02182258|Drug|Placebo ampoule|
75819737|NCT02182336|Drug|BI 201335 NA|"480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10~240 mg BI 201335 NA bid from day 11 to 23"
75819738|NCT02182336|Drug|Caffeine|days 1, 10 and 19
75819739|NCT02182336|Drug|Warfarin sodium|days 1, 10 and 19
75940365|NCT05676086|Behavioral|no indoor light|Persons allocated to the control group will receive no indoor light supplementation and will undergo assessment procedures only. Exposure to the outdoor intervention will be taken into account in the analysis in three ways, (1) by locating the distance between people's home and the modified outdoor light, (2) by a question about the awareness of the change in outdoor light, timing, and duration of exposure and what they think of it, and (3) by recording the amount of light exposure over the 24 hours during two weeks at baseline and after the 1-year light interventions
75654470|NCT05674110|Behavioral|DSMES Intervention|This study will provide participants with on-line education, plus weekly text messaging that will contain messages of support or encouragement sent to participants in the individual's preferred language (English or Spanish). Participants will be encouraged to attend monthly group support meetings to review the content and address any questions. Group meetings will occur at 3-time intervals (end of months: 1, 2, and 3). Group support meetings will be held in-person at a food pantry and moderated by peer mentors, nursing students, registered dietitian nutritionist (RDN), and/or a diabetes care and education specialist (DCES). Group support meetings will be held in Spanish and/or English, with no more than 10 participants in a group at one time, and will last approximately 50 minutes. For the duration of the study, participants will continue to receive monthly food items from the food pantry.
75654471|NCT05663658|Other|Intravenous morphine patient control device|24-hour morphine consumption will be recorded
75940366|NCT03474783|Behavioral|Health education|Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
75940367|NCT05513248|Procedure|anatomic lung resection|includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy
75940368|NCT03474705|Device|Eccentric Training Protocol|A custom-built dynamic shoulder dynamometer (Aalborg University, Aalborg, Denmark) will be used. Participants will be seated with back support and no feet support. The maximal voluntary contraction (MVC) of the painful side will be assessed. Sessions will start with a 5-min warm-up. After that, participants will sit in the dynamometer, and the range of shoulder elevation (highest and lowest vertical position) will be measured for the affected side. During training, subjects will have to counteract a dynamometer vertical force from the highest to the lowest shoulder position at a force equal to 60% (training sessions 1-3), 70% (training sessions 4-6), and 80% (training sessions 7-10) of the MVC recorded during baseline. Three bouts of 10 repetitions (sessions 1-3), 8 repetitions (sessions 4-6) and 6 repetitions (sessions 7-10) will be performed, with a 3-second rest between contractions and a 2-minute break between bouts.
75940369|NCT03160820|Biological|Measles, mumps and rubella Combined Vaccine, Live|Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
75940370|NCT03114722|Drug|Citrate 4%|In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
76090125|NCT05026671|Procedure|Endotracheal Tube + Video-laryngoscope|Intubating the trachea with an endotracheal tube + Video- laryngoscope
75343860|NCT05604521|Biological|PfSPZ Challenge (7G8)|PfSPZ Challenge (7G8) is similar to PfSPZ Vaccine but has not been attenuated by radiation and is therefore infectious.PfSPZ Challenge (7G8) is composed of PfSPZ derived from the 7G8 clone of Pf, which is from Brazil.
75343861|NCT05604521|Other|Normal Saline|0.9% sodium chloride
75343862|NCT05604131|Drug|Deferiprone Tablets|Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
75343863|NCT05604131|Drug|Placebo|Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
75801837|NCT05206006|Other|Computerized Decision support app (CDSA)|Implementation of an Computerized Decision support app (CDSA) : physician will use this app to help him in the antibiotic choice. This app is an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics. Secondly, the application is also designed to propose an algorithm of antibiotic revaluation at day 3 for hospitalized patients, depending on patient clinical course, and biological and microbiological results. The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines.
75801838|NCT03754608|Diagnostic Test|MRI including cf-MRI, DTI, ASL and CVR.|A paradigm developed at Yale University called Cognitive Predictive Modelling which takes connectivity data and reduces it to two smaller network which predict higher and lower performance in a particular task for which these networks have been optimized. This will be supplemented by MRI vascular measures.
75343865|NCT05585320|Drug|IMM-1-104 Monotherapy (Treatment Group A)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met
75343866|NCT05585320|Drug|IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met.~Gemcitabine will be administered at a dose of 1000 mg/m^2 nab-Paclitaxel will be administered at a dose of 125 mg/m^2"
75801839|NCT03754530|Drug|Icotinib|orally three times per day
75801840|NCT03754530|Radiation|WBRT or SRS|>3 with WBRT;<=3 with SRS
75819740|NCT02182336|Drug|Vitamin K|days 1, 10 and 19
75819741|NCT02182336|Drug|Omeprazole|days 1, 10 and 19
75819742|NCT02182336|Drug|Dextromethorphan hydrobromide|days 1, 10 and 19
75819743|NCT02182336|Drug|Midazolam HCl solution|Days 3 and 21
75343867|NCT05585320|Drug|IMM-1-104 + modified FOLFIRINOX (Treatment Group C)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met.~FOLFIRINOX will be administered as follows:~Folinic Acid will be administered at 400 mg/m^2 Fluorouracil will be administered at 2400 mg/m^2 Irinotecan will be administered at 150 mg/m^2 Oxaliplatin will be administered at 85 mg/m^2"
75343868|NCT05582395|Drug|Mavacamten|Specified dose on specified days
76090126|NCT05026671|Procedure|Endotracheal tube + stylet with Video-laryngoscope|Intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
75343869|NCT05582395|Other|Placebo|Specified dose on specified days
75343870|NCT05578300|Diagnostic Test|Thrombus analyses|Physical, histology, biochemical or protein expressions of the thrombi obtained from thrombectomy procedures may contain information regarding the etiology of stroke and relevant disease pathology. The investigators shall store the thrombus, if any, yielded from thrombectomy procedures for future analyses.
75654472|NCT05663658|Other|External oblique intercostal plane block|External oblique intercostal plane block will be administered before the surgery.
75654473|NCT05660135|Drug|Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca|Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/10 mg
75654474|NCT05647798|Other|Blood sugar check every 2 hours|Blood sugar check every 2 hours
75343871|NCT05578300|Diagnostic Test|Imaging assessment|All imaging data will be deidentified before assessment. Plain computer tomography of the brain (CT brain), CT angiography (CTA), CT perfusion (CTP), magnetic resonance imaging of the brain (MRI), digital subtraction imaging (DSA) will be analysed. The investigators shall blind the assessors from treatment choice and outcome in all analyses that require human assessment.
75343872|NCT05576922|Other|Prosthetic-surgical approach + autogenous graft|Coronally advanced flap with an autogenous graft (CTG)
75343873|NCT05576922|Other|Prosthetic-surgical approach + graft substitute|Coronally advanced flap with a graft substitute (collagen matrix and rhPDGF-BB)
75654475|NCT05647798|Other|Blood sugar check every 4 hours|Blood sugar check every 4 hours
75801841|NCT05761678|Other|Questionnaire quality of life|"Quantitative - Validated online self-questionnaires scientifically to assess quality of life and support perceived social. Items created for the study concerning socio-demographic characteristics and satisfaction of health services concerning the accompaniment of the transidentity.~Qualitative - Semi-structured interviews based on a guide maintenance."
75343874|NCT05564728|Other|Conversational Agent/Chatbot App|Well Feet is developed based on adaptive learning frameworks to deliver diabetes foot care education through a conversational agent. The learning path for each participant will be customised based on their responses to pre-module quizzes.
76090127|NCT05028699|Other|Snack|Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
75343876|NCT05563844|Drug|PM 8.4 mg/m2|1 case, Take the medicine once on D1,D 1-21.
75476263|NCT02005419|Drug|Metformin|Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
75654476|NCT05644834|Other|I'm Fully Empowered for Her (IFE4Her)|IFE4Her consists of 2 key components: 1) An awareness-raising messaging campaign with messages about PrEP that includes posters and Peer Networkers; and 2) access via a mobile medical unit outreach delivery model linking women in public housing to care from the PrEP providers of a university healthcare system and other complementary screening services (i.e., blood pressure, blood glucose monitoring, and HIV testing).
75654477|NCT05625659|Diagnostic Test|Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)|In addition to their standard, digital breast tomosynthesis mammogram (DBT) performed at their regular screening visits, all participants will also receive a contrast-enhanced spectral mammography (CESM). These same diagnostic tests, both the DBT and CESM, with be repeated at 1 year post study entry for all participants. At year 2 post study entry, all participants will return to their usual breast screening exams and no longer received a CESM.
75801842|NCT03751332|Drug|Tacrolimus|Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
75801843|NCT04425252|Drug|Brequinar|DHODH inhibitor, 100 mg daily x 5 days
75801844|NCT04425252|Other|Standard of Care|Standard of Care per institutional guidelines for COVID-19 patients
75343877|NCT05563844|Drug|PM 11.2 mg/m2|1 case, Take the medicine once on D1,D 1-21.
75343878|NCT05562947|Device|PDS with ranibizumab (100 mg/mL)|Patients randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 uL of the 100-mg/mL formulation of ranibizumab [approximately 2 mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for patients randomized to the intravitreal arm. After the initial fill of the implant with ranibizumab, patients will receive implant refill-exchanges at fixed 24-week intervals.
75343879|NCT05562947|Drug|Ranibizumab (10 mg/mL)|Patients in the intravitreal arm will receive their first intravitreal injection of 50 uL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, patients will receive intravitreal ranibizumab injections of 50 uL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44
75801845|NCT03751254|Device|Stellaris Elite|The Stellaris and the Stellaris Elite platform will be used in myopic patients (axial length > 25.0 mm) during cataract surgery
75801846|NCT05205148|Device|Percutaneous coronary intervention with the following platforms: Orsiro; Mistent; BioMime; Supraflex Cruz|Patients treated with ultrathin coronary stents (namely stents with strut thickness < 70 um) for specific coronary disease scenarios: unprotected left main stenosis; Bifurcation coronary stenosis (with side branch diameter ≥ 2.5 mm); Chronic total coronary occlusion; In-stent restenosis
75801847|NCT01569958|Other|transcranial direct current stimulation|transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
75801848|NCT01569958|Other|Sham stimulation|1 mA stimulation for 30 seconds every 900 seconds per session
75343880|NCT05560971|Dietary Supplement|Palmitoleic acid|Participants will be randomized to either POA or placebo and will be asked to take 2 capsules of the POA or placebo twice a day for 8 weeks.
75343881|NCT05560971|Other|Placebo|Medium chain fatty acids in triglyceride form in capsules with the same shape, color, size and odor of POA capsules
76090128|NCT04346355|Drug|Tocilizumab|In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
76090129|NCT04272255|Drug|scopolamine HBr|Nasal Gel
76090130|NCT04272255|Drug|Transdermal Scopolamine|Patch
76090131|NCT04271787|Other|questionnaire|Questionnaire
76090132|NCT01458015|Drug|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
76090133|NCT02843763|Other|Blood sample|Blood sample (28 ml)
75654478|NCT05619523|Behavioral|Developing Inclusive Youth (DIY)|Developing Inclusive Youth (DIY) is a web-based curriculum tool that serves as the intervention program. The animated and narrated tool displays eight peer social exclusion scenarios in a range of familiar everyday social contexts (such as the playground and school). Children enter their responses while watching the scenarios. Responses include making decisions about inclusion and exclusion, evaluating the actions as okay or not okay, attributing feelings to includers, excluders, and excluded characters, and selecting reasons that best match their justification for their decisions and evaluations. The program includes teacher-guided group discussions following use of the tool in which teachers facilitate discussions about children's interpretations of the scenarios, evaluations, reflections regarding their own experiences of exclusion, and solutions. Participants will view and discuss 8 scenarios and engage in a discussion for each one over the course of 8 weeks.
76090134|NCT01891071|Procedure|Lung volume recruitment|Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
76090135|NCT01891227|Drug|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
76090136|NCT01891227|Drug|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
75343882|NCT05557045|Drug|JZP815|JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.
75343883|NCT05551754|Dietary Supplement|Ketone Supplement|Drink a single dose of ketone supplement 25g
75343884|NCT05551754|Other|Alcohol Beverage|Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%
75654479|NCT05611632|Device|Multi-cancer early detection test (Galleri test)|Blood collection and multi cancer early detection testing with return of positive test results.
76090137|NCT04273113|Other|Difficulties in Emotional Regulation Scale, Five Facet Mindfulness Questionnaire, Becks Depression and Becks Anxiety|Patients asked to complete these 4 questionnaires pre, during and post biofeedback training
75476264|NCT02005419|Drug|placebo|Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
75476265|NCT02005432|Drug|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
75654480|NCT05606263|Drug|Caldonirimab and Nimotuzumab|Subjects will receive caldonirimab (6mg/Kg, q2w) until disease progression or for a maximum of 12 months, and Nimotuzumab (400mg/time, q2w) for a total of 8 cycles
75801849|NCT05204914|Device|Supra glottic airway devices|Using the device in save air way in patients under general anesthesia and the change in the tempromandibular joint will be evaluated
76090138|NCT04273113|Behavioral|HRV Biofeedback (Healing Rhythms)|Sensors placed on fingers to capture heart rate and skin temperature
75343888|NCT05548075|Drug|Psilocybin|Up to 25mg of Psilocybin on 2 occasions.
75343889|NCT05548075|Behavioral|Therapeutic support|Psychological and physical therapeutic support
75343890|NCT05547178|Other|Qualitative interview - eurythmy group|Participants will be interviewed about self-perceived changes in everyday life during participation in the eurythmy intervention of the ENTAiER study.
75343891|NCT05547178|Other|Qualitative interview - tai chi group|Participants will be interviewed about self-perceived changes in everyday life during participation in the tai chi intervention of the ENTAiER study.
75343892|NCT05547178|Other|Qualitative interview - standard care group|Participants will be interviewed about self-perceived changes in everyday life during participation in the standard care group of the ENTAiER study.
75343893|NCT05543252|Drug|Minzasolmin (UCB0599)|Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period.
75801850|NCT03696576|Device|EMST|Training of the respiratory system muscles using the EMST device.
75801851|NCT03696576|Behavioral|PhoRTE|Completing of PhoRTE voice therapy.
75801852|NCT04003610|Drug|Pemigatinib|13.5 mg once a day orally
75801853|NCT04003610|Drug|Pembrolizumab|200 mg Q3W intravenously
75801854|NCT04003610|Drug|Gemcitabine|1000 mg/m^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle
75801855|NCT04003610|Drug|Carboplatin|Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle
76090139|NCT04391439|Drug|Intravenous Methylprednisolone|
76090140|NCT01458483|Device|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
75801856|NCT03754374|Other|access to healthcare|use or non-use of dedicated health facilities
75801857|NCT03754296|Device|CATCHVIEW|Revascularization device
75801858|NCT03744182|Drug|HM15211|A sterile solution of HM15211 contained in pre-filled syringes
76090141|NCT02884245|Drug|Estrogens|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
75343894|NCT05542550|Behavioral|Voice Rest|Voice rest restricting patient phonation
75343895|NCT05542550|Behavioral|No Voice Rest|No Voice rest
75476266|NCT02005432|Drug|panfotocoagulation (PASCAL)|
75476267|NCT02005432|Drug|panfotocoagulation (PRP) single shoot (ETDRS)|
75476268|NCT02005458|Drug|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
75476269|NCT02005458|Drug|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
75819744|NCT02182336|Drug|Midazolam HCl oral syrup|days 1, 10 and 19
75654481|NCT05606172|Behavioral|Primary Care Intervention for PTSD (PCIP) Youth aged 6 -11|This treatment ranges from 1-4 sessions which last 50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the parent or both the parent and child. The first session will also teach the parent and child a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the child's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that the parent and child can learn together. There is also material for parents to address behavior problems in youth. This treatment will be delivered via telehealth.
75801859|NCT03744182|Drug|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
76090142|NCT01891461|Drug|Floseal|Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
76090143|NCT01458717|Drug|Neoadjuvant chemoradiation|"Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~4 weeks rest, re-evaluation for resectability~operation~start maintenance chemotherapy within 4~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
76090144|NCT01458717|Procedure|Upfront surgery|"Operation at time of diagnosis~Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~start maintenance chemotherapy within 4~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
76090145|NCT01891617|Other|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
76090146|NCT01458795|Procedure|Endovenous laser ablation|
76090147|NCT04272567|Drug|Norepinephrine|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.
76090148|NCT04272567|Drug|Normal saline|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
75801860|NCT03999554|Biological|LD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
76090149|NCT01458873|Drug|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
75940371|NCT03114722|Drug|Heparinised saline (10U/ml)|In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
75476270|NCT02005458|Drug|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
75654482|NCT05606172|Behavioral|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
75654483|NCT05599451|Other|THS Blade device|Tobacco Heating System (THS) device with Blade technology for Blade tobacco stick use
75654484|NCT05599451|Other|THS Induction Mono device|Tobacco Heating System (THS) device with Induction technology (combined Charger-Holder device for Induction tobacco stick use).
75654485|NCT05599451|Other|THS Induction Mid device|Tobacco Heating System (THS) device with Induction technology (device with Induction stick Holder for Induction tobacco stick use and separate Charger).
75801861|NCT03999554|Biological|MD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
75801862|NCT03999554|Biological|HD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
75801863|NCT03999554|Biological|LD Bris10 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.
75801864|NCT03999554|Other|Placebo|This group will receive saline placebo administered intranasally.
75819745|NCT02182336|Drug|Digoxin|Days 2 and 20
75819746|NCT02176954|Device|Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
75940372|NCT03474627|Device|Non-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
75940373|NCT03474627|Device|PLGA-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
76090150|NCT01458873|Drug|diluted sodium bicarbonate 2.1%|50ml
76090151|NCT01458873|Drug|normal saline|50ml
76090152|NCT01891773|Behavioral|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
76090153|NCT01459029|Drug|D-serine|Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
76090154|NCT01891851|Drug|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
76090155|NCT01891851|Drug|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
76090156|NCT02831283|Drug|11C-PBR28|11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
76090157|NCT02831283|Drug|18F-Florbetaben|18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
76090158|NCT02831283|Procedure|Lumbar puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
76090159|NCT01459185|Drug|S-1|Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
75654486|NCT05599451|Other|CIG|Subject's preferred brand of commercially available regular (non-mentholated) cigarettes. (Cigarettes are not provided by the study sponsor.)
75940374|NCT03114410|Behavioral|Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17|Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and young parent educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of young parent educators delivered the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth received roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
75940375|NCT03482271|Other|No intervention - data collection only|No intervention - data collection only
75343896|NCT05538650|Behavioral|Mindfulness-Based Social Work and Self Care (MBSWSC)|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory. This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The programme has been the subject of an initial RCT, which has helped to inform the current programme content and structure. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
75476271|NCT02005458|Drug|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
75476272|NCT02005497|Other|HealthLinks|
75654487|NCT05597722|Behavioral|Digital cognitive behavioral intervention-RxWell|RxWell is a coach enhanced digital behavioral health intervention that teaches techniques to help manage emotional distress, which may improve cognitive fog and/or depression. Participants will have access to this app for three months.
75801865|NCT04129346|Behavioral|Fit2ThriveMB App|The Fit2thriveMB app will encourage participants to increase their physical activity. Participants will be provided with educational information on physical activity and effective behavior change strategies for incorporating more physical activity into their daily lives to increase their step count. Participants will be prompted each morning to report the intensity of their symptom burden (0 to 10). Based on their symptom rating and their previous day's step counts, participants will be provided with three different options or levels of goals for that day to either increase or decrease 10-20% or remain constant.
75476273|NCT02005523|Drug|RNS60|
75476274|NCT02005523|Drug|Saline|
75476275|NCT02005575|Drug|Bupivacaine and Dexamethasone|The standard of care is to use a regional block solution containing both decadron and bupivicaine.
75940376|NCT05675852|Other|68-electrode electroencephalography with steady state visual evoked potentials|"Electroencephalography is registered through a 68-electrode electroencephalography while stimuli will be presented at the centre of the screen at a distance of 150cm.~The pattern of visual stimulation is based on the technique of steady state visual evoked potentials. These potentials consist of the presentation of a visual stimulus at a (relatively fast) periodic rate to produce an EEG signal over the occipital cortex exactly at the frequency of stimulation. By varying the value of a parameter of the stimulation (e.g. the contrast of the stimulus) varies. This variation makes it possible to determine the threshold value where an EEG response is perceived, and thus to evaluate visual parameters such as visual acuity, contrast sensitivity or recognition of more complex shapes."
75940377|NCT03474549|Device|Tigertriever revascularization device|Mechanical Thrombectomy
75476276|NCT02005575|Drug|Placebo|
75940378|NCT05313490|Dietary Supplement|Beetroot Juice|7 days of 140 mL per day of beetroot juice
75940379|NCT05313490|Other|Placebo Beetroot Juice|7 days of 140 mL per day of placebo beetroot juice
75940380|NCT03163082|Other|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
75654488|NCT05597722|Drug|Amphetamine-Dextroamphetamine|Participants randomized to this arm will be prescribed 10mg of amphetamine-dextroamphetamine to take as needed to help with cognitive fog. Participants in this arm will be contacted at 2 and 6 weeks to assess for any side effects from taking the medication.
75654489|NCT05555667|Drug|Remimazolam besylate|Sedation drug
75654490|NCT05555667|Drug|Propofol|Propofol. Sedation drug
75654491|NCT05547438|Drug|NTS-104 TRIS|Subjects will receive a single IV infusion of either 0.8, 4, 8, or 16 mg/mL NTS-104 depending on the Cohort number
75940381|NCT03163082|Behavioral|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
75476277|NCT02005588|Drug|amino acid chelated iron|the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
75476278|NCT02005588|Drug|iron salt (ferrous fumarate)|this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
75654492|NCT05547438|Drug|Placebo|Subjects will be administered an IV infusion of placebo and the same duration and volume as the subjects administered NTS-104 TRIS in the cohort
75801866|NCT04129346|Behavioral|Fitbit|The Fitbit measures PA intensity, steps, and heart rate and syncs directly with the smartphone and will automatically sync with the Fit2ThriveMB app and provide Fitbit data to the study team in real-time.
75940382|NCT03163082|Other|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
75940383|NCT03163082|Other|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
75940384|NCT03163004|Behavioral|Implementation of standing desks|Three standing desks will be introduced to the classroom
75940385|NCT03474315|Diagnostic Test|Multivariate assessment|Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
75940386|NCT05246878|Drug|EDP-235|Oral administration
76090160|NCT02826681|Drug|Injectafer® (Ferric Carboxymaltose - FCM)|Intravenous Iron
75343897|NCT05538650|Behavioral|Mindfulness-Based Self-Care (MBSC)|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion/self-care. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
75654493|NCT05534568|Other|Parent-Child Assistance Program|Case managers work closely with mothers over the course of three years, meeting the mothers in their own homes when possible, to help them to set goals and take advantage of available resources.
75654494|NCT05533658|Dietary Supplement|VisionPure Dietary Supplement|Subjects will consume two softgels capsules of the Treatment (VisionPure) once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
75801867|NCT04129346|Behavioral|Physical Activity Coaching Calls|Participants will receive weekly coaching calls which will: a) provide feedback on the previous week's symptom burden and progress on PA goals; b) review personalized goals and strategies for increasing PA for the next week; c) provide instruction on effective behavioral change techniques
76090161|NCT02826681|Drug|Placebo (Normal Saline)|Normal Saline Solution
76090162|NCT01891929|Behavioral|RECOS (COgnitive REmediation for Schizophrenia)|"Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
76090163|NCT01891929|Behavioral|TAU (Treatment As Usual)|"The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
75801868|NCT04129346|Behavioral|Healthy Living Coaching Calls|Participants will receive weekly calls that will cover health and well-being topics for instance: symptom and stress management, healthy diet, hydration, sun safety, sleep hygiene, and meditation.
75940387|NCT05246878|Drug|Placebo|Placebo to match EDP-235, oral administration
75940388|NCT03162770|Behavioral|Mindfulness meditation practice|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
75940389|NCT05245084|Drug|CKD-386(3)|QD, PO
75343898|NCT05536076|Other|Hypercapnia treatment|Intermittent hypercapnia treatment five days per week for two weeks.
75343899|NCT05534243|Other|Standard neuromuscular blocker practices|Usual care neuromuscular blocker in the ED
75343900|NCT05534243|Behavioral|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of shorter acting neuromuscular blockers, and the objectives of the research. Education will include in-services and lectures focused on the importance of neuromuscular blocker protocols on patient outcome. The use of neuromuscular blokers will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based neuromuscular blocker protocols.
75343901|NCT05528861|Drug|Lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
75343902|NCT05528861|Other|Placebo|Placebo
75654495|NCT05533658|Dietary Supplement|Placebo|Subjects will orally consume two softgel capsules of Placebo once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
75654496|NCT05481450|Dietary Supplement|Nutritears®|Strength: Lutein/Zeaxanthin - 20/4 mg; Curcuminoids 200 mg; Vitamin D3 600 IU (Total capsule weight ≈670 mg)
75801869|NCT04129346|Behavioral|Cancer.net app|Cancer.net app content includes information about health and well-being, treatment guidelines specific to cancer type, symptom tracking and medication tracking
76090164|NCT01459263|Device|ClariVein|Using the ClariVein device, the GSV will be occluded.
75940390|NCT05245084|Drug|D013, D326, D337|QD, PO
75940391|NCT03480321|Drug|Cilostazol 100 mg|One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)
75940392|NCT03480321|Drug|PMR 150 mg|Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
75940393|NCT03480321|Drug|PMR 200 mg|Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
75940394|NCT05244616|Other|arabic version of the postoperative Quality of Recovery Score 15|The Arabic version of the Postoperative Quality of Recovery Score 15 to be completed twice by the patients: once preoperatively and once within 24 to 48 hours postoperatively.
75940395|NCT03160664|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
76090165|NCT04390035|Device|Blood Flow Restriction using Delfi Personalized Tourniquet System|Participants assigned to the test group will undergo blood flow restriction training 2 days per week beginning at week 1-2 post-surgery and continuing through week 16 post-surgery using the FDA-approved Delfi Personalized Tourniquet System (PTS) with personalized pressure of 80% of the limb occlusion pressure (LOP). The LOP is the amount of pressure required to fully occlude arterial and venous blood flow to the limb. Otherwise, both the test group and control group will follow a standard 6-month post-surgery rehabilitation protocol which is standard of care for ACLR recovery.
76090166|NCT05022693|Drug|BIO89-100|Subcutaneous Injections
76090167|NCT05029089|Procedure|Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.|Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
75476279|NCT02005614|Procedure|Gamma Knife Radiosurgery|"Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.~Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours."
75476280|NCT02005653|Drug|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
75654497|NCT05481450|Dietary Supplement|Placebo|Soybean oil capsule (Total capsule weight ≈670 mg)
75654498|NCT05463484|Combination Product|Test|Toothpaste including a Saliactive® that is the combination of an olive product, betaine and xylitol.
75654499|NCT05463484|Combination Product|Placebo|Toothpaste with the same composition as the test product but without Saliactive®.
75654500|NCT05463484|Combination Product|Control|Toothpaste marketed for gingivitis with zinc citrate.
75801870|NCT05280626|Drug|Sintilimab|After one cycle of standard R-CHOP chemotherapy, Group A uses Sintilimab with R-CHOP, with Sintilimab administered on day 10 post-chemotherapy, scheduled for 5 cycles. After 5 cycles CR patients in group A continue Sindilizumab treatment for 8 times, once every 21 days.
75801871|NCT05280626|Drug|Rituximab|After one cycle of standard R-CHOP chemotherapy, Group B uses R-CHOP for 5 cycles. After 5 cycles, CR patients in group B are followed up for observation.
75801872|NCT04526574|Biological|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
75801873|NCT04526574|Other|Saline|Normal saline for injection
75801874|NCT04526574|Biological|Influenza vaccine|Seasonal inactivated influenza vaccine (SIIV)
75801875|NCT03993392|Drug|TM buprenorphine|4mg TM buprenorphine, investigator choice as to brand
75801876|NCT03993392|Drug|SUBLOCADE|300mg subcutaneous injection
75801877|NCT04422990|Device|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
75940396|NCT03160664|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
75940397|NCT03160664|Other|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
75940398|NCT04928950|Drug|Activated charcoal|Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
75940399|NCT03160742|Device|Mespere VENUS 200CVP system|Non-invasive sensor placed on the neck
76090168|NCT05029089|Device|Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)|Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.
76090169|NCT05029089|Procedure|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.
76090170|NCT05029089|Procedure|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.
76090171|NCT05029089|Procedure|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft and sCTG For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft and sCTG for regenerative periodontal therapy.
76090172|NCT01459419|Drug|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
75654501|NCT05451888|Behavioral|Spa treatment|A 40 minute period of lying in the spa treatment pool
75654502|NCT05740280|Drug|iCP-NI|20 mg/mL iCP-NI solution for intravenous injection
75801878|NCT04422990|Device|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
75801879|NCT04422990|Device|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
75801880|NCT03743948|Genetic|Non invasive prenatal diagnosis|15 pregnant women and their spouses Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
75801881|NCT03751176|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
75801882|NCT03751176|Drug|Irinotecan|Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
75940400|NCT03160586|Diagnostic Test|Stuttering severity instrument-3|To measure of degree of stuttering in child
75654503|NCT05740280|Drug|Placebo|Placebo solution for intravenous injection
76090173|NCT01459419|Drug|Sodium Chloride placebo|Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
76090174|NCT01892241|Drug|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
76090175|NCT01892241|Drug|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
76090176|NCT04391127|Drug|Hydroxychloroquine|Hydroxychloroquine: 400 mg PO every 12 hours for one day. Subsequently 200 mg every 12 hours per 4 more days.
76090177|NCT04391127|Drug|Ivermectin|Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.
76090178|NCT04391127|Drug|Placebo|Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
76090179|NCT05024253|Drug|Tranexamic acid injection|. TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)
75476281|NCT02005653|Drug|Albendazole|Experimental
76090180|NCT05024253|Other|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
75476282|NCT02005653|Drug|Doxycycline|Experimental
75476283|NCT02005679|Behavioral|application of the mini-mental state test|
75940401|NCT03160586|Diagnostic Test|Child Behavior Checklist for age 4-18|To measure of percent of anxiety in child by ask parents about his or her behaviour
75940402|NCT02523651|Genetic|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
75476284|NCT02005705|Other|Outpatient Management of Low-risk Patients|"Labs will be obtained within 2-3 days of discharge from ED~Clinic visit will be scheduled within 3 days of discharge from ED~EGD will be scheduled within 7 days of discharge from ED~Phone follow-up at day 7 and 30"
75654504|NCT05421754|Device|ANNE Sleep|ANNE Sleep system for 1 night with HST followed by 3 nights of ANNE Sleep system alone.
75801883|NCT03751176|Drug|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
75801884|NCT03751176|Drug|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
75940403|NCT02523651|Other|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
76090181|NCT04390893|Device|ultrasound|Anesthesiologist would scan three planes of the neck to position the LMA
75654505|NCT05411887|Drug|Rosuvastatin, Olmesartan Medoxomil|Olostar Tablet
75654506|NCT05411822|Device|Lighting Intervention Blue light|Custom made lighting fixture that will deliver the blue lighting intervention
75654507|NCT05411822|Device|Lighting Intervention Green light|Custom made lighting fixture that will deliver the green lighting intervention
75654508|NCT05409911|Drug|S-217622|Tablet for oral administration
75801885|NCT04377308|Drug|Fluoxetine|Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
75801886|NCT01562912|Device|Radiofrequency Ablation Procedure|Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.
75801887|NCT01562912|Device|PVAC Ablation Procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
75801888|NCT04447404|Drug|DUR-928|IV infusion
76090182|NCT04390893|Diagnostic Test|air leakage test|Anesthesiologist would use air leakage test to position the LMA
76090183|NCT01892475|Behavioral|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~Accurately predicting step target attainment the following months (SGD10)~Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
75476285|NCT02005705|Other|Inpatient Management of Low-risk Patients|"Labs will be obtained on day of discharge or day 2-3~EGD will be performed in the hospital~Phone follow-up at day 7 and 30"
75476286|NCT02005718|Drug|Cholecalciferol|
75476287|NCT02005731|Device|Low intensity linear focused shockwave device ('Renova')|
75476288|NCT02005744|Drug|CKD-501|CKD-501 0.5mg, PO(per oral), once
75801889|NCT04447404|Drug|Placebo|IV infusion
75801890|NCT03743870|Drug|Levobupivacaine|Levobupivacaine will be spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
76090184|NCT01892475|Behavioral|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
75476289|NCT02005757|Drug|Bredinin tablet 150mg|Bredinin 150mg qd vs Bredinin 50mg tid
75476290|NCT02005757|Drug|Bredinin tablet 50mg|Bredinin 150mg qd vs Bredinin 50mg tid
75476291|NCT02005770|Drug|Sevoflurane|
75476292|NCT02005770|Drug|Propofol|
75940404|NCT03482037|Drug|Rec 0/0438 1 mg or Rec 0/0438 2 mg|Each vial content will be administered via the catheter used for the self-catheterization
75940405|NCT03482037|Drug|placebo|Each vial content will be administered via the catheter used for the self-catheterization
75940406|NCT05313412|Device|Lens A (comfilcon A lens)|6 hours
75940407|NCT05313412|Device|Lens B (lehfilcon A lens)|6 hours
75940408|NCT02986269|Procedure|general anesthesia across LMA|general anesthesia across LMA
75801891|NCT03743870|Drug|Bupivacaine|Bupivacaine has been spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
75940409|NCT02986269|Procedure|Spontaneous breathing(SB)|general anesthesia across LMA under SB without PSV
75940410|NCT02986269|Procedure|Pressure Support Ventilation|general anesthesia across LMA under SB with PSV
76090185|NCT01892553|Device|tDCS|"Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~Cathodal tDCS: Intensity of 1.25 mA during 15 min~Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)"
76090186|NCT01459809|Drug|GLIMEPIRIDE|"Pharmaceutical form: oral~Route of administration: oral"
76090187|NCT01459809|Drug|METFORMIN|"Pharmaceutical form: oral~Route of administration: oral"
76090188|NCT01459887|Drug|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
75343903|NCT05520099|Procedure|Core needle biopsy|"Additional core needle biopsy (CNB) passes will be obtained for tumors amenable to an additional pass that are at least 10 mm in length. If a 16 gauge needle is used for collection, a minimum of 1 additional core needle biopsy pass must be taken. If an 18 gauge needle is used, a minimum of 2 additional passes must be taken. Up to 4 additional passes may be taken with either gauge size for this study as deemed amenable by the clinician. For (suspected) NSCLC patients, an extra CNB will only be taken through metastatic sites amenable to a secondary pass (e.g. liver or lymph node metastases), not through the primary lung tumor to prevent potential complications.~An optional peripheral blood collection will be performed on the same day as the biopsy procedure occurs, ideally prior to the biopsy. 10 mL of blood will be collected."
75343904|NCT05518461|Device|iThrive WI Intervention|Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
75343905|NCT05514730|Behavioral|Phase-based Treatment (PBT) for Problematic Sexual Behavior of Preteen Children|PBT is a skills-based protocol that primarily works with caregivers to manage problematic behavior and to teach children healthy information about sex and sexuality. It was designed based on the current empirical knowledge regarding the etiology and treatment of childhood problematic sexual behavior. It is delivered in 12 weekly sessions, with each session lasting approximately 50 minutes.
75476293|NCT02005783|Drug|DBD|DBD:one dose of medicine twice per day, orally
75476294|NCT02005783|Drug|Epirubicin|Epirubicin:90mg/m2, d1, q3w*4
75476295|NCT02005783|Drug|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w*4
75801892|NCT01562106|Procedure|Fluorescence-guided sentinel lymph node detection|During standard endometrial cancer surgery, ICG dye will be injected into the cervix to identify sentinel lymph nodes in the pelvis.
75801893|NCT03988166|Procedure|Chronic Total Occlusion Revascularization|Teleflex's series of study guidewires and catheters will be used to facilitate the safe and effective crossing of de novo CTOs and placement of conventional guidewires beyond the lesion via either a true lumen or subintimal pathway.
75801894|NCT03988166|Device|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
75940411|NCT03160508|Procedure|Fracture fixation with the TFNA|Fracture fixation with the TFNA
75940412|NCT03474237|Other|Hormone study and Imaging study|"Blood (basal hormone and follow up hormone study)~Imaging examination including computed tomography scan or magnetic resonance imaging"
75940413|NCT05277688|Drug|adjuvant concurrent chemoradiotherapy|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
76090189|NCT01459887|Drug|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
76090190|NCT01892631|Other|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
75476296|NCT02005783|Drug|Docetaxel|Docetaxel:75mg/m2, d1, q3w*4
75476297|NCT02005796|Other|Dietary intervention|
75654509|NCT05398081|Drug|Cefuroxime (Zinnat®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
75654510|NCT05398081|Drug|Ceftriaxone (Rocephin®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
75654511|NCT05364008|Drug|Green Tea Extract|Green tea extract 1650 mg/day (45% EGCG) along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
75654512|NCT05364008|Other|Placebo|Placebo 1650 mg/day along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
75801895|NCT03988088|Drug|Lasmiditan|Administered orally.
75819747|NCT02176954|Device|Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
75819748|NCT02176954|Device|Comparator|"Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed."
75819749|NCT03538132|Other|dental regenerative techniques|dental regenerative techniques
75819750|NCT02182414|Drug|BI 207127 NA (TF-I)|200 mg tablet
75819751|NCT02182414|Drug|BI 207127 NA (TF-II)|400 mg tablet
75819752|NCT02182414|Drug|BI 207127 NA delayed release|400 mg tablet
75819753|NCT02182414|Drug|BI 207127 NA extended release (10% HPMC)|400 mg tablet
75819754|NCT02182414|Drug|BI 207127 NA extended release (15% PEO)|400 mg tablet
75819755|NCT02182414|Drug|BI 207127 NA extended release (20% HPMC)|400 mg tablet
75819756|NCT02182570|Drug|WAL 801 CL dry syrup|
75819757|NCT02182648|Drug|etomidate|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~infusion of etomidate at 2 minutes before anesthesia induction"
75940414|NCT05277688|Radiation|radiotherapy|Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
76090191|NCT01892631|Other|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
76090192|NCT01890057|Drug|Sugammadex|The dose of sugammadex
76090193|NCT01890135|Drug|Zibotentan (ZD4054)|10 mg
76090194|NCT01890135|Drug|placebo|randomized double blind
76090195|NCT02876211|Drug|Paricalcitol|Paricalcitol 2 capsules/three times per week
75343906|NCT05514730|Behavioral|Treatment-as-Usual (TAU)|The TAU intervention designed for this trial relies largely on the delivery of child-focused treatment techniques, particularly on the development of therapeutic rapport through the utilization of non-directive techniques. These sessions are supplemented with educational materials for the caregiver on child behavior and parenting recommendations. This treatment is designed to be administered over 12 weekly sessions, with each session lasting approximately 50 minutes.
75343907|NCT05512390|Drug|ABBV-319|Intravenous (IV); Infusion
75343908|NCT05503264|Drug|Satralizumab|"In Part 1, study drug will be administered after all other study related procedures have been performed at a site visit at Weeks 0, 2, 4, and Q4W thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.~In Part 2, participants will be asked to choose from one of the following options:~Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments"
75476298|NCT02005809|Procedure|second look endoscopy|Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
75654513|NCT05343390|Behavioral|Enhanced implementation package|Individual training with teaching and modeling (tablet-guided, ~8 hours) Small group training with practice and feedback (tablet-guided, ~16 hours) Ongoing continuous quality improvement sessions (tablet-guided, ~2 hours/month)
75654514|NCT05343390|Behavioral|Standard implementation package|Individual training with teaching (facilitator-guided, ~2 hours) Small group practice (facilitator-guided, ~1 hour) Ongoing clinic support (facilitator-guided, ~30 minutes/month)
75654515|NCT05323045|Drug|BYON3521|BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
75654516|NCT05307770|Dietary Supplement|Immediate Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
75654517|NCT05307770|Dietary Supplement|Extended Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
75654518|NCT05307458|Drug|Buprenorphine/naloxone|Participants will receive gradually increasing doses of buprenorphine while tapering down on their methadone dose.
75801896|NCT03987932|Behavioral|NEAT!2|Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.
75801897|NCT03987932|Behavioral|NEAT!2+Calls|Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
75801898|NCT03987932|Behavioral|Delayed NEAT!2|Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
75654519|NCT05275634|Other|Stander treatment|Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).
75801899|NCT03987620|Drug|Ibrexafungerp|Ibrexafungerp 300mg BID for one day
75801900|NCT03987620|Drug|Placebo|Matching Placebo
75801901|NCT03746132|Device|EPIFLO|EPIFLO is a 3 ounce oxygen generator that continuously delivers 3 ml/hr of pure oxygen to the wound site, to enable tissue regenerative processes, thus driving closure of delayed-healing acute or chronic wounds.
75940415|NCT02923401|Other|Exercise|"High-Intensity Interval Training (HIIT) Group: Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.There is a 5-minute warm up, followed by four 4-minute intervals. Between each interval, participant walks for 3 minutes. There is a 3 minute cool down.~Moderate-Intensity Continuous Training (MICT) Group: Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks."
75940416|NCT02923401|Behavioral|Questionnaires|Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
75940417|NCT02923401|Behavioral|Motivational Session|One (1) time each month, participant attends a motivational session for 12 weeks.
75940418|NCT02923401|Behavioral|Phone Call|Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals. Each phone call should take about 15 minutes.
75940419|NCT02923401|Other|Printed Materials|"High-Intensity Interval Training (HIIT) Group and Moderate-Intensity Continuous Training (MICT) Group: Participants receive written materials and instructions on how to perform their exercises.~Control Group: Participants receive written materials and counseling by an exercise physiologist."
75940420|NCT05277376|Drug|Bemotrizinol (6%)|Active sunscreen ingredient (Broad spectrum UV-Filter)
75940421|NCT05259579|Procedure|Anti-reflux mucosal ablation|Mucosal ablation is planned around the cardia on the gastric side in a butterfly shape. Submucosal layer is raised by injecting saline with indigo carmine dye. Mucosal ablation is performed using the triangle-tip knife in spray coagulation mode.
76090196|NCT02876211|Drug|Epoetin beta|epoetin 1-3 times per week
76090197|NCT02876211|Drug|Placebo|Placebo 2 capsules/three times per week
76090198|NCT05587023|Procedure|stellate ganglion block|The experimental group was given 6ml ropivacaine for stellate ganglion block. In the control group, 6ml saline was used for stellate ganglion block.
75343909|NCT05503264|Other|Placebo|Satralizumab placebo PFS is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an NSD and extended finger flange) filled with 0.5 mL of solution, corresponding to 60 mg satralizumab, may be used in Part 2 once it becomes available at the study site.
75654520|NCT05275634|Device|Interferential current with carrier frequency 2 KHz|Interferential current treatment parameters will be as following; carrier frequency 2 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
75654521|NCT05275634|Device|Interferential current with carrier frequency 4 KHz|Interferential current treatment parameters will be as following; carrier frequency 4 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
75654522|NCT05275634|Device|Interferential current with carrier frequency 8 KHz|Interferential current treatment parameters will be as following; carrier frequency 8 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
75654523|NCT05275634|Device|placebo interferential current|Interferential current intensity will not be raised.
75801902|NCT04376060|Device|Gen-Os®; The soft lamina (OsteoBiol®)|"The xenograft used in this study was the Gen-Os® by OsteoBiol; as described by the manufacturer, it is a carbonated nanocrystal bone mineral and collagen of natural heterologous origin, obtained by the treatment of cortical bone tissue of equine origins. Its granulometry ranges between 0.25 to 1 mm and it is described as being slightly radiopaque.~The soft lamina (OsteoBiol®) used is a 35x35mm medium curved membrane of porcine origins. Its clinical indications as described by the fabricator: a co-adjuvant for the reconstruction or the partial or complete recovery of lost bone portions, fillers of non-infected, non-sclerotic and well blood bedewed bone defects."
75654524|NCT05235204|Procedure|Removal of Foley Catheter 2 to 3 days post Colovesical Fistula (CVF) repair surgery|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
75654525|NCT05228834|Drug|Voxelotor Only Product in Oral Dose Form|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants < 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
75654526|NCT05228834|Drug|Placebo|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants < 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
75654527|NCT05202210|Biological|blood and urine sampling|extra sample of blood and urine will be collected
75654530|NCT05154526|Other|Manual Therapy|Manual Therapy: High velocity-low amplitude technique
75654531|NCT05154526|Other|Exercise Program|Exercise program
75654532|NCT05123053|Drug|Amifampridine|10mg tablet
75654533|NCT05117619|Behavioral|HOME for Us|HOME is an in-home, family inclusive, rehabilitation intervention in 8 sessions. Six of the sessions will be in-home and 2 will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
75801903|NCT05204758|Drug|TCM Formula|three packages of TCM preparations with each meal three times a day
75801904|NCT05204758|Drug|Placebo|three packages of placebo preparations with each meal three times a day
75801905|NCT05204524|Drug|Temozolomide for injection combined with epirubicin|Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months.
75801906|NCT05204056|Drug|iced normal saline|Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy
75940422|NCT03357068|Procedure|Control|Control side will receive only perforations on recipient site, which is the conventional technique for bone blocks graft.
75940423|NCT03357068|Procedure|Acid|Test side will receive treatment with citric acid (10%) for 30s at bone block surface and recipient site
75940424|NCT03480165|Drug|Parecoxib 20 MG/ML|1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)
75940425|NCT03480165|Drug|Ropivacaine|19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
75940426|NCT03022799|Drug|KM-819|
76090199|NCT01890213|Biological|AVX701|
76090200|NCT02682147|Drug|Hypoxia administration study group|scan completed after 5 minutes of breathing in hypoxic air
75940427|NCT03022799|Drug|Placebo|
75801907|NCT05204056|Drug|Tranexamic acid injection|20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
75940428|NCT02674334|Device|NIRS|Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline
76090201|NCT02682147|Drug|Hyperoxia administration study group|scan completed after up to 15 minutes of breathing in hyperoxic air
76090202|NCT02682147|Drug|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
76090203|NCT02681601|Dietary Supplement|Nutrawell Powder|"The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
75801908|NCT05204056|Other|Cocktail (composing by Ropivacaine, Morphine and Epinephrine) perfusion|Cocktail was formulated during the operation by mixing Ropivacaine 150mg, Morphine 10mg and Epinephrine 1mg, then normal saline was used to dilute the mixture to 60ml. Then the cocktail mixture was applied for the joint cavity perfusion.
75801909|NCT05203744|Drug|Tafenoquine prophylaxis|"The study will be conducted in three parts with 200 participants invited to participate in the study.~Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose."
75343912|NCT05498025|Other|Deterra activated charcoal pouch|drug disposal pouch
75940429|NCT02674334|Device|NIRS monitored not treated|Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
75343913|NCT05497778|Drug|Gemcitabine|Given by IV (vein)
75343914|NCT05497778|Drug|Nab paclitaxel|Given by IV (vein)
75801910|NCT04413552|Drug|INDV-2000|INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.
75343915|NCT05497778|Drug|IM156|Given by PO
75476299|NCT02005822|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
75476300|NCT02005835|Other|Community based peer support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment"
75654534|NCT05117619|Behavioral|Attention-control condition|The Attention-control condition consists of educational materials presented over 8 contacts. Two of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
75654535|NCT05104125|Drug|ASC40 25mg|25mg of ASC40 orally once daily for 12 weeks.
75654536|NCT05104125|Drug|ASC40 50mg|50mg of ASC40 orally once daily for 12 weeks.
75654537|NCT05104125|Drug|ASC40 75mg|75mg of ASC40 orally once daily for 12 weeks.
75654538|NCT05104125|Drug|Placebo|Placebo orally once daily for 12 weeks.
75654539|NCT05102084|Device|Listening to music with a bluetooth headset to patients receiving CPAP support|Listening to music with a bluetooth headset during the CPAP application to the patients and checking the compatibility on the CPAP device.
75801911|NCT04413552|Drug|Placebo|Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
75940430|NCT05276518|Procedure|Closure of cesarean section incision|"After the delivery the first group will undergo Two Layer Uterine Closure:~Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.~The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa."
75940431|NCT05676866|Procedure|Targeted axillary lymph node dissection|Targeted axillary lymph node dissection is done by marking suspicious node with metallic clip prior to neo adjuvant therapy ,then neo adjuvant therapy is given and after complete axillary response (proved by radiological and clinical examination) , targeted axillary lymph node dissection of clipped node is done along with sentinel lymph node dissection
75940432|NCT05676788|Device|Hyperspectral Imaging|Identification of the intersegmental plane
75940433|NCT05311852|Dietary Supplement|palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)|assumption of the product at dosage of 700/70 mg 2 time/day for 8 weeks
75940434|NCT05311852|Dietary Supplement|Placebo|assumption of a placebo product 2 time/day for 8 weeks
75940435|NCT03026075|Device|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
75940436|NCT01373918|Drug|Intralipid|The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
75940437|NCT01373918|Drug|Intralipid|The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
75940438|NCT05310136|Behavioral|BBTi|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi, sleep diaries, and adherence record. In the end of weeks 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
75343916|NCT05497557|Drug|Omeprazole|Omeprazole will be administered as an oral capsule.
75940439|NCT03474003|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2002 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; RCT conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
75940440|NCT03671915|Device|Continuous Glucose Monitoring|collection of glucose data
75343917|NCT05497557|Drug|Sotorasib|Sotorasib will be administered as an oral tablet.
75343918|NCT05495984|Behavioral|ERPs with electroencephalography (EEG)|E-Prime 2.0 software will present visual and auditory stimuli in an experimental paradigm lasting approximately 30 minutes (ERPs). Visual stimuli will include photographs of color photographs of unfamiliar infants (aged 5- 10 months) balanced for ethnicity (Black/White) and gender (male/female) displaying happy neutral, and sad affective expressions. Auditory stimuli will include 2-second audio clips of high-distress and low-distress infant cries. Experimental procedure: Trials will consist of a central fixation cross (jittered 400-600ms), stimulus presentation (500ms faces, 2000ms cries), and blank screen (1000ms). Continuous electroencephalography (EEG) will be recorded using Net Station 4.2.1. A 128 Ag/Silver Chloride (AgCl) electrode net will be soaked in a warm potassium chloride solution, and net electrodes will be spaced evenly and symmetrically on each participant's head to cover the scalp.
75343919|NCT05495984|Behavioral|MIO|A 12-week, manualized, individual parenting psychotherapy developed specifically for mothers with addictions administered by the Principal Investigator. It is designed to foster a mother's capacity for mentalization or reflective functioning (RF). MIO is offered in conjunction with standard addiction treatment.
75343920|NCT05487235|Drug|GDC-1971|Capsule or tablet administered orally.
75343921|NCT05487235|Drug|Atezolizumab|Administered as IV infusion.
75343922|NCT05487235|Drug|Omeprazole|Administered orally as tablet or capsule in the acid-reducing agent assessment.
75343923|NCT05483140|Other|Option 1|Partial meal replacement to achieve 900-1000 kcal/day (4 meal replacement products per day combined with 150-200 kcal from vegetable meals (recipes provided))
75343924|NCT05483140|Other|Option 2|Partial meal replacement to achieve 900-1000 kcal/day (2 meal replacement products per day combined with one balanced meal (recipes provided))
75343925|NCT05483140|Other|Option 3|A real food low energy diet to achieve 800-1000 kcal/day (recipes provided)
75476301|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment"
75476302|NCT02005848|Biological|Alpha-1 Antitrypsin|
75654540|NCT05100368|Other|patients|Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
75654541|NCT05098405|Drug|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
75801912|NCT03987074|Drug|Semaglutide|Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
75801913|NCT03987074|Drug|Firsocostat|Tablets administered orally once daily
75801914|NCT03987074|Drug|Cilofexor|Tablets administered orally once daily
75801915|NCT05761366|Drug|Al18F-PSMA-BCH PET/CT|Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
75801916|NCT05203666|Other|percutaneous removable interspinous process|percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
75801917|NCT05302466|Device|gymnastics plus silicon dental bite pad|Gymnastics (see below) plus dental bite pads. The dental bite pads TJ Motion (BELY Balance GmbH & Co. KG, Weisendorf, Germany) are made of medical silicone. Accordingly, they are BPA- and latex-free, odourless, tasteless and dimensionally stable. The splints are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise. After use, the splints are rinsed with water and placed dry in the corresponding storage box.
75801918|NCT05302466|Other|gymnastics only|Gymnastics, which are completed daily (7x/week), each consist of three to six exercises and have a total duration of three minutes. The gymnastic programme contain low-intensity exercises from functional gymnastic or physiotherapy.
75801919|NCT05203588|Drug|Denosumab 60 mg/ml Injectable Solution [Prolia]|Denosumab, 60mg(1ml), subcutaneously, totally two times, with one time at 1-week postoperatively and another time at 26-week postoperatively.
75801920|NCT05203588|Drug|calcium and vitamin D|calcium (≥1·0 g) and vitamin D (≥400 IU).
75940441|NCT03671915|Device|External Insulin Pump|Insulin delivery
75343926|NCT05481593|Behavioral|Scheduled Coaching + Gamified Rewards|Participants will receive scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
76090204|NCT02681601|Other|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
75343927|NCT05481593|Behavioral|Scheduled Coaching Calls + Independent Rewards|Participants will receive scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
75343928|NCT05481593|Behavioral|No Scheduled Coaching Calls + Gamified Rewards|Participants will not have scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
75343929|NCT05481593|Behavioral|No Scheduled Coaching Calls + Independent rewards|Participants will not have scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
75476303|NCT02005848|Other|Placebo|Placebo
75476304|NCT02005900|Drug|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART|Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
75801921|NCT05203354|Radiation|Narrowband Ultraviolet B|patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months
75940442|NCT03671915|Device|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
75940443|NCT03671915|Other|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
75940444|NCT03671837|Other|Oxygen|15 L/min O2
75940445|NCT03671837|Other|Air|15 L/min air
75940446|NCT03302195|Drug|Heparin|Based on patient body weight (UI/kg)
75940447|NCT03302195|Procedure|cardiopulmonary bypass pump flow rate|Based on patient body weight (L/min/m2)
75940448|NCT03113786|Other|CLARIX™100|CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
75940449|NCT03113786|Other|CLARIX CORD 1K|CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues & Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.
75940450|NCT03676595|Other|interactive video game-based exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
75940451|NCT03676595|Other|no exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
75654542|NCT05098405|Drug|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
75654544|NCT05060744|Device|Antacid|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
75654545|NCT05060744|Other|Control|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
75654546|NCT05057117|Device|Microwave thermolysis|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
75654547|NCT05057117|Drug|Botulinum toxin A|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
75654548|NCT05051358|Procedure|Therapeutic Endoscopic Ultrasound|Therapeutic Endoscopic Ultrasound or Interventional Endoscopy for Gastrointestinal Indications
75940452|NCT02667626|Other|Reproductive Health Survivorship Care Plan (SCPR)|The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
75940453|NCT02667626|Other|Control|Web-based resource lists and text-based study adherence reminders
75343930|NCT05478538|Procedure|Core needle biopsy|Additional core needle biopsy (CNB) passes from either the primary lung or a metastatic site will be obtained for tumors amenable to an additional pass that are at least 10 mm in length. If a 16 gauge needle is used for collection, a minimum of 1 additional core needle biopsy pass must be taken. If an 18 gauge needle is used, a minimum of 2 additional passes must be taken. Up to 4 additional passes may be taken with either gauge size for this study as deemed amenable by the clinician.
75343931|NCT05474105|Dietary Supplement|Oral nutritional supplement|Daily drink 125 ml together with meal
75654549|NCT05047939|Drug|remimazolam-based TIVA|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
75654550|NCT05047939|Drug|propofol-based TIVA|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
75801922|NCT05203354|Drug|Acitretin|patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months
75801923|NCT04439214|Biological|Nivolumab|Given IV
75801924|NCT05761210|Diagnostic Test|Blood sample collection|Blood sample collection
75801925|NCT03754062|Drug|Placebo - Cap|Administration of Placebo by pill.
75801926|NCT03754062|Drug|L-dopa|Administration of L-dopa by pill.
75801927|NCT03754062|Drug|Haloperidol|Administration of Haloperidol by pill.
75801928|NCT05202886|Diagnostic Test|Liver from deceased donors|Liver donors photographed
75801929|NCT05185960|Other|ALLSWEET®|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be diluted in water.
75801930|NCT05185960|Other|ALLSWEET® and sucrose|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be added to sucrose (table sugar) and diluted in water.
75801931|NCT05185960|Other|Sucrose|Table sugar. It will be consumed by diluting it in water.
75801932|NCT03696342|Drug|Pazufloxacin|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
75801933|NCT03696342|Drug|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
76090205|NCT02681601|Dietary Supplement|OmegaRich fish oil supplement|"OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
75343933|NCT05468424|Other|tablet (iPad or android) based role-playing game|The intervention is a tablet (iPad or android) based role-playing game called FarmVille. In FarmVille the player assumes the role of a farmer tasked with tending to crops and farm animals and using what is produced to craft goods which can be sold to expand the farm. The participant is required to play FarmVille for 5 or more hours a week for 8 weeks.
75343934|NCT05468424|Other|tablet (iPad or android) based word puzzles and image puzzles|"This intervention is a selection of tablet (iPad or android) word puzzles and image puzzles. One word puzzle involves word making (i.e., making words from a set of random letters), and the other word searching (i.e., finding words on a grid of letters). One image puzzle is Flow Free, a game that requires the player to connect pairs of same coloured dots positioned on a grid ranging from 5x5 to 9x9. The other image puzzle is a jigsaw. The participant is required to play these games for 5 or more hours a week for 8 weeks."
75343935|NCT05466799|Drug|FOLFIRINOX chemotherapy|Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer
75343936|NCT05466799|Device|OncoSil™|Implantation of OncoSil 32P microparticles into the Pancreatic Tumour under EUS guidance
75343937|NCT05464966|Drug|Glucose insulin potassium|After induction of anaesthesia,cardiac systolic-diastolic function was first measured by TEE, GIK solution was continuously pumped until the end of the procedure at a dose of 30 mU/kg/h of insulin, 0.12 g/kg/h of glucose and 0.06 mmol/kg/h of potassium chloride
75801934|NCT05184244|Other|Activity Limitation Assessment|The ACTIVLIM-CP scale evaluates the global activity performance and combined movements of the body.
75801935|NCT03753984|Other|Low-level laser therapy|In both arms will be applied Low-level laser therapy and induced muscle fatigue.
75343940|NCT05453695|Drug|Intravenous DNase I|Dose-escalating intravenous infusion of DNase I
75343941|NCT05444699|Drug|Prednisolone Sodium Phosphate|Oral suspension administered 1 mg/kg once a day for three days
75343942|NCT05444699|Drug|Sugar syrup|Oral suspension administered the same amount in milliliters as experimental product once a day for three days
75343943|NCT05431010|Device|electroacupuncture|Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.
75476305|NCT02005926|Procedure|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
75654551|NCT05041608|Procedure|Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
75801936|NCT03753906|Device|Osmed® hydrogel expander implantation|Under local anaesthesia, a small vertical incision, adapted to the diameter of the Osmed® sself-inflating hydrogel expander, was made with #15 scalpel blade at the mesial line angle of the adjacent tooth which started below the gingival margin extending from the keratinized tissue above the MGJ to the non-keratinized tissue beyond the MGJ. A minimally invasive preparation of a subperiosteal pouch was performed with KPA tunnelling knife. Size of the pouch was controlled with the specific surgical template to ensure the device easily fits into the prepared pouch without tension. Expanders were secured in the correct position with a bone fixation screw, at the flat end, which does not possess an expansion capability. The wound was closed with 3-0 silk suture using simple interrupted sutures.
75801937|NCT05761132|Drug|Pembrolizumab|neoadjuvant immunotherapy
76090206|NCT01892787|Drug|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
75476306|NCT02005939|Dietary Supplement|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
75654552|NCT05037578|Behavioral|Project Grace|A multilevel church-based intervention to encourage cognitive screens and brain health.
75654553|NCT04994795|Other|Predictive models (data collection)|Machine learning predictive models
75654554|NCT04981756|Other|observation|This observational study does not have any intervention.
75654555|NCT04926285|Drug|Omacetaxine|Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h
75654556|NCT04926285|Drug|Venetoclax|Venetoclax at 400mg
75654557|NCT04899284|Other|Early Intensive Bimanual Stimulation|Early intensive bimanual stimulation program for infants showing early signs of UCP, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.
75940454|NCT03671681|Behavioral|Mindfulness|The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
75940455|NCT03671681|Drug|Prophylactic|Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
75343944|NCT05431010|Behavioral|Rehabilitation Training|"The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia.~Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load.~Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period"
75343945|NCT05427461|Other|Blood samples will be collected at different times.|"For patients with localized leiomyosarcoma, samples will be collected:~At Baseline.~Before surgery (for patients who have had neoadjuvant treatment (external radiotherapy and/or chemotherapy)).~After surgery.~At each control visit.~At local or metastatic recurrence (or at 24 months post inclusion if no progression).~For patients with metastatic leiomyosarcoma, samples will be collected:~At Baseline.~At each therapeutic line.~At progression (or at 24 months post inclusion if no progression)."
75343946|NCT05419388|Drug|RO7247669|Participants will receive intravenous (IV) RO7247669 Q3W
75476307|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
75343947|NCT05410509|Procedure|Trans-arterial embolization (TAE)|Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.
75801938|NCT05761054|Radiation|RT|"The treatment will be administered in 25 daily fractions (Monday-Friday) at the disease site to include the region of suspected micrometastatic spread (Clinical Target Volume 1, CTV1) at a dose of 50 Gy (2Gy~/ fraction) with SIB intensification on volume reduced corresponding to the interface sites between the tumor and the vascular / nerve axes (Clinical Target Volume 2, CTV2) at a dose of 60 Gy (2.4 Gy / fraction). The association with neoadjuvant chemotherapy based on anthracyclines is allowed."
75801939|NCT04411680|Drug|Sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). Dosage for inhaled sargramostim: 125 mcg twice a day. Dosage for intravenous sargramostim: 125mcg/m2/day given over a 4 hour period.
75476308|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
75654558|NCT04895033|Behavioral|Responsibility condition|During the fMRI scan, participants will complete alcohol purchase task paradigm for hypothetical alcohol rewards under two conditions. In the next-day responsibility condition, we will present a vignette describing a drinking scenario in which participants have a significant activity the next day (e.g., a work, family, or academic obligation the next morning) and participants are asked to imagine they are deciding how much they want to drink in this situation. The control condition will use a vignette describing a typical drinking scenario with no explicit responsibilities the next day
75654559|NCT04867369|Drug|Pecs II block|Patients will receive an interscalene nerve block with 15 mL 0.5% bupivacaine + a Pecs II fascial plane block with 20 mL 0.25% bupivacaine
75654560|NCT04867369|Drug|Surgical infiltration|Patients will receive an interscalene nerve block with 20 mL 0.5% bupivacaine + local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL
75801940|NCT04411680|Drug|Standard of care|Standard of care for COVID-19
75801941|NCT03629392|Behavioral|Low met/cys diet|Dietary intervention with low contents of methionine and cysteine
75801942|NCT03629392|Behavioral|Moderate met/cys diet|Dietary intervention with moderate contents of methionine and cysteine
75801943|NCT03629392|Behavioral|High met/cys diet|Dietary intervention with high contents of methionine and cysteine
75940456|NCT03479853|Procedure|Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
75940457|NCT03676517|Radiation|preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
75940458|NCT05275114|Device|tDCS stimulation with hand task|30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
75940459|NCT05275114|Device|sham tDCS stimulation with hand task|30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
75940460|NCT05676632|Other|Routine Clinical Care|All participants attending the Achilles Tendon Rupture clinic will receive usual clinical care
75940461|NCT03757455|Procedure|ERAS protocol preoperative actions|"First appointment:~- Enlightenment on the benefits and objectives of the ERAS protocol~Call to the patient day before the surgery:~Discussing the course, benefits and goals of care in ERAS 4 dl PreOp drink before bedtime~Operation day:~Fluid intake allowed 2 hours before surgery 2 dl PreOP drink 2 h before cutting"
75940462|NCT03757455|Procedure|ERAS protocol intraoperative actions|"Intraoperative:~Drains in the peripancreatic or perihepatic regions are not set unless the surgeon sees this particular reason The nasogastric tube is removed at the end of the surgery"
75801944|NCT05098756|Other|Art therapy|The art therapy in this study is once a week, 90 minutes each section for a total of 8-week, and using theme-oriented group art therapy. Each section has one theme, and the researcher guides the elderly to make artistic creations. Each section includes a warm-up phase is 15 minutes, the creative phase is 60 minutes, and sharing phase is 15 minutes.
75801945|NCT05760976|Drug|Cisatracurium|Advanced intravenous injection of cisatracurium before the succinylcholine injection
75801946|NCT04974346|Radiation|Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation|The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm.
75940463|NCT03757455|Procedure|ERAS protocol postoperative actions|"Postoperatively:~Mobilization with nurses assisted Drinks allowed after 4h surgery~POP 1:~Drinking and normal food Removal of urinary catheter Intravenous liquids only if needed Mobilization Pain management by epidural cannula Discussion of the ERAS protocol Pancreatin capsules per os before eating~Postoperative day 2:~- Mobilization: As much as possible, autonomous movement~Postoperative day 3:~Ending epidural infusion cannula removal Mobilization as independently as possible~Pain relief: oxycodone/naloxone p.o. to keep mobilization possible:~Postoperative day 4:~Support and encouragement continues Pain management at a level that allows mobility"
75801947|NCT04974346|Radiation|Pelvic definitive concurrent chemoradiation|Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
75801948|NCT04956796|Behavioral|Airway Video Library Training|A video airway library consisting of real-life clinical videos of laryngoscopy and endotracheal intubation was developed by the study investigators. This library consists of video clips of normal and easy airways, pediatric airways as well as pathological or difficult airways that is devoid of patient identifying data. The participants of the study group will be exposed to the video library by two learning sessions. Each learning session consists of 1 hour of interactive & immersive learning of 30 airway videos. At the end of the session, the participants will be oriented to the airway and identify key airway structures, learn to troubleshoot and navigate difficult anatomy, optimize visualization, and use accessory airway equipment.
75940464|NCT03114020|Drug|Hyaluronic Acid Inhalation Solution|twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
75801949|NCT04956796|Behavioral|Conventional Airway Training|The endotracheal intubation training Anesthesiology students currently receive routinely as part of their education.
75801950|NCT04410198|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
75801951|NCT04947202|Device|Hernioplasty|Hernioplasty is the repair of the defect using mesh patches.
75801952|NCT04887766|Device|GS300|Gelesis300 hydrogel in gelatin capsules
75654561|NCT04858854|Other|Sulforaphane, administered as Broccoli sprout extract|Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.
75801953|NCT04887766|Device|Placebo|Placebo capsules
75476309|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
75801954|NCT05457114|Device|Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA)|PAC was inserted and connected to a continuous cardiac output monitor (Vigilance I from 2006 to 2012; Vigilance II from 2012 to 2022, Edward Lifesciences, Irvine, USA)
75940465|NCT03114020|Drug|Placebo Inhalation Solution|Twice a day 3 ml of placebo inhalation solution
75940466|NCT02522728|Device|Triathlon CR|Implantation of Knee Prosthesis
75940467|NCT02522728|Device|Triathlon PS|Implantation of Knee Prosthesis
75940468|NCT04460079|Drug|Peg-filgrastim|PegaGen® was injected as a single subcutaneous dose after completion of cytotoxic chemotherapy
75940469|NCT03113864|Dietary Supplement|Placebo|Daily supplementation for 9 months
75343955|NCT05400369|Drug|Sitafloxacin|Oral administration, 50 mg tablets
75940470|NCT03113864|Dietary Supplement|Lutein|Daily Supplementation for 9 months
75476310|NCT02006017|Other|Evidence summary alone plus a recommendation|
75476311|NCT02006017|Other|Evidence summary alone|
75343956|NCT05400369|Drug|Moxifloxacin Hydrochloride|Oral administration, 400 mg tablets
75343957|NCT05397028|Dietary Supplement|Meal replacement system|Participants will replace meals with a meal replacement system to assess the efficacy of weight loss leading to remission of diabetes (optimal A1C levels).
75343958|NCT05397028|Behavioral|Intensive lifestyle Intervention|Participants will sign up with a virtual health program which they will interact with.
75476312|NCT02006043|Drug|Erlotinib 150mg|
75476313|NCT02006082|Device|Telemedicine video-consultation (TVC)|All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
75476314|NCT02006173|Drug|Lidocaine|Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
75476315|NCT02006173|Drug|Normal Saline|
75654562|NCT04856566|Drug|Low Marijuana, Hash, THC, or Grass|Cannabis with low amount of THC
75654563|NCT04856566|Drug|High Marijuana, Hash, THC, or Grass|Cannabis with high amount of THC
75654564|NCT04856566|Drug|Placebo|Placebo drug with no THC
75654565|NCT04856566|Drug|0.05 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.05
75801955|NCT05457114|Device|FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)|Without PAC, monitoring with FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA) was performed for continuous cardiac output monitoring.
75940471|NCT03479619|Device|Lancing device A|Glucoject Dual Plus lancing device
75940472|NCT03479619|Device|Lancing device B|Droplet lancing device
75654566|NCT04856566|Drug|0.08 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.08
75940473|NCT03479619|Device|Lancing device C|Commercially available lancing device
75940474|NCT03479619|Device|28 G lancet|Droplet 28 G
75940475|NCT03479619|Device|30 G lancet|Droplet personal lancet 30 G
75940476|NCT03479619|Device|33 G lancet|Droplet personal lancet 33 G
75940477|NCT03479619|Other|Lancing depth setting (1)|The lowest depth setting (1)
75940478|NCT03479619|Other|Lancing depth setting (5)|The highest depth setting (5)
76090207|NCT01892787|Drug|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
76090208|NCT01893723|Procedure|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
76090209|NCT01893723|Procedure|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
75476316|NCT02006186|Behavioral|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
75819758|NCT02182648|Drug|propofol|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~infusion of propofol at 2 minutes before anesthesia induction"
75819759|NCT02182648|Drug|sevoflurane|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~inhale sevoflurane for anesthesia induction and maintenance"
75819760|NCT02182726|Drug|MOBEC|
76090210|NCT01453959|Drug|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
76090211|NCT01453959|Other|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
76090212|NCT02669901|Behavioral|Naloxone Auto-Injector|Naloxone auto-injector is the only product FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
75476317|NCT02006199|Behavioral|mindfulness meditation|8 weeks of mindfulness meditation specified for OCD patient
75819761|NCT02179996|Biological|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
75819762|NCT02179996|Biological|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
75940479|NCT03669731|Other|food diary|This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
75940480|NCT03623399|Procedure|low gas pressure laparoscopy|To apply different CO2 entrance and intraoperative pressures
75940481|NCT03473691|Drug|Glembatumumab Vedotin|Standard neo-adjuvant dose-dense doxorubicin 60 mg/m2 and Cytoxan 600 mg/m2 IV every 14 days for 4 cycles followed by GV 1.9 mg/kg IV every 21 days for 4 cycles.
75476318|NCT02006212|Procedure|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
75476319|NCT02006225|Drug|Plerixafor|
75476320|NCT02006238|Device|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
75476321|NCT02006238|Device|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
75476322|NCT02006277|Drug|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
75654567|NCT04854122|Behavioral|Combined exercise intervention|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week. Aerobic exercise will be part of all three sessions, with resistance exercise during two out of three sessions. Training sessions will be supervised by personal trainers to ensure the safe use of the equipment and the correct form when performing each exercise. The first 3 weeks of the intervention will be familiarization with the exercises and the program. After a warm-up, the participant will perform 30 min of aerobic exercise at a heart rate of 65% of the participant's maximum heart rate [43], which increases to 65-85% during weeks 4-12 of the intervention. The resistance exercise part will include all major muscle groups, both upper and lower body.
75940482|NCT03676361|Drug|Desmopressin|Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
75940483|NCT05309278|Behavioral|Physical training|Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
76090213|NCT01755767|Drug|Tivantinib|Tivantinib tablets
76090214|NCT01755767|Drug|Placebo|Matching placebo tablets
76090215|NCT05023707|Biological|anti-FLT3 CAR-T|Single intravenous infusion of anti-FLT3 CAR-T cells
76090216|NCT01893099|Drug|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
76090217|NCT01893099|Device|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
75343959|NCT05389332|Behavioral|Hispanics Skin Cancer intervention|With the insights from the community, the investigators will then develop the mobile intervention targeting Hispanics at risk for skin cancer to promote sun protection and SSE and get feedback to optimize the intervention. After the random allocation participants will receive instructions on how to use WhatsApp and then the intervention. They will receive WhatsApp messages about skin cancer for three months with optimal frequencies determined by prior aims and complete a post-intervention survey which contains the same questions in the pre-survey. The pilot RCT will be conducted around the spring/summer of Year four of the R00 when UVR is generally the highest in the US. The participants will be contacted at six months after the baseline survey to complete another survey similar to the post-intervention survey.
75801956|NCT05280678|Procedure|Orthodontic miniscrew insertion in the mandibular buccal shelf|"Each patient received miniscrews in both sizes. The same orthodontist (M.S.) performed all the insertion procedures. Miniscrews were always placed in the mandibular buccal shelf, laterally to the first and second molar interproximal area, with angulation 30 degree to the bone surface, meaning that miniscrew angulation should be approximately the same as the axial inclination of the adjacent molar. Miniscrews were loaded with orthodontic force 2 weeks after the surgery. The investigated factors were:~long-term success rate of the miniscrews in the buccal shelf of the mandible (miniscrews were considered long-term stable if they served as an anchorage until completion of mandibular distalization, at least 9 months);~peri-implantitis development (enlargement of the gingiva and/or redness and/or tendency to bleed);~the patient's report of pain lasting longer than 48 hours after miniscrew insertion."
75801957|NCT04876300|Other|No intervention|All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place.
75940484|NCT05309278|Behavioral|Cognitive training|These participants will also perform a weekly remote and supervised cognitive training session with neurobic exercises for 1 hour. In addition to the supervised cognitive training session, participants will also be prescribed asynchronous neurobic exercises to be performed on the remaining days of the week (without supervision). The intervention will last for 12 weeks, and all asynchronous neurobic exercises will be recorded in the following synchronous sessions by the supervisor. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
75940485|NCT04459845|Behavioral|Parent Child Interaction Therapy|Parent-child Interaction therapy (PCIT; Eyberg and Robinson, 1982) s a manualized evidence-based behavioral parent training program that integrates social learning and attachment theories. Parents proceed through two distinct phases: Child-Directed Interaction (CDI) resembles traditional play therapy, and Parent-Directed Interaction (PDI) resembles clinical behavior therapy. During all sessions, the therapist coaches each parent in vivo in their use of the CDI and PDI skills with their child.
76090218|NCT05586633|Procedure|deep paravertebral periforaminal ozone injeciton|"Deep paravertebral periforaminal ozone injection was administered to the patients in the ozone injection group 4 times under ultrasound guidance, 10 ug/ml 5ml twice a week in the first week and 15 ug/ml 5ml twice a week in the second week.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
75476323|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
76090219|NCT05586633|Procedure|transforaminal steroid injeciton|"Transforaminal epidural steroid injection group, steroid (dexamethasone 8mg/2ml 2ml) injection was performed under the guidance of fluoroscopy.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
75654568|NCT04854122|Behavioral|Usual care / Sham intervention|The control condition consists of usual activities.
75654569|NCT04849273|Drug|TPX-0131|Oral TPX-0131 tablets
75654570|NCT04837742|Drug|ESPB group|ESPB injection at T10 region with Chirocaine 100mg(20 cc)+ Omnipaque 10cc
75654571|NCT04837742|Drug|Control group|ESPB injection at T10 region with Normal saline 20cc + Omnipaque 10cc
75801958|NCT03750474|Diagnostic Test|magnetic resonance elastography and shear wave elastography|magnetic resonance elastography and shear wave elastography of the back muscles
75801959|NCT05760040|Other|vırtual reality|During the intrauterine device application, 40 women who were included in the virtual reality group will be put on virtual reality glasses and watched the video.
75801960|NCT05760040|Other|Control Group|Routine hospital protocol will be applied to 40 women included in the control group while intrauterine device application is being made.
75654572|NCT04798482|Drug|Dexmedetomidine|Patients will undergo the usual anal manometry study, with no adjuvant medications, per routine practice currently in the gastrointestinal unit. Following completion of manometry, 0.5 mcg/kg DEX will be administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Manometry measurements will be followed for 15 minutes in response to DEX.
75654573|NCT04774250|Drug|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
75654574|NCT04774250|Drug|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
75343960|NCT05389332|Behavioral|Control group: physical activity and nutrition for Hispanics|Content will be developed from established websites such as CDC's Division of Nutrition, Physical Activity and Obesity. We selected these topics because they are also of concern among Hispanics and provide an unrelated attention control.
75343961|NCT05388851|Other|Educational Intervention|Complete educational training module
75343962|NCT05388851|Other|Questionnaire Administration|Complete questionnaire
75654575|NCT04746976|Drug|Diroximel Fumarate|As described in the arm.
75343963|NCT05386680|Genetic|OAV101|Intrathecal administration of OAV101 at a dose of 1.2 x 10^14 vector genomes, one time dose
75476324|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
75476325|NCT02006277|Drug|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
75940486|NCT04459845|Behavioral|Child Parent Psychotherapy|Child-parent psychotherapy (CPP; Lieberman et al., 2005) is a relationship-based treatment that integrates attachment, cognitive-behavioral, social-learning, and psychodynamic theories. CPP focuses on the child-parent relationship as a way to improve the child's adaptive functioning. Various treatment strategies are employed including a focus on safety, affect regulation, the joint construction of a trauma narrative, and engagement in developmentally appropriate activities.
75801961|NCT03753672|Diagnostic Test|preload responsiveness|We investigated whether an increase in CVP ≥ 5 mmHg during PLR predict preload unresponsiveness diagnosed by the absence of increase in velocity-time integral (VTI) of the flow in the left ventricular outflow tract by more than 10%
75801962|NCT03750396|Procedure|Surgical resection|Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.
75801963|NCT03750396|Radiation|Stereotactic body radiotherapy|Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57~97.5Gy/6~10 Fraction).
75801964|NCT03750396|Procedure|Radiofrequency ablation|RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.
75940487|NCT03676205|Biological|PRP|Platelet-Rich Plasma
75940488|NCT03676205|Other|Traumeel|Homeophatic Treatment
75940489|NCT03676127|Other|ultrasonographic dermal thickness measurements|ultrasonographic dermal thickness measurements
75476326|NCT02006277|Drug|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
75476327|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
75476328|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
75476329|NCT02006277|Drug|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
75654576|NCT04736056|Behavioral|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
75654577|NCT04732962|Device|AposHealth|"AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately."
75801965|NCT04670848|Device|Sleepiz One+ vs. polysomnography|Simultaneous sleep recording with polysomnography and Sleepiz One+ device
75801966|NCT04660864|Device|Nasal cavity cooling device.|The RhinoChill® system cools by intranasal evaporation of a liquid coolant sprayed onto the surface of the nasal cavity. The RhinoChill® system is intended for use for the relief of pain and symptoms associated with acute migraine attack.
75801967|NCT03750942|Device|Adhesix® monofilament polypropylene mesh (Bard Davol)|The intervention group will receive preventive mesh placement and in the control group no mesh is placed, the stoma is closed according to standard practise.
75801968|NCT03747978|Drug|Perindopril and Amlodipine|Fixed combination of Perindopril 5mg and Amlodipine 5mg
75801969|NCT03747978|Drug|Perindopril-indapamide|Perindopril 5mg and Indapamide 1.25mg
75801970|NCT04603846|Drug|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
75801971|NCT04603846|Drug|albumin bound paclitaxel|Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .
75801972|NCT03750162|Device|VDW Ultra|supplementary disinfection technique
75801973|NCT03750162|Device|AMD picasso|supplementary disinfection technique
75801974|NCT03750162|Device|ProtaperNext X3 gutta-percha|supplementary disinfection technique
75801975|NCT03747900|Drug|Botulinum Toxin Type A|200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
75940490|NCT03481803|Drug|MS1819-SD|Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.
75940491|NCT02523417|Procedure|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
75940492|NCT01712763|Drug|degarelix|180 women will be treated with degarlix 80 mg, in only one administration covering three months
75940493|NCT01712763|Drug|goserelin|180 women will be treated with decapeptyl 3.6 every month for three months
75940494|NCT05237518|Device|EarlySense Noomi system|The EarlySense device is intended for continuous contact-free monitoring of heart rate and respiration rate at home, or in professional healthcare settings. The system is intended for remote monitoring of patients by healthcare professionals and is indicated mainly for elderly population monitoring.
75940495|NCT04458519|Other|Probiorinse|Nasal irrigations with probiotic twice-daily for a period of fourteen days
75940496|NCT04458519|Other|Saline solution|Nasal irrigations with saline-only twice-daily for a period of fourteen days
75940497|NCT02523183|Drug|Medical Cannabis|Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
75940498|NCT05218486|Drug|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
75476330|NCT02006277|Drug|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
75476331|NCT02006290|Drug|PF-06412562|single oral split dose 30+20 mg QD
75476332|NCT02006290|Drug|Placebo|tablet, matching placebo, QD
75940503|NCT03251183|Diagnostic Test|Comprehensive Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
75940504|NCT03251183|Diagnostic Test|Blood sampling|Blood samples will eventually be analysed for markers related to heart failure (BNP/NT)-pro-BNP, myocardial inflammation and fibrosis (cytokine profiling, Galectin-3, Procollagen Type I and III, hsCRP). Whole blood will be frozen for DNA isolation and genome analysis. Peripheral blood mononuclear cells will be isolated by Ficoll in a subset of patients and will be used for RNA isolation allowing RNA-seq or reverse transcription (RT) - polymerase chain reaction (PCR) analysis.
75654578|NCT04732962|Procedure|Total Knee Replacement (TKR)|A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
75940505|NCT03251183|Diagnostic Test|TTE (EchoErgo)|Measurements will include cavity dimensions, flow velocities, myocardial motion velocity and strain as well as for change of parameters during ergometric stress.
75940506|NCT03251183|Diagnostic Test|Invasive pressure-volume (PV) Loops|Multiple parameters (including EDPVR, ESPVR, dp/dt min, Tau, Ea) will be derived from the various PV loop assessments and additional relevant parameters will be calculated. Right ventricular and pulmonary pressures including pulmonary vascular resistance will be measured with Swan-Ganz catheters using right venous femoral approach.
75940507|NCT03251183|Diagnostic Test|Left ventricular (LV) biopsy|"A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).~A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status."
76090220|NCT02327403|Drug|Belatacept|Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.
76090221|NCT02372877|Device|Amicus Red Cell Exchange in SCD patients|Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
76090222|NCT01893177|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
76090223|NCT01922050|Drug|LEO 43204 Formulation 1|
76090224|NCT01922050|Drug|LEO 43204 Formulation 2|
75801976|NCT03747900|Combination Product|Botulinum Toxin Type A and dry needling.|Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
75801977|NCT04578106|Biological|Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination|After 13 weeks of neoadjuvant treatment, a breast MRI will be performed. If a complete response is observed on breast MRI, patients will undergo a stereotactic-guided VAB of the marker area to obtain 12 cylinders of breast parenchyma, which is equivalent to 2 grams of tissue. If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB, patients will be eligible to omit loco-regional surgery.
75801978|NCT03747822|Procedure|fat filler,PEEK,sliding genioplasty|The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.
76090225|NCT01922050|Drug|LEO 43204 Formulation 1 Dose X|
76090226|NCT01922050|Drug|LEO 43204 Formulation 1 Dose Y|
76090227|NCT01922050|Drug|LEO 43204 Formulation 2 Dose XX|
76090228|NCT01922050|Drug|LEO 43204 Formulation 2 Dose YY|
76090229|NCT01922050|Drug|Placebo Formulation 1|
76090230|NCT01922050|Drug|Placebo Formulation 2|
76090231|NCT02655393|Dietary Supplement|Mitopure|
76090232|NCT02360943|Other|4 blood samples|PK and / or PD measurements during hospitalization
75476333|NCT02006303|Procedure|Green light PVP|The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
75654579|NCT04703192|Drug|Valemetostat Tosylate|Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
75654580|NCT04669457|Drug|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
75801979|NCT04472182|Drug|Fluoride varnish with xylitol coated calcium and phosphate|Fluoride varnish with xylitol coated calcium and phosphate
75801980|NCT04423744|Drug|BAY1817080|Film-coated tablet
75801981|NCT04423744|Drug|Moxifloxacin|Film-coated tablet
75801982|NCT04423744|Drug|Placebo|Matched placebo as film-coated tablet
75801983|NCT01562652|Device|AposTherapy (All Phases of Step-cycle {APOS} system, APOS-Medical and Sports Technologies Ltd. Herzliya, Israel)|
75940508|NCT05216770|Other|Brain imaging|Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers
75801984|NCT04884204|Behavioral|Lee Symptom Scala|Symptom identification and management with Lee Symptom Scale in follow up care
75801985|NCT05759416|Drug|Melatonin2%gel|Intra-pocket application of 2% Melatonin gel
76090233|NCT01922986|Device|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
76090234|NCT01922986|Device|sham rTMS|20 minutes of sham rTMS stimulation
76090235|NCT01922986|Behavioral|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
75801986|NCT05759416|Drug|PLACEBO|placebo intra-pocket application
76090236|NCT05740150|Device|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
75343964|NCT05378035|Diagnostic Test|Blood Tests|Eligible subjects will receive additional blood tests for determination of DOAC levels and pharmacogenomic studies. Participants shall undergo DOAC level testing at peak, trough, 24, and 48 hours after discontinuation of DOAC for elective medical procedures. We shall also record their baseline demographics, clinical assessments, medical comorbidities, blood parameters, and concurrent medications. We shall minimize the blood taking by combining DOAC levels and blood tests essential for routine medical consultation and pre-procedural workup. Blood taking will only be performed by clinicians or phlebotomists who are experienced in the procedure.
75654581|NCT04669457|Drug|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
76090237|NCT05740150|Device|Heparin lock (heparin 100 IU/mL)|The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
76090238|NCT02359383|Other|Chest physiotherapy|Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
76090239|NCT05734612|Drug|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
76090240|NCT05734612|Drug|Placebo (lactose)|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
75343966|NCT05368870|Procedure|Carlevale implantation|Vitrectomy and Carlevale implantation
75343967|NCT05364021|Drug|LP352|LP352 administered three times daily, orally or through G-tube
75343968|NCT05364021|Drug|Placebo|Matching placebo for LP352 administered three times daily, orally or through G-tube
75343969|NCT05362760|Drug|Abemaciclib + Aromatase Inhibitor|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
75476334|NCT02006303|Procedure|Prostatic artery embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
75476335|NCT02006316|Procedure|Microsurgical subinguinal varicocelectomy|
75476336|NCT02006329|Device|acupuncture|
75476337|NCT02006355|Drug|Ropivacaine|
75476338|NCT02006368|Other|Blood Collection and autologous re-infusion|"Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.~After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated."
75476339|NCT02006394|Dietary Supplement|Fish Oil|fish oil capsules
75654582|NCT04647851|Other|Remote exercise intervention Down syndrome|See arm description
75801987|NCT04386538|Behavioral|Low Starch Diet (LSD)|6-week balanced diet program, adapted to individual energetic needs, with significant reduction of high content starchy food, naturally present in plant cells, roots, tubers, seeds, beans, legumes, fruits, and highly present in most farinaceous grains, especially in potatoes, corn, rice, pasta, bread, cookies and cakes.
75801988|NCT04386538|Behavioral|General healthy eating|6-week balanced healthy eating counseling program, according to the World Health Organization recommendations.
75801989|NCT03746340|Drug|Propofol|Propofol group: intravenous Propofol (2.0mg / kg) for general anesthesia induction, maintained for 30~60s. Continuous intravenous infusion of Propofol (7~8 mg·kg-1·h-1) with a syringe pump maintains a smooth general anesthetic sedative effect.
75801990|NCT03746340|Drug|Sevoflurane|Sevoflurane group: Inhalation of 1-8% sevoflurane for induction.Then Inhalation of sevoflurane (2.0~2.5Vol%) was maintained
75940509|NCT05216770|Drug|Laryngeal sensory block with topical bupivacaine|Laryngeal sensory block with bupivacaine will be used to modulate sensory feedback from vocal fold mucosa and examine the impact of sensory feedback on abnormal neural activity in LD and VT
75940510|NCT03675971|Drug|Cannabinol|Postoperative pain treatment
75940511|NCT03675971|Drug|Placebo oral capsule|Placebo comparator
76090241|NCT02349867|Drug|Gemcitabine|Given IV
76090242|NCT02349867|Drug|Sorafenib|Given PO
76090243|NCT02349867|Drug|Vorinostat|Given PO
76090244|NCT02349867|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
76090245|NCT02349867|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75801991|NCT04873206|Other|routine stain by H&E.|formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.
75801992|NCT05758480|Biological|Blood sample (at inclusion and 6 months later)|(56ml of blood, 8 tubes) 3 heparin, 1 EDTA , 2 SST, 2 CPT
75343970|NCT05362760|Drug|Abemaciclib + Fulvestrant|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
75940512|NCT05236270|Behavioral|Text Message|Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
75940513|NCT05236270|Behavioral|Motivational Interviewing|Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
75940514|NCT05236270|Behavioral|Electronic Educational Message with Tailored Questions/Prompts|Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
75343971|NCT05357105|Other|Numerical Pain Scales|Patients who are about to receive regional nerve blocks will be administered a numerical pain scale (NRS) before, during and after the offset of the nerve block.
75343972|NCT05356104|Drug|Exenatide extended release|2mg once weekly via subcutaneous injection
75343973|NCT05355753|Drug|CFT8634|Oral dose of CFT8634
75343974|NCT05354778|Drug|Hydrocortisone|Corticosteroid
75654583|NCT04644276|Device|Mask with Mask Adhesive/Arm 1|Patients will be randomized to Arm1 if they receive the mask adhesive and mask on the first study night then the mask without the mask adhesive on the second study night.
75343975|NCT05354778|Drug|Placebo|Normal saline only
75343976|NCT05353985|Drug|TAK-062|TAK-062 tablets.
75343977|NCT05353985|Dietary Supplement|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar|SIGE gluten bars.
75654584|NCT04644276|Device|Mask without Mask Adhesive / Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then the mask adhesive with the mask on the second study night.
75654585|NCT04633980|Drug|Mixture 3,6% H2 in N2 (96.4%)|Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
75654587|NCT04566432|Other|Observation|observe the association of ctDNA with efficacy of treatment
75801993|NCT05758480|Other|Patient questionnaires (at inclusion and 6 months later)|(4 questionnaires) Symptoms in the last week, Fatigue Impact Scale (FIS), Short-Form 36 (SF-36) and Nijmegen.
75801994|NCT04222816|Drug|Lithium Carbonate|Lithium carbonate 800-900 mg orally daily for 12 weeks
75940515|NCT05236036|Drug|Mycophenolate Mofetil|Given PO
75343978|NCT05353985|Drug|TAK-062 Placebo|TAK-062 placebo-matching tablets.
75343979|NCT05353985|Dietary Supplement|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar|SIGE gluten-free bars.
75801995|NCT04222816|Drug|Sodium chloride|Sodium chloride 1gm daily per orally for 12 weeks
75654588|NCT04537715|Drug|Tazemetostat|A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.
75654589|NCT04537715|Drug|Itraconazole|Oral 200 mg itraconazole once daily on Days 18 - 38
75801996|NCT04161144|Drug|sirolimus|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
75801997|NCT04161144|Drug|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
75801998|NCT03747744|Other|CD1c (BDCA-1)+ myDC|Intratumoral injection in subcutaneous, cutaneous, soft tissue metastases
75940516|NCT05236036|Other|Quality-of-Life Assessment|Ancillary studies
75801999|NCT04823364|Other|Neurotransmitters evaluation by MRS|Baseline MRS screening for volunteers and ADHD groups and repeated measurement for ADHD group after taking stimulant drug treatment
75802000|NCT03750084|Other|questionary|The intervention consists of a digitally distributed questionary.
75802001|NCT03984812|Drug|GSK3732394|It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL
75802002|NCT03984812|Drug|Placebo|Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.
75802003|NCT03743714|Other|yoga treatment; flexibility, balance and strength exercises.|yoga treatment including flexibility exercises, balance exercises, and strength exercises.
75476340|NCT02006394|Dietary Supplement|Polyphenol Capsules|delphinidin polyphenol capsules
75476341|NCT02006394|Dietary Supplement|Corn Oil Capsules|Corn Oil Capsules
75476342|NCT02006394|Dietary Supplement|Corn starch capsules|Maltodextrin capsules
75476343|NCT02006394|Other|Reduced glycemic index bread products|Made by Zone Labs
75476344|NCT02006394|Other|Market variety bread products|placebo bread products
75476345|NCT02006433|Device|Deep Brain Stimulation|Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
75940517|NCT05236036|Radiation|Radiation Therapy|Receive radiation therapy
75940518|NCT05236036|Drug|Temozolomide|Given Orally (PO)
75940519|NCT02781779|Device|Silverlon®|Silverlon wound dressings
75940520|NCT02781779|Device|AQUACEL® AG|AQUACEL® AG wound dressings
75940521|NCT05270200|Drug|Azacitidine|Patients will recieve six courses of azacitidine 100mg through a needle under skin on Days 1-5.Each course is 28 days long.
75940522|NCT05270200|Drug|Chidamide|Patients will recieve oral chidamide 5mg per day for no more than 2 years.
75940523|NCT03025217|Behavioral|Total Lifestyle Coaching (TLC)|
75940524|NCT03671135|Other|TCA Intrastromal Inlay|Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
75940525|NCT03671057|Device|HospiAvontuur|To be included in the study children should play the game at least one time together with one parent
75802004|NCT04764630|Drug|Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min
75940526|NCT03671057|Drug|Midazolam|current practice in Jessa
75940527|NCT03669575|Dietary Supplement|omega 7|Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
75940528|NCT03669575|Dietary Supplement|Placebo|Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
75940529|NCT05166850|Behavioral|PICHA7 mHealth program|The PICHA7 mHealth program is first delivered during a health facility visit by a health promoter bedside to a diarrhea patient (adults and child) and their accompanying household members during the time of illness followed by two home visits during the 7-day high risk period for diarrheal disease transmission. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A diarrhea prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After health facility delivery of the program, patient households receive weekly voice and text messages from the PICHA7 mHealth program over 12 months on the recommended WASH behaviors.
75940530|NCT05166850|Other|Standard Arm|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
75940531|NCT03675659|Drug|intra-articular injection|intra-articular injection with magnesium sulfate with four injections at weekly intervals
75343988|NCT05336227|Behavioral|Virtual Reality Exergaming|The VR intervention will include home-based exercise using the Oculus Quest, a heart rate monitor (Polar OH1), BP cuff, and mobile application. The games will include rhythmic movements to music and sport/recreation activities that elicit high energy expenditure. Participants will be instructed to reach 150 minutes per week of moderate-exercise in week 1 and maintain this volume across the 12-week intervention. The intervention will include behavioral, physical education coaching through videoconference, which we refer to as Tele-PE. Tele-PE will aim to enhance adherence, provide basic exercise knowledge, and increase mastery playing the games. Calls will last 15 minutes, and be provided weekly in month 1, bi-weekly in month 2, and one call at the end of month 3.
75343989|NCT05332262|Diagnostic Test|Assessment of platelet reactivity|Assessment of platelet reactivity and HPR status will be performed post-PCI. Platelet reactivity will be measured by VerifyNow P2Y12 and HPR status will be defined using a cut-off value of platelet reactivity units (PRU)>208.
75476346|NCT02006485|Drug|Ublituximab + TGR-1202|Ublituximab IV infusion TGR-1202 oral daily dose
75654590|NCT04537715|Drug|Tazemetostat|A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.
75654591|NCT04537715|Drug|Rifampin|Oral 600 mg rifampin once daily on Days 17 - 25.
75654592|NCT04532528|Drug|Dabigatran|Dabigatran
75654593|NCT04528992|Other|Blood Flow Restriction Therapy|BFR is a rehabilitation method that involves wearing a tight band around the exercising extremity to briefly limit blood flow while doing light weight exercises. The response is similar to heavy weight training or lifting but without the stress on the extremity that is still healing from surgery. Will be given after 2 weeks standard postoperative physical therapy per surgeon's ACL reconstruction protocol following surgery.
75654594|NCT04528992|Other|Standard Postoperative Physical Therapy|This is the surgeon's standard postoperative physical therapy protocol after ACL reconstruction.
75654595|NCT04463225|Other|Internet-Delivered Brief Intervention|The internet-delivered brief intervention developed for the study can be accessed via computers and mobile devices.. The intervention will employ assessment data to give study participants feedback on their drinking behavior and offer strategies to avoid risky behavior.
75654596|NCT04427956|Procedure|Corneal crosslinking: CXL (UVA 9mW/cm2)|CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.
75654597|NCT04427956|Drug|Isotonic riboflavin|CXL protocol with isotonic riboflavin
75654598|NCT04427956|Drug|Hypotonic riboflavin|CXL protocol with hypotonic riboflavin
75654599|NCT04427956|Procedure|Iontophoresis|CXL protocol with iontophoresis and ricrolin
75654600|NCT04427241|Drug|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
75654601|NCT04427241|Drug|Control|100 ml normal saline, days 4-17, once/day, IV
75654602|NCT04410731|Drug|Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy|Single bilateral intra-articular injection of manufactured cell cultured expanded allogeneic BM-MSCs for painful lumbar facet joint arthropathy
75654603|NCT04385498|Behavioral|BREATHE Intervention|5 session program focusing on breathing retraining, psychoeducation, and positive coping.
75654604|NCT04385498|Behavioral|Waitlist Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm. At the end of the trial Participants will be able to receive the BREATHE Ethiopia treatment.
75654605|NCT04380116|Device|Soberlink|Soberlink is a comprehensive alcohol monitoring system designed to remotely monitor a person's Blood Alcohol Concentration (BAC). Combining a professional grade handheld breathalyzer with wireless connectivity, the technology includes real-time facial recognition, robust tamper detection and real-time alerting.
75654606|NCT04360005|Drug|Asciminib|Asciminib 20 or 40 mg strength tablets will be administered orally twice-daily, without food
75654607|NCT04335643|Behavioral|TEACH|TEACH is a remotely delivered psychological intervention. It consists of six one-hour weekly sessions that are HIPAA compliant and conducted over video conferencing.
75802005|NCT04764630|Drug|Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
75802006|NCT04764630|Drug|Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
75802007|NCT03745976|Procedure|questionnaire and Xray for all patients|questionnaire and Xray for all patients
75802008|NCT03748394|Behavioral|Work-directed rehabilitation|Each participant starts with a meeting together with an occupational therapist or a physical therapist, focusing on the participant's resources and obstacles for functioning well at work. A plan is designed and carried out over 8 weeks, including 1-4 different treatment modules of occupational and physical therapy, to support the person's ability to function at work
75802009|NCT03748394|Behavioral|Physical activity|In a meeting with a physical therapist, each participant receives advice on physical activity to support mental health, according to national recommendations. The participant is offered to train at a local gym during 8 weeks.
75343990|NCT05332262|Diagnostic Test|Troponin measurement|Measurement of high sensitivity troponin for the assessment for the presence of myocardial infarction/myocardial injury will be performed post-PCI.
75343991|NCT05329194|Drug|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab.
75940532|NCT05234398|Biological|Blood and saliva samplings|At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.
75343992|NCT05328908|Drug|Nivolumab-relatlimab FDC|Specified dose on specified days
75654608|NCT04315701|Biological|Cemiplimab|Given IV
75940533|NCT03670979|Procedure|bone swaging|osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone
75940534|NCT05234320|Drug|CG-SpikeDown, intranasal formulation|The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
75940535|NCT05234320|Drug|Vehicle (Placebo)|patients will receive active drug or placebo in addition to standard of care
75654609|NCT04315701|Procedure|Resection|Undergo surgical resection
75654610|NCT04240093|Behavioral|Behavioral Activation (BA) Therapy|8 sessions of behavioral activation therapy
75654611|NCT04240093|Behavioral|Substance Abuse and Health Navigation Counseling|2 standard substance abuse and health navigation counseling
75802010|NCT04153188|Device|The Vbeam® Prima System|3 monthly Vbeam® Prima PDL treatments with a 3-day washout of topical Oxymetazoline HCL 1% cream before each treatment.
75802011|NCT04153188|Drug|Oxymetazoline HCL 1% Cream|Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
75802012|NCT04113746|Behavioral|Better asthma self-management and incorporation of physical activity|Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
75802013|NCT04113746|Behavioral|Asthma Education|General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
75802014|NCT03747666|Procedure|2.0 single locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates placed on the inferior border of the mandible.
75802015|NCT03611010|Drug|Atorvastatin injection|statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
75802016|NCT03749850|Drug|LTLD|"Patients will receive up to six cycles at three-weeks intervals of:~Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol."
75940536|NCT05234320|Drug|Standard of core (type of therapy is depend of decide of the site)|patients will receive active drug or placebo in addition to standard of care
75940537|NCT03670901|Biological|JHL1101|JHL1101, 100mg/10mL
75343993|NCT05328908|Drug|Regorafenib|Specified dose on specified days
75343994|NCT05328908|Drug|TAS-102|Specified dose on specified days
75654612|NCT04240093|Other|Medications for Opioid Use Disorder|Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
75654613|NCT04180696|Device|aCRT ON|CRT device with AdaptivCRT enabled
75343995|NCT05322122|Device|Side-to-side anastomosis duodeno-ileostomy diversion procedure|Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.
75654614|NCT04180696|Device|aCRT OFF|CRT device with AdaptivCRT disabled
75654615|NCT04115774|Drug|bisphosphonates|Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
75654617|NCT04093557|Other|Orton Score|Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.
75654618|NCT04093557|Other|Typical Standard of Care|Clinician usual practice of prescribing bowel preps to patient
75654619|NCT04025359|Drug|Dronabinol|Dronabinol 2.5 mg
75654620|NCT04025359|Drug|Dronabinol|Dronabinol 5 mg
75654621|NCT04025359|Drug|Placebo|Placebo
75940538|NCT03670901|Biological|MabThera|Rituximab, 100mg/10mL
75940539|NCT03675425|Other|Group 1: non chest shielding|non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
75940540|NCT03675425|Other|Group 2: chest shielding|chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
75940541|NCT05166616|Procedure|Biopsy|Correlative studies
75940542|NCT05166616|Drug|Osimertinib|Given PO
75940543|NCT05166616|Drug|Triptolide Analog|Given PO
75940544|NCT05213728|Biological|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN) E1/E3-Deleted Replication-Defective Recombinant Adenovirus 5 with Adjuvant Oral Tablet Vaccine.
75940545|NCT03023813|Other|Intervention|Written material provided.
75802017|NCT03749850|Procedure|MR-HIFU induced hyperthermia|"Patients will receive up to six cycles at three-weeks intervals of:~- 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour.~In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol."
75802018|NCT03749850|Drug|Cyclophosphamide|"Patients will receive up to six cycles at three-weeks intervals of:~- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol."
75654622|NCT04005716|Drug|Tislelizumab, Carboplatin /Cisplatin, Etoposide|Tislelizumab (200 mg IV Q3W) in combination with chemotherapy consisting of etoposide (100 mg/m² IV Days 1-3 of each 21-day cycle) and platinum (cisplatin 75 mg/m² IV Q3W or carboplatin area under the plasma or serum concentration-time curve (AUC) 5 IV Q3W) for 4 cycles. Then maintenance consists of Tislelizumab Q3W and will continue until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of informed consent.
75802019|NCT01562496|Behavioral|Exercise|six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).
75802020|NCT04357782|Drug|L-ascorbic acid|50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)
75654623|NCT04005716|Drug|Carboplatin / Cisplatin, Etoposide|Placebo Q3W in combination with chemotherapy consisting of etoposide (100 mg/m² IV Days 1-3 of each 21-day cycle) and platinum (cisplatin 75 mg/m² IV Q3W or carboplatin AUC 5 IV Q3W) for 4 cycles. Then maintenance consists of Placebo Q3W and will continue until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of informed consent.
75654624|NCT03972280|Biological|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody|Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
75802021|NCT03749772|Behavioral|Cognitive Training|The intervention was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). Participants held the training sessions on an HP 250 G3 Notebook PC (Windows 10), with a 15-inch screen, and a resolution of 1366x768x40 Hz. The performance achieved by each participant in each session was recorded to analyze the evolution of the subjects. The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
75819763|NCT04466098|Biological|Mesenchymal stromal cells|Thawed product containing MSC(300x10^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin [total volume 60 mL]
75819764|NCT04466098|Other|Placebo|Dextran 40 + 5% human serum albumin [total volume 60 mL]
75819765|NCT02180152|Behavioral|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
75819766|NCT02177188|Device|LBNP Lower Bodi Negative Pressure Chamber|
75819767|NCT02256202|Other|Interview|Monitoring interviews to show medical and economic advantages of given therapy
75819768|NCT03536650|Device|DMR|"Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita"
75819769|NCT02177344|Drug|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
75819770|NCT02177344|Drug|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
75819771|NCT02177344|Drug|Atrovent|Two puffs, 4 times daily by oral inhalation
75819772|NCT02177344|Drug|Placebo|
75819773|NCT03536494|Behavioral|Review the use of mirabegron and its discontinuation|"A structured intervention was designed consisting of four major sections:~General practitioners: information and training with written material and patient-centred prescribing.~Specialized hospital care: information regarding the intervention for urologists and gynaecologists.~Management support with the definition of a structured strategy.~Monthly monitoring of the intervention."
75819774|NCT02180308|Device|PET/MRI|Simultaneous PET/MRI (3T system)
75819775|NCT02177422|Drug|Telmisartan|telmisartan 80 mg once daily
75819776|NCT02177422|Drug|Hydrochlorothiazide|12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure < 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
75476347|NCT02006485|Drug|Ublituximab + TGR-1202 + ibrutinib|Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
75819777|NCT02180386|Behavioral|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
75819778|NCT02182882|Drug|GINSANA|
75819779|NCT02182882|Drug|Placebo|
75819780|NCT02182960|Drug|Ibuprofen syrup|
75819781|NCT02182960|Drug|Brufen syrup|
75819782|NCT05141968|Dietary Supplement|vitamin D supplements (2000 IU/day)|The interventional (experimental) group received vitamin D supplements (2000 IU/day). According to previous studies and after the direct supervision from the treating pediatrician and endocrinologist, the best preparation and dosage of vitamin D was used (According to FDA the recommended dose for children age 1 year and older is 2,000 IU/day).
75819783|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
75819784|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
75940546|NCT05165836|Procedure|Erector Spinae Plane block without Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL saline will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
75940547|NCT05165836|Procedure|Erector Spinae Plane block with Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
75940548|NCT05165758|Other|Self-assessment questionnaires|Subjects will pass the SF-36 score (mental health items) and the EPICES index
75940549|NCT03675347|Other|angioplasty|angioplasty
75819785|NCT02183038|Drug|Meloxicam low|
75940550|NCT05232448|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation and the development of personal coping strategies that target solving current problems.
75940551|NCT01365130|Drug|jevtana|Cabazitaxel 25mg/m2, IV every 21 days until progression
75940552|NCT04238416|Drug|Branched chain amino acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
75940553|NCT04238416|Drug|Lactulose|Oral lactulose will be given to patients in both arms
76090246|NCT02349867|Other|RosetteSep|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
76090247|NCT02349867|Other|DEPfff|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
75654625|NCT03969134|Biological|ChAd63-KH|The vaccine will be injected intramuscularly into the arm.
75940554|NCT05162014|Drug|empagliflozin|empagliflozin
75819786|NCT02183038|Drug|Meloxicam high|
76090248|NCT01924390|Device|Mineralized freeze-dried bone allograft alone|
76090249|NCT01924390|Device|Combination of Mineralized and demineralized freeze-dried bone allograft alone|
76090250|NCT01730339|Drug|PF-06473871|Single dose administered by injection four different times
76090251|NCT01730339|Drug|PF-06473871|Single dose administered by injection three different times
76090252|NCT01925404|Behavioral|Free physical activity classes|100 hours of free activity classes will be provided
75344006|NCT05309616|Drug|Taltz|Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
75819787|NCT02183038|Drug|Naproxen sodium|
75344007|NCT05308979|Drug|OnabotulinumtoxinA 100 UNT [Botox]|Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
75654626|NCT03969134|Other|Placebo|The placebo will be injected intramuscularly into the arm.
75654627|NCT03961568|Drug|Cenobamate|active drug
75654628|NCT03900286|Dietary Supplement|Total Dietary Replacement|Total Dietary Replacement
75654629|NCT03898843|Other|Animal assisted therapy|Patients of AAT group will leave their hospital bedroom to go in the session room, where they will meet a dog, who has come with his veterinary student master. Animal assisted therapy session will last at most 20 minutes, in which the patient is going to interact with the dog, pet him, play with him, etc.
75654630|NCT03898843|Biological|Nasal swab sampling|All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
75654631|NCT03898843|Behavioral|STAI-Y and POMS Questionnaires|Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.
75819788|NCT02183038|Drug|Meloxicam placebo low|
75819789|NCT02183038|Drug|Meloxicam placebo high|
76090253|NCT01925404|Behavioral|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
76090254|NCT05734534|Other|BFR during training|Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
75819790|NCT02183038|Drug|Naproxen sodium placebo|
76090255|NCT05734534|Other|BFR during rest|Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
76090256|NCT02629419|Drug|Amphotericin B|Lipid crystal nano-particle formulation of amphotericin B
75802022|NCT03980522|Drug|KPL-914|"KPL-914 (rilonacept) will be provided in its commercially available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult participants (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as 2 subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric participants (6 to <18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as 2 subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL.~Participants considered to be 'treatment responders' will be offered participation in an optional 18-week extension period (EP) in which KPL-914 can be continued for a total duration of KPL-914 treatment of up to 24 weeks."
75940555|NCT05162014|Drug|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
75940556|NCT04237558|Procedure|Vaginal hysterectomy|Vaginal hysterectomy by removal of uterus through vagina in absence of prolapse
75940557|NCT04237558|Procedure|Laparoscopic hysterectomy|Laparoscopic hysterectomy through key hole surgery through small incisions of the abdomen
75344008|NCT05306340|Drug|Giredestrant|Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
75344009|NCT05306340|Drug|Exemestane|If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
75344010|NCT05306340|Drug|Fulvestrant|If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
75344011|NCT05306340|Drug|Tamoxifen|If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
75344012|NCT05306340|Drug|Everolimus|Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
75344013|NCT05306340|Drug|LHRH Agonist|Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
75344014|NCT05306340|Drug|Dexamethasone Mouth Rinse|A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
75654632|NCT03898843|Procedure|physiological parameters measure|Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.
75654633|NCT03898843|Other|Visual Analog Scale (VAS)|Before and after AAT or sham session, pain will be evaluated thanks to VAS
75654634|NCT03898843|Behavioral|Impact of Event Scale - Revised (IES-R)|Patients will answer IES-R questionnaire 3 months after AAT or sham session
75654635|NCT03898843|Behavioral|satisfaction questionnaire|Patients of the AAT group will answer satisfaction questionnaire at the end of the AAT session and 3 months after AAT
75654636|NCT03898843|Biological|Rectal swab sampling|All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
75802023|NCT04402866|Drug|TD-0903|Study Drug to be administered by inhalation
75802024|NCT04402866|Drug|Placebo|Placebo to be administered by inhalation
75802025|NCT04400682|Drug|FAVIRA 200 MG Film Tablet|FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.
75802026|NCT04400682|Drug|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
75802027|NCT03066778|Biological|Pembrolizumab|IV infusion on Day 1 of each cycle prior to chemotherapy
75940558|NCT05226754|Drug|Diacerein|After enrolment, patients will be randomized (n=20 group A) to receive diacerein capsules 50 mg every 12 hours for 10 days.
75940559|NCT05226754|Drug|placebo capsules|After enrolment, patients will be randomized (n=20 group A) to receive placebo capsules (lactose and magnesium stearate) every 12 hours for 10 days.
75940560|NCT01657162|Drug|Alendronate|Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.
75940561|NCT04241692|Device|CarnationTM Ambulatory Monitoring Sternal ECG Patch System|A newly developed cardiac rhythm monitoring system
75940562|NCT04241692|Device|Conventional 24-Hour 7 Lead Holter Monitor Recorder|Traditional recordings made using a standard 24-hour Holter monitor.
75940563|NCT05209906|Drug|Fentanyl Buccal Soluble Film|Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.
75940564|NCT05209828|Device|pfmmedical implantable vascular access ports|Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.
75476348|NCT02006485|Drug|Ublituximab + TGR-1202 + bendamustine|Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
75476349|NCT05970926|Device|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the extremity arteries, which is non-invasive, and the parameters of arterial structure and blood flow will be measured.
75476350|NCT05970900|Drug|Imatinib Mesylate|"For patients with c-KIT exon 11 mutation, imatinib mesylate, 400mg, qd.~For patients with c-KIT exon 9 mutation, imatinib mesylate, 600mg or 800mg, qd."
75344023|NCT05296408|Behavioral|motor learning based therapy|Motor learning based therapy will include functional task/task component training and will be employed to practice hand-to-mouth, forward reach, grasp-release, and object manipulation. Training will include high repetition both in the clinic and during home exercise practice. Tasks will be decomposed into component parts and practiced in this manner with the goal of returning to full task performance as skill develops Training will be tailored to each individual subject's capability and progressed according to a motor control hierarchy to ensure adequate challenge. Training is always started at the appropriate level of challenge for an individual to ensure adequate challenge is delivered whether the individual is higher or lower functioning.
75940565|NCT05209282|Other|Video Based Action Observation|Individuals in this group will receive video-based action observation training in addition to the conventional physiotherapy program.
75344024|NCT05296408|Behavioral|MyoPro|The MyoPro supports motor learning-based training by reinforcing coordinated movement practice, allowing for finely incrementalized training progression, and encouraging high repetition of movement. Importantly, the device assists the user to move the paretic limb in a manner they may otherwise be unable to do. This further motivates the user to continue attempts to move the paretic limb. When a user attempts to volitionally contract a weak muscle, sensors embedded within the MyoPro detect the EMG signal, which triggers activation of a motor within the device. The motor assists the user to complete the desired movement (e.g. opening of the hand).Subjects experience real-time biofeedback through their ability to sense and see movement of the target joint(s) and via their interface with the software on a computer that provides visual feedback of the EMG level of the contracting muscle
75344025|NCT05296408|Behavioral|Home Exercise Program|Every subject will be assigned an individualized HEP. Therapy staff will create written handouts for the user to follow. The HEP will include photographs of the study participant performing his/her exercises/functional tasks along with written instructions. Each individual will have their own personalized HEP that will be created during their study participation and will be dispensed only to them. The HEP will reinforce in-clinic therapy. The HEP will be progressed regularly, and individuals will log practice time. The HEP for M+ML will include practice with and without the MyoPro; the HEP for ML-alone will include practice without MyoPro. Each HEP session will require approximately 90 minutes to complete.
75654637|NCT03837704|Other|IQOS|AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.
75940566|NCT05209282|Other|Live Action Observation|Individuals in this group will receive live action observation training in addition to the conventional physiotherapy program.
75654638|NCT03837704|Other|Cigarette|AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
75654639|NCT03837704|Other|Smoking Cessation|AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
75802028|NCT03066778|Drug|Normal saline solution|IV infusion on Day 1 of each cycle prior to chemotherapy
75802029|NCT03066778|Drug|Carboplatin|IV infusion on Day 1 of each cycle
75802030|NCT03066778|Drug|Cisplatin|IV infusion on Day 1 of each cycle
75802031|NCT03066778|Drug|Etoposide|IV infusion on Days 1, 2 and 3 of each cycle
75802032|NCT04348656|Biological|Convalescent plasma|Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.
75940567|NCT05209282|Other|Conventional physiotherapy program|Individuals in this group will only receive a conventional physiotherapy program.
75802033|NCT04136548|Drug|Fentanyl|Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
75802034|NCT04136548|Other|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
75802035|NCT04348500|Drug|Clazakizumab|IV Infusion
75940568|NCT05207956|Behavioral|Behavioral economics strategies|Behavioral economics features designed to increase motivation to collect data and ease of data collection on the electronic platform.
75940569|NCT05207956|Other|Electronic platform|Electronic platform to collect data
75940570|NCT05157646|Behavioral|Fitness tracker|Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
75344026|NCT05289167|Drug|Cyclophosphamide|50 mg/kg IV over 1 hour on Day +3 and +4
75344027|NCT05289167|Drug|Abatacept|"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"
75344028|NCT05289167|Drug|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
75654640|NCT03813108|Biological|CPS-immunization|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.
75654641|NCT03813108|Biological|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
75654642|NCT03813108|Biological|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
75654643|NCT03813108|Biological|CPS-immunization (A/L)|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.
75802036|NCT04099264|Other|Personalized music|Patients in the intervention group will listen to personalized music from the Musicare application
75940571|NCT05633810|Drug|Aspirin|40 mg non-enteric-coated tablet taken twice daily.
75940572|NCT05633810|Drug|Aspirin Placebo|non-enteric-coated tablet taken twice daily.
75940573|NCT05633810|Drug|Colchicine|0.5 mg tablet taken once daily
75940574|NCT05633810|Drug|Colchicine Placebo|tablet taken once daily.
75940575|NCT05206552|Other|Questionnaire|Maternal - Infant bonding questionnaire. EPDS - Postpartum depression questionnaire
75344029|NCT05267106|Drug|Pemigatinib|13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
75802037|NCT04099264|Other|Audio Books|Patients in the active comparator group will listen to audio books
75940576|NCT05611346|Behavioral|Hypnosis|"The experimental group will receive 2 standardized hypnosis sessions via the superhero costume technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording"
75940577|NCT04889560|Other|Experimental group|Home-based version of a computerized cognitive training (CoRe)
75940578|NCT04889560|Other|Control group|Computerized cognitive training (CoRe)
75940579|NCT02933606|Drug|BNC210|
75654644|NCT03813108|Drug|Atovaquone / Proguanil Oral Tablet [Malarone]|All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
75940580|NCT02933606|Drug|Placebo|
75940581|NCT05203822|Drug|Tepotinib (HydroChloride hydrate)|Participants will receive Tepotinib (Hydrochloride hydrate) Film-coated tablet with food on Day 1 and 12 in the morning.
75654645|NCT03797807|Procedure|MINST|A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
75654646|NCT03797807|Procedure|MIST|A minimally invasive surgical treatment protocol, named MIST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
75940582|NCT05203822|Drug|Itraconazole|Participants will receive Itraconazole Hard-gelatin capsule with food once daily at the same time in the morning from Day 8 to Day 18; on Day 12 itraconazole is administered concomitantly with tepotinib.
75940583|NCT04883788|Other|Pandemic period|Perioperative care (nursing and physiotherapy) provided to patients treated with hip and knee replacement during the pandemic period
75940584|NCT05201482|Device|SightPlus|SightPlus is a head-mounted, augmented reality low vision aid. SightPlus enables people with a visual impairment to use their remaining vision to see more clearly up close and at a distance. SightPlus is commercially available, non-invasive, CE marked, and a MHRA approved class 1 medical device.
75802038|NCT04062058|Radiation|SIB-IMRT|45Gy in 25 fractions using intensity-modulated radiotherapy to the radiation target
75802039|NCT04062058|Drug|S-1|40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment
75802040|NCT04062058|Drug|SOX|SOX (S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
75802041|NCT04062058|Procedure|Surgery|Surgery, preferred D2 lymphadenectomy
75802042|NCT04347954|Drug|Povidone-Iodine 2%|Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day
75802043|NCT04347954|Drug|Povidone-Iodine 0.5%|Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day
75940585|NCT01373294|Drug|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
75940586|NCT01373294|Drug|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
75654647|NCT03797807|Diagnostic Test|GTI subgroup (Geometrical/Thermal Imaging)|Geometrical/Thermal Imaging
75654648|NCT03733626|Combination Product|ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system|ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion.
75802044|NCT04347954|Drug|Isotonic saline 0.9%|Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
75802045|NCT03065530|Drug|Normal Saline|Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
75802046|NCT03065530|Drug|Dexmedetomidine 0.03ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
75819791|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) [Original], single dose
75940587|NCT05148598|Device|ADRCs|Adipose Derived Regenerative Cells (ADRCs) processed with Celution System
75940588|NCT05148598|Other|Standard Care|Standard care
75940589|NCT05148598|Other|Placebo|Placebo visually indistinguishable from ADRCs
75940590|NCT04367246|Other|No Intervention|No intervention is assigned.
75940591|NCT05147428|Other|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
75940592|NCT04422028|Drug|Desogestrel 0.075 MG|Test Drug
75940593|NCT04422028|Drug|Desogestrel 0.075 MG|Reference Product
75940594|NCT04236856|Device|Robotic Endovascular Procedure|After providing written informed consent, subjects with cerebral aneurysms may have their aneurysm treated using the CorPath GRX System.
75940595|NCT01656304|Biological|bevacizumab|Given IV
75940596|NCT01656304|Other|laboratory biomarker analysis|Correlative studies
75940597|NCT05143216|Other|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Canula)|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Cannula)
75940598|NCT05143216|Other|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)
75940599|NCT05107648|Behavioral|Gardner GOALS|12 lesson curriculum focusing on healthy eating, increased physical activity and decreased screen time
75344030|NCT05259501|Other|RMIST|"RMIST will involve:~A study automated visual recognition web-based platform accessible on the participant's smartphone web browser.~A supply of methadone in single use bottles and previously described packaging to be kept securely at the methadone clinic/lab setting."
75344031|NCT05257083|Drug|Daratumumab|Daratumumab will be administered SC.
75940600|NCT05107570|Other|Cold exposure|Cold air exposure (~ 9°C, maximum 1 hour duration)
75344032|NCT05257083|Drug|Bortezomib|Bortezomib will be administered SC.
75344033|NCT05257083|Drug|Lenalidomide|Lenalidomide will be administered orally.
75344034|NCT05257083|Drug|Dexamethasone|Dexamethasone will be administered orally.
75344035|NCT05257083|Drug|Cilta-cel|Cilta-cel will be administered intravenously
75344036|NCT05257083|Drug|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
75344037|NCT05257083|Drug|Fludarabine|Fludarabine will be administered intravenously.
75344038|NCT05249556|Drug|Ganaxolone|Ganaxolone
75654649|NCT03733626|Combination Product|Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system|Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion.
75654652|NCT03694652|Behavioral|PACE|Patient-centered Assessment and Counseling for Exercise [PACE] program
75654653|NCT03694652|Behavioral|Diet|Motivating healthy dietary habits
75654654|NCT03694652|Other|App|Using an app to deliver communication to the participant.
75654655|NCT03694652|Other|Face-to-face|Using in person meetings and/or phone communication with the participant.
75654656|NCT03664362|Behavioral|The BSHAPE Intervention|The BSHAPE intervention program key elements include strengths based assessments, individualized plans and support based on priorities and needs, motivational interviewing strategies, psychoeducation (education with skill building exercises), mindfulness activities, danger assessment, safety planning, behavioral activation and linkage to community resources
75654657|NCT03621748|Procedure|Awake Anesthesia Protocol|Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.
75654658|NCT03621748|Procedure|Non-awake Anesthesia Protocol|Non-awake is general anesthesia as per convention with intubation.
75654659|NCT03552796|Other|Pharmacokinetic Study|Correlative studies
75940601|NCT05197894|Device|Virtual Reality|The intervention is a Virtual Reality experience within a selected application using an Oculus Quest 2 ©, as previously in the relevant intervention arm.
75940602|NCT05142514|Biological|COVID-19 Vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
75940603|NCT05142514|Biological|Cominarty (Pfizer-BioNtech)|Subjects will receive 2 injections of Cominarty administered 21 days apart
75654660|NCT03552796|Biological|Recombinant EphB4-HSA Fusion Protein|Given intravesically
75654661|NCT03469505|Behavioral|COPES|Cooperative Pain Education and Self-Management for chronic pain therapy.
75654662|NCT03469505|Behavioral|CBT-CP|Cognitive Behavioral Therapy for Chronic Pain
75654663|NCT03454997|Other|training including in-person and online|training, motivational interviewing practice
75654664|NCT03454997|Other|organizational strategy meetings|meetings with leadership to optimize implementation of evidence-based practices
75654665|NCT03454997|Other|performance coaching|to enhance ability to deliver the weight management intervention
75654666|NCT03431493|Behavioral|Behavioral Activation - Rehabilitation|"Participants will first receive a home visit from a physical therapist (PT) who will evaluate home safety and establish/verify the participant's exercise prescription. Within 1 week, an occupational therapist (OT) will visit the home to: 1) explain the purpose of behavioral activation (BA); 2) help the participant identify long-term recovery goals regarding valued activities; and 3) then, using the principles of BA, identify short-term goals for the next week and an action plan. The OT will then call the participant weekly (weeks 2-5) to review the status of the prior week's goals and use BA to set new goals for the upcoming week. The PT and OT will repeat home visits at week 6 to assess the participant's progress, and the OT will conduct phone calls every 2 weeks for weeks 8-12."
75654667|NCT03423459|Device|TAVR|Transcatheter Aortic Valve Replacement
75940604|NCT05103124|Device|Hydral|The investigational product GUM Hydral will be administered for a 30-days treatment period
75940605|NCT05103124|Other|Placebo|The placebo product will be administered for a 30-days treatment period
75344039|NCT05249556|Drug|Placebo|Placebo (for ganaxolone)
75654668|NCT03421704|Device|DreamStation BiPAP autoSV|Philips Respironics DreamStation BiPAP autoSV (PR DS-autoSV) is designed to deliver pressure support for patient ventilatory assistance
75654669|NCT03417154|Drug|Nivolumab|3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
75654670|NCT03417154|Drug|Low dose Cyclophosphamide (CTX) Daily|Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
75344043|NCT05231200|Behavioral|QI Team Building|Each NICU will create a core QI team composed of 6-8 multidisciplinary members including a parent advisor, when feasible. This team will lead the QI activities and education, and champion the culture and practice change in the unit.
75344044|NCT05231200|Behavioral|QI education|Each NICU QI team will receive standardized QI education using the 6-hour EPIQ Workshop which involves hands-on approach to enable teams to successfully implement QI projects together. EPIQ 10 Steps and QI Tools will be used to build the team's understanding of QI using realistic improvement opportunities based on the standardized care bundles identified in the trial.
75344045|NCT05231200|Other|Standardized care bundle- respiratory care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for stabilization and respiratory care in moderate and late preterm infants (MLPIs) including~establishing effective ventilation in the delivery room~prevention of hypothermia~early diagnosis and management of respiratory distress with continuous positive airway pressure (CPAP)~standardized approach for surfactant indications and administration~standardized approach for early extubation."
75654671|NCT03417154|Drug|Low dose Cyclophosphamide (CTX) Every 7 Days|Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
75940606|NCT04421872|Other|receiving general anesthesia|patients receiving surgery under general anesthesia
75940607|NCT04227028|Biological|Bevacizumab|Given IV
75940608|NCT04227028|Drug|Brigatinib|Given PO
75940609|NCT05138770|Drug|VC005 Tablets|VC005 Tablets 1、5、10、25、50、100mg single dose
76090257|NCT05740072|Other|Drying before wrapping|Immediately after birth, the infant's body will be dried before wrapping in a plastic bag
75940610|NCT05138770|Drug|VC005 Tablets Placebo|VC005 Tablets Placebo 1、5、10、25、50、100mg single dose
76090258|NCT05740072|Other|No drying before wrapping|Immediately after birth, the infant will be put in a plastic bag without wrapping
76090259|NCT02334735|Biological|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10^6 cells)"
76090260|NCT02334735|Biological|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
75344046|NCT05231200|Other|Standardized care bundle- nutritional care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for nutritional support in MLPIs including~early initiation of enteral or parenteral nutrition;~standardized tables for feeding initiation and progression~optimizing breastfeeding and use of mother's own milk~standardized approach for a transition from enteral nutrition via tube feeds to oral feeds."
76090261|NCT02334735|Biological|Poly-ICLC|1.4 mg
75344047|NCT05231200|Behavioral|QI mentoring|Each NICU in the intervention arm will have one or more assigned members of the study team who are experienced in collaborative QI and EPIQ methods. The mentors will help local QI teams to engage frontline staff in QI and navigate the unit-specific challenges.
75476351|NCT05970900|Procedure|Local resection|"According to the characteristics of the location of the tumor, the surgeon decides the surgical approach based on the existing literature and the availability of surgical equipment, including:~Local transanal resection (TA)~Local resection transsacralapproach~Local resection via perineal approach~Local resection transvaginal approach"
75476352|NCT05970861|Dietary Supplement|Freeze-dried Mare Milk (Saumal)|Freeze-dried Mare Milk (Saumal) is frequently reported for having therapeutic and dietary properties associated with specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, and B12, amino acids, enzymes, and trace elements (low molecular weight peptides, lactalbumins, and globulins). Saumal will be administered to patients at a dose of 20 grams of dry powder per 200 ml of water, 2 times a day, 30 minutes before the meal, for 4 weeks.
75476353|NCT05970848|Device|Washing Pipe With a Spray Nozzle|Administration of topical airway anesthesia via a washing pipe with a spray nozzle using the spray-as-you-go technique
75476354|NCT05970835|Other|Control group|Participants assigned to control group will receive the usual care provided by clinicians and physiotherapists from the Complexo Termal de Caldelas. Participants will have an educational session conducted by one of the researchers, and a paper sheet will be distributed with exercises and a written explanation of how to perform those exercises and the number of sets and repetitions. data collection will be conducted in moments t2 and t3 by a phone call.
75654672|NCT03396315|Drug|Alendronate|oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis
76090262|NCT02329600|Drug|green tea tablets (Green tea extract 5:1) 200 mg|Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
75654673|NCT03396315|Drug|Zoledronic Acid|single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
75654674|NCT03331796|Device|Active rTMS (Bilateral DLPFC)|TMS Stimulation Parameters for the active DLPFC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
75940611|NCT05138770|Drug|VC005 Tablets food effects group|VC005 Tablets qd per period, for two periods
75940612|NCT03023423|Drug|Atezolizumab|Participants will receive atezolizumab 1200 mg intravenously.
76090263|NCT02329600|Drug|Triamcinolone Acetonide|topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
76090264|NCT02620761|Drug|Fenoldopam|Randomized to receive Fenoldopam or 0.9%NS
75940613|NCT03023423|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg intravenously.
75940614|NCT03670823|Device|SIEMENS PRISMA MRI|Collect data on brain activation from different methods
76090265|NCT02620761|Drug|0.9%NS|Randomized to receive Fenoldopam or 0.9%NS
75940617|NCT03675269|Other|HBOT|Standard practice
76090266|NCT01754753|Other|Telephone Friendship groups|
76090267|NCT04758273|Biological|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
75940618|NCT03675269|Behavioral|Standard wound care|Standard wound care
76090268|NCT04758273|Biological|high dosage inactivated SARS-CoV-2 vaccine|high dosage
76090269|NCT04758273|Biological|Placebo|placebo
76090270|NCT02613273|Behavioral|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
76090271|NCT02613273|Behavioral|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
75344048|NCT05231200|Behavioral|Collaborative networking|The study team will conduct virtual meetings every 2 months for the NICUs in intervention arm allowing local QI teams to discuss progress, and share data. The investigators will arrange annual in-person or virtual meetings for the NICUs in the intervention arm to present projects, successes, and lessons learned. These NICUs will have continuing access to the data and will receive quarterly reports using statistical process control charts outlining the unit's performance compared to other units and to the group average.
75802047|NCT03065530|Drug|Dexmedetomidine 0.05ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
75940619|NCT05136664|Drug|Patiromer Powder for Oral Suspension (Part A)|"Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
75940620|NCT05136664|Drug|Placebo (Part B)|Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.
75940621|NCT05136664|Drug|Patiromer Powder for Orals Suspension (Part B)|"Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
75940622|NCT03675191|Drug|Orlistat 120Mg Cap|Drug,Orlistat 120Mg Cap, three times a day, within 1hour after meal
75940623|NCT03675191|Drug|Phentermine Pill|Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
76090272|NCT01729871|Drug|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
76090273|NCT01729871|Drug|uninterrupted vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
75654675|NCT03331796|Device|Active rTMS (Bilateral LPC)|TMS Stimulation Parameters for the active LPC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
75654676|NCT03331796|Device|Placebo rTMS (Inactive)|For the Placebo rTMS (Inactive) group, the participant will wear scalp electrodes through which a low voltage, low electric current (2-20mA at no more than 100V) is passed to mimic the sensation of receiving actual rTMS. Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
75654677|NCT03288844|Procedure|Ophthalmologic examinations|epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
75654678|NCT03288844|Other|Digital pictures|Digital pictures 2D to be taken at each visit
75654679|NCT03288844|Other|QoL Questionnaires|Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
75654680|NCT03221036|Drug|Vedolizumab IV|Vedolizumab IV infusion
75654681|NCT03221036|Drug|Placebo|Matching-placebo IV infusion
75654682|NCT03189576|Diagnostic Test|blood draw|
75802048|NCT03065530|Drug|Dexmedetomidine 0.08ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
75802049|NCT03629158|Behavioral|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks. Sessions range from 1-2 hours in length, including questionnaire completion. Participants will be given information and taught relevant skills to increase engagement in lifestyle behaviors relevant to cardiac health."
75802050|NCT03979820|Drug|BI 1467335|Film-coated tablet
75802051|NCT03979820|Drug|Placebo|Film-coated tablet
75940624|NCT03675113|Other|Upper extremity aerobic exercise|"Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
75940625|NCT03675113|Other|Control Group|Deep breathing exercises combinated with arm movements
75940626|NCT05187988|Procedure|supraclavicular brachial plexus block|group will receive brachial plexus block above clavicle,Injection of anaesthetic will be done in brachial plexus around subclavian artery
75940627|NCT05187988|Procedure|Retroclavicular brachial plexus block|group will receive brachial plexus block inferior to the clavicle,injection of anaesthetic will be done around axillary artery
75940628|NCT03198689|Drug|Brentuximab Vedotin|Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
75940629|NCT05135026|Diagnostic Test|Ultrasonograpgy|2 USG in 3rd and 5th ANC visits and even more USG if needed + 4 ANC + Health education
75940630|NCT03675035|Device|Endomina|Reduction of the gastro-jejunal anastomosis through sutures
75940631|NCT05096416|Device|The three-dimensional (3D) printed hemodialysis vascular model|The three-dimensional (3D) printed hemodialysis vascular model will be used as a guide map to cannulate the patients for hemodialysis and to minimize the risk of vascular access complications
75940632|NCT05187598|Other|Effective communication training in perinatal patient safety|Students will be given theoretical training, group discussion will be made over sample videos, and students will participate in the standard participant practice and a post-analysis session will be held.
75802052|NCT03979820|Drug|Phenelzine sulfate|Film-coated tablet
75802053|NCT03979820|Drug|Tyramine|Capsules
75940633|NCT03670589|Radiation|Radiosurgery gammaknife|This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
75940634|NCT03670589|Procedure|Microsurgery resection|Classical surgical approach with oto-neurosurgery procedures
76090274|NCT02611323|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 milligrams (mg) via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month (starting from Month 2) for up to 24 months, until disease progression or unacceptable toxicity.
75654683|NCT03142009|Other|Intergenerational culturally adapted curriculum|"Each session starts with a collective dinner with families eating together. Then practice their Indian and clan names. The sessions are led by facilitators in their own language or bilingually. The facilitators then divide the families into children and adult groups to address the theme of the session, and they then return together at the end of the session to share their learnings. The sessions always end with the children and adults writing in their journals which are individual pages that they then put in their curriculum binders. Families are then given their home practice, which is a task that the families do together during the intervening week. The facilitators collect the curriculum binders after each session to bring back to the families the next week."
75654684|NCT03096743|Diagnostic Test|MR elastography|MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
75802054|NCT03647488|Drug|Capmatinib|Capmatinib 400 mg (tablets) orally taken twice daily
75940635|NCT05134246|Procedure|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
75344049|NCT05231200|Other|Current practice- standard of care|All participating NICUs will be in the control arm during the first year prior to randomization to create a baseline of the current practices and between-units variation. NICUs in the control arm can continue conducting QI activities relevant to current practice, but without receiving the interventions outlined above until they transition to the intervention arm. The investigators will capture these activities and account for them in the analysis.
75802055|NCT03647488|Drug|Spartalizumab|Spartalizumab 400 mg via intravenous infusion once every 28 days
75802056|NCT03647488|Drug|Docetaxel|Docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
75344050|NCT05231174|Other|A self-evlaution tool based on Large Language Model|"Following the baseline assessment, participants will be guided to use a self-evaluation tool independently to assess their risk of diabetic retinopathy (DR). This tool is a fusion of a conversational AI system based on LLM and an existing logistic diagnostic model.~The AI system is designed to collect clinical variables, including age, duration of diabetes, Body Mass Index (BMI), and insulin usage. Additionally, clinical test data such as mean arterial pressure, HbA1c, serum creatinine, and microalbuminuria will be extracted from a local dataset using the patient's name and ID. Once collected, these data will be transmitted to a server-based diagnostic model for further analysis to determine the presence of DR."
75654685|NCT03096743|Diagnostic Test|MRI structural brain imaging|MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
75654686|NCT03096743|Procedure|Lumbar puncture|All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
75802057|NCT03693950|Biological|BCD-066|BCD-066 will be administered once a week intravenously in a dose 1 µg/kg
75802058|NCT03693950|Biological|Aranesp|Aranesp will be administered once a week intravenously in a dose 1 µg/kg
75802059|NCT04110314|Behavioral|Portal Reminders for Influenza Vaccination: Gain-framed|Patients receive gain-framed reminder/recall messages via the patient portal to get an influenza vaccination.
75802060|NCT04110314|Behavioral|Portal Reminders for Influenza Vaccination: Loss-framed|Patients receive loss-framed reminder/recall messages via the patient portal to get an influenza vaccination.
75940636|NCT05134246|Procedure|Carotid artery stenting (CAS)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.
75802061|NCT04110314|Behavioral|Pre-commitment prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
75802062|NCT03579160|Drug|0.25% timolol gel with full-thickness skin grafts|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied.
75802063|NCT03579160|Other|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied.
75940637|NCT03674879|Other|Text Message|Patient contact attempted with text message.
75940638|NCT05185102|Other|Cognitive tasks|Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
75940639|NCT03185741|Behavioral|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
75940640|NCT03185741|Behavioral|SMS Text Messaging|Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
75940641|NCT03669419|Diagnostic Test|QoR 9 Questionnaire|The QoR-9 as established patient-centred outcome measure, which is validated in German language, is surveyed preoperatively, as well as on postoperative day 1 and 3 after non-cardiac surgery. Postoperative complications are evaluated using the Clavien-Dindo Score. A follow-up is intended after 6 months. Preoperative risk is estimated using the ASA (American Society of Anesthesiologists) and the POSPOM (Preoperative Score to predict postoperative mortality) score.
75819792|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
75940642|NCT04421716|Drug|Ursolic Acid|Ursolic Acid 150mg
75940643|NCT04421716|Drug|Curcumin|Curcumin 600mg
75940644|NCT03176225|Procedure|Open heart surgery to address the heart disease|The patient will first have open heart surgery to achieve access to the diseased site in the heart
75940645|NCT03176225|Device|Close the defects with XenoSure Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.
75654687|NCT03096743|Diagnostic Test|Optical Coherence Tomography (OCT) imaging|Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
76090275|NCT02611323|Drug|Rituximab|Participants will receive a fixed dose of rituximab, 375 milligrams per square meter (mg/m^2) via IV infusion to be given on Day 1 of Cycles 1 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 375 mg/m^2 via IV infusion on Day 1 of every other month (starting from Month 2) for up to 8 months, until disease progression or unacceptable toxicity.
76090276|NCT02611323|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) (for FL), and 1.8 mg/kg (for DLBCL) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
76090277|NCT02611323|Drug|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 200, 400, 600, or 800 mg (for FL), and 400, 600, or 800 mg (for DLBCL) on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
76090278|NCT02608359|Drug|Abiraterone Acetate|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
76090279|NCT01729559|Drug|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
76090280|NCT01729559|Drug|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
75344051|NCT05230459|Genetic|AB-1003 dose level 1|Single intravenous infusion of AB-1003 gene therapy at dose level 1
75344052|NCT05230459|Genetic|AB-1003 dose level 2|Single intravenous infusion of AB-1003 gene therapy at dose level 2
75654688|NCT03096743|Diagnostic Test|Optic nerve B-scan ultrasound|Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
75344053|NCT05230459|Other|Placebo|Single intravenous infusion of Placebo
75654689|NCT03075670|Drug|N9-GP|A single dose of 50 IU/kg for intravenous (i.v.) injection
75654690|NCT03075670|Drug|ALPROLIX®|A single dose of 50 IU/kg for intravenous (i.v.) injection
75654691|NCT03032783|Radiation|Total-Body Irradiation|Undergo Total Body Irradiation
75802064|NCT03483220|Diagnostic Test|MRI brain|"1. Emotion Regulation Questionnaire (ERQ): A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale .~UPPS-P Impulsive Behavior Scale- Short form: The UPPS-P impulsivity scale is a 20-item scale designed to assess five distinct personality traits to impulsive behavior: Negative Urgency, Lack of Perseverance, Lack of Premeditation, Positive Urgency and Sensation Seeking .~Magnetic resonance imaging examination:~The MR examination of brain was done using 1.5T MR scanner (Achieva, Philips Medical Systems, The Netherlands) with a 16 channel head coil without using any sedation."
75940646|NCT03176225|Device|Close the defects with Chest Polyester Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.
75940647|NCT05184868|Drug|AT247|Ultra rapid acting prandial insulin aspart
75940648|NCT05184868|Drug|NovoLog|Rapid acting prandial insulin aspart
75940649|NCT05184868|Drug|Fiasp|Fast acting prandial insulin aspart
75654692|NCT03032783|Procedure|Donor Lymphocyte Infusion|Undergo Donor Lymphocyte Infusion
75654693|NCT03032783|Drug|Cyclophosphamide|Given IV
75654694|NCT03032783|Drug|Tacrolimus|Given IV
75654695|NCT03032783|Drug|Mycophenolate Mofetil|Given IV
75654696|NCT03032783|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo Hematopoietic Stem Cell Transplantation
75940650|NCT03670511|Other|sit-to-stand test|to sit and stand from a chair
75940651|NCT03670511|Other|six minute walking test|to walk for six minutes
75940652|NCT02672852|Drug|Risankizumab|Risankizumab administered by subcutaneous injection
75940653|NCT02672852|Drug|Placebo|Placebo for risankizumab administered by subcutaneous injection
75654697|NCT03002272|Device|TAVR|subjects that underwent TAVR more than 3 years ago
75940654|NCT05370742|Procedure|Latarjet surgery|Results of using a screw-only plate for fixation of the corocoid bone in recurrent shoulder dislocations
75940655|NCT03168659|Device|HeartLight|HeartLight Endoscopic Ablation System
75940656|NCT03168659|Procedure|Ablation|Pulmonary vein isolation ablation
76090281|NCT01893333|Procedure|Nerve sparing radical hysterectomy|"Nerve sparing radical hysterectomy~sparing hypogastric nerve~sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
76090282|NCT01926496|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
76090283|NCT01926496|Drug|Imiquimod Cream, 5%|Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
76090284|NCT04559555|Drug|Nilotinib|The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
76090285|NCT05739916|Drug|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
76090286|NCT05739916|Drug|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
76090287|NCT01728779|Drug|Nelfinavir|Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
76090288|NCT01728779|Radiation|Stereotactic Body Radiation (SBRT)|15 Gy dose (per lesion site) of SBRT will be administered
75344054|NCT05229029|Drug|TCM Formula|TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.
76090289|NCT01927120|Drug|IL-2|A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
76090290|NCT01927120|Drug|Tacrolimus|Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
75940657|NCT05129254|Device|Fractionated Thulium laser|For this study, the investigators will use non-ablative fractional Thulium laser (1927 nm), provided by LaseMD, (Lutronic, Inc, USA). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by LaseMD. More than one affected area of the scalp may be treated per session. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment preparation will consist of cleaning the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide.
76090291|NCT01927120|Drug|Sirolimus|Orally on day -1. The dose for loading is 12 mg by mouth (PO)
76090292|NCT05586867|Procedure|Blood test|15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
76090293|NCT01728623|Drug|E7080 capsule|E7080 is administered as continuous once daily dosing in an uncontrolled manner
76090294|NCT05586399|Behavioral|Maximal strength training in COPD|Participate in a rehabilitation program for 4 weeks, with exercise 5 times a week. Supervised maximal strength training in a leg press machine for a total of 20 exercise sessions. Patients will participate in rehabilitation in one of two rehabilitations centers in Trondheim, Norway.
76090295|NCT02579655|Behavioral|Copayment Elimination|Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
75344055|NCT05229029|Drug|Placebo|Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs
75344056|NCT05218655|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
75344057|NCT05216393|Other|RecTech Match Website|Participants will have access to the Rectech Match website. These participants will receive 9 health coaching calls. Fitbit physical activity data will be collected on an ongoing basis during the intervention.
75802065|NCT03461458|Drug|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose-derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Immune Progenitor and Cell Therapeutics Laboratory using current good manufacturing practices (cGMPs).
75654698|NCT03002272|Device|SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
75654699|NCT02823730|Other|PCI with Synergy Stent|500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
75802066|NCT04098458|Behavioral|NDURE|NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.
75819793|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) [Blended], single dose
75819794|NCT01067807|Drug|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) [Blended], single dose
75819795|NCT01067885|Device|MARIS-stent (Invatec)|stenting of SFA with Maris nitinol stent/s
76090296|NCT02579655|Behavioral|Personalized Education|Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
76090297|NCT02573337|Device|Emervel Classic Lidocaine|Treatment of wrinkles and folds
75344058|NCT05215340|Drug|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
75344059|NCT05215340|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
75344060|NCT05202808|Device|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments
75344061|NCT05202808|Device|Control IOL|Control treatment group will receive a Control IOL
75344062|NCT05199688|Drug|Satralizumab|Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
75344063|NCT05191472|Biological|Pembrolizumab|Given IV
75654700|NCT02778165|Other|MyCaRe (my cardiac recovery Android application)|Android application & Fitbit Inspire 2 activity monitor
75344064|NCT05189171|Device|MicroOrganoSphere (MOS) drug screen|Patient-derived models of cancer, called MOS, will be generated from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and a drug screen using standard-of-care drugs used will be completed (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab). Subjects will receive standard-of-care therapy for CRC dictated by their treating physicians.
75654701|NCT02740985|Drug|AZD4635|AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
75344065|NCT05181618|Drug|Emicizumab|The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
75940658|NCT05129254|Procedure|Autologous Platelet Rich Plasma Injection|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be injected with a syringe and needle subcutaneously into the participant's scalp.
75940659|NCT05129254|Procedure|Autologous Platelet Rich Plasma Topical Application|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be applied topically with a syringe to one or more affected areas on the participant's scalp that were previously treated with thulium laser.
76090298|NCT02573337|Device|Emervel Deep Lidocaine|Treatment of wrinkles and folds
75654702|NCT02740985|Drug|Durvalumab|Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
76090299|NCT02781363|Other|Thoracic ultrasound|
76090300|NCT02781363|Other|CXR|
76090301|NCT04757727|Other|Decriptive study of EDB|data on EDB will be register
76090302|NCT01728077|Drug|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
75654703|NCT02740985|Drug|Abiraterone Acetate|"Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets."
75802067|NCT03745742|Other|HRV measurement|"Patients in group A (control) will benefit from a standard re-training protocol based on initial functional abilities. The training is done at a target heart rate corresponding to the heart rate reached at the first ventilatory threshold (about 55% of VO2max).~Patients in group B (study strategy) will benefit from a re-training protocol based on HRV and initial functional abilities. Any increase in HRV compared to the previous day will result in an increase in workload of 10Watt. Any increase or decrease in HRV for 3 days in a row will cause the stagnation of the workload for 2 days.~HRV is measured every day in each group via a heart rate belt and a smartphone App."
76090303|NCT04757181|Other|The IBD-AID|Subjects will meet with study personnel for to fill out baseline questionnaires (approximately a 1-hour visit). Subjects will be instructed to make dietary changes based one the IBD-AID guidelines. Dietary instruction will be delivered via individual and group sessions led by trained study personnel. Participants will be expected to learn the skills of dietary change to the IBD-AID and will begin their 8 weeks compliance period followed by endpoint measures. Participants are encouraged to attend 3 cooking classes (1.5 hours duration) in our teaching kitchen.
76090304|NCT02307279|Device|Gelesis100|
75654704|NCT02740985|Drug|Enzalutamide|"Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules."
75654705|NCT02740985|Drug|Oleclumab|Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
75654706|NCT02740985|Drug|Docetaxel|"Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice."
75654707|NCT02723331|Drug|Nab-paclitaxel and gemcitabine for R-PDAC Patients|Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
75654708|NCT02723331|Drug|Nab-paclitaxel and gemcitabine for BR-PDAC Patients|Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
75802068|NCT03745664|Drug|Methylprednisolone Sodium Succinate|During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
75344066|NCT05176223|Procedure|Computed Tomography|Undergo 68Ga PSMA PET/CT
76090305|NCT02307279|Device|placebo|
76090306|NCT01606007|Drug|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
76090307|NCT01606007|Drug|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
76090308|NCT01606007|Drug|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
75344067|NCT05176223|Drug|Gallium Ga 68 Gozetotide|Undergo 68Ga PSMA PET/CT
75344068|NCT05176223|Procedure|Positron Emission Tomography|Undergo 68Ga PSMA PET/CT
75344069|NCT05171855|Drug|Lonapegsomatropin|Study participants are individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks
75344070|NCT05171075|Biological|Abelacimab|Abelacimab 150 mg
75344071|NCT05171075|Drug|Dalteparin|Dalteparin 200 IU/kg/day followed by 150 IU/kg/day
75654709|NCT02660268|Other|Clinical Pathway|Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
75654710|NCT02628899|Device|Transfemoral TAVR|
75654711|NCT02628899|Device|SAVR|
75654712|NCT02571790|Behavioral|Relaxation optimized virtual reality|
75654713|NCT02571790|Behavioral|Classical relaxation (without Virtual Reality)|
75940660|NCT05183620|Device|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and the outer thigh of the test subject to measure skin temperature during erection
76090309|NCT01606007|Drug|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
76090310|NCT01606007|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
76090311|NCT02304783|Drug|Piroxicam|Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
75344072|NCT05171049|Biological|Abelacimab|Abelacimab 150 mg
75344073|NCT05171049|Drug|Apixaban|Apixaban 10 mg followed by 5 mg
76090312|NCT02304783|Drug|Placebo|Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
76090313|NCT02304783|Drug|paracetamol|Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
76090314|NCT02301819|Device|Veno-arterial extracorporeal membrane oxygenation (ECMO)|Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
75344074|NCT05170204|Drug|Alectinib|Participants will receive oral alectinib twice daily with food.
75344075|NCT05170204|Drug|Entrectinib|Participants will receive oral entrectinib once daily, with or without food.
75344076|NCT05170204|Drug|Durvalumab|Participants will receive IV durvalumab every 4 weeks.
75654714|NCT02515110|Radiation|External Beam Radiation Therapy|Undergo hypofractionated RNI
75654715|NCT02515110|Other|Questionnaire Administration|Ancillary studies
75802069|NCT03745664|Drug|Saline Solution for Injection|During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
75802070|NCT03447262|Drug|VX-659/TEZ/IVA|Fixed-dose combination tablets for oral administration qd in the morning.
75802071|NCT03447262|Drug|IVA|IVA tablet qd in the evening.
75802072|NCT04094870|Drug|Sertraline|daily SSRI (Sertraline 25mg)
75802073|NCT04094870|Behavioral|Interpersonal therapy|11 sessions over a 24-week period
75802074|NCT04399356|Drug|Niclosamide|Participants in the treatment arm will receive Niclosamide 2 grams orally once daily for 7 days in addition to current standard of care treatment. Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14. Fecal samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14, 21. A baseline fecal and oropharyngeal sample will be obtained on Day 1 prior to starting dosing of Niclosamide/ placebo.
75344077|NCT05164549|Drug|Buprenorphine Injectable Product|Investigational Medicinal Product
75344078|NCT05164549|Drug|Methadone|Standard of Care
75344079|NCT05164549|Drug|Buprenorphine|Standard of Care
75344080|NCT05164133|Drug|Tocilizumab|Participants will receive intravenous (IV) tocilizumab
75344081|NCT05155085|Drug|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
75344082|NCT05155085|Other|Placebo|Placebo
75344083|NCT05147636|Procedure|Extubation with PEEP|No aspiration within the 3 minutes before extubation and extubation with 10cmH2O PEEP
75344084|NCT05147636|Procedure|Endotracheal Aspiration|Aspiration during cuff deflation
75344085|NCT05140759|Device|automated continual water removal system|The device removes excess fluids in heart failure patients with diuretic resistance
75802075|NCT04399356|Drug|Placebo|The collection of oropharyngeal samples will be observed by a Study Team member via the telehealth platform.
75802076|NCT04399356|Other|Telehealth monitoring|In addition to Niclosamide or placebo treatments, all enrolled patients will be provided a home thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. The collection of oropharyngeal samples will be directly observed by a Study Team member via the telehealth platform.
75802077|NCT03692676|Device|Spiriva Respimat|soft-mist inhaler
75819796|NCT02752906|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
75819797|NCT02752906|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
75654716|NCT02515110|Other|Laboratory Biomarker Analysis|Correlative studies
75654717|NCT02484677|Drug|Cisplatin|Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
75654718|NCT02484677|Drug|Docetaxel|Taxanes. Blood sampling for pharmacokinetic evaluation
75654719|NCT02484677|Drug|5-Fluorouracile|Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
75819798|NCT01067963|Behavioral|Computer assisted education and motivational interviewing.|9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
75819799|NCT01067963|Behavioral|Group talks/social chat|9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
75819800|NCT01068041|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
75819801|NCT02180464|Drug|LAS41004|
75819802|NCT02180464|Drug|control|
75819803|NCT02756338|Device|BioMonitor 2 Insertable Cardiac Monitor|
75654720|NCT02480699|Biological|Recurring blood sample|
75819804|NCT02180620|Other|No exercise|During the no exercise trial (NoEX), the participants will remain sedentary during testing.
75819805|NCT02180620|Other|Meal then exercise|During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed
75819806|NCT02180620|Other|exercise then meal|During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed
75819807|NCT02180698|Other|Laboratory Biomarker Analysis|Correlative studies
75819808|NCT02180698|Radiation|Radiation Therapy|Undergo radiation therapy
75819809|NCT02180698|Drug|TLR4 Agonist GLA-SE|Given intratumorally
75940661|NCT03674489|Other|Neurodynamic Slider Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULNT2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to slide the nerve proximally and distally in an alternating manner via providing wrist extension with concurrent shoulder girdle elevation and then providing wrist flexion with concurrent shoulder girdle depression. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
75940662|NCT03674489|Other|Neurodynamic Tensioner Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULND2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to tension the nerve in an alternating on/off manner via providing wrist extension with concurrent shoulder girdle depression and then providing wrist flexion with concurrent shoulder girdle elevation. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
75802078|NCT03691428|Behavioral|Wish Outcome Obstacle Plan|"1. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if [specified obstacle - when I feel impatient], then I will [specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly] plan."
75344091|NCT05133414|Other|Selective left subclavian ansae stimulation|Percutaneous, transarterial approach for target stimulation
75654721|NCT02480699|Other|dietary survey|A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
75344092|NCT05130970|Drug|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
75654722|NCT02476097|Drug|Esomeprazole: Nexium® 20mg, Astra Zeneca|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
75344093|NCT05130970|Drug|Placebo|Same as the CSL312 formulation buffer
75344094|NCT05120869|Behavioral|Tailored HPV Education and Professional Skills Intervention Group|The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
75344095|NCT05120869|Behavioral|General HPV Education and Communication Skills Control Group|The general provider education intervention will involve audio and visual content and will be delivered in the English language.
75344096|NCT05120739|Drug|2% CHX cloths|skin preparation in 2% CHX cloths
75476355|NCT05970835|Other|Experimental group|"Experimental group evaluation: balance, functionality- 30 Second Sit To Stand Test, Modified Medical Research Council and functional status questionnaire, pain using VAS, cognitive variables-Montreal Cognitive Assessment and self-reported thermal water effects.After evaluation the App will display exercises related to data collected. Outcome measures will be collected at baseline, and 1 week, 1 month and 3 months after baseline.~After evaluation the App will display exercises related to data collected concerning participants condition improvement."
75654723|NCT02476097|Other|CYP2C19 phenotypical analysis|All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.
75654724|NCT02476097|Drug|Placebo|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
75476356|NCT05970822|Drug|BC3402|Escalating of BC3402 will be administered IV(intravenous)
75476357|NCT05970822|Drug|Azacitidine|Azacitidine will be administered daily
75654725|NCT02434809|Procedure|Bronchoscopic Implantation|Calypso transponders
75654726|NCT02434809|Device|Cone-Beam CT-Guided|
75654727|NCT02434809|Radiation|stereotactic body radiation treatments|
75476358|NCT05970783|Drug|Jincaopian Tablets|Jincaopian Tablets 0.2g tid p.o.
75476359|NCT05970783|Other|Placebo|Placebo 0.2g tid p.o.
75476360|NCT05970757|Diagnostic Test|Extended MRI|Extension of the brain tumor MRI-protocol
75654728|NCT02335996|Biological|Blood samples for measuring adiponectin, leptin and omentin plasma|
75344097|NCT05118295|Device|SAVI Scout®|Savi Scout marker is placed within 1 cm of the breast tumor
75476361|NCT05970705|Drug|Regorafenib|this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer
75476362|NCT05970705|Drug|Trifluridine/Tipiracil|this chemotherapeutic drug is also one of the standard third-line treatment options for patients with metastatic colorectal cancer
75476363|NCT05970679|Drug|Ezetimibe/Atorvastatin 10/5 mg|DW1125
75476364|NCT05970679|Drug|Atorvastatin 5mg|DW1125A
75476365|NCT05970679|Drug|Ezetimibe 10mg|DW1125E
75476366|NCT05970679|Drug|Atorvastatin 10mg|DW1125A-1
75476367|NCT05970679|Drug|DW1125 placebo|Ezetimibe/Atorvastatin 10/5 mg placebo
75476368|NCT05970679|Drug|DW1125A placebo|Atorvastatin 5mg placebo
75476369|NCT05970679|Drug|DW1125E placebo|Ezetimibe 10mg placebo
75476370|NCT05970679|Drug|DW1125A-1 placebo|Atorvastatin 10mg placebo
75344098|NCT05111041|Behavioral|#EnufSnuff.TXT- First Responder|Participants in this intervention will be given the choice of following the Gradual Reduction to Quit program or to choose their own quit date within 2-4 weeks. The Gradual Reduction to Quit program will reduce smokeless tobacco use via text message support and weekly prompts guiding the participants to gradually decrease their use of smokeless tobacco until they are down to zero. A four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges will also be provided to all participants. The intent of this program is to reduce the number of times participants use smokeless tobacco.
75344099|NCT05111041|Behavioral|Enough Snuff Intervention|Participants will be sent the Enuf Snuff cessation manual, support text messages, as well as a four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges.
75344100|NCT05103358|Drug|nab-sirolimus|Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
75344101|NCT05102123|Drug|Cytisine|Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
75344102|NCT05102123|Behavioral|Video Messaging|Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.
75344103|NCT05102110|Diagnostic Test|Oricol Test|Assessment of rectal mucus for material from aero-digestive cancers.
75344104|NCT05089656|Genetic|OAV101|Gene therapy
75344105|NCT05089656|Procedure|Sham control|The sham procedure will consist of a small needle prick on the lower back at the location where the LP injection is normally made. The needle will break the skin, but no needle insertion for lumbar puncture will occur.
75344106|NCT05079230|Drug|Magrolimab|Administered intravenously (IV)
75654729|NCT02335996|Device|MRI at 3 Tesla|Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.
75476371|NCT05970653|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
75344107|NCT05079230|Drug|Venetoclax|Tablets administered orally
75476372|NCT05970653|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
75476373|NCT05970627|Drug|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
75476374|NCT05970627|Drug|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
75476375|NCT05970627|Drug|S1|S-1 orally intake as perioperative chemotherapy
75476376|NCT05970601|Dietary Supplement|Soup|Intake of a single soup with different sodium chloride and potassium chloride content
75476377|NCT05970575|Drug|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (6 months)
75654730|NCT02316951|Device|single-arm study group|Study participants will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room. Study participants will be questioned about their sociodemographic, pain, and health history.
75654731|NCT02227251|Drug|Selinexor|Dose: 60 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
75654732|NCT02227251|Drug|Selinexor|Dose: 40 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
75654733|NCT02227251|Drug|Selinexor|Dose: 60 mg (BIW) and 60 mg (QW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
75654734|NCT03946358|Biological|Blood sample collection|"Four blood samples will be collected at:~baseline~2 months from inclusion (+/- 1 week)~4 months from inclusion (+/- 1 week)~the end of vaccination visit (+/- 1 week).~A total of 8 EDTA (ethylenediaminetetraacetic acid) tubes of 6 ml will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell [PBMC] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: One 6 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
75654735|NCT03946358|Procedure|Tumor biopsies|A tumor biopsy will be realized and centralized at baseline and at 2 months. Collection of tumor biopsies will be guided by ultrasound or CT scan
75654736|NCT03946358|Other|CT scan|"A CT scan will be planned~at baseline~at tumor evaluation visit (8 weeks)~every 8 weeks (+/- 1 week)~at end of treatment visit."
75344108|NCT05079230|Drug|Azacitidine|Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
75344109|NCT05079230|Drug|Magrolimab Placebo|Administered intravenously (IV)
75344110|NCT05077904|Drug|Staccato alprazolam|"Route of administration: Inhalation~Participants will receive one dose of Staccato alprazolam during the Treatment Period."
75344111|NCT05077904|Other|Placebo|"Route of administration: Inhalation~Participants will receive one dose of placebo during the Treatment Period."
75344112|NCT05076617|Drug|Staccato alprazolam|"Pharmaceutical form: Inhalation powder~Route of administration: Inhalation~Participants will receive Staccato alprazolam during the Treatment Period."
75344113|NCT05075824|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight >= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight >= 100 kg). Dosing schedule will be as per Arm Description.
75344114|NCT05075824|Drug|Placebo|Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
75344115|NCT05067595|Procedure|Colonoscopy|Undergo lower FMT via colonoscopy
75344116|NCT05067595|Biological|Fecal Microbiota Transplantation|Given upper FMT PO
75344117|NCT05067595|Biological|Fecal Microbiota Transplantation|Undergo lower FMT via colonoscopy
75940663|NCT03674489|Other|Sham Neurodynamic Mobilization|Subjects will be positioned in supine with the examiner supporting his/her arm and facing cranially - in a similar position as the UNLD1 test described previously. From here, the therapist will position the patient's arm in 45 deg. of shoulder abduction without scapular depression, 45 deg. of shoulder external rotation, 45 deg. of elbow flexion, and forearm pronation. From this position, a series of sham mobilizations will be performed by passively alternating flexion and extension of the wrist for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position).
75940664|NCT02538809|Other|measurement of tumor mRNA concentration in urine|bed-side test of tumor mRNA concentration in urine
75940665|NCT03114098|Other|gene abnormalities|A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
75940666|NCT05089786|Device|Exablate Neuro Type 1.0 System with Echo Focusing|MR-Guided Focused Ultrasound
75940667|NCT02671760|Drug|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
75940668|NCT02671760|Drug|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
75344118|NCT05067595|Dietary Supplement|Nutritional Supplementation|Given dietary fiber supplementation PO
75654737|NCT03946358|Drug|Atezolizumab|"Induction phase: Atezolizumab 1200 mg intravenous every 3 weeks since day 1~Boost phase: Atezolizumab 1200 mg intravenous every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
75654738|NCT03946358|Drug|UCPVax|"Induction phase: UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase: UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)."
75654739|NCT02106507|Drug|apalutamide|apalutamide, 240 mg/day, oral
75940669|NCT02671760|Drug|Placebo|Placebo
75940670|NCT04250714|Device|Boston Scientific Cardiac Cryoablation System|cryoablation of atrial fibrillation consisting in electrical isolation of the pulmonary veins
75940671|NCT03114176|Dietary Supplement|Ketogenic Diet|Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
75940672|NCT05085340|Drug|Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)|IPTi will be administered as full therapeutic courses of SP alongside routine EPI immunisations at defined intervals corresponding to vaccination schedules - usually at 10 weeks, 14 weeks, and 9 months of age - to infants living in project districts. Additional doses of IPTi will be administered at 6, 12, and 15 or 18 months of age, coinciding with vitamin A administration and measles booster immunisation. The number of doses of IPTi a child will receive will depend of the EPI schedule in the country, with a maximum of six doses in the first two years of life.
76090315|NCT02301819|Other|Early conservative therapy according to standard practice|Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
76090316|NCT01928290|Drug|Irinotecan|
76090317|NCT01928290|Drug|Trastuzumab|
75344119|NCT05067595|Other|Survey Administration|Ancillary studies
75344120|NCT05065541|Drug|CC-97489|Specified dose on specified days
75344121|NCT05065541|Drug|[18F]T-401|Specified dose on specified days
75344122|NCT05065541|Drug|[11C]MK-3168|Specified dose on specified days
75344123|NCT05061134|Drug|Ceralasertib|Ceralasertib (240 mg) will be administered orally twice daily.
75344124|NCT05061134|Biological|Durvalumab|Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above > 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.
75344125|NCT05052996|Drug|ISL|Capsules administered orally without regard to food
75344126|NCT05052996|Drug|LEN|Tablets administered orally without regard to food
75654740|NCT02106507|Drug|Everolimus|5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
75654741|NCT02085668|Device|Renal denervation (Symplicity™)|Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
75654742|NCT02051218|Drug|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
75654743|NCT02051218|Drug|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
75654744|NCT01964261|Device|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 3 NeuroPort Arrays (SIROF). The tip of the electrodes are sputtered iridium oxide film (SIROF). Each array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
75654745|NCT01905046|Drug|metformin hydrochloride|given PO
75654746|NCT01905046|Other|placebo|given PO
75654747|NCT01596621|Drug|Bendamustine hydrochloride|Bendamustine will be be administered per dose and schedule specified in the arm description.
75654748|NCT01337245|Drug|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
76090318|NCT01928290|Drug|Oxaliplatin|
76090319|NCT01928290|Drug|Leucovorin|
75802079|NCT03745872|Behavioral|Knowledge Assessment|Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
75965969|NCT02086721|Drug|L19-IL2|"Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle."
76090320|NCT01928290|Drug|Fluorouracil|
76090321|NCT04272177|Other|Shared decision making with the used of patient decision aids|PDA is used to explain choices of reversal drugs using SDM approach during consultation. The patients and medical staff explore the preferences with PDA and make decision together.
76090322|NCT01893489|Other|68Gallium-MSA|68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
76090323|NCT01894113|Procedure|transbronchial lung biopsy|
76090324|NCT02772939|Device|Renal sympathetic denervation (RDN)|Catheter based renal sympathetic denervation for therapy resistant arterial hypertension
76090325|NCT02282319|Drug|spinal dexmedetomidine 0.5 mcg|Administration of dexmedetomidine 0.5 mcg
76090326|NCT02282319|Other|spinal chloroprocaine 40 mg|spinal anesthesia with chloroprocaine 40 mg
75654749|NCT01264315|Drug|Lenalidomide|"Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~absolute neutrophil count >1x109/L without growth factors~platelet count >75x109/L without transfusion support~calculated/measured creatinine clearance: ≥20mL/minute~total bilirubin <2 x the upper limit of normal~AST (SGOT) and ALT (SGPT) <2.5 x upper limit of normal~<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart."
75802080|NCT04122534|Behavioral|Somatic Mindfulness Training|Educational and experiential training to reduce occupational-based secondary trauma.
75802081|NCT04091360|Drug|Part A: RPL554|Single dose RPL554 via metered dose inhaler.
75802082|NCT04091360|Drug|Placebos|Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
76090327|NCT02282319|Drug|IV dexmedetomidine 0.5 mcg/kg|intravenous administration of dexmedetomidine 0.5 mcg/kg
76090328|NCT02281695|Other|PEEP adjusment during the Weaning process|The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
76090329|NCT02278965|Drug|Metformin|Metformin 850mg, oral, twice a day for 12 months
76090330|NCT02278965|Drug|Omega-3 fatty acids|Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
76090331|NCT02514837|Device|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
76090332|NCT02276313|Device|Passeo-18 Lux|Endovascular Therapy
76090333|NCT01928446|Drug|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
76090334|NCT01928446|Drug|Placebo|Oral placebo tablets will be administered for the duration of follow-up (1 year).
76090335|NCT02983149|Device|Double lumen tube|Use an double lumen tube to achieve one lung ventilation in thoracic surgeries
76090336|NCT02983149|Device|Fuji blocker|Use the Fuji blocker to achieve one lung ventilation in thoracic surgeries
75802083|NCT04091360|Drug|Part B: RPL554|Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
75802084|NCT04346628|Drug|Favipiravir|Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).
75802085|NCT04346628|Drug|Placebo|Placebo to match favipiravir administered orally through day 10.
75802086|NCT04346628|Other|Standard of care treatment|Standard of care treatment for COVID-19 infection
75802087|NCT03681470|Drug|Aczone Gel|Aczone Gel 7.5%
75802088|NCT02414750|Drug|Vemurafenib plus cobimetinib|Molecular targeted therapy for BRAF mutated advanced melanoma patients
75802089|NCT02414750|Device|Positron Emission Tomography|Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
76090337|NCT02983149|Device|EZ blocker|Use the EZ blocker to achieve one lung ventilation in thoracic surgeries
76090338|NCT02983383|Procedure|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
76090339|NCT02983383|Procedure|spinal anesthesia|Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
76090340|NCT02987296|Dietary Supplement|Immunonutrition with arginine|Nutritional beverage containing supplemental arginine taken 3 times per day
76090341|NCT02987296|Dietary Supplement|Immunonutrition without Arginine|Nutritional beverage without supplemental arginine taken 3 times per day
76090342|NCT02748369|Drug|Somatostatin|Somatostatin infusion to create a low insulin state.
75344127|NCT05052996|Drug|B/F/TAF|Tablets administered orally without regard to food
75940673|NCT03670433|Other|Cost analysis of medication reconciliation|"The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS."
75940674|NCT02667236|Drug|A-101 Solution|Active Drug
76090343|NCT02748369|Drug|Glucagon|Glucagon infusion in the setting of ongoing somatostatin.
76090344|NCT01928524|Drug|DOS2w Dose level 1A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
76090345|NCT01928524|Drug|DOS2w Dose level 2A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
76090346|NCT01928524|Drug|DOS2w Dose level 3A|Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
76090347|NCT01928524|Drug|DOS2w Dose level 4A|Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
75344128|NCT05042882|Dietary Supplement|Early enteral nutrition|Enteral nutrition via nasojejunal tube
76090348|NCT01928524|Drug|DOS3w Dose level 1B|Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
76090349|NCT01928524|Drug|DOS3w Dose level 2B|Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
75344129|NCT05032235|Drug|Fluzoparib|Normal Renal Function:A single oral dose of Fluzoparib will be administered.
75654750|NCT01108627|Drug|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
75344130|NCT05032235|Drug|Fluzoparib|Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
75476378|NCT05970562|Device|Ambulatory Voice Monitoring with Biofeedback (AVM-B)|AVM-B is software on the Voice Health Monitor that uses a neck-placed accelerometer to sense neck skin vibrations during voicing in daily life. The AVM-B consists of cues every time the patient exceeds a subject-specific threshold, [100% frequency AVM-B] and/or summary statistics every 2 minutes of voicing [Summary AVM-B].
75654751|NCT01108627|Drug|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
75654752|NCT01108627|Drug|foradil|open-labeled inhaled corticosteroids (ICS); foradil
75940675|NCT02667236|Other|Vehicle Solution|Placebo
75940676|NCT01126749|Drug|Gemcitabine|Gemcitabine
75940677|NCT01126749|Drug|E7389|E7389
75476379|NCT05970562|Behavioral|Conversation Training Therapy|CTT is a 4-week (1 45-minute session per week) evidence-based voice therapy for patients with VH, developed primarily to maximize the amount and speed of generalization outside the therapy session. It consists of 3 required targets: Decreased overall auditory-perceptual voice severity, improved discrimination between baseline and improved voicing, and adherence to CTT recommendations in daily life. The three optional targets are decreased overall auditory-perceptual severity across an increased pitch range, loudness range, and decreased rate of speech. All voice-related targets are modified through practicing voicing with increased forward resonance and mean airflow in spontaneous speech/conversation.
75654753|NCT00890149|Drug|Ondansetron|Ondansetron (4ug/kg bid),
75654754|NCT00890149|Drug|Placebo|Placebo bid
75654755|NCT00890149|Behavioral|BASICS Plus|Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.
75654756|NCT00813982|Device|Lotrafilcon A Experimental Contact Lens|Experimental spherical, silicone hydrogel soft contact lens
75940678|NCT01126749|Drug|Cisplatin|Cisplatin
75344131|NCT05032235|Drug|Fluzoparib|Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
75344132|NCT05028062|Drug|XR-NTX 380 mg, intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
75476380|NCT05970536|Other|Apple vinegar or EDTA 17%|Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.
75476381|NCT05970523|Other|Core Stabilization Exercises|Core stabilization exercises are known as a very effective exercise method based on the motor learning principle, performed with the individual's own body weight to strengthen the muscles, improve balance, posture, trunk muscle endurance and flexibility.
75344133|NCT05028062|Behavioral|Medical Management|All subjects will receive 8 weeks of medical management (Pettinati et al. 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
75344134|NCT05028062|Drug|Placebo intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
75344135|NCT05024032|Drug|Tirzepatide|Administered SC
76090350|NCT01928524|Drug|DOS3w Dose level 3B|Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
75344136|NCT05024032|Drug|Placebo|Administered SC
76090351|NCT05739760|Behavioral|Poem book about relational health|Poem book will consist of illustrations, poetry, and tips for parents on how to resolve their child's upset, their own upset, and to develop a stronger relationship. The study physician may read the book to the families at the visit. Then, families are instructed to read the book at least once, for as many times as the parent opts to.
75344137|NCT05020236|Drug|Elranatamab|subcutaneous
75654757|NCT00813982|Device|Lotrafilcon A Commercial Contact Lens|Commercially marketed spherical, silicone hydrogel soft contact lens
75654758|NCT00566098|Biological|MILs|
75476382|NCT05970432|Drug|TQH2722 injection 300mg-150mg|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
75344138|NCT05020236|Drug|Daratumumab|Daratumumab / hyaluronidase, subcutaneous
75344139|NCT05020236|Drug|Pomalidomide|oral
75344140|NCT05020236|Drug|Dexamethasone|oral
75344141|NCT05016700|Diagnostic Test|blood sample|we want to identify a diagnostic option to identify patients, who have a neuropathological distraction of their ganglia cells in the bowel
75344142|NCT05005013|Other|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
75344143|NCT05005013|Other|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
75654759|NCT00566098|Drug|Melphalan|
75344144|NCT05005013|Other|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
75344145|NCT05004350|Drug|Encorafenib|oral hard capsule
75344146|NCT05004350|Drug|Cetuximab|intravenous infusion
75476383|NCT05970432|Drug|TQH2722 injection 600mg-300mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
75476384|NCT05970432|Drug|TQH2722 injection 900mg-450mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
75654760|NCT00566098|Biological|PCV13|
75654761|NCT00248287|Drug|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
75654762|NCT00248287|Drug|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
75654763|NCT04250220|Diagnostic Test|e-Health based strategy: PPG-based screening using a smartphone and ECG patch|PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch
75654764|NCT00703599|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
75654765|NCT04249284|Drug|BMS-986165|Specified dose on specified days
75654766|NCT04249284|Drug|BMS-986165 prototype 1|Specified dose on specified days
75654767|NCT04249284|Drug|BMS-986165 prototype 2|Specified dose on specified days
75654768|NCT04474938|Drug|Daratumumab|16mg/kg, QW Cycles 1-2 (28 days/cycle), Q2W Cycles 3-6, and Q4W thereafter for up to 1 year
75654769|NCT04474938|Drug|Bortezomib|1.3mg/m2 of subcutaneous bortezomib on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
75654770|NCT04474938|Drug|Dexamethasone|20mg of dexamethasone on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
75654771|NCT00837213|Drug|Benzoyl peroxide with clindamycin|Benzoyl peroxide wash - Clindamycin foam
75654772|NCT00837213|Drug|Benzoyl peroxide with clindamycin and doxycycline|Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
75940688|NCT02521948|Device|MANTA Vascular Closure Device|The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
75940689|NCT03674333|Dietary Supplement|Folic Acid|Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
75654773|NCT04249050|Dietary Supplement|Oral Impact powder|Oral nutritional supplement containing fish oil, arginine and RNA
75654774|NCT05602155|Procedure|Group 1|Even numbered patients will partial weight bearing after treatment,
75940690|NCT03674333|Other|Placebo|Placebo - a sugar pill
75940691|NCT04216238|Behavioral|quasi-experimental Pre-test/Post-test design|surveys to document progress
75940692|NCT03479463|Biological|Dehydrated human amnion/chorion membrane|Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
75940693|NCT05126134|Diagnostic Test|KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)|completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h
75940694|NCT04059107|Device|3D Printed Myoelectric Prosthetic Device|3D Printed Myoelectric Prosthetic Device
75940695|NCT03674099|Drug|Imatinib Mesylate|Tablets 400 mg
75344147|NCT05004350|Drug|FOLFIRI|"Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion"
75344148|NCT04998851|Drug|Ocrelizumab|Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
75344149|NCT04998812|Drug|Ocrelizumab|Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
75344150|NCT04990466|Drug|IIBR-100|Administration of IIBR-100 vaccine
75344151|NCT04990466|Drug|Active Comparator|Administration of a currently-approved vaccine for COVID-19
75476385|NCT05970432|Drug|TQH2722 injection matching Placebo|Placebo without active substance.
75654775|NCT05602155|Procedure|Group 2|patients with odd numbers will walk with full weight bearing after treatment
75654776|NCT02836392|Behavioral|Questionnaire|
75654777|NCT02833038|Drug|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
75654778|NCT02833038|Drug|Normal saline|the same bolus and infusion volumes of normal saline
75654779|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
75802090|NCT02414750|Procedure|Tissue sampling|Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
75654780|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
75940696|NCT03674099|Drug|Methylprednisolone|1 g tablets or infusion
75654781|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
75654782|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
75654783|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
75654784|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
75654785|NCT00703755|Drug|Placebo|Placebo
75654786|NCT02836158|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
75654787|NCT05600205|Behavioral|GOAL!|GOAL! is a integrated support focused on a combination of lifestyle factors for achieving a healthier lifestyle for people with severe mental illness. The intervention consists of two year of guidance from a lifestyle coach and qualified professionals.
75654788|NCT04201314|Dietary Supplement|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
75654789|NCT04201314|Dietary Supplement|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
75654790|NCT00703833|Drug|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
75654791|NCT00703833|Drug|Placebo (unspecified)|matching placebo
75802091|NCT02414750|Procedure|Blood sampling|Before and during treatment and at time of progression patients will undergo blood sampling
75802092|NCT04343976|Drug|Pegylated interferon lambda|180 mcg subcutaneous injection of pegylated interferon lambda
75802093|NCT03322540|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
75802094|NCT03322540|Drug|Epacadostat|Epacadostat administered orally twice daily.
75802095|NCT03322540|Drug|Placebo|Matching placebo administered orally twice daily.
75802096|NCT03619226|Other|test patch|the test patch consists of an adhesive patch
75940697|NCT05124340|Biological|BCG vial vaccine|Intradermal injection
75940698|NCT05124340|Biological|BCG ampoule vaccine|Intradermal injection
75940699|NCT03479385|Behavioral|Integrative Medicine Intervention|Study participants will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months, potentially followed by a 6 month maintenance phase.
75940700|NCT03479385|Behavioral|Health Education Intervention|Study participants will attend 14 sessions with a Health Educator over the course of 6 months.
75940701|NCT04762628|Dietary Supplement|MAF capsules 148 mg|enteric capsules based on enzymatically treated bovine colostrum
75940702|NCT04762628|Dietary Supplement|M capsules 148 mg|enteric capsules based on enzymatically treated bovine whey
75940703|NCT04762628|Other|Standard of care|Standard of care
75940704|NCT03670199|Other|Dietary advice|Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet
75940705|NCT03670199|Other|Physiotherapist intervention|Respiratory capacity Functional capacity
75940706|NCT03670199|Other|Dietary intervention|Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
75940707|NCT03670199|Other|Intensify physiotherapist intervention|Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
75940708|NCT03481647|Procedure|Oral care programme|Professional oral care (dental hygienist), intensified oral care measures by the patient
75476386|NCT05970393|Procedure|pressure support level tatrition|Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Upward and downward PS level adjustments were performed from the baseline PS level at a 1cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. PMI mean value was measured and calculated at every PS level. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O, and titrating PS was stopped until PMI was less than -1cmH2O and more than 3cmH2O.The inspiratory effort is measured as the pressure generated by inspiratory muscles using esophageal pressure monitoring.
75476387|NCT05970367|Other|Intensive rehabilitation programme|"Intensive rehabilitation using advanced technology, based on the patient's goals.~Including cardiovascular fitness training, goal-oriented training, physiotherapy with and without advanced technology and self-management."
75940709|NCT04159688|Drug|Alcohol|Alcohol Challenge
75940710|NCT05084404|Drug|Experimental: 4 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
76090352|NCT05739760|Behavioral|Poem book about physical health and safety|Poem book will consist of illustrations, poetry, and tips for parents on how to keep their child physically healthy and safe, and to avoid accidental injuries. The study physician may read the book to the families at the visit. Then families are instructed to read the book at least once, for as many times as the parent opts to.
76090353|NCT01894191|Procedure|Air insufflation|Insufflation during colonoscopy including insertion phase
75344152|NCT04989309|Device|Transcranial Magnetic Stimulation|TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.
75344153|NCT04985942|Drug|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
75344154|NCT04985942|Drug|Placebo|Matching capsules administered orally, once daily.
75654792|NCT05599893|Other|Tele physical therapy|Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm up, 60 minutes of training and 10 minutes of cool down phase. The participants in the TPG received training four times a week, for 8 weeks, each session lasted for 60 minutes.
75344155|NCT04963270|Drug|Satralizumab|Satralizumab will be administered as a subcutaneous injection
75654793|NCT05599893|Other|Patient educationa and Conventional exercises|They were informed to do their normal daily activities, avoid a sedentary lifestyle, perform regular physical activities such as household activities, maintain a balanced diet and have 6-8 hours of sleep per day.
75654794|NCT02838342|Drug|Metronomic cyclophosphamide|50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance
75654795|NCT02838342|Drug|Interferon-alpha|3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
75654796|NCT05333640|Device|Sirolimus Drug Coated Balloon|AVFs treated with SDCB
75654797|NCT05333640|Device|Paclitaxel Drug Coated Balloon|AVFs treated with PDCB
75654798|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
75654799|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
75654800|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
75654801|NCT02838264|Drug|PF-06463922|Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
75940711|NCT05084404|Drug|Experimental: 8 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
75940712|NCT03473613|Drug|Oral Cabergoline|Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days
75940713|NCT03473613|Drug|Calcium Gluconate|Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days
75940714|NCT03673631|Device|NIV|NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
75940715|NCT03673631|Device|NFHC-O2|NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
75940716|NCT04143776|Procedure|Abdominal reconstruction|No restrictions are set on surgical procedures or anaesthetic management.
75940717|NCT03859011|Other|Acupuncture|"Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion."
75940718|NCT03859011|Other|Usual Care|Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
75940719|NCT03670043|Drug|Psyllium powder|To evaluate whether Psyllium will alleviate diarrhea
75940720|NCT03670043|Drug|Metformin Extended Release Oral Tablet|Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin
75344156|NCT04963270|Other|Placebo|Satralizumab placebo will be administered as a subcutaneous injection
75654802|NCT02838264|Drug|Itraconazole|200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
75654803|NCT00902486|Drug|INCB028050|4 mg capsules QD
75802097|NCT04339296|Device|Spencer|The MDS dispenses medications on time with visual and audio reminders. The audio alert get louder if the plastic medication packet is not dispensed from the system. The MDS allows participants to dispense their medications early if they are going to be away from home. The system also displays personalized and health-condition speciﬁc questions. The pre-packaged medications are delivered by pharmacy that inserted directly into the spencer device. Spencer system is non-inclusive and approved by Health Canada.
75940721|NCT05084092|Radiation|Intraoperative Radiotherapy (IORT)|If biopsy is positive, local treatment with IORT will be performed. After IORT (15,40 Gray at 2 mm dept), the applicator will be removed and surgery will be continued in a standard fashion.
75940722|NCT05084092|Procedure|Brain surgery|Surgery should be performed according to the local standard of care, preferentially as image-(neuronavigation) guided surgery. To establish the diagnosis of a metastasis and to exclude primary CNS tumors, lymphomas, SCLCs or germinomas it will be performed a peroperative biopsy
75940723|NCT02388464|Drug|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
75940724|NCT02388464|Drug|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
75940725|NCT02388464|Drug|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
75476388|NCT05970315|Behavioral|PPC|Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.
75654804|NCT00902486|Drug|INCB028050|7 mg capsules QD
75654805|NCT00902486|Drug|INCB028050|10 mg capsule QD
75940726|NCT02388464|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
75940727|NCT03131427|Drug|Standard of care|Standard of care according to the updated national and/or international guidelines
75940728|NCT03114345|Other|Measurement of interface pressure|A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
76090354|NCT01894191|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
75476389|NCT05970315|Behavioral|Usual care|Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.
75802098|NCT02963740|Behavioral|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
75802099|NCT02963740|Behavioral|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
75802100|NCT02963740|Behavioral|Group Phone Calls|Once weekly phone calls that are group-based. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
75940729|NCT03114345|Other|Measurement of micro-vascularization related parameters|A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
75940730|NCT05082376|Drug|ChapStick Lip Moisturizer Original|Sunscreen lip balm.
75940731|NCT04446429|Drug|Proxalutamide|200 mg q.d.
75940732|NCT04446429|Other|Standard of Care|Standard of care as determined by the PI
75476390|NCT05970302|Drug|Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine|Use the above medications on a regular basis.
75476391|NCT05970250|Other|Whole body vibration group|Whole body vibration apparatus (model Power plate -my5tm, made in United States) with frequency 30 - 40 Hz was used for the whole body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum.
75654806|NCT00902486|Drug|Placebo|Placebo matching INCB028050 QD
75654807|NCT00633438|Other|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
75654808|NCT00633438|Drug|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
75654809|NCT00836745|Other|Non Interventional|Sutent capsule, once daily administered per the locally approved product information.
75654810|NCT02833116|Drug|Betamethasone|
75654811|NCT02833116|Drug|Dexamethasone|
75654812|NCT02838654|Procedure|cervical epidural injection|sensitivity, specificity, positive predictive value, negative predictive value
75802101|NCT02963740|Behavioral|Diet|Participants will consume a nutritionally balanced, reduced calorie diet as recommended by the Academy of Nutrition and Dietetics.
75802102|NCT02909452|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
75940733|NCT05675384|Device|TENS Active Treatment|Using a 7-day/week wearable TENS device controlled by a Smart Phone App combined with moderate intensity lifestyle therapy,
76090355|NCT01894191|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
76090356|NCT01928680|Drug|Cisplatin/Capecitabine|Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
75476392|NCT05970250|Other|Weight bearing exercises|Electronic treadmill Kettler- marathon model No 7899-800, made in Germany (as form of weight bearing exercises), which was adjusted to the subject's comfortable walking speed. Generally, during the treadmill training, its speed and inclination are electronically adjusted, and it is also provided with a control panel to display the exercise parameters. It allows for the comfortable running without joint or back pains through a perfect combination between aluminium-pertinax running deck, shock absorbers and overall shock-damping design.
75476393|NCT05970250|Drug|vitamin D supplements and calcium|vitamin D supplements and calcium
75476394|NCT05970211|Device|Phonak Audeo Lumity Receiver in Canal Hearing Aid|bilateral receiver in canal hearing aids provided as part of a best practices hearing loss intervention including devices, hearing centered counseling, and self management skills training for hearing loss
75476395|NCT05970198|Radiation|Total Marrow irradiation，TMI|"TMI radiation dose On the 5th day (-5 days) before transplantation, an irradiation dose of 8 Gy is given.~TMI uses a 6-18MV linear accelerator, the patient lies on his side in a single irradiation field, covered with a 1 cm thick plexiglass frame, and the radioactive source is 4 meters away from the body surface of the human side. The anterior and anterior positions were alternately irradiated, and the horizontal beam was irradiated in the opposite direction, and the actual irradiation dose was detected by the thermo-optical element of the 2570 roentgen dosimeter scale, and the irradiation dose of all parts of the body was adjusted to make the abdominal irradiation dose difference within 10%, the total dose was 8Gy, divided into 2 times a day, with an interval of 5 hours, and the dose rate was 4.99-6.96cGy/min."
75476396|NCT05970198|Procedure|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation;Porting method melphalan
75476397|NCT05970133|Procedure|Colectomy with NOSE procedure|The specimen will be extract from the anus.
75476398|NCT05970055|Procedure|elective surgery|All elective surgical procedures performed under the study period will be included.
75476399|NCT05970029|Behavioral|Communication style|The verbal communication between the nurse and the patient at the time of analgesic administration
75476400|NCT05970003|Other|Copenhagen exercises|"Group A performs copenhagen exercises~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
75654813|NCT00703989|Dietary Supplement|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
76090357|NCT02488785|Behavioral|Virtual Diabetes Self-Care and Education Program|Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
76090358|NCT02488785|Device|Fitbit|Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
75802103|NCT02909452|Drug|Pembrolizumab|A selective humanized monoclonal antibody (mAb)
75802104|NCT02517502|Drug|DHA|4 capsules of 400 mg DHA daily
75940734|NCT05675384|Device|Sham Device|Using the sham (control) device combined with a moderate intensity lifestyle follow-up
75940735|NCT04432467|Biological|Autologous mesenchymal stem cells|Autologous adipose tissue-derived mesenchymal stem cells
75940736|NCT04432467|Other|standard treatment|standard treatment according to clinical protocols
75940737|NCT05561660|Device|PFO device closure|Participants randomized into this group will take PFO device closure.
75940738|NCT05561660|Drug|Aspirin|Participants randomized into this group will take aspirin 200mg qd for 6 months.
75940739|NCT03042819|Drug|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
75654814|NCT02838186|Procedure|retroflexion|examination of the right colon with scope retroflexion
75654815|NCT02838186|Procedure|forward view|examination of the right colon in forward view
75654816|NCT02835924|Drug|Regorafenib|
75654817|NCT03823430|Diagnostic Test|Pupillometry|Pupillar diameter variation measurement
75802105|NCT02517502|Drug|Placebo|Matched, blinded placebo
75802106|NCT03629002|Biological|Study of the gene expression profile|qPCR analysis
75654818|NCT00891618|Other|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
75654819|NCT05335460|Drug|Envafolimab|300mg,sc,d1,Q3W
75802107|NCT02025556|Drug|LBR-101 High Dose|Subcutaneously Administered High Dose LBR-101 Monthly x 3
75940740|NCT03042819|Drug|Doxorubicin|Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
75654820|NCT03816878|Biological|H5N1 pISV|Administered as an intramuscular (IM) injection
75654821|NCT02836002|Drug|Sulfadoxine-pyrimethamine (low dose)|- subcurative regimen (500mg/25mg)
75654822|NCT02836002|Drug|Piperaquine (low dose)|- subcurative regimen (480 mg)
75654823|NCT02836002|Drug|Sulfadoxine-pyrimethamine (high dose)|- curative regimen (1000mg/50mg)
75802108|NCT02025556|Drug|LBR-101 Low Dose|Subcutaneously Administered Low Dose LBR-101 Monthly x 3
75802109|NCT02025556|Drug|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
75802110|NCT04334460|Drug|BLD-2660|BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.
75802111|NCT01935466|Drug|Pioglitazone|Ever users of Pioglitazone
75940741|NCT02388308|Device|Clarity ultrasound|Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
75965970|NCT03046160|Other|Manual therapy (Mobilization with movement)|grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
76090359|NCT02488785|Device|Smartphone|All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
75940742|NCT02388542|Behavioral|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
76090360|NCT01929460|Drug|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
76090361|NCT01929460|Other|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
76090362|NCT03029416|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy using different fractionation schedules
76090363|NCT01753193|Biological|Anifrolumab|Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
76090364|NCT02477163|Other|Ayurveda treatment|"Gokshuradi Guggulu (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) - 1 g, 3 times in a day after food with warm water.~Varunadi kvath (ingredients: Varuna tvak + Bilva moola + Apamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) - 40 ml 2 times in a day after food.~Rasayan Churna (powder of Gokshura + Amalaki + Guduchi in equal quantities ) - 3 g, 3 times a day with water.~Bhumyamalaki (Tamalaki Rasayan) tablet - 1 g, 2 times in a day after food with water.~Uricare (of Punarvasu Pharmacy, Petlad road, Nadiad) tablet - 1 g, 3 times in a day after food with warm water.~Niruha Basti (procto-colonic administration of ayurvedic medicine) with Punarnavadi kvath (decoction) - in the morning, before one hour of the lunch."
75654824|NCT02836002|Drug|Piperaquine (high dose)|- curative regimen (960 mg)
75654825|NCT02836002|Biological|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
76090365|NCT02470377|Device|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
76090366|NCT02283814|Drug|BIA 2-093|
75654826|NCT02836002|Drug|Atovaquone-proguanil|- curative regimen: 1000/400 mg, for 3 days
75654827|NCT00836589|Device|ICD Therapy - ICD Lead Registry|Collecting long-term safety and efficacy data on a family of market-released ICD leads.
75654828|NCT03711812|Procedure|Serratus Anterior Plane Catheter|Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
75802112|NCT01776034|Behavioral|SystemCHANGE Group Lifestyle counseling|
75802113|NCT01776034|Behavioral|Phone Lifestyle Counseling|
75940743|NCT02832687|Drug|Acetaminophen|patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. <50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
75654829|NCT03711812|Procedure|Thoracic Epidural Catheter|Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
76090367|NCT02283814|Drug|Topamax|
76090368|NCT02737293|Other|Control Diet|4-week intake of Control Diet 5 day rotating menu
76090369|NCT02737293|Other|Med Diet|4-week intake of Med Diet 5 day rotating menu
76090370|NCT02737293|Other|Med Diet + Whole Egg|4-week intake of Med Diet plus Whole Egg 5 day rotating menu
76090371|NCT02231697|Other|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
75654830|NCT02835768|Other|Internet-based injury prevention program|"An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum."
75654831|NCT02835456|Device|Sharklet Catheter insertion|
75654832|NCT02835456|Device|Silicone Foley Catheter insertion|
75654833|NCT02842658|Other|A high-intensity interval exercise group|To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
75654834|NCT02842658|Other|An Attention-Control Group|Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
75654835|NCT05325060|Device|Electromagnetically navigated total knee arthroplasty|The navigated group had surgery using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
75654836|NCT05325060|Device|Conventional total knee arthroplasty|The conventional group received surgery using conventional instrumentation and jigs from the implant manufacturer (Zimmer Inc, Warsaw, IN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
75802114|NCT04334148|Drug|Hydroxychloroquine|oral self administered tablet
75802115|NCT04334148|Drug|Placebo oral tablet|oral self administered tablet
75802116|NCT01423630|Dietary Supplement|Probiotics and fruit fibre|probiotics and fruit fibre
75802117|NCT04399122|Drug|acetaminophen/codeine vs acetaminophen/oxycodone|pain medications
75802118|NCT00826462|Drug|triamcinolone|Injection with triamcinolone 10 mg at start and at 3 weeks
75802119|NCT00826462|Drug|Placebo|Injection with sodium chloride at start and at 3 weeks
75802120|NCT00826462|Drug|Lidocaine|10 mg of lidocaine at start and at 3 weeks
75940744|NCT02832687|Drug|normal saline|100mL of normal saline every 4 hours to a maximum administration of 400mL
75654837|NCT00574795|Biological|13vPnC|"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
75940745|NCT04421794|Device|NMES|Neuromuscular Electrical Stimulation (NMES) is a non pharmacological intervention that sends electrical impulses to nerves leading to muscle contraction. The electrical stimulation can increase strength and is often used to re-educate or re-train muscles.
75940746|NCT04421794|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.
75940747|NCT02388152|Drug|Lu AF20513, low dose|
75940748|NCT02388152|Drug|Lu AF20513, medium dose|
75940749|NCT02388152|Drug|Lu AF20513, high dose|
75940750|NCT02388152|Drug|Lu AF20513, double high dose|
75344157|NCT04958265|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing 40 to <100 kg) or 1500 mg IV (for participants weighing >=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing 40 to <100 kg) or 1020 mg SC (for participants weighing >=100 kg). Enrollment of participants weighing <40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing >=20 kg to <40 kg, followed by Group 2 participants weighing >=5 kg to <20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.
75802121|NCT00826462|Other|Physiotherapy|12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises
75344158|NCT04952220|Device|ultrasound|Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
75802122|NCT00826462|Drug|Naproxen|Naproxen 500 mg bid for 14 days
75344159|NCT04949256|Drug|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
75344160|NCT04949256|Drug|Lenvatinib|8 mg QD (induction) or 20 mg QD (consolidation) via oral capsule.
75344161|NCT04949256|Drug|Cisplatin|80 mg/m^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.
75802123|NCT04398732|Drug|Enbrel|As provided in real world practice
75802124|NCT04398030|Device|coil-reinforced soft polymer indwelling cannula|Insulin infusion set will be used for up to 7 days of continuous use or until failure
75802125|NCT04398030|Device|soft Teflon indwelling catheter|Insulin infusion set will be used for up to 7 days of continuous use or until failure
75344162|NCT04949256|Drug|5-FU|4000 mg/m^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m^2 Q2W via bolus IV infusion followed by 2400 mg/m^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
75344163|NCT04949256|Drug|Oxaliplatin|85 mg/m^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
75344164|NCT04949256|Drug|Leucovorin|400 mg/m^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
75654838|NCT02297516|Drug|Azzalure or Dysport|Glabellar lines
75654839|NCT02297516|Device|Restylane or Emervel filler|Facial tissue augmentation
75654840|NCT02297516|Device|Restylane Skinbooster|Facial skin rejuvenation
75654841|NCT00830479|Procedure|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
75654842|NCT00830479|Procedure|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
75802126|NCT03064438|Drug|ACCU-D1|ACCU-D1
75802127|NCT03064438|Drug|Vehicle|Placebo Comparator
75802128|NCT04327986|Drug|M7824|Intravenous (IV) on Days 1 and 15 of every cycle
75802129|NCT04327986|Drug|M9241|Subcutaneous injection on Day 1 of every cycle
75802130|NCT04327986|Radiation|SBRT|Radiation therapy will be starting on Day 17 (+5 days) of Cycle 1 and continue for 5 consecutive business days.
75940751|NCT02388230|Device|Ultrasound imaging|
75940752|NCT04372017|Drug|Hydroxychloroquine|Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.
75940753|NCT04372017|Dietary Supplement|Vitamin D|Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.
75802131|NCT05209516|Behavioral|Behavioral data|Participants will be seated comfortably in front of a cathode ray tube screen, at a distance of 50-70 cm. The refresh rate of the monitor will be kept above 75 Hz to avoid visual fatigue. Participants will be asked to perform an instructed-delay choice reaction-time task in which they will have to choose between a left and right finger response. In this task, we measure the reaction-times and movement times.
75940754|NCT04422106|Diagnostic Test|Predictors of intestinal anastomosis leakage, application of new predictors and new scores|Early detection of disruption and leakage of intestinal anastomotic sites whether small or large intestine by using biochemical markers as predictors and indicators of leakage with application of scoring scale to assess presence or absence of leakage.
75940755|NCT03479229|Device|Geneveve Treatment|The active treatment group will receive a treatment dose of 90 J/cm^2
75940756|NCT03479229|Device|Sham Treatment|The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm^2.
75940757|NCT05233358|Procedure|Hepatic Artery Infusion Chemotherapy|HAIC adopts FOLFOX chemotherapy regimen, hepatic arteriography through a radial artery or femoral artery cannulation, routine hepatic artery cannulation, imaging, infusion of chemotherapy drugs into hepatic artery: oxaliplatin 85 mg/m2 on the first day for 0-3 hours, folinic acid 400 mg/m2 for 3-4.5 hours on day 1, fluorouracil 400 mg/m2 for 4.5-6.5 hours on day 1, and fluorouracil 2500 mg/m2 for 46 hours on days 1-3.
75965971|NCT03046160|Other|neck and scapular exercises.|A program of 12 neck and scapular exercises.
75965972|NCT03046160|Other|corrective tape|elastic tape used to correct the anterior tilt of the scapula
75965973|NCT02086799|Drug|IV thyroxin|Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.
75965974|NCT02086799|Drug|Placebo|Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
75940758|NCT05233358|Procedure|Transarterial Chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
75344165|NCT04949256|Drug|Levoleucovorin|200 mg/m^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
75344166|NCT04949256|Drug|Paclitaxel|175 mg/m^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.
75344167|NCT04948619|Biological|Vaccine|Patients will have lab evaluations for immune function at baseline, 3, 6, 12, and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
75344168|NCT04941183|Drug|NTR-441|NTR-441
75940759|NCT05233358|Drug|Regorafenib|Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
75940760|NCT05233358|Drug|Immune Checkpoint Inhibitors|Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
75344169|NCT04941183|Drug|Placebo|Placebo
75344170|NCT04940624|Drug|Soticlestat|Soticlestat mini-tablets or tablets.
75344171|NCT04940624|Drug|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
75344172|NCT04930198|Behavioral|PeerNaija|All participants (N=50) will receive daily medication reminders and access to the virtual support group on the PEERNaija app. Participants will be randomized to receive a social incentive (n=25) or a social plus financial incentive (n=25), PEER+, and be followed for 24 weeks.
75940761|NCT05120752|Other|FODMAP diet|all participants need to follow a low FODMAP diet, the information will be given by a trained dietitian
75344173|NCT04924114|Drug|MK-6194|Subcutaneous injection
75344174|NCT04924114|Drug|MK-6194-matching placebo|Subcutaneous injection
75344175|NCT04922229|Procedure|RCT|This is the standard of care for this diagnosis
76090372|NCT05739682|Procedure|Local anaesthetic injection of 4% articaine with 1:100000 epinephrine|Buccal infiltration injection using a side loading aspirating syringe and a 30-gauge needle
75940762|NCT05120440|Other|Breakfast omission|Breakfast omission will consist of not eating breakfast on the morning of afternoon resistance training performance assessment.
75940763|NCT05120440|Other|Breakfast consumption|Breakfast consumption will consist of eating a standardized breakfast on the morning of afternoon resistance training performance assessment.
75940764|NCT03479151|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|MRgHIFU treatment will be delivered using a Philips Sonalleve system, which integrates a high intensity phased array focused ultrasound transducer with our Philips 3T Achieva imaging system. An electromechanical transducer positioning system is used to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively. The MR system is used to provide images to plan the therapy, and to guide and monitor the thermal ablation with thermal imaging during the treatment.
75344176|NCT04922229|Procedure|Pulpotomy|For cases with normal apical tissues, pulpotomy using tricalcium silicates has been shown to have high clinical success. Either partial or complete pulpotomy will be performed depending on the size of pulp exposure.
75940765|NCT05675228|Other|data collection|Knowledge about genital herpes
75940766|NCT02387918|Drug|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
75940767|NCT02387918|Device|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
76090373|NCT05739682|Procedure|Tooth isolation|Rubber dam application to the affected tooth
76090374|NCT05739682|Procedure|Access cavity preparation|Complete removal of caries, undermined tooth structure, and defective restoration. Access cavity preparation with complete removal of the pulp chamber roof using a sterile bur other than the ones used for caries removal.
76090375|NCT05739682|Procedure|Root canal shaping and cleaning|Working length determination using an electronic apex locator and then canal instrumentation using Hyflex CM rotary files up to size 40.04 with irrigation using 2.5% NaOCl between files.
75344177|NCT04910204|Other|FES Therapy combined with task-specific training (FEST+TST)|The FEST+TST protocol consists of a 1-hour session, 3 to 5 days a week, for up to 12 weeks (40 sessions total) in addition to conventional occupational and physical therapies according to the standard of care.
75344178|NCT04907136|Other|Preferred ENDS|Preferred ENDS without HWL on device
75344179|NCT04907136|Other|Preferred ENDS with HWL|Preferred ENDS with a HWL on device
75344180|NCT04904094|Other|Casting of the lower limb and homebased stretching exercise program.|Lower leg casting in combination with removable upper leg casts for approximately 2 weeks and stretching exercises during casting and 4 weeks after casting.
75344181|NCT04901195|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
75344182|NCT04899765|Biological|BCG vaccine|It is an attenuated live bacterial vaccine. This vaccine is a freeze-dried product that must be reconstituted.
75654843|NCT02842580|Drug|5 FLUOROURACYL|"Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days."
75940768|NCT04312971|Drug|Placebo|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
75940769|NCT04312971|Drug|Norepinephrine|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
75940770|NCT04312971|Other|Increase infusion rate|Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments
75940771|NCT04312971|Other|Decrease infusion rate|Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements
75940772|NCT01194596|Behavioral|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine), will be given in both arms.
75940773|NCT01194596|Behavioral|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
75940774|NCT02737215|Device|CPAP|patients will receive CPAP therapy with Auto-CPAP
76090376|NCT05739682|Procedure|Final irrigation with antimicrobial-corticosteroid mixture|1 ml of levofloxacin will be withdrawn in a 3ml plastic syringe followed by 1 ml of fluconazole and 1 ml of dexamethasone sodium phosphate, the whole solution is then passively delivered into the canal using a 30-gauge side vented needle reaching 1 mm shorter than the working length. The solution will be left inside the canal for 5 minutes
76090377|NCT05739682|Procedure|Final irrigation with cold saline|Frozen sterile saline will be brought at room temperature and monitored using a digital liquid thermometer till the temperature reaches 2.5°c. 4ml are then withdrawn in a 5ml plastic syringe and delivered inside the canal in 1 minute. The process is then repeated 5 times so that the canal receives 20 ml of 2.5°c cold saline for 5 minutes.
75940775|NCT02697123|Other|antepartum and postpartum|This is a prospective observational cohort study.
76090378|NCT05739682|Procedure|Temporary restoration and patient's instructions|The canals are dried using paper points and the access cavity is sealed using a non-eugenol temporary filling.
75802132|NCT05209516|Diagnostic Test|Single-pulse transcranial magnetic stimulation (TMS)|While being comfortably seated in a chair and performing the pre-mentioned task, the participants will undergo single-pulse TMS over both primary motor cortices (M1). In order to guarantee the position of the stimulation coils throughout the testing, participants are asked to wear an EEG cap which will be used to mark various scalp locations. Bipolar surface electrodes, linked to an electromyography (EMG) system, will be placed over one or more muscles of each hand in order to measure the amplitude of motor evoked potentials at various stages of the task. Prior to the placement of each adhesive surface electrode, the skin will be gently swabbed with an alcohol solution.
75940776|NCT03473457|Biological|CART therapy in Acute myeloid leukemia(AML)|one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
76090379|NCT05739682|Procedure|Root canal obturation|After the 1st visit by 3 days to 1 week, the patient is scheduled for a second appointment for root canal obturation.
75654844|NCT02842580|Drug|acide folinique|200 mg/m² if Elvorine
75654845|NCT02842580|Drug|irinotecan|"Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
75802133|NCT05209516|Other|Questionnaires|Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI) II, Scale on impulsive behaviour (UPPS).
75940777|NCT05231330|Drug|silvernanoparticles|silvernanoparticles in fluoride varnish
75940778|NCT05231330|Drug|SDF|silver diamine fluoride
75940779|NCT05305118|Procedure|TSCS Mapping|"Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention."
75965975|NCT02082665|Drug|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
75965976|NCT02082665|Drug|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
76090380|NCT02466009|Drug|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
76090381|NCT05739604|Diagnostic Test|Blood sample analysis|The concentrations of AAs and related compounds were determined by liquid chromatography/mass spectrometry (LC/MS)
76090382|NCT05729152|Other|Sample blood|Partecipants will undergo a baseline assessment by history, objective examination, laboratory tests, ECG, 6-minute walking test and echocardiogram
76090383|NCT02462421|Drug|Canagliflozin|A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
76090384|NCT02727387|Drug|TEMIRI|Window therapy frontline for VHR patients
76090385|NCT02727387|Drug|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
76090386|NCT02727387|Drug|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
75344183|NCT04899765|Biological|Measles vaccine|It is an attenuated live virus vaccine. This vaccine is a freeze-dried product that must be reconstituted.
75654846|NCT02842580|Drug|Oxaliplatin|"Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
75802134|NCT05209516|Other|MDS (Movement Disorder Society) UPDRS (Unified Parkinson's Disease Rating Scale) Part 3 (Motor Part)|Specific Parkinson Questionnaire on Clinical motor status
75476401|NCT05970003|Other|Holmich exercises|"The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period.~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
75940780|NCT05305118|Procedure|Transcutaneous spinal cord stimulation|"TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device)."
76090387|NCT02727387|Drug|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
75344184|NCT04899765|Other|Placebo|Saline
75476402|NCT05969990|Other|tryptophan metabolites in plasma|we will investigate the tryptophan metabolites in plasma of children with migraine
75476403|NCT05969977|Drug|PPI-1011|PPI-1011 is a liquid oil with light yellow to amber color, clear to slightly opalescent and flows readily at room temperature. It is insoluble in water and miscible with dichloromethane and liquid coconut oil. It is a synthetic glycerolipid derivative, comprised of an assembly of naturally-occurring products including glycerol backbone, an ether-linked hexadecyl group at sn1 position, an all-cis-4, 7, 10, 13, 16, 19-docosahexaenoyl group at sn2 position, and a lipoyl group at sn3 position. It was designed as a plasmalogen precursor and is similar in structure to naturally occurring alkyl-diacyl lipids with the primary difference being the presence of a lipoic acid moiety at the sn3 position. PPI-1011 is formulated in liquid coconut oil containing 0.1% 1-thioglycerol as an antioxidant.
75476404|NCT05969977|Drug|Placebo|Placebo
75476405|NCT05969938|Diagnostic Test|MRD detection|Peripheral blood samples were collected for MRD detection before neoadjuvant chemoradiotherapy, during neoadjuvant chemoradiotherapy, and 3-4 weeks after radical surgery. For patients who achieved cCR after neoadjuvant therapy and adopted the W & W strategy, the sampling time point was 3 months after the start of watching and waiting.
75654847|NCT02842580|Drug|capécitabine|For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
75802135|NCT05209204|Diagnostic Test|ASOCT|Anterior segment imaging using RTVue XR 100 Avanti OCT platform (Optovue Inc.,Fairmont, CA).
75802136|NCT05209204|Diagnostic Test|Pentacam|Anterior segment imaging using Oculus Pentacam HR (Oculus Optikgeräte, Wetzlar, Germany).
75802137|NCT05208658|Other|Experimental: Classical Vision Therapy Treatment|Do classical vision therapy treatment for improve vergence
75940781|NCT05675072|Drug|FB2001|FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
75940782|NCT05675072|Drug|FB2001 placebo|FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
75940783|NCT05116618|Diagnostic Test|InVisionFirst-Lung ctDNA assay|An enhanced tagged/targeted-amplicon sequencing technology for detection of genomic alterations in 36 commonly mutated genes in plasma ctDNA with a sensitivity of 73.9% and specificity of 99.8%.
75940784|NCT03298269|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.
75940785|NCT03298269|Behavioral|Supportive Counseling|A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
75654848|NCT02842580|Drug|bevacizumab|Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
75654849|NCT00836277|Drug|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
75965977|NCT02082665|Drug|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
75965978|NCT03046004|Other|Decision aid for breast cancer screening|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
76090388|NCT02727387|Drug|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
76090389|NCT02727387|Drug|BUMEL|Consolidation phase
75802138|NCT05208658|Other|Control: Eye Movement Therapy Treatment|Do eye movement therapy treatment in order not to improve vergence
75344185|NCT04891991|Drug|Intravitreal infliximab|1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
75344186|NCT04891991|Procedure|Pars plana vitrectomy|Standard pars plana vitrectomy
75344187|NCT04887480|Device|Abthera™ Open Abdomen Negative Pressure Therapy Device System|Suction set at -125mmHg
75344188|NCT04887480|Drug|Dianeal PD-2 with 2.5% Dextrose|800mL to 1000mL of Dianeal PD-2 into Abthera™ and dwell for 1 hour.
75802139|NCT04322682|Drug|Colchicine|Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
75940786|NCT03179475|Drug|Oxycodone Naloxone Combination|"A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.~Oxycodone-Naloxone is available in the following oral dosages:~5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride~10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride~20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride~40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride"
75344189|NCT04878562|Behavioral|I-COPE|The patient survey will be sent out via MyChart 3 days before the visit. It asks about current pain, goals, treatment history, treatment preferences, and health status. Alternatively, patients will be asked to compete a survey in clinic on paper or a tablet. The surveys will be identical, except screening for screening for depression and opioid use will depend on the availability of previous scores. Survey and the EHR will help auto-generate best practice advisories (BPAs) and a tailored smart set. The smartset is based on AGS and CDC guidelines for chronic pain and opioids. It shows which treatment options are not recommended based on the patient's history, comorbidities, and preferences. The smartset also includes links to decision aid and patient education tools. Personalized action plan will be created with pain rating and goal, treatment plan, and relevant tips and educational materials. Action plan will be clearly laid out using max 6 grade reading level, and simple graphics.
75344190|NCT04875351|Diagnostic Test|Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test|The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (>5 year) endocrine therapy.
75476406|NCT05969899|Drug|FOLFIRI+Bevacizumab|irinotecan liposome 60 mg/m2, iv, for at least 90 minutes LV 400 mg/m2, iv, for at least 2 hours FU 400 mg/m2, iv, followed by FU 2400 mg/m2, iv for at least 46 hours bevacizumab 5mg/kg IV. The above scenario is repeated every two weeks. Patients were treated until disease progression, toxic intolerance, initiation of a new antitumor therapy, withdrawal of knowledge, or investigator judgment that subjects should withdraw from study therapy.
75476407|NCT05969873|Other|Pilates exercise|Patients in this group will be treated with pilates exercise and conventional physical therapy as baseline treatment.
75476408|NCT05969873|Other|Balance training|Patients in this group will be treated with balance training and conventional physical therapy as baseline treatment.
75476409|NCT05969847|Radiation|split-course hypofraction radiotherapy|After reaching a cumulative radiotherapy dose of 25Gy in the entire pelvic cavity (PTV1), the treatment field was subsequently narrowed to solely focus on the primary tumor (PTV2), with a total dose of 35Gy administered. All patients will undergo fractionated radiotherapy, following a regimen of 7Gy per fraction, delivered every 3 weeks for five cycles.
75476410|NCT05969847|Drug|CAPOX|Drug: Oxaliplatin,130mg/m2，ivgtt，d1,for 6 cycles. Drug: Capecitabine,1000mg/m2，po，bid，d1-14, for 6 cycles.
75476411|NCT05969847|Drug|Envafolimab|Envafolimab is administered by subcutaneous injection. The recommended dose is 300 mg per 3 weeks (Q3W) for 6 cycles.
75654850|NCT00836277|Drug|Irinotecan|125mg/m2 IV Day 1 and Day 8
75654851|NCT00831025|Biological|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
75654852|NCT00831025|Biological|Placebo|Placebo for subcutaneous monthly administration
75802140|NCT04322682|Drug|Placebo oral tablet|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
75802141|NCT05207878|Other|STEGA-MRI|Precision drawing task (movement assessment)
75802142|NCT04322526|Drug|Naltrexone 50 Mg Oral Tablet|Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours).
75802143|NCT04322526|Drug|Placebo oral tablet|Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.
75940787|NCT05115604|Behavioral|cognitive behavioural intervention|Six sessions of cognitive behavioural and psychoeducational therapy will be conducted to treat insomnia.
75940788|NCT05259267|Behavioral|Online Group Therapy for PTG|Online Group Therapy for PTG consists of eight sessions. Each sessions have specific themes. First session: psychoeducation, normalization of the experiences and emotions. Second session: emotion regulation skills. Third session: awareness of the negative thoughts that make patients worried, anxious, feared. Forth session: restructuring of the thoughts and practicing mindfulness technics. 5. session: practicing of self-disclosure skills 6. session: creating a breast cancer story with balancing losses and gains. 7. session: sharing of the effects of breast cancer on life and developing new life priorities 8. session: making life meaning and developing new life goals.
75965979|NCT03046004|Other|Standard leaflet|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
75965980|NCT02082743|Behavioral|Outdoor activity in recess time|Outdoor activity in recess time
75965981|NCT05256524|Drug|The effect of LMWH|Quantified by aFXa-levels
75476412|NCT05969847|Procedure|Local excision|Local full-thickness resection is employed for patients with clinical complete response (cCR) or near-clinical complete response (ncCR) following TNT.
75654853|NCT00843427|Behavioral|CIAT|Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
75654854|NCT02842502|Procedure|Collection of supernumerary biopsies during skin graft pellet procedure|
75476413|NCT05969834|Drug|uHCG|Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
75476414|NCT05969834|Drug|rHCG|Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
75476415|NCT05969834|Drug|uHCG and GnRHa|Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
75476416|NCT05969782|Device|EVAR|Endovascular repair of aortoiliac aneurysm using Zenith or Endurant
75476417|NCT05969743|Drug|Letermovir|Patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier.
75344191|NCT04873050|Drug|Semaglutide Pen Injector [Ozempic]|Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
75476418|NCT05969717|Drug|GD-iExo-001|One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
75476419|NCT05969717|Other|normal saline|One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
75344192|NCT04873050|Drug|Placebo semaglutide pen injector|Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
75476420|NCT05969639|Behavioral|HEYA|The HEYA program is a 12-week app-delivered psychoeducational program that comprises of nutrition education, skills training on self-regulation, and weekly feedback.
75476421|NCT05969613|Procedure|Regional block|regional block with 0.25% Bupivacaine at a dose of 2ml/kg with adrenaline
75476422|NCT05969613|Procedure|Wound infiltration|Infiltration of surgical site with 0.25% Bupivacaine at 0.5ml/kg dose
75476423|NCT05969613|Procedure|Caudal block|Infiltration of caudal epidural space with 0.25% Bupivacaine at 1ml/kg dose
75476424|NCT05969561|Procedure|ultrasound-guided femoral nerve block|The local analgesia is injected and infiltrated around the femoral nerve under ultrasound guidance.
75476425|NCT05969561|Drug|Intravenous or intramuscular pain medication|Intravenous or intramuscular pain medication is given for patients with hip fracture.
75654855|NCT00835731|Drug|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D&E
75654856|NCT00835731|Device|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D&E
75802144|NCT05207800|Other|The concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.|The concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.
75940789|NCT05259267|Behavioral|Online Support Group|Online support groups also consist of eight sessions. 1. session: introducing the program and learning the expectancies 2. session: sharing what is known about breast cancer 3. session: risk and protective factors for breast cancer 4. session: sharing side effects of surgical operation and treatments 5. session: sharing the reactions of family, close friends 6. session: patient-doctor relationship and also sharing the challenges and facilitators of healthcare system 7. session: sharing the current position in the treatment and of what has been done for improvement 8. session: sharing the reliable information sources for breast cancer and close
75654857|NCT00843505|Behavioral|Telemedicine Smoking Cessation Program|Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.
75654858|NCT00843505|Behavioral|Telephone Quitline Smoking Cessation Program|Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
75344193|NCT04865965|Procedure|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
75344194|NCT04861259|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg).
75344195|NCT04858009|Drug|Cisplatin|Given via HIPEC
75344196|NCT04858009|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with mitomycin and cisplatin
75476426|NCT05969522|Drug|GlucoCorticoid|The high-risk group: methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)*3 days , with 2 courses, interval 5-7 days;Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage, with the first reduction after 2-4 weeks. The dose was reduced once every 3 weeks in the first 3 months, and once every 4 weeks in the next 3 months, with a reduction of 5-10mg/ day each time; Rituximab：375 mg/m2/ time, once a week for 4 times;Intravenous cyclophosphamide 7.5-10mg/kg.d*2 days(Max.500mg/d), once every 4 weeks, twice in total, at the 8th and 12th week.The medium-low risk group: methylprednisolone was the same dose as before, but only with 1 course, then followed by oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d), divided into three times for 3 weeks, and then changed to morning daily; The dose was reduced as the high-risk group ;Rituximab was the same dose as before.
75476427|NCT05969509|Other|progressive relaxation exercise|applying progressive relaxation exercise to the experimental group after postoperative cholecystectomy and observing the experimental-control groups
75476428|NCT05969483|Device|pEEG monitoring|pEEG monitoring during PICU admission
75476429|NCT05969457|Drug|Naropeine|Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg)
75476430|NCT05969457|Other|questionnaires|Numerical Rating scale Questionnaire FSFI Qustionnaire SF12 Questionnaire DN4
75476431|NCT05969457|Other|Placebo|Injection of 20 mL of NaCl
75476432|NCT05969405|Procedure|Laparoscopic staging|Laparoscopic staging
75476433|NCT05969405|Procedure|Robotic staging|Robotic staging
75476434|NCT05969405|Procedure|Laparotomic staging|Laparotomic staging
75654859|NCT03721406|Drug|Ropivacaine|ropivacaine administerd via thoracic paraveretebral catheter
75802145|NCT04115358|Procedure|Hyaluronic acid: Gengigel teething|Applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
75802146|NCT04115358|Procedure|Formocresol Buckley formula: Formacresol|Applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
75344197|NCT04858009|Drug|Nab-paclitaxel|Given via HIPEC
75344198|NCT04858009|Procedure|Computed Tomography|Undergo CT scan
75344199|NCT04858009|Procedure|Magnetic Resonance Imaging|Undergo MRI
75476435|NCT05969392|Device|Intradiscal Gelified Ethanol|Intradiscal percutaneous injection of an intradiscal Gelified Ethanol
75940790|NCT02387528|Behavioral|1- Mindfulness Intervention|An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and illness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
75940791|NCT02387528|Behavioral|2- Relaxation Intervention|Eight meetings where the participants will practice relaxation techniques.
75940792|NCT02387528|Other|3- Wait List Control Group|No intervention
75940793|NCT01656850|Other|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
75940794|NCT01656850|Other|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
75940795|NCT03113630|Device|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
75940796|NCT03113630|Device|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
75940797|NCT03113630|Device|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
75940798|NCT03113630|Device|Acquisition on TouchScreen Control Group|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
75940799|NCT03113630|Device|Acquisition on Kinect Control Group|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
75940800|NCT03113630|Device|Acquisition on LeapMotion Control Group|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
75940801|NCT03177525|Behavioral|Social SUCCESS|"Social SUCCESS will run for 12 weeks, with up to 5 children with ASD per group. Parents will attend didactic group sessions focused on motivating children with ASD to initiate to peers (90 min weekly) and will attend a portion of the existing 90 min social group to practice applying these strategies with their children and peer volunteers. Parent training will utilize the manual Improving Socialization in Individuals with Autism."
75476436|NCT05969379|Genetic|Analysis of biomarkers and their correlation with clinical characteristics and outcome|"This is a non-interventional study involving clinical data, neuroimaging analysis, and biological samples. Demographics and clinical data are collected in the database of the French Reference Centre. Additional or missing data will be obtained by contacting the referral physicians. All the neuroimages available will be analysed by dedicated software. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids). Additional samples for genetic testing will be collected upon explicit written consent."
75940802|NCT03177525|Behavioral|Wait List|Participants assigned to the Wait List will continue stable community treatments for 12 weeks and will be provided an intervention similar to Social SUCCESS upon completion of all post measures.
75940803|NCT03105986|Drug|JNJ-64041575|Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
75940804|NCT03105986|Drug|Probenecid|One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
75940805|NCT02391740|Other|Questionnaire|
75940806|NCT02391662|Drug|Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 days 1,8 & 15 in a 28 days cycle
75940807|NCT02391662|Drug|Gemcitabine 1000 weeks 1,2,3/4|Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
75965982|NCT05256524|Diagnostic Test|Monitoring frequency of aFXa-levels|The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking
75965983|NCT05256446|Drug|AMG 701|
76090390|NCT02727387|Drug|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
76090391|NCT01727297|Device|REVEAL Implantable Cardiac Monitor|
75344200|NCT04858009|Procedure|Positron Emission Tomography|Undergo PET scan
75476437|NCT05969366|Procedure|Total hip arthroplasty|
75476438|NCT05969353|Other|accupunture|BFA
75654860|NCT00751166|Drug|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
75654861|NCT00751166|Drug|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
75654862|NCT00751166|Drug|placebo|placebo once daily for 28 days
75654863|NCT03685448|Drug|Cabozantinib|The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
75344201|NCT04837820|Procedure|Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
75344202|NCT04837820|Procedure|Sham Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
75344203|NCT04837820|Other|Wait-List Control (WLC)|Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians.
75344204|NCT04837820|Other|Questionnaires|Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 0, 10, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data; 20 minutes of these 30 minutes will be completed during the neurocognitive battery. Patients will complete PROs online using Research Electronic Data Capture (REDCap) or over the phone with the CRC. Biospecimens will be collected in person at assessment visits. The neurocognitive battery will be administered remotely.
75940808|NCT05076604|Drug|Cardioplegia Solution|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
75965984|NCT03047954|Drug|Broncho-Vaxom|BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
75802147|NCT04115358|Procedure|Ferric sulfate: ViscoStat|Applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
75344205|NCT04825132|Other|Geriatric assessment tools|Multidimensional Prognostic Index (Living status, medications, ADL, IADL, MMSE mental evaluation, ESS pressure sores, chronic disease, nutritional assessment)
75344206|NCT04805177|Procedure|hematoma evacuation|early minimally invasive image guided hematoma evacuation in patients suffering from ICH
75344207|NCT04804046|Dietary Supplement|Synbiotic|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with three Bifidobacterium spp. (3x10^9 CFU) plus three dietary fibers (24 g fiber) daily for six months.
75344208|NCT04804046|Other|Digestible Maltodextrin|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with Maltodextrin daily for six months.
75344209|NCT04798651|Biological|blood sample|28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
75344210|NCT04798651|Biological|cerebro-spinal fluid|1 ml of cerebro-spinal fluid
75344211|NCT04788004|Other|Online survey|There are no interventions planned for this study. This is an observational study only.
75344212|NCT04770909|Behavioral|Incentives for dietary self-monitoring and weight loss|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
75344213|NCT04770909|Behavioral|Incentives for dietary self-monitoring|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
75654864|NCT00837343|Drug|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
75344214|NCT04770909|Behavioral|Incentives for weight loss|Participants can earn up to $300 during the trial for achieving weight loss
75654865|NCT00732368|Drug|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
75654866|NCT00704067|Behavioral|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
75654867|NCT00704067|Behavioral|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
75654868|NCT02547571|Drug|High volume PEG split-dose|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
75802148|NCT05207332|Dietary Supplement|CHO+PRO|A vegan product containing carbohydrate and protein
75965985|NCT03047954|Drug|Placebo - Cap|Matching Placebo capsule administered
75654869|NCT02547571|Drug|Low volume PEG split-dose|Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
75654870|NCT02547571|Drug|High volume PEG non split, day before|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
75802149|NCT05207332|Dietary Supplement|CHO|containing carbohydrate
75802150|NCT05207176|Drug|DWP16001|Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.
75802151|NCT03628690|Device|BandGrip|Topical skin closure device
75802152|NCT03628690|Device|Suture|Wound closure
75344234|NCT04758819|Procedure|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)|In vitro Fertilization by ICSI then embryo culture until Day 5/6; all blastocysts with morphological scores compatible with TE biopsy and vitrification will be submitted to Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB) and vitrified.
75802153|NCT05668884|Combination Product|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
75802154|NCT05187208|Drug|Niraparib|"Niraparib 200mg or 300mg (once daily [QD])*~*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
75940809|NCT05076604|Drug|Microplegic Solution No. 1|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
75940810|NCT02391506|Device|Cartiva|Cartiva Synthetic Cartilage Implant
75344235|NCT04755699|Device|Transcutaneous Electrical Stimulation|The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
75344236|NCT04743661|Drug|Irinotecan|"Irinotecan is a semisynthetic water-soluble analog of camptothecin (a plant alkaloid isolated from Camptotheca acuminata). Irinotecan is available in single-dose amber glass vials in 40 mg (2 mL) and 100 mg (5 mL), 300 mg (15 mL), and 500 mg (25 mL).~Patients on Stratum 1 will be given irinotecan at 50 mg/m2/day IV on Days 1 through 5 of each chemotherapy course."
75654871|NCT02547571|Drug|Low volume PEG non split, same day|Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
75654872|NCT02547571|Other|Clear liquid diet|
75654873|NCT02547571|Other|Low residue diet|
75940811|NCT05177380|Procedure|Personalized rehabilitation program of facial involvement in systemic sclerosis|Personalized rehabilitation program of facial involvement in systemic sclerosis
75344237|NCT04743661|Drug|Temozolomide|"An orally administered alkylating agent, a second generation imidazotetrazine. A prodrug of MTIC, temozolomide spontaneously decomposes to MTIC at physiologic pH. Exerts its effect by cross-linking DNA. Temozolomide capsules are available in six different strengths (5, 20, 100, 140, 180, 250 mg). The capsules vary in size, color, and imprint according to strength. In the US, capsules are packaged in 5-count and 14-count bottles.~Patients on Stratum 1 will be given temozolomide at 150 mg/m2/dose PO on Days 1-5 of each chemotherapy course."
75940812|NCT05177380|Other|Delivery of a standard prescription for facial rehabilitation|Delivery of a standard prescription for facial rehabilitation
75940813|NCT03116685|Biological|Oxabact OC5 - Oxalobacter formigenes HC-1|Active study drug
75940814|NCT03116685|Other|Placebo|Placebo
75940815|NCT05177068|Drug|fruquintinib + sintilimab + SOX|fruquintinib: 4mg/d, qd po, d1-14, q3w; sintilimab: 200 mg/d, IV d1, q3w; S-1: BSA<1.25 m2, 40mg twice/day; BSA1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, d1-14, q3w; oxaliplatin: 130mg/m2, ivgtt 2-6h, d1, q3w
75940816|NCT03058107|Dietary Supplement|Nutrition Therapy|At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
75940817|NCT03058107|Dietary Supplement|Control Therapy|At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
75940818|NCT02391272|Drug|rhTPO|
75940819|NCT05258955|Other|Natural honey|Natural Sidr honey based mouthwash used as intervention group B (Arm Group B) for the reduction of plaque index
75940820|NCT05258955|Drug|Chlorhexidine mouthwash|Chlorhexidine gluconate 0.12% mouthwash is used as intervention in Group A (Arm Group A) for the comparison of plaque reduction among group A and B
75344238|NCT04743661|Drug|Bevacizumab|"Bevacizumab is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody. Bevacizumab is supplied as a clear to slightly opalescent, sterile liquid ready for parenteral administration. Each 400 mg (25 mg/mL, 16 mL fill) glass vial contains bevacizumab with phosphate, trehalose, polysorbate 20, and Sterile Water for Injection.~Patients on Stratum 1 will be given bevacizumab at 10 mg/kg/day IV on Days 1 and 15 of each chemotherapy course, with the exception of the last course of Induction Chemotherapy (i.e., Course 2 or 4) where it will be administered on Day 1 only."
75654874|NCT02547571|Other|Early colonoscopy (stratified)|"Early appointments: 7:30 AM to 10h30 AM"
75654875|NCT02547571|Other|Later colonoscopy (stratified)|"Later appointments: 10:30 AM to 4:30 PM."
75654876|NCT00704145|Device|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
75654877|NCT03508232|Drug|Placebo|Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
75654878|NCT03508232|Drug|Doxycycline Hyclate|Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.
75654879|NCT00704223|Drug|biphasic insulin aspart|Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
76090392|NCT05583357|Biological|V-01D-351|One dose of V-01D-351 on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
75940821|NCT05174260|Device|perfusion index, pleth variable index|a clip will be attached to the patient's finger and the perfusion index and pvi will be measured
75940822|NCT02391194|Drug|AVB-620|
76090393|NCT05583357|Biological|V-01D-351|One dose of V-01D-351 on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
76090394|NCT05583357|Biological|CoronaVac|One dose of CoronaVac on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
75344239|NCT04743661|Drug|Omburtamab I-131|"Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276) manufactured by in vivo growth of the hybridoma cell line without the use of animal-derived components. Omburtamab will be radiolabeled with iodine-131 at a designated radiolabeling facility. 131I-omburtamab is supplied as a sterile, injectable, radioactive product in a vial. Each supplied vial will contain enough radioactivity to prepare 50 mCi of 131I-omburtamab, formulated in 3.5-4 mL of solution. 131I-omburtamab should be administered via an intraventricular access device (i.e., Ommaya catheter or programmable VP shunt). Radioimmunotherapy consists of 56 days.~Patients on Stratum 1 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 8 and 36 of Radioimmunotherapy.~Patients on Stratum 2 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 1 and 29 of Radioimmunotherapy."
75654880|NCT00704301|Drug|Rivastigmine|Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
75654881|NCT00704301|Drug|Placebo|Placebo, 2 times a day
75940823|NCT02391428|Procedure|blood test|Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
75940824|NCT02391428|Dietary Supplement|omega3 capsules|Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
75654882|NCT03618446|Other|The presence of a pelvic fracture|
75940825|NCT03034863|Behavioral|Safe Actions for Families to Encourage Recovery|A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
75940826|NCT03034863|Behavioral|Individual Safety Planning Intervention|The comparison condition will be an assessment-only enhanced treatment-as-usual intervention called the Individual Safety Planning Intervention (I-SPI).
75940827|NCT05173324|Biological|HPV vaccine|Licensed HPV vaccines (bivalent, quadrivalent, or nonvalent) available in the country of the study site
76090395|NCT05583357|Biological|CoronaVac|One dose of CoronaVac on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
76090396|NCT05726968|Drug|Pilocaine 2% (1.5 ml) and 25 ug fentany|"Patients will be randomly allocated into the study groups according to the list of random numbers. The study groups will be as follows:~Group P1 (N 15): patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).~Group P2 (N 15): patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).~Group P3 (N 15): patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)."
76090397|NCT04757025|Device|Electrical Impedance Tomography|In 27 patients ventilation will be guided with an Electrical Impedance Tomography system
76090398|NCT04757025|Device|Peripheral arterial Saturation|The ventilation of 27 patients will be guided by Peripheral arterial Saturation alone
75476439|NCT05969314|Drug|Cannabis capsules|Cannabis capsules containing 5 mg of THC and CBD each or 2.5 mg of THC and CBD each.
75654883|NCT00837499|Behavioral|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
75654884|NCT00831103|Drug|EPB-348|Treated over seven days
75654885|NCT00831103|Drug|Valacyclovir|Treated over seven days
75654886|NCT00704444|Drug|Ezetimibe|Ezetimibe, 10-mg tablets
75654887|NCT00704444|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
75654888|NCT02611791|Device|Radiofrequency|The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
76090399|NCT05583045|Other|Olive Leaf Tea|Olive leaf tea (individual tea bags provided to participants with instructions of preparation)
76090400|NCT05583045|Behavioral|Lifestyle behavior change program (LBC)|"Lifestyle behavior change program as defined by America Diabetes Association on Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers(Association 2022)"
75940828|NCT05173324|Diagnostic Test|HPV testing|HPV testing with partial genotyping of HPV16/18 (and/or 45) to be used as a primary cervical screening test for all participants regardless of the study arm
75940829|NCT05173324|Biological|HAV vaccine|Hepatitis A virus (HAV) vaccine to be offered as a placebo
76090401|NCT05583045|Other|Placebo tea|Placebo tea containing 2,6g cellulose and a caramel coloring
76090402|NCT01753115|Biological|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
76090403|NCT01753115|Drug|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
76090404|NCT02445651|Dietary Supplement|Intravenous and Oral n-acetyl cysteine|
75344240|NCT04743661|Drug|Liothyronine|Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight < 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
75802155|NCT04109118|Behavioral|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a psychosocial intervention. It is paired with a benzodiazepine taper. The aim of the psychosocial intervention is to improve individuals' ability to tolerate distress in order to assist benzodiazepine discontinuation in patients treated with OAT. There will be 5 sessions between therapist and participant prior to the start of the benzodiazepine taper. The taper for both the intervention and control conditions occurs over 9 weeks and involves weekly meetings with a benzodiazepine prescriber during which a gradual benzodiazepine dose reduction will take place. The DT-BD intervention combines elements of existing psychosocial interventions. Specifically, interoceptive exposure techniques will be paired with elements of acceptance and commitment therapy (ACT) and relapse prevention (RP).
75654889|NCT02611791|Device|Radiofrequency - OFF|The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
75654890|NCT05335382|Behavioral|Brief Interventions (BI)|'Brief Interventions' (BI) is a multitude of interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI), however interventions from other schools of therapy can also be used. The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
75654891|NCT05335382|Behavioral|Care As Usual (CAU)|Care As Usual includes the PCC's current routine care for patients with mental and behavioral problems. This can include a multitude of procedures and treatment, such as pharmacological treatment, supportive care, cognitive behavioural therapy (CBT) and psychodynamic therapy of varying lengths. Interviews with patients as well as medical journals will be used to categorise what type of care each individual patient has received.
75654892|NCT00704691|Drug|Lenalidomide|Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
75802156|NCT04109118|Drug|BZD discontinuation protocol|All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
75802157|NCT03619954|Biological|NK cells infusion|"Pretreatment：patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor once daily for 3 times. NK cells infusion is allowed within 2-14 days after treatment.~NK cells infusion：30-60 minutes before infusion，ant-allergic agents are applied (promethazine 25mg,i.m. ; Cimetidine 0.4g i.v. ; diphenhydramine 50mg po.). NK cells are intravenously infused into patients with 15-30 minutes every other day for one to three times. The number of every infused NK cells is 1-3×10^7/kg, counted as the number of CD56+ cells. Patients with severe pleural or ascites can also receive pleural or abdominal cavity perfusion simultaneously. The total number of infused NK cells is no more than 5×10^9 cells. 4 hours after NK cells infusion，IL-2 is applied every other day for six times"
75802158|NCT05081206|Drug|Propofol infusion via manually controlled pump.|Patients will receive propofol bolus 2.5-3 mg/kg, for anesthesia induction and anesthesia maintenance was continued according to the Mc Farlan scheme, meaning continuous propofol infusion is used, with gradual reduction of the infusion speed in timely manner, depending on the duration of surgery: 15mg/kg/h...13mg/kg/h...11mg/kg/h...9mg/kg/h...6mg/kg/h.
75802159|NCT05081206|Drug|Propofol infusion via target controlled pump.|Pedfusor model was used for delivering target controlled plasma concentration, with target concentration for anesthesia induction of 4 mcg/kg body weight and then 3 mcg/kg.
75802160|NCT04105998|Drug|Oxytocin|Oxytocin 10 IU
75802161|NCT04105998|Drug|Placebo|Placebo
75802162|NCT05008822|Other|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
75802163|NCT05008822|Other|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
75802164|NCT03747510|Device|CarpX Device|Transverse carpal ligament release with CarpX Device
75940830|NCT05178056|Device|Spinal Cord Epidural Stimulation|Spinal Cord Epidural Stimulation (scES) will be administered by a multi-electrode array (5-6-5 SpecifyTM electrode, MEDTRONIC, Minneapolis, MN, USA) previously implanted in the epidural space over the dorsum of the spinal cord.
75654893|NCT02842346|Other|ultrasonography|
75654894|NCT00704925|Drug|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
75654895|NCT02842190|Device|NIPPV|after ekstubation
75654896|NCT00574249|Biological|adalimumab|subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
75940831|NCT05178056|Other|Respiratory Training|Standard threshold Positive Expiratory Pressure Device and standard threshold Inspiratory Muscle Trainer (Respironics Inc., Cedar Grove, NJ) assembled together will be used for respiratory training sessions to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure treshold load.
75940832|NCT04223518|Dietary Supplement|Serum bovine immunoglobulin|Serum bovine immunoglobulin (SBI), also known by the brand name of Enteragam (Proliant Biologicals, Ankeny, Iowa) is derived from bovine serum and classified as a medical food composed of >90% protein which consists primarily of immunoglobulins (>50% of IgG) along with other bovine proteins and peptides similar to those commonly consumed by humans in beef products.
75940833|NCT04223518|Dietary Supplement|Placebo|Hydrolyzed Collagen
75654897|NCT00574249|Drug|Calcipotriol/Betamethasone Ointment|Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
75654898|NCT00574249|Drug|placebo (vehicle ointment)|Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
75654899|NCT00891228|Drug|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
75940834|NCT03478995|Drug|GX-I7|GX-I7 25mg/ml/vial
75940835|NCT02387450|Drug|Sildenafil|100 mg per day
75654900|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
75654901|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
75802165|NCT04913116|Diagnostic Test|Comparison of antigen tests with RT-PCR as reference method|Antigen tests are performed locally including sampling from multiple anatomical testing sites. A reference oropharyngeal swab is always send for RT-PCR for SARS-CoV-2 at DTU to verify the status of the patient. RT-PCR samples from other anatomical test locations may be included.
75344241|NCT04743661|Drug|SSKI|SSKI (potassium iodide) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. SSKI (potassium iodide) will be administered as 7 drops (~0.35 mL) PO, NG, or G-tube daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
75940836|NCT02387450|Drug|Placebo|Placebo with same presentation as the active drug
75940837|NCT04223440|Other|MRI|MRI on both shoulder
75654902|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
75802166|NCT04902898|Device|Circumcision in adults using sterile single-use circular stapling device|Circumcision in adults using sterile single-use circular stapling device CIRCCURER II (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
75940838|NCT04223440|Other|ultrasonographic explorations|ultrasound and elastography explorations on both shoulder
75940839|NCT04458675|Device|Vibrant capsule|The capsule vibration mechanically stimulates the inner wall of the GI and stimulates motility
75940840|NCT04458675|Drug|Placebo|A biodegradable capsule, which visually similar to the Vibrant active capsule
75940841|NCT04009395|Other|Pregnant Women qualitative interviewing|one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.
75654903|NCT00896168|Drug|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
75654904|NCT00896168|Drug|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
75654905|NCT00833703|Drug|Clopidogrel|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
75654906|NCT00833703|Drug|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
75654907|NCT02842034|Device|Repetitive Transcranial Magnetic Stimulation|Stimulate the dorsomedial prefrontal cortex for 4 weeks.
75654908|NCT00833547|Drug|eszopiclone|3 mg of eszopiclone at bedtime on two consecutive nights
75654909|NCT00833547|Drug|placebo|Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
75654910|NCT02831634|Procedure|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
75654911|NCT00833469|Drug|Escitalopram|Once daily by mouth
75802167|NCT04902898|Procedure|Circumcision in adults|Circumcision in adults
75940842|NCT04009395|Other|Midwives qualitative interviewing|one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.
75940843|NCT02666222|Device|The Esteem Hearing Implant|The Esteem® Hearing Implant is designed to improve hearing in subjects suffering from moderate to severe hearing loss that is sensorineural in origin. The Esteem® has been approved by FDA for the US market under Pre-Market Approval P090018 and this study fulfills the requirement for one of the Post Approval Studies.
75940844|NCT03473067|Behavioral|Social Norms Marketing Campaign|This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.
75940845|NCT03473067|Other|Capacity Building|Schools will participate in teacher training and parent training.
75940846|NCT00739401|Device|Suprarenal Proximal Cuff Extension|Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
75940847|NCT02390882|Drug|Placebo|Placebo
75940848|NCT02390882|Drug|HGP0412 capsule|Tamsulon high dose
75940849|NCT02390882|Drug|HIP1402 capsule|Tamsulon high dose
75940850|NCT02390570|Other|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
75344242|NCT04743661|Drug|Dexamethasone|Dexamethasone will be given as premedication for 131I-omburtamab to prevent possible meningeal inflammatory reaction. Starting within 24 hours prior to each 131I-omburtamab injection, dexamethasone will be administered orally at 0.5 mg (if weight < 15 kg) or 1 mg (if weight ≥ 15 kg) twice-daily doses for a total of 6 doses to alleviate infusion-related AEs: Two doses starting 24 hours pre-131I-omburtamab injection, two doses on the day of the injection (can be given before or after), and two doses 24 hours post-131I-omburtamab injection.
75344243|NCT04743661|Drug|Antipyretic|An antipyretic (e.g., oral acetaminophen [15 mg/kg, 650 mg maximum] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
75476440|NCT05969249|Device|Upper limb in vibration training|"The stroke subjects were all involved in the training,wear upper and lower extremity vibrators,the posture for intervention is hemiplegic upper limbs with shoulder joints slightly bent and abducted at 45 degrees, with elbows bent at 90 degrees and wrists centered. The elbow angle of this posture is set by the elbow joint rotation axis of the upper limb vibrator.~The set angle is the movable angle range of 80-110 degrees of elbow bending. The vibration rehabilitation password accepted by all subjects is Try to keep the elbow joint bent at 90 degrees during the vibration process, Resist the force of the vibration and try not to move."
75654912|NCT02831478|Drug|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
75654913|NCT02831478|Drug|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
75654914|NCT00837655|Drug|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of <1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of <1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
75654915|NCT00837655|Drug|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration <1.8 mmol/l.
75654916|NCT02842268|Drug|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
75654917|NCT02611869|Procedure|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
75802168|NCT04900714|Procedure|Decremental PEEP|High PEEP to low PEEP.
75802169|NCT04900714|Diagnostic Test|Lung ultrasound score|lung ultrasound to determine the extend of atelectasis. Uses validated lung ultrasound score.
75802170|NCT04900714|Diagnostic Test|Blood gas analysis|Blood gas analysis to determine arterial oxygen tension
75802171|NCT04900714|Diagnostic Test|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
75802172|NCT04900714|Diagnostic Test|Evaluation of dead space|Dead space will be measured non-invasively using volumetric capnography on the FluxMed respiratory monitor (MBMED, Argentina)
75940851|NCT02387138|Drug|S-1|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels)."
75802173|NCT04397718|Drug|Degarelix|Degarelix is an FDA-approved drug for prostate cancer
75802174|NCT04397718|Other|Saline|09% Saline
75802175|NCT04679038|Biological|SHR-1701|Intravenous (IV) on Day 1 of each cycle
75802176|NCT04679038|Drug|Famitinib|Famitinib, po, qd
75940852|NCT02387138|Drug|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
75940853|NCT02387138|Drug|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
75940854|NCT02387138|Other|G-csf|G-csf : d8 to d13 systematically
75940855|NCT05258643|Other|Blood analysis|Venipuncture and collection of serum and whole blood
75940856|NCT02386982|Drug|HMS5552|
75940857|NCT03418857|Drug|Yogurt smoothie with BB-12|During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.
75940858|NCT03418857|Drug|Yogurt smoothie|During the one month control period, the participants will consume one yogurt smoothie daily.
75940859|NCT02387060|Drug|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
75940860|NCT02387060|Drug|Fentanyl|Intrathecal administration of fentanyl 25 mcg
75940861|NCT01365052|Drug|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
75940862|NCT01365052|Drug|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
75940863|NCT05155215|Biological|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level: 100×10^6 CAR-T cells or 200×10^6 CAR-T cells
75940864|NCT05155215|Drug|Cyclophosphamide|300 mg/m^2 per day for 3 days (IV)
75940865|NCT05155215|Drug|Fludarabine|30 mg/m^2 per day for 3 days (IV)
75940866|NCT03471585|Drug|THC|A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.
75940867|NCT03471585|Drug|Placebo oral capsule|A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
75940868|NCT02386904|Drug|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
75965986|NCT02086955|Behavioral|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention lasts five weeks. During a period of five weeks, the participants are provided with weekly skill training, and counseling sessions on foot care. Each participant receives a foot care kit with essential foot care material and a foot care diary.
75654918|NCT02611869|Procedure|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
75940869|NCT05171608|Procedure|Ultrasound-based protocol based fluid therapy|"Protocol of the interventional group according to the ultrasonographic findings:~Ultrasound scan 2 hours before surgery:~IVCCI>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate intravenous (IV) fluid therapy: 8 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.~A 2nd ultrasound scan at 30 minutes before surgery:~IVCCI>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate further IV fluid therapy: 5 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy."
75344244|NCT04743661|Drug|Antihistamine|An antihistamine (e.g., IV diphenhydramine [1 mg/kg, 50 mg maximum] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
75344245|NCT04743661|Drug|anti-emetics|An anti-emetic (e.g., IV ondansetron [0.25 mg/kg, 16 mg maximum] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
75654919|NCT02841956|Other|Electronic Screen + Education (Phase 1)|PHASE 1 Electronic Screening Arm + Targeted Education: Referral sources will receive the same standard targeted education as active comparator. In addition, the PQ-B (a 21 item screening questionnaire) will be administered to all patients at their first visit to the referral sites (e.g. intake) via an android tablet provided to the site for ease of administration and scoring. The investigators will provide multiple tablets per site so that the screening is available for more than one individual simultaneously and can be completed in any appropriate location. The investigators will allow paper-and-pencil administration for situations where it is more appropriate (e.g. emergency room).
75654920|NCT02841956|Other|Targeted Provider Education (Phase 1)|PHASE 1 Targeted Education Intervention: EDAPT standard targeted provider education1 focuses on increasing awareness about the signs of early psychosis & building collaborative relationships with community members so community members see EDAPT as a rapid, effective source of help. It consists of a 2-hour workshop describing: 1) how to identify specific early symptoms & changes associated with the onset of psychotic illness, 2) the benefits of early intervention on treatment outcomes in psychosis, 3) the structure, philosophy & treatment model of the EDAPT Clinic, and 4) procedures for expeditious referral to our program. Case-based vignettes are reviewed to ensure understanding of the key symptoms.
75654921|NCT02841956|Other|Community Mobile Engagement (Phase 2)|PHASE 2 Community-based Mobile Engagement: Clinical assessment appointments will take place at the EDAPT clinic or within the community, wherever the individual would prefer. With patients deemed eligible for EDAPT services, the EDAPT clinician will obtain vitals and contact the EDAPT psychiatrist with a telemedicine-enabled laptop to complete the psychiatric evaluation remotely. The psychiatrist will prescribe medications and order labs, as indicated. The EDAPT clinician will follow up with the individual within 5 days to determine if the prescribed medication regimen has started.
75654922|NCT02841956|Other|Clinic based Engagement (Phase 2)|PHASE 2 Clinic-based Engagement: The clinical assessment appointment will be completed within the EDAPT clinic. If deemed eligible for EDAPT services, the individual will be scheduled for a clinic-based appointment with the EDAPT psychiatrist within 5 days, who will prescribe medications and order labs as indicated. The EDAPT clinician will follow up with the individual within 5 days of the psychiatric evaluation (by phone or in the clinic) to determine if the prescribed medication regimen has started.
75654923|NCT00843661|Drug|ezetimibe|10 mg ezetimibe/day
75654924|NCT00843661|Drug|fenofibrate|200 mg fenofibrate/day
75654925|NCT00843661|Drug|pravastatin|40 mg pravastatin/day
75654926|NCT00832377|Drug|timolol/dorzolamide combination|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
75654927|NCT00843739|Device|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
75654928|NCT00843739|Device|sham EMST|Four week sham device training program
75940870|NCT02386670|Other|tDCS + CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
75940871|NCT02386670|Other|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
75940872|NCT02523261|Procedure|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
75940873|NCT02523261|Procedure|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
75940874|NCT05072782|Drug|Infliximab CT-P13|"Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors"
75940875|NCT05072782|Drug|Immunosuppressors (Thiopurines or Methotrexate)|"Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose"
75940876|NCT05109754|Device|BiPAP EFL|Non-invasive ventilation using a novel ventilatory mode targeting expiratory flow limitation in COPD
75940877|NCT03379389|Drug|Methenamine + Methylthioninium|Methenamine + Methylthioninium
75344246|NCT04739059|Biological|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
75476441|NCT05969210|Other|Toe strengthening exercise|12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.
75802177|NCT04643860|Diagnostic Test|Differential Leucocyte Count (CLDC) device and algorithm|Boold sample that detecting the early rise in leukocyte levels which has a characteristic set of ratios of leukocyte types, which identify the viral pathogen and distinguish it from a number of others. This test allows prediction of positives from full blood count results.
75940878|NCT03379389|Drug|Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Methenamine + Methylthioninium + Acriflavine + Atropa belladona
75476442|NCT05969210|Other|Control Group|12 participants will be in control group they will do only there running training.
75654929|NCT00705237|Procedure|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
75819810|NCT00293033|Drug|BEMA™|BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
75940879|NCT03379389|Drug|Antibiotics|Antibiotics based on individual subjects urine culture / antibiogram
75476443|NCT05969197|Other|Match Play Training|15 participants will be in Match play training group giving the Match play exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
75654930|NCT00843895|Biological|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
75654931|NCT00705315|Drug|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
75476444|NCT05969197|Other|Plyometric Training|15 participants will be in Plyometric training group giving isotonic exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
75940880|NCT05170438|Drug|Lenvatinib Pill,Paclitaxel|Regimen Every 28 days as one cycle.Lenvatinib 16 or 12 mg/day orally (depends on the result of safety run-in phase), on day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15.
75940881|NCT01372748|Other|Standard CPR|30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
75940882|NCT01372748|Other|Continuous chest compressions|Continuous chest compressions during the first 6 minutes of the resuscitation.
75654932|NCT00705315|Drug|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
75940883|NCT05109520|Drug|Insulin Glargine 300 UNT/ML [Toujeo]|Switch during standard routine care to Gla-300.
75940884|NCT03478605|Drug|Olanzapine|Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)
75654933|NCT00705315|Drug|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
75654934|NCT00837733|Procedure|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
75654935|NCT00837733|Procedure|Endometrial Biopsy|Biopsy catheter
75654936|NCT00892008|Drug|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
75654937|NCT02548507|Other|observational study, no intervention|
75654938|NCT05238168|Other|ePIPARI digital follow up tool|A digital platform includes questions to parents about child wellbeing and development and parent wellbeing. A notification by email or app comes two weeks before the follow up time point. The parents respond via a link to a webpage or via an app.They also receive information (text and video) about age-appropriate child development. ePIPARI includes 8 assessment points from term age until 2 years of corrected age.
75654939|NCT04247490|Diagnostic Test|pediatric AIH|pediatric patients with clinical, laboratory (transaminase and IgG increase), instrumental (ultrasound, liver biopsy) characteristics
75654940|NCT04201236|Other|respiratory muscle strengthening exercise|These exercises strengthen locally inspiratory muscles. IMT can be done with threshold loaded devices.
75654941|NCT04201236|Other|oropharyngeal muscles strengthening exercise|These exercises strengthen locally oropharyngeal muscles. Oropharyngeal exercise can be done with some facial movements .
75654942|NCT00623233|Drug|Gemcitabine|Gemcitabine 2500 mg/m^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
75654943|NCT00623233|Drug|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event [AE], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
75654944|NCT02835612|Other|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
75344253|NCT04736121|Device|Resin microspheres containing yttrium-90 (Y-90)|Biocompatible resin microspheres are an injectable permanent implant and preferentially placed into the distal microvascular supply of tumors to provide direct irradiation of tissue and destruction of the microvascular bed. Spheres contain yttrium-90 (Y-90) and are a size between 20 and 60 microns in diameter.
75802178|NCT04105218|Behavioral|Exercise|Participants will perform 4 study visits over 1-3 months. The 1st study visit is a screening visit, during which eligibility will be determined. During the 2nd visit, resting metabolic rate (RMR) and body composition will be measured. Participants will also perform a submaximal exercise test. Prior to each condition, habitual sleep/wake patterns will then be measured for 1 week. Participants will then perform each of the 2 study conditions (evening exercise and control) in randomized order with at least a 1-week washout period between conditions. Females will be studied during the luteal phase to control for potential confounding effects of hormonal variations across the menstrual cycle.
75940885|NCT03478605|Drug|Aprepitant Pill|Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
75940886|NCT03478605|Drug|Ondansetron|Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
75344254|NCT04727736|Drug|18F-DCFPyL|18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
75344255|NCT04722224|Other|Home-based pulmonary rehabilitation|The reabilitAR program includes the self-management educational program Living Well with COPD. The exercise training will include endurance, resistance/strength, flexibility and balance training.
75344256|NCT04714281|Device|Dialyser|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
75344257|NCT04711057|Other|Community-based PA program|After completing the PR program, the experimental group (EG) will enroll in a 6-month personalized community-based PA program, which should be attended twice-weekly, minimum. During the first month the physiotherapist will guide patients through all available physical activities; afterwards, patients will be asked to choose one or two activities, according to their preference, which they'll attend for five more months. Physiotherapists' support will gradually decrease over time.
75344258|NCT04711057|Other|Pulmonary Rehabilitation|Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.
75344259|NCT04710043|Drug|BNT152|intravenous
75344260|NCT04710043|Drug|BNT153|intravenous
75344261|NCT04696055|Drug|Pembrolizumab|Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).
75344262|NCT04696055|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.
75344263|NCT04691570|Drug|ANX005|ANX005 is provided as a solution for IV infusion
75344264|NCT04682379|Diagnostic Test|Proprioceptive measurements|"Trunk flexion-extension repositioning test~Trunk lateral-flexion repositioning test~Trunk axial-rotation repositioning test~Neck rotation repositioning test~Elbow flexion repositioning test~Knee extension repositioning test"
75344265|NCT04674254|Drug|Bevacizumab Injection|Bevacizumab will be intravitreally injected every 4 weeks through 12 weeks then pro re nata thereafter for 12 months.
75344266|NCT04674254|Procedure|Targeted retinal photocoagulation|Targeted retinal photocoagulation will be administered to nonperfused areas detected on fundus fluorescein angiography at baseline and repeated every 3 months as needed for 12 months.
75344267|NCT04674254|Procedure|Standard pan-retinal photocoagulation|Standard pan-retinal photocoagulation will be applied to perfused and nonperfused areas of the retinal periphery at baseline and every 3 months as needed for 12 months.
75344268|NCT04666610|Drug|Brivaracetam|"Pharmaceutical form: Oral solution~Route of administration: Oral use~Brivaracetam (oral solution [10 mg/ml, 5 mg/ml or 2.5 mg/ml] will be administered."
75344269|NCT04666610|Other|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding.
75344270|NCT04666545|Behavioral|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
75344271|NCT04665843|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
75654945|NCT02835612|Other|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
75654946|NCT00837889|Drug|diuretics, inotropica|
75654947|NCT02832882|Procedure|No-touch RFA|No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.
75654948|NCT02832882|Procedure|Conventional tumor puncture RFA|Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.
75654949|NCT02546557|Procedure|Coronary Artery Bypass Graft surgery|
75802179|NCT03747354|Diagnostic Test|blood samples|blood samples
75802180|NCT05730556|Device|Nerivio ®|Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.
75940887|NCT03478605|Drug|Dexamethasone|Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
75344272|NCT04665843|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
75344273|NCT04665843|Drug|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
75654950|NCT04201002|Procedure|Resection plus intraoperative radiotherapy|En-bloc resection plus intraoperative radiotherapy
75802181|NCT05730556|Device|Sham|Electrical stimulation to mimic study treatment intervention
75802182|NCT04543968|Dietary Supplement|hydroxytyrosol (HT) intake|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
75940888|NCT03478527|Dietary Supplement|Vivomixx® powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
75940889|NCT03478527|Other|Placebo powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
75940890|NCT03673475|Procedure|Assessment of fluid responsiveness|assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
75344274|NCT04660500|Other|PD Drivers Using AV Technologies On-road|All drives will include events to assess the impact of in-vehicle information systems (IVIS) and advanced driver assistance systems (ADAS) on the driving performance (driving errors) of drivers with PD. For IVIS the investigators will include options to assess errors with lane maintenance (with and without the lane departure warning system) and signaling (with and without blind spot detection). For ADAS the investigators will include conditions to assess errors in speeding (with and without adaptive cruise control) and lane exceedances (with and without lane keeping assist).
75940891|NCT02386748|Dietary Supplement|Chewing gum|Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
75344275|NCT04658186|Drug|UCB0599|Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
75344276|NCT04658186|Drug|Placebo|Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
75344277|NCT04657302|Drug|Obinutuzumab|Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
75344278|NCT04657302|Drug|Glofitamab|Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
75802183|NCT04543968|Dietary Supplement|hydroxytyrosol (HT) intake and withdraw|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
75654951|NCT00843973|Procedure|iliac crest bone graft|iliac crest bone graft procedure
75802184|NCT04097106|Dietary Supplement|Synbiotic|Synbiotic dietary supplement in capsule form
75940892|NCT02386748|Dietary Supplement|Oral fluids|Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
75940893|NCT02386748|Other|Intravenous fluids|Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
75940894|NCT05054062|Diagnostic Test|Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
75940895|NCT02736825|Device|Ulthera System with standard transducer|Focused ultrasound energy delivered below the surface of the skin using commercially available transducer to deliver one line of treatment at a time
75940896|NCT02736825|Device|Ulthera System with prototype 2 simulines transducer|Focused ultrasound energy delivered below the surface of the skin using new transducer to deliver two lines of treatment simultaneously
75940897|NCT04439708|Other|Blood and aqueous humor biomarker of treatment response|Blood analyses and aqueous humor analysis
75940898|NCT02390804|Device|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
75940899|NCT02390804|Device|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
75940900|NCT05071066|Other|ADHD+|"The group-based intervention is designed to reduce participants' ADHD and related symptoms. The content of the treatment will follow an established manual which is developed by an expert group comprised of psychiatrists and clinical psychologists. Core treatment components include internet use/addiction intervention, cognitive training, emotion management, social skills training, occupational training, emotion support/befriending, parenting training, and career guidance.~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months. The post- intervention assessments (3-month [T1], and 6-month [T2]) will be administered to all participants. During the period of intervention, all participants shall be clean from other forms of interventions to reduce any other possible confounders."
75344279|NCT04657302|Drug|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
75802185|NCT04368910|Drug|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
75802186|NCT04368910|Drug|Chloroquine|Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
75802187|NCT04249258|Drug|Dobutamine|Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
75344283|NCT04623216|Biological|Sabatolimab|Sabatolimab is a solution in vial for IV infusion
75654952|NCT00843973|Procedure|Reamer Irrigator Aspirator|Reamer Irrigator Aspirator (RIA) Procedure
75654953|NCT02832804|Device|transcranial Direct Current Stimulation|Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
75654954|NCT02841488|Procedure|Continuous peripheral sciatic nerve block|Continuous infusion of local anesthetics through perineural sciatic nerve catheter
75654955|NCT02841488|Drug|Fentanyl|Use of patient controlled analgesia device with intravenous fentanyl
75654956|NCT02841488|Drug|Ropivacaine|
75654957|NCT02841488|Device|Perineural catheter|
75802188|NCT03938584|Dietary Supplement|Vitamin C|Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91
75819811|NCT00293033|Drug|Placebo|
75819812|NCT02180776|Other|Summit 456 TLSO|Thoracolumbarsacral orthosis
75819813|NCT02183116|Drug|Meloxicam|
75344284|NCT04623216|Drug|Azacitidine|Azacitidine comes in Vial for IV infusion or subcutaneous administration
75344285|NCT04616781|Dietary Supplement|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|nutritional ketone ester
75654958|NCT02832726|Dietary Supplement|Vitamin B12|
75654959|NCT00831337|Dietary Supplement|VSL3|2 times daily 450 billion live bacteria (in each saschet)
75654960|NCT04201158|Diagnostic Test|Exercise Capacity|Modified Shuttle Walk Test
75654961|NCT00838045|Device|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch & Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
75802189|NCT03938584|Other|Placebo|Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).
75940901|NCT05672498|Drug|Traditional Chinese Medicine Formulation|The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
75940902|NCT05672498|Other|Placebo Treatment|Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo every morning and evening for 7 days. All medications and placebo are packed identically in packing bags with the same labeling form.
75940903|NCT03478449|Procedure|lymph node sorting for pathological examination|In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.
75940904|NCT05674838|Other|Leg Elevation|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge and both of her legs elevated on an orange peanut ball. She will remain in this position for approximately 40 minutes.
75940905|NCT05258799|Drug|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count > 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
75940906|NCT02670122|Device|DEB-TACE|Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
75940907|NCT02390648|Drug|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
75940908|NCT02390648|Drug|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
75940909|NCT04233892|Drug|CBD-bFGF|CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound
75940910|NCT04233892|Drug|Collagen/BMMNCs|A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
75344286|NCT04616781|Drug|Isocaloric dextrose placebo|Drink indistinguishable from ketone ester
75654962|NCT02548754|Device|Parasym device|
75802190|NCT03781726|Drug|glecaprevir/pibrentasvir treatment|combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
75940911|NCT04233892|Drug|Estrogen|Patients will receive regular estrogen therapy
75940912|NCT02386358|Drug|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
75344287|NCT04616781|Other|Alcohol drinks|drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
75802191|NCT03721276|Behavioral|EQuIP (Empowering Queer Identities in Psychotherapy)|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
75940913|NCT02386358|Drug|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
75344288|NCT04609410|Procedure|Neuromuscular blockade|Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring
75344289|NCT04607850|Biological|ChAdOx1-HPV|Trial vaccine
75344290|NCT04607850|Biological|MVA-HPV|Trial vaccine
75654963|NCT02831322|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
75802192|NCT03311854|Drug|Emapalumab|Emapalumab was administered at an initial dose of 6 mg/kg by intravenous infusion. Emapalumab treatment continued at a dose of 3 mg/kg, every 3 days until study day 15, and then twice-a-week for an additional 2 weeks, i.e., until study day 28. The emapalumab regimen could be adapted (the frequency between infusions shortened, the dose increased, or the treatment prolonged beyond 4 weeks) upon assessment of a favourable benefit-risk profile. There was a 4-week off-drug follow-up period (up to Week 8).
75819814|NCT02183194|Device|Lutonix Paclitaxel Drug Coated Balloon|
75940914|NCT05053204|Other||
75940915|NCT02390726|Biological|Fecal Microbiota Transplant|
75940916|NCT02390726|Biological|Placebo|
75940917|NCT03283371|Drug|Natalizumab|As specified in the treatment arm.
75940918|NCT03283371|Other|Placebo|As specified in treatment arms.
75940919|NCT05069350|Drug|bupivacaine 0.5% and oxubuprocaine|using each drug as surface anesthesia before intravitreal injections
75940920|NCT03471351|Drug|Tenalisib|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
75940921|NCT03471351|Biological|Pembrolizumab|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
75344291|NCT04607850|Biological|Placebo|Saline placebo vaccine
75344292|NCT04601831|Radiation|Focal radiation therapy (RT)|"Radiation therapy for phase II:~Definitive 40-50 Gy EQD2 (i.e. 30 Gy in 5 fractions)~Hypofractionated regimen (i.e. 5 fractions in 1-2 weeks) recommended, but other fractionation schemes (10-20 fractions in 2-4 weeks) allowed."
75344293|NCT04594070|Drug|Ferrous sulfate|Iron supplementation
75344294|NCT04583501|Biological|Omalizumab|Omalizumab will used as dose comparable to to 0.016 mg/kg/IU in serum.
75344295|NCT04580771|Drug|Cisplatin|Given IV
75654964|NCT02547259|Procedure|pain words test|"words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
75940922|NCT02386280|Behavioral|Motivational Interviewing for Change of Parenting Styles|
75940923|NCT02386280|Behavioral|Psicoeducation|
75940924|NCT02386436|Drug|GSK2330811|GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
75940925|NCT02386436|Drug|Placebo|Placebo will be supplied as Normal Saline (0.9% weight by volume [w/v] Sodium Chloride) administered as single dose s.c.
75940926|NCT05154435|Drug|mostcare hemodynamic monitor|mostcare hemodynamic monitoring integrated into the radial artery catheter. According to the data obtained, intraoperative fluid management was arranged with certain algorithms.
75940927|NCT02386592|Drug|Chlorhexidine gluconate (CHG)|All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
75940928|NCT02386592|Behavioral|Hand hygiene (HH)|Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.
75940929|NCT02386592|Behavioral|Infection control training|All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.
75940930|NCT02386592|Other|Infection control reminders via SMS text|Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
75344296|NCT04580771|Biological|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
75344297|NCT04580771|Radiation|Radiation Therapy|Undergo radiation therapy
75344298|NCT04578834|Drug|Placebo|Placebo to LNP023 200mg b.i.d
75344299|NCT04578834|Drug|LNP023|LNP023 200mg b.i.d
75344300|NCT04577599|Other|Mobile Low-dose Computed Tomography (LDCT) Screening|Low Dose CT Scan of the Chest
75344301|NCT04573023|Drug|JR-141|IV infusion, 2.0 mg/kg/week
75344302|NCT04573023|Drug|Idursulfase|IV infusion
75654965|NCT02547259|Procedure|negative words test|"words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
75940931|NCT02390180|Other|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
75940932|NCT05138679|Procedure|Revascularization|Endovascular or surgical restoration of arterial blood flow.
75344303|NCT04573023|Drug|JR-141 or Idursulfase|"The subjects who have achieved the pre-specified criteria* are able to change the drug.~*If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141.~If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase."
75344304|NCT04569032|Drug|brentuximab vedotin|1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
75344305|NCT04569032|Drug|cyclophosphamide|750 mg/m^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
75654966|NCT02831244|Device|Agili-CTM|Consenting individuals will be selected from the population of patients with osteoarthritis of the great toe examined by a participating investigator. Following signing an informed consent, candidates will be evaluated by an adjudication committee for possible inclusion in the trial based on medical history and Standing Foot X-ray. Candidates that are approved or conditionally approved by the adjudication committee will undergo Agili-CTM implantation procedure
75344306|NCT04569032|Drug|doxorubicin|50 mg/m^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
75654967|NCT02499302|Behavioral|Mental training|
75344307|NCT04569032|Drug|prednisone|100 mg daily administered orally on Days 1-5 of each cycle
75344308|NCT04568486|Other|Diabetes Empowerment Education Program|The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
75344309|NCT04544046|Other|Supportive Oncology Care at Home|Remote monitoring of symptoms, vital signs, and body weight with home-based care to address any concerning issues identified.
75344310|NCT04544046|Other|Usual Care|Standard care arm will receive standard oncology care and attend regular clinic visits.
75654968|NCT02831400|Behavioral|Walking test|Walking test to increase cardiac output, maximum 12 minutes
75654969|NCT02831400|Behavioral|Standard Meal|After the walking test, volunteers eat a standard warm meal
75654970|NCT00202904|Drug|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
75344311|NCT04542330|Biological|BCG-Denmark|Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) administered by intradermal injection in the left deltoid region.
75344312|NCT04542330|Biological|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
75344313|NCT04527991|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
75344314|NCT04527991|Drug|Paclitaxel|Administered intravenously
75654971|NCT00202904|Drug|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
75940933|NCT05138679|Procedure|Primary major amputation|Primary below- or above knee major amputation without prior revascularization.
75940934|NCT05138679|Other|Best medical treatment|Conservative treatment of acute lower limb ischemia - without prior revascularization.
75940935|NCT02390258|Drug|10mg XEN-D0103|
75940936|NCT02390258|Drug|Placebo|
75940937|NCT02390258|Drug|30mg XEN-D0103|
75940938|NCT02390258|Drug|60mg XEN-D0103|
75940939|NCT02390258|Drug|120mg XEN-D0103|
75940940|NCT02390258|Drug|200mg XEN-D0103|
75344315|NCT04527991|Drug|Docetaxel|Administered intravenously
75344316|NCT04527991|Drug|Vinflunine|Administered intravenously
75654972|NCT04248660|Other|uterine artery doppler measurement|"The effect of delivery type on changes in uterine blood flow will be investigated.~Doppler results groups will be defined according to the effect of deviations in uterine blood flow on neonatal and perinatal results."
75940941|NCT02390258|Drug|150mg XEN-D0103|
75344317|NCT04506164|Other|Multicomponent Implementation Strategy|The eScreening MCIS was developed over the past seven years and consists of: 1) eScreening software provision, 2) training, 3) RPIW, and 4) ongoing blended facilitation. The investigators developed our MCIS to address specific eScreening implementation barriers found in the investigators' prior research.
75344318|NCT04506164|Other|eScreening|eScreening is a clinical patient self report system that allows Veterans to complete clinical reminders and other self report screens using a secure connection from any internet connected device.
75344319|NCT04496960|Drug|tofacitinib|XELJANZ(R) is the citrate salt of tofacitinib. Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) It is freely soluble in water and has a molecular weight of 504.5 Daltons. XELJANZ(R) is supplied for oral administration as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet. Each tablet of XELJANZ(R) contains the appropriate amount of XELJANZ(R) as a citrate salt and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.
75344320|NCT04496960|Other|Placebo|white, round, film-coated tablet
75344321|NCT04496063|Drug|Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
75940942|NCT03891446|Drug|Bimatoprost SR|Intraocular implant
75940943|NCT03891446|Other|Standard of Care|Standard of care treatment based on investigator's judgement.
75476445|NCT05969184|Drug|CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)|CDK4/6 inhibitor (Qilu) have got the cFDA approval and Trastuzumab (Hanquyou) have few data on combination use, this two drugs need clinical treatment data
75654973|NCT02690870|Drug|Tamoxifen|Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
75940944|NCT03069417|Behavioral|Integrating Nuanced Support for Perinatal adherence and Depression|A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
75940945|NCT02390336|Other|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
75940946|NCT02390336|Other|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
75940947|NCT03059511|Drug|Nalbuphine|Opioid Pain Medicine
75940948|NCT02390492|Drug|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous [14C]-ipatasertib on Day 1 of study
75476446|NCT05969171|Drug|Sofantinib、abraxane、gemcitabine|The combination of 3 weeks was a treatment cycle, and AG chemotherapy was defined as a maximum of 6 treatment cycles, and soantinib was continued until disease progression (PD, RECIST 1.1) or death (during patient treatment) or toxicity intolerance or other criteria for discontinuation of study therapy were met in the protocol.
75476447|NCT05969171|Drug|Abraxane combined with gemcitabine|Abraxane combined with gemcitabine
75654974|NCT02690870|Drug|Clomiphene|Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
75654975|NCT02835378|Other|No intervention|
75654976|NCT00844207|Drug|Fixed combination of Azithromycin and Chloroquine|Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
75654977|NCT00844207|Drug|Azithromycin and Chloroquine|Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
75654978|NCT02835300|Behavioral|CampAir|CampAir is a dynamic e-learning intervention to help adolescents with uncontrolled asthma to manage their illness and to improve their asthma control. CampAir consists of seven online modules with one module being completed each week over seven weeks. Each module provides a brief introduction to the topics and strategies focused on in that module followed by a set of interactive exercises and games for practice and personalized feedback.
75654979|NCT02835300|Behavioral|Information and Referral|The information and referral comparator condition will provide access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will have access to CampAir.
75654980|NCT02841722|Procedure|ERIBULIN + G-CSF (Granulocyte-Colony Stimulating Factor)|8 additional blood samples
75940949|NCT02390492|Drug|Period 2 treatment|200-mg/100-mcCi oral [14C]-ipatasertib on Day 15 of study
75940950|NCT03014037|Procedure|Unilateral Bone Marrow Procurement|A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
75654981|NCT02548117|Drug|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
75654982|NCT05263518|Procedure|Cataract surgery with AcrySof IQ IOL implantation.|Patients in this study will receive cataract surgery with AcrySof IQ IOL implantation.
75654983|NCT05263518|Procedure|Cataract surgery with TECNIS toric IOL implantation.|Patients in this study will receive cataract surgery with TECNIS toric IOL implantation.
75654984|NCT02841566|Other|questionnaire|
75654985|NCT02546947|Other|Train of four monitoring|with an end point of one or two response at orbicularis oculi to TOF stimulation
75654986|NCT02841878|Genetic|Analysis on colorectal biopsy|
75802193|NCT03269344|Drug|Gabapentin|Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures
75802194|NCT03269344|Drug|Placebo Oral Capsule|Placebo
75802195|NCT03619798|Device|HemoTypeSC|Point-of-Care Rapid Test for Detection of Sickle Cell Disease-Relevant Hemoglobin Phenotypes in Whole Blood
75940951|NCT03014037|Procedure|Bilateral Bone Marrow Procurement|30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
75940952|NCT04439786|Drug|placebo|the control group will be given the same volume of saline.
75940953|NCT04439786|Drug|lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
76090405|NCT05739370|Other|Problem-Solving Therapy for Older Adults|"Problem-Solving Therapy for Older Adults (Ger-iPST) is an 8-week online psychotherapy program with online therapist support delivered through the Online Psycho Therapy Tool (OPTT). Ger-iPST has several evidence-based elements tailored to the specific needs of older adults, including relevant content (e.g. aging-related examples); process adaptations (e.g. more repetition); and digital usability modifications (e.g. high-contrast text).~Ger-iPST contains therapy modules assigned weekly and accessible at any time during the week. Modules begin with a brief, guided mindfulness relaxation exercise, followed by approximately 20 slides taking, on an average 1 hour to complete. Each module highlights a different step of Psychotherapy (PST) and includes an overview of a new skill, interactive activities and examples. A homework exercise designed to guide participants in applying a new PST skill exercise is submitted through the platform, and a clinician will provide personalized feedback."
75344322|NCT04496063|Drug|Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
75344323|NCT04493060|Biological|Dostarlimab|Given IV
75344324|NCT04493060|Drug|Niraparib|Given PO
75344325|NCT04489238|Other|Risk Factor Questionnaire|Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit
75344326|NCT04468607|Drug|BLYG8824A|BLYG8824A will be administered at a flat dose independent of body weight.
75344327|NCT04464226|Drug|Darolutamide (Nubeqa, BAY1841788)|Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
75654987|NCT02841800|Device|'Intra-luminal radiofrequency ablation (Habib EndoHPB)|endobiliary radiofrequency ablation device
75344328|NCT04445805|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, cognitive therapy, and relaxation. Treatment will be delivered via telemedicine.
75344329|NCT04445805|Behavioral|Perinatal-enhanced Behavioral Therapy for Insomnia|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, and metacognitive exercises. Treatment will be delivered via telemedicine.
75654988|NCT02832336|Drug|Vivarin|Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
75654989|NCT02832336|Drug|Fiber|Fiber will be used as placebo.
75802196|NCT04389840|Drug|Dociparstat sodium|Dociparstat is a glycosaminoglycan derived from porcine heparin.
75802197|NCT04389840|Drug|Placebo|0.9% Normal Saline
75802198|NCT03747198|Dietary Supplement|methylsulfonylmethane|Subjects will be given 2 g/day methylsulfonylmethane.
75802199|NCT03747198|Other|Placebo|Subjects will be given 2 g/day placebo (rice flour).
75344330|NCT04445805|Behavioral|Attention Control|Will include education on sleep, circadian rhythms, and good sleep hygiene in addition to self-monitoring with sleep diaries.
75344331|NCT04440566|Biological|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
75344332|NCT04436640|Drug|Bimekizumab|Subjects will receive bimekizumab at prespecified time-points.
75344333|NCT04434066|Procedure|Total Laparoscopic Hysterectomy|Participants will be randomized into either abdominal or vaginal morcellation at time of total laparoscopic hysterectomy
75802200|NCT02940106|Device|Cryotop device|a different device for oocyte vitrification (with a very high cooling rate)
75802201|NCT02940106|Device|CBSvit device|a different device for oocyte vitrification (with a lower cooling rate)
75802202|NCT02933944|Biological|TG02-treatment|
75802203|NCT02933944|Drug|Pembrolizumab|
75802204|NCT04307940|Drug|Naproxen Sodium (Aleve, BAY117031)|220 mg per tablet, two tablets (440 mg), intake a single dose orally.
75802205|NCT04307940|Drug|Hydrocodone/Acetaminophen|5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally.
75940954|NCT03131115|Procedure|Lateral Crural Strut Graft|surgical technique as described
75940955|NCT03131115|Procedure|Bone Anchored Suspension|Surgical technique as described
75940956|NCT02686203|Device|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment"
75940957|NCT02386124|Other|frailty evaluation|assessment of mental and physical frailty before discharge from cardiac departement
75940958|NCT02386202|Other|No intervention|No interventions
75940959|NCT04930263|Behavioral|Aerobic exercise|The intervention was 24 weeks walking exercise program. Participants exercised frequency at 5 sessions a week for 30 minutes per section with moderate-intensity and wearable device assisted. Each session consisted of a 5 minutes warm-up, moderate-intensity walking exercises and 5 minutes cool-down. The program included individualized education, telephone and social media counselling, and booklet guidance
75940960|NCT04930263|Behavioral|control group|control group received routine care and a manual on healthy living
75940961|NCT02665286|Drug|Orphenadrine|Orphenadrine 100mg PO BID x 7 days
75344334|NCT04432584|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.
75344335|NCT04432584|Drug|Eculizumab|Eculizumab will be administered at a dose of 900 mg every 2 weeks, as per the dosing schedule described above.
75940962|NCT02665286|Drug|Methocarbamol|Methocarbamol 750mg 1-2 tabs po TID x 7 days
76090406|NCT02986828|Drug|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
76090407|NCT02986828|Drug|Normal saline|Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
76090408|NCT02986828|Device|Ultrasound|
75344336|NCT04432376|Drug|miconazole 2% oil|Drug treatment of otomycosis for 14 days
75344337|NCT04432376|Drug|vehicle oil|Placebo treatment of otomycosis for 14 days
75344338|NCT04430426|Other|Controlled Diet|Participants will consume a controlled low oxalate diet for five days.
75802206|NCT04307940|Drug|Placebo|two tablets, intake a single dose orally.
75802207|NCT04495530|Other|Non-interventional study|semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions
75802208|NCT02717416|Device|Endo-Clot|After epinephine injection therapy, Endo-Clot is applied immediately onto the bleeding lesion. A total of 2 g of AMP® particle powder will be sprayed onto the bleeding lesion by a catheter inserted through a working channel of the endoscope under continuous air flow.
75476448|NCT05969158|Drug|Hetrombopag|"After screening, patients who were treated with XPO-1 inhibitor Selinexor combined with chemotherapy and developed chemotherapy-related thrombocytopenia (CIT) after treatment and met the secondary prevention criteria were eligible for inclusion criteria.~The platelet reduction after the previous chemotherapy was used as the control group:~The patients did not routinely receive prophylactic platelet elevation therapy after the previous Selinexor combined chemotherapy, and when PLT < 50×109/L.~Platelet reduction after chemotherapy in secondary prevention unit was used as the experimental group:~The subjects will initiate treatment with 5 mg hetrombopag once a day, starting orally 5 days before chemotherapy, take it for 5 days (D-5-D-1), and continue taking it orally for 5 days after chemotherapy (D1-D5)."
75344339|NCT04430426|Other|Glycolate Administration|Participants will come to the UAB Clinical Research Unit (CRU) and be administered a glycolate load via intravenous (IV) catheter.
75654990|NCT03369236|Drug|Danicopan|Danicopan was administered as an oral tablet.
75654991|NCT03369236|Drug|Placebo|Matching placebo was administered as an oral tablet.
75654992|NCT02841410|Other|Magnetic Resonance Imaging|
75802209|NCT02717416|Device|hemoclip or electrical coagulation|After epinephrine injection therapy, hemoclip (HX-610-135, Olympus, Japan) will be applied onto the bleeding lesions. The number of hemoclip will be decided by endoscopist. Electrical coagulation will be applied onto the bleeding lesions.
75802210|NCT02054104|Biological|H1299 cell lysates|H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
75802211|NCT02054104|Drug|Cyclophosphamide|50 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
75802212|NCT02054104|Drug|Celecoxib|400 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each treatment cycle.
75802213|NCT02054104|Biological|Iscomatrix adjuvant|H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
75802214|NCT04377334|Biological|MSC|infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells
75654993|NCT00621751|Drug|Carbamazepine|800 mg daily
75654994|NCT00621751|Drug|Placebo|Placebo
75654995|NCT02690792|Other|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
75654996|NCT02690792|Dietary Supplement|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
75654997|NCT05335304|Other|intervention group 1|Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.
75654998|NCT05335304|Other|intervention group 2|Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.
75802215|NCT04333732|Drug|MR or M-M-R II ® vaccine|Education and surveillance plus MR or M-M-R II ® vaccine
75802216|NCT04333732|Drug|Placebo|Placebo injection
75819815|NCT02756182|Device|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP & AC measurements
75940963|NCT02665286|Drug|Naproxen|Naproxen 500mg PO BID x 7 days
75940964|NCT02665286|Drug|Placebo|1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
75940965|NCT03471273|Procedure|endoscopic management, surgery and follow up|endoscopic management, surgery and follow up
75940966|NCT05440136|Drug|LY3462817 (SC)|Administered SC.
75940967|NCT05440136|Drug|Placebo (SC)|Administered SC.
75940968|NCT05440136|Drug|LY3462817 (IV)|Administered IV.
75940969|NCT05440136|Drug|Placebo (IV)|Administered IV.
75940970|NCT02390102|Drug|Erythropoietin|Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
75940971|NCT02390102|Drug|Placebo|Saline solution 0.9%
75344344|NCT04419428|Device|BiPAP A40 Expiratory Flow Limitation (EFL)|All participants in the observational registry will be using the BiPAP A40 EFL noninvasive ventilator as part of standard of care and will be participating in the same follows up and data collection. The BiPAP A-40 EFL ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Respiratory Insufficiency with the primary cause being COPD. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments.
75344345|NCT04412096|Drug|Timolol 0.5% ophthalmic solution|1 drop BID
75344346|NCT04412096|Drug|Latanoprost 0.005% Ophthalmic Solution|1 drop QD
75654999|NCT05335304|Other|intervention group 3|Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants
75655000|NCT05335304|Other|intervention group 4|Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.
75655001|NCT05335304|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
75802217|NCT03749382|Other|AprilAge- facial morphing appearance based intervention for smoking|"Appearance-based intervention: The intervention is a software that ages an individual's face with and without the effects of smoking. Participants have their photo taken on a laptop webcam, they are then asked to report their age and ethnicity in order to calibrate the software, the participants picture is then matched to a stock image. The participants will see two images on the screen, on the left is there face aged without the effects of smoking and one the right aged with the effects of smoking. Participants will be led through a series of morphing sequences (1-5). In-between each of the morphing sequences (Morph1 to Morph5) the participant will be asked to comment on the differences they can see between the two images.~General stop smoking intervention: The General stop smoking intervention comes in the form of a NHS stop smoking information leaflet. The participants will be given the leaflet on a laptop screen and asked to read through the whole document."
75655002|NCT00831649|Drug|natalizumab|
75655003|NCT02841332|Drug|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
75655004|NCT02841332|Other|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :~Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~magnetic resonance imagery spectroscopy sequence~Perfusion magnetic resonance imagery sequence~Diffusion magnetic resonance imagery sequence"
75802218|NCT04323124|Drug|PF-07059013|Participants will recieve PF-07059013
75802219|NCT04323124|Drug|Placebo|Participants will recieve placebo
75802220|NCT04090242|Device|BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle|Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
75802221|NCT04229290|Drug|Dolutegravir|Switch of virally suppressed participants to Dolutegravir
75802222|NCT04181476|Drug|Sunscreening Agents|Four different sunscreens
75802223|NCT04156438|Device|Low tidal volume ventilation|Conventional ventilation strategy for patient with ARDS
75802224|NCT04156438|Device|Airway pressure release ventilation|Experimental ventilation protocol for patients with ARDS
75819816|NCT02183272|Drug|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
75940972|NCT02389790|Drug|MT-1303|
75940973|NCT03664219|Other|isolation of IAN from implant with collagen membrane|comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
75940974|NCT03663673|Drug|EpiCeram|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
75940975|NCT03663673|Drug|Aveeno Daily Moisturising Sheer Hydration Lotion®|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
75940976|NCT04057963|Other|Conventional plus Functional Inspiratory Muscle Training Group|functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.
75940977|NCT04057963|Other|Conventional Physiotherapy Program|conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
75940978|NCT04058041|Procedure|Neural Mobilization|neural exercise Will be performed in the patients
75819817|NCT02183272|Drug|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
75940979|NCT04058041|Procedure|Surgery|open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome
75940980|NCT04058041|Procedure|Surgery and neural mobilization|following the surgery patients will be treat with neural mobilization exercises.
75940981|NCT04057885|Device|Orthosensor™ VERASENSE™ Knee System|A group of patients will receive a total knee arthroplasty using the Orthosensor device
75940982|NCT04057729|Drug|IMP4297|10mg/capsule.
75940983|NCT03664141|Drug|Cannabis oil|Treatment with cannabis oil
75940984|NCT03664141|Drug|Placebo/ Regular Oil|Treatment with placebo (Regular Oil)
75940985|NCT03664531|Other|Purified gluten|1 low FODMAPs, vegan muesli bar containing purified gluten per day for 1 week, for a total of 10 g purified gluten per day.
75940986|NCT03664531|Other|Non-purified gluten (containing ATIs)|1 low FODMAPs, vegan muesli bar containing whole wheat flour with non-purified gluten per day for 1 week, for a total of 10 g non-purified gluten per day.
75802225|NCT04086654|Diagnostic Test|International Trauma Interview (ITI) for ICD-11 PTSD and Complex PTSD - German version|The ITI consists of 18 items and for each symptom, standardized questions as well as probes are presented. A trained professional rates both symptom frequency and intensity, which are converted into an overall index of symptom severity. A diagnosis of PTSD/CPTSD is established by applying the ICD-11 diagnostic rules. It takes approximately 30-60 minutes to administer.
75940987|NCT03664531|Other|Nocebo|1 gluten-free, ATI-free, low FODMAPs, vegan muesli bar per day for 1 week. This is a nocebo because we expect that participants will feel worse even though there is no potential irritant.
75940988|NCT02911519|Other|Brief Group Psychoeducation|First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
75940989|NCT02911519|Other|Treatment as Usual|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
75940990|NCT03664063|Drug|Azithromycin|Treatment with Azithromycin single dose - weight based dosing max 2gm
75940991|NCT03664063|Drug|Albendazole|"Single dose of Albendazole weight based dosing~- 400mg"
75940992|NCT03664063|Drug|Ivermectin|Ivermectin weight based dosing - max 21mg
75802226|NCT04099108|Combination Product|Combined cycle ergometry and bolus amino acid supplementation|A 4-hour bolus amino acid supplement administered within 30 minutes after a 30-minute in-bed cycling session.
75476449|NCT05969132|Procedure|Fully digital guided gingivectomy procedure|"Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~Supra- and sub-gingival debridement.~Oral hygiene instructions (OHI)~Presurgical intraoral scanning using an intraoral scanner (IOS)~Fabrication of the Gingivectomy guide:~Convert (DICOM) file to STL file then merged to STL file corresponding oral soft tissues 3D data obtained by IOS using software of surgical planning.~Digital waxing up with new desired positions of gingival margins and zenith points performed.~Designing Gingivectomy guide then exported to a 3D printer and mill a transparent resin gingivectomy guide.~Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~Postoperative care"
75655005|NCT02841332|Drug|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
75655006|NCT02841332|Other|Clinical examination|"During the examination, the following parameters will be checked :~Neurological examination~Corticotherapy prescribed~General status of patient (world health organization score)~Weight and height~Control of arterial pressure~Chirurgical and medical history~Concomitant treatment"
75819818|NCT02177500|Drug|Telmisartan + hydrochlorothiazide|
75819819|NCT02177500|Drug|Telmisartan|
75655007|NCT00838357|Drug|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
75655008|NCT02841254|Other|Non interventional study|
75940993|NCT03664063|Drug|Diethylcarbamazine|Diethylcarbamazine weight based dosing - max 500mg
75940994|NCT04057495|Other|further fasting|2 hours of fasting
75940995|NCT04057495|Other|white bread consumption|113 grams of white bread consumption
75655009|NCT00156104|Drug|Asenapine|5 mg BID
75655010|NCT00156104|Drug|Asenapine|10 mg BID
75940996|NCT04057495|Other|mango consumption|330 grams of mango consumption
75940997|NCT04054921|Drug|PTG-300|PTG-300 is a hepcidin Mimetic
75940998|NCT02911285|Drug|N-acetylcysteine|1200mg bid (2400mg/day)
75940999|NCT02911285|Drug|Placebo|Placebo pills bid
75941000|NCT02911285|Behavioral|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
75941001|NCT02910739|Drug|MK-8931|MK-8931 40 mg
75941002|NCT03673397|Behavioral|Aerobic exercise, bicycle ergometer|Exercise performed below individual anaerobic threshold for 30 minutes
75941003|NCT03663985|Other|Groupe FALCOn|The objective of the study is to determine what are the anthropo-sociological factors in the surgeon, the oncologists and radiotherapists influencing decision making in ENT carcinology.
75941004|NCT04055935|Procedure|elevation of full thickness mucoperiosteal flap|A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
75941005|NCT04055935|Device|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
75941006|NCT04997902|Drug|Tipifarnib|Oral administration
75941007|NCT04997902|Drug|Alpelisib|Oral administration
75941008|NCT01061515|Drug|Intraperitoneal Oxaliplatin|
75941009|NCT01061515|Drug|Bevacizumab|
75819820|NCT02177500|Drug|Placebo|
75819821|NCT02183350|Drug|BI 1356 BS - single rising dose|
75819822|NCT02183350|Drug|Placebo|
75819823|NCT04289597|Diagnostic Test|Distance between hyoid bone-skin (DSHB)|Distance between hyoid bone-skin
75941010|NCT01061515|Drug|Capecitabine|
75344347|NCT04409834|Drug|Unfractionated Heparin IV|Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE
75344348|NCT04409834|Drug|Enoxaparin 1 mg/kg|Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours
75802227|NCT04068142|Other|Peer Supporter Safety Planning|The rationale for testing a peer-delivered intervention in the ED relies on the following evidence: a) a peer is an individual with lived experience who is now supporting other mental health patients in crisis; b) the experience of a mental health patient in the ED often shapes the perception of the health system, and may influence willingness to seek future care; c) peers may provide more empathetic care than providers without lived experience, which may positively impact patients; d) peer-based programs for patients with serious mental illness that do not involve safety planning are at least as good as non-peer based programs at preventing hospitalizations and promoting engagement in care, with the most promising interventions involving self-management or peer-navigator roles; and e) existing evidence from high-quality studies is scarce, but in moderate-low quality studies has indicated that peers are no less effective than mental health workers
75344349|NCT04409834|Drug|Clopidogrel|Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days
75655011|NCT00156104|Drug|Haloperidol|4 mg BID
75655012|NCT00156104|Other|Placebo arm|
75655013|NCT02841020|Procedure|Additional biopsy|• Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).
75655014|NCT05334602|Procedure|Addition of dermal fat graft as protection over bone graft|A barrier membrane
75655015|NCT00844363|Procedure|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
75802228|NCT03628222|Device|ENB-TBLB|"ENB Guidance: The iLungTM SuperNavigator system will be used, it comprises of iLungTM ENB system, location catheter and guide catheter. The guide catheter can supply a 1.9 mm working channel for biopsy tools.~The location catheter is inserted into the guide catheter beforehand, then both are introduced via the working channel of the bronchoscope. Under guidance of ENB system, the location catheter reaches the lesion, and actual distance is confirmed by the X-ray.~TBLB: Location catheter is retracted, then the biopsy forceps and brush was introduced, and pathologic specimens are obtained."
75802229|NCT03628222|Device|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and pathologic specimens are obtained.
75819824|NCT04289597|Diagnostic Test|Vocal cord anterior commissura-skin distance (DSAC)|Vocal cord anterior commissura-skin distance
75819825|NCT04289597|Diagnostic Test|minimum distance of the trachea to the skin at the level of suprasternal notch|Distance of the trachea to the skin at the level of suprasternal notch
75655016|NCT00844441|Other|medical chart review|
75655017|NCT00844441|Other|questionnaire administration|
75655018|NCT00844441|Procedure|quality-of-life assessment|
75344350|NCT04409834|Drug|Unfractionated heparin SC|Heparin 5,000 units administered subcutaneous three times daily
75344351|NCT04409834|Drug|Enoxaparin 40 mg SC|Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl<30 ml/min)
75344352|NCT04365023|Drug|platinum chemotherapy|First line platinum chemotherapy
75655019|NCT00254462|Drug|Atomoxetine|Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
75655020|NCT00254462|Drug|Placebo|Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
75655021|NCT00254462|Behavioral|Parent Training|All children will receive parent training for the duration of the study.
75655022|NCT00831727|Behavioral|Expressive Writing|Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
75655023|NCT00831727|Behavioral|Control|Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
75655024|NCT00891930|Biological|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
75655025|NCT00891930|Biological|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
75941011|NCT01069939|Drug|Esomeprazole|20mg, capsule, 72 weeks
75941012|NCT01069939|Drug|Placebo|Placebo, capsule, 72 weeks
75941013|NCT01069705|Drug|Tobramycin inhalation powder|Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.
75344355|NCT04340076|Drug|Secukinumab|Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
75344356|NCT04340076|Drug|Ixekizumab|Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
75655026|NCT00891930|Drug|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
75655027|NCT04248426|Drug|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
75655028|NCT04248426|Drug|ATI-2173 Placebo|ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
75655029|NCT02835066|Other|Integrated Fitness Assessment|Undergo function/fitness assessment
75655030|NCT02835066|Procedure|Psychosocial Assessment and Care|Undergo psychosocial health assessments
75941014|NCT01069627|Drug|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
75941015|NCT01069627|Drug|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
75941016|NCT04057261|Drug|Liraglutide Pen Injector [Victoza]|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
75344357|NCT04340076|Drug|Brodalumab|Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
75344358|NCT04340076|Drug|Guselkumab|Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
75344359|NCT04340076|Drug|Risankizumab|Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
75344360|NCT04340076|Drug|Tildrakizumab|Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
75655031|NCT02835066|Procedure|Quality-of-Life Assessment|Complete EORTC QLQ-C30 and QLQ-LC13 questionnaires
75655032|NCT02831166|Procedure|Transradial primary percutaneous coronary intervention|Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
75655033|NCT02831166|Procedure|Transfemoral primary percutaneous coronary intervention|Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
75655034|NCT04392024|Device|Triumf|Triumf is intraocular lens which offers multifocal vision by extended depth of focus and diffractive optics.
75344361|NCT04340076|Drug|Bimekizumab|Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
75655035|NCT04247568|Other|Listening to an audiotape|The participants listen to a audiofile that consists of hypnosis
75655036|NCT02832414|Behavioral|Intensive weight loss program|behavioral and dietary supplement
75655037|NCT02842112|Other|PBSC mobilization and leukapheresis|"Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques."
75655038|NCT02831088|Drug|Neu2000KWL High-does group|1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
75655039|NCT02831088|Drug|Neu2000KWL Low-does group|1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
75655040|NCT02831088|Drug|Placebo|1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
75655041|NCT02835144|Other|TIQAAM_therapy|The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
75655042|NCT02835144|Other|Psychoeducation|This intervention is a psychoeducation module pertaining to substance use disorders.
75655043|NCT02841098|Other|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
75344362|NCT04332211|Procedure|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.
75802230|NCT03628144|Dietary Supplement|Impact® Advanced Recovery|The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
75344363|NCT04332211|Drug|Pseudoephedrine 60 MG|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
75344364|NCT04332211|Drug|Placebo oral tablet|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
75344365|NCT04330716|Behavioral|Standard Genetic Counseling|Standard of care genetic counseling
75344366|NCT04330716|Behavioral|Educational Video|Video tutorial about genetic testing
75344367|NCT04318665|Diagnostic Test|CT Perfusion|Severe Traumatic Brain Injury patients will be undergoing CT perfusion test
75344368|NCT04316611|Drug|Potassium chloride|Direct intravenous injection (IVD) 20 mmol potassium chloride
75344369|NCT04314089|Drug|GT103|intravenously (dose depending)
75344370|NCT04305834|Drug|Abemaciclib|Given PO
75655044|NCT02841098|Drug|Optimal medical therapy alone|Optimal medical therapy alone
75819826|NCT04289597|Diagnostic Test|Thyroid isthmus-skin distance (DSI)|Thyroid isthmus-skin distance
75344371|NCT04305834|Other|Questionnaire Administration|Ancillary studies
75344372|NCT04297280|Drug|Sintilimab|a PD-1 immune check inhibitor
75344373|NCT04297280|Combination Product|TACE|TACE is performed by using drug eluting beads, or using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
75941017|NCT04057261|Drug|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
75941018|NCT03673319|Procedure|Dry needling with positives expectation|"DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
75941019|NCT03673319|Procedure|Dry needling with neutral expectation|"DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
76090409|NCT05724940|Other|clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients|"All patients will be subjected to the following:~Thorough medical history of the patients~Full clinical examination including:~General examination and vital signs.~Complete rheumatological examination.~SLE disease activity index SLEDAI (ref).~SLICC( Systemic Lupus International Collaborating Clinics) damage index (ref).~Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).~Renal investigations:~Kidney functions~Urine analysis~24 hours protein in urine and/or A/C ratio~Renal biopsy if indicated.~ANA (Antinuclear Antibodies)test.~ANA profile for the most common 19 autoantibodies by immunoblot."
76090410|NCT02204709|Other|2N Trout|Diploid/2N trout source
75655045|NCT05334446|Behavioral|The Effect of the Mobile Application|"This study was planned to determine the Effect of Mobile Application Use on Treatment Adherence and Self-Care Management in Patients with Hypertension. The study was designed to improve individuals' knowledge about the disease, regular drug use, diet compliance, physical activity level, quitting smoking and alcohol if using, and weight control."
75655046|NCT02841176|Other|Thermography|Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
75802231|NCT03628144|Dietary Supplement|Boost® High Protein|The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
75802232|NCT03628144|Radiation|Radiation Therapy|Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
75802233|NCT03628144|Drug|Chemotherapy|Standard of Care: Chemotherapy as already planned for each participant.
75941020|NCT03622801|Drug|Iopromide (Ultravist, BAY86-4877)|Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
75941021|NCT01064245|Drug|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
76090411|NCT02204709|Other|3N Trout|Triploid/3N trout source
76090412|NCT02204709|Other|Tilapia|Tilapia/control fish source
75655047|NCT02841176|Biological|Golimumab|Participants will start monthly Golimumab after their baseline visit
75655048|NCT01615874|Drug|MF/F Metered Dose Inhaler (MDI) 25/5 mcg|MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
75655049|NCT01615874|Drug|MF/F MDI 50/5 mcg|MF/F MDI 50/5 mcg, 2 inhalations BID
75802234|NCT03628144|Other|Quality of life (EORTC-QLQ-30)|Participants will undergo pre- and post-treatment assessments.
75802235|NCT03628144|Other|Evaluation of Cognitive Function (FACT-Cog, v. 3.0)|Participants will undergo pre- and post-treatment assessments.
75802236|NCT03628144|Other|Mindfulness Questionnaire (FFMQ)|Participants will undergo pre- and post-treatment assessments.
75802237|NCT03988192|Device|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
75802238|NCT03935698|Other|Physiotherapy|
75802239|NCT03855046|Drug|IncobotulinumtoxinA 50 U Intramuscular Powder for Solution|"Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution."
75819827|NCT04289597|Diagnostic Test|Skin-epiglottic distance (DSE)|Skin-epiglottic distance
75941022|NCT01064245|Other|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
75941023|NCT03669965|Drug|KRT-232|KRT-232, administered by mouth
75941024|NCT03669965|Drug|Ruxolitinib|Ruxolitinib per approved prescribing label
75941025|NCT03663049|Drug|discontinue statin|Discontinue statin as prescribed for 12 weeks
75941026|NCT03663439|Procedure|modified shell technique|divided block of bone into two shells and grafting one shell in anterior maxilla
75941027|NCT04056949|Drug|Paclitaxel/Albumin-Bound Paclitaxel|Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;
75941028|NCT04056949|Drug|IBI308|IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
75941029|NCT04057417|Other|Urban Trail|A newly built urban trail that was part of a large policy/infrastructure investment from the city/province to enhance the built environment for active transport and recreational physical activity in the city of Winnipeg, Manitoba Canada between 2010 and 2012.
75941030|NCT04056793|Other|Optimized birthing position|The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.
75941031|NCT03673241|Device|Guardian System|The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
75819828|NCT02180854|Other|Control group|
75819829|NCT02180854|Other|Increased monitoring frequency|
75819830|NCT01068119|Procedure|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
75819831|NCT03537898|Other|Lactated Ringer's|Lactated Ringer's will be used whenever an isotonic crystalloid is ordered
75819832|NCT03537898|Other|Normosol|Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
75802240|NCT03855046|Procedure|Lateral subcutaneous sphincterotomy.|The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
75655050|NCT01615874|Drug|MF/F MDI 100/5 mcg|MF/F MDI 100/5 mcg, 2 inhalations BID
75655051|NCT01615874|Drug|BDP hydrofluoroalkane (HFA) 80 mcg|BDP HFA 80 mcg, 2 inhalations BID
75344374|NCT04281771|Procedure|cardiac MRI|"Patients are studied on a clinical 1.5 Tesla scanner with cardiac radiofrequency receiver coil centered over the heart, and ECG monitoring. The following parameters are assessed:~Functional imaging: ECG-gated cine Steady-state free precession (SSFP) MRI images are obtained during repeated breath holds in long axis and short axis orientations covering the entire left ventricle. Global systolic and diastolic function are assessed, and left ventricular mass is calculated.~Flow imaging: ECG-gated 2D flow measurements are assessed above the prosthetic valve, and at the level of the pulmonary trunk."
75802241|NCT03483298|Other|ICSI|The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI
75941032|NCT03662425|Drug|Oxytocin|It's a two-week treatment trial.Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of OT
75941033|NCT03662425|Drug|Saline|It's a two-week treatment trial. Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
75941034|NCT03673163|Drug|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
75344375|NCT04265144|Biological|Blood samples|62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
75344376|NCT04265144|Other|Biopsy|Skin biopsies
75344377|NCT04265144|Other|Bronchoalveolar samples|50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration
75344378|NCT04264026|Drug|3,4-methylenedioxymethamphetamine|Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
75344379|NCT04260529|Drug|CyPep-1|Intratumoral injection
75344380|NCT04260529|Drug|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
75344381|NCT04254107|Drug|SEA-TGT|Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
75344382|NCT04254107|Drug|sasanlimab|Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle
75655052|NCT01615874|Drug|Montelukast tablets 5 mg (4 mg for children 5 years of age)|"Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age~OR~Montelukast chewable tablets 4 mg QD for children 5 years of age"
75655053|NCT01615874|Drug|Rescue medication: short-acting beta-2 agonist (SABA) MDI|albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
75655054|NCT01615874|Drug|Rescue medication: Prednisone/Prednisolone|Prednisone/Prednisolone for rescue medication, taken as directed
75655055|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
75655056|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
75802242|NCT03283852|Genetic|blood sample|search for genetic mutations
75802243|NCT03255772|Diagnostic Test|Magnetocardiography|Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
75941035|NCT03673163|Drug|Control|Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
75941036|NCT03662269|Drug|indomethacin|indomethacin (75mg, bid, po, 14days)
75941037|NCT03662269|Drug|Placebo|placebo (75mg, bid, po, 14days)
75941038|NCT03662269|Drug|Omeprazole|placebo (20mg, qd, po, 14days)
75941039|NCT04056325|Drug|Moxidectin|Monotherapy, oral administration, single dose, fixed dose
75941040|NCT04056325|Drug|Ivermectin|Monotherapy, oral administration, single dose, weight dependent
75941041|NCT04056325|Drug|Placebo oral tablet|Monotherapy, oral administration, single dose, matching number of tablets
75941042|NCT03673085|Drug|CN128|CN128
75941043|NCT03673085|Other|placebo|The tablets without CN128
75941044|NCT03662191|Drug|Tafamidis|bioavailability study
75344383|NCT04254107|Drug|brentuximab vedotin|Given by IV on Day 1 of each 21-day cycle
75344384|NCT04224480|Drug|Pembrolizumab|200mg of intravenous infusion every 3 weeks
75344385|NCT04218591|Other|PRP|Platelet rich plasma
75344386|NCT04218591|Other|Placebo|Saline
75344387|NCT04218084|Drug|Voxelotor|Participants are randomized 1:1 to receive voxelotor or placebo.
75344388|NCT04218084|Drug|Placebo|Matching placebo.
75344389|NCT04209738|Other|This is an observational study being conducted as a substudy of another trial.|This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.
75344390|NCT04201457|Drug|Dabrafenib|Dabrafenib capsule; Dabrafenib Dispersible Tablet
75344391|NCT04201457|Drug|Trametinib|Tablet; Powder for Oral Solution
75344392|NCT04201457|Drug|Hydroxychloroquine|Tablet
75344393|NCT04199117|Drug|Varenicline|Participants randomized to intensive treatment who choose to use this intervention will receive one 0.5 mg pill for the first 3 days, starting 7 days prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. This will not be used at the same time as combination nicotine replacement therapy.
76090413|NCT01893957|Procedure|high voltage electrical stimulation - axillary lymphadenectomy|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
76090414|NCT01893957|Procedure|High voltage electrical stimulation - ( healthy women )|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
76090415|NCT01893957|Device|Neurodyn High Volt Model (IBRAMED)|
76090416|NCT02284516|Drug|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
75941045|NCT03662971|Drug|Germinal peptide eye drops|Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
76090417|NCT02284516|Drug|Placebo|Placebo to match active treatment, BID for 84 days
76090418|NCT05581485|Procedure|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow(HFNO).
76090419|NCT05738980|Biological|Autologous RAK cells|Autologous RAK cells were treated by intravenous reinfusion
76090420|NCT02721537|Dietary Supplement|Nicotinamide Riboside|Three capsules, twice per day for 84 days
75655057|NCT00891462|Drug|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
75655058|NCT02834910|Other|collection of bacterial sample|
76090421|NCT02721537|Other|Matching placebo|Three matching capsules, twice per day for 84 days
76090422|NCT04748614|Other|Cost|ICU cost
76090423|NCT02185209|Drug|Placebo|Place capsule to mimic antibiotics
76090424|NCT02185209|Drug|Amoxicillin Sandoz|Tablet 500 mg amoxicillin Sandoz three times a day
76090425|NCT02185209|Drug|Metronidazole Sanofi|400 mg metronidazole Sanofi administered three times a day (TID)
75476450|NCT05969132|Procedure|Convectional guided gingivectomy procedure|"Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~Supra- and sub-gingival debridement with OHI~Gingivectomy guide fabrication:~Impressions and casts obtained.~Waxing-up included new positions of gingival margins and zenith points.~Silicone index with condensation silicone impression materials made with pressure on the cast to reproduce the details of the wax, then filled after setting with resin material and placed in the patient's mouth.~Resin mock-up trimmed with blade to define the correct new gingival level.~After the patient accept the mock-up design will used as Gingivectomy guide.~Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~Postoperative care"
75655059|NCT04248348|Drug|Low Molecular Weight Heparin|Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
75655060|NCT02830854|Other|Molecular Hydrogen|
75655061|NCT02832024|Device|plaque excision system|
75655062|NCT02832024|Device|stent|
75655063|NCT02832024|Device|Balloon|
75655064|NCT04247022|Other|Health care product (intimate gel)|heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days
75655065|NCT04245774|Drug|Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule|7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine (1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) plus 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
75802244|NCT03143842|Device|Vagus Nerve Stimulation|Delivering electrical pulses to the Vagus Nerve
75802245|NCT04292730|Drug|Remdesivir|Administered as an intravenous infusion
75802246|NCT04292730|Drug|Standard of Care|Standard of Care Treatment for COVID-19 Infection
75802247|NCT02861014|Biological|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
75802248|NCT04382586|Drug|Zanubrutinib|320 mg (4 x 80 mg) capsules administered orally once daily
75802249|NCT04382586|Drug|Supportive Care|Supportive care treatment was selected and administered as deemed appropriate by the study investigator
75802250|NCT04382586|Drug|Placebo|Placebo to match zanubrutinib
75802251|NCT02737306|Drug|PRO 140|Two 1 mL injections, 175mg/ml each, of PRO 140 to opposite sides of the abdomen.
75802252|NCT02728648|Drug|Oxycodone|Pain Management
75819833|NCT01080833|Device|ERCP mechanical simulator practice|Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
75941046|NCT03669341|Other|Deep Inspiration Breath Hold (DIBH)|human-based DIBH method with short-term breath-hold training
75941047|NCT03669341|Other|High Frequency Percussive Ventilation (HFPV)|device-based HFPV technique
75819834|NCT02183428|Drug|BI 1356|
75819835|NCT02183428|Drug|Glyburide|
75819836|NCT02183428|Drug|BI 1356 + Glyburide|
75819837|NCT01080911|Drug|Morphine|spinal morphine 0.05 mg
75941048|NCT04057183|Diagnostic Test|Carotid Stenotic Scan|Noninvasive determination of presence or absence of carotid artery stenosis
76090426|NCT02185209|Drug|Phenoxymethylpenicillin Meda|1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
76090427|NCT02718105|Genetic|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
76090428|NCT01894035|Drug|Iloprost (Ventavis, BAYQ 6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
76090429|NCT05457400|Drug|ENSO 16|30 g ENSO 16 dissolved in Water
76090430|NCT05457400|Drug|Glucose Powder|30 g Glucose Powder dissolved in Water
76090431|NCT01727141|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
75941049|NCT03672851|Drug|anti-CD123 CAR-T treatment|Patients receive fludarabine phosphate(300 mg/m^2) and cyclophosphamide (30 mg/m^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
75941050|NCT04057027|Procedure|Delayed umbilical cord clamping|During the C section, infants' umbilical cord clamping will be delayed for 30-60 seconds.
75655066|NCT04245774|Drug|Bupivacaine/Dextrose|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
76090432|NCT01727141|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
75476451|NCT05969119|Drug|Pyridostigmine|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
75802253|NCT02717728|Procedure|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.~Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.~Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
75802254|NCT02717728|Procedure|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.~Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.~Device: Dressing~Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
75802255|NCT03912454|Other|Autologous Bone Marrow Aspirate Concentrate (BMAC) Injection|Subjects will undergo bone marrow aspiration from the iliac crest. Bone marrow will be concentrated and injected into the symptomatic lumbar disc.
75802256|NCT04480710|Drug|CRV431 75mg|1 x 75mg softgel capsule
75802257|NCT04480710|Drug|Placebo (1 softgel)|1 x placebo softgel capsule
75941051|NCT04057027|Procedure|Cord Milking|Umbilical cord will be milked from th distance of 20cm from mother's side to the baby, for 3-4 times.
75941052|NCT03021551|Device|Rainbow sensor|Masimo Radical-7 and Root System with ORi parameter in all subjects are enrolled in the test group and receive an Rainbow sensor during their elective surgery.
75941053|NCT03662893|Behavioral|behavioural therapy with written checklist form to complete|Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes
75941054|NCT03662893|Drug|Antimuscarinic drugs used in overactive bladder|Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
75941055|NCT03662893|Behavioral|behavioural therapy with written guideline|behavioural therapy with written guideline,which are the same as those in the checklist
75941056|NCT04056637|Other|Choice of follow-up option|Participant will be given the opportunity to choose from 3 follow-up options.
75476452|NCT05969119|Drug|Placebo|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
75655067|NCT04245696|Device|Dermal Handpiece / SubQ Handpiece|Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
75655068|NCT02832102|Procedure|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
75655069|NCT02832180|Drug|OC containing EE and NET|
75802258|NCT04480710|Drug|CRV431 225mg|3 x 75mg softgel capsule
75802259|NCT04480710|Drug|Placebo (3 softgels)|3 x placebo softgel capsule
75802260|NCT03749304|Device|ANI monitor|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index
75802261|NCT02358928|Other|Diet Intervention|
75802262|NCT02351518|Other|No intervention|There will be no interventions in this study
75802263|NCT02324764|Device|Glidesheath Slender|testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
76090433|NCT01727141|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
75476453|NCT05969106|Device|Tandem Control-IQ|AID-system
75476454|NCT05969093|Diagnostic Test|Tinel's Sign performed at different wrist positions|Participants will undergo the Tinel's Sign at different wrist positions while EMG activity and NCV are recorded to investigate the effect of wrist position on median nerve activity.
75476455|NCT05969080|Behavioral|Treatment for Self-Injurious Behaviors|Treatment for Self-Injurious Behaviors (T-SIB) incorporates evidence-based approaches to replace NSSI with behaviors that improve psychosocial functioning.
75476456|NCT05969080|Other|Treatment As Usual|Participants randomized to the TAU condition will be provided with referrals to both Durham VA and local community mental health resources and offered a consult for Durham VA mental health services.
75476457|NCT05969067|Procedure|Tunneling Technique during RA SCP|As described in the intervention arm above
76090434|NCT01727141|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
75344394|NCT04199117|Drug|Combination nicotine patch and nicotine mini-lozenge treatment|Participants randomized to intensive treatment who choose to use this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges for use starting on the target quit date and the following 12 weeks. Participants will be instructed to use 9-20 mini-lozenges per day (one every 1-2 hours) for the first 6 weeks, then reduce to a mini-lozenge every 2-4 hours for 3 weeks, and then a mini-lozenge every 4-8 hours for 3 weeks. Combination nicotine patch and nicotine mini-lozenge treatment will not be used at the same time as varenicline.
75655070|NCT02832180|Drug|BMS-986142|
75655071|NCT02831868|Device|HAVAI|implantation of the HAVAI device to correct the IMA angle
75655072|NCT02831946|Device|MODIFIED VICRYL PLUS|closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture
75344395|NCT04199117|Behavioral|Monetary incentives for initiating treatment|Participants randomized to this intervention will earn an incentive each time they complete a first counseling session in an available treatment, up to 2 rounds of counseling per year, and up to 4 rounds of counseling over 2 years of enrollment.
75344396|NCT04199117|Behavioral|Automated tailored outreach|Participants randomized to this intervention will receive 5 tailored letters delivered every 4-6 months. Letter content will be tailored to participant demographics and use of study treatment, and personalized with references to their primary care teams and tobacco care manager. Letters offer encouragement to quit and information about how to access available treatments.
75344397|NCT04199117|Behavioral|Care management|Participants randomized to this intervention will receive 5 live, proactive phone calls lasting 10-15 minutes from as assigned Tobacco Care Manager who will provide manualized support and motivational encouragement, discuss available treatment options, and inform the participant how to initiate treatment when ready to quit.
75344398|NCT04199117|Other|Wisconsin Tobacco Quit Line referral|This is recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. The Wisconsin Tobacco Quit Line (WTQL) offers a single 20-minute counseling session to all Wisconsin residents ready to set a date to stop smoking in the next month, at no charge, and offers those who meet their medical eligibility criteria a 2-week supply of either nicotine patches, lozenges, or gums, at no charge. The WTQL assumes full clinical responsibility for participants' use of cessation medications dispensed by the WTQL.
75655073|NCT02831946|Device|DERMABOND GLUE|closing the intra-cuticular layer with Dermabond glue
75802264|NCT02324764|Device|standard 6- French radial sheath|
75802265|NCT04268316|Device|Virtual Reality Behavioral Activation|"Participants will choose four activities to complete in virtual reality over the course of the week. These activities are video 360 and range from viewing animals, to viewing nature scenes, to traveling to a different location in the world, to viewing adrenaline-pumping activities."
75802266|NCT04268316|Behavioral|Behavioral Activation in real-life|Participants will choose four pleasurable and/or mastery activities to complete over the course of the week in real life.
75941057|NCT04056637|Device|Multi-level pregnancy test|The Multi-level pregnancy test (MLPT) strategy involves the use of the MLPT to estimate a pregnant person's baseline hCG range prior to beginning their abortion (i.e. prior to mifepristone administration). A follow-up test is then administered one week later to again estimate the woman's hCG range. A decline in hCG range reliably signifies absence of an ongoing pregnancy. Among clients ≤63 days' LMP at initiation of treatment, this strategy has shown to be highly effective: 100% of clients (n=1487/1487) with a decline in hCG range did not have an ongoing pregnancy and 100% of clients (n=21/21) with an ongoing pregnancy showed steady or increase in hCG range on their follow-up MLPT.
75344399|NCT04199117|Other|Primary care provider referral|This is a form of recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. Participants who choose to use this intervention will be referred electronically to their primary care provider for counseling and/or medication if they express an interest in quitting in the next 30 days and agree to this referral.
75476458|NCT05969067|Procedure|Dissection Technique during RA SCP|As described in the intervention arm above
75476459|NCT05969028|Device|igel|First responder ventilation strategy. First responders in King County routinely use the BVM as part of core treatment of SCA. As part of EMS training, we have introduced a training module for use of the igel in simulated resuscitation, which has been enthusiastically accepted by EMS leadership and providers. The i-gel is already successfully practiced by BLS providers in a number of other communities and challenges in training and clinical application will be monitored, but not anticipated.
75655074|NCT00900146|Drug|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
75655075|NCT00900146|Drug|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
75655076|NCT00900146|Drug|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
75655077|NCT04247724|Behavioral|Recreational handball|
75655078|NCT04247724|Behavioral|Control|
75655079|NCT02828748|Other|no intervention in patients treatment, only biopsy taken|
75802267|NCT01971970|Biological|Infliximab|Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
75802268|NCT01971970|Biological|Adalimumab|ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
75802269|NCT01161394|Drug|Pioglitazone 15mg|
75802270|NCT01161394|Drug|pioglitazone 30mg|
75802271|NCT01161394|Drug|placebo|
75802272|NCT05216458|Behavioral|Emails and letter intervention|Emails and letters for households assigned to the treatment group
75941058|NCT03471195|Diagnostic Test|Total Salivary Cytokine profile|Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
75941059|NCT04056559|Device|Adaptable mouthguards|Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).
75344400|NCT04199117|Behavioral|Untailored outreach|Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
75344401|NCT04199117|Behavioral|Multiple smoking cessation coaching calls|Participants randomized to intensive treatment access who choose to quit will receive three 15-20-minute quit coaching calls from a trained smoking cessation health counselor. Calls will be scheduled for one week pre-quit, one day after the target quit day, and one week after the target quit day.
75655080|NCT02831790|Other|Fontan Education Videos|"The intervention will consist of three brief (~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~Anticoagulation~Prolonged pleural drainage"
75941060|NCT01585025|Drug|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
75344402|NCT04185402|Drug|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
75344403|NCT04183023|Genetic|Collection of a salivary sample|"Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and 4,000 of them will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~A subset of 4,000 individuals will be selected to provide a homogeneous geographic coverage and to avoid inclusion of related individuals who will share large genomic regions. Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
75476460|NCT05969028|Procedure|Compression Rate|Compression rates. The EMS system routinely measures EMS CPR performance and specifically the chest compression rate using information derived and electronically recorded from defibrillator patches. As detailed in the Background section, this CPR surveillance activity highlights the variability of compression rates across the guideline-directed range of 100-120 compressions per minute. In addition our CPR surveillance indicates that a metronome can be used to obtain and maintain a specific compression rate within the parameters specified by this trial. This will be the tool used to guide compliance with the assigned chest compression rate by on-scene providers.
75655081|NCT02828670|Biological|blood sample|
75655082|NCT02828670|Procedure|spleen sample|
75655083|NCT03621644|Radiation|Stereotactic MRI-guided On-table Adaptive Radiation Therapy|Radiation therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian or MRIdian Linac). The prescribed dose will be 50 Gray (Gy) in 5 fractions. Stereotactic body radiotherapy (SBRT) fractions will be delivered at least twice per week, and with at least 18 hours between fractions. Each participant will be aligned in the treatment system with MRI image-guidance. On-table adaptive re-planning will be used when clinically indicated. In all patients, real-time MRI imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam as necessary.
75655084|NCT04245462|Other|No intervention|Cross-sectional
75655085|NCT00140972|Drug|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
75655086|NCT00140972|Drug|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
75802273|NCT05216458|Behavioral|Control group|No outreach during the intervention period.
75655087|NCT02828826|Other|telephone coaching|
75802274|NCT04079790|Drug|Gepotidacin|Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.
75655088|NCT02830932|Biological|VXA-RSV-f Tablets (high dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.
75802275|NCT04079790|Drug|Placebo|Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
75802276|NCT03749226|Drug|Aztreonam lysine|nebulization
75655089|NCT02830932|Other|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
75655090|NCT02830932|Biological|VXA-RSV-f Tablets (low dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose
75655091|NCT00895310|Drug|Ketoconazole|Ketoconazole is taken three times a day by mouth.
75655092|NCT00895310|Drug|Hydrocortisone|Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
75819838|NCT01080911|Drug|Morphine|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
75819839|NCT02183506|Drug|Metformin|
75819840|NCT02183506|Drug|BI 1356 BS|
75941061|NCT01068769|Drug|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
75655093|NCT02830386|Device|LVIS stent|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
75655094|NCT02840864|Device|Sonography assisted breast surgery|
75941062|NCT03663127|Dietary Supplement|Beauty Drink|"Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks."
75941063|NCT03663127|Dietary Supplement|Placebo|Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
75941064|NCT00328653|Drug|Cyclosporine NOVA22007 0.05%|
75941065|NCT00328653|Drug|Cyclosporine NOVA22007 0.1%|
75941066|NCT00328653|Drug|Vehicle|
76090435|NCT05738668|Other|Description of clinical characteristic|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
76090436|NCT02716311|Drug|Afatinib|
76090437|NCT02716311|Drug|Cetuximab|
76090438|NCT05439694|Drug|Tranexamic acid|have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
76090439|NCT04558619|Behavioral|Kōmmour Prenatal|Centering Pregnancy, a group prenatal care model, is a promising intervention that challenges the standard model of one-on-one counseling of prenatal care. The model, is currently implemented at the UAMS, but as of yet to be adapted for Pacific Islanders. Centering Pregnancy replaces the individual prenatal care visit with a group model for obstetrically low-risk women. This model provides substantially more health promotion content than the traditional one-on-one prenatal care model. The intervention occurs from week 14 of pregnancy through birth, following the same same schedule as individual care. Group visits are 90-120 minutes each and follow a unique structured curriculum that incorporates standards of care. In the group setting, credentialed prenatal providers conduct a one-on-one assessment with each patient (30 min) and then facilitate group discussions on the topics of pregnancy, using adult learning principles (60-90 min).
76090440|NCT05738590|Procedure|muscle biopsy|true cut needle biopsy
75344404|NCT04174560|Biological|Norovirus GII.4 Challenge Pool|Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.
75476461|NCT05969015|Behavioral|Prochaska and DiClemente transtheorical model|The Prochaska and DiClemente model will be combined to a self-management program in patients with T2DM within 18 months. They will be classified accordingly to their readiness for changing. A care provider will manage the group towards an optimal self-management, aiming to improve their glycemic control and other outcomes of relevance. We will conduct 1 session per week until the end of 12nd intervention month. After, the sections will be conducted each 2 weeks until the end of the trial. Healthcare professional will provide support to the care provider. The recommended processes to progress the patients will be used to trigger them accordingly to their stage, at the discretion of the care provider. We will also consider individualities and non-anticipated problems as a part of the process of behavior changing.
75655095|NCT04245618|Drug|neoadjuvant chemotherapy ( cisplatin - gemcitabine)|Neoadjuvant chemotherapy before TURBT
75655096|NCT00092768|Drug|MK0663, etoricoxib|
75655097|NCT00092768|Drug|Comparator: celecoxib|
75655098|NCT02831712|Dietary Supplement|Ferrous Fumarate|One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
75655099|NCT00895154|Behavioral|General Tutoring|Participants will be tutored for approximately 8-10 hours per month during the school year.
75655100|NCT00895154|Behavioral|Memory Training|Participants will receive memory training for approximately 8-10 hours per month during the school year.
75655101|NCT01769924|Other|Nephrectomy|Nephrectomy for the purposes of living kidney donation
75655102|NCT02843984|Drug|Lactoferrin|
75655103|NCT02840552|Drug|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
75941067|NCT03662581|Behavioral|Mindfulness Group Program|"The mindfulness program has the following aims (Iacono, 2018): to teach mindfulness skills for stress reduction, self-compassion, and dealing with difficult thoughts and emotions, to promote an integrative concept of health, which treats the whole person, to promote community building and positive relationships, and to capitalize on the power of groups to:~Foster peer-to-peer learning and support when it comes to coping with life challenges~Combat isolation~Increase efficiency, quality, and timeliness of care"
75941068|NCT05258253|Other|High intensity aerobics|"London bridges (8mins) Jumping lunges(8mins) Mountain climbers(8mins) Quadruped bent knee hip extension (8mins)"
75344405|NCT04163614|Other|IBPS-Guided Ultrafiltration|Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal/weight reduction based on this slope.
75476462|NCT05968976|Procedure|Awake DBS|55 patients receive awake DBS (current standard procedure)
75941069|NCT05258253|Other|Pelvic clock exercises|Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
75941070|NCT03662113|Drug|Domperidone|5ml Domperidone prior to VCE
75941071|NCT03662113|Dietary Supplement|water|5ml water prior to VCE
75941072|NCT03478137|Behavioral|CPAP intervention|Participants who agree to participate will be evaluated by a sleep specialist who will confirm eligibility for CPAP treatment.Eligible participants will be referred to VitalAire for initiation of treatment following a standard protocol for CPAP use at home. CPAP treatment will continue until the next visit for the main study, between 4-7 months, based on the timing of the evaluations, after which the study will end.
75941073|NCT04924023|Behavioral|kaleidoscope application|The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished.
75941074|NCT03662035|Drug|Apatinib|"Apatinib~Patients with advanced pancreatic cancer after failure of first-line chemotherapy will receive Apatinib (500mg/d, orally) 30 minutes after meal with warm water.Take 21 days as a cycle, patients will receive this treatment until they have got disease progressed. Dose adjustment: with 3/4 level of adverse reactions, the dose should be lowered to 250 mg/d."
75941075|NCT03662035|Drug|S-1|"S-1~Patients will receive S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2, orally) twice a day, once after breakfast and once after dinner, for 14 days, 7 days for suspension and 21 days as one cycle."
75941076|NCT04861311|Behavioral|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention|The intervention is based on the principles of Acceptance and Commitment Therapy (ACT). Therefore, the intervention is an ACT-based smartphone app delivered for 6 weeks in which participants will be applying the mindfulness and acceptance exercises embedded in the app. The mindfulness and acceptance exercises are audio-guided mindfulness meditations and video lessons about ACT.
75344406|NCT04139200|Behavioral|Type 1 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
75476463|NCT05968976|Procedure|Asleep DBS|55 patients receive asleep DBS
75476464|NCT05968950|Device|Thoracic ultrasound|The use of ultrasound to count ribs in order to surface mark the corresponding spinal level
75655104|NCT02828280|Device|NuMask|The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
75655105|NCT02828280|Device|Traditional mask|A traditional air inflated facemark used to ventilate patients
75655106|NCT02840708|Drug|Sargramostim|
75941077|NCT03661957|Procedure|Non grafted maxillary sinus floor elevation with simultaneous implant placement|lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure
75655107|NCT02840786|Device|plaque excision system|
75655108|NCT02840786|Device|balloon and Stent|
75655109|NCT04245072|Procedure|Intravitreal injection|Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.
75655110|NCT04245072|Diagnostic Test|Fluorescent angiography|Ophthalmic examination
75802277|NCT03749226|Device|Aerogen Solo|Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.
75941078|NCT03661957|Procedure|using short dental implants for posterior atrophic maxilla|placement of short dental implant with bone height below 8mm
75941079|NCT03661879|Drug|NNC9204-1706|Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
75941080|NCT03661879|Drug|Placebo (NNC9204-1706)|Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
75941081|NCT03478059|Behavioral|Cognitive and Motor Dual-task Intervention|The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
75655111|NCT04245072|Diagnostic Test|Visometry|Ophthalmic examination
75655112|NCT04245072|Diagnostic Test|Refractometry|Ophthalmic examination
75655113|NCT04245072|Diagnostic Test|Slit lamp examination|Ophthalmic examination
75655114|NCT04245072|Diagnostic Test|Ophthalmoscopy|Ophthalmic examination
75655115|NCT04245072|Diagnostic Test|OKT|Ophthalmic examination
75655116|NCT04208360|Device|StethoMe stethoscope|Assessing whether use of the StethoMe AI lung sounds analysis software provides clinical benefit by improving the identification of abnormal lung sounds.
75655117|NCT00817076|Drug|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
75941082|NCT05158881|Device|Near-infrared spectroscopy|Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion. Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.
75941083|NCT05158803|Radiation|ultrasound and C.T|lung ultrasound in comparison to C.T
75941084|NCT04802577|Diagnostic Test|FACT-F questionnaire|The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.
75941085|NCT04802577|Diagnostic Test|Beck Depression Inventory|The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.
75941086|NCT04802577|Diagnostic Test|Beck Anxiety Inventory|The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.
76090441|NCT03029182|Other|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
76090442|NCT03029182|Behavioral|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
76090443|NCT05738512|Procedure|Medial Flap Coblation Turbinoplasty|Reduction of the inferior turbinate to manage inferior turbinate hypertrophy
76090444|NCT05738512|Procedure|Submucous Resection|Submucous Resection
76090445|NCT05430178|Other|Oral sugar tolerance test|Measurement of glucose and insulin for calculation of insulin sensitivity
76090446|NCT05430178|Other|De novo lipogenesis test|Oral consumption of deuterated water to measure incorporation of label into lipids
76090447|NCT05430178|Other|Gluconeogenesis test|Oral consumption of 13C-labeled glycerol to measure incorporation into glucose
76090448|NCT04350034|Other|Xbox training|"patients in this group received routine physical therapy protocol plus Xbox training.~Before the intervention started, the Xbox group was given a 45 min introductory session on how to use the xbox adventure games and its tools. All sessions were led by a single experienced physiotherapist (different to the physiotherapist who performed the assessments tests) in order to provide instruction on how to perform each exercise."
76090449|NCT04350034|Other|Control group|routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
76090450|NCT02290444|Drug|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
76090451|NCT01726517|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
75476465|NCT05968885|Procedure|Intradetrusor Botox® (onabotulinumtoxinA) injection|The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
75655118|NCT02844062|Biological|anti-EGFRvIII CAR T cells|CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
75655119|NCT02844062|Drug|cyclophosphamide|250 mg/m^2 d1-3
75655120|NCT02844062|Drug|Fludarabine|25mg/m^2 d1-3
75802278|NCT03749226|Device|CombiHaler|The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
75655121|NCT02828046|Biological|M281|
75655122|NCT02828046|Other|Placebo|
75655123|NCT02830230|Drug|Tab cefixime,Tab Azithromycin|The women with clinical cervicitis will receive treatment for cervicitis.
75655124|NCT02840396|Device|rTMS|repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.
75655125|NCT02840396|Device|Sham rTMS|Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
75820002|NCT02185144|Behavioral|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
75941087|NCT04802577|Diagnostic Test|Insomnia severity index.|The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.
75941088|NCT04802577|Other|ESSPRI|The questionnaire, based on patient report outcome data in which the severity of Sjögren's syndrome is investigated in participants.
75941089|NCT04802577|Other|ESSDAI|Activity scale in which the activity of Sjögren's syndrome is evaluated based on the laboratory and imaging tests of the patients and the examination findings of the evaluator.
75941090|NCT04802577|Other|Pain Detect Questionnaire|The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.
76090452|NCT01726517|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
76090453|NCT05738356|Combination Product|Adhesive bonding systems|Three different adhesive bonding systems were used; one system per group
75476466|NCT05968885|Drug|Combine Mirabegron and Solifenacin.|Combination pharmacotherapy
75941091|NCT05798702|Procedure|roux -en-y- gastric bypass|Roux-&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
75941092|NCT05798702|Dietary Supplement|intensive life style modification|Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
75941093|NCT05798689|Combination Product|Probiotic administration and gluten|Probiotic preparation including multi-species strains of Lactobacillus and Bacillus. The probiotic was administered at baseline and interrupted after 32 days. At the same time the other arm received placebo. Gluten was provided after 10 days of gluten free diet in increasing amounts
75941094|NCT05798689|Combination Product|Placebo administration and gluten|The placebo was administered at baseline and interrupted after 32 days. At the same time the other arm received probiotic. Gluten was provided after 10 days of gluten free diet in increasing amounts
75941095|NCT05798676|Other|overweight/obesity|the consequences of maternal pregestational overweight/obesity on infant´s growth and adiposity will be studied
75941096|NCT05798598|Other|Scientific writing training course|Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
75941097|NCT05798546|Biological|Neo-T|Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
76090454|NCT01752023|Drug|Cisplatin + Gemcitabine with SUBATM-itraconazole|Experimental Arm
76090455|NCT01752023|Drug|Cisplatin + Gemcitabine|Active Comparator
75476467|NCT05968846|Drug|Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)|124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.
75941098|NCT05798546|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.
75655126|NCT00888654|Drug|B-Dim|B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
75655127|NCT00888654|Procedure|Radical Prosatectomy|
75655128|NCT03238430|Drug|intrathecal morphine|A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.
75655129|NCT03238430|Drug|Morphine PCA|a postoperative Morphine PCA
75802279|NCT03745482|Other|Lumbar Mobilisations|The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The side of the mobilisation will be determined by dominant leg - considered the kicking foot. The mobilisations will be administered by a physiotherapist with at least 10 years clinical experience. Teksan grip sensors will be worn by the physiotherapist to calculate the force applied to the participant. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
75802280|NCT04259346|Drug|Ixekizumab|Administered SC.
75941099|NCT05798546|Drug|Fludarabine|Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.
75941100|NCT05798546|Drug|Interleukin-2|500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
75941101|NCT05798494|Behavioral|Weight loss intervention|Subjects will receive dietary counseling by a dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother (and father if overweight, BMI ≥25 kg/m^2) will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and power walk 2-4 times a week for a half an hour and attend physical activity sessions every 2nd week to attain a minimum weight loss of approximately 0,5-1,0 kg/week. The weight loss will last until a 10% weight loss (according to pre-pregnancy weight) has been achieved or until 1-year post-partum. If the subject has not achieved a weight loss of 10%, she or he will receive Very low-calorie diet (VLCD) until target weight loss is reached, though no longer than 8 weeks. After weight loss subjects will receive counseling to maintain weight loss and healthy weight gain during pregnancy until birth of the 2nd child.
75941102|NCT05798455|Drug|Sodium Pentaborate|Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
76090456|NCT02986906|Drug|5% dextrose|Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
76090457|NCT02986906|Drug|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
76090458|NCT02986906|Device|Ultrasound|The ultrasound was used for injection guidance
76090459|NCT01726049|Drug|Sildenafil|Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
76090460|NCT01726049|Drug|Placebo|Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
76090461|NCT02162667|Drug|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
75655130|NCT03238430|Drug|Ropivacaine infiltration|Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector after bolus of 20 ml
75655131|NCT04246866|Biological|GEM103|GEM103
75655132|NCT02843906|Procedure|Lombar Punction|cerebrospinal fluid testing at screening and M36
75655133|NCT02843906|Radiation|Magnetic Resonance Imaging (MRI)|MRI done at screening and M36
75655134|NCT02843906|Radiation|Positron-Emission Tomography (TEP) /(FDG)|TEP/FDG done at screening and M36
75655135|NCT02843906|Other|Psychiatric tests|
75655136|NCT02843906|Other|Neuropsychological Tests|done at screening, M12, M24 and M36
76090462|NCT01605617|Drug|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
76090463|NCT01605617|Drug|Placebo|PTNS + placebo for 12 weeks
76090464|NCT01605617|Procedure|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
75344407|NCT04139200|Behavioral|Type 2 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
75476468|NCT05968755|Device|A chatbot designed to promote PrEP awareness and uptake for Black MSM|Participants in the intervention group will have access to a theory-informed (Self-Determination Theory) chatbot and receive an automated personalized question message (root-node message) from the chatbot. The root-node messages are questions written into the chatbot algorithms to initiate interactive communication with participants. In each round of the interactive communication, the chatbot will provide automated personalized PrEP-related information, autonomous motivation, and psychological needs based on Self-Determination Theory constructs.
75476469|NCT05968755|Other|General educational messages|Participants in the control group will received general education messages from a research assistant including healthy diet, exercise, and COVID-19 prevention. The frequency of contact will be pre-specified by participants in interviews prior to the RCT.
75476470|NCT05968729|Other|Active Comparator: 0.25 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s.
75476471|NCT05968729|Other|Active Comparator: 0.50 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s.
75476472|NCT05968716|Other|Social needs screening protocol|Pediatric hospital ward stakeholders will develop and implement a social needs screening protocol designed to screen families of hospitalized children for social risk factors and then provide resources to address their social needs. The intervention will consist of the protocol that is developed and implemented.
75476473|NCT05968664|Device|Spinal Cord Stimulator|Spinal Cord Stimulator modified to deliver Time Variant Pulse (TVP) stimulation.
75655137|NCT02843906|Genetic|Apolipoprotein (ApoE) detection|ApoE detection done at screening
75655138|NCT02829840|Drug|Ponatinib|"Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle."
75802281|NCT03748914|Other|Intervention Group|After delivery of the neonate via caesarean section the umbilical cord will be clamped within 30 seconds and cut long at least 30 cm by the obstetrician. The neonate is then placed under an overhead heater by the midwife. There, the umbilical cord must be untwisted and held in a vertical position. It is milked once by the neonatologist towards the baby at a speed of approximately 10 cm/s and then clamped 3 cm from the umbilicus by one member of the clinical team.
75802282|NCT03748914|Other|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
75802283|NCT03748836|Drug|ALPN-101|Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
75802284|NCT03748836|Drug|Placebo|Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
75941103|NCT05798442|Other|smartphone health application (Opulse)|The Opulse app will be designed as a multifunction app that targets the modification of the behavioral and metabolic risk factors and provides comprehensive interventions for healthy diet, physical activity and smoking cessation among smokers.
75941104|NCT05798429|Other|compassion education|6 weeks of compassion training
75941105|NCT05798312|Other|Customizable support material|Customizable support material will enable patients to identify their personal breast cancer information.
75941106|NCT05798312|Other|Non-customizable support material|Non-customizable support material will include general breast cancer information.
75941107|NCT05798299|Behavioral|Arm 1: Transdiagnostic intervention|The UP-C/C consists of 15 weekly sessions for children, each lasting 90 minutes. It is also composed by three sessions for parents and a meeting with the family prior to the exposure sessions. Parents have access to weekly psychoeducational material (in written and in video format) and help the children with homework completion.
75941108|NCT05798299|Behavioral|Arm 2: Anxiety-focused intervention|The Coping Cat in group format is a cognitive-behavioral evidence-based intervention for anxiety problems. It is composed by 16 90-minute sessions for children and two parenting sessions.
76090465|NCT05651854|Other|pranayama breathing|Bhramari and sheetali pranayama breathing
76090466|NCT05403190|Device|da Vinci SP system|using da Vinci SP system to perform extraperitoneal approach radical prostatectomy
76090467|NCT05402020|Drug|Tiotropium (Tio)|Tiotropium (Tio)
76090468|NCT05402020|Drug|Inhaled corticosteroids (ICS)|Inhaled corticosteroids (ICS)
76090469|NCT05402020|Drug|Olodaterol (Olo)|Olodaterol (Olo)
76090470|NCT05402020|Drug|Long-acting β2-agonists (LABA)|Long-acting β2-agonists (LABA)
76090471|NCT05402020|Device|Combined Inhaler|Combined Inhaler
76090472|NCT02284828|Drug|BIA 2-093|
75941109|NCT05798260|Diagnostic Test|Agilent Seahorse XF Cell Mito Stress Test|The Agilent Seahorse XF Cell Mito Stress Test measures key parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells on the Seahorse XFe and XF Extracellular Flux Analyzers. It is a plate-based live cell assay that allows to monitor spare respiratory capacity (SRC), basal respiration, ATP production-coupled respiration, maximal respiration, and non-mitochondrial respiration in real time before and after ketone monoester
75941110|NCT05798234|Device|high flow oxygen device|no intervention
75941111|NCT05798208|Diagnostic Test|blood pressure measurement|Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
75941112|NCT05798195|Other|conventional western medicine treatment|conventional western medicine treatment only
75941113|NCT05798195|Drug|Dexamethasone oral tablet|treat with Dexamethasone for 2 weeks
75941114|NCT05798195|Other|Traditional Chinese medicine decoction|treat with strengthening spleen and tonifying lung decoction for 2 weeks
75655139|NCT02829840|Drug|5-azacytidine|"Part 2 Phase I Dose Escalation: 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
75655140|NCT02829840|Behavioral|Phone Calls|"About 30 days after end-of-study visit, study staff calls participant and asks if they have had any side effects and/or started any new treatment(s).~If disease appears to be responding to study drugs, study staff calls participant every 3-6 months for up to 5 years and asks how they are doing and about any side effects they may be having."
75655141|NCT02844296|Behavioral|Video about exercise|Video about short-bout exercise will be played for the participants.
75802285|NCT04230876|Behavioral|Auditory Brian Training Games/Activities|Game-based activities that encourage listening to words and sentences in noisy situations. Participants will receive subscriptions to the clEAR online auditory training activities and recommended protocol for those who recently received new hearing aids.
75941115|NCT05798182|Diagnostic Test|Ultrasound measurement|Study was conducted with Mindray T7 ultrasound machine using linear probe. Vascular ultrasound mode was used with settings depth of 50 mm and gain of 40 dB during the entire study period. The diameter and flow velocity of the brachial artery and wrist edema of the fist were measured within 24 hours of admission and the following day.
75941116|NCT05798169|Other|Resistance training|Moderate resistance training by a innovative training robot 2 times a day during hospitalisation
75820003|NCT02185144|Behavioral|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
75344408|NCT04118283|Behavioral|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
75820004|NCT02190448|Dietary Supplement|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
75941117|NCT05798143|Device|Accelerated Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
75941118|NCT05798065|Procedure|Inpatient gastrointestinal endoscopy|all inpatient endoscopy procedures (gastroscopy, colonoscopy, ERCP, sigmoidoscopy) during 2016-2022.
75941119|NCT05798052|Behavioral|Psychological stressors added to simulated clinical scenarios.|In both low and high stress scenario versions, the underlying mechanism of disease or injury will be identical, as will be the expected clinical management of the situation. Known stressors9,10 will be added to the scenarios, ensuring ecological validity (stressors that occur in real life). The stressors will include a) socio-evaluative stressors (presence of other with ability to negatively judge); b) increases in the severity of the situation (unstable patient); c) increases in the stakes (e.g. woman in early stages of pregnancy), d) noise, as well as e) unexpected brief complications (e.g. brief equipment challenge).
76090473|NCT01751867|Drug|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
76090474|NCT01751867|Drug|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
76090475|NCT05637658|Other|Exercise|aerobic exercise
76090476|NCT02418195|Drug|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
76090477|NCT05633914|Drug|Tucidinostat|20mg, po., biw, q3w
75476474|NCT05968664|Device|Spinal Cord Stimulator|Spinal Cord Stimulator to deliver standard of care Time Invariant Pulse (TIP) stimulation.
75476475|NCT05968651|Drug|Oxytocin nasal spray|Single acute administration of 24 international units (IU) oxytocin
75476476|NCT05968573|Other|Video Format|A video created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
75476477|NCT05968573|Other|Health Educator|The video created by the research will be compared to a healthcare provider in terms of effectiveness in getting patients screened for HIV/HCV.
75655142|NCT02844296|Behavioral|App about exercise|A smartphone App about exercise will be installed in participants' mobile phone.
75941120|NCT05798026|Drug|EU103|EU103 will be administered via intravenous infusion.
76090478|NCT05633914|Drug|nab-paclitaxel|125mg/m2, d1, iv.drip, q7d
76090479|NCT04756947|Procedure|surgical treatment according to standard indication criteria|internal fixation according to standard indication criteria
75941121|NCT05797961|Behavioral|HIV self-testing with online supervision|A pilot study to assess the feasibility of HIV self-testing with online supervision
75941122|NCT05797961|Other|Control|venue-based HIV testing
75941123|NCT05797948|Drug|Obinutuzumab|Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；
75941124|NCT05797948|Drug|Zanubrutinib|Zanubrutinib 160mg (2 capsules) oral bid；
75941125|NCT05797948|Drug|Lenalidomide|Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.
75941126|NCT05797948|Drug|CD19/CD22 CAR-T|Targets of CAR-T cells are tandem CD19/CD22. 1 * 10 ^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
75941127|NCT05797948|Drug|Azacitidine For Injection|Azacitidine For Injection 100mg i.h. d1-d5;
75941128|NCT05797948|Drug|Fludarabine|Fludarabine 300mg/m2 ivgtt d3-d5;
75941129|NCT05797948|Drug|Cyclophosphamide|Cyclophosphamide 300mg/m2 ivgtt d3-d5.
75941130|NCT05797922|Drug|DWP16001|DWP16001 0.3mg
75941131|NCT05797883|Drug|FOLFOX/FOLFIRI|mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
75941132|NCT05797844|Other|Active implementational educational strategy|4 follow-up visits (active implemantation strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days. These follow-ups included adherence to evidence-based guidelines, nurses' application of endotracheal cuff pressure measurement and solving the problems encountered during its implementation. Uncertainties associated with evidence-based guidance on endotracheal tube cuff pressure control were clarified during these sessions.
75941133|NCT05797844|Other|Passive implementational educational strategy|Theoretical training on endotracheal tube cuff pressure management through a 4-hour presentation prepared with evidence-based guide and literature. A PowerPoint presentation including endotracheal tube cuff pressure normal values, complications related to endotracheal tube cuff pressure, management of endotracheal tube cuff pressure, endotracheal tube cuff pressure control methods, methods affecting endotracheal tube cuff pressure, how to measure endotracheal tube cuff pressure was made.
75941134|NCT05797818|Device|Methylene Blue Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene Blue (0.01%) + 4 minutes of light treatment"
75941135|NCT05797818|Device|Chlorhexidine Gluconate Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
75941136|NCT05797818|Device|Methylene Blue + Chlorhexidine Gluconate|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene blue (0.01%) + chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
75941137|NCT05797818|Device|Light Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- 4 minutes of light treatment only"
75344409|NCT04118283|Behavioral|Health and Wellness|Health & Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health & Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
75941138|NCT05797792|Drug|Intraarterial alteplase|See arm/group descriptions.
75655143|NCT02844296|Behavioral|Leaflet about exercise|A leaflet about exercise will be provided for the participants.
75941139|NCT05797779|Procedure|Skin biopsy|Punch biopsy of the skin
75941140|NCT05797753|Drug|SAR443820|Tablet by oral administration
75344410|NCT04118114|Drug|PRL3-zumab|IV administration every 2 weeks
75344411|NCT04112641|Drug|Nicotinamide riboside|Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
75655144|NCT02844296|Behavioral|Video about diet|Video about healthy diet will be played for the participants.
75655145|NCT02844296|Behavioral|App about diet|A smartphone App about healthy diet will be installed in participants' mobile phone.
75655146|NCT02844296|Behavioral|Leaflet about diet|A leaflet about healthy diet will be provided for the participants.
75655147|NCT00633516|Device|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
75655148|NCT04246632|Device|CapsoCam Colon Capsule Endoscopy|CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.
75655149|NCT02827890|Drug|Januvia Tab. 100mg|Januvia Tab. 100mg*1T/day for 5days, QD, PO
75655150|NCT02827890|Drug|Januvia Tab. 100mg + Duvie Tab. 0.5mg|Januvia Tab.100mg + Duvie Tab. 0.5mg*1T/day for 5 dyas, QD, PO
75655151|NCT04250792|Drug|Naltrexone Pill|role of low dose naltrexone in patients affected with psoriasis
75820005|NCT02190448|Dietary Supplement|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
75820006|NCT01083953|Drug|Sevoflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
75820007|NCT01083953|Drug|Desflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
75820008|NCT02190526|Drug|Mesalazine(asacol 800 mg)|
75820009|NCT02190526|Drug|Amitriptyline|
75820010|NCT02190526|Drug|placebo like asacol|
75820011|NCT02190526|Drug|placebo like amitriptyline|
75820012|NCT01084031|Drug|propofol|intravenous propofol with sevoflurane inhalation induction
75820013|NCT02186080|Drug|Gemigliptin|
75820014|NCT02186080|Drug|Placebo|
75941141|NCT05797753|Drug|SAR443820|Capsule by oral administration
75941142|NCT05797753|Drug|Erythromycin ethyl succinate|Tablet by oral administration
75941143|NCT05797753|Drug|Itraconazole|Capsule by oral administration
75941144|NCT05797714|Drug|Tenofovir Amibufenamide（TMF）|TMF, 25mg QD, from baseline to 48 weeks
75941145|NCT05797701|Drug|SAR443820|Tablet by oral administration
75941146|NCT05797701|Drug|SAR443820|Capsule by oral administration
75941147|NCT05797688|Device|The Celution System|The Celution System will isolate regenerative cells, including stem cells, from fat harvested from the treatment patients.
76090480|NCT04756947|Procedure|conservative treatment according to standard indication criteria|conservative therapy according to standard indication criteria
76090481|NCT05383612|Procedure|Warm compresses|Commercial eye patch, 10 min before lid massage.Warm compresses and lid massage every 2 weeks，5 times in total（0，2, 4, 6, 8W）.
75344412|NCT04112641|Drug|Placebo capsules|Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
75655152|NCT04244994|Device|Aptima-Combo2 and Aptima Mgen|Self-taken penile meatal swabs versus first-catch urine samples for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
75802286|NCT05668806|Device|Cerviron|Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21 (devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body). Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
76090482|NCT05383612|Drug|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops (DIQUAS ophthalmic solution 3%; Santen Pharmaceutical Co. Ltd, Osaka, Japan)，3% diquafosol was administered six times a day for 12 weeks.
76090483|NCT05382364|Drug|Tucatinib|Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.
75344413|NCT04099160|Other|Evaluation|The Turkish version of the Revised Neurophysiology of Pain Questionnaire will be applied to patients with chronic spinal pain at the beginning of the study and a week later. The Visual Analogue Scale and the Short Form-36 (SF-36) questionnaire will be applied to patients only at the beginning of the stuy.
75344414|NCT04090411|Drug|Induction- PF-06480605 50 mg SC Q4W|PF-06480605
75344415|NCT04090411|Drug|Induction- PF-06480605 150 mg SC Q4W|PF-06480605
76090484|NCT02712801|Drug|Zidovudine|Dose will be adjusted according to the child's weight.
75344416|NCT04090411|Drug|Induction- PF-06480605 450 mg SC Q4W|PF-06480605
75344417|NCT04090411|Other|Induction- Placebo SC Q4W|0 mg Placebo
75344418|NCT04090411|Drug|Chronic- PF-06480605 50 mg SC Q4W|PF-06480605
75344419|NCT04090411|Drug|Chronic- PF-06480605 150 mg SC Q4W|PF-06480605
75344420|NCT04090411|Drug|Chronic- PF-06480605 450 mg SC Q4W|PF-06480605
75655153|NCT02840318|Other|Compassion Intervention|See arm description
75655154|NCT02827968|Drug|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
75941148|NCT05797584|Drug|Dobutamine|Dobutamine 5.0 - 10.0 mcg/Kg/min ev
75941149|NCT05797584|Other|Passive leg raising|Passive leg raising for acute volume load
75941150|NCT05797532|Other|breastfeeding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
75941151|NCT05797532|Other|skin to skin contact|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
75941152|NCT05797532|Other|swaddling and holding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
75941153|NCT05797493|Drug|Atezolizumab|Upfront chemo-immunotherapy
75344421|NCT04074967|Drug|Phase Ib ARRY-614 + nivolumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
75655155|NCT02840162|Drug|Celecoxib|Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
75655156|NCT02840162|Drug|Placebo|
75344422|NCT04074967|Drug|Phase Ib ARRY-614 + nivolumab+ipilimumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
75344423|NCT04074967|Drug|Phase II ARRY-614 + nivolumab|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule."
75941154|NCT05797428|Other|logotherapy|The logotherapy is carried out in an individual way in this study. The full-time assistant will give the experimental group 3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy to guide the participant to find the meaning of his life and value.The location is mainly in the hospital when the participant has to return for consultation, or at the participant's home.
76090485|NCT02712801|Drug|Nevirapine|Dose will be adjusted according to the child's weight.
76090486|NCT02712801|Drug|Lamivudine|Dose will be adjusted according to the child's weight.
75941155|NCT05797415|Procedure|Sentinel Lymph Node Biopsy|"Injection of 99mTc-labeled nanocolloids~Preoperative lymphoscintigraphy~Intraoperative gamma probe search of the sentinel lymph node~Sentinel lymph node biopsy~Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy."
75941156|NCT05797363|Other|Continuous midwife support|The individuals included in the experimental group will be provided with consultancy services on many issues from the pre-pregnancy period to the postpartum period.
75802287|NCT04228302|Drug|EC5026 oral capsule|"5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort).~Oral doses of EC5026 tested in each cohort: 0.5 mg (Cohort 1), 2 mg (Cohort 2), 8 mg (Cohort 3), 16 mg (Cohort 4), and 24 mg (Cohort 5).~A blinded sentinel group of 2 subjects (1 active and 1 placebo) will be dosed at least 2 days before the remaining 6 subjects (5 active and 1 placebo) will receive blinded doses of active study drug or placebo."
75941157|NCT05797350|Device|Glaucoma Drainage Device|Both the Paul glaucoma implant (PGI) and Ahmed glaucoma valve (AGV) are types of glaucoma drainage devices (GDDs) used to lower intraocular pressure in patients with refractory glaucoma. Devices will be implanted during a surgical procedure and work by diverting excess fluid from the eye to an external drainage tube, allowing the fluid to drain away from the eye and be absorbed into the surrounding tissue. This will help to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.
75655157|NCT02827812|Other|Comprehensive evaluation|At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
75655158|NCT02827812|Other|Physical Intervention at home|A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
75802288|NCT04228302|Other|Placebo oral capsule|5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort)
75802289|NCT03746886|Other|Breast-milk|A single breast-milk sample will be collected from 20 women. Milk samples will be pooled for analysis.
75802290|NCT01562340|Other|Pomegranate juice|Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
75941158|NCT05797220|Drug|Botulinum Toxin Type A Injection [Botox]|
75941159|NCT05797220|Drug|Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel|
75941160|NCT05797207|Diagnostic Test|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
75941161|NCT05797207|Procedure|Colonoscopy|Colonoscopy procedure
75941162|NCT05797181|Other|medical nutrition therapy in kidney diseases|Planning and implementation of diets containing high protein, low potassium, low phosphorus, personalized adjusted carbohydrates
75941163|NCT05797142|Other|Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
75941164|NCT05797129|Device|CEDM|Women underwent CEDM screening
75941165|NCT05797077|Procedure|Colorectal resection surgery.|Colorectal cancer radical resection combined with liver metastasis resection or ablation.
75941166|NCT05797077|Drug|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
75941167|NCT05797077|Drug|Capecitabine|Maintenance therapy is recommended to be continued with low-toxicity drugs such as 5-FU/LV or capecitabine, and may be combined with targeted therapy. Treatment should be discontinued once ctDNA testing is negative.
75941168|NCT05797064|Procedure|Natural Orifice Specimen Extraction Surgery|Natural Orifice Specimen Extraction Surgery (NOSES) is a minimally invasive surgical technique that aims to reduce the size and number of incisions required during certain surgeries. In NOSES, the surgical specimen (such as a diseased organ or tumor) is removed from the body through a natural orifice (such as the mouth, anus, or vagina), rather than through an incision in the abdominal wall. In this trial, we will extract surgical specimens from the rectum to reduce trauma to the abdominal wall.
75655159|NCT02827812|Other|Home-Based telemedicine program|"A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences."
75802291|NCT01562340|Other|Pomegranate fruit extract|Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
76090487|NCT02712801|Drug|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
75802292|NCT01562418|Behavioral|Ergonomic intervention|Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
75802293|NCT01562418|Behavioral|Standard ergonomic intervention|Standard ergonomic intervention , how to sit and work with computers
75802294|NCT01562418|Behavioral|control group|general instructions no intervention
75802295|NCT01348100|Drug|Iloperidone crystalline formulation|Iloperidone was formulated as 100 µm crystals for IM depot injection.
75802296|NCT01348100|Drug|Iloperidone microparticle formulation|Iloperidone was formulated as microparticles for IM depot injection.
75820015|NCT01084109|Other|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
75941169|NCT05797038|Drug|Tacrolimus for the treatment of IMN|Remission after tacrolimus treatment of IMN
76090488|NCT05381896|Other|Conventional Scoliosis Exercise Program|Program will include breathing exercises, spinal stabilization and strengthening exercises, posture exercises and stretching execises.
75344424|NCT04074967|Drug|Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
75476478|NCT05968560|Behavioral|CBT Skills Group for CHR Youth|"CBT skills group is designed to boost peer support, reduce isolation, normalize psychotic-like experiences to lessen distress, reduce cognitive biases, facilitate positive beliefs, and enhance reasoning and decision-making. CBT skills group uses CBT to Prevent Paranoia manual to teach individuals to make adaptive appraisals of their experiences (e.g. voices and other cognitive intrusions) to prevent the perception of such events as threatening."
75941170|NCT05796986|Procedure|Endovascular procedure of treatment of wide neck saccular cerebral aneurysm|Endovascular different modalities for occlusion of wide neck saccular cerebral aneurysms include stent assisted coiling or balloon assisted coiling or flow diverter or 3D coiling
75941171|NCT05796960|Procedure|Thyroidectomy with or without lymphadenectomy or multivisceral resection|Lymph node dissection, as well as its surgical extension, was performed according to the surgeon's discretion. Multivisceral operations involved oesophagus, trachea and larynx.
75941172|NCT05796934|Behavioral|Moments that Matter (MTM) Program|"MTM aims to empower caregivers, enhance nurturing care practices, and ultimately improve early child development (ECD). MTM will be targeted to primary caregivers of children aged 0-3 years and implemented over an 18 month period. The primary program delivery agent will be local volunteers (ECD promoters) who will facilitate monthly peer group sessions and conduct monthly home visits to participants residing in their village. The MTM curriculum covers topics relating to responsive caregiving, early learning, and child security & safety, and gender equality. Faith leaders will also be trained to promote nurturing care and ECD within their sermons and Bible study groups. ECD committees will be also formed among leaders across various sectors (e.g., health, education, faith institutions) to promote nurturing care and ECD at the community level and coordinate MTM activities with program staff, delivery agents, and other existing service providers (e.g., community health volunteers)."
76090489|NCT05381896|Other|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
75476479|NCT05968560|Behavioral|Individual CBT sessions|CBT skills learned in group are personalized in individual sessions focused on: a) facilitating learning of CBT skills; b) tailoring CBT skills to personal goals; c) facilitating successful interaction with peers in the group; and d) providing academic and vocational support. Youth may opt to invite family members to join individual sessions as needed.
75802297|NCT01348100|Drug|Oral iloperidone|Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.
75941173|NCT05796908|Device|Aptis PRUJ Prosthesis|A prosthetic implant for replacement of the proximal radial ulna joint.
75941174|NCT05796895|Behavioral|Videogame|Children will be provided with the videogame for eight weeks, through which they will be taught symptom management strategies. Children and their parents will be telephoned every week by a nurse to inquire whether children performed the strategies taught to them and if they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
75941175|NCT05796895|Behavioral|WhatsApp|Children will be provided with weekly WhatsApp messages on healthy behaviors. Children and their parents will be telephoned every week by a nurse to inquire whether they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
76090490|NCT02712723|Drug|Letrozole|Nonsteroidal aromatase inhibitor
76090491|NCT02712723|Drug|Ribociclib|Oral cyclin-dependent kinase (CDK) inhibitor
76090492|NCT02712723|Drug|Placebo|Placebo for ribociclib
76090493|NCT02152683|Device|Renova|Low- Intensity Shockwave
76090494|NCT02149719|Other|Desensitisation using boiled peanut|
76090495|NCT02149719|Other|Desensitisation using boiled peanut (deferred start)|
76090496|NCT05736250|Diagnostic Test|biopsie|gingival biopsie
76090497|NCT01751165|Biological|Herpes zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
76090498|NCT02145351|Device|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
76090499|NCT02145351|Device|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
75344425|NCT04074967|Drug|Phase II ARRY-614 + nivolumab+ipilimumab (RCC)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
75802298|NCT03676634|Biological|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
75802299|NCT03675776|Drug|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
75802300|NCT03675776|Drug|Placebo|Placebo (prefilled syringe, weekly IV administration).
76090500|NCT01751087|Other|Mifepristone|oral mifepristone 200 mg on Day 1.
76090501|NCT01751087|Drug|misoprostol|buccal misoprostol 400 mcg on Day 2
76090502|NCT01751087|Device|Osmotic dilators|osmotic dilators on Day 1
76090503|NCT01751087|Other|placebo|placebo for mifepristone, on day 1
75344426|NCT04060927|Device|SGRT|Surface Guided Radiation Therapy
75802301|NCT03673670|Drug|RPL554 Suspension|A PDE3/4 inhibitor
75802302|NCT03673670|Drug|Placebo|A placebo solution
75802303|NCT03673670|Drug|Tiotropium/olodaterol (Respimat)|An anticholinergic/β-agonist combination medication
75802304|NCT04369742|Drug|Hydroxychloroquine (HCQ)|HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)
75344427|NCT04051151|Behavioral|Gameficiation|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
75655160|NCT05335538|Diagnostic Test|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
75802305|NCT04369742|Drug|Placebo: Calcium citrate|Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5
75802306|NCT04369430|Drug|AKST4290|Oral AKST4290
75802307|NCT04369430|Drug|Placebo|Oral Placebo
75655161|NCT04244526|Other|Talking a urine sample|Just taking a urine sample
75655162|NCT02827656|Drug|Decapeptyl|luteal support as described and vaginal progesterone 200 mg 3 times a day
75802308|NCT04363736|Drug|Tociliuzumab|Participants will receive IV TCZ.
76090504|NCT01751087|Other|placebo|placebo for misoprostol, on day 2
76090505|NCT04566419|Device|HFNC - Airvo 2|high flow nasal cannulae delivering 60 l/min
76090506|NCT04566419|Other|Oxygen|oxygen delivered by Venturi mask
75344428|NCT04027699|Procedure|Mini-bolus|"First injection of 2ml/kg (saline solution)~Second injection of 18ml/kg (saline solution)"
75655163|NCT02827656|Drug|hCG luteal support|luteal support as described and vaginal progesterone 200 mg 3 times a day
75802309|NCT04362176|Biological|pathogen reduced SARS-CoV-2 convalescent plasma|Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.
75941176|NCT05796830|Other|Puzzle application|Five expert opinions will be taken for the puzzle application to be applied after the surgery, and the application and difficulty level of the puzzle will be decided.
75941177|NCT05795985|Diagnostic Test|calprotectin levels|dosage of calprotectin levels in patients with abdominal pain
75941178|NCT05795972|Dietary Supplement|inulin|patients treated with standard therapy with a supplementation of Inulin 6g twice a day for 3 months.
75344429|NCT04009499|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
75344430|NCT04008030|Biological|Ipilimumab|Specified dose on specified days
75344431|NCT04008030|Drug|Oxaliplatin|Specified dose on specified days
75344432|NCT04008030|Drug|Leucovorin|Specified dose on specified days
75344433|NCT04008030|Drug|Fluorouracil|Specified dose on specified days
75344434|NCT04008030|Drug|Irinotecan|Specified dose on specified days
75344435|NCT04008030|Drug|Bevacizumab|Specified dose on specified days
75344436|NCT04008030|Drug|Cetuximab|Specified dose on specified days
75655164|NCT02829450|Other|peritoneal ultrafiltration|Peritoneal fluids should be inserted intraperitoneally for several hours dwell
75655165|NCT02826954|Other|Upper airway assessment, including nasal biopsy|
75655166|NCT02829762|Other|Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance|Implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance
75802310|NCT04362176|Biological|Placebo|Lactated Ringer's solution with multivitamins
75802311|NCT03748238|Procedure|Endometrial Injury with Hysteroscopy|All office hysteroscopy procedures will be done transvaginally under sedation with a 5 mm 30 degree lens supplied with a 5 F working channel continuous flow office hysteroscope (Bettocchi office hysteroscope, Karl Storz, Tuttlingen, Germany) without speculum or tenaculum. Briefly, following cervical passage and initial endometrial cavity investigation endometrial injury will be performed without energy modality (i.e. with scissors). Endometrial injury will perform first on the fundus by cutting into the endometrium (without injuring the myometrium) transversally. Later, vertical incisions will perform 0,5 cm apart each other, on the anterior and posterior walls of the uterus, 1-1.5 cm away from the fundus and one cut for each lateral wall
75802312|NCT03745586|Drug|Tocilizumab|Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals
75802313|NCT03745586|Drug|Glucocorticoids|Day0-day2: methylprednisolone 500mg i.v.
75802314|NCT05717920|Drug|Part 1 ADX-629 (Open-label)|ADX-629 (250 mg) administered BID for 90 days
75802315|NCT03745508|Other|Instant Coffee|Instant coffee prepared at different caffeine concentrations
75344437|NCT04008030|Biological|Nivolumab|Specified dose on specified days
75344438|NCT03992404|Drug|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
75344439|NCT03992404|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
75344440|NCT03983850|Drug|Busulfan|Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.
75941179|NCT05795972|Other|standard therapy|control group (patients treated also with standard therapy)
75941180|NCT05795933|Drug|Vitamin D3|A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
75941181|NCT05794269|Other|TQoR-15 questionnaire|The TQoR-15 questionnaire (Turkish version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
76090507|NCT02706093|Other|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at ~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
76090508|NCT02706093|Other|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
76090509|NCT02706093|Other|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax [25min; ~150kcals; 4d/wk]
75802316|NCT03748160|Other|Letter|Intervention consists of two different types of postal letters reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers
75802317|NCT04079816|Device|INVSENSOR00025|Noninvasive pulse oximeter sensor
75941182|NCT05793476|Device|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 15-21 days. She receives 3 sessions, in total. 5% Lidocaine cream is applied 30 minutes before each procedure. Each session consists of application of R11 handpiece to the episiotomy scar at Turbo3 Micro Short Pulse mode, with spot size of 2 mm, fluence of 9.5-10 j/cm2, frequency of 2 Hz and 4 pulses per point and 3 passes followed by PS03 handpiece at Basic Long Pulse mode, with spot size of 5 mm, energy of 800 mJ, frequency of 1.4 Hz and 4 pulses per point and 2 passes.
75941183|NCT05793476|Device|Fotona Dynamis Er:YAG Laser System with Sham handpiece|The same procedure is applied above but with a sham handpiece and parameter presentations masked.
75941184|NCT05793125|Device|Ultrasonography|"A full obstetrics ultrasound scan will be performed within 24 hours before delivery to document fetal biometry, estimated fetal weight and correlate it to fetal growth charts to exclude IUGR, amniotic fluid index and umbilical artery Doppler studies.~Fetal echocardiography will be done.Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time (At/Et) ratio will be measured in the main pulmonary artery."
75941185|NCT05792033|Other|Prospective registry|Prospective registry of patients with primary diagnosis of T1 urinary bladder cancer
75941186|NCT05791773|Procedure|the robot assisted total knee arthroplasty|the robot assisted total knee arthroplasty
75941187|NCT05791773|Procedure|the conventional jig-based total knee arthroplasty|the conventional jig-based total knee arthroplasty
75344441|NCT03983850|Drug|Fludarabine|Fludarabine will be infused by IV over 60 minutes.
75476480|NCT05968560|Behavioral|CBT Skills Group for Families|"Family members are taught the same CBT skills that are taught to CHR youth to facilitate use of CBT skills at home. Family members also learn how to prompt CHR youth to use CBT skills through effective communication, such as empathic listening and encouraging alternative explanations. CBT skills group for family members uses a combination of didactic learning (skills are described in CBT Skills for Families manual and demonstrated via video examples) and practice (skills are role-played). Youth attend one group session and one individual session per week, and family members attend one group session per week."
75655167|NCT04246398|Other|FMT|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
75655168|NCT04246398|Other|FMT - placebo|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
75655169|NCT02827578|Drug|Tamsulosin|Tamsulosin
75344442|NCT03983850|Drug|Cyclophosphamide|IV cyclophosphamide will be administered over 2 hours. Slower rates of infusion may be used to decrease side effects. A fluid intake of greater than 2 L/day is recommended during and for 1 to 2 days after cyclophosphamide administration.
75655170|NCT02827578|Drug|Solifenacin|Solifenacin
75344443|NCT03983850|Drug|Mycophenolate Mofetil|Any oral formulation should be taken on an empty stomach, 1 hour before or at least 2 hours after meals. Oral formulations should not be administered simultaneously with antacids. Avoid inhalation or direct contact with skin or mucous membranes of dry powder contained in capsules or suspension. IV solutions should be administered over at least two hours through either a peripheral or central vein and should not be administered by rapid or bolus injection.
75655171|NCT02827578|Drug|Solifenacin placebo|Solifenacin placebo
75655172|NCT04323930|Device|eyeWatch|The eyeWatch system will be implanted as per the manufacturer's instruction, and trabeculectomy will be performed using mitomycin C as per standard surgical protocols.
75655173|NCT04244838|Diagnostic Test|Gait Analysis|The patients will undergo Gait analysis (integrated movement analysis system) performed at the Complex Laboratory for Movement Analysis and functional-clinical evaluation of the prosthesis of the Rizzoli Orthopedic Institute. The instrumentation used in the Movement Analysis Laboratory consists of a stereophotogrammetric system equipped with eight infrared cameras (Vicon® 460-Oxford system) and 2 dynamometric platforms (Kistler® Instrument, AG Switzerland). The IOR GAIT protocol will be used as a marker set (Leardini et al. 2007). For the evaluation of muscle activation, surface electromyography with 16-channel system will be used (ZeroWire Cometa, Milan). Spatio-temporal parameters, kinematics, kinetics and muscle activation will be evaluated.
75655174|NCT02827734|Device|multiple breath washout tests|
75344444|NCT03983850|Drug|Sirolimus|Oral tablets should be administered approximately 4 hours after cyclosporine administration. Sirolimus is administered orally, once daily, without food. Patients unable to tolerate tablets may take the oral solution formulation.
75476481|NCT05968547|Other|Driving assessment in glaucoma patient|One group of patient will be given questionnaire while the other group will respond to a questionnaire while the other group will have vision assessment. Patients could participate in both groups.
75476482|NCT05968482|Drug|Diclofenac Sodium Gel|Topical application on both knees
75655175|NCT02827734|Device|impulse oscillometry|
75655176|NCT02827734|Device|body plethysmography|
75655177|NCT02827110|Device|fiberoptic bronchoscope|Tracheal intubation using fiberoptic bronchoscope
75655178|NCT02827110|Device|pentax-airway scope|Tracheal intubation using pentax-AWS
75802318|NCT04079114|Device|Patients who received the Stafit Acetabular System|Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.
75802319|NCT03055936|Drug|Levodopa|Levodopa 50 mg or 100 mg or 150 mg
75802320|NCT03055936|Drug|Carbidopa|Carbidopa 12.5 mg or 25 mg or 65 mg
75802321|NCT03055936|Drug|ODM-104|ODM-104 50 mg or 100 mg
75802322|NCT05215444|Diagnostic Test|some prognostic factors|cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count
75655179|NCT02827110|Procedure|semi-rigid collar|semi-rigid collar immobilization of the cervical spine
75941188|NCT05788315|Other|Cultural Formulation Interview|The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.
76090510|NCT02706093|Other|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax [15min; ~90kcals; 4d/wk]
75655180|NCT02829372|Drug|CD3/HER2 bispecific monoclonal antibody|Increasing doses, IV on day 1 and 15 of each 28 day cycle
75655181|NCT00899678|Drug|Certolizumab Pegol|"400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg~*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg"
75476483|NCT05968443|Device|ophthalmic surgery|any ophthalmic surgery using Dafilon® suture
75476484|NCT05968391|Radiation|PET scan metabolic day|11C-Acetate and 11C-Acetoacetate PET scans
75655182|NCT00899678|Drug|Certolizumab Pegol|"200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg~*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg"
75655183|NCT00887484|Drug|BENZOYL PEROXIDE/ CLINDAMYCIN|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
75655184|NCT00887484|Drug|BENZOYL PEROXIDE/ ADAPALENE|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
75655185|NCT00794378|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
75655186|NCT00794378|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
75802323|NCT05215366|Diagnostic Test|copeptin biomarker in children with febrile seizures|biomarkers increase in children with febrile seizures
75802324|NCT05201170|Drug|Vehicle Opthalmic Solution|Opthalmic Solution
75941189|NCT05787717|Other|Parental presence|The parent is encouraged to stay close to their child and are given ample room on one side of the OR table for this purpose
75941190|NCT05786521|Drug|Semaglutide Injectable Product|Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
75476485|NCT05968378|Behavioral|Standard healthy eating advice|Subjects in this group will be provided with standard healthy eating advice according to the Irish National Healthy Eating Guidelines and Food Pyramid and will be asked to follow this advice for 8-weeks.
75655187|NCT00789152|Drug|desloratadine|desloratadine 5 mg daily x 8 days
75802325|NCT05201170|Drug|PL9643 Opthalmic Solution|Opthalmic Solution
75802326|NCT05194696|Behavioral|Questionnaire|Patients have to answer a questionnaire about their caffeine consumption habits during lifetime
75476486|NCT05968378|Behavioral|eTRE plus Mediterranean diet|Subjects in this group will be asked to consume all meals between 8am - 4pm and to adhere to a Mediterranean style diet daily for 8-weeks.
75476487|NCT05968287|Diagnostic Test|The Leukocyte ImmunoTest™ (LIT™)|The baseline LIT scores was performed for two parallel groups. The sequential LIT score was also performed for patients with various infection conditions with/without sepsis.
75655188|NCT00789152|Drug|levocetirizine|levocetirizine 5 mg daily x 8 days
75655189|NCT00886938|Device|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
75655190|NCT00783458|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
75802327|NCT03891524|Drug|JNJ-70033093 25 mg|Participants will receive JNJ-70033093 25 mg (1*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
75802328|NCT03891524|Drug|JNJ-70033093 50 mg|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules) BID orally for 10 to 14 postoperative days.
75802329|NCT03891524|Drug|JNJ-70033093 100 mg|Participants will receive JNJ-70033093 100 mg (1*100 mg capsule) BID, orally for 10 to 14 postoperative days.
75941191|NCT05786521|Behavioral|Lifestyle Counseling|Lifestyle Counseling will be provided throughout study intervention
75941192|NCT05756712|Dietary Supplement|Phase 1 Wonderlab Product|Chew two tablets of Wonderlab Product for phase 1 (day 1)
76090511|NCT05335486|Device|RELEARN Neurofeedback|"Standard care + The RELEARN intervention.~Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines.~During standard care, intervention group participants will be subject to the RELEARN intervention, consisting of encephalography (EEG) neurofeedback of cerebral movement evoked signatures of pain, where the participants will be instructed in attempting to manipulate these signatures to reduce pain perception."
75802330|NCT03891524|Drug|JNJ-70033093 200 mg|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
75802331|NCT03891524|Drug|Placebo|Participants will receive placebo matching to JNJ-70033093, orally.
75802332|NCT03891524|Drug|Enoxaparin 40 mg|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
75820016|NCT01084109|Other|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
75941193|NCT05756712|Dietary Supplement|Phase 1 Placebo|Washout 72 hours and chew two tablets of placebo for phase 2 (day 4).
75941194|NCT05756712|Dietary Supplement|Phase 2 Placebo|Chew two tablets of placebo for phase 1 (day 1)
75941195|NCT05756712|Dietary Supplement|Phase 2 Wonderlab Product|Washout 72 hours and chew two tablets of Wonderlab Product for phase 2 (day 4).
75655191|NCT00783458|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
75655192|NCT02690636|Radiation|radiotherapy|daily fractions, five fractions per week.
75941196|NCT05747144|Diagnostic Test|Biometry|Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
75941197|NCT05747144|Diagnostic Test|Retinography (Color) + Autofluorescence (AF)|Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)
75344448|NCT03973268|Device|Arm 1, 2, 3 device interventions|MagPro 100 TMS Therapy System
75655193|NCT00620659|Drug|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
75344449|NCT03973268|Other|Arm 2 Interventions|Placebo
75344450|NCT03973268|Drug|Arm 1, 2, 3 drug Interventions|Ketamine
75344451|NCT03973268|Drug|Arm 1 and 2 Interventions|Perampanel
75476488|NCT05968248|Procedure|MLR-DBS|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices~(1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
75802333|NCT03055624|Device|Embosphere microparticles for prostate artery embolization|Pelvic angiograms will be performed and microspheres delivered to the arteries supplying the prostate to alleviate symptoms of benign prostatic hyperplasia.
75802334|NCT04695652|Biological|MVC-COV1901(S protein with adjuvant)|Approximately 3180 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
75802335|NCT04695652|Biological|MVC-COV1901(Saline)|Approximately 530 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
75344452|NCT03971669|Drug|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
75344453|NCT03947827|Drug|Minocycline|Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
75344454|NCT03946670|Drug|MBG453|MBG453 is being administered i.v.
75344455|NCT03946670|Drug|Placebo|Placebo is being administered i.v.
75344456|NCT03946670|Drug|Hypomethylating agents|Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
75344457|NCT03932032|Behavioral|Attention Bias Modification Treatment|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
75655194|NCT00620659|Drug|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
75655195|NCT00620659|Drug|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
75655196|NCT05188638|Drug|SoftOx Inhaled Solution (SIS)|SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
75655197|NCT05188638|Drug|Placebo|Sterile isotonic saline
75655198|NCT00632996|Other|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
75655199|NCT04245930|Procedure|Bovine Pericardial Patch in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch
75655200|NCT04245930|Procedure|TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh
75655201|NCT04245852|Other|Strength education video|The Strength education video must be watched by the patient at the University of Illinois at Chicago Faculty Practice (UICFP) prior to leaving from the 3rd physical therapy visit. The Experimental Group (EG) will watch the video in the waiting room or other quiet available rooms on the 3rd floor within the UICFP. The video will be watched from an iPad/tablet/laptop/desktop computer device as available in the clinic. The EG will also be provided a handout with a link and quick response code to the video on YouTube.com
75655202|NCT04245852|Other|standard PT care|standard PT care
75655203|NCT02547415|Other|questionnaires and psychological testing|"Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.~Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:~Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires~Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview."
75655204|NCT05182398|Other|Assesment|Modified Four Square Step Test, Berg Balance Scale, Dynamic Gait Index ,Activity-Specific Balance Confidence Scale
75802336|NCT04636060|Dietary Supplement|Eisen|Treatment with low-dose iron in the form of tablets containing 6mg of iron. Treatment consists of twice-daily oral administration of iron-tablets for 8 weeks in total.
75476489|NCT05968248|Procedure|Conventional rehabilitation group|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
75476490|NCT05968235|Other|Collecting blood samples|Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.
75941198|NCT05747144|Diagnostic Test|OCT B-scan and OCT angiography (OCTA)|"OCT B-scan:~2 scans (6 mm)~1 cross line~OCTA:~3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve"
75344458|NCT03932032|Behavioral|Neutral Control Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
75802337|NCT04489108|Drug|Tranexamic acid|Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours
76090512|NCT05335486|Other|Standard care control|"Standard Care control.~Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention"
76090513|NCT02393157|Drug|Obinutuzumab|Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
76090514|NCT02393157|Drug|Liposomal ARA-C|Will be given intrathecally for both prophylaxis and treatment of CNS disease.
75941199|NCT05747144|Diagnostic Test|Microperimetry|1) fixation pattern 2) retinal sensitivity map
75655205|NCT02843750|Behavioral|Inspiratory Muscle Training-Rehabilitation|"The training will include the following components:~Breathing Awareness~Upper and Lower Extremity Exercise.~Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~Practice at home"
75655206|NCT02843750|Other|Questionnaires|Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
75655207|NCT02829060|Drug|Nitrofurantoin 100 MG, 7d|7 day course, 100 mg twice daily, PO
76090515|NCT02393157|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
76090516|NCT02393157|Drug|Carboplatin|Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
76090517|NCT02393157|Drug|Etoposide|Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
75476491|NCT05968222|Other|Vibration exercise|Each training session on the vibrating platform is composed of 6 exercises with a duration of 60 seconds with 60-second pauses between exercises and a warm-up exercise
75655208|NCT02829060|Drug|Gentamicin, 5mg/kg|Peri-operative dose: 5 mg/kg of ideal body weight, IV
75655209|NCT02829060|Drug|Ampicillin 2g|Peri-operative dose: 2 grams, IV
75655210|NCT02829060|Drug|Nitrofurantoin 100 mg, 48 hrs|48 hour course, 100 mg twice daily, PO
75655211|NCT02829060|Drug|Gentamicin, 80 mg, 7d|7 day course, 80 mg daily, IM or IV
75655212|NCT02829060|Drug|Gentamicin, 80 mg, 48hr|48 hour course, 80 mg daily, IM or IV
75476492|NCT05968209|Dietary Supplement|Lab4P|"Probiotic containing:~Lactobacillus acidophilus - CUL 60 Lactobacillus acidophilus - CUL 21 Bifidobacterium bifidum - CUL 20 Bifidobacterium animalis subsp. lactis - CUL34 Lactobacillus plantarum - CUL 66"
75655213|NCT00838669|Drug|Extended release OROS paliperidone|
75655214|NCT00783146|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
75655215|NCT00783146|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
75802338|NCT04489108|Other|Standard Medical Treatment|Standard Medical Treatment
75802339|NCT04489108|Other|Placebo|isotonic solution (saline)
75476493|NCT05968209|Other|Placebo|Placebo
75476494|NCT05968118|Drug|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
75655216|NCT00783146|Drug|placebo|placebo, once daily for 15 days
75802340|NCT03931252|Dietary Supplement|Boost VHC|8 ounce can liquid meal, calories 530kcal, Carbohydrate 46g, Protein 22g, Fat 30g
75802341|NCT03931252|Dietary Supplement|Ensure High Protein|8 ounce can liquid meal, calories 160kcal, Carbohydrate 13g, Protein 16g, Fat 2g
75802342|NCT03771586|Drug|SAGE-718|SAGE-718 in combination with Ketamine
75802343|NCT03771586|Drug|Placebo|Placebo in combination with Ketamine
75802344|NCT03717376|Other|Self-questionnaire YSQ-S3 (Young Schema Questionnaire)|All participants will fill the YSQ-S3 at home and send it back to the main investigator.
75941200|NCT05747144|Diagnostic Test|Electrophysiological exams|Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus < 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.
75941201|NCT05744336|Other|Group 1 Immersive Virtual Reality (VR)|Participants in Group 1 Immersive Virtual Reality (VR) participants wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure
75941202|NCT05744336|Other|Group 2 Control Group|Group 2 control group participants have no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
75941203|NCT05741723|Device|OCS Heart|Transplanted with OCS preserved heart.
75941204|NCT05740865|Procedure|open posterior instrumented thoracolumbar surgery|Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
75941205|NCT05738837|Behavioral|A-EAAA Sexual Assault Resistance Education Program immediately|Adapted from the EAAA program created for university women, A-EAAA is designed for teen girls of all sexual identities and experience levels. It focuses on resisting sexual assault (SA) committed by male acquaintances with 4, 3-hour units: Unit 1(Assess) strengthens girls' ability to detect risk in contexts involving male acquaintances and helps develop strategies to reduce it. Unit 2(Acknowledge) helps girls explore ways to overcome their own emotional barriers preventing them from acknowledging risk and employing effective resistance strategies with males they know. Unit 3(Act) provides evidence on effectiveness of various resistance strategies and teaches verbal and physical self-defense focused on common acquaintance SA situations. Unit 4 (Relationships&Sexuality) is an adaptation of Our Whole Lives curriculum and aims to increase girls' comfort talking about sex/sexuality and identify their sexual values/desires and explore possibilities for sexual practices beyond intercourse.
75941206|NCT05738837|Behavioral|Usual care + A-EAAA at 6 months|Participants assigned to the waitlist control group will immediately receive a brief educational session on sexual assault that represents the current 'standard of care' at Canadian high schools (often presented by local Sexual Assault Centres or Public Health nurses). This 30-min session will involve a brief 15 - 20-minute presentation on sexual consent, respect in relationships, and sexual assault (e.g., definitions, prevalence statistics). This will be conducted by a well-trained and knowledgeable Research Assistant. Following the presentation, participants will be invited to take and read brochures provided on sexual assault, and to ask questions about the content of the presentation and brochures. At 6-months, participants will be scheduled to receive A-EAAA.
75941207|NCT05714683|Drug|Semaglutide|All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
75941208|NCT05703854|Drug|CAR.70/IL15-transduced CB-derived NK cells|Given by IV (vein)
76090518|NCT01750697|Drug|Rituximab|Participants will receive rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15 and 22. Rituximab infusions will be given at a rate of 25 milligrams per hour (mg/h). This may be escalated at a rate of 25 mg/h increments every 30 minutes to a maximum of 200 mg/h.
75344478|NCT03902223|Diagnostic Test|Enhanced Screening Protocol for Cardiac Sarcoidosis.|To utilize enhanced screening tests for cardiac sarcoidosis in an undiagnosed and potentially under-diagnosed patient population to determine the rate of missed cardiac sarcoidosis diagnosis. Following testing by the standard screening tests, this intervention includes a subsequent echocardiogram and a wearable ECG, also known as a Holter Monitor or ambulatory ECG.
75344479|NCT03902223|Diagnostic Test|Routine Screening for Suspected Cardiac Sarcoidosis|To utilize standard of care screening tests for cardiac sarcoidosis. This includes symptom check and a standard ECG.
75344480|NCT03896516|Other|Placebo|Participants will take GL WL-01 450 mg b.i.d or matched placebo for 16 days.
75344481|NCT03896516|Drug|GLWL-01|A within-subject, counterbalanced, double-blind, placebo-controlled study. Participants will take GLWL-01 450 mg b.i.d. or matched placebo for a minimum of 4 days (Stage I). After a wash-out window, Stage II will take place during which the counterbalanced study drug will be administered for a minimum of 4 days.
75344482|NCT03860987|Drug|goserelin|Goserelin will be administered SC at 10.8 mg every 12 weeks
75802345|NCT03263416|Other|Dedicated and coordinated follow-up|"Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period~Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist~Completion of QLQ-C30 and GIRERD questionnaires"
75344483|NCT03860987|Drug|Enzalutamide|Enzalutamide will be given orally at 160mg once daily
75655217|NCT00844675|Drug|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
75802346|NCT03263416|Other|Standard follow-up|- Completion of QLQ-C30 and GIRERD questionnaires
75941209|NCT05703854|Drug|Fludarabine phosphate|Given by IV (vein)
76090519|NCT02127723|Device|Hyaluronic acid injection (Macrolane VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
76090520|NCT01750229|Device|Sham|Frequency Setting - Sham
75344484|NCT03860987|Drug|Abiraterone|Abiraterone will be taken orally at 1000 mg once daily
75344485|NCT03860987|Drug|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
75344486|NCT03860987|Drug|Prednisone|Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
75344487|NCT03860987|Procedure|Radical Prostatectomy|Radical Prostatectomy
75655218|NCT00844675|Drug|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
75655219|NCT02837900|Drug|TPX-100 200 mg 4 times weekly for 4 weeks|Ea. subject will received active TPX-100 200mg in the Left knee
75655220|NCT02837900|Drug|TPX-100 200 mg 4 times weekly for 4 weeks|TPX-100 100mg Right
75655221|NCT02826096|Behavioral|Biofeedback therapy|The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
75655222|NCT00831883|Behavioral|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
75802347|NCT03627910|Dietary Supplement|symbiotic|Feed supplementation
75476495|NCT05968118|Drug|Placebo|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo
75476496|NCT05968053|Diagnostic Test|biological samples analysis|biological samples analysis
75802348|NCT03627910|Dietary Supplement|zinc and arginine|Feed supplementation
75820017|NCT02185222|Drug|Cholecalciferol 100 000 UI|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
75941210|NCT05703854|Drug|Cyclophosphamide|Given by IV (vein)
75941211|NCT05702918|Device|BTL-6000 FSWT|The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal).
75802349|NCT02582164|Device|Duke Biomedical Engineering's Long-working distance OCT|The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
75802350|NCT02541838|Other|Muscle power|
75344488|NCT03854214|Device|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc). Bilateral glutei, quadriceps and hamstrings will be stimulated. The stimulation parameters will be set as follows: waveform biphasic, charged balanced; phase duration of 250 microseconds; pulse rate 33-45 pps. The stimulus intensity will be adjusted for individual patients and muscle group so that a tolerable stimulation is provided that will generate a cycling action. Target cycling speed is 50 RPM. Resistance will be automatically adjusted by the FES bike according to the subject's performance. When fatigue occurs, participants will continue cycling with electrical stimulation and motor support. FES therapy will be administered for one hour per session 3 times a week.
75655223|NCT00831883|Behavioral|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
75655224|NCT02840006|Procedure|General anesthesia only|Induction drugs: Citrate of fentanyl, atracurium, etomidate
75655225|NCT02840006|Procedure|General anesthesia and Spinal anesthesia|Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
75655226|NCT02826252|Drug|Iloprost,(Ventavis, BAYQ6256)|Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
75655227|NCT02826252|Device|I-Neb AAD system|Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
75655228|NCT02547961|Biological|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
75655229|NCT00844909|Drug|CNTO 136|
75655230|NCT02839928|Drug|Intranasal ketamine|The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
75655231|NCT02839928|Device|Intranasal atomizer|Ketamine will be applied to each nare via intranasal atomizer
75655232|NCT02839928|Drug|EMLA|
75655233|NCT05018520|Drug|Six Courses of R-CHOP Plus Two Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 2 courses)
75655234|NCT05018520|Drug|Four Courses of R-CHOP Plus Four Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 4 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 4 courses)
75655235|NCT02840084|Device|Aspen(TM) Ultrasound System|"Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts."
75655236|NCT00838825|Other|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
75655237|NCT04321746|Drug|Ketamine|ketamine will be administered at a dose of 0.3 mg/kg in normal saline at 0.9% (250 mL)
75802351|NCT02541838|Other|balance perturbation|
75802352|NCT02541838|Other|aerobic exercise|
75941212|NCT05702918|Other|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
75941213|NCT05699070|Drug|DWC202211 100mg|"DWC202211 for 5 days~Aspirin 100mg"
75941214|NCT05699070|Drug|DWC202212 5mg|"DWC202212 for 3 days~Rabeprazole 5mg"
75941215|NCT05699070|Drug|DWC202211 100mg + DWC202212 5mg|"DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg"
75941216|NCT05697653|Behavioral|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
75802353|NCT02335060|Drug|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
75802354|NCT02335060|Drug|N-acetylcysteine|A pill given orally.
75802355|NCT02335060|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
75802356|NCT02335060|Drug|Placebo|"Placebo sugar pill given orally with no N-acetylcysteine."
75802357|NCT00284986|Drug|Prochymal®|Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells
75802358|NCT05219188|Radiation|3.7 mS, CT radiation|Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS
75802359|NCT05219032|Behavioral|Professional Medical Interpreter|A professional medical interpreter accompanies patient to each appointment.
75802360|NCT05218954|Diagnostic Test|Biomechanical analysis of risk fall|Biomechanical analysis of risk fall in terms of balance
75941217|NCT05692999|Drug|Pembrolizumab 200 mg Q6W|Pembrolizumab 200mg Q6W
75941218|NCT05692999|Drug|Pemetrexed 500 mg/m^2 Q3W|Pemetrexed 500 mg/m^2 Q3W
75941219|NCT05692999|Drug|Pembrolizumab 200 mg Q3W or 400 mg Q6W|Pembrolizumab 200 mg Q3W or 400 mg Q6W
75344489|NCT03854214|Device|Passive cycling|The passive cycling group will use the same RT300 ergometer however during this period stimulation will not be turned on. Instead, continuous motor support will be activated resulting in passive cycling. Target cycling speed is 50 RPM. Participants assigned to passive cycling will be required to have one hour of passive therapy 3 times a week for the entire duration of treatment assignment.
75941220|NCT05692934|Drug|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
75941221|NCT05692934|Drug|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
75476497|NCT05968040|Procedure|Inferior vena cava diameter measurement by ultrasonography|The diameter of the inferior vena cava will be measured at 2 cm close to the entrance of the right atrium. Ultrasound images will be taken at the end of inspiration (Dmax) and at the end expiration (Dmin) to calculate the inferior vena cava dispensability index (dIVC), and will be recorded before and after fluid challenge test of 5 ml/kg crystalloid within 15 min. The IVC distensibility index (IVC-DI) will be calculated using the formula: IVC-DI = IVCmax - IVCmin/ IVCmin. The indices will be expressed as a percentage.
75655238|NCT04321746|Other|Placebo|the control group will receive only normal saline at 0.9%, with the same physical characteristics of the ketamine solution
75941222|NCT05692934|Drug|HR20031 FDC|Subjects will receive treatment S HR20031 FDC 5/50/750 mg*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg*2 in the fed state.
75655239|NCT02994680|Device|Three-burner LPG stove|The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
75655240|NCT02994680|Other|Delivery of LPG tanks|One year supply of LPG fuel, in the form of delivery of 20 kg tank that holds 10 kg of LPG. Delivered to homes.
75655241|NCT02994680|Other|Vouchers for LPG tanks|One year supply of LPG, in the form of vouchers to obtain a free LPG tanks from a distribution center. (Beginning one year after enrollment, for one year)
75655242|NCT04043767|Procedure|Measurements of thyromental distances, hyomental distances and neck circumferences|thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
75655243|NCT04243824|Drug|Gallium 68 Macro-aggregated albumin|The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
75802361|NCT05218876|Other|Low- to moderate intensity strength and endurance training|Combination of strength and endurance training with low- to moderate intensity during chemotherapy
75802362|NCT05218876|Other|High intensity strength and endurance training|Combination of strength and endurance training with high intensity during chemotherapy
75820018|NCT02185222|Drug|Placebo|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
75820019|NCT01084187|Drug|Vardenafil|vardenafil 20 mg on demand or vardenafil daily or placebo
75941223|NCT05692934|Drug|HR20031 FDC|Subjects will receive treatment HR20031 FDC 5/50/750 mg*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg*2 in the fast state.
75941224|NCT05661591|Drug|SHR2554 Tablets|SHR2554 Tablets+ Fluconazole Capsules
75941225|NCT05661591|Drug|Fluconazole Capsules|SHR2554 Tablets+ Fluconazole Capsules
75941226|NCT05661201|Drug|NEROFE|weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
75941227|NCT05661201|Drug|Doxorubicin|weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
75941228|NCT05660369|Drug|CARv3-TEAM-E T cells|Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.
75941229|NCT05660018|Device|active rTMS first, then sham rTMS|Active rTMS is delivered on the first visit, then sham rTMS is delivered on the second visit.
75941230|NCT05660018|Device|sham rTMS first, then active rTMS|Sham rTMS is delivered on the first visit, then active rTMS is delivered on the second visit.
75941231|NCT05647174|Procedure|MGPOCUS-assisted bronchoscope-guided intubation|Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.
75941232|NCT05647174|Procedure|Bronchoscope-guided intubation|Routine bronchoscope- guided intubation.
75941233|NCT05634148|Drug|Dexmedetomidine|Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
75941234|NCT05630482|Behavioral|Healthy Family Foundations|Healthy Family Foundations Curriculum
75941235|NCT05630482|Other|Standard of Care|Standard of Care
75941236|NCT05625126|Other|Rumination Intervention for individuals with PTSD|The intervention utilises evidence-based cognitive behavioural therapy (CBT) techniques.
75941237|NCT05624385|Device|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Tremor-Related Subjects
75941238|NCT05622253|Combination Product|Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser|Selected patients will be treated with low-dose oral isotretinoin (10mg/day) over a period of sessions and six sessions of 1064 ND- YAG laser (Deka motous AY) using 150 J/cm2, 20-25 milliseconds pulse duration, and 5 mm spot size, at 2 weeks' interval.
75941239|NCT05622123|Drug|68Ga-NODAGA-Exendin-4|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4
76090521|NCT01750229|Device|1200 Hz|Frequency Setting - 1200 Hz
76090522|NCT01750229|Device|3030 Hz|Frequency Setting - 3030 Hz
76090523|NCT01750229|Device|5882 Hz|Frequency Setting - 5882 Hz
75344490|NCT03849651|Drug|Cyclophosphamide|"Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9"
75941240|NCT05616806|Behavioral|iENDURE|"Two delivery modes: computer and text message. The intervention provides introductory strategies for managing physical and emotional distress associated with Long COVID through a computer-delivered session followed by 4-weeks of theoretically-informed text messages intended to promote distress tolerance (DT).~Computer - the initial intervention will be delivered online via the Qualtrics survey tool following informed consent. The intervention provides strategies to better tolerate emotional and physical discomfort to persist with behavioral goals. Text Message - The text message intervention will be delivered using Marigold Health (a HIPAA compliant platform for secure text messaging). Participants will receive daily text messages that focus on emphasizing adaptive strategies for tolerating physical and emotional discomfort in order to work toward behavioral goals. The text messages will be personalized and offer skills training (reminders of previously learned DT skills)."
75802363|NCT05218564|Drug|Oxygen Therapy|During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
75941241|NCT05614245|Biological|VBI-2901e|Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants
75941242|NCT05599321|Diagnostic Test|Virtual Navigation System|The Virtual Navigator guidance computer is interfaced to the bronchoscopy hardware to tap off the live bronchoscopy and EBUS video feeds. The standard OR medical team (technicians, clinical fellows, et al.) is on hand, and standard clinical facilities (e.g., fluoroscopy, CT/PET image viewer) are available. Our technical team is also present to record all procedural video and computer display information. It also operates the guidance computer during the guided procedure and offers any assistance in case of unanticipated issues. The participant's clinical bronchoscopy will be recorded by the radiology imaging management system.
75941243|NCT05594082|Drug|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan, 5.4 mg/kg ivgtt q3w
75941244|NCT05593185|Biological|Galinpepimut-S|
75941245|NCT05577026|Behavioral|Educational intervention and prescription feedback|Brief educational intervention and patient and provider materials regarding prescription of opioids. Subsequent feedback on clinic prescription of opioids over 12 months.
75941246|NCT05577026|Behavioral|General information on treatment guidelines|Written information on guidelines and recommendations regarding prescription of opioids.
75802364|NCT05218564|Other|Compressed Medical Air|During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
75941247|NCT05574374|Drug|DWP14012|Potassium-competitive acid blocker
75941248|NCT05574374|Drug|DWC202202|Clopidogrel Bisulfate
75941249|NCT05574374|Drug|DWC202203|Proton pump inhibitor
75344491|NCT03849651|Biological|Fludarabine|"Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.~fludarabine phosphate IV QD on days -8 to -4"
75655244|NCT02839694|Drug|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
75655245|NCT02839694|Drug|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
75344492|NCT03849651|Drug|Thiotepa|Thiotepa is a cell-cycle nonspecific polyfunctional alkylating agent.
75655246|NCT02839694|Drug|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
75941250|NCT05550779|Behavioral|Mental Exercise|Participant perform a 10-minute mental exercise
75655247|NCT00831961|Procedure|Conjunctival and nasopharyngeal bacteria cultures|Conjunctival and nasopharyngeal bacteria cultures
75655248|NCT00894686|Biological|FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)|Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
75655249|NCT04243434|Drug|Vincristine Sulfate Liposome|Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.
75655250|NCT04243434|Combination Product|CHOP|CHOP to be administered on Day 1 on Cycle 1 & 2 ( 21-day Cycle) & prednisone administration on Days 2 to 5 on Cycle 1 & 2 ( 21-day Cycle)
75941251|NCT05539157|Drug|JCXH-211|JCXH-211 administered once every 28 days
75941252|NCT05535816|Diagnostic Test|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound instead of fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
75941253|NCT05528965|Procedure|Perpendicular Group|Radiofrequency ablation was applied to the perpendicular group by placing the tip of electrode perpendicularly to contact the genicular nerves.
75941254|NCT05528965|Procedure|Parallel Group|Radiofrequency ablation was applied to the parallel group by placing the electrode lay parallel to contact the genicular nerves.
75941255|NCT05524116|Behavioral|Mindful Exercise program|In this 8-week intervention, components of Mindful Based Stress Reduction Program will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis. The goal of this program is to train participants how to be mindful during their exercises.
75941256|NCT05524116|Behavioral|Exercise|In this 8-week intervention, participants will be given recommended strengthening and neuromuscular exercises for knee osteoarthritis. Participants in both the intervention and control group will receive these exercises.
75941257|NCT05520463|Procedure|Sacral lateral branch radiofrequency ablation under ultrasound guidance|Sacral lateral branch radiofrequency ablation will be performed under ultrasound guided approach.
75941258|NCT05520463|Procedure|Sacral lateral branch radiofrequency ablation under fluoroscopy guidance|Sacral lateral branch radiofrequency ablation will be performed under fluoroscopy guided approach.
75941259|NCT05506787|Drug|Esketamine|Esketamine
75941260|NCT05506787|Drug|Placebo|Placebo
75941261|NCT05503511|Drug|NPT 2042 (bumetanide analog) or Matching Placebo|Soft gelatin capsules
75941262|NCT05503355|Drug|BST-236|"In part 1: During the induction (in combination with venetoclax), the BST-236 doses are:~In cohort 1 - 2.3 g/m2/d X6 days In cohort 2 - 2.3 g/m2/d X6 days In cohort 3 - 4.5 g/m2/d X6 days In cohort 4 - 4.5 g/m2/d X6 days In cohort 5 - 4.5 g/m2/d X6 days In part 1: During maintenances (for responding patients) the BST-236 dose- 4.5 g/m2/d X6 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
75802365|NCT05218174|Other|Exercise Prescription|In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
75941263|NCT05503355|Drug|venetoclax|"In part 1: During the induction (in combination with BST-236), the venetoclax doses are:~In cohort 1 - 200 mg QD X 7 days In cohort 2 - 400 mg QD X 7 days In cohort 3 - 200 mg QD X 7 days In cohort 4 - 400 mg QD X 7 days In cohort 5 - 200 mg QD X 14 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
75344493|NCT03849651|Drug|Melphalan|"Melphalan, a derivative of nitrogen mustard, is a bifunctional alkylating agent. Melphalan is active against tumor cells that are actively dividing or at rest.~melphalan IV QD on days -2 to -1"
75344494|NCT03849651|Biological|G-csf|G-csf (granulocytic colony stimulating factor), is a biosynthetic hematopoietic agent that is made using recombinant DNA technology in cultures of Escherichia coli. G-CSF stimulates production, maturation and activation of neutrophils. In addition, endogenous G-CSF enhances certain functions of mature neutrophils, including phagocytosis, chemotaxis and antibody--dependent cellular cytotoxicity.
75476498|NCT05968040|Procedure|difference between peak velocities of carotid artery by ultrasound|"Carotid ultrasound images will be obtained from the left CCA in both short-axis and long-axis views by experienced sonographers. The patient will be in supine position, with the head rotated slightly to the right. A broadband linear array transducer 12-4 MHz and the short-axis view will be used for orientation and identification of the CCA. Next, in the long-axis view, Peak Waveform Doppler signals will be acquired by placing a 0.5 mm calliper at the center of the vessel and parallel to the vessel walls, approximately 2 cm proximal from the carotid bifurcation. Insonation-angles between the ultrasound beam and blood flow will be maintained.~ΔVpeakCCA = (MaxCDPV-MinCDPV)+(MaxCDPV+MinCDPV)x100"
75476499|NCT05968040|Procedure|cardiac output be transthoracic echocardiography|"CO will be recorded as baseline measure and after fluid administration. If CO increased more than 15%, it will be considered fluid responder. Increase in cardiac output = (cardiac output after first fluid challenge - cardiac output before)/cardiac output before) X 100.~TTE will be used to measure LTOT and VTI x HR."
75655251|NCT04243434|Combination Product|R-CHOP|R-CHOP to be administered on Day 1 on Cycle 1 & 2 ( 21-day Cycle) & prednisone administration on Days 2 to 5 on Cycle 1 & 2 ( 21-day Cycle)
75802366|NCT01346176|Other|Advance Directive Forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
75655252|NCT00832039|Drug|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
75655253|NCT00832039|Drug|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
75802367|NCT05217862|Diagnostic Test|PCR for COVID-19 testing|PCR for asymptomatic adult undergoing elective cataract surgery
75941264|NCT05486052|Other|Evaluation of reliability, repeatability and validity of devices among healthy subjects|"Evaluation of reliability, reproducibility and validity of devices among healthy subjects Prior to the study among individuals with neurological disorders, an evaluation of the reliability, repeatability and credibility of the devices to be included in the biofeedback rehabilitation and optical oximetry measurements will be carried out.~The evaluation of the devices will be carried out by two independent researchers twice"
76090524|NCT05586711|Drug|vaginal estradiol 10 μg|Vagifem® (estradiol), vaginal tablets
76090525|NCT05586711|Drug|vaginal DHEA 6.5 mg|Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
76090526|NCT03029260|Other|Neural mobilization - tension.|"Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.~The intervention will be delivered in one session only."
75344495|NCT03849651|Drug|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide. Following glomerular filtration, mesna disulfide is rapidly reduced in the renal tubules back to mesna, the active form of the drug.
75344496|NCT03849651|Device|CliniMACS|Cells for infusion are prepared using the CliniMACS
75344497|NCT03849651|Biological|ATG (rabbit)|"Anti-thymocyte globulin is a purified, pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes.~rabbit anti-thymocyte globulin IV daily over 6 hours on days -5 to -3,"
75941265|NCT05486052|Other|Biofeedback method and Health-resort based rehabilitation Health-resort based treatments supplemented with biofeedback training|"The rehabilitation programme will run for 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massages, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.~Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, peat wraps, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy."
75941266|NCT05486052|Other|Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.|Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy
75655254|NCT00832039|Procedure|Procalcitonin guided therapy|"Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline >=50%: no change in causal therapy; PCT drop from baseline <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT <=1.0 ng/ml: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement >=50%: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control."
75344498|NCT03849651|Drug|Blinatumomab|"Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that mediates formation of a synapse between T cells and the CD19+ target cell, resulting in lysis of that CD19+ cell.Blinatumomab will be given to patients with a history of CD19+ malignancy as determined by St. Jude hematopathologist review of current and historical specimens and reports.~blinatumomab IV for 28 days beginning at least 1 week post-DLI"
75344499|NCT03849651|Biological|TCRα/β+|IV on day 0 and may receive an additional dose on day 1
75344500|NCT03849651|Biological|CD19+|IV on day 0 and may receive an additional dose on day 1
75655255|NCT02826564|Drug|pembrolizumab|
75344501|NCT03849651|Biological|CD45RA-depleted DLI|infusion IV
75655256|NCT05333588|Biological|Tumor Infiltrating Lymphocytes (TIL)|The autologous TILs will be intravenous infused into patients.
75802368|NCT04075604|Biological|Nivolumab|Specified Dose on Specified Days
75344502|NCT03821935|Drug|Livmoniplimab|Liquid for intravenous infusion.
75344503|NCT03821935|Drug|Budigalimab|Lyophilized powder for solution for intravenous infusion.
75476500|NCT05968027|Other|"Nouveal numeric application Onco'nect"|A remote monitoring application, Onco'nect® (smartphone /tablet /PC), in partnership with the company Nouveal facilitates communication between patients undergoing Intra Vascular (IV) chemotherapy and the care team. A questionnaire before and after each session can be used to alert the oncology department and adapt patient management.
75655257|NCT02826642|Drug|IDH305|
75476501|NCT05968014|Procedure|PENG vs FICB|pericapsular nerve group block versus fascia iliaca compartment block
75476502|NCT05968001|Drug|Obinutuzumab|obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
75655258|NCT00832195|Device|Motion Controlling Running Shoe|Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
75802369|NCT04075604|Drug|Anastrozole|Specified Dose on Specified Days
75802370|NCT04075604|Drug|Palbociclib|Specified Dose on Specified Days
75802371|NCT05217550|Behavioral|Veggie Brek|Offering vegetables to children at breakfast alongside their main breakfast food for three consecutive weeks (five days a week) between baseline and follow-up weeks where vegetables are also offered to children at breakfast alongside their main breakfast food for five days a week.
75802372|NCT05217472|Drug|Ravaglimab|Intravenous Injection
75802373|NCT05217472|Drug|Ravagalimab|Subcutaneous Injection
75802374|NCT05217472|Drug|Placebo|Intravenous Injection
75802375|NCT05217472|Drug|Placebo|Subcutaneous Injection
75802376|NCT05217394|Other|OTHIG|Occupational Therapy Handwriting Intervention Guideline
75344504|NCT03819478|Behavioral|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
75476503|NCT05967988|Device|Immersive atmospheric projection|Projection of computer-generated videos or videos of real moving landscapes on the walls of the examination room
75655259|NCT00832195|Device|Neutral Running Shoe|Standard running shoe with single density mid-sole foam.
75655260|NCT00885846|Other|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
75655261|NCT00885846|Other|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
75802377|NCT05217316|Behavioral|Supervised Virtual Toothbrushing|"A supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child. All virtual appointments will be conducted using the collaboration of two national platforms. Mawid, a Ministry of health (MOH) Central Appointment System, to be used by the subjects. And ANAT system, a Saudi Commission for Health Specialists (SCHS) application for the hygienists to use for their virtual supervision."
75802378|NCT05217238|Drug|Remifentanil|Advanced intravenous injection of remifentanil before the rocuronium injection
75941267|NCT05484206|Drug|VIR-2218|VIR-2218 given by subcutaneous injection.
75941268|NCT05484206|Drug|VIR-3434|VIR-3434 given by subcutaneous injection.
75941269|NCT05473143|Other|Protocol-based fluid management|"Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components.~The first component of this prescription will be to define the 24h-fluid balance target either aiming for a negative fluid balance of 2 to 3% body weight (1.4-2.1 liters in a 70 Kg participant) (Option 1) or by aiming to avoid fluid accumulation by targeting a neutral fluid balance within 0.5% of body weight variation (-350 to +350 mL in a 70 Kg participant) (Option 2).~The second component is to pre-specify a prescription for fluid removal using KRT.~The third component is to prompt a daily re-evaluation of fluid intake by the attending care team."
75941270|NCT05473143|Other|Usual care|The net fluid removal and the rate of net fluid removal will not be protocolized and will be prescribed and adjusted according to the attending care team without any specific guidance. The use of the documents provided for the intervention group will not be permitted in the control arm.
75655262|NCT02843828|Device|gait rehabilitation with Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
75655263|NCT02843828|Other|gait rehabilitation without Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
75941271|NCT05458193|Drug|Daridorexant|Film-coated tablet for oral use
75941272|NCT05458193|Drug|Placebo|Film-coated tablet for oral use
75476504|NCT05967988|Device|Minimal atmospheric projection|Projection of a colors on the walls on the walls of the examination room
75655264|NCT00839059|Drug|lenalidomide|"Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days"
75941273|NCT05453851|Procedure|Pancreatectomy|Undergo pancreatectomy
75941274|NCT05453851|Other|Quality-of-Life Assessment|Ancillary studies
75802379|NCT03796208|Behavioral|Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC)|Women enrolled in the intervention group will receive TAU plus B-EPIC, which includes four core components: 1) Individualized tobacco treatment plus supplemental counseling, 2) Biomarker validation and feedback, 3) Change in maternal thought process and adoption of healthy behavior (e.g. exercise, based on PI framework), and 4) Pharmacotherapy as needed (see Table 3 for a summary of the study design). The initial assessment for this intervention takes 60 minutes, with follow-up sessions typically lasting 15-20 minutes. All sessions occur prior to or after pre-scheduled perinatal appointments. The intervention will be led by a certified tobacco treatment specialist (CTTS).
75941275|NCT05453851|Other|Treatment Planning|Undergo IV autologous islet cell transplant
75941276|NCT05445024|Procedure|nalbuphine group|nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
75941277|NCT05445024|Procedure|sufentanil group|sufentanil (1/1000* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
75941278|NCT05440955|Device|left fronto-temporal transcranial Direct Current Stimulation (tDCS)|"The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session."
75941279|NCT05440669|Behavioral|white noise|white noise will reduce pain and stress in nasal cpap application
75941280|NCT05440318|Device|Wireless wearable digital devices|Wireless wearable digital devices (including a small patch, modified watch, and datahub smartphone with electronic Patient Reported Outcomes [ePRO] capability) will be provided to each participant enrolled in the study.
75941281|NCT05439252|Behavioral|Exercise Snacking|Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are sit-to-stand from a chair, seated overhead arm raises, march on the spot, seated arm raises and shoulder touches, and seated calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.
75941282|NCT05437146|Behavioral|puppet|pain and fear during blood collection
75476505|NCT05967949|Drug|chidamide|This subset of patients received chidamide as first-line maintenance therapy.
75655265|NCT02839538|Procedure|Local Infiltration|Injection at perianal region with ropivacaine 0.75%(20ml)
75655266|NCT02839538|Procedure|Subarachnoidal block|Injection at subarachnoidal space with bupivacaine 0.5% ( 2ml)
75476506|NCT05967936|Drug|Bupivacaine Injection|evaluation of pain by using two different types of local anesthesia
75476507|NCT05967923|Radiation|Shock wave therapy|Patients in this group will receive shock wave therapy once a week for four weeks in addition to routine physical therapy program.
75476508|NCT05967923|Radiation|Low level lazer therapy|Patients in this group will receive low level lazer therapy three times a week week for four weeks in addition to routine physical therapy program.
75941283|NCT05429814|Other|Menthol Application|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
75941284|NCT05420337|Procedure|Group ıntramuscular|Group I will be applied 20 ml of % 0.25 bupivacain internal oblique and transversus abdominis muscle and 0.1 mg/kg morphine ıntramuscular. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
75941285|NCT05420337|Procedure|Group TAP|Group T will be applied 20 ml of % 0.25 bupivacain and 0.1 mg/kg morphine internal oblique and transversus abdominis muscle. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
75941286|NCT05418751|Other|Manual therapy|Participants will received a manual therapy protocol consisting of the following techniques: manipulation of the occipito-atlanto-axial joint (C0-C1-C2), suboccipital inhibition technique, manipulation of the thoracolumbar hinge (T12-L1), global manipulation of the bilateral pelvis, global abdominal hemodynamic technique, functional technique of the pelvic diaphragm and stretching of the lumbopelvic musculature.
75941287|NCT05418751|Other|Placebo treatment|Participants will receive light contact on the same points and for the same amount of time as the experimental group, with no intention to treat.
75941288|NCT05390905|Drug|HSK21542 Injection|1μg/kg/dose
75941289|NCT05390905|Drug|Tramadol hydrochloride|50mg/dose
75941290|NCT05390905|Drug|placebo|placebo
75941291|NCT05379348|Other|Cognitive Assessment|Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.
75941292|NCT05367505|Device|iFuse-3D implant|The iFuse Implant System consists of cannulated triangular titanium implants (Ti 6AI4V ELI, ASTM F136) with a porous coating of commercially pure titanium plasma spray (C.P. Ti, ASTM F1580) and a setting instrument. The coating and special shape of the implants prevent rotation or displacement of the sacroiliac (SI) joint. The placement instrument uses guide pins to achieve precise placement.
75655267|NCT02826018|Drug|ALN-HBV|Ascending doses of ALN-HBV by subcutaneous (sc) injection
75941293|NCT05367115|Other|longitudinal observational study|longitudinal observational study
75941294|NCT05366621|Drug|Anti-osteoporosis medications|Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
75941295|NCT05362227|Drug|Low volume macrogol|Clensia 2 lt
75941296|NCT05362227|Drug|High volume macrogol|Selg 4 lt
75655268|NCT02826018|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
75655269|NCT00832273|Device|ELAD®|liver assist system
75941297|NCT05359146|Drug|161Tb-DOTA-LM3|"161Tb-DOTA-LM3 is a therapeutic medicinal product with three main components, namely (a) Terbium-161 (161Tb), a beta minus-, gamma- and Auger-/conversion electron-emitting radionuclide with a half-life of 6.96 days; (b) DOTA, a chelator that allows stable complexation of 161Tb; and (c) LM3, an antagonistic SST analogue which binds to SST2 receptors (SST2 receptor antagonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
75941298|NCT05359146|Drug|177Lu-DOTATOC|"177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a half-life of 6.65 days; (b) DOTA, a chemical chelator that allows stable complexation of 177Lu; and (c) TOC (= [Tyr]3-octreotide) an agonistic somatostatin analogue which binds to SST2 and much less to SST5 receptors (SST2 receptor agonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
75941299|NCT05344599|Diagnostic Test|Autonomic Function Testing|Autonomic function test (orthostatic blood pressure and heart rate response to tilt, heart rate response to deep breathing, the Valsalva ratio, and beat-to-beat blood pressure measurements during phases II and IV of the Valsalva maneuver, tilt, and deep breathing). These combined tests provide a measurement of adrenergic, cardiovagal responses.
75941300|NCT05344599|Diagnostic Test|Genetic Testing|Genetic testing: for Acute hepatic porphyria panel - with intent to use Saliva kit
75941301|NCT05344599|Diagnostic Test|Urine Testing|Urine PBG, ALA and porphyrins in a spot urine sample with results normalized to urine creatinine
75941302|NCT05344599|Diagnostic Test|Blood laboratory Testing|"To determine the following laboratory analyses:~CBC, CMP, Iron studies (Ferritin and iron studies)"
75941303|NCT05340166|Procedure|Genicular nerve radiofrequency neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
75941304|NCT05340166|Procedure|Genicular nerve chemical neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
75941305|NCT05335252|Drug|Dronabinol|5mg 2x daily for 7 days
75655270|NCT02839616|Procedure|orthotopic liver transplantation|
75655271|NCT02826174|Procedure|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
75655272|NCT02826174|Procedure|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
75655273|NCT02826174|Drug|Anti-Rejection Agents|Anti-Rejection Agents for both groups
75655274|NCT02826174|Drug|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
75655275|NCT02839460|Procedure|Outpatient Muscle Biopsy|Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
75655276|NCT00621517|Drug|Bupropion|Partipants will receive 150 mg bupropion per night
75655277|NCT00621517|Drug|Placebo|1 capsule nightly for six weeks
75941306|NCT05335252|Drug|Placebo|1 caplet 2x daily for 7 days
75655278|NCT02827266|Drug|Epoetin beta|Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
75655279|NCT02839226|Drug|AR/101|
75344505|NCT03819478|Behavioral|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
75941307|NCT05331846|Behavioral|the smell of breast milk|Smell of breast milk during endotracheal aspiration will reduce pain and stress
75941308|NCT05325775|Drug|ACER-801 50 mg BID|50 mg BID (twice daily)
75655280|NCT02839226|Drug|Placebo|
75476509|NCT05967923|Other|Routine physical therapy program|Patients in this group will receive only routine physical therapy program three times a week for four weeks.
75344506|NCT03819478|Dietary Supplement|NutraBio™ CarboMax Supplement|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (NutraBio™ CarboMax, ~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
75941309|NCT05325775|Drug|ACER-801 100 mg BID|100 mg BID (twice daily)
75941310|NCT05325775|Drug|ACER-801 200 mg BID|200 mg BID (twice daily)
75655281|NCT00845221|Drug|Imatinib mesylate 100 mg (Glivec)|260 mg/m2/day tablets
75344507|NCT03819478|Dietary Supplement|6-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 6-month higher protein / lower CHO diet group (6-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, ~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
75476510|NCT05967897|Dietary Supplement|Blueberries|22 g freeze-dried blueberry powder mixed with water
75476511|NCT05967897|Dietary Supplement|Blueberries and Whey Protein|22 g freeze-dried blueberry powder mixed with whey protein and water
75655282|NCT02950844|Other|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
75941311|NCT05325775|Drug|Placebo|Placebo
75476512|NCT05967897|Dietary Supplement|Blueberries and Pea Protein|22 g freeze-dried blueberry powder mixed with pea protein and water
75476513|NCT05967897|Dietary Supplement|Blueberries and Hemp Protein|22 g freeze-dried blueberry powder mixed with hemp protein and water
75655283|NCT00832351|Procedure|Mobilisation|Mobilisation
75941312|NCT05324033|Radiation|multiparametric MRI on the bladder|comparison between mpMRI and histopathology
75941313|NCT05324033|Procedure|diagnostic cystoscopy +/- TURBT|conventional way of diagnosis
75941314|NCT05319028|Drug|Mivavotinib|oral tablet
75941315|NCT05310045|Behavioral|Personalised primary prevention intervention|"Personalised primary prevention intervention~Consultation 1~Assess caregiver's situation regarding their cancer risk factors~Explain the causal links between risk factors and cancer~Inform about national recommendations to prevent and limit cancer risk~Clarify informal caregiver situation with respect to national screening programs~Define a personalised primary prevention program~Implementation: personalised primary prevention program~Carried out by the informal caregiver~Supervised by the coordinating nurse~Consultation 2~Assess prevention actions realised by informal caregiver in relation to actions defined in the personalised primary prevention program~Identify barriers and facilitators to their implementation whether actions or no actions have been done.~Adapt the personalised primary prevention program to informal caregiver needs."
75941316|NCT05308381|Behavioral|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
75941317|NCT05308381|Behavioral|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
75941318|NCT05308381|Behavioral|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
75941319|NCT05287997|Diagnostic Test|Neurolytixs Index|Capillary blood sample will be collected on a dried plasma sample (DPS) filter paper. The sample will be sent to a central laboratory where they will undergo metabolite extraction and analysis via mass spectrometry.
75941320|NCT05284084|Other|Bed Head elevation, H2 blockers and mouth wash|Elevation of the bed head to 15, 30 and 45 degrees, daily H2 blockers administration and mouth wash BID.
75941321|NCT05284084|Other|Data collection for comparison|Data collection for comparison
75941322|NCT05275673|Drug|sapanisertib|capsules for oral administration
75941323|NCT05271760|Procedure|Single-shot spinal analgesia|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml
75941324|NCT05271760|Procedure|Continuous epidural analgesia|Epidural analgesia is performed using a 16-gauge Tuohy epidural needle using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid a test dose of 3 ml lidocaine 1.5% with epinephrine 1:200000 will be given via inserted catheter, 10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse in a rate of 6 -14 ml/h.
75941325|NCT05271760|Procedure|Combined spinal-epidural analgesia|"Epidural analgesia is performed using a combined spinal-epidural set. using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance, once epidural space will be detected, 27 G Whitacre spinal needle inserted through Touhy epidural needle, intrathecal injection of 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml. Then an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid.~10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse at a rate of 6 -14 ml/h if needed."
75941326|NCT05269875|Other|ACP|The intervention covers a formal ACP discussion, including provision of a holistic approach (physical, psychological, spiritual, social) and includes symptom control and discussion on illness limitations and prognosis, goal assessment and goal adjustment, financial issue, (un)desirable treatments for current and future care, hopes and wishes, and possibility of involvement of a palliative care team.
75941327|NCT05263401|Dietary Supplement|3-hydroxybutyrate|Orally administered pre-meal drinks.
75941328|NCT05257109|Other|Water Concentration 1|E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.
75655284|NCT02838056|Drug|epidural injection|drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
75476514|NCT05967884|Drug|Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab|Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery
75655285|NCT04243200|Other|Hypos can strike twice|"The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover."
75655286|NCT02546401|Drug|Insulin Aspart|Injection of Insulin Aspart before or after meals
75655287|NCT02843516|Other|No intervention|No intervention
75941329|NCT05257109|Other|Water Concentration 2|E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.
75655288|NCT02547181|Behavioral|Behavioral Modification|Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
75655289|NCT02547181|Behavioral|Splint|fibreglass splint
75655290|NCT02826876|Drug|Topical use|Topical use of Ropivacaine in laparoscopic surgery
75655291|NCT02826876|Other|laparoscopic repair of inguinal hernia|intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia
75941330|NCT05257109|Other|Water Concentration 3|E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.
75941331|NCT05257109|Other|Water Concentration 4|E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.
75941332|NCT05251571|Other|Conventional Exercise Group with Telerehabilitation|Exercises such as conventional muscle strengthening and stretching given with telerehabilitation are applied.
75941333|NCT05251571|Other|Balance Coordination Group with Telerehabilitation|Functional muscle strengthening, stretching, balance and coordination exercises given with telerehabilitation are applied.
75941334|NCT05248295|Behavioral|Unison speech (vs. solo)|Participants will repeat sentences in four conditions, in a 2x2 design with the factors unison vs. solo repetition, and metrical vs. conversational speech timing. Measures of speech accuracy and timing will be collected.
75941335|NCT05238532|Genetic|CT303|"Once a time, intravenous injection~CT303 Starting Dose : 1.0*10^6 cells/kg~CT303 Increasing Quantity Dose : 2.0*10^6 cells/kg"
75941336|NCT05226351|Drug|Dronabinol 2.5 mg|single administration of 2.5mg Dronabinol oral (oily solution)
75941337|NCT05226351|Drug|Placebo|single administration of placebo oral (oily solution)
75655292|NCT02826876|Other|laparoscopic bariatric surgery|intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
75655293|NCT02839304|Device|Cryoablation System|Pulmonary Vein Isolation, Posterior Wall Isolation. May Include Mitral Line ablation, AF Driver ablation, and Cavo-tricuspid Isthmus ablation as indicated
75655294|NCT04043533|Behavioral|Exercises|The women in the experimental group were given information about the benefits of exercises done in the postpartum period, the time to start these exercises, and the exercises to be conducted in three different phases (mild, medium, severe). The first physical exercise practice was done in the FHC together. In line with the recommendations by ACOG (2015), the women were told to do mild and medium level exercises in the first two weeks, at least five days in a week and at least half an hour daily (ACOG, 2015). They were also told that they should do medium and severe level exercises in the following two weeks. They were asked to mark on the form what time, how long, and at what level they did the exercises every day. The education booklet that included this information and the visuals of the exercises were given to the women in the experimental group. In addition, the women were called once a week in order to check whether the training was applied.
75941338|NCT05223556|Device|Full Self-Diagnostic device in a remote diagnostic imaging site|Full Self-Diagnostic CRP+OCT imaging, followed by online consultation
75941339|NCT05223556|Device|Human imager operated diagnostic device in the hospital|Human imager operated CRP imaging with dilated pupils, followed by face-to-face consultation
75941340|NCT05215548|Procedure|therapeutic thoracic surgery|The surgery group would receive therapeutic thoracic surgery with maximal local regional control intent and would prescribe with maintenance afatinib therapy after operation. Patients continue afatinib 1 to 2 weeks after surgery.
75941341|NCT05215548|Drug|Afatinib|The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).
75941342|NCT05209555|Diagnostic Test|MoCA|MoCA test to identify Mild Cognitive Impairment
75476515|NCT05967845|Procedure|cartilage tympanoplasty|cartilage tympanoplasty procedure entails repairing the tympanic membrane perforation by using a piece of cartilage harvested from the patient's auricle.
75941343|NCT05209555|Device|BAMCOG|Three games, compared to the MoCA to identify Mild Cognitive Impairment
75941344|NCT05209555|Diagnostic Test|DeltaScan|EEG to detect acute encephalopathy
75941345|NCT05209555|Diagnostic Test|Salivette|To collect saliva for cortisol analysis
75941346|NCT05209555|Diagnostic Test|Pilocarpine iontophoresis|To collect sweat for cortisol analysis
75941347|NCT05202145|Drug|ALXN2050|Oral tablet.
75941348|NCT05202145|Drug|Cyclosporine|Oral capsule.
75941349|NCT05202145|Drug|Tacrolimus|Oral capsule.
75941350|NCT05202145|Drug|MMF|Oral tablet.
75941351|NCT05172102|Other|breathing exercise, Aerobic exercises|6 min of quiet breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).
75941352|NCT05168722|Other|No interventions|No interventions
75941353|NCT05156073|Other|Educational Materials|"Patient care partner cohort:~a. mailing of an educational brochure introducing deprescribing to patients with mild cognitive impairment or dementia and/or MCC and MCC care partners.~Primary care physician cohort:~education on deprescribing through a 15-45-minute presentation~one-page weekly tip sheets on options for deprescribing in specific clinical situations and suggested language for deprescribing conversations."
75655295|NCT04244448|Drug|receive dissolved form of BIKTARVY®|The healthy volunteers will receive dissolved form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
75655296|NCT04244448|Drug|receive crushed form of BIKTARVY®|The healthy volunteers will receive crushed form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
75941354|NCT05152446|Other|Infusion management scheme|"To set up a pediatric intravenous infusion team;~To form standardized procedures by carrying out a quality improvement program in collecting and sending samples for inspection once suspected CLABSI occurs (1 month for training and 3 months for continuous improvement ); providing infusion training curriculums to nurses in forms of lectures, group discussions, operation demonstrations, and scenario simulations, holding practice review meeting with them; providing elements to caregivers of educational leaflet, nurse-provided education during patients' infusion therapy( 6-month implementation);~To observe the continued daily infusion practice in 6 months."
75941355|NCT05147922|Behavioral|Booster Training with the Neonatal Resuscitation Quality Improvement Cart|The cart will give providers audio-visual feedback and walk them through how to perform effective positive pressure ventilation with correct head positioning, appropriate Peak Inspiratory Pressure and Peak End Expiratory Pressure, no mask leak and ventilation rate of 40 per minute. Participants will be able to spend up to 30 minutes with the cart before undergoing their 1 minute assessment, which will be without feedback.
75941356|NCT05147831|Other|Remote Ischemic Preconditioning|Place blood pressure cuff around upper, non-dominant arm (e.g. upper left arm in a right-handed patient). Inflate blood pressure cuff to a pressure set at 50 mmHg higher than baseline systolic BP to induce ischemia of arm for 5 minutes. Completely deflate blood pressure cuff to allow for 5 minutes of reperfusion. Subjects would undergo 4 cycles of ischemia and reperfusion,
75941357|NCT05146284|Drug|PXL770|Tablet
75941358|NCT05144815|Other|Exercise protocol + IPC|"Exercise protocol: endurance training protocol consisting of walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks.~IPC: participants will be placed in a supine position and a pneumatic compression cuff (Riester Komprimeter, Jungingen Germany) (96 centimetres long x 13 centimetres wide) will be placed on the proximal part of each lower extremity. Occlusion will then be performed by inflating the cuff to 220 mmHg for 5 minutes, followed by reperfusion to 0 mmHg for 5 minutes. Each session will consist of 3 sets of 5 minutes of ischaemia followed by 5 minutes of reperfusion."
75941359|NCT05144815|Other|Exercise protocol + Sham IPC|Patients in this group (n=20) will undergo the same training as the previous group and with the same frequency and duration (i.e. 3 times a week, for 6 weeks), but the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.
75344508|NCT03819478|Dietary Supplement|18-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 18-month higher protein / lower CHO diet (18-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, ~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention and the 12-month follow-up.
75941360|NCT05142904|Device|Radiofrequency ablation|Ultrasound-guided radiofrequency ablation of the solitary autonomous thyroid nodule.
75344509|NCT03810417|Drug|Digoxin Antibodies Fab Fragments|Digoxin antibodies
75344510|NCT03810417|Other|Placebo|Saline
75344511|NCT03808818|Other|Behavioral, Psychological or Informational Intervention|Receive information about tobacco cessation
75655297|NCT04244448|Drug|receive solid form of BIKTARVY®|The healthy volunteers will receive solid form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
75655298|NCT02843594|Procedure|LEEP intervention|Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
75655299|NCT02843594|Procedure|Standard Phaco Control|
75476516|NCT05967845|Procedure|platelet rich fibrin augmented tympanoplasty|platelet rich fibrin augmented tympanoplasty entails performing the traditional tympanoplasty using the tempralis fascia as a grafting material. However, platelet rich fibrin clot is obtained from the patient's own blood, and applied to the graft to enhance healing process.
75344512|NCT03808818|Drug|Nicotine Replacement|Given NRT patch or lozenge (or both)
75344513|NCT03808818|Other|Quality-of-Life Assessment|Ancillary studies
75344514|NCT03808818|Other|Survey Administration|Ancillary studies
75344515|NCT03808818|Other|Tobacco Cessation Counseling|Receive virtual tobacco cessation counseling
75476517|NCT05967832|Other|7T MRI|Patients and healthy volunteers will have a 7T MRI
75476518|NCT05967793|Other|kinesio tape|Kinesio Tape will be applied on paraspinal trunk extensors muscles for 8 weeks, changed every 3 days.
75344516|NCT03797794|Device|Pulsating Electrostatic Field|A pulsating electrostatic field is generated by the New Health 9000 (Akern). During the session the patients sits on a chair which contains the apparatus for 30 minutes.
75476519|NCT05967767|Device|Normobaric Hypoxia Exposure|Hypoxia group were exposed to normobaric hypoxia equal to 3420 m (FiO2: 13.5-13.6 %).
75476520|NCT05967767|Device|Normobaric Normoxia Exposure|Placebo group were exposed to normobaric normoxia equal to 162 m (FiO2: 20.9 %) through wearing the altitude generator mask.
75476521|NCT05967754|Diagnostic Test|polysomnography|polysomnography and serum uric acid measurement
75941361|NCT05142904|Drug|Radioactive iodine|I-131 according to standardized doses-calculation.
75941362|NCT05142904|Drug|Radioactive iodine|I-131 according to local standard.
75941363|NCT05136248|Procedure|intraarticular injection|Ultrasound-guided intraarticular injection
76090527|NCT03029260|Other|Neural mobilization - gliding|"Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.~The intervention will be delivered in one session only."
75802380|NCT03796208|Behavioral|Treatment As Usual|Women enrolled in the control group are informed of the risks of tobacco use and benefits of quitting using the ACOG 5'A's approach by their healthcare provider. This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The five steps of the ACOG recommendation are: 1.) Ask about tobacco use, 2.) Advise to quit, 3.) Assess willingness to make a quit attempt, 4.) Assist in quit attempt, and 5.) Arrange follow-up. The provider may also talk to the participant about nicotine replacement therapy.
76090528|NCT01724489|Drug|Growth hormone|
76090529|NCT01724489|Drug|Placebo|
76090530|NCT01996293|Drug|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
75344517|NCT03797794|Device|SHAM Pulsating Electrostatic Field|The same apparatus which produces the pulsating electrostatic field contains a 'sham-inlet'. This inlet will be used as placebo.
75344518|NCT03780452|Device|novel dynamic compression intramedullary nail|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
75344519|NCT03761173|Device|FlowTriever System|Thrombectomy
75344520|NCT03761173|Drug|Anticoagulation Agents|Anticoagulation medication
75344521|NCT03750838|Behavioral|Text Messaging Intervention|The content for the text messaging Intervention will be designed to be non-confrontational in tone, seek to increase motivation to drink lightly or not at all, and based both on general information about light and non-drinking as well as information provided during the baseline assessment.
75802381|NCT05217160|Drug|KeraStat® Gel with Morphine application|"Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes."
75344523|NCT03742349|Biological|spartalizumab|LIVI (Liquid in vial) Concentrate for Solution for infusion
75344524|NCT03742349|Biological|LAG525|LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion
75476522|NCT05967728|Device|Remote ischemic conditioning (RIC) progammable device|RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.
75476523|NCT05967715|Behavioral|exercise training|high intensity interval training
75941364|NCT05136248|Procedure|peng block|Ultrasound-guided PENG block
75344525|NCT03742349|Drug|NIR178|Capsule
75344526|NCT03742349|Drug|capmatinib|Tablet
75344527|NCT03742349|Biological|MCS110|LIVI (Liquid in vial) Concentrate for Solution for infusion
75344528|NCT03742349|Biological|canakinumab|LIVI (Liquid in vial) Solution for injection
75941365|NCT05134038|Diagnostic Test|anthropomorphic measurements|anthropomorphic measurements + FES questionnaire + demographic data and medications
75476524|NCT05967715|Other|Probiotics|VSL#3# Probiotic
75476525|NCT05967715|Other|Placebo|Probiotic Placebo
75476526|NCT05967650|Biological|standard hepatitis B vaccine|IBD patients with negative HBV will be diveded in to two arms first arm vaccinated with standard HBV vaccine regemin( dose 0.2.6)
75476527|NCT05967650|Biological|accelerated HBV Vaccine|IBD patients with negative HBV will be diveded in to two arms second arm vaccinated with accelerated HBV vaccine regemin( dose 1.2.3)
75941366|NCT05115864|Device|PFMT with device|The wearable PFMT device (XFT-0010CK) is made by two parts. One part is the screen device which is able to show the real-time vaginal resting pressure and voluntary contraction pressure in units of mmHg. The other part is a vaginal air-filled probe. The two parts are combined with a thin air tube. The whole device is connected to a smartphone app by Bluetooth to record the progress of PFMT. There are two modes of the device, one is assessment mode, when it comes to the assessment mode that the device is able to assess the grade of type I and II pelvic floor muscle fiber strength by the patients themselves, the other mode is practice mode by displaying real-time visual pressure value according to the completeness of the PFMT program.
75941367|NCT05114564|Device|Lens A (comfilcon A lens)|1 month
75941368|NCT05114564|Device|Lens B (lehfilcon A lens)|1 month
75941369|NCT05105113|Procedure|Zirconia dental implant installation surgery|Dental implant installation surgery using zirconia one-piece implant (Tav-dental)
75941370|NCT05081414|Behavioral|Program for Teaching Self-Care in HF (PEAC-IC)|As described previously
75941371|NCT05062369|Device|TaskFlow Transcranial Electrical Stimulation device|The TaskFlow Transcranial Electrical Stimulation device (TaskFlow-TES) is a custom brain stimulation device developed in-house at the University of Minnesota. Each tDCS intervention will last 20 minutes of either (i) 10 active (2-mA) or (ii) 5 active and 5 sham transcranial direct current stimulation (tDCS) over the course of 10 treatment sessions.
76090531|NCT02986750|Device|Thealoz Duo Eye Drops|Manufacturer: Laboratoires Thea, France
76090532|NCT02986750|Device|Optive Eye Drops|Manufacturer: Allergan Pharmaceuticals, Ireland
76090533|NCT02986750|Device|Systane Ultra Eye Drops|Manufacturer: Alcon Pharma GmbH
76090534|NCT05304364|Combination Product|Combination Product: Naltrexone|Naltrexone Implant
76090535|NCT01992393|Behavioral|TIME|TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
76090536|NCT01724177|Drug|Lenalidomide|25 mg of Lenalidomide administered orally once daily
76090537|NCT02117817|Drug|BKM120|
75655300|NCT02843672|Procedure|Triple Weil´s Osteotomy|"A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture."
75655301|NCT02843672|Procedure|Distal metatarsal minimally invasive osteotomy|A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
76090538|NCT02117817|Drug|Nabpaclitaxel|Given IV
76090539|NCT05257798|Drug|IFN-β inhibitor treatment|PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
76090540|NCT05257798|Other|Placebo|Placebo for PF-06823859, 0 mg/mL solution for injection
76090541|NCT05693740|Procedure|Accelerated crosslinking (ACXL)|Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.
76090542|NCT05529784|Drug|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab 300mg in pre-filled injector Q2W
76090543|NCT05256706|Diagnostic Test|SomaSignal Informed Medical Management SSCVD|For participants randomized to the Informed arm, the SSCVD test results will be provided to the participant's clinicians approximately 2-4 weeks after the baseline blood draw. Clinicians will discuss results with the participant and make adjustments to the care plan as needed based on the SSCVD test results within 50 days of receiving results. Clinicians may advise participants to (i) either change the doses of existing medications within existing guidelines, (ii) prescribe additional guideline-based medications, (iii) advise additional lifestyle interventions, or (iv) advise no change. This information will be documented in the case report forms. This test is neither intended to diagnose cardiovascular disease (CVD) nor replace the standard of care protocols for this disease. The physician should not rely solely on this information to make a decision on the best course of action for this patient.
75344529|NCT03734705|Behavioral|Imaginal Exposure Writing|Imaginal exposure is a psychotherapy strategy that has been studied and shown to be helpful in the improvement of symptoms (e.g., anxiety, worry) for other psychiatric conditions, including excessive worry and obsessive-compulsive disorder symptoms.
75802382|NCT05217160|Drug|KeraStat® Gel application|"Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes."
75802383|NCT03739346|Behavioral|Hypnosis|Therapeutic technique in which clinicians make suggestions to individuals who have undergone a procedure designed to relax them and focus their minds.
75941372|NCT05062369|Behavioral|Executive Function Focused Cognitive Training|Working memory focused training occurs on a computer and consists of a variety of exercises selected to (i) place demands on the executive and storage functions of working memory (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across verbal, visual and spatial modalities. Training tasks are developed in-house. Tasks for each participant are delivered from and responses, audio, and video are stored on the HST server. The aim of using multiple tasks that require executive functions is to engage brain network functional connectivity in a number of different ways to promote generalization. Investigators will monitor each participant's training and customize the intervention to balance challenge and engagement. In addition, pre- and post-intervention, participants will perform 4-minute versions of a word and a spatial 3-back task identical across all weeks (but differing from the assessment versions).
75941373|NCT05057377|Diagnostic Test|Standard Overground Assessment|The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).
75941374|NCT05057377|Diagnostic Test|Robotic Safety-Environment Assessment|The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
75941375|NCT05048758|Other|No intervention|No intervention
75941376|NCT05042648|Drug|Buprenorphine patch|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest. The skin should be dry, clean, non irritated, non hairy (hair should be trimmed with scissors, not shaved), and without large scars.
75344530|NCT03734705|Other|Neutral Writing|Used in prior research as a control condition for imaginal exposure. Neutral writing will involve writing about what one would do on a day off work or school.
75344531|NCT03733314|Drug|E6011|E6011, infusion, intravenously.
75344532|NCT03733314|Drug|Placebo|Placebo, infusion, intravenously.
75344533|NCT03728985|Device|GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis|Endovascular Aortic Stent-Graft
75941377|NCT05038865|Other|Malocclusion and Orthodontic Treatment|"Group 1 is exposed to malocclusion and orthodontic treatment. However, the inclusion in the study does not affect the treatment since it is an observational study.~The exposure of group 2 is no malocclusion, no orthodontic treatment."
75941378|NCT05036395|Other|The routine assessment protocol and AI-assisted cEEG Diagnostic tool|The AI-assisted cEEG diagnostic tool is an automated seizure reporting system, including a quantitively EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction. The tool can report electrographic seizures in real time during cEEG monitoring. The neonatologists will evaluate the neonates by AI-assisted cEEG diagnostic tool, clinical conditions, real-time cEEG and amplitude-integrated EEG traces. The investigators will make a decision after review the neonates clinical conditions, AI-assisted cEEG diagnostic report, the cEEG and amplitude-integrated EEG.
75941379|NCT05036395|Other|The routine assessment protocol|The routine assessment protocol is that the neonatologists will evaluate the neonates by clinical conditions, real-time cEEG and amplitude-integrated EEG traces.
75941380|NCT05036317|Drug|Empagliflozin (Jardiance®;|Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
75941381|NCT05036317|Other|Placebo Control Intervention|Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.
75941382|NCT05034874|Drug|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
75941383|NCT05034874|Other|Placebo|Saline
75941384|NCT05026476|Dietary Supplement|Resource Thicken up Junior|Each infant and child will be switch over to receive for a period of 7 days (new thickener)
75941385|NCT04990388|Biological|UX053|mRNA-based biologic
75941386|NCT04990388|Other|Placebo|consists of the same components as the formulation buffer for UX053
75941387|NCT04990388|Drug|Antipyretic|participants will receive oral premedication prior to infusion
76090544|NCT05256706|Other|Standard of Care|Clinicians will provide the standard of care based on routine test results and without the SSCVD results. The SSCVD and SomaSignal Metabolic Factor Panel results from participants from both the baseline and 6-month period will be provided to the study team at the 6-month study visit. The SomaSignal Metabolic Factor tests include evaluation of Liver Fat, Glucose Tolerance, Kidney Function, Alcohol Impact, Cardiorespiratory Fitness/oxygen consumption (VO2) max, Resting Energy Rate, Body Fat Percentage, Visceral Fat, and Lean Body Mass. Any recommendations made to the participant by the physicians, based on obtaining the aforementioned test results will be collected.
76090545|NCT04416412|Other|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
76090546|NCT04415866|Behavioral|Paced Auditory Serial Addition task (PASAT)|Single and double digits are presented at intervals between 2 and 3 seconds and the participant must add each new digit to the one immediately prior to it. The participants will be asked to indicate by electronic button press whether the sum of the addition is 13 or not. The duration of the PASAT will be two 12-min tasks.
76090547|NCT04349488|Device|Anodal Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
75476528|NCT05967611|Diagnostic Test|Trendelenburg hip abduction test|The Trendelenburg test performed at different hip flexion, extension, adduction and abduction angles.
75802384|NCT03739346|Behavioral|Tell, show, do technique|The technique involves verbal explanations of procedures in phrases appropriate to the developmental level of the patient (tell); demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do). Tell-show-do technique is used with communication skills (verbal and nonverbal) and positive reinforcement.
75802385|NCT03668600|Drug|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
75655302|NCT04242966|Other|Usual Care|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
75802386|NCT05103982|Behavioral|Coping with Infertility Program|6 10-minute videos with assigned homework
75802387|NCT04073186|Device|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
75344536|NCT03703492|Drug|(18F)FES|"18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: [18F]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors"
75344537|NCT03703492|Drug|Gadobenate dimeglumine|Gadolinium-based intravenous contrast agent used for the MRI portion of this study
75655303|NCT04242966|Other|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
75802388|NCT03737396|Procedure|Self-administered electronic health screening|Health assessment using an electronic device
75802389|NCT05052970|Drug|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
75802390|NCT05052970|Drug|Bortezomib for Injection|Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
75941388|NCT04990388|Drug|H2 Blocker|participants will receive oral premedication prior to infusion
75941389|NCT04990388|Drug|H1 Blocker|participants will receive oral premedication prior to infusion
76090548|NCT02076867|Behavioral|Intensive Short-Term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
75655304|NCT04242966|Other|Ultrasound measure|Patients will undergo the ultrasound measures at baseline (within 24 hours of randomization, day 10 days post randomization (if still in hospital) and just prior to hospital discharge. In the event that hospital discharge is prior to day 10, the day 10 measure will not be done.
75655305|NCT00832663|Drug|NSAID|Effect of NSAID ingestion on muscle regeneration
75655306|NCT00832663|Drug|placebo|receive placebo
75655307|NCT05333900|Behavioral|Plant-Based Diet then animal-based diet|Participants started with plant based diet: high in fiber, low in animal products for 7 days, with 14 day washout period between interventions. Following that, participants were switched to animal-based diet: high in animal products, low in fiber for 7 days.
75655308|NCT05333900|Behavioral|Animal-based diet then plant-based diet|Participants were started with animal-based diet: high in animal products, low in fiber for 7 days, with 14 days washout period between interventions. Following that, participants were switched to plant-based diet: high in fiber, low in animal products for 7 days
75344538|NCT03692052|Drug|AG-348|AG-348 tablet orally BID
75344539|NCT03683251|Drug|PDS Implant with Ranibizumab 100 mg/mL|Will be administered as per the schedule described in individual arm
75344540|NCT03680872|Device|Bidirectional Neural Bypass System|These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
75344541|NCT03672292|Drug|SCY-078|Oral tablets of SCY-078
75476529|NCT05967559|Other|Online Flipped Learning Group|The experimental group is the group that receives online flipped learning training.
75655309|NCT04250324|Biological|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
75802391|NCT05052970|Drug|Dexamethasone Acetate Tablets|Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
75802392|NCT04903210|Dietary Supplement|Nicotinamide mononucleotide supplied as 400mg capsule|NMN10000 WRIGHT LIFE® + lifestyle modification NMN10000 WRIGHT LIFE®: 800mg, qd, for two months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
75655310|NCT00839293|Drug|ABT-335|Once, see arm description for more information
75802393|NCT04903210|Behavioral|Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
75802394|NCT04879810|Procedure|Sigmoidoscopy and biopsy, blood work|Flexible tube up lower colon, blood draws, quality of life questionnaires
75802395|NCT04719208|Other|Water (E) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
75802396|NCT04719208|Other|Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
75941390|NCT04964206|Procedure|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed according to the routine practice of each study center.
75941391|NCT04964206|Procedure|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
75655311|NCT04201730|Procedure|Enhanced Recovery After Surgery （ERAS）|Preoperative education，Preoperative nutritional support，Preoperative bowel preparation，Preventative applying of antibiotics，Intraoperative warming，Goal-directed fluid therapy，Postoperative analgesia，Postoperative diet, drainage and activity management，Prevention of deep vein thrombosis.
75802397|NCT04719208|Other|Hydrogen peroxide (B) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
75802398|NCT04719208|Other|Betadine (C) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
75802399|NCT04719208|Other|Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
75941392|NCT04958200|Behavioral|mhealth-pc for alcohol and pain|Smartphone-based intervention that includes in-person initial session and 8 video lessons, daily activities, and weekly check-ins.
75941393|NCT04958200|Behavioral|Treatment As Usual|psychoeducation on pain and alcohol use and treatment resource information
75941394|NCT04909541|Other|CEGSSS-Canadian Endourology Group Stent Symptom Score|Patient with ureteral stent complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
75344542|NCT03672292|Drug|Voriconazole|Voriconazole IV vials or oral tablets
75344543|NCT03672292|Other|Oral Placebo Tablets|Oral Placebo Tablets matching SCY-078
75344544|NCT03651076|Device|Traxi panniculus retraction (Clinical Innovations, LLC)|class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
75344545|NCT03604198|Drug|relacorilant|CORT125134 is supplied as capsules for oral dosing.
75941395|NCT04908241|Other|TRAIL|"Each week has a specific focus for lower extremity rehabilitation:~Week 1) Building a base: 8 exercises, 10-15 repetitions x 2-3 sets~Week 2) Increasing repetitions: 8 exercises, 15-20 repetitions x 3 sets~Week 3) Building exercise tolerance:10 exercises, 15-20 repetitions x 3 sets~Week 4) Maximizing repetitions: 10 exercises, 30 seconds as many reps as possible x 2 sets~At the end of the second exercise session each week, the therapist and participants work collaboratively to develop an independent exercise action plan to be completed before the first session of the next week. The self-managed plans includes exercises selected from TRAIL, agreed upon by the participant and therapist, that are safe to perform without therapist oversight. The aims of the exercise action plan are to: i) Add exercise volume without using program resources (e.g., therapist time); and ii) Build capacity for self-management for long-term health and well-being after TRAIL has ended."
75941396|NCT04908241|Other|EDUCATION|"EDUCATION has a specific focus on:~Week 1) What is stroke (e.g., gaining an understanding of the function of the brain, types of stroke and how stroke affects physical function) and introduction to self-management;~Week 2) What is self-management;~Week 3) Self-management for post-stroke complications (e.g., activities of daily living);~Week 4) Self-management for secondary prevention (e.g., blood pressure, diet, medication, stress management).~Education therapists will be provided with lesson plans and manuals to be circulated with the participants, and will facilitate the educational session through interactive Powerpoint presentations. In addition, participants will be asked to complete 30-60 minutes of educational homework, which will be discussed at the commencement of the following session."
75941397|NCT04906135|Other|Experimental manipulation of stimulation parameters|This translational mechanistic study involves changing stimulation parameters (i.e., experimental manipulation) for measuring the electrically evoked compound action potential in order to understand the pathophysiology of the auditory system in patients with Usher syndrome.
75655312|NCT00845377|Behavioral|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
75965987|NCT03048032|Procedure|Blood sampling|Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.
75344546|NCT03600103|Behavioral|Tech2Check|The intervention uses behaviors to improve HIV adherence and self-care. Investigators will use the Center for Disease Control (CDC) Partnership for Health (PfH) Medication Adherence.The CHN will administer PfH at all home/venue-based encounters, using communication styles that are more receptive to adolescents and young adults. Resources will be provided. At the end of the session, the participant will be able to state/demonstrate: goals of HIV care and adherence, meaning of CD4 and Viral Load (VL) measurements and the significance of their own measurements,signs of complications or problems for which participants need to seek additional care,understanding of optimal self-care.Further, CHNs will also provide tips to stay on schedule with taking their ART and problem-solve adherence barriers.
75476530|NCT05967559|Other|Traditional learning Group|The control group is the group that received traditional learning training.
75655313|NCT04582214|Device|MetaNeb® System|The intervention device use in this study is The MetaNeb® System (Hill-Rom; St. Paul, MN). It is an FDA 510k cleared device (k124032), powered by compressed gas, that delivers oscillation and lung expansion (OLE) therapy using both continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP). The device also provides supplemental oxygen when used with compressed oxygen and can deliver aerosol therapy during CPEP and/or CHFO. The therapy is indicated for mobilization of secretions, lung expansion therapy and the treatment and prevention of pulmonary atelectasis. The device also provides supplemental oxygen when used with compressed oxygen.
75476531|NCT05967546|Other|Observational|No interventions will be given to patients.
75655314|NCT02826720|Other|No intervention was applied|No intervention was applied
75655315|NCT00839371|Drug|Propofol|i.v. propofol titration until adequate depth of sedation
75802400|NCT04701190|Drug|Noradrenalin 10 microgram bolus|The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
76090549|NCT02076867|Behavioral|Medical Care As Usual (MCAU)|This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
75476532|NCT05967533|Drug|Fermented Wheat Germ Extract|Given PO
75655316|NCT00839371|Drug|Midazolam|i.v. midazolam titration until adequate depth of sedation
75802401|NCT04701190|Drug|Noradrenaline 5 microgram bolus|The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
75802402|NCT04701190|Drug|Noradrenaline 0.1 microgram/kg/minute infusion|"Infusion dosage: 0.1 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
75476533|NCT05967442|Drug|Magnesium Sulfate|Magnesium Sulfate 2gm in 50ml D5W over 20 minutes
75476534|NCT05967442|Drug|Metoclopramide 10mg|Metoclopramide 10mg in 50ml D5W over 20 minutes
75476535|NCT05967442|Drug|Prochlorperazine (Compazine) Injection|Prochlorperazine 10mg in 50ml D5W over 20 minutes
75655317|NCT02837822|Device|Spinal cord stimulator|Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.
75655318|NCT02837822|Procedure|Implantation of a spinal cord stimulator|The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
75655319|NCT02826408|Drug|Rabeprazole sodium|WIll study effect of the medication on palpittions
75655320|NCT02826408|Drug|Pacebo|Placebo comparison to active treatment
76090550|NCT04406740|Device|TwitchView EMG Unit|The TwitchView device is a new generation electromyographic monitor that uses a disposable electrode array that combines stimulating and recording electrodes.
75655321|NCT00633230|Drug|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
75655322|NCT00633230|Other|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
75655323|NCT04242888|Other|pragmatic manual therapies|three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.
75655324|NCT04250870|Diagnostic Test|Senior Fitness Test|"Chair stand test:The number of full stands performed on a seated position that can be completed within 30 seconds was recorded.~Arm curl test: The participants were asked to lift weights starting with a full elbow extension and then full flexion.~2-minute step test: The participant was asked to begin stepping as quickly as possible to reach the marked height for two minutes.~Chair sit-and-reach test:The participant could extend right or left knee to a full extension, heel on the floor and ankle in a neutral position of 90 degrees. Then, the participant was asked to reach to the toes.~Back-scratch test:The participant was asked to stand up and place his/her preferred hand over the same shoulder, palm down and fingers extended, and reach down the middle of the back as far as possible.~8-foot up and go test:The participant was asked to get up from a chair without any arm support and walk a distance of 2.44 meters; then turn around a cone and come back to sit down on the chair."
75655325|NCT02839382|Other|Coaching|An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
75655326|NCT02839382|Other|Educational Outreach|Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting
75655327|NCT02839382|Other|Site Visits|"Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities."
75802403|NCT04701190|Drug|Noradrenaline 0.05 microgram/kg/minute infusion|"Infusion dosage: 0.05 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
75802404|NCT04701190|Drug|Infusion dosage: 0.075 microgram/kg/minute infusion|"nfusion dosage: 0.075 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
75802405|NCT04701190|Procedure|Spinal anesthesia|Spinal anesthesia using 0.5% 10 milligram heavy bupivacaine plus 12.5 microgram fentanyl
75802406|NCT04629664|Drug|FX-322|Active Comparator
75941398|NCT04896866|Behavioral|Antimicrobial stewardship prospective audit and feedback|Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.
76090551|NCT04406740|Device|Novel QTOF Device|The QTOF consists of an electrical stimulator that is just like the stimulator in the traditional TOF devices that are commonly used (both accelerometric and EMG-based), combined with a novel sensor that sticks to the belly of the muscle being measured (most commonly the adductor pollicis, the thumb muscle in the palm of the hand).
76090552|NCT01894659|Other|24% oral sucrose|
76090553|NCT01894659|Other|30% oral glucose|
76090554|NCT04404712|Drug|[11C]MK-3168|One PET scan involving administration of PET ligand [11C]MK-3168
76090555|NCT04349800|Drug|KVD900|Active
76090556|NCT04349800|Drug|Placebo to KVD900|Placebo
76090557|NCT05238688|Procedure|Thoracic Epidural Analgesia (TEA) group|Under full aseptic conditions while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine an 18-G Tuohy needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal . After negative response, 15 ml of 0.25% epidural bupivacine will be injected and the patient will be turned to the supine position.
75655328|NCT00573937|Drug|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
75655329|NCT00573937|Drug|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
75655330|NCT02825862|Behavioral|Question-behaviour effect (for affective attitudes)|Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).
75802407|NCT04629664|Other|Placebo|Placebo
75941399|NCT04882592|Device|SCiP|Noninvasive spinal cord neuromodulator
75941400|NCT04871269|Drug|Dronabinol|Dronabinol
75941401|NCT04871269|Drug|Placebo|Placebo
75941402|NCT04837131|Drug|Ixazomib|Ixazomib 4 mg capsule taken orally on days 1, 8, and 15 of a 28-day treatment cycle repeated for 6 cycles
75941403|NCT04821570|Biological|COVID-19 Vaccine|Per recommended dosing schedule
75655331|NCT02825862|Behavioral|Question-behaviour effect (negatively-worded attitudes)|Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
75802408|NCT04496362|Drug|subcutaneous heparin anticoagulation|The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
76090558|NCT05238688|Procedure|Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group|Thoracic Epidural Analgesia will be done at first. Then, the ultrasound probe will be placed longitudinally 2-3 cm lateral to the T2 spinous process in the sagittal line. The T2 spinous process will be identified by counting down anatomically from the vertebral prominens (C7), and the T2 transverse process will be visualized by counting down from the first rib via real-time ultrasound guidance. The erector spinae muscle will be visualized above the T2 transverse process. The needle will be inserted in a caudal cranial direction using the in-plane technique. A dose of 5 mL normal saline will be injected into the inter-fascial area between the erector spinae muscle and the transverse process for the correction of the injection site (hydro-dissection). After hydro-dissection, 15 mL of 0.25% bupivacaine will be injected here, and the linear spread of the solution will be visualized in the inter-fascial plane.
76090559|NCT01962753|Drug|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
76090560|NCT01530009|Drug|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
76090561|NCT01530009|Other|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
75802409|NCT04429126|Behavioral|Acupressure|Two types acupressure interventions, 5-point and 2-point acupressure groups, will be conducted in the current study.
75802410|NCT04423588|Diagnostic Test|dexlansoprazole serum concentration|6 blood samples are collected at fixed time Points after oral Administration of 1 dose of dexilant at regular patients visits preoperatively and 3 and 6 months post-surgery.
76090562|NCT04919590|Behavioral|This is Quitting|Text message-based intervention for quit vaping support.
75655332|NCT00845533|Drug|Dihydroartemisinin-Piperaquine|
75655333|NCT00839449|Drug|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
75655334|NCT04958538|Drug|Methotrexate|Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
75655335|NCT02825472|Behavioral|exercise training|3 times per week 30 minutes of exercise training in the target heart rate zone
75655336|NCT02548195|Drug|oxaliplatin and gemcitabine|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.
75655337|NCT02548195|Drug|capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
75655338|NCT02827422|Other|not provided|
76090563|NCT04919590|Other|Assessment only control|Assessment only
75655339|NCT02546089|Other|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
75802411|NCT04423588|Diagnostic Test|upper endoscopy|6 and 12 months after surgery the occurrence of marginal ulcers in the same Patient Group is examined by upper endoscopy. The 12-month endoscopy is part of the Routine postoperative diagnosis, the 6-month endoscopy is for study purpose.
75802412|NCT03054064|Device|Indego Exoskeleton|Six study sessions including five Indego training sessions over two weeks.
75802413|NCT04314778|Behavioral|social incentive-based gamification|At the beginning of each week, starting from postoperative day 3, the participant receives 70 points (10 points for each day that week). If the participant does not meet their daily step goal, they lose 10 points from their balance. This leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. At the end of each week if the participant has at least 40 points, they will move up a level (levels from lowest to highest: blue, bronze, silver, gold, platinum). If not, the participant will drop a level. All participants begin at the silver level. Each week, participants get a fresh set of 70 points. Participants will receive daily feedback for the step counts, and weekly feedback for their levels. Participants in the intervention arm will be asked to identify a family member or friend to be their support sponsor. A weekly report will be sent to this person with the participant's performance (points and level).
75941404|NCT04807400|Drug|Inclisiran|Inclisiran 300 mg 3 monthly (Day 1 and Day 90)
75941405|NCT04807400|Behavioral|Behavioural Support|Regular telephone based behavioural support programme delivered throughout the study period.
75941406|NCT04788433|Diagnostic Test|glycomic analysis|Analysis of glycans on plasma samples
75941407|NCT04788433|Other|Phone interview|patients are followed up by phone up to 1 year
75941408|NCT04764214|Drug|3rd generation EGFR-TKI|Osimertinib will be administered orally at the dose of 80 mg once daily.
75941409|NCT04764214|Radiation|Consolidative SBRT|Patients who possess oligoresidual disease after 3rd generation EGFR-TKI therapy will be treated with the intent to ablate all residual disease with consolidative SBRT. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. TKI will be continued during and after consolidative SBRT until disease progression or intolerable toxicity.
75655340|NCT02546089|Other|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
75344551|NCT03578419|Device|Small-Volume Blood Collection Tubes|Small-volume vacuum (< 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
75344552|NCT03578419|Device|Standard-Volume Blood Collection Tubes|Standard-volume (≥ 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
75344553|NCT03568656|Drug|CCS1477|Capsules, oral
75344554|NCT03568656|Drug|Abiraterone acetate|Abiraterone acetate 500mg tablets plus prednisone/prednisolone
75344555|NCT03568656|Drug|Enzalutamide|Enzalutamide 40mg capsules/tablets
75655341|NCT02546089|Other|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
75655342|NCT04244292|Other|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
75655343|NCT00573859|Drug|ADHD medication|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
75655344|NCT00573859|Drug|Placebo|For the placebo condition, participants received placebo pills for two consecutive days.
75655345|NCT04243980|Device|Short anatomical femoral stem in THR|Patients with osteoarthritis after total hip arthroplasty
75802414|NCT04297852|Dietary Supplement|Vegan drink|Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day
75802415|NCT04297852|Dietary Supplement|Control|Placebo drink Dose: 500 mL a day
75802416|NCT03053518|Device|Abbott Freestyle Libre Pro|A professional, blinded, continuous glucose monitoring device will be inserted on the back of the upper arm to measure interstitial glucose every 5 min for 4 times / day.
75802417|NCT03053518|Behavioral|LifeStyle|Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.
75802418|NCT05659498|Behavioral|Cardiac Rehabilitation Program|The standard cardiac rehabilitation program consists of the following: a (1) consultation with a kinesiologist to assess level of fitness and to prepare an individually customized exercise plan, (2) consultation with a dietitian to guide the participant with healthy nutrition choices, (3) on site supervised and/or virtual exercise sessions with gradual elaboration of a home program, (4) weekly educational capsules and monthly workshops related to cardiac health, and, (5) if deemed necessary by the treating team, consultation with a psychologist, an occupational therapist, a physiotherapist, or a social worker.
75802419|NCT04090684|Drug|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
75941410|NCT04755101|Procedure|EPS, electro-anatomical mapping, ARGP ablation, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. Sequential ablations will be delivered along theTL until the procedure endpoint is reached. Pharmacological evaluation.
75344556|NCT03568656|Drug|Darolutamide|300mg tablets
75655346|NCT04244214|Other|More Stamina|More Stamina is a gamified task organization tool designed to help persons with MS manage their energy, to minimize the impact of fatigue in their day to day life.
75655347|NCT00832897|Procedure|Corneal collagen crosslinking|"The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop."
75655348|NCT04043065|Biological|Liver-enriched antimicrobial peptide 2|Infusion of LEAP-2 during a 180 min grated glucose infusion.
75655349|NCT04043065|Other|Placebo|Saline
75655350|NCT00839605|Drug|Dexmedetomidine|loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
75655351|NCT05660304|Device|Cortico-cortical paired associative stimulation|Two brain areas will be stimulated with transcranial magnetic stimulation pulses. The pulses will be delivered with a time difference, on other words, one pulse after another.
75655352|NCT05660304|Device|Sham cortico-cortical paired associative stimulation|Two brain areas will be stimulated with sham transcranial magnetic stimulation. The sham pulses will be delivered with a time difference, on other words, one pulse after another.
75655353|NCT04043611|Other|Conservative physical therapy management|Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I & II for pain, Grade III & IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold), Hamstring, Piriformis McKenzie Prone Extension Exercises
75802420|NCT04015336|Biological|E7 T-Cell Receptor (TCR)|The dose of E7 T-Cell Receptor (TCR) T cells will be 3 x 10^10 TCR+ T cells (unless fewer cells are generated) administered once.
75802421|NCT03970642|Other|Video directly observed therapy|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit. The app will automatically upload the video to a HIPAA compliant server. Research staff will regularly monitor videos using a password protected website and document each medication dose.
75802422|NCT05044078|Other|Autogenic Inhibition MET|If a sub-maximal contraction of the muscle is followed by stretching of the same muscle it is known as Autogenic Inhibition MET.
76090564|NCT04919590|Other|Waitlist control|No contact until follow-up survey, waitlisted to receive intervention post study
75344557|NCT03568656|Drug|Olaparib|150mg tablets
75344558|NCT03568656|Drug|Atezolizumab|840mg/14ml concentrate for solution for infusion vials
75344559|NCT03564821|Drug|Ivosidenib|Ivosidenib is an inhibitor of the protein IDH1
75476536|NCT05967429|Diagnostic Test|The neutrophil-to- lymphocyte ratio|It was calculated by dividing the neutrophil count by the lymphocyte count.
75941411|NCT04755101|Procedure|EPS, electro-anatomical mapping, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. No ablation is performed (sham). Pharmacological evaluation.
75941412|NCT04751916|Dietary Supplement|Essential Amino Acid Protein Supplement|Proprietary essential amino acid protein supplement
75941413|NCT04751916|Dietary Supplement|Beneprotein®|Whey protein supplement
75344560|NCT03554798|Biological|nOPV2 (monovalent oral polio vaccine)|"Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2."
75344561|NCT03549507|Drug|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
75344562|NCT03539536|Drug|Telisotuzumab vedotin|Intravenous (IV) infusion
75476537|NCT05967429|Diagnostic Test|Prognostic nutrition index|It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL
75802423|NCT05044078|Other|Reciprocal Inhibition MET|If a submaximal contraction of a muscle is followed by stretching of the opposite muscle then this is known as Reciprocal Inhibition MET.
75655354|NCT04043611|Other|ELDOA|ELDOA positions (hold for 1 minute,4 alternate days a week) under supervision during session Conservative physical therapy management Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I & II for pain, Grade III & IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold),Hamstring,Piriformis
75344563|NCT03517852|Device|Human Intravital Microscopy|Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
75344564|NCT03516942|Other|Quality-of-Life Assessment|Ancillary studies
75476538|NCT05967377|Drug|Sorafenib - Period 1|Sorafenib (Nexavar®) Tablet, 200 mg
75476539|NCT05967377|Drug|XS005 Sorafenib Capsule A - Period 1|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
75655355|NCT04242732|Diagnostic Test|CT scan of the knee under weight-bearing with the Cone Beam Computed Tomography (CBCT) scanner system.|The patient will be evaluated under weight-bearing, with knee flexed at 30 ° and therefore with contracted thigh muscles. The measurement and maintenance of the 30 ° of flexion will be controlled by a goniometer applied laterally to the knee and fixed by means of an elastic band.
75655356|NCT04242732|Diagnostic Test|Conventional CT scan|The patient will be evaluated in supine position, with the muscles relaxed and the knee in full extension by conventional CT scan
75802424|NCT03627442|Procedure|Mastectomy with PhotonBlade|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with PhotonBlade
75802425|NCT03627442|Procedure|Mastectomy with Bovie|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with Bovie
75802426|NCT04963816|Procedure|ultrasound guided quadratus lumborum block|Ultrasound guided quadratus lumborum block will be done to all groups using curved array transducer 5_2 MHz with the patient in supine position and the block will be done by anterior approach
75476540|NCT05967377|Drug|XS005 Sorafenib Tablet A - Period 1|XS005 Sorafenib Tablet A, 100 mg
75655357|NCT00839683|Drug|simvastatin|Tablets, Oral, 20 mg, Single Dose
75655358|NCT00839683|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
75655359|NCT00839683|Drug|simvastatin|Oral, 40 mg, Single Dose
75802427|NCT04963816|Drug|Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given intravenously in group A
75802428|NCT04963816|Drug|Bupivacaine Injection|Bupivacaine will be given to all groups locally with QLB
75802429|NCT04963816|Drug|Dexamethasone Phosphate 4 MG/ML Injectable Solution locally|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given locally in Group B
75802430|NCT04957732|Device|Standard of Care (SoC)|SoC consisted of irrigation with normal saline, using the same proprietary abscess irrigation tip as the Irrisept arm. SoC was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
75941414|NCT04748146|Other|Brain stimulation|Theta-burst stimulation will be applied to selected regions of distributed networks to test whether distal stimulation can modulate hippocampus-mediated episodic recollection.
75941415|NCT04745715|Procedure|craniectomy|craniectomy outcomes and survival
75941416|NCT04729075|Other|ARDS and COVID19 treatments|Interventions that will be analyzed will include: immunomodulation; oxygen supplementation type, duration and level; mechanical ventilation type, duration; diuresis; inotrope/vasopressors; prone positioning
75344565|NCT03516942|Other|Questionnaire Administration|Ancillary studies
75344566|NCT03515512|Drug|Enasidenib|Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells
75476541|NCT05967377|Drug|XS005 Sorafenib Capsule A - Period 2|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
75476542|NCT05967377|Drug|XS005 Sorafenib Tablet A - Period 2|XS005 Sorafenib Tablet A, 100 mg
75476543|NCT05967377|Drug|Sorafenib - Period 2|Sorafenib (Nexavar®) Tablet, 200 mg
75476544|NCT05967377|Drug|XS005 Sorafenib Tablet A - Period 3|XS005 Sorafenib Tablet A, 100 mg
75476545|NCT05967377|Drug|Sorafenib - Period 3|Sorafenib (Nexavar®) Tablet, 200 mg
75476546|NCT05967377|Drug|XS005 Sorafenib Capsule A - Period 3|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
75655360|NCT00839683|Drug|valsartan|Tablets, Oral, 320 mg, Single Dose
75655361|NCT04242420|Diagnostic Test|Genotyping|Genotyping for single nucleotide polymorphisms for Connexin 37&43, Mannose binding lectin (MBL) and transforming growth factor beta (TGF beta) genotypes
75941417|NCT04724460|Drug|Long DOAC|Administration of Rivaroxaban for 18 months
75941418|NCT04724460|Drug|Short DOAC|Administration of Rivaroxaban for 6 months
75655362|NCT04242420|Diagnostic Test|Lung function|Spirometry,
76090565|NCT01895595|Behavioral|Guided Imagery|
75941419|NCT04723069|Drug|Control Group|metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
75941420|NCT04723069|Drug|Test Group|metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
75941421|NCT04706416|Dietary Supplement|N-acetyl glucosamine (NAG)|Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
75344567|NCT03496571|Drug|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
75344568|NCT03496571|Other|Placebo|Placebo
75655363|NCT04242420|Diagnostic Test|Microbiology|Bacterial culture from Sputum or swab
75655364|NCT04242420|Diagnostic Test|Blood sample|Interleukin-8 assay (via chemiluminescence) blood cell count
75655365|NCT04242420|Diagnostic Test|Induced Sputum|Interleukin-8 assay (via chemiluminescence) blood cell count
75655366|NCT00833131|Radiation|Short course of radiotherapy|5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
75655367|NCT00833131|Radiation|Radiochemotherapy|28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
75655368|NCT02826330|Other|biomarkers|fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
75655369|NCT00839761|Dietary Supplement|iron fortified rice|
75655370|NCT00839761|Dietary Supplement|iron drops|
75655371|NCT02825706|Other|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
75655372|NCT00839839|Procedure|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
75802431|NCT04957732|Device|Irrisept Delivery System|Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression. The device had an option for use with an Irriprobe applicator or an abscess irrigation tip. Irrisept was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
75802432|NCT05639530|Biological|IBI333|Intravitreal injection of IBI333
75802433|NCT04933240|Drug|Tamoxifen Citrate 10Mg Tab|nonsteroidal antiestrogen for oral administration in 10 mg tablets. Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.
75941422|NCT04706416|Other|Control|Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.
75941423|NCT04701749|Device|Percutaneous left atrial closure|Percutaneous left atrial closure was performed under general anesthesia with angiographic control and transesophageal echocardiography. The procedure takes between 15 and 20 minutes. This begins with a right femoral venipuncture, progression of the guide in the right atrium allowing atrial trans-septal puncture to catheterize the left atrium. A nitinol prosthesis is implanted (Boston Watchman) at the ostium of the left auricle between the left superior pulmonary vein and the circumflex artery. After a tensile test verifying the stability of the prosthesis, the absence of peri-prosthetic leakage is verified by ETO and angiographic control. The patient is monitored 48 hours before discharge to eliminate the appearance of pericardial effusion and prosthetic embolization. Aspirin 75 mg monotherapy is started the same day with stopping anticoagulation.
75941424|NCT04701749|Other|No Percutaneous left atrial closure|No Percutaneous left atrial closure
76090566|NCT01895595|Behavioral|Digital Storytelling|
75655373|NCT02825394|Other|anti-Xa activity point-of-care testing (aXa-POCT)|
75655374|NCT02825394|Other|ecarin clotting time point-of-care testing (ECT-POCT)|
75655375|NCT00845611|Biological|peptide vaccine|peptides emulsified with Montanide ISA51
75655376|NCT00845689|Drug|placebo|NaCl 0,9 %
75655377|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0, 2 %
75655378|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0,2 %
75655379|NCT00845689|Procedure|Liver resection|Liver resection with Pringle maneuver
75802434|NCT04933240|Drug|Estradiol|estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.
75802435|NCT04933240|Drug|Placebo|A sugar tablet that does not contain any active medicine
76090567|NCT01894737|Other|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
76090568|NCT01894737|Other|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
76090569|NCT04915144|Drug|177Lu-DOTATOC|Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
76090570|NCT05229952|Dietary Supplement|Low-oxalate controlled diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
75941425|NCT04692922|Diagnostic Test|MRI|MRI will include structural sequences (e.g., T1 weighted imaging, T2 weighted imaging, T2 FLAIR, diffusion weighted imaging with apparent diffusion coefficient, susceptibility weighted imaging, and diffusion tensor imaging). Using the structural sequences we will make note of the types of brain lesions (e.g., ischemic stroke, hemorrhage, hypoxic-ischemic brain injury), and the locations of these brain lesions. MRI will also include fMRI under three conditions: while the patient is at rest (to evaluate resting state functional connectivity), while the patient is exposed to auditory stimuli (to evaluate passive fMRI responses to stimuli), and while the patient is asked to follow commands (to evaluate active fMRI responses to tasks).
75941426|NCT04692922|Diagnostic Test|EEG|The EEG will include resting, stimulus-based, and task-based assessments of brain function.
75941427|NCT04684563|Biological|huCART19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
75941428|NCT04683926|Drug|Desmetramadol|Analgesic
75941429|NCT04681170|Drug|Lomitapide|2mg,5mg, 10mg and 20mg capsules
75941430|NCT04670133|Dietary Supplement|Inulin|Supplementation with a prebiotic, specifically inulin.
75941431|NCT04670133|Dietary Supplement|Maltodextrin|Supplementation with maltodextrin (placebo)
75941432|NCT04667793|Drug|Toripalimab + Chemotherapy|"Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel"
76090571|NCT05229952|Other|Primed, continuous intravenous infusion of 13C2-oxalate|Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
75655380|NCT04196478|Device|doppler ultrasound|a 7.5 MHz ultrasound (US) linear probe is needed, grey-scale ultrasound and Color Doppler and a minimum display facility of the Doppler velocity spectrum for blood flow calculation are mandatory tools.
75802436|NCT04071158|Biological|RSV Vaccine|RSV vaccine
75802437|NCT04071158|Biological|Tdap|Tetanus, Diphtheria, and Acellular Pertussis Vaccine
75802438|NCT04071158|Biological|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
75344572|NCT03461354|Other|MucoLox|MucoLox formulation, with MucoLox as the delivery vehicle, combined with preserved water, beta-glucan, dexpanthenol, and glutamine
75655381|NCT00845767|Procedure|Forearm Vascular Study|"Forearm venous occlusion plethysmography during intraarterial infusion of L-NMMA (2-8 µmol/min) followed by co-infusion of sodium nitroprusside (90-900 ng/min) as a nitric oxide clamp. Forearm blood flow then measured during the clamp in response to infused vasodilators acetylcholine (5-20 mg/min), bradykinin (100-1000 pmol/min), verapamil (10-100 µg/min) and sodium nitroprusside (2-8 µg/min)."
75802439|NCT01317940|Dietary Supplement|Vitamin D and Calcium Citrate|"Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)~Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months"
75802440|NCT05706922|Other|Venous blood sample, vaginal swab|Venous blood samples and vaginal swab will be obtained on the same day.
75802441|NCT05706688|Procedure|Anesthetic technique (regional versus general)|Anesthetic technique (regional versus general)
75802442|NCT05706454|Drug|Ramatroban|"Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.~Subjects will be evaluated over a study period of approximately 365 days."
75802443|NCT05706454|Drug|Placebo|Matching placebo will be administered orally twice a day
75941433|NCT04653818|Drug|Velpatasvir/Sofosbuvir|sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.
75941434|NCT04640857|Device|Silk'n Toothwave|patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
75941435|NCT04629807|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)
75941436|NCT04629794|Procedure|Posterolateral Lumbar Fusion with Demineralized Bone Fibers|Posterolateral Lumbar Fusion with Demimeralized Bone Fibers
75941437|NCT04629794|Procedure|Posterolateral Lumbar Fusion with Bone Morphogenic Protein|Posterolateral Lumbar Fusion with Bone Morphogenic Protein
75941438|NCT04626076|Other|Comparative Observational Cohort Study|This is a comparative observational cohort study; therefore, no preventive interventions, visits or laboratory tests are mandated. Dosing and duration of potential prophylactic treatment is at the discretion of the institution and/or healthcare provider, in accordance with regular local practice. However, serology testing for SARS-CoV-2 antibodies will be offered to the first 50% of participating HCWs per country, at enrollment and at the last follow-up (i.e. at Week 12)
75941439|NCT04605302|Device|MCC/MCC-T|Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract
75941440|NCT04605302|Device|Standard gastroscopy|Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum
75941441|NCT04598841|Dietary Supplement|supplement nutritional supporting|Special medical formula for the purpose of formula food
75941442|NCT04581304|Device|Geistlich Bio-Oss® Collagen|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation.
75344573|NCT03461354|Other|Sodium Bicarbonate|Sodium bicarbonate oral rinse
75655382|NCT05660694|Drug|Triamcinolone|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
75655383|NCT05660694|Drug|Pentoxifylline with Vitamin E|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
75941443|NCT04581304|Device|Geistlich Bio-Oss® Granules|Geistlich Bio-Oss® Granules is intended to be used for filling bone defects and for bone augmentation.
76090572|NCT04378270|Device|PopSole™ Offloading Device|Specifically, the PopSole™ Offloading Device allows the provider to pop bubbles in the device (like popping paper or plastic bubble sheeting), thereby offloading the surgical area or area of pain. This customizable approach to offloading may increase compliance as it can easily fit in a normal walking shoe and is personalized for each patient. It can also be attached to a slide for use in the shower. Currently no post-operative devices for offloading the foot can be used in the shower.
76090573|NCT04871464|Drug|Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules|Oral
75655384|NCT00833209|Procedure|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
75655385|NCT00833209|Procedure|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
75655386|NCT00833209|Procedure|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
75655387|NCT00848029|Biological|Monovalent inactivated influenza vaccine|Two doses of monovalent inactivated influenza adjuvanted vaccine
75655388|NCT04241952|Other|Exercise|Bedcycling
75802444|NCT01345786|Drug|Commercial NOMAC-E2|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
75802445|NCT01345786|Drug|"Phase 3 NOMAC-E2 Batch A"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods"
75941444|NCT04580693|Other|PET Scan|PET scan using a tracer that is under a physician sponsored IND.
76090574|NCT04871464|Other|Placebo|Oral
76090575|NCT01724021|Drug|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
76090576|NCT01724021|Drug|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
76090577|NCT01724021|Drug|Bendamustine|Standard chemotherapy
76090578|NCT01724021|Drug|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
76090579|NCT01724021|Drug|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
76090580|NCT01724021|Drug|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
76090581|NCT01724021|Drug|Rituximab|1400 mg SC, Day 1 Cycles 5-8
76090582|NCT05197504|Drug|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
75655389|NCT02824614|Dietary Supplement|E967-Xylitol|
75655390|NCT02824614|Dietary Supplement|E968-Erythritol|
75655391|NCT00840151|Behavioral|contingency management|Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
75655392|NCT04933968|Biological|ALVR106|Infusion, visually identical to placebo
75655393|NCT04933968|Biological|Placebo|Infusion, visually identical to ALVR106
75655394|NCT00840229|Drug|Triamcinolone hexacetonide|20 mg
75655395|NCT00840229|Drug|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
75655396|NCT02825628|Drug|Osteodex|formulation: solution for infusion route of administration: intravenous infusion
75655397|NCT00831441|Drug|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
75655398|NCT00831441|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
75655399|NCT00833599|Drug|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
75802446|NCT01345786|Drug|"Phase 3 NOMAC-E2 Batch B"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods"
75802447|NCT05706220|Diagnostic Test|Eye tracking|Eye tracker will be used to evaluate eye movements
75802448|NCT05706220|Diagnostic Test|Microperimetry|Perimetric examination with Expert Exam strategy Microperimetry be used for fixation test
75941445|NCT04578652|Drug|Metformin 850 mg oral tablet bid|MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).
75941446|NCT04578652|Dietary Supplement|Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.|The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.
76090583|NCT02293096|Drug|metoprolol succinate|
76090584|NCT02293096|Genetic|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
76090585|NCT02293096|Procedure|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
76090586|NCT04866082|Other|questionnaire|Members of European Society of Intensive Care and European Society of ANaesthesiology and Intensive care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS
76090587|NCT01723397|Drug|Nasaleze Spray|Subjects are treated with over the counter Nasaleze cellulose powder nasal spray then challenged with allergen
76090588|NCT01723397|Other|Placebo spray|Subjects are treated with placebo nasal spray then challenged with allergen
76090589|NCT01723397|Biological|Allergen|Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
75941447|NCT04570631|Drug|Eftozanermin alfa|Intravenous (IV) infusion
75655400|NCT04242108|Diagnostic Test|Deep learning algorithm based on AS-OCT scans|The OCT scans of study subjects would be imported into the algorithm. Automated classfication of angle width and detection of synechia would be performed by the algorithm. The diagnostic performance of the algorithm would be compared with gonioscopy records.
75655401|NCT00840385|Drug|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
75655402|NCT02825784|Dietary Supplement|Renastart|Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
75655403|NCT02546245|Behavioral|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
75655404|NCT02546245|Behavioral|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
75655405|NCT02824848|Behavioral|Passive Stretching|Passive stretching and associated strengthening activities to change head/neck and body alignment
75655406|NCT02824848|Behavioral|Perception-Action Approach|Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
75655407|NCT00848263|Procedure|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
75655408|NCT00848263|Procedure|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
75344574|NCT03442465|Behavioral|Toronto Extremity Salvage Score|Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.
75344575|NCT03442465|Behavioral|Musculoskeletal Tumor Society Score|Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.
75655409|NCT02824458|Drug|Apatinib|Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily
75655410|NCT02824458|Drug|Gefitinib|Patients will be treated with Gefitinib, 250 mg p.o., daily
75655411|NCT02824458|Drug|Placebo|
75655412|NCT00833677|Behavioral|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
75655413|NCT02827188|Other|Mega Team-videogame|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
75655414|NCT00848341|Device|GUIDANT ICD SYSTEM|
75655415|NCT00840697|Behavioral|Exercises and work related rehabilitation|Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
75655416|NCT00840697|Behavioral|Brief intervention|1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
75655417|NCT00840697|Behavioral|multidisciplinary exercise group|10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
75655418|NCT02824146|Other|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
75941448|NCT04570631|Drug|Bortezomib|Intravenous (IV) or Subcutaneous (SC) injection
75941449|NCT04570631|Drug|Dexamethasone|Oral Tablet
75655419|NCT00834145|Device|A mechanical compression pump|Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
75802449|NCT05706220|Diagnostic Test|Optical coherence tomography (OCT)|Macular Cube 512x128 or 200x200 scan. OCT will be used to analysis of retinal nerve fiber layer, ganglion cell complex and ganglion-cell/inner plexiform layer
75802450|NCT05706220|Diagnostic Test|Visual processing speed test|"Visual processing speed test will be used for assessing subject visual stimulus search and reach times.~Thirty-two different everyday visual stimuli divided in four complexity groups that were presented along 8 radial visual field positions at three different eccentricities."
75802451|NCT05705986|Other|Blood Draw|Single blood draw
75802452|NCT01317550|Drug|Armodafinil|150 mg by mouth once a day for a 10 week cycle.
75802453|NCT01317550|Other|Placebo|Capsules taken by mouth once a day for a 10 week cycle.
75802454|NCT01317550|Drug|Minocycline|100 mg by mouth twice a day for a 10 week cycle.
75802455|NCT01317550|Behavioral|Questionnaires|Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
75802456|NCT01317472|Drug|dexlansoprazole|60 mg dexlansoprazole QAM (1 hour AC) for 2 months
75802457|NCT01317472|Drug|Placebo|1 tablet of placebo QAM (1 hour AC) for 2 months
75655420|NCT04241484|Device|Piezowave 2|Piezowave Myofascial Acoustic Compression Therapy (MyACT), which provides mechanical stimuli delivery to improve circulation and provide relief of pain. The focused sound waves produced by the Piezowave MyACT device are classified by a pressure surge, which is followed by a drop in pressure and a brief negative pressure phase low energy/low pressure application. It is this transformation of mechanical stimuli into biochemical signals, or mechanotransduction, which yields the treatment of myofascial and musculoskeletal pain
75802458|NCT05702086|Other|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.
75655421|NCT00840775|Device|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
75941450|NCT04550832|Drug|Delpazolid|Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.
75655422|NCT02825238|Other|Supervised exercise program|
75655423|NCT00840931|Drug|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
75941451|NCT04550832|Drug|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
76090590|NCT01723163|Behavioral|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
76090591|NCT01723163|Behavioral|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
76090592|NCT02293798|Device|silk surgical scaffold|surgical implant
75655424|NCT00840931|Biological|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
75655425|NCT02825082|Procedure|Abdominal emergency surgery|all abdominal emergency surgery procedures
75655426|NCT00848419|Drug|Epidural administration of bolus|
75655427|NCT05659992|Drug|azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte|"azacytidine (75 mg/m2/day, days 1 to 7).~cytarabine (75 mg/m2 bid, days 1 to 5).~aclamycin (10 mg/m2/day, day1,3,5).~Chidamide (30 mg/day , days 0,3).~venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)"
75655428|NCT00848575|Device|Flexible Endoscope|
75802459|NCT05701618|Other|Psychologically Informed Education Video Series|A short three video series (5-8.5 minutes each) provides psychologically-informed education at an age-appropriate level to address kinesiophobia, pain catastrophizing, and fear-avoidance beliefs.30 Participants will view the three-part education video series on an iPad at their first visit (video 1), one week (video 2), and three weeks (video 3).
75941452|NCT04533542|Other|Measurement|Undergo sensory measurements
75941453|NCT04533542|Other|Questionnaire Administration|Ancillary studies
76090593|NCT01722071|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
76090594|NCT01722071|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
76090595|NCT05171842|Behavioral|Observe the prognosis after stent implantation|Observe the prognosis of patients after undergoing specific operations. Specific surgery: Use femoral artery or brachial artery to implant naked stent (stent with diameter ≤7mm, stents with >7mm are not restricted) to restore the blood flow of the true lumen superior mesenteric artery. If the false cavity is large, it can be combined with a spring coil to assist embolization. Anticoagulant therapy should be performed for at least 1 day after surgery. Anticoagulant drugs are not restricted. After discharge from the hospital, the double antibody should be taken for 3 months, and the monoclonal antibody should be maintained for at least 1 year.
75941454|NCT04508998|Diagnostic Test|Blood tests including genotyping|Blood tests for alternative SNPs altering levels of ET-A receptor expression; blood will be further analysed for endothelin receptor mRNA and other plasma peptides important in the endothelin signalling pathway
75941455|NCT04508998|Diagnostic Test|Exercise Tolerance Test|Treadmill exercise test using the Bruce protocol
75344576|NCT03442465|Behavioral|Timed Get Up and Go Test|Validated functional measurement, for lower extremities only. The patient is observed and timed while s/he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The test predicts the patient's ability to go outside alone safely and quantifies functional mobility. The test requires no special equipment and will take less than one minute to complete.
75655429|NCT04242576|Device|Right Left Judgement|It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.
75655430|NCT04242576|Other|Action Observation|Videos of cervical movements.
75655431|NCT04242576|Behavioral|Exercise|Evidence based exercises for the neck.
75655432|NCT00834223|Device|Aquashunt|A shunt which is implanted into the suprachoroidal space.
75655433|NCT04042909|Behavioral|Counter Attitudinal Advocacy|same as Counter Attitudinal Advocacy arm
75655434|NCT04042909|Behavioral|Personalized Normative Feedback|same as Personalized Normative Feedback arm
75655435|NCT00834301|Dietary Supplement|Oral Multivitamin|Oral Multivitamin
75941456|NCT04507061|Drug|runcaciguat|Titrated dose of active dose 1, dose 2, dose 3, dose 4 of runcaciguat will be administered orally once a day.
75941457|NCT04507061|Other|Placebo|Sham-titrated dose of matching placebo will be administered orally once a day.
75941458|NCT04477629|Drug|Belatacept|Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.
75476547|NCT05967364|Behavioral|Wingman-Connect|Training occurs in three 2-hr blocks over several days in class groups. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work. To extend training impact, facilitators implement activities once per quarter that bring concepts into base activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
75941459|NCT04477629|Drug|Tacrolimus|Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.
75941460|NCT04477629|Drug|Mycophenolate Mofetil|Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).
75941461|NCT04477629|Drug|Corticosteroid|Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
75941462|NCT04476589|Diagnostic Test|Functional MRI|measurement of functional brain networks
75941463|NCT04476277|Drug|Biotin label|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
75941464|NCT04436835|Behavioral|Psychotherapy|Undergo ART
75941465|NCT04436835|Other|Questionnaire Administration|Ancillary studies
75941466|NCT04430517|Drug|Nicotinamide riboside|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
75941467|NCT04414943|Drug|S-ketamine|For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
75941468|NCT04414943|Drug|Placebo|For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
75941469|NCT04405258|Procedure|Pulmonary vein isolation|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
75941470|NCT04405258|Procedure|Left posterior wall isolation|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
75941471|NCT04396613|Procedure|Closure technique|Randomized assignment to one of three known, effective closure techniques
75655436|NCT04242030|Other|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
75655437|NCT04242030|Device|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.
75655438|NCT00834379|Drug|pravastatin sodium|40 mg Tablet
75655439|NCT00834379|Drug|Pravachol®|40 mg tablet
75802460|NCT05701618|Other|Anatomy and biomedical education videos|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
75802461|NCT01345630|Drug|Maraviroc|Maraviroc tablet 150 mg once daily for 96 weeks.
75941472|NCT04364295|Device|Spinal Surgery with SeaSpine product|Implanted with SeaSpine spinal or orthobiologic product
75941473|NCT04354025|Biological|Cytokine induced memory-like NK cells|-The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.
75802462|NCT01345630|Drug|Emtricitabine/tenofovir|Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
75802463|NCT01345630|Drug|darunavir/ritonavir 800/100 mg|darunavir/ritonavir 800/100 mg
75802464|NCT01345630|Drug|placebo for emtricitabine/tenofovir|placebo for emtricitabine/tenofovir
75802465|NCT01345630|Drug|placebo for maraviroc|placebo for maraviroc
75941474|NCT04354025|Drug|Fludarabine|-Fludarabine (dose: 30 mg/m^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
75941475|NCT04354025|Drug|Ara-C|-Ara-C (dose: 2000mg/m^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
75941476|NCT04354025|Drug|G-CSF|-Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
75941477|NCT04354025|Drug|Interleukin-2|-IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
75941478|NCT04354025|Procedure|Leukapheresis|-Donor only
75941479|NCT04347720|Drug|Indomethacin|Intravenous formulation
75941480|NCT04347720|Drug|Ibuprofen|Intravenous and oral formulations
75941481|NCT04347720|Drug|Acetaminophen|Intravenous and oral formulations
75941482|NCT04343755|Biological|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
75941483|NCT04325802|Drug|Naltrexone|50mg Naltrexone daily
75655440|NCT02825316|Behavioral|Mediterranean diet|Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
75802466|NCT03693612|Drug|feladilimab|feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.
75941484|NCT04325802|Other|Placebo|Placebo (Mannitol) daily
75941485|NCT04314583|Behavioral|Attention Control|Participants in this group will be asked to recall 3 to 5 events from the prior day of the intervention and write, or if unable to write, speak about these events.
75941486|NCT04314583|Behavioral|Gratitude Journaling|The gratitude journaling intervention involves participants writing or speaking 3-5 things for which they are grateful and focusing on these attributes. Participants will do this weekly for 12 weeks.
75941487|NCT04300777|Device|SeaSpine Non-Cervical Pedicle Screw Systems|Any patient treated with a SeaSpine Non-Cervical Pedicle Screw System
75941488|NCT04285346|Drug|Ganaxolone|titration followed by maintenance and extension period
75941489|NCT04266873|Device|AffloVest|Form of High Frequency Chest Wall Oscillation mimicking manual techniques on a patients thorax to assist with secretion clearance. Delivered for 30 minutes, twice a day
75941490|NCT04253899|Procedure|Appendectomy|Interval Appendectomy
75941491|NCT04253899|Other|Observation|observation and follow up
75941492|NCT04241562|Other|Injection of Nerve Growth Factor|Injection of Nerve Growth Factor to the right masseter
75941493|NCT04234555|Diagnostic Test|Corticomotor excitability to the pelvic floor muscles|Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.
75941494|NCT04234555|Diagnostic Test|Pelvic floor muscle response to pressure applied at the vulvar vestibule|Electromyography will be used to determine whether the pelvic floor muscles (PFMs) respond to pressure applied to the vulvar vestibule as anticipatory (i.e. PFMs are active before the pressure is applied) and as behavioural (i.e. PFMs are active after the pressure is applied) responses. The amplitude of the EMG responses will also be recorded.
75941495|NCT04234555|Diagnostic Test|Pressure pain threshold (PPS)|A custom vulvalgesiometer will be used to determine the mean pressure at which participants first report pain at the posterior vaginal fourchette.
75655441|NCT02825316|Behavioral|Low residue diet|Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
75655442|NCT02825004|Behavioral|Psychological Intervention|
75655443|NCT00834457|Drug|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
75655444|NCT00834457|Drug|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
75802467|NCT03693612|Drug|Tremelimumab|Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .
75802468|NCT03693612|Drug|Docetaxel|Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m^2).
75802469|NCT03693612|Drug|Paclitaxel|Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m^2.
75802470|NCT03693612|Drug|Cetuximab|Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m^2 followed by 250 mg/m^2 once weekly.
75941496|NCT04234555|Diagnostic Test|Temporal summation of pain|A custom vulvalgesiometer will be used to apply the same pressure (rated as 4/10 duiring PPS testing as described above) to the vulvar vestibule across 10 repetitions. The difference in pain rated on the tenth application and that rated on the first application will be the outcome.
75941497|NCT04234555|Diagnostic Test|Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)|Electromyography will be used to measure the mean smoothed, rectified activation amplitude across 1 second of complete rest, across three maximal effort PFM contractions, and across three attempts at a bearing down maneuver.
75941498|NCT04234542|Other|Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be increased along with intensity as the stages progress.
75941499|NCT04234542|Other|Sham Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be progressed, but power will always be set to 1%..
75941500|NCT04226144|Device|Breath Stacking Group|Lung recruitment technique using manual bag resuscitation with oronasal mask interface
75941501|NCT04226144|Device|Breath stacking and EMT|Lung recruitment technique with one way valve with counter resistance during all expiratory phase
75941502|NCT04213144|Device|Magdent Cap MED|Magdent is intended to be used for accelaration of soft tissue and bone healing
75941503|NCT04213144|Device|Sham MED|Sham MED is intended to be used for soft tissue healing
75941504|NCT04213053|Procedure|strabismus surgery|Lees screen before and after concomitant strabismus surgery
75941505|NCT04209192|Drug|Fosfomycin Tromethamine 3G Sachet|Is the prophylactic drug which will be used in the intervention group.
75941506|NCT04209192|Drug|Amikacin|Is the prophylactic drug which will be used in the control group.
75941507|NCT04199468|Drug|Active Delta-9-THC|Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)
75941508|NCT04199468|Drug|Placebo Delta-9-THC|A placebo dose given intravenously (IV)
75941509|NCT04199468|Drug|Active Ketamine|Active Ketamine (0.2 mg/kg) given intravenously (IV)
75941510|NCT04199468|Drug|Placebo Ketamine|A placebo dose given intravenously (IV)
75941511|NCT04178148|Other|Amikacin dose optimization|Therapeutic drug optimization of amikacin using the BestDose software algorithm
75941512|NCT04163822|Other|no intervention|no intervention, only observation
75941513|NCT04148287|Drug|APX001|Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
75941514|NCT04138914|Device|Focal Cryotherapy|Ablation of the cancer focus within the prostate using cryotherapy
75941515|NCT04126681|Drug|HQP1351|HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I
75941516|NCT04126681|Drug|Hydroxyurea or Interferon-based therapy|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
76090596|NCT05169814|Drug|Micro/nanobubble (MNB) - Irrigation|An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
76090597|NCT05169814|Other|0.9% Normal Saline - Irrigation|A normal saline solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The normal saline solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
75655445|NCT03851965|Diagnostic Test|Soluble Urokinase Plasminogen Activator Receptor|Preoperative and postoperative determination of the Soluble Urokinase Plasminogen Activator Receptor levels in patients undergoing non-cardiac major surgery.
75655446|NCT02823522|Other|Patients recruitment|Between July and November 2016, the patients included in the previous retrospective study were contacted by phone, mail and e-mail and invited to come back to the respective clinics where they had been initially diagnosed as NCWS patients: the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (province of Agrigento).
75802471|NCT04189146|Behavioral|Inner Engineering Intervention|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
75802472|NCT03746652|Drug|Daratumumab, Ixazomib, Dexamethasone|Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
75802473|NCT03745248|Behavioral|Aerobic training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 1 month
75802474|NCT03745248|Behavioral|Balance Training|Standard of care
76090598|NCT05169814|Drug|Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
75655447|NCT04241406|Device|Transcutaneous spinal cord stimulation|Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequentl
75655448|NCT02611635|Drug|VKA: Warfarin (Waran)|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
75655449|NCT02611635|Drug|NOAC: Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
75802475|NCT01562808|Drug|Aripiprazole|single oral administration of aripiprazole
75802476|NCT04223232|Drug|[14C]-MD1003|single oral dose of 100mg [14C]-MD1003
75802477|NCT03748524|Drug|Influenza Vaccine|Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0
75802478|NCT03746574|Behavioral|Compassion Curriculum|12 session curriculum offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
75802479|NCT04206384|Device|Ultrasound|Ultimate Contour Body Sculpting Device
75941517|NCT04126681|Drug|Homoharringtonine|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
75941518|NCT04126681|Drug|Imatinib, Dasatinib or Nilotinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
75941519|NCT04118855|Drug|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
75941520|NCT04118855|Drug|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
75941521|NCT04092790|Device|Virtual Gate Device (VGD)|A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
75941522|NCT04074226|Procedure|Erector Spinae Plane block|The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.
75941523|NCT04074226|Procedure|Quadratus Lumborum Block|Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
75941524|NCT04021394|Diagnostic Test|CellSearch CTC platform|epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs
75941525|NCT04021394|Diagnostic Test|Parsortix CTC platform|EMT-independent platform
75941526|NCT04012151|Other|Physical measurement|Parturients of gestational week >= 32 weeks will have their arms and fingers measured to generate the conicity index.
75941527|NCT04012151|Other|Cuff size fitting|Fit on arm cuff and finger cuff as selected by investigators based on the measurement.
75344577|NCT03442465|Diagnostic Test|Orthogonal Radiographs|The distance of bone transport is measured, accounting for calibration of the radiographs. The presence of bone regenerate between the transported segment is determined by the presence of continuous calcified callus from the proximal segment to the distal segment. Each of the orthogonal radiographs is used to visualize two cortices: the AP radiographs visualizes the medial and lateral cortices and the lateral radiograph measures the anterior and posterior cortices. Each continuous calcified cortex is counted with a range from 0 to 4 cortices intact.
75344578|NCT03442465|Diagnostic Test|Weight Bearing for lower extremities only|As part of the current standard of care, patients are asked to stand on a scale with the affected lower extremity on the scale and the unaffected extremity on a block which is level with the scale. The patient is asked to place as much weight as possible on the affected extremity and this weight Is recorded. Each patient's total weight is then measured and the percent of weight bearing is calculated as the amount of weight bearing over the total body weight.
75655450|NCT02611635|Drug|NOAC: Dabigatran etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
75655451|NCT02611635|Drug|NOAC: Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
75802480|NCT04051944|Drug|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
75802481|NCT04050618|Device|fanfilcon A test lens|Silicone hydrogel contact lens
75802482|NCT04050618|Device|ocufilcon D control lens|hydrogel contact lens
75802483|NCT04050618|Device|etafilcon A control lens|hydrogel contact lens
75802484|NCT04067492|Drug|RPH - 104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
75802485|NCT04067492|Drug|Voltaren®|Enteric-coated tablets, 25 mg and 50 mg
75802486|NCT05280522|Other|Volitional Contractions (VOL)|Participants are provided visual feedback showing the 20% MVIC force and instructed to produce the target force for 10 s then relax for 50 s. The timing is provided by the research personnel until 10 contractions are completed. Participants rate their pain during each contraction on a visual analog scale. The pain ratings are averaged across all 10 contractions and the average is used in the analysis.
75802487|NCT05280522|Device|Neuromuscular Electrical Stimulation (NMES)|Participants are instructed to relax throughout the NMES contractions. The amplitude of the stimulation is increased until 20 percent MVIC force is achieved and the amplitude is recorded. The timing of the NMES is 12 s on: 50 s off for 10 contractions. The on-time included a 2s ramp up to the target amplitude. Participants rate their pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 contractions and the average was used in the analyses.
75941528|NCT04011150|Device|Epidural infusion pump|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
75941529|NCT04011150|Drug|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
75941530|NCT04011150|Drug|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
75941531|NCT03984695|Behavioral|SHE-WOMEN|SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
75941532|NCT03972709|Drug|Galegenimab|Intravitreal (ITV) injections of galegenimab
75941533|NCT03972709|Drug|Sham Control|Sham control
75941534|NCT03935321|Drug|NG-101|6 intrathecal bolus injections, each of 45mg
75941535|NCT03935321|Drug|Placebos|6 intrathecal bolus injections, each of 45mg
75941536|NCT03928626|Behavioral|Regulation of craving|Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.
75941537|NCT03928626|Behavioral|Control (NO REGULATION)|In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
75941538|NCT03927378|Drug|S-ketamine|S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
75941539|NCT03927378|Drug|Placebo|Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
75941540|NCT03923686|Procedure|EUS-guided drainage using LAMS with DPS|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent with coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
75941541|NCT03923686|Procedure|EUS-guided drainage using LAMS alone|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent without coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
75941542|NCT03875391|Drug|Oxytocin|Drug: Oxytocin nasal spray
75941543|NCT03875391|Drug|Placebo|Drug: Placebo nasal spray
75941544|NCT03869905|Drug|Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
75941545|NCT03869905|Drug|Placebo first then Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening
75941546|NCT03857620|Other|Best Practice|Receive usual care
76090599|NCT05169814|Other|0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with normal saline will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
75344579|NCT03442465|Diagnostic Test|Range of Motion|As part of the current standard of care, the joints of the affected extremity are assessed for passive range of motion at each follow up visit by the clinician. If surgery is on the femur, the hip and knee joints are assessed for range of motion. Whereas for the tibia, the knee and ankle joints are assessed. These assessments would be measured using a goniometer placed alongside the extremity and recorded for each direction of movement. Hip range of motion includes flexion, extension, abduction, internal rotation and external rotation. Knee range of motion includes flexion and extension. Ankle range of motion includes dorsiflexion and plantarflexion.
75655452|NCT02611635|Drug|NOAC: Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
75941547|NCT03857620|Other|Informational Intervention|Receive OPTI-Surg program materials
75344580|NCT03434509|Other|Continuous Tai Chi and Mindful Movement classes|"Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing)."
75344581|NCT03396601|Drug|Ketamine Hydrochloride|Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
76090600|NCT04191460|Drug|cRGD-ZW800-1.|Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery
76090601|NCT04155580|Drug|ASTX660|Capsule for oral administration
75344582|NCT03396601|Drug|Placebo|Normal Saline placebo will be infused IV over 40 minutes
75344583|NCT03395392|Drug|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
75655453|NCT02611635|Drug|NOAC: Lixiana|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
75655454|NCT05659758|Procedure|Head up positioning during preoxygenation|patients will be preoxygenated in head up position
75655455|NCT02824926|Drug|Dapaconazole|
75655456|NCT02824926|Drug|Ketoconazole|
75655457|NCT00705471|Biological|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
75655458|NCT00705549|Drug|Gemcitabine|Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
75655459|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 75mg/m2 on Day 1
75655460|NCT00705549|Drug|Docetaxel|Docetaxel I.V at the dose of 75mg/m2 on Day 1
75655461|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 80mg/m2 on Day 1
75655462|NCT00705549|Drug|Vinorelbine|Vinorelbine per os 50mg every Monday, Wednesday and Friday
75655463|NCT00705549|Drug|Pemetrexate|Pemetrexate I.V 500mg/m2 on Day 1
75802488|NCT05280522|Device|Noxious Electrical Stimulation (NXES)|The intensity of the electrical stimulation is increased slowly over 30 s to the maximum tolerated level. Trains of NXES are delivered at the maximum tolerated intensity with a timing ratio of 12 s on: 50 s off for a total of 10 trains. The on-time included a 2s ramp up to the target amplitude. Participants rate the pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 trains of NXES and the average is used in the analyses.
75802489|NCT04060446|Device|Medical Device|Smoke cigarettes with CReSSMicro topography measurement device and BioRadio device
75802490|NCT04060446|Other|Questionnaire Administration|Ancillary studies
75802491|NCT04060446|Behavioral|Tobacco Smoking|Smoke cigarettes
75802492|NCT03739190|Device|NRL Condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
75941548|NCT03857620|Other|Questionnaire Administration|Ancillary studies
75941549|NCT03857620|Other|Informational Intervention with Coaching|Receive OPTI-Surg program materials plus individual coaching
75941550|NCT03836066|Drug|Atezolizumab-Bevacizumab|Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
75941551|NCT03835741|Device|FreeO2|an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
76090602|NCT04155580|Drug|ASTX727|Tablet for oral administration
75655464|NCT02824692|Device|heart lungs and abdomen ultrasound|
75655465|NCT00705627|Drug|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
75655466|NCT00705705|Behavioral|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
75941552|NCT03835741|Other|manual titration|a manual adjustment of oxygen during patient hospitalisation by hospital staff
75941553|NCT03831256|Diagnostic Test|Traditional integrated prenatal screening|biochemical prenatal screening with or without nuchal translucency by US
75941554|NCT03831256|Diagnostic Test|Second-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS after a positive traditional prenatal screen
75941555|NCT03831256|Diagnostic Test|First-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS at first trimester
75941556|NCT03831256|Diagnostic Test|Invasive prenatal testing for fetal aneuploidy|amniocentesis or chorionic villi sampling (CVS)
75941557|NCT03826173|Behavioral|PPPA|The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
75941558|NCT03826173|Behavioral|PA|The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
75941559|NCT03803995|Procedure|Mapping and Pacing the His Bundle|During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.
75941560|NCT03803995|Procedure|Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing|During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
76090603|NCT01721759|Drug|Nivolumab|
76090604|NCT01721369|Diagnostic Test|Transient Loss of Consciousness (T-LOC)|
76090605|NCT02298322|Device|CoolSculpting System|
76090606|NCT04776850|Drug|Bortezomib|Given IV
76090607|NCT04776850|Drug|Busulfan|Given IV
75655467|NCT00705705|Behavioral|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
75941561|NCT03778242|Drug|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
75941562|NCT03778242|Drug|normal saline|2 placebo ampoules to TA in 100 ml saline by slow infusion
75655468|NCT02824770|Behavioral|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
75655469|NCT02824770|Drug|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
75655470|NCT02824770|Drug|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
75655471|NCT02824770|Procedure|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
75941563|NCT03772613|Drug|Unfractionated heparin|Administration of unfractionated heparin will be assessed using the activated clotting time
75941564|NCT03766022|Device|Neo dental implant Alpha Bio Tec. Ltd.|Neo dental implant is used to restore missing teeth
75941565|NCT03760029|Other|Visit frequency|All subjects need to visit sites more frequently than in routine clinical practice.
76090608|NCT04776850|Drug|Cyclophosphamide|Given IV
76090609|NCT04776850|Drug|Dexamethasone|Given IV
76090610|NCT04776850|Drug|Fludarabine Phosphate|Given IV
76090611|NCT04776850|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
76090612|NCT04776850|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
76090613|NCT04776850|Drug|Mycophenolate Mofetil|Given IV or PO
76090614|NCT04776850|Procedure|Plasmapheresis|Undergo plasmapheresis
76090615|NCT04776850|Biological|Rituximab|Given IV
75655472|NCT02824536|Drug|3BNC117|Intravenous Infusion of 3BNC117
75655473|NCT02824536|Drug|10-1074|Intravenous Infusion of 10-1074
75655474|NCT02824536|Drug|Placebo|Intravenous Infusion of Sterile Saline (NaCl 0.9%)
75655475|NCT00831129|Drug|Rosiglitazone|4 mg daily
76090616|NCT04776850|Drug|Tacrolimus|Given IV or PO
76090617|NCT04132648|Drug|Curcumin|Oral supplement one time at 2,000 mg
76090618|NCT04132648|Other|Placebo|Oral supplement one time at 2,000 mg
76090619|NCT02331940|Drug|tiotropium|Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
76090620|NCT02331940|Device|Handihaler|Inhalation via the HandiHaler once daily
76090621|NCT02331940|Device|Respimat|Inhalation via the Respimat once daily
76090622|NCT04095208|Drug|Association of Nivolumab + Relatlimab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - [240 mg].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - [80 mg]."
76090623|NCT04095208|Drug|Nivolumab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - [240 mg]."
76090624|NCT02291302|Other|integrated pest management|integrated pest management and environmental strategy
75941566|NCT03739437|Behavioral|Mobile Contingency Management|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
75802493|NCT04375878|Drug|MS1819|MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
75802494|NCT04375878|Drug|Porcine PERT|Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.
75802495|NCT03746496|Diagnostic Test|point-of-care laboratory analysis|POC analysis with i-STAT POC analyser from the intraosseous and arterial blood
75802496|NCT04039776|Diagnostic Test|"Cone Beam Computed Tomography (CBCT)"|"Cone Beam Computed Tomography (CBCT), a machine that use a low dose of radiation compared to traditional CT systems, and allows the examination in supine and standing position knee . In this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism."
75802497|NCT04189224|Device|JJV Investigational Multifocal Contact Lens|TEST
75655476|NCT00831129|Drug|Placebo Rosiglitazone|1 tab daily
75655477|NCT00831129|Drug|Simvastatin|40 mg daily
75802498|NCT04189224|Device|1-Day Acuvue® Moist Brand Multifocal Contact Lens|CONTROL
75802499|NCT04186806|Device|3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray|20 ml bottle
75802500|NCT04186806|Device|Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray|44.3 ml bottle
75655478|NCT00637962|Biological|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
75941567|NCT03739437|Behavioral|Standard Care|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
75655479|NCT00637962|Biological|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
75655480|NCT02824380|Drug|DA-4001 H|5% minoxidil / high dose of finasteride
75655481|NCT02824380|Drug|DA-4001 L|5% minoxidil / low dose of finasteride
75802501|NCT04041414|Other|Proud & Empowered!|Proud & Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
75802502|NCT03748446|Drug|Xenon|The investigators have chosen to use as a maximum concentration about half the general anesthetic partial pressure of xenon (35%=70%/2) to achieve a dose that is sub-anesthetic. This concentration of xenon is very close to that at which subjects emerging from xenon anesthesia first respond to verbal commands, commonly referred to as MAC awake.
75802503|NCT03748446|Drug|Nitrogen gas|nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual
75802504|NCT04370028|Drug|Divaza|Oral administration.
75802505|NCT04037748|Drug|Puran T4®|Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
75802506|NCT04037748|Drug|Eutirox®|Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
75802507|NCT04036110|Dietary Supplement|Vitamin C 500 mg|500 mg tablet taken orally with one meal daily
75802508|NCT04036110|Dietary Supplement|Vitamin C 1000 mg|1000 mg tablet taken orally with one meal daily
75802509|NCT04036110|Other|Placebo|1 tablet taken orally with one meal daily
75941568|NCT03701555|Other|PvP001 placebo|placebo
75941569|NCT03701555|Drug|PvP001 100 mg|PvP001 100 mg
75941570|NCT03701555|Drug|PvP001 300 mg|PvP001 300 mg
75941571|NCT03701555|Drug|PvP001 900 mg|PvP001 900 mg
75941572|NCT03701555|Drug|Maximum Feasible Dose (MFD) of PvP002|MFD of PvP002
75941573|NCT03701555|Drug|Maximum Tolerated Dose (MTD) of PvP001|Maximum Tolerated Dose (MTD) of PvP001
75941574|NCT03701555|Drug|MTD of PvP001 following 7 days of PPI treatment|Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
75941575|NCT03701555|Other|PvP002 placebo|Placebo
75344584|NCT03395392|Drug|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
75941576|NCT03701555|Drug|PvP001 600 mg|PvP001 600 mg
75941577|NCT03701555|Drug|PvP003 placebo|Placebo tablet orally.
75941578|NCT03701555|Drug|PvP003|PvP003 tablet orally.
75941579|NCT03701555|Drug|PvP003 150 mg|PvP003 150 mg
75655482|NCT00705861|Drug|Placebo|Placebo as a substitute of SK3530 100mg
75655483|NCT00705861|Drug|SK3530|SK3530 100mg
75655484|NCT00913341|Drug|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)|
75655485|NCT00913341|Drug|Alprazolam Tablets, 1 mg (The Upjohn Company)|
75655486|NCT00620113|Drug|Odanacatib|Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.
75655487|NCT00620113|Dietary Supplement|Vitamin D3|Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.
75655488|NCT00620113|Dietary Supplement|Calcium carbonate|Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.
75655489|NCT00620113|Drug|Placebo|Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
75941580|NCT03698461|Drug|Atezolizumab|"1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~840mg IV D1 of C1-12 (Cycle: every 2 weeks)"
75941581|NCT03698461|Drug|Bevacizumab|5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab
75941582|NCT03698461|Drug|Oxaliplatin|85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
75941583|NCT03698461|Drug|Levoleucovorin|200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
75941584|NCT03698461|Drug|5-FU|"5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)"
76090625|NCT02291302|Other|air purifier|air purifiers
75941585|NCT03685422|Other|Virtual Reality|Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Hospital Anxiety and Depression Scale (HADS), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.
75941586|NCT03673748|Drug|Mesenchymal stem cells (MSC)|Endovenous injection of MSV in saline solution
75941587|NCT03673748|Drug|Placebo|Endovenous injection of saline solution without cells
75941588|NCT03659617|Device|xenograft (BioOss Collagen)|Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)
75941589|NCT03657667|Procedure|Ureteroscopy|Endoscopic removal of kidney stones
75941590|NCT03640858|Device|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
75476548|NCT05967364|Behavioral|Stress Management|Stress management training (also done in class groups) reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
75476549|NCT05967338|Device|using McGrath Video Laryngoscope|glottis visualization in indirect and direct lifting methods by using McGrath Video Laryngoscope
75655490|NCT00830115|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
75655491|NCT02824302|Other|Survey|Patients coming for induction of labor will be handed a survey regarding their expectation of their coming labor pain. And then will be followed up after 24 hours of their delivery.
75655492|NCT02824068|Drug|glucosidase alfa|Long-term use in an observational study of licenced drug
75655493|NCT00633672|Drug|Esomeprazole|20mg Oral tablet once daily
75655494|NCT00633672|Drug|Ranitidine|150mg oral twice daily
75655495|NCT00633672|Drug|Esomeprazole|40mg oral tablet once daily
75655496|NCT00848653|Device|CRT device|market approved CRT device
75655497|NCT02547103|Other|Chlorhexidine gluconate-soaked cloths|
75941592|NCT03604705|Drug|APX001|APX001
75941593|NCT03571165|Behavioral|My Tools 4 Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
75941594|NCT03569059|Device|Early Robotic/VR Therapy (EVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.
75941595|NCT03569059|Behavioral|Dose-Matched Usual Physical Therapy Care|Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.
75941596|NCT03569059|Device|Delayed Robotic/VR Therapy (DVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
75941597|NCT03552731|Behavioral|Surveys|GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.
75941598|NCT03541733|Other|mid-gut tubing|mid-gut tubing at different time
75655498|NCT02547103|Other|Normal saline|
75655499|NCT02547103|Other|mupirocin ointment|
75655500|NCT05659524|Other|Nasal saline irrigation|"The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations:~Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily.~Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative."
75655501|NCT02822664|Behavioral|Pedophiles patients|cerebral MRI and/or cerebral PET imaging
75655502|NCT02822664|Behavioral|Healthy subjects|cerebral MRI and/or cerebral PET imaging
75655503|NCT02822664|Device|PET/MRI|
75655504|NCT00841165|Device|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
75655505|NCT00841165|Device|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
75655506|NCT02823756|Procedure|Physical Therapy|Exercise, education, spinal manipulation
75655507|NCT00841243|Dietary Supplement|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
75802510|NCT03053050|Drug|SEL|Tablets administered orally once daily
75802511|NCT03053050|Drug|Placebo to match SEL 6 mg|Tablets administered orally once daily
75802512|NCT03053050|Drug|Placebo to match SEL 18 mg|Tablets administered orally once daily
75802513|NCT04369950|Drug|2% lidocaine with 1:200,000 epinephrine and epidural morphine|Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
76090626|NCT02291302|Other|No intervention (control)|no integrated pest management and sham air purifier
75344585|NCT03395197|Drug|Talazoparib with enzalutamide|Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
75655508|NCT02822586|Radiation|TSEB Therapy|TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.
75655509|NCT02822586|Drug|Brentuximab vedotin|An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
75655510|NCT04239768|Device|MonoDermà HA gel combined to a low level laser|"Two intradermal injections of the filler were performed during the basal and after 1 month, on the middle and inferior third of the face (1ml for each face side) using a needle (30G).~Immediately after both injection procedures, LLLT session were performed on the same face area for a total of 8 minutes, using three different wavelengths (450 nm, 650 nm and 1064 nm) simultaneously."
75655511|NCT02822274|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-70_R84-064)
75655512|NCT00841399|Biological|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
75802514|NCT04369950|Drug|3% 2-chloroprocaine and epidural morphine|Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
75655513|NCT02822118|Drug|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
75655514|NCT02822118|Drug|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
75655515|NCT00848809|Procedure|Blood sample|9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
75655516|NCT00848809|Procedure|Blood sample|10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
75655517|NCT04240938|Procedure|Dacryocystorhinostomy|Anastomosis between lacrimal sac and nasal cavity
75655518|NCT00848887|Biological|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
75655519|NCT04240782|Behavioral|Nutrition and hands on cooking classes for parents and their children|The adults and children will learn how to prepare the fresh produce during an age appropriate, evidence-based, family cooking school. The class will provide participants with a no-cost, low-risk incentive to try new vegetables, and will empower them to build healthier lives through nutrient-rich, locally sourced meals. Participants will also receive nutrition education and information on how they can integrate local produce into their food budget. One of the class sessions will focus solely on how to budget for healthy food, comparison shop, and make the most of their food dollars. Participants will learn how to use their SNAP benefits at local farmers markets.
75655520|NCT04240782|Behavioral|Produce allocations|Participants will also receive a produce allocation from a local farm during each session of the class.
75655521|NCT00834847|Drug|pravastatin|40 mg tablet
75655522|NCT00834847|Drug|Pravachol®|40 mg Tablet
75655523|NCT02823132|Biological|blood sample|
75655524|NCT00841477|Biological|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
75655525|NCT00841477|Behavioral|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
75655526|NCT00830037|Drug|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
76090627|NCT02292082|Drug|Bupivacaine|
76090628|NCT02292082|Drug|Morphine|
76090629|NCT02292082|Drug|Methylprednisolone|
76090630|NCT02292082|Drug|Cefazolin|
75344586|NCT03395197|Drug|Placebo with enzalutamide|Placebo plus enzalutamide 160 mg/day
75344587|NCT03388619|Radiation|Dose to prostate bed with integrated boost|Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed
75344588|NCT03388619|Radiation|Dose to prostate bed irradiation only|Radiation will be delivered to the prostate bed only
75476550|NCT05967325|Procedure|Stromal Vascular Fraction (SVF) combined with Functional self-assembling peptide nanofiber hydrogels|Transplantation of SVF and biomimetic nanohydrogel
75476551|NCT05967312|Diagnostic Test|Minuteful Kidney Test Kit|The Minuteful Kidney Test is an Artificial Intelligence (AI) based innovative technology to enable people at risk of CKD to undertake an ACR test at home using smartphone technology
75655527|NCT00830037|Drug|Ferrous Sulfate|Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
75655528|NCT00834925|Drug|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
75655529|NCT05659680|Device|WiSE-CRT|Participants undergo pre-procedural CT, implantation of the WiSE-CRT system targeting the left bundle branch area, and post procedural non-invasive electro-anatomical mapping using electrocardiographic imaging and haemodynamic assessment.
76090631|NCT02292082|Drug|Normal saline|
76090632|NCT02292082|Drug|Midazolam|
76090633|NCT02292082|Drug|Propofol|
76090634|NCT02292082|Drug|Dexamethasone|
76090635|NCT02292082|Device|8 MHz. Chiba needle, 22 G / 4 inches|
75941599|NCT03406468|Radiation|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
75941600|NCT03403998|Other|Exercises|The treatment will consist of an 8-week progressive exercise program of neck flexors and extensors exercises supervised by a physical therapist for 30-45 min twice a week per 8 weeks as described in Arm/group descriptions.
75941601|NCT03403998|Other|Placebo|The placebo treatment will be for 30-45 min twice a week for 8 weeks, as for the intervention group. ( see details in arm description)
75941602|NCT03395145|Device|Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation after tooth extraction
75941603|NCT03377179|Drug|ABC294640|Two 250 mg capsules of ABC294640 will be taken twice daily
75941604|NCT03377179|Drug|Hydroxychloroquine Sulfate 200 MG|HCQ tablets will be taken at a dose that will be determined
75941605|NCT03261102|Biological|Adalimumab|
75941606|NCT03104257|Drug|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
75941607|NCT03083548|Diagnostic Test|Imaging|Conventional radiographs (hands/feet), CT of dominant hand, MRI of dominant hand, ultrasound (hands/shoulder/feet/hips/knees), fluorescence optical imaging of hands
75941608|NCT03083548|Diagnostic Test|Physical examinations|Joint assessment of hands and feet, pain sensitization test and functional tests
75941609|NCT03083548|Diagnostic Test|Questionnnaires|Self-reported demographic factors, clinical variables and OA history and symptoms
75941610|NCT03052283|Diagnostic Test|Questionnaire Patient Reported Outcome Measure (PROM)|non-interventional
75941611|NCT03045965|Procedure|Salpingectomy|The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
75941612|NCT02960776|Behavioral|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
75941613|NCT02902952|Behavioral|Physical Exercise|An eight week physical exercise intervention
75941614|NCT02902952|Behavioral|Control Intervention|An eight week sedentary control intervention
75941615|NCT02856412|Other|Veterans Group Exercise (VGX)|Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
75941616|NCT02856412|Other|Illness Management and Recovery|Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
75655530|NCT02611557|Procedure|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
75941617|NCT02848131|Drug|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
75941618|NCT02848131|Drug|Group 2: Quercetin|Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
75941619|NCT02846376|Drug|Nivolumab|Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
75941620|NCT02846376|Drug|Ipilimumab|Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
75941621|NCT02792075|Other|5-year Follow-up|
75941622|NCT02712385|Other|'The Healthy Brain Rehabilitation Manual'|The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.
75941623|NCT02712385|Device|Pedometer|Pedometer used to measure step counts as an objective measurement of level of physical activity.
75941624|NCT02712385|Procedure|Usual care|Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.
76090636|NCT05072704|Drug|Sufentanil|Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
75802515|NCT04035564|Drug|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
75802516|NCT04035564|Drug|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
75802517|NCT03748368|Other|Cataract presentation|Presentation about cataract surgery
75802518|NCT03748368|Other|Placebo presentation|Presentation about the history of the hospital
75941625|NCT02712385|Behavioral|Telephone follow-up|Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.
75941626|NCT02650778|Procedure|Breast ultrasound|automated whole breast ultrasound
75941627|NCT02619760|Drug|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
75941628|NCT02619760|Drug|12-month DAPT|12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
75941629|NCT02613988|Device|3 Tesla magnetic resonance imaging|High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)
76090637|NCT05072704|Drug|Dexmedetomidine|Pre-operative infusion of dexmedetomidine 1µg/kg in 100ml of normal saline before surgery + per-operative infusion of dexmedetomidine 0.4 µg/kg in 100ml of normal saline during the surgery if needed.
75344589|NCT03323463|Diagnostic Test|F-FMISO PET/CT Scan|All subjects on Cohort A and the first 100 subjects accrued to Cohort B will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment. For both Cohort A and Cohort B, FMISO scan will be repeated between the 5th-10th RT day if pre-treatment scan is hypoxic. If the repeat 18F-FMISOscan PET/CT demonstrates hypoxia, the subject will receive 70Gy concurrent with 2 cycles of chemotherapy. All subjects accrued onto Cohort B after 100 accruals will undergo only one 18F-FMISO scan done 5-10 treatment days after start of radiation therapy.
75941630|NCT02613988|Device|Chemical exchange saturation transfer MRI|Amide proton transfer-weighted image
75941631|NCT02613988|Device|Diffusion weighted MRI|diffusion-weighted image with b value 0, 1000, and 3000
75941632|NCT02613988|Device|Dynamic susceptibility contrast MRI|dual echo EPI sequence
75941633|NCT02600936|Device|vein stent placement|Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
75941634|NCT02590601|Drug|Bromocriptine|
75941635|NCT02590601|Other|Guideline-driven medical therapy (GDMT)|
75941636|NCT02554773|Drug|Fitusiran (SAR439774)|Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
75941637|NCT02406274|Other|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated & or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) & record their findings. They will then interpret the CESM & record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding & will either be called negative & followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
75476552|NCT05967273|Other|CirrhosisRx CDS|CirrhosisRx is a cirrhosis-specific CDS that organizes clinical data into clinically relevant groupings and links them to order sets consistent with national practice guidelines for inpatient cirrhosis care.
75476553|NCT05967234|Behavioral|Telehealth solution|Telehealth solution offered for breastfeeding education.
75941638|NCT02393885|Device|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
75476554|NCT05967208|Behavioral|CONSORT referrals|"Participants will be offered SMS-based confidential social network referrals for HIV testing (CONSORT referrals) to extend to any of their social and sexual network contacts."
75476555|NCT05967208|Behavioral|Card referrals|"Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts."
75476556|NCT05967156|Drug|Empagliflozin10Mg Tab|10 mg daily
75476557|NCT05967130|Biological|Phage|Inserting specific specimen of phages in to the bladder
75476558|NCT05967104|Other|Education based on the PLISSIT model|Training to the intervention group was carried out in 3 sessions of 45 minutes each week, organized by the first author (AD). In each session, training was organized based on the PLISSIT framework.
75476559|NCT05967091|Device|Targeted Lung Denervation|Targeted Lung Denervation (TLD) is a bronchoscopically guided, minimally invasive procedure using the Ryme Medical Lung Denervation System
75941639|NCT02240498|Drug|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
76090638|NCT03951454|Behavioral|Conexiones|5 Conexiones telephone sessions
75941640|NCT02240498|Drug|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
75941641|NCT02240498|Device|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
75344590|NCT03323463|Radiation|30 Gy over 3 weeks|Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the primary/postoperative bed if applicable, all subclinical areas at risk for disease will receive the same dose at 30Gy.
75941642|NCT02240498|Device|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
75941643|NCT02240498|Device|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
75941644|NCT02240498|Device|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
76090639|NCT03951454|Behavioral|Taking Time|1 Taking Time telephone session
76090640|NCT04349956|Drug|UBX0101 or placebo|This is an observational study. No intervention is administered.
76090641|NCT04678336|Biological|CART123 cells; cyclophosphamide; fludarabine|CART123 cells following lymphodepleting chemotherapy in pediatric patients with relapsed/refractory AML. Subjects will be treated with a single IV dose of CART123 cells on Day 0.
75476560|NCT05967078|Device|ExerG|"The intervention for primary end users (PEU, (patients)) includes the performance of two training rounds with the device. The first round includes a predefined training sequence, whereas the second round is a training sequence defined by the therapist.~For the secondary end user group (SEU, (therapists)), there are two study visits. At their first visit they get an introduction and training on how to use the system. At their second visit, SEU will have to prepare the device (switch on hard- and software) and guide the patient through the training."
75476561|NCT05967065|Diagnostic Test|vibration induced nystagmus test|Vibration induced nystagmus test by bone transducer B250.
75941645|NCT02240498|Device|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
75941646|NCT02240498|Device|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
75941647|NCT02240498|Device|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
75941648|NCT02240498|Device|Optical spectroscopy measurement|A fiber-optic probe that has undergone high-level disinfection will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity white light will be delivered by a tungsten halogen lamp by a single fiber within the probe, and detected by eight other fibers within the probe. Following this, low-power laser light will be delivered by a fiber-coupled laser diode at 640 nm in order to excite methylene blue fluorescence. Emitted fluorescence will similarly be collected by the eight detection fibers contained within the probe. Upon completion of these measurements, the fiber-optic probe will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
75941649|NCT02178098|Drug|ETC-1002|ETC-1002 capsules taken once daily
75344591|NCT03323463|Drug|Cisplatin|Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.
75344592|NCT03323463|Drug|Carboplatin|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.
75344593|NCT03323463|Drug|5Fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
75344594|NCT03323463|Radiation|Proton Therapy|Proton beam using pencil beam delivery either with the Varian or IBA delivery systems will be allowed for Cohort B. Proton beam therapy will be given at the New York Proton Center in New York City, where MSKCC has a well-established business associate agreement and cooperative research agreement with, respectively. If treatment at NYPC is not feasible, patients may be referred to ProCure in Somerset, NJ.
75344595|NCT03321552|Procedure|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
75344596|NCT03321552|Device|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
75476562|NCT05967013|Combination Product|Injections in thigh of 0.625 mL of physiological serum with ZENEO® injector, on bare skin and through clothing.|"All injections with ZENEO® injector will be performed in the thigh. Due to MRI performance constraints, injection sites will be identified on the same thigh/leg at each treatment period: first leg on treatment period 1, opposite leg on treatment period 2.~At each treatment period, two injection sites will be identified spaced 8 to 15 cm apart. The 2 injections should be performed on the same leg at each treatment period.~In total, 2 injections will be performed per treatment period, and subjects will receive 4 injections during the study :~2 injections on bare skin: 1 with GAMMA configuration of ZENEO® injector & 1 with GAMMA-Low configuration ZENEO® injector.~2 injections through clothing: 1 with GAMMA configuration of ZENEO® injector & 1 with GAMMA-Low configuration ZENEO® injector."
75655531|NCT00841633|Drug|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
75655532|NCT02823678|Procedure|Pancreatectomy|Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
75655533|NCT02823912|Drug|Capsaicin|
75655534|NCT02823912|Drug|Magnesia calcinada|
75802519|NCT02955602|Drug|MBX-8025 2 mg Capsule|"Initial 8-week treatment:~• MBX-8025 2 mg~Extension:~The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
75802520|NCT02955602|Drug|MBX-8025 5 mg Capsule|"Initial 8-week treatment:~• MBX-8025 5 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
75802521|NCT02955602|Drug|MBX-8025 10 mg Capsule|"Initial 8-week treatment:~• MBX-8025 10 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
75802522|NCT04179786|Biological|Sci-B-Vac™|Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.
75344597|NCT03320902|Behavioral|Sudden death counselling|"The Sudden Death Counselling with included relatives at 1 month (+/-15 days) after the eventafter the event will be at the Europeen Georges Pompidou hospital in Paris.~The purpose of this Sudden Death Counselling is to provide to family members of sudden death victims information, support, referral and follow-up services relating to sudden death and their grief, if needed.~The bereaved people will tell their experience. The Sudden Death Counselling would help them to integrate life's losses by companioning them.~Cardiologist and psychologists will be present to listen to their pain and try to bring comfort by answering to their questionings."
75941650|NCT02178098|Drug|Placebo|Placebo capsules taken once daily
75941651|NCT02087852|Other|salvia for germline DNA|
75941652|NCT02087852|Behavioral|the Kidney Cancer Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
75941653|NCT02087852|Behavioral|Family History Questionnaire (when applicable)|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
75941654|NCT02087852|Other|Blood draw|
75655535|NCT00841711|Behavioral|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
75655536|NCT02823288|Other|Sonke CHANGE intervention|"The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability."
75655537|NCT04240860|Biological|platlet rich plasma|"Drug: PRP PRP subendometrial infusion~Device: ovum oickup needle PRP subendometrial infusion by hysteroscopic guided ovum pickup needle day 9 of the cycle"
75655538|NCT04240860|Procedure|endometrial scratch|Three Snip Hysteroscopic Endometrial Scratching in luteal phase of preceeding cycle
75655539|NCT00841867|Procedure|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
75655540|NCT00829413|Drug|SonoVue®|SonoVue (2.4 mL)
75802523|NCT03748290|Drug|Pregabalin|Pregabalin 75 mg for 12 weeks
75941655|NCT02087852|Behavioral|Epidemiologic Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
75941656|NCT01915498|Drug|Enasidenib|Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
75941657|NCT01885689|Drug|clofarabine|Given IV
75941658|NCT01885689|Drug|melphalan|Given IV
75941659|NCT01885689|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
75941660|NCT01885689|Drug|tacrolimus|Given IV or PO
75941661|NCT01885689|Drug|sirolimus|Given PO
75941662|NCT01885689|Other|Pharmacological Study|Correlative studies
75655541|NCT00841945|Drug|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
75655542|NCT00841945|Drug|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
75802524|NCT03748290|Drug|Placebo Oral Tablet|Placebo Oral Tablet
75941663|NCT01798004|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
75941664|NCT01798004|Drug|Busulfan|Given IV
75941665|NCT01798004|Drug|Cisplatin|Given IV
75941666|NCT01798004|Drug|Cyclophosphamide|Given IV
75941667|NCT01798004|Drug|Doxorubicin Hydrochloride|Given IV
75941668|NCT01798004|Drug|Etoposide|Given IV
75941669|NCT01798004|Radiation|External Beam Radiation Therapy|Undergo EBRT
75941670|NCT01798004|Biological|Filgrastim|Given SC or IV
75941671|NCT01798004|Other|Laboratory Biomarker Analysis|Optional correlative studies
75941672|NCT01798004|Drug|Melphalan|Given IV
75941673|NCT01798004|Drug|Mesna|Given IV
75941674|NCT01798004|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
75941675|NCT01798004|Other|Pharmacological Study|Correlative studies
75941676|NCT01798004|Drug|Topotecan Hydrochloride|Given IV
75941677|NCT01798004|Drug|Vincristine Sulfate|Given IV
75941678|NCT01770418|Radiation|Radiation with Concurrent Chemotherapy|"RADIATION: Proton Radiotherapy~Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions~Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions~Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions~Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions~CONCURRENT CHEMOTHERAPY:~Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.~Adjuvant chemotherapy is optional."
75941679|NCT01766297|Radiation|Proton Radiotherapy|
75655543|NCT00841945|Drug|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
75802525|NCT03746418|Drug|Ultrasound Guided Bilateral single shot Erector Spinae Plane Block|Under aseptic technique and after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle (visioplex® - vygon - France) was introduced in plane in a cephalad to caudad direction until (L3) transverse process was hit [figure1(A)(B)(C)] and the needle was slightly withdrawn. The confirmation of the correct position of the needle tip was done by injecting 0.5-1 ml of LA. Once confirmed, 20 ml of the drug was administered under vision after confirming negative aspiration of blood. LA distribution was observed in both cranial and caudal directions. This was repeated on the other side also. Twenty minutes later, sensory loss to cold was evident between (T10-T 12) and (L5-S1) vertebral level of the posterior dermatomes and dermatomes of the anterior roots of the spinal nerves (lumbar plexus, upper leg) on both sides without hemodynamic changes. Motor function of the legs was evaluated with a Bromage (0-3) score.
75941680|NCT01758445|Radiation|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol & physician.
75655544|NCT00841945|Drug|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
75655545|NCT00841945|Procedure|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
75655546|NCT02823054|Device|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
75655547|NCT04239612|Behavioral|Physical exercise|Regular physical exercise in groups. Circular training: both strength and fitness
75655548|NCT04239690|Other|Micromethods for blood sample analysis|Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses
75655549|NCT02822196|Drug|Lidocaine|Local Anesthesia using 1% Lidocaine
75802526|NCT05651074|Drug|Vicagrel and omeprazole|18 mg vicagrel capsules and 40 mg omeprazole magnesium enteric-coated tablets
75941681|NCT01693380|Biological|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:~From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
75941682|NCT01693380|Biological|Control vaccine|"Schoolchildren from 6 to 8 years of age:~- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
75941683|NCT01630434|Device|OCS Lung|OCS Lung will be used to preserve the donor lungs (Treatment Group).
75941684|NCT01630434|Device|Cold flush and storage|Donor lungs will preserved using standard cold flush and storage
75941685|NCT01542879|Procedure|WB-DW-MR scan|WB-DW-MR scans will be obtained on a 3T PET-MR system
75941686|NCT01542879|Procedure|18-F-FDG PET scan|
75941687|NCT01542879|Drug|Ferumoxytol|
75941688|NCT01542879|Procedure|18-F-FDG PET/MR scan|
75941689|NCT01492972|Radiation|Radiation|"Consists of:~Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)"
75655550|NCT02822196|Drug|Bupivacaine|Local Anesthesia using 0.25% Bupivacaine
75655551|NCT00706017|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
75655552|NCT04240236|Procedure|Scalp block|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
75655553|NCT04240236|Other|Control Group|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
75655554|NCT00849277|Drug|Lactobacillus casei Shirota|
75655555|NCT00829179|Drug|RhuMab-E25|three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
75344606|NCT03312400|Drug|Danazol|Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.
75344607|NCT03298061|Drug|Mepolizumab|Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
75941690|NCT01492972|Drug|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
76090642|NCT04648774|Procedure|Serratus anterior plane (SAP) block|With the patient in supine position, an ultrasound transducer will be used to find the 4th rib in the mid-axillary line. A 17g touhy needle will be introduced in-plane in an inferior to superior direction until its tip rests between the serratus anterior muscle and the 4th rib or the 3rd external intercostal muscle. A bolus of study drug 10ml (either ropivacaine 0.2% or normal saline) will be delivered though the needle. A 18g multiholed catheter will be inserted and secured to the patients' skin with adhesive dressings. A further 10ml of study drug will be administered through the catheter. The same procedure will be followed on the contralateral side. The study drug will be administered by programmed intermittent bolus (PIB) 10ml every 2 hours to each side in a staggered, alternating fashion. The PIB study drug will to be continued for 72 hours post-insertion.
76090643|NCT04648774|Procedure|Normal saline placebo|Patients in both groups will receive the standard of care analgesic medications in the cardiovascular intensive care unit and the ward.
76090644|NCT02980588|Device|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
75344608|NCT03298061|Drug|Prednisolone|Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
75802527|NCT03738956|Drug|Tofacitinib|"The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment."
75802528|NCT05645224|Other|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
76090645|NCT03208504|Device|Nexus™ Aortic Arch Stent graft|surgical implantation of Nexus™ Aortic Arch Stent graft
75344609|NCT03247660|Other|PFM training|See information included in arm/group descriptions.
75941691|NCT01376752|Procedure|Maximal cytoreductive surgery|Maximal cytoreductive surgery
75655556|NCT02820636|Behavioral|S-CBT|The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual & 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication & trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
75344610|NCT03247660|Other|HE|See information included in arm/group descriptions.
75655557|NCT02820636|Behavioral|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
75655558|NCT00849355|Drug|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
75655559|NCT00835393|Drug|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
75941692|NCT01376752|Drug|HIPEC|HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
75941693|NCT01256398|Biological|Alemtuzumab|Given IV
75655560|NCT00835393|Drug|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
75655561|NCT02690610|Procedure|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
75941694|NCT01256398|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
75941695|NCT01256398|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
76090646|NCT04349878|Diagnostic Test|gingival crevicular fluid evaluation|anaysis of interleukins in gingival crevicular fluid
76090647|NCT02299258|Device|Standard stents MTN-CG-s-20/100|The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
76090648|NCT02299258|Device|Tailored stents MTN-WE-20/100-A|cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
75941696|NCT01256398|Drug|Cyclophosphamide|Given IV
75941697|NCT01256398|Drug|Cytarabine|Given IV
75344611|NCT03247660|Behavioral|Educational strategy|See information included in arm/group descriptions.
75344612|NCT03213652|Procedure|Biospecimen Collection|Undergo blood sample collection
75344613|NCT03213652|Procedure|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
75344614|NCT03213652|Procedure|Bone Scan|Undergo a bone scan
75344615|NCT03213652|Procedure|Computed Tomography|Undergo a CT scan
75344616|NCT03213652|Drug|Ensartinib|Given PO
75344617|NCT03213652|Other|Laboratory Biomarker Analysis|Correlative studies
75344618|NCT03213652|Procedure|Magnetic Resonance Imaging|Undergo MRI
75941698|NCT01256398|Drug|Dasatinib|Given PO
75941699|NCT01256398|Drug|Daunorubicin Hydrochloride|Given IV
75941700|NCT01256398|Drug|Dexamethasone|Given PO or IV
75941701|NCT01256398|Drug|Etoposide Phosphate|Given IV
75941702|NCT01256398|Biological|Filgrastim|Given SC
75941703|NCT01256398|Drug|Fludarabine Phosphate|Given IV
75941704|NCT01256398|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
76090649|NCT04607122|Drug|Landiolol|Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.
76090650|NCT04607122|Drug|Saline|Continuous infusion of saline solution at the same rate as landiolol infusion.
76090651|NCT04593472|Behavioral|Sharing Healthcare Wishes in Primary Care (SHARE)|SHARE is a multicomponent communication intervention to proactively engage family members or friends to support advance care planning in primary care.
76090652|NCT04593472|Behavioral|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
76090653|NCT04590664|Drug|Verteporfin|Given IV
76090654|NCT03057964|Device|PDL (Pulsed Dye Laser)|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
76090655|NCT03057964|Device|Fractional Photothermolysis Laser|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
76090656|NCT03755206|Other|Sustainability strategies|The investigators will work with each site to determine strategies that are relevant locally to help promote sustainability of the suicide prevention program.
76090657|NCT01721057|Drug|Placebo|Administered orally
76090658|NCT01721057|Drug|Baricitinib|Administered orally
75655562|NCT00591591|Device|OxiplexTS|OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.
75655563|NCT04240548|Radiation|Regional Nodal Irradiation|
75655564|NCT00706173|Drug|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
75655565|NCT00706173|Drug|Placebo|"Placebo 10-20 mg PO daily for 4 weeks."
75344619|NCT03213652|Other|Pharmacological Study|Correlative studies
75655566|NCT02822742|Drug|DE-117 ophthalmic solution|
75655567|NCT02822742|Drug|Latanoprost ophthalmic solution 0.005%|
75655568|NCT00835471|Drug|erlotinib plus docetaxel or pemetrexed|"non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.~squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression."
75802529|NCT03639974|Other|PEP in a blow-bottle device|A 500-milliliter enteral nutrition vial will be used, which will contain a hole in the side, where two silicone tubes of 20 centimeters long will be inserted together with tape on the bottleneck of the vial. To perform the exercise, the vial will be filled with water leaving a water column of 10 cm high. Deep inspirations will be requested at a volume greater than the tidal volume and less than the total lung capacity that can be performed via nasal or oral, then with the mouth connected to the extensors, the patient will exhale slowly, avoiding to totally empty the lungs. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA.
75941705|NCT01256398|Other|Laboratory Biomarker Analysis|Correlative studies
75941706|NCT01256398|Drug|Leucovorin Calcium|Given IV or PO
75941707|NCT01256398|Drug|Melphalan|Given IV
75941708|NCT01256398|Drug|Mercaptopurine|Given PO
75941709|NCT01256398|Drug|Methotrexate|Given IT, IV, or PO
75941710|NCT01256398|Biological|Pegfilgrastim|Given SC
75941711|NCT01256398|Other|Pharmacological Study|Correlative studies
75941712|NCT01256398|Drug|Tacrolimus|Given IV or PO
75655569|NCT00835471|Drug|erlotinib|erlotinib 150 mg/day continuously until disease progression
75941713|NCT01256398|Drug|Vincristine Sulfate|Given IV
75941714|NCT01255748|Radiation|Proton Therapy, Photon Therapy, SRS, Brachytherapy|Outcomes Tracking
75941715|NCT01230866|Radiation|Proton Radiation Hypofractionation|Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
75941716|NCT01230866|Radiation|Proton Radiation Standard Fractionation|Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
76090659|NCT01721057|Drug|cDMARD|Conventional disease-modifying anti-rheumatic drug as a background therapy
76090660|NCT04570384|Drug|L-Citrulline|L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.
76090661|NCT04570384|Drug|Placebo|Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
76090662|NCT02928172|Device|qCON-qNOX|Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
76090663|NCT02928172|Device|BIS|Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
76090664|NCT04541212|Diagnostic Test|Cardiac Imaging|Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test
76090665|NCT04541212|Other|Data Collection|Collection of retrospective data
76090666|NCT02299570|Biological|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
76090667|NCT02299570|Other|Placebo|A suspension of saline and cryoprotectant
76090668|NCT02301364|Drug|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
75655570|NCT02822898|Drug|NaCl 0.9% in Glucose 5% with 40mEq Potassium|NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
75802530|NCT03639974|Other|EPAP|The Vital Signs ® EPAP kit will be used. Exercises will be performed in the bed, and as soon as the patient is released by the medical team to leave the bed, they can be performed in the sitting position or in orthostasis. For performing the exercise, the EPAP mask will be connected to the face of the patient. The expiratory pressure will be adjusted to 10cmH2O. Deep inspirations will be requested at a volume greater than the tidal volume and below the total lung capacity, then the patient will exhale slowly. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA, as described in the conventional physiotherapy group.
75655571|NCT02822898|Drug|Glucion 5%|Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
75802531|NCT03639974|Other|conventional physiotherapy|Conventional physical therapy consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resisted lower limb exercises; stretching, cough and walking guidelines. Initially the exercises will be performed in the bed, as soon as this is withdrawn and the patient is released by the medical team to leave the bed, the progression of the exercises to be performed in the sitting position, orthostasis, and ambulation is performed, this usually occurs on the 2nd postoperative day, after the removal of the mediastinal drain . Under supervision of the physiotherapist, the protocol will be performed twice daily, two sets of ten repetitions.
75802532|NCT05630092|Diagnostic Test|Maximal 6-minute Walk Test (Max_6MWT)|Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.
75802533|NCT05630092|Diagnostic Test|Normal speed 6-minute Walk Test (Nor_6MWT)|Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
75802534|NCT05609656|Device|Irreversible electroporation|"Percutaneous ablation of a metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use."
76090669|NCT04507828|Radiation|Treatment Planning using the DIBH Technique|Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours. The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan. Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
75655572|NCT00828945|Device|Lipid Self Test|Self test for lipid levels, twice during study period
75655573|NCT00849511|Drug|melatonin|Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
75655574|NCT02822040|Other|Intraoral Scan|All patients will have an intraoral scan performed for measurements to be taken on.
75655575|NCT00849589|Behavioral|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
75655576|NCT00849589|Behavioral|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
75655577|NCT00706251|Device|Silicone tube|Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
75655578|NCT02546791|Drug|Dasatinib|
75655579|NCT00842101|Device|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
75655580|NCT00966875|Biological|LY2439821|Subcutaneous
75655581|NCT00966875|Drug|Placebo|Subcutaneous
75655582|NCT04201080|Drug|Part A: TRV250-20mg/ml|TRV250 SC Injections
75655583|NCT04201080|Drug|Placebo|Placebo SC injections
75655584|NCT04201080|Drug|Part B: TRV250 Dose 1|Dose 1of3 TRV250
75655585|NCT04201080|Drug|Part B: TRV250 Dose 2|Dose 2of3 TRV250 SC injections
75655586|NCT04201080|Drug|Part B: TRV250 Dose 3|Dose 3of3 TRV250 SC injections
75655587|NCT04201080|Drug|Placebo|Placebo SC injections
75655588|NCT02820792|Procedure|function tests|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
75655589|NCT02820792|Device|LMA ProtectorTM|
75655590|NCT02820792|Device|Ambu AuraGainTM|
75655591|NCT00849745|Procedure|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
75655592|NCT02821884|Device|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
76090670|NCT02637778|Dietary Supplement|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
75655593|NCT02821884|Device|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
75344620|NCT03213652|Procedure|Positron Emission Tomography|Undergo a PET scan
75344621|NCT03213652|Procedure|Radionuclide Imaging|Undergo radionuclide imaging
75802535|NCT05609656|Device|Calcium electroporation|"Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor.~The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved."
75802536|NCT05609656|Drug|Pembrolizumab|"Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months~Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
75802537|NCT03737162|Procedure|Stent implantation of subclavian artery|Stent implantation of subclavian artery
75802538|NCT01064024|Drug|Phenazopyridine Hydrochloride|Tablets, 200 mg, every 8 hours for 48 hours.
75802539|NCT01064024|Drug|Placebo|Tablets, every 8 hours for 48 hours
75802540|NCT03738722|Drug|Oxygen|HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher&Paykel.
75802541|NCT04175808|Drug|Omecamtiv Mecarbil (OM)|Oral solution
75802542|NCT04175808|Drug|Placebo|Placebo oral solution
75802543|NCT04175808|Drug|Moxifloxacin|400 mg moxifloxacin oral tablet
75802544|NCT04057196|Behavioral|Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)|The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.
75802545|NCT05598424|Drug|Oral Glucocorticoids|Oral Glucocorticoids（methylprednisolone） 24mg qd, 2-week duration
75802546|NCT03748212|Drug|D935 Cap. 1T|single oral administration under fed condition
75802547|NCT03748212|Drug|CKD-385 Tab. 1T|single oral administration under fed condition
75802548|NCT03745014|Diagnostic Test|Accelerate Pheno|The Accelerate Pheno™ system and PhenoTest™ BC Kit is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture.
75802549|NCT03745014|Diagnostic Test|Standard of Care|Standard blood culture work up as determined by the site's microbiology lab.
75802550|NCT05552560|Other|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection before the first consultation with the centre's psychologist.~This questionnaire includes questions on the socio-demographic characteristics, the motivations, as well as the procreative history of the patients."
75802551|NCT04027686|Device|Laser Therapy|Adjunctive application of laser therapy in the periodontal pocket
75802552|NCT04027686|Procedure|Non-surgical Scaling and Root Planing|Scaling to remove calculus deposits and root planing to smooth root surfaces
75344622|NCT03213652|Procedure|X-Ray Imaging|Undergo an x-ray
75344623|NCT03182335|Other|sedation awakening trial|vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
75344624|NCT03178552|Drug|Alectinib|Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
75344625|NCT03178552|Drug|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
75344626|NCT03178552|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV infusion on Day 1 Q21D.
75344627|NCT03178552|Drug|Cisplatin|Participants will receive cisplatin 75 mg/m^2 IV on Day 1 Q21D.
75344628|NCT03178552|Drug|Carboplatin|Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
75344629|NCT03178552|Drug|Gemcitabine|Participants will receive gemcitabine 1000 or 1250 mg/m^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
75802553|NCT05514418|Procedure|Intensive Adherence Counselling (IAC)|Intensive adherence counselling is offered to people living with HIV (PLHIV) having a non-suppressed viral load (VL) result ( a VL of 1,000 copies/ml or more) and this is given once every month for three months. In our study, we are going to give IAC to PLHIV with low-level viraemia (having a VL of 50 copies/ml but less than 1,000 copies/ml) and determine its effectiveness in causing a non-detectable VL (less than 50 copies/ml), which is desirable for PLHIV on ART.
75802554|NCT05513482|Diagnostic Test|Tissue Doppler Imaging|With tissue Doppler ultrasonography (TDI), the maximum contraction rate of the diaphragm, maximum relaxation rate, and integral against time will be examined.
75802555|NCT05513482|Diagnostic Test|M Mode Imaging|Diaphragm displacement during inspiration and expiration will be measured with M mode imaging
75344630|NCT03178552|Drug|Entrectinib|Participants will receive entrectinib 600 mg orally QD.
75344631|NCT03178552|Drug|Cobimetinib|Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
75941717|NCT01151423|Biological|Caplacizumab|"Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure.~All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~Subjects received caplacizumab up to 30 days after the last PE session."
75941718|NCT01151423|Biological|Placebo|"Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure.~All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~Subjects received placebo up to 30 days after the last PE session."
75941719|NCT01040026|Other|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at <1x10e5/kg
75941720|NCT01020383|Drug|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
75941721|NCT01020383|Drug|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
75941722|NCT00889876|Drug|Metformin group|2000 mg/day for one year
75941723|NCT00889876|Behavioral|Exercise|3 times/week with a personal coach for one year. Endurance training.
75655594|NCT02821884|Device|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
75941724|NCT00625417|Procedure|breast biopsy|
75941725|NCT00625417|Procedure|histopathologic examination|
75344632|NCT03178552|Drug|Vemurafenib|Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
75802556|NCT05501860|Drug|AG-920|AG-920 Sterile Topical Ophthalmic Solution
75802557|NCT05501860|Drug|Placebo|Placebo Sterile Topical Ophthalmic Solution
75941726|NCT00625417|Procedure|light-scattering spectroscopy|
75941727|NCT00625417|Procedure|therapeutic conventional surgery|
75344633|NCT03178552|Drug|Bevacizumab|Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
75344634|NCT03178552|Drug|GDC-6036|Participants will receive GDC-6036 PO QD until disease progression or unacceptable toxicity.
75344635|NCT03178552|Drug|Docetaxel|Participants will receive IV docetaxel Q3W (75 mg/m^2) until disease progression or unacceptable toxicity
75655595|NCT00835627|Drug|sertraline|flexible dose sertraline
75655596|NCT00835627|Behavioral|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions
75941728|NCT00587067|Drug|FLOXURIDINE|"[0.16* mg/kg/day X 30 ml] / pump flow rate~* If the patient is >25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles."
75941729|NCT00579514|Genetic|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
75941730|NCT00565617|Device|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
75655597|NCT00835627|Other|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions
75655598|NCT00835627|Other|Standard Care|community care, treatment as usual: routine follow up with existing providers
75802558|NCT03052426|Device|Ergotron WorkFit - TL|A sit to stand work station.
75802559|NCT05465668|Drug|DWP16001 Drug A|DWP16001 Drug A
75802560|NCT05465668|Drug|DWP16001 Drug C|DWP16001 Drug C
75802561|NCT05446948|Device|beveled 27G+ vitrectomy system|The device is a novel 27G+ vitrectomy system, whose probe tip is beveled.
75802562|NCT05446948|Device|standard 25G+ vitrectomy system|The device is a traditional instrument, and its probe tip is flat.
75802563|NCT03688880|Device|MAR-CUTIS|MAR-CUTIS was applied in 1 to 2 mm thick layer, ensuring that at least 1 cm of the glue was applied over the length of the wound on each side. The amount of the glue applied was calculated such that one 5-mL syringe covers approximately 8 cm of wound length (giving a total of 10 cm per syringe). For wounds >8 cm, 2 syringes were required.
75802564|NCT03688880|Device|Dermabond Advanced|Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions, taking care not to apply adhesive between the wound edges.
75802565|NCT03737084|Behavioral|CBCT Intervention|The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
75655599|NCT05659446|Procedure|endoscopy management of low output colonic fistula or leak after anterior resection for rectal cancer|Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical & mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
75941731|NCT00453154|Drug|Carboplatin|Given IV
75941732|NCT00453154|Drug|Cisplatin|Given IV
75941733|NCT00453154|Drug|Etoposide|Given IV
75941734|NCT00453154|Other|Laboratory Biomarker Analysis|Correlative studies
75941735|NCT00453154|Other|Placebo Administration|Given PO
75941736|NCT00453154|Drug|Sunitinib Malate|Given PO
75941737|NCT00309257|Drug|ACE I, ATA II and Statins|
75344636|NCT03175302|Behavioral|digital cognitive testing|The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
75655600|NCT00849823|Behavioral|Male Sexual Health Program|"An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex."
75655601|NCT00849823|Behavioral|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
75655602|NCT02822820|Device|Ligasure-Covidien|Vessel sealing device Ligasure-Covidien used during laparoscopic hysterectomy and pelvic lymphadenectomy
75655603|NCT02822820|Device|RoBi forceps-Karl Storz|Vessel sealing device RoBi forceps-Karl Storz used during laparoscopic hysterectomy and pelvic lymphadenectomy
75655604|NCT00849979|Behavioral|Questionnaire|Day 1 MDASI-GI Questionnaire
75802566|NCT05581966|Diagnostic Test|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
75802567|NCT05018390|Other|Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. Osteopathic manipulations will consist in corrective micro-movements applied on synovial joints, on the skull, the teeth and/or visceral structures of the abdomen or the thorax. Local pressures won't exceed a few tens of grams/cm². Practitioners will realize between 15 and 25 technical gestures per participant. Treatment will last 30 minutes (plus or minus 5 minutes) on average. The technical gestures are referenced in the Glossary of Osteopathic Terminology published by the American Association of Colleges of Osteopathic Medicine (2017).
75941738|NCT00309257|Drug|Benazepril, Valsartan and Fluvastatin|"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."
75941739|NCT00258960|Drug|Liposomal Doxorubicin|
75941740|NCT00258960|Drug|Cyclophosphamide|
75941741|NCT00258960|Drug|Trastuzumab|
75941742|NCT00149305|Other|Genetic analyses|
75941743|NCT00149305|Other|Genetic analyses|
75941744|NCT00121992|Drug|Docetaxel|
75941745|NCT00121992|Drug|5-fluorouracil|
75941746|NCT00121992|Drug|Doxorubicin|
75941747|NCT00121992|Drug|Cyclophosphamide|
75941748|NCT00070564|Biological|pegfilgrastim|Given IV
75941749|NCT00070564|Drug|AC regimen|Given IV
75941750|NCT00070564|Drug|cyclophosphamide|Given IV
75941751|NCT00070564|Drug|doxorubicin hydrochloride|Given IV
75941752|NCT00070564|Drug|paclitaxel|Given IV
75941753|NCT04610775|Other|Order of cuff sizes during blood pressure measurements|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the cuff sizes are used.
75941754|NCT05158725|Device|Standard Colonoscopy|In this arm, subjects will undergo colonoscopy using a standard colonoscope
75941755|NCT05158725|Device|Discovery aided colonoscopy|the Discovery is a customized detection support software, developed utilizing AI deep learning technology to support endoscopic lesion detection in the colon. In this arm, a standard colonoscope is used with the Discovery.
75941756|NCT05158725|Device|Discovery and G-EYE|The G-EYE® Endoscope is a standard colonoscope which is remanufactured by installing the G-EYE® balloon on the distal bending section of the colonoscope. in this arm, the G-EYE® Endoscope is used with the Discovery
75941757|NCT00702351|Drug|Org 36286 (corifollitropin alfa)|A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing >= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing <= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
75941758|NCT05158647|Other|normal saline|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
75941759|NCT05158647|Drug|MgSo4|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
75941760|NCT03477981|Other|Alginate bread|White bread with 4% alginate (wet weight of dough) included into the bread.
75344637|NCT03170375|Behavioral|Performance of WHEELS-I in promoting DASH/SRD adoption|Participants will receive the WHEELS-I electronically-delivered tailored messaging intervention in addition to motivational interviewing-based counseling.
75941761|NCT03477825|Dietary Supplement|Placebo Oral Tablet|"Group A: Placebo group (n = 10)~Supplement appearing similar to Herbal formulations~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 4 placebo tablets per day"
75941762|NCT03477825|Dietary Supplement|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~Each tablet contains 500 mg of R. cordifolia per tablet."
75941763|NCT03477825|Dietary Supplement|Triphala|"Group C: Triphala group (n= 10)~Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
75941764|NCT04234659|Device|Clinical placement of a temporary IMPELLA® mechanical circulatory support device.|Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.
75344638|NCT03170375|Behavioral|Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors|Participants will be randomized to the sequence DASH/SRD-control diet or control diet-DASH/SRD, and consume the diets for 14 days each.
75344639|NCT03141359|Radiation|SBRT|Primary tumor SBRT
75655605|NCT00849979|Other|Interview|Open-ended, audiotaped interviews
75655606|NCT02546869|Drug|Lebrikizumab|Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
75655607|NCT02546869|Device|Prefilled Syringes|
75655608|NCT02820480|Device|Rehab in a Crate System|"The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use."
75802568|NCT05018390|Other|Sham Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. They will receive 20 gestures that will be standardized and different from actual osteopathic manipulations (but not identifiable as sham manipulations by the participants). The duration of the sham treatment will be the same as the actual treatment.
75344640|NCT03141359|Drug|Carboplatin|concurrent chemotherapy
75655609|NCT02822430|Other|Pain scales|"Visual analogic scale of pain~Pain behaviour scale~Short-FormHealth Survey (SF-36)~Clinical Global impression~Mini International Neuropsychiatric Interview (MINI)"
75802569|NCT03738488|Device|3D printing + images|To perform a surgery planification with the combination of the images available and the 3D biomodel in terms of: anticipation of potential complications and the human resources and necessary materials
75941765|NCT02523105|Device|EEG monitoring|"EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises."
76090671|NCT02637778|Dietary Supplement|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
76090672|NCT03664726|Behavioral|Episodic Future Thinking|Participants will be instructed to use their episodic future cues as they engage in different decision making tasks.
76090673|NCT03664726|Behavioral|Episodic Recent Thinking|Participants will be instructed to use their episodic recent cues as they engage in different decision making tasks.
75344641|NCT03141359|Drug|Paclitaxel|concurrent chemotherapy
75344642|NCT03141359|Drug|cis Platinum|concurrent chemotherapy
75655610|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
75655611|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
75655612|NCT02821494|Biological|Hespecta|A dose escalation of Amplivant® conjugated peptide
75655613|NCT00842491|Drug|endostar, cisplatin, capecitabine|"Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously"
75802570|NCT03738488|Other|Images|To perform a surgery planification with the images available in terms of: anticipation of potential complications and the human resources and necessary materials
75802571|NCT03795142|Biological|BGB149|Single Ascending Dose
75802572|NCT03795142|Biological|Placebo|Matching placebo
75802573|NCT03051178|Device|Responsive deep brain stimulation|Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
76090674|NCT03664726|Behavioral|Scarcity Narrative|Participants will read a narrative to induce a scarcity mindset, in which they are asked to imagine a scenario in which they have lost their job and have no current secondary income.
76090675|NCT03664726|Behavioral|Neutral Narrative|Participants will read a narrative in which they are asked to imagine a scenario in which they have been transferred between departmental jobs, with little change in salary/commute.
76090676|NCT03648112|Dietary Supplement|Intervention 1|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes per day.
75344643|NCT03141359|Drug|Etoposide|concurrent chemotherapy
75344644|NCT03141359|Radiation|IMRT|mediastinal radiation
75344645|NCT03141359|Drug|Durvalumab|adjuvant immunotherapy
75655614|NCT00842491|Drug|capecitabine|"Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally"
75655615|NCT00842491|Drug|cisplatin|"Product 3: cisplatin~Dosing schedule: 80mg/m2, day 1 of every 3 weeks~Mode of administration: intravenously"
75941766|NCT03637959|Device|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
76090677|NCT03648112|Dietary Supplement|Intervention 2|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes per day.
75802574|NCT03736850|Drug|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
75941767|NCT02738151|Drug|Insulin glargine, 300U/mL|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
75941768|NCT02738151|Drug|Insulin degludec, 100 U/mL|"Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous"
76090678|NCT03648112|Dietary Supplement|Intervention 3|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes per day.
76090679|NCT03648112|Dietary Supplement|Intervention 4|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes per day.
75802575|NCT03738254|Other|The Guardians: A smartphone game|"The Guardians is a mix of two popular game genres: idle games (a game that doesn't require constant player input in order to progress in the game, but often progresses exponentially in response to a few user inputs, e.g., Cookie Clicker and Adventure Capitalist) and pet collection games (a game where the player seeks to collect all of the pets in a set, e.g., Pokemon or Neko Atsume). The game gives the player an in-game reward for completing a survey."
76090680|NCT03648112|Dietary Supplement|Control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
75655616|NCT02821728|Dietary Supplement|Dietary intervention|Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.
75655617|NCT02821728|Other|Normal diet|Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
75655618|NCT00850057|Biological|Intranodal injection of Ad-ISF35|Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).
75655619|NCT02821572|Biological|blood sample|
75802576|NCT03738254|Other|Paper Survey|Paper version of daily survey
75802577|NCT03738254|Other|Electronic Survey|Electronic version of daily survey administered via a smartphone app.
75802578|NCT03738176|Drug|Sesame Oil|Sesame oil(80 gm NaCMC-20 gmSesame oil)
75941769|NCT02738151|Drug|Non-insulin anti-diabetic treatment|Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
76090681|NCT02563522|Genetic|Engensis (VM202)|gene therapy
76090682|NCT02563522|Drug|Placebo|Standard of care plus placebo
76090683|NCT03578146|Combination Product|PRT064445/Rivaroxaban|
76090684|NCT03578146|Combination Product|Placebo/Rivaroxaban|
76090685|NCT03578146|Drug|Placebo|
76090686|NCT02464332|Drug|BLZ-100|"All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.~Three different imaging windows will be investigated during the study:~Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)~All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups."
76090687|NCT02518594|Drug|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
76090688|NCT02518594|Drug|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
75344646|NCT03072927|Device|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
75344647|NCT03032029|Device|Adaptive Servo-Ventilation|Adaptive Bi-Level positive airway pressure with a targeted minute ventilation and auto-adjusting expiratory pressure level.
75655620|NCT02821572|Procedure|spleen sample|
75655621|NCT00828711|Drug|MVI 100|Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
75655622|NCT00828711|Drug|MVI 150|Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
76090689|NCT02518594|Device|Arabin Pessary|Placement management from randomization to < 35 wks
76090690|NCT02986438|Device|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold."
75941770|NCT03472911|Other|minimum effective volume|The determination of MEV50 and its 95% confidence interval (CI) was based on the staircase up-and-down method by Dixon and Massey.
75941771|NCT04457661|Dietary Supplement|Bacillus coagulans TCI711|Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.
75941772|NCT05222139|Biological|COVID-19 vaccination|Monitoring COVID-19 vaccination
75941773|NCT02120222|Drug|selinexor|Given PO
75941774|NCT02120222|Other|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
75344648|NCT02983682|Drug|Lidocaine Infusion|Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
75655623|NCT00828711|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
75941775|NCT00969111|Radiation|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE|Postop High Risk
75344649|NCT02980029|Drug|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
75655624|NCT05659212|Drug|Dexmedetomidine|Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
75655625|NCT05659212|Drug|Magnesium sulphate|Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
75655626|NCT05659212|Drug|Lidocaine|Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
75802579|NCT03738176|Drug|triamcinolone in orabase|triamcinolone 140 gm-Na CMC 50 gm
75802580|NCT03745274|Biological|GHB04L1|Solution
75802581|NCT03745274|Other|Placebo|Buffer solution
75655627|NCT05659134|Other|Alfredson protocol|Alfredson eccentric therapeutical protocol.
75941776|NCT00969111|Radiation|Proton (prostate bed) to 70.2 CGE|Salvage Non-High Risk
75941777|NCT00969111|Radiation|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE|Salvage High Risk
75941778|NCT00969111|Radiation|Proton to 66.6 CGE|Post-Op Non High Risk
75941779|NCT05212389|Drug|Femicept|150 μg levonorgestrel +30 μg ethinylestradiol
75344650|NCT02980029|Other|Placebo|Placebo
75344651|NCT02971748|Biological|Pembrolizumab|Given IV
75344652|NCT02943681|Biological|Measles vaccine|
75344653|NCT02861573|Biological|Pembrolizumab 200 mg|IV Q3W
75655628|NCT05659134|Other|Silbernagel protocol|Silbernagel concentric-eccentric protocol.
75344654|NCT02861573|Drug|Olaparib 400 mg|Eight 50-mg capsules PO BID
75344655|NCT02861573|Drug|Docetaxel 75 mg/m^2|IV Q3W
75655629|NCT04043169|Diagnostic Test|Clearblue pregnancy test|Urine pregnancy test
75655630|NCT00966719|Other|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
75655631|NCT02821650|Other|TEJ (Traditional stove to Efficient stove in Jhuggi)|TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
75655632|NCT00835939|Drug|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
75941780|NCT05212389|Drug|Placebo|Placebo
75941781|NCT03472755|Other|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
75941782|NCT03472755|Other|Direct anterior technique|patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
75655633|NCT00835939|Drug|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
75655634|NCT00835939|Procedure|sclerotherapy|
75655635|NCT04708704|Dietary Supplement|Erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be obtained from Roxy & Rich Inc. (Intense Water-Soluble Food Colorant - Pink), which is certified to be edible and complies with US FDA, Health Canada, and European food safety standards. The erythrosine will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.69 mg/kg bw.
75802582|NCT03736772|Drug|LY3090106|Administered SC
75802583|NCT03736772|Drug|Placebo|Administered SC
75802584|NCT03051100|Drug|Bempedoic acid 180mg|bempedoic acid 180 mg
75802585|NCT03051100|Drug|Ezetimibe 10mg|ezetimibe 10 mg
75802586|NCT03051100|Drug|Atorvastatin 20mg|atorvastatin 20 mg
75802587|NCT03051100|Other|Placebo|placebo
75802588|NCT05280028|Drug|Tibolone 2.5 mg|Tibolone 2.5 mg per day
75941783|NCT03471039|Drug|PACAP27|Infusion of PACAP27 over 20 minutes.
75941784|NCT03471039|Drug|Saline|Infusion of Saline over 20 minutes.
75941785|NCT03472677|Other|Ice Pack and Cooling Device|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
75941786|NCT03472677|Drug|CNTX-4975-05 (trans-capsaicin)|Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).
75344656|NCT02861573|Drug|Prednisone 5 mg|One 5-mg tablet PO BID
75344657|NCT02861573|Drug|Enzalutamide 160 mg|Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
75941787|NCT03472677|Drug|CNTX-4975-05 (trans-capsaicin)|Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
75941788|NCT03472677|Drug|CNTX-4975-05 (trans-capsaicin)|Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
75344658|NCT02861573|Other|Dexamethasone 8 mg|Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
75344659|NCT02861573|Drug|Olaparib 300 mg|Two 150-mg tablets PO BID
75344660|NCT02861573|Drug|Abiraterone acetate 1000 mg|Two 500-mg or four 250-mg tablets PO QD
75344661|NCT02861573|Drug|Lenvatinib|20 mg PO QD
75476563|NCT05967000|Other|Preventive heart health and menopause programme|"This is a one-stop women's heart and menopausal service in a public hospital led by cardiologists and gynaecologists with a multidisciplinary team. Pre-existing speciality care and services are repackaged, and clinic workflows are reworked to provide more streamlined, convenient, and integrated care. Services encompass:~Individualised risk assessment, screening, diagnosis, and treatment of CVD.~Lifestyle education, adjustment, stress management, and counselling.~Smoking cessation programs.~Bone health screening, mammogram with access to our co-located gynaecologists and hormone replacement therapy.~Virtual consults and health coaching."
75476564|NCT05966987|Combination Product|Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin|laser and platelet rich fibrin
75476565|NCT05966857|Device|Wearable: Smartwatch|The SAMSUNGTM Galaxy Watch5 Smartwatch, is a new generation of smartwatches, features an innovative 3-in-1 BioActive sensor, which uses a chip to capture optical and read cardiac electrical current, allowing to carry out high-quality real-time single-lead electrocardiogram. Despite the more compact design, there is no decrease in accuracy. These signals are then processed by the device's algorithms and can be sent to a trained professional for evaluation immediately after the measurement, facilitating the monitoring and diagnosis of arrhythmias.
75476566|NCT05966844|Behavioral|Mindfluness and Virtual Reality|They will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
75476567|NCT05966818|Drug|Dapagliflozin and Standard therapy (ACEI or ARB).|Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).
75476568|NCT05966818|Drug|Standard Therapy (ACEI or ARB).|Standard Therapy which include either ACEI or ARB for 24 weeks.
75476569|NCT05966792|Drug|SGLT2 inhibitors combined with metformin|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
75655636|NCT04708704|Dietary Supplement|SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be SODIS-treated to produce photobleached erythrosine. Transparent 500 mL polyethylene terephthalate (PET) plastic water bottles will be commercially purchased (Kirkland Signature Purified Water). All branding information and labeling will be removed from the bottles. Water bottles will be dosed with ~41 mg erythrosine (0.69 mg/kg bw) using an erythrosine stock solution (8.2 g/L) and will be shaken to mix. The erythrosine-dosed bottles will be placed on a metal shelf and exposed to natural sunlight on the roof of Yale Engineering. Sunlight exposure will be conducted until the absorbance value of erythrosine at the absorption maximum of 526 nm falls below 0.05 above baseline, as measured by ultraviolet-visible spectroscopy. The water bottles containing photobleached erythrosine will be stored under refrigeration in the dark until consumption by participants.
75655637|NCT04708704|Dietary Supplement|Iodine, prepared in drinking water 0.075 mg/kg bw/day)|Iodine used in the study will be in the form of FCC-grade potassium iodide, which will be obtained from VWR. FCC grade potassium iodide meets the requirements set by the Food Chemical Codex and is suitable for all applications in foods and beverages. Iodine (control exposure) will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.75 mg/kg bw.
75655638|NCT00842803|Drug|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
75344662|NCT02861573|Biological|Pembrolizumab/Vibostolimab coformulation|IV Q3W
75344663|NCT02861573|Drug|Carboplatin|IV Q3W
75344664|NCT02861573|Drug|Etoposide|IV on Days 1, 2 and 3 of each cycle
75344665|NCT02861573|Biological|Belzutifan 120mg|PO QD
75655639|NCT04759170|Other|Music therapy|The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby
75655640|NCT00842881|Device|Healingstone navel belt|6~8hours/day for 3months
75941789|NCT03472677|Drug|Capsaicin|Four intradermal injections of capsaicin, two on each forearm.
75941790|NCT04943601|Other|action observation therapy|The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients
75344666|NCT02846246|Other|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
75476570|NCT05966792|Drug|Placebo combined with metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
75476571|NCT05966779|Other|modified CDT physical therapy protocol, based on Godoy's Method|modified CDT physical therapy protocol
75476572|NCT05966714|Device|NIRS|cerebral oxygenation and electrical activity monitoring
76090691|NCT02986438|Device|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks."
75941791|NCT04943601|Other|conventional physical therapy|Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
75941792|NCT04917705|Other|Collection of biological samples|Skin, muscle fiber and blood sampling
75941793|NCT02673567|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
76090692|NCT01895673|Other|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
75344667|NCT02846246|Other|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
75344668|NCT02840422|Device|ARTHRUM H 2%|ARTHRUM H 2%
75344669|NCT02807558|Drug|Tamibarotene|Administered as oral tablets
75344670|NCT02807558|Drug|Azacitidine|Administered via intravenous (IV) or subcutaneous (SC) infusion
75655641|NCT05164289|Other|Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
75655642|NCT05164289|Other|EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
75344671|NCT02807558|Drug|Daratumumab|Administered via IV infusion
75344672|NCT02765672|Behavioral|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
75344673|NCT02765672|Other|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
75655643|NCT05659368|Drug|Tirzepatide|tirzepatide once weekly
75655644|NCT00818649|Drug|bortezomib|1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
75941794|NCT02673567|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
75941795|NCT02673567|Drug|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
75941796|NCT02673567|Drug|Placebo|Matching Placebo
75941797|NCT00702195|Drug|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
75941798|NCT00702195|Drug|Placebo|single dose of placebo (administered under protocol 38805)
75941799|NCT00702195|Drug|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
76090693|NCT02716896|Radiation|Radiation and chemoradiation|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
76090694|NCT02716896|Procedure|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
75344674|NCT02765672|Behavioral|Propensity for Angry Driving Scale|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
75344675|NCT02765672|Behavioral|Community Integration Questionnaire|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
75344676|NCT02765672|Behavioral|Satisfaction with Life|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
75344677|NCT02765672|Behavioral|Fitness-to-Drive Screening Measure (FTDS)|Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
75344678|NCT02765672|Procedure|Simulated Driving Evaluation|This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
75476573|NCT05966714|Device|aEEG|amplitude-integrated electroencephalography
75655645|NCT00818649|Drug|vorinostat|400 mg orally (po) every day on days 1-14 of a 21 day cycle
75655646|NCT00850213|Device|Endeavor Resolute Stent|Single implantation
75941800|NCT01550237|Radiation|radiotherapy daily verification reduced safety margins|curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)
75941801|NCT01550237|Radiation|radiotherapy weekly verification standard safety margins|curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
75941802|NCT02915159|Biological|Abatacept|
75941803|NCT02915159|Other|Placebo|
75655647|NCT04808544|Drug|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
75655648|NCT04808544|Drug|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
75655649|NCT02822352|Other|Chromoendoscopy|High definition virtual chromoendoscopy
75655650|NCT02861105|Drug|LMWH|LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
75941804|NCT04058951|Other|High Animal Protein Diet (HAPD)|A diet containing 2,0 g protein per kilo body weight per day from primarily animal origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on beef isolate.
76090695|NCT02986360|Behavioral|Vidscrip educational video|Vidscrip educational video provide to women
76090696|NCT02465346|Device|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
76090697|NCT02465346|Device|Control stroke management|Conventional stroke management
76090698|NCT03510988|Diagnostic Test|Hybrid breast FDG PET/MRI|Hybrid breast FDG PET/MRI
75941805|NCT04058951|Other|High Plant Protein Diet (HPPD)|A diet containing 2,0 g protein per kilo body weight per day exclusively from plant origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on soy isolate.
75941806|NCT03669263|Drug|Fentanyl buccal soluble film (FBSF)|"After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed."
76090699|NCT02462226|Behavioral|The-Optimal-Lymph-Flow|"The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI."
75655651|NCT02861105|Other|0.9% saline solution|0.9% saline solution will be given subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
75655652|NCT00842959|Device|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
75655653|NCT00842959|Device|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
75655654|NCT04283357|Other|Exercise|Short Foot Exercises
75655655|NCT04283357|Device|Virtual Reality|Exercise with virtual reality
75655656|NCT02820558|Drug|Substance P|
75941807|NCT03658915|Device|Smartphone application (Goniometer Pro )|Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
75941808|NCT01208987|Other|Medication History was printed|
75965988|NCT03048032|Procedure|Echocardiography exam|A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
75965989|NCT02089139|Device|Discogel|DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
75344679|NCT02765672|Procedure|Driving Safety Education|This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
75655657|NCT04043299|Drug|100% Oxygen|High flow cylinder oxygen will be administered to women with fetal distress during labor
75655658|NCT04043299|Drug|21% oxygen|High flow cylinder packaged medical air will be administered to women with fetal distress during labr
75655659|NCT02820246|Other|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
75344680|NCT02765672|Procedure|Occupational Therapy Driving Intervention (OT-DI)|This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
75344681|NCT02765672|Procedure|On-road driving test|This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
75344682|NCT02765672|Procedure|Driving triggers evaluation|The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
75344683|NCT02751710|Other|Whole-body FDG PET-CT alone|FDG PET-CT imaging
75655660|NCT00961571|Drug|sunitinib and capecitabine|Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
75655661|NCT02818608|Device|Functional Electrical Stimulation (FES)|Functional Electrical Stimulation (FES) + Sham Transcranial direct brain stimulation (tDCS)
75655662|NCT02818608|Device|Combination of Transcranial direct brain stimulation (tDCS) and FES|Real Functional Electrical Stimulation (FES) + Real Transcranial direct brain stimulation (tDCS)
75655663|NCT04284995|Drug|RUC-4 Compound|All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.
75655664|NCT02820948|Drug|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
75655665|NCT04239378|Procedure|socket preservation|Autogenous dentin matrix and collagen membrane(test group) Bovine derived xenograft and collagen membrane (control group)
75655666|NCT04283279|Other|Virtual reality exercise|"Participants will do exercises in a virtual environment, solving tasks that require cognitive efforts and motor/balance efforts. The virtual environment/tasks will be delivered through a head-mounted display (goggles). Difficulty will progress from standing/sitting, to walking on a treadmill. The environments that will be used will be both over-the-counter environments, as well as in-house designed environments."
75941809|NCT03477747|Device|Microcurrent|Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially should calibrate the microcurrent devices. There is no physical sensation associated with microcurrent based treatments as the strength of the current is not high enough to stimulate sensory nerve fibres. The application of electric fields and currents similar to those generated within the body can substantially change the cell structure and the metabolic behaviour of cells. For example, the application of microcurrent increases the number of organelles responsible for cellular activities; it increases concentrations of adenosine triphosphate (ATP) and amino acid transport; promotes protein synthesis; fastens regrowth of atrophied soleus muscle and would also activate hormone-sensitive lipase which can increase lipolysis from the internal and external adipose tissue. The microcurrent treatment with training would maximize exercise and recovery outcomes in athletes.
75941810|NCT04058483|Other|Hypnotizability testing|Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.
75941811|NCT02924051|Behavioral|Motivational Interviewing|"Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence."
75941812|NCT02924051|Behavioral|Cooking skills and nutritional education|Participants in this group will develop an understanding of healthy food options and healthy food preparation.
75941813|NCT04058249|Device|Accelerated intermittent theta-burst stimulation over right DLPFC|"All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator."
75941814|NCT03668795|Procedure|Bakrey balloon insertion within the uterus and caesarean hysterectomy|Creating an intrauterine tamponade to stop the uterine bleeding by inflating an intrauterine balloon with 600 cc of saline versus undergoing hysterectomy if conservative management failed
75941815|NCT02923427|Device|Laryngeal mask Supreme Evaluation|Evaluation of clinical performance in terms of Insertion, ventilation and complications
75941816|NCT02923427|Device|i-gel Evaluation|Evaluation of clinical performance in terms of Insertion,ventilation and complications
76090700|NCT02462226|Behavioral|Arm Precaution|"The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb."
75344684|NCT02726386|Drug|ND0612|ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
75802589|NCT05280028|Drug|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
75802590|NCT05569876|Other|Controlled hypoglycemic state|Voice sampling is performed in different glycemic states (euglycemia and hypoglycemia).
75344685|NCT02711553|Drug|Ramucirumab|Administered IV
75655667|NCT04283279|Other|Vestibular rehabilitation exercise|Vestibular rehabilitation exercises focus on head and eyes movements, as well as whole-body movements. The aim is to facilitate the use of other sensory organs than the vestibular organs, which will also be relevant to persons who are not receiving sufficient sensory information from the auditory system. The exercises will progress as tolerated, under careful supervision of trained therapists.
75655668|NCT04283279|Other|Control|Participants will not be randomised to either of the exercise interventions, but will be adviced to stay active
75802591|NCT05229328|Diagnostic Test|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
75802592|NCT01343368|Drug|Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
75941817|NCT02669264|Drug|ADCT-402|Intravenous infusion
75941818|NCT02521870|Drug|SD-101(1)|SD-101 administered intratumorally at escalating doses (up to 11 doses).
75941819|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
75941820|NCT02521870|Drug|SD-101(2)|Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
75941821|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
75344686|NCT02711553|Drug|Merestinib|Administered orally
75344687|NCT02711553|Drug|Cisplatin|Administered IV
75344688|NCT02711553|Drug|Gemcitabine|Administered IV
75941822|NCT02521870|Biological|SD-101(3)|Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
75941823|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
75941824|NCT02923349|Drug|INCAGN01949|Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
75941825|NCT02386046|Other|Pulse oxymeter measurements|Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
75941826|NCT02385656|Drug|Modafinil|200mg of modafinil daily for 4 weeks
75941827|NCT02389868|Drug|Lovastatin|
75941828|NCT03668717|Device|Robotic-arm assisted medical MCK implant|Robotic-arm assisted medical MCK implant system to replace the medial compartment of the knee.
75344689|NCT02711553|Drug|Placebo Oral|Administered orally
75344690|NCT02711553|Drug|Placebo IV|Administered IV
75344691|NCT02667587|Drug|Nivolumab|
75344692|NCT02667587|Drug|Temozolomide|
75655669|NCT02818686|Drug|TD-1473|
75655670|NCT02818686|Drug|Placebo|
75655671|NCT02860949|Drug|0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL|
75802593|NCT01343368|Biological|hematopoietic cell transplant|Conventional bone marrow transplant regimen.
75344693|NCT02667587|Radiation|Radiotherapy|
75344694|NCT02667587|Other|Nivolumab Placebo|
75344695|NCT02576509|Drug|Nivolumab|Specified Dose on Specified Days
75655672|NCT02860949|Procedure|Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)|
75655673|NCT02860949|Procedure|Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL|
75655674|NCT02690376|Device|Magnetic Assisted Capsule Endoscopy|Swallowed magnetic capsule for endoscopy purposes
75655675|NCT04200612|Behavioral|Equine-Assisted Psychotherapy|Equine-Assisted Psychotherapy (EAP) involves working on the psychological goals set between the client and the mental health professional. This is done through the experiential interactions between the clients and the horse. This experiential aspect is vital as it allows clients to process the emotions, thoughts and behaviors that were expressed during sessions with the horse.
75802594|NCT01343368|Biological|reduced intensity allogeneic HCT|A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
75802595|NCT05204992|Procedure|ultrasound guided hydrodissection|Injection of steroids, saline and bupivicaine ultrasound guided
75802596|NCT02955212|Drug|Upadacitinib|Tablets for oral administration
75941829|NCT02521792|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
75941830|NCT03623087|Drug|Cisplatin|SIMPLE
75941831|NCT03623087|Drug|Gemcitabine|SIMPLE
75941832|NCT03623087|Drug|Etoposide (VP-16)|SIMPLE
75941833|NCT03623087|Device|Ifosfamide|SIMPLE
75941834|NCT03623087|Drug|Dexamethasone|SIMPLE
75941835|NCT03623087|Drug|L-asparaginase|SIMPLE
75941836|NCT02390024|Device|Invasive Mechanical Ventilation|"Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:~Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840"
75941837|NCT05066932|Other|Additionnal blood samples|Additionnal blood samples
75941838|NCT03668171|Procedure|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
75941839|NCT03669185|Drug|Pentalong|Pentalong, 2 x daily 1 tablet, intake max. 133 days
75941840|NCT03669185|Drug|Placebos|Placebos, 2 x daily 1 tablet, intake max. 133 days
75941841|NCT03668093|Other|ICCM|comprehensive system for caries management
75941842|NCT03668093|Other|CAMBRA|Caries risk assessment model
75941843|NCT03623165|Device|Cordella™ Heart Failure System|The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.
75941844|NCT04058327|Diagnostic Test|blood ammonia test, neurophysiological/psychological tests, blood markers.|Let the patients do neuropsychological/psychological tests and use blood test for ammonia and blood markers.
75941845|NCT04058327|Drug|HE drug treatments in clinical real world|record the HE drug treatments in clinical real world if doctors use them
75941846|NCT05021120|Drug|AK127|Subjects will receive AK127 by intravenous administration
75344696|NCT02576509|Drug|Sorafenib|Specified Dose on Specified Days
75655676|NCT04200612|Behavioral|Equine-Assisted Activities|Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
75655677|NCT04200612|Other|Placebo-control group|This group will only be watching movies related to horses and they are told that this is another form of EAP even though this is not the case. This type of intervention has not been known to provide any therapeutic effect relevant to the study and thus is used as the placebo-control.
75802597|NCT02955212|Drug|Placebo|Tablets for oral administration
75802598|NCT03050398|Drug|Ribociclib|ribociclib + letrozole
75802599|NCT03050398|Drug|letrozole|ribociclib + letrozole
75802600|NCT05175118|Device|Minimal invasive surgical fixation of distal radius Fractures|Fixation of distal radius Fractures by minimal invasive technique
75820020|NCT03536182|Radiation|Carbon Ion Radiation Therapy (CIRT)|Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
75941847|NCT05021120|Drug|AK104|After AK127 infusion, on the same day subjects will receive AK104 by intravenous administration
75941848|NCT05065528|Dietary Supplement|Magnesium|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with 400 mg supplemental magnesium twice daily for 3 days
75941849|NCT05065528|Drug|Placebo|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
75941850|NCT03113396|Drug|Baclofen|baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
75941851|NCT03113396|Drug|Placebo oral capsule|placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
75941852|NCT03020615|Drug|Hydroxyurea|Given orally once daily.
75941853|NCT03020069|Device|CGMS Device|
75941854|NCT03020069|Other|No Device|
76090701|NCT02465502|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
75802601|NCT03736694|Behavioral|Cognitive behavioural therapy for insomnia|CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, & Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, & Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, & Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, & Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, & Meijer, 2015).
75941855|NCT05064046|Behavioral|LuCa + Health Disparity module|"The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making."
76090702|NCT01516593|Drug|Induction Phase|"dd -2 to 1: Methylprednisolone~dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~dd 2, Rituximab~dd 7, Methotrexate~dd 14, Rituximab~dd 15, Etoposide~dd 21, Methotrexate~dd 29, Rituximab and Doxorubicin~dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~pts in CR: consolidation phase followed by bulky site irradiation~pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation"
76090703|NCT01516593|Drug|Consolidation Phase (on day +50)|"dd 1-2: cytarabine twice a day~dd 3 and 11: rituximab~dd 11-13: leukapheresis for PBPC collection."
76090704|NCT01516593|Drug|Intensification phase|"One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.~CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);~AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed)."
76090705|NCT01516593|Drug|BEAM conditioning|BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
75344697|NCT02517554|Behavioral|Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Baseline and follow up survey
75802602|NCT03736694|Behavioral|Sleep hygiene education|SHE, is commonly provided verbally or through leaflets during consultations (Espie, 2009), and is also included as a part of CBTI (Morin, Savard, Ouellet, & Daley, 2003).
75344698|NCT02517554|Behavioral|Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Baseline and follow up surveys
75344699|NCT02517554|Behavioral|Patient receives written information on how to find genetic services in their area|Baseline and follow up surveys
75344700|NCT02476916|Drug|AG-348|Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
75344702|NCT02296229|Radiation|stereotactic body radiation therapy|Undergo SBRT
75344703|NCT02296229|Other|quality-of-life assessment|Ancillary studies
75344704|NCT02296229|Other|laboratory biomarker analysis|Correlative studies
75344705|NCT02296229|Drug|androgen deprivation therapy|up to 9 months at the discretion of the treating physician
75476574|NCT05966701|Drug|SSGJ-613|SSGJ-613 subcutaneous injection.
75476575|NCT05966701|Drug|Placebo|Placebo subcutaneous injection.
75655678|NCT00964223|Drug|Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
75655679|NCT00964223|Drug|benzoyl peroxide and adapalene gel (EPIDUO™ Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
75655680|NCT00620815|Biological|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
75655681|NCT00620815|Biological|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
75802603|NCT05173480|Other|Conventional rehabilitation|Exercise therapy through conventional rehabilitation training made by physiotherapists.
75802604|NCT05173480|Device|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS).
75802605|NCT05173480|Device|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS) with sensors not connected.
75941856|NCT04058405|Behavioral|Observational|Cross-sectional observations
75941857|NCT05063500|Drug|bicyclol, 25mg/ tablet|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
75941858|NCT05063500|Drug|polyene phosphatidylcholine capsules, 228mg/ particle.|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
75941859|NCT04058171|Diagnostic Test|Treadmill walking test|Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
75941860|NCT03693170|Drug|encorafenib|300 mg administered orally once daily (QD)
75941861|NCT03693170|Drug|Binimetinib|Binimetinib 45 mg administered orally twice daily (BID)
75941862|NCT03693170|Drug|Cetuximab|"Standard of care for the 28 first weeks(*) and then every 2 weeks (**) :~(*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (**) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward.~Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic."
75941863|NCT04995796|Other|Surveys for Research Purposes|"VISIT #1:~Pre-Testing:~Pre Knowledge Test~Pre SURE (decisional conflict) test~Independent DSI/DA Interaction~Post-Testing:~Post Knowledge Test~Post SURE (decisional conflict) Test~Acceptability Index~Modified Single Item Literacy Screen~Additional Demographics~VISIT #2: Check-In Call 1 week later:~After viewing the DSI/DA and completing the post-test components above, the subjects will also complete a 5 minute debrief interview about 1 week later via phone or video conference with a team member to give feedback on their experience using the DSI/DA, including its strengths and weaknesses. This will allow for further improvement and refinement of the DSI."
75941864|NCT04058093|Behavioral|Functional Training Program|"Functional training program (FTP) include:~Functional training sessions will be oriented by graduates or masters in sport with the supervision of a sports medicine doctor;~Group nutrition counseling, in the form of healthy cooking classes direct by nutritionists with the support of culinary students."
76090706|NCT01516593|Radiation|Consolidation radiotherapy|At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
75344706|NCT02203799|Biological|Peanut Oral Immunotherapy (POIT)|The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
75655682|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
75655683|NCT00620815|Biological|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
75655684|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
75655685|NCT00620815|Biological|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
75655686|NCT02818764|Procedure|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
75802606|NCT03736460|Behavioral|Mindfulness|The mindfulness-based intervention adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of four 3h group sessions spread over 8 weeks. Each session consists of guided experiential mindfulness exercises (e.g. focus on the breath, body scan, breathing space, mindful movement, sitting meditation), sharing of experiences of these exercises, reflection in small groups, psycho-education (e.g. stress, depression, fear of cancer recurrence, self-care) and review of home practices.
75802607|NCT03736460|Behavioral|Physical training|This intervention is based on the recommended levels of physical activity for adults aged 18 - 64 year from the World Health Organization. These recommendations are the same for women after a breast cancer treatment (Schmitz et al., 2010). Just as the mindfulness intervention this will consist of four 2h group sessions spread over 8 weeks. Each session will consist of psycho-education (e.g. basics of movement, advantages of physical activity, training-principles), endurance and resistance training, stretching, balance and relaxation exercises, sharing of experiences of these exercises and review of home practices.
75802608|NCT03737942|Device|monitoring of neuromuscular function|started by percutaneous stimulation of the cubital nerve at the wrist level
75802609|NCT03627052|Drug|Itacitinib|In the double-blind period, itacitinib administered orally once or twice daily at the protocol-defined dose according to treatment group randomization. In the open-label extension, itacitinib administered at doses determined from the double-blind period.
75802610|NCT03627052|Drug|Placebo|Placebo administered orally twice daily in the double-blind period.
75802611|NCT04246918|Dietary Supplement|Branched Chain Amino Acid|Branched chain amino acid is a group of three amino acids known for there role in muscle growth.
75941865|NCT03669107|Drug|Gum|no gum
75941866|NCT05063110|Drug|Itacitinib|Administration of 300 mg of ITACITINIB per os every day for 30 days.
75941867|NCT03668483|Other|Pulmonary rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
75941868|NCT05062954|Dietary Supplement|Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins|Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.
75941869|NCT05062954|Dietary Supplement|Placebo supplement|Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.
75344707|NCT02180724|Drug|Acalabrutinib (ACP-196)|
76090707|NCT02042391|Drug|Rituximab sc|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
75802612|NCT04246918|Dietary Supplement|Whey Protein concentrate powder|Whey protein will be given to the standard treatment arm including in the same amount of 1.5gm/kg/IBW.
75941870|NCT03021005|Behavioral|HIV Self-testing|
75941871|NCT02389478|Procedure|Oropharyngeal administration of colostrums|rubbing drops of colostrum inside a baby's cheeks using a sterile syringe
75941872|NCT02389478|Procedure|Oropharyngeal administration of Normal saline|rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
75941873|NCT05048524|Drug|S-1, leucovorin, oxaliplatin and gemcitabine|"Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day [depending on patient's body surface area (BSA)] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~BSA < 1.25 m2: 80 mg/day~1.25 m2 ≤ BSA < 1.5 m2: 100 mg/day~BSA ≥ 1.5 m2: 120 mg/day"
75941874|NCT02389400|Drug|methotrexate|Single Group Assignment
75941875|NCT02914457|Procedure|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
75941876|NCT05048446|Other|observational|Non intervention
75941877|NCT05047744|Device|Touch Dual Mobility CMC I Prosthesis|Surgery
76090708|NCT02042391|Drug|Rituximab sc consolidation|Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
76090709|NCT02042391|Drug|Rituximab sc combined with CHOP chemotherapy|Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
75344708|NCT02180724|Drug|Acalabrutinib (ACP-196)|
75655687|NCT02818764|Procedure|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
76090710|NCT02042391|Drug|Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx|Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
76090711|NCT02465424|Other|quality of life questionnaires|Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
76090712|NCT02465580|Drug|hrIL-2 active|active group: placebo group =1:1
75941878|NCT04221412|Drug|JNJ-53718678|JNJ-53718678 will be administered as directed by treating physician.
76090713|NCT02465580|Drug|hrIL-2 placebo|active group: placebo group =1:1
76090714|NCT02461836|Drug|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
76090715|NCT02461836|Radiation|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
76090716|NCT01986946|Other|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
76090717|NCT01986946|Drug|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
76090718|NCT02034747|Drug|Advagraf|oral
76090719|NCT02034747|Drug|Corticosteroid|oral
76090720|NCT01987414|Behavioral|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
75941879|NCT02389322|Biological|5μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
75941880|NCT02389322|Biological|10μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
75344709|NCT02135419|Drug|imiquimod|Applied topically
75344710|NCT02135419|Drug|fluorouracil|Applied topically
75655688|NCT02818764|Device|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
75655689|NCT02818764|Device|Cerebral blood flow and oxygen extraction fraction|NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
75655690|NCT00850369|Other|RBC transfusion|Study subjects will receive monthly transfusions with 2 units of red blood cells
75655691|NCT02861963|Procedure|Experimental: RVOT reconstruction by femoral allogenic vein valve conduit|Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation
76090721|NCT01987414|Device|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
75344711|NCT02135419|Device|infrared photocoagulation therapy|Undergo infrared coagulation
75655692|NCT02861963|Procedure|Systemic-to-pulmonary artery shunts|"Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side."
75344712|NCT02135419|Device|thermal ablation therapy|Undergo hyfrecation/electrocautery therapy
75344713|NCT02135419|Device|laser therapy|Undergo laser therapy
75655693|NCT05658744|Behavioral|Video group|Insulin administration video was sent to the mobile phones of the patients assigned to the video group
75655694|NCT00850447|Other|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
75655695|NCT00850447|Other|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
75802613|NCT03662750|Diagnostic Test|Brain Imaging|"The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans."
75802614|NCT03626506|Drug|Spironolactone|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
75802615|NCT03626506|Drug|Indapamide|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
75802616|NCT03626506|Drug|Amlodipine|After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
75802617|NCT03737708|Drug|tacrolimus|Administered orally
75802618|NCT03737708|Drug|methotrexate|Administered orally
75802619|NCT03737708|Biological|adalimumab|Administered as subcutaneous injection
75802620|NCT03737708|Biological|tocilizumab|Administered by intravenous injection
75802621|NCT03737708|Biological|abatacept|Administered by intravenous injection
75941881|NCT02389322|Biological|BCG|The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
75941882|NCT02389322|Biological|placebo|The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
75941883|NCT04993768|Drug|TPN-101, 100 mg/day|100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
75941884|NCT04993768|Drug|TPN-101, 200 mg/day|200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
76090722|NCT01987414|Other|No treatment|Participants will maintain their daily routines during the no treatment period.
76090723|NCT02464254|Behavioral|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
76090724|NCT02464254|Behavioral|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
76090725|NCT01909713|Drug|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
76090726|NCT02427724|Drug|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
76090727|NCT02427724|Drug|lidocaine 7%/tetracaine 7% topical anesthetic|
76090728|NCT02427724|Drug|placebo vehicle|
76090729|NCT02427724|Device|Q-switched 532nm Laser|
75344714|NCT02135419|Other|clinical observation|Undergo active monitoring (High Resolution Anoscopy [HRA]) with biopsies
75344715|NCT02135419|Other|laboratory biomarker analysis|Correlative studies
75344716|NCT02043678|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of NIST update) body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles
75344717|NCT02043678|Drug|Matching placebo (normal saline)|Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles
75344718|NCT02043678|Drug|Abiraterone|1000 mg once daily, oral, with best supportive care
75344719|NCT02043678|Drug|Prednisone/Prednisolone|5 mg twice daily, oral, with best supportive care
75344720|NCT01853748|Drug|Trastuzumab|
75344721|NCT01853748|Drug|Paclitaxel|
75941885|NCT04993768|Drug|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
75941886|NCT04993768|Drug|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
75941887|NCT02665052|Device|Home-Based BATRAC plus TTT|Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
75941888|NCT02665052|Device|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
75941889|NCT02665052|Behavioral|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
75941890|NCT03019289|Drug|pridopidine (90 mg)|single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
75941891|NCT02389166|Device|Optiflow|"Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.~High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%."
75941892|NCT02389166|Device|Conventional oxygen therapy|Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
75941893|NCT03669029|Drug|Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg|Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
75344722|NCT01853748|Drug|Trastuzumab emtansine|
75802622|NCT05090072|Behavioral|Advance Directives|The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document
75802623|NCT05090072|Behavioral|Control|The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
75941894|NCT03669029|Drug|Golimumab treatment optimization.|Golimumab dosing will be optimized in patients without clinical response at week 6.
75941895|NCT05059444|Diagnostic Test|Guardant Reveal|Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.
75344723|NCT01843374|Drug|Tremelimumab|Tremelimumab is to be administered as an IV solution, followed by observation.
75344724|NCT01843374|Drug|Placebo|Placebo is to be administered as an IV solution, followed by observation.
75802624|NCT05517928|Drug|Omeprazole|40 MG oral capsules daily
75802625|NCT05517928|Dietary Supplement|Lactobacillus rhamnosus GG|Given as Culturelle Digestive Probiotic in the form of oral capsules daily
75941896|NCT02385578|Other|an educational intervention|"the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on"
75941897|NCT03668015|Other|Xylitol then Sorbitol gum|Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
75941898|NCT03668015|Other|Sorbitol then Xylitol gum|Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
75941899|NCT03668405|Drug|Lu AF20513|Injection
75344725|NCT01810913|Drug|Atezolizumab|Given IV
75344726|NCT01810913|Procedure|Biospecimen Collection|Undergo collection of blood
75802626|NCT05517928|Drug|Placebo|Oral capsules daily that look exactly like the study drug, but contains to active ingredient
75344727|NCT01810913|Biological|Cetuximab|Given IV
75802627|NCT04052204|Drug|avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
75802628|NCT04052204|Drug|Bempegaldesleukin|Investigational CD122-biased cytokine agonist
75802629|NCT04052204|Drug|talazoparib|poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor
75802630|NCT04052204|Drug|enzalutamide|androgen receptor inhibitor
75802631|NCT03745196|Drug|PC945|Study drug under investigation
75802632|NCT03745196|Drug|Placebo|Placebo control
75802633|NCT04050722|Drug|Sensodyne Repair and Protect|Participants will brush their teeth with Sensodyne Repair and Protect (containing 0.454% stannous fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
75344728|NCT01810913|Drug|Cisplatin|Given IV
75344729|NCT01810913|Procedure|Computed Tomography|Undergo CT
75344730|NCT01810913|Drug|Docetaxel|Given IV
75802634|NCT04050722|Drug|Colgate Cavity Protection|Participants will brush their teeth with Colgate Cavity Protection repair and protect (containing sodium fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
75941900|NCT02385734|Other|Concentrated Growth Factor Membrane|Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
75655696|NCT05658900|Other|Enucleation with albumin PRF|"The protocol that will be used in the preparation of albumin PRF~A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.~The venous blood sample will be centrifuged at 700 g for 8 minutes.~* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P~The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.~Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes."
75941901|NCT02385734|Procedure|Coronally Advanced Flap|Periodontal plastic surgery technique
75941902|NCT03020927|Behavioral|Reciprocal Imitation Training (Therapist-Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.
75941903|NCT03020927|Behavioral|Reciprocal Imitation Training (Therapist + Parent Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
75344731|NCT01810913|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
75344732|NCT01810913|Other|Laboratory Biomarker Analysis|Correlative studies
75344733|NCT01810913|Procedure|Magnetic Resonance Imaging|Undergo MRI
75344734|NCT01810913|Other|Quality-of-Life Assessment|Ancillary studies
75344735|NCT01757535|Drug|Oral Azacitidine|300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
75344736|NCT01757535|Drug|Placebo|Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
75344737|NCT01584258|Procedure|Prostatectomy|Radical prostatectomy: performed open, laparoscopically or using a robotically assisted laparoscopic approach.
75344738|NCT01584258|Radiation|Conventionally Fractionated Prostate Radiotherapy|"Conventional fractionation delivered to a dose of:~(PACE-B) 78 Gy in 39 fractions or 62 Gy in 20 fractions; (PACE-C) 60 Gy in 20 fractions"
75941904|NCT02385500|Drug|Fesoterodine|"For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
75941905|NCT02385500|Drug|Placebo|"For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
76090730|NCT03437200|Drug|Nivolumab|Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
75344739|NCT01584258|Radiation|Prostate SBRT|Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
75344740|NCT01447329|Other|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.
75344741|NCT01447329|Drug|Standard Treatment|
75344742|NCT01117779|Device|Cryoablation|Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
75802635|NCT03736382|Other|Mild intermittent hypoxia|Participants will be exposed to twelve two minute episodes of mild intermittent hypoxia 5 days a week for 3 weeks.
75802636|NCT03736382|Other|Sham protocol|Participants will be exposed to twelve two minute episodes of sham mild intermittent hypoxia (i.e. room air) 5 days a week for 3 weeks.
75802637|NCT03736382|Other|Continuous positive airway pressure (CPAP)|All participants will be treated with CPAP each night for a duration of 3 weeks.
75802638|NCT04049552|Drug|Rapamycin 8% Ointment|A compounded ointment containing 8% rapamycin
75802639|NCT04049552|Drug|Placebo|Petrolatum ointment placebo
75344743|NCT01110005|Other|D5 Lactated Ringer's Solution (D5LR)|D5LR IV fluid
75344744|NCT01110005|Other|Lactated Ringer's Solution (LR)|LR IV fluid
75344745|NCT01013714|Procedure|Cardiac Sympathetic Denervation (CSD)|Cardiac sympathetic denervation is performed using an endoscopic procedure called VATS (video-assisted thoracoscopic sympathectomy). The surgeon removes the lower half of the stellate ganglia in addition to the thoracic ganglia of T2 - T4 on both the right and left side. The VATS procedure provides a minimally invasive endoscopic approach that is safe and effective. The procedure can be completed in less than 45 minutes on each side.
75344746|NCT01013714|Drug|Routine Care|Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
75344747|NCT00923013|Drug|Cladribine|Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.
75344748|NCT00923013|Drug|Rituximab|Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.
75344749|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360
75344750|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
75344751|NCT00804128|Procedure|Magnetic Resonance Imaging (MRI)|Undergo MRI
75344752|NCT00804128|Drug|Gadavist|Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging
75941906|NCT02385422|Drug|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
75941907|NCT02385422|Drug|Propranolol|Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
75941908|NCT02520388|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
75941909|NCT02520388|Drug|Placebo|
75941910|NCT03667937|Combination Product|CUTIMED|Hydrophobic Dressing
76090731|NCT03437200|Drug|Ipilimumab|Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
75344753|NCT00533780|Procedure|Healing Touch|A gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy.
75476576|NCT05966571|Procedure|Ovary Biopsie|Ovarian biopsy will be performed on patients meeting the inclusion criteria undergoing surgery for other reasons. Ovarian biopsy will be of a few millimeters in size and taken on only one of the ovaries.
75655697|NCT05658900|Other|Enucleation without albumin PRF|"The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.~The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.~Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst."
75802640|NCT03737630|Device|Inspiratory muscle training|This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training
75802641|NCT03737552|Other|Polysomnography|Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).
75802642|NCT03737474|Drug|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
75802643|NCT03048058|Drug|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
75802644|NCT03048058|Drug|brimonidine topical gel 0.33% & SOC|All subjects will receive standard-of-care brimonidine topical gel 0.33%
75802645|NCT03047980|Drug|Sirolimus|Low dose oral sirolimus
75941911|NCT03667937|Other|AQUACEL silver|Silver Dressing
75941912|NCT03666767|Other|Comparisons will be made between LMICs and HICs|Countries will be defined as low, middle or high-income using the World Bank classification.
75941913|NCT02385344|Device|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
76090732|NCT03437200|Other|Chemoradiation|All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
76090733|NCT05566587|Other|Mediteranean to Western to Mediteranean Diet|week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet
75344754|NCT00515359|Procedure|Intermittent Propofol Sedation|Intermittent versus continuous dosage
75344755|NCT00515359|Procedure|Continuous Propofol Sedation|intermittent vs continuous dosage
75344756|NCT00494234|Drug|Olaparib|Participants will receive capsules of olaparib orally as stated in arm description.
75344757|NCT01268111|Drug|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
75344758|NCT01268111|Drug|Placebo|matching placebo
75344759|NCT01349231|Drug|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
75344760|NCT01349933|Drug|Akt inhibitor MK2206|Given PO
75655698|NCT00850681|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
75655699|NCT04283591|Procedure|Acupuncture Treatment|Acupuncture Treatment Group will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points of the hemiplegic side and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week.
75655700|NCT04283591|Other|Conventional Rehabilitation Programme|They will continue to receive the conventional rehabilitation programme.
75655701|NCT04238988|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
75655702|NCT04238988|Drug|Carboplatin|Chemotherapy medication
75655703|NCT04238988|Drug|Taxol|Chemotherapy medication
75941914|NCT03667235|Other|Treatment of human pericardium with glutaraldehyde in OZAKI procedure|10 versus 20 minutes treatment of human pericardium with 0.6% glutaraldehyde in OZAKI procedure
75941915|NCT03667235|Other|Treatment of human aortic valve tissue with glutaraldehyde|10 versus 20 minutes treatment of human aortic valve tissue with 0.6%glutaraldehyde
75941916|NCT03666689|Procedure|surgical technique|surgical reconstruction
75941917|NCT05043922|Drug|CYH33|a Selective PI3Kα Inhibitor
75941918|NCT02668640|Biological|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
75941919|NCT05043766|Drug|PF614|PF614 is an oxycodone prodrug
75941920|NCT05043766|Drug|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers
75941921|NCT05043766|Drug|OxyContin|Bioequivalence single-dose comparison to OxyContin
75941922|NCT05043298|Drug|IBI 360 Injection|IBI 360 dose level of escalation IV Q3W Day 1
75941923|NCT04991818|Other|OneBiome microbiome profiling service|participants will be asked to complete the user experience of the OneBiome service
75941924|NCT02389010|Biological|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
75941925|NCT02389010|Other|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
75941926|NCT05042830|Procedure|Blood sampling|Blood samples will be taken by puncture of the antecubital vein for peripheral blood mononuclear cells (PBMCs) isolation, cytokines measurement, and flow cytometry analysis
75344761|NCT01350245|Radiation|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
75941927|NCT05042830|Procedure|Nasal biopsies|Nasal biopsies will be taken from the lower fringe of the inferior turbinate, approximately 1-2cm from the anterior curved edge for RNA sequencing and confocal microscopy staining
75941928|NCT05042830|Biological|Nasal specimen collection|Nasal specimen collection will be conducted. Nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)) will be obtained.
75941929|NCT05042830|Procedure|Mucosal RNA sampling|A 10 cm nasal curette will be used (Rhino-Probe, Arlington Scientific, USA). The curette is brought to lie against the mid-inferior portion of the inferior turbinate under direct visualisation. The curette is rubbed against the mucosal surface, going outwards. To ensure successful sample acquisition, this motion will be repeated 2-3 times
75941930|NCT05042830|Procedure|Intranasal challenge|The extract of birch pollen (Allergopharma, Vienna, Austria) will be freshly diluted in a 0.9 percent sterile sodium chloride solution and administered by means of a metered pump. The allergen will be administered supplying 15 μl per puff to both nostrils. Azelastine nasal spray or desloratadine 5mg will be given if the patient suffers from nasal or eye symptoms after the challenge. Equivalent amount of saline without allergens will be given to the control group.
75941931|NCT05042830|Procedure|Skin prick test|"In order to evaluate the patient's sensitization profile at the screening visit, a regular skin prick test will be conducted with commercial birch pollen extract and a panel of allergens used in routine diagnosis in the allergy clinic of the ear, nose, and throat (ENT) department.~Titrated skin prick test: Titrated skin prick test (SPT) to birch pollen extract is conducted by using increasing dilutions up to 1:100 000. As a result, it is possible to determine the lowest concentration that leads in a skin reaction."
75941932|NCT05042830|Procedure|Peak Nasal Inspiratory Flow (PNIF)|The functionality and convenience of the PNIF presents a rare opportunity to rapidly obtain objective measurements of nasal peak inspiratory flow. It was also validated during other nasal allergen challenge as a study tool
75941933|NCT05042830|Biological|Pregnancy test|In female patients, a regular urine pregnancy test will rule out pregnancy. The test will be conducted at the screening visit before the first skin prick test and then once a month afterwards.
75344762|NCT01350245|Biological|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
75941934|NCT02388854|Genetic|SNPs analysis with Sanger sequencing|Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls
75941935|NCT03462368|Procedure|Control|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by scaling and root planing only.
75941936|NCT03462368|Procedure|antimicrobial photodynamic therapy|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by antimicrobial photodynamic therapy with toluidine blue O (10mg/ml)
75941937|NCT03462368|Procedure|Photobiomodulation|After the procedure of subepithelial connective tissue graft the whole surgical site will receive red laser application.
75941938|NCT02664272|Procedure|Total Hip Arthroplasty|
75941939|NCT02663882|Behavioral|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
75344763|NCT01350245|Drug|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
75344764|NCT01350245|Drug|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
75344765|NCT01350245|Drug|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
75344766|NCT01350245|Device|Hematopoietic stem cell transplantation (HSCT)|"One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
75344767|NCT01350401|Genetic|Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|Cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T
75344768|NCT01320137|Procedure|Blood withdrawal|Blood sampling
75344769|NCT01321151|Drug|Resveratrol|The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
75802646|NCT03971188|Procedure|Trapeziectomy with Internal Brace|Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
75344770|NCT01321151|Drug|Placebo|The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
75344771|NCT01350947|Drug|5-Azacitidine|"Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes."
75941940|NCT02663882|Behavioral|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
75941941|NCT02388620|Drug|LEE011|400 mg
75941942|NCT02388698|Procedure|Cervical swab|"Cervical Swab at baseline.~HPV testing at recurrence, if applicable."
75941943|NCT02388698|Radiation|PET-CT|PET-CT will be completed 3 month post chemoradiation.
75941944|NCT02388698|Biological|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
75941945|NCT02383238|Drug|Dapagliflozin|10 mg, oral for 6 weeks
76090734|NCT05566587|Other|Western to Mediteranean to Western Diet|week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet
75802647|NCT03946774|Dietary Supplement|Dietary protein shake|"It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate."
75941946|NCT02383238|Drug|Placebo|oral for 6 weeks
75941947|NCT03011333|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam) via nerve block or instillation.
75941948|NCT03011333|Drug|Bupivacaine HCl without epinephrine|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
76090735|NCT01903473|Drug|Rapamycin|"Rapamycin will be started within 2 weeks after inclusion. Rapamycin will be given at 2-6 mg loading dose for one day, followed by approximately 1 mg daily to achieve a target trough level of 5 to 10 ng/mL. The frequency of trough level measurements will be done according to the investigator choice; Rapamycin may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.~Calcineurin inhibitor discontinuation within 2 weeks after rapamycin initiation. No other modification of immunosuppressive drugs and in particular no decrease in the dose of steroids (unless necessary for side effects)."
76090736|NCT01903473|Other|T regulatory cells|"One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 60-90 days after first day of rapamycin administration and after calcineurin inhibitor discontinuation. The infusion procedure will take one hour.~Low-dose Il-2 (1x106 IU/day) will be started the day of DTI and will be continued for a period of 2months in order to expand infused donor Tregs."
76090737|NCT01900977|Other|Universal Testing with immediate ART|"• Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
75655704|NCT00836173|Drug|RICE|RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
75655705|NCT00836173|Drug|GaRD Treatment|After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
75802648|NCT03876028|Biological|Tisagenlecleucel|Infusion
75802649|NCT03876028|Drug|Ibrutinib|Oral (tablets or capsules)
75802650|NCT03732482|Drug|Temozolomide capsules|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
75941949|NCT03011333|Drug|Saline Placebo|Saline placebo via nerve block.
75941950|NCT02383004|Other|Acupuncture|If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
75941951|NCT02383316|Other|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
75655706|NCT02862041|Device|Echogenic needle - Pajunk sonoplex echogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
75655707|NCT02862041|Device|Non Echogenic needle - Stimuplex Braun Nonechogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
75965990|NCT02089139|Other|conventional treatment|"Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~medications (analgesics, NSAIDs, muscle relaxants),~physical therapy,~manual techniques,~transcutaneous electrical nerve stimulation (TENS),~blocks"
75965991|NCT04869410|Procedure|Modification Broselow Tape|Intubation using modified Broselow Tape prediction for predicting ETT size
75941952|NCT03011099|Device|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
75941953|NCT03011099|Other|Conventional physical therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
75941954|NCT02382926|Other|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
75941955|NCT03667157|Drug|every week IVMP therapy|12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
75941956|NCT03667157|Drug|very high doses IVMP therapy|3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations
75941957|NCT02382770|Procedure|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
75941958|NCT03667859|Diagnostic Test|Vaginal Tactile Imaging|Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
75941959|NCT04570397|Drug|Ravulizumab|Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
75941960|NCT02385188|Drug|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
76090738|NCT01900977|Other|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
76090739|NCT01900977|Other|Standard of Care|
76090740|NCT02715726|Drug|Alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
75655708|NCT00836251|Dietary Supplement|H218O and 2H2O, administered as a mixed cocktail|0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
75655709|NCT04284215|Drug|Albumin paclitaxel combined with cisplatin|Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
75655710|NCT02816970|Drug|Vildagliptin|1 tablet contains 50 mg vildagliptin
75655711|NCT02816970|Drug|Vildagliptin|1 tablet contains 50 mg vildagliptin
75655712|NCT04283123|Behavioral|Automated Bidet|During the first intervention visit, a licensed contractor will install the bidets in participants' homes. The OT will then educate and train the caregiver and care recipient to successfully use the bidet, and make any modifications to the remote as needed. Throughout the intervention, the OT will use motivational enhancement strategies. The OT will make minor modifications to the remote as needed. A second intervention visit will occur 1-2 weeks post-installation to address any new difficulties. Check-in phone calls will be offered to the caregiver and care recipient if needed.
75655713|NCT04283123|Other|No Intervention|Waitlist control
75802651|NCT03732482|Device|radiotherapy|Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost
75941961|NCT02385188|Drug|paracetamol|
75802652|NCT04051762|Device|High flow nasal cannula vs. Nasal continuous positive airway pressure|High flow nasal cannula
75941962|NCT02385188|Drug|lidocaine in Vaseline ointment|
75965992|NCT04869410|Procedure|Cole Formula|Intubation using Cole Formula prediction for predicting ETT size
75965993|NCT03558971|Drug|Cortisol|Participants determine when to administer 5-day regimens of cortisol
76090741|NCT02715726|Drug|Placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
76090742|NCT02715726|Drug|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
75655714|NCT04239066|Procedure|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
75802653|NCT04048382|Behavioral|Patient Navigation|Spanish-English bilingual peer lay navigators hired by Family Health Centers of San Diego will provide the PN intervention during the study, trained using manuals developed in formative research and via the Patient Navigation Research Program training approach. Services will generally focus on: 1) overcoming community, health system, interpersonal, and individual barriers to accessing PrEP-related healthcare; 2) increasing each patient's knowledge, attitudes, and self-efficacy for initiating and adhering to PrEP; 3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and 4) sexual risk reduction counseling.
76090743|NCT02715726|Drug|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
76090744|NCT02715726|Drug|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
76090745|NCT02715726|Drug|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
75655715|NCT04239066|Procedure|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
75655716|NCT04284137|Behavioral|Modified FE-SaLiR|Participants will attend a 60-minute exercise program (modified Wu Qin Xi and Ba Duan Jin) in a non-clinical community setting twice a week and will perform the exercises at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
75655717|NCT04284137|Behavioral|Unmodified Chinese Medicine Exercise|Participants will attend a 60-minute exercise program (Wu Qin Xi and Ba Duan Jin published by the General Administration of Sport of China) in a non-clinical community setting twice a week and will be expected to practice exercise at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
76090746|NCT02715726|Drug|simvastatin|Pharmaceutical form:tablet Route of administration: oral
76090747|NCT01893567|Drug|Clobex Spray|
76090748|NCT04249596|Drug|Tianeptine Sodium|At baseline, and following 8 weeks of treatment with tianeptine(12.5 mg, 3x daily), participants will be assessed in a number of procedures to evaluate their emotional and physical pain state and pain stimulus response and the relationship of such states/responses to endogenous opioid signaling. To further assess emotional pain, participants will also undergo fMRI while performing a validated social rejection and social acceptance paradigm known to induce endogenous opioid release in control subjects and blunted release in MDD. Examining both rejection and acceptance is important because the MOR system regulates both social distress and social reward in animals and humans, and tianeptine may also act on abnormal MOR-mediated responses to social acceptance in MDD. Likewise, a second fMRI scan will be used to explore physical pain response using an established thermal pain sensitivity task. The protocol at Stanford University will not include pain testing or imaging studies.
75344772|NCT01268189|Device|Oxygen diffusing dressing|Oxygen diffusing dressing applied to study wound
75344773|NCT01268189|Device|Standard of care dressing|Xeroform control dressing applied to control wound
75344774|NCT01269047|Drug|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
75344775|NCT01269047|Drug|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
75344776|NCT01269047|Drug|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
75344777|NCT01351337|Procedure|diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation|All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
75344778|NCT02147990|Drug|Rociletinib|Rociletinib will be administered to patients orally
75655718|NCT04284137|Behavioral|Active Control|Participants will attend a 60-minute health education program once a week.
75655719|NCT02817282|Other|Hand hygiene implementation strategy|Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
75655720|NCT03372941|Drug|Dalbavancin|Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.
75802654|NCT04048382|Other|Usual Care|The booklet given is a 2-page booklet including the following information: 1) overview of PrEP; 2) eligibility for PrEP; 3) efficacy of PrEP; 4) safety of PrEP; and 5) obtaining, initiating, and adhering to PrEP. Participants will also be provided with both verbal and written information regarding available sexual health and HIV prevention services, including PrEP, at Family Health Centers of San Diego (FHCSD). Comprehensive HIV-prevention healthcare, including PrEP, is available to study participants at FHCSD at no or minimal cost. If a UC participant is diagnosed with a sexually transmitted infection, including HIV, treatment and follow-up will be coordinated by FHCSD staff as per usual care procedures.
75941963|NCT04580927|Behavioral|Breastfeeding self-efficacy (BSE)|Self-efficacy is determined by factors such as prior experience, vicarious learning, persuasion of others and physiological state, which in turn impact on one's behaviours and actions. One's sense of self-efficacy is modifiable, and can be readily targeted for intervention. An increasingly studied key determinant of breastfeeding outcomes is breastfeeding confidence, also referred to as breastfeeding self-efficacy (BSE). The investigators will use a nurse-administered validated BSE intervention tool.
75941964|NCT02385032|Drug|Ursodiol|
75941965|NCT02385032|Drug|URSO Forte|
75941966|NCT02384798|Other|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
75941967|NCT02384798|Other|interval training|interval training
75344779|NCT02148302|Device|Harvesting Device (CelluTome©)|Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
75344780|NCT03800498|Other|DASH Education|DASH health education about general knowledge of DASH diet Plan and lifestyle modification
75344781|NCT03800186|Other|Proximal type A|Patients with fracture of proximal type A
75344782|NCT03800186|Other|Proximal type B|Patients with fracture of proximal type B
75344783|NCT03800186|Other|Proximal type C|Patients with fracture of proximal type C
75344784|NCT03800186|Other|femoral shaft|Patients with fracture of femoral shaft
75344785|NCT03800186|Other|distal femur|Patients with fracture of distal femur
75344786|NCT04383860|Procedure|5-0 suture|5-0 suture administration during surgery
75941968|NCT02384954|Biological|Rituximab|Intravenous infusion; Patients will receive a 4-week induction cycle consisting of Rituximab given on Day 1, 8, 15, 22. Eligible patients will receive a consolidation treatment consisting of Rituximab given on Day 78, 134, 190, 246.
75941969|NCT02384954|Biological|ALT-803|Intravenous infusion for cohort 1, 2 and 3; subcutaneous injection for cohort 4, 5, 6 and 7; Patients will receive a 4-week induction cycle consisting of ALT-803 given on Day 2, 8, 15, 22 for patients in cohort 1, 2, 3, 4 and Day 1, 8, 15 and 22 for patients in cohort 5, 6, 7. Eligible patients will receive a consolidation treatment consisting of ALT-803 given on Day 78, 134, 190, 246.
75941970|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|
75941971|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.|
75941972|NCT02384642|Behavioral|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
75941973|NCT02384642|Behavioral|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
75941974|NCT02384720|Other|Age: 20-40years|
75941975|NCT02384720|Other|Age: 41-64years|
75941976|NCT02384720|Other|Age: ≥65years|
75941977|NCT03013985|Drug|Glargine U300|Glargine U300 is a new generation long-acting insulin.
75941978|NCT03013985|Drug|Glargine U100|Glargine U100 is a long-acting insulin.
75941979|NCT03013985|Drug|Glulisine Insulin|Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
75941980|NCT02377388|Drug|sitagliptin OR saxagliptin|sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
75941981|NCT02377388|Drug|placebo|placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
75941982|NCT03016403|Behavioral|Stepped-Care Intervention|The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
75941983|NCT03016403|Behavioral|Enhanced Usual Care|Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
75941984|NCT02382536|Device|BD Scarlett Infusion set|Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
75941985|NCT02382536|Device|Medtronic QuickSet Infusion Set|Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
75941986|NCT02382380|Drug|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
75941987|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
75655721|NCT02819934|Drug|KD101|after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
75941988|NCT02382302|Device|Telemedicine system|The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
75941989|NCT02382224|Behavioral|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
75941990|NCT02382224|Behavioral|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
76090749|NCT01476501|Drug|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
75344787|NCT04383860|Procedure|4-0 suture|4-0 suture administration during surgery
75344788|NCT03800264|Drug|Bisoprolol|PREVENTIVE DOUBLE BLINDED
75344789|NCT03800342|Other|Aerobic Exercise Training|see arm/group description
75344790|NCT05287724|Drug|N-acetyl cysteine|1,500 mg twice daily for seven days
75655722|NCT00630227|Biological|Biologic Lung Volume Reduction|20 mL Hydrogel
75655723|NCT04238832|Other|Salt Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home salt base nicotine
75655724|NCT04238832|Other|Free Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home free base nicotine
75655725|NCT02819700|Behavioral|prevalence of behavioural dysexecutive syndrome|Behavioural Dysexecutive Syndrome Inventory (ISDC)
75655726|NCT02861651|Other|DNA sequencing|
75655727|NCT02818530|Device|IOP by tonometer|Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
75941991|NCT02382458|Behavioral|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
76090750|NCT04248816|Behavioral|Usual care|Subjects will receive outreach through their providers as is standard of care.
76090751|NCT04248816|Behavioral|Opt-out|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.
75344791|NCT05287724|Drug|Placebo|Placebo taken twice daily for seven days
75802655|NCT04051840|Drug|ClinOleic (Baxter Healthcare, Deerfield, IL, USA)|ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
75344792|NCT01321541|Drug|Pixantrone + Rituximab|Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
75344793|NCT01321541|Drug|Gemcitabine + Rituximab|Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
75344794|NCT05282186|Behavioral|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
75655728|NCT02818530|Device|Anterior chamber depth measurement by ultrasound|Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
75655729|NCT04622904|Drug|lidocaine-magnesium infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 0.2 mg/kg/h of ketamine will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
75655730|NCT04622904|Drug|lidocaine-ketamine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
75655731|NCT04622904|Drug|lidocaine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of normal saline 100 mL will be administered preoperatively within 10 minutes. Followingly, normal saline will be administered intraoperatively at a rate of 20 mL/h
75655732|NCT02817048|Device|chest tube|
75655733|NCT02817048|Procedure|VATS without chest tube placement|Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)
75655734|NCT02817048|Procedure|VATS with chest tube placement|
75802656|NCT03412162|Behavioral|Ethnic and Racial Identity Promotion|See arm description
75802657|NCT03412162|Behavioral|Academic Skills Promotion|See arm description
75802658|NCT04047446|Drug|Exparel 133 MG Per 10 ML Injection|10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
75802659|NCT04047446|Drug|Dexamethasone|15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected
75802660|NCT03655106|Device|Standard Long IV 4.78 cm 20 g catheter|Standard Long IV 4.78 cm 20 g catheter
75802661|NCT03655106|Device|Ultra-Long IV 6.35 cm 20 g catheter|Ultra-Long IV 6.35 cm 20 g catheter
75941992|NCT02382458|Behavioral|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
75941993|NCT02377154|Device|Slit lamp|Examination of cornea
75941994|NCT02377154|Device|Autorefractor|Measurement of refraction
75941995|NCT02377154|Device|IOLMaster 500|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
75941996|NCT02377154|Device|Pentacam HR|Measurement of white-to-white distance; Keratometry
75941997|NCT02377154|Device|LenStar LS900|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
75941998|NCT02377154|Device|VERION Image Guided System|Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
75941999|NCT02377232|Behavioral|Decision Aid for Colon Cancer Screening|Paper decision aid describing different screening options for colon cancer
75942000|NCT02377232|Behavioral|Usual Care Outreach for Colon Cancer Screening|Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
75942001|NCT02382146|Drug|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
75942002|NCT02382146|Drug|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
75942003|NCT02382068|Drug|Dexamethasone|Given via intratympanic injection
75942004|NCT02382068|Other|Placebo|Given via intratympanic injection
76090752|NCT04248816|Behavioral|Opt-out + Incentive|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.
76090753|NCT03426124|Device|EkoSonic Endovascular System with thrombolytic|The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.
76090754|NCT04240080|Device|Accuvein® Veinfinder|Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.
76090755|NCT02464020|Drug|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
75655735|NCT02817204|Behavioral|Aerobic Exercise|Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
75655736|NCT02817204|Behavioral|Health Education|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
75655737|NCT04239300|Behavioral|Delivery in water|Participants delivery in water
75802662|NCT03630302|Device|DBS|Deep Brain Stimulation
75802663|NCT03736148|Other|Manual Manipulation|Subject was in supine position, and the therapist applied a manual manipulation with right side bending and left rotation of the neck.
75942005|NCT02382068|Drug|Cisplatin|"Standard of care treatment with the following treatment course criteria:~Dose: > 50 mg/m2~Frequency: q3 -q4 weeks~Cycles: 7 maximum"
75942006|NCT02376842|Behavioral|Severe sepsis early warning best practice alert|
75344795|NCT05282186|Behavioral|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
75344796|NCT01270529|Other|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
75344797|NCT05254262|Procedure|Elderly surgical patients|Patients who needs elective or emergency surgery for any reason
75344798|NCT04351607|Dietary Supplement|Oleovital® Eisen Forte|60 mg daily oral Supplementation for 3 to 6 weeks
75344799|NCT03801434|Drug|Ruxolitinib|Given PO
75344800|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
75942007|NCT02376842|Behavioral|Standard care|
75942008|NCT04731272|Drug|Dulaglutide 0.75Mg/0.5Ml Inj Pen|Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
75942009|NCT02520310|Device|AVJ-514|Patients receiving AVJ-514 device
75942010|NCT02381912|Other|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
75942011|NCT02381600|Drug|Vitamin D|"Experimental :~Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery."
75344801|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
75655738|NCT00634062|Drug|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
75655739|NCT00634062|Drug|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
75655740|NCT00634140|Drug|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
75655741|NCT00634140|Drug|Placebo|placebo for 4-6 weeks
75655742|NCT02819544|Drug|Sodium chloride administration|Sodium chloride administration
75655743|NCT02819544|Drug|Ropivacaine administration|Ropivacaine administration
75655744|NCT02816814|Other|Diet rich in omega-3 fatty acids|A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause
75655745|NCT02816814|Other|Diet with extra virgin olive oil|A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
75802664|NCT03736148|Other|Instrument-assisted Manipulation|The instrument-assisted manipulation was applied using a handheld Activator IV Adjusting Instrument. Contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. The spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of C3.
75802665|NCT03736148|Other|Placebo|Subject was in supine position, and the therapist placed ths subject's cervical with right side bending and left rotation but no manual manipulation was applied.
75802666|NCT03732404|Drug|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
75942012|NCT03113084|Biological|Sodium Heparin UQ subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
75942013|NCT03113084|Biological|Sodium Heparin FK subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
75942014|NCT02384408|Procedure|Endometrial Biopsy|Histological assessment
75942015|NCT02384408|Device|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
75942016|NCT02384408|Procedure|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
75942017|NCT04852640|Procedure|Active Rehabilitation Program (ARP)|The ARP intervention consists of therapeutic exercises designed to increase shoulder strength and endurance using a cluster of common exercises used for the treatment of shoulder pain. Specifically, the ARP program will focus on increasing scapular motor-control through a phasic program of common therapeutic exercises. This concept has been shown in the literature as capable of reducing shoulder pain and improving function in a variety of pathological conditions, however, the effect of this approach to reducing pain and increasing function for symptomatic shoulder instability is unknown. The selection of exercises and application for each exercise included in the ARP is based on recommendations from the literature and will incorporate participant feedback to customize dosages.
75942018|NCT04852640|Procedure|Nonspecific Passive Intervention (NPI)|The NPI intervention consists of a non-specific treatment approach to shoulder pain that is commonly administered in the clinical setting. Specifically, passive modalities such as ultrasound, massage, and sensory electric stimulation are commonly prescribed in the treatment of shoulder pain to modulate pain. Further, general core strengthening exercises are often implemented. Therefore, the NPI will consist of regularly prescribed passive treatments and general core strengthening exercises, as commonly administered in routine treatment of shoulder pain.
75942019|NCT02377076|Dietary Supplement|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
75942020|NCT02377076|Dietary Supplement|Control|Control (Whey protein, vitamin D, sugar and salt)
75344802|NCT03804008|Drug|Ultrasound-guided corticosteroid injection|A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
75344803|NCT03804008|Other|Heavy-slow resistance training|Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. Participants are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
75344804|NCT03804008|Other|Fundamental advice and a silicone heel cup|Participants receive brief information about pathology, risk factors and advice on how to decrease activities that lead to symptom flares and slowly increase their activity level based on their symptoms. They also receive a leaflet that includes the same information as the research assistants will deliver orally after inclusion and a silicone heel cup.
75344805|NCT01271543|Device|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
75344806|NCT05655572|Other|Action Observation Theraoy|After initial baseline assessment patients allocated in AOT group will undergo treatment protocol of 6 weeks having 4 stages of duration 1.5 weeks each performed 3 days per week. . Assessment will be perform at baseline after 2, 4 and 6 weeks
75802667|NCT03732404|Drug|Placebo|The control group will receive plain water with the same volume and timing of treatment.
75802668|NCT04041440|Behavioral|clEAR auditory training|Children play auditory brain training computer games
75942021|NCT02381756|Device|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
75802669|NCT03158896|Biological|MSCTC-0010 Dose Escalation|"Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD"
75942022|NCT02376764|Procedure|Blood drawing (venipuncture)|Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.
75942023|NCT02381834|Procedure|Bladder stimulation technique|
75942024|NCT02381210|Device|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
75942025|NCT02384252|Other|functional tissu atrial analysis|
75942026|NCT02384564|Device|Ambu King Vision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
75965994|NCT04873544|Procedure|ERAS protocols for TKA|ERAS protocols for TKA
76090756|NCT04756089|Device|Electronic breast pump|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
75655746|NCT02819388|Behavioral|Contraceptive counseling|A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
75655747|NCT05658588|Device|Cytosorb|Cytosorb cartridge It is composed of polystyrene divinylbenzene and polyvinylpyrrolidone copolymers and targets molecules in the 5-50 kDa range, which includes the molecular mass of several cytokines
75655748|NCT02818296|Behavioral|Active IU CBM-I|
75942027|NCT02384564|Device|Direct Laryngoscopy via Miller Straight Blade|At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
76090757|NCT04756089|Other|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
76090758|NCT02465112|Drug|In111-Pentetréotide|
75344807|NCT05655572|Other|Functional Training|after baseline assessment participants including in this group will perform the tasks for 6 weeks (3 days per week) s and after that again assessment will be made for examining the improvements.Assessment will be perform at baseline after 2 ,4 and 6 weeks
75344808|NCT01323959|Biological|BoostrixTM Polio|Single dose, intramuscular administration.
75344809|NCT05652608|Behavioral|Immune Strength|Multi-week wellness program provided by the Cleveland Clinic
75476577|NCT05966077|Other|IMPACT OF SENDING AN SMS|"Each subject of the experimental group will receive, in addition to the usual procedure of the VigilanS Lorraine device, an SMS 48 hours before the telephone call for evaluation at 3 months, warning him of this call.~The time of this SMS has been set at 1:00 p.m. for all the people included in this group.~At the end of this evaluation call, the caller will pass a satisfaction questionnaire to the subject in relation to the sending of the SMS"
75655749|NCT02818296|Behavioral|Control CBM-I|
75802670|NCT02868268|Other|Gene panel sequencing of tumor specimens|Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
75802671|NCT03654560|Device|HemoStyp|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.
75655750|NCT02818374|Device|oral accessibility spatula (SAB)|
75655751|NCT02819466|Device|3D echography|ultrasound visualization of the stomach in fasting patients.
75802672|NCT03654560|Device|Surgicel|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.
75802673|NCT03629054|Drug|Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)|single dose
75655752|NCT00633906|Behavioral|HORIZONS HIV Intervention|Two-session, group-based interactive HIV prevention intervention
75655753|NCT00633906|Behavioral|enhanced standard-of-care|1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
75802674|NCT03629054|Drug|Empagliflozin|single dose
75344810|NCT00792428|Device|Real Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
75802675|NCT03629054|Drug|Linagliptin|single dose
75802676|NCT03629054|Drug|Metformin HCl|single dose
75802677|NCT03628898|Device|INVSENSOR00025|Noninvasive pulse oximeter sensor
75802678|NCT03628508|Other|Exercise|Comprehensive exercise program including strengthening, stretching, gait modification etc.
75476578|NCT05965908|Drug|liraglutide|glucagon-like peptide 1 receptor agonist
75476579|NCT05965908|Drug|Metformin|biguanide antihyperglycemic
75476580|NCT05965115|Diagnostic Test|Sample of Blood|All participants will receive M-protein screening by serum electrophoresis. Individuals with detected M-protein will undergo further diagnostic tests to determine their accurate diagnosis. Patients with monoclonal gammopathy of undetermined significance (MGUS) would be carefully assessed and followed up.
75802679|NCT03045328|Drug|Ibrutinib|Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.
75802680|NCT03045328|Drug|Venetoclax|Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).
75942028|NCT05041972|Drug|ARX788|ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).
75942029|NCT02384486|Behavioral|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
76090759|NCT02465112|Other|simple monitoring without active therapy|
76090760|NCT01888887|Other|Cetaphil Daily Facial Cleanser|
76090761|NCT03397888|Drug|Betrixaban|80 mg capsule
76090762|NCT01886859|Drug|Ibrutinib|Given PO
76090763|NCT01886859|Drug|Lenalidomide|Given PO
75942030|NCT02384486|Other|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
75942031|NCT05041348|Diagnostic Test|CT at the level of the third lumbar vertebra (L3)|Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
75942032|NCT02384174|Dietary Supplement|Resistant starch|
75655754|NCT02819154|Behavioral|phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay|"phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay. Investigators will use :~Questionnaire SF 36: Only the first two questions of the SF-36 are used exploring the felt quality of life at the time of the telephone call and in comparison with the period before hospitalization in intensive care.~Stress Assessment Questionnaire posttraumatic (Revised Impact of Event Scale, IES-R)~ADL: Assessment of independence in activities of daily life"
75655755|NCT02819076|Other|pain scale|
75802681|NCT02281864|Behavioral|Smoking Cessation Intervention Bundle|Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
75655756|NCT02818140|Procedure|Ropivacaine TQL block|Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
75802682|NCT02281864|Other|Control Group: Quitline|Referral to the Quitline
75802683|NCT03626272|Other|educational intervention|The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
75802684|NCT02154490|Drug|Docetaxel|Given IV
75802685|NCT02154490|Biological|Durvalumab|Given IV
75802686|NCT02154490|Drug|Erlotinib Hydrochloride|Given PO
75802687|NCT02154490|Drug|FGFR Inhibitor AZD4547|Given PO
75942033|NCT02384174|Dietary Supplement|Dietary fibre (arabinogalactan, gum guar, pectin)|
75344811|NCT00792428|Device|Sham Transcranial Direct Current Stimulation|A sham current runs between two electrode positions and might affect the underlying brain tissue.
75655757|NCT02818140|Procedure|Saline TQL block|Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
75655758|NCT02818140|Drug|Ropivacaine|
75655759|NCT02818140|Drug|Saline|
75655760|NCT02818140|Device|Ultrasound|
75802688|NCT02154490|Biological|Ipilimumab|Given IV
75802689|NCT02154490|Other|Laboratory Biomarker Analysis|Correlative studies
75802690|NCT02154490|Biological|Nivolumab|Given IV
75802691|NCT02154490|Drug|Palbociclib|Given PO
75802692|NCT02154490|Other|Pharmacological Study|Correlative studies
75344812|NCT05201612|Drug|Olaparib|Olaparib 300 mg, orally (po), twice a day (BID) continuously
75344813|NCT05201612|Drug|Pembrolizumab|Pembrolizumab 200 mg, intravenously (IV), every 21 days. Max 2 years (i.e. 35 cycles)
75344814|NCT01271855|Drug|Belladonna and opioid suppository|Belladonna and opioid suppository 16.2mg/30mg per rectum every 8 hours for 24 hours following delivery
75344815|NCT01271855|Drug|Glycerin Suppository|A vegetable oil suppository (placebo) per rectum every 8 hours for the first 24 hours following delivery.
75655761|NCT02818452|Other|Oatmeal + OatWell28XF|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
75655762|NCT02818452|Other|Oatmeal|
75655763|NCT02818452|Other|Hot cereal|
75655764|NCT04238208|Drug|Lidocaine 5% patch|5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm
75655765|NCT04238208|Drug|Capsaicin 8% Patch, Per 10 Square Centimeters|8% Capsaicin patch [8% w/w] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)
75802693|NCT02154490|Biological|Rilotumumab|Given IV
75802694|NCT02154490|Drug|Talazoparib|Given PO
75802695|NCT02154490|Drug|Taselisib|Given PO
75802696|NCT02154490|Biological|Tremelimumab|Given IV
75802697|NCT01682356|Dietary Supplement|Beetroot Juice (BRJ)|double-blind placebo-controlled cross-over study
75802698|NCT01682356|Dietary Supplement|placebo|double-blind placebo-controlled cross-over study
75802699|NCT01512316|Drug|d-Cycloserine|250mg, one dose, 2hrs prior to fMRI
75802700|NCT01512316|Drug|Lactose pill|one dose, 2hrs prior to fmri
75942034|NCT04439474|Drug|Vitamin D3|For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.
75942035|NCT04439474|Drug|Routine treatment|In this group, patients receive their usual medications and treatments
75942036|NCT02662556|Drug|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
75942037|NCT05055076|Device|PODEYE TORIC|Patients will be contacted consecutively and will be enrolled after the patient informed leaflet has been given to them and after obtaining their consent to the scientific use of their data collected retrospectively (preoperative, surgery, postoperative routine visits). Patients will only be enrolled after the routine 4-6 months visit has been performed.
75942038|NCT05039242|Other|Conventional Physical Therapy)|"Participants will receive a Hand exercise program including 8 different movements according to Flat 20 (flexion, extension, radial deviation of the fingers, dorsal flexion, palmar flexion, ulnar deviation of the fingers, and opposition and abduction of thumbs.~Repetitions include 5 times during each session, as given in the study. Balanced resistive hand exercise with use of physio hand ball squeezes including finger abduction and adduction exercises with MCP extended and gross grip.~Each contraction to be held for 3-5 seconds with a 20-second rest between contractions. Five repetitions of each resistive exercise will be done."
75942039|NCT05039242|Other|Kinesiotaping with I shaped application|Participants will receive Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm with less than 50% stretch of the subjects on both hands, once a week for a total time period of 4 weeks with 4 KT applications in total (19). Kinesiotape will be worn by the subjects for 3 days. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs.
75942040|NCT05039242|Other|Kinesiotaping with Fan-shaped Application|"Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects, once a week for a total time period of 4 weeks with 4 KT applications in total.~Kinesiotape will be worn by the subjects for 3 days. Less than 50% stretch with space correction technique. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs."
75942041|NCT05054686|Other|Stretching and Aerobic Exercise at Clinic|In this group of knee osteoarthritis patients will be applied both stretching and 30 minutes bicycle exercises in the same session, strengthening exercises and 30 minutes walking will be given in seperate days as home program.
75942042|NCT05054686|Other|Strenghthening and Aerobic Exercise|In this group of knee osteoarthritis patients will be applied both strengthening and 30 minutes bicycle exercises in the same session, 2 days strecthing exercises and 30 minutes walking will be given in seperate days as home program.
75942043|NCT05054686|Other|Strengthening, Stretching and Aerobic Exercises at clinic|In this group of knee osteoarthritis patients will be applied all stretching, strengthening and 30 minutes bicycle exercises in the same session, only 30 minutes walking will be given as home program.
75942044|NCT04439864|Device|MyIDEA|An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
75344816|NCT00777764|Drug|Cohort I|"In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were in SWFI."
75802701|NCT01512316|Genetic|Saliva sample|Buccal cell material will be sampled from all participants on day3
75344817|NCT00777764|Drug|Cohort 2|"In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.~For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were made in saline."
75344818|NCT00808340|Device|balafilcon A|multifocal contact lens
75942045|NCT04988620|Other|Whole Blood transfusion|In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
75942046|NCT02376608|Dietary Supplement|Pronova Pure 150:500 EE EU|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
75942047|NCT02376608|Dietary Supplement|Pronovum PRF-037|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
76090764|NCT00877344|Procedure|Immediate insertion|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
75344819|NCT00808340|Device|senofilcon A production|multifocal contact lens
75344820|NCT00808340|Device|senofilcon A test|multifocal contact lens
75655766|NCT04238286|Procedure|Dry needling|All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray [Skin-des. Agupunt ®]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
75802702|NCT01512316|Other|Functional neuroimaging (fMRI)|
76090765|NCT00877344|Procedure|Interval insertion|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
75344821|NCT01354145|Drug|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
75344822|NCT01354145|Drug|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
75802703|NCT03627494|Drug|GSK3439171A|Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
75802704|NCT03627494|Drug|Placebo|Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
75802705|NCT03735914|Other|MRI|Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.
75655767|NCT02816502|Behavioral|Stress Management Skill Building Program A|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
75942048|NCT02376608|Dietary Supplement|Pronovum PRF-041|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
76090766|NCT01885377|Other|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
76090767|NCT01885377|Other|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
76090768|NCT01989130|Device|Roche AMPLICOR CT/NG|
76090769|NCT01989130|Device|Cepheid Xpert CT/NG Test|
76090770|NCT01894971|Device|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|
76090771|NCT03298932|Procedure|Aortic valve surgery|Aortic valve surgery
76090772|NCT01989910|Drug|Raltegravir|Raltegravir 400mg oral twice daily
76090773|NCT01989910|Drug|Efavirenz|Efavirenz 600mg oral at bedtime
75344823|NCT05168462|Drug|Reduced noradrenaline use|Reduced noradrenaline by using a lower MAP target
75344824|NCT04383782|Behavioral|Expectancy Challenge|Expectancy challenge intervention (see description in study arms).
75802706|NCT03627416|Device|rTMS|high frequency rTMS to induce the long term potentiation of primary motor areas for the muscles of lower extremities
75802707|NCT03732326|Procedure|bariatric surgery|Bariatric surgery for enrolled patients who fulfill the including criteria
75942049|NCT02376608|Dietary Supplement|Eskimo-3|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
75942050|NCT02381366|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
75655768|NCT02816502|Behavioral|Stress Management Skill Building Program B|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
75942051|NCT04987918|Diagnostic Test|Applied Biosystems TaqPath COVID- 19 Combo Kit|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
76090774|NCT02464722|Drug|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
75344825|NCT04383782|Behavioral|Expectancy Challenge + Behavioral Activation|Expectancy challenge + behavioral activation interventions (see description in study arms)
75942052|NCT04732520|Device|Pulsed electric field treatment using the Aliya System|pulsed electric field treatment of a single NSCLC tumor
75655769|NCT02816112|Drug|Ciprofloxacin|Antibiotic
76090775|NCT02464722|Drug|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
76090776|NCT02464722|Drug|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
76090777|NCT02464722|Drug|Propofol|Anesthesia was induced with propofol 2 mg kg-1
76090778|NCT02464722|Drug|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
76090779|NCT04197258|Other|Peer support|"The intervention studied is the psycho-social support by a peer-helper to the patients and their main informal caregiver during the return home following a stay in rehabilitation center for a stroke.~Peer support intervention will be based on evidence, Bandura's social learning and social support theory, and the results of our ongoing study of the needs of patients and their caregivers as a result of returning home (Stroke69). It will include a meeting before the discharge and a regular follow-up for 6 months (face-to-face meetings, virtual or by phone), adapted to the needs of the patient and his caregiver, taking into account the social environment and in connection with the devices existing sanitary and social."
76090780|NCT02314156|Drug|Telapristone Acetate|Given transdermally
76090781|NCT02314156|Other|Placebo|Given PO
75655770|NCT02816112|Drug|Neupogen|Granulocyte-colony stimulating factor
75655771|NCT04238130|Diagnostic Test|Perioperative ctDNA Dynamic Monitoring|To apply ctDNA dynamic monitoring in early stage NSCLC patients with driver mutations positive at baseline
75802708|NCT03735836|Other|MAG-EPA/MAG-DHA omega-3 oils|The monoglyceride (MAG) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are chemically modified fish oils that fall into the Natural Health products category in Canada.
75802709|NCT03735758|Drug|pazopanib or guideline conform chemotherapy|Pazopanib (800mg/each day) or guideline conform chemotherapy
75802710|NCT05665946|Diagnostic Test|Blood sample analysis|Analysis of proposed biomarkers.
75942053|NCT04950322|Drug|SHR-1701、CAPOX|SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
75942054|NCT04950322|Drug|Placebo、CAPOX|Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
76090782|NCT02314156|Drug|Telapristone Acetate|Given PO
76090783|NCT02314156|Other|Placebo|Given transdermally
76090784|NCT02314156|Other|Laboratory Biomarker Analysis|Correlative studies
76090785|NCT02314156|Other|Questionnaire Administration|Ancillary studies
76090786|NCT02463786|Other|No intervention|No intervention
75344826|NCT04383782|Behavioral|Control|Neutral reading condition (see description in study arms).
75344827|NCT02196857|Drug|Azacytidine|75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
75344828|NCT02196857|Drug|Sorafenib|400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
75942055|NCT04845776|Dietary Supplement|ANRC Essentials Plus|a vitamin/mineral supplement designed for children and adults with autism
75942056|NCT05036590|Other|control group|The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
75942057|NCT05036590|Other|Intervention group|The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
75942058|NCT02376452|Drug|Raltitrexed|2mg/m2 iv gtt, d1
75942059|NCT02376452|Drug|Irinotecan|180 mg/m2 iv gtt, d1
75344829|NCT01272245|Drug|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
75802711|NCT03639818|Other|individual sessions of cognitive remediation|The cognitive remediation will be led by a psychologist specialized in neuropsychology, trained and experienced in this method. Cognitive remediation will be performed at a rate of 1 to 2 sessions per week for the duration of the study. This treatment will be carried out individually for half in face-to-face session in the clinical immuno-hematology department, face-to-face with the neuropsychologist, half at home with computer-based home exercises using PRESCO software ® from HAPPYNEURON®
75942060|NCT02376452|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
75942061|NCT02376452|Drug|Leucovorin|400mg/m2 iv gtt,d1
75942062|NCT02383784|Dietary Supplement|Low GI index diet|Low glycemic index diet
75942063|NCT02383784|Dietary Supplement|High GI diet|High glycemic index diet
75942064|NCT02383394|Other|follow up antenatal care|ultrasound follow up of pregnancy
75942065|NCT02383550|Other|Observational Cognitive assessments|Observational
75942066|NCT02372084|Drug|osilodrostat|
75942067|NCT02516098|Drug|hyoscine butylbromide|
75655772|NCT02818062|Biological|Cytokines dosage in Aqueous humor|Specify details not covered in associated Arm Description.
75655773|NCT02815722|Drug|SP2086|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
75655774|NCT02815722|Drug|Simvastatin|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
75655775|NCT04238442|Device|A&D TM-2657W oscillometric device|Assessing the accuracy of the A&D TM-2657W oscillometric device using International Standards Organization validation protocol. This involves comparing the accuracy of the A&D device to 2 observer mercury auscultation (gold standard).
75802712|NCT03639740|Drug|Secukinumab 150 milligram [Cosentyx]|For intervention description: see arm/group description
75802713|NCT03735602|Behavioral|perceptual training|orientation discrimination task
75802714|NCT03639662|Other|sophrology sessions|"Patients benefit from additional support consisting of at least 3 sessions of sophrology, one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for irathérapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
75802715|NCT01048138|Drug|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
76090787|NCT03297138|Procedure|FiLAC laser|The technique consists in applying in a radial way to 360 ° an energy laser in the fistulous route. This energy allows a thermal destruction by coagulation of the wall of the fistula and the fabrics of granulations in a circular and regular way as well as a shrinkage of neighbouring fabrics. The repair is made by a call of macrophages and fibroblasts of neighbouring healthy fabrics so ending in a closure of the fistulous route
76090788|NCT01991548|Device|MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|
75802716|NCT01048138|Drug|Placebo|5mg IV(in the vein)every 6 hours for 10 days
75942068|NCT02372318|Drug|Nalmefene|18mg of Nalmefen will be administered orally
75942069|NCT02372318|Drug|Placebo|Placebo tablet
75942070|NCT03105752|Other|Questionnaire of understanding|"The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.~Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved."
75942071|NCT03105674|Drug|Multi-drug local anesthetics (Combination)|"Ropivacaine 0.5% - 30 ml~Ketorolac 30mg/ml - 1 ml~Kenalog 10 mg/ml - 5 ml~Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
75942072|NCT03105674|Drug|Standard local anesthetics (Combination)|Marcaine and Lidocaine
75942073|NCT02380898|Drug|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
75942074|NCT02380898|Drug|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
75942075|NCT02380976|Drug|combination drug: DW330SR, DW1030|
75942076|NCT02380976|Drug|DW340|
75942077|NCT02381132|Drug|Norco 7.5mg/325|
75942078|NCT02381132|Drug|MNK155|
75344830|NCT01272245|Drug|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
75344831|NCT00802100|Drug|Olanzapine|Daily tablets of 10 to 30 mg
75344832|NCT00802100|Drug|Perphenazine|Daily tablets of 8 to 24 mg
75344833|NCT00802100|Drug|Aripiprazole|Daily tablets of 10 to 30 mg
75344834|NCT00802100|Drug|Metformin|Daily tablets of 850 to 2550 mg
75344835|NCT00802100|Drug|Simvastatin|Daily tablets of 20 to 40 mg
75344836|NCT00802100|Drug|Benztropine|Daily tablets of 1 to 2 mg
75942079|NCT05034484|Drug|ALPN-303|Multiple dose levels will be evaluated.
75942080|NCT05034484|Drug|Placebo|Placebo will be administered
75942081|NCT04985032|Radiation|stereotactic body radiation therapy|Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less
75942082|NCT02376296|Drug|docetaxel|3-weekly docetaxel therapy (starting dose of 75 mg/m2)
75942083|NCT02376296|Other|Blood draws|Blood draws for determination of docetaxel plasma levels and exposure (AUC)
75942084|NCT05034172|Other|Clinical follow-up|"Clinical Follow-up:~demographic data and history,~Retrospective interview (collection of data useful for genetic studies): -disease history (for patients only);~Family history - Neurological examination:~Diagnosis Clinical examination;~Rating scales specific to the pathology under investigation;~Cerebral MRI (optional)~Biological samples (optional)"
75942085|NCT02380820|Device|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
75942086|NCT02380820|Device|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
75942087|NCT02371928|Other|Neuromuscular exercise program|"Exercises can be individually progressed from basic to elite level.~Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.~Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.~Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.~Supervision will be given two times a week for the first two weeks and then once a week for the remaining period."
75942088|NCT02371928|Other|Standard home exercise program|"Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.~All exercises are performed three times a week with 2 sets of 10 repetitions."
75942089|NCT02380664|Device|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
75942090|NCT02380664|Behavioral|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
75942091|NCT01364428|Drug|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
75344837|NCT01354691|Drug|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
75655776|NCT00634218|Behavioral|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
75655777|NCT00634218|Behavioral|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
75655778|NCT00634218|Behavioral|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
75802717|NCT05491174|Behavioral|DBT-Informed skills group|10 session group ran weekly by junior staff (P-BIFs) following a standardised manual-based protocol which can be delivered either face-to-face or via video-call. The groups will be skills-based, covering each of the four modules of DBT: Mindfulness, Distress Tolerance, Emotion Regulation and Interpersonal Effectiveness.
75344838|NCT00809276|Drug|Busulfan, Fludarabine, Cytoxan|"Busulfan once a day for 4 days~Fludarabine once a day for 4 days~Bone marrow transplant~Cytoxan two doses"
75344839|NCT03009617|Behavioral|the educational program and counseling|to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
75802718|NCT00823342|Drug|CLEVUDINE + TENOFOVIR PLACEBO|30 MG
75802719|NCT00823342|Drug|CLEVUDINE IN ASSOCIATION TENOFOVIR|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
75802720|NCT00823342|Drug|TENOFOVIR + CLEVUDINE PLACEBO|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
75802721|NCT00097539|Biological|Somatrem|
75802722|NCT00097539|Biological|Somatropin|
75802723|NCT01082445|Drug|N-acetylcysteine|600 mg, 1 tablet 3 times a day for 3 months
75802724|NCT01082445|Drug|Placebo|Placebo
75802725|NCT03963219|Device|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
75802726|NCT03963219|Device|Standard Bolus Calculator|Standard bolus calculator
75344840|NCT01355471|Drug|CD07805/47 Gel|applied topically once daily
75344841|NCT01355471|Drug|Placebo|applied topically once daily
75344842|NCT00802412|Drug|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
75344843|NCT00802412|Drug|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
75344844|NCT01355705|Drug|Amrubicin|40, 60, or 80 mg/m2 intravenous (IV)
75344845|NCT01355705|Drug|Lenalidomide|15 mg daily by mouth
76090789|NCT03298854|Device|99mTc-MDP SPECT/CT|Delayed whole body images, using Symbia-T-Siemens dual headed gamma camera, will be obtained 2-3 hours after injection of 15-25 mCi of Tc-99m MDP (Methylene diphosphonate) followed by SPECT images of the lumbar spine and pelvis.
76090790|NCT02461680|Procedure|tangential resection|the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
76090791|NCT02461680|Procedure|suture|
76090792|NCT02461914|Drug|PEX168|200µg,injected subcutaneously,once a week.
76090793|NCT02461914|Drug|Warfarin|5mg,oral,two times.
76090794|NCT01991860|Drug|APD421- Amisulpride for IV injection|APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
76090795|NCT01991860|Drug|Placebo|Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
76090796|NCT01986790|Behavioral|Plain Language|
75655779|NCT00634218|Behavioral|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
75655780|NCT04237818|Dietary Supplement|Placebo drink|consume 2 bottle (30 mL) per day for 56 days
75655781|NCT04237818|Dietary Supplement|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|consume 2 bottle (30 mL) per day for 56 days
75655782|NCT04237740|Drug|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
75802727|NCT01089777|Device|ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test
75802728|NCT01085877|Drug|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
75802729|NCT01085877|Drug|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
75802730|NCT01089855|Drug|Carbamazepine|
75802731|NCT01589289|Device|Immunochromatographic HAT tests (DSD)|Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
75802732|NCT01589289|Device|Card Agglutination Trypanosoma Test|Card Agglutination Trypanosoma Test on whole blood and as dilution
75802733|NCT01589289|Device|TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|"TB POC Nucleic Acid Amplification Test: microPCR handheld device (Molbio Diagnostics PVT ltd, India)"
75802734|NCT01589289|Device|TB 3-marker RDT (Tulip diagnostics)|TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
75802735|NCT01589289|Device|Cryptococcal Antigen Lateral Flow Assay (Immy)|Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
75802736|NCT04676932|Other|Nursing Care Based on Kolcaba's Comfort Theory|In this study, Nursing care based on Kolcaba's Comfort Theory will be applied for women undergoing HSG.
75802737|NCT04600960|Drug|Eltrombopag|The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count >100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
75802738|NCT04540042|Drug|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
75655783|NCT00634296|Other|Inspiratory muscle added by aerobic to aerobic alone|Inspiratory muscle added by aerobic to aerobic alone
75655784|NCT02816034|Behavioral|Visuo-motor rotation|Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.
75802739|NCT04540042|Drug|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
75655785|NCT02816034|Behavioral|Explicit strategy|Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target
75802740|NCT04540042|Drug|SelK2 (Part 2)|I.V., single-dose (Day 1)
75802741|NCT04540042|Drug|Placebo (Part 2)|I.V., single-dose (Day 1)
76090797|NCT01986790|Behavioral|Plain Language + Visuals|
76090798|NCT01986790|Behavioral|Plain Language + Narratives|
76090799|NCT02463552|Drug|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
76090800|NCT01992016|Drug|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
76090801|NCT01871571|Biological|bevacizumab|Given IV
76090802|NCT01871571|Drug|oxaliplatin|Given IV
76090803|NCT01871571|Drug|leucovorin calcium|Given IV
76090804|NCT01871571|Drug|fluorouracil|Given IV
76090805|NCT01871571|Other|laboratory biomarker analysis|Correlative studies
76090806|NCT01992172|Drug|Photocil for Atopic Dermatitis|Photocil for Atopic Dermatitis
76090807|NCT01992172|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
76090808|NCT03296982|Other|Blood drawn by direct venipuncture|Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.
76090809|NCT03296982|Drug|edoxaban|
76090810|NCT03296982|Drug|Enoxaparin|
76090811|NCT03296982|Drug|Saline sham|
76090812|NCT03296904|Device|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
75942092|NCT01364428|Drug|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
75942093|NCT02376374|Other|Controlling vaccination rates in communities|Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
75942094|NCT05032534|Device|Cone Small, Qufora A/S|Newly developed cone in a softer material and a design matching the use for transanal irrigation.
75942095|NCT05032534|Device|Colotip, Coloplast A/S|Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.
75344846|NCT01355705|Drug|Dexamethasone|40 mg weekly by mouth
75655786|NCT02817984|Biological|Acellular Adipose Tissue (AAT)|The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
75655787|NCT02817750|Drug|zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
75655788|NCT02817750|Drug|zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
75655789|NCT02817672|Behavioral|PRIME 1.0|Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).
75655790|NCT02817672|Behavioral|PRIME 2.0|Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
75655791|NCT02815410|Drug|levetiracetam|Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
75655792|NCT02817438|Behavioral|Good Days Ahead|Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
75655793|NCT02814630|Biological|Xolair|The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
75802742|NCT04481074|Other|Inspiratory muscle training|Inspiratory muscle training will be performed using the tapered flow-resistive loading trainer (POWERbreathe®).
75802743|NCT04426786|Other|Active exercise|Thrice-weekly supervised intense aerobic exercise classes on cycle ergometers, in groups, for six months. Percentage of VO2 max will be used to regulate exercise intensity, based on an initial aerobic exercise test.
75802744|NCT04426786|Other|Passive exercise|Thrice-weekly supervised passive exercise classes consisting of stretching and/or yoga, in groups, for six months.
75802745|NCT04252144|Procedure|Dietary assessment|Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
75802746|NCT04239430|Diagnostic Test|Serum Bactericidal Assays|Blood samples will be taken from participants at two time points in the study. Serum Bactericidal Assays from participant serum using relevant MenB and MenACWY strains will be undertaken at 18 and 30 months post two doses of 4CMenB (Bexsero, GSK) and MenACWY-conjugate (Menveo, GSK) vaccine. The Vaccines were given to participants during an earlier clinical trial (Propositive). This trisal is a follow up study.
75942096|NCT02371694|Other|Test drink|"The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour."
75942097|NCT02371772|Other|Training|Patients were trained to monitor INR and dose warfarin
75942098|NCT02380586|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
76090813|NCT02463630|Procedure|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
76090814|NCT00493701|Behavioral|High Fat Diet|Daily eating
75344847|NCT01355705|Drug|Aspirin|81 or 325 mg daily by mouth
75344848|NCT01355705|Drug|Pegfilgrastim|6 mg subcutaneous on Day 2
75344849|NCT03009071|Procedure|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
75344850|NCT03009071|Device|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
75655794|NCT04295382|Device|Software Application|A software application targeting suicidal ideation via interactive exercises.
75655795|NCT02816268|Other|Pulmonary vein isolation|
75344851|NCT01274585|Device|Posterior tibial nerve stimulation (PTNS)|Stimulation using PTNS device for 30 minutes weekly for 12 weeks
75655796|NCT00619957|Drug|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
75942099|NCT02375828|Drug|Glibenclamide|Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
75942100|NCT02380508|Drug|BCG SSI|Intradermal injection
75942101|NCT02380508|Other|No vaccination|
75942102|NCT02380508|Drug|BCG Sii|intradermal injection
75942103|NCT02380430|Other|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
75942104|NCT02371538|Dietary Supplement|Donor Breastmilk|Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
76090815|NCT00493701|Behavioral|Low Fat Diet|Life style eating habits
76090816|NCT01895829|Procedure|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
76090817|NCT01895829|Drug|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
76090818|NCT03296748|Procedure|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
75344852|NCT01274585|Device|Posterior tibial nerve stimulation|Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
75344853|NCT01327157|Procedure|occlusal adjustment.|It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this to start. Will be held palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After starts the adjustment following the rules of Guichet with a cylindrical drill with a thin cut . basic principles 1 Occlusive stress maximum distribution in centric relation 2 The occlusive strengths should by the teeth's major axis.3 When the contact is surface to surface, it must be exchanged to another surface point. 4 Once the stability to the centric relation is achieved, it should be kept. The rules to guide the occlusal adjustment selective grinding .
75344854|NCT01327157|Behavioral|Visual analog scale.|"Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient."
75344855|NCT00802880|Drug|Dacarbazine|
75344856|NCT04814186|Drug|Tafamidis|61 mg, once daily, oral administration, for 12 months.
75655797|NCT00619957|Drug|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
75655798|NCT02816190|Procedure|prone position|
75655799|NCT02815956|Device|percutaneous tibial nerve stimulation|
75655800|NCT02815956|Device|Placebo|
75655801|NCT02815878|Behavioral|Enhance Wellness|A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
75655802|NCT02815800|Dietary Supplement|ETHNODYNE VISIO|
75655803|NCT00851149|Device|Sangvia blood sampling system|Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
75655804|NCT02546011|Other|Fetal Heart Rate Monitor|Standard of care, not part of research
75655805|NCT00961415|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3-week cycle
75655806|NCT00961415|Drug|cisplatin|75mg/m2 iv on day 1 of each 3-week cycle
75655807|NCT00961415|Drug|pemetrexed|500mg/m2 iv on day 1 of each 3-week cycle
75942105|NCT02376218|Drug|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
75942106|NCT02376062|Other|Bundled Intervention|"The authors have designed continuing medical education curriculum to improve clinical capacity and competency about mental health for Nepali Primary Care Providers. Specifically:~On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~Weekly case conferences~Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
75942107|NCT02371226|Drug|AGT-181 (HIRMAb-IDUA)|intravenous infusion over 3-4 hours
75942108|NCT02371304|Radiation|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
75942109|NCT02371304|Procedure|Additional TME surgery|
75942110|NCT02371304|Drug|capecitabine|
75942111|NCT02380352|Drug|Amoxicillin|
75942112|NCT02380352|Drug|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
75942113|NCT02375750|Device|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
76090819|NCT03296748|Procedure|anterior colporraphy|
76090820|NCT03298776|Device|I-Scan|I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
76090821|NCT03298776|Diagnostic Test|Standard endoscopy|Patients referred for standard endoscopy to receive standard of care only
76090822|NCT03298698|Drug|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
75344857|NCT04382378|Device|neuromuscular electrical stimulation|application of an electric current through electrodes placed on the skin over the targeted musclesto induce skeletal muscle contractions
75344858|NCT04932824|Biological|SCB-2019|a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.
75655808|NCT00836329|Behavioral|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
75802747|NCT04051528|Procedure|aerobic exercise training|The aerobic exercise will first perform 3 minutes of warm-up followed by 25 minutes of resistive aerobic exercise and then 2 minutes cool-down. During the aerobic exercise the target heart rate will be 40 to 70% of maximal heart rate calculated as (208 - 0.7 age). The exercise intensity will be progressed as the participants improve their performance throughout practice. Vital signs and the Borg Perceived Exertion Scale will be monitored and recorded during exercise for each session.
75802748|NCT04051528|Procedure|computerized cognitive training|The core function of cognitive training will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance. Cognitive training group will use commercialized cognitive based training programs to facilitate several cognitive functions. The core function will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
75802749|NCT04051528|Procedure|guiding training|At the first time in guiding training will focus on introducing the Goal-Plan-Do-Check strategy and identifying initial three goals by the Canadian Occupational Performance Measure. At the second time in guiding training will begin with a review of the Goal-Plan-Do-Check and will apply the Goal-Plan-Do-Check to the first initial goal. Participants will review this goal and plan, describe the execution of the plan (do), and evaluate the execution of the plan (check). After each execution of the plan, the participant will rate his performance using the COPM Performance Scale, producing iterative scores for each activity. The remaining session of guiding sessions will repeat this process, review performance of identified activities, and applying the Goal-Plan-Do-Check strategy to improve performance.
75802750|NCT04051372|Diagnostic Test|Bronchoscopic Alveolar Lavage|"The diagnostic yield of different diagnostic methods for lung infection and non-infectious diseases under allo-HSCT patients.~Classic microbiological cultures designed for bacteria, fungi, and mycobacteria.~Detection of human cytomegalovirus (CMV) and EB virus in serum and BAL was tested using a Real-time PCR kit.~Detection of aspergillus galactomannan antigen 1,3-beta-D-glucan in serum and BAL was performed using an enzyme immunoassay method.~Cytological and pathogenic microscopic evaluation in BALF~Flow cytological analysis of T lymphocyte subsets in BALF and serum~Cytokine detection in BALF and serum~Microbiology detection in BALF by mNGS"
76090823|NCT03298698|Drug|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
75344859|NCT03839888|Drug|0.125% Atropine|patients used 0.125% atropine eyedrop per night before sleep for 7 days.
75344860|NCT03839966|Behavioral|Interpretation Bias Modification for Loneliness|Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard & Amir, 2008 and Beard, Weisberg, & Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
76090824|NCT02463942|Drug|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
76090825|NCT02463942|Drug|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
76090826|NCT02463942|Other|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
76090827|NCT03385408|Device|HIRO® 3.0|Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).
75344861|NCT03839966|Behavioral|Healthy Habits Psychoeducation and Relaxation|Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
75344862|NCT03839654|Device|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
75344863|NCT04768868|Drug|IMP7068|To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
75344864|NCT04754048|Device|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
75942114|NCT02375750|Other|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
75942115|NCT02375594|Other|Exercise in park equipment|
75942116|NCT02380118|Drug|Olanzapine|Intramuscular injection
75942117|NCT02380118|Drug|Haloperidol|Intramuscular injection
75942118|NCT02380118|Drug|Midazolam|Intramuscular injection
75942119|NCT03113708|Drug|Heparin Sodium|Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
75942120|NCT03113474|Other|Food palatability|Food palatability is modulated
75655809|NCT00836329|Behavioral|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
75802751|NCT03626116|Procedure|silicone metacarpophalangeal arthroplasty (SMPA)|Replacement of the metacarpophalangeal (MCP) joint using a silicone arthroplasty
75942121|NCT02371148|Drug|Bortezomib-Rituximab-Bendamustine|"Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22* Rituximab: 375 mg/sqm i.v. day 1** Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles *In case of toxicity is omitted~**In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8"
75942122|NCT02375360|Other|Oral immunotherapy|
75942123|NCT02379962|Other|no intervention|
76090828|NCT03385408|Device|Sham laser|For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
75802752|NCT05475574|Other|Discontinuation of contact precautions for ESBLE|Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
75655810|NCT04237662|Procedure|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
75655811|NCT04237662|Device|Enamel Matrix Derivative application|Enamel Matrix Derivative will be applied in the sites with at least 6 mm of pocket depths
75655812|NCT02815488|Drug|CHF6297 (Part 1 - SAD)|Single doses of CHF6297 at each period (for up to 3 periods per subject)
75655813|NCT02815488|Drug|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
75655814|NCT02815488|Drug|CHF6297 (Part 2 - MAD)|Twice daily doses of CHF6297 for 7 days
75655815|NCT02815488|Drug|Placebo (Part 2 - MAD)|Twice daily doses of placebo matching CHF6297 for 7 days
75655816|NCT02815488|Drug|CHF6297 (Part 3)|Twice daily doses of CHF6297 for 14 days
75802753|NCT04092166|Other|Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
75942124|NCT02375516|Behavioral|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
76090829|NCT01853163|Procedure|Gadolinium analysis in bone and tissue samples|Gadolinium analysis in bone and tissue samples from patients undergoing an orthopaedic surgical procedure who had received GBCAs in the past.
76090830|NCT03298620|Other|Electric toothbrush|
75655817|NCT02815488|Drug|Placebo (Part 3)|Twice daily doses of placebo matching CHF6297 for 14 days
75655818|NCT02815488|Drug|CHF6297 (Part 4)|Twice daily doses of CHF6297 for 7 days
75655819|NCT02815488|Drug|Placebo (Part 4)|Twice daily doses of placebo matching CHF6297 for 7 days
75655820|NCT00851227|Drug|conivaptan hydrochloride|intravenous
75655821|NCT00850837|Drug|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
75655822|NCT00850837|Drug|HEC gel|5 g application of hydroxyethylcellulose gel
75802754|NCT04037020|Other|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (extreme dark (90%), dark (70%), milk (38%), and white (0%)).
75802755|NCT03925324|Biological|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg
75802756|NCT03925324|Other|Placebo|1.5 mL/kg Lactated Ringer's Solution
75802757|NCT03841318|Biological|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
75942125|NCT02380040|Device|PPG|A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
75942126|NCT03113318|Procedure|Total mediastinal lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection where all lymph nodes and fatty tissues is removed conjunction with pulmonary metastasectomy
76090831|NCT03298620|Other|Control|Manual toothbrush
76090832|NCT03360136|Behavioral|Multi-professional CBT-rehabilitation|"See Detailed description"
75942127|NCT03113318|Procedure|Only pulmonary metastasectomy|
75942128|NCT02370992|Radiation|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
75942129|NCT02370680|Drug|Aspirin|steady-state run-in prior to Durlaza treatment
75942130|NCT02370680|Drug|Durlaza™|comparison of different numbers of capsules
75942131|NCT02370758|Drug|Valganciclovir or Ganciclovir|
75942132|NCT03113240|Drug|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
76090833|NCT03298542|Drug|Golimumab|Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
76090834|NCT03298542|Drug|Placebo|Matching placebo to golimumab.
76090835|NCT03350698|Biological|Gardasil-9|3 vaccine series
76090836|NCT03296670|Drug|Alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
76090837|NCT03296670|Drug|Nitroglycerin|Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
75344865|NCT05089526|Drug|ketamine-lidocaine-dexmedetomidine|"In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
75802758|NCT03841318|Biological|biopsy of the labial salivary gland|Part of the biopsy of the labial salivary gland
75942133|NCT03113240|Other|Maltodextrin|Maltodextrin mixed with water given via NG tube q 4 hours.
75942134|NCT02370836|Other|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
75942135|NCT02375282|Procedure|Ambulation orderly|The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
75942136|NCT03105596|Drug|Chidamide plus DICE Regimen|Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
75942137|NCT04669964|Procedure|Intravenous Hydration|Patients will receive daily intravenous hydration of normal saline based on their ileostomy output.
76090838|NCT02463864|Other|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
76090839|NCT02463864|Other|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
76090840|NCT01976260|Device|Fractional Radiofrequency|
75655823|NCT00850915|Other|community IPT|"In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB."
75802759|NCT03794986|Behavioral|Trauma-informed SGM affirmative care|"All SGM male survivors who meet inclusion criteria, including significant emotional distress, will complete pre-test measures and be randomized to 6-week Motivational Interviewing (MI) delivered by peers in online groups or 6-week MI with trauma-informed, SGM affirmative care delivered by peers in online groups.~Participants will complete pre-intervention (baseline), end of the 6-week intervention, 60- and 120-days follow-up assessments via an online survey platform, to determine if there was an increase in formal treatment engagement, and any significant changes in mental health symptomology (i.e., PTSD, depression, high-risk drinking, and illicit substance use)."
75802760|NCT03794986|Behavioral|Motivational Interviewing|"Major principles and tenets of Motivational Interviewing (MI) group include: Non-confrontational nature of group; environment is one of respect, safety, and encouragement of all group members; purpose is to learn about members' personal thoughts and choices and not to push an agenda"
75802761|NCT03674320|Drug|Testosterone Enanthate|Testosterone Enanthate (25 mg women, 100mg men) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
75802762|NCT03674320|Drug|Placebo|Placebo Injection (saline) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
75802763|NCT05457946|Biological|LBVD (Hexavalent vaccine)|Injection within the muscle into the front area of the thigh
75802764|NCT05457946|Biological|Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)|Injection within the muscle into the front area of the thigh
75802765|NCT03625960|Drug|Cantharidin|A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
75802766|NCT03625960|Drug|Trichloroacetic Acid|Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
75802767|NCT03042910|Drug|Talazoparib|Talazoparib 1 mg orally once daily.
75942138|NCT02379182|Behavioral|standard clinical care|adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
76090841|NCT01976260|Device|1550-nm Fractional Photothermolysis|
76090842|NCT03296514|Behavioral|MBSR|Eight week class on MBSR in addition to an orientation class and a half day retreat
76090843|NCT03328468|Other|Breathing Exercise|Breathing exercise for stroke patients
76090844|NCT03296436|Biological|NEOX® CORD 1K®|NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
76090845|NCT03298464|Biological|NGM313|Subcutaneous injection
76090846|NCT03298464|Drug|Pioglitazone|White to off-white round tablet
76090847|NCT03287596|Device|MRI ZTE2 sequence|feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
75942139|NCT02379182|Device|transcutaneous electrical stimulation at sensory level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
75942140|NCT02379182|Device|transcutaneous electrical stimulation at motor level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
75942141|NCT02370524|Drug|[18F]T807|All enrolled subjects will undergo an [18F]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
75942142|NCT02370446|Other|personalized medication log|
75942143|NCT02370446|Other|standard of care|
75655824|NCT02811276|Other|Diet|The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
75802768|NCT05450302|Other|PURE EP (Observational Study)|This is an observational study. No interventions involved in this study.
75802769|NCT03243838|Drug|Apatinib|All enrolled patients were administered oral apatinib at a dose of 250 mg once daily and intravenously docetaxel (100 mg/m2) every three weeks for four cycles, followed by epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) every three weeks for four cycles. All the treatments were continued until disease progression, patient withdrawal, or unacceptable toxic effects.
75802770|NCT03059446|Drug|Cenicriviroc|Cenicriviroc immediate release tablets
76090848|NCT01852071|Genetic|Infusion of autologous EFS-ADA LV CD34+ (OTL-101)|autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
75344866|NCT05089526|Drug|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
75655825|NCT03365609|Drug|triple therapy|Omeprazole+Amoxicillin+Clarithromycin
75655826|NCT03365609|Drug|sequential therapy|the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
75655827|NCT03365609|Drug|bismuth quadruple therapy|Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
75655828|NCT03365609|Drug|concomitant therapy|Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
75802771|NCT00090519|Drug|ruboxistaurin|32 mg once daily (QD) oral for up to 36 months
75802772|NCT00090519|Drug|placebo|QD oral for up to 36 months
75942144|NCT02370446|Behavioral|questionnaires|
75942145|NCT02370446|Behavioral|Cognitive Interview|
75344867|NCT00804596|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
75655829|NCT02860871|Other|infrared spectroscopy|
75655830|NCT02814240|Other|NMR|
75655831|NCT02814240|Biological|Blood samples|
75655832|NCT02814240|Other|fibroscan|
75655833|NCT00851305|Device|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
75655834|NCT00851305|Device|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
76090849|NCT01852071|Drug|busulfan|Busulfan is used for non-myeloablative conditioning
76090850|NCT01852071|Drug|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
75802773|NCT02980666|Drug|Teduglutide|0.05 mg/kg/day SC injection once daily for 24 weeks.
75802774|NCT02962102|Drug|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
75802775|NCT02962102|Drug|Calcitriol|Calcitriol 4mcg orally daily x 5
75802776|NCT02962102|Drug|Placebos|Placebo (medium chain triglyceride oil) orally daily x 5
75802777|NCT02853448|Device|Novel Blood Drawing Apparatus|
75802778|NCT02630368|Drug|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
76090851|NCT03219736|Procedure|Standard of Care therapies|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
75942146|NCT03105440|Other|Virtual reality|"This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
75942147|NCT03105440|Other|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
75942148|NCT03105440|Other|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
75942149|NCT03105440|Other|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
75942150|NCT03105440|Other|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
75942151|NCT03105440|Other|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
75942152|NCT02379026|Dietary Supplement|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
75942153|NCT02379026|Behavioral|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
75802779|NCT02630368|Drug|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
75942154|NCT02379026|Dietary Supplement|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
75344868|NCT01327313|Biological|EMD525797|Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.
75344869|NCT01327313|Biological|EMD525797|Subjects will receive 500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
75655838|NCT00963599|Drug|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
75655839|NCT00963599|Drug|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
75655840|NCT00963599|Drug|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
75655841|NCT00963599|Drug|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
75655842|NCT00851383|Biological|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
75802780|NCT02630368|Drug|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
75942155|NCT02515942|Drug|CLG561|
75942156|NCT02515942|Drug|LFG316|
75942157|NCT02515942|Drug|Sham injection|Empty syringe (without a needle) placed against the eye
75942158|NCT02374892|Behavioral|CHAPTER III Study Intervention|This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
75942159|NCT02991859|Drug|Fluticasone furoate (FF) Dry Powder Inhaler|Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
75942160|NCT02991859|Drug|Fluticasone propionate (FP) Dry Powder Inhaler|Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
75344870|NCT01327313|Biological|EMD525797|Subjects will receive 1000 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
75344871|NCT01327313|Biological|EMD525797|Subjects will receive 1500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity, or withdrawal of consent.
75802781|NCT02630368|Drug|Avelumab and JX-594 and Cyclophosphamide|"Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections ."
75802782|NCT05693116|Procedure|Rhinectomy|Surgery will be performed according to extension of the tumour, i.e. local resection limited to the vestibule, partial rhinectomy, total rhinectomy, extended total rhinectomy
75942161|NCT02991859|Drug|Budesonide (BUD) Turbuhaler|Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
75942162|NCT02991859|Drug|Placebo (ELLIPTA or DISKUS)|Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
75942163|NCT04721366|Other|Standard of Care|Neonatal and pediatric participants who has been on ERT (VPRIV) will be assessed as per SOC.
75942164|NCT02370290|Other|Medical Chart Review|Clinical and imaging information collected
75942165|NCT02370290|Other|Informational Intervention|Clinical and imaging data collected
75942166|NCT02370134|Device|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
75942167|NCT02370134|Device|sham glove|
75942168|NCT02374970|Other|Lumbar stability exercises|Four individualized learning sessions will be held during the same period of protocolized physiotherapy. Biofeedback training using the ultrasound machine will be performed in the first session, in order to show the specific contraction of the abdominal muscles with the stability exercises. The other three learning sessions will be performed without feedback, for the patient learn the exercises to make at home during the follow-up period.
75942169|NCT02374970|Other|Protocolized Physiotherapy|Therapeutic exercises and thermotherapy during 12 daily sessions
75344872|NCT04382846|Drug|Nitazoxanide|Nitazoxanide
75344873|NCT04641260|Drug|Fezolinetant|Oral
75344874|NCT02200055|Device|Bodystat Quadscan 4000|"Each patient involved in the study will be evaluated with a bioimpedance monitor to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
75344875|NCT02200523|Device|SARA electrode|
75344876|NCT02200523|Device|Gold cup|
75344877|NCT01328405|Device|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
75344878|NCT05021510|Other|Simultaneous Cervical Traction & Neural Mobilization|Simultaneously Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
75655843|NCT00851383|Biological|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
75942170|NCT02370212|Dietary Supplement|Creatine|
75655844|NCT05636592|Drug|Statin|statins will be taken according to directions.
75942171|NCT02370212|Dietary Supplement|Placebo|
75942172|NCT02370212|Other|High intensity interval training|
75942173|NCT02374736|Drug|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL."
75942174|NCT02375048|Radiation|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
75942175|NCT02375048|Radiation|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
75942176|NCT02369978|Drug|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
75942177|NCT02369978|Drug|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
75344879|NCT05021510|Other|consecutive Cervical Traction & Neural Mobilization|consecutive Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
75655845|NCT02814006|Other|health educational video|visualization of health educational video
75655846|NCT04285385|Other|Lavender aromatherapy|0.10 ml of lavender essential oil
75655847|NCT04285385|Other|Sham aromatherapy|0.10 ml of mineral oil
75655848|NCT04016467|Other|Thoracic manipulation|High velocity, small amplitude thrust treatment to spine that elicits a neurophysiologic response.
75655849|NCT04016467|Other|Sham thoracic treatment|Hand placement on thorax without thrust.
75655850|NCT02811120|Other|venepuncture only|single venepuncture
75655851|NCT02862821|Other|HR-EEG|
75942178|NCT02369978|Drug|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
75942179|NCT04055545|Other|HIIT|"5 min. warm up~10 × 60 seconds burst~60 seconds recovery after each burst~Burst phase: HRR >90%~Recovery phase: HRR btw. 30-39%~5 min. cool down"
75942180|NCT04055545|Other|MICT|"5 min. warm up~20 min. continuous cycling: HRR btw. 40% - 59%~5 min. cool down"
75942181|NCT02379260|Other|Interview with a sociologist|
75344880|NCT04639622|Diagnostic Test|Investigation procedures|All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)
75344881|NCT01274897|Biological|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
75655852|NCT00851461|Drug|Goserelin|Goserelin 10.8 mg SC every 3 months
75655853|NCT00851461|Procedure|Electrophysiologic study|Nerve conduction study Electromyogram
75655854|NCT00851461|Procedure|tissue biopsy|skin and muscle biopsy before and after treatment every year
75655855|NCT04205136|Drug|Spironolactone|If tolerated and serum potassium <5.0 meq/L, the dose will be increased to 50 mg (2 pills) after 4 weeks. If serum potassium is >5.0 but less than 5.5 or creatinine >4.0 mg/dL, the dose will be adjusted to 25 mg every other day; if potassium levels ≥5.5 in a non-hemolyzed blood sample, the medication will be discontinued.
75655856|NCT04205136|Drug|Placebo|Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
75344882|NCT01274897|Biological|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
75344883|NCT04693130|Behavioral|Mindfulness-based prenatal education|Mindfulness-based prenatal education involves mindfulness breathing and other skills with mindfulness meditations.
75942182|NCT02379104|Device|ROTEM sigma|Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
76090852|NCT03219736|Device|NiPPV Therapy|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
76090853|NCT03219736|Procedure|Routine Respiratory Care|It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
76090854|NCT04084548|Drug|Lidocaine and ketamine|Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
75655857|NCT00851539|Behavioral|Video|Behavioral Intervention Video
75344884|NCT04693130|Behavioral|Hospital-based antenatal care|Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
75344885|NCT03947840|Behavioral|Physical activity|Se their physical activity level
75344886|NCT02323217|Radiation|[11C]BU99008|Baseline Scan, Test-ReTest or Dosimetry
75344887|NCT02323217|Drug|Idazoxan|Idazoxan block of [11C]BU99008
75942183|NCT03661489|Drug|Remimazolam|For induction and maintenance of general anesthesia
75344888|NCT02323217|Drug|Isocarboxazid|Isocarboxazid block of [11C]BU99008
75942184|NCT03661489|Drug|Propofol|For induction and maintenance of general anesthesia
75344889|NCT01275053|Drug|leptin|0.01mg/kg
75344890|NCT02324075|Behavioral|Behavior change|Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
75344891|NCT04979234|Device|Endomina- Endoscopic Sleeve Gastroplasty|Endoscopic gastric reduction
75344892|NCT04979234|Behavioral|Diet|Multidisciplinary follow up
75655858|NCT02815332|Drug|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
75655859|NCT02815332|Drug|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
75655860|NCT02815332|Drug|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
75655861|NCT00923923|Behavioral|stress|compare levels of stress
75655862|NCT02811042|Device|Ambu AuraOnce|Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
75655863|NCT02811042|Device|Ambu AuraGain|The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
75655864|NCT02811354|Drug|AZD9291|oral administration as a single daily dose of 80 mg
75655865|NCT04285398|Other|Ophthalmic examinations|Slit-lamp examination, IntraOcular Pressure, Visual Acuity, Visual Field, Full-field Stimulus Threshold, Dark adaptometry, Color Vision testing, Optical Coherence Tomography, Fundus AutoFluorescence and Adaptive Optics imaging.
75655866|NCT04285398|Other|Mobility Test|Functional test to evaluate mobility and postural condition of patients
75655867|NCT02813772|Dietary Supplement|Milk formula NAN Sensitive, Nestle|Infants randomized to group 1 will receive the milk formula NAN Sensitive, Nestle for a period of 4 weeks.
75655868|NCT02813772|Dietary Supplement|Milk formula Optipro, Nestle|Infants randomized to group 1 will receive the milk formula NAN Optipro, Nestle for a period of 4 weeks.
75655869|NCT02814942|Device|Cardiac Resynchronization Therapy|Cardiac resynchronization therapy with or without ICD
75655870|NCT02810808|Procedure|1+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the injection of the same does at the first month.
75655871|NCT02810808|Procedure|3+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the first three monthly intravitreal injections of the same does.
75942185|NCT02378948|Dietary Supplement|Liquid oral feeding|Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
75942186|NCT04056169|Drug|high-dose rosuvastatin|rosuvastatin 20 mg once a day for 6 months
75942187|NCT04056169|Drug|low-dose rosuvastatin plus ezetimibe|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
75942188|NCT04947670|Procedure|Renal arteriography followed by renal denervation|Renal arteriography followed by renal denervation
75942189|NCT04947670|Procedure|Sham Renal arteriography|Renal arteriography only
76090855|NCT04084548|Drug|Lidocaine|Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
76090856|NCT04084548|Drug|Ketamine|Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
76090857|NCT04084548|Drug|Placebo|Perioperative placebo infusion (normal saline)
76090858|NCT02059642|Drug|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
76090859|NCT02059642|Drug|placebo|Placebo 1400 mg administered orally once daily
75344893|NCT04382768|Drug|Inhaled Hypertonic ibuprofen|Standard of care plus lipid ibuprofen 50mg tid
75354656|NCT04813172|Behavioral|Symptom Assessment|"Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit."
75942190|NCT04439630|Dietary Supplement|Nopal fractions|Nopal flour were divided in two fractions and mixed in two different test breads
75942191|NCT04439630|Dietary Supplement|Test product without the active components|Test product without the active components
75942192|NCT03660709|Behavioral|Intervention|"Standard-of-care HIV testing and counseling~Watch a video clip while waiting for the HIV testing result on a tablet.~Receive a pamphlet and post-test counselling promoting HIV retesting.~Receive the e-health HIV risk calculator through e-mail, SMS or social media means 3 and 5 months afterwards.~Receive brief e-health reminder for retesting at Month 3 and 5."
75942193|NCT03660709|Behavioral|Control|Standard-of-care HIV testing and counseling
75942194|NCT02374658|Behavioral|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
75942195|NCT02369822|Dietary Supplement|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
75942196|NCT03016325|Drug|HNO Donor|Infusion
75942197|NCT03016325|Drug|Placebo|Infusion
75942198|NCT04983004|Behavioral|tele-rehabilitation|According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.
75802783|NCT05693038|Diagnostic Test|Electromyography|Electromyography (EMG) monitoring will be performed, using the instrumentation available (Nemus 2, EB Neuro, Italy), to evaluate the occurrence of brachial plexus injury (BPI). EMG will be performed at the end of each pronation cycle. To rule out BPI at ICU admission, an EMG will be performed within two hours from the first pronation maneuver. Particularly, somatosensory evoked potential (SSEP) and sensory action potential (SAP) will be obtained from radial, ulnar, median and sural nerves. In case patients are awake, compound muscle action potential (CMAP) will be obtained as well.
75942199|NCT04983004|Behavioral|bedside rehabilitation|The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
75942200|NCT02988115|Drug|bempedoic acid|bempedoic acid 180 mg tablet
75942201|NCT02988115|Other|placebo|Matching placebo tablet
75942202|NCT02374502|Behavioral|Brief Intervention|'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
75942203|NCT02378792|Device|Vagus Nerve Stimulation|Vagus Nerve Stimulator
75942204|NCT04982770|Other|Survey|Reading of ethical guidelines.
75942205|NCT02378870|Drug|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
75942206|NCT02378870|Drug|Placebo|
75802784|NCT05693038|Diagnostic Test|Muscle strength measurement|Muscle strength measure willl be assessed at ICU discharge using hand-held dynamometer.
75802785|NCT05364658|Device|Juvene IOL|Indicated for Implantation in the human eye after removal of a cataractous crystalline lens
75655872|NCT02810808|Drug|Ranibizumab|Ranibizumab - a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration
75942207|NCT03127111|Genetic|Gene mutations analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
75655873|NCT00619801|Drug|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
75802786|NCT05244460|Drug|Droperidol Injectable Product|Treatment
75802787|NCT05244460|Drug|Diphenhydramine|Treatment
75354657|NCT04808310|Device|Quantitative flow ratio|Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)
75655874|NCT00619801|Drug|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
75655875|NCT02815020|Other|Boot Camp Translation - community-participatory process|Series of meetings and conference calls with expert presentation on patient self-management support, facilitated discussion, and creation of product to bring to community to improve patient self-management support
75802788|NCT00096993|Drug|Placebo|Placebo was provided as a single-use formulation for infusion.
75942208|NCT03127111|Genetic|Gene methylation analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for specific gene methylation or CIMP status analysis by MethyLight or bisulfite sequencing. Whole-genome bisulfite sequencing will be used to identify novel candidate set of predictive markers.
75942209|NCT03127111|Genetic|Gene expression analysis|RNA extracted from paired fresh-frozen tumor and normal tissues or serum is used for specific gene expression analysis by real-time reverse-transcription PCR (RT-qPCR). RNA-seq will be used to identify novel candidate set of predictive markers.
75942210|NCT03127111|Genetic|SNP analysis|Genomic DNA extracted from serum is used for specific SNP analysis by using sequencing. GWAS with SNPs array will be used to identify novel candidate set of predictive markers.
75942211|NCT03127111|Genetic|Protein expression analysis|Tissue microarray made from formalin-fixed paraffin-embedded (FFPE) paired tumor and normal tissues is used for specific protein expression analysis by immunohistochemistry staining.
75942212|NCT02369666|Dietary Supplement|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
75942213|NCT02369666|Dietary Supplement|Placebo|Contains MCT oil.
75655876|NCT04237506|Behavioral|Targeted ballet dance|The one-hour ballet dance class will be provided twice per week for six weeks. The syllabi are adapted from the Joffrey Ballet Academy and Royal Academy of Dancing that are targeting grades primary to level 1 and typically developing kids at the age of 6 to 10 years old. PI will be the class instructor, and the class structure will follow the guidelines in 'Dance program for physical rehabilitation and participation in children with cerebral palsy' by Lopez-Ortiz et al.
75942214|NCT02374268|Behavioral|Exercise program alone|
75942215|NCT02374268|Dietary Supplement|Combined exercise program and nutrition supplement|
75942216|NCT02374268|Other|Waitlist control group|
75942217|NCT03658681|Other|Saturated fat 14.9 E%|Dietary cross-over study with saturated fat
75942218|NCT03658681|Other|Polyunsaturated fat 13.6 E%|Dietary cross-over study with polyunsaturated fat
75942219|NCT02369588|Other|Food portion size|
75942220|NCT02921425|Behavioral|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
75344894|NCT04617548|Combination Product|tDCS and CO-OP Group|Transcranial direct current stimulation modulates the excitability of targeted brain regions, and is thought to facilitate or inhibit neuroplasticity. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
75655877|NCT02545777|Drug|diclofenac sodium enteric-coated|
75655878|NCT02545777|Drug|Oral medicine of tonifying spleen and descending turbid|Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
75655879|NCT02545777|Drug|Steeping and washing medicine of descending turbid and clearing heat|Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
75655880|NCT02545777|Drug|Wet wrapping medicine of descending turbid and clearing heat|Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
75655881|NCT04117152|Other|Latent class mixed modeling|To identify CAV trajectories after heart transplantation using a contemporary unsupervised trajectory-based approach known as latent class mixed modeling
75655882|NCT00851617|Device|Threshold® IMT|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
75802789|NCT00096993|Drug|Gemcitabine|Gemcitabine was provided as a solution for infusion.
75802790|NCT00096993|Drug|Pertuzumab|Pertuzumab was provided as a single-use formulation for infusion.
75802791|NCT03040336|Behavioral|Prehabilitation|The 6-week long prehabilitation intervention will include (1) strength and balance training; (2) inspiratory muscle training; and (3) nutritional coaching and supplementation.
75802792|NCT00072189|Drug|7-hydroxystaurosporine|Given IV
75942221|NCT05028712|Behavioral|Visual Information Training|Participants in this arm will receive training to improve the use of residual vision to enhance functional performance.
75942222|NCT05028712|Behavioral|Multimodal training|Participants in this arm will receive training in integrating input from different senses to enhance functional performance.
75942223|NCT03008915|Drug|Aspirin|81mg aspirin taken once per day in the morning
75942224|NCT03008915|Drug|Placebo|placebo taken once per day in the morning
75942225|NCT03008915|Other|Withdrawal from alpha1 antitrypsin replacement therapy|After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
75965995|NCT05475509|Other|Virtually reality|Before chemotherapy, saliva samples will be taken from the control group, Personal Information Form, State Anxiety Scale and Visual Analogue Scale (VAS) pre-test questionnaires will be applied to the patients who accepted to participate in the study, vital signs measurements will be made and post-test questionnaires will be applied at the 30th minute of chemotherapy, vital signs measurements will be made, and A saliva sample will be taken. In the experimental group, a saliva sample will be taken before chemotherapy.
75802793|NCT00072189|Other|laboratory biomarker analysis|Correlative studies
75802794|NCT00072189|Other|pharmacological study|Correlative studies
75802795|NCT03040024|Drug|Ketamine|Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
75802796|NCT03040024|Drug|Placebo|Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
75802797|NCT03040024|Device|Electroencephalogram (EEG)|A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
76090860|NCT03296358|Drug|IV Dexamethasone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
75942226|NCT02374190|Other|Standard Hospital Care|We described patient characteristics using percentages for categorical data, means and SD or medians and IQRs for normally and non-normally distributed continuous variables, respectively. Statistical comparisons for differences in baseline characteristics among patients admitted during regular hours and off-hours were performed using χ2 tests for categorical variables, t-tests and Wilcoxon rank sum tests for normally and non-normally distributed continuous variables, respectively. DTB times were described using median and IQR based on time of admission. All p values were calculated as two-tailed analyses, using a significance level of 5%.
75942227|NCT03658603|Procedure|thoracodorsal artery perforator flap|fascio-cutaneous flap used in cases of trauma or burns
75942228|NCT03658603|Procedure|latissimus dorsi flap|musculo-cutaneous flap used in cases of trauma or burns
75942229|NCT04439162|Procedure|retrograde cardioplegia protection|antegrade-retrograde cardioplegia
75942230|NCT04945018|Biological|HS-001 CS|Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension
75942231|NCT04945018|Device|HS-001-D needle, HS-001-D Adaptor|Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors
75942232|NCT03667625|Other|Multidimensional Mobility Exercises|Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).
75942233|NCT03667625|Other|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks
75942234|NCT03658525|Device|MR LINAC|MR GUIDED PROSATE RADIOTHERAPY
75942235|NCT03622489|Drug|Acetaminophen|mentioned above
75942236|NCT03622489|Drug|Ibuprofen 400 mg|mentioned above
76090861|NCT03296358|Drug|Oral prednisolone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
76090862|NCT04756323|Biological|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
76090863|NCT04756323|Biological|high dosage inactivated SARS-CoV-2 vaccine|high dosage
76090864|NCT04756323|Biological|Placebo|placebo
75655883|NCT02810886|Drug|68Ga-(HBED-CC)-PSMA|68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
75655884|NCT00634374|Device|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
75802798|NCT05128942|Drug|Tildacerfont|Oral tablet formulation taken once daily in combination with glucocorticoid therapy.
75802799|NCT03625804|Genetic|PNS+AO+Training|Electrical stimulation was applied to the radial and ulnar nerve (PNS) of the paretic arm for 60 minutes. During the last 30 minutes of PNS, action observation (AO) was introduced in which subjects were required to watch a series of video clips. After one hour's PNS+AO, the subjects then proceeded to a 30-minute period of motor training of paretic hand.
75802800|NCT03625804|Genetic|PNS+AOsham+Training|PNS was given as described before. During the last 30 minutes of the PNS, subjects were shown different photos illustrating a letter, a number or a hand as AOsham. The protocol of motor training was the same as described before.
75942237|NCT03622489|Drug|Dipyrone|mentioned above
75942238|NCT03622489|Drug|Tramadol|mentioned above
75942239|NCT03622489|Drug|Morphine|mentioned above
75942240|NCT03622489|Drug|Tramal|mentioned above
75942241|NCT03667001|Drug|Lidocaine Hydrochloride|The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
75942242|NCT03667001|Drug|Saline Solution|The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
75942243|NCT04439084|Other|Prospective Chart Review|Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.
75965996|NCT02087189|Device|First ICD/CRT-D implantation or upgrade from pacemaker|
76090865|NCT03298386|Other|Systematic medication review with the STOPP/START tool|The STOPP / START tool includes a list of 42 substances / drug classes whose prescription could be discontinued based on specific criteria (81 STOPP criteria: Screening Tool of Older Person's Prescriptions) and a list of 34 clinical situations involving consideration of the usefulness of a new prescription (START criteria: Screening Tool to Action the Right Treatment).
76090866|NCT04756713|Procedure|Uterine curettage|Manual or electric vacuum aspiration under ultrasound guidance.
75655885|NCT00962741|Drug|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
75655886|NCT00851773|Drug|semaglutide|0.1 mg once weekly, s.c. injection
75655887|NCT00851773|Drug|semaglutide|0.2 mg once weekly, s.c. injection
75655888|NCT00851773|Drug|semaglutide|0.4 mg once weekly, s.c. injection
75655889|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
75655890|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection
75655891|NCT00851773|Drug|placebo|0.1 mg once weekly, s.c. injection
75655892|NCT00851773|Drug|placebo|0.2 mg once weekly, s.c. injection
75655893|NCT00851773|Drug|placebo|0.4 mg once weekly, s.c. injection
75802801|NCT03625804|Genetic|PNSsham+AOsham+Training|The 1-hour PNSsham was conducted with the electrical stimulation unit turned on but without current output. The protocols for AOsham and motor training were the same as those described before.
75942244|NCT04055779|Other|estimation method for arterial occlusion pressure|The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=[SBP+10]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
75965997|NCT02341456|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
75655894|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
75802802|NCT05332834|Biological|SM17|Peripheral intravenous injection
76090867|NCT04756713|Drug|Chemotherapy|conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
75344895|NCT04595474|Device|Transient Elastography|Transient elastography is a noninvasive imaging modality used to assess NAFLD and advanced fibrosis
75344896|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
75344897|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
75655895|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
75802803|NCT05332834|Other|Placebo|Peripheral intravenous injection
75344898|NCT04155164|Drug|Metformin|Participants will receive Metformin at 1000mg for 12 months.
75344899|NCT04155164|Drug|Placebos|Placebo group will take Placebo at 1000mg for 12 months.
75655896|NCT04376112|Other|Pharmacist and pillpack intervention|These participants will be randomized into one of the following two cohorts: standard of care (SOC) and pharmacy intervention group (blister packaging + MTM services). For pharmacy intervention (PI) group, the POCT will be used to measure HbA1c and blood pressure (BP) at baseline, 3, and 6 months during medication therapy management (MTM) service. Recommendation from MTM services will be documented in the patients' electronic medical records (EMRs) and shared with their primary care providers. For the SOC group, HbA1c and BP will be measured at the physician's office and researchers will have an access to participants' EMR.
75802804|NCT03039790|Biological|NoV Vaccine|NoV vaccine injection administered.
75344900|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
75802805|NCT05330806|Procedure|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
75802806|NCT05330806|Procedure|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
75344901|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
75344902|NCT00806234|Drug|Aripiprazole or Perphenazine|Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
75344903|NCT00806234|Drug|Metformin|Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
75344904|NCT00806234|Drug|Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine|Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
75942245|NCT04055779|Other|the limb occlusion pressure|: using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
75942246|NCT02379650|Drug|Hydroxychloroquine (HCQ)|
75655897|NCT04376112|Other|Standard of care|None. Regular visits to primary care physician. Will measure HbA1c and blood pressure at baseline, 3, and 6 months
75802807|NCT04906408|Device|Prevena|Incisions will be dressed with closed incisional negative pressure wound therapy
75655898|NCT02813304|Behavioral|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
75655899|NCT02813304|Behavioral|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
75802808|NCT04906408|Device|Prineo|Incisions will be dressed with Prineo
75802809|NCT04906408|Drug|Traditional|Incisions will be dressed with bacitracin/xeroform
75802810|NCT04838236|Other|MASP app + NRT|MASP is a mobile intervention that targets anxiety sensitivity among African American smokers (Mobile Anxiety Sensitivity Program for Smoking: MASP). Our intervention is framed within the cultural context of interoceptive stress among African American smokers, which is supported by theory, empirical evidence, and characteristics of this group. The MASP app employs a variety of features to educate its users on how to deal with stress, anxiety, and nicotine withdrawal symptoms. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos. MASP also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time.
75802811|NCT04838236|Other|QuitGuide app + NRT|Quitguide is a smartphone-based National Cancer Institute (NCI) app for standard mobile smoking cessation treatment. The app contains features that allows its' users to better understand their smoking patters, and build skills needed to becomes and stay smoke free. The app allows users to track their cravings, and delivers motivational messages to users for each craving they track.
75802812|NCT05282134|Procedure|Wet cupping therapy|Wet cupping therapy is a bloodletting application done by cups on the skin
75802813|NCT05282134|Procedure|Acupuncture|Acupuncture is a complementary application of TCM done by needles
75802814|NCT05278780|Other|Screening for eligibility|Asynchronous screening
75802815|NCT05273164|Device|Computerized Cognitive Training|Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.
75344905|NCT00807560|Behavioral|FBT-PO|The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
75344906|NCT00807560|Behavioral|NEC|Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
75344907|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
75655900|NCT00851929|Drug|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
75655901|NCT02813460|Drug|Formulation A (ALS-008176)|Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
75344908|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
75655902|NCT02813460|Drug|Formulation B (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
75344909|NCT00811850|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
75344910|NCT00811850|Drug|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
75655903|NCT02813460|Drug|Formulation C (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.
75655904|NCT02813460|Drug|Formulation D (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
75655905|NCT02813460|Drug|Formulation E (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
75655906|NCT02813460|Drug|Formulation F (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
75802816|NCT04763278|Device|Point Digit|The Point Digit partial hand prosthetic system consists of 1-4 ratcheting mechanical digits and a mounting bracket
75942247|NCT02379650|Drug|Placebo|
75942248|NCT02374034|Other|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
75942249|NCT03666923|Drug|THR-687 dose level 1|single intravitreal injection of THR-687 dose level 1
75942250|NCT03666923|Drug|THR-687 dose level 2|single intravitreal injection of THR-687 dose level 2
76090868|NCT04489056|Genetic|Swabs for microbiome analysis|After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.
76090869|NCT00469755|Drug|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
76090870|NCT00469755|Drug|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
76090871|NCT00469755|Drug|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
75655907|NCT02813460|Drug|Formulation G1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
75344911|NCT03678506|Drug|Apixaban|Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
75655908|NCT02813460|Drug|Formulation G2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
75655909|NCT02813460|Drug|Formulation G3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
75655910|NCT02813460|Drug|Formulation H1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
75655911|NCT02813460|Drug|Formulation H2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
75942251|NCT03666923|Drug|THR-687 dose level 3|single intravitreal injection of THR-687 dose level 3
75942252|NCT02369432|Drug|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
75942253|NCT03658369|Dietary Supplement|Lanconone®|2 capsules
76090872|NCT02463396|Behavioral|MBCT for ADHD|
76090873|NCT00458133|Behavioral|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching & relaxing groups.
75344912|NCT01328873|Other|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
75344913|NCT00844298|Drug|Nilotinib+mVPD|"Induction:~Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~Vincristine 2 mg iv push (d1, 8, 15, 22)~Prednisolone 60 mg/m2/day po (d1-28)~Nilotinib 400mg bid/d (d8-)~Consolidation A (cycle1)~Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~Vincristine 2 mg iv (d1, 8)~Prednisolone 60 mg/m2/day po (d1-14)~Nilotinib 400mg bid/d~Consolidation B (cycles 2&4)~Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~Nilotinib 400mg bid/d~Consolidation C (cycles 3&5)~Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~Nilotinib 400mg bid/d~Maintenance~◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~Consider alloHCT"
75344914|NCT01329185|Drug|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
75942254|NCT03658369|Dietary Supplement|Methyl crystalline cellulose|2 Capsules
75942255|NCT03667469|Procedure|Laparoscopic one anastomosis gastric bypass|Laparoscopic surgical bariatric procedure with creation gastric pouch. A jejunal loop was created about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
75942256|NCT03667469|Dietary Supplement|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
75344915|NCT01329185|Drug|Placebo|1 capsule twice a day for 14 days prior to transplant date
75344916|NCT01276301|Drug|Verapamil|single dose verapamil
75344917|NCT01276301|Drug|BI 10773|single dose BI 10773
75344918|NCT01276301|Drug|BI 10773|single dose BI 10773
75476581|NCT05963802|Other|Artificial Intelligence (ChatGPT) Group|Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process.
75476582|NCT05960500|Procedure|implant|All on six versus parallel implant distribution
75655912|NCT02813460|Drug|Formulation H3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
75655913|NCT02813538|Drug|Indocyanine green clearance|To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
75942257|NCT03622645|Device|Assessment of Range of Motion with Leap Motion sensor|An ROM measurement method called as HandROM by us will be developed with leap motion sensor
75942258|NCT03666299|Drug|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
75942259|NCT03666299|Drug|Control|Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
75942260|NCT03661099|Diagnostic Test|colonoscopy|endoscopists' performance outcome
76090874|NCT01824771|Other|Plasma lactate were measured|Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately
76090875|NCT03296046|Biological|Blood test|30 ml
76090876|NCT00453531|Procedure|Limb Ischemia|
75942261|NCT04420780|Dietary Supplement|Administration of sugar-free gums sugar-free gums containing 100% Xylitol as sweetener|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
75942262|NCT04420780|Dietary Supplement|Administration of sugar-free gums sugar-free gums containing containing a polyols mixture plus a low amount of Xylitol (22%)|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
75942263|NCT03660397|Procedure|Selective endovascular chemical ablation of adrenal gland|Intervention with selective endovascular chemical ablation of adrenal gland is performed after adrenal angiography in the group.
75942264|NCT03660397|Drug|Traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
75942265|NCT03591380|Drug|Belimumab|Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.
75942266|NCT03704740|Biological|NBP607-QIV|Purified inactivated influenza virus surface antigens of four strains (quadrivalent)
75942267|NCT03704740|Biological|Agrippal|Influenza virus surface antigens of three strains (trivalent)
75344919|NCT00845000|Drug|SCH 420814 10 mg|one 10-mg capsule, orally, at hour 0 of treatment period
75942268|NCT04057469|Drug|Tulobuterol Hydrochloride|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
75942269|NCT04057469|Drug|Placebo transdermal patch|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
75942270|NCT03660319|Other|Environmental Music Therapy|Experiencing Environmental Music Therapy during wait time in radiation oncology waiting room.
75802817|NCT05264116|Device|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
75344920|NCT00845000|Drug|SCH 420814 100 mg|single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
75802818|NCT05237752|Drug|LG00034053|a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis
75802819|NCT05233618|Drug|Tagraxofusp|inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
75942271|NCT03666221|Drug|Nimotuzumab|Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy
75942272|NCT02378324|Other|Screening without fee|All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
75344921|NCT00845000|Drug|Placebo|Placebo capsule, oral, at hour 0 of treatment period
75344922|NCT00845000|Drug|Levodopa|levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
75344923|NCT00845000|Drug|Carbidopa|one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
75802820|NCT04714216|Device|The Omnipod 5/Horizon HCL system|"The Omnipod 5/Horizon HCL system, consists of a disposable insulin infusion pump (or pod), a built-in model predictive control (MPC) insulin dosing algorithm, and a remote Personal Diabetes Manager (PDM) interface, that interact with a Dexcom G6 continuous glucose monitor (CGM) to automatically control insulin delivery based upon real-time glucose values. The PDM component also enables remote interaction with the system, including glucose monitoring as well as insulin dosing management and adjustments."
75942273|NCT03623009|Behavioral|An article meant to trigger certain psychosocial behaviors|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
75942274|NCT03623009|Behavioral|a neutral article|The control arm will receive a neutral article prior to completing the assessment.
75942275|NCT03658291|Drug|Sanjin tablets|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.
75344924|NCT01330043|Drug|Bupropion|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
75344925|NCT01330043|Drug|Nicotine patch|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
75344926|NCT01330043|Drug|Varenicline|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
75344927|NCT01330355|Drug|Besivance|Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days
75344928|NCT01330355|Drug|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
75942276|NCT03658291|Drug|Sanjin tablets simulants|levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
75942277|NCT03658291|Drug|Levofloxacin|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
75942278|NCT02378168|Other|no intervention; retrospective study|
75942279|NCT04054973|Drug|L-arginine|6000mg of L-arginine daily for 14 days
75942280|NCT04054973|Drug|Sapropterin Dihydrochloride|800mg of Kuvan daily for 14 days
75942281|NCT02373956|Device|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
76090877|NCT00453531|Drug|Acetylcholine|
75655914|NCT02813538|Other|Thromboelastometry|To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
75655915|NCT02813382|Drug|Bupivacaine|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
75942282|NCT02373956|Procedure|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
75802821|NCT03038620|Drug|Liraglutide|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
75942283|NCT02369198|Drug|TargomiRs|"TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected."
75942284|NCT03658213|Drug|ZOLADEX 10.8 mg|10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
76090878|NCT03295968|Other|High Intensity Exercise/Ibuprofen|HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
76090879|NCT03298308|Device|Cranial Electric Stimulation|Micro amperage TCDS
75344929|NCT01359371|Behavioral|Peer telephone cessation counseling|For Veterans who received the inpatient Tobacco Tactics intervention, trained volunteers initiated follow-up telephone cessation counseling at 2, 14, 21 and 60 days after in-patient discharge; three attempts were made per time point.
75354658|NCT04808310|Diagnostic Test|Assessment of angiographic severity of the stenosis|The indication to coronary stent intervention will be based on angiography
75354659|NCT04805333|Drug|Artemisia annua 450mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
75655916|NCT02813382|Drug|Prilocaine|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
75655917|NCT02813382|Drug|Chloroprocaine|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
75655918|NCT00619645|Drug|busulfan|
75655919|NCT00619645|Drug|cyclosporine|
75655920|NCT00619645|Drug|fludarabine phosphate|
75655921|NCT00619645|Drug|mycophenolate mofetil|
75655922|NCT00619645|Procedure|allogeneic hematopoietic stem cell transplantation|
75655923|NCT00619645|Procedure|peripheral blood stem cell transplantation|
75655924|NCT02810730|Procedure|Pancreatic MRI|Pancreatic MRI in the 6 months following the first consultation
75802822|NCT03038620|Drug|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
75802823|NCT04595656|Other|verbal autopsy interview|The study involves filling of verbal autopsies for deaths in SEACTN villages. This is an observational study being conducted as a substudy of rural febrile project of SEACTN program.
75802824|NCT03689842|Procedure|Uterine transplantation|Uterine transplantation from living donor
75802825|NCT02032810|Drug|Panobinostat|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
75802826|NCT02032810|Drug|Ipilimumab|Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
75942285|NCT03658213|Drug|ZOLADEX 3.6mg|3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
75942286|NCT02373878|Behavioral|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
75942287|NCT02373878|Behavioral|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
75942288|NCT02369276|Other|ultrasonography and elastography|Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
75942289|NCT02920957|Device|comfilcon A|contact lens
75942290|NCT02920957|Device|senofilcon C|contact lens
75965998|NCT02341456|Drug|Paclitaxel|Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
75965999|NCT02341456|Drug|carboplatin|Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
75966000|NCT02082899|Drug|Active Comparator EBI-005 5 mg/mL|
76090880|NCT01812291|Behavioral|Step 1: Diabetes-Specific CBT (5 group sessions)|"Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~Diabetes problem analysis/ definition~Diabetes problem solving intervention~Cognitive restructuring of diabetes problems~Activation of personal and social resources~Goal definition and agreement"
75802827|NCT02024854|Behavioral|skin-to-skin|
75802828|NCT02024854|Behavioral|standard care|
75802829|NCT05034328|Device|Healsea® Children|Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed
75942291|NCT02369120|Other|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
75942292|NCT02369120|Other|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
75942293|NCT03006887|Drug|lenvatinib|lenvatinib capsules
75942294|NCT03006887|Drug|pembrolizumab|pembrolizumab intravenous infusion
75942295|NCT02377934|Radiation|Cardiac Magnetic Resonance Imaging (MRI)|
75942296|NCT02377856|Drug|pegylated interferon alpha 2a, ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
75942297|NCT03658135|Drug|BIIB092|BIIB092 is an investigational monoclonal antibody directed at tau protein
75942298|NCT03658135|Other|Placebo|Inactive ingredient
75942299|NCT02373800|Device|Cervical ultrasound with elastography|Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
75942300|NCT03665987|Behavioral|consultation in preoperative assessment clinic|The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
75476583|NCT05960422|Procedure|Popliteal Sciatic Nerve Block|Patients undergoing popliteal sciatic block, the side where the procedure would be performed in the prone position was sterilized after appropriate antisepsis. After visualizing the popliteal artery in the popliteal fossa with the probe it was advanced proximally in a horizontal and minimally lateral position to determine the point of separation of the tibial and peroneal nerves from the sciatic nerve. Subcutaneous local anesthesia was applied at this point after the skin, and the stimulator needle was advanced towards the sciatic nerve in an in-plane approach, passing through the skin and subcutaneous tissue, and then the nerve stimulator was opened up to 1 mA. After observing motor movement in the foot, the stimulator was reduced to 0.3-0.5 mA, and after observing motor movements for duration of 0.1 ms, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were administered to the target tissue
75655925|NCT02861027|Procedure|PPTHA|The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
75655926|NCT02861027|Procedure|FES and PPTHA|The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
75802830|NCT05034328|Other|Conventional therapies for common cold|Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)
75802831|NCT01415674|Drug|Afatinib|Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
75802832|NCT05654974|Other|measurements and questionnaire|paper-based survey administration; erect penis length and girth measurements
75802833|NCT01350934|Drug|alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)|one combination tablet once weekly
75802834|NCT01350934|Drug|Calcitriol|0.25 μg once daily orally
75802835|NCT01350934|Dietary Supplement|Calcium 500 mg|one 500 mg tablet once daily
75802836|NCT01330576|Procedure|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
75802837|NCT01330576|Procedure|Standard treatment of care at normothermia|Standard treatment of care in 33.5C for 48 hours
75942301|NCT02377778|Drug|Propofol|Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval
75942302|NCT02377778|Drug|Thiopental|Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
75942303|NCT02514772|Biological|GP2013 - A Proposed biosimilar rituximab|
75942304|NCT02514772|Biological|Originator rituximab - Rituxan ® or MabThera ®|
75942305|NCT03658057|Drug|Rocuronium|whether neuromuscular blockade by administering rocuronium is performed or not.
75942306|NCT02378012|Other|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
75942307|NCT02378012|Other|Computer-Assisted Intervention|Receive iPad and instruction manuals.
75942308|NCT02378012|Other|Questionnaire Administration|Ancillary studies
75942309|NCT03664817|Behavioral|social capital intervention|The social capital intervention will focus on developing skills and group-work that culminate in participant-derived photovoice projects. Each group of YBMSM will be encouraged to complete a 30 day photovoice challenge. The 30 day challenge is based on a prior community action project done as a part of our Centers for AIDS Research (CFAR)-funded research, which was a Photovoice project conducted by Dr. Hussen. Photovoice is a participatory action research methodology in which groups of individuals from a population of interest are given cameras to document events, people and places of significance in their lives.
75966001|NCT02082899|Drug|Placebo Comparator|
75942310|NCT03664817|Behavioral|group-based health promotion intervention|"The control arm will participate in a health education intervention that will be delivered in a group, but without a specific goal of creating group cohesion or social capital. The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)."
75942311|NCT03657979|Drug|Ropivacaine|TAP-block Ropivacaine 0.2% during 48 hours
75942312|NCT03657979|Drug|Placebo|TAP-block with placebo
75802838|NCT05014984|Behavioral|mental contrasting with implementation intentions|"To deliver MCII, Dr. Oettingen developed a step-wise procedure called WOOP (Wish, Outcome, Obstacle, Plan; Figure 1).36 In a quiet setting, patients identify an important wish (e.g., losing weight) and then name and vividly imagine the best outcome (e.g., feeling healthier). Next, they name a current internal obstacle (e.g., urge to eat when feeling stressed) and try to vividly imagine their experience when they encounter this obstacle. Finally, they address their obstacle with an if-then plan specifying when, where, and how to overcome it (e.g., If I have the urge to eat when feeling stressed, I will go for a walk) and then imagine themselves experiencing the obstacle and carrying out the action of surmounting it. To facilitate use of the WOOP technique, Dr. Oettingen developed a free, publicly available WOOP app"
75802839|NCT05014984|Behavioral|telephone-delivered MOVE!|MOVE! is a national VA weight management and health promotion program to improve the quality of life of Veterans.6,75 This effective program encourages healthy eating behavior and increased physical activity. MOVE! will be delivered via telephone (16 sessions) by existing staff consistent with national MOVE! program guidelines. The program has 16 modules and will offered weekly, but Veterans will be able to make up sessions at their own pace if they miss one. MOVE! staff use the MOVE! facilitator guide that provides instruction on delivering the program via telephone.
75344930|NCT01276535|Device|Erchonia MLS + Erchonia THL|"The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.~The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.~Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.~The intent is to evaluate the effectiveness of Erchonia MLS & Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL"
75344931|NCT01360229|Procedure|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
75802840|NCT05014984|Behavioral|Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All|All participants will receive handouts that they review with a lay educator on weight management, adapted from the educational materials developed for our FIReWoRk Study.Topics include losing weight at a healthy rate, setting a 6-month weight loss goal of 5-10%, limiting sugar-sweetened beverages and portion sizes, making better choices when eating at restaurants, self-monitoring diet and weight, and participating in at least moderate-intensity physical activities.
75344932|NCT01360229|Other|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
75655927|NCT00852007|Biological|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
75655928|NCT02810574|Behavioral|Cognitive training|
75655929|NCT02810574|Device|Noninvasive brain stimulation (active)|Neuroconn DC-STIMULATOR PLUS
75655930|NCT02810574|Device|Noninvasive brain stimulation (sham)|Neuroconn DC-STIMULATOR PLUS
75655931|NCT02545699|Device|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
75655932|NCT02545699|Device|Standard Colonoscopy|Standard Colonoscopy
75655933|NCT02810262|Other|Bone metastases biopsy|The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
75655934|NCT00852085|Behavioral|Enhanced community service|Two educational sessions and volunteering at a local community service site
75655935|NCT00852085|Behavioral|Group MI|Four group counseling sessions and two directed observational visits to an emergency department
75655936|NCT02545855|Device|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
75344933|NCT02193815|Drug|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
75344934|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 4% solution
75655937|NCT02545855|Device|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
75655938|NCT05584410|Other|Patient information|Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
75942313|NCT02373488|Other|lifestyle advice|lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
75942314|NCT02373488|Other|connective tissue manipulation|CTM wil be applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients are in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment, respectively.
75942315|NCT02373488|Other|abdominal massage|Abdominal massage will be applied five days a week for four weeks. Each session will last around 15-20 minutes.
75942316|NCT03660007|Procedure|Fresh or frozen embryo transfer IVF|
75942317|NCT03659851|Drug|Levosimendan 2.5 MG/ML Injectable Solution|LVAD implantation
75942318|NCT05026060|Diagnostic Test|Imaging|4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
75942319|NCT03659695|Dietary Supplement|Grape Powder|69 g/d freeze dried grape powder
75942320|NCT03659695|Dietary Supplement|Placebo Powder|69 g/d placebo powder matched for taste and appearance
75942321|NCT03659383|Combination Product|Optimal hypoglycemic treatment|Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
75942322|NCT04978792|Behavioral|Online self-compassion intervention|An online self-guided intervention that uses widely available exercises and information.
75942323|NCT04978792|Behavioral|Active Control|Participants will complete written exercises and breathing exercises that are not associated with self-compassion
75942324|NCT02368730|Drug|desmopressin|
75344935|NCT02193815|Drug|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
75942325|NCT03622931|Drug|Standard chemotherapy|Chemotherapy
75942326|NCT03622931|Drug|Romiplostim|
75942327|NCT03622931|Drug|Placebos|
75942328|NCT03659305|Biological|RPH-001|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
75344936|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 2% Ointment
75655939|NCT05584410|Other|Smartphone application based exercises|Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
75802841|NCT05014984|Behavioral|Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)|The lay educator will review and practice the WOOP technique based on protocols from prior studies.12 To probe Veterans' comprehension, the lay educator will ask for their four steps and ask about their WOOP use and experiences. If needed, the lay educator will help the Veteran to create a new WOOP for the next month and address any questions and concerns about using WOOP.
75802842|NCT01146418|Biological|Corifollitropin alfa|Single injection of 150 μg corifollitropin alfa administered under protocol P06029
75942329|NCT03659305|Biological|Avastin|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
75942330|NCT02368808|Behavioral|Abangane Support Group|The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
75942331|NCT04978246|Behavioral|Neuropsychometric Test|Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
75344937|NCT02193815|Drug|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
75802843|NCT01146418|Biological|recFSH (follitropin beta)|Daily recFSH 300 IU administered under protocol P06029.
75802844|NCT05654896|Drug|Ceftriaxone Sodium|Antibiotic will be administered prophylactically for TACE
75802845|NCT00745108|Drug|tibolone|oral 1.25 mg tablet, once daily, for 2 years
75802846|NCT00745108|Drug|Tibolone 2.5 mg|oral 2.5 mg tablet, once daily, for 2 years
75344938|NCT02193815|Drug|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
75344939|NCT01277081|Drug|Paracetamol hot drink|Hot drink containing paracetamol
75344940|NCT01277081|Drug|Paracetamol tablets|Paracetamol tablets
75344941|NCT01361633|Drug|d-cycloserine|single oral administration of 250 mg d-cycloserine
75802847|NCT00745108|Drug|CE/MPA|oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
75942332|NCT03107455|Device|MitraClip|MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
75344942|NCT01361633|Drug|Sugar Pill|Single oral administration 250 mg Sugar Pill
75655940|NCT05584410|Other|Web based exercises|Generic OA exercise, including about 20 different exercises, provided by real-time videos and written description
75655941|NCT05584410|Other|Group based information|OA specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
75655942|NCT05584410|Other|Supervised rehabilitation|The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
75942333|NCT02369042|Device|Kyma Device u-Cor System|The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
75966002|NCT02083055|Drug|Dexmedetomidine|controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
75966003|NCT02083055|Drug|Nitroglycerin|controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
75966004|NCT02089295|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
75344943|NCT01331213|Drug|Pregabalin|FDA approved medication (capsules) at 200mg dose.
75344944|NCT01331213|Drug|Placebo|Placebo capsules
75344945|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg|Avandamet reference product
75802848|NCT00725374|Drug|tibolone|one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).
75942334|NCT05024890|Other|Splash WASH in Schools programme (Project WISE)|"The Project WISE intervention includes:~WASH infrastructure~Water storage tanks and water filtration systems~Durable plastic drinking water and handwashing stations~New/rehabilitated toilet facilities (gender-segregated, wheelchair-accessible, well-lit, ventilated, durable door and lock)~Behaviour change promotion~Training of focal teachers to organise student 'hygiene club'~Annual soap drive and soap restocking~Behavioural 'nudges' (posters and mirrors at handwashing stations, colourful vests for hygiene clubs)~MHM services~Toilets have water tap, bucket and waste bin~Emergency menstrual hygiene products available at school~Training of focal teachers to organise student 'gender club'~Education on puberty and menstruation for all pupils above 10 and parent resource guide"
75942335|NCT02788981|Drug|Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
75942336|NCT02788981|Other|Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
75942337|NCT02788981|Drug|Nab-Paclitaxel|Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
75942338|NCT02368964|Drug|GnRH agonist 0.2 mg + hCG 250 mcg|Treatment for triggering
75942339|NCT02368964|Drug|high dose hCG 500 mcg|Treatment for triggering
75942340|NCT05024812|Drug|fruquintinib＋toripalimab + SOX|phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m^2, ivgtt 2h, D1,Q3W.
75942341|NCT02786251|Other|Cold exposure|During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
75942342|NCT02786251|Other|Exposure to thermoneutral conditions|For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (~26-28°C).
75942343|NCT02373722|Procedure|Mohs Surgery|Undergo Mohs surgery
75942344|NCT02373722|Other|Internet-Based Intervention|Watch website application based educational video
75942345|NCT02373722|Behavioral|Telephone-Based Intervention|Receive text messages
75942346|NCT02373722|Other|Educational Intervention|Watch website application based educational video
75942347|NCT02373722|Behavioral|Exercise Intervention|Use Fitbit
75655943|NCT05584410|Other|Self-monitoring|Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
75655944|NCT05584410|Behavioral|Motivational notifications|Automatic and daily reminders and / or motivational notifications
75655945|NCT05584410|Other|Home based rehabilitation|Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
75655946|NCT00852163|Drug|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
75655947|NCT00851071|Behavioral|Cognitive Behavioral Therapy|Three 45 minute CBT sessions scheduled over a 3 month period.
75655948|NCT04237038|Procedure|laparoscopic Nissen fundoplication short gastric vessel division|Randomized clinical trial conducted in forty patients submitted to SGVD and forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life. A randomized clinical trial was conducted with 87 patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of Gastroesophageal reflux disease (GERD
75655949|NCT00855517|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
75655950|NCT02690220|Device|TiLOOP® PRO Plus A|The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
75802849|NCT00725374|Drug|placebo|Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
75802850|NCT00480766|Drug|MK0217/Duration of Treatment : 12 Months|
75802851|NCT03622580|Drug|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
75802852|NCT03622580|Drug|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
75802853|NCT03622580|Procedure|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
75942348|NCT02373722|Other|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
75942349|NCT02373722|Other|Questionnaire Administration|Ancillary studies
75942350|NCT02373722|Other|Survey Administration|Ancillary studies
75942351|NCT05024578|Device|DREEM2|Closed-loop EEG monitoring and auditory stimulation in which 100ms pulses of pink noise are delivered on the ascending phase of slow oscillations during N3 sleep.
75942352|NCT05024578|Device|Placebo|EEG monitoring with the same headband as in the DREEM2 intervention, but without any sound stimulation.
75942353|NCT03659149|Drug|CKD-333 formulation I|1 tablet administered before the breakfast(single-dose)
75942354|NCT03659149|Drug|CKD-333 formulation II|1 tablet administered before the breakfast(single-dose)
75942355|NCT03659149|Drug|CKD-330+D086|2 tablet administered before the breakfast(single-dose)
75655951|NCT00855673|Device|Intermittent Mechanical Compression|FM220 device
75802854|NCT00461032|Drug|montelukast|montelukast 5 mg tablet Once a day (QD) for 8 weeks
75802855|NCT00461032|Drug|Comparator: Placebo|Placebo to montelukast QD for 8 weeks
75802856|NCT00446056|Drug|MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|
75344946|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg|Avandamet test product
75802857|NCT00446056|Drug|Comparator: ketotifen / Duration of Treatment: 4 Weeks|
75802858|NCT00389740|Drug|MK0217, /Duration of Treatment : 12 Months|
75802859|NCT00389740|Drug|Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months|
75802860|NCT00092092|Drug|Montelukast chewable tablets|Montelukast sodium 5 mg chewable tablets
75942356|NCT04202770|Other|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
75942357|NCT03000179|Drug|Avelumab|Avelumab through a vein once every 2 weeks
75942358|NCT03622567|Behavioral|Smartphone push notifications|The purpose of this study is to assess how smartphone push notifications can impact the overall score, accuracy and reaction time of participants using the Brain Power Score application (app). Push notification quantity will be varied and counter-balanced.
75942359|NCT03659071|Other|questionnaire VSP-A|VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
75344947|NCT01277159|Drug|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
75344948|NCT01277159|Drug|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
75476584|NCT05960422|Procedure|Adductor canal block|Patients in the group undergoing popliteal sciatic block + adductor canal block, with the extremity to be blocked slightly externally rotated, the anterior part of the thigh was prepared with the necessary antiseptic procedures while the patient was in the supine position. Using an ultrasound probe, the femoral artery was visualized by advancing the ultrasound probe distally, and the saphenous nerve was identified just lateral to the femoral artery, beneath the sartorius muscle. At the junction of the sartorius muscle and vastus medialis, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were applied to the periphery of the saphenous nerve. Subsequently, the patient was turned prone, and a popliteal sciatic block was performed.
75655952|NCT00855673|Drug|Control|Standard medical treatment
75655953|NCT02814864|Drug|Mesenchymal Stromal Cell (MSC) injections|12 patients suffering of PRD (LENT-SOMA scale>2) will receive Mesenchymal Stromal Cell (MSC) injections
75655954|NCT00855829|Device|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
75655955|NCT00855829|Device|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
75802861|NCT00092092|Drug|Budesonide inhaler|Budesonide 200 mcg inhalation powder
75802862|NCT00092092|Drug|Placebo to montelukast chewable tablets|Placebo chewable tablets
75802863|NCT00092092|Drug|Placebo to budesonide inhaler|Placebo inhalation powder
75802864|NCT00092014|Drug|Alendronate|Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
75802865|NCT00092014|Drug|Risedronate 35 mg|Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
75942360|NCT02373644|Other|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
75942361|NCT02373644|Other|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
75942362|NCT03664973|Procedure|Serratus plane block|Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
75942363|NCT03658993|Drug|Rifaximin 550 MG|Oral Rifaximin 550 mg TID for 4 weeks.
75942364|NCT02373566|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
75966005|NCT02089295|Drug|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
75966006|NCT02089295|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
75344949|NCT01277159|Drug|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
75344950|NCT01277159|Drug|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
75344951|NCT01277159|Drug|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
75344952|NCT01361867|Device|Robot-induced perturbations|A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
75476585|NCT05959993|Behavioral|Human Care Model Based Nursing Interventions|The interviews scheduled for the intervention group were organized in accordance with the sub-dimensions of the PAIS-SR scale, and the content of each interview was informed by the 10 improvement processes of HCT.
75476586|NCT05959876|Other|Training group|Face-to-face perineal care training
75942365|NCT03664661|Drug|BCMA nanobody CAR-T cells|"step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
75942366|NCT03657901|Behavioral|Music listening|Guided music listening for 30 minutes before sleep onset
75942367|NCT03657901|Behavioral|Slow breathing|Guided slow breathing for 30 minutes before sleep onset
75942368|NCT02373410|Procedure|Umbilicus|"Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.~The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus"
75942369|NCT02373410|Procedure|Lowest rib margin|The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin
75942370|NCT02373410|Procedure|Xiphoid|The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid
75942371|NCT02373410|Procedure|Nipple|The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple
75942372|NCT02373410|Drug|Umbilicus Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
75942373|NCT02373410|Drug|Lowest rib margin Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
75942374|NCT02373410|Drug|Xiphoid Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
75942375|NCT02373410|Drug|Nipple Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
75942376|NCT04975672|Other|Myofuncional Therapy|Group 1, with myofunctional therapy and SN1 functional orthopedic appliances The participant underwent a myofunctional therapy session every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system. The myofunctional therapy performed will be by an expert speech therapist
75942377|NCT02920177|Drug|platelet-rich plasma injection|platelet-rich plasma injection
75344953|NCT01277783|Device|Endocardial Left Ventricular pacing|Subjects receive an endocardial LV lead placement via superior approach using Medtronic Model 3830 lead and Medtronic Model 6227ATS deflectable delivery catheter and Medtronic Model 6248HS, 6248JL, or 6248JS delivery catheter, using trans esophageal echo (TEE) or intra-cardiac echo (ICE) to guide the procedure.
75344954|NCT01278485|Drug|Sulphonylurea|SU administered according to usual practice.
75344955|NCT01278485|Drug|Metformn|Metformin administered according to usual practice.
75344956|NCT01362959|Drug|Transdermal nicotine patch|The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.
75344957|NCT01362959|Other|Cutaneous patch, containing no active substances|During the study period of thirty (30) days, the control product will be applicated daily.
75655956|NCT02810496|Genetic|blood collection for mutation characterization|
75655957|NCT00855907|Other|clinical evaluation|"Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography."
75655958|NCT00855985|Procedure|type of anastomosis after pancreaticoduodenectomy|pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
75802866|NCT00092014|Dietary Supplement|Elemental Calcium|Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
75802867|NCT00092014|Dietary Supplement|Vitamin D|Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
75802868|NCT00092014|Drug|Risendronate placebo|Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
75942378|NCT02920177|Drug|Kenalog 10 MG/ML Injectable Suspension|4 mL corticosteroid injection
75942379|NCT04478318|Device|uEXPLORER/mCT|Participants will undergo a total-body PET/CT scan with the uEXPLORER scanner first, followed by a PET/CT scan with the conventional mCT PET/CT scanner.
75942380|NCT04478318|Device|mCT/uEXPLORER|Participants will undergo a PET/CT scan with the conventional mCT PET/CT scanner, followed by a total-body PET/CT scan with the uEXPLORER scanner
75942381|NCT03006341|Drug|Dabigatran etexilate|observed upto 12 months
75942382|NCT03006341|Drug|Warfarin|Observed upto 12 months
75942383|NCT05022784|Drug|Nintedanib|Nintedanib
75344958|NCT01278953|Device|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
75344959|NCT01332461|Drug|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
75354660|NCT04805333|Drug|Artemisia annua 900mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
75655959|NCT02815176|Other|Blood sampling|Sampling the blood including DNA to investigate the thrombotic profile
75655960|NCT02809794|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
75802869|NCT00092014|Drug|Alendronate placebo|Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
75942384|NCT02368574|Procedure|Class II hysterectomy|Class II hysterectomy
75942385|NCT02368418|Procedure|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
75942386|NCT02368418|Procedure|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
75942387|NCT02744365|Other|Observational|"All women of the biobank have provided:~blood samples (plasma, serum and Buffy-coat)~urine samples~demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)~mean arterial blood pressure~ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)~access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)"
75942388|NCT03455465|Other|Community Health Worker Assessment|Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
75344960|NCT01332461|Drug|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
75476587|NCT05959876|Other|Control group|No intervention
75476588|NCT05956808|Device|Phonak Naida BTE hearing aid|Newest generation of ultra-power Phonak BTE hearing aids
75655961|NCT04187274|Device|IKORUS technology|Ikorus technology is a new micro perfusion device measuring via urethral photoplethysmography, the urethral perfusion index (uPI) in patients equipped with an urinary catheter.
75942389|NCT02368496|Device|HR-pQCT|
75942390|NCT03935594|Biological|PRP Injection|1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.
75942391|NCT03935594|Drug|Saline Injection|1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
75942392|NCT03665753|Drug|Ketorolac|Subject will receive 10, 20, and 30mg of Ketorolac.
75942393|NCT03566108|Procedure|VISTA|Vestibular incision supraperiosteal tunnel access (VISTA) incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
75942394|NCT03566108|Procedure|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
75942395|NCT02512042|Drug|Test-Brinzolamide 1% Ophthalmic suspension|
75942396|NCT02512042|Drug|Reference-Brinzolamide 1% Ophthalmic suspension|
75942397|NCT02377544|Dietary Supplement|Probiotic|
75942398|NCT02377544|Other|Placebo|
75476589|NCT05956808|Device|Phonak Naida legacy BTE hearing aid|Previous model/generation of the Naida BTE hearing aid
75476590|NCT05953155|Other|Control|Each educational class will last for 1 hour and consists of evidence-based information about low back pain, including, for example, self-management strategies, pain education, reassurance and common misconceptions about back pain.
75476591|NCT05953155|Other|Yoga|Participants in the intervention group will receive, in addition to the educational classes, a course of yoga program led by certified yoga instructors. The program consists of a 60-min group session with up to 10 participants, delivered twice a week for 12 weeks.
75655962|NCT02814474|Other|Na-3-hydroxybutyrate|Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
75655963|NCT02814474|Other|Saline|Infusion of 0.9 % saline
75655964|NCT02812836|Device|Manometry|Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
75655965|NCT02544919|Drug|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
75655966|NCT02812914|Other|Low-cost gas stove|Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas
75942399|NCT03665519|Dietary Supplement|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh mare milk (few hours) through sublimation process.
75942400|NCT03665519|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid treatment will be given for 3 months.
75942401|NCT02919475|Drug|JTE-051|Active drug tablets containing JTE-051
75942402|NCT02919475|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
75942403|NCT02373332|Other|omega-3 and -6 fatty acids and their 12-LOX oxylipins|platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
75942404|NCT03664505|Device|Compression garment (manual)|Garment based on manual measurement
75942405|NCT03664505|Device|Compression garment (scan)|Garment based on scan measurement
75942406|NCT03543605|Behavioral|PROA Experimental|PROA Control plus clinical advice
75942407|NCT03543605|Other|PROA Control|PROA Control
75942408|NCT02368262|Other|Questionnaire and micturition and drinking diaries|"Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart"
75942409|NCT02368262|Procedure|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
75344961|NCT01279109|Behavioral|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
75344962|NCT01279109|Behavioral|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
75344963|NCT01279187|Drug|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
75344964|NCT01279187|Drug|Placebo|20ug per day, self administered injection, for 7 weeks
75344965|NCT01279265|Dietary Supplement|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
75942410|NCT01066897|Drug|Pramipexole|Patients will received increasing dose of pramipexole
75942411|NCT02373254|Drug|Ibuprofen|Ibuprofen 400 mg and 800 mg
75655967|NCT02812914|Behavioral|Peer education classes|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution
75942412|NCT02373254|Drug|Acetaminophen/hydrocodone|Norco 5/325 mg and 10/325 mg
75942413|NCT04376372|Diagnostic Test|Functional testing, Magnetic resonance imaging, Electromyography|Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)
75942414|NCT03657355|Drug|ACT-541468|ACT-541468 will be administered as 50 mg tablets for oral use.
75942415|NCT03657355|Drug|Suvorexant|Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.
75942416|NCT03657355|Drug|Zolpidem|Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
75942417|NCT03657355|Drug|Placebo|Matching-placebo will be used.
75942418|NCT03818516|Other|Oral Glucose Tolerance Test (OGTT)|Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.
75942419|NCT02985541|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
76090881|NCT01812291|Behavioral|Step 2: Depression-Specific CBT (6 single sessions)|"Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~Functional explanatory model of depression~Cognitive restructuring of negative thoughts~Practice of alternative beneficial thoughts~Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity."
76090882|NCT01812291|Behavioral|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
75344966|NCT01279265|Dietary Supplement|Nutramigen A+|Hypoallergenic formula without lactobacillus
75354661|NCT04805333|Drug|Artemisia annua 1350mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
75354662|NCT04805333|Drug|Artemisia annua 1800mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
75655968|NCT02812914|Behavioral|Resource-intensive behavioral intervention approach|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
75655969|NCT02812680|Other|Blood Draw|Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
75655970|NCT00818259|Drug|Experimental: aprepitant|aprepitant powder for suspension, 125 mg/sachet, PO
75655971|NCT00818259|Drug|Experimental: fosaprepitant|fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
75655972|NCT00818259|Drug|Comparator: ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
75655973|NCT00818259|Drug|Ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
75802870|NCT00090142|Drug|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
75802871|NCT00090142|Drug|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
75802872|NCT00043108|Drug|carboplatin|
75942420|NCT01946672|Procedure|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
75942421|NCT02368028|Other|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
75942422|NCT04385095|Drug|SNG001|SNG001 via inhalation
75942423|NCT04385095|Drug|Placebo|Placebo via inhalation
75802873|NCT00043108|Drug|paclitaxel|
75802874|NCT00043108|Procedure|conventional surgery|
75802875|NCT00043108|Radiation|radiation therapy|
75802876|NCT05225662|Diagnostic Test|radiofrequency ablation|Mesuring change in Speckle tracking analysis before and after the radiofreqency ablation
75802877|NCT05225194|Other|COVID-19|SARS-CoV-2 infection
75802878|NCT05225194|Other|ARDS|Acute respiratory distress syndrome
75802879|NCT05224960|Biological|UC-MSCs|3 doses of UC-MSCs intravenously at week 0, week 4, week 8.
75802880|NCT05224960|Biological|Placebo(solution without UC-MSCs)|3 doses of placebo intravenously at week 0, week 4, week 8.
75942424|NCT02368106|Radiation|Radiation Therapy|targeted radiation treatment
75942425|NCT03113006|Procedure|Panretinal Photocoagulation|Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
75942426|NCT02367950|Behavioral|Exercise|10 exercise sessions with a personal trainer
75942427|NCT02365532|Drug|GS-6615|GS-6615 tablets administered orally
76090883|NCT01812291|Behavioral|Standard Diabetes Education|"Standard diabetes education and professional care.~Includes:~Health care and specific topics (e. g. blood pressure)~Diabetes complications~Healthy and unhealthy foods, cooking recommendations and recipes~Foot care: exercises, care and control, injuries, and diabetic neuropathy~Sports, activities and exercise~Social aspects of living with diabetes"
76090884|NCT03298230|Behavioral|REmotely SuPervised Exercise Training|As described in the Arms section.
76090885|NCT03298230|Behavioral|Supervised Exercise Training|As described in the Arms section.
76090886|NCT02461524|Device|Endurant Evo AAA Stent Graft System|
76090887|NCT02461524|Procedure|Endovascular aneurysm repair (EVAR)|
76090888|NCT02087163|Device|Movement Enhancement Technique|Conventional Orthodontic treatment
76090889|NCT02087163|Device|Clear Aligner|Orthodontic treatment with Clear Aligner
75942428|NCT02365532|Drug|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
75942429|NCT02365532|Drug|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
75655974|NCT00818259|Drug|Dexamethasone|dexamethasone solution for infusion, IV, administered per local standard of care
75942430|NCT02365532|Drug|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
75942431|NCT03113162|Biological|Autologous Hematopoietic Stem Cell|
75344967|NCT00848510|Biological|EMD 525797|Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease [SD], complete response [CR], or partial response [PR]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
75344968|NCT00848744|Drug|Formulation A|Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
75344969|NCT00848744|Drug|Formulation B|Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
75344970|NCT03717974|Other|Telemedecine follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by telemedicine. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
75344971|NCT03717974|Other|Mobile team follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by mobile team. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
75942432|NCT03113162|Drug|BEAM Regimen|Reduced-intensity BEAM for Immunoablation
75655975|NCT02810028|Behavioral|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is a form of cognitive behavioural therapy focused explicitly on promoting psychological flexibility. An ACT programme suits the aims of the study because it targets avoidance of distress, promotes acceptance of illness through motivating meaningful activity outside of illness, improves the processes that underlie beliefs rather than by directly challenging beliefs, thus reducing possible trivialisation of the understandable distress caused by living with MD.
75655976|NCT02809950|Other|oral carbohydrate beverage|oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively
75802881|NCT05224804|Behavioral|knwoledge|Knowledge and Attitudes about ADRs Reporting
75802882|NCT05224024|Procedure|Retzius-repairing robot-assisted radical prostatectomy|Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.
75802883|NCT05223946|Diagnostic Test|Microwave Radiometry|The MWR 2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases. There were several works on identification of excess of microwave emission due to inflammatory, process, cancer and other disorders.
75802884|NCT05223946|Device|SCENAR-CHENS-01|Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
75802885|NCT05223946|Combination Product|Traditional Combination Therapy|ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )
75942433|NCT02461225|Device|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
75655977|NCT02809950|Other|control group|NPO from midnight of the day before surgery
75942434|NCT02461225|Device|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
75344972|NCT03698708|Behavioral|CARES Intervention|A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
75802886|NCT05223712|Other|Diagnostic Test: Chronic Kidney Diseases|The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.
75802887|NCT05223634|Other|Collection of oral and/or nasal samples|Collection of oral and/or nasal samples after SOC test performed
75942435|NCT02368340|Other|Pulmonary function test|Pulmonary function testing performed
75942436|NCT02368340|Other|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
75942437|NCT02368340|Other|Sample collection|Blood and urine sample collections
75344973|NCT01280123|Drug|Pioglitazone|"Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated."
75344974|NCT01280123|Drug|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
75344975|NCT04345640|Other|no intervention|no intervention
75344976|NCT01280201|Drug|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
75802888|NCT05199064|Other|Ultrasound guided greater occipital nerve (GON) radiofrequency|After identifying the GON with ultrasound guidance, a catheter needle (22-gauge 5 cm 5 mm active tip hybrid electrode) is inserted with an in-plane technique from lateral to medial.After visualizing the electrode tip placed close to the right or left GON, a sensory stimulation test is performed using an RF generator (URF-3AP Diros Tecnology Inc.). After the patient reports dysesthesia and a tingling sensation at the occipital area with less than 0.2 V, the PRF treatment is administered at 5 Hz and 5 milliseconds pulsed width for 360 seconds at 45 V under the constraint that the temperature of the electrode tips does not exceed 42°C
75942438|NCT02910037|Device|mNGS for pathogen detection|This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
75942439|NCT02372864|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
75942440|NCT04059848|Combination Product|tDCS(Intelect Mobile Stimulation and Combination, DJO, France)|
75344977|NCT00851006|Drug|Creatine Monohydrate|Creapure brand of creatine monohydrate
75476592|NCT05951387|Drug|dexmedetomidine plus ketamine|titrating the dose of dexmedetomidine mixed with ketamine (staring dose 0.5ug/kg/hr, 0.5mg/kg/hr respectively)to achieve full sedation
75655978|NCT02809872|Other|Diagnostic Thoracic Ultrasound|
75942441|NCT04059848|Combination Product|NMES(Enraf Nonius, Endomed-182, Netherlands)|
75942442|NCT02356705|Drug|Midazolam|midazolam 0.2 mg/kg given intranasally
75942443|NCT02356705|Drug|xylocaine|intransal xylocaine given in conjunction with intranasal midazolam
75942444|NCT02356705|Drug|saline placebo|intranasal saline given as placebo
75942445|NCT02373176|Drug|[14C]PRC 4016 (Icosabutate)|Single oral dose
75942446|NCT02511184|Drug|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
75942447|NCT02511184|Drug|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
75942448|NCT02367638|Biological|MG1111|Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
75942449|NCT02367638|Biological|VARIVAX|VARIVAX is administered by subcutaneous injection
75942450|NCT02367560|Procedure|Needle decompression|Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
76090890|NCT03298152|Procedure|CERASMART Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks
76090891|NCT03298152|Procedure|Emax Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
75344978|NCT01364207|Other|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
75802889|NCT03619408|Drug|Antacids|Omeprazole 1 mg/kg/dose BID or Omeprazole 1mg/kg/dose BID plus Ranitidine 3 mg/kg/dose BID
75476593|NCT05951387|Drug|Dexmedetomidine|starting intravenous infusion with dexmedetomidine starting at dose 0.5ug/kg//hr and titrate the dose to achieve full sedation
75802890|NCT03622112|Drug|AZD7594 DPI 55μg/50μg.|A non-steroidal and selective modulator of the GR.
75802891|NCT03622112|Drug|AZD7594 DPI 99 µg/90 µg|A non-steroidal and selective modulator of the GR.
75802892|NCT03622112|Drug|AZD7594 DPI 198 µg/180 µg|A non-steroidal and selective modulator of the GR.
75802893|NCT03622112|Drug|AZD7594 DPI 396 µg/360 µg once daily.|A non-steroidal and selective modulator of the GR.
75942451|NCT02367560|Procedure|Shockwave therapy|A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
76090892|NCT00443001|Device|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
76090893|NCT01892592|Behavioral|Diet and Lifestyle|Patients will receive up to 16 phone based coaching sessions
75655979|NCT00913575|Other|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
75655980|NCT00913575|Behavioral|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
75655981|NCT02809638|Other|ultrasound elastography|
75655982|NCT05578482|Drug|Dicloxacillin Oral Capsule|Randomized to either systemic dicloxacillin & elocon or placebo & elocon
75802894|NCT03622112|Drug|AZD7594 DPI 792 µg/720 µg|A non-steroidal and selective modulator of the GR.
75802895|NCT03622112|Drug|Placebo for AZD7594 once daily.|Placebo for AZD7594
75655983|NCT05578482|Drug|Elocon 0.1 % Topical Cream|Both groups are treated with elocon for five days.
75802896|NCT03622112|Drug|FF 100 µg once daily (open-label)|Fluticasone furoate
75802897|NCT04032158|Drug|Evobrutinib|Participants received evobrutinib twice daily (BID).
75802898|NCT04032158|Drug|Avonex®|Participants received avonex® IM injection once a week.
75802899|NCT04032158|Drug|Avonex® matched Placebo|Participants received IM injection of placebo matched to Avonex® once a week.
75802900|NCT04032158|Drug|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
76090894|NCT02318979|Device|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
75942452|NCT02367560|Drug|Depo medrol|Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
75476594|NCT05942261|Other|Survey to collect data|The study is a survey aimed to collect data about rehabilitation methods
75476595|NCT05940467|Other|Sleep Loss|Participants will undergo periods of sleep loss in a laboratory setting and be monitored hourly for changes in indicators of arterial stiffness (i.e., pulse wave velocity).
75942453|NCT02367560|Device|Ultrasound device|Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
75942454|NCT02372942|Drug|Lattoferrin|515 pregnant women using lattoferrin to prevent preterm delivery
75942455|NCT02372942|Drug|Progesterone|515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
75942456|NCT04975048|Dietary Supplement|Egg yolks|Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
75942457|NCT04975048|Dietary Supplement|Macronutrients equivalent control|The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
75942458|NCT02365220|Behavioral|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
75942459|NCT02365220|Behavioral|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
75942460|NCT02365220|Behavioral|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
75942461|NCT02365220|Behavioral|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
75802901|NCT01562834|Drug|somatropin|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
75802902|NCT01562834|Drug|placebo|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
75942462|NCT02365142|Biological|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
75344979|NCT01364207|Other|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
75802903|NCT03620708|Behavioral|Motivational Interviewing|Participants are provided with a 35 minute counseling session designed to increase motivation to quit smoking and then provided with a written referral for tobacco dependence treatment.
75802904|NCT03620708|Drug|Nicotine Replacement Therapy Sampling|Participants are provided with a two-week sample of over-the-counter nicotine replacement therapy (i.e., nicotine lozenge and nicotine patch) and then provided with a written referral for tobacco dependence treatment.
75942463|NCT02365142|Biological|Platelet Rich plasma (PRGF)|3 injections of PRGF
75344980|NCT03608696|Drug|Buprenorphine|buprenorphine 0.075 mg/ml solution
75344981|NCT02247089|Other|Massage Therapy|Intervention consists of administering a 30-minute-long upper body massage by a registered massage therapist following a massage protocol developed by Vancouver College of Massage Therapy (VCMT).
75344982|NCT02247089|Other|Journal reading (No massage therapy)|Intervention consists of journal reading in the same sitting position as the massage therapy session for approximately 30 minutes.
75476596|NCT05940220|Other|Acetazolamide|Acetazolamide placebo add-on a standard therapy of iv furosemide in one day and oral furosemide during three consecutive days will be used for the comparator arm
75655984|NCT04237428|Biological|CD19 CAR-T cells infusion|"Biological: CD19 CAR-T cells infusion Biological: CD19 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD19 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD19 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD19 CAR-T cells are infused into patients for one time, the number of infused CD19 CAR-T cells are 0.5-4×10^6/kg."
75344983|NCT04382690|Behavioral|All participants will be asked to respond to the same survey questions|All participants will be asked to respond to the same survey questions
75344984|NCT01334723|Drug|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
75476597|NCT05940220|Other|placebo|placebo
75476598|NCT05939856|Other|Lymph node dissection before bladder resection|Lymph node dissection before bladder resection
75476599|NCT05939856|Other|Lymph node dissection after bladder resection|Lymph node dissection after bladder resection
75942464|NCT02364986|Drug|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
75942465|NCT02364986|Drug|Avonex|Avonex 30µg (day 1 and 8) i.m.
75942466|NCT02373020|Other|colonoscopic biopsies|
76090895|NCT02318979|Device|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
75344985|NCT01334723|Drug|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
75344986|NCT04311710|Drug|ipilimumab|Specified Dose on Specified Days
75344987|NCT04311710|Drug|nivolumab|Specified Dose on Specified Days
75344988|NCT04311710|Drug|ENHANZE (rHuPH20)|Specified Dose on Specified Days
75344989|NCT04311710|Drug|nivolumab|Specified Dose on Specified Days
75344990|NCT01334957|Drug|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
75344991|NCT01402427|Drug|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
75344992|NCT01402427|Drug|Placebo|Intraarterial administration of 10 mL saline.
75802905|NCT03620708|Behavioral|Referral Only|Participants are provided with a written referral for tobacco dependence treatment.
75802906|NCT03654326|Drug|Gefapixant|Gefapixant tablet 45 mg taken orally
75802907|NCT03654326|Drug|Placebo|Placebo matching gefapixant tablet taken orally
75802908|NCT03654326|Drug|Naproxen|Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
75802909|NCT03735524|Other|Exercise|Different exercises will be adopted including: repetition of different movements for ambulation and stair climbing, repetition of crossed patterns of movements for coordination, postural reactions while standing with eyes open and closed and oscillatory boards for balance, strengthening lower limb muscles, and low-intensity and long-duration static stretching of iliopsoas, rectus femoris, hamstrings, triceps surae, and lumbar spinal muscles for muscular flexibility and range of motion. In addition, advanced robotic therapy will be used to standardize rehabilitative treatment and to obtain more objective indexes of motor function. The Lokomat exoskeleton and the Biodex stability system will be used.
75802910|NCT04025684|Other|Oral B Indicator 123|Manual toothbrush (medium bristle stiffness; compact head, UK market).
75802911|NCT04025684|Other|Dr Best Original|Manual toothbrush (medium bristle stiffness; regular head, German market)
75344993|NCT00813176|Device|Double Lumen Endotracheal Tube|
75344994|NCT00813176|Device|Arndt Bronchial Blocker|
75344995|NCT01335191|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
75802912|NCT04025684|Other|Dr Best Multi Expert|Manual toothbrush (medium bristle stiffness; compact head, German market)
75802913|NCT04025684|Other|parodontax Interdental|Manual toothbrush (soft bristle stiffness; compact head, German market)
75802914|NCT03735446|Drug|Prexasertib|Checkpoint kinase 1 (CHK1) inhibitor
75344996|NCT01335191|Other|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
75802915|NCT03735446|Drug|Mitoxantrone|Standard chemotherapy (topoisomerase inhibitor)
75802916|NCT03735446|Drug|Etoposide|Standard chemotherapy (topoisomerase II inhibitor)
75802917|NCT03735446|Drug|Cytarabine|Standard chemotherapy (anti-metabolite)
75942467|NCT02372786|Drug|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
75942468|NCT02372786|Drug|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
75942469|NCT02372786|Device|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
75942470|NCT02372786|Device|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
75942471|NCT02364908|Other|therapeutic education|This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
75942472|NCT02372552|Device|CROMA|Microwave coagulation of small blood vessels
75942473|NCT02372708|Drug|dinitrophenyl(DNP)|
75942474|NCT02372708|Radiation|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
75942475|NCT02364674|Radiation|High Resolution Computed Tomography scan|"a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
75942476|NCT02367404|Drug|Duloxetine|Duloxetine 60mg OD for 3 months
75344997|NCT01365611|Drug|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
75344998|NCT01365611|Drug|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
75344999|NCT01403441|Device|Radiosurgical Neuromodulation using the Cyberknife|our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
75345000|NCT01404611|Drug|DF289|Ear drops
75345001|NCT01404611|Drug|DF277|Ear drops
75345002|NCT01404611|Drug|DF289 plus DF277|Ear drops
75345003|NCT01365845|Radiation|Photon|50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
76090896|NCT02318979|Device|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
76090897|NCT03298074|Drug|Apatinib|Apatinib, 500mg,po qd for continuous administration
76090898|NCT03298074|Drug|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
75802918|NCT05665868|Device|integrated care mode|The information system consists of big data platform and nursing strategy platform. The system includes medical work end, patient operation end and administrator management end. The big data platform can automatically extract patient data from HIS, Medcare and other patient diagnosis and treatment systems, complete registration and establish patient health files according to the preset patient registration standards. By comparing the data input on the patient side with the database set on the platform, the system decision-making module can generate personalized measures and plans for feedback to patients, and can generate patient information overview feedback to the nurse side. Complete intelligent push of symptom management decision model
75345004|NCT01365845|Radiation|3D-Proton/Conventional plan or 3D-proton only|50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
75655985|NCT05577546|Other|Moor S brace treatment|The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.
76090899|NCT03295890|Procedure|Dry Needing|Dry Needling
76090900|NCT03297996|Diagnostic Test|Mobio PowerSoil DNA Isolation Kit|16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
75345005|NCT03008681|Device|Andresen functional removable orthodontic appliance|Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
75345006|NCT01472549|Drug|Iodine-alcohol|Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.
75345007|NCT01472549|Drug|Chlorhexidine-alcohol|Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation
75942477|NCT02367404|Behavioral|Pelvic Floor Muscle Training|PMFT weekly for 3 months
75942478|NCT02367248|Drug|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
76090901|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
76090902|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
75942479|NCT02367248|Drug|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
75942480|NCT02367248|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
75942481|NCT02984995|Drug|Quizartinib|Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
75942482|NCT02367326|Other|data collection|data collection will be carried out by the investigator during a standard hospitalization of the patient
76090903|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
75345008|NCT00852644|Procedure|computed tomography|Standard CT scans
76090904|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
75345009|NCT00852644|Radiation|fludeoxyglucose F 18|standard doses with CT scans
75345010|NCT00852644|Radiation|hypofractionated radiation therapy|4 doses over 2 weeks
75345011|NCT00852644|Radiation|stereotactic radiosurgery|CyberKnife radiosurgery
75345012|NCT01404923|Drug|anti spasmodic agents|best standard of care prescriptions
75345013|NCT01404923|Drug|alverine citrate, simeticone|on-demand therapy
75345014|NCT00854594|Behavioral|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
75345015|NCT01368263|Drug|goserelin acetate|Given SC
75345016|NCT01368263|Drug|letrozole|Given PO
75345017|NCT01368263|Drug|anastrozole|Given PO
75345018|NCT01368263|Drug|chemotherapy|Standard chemotherapy
75345019|NCT01368263|Procedure|Surgery|
75354663|NCT04805333|Drug|Artemisia annua - recommended phase II dose|Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.
75476600|NCT05935631|Dietary Supplement|Salt with folic acid and iodine|Assess serum and RBC folate levels in women at baseline and 1 month after ingesting salt with folic acid
75942483|NCT03656965|Drug|Acyclovir 800 MG|Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.
76090905|NCT01992874|Drug|Pimasertib Capsule (Part B and trial extension phase)|Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
75345020|NCT03032276|Other|Safe motherhood and newborn health promotion package|The intervention package consists of three components: facility, community and linkages between the community and health facilities. Facility based interventions will serve both the comparison and intervention arms. However, other two interventions will serve the intervention arm only. Specific interventions and approaches for the three components will be implemented within the MOH&FW service delivery system to improve MNH practices in families and communities and to increase the use of MNH services from appropriate facilities/providers. The intervention package has been developed based on the experiences from SMPP in Narsingdi district and on the basis of consultations with the International Advisory Body (IAB) that included GoB, JICA, ICDDR,B, other experts and stakeholders.
75345021|NCT01405313|Device|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
76090906|NCT04489836|Dietary Supplement|Glutalytic®|Glutalytic® capsule
76090907|NCT04489836|Dietary Supplement|DE111®|DE111® capsule
76090908|NCT04489836|Other|Meal A|Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
76090909|NCT04755621|Other|Core stability training|Core stability exercises
75345022|NCT01405313|Device|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
75345023|NCT00814970|Device|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
75345024|NCT00815360|Drug|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
75476601|NCT05934214|Drug|Immune checkpoint inhibitor|"Reports associated with an an Immune checkpoint inhibitor with a status of Suspect or Interacting~ICI will include the following list of FDA-apporved ICIs:~nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab"
75655986|NCT05577546|Other|Schroth Three-Dimensional Scoliosis Exercise Treatment|Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
75802919|NCT05665868|Device|conventional care mode|① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
75802920|NCT03735368|Drug|Dexmedetomidine Injection|Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion
75802921|NCT03735368|Drug|Placebo oral capsule|placebo oral capsules
76090910|NCT04755621|Other|Rocabado Exercises|Exercises for Temporomandibular Disorders
75802922|NCT03735368|Drug|Pregabalin Oral Capsule|150 mg pregabalin Oral Capsule
75802923|NCT03735368|Drug|topical anesthesia|topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
75345025|NCT00815360|Procedure|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
75345026|NCT00815360|Drug|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
75476602|NCT05931887|Device|SILQ ClearTract 100% Silicone 2-Way Foley Catheter|A foley catheter is assigned and used according to regular standard of care
75345027|NCT00815360|Procedure|macular laser|macular laser to areas of retinal thickening or leakage
75942484|NCT03656965|Combination Product|Radiotherapy and chemotherapy|Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
75942485|NCT02364830|Drug|Anise-oil EC Capsule|Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
75942486|NCT02364830|Other|Placebo|One Placebo Capsule/Day for 4 Weeks
75942487|NCT02364830|Drug|Colpermin®|Colpermin® Capsule/Day for 4 Weeks
75942488|NCT03622333|Genetic|Research of constitutional genetic alterations|Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis
75942489|NCT02364518|Procedure|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
75942490|NCT03270956|Biological|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
75942491|NCT02384239|Drug|Palbociclib|Given orally (PO)
75942492|NCT02384239|Drug|Tamoxifen|Given orally (PO)
75942493|NCT02384239|Drug|Fulvestrant|Given by intramuscular (IM) injection.
75966007|NCT02370784|Drug|atorvastatin|Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
75966008|NCT02370784|Drug|Placebo|oral drug of similar appearance to atorvastatin
75655987|NCT02809560|Procedure|Induced sputum method using hypertonic serum|Collection of expectoration in sterile vial, conserved in ice all along the examination
75655988|NCT02809404|Drug|Everolimus|
75345028|NCT00855842|Device|osmotic dilator insertion|osmotic dilators are placed in the cervix to cause cervical dilation
75802924|NCT03617588|Drug|Gallium-68 THP-PSMA|Subjects will undergo a Gallium-68 THP-PSMA scan in addition to standard of care monitoring. The results of this scan may influence the patient management plan.
75942494|NCT02372474|Biological|Stem cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
75802925|NCT03732092|Diagnostic Test|Coma Recovery Scale-Revised|Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
76090911|NCT01804179|Other|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
76090912|NCT01804179|Other|Standard Intervention (SI) Educational Materials|"Screen for Life brochure"
75345029|NCT00856232|Biological|Medical Air|Compressed medical air
75345030|NCT00856232|Biological|Oxygen|Medical Oxygen
75345031|NCT01474109|Drug|macitentan 3mg|macitentan 3mg tablet once daily
75345032|NCT01474109|Drug|macitentan 10mg|macitentan 10mg tablet once daily
75345033|NCT01474109|Drug|placebo|matching placebo once daily
75354664|NCT04802174|Drug|Lurbinectedin|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
75802926|NCT03616106|Other|Infographic intervention|All study participants will receive health education using infographics during their regularly scheduled clinic appointments.
75655989|NCT00619099|Drug|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
75655990|NCT00619099|Drug|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
75802927|NCT04019054|Device|Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)|iTBS delivered to vmPFC for active treatment of spider phobia.
75802928|NCT04019054|Device|Intermittent Theta Burst Stimulation (iTBS), vertex|iTBS delivered to vertex for placebo treatment of spider phobia.
75802929|NCT00071799|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
75802930|NCT00071799|Other|Physician Choice|"Physician Choice was one of three options:~Best supportive care (BSC) alone,~Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or~Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).~All three options included best supportive care"
75802931|NCT03615482|Biological|V114|Single 0.5 mL injection
75802932|NCT03615482|Biological|QIV|Single 0.5 mL injection
75802933|NCT03615482|Biological|Matching Placebo for V114|Single 0.5 mL injection
75942495|NCT02364752|Procedure|Blood Draw|
75942496|NCT02364752|Procedure|Loop Diuretic Withdrawal/Salt Load|
75942497|NCT03657199|Diagnostic Test|Cardiac computed tomography|Routine computed tomography of the heart before discharge
75942498|NCT02372240|Drug|VLX1570 and dexamethasone|
75942499|NCT02364596|Biological|SA4Ag vaccine|Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
75655991|NCT02812992|Drug|Nab-paclitaxel|
75655992|NCT02812992|Drug|Gemcitabine|
75942500|NCT02364596|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
75942501|NCT02364440|Device|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
75942502|NCT02364206|Drug|LY2228820|
75942503|NCT02364206|Drug|Temozolomide|
75942504|NCT02364206|Radiation|radiotherapy|
75942505|NCT02366858|Procedure|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
76090913|NCT01804179|Other|CARES Intervention Educational Materials|Newly developed digital video disc (DVD) and booklet
76090914|NCT01804179|Other|Baseline Visit Survey|In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
75942506|NCT02366858|Procedure|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
75942507|NCT02372162|Other|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
75942508|NCT02372162|Other|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
75942509|NCT02366546|Drug|TBI-1301|TBI-1301(5*10^8 or 5*10^9) is administered.
75942510|NCT02366546|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
75942511|NCT02366546|Drug|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
75942512|NCT02984683|Drug|SAR566658 (ACT14884)|Pharmaceutical form:Solution Route of administration: Intravenous
75802934|NCT00090363|Drug|ZD4054 15 mg|15 mg oral tablet once daily
75942513|NCT02524327|Other|Toolbox: Automated group|A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
75942514|NCT02524327|Other|Manual group|The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
75942515|NCT02364362|Drug|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m^2
75942516|NCT02364362|Drug|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m^2
75802935|NCT00090363|Drug|Placebo|
75802936|NCT00090363|Drug|ZD4054 10 mg|10mg oral tablet once daily
75802937|NCT03652610|Biological|MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
75802938|NCT03652610|Biological|Licensed GSK MenACWY vaccine (Menveo)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
75942517|NCT02364362|Drug|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m^2
75942518|NCT02364128|Behavioral|Decider Guider: Weight Loss|Decision aid tool about weight loss treatment
75942519|NCT04574180|Other|Dental Crown|Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
75942520|NCT02909101|Device|Active Cognitive Training (ACT)|Cognitive training games
75942521|NCT02909101|Device|Control Training (CON)|Cognitive training games
75942522|NCT03656575|Biological|synovial fluid biomarker concentrations|Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
75942523|NCT03656887|Device|Continuous interstitial glucose sensor|Installing and removing the sensor
75942524|NCT03656887|Other|Sensor Scan|Scan of the sensor, using the Freestyle Pro free version reader, at installation then before removal after 14 days.
75942525|NCT03004469|Drug|P-3074|
75942526|NCT03004469|Drug|Finasteride|
76090915|NCT01804179|Other|Follow-up Questionnaire|12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
76090916|NCT04755543|Drug|LP002|600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
76090917|NCT04755543|Drug|Cisplatin|50mg/m2 IV on Day 1, Q2W
76090918|NCT04755543|Drug|Fluorouracil|2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
75655993|NCT02812992|Other|Best Supportive Care|
75802939|NCT03615404|Biological|CMV-DCs with GM-CSF|CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.
76090919|NCT04755543|Biological|OH2 oncolytic virus|106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
76090920|NCT01993108|Drug|Methylphenidate|One dose 40mgs of methylphenidate one hour before fMRI scanning.
76090921|NCT01993108|Drug|Naltrexone|One dose 40mgs of naltrexone one hour before fMRI scanning.
76090922|NCT01993108|Drug|Placebo|One dose of placebo one hour before fMRI scanning.
76090923|NCT00437151|Other|More frequent than normal office visits|Mode of patient reminder
76090924|NCT00437151|Other|Electronic reminders (voice, e-mail, text messages)|Mode of patient reminder
75655994|NCT04018573|Behavioral|PATHS Sexual Communication Toolkit|The PATHS Sexual Communication Toolkit is a self-guided, online intervention. The toolkit is comprised of 6 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. A 1-month booster module queries parents about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact.
75942527|NCT03004469|Drug|P-3074 Vehicle|
75942528|NCT03004469|Drug|Finasteride Placebo|
75942529|NCT02358902|Device|tDCS|tDCS - DC stimulator, Neurocom, Germany
75942530|NCT02358902|Procedure|active intervention of aerobic exercise|different types of aerobic exercise
75942531|NCT02358902|Device|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
75942532|NCT02358902|Procedure|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
75942533|NCT02366702|Device|Lower Limb Powered Knee-Ankle Prosthesis|
75942534|NCT02366780|Procedure|Pump|Breast milk expression using manually or using an electric pump
75942535|NCT02910713|Device|Intranasal Tear Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
75942536|NCT04478786|Other|Focus group discussion|There is no intervention. This is a qualitative piece of work only.
75942537|NCT02358824|Drug|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)"
75942538|NCT02358824|Drug|Telmisartan|"- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)"
75942539|NCT02358824|Drug|S-amlodipine|"- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)"
75942540|NCT02998541|Drug|SHP640|Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
75942541|NCT02998541|Drug|PVP-I 0.6%|Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
76090925|NCT00437151|Other|Parenteral involvement / intervention reminders|Mode of patient reminder
76090926|NCT00437151|Other|No intervention or reminders|Mode of patient reminder
76090927|NCT02307526|Drug|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
76090928|NCT02307526|Device|Tilt table test|After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
75655995|NCT04018573|Behavioral|Parent Support Film|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance."
75802940|NCT03615404|Biological|Td (tetanus toxoid)|Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.
75802941|NCT03614156|Drug|Rapastinel|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
75802942|NCT03614156|Drug|Placebo|Placebo (prefilled syringe, weekly IV administration)
75802943|NCT03614078|Drug|PRCL-02|Oral tablets
75942542|NCT02998541|Other|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
75942543|NCT02359136|Procedure|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
76090929|NCT02307838|Other|Assessments arm|Protocol required assessments not provided in standard of care
76090930|NCT01371201|Drug|Sunitinib|sunitinib 37.5 mg per day
75655996|NCT02812446|Other|IAI infection|
75655997|NCT02812446|Other|Staphylococcus aureus nasal carriage infection|
76090931|NCT01371201|Drug|Placebo|Placebo 37.5 mg per day
75802944|NCT03614078|Drug|Placebo|Oral tablets
75802945|NCT03731936|Other|No intervention|No intervention
75802946|NCT03613454|Device|Splenic artery embolization with vascular embolic coils|Splenic artery embolization with vascular embolic coils
75802947|NCT03613454|Device|Splenic artery embolization with vascular embolic plugs|Splenic artery embolization with vascular embolic plugs
75802948|NCT03730064|Drug|N-acetyl cysteine (NAC)|Experimental medication with N-acetyl cysteine (NAC) for six weeks
75802949|NCT03581786|Biological|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
75802950|NCT03581786|Drug|Placebos|placebo combine with chemotherapy
75802951|NCT03580382|Drug|Trametinib daily Until PD|1.0 mg daily
75802952|NCT03580382|Drug|CDX-3379 (ERBB3 antibody)|15mg/kg IV Q3W
75802953|NCT03729986|Other|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% of maximal inspiratory pressure in sitting and supine positions. The orders of the two loaded test conditions will be conducted in random order with at least 20 minute separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
75802954|NCT05667350|Other|Blood drawing|Blood drawing before anti-cancer therapy
75802955|NCT05667350|Other|Blood drawing|Blood drawing before radical treatment
75942544|NCT02359136|Procedure|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
75942545|NCT02359136|Procedure|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
75942546|NCT02363582|Other|formula|An infant formula contains prebiotics and lactoferrin
75942547|NCT02366078|Behavioral|SMART|Paced breathing meditation with cognitive training
75942548|NCT02366156|Dietary Supplement|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
75942549|NCT02366156|Dietary Supplement|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
76090932|NCT00436527|Drug|Metronidazole gel 1%|Applied once to a test site on the right or left cheek (as determined by a randomization design)
76090933|NCT02307916|Drug|FGF-2|The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.
76090934|NCT02307916|Other|Placebo|Placebo comparator using a sterile saline solution.
75345034|NCT01405469|Other|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
75345035|NCT01405937|Drug|vaniprevir|vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
75345036|NCT01405937|Biological|peg-IFN|peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
75655998|NCT00856063|Drug|atomoxetine (or placebo)|Each child will be randomized to receive either ATMX or placebo in the 1st crossover phase followed by the alternative drug condition in the 2nd crossover phase. The study drug (ATMX or placebo) will be administered BID and will be titrated blindly based on clinical response and tolerability. ATMX will be initiated at 0.5 mg/kg/day for 3 days. Based on clinical response, ATMX dose will be titrated to 0.8 mg/kg/day during week 1, 1.4 mg/kg/day during week 2, and a maximum of 1.8 mg/kg/day during week 3, unless serious untoward effects intervene.
75802956|NCT03579290|Behavioral|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of drug use,~Coping with craving,~Substance refusal skills,~Seemingly irrelevant decisions,~Planning for emergencies, and~Problem-solving skills.~Staying Safe"
75802957|NCT03611582|Drug|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
75802958|NCT03611582|Drug|Placebo (semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
75802959|NCT04015518|Drug|Spesolimab|Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.
75802960|NCT04015518|Drug|Placebo|Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
75802961|NCT04015518|Drug|Spesolimab|Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
75802962|NCT04015518|Drug|Spesolimab|Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
75942550|NCT02366156|Dietary Supplement|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
75942551|NCT02366390|Behavioral|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
75942552|NCT02358980|Device|KIDNEY therapy|
75942553|NCT02998151|Drug|Acamprosate|two 666mg pills
75942554|NCT02998151|Drug|Lovastatin|two 20mg pills
75942555|NCT02998151|Drug|Minocycline|two 135mg pills
75942556|NCT02998151|Drug|Placebo|placebo pill
76090935|NCT00433563|Radiation|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
76090936|NCT00433563|Radiation|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
76090937|NCT00419367|Drug|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
76090938|NCT01994746|Drug|Nasal Glucagon|
76090939|NCT01994746|Drug|Intramuscular Glucagon|
75942557|NCT02998151|Drug|Baclofen|one 30mg pill
75942558|NCT02358590|Behavioral|HAPA menu-based mini-video|The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis
75942559|NCT02358590|Behavioral|Standard care|The treating physician will advice participants to take vitamin D
75942560|NCT03664349|Device|SuperEar9000|Handheld hearing amplifier, not FDA regulated.
75942561|NCT02994290|Drug|HPV vaccine|After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
75966009|NCT03558269|Biological|Autlogous UCB infusion|Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
76090940|NCT05333601|Behavioral|eSCCIP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
75942562|NCT02994290|Behavioral|Inpatient Postpartum HPV Immunization Quality Improvement Program|"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."
75942563|NCT04058015|Other|Stress-induced hyperglycemia|Stress-induced hyperglycemia (SIH)was defined as a serum glucose ≥ 200 mg/dL in the patients without Diabetes mellitus.
75942564|NCT04058015|Other|Diabetic hyperglycemia|Diabetic hyperglycemia (DH) which indicated a serum glucose ≥ 200 mg/dL in patients with Diabetes mellitus.
75942565|NCT04058015|Other|Diabetic normoglycemia|Diabetic normoglycemia (DN), which was defined when there was a serum glucose < 200 mg/dL in the patients with Diabetes mellitus.
75942566|NCT04058015|Other|Non-diabetic normoglycemia|Non-diabetic normoglycemia (NDN) indicating a serum glucose < 200 mg/dL in patients who were absent of Diabetes mellitus.
75942567|NCT04057781|Procedure|Dry Needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and the subject will lie on a treatment table without moving arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
75966010|NCT04897750|Combination Product|CT001|Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.
75345037|NCT01405937|Drug|ribavirin|Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
76090941|NCT01722916|Drug|Hyaluronidase|
75802963|NCT04015518|Drug|Spesolimab|Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
75802964|NCT04015518|Drug|Spesolimab|Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
75345038|NCT01368653|Behavioral|Standard treatment|Standard treatment includes a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help smokers quit smoking
75802965|NCT03577730|Drug|Caffeine Citrate|Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
75802966|NCT03577730|Drug|Dextrose Water|Prepared intravenous piggyback solutions of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants.
75802967|NCT03731780|Other|Personalized Treatment|Targeting individual caries risk factors
76090942|NCT01795677|Drug|Ruxolotinib|Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
75802968|NCT03731780|Other|Chlorhexidine and Remineralization|chlorhexidine mouth wash and remineralizing agent
75345039|NCT01368653|Behavioral|Standard treatment+practice quitting|This intervention includes standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling
75802969|NCT03731780|Other|Control|Control is standard preventive measures (tooth brushing, fluoride tooth paste, interdental cleaning)
75802970|NCT03729908|Behavioral|Animal assisted mindfulness based intervention|A mindfulness based intervention in the presence of an animal
75802971|NCT03729908|Behavioral|Anti-stress program|A mindfulness based intervention with no reference to animals
75802972|NCT03735134|Drug|Colchicine Loading Dose|Two milligrams of colchicine will be administrated in addition to the standard of care treatment
75802973|NCT03735134|Drug|Standard of care treatment prior to elective PCI|All medications normally given to patients prior to elective PCI
75802974|NCT05665478|Other|Dose prediction using population pharmacokinetic models|Dose prediction using population pharmacokinetic models.
75802975|NCT03907878|Biological|Ligelizumab|Liquid in vial
75354665|NCT04802174|Drug|Berzosertib|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
75802976|NCT03608774|Drug|Azithromycin|Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
75802977|NCT03608774|Drug|Doxycycline|Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
75802978|NCT03608774|Other|Placebo|Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.
75802979|NCT03744858|Procedure|Peripheral blood draw|Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.
75966011|NCT02083211|Drug|mAb Nimotuzumab|This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
76090943|NCT01347177|Procedure|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
76090944|NCT01347177|Procedure|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
76090945|NCT04489290|Device|D005 Vaginal Mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
76090946|NCT04489290|Other|Placebo|Placebo
76090947|NCT01999192|Drug|Tregalizumab|humanized anti-CD4 mAb
76090948|NCT01999192|Drug|Placebo|identical end formulation buffer
76090949|NCT00291525|Device|On-X valve using reduced anticoagulation|Valve replacement with antiplatelet agents or lowered warfarin
75942568|NCT04057781|Procedure|Dry needling with Intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject lies on a treatment table without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
75942569|NCT03388775|Other|deep venous thrombosis|Five-year prospective analysis of deep venous thrombosis performed by the RHEUNI group of five public schools in the State of São Paulo.
75942570|NCT03664271|Behavioral|in-clinic video intervention|Video with information about eczema and eczema treatment, to be watched in clinic and at home
75942571|NCT03664271|Behavioral|at home video intervention|Video with information about eczema and eczema treatment, to be watched at home only
75942572|NCT03663491|Procedure|Nasal Gastroscopy|Use of transnasal endoscopes for routine gastroscopy in adults.
75942573|NCT03663491|Procedure|Oral Gastroscopy, unsedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of local anesthesia.
75942574|NCT03663491|Procedure|Oral Gastroscopy, sedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of intravenous sedation.
75942575|NCT03663491|Procedure|Oral Gastroscopy with transnasal endoscope, sedated|Use of transnasal endoscopes for routine gastroscopy in adults, following a failed attempt to perform transnasal gastroscopy
75942576|NCT04057625|Device|transthoracic ultrasound|using transthoracic ultrasound in the diagnosis and follow up of vap,measuring the largest area of consolidation according to intercostal space and the direction of the probe.
75942577|NCT01066819|Drug|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
75942578|NCT01066819|Drug|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
76090950|NCT00291525|Device|On-X Valve with Standard warfarin Therapy|Valve replacement with standard dosage warfarin
75476603|NCT05931172|Other|Dual tasking|"Dual-task training is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Dual tasking is given by therapist in unexpected directions to challenge patients reactive balance. In this study dual tasking will be given manually and on hurdles.~Daily 45 mins of exercise sessions of dual-task training like walking with talking , walking with a filled cup of water, walking with looking on clock performed for total eight weeks and 5 days a week."
75476604|NCT05931172|Other|PNF(proprioceptive neuromuscular facilitation exercises)|"PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session will be given to patients. 45 mins session/each day for 5 days a week."
75802980|NCT04021524|Drug|Benzoyl Peroxide 10% Bar|Patients will wash with Benzoyl Peroxide 10% Bar
75802981|NCT04021524|Drug|Chlorhexidine Gluconate|Patients will wash with Chlorhexidine Gluconate
75802982|NCT03607682|Procedure|Tumor Treating Fields (TTF) Therapy|Undergo TTF therapy
75802983|NCT03607682|Device|NovoTTF-200A Device|Undergo TTF therapy
75655999|NCT04188210|Other|Presence of elbow pain in patients with end stage renal disease|The Beck Depression Inventory (BDI), the Nottingham Health Profile (NHP) scores were measured for all patients to evaluate depression symptoms and health-related quality of life. The elbow pain presence was asked to all the patients, the patients with elbow pain were also evaluated with The Disabilities of the Arm, Shoulder and Hand Score (Q-DASH) and Visual Analogue Scale (VAS). VAS detected as pain during rest, activity, night and pain at last week.
75802984|NCT03607682|Other|Quality-of-Life Assessment|Ancillary studies
75802985|NCT03606668|Device|HTC Vive Virtual Reality (VR) system|VR treatment will entail use of computer software designed to immerse participants and engage them in exercises. Software includes virtual painting, walking through vivid and calming settings, solving puzzles, among others.
75802986|NCT05666492|Other|Platelet rich plasma|Platelet-rich plasma will be placed on the olfactory epithelium topically.
75802987|NCT05666492|Other|Saline|Saline will be placed on the olfactory epithelium topically.
75942579|NCT04056299|Biological|AR201 powder|AR201 powder (Hen Egg allergen formulation) provided in capsules
75942580|NCT04056299|Biological|Placebo powder|Placebo powder provided in capsules
75942581|NCT04057937|Drug|Apremilast|Apremilast
75656000|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
75656001|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
75942582|NCT04057937|Drug|Placebo|Placebo
75942583|NCT04057547|Drug|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
75942584|NCT01069523|Drug|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
75942585|NCT01069523|Drug|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
75942586|NCT01069289|Drug|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
75942587|NCT01069289|Drug|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
75942588|NCT04057313|Dietary Supplement|Coffee|Coffee used will be the boiled unfiltered Arabica coffee
75942589|NCT03663413|Device|non-invasive monitor|cutaneous EEG monitor
76090951|NCT04030650|Other|Functional analyses|2-minute walking test 200-metre walking test
76090952|NCT04030650|Other|3D analysis of walking and balance|Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb
75942590|NCT03303989|Drug|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
75942591|NCT03303989|Drug|MMF|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
75942592|NCT03303989|Drug|Placebo|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
75942593|NCT03303989|Drug|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
75802988|NCT03735056|Other|MS Nurse Support|MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
75942594|NCT02510794|Drug|Ranibizumab|Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
75942595|NCT04056923|Procedure|3D-printing guided|3D printed navigational template guided
75942596|NCT04056923|Procedure|CT-guided|CT-guided
75942597|NCT04056923|Drug|Indocyanine Green|The results are shown by comparison of different colors.
75942598|NCT04056923|Drug|Methylene blue|The results are shown by comparison of different colors.
75942599|NCT04056923|Procedure|Preoperative|Preoperative localization.
75942600|NCT04056923|Procedure|Intraoperative|Intraoperative localization.
75942601|NCT03664115|Drug|Itraconazole 200 mg|itraconazole 200 mg oral tablet daily, on a 21-day cycle.
75942602|NCT03664115|Drug|Chemotherapy|"intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
75942603|NCT03370757|Other|3-hour bundled care|Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.
76090953|NCT04030650|Other|Functional analyses|400-metre walking test 200-metre walking test
75476607|NCT05928858|Drug|Premixed Bio-ceramic MTA|Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
75656002|NCT02812758|Device|transthoracic echocardiography|recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
75656003|NCT00856219|Dietary Supplement|Enteral Continuous|Continuous Tube Feeding for 72 hours
75656004|NCT00856219|Dietary Supplement|Enteral Intermittent|Intermittent Tube Feedings
75656005|NCT00856219|Dietary Supplement|Parenteral Continuous|Parenteral Continuously for 72 hours
75656006|NCT02812602|Drug|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
75656007|NCT02812602|Drug|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
75802989|NCT03735056|Other|Peer Support|Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
75802990|NCT03734978|Diagnostic Test|Diagnosis|biochemistry
75942604|NCT03370757|Other|6-hour bundled care|Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
75942605|NCT03622853|Drug|Steroid (shincort)|intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
75942606|NCT02363426|Device|INVOcell Culture Device|INVOcell is a vaginal culture device
75942607|NCT02363426|Device|IVF Incubation|IVF Incubator
75942608|NCT02363504|Other|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
75942609|NCT04052243|Diagnostic Test|Invasive exercise testing|Invasive hemodynamic exercise testing
76090954|NCT01337349|Drug|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
76090955|NCT01337349|Drug|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
76090956|NCT03297918|Behavioral|Respiratory muscle training|The intervention is two-parted and includes weekly singing lessons in a choir, held by a professional instructor, with additional instructions for daily breathing exercise at home.
75942610|NCT02363348|Dietary Supplement|L arginine|L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
75942611|NCT02363348|Other|Placebo|calcined magnesia
75942612|NCT02358434|Radiation|Observational use of fluoroscopy|
75942613|NCT04056845|Device|Valgus knee brace (Medex K39-OA Corrector)|Valgus knee brace given to patients as part of the conservative management for knee osteoarthritis.
75942614|NCT04056845|Other|Physiotherapy and oral analgesic (diclofenac and panadol)|Physiotherapy and oral analgesic (diclofenac and panadol)
75942615|NCT02363192|Behavioral|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
75942616|NCT03663959|Procedure|vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier|A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.
75942617|NCT03663959|Procedure|Laparoscopic Pectocolpopexy procedure|First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
75942618|NCT02836574|Biological|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC).
75942619|NCT02510014|Drug|SUBOXONE sublingual film|SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period.
75942620|NCT02510014|Drug|RBP-6000|Injections administered subcutaneously every 28 days on alternate sides of participant's abdomen starting at 300 mg. Subsequent doses of RBP-6000 could be adjusted down to 100 mg with the possibility of adjusting back up to 300 mg based on the medical judgment of the investigator. De novo subjects receive up to 12 injections and roll-over subjects receive up to 6 injections.
75942621|NCT03663881|Drug|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
76090957|NCT01895985|Drug|Latanoprostene bunod|
75802991|NCT03729674|Drug|Biosimilar|Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.
75942622|NCT02358512|Other|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
75942623|NCT03257579|Other|90 Day Supply|Policy Change implementing a 90 day standardized discharge prescription form with 3 repeats for all cardiac medications available on all wards where MI patients are managed at Hamilton Health Sciences sites
75942624|NCT03257579|Behavioral|Education|Education Alone provided at St. Joseph's Hospital and Niagara Health System
76090958|NCT01999348|Drug|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
76090959|NCT02463474|Behavioral|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
76090960|NCT03297840|Behavioral|Dialectical Behavioural Therapy (DBT)|Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
76090961|NCT03297762|Behavioral|gamification|incentives/rewards and contact between standard visits
76090962|NCT03297762|Behavioral|Use of Dexcom G5|Dexcom G5 continuous glucose monitor
75942625|NCT02358746|Other|combined endo/epicardial approach|
75942626|NCT02358746|Other|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
75802992|NCT03729674|Drug|Originator (legacy) drug|Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
75802993|NCT01310270|Dietary Supplement|Pro-Omega|Pro-Omega, 4.4gm/day x 1 month
75802994|NCT01310270|Dietary Supplement|Omega 3 Fatty Acid|4.4 gm/day for 1 month
75802995|NCT03731468|Drug|local anesthetic|ultrasound guided superficial cervical block in thyroid surgery
75802996|NCT03731468|Drug|Dexamethasone|dexamethasone will be added to ultrasound guided superficial cervical block in thyroid surgery
75802997|NCT03734900|Other|Saline injection|5ml Placebo infusion of 0.9% Sodium Chloride
76090963|NCT00280761|Drug|capecitabine|Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
76090964|NCT00280761|Drug|5-fluorouracil|Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
76090965|NCT00280761|Procedure|Surgical Resection|Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
75942627|NCT03663803|Behavioral|Brief theory-based health promotion intervention (group-based)|The intervention is depicted using a PaT Plot in the published paper: Juul, L et al. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting. Primary Care Diabetes 1 0 ( 2 0 1 6 ) 111-120.
75942628|NCT02789774|Procedure|Posterior fusion C1-C2|Posterior access and screws in C1 (atlas) and C2 (axis) and fusion with addition of iliac crest bone graft. No postoperative collar.
75942629|NCT02789774|Procedure|Rigid cervical collar|External immobilization of cervical spine in a rigid collar for 12 weeks.
75942630|NCT03662945|Other|Mobile Geriatric Team intervention|Person-centred intervention based on Comprehensive Geriatric Assessment
75942631|NCT02509312|Drug|Ketorolac|Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
75942632|NCT02509312|Drug|Placebo|Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
75942633|NCT03662477|Biological|NK cells|"NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality."
75942634|NCT02362880|Radiation|Florbetaben|single dose of Florbetaben followed by PET scan
75942635|NCT04057079|Combination Product|Anugel, Hydrogel sponge|A calibrated sponge impregnated with hydrogel is inserted to the rectum post hemoroidectomy.
75942636|NCT04057079|Combination Product|Gelatine Sponge|A gelatine sponge is inserted in to the rectum pos hemoroidectomy.
75942637|NCT03662399|Device|Insoles|Orthotic Insoles
75942638|NCT03662399|Other|Standard shoe|Standard shoe
76090966|NCT00280761|Radiation|Radiation therapy|Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
76090967|NCT02716584|Behavioral|Physical exercise|Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
75476608|NCT05928858|Drug|Calcium hydroxide|Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
75656008|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
75476609|NCT05928845|Diagnostic Test|Muscle thickness measurement|Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission
75802998|NCT03734900|Biological|PRP injection|"Device: Aeon Acti-PRP~5ml autologous platelet rich plasma injection"
75802999|NCT03734900|Biological|PL injection|"Device: Aeon Acti-PRP~5ml autologous platelet lysate injection"
75803000|NCT03734510|Dietary Supplement|Dietary Supplement: hesperidin and flaxseed|2 capsules hesperidin and 30 g flaxseed
75803001|NCT03734510|Dietary Supplement|Dietary Supplement: hesperidin|2 capsules hesperidin
75803002|NCT03734510|Dietary Supplement|Dietary Supplement: flaxseed|30 g flaxseed
75803003|NCT03734510|Other|control|no supplementation
75942639|NCT02362958|Drug|lapatinib and capecitabine or vinorelbine|lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
75942640|NCT04973800|Drug|Simvastatin 20mg|Simvastatin 20mg ON PO for 28-30 days
75942641|NCT04973800|Drug|Placebo|Sucrose placebo ON PO for 28-30 days
75942642|NCT03662867|Behavioral|Family-based mindfulness intervention|"For the parent program of family-based mindfulness intervention, the content includes: guide body scan practice; guide stretching exercise and mindful breathing; guide practice of mindfulness to breath and body; teach three-minute breathing exercise; guide joint session and let parents practice mindfulness with children; guide mindfulness practice of exploring difficulties; and teach loving-kindness practice.~For the child program, the content includes: guide mindful breathing exercise; guide mindful movement exercises; use stories of animal characters to guide body scan exercise; guide mindful eating and mindful walking exercise; tell stories about different emotions and guide discussion; guide the imagination exercise about different emotions; and guide loving-kindness practice."
75476610|NCT05923476|Drug|Lithium|Placebo + ECT
75476611|NCT05923268|Drug|[99mTc]Tc-G3-(G3S)3C|One single injection of [99mTc]Tc-G3-(G3S)3C, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours
75803004|NCT03731390|Drug|GR1405 injection|Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
75803005|NCT03601052|Drug|Remlarsen|Intradermal injection at site of one excisional wound
75803006|NCT03601052|Drug|Placebo|Intradermal injection at site of second excisional wound
75803007|NCT03600740|Device|DBS Programming|DBS Programming may be temporarily altered based on imaging data to measure a change in clinical symptoms.
75803008|NCT03600428|Biological|Live Attenuated Influenza Vaccine (LAIV)|1 dose, 0.2 mL, intranasal administration
75803009|NCT03600428|Biological|Inactivated Influenza Vaccine (IIV)|1 dose, 0.5 mL, intramuscular administration
75803010|NCT03729440|Behavioral|development of complications or not|assessment of development of complications
75803011|NCT03575702|Drug|Uritos®|film-coated tablets 0.1 mg
75803012|NCT03575702|Drug|Urotol®|film coated tablets, 2 mg
75476612|NCT05912920|Procedure|gastric band|gastric band
75476613|NCT05911789|Radiation|Online adaptive radiation therapy|A dose of 45Gy will be delivered to planning target volume (PTV)
75476614|NCT05910788|Device|high flow nasal cannula|"The purpose of this intervention is clarify the benefit with the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications.~is to clarify whether there is benefit from the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications."
75656009|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
75656010|NCT02809170|Dietary Supplement|Arginine|Arginine is an amino acids
75656011|NCT02809170|Dietary Supplement|Citrulline|Citrulline is an amino acid
75656012|NCT00837109|Behavioral|Veteran Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
75656013|NCT00837109|Behavioral|Treatment-as-usual|Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
75803013|NCT05665400|Device|Bloomlife Lovelace FT|Bloomlife Lovelace FT is a non-invasive, wireless, external measurement system used to measure accelerometer and electrophysiological signals on pregnant women with a singleton pregnancy, by acquiring biopotential signals from abdominal surface electrodes.
75803014|NCT03639896|Drug|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
75803015|NCT03639896|Drug|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
75803016|NCT03573908|Drug|Linaclotide|Oral capsule
75803017|NCT03573908|Drug|Placebo|Matching placebo oral capsule
75803018|NCT03734432|Device|IGAR-Breast TeleOp|Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.
75803019|NCT03573830|Behavioral|Transport Canada material|The current Transport Canada booster seat education material focuses on imparting guidelines; that is, it describes, in plain language, the minimum and maximum ages, heights, and weights to determine when a child should use a booster seat, and when it is safe for a child to use only the seat belt. This material does not describe the principle of operation of seat belts (i.e., redirecting crash forces to the rib cage and pelvis), nor the principle of operation of booster seats (i.e., ensuring the seat belt is placed correctly across the chest and hips).
75803020|NCT03573830|Behavioral|Enhanced material|Enhancements to the booster seat education material were developed based on the hypothesis that parents would better appreciate the additional injury risk reduction afforded by booster seats, if they understand that: (1) seat belts prevent injuries by redirecting crash forces to stronger parts of the body (i.e., rib cage and pelvis); and (2), without booster seats, children would wear the seat belt on their abdomen and neck, which directs crash forces to more vulnerable anatomical structures (i.e., internal organs and spine).
75803021|NCT03729284|Drug|Cymbalta Capsules|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
75803022|NCT03729284|Drug|Duloxetine Hydrochloride Capsules|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
75803023|NCT03729128|Drug|dextromethorphan and memantine (DM+MM)|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.
75803024|NCT03729128|Drug|Placebos|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
75803025|NCT03731312|Other|No intervention|This is an observational study and no interventions will be administered.
75803026|NCT03595904|Behavioral|E-Motivate group|Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders). They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy. The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).
75803027|NCT03595904|Behavioral|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy. In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
75803028|NCT03621020|Diagnostic Test|T-TAS 01 PL Chip|Flow chamber microchip system specific for measuring primary hemostatic ability
75803029|NCT03621020|Diagnostic Test|PFA-100 Col/Epi and Col/ADP|System for measuring platelet dysfunction
75803030|NCT03731078|Other|CBT Informed physical therapy Intervention|The 12 physical therapy sessions delivered in Massachusetts General Hospital outpatient physical therapy sites sessions include:1) evaluation and education; 2) strategy identification and goal setting; 3) functional strengthening part one; 4) functional strengthening part two; 5) pre-gait activities with distraction; 6) gait training with distraction and use of strategies; 7) minimizing tremor with use of strategies; 8) higher level balance training; 9) functional reintegration part one; 10) functional reintegration part two; 11) identification of strategies to limit recurrence; 12) education for relapse prevention.Patients will also be given and asked to complete the self-guided CBT workbookL Overcoming Functional Neurological Symptoms: A Five Area Approach. They will be asked to complete the first two chapters over the first 4 weeks and the remaining 8 chapters over the following 8 weeks.
76090968|NCT02716584|Behavioral|Stretching exercise|Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
76090969|NCT02061748|Drug|Observational|Retrospective Chart Review
75476615|NCT05909046|Diagnostic Test|Immediate inpatient postpartum OGTT|The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
75942643|NCT03662867|Other|Wait-list|No intervention is given between T1 and T2. Family-based mindfulness intervention would be received after posttest of intervention groups.
75942644|NCT03662243|Behavioral|Multicomponent reading and writing treatment|Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
75942645|NCT03662555|Device|Neuromuscular electrical stimulation|"Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions."
75942646|NCT03662165|Behavioral|Intervention|"A text was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority. Participants who came to any North Star clinic in Kenya in the intervention arm were given a demonstration of the self-testing kit and then offered a choice among (1) the standard provider-administered blood-based HIV test; (2) the self-administered oral HIV test for use in the clinic with provider supervision; or (3) the self-administered oral HIV test kit for home use with phone-based post-test counseling."
75942647|NCT03662165|Behavioral|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the enhanced SOC arm only offered the standard provider-administered blood-based HIV test."
75942648|NCT03662165|Behavioral|Traditional Standard of Care|"Those randomized to the traditional Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent one time in both Kiswahili, then in English and Kiswahili simultaneously. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the traditional SOC arm only offered the standard provider-administered blood-based HIV test."
75942649|NCT02509156|Biological|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
75942650|NCT02509156|Biological|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
75942651|NCT03662087|Combination Product|HMA+DLI|HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days. DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
75942652|NCT03662087|Biological|DLI|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
75942653|NCT03661619|Procedure|Sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
75656014|NCT02809326|Behavioral|17 week Exposure Therapy Control Arm|15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
75803031|NCT03595280|Behavioral|Hookah tobacco risk messages|Mobile multimedia messages consisting of text and imagery conveying the risks of hookah tobacco use.
75476616|NCT05909046|Diagnostic Test|Standard of care 4-12 week postpartum OGTT|Standard of care is 4-12 week outpatient postpartum OGTT
75803032|NCT03729050|Behavioral|Rehabilitation Coordinator in Specialist Psychiatry|Rehabilitation Coordinator service in Specialist Psychiatry
75803033|NCT03734276|Other|High intensity activity|Cyclo-ergometer session in high intensity setting
75803034|NCT03734276|Other|control arm|Usual care
75942654|NCT03661619|Procedure|Sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
76090970|NCT03295812|Other|standard therapy|standard therapy,non-interventional study
75476617|NCT05903560|Procedure|endovascular recanalization via radial approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach
75476618|NCT05903560|Procedure|endovascular recanalization via femoral approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach
75803035|NCT03593876|Behavioral|Strategy Training|This study will use an adapted form of strategy training for people with communication impairments.
75803036|NCT03734120|Other|cryopreservation|Samples were frozen with a programmable freezing unit. Each semen sample was divided into two aliquots. One aliquot was plunged into liquid nitrogen and the other was stored in dry-phase nitrogen for 3 or 6 month. Thawing was performed at room temperature
75942655|NCT03661931|Diagnostic Test|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a brief User Experience Questionnaire for each dietary assessment method.
75942656|NCT01654666|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
75942657|NCT01654666|Procedure|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
76090971|NCT03999996|Biological|Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)|TDV subcutaneous injection
76090972|NCT03999996|Biological|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
76090973|NCT03295656|Drug|Sulfur hexafluoride lipid-type A microspheres|Contrast-enhanced US imaging of the appendix
76090974|NCT02463318|Drug|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
76090975|NCT02463318|Other|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
75345040|NCT01368653|Drug|Very low nicotine cigarettes|This intervention will be offered to a subset of smokers from both of the other study arms. To be eligible for this intervention, participants must be smoking at the follow-up interview conducted four weeks after a target quit day in the two arms listed above. Tobacco cigarettes containing very low levels of nicotine (.016-.019 mg in smoke from the cigarettes). These are to be smoked no more often than a smoker normally smokes regular cigarettes and for no longer than 6 weeks.
75345041|NCT01407107|Drug|Nitroglycerin 0.2 MG/HR|0.2mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr).
75345042|NCT01407107|Drug|Nitroglycerin 0.4 MG/HR|0.4mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients.
75345043|NCT01407107|Drug|Nitroglycerin 0.6 MG/HR|0.6mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients and if this is well tolerated an even higher dose patch (0.6mg/hr) will be used.
75656015|NCT02809326|Behavioral|Trauma Management Therapy|TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
75803037|NCT03728894|Drug|Midazolam-hydroxyzine with 100% O2|Patients received Oral Sedatives with 100% O2 ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
75803038|NCT03728894|Drug|Midazolam-hydroxyzine with 50% N2O/O2|Patients received Oral Sedatives with 50% nitrous ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
76090976|NCT01436968|Biological|Aglatimagene besadenovec + valacyclovir|"Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~The second injection will be 0-3 days before initiation of radiation therapy.~The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
75345044|NCT01368809|Drug|Saline|2 ml at induction 1-2 ml boluses as needed
75803039|NCT01310426|Other|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
75803040|NCT03730766|Drug|Esomeprazole|Proton pump inhibitor
75803041|NCT03730766|Drug|Amoxicillin|Antibiotics for H. pylori eradication
75803042|NCT03730766|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
75803043|NCT03733964|Procedure|Manual therapy|Manual therapy - the mobilisation of joint segments L4-L5 and L5-S1 and mobilisation techniques for soft tissues (functional massage of soft tissues and skin relaxation using the methods of stretching).
75803044|NCT03733964|Procedure|PNF|The PNF method - the movement patterns of the scapulae and the pelvis were used (anterior and posterior elevations and depression) along with the patterns of upper extremities (e.g. bending, abduction, outward rotation) and lower extremities (e.g. bending, abduction, inward rotation with bending of the knee joint).
75803045|NCT03733964|Procedure|Manual therapy + PNF|Combination therapy - Manual therapy and Proprioceptive Neuromuscular Facilitation
75345045|NCT01368809|Drug|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
75345046|NCT01369745|Drug|Prednisolone|Prednisolone 2.7 mg daily
75345047|NCT01369745|Drug|dipyridamole|dipyridamole 360 mg daily
75345048|NCT01369745|Drug|Prednisone|Prednisone 5 mg daily
75345049|NCT01369745|Drug|Z102|Prednisolone 2.7 mg plus dipyridamole 360 mg daily
75345050|NCT01369745|Other|placebo|
75345051|NCT01475513|Drug|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
75345052|NCT01407575|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
75345053|NCT01407575|Drug|Placebo|matched placebo
75942658|NCT01654666|Procedure|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
75942659|NCT04973332|Device|Intracranial thrombectomy stent|Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset
75942660|NCT04971928|Drug|GSK3228836|GSK3228836 will be administered
75942661|NCT02519842|Drug|Fosaprepitant|
75942662|NCT02519842|Drug|Placebo for fosaprepitant|
75942663|NCT02519842|Drug|Ondansetron|
75803046|NCT03733964|Procedure|Kinesiotherapy|Traditional kinesiotherapy in the form of active slow exercises of back muscles, abdominal and gluteal muscles on a mat. The patients participated in a uniform treatment programme consisting of ten exercises. Each of the exercises was performed in a number of 20 repetitions.
75803047|NCT00071487|Drug|Placebo|Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
75942664|NCT02519842|Drug|Dexamethasone|
76090977|NCT01436968|Biological|Placebo + valacyclovir|"Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~The second injection will be 0-3 days before initiation of radiation therapy.~The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
76090978|NCT02461212|Procedure|Magnetic Resonance Imaging (MRI)|A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
75803048|NCT00071487|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
75942665|NCT02519842|Drug|5-HT3 antagonist|
76090979|NCT02463162|Other|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
76090980|NCT04441866|Diagnostic Test|Automated algorithms|Automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
75345054|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
75345055|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
75345056|NCT01370369|Drug|Testosterone gel (FE 99903)|
75656016|NCT02809326|Behavioral|Intensive 3-Week Trauma Management Therapy|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
75656017|NCT02809248|Device|ZES|stent implantation (zotarolimus eluting stent)
75942666|NCT02509078|Drug|Cisatracurium Besylate|Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
75942667|NCT02993783|Drug|Vedolizumab|Vedolizumab IV infusion
75942668|NCT03661853|Behavioral|Control|60 minute psycho-education on alcohol and drugs.
75942669|NCT03661853|Behavioral|Functional Analysis|"Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use."
75942670|NCT03661853|Behavioral|Cognitive Restructuring|CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.
75942671|NCT03661853|Behavioral|Dealing With Cravings|DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.
75942672|NCT03661775|Drug|Magnesium sulfate administration|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
75942673|NCT04055597|Other|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
75942674|NCT04055597|Other|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
75942675|NCT04055363|Other|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
75942676|NCT03205475|Behavioral|Alternate Coaching and Video Feedback Phase 1|Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)
75942677|NCT03205475|Behavioral|Weekly Coaching in Phase 1|Weekly coaching (live or telehealth)
75942678|NCT03205475|Behavioral|Weekly Coaching plus Intensive Refresher Course Phase 2|Continue weekly coaching with senior trainer and add one week intensive refresher course
76090981|NCT04441866|Diagnostic Test|Standard technique|Standard ultrasound examination without use of automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
75942679|NCT03205475|Behavioral|Weekly Coaching plus Peer Coaching Phase 2|Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity
75656018|NCT02809248|Device|BMS|stent implantation (bare metal stent)
76090982|NCT02462772|Drug|cabotegravir|Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
76090983|NCT02462772|Drug|Placebo|Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
75942680|NCT03205475|Behavioral|Video Feedback Only Phase 2|Receive video feedback and calls only
75942681|NCT03660761|Drug|apatinib|The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.
75942682|NCT03660761|Drug|temodar|dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d
75656019|NCT00837187|Drug|Intravenous dexmedetomidine|100 ug
75803049|NCT00071487|Drug|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
76090984|NCT04441632|Behavioral|Positive feedback|Participants will submit positive feedback comments to their colleagues (anonymously or signed, participant-dependent) through an anonymous survey link, a minimum of twice weekly to 6 uniquely different individuals over a 4 week period (total minimum 24 unique individuals over the study period).
75942683|NCT02993471|Drug|Drug Cocktail|Administered orally
76090985|NCT03295578|Other|Personalized feedback|"The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake."
76090986|NCT03295578|Other|Generic feedback|The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
76090987|NCT03295578|Device|Continuous glucose monitoring device|This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
75942684|NCT02993471|Drug|Ixekizumab|Administered SC
75942685|NCT02988713|Device|Programming|Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
75942686|NCT01068743|Drug|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
75942687|NCT01068743|Drug|metformin|Tablets, Oral, 850 mg, once daily, single dose
76090988|NCT03295422|Procedure|RF ablation PVI alone|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
75345057|NCT01370837|Other|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
75476619|NCT05899634|Behavioral|Defaults|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention). In addition, in this group, participants' online grocery shopping carts will be pre-filled with ingredients corresponding to the provided recipes. They will be told that their cart has been filled with items that can be used to make recipes from the provided recipe cards, and that they can modify it as they like.
75656020|NCT00837187|Drug|Intranasal dexmedetomidine|100 ug
75656021|NCT02809482|Other|Eucaloric feeding|3 days of a diet designed to maintain energy balance
75803050|NCT00071487|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
75803051|NCT03962283|Drug|Rifaximin|Rifaximin 200mcg four times daily
75803052|NCT03962283|Drug|Placebo oral tablet|Placebo Rifaximin four times daily
75803053|NCT03591146|Drug|TLC590|TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
75942688|NCT01068743|Drug|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
75942689|NCT02992691|Drug|20% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
75942690|NCT02992691|Drug|35% w/w sodium bicarbonate|Dentifrice containing 35% w/w sodium bicarbonate.
75942691|NCT02992691|Drug|50% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
75656022|NCT02809482|Other|Overfeeding|3 days of a diet designed to induce a 40% positive energy balance
75656023|NCT00962585|Drug|Placebo|
75656024|NCT00962585|Drug|S-equol|"Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~S-equol 10 mg BID (20 mg total daily dose)~S-equol 50 mg BID (100 mg total daily dose)~S-equol 150 mg BID (300 mg total daily dose)"
75656025|NCT00856453|Behavioral|Home yoga practice|training for and tracking of patient's practice of yoga at home
75656026|NCT00856453|Behavioral|yoga classes|organized out of home classes for yoga
75942692|NCT02992691|Drug|67% w/w sodium bicarbonate|Dentifrice containing 67% w/w sodium bicarbonate.
75942693|NCT02992691|Drug|0% w/w sodium bicarbonate|Dentifrice containing 0% sodium bicarbonate and 1450 parts per million (ppm) fluoride.
75656027|NCT04236960|Biological|Meningococcal Group ACYW135 Conjugate Vaccine|1 dose in Stage 1 (2~55 yrs), 2 doses in Stage 2 (7~23 mos), and 3 doses in Stage 3 (2&3 mos)
75656028|NCT00621985|Drug|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
75803054|NCT03591146|Drug|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg [0.5%, 5mg/mL] x 30mL
75803055|NCT00096447|Drug|lapatinib ditosylate|
75803056|NCT03590366|Biological|B244|B244 Suspension
75803057|NCT03590366|Biological|Vehicle|Vehicle suspension
75803058|NCT03728738|Procedure|Head of Bed Positioning|The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
75803059|NCT03728660|Device|Virtual bioptic magnification with large field of view|The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).
75803060|NCT03728660|Device|Full field magnification with small field of view|Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
75803061|NCT03733808|Device|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
75803062|NCT03730532|Other|Cognitive Behavioural Therapy Guided Self Help|6-week manualised Cognitive Behavioural Therapy Guided Self Help
75803063|NCT03730532|Other|Cognitive Analytic Therapy Guided Self Help|6-week manualised Cognitive Analytic Therapy Guided Self Help
75803064|NCT03588572|Drug|Venlafaxine hydrochloride capsules|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
75803065|NCT00090285|Biological|(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
75803066|NCT00090285|Biological|Comparator: placebo (unspecified)|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
75803067|NCT00070941|Drug|SAM-e|oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo escitalopram.
75803068|NCT00070941|Drug|oral escitalopram|20mg or 30mg daily in two divided doses, along with placebo SAM-e.
75803069|NCT00070941|Drug|placebo|oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
75942694|NCT03622541|Drug|Sorafenib 200mg|Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
75656029|NCT00621985|Drug|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
75803070|NCT03960489|Drug|Roxadustat|Participants will receive single dose of 100 mg azo dye free tablet or mini tablet suspension or solid mini tablet or dye containing tablet.
75803071|NCT00070707|Drug|Mometasone|Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.
75942695|NCT03658733|Drug|esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
75803072|NCT00070707|Drug|Placebo|Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
75803073|NCT00070707|Drug|Albuterol/Salbutamol|Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
75803074|NCT01082523|Other|Text message reminders|Subjects in this arm will receive twice daily automated text messages reminding them to apply their medications.
75803075|NCT01082601|Procedure|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
75803076|NCT03036124|Drug|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
75803077|NCT03036124|Drug|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg.
75803078|NCT00070317|Drug|Isosulfan Blue|Undergo lymphangiography using isosulfan blue or methylene blue
75803079|NCT00070317|Procedure|Lymph Node Mapping|Undergo lymphatic mapping
75803080|NCT00070317|Procedure|Lymphangiography|Undergo lymphangiography using isosulfan blue or methylene blue
75803081|NCT00070317|Drug|Methylene Blue|Undergo lymphangiography using isosulfan blue or methylene blue
75803082|NCT00070317|Procedure|Radionuclide Imaging|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
75803083|NCT00070317|Procedure|Sentinel Lymph Node Biopsy|Undergo complete pelvic and low para-aortic lymphadenectomy
75803084|NCT00070317|Radiation|Technetium Tc-99m Sulfur Colloid|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
75803085|NCT00070317|Procedure|Therapeutic Conventional Surgery|Undergo radical hysterectomy
75803086|NCT01086345|Radiation|radiosurgery|Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
75803087|NCT01086345|Biological|bevacizumab|Given IV
75803088|NCT01086345|Drug|irinotecan hydrochloride|Given IV
75803089|NCT03960411|Drug|Doxycycline 100Mg Capsule|Doxycycline capsule
75942696|NCT03658733|Drug|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
75942697|NCT02921087|Device|Test Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
75942698|NCT02921087|Device|Control Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
75942699|NCT03660605|Other|Rhythmic Auditory Stimulation|Participants will complete 6 weeks of walking training (3x/week). During each session, participants will walk on a treadmill for up to 20 minutes (stepping to a metronome at 85% of typical cadence) followed by overground walking for up to 15 minutes (stepping to a metronome at 115% of typical cadence).
76090989|NCT03295422|Procedure|RF ablation PVI plus LPAW|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
75942700|NCT04056143|Diagnostic Test|Pharmacogenomics|Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.
76090990|NCT03297528|Drug|donor lymphocyte infusion|Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
75656030|NCT02812368|Drug|Clonidine|
75656031|NCT02812368|Drug|Placebo (for clonidine)|Placebo pill manufactured to mimic clonidine
75656032|NCT02545621|Other|RAGE TXNIP Inflammasome axis|
75656033|NCT02547805|Drug|ALLN-177|ALLN-177 7,500 units (5 capsules) PO TID with meals
75656034|NCT02547805|Drug|Placebo|Placebo 5 capsules PO TID with meals
75656035|NCT02814552|Other|HTN PRA App|The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.
75656036|NCT02814552|Other|Blood Sample|Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
75942701|NCT03658655|Biological|Stem Cells From Human Exfoliated Teeth|"Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline."
76090991|NCT02062606|Device|MESA Rail™ Deformity System|MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
76090992|NCT02063230|Drug|Selumetinib 50mg|HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
76090993|NCT02063230|Drug|Selumetinib 25mg|Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
76090994|NCT02000908|Device|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
76090995|NCT02000908|Other|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
75656037|NCT02544841|Behavioral|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
75656038|NCT02544841|Behavioral|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
75656039|NCT02861729|Other|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
75656040|NCT02861729|Other|IPS e.max|lithium disilicate partial coverage restorations
75656041|NCT02814318|Biological|Vaginal and rectovaginal swab cultures|The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
75656042|NCT02808000|Device|BIP Foley (latex) or BIP Foley -silicone|
75656043|NCT02808000|Device|Standard catheter|
75656044|NCT03312257|Combination Product|Multifocal D +2.50 add & 0.01% atropine|Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
75656045|NCT00856687|Drug|PF-03893787|Oral, two doses 12 hours apart
75656046|NCT00856687|Drug|Placebo|Oral, two doses 12 hours apart
75656047|NCT00856687|Drug|Montelukast|Oral, two doses 12 hours apart
75942702|NCT03661463|Drug|Aspirin|Drug
75942703|NCT03660527|Other|Not refered|No intervention was refered.
75942704|NCT03622463|Drug|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
75942705|NCT03622463|Other|Placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
75942706|NCT03658499|Behavioral|two day skills group plus treatment adjuncts|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.
75942707|NCT03658499|Behavioral|two day skills group control group|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
75942708|NCT03661229|Device|CVInsight Monitoring|All participants (n=50) will receive CVInsight non-contact device and CVInsight contact device application during two of their regularly scheduled dialysis sessions.
75942709|NCT03658421|Drug|Dexmedetomidine|Dexmedetomidine added to lower concentration of ropivacaine for postoperative analgesia in FNB
75942710|NCT03658421|Procedure|ultrasound-guided femoral nerve block|ultrasound-guided femoral nerve block, a single bolous of 20 ml ropivacaine (concentration 0.2% for H group or 0.1% for L group) before surgery followed by continuous femoral nerve block using an infusion rate of ropivacaine 0.2% 5 ml/h for postoperative analgesia started right after surgery
75942711|NCT03658421|Device|intravenous patient-controlled analgesia pump with morphine|All subjects received intravenous patient-controlled analgesia (IV-PCA) pumps to measure additional morphine consumption, which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
75942712|NCT03658421|Procedure|Continuous femoral nerve block|All the continuous femoral nerve block infusion regimes in the pump were connected to CFNB catheter, which contained only ropivacaine with different concentrations (ropivacaine 0.1% for L group and LD group; ropivacaine 0.2% for H group, 5 ml/h).
75942713|NCT02991521|Procedure|Fast exam|Positional change before Fast exam
75345058|NCT01370837|Other|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
75656048|NCT02862665|Drug|iron isomaltoside 1000 (Monofer®)|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
75656049|NCT02862665|Drug|normal saline 100 ml|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
75656050|NCT02807922|Drug|Zopiclone|
75656051|NCT02807922|Drug|Placebo|
75803090|NCT03960411|Drug|Placebo oral capsule|Capsule manufactured to mimic doxycycline 100 mg capsule
75803091|NCT02531139|Other|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
75803092|NCT02531139|Other|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
75942714|NCT03660293|Drug|Atorvastatin|cardio-protective agents
75942715|NCT03660293|Drug|Captopril|cardio-protective agents
75942716|NCT03660293|Drug|L-carnitine|cardio-protective agents
75345059|NCT01477463|Drug|Vitamin D3|4,000 IU oral vitamin D3
75656052|NCT00861367|Drug|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
75803093|NCT03649412|Drug|GSK2982772 Modified Release|GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
75803094|NCT03649412|Drug|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
75942717|NCT03660137|Device|MOLLI Localization|All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
75345060|NCT01477463|Drug|placebo and vitamin D|
75345061|NCT01410773|Device|Ninja 2 Investigational Blood Glucose Monitoring System|The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
75345062|NCT01478009|Dietary Supplement|Korean red ginseng|Korean red ginseng(3.0g/day) for 12 weeks
75345063|NCT01478009|Dietary Supplement|Placebo|Placebo (3.0g/day) for 12 weeks
75656053|NCT04285073|Device|Paclitaxel-eluting graft|Implantation of e-PTFE Grafts inner surface-treated with paclitaxel as access for hemodialysis
75656054|NCT00861445|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
75656055|NCT00861445|Other|Placebo|Placebo tablets two times a day for 10 weeks
75656056|NCT04284059|Drug|Placebos|Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
75656057|NCT04284059|Dietary Supplement|vitamin AD|A vitamin AD capsule contains vitamin A 2000 IU and vitamin D 700 IU. The patients need to administrate 3 capsules once a day for 8 weeks.
75942718|NCT02907619|Biological|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
75942719|NCT02986373|Biological|risankizumab|Risankizumab administered by subcutaneous injection.
75942720|NCT03659903|Procedure|pancreaticoduodenectomy|pancreaticoduodenectomy
75345064|NCT02203565|Drug|Dakin's solution|Applied topically
75345065|NCT02203565|Radiation|radiation therapy|Undergo radiation therapy
75942721|NCT02986139|Drug|Commercial Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.
75942722|NCT02986139|Drug|New Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
75942723|NCT02989805|Behavioral|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
75942724|NCT03622255|Procedure|MINST|Minimally invasive non-surgical technique (MINST) for the treatment of intrabony defects has been compared with minimally invasive surgical treatment of these defects and has shown to achieve similar beneficial clinical results. In this study MINST will be used as the control treatment.
75942725|NCT03622255|Procedure|MINST with EMD|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal intrabony defects, using a minimally invasive surgical technique (MINST). Recent studies have suggested that this product could also be used in the non-surgical treatment of intrabony defects using a minimally invasive technique with very good results. This study will evaluate the effect of enamel matrix derivative in the non-surgical treatment of periodontal intrabony defects when a minimally invasive technique is used. Besides clinical measurements, radiographic analysis will also be performed to evaluate the treatment results.
75942726|NCT02236351|Device|Pinch Patch/ flat Patch|
75942727|NCT03659825|Dietary Supplement|Ketone Ester|Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
75942728|NCT03659825|Dietary Supplement|Taste Matched Placebo|Placebo that tastes similar to active intervention
75942729|NCT03659825|Other|Hypoxic exposure|Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
75942730|NCT03659747|Dietary Supplement|Probiotic|- 6 g sachet containing probiotic powder (1.8 x 10^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
75803095|NCT01326897|Behavioral|Healthy Homes/Healthy Families|"Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings."
75942731|NCT03659747|Dietary Supplement|Lactrase|- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
75942732|NCT03659747|Other|Placebo|- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
75942733|NCT03658265|Other|7 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
75345066|NCT02203565|Other|questionnaire administration|Ancillary studies
75942734|NCT03658265|Other|7 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
75942735|NCT03658265|Other|3 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
75942736|NCT03658265|Other|3 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
75942737|NCT03658187|Dietary Supplement|Placebo|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
75942738|NCT03658187|Dietary Supplement|IP|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
75942739|NCT03659591|Behavioral|Cognitive Behaviour Therapy|CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
75942740|NCT03659591|Behavioral|Adaptive Psychological Training|APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
75345067|NCT02203565|Other|laboratory biomarker analysis|Optional correlative studies
75345068|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
75656058|NCT04284059|Dietary Supplement|vitamin D|A vitamin D capsule contains vitamin D 400 IU. The patients need to asministrate 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks.
75656059|NCT00856765|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
75656060|NCT00856765|Device|Bare metal stent|Bare metal stent
75656061|NCT00856765|Device|Drug eluting stent|Paclitaxel eluting stent
75656062|NCT00852709|Drug|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
75803096|NCT01326897|Behavioral|Health Education|Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
75803097|NCT03962049|Drug|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
75803098|NCT01090167|Drug|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
75345069|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
75345070|NCT02960204|Drug|Emricasan|
75345071|NCT02960204|Drug|Placebo|
75345072|NCT02152826|Device|Potassium oxalate|Professional application
75942741|NCT03656497|Other|Observational|No intervention is conducted as the study aim is to explore the link between pheno- and genetype of trigeminal neuralgia
75942742|NCT03656419|Procedure|photodynamic therapy|aPDT with methylene blue and red led irradiation.
75942743|NCT03656419|Procedure|Tongue scraper|Tongue scraper 10 times from de back to the top.
75942744|NCT04295395|Device|NONIN SenSmart model X-100 near- infrared spectrometer|for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank
75942745|NCT02906917|Drug|Insulin degludec/insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
75942746|NCT02906917|Drug|Insulin glargine|Administered subcutaneously (s.c. under the skin) once daily.
75942747|NCT02906917|Drug|Insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
75942748|NCT03656341|Behavioral|2 Feet 4 Life|2 Feet 4 Life consists of four weekly group intervention sessions of one hour each. 2 Feet 4 Life includes self-management teaching, interactive lecture, and group activities, including instruction and demonstration of routine foot care. The program includes education regarding appropriate footwear and how to find it, evidenced based practices on hygiene, skin care and self-care of the lower extremities, nail trimming and filing, and care of common foot problems.
75942749|NCT03656263|Diagnostic Test|Doppler assessment of portal vein flow|Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.
75942750|NCT03655795|Biological|Bronchial basal cells|Autologous transplantation of bronchial basal cells
75942751|NCT02982187|Device|Placebo ELLIPTA|It is a dry powder inhaler device that can hold two individual blisters: one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
75345073|NCT00857714|Drug|lapatinib|1500 mg lapatinib for 14-21 days
76090996|NCT02000908|Other|Physiotherapy|Chiropractic massage and lymphedema treatment
76090997|NCT02716194|Biological|BAX 826|
75656063|NCT00852709|Drug|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
76090998|NCT02716194|Biological|Octocog alfa|
75656064|NCT05612256|Diagnostic Test|Electrical impedance tomography (EIT)|EIT is the measurement of impedance changes of the lung against the flow of alternating electrical currents applied to the thorax. The signal of the electrodes is transmitted to a monitor, which enables real-time assessment of lung aeration and changes in lung volume. EIT is able to reconstruct impedance changes with a high temporal resolution and allows calculation of tidal volumes, relative stretch of lung tissue and areas of poor ventilation. Areas with impedance changes of < 10 % of the maximum impedance changes are called 'Silent Spaces'.
75803099|NCT05109130|Procedure|Surgical approach|Different surgical methods for rectal cancer resection
75803100|NCT03772444|Dietary Supplement|Beetroot juice|Patients will drink 70 ml of beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
76090999|NCT02002702|Drug|Serelaxin|Intravenous infusion
75345074|NCT02839148|Dietary Supplement|Food supplementation|"Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS."
75345075|NCT00858494|Drug|Hyland's Cold 'n Cough 4 Kids|Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
75803101|NCT03772444|Dietary Supplement|Nitrate-depleted beetroot juice|Patients will drink 70 ml of nitrate-depleted beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
75803102|NCT03772444|Dietary Supplement|Water|Patients will drink 70 ml of water in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
75656065|NCT05612256|Diagnostic Test|Forced oscillation technique (FOT)|FOT enables non-invasive assessment of lung mechanics using sound waves to inform about the respiratory impedance of the respiratory system (Zrs). Reactance of the respiratory system (Xrs) as part of Zrs is a surrogate measure of compliance of the respiratory system. Xrs was previously used to identify optimal PEEP level, i.e., the PEEP at highest compliance equivalent, in newborn infants using a setup requiring research-specific hardware and software. The FOT module integrated in the commercially available neonatal ventilator is routinely used. FOT measurements are performed twice at each PEEP level to assess the reproducibility of the measurements.
75803103|NCT03587636|Drug|liposome bupivacaine|interscalene block with liposomal bupivacaine plus bupivacaine
75803104|NCT03587636|Drug|Bupivacaine|interscalene block with bupivacaine
75942752|NCT02982187|Device|Placebo DISKUS|It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate.
75942753|NCT02982187|Device|Placebo TURBUHALER|It is a placebo dry powder inhaler containing lactose monohydrate.
75942754|NCT02982187|Device|Placebo HANDIHALER|Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device.
75942755|NCT02982187|Other|PQ1|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
75942756|NCT02982187|Other|PQ2|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
76091000|NCT02002702|Drug|Placebo|Placebo
76091001|NCT02002936|Drug|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
75942757|NCT02982187|Other|PQ3|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
75942758|NCT02982187|Other|PQ4|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
75942759|NCT03655483|Drug|GLS-010|Full-human anti-pd-1 monoclonal antibodies
75942760|NCT02981953|Device|Cardioband Tricuspid|The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
75942761|NCT03656653|Behavioral|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder
75942762|NCT03655873|Drug|HEC30654AcOH capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.~Multiple ascending-dose study:~15-、30-、60mgHEC30654AcOH capsule in day1-day7，2 times everyday."
75942763|NCT03655873|Drug|Placebo capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.~Multiple ascending-dose study:~15-、30-、60mg placebo capsule in day1-day7，2 times everyday."
75803105|NCT03730376|Other|Cost Information|participants will be given information on the personal and societal costs
75803106|NCT03053362|Drug|Vortioxetine|Observing change in cognition using THINC-it tool in patients with MDD.
75942764|NCT03655327|Other|reach to grasp a cup|reach to grasp a cup of different weights located at different heights of table
75942765|NCT03655249|Other|Autogenic drainage|Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity.
75656066|NCT05612256|Diagnostic Test|Saturation oxygenation pressure index (SOPI)|SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
76091002|NCT02461056|Drug|Ibuprofen|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
75656067|NCT03242447|Behavioral|e-Practice Self-Regulation|e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
75656068|NCT03242447|Behavioral|Video Health Group|The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
76091003|NCT02461056|Drug|Hydromorphone|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
76091004|NCT02003404|Device|Control Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
75656069|NCT00861523|Drug|thiamine & promethazine|thiamine 100 mg IV promethazine 25 mg IV
75345076|NCT00858962|Drug|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
75656070|NCT02811978|Drug|Bortezomib|Participants will receive 1.3 mg/m^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.
75656071|NCT02811978|Drug|Dexamethasone|Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
75656072|NCT00630149|Drug|Pemetrexed (Alimta)|500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.
75656073|NCT02812056|Drug|Alisertib|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
75656074|NCT02812056|Drug|TAK-228|"Dose Escalation Phase:~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
75803107|NCT03053362|Other|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
75803108|NCT03733652|Drug|Interferon Alfa 2a|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
75803109|NCT03586544|Drug|Albuterol Sulfate|Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
75942766|NCT03655249|Drug|Aerosoltherapy|Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
75942767|NCT03655171|Diagnostic Test|Video-based quantitative methods|The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.
75966012|NCT02083211|Device|Placebo|This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
76091005|NCT02003404|Device|Peristomal Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
76091006|NCT05229978|Other|Showing an existing Dynamic Consent (computer interface) as prompt|An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.
75345077|NCT03839810|Other|stochastic resonance electrical stimulation|"stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training"
75656075|NCT04283825|Behavioral|Psychological and physical rehabilitation based humanistic care|This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.
75656076|NCT04042207|Device|Low Glucose Predictive Suspend system|consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
75656077|NCT04042207|Device|DBLHU System|DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
75656078|NCT04204577|Drug|Apatinib Mesylate|Evaluation of the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for advanced liver cancer.
75656079|NCT02809092|Biological|NK Cells + Chemotherapy Starting|"Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.~Other Names:~Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m^2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
75803110|NCT03586544|Behavioral|Interval Warm-up exercise|Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
75803111|NCT03730298|Dietary Supplement|American Ginseng|cpr
75803112|NCT03730298|Other|Placebo|cpr
75803113|NCT03737448|Drug|Trimetazidine|Subjects with receive up to 60 mg daily
75803114|NCT03585296|Drug|ATI-502|Topical Solution
75803115|NCT03728270|Device|Patient Specific Titanium Eminoplasty|"The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~A multilayer closure of the incisions will be accomplished using Vicryl"
75803116|NCT03728270|Procedure|Inlay Autogenous Bone Graft|"* Steps to harvest the bone graft:~Down-fracture of the articular eminence to be augmented with Inlay bone graft to increase the vertical height of the articular eminence. A green-stick fracture will be created avoiding a possible complete fracture of the lower segment of the eminence~To obtain Inlay bone graft from the chin, anterior mandibular vestibule incision will provide good access to the mandibular symphysis."
75803117|NCT03748056|Behavioral|Targeted incentives|Participants receiving individually-targeted incentives will receive weekly coupons for healthier foods that are informed by their purchase history, responses to behavioral and health questions, food preferences, and need for improvement in different categories
75803118|NCT03748056|Behavioral|Nominal loyalty card discount and nutrition education|All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
75803119|NCT03733574|Drug|LY03005|Drug: LY03005 80 mg, oral tablets, single dose
75803120|NCT03733574|Drug|Pristiq|Drug: Pristiq 50 mg, oral tablets, single dose
75803121|NCT03728192|Other|mangosteen extract|For Mangosteen group :DNA fragmentation assay is used to identify apoptosis.1×106 cells were harvested and treated with mangosteen pericarp extract for 48 h For Camptothecin group : Cells were also treated with standard anticancer drug Camptothecin to act as a positive control.
75966013|NCT02307370|Device|Turbo-Elite Laser Catheter|Application of laser energy to remove blockage
75966014|NCT05483777|Procedure|PRF|Platelet-rich fibrin preparation and application technique will applied to the experimental group.
75966015|NCT03557645|Device|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV).
75966016|NCT03557645|Device|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory pause.
75966017|NCT03557645|Device|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) without an inspiratory pause.
76091007|NCT01173172|Radiation|Boron Neutron Capture Therapy|Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
76091008|NCT00003270|Biological|anti-thymocyte globulin|IV
76091009|NCT00003270|Biological|filgrastim|IV
75345078|NCT01376297|Drug|Netupitant and Palonosetron|
75345079|NCT01376297|Drug|Aprepitant|
75345080|NCT01376297|Drug|Palonosetron|
75345081|NCT01376297|Drug|Dexamethasone|
75345082|NCT00859040|Drug|SOM230C|Injection in the buttocks every 28 days
76091010|NCT00003270|Drug|busulfan|IV
76091011|NCT00003270|Drug|cyclophosphamide|IV
76091012|NCT00003270|Drug|cyclosporine|IV
76091013|NCT00003270|Drug|methylprednisolone|IV
76091014|NCT00003270|Procedure|bone marrow ablation with stem cell support|IV
75803122|NCT03589768|Biological|Tetanus and Diphtheria Toxoids Adsorbed|Used for active immunization of adults and children 7 years of age and older against diphtheria and tetanus.
75803123|NCT03589768|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide|A sterile isotonic suspension of tetanus and diphtheria toxoids and pertussis antigens adsorbed on Aluminum hydroxide.
75803124|NCT03733340|Drug|Imipenem|Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin
75803125|NCT03730142|Drug|WXFL10030390|WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
75803126|NCT02892422|Drug|Lu AF35700|"Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.~From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)~Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study"
75803127|NCT03728114|Device|RIC|Adults allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
75803128|NCT03728114|Device|sham RIC|Adults allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
75803129|NCT03571646|Behavioral|Capnostream 20 monitoring|Continuous monitoring on a general ward
75803130|NCT03571646|Device|PM1000N-RR monitoring|Continuous monitoring on a general ward
75803131|NCT05183308|Drug|Clodronic Acid|Osteoporotic fracture treated with surgical and medical therapy
76091015|NCT00003270|Procedure|umbilical cord blood transplantation|IV
76091016|NCT00003270|Radiation|radiation therapy|High energy X-rays
76091017|NCT02005354|Device|Trans-cutaneous Electrical Nerve Stimulation (TENS)|Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (>50Hz and below the pain threshold for the patient).
75345083|NCT00859508|Device|SyntheCel|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
75345084|NCT00859508|Device|Other FDA cleared dura replacements|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
75345085|NCT01377467|Drug|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
75345086|NCT02348762|Dietary Supplement|Cysteine (as n-acetylcysteine) and Glycine|Older subjects will be studied before and after receiving cysteine and glycine
75345087|NCT00859976|Device|BoneMaster coated acetabular shell.|Bonemaster coated Exceed Acetabular Shell
75345088|NCT00859976|Device|Plasma Coated Acetabular Shell|Plasma HA coated Exceed Acetabular Shell
75345089|NCT01377623|Drug|Dexmedetomidine group|Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
75345090|NCT01377623|Drug|Placebo group|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
75345091|NCT01479725|Procedure|HBOT|HBOT
75345092|NCT01481129|Drug|Akt Inhibitor MK2206|Given PO
75345093|NCT01481129|Other|Laboratory Biomarker Analysis|Correlative studies
75345094|NCT01481129|Other|Pharmacological Study|Correlative studies
75345095|NCT03008447|Drug|LEM5|Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.
75345096|NCT03008447|Drug|LEM10|Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.
75345097|NCT03008447|Drug|ZOL|Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.
75345098|NCT03008447|Drug|PBO|Single dose of placebo administered within 5 minutes before bedtime.
75345099|NCT01486043|Drug|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
75354666|NCT04797611|Device|Non-invasive brainstem stimulation|Study participants will self-administer ~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
75656080|NCT04041193|Behavioral|SIDERA^B|The group will receive a kit home-based (a tablet home, access to a daily individualized training program). Five sessions for a week (3 components: monitoring, motor rehabilitation acitivities, motivational support)
75656081|NCT04041193|Behavioral|Usual Care Program|Usual Care program activities (paper and pencil at home)
75656082|NCT02862587|Drug|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
75656083|NCT02862587|Biological|precision cells|precision cells DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
75656084|NCT00852787|Drug|Digoxin immune fab|Intravenously one time
76091018|NCT02005354|Drug|Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)|All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
75942768|NCT03655093|Other|Validation of AMSQ questionnaire|"Participation in the study will be proposed to any patient meeting the inclusion criteria and consulting a neurologist from the SEP reference center of the University Hospital of Rennes.~The neurologist will explain the purpose of the study to the patient, give him the information form.~Without opposition from the patient, the neurologist will give him the self-questionnaire. The patient will fill it during the consultation. In case of disability to the upper limbs making it impossible to fill the questionnaire by the patient, it will be filled by the neurologist or the patient's companion, according to the answers given by the patient.~While the patient completes the questionnaire, a record of clinical information will be filled in by the neurologist.~No additional act will be performed except the questionnaire, which result will not change the patient's management."
75942769|NCT02021071|Radiation|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
75942770|NCT02021071|Radiation|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
75656085|NCT00852787|Drug|Placebo|Intravenously one time
75803132|NCT05137600|Drug|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
75803133|NCT05137600|Drug|Midazolam|Midazolam is a sensitive CYP3A index substrate
75803134|NCT05137600|Drug|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
75942771|NCT03654937|Biological|Influenza Vaccination|"Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH & Co. KG, Munich, Germany, batch: AFLBA 152AB."
75942772|NCT01066585|Drug|Ivermectin Cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
75345100|NCT03007901|Behavioral|Mindful Climate Action|Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (~30 min) relating to climate change, energy use, and carbon footprint.
75942773|NCT01066585|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
75942774|NCT03654781|Drug|Triple therapy|triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)
75942775|NCT03654781|Procedure|professional periodontal treatment|periodontal treatment consisting of mechanical periodontal treatment (scaling and root planing) Oral hygiene insruction Periodontal treatment started concurrently with triple therapy
75942776|NCT03654703|Drug|Cyclophosphamide|cyclophophamide
75942777|NCT02980783|Device|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
76091019|NCT03290898|Behavioral|High Intensity Interval Training|Training (HIIT)
75345101|NCT03008525|Biological|subcutaneous and visceral adipose tissue biopsies|Subcutaneous and visceral adipose tissue biopsies during operation
75656086|NCT00634452|Biological|MDX-1401|IV weekly for 4 weeks
75803135|NCT03645434|Drug|AZD8871|Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.
75803136|NCT03645434|Drug|Anoro® Ellipta®|Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
75345102|NCT03008525|Biological|blood samples analysis|"Blood sampling is required to measure plasma cholecalciferol, calcidiol and calcitriol concentrations, as well as biological parameters of interest.~Another plasma/serum tube is used to measure pro- and anti-inflammatory cytokines and adiponectin."
75656087|NCT02545465|Drug|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
75656088|NCT02808936|Procedure|Remote ischemic preconditioning|three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff
75656089|NCT02808936|Procedure|Sham control|The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
75656090|NCT04041271|Other|Cervical range of motion (CROM)|Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.
75656091|NCT04041271|Other|Pressure pain threshold (PPT)|A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.
75656092|NCT04041271|Other|Cranial-cervical angle (CCA)|Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.
75656093|NCT04041271|Other|Jaw kinematics|Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.
75656094|NCT04041271|Other|Muscle activation|Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.
75803137|NCT00089505|Drug|Emtricitabine|200 mg taken orally
75942778|NCT02980705|Drug|SUNPG1622 I dose|Injection
75942779|NCT02980705|Drug|Placebo dose|Injection
75942780|NCT03654625|Behavioral|Standard Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry.
76091020|NCT02066740|Device|EverFlex™ stent with Entrust™ delivery system|
76091021|NCT03290820|Radiation|Radiotherapy|Technique: intensity-modulated radiotherapy; Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
75942781|NCT03654625|Behavioral|Enhanced Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry and rescript it.
75942782|NCT03654625|Behavioral|Control Condition|Four spaced, 30-minute sessions occurring within a period of 2 weeks. At each session, participants write a narrative about a neutral topic.
75942783|NCT02989649|Drug|Alogliptin|Alogliptin tablets
75942784|NCT02989649|Drug|Alogliptin FDC With Pioglitazone|Alogliptin FDC with pioglitazone tablets
75942785|NCT02989649|Drug|Alogliptin FDC With Metformin|Alogliptin FDC with metformin tablets
75942786|NCT03659435|Drug|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
75942787|NCT03659435|Drug|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
75942788|NCT02905435|Device|Biodegradable Temporizing Matrix|The Biodegradable Temporizing Matrix (BTM) (also known as NovoSorb BTM) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
75942789|NCT02978833|Biological|PRP|
75803138|NCT00089505|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
75942790|NCT02978833|Biological|Whole Blood|
75942791|NCT02978833|Device|Ultrasound|
75942792|NCT01067339|Drug|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
75942793|NCT01067339|Drug|placebo|placebo, by mouth, once daily for six months
75942794|NCT02198911|Other|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
75942795|NCT02198911|Other|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
75656095|NCT02811900|Procedure|Roux en Y gastric bypass|Laparoscopic RYGB is performed as following: a gastric pouch of approximately 30mL was obtained using successive firings of the Endo GIATM linear stapler, followed by the creation of an antecolic alimentary limb of 150cm and of a biliopancreatic limb of 75cm. A gastrojejunal anastomosis was fashioned with the PCEEA™ 28 circular stapler until 2012, and using the Endo GIA™ linear stapler afterwards. The mesenteric defect and Petersen's defect were closed using a non-absorbable running suture.
75345103|NCT01490723|Drug|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
75345104|NCT01490723|Drug|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
75656096|NCT02811900|Procedure|Sleeve gastrectomy|Laparoscopic SG is performed as following: after greater curvature mobilization, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using successive firings of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
75803139|NCT00089505|Drug|Lopinavir/Ritonavir|400/100 mg taken orally
75803140|NCT00089505|Drug|Nevirapine|200 mg taken orally
75803141|NCT00089505|Drug|Tenofovir disoproxil fumarate|300 mg taken orally
75803142|NCT05043376|Drug|Standard of care|Standard COVID-19 care as per the hospital guidelines
75803143|NCT05043376|Dietary Supplement|BLIS K12|Daily 2 oral BLIS K12 tablets for up to 14 days.
75803144|NCT04009824|Biological|AGS-v PLUS Vaccine|Administered by subcutaneous injection
75803145|NCT04009824|Biological|Montanide ISA-51 Adjuvant|Administered by subcutaneous injection
75803146|NCT04009824|Biological|Alhydrogel® Adjuvant|Administered by subcutaneous injection
75803147|NCT04009824|Biological|Saline Placebo|Administered by subcutaneous injection
75803148|NCT03727958|Diagnostic Test|Lung and coronary CT assessment|Subjects will undergo simultaneous coronary arteries and thoracic CT assessment
75803149|NCT03727958|Diagnostic Test|Coronary CT assessment|Subjects will undergo coronary arteries CT assessment only
75942796|NCT02198911|Other|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
75942797|NCT03654391|Dietary Supplement|InnoSlim|Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
75942798|NCT03654391|Dietary Supplement|Placebo|Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
75942799|NCT04484675|Drug|Milrinone inhalation|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
75942800|NCT04484675|Drug|Milrinone infusion|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
75942801|NCT03658109|Drug|Lidocaine Bolus Infusion|Patients will undergo Lidocaine Bolus infusion.
75942802|NCT03658109|Procedure|QL block|Patients will undergo a posterior QL block pre-operatively
75942803|NCT03658109|Drug|Saline Bolus Infusion|Patients will undergo Saline Bolus infusion.
75942804|NCT03658109|Procedure|Simulated QL block|Patients will undergo a simulated posterior QL block pre-operatively.
75942805|NCT03654313|Biological|MEDI6570|MEDI6570
75942806|NCT03654313|Biological|Placebo|Placebo
75942807|NCT03654313|Biological|Part B Placebo|Placebo
75803150|NCT05041426|Drug|Letermovir|Participants who are CMV R+ will receive LET prophylaxis for 6 months, and participants who are CMV D+/R- will receive LET prophylaxis for 12 months. The duration of prophylaxis is per current standard of care. LET will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If LET is co-administered with cyclosporin A (CsA), the dosage of LET should be decreased to 240 mg once daily. All patients will be followed for 12 weeks after completion of LET for the occurrence of CMV infection or disease after prophylaxis. Participants on this protocol will receive acyclovir 400 mg orally BID for the duration of LET therapy for herpes simplex virus and varicella zoster virus prophylaxis.
75803151|NCT05041426|Drug|Valganciclovir|Historical controls will have received CMV prophylaxis with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
75942808|NCT03660995|Behavioral|Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.|"Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child."
75942809|NCT03654235|Other|Health Education|6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.
75942810|NCT03654235|Other|Physical exercise|Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.
75942811|NCT03654235|Other|Usual care in Primary Care Physiotherapy Units|"Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise"
75942812|NCT03658031|Drug|Dapagliflozin 10mg|Dapagliflozin 10 mg administered each morning before breakfast
75942813|NCT03660917|Drug|Riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
75942814|NCT03660917|Drug|Placebo|Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
75942815|NCT02573259|Drug|PF-06801591|IV every 21 days (Part 1)
75942816|NCT02573259|Drug|PF-06801591|300 mg SC every 28 days (Part 1 and 2)
75942817|NCT02785991|Procedure|Balloon cryoablation|pulmonary vein cryoablation for atrial fibrillation
75942818|NCT02977507|Other|Lytera 2.0|Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
75942819|NCT02977507|Drug|4% Hydroquinone Topical Cream|4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
75942820|NCT02977507|Other|SkinMedica Facial Cleanser|SkinMedica facial cleanser applied to the face as directed.
75942821|NCT02977507|Other|SkinMedica Rejuvenative Moisturizer|SkinMedica rejuvenative moisturizer applied to the face as directed.
76091022|NCT03290820|Drug|Concurrent chemotherapy|Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
75656097|NCT02811900|Procedure|Gastric banding|Laparoscopic gastric banding is performed as following: a perigastric tunel is performed by blunt dissection and the banding is calibrated over the stomach.
75803152|NCT01090245|Behavioral|Contingency management: voucher/monetary incentives for treatment attendance|Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
75656098|NCT02811900|Procedure|Intragastric balloon|Flexible endoscopy is used to place intragastric balloon for a maximum interval of six months.
75803153|NCT01090245|Behavioral|Information|Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
75656099|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
75656100|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
75656101|NCT00961259|Drug|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
75656102|NCT00852865|Drug|Lactobacillus farciminis|1 capsule per day. Each capsule containing 4*109 CFU
75656103|NCT00852865|Drug|Placebo|1 capsule per day
75656104|NCT02807688|Behavioral|Health Promotion Intervention|"The intervention package consists of the following elements:~i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer."
75656105|NCT04283747|Diagnostic Test|Serum immunoglobulin titer|Serum IgG and IgM levels, VZV titer every 6 month at before rituximab administration 3 times
75942822|NCT02977507|Other|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
75942823|NCT03657953|Other|surgical approach|
75942824|NCT03622177|Procedure|biopsie|Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
75942825|NCT03622177|Biological|blood drawn|Additional blood drawn by venepuncture
75942826|NCT04471415|Drug|DRP-104|"DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week"
76091023|NCT03290820|Drug|Aspirin|Daily aspirin of 75mg, from the starting date of radiotherapy.
76091024|NCT01135342|Behavioral|Diet and exercise|Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
76091025|NCT01135342|Behavioral|Cognitive Behavioral Therapy|Standardized cognitive behavioral therapy for insomnia (8 classes)
76091026|NCT01135342|Behavioral|Passion and Balance|Attention-match sessions of general interest, but unrelated to diet, exercise, or sleep (8 sessions)
75942827|NCT04471415|Biological|atezolizumab|atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.
75942828|NCT02976103|Device|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
75656106|NCT00861679|Procedure|Transplantation with Stem Cells from Umbilical Cord|"According to results from published experiences in children following suggestions are given:~Number of Cells:~Number of nucleated cells infused exceed 2,5x10*7/kg recipient BW or~Number of nucleated cells collected exceed 3x10*7/kg BW~Number of CD34+ cells infused exceed 2x10*5/kg Recipient BW~GVHD-prophylaxis:~• MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~• UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~If many choices available ABO- major incompatibility should be avoided."
75942829|NCT02976103|Other|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
75942830|NCT03659279|Behavioral|Let's Get Organized|Group intervention aiming to enhance time-management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with a PowerPoint presentation and a course manual, and information from the group leaders is intermixed with discussion among the participants and tasks to complete.
75345105|NCT01490723|Procedure|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
75656107|NCT04111926|Drug|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
75656108|NCT04111926|Drug|Placebo|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
75656109|NCT04041349|Drug|mouse nerve growth factor|mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
75656110|NCT00961181|Device|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
75803154|NCT04928092|Procedure|Standard of care Ultra Low Contrast PCI|PCI using low amounts of contrast media which is standard of care at VCU Medical Center
75803155|NCT03555890|Drug|Levocetirizine IRT 5 mg|Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
75803156|NCT03555890|Drug|Levocetirizine ODT 5 mg|Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
75942831|NCT03654001|Biological|Albumin|Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
75942832|NCT03654001|Other|Balanced|Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
76091027|NCT03295188|Dietary Supplement|Plasmalogen|Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
75345106|NCT01490723|Drug|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
75345107|NCT01490723|Drug|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
75345108|NCT01490723|Drug|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
75345109|NCT01490723|Drug|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
75656111|NCT02807610|Drug|Inj Etomidate|Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0'.2mg kg-1 and IV Fentanyl 2ug kg-1.
75656112|NCT02807610|Drug|Injection Propofol|Induction of anesthesia using IV Propofol 2mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0.2mg kg-1 and IV Fentanyl 2ug kg-1
75656113|NCT02807610|Drug|Placebo for Propofol|After premedication with IV midazolam 0.2mg/kg and IV Fentanyl 2ug/kg Placebo was given.
75656114|NCT00861835|Other|ROSE|rapid on-site evaluation by cytopathology
75656115|NCT04041661|Other|Active tDCS plus gait training|Participants in experimental group will accept Active tDCS which combined with treadmill
75656116|NCT04041661|Other|Sham tDCS plus gait training|Participants in control group will accept Sham tDCS which combined with treadmill
75656117|NCT00857077|Drug|Sulfadoxine-pyrimethamine|
75656118|NCT00857077|Drug|Placebo|
75942833|NCT03659201|Drug|Neosil complete|Oral, during 24 weeks.
75942834|NCT03659201|Drug|Pantogar|Oral, placebo for 12 weeks and pantogar for 12 weeks.
75942835|NCT03659201|Drug|Neosil|Oral, during only 12 weeks.
76091028|NCT03295188|Dietary Supplement|Placebo|Placebo Group takes two placebo capsules per day for 12 weeks.
76091029|NCT03295110|Other|Functionalities of the Lili Smart Solution activated|Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
75942836|NCT03653923|Behavioral|Exposure Therapy|"Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. Each session lasts for approximately 90 minutes. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained.~Subjects of the waiting-list will be treated in the second study phase."
76091030|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
75345110|NCT01490723|Drug|Tacrolimus|"Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.~For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present."
75345111|NCT01490723|Drug|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
75345112|NCT01490723|Drug|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
75345113|NCT01490723|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
75345114|NCT01490723|Procedure|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
75656119|NCT00629993|Behavioral|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
75656120|NCT02808624|Drug|L-CARNOSINE|L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
75656121|NCT00857155|Other|Clopidogrel withdraw prior to CABG|Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
75656122|NCT02544685|Dietary Supplement|Probio-Fix Inum|"Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration~Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin"
75656123|NCT02544685|Dietary Supplement|Beneo Synergy 1|Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
75656124|NCT02544685|Other|Placebo|Same dosage regimen as active drugs
75656125|NCT04264091|Other|Observational|Observational
75656126|NCT02808468|Behavioral|Brief Cognitive Therapy|Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
75803157|NCT04905862|Diagnostic Test|Immune response|"Venous blood samples will be collected at seven-time points: before dose 1 of vaccine, 21 days after dose 1, within 14-21 days after dose 2 and 3,6,9,12 months after vaccination. From the volume of about 8 ml of the patient's peripheral blood, a fraction of PBMC (peripheral blood mononuclear cells) will be isolated.~The level of antibodies against the SARS-CoV-2 nucleocapsid (N) antigen will be detected in serum using the Abbot Architect™SARS-CoV-2 IgG test.~The level of neutralizing IgG and IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S) will be detected in serum using the DiaSorin LIAISON®SARS-CoV-2 S1/S2 IgG serology COVID-19 S-Protein (S1RBD) Human IgA ELISA Kit respectively.~The cellular component of the immune response will be tested using the ELISPOT method, which involves testing the amount of INF-γ and IL-2 released from leukocyte cells."
75942837|NCT03653845|Procedure|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
75942838|NCT03653845|Drug|Sequenced antihypertensvie drugs with titrated dosage|Patients will be treated with different antihypertensive drugs in two groups.
75942839|NCT04630977|Dietary Supplement|Multi-ingredient Pre-workout supplement|Every important issue has been detailed before.
75942840|NCT04630977|Other|Progressive Resistance Training|The information about it has been detailed in advance.
75942841|NCT04630977|Behavioral|Nutritional Patterns Guideline|This intervention has also been described in advance.
75942842|NCT03470961|Drug|Anti-Tlymphocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
75942843|NCT03470961|Drug|Anti-Thymocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
75345115|NCT04351217|Behavioral|Music|Raga Ahir Bhairav and Bhairavi were used, played primarily on flute, without lyrics.
75345116|NCT04351217|Behavioral|Progressive Muscle Relaxation|The instructions were recorded in both English and the local language, Kannada
75345117|NCT01491113|Drug|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
75345118|NCT01491113|Drug|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
75345119|NCT00816062|Device|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
75345120|NCT01415453|Procedure|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
76091031|NCT02066896|Device|Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
76091032|NCT02066896|Device|Sham Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
75656127|NCT04281563|Other|massage with MCT oil (group 1)|Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.
75803158|NCT04905862|Other|Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events|The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials. Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination. Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
75803159|NCT03688074|Biological|Tezepelumab|Tezepelumab subcutaneous injection
76091033|NCT03773484|Behavioral|Opioid naive|Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days
76091034|NCT03773484|Behavioral|At-risk for long term use|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days
76091035|NCT03773484|Behavioral|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days
75656128|NCT02811588|Device|Non-invasive ventilation|
75656129|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
75656130|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
75656131|NCT00817635|Drug|LCI699|LCI699 oral capsules
75803160|NCT03688074|Other|Placebo|Placebo subcutaneous injection
75803161|NCT03625570|Behavioral|Power training combined with interval treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors according to resistance training guidelines for muscle power training. The interval treadmill training portion will include short-bursts (30 seconds) of high speed walking intervals alternating with 30 seconds of low to moderate speed walking for a total of 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
75803162|NCT03625570|Behavioral|Strength training combined with traditional treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors following the dosing and resistance training guidelines for muscle strength. Traditional treadmill training will consist of walking at steady-state speeds for 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
75803163|NCT03630120|Drug|Lenvatinib|"Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
75942844|NCT03470883|Other|Evaluation of the long-term complete remission rate (> 12 months)|Evaluation of the long-term complete remission rate (> 12 months)
75942845|NCT05017857|Device|RepetiveTranscrainal Magnetic Stimulation (rTMS)|RepetiveTranscrainal Magnetic Stimulation (rTMS): rTMS is a non-invasive electromagnetic stimulation of the brain. A train of electric pulses is delivered at the same intensity over a set period of time to a targeted region of the brain. The current stimulates or suppresses neuronal activity based on the frequency and inter-train interval between the pulses.
75942846|NCT05017857|Behavioral|Problem-Solving Training (PST)|Problem-Solving Training (PST) is a metacognitive strategy training in which patients are guided through a process of conscious self-assessment resulting in problem identification, generation of solutions, development of specific goals and action plans, and evaluation and revision of plans as needed. PST thus helps to circumvent impulsive or unrealistic problem-solving attempts that lead to failure, discouragement, and feelings of helplessness.
75942847|NCT03130881|Drug|PLB1003|PLB1003 is a capsule and is administered orally.
75942848|NCT01066039|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
75942849|NCT02919995|Drug|RPL554|RPL554 suspension administered using a nebuliser
75942850|NCT02919995|Drug|Placebo|Placebo solution administered using a nebuliser
76091036|NCT02334358|Device|YVOIRE Classic s|
76091037|NCT02005510|Behavioral|Mailed in-home high-risk HPV testing kit|
76091038|NCT02005510|Other|Usual care|
75942851|NCT04972695|Diagnostic Test|Fundus Photographs (retinographies)|Fundus photographs under mydriasis
75942852|NCT04355793|Drug|Ruxolitinib|Ruxolitinib starting dose level 5 mg orally, twice daily (BID).
75942853|NCT03653767|Device|Adjustable Furniture|The intervention will include adjustable school furniture.
75942854|NCT03653689|Dietary Supplement|FODMAP|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
75354667|NCT04794803|Drug|Reparixin|Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.
75354668|NCT04794803|Drug|Standard of care|Standard of care
75656132|NCT00817635|Drug|Eplerenone|Eplerenone oral capsules
75656133|NCT00817635|Drug|LCI699-matching Placebo|LCI699-matching placebo oral capsules
75656134|NCT00817635|Drug|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
75656135|NCT02861339|Device|Opthalmologic measure with DM OPD scan III (Nidek)|Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
75656136|NCT00853177|Procedure|MEOPA inhalation|N2O of 50% and 50% O2
75656137|NCT00853177|Procedure|xylocaine|Ampoule-bottle of 20 ml
75656138|NCT02861495|Device|Humeral Compression/Distraction (CD) Nail|Surgical fixation of humeral shaft fractures with Humeral Compression/Distraction (CD) Nail implant
75656139|NCT00924079|Drug|nalbuphine|oral dosage form, 66 mg, single dose
75656140|NCT04264247|Diagnostic Test|routine fetal ultrasonography at 11-14 weeks|routine fetal ultrasonography at 11-14 weeks
75803164|NCT03630120|Drug|Sorafenib|"Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
75656141|NCT00853255|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
75656142|NCT02807532|Other|atrial fibrillation|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
75803165|NCT03630120|Drug|Cabozantinib|"Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
75803166|NCT03630120|Drug|Vandetanib|"Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
75656143|NCT02807532|Other|non-atrial fibrillation|In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
75656144|NCT00861991|Behavioral|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
75803167|NCT03733262|Other|De-prescribing Trial|Validated de-prescribing algorithms will be applied for any patients identified as taking one of the 9 study drugs in order to determine whether or not physician should consider a deprescribing trial. If they are are identified as candidates for deprescribing and consent to participate in the trial, they will enter the Deprescribing Trial group and begin the deprescribing trial.
75803168|NCT03744702|Drug|Ascorbic Acid|Patients will receive IV ascorbic acid.
75803169|NCT03725774|Other|GRIP (Getting Research into Practice) model|"The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.~The GRIP model is a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying the obstacles to improvements in clinical practice, and drawing up and implementing a plan of action for the purpose of improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the obstacles that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles."
75803170|NCT01060254|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
75803171|NCT01060254|Drug|JNJ-42160443|Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
75803172|NCT03725696|Diagnostic Test|Semen Analysis|Sperm counts will be determined by semen analysis.
75803173|NCT03725696|Diagnostic Test|Hormonal panel|Blood test for LH, FSH, testosterone, and estradiol
75803174|NCT03725696|Procedure|RYGB Gastric Bypass|Roux-en-Y Gastric Bypass
75942855|NCT03653689|Dietary Supplement|Gluten|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
75803175|NCT03725696|Diagnostic Test|IIEF Survey|International Index of Erectile Function is a validated 5-question survey examining sexual health in men
76091039|NCT03295032|Behavioral|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention; in this study it is being delivered as a 4-week psycho-educational group to stroke survivors and carers.~Rather than attempting to control or ameliorate pain and suffering, ACT advocates that individuals remain open to internal private experiences (both positive and negative) and should focus on committing to a life which is congruent with their core values. Individuals learn to modify their relationship with these experiences, rather than change the experiences per se through processes such as mindfulness, acceptance and attention to values. This fundamental premise of ACT helps cultivate psychological flexibility."
75345121|NCT03839498|Drug|Axitinib|"Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered."
75803176|NCT03736980|Drug|Placebo|100% lactose
75803177|NCT03736980|Drug|Psilocybine|Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight
75803178|NCT03555266|Device|NSS-2 Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care ERAS protocol.
75345122|NCT02252432|Drug|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
75345123|NCT02252432|Drug|Methadone|A single dose of IV methadone (0.2 mg/kg) preinduction.
75345124|NCT02252432|Drug|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
75345125|NCT01492673|Drug|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
75345126|NCT01494545|Device|Delefilcon A contact lens|Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
75345127|NCT00818324|Drug|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
75345128|NCT01419275|Drug|Xenon contrast agent|
75656145|NCT00817479|Drug|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
75656146|NCT00817479|Drug|Placebo|Placebo saline
75656147|NCT02811822|Drug|GMI-1271|
75803179|NCT03555266|Device|Sham NSS-2 BRIDGE|NSS-2-Bridge sham will be used in addition to standard of care ERAS protocol.
75656148|NCT00853411|Drug|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
75656149|NCT04030533|Drug|Guselkumab (SC): Dose 1|Participants will receive a single dose of guselkumab (dose 1) subcutaneously.
75656150|NCT04030533|Drug|Guselkumab (SC): Dose 2|Participants will receive a single dose of guselkumab (dose 2) subcutaneously.
75803180|NCT03736824|Procedure|endoscopy|All endoscopy was performed by qualified gastroenterologists or endoscopic physicians in Renji hospital,Shanghai Jiaotong University School of Medicine.
75803181|NCT03725618|Biological|Yellow Fever 17DD Vaccine|live attenuated vaccine based on the 17DD strain
75803182|NCT03629886|Biological|HPV (Types 16, 18) Vaccine, Adsorbed|Three doses of Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed administered intramuscularly in the deltoid region of the upper arm, according to a 0, 1, 6-month schedule.
75803183|NCT01310504|Procedure|SonoSite Ultrasound|Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
75803184|NCT01310504|Procedure|SonoSite Ultrasound|Paramedics will scan the abdomen and determine it there's fluid within.
75656151|NCT04030533|Drug|Guselkumab (IV): Dose 1|Participants will receive a single IV infusion of guselkumab (dose 1).
75656152|NCT04030533|Drug|Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2).
75656153|NCT04030533|Drug|Ustekinumab 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
75656154|NCT02807298|Drug|4%articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine
75803185|NCT03727646|Dietary Supplement|Nicotinamide riboside|nicotinamide riboside supplied as 250mg capsules
75803186|NCT03656874|Other|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care
75803187|NCT03554486|Drug|Fiasp|Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system
75803188|NCT03554486|Drug|Novolog|Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system
75803189|NCT03554018|Drug|Acetaminophen|Acetaminophen 500-1000mg every 6 hours
75803190|NCT03554018|Drug|Ibuprofen 600 mg|Ibuprofen 600mg every 6 hours
75345129|NCT01419275|Device|Magnetic Resonance Imaging|Arterial spin label sequence for the purpose of measuring collateral flow
75345130|NCT02155010|Drug|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
75345131|NCT02155010|Drug|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
75345132|NCT01495481|Drug|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
75803191|NCT03554018|Behavioral|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp)
75803192|NCT03554018|Drug|Placebo oral capsule|To match acetaminophen, patients will take one or two capsules every 6 hours
75803193|NCT03733106|Diagnostic Test|digital breast tomosynthesis|pseudo three dimension mammography
75803194|NCT03733106|Diagnostic Test|standard two dimension digital mammogram|standard two dimension mammogram
75803195|NCT04889794|Other|GPS clinical intervention|Nurses and doctors in exposed FMGs and home care teams (HCTs) will be asked to refer to the FMG pharmacist all seniors undergoing cognitive evaluation OR referred to a memory clinic OR recently diagnosed with a cognitive disorder, for a complete and critical review of their medication therapy. FMG pharmacists will be asked to conduct an interview with each referred senior and his or her caregiver, if applicable, in order to establish the best possible treatment regimen. They will compare the information collected with another reliable data source (e.g., pharmacy records) in order to perform medication reconciliation and will then evaluate the medication related problems. Pharmacist will establish a care plan and the follow-ups to be carried out with the patient in collaboration with the health care team. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
75803196|NCT03725540|Device|I-gel|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
75803197|NCT03725540|Device|Baska_mask|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
75345133|NCT01495481|Drug|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
75345134|NCT01954550|Behavioral|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
75345135|NCT01954550|Behavioral|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
75345136|NCT00861146|Behavioral|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
75656155|NCT02807298|Drug|2% Lignocaine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
75345137|NCT00819182|Behavioral|Paced respiration|Breathing exercise
75345138|NCT00819182|Behavioral|Sham comparator: fast shallow breathing|sham breathing exercise
75476620|NCT05897827|Behavioral|PLANTS|PLANTS intervention is an online-delivered training program, including asynchronous and synchronous activities. This intervention was informed by the Information-Motivation-Behavior theory to target skills, self-efficacy, knowledge, and outcome expectations. There are 3 asynchronous online modules that cover a variety of topics including lessons on LGBTQ+ terminology, names and pronouns, resources, antibullying, gender neutral bathrooms, student confidentiality, active empathic listening, and school policies. Module include recorded presentations, student testimonials, activities, and downloadable resources for future reference. Every month, 7-9 lessons are opened. There are 2 synchronous group events delivered via Zoom and are 1.5 hours each.
75656156|NCT02807298|Drug|Epinephrine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
75656157|NCT04041427|Drug|Albendazole Pill|Albendazole 400mg po
75345139|NCT01497665|Drug|GRN1005|650 mg/m2 IV every 3 weeks
75345140|NCT00819260|Device|Harmonic Scalpel|harmonic scalpel used to reduce breast on this side
75345141|NCT00819260|Device|Electrocautery|Electrocautery used to reduce breast on this side
75345142|NCT01379183|Drug|Erythromycin|200 mg suspension
75656158|NCT04041427|Other|High fat content diet|High fat content diet
75656159|NCT04041427|Other|Moderate fat content die|Moderate fat content die
75656160|NCT00961961|Drug|Lithium / Fluoxetine|Individualized Daily Dosage
75656161|NCT00961961|Drug|Lithium / Placebo|Individualized Daily Dosage
75656162|NCT02811666|Device|Assessment of sarcopenia by CT-Scan|
75656163|NCT02811666|Device|hand gauge|
75656164|NCT02610933|Drug|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
75656165|NCT02610933|Dietary Supplement|Vitamin K2|Vitamin K2 supplementation
75656166|NCT02807220|Drug|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
75656167|NCT04042441|Drug|Insulin Degludec/Insulin Aspart|Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.
75345143|NCT01379183|Drug|Placebo|200 mg suspension
75345144|NCT01379183|Procedure|Magnetic Resonance Imaging|An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
75345145|NCT01379183|Other|Barium Sulfate Solution|Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
75942856|NCT03653689|Dietary Supplement|Placebo|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
76091040|NCT03108222|Other|Phosphorus Absorption Test|Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
76091041|NCT03108144|Behavioral|Brief alcohol intervention|The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
76091042|NCT03283410|Drug|Propofol|Propofol plasmatic concentration (Marsh)
76091043|NCT04318704|Drug|Ifenprodil|Ifenprodil 20 mg TID
75354669|NCT04794764|Device|McGrath Mac|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
75803198|NCT05462626|Behavioral|Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program|The intervention is comprised of the following sessions and themes; Session 1: Informed Consent and Pre-Testing; Session 2: Occupation and Healthy Aging; Session 3: Longevity and Thriving; Session 4: Movement Matters; Session 5: Thoughtful Eating; Session 6: Stress and Sleep; Session 7: Navigating Health Care; Session 8: Post-Testing and Discharge.
75803199|NCT03725462|Device|Cardioskin|Subjects have a monitoring with cardioskin and comparator
75803200|NCT03725462|Device|Neuronaute|Subjects have a monitoring with Neuronaute and comparator
75803201|NCT04788238|Behavioral|Dual-Task Zumba Gold|Dual-Task Zumba Gold is a 12-week program to be conducted thrice weekly for 45-60 minutes. The intervention involves the concurrent performance of cognitive tasks and physical movements during specific parts of the dance. The activity will begin with warm-up and end with cool-down periods, at 5 to 10 minutes each. Orientation training will be done during the warm-up period, by asking questions to participants about time, place, and person. In the actual dance (30 to 40 minutes), the following domains will be trained: executive function (forward and backward serial counting); perceptual-motor ability (performing arm clock positions based on instructions); memory (forward and backward repetition of number/word series), and attention (forward and backward spelling of 3- to 5-letter words). The cool-down period will incorporate memory training by reminding the participants to summarize the activities performed.
75942857|NCT04396379|Device|Implant an epicardial device to reshape the mitral valve annulus|The implant is intended to epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy), in patients with left ventricular dilation and mitral valve insufficiency in patients with ischemic or functional MR.
75942858|NCT04457427|Device|NeuRx Diaphragm Pacing System (DPS)|4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.
76091044|NCT03283332|Other|No intervention|
75656168|NCT02859935|Behavioral|Screening and feedback|Screening via questionnaires on mental health problems and feedback on the questionnaires
76091045|NCT03283176|Diagnostic Test|Vitamin B12 and Folic Acid|Vitamin B12 and Folic Acid measurement by ELISA technique
76091046|NCT03290586|Device|Flower Cube|single use, sterile disposable fixation construct
76091047|NCT03290430|Behavioral|Group Counseling|8 sessions over 4 weeks. Lasting 1-2 hours each
76091048|NCT03290430|Behavioral|Individual Counseling|8 in person sessions over 4 weeks. Lasting 30-45 minutes each
75476621|NCT05897827|Behavioral|EMAILS|The active control arm is an email-based intervention, EMAILS, in which existing public resources for supporting, affirming, and protecting LGBTQ+ students are emailed to participants.
76091049|NCT03290430|Behavioral|Phone Counseling|8 phone sessions over 4 weeks. Lasting 30-45 minutes each
76091050|NCT03290430|Behavioral|Video Counseling|8 video call sessions over 4 weeks. Lasting 30-45 minutes each
75354670|NCT04794764|Device|Macintosh Laryngoscope|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
75354671|NCT04793958|Drug|MRTX849|28 Day Cycle
75354672|NCT04793958|Biological|Cetuximab|28 Day Cycle
75656169|NCT00817089|Drug|Placebo Oral Tablet|Placebo pill
75656170|NCT00817089|Drug|Naltrexone|50 mg of naltrexone prior to challenge session
75656171|NCT02807064|Drug|Bifidobacteria|0.5 ml per os all days for 2 months
75942859|NCT04457583|Device|Inspiratory muscle training with powerbreathe|Participants will be submitted to a linear pressure resistance (Powerbreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 exercises for 12 weeks.
76091051|NCT03290430|Behavioral|Texting support|Texts with smoking cessation support throughout the program
76091052|NCT03290430|Drug|Nicotine Replacement Therapy|Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
76091053|NCT03290352|Other|Questionnaire|Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
75656172|NCT02807064|Drug|placebo|0,5 ml per os all days for 2 months
75656173|NCT04282577|Diagnostic Test|urinary nephrin and alpha one microglobulin|urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA
75656174|NCT02804802|Other|questionnaire|dietary habits and physical activity questionnaire
75942860|NCT03109821|Other|Home-based exercise|"The intervention reflects the standard rehabilitation practice at Elective Surgery Centre. 3 weeks after surgery the patients will receive a thorough instruction and supervision in the strength training exercises that they are to perform without supervision at their own homes the following 7 weeks. The instruction is conducted one-to-one by physiotherapists and supported by an instruction booklet with written and illustrated exercise descriptions. The exercises included are: hip abduction, flexion and extension with elastic band resistance and sit-to-stand and one-legged stance. The prescribed training load will be two sets with repetitions to failure and a relative load of 10 to 20 RM (Repetition Maximum), performed every second day (3-4 times a week).~Exposure: Performed exercise dose will be quantified as the total physiological exercise stimulus (Time under tension summary dose) recorded by a sensor (BandCizer) attached to the elastic exercise band."
76091054|NCT03294798|Biological|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
76091055|NCT03294798|Biological|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
75345146|NCT01333436|Other|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
75345147|NCT04382456|Dietary Supplement|acacia gum|Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
75656175|NCT00853801|Behavioral|Lifestyle intervention and provider feedback|"Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.~Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months."
75656176|NCT04282499|Procedure|combined exercise|Patients will be undergone to aerobic exercises in addition to the resistance training.
75656177|NCT04282499|Procedure|aerobic exercise|Patients will be trained through the aerobic exercises only.
75803202|NCT04787692|Behavioral|Opioid and Benzodiazepine Naive-patients|Duration of treatment : 1 month Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT & MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, Cognitive behavioral therapy(CBT), Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
75942861|NCT05156697|Dietary Supplement|Capsinoids + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)
75942862|NCT05156697|Other|Placebo + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
75942863|NCT04217967|Drug|Ixazomib|the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
75942864|NCT04217967|Drug|Lenalidomide|the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
76091056|NCT03294720|Procedure|Bio-ACL|ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
76091057|NCT03294720|Device|amnion wrap and BMAC|amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
76091058|NCT04488744|Drug|Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s|Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
76091059|NCT02005666|Drug|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
76091060|NCT02005666|Drug|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
75942865|NCT02919761|Drug|Acthar Gel|80 Units Acthar Gel per 1 mL for subcutaneous injection
75942866|NCT02919761|Drug|Placebo|Matching placebo 1 mL for subcutaneous injection
76091061|NCT02005666|Drug|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
76091062|NCT03283020|Drug|RemifentanilMNTX|Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
76091063|NCT03283020|Drug|PlaceboMNTX|Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
76091064|NCT03294642|Dietary Supplement|Potatoes|Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.
75345148|NCT01379651|Other|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
75345149|NCT01380197|Drug|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
75656178|NCT02804958|Procedure|STEMI treated with primary PCI|Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
75354673|NCT04793958|Drug|mFOLFOX6 Regimen|"Fluorouracil~Oxaliplatin~Folinic acid"
75354674|NCT04793958|Drug|FOLFIRI Regimen|"Fluorouracil~Irinotecan~Folinic acid"
75942867|NCT04211181|Other|The multifaceted interventions|"An evidence-based clinical guideline and pathway in hospital.~A series Written care protocols for the implementation of performance measures.~A computer-based clinical decision support system(CDSSs) and a computerized reminder, which was referred to as a key element to enhance VTE assessment and prophylaxis. A well-designed computer program will be integrated into the Electronic Medical Record(EMR) of intervention group and By processing, analyzing, summarizing and representing crucial information, physicians can be altered.~A full-time quality coordinator~A trained physician or nurse in each intervention cluster will be acted as a quality coordinator. The responsibility of the quality coordinator includes:"
75942868|NCT04211181|Other|Routine VTE prophylaxis|Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices
75656179|NCT00857701|Device|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
76091065|NCT03294642|Dietary Supplement|Carbohydrate Gel|Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
75656180|NCT00857779|Biological|subcutaneous immunotherapy|7 injections
75942869|NCT02910167|Drug|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
75942870|NCT02910167|Drug|Paracetamol|Paracetamol 500 mg
75942871|NCT02910167|Drug|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
75942872|NCT02910167|Drug|Paracetamol|Paracetamol 500 mg
76091066|NCT03294642|Dietary Supplement|Water|Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
76091067|NCT00494182|Drug|Carboplatin|Given IV
76091068|NCT00494182|Drug|Paclitaxel|Given IV
76091069|NCT00494182|Drug|Sorafenib|Given PO
76091070|NCT03294564|Biological|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
76091071|NCT03294564|Biological|Placebo|The placebo injection will consist of 0.5mL of saline.
75345150|NCT01380197|Drug|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
75345151|NCT00862784|Biological|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
75345152|NCT00862784|Drug|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
75656181|NCT02860793|Other|Bone marrow aspiration|
75656182|NCT02860793|Other|Blood sampling|
75656183|NCT00857935|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
75656184|NCT00857935|Drug|NIX Creme Rinse - 1% permethrin|NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
75942873|NCT04458285|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
76091072|NCT03290274|Device|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
76091073|NCT03290274|Device|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
75345153|NCT00862784|Drug|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
75656185|NCT02808234|Procedure|One or two level lumbar interbody fusion surgery|One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
75656186|NCT02808234|Other|Nucel|Allograft derived from human amnion and amniotic fluid
75656187|NCT04282655|Other|Treatment Guardian Milk Warmer (Medela TM)|Infants were randomized to receive prepared syringes of breast milk via the continuous milk warmer (treatment arm)
75656188|NCT04282655|Other|Control|Standard warming procedure of breast milk in syringe prior to feeding.
76091074|NCT02006056|Drug|Ondansetron|Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
76091075|NCT03290196|Drug|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
76091076|NCT03282942|Other|Strength training group|"Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~Squatting~Leg press~Knee Extension~Knee Flexion~Supine Challenge~High Pull~Elbow flexion~Extension of elbows~Development~Abdominal"
76091077|NCT03282942|Other|Aerobic Training Group|Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
75345154|NCT00862784|Drug|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
75942874|NCT04458285|Drug|Valsartan 80mg Tablet|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
75942875|NCT05156541|Drug|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
75942876|NCT03469869|Other|balanced and sustainable diet|"the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp."
75942877|NCT01067105|Drug|ciclesonide HFA 160 μg|ciclesonide HFA 160 μg once daily
75942878|NCT03470727|Device|Citrate dialysate|Change form acetate to citrate dialysate
75942879|NCT03657719|Biological|GC3114|High-dose Quadrivalent influenza vaccine
75942880|NCT03657719|Biological|GCFLU Quadrivalent|Quadrivalent influenza vaccine
75942881|NCT03924765|Device|Powered hip exoskeleton|The study team will be testing a powered hip exoskeleton and its capability to improve locomotion in stroke survivors.
75942882|NCT02910089|Behavioral|Shared Decision Making|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
75942883|NCT02985515|Behavioral|Smell training|Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
75942884|NCT03470649|Drug|Iron Isomaltoside 1000|Iron Isomaltoside 1000 would be intravenously administrated to treatment group after main procedure of total knee arthroplasty.
75942885|NCT03657563|Other|Positive psychological intervention|"Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available."
76091078|NCT02006836|Dietary Supplement|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
76091079|NCT02006836|Dietary Supplement|Glucose|We dissolved 50 g of glucose in 200 ml water.
76091080|NCT02006836|Other|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
76091081|NCT02006836|Drug|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
76091082|NCT02006836|Drug|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
75656189|NCT00853879|Dietary Supplement|Folic Acid, Vitamin B6, Vitamin B12|"Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate."
75656190|NCT00853879|Dietary Supplement|B6, B12, L-methylfolate|Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
75942886|NCT03657329|Diagnostic Test|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG. Pursuant to the physician-ordered diagnostic study, clinical staff may determine a split-night study with CPAP to be appropriate for any participant, simultaneous with the PSG and Dreem.
75942887|NCT02696759|Other|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
75942888|NCT03706911|Drug|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
75942889|NCT03469635|Other|Nutritional deficiencies in pregnant women after bariatric surgery|compare maternal nutritional parameters and neonatal outcomes after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) and to assess the impact of nutritional alterations on fetal growth.
75942890|NCT02910011|Drug|Nanodox 1% (doxycycline monohydrate hydrogel)|Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
75942891|NCT03472131|Procedure|Unilateral Posterolateral Approach and Debridement|
76091083|NCT03290118|Other|Nutrition Rating System - Traffic Light|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.
76091084|NCT03290118|Other|Nutrition Rating System - Health Star|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.
75656191|NCT00853879|Dietary Supplement|B6, B12, Placebo|"Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo"
75345155|NCT00862784|Drug|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
75656192|NCT00634530|Behavioral|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
75942892|NCT03472131|Other|Titanium cage insertion supplemented by screw fixation|
75942893|NCT03657485|Dietary Supplement|containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A|we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
75942894|NCT03472053|Drug|BIO-11006 plus standard of care|BIO-11006 is administered 125mg BID plus standard of care.
75803203|NCT04787692|Behavioral|Opioid and Benzodiazepine Tolerant-patients|Duration of treatment : 6 months Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT & MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, CBT, Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
75345156|NCT00246116|Procedure|Functional Imaging of Treatment Effects|PET & VQ Scans
75345157|NCT03532100|Device|Torsionally adaptive prosthesis with 0:1 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
75345158|NCT03532100|Device|Torsionally adaptive prosthesis with 1:6 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
75803204|NCT04775446|Other|Data collection|Data entered in a secure computer database
75803205|NCT03571256|Drug|TEV-50717|6-, 9-, 12-, 15-, and 18 mg oral tablets
75656193|NCT05271279|Biological|OVV-01 Injection+IBR900 Cell Injection|"2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10^9 cells per cycle.~OVV-01 injection will be first administered at W1D1 and then at W4D1 followed by every 2 weeks as a treatment cycle, for a total of 6 doses; after the test in the high-dose group is completed, the investigator and sponsor will determine whether to adjust the dosing frequency of OVV-01 (such as once a week) based on the result evaluations. The IBR900 cell injection will be first administered at W1D3 and W1D5 for 2 infusions, and then at W4D3 and W4D5, followed by every 4 weeks as a cycle, for a total of 4 doses, and cell infusions will be conducted at W1, W4, W8 and W12, respectively."
75345159|NCT03532100|Device|Torsionally adaptive prosthesis with 1:4 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
75345160|NCT03532100|Device|Torsionally adaptive prosthesis with 1:3 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
75345161|NCT03532100|Device|Torsionally adaptive prosthesis with 1:2 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
75345162|NCT00864032|Drug|Sorafenib|400mg twice daily
75345163|NCT00820664|Drug|Comparator: Estrace 0.5 mg|0.5 mg tablet taken once daily for 28 days
75345164|NCT00820664|Drug|Comparator: Estrace 2 mg|2 mg tablets taken once daily for 28 days.
75656194|NCT00862147|Behavioral|ICDP|Parent training group
75656195|NCT00862147|Behavioral|Treatment as usual|Parent and/or child focused interventions
75803206|NCT03571256|Drug|Placebo|Placebo matched to TEV-50717 tablets will be taken BID.
75345165|NCT00820664|Drug|Comparator: Placebo|Placebo 0 mg capsule taken once daily for 28 days
75656196|NCT04282265|Dietary Supplement|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks
75345166|NCT01380743|Drug|duvoglustat|Single oral dose
75345167|NCT01380743|Drug|rhGAA|Single intravenous infusion
75354675|NCT04792073|Drug|Avelumab|Avelumab 800 mg given intravenously over 60 minutes every 2 weeks (+/- 3 days)
75656197|NCT04282265|Dietary Supplement|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
75656198|NCT02611011|Device|Congo Red Test (GV-005)|The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
75656199|NCT03911076|Biological|PVX-2|pNGVL4a-Sig/E7(detox)/HSP70 (naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)
75656200|NCT03911076|Other|Placebo|PBS and PGC
75656201|NCT02860559|Biological|TBX-1400|Hematopoietic stem cells transplantation
75656202|NCT03845803|Other|Reducing sedentary behaviour|Implementing sit/stand workstations at work
75803207|NCT05462548|Drug|Luspatercept Injectable Product|1-1.25mg/kg every 3 weeks subcutaneous injection
75803208|NCT04625764|Procedure|Blood sampling and analysis|Blood sampling for pharmacokinetics (Plasma ticagrelor concentrations and its metabolite) and MEA platform testing (ADPtest, TRAPtest)
75942895|NCT03472053|Drug|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
75942896|NCT03657017|Diagnostic Test|PET/MR|Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.
75942897|NCT02908841|Device|Surgicel Snow|
75942898|NCT02908841|Other|Standard of Care|
75656203|NCT00815919|Drug|bortezomib|Given intravenously at a dose of 1.3 mg/m^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
75656204|NCT00815919|Drug|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
75656205|NCT03903744|Procedure|Cardioneuroablation|The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
75803209|NCT03408340|Procedure|Paravertebral Nerve Block|Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established. A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry. The patient will be intubated, and then will be positioned laterally for the nerve block at approximately the left T3-4 level. A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block. The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.
75803210|NCT03408340|Drug|Standard of Care Anesthesia|Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
75942899|NCT04706559|Drug|Probiotic sachet containing mixture of four strains i.e.Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii|Interventional group: Children with AD meeting eligibility criteria receiving probiotics and conventional treatment (topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients).
75942900|NCT04706559|Drug|Conventional treatment|topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients as per atopic dermatitis treatment guidelines.
75942901|NCT04457037|Biological|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells
75942902|NCT04456803|Drug|Ferric citrate tablet|250mg/tablet, manufactured by Sinomune Pharmaceutical
75942903|NCT04456803|Drug|Sevelamer carbonate tablet|800 mg/tablet, manufactured by Genzyme Ireland Limited
75942904|NCT02909153|Drug|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
75345168|NCT01380899|Procedure|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
75656206|NCT02808078|Device|Gait training with augmented reality|20 sessions (30 min. duration) over 4 weeks of gait training with augmented reality.
75656207|NCT02808078|Device|Standard training|20 sessions (30 min. duration) over 4 weeks of gait training without augmented reality.
75656208|NCT02545153|Drug|Tisseel, Baxter (Aprotinin and Fibrinogen)|After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
75656209|NCT02545153|Drug|Control|No fibrin sealant applied
75942905|NCT03470571|Diagnostic Test|CMR|Outcome analysis of CMR features in suspected myocarditis patients
75942906|NCT02522949|Device|ColdZyme® mouth spray|
75942907|NCT02522949|Device|Placebo|
75942908|NCT02908529|Drug|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
75942909|NCT02908529|Drug|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
75942910|NCT04456725|Behavioral|Intensive management|The intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them intensively, with the support of the study team.
75345169|NCT01498601|Other|Enhanced oral care protocol|"Changing mouth suction equipment every 24 hours~Mouth assessment every 2-4 hours~Cleansing mouth with toothbrush every 12 hours~Cleansing oral mucosa with oral rinse solution every 2-4 hours~Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~Suction mouth and throat as needed~Head of the bed elevated to a minimum of 30° during oral care"
75345170|NCT01419977|Drug|Placebo|Normal saline solution, administered by nursing staff once daily
75345171|NCT01419977|Drug|Dalteparin|Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
75345172|NCT01420289|Device|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
75345173|NCT01420289|Behavioral|Excercise|Treadmill walking 45 minutes once daily
75656210|NCT02800746|Drug|Ferric carboxymaltose|Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
75656211|NCT02800746|Drug|Placebo|normal saline 100 ml is intravenously administered on 7-10 day before surgery
75656212|NCT00913653|Drug|LCZ696|
75656213|NCT04042129|Other|gynecologic operations with urological complications|
75942911|NCT04456725|Behavioral|Control|Usual care
75942912|NCT04989543|Diagnostic Test|vaginal swabs|"Nugent score: Vaginal swabbing with the dry swab, make two smears on slides.~Cytobacteriological examination: swabbing at the exo-endocrine junction using the swab~Evaluation of the vaginal microbiota: swabbing at the exo-endocrine junction using the swab"
75942913|NCT02443181|Device|Activa PC+S|Implementation of closed loop DBS for essential tremor
75942914|NCT03656861|Other|Physical load|The impact of training on cardiac structure and function depends on the type, intensity and duration of the activity, as well as previous physical activity engagement, genetics and gender type. More knowledge about cardiac pathophysiologic training adaptation is needed.
75942915|NCT03130803|Behavioral|Insufficient Sleep|2 days with 5 hour sleep opportunity per day
75942916|NCT02984267|Device|Ultrasound|Using ultrasound guidance to evaluate the spine prior to epidural placement
76091085|NCT03290118|Other|Nutrition Rating System - Warning Label|"Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes."
76091086|NCT03290118|Device|Smartphone application FoodFlip Device®|This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
76091087|NCT04378530|Behavioral|Personalized Anchoring Strategy|"The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders.~Participants will be asked to choose a cue to use as an anchoring strategy. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm)."
76091088|NCT04378530|Behavioral|Non-Anchoring Strategy Control|The study will run for 8 weeks. Control participants will participate in the meditation features in their Calm account. Each participant will receive non-anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The control group will not be provided an anchoring strategy video on the persistence of daily meditation practice and receive non-anchoring strategy specific push notification study reminders. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
76117250|NCT04438356|Combination Product|M-Health|The study was randomized (wait-list-control), and it was estimated that 80 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the mHealth. After the first questionnaire evaluation, the experimental group was involved in the mHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the mHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month.
76117251|NCT03682601|Drug|5% sinecatechins ointment|Topical 5% sinecatechins ointment will be applied once daily.
76117252|NCT03682601|Drug|Placebo|Aquaphor/vehicle
75345174|NCT01499147|Drug|fludarabine/busulfan|All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
75656214|NCT02804880|Behavioral|HAR|Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
75803211|NCT05074264|Procedure|Biopsy|Undergo biopsy
75656215|NCT02804880|Behavioral|LTM|Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
75656216|NCT02804880|Behavioral|AWARD|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
75656217|NCT02804880|Other|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
75803212|NCT05074264|Procedure|Biospecimen Collection - Anal|Undergo collection of anal swabs
75354676|NCT04792073|Radiation|Comprehensive Ablative Radiation Therapy|Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
75803213|NCT05074264|Procedure|Biospecimen Collection - Cervical|Undergo collection of cervical swabs
75803214|NCT05074264|Procedure|Colposcopy|Undergo colposcopy
75803215|NCT05074264|Procedure|High Resolution Anoscopy|Undergo high-resolution anoscopy
75803216|NCT05074264|Procedure|Imaging Technique|Undergo cervical imaging
75803217|NCT03570554|Drug|Naproxen Sodium (Aleve, BAY117031)|660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)
75803218|NCT03570554|Drug|Acetaminophen ER|3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)
75803219|NCT03570554|Drug|Celecoxib|200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)
75803220|NCT03570554|Drug|Placebo|Over-encapsulation capsule, 4 days, oral (Treatment D)
75942917|NCT02984267|Other|Palpation|Using palpation only to evaluate the spine prior to epidural placement
75942918|NCT03130725|Procedure|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
75942919|NCT03130725|Procedure|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
75942920|NCT04579575|Device|Trans-abdominal Ultrasound|"All patients will undergo trans- abdominal and trans-vaginal examination (The trans-abdominal US was performed for virgin patients or patients with large tumors that cannot be completely seen by the TV route) performed on the devices available in South Egypt Cancer Institute in supine position.~The most important b-mode parameters (such as gain, frequency, number of foci and their depth, etc.) of the US machines were manually adjusted to obtain similar image impressions.~The morphological features of each AM, and independently categorized the US images of each AM according to the O-RADS published by ACR and GI-RADS simple rules . The results of consensus reviewing were used to calculate the validity of each US classification system.~The definite diagnoses of AM were preferentially established based on~Histo-pathological findings and other modalities."
75942921|NCT03469557|Drug|Tislelizumab|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
75942922|NCT03469557|Drug|Cisplatin|Subjects will be treated with cisplatin 80 mg/m² IV on Day 1 during each 21-day cycle. Cisplatinwill be given for up to 6 cycles.
75942923|NCT03469557|Drug|5-FU|Subjects will be treated with 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. 5-FU will be given for up to 6 cycles.
75942924|NCT03469557|Drug|Oxaliplatin|Subjects will be treated with oxaliplatin 130 mg/m² IV on Day 1 during each 21-day cycle. Oxaliplatin will be administered for up to 6 cycles.
76117253|NCT03682601|Drug|10% sinecatechins ointment|Topical 10% sinecatechins ointment will be applied three times per week up to once daily.
75345175|NCT01499147|Drug|fludarabine/ melphalan|All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl).
75345176|NCT01499147|Drug|ATG|Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
75345177|NCT00823082|Drug|Antithrombin III|Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
75345178|NCT01382303|Drug|Pentoxifylline|Pentoxifylline 400mg three times a day
75345179|NCT01382303|Drug|Placebo|placebo tablet three times a day
75656218|NCT02804880|Other|A4 leaflet|The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
75656219|NCT02804880|Behavioral|Brief advice|Very brief, minimal and general smoking cessation advice
75803221|NCT03630172|Procedure|Dry needling|Using a thin, filiform needle to penetrate a muscle and its trigger point to produce a local twitch response
75803222|NCT04459624|Procedure|Erector Spina Plane Block|Group E (ESP block) will be applied 20 ml of % 0.25 bupivacaine between the erector spina muscle and transverse process at the 8th thoracic level. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
75803223|NCT04459624|Procedure|Quadratus Lumborum Block 2|Group Q (QLB2 block) lumbar interfacial triangle (LIFT) will be applied 20 ml of % 0.25 bupivacaine. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
75803224|NCT04004208|Drug|Eylea (Aflibercept, BAY86-5321)|Solution in a sterile glass vial, Dose A, IVT injection.
75803225|NCT04004208|Procedure|Laser photocoagulation|Transpupillary conventional laser ablative therapy
75803226|NCT03727412|Drug|Drugs, Generic (Naprosyn)|naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
75345180|NCT03008993|Behavioral|HQIS implementation|
75803227|NCT03727412|Drug|Placebo Oral Tablet|placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
75803228|NCT03643952|Drug|Daptomycin for Injection|Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.
76117254|NCT03681041|Other|Standard treatment|Treatment according to guidelines for pancreatic trauma according to the Chinese Trauma Association and the American Association for the Surgery of Trauma
75354677|NCT04791943|Drug|Melatonin 10 MG|3 melatonin 10mg capsules will be given to the treatment arm
75354678|NCT04791943|Drug|Lactose pill|3 lactose pills will be provided to the control arm
75656220|NCT02804880|Other|12-page booklet|12-page smoking cessation self-help booklet
75656221|NCT05758155|Other|mental health literacy training supported by creative drama|nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.
75803229|NCT03725306|Device|Librata|Hyperthermic endomyometrial treatment via Librata catheter and balloon device
75803230|NCT03035032|Drug|Leuprolide|Subcutaneous Injection
75942925|NCT03469557|Drug|Capecitabine|Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
75942926|NCT04466553|Device|NICO BrainPath™ System|Patients who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for participation in the trial by their treating physician. Once blood pressure has been stabilized and the best medical treatment has been determined, the patient will need to undergo a standard of care, repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.
75803231|NCT03629184|Drug|Baloxavir Marboxil|"Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days."
75803232|NCT03629184|Drug|Oseltamivir|Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
75803233|NCT03725228|Drug|Magnesium Sulfate|Magnesium Sulfate 15mg/kg/h
75803234|NCT03725228|Drug|Lidocaine|Lidocaine 1,5mg/kg/h
75803235|NCT03732872|Diagnostic Test|Biopsy tissue analysis|biopsy samples for IHC staining and PCR
75942927|NCT03109587|Dietary Supplement|Vivomixx|900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
75345181|NCT05236634|Drug|Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
76091089|NCT04378530|Behavioral|Fixed Anchoring Strategy|The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders. Participants will be asked to use a cue given by the research team. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
75656222|NCT05758155|Other|mental health literacy training supported by classroom instruction|nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
75803236|NCT03732872|Diagnostic Test|Saliva analysis|Saliva samples for miRNA 21 expression analysis
75656223|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
75656224|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
75656225|NCT00957905|Drug|Alvocidib Hydrochloride|Given IV
75656226|NCT00957905|Drug|Fluorouracil|Given IV
75656227|NCT00957905|Drug|Leucovorin Calcium|Given IV
75656228|NCT00957905|Drug|Oxaliplatin|Given IV
75803237|NCT03725072|Drug|Evobrutinib|Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain [14C]-evobrutinib.
75803238|NCT04393948|Radiation|Phase 1|Dose Level 1 - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
75803239|NCT04393948|Radiation|Phase 1|Dose Level 2 - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
75803240|NCT04393948|Radiation|Phase 2|Arm A - No irradiation
75803241|NCT04393948|Radiation|Phase 2|Arm B - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
75803242|NCT04393948|Radiation|Phase 2|Arm C - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
75803243|NCT03549338|Drug|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
75803244|NCT03549338|Drug|Futuximab|Futuximab is one of two mAb components that constitute Sym004.
75803245|NCT03549338|Drug|Modotuximab|Modotuximab is one of two mAb components that constitute Sym004.
75942928|NCT03109587|Dietary Supplement|Placebo|maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
75942929|NCT02675751|Device|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
75656229|NCT02804724|Other|No intervention|
75656230|NCT04042597|Drug|Anlotinib Hydrochloride|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
75656231|NCT02804568|Drug|ALKS 3831|Oral capsule, daily administration
75656232|NCT00862225|Drug|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
75656233|NCT00862225|Drug|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
75656234|NCT00862225|Drug|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
75656235|NCT02804646|Drug|recombinant human endostatin|endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
75803246|NCT03629028|Diagnostic Test|Residual myometrium thickness|The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
75803247|NCT03629028|Diagnostic Test|Niche Presence|The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.
75803248|NCT03629028|Diagnostic Test|Adjacent myometrium thickness|The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
75942930|NCT03109665|Diagnostic Test|SD-OCT Angiography|SD-OCT Angiography
75942931|NCT03109665|Diagnostic Test|SD-OCT|SD-OCT
75942932|NCT02643381|Drug|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
75942933|NCT02643381|Drug|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
75656236|NCT02804646|Drug|pemetrexed plus cisplatin or carboplatin|the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
75942934|NCT02643381|Procedure|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
75942935|NCT02643381|Device|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
75942936|NCT04363281|Other|preoperative questionnaire|"Three questions to predict acute pain:~Verbal numeric score Anxiety 0-10~Anticipated postoperative pain level~Anticipated analgesic requirements~Speilberger STATE-TRATE inventory index~Pain Catastrophizing Scale"
75942937|NCT04363281|Other|PACU questionnaire|parturients will be approached and requested to fill out a questionnaire regarding intraoperative pain, medication consumption, anxiety and nausea.
76091090|NCT02068846|Drug|Ciprofloxacin|Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
75656237|NCT00862303|Biological|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
75656238|NCT00862303|Drug|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
75656239|NCT02768831|Other|CPAP|Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
76091091|NCT02068846|Drug|Placebo|Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
75656240|NCT02768831|Other|Tidal volume|The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
75656241|NCT00854191|Device|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
75656242|NCT02807142|Biological|NC 1 cell therapy|All patients will be treated with NC1
75656243|NCT02858297|Drug|Glucosamine sulfate|Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
75656244|NCT02858297|Drug|triamcinolone acetonide|Topical corticosteroid
75656245|NCT00858325|Drug|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
75803249|NCT03629028|Diagnostic Test|Niche Measurements (depth of niche, width of niche, length of niche)|The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.
75656246|NCT04236648|Procedure|Minimally-invasive non-surgical therapy (MINST)|subgingival root debridement with a minimally-invasive approach using piezoelectric/ultrasonic instruments
75656247|NCT04200846|Behavioral|Exercise intervention|Subjects in this group will be asked to exercise 5 days a week. Two days on-site with an Exercise Physiologist and the other 3 days at home.
75656248|NCT02804490|Dietary Supplement|Conventional white maize|Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
75656249|NCT02804490|Dietary Supplement|Provitamin A carotenoid biofortified maize|Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
75803250|NCT03724838|Drug|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day
75803251|NCT03724838|Drug|Sildenafil Citrate|Patients will take Sildenafil Citrate 40mg every 8 hours
75803252|NCT03724838|Drug|Placebo to Esomeprazole|Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day
75803253|NCT03724838|Drug|Placebo to Sildenafil Citrate|Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
75803254|NCT03744234|Procedure|PRP|Autologous platelet-rich plasma
75803255|NCT03744234|Procedure|Steroid Injection|Steroid injection
75942938|NCT04363281|Other|Postoperative questionnaire|Parturients will be approached at 24 hours postpartum and questioned regarding anxiety levels and medication consumption and requested to fill out the OBSQOR 11 questionnaire at 24 hours postpartum.
75942939|NCT04363281|Other|Postoperative questionnaire- Obstetrician|The attended obstetrician will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
75942940|NCT04363281|Other|Postoperative questionnaire- anesthesiologist|he attended anesthesiologist will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
75942941|NCT03469479|Drug|FOLFOX|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
75942942|NCT03469479|Procedure|Hepatic resection|R0 resection
75942943|NCT02974855|Biological|PF-06741086|PF-06741086 subcutaneous (SC) injection
75942944|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
75803256|NCT03549104|Behavioral|Fear Reduction Intervention|FREE
75803257|NCT03549104|Behavioral|Attention Control|DSMES
75942945|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
75942946|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
76117255|NCT00981045|Drug|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
76117256|NCT00981045|Drug|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
75345182|NCT05236634|Drug|Alpha Blockers|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
75942947|NCT04473651|Drug|Lu AG06479|capsules, orally (Part A and B)
75942948|NCT04473651|Drug|Placebos|Placebo - capsules, orally (Part A only)
75942949|NCT04328961|Drug|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
75345183|NCT05236634|Drug|Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
75345184|NCT05236322|Device|soft tissue laser|Surgical laser used in excision purpose
75942950|NCT04328961|Drug|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
75345185|NCT01422161|Drug|Botulinum Toxin commonly known as BOTOX®|"A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study."
75345186|NCT01422161|Drug|Placebo|The control group will receive a placebo injection.
75345187|NCT05236166|Drug|Rapid withdrawal of antiepileptic|"Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
75345188|NCT05236166|Drug|Slow withdrawal of antiepileptic|"Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
75345189|NCT03495128|Other|Bed Rest|3 days of head down tilt (-6 degrees) bed rest
75345190|NCT03495128|Other|Reconditioning|daily resistance training (for 3 days) on one leg
75656250|NCT02804490|Dietary Supplement|Preformed vitamin A fortified maize|Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
75656251|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
75656252|NCT00960323|Drug|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
75656253|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
75656254|NCT00617929|Biological|anti-thymocyte globulin|administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
75942951|NCT04228575|Behavioral|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend ~15 mins. per week/per client.
75942952|NCT03653533|Device|MiniMed™ 640G|The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin
75942953|NCT03653533|Device|Captor CGM Enlite®|The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level
75942954|NCT03653533|Device|SmartGuard®|This SmartGuard® function is used to improve the glycemia stability in real condition
75942955|NCT04172025|Diagnostic Test|Analysis of Bacterial Genome|genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
75942956|NCT03653377|Other|Self administrated questionnaire|Questionnaires are distributed to patients with their parents during their visit to the CF center.
75942957|NCT00455403|Drug|Chloroquine|One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
75942958|NCT00455403|Drug|Placebo Comparator|Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
75942959|NCT04061031|Behavioral|Parent-Child Interaction Therapy (PCIT)|A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.
75942960|NCT04061031|Behavioral|Child-Centered Therapy with Parent Education|A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
76117257|NCT04432896|Other|Dietary protocol|Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.
75345191|NCT01502813|Drug|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
75345192|NCT00865202|Drug|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
75942961|NCT04397367|Drug|Ruxolitinib 10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
75942962|NCT04397367|Drug|Ruxolitinib 5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
75942963|NCT04397367|Drug|Ruxolitinib 5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
75942964|NCT04397367|Drug|Ruxolitinib 2.5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
75942965|NCT05160909|Procedure|Beach Chair Position|Patients positioned in beach chair during arthroscopic shoulder stabilization
75942966|NCT05160909|Procedure|Lateral Decubitus Position|Patients positioned in lateral decubitus position during arthroscopic shoulder stabilization
76091092|NCT03282864|Device|Bedroom air filtered by an air filtration device to remove airborne pollutants|The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
76091093|NCT03282786|Other|carbon dioxide insufflation during colonoscopy|Use of Carbon dioxide instead of air insufflation
76091094|NCT03289884|Other|MRI scan (not involving ionising radiation)|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
76091095|NCT03289884|Other|Ultrasound scan (not involving ionising radiation)|The US scan will be conducted by a nominated researcher
76091096|NCT03289884|Other|Ex vivo MRI scan of cyst fluid sample|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
76091097|NCT03289884|Other|Aspiration of cyst fluid|For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist
75656255|NCT00617929|Biological|rituximab|administered 375 mg/m^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
75942967|NCT05160831|Biological|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.
75656256|NCT00617929|Drug|clofarabine|administered 30 mg/m^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
75803258|NCT03736434|Behavioral|Mindfulness and DASH Diet Education|"Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines."
76091098|NCT03289884|Other|Blood test for confirmation of serum IgG levels consistent with hydatid infection|The blood sample will be drawn by a member of the clinical team
76091099|NCT03289806|Procedure|Samples of fibroblasts from Tenon's capsule|
76117258|NCT00981435|Drug|Prednisolone 1%|Prednisolone 1% to lasered eye 4 times/day for 4.5 days
76117259|NCT00981435|Drug|Ketorolac|Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
76117260|NCT00981435|Drug|Artificial Tears|Artificial saline tears to lasered eye 4 times/day for 4.5 days
76117261|NCT03676907|Procedure|double layer suturation technique|in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
75656257|NCT00617929|Procedure|stem cell transplantation|administered on Day 0 per institutional guidelines.
75656258|NCT02804412|Other|Control group|This is the control group with 14 h treatment over 10 workdays.
75656259|NCT02804412|Other|CIAT-group|Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
75656260|NCT02804412|Other|communication treatment group (CTG)|Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
75656261|NCT00862381|Drug|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
75656262|NCT00862381|Drug|Placebo|NaCl 0.9%
75656263|NCT02800668|Device|DJBL (Duodenal jejunal bypass liner, EndoBarrier)|Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
75942968|NCT03471897|Diagnostic Test|Glycosaminoglycan plasma score|A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
75942969|NCT04394169|Behavioral|Intervention program|"Medical visits:~There will be three medical visits stipulated as follows:~Visit 1 Intervention Group, four weeks after hospital discharge.~Visit 2 Intervention Group, eight weeks after hospital discharge.~Visit 3 Intervention Group, 18 weeks after hospital discharge.~Components of visits:~Interview and physical examination.~Therapeutic education about the intensive care syndrome orally and with a specific document that will be delivered at the end of the visit.~Therapeutic education around pain. If the patient reports pain, a specific document will be prepared that will be delivered at the end of the visit.~Psychological intervention:~Inclusion criteria for psychological intervention: Patients with a score higher than 8 on the HAD (hospital anxiety and depression) test depression subscale.~Description :~The intervention protocol consists of 7 weekly sessions lasting one hour and a half. The intervention in depression is based on Rehm's model of self-control."
75942970|NCT03470337|Drug|Phlogenzym|Bromelain / Trypsin / Rutoside
75942971|NCT03470337|Other|Placebo|
75942972|NCT04162275|Drug|Finamine tablets|taken Finamine tablets orally
75942973|NCT04162275|Drug|Placebo tablets|taken Placebo tablets orally
75942974|NCT03470259|Drug|IV adminstration of EMI-137|Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.
75942975|NCT03470259|Device|Multispectral Fluorescence Reflectance Imaging|A multispectral Near Infrared Fluorescence (NIRF) camera system sensitive for EMI-137 fluorescence will be used for only ex-vivo Multispectral Fluorescence Reflectance Imaging (MFRI) of the thyroid gland and/or lymph node compartment.
75942976|NCT03470259|Device|Spectroscopy|A spectroscopy system sensitive for EMI-137 fluorescence will be used for only ex-vivo spectroscopy of the thyroid gland and/or lymph node compartment.
75942977|NCT02979613|Drug|TAF|25 mg tablet administered orally once daily
76117262|NCT03063996|Procedure|peripheral IV access procedure|standard of care guided IV access into peripheral vein excluding IJ
75345193|NCT00865202|Drug|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
75345194|NCT01424033|Drug|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
75345195|NCT01503749|Drug|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
75656264|NCT02860637|Other|Questionnaires|Sexual function was assessed by the International Index of Erectile Function (IIEF) and level and degree of injury were determined following the guidelines of the International Standards for Neurological and Functional Examination Classification of Spinal Cord Injury.
75345196|NCT01503749|Other|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
75345197|NCT00867932|Drug|Eculizumab|5 mg/mL solution in 5% Dextrose
75345198|NCT05236088|Device|Neuromuscular electrical stimulation application|It was applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device. It was applied for 30 minutes 3 days a week during 4 weeks
75345199|NCT05236088|Device|Sham neuromuscular electrical stimulation application|Sham group will be applied from the same device, again 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
75345200|NCT02209259|Other|PROMIS Upper Extremity Function|
75345201|NCT02209259|Other|Pain intensity|
75803259|NCT03736434|Behavioral|Education group|The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
75345202|NCT02209259|Other|PROMIS depression|
75345203|NCT02209259|Other|Positive affect negative affect scale (PANAS)|
75345204|NCT02209259|Other|standard PCS|
75345205|NCT02209259|Other|positively-adjusted version of the PCS|
75345206|NCT00825266|Drug|bosentan|Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
75345207|NCT00825266|Drug|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
75656265|NCT00858481|Drug|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
75656266|NCT00858481|Drug|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
75656267|NCT00858481|Drug|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
75656268|NCT00858481|Drug|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
75803260|NCT02892344|Drug|QMF149 150/80 μg|QMF149 150/80 μg o.d via Concept1
75803261|NCT02892344|Drug|MF 200 μg|MF 200 μg o.d. via Twisthaler®
75803262|NCT03724760|Other|personalized repeated feedback approach|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
75803263|NCT03724682|Device|Carry Life UF device|Treatment with the Carry Life UF device compared to standard PD therapy
75942978|NCT02979613|Drug|TDF|300 mg tablet administered orally once daily
75942979|NCT02979613|Drug|TAF Placebo|Tablet administered orally once daily
75942980|NCT02979613|Drug|TDF Placebo|Tablet administered orally once daily
75942981|NCT03811665|Procedure|Radiofrequency Ablation|RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.
76117263|NCT03063996|Procedure|Peripheral IJ access procedure|standard of care guided IV access into IJ
76117264|NCT00981669|Biological|rotavirus vaccine|3 doses with 6 weeks interval
76117265|NCT00981669|Biological|placebo|3 doses with 6 weeks interval
75803264|NCT03724604|Diagnostic Test|Neuron-Specific Enolase to Albumin Ratio|Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
75803265|NCT03727256|Other|ultrasound therapy|Group 1, ultrasound therapy ;1 watt/cm² dose, 1 MHz, 5 minutes
75942982|NCT03811665|Radiation|Stereotactive body radiation therapy|The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
75345208|NCT05235932|Procedure|Robotic radical total gastrectomy with D2 lymphadenectomy|Most surgical procedures are performed using the robot system.
75656269|NCT05494008|Procedure|Korean herbal medicine treatment|Korean herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients with post-traffic accident syndromes.
75656270|NCT05494008|Procedure|Non-Korean herbal medicine treatment|acupuncture, pharmacoacupuncture, cupping, chuna
75942983|NCT03469401|Other|Intervention|Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
75942984|NCT04458129|Drug|Treatment with polyethylene glycol (Macrogol 4000)|3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.
75942985|NCT03576261|Other|Preoperative colloid fluid bolus (Gelofusine)|Preoperative colloid fluid bolus
75942986|NCT03576261|Diagnostic Test|Preoperative transthoracic echocardiography|Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
75942987|NCT03469323|Drug|Succinylcholine|Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
75942988|NCT03469323|Drug|Placebo|Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
75942989|NCT05160285|Drug|Nivolumab 100 MG in 10 ML Injection|If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
75942990|NCT03652831|Other|Soft Tissue Mobilization with Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints~Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
75942991|NCT03652831|Other|Soft Tissue Mobilization without Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints~Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
75345209|NCT05235932|Procedure|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|Without the robot system, Most surgical procedures are performed using laparoscopic equipment.
75345210|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
75345211|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
75656271|NCT02858141|Other|Data collection|
75656272|NCT00858559|Device|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
75656273|NCT00858559|Device|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
75656274|NCT02800590|Drug|ABP-700|
75656275|NCT00815295|Drug|Sorafenib|Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
75656276|NCT00815295|Drug|Cetuximab|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
75656277|NCT00854269|Procedure|surgery|cervical biopsy or specimen of hysterectomy
75656278|NCT04235790|Device|Eye Tracking Device|Eye tracking glasses
75803266|NCT03727256|Other|neuromuscular electrical stimulation application|Group 2, neuromuscular electrical stimulation application;20 mins/session
75803267|NCT03567980|Drug|Crisaborole|Application of topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.
75803268|NCT03726944|Behavioral|Calm App Meditation|The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.
75345212|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
75942992|NCT03622099|Drug|Normal Saline Flush, 0.9% Injectable Solution|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
76091100|NCT03294486|Drug|Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)|"Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:~Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu~Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.~5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L."
75345213|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
75656279|NCT00630383|Biological|Live Hookworm Larvae|25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
75656280|NCT00630383|Other|Histamine|0.01% histamine solution is pipetted onto a plaster dressing.
75803269|NCT03726944|Behavioral|Unnamed Consumer-Based App Meditation|The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.
75803270|NCT03726944|Other|Educational Control|The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.
75803271|NCT02894840|Biological|an inactivated influenza vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
75803272|NCT02894840|Other|Placebo|The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
75803273|NCT03358030|Drug|ISIS 416858|Subcutaneous injection
75803274|NCT03358030|Drug|Placebo|Subcutaneous injection
75803275|NCT03566810|Drug|Test GXR|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
75803276|NCT03566810|Drug|Reference GXR|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
75942993|NCT03470181|Dietary Supplement|Ensure|Participants will perform a Nutrient Drink Test. This consists of drinking 125mL of liquid Ensure four times, at five-minute intervals.
75942994|NCT03622021|Drug|AK111 or Placebo|All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
75942995|NCT05160051|Diagnostic Test|68Ga-FAPI-46 PET Scan|68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.
76091101|NCT05235048|Procedure|Tooth extraction|Atraumatic tooth extraction without flap elevation
76091102|NCT05235048|Procedure|Tooth extraction and socket seal with connective tissue graft|Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)
75803277|NCT04013932|Behavioral|KUPAA Intervention Group (Culturally Tailored Family Psychoeducation)|"KUPAA is composed of 3 key components:~1-2 Joining sessions [~30 to 45 minutes each] give the facilitator and participants a chance to get to know each other before KUPAA groups begin and allows time for questions.~Educational Workshop is an interactive, one day workshop offering information about biological, psychological and social aspects of mental illness; the nature, effects and side effects of psychiatric treatments; what families can do to help recovery and prevent relapse; and guidelines for managing mental illnesses.~12 Family psychoeducation group sessions [~1.5 hours each session] occur weekly in multi-family groups. These sessions follow an empirically tested format and focus on solving problems that interfere with treatment, illness, and symptoms management and that support coping skills and personal care. Case management may also be provided."
75345214|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
75345215|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
75345216|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
75345217|NCT05235776|Other|observation|observation
75476622|NCT05897281|Procedure|SHOOT exercise group|In addition to routine training, the experimental group will be done a progressive resistance band exercise program (SHOOT) created for shooters, 3 days a week for 8 weeks, accompanied by a physiotherapist.
75656281|NCT04042519|Diagnostic Test|Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.|This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.
75656282|NCT04042519|Diagnostic Test|Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.|We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.
75656283|NCT04042519|Diagnostic Test|Routine blood test|Blood routine test results include CRP, PCT, white blood cell count, red blood cell count, neutrophil percentage, eosinophil, basophil, et al.
75656284|NCT02806830|Drug|Optive|Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
76091103|NCT05235048|Procedure|Tooth extraction and socket seal with BRG and connective tissue graft and|Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
75803278|NCT03628716|Biological|CV301|"Prime with MVA-BN-CV301 (nominal titer 1.6 x 10^9 Inf.U) given subcutaneously (SC) on Day 1 and Day 22. One dose = four 0.5 mL injections. One injection = nominal titer 4 x 10^8 Inf.U in 0.5 mL.~Boost with FPV-CV301 (nominal titer of 1 × 10^9 Inf.U in 0.5 mL, given SC every 21 days for 4 doses (on days 43, 64, 85, and 106), followed by boosts every 6 weeks until 6 months on trial (i.e., days 148 and 190), then every 12 weeks until completion of 2 years. One dose = one 0.5 mL injection."
75803279|NCT03628716|Biological|Atezolizumab|Atezolizumab fixed dose of 1200 mg intravenous on Day 1 of each 21-day cycle
75942996|NCT03653299|Device|Placebo or Active Phototherapy (MR4)|Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.
75942997|NCT03469245|Other|numerical simulation|After patients have been treated by fenestrated endovascular of society Vascutek data will be collected by society Vascutek and send to Predisurge society. They will perform numerical simulation and compare with the method of Vascutek.
75345218|NCT01385579|Other|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
75345219|NCT01386983|Drug|5ARI|Dutasteride or Finasteride
75656285|NCT03203135|Behavioral|Nutritional prevention programme|The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
75803280|NCT03844906|Drug|SAGE-718|SAGE-718 in combination with Ketamine
75803281|NCT03844906|Drug|Placebo|Placebo in combination with Ketamine
75803282|NCT03736200|Other|Exergaming group|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (1/day)
75803283|NCT03736200|Other|Physiotherapy|Physiotherapy 4-week-long.
75803284|NCT03736200|Other|Exergaming group 2/day|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/day)
75803285|NCT04002960|Device|INVSENSOR00036|Noninvasive regional oximeter
75803286|NCT04002648|Procedure|Right minithoracotomy|Incision of the right chest between 3rd and 4th or 4th and 5th intercostal space
75942998|NCT03130491|Procedure|Transcatheter Aortic Valve Replacement (TAVR)|placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
75345220|NCT01386983|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
75656286|NCT02610699|Other|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
75942999|NCT03130491|Device|EMBLOK filter|Embolic Filter Protection System During TAVR
75656287|NCT02610699|Other|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
75943000|NCT03471819|Diagnostic Test|Serum serotonin level|blood sample will be obtained to evaluate serum level of serotonin
75943001|NCT03653221|Other|Standard patients with VRNET|In group of standard patients with VRNET, the medical students examine the standard patient of neurologic deficits. When they examine, they get some information of neurologic signs via the VRNET which presents neurologic deficits directly by alternating facial expressions. The students should interpret that signs to have a diagnosis.
75943002|NCT03653221|Other|standard patients|In group of standard patients, those neurological deficits are presented only by words or pictures which are not realistic.
75943003|NCT04055077|Device|Low-flow nasal oxygenation (LFNO) ASA I|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
75943004|NCT04055077|Device|Low-flow nasal oxygenation (LFNO) ASA II|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
76091104|NCT05235048|Procedure|Tooth extraction and socket seal with membrane placement, BRG and connective tissue graft|Atraumatic tooth extraction without flap elevation, position of a collagen membrane and bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
75656288|NCT02806752|Drug|Triamcinolone Acetonide|Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
75656289|NCT02806752|Drug|Ranibizumab|Intravitreal inject 0.5mg of Ranibizumab.
75656290|NCT00854425|Drug|L-asparaginase|L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
75803287|NCT04002648|Procedure|Sternotomy|Longitudinal resection of the sternum
75803288|NCT03732378|Dietary Supplement|Omega-3 capsule|Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)
75803289|NCT03639792|Procedure|gastric cancer surgery|Gastric cancer surgery
75803290|NCT03840616|Drug|Oteseconazole (VT-1161) 150mg capsule|600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.
75803291|NCT03840616|Drug|Fluconazole 150mg capsule|150mg administered every 72 hours in 3 sequential doses starting on Day 1.
75803292|NCT03840616|Drug|Placebo|Administered once weekly starting on Day 14.
76117266|NCT03676673|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
75943005|NCT04055077|Device|Low-flow nasal oxygenation (LFNO) ASA III|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
75943006|NCT04055077|Device|High-flow nasal oxygenation (HFNO) ASA I|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
75943007|NCT04055077|Device|High-flow nasal oxygenation (HFNO) ASAII|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
75943008|NCT04055077|Device|High-flow nasal oxygenation (HFNO) ASA III|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
75943009|NCT03618693|Procedure|Spinal anesthesia|Injection of a single shot of local anesthetic bupivacaine 0.5% combined with 20 mcg fentanyl intrathecally.
76091105|NCT03294252|Drug|5-Fluorouracil|Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
76091106|NCT03294252|Drug|L-Folinic acid|Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
75476623|NCT05897281|Procedure|routine training group|The control group will continue their routine training
75656291|NCT00814983|Procedure|Naive T-cell Depleted Stem Cell Transplant|"The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant."
75656292|NCT00814983|Procedure|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
75943010|NCT03618693|Device|TAP Block|TAP block with a single shot of 20ml ropivacaine 0.375% combined with 75 mcg clonidine bilaterally
75943011|NCT03618693|Other|Standard|Concomitant systemic administration of lidocaine (as an adjuvant) to the standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.
76091107|NCT03294252|Drug|Oxaliplatin|Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
76091108|NCT03282708|Other|Fresh stool collection|"One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
76091109|NCT03294174|Drug|Ropivacaine injection|Ropivacaine administered to provide nerve block
76091110|NCT03289494|Other|Balanced diet high in Slowly Digestible Starch|The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
75345221|NCT01387139|Drug|Ketamine|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
75656293|NCT00814983|Device|Isolex device from Baxter|
75656294|NCT02804256|Other|Blood Sample Collection|10 patients with ICCs to provide a second blood sample (20mls - 2 tablespoons) on top of the samples that will be collected for the biorepository.
75656295|NCT02544529|Drug|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
75943012|NCT01064167|Drug|Tranexamic Acid|In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
75943013|NCT04205305|Drug|conventional blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure <180 mmHg.
75943014|NCT04205305|Drug|intensive blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure <140 mmHg.
75943015|NCT03470103|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Use of intravitreal aflibercept in routine clinical practice in Latin America
75943016|NCT02974543|Device|Sham Treatment: unimodal auditory stimulation|All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.
75943017|NCT02974543|Device|Active Treatment: Bimodal auditory-somatosensory stimulation|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone."
75943018|NCT03471741|Radiation|IMRT with concomitant boost|
75943019|NCT03471741|Radiation|3D-RT with sequential boost|
76091111|NCT03289494|Other|Balanced diet low in Slowly Digestible Starch|The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
75476624|NCT05895344|Radiation|Proton-therapy|Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)
75476625|NCT05895344|Radiation|Photon radiotherapy|Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)
75476626|NCT05894941|Other|Corrective Exercises|A total of 6 evidence-based exercises and stretches namely; Upper trapezius stretch, Sternocleidomastoid stretch, pectoral stretch; Chin tuck exercise, YTWL exercise, and resisted/isometric neck extension exercise will be prescribed to the exercise group while the postural education group will follow the guidelines provided by National Institutes of Health (NIH) for using computers and other sources. The control group will receive no intervention.
75656296|NCT02544529|Drug|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
75943020|NCT01064947|Drug|Retapamulin 1%|Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
75943021|NCT02523027|Dietary Supplement|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
76091112|NCT03282630|Procedure|Sphenopalatine ganglion acupuncture|"active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment."
75345222|NCT01387139|Drug|Ketamine Co-administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
75943022|NCT02523027|Dietary Supplement|Oral nutritional supplement|(List No- P968/Z0)
75943023|NCT02523027|Other|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
75943024|NCT05391009|Diagnostic Test|PNF|PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation
75943025|NCT05391009|Diagnostic Test|TRT|The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
75943026|NCT05159271|Device|Azeol spray nasal|Azeol Spray Nasal is a nasal spray intended to reduce the nasal congestion due to rhinitis, rhinosinusitis and colds which is marketed. The ID is conforming to the European Union (EU) legislation and is bearing the CE-mark. The ID is manufactured by PILEJE S.A.S (France).
75943027|NCT05159271|Device|Placebo nasal spray|with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
75656297|NCT02806596|Drug|Sevoflurane|After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
75943028|NCT03469947|Drug|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
75943029|NCT05157087|Drug|Omalizumab|"Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab."
75943030|NCT02974153|Biological|ALD403 (Eptinezumab)|
75943031|NCT02974153|Biological|Placebo|
76091113|NCT03289416|Combination Product|Pure PRP II|The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
75345223|NCT00870896|Drug|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
75345224|NCT03008135|Other|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
75656298|NCT02610621|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
75656299|NCT00854503|Drug|Simvastatin|20 mg/day in one oral administration
75656300|NCT00854503|Drug|Rosuvastatin|20 mg/day in one oral administration.
75656301|NCT00854659|Drug|ABT-102|BID tablets, 7 days of treatment
75656302|NCT00854659|Drug|Placebo|BID tablets, 7 days of treatment
75656303|NCT02610543|Drug|UCB5857|Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
75656304|NCT02610543|Drug|Placebo|Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
75656305|NCT00854737|Dietary Supplement|cytidine|cytidine (2g po daily for 4 months)
75943032|NCT05134623|Diagnostic Test|immunohistochemistry of tumors samples|routine resection of tumors, further analysis and immunohisochemical staining of the tissue slides.
75943033|NCT05124639|Behavioral|Group self-management support program for anxiety disorders|The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.
76091114|NCT03289416|Combination Product|PureBMC|The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
76091115|NCT03294096|Dietary Supplement|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
76091116|NCT03294096|Other|Routine care|Routine post-op care
76091117|NCT03282552|Device|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
76091118|NCT03294018|Other|Recording heart rate changes|Recording heart rate changes during planned sugammadex administration.
76091119|NCT03289338|Drug|Zoledronic Acid|Zoledronic acid 5mg intravenous once a month for 3 months
76091120|NCT03289338|Drug|Methylprednisolone|Methylprednisolone 1gm intravenous once a month for 3 months
76091121|NCT03289338|Drug|Placebos|Normal saline intravenous once a month for 3 months
75803293|NCT03744078|Device|Foley balloon catheter|18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
75803294|NCT00088413|Biological|PANVAC-V|Patients receive 2 x 10(8) pfu PANVAC-V (vaccinia) subcutaneously on Day 1.
76091122|NCT02069704|Drug|Bevacizumab biosimilar (BEVZ92)|"Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
76091123|NCT02069704|Drug|Avastin® (bevacizumab, reference product)|"Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
75345225|NCT03008135|Other|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
75656306|NCT00854737|Dietary Supplement|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
75803295|NCT00088413|Biological|PANVAC-F|Patients receive 1 x 10(9) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43 then every month for 12 doses then every 3 months until disease progression or toxicity.
75656307|NCT00854737|Drug|placebo|sugar pill
75656308|NCT02800044|Device|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
75656309|NCT05223153|Diagnostic Test|Optical Coherence tomography angiography|Measurement retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia
75656310|NCT00858715|Drug|aspirin|100 mg aspirin
75656311|NCT00858715|Drug|clopidogrel|75 mg (Arm 1) and 150 mg (Arm 2)
75803296|NCT00088413|Drug|Sargramostim (GM-CSF, Leukine)|100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.
75803297|NCT04924348|Procedure|Experimental: WALANT procedure|"The WALANT technique, performed under ultrasound, includes two punctures.~The first is a puncture through a medial approach above the wrist and includes two injections. A first subcutaneous injection reproducing a bar above the wrist flexion line, and a second injection above the median nerve. The volumes injected vary from 8 to 10 milliliters (ml).~The second puncture is performed at the base of the palmar surface of the hand and consists of a 10 ml subcutaneous injection of the local anesthetic in order to take advantage of the vasoconstrictive effects of adrenaline, thus allowing the surgical procedure to be performed without a pneumatic tourniquet."
75943034|NCT04053829|Device|HOLOBalance|"The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists."
75656312|NCT02806284|Biological|PPSV23, Act-HIB|"described in Arm description"
75656313|NCT02544997|Drug|Poziotinib|12mg P.O. for 2wks q21days
75656314|NCT00960869|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
75656315|NCT00960869|Drug|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
75656316|NCT02799888|Drug|Maraviroc|Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.
76091124|NCT02314546|Drug|Midazolam|"Study participants will be randomly assigned to one of three treatment groups:~Group 1 - Placebo - Control patients will receive intranasal saline.~Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.~Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam."
76091125|NCT02314546|Drug|xylocaine|Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
76091126|NCT02314546|Drug|saline placebo|Placebo - Control patients will receive intranasal saline.
76091127|NCT02314936|Dietary Supplement|Litesse powder containing 12 g polydextrose|12 g polydextrose
76091128|NCT02314936|Dietary Supplement|Litesse powder containing 8 g polydextrose|8 g polydextrose, 4 g maltodextrin
76091129|NCT02314936|Dietary Supplement|Litesse powder containing 4 g polydextrose|4 g polydextrose, 8 g maltodextrin
76091130|NCT02314936|Dietary Supplement|Placebo|12 g Maltodextrin
76091131|NCT03289260|Drug|Imiquimod 5% cream|Patients receive topical Imiquimod therapy for 12 weeks.
76091132|NCT03289260|Drug|Placebo cream|Patients receive topical Doritin therapy for 12 weeks
76091133|NCT03289260|Procedure|Fulguration|Surgical Excision and Fulguration of condyloma
76091134|NCT03289182|Drug|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
76091135|NCT03289104|Device|Steel Wires|Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
75345226|NCT00825344|Drug|Etanercept|50 mg subcutaenous preoperatively
75656317|NCT02799888|Drug|Cyclosporine (in HLA-Unrelated Donor Transplantation)|Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.
75803298|NCT04924348|Procedure|Active Comparator: Axial ALR|The anesthetic protocol in the axillary block consists of performing a puncture, using a needle (50 mm 22G with a short bevel), under the armpit at the level of the axillary hollow after skin disinfection. This puncture, performed under ultrasound, allows the injection of the local anesthetic around the median, radial, ulnar and musculocutaneous nerves. The volume injected per nerve can vary from 5 to 8 ml depending on the visual appreciation during the injection.
75943035|NCT04053829|Other|OTAGO Home Exercise Programme|The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 8 week programme.
75345227|NCT00825344|Drug|Saline|Given subcutaneously preoperatively
75345228|NCT00871286|Procedure|Pre-treatment Sinus CT Scan|Pre-treatment Sinus CT Scan
75345229|NCT00871286|Procedure|Post-treatment Sinus CT Scan|Post-treatment Sinus CT Scan
75656318|NCT02799888|Drug|Tacrolimus (in HLA-Mismatched Related Donor Transplantation)|Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
75803299|NCT04924348|Procedure|Active Comparator: Truncal ALR|The anesthetic protocol in truncal block consists in injecting the local anesthetic around the median and ulnar nerves by a puncture performed at the elbow or forearm (depending on the practitioner's experience). The volumes injected remain the same and the puncture is also performed under ultrasound guidance. Additional local anesthesia is administered by injecting an additional 5 ml above the wrist flexion line to block the sensory territory of the musculocutaneous nerve.
75803300|NCT03995784|Biological|Coagulation Factor IX variant|Single intravenous injection of CB2679d/Dalcinonacog alfa
75943036|NCT04054063|Drug|HSK3486+ etomidate|
75943037|NCT03652519|Behavioral|Exercise Training|Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
75943038|NCT05107245|Diagnostic Test|1test1|Loss of bacterial diversity diagnosis
75943039|NCT03652441|Drug|Brentuximab Vedotin|BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
75943040|NCT02508532|Drug|Avapritinib|avapritinib tablets
75943041|NCT04455165|Procedure|Aortic valve replacement|Aortic valve replacement with or without associated cardiac surgery (coronary bypass, mitral valve surgery,...)
76091136|NCT03289104|Device|ZipFix Sternal Closure System|Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
75345230|NCT01426763|Biological|CINRYZE with rHuPH20|
75345231|NCT00825500|Drug|Inhaled Placebo|Inhaled Staccato placebo (0 mg)
75345232|NCT00825500|Drug|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
75345233|NCT00825500|Drug|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
76091137|NCT03289026|Drug|Aripiprazole|Doses were flexibly titrated to between 10 and 30 mg once daily based on the individual needs of the patient as determined by the investigator.
76091138|NCT03293940|Procedure|Cryoablation|The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.
76091139|NCT03293940|Procedure|Therapeutic Peripheral Nerve Block (tPNB) Injection|"During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.~The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone."
76091140|NCT02460510|Drug|Mannitol|
76091141|NCT02460510|Drug|3% hypertonic saline|
75345234|NCT01504997|Device|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
75345235|NCT03489434|Behavioral|Intervention|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
75656319|NCT02799888|Drug|Methotrexate|Methotrexate will be administered intravenously at a dose of 15 mg/m^2 on day +1, and 10 mg/m^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m^2 IV bolus on Day +1, and 10 mg/m^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10^9/L.
75656320|NCT00618787|Device|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
75345236|NCT01505933|Drug|Dexmedetomidine|"Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
75345237|NCT01505933|Drug|propofol|"Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.~Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
75656321|NCT00618787|Device|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
75656322|NCT02860715|Drug|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
75803301|NCT03995784|Biological|Coagulation Factor IX variant|Daily subcutaneous injections of CB2679d/Dalcinonacog alfa for 28 days
75345238|NCT00825734|Drug|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
75345239|NCT00825734|Drug|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m^2)
75656323|NCT02860715|Drug|Placebo|This is the placebo of GX-I7 described above.
75656324|NCT02800200|Procedure|Platelet rich plasma|Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
75656325|NCT02800200|Device|shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
75803302|NCT03787654|Device|electroacupuncture|"BL33 and BL35 are inserted by needles of 0.30×75mm size till a depth of 60~70mm. SP6 is inserted by needle of 0.30×40mm size till a depth of 25-30mm. After manipulation and deqi sensation generation, the electrodes will be attached to the acupoints transversely with 20Hz continuous wave and an electricity current of 2mA-6.5mA at BL33 and BL35, and 1-3.5mA at SP6. The current is adjusted from zero to the degree where patients can tolerate.~Subjects receive 3 sessions per week（every other day ideally) for 12 weeks, 36 sessions in total."
75803303|NCT03787654|Device|sham electroacupuncture|"In sham electroacupuncture group, sham acupoints 1 cun(≈15mm） horizontally outwardly lateral to BL33 and BL35, and 0.5 cun (≈10mm) horizontally behind SP6 are stimulated by needles of 0.30×40mm size. The needles are inserted to a depth of 2-3mm to stand still, without any manipulation and sensation of deqi. The electrodes will also be attached to needles with an electricity current of 0.1-0.3mA.~The sessions will be the same as the electroacupuncture group."
75943042|NCT04455321|Procedure|Suture materials effect on istmocel|Effect of suture materials with different absorption times on istmocel
75943043|NCT02918071|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
75943044|NCT05162703|Diagnostic Test|AsthmaTuner|Exercise challenge test using AsthmaTuner mobile phone app and spirometer.
75943045|NCT05162625|Drug|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|Topical moxifloxacin 0,5% 01 drop every 3 hours
75943046|NCT05162625|Drug|Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV]|Intravenous ciprofloxacin 400mg every 12 hours and cefazolin 1000mg every 6 hours
75943047|NCT05314959|Other|Physician Awareness|The patients' pre-visit Control Preference Scale responses are shared with their physician.
75943048|NCT05314959|Other|Usual Care|The patients' pre-visit Control Preference Scale responses are not shared with their physician.
75943049|NCT02506816|Drug|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
75943050|NCT02506036|Other|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
75943051|NCT05017168|Drug|CT-P63|CT-P63 will be administered
75943052|NCT05017168|Drug|Placebo|Placebo-matching CT-P63
75943053|NCT05009901|Drug|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha lipoic acid 600 mg daily for 8 weeks
75943054|NCT05009901|Drug|Placebo|Placebo one tablet daily for 8 weeks
75943055|NCT05015374|Dietary Supplement|Astaxanthin|350 mg/capsule (2mg Astaxanthin)
75943056|NCT05015374|Dietary Supplement|Placebo|Placebo
75943057|NCT04988529|Behavioral|Smartphone-based serious game intervention|Smartphone-based serious game intervention consists in the use of a serious game designed specifically to improve depressive symptoms. The psychological content consists of CBT intervention with the following psychotherapeutic components: Motivation for change, Psychoeducation, Cognitive Flexibility, Behavioural Activation, and positive psychotherapeutic strategies. To encourage physical activity, the serious game incorporates a mixed reality through physical activities such as taking a walk in real life affects aspects inside the game.
75943058|NCT04970680|Procedure|glossopharyngeal nerve block|glossopharyngeal nerve block either blindly or using the ultrasonic technique
75943059|NCT03109509|Behavioral|Fitbit + Pokemon Go|Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.
75345240|NCT00826202|Drug|D-serine|60 mg/kg/day
75656326|NCT00813813|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
75943060|NCT03109509|Behavioral|Fitbit Only|Participants received a Fitbit Zip to wear daily for 8 weeks.
76091142|NCT02460744|Radiation|Hypofractionation|Radiation dose of 34Gy in 10 fractions over 2 weeks.
75345241|NCT00826202|Other|Placebo|Inert Placebo
75345242|NCT02153528|Drug|double rimfampicin|Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
75943061|NCT04421326|Other|Analysis of the clot|Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
75345243|NCT02153528|Drug|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
75345244|NCT00872534|Drug|acetylsalicylic acid|325mg once a day for 7 days
75345245|NCT00873782|Other|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
75345246|NCT02513160|Drug|Beclomethasone Dipropionate 640|Beclomethasone Dipropionate 640 mcg BAI
75345247|NCT02513160|Drug|Placebo|"Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug."
75656327|NCT02803866|Behavioral|Training program CAP-PREM|1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
75656328|NCT02857985|Device|3D RA|3D RA is realised just after angioplasty.
75803304|NCT03787654|Drug|Solifenacin|Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
75803305|NCT03744000|Procedure|Immediate stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
75943062|NCT05162235|Device|Augmented Reality-assisted localization of solitary pulmonary nodule|In this study, AR was utilized to assist in the localization of SPNs during sublobectomy lung resection in patient to assess the safety and effectiveness of the technique.
75943063|NCT01063855|Drug|Placebo|Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
75943064|NCT01063855|Drug|Dapoxetine|30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
75943065|NCT01063855|Drug|PDE5I (phosphodiesterase-5 inhibitor)|Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
76091143|NCT04137042|Drug|Saline|Intraoperative fluid therapy is administrated by using 0.9% saline
76091144|NCT04137042|Drug|Balanced crystalloid|Intraoperative fluid therapy is administrated by using balanced crystalloid
75656329|NCT02857985|Device|MRI|MRI is realised between 24h and 96h post angioplasty.
75656330|NCT00862615|Other|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|"Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.~Isotopes are :~(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)"
75656331|NCT04118621|Device|chest ultrasound|detection of postoperative pulmonary complications after cardiothoracic surgery
75656332|NCT00859105|Drug|Imiquimod 5%: manufactured by Apotex|Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
75943066|NCT05162001|Drug|Disulfiram 250 mg|Disulfiram used qd during nine weeks to observe effects on body weight
75943067|NCT03469167|Device|CEGP003|Application of CEGP003 to peptic ulcer bleeding
76091145|NCT02334436|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
76091146|NCT02334436|Other|0.9% sterile, unpreserved saline|Placebo Comparator Arm
76091147|NCT03293862|Device|prophylactic polypropilene mesh|Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
76091148|NCT03293862|Procedure|Midline Fascial Closure|midline fascial closure using uninterrupted PDS 0 suture
76091149|NCT03293862|Device|vacuum drainage system|Placement of a subcutaneous vacuum drainage system
75345248|NCT02513160|Drug|Beclomethasone dipropionate via 320 mcg BAI|Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
75345249|NCT02513160|Drug|albuterol/salbutamol|Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
75345250|NCT02513160|Drug|Beclomethasone dipropionate via 320 mcg MDI|Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
75345251|NCT00874094|Biological|Platelet rich fibrin matrix|0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
75943068|NCT03469167|Device|Injection Tx|Injection of epinephrine to peptic ulcer bleeding
76091150|NCT01958788|Behavioral|Cognitive-Behavioural Treatment|12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
75345252|NCT01507103|Biological|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
75345253|NCT01507103|Drug|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
75656333|NCT00859105|Drug|Adara 5% Cream US|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
75943069|NCT01063153|Drug|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
75803306|NCT03744000|Procedure|Deferred stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 3 to 7 days after TIMI Ⅲ flow has achieved.
75803307|NCT00086385|Drug|Nicotine polacrilex, Bupropion|Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
75803308|NCT03993288|Drug|Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
75803309|NCT03993288|Drug|MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
75803310|NCT01093989|Dietary Supplement|Ferrous Sulphate Syrup|Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
75943070|NCT05161299|Procedure|Surgery (across all specialities)|Surgery performed by a surgeon in an operating theatre during the patient inclusion period
75943071|NCT01062841|Behavioral|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
75943072|NCT05161221|Drug|OxyCODONE 5 mg Oral Tablet|Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control
75656334|NCT00859105|Drug|Adara 5% Cream Canada|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
75943073|NCT05161221|Drug|Naproxen 500 Mg|Participant will receive Naproxen 500 Mg post surgery for pain control
76091151|NCT03288870|Drug|BCD-100|monoclonal antibody to PD-1 receptor
76091152|NCT03288870|Drug|Docetaxel|Chemotherapy drug (taxane)
76091153|NCT03288792|Device|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
75476627|NCT05894941|Other|Postural Education|Postural guidelines for doing daily activity especially sitting for prolonged periods and using electronic devices like computers and other electronic devices.
75476628|NCT05887323|Device|Implantation of the Tendril 2088 lead in the LBBA|Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.
75476629|NCT05884801|Drug|QLS1103|Oral dose
75656335|NCT00859105|Drug|Imiquimod Vehicle|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
75656336|NCT02610387|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
75656337|NCT02610387|Device|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
75656338|NCT02804334|Procedure|Psychiatric Questionnaires|
75656339|NCT02804334|Procedure|Blood draw|
75656340|NCT00859183|Drug|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
75656341|NCT00859183|Drug|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
76117267|NCT03064308|Other|Exercise Programme|Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
75656342|NCT00859183|Drug|Placebo|Placebo oral
75656343|NCT05757765|Other|deprescribing pharmacotherapy approach (DPA)|A new way of medication review in patients with sarcopenia. This method is based on previous scientific research and is aimed at minimizing pharmacotherapy. The aim is to combat symptoms and complaints and to stop (preventive) medication as much as possible
75476630|NCT05878639|Drug|3 bottles of Lactulose oral solution|Patients will take lactulose for bowel preparation.
75476631|NCT05878639|Drug|3L-polyethylene glycol|Patients will take 3L-polyethylene glycol for bowel preparation.
75476632|NCT05876858|Drug|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
75943074|NCT05161221|Drug|Tylenol Pill|Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control
75943075|NCT05161221|Drug|Liposomal bupivacaine|Participants will receive pre-operative adductor canal block with liposomal bupivacaine (Exparel)
75943076|NCT05161221|Procedure|Femoral Nerve Catheter|Participants will receive pre-operative femoral nerve catheter
75943077|NCT02505334|Drug|liraglutide|Injected subcutaneously s.c. (under the skin) once daily.
75943078|NCT03469089|Drug|Ketamine 0.58|Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
75943079|NCT03469089|Drug|Ketamine 0.31|Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
75656344|NCT05757765|Other|STOPP-START deprescribing approach (SSA)|The usual care in the geriatric medicine in the Netherlands consisting of a medication review based on the STOPP-START criteria. These criteria have been combined in a protocol that describes when certain medication(groups) must be continued or discontinued for specific patient characteristics.
75943080|NCT03469089|Drug|Modafinil|Modafinil tablet 100 mg placed in a capsule
75943081|NCT03469089|Drug|Placebo for ketamine|0.9 % NaCl infusion solution
75943082|NCT03469089|Drug|Placebo for modafinil|Placebo capsule for modafinil capsule
75656345|NCT02803944|Drug|Azithromycin|
76091154|NCT02070640|Drug|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
76091155|NCT02070640|Device|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
76091156|NCT03282474|Drug|Sofosbuvir|Sofosbuvir 400 MG Oral Tablet [Sovaldi]
75656346|NCT00859261|Procedure|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
75656347|NCT00859261|Procedure|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
75656348|NCT05297721|Other|Knowledge|Measuring the level of knowledge about skin tears
75656349|NCT02803710|Other|Microbiological study|
75656350|NCT05980312|Other|Splint Immobilization|Patients will be randomized to receive a splint following their surgical procedure.
75656351|NCT05980312|Other|Early Motion|Patients will be randomized to receive no splint following their surgical procedure.
75803311|NCT01090401|Device|Linox smart S DX|ICD lead
75803312|NCT05093608|Drug|Selinexor Pill|Selinexor 60 mg or 80 mg (oral table) will be administered once a week.
75803313|NCT05093608|Drug|Bevacizumab|Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.
75803314|NCT05093608|Drug|Atezolizumab|Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.
75803315|NCT01090557|Other|Collection of exhaled breath|balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
75803316|NCT03625492|Behavioral|Reducing Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
75943083|NCT05161143|Drug|Donafenib|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once."
75943084|NCT01062061|Biological|VARIVAX™|Attenuated live varicella vaccine
75943085|NCT03652207|Other|isomaltulose (Palatinose(TM)|isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
75943086|NCT03652207|Other|Sucrose|sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
75943087|NCT04969510|Drug|10 mg PRAX-114|Once daily oral treatment
75943088|NCT04969510|Drug|20 mg PRAX-114|Once daily oral treatment
75943089|NCT04969510|Drug|40 mg PRAX-114|Once daily oral treatment
75943090|NCT04969510|Drug|60 mg PRAX-114|Once daily oral treatment
75943091|NCT04969510|Drug|Placebo|Once daily oral treatment
75943092|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F1|Febuxostat extended-release (XR) capsules formulation 1
75943093|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F2|Febuxostat XR capsules formulation 2
75943094|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F3|Febuxostat XR capsules formulation 3
75943095|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F4|Febuxostat XR capsules formulation 4
75943096|NCT05014516|Drug|129Xenon gas|Observational
75943097|NCT01061671|Drug|simvastatin|40 mgms of simvastatin daily
75943098|NCT01061671|Drug|Placebo|Matched placebo pill daily
75943099|NCT04969120|Drug|Metoclopramide 10mg|this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
75943100|NCT04969120|Drug|Placebo (0.9 sodium chloride)|this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
75943101|NCT03652363|Drug|glial cell line-derived neurotrophic factor|Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
75943102|NCT00709995|Drug|Enzastaurin|Administered orally
75943103|NCT00709995|Drug|Sunitinib|Administered orally
75943104|NCT00709995|Drug|Placebo|Administered orally
75345254|NCT01507103|Other|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
75345255|NCT00874250|Device|GORE CTAG Device|Endovascular aortic stent-graft
75656352|NCT05980260|Other|Symptom-based Dosing Approach|During this approach to care, all enrolled infants with NOWS at the study site will be treated with the symptom-based dosing approach if they meet the withdrawal threshold for pharmacologic treatment. Participants may receive up to 3 doses of the study site's preferred opioid during a 24-hour period (midnight to midnight) to treat signs of withdrawal once the threshold for pharmacologic intervention is met. If a 4th dose is required within a 24-hour period, the study site will transition to the scheduled opioid taper algorithm used at the study site to complete the infant's pharmacologic treatment.
75656353|NCT05980260|Other|Scheduled Opioid Taper Approach|• During this approach to care, all enrolled infants with NOWS at the study site will be treated with the study site's usual scheduled opioid taper approach, as detailed in each site's treatment algorithm, if they meet the withdrawal threshold for pharmacologic treatment.
75656354|NCT05980221|Diagnostic Test|Metabolomics|Plasma samples taken for the investigation of the metabolome
75943105|NCT03652129|Procedure|Disinfection|Disinfection maneuver using LASER and nano irrigant
75943106|NCT02503540|Drug|Aflibercept|Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
75943107|NCT03621865|Dietary Supplement|TG|Turmipure GOLD™ 30% curcuminoids (300 mg)
75656355|NCT05980221|Diagnostic Test|13C MTGT|sequential breath samples taken for investigation of PEI (reference test)
75943108|NCT03621865|Dietary Supplement|STE|Standard turmeric powder extract 95% curcuminoids (1500 mg)
75656356|NCT05980156|Drug|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
75656357|NCT05980156|Drug|Chloroquine|Treatment of females 10 years old and older in Arm 1 and treatment of all participants in Arm 2.
75803317|NCT03625492|Behavioral|Adopting the USDA Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
75803318|NCT03991494|Drug|[14C]-pamiparib|During the treatment phase, pamiparib 60 mg administered orally twice daily
75803319|NCT05080036|Other|Medio-lateral imbalance|Thrust on the pelvis in the medio-lateral direction in order to create a balance perturbation
75803320|NCT03736122|Drug|BSG-001|"BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle)."
75803321|NCT03736044|Drug|TNF-blockers suspension in patients with rheumatoid arthritis|in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
75803322|NCT05062798|Procedure|Standart bottle|"After the surgery, standard bottle will be used for feeding.~Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
75943109|NCT03621865|Dietary Supplement|NOV|Novasol® Liquid micellar formulation 6% curcuminoids (1000 mg)
75943110|NCT03621865|Dietary Supplement|PHYT|Meriva® Turmeric Phytosome formulation 20% curcuminoids (1000 mg)
75943111|NCT03621865|Dietary Supplement|TEP|Turmeric extract C3 complex® 95% curcuminoids (1500mg) + BioPerine® 95% piperine (15 mg)
75943112|NCT04222101|Diagnostic Test|Oral glucose tolerance test|measure insulin, glucose and FGF21 levels in response to oral glucose challenge
75943113|NCT04054297|Behavioral|High GI/SFA diet|Subject will adhere to a 2 week high GI/SFA diet.
75943114|NCT04054297|Behavioral|Low GI/SFA diet|Subject will adhere to a 2 week low GI/SFA diet.
75943115|NCT04054219|Device|Bone graft substitute|Evaluation of a device made of deproteinized bovine bone material as bone graft substitute in different indications requiring bone grafting procedures before implant placement
75943116|NCT04921215|Behavioral|Morning bright light|All participants will receive phase advancing morning bright light.
75943117|NCT03652597|Device|Transcranial magnetic stimulation (TMS)|Subjects receive TMS on several cortical brain locations, while recording the heart rate.
75943118|NCT02502526|Device|Centurion® Vision System, 45° Balanced Tip|
75943119|NCT02502526|Device|Centurion® Vision System, 45° MFK Tip|
75943120|NCT02502526|Device|lnfiniti® Vision System, 45° MFK Tip|
75943121|NCT02502526|Device|INTREPID® Ultra infusion sleeve|
75943122|NCT02502526|Device|Ultra infusion sleeve|
75345256|NCT02480010|Drug|Pertuzumab|Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
76091157|NCT02460354|Drug|Metformin|Metformin 500 mg pill dispensed once orally
76091158|NCT02071108|Device|Shockwave Lithoplasty System|
76091159|NCT03293706|Other|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
75345257|NCT01388777|Device|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
75345258|NCT01388777|Procedure|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
76117268|NCT00981825|Drug|Fluoride|Whole mouth brushing for 7 days
75345259|NCT01388777|Procedure|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
75345260|NCT00875342|Drug|DCS|1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
75345261|NCT00875342|Other|Placebo|2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
76091160|NCT03293706|Other|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
76091161|NCT03293706|Other|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
76091162|NCT03293706|Other|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
75476633|NCT05876858|Drug|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
75656358|NCT05980156|Drug|Sulfadoxine pyrimethamine|Treatment will be with SP and chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
75656359|NCT05980143|Other|Metacognitive Therapy|The transdiagnostic Metacognitive model suggests that psychological difficulties arise from the activation of a thinking style called the CAS (Cognitive Attentional Syndrome). Metacognitive Therapy (MCT) aims to bring the CAS under control. The therapist helps the patient to learn new ways of relating to stressful thoughts.
75656360|NCT05980130|Behavioral|Rumination-Focused Cognitive Behavior Therapy|The RFCBT exclusively addresses one possible mechanism underlying depression, rumination. In general, a participant and their therapist will identify when the participant ruminates in an unhelpful manner, what triggers the rumination, what function the rumination fulfills for the participant, and how the participant already does to stop ruminating. Building on this knowledge both together will change the environment to reduce the likelihood of the participant to ruminate, use consciously strategies to stop rumination when it occurs, and replace rumination by more helpful strategies. In the proposed single subject study, the participant and the therapist will meet in person or using a UofL approved video platform up to 18 times for 50-minutes.
75656361|NCT05980078|Other|Interactive consent|They were randomized to complete an interactive consent.
75656362|NCT05980078|Other|Standard consent|They were randomized to complete a standard written consent.
75656363|NCT05980052|Behavioral|Physical Activity|Theory-driven behavioral physical activity promotion intervention.
75656364|NCT05980026|Drug|oral omega-3 fatty acids supplementation|oral omega-3 fatty acids supplementation
75656365|NCT05980026|Dietary Supplement|Placebo|Patients in placebo group received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
75656366|NCT05979987|Behavioral|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
75656367|NCT05979987|Behavioral|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message prompts patients to click on a link to read the story about the patient.
75656368|NCT05979987|Behavioral|Persuasion via anecdote without link|The message will contain a link to an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message won't contain a link to the story, but it will briefly describe the story.
75803323|NCT05062798|Procedure|Squeezable bottle|"After the surgery, squeezable bottle will be used for feeding.~Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
75803324|NCT03735810|Drug|LBS-008|LBS-008 oral capsules
75803325|NCT03735810|Drug|Placebos|Oral capsules
75803326|NCT03383770|Procedure|Regional Anesthesia Touhy|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A touhy cannula is used.
75803327|NCT03383770|Procedure|Regional Anesthesia Facet|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A facet cannula is used.
75943123|NCT05390697|Other|Educational videos|Educational videos include (1) danger and prevention of VPD; (2) rationales of completing immunization; (3) immunization amid the COVID-19 pandemic; (4) vaccine misconception; and (5) adverse events following immunization and how to treat it. Each video was less than 2 minutes with clear and straightforward messages according to the National Institute of Health guideline for health education. Materials were distributed through WhatsApp and viewed for five weeks.
75943124|NCT02972515|Behavioral|See Me Smoke-Free|See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.
75943125|NCT02972515|Device|Smart phone|See Me Smoke-Free mHealth app delivered via a smart phone
76091163|NCT03293706|Other|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
76091164|NCT03293628|Procedure|Vaginal Packing|This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
76091165|NCT02008942|Drug|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
76091166|NCT02008942|Drug|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
76091167|NCT03288636|Drug|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
76091168|NCT03288636|Drug|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
76091169|NCT03288636|Drug|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
76091170|NCT03288636|Drug|Placebo|Placebo
76117269|NCT00981825|Drug|Triclosan/Fluoride|Brush whole mouth twice daily for 7 days
76091171|NCT02071420|Behavioral|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
76091172|NCT02071420|Behavioral|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
76091173|NCT02071420|Behavioral|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
76091174|NCT02071420|Device|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
75345262|NCT00876200|Drug|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
75345263|NCT00876200|Drug|Placebo|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
75345264|NCT02512302|Drug|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
75345265|NCT02512302|Drug|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
75345266|NCT02512302|Drug|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
75345267|NCT02512302|Drug|Seebri® Breezhaler® with activated charcoal|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
75656369|NCT05979987|Behavioral|Persuasion via research|This message will mention that research has shown promptly closing health gaps saves lives.The message will contain a link to an official website that supports the statement.
75656370|NCT05979961|Radiation|IMRT and concurrent cisplatin|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated radiotherapy (IMRT)
75803328|NCT00086307|Drug|Pramipexole|Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
75943126|NCT05012332|Procedure|Erector Spinae Plane Block|All volunteers receive an Erector Spinae Plane Block and an MRI.
75943127|NCT04455087|Other|sensitization|sensitization of doctor to decrease the prescription of abuse exams
75656371|NCT05979961|Drug|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy
75656372|NCT05979922|Behavioral|Mindfulness-based Cognitive Coping|Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.
75943128|NCT04967482|Procedure|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|The patients will receive DEB-TACE if they choose DEB-TACE as the primary treatment. DC Bead loaded with epirubicin (1 vial of DC Bead loaded with 60 mg of epirubicin) is used for chemoembolization. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. DEB-TACE) for the same patient should be consistent.
75943129|NCT04967482|Procedure|Conventional transarterial chemoembolization (cTACE)|The patients will receive cTACE if they choose cTACE as the primary treatment. An emulsion of epirubicin in lipiodol wiil be injected into the tumor feeding artery. Afterwards, microspheres or polyvinyl alcohol particles mixed with contrast agent will be administered intraarterially until arterial flow stasis was achieved. Generally, the dose of lipiodol and epirubicin should not exceed 30 mL and 60 mg for each procedure. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. cTACE) for the same patient should be consistent.
75943130|NCT04053985|Combination Product|TAI combine lenvatinib|TAI combine lenvatinib
75943131|NCT04053985|Drug|Lenvatinib|lenvatinib only
75656373|NCT05979922|Behavioral|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
75656374|NCT05979909|Drug|Mitomycin C|Mitomycin (40 mg in 40 mL of sterile water) will be administered through a Foley catheter, which will be clamped for two hours.
75803329|NCT00086307|Drug|Escitalopram|Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
75803330|NCT03624972|Behavioral|Starting the Conversation Video|The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
75803331|NCT03624972|Behavioral|Sexual and Menopausal Health Resources|Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal & sexual health clinic.
75943132|NCT04455243|Drug|N-Acetyl cysteine|150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
75943133|NCT04455243|Drug|Placebo|Matching placebo administered in the same schedule and volume as NAC
76091175|NCT01959178|Device|LD127025 MF|At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
75345268|NCT02512302|Drug|Glycopyrrolate Injection|50 mcg glycopyrrolate via IV
75943134|NCT04854993|Drug|Sugammadex 6 mg/kg|i.v. injection of an increased (by 50%) dose of sugammadex to reverse dNMB
75943135|NCT04854993|Drug|Sugammadex 4 mg/kg|i.v. injection of a standard dose of sugammadex to reverse dNMB
75943136|NCT02972359|Drug|Neridronic acid|Neridronic acid administered as intravenous infusion.
75345269|NCT01507181|Drug|Ketamine|single dose IV ketamine, .5mg/kg infused over 40 minutes
75656375|NCT05979896|Drug|Standard age based SPAQ administration for SMC|"Sulfadoxine-pyrimethamine and amodiaquine (SPAQ) is administered in standard WHO approved age based regimens as used in Seasonal Malaria Chemoprevention Programmes.~Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug. AQ Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine."
75803332|NCT04050904|Device|ExpHeart|ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the Information System. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System.
75803333|NCT05031364|Behavioral|Behavioral Interventions for Anxiety in Children with Autism (BIACA)|In the BIACA CBT program (e.g., Wood et al., 2020), clinicians work with families for 16 weekly sessions that include both the child and parent(s). In BIACA, anxiety, rigidity and inflexible routines, and irritability are all addressed using in vivo exposure therapy strategies during sessions as well as parent (and teacher) training to promote regulation across settings. ASD-related clinical needs that can impact mental health and emotion regulation such as friendship skills and social entry skills (e.g., joining games at school) are addressed with modeling, self-management, and parent- (or teacher-) implemented social coaching in daily settings. For youth with limited communication, therapy is adapted through the use of play-based representations of challenging situations and an emphasis on more action-oriented exposure therapy.
75803334|NCT05031364|Behavioral|Treatment-as-Usual Supplemented by Internet-Based Self-Instruction (MEYA)|Participating clinicians are expected to have varied training in numerous psychological therapy procedures (e.g., insight-oriented procedures, cognitive interventions, family therapy, etc.), any or all of which they may choose to implement with a participating child. These practices will be characterized through the Therapy Procedures Checklist (Weersing et al., 2002). Additionally, participating clinicians will be provided with information about self-instruction resources on CBT for children with autism, namely, the Modular Evidence-Based Practices for Youth with Autism (MEYA) website developed by our research group. MEYA is freely accessible to clinicians worldwide at meya.ucla.edu. MEYA incorporates treatment elements of both BIACA (Wood et al., 2020) and SEBASTIEN (Wood et al., 2021), which was designed to address additional autism-related clinical needs (e.g., reciprocal conversation). Clinicians in this arm will provide up to 16 therapy sessions.
75943137|NCT04455009|Dietary Supplement|Fitness Drink Formula|Single drink provided following baseline assessments
75803335|NCT01086579|Device|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
75943138|NCT04454775|Diagnostic Test|coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.|
76091176|NCT01959178|Device|Air Optix Aqua MF|At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
76091177|NCT03107832|Procedure|thoracic epidural anesthesia procedure|general anesthesia procedure
76091178|NCT03293472|Drug|Ropivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
76091179|NCT03293472|Drug|Bupivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
76117270|NCT00983307|Drug|Erlotinib|Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
75943139|NCT04911777|Drug|Pentarlandir™ UPPTA|Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
75943140|NCT04911777|Drug|Placebo|The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
75943141|NCT05390619|Procedure|50% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
75943142|NCT05390619|Procedure|70% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
75943143|NCT04857411|Behavioral|Peers LEAD plus HLWD|Combined Peers LEAD and Healthy Living with Diabetes is a culturally-appropriate program to increase medication adherence
75943144|NCT03770559|Procedure|Minimal Invasive RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in MI-RAMPS group will be treated by minimal invasive RAMPS surgery
75943145|NCT03770559|Procedure|Open RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in Open-RAMPS group will be treated by open invasive RAMPS surgery
75803336|NCT01086579|Device|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
75803337|NCT03743922|Drug|Calciferol|calciferol capsule
75943146|NCT01790035|Drug|LGG|
75943147|NCT01790035|Drug|Placebo|
76117271|NCT00983307|Radiation|Hypofractionated Radiotherapy|Patients undergo hypofractionated thoracic RT 5 days a week for approximately 2.5 weeks beginning on day 0. Patients also receive erlotinib hydrochloride PO daily beginning on day -5 and continuing for up to 24 months in the absence of disease progression or unacceptable toxicity.
76117272|NCT03979794|Behavioral|Behavioral Intervention for Wellness and Engaged Living (Be-WEL)|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
75656376|NCT05979805|Other|Conventional Educational interventions|Conventional educational methods can be verbal, written or visual and can be combined for greater understanding and effectiveness in oral health and dietary routines. The education are imparted in the first appointment of the appliances cementation by a video and oral health instruction booklet and each patient receive an oral hygiene kit. This education is repeated in month 1 and 3 after appliances cementation.
75656377|NCT05979805|Behavioral|Motivational intervention|In addition to the conventional educational method, a motivational interviewing (MI) by Miller and Rollnick of 30 minutes will be used, with an initial script according to the stage of change in each patient in T0. The reinforcements of motivational interviewing are in month one and three after the installation of the braces, they will have the same methodology but will be focused on the aspects that in the previous session or in the clinical assessment were detected as the most important deficiencies or risk factors for the patient.
75656378|NCT05979766|Other|Manual lymphatic drainage versus marian clark drainage|Manual lymphatic drainage versus marian clark drainage
75656379|NCT05979753|Other|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH IN SPRINTER
75803338|NCT03743922|Drug|Placebo|placebo capsule
75803339|NCT02780206|Other|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
75803340|NCT03988842|Drug|Alteplase|Lyophilized powder for reconstitution in 50mg vials
75803341|NCT03988842|Drug|Unfractionated heparin|Heparin sodium in 0.45% sodium chloride injection for intravenous use
75803342|NCT03988842|Drug|Placebo|Saline solution reconstituted to mimic Alteplase 50mg vial
75943148|NCT03651817|Device|Mechanical ventilation|Patients will be ventilated with anesthesia machine according to the group they belong to
75943149|NCT05390541|Behavioral|Empowered to Test Yourself|There will be 5 sessions of the intervention, all of which will follow the same format. Participants will be sent push notifications for each session. Each session will begin with using relevant constructs from sIMB (i.e., information and behavioral skills). Next, participants will choose positive outcomes resulting from the behavior, barriers to performing the behavior (mental contrasting), select situational cues and action plans to overcome selected barriers (implementation intentions), and practice typing in implementation intentions and positive outcomes from memory (memory practice). To ensure participants retain the implementation intentions, we will use memory practice. Participants will be asked to self-code if they are correct or incorrect. Lastly, participants will learn behavioral skills to engage in each of the 5 actions to increase self-efficacy.
75943150|NCT01381159|Behavioral|Motivational Communication|Brief MC sessions focused on medication adherence within 4-6 week period
75943151|NCT01381159|Behavioral|Control|Standard medical care
75943152|NCT03651739|Device|Knee Connect|An electronic goniometer with smart phone application
75943153|NCT04723251|Behavioral|taking photographs|"Participants will photograph images (using a cell phone) that invoke a feeling of gratitude. At least 1 photograph (at any time of the day) should be taken for a period of three weeks.~Once the photo images are captured, the participant should spend a moment looking at the image and reflecting on why they are grateful for the subject of the photograph."
75943154|NCT03604185|Behavioral|Choir Singing|A weekly 2-hour group choral session over fourteen weeks. Plus an optional weekly 1-hour online musical and vocal training session.
75943155|NCT03604185|Behavioral|Music Appreciation|A fourteen week course which will emphasize analytic listening to musical excerpts, and will match the choir class in terms of duration, homework demands, and instructor.
75943156|NCT00843817|Drug|Pulmozyme|Pulmozyme® 2.5mg by inhalation
75803343|NCT03988842|Drug|Apixaban|Apixaban tablet
75803344|NCT02668822|Drug|ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)|Medicated vaginal ring
75803345|NCT02668822|Drug|Placebo vaginal ring|Placebo vaginal ring
75803346|NCT02668822|Drug|Ibuprofen|Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
75803347|NCT04112589|Drug|Quizartinib|Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.
75803348|NCT04112589|Drug|Fludarabine|30 mg/m2 intravenous days 1 to 4 of the cycle
75803349|NCT04112589|Drug|Cytarabine|2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle
75803350|NCT04112589|Drug|Idarubicin|10 mg/ 2 intravenous days 1 to 3 of the cycle
75803351|NCT04112589|Drug|glycosylated G-CSF|daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle
75803352|NCT02524288|Drug|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
75943157|NCT04655547|Other|Dietary guidance|Dietary guidance with focus on texture and energy intake, preformed by certified dietitians.
75803353|NCT03624504|Device|Micra Transcatheter Pacing System (TPS)|Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements
76091180|NCT03288558|Other|A comprehensive perioperative mechanical ventilation strategy|"1) Intervention group.~Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
76091181|NCT02071810|Drug|BIA 9-1067|
76091182|NCT02071810|Drug|Placebo|
75345270|NCT01507181|Drug|Midazolam|single dose IV midazolam, .45mg/kg infused over 40 minutes
76091183|NCT02715258|Drug|Bexagliflozin|tablets containing 20 mg bexagliflozin
75345271|NCT00877058|Behavioral|preventive home visit|
75345272|NCT00877058|Behavioral|senior meetings|
75345273|NCT01428245|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
75476634|NCT05872490|Other|Semi-structured interviews|An interview guide was developed for each population. Depending on the population interviewed, this interview guide focuses on the current state of driving, the obstacles and levers to driving, the representations related to driving by the elderly, their opinion concerning the implementation of a potential aptitude test and more generally their opinion on policies related to road safety.
75656380|NCT05979714|Other|Patient-centered injection site|CAB-RPV LA will be delivered in a trans-friendly injection clinic at Bridge HIV, which is centrally located in SF. The clinic is staffed by physicians, nurses, and peer navigators who are experienced working with the trans community and are experts in delivery of injectable formulations. For patients unable to attend follow-up clinic visits, arrangements will be made for a clinical provider and peer navigator to conduct a home visit for injection delivery. This implementation strategy will overcome structural barriers where it is difficult to get a visit appointment, and when appointments are missed, even harder to re-schedule. The central location in a quiet, safe and trans-affirming clinical site will make injections easy-to-access. Because the Bridge HIV clinic is not a primary care site, injections can be delivered with minimal wait times due to low patient load relative to clinical capacity.
75943158|NCT03651661|Drug|human insulin|human insulin administered as nasal spray
75943159|NCT03651661|Drug|placebo|placebo administered as nasal spray
75943160|NCT03651661|Diagnostic Test|Pupillography|Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.
75943161|NCT01682317|Behavioral|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, < 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
75943162|NCT03574389|Biological|13vPnC|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
76091184|NCT02715258|Drug|Placebo|tablets matching the appearance of bexagliflozin tablets
75345274|NCT01428245|Drug|Estrace (estrogen)|oral estrace, 0.5-1 mg once a day for seven days
75345275|NCT00877370|Drug|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
75476635|NCT05872490|Other|Questionnaire|The questionnaire asks people aged 80 and over included in the PROOF cohort about their relationship to driving, their driving status, their societal and personal environment, the circumstances in which they stopped driving, recent accidents and, more generally, their driving habits.
75476636|NCT05871684|Drug|BTK inhibitor|Intervention were given during bridging therapy and maintanance treament of CAR-T cell therpay.
75476637|NCT05871684|Drug|PD-1 inhibitor|Intervention were given during maintanance treament of CAR-T cell therpay.
75803354|NCT02954952|Device|PSI Rev 1.X|PSI Rev 1.X is an older version of the PSI measurement.
75803355|NCT02954952|Device|PSI Rev 2.X|PSI Rev 2.X is a newer version of the PSI measurement.
75803356|NCT03547154|Biological|Pegylated interferon alfa-2b|Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg
75803357|NCT03547154|Biological|Interferon alfa-2b|Daily SC injection of interferon alfa-2b, 5 MIU/m^2
75803358|NCT02275546|Drug|Placebo vaginal ring|Drug-free placebo vaginal ring
75803359|NCT02275546|Device|Single-use, non-sterile applicator|Single-use, non-sterile, plastic applicator for insertion of vaginal ring.
75803360|NCT03624192|Device|RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings
75803361|NCT03624192|Other|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
75803362|NCT03724292|Drug|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
75803363|NCT03724292|Drug|VTP-43742|VTP-43742 administered as oral capsule(s) once daily
75943163|NCT03574389|Biological|Hib|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
75943164|NCT04455945|Procedure|Open Rectal cancer surgery|Open sphincter preserving surgery for rectal cancer
76091185|NCT01959490|Biological|trastuzumab|Given IV
76091186|NCT01959490|Biological|Pertuzumab|Given IV
75803364|NCT03034954|Device|Active HD-tDCS|Participants will receive active HD-tDCS at 3mA for 20 minutes
76091187|NCT01959490|Drug|docetaxel|Given IV
76091188|NCT01959490|Drug|carboplatin|Given IV
76091189|NCT01959490|Drug|doxorubicin|Given IV
76091190|NCT01959490|Drug|cyclophosphamide|Given IV
76091191|NCT01959490|Drug|paclitaxel|Given IV
76091192|NCT01959490|Drug|Bevacizumab|
76091193|NCT03282318|Drug|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
75345276|NCT02210039|Device|SECM Probe|Imaging of the esophagus using SECM probe and system.
75476638|NCT05867953|Device|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Adjunct Real-time Imaging
75656381|NCT05979714|Behavioral|Patient-centered adherence support|A Trans peer navigator will support trans women living with HIV receiving long-acting injectable treatment through our delivery model. Peer navigators will reach out to trans women using our highly effective mobile SMS platform to provide additional support before and between visits. This platform provides automated weekly check-ins for streamlined support and bi-directional asynchronous texting with a peer navigator. Peer navigators will use this SMS platform to send appointment reminders, assess needs for re-scheduling, answer questions and triage concerns regarding CAB-RPV LA, and offer support for transportation or scheduling a home visit. This approach has demonstrated efficacy in improving ART adherence and viral suppression in people living with HIV as well as retention in care and adherence to PrEP.
75803365|NCT03034954|Device|Sham HD-tDCS|Participants will receive sham HD-tDCS
75803366|NCT03546842|Biological|9vHPV vaccine|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine in a 0.5-mL intramuscular injection
75803367|NCT03724214|Combination Product|Pre-hospital interventional care bundle|"The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment.~Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres.~Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol."
76091194|NCT03282318|Drug|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
76091195|NCT02714868|Behavioral|Project TEAM|Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.
76091196|NCT02714868|Behavioral|Matched Comparison|Participants set goal to try a new activity in the community
76091197|NCT03288402|Other|ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast|effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
76091198|NCT03288246|Diagnostic Test|point-of-care viral load test|A point-of-care viral load test returns viral load test results within 90 minutes.
76091199|NCT02011516|Drug|Baclofen|
75345277|NCT00877604|Drug|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
75345278|NCT00877604|Drug|Placebo|identical placebo by oral route at the same dosing schedule
75345279|NCT01508117|Drug|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
75345280|NCT01508117|Radiation|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
75345281|NCT00878228|Drug|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
75476639|NCT05867940|Behavioral|Physical activity on prescription|"Physical activity on prescription (PAP) is a well-established method to enhance physical activity in adults in primary care. The prescribed activity should lead to moderate increase of the pulse, such as walking, cycling, swimming, or gardening, and should be performed over a longer period of time in order to achieve a change towards a more active lifestyle. The activity may be prescribed by a physiotherapist, physician, nurse, or other health professional. PAP has shown to be feasible to increase participation in physical activity and to reduce sedentary behaviour in children with cerebral palsy.~Motivational interviewing is used for our PAP with participants with disabilities. During PAP-period, the participants are asked to fill in an activity logbook."
76091200|NCT02011516|Behavioral|Psychosocial|
76091201|NCT02011516|Drug|Placebo|
76091202|NCT03287934|Device|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
76091203|NCT03287934|Device|digital light processing(dlp)|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
76091204|NCT04349410|Drug|Hydroxychloroquine, Azithromycin|FMTVDM Planar, SPECT, PET
76091205|NCT04349410|Drug|Hydroxychloroquine, Doxycycline|FMTVDM Planar, SPECT, PET
76091206|NCT04349410|Drug|Hydroxychloroquine, Clindamycin|FMTVDM Planar, SPECT, PET
76091207|NCT04349410|Drug|Hydroxychloroquine, Clindamycin, Primaquine - low dose.|FMTVDM Planar, SPECT, PET
75476640|NCT05866081|Device|Standard of care stent placement|Participants will have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
75943165|NCT04455945|Procedure|Laparoscopic Rectal cancer surgery|Laparoscopic sphincter preserving surgery for rectal cancer
75656382|NCT05979714|Other|Provider education|To support effective outreach to and education of providers on novel evidence-based practices, SFDPH has utilized public health detailing (brief educational visits via a nurse practitioner) to ensure providers are prepared to implement new interventions. This strategy has been effective in expanding the implementation of PrEP, RAPID ART initiation, and comprehensive STI screening across clinics in SF. For this study, we will develop educational materials on the CAB-RPV LA regimen, including a summary of results from Phase 3 trials (ATLAS20, FLAIR21), the FDA labeling indication, and details about SFDPH's implementation of CAB-RPV LA within our safety-net system and our new delivery model. These materials will include information on which patients will be eligible for this treatment modality and eligible for referral to our new delivery model, and how to make these referrals.
75803368|NCT03724214|Combination Product|In-hospital interventional care bundle|"In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme.~In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available."
75943166|NCT01060111|Drug|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
75943167|NCT01060111|Drug|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
75943168|NCT01060111|Drug|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
76091208|NCT04349410|Drug|Hydroxychloroquine, Clindamycin, Primaquine - high dose.|FMTVDM Planar, SPECT, PET
76091209|NCT04349410|Drug|Remdesivir|FMTVDM Planar, SPECT, PET
75476641|NCT05866081|Other|No stent placement|Participants not have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
75803369|NCT01086657|Biological|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
75803370|NCT01086657|Biological|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
75803371|NCT01090713|Drug|lisdexamfetamine|oral; 20-70mg/day
75803372|NCT01090713|Drug|Placebo control|20-70mg; oral
75476642|NCT05866081|Other|Surveys|"All participants in the trial cohort and observational arms will be asked to complete survey instruments (evaluating their pain, quality of life, and experiences following ureteroscopy, as well as surveys evaluating their opinions and preferences around ureteral stenting, etc.).~Participants will also have routine clinical data (preoperative, perioperative, and postoperative) to be collected and analyzed for research purposes."
75803373|NCT03732716|Diagnostic Test|blood pressure measurement|Intervention: Each patient's supine and standing blood pressure measurements will be recorded
75803374|NCT01086735|Biological|donor lymphocyte infusion|Donor T-cell transduction
75803375|NCT01086813|Drug|AZD3043|single dose/IV, bolus over 60secs - infusion over 30 mins
75803376|NCT03640052|Drug|Placebo oral capsule|Placebo capsule before sleep
75803377|NCT03640052|Drug|LTM1201L|LTM1201L capsule before sleep
75803378|NCT03640052|Drug|LTM1201LN|LTM1201LN capsule before sleep
75943169|NCT04586907|Drug|LY3537021|Administered SC.
75943170|NCT04586907|Drug|Placebo|Administered SC.
75943171|NCT03651583|Behavioral|Kiko exercises-combines breathing and movement|
75943172|NCT02969863|Device|Bihormonal Bionic Pancreas|Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
75943173|NCT02969863|Device|Insulin Only Bionic Pancreas|Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
75943174|NCT02969863|Other|Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
75943175|NCT02969863|Other|Not Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
75943176|NCT03651427|Drug|Estradiol|Induced hypogonadism and re-institution of CSHT
75943177|NCT05285293|Biological|Platelet Rich Fibrin (PRF)|Platelet rich fibrin (PRF) in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
76091210|NCT04349410|Drug|Tocilizumab|FMTVDM Planar, SPECT, PET
76091211|NCT04349410|Drug|Methylprednisolone|FMTVDM Planar, SPECT, PET
76091212|NCT04349410|Drug|Interferon-Alpha2B|FMTVDM Planar, SPECT, PET
76091213|NCT04349410|Drug|Losartan|FMTVDM Planar, SPECT, PET
76091214|NCT04349410|Drug|Convalescent Serum|FMTVDM Planar, SPECT, PET
76091215|NCT03287856|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
76091216|NCT03287700|Other|No intervention|No intervention will be administered to any group in this observational study.
76091217|NCT03287466|Drug|Oxygen|targeted oxygen therapy
76091218|NCT03287388|Procedure|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
75943178|NCT05285293|Biological|Platelet Rich Fibrin (PRF) and Retinol|Platelet rich fibrin (PRF) mixed with Retinol in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
76091219|NCT03287388|Drug|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
75476643|NCT05856903|Diagnostic Test|ACT|"ACT will be measured :~after in vitro spiking with unfractionated heparin of blood samples from severe hemophilia A patients already treated with emicizumab~after in vitro spiking with unfractionated heparin with or without emicizumab of blood samples from healthy volunteers"
76091220|NCT03287388|Drug|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
76091221|NCT03293316|Device|Transcranial Random Noise Stimulation|The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
75476644|NCT05856435|Behavioral|Chicago Parent Program for Foster Care|The Chicago Parent Program for Foster Care FC consists of a 12-session parent training program that focuses on building caregiver-child relationships, behavioral management strategies, managing caregiver stress, and skill maintenance.
75476645|NCT05852925|Other|Traditional Venipuncture|Traditional blood collection is performed and the necessary amount of blood is collected into the collection tubes (either SST or Lithium Heparin tubes based on the biomarker being tested).
75656383|NCT05979714|Behavioral|Improved clinic communication strategies|For SFDPH clinics, Bridge HIV providers will communicate with primary care providers through EPIC, SFDPH's electronic health record (EHR), and one of the most common EHR systems used across clinic systems in the US. For this study, secure email and/or telephone encounters within EPIC will be used to facilitate efficient referrals of TGW living with HIV from their primary providers to the Bridge HIV injection clinic and ongoing secure communication between Bridge HIV clinicians and the primary care team. For non-SFDPH clinics, communication will be via secure email or other secure communication strategies.
75656384|NCT05979662|Procedure|Endoscopic frontal sinus surgery grade 6(Draf III).|Patients will receive endoscopic frontal sinus surgery grade 6(Draf III).
75656385|NCT05979662|Procedure|Endoscopic frontal sinus surgery grade 1-3(Draf I or IIa)|Patients will receive endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).
75803379|NCT03640052|Drug|LTM1201LB|LTM1201LB capsule before sleep
75803380|NCT03640052|Drug|LTM1201LD|LTM1201LD capsule before sleep
75656386|NCT05979636|Other|Novamin containing toothpaste|children's teeth will be brushed using Novamin containing toothpaste.
75656387|NCT05979636|Other|Fluoride containing toothpaste|children's teeth will be brushed using Fluoride containing toothpaste.
75803381|NCT01094145|Other|Deep brain stimulation|DBS in the Nucleus basalis Meynert
75943179|NCT02969707|Device|MagPro TMS system (MagVenture, Denmark)|The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process. rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark). sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).
75943180|NCT02969707|Behavioral|Hypnosis|Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnosis will be employed to influence Stroop performance (conflict detection) and for pain management. The hypnotic instructions for this will be pre-recorded and played during fMRI.
76091222|NCT03293160|Other|Care management services|Patients who receive care management services will interact with a care manager who will take an inventory of the patient's needs (including social determinants of health such as housing) and provide guidance about available social supports and clinical resources.
75656388|NCT05979558|Drug|ropivacaine with dexmedetomidine|this group received with ropivacaine with dexmedetomidine
75656389|NCT05979558|Drug|Ropivacaine with placebo|this group received with ropivacaine with normal saline
75656390|NCT05979545|Diagnostic Test|Rapid Diagnostics|Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
75656391|NCT05979480|Diagnostic Test|Dual energy X-ray absorptiometry (DXA)|DXA scan to assess bone mineral density, fat mass and muscle mass.
75656392|NCT05979402|Other|Training group Face-to-face pressure ulcer training|Face-to-face presure ulcer training
75656393|NCT05979402|Other|Control group|No intervention
75803382|NCT01096797|Drug|Sevoflurane|"Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.~Anaesthesia maintenance: sevoflurane 2-3 %~Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg~Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg"
75803383|NCT00068601|Drug|cyclophosphamide|Part of planned chemotherapy regimen
75803384|NCT00068601|Drug|goserelin acetate|Given subcutaneously
75803385|NCT03638258|Drug|Roflumilast Cream 0.3%|Applied once daily for 12 weeks
75803386|NCT03638258|Drug|Roflumilast Cream 0.15%|Applied once daily for 12 weeks
75803387|NCT03638258|Drug|Vehicle Cream|Applied once daily for 12 weeks
75803388|NCT01670656|Drug|Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)|Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
75943181|NCT03651193|Diagnostic Test|Exon sequencing and Methylated sequencing|Exon sequencing and Methylated sequencing
75943182|NCT03650257|Biological|gp96|25 mcg IH
75943183|NCT03650257|Drug|Temozolomide|temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).
75943184|NCT03650257|Radiation|radiotherapy|Stupp regimen of radiotherapy
75943185|NCT03649399|Diagnostic Test|Abdominal ultrasound|Abdominal ultrasound for detection of the pancreatic stent
75943186|NCT03651115|Diagnostic Test|therapeutic drug monitoring|To monitor the blood concentrations of gentamicin and vancomycin
75943187|NCT03650179|Other|Observational study : No intervention|Observational study : No intervention. Only exporting data
75943188|NCT03649243|Drug|Propolis spray|Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
75943189|NCT03649165|Drug|Treatment A|During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
75943190|NCT03649165|Drug|Treatment B|During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
75943191|NCT03649165|Drug|Treatment C|During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
75943192|NCT03649165|Drug|Treatment D|During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
75943193|NCT03649165|Drug|Acetaminophen|Participants will receive a single 500mg dose of acetaminophen at the same time.
75943194|NCT03649087|Other|Vitrification|Vitrification of ovarian tissue
75803389|NCT01670656|Drug|Etonogestrel containing contraceptive vaginal ring (ENG-CVR)|Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles
75803390|NCT01670656|Drug|Placebo|Placebo to match vaginal ring, intravaginally for two 28-day cycles
75803391|NCT01670656|Drug|Ibuprofen|Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
75803392|NCT00068445|Drug|lamotrigine|
75803393|NCT00068445|Other|Placebo|
75803394|NCT03653208|Drug|hzVSF-v13|Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
75943195|NCT03651037|Behavioral|Thrivors+BH|Digital health platform for breast cancer patients that measures adherence and engagement.
76091223|NCT03293082|Device|CGM ON|The period of time when continuous glucose monitoring was used, in edition to SMBG
75803395|NCT03653208|Drug|Placebo|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
75943196|NCT03649009|Other|Normal Saline|Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.
75943197|NCT03649009|Drug|Thiamine|IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
75943198|NCT03649009|Drug|Hydrocortisone|If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
75345282|NCT00878228|Drug|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
75943199|NCT03649009|Other|Metoclopramide|If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
75656394|NCT05979324|Device|ABAStroke Digital Therapeutics|The total time of the study is 30 weeks in total, i.e. 15 weeks of patient recruitment and then a maximum of another 15 weeks until the end of the observation of the last patient. Within 2 weeks from the last patient, the last Monitor's visit will be performed to close the study. The patient will use the ABAStroke application for a maximum of 91 days (the minimum time is 28 days) and standard therapy, including rehabilitation (as recommended by researchers or other physicians rehabilitating a patient after a stroke).
75656395|NCT05979298|Drug|Gemcitabine|Chemotherapeutics
75656396|NCT05979298|Biological|ELENAGEN|DNA plasmid
75656397|NCT05979285|Device|N1-Headache App (by Curelator)|Digital application allowing patients to monitor their migraines, and to identify triggers and/or protectors for their migraines.
75943200|NCT03650023|Dietary Supplement|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
75943201|NCT03650023|Dietary Supplement|White egg|White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
75943202|NCT04054999|Drug|Hydroxocobalamin|Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
75943203|NCT04054999|Drug|Methylene Blue|Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
76091224|NCT03293082|Device|CGM OFF|The period of time when continuous glucose monitoring was not used, only SMBG
76091225|NCT03293004|Dietary Supplement|Hydrolyzed collagen|Escalating dose of Hydrolyzed collagen
75943204|NCT03649945|Drug|Docetaxel|75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
76091226|NCT03293004|Dietary Supplement|Vitamin C|Escalating dose of Vitamin C
75803396|NCT05053360|Behavioral|Healing Touch|"Healing Touch (HT), with a foundation in holistic nursing, is a gentle therapy that uses touch to promote health and well-being by balancing the human energy system. Healing Touch (HT) is a biofield therapy in which practitioners use their hands in a heart-centered and intentional way to provide energetic balance to support physical, emotional, mental and spiritual health. It is safe for all ages and works in harmony with, is complementary to, and may be integrated with standard medical care. Healing Touch is a collection of standardized, noninvasive techniques that clear, energize, and balance the human and~environmental energy fields."
76091227|NCT03293004|Dietary Supplement|Optimized Hydrolyzed Collagen and Vitamin C|combination of optimized doses of Hydrolyzed Collagen and Vitamin C
76091228|NCT03293004|Dietary Supplement|Gummy Placebo|Gummy placebo
75656398|NCT05979259|Other|Serious game nutrition education intervention|"Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will play the Foodbot Factory nutrition education serious game for 10-15 minutes. The Foodbot Factory serious game and lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide."
75803397|NCT05053360|Other|Control|Quiet Time (QT) session is when a subject is provided with quiet for 15 minutes
75345283|NCT01390259|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
75476646|NCT05852925|Device|Tasso+|The Tasso+ is the blood self-collection device used in the study and this device enables the collection of microliter capillary whole blood samples into compatible reservoirs. In this study, the reservoirs utilized include either SST or Lithium Heparin microtainers based on the biomarker being tested.
75656399|NCT05979259|Other|Conventional nutrition education intervention|Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will use conventional learning activities, such as worksheets, sourced from an online teaching resource repository. The lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide.
75803398|NCT03957993|Other|Occupational Therapy via Telehealth|The caregiver will be with the participant in their home environment receiving occupational therapy via Telehealth (video-calling) with the occupational therapist.
75803399|NCT03957993|Other|Standard of Care Occupational Therapy|The caregiver and participant will be in the clinic receiving occupational therapy in-person with the occupational therapist.
75803400|NCT03735342|Other|Audio Recording|All participants will be provided with a re-playable audio recording of the discharge discussion on a portable electronic device. In addition, participants will have the option to record the discharge discussion on a personally-owned smartphone or receive access to the recording online, via the Open Recording Automated Logging System (ORALS).
75803401|NCT03953469|Dietary Supplement|Passiflora incarnata|One-time administration of 1/8 tsp solid extract Passiflora incarnata providing 900mg of Passiflora incarnata
75803402|NCT05665920|Radiation|Ultra-hypofractionated whole breast radiotherapy|Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
75803403|NCT05665920|Radiation|Standard Radiation|Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
75803404|NCT03545984|Other|Simulation-based learning|Simulation-based teaching involves using done on a mannequin to simulate actual conditions
75943205|NCT03649945|Drug|Nedaplatin|80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
75943206|NCT03649945|Drug|Endostar|7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
75943207|NCT03650959|Other|Method of learning simple interrupted sutures with instrument tie|Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
76091229|NCT03292848|Drug|Brexpiprazole|Tablet
76091230|NCT03292770|Device|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
75656400|NCT05979246|Device|Lance CLEAR dental implant|The surgical procedure will be performed by experienced periodontists, all implants will be at least Ø 3.75 mm and 8-11.5 mm long. After reflecting the flaps, a bone biopsy will be harvested as part of the drilling procedure using a Ø 2.4 mm trephine drill and the implants will be seated into a crestal position
75656401|NCT05979220|Drug|Dalpiciclib combined with Letrozole|A multicenter, single arm, prospective Phase II clinical study
75656402|NCT05979194|Behavioral|Labor Care Guide|Identifying information and labor characteristics at admission, supportive care, care of the baby, care of the woman, labor progress, medication, and shared decision-making
75943208|NCT03648775|Device|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
76091231|NCT03292536|Drug|Merestinib|"*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks"
76091232|NCT03292380|Other|No intervention was included|
76091233|NCT03282162|Drug|intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
76091234|NCT03282162|Drug|intranasal placebo|An identical amount of intranasal administration of placebo will be assigned to each subject.
76091235|NCT03292224|Diagnostic Test|- Microscopic examination and culture of collected specimens|"Unstained wet mount with 10%-20% KOH.~Wet mounts stained with:~Lactophenol cotton blue.~India ink~Gram stain Culturing on Sabouraud´s dextrose agar ."
76091236|NCT03287076|Drug|Exenatide Injection|5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
76091237|NCT03282084|Diagnostic Test|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
75943209|NCT03650881|Drug|Neutrogena ® Light Therapy Acne Mask (MASK)|Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
75943210|NCT03650881|Drug|Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene|Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
75943211|NCT03648307|Diagnostic Test|Blood sample|Blood sample for Hb A1C and lipid profile, blood pressure and BMI
75943212|NCT02904265|Drug|Diazepam|
75943213|NCT02904265|Drug|Acetazolamide|
75943214|NCT03648229|Procedure|Selective laser trabeculoplasty (SLT)|Delivery of laser energy to the trabecular meshwork of the eye with the goal of reducing intraocular pressure
75943215|NCT03648229|Drug|Latanoprost ophthalmic solution|Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure
75476647|NCT05851365|Drug|Hyperpolarized Bicarbonate (13C)|Given IV
75476648|NCT05851365|Procedure|Magnetic Resonance imaging|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
75476649|NCT05845138|Drug|SHR-A1811 for injection ; capecitabine|SHR-A1811 for injection; Capecitabine tablets
75803405|NCT03545984|Other|interactive problem based learning|Standard teaching (problem based learning discussion) during cardiac/vascular rotation
75803406|NCT03033784|Drug|8 International Units (IU) of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 8IU.
75803407|NCT03033784|Drug|24IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 24IU.
75803408|NCT03033784|Drug|48IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 48IU.
75943216|NCT03648229|Drug|Timolol ophthalmic solution|Timolol ophthalmic solution 0.5% for reduction of intraocular pressure
75943217|NCT03461211|Biological|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
75943218|NCT03648697|Biological|EBV-TCR-T (YT-E001) cells|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment."
75943219|NCT03648619|Diagnostic Test|Semi whole-body MRI|Single semi-automatic, semi whole-body MRI protocol (Dot engine)
75943220|NCT04535037|Biological|DTPa-HBV-IPV/Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh
75943221|NCT04535037|Biological|DTaP5-HBV-IPV-Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh
75943222|NCT04535037|Biological|Pneumococcal 13-valent conjugate vaccine|3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
76091238|NCT03282084|Diagnostic Test|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
75476650|NCT05842525|Drug|intensive treatment|Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off Irinotecan 150 mg/m2 LV 400 mg/m2 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 on day 1, q2w （intensive treatment up to 8 cycels）
75476651|NCT05842525|Drug|Maintenance treatment|Fruquintinib 5mg, orally, once daily, 3 weeks on/ 1 week off
76091239|NCT03286920|Dietary Supplement|Oral nutrition supplement|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
76091240|NCT03286920|Dietary Supplement|Tube feeding nutrition supplement|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
76091241|NCT02460276|Drug|Lenalidomide|
75476652|NCT05835258|Dietary Supplement|Melatonin with phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement with phenyl capsaicin
75476653|NCT05835258|Dietary Supplement|Melatonin without phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement without phenyl capsaicin
75656403|NCT05979181|Procedure|Cesarean hysterectomy|Cesarean hysterectomy due to placenta previa percreta with no extrauterine disease (FIGO grade 3a) or with extrauterine disease (FIGO grades 3b and 3c)
75656404|NCT05979142|Other|community-based primary care program|See group description
75656405|NCT05979129|Other|zero PEEP|zero end-expiratory pressure during face mask ventilation
75656406|NCT05979129|Other|low PEEP|4 cmH2O PEEP during mask ventilation
75656407|NCT05979129|Other|high PEEP|8 cmH2O PEEP during mask ventilation
75656408|NCT05979116|Other|myofascial release|MFR in its simplest form targeted restoration of mobility of myofascial and fascial layers from within, and with the surrounding structure. MFR techniques utilized with the cases include different variations of application: 1. Muscle was stroked in a long
75803409|NCT03033784|Drug|Placebo|Participants will receive an intranasal placebo to match the oxytocin doses.
75803410|NCT03724058|Device|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty
75803411|NCT03724058|Device|Trident® Hemispherical Acetabular Shell|Hip arthroplasty
75803412|NCT00038649|Drug|Gleevec|400 mg orally twice daily
75803413|NCT01090791|Device|Flotrac/Vigileo third generation software|Measurement of stroke volume according to the arterial pressure waveform
75803414|NCT01090791|Device|Transthoracic echocardiography|Measurement of stroke volume according to the aortic time-velocity integral
75943223|NCT02967679|Drug|MD1003|
76091242|NCT02460276|Drug|Ibrutinib|
76091243|NCT02460276|Drug|Rituximab|
75943224|NCT04447053|Drug|Belimumab Injection [Benlysta]|Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.
76091244|NCT02460432|Device|Paclitaxel-eluting metal Stent|Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
75656409|NCT05979103|Behavioral|Listening to Reggae Music and told the stereotype|Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks. Each day, we will send them a playlist to listen to.
75656410|NCT05979103|Behavioral|Listening to Nature Sounds|Participants in this group will NOT be told the stereotype for the audio they are listening to. They will listen to nature sounds over the 4 weeks. Each day, we will send them a playlist to listen to.
75803415|NCT03544268|Device|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
75803416|NCT03544268|Drug|Definity|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
75803417|NCT04893070|Other|Questionnaires COVID+|"1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms~1 questionnaire on quality of life 18 months after COVID-19 first symptoms"
75803418|NCT04893070|Other|Questionnaires COVID-|"1 questionnaire on quality of life at enrollment~1 questionnaire on quality of life 6 months after enrollment"
75803419|NCT01094379|Procedure|Standard laparoscopic cholecystectomy|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
75803420|NCT01094379|Procedure|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
75803421|NCT02941900|Genetic|MC1R genotyping|
75803422|NCT02941900|Behavioral|MC1R Testing Website|The website includes three educational modules about genetic testing with corresponding knowledge questions.
76091245|NCT02460432|Device|Covered Metal Stent|Insertion of ComVi Biliary Covered Stent using ERCP
75803423|NCT02941900|Behavioral|Baseline Survey|
75803424|NCT02926690|Drug|OTS167PO|Single arm, no competitor
75943225|NCT03650647|Procedure|Carious dentin removal|Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
76091246|NCT03282006|Drug|pivmecillinam|Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
76091247|NCT03291912|Procedure|Chuna Manual Therapy|"Unique manual therapy in traditional Korean medicine~Mandatory techniques for neck part and selective techniques for other part (if necessary)~Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
75656411|NCT05979090|Behavioral|Mastery learning in communication skills|Participants will undergo simulation-based mastery learning curriculum in difficult conversations.
75656412|NCT05979012|Behavioral|MIndfulness Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.It is up to them if they want to listen to the daily recordings."
75656413|NCT05979012|Behavioral|Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.They will have access to electronic audio recordings, with the order of listening labeled for each day. The recordings will increase gradually throughout the study, starting with about 10 minutes each day in the first week and reaching 30 minutes each day in the final week. The schedule is as follows: Week 1= 10 minutes, Week 2= 15 minutes, Week 3= 20 minutes Week 4= 30 minutes. It is up to them if they want to listen to the daily recordings."
75943226|NCT03104205|Behavioral|Evaluate home-based MOWI|MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and remote fitness device monitoring. We plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 8, 16 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2 (NCT03104192).
75943227|NCT03647605|Behavioral|VR Mind|"Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes."
75943228|NCT02966509|Behavioral|EPAC|Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
75943229|NCT04361799|Device|CamAPS|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
75943230|NCT04361799|Drug|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
75943231|NCT03647995|Dietary Supplement|Probiolife by Green Made (Pharma M)|A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
75943232|NCT03647995|Other|Placebo|A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
75943233|NCT05390073|Diagnostic Test|growth hormone level and insulin like growth factor 1|laboratory test
75943234|NCT03752541|Biological|BCMA-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.
75943235|NCT02966353|Drug|ruxolitinib|Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)
75943236|NCT04260789|Device|Seraph 100,The Microbind Affinity Blood Filter|Treatment with Seraph 100 in one arm
75943237|NCT03647839|Drug|Nivolumab 10 MG/ML|Nivolumab will be supplied free of charge by Bristol-Myers Squibb (BMS) as sterile liquid in 10mL glass vials.
75943238|NCT03647839|Drug|BNC 105|BNC105 will be provided free of charge by Bionomics, as a sterile solution of BNC105P. BNC105P is a clear, colorless to yellow liquid presented in a clear glass vial and is intended to be diluted with commercially available sterile 0.9% saline prior to IV administration.
75943239|NCT03647839|Drug|BBI608|BBI-608 will be supplied free of charge by Boston Biomedical as capsules.
75943240|NCT05389917|Procedure|Pancreaticoduodenectomy|"In Pre Operative phase~64 Slice MD CT scan will be taken in all patients undergoing PD in pre op period 3D reconstruction of Peripancreatic vascular system using MDCT images Measure longitudinal distance between Root of Left renal vein, origin of IPDA Measure distance between origin of SMA , MCA and the IPDA~In Intraoperative period~Distance will be measured using standard disposable ruler from Root of Left renal vein to IPDA after Transection of Pancreas followed by specimen removal and to measure the distance between MCA, SMA and IPDA using standard disposable ruler ."
75943241|NCT03647683|Other|Self-Compassion|"Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus."
75943242|NCT03647683|Other|Acceptance|"Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
75943243|NCT03647683|Other|Distraction|"Participants are introduced to the concept of distraction. Distracting oneself from the present situation helps with not perceiving pain, painful thoughts or feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
75943244|NCT03647683|Other|Heat pain|Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
75943245|NCT04454541|Procedure|Ultrasound-guided nerve block for headache management|The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
75943246|NCT05284825|Radiation|12 Gy in 6 daily fractions|12 Gy in 6 daily fractions
75943247|NCT04454619|Drug|Hand antisepsis with Clorhexidine and solution|Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
75803425|NCT03723902|Other|Heavy-load strength training|Three weekly sessions of heavy-load strength training for 10 weeks
75803426|NCT03723902|Dietary Supplement|Protein supplementation|Daily supplementation of 2 x 17 grams of milk protein
75943248|NCT04454853|Other|Lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
75943249|NCT04454853|Other|Suspected lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
75803427|NCT03652818|Drug|Pre-Op pregabalin|Pre-op pregabalin will be administered 60 min prior to surgery.
75803428|NCT03652818|Drug|Pre-Op Placebo 1|Placebo 1 will be administered 60 min prior to surgery.
75943250|NCT04454853|Other|Positive methylated DNA|Tumor-free DNA (cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells.
75943251|NCT03647449|Dietary Supplement|Juice|Participants will be drinking 800-900 kcal/day in cold-pressed juices.
75656414|NCT05978960|Other|Nutrition and resistance training exercise intervention|"3 month 2-3 times/week, 60 min exercise regimen utilizes compound movements to focus on body composition, strength, and mobility. Classes are run by certified strength and conditioning specialists and adjusted for linear progression and safety, progressing from compound to isolated movements to maximize safety.~The nutrition intervention focuses on dietary quality by following a healthy low-carbohydrate diet, focusing on nutrient dense foods high and avoiding processed foods and simple carbohydrates to keep totals under 100g/day. Participants will be advised to eat vegetables, avoid snacking, cook all meals with family and friends, avoid eating on the run, and focus on whole foods that require preparation. Calculations and quantification of calories will be avoided, while protein consumption goals are 1.3-1.8 g/kg per. Dietary strategy will be continuously discussed during exercise sessions and the PI will have twice monthly meetings with participants."
75656415|NCT05978934|Behavioral|Static Lighting Condition (L1)|This indoor lighting condition keeps a constant brightness and correlated color temperature.
75803429|NCT03652818|Drug|Post-Op pregabalin|Post-op pregabalin will be administered Post-operatively.
75803430|NCT03652818|Drug|Post-Op Placebo 1|Placebo 1 will be administered post-operatively.
75803431|NCT03652818|Drug|Post-Op Placebo 2|Placebo 2 will be administered post-operatively.
75803432|NCT03652818|Drug|Post-Op acetaminophen|Acetaminophen will be administered Post-operatively.
75943252|NCT03647449|Behavioral|Caloric restriction via Plant-based meals|Participants' caloric intake will be limited to 800-900 kcal/day.
75943253|NCT03647449|Dietary Supplement|Plant-based meal|Participants will be eating ~900 kcal/day in pre-prepared plant-based meals.
75943254|NCT04454307|Drug|Tramadol|tramadol 100 mg twice daily for 10 days
75476654|NCT05834296|Biological|ALZN002 (autologous DCs pulsed with E22W mutant peptide).|The cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide (Aβ1 42) containing a mutation at position 22 from glutamic acid to tryptophan (E22W). This mutation produces novel CD4+ T cell epitopes specific for the mutant E22W peptide that can facilitate an anti-Aβ1-42 antibody response. The activated E22W peptide specific CD4+ T cells license Aβ1-42-specific B cells to secrete anti Aβ1-42 antibodies, resulting in systemic reduction of amyloid and reduction or slowed accumulation of amyloid plaques in the brain.
75656416|NCT05978934|Behavioral|Dynamic Lighting Condition (L2)|This indoor lighting condition has increased brightness and more blue correlated color temperature in the morning hours followed by decreased brightness and less blue correlated color temperature in the afternoon and evening hours.
75943255|NCT04454307|Other|Standard care delivered in the isolation hospitals.|Oxygen ventilation.
75943256|NCT03647371|Procedure|Macintosh laryngoscopy|intubation with MAcintosh laryngoscopy after anesthetic induction
75943257|NCT03647371|Procedure|McGrath MAC video laryngoscopy|intubation with McGrath MAC videolaryngoscopy after anesthetic induction
75943258|NCT02522793|Other|No intervention; this is an observational study|
75943259|NCT03647293|Procedure|Ultrasound Guided Central Catheter Insertion|
75656417|NCT05978934|Behavioral|Dynamic Lighting Condition (L3)|This exploratory indoor lighting condition matches the same pattern as L2 except the brightness in the morning hours is increased.
75656418|NCT05978882|Procedure|Laparoscopic sentinel navigation surgery using fluorescence|If the frozen biopsy of sentinel lymph nodes are all negative using fluorescence, stomach-preserving surgery is performed
75803433|NCT03723824|Drug|grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
75803434|NCT03723746|Biological|JNJ-67670187|Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
75803435|NCT03723746|Biological|Placebo|Participants will receive matching placebo in all cohorts.
75943260|NCT03647293|Procedure|Peripherally Inserted Central Catheter|
75943261|NCT05388123|Drug|Low dose vemurafenib plus rituximab|Vemurafenib 960 mg twice daily for 8 weeks with concurrent rituximab 375 mg/m2 every 2 weeks followed by maintenance consolidative rituximab 4 times every 2 weeks post-vemurafenib
75943262|NCT03647059|Diagnostic Test|LSCM examination|Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
76091248|NCT03291912|Procedure|Usual care|"Physical therapy based on traditional Korean medicine theory~Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~Heat stimulation: either Hot pack or Infrared lamp~Patient education~Physical and pathological explanation of cervicogenic dizziness~Cause and risk factors of cervicogenic dizziness~Functions of muscles related to cervicogenic dizziness~Home exercising to self-manage cervicogenic dizziness"
76091249|NCT03281928|Dietary Supplement|Sodium and Potassium Citrate|Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
76091250|NCT03281928|Dietary Supplement|Placebo|Sodium without Potassium Citrate
76091251|NCT02460120|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
76091252|NCT02459652|Drug|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
75656419|NCT05978869|Other|physical fitness training|Through a three-step process, gamified physical fitness training was developed by a multidisciplinary team.
75803436|NCT05665010|Other|Genetic susceptibility|Genetic susceptibility increases the risk of ovarian injury
75943263|NCT04455711|Drug|Lidocaine Iv|Bolus dose of 1.5 mg/kg lidocaine was injected immediate after operation.
76091253|NCT02459652|Radiation|Radiation Therapy|Radiation therapy is delivered with >6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
75476655|NCT05834296|Drug|Placebo|Saline
75943264|NCT04455711|Drug|Remifentanil|Continuous infusion of remifentanil 1.5 ng/ml until extubation
75943265|NCT04052503|Behavioral|Knowledge Broker|Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
75943266|NCT04052347|Behavioral|Shared decision-making with a Decision-aid|A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9
75943267|NCT04052347|Behavioral|routine shared decision-making|control group
76091254|NCT03281772|Other|Clinical Decision Software - provider portal|As noted in Arms
76091255|NCT03281772|Other|Clinical Decision Software - patient portal|As noted in Arms
75803437|NCT03619902|Biological|Imsidolimab|Humanized monoclonal antibody
75803438|NCT00620464|Drug|Radiopaque Implanon|Radiopaque rod for 3 years
75803439|NCT00620464|Drug|Implanon (etonogestrel implant)|Implanon (etonogestrel implant) for 3 years
75803440|NCT03726866|Drug|Sequence 1|D326, D337 or CKD-828 for 9 days
75803441|NCT03726866|Drug|Sequence 2|D326, D337 or CKD-828 for 9 days
75803442|NCT03726866|Drug|Sequence 3|D326, D337 or CKD-828 for 9 days
75803443|NCT03726866|Drug|Sequence 4|D326, D337 or CKD-828 for 9 days
75803444|NCT03726866|Drug|Sequence 5|D326, D337 or CKD-828 for 9 days
75803445|NCT03726866|Drug|Sequence 6|D326, D337 or CKD-828 for 9 days
76091256|NCT03286764|Other|Peppermint Oil|
76091257|NCT03286764|Other|Distilled water|Distilled water spray as a placebo during Colonoscopy
76091258|NCT03291678|Procedure|new laparoscopic orchiopexy|closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous
76091259|NCT03291678|Procedure|classic laparoscopic orchiopexy|delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
75943268|NCT03717987|Drug|Botulinum toxin type A|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015)."
75943269|NCT03717987|Dietary Supplement|Zinc supplementation|zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
75943270|NCT03646903|Behavioral|Cognitive Bias Modification|Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.
75943271|NCT03646903|Behavioral|Psychoeducation|Psychoeducation-based interventions rely on the premise that enhancing knowledge about psychiatric symptoms and treatment will facilitate treatment engagement.
76091260|NCT03291600|Behavioral|Virtual Psychiatric Care|Virtual psychiatric care for perinatal depression will be offered to participants, in addition to care as usual, for a 12-week period by their treating perinatal psychiatrist. Virtual care will be delivered by video-based visits through the Ontario Telemedicine Network (OTN). The treating psychiatrist may request that an intervention group participant present for in-person care at any visit, and this may include need for behavioural activation, or another health-related indication at the discretion of the treating psychiatrist.
76091261|NCT03291444|Biological|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
76091262|NCT03291444|Biological|peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
76091263|NCT03291366|Drug|UCMSCC|infusion of aUCMSC and conventional therapy
76091264|NCT03291366|Drug|conventional treatment|conventional treatment
75476656|NCT05834153|Device|kinesiotaping|"This group underwent a KT application on rectus abdominis muscle (RAM), oblique abdominal muscles (OAM) and cesarean incision twice a week for a period of 4 weeks. First, the scar technique will apply using I band with a tension of 50 % on cesarean incision when the patient will be in supine position. Then, tape will apply on RAM using muscle technique from origin to insertion of the muscle with a tension between 15 and 25 %.~Band will start on symphysis pubis with no tension, and then the patient was asked to stretch the abdominal region by deep abdominal respiration, and it will ended on xiphoid process.~Finally, it will perform on the right and left external oblique muscles. The procedure will start with no tension from the bottom end of the 6-12th ribs and then the hip will placed in flexion and rotation to the opposite direction and the band will taped on pubic bone with a tension between 15 and 25 %"
75803446|NCT03652662|Device|RESP-FIT|Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
75803447|NCT03652662|Behavioral|RESP-FIT Comparator|Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
75803448|NCT00541684|Drug|MK0954, /Duration of Treatment : 16 Weeks|
75803449|NCT00541684|Drug|Comparator : atenolol /Duration of Treatment : 16 Weeks|
75803450|NCT05666024|Other||Prospective observational study
75803451|NCT03732222|Procedure|Stretching the diaphragm muscle|Place the hands on the last costal cartilages and maintain the ascent of the ribs in the expiration.
75803452|NCT03732222|Procedure|Impulse technique in rotation of cervical level 3 and 4|head to double chin position and then placed with neutral flexo-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
75803453|NCT03732222|Procedure|Combined technique of diaphragm muscle stretch and cervical rotation impulse technique level 3 and 4|"The same initial position, hand placement and technique guidelines will be used, cited in each of the techniques performed in the intervention 1 group and the intervention 2 group."
75803454|NCT00413764|Drug|tibolone|tibolone (2.5 mg) over 24 weeks
75803455|NCT00413764|Drug|estradiol-norethisterone|transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
75803456|NCT03726788|Drug|Botulinum Toxin Type A 100U|one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI
75803457|NCT03726788|Drug|Botulinum Toxin Type A 200U|one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI
75803458|NCT03726788|Drug|Triamcinolone Hexacetonide Inj Susp 20 MG/ML|one intra-articular injection of 2 ml Triamcinolone Hexacetonide
75803459|NCT03735264|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
75803460|NCT04789174|Drug|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
75943272|NCT04101903|Diagnostic Test|The 6-week Hip Checklist|Comprehensive 9-item structured guide to aid in correct diagnosis of developmental dysplasia of the hip.
75943273|NCT04062669|Biological|Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the low dose (Ld-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) low dose formulation, administered intramuscularlyat Days 1 and 61.
75943274|NCT04062669|Biological|Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the medium dose (Md-) RG SAM (CNE) group will receive 1 doses of RG SAM (CNE) medium dose formulation, administered intramuscularly at Day 1.
75943275|NCT04062669|Biological|Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lower dose (Lrd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lower dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
76091265|NCT03281694|Drug|Placebo|placebo skin patch and placebo oral solution
76091266|NCT03281694|Drug|Nicotine|nicotine skin patch (7 mg/24 hrs) and placebo oral solution
76091267|NCT03281694|Drug|AVL-3288|placebo skin patch and AVL-3288 oral solution (3 mg)
76091268|NCT03281694|Drug|Nicotine + AVL-3288|nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
76091269|NCT03281616|Behavioral|Diet|Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
75656420|NCT05978856|Other|Accuracy of computer software in predicting soft tissue profile changes|"Separate analyses will be performed on the initial and final cephalograms.~All of the cephalometric analyses will be done via computer software,the linear and angular measurements will be done via the software.~Through the use of software, the initial cephalogram and the initial photograph will be linked.~Then, the final values of some angles will be tracted from the post-treatment cephalogram.~These values will be inserted in the treatment simulationsection of the software.~A post-treatment projected image of the patient will be simulated by the software.~Then the actual post-treatment photograph will be placed on the simulated image in transparent form.~From the pupil , real horizontal and vertical reference lines will be drawn.~Then certain measurements will be taken from referance lines to fixed points on the soft tissue to determine the discrepancies between the real and simulated images."
75943276|NCT04062669|Biological|Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lowest dose (Ltd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lowest dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
75943277|NCT04062669|Drug|Saline Placebo|Subjects in the Saline Placebo group will receive 2 doses of saline Placebo, administered intramuscularly Day 1 and 61.
75943278|NCT04062669|Biological|RabAvert|Subjects in the RabAvert Group will receive 2 doses of RabAvert vaccine, administered intramuscularly, at Days 1 and 61.
75943279|NCT04456335|Genetic|Collection of supragingival plaque from caries free children|Supragingival plaque samples were collected from posterior molar teeth
75943280|NCT04456257|Device|fractional picosecond 1,064 nm laser|The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
75943281|NCT05387967|Drug|Sacubitril/valsartan|All the recruited patients were prescribed Sacubitril/Valsartan at a starting dose of 50 (24/26) mg BID which was up-titrated, over the period of initial 6 weeks, to the maximum tolerated dose up to 200 (97/103) mg BID and further followed for a total of 12 weeks.
75943282|NCT00389649|Device|heart rate setting|
75656421|NCT05978830|Device|Transcranial ultrasound stimulation|In each active/sham-ultrasound stimulation experiment, subjects first underwent two baseline motor evoked potential (MEP) tests, with an interval of 15 minutes between the two baseline tests. After 15 minutes of true/pseudo-transcranial ultrasound stimulation, subjects immediately underwent a MEP test, and then 15 minutes later, subjects underwent another MEP test. The MEP was tested again 15 minutes later.
75803461|NCT04789174|Drug|Placebo|Placebo
75943283|NCT05389137|Biological|Inavtivated Quadrivalent Influenza Virus Split Vaccine|Prevent influenza caused by H1N1, H3N2, B (V), B (Y) strain virus infection.
76091270|NCT03286608|Other|observational study (no intervention)|Statistical association between adherence to a pattern of polyphenol intake and the risk to develop dementia and Alzheimer's disease over 12 years
75803462|NCT03743688|Biological|Influenza Vaccine Recipients|0.5 mL intramuscular injection
75803463|NCT03726710|Behavioral|Blood Pressure measurement and pharmacy|Blood Pressure monitoring by barber, Blood pressure measurement and management by pharmacist in person and through telemedicine
75803464|NCT03639506|Procedure|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
75345284|NCT01390259|Device|Closed-Loop|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
75345285|NCT04091516|Behavioral|Low-fat plant-based diet|Participants will follow a diet that consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
75345286|NCT05235386|Device|Automated oxygen titration|Automated oxygen administration to maintain the SpO2 target at a predefined value during emergency length of stay
75345287|NCT01391273|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
75345288|NCT01391273|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
75803465|NCT03639506|Combination Product|autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|autologous mitochondria transplantation
75345289|NCT05235230|Drug|Test product (T) 25 mg Film Coated Tablets|Film Coated Tablets products containing 25 mg Quetiapine
75345290|NCT05235230|Drug|Reference product (R) 25 mg Film Coated Tablets|Reference product (R) 25 mg Film Coated Tablets
75345291|NCT01429259|Drug|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
75476657|NCT05834153|Device|electrical muscle stimulation|"It consists of 24 patients who will receive NMES and core stabilization exercises.~The subjects will explain to relax their abdominal muscles while application Stimulation will apply by four large rectangular electrodes placed over the origin (pubic crest) and insertion (xiphoid process) of the rectus abdominis muscles bilaterally. Straps will used to fix the electrodes in place. A frequency of 80 pulses/min and with a pulse width of 0.1-0.5ms, will the parameter settings apply in this study. The total time for the application of stimulation will 30mins and until a good enough observable muscle contraction will achieve a gradual increase in intensity will perform"
75803466|NCT03639506|Drug|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
75345292|NCT05177198|Procedure|M-MIST + Clindamycin augmented PRF|modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
75345293|NCT05177198|Procedure|M-MIST + PRF|modified minimally invasive surgical technique with platelet-rich fibrin alone.
75943284|NCT03856359|Drug|Rifaximin 550 milligrams (MG)|Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
75943285|NCT03663855|Drug|Tiopronin|Phase 1: No medication, Phase 2: 500mg PO daily x 7 days (total 500mg), Phase 3: 500mg PO BID x 7 days (total 1g), Phase 4: 1g PO BID x 7 days (total 2g)
75943286|NCT02965573|Biological|ARGX-113|
76091271|NCT03281460|Device|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation
76091272|NCT03281460|Procedure|laparoscopic myomectomy or hysterectomy without any morcellation bag|laparoscopic myomectomy or hysterectomy without any morcellation bag
76091273|NCT03286452|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly™ Antimicrobial Wound Matrix consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB) intended for the management of wounds.
75345294|NCT01392053|Other|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
75345295|NCT02979821|Drug|Poziotinib|A cycle of study treatment is defined as 28 days.
75345296|NCT02204657|Device|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
75345297|NCT03008603|Device|XACT Robotic System|The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
75345298|NCT02511678|Device|Cryoablation|The application of repeated freeze and thaw cycles to the identified tissues.
75345299|NCT01392989|Drug|CIK cells|Standard of care
75345300|NCT01392989|Drug|Cyclosporine|5 mg/kg, po
75803467|NCT04949074|Other|saliva sampling|when the patient goes to the laboratory for a covid 19 diagnostic from a routine nasopharingeal sample, an additionnal sample of saliva is asked
75345301|NCT01392989|Drug|Mycophenolate Mofetil|15 mg/kg, oral
75803468|NCT03560258|Biological|p24CE1/2 pDNA vaccine|4 mg administered by one injection/electroporation
75803469|NCT03560258|Biological|p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine|2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55^gag pDNA administered by one injection/electroporation
75803470|NCT03560258|Biological|Full-length p55^gag pDNA vaccine|4 mg full-length p55^gag pDNA vaccine administered by one injection/electroporation
75943287|NCT02965573|Drug|Placebo|
75943288|NCT04052659|Drug|Sintilimab|200 mg IV, every 3 weeks, d1
75345302|NCT01392989|Drug|Thymoglobulin|7.5 mg/kg, IV
75656422|NCT05978765|Device|Dry Cupping|treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.
75943289|NCT04052659|Drug|Chidamide|30 mg PO, 2 times every week, d1 and d4
75943290|NCT04052659|Drug|Azacidine|100 mg SC, every 3 weeks, d1 to d7
75943291|NCT02898727|Other|Local Therapy|"Neurosurgery: The decision whether or not to recommend neurosurgery will be made independently of this research study. The complexity and length of the surgery depends on the size and location of the tumour(s).~Stereotactic Radiosurgery: If the participant will be receiving stereotactic radiosurgery (either alone or in combination with neurosurgery), the Radiation Oncologist will organise for the participant to have a Radiotherapy planning. Single metastasis, smaller than or equal to 2cm, may require 1 fraction. Alternately, multiple metastasis, metastasis in the brain stem, or those bigger than 2cm will required multiple fractions to treat. The dose range for the study is 20Gy/1 fraction to 24Gy/3 fractions."
75345303|NCT01392989|Radiation|Total Lymphoid Irradiation (TLI)|
75345304|NCT02511444|Other|GBS culture and real time PCR|patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
75656423|NCT05978765|Other|Myofascial Release|e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8
75803471|NCT03560258|Biological|Placebo|1 mL placebo administered by one injection/electroporation
75345305|NCT01393457|Drug|levodopa/carbidopa|800/200 mg/d
75345306|NCT01393457|Drug|Ropinirole 2 mg/d|2 mg/d
75345307|NCT01393457|Drug|Placebo|sugar pill
75345308|NCT01393457|Drug|Ropinirole 4 mg/d|4 mg/d
75803472|NCT02768662|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
75803473|NCT02759380|Other|Phytoestrogen-rich foods|The patients will be given a package containing food with a high amount of phytoestrogens (≥100 mg isoflavonoids and ≥100 mg lignans) that are to be consumed daily. The food-package contains 30 grams of flaxseed, 25 grams of roasted soybeans and 50 grams of frozen green edamame beans to be consumed daily.
75803474|NCT03539432|Drug|Gemfibrozil 600 MG|Gemfibrozil capsules (600 mg) taken twice per day
75803475|NCT03539432|Drug|Placebo oral capsule|Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
75803476|NCT04779970|Other|Cessation of ongoing treatment|Cessation of ongoing treatment
75345309|NCT02518464|Drug|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
75345310|NCT02479230|Biological|tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Given ID
75943292|NCT02964325|Device|Mirasol platelets (MIR PLTs)|The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.
75943293|NCT02964325|Device|Reference platelets (REF PLTs)|The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.
75943294|NCT03645889|Other|PLTG|A combination of 13 herbal granules
75943295|NCT03645889|Other|Placebo|90% starch filler and 10% PLTG
75345311|NCT02479230|Drug|gemcitabine hydrochloride|Given IV
75345312|NCT04985136|Drug|camrelizumab；Rivoceranib|Camrelizumab at 200 mg via intravenous administration (IV), once every 2 weeks (Q2W), in combination with 250 mg of rivoceranib mesylate, oral administration, once a day (QD)
75345313|NCT04985136|Drug|Rivoceranib|Rivoceranib mesylate (750 mg, QD, po)
75345314|NCT04985136|Drug|Sorafenib|Sorafenib tosylate (400 mg, twice a day (BID), po)
75345315|NCT04985136|Drug|Regorafenib|Regorafenib (160 mg, administer for 21 days then stop for 7 days, po)
75345316|NCT02510820|Device|comfilcon A|soft contact lens
75345317|NCT02510820|Device|Synergi|Multipurpose solution
75345318|NCT02510820|Device|Biotrue|Multipurpose solution
75345319|NCT02510820|Other|stenfilcon A|daily disposable contact lenses for washout period
75345320|NCT02510664|Behavioral|Diabetes Strengths Study|"The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments."
75476658|NCT05824923|Procedure|Pulmonary arterial denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 ℃ for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA."
75656424|NCT05978726|Drug|Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel|Patients with acute myocardial infarction randomly received dual antiplatelet therapy with with aspirin 100mg daily and either ticagrelor 90mg twice daily or clopidogrel 75mg once daily for at least 9 months after PCI as needed.
75803477|NCT03723434|Device|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
75803478|NCT03723434|Device|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, St Augustin, Germany).
75803479|NCT03723434|Device|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) will be applied at 1 and 20 Hz with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 300 rTMS pulses will be delivered during 1 and 20 Hz stimulation. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
75656425|NCT05978700|Device|Video-game|The video-game has three games: (1) Game One - Lip Exercise; (2) Game Two - Tongue Exercises; (3) Game Three - Lower Jaw Exercise. The whole training will take about once a day for 30 min per session, 5 times a week for 4 weeks.
75943296|NCT02964247|Drug|liraglutide|Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
75943297|NCT02964247|Drug|placebo|Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
75943298|NCT03645733|Procedure|Lower Temperature Group|Dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached.
75345321|NCT01509677|Drug|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
75345322|NCT01509677|Drug|Placebo|tablet, once daily, oral administration in the morning after breakfast
75656426|NCT05978700|Behavioral|Conventional therapy|The control group used the conventional swallowing function training. The lip exercise consisted of the following specific movements: opening mouth, closing mouth, drumming cheeks, left drumming cheeks, and right drumming cheeks; the tongue exercise consisted of the following specific movements: extending the tongue, tongue up, tongue down, tongue left, and tongue right. Each specific movement in the steps lasts 2-3s, repeat 15 times and continue with the next movement. The lower jaw movement contains the following specific movements: keep the head as low as possible, and squeeze the rubber ball placed on the neck for 2-3 seconds, repeat 15 times.
75943299|NCT05284279|Other|Exploring health professionals' perceptions of patients with ECC using semi-structured interviews|"Following a literature review on the topic of children with ECC and their family, a guidebook will be built by main investigators. Several test interviews will be conduct to ensure that guidebook is adapted, and that the interviewer is enough trained.~Interview will be conducted by one or two of the main investigators. As much as possible, they will be performed face to face or using videoconference due to COVID19 pandemic context. All the interviews will be audio recorded. The interviewer will take notes including non-verbal communication; and will adopt an active listening position.~After collecting respondents' characteristics (age, gender, profession, exercise duration, type of practice), the subsequent themes will be explored: disease perception, educational context's responsibility, barriers and facilitators to family behaviour changes, health professional's emotional consequences."
75943300|NCT03645655|Diagnostic Test|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II, AFP, and biochemical tests.
75943301|NCT04051801|Drug|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
75803480|NCT03615924|Drug|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~>48 kg: Ticagrelor 45 mg, twice a day."
75943302|NCT04051801|Drug|Dose Escalation of Placebo|dose levels of the cohorts will be increased step wise
76091274|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
76091275|NCT03281226|Drug|RIPE (2m) and RI (4m)|Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
76091276|NCT03281226|Drug|RIPE+NAC (2m) and RI (4m)|Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
76091277|NCT03291054|Drug|Pembrolizumab|Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
75656427|NCT05978674|Behavioral|rocking bed group|Babies assigned to the intervention group first will be placed on a rocking bed after routine care such as feeding and diaper changes and when the newborn is stable. A rocking attempt will be applied to the baby placed in the rocking bed for 30 minutes. After 30 minutes, the baby will not be lifted from the bed and will lie in bed for 90 minutes. After a period of two hours in total, the babies will be cared for and fed. Then, babies will be quota and control group measurements will be made.
75656428|NCT05978635|Behavioral|Group A Standard 4 deep breaths measured in milliliters from the ventilator.|Tidal volume breath measured in milliliters
75656429|NCT05978635|Behavioral|Group B Coached 4 deep breaths measured in milliliters from the ventilator|Coached tidal volume breath measured in milliliters
75656430|NCT05978609|Drug|Candonilimab|Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
75656431|NCT05978609|Drug|Cisplatin|Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
75656432|NCT05978609|Drug|Gemcitabine|gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
75656433|NCT05978544|Drug|Itolizumab|Patients to be treated with Itolizumab.
75803481|NCT03615924|Drug|Placebo|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
75943303|NCT03846115|Behavioral|Peer-Led Seeking Safety app|This app offers participants sessions of Seeking Safety plus enhanced app features designed to engage and sustain participants in their recovery work.
75943304|NCT03846115|Behavioral|Control app|This app offers the Seeking Safety content but without the enhanced features
75943305|NCT05283967|Diagnostic Test|urine colorimetric assay|Colorimetric assays will be performed for urine drug concentrations of rifampin, isoniazid and pyrazinamide from urine collected throughout one dosing interval. Assay results will experimental only and not used to change patient care.
75943306|NCT03654729|Drug|Calmangafodipir (2 µmol/kg)|Solution in 20 mL single dose glass vials
75943307|NCT03654729|Drug|Calmangafodipir (5 µmol/kg)|Solution in 20 mL single dose glass vials
75943308|NCT03654729|Drug|Placebo|Solution in 20 mL single dose glass vials
75943309|NCT03646747|Diagnostic Test|MRI scan|Additional imaging using MRI scan
75943310|NCT04052269|Drug|Sildenafil 100mg|study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
75943311|NCT03827317|Radiation|[18F]GE-226|[18F]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
75943312|NCT03130647|Device|Focused ultrasound|Focused ultrasound
75656434|NCT05978531|Drug|Monomethyl Fumarate|95 mg oral capsule, 190 mg (2 x 95 mg) twice daily
75656435|NCT05978505|Drug|Reboxetine 4 MG Oral Tablet|7 nightly doses (4mg) to commence after surgery.
75943313|NCT03646591|Drug|Chemotherapy|Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.
75943314|NCT03645265|Behavioral|Auditory|Use of auditory cues to improve speech production
76091278|NCT03291054|Drug|Epacadostat|Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
75476659|NCT05824923|Drug|Guideline-directed medical therapy (GDMT) for heart failure|"GDMT medication recommendation including:~Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~Beta-receptor blocker (BB)~Mineralocorticoid receptor antagonist (MRA)~Sodium-glucose co-transporter 2 (SGLT2) inhibitor~Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2022 AHA/ACC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 6-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion."
75803482|NCT03625180|Biological|NAMIC: nanofractured autologous matrix-induced chondrogenesis|the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
75803483|NCT03535844|Other|Wolfberry|Consumption of cooked dehydrated wolfberry as part of a mixed meal.
75803484|NCT03535844|Other|Healthy diet|Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
75803485|NCT05573932|Other|Leaderboard|De-identified leaderboard showing average durations of exercises completed by all participants in leaderboard group.
75803486|NCT05573932|Other|Take-home packet|Take-home packet of exercises.
75803487|NCT04660240|Device|Abluminus Sirolimus Eluting Stent System (ASES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the ASES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
75943315|NCT03645265|Behavioral|Gestures|Use of gestures to improve speech production
75476660|NCT05821998|Other|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
75656436|NCT05978505|Drug|Placebo|7 nightly doses to commence after surgery.
75803488|NCT04660240|Device|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the OSES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
75803489|NCT03533114|Drug|JZP-258|Participants randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.
75943316|NCT01377987|Drug|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
75943317|NCT01377987|Drug|Placebo|4 mg/kg, once daily before bed, for 7 days
75943318|NCT03645187|Drug|FOLFERI|FOLFERI regimen
75943319|NCT03645187|Drug|Folferi and celecoxib|Folferi regimen and celecoxib
75943320|NCT03646513|Device|SMF Short Modular Femoral Hip System|Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
75656437|NCT05978479|Other|Teach-Back Method|No intervention will be given to the patients in the control group.
75656438|NCT05978440|Procedure|onlay preparation|CAD-CAM onlay restorations will be fabricated using rubber dam scanning techniques and evaluated clinically up to 12 months
75943321|NCT03645109|Dietary Supplement|Vitamin D3|Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
75656439|NCT05978427|Procedure|interscalene block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in interscalene block.
75803490|NCT03533114|Drug|Placebo Oral Solution|Participants randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.
75803491|NCT03033394|Drug|Beta-lactam antibiotic|Routine clinical dosing
75803492|NCT03723356|Diagnostic Test|Siemens Biograph mMR (molecular MR)|5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,
75943322|NCT03645109|Other|Capsules with placebo (talcum food grade)|Capsules with placebo (talcum food grade)
75943323|NCT05380167|Dietary Supplement|BRJ Nitrate|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink with nitrate.
75943324|NCT05380167|Dietary Supplement|BRJ Placebo|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink without nitrate
75943325|NCT03573375|Behavioral|Questionnaires|Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
75943326|NCT05165745|Behavioral|Individualized Feedback|Participants taking PrEP will receive questionnaires regarding self-reported weekly PrEP adherence; they will then receive individualized text-message or email feedback based on their self-reported adherence.
75943327|NCT05165667|Other|rehabilitation team|The meeting comprised physiotherapist, occupational therapist, rehabilitation nurse, speech and language therapists, social worker, nutritionist, psychologists under the team leader guidance by physiatrist. Respondents of both groups will be assessed to see the effects of treatment at 6 th weeks, 12 th weeks and 24 th weeks. Outcomes will be measured by FIM (Functional independence Measure) scores.
75943328|NCT03351387|Combination Product|SPY Intra-operative Angiography|The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.
75943329|NCT05165589|Device|ActiveInsights accelerometer device|Accelerometer device
75803493|NCT03723356|Diagnostic Test|fMRI|High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.
75943330|NCT04455555|Drug|LY03003( the name of rotigotine)|LY03003 (Continuous Dopamine Stimulation) sustained release microspheres / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
75345323|NCT05460936|Other|Lower Extremity Functional Training|motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
75345324|NCT05460936|Other|conventional physical therapy|Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
75345325|NCT04411446|Drug|Vitamin D|5 capsules of 100.000 UI Vitamin D orally given all at once. One dose.
75345326|NCT04411446|Drug|Placebo|5 capsules of containing placebo orally given all at once. One dose.
75345327|NCT01510379|Device|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
75656440|NCT05978427|Procedure|superior trunk block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in superior trunk block.
75803494|NCT03723356|Diagnostic Test|Diffusion Spectrum Imaging (DSI)|DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
75345328|NCT01510379|Drug|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
75345329|NCT01510379|Drug|IV promethazine 25 mg q 6 hours prn|
75345330|NCT01510379|Drug|Elixir promethazine 25 mg q 6 hours prn after discharge|
75345331|NCT03784716|Other|Ketogenic Diet|Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.
75345332|NCT03784716|Other|Standard Weight Loss Diet|Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
75656441|NCT05978401|Drug|GLS-012+GLS-010|Two dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
75656442|NCT05978401|Drug|GLS-012+GLS-010|Target dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
75803495|NCT03639428|Drug|Midazolam|All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
75345333|NCT01363986|Drug|trastuzumab [Herceptin]|Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
75476661|NCT05821998|Other|Designed chest physical therapy program|Percussion, vibration and modified postural drainage
75803496|NCT04575688|Drug|Exparel|Exparel will be administered by periarticular injection to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
75803497|NCT04575688|Drug|Bupivicaine|Bupivicaine will be administered by popliteal block to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
75943331|NCT04455555|Other|Placebo|Null sustained release microspheres placebo / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
75943332|NCT02898259|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 2.0, 3.0 or 4.0 mg ixazomib on days 1, 8 and 15 of each 28 day cycle.
75943333|NCT02898259|Drug|Lenalidomide|"Lenalidomide starting dose will be based on baseline calculated creatinine clearance as follows:~Starting lenalidomide Dose (20mg)~Calculated Creatinine Clearance: >=60ml/min receive 20 mg daily on Days 1 - 21 of each 28-day cycle~Calculated Creatinine Clearance: >= 30 and < 60 ml/min receive 10 mg daily on Days 1 - 21 of each 28-day cycle"
75943334|NCT02898259|Drug|Rituximab|Rituximab is administered intravenously at 375mg/m2 on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6 and day 1 of cycles 8, 10, and 12.
75656443|NCT05978401|Drug|GLS-012+GLS-010+pemetrexed+carboplatin|GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with pemetrexed and carboplatin. Combination treatment will be administered 4~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
75943335|NCT03646435|Device|Fitbit Charge 2|The Fitbit Charge 2 is the electronic wearable chosen for this pilot study. This particular Fitbit is capable of measuring patient heart rate, sleep and physical activity. The data collected will then be analyzed with respect to the outcomes of this study. To determine the accuracy of the Fitbit, data collected will be compared to the nurses' standard patient assessment (for HR and physical activity) and to patient responses on the Richards-Campbell Sleep Questionnaire (for sleep).
75943336|NCT03645343|Device|Activator|This appliance is constructed in one piece to guide the position of the mandible on closure
75943337|NCT03645343|Device|Twin Block|This appliance is constructed in two pieces to guide the position of the mandible on closure
75345334|NCT01510457|Drug|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
75345335|NCT01510457|Drug|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
75476662|NCT05820126|Biological|Cold-stored platelet concentrate|Patients will be transfused a unit of pooled, pathogen reduced platelets that have been stored for >24 hours at 1-6˚C
75345336|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
75656444|NCT05978401|Drug|GLS-012+GLS-010+paclitaxel+carboplatin|GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with paclitaxel and carboplatin. Combination treatment will be administered 4~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
75656445|NCT05978349|Drug|adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
75656446|NCT05978193|Radiation|LDRT+CFRT|"LDRT: Primary tumor and all visible metastatic lesions, DT: 2Gy/2fx, d1-2, Q3W × 4 cycles~; CFRT: Primary tumor, DT:40-50Gy/20-25fx, starting from the 5th immunotherapy cycle"
75656447|NCT05978193|Drug|Immunotherapy|PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years
75656448|NCT05978193|Drug|Chemotherapy|Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles
75656449|NCT05978167|Drug|Methylphenidate|Oral administration of 20 mg Methylphenidate
75656450|NCT05978167|Behavioral|Memory reconsolidation|Retrieval of drug-cue memories before extinction.
75803498|NCT03704896|Other|Lung function measurement|Spirometry-derived lung function measurements
75803499|NCT05536960|Other|68Ga-Dotatate PET/CT|One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
75943338|NCT05283733|Procedure|reverse conversion technique|converting open appendectomy to laparoscopic technique for proper control of intraabdominal sepsis
75943339|NCT03644875|Device|etacoat|Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.
75943340|NCT03704545|Other|Pharmaceutical consultation at the hospital|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
75943341|NCT03704545|Other|Pharmaceutical consultation at the pharmacy|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
75354679|NCT04788888|Device|Navitor Transcatheter Aortic Valve and FlexNav Delivery System|"For traditional application, the Navitor valve is indicated for transcatheter delivery in patients with symptomatic severe native aortic stenosis who are intermediate or low surgical risk.~For the valve-in-valve application, the Navitor valve is indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve.~Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve and FlexNav Delivery system"
75803500|NCT04561648|Drug|Unfractionated Heparin|Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.
75803501|NCT04792060|Procedure|Hook plate|We used titanium 2.4 mm hooked distal ulnar locked plate used for fixation of distal ulna fractures , this plate have low profile which is anatomically precontoured
75943342|NCT03704545|Other|Follow-up pharmaceutical consultation at the pharmacy|During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
75943343|NCT03646279|Device|Calibrace|The CALIBRACE is a new product designed to improve posture using a front-to-back tensioning system that lifts shoulders up and back.
75943344|NCT03644797|Genetic|Exome sequencing|Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
75943345|NCT03644407|Other|Spine Surgery|Patients undergoing spine surgery, who are the subjects eligible for participation to this observational prospective registry
75476663|NCT05818527|Device|Acceledent vibrating device|used to accelerated the movement of teeth during orthodontic treatment
75476664|NCT05813236|Device|Novosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
75943346|NCT03646201|Behavioral|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family eating environment, mothers' own eating behaviors, and food parenting practices.
75943347|NCT02963935|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
75803502|NCT03981822|Combination Product|VP-102 and applicator|In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.
75943348|NCT02963935|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
75943349|NCT02963935|Behavioral|CMS Intensive Behavior Therapy|Intensive Behaviour Therapy for obesity
75943350|NCT03644329|Other|Control group|The volunteers will not performed the interventions.
75943351|NCT03644329|Other|Lower-load resistance training (LL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
75943352|NCT03644329|Other|Higher-load resistance training (HL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
75476665|NCT05813236|Device|Monosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
75476666|NCT05813067|Dietary Supplement|JDS-HF 3.0|Take 2 capsules once daily in the mornings with food
75476667|NCT05813067|Dietary Supplement|Placebo|Take 2 capsules once daily in the mornings with food
75656451|NCT05978167|Drug|Placebo|Matching placebo pill
75656452|NCT05978154|Other|Thigh muscle mass and muscle wasting (exposure)|Thigh muscle mass and muscle wasting (exposure variable)
75656453|NCT05978115|Procedure|implant supported prosthesis|Group A: short dental implant placement + Removable partial denture Group B: Short implant placement + Fixed partial denture Group c: Bone Augmentation + Implant placement + Fixed Partial denture
75656454|NCT05978076|Other|data collection|data collection : mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications.
75803503|NCT03981822|Combination Product|Placebo|The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin
75803504|NCT05506930|Drug|Intrathecal Morphine|One group of subjects will receive intrathecal morphine: spinal (neuraxial) dose of preservative free morphine (Duramorph), usually about 4-5mcg/kg. This is injected into the cerebrospinal fluid under sterile technique by a pediatric anesthesiologist while the subject is already under general anesthesia. This procedure is well-described in the pediatric population and used regularly for postoperative pain relief for a variety of procedures including ureteral reimplantation.
75803505|NCT05506930|Drug|Quadratus lumborum block|The second group of subjects will have bilateral quadratus lumborum blocks: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per/ kg per side (total dose approximately 1mL/kg). This is injected in the subject's flank in the fascial plane between the quadratus lumborum muscle and the psoas muscle. Ultrasound guidance is used for needle and structure localization and this procedure is done by a pediatric anesthesiologist while the subject is already under general anesthesia. Quadratus lumborum blocks are regularly used in clinical practice for postoperative pain relief for a variety of abdominal procedures.
75656455|NCT05978050|Drug|nimotuzumab plus paclitaxel|Nimotuzumab injection: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
75803506|NCT03625336|Diagnostic Test|MRI|An MRI will be obtained utilizing 3 different MRI sequences
75656456|NCT05978050|Drug|placebo plus paclitaxel|placebo: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
75803507|NCT04329754|Device|Cataract surgery|Cataract surgery with implantation of an intraocular lens (IOL)
75803508|NCT04322656|Device|Lipiflow treatment|Patients will be treated on one eye with Lipiflow
75943353|NCT03644329|Other|Higher-volume resistance training (HV)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
75943354|NCT03644719|Behavioral|Cognitive behavioral skills training|A brief cognitive behavioral skills training was applied to teach ketamine abusers about stimulus control, refusal skills, communication skills, decisional balance, and infectious diseases prevention.
75943355|NCT03644641|Procedure|Desflurane Group|General anesthesia will be held using desflurane in end- tidal concentration according to target value of entropy levels (between 40 and 60).
75943356|NCT03644641|Procedure|Propofol Group|General anesthesia will be held using Schnider effect model for propofol (target control anesthesia). Titration will be done according to target value of entropy levels (between 40 and 60).
75943357|NCT05283421|Diagnostic Test|Estrogen|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
75345337|NCT01430741|Other|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
75476668|NCT05812742|Behavioral|Early intervention programme|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
75476669|NCT05812742|Behavioral|Enhanced usual care|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
75656457|NCT05977985|Drug|Rotator interval hydro-dissection with dextrose 5%|Single injection of 20ml dextrose 5% into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
75656458|NCT05977985|Drug|Rotator interval hydro-dissection with corticosteroid solution|Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
75656459|NCT05977881|Other|CHECKIT!|"Participants will not be assigned to the intervention as it will be available to everyone.~Check it will be a van-based HIV- and overdose-prevention program offered in the 5 areas of Baltimore city from which study participants are recruited. Intervention services will include point-of-care drug checking and PrEP assessment, prescription, and management, and they will be available to everyone, regardless of whether they are part of the SCOPE study cohort or not.~Individual-level service usage data collected by intervention staff will not be considered in analysis of outcomes. However, study participants will self-report Check it utilization on the internally-developed surveys at 6, 12, and 18 months."
75803509|NCT04891978|Behavioral|AIRQ|A validated tool designed to identify patients who may be at risk for adverse outcomes from uncontrolled asthma.
75656460|NCT05977868|Drug|Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid|COpAT (oral antimicrobial therapy) on hospital discharge
75656461|NCT05977868|Drug|Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem|Standard of care (IV antimicrobial therapy) on hospital discharge
75803510|NCT04891978|Behavioral|Asthma Checklist|A validated, 3-page tool, based on GINA and NAEPP guidelines to assist providers with recognition, evaluation, and optimization of all patients with asthma. In this study, healthcare providers will be required to complete the assess component (page 1) of the Asthma Checklist .
75803511|NCT04891978|Behavioral|PRECISION Program (Educational Resources)|Educational resources accessible to all providers in the study. There are provider-facing and patient-facing educational materials that can be accessed during the patient visit or as resources for before/after visits. Resources can be downloaded and sent to patients per the discretion of providers.
75803512|NCT03735186|Behavioral|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
75803513|NCT03650556|Device|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™|Ablation procedure for Persistent AF
75803514|NCT03531632|Biological|MGD007 + MGA012|MGD007 and MGA012 are administered by IV infusion.
75803515|NCT05666466|Diagnostic Test|extratympanic electrocochleograhy|electrophysiological test
75803516|NCT03732066|Behavioral|Usual Text Messages|Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
75803517|NCT03732066|Behavioral|Personalized Reminders|"The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of >180 mmHg or <90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days."
75803518|NCT03732066|Behavioral|Interactive Responses|"Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~The researchers will communicate with the patients every month."
75803519|NCT04880824|Behavioral|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
75803520|NCT03722186|Drug|SHR-1603|SHR-1603 monotherapy
75803521|NCT03735030|Drug|Human hCG 10'000 IU|A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.
75803522|NCT03735030|Drug|Recombinant hCG 6'500 IU|A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.
75803523|NCT01310738|Drug|Antimoniate of N-methylglucamine|Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
75803524|NCT01310738|Drug|amphotericin B deoxycholate|1mg/kg/d, I.V. for 14 consecutive days.
75803525|NCT01310738|Drug|Liposomal amphotericin B|3mg/kg/d, I.V. for 7 consecutive days.
75656462|NCT05977855|Other|BPSDiary|The BPSDiary is a diary to register severity, hour, day and triggers of a number of BPSD (namely, agitation, aggression, delusions/hallucinations, insomnia, aberrant motor behavior).
75803526|NCT01310738|Drug|Liposomal amphotericin B|10mg/kg/d, I.V. single dose.
75803527|NCT01310738|Drug|Antimoniate of N-methylglucamine|20mg/kg/d of pentavalent antimonial I.V. for 10 days
75803528|NCT03721978|Biological|VGX-3100|1 milliLiter (mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
75803529|NCT03721978|Biological|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
75803530|NCT03721978|Device|CELLECTRA™-5PSP|CELLECTRA™-5PSP is used for EP following IM injection of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
75803531|NCT03723122|Behavioral|Dyadic Communication Reinforcement Intervention|Psycho-educative and behavioral intervention centered on cancer-related dyadic communication
75943358|NCT05283421|Diagnostic Test|Placebo|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
75656463|NCT05977504|Other|Multi-Psychological Empowerment Courses|9 times online course and 3-days workshop for 6 months of psychological Empowerment Courses.
75656464|NCT05976412|Radiation|Regional lymph node radiotherapy|Regional lymph node radiotherapy
75943359|NCT03643627|Drug|SYNT001|single IV infusion
75943360|NCT03643627|Drug|Placebo|single IV infusion
76091279|NCT03290976|Other|Acupuncture|"Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5"
75476670|NCT05812703|Behavioral|Cognitive Behavioral Therapy|The participants will attend one of the behavioral group treatments programs offered by the Stanford Pain Management Center. This class may be held online via Zoom, or in person based at the Stanford Pain Management Center. The class may be recorded for training purposes. No names or images/faces will be recorded for privacy reasons. The behavioral groups are 3 types, with or without exercise/movement. Current Evidence Based treatments that are provided as standard practice include: Cognitive Behavioral Therapy Group, with movement, Acceptance and Commitment Therapy Group, with or without movement. Group participants will learn different skills in each group and develop a personalized plan to use the skills after group ends. At the end of group participants will be given an anonymous survey about the class to evaluate satisfaction of the treatment. Movement in this portion of class is designed to low impact and restorative/gentle, with no significant increases in HR > 50% HRmax.
75476671|NCT05812703|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a 6 week behavioral group program led by a psychologist to improve psychological flexibility and reduce pain interference in patients with chronic pain.
75656465|NCT05976412|Radiation|chest/whole breast irradiation|chest/whole breast irradiation
75943361|NCT03641521|Behavioral|Parent-led behavioral strategies|Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
75943362|NCT03641443|Device|Non-invasive measurement of intracranial pressure|Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
75656466|NCT05975203|Procedure|skin-to-skin contact|Immediately after delivery the infant will receive skin-to-skin contact with the mother.
75803532|NCT03723044|Other|EEG and occulometry|Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).
75803533|NCT03979638|Drug|BLU-5937|Four escalating doses of BLU-5937 administered BID over the course of the study
75803534|NCT03979638|Drug|Placebo|Matching placebo for BLU-5937
75943363|NCT03641365|Device|Test group|Guided Implant placement Positioning/placement of dental implants thought the fully acrylic surgical template without metallic sleeves.
75354680|NCT04788095|Behavioral|Behavioral Intervention|Participate in an app-based mindfulness program
75354681|NCT04788095|Other|Quality-of-Life Assessment|Ancillary studies
75476672|NCT05812703|Behavioral|Moderate to high Intensity Group Exercise|Group exercise led by supervised clinician with Cardiovascular focus to increase HR into zones to see adaptations to improve cardiovascular fitness.
75476673|NCT05806580|Drug|Relmacabtagene Autoleucel Injection|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
75476674|NCT05804604|Procedure|Surgical treatment of proximal femur fracture and blood sample test|Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB
75656467|NCT05975177|Device|Sterify Gel|A mucoadhesive polymeric hydrogel in a prefilled syringe for nonsurgical treatment of periodontal and peri-implant pockets, composed of polyvinyl polymers, hydroxytyrosol, nisin, and magnesium ascorbyl phosphate
75803535|NCT03704506|Drug|Reyanning mixture|Reyanning mixture , 20ml by mouth , 3 times per day for 7 days
75656468|NCT05975177|Procedure|Scaling and root planing|The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.
75803536|NCT03704506|Drug|amoxil capsule|amoxil capsule , 0.5g by mouth , 3 times per day for 7 days
75803537|NCT03704506|Drug|Reyanning mixture simulator|Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
75803538|NCT03704506|Drug|amoxil capsule simulator|amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
75803539|NCT03655054|Device|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
75803540|NCT03615144|Drug|Melphalan|Melphalan 70 mg/m2/day x 2
75354682|NCT04788095|Other|Questionnaire Administration|Ancillary studies
75354683|NCT04786821|Behavioral|Standard Exercise Training|Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.
75803541|NCT03615144|Drug|Thiotepa|Thiotepa 7.5 mg/kg/day x 2
75803542|NCT03615144|Drug|Clofarabine|Clofarabine 20-30 mg/m2/day x 5
75803543|NCT03615144|Drug|Fludarabine|Fludarabine 30 mg/m2/day x 5
75943364|NCT03641365|Device|Control group|Guided Implant placement Positioning/placement of dental implants thought the acrylic surgical template with metallic sleeves.
75345338|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
75345339|NCT01430741|Other|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
75345340|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
75345341|NCT02478372|Drug|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
75345342|NCT02478372|Drug|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
75656469|NCT05974241|Drug|Methylphenidate, aripiprazole, and combination|Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks). The primary outcome was improvement of irritability as measured by Aberrant Behavior Checklist-irritability subscale (ABC-I). During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate (reduction of ABC-I score < 25%) entered the second step and the medication was switched to aripiprazole. After 4 weeks of treatment, those whose ABC-I scores reduced < 25% entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
75803544|NCT03615144|Drug|Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)|antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
75803545|NCT03615144|Procedure|CliniMACS reagents|Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
75803546|NCT03704428|Drug|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
75803547|NCT03682302|Drug|Exparel|EXPAREL 4mg/kg (maximum 266 mg)
75803548|NCT03682302|Drug|0.5% Bupivacaine HCl|Bupivacaine HCl 2mg/kg
75803549|NCT03734874|Dietary Supplement|hesperidin|500 mg hesperidin as two capsuls
75803550|NCT03734874|Other|control|no supplementation
75803551|NCT03522506|Drug|TAK-925|TAK-925 intravenous infusion.
75803552|NCT03522506|Drug|TAK-925 Placebo|TAK-925 placebo-matching given as saline intravenous infusion.
75803553|NCT03522506|Drug|Modafinil|Modafinil tablets.
75803554|NCT03522506|Drug|Modafinil Placebo|Modafinil placebo-matching tablet.
75656470|NCT05970809|Device|SAGA-001 (A)|Use of a novel microneedle and laser device as a treatment for male patten hair loss with additional microwounding.
75345343|NCT01511315|Drug|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
75345344|NCT01654536|Drug|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
75345345|NCT01654536|Drug|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
75345346|NCT01654380|Drug|LY2605541|LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).
75345347|NCT01654380|Other|Insulin glargine|Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.
75345348|NCT02477670|Drug|AVP-786|
75345349|NCT02477670|Drug|Placebo|
75476675|NCT05804604|Procedure|Blood sample test|Analysis of serum concentration of: SHBG, CTX - I, CK-MB
75803555|NCT03320434|Drug|PRT-2761 0.5%|Six drops in each eye over a 17 day period.
75803556|NCT03320434|Drug|PRT-2761 1%|Six drops in each eye over a 17 day period.
75803557|NCT03320434|Drug|Patanol|Six drops in each eye over a 17 day period.
75803558|NCT03320434|Drug|Pred-forte|Four drops in each eye over a 3 day period.
75943365|NCT02963701|Drug|Ibuprofen|Fixed dose combination
75943366|NCT02963701|Drug|Pseudoephedrine-HCl|Fixed dose combination
75943367|NCT01345591|Procedure|Fat Grafting|
75943368|NCT03644251|Other|amniotic and umbilical cord matrix|Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
75803559|NCT03320434|Drug|PRT-2761 0%|Six drops in each eye over a 17 day period.
75803560|NCT03722888|Device|smokeSCREEN video game|smokeSCREEN video game is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
75943369|NCT03621319|Device|Hybrid argon plasma ablation (HAPC)|-The assigned HAPC ablation will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
75943370|NCT03621319|Device|Radiofrequency ablation (RFA)|-The assigned RFA procedure will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
75345350|NCT04943562|Diagnostic Test|ACT+EEG|Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
75476676|NCT05802901|Procedure|Spinal manipulation|Spinal manipulation of the lumbar spine only to be performed in the spinal manipulation arm/group.
75803561|NCT05232214|Device|Biometry|Only one eye from each patient will be included in the study. All patients included in the study will undergo biometric measurements in a random fashion with the three devices (IOLMaster 700, Argos and Anterion Heildelberg). Each patient will be measured three times with each device
75803562|NCT02892734|Biological|Ipilimumab|Given IV
75803563|NCT02892734|Other|Laboratory Biomarker Analysis|Correlative studies
75803564|NCT02892734|Biological|Nivolumab|Given IV
75803565|NCT05231590|Biological|Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (12.5 µg) with Advax-SM adjuvant (7.5 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
75803566|NCT05231590|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
75803567|NCT05198752|Drug|Neoantigen mRNA Personalised Cancer SW1115C3|Subcutaneous Injection
75803568|NCT00055497|Biological|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
75803569|NCT00055497|Biological|DB adalimumab 40 mg eow|Double-blind adalimumab 40 mg every other week by subcutaneous injection
75943371|NCT02961751|Drug|Ciprofloxacin|Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
75803570|NCT00055497|Biological|DB adalimumab 40 mg ew|Double-blind adalimumab 40 mg every week by subcutaneous injection
75803571|NCT00055497|Biological|OL adalimumab 40 mg|Open-label adalimumab every other week or every week by subcutaneous injection
75803572|NCT03520400|Behavioral|Exercise Therapy|Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
75943372|NCT03643549|Drug|Bortezomib and Temozolomide Phase IB|In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w. If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.
75943373|NCT03643549|Drug|Bortezomib and Temozolomide Phase II|The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
75943374|NCT02963311|Drug|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
75943375|NCT02963311|Drug|Standard of Care|Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
75943376|NCT05262205|Other|measuring depth of anesthesia and its relation to the globe|measuring feasibility of BIS monitor in detecting depth of anesthesia in pediatric population and whether it will be beneficial as a tool for helping anesthesiologist in maintaining central globe alignment
75943377|NCT03643471|Device|MRI|Magnetic resonance imaging with advanced sequences including volumetry, spectroscopy and tractograpghy.
75345351|NCT02509026|Biological|Etanercept|50 mg subcutaneous, once weekly, 24 weeks
75476677|NCT05802901|Procedure|Dry needling|Dry needling of the lumbar erector spinae, multifidus, and gluteus medius on the symptomatic side performed in the dry needling arm/group.
75803573|NCT03615066|Drug|Placebo|Tablet(s) administered orally every 7 days for 24 doses in fasted state
75345352|NCT03439280|Drug|Mezagitamab|Mezagitamab subcutaneously.
75345353|NCT03439280|Drug|Pomalidomide|Pomalidomide orally.
75345354|NCT03439280|Drug|Dexamethasone|Dexamethasone orally.
75345355|NCT03438032|Diagnostic Test|Bronchoscopy with lavage|During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
75476678|NCT05802901|Procedure|Spinal manipulation and dry needling|The spinal manipulation and dry needling arm/group receive both spinal manipulation and dry needling as outlined in the other groups.
75803574|NCT03615066|Drug|Selgantolimod|Tablet(s) administered orally every 7 days for 24 doses in fasted state
75803575|NCT03615066|Drug|TAF|Tablet(s) administered orally once daily with food
75803576|NCT03726398|Drug|Opsumit 10 Mg Tablet|Oral tablet taken once daily
75803577|NCT04050592|Drug|Estradiol|Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
75803578|NCT04050592|Other|Placebo|Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.
75803579|NCT03726242|Drug|Levcromakalim|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
75803580|NCT03726242|Drug|Saline|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
75476679|NCT05802758|Behavioral|Psychopathy.comp and training in virtual reality (VR)|Psychopathy.comp is a CFT-based manualized program of 20 sessions a 60 min, on a weekly basis. During the CFT-intervention, partipants try out their new skills in a tailored VR setting (x5)
75656471|NCT05970809|Device|SAGA-001 (B)|Use of a novel microneedle and laser device as a treatment for male patten hair loss without additional microwounding.
75656472|NCT05969587|Combination Product|5% cysteamine cream|5% cysteamine cream (Cyspera®) was acquired from Scientis APAC Pte. Ltd. (Singapore, Singapore).Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. The cysteamine cream was washed off 15 minutes after application
75943378|NCT02263209|Device|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
76091280|NCT03290976|Other|"Multi-modality (Acupuncture plus)"|"A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner."
76091281|NCT03286374|Behavioral|Occupational rehabilitation|"The participants in the occupational rehabilitation program get both practical and theoretical intervention in groups. Four main interventions; cognitive therapy, physical activity, diets and training in work-oriented approach. The rehabilitation stay is as followed:~Four weeks with an institutional stay at Muritunet (BL)~Follow-up;~Eight weeks, telephone contact between therapist at Muritunet and the participant.~16 weeks, video conference on SKYPE between all the participants and a therapist. Lecture on diets.~28 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T1)~40 weeks, telephone contact between therapist at Muritunet and the participant.~52 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T2)"
76091282|NCT03286296|Biological|LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection|LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
75803581|NCT04050748|Procedure|Achilles tendon repair|Patients will be undergoing achilles tendon repair
75345356|NCT00828074|Drug|sorafenib tosylate|Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.
75345357|NCT00828074|Drug|vinorelbine ditartrate|Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
75345358|NCT01394003|Drug|LY2584702|administered orally
75476680|NCT05797103|Device|A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands|Electrolyzed water spray group will use the novel electrolyzed water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate. Untreated tap water group will use the untreated tap water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate.
75656473|NCT05969587|Combination Product|hydroquinone cream group|4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co., Ltd. (Yilan, Taiwan). Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. Subjects in the hydroquinone cream group were told to apply a 2:1 ratio of the hydroquinone and betamethasone creams. The hydroquinone/betamethasone creams were left on the skin until the following morning.
75345359|NCT03434444|Drug|Oxytocin|Oxytocin in solution, ranging from 10 -12M to 10 -5M
75345360|NCT03434444|Drug|Propranolol|Propranolol in solution, 10-6M
75345361|NCT04382300|Drug|pyrotinib combined with thalidomide|Single Group Assignment
75656474|NCT05969418|Diagnostic Test|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
75803582|NCT03726008|Behavioral|Perinatal health promotion program and regular prenatal care|Regular prenatal care and perinatal health promotion program including health promotion during pregnant period, health promotion during the ritual of Tso-Yueh-Tzu, health promotion during postpartum period, newborn care
75943379|NCT02263209|Device|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
75943380|NCT03641053|Other|Honey|Substance is given topically after the wound has been sutured
75345362|NCT01394081|Other|Enhanced Engagement and Enrollment (EEE)|Consists of motivational interviewing, educational outreach, and patient navigation.
75345363|NCT01394081|Other|Administrative Outreach (AO)|Consists of giving information about enrolling for VA medical care or scheduling an appointment
75943381|NCT03641053|Other|Povidone-iodine|Substance is given topically after the wound has been sutured
75943382|NCT03641053|Other|Paraffin gauze|Substance is given topically after the wound has been sutured
75943383|NCT04455477|Drug|Nesiritide|The attending physicans decide whether to use Nesiritide for congestive heart failure patients. Only patients who will use Nesiritide are enrolled.
75943384|NCT05261113|Procedure|CE-IOUS|Use of contrast-enhanced intraoperative ultrasound during liver surgery
75943385|NCT05348343|Biological|Autologous platelet-rich plasma|PRP created using a commercially available system will be used for treatment. PEFA-PRP will be created by subjecting PRP to a pulsed electrical field in a specially designed instrument developed by sponsor. Two 9 cm2 contralateral regions of interest (ROI) on the scalp will be treated with approximately 6mL of either PRP or PEFA-PRP by subcutaneous injection.
75476681|NCT05794685|Procedure|adductor canal block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle (adductor canal block).
75656475|NCT05969275|Biological|Allogeneic umbilical cord-derived human mesenchymal stromal cells|Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
75803583|NCT01090869|Behavioral|12 weeks of lifestyle change|Participants were randomly assigned to a 12-week intervention in one of four groups: Training (T), energy-reduced Diet (D), Training and increased- Diet (T-iD) or Control (C). The interventions consisted of: T: increased physical activity through daily endurance training equivalent to 600 kcal/day, unchanged diet; D: sedentary lifestyle, reduced diet by 600 kcal/day primarily through reducing serving sizes and substituting energy dense with less energy dense nutrients; T-iD: increased physical activity through daily endurance training equivalent to 600 kcal/day, increased diet by 600 kcal/day primarily through increasing serving sizes and consuming energy dense nutrients; C: sedentary lifestyle and unchanged diet.
75803584|NCT03704272|Behavioral|SunBrite|SunBrite is a family-empowered injury risk mitigation intervention with 3 core components: screening for the risk of supervisory neglect associated with traumatic injury in very young children; a brief behavioral intervention using motivational interviewing designed to provide feedback to the caregiver on supervisory risk and traumatic injury; and a referral to treatment for ongoing risks such as substance abuse, trauma or mental illness, requiring specific clinical interventions.
75803585|NCT03722732|Procedure|pancreaticoduodenectomy|pancreaticoduodenectomy either laparoscopically or open will be done
75803586|NCT04099095|Behavioral|Immediate Appointment|The participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
75803587|NCT04099095|Behavioral|Delayed Appointment|After a period of delay (control) the participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
75803588|NCT03731988|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
75803589|NCT03731988|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 5.5% or 11% or 22% laser density with 350 µm ablation depth, level 1 coagulation and a single pulse
75803590|NCT03731988|Drug|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
75803591|NCT03731988|Other|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
75803592|NCT03731988|Device|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
75803593|NCT01094457|Drug|aspirin, clopidogrel|patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
75476682|NCT05794685|Procedure|4 in one block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery (4 in one block).
75476683|NCT05791903|Other|Nursing Care Based on Kolcaba's Comfort Theory|Comfort-orientated care
75476684|NCT05790109|Device|RF track cautery during percutaneous organ biopsy|After biopsy samples are obtained, the physician operator will place a radiofrequency bipolar cautery electrode through the biopsy introducer needle into the biopsy track and cauterize the track using a standardized protocol.
75476685|NCT05786872|Device|dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
75476686|NCT05786625|Device|Ablation|Bronchoscopy and microwave ablation of lung nodule
75476687|NCT05784532|Device|STERN FIX|Sternotomy closure with STERN FIX and supplemented with wires
75476688|NCT05783544|Diagnostic Test|Interleukin-1B|Level of serum interleukin-1B will be detected
75476689|NCT05783544|Diagnostic Test|Interleukin-4|Level of serum interleukin-4 will be detected
75476690|NCT05783544|Diagnostic Test|Interleukin-6|Level of serum interleukin-4 will be detected
75476691|NCT05783544|Diagnostic Test|tumor necrosis factor - a|Level of serum tumor necrosis factor - a will be detected
75476692|NCT05783544|Diagnostic Test|interferon- gamma|Level of serum interferon- gamma will be detected
75476693|NCT05782231|Behavioral|GetActive+|This is a 10-week group mind body program focused on improving self- report, performance based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
75656476|NCT05969275|Other|Placebo|Intravenous infusion of placebo, with excipients
75656477|NCT05968872|Behavioral|no intervation|it is observational, no intervention was taken
75656478|NCT05967039|Other|Physiotherapy|Physiotherapy in respiratory rehabilitation
75656479|NCT05963503|Other|Assessments|Health literacy Anxiety and depression Physical activity Adherence to airway clearance techniques
75656480|NCT05956093|Radiation|FAPI PET CT|the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT to accurately stage high-grade epithelial ovarian cancers.
75656481|NCT05955612|Procedure|Procalcitonin measurement|Daily measurement of serum procalcitonin concentrations to guide de-escalation of antibiotics
75803594|NCT01094457|Drug|aspirin, clopidogrel, cilostazol|Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
75943386|NCT03643393|Procedure|perineal rectosigmoidectomy|In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.
76091283|NCT04539522|Behavioral|Three-dimensionally corrective exercise for scoliosis|Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.
76091284|NCT04539522|Behavioral|Conventional exercise|Conventional exercise consists a series of spine exercises focusing on core strength training.
76091285|NCT03281148|Device|Computer guided implant insertion group|Implants will be immediately inserted in fresh extraction sockets using CAD/CAM guides
76091286|NCT03281148|Device|Free hand implant insertion group|Implants will be immediately inserted in fresh extraction sockets using free hand technique
76091287|NCT04443504|Behavioral|The Connected Family Series|The intervention is an online, self-paced post-adoption family intervention that occurs over a 4-week period to support adoptive families post-adoption.
76091288|NCT03286140|Procedure|Early endovenous ablation|
76091289|NCT03286140|Procedure|Delayed endovenous intervention|
75656484|NCT05934656|Other|Latent class analysis|"The investigators will conduct a longitudinal study comprising nested groups A to C of the study population, with progressively more detailed mechanistic investigations. No control group.~Group A will complete a CF-specific measure of gut symptoms (CFAbd-Score), a generic constipation score (PAC-SYM) and 24 hour dietary recall (Intake24).~Group B will have stool and blood for microbiome, inflammatory mediators and faecal fat.~Group C will have gut MRI and exploratory studies of inflammation."
76091290|NCT03286062|Combination Product|Agent VM110 and laproscopic infra-red probe|Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
76091291|NCT01776723|Drug|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
76091292|NCT01775007|Device|Brillouin Ocular Analyser|Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
76091293|NCT03280914|Device|Auto-CPAP|Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
76091294|NCT03285906|Drug|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
76091295|NCT01895205|Drug|Iron isomaltoside 1000|
76091296|NCT01895205|Drug|Red blood cell transfusion|
75656485|NCT05929898|Behavioral|Ventral tegmental area of dopaminergic midbrain (VTA) fMRI neurofeedback|fMRI neurofeedback training of sustained midbrain/VTA activation via motivational imagery.
75656486|NCT05900973|Drug|Darolutamide Oral Tablet [Nubeqa]|Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
75656487|NCT05884203|Device|Caregiver socket|A prosthetic socket whose shape was captured by a study helper using digital methods (i.e., 3D scanner). The digital file describing the socket dimensions will be sent to a central fabrication facility where the prosthetic socket will be manufactured.
75656488|NCT05884203|Device|Prosthetist socket|A prosthetic socket whose shape was captured by a prosthetist using traditional, hand casting methods. The hand cast will be plaster filled to create a positive model. A prosthetist socket will be fabricated over the positive model using thermoplastic materials.
75656489|NCT05880329|Diagnostic Test|Candidate POCTs for detecting UTI|POCT performance will be evaluated in participants who experience possible UTI.
75656490|NCT05875779|Behavioral|Peer-led vaccine education intervention|"The intervention will be delivered face-to-face by a trained peer-educator and will consist of one session of 10-20 minutes.~Peer vaccine educators will receive written vaccine materials for distribution. These materials will present content that accurately represents the risks and benefits of vaccination.~Responsibilities of the vaccine educators will be to: provide motivational interviewing with patients, provide vaccine counseling, address questions and concerns regarding available vaccines, brief clinical provider on hesitant patients and areas of their vaccine-related concerns, and provide follow-up with participants at day 30, day 60 and day 90 for additional engagement."
75656491|NCT05874726|Diagnostic Test|Blood Collection|Blood collection via venipuncture
75656492|NCT05874726|Diagnostic Test|Urine Collection|Free catch urine sample collection
75656493|NCT05874726|Diagnostic Test|Tissue Sample Collection|Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.
75656494|NCT05868928|Diagnostic Test|Magnetic resonance imaging (MRI)|Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
75656495|NCT05868928|Diagnostic Test|Diffusion-weighted MRI|Diffusion-weighted MRI
75656496|NCT05868928|Diagnostic Test|Arterial spin labeling (ASL)|Cerebral blood flow imaging parameter
75803595|NCT03527966|Biological|5cc Vivigen and local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft
75803596|NCT03527966|Biological|Small kit rhBMP-2 with local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft
75803597|NCT01096953|Behavioral|Mental health care implemented by telepsychiatry|Care of 6-17 year-olds with ADHD
75803598|NCT01096953|Behavioral|Face-to-face care|Psychiatry provided for treatment of ADHD face-to-face in office
75803599|NCT03734718|Drug|GIP|Infusion of Glucose-dependent insulinotropic peptide
75803600|NCT03957837|Diagnostic Test|Optical nerve sheath diameter ultrasound measurement|"In cases: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline before the induction of general anesthesia (5 min after the beginning of mechanical ventilation in supine position); (T2) after 10 min from 25 degrees head down positioning and with pneumoperitoneum insufflation; (T3) after 60 min from T2, in head down position; (T4) after 10 min from tracheal tube removal, in supine position.~In healthy controls: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline in supine position; (T2) after 10 min from 25 degrees head down positioning; (T3) after 60 min from T2, in a head down position; (T4) after 10 min from positioning supine"
75803601|NCT03701698|Drug|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet （Jakafi）, 5~10mg bid po for at least 28 days.
75803602|NCT03701698|Drug|Methylprednisolone|Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.
75803603|NCT03734562|Procedure|Ablation|Substrate-based radiofrequency catheter ablation
75803604|NCT03734562|Drug|Antiarrhythmic drug|Amiodarone or sotalol therapy
75803605|NCT03034096|Drug|Propofol|Maintenance of general anesthesia with propofol infusion
75943387|NCT04805619|Device|Biomime Morph, a tapered drug eluting stent (DES) with hybrid design|Biomime Morph DES is a cobalt-chromium stent, with strut thickness of 65 µm, a hybrid cell design (closed cells in the extremity and open cells in the middle) and a conic shape, where the proximal part of the stent is 0.5 mm larger than the distal part (Table 1). In addition, the Biomime Morph elutes Sirolimus from a biodegradable polymer matrix.
75345364|NCT04382534|Combination Product|Respiratory rehabilitation|Health education and energy saving techniques, chest activity training, local lung dilation techniques, breathing training, airway clearance training, aerobic exercise, resistance training
75656497|NCT05868928|Diagnostic Test|Dynamic susceptibility contrast-MRI (DSC-MRI)|Cerebral blood volume and vessel architectural imaging parameters
75656498|NCT05858528|Diagnostic Test|PEST screening questionnaire|PEST questionnaire to screen for PsA performed every 6 months
75656499|NCT05857787|Device|Ultrasound with nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use this feature to educate subjects before seeking brachial plexus and median nerve.
75656500|NCT05857787|Device|Ultrasound without nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use ultrasound alone without this feature to educate subjects before seeking brachial plexus and median nerve.
75803606|NCT03034096|Drug|Volatile Agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
75803607|NCT01090947|Device|ProtoCAD|Aquiring acoustic signals from heart patients.
75803608|NCT03012490|Other|CRT-P or CRT-D standard remote monitoring|standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system
75803609|NCT03012490|Other|CRT-P or CRT-D full remote monitoring|Full follow-up for the Active group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system + supraventricular rhythm disorders, parameters related to heart failure, including symptoms and clinical signs of the patient
75803610|NCT03012490|Other|Symptoms and signs remote monitoring|symptoms and clinical signs of the patient
75803611|NCT03953391|Other|Tea|Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.
75803612|NCT03953391|Other|Water|150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
75656502|NCT05836740|Drug|Minocycline hydrochloride capsule|50 mg per capsule, containing 50mg of Minocycline Hydrochloride.
75656503|NCT05836740|Drug|Placebo capsules of Minocycline hydrochloride capsules|50 mg per capsule, containing 0mg of Minocycline Hydrochloride.
75803613|NCT03808545|Behavioral|Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)|This is a newly developed Internet website that delivered a Social Cognitive Theory-based behavioral intervention using e-learning and one-on-one video chats approaches for increasing physical activity and improving symptoms, walking impairment, and neurological disability. The intervention will last 16 weeks and will include physical activity information.
75943388|NCT03640975|Other|Endoscopy|The endoscopy will be performed under general anaesthesia using a flexible endoscope with an external diameter of between 4.9 and 9.2 mm, depending on the size of the child. In line with the guidelines, eight biopsies will be collected from the proximal, median and distal oesophagus for the routine analysis of esophageal remodelling and inflammation. Three of these biopsies will be used in the context of this study to analyse innate immune cells using flow cytometry and to determine the profile of cytokine expression. Two biopsies will be placed in sterile, 0.5 ml Nunc tubes containing a storage buffer (MACS® Tissue Storage Solution) and then stored in ice until the extraction of cells for cytometric analysis . The third specimen will be placed in a sterile tube and frozen immediately in liquid nitrogen for analyses of the esophageal microbiome.
75943389|NCT03160365|Procedure|ACQUISITION OF IMAGES|In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
75803614|NCT03808545|Behavioral|BIPAMS + Diet|For 8 weeks a participant will complete the standard BIPAMS intervention. For the subsequent 8 weeks, in addition to the BIPAMS website, participants will receive a diet prescription with instructions and guidance on their one-on-one video calls and will utilize the HealthWatch360 app and/or desktop website to track their dietary intake. The total intervention will last 16 weeks and will include physical activity information and dietary information.
75943390|NCT05165277|Drug|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
75943391|NCT03468777|Drug|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
75943392|NCT03468777|Drug|Lansoprazole|Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
75943393|NCT03468777|Drug|Ranitidine|Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
76091297|NCT03285828|Behavioral|motivationnal interviewing training|"The students received three four-hour sessions of basic motivationnal interviewing training :~Viewing and commenting on video clips illustrating motivational and non-motivational doctor-patient interactions.~Lectures and the distribution of memory aids.~Practical exercises: making reflections, asking open questions; exploring ambivalence; dealing with resistance; expressing empathy, summarising.~Role-playing, based on several situations, each involving two students. The investigators deliberately chose a non-medical situation (conflict between a mother and a student asking her for pocket money to go out for fun, the day before a university examination) for the first situation. All the other situations concerned changes to healthier behaviour in a medical setting, but with a goal different from that used for the first or the second simulated interview before motivationnal interviewing training."
76091298|NCT01895283|Behavioral|Moderate-intensity training|Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
75345365|NCT00880022|Device|Flexitouch System|( 10 to 30 treatments depending on group assignment)
75656504|NCT05827822|Device|Sober Time ACT|Mental health assessment (regular assessment and reporting feedback), daily clock-in (reporting alcohol use and providing encouragement and reinforcement), mental knowledge base (Tips for the Day based on cognitive behavioral techniques, popular alcohol withdrawal courses, alcohol health education manuals) and self-assistance tools (mindfulness meditation training and emergency help buttons)
75656505|NCT05825430|Procedure|Direct pecs block|"Patients will receive direct PECS block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
75656506|NCT05825430|Procedure|Ultrasound guided pecs block|"Patients will receive ultrasound guided pecs block after induction and before skin incision.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
75803615|NCT03721874|Drug|Dapagliflozin 10mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered dapagliflozin 10 mg during Period 1 or Period 2."
76091299|NCT04264962|Drug|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
76091300|NCT04264962|Other|Routine medical care|Routine medical care
75803616|NCT03721874|Drug|Placebo matching to Dapagliflozin 10 mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered placebo during Period 1 or Period 2."
75943394|NCT00431457|Device|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
75943395|NCT00431457|Procedure|amygddohyppocampertomy|Resective surgery
75345366|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
75943396|NCT03640377|Drug|Praziquantel|Praziquantel given as crushed tablets (40 or 80 mg/kg)
75943397|NCT05283655|Behavioral|Gut-directed hypnotherapy|hypnotherapy
75943398|NCT00260559|Procedure|Questionnaires|Quality of life and heartburn assessment questionnaires are administered preoperatively and at set intervals postoperatively.
75345367|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
75345368|NCT00828542|Drug|etonogestrel implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
75345369|NCT00828542|Drug|depot medroxyprogesterone acetate|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
75345370|NCT01394159|Procedure|22G ProCore biopsy needle|Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.
75943399|NCT03643315|Behavioral|Exercise and Meal (EX)|30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
76091301|NCT01748175|Drug|Triamcinolone Acetonide|Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
76091302|NCT04261764|Device|"Fastening-mimicking diet combined with a dispelling dampness meal replacement"|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
76091303|NCT04261764|Other|Normal diet|Carrying out normal diet under the guidance of a dietitian.
76091304|NCT03280758|Behavioral|Muscle Strengthening exercises|Participants will be required to participate in resistance training 3 hours per week.
75803617|NCT01310816|Drug|IPI-926|Oral
76091305|NCT04755387|Drug|Ticagrelor 90mg|Standard strategy initially receive ticagrelor 90mg twice daily for 12 months.
76091306|NCT04755387|Drug|Ticagrelor 60/45mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60/45mg twice daily after discharge for 12 months.
76091307|NCT04046328|Drug|Enteric-Coated Cholestyramine (ECC) Capsule|Enteric-Coated Delayed Release Cholestyramine Capsules
76091308|NCT04046328|Drug|Placebo|Enteric-Coated Delayed Release Placebo Capsules
75476694|NCT05775315|Other|Action Observation Therapy|"Exercises of AO protocol MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
75656507|NCT05825430|Drug|general anaesthetic technique only|All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
75656508|NCT05804214|Other|Dairy and plant based infant formula feeding|Parents have already decided to feed their infant with the product (a dairy and plant based infant formula) daily, starting within the first 4 months of life, continuing for at least 2 months
75803618|NCT01310816|Drug|Placebo Arm|oral placebo
75803619|NCT03807843|Biological|V184|Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10^5 TCID50 (+/- 0.5 log) per dose.
75803620|NCT03807843|Other|Placebo|Sterile physiological saline for IM injection
75803621|NCT03519932|Device|comfilcon A toric lens|Contact lens
75803622|NCT03519932|Device|samfilcon A toric lens|Contact lens
75943400|NCT03643315|Behavioral|No-Exercise and Meal (NEX)|30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
75943401|NCT03643237|Behavioral|Video game-based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework
75943402|NCT03643237|Other|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
75943403|NCT05044923|Device|Targeted Epidural Spinal Stimulation|Two lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) will be implanted epidurally over the dorsal aspect of the spinal cord through two laminotomies. Two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) will be connected to the lead electrodes and implanted in the upper buttocks of the participant.
75943404|NCT05246449|Other|individualised treatment plan (VitalCare) and associated remote medical monitoring|VitalCare is a treatment plan to help in the personalisation of patient care.
75943405|NCT05165043|Procedure|position change|The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included,patients changed from the left lateral position to the right lateral position.
76091309|NCT03285672|Drug|FP-101|Dose 1
76091310|NCT03285672|Drug|Placebo Comparator|Dose 1
76091311|NCT03285516|Behavioral|Safety Aid Reduction Treatment|START includes many of the key elements found in empirically supported treatments for emotional disorders including a) psychoeducation regarding the nature of distress and b) exposure to internal sensations and external situations that are connected to one's distress response via identification and reduction in safety aids. Safety aids discussed in the current protocol include cognitive avoidance, situational avoidance, checking behaviors, reassurance seeking, avoidance of bodily sensations, companions, and use of alcohol and other substances.
76091312|NCT03280680|Other|Female+male group sessions|Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
75656509|NCT05788042|Device|MagPro TMS device (ARTG: 204659)|rTMS will be administered using a MagPro TMS device (ARTG: 204659) which is approved for its intended use in this trial. rTMS involves the application of transient magnetic pulses which induce small currents in the underlying cortex via the principal of electromagnetic induction. rTMS will be administered using a patterned frequency stimulus called intermittent theta-burst stimulation (iTBS).This form of rTMS was chosen because a recent large multicentre trial showed 3 minutes of iTBS attained the same therapeutic effect as 30 minutes of standard rTMS, leading to FDA approval for depression. Each treatment session will comprise an extended iTBS session, i.e., 6.6 mins, delivered at 100% resting motor threshold (RMT). It will be targeted to the left DLPFC (F3 using the 10-20 International EEG system), consistent with the prior RCT of rTMS for AN.
75943406|NCT03643081|Device|"Use of the camera Fluobeam"|"Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy."
75803623|NCT01094535|Drug|Synthetic Human Secretin|S-MRCP has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in the pancreatic ducts, as well as functional secretory capacity of the gland. Twelve patients will each undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations, at a dose of 0.2 ucg/kg per exam, each S-MRCP will require 16-32 ucg of secretin (12 vials). Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
75943407|NCT03130569|Behavioral|Web-based Module Group|
75943408|NCT03642925|Dietary Supplement|Meal replacement diet|Obese subjects were requested to replace two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks with one regular meal and make sure the daily target calorie limit should be less than 1500 kcal/day for men and 1200 kcal/day for women.
75943409|NCT03640897|Device|Liniderm|Cleaning of the diaper area with Liniderm at each diaper change during 28 days
76091313|NCT03280680|Other|Female group sessions|Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
76091314|NCT03280680|Other|No group sessions|Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
75345371|NCT01394159|Procedure|22G standard FNA needle|Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
76091315|NCT03285360|Combination Product|Sylc|a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment
75656510|NCT05788042|Device|tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637)|tDCS will be self-administered using the 1x1 tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637) with two saline-soaked sponge electrodes held in place on the scalp using the Soterix Ole-2 headband. The device is intended to treat different neurological and psychiatric disorders. tDCS involves the passing of weak electrical current through the brain via electrodes placed upon the scalp. The current modulates the resting membrane potential of stimulated neurons which causes changes in neuronal excitability. The anode will be placed over the left F3 (10-20 System) and the cathode over F4 (electrode sizes 5 x 5cm, 25cm2). This montage was chosen to target the left DLPFC, consistent with prior pilot studies of tDCS in AN.
75656511|NCT05786079|Behavioral|Footstrike modification|
75345372|NCT03008759|Other|Dentifrice 100% Nano-F|Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.
75656512|NCT05786079|Behavioral|Control|
75803624|NCT01097031|Other|Infusion Intermittent|
75803625|NCT03806127|Drug|Vibegron|oral administration
75803626|NCT03806127|Drug|Placebo|oral administration
75943410|NCT03640897|Other|Wipes|Cleaning of the diaper area with wipes at each diaper change during 28 days
75943411|NCT03640897|Other|Water|Cleaning of the diaper area with water and cotton pads at each diaper change during 28 days
75943412|NCT03642847|Biological|Prevnar 13|13 valent Pneumococcal Conjugate
75803627|NCT02770300|Device|Arm Light Exoskeleton Rehab Station (ALEx RS)|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress.
75943413|NCT03642847|Biological|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
75943414|NCT03642847|Biological|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
75943415|NCT03621163|Procedure|Bleaching agent ( BOOST 40%)|Opalescence Boost 40% is a 40% hydrogen peroxide, medical power bleaching gel. The jet mix syringe ensures freshness for each application and precise dosing of the activator. One barrel contains a unique chemical activation with sodium fluoride and potassium nitrate, which have been demonstrated to reduce caries susceptibility, lower sensitivity, and improve enamel micro-hardness. The other barrel contains the concentrated hydrogen peroxide. When mixed, Opalescence Boost results in a 1.1% fluoride and 3% potassium nitrate concentration.
76091316|NCT03285360|Combination Product|fluoride varnish (Bifluorid 10)|It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
76091317|NCT00160173|Drug|Estrogel|
76091318|NCT00160173|Other|Placebo|
76091319|NCT03285282|Procedure|Thoracolumber interfascial plane block|Thoracolumber interfascial plane block versus placebo
75345373|NCT03008759|Other|Dentifrice 50% Nano-F|Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.
75345374|NCT03008759|Other|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
75345375|NCT01394705|Device|BodyMedia|Accelerometer
75345376|NCT01395329|Drug|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
75345377|NCT01395329|Drug|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
75943416|NCT03621163|Procedure|laminate veneers(lithium-silicate)|A lithium-silicate glass ceramic is newly introduced to the market. After crystallization, it demonstrates an ideal combination of strength, aesthetics and translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns. It differentiated from other ceramics by its high chipping resistance, due to their monolithic composition and average flexural strength of 385 MPa. Also Milling Block has good wear resistance due to the high content of ultra-fine nano-meter size crystalline structure. Lithium-silicates ceramic blocks are available in the commonly used VITA Classical and Chromascop Bleach shades.
75943417|NCT04871763|Other|Retainers' Cleansing with Geldis®|Patients will clean their essix retainers with Geldis® using a toothbrush every night for 2 months.
75943418|NCT04871763|Other|Retainers' Cleansing with tablets|Patients will leave their essix retainers in a glass with water and Polident tablets every night for 2 months.
75943419|NCT04871763|Other|Retainers' cleansing with water|Patients will brush their essix retainers with a toothbrush under water every night for 2 months.
75943420|NCT04760535|Device|Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)|Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
75943421|NCT04760535|Device|Tooth-borne Hyrax-type maxillary expander|The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
75943422|NCT03632187|Drug|Abatacept|Subcutaneous abatacept every weeks during 3 months
75656513|NCT05782270|Drug|Warfarin|dual antiplatelet therapy combined with warfarin
75803628|NCT02770300|Device|Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress. The movements to be performed by the patient are automatically decided by the exoskeleton.
75803629|NCT02667574|Drug|ERIVEDGE|
75345378|NCT01395329|Drug|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
75345379|NCT01395329|Other|Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)|The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.
75345380|NCT01395329|Other|FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
75345381|NCT01395329|Other|FBF response to Acetylcholine|The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.
75656514|NCT05782270|Drug|DAPT|Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)
75803630|NCT03704116|Behavioral|Expedition|On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.
75345382|NCT01395329|Other|FBF response to Sodium Nitroprusside|The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.
75345383|NCT01395329|Other|FBF response to BQ-123+BQ-788+ACh|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
75345384|NCT00882206|Drug|cytarabine|"At baseline when peripheral blood draw and bone marrow aspirate performed.~*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg."
75345385|NCT00882206|Drug|decitabine|Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
75656515|NCT05782270|Other|CE+CABG|Coronary endarterectomy combined with coronary artery bypass grafting
75656516|NCT05781360|Drug|SIM0237|SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens
75656517|NCT05780710|Other|Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs|"The device under test is Aktiia Optical Blood Pressure Monitoring (OBPM) device and the comparator is the Aktiia cuff.~The 3 drug treatments are the following ones:~Perindopril 5 mg (Angiotensin Converting Enzyme (ACE) inhibitors)~Indapamide 1.5 mg (Diuretics)~Amlodipine 5 mg (Calcium channel blockers)"
75656518|NCT05776680|Other|Psychological support|60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
75656519|NCT05764954|Device|NovoTTF-200T System|The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
75656520|NCT05756634|Behavioral|Care Coordination after Preterm Birth (CCAPB)|For participants randomized to CCAPB, the care coordinator will follow a manualized intervention to support care planning, health care access, and wellbeing. Contact with participants will be initiated as soon as possible after enrollment, and will continue until six months after enrollment.
75345386|NCT00882206|Drug|doxorubicin hydrochloride|Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
75345387|NCT00882206|Drug|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age <18 years and 400 mg orally every day for >18 years on Days 5-33.
75345388|NCT00882206|Drug|methotrexate|**Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
75345389|NCT00882206|Drug|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
75345390|NCT00882206|Drug|prednisone|40mg/m2/day divided BID (days 5 - 33)
75345391|NCT00882206|Drug|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
75943423|NCT03632187|Drug|Placebos|Subcutaneous placebo every week during 3 months
75943424|NCT05110209|Other|Aflibercept|intravitreal injection
75943425|NCT05110209|Other|Ranibizumab|intravitreal injection
75943426|NCT05110209|Other|Bevacizumab|intravitreal injection
75943427|NCT04454151|Drug|Azithromycin Tablets|given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
75345392|NCT00882206|Drug|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
75943428|NCT05697315|Procedure|Control|No block was performed
75656521|NCT05754528|Drug|Standard of care administration of Endocrine therapy|Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.
75943429|NCT05697315|Procedure|Erector spinae plane block|Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
75656522|NCT05754528|Drug|Dose-frequency escalation administration of Endocrine therapy|Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
75943430|NCT00965757|Drug|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
75656523|NCT05751811|Device|Virtual reality|"The immersive video simulated a magical journey through a calming starry sky on a flying carpet. The headset will play the immersive video content throughout the hysteroscopic procedure; and will stop playing the content as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
75656524|NCT05751811|Procedure|Music therapy|"Relaxing and light music will play throughout the hysteroscopic procedure; and will stop playing as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
75656525|NCT05750329|Procedure|assisted liver transplantation combined with two-stage hepatectomy|"Stage 1 Surgery: Left Hepatectomy, Left Lateral Graft Implantation, Portal Shunt to Graft Intermediate stage: continuous monitoring of liver function indexes and liver transplant donor volume after the first stage of surgery. Until the graft size reaches 0.8% of body weight (GBWR), or 35%-45% of the standard liver volume.~Stage 2 Surgery: Residual Right Hepatectomy"
75656526|NCT05716061|Procedure|Sacral ESPB|Cadaver study
75656527|NCT05708599|Diagnostic Test|Liquid biopsy|Liquid biopsy
75656528|NCT05691660|Drug|TAS3731 Dose1|Oral administration,1 day,QD
75656529|NCT05691660|Drug|TAS3731 Dose2|Oral administration,7 days,QD
75656530|NCT05691660|Drug|TAS3731 Dose3|Oral administration,7 days,BID
75943431|NCT00965757|Drug|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
75943432|NCT03468699|Combination Product|Autologous BMMC transplantation|Stem cell transplantation
75943433|NCT03130413|Device|Ambu Aura Gain supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
75943434|NCT03130413|Device|Air-Q supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
75943435|NCT05697237|Drug|Carrelizumab|Carrelizumab 200mg/3 weeks
75656531|NCT05691660|Drug|Placebo|Oral administration, 1 day,QD
75943436|NCT05697237|Drug|Solfantinib|Solfantinib 300mg/d
75943437|NCT05164497|Other|Deliberate practice training|"The experimental condition consists of five weeks of deliberate practice training of non-specific psychotherapy skills organized as (1) classroom training and (2) homework. The classroom training consists of 15 hours (5 days x 3 hours) of deliberate practice training. Each day will be organized around a theme: (a) Empathy, (b) establishing the therapeutic alliance, (c) working with alliance ruptures, (d) formulation of an interpersonal focus, and (e) clinical expertise - a synthesis. The training will include theoretical introductions, students defining individual training goals, model responses of good psychotherapeutic skills, and student role-play. Regarding homework, after each of the five classes, the students will use Theravue to watch and respond to three therapy videos related to the theme of the previous class. The students have to deliver at least two new responses to each video informed by feedback from teachers and peers and a checklist describing a good response."
76091320|NCT04046172|Procedure|supra/sub gingival root surface debridement|The test group will undergo Intensive periodontal treatment (IPT)
76091321|NCT04046172|Procedure|supra-gingival scaling and polishing|Control group will receive the Control periodontal treatment (CPT).
76091322|NCT00136695|Drug|anastrozole|1 mg QD
75345393|NCT00831272|Drug|naltrexone|50mg/day
75345394|NCT00831272|Drug|Placebo|Placebo
75345395|NCT00831428|Other|no intervention|this is a screening study, not an interventional study
75345396|NCT00832130|Device|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
75345397|NCT00832130|Device|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
75345398|NCT00885092|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
75943438|NCT05164497|Other|Theoretical teaching|The control condition will consist of five weeks of theoretical teaching of non-specific psychotherapy skills performed as (1) classroom teaching and (2) homework. Regarding classroom teaching, the 15 hours (5 days x 3 hours) of teaching will be organized around the same five themes as the experimental condition (see points a-d above). The class will consist of the teacher's presentation of theory and research findings, videos with master therapists defining core concepts, and group discussions of literature. Regarding homework, the participants will read literature and use a restricted version of Theravue to complete home assignments where they record their answers to three theoretical questions related to the theme of the preceding classroom teaching.
75943439|NCT05272683|Drug|GLPG3667|On day 1 and day 8, participants will receive a single dose
75803631|NCT03734484|Diagnostic Test|InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between various Gram-type infections.
75943440|NCT05272683|Drug|Itraconazole|On days 5 to 11, participants will receive itraconazole once daily
75943441|NCT05649423|Other|POSTURAL DRAINAGE WITH PERCUSSION|"Each position should be held for a minimum of five minutes. In each position, your chest should be lower than your hips to allow mucus to drain. On your back: Patient's chest should be lower than his hips, which you can achieve by lying on a slanted surface up about 18 to 20 inches. On your sides: With pillows under your hips, lie on one side. To clear congestion from the right and left lobes. On your stomach: Drape patient's body over a stack of pillows, this is best in clearance of mucus from the lower back area of the lungs.~Percussion The equipment required here is cupped hands of caregiver to deliver the force required to drain the thick secretions. Patient should be in a comfortable position to enhance the effect. This loosens the thick, sticky secretions from the walls of the lung allowing them to into the larger airways, The sound heard must be hollow. The force applied must be equal."
75966018|NCT02370394|Behavioral|ROSE Program|The ROSE Program was specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It was tailored to the current IPV risk assessment, pregnancy or postpartum status of each participant, was designed to reach participants across levels of motivation for change. The content of ROSE was theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
75345399|NCT00885092|Device|RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)|Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
75345400|NCT00885092|Device|Senofilcon A contact lens (ACUVUE® Oasys™)|Commercially marketed silicone hydrogel contact lens for daily wear use
75345401|NCT00885092|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
75345402|NCT01512251|Drug|BKM120 Combined with Vemurafenib (PLX4032)|"Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D"
75345403|NCT00885638|Drug|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
75345404|NCT00885638|Drug|placebo|A placebo tablet is given before ingestion of macronutrients
75656532|NCT05691660|Drug|Placebo|Oral administration, 7 days,QD
75656533|NCT05691660|Drug|Placebo|Oral administration, 7 days,BID
75803632|NCT03734328|Procedure|connective tissue graft|"anesthesia of the palatal mucosa~subepithelial connective tissue graft harvesting~suturing (5/0 silk suture)"
75656534|NCT05688618|Dietary Supplement|Enteroccocus Facieum and Agave Inulin|A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
75656535|NCT05688618|Other|Placebo|A pack of unsweetened almond powder milk will be administered daily for 8 weeks
75656536|NCT05684120|Behavioral|Mood Lifters for Undergraduates|Participants will need to attend 14 hour-long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
75803633|NCT03734328|Procedure|connective tissue graft&PRF|"anesthesia of the palatal mucosa subepithelial connective tissue graft harvesting~-suturing (5/0 silk suture)"
75803634|NCT03734328|Other|connective tissue graft&PRF|"taking blood from patient~centrifuging blood~obtain PRF"
75803635|NCT03650400|Drug|Fevipiprant|Chewable tablet
75803636|NCT03734094|Device|Ceramic barrier|The use of a ceramic barrier to induce bone formation during GBR
75803637|NCT03734094|Device|Titanium Mesh|The use of a titanium mesh to induce bone formation during GBR
75803638|NCT00038103|Drug|Exemestane|Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
75803639|NCT00038103|Drug|Celecoxib + Exemestane|Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
75803640|NCT03680742|Device|Contour Neurovascular System|The Contour Neurovascular System™ is an intrasaccular, self-expanding, embolization device intended for the treatment of unruptured intracranial aneurysms.
75803641|NCT03678870|Other|Opioid Education Handout|a single page handout with information about how to use medications for pain after discharge.
75345405|NCT01512797|Drug|Sitagliptin phosphate|100 mg/day orally
75345406|NCT01512797|Other|Placebo|1 Placebo Pill per day
75345407|NCT03838952|Drug|Herbal medicine|Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
75345408|NCT05620940|Drug|Vivitrol Injectable Product|Naltrexone Long-Acting Injection
75345409|NCT05620940|Drug|IVL3004|Naltrexone Long-Acting Injection
75345410|NCT01395797|Drug|PIO|0, 15, and 45 mg per day.
75345411|NCT01395797|Drug|Placebo|Placebo
75943442|NCT05649423|Other|Postural drainage|"Each position should be held for a minimum of five minutes.~In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs."
75943443|NCT05164185|Procedure|Remote ischemic conditioning|Brief cycles of ischemia to a limb. A blood pressure cuff was placed around the right thigh and inflated to 200 mmHg for 4 cycles of 5 minutes.
75943444|NCT03789357|Diagnostic Test|Aldosterone renin ratio|Aldosterone Renin Ratio to screen for Primary Aldosteronism
75943445|NCT05164029|Other|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
75943446|NCT04455399|Device|Intravitreal injection guide (Malosa)|A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion
75943447|NCT04455399|Device|Dual Blade Eyelid Speculum|A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.
76091323|NCT01896453|Procedure|Transcranial direct current stimulation (tDCS)|Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
75345412|NCT05124704|Drug|5-8ml 0.375% ropivacaine|5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
75345413|NCT05124704|Other|5-8ml normal saline|5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
75345414|NCT00834236|Other|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
75345415|NCT00834236|Other|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
75803642|NCT03805971|Device|Study of the pleural cavity with a confocal laser endomicroscope.|Probe based confocal laser endomicroscope can be introduced through the working chanel of the thoracoscope. this allows the study of the pleural cavity with this new tool.
75803643|NCT03032380|Drug|Cefiderocol|2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)
75803644|NCT03032380|Drug|Meropenem|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)
75803645|NCT03032380|Drug|Linezolid|600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.
75803646|NCT03519854|Drug|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
75943448|NCT05219721|Drug|CAR-T (CAR-GPRC5D)|CAR-GPRC5D is an individualized, gene-modified autologous T cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. CAR specifically recognizes GPRC5D with a hypoimmunogenic human single-chain variable fragment (ScFv) that promotes car-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain. The amplification and persistence of CAR T are enhanced by 4-1BB costimulation signal.
75803647|NCT03519854|Drug|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.
76091324|NCT01896453|Procedure|Transcutaneous electrical nerve stimulation (TENS)|Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
76091325|NCT02459730|Procedure|ART with GIC containing 1.25% CHX.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
75345416|NCT01431131|Procedure|Intrasocket graft|Intrasocket mineralized cancellous allograft
75345417|NCT01431131|Procedure|Intrasocket plus facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
75345418|NCT05102318|Procedure|Direct Pulp Capping|Direct Pulp Capping
75345419|NCT05102318|Procedure|Partial Pulpotomy|Partial Pulpotomy
75345420|NCT05102318|Procedure|Pulpotomy|Pulpotomy
75345421|NCT02203019|Drug|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
75345422|NCT02203019|Drug|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
75345423|NCT02203019|Drug|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
75345424|NCT00886262|Drug|Vasopressin|Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
75803648|NCT03519854|Drug|Esmeron®|Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
75803649|NCT03704038|Procedure|PEEP level|Patients will have variable PEEP levels and will be monitored
75803650|NCT04587154|Other|low-fat vegan diet with 1/2 cup soybeans daily|Weekly instructions will be given to the participants in the intervention group about following vegan diet with 1/2 cup of soybeans daily.
75656537|NCT05682118|Procedure|roadmap|"FFR and iFR tests using the roadmap system, or FFR and iFR tests without using the roadmap system.~Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg."
75943449|NCT03934671|Device|Antioxidant dressing (active product)|"Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary.~Device: Reoxcare®"
75943450|NCT03934671|Device|Usual care dressing that create a moist environment (standard clinical practice)|Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings). Compression bandage if necessary
75943451|NCT03891381|Device|Tetragraph quantitative monitoring|Neuromuscular monitoring will be guided by information provided by the Tetragraph
75943452|NCT05547633|Other|sinusitis screening consultation|"Questioning to look for suspicious anamnestic elements such as rhinorrhea, nasal obstruction, smell disorders, facial pain and clinical examination including nasofibroscopy.~Patients with signs of sinusitis will be managed according to current recommendations (diagnostic imaging tests, medical treatment or even surgery if necessary)."
75943453|NCT03791853|Diagnostic Test|Light-CT|Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
75943454|NCT03338361|Behavioral|active approach avoidance training and sham visual probe training|patients receive active AAT training and sham VPT training
75943455|NCT03338361|Behavioral|sham approach avoidance training and active visual probe training|patients receive sham AAT training and active VPT training
75943456|NCT03338361|Behavioral|active approach avoidance training and active visual probe training|patients receive active AAT training and active VPT training
75943457|NCT03338361|Behavioral|sham approach avoidance training and sham visual probe training|patients receive sham AAT training and sham VPT training
75943458|NCT03587883|Other|Cocoa flavanols I|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
75943459|NCT03587883|Other|Control I|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
75803651|NCT03479216|Drug|Precedex|10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
75803652|NCT03479216|Drug|Magnesium Sulfate|10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
76091326|NCT02459730|Procedure|ART with GIC.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
76091327|NCT04756167|Other|Conventional Treatment|Hotpack, TENS, ultrasound and exercise
76091328|NCT04756167|Other|Myofascial Release Treatment|Hotpack, TENS, ultrasound, exercise and myofascial release therapy for subscapularis and serratus anterior muscles
76091329|NCT03280602|Procedure|Tension band wiring (TBW)|2 x K-wire fixation (1.6 mm) and wire cerclage.
76091330|NCT03280602|Procedure|Plate fixation|Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
76091331|NCT03280524|Other|reflexology|
75803653|NCT03701620|Diagnostic Test|HRV monitoring|HRV monitoring derived from electrocardiogram
75803654|NCT03701542|Diagnostic Test|Microperymetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
75803655|NCT03701542|Diagnostic Test|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
75803656|NCT03518840|Device|SIJ Belt|Support Belts
75803657|NCT05660798|Behavioral|heated tobacco - lifestyle intervention|Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.
75803658|NCT03717116|Diagnostic Test|parathormone level|From the patients, blood will be taken preoperatively and postoperatively.
75943460|NCT03587883|Other|Cocoa flavanols II|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
75943461|NCT03587883|Other|Control II|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
75943462|NCT03160443|Behavioral|Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders|"All patients assessed in the day-hospital will performed the same evaluation :~Blood sampling~Calorimetry~Osteodensitometry~Psychiatric assessment~Endocrinologic assessment~Dietetic assessment~Neuropsychological assessment~Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
75943463|NCT05216679|Device|Night splints|A night splint is a brace the patient wears on their foot to keep it in a dorsiflexed position while they sleep. It is the first line treatment for plantar fasciitis.
75943464|NCT05216679|Device|Triceps Surae Stretching and Flexibility Assessment Device (TESS)|The TESS device is a slant board with a bar added for balance that the participant will stand on in 5 minute intervals throughout the day to stretch their calves, and potentially treat their plantar fasciitis symptoms.
75943465|NCT05159895|Drug|[14C]-DZD9008|Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of [14C] as a single administration
76091332|NCT03280524|Other|self-care guidelines with feet|
75943466|NCT03130179|Drug|Nicorette Strongmint lozenge 4 mg|A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
75943467|NCT03130179|Drug|Niquitin MiniMint lozenge 4 mg|A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
75943468|NCT03467529|Other|Non interventional study|Non interventional study
75943469|NCT05400135|Behavioral|Qungasvik (Tools for Life)|The Qungasvik (toolbox) intervention is designed to build protection against alcohol use disorder (AUD) and suicide in Yup'ik Alaska Native youth 12-18 years old. The intervention is a community-driven and culturally-based process that develops and delivers 18-24 prevention activities leading to the two primary prevention variables, Reasons for Life and Reflective Processes about the Consequences of Alcohol Use and secondary prevention variables of multi-level protective factors and social networks.
75943470|NCT05399901|Other|Electromyographic biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and EMG Biofeedback
75672307|NCT04269720|Behavioral|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques, guided imagery, and/ or self-talk.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to use this device daily for 10 mins for the duration of the 8-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the 8-week biofeedback intervention.
75803659|NCT03703726|Dietary Supplement|Reference meal|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
76091333|NCT04756011|Other|Health related quality of life|Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL
76091334|NCT01896063|Procedure|Electroacupuncture|
76091335|NCT03280446|Device|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
76091336|NCT03285048|Behavioral|Cognitive Remediation Therapy|Brain HQ is a computer based cognitive training that uses hierarchical adaptive technology to provide challenging and demanding training that is not too frustrating or discouraging. Training includes auditory and visual sensory training, memory and executive function exercises. The Bridging group is based on similar training programs that focus on self-regulation training, problem focused cognitive behavior therapy and compensatory cognitive strategies.
75345425|NCT00886262|Drug|Normal saline placebo|Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
75803660|NCT03703726|Dietary Supplement|Test meal A|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
75803661|NCT03703726|Dietary Supplement|Test meal B|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Warm temperature extruding process (60-70 C°) was used to produce the extruded rice"
75803662|NCT03703726|Dietary Supplement|Test meal C|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 °C) was used to produce the extruded rice."
75943471|NCT05399901|Other|M-mode US biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and M-mode Ultrasound Biofeedback
75943472|NCT03467451|Procedure|Endoscopic Mucosectomy|Endoscopic Mucosectomy with anchorage of the tip of the loop
76091337|NCT04802343|Drug|BAY1817080|Oral, tablet.
75345426|NCT00887510|Drug|Hydrochlorothiazide|"25 mg tablet once daily for 6 weeks~Other Names:~HCTZ"
75345427|NCT00887510|Drug|Trandolapril|4 mg tablet once daily for 6 weeks
75803663|NCT03703726|Dietary Supplement|Test meal D|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
75943473|NCT03467295|Procedure|Surgery|For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.
75943474|NCT03467295|Procedure|Observation|Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
75943475|NCT05399745|Other|Neurocognitive monitoring|Neurocognitive tests and MRI of the brain
76091338|NCT04802343|Drug|Placebo|Oral, tablet.
76091339|NCT02459496|Behavioral|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
76091340|NCT04782375|Drug|Stop group|discontinue antiviral treatment
76091341|NCT02459574|Procedure|AVATAR-AF ablation|Experimental ablation protocol
75345428|NCT00834626|Procedure|Ileal Interposition with Sleeve Gastrectomy|Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
75345429|NCT01431989|Drug|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
75345430|NCT01431989|Drug|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
75345431|NCT01397591|Biological|Ofatumumab|Given intravenously
75476695|NCT05775315|Other|Action Observation Therapy along with visual feedback|"Exercises of AO protocol in front of a mirror MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
75345432|NCT01397591|Drug|Bortezomib|Given intravenously
75656538|NCT05682118|Procedure|iFR/FFR|Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
75656539|NCT05678699|Behavioral|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment)|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1) health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries"
75345433|NCT01398059|Other|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
75345434|NCT01398059|Other|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
75345435|NCT01398059|Other|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
75345436|NCT03855332|Drug|Sildenafil|See above
75672308|NCT00620672|Dietary Supplement|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
75345437|NCT03855332|Drug|Cilostazol|See above
75345438|NCT03855332|Drug|Placebo|Overencapsulated placebo
75672309|NCT00620672|Dietary Supplement|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
75803664|NCT03703726|Dietary Supplement|Test meal E|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~warm temperature extruding process (60-70 C°) was used to produce the extruded rice."
75803665|NCT03703726|Dietary Supplement|Test meal F|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 C°) was used to produce the extruded rice."
75803666|NCT03717038|Drug|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
75943476|NCT05399667|Other|Early stimulation|Preterm born children submitted to skin-to skin care (kangaroo care ) plus massage therapy by their mothers. This group received tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
75943477|NCT05399667|Other|Conventional care|Preterm born children submitted to skin-to skin care by their mothers (kangaroo care), associated to standard care according to the routine care in the Neonatal Intensive Care Unit (NICU).
75943478|NCT05439837|Procedure|Infraclavicular and subomohoid block|Its blockade of subscapular nerve in the subscapular fossa and axillary nerve as it curves around humeral And blocking of brachial plexuses cord and supra scapular nerve And blocking of the brachial plexuses cord and supra scapular nerve
75943479|NCT05439837|Procedure|Paracoracoid subscapularis plane block|Blocking of suprascapular nerve in supra scapular fossa and axillary nerve as it curves the humeral head
75943480|NCT05399589|Combination Product|use on1 abutment instead of healing cap in test group|We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.
75345439|NCT02335580|Drug|Somatostatin and its analogs|Somatostatin and/or octreotide will be intravenously infused.
75345440|NCT02335580|Procedure|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|Endoscopic sclerotherapy, endoscopic variceal ligation, and/or endoscopic tissue glue injection will be performed based on the endoscopists' choice.
75345441|NCT01514279|Behavioral|HealthyCHANGE|"Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
75345442|NCT01514279|Behavioral|SystemCHANGE|"Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
75656540|NCT05678699|Behavioral|Doula|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries.~care intervention by coverage of doula services for all Medicaid beneficiaries across Pennsylvania."
75656541|NCT05678699|Behavioral|Standard Care|Participants receive standard care without quality interventions or doula care
75656542|NCT05668481|Behavioral|Transdiagnostic sleep and circadian intervention (TranS-C)|TranS-C is a psychosocial treatment that helps people who have sleep and circadian problems to improve their sleep health.
75656543|NCT05625256|Device|SentiCor-300|Continuous blood pressure measurement with the SentiCor-300.
75656544|NCT05621447|Drug|TAS-303, [14C]TAS-303|oral administration on day 1
75672310|NCT04032912|Diagnostic Test|iScan|this instrument provides extra confidence for in vivo diagnosis through improved vessel and mucosal pattern characterization.
75803667|NCT03717038|Drug|TAS-102|TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
75803668|NCT03716960|Other|Pumpkin Seed Oil|This intervention consisted of 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner).
75803669|NCT03716960|Other|Placebo|This intervention consisted of 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
75803670|NCT03716882|Device|Song Meter (SM)4|Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights. This record will take place at 15 days of life, 1 and half months, 2 and half months and 3 and half months.
75803671|NCT01310894|Drug|TOOKAD® Soluble|TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
75803672|NCT03701464|Procedure|Endoscopic naso-gallbladder drainage|Using ERCP technique insert a naso-gallbladder drainage tube through common bile duct and cystic duct.
75943481|NCT05399589|Combination Product|use healing cap in control group|use healing cap in control group
75943482|NCT03467139|Other|Abdominal breathing exercise|Deep Breathing Exercise
75943483|NCT04726761|Diagnostic Test|Ambulatory Blood Pressure Monitoring, frequent/non-frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a frequent interval, and then a non-frequent interval.
75943484|NCT04726761|Diagnostic Test|Ambulatory Blood Pressure Monitoring, non-frequent/frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a non-frequent interval, and then a frequent interval.
75943485|NCT05439525|Other|mulligan technique|The patient will be in sitting and the therapist stands on the contralateral side of pain, stabilizing the scapula posteriorly with one hand. The head of the humerus is translated posteriorly and laterally with the other hand, along the plane of the glenoid fossa. While the glide is sustained, the patient actively elevates their arm through the plane of abduction or scaption (elevation). Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session the perform mobilization on acromioclavicular and sternoclavicular joint
75943486|NCT05439525|Other|conventional therapy|"Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~Strengthen the rotator cuff and scapular stabilizers.~Improve upper-quarter postural awareness"
75943487|NCT05398965|Drug|Eucalyptus Oil|The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.
75943488|NCT05398965|Drug|Standard COVID medication|This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.
75943489|NCT03467061|Dietary Supplement|Nitrate-rich beetroot juice|concentrated beetroot juice
75943490|NCT03467061|Dietary Supplement|Nitrate-depleted beetroot juice|concentrated beetroot juice
75943491|NCT03467061|Other|Mouthwash|2 x 10 mL antibacterial mouthwash per day for 14 days
75943492|NCT05398887|Radiation|Low radiation dose CT|Underwent low dose chest CT with 30% lower radiation dose
75943493|NCT05398887|Radiation|Underwent ultra dose chest CT|Underwent ultra dose chest CT with 90% lower radiation dose
75943494|NCT05398887|Other|Artificial Intelligence based model|Deep-learning based contrast boosting algorithms
75943495|NCT03466983|Drug|Iron Isomaltoside|administered IV
75943496|NCT03466983|Drug|Ferric Carboxymaltose|administered IV
75943497|NCT03466905|Other|Ambulant assessment|
75943498|NCT05439213|Drug|Adrenaline 0,33 Mg/mL Solution for Injection|adrenaline dosage
75354684|NCT04786821|Device|Phoenix Exoskeleton suit|Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
75354685|NCT04776018|Drug|TAK-981|TAK-981 IV infusion.
76091342|NCT02459574|Drug|Anti-Arrhythmic therapy|"Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed."
75345443|NCT03226730|Behavioral|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
75345444|NCT03226730|Behavioral|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
75656545|NCT05602519|Drug|propofol, rocuronium and fentanyl|In fentanyl group (36 patients), 50 ug of fentanyl, and in oxycodone group, 4 mg of oxycodone will be administered 20 minutes before the end of the surgery, in triple blind manner.
76091343|NCT02459574|Procedure|Conventional AF ablation|Conventional ablation procedure
75656546|NCT05590169|Other|Exercise training|Group 1: Group exercises via Zoom application Group 2: Individual exercises via Zoom application Group 3: Routine treatment
75656547|NCT05587816|Device|Validation of the PortionSize app|The investigators will recruit 40 dyads (40 children aged 7-12 years old and 40 parents or caregivers) using a convenience sample for this pilot study. Children and their parents or caregivers will be trained to use the PortionSize app at Pennington Biomedical Research Center (PBRC). Children will use the PortionSize app and estimate food intake from pre-weighed meals (simulated meals) at PBRC clinic. Children will not consume the simulated meals. Children's parents or caregivers will also use the PortionSize app and estimate the food intake of their children (at least one meal and a snack each day) for two consecutive days at home.
75656548|NCT05527639|Behavioral|strength training program|12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises
75656549|NCT05513183|Procedure|Intraoperative blood and peritoneal fluid samplings during HIPEC|"- Intraoperative samplings of blood and peritoneal fluids during HIPEC :~Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min)~Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)"
75656550|NCT05487885|Device|Continuous theta burst stimulation (cTBS)|a form of transcranial magnetic stimulation, to dorsomedial prefrontal cortex (dmPFC)
75803673|NCT03701464|Procedure|Percutaneous gallbladder drainage|Percutaneous transhepatic technique insert drainage tube into gallbladder
75803674|NCT03436082|Device|A mobile health platform|Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.
75803675|NCT00143182|Drug|Asenapine|Asenapine , 9 weeks
75803676|NCT00143182|Drug|Olanzapine|Olanzapine, 9 weeks
75803677|NCT03677934|Drug|PDS Implant filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
75803678|NCT03677934|Drug|Intravitreal Injections of 10 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
75803679|NCT03701386|Procedure|cesarean hysterectomy|Elective cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. Delivery will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
75803680|NCT03701386|Procedure|N&H sandwich technique|In the N&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade will be performed
75803681|NCT03435692|Procedure|Lumbar Plexus Catheter|lumbar plexus catheter placed intraoperatively for perioperative pain control
75803682|NCT03435692|Procedure|Lumbar Epidural Catheter|lumbar epidural catheter placed intraoperatively for perioperative pain control
75943499|NCT05439213|Drug|Adrenaline 1 Mg/mL Solution for Injection|adrenaline dosage
75943500|NCT03466827|Drug|Selinexor|Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.
75803683|NCT03435692|Procedure|Patient Controlled Analgesia|Patient Controlled Analgesia (PCA) was started post operatively for perioperative pain control
75943501|NCT05398575|Behavioral|Music|Participants listen to music during physiotherapy rehabilitation (tailored or radio music)
75943502|NCT03466749|Device|Paclitaxel Eluting Balloon Catheter|Paclitaxel Eluting Balloon Catheter
76091344|NCT03284814|Dietary Supplement|Single dose intervention with Standard product (SP)|hard capsules, 100 mg
76091345|NCT03284814|Dietary Supplement|Single dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg
76091346|NCT03284814|Dietary Supplement|Single dose intervention with Investigational product (IP)|syrup, 100 mg
75943503|NCT05398419|Other|Music listening intervention|Participants will listen to the music at bedtime and overnight for 7 consecutive nights. The music will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
75943504|NCT05398419|Other|Non-musical sounds listening intervention|Participants will listen to the non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
76091347|NCT03284814|Dietary Supplement|Multiple dose intervention with Standard product (SP)|hard capsules, 100 mg - 14 days
76091348|NCT03284814|Dietary Supplement|Multiple dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg - 14 days
76091349|NCT03284814|Dietary Supplement|Multiple dose intervention with Investigational product (IP)|syrup, 100 mg - 14 days
76091350|NCT00047853|Device|Shock device|Electric shock stimulus
75345445|NCT02476968|Drug|Olaparib|"Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water."
75656551|NCT05487885|Behavioral|Positive Affect Training|Psychosocial add-on intervention that could enhance the effects of TBS. PA Therapy (Craske et al., 2016) is an innovative cognitive and experiential technique developed to address anhedonia specifically and, ideally, change altered patterns of frontostriatal function. Standing in contrast to Cognitive Behavioral Therapy, PA training has efficacy for enhancing positive affect and reducing negative affect (Craske et al., 2018). This treatment can be easily applied, and we propose that it will enhance neural circuit-level changes elicited by TBS.
75803684|NCT03435692|Drug|Fentanyl|Intravenous fentanyl was administered in the operating room for induction of anesthesia. Subsequent doses in the operating room were standardized to be given only for heart rate or blood pressure increases > 20% above baseline and occurring more than 30 minutes after the block if applicable.
75803685|NCT03435692|Drug|Morphine|In the operating room patients, intravenous morphine was administered if patients had a failed block and standardized to be given only for heart rate or blood pressure increases > 20% above baseline and after fentanyl had been administered. Intravenous Morphine was also administered in the operating room if the patient was randomized to the Patient Controlled Analgesia (PCA) arm of the study. Post operatively intravenous Morphine was administered as needed for severe pain.
75345446|NCT03201068|Dietary Supplement|Probiotic supplement|Probiotic supplement capsule
75345447|NCT03201068|Dietary Supplement|Placebo|Placebo capsule
75345448|NCT01514513|Drug|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
75345449|NCT01514513|Drug|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
75345450|NCT02476578|Other|Email|Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
75656552|NCT05487885|Drug|Ketamine Injectable Solution|Ketamine is FDA-approved as an anesthetic agent that will be used off-label in this study. It is used routinely in both pediatric and adult patients and is considered extremely safe in substantially higher, anesthetic doses. The dose to be administered here (0.5 mg/kg) is a much lower, subanesthetic dose, and the administration route (intravenous) is the standard when used in anesthesia. Published studies and metaanalyses of this dose of intravenous ketamine as an off label use in depression show clearly that there are no increased risks in this population, including a recent study in adolescents (Dwyer et al, 2021, American Journal of Psychiatry). A single dose of ketamine will be used to determine if it alters the functioning of the anhedonia-related reward functioning and frontostriatal biomarkers assessed in this study.
75656553|NCT05485779|Drug|AQ280|"Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral"
76091351|NCT00047853|Device|Acoustic startle|Acoustic startle for MEG only
76091352|NCT02459340|Other|therapeutic treatment (inpatient and outpatient setting)|
76091353|NCT03284736|Procedure|Resorbable membrane|
76091354|NCT03284736|Procedure|periapical surgery without membrane|after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
75345451|NCT01432145|Drug|6-Mercaptopurine|6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.
75354686|NCT04776018|Drug|Mezagitamab|Mezagitamab SC injection.
75476696|NCT05771766|Other|Postural Drainge and aerobic training|This will be a randomized controlled trial Patients will be divided into two groups randomly. Both groups will receive postural drainage as baseline treatment thrice a week for two weeks. The intervention group will undergo additional Aerobic Training thrice a week for two weeks as well along with postural drainage. Aerobic training will include 5-step stair-climbing and 10 step walk during each session.
75476697|NCT05771766|Other|Postural Drainage|Postural Drainage
75476698|NCT05764967|Other|Low Dye Taping|The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive is used for all of the taping procedures.
75943505|NCT03466671|Drug|TTA-121|A nove intranasal spray of oxytocin and placebo
75943506|NCT05438901|Biological|leech therapy|effects of medicinal leeches
76091355|NCT03280368|Other|Bloodtest|
76091356|NCT03280368|Other|Questionnaires|
76091357|NCT03280290|Biological|blood|assessment pre-donation of hematopoietic stem cells (blood sample)
76091358|NCT04168398|Drug|Combination drug|Anticoagulation
76091359|NCT00011193|Behavioral|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
76091360|NCT03280212|Drug|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets.
76091361|NCT03536520|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
76091362|NCT03536520|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
76091363|NCT04784169|Device|free middle turbinate flap|Repairing low flow leak using free middle turbinate flap
75345452|NCT01432145|Drug|Methotrexate|Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
75345453|NCT04979520|Drug|Brodalumab|Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
76091364|NCT04784169|Device|vascularized nasoseptal flap|Repairing low flow leak using fascia lata
75345454|NCT00889928|Device|NOTES GEN 1 Toolbox|"Articulating Hook Knife~Articulating Snare~Articulating Needle Knife~Articulating Graspers~Articulating Biopsy Forceps~Steerable Flex Trocar with Rotary Access Needle~Flexible Bipolar Hemostasis Forceps~Flexible Maryland Dissector"
76091365|NCT03280134|Procedure|axillary lymph node dissection (ALND)|If the patients had predictive nSLN+, need further axillary lymph node dissection.
76091366|NCT03521466|Behavioral|Smoking Cessation Counseling|Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
75803686|NCT03435692|Drug|Lorazepam|Intravenous Lorazepam was administered as needed for muscle spasm post operatively.
75803687|NCT03435692|Drug|Ondansetron|Intravenous Ondansetron was administered as needed for nausea and vomiting post operatively.
75656554|NCT05485779|Drug|Placebo|"Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral"
75943507|NCT03466593|Other|Prehabilitation|Prehabilitation concerning eating, smoking, drinking and physical activity
75345455|NCT01432379|Biological|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
75345456|NCT02504892|Drug|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
75345457|NCT02504502|Other|enhanced genomic report|a patient-centered version of a genomic results report delivered to patient through the electronic record portal
75656555|NCT05482958|Device|HOP watch|Prospective observational study
75656556|NCT05482360|Other|PrEP Optimization Interventions|There will be three strategies or bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders and are unknown at this time.
75656557|NCT05470790|Other|patient reported outcome measures|Activity Rating Scale, Knee Stability in Sports/Cutting-Pivoting Ability scale, Knee Injury and Osteoarthritis Outcome Score, Lysholm Knee Score, and International Knee Documentation Committee Subjective Knee Form.
75943508|NCT03466593|Other|Routine care|Preoperative information
75943509|NCT03466593|Other|Extra early mobilization|Mobilization the day of surgery
75943510|NCT03466593|Other|Standard mobilization|Mobilization the day after surgery
75345458|NCT01432535|Drug|PegIFN-2b (Sylatron®)|Single 4.5 μg/kg dose
75656558|NCT05467813|Other|mirror therapy|The mirror therapy (MT) will be done with participants seated at a table. The affected upper-extremity (UE) will be placed behind the mirror and the unaffected UE in front of the mirror. Participants will be asked to do the same movements using both the unaffected and affected UE as possible. Each participant will practice two different MT protocols: unilateral mirror therapy (UMT) and bilateral mirror therapy (BMT). During UMT, the affected hand is static, while during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements, fine motor movements, and object manipulation.
75803688|NCT03435692|Drug|Diphenhydramine|Intravenous Diphenhydramine was administered as needed for itching postoperatively.
76091367|NCT04784325|Diagnostic Test|Blood draw through TAP II|Two self-administered blood draws through TAP II device
76091368|NCT04784325|Diagnostic Test|Blood draw through ADx cardT|One self-administered ADx card blood draw
76091369|NCT04784325|Diagnostic Test|Blood draw through standard venipuncture|One phlebotomist-performed standard venipuncture
75803689|NCT03435692|Drug|Acetaminophen|Oral Acetaminophen was administered as needed for pain in the Post-Anesthesia Care Unit (PACU) and then scheduled for 72 hours.
75803690|NCT03435692|Drug|Oxycodone|Oral Oxycodone was administered as needed for breakthrough pain post operatively.
75803691|NCT03435692|Drug|Ropivacaine|Intravenous Ropivacaine was administered as part of the initial bolus after placement of the lumbar epidural or lumbar plexus catheter and then as a continuous infusion post operatively.
75803692|NCT04740658|Other|No intervention|There is no intervention
75943511|NCT05438823|Other|Educational Programe|IBK-EBP will be administered to parents in six sessions in six days. After six days of training, the mobile application will be used by parents for 8 weeks. The frequency of use of the mobile application will be left entirely to the needs of the parents and reminders will be made through the mobile application. In addition, the video used during the face-to-face training, progressive relaxation exercise videos and motivational sentences will also be included in the mobile application.
76091370|NCT05228184|Drug|Tirosint®-SOL|Dosage will be according to the USPI and Standard of Care.
76091371|NCT05228184|Drug|Levothyroxine Sodium|Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
76091372|NCT04784403|Diagnostic Test|SARS-CoV-2 PCR and serology tests|Once the informed consent has been signed, the selected subjects must complete an epidemiological survey and go to a UB sample collection center to perform a PCR and serology test for SARS-CoV-2.
76091373|NCT03284580|Other|Ergonomic intervention|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
76091374|NCT03284580|Other|Postural plus kinesiotherapy intervention program|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
75345459|NCT05947045|Other|Cognitive training via iPad|Participants will complete five sessions of the Cogmed training program on an iPad. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
75354687|NCT04776018|Drug|Daratumumab and Hyaluronidase-fihj|Daratumumab and Hyaluronidase-fihj SC injection.
76091375|NCT03284580|Other|Control or conservative intervention|A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
76091376|NCT04783623|Procedure|Surgical endometrioma excision|We collect medical records of patients who had underwent surgical endometrioma excision at different sites in our hospital and conduct telephone or clinical interview
76091377|NCT03279588|Diagnostic Test|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
76091378|NCT01679457|Behavioral|ACT-Focused ERP|
76091379|NCT01679457|Behavioral|TAU-ERP|
76091380|NCT03284346|Behavioral|Exercise Intervention|Undergo CARE
76091381|NCT03284346|Behavioral|Exercise Intervention|Undergo standard stretching program
76091382|NCT03284346|Other|Laboratory Biomarker Analysis|Correlative studies
76091383|NCT03284346|Device|Monitoring Device|Receive Polar heart rate monitor
76091384|NCT03284346|Other|Quality-of-Life Assessment|Ancillary studies
76091385|NCT03284346|Other|Questionnaire Administration|Ancillary studies
75656559|NCT05467813|Other|augmented reality (AR)|The training program provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. To ensure safety, the investigators will place a handrail in front of the participant for support. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg), activities of daily living training (i.e., reaching), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
75672311|NCT04060160|Other|Self- learning software that can detect acne lesions|Self- learning software that can detect acne lesions from patients who take a picture of their face every single day for 3 months with a secure mobile phone.
75803693|NCT03705442|Dietary Supplement|Omni-Biotic 10|All patients will have at their disposal current medications for diarrhea based on guidelines, and education regarding side effects and dietary recommendations will be undertaken. One cohort will also ingest a probiotic (OMNi-BiOTiC® 10AAD), while other cohort will take a placebo, same in colour, shape, taste and smell; both medications will be taken 2 per day, every 12 hours, over 84 days (6 chemotherapy cycles every 14 days).
75803694|NCT03705442|Drug|"loperamide (Seldiar)"|All the patients will have access to standard drugs for diarrhoea
75803695|NCT03475316|Behavioral|Social Dancing|90-min dance sessions twice weekly for 6-months. The session includes warm-up, dance and cool down.
75803696|NCT03475316|Behavioral|Treadmill Walking|Each session starts with 5-10 minutes of warm-up walking at comfortable speed. Speed is gradually increased to the level at which participants felt it is 'somewhat hard' for two 35 minute sessions with breaks in between followed by 5-10 minute cool down period (total 90 min to match dance group).
75966019|NCT02089373|Procedure|Probe-based confocal laser endomicroscopy|In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.
75966020|NCT02089373|Procedure|White light endoscopy|In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
75966021|NCT01595438|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
76091386|NCT01673217|Drug|decitabine|Given IV
76091387|NCT01673217|Biological|NY-ESO-1 peptide vaccine|Given SC
75803697|NCT03705364|Other|Fall Management program|Comprehensive fall management program that develops strategies for non-ambulatory wheelchair users living with MS to develpo strategies to recover from a fall.
75803698|NCT02355990|Procedure|Minimally Invasive Micro Sclerostomy|Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).
76091388|NCT01673217|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
76091389|NCT01673217|Biological|sargramostim|Given SC
75803699|NCT03731754|Procedure|Traditional Closure|Primary closure discontinuously the perineal wound of APR
75803700|NCT03731754|Procedure|"Cross closure"|Two triangles of skin in the horizontal direction are excised to enlarge the skin incision, and the tumor resected. Then circumferential subcuticular suture of wound, and with tightening of the circumferential suture, the wound resembles a cross.
76091390|NCT01673217|Biological|incomplete Freund's adjuvant|Given SC
76091391|NCT01673217|Other|immunohistochemistry staining method|Correlative studies
76091392|NCT01673217|Other|liquid chromatography|Correlative studies
76091393|NCT01673217|Other|mass spectrometry|Correlative studies
76091394|NCT01673217|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
76091395|NCT01673217|Other|laboratory biomarker analysis|Correlative studies
76091396|NCT01673217|Genetic|DNA methylation analysis|Correlative studies
76091397|NCT01673217|Other|enzyme-linked immunosorbent assay|Correlative studies
76091398|NCT03475134|Other|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
76091399|NCT03475134|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
76091400|NCT03475134|Drug|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
75354688|NCT04772157|Diagnostic Test|Cardiac Troponin Testing|Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
75943512|NCT03466515|Procedure|stem cells injection|two surgical interventions as day-surgery, starting with liposuction from the abdomen (about 200-300 ml), and fistula tract debridement and closure of internal opening. The external opening is excised. About 30-40 ml fresh harvested patients own fatty tissue are then injected with large needle around the fistula from internal til external opening.The resting harvested fatty tissue will be sent to stem cells (Adipose Derived Regenrative Cells ADRCs) isolation, using Cytori Celusion system®. When the stem cells isolation is completed, 4ml concentrated stem cells ( contains around 20-40 millions cells ) will be injected around the prepared fistula tract, the same site where the fresh harvested fatty tissue injected before.
75943513|NCT04520841|Device|Prevena TM|A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.
75943514|NCT04520841|Device|Dry dressing|A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery
75943515|NCT04501731|Other|Transcranial Magnetic Stimulation (TMS)|With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.
75943516|NCT04501731|Other|Magnetic Resonance Imaging (MRI)|With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.
75803701|NCT03703648|Radiation|Radiotherapy (curative) for head and neck cancer|Curative intent radiotherapy for head and neck cancer. Doses will be prescribed by an independent Clinical Oncology team. There will be no alteration or experimentation of radiotherapy dosage
75943517|NCT04501731|Other|Motor assessment|"The motor assessment includes a pegboard game, a grab the alien nose game and measure of your maximum grip force. In total it will last around 30 minutes."
75943518|NCT04501731|Other|Questionnaires|Feasibility, tolerability of such intervention as well as quality of life of PFT survivors will be assessed thanks to questionnaires.
75943519|NCT03466437|Device|Glass-fiber post and composite resin restoration|Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication
75943520|NCT03466437|Device|Glass-fiber post and metalceramic crown|Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
75943521|NCT03466437|Device|Cast-metal post and metalceramic crown|Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
75672312|NCT04060160|Other|Patient reported outcomes|Collection of patient reported outcomes and clinical data via a mobile electronic case report form
76091401|NCT03475134|Drug|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
76091402|NCT03475134|Drug|Nivolumab|Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
76091403|NCT01672749|Device|Growth guiding construct using TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)
76091404|NCT01672749|Device|Spine based dual growing rod or rib based VEPTR|spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
75476699|NCT05764967|Other|Temporary Felt Insoles|A temporary orthosis is fabricated from 7-mm orthopedic felt.The subject stands on his or her template while the TTR pointer is attached to the medial tibial plateau of the leg using a Velcro strap. An outline of the position of the device on the tibial plateau is drawn onto the skin with an indelible ink pen to allow for accurate relocation between all trials. TTR is measured in relaxed calcaneal stance while the subject wearing shoes. Measurements are recorded onto a data-collection sheet. Each measurement performes twice. The subject are given orthosis inserted into the shoe. All shoes are visually assessed to ensure that they will not induce pronation or internal rotation.
75476700|NCT05764369|Behavioral|Parenting Wisely Residential Treatment (PWRT)|PWRT experimental intervention
75672313|NCT02655822|Drug|Ciforadenant|100 mg orally twice daily for the first 14 days of each 28-day cycle.
75672314|NCT02655822|Drug|Ciforadenant|100 mg orally twice daily for 28 days of each 28-day cycle.
75672315|NCT02655822|Drug|Ciforadenant|200 mg orally once daily for the first 14 days of each 28-day cycle.
75803702|NCT03673956|Drug|Mupirocin|30mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
75672316|NCT02655822|Drug|Ciforadenant + atezolizumab|Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.
75803703|NCT03673956|Drug|Tobramycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
75803704|NCT03673956|Drug|Levofloxacin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
75943522|NCT05438745|Other|Copenhagen Burnout Inventry|Questionnaire
76091405|NCT01668849|Dietary Supplement|Grape extract|Grape extract self-administered by mouth daily for 35 days
76091406|NCT01668849|Drug|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
76091407|NCT01668225|Procedure|Blood test|"Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.~Taking the follicular fluid during the oocyte collection day"
76091408|NCT03284190|Procedure|Surgery|Surgery
76091409|NCT03279198|Behavioral|TIWeb|Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
76091410|NCT03279198|Behavioral|CSC|Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
76091411|NCT03279198|Behavioral|UC|Intervention: The usual care group received usual care that varies dependent upon the practice setting.
75656560|NCT05467813|Other|control therapy|The control intervention will include practice of upper limb activities, balance activities, activities of daily living, and cognitive enhancement tasks. The protocols of the conventional therapy will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their prioritized goals. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
76091412|NCT03279198|Behavioral|TIWeb+CSC|Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
76091413|NCT03278964|Procedure|Orbital decompression|
76091414|NCT03107910|Behavioral|Stigma and Structural Interventions|Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions
75476701|NCT05764369|Behavioral|TAU|The TAU condition is the standard of care offered to parents in RT settings.
75656561|NCT05445609|Drug|VLP-encapsulated TLR9 Agonist CMP-001,|Given SC or IT
75656562|NCT05445609|Biological|Nivolumab|Given IV
75803705|NCT03673956|Drug|Vancomycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
75803706|NCT03705208|Other|Youth First Curriculum|A 25 session emotional resilience and health curriculum designed for 7th and 8th grade students.
75803707|NCT03673098|Behavioral|Adapted 3RP|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The adapted 3RP intervention consists of 10, 90-minute weekly group sessions. Content specific to older women living with HIV, including self-compassion exercises, was added to the intervention in the first phase of this study (open pilot).
76091415|NCT03107910|Behavioral|Health Information Seeking|Seeking and evaluating online health information will be assessed.
76091416|NCT03277716|Procedure|TACE|TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.
75656563|NCT05442060|Biological|30 μg OBI-833/100 μg OBI-821|Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.
75656564|NCT05442060|Drug|Erlotinib (150 mg daily)|All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
75803708|NCT03716804|Drug|Tablet Nitrofurantoin|Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
75803709|NCT03716804|Drug|Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime|Tablet Ciprofloxacin (500 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefixime (200 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefuroxime (250 mg), two times daily in 12 hours interval for 7 days
75803710|NCT03701152|Device|Negative pressure therapy|Negative pressure therapy at sub atmospheric level
75345460|NCT05947045|Other|Cognitive training via virtual reality|Participants will complete five sessions of the Cogmed training program within virtual reality. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
75345461|NCT05947019|Device|Myopic amblyopia comprehensive treatment instrument|Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.
75345462|NCT05947019|Device|Glasses|Optometry with glasses as a routine treatment
75476702|NCT05761379|Device|Photobiomodualtion Therapy|low lever light therapy with laser semi-conductor at wavelength of 650nm
75803711|NCT03703570|Drug|KW-6356|Oral administration
75803712|NCT03703570|Drug|Placebo|Oral administration
75476703|NCT05761379|Device|Single vision spectacles for correction myopia|Provide the distance best corrected vision acuity of refractive error of myopia for all the groups
75476704|NCT05760677|Drug|pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone|the pioglitazone group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
75476705|NCT05760677|Drug|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)
75476706|NCT05757453|Device|MHealth|Mobile application
75476707|NCT05756816|Device|SurePulse VSP|A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VSP placed on the volunteer.
75476708|NCT05756816|Device|SurePulse VS|A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VS placed on the volunteer.
75476709|NCT05756270|Diagnostic Test|pCASL|Brain 3 Tesla MRI with pCASL sequence
75943523|NCT03466359|Behavioral|DEF-EI : Energy restriction induced energy deficit|DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.
75943524|NCT03466359|Behavioral|DEF-EX : Exercise induced energy deficit|DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
75345463|NCT05947006|Other|Standard care|Patients in this arm will receive the standard care stablished in the emergency room after a febrile seizure, consisting of a medical assessment of the child, followed by 6 hours of supervision of the child and his parent in the waiting room, a reassessment of the child by the doctor, and finally they can return home
75656565|NCT05431751|Dietary Supplement|Whole Algae|Whole Euglena gracilis algae, produced by proprietary fermentation.
75656566|NCT05422105|Drug|18F-PSMA-1007|18F-PSMA-1007 PET/CT
75656567|NCT05421273|Device|Spinal cord stimulation using passive recharge burst stimulation|Passive recharge burst is marked by a recharge pattern that passively compensates for charge differences.
75803713|NCT03435224|Device|INVSENSOR00012|Noninvasive pulse oximeter sensor
75943525|NCT05438433|Device|St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets|St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
75656568|NCT05421273|Device|Spinal cord stimulation using active recharge burst stimulation|Active recharge burst is characterized by negative pulses that directly compensate for charge differences.
75803714|NCT01310166|Drug|Fingolimod|
75803715|NCT03705130|Device|Single Vision Contact Lens|Spherical Contact Lens worn on non-dispensing basis
75803716|NCT03705130|Device|Multifocal Contact Lens 1|Multifocal Contact Lens worn on non-dispensing basis
75943526|NCT01909245|Biological|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
75803717|NCT03705130|Device|Multifocal Contact Lens 2|Multifocal Contact Lens worn on non-dispensing basis
75943527|NCT01909245|Drug|Immunosuppressive Agents|Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
75943528|NCT01909245|Drug|Gastrin 17|Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
75943529|NCT03466281|Behavioral|Structured patient group education|Patient education in a group setting
75943530|NCT03466281|Behavioral|Education via Internet|Patient education via the internet
75943531|NCT03465969|Drug|tacrolimus|oral
75943532|NCT05397873|Device|Biofeedback training|The training of oculomotor functions is done on the biofeedback module of a microperimeter MAIA.
75943533|NCT05397795|Drug|10000 IU hCG (Choriomon5000 IU; IBSA)|10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly
75943534|NCT05397795|Drug|Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring)|GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
75943535|NCT03130101|Other|Change in their basal insulin rate|Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
75943536|NCT01067521|Drug|Glatiramer acetate (GA)|GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
75943537|NCT01067521|Drug|Placebo|Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
75966022|NCT01595438|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
75656569|NCT05417009|Device|trans-cutaneous auricular sensory stimulation|Transcutaneous auricular sensory stimulation
75656570|NCT05406388|Procedure|Erector Spinae Plane Block|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
75656571|NCT05406388|Procedure|Intravenous fentanyl patient control device|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
75345464|NCT05947006|Other|CONSULFE consultation|In addition to the standard care, patients in this arm will receive a consultation managed by the pediatric nurse (CONSULFE) during the 6 hour supervision time in the waiting room
75656572|NCT05403502|Device|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.
75656573|NCT05402033|Behavioral|Survey / Interview Group|Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.
75656574|NCT05399550|Drug|Balovaptan|Intravenous Solution
75656575|NCT05399550|Drug|Placebo|Matching Intravenous Solution
75656576|NCT05371249|Drug|Vonoprazan-based triple therapy|vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days
75656577|NCT05371249|Drug|Extended sequential therapy|Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days
75656578|NCT05351047|Drug|AZD2373 subcutaneous injection|Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).
75656579|NCT05351047|Drug|Placebo|Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.
75803718|NCT03716648|Diagnostic Test|DISE-assisted titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
75345465|NCT05946980|Other|Multi-component hand hygiene intervention in primary health care facilities|"Intervention facilities will receive (1), two novel Gravit'eau (https://www.graviteau.ch/) handwashing systems which are locally produced. These systems recycle water for handwashing with gravity through a membrane filter without electricity up to a month. Facilities also receive (2), a behavior change intervention lead by RANAS (https://www.ranasmosler.com/ranas), expert psychologist for behavior change in WASH. They will also receive (3), support to implement WASH FIT (https://washfit.org/#/) in their facilities, a tool developed by WHO to sustainably maintain and improve WASH infrastructure in health care facilities. Additionally, we are recruiting a circuit rider responsible for the regular inspection and maintenance of WASH infrastructure. (4), the facilities will receive support for regular water chlorination."
75345466|NCT05946967|Other|Biofeedback with TENS|Constipation patients will be given biofeedback treatment along with transcutaneous electrical stimulation (TENS) of posterior tibial nerve
75345467|NCT05946967|Other|Biofeedback only|Constipation patients will be given biofeedback treatment only
75476710|NCT05751213|Other|knack technique.|"It consists of 11 patients who will receive pelvic floor muscle exercise and knack technique at outpatient clinic and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine sustained for 6s with a resting interval twice as long between contractions, followed by 3 fast contractions. 3 times per day. 3 days per week at home for 3 months. 3 exercises in supine position. 8 repetitions of each exercise 3times per day , 3 days per week. .~Orientation to perform the knack during activities of daily life. The knack consists of voluntary pelvic floor muscles contraction before and during activities that increase abdominal pressure.~The exercise will be performed in the supine (first month), sitting (second month), and standing (third month) positions twice a month for 3 months at outpatient clinic. (6 outpatient sessions)"
75476711|NCT05751213|Other|pelvic floor muscle exercises|It consists of 11 patients who will receive pelvic floor muscle exercises at the outpatient and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine position sustained for 6s with a resting interval twice as long between contractions followed by 3 fast contractions. 3 times per day , 3 days per week at home for 3 months. Two sessions per month at outpatient clinic for 3 months
75476712|NCT05744596|Other|Incisura biopsy analysis|a pathologist blinded to the other biopsies analyzes the biopsy from the incisura
75803719|NCT03716648|Diagnostic Test|PSG-guided titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
75656580|NCT05335499|Drug|TAS5315 Dose 1|Treatment period: oral administration for 12 weeks, QD
75943538|NCT05434455|Device|RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion|RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
75943539|NCT05397483|Behavioral|Legal Education plus Trauma-informed Therapy (LETiT)|Group-1: Experimental (n=75 participants) will receive the LETiT which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
75803720|NCT03716648|Device|subjective titration|Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
75943540|NCT05397483|Behavioral|Intervention As Usual (IAU)|Group-2: Controlled (n=75 participants) will receive the IAU which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
75943541|NCT02735577|Drug|Disulfiram|Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
75943542|NCT03642535|Drug|ALA|In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
75943543|NCT04453605|Other|standard treatments|patients were treated according to the good clinical practice recommended by the international guidelines, and followed a six-month or an yearly calendar of follow-up visits
75943544|NCT02522559|Other|Spice Intervention|Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
75943545|NCT05171257|Drug|IV antibiotic treatment from prior|patients receiving same IV antibiotic treatment from prior
75943546|NCT05171257|Drug|differing IV antibiotic treatment|patients receiving differing IV antibiotics from prior
75656581|NCT05335499|Drug|TAS5315 Dose 2|Treatment period: oral administration for 12 weeks, QD
75656582|NCT05335499|Drug|TAS5315 Dose 3|Treatment period: oral administration for 12 weeks, QD
75943547|NCT03640741|Procedure|Laparoscopy|The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
75943548|NCT05397327|Other|3D virtual planning software|3D virtual planning software developed by Sectra AB (Linköping, Sweden)
75966023|NCT01595438|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
75345468|NCT05946811|Drug|Macitentan 10mg|Macitentan 10 mg oral once daily for 3 months. vs placebo
75345469|NCT05946772|Drug|Cyclosporine A|2.5mg/kg body weight Cyclosporine A as an intravenous bolus
75345470|NCT05946772|Drug|Placebo|The same amount of 0.9% sodium chloride (NaCl0.9%) will be applied in an indistinguishable package as an intravenous bolus
75354689|NCT04770896|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
75803721|NCT03705052|Other|Questionnaire|Patients and caregivers were asked to complete a questionnaire
75943549|NCT03640819|Procedure|Tattooing of biopsied node|Tattooing (marking) of biopsied node with carbon dye (SPOT dye) at the time of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
75345471|NCT05946720|Other|Training including aggression and the use of BVC.|After obtaining verbal consent from the nurses who met the inclusion criteria of the study before the pre-test was applied to the nurses, the nurses who volunteered to participate in the study were randomized within their own clinic using the simple randomization method. For this, after the data collection form was distributed before the pre-test, the nurses were asked to write the letter that came to them on the data collection form and not forget it. In order for nurses to be included in the training or comparison group, the letter A, written on the closed papers in the box prepared for simple randomization, represents the Education group, and the letter B represents the comparison group.
75476713|NCT05735600|Behavioral|AyuDa Virtual: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
75345472|NCT05946694|Other|intubation in manikin|Evaluation of 3 videolaryngoscopes under simulated out-of-hospital conditions by people without clinical experience on a manikin model
75476714|NCT05735600|Behavioral|AyuDa Written: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
75476715|NCT05733572|Drug|CHF6467|drug eyedrops
75476716|NCT05733572|Drug|Placebo|placebo eyedrops
75476717|NCT05732207|Procedure|cerebellar transcranial direct current stimulation|TDCS is a safe and non-invasive technique for modulating cortical excitability and behavior. TDCS, delivered via surface electrodes, induces an intracerebral current flow sufficient to achieve changes in cortical excitability. Anodal stimulation up-regulates cortical excitability, while cathodal stimulation decreases excitability.
75476718|NCT05731661|Other|Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse|During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.
75656583|NCT05335499|Drug|TAS5315 Dose 4|Treatment period: oral administration for 12 weeks, QD
75656584|NCT05335499|Drug|TAS5315 Dose 5|Treatment period: oral administration for 12 weeks, QD
75803722|NCT03672396|Behavioral|Home-based exercise|The intervention consists of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
75803723|NCT03698578|Other|combat fight|Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
75803724|NCT03731676|Device|Fixed bearing total knee arthroplasty|Fixed bearing total knee arthroplasty
75803725|NCT03731676|Device|Rotating platform total knee arthroplasty|Rotating platform total knee arthroplasty
75803726|NCT03434834|Device|optical coherence tomography|OCT measurements of 5 locations in the esophagus
75943550|NCT05397249|Behavioral|Mindfulness Training|The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.
75943551|NCT01068613|Drug|QAX028|QAX028 60 mcg via inhalation device
75345473|NCT05946668|Procedure|Biospecimen Collection|Undergo vaginal specimen self-collection via vaginal swab collection kit
75345474|NCT05946668|Other|Electronic Health Record Review|Medical records reviewed
75345475|NCT05946668|Other|Questionnaire Administration|Complete questionnaires
75345476|NCT05946616|Other|Transcranial alternating current stimulation (tACS) combined with behavioral intervention|Transcranial alternating current stimulation (tACS) combined with behavioral intervention (memory interference).
75345477|NCT05946616|Other|Inactive (sham) stimulation combined with behavioral intervention|Inactive (sham) stimulation combined with behavioral intervention (memory interference)
75345478|NCT05946564|Drug|Pioglitazone (ACTOS®)|Patient will be randomize in the intervention group receive treatment by pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
75656585|NCT05335499|Drug|Placebo|"Screening period: oral administration for 2 weeks, QD~Treatment period: oral administration for 12 weeks, QD"
75672317|NCT02655822|Drug|Ciforadenant|Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.
75672318|NCT04209374|Device|THA with SYMBOL CUP DM HA|
75672319|NCT00650442|Drug|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
75672320|NCT00650442|Drug|Estradiol Transdermal System Placebo - Current Adhesive|single application
75672321|NCT00890825|Drug|AZD6244|oral capsules, 75mg twice daily
75820021|NCT03536182|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
75943552|NCT01068613|Drug|QAX028|QAX028 20 mcg via inhalation device
75943553|NCT01068613|Drug|Tiotropium|Tiotropium via inhalation device
75943554|NCT01068613|Drug|Placebo|Placebo to QAX028 via inhalation device
75943555|NCT05222425|Drug|Xagrotin|A herbal compound
75943556|NCT05222425|Drug|Green tea|Normal green tea
75943557|NCT05396937|Radiation|Multifocal Stereotactic Radiotherapy|Radiotherapy will be given in combination with atezolizumab and bevacizumab. The patient will be initially treated with atezolizumab and bevacizumab after enrollment. Radiotherapy will be administered to the metastases 1-2 weeks after the completion of the first intravenous injection of atezolizumab and bevacizumab, in the mode of multifocal stereotactic radiotherapy, with a planned total dose to the planned target volume of 25-50 Gy in five divided doses of 5-10 Gy/fraction. Systemic therapy could be continued 48 hours after completion of radiotherapy.
75943558|NCT05396937|Drug|Atezolizumab Injection [Tecentriq]|Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
75943559|NCT05396937|Drug|Bevacizumab|Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle
75943560|NCT01345123|Behavioral|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
75943561|NCT01345123|Behavioral|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
75943562|NCT03642223|Other|Stable iron isotopes|Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
75943563|NCT03640663|Other|Midwife led continuity model of care|Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
75943564|NCT03642145|Drug|Deflazacort|Deflazacort tablets will be administered as per schedule and dose specified in respective arms.
75943565|NCT05396625|Behavioral|Usual Care|All participants will receive the following services: case management and psychosocial support (e.g., assessment and identification of families eligible for reunification; preparing children and parents for reunification; and assistance with receiving social benefits such as Targeted Social Assistance, alimonies, or disability benefits); referrals to schools outside of their orphanage; and leisure activities for children (e.g., music, sport, and drama) provided by the orphanage staff and municipal social services.
75943566|NCT05396625|Behavioral|Family Strengthening|Due to its focus on family-strengthening, the study uses the evidence-based intervention 'SAFE Children,' which employs a multiple family group format and is designed to improve family functioning, strengthen child-parent relationships and communication, enhance supportive parenting strategies, and prevent emotional and behavioral problems among at-risk children. The family-focused intervention consists of weekly multiple family group meetings (e.g. about 5 families per group). All interested family members are invited to join the sessions. The adapted intervention incorporates new sessions that address unique issues faced by families reuniting with formerly institutionalized children (e.g., separation and attachment issues, children's feelings of resentment, parents' feelings of guilt and shame, stigmatized status in the community). Each session lasts about one to one and a half hours and will be delivered by facilitator and co-facilitator at the SOS Child and Family Center.
75943567|NCT05396625|Behavioral|Mental Health Screening, Referral and Connection to Services|Children assigned to this intervention will receive clinical assessment performed by psychiatrists at the National Mental Health Centre in Azerbaijan. From there, each child will have an individual plan developed by the multidisciplinary team and will be connected to the National Mental Health Centre clinicians to receive corresponding mental health services.
75345479|NCT05946564|Drug|Placebo of Pioglitazone|Patient will be randomize in the intervention group receive treatment by placebo of pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
75345480|NCT05946538|Diagnostic Test|SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel|The SARS-CoV-2, Influenza and RSV PCR test is multiplex-tandem polymerase chain reaction (MT-PCR) based on qualitive in vitro diagnostic testing for the detection and identification of pathogens in nucleic acid extracts.
75345481|NCT05946538|Diagnostic Test|BioFire Respiratory Panel 2.1|The BioFire Respiratory Panel 2.1 (RP2.1) is a PCR-based multiplexed nucleic acid test intended for use with the BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.
75672322|NCT00890825|Drug|docetaxel|75mg/m2 iv on day 1 of every 21 day cycle
75345482|NCT05946512|Behavioral|yoga|yoga breathing techniques for dysfunctional breathing
75672323|NCT00890825|Drug|Placebo|placebo
75672324|NCT02656758|Behavioral|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
75672325|NCT04780334|Diagnostic Test|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
75672326|NCT04780334|Diagnostic Test|Biosensor|Portable and Connected Biosensor viral
75672327|NCT02656992|Device|Inspiratory muscle training group|
75943568|NCT05396625|Other|Economic Empowerment|The economic component will be in the form of Child Development Accounts/CDAs, an asset-based strategy encouraging savings and investment. This component will connect families to a bank and train them on how to save small amounts, which will be matched by contributions from the project. Matched savings will be deposited in a separate account and can be used only towards a child's education or for housing. The project will provide $50 as seed money to open a savings account in the child's name. The child's family members will make small monthly contributions to the CDA, and savings of up to $20 per month will be matched with project funds at a rate of 2:1. Caregivers will also receive training on savings and financial planning. The curriculum will be taught by trainers from the SOS in a group format for 5 sessions and will cover these topics: The Importance of Saving; Identifying and Managing Resources; Setting Up a Savings System; Sources of Income; and Budgeting and Spending.
75943569|NCT03640585|Other|Music therapy|Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
75943570|NCT01064791|Drug|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
75476719|NCT05731661|Other|Delivery of useful information according to support care needs, concerning support care professionals in the city|Delivery of useful information according to support care needs, concerning support care professionals in the city
75476720|NCT05731661|Other|Delivery of a personalized post-cancer plan|Delivery of a personalized post-cancer plan
75656586|NCT05331508|Behavioral|gender-based violence screening, first-line support (LIVES) and reproductive coercion empowerment counseling (ARCHES)|Providers will (1) introduce routine client screening for GBV, including intimate partner violence, sexual violence, and reproductive coercion using a standardized screening form, in FP and ANC services,(2) for individuals disclosing GBV, provide first-line response-empathetic counseling, including listening, inquiring about experiences sensitively, and validating experiences, helping clients develop safety plans, and providing support; (3) regardless of disclosure of GBV, provide counseling and information, education and communication (IEC) materials on IPV, including reproductive coercion, and FP options, to both FP and ANC clients.
75943571|NCT01064791|Drug|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
75943572|NCT01064791|Drug|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
75345483|NCT05946512|Behavioral|social contact|social contact as active comparator
75476721|NCT05725031|Drug|Ephedrine|70 μg/kg as pretreatment
75656587|NCT05330338|Biological|Genetic analyses: whole genome sequencing|Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis
75820022|NCT03964025|Device|Wearing Cardioskin™ for 14 days|The current standard of care for diagnosing AF is through the use of a 24 hour Holter device. In this study, in addition to wearing the 3-lead Holter recorder for 24 hours, the subject will be wearing the Cardioskin™ for a period of 24 hours as well, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
75943573|NCT01064791|Drug|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
75943574|NCT03465501|Radiation|Brachytherapy|Brachytherapy
75943575|NCT05191147|Dietary Supplement|Dietary supplement|We will study dietary supplement consumption among pregnant women
75943576|NCT03641989|Other|Plaque disclosing toothpaste|Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD&C Blue No. 1.
75345484|NCT05946486|Drug|immunomodulatory treatment by rituximab|1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)
75345485|NCT05946473|Dietary Supplement|Gum base containing xylitol and essencial oils|Participants will be asked to chew 2 pieces of chewing gum containing additives for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
75345486|NCT05946473|Dietary Supplement|Gum base with no additives|Participants will be asked to chew 2 pieces of pure gum base for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
75476722|NCT05725031|Drug|Rocuronium 0.6|0.6 mg/kg
75476723|NCT05725031|Drug|Rocuronium 0.8|0.8 mg/kg
75476724|NCT05725031|Drug|Rocuronium 1.2|1.2 mg/kg
75476725|NCT05724186|Device|Test myopia control lenses (CSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
75476726|NCT05718284|Device|AIRVO2|APPLICATION OF HIGH FLOW NASAL CANNULA OXYGEN FOR 48 HOURS AFTER ESOPHAGECTOMY
75476727|NCT05718284|Other|STANDARD CARE|APPLICATION OF OXYGEN THROUGH STANDARD CARE FOR 48 HOURS AFTER ESOPHAGECTOMY
75476728|NCT05716139|Procedure|Natural Cycle|The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH < 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.
75820023|NCT02185300|Drug|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
75943577|NCT03641989|Other|Non-plaque disclosing toothpaste|Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD&C Blue No. 1.
75943578|NCT03465423|Procedure|Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)|The patients of two cohort group will undergo general anesthesia in the same way and therefore there is no intervention in this study.
75943579|NCT05161351|Drug|Baclofen|Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
75943580|NCT05161351|Drug|Vitamin D3|Placebo tablets will be vitamin D3, (colecalciferol).
75803727|NCT04526002|Device|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses, as done routinely by others. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 70-120%* resting motor threshold (RMT) (The ideal %RMT will be determined first in a pilot study). In part two, stimulation intensity for patients will be 120% RMT (titration to full therapeutic dose over the first three days), as approved by the FDA in the U.S. (Blumbeger et al. 2018). The stimulation site will be the same as in the concurrent TBS/fNIRS stimulation (see above).
75803728|NCT03733938|Other|endodontic microsurgery|teeth with failed root canal treatment will be treated by endodontic microsurgery
75803729|NCT03698500|Other|Removal of blood|10 ml of blood will be removed from a peripheral vene during routine diagnostical blood draw
76091417|NCT03277716|Procedure|MWA|MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.
76091418|NCT03277716|Device|MWA system|MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.
76091419|NCT03277716|Drug|Chemoembolization|Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
75656588|NCT05325333|Behavioral|Retrieval-based word learning|"Learning sessions: Novel nouns and their meanings are practiced on Day 1. In both conditions, retrieval trials will initially be immediate. In the expanding condition, the next two retrieval trials will each occur after 1 intervening word and then after 3 intervening words for the remainder of the session. In the standard condition, all remaining retrieval trials will occur after 3 intervening words. This practice schedule is repeated the next day (Day 2).~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word and its meaning twice. One week after Day 1, this recall test is completed again. At this time, the child will complete a recognition test: viewing sets of 4 pictures, the child will hear each novel noun and point to its referent in the array."
75656589|NCT05320055|Procedure|robotic repair|robotic assisted retromuscular hernia repair
75656590|NCT05317312|Drug|MR-107A-02|MR-107A-02 oral tablet
75656591|NCT05317312|Drug|Placebo|Placebo oral tablet
75656592|NCT05307666|Other|Medication minimization|During the medication minimization visit, and any necessary follow-up visits, patients and providers work together to gradually minimize medication dosages (e.g. reducing 1/4 or 1/2 dose at a time) using the following approach: 1) Medications Treating Symptoms: Find the minimum dose that controls the symptom, 2) Drugs that Lower Blood Pressure: Reduce dosages until systolic BP is in the upper 10mmHg of the target range (e.g. target 130 - 140 mmHg), 3) Drugs That Lower Blood Sugar: Reduce dosages until HbA1c is in the upper 5% of the target range (e.g. target 7.5 - 8.0%).
75656593|NCT05295277|Other|Standard of care genetic testing group|N/A - no intervention as this is an observational study.
75656594|NCT05293236|Drug|ApTOLL|ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)
75656595|NCT05293236|Other|Saline|Saline for intravenous infusion
75656596|NCT05284032|Drug|isatuximab 10 mg/kg|Given by intravenous infusion
75656597|NCT05270395|Behavioral|mPal|"mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider.~The provider-level component includes provider education on palliative care. The system-level component includes electronic health record modifications to facilitate palliative care discussions and referrals."
75656598|NCT05267262|Drug|R3R01|R3R01 administered orally for 12 weeks
75656599|NCT05260463|Device|Implantation|Fractures of the distal fibula are treated with a trauma implant.
75656600|NCT05256017|Drug|Acoziborole|Acoziborole tablets
75656601|NCT05256017|Drug|Placebo|matching placebo of acoziborole tablets
75656602|NCT05239468|Drug|Bezafibrate 100 mg|One tablet of bezafibrate 100 mg IR once daily
75656603|NCT05239468|Drug|Bezafibrate 200 mg|Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR
75656604|NCT05239468|Drug|Obeticholic Acid 5 mg|One tablet of obeticholic acid 5 mg tablet once daily.
75803730|NCT03733860|Procedure|Cavernous tissue sparing penile prosthesis implantation|Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.
75943581|NCT02588001|Drug|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
75943582|NCT03465345|Drug|Metformin|Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
76091420|NCT01252719|Drug|Single-Dose IV Oritavancin Diphosphate|Oritavancin was administered as a single IV dose.
75345487|NCT05946460|Drug|Aumolertinib|Aumolertinib treatment (110mg, p.o., QD) for 8 weeks
75656605|NCT05239468|Drug|Obeticholic Acid placebo|One tablet of obeticholic acid placebo tablet once daily
75943583|NCT03465345|Drug|Oligomeric Procyanidin Complex|OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
75943584|NCT03465267|Device|Armeo power|"Intervention with Armeo power rehabilitation robot for upper extremity (made by Hocoma), which provide assistive force.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
75943585|NCT03465267|Device|Armeo spring|"Intervention with Armeo spring rehabilitation robot for upper extremity (made by Hocoma), which is operated only by participants, without any assistive force from robot.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
76091421|NCT01252719|Drug|IV Vancomycin|Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
76091422|NCT01252719|Drug|Placebo|Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
76091423|NCT03283956|Device|Patient records|Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
76091424|NCT01233531|Behavioral|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
76091425|NCT01233531|Behavioral|B--No cash transfers|No monthly cash transfers
75345488|NCT05946434|Other|Kinesio Tape Group|"Physiotherapy Protocol Followed:~Hot pack and TENS application for 10 minutes.~Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~Tibio-femoral glides and patellar mobilizations will be performed.~At the end kinesio taping will be performed at knee joint for inhibition.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28."
75476729|NCT05716139|Procedure|Artificial Cycle|Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
75656606|NCT05239468|Drug|Bezafibrate Placebo|One tablet of bezafibrate placebo tablet once daily
75656607|NCT05230810|Drug|Alpelisib|Orally twice a day
75656608|NCT05230810|Drug|Tucatinib|Orally once a day
75656609|NCT05230810|Drug|Fulvestrant|"500 mg intramuscularly into the buttocks slowly~*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer"
75656610|NCT05217992|Other|Genetic assessment (hemophilia testing)|Determination of carrier ship of hemophilia with molecular tests
75656611|NCT05207527|Other|cardiovascular exercise|Exercise that mainly stimulates the cardiovascular and respiratory systems.
75656612|NCT05207527|Other|Muscle strength|Exercise that primarily stimulates the musculoskeletal system.
75803731|NCT03733860|Procedure|Conventional penile prosthesis implantation|Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine
76091426|NCT03272490|Procedure|Medartis|Surgery using the medartis implant
76091427|NCT03272490|Procedure|Synthes|Surgery using the Synthes implant
76091428|NCT02342314|Drug|LY3143753 (Part A)|Administered via SC injection
75354690|NCT04770896|Drug|Lenvatinib|Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of < 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
75476730|NCT05715333|Biological|CM326|CM326 Injection
75476731|NCT05715333|Other|Placebo|Subcutaneous injection
75476732|NCT05715320|Biological|CM310|IL-4Rα monoclonal antibody
75656613|NCT05207527|Other|Mixed|Exercise that stimulates the musculoskeletal, cardiovascular and respiratory systems.
75656614|NCT05514236|Other|Virtual Reality Therapy|"Participants will be given the virtual reality device (a headset) with immersive video content for use during the hysteroscopy. Designated moving objects with sound will be broadcasted on the screen to the participant in this group.~Participant can adjust the volume of the sound according to her comfort."
75803732|NCT03733860|Procedure|Intracavernosal injection of alprostadil|Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group
75803733|NCT04390360|Procedure|Protective ventilation implementation|In this condition, we will implement the protective ventilation related with gender and height . A blood gas will be performed at before protective ventilation implementation and at the end of this condition.Time condition 30 minutes
75803734|NCT04390360|Procedure|Protective ventilation with HME|In this condition, the patient will received protective ventilation with a Heat Moisture Exchanger (HME). A blood gas will be performed at the end of this condition.Time condition 30 minutes
75803735|NCT04390360|Procedure|Protective ventilation with Heated humidifier|In this condition, the patient will received protective ventilation with a Heated humidifier. A blood gas will be performed at the end of this condition.Time condition 30 minutes
75943586|NCT04230135|Device|Hap-pas-Hapi|Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
76091429|NCT02342314|Drug|LY3185643 (Part B)|Administered via SC injection
76091430|NCT02342314|Drug|Placebo (Part A and Part B)|Administered via SC injection
76091431|NCT02342314|Drug|rGlucagon (Part B)|Administered via SC injection
76091432|NCT01230411|Other|saline placebo|250 cc of placebo administered IV
75943587|NCT02735421|Drug|ABPO Forte Gel|Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
75345489|NCT05946434|Other|Rigid Tape Group|"Physiotherapy Protocol Followed:~Hot pack and TENS application for 10 minutes.~Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~Tibio-femoral glides and patellar mobilizations will be performed.~At the end rigid tape will be applied on knee joint to provide stability.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28"
75943588|NCT02735421|Drug|Vehicle gel|Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
75943589|NCT04469205|Other|Coaching sessions|There are 3 sessions : the first session will last 1h30 and will be in consultation within the Institut Curie. The second session will last 1h30 and will be done remotely (by phone or by videoconference). The duration of the 3rd and last session will be adapted according to the needs of each patient and will last a maximum of 1 hour. It will also be done remotely (by phone or by videoconference).
75943590|NCT02983799|Drug|OLAPARIB|300 mg olaparib tablets taken orally twice daily
75943591|NCT03622307|Device|Subcutaneous ICD Therapy Combined with VT Ablation|S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
75966024|NCT01595438|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
75345490|NCT05946421|Device|exhaled breath analysis|non invasive technology to measure components of exhaled breath
75345491|NCT05946356|Other|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
75345492|NCT05946343|Diagnostic Test|Surface Electromyography (sEMG) Assessment|Surface electromyography (sEMG) will be used to assess the activation patterns of scapular and rotator cuff muscles during functional tasks, such as shoulder flexion, abduction, and external rotation. The sEMG assessment will be conducted using a wireless sEMG system with a sampling rate of 2000 Hz and a bandwidth of 20-500 Hz. Pre-gelled, disposable, self-adhesive Ag/AgCl electrodes will be placed on the muscle belly according to SENIAM guidelines, with an inter-electrode distance of 20 mm.
75476733|NCT05707754|Drug|Bupivacaine|Topically applied to sphenopalatine ganglion
75476734|NCT05707754|Device|angiocatheter|Introduced into nose to reach sphenopalatine ganglion nerve
75476735|NCT05707325|Drug|engineered red blood cell WTX212|engineered red blood cell WTX212
75476736|NCT05707143|Other|home based stabilization exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
75656615|NCT05514236|Other|Music Therapy|"Participants will be given a headphone playing either classical light music or 'POP' songs according to their option during the hysteroscopy.~Participant can adjust the volume of the music according to her comfort."
75656616|NCT05201534|Other|Interventions in Mathematics and Cognitive Skills - Experimental|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
75656617|NCT05201534|Other|Interventions in Mathematics and Cognitive Skills - Active Comparator|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
75656618|NCT05200546|Diagnostic Test|molecular assays to screen for eXDR|"VRE detection will be performed using VIASURE Vancomycin resistance Real Time PCR Detection Kit.~BD MAX Check-Points CPO will be used to detect carbapenemase-producing organisms."
75656619|NCT05193591|Other|Autoantibodies evaluation in lupus|"Biological analysis: anti-C1s, anti-HMGB1 and anti-C1q autoantibodies; C1s, HMGB1 and C1q proteins.~Purification of patients' autoantibodies (anti-C1s, anti-HMGB1and anti-C1q). Identification of the molecular targets recognized by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients' serum."
75803736|NCT04390360|Procedure|Tidal Volume reduction|n this condition, we will reduce Tidal volume (with smartphone application calculation) to obtain the same alveolar ventilation (PaCO2) obtained on the HME condition
75803737|NCT03700840|Device|Interdental brushes|interdental brush at 4 sites and PCR analysis
75803738|NCT03698422|Diagnostic Test|Blood and urine samples|Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
75803739|NCT03605862|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
75803740|NCT03605862|Drug|Placebo|Placebo administered orally twice daily for five days
75803741|NCT03700762|Diagnostic Test|ultrasound gray-scale ratio|RADinfo radiograph reading system was used to measure the gray-scales of PTMC, NG, and thyroid tissues at the same gain level, the UGSR values of the PTMC, NG, and thyroid tissue were calculated.
75803742|NCT04709302|Biological|COVID-19|Patients diagnosed with a COVID-19 infection
75803743|NCT04709302|Biological|HIV|Patients diagnosed HIV-positive
75803744|NCT04709302|Drug|ART|Patients on ART
75345493|NCT05946252|Other|Motor imagery|"Motor imagery will be performed according to the PETTLEP (Physical,Environment,Task,Time,Learn,Emotion,Perspective) model for 15 minutes.~To imagine walking activity in different environments (seaside, beach, walking path).~The rest activity will be imagined by sitting on a bench.~Upper extremity strengthening exercises with dumbbells, lower extremity strengthening exercises with elastic band and trunk-oriented bridging, posterior pelvic tilt and table top stabilization exercises will be visualized.~The rest activity will be imagined by sitting on a bench.~Imagination will end with homecoming and domestic activities."
75943592|NCT04320017|Diagnostic Test|Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care|"12 derivations electrocardiogram done at baseline and repeated every 3 days~transthoracic echocardiography at baseline~clinical features at baseline: WHO performans status comorbidities and treatments~biological results in routine care, such as baseline full blood count, inflammation markers: C-reactive protein, procalcitonin, interleukin-6 and ferritin, coagulation and troponin and brain natriuretic peptide"
75943593|NCT03465033|Other|Early Physiotherapy|"From T1 to T2 patients will perform 3 daily repetitions of active exercises:1 5 repetitions of oral opening exercises and bilateral manual progressive stretching, protrusion and maximum lateralization of the jaw on both sides, holding each movement for 5s and a session of cryotherapy applied to the masseter, temporal and suprahyoid muscles for 120s in two 60s sessions. They will also perform 30 repetitions of exercises aimed at improving the labial seal (inflate cheeks) and the symmetry of the upper lip (broad smile). From T2 to T3 30 repetitions of the same exercises will be performed and passive progressive opening will be implemented by clamping Patients will also perform isometric contraction exercises in opening, closing, laterotrusion, protrusion and retrusion. Each movement will be repeated 5 times and it will remain for 5s."
75943594|NCT03954249|Procedure|Erecto Spinae nerve block|The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.
75943595|NCT03954249|Procedure|Multimodal Analgesia|Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
75943596|NCT05386641|Other|measurement of tissue stiffness (N/m)|Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
75943597|NCT05386641|Other|measurement of passive muscle tone (Hz)|muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
75943598|NCT05386641|Other|measurement of creep of tissue|creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
75345494|NCT05946252|Other|Diaphragmatic breathing|Diaphragmatic breathing will be shown to pregnant women in the supine position, eyes closed, with one hand on the chest and the other hand on the abdomen. This practice will last for five minutes.
75656620|NCT05169320|Device|Subcutaneous implantable loop recorder (ILR) implantation|All patients will undergo subcutaneous implantable loop recorder (ILR) implantation to quantify AF burden 1 month before the ablation procedure and at least 1 year after the ablation procedure.
75656621|NCT05169320|Procedure|Mapping and catheter ablation|Driver regions will be identified during persistent AF using a conventional electroanatomical mapping system, multielectrode mapping catheters, and leading-driver maps generated by novel single-signal algorithms based on an automatic and accurate analysis of the instantaneous amplitude and frequency modulations displayed by atrial signals (iAM and iFM, respectively). Such maps enable the location of the spatiotemporally stable regions that drive persistent AF (leading drivers). Leading-driver regions that can be reasonably targeted/isolated with catheter ablation without high-risk of complications upon radiofrequency delivery will be targeted for ablation.
75656622|NCT05169320|Procedure|Minimally invasive surgical ablation via thoracoscopy|"This procedure will be performed only in those patients whose leading-driver maps in the previous mapping and catheter ablation procedure fulfill the following requirements:~Extensive atrial remodeling who will not likely get any benefit from catheter-based ablation due to too large atrial leading driver areas (≥10-15% of atrial surface), or~Leading drivers located at regions with high-risk of complications upon radiofrequency delivery (e.g. left and right atrial appendages, coronary sinus, in the vicinity [≤5 mm] of the cardiac specific conduction system).~In such patients, the leading-driver regions not completely targeted or not targeted at all in the previous index mapping and catheter ablation procedure, will be specifically ablated/isolated by minimally invasive surgical ablation techniques via thoracoscopy."
75943599|NCT05386641|Other|measurement of the range of shoulder joint motion|The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
75476737|NCT05707143|Other|kegel exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
75943600|NCT05386641|Other|measurement of skin temperature|measurements will be taken by the thermographic camera
75354691|NCT04770896|Drug|Sorafenib|Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
75354692|NCT04770844|Other|Acquisitions|"Three acquisitions of 1 hours during hospitalization will be realized:~a few days after hospitalization,~in the middle of the hospitalization,~a few days before hospital discharge. The child will be lying on his back in a heated cradle and filmed with a specific camera. The signal will be obtained by 2k ZED 2 stereo camera in order to obtain a three-dimensional location of the child"
75672328|NCT02656602|Other|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI. All elements of informed consent for colonoscopy (risks, alternatives) were included.
75476738|NCT05700760|Behavioral|ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)|Evidence-based 5 session psychosocial intervention that has been found to prevent ~50% of postpartum depression among low-income, at risk women.
75672329|NCT04760132|Biological|COMIRNATY - BioNTech Manufacturing GmbH|Vaccination as part of the the Danish national government programme
75656623|NCT05169190|Procedure|Stellate Ganglion Block|After procedure informed consent, the procedure will be done using an ultrasound guided technique with a high frequency (6 to 13 MHz) linear transducer and confirmation of placement by fluoroscopy at sites who do this in clinical practice. The subject will be prepped and draped and placed in supine position in a suite with continuous vital sign monitoring and advanced cardiac life support equipment and IV placement. Local anesthesia with 1% buffered lidocaine will be achieved. After visualization of Chassaignac's tubercle of C6 is identified along with the carotid artery, internal jugular vein and longus colli and capitus muscles, a 25-gauge echo-enhanced needle will be inserted to inject anesthetic over 2 minutes anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle. The needle will be withdrawn and the subject will be monitored for a minimum of 30 minutes.
75656624|NCT05169190|Procedure|Sham Stellate Ganglion Block|"The Sham protocol is identical to the SGB protocol except After needle tip confirmation and negative aspiration, normal saline (0.9%) + contrast (unlabeled to keep treater blinded) will be slowly injected over 2 minutes while closely monitoring the subject."
75656625|NCT05168657|Device|Bionic Pancreas|14 days using the insulin-only configuration of the iLet Bionic Pancreas (Beta Bionics, Inc.), which automates insulin delivery, as the only intended mode of insulin delivery.
75943601|NCT05386641|Other|measurement of pain|Pain will be evaluated by visual analog scale (VAS)
75943602|NCT05386641|Other|measurement of pain pressure threshold|Pain pressure threshold will be evaluated by a digital algometer
75943603|NCT05386641|Other|measurement of grip strength|"The grip strength of both hand will be evaluated by hand-held dynamometer."
75943604|NCT03464877|Other|Multi-station full-body supervised exercise program|The exercise program was 6-week duration, 2-3 visits per week. It was composed of 7 stations, each consisting of numerous exercises of increasing difficulty. The exercises were grouped together as follows: Hip strengthening and control (Station 1); The squat and its variants (Station 2); Elastic bands and the Bodyblade (Station 3); Abdominal planks and their variants (Station 4); Abdominal strengthening (Station 5); Back extensor strengthening (Station 6); and Lifting techniques (Station 7).
75943605|NCT05385705|Drug|Cyclophosphamide|Cyclophosphamide at a single dose of 600mg/m2 IV between days -5 and -3 before NK cell infusion for preconditioning the tumoral microenvironment by reducing the levels of lymphocyte T regulators (Tregs FOXP3+, CD3+, CD4+, CD25+).
75345495|NCT05946187|Behavioral|Apolo_Bari Stepped-care intervention|"Step 1 - Low-intensity intervention that will run on a private Facebook® group. Weekly, a subtopic and related activities are posted as short text/images. Patients are encouraged to participate by viewing publications, commenting, and posting their content.~Step 2 - Will consist of an adjusted version of the Cognitive Behavior Treatment (CBT) program developed by Conceição et al. (2016). The intervention will last for 12-months and be delivered online by Facebook's functionalities, namely chat and calls. The intervention offered includes three components: 1) a psychoeducational cognitive-behavioral-based self-help manual that consists of 12 different modules. Each month a different topic will be covered and divided into four weekly sub-topics, which are supported with a set of related CBT tasks; 2) interactive call sessions with a psychologist (30 min at the beginning of each month); 3) monthly monitoring of risk-behaviors responded every session."
75345496|NCT05946187|Other|Treatment as Usual for Bariatric Surgery|Treatment as Usual for bariatric surgery in portuguese public hospitals.
75345497|NCT05946148|Drug|Empagliflozin|Empagliflozin 10mg daily, as add-on to previous treatment regimen.
75345498|NCT05946148|Drug|Dulaglutide|Dulaglutide 1.5mg weekly, as add-on to previous treatment regimen
75345499|NCT05946148|Drug|Control Rx|Optimal anti-diabetic treatment excluding agents of the GLP1-ras or SGLT2-is families.
75345500|NCT05946135|Drug|Lansoprazole|taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks
75803745|NCT03624868|Behavioral|Tai Chi|See above description
75943606|NCT05385705|Drug|Trastuzumab|Trastuzumab at a dose of 8mg/kg IV for the loading dose on Day 1, and 6mg/kg IV for the maintenance dose every 3 weeks (Q3W).
75656626|NCT05168657|Other|Telehealth|Study participation will be managed via telehealth visits.
75656627|NCT05168657|Other|Usual Care|14 days of the participant's usual care of their type 1 diabetes
75672330|NCT04760132|Biological|COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|Vaccination as part of the the Danish national government programme
75672331|NCT04760132|Biological|COVID-19 Vaccine AstraZeneca suspension for injection|Vaccination as part of the the Danish national government programme
75672332|NCT04248101|Procedure|Double Ligation|
75672333|NCT04248101|Drug|Topical Silver Nitrate|
75672334|NCT00649818|Drug|Lorazepam Tablets 2 mg|2mg, single dose fasting
75672335|NCT00649818|Drug|Ativan Tablets 2 mg|2mg, single dose fasting
75672336|NCT00620906|Procedure|Manipulation|HVLA manipulation to Sacroiliac Joint
75672337|NCT02656524|Drug|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
75803746|NCT03624868|Behavioral|Wellness Education|See above description
75803747|NCT01310244|Drug|Belinostat, Carboplatin, Paclitaxel|Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
75803748|NCT03698344|Other|Biodiesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute biodiesel exhaust via mask.
75803749|NCT03672006|Biological|alteplase (recombinant t-PA)|Medication administered to dwell in central venous catheter
75803750|NCT03672006|Drug|Heparin|Medication administered to dwell in central venous catheter
75943607|NCT05385705|Drug|Pertuzumab|Pertuzumab at a dose of 840mg IV for the loading dose on Day 1, and 420 mg IV for the maintenance dose every 3 weeks (Q3W).
75943608|NCT05385705|Biological|NK cells|NK product is a cellular investigational product comprising a live cell suspension of allogenic NK cells derived from a compatible donor that will be infused on Day 2.
75943609|NCT05385705|Drug|Interleukin-2|IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.
75943610|NCT05329701|Other|Individualized treatment duration strategy|As listed under arm description.
75943611|NCT04390503|Biological|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2.
75943612|NCT04390503|Biological|Control (albumin 5%)|Albumin (Human) 5% is a sterile aqueous solution for intravenous use containing the albumin component human plasma.
75943613|NCT05381337|Procedure|sideburns mini incision|The investigators present a new method to calculate the shortest incision for zygomatic fracture, and use this method to calculate the sideburns mini incision for the surgical treatment of zygomatic arch fracture.
76091433|NCT01230411|Drug|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
76091434|NCT03283800|Other|Copper impregnated compression stocking|Copper impregnated compression stocking
75656628|NCT05166564|Behavioral|A Protein Enriched Mediterranean Diet (PROMED) Intervention|Researchers will provide individually tailored dietary advice and written materials to encourage 'a little and often' meal plan to support adoption of the PROMED intervention. The daily energy and protein requirements of each participant will be calculated based on National Institute of Health & Care Excellence guidance for Nutrition Support in Adults at Risk of Malnutrition. Several resources have been developed to facilitate behaviour change: a) A PROMED Diet Information Booklet to include an overview of the PROMED Diet, tips for incorporating more PROMED foods into the diet and information on the health benefits of a PROMED diet, b) A PROMED Recipe Book offering ideas for breakfast, lunch and dinner as well as suitable snack ideas and c) key PROMED foods ordered through a local supermarket's online delivery service and delivered to participants' homes on a weekly or fortnightly basis for the 3-month active intervention phase.
75345501|NCT05946135|Drug|Fexuprazan Hydrochloride|taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks
75345502|NCT05946122|Drug|Atorvastatin 40 Mg Oral Tablet|oral atorvastatin for renal protection
75345503|NCT05946122|Drug|placebo drug|tablet resembles atorvastatin
75345504|NCT05946109|Behavioral|ACTIVE-AGE@home|"functional, homebased training program offering basic functional exercises connected to meaningful activities, lifestyle coaching and motivational interviewing; derived from evidence-based training principles . Through a precise application of the FITT-VP* guidelines, a progressive and balanced program was designed and piloted in different proof-of-concept studies. The uniqueness of the program lies in the multi-component approach which brings together functional exercises for (1) muscle strength/muscle endurance, (2) aerobic endurance, (3) flexibility, motor ability and balance and (4) meaningful daily activities, in a home-based environment.~The frail participants are visited three times a week during 24 weeks with in total 72 sessions. Each session is 1 hour in duration. Thus they receive 72 training hours.~*(Frequency, Intensity, Time, Type of exercises, Volume and Progression)"
75345505|NCT05946096|Other|Dynamic surface exercise training|Dynamic surface exercise training involves a set of exercises that are performed on various dynamic surfaces like gym ball and vestibular swing. All these exercise provide optimal arousal as they provide proprioceptive and vestibular stimulus. This group received a set of exercises on various dynamic surfaces.These exercises were implemented for 60 minutes for four days a week for two months.And it was observed how these exercises impacted gross motor function and trunk control of children with diplegic cerebral palsy of GMFCS level 3 and 4
75476739|NCT05700760|Behavioral|Enhanced Care as Usual (CAU)|Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
75345506|NCT05946096|Other|conventional physical therapy|conventional physical therapy based on NDT involves a set of exercises that mostly include positioning exercises such as quadruped, side sitting, reaching sideways and overhead in sitting and catch and throw activities.
75476740|NCT05699824|Drug|Carvedilol Day2|Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
75476741|NCT05699824|Other|Standard Medical Treatment|All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment
75476742|NCT05699824|Drug|Carvedilol Day6|Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
75672338|NCT02833181|Device|BIS monitor|Monitoring circadian variation of EEG
75672339|NCT02828423|Procedure|EMD|Regenerative surgery with EMD
75803751|NCT03698266|Procedure|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP
75803752|NCT03698188|Procedure|Injectable platelet-rich fibrin|A blood sample will be drawn from the patient, centrifuged at 700 rpm for 3 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
75803753|NCT03698188|Procedure|Platelet-rich plasma|A blood sample will be drawn from the patient, centrifuged at 3000 rpm for 10 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
75943614|NCT05381337|Procedure|coronal scalp incision|Coronal scalp incisions were used as control group.
75943615|NCT03654261|Behavioral|Cognitive Behavioural Therapy|The intervention is a 1-day Cognitive Behavioural Therapy based workshop.
75943616|NCT02186847|Radiation|Radiation Therapy|Radiation therapy (RT) is given in 2 Gy fractions once daily 5 days per week to a total of 30 fractions and 60 Gy. Photons required; 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) permitted. Starts within 14 days of randomization (Chemoradiation arm) or 14 days after metformin starts (Chemoradiation + Metformin arm).
76091435|NCT03283800|Other|Normal compression stocking|Normal compression stocking without copper
75943617|NCT02186847|Drug|Carboplatin|2 AUC (area under the curve) via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 6 AUC via IV starting 28-42 days after the end of radiation therapy.
75943618|NCT02186847|Drug|Metformin|Metformin is taken orally. Dose escalation begins 2 weeks prior to the initiation of chemoradiation. 500 mg twice daily days 1-7 of metformin. 500 mg three times daily days 8-14 of metformin. Three times a day with the following dosage: 500mg in the morning, 1000mg at noon, and 500mg in the evening concurrent with chemoradiation and through consolidation chemotherapy (days 15-126 of metformin),
75943619|NCT02186847|Drug|Paclitaxel|50 mg/m2 via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 200 mg/m2 via IV 28-42 days after the end of radiation therapy.
75943620|NCT01066871|Drug|Sprifermin (AS902330) 10 mcg|Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
75943621|NCT01066871|Drug|Sprifermin (AS902330) 30 mcg|Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
75943622|NCT01066871|Drug|Sprifermin (AS902330) 100 mcg|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
75943623|NCT01066871|Other|Placebo|Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
75943624|NCT03464799|Other|immunohistochemical staining|immunohistochemical staining
75345507|NCT05946083|Dietary Supplement|Inulin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of a dietary fiber with benefits for intestinal bacteria (inulin).
75476743|NCT05699486|Drug|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
75476744|NCT05699486|Drug|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
75672340|NCT02828423|Procedure|BC|Regenerative surgery with BC
75803754|NCT03731520|Diagnostic Test|Assessing exercise behavior|11-point Numeric Analogue Scale (NRS) for satisfaction of exercising, Exercise Stages of Change Scale-Short Form (ESCS), Exercise Self-Efficacy Scale (ESES), and Decisional Balance Scale (DBS) for exercise behaviour will be inquired for the patients with JIA.
75943625|NCT05288205|Drug|JAB-21822|KRAS G12C inhibitor
75943626|NCT05288205|Drug|JAB-3312|SHP2 inhibitor
75943627|NCT05274789|Drug|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
75943628|NCT05274789|Other|Saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
75943629|NCT03622229|Diagnostic Test|Histologic evaluation|Samples collected by EUS-FNB without ROSE will be processed as histologic samples
75943630|NCT05266521|Device|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
75943631|NCT02353247|Drug|Norethindrone acetate|
75943632|NCT03389217|Device|Real-tDCS + rehabilitation programme|tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
75672341|NCT02656446|Device|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
75345508|NCT05946083|Dietary Supplement|Maltodextrin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of dietary fiber with no specific benefits for the intestinal microbiome (maltodextrin).
75345509|NCT05946070|Other|ONKOSIS|ONKOSIS is a mobile phone-based monitoring system in the management of chemotherapy-related symptoms
75345510|NCT05946005|Drug|honey|Tresno Joyo honey applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: MD252109001219
75354693|NCT04763759|Drug|TRL1068, a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
75672342|NCT02656446|Device|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
75672343|NCT02691728|Drug|LDV/SOF FDC|
75672344|NCT05147207|Procedure|Superpath Approach|This is a minimally invasive surgical approach for THA.
75803755|NCT04514692|Diagnostic Test|FDG PET/CT|Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)
75803756|NCT04514692|Drug|GCSF|Granulocyte Colony Stimulating Factor (GCSF)
75820024|NCT02185300|Drug|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
76091436|NCT02459184|Other|Income Security Health Promotion|"The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs."
76091437|NCT01962688|Device|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
75803757|NCT03733782|Dietary Supplement|Modular enteral protein - Prosource|Supplemental protein (2 gm/kg/day of Prosource; Medtrition, Lancaster, PA) was administered via the nasal/oral feeding tube in 60 - 180 ml bolus infusions 2 - 4 times per day, independently of the enteral formula received. That is, the daily target amount of protein was initially administered as the supplement boluses and only after the enteral formula infusion approached the target rate was the amount of supplement decreased. Supplemental protein was reduced by 50% once the patient received 75% of targeted caloric intake over the previous day (0700 - 0700). Once the patient reached the target caloric intake for 48 hours, the amount of supplemental protein was decreased in order that the total protein prescribed equaled 2 gm/kg/day.
76091438|NCT01962688|Device|Sham ultrasound|sham ultrasound to facilitate blinding
76091439|NCT04389723|Dietary Supplement|Qualia Mind|Multi-ingredient Dietary supplement
75803758|NCT03733704|Diagnostic Test|Heart rate variability analysis|Heart rate variability analysis extracted from ECG during normal and obstructed breathing
75803759|NCT03703414|Diagnostic Test|Fecal microbiota composition analysis and blood cytokine level analysis|Fecal microbiota composition analysis and blood cytokine level analysis
75803760|NCT03621072|Drug|Fluconazole 150mg Capsule Originator|150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
75803761|NCT03621072|Drug|Fluconazole 150mg Capsule Localized Originator|150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
75803762|NCT03698110|Behavioral|Intervention Group|PUEDES program included eight hours in groups and activities to practice at home.
75803763|NCT03733548|Behavioral|RELAX|Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly, 90-minute sessions delivered (60 minutes of parents and adolescents meeting separately, 30 minutes of a combined meeting) in a group format. RELAX equips adolescents with emotion regulation and conflict management skills. This program includes a parent involvement component designed to help parents support adolescents' use of these skills. Each week skills will be discussed and practiced in group, and a skills rehearsal homework activity will be assigned. Following the program, an 8-week follow-up review session will be offered. Additionally, a single 60 minute focus group will be held following the review session to solicit parent and adolescent feedback on the intervention.
75803764|NCT03697954|Device|full stage implantation of sacral neuromodulation|full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence
75803765|NCT03700528|Behavioral|Acceptance and Commitment Therapy (ACT)|The process will involve, two, brief, one-to-one contact sessions, one at the beginning and one at the end of the intervention, in a way that is convenient for participants, including Skype, phone, or face to face in person. Following the first one-to-one session there will be eight short online sessions, about 20-30 minutes each. Participants will also be asked to complete some tasks between the sessions, in particular to record their progress briefly and any changes at their medication (i.e. type of drug, dose) in a diary weekly so that they can keep track of your developing skills.
75803766|NCT03512288|Biological|Multivalent|Pneumococcal conjugate vaccine
75803767|NCT03512288|Biological|13vPnC|Pneumococcal conjugate vaccine
75803768|NCT03031678|Device|Electric-Acoustic Stimulation (EAS) Cochlear Implant System|Combination of a cochlear implant and a hearing aid
75943633|NCT03389217|Device|Sham-tDCS + rehabilitation programme|The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
75943634|NCT03656471|Device|clear aligners or fixed appliances|Patients choose clear aligners or fixed appliances to treat their malocclusions
75943635|NCT05357703|Device|Standard treatment + Active B-Cure laser|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/minute.
75943636|NCT03368937|Device|Tandem t:slim X2 with Control-IQ Technology|Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
75943637|NCT05354661|Device|Hypotension Prediction Index|treatment of hypotension before the appearance following HPI algorithm
76091440|NCT04389723|Dietary Supplement|Placebo|Multi-ingredient Placebo
76091441|NCT00149487|Behavioral|Tailored Problem Solving Intervention|
76091442|NCT00149487|Behavioral|Family Education Intervention|
75345511|NCT05946005|Drug|lidocaine|Dolones cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: DKL0922246629AI
75345512|NCT05946005|Drug|povidone-iodine|Betadine cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: PKD20501710037
75345513|NCT05946005|Other|control groups|no intervention is given
75345514|NCT05945992|Behavioral|Emotion regulation|Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises
75345515|NCT05945992|Behavioral|Self-acceptance|Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.
75354694|NCT04760548|Other|Observational study|
76091443|NCT03276000|Procedure|office hysteroscopy|A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
75345516|NCT05945992|Behavioral|Mindfulness|Guided mindfulness-exercises, different meditation techniques like body scan, breathing meditation. Reflection and exchange within the group
75943638|NCT03464721|Device|issued with SMART ANGEL device|patients will use the technology at home to record and transmit data for blood pressure and oxygen saturation
75943639|NCT04343651|Drug|Placebo|Placebo
76091444|NCT04058769|Device|Premedication Guide|Software with guidelines recommendations for preoperative assessment
76091445|NCT02459886|Drug|BIIB054|IV infusion
76091446|NCT02459886|Drug|Placebo|IV infusion
75943640|NCT04343651|Drug|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
76091447|NCT02309944|Procedure|Standard Wound Closure|The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if >2 cm deep, followed by staple or suture closure of the skin.
76091448|NCT02309944|Device|Prevena™ Incision Management System|At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
75345517|NCT05945992|Behavioral|Resource activation|Exercises focusing on developing positive emotions and fostering personal strengths, based on the Positive Psychology movement of Martin Seligman, working on individual values, life goals and sense of life.
76091449|NCT03271398|Behavioral|EMDR|Eye movement desensitization and reprocessing (intensive format)
75345518|NCT05945992|Behavioral|Control component 1_social behaviors in groups|Control component for emotion regulation
76091450|NCT03271398|Behavioral|PC|Progressive counting (intensive format)
76091451|NCT02311972|Device|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
76091452|NCT02311972|Device|Standard of care feeding tube|
76091453|NCT03271008|Device|Direct laryngoscopy|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.
75345519|NCT05945992|Behavioral|Control component 2_communication skills|Control component for self-acceptance
75345520|NCT05945992|Behavioral|Control component 3_stress management|Control component for mindfulness
75345521|NCT05945992|Behavioral|Control component 4_constructive conflict resolution|Control component for resource activation
75345522|NCT05945979|Dietary Supplement|A power supplement with biotin|A power dietary supplement containing aminoacids and vitamins
75345523|NCT05945914|Procedure|Oncoplastic Entirely Robot-Assisted Approach (OPERA)|Robotic-assisted surgery in both mastectomy and free DIEP flap harvest, so-called Oncoplastic Entirely Robot-Assisted Approach (OPERA).
75345524|NCT05945862|Behavioral|NUTRIGANDO|Program consisting in nutrition education and physical activity training to promote healthy lifestyles
75345525|NCT05945771|Dietary Supplement|Grape seed extract|Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.
75656629|NCT05166564|Behavioral|A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention|Participants will receive a dietary intervention identical to PROMED participants, plus an exercise intervention. The home-based exercises are based on a modified version of the 'ExWell@home' programme developed by health professionals with significant expertise in community-based exercise rehabilitation for chronic disease. Cardiorespiratory fitness will be determined using a 3-minute step test and pulse rate. Participants will receive access to pre-recorded exercise classes and a written resource designed for older adults (ExWell@home) and adapted for the current study. Participants will be encouraged to complete two sessions per week (30-60 minutes per session). To cater for differing abilities, four levels of classes will be available for participants: Chair based, basic, standard and advanced.
75656630|NCT05148039|Behavioral|Dietician advice|Personalised dietetic advice
75656631|NCT05135910|Drug|Hallux Terbinafine Subungual Gel|Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.
75656632|NCT05117008|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered IV over approximately 30 minutes at the recommended dose of 2.5 mg/kg IV over 30 minutes on day 1 of every eight-week (+/- three days) cycle for a maximum of 12 cycles. Maintenance therapy with belantamab mafodotin will continue until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or end of study (maximum of 12 cycles), whichever occurs first.
75656633|NCT05105789|Diagnostic Test|BinaxNOW Test|diagnostic test for SARS-CoV-2
75943641|NCT03464643|Other|embryo culture|Single embryo culture means only one embryo is cultured in one drop, and the group culture refers to culture of 2-5 embryos in one drop. The main advantage of group culture may be secreting some paracrine cytokines by embryos and benefit each other; and the possible disadvantage of group culture is that embryo secreting of some harmful substances which accumulated to a certain extent will damage the developmental potential of embryos. The advantages and disadvantages of single embryo culture are contrary to group culture.
75943642|NCT03464565|Device|Penumbra System|Penumbra System
75943643|NCT05333367|Other|Samples collection|Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)
75943644|NCT03464487|Dietary Supplement|Low Glycemic Index Therapy Diet|Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.
76091454|NCT03271008|Device|Vividtrac videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.
76091455|NCT03271008|Device|KingVision videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
76091456|NCT03274596|Drug|Vitamin E|
76091457|NCT03274596|Drug|Placebo|
75345526|NCT05945758|Procedure|Injectable resin composite technique.|A metal impression tray was filled with transparent vinyl polysiloxane (EXACLEAR, GC) and used to copy the stone model with the wax-up. Then, the replica will be separated from metal tray and a needle-shaped bur will be used to drill holes through the silicone key ending in the middle of the incisal edge. It will be checked whether the holes were large enough to enable the tip of the composite syringe to pass easily and completely. Neighbouring teeth (mesial and distal one) isolated using Teflon tape, as each tooth will individually be restored for establishment of satisfactory contact points. Following etching and rinsing, the tooth dried, and a dental cord (Ultrampak, Ultradent) will be packed into sulcus for mechanical prevention of subgingival composite flow. Then, the transparent silicone index will be placed in the correct intraoral position, and a syringe filled with flowable composite will be inserted through the hole on the incisal edge.
75345527|NCT05945758|Procedure|Conventional layering technique|the palatal surface will be restored by enamel shade; adapted on the index in the spacing area then The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
75803769|NCT03669588|Biological|ARGX-113|Intravenous administration of ARGX-113
75345528|NCT05945745|Drug|Chemotherapy|different treatments based on the molecular analysis
75476745|NCT05697679|Behavioral|Treatment group|WeChat groups will be set up, and once a week on Monday, articles on physical exercise and once a week on Wednesday, 3-minute films about health education will be shared. For the duration of the 3-month intervention period, the following technologies will be used to deliver the GAT-pap: (1) Short Messaging Service (SMS) text (batch messaging); (2) WeChat (e.g., physical activity guidelines, group chats); and (3) monthly face-to-face interviews (behaviour change promotion, risk factor management). Although not essential, participants will be urged to register their daily exercise in the group chat. In order to determine if they are accomplishing their goals and what objectives they should be pursuing, the researchers will develop customised training regimens for each participant.
75803770|NCT03669588|Biological|Placebo|Intravenous administration of placebo
75803771|NCT03697798|Biological|Boostrix®-IPV combination vaccine|A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.
75803772|NCT03716570|Drug|BIIB054|Administered as specified in the treatment arm.
75803773|NCT03716570|Drug|Placebo|Administered as specified in the treatment arm.
75943645|NCT03464331|Behavioral|Zero-time exercises|The Investigators/research staff (RS) will help EXP download, operate the Zero-time exercises (ZTE) app and ZTE e-diary. The EXP can enter their goal for the chosen exercise by setting the target duration or number of completed repetitions, review their previous record, and compare their exercise frequency and time ranking with those of the other EXP. After the EXP uploads the goal and results to the ZTE e-diary, the data will be automatically sent to the ZTE app database for data analysis. The EXP will be given a paper diary to record their Zero-time exercises (ZTE). Twenty-five EXP will be given activity trackers (e.g. Fitbit) to record their steps/motion throughout the 3 months.
75943646|NCT03464331|Behavioral|relaxation exercises and deep-breathing exercises|The Investigators/RS will teach the CON group (CON) to do relaxation exercises (RE) and deep-breathing exercises (DBE) for at least 30 mins every day. They will be helped download and use the electronic diary (CON_e-diary) to record their RE and DBE. The CON will also be given a paper diary to record RE and DBE they have done if they prefer to use paper diary.
75943647|NCT03343431|Drug|Anti-HBV antiviral prophylaxis|Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum
75943648|NCT05324241|Dietary Supplement|Fat Microcapsules|Consumption of a drink that contains microencapsulated fat that will be released either in the stomach or in the distal small intestines.
75943649|NCT05309889|Other|no intervention|no intervention
75943650|NCT03464253|Device|Performance of the transcranial Doppler (TCD)|Within 24 hour before the operation, TCD is performed using Siemens Acuson X300 machine with ultrasound frequency is 1 - 5 MHz probe to measure Mean Velocity and Pulsatility Index in the right middle cerebral artery.postoperatively, TCD study is performed twice at 24h and 48h after spinal anesthesia. For 5 days postoperatively, the Patients are assessed clinically for the occurrence of headache. Patients who developed PDPH will be identified and their pre and post puncture measurements will be compared with the corresponding measurements of PDPH free patients.
75943651|NCT04327089|Drug|Setanaxib|Nox 1/4 inhibitor
75943652|NCT05302869|Other|None intervention|None intervention
75943653|NCT05301699|Other|data analysis; validating the nomogram|Not Applicable. Our study did not involve intervention
75943654|NCT03463863|Procedure|rectus sheath midurethral sling|
75943655|NCT03129789|Other|Volumetric Bladder Ultrasound Training|teaching residents to perform bladder volumetric ultrasound
75943656|NCT05150223|Other|traditional strength training|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband). Participation in the traditional strength training group will complete these exercises with a load and without time limitations and speed.
75943657|NCT05150223|Other|Power training|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
75803774|NCT05650502|Drug|saisonal malaria chimoprevention|Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection
75803775|NCT01311050|Drug|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
75943658|NCT05253105|Drug|TAB006|Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))
75943659|NCT05253105|Drug|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
75943660|NCT03463707|Drug|BP101|Investigational product BP101, nasal spray
75943661|NCT03463707|Drug|Placebo|Placebo to Investigational product BP101, nasal spray
75943662|NCT05226897|Drug|YYC405-T|Subjects take the investigational products once a day for 24 weeks.
75943663|NCT05226897|Drug|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
75943664|NCT05226897|Drug|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
76091458|NCT01963078|Drug|Oxytocin|
75803776|NCT03719534|Procedure|haplo-HCT|HCT will be performed with a haploidentical donor
76091459|NCT01963078|Drug|Placebo|
76091460|NCT03269760|Drug|Zolpidem|Addition of both non-pharmacologic nursing directed sleeping hygiene practices with pharmacologic zolpidem to improve sleep latency
75656634|NCT05105789|Diagnostic Test|"Lollipop swab"|A lollipop swab, is an oral swab to collect saliva, sucked on like a lollipop for 20 seconds.
75943665|NCT05226897|Drug|YYC405-T placebo|Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
75943666|NCT05224635|Procedure|Vascular Injury|The Society of Vascular Surgery has established a robust vascular disease registry but this organization's focus is on vascular disease and lacks capture of the data points necessary to discern trauma-specific outcomes. Recent military experience from the United States and United Kingdom, including the Balad Vascular Registry and the Global War on Terror (GWOT) Vascular Registry have provided a contemporary assessment of wartime vascular injury, but again these studies have been retrospective case series and registry reviews. Furthermore, applications of lessons learned in wartime vascular injury do not completely translate to management in trauma centers in the United States.
75943667|NCT04453761|Drug|Neurobion|Intravenous Thiamine 2 mg/kg in Neurobion injection
75943668|NCT04453761|Drug|Placebo|Intravenous NaCl0.9%
75943669|NCT03463629|Other|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
75943670|NCT03463629|Other|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services
76091461|NCT03269916|Other|Anti Mueller hormone|used to assess ovarian reserve parameters
76091462|NCT03269916|Other|Estrogen|used to assess ovarian reserve parameters
76091463|NCT03269916|Other|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
76091464|NCT03269916|Other|Antral alveolar cell count|used to assess ovarian reserve parameters
75656635|NCT05105035|Drug|Ceftazidime or meropenem|Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital
75656636|NCT05105035|Drug|ARV-1801|Patients will be prescribed ARV-1801 at 1500mg 12 hours apart on Day 1 and 600mg every 12 hours for Days 2-14.
75656637|NCT05105035|Drug|Placebo|Patients will be prescribed placebo every 12 hours for Days 1-14.
75803777|NCT03719534|Procedure|haplo-cord HCT|Haploidentical donor HCT will be performed with coinfusion of unrelated cord blood unit
75803778|NCT03700450|Drug|Cyclophosphamide|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
75803779|NCT03697642|Procedure|With nasopharyngeal airway|Nasopharyngeal airway is previously inserted into selected nostril. NG tube is properly lubricated and placed through Nasopharyngeal airway.
76091465|NCT01963234|Behavioral|Seva|Patients were given access to use Seva. This is a mobile application that uses social and behavioral theories to help support people after alcohol use disorder recovery.
76091466|NCT02457858|Drug|Islet isolation using BMX-010|BMX-010 will be used as a supplement in islet isolation process.
76091467|NCT02457624|Behavioral|Education and feedback|Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
75345529|NCT05945693|Dietary Supplement|Placebo|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule for 16 weeks.
75345530|NCT05945693|Dietary Supplement|Omega-3|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA for 16 weeks.
75345531|NCT05945693|Dietary Supplement|Aerobic exercise|The participants will perform aerobic-type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day for 16 weeks.
75345532|NCT05945667|Drug|Monural|1 sachet, only 1st day of trial
75656638|NCT05077956|Diagnostic Test|Cerebrospinal and Blood Serum Semaphorin 4A Levels|Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.
75656639|NCT05074121|Drug|N-acetylcysteine|N-acetylcysteine
75656640|NCT05074121|Other|Placebo|Placebo
75656641|NCT05053308|Drug|Intravenous Infusion|IV PCA(fentanyl) Fentanyl bolus = MME * 15%
75656642|NCT05053308|Drug|Sublingual Tablet|subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
75803780|NCT03697642|Procedure|Without nasopharyngeal airway|NG tube is properly lubricated and placed into selected nostril
75803781|NCT03624556|Dietary Supplement|EGCG FontUp|Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.
75803782|NCT03624556|Other|Placebo FontUp|Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
76091468|NCT02346916|Drug|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
76091469|NCT01964092|Behavioral|Individual Placement and Support|
76091470|NCT01964092|Behavioral|Ordinary employment schemes|
75345533|NCT05945667|Dietary Supplement|UroNext|1 sachet per day for the first 7 days, followed by 7 days break Same scheme to be repeated for 3 months
75345534|NCT05945654|Procedure|Anastomotic Leak after Ivor Lewis Oesophagectomy|Surgical resection of the esophagus with oesophagogastrostomy. Groups depend on postoperative complication
75345535|NCT05945628|Behavioral|Different cognitive and memory demands during the memory experiment|Study conditions will involve attempting to memorize visual scenes, attempting to memorize arrays of visual objects, viewing in a self-directed manner, viewing in a passive other-directed manner, and making memory judgments about whether stimuli are studied versus novel.
75656643|NCT05025462|Dietary Supplement|Supplement dose 15g/d|Supplementation with 15g/day of SPF or Comparator
75345536|NCT05945628|Other|Different electrical stimulation parameters during cognitive and memory demands|Study conditions will involve different parameters for electrical stimulation delivered through iEEG electrodes, including the presence of stimulation (no stimulation versus stimulation) and the location of stimulation (hippocampus versus amygdala).
75345537|NCT05945589|Behavioral|Singapore A-Health Intervention|The Singapore A-Health Intervention spanned 12 weeks, with each weekly session lasting for two hours. The program is structured around three thematic domains of the past, present, and future. In each thematic domain consisting of four weeks, participants were tasked with creating an artwork related to the theme and incorporating the learned art techniques. The structure of each thematic domain follows the same structure: the first week involved a 45-minute docent-led gallery tour on three selected pieces of artworks, followed by a 75-minute artist-led brainstorming session where participants were introduced to the techniques and discuss ideas on the artwork to be created. The subsequent three sessions involved further guidance from the artist and a scaffolded delivery of art techniques for participants to incorporate their learning to their artwork. At the end of each domain, there was a showcase where participants present their artwork.
75345538|NCT05945537|Drug|INI-822 (A)|Different dose levels of INI-822
75656644|NCT05025462|Dietary Supplement|Supplement dose 7.5g/d|Supplementation with 7.5g/d of SPF ou comparator
75656645|NCT05025332|Drug|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
75656646|NCT05012397|Drug|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
75656647|NCT05011851|Drug|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
75656648|NCT05005117|Procedure|Laparoscopic operation|Operation
75803783|NCT03700294|Drug|ADCT-601|Intravenous (IV)
75803784|NCT03703024|Dietary Supplement|Raspberry Leaf Extract|Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.
75803785|NCT03703024|Dietary Supplement|Placebo|Delivered in a capsule
75943671|NCT03463551|Drug|ABL-101|ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.
75943672|NCT03463551|Other|0.9% NaCl|Placebo
75943673|NCT03463395|Device|Reza band|Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
75943674|NCT03463317|Device|CE-mark approved LAA closure devices|LAA closure with post procedure treatment
75943675|NCT03463317|Drug|Acetylsalicylic acid|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
75656649|NCT05005117|Procedure|Open operation|Operation
75656650|NCT04996511|Device|PulseOn|Postoperative HRV measurement
75672345|NCT02656134|Procedure|Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.
75672346|NCT02656134|Genetic|Molecular analysis.|DNA analysis
75803786|NCT03702946|Other|oxytocin in abdominal myomectomy|Women were divided into two groups randomly. In the study group 30 Units of oxytocin in 1000 ml normal saline were given during surgery, at the rate of 15units/hour. In control group, pure normal saline was given
75943676|NCT03463317|Drug|Clopidogrel|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
75943677|NCT03463317|Drug|Dabigatran|Patients allocated to the best medical care group receive either NOAC therapy or VKA
75943678|NCT03463317|Drug|Rivaroxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
75943679|NCT03463317|Drug|Apixaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
75943680|NCT03463317|Drug|Edoxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
75943681|NCT03463317|Drug|Phenprocoumon|Patients allocated to the best medical care group receive either NOAC therapy or VKA
75943682|NCT03463317|Drug|Warfarin|Patients allocated to the best medical care group receive either NOAC therapy or VKA
75943683|NCT03462147|Device|Spinal cord stimulation|Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
75943684|NCT02906579|Drug|Matching Placebo|
75943685|NCT02906579|Drug|IW-1973|
75943686|NCT03461913|Procedure|Cesarean section|Lower segment elective Cesarean section
75943687|NCT04975347|Drug|kisspeptin 112-121|Six IV doses of kisspeptin 112-121
75943688|NCT04975347|Drug|GnRH|Two IV doses of GnRH
75943689|NCT04975347|Drug|Naloxone|One bolus and one infusion of naloxone
75943690|NCT03463083|Drug|Dexmedetomidine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgery an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~The pain score, by using VAS~Onset of analgesia (fall of VAS<4 ).~Peak level of analgesia ( VAS score 0).~Duration of analgesia (once the patient asks fwith VAS>4).~Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension."
75656651|NCT04983862|Drug|Illuminare-1|Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Dose levels of the agent will be administered starting at 0.25mg/kg, with increases in dose between cohorts of no more than 0.5 mg/kg until a maximum dose of 2.25mg/kg is reached, if needed. At the dose identified to have the acceptable NMR and no associated DLTs, Illuminare-1 will be studied in up to 20 additional patients at this dose to optimize the imaging protocol and provide additional safety data.
75656652|NCT04983862|Device|Karl Storz D-Light C photodynamic diagnostic (PDD)|The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.
75656653|NCT04971057|Other|multimedia information program of renal biopsy|Multimedia information program is based on self-efficacy theory. The multimedia videos contain the information associated with renal biopsy, which including the purpose, indications, preparations for the examination, process, patient experience sharing, complications, precautions, home care and stress adjustment strategies.
75656654|NCT04969991|Drug|Varespladib|250 mg immediate-release oblong, white, film-coated tablet for oral administration
75803787|NCT04491526|Drug|TAMSULOSIN Mepha Ret Depocaps 0.4 mg|"0.4mg/day Tamsulosin hydrochloride (TAMSULOSIN Mepha Ret Depocaps 0.4 mg) from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)"
75803788|NCT04491526|Drug|Control Intervention|One placebo capsule matching the active study drug per day from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)
75803789|NCT03699982|Other|Daily calorie target based on resting energy expenditure|"Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.~Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake."
75803790|NCT03699904|Drug|Valaciclovir|Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.
75803791|NCT03699904|Drug|Placebo capsules (containing Avicel blend)|Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
75803792|NCT03697486|Behavioral|diet with different composition|"Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
75803793|NCT03697330|Drug|Ringer lactate|"Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood."
75803794|NCT03697174|Other|200 ppb ozone group|The exposure group will be exposed to 200 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 ~ 27 L/min(approximately equal to 15 ~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
75943691|NCT03463083|Drug|Bupivacaine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~The pain score, by using VAS~Onset of analgesia (fall of VAS<4 ).~Peak level of analgesia ( VAS score 0).~Duration of analgesia (once the patient asks fwith VAS>4).~Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension."
75345539|NCT05945537|Other|Placebo (B)|Matching placebo to INI-822
75803795|NCT03697174|Other|0 ppb ozone group|The control group will be exposed to 0 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 ~ 27 L/min(approximately equal to 15 ~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
75803796|NCT03702712|Behavioral|Aerobic Exercise and Relaxation|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of mindfulness training.
75345540|NCT05945524|Other|Bone marrow sampling|Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)
75345541|NCT05945498|Biological|TB/Flu-05E vaccine|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the TB10.4 and HspX antigens of M. tuberculosis
75345542|NCT05945498|Biological|Placebo|Participants will receive single intranasal injection of placebo buffer solution
75943692|NCT03463083|Drug|Fentanyl|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~The pain score, by using VAS~Onset of analgesia (fall of VAS<4 ).~Peak level of analgesia ( VAS score 0).~Duration of analgesia (once the patient asks fwith VAS>4).~Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension."
75943693|NCT04971837|Dietary Supplement|Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate
75943694|NCT04971837|Dietary Supplement|Cannabidiol (CBD) Oil based tincture formulation|30 mg CBD isolate in MCT oil (1:1 ratio of CBD to Medium Chain Triglycerides oil)
75943695|NCT04971837|Dietary Supplement|Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation|10% CBD Gum Arabic, maltodextrin base
76091471|NCT03274362|Behavioral|Headspace Mindfulness App|Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
76091472|NCT04349176|Drug|Dose|Randomized to either 100U or 155U
75345543|NCT05945459|Dietary Supplement|High-calorie density formula (1 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
75345544|NCT05945459|Dietary Supplement|Standard formula (0.67 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
75476746|NCT05697679|Behavioral|Contral group|One or two times each week, participants in the control group will get general lifestyle advice through SMS. They will not participate in the intervention's fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group's complaints or questions will always be answered with basic health information and suggestions. Researchers won't ask for individual advice or comments from other professionals.
75803797|NCT03702712|Behavioral|Aerobic Exercise Only|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of quiet rest.
75803798|NCT03702712|Behavioral|Relaxation Only|This intervention will combine 20 minutes of mindfulness-based relaxation training followed by 20 minutes of quiet rest.
75476747|NCT05694767|Drug|CM313 Injection|"intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
75656655|NCT04969991|Drug|Placebo|Oral formulation matched to the oral varespladib tablet
75656656|NCT04964778|Device|SKED©|A SKED device is lightweight plastic stretcher used for moving patients through difficult terrain.
75656657|NCT04960618|Drug|Gemcitabine|Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles
75656658|NCT04960618|Drug|Pembrolizumab|Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles
75943696|NCT04971837|Dietary Supplement|Cannabidiol (CBD) Gum Arabic, sorbitol base formulation|10% CBD Gum Arabic, sorbitol base
75656659|NCT04954664|Biological|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
75943697|NCT04971837|Dietary Supplement|Cannabidiol (CBD) Isolate in water formulation|formulation
75943698|NCT04971837|Dietary Supplement|CBD matching Placebo|Matching Placebo
75656660|NCT04954664|Biological|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane
75656661|NCT04948307|Device|OXD01 digital therapy|OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.
75656662|NCT04948307|Other|Standard of Care|sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling
75672347|NCT02830061|Other|Interviews|Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
75943699|NCT03465189|Device|Medtronic LINQ Device|Using two LINQ devices that are fixed to scalp to record EEG (in addition to the standard scalp EEG).
75943700|NCT01328535|Drug|temozolomide|Given PO
75943701|NCT01328535|Other|flow cytometry|Correlative studies
75943702|NCT01328535|Other|staining method|Correlative studies
75943703|NCT01328535|Procedure|biopsy|Optional correlative studies
75943704|NCT01328535|Other|laboratory biomarker analysis|Correlative studies
75943705|NCT03129633|Other|Intervention group|One-on-one contact with a promotor(a) over the 6 month intervention.
75943706|NCT03461679|Procedure|Adductor canal block|Single shot block with 0.5% bupivacaine 10mls
75943707|NCT03461679|Procedure|Femoral triangle block|Single shot block with 0.5% bupivacaine 10mls
75943708|NCT03461601|Procedure|HCG Uterine flushing|HCG Uterine flushing was done one day before IUI with HCG (500 IU) in 10 ml of saline.
75943709|NCT03461601|Procedure|IUI|Intrauterine insemination (IUI)
75943710|NCT03461601|Procedure|Vaginal flushing with 10 ml normal saline|Flushing of the vagina with 10 ml of saline
75943711|NCT03463005|Other|Royal jelly|The study subjects in the Royal jelly group used 10 ml of the vaginal Royal jell few minutes before and few minutes after intercourse one day after the end of menstruation for two weeks.
75943712|NCT03463005|Procedure|IUI|Subjects in IUI group received 75 units of FSH from the second day of the cycle.
75803799|NCT03699592|Behavioral|Reach Home and Read Toolkit|The toolkit currently includes one age-appropriate book along with a set of educational pamphlets explaining the importance home literacy. These educational materials focus on appropriate literacy milestones and descriptions of how parents can engage with their children around books. In addition, we will create an information sheet outlining zipcode-specific community literacy resources, including location and information on how to access the library, where to obtain low-cost books, and a schedule of literacy promotion activities in their community (e.g. community reading sessions). All materials will also be translated into Spanish by a certified interpreter, and will be reviewed to ensure that they are written at a fifth grade reading level. Additionally, EDCI families receiving this intervention will also receive an additional new book at each home visit conducted during the study period.
76091473|NCT03274128|Radiation|Radon therapeutic baths and inhalations|The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.
75345545|NCT05945446|Diagnostic Test|Galectin 3|Women diagnosed with Placenta Accreta Spectrum (PAS) were invited to join the study, providing they had no known systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. They also did not have cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection.
75803800|NCT03697018|Other|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
75345546|NCT05945433|Device|anovo™ Surgical System|The anovo Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS during single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.
75345547|NCT05945420|Drug|Desmopressin Acetate|This arm will receive tamsulosin and desmopressin acetate daily a
75656663|NCT04936607|Procedure|Personalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; >18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio <2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
75803801|NCT03699514|Device|Brain Network Activation (BNA™) technology|"The BNA™ technology was developed and is utilized by ElMindA Ltd. The BNA Analysis System is cleared for use by qualified medical professionals for the post hoc statistical analysis of the human electroencephalogram (EEG), utilizing evoked response potentials (ERP'). This device is indicated for use in individuals 14 to 24 years of age. The BNA Analysis System is to be used with the auditory oddball task only."
75803802|NCT04483804|Combination Product|Endocrine therapy|Endocrine therapy
75943713|NCT04949061|Behavioral|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This trans-diagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase quality of life by targeting cognitive and behavioral changes.
75943714|NCT04949061|Other|Enhanced Treatment as Usual (ETA-U)|Participants who receive ETAU will be provided a brief psychoeducation via online leaflets and will be informed about centers where they can receive free psychosocial support.
75345548|NCT05945420|Drug|Placebo|This arm will receive tamsulosin and placebo
75656664|NCT04936607|Procedure|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
75656665|NCT04900792|Drug|Ferumoxytol injection|Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.
75656666|NCT04900792|Drug|Pharmacological ascorbate|Intravenous ascorbate
75943715|NCT02905331|Drug|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
75943716|NCT02905331|Drug|Placebo|Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
75943717|NCT02522169|Drug|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A< 6month, group B < 6 month). Observation period is one year."
75943718|NCT04307537|Procedure|Post-urethroplasty urethrography|Imaging of the urethra after reconstructive surgery to identify contrast leakage (no, insignificant, signficant).
75943719|NCT03656393|Drug|Gefitinib|Gefitinib (250 mg, orally, every day) for 56 days
75943720|NCT03656393|Drug|Vinorelbine|Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
75354695|NCT04760353|Dietary Supplement|Probiotic mixture (OMNi-BiOTiC STRESS)|OMNi-BiOTiC STRESS containing 9 human bacterial strains [Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)] and vitamin B (B2, B6, B12),
75943721|NCT03656393|Drug|Carboplatin|Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
75943722|NCT03656237|Other|Usual Training|Training in a classroom setting of health care providers
75943723|NCT03656237|Other|Audits + LDHF Training|Clinical audits followed by case-based low-dose high-frequency training
75943724|NCT03656003|Device|Procore biopsy needle|EBUS-TBNA with the EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
75943725|NCT03656003|Device|Conventional biopsy needle|EBUS-TBNA with the conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
75943726|NCT02979197|Drug|OE 10 mg amlodipine besylate tablet|
75943727|NCT02979197|Drug|OE 200 mg celecoxib capsule|
75943728|NCT02979197|Drug|Matched placebo for OE amlodipine besylate tablet|
75943729|NCT02979197|Drug|Matched placebo for OE celecoxib capsule|
75943730|NCT02982239|Behavioral|Sleep Diary|All 40 chosen students will be provided a link to complete a daily sleep diary for 10 weeks. Sleep diary will assess activity before bed, bedtime, time to fall asleep, number of awakenings, time awake after sleep onset, time out of bed, time of final awakening, perceived sleep quality. Diary also asks about naps taken during the day, caffeine and tobacco consumption, and an additional space for open-ended comments from the participant.
75943731|NCT02982239|Device|Fitness tracker|All 40 chosen students will receive a fitness tracker. The fit bit will estimate sleep and physical activity as well as adherence to the program. participants will have access to their own data. Data will also be monitored from the lab using Fitabase which provides access to day, hour, and minute-level resolution of data for steps taken, intensity class, calories burned, and sleep (length, movement, and quality).
76091474|NCT03274128|Procedure|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
75803803|NCT04373122|Device|REBOA|Resuscitative Endovascular Balloon Occlusion of the Aorta
75803804|NCT03696940|Drug|L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg|Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
76091475|NCT04329546|Other|NA (no intervention)|NA (no intervention)
75354696|NCT04760353|Other|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~Powder portion bags are suitable for participants with intolerance to yeasts or lactose~Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
75656667|NCT04900792|Radiation|External beam radiation therapy|Photon based, focal radiation therapy delivered consistent with national guidelines, standard for treatment of GBM.
75656668|NCT04900792|Drug|Temozolomide|Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.
75656669|NCT04890223|Behavioral|Brief MI intervention|Brief MI intervention
75803805|NCT03696940|Drug|Atorvastatin 10mg|Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
75803806|NCT03696862|Procedure|free gingival graft|Use of free gingival graft to seal the socket after flapless atraumatic tooth extraction is performed, implant placement and filling the socket with bone graft.
75656670|NCT04890223|Behavioral|Placebo intervention|Generic health advice consultations and self-help smoking cessation booklets
75656671|NCT04882202|Drug|Acetaminophen|Acetaminophen 1g IV every 6 hours for a weight > 50kg (maximum of 4g per 24 hours) or 15mg/kg every 6 hours for a weight < 50kg (maximum of 75mg/kg per 24 hours)
75803807|NCT03699436|Other|Electrotherapy with Galvanic Current|The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period. They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.
75943732|NCT02982239|Device|Blue-Blocking Glasses|Half of the 40 chosen students (N=20) will be provided with blue blocking glasses. The blue-blocking glasses will ensure that blue light from electronic devices will not interfere with circadian rhythm or sleep onset, and allow students to fall asleep earlier.
75656672|NCT04882202|Other|Placebo|Normal saline 100 ml (equal amount of acetaminophen) IV every 6 hours
75656673|NCT04875754|Genetic|ICM-203|Intra-articular injection
75656674|NCT04875754|Drug|Placebo|Intra-articular injection
75656675|NCT04869670|Procedure|Gastric peroral endoscopic myotomy.|Under propofol anesthesia, EndoFLIP will be used to assess pyloric diameter and distensibility, prior to and after G-POEM, performed by an endoscopist skilled in this technique. After the procedure, the patient will be observed in the hospital for 2 days. Patients will undergo an upper GI series the next day to rule out perforation. If the patient develops a complication from the procedure, he or she will be managed per standard clinical practice by the treating (unblinded) endoscopist.
75943733|NCT02982239|Device|LED light|Half of the 40 chosen students (N=20) will be provided with a bright LED light. The bright LED light will provide bright blue light in the morning to help students wake and an amber light to promote earlier bedtimes.
75943734|NCT02982239|Other|Information Session|"all 40 participants will attend a 1-hour information session about sleep delivered by the PIs, to be followed by a 1-hour Q&A period.~Peer educators will receive and extra 1-hour training session on how to handle questions and when to refer back to the PIs."
75943735|NCT02982239|Behavioral|Text messages|All participants will receive text messages in the evening that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action without being overly repetitive or predictable.
75943736|NCT03655925|Diagnostic Test|plasmatic HLA-G|plasmatic HLA-G by blood sample
75943737|NCT03655535|Drug|BTI320|Non-systemic galactomannan complex polysaccharide
75943738|NCT03655535|Other|Placebo|Placebo
75943739|NCT03654365|Other|Bulk ordering and bulk messaging|Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.
75943740|NCT03654365|Other|Routine alerting|Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
75803808|NCT03699436|Other|Control without Electric Stimulation Therapy|The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment. They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
75943741|NCT03654287|Other|Treatment|The CELS way to intervene severe sepsis and refractory shock
75943742|NCT03655847|Drug|Dexmedetomidine|Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
75943743|NCT03655457|Device|group 1 Poractant alfa|Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
75943744|NCT03655457|Device|group 2 beractant|lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
75943745|NCT03653975|Other|no intervention|no intervention
75943746|NCT03655379|Device|Fetal nasal Doppler by ultrasonography|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns and measurements will be performed
75943747|NCT01066793|Drug|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
75943748|NCT01066793|Drug|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
75354697|NCT04743141|Drug|Rimegepant / BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
75943749|NCT03985293|Drug|Placebo|4 matching placebo tablets taken twice a day (BID)
75943750|NCT03985293|Drug|PF-06882961|Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
75943751|NCT03655145|Other|Haplo donor stem cell transplantation|The algorithm for selection of haploidentical donor has been defined by the french society for stem cell transplantation The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
75656676|NCT04869670|Procedure|Sham Gastric peroral endoscopic myotomy.|Patients assigned to the sham procedure will be treated identically as above, except for the performance of the G-POEM. Endoscopy and EndoFLIP will be performed and sedation will be stopped when the upper endoscopy is completed. Since sham endoscopy is expected to take less time than G-POEM, the patient should remain in the endoscopy procedure room for a minimum of 30 minutes (including the time required to complete the upper endoscopy). After the procedure, the patient will be observed in the hospital for 2 days. All patients will undergo an upper GI series radiographic examination the next day to rule out perforation in order to maintain study blind.
75656677|NCT04864405|Other|Morning administration of endocrine therapy|Endocrine therapy administered within one hour of patient wake up time
75656678|NCT04864405|Other|Evening administration of endocrine therapy|Endocrine therapy administered within one hour of the patient bed time
75656679|NCT04853888|Behavioral|ATTACH™ Parenting Program|"ATTACH™ parenting program offers an innovative, novel approach to early intervention, focusing on improving parent-child relationship quality by targeting parents' underlying reflective function (RF)-the ability to better understand one's own and one's child's thoughts and feelings. RF is essential for high quality parent-child relationships and secure parent-child attachment, both tied to child development and health, especially cognition, communication and inflammation.~."
75943752|NCT03655145|Other|HLA 10/10 MUD stem cell transplantation|HLA 10/10 matched unrelated donor myeloablative transplantation
75656680|NCT04822350|Drug|Avelumab|As provided in real world practice
75803809|NCT04694560|Other|Treatment Free Observation|Participants without evidence of clinical relapse will remain off therapy and continue serial monitoring through end of study at 24 cycles. Participants with clinical relapse will continue to be monitored off therapy through 24 cycles or until meeting criteria for treatment per iwCLL criteria. If participants experience clinical relapse requiring treatment, radiology assessment, disease assessment, and testing for resistance mutations will be performed. Participants will be observed for an additional 12 cycles following start of reintroduction of therapy.
75943753|NCT03654911|Diagnostic Test|EEG|EEG
75354698|NCT04738708|Other|Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients are given a series of questions evaluating cognitive and psychosocial outcomes, either via hardcopy in-person or online internet-facing questionnaire.
75943754|NCT03654911|Genetic|ApoE|ApoE
75943755|NCT03654755|Drug|ASN002|Daily dose of ASN002 for up to 110 weeks
75943756|NCT03654677|Biological|inactivated hepatitis A vaccine|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
75943757|NCT03654677|Biological|Havrix Inj|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
75943758|NCT03468621|Procedure|Wound closure|Method of wound closure
75943759|NCT03653897|Device|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
75943760|NCT03653897|Device|Wearable Sensor|Subjects will wear an ID-Reader
75345549|NCT05945407|Combination Product|Indication-extended Fertility-sparing Therapy|"Patients will receive medroxyprogesterone acetate (FARLUTAL) 250-500mg/d or megestrol acetate (YiLiZhi) 160-320mg/d orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (Mirena) and gonadotropin-releasing hormone agonist (Leuprorelin, Goserelin or Triptorelin) 3.75mg/28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (Mirena, Progesterone, Dydrogesterone, or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions."
75345550|NCT05945381|Combination Product|GIC on MIH|Subjects will be seated in a dental chair set-up using standard infection control guidelines. Then the study and its objectives will be explained to the patients and their caregivers. The tooth will be cleaned with a prophylactic paste and brush for complete debris and plaque removal. The tooth will then be dried with a cotton roll, as the patient doesn't tolerate the air-drying (which is the case in SCASS 2 and 3). Moisture control will be kept with cotton roll, the tooth is then sealed with a hard setting glass-ionomer cement (IonoStar Plus, VOCO, Germany) followed by an application of a surface coat (Easy Glaze, VOCO, Germany) for moisture and dehydration protection after sealant application. The distributed questionnaire will include questions regarding the attitude of the child's caregiver to the idea and their estimation of the child's fair regarding dental visit.
75345551|NCT05945368|Drug|Eribulin mesylate injection、Pertuzumab、Trastuzumab|"Eribulin mesylate, 1.4 mg /m², day 1 and day 8;~Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1;~Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1; There are four cycles in 21 days"
75656681|NCT04801615|Other|Surgery|All patients in the database undergo surgery due to a suspicion of necrotizing soft tissue infections
75656682|NCT04782245|Drug|Dapagliflozin 10mg|The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
75803810|NCT03696706|Radiation|LED photobiomodulation|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
75803811|NCT03696706|Radiation|Placebo LED photobiomodulation|In this group, the same procedures as the LED group will be made, but the device will be turned off.
75943761|NCT03462849|Other|increase in positive end expiratory pressure|increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O
75656683|NCT04782245|Drug|Placebo|Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
75656684|NCT04775108|Device|Epygon™ Transcatheter Mitral Valve System|"The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.~The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent."
75656685|NCT04751201|Behavioral|Mindfulness open and circular program|"At the end of the first and the last cycle, as well as 3 weeks after the last cycle, the patient will be invited to answer different questionnaires evaluating his or her quality of life (HADS, QLQC30, FA12). This is why the observation period is 3 months (3 cycles of 3 weeks + 3 weeks).~Similarly, some of the patients included in the study will be asked to complete a semi-structured interview at the end of the MAEva programme.~Patients and nursing staff participating in the study will be asked to complete a satisfaction questionnaire"
75672348|NCT02830139|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.
75943762|NCT02980601|Device|Integra plus STSG|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
75943763|NCT02980601|Procedure|STSG|0.012mm STSG
75943764|NCT03462771|Drug|Fish oil|4g of fish oil daily for 14 weeks
75943765|NCT03462771|Drug|sunflower oil|4g of sunflower oil daily for 14 weeks
75943766|NCT04453371|Drug|Tissue plasminogen activator|"In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
75943767|NCT04453371|Drug|Ringer solution|"In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
75943768|NCT03461133|Other|Intervention|The emergency notification system is linked to a paging system to the surgeon in charge and to the Hospital Medical Emergency Team. Depending on individual Multiparameter Early Warning Score communication protocols are activated.
75803812|NCT03731442|Radiation|Involved field irradiation|Involved field irradiation; intensity-modulated radiation therapy
75476748|NCT05694637|Behavioral|Screening, Brief Intervention and Referral to Treatment (SBIRT) intervention consisting of the 5As, (Ask, Advise, Assess, Assist, Arrange)|"Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline."
75345552|NCT05945342|Drug|Fluoxetine|The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression
75803813|NCT03731442|Radiation|Elective field irradiation|Elective field irradiation; intensity-modulated radiation therapy
75943769|NCT03654521|Diagnostic Test|Fetal interventricular septum thickness|Two-dimensional ultrasound fetal cardiac imaging test
75943770|NCT03462693|Other|Dry needling|The DNHS® dry-puncture technology is specifically marked for stroke patients. the muscle to be treated is placed in a submaximal position; the needle is inserted into the present tense bandage and mobilized in the inside and outside for about 1 minute or until the reaction of global spasm ceases
75943771|NCT03462615|Diagnostic Test|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
75943772|NCT03462537|Device|Low level laser therapy|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes.
75943773|NCT03462537|Device|Aerobic Exercise|Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.
75943774|NCT03462537|Device|Low level laser therapy without power|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
75943775|NCT03461055|Other|Lavender|Lavender aromatherapy
75943776|NCT03461055|Other|Water|Water
75943777|NCT03462381|Dietary Supplement|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
76091476|NCT01966354|Procedure|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
76091477|NCT02459028|Behavioral|Positive Psychology intervention|"Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
75345553|NCT05945342|Other|Interpersonal Psychotherapy for Adolescent|Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.
75943778|NCT04928157|Device|Positive Airway Pressure (PAP)|A device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
75656686|NCT04750707|Drug|Hydroxyurea|The study intervention will be daily oral Hydroxyurea given in single doses starting at approximately 20mg/kg/day and escalated to a maximum 30mg/kg/day depending on clinical need and according to standard guidelines.
75656687|NCT04748809|Other|Diet 1|Dietary intervention
75656688|NCT04748809|Other|Diet 2|Dietary intervention
75672349|NCT02830139|Procedure|Radical colorectal resection|radical colorectal resection with lymphadenectomy
75672350|NCT02830139|Drug|Oxaliplatin , Capecitabine|XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
75345554|NCT05945342|Other|Fluoxetine combined with psychotherapy|The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication
75345555|NCT05945342|Other|Fluoxetine combined with rTMS|The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication
75672351|NCT02830139|Drug|Normal saline , Cisplatin , 5-Fu|
75672352|NCT02651766|Procedure|Cupping massage|Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
75803814|NCT03731442|Drug|Paclitaxel|Paclitaxel 135-150mg/m2, d1, every 3 weeks
75803815|NCT03731442|Drug|Platinum|for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;
75803816|NCT03731442|Drug|PEG-rhG-CSF|PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
75803817|NCT03702478|Other|Questionnaire|No intervention only observational
75803818|NCT03739320|Drug|Mepolizumab 100 MG Injection [Nucala]|100 milligrams subcutaneously once every 4 weeks
75943779|NCT03462303|Combination Product|Sham tDCS and tyrosine depleted drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.
75943780|NCT03462303|Combination Product|Anodal tDCS and tyrosine depleted drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.
75943781|NCT03462303|Combination Product|Sham tDCS and balanced drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
75943782|NCT03462303|Combination Product|Anodal tDCS and balanced drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
75656689|NCT04743921|Device|Reparel Knee Sleeve|Patients who are recommended for non-operative management of knee osteoarthritis and have been consented in clinic to participate in the study will be given a Reparel™ knee sleeve to wear for knee osteoarthritis management. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Reparel™ knee sleeve, patients will be given instructions on how to use/wear the sleeve while performing activities of daily living or sports that had previously resulted in knee pain and also be asked to do the follows: wear the sleeve as much as they possibly can; not change their usual activities and diet during the time they are on this study; record in a diary the number of hours sleeve was worn per day; record any adverse eﬀects or discomfort due to sleeve use; refrain from altering treatment for knee osteoarthritis.
75803819|NCT03702400|Drug|Phenylephrine 100 mcg|Phenylephrine at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug, 5 mL each bolus
75803820|NCT03702400|Drug|Norepinephrine 5 mcg|Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
75803821|NCT05666388|Procedure|Rescue stenting|Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RES
75803822|NCT03699202|Drug|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
75803823|NCT03699202|Drug|Placebo|The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
75803824|NCT03598140|Drug|Sildenafil Citrate|Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
75803825|NCT03598140|Drug|Placebo oral capsule|Placebo once (Group 1) or daily for 2 weeks (Group 2)
75803826|NCT03733236|Device|ISS Active Stimulation|ISS SPG stimulation and standard of care
75803827|NCT03733158|Device|the standard Bougie stylet for difficult intubation|intubation with the standard Bougie stylet for difficult intubation and endotracheal tube 7.0 internal diameter
75803828|NCT03733158|Device|The new Flexible Tip Bougie catheter|intubation with The new Flexible Tip Bougie catheter and endotracheal tube 7.0 internal diameter
75803829|NCT03639870|Device|Model iS3 three-stent trabecular micro-bypass system|Provided in Arm/Group descriptions.
75803830|NCT03644550|Drug|LMB-100|Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles.
75803831|NCT03644550|Biological|Pembrolizumab|Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
75803832|NCT03738930|Behavioral|AI based mHealth system|AI based mHealth system is used to deliver self-management contral message and health education message to make patients take notice of bleeding events after PCI.
75803833|NCT03716414|Procedure|SLN mapping|"Intra-operative SLN mapping with indocyanine green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and Arms Assigned Interventions another 1ml will be injected superficially (2mm-depth).~The time between the injection and the search for SLN must be as soon as possible."
75803834|NCT00054717|Drug|Tipranavir|
75345556|NCT05945342|Drug|Fluoxetine combined with sham rTMS|The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication
75345557|NCT05945251|Other|Internet-delivered cognitive behavioral therapy|Ten weekly modules for children and ten weekly modules for parents. Exposure-based cognitive behavioral therapy delivered online with asynchronous support via text messages from psychologists.
75345558|NCT05945238|Other|Thrower's Ten Exercise Program|T10 group were given thrower's ten exercises 3 times per week for 10 weeks, each exercise being 2x10 repetitions.
75345559|NCT05945199|Device|tDCS|"1 session/day for 5 consecutive days~stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group"
75803835|NCT00054717|Drug|Ritonavir(r)|
75803836|NCT00054717|Drug|Comparator Protease Inhibitor (CPI)|
75803837|NCT03721718|Biological|GLS-5300|[Part A] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) [Part B] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)
75803838|NCT03721718|Device|Cellectra 2000 Electroporation|GLS-5300 administered ID followed by Cellectra 2000 Electroporation
75943783|NCT02980523|Drug|PRO-157|PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution
75943784|NCT02980523|Drug|Vigamox|Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution
75943785|NCT02980523|Drug|Zymar®|Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution
75943786|NCT02980523|Drug|Lagricel Ofteno®|Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
75345560|NCT05945199|Behavioral|Assessment of risk behaviours|Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
75943787|NCT03468465|Drug|Solifenacin Succinate|10 mg tablet daily during 75 days maximum
76091478|NCT02459028|Behavioral|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
75656690|NCT04731337|Device|Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the tip of the upper and lower canine teeth.
75803839|NCT03716336|Other|Resistance exercise|Resistance exercise were performed for all participants in group (A) only included 9 exercise for big muscles of upper limbs (shoulder flexors muscles, shoulder extensors and shoulder abductors), lower limbs (hip flexors, hip extensors and knee flexors and knee extensors) and abdominal muscle using moderate work load (60 - 75% of IRM) 1set of 10 repetitions, progressing to 2 sets of 10 repetitions after four weeks for 20 minutes
75803840|NCT03716336|Other|Aerobic exercise|aerobic exercise were performed on treadmill. For 20 minutes. All patients in both groups (A,B) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.
75803841|NCT03716336|Dietary Supplement|diet restriction|All participants in both groups (A,B) were instructed to follow a moderate restricted diet limited to (1800-2000) kcal/ day under supervision of a certified dietician. The diet contained: Protein and fibers: 20% carbohydrate: 50-60%, fat: low 20%.
75345561|NCT05945199|Other|Scales|EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
75345562|NCT05945186|Device|Intermittent Pneumatic Compression (IPC)(Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves)|External intermittent pneumatic compression (IPC) systems are applied to subject legs and comprise of a controller, associated tubing set and single patient use disposable leg sleeves. The disposable sleeves are latex free and contain air bladder(s) that are inflated by the controller to provide compression to the legs/feet. These devices are designed to increase venous blood flow in at risk patients in order to help prevent Venous ThromboEmbolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
75656691|NCT04644315|Drug|Alectinib|Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.
75656692|NCT04642898|Behavioral|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
75803842|NCT03430856|Drug|Insulin Tregopil|Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.
75803843|NCT03430856|Drug|Insulin Aspart|Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit
75803844|NCT01091025|Other|Glucose profile for 2 weeks|A study subject has an abnormal OGTT will be referred to a cystic fibrosis consultant who is not involved in the study.
75345563|NCT05945173|Procedure|Evaporation time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 5 seconds.
75656693|NCT04642898|Behavioral|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
75803845|NCT03731364|Drug|CA-008|5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)
75803846|NCT03731364|Drug|Placebo|Placebo
75656694|NCT04642898|Behavioral|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
75656695|NCT04629859|Procedure|mandibular setback and maxillary advancement|12 patients will undergo mandibular setback and maxillary advancement
75803847|NCT01097265|Drug|capecitabine|
75345564|NCT05945173|Procedure|Evaporation time for 25 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 25 seconds.
75656696|NCT04629859|Procedure|mandibular setback|12 patients will undergo mandibular setback
75656697|NCT04608877|Behavioral|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
75656698|NCT04608877|Behavioral|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
75803848|NCT01097265|Drug|oxaliplatin|
75803849|NCT01097265|Other|active surveillance|
75656699|NCT04597827|Other|Metacognition tests|Test on episodic or semantic memory
75803850|NCT01097265|Other|laboratory biomarker analysis|
75803851|NCT01097265|Procedure|adjuvant therapy|
75803852|NCT01097265|Procedure|lymph node mapping|
75803853|NCT01097265|Procedure|sentinel lymph node biopsy|
75656700|NCT04596098|Other|Blood sampling|During a care-related blood sampling, patient will provide additional blood sample for research purpuse.
75656701|NCT04594694|Drug|Obeticholic acid|5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily
75656702|NCT04594694|Drug|Bezafibrate 200 MG|200 mg IR tablet of Bezafibrate once daily for the remainder of the study
75803854|NCT03510182|Device|transcranial direct current stimulation|
75943788|NCT03468465|Device|Neuro-Muscular Stimulators (NMS)|Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
75943789|NCT04939233|Device|Exoskeleton glove|A robotic hand orthosis (exoskeleton glove) will have been developed that is able to naturalistically bend the finger joints of the individuals based on intuitive voice commands
75345565|NCT05945173|Device|alcohol/water-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an alcohol/water-based universal adhesive (Scotchbond Universal Plus; 3M).
75345566|NCT05945173|Device|acetone-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an acetone-based universal adhesive (Gluma Universal Bond; Kulzer).
75345567|NCT05945095|Other|Gum chewing group|The mothers in the experimental group, on the other hand, will chew sugar-free gum for at least 15 minutes, starting from the second hour after the surgery.
75345568|NCT05945082|Other|biopsy|biopsy of a colorectal cancer site
75345569|NCT05945056|Other|Frog Leg Exercise|The patient lies supine with legs flexed, knees apart and the soles of the feet put together on couch. The physiotherapist stands at the side of the table, moves one arm between the legs to place the hand under the sacrum and cup it. The fingers spread to accommodate the spinous process of the fifth lumbar vertebra. The tips of the fingers contact and grasp the junction of the fifth lumbar vertebra and the base of the sacrum. This hand will give traction in a caudal direction throughout the procedure to move the sacral base posteriorly and the apex interiorly. patient is asked to take a deep breath and hold it, while at the same time they steadily slide the feet downward toward the end of the table.Then patient brings their legs back to the frog leg position, but as they do so the therapist maintains traction preventing the sacrum from moving cephalad. Procedure is repeated for a total of 8 repetitions.
75345570|NCT05945056|Other|Electrotherapy(Transcutaneous Electrical Nerve Stimulator)|TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.
75803855|NCT01091181|Procedure|hysterotomy at cesarean|incision to open the uterus at cesarean.
75476749|NCT05694637|Drug|Varenicline|Referral to treatment with varenicline will be provided to those identified as needing more than a brief intervention. Participants will initiate medication treatment with varenicline for smoking cessation with a quit date scheduled for day 8 following first study dose of the medication. Participants will meet with the study clinician at baseline who will provide medical clearance and sign off on prescription orders. All medication will be provided to participants by the study team. Participants will receive a weekly supply of medication for the first four weeks to ensure proper dosing and monitor for adverse events. For the subsequent 8 weeks, participants will return every 4 weeks to receive the next month's supply of medication. Dosage adjustments will be permitted in an effort to control adverse effects throughout the trial. This will allow us to balance internal validity with good clinical practice. Varenicline will be dosed in accordance with package labeling.
75656703|NCT04594694|Drug|OCA Placebo|One tablet daily for the remainder of the study
75803856|NCT03738540|Behavioral|TALK study group|Telephone Delivered Intervention
75803857|NCT03738540|Behavioral|TALK control group|Telephone Delivered Intervention
75943790|NCT03460743|Biological|Study group - quadrivalent recombinant hemagglutinin influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
75345571|NCT05945056|Other|Exercise Therapy|Stretching of tight muscles(hip flexors and lower back extensors) Abdominal Curl-Ups and Bridging exercises.
75345572|NCT05945043|Other|Surface parasternal eletromyogram|The surface parasternal EMG of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
75656704|NCT04594694|Drug|Bezafibrate 200 mg Placebo|One tablet daily for the remainder of the study
75656705|NCT04594694|Drug|Bezafibrate 400 MG|400 mg SR tablet of Bezafibrate once daily for the remainder of the study
75656706|NCT04594694|Drug|Bezafibrate 400 mg Placebo|One tablet daily for the remainder of the study
75803858|NCT03731286|Dietary Supplement|Alpinia Galanga|2 capsules
75803859|NCT03731286|Dietary Supplement|Alpinia Galanga|2 capsules
75656707|NCT04594694|Drug|OCA|OCA one tablet will be administered.
75656708|NCT04594694|Drug|Bezafibrate|Bezafibrate one tablet will be administered.
75656709|NCT04586504|Drug|Intranasal midazolam|5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.
75656710|NCT04579900|Procedure|Endoscopy and duodenal biopsy and sampling|All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
75803860|NCT03731286|Dietary Supplement|Microcellulose crystalline|2 capsules
75803861|NCT00066807|Drug|chemotherapy|Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
75803862|NCT00066807|Drug|exemestane|Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
75803863|NCT00066807|Drug|tamoxifen|Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
75803864|NCT00066807|Drug|triptorelin|Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
75803865|NCT00066807|Procedure|oophorectomy|Bilateral surgical oophorectomy via laparotomy or laparoscopy.
75803866|NCT00066807|Procedure|ovarian irradiation|Bilateral ovarian irradiation.
75803867|NCT03619330|Drug|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
75966025|NCT02089451|Drug|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
75966026|NCT02340520|Drug|Theophylline|Oral
75943791|NCT03460743|Biological|Control group - quadrivalent inactivated influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
75943792|NCT02980133|Drug|Fluticasone Propionate|Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.
75943793|NCT02980133|Drug|Fluticasone Propionate/Salmeterol|Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.
75943794|NCT02980133|Drug|Placebo MDPI|Matching placebo was administered via MDPI per the schedule specified in the arm.
75943795|NCT03460665|Procedure|Arteriography|knee arteriography
75943796|NCT03654443|Diagnostic Test|Critical care pain observation tool|The CPOT tool is administered in a crossover manner by two study observers
75943797|NCT04867161|Diagnostic Test|Inflammatory markers sampling|"Laboratory sampling:~Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin)~BALF (bronchoalveolar lavage fluid) processing protocol:~microbiology: microscopic examination, standard cultivation test~biochemistry: albumin, total protein~Pathology: cytology~PCR:~a. Multiplex PCR b. SARS-CoV-2 RNA load"
75966027|NCT02340520|Drug|Roflumilast|Oral
75345573|NCT05945043|Other|Surface diaphragm electromyogram|The ipsilateral and contralateral surface diaphragm EMG of participants will be measured pre and immediately post pleural fluid removal
75803868|NCT03619330|Drug|Testosterone|In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
75345574|NCT05945043|Other|Parasternal muscle ultrasound|The thickness of the parasternal intercostal muscle of participants will be measured using thoracic ultrasound pre and immediately post pleural fluid removal
75345575|NCT05945043|Other|Breathlessness assessment|The VAS breathlessness score and Dyspnoea-12 questionnaire of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
75345576|NCT05945030|Other|Clinical Examination|T2DM patient visiting Fortis CDOC will undergo clinical examination to determine the grade of Xanthelasma.
75345577|NCT05945004|Other|ChatGPT-4|Subjects' clinical records will be read by ChatGPT-4 to write preoperative visit sheets.
75345578|NCT05945004|Other|Clinician|Subjects' clinical records will be read by clinicians to write preoperative visit sheets.
75345579|NCT05944991|Other|Olive oil message|Message of olive oil 2 times daily
75803869|NCT03428750|Biological|EN3835|Collagenase clostridium histolyticum
75345580|NCT05944952|Drug|buprenorphine/naloxone|Participants will be dosed with buprenorphine/ naloxone strips
75345581|NCT05944627|Biological|FURESTEM-OA Kit Inj.|FURESTEM-OA Kit Inj. is a combination medical product in which FURESTEM-OA Inj. (solution 1) is the primary mode of action and CAM Inj. (solution 2) acts as an auxiliary. The product is administered after mixing solution 1 and solution 2.
75803870|NCT03428750|Biological|Placebo|Placebo
75345582|NCT05944627|Biological|Placebo|placebo administration in Phase 2a clinical trial
75345583|NCT05944575|Device|active taVNS|The clip electrode will be attached to the cymba conchae of the left ear, the location of the auricular branch of the vagus nerve.
75345584|NCT05944575|Device|sham-taVNS|The clip electrode will be attached to the lobule of the left ear that is not innervated by the auricular branch of the vagus nerve.
75345585|NCT05944185|Drug|αPD1-MSLN-CAR T Cells|αPD1-MSLN-CAR T Cells
75354699|NCT04734821|Procedure|Near Infra-Red Fluorescence Guided Surgery|ICG injection around tumor each four direction by endoscopy followed by NIR fluorescence guidance laparoscopic or robotic esophagectomy or gastrectomy
75476750|NCT05687253|Drug|BX1000|IV BX1000
75476751|NCT05687253|Drug|Rocuronium Bromide|IV Rocuronium
75672353|NCT02833025|Device|Thrombin generation and Platelet Function Testing|Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry
75672354|NCT04245059|Device|Multi-channel Transcranial direct current stimulation|A commercial tDCS device will be use in this study. The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
75803871|NCT03956199|Procedure|pulpotomy|removal of the pulp from pulp chamber
75803872|NCT03956199|Procedure|Root canal treatment|Removal of at the entire content of the root canal system and root canal obturation
75803873|NCT04457284|Drug|Temozolomide (TMZ)|"TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1~TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +"
75803874|NCT04457284|Drug|Cisplatin|Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +
75803875|NCT04457284|Drug|Nivolumab|Nivolumab 480 mg Q4W IV infusion Cycle 1 +
75803876|NCT05666232|Diagnostic Test|renal resistive index and myocardial performance index|"Transthoracic echocardiography and transabdominal ultrasonography will be performed before induction of anesthesia, after termination of operation and before transmission to ICU and then daily for the early seven postoperative days.~RRI = (peak systolic velocity - end diastolic velocity) ∕ peak systolic velocity: Then, we will obtain the mean RRI from the above three measurements.~We will consider RRI ≥0.7 as abnormal and define it as subclinical AKI.~Myocardial performance index (using tissue doppler) =~(isovolumetric contraction time + isovolumetric relaxation time) / ejection time. We will consider MPI ≥0.4 as abnormal and define it as subclinical LV dysfunction."
75803877|NCT00054639|Biological|oblimersen sodium|Given IV
75803878|NCT00054639|Biological|rituximab|Given IV
75803879|NCT00054639|Other|laboratory biomarker analysis|Correlative studies
75803880|NCT04686682|Drug|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
75803881|NCT04686682|Drug|JAB-8263|RP2D dose, orally Q2D with 28 days each cycle
75943798|NCT03653819|Other|First exercise session + compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
75943799|NCT03653819|Other|First exercise session - compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
76091479|NCT03269682|Device|3D PD T1 MRI sequence|After MRI has been performed (about 5 minutes of additional time compared to the usual sequences), a double reading of the MRI will be performed by two radiologists (1 experienced and 1 junior).
76091480|NCT03269448|Diagnostic Test|Peripheral venous blood sampling|Blood collected from peripheral venous (extremities) and central venous (central catheter) for blood gas analyses
76091481|NCT02458482|Device|AccuPAP|The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
75656712|NCT04571255|Behavioral|Music-Assisted Relaxation|The music therapy sessions are based on MAR (Music-Assisted Relaxation), a music therapy technique that includes listening to live music, combined with deep diaphragmatic breathing and/or guided imagery relaxation. In a first step, the procedure will explained to the patient and he/she will be asked to close his/her eyes or focus on a fixed point on the ceiling or wall. Subsequently, a verbal introduction will be provided for fostering body and respiratory awareness. Then a mental image will be introduced (e.g., sitting on a beach watching the waves of the sea; being on top of a mountain looking at the horizon; imagining a safe and comfortable personalized place) and live music will be provided based on the principles of entrainment. The patient is asked to let himself/herself guide by the music and breath with the music while concentrating on the imagery. Once the music is over, the patient is again asked to become aware and the experience during the session will verbally discussed.
75345586|NCT05944107|Other|Activated Clotting Time measurements combined with heparin concentration monitoring|In the HC group, the initial heparin dose is calculated using the HepCon HMS Plus . Except for ACT, heparin concentration is measured to maintain target heparin levels during CPB. The protamine dose for reversal is computed based on actual measured heparin levels using the device. ACT is also performed in all instances.
75656713|NCT04557891|Device|Active LIFUP Treatment|8 LIFUP Treatments
75803882|NCT03733002|Drug|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
75803883|NCT03733002|Drug|Placebo of AngongNiuhuang pill|This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
75803884|NCT03733002|Other|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke.
75803885|NCT02530359|Drug|Pirfenidone extended release|Pirfenidone extended release 600mg per mouth
75803886|NCT02530359|Drug|Placebo equivalent|Placebo equivalent per mouth
75803887|NCT03731208|Device|Telerehabilitation|"The telerehabilitation program equipment consists of the following devices:~a tablet with a keyboard and a fingerprint sensor~two wearable sensors~a wireless modem~measuring tape"
75803888|NCT03696472|Procedure|robotic assisted surgery|robotic assisted surgery was benefit to operation
75803889|NCT03696472|Procedure|laparoscopic|conventional laparoscopic surgery
75803890|NCT03428360|Drug|Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category|The subjects in this study administered DBF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically used the diazepam rectal gel or other rescue medication, without the presence of study staff.
75803891|NCT03731130|Other|EORTC QLQ C30|standardized questionaire
75803892|NCT03731130|Other|EORTC QLQ CR29|standardized questionaire
75803893|NCT03699046|Procedure|Subchondroplasty and Knee Arthroscopy|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The bone marrow lesion(s) will be located using pre-operative MRI combined with fluoroscopy (intra-operative X-ray) and a small, drillable AccuPort® Delivery Cannula will be placed in the appropriate position. The cannula will then be drilled into the bone marrow lesion(s) and a flowable, synthetic, calcium phosphate bone substitute (AccuFill® Bone Substitute Material, Zimmer Biomet) will be injected into the lesion(s). The calcium phosphate bone substitute will then harden, improve the structural integrity of the damaged subchondral bone, and will gradually be resorbed and replaced with new bone.
75943800|NCT03653663|Drug|Simvastatin 20 mg|Subjects are treated with 20 mg simvastatin for 8 weeks
75943801|NCT03653663|Drug|Placebo Oral Tablet|Subjects are treated with placebo for 8 weeks
75803894|NCT03699046|Procedure|Knee Arthroscopy Alone|Knee arthroscopy is a surgical procedure that involves the orthopaedic surgeon making small incisions in the knee and then inserting a small camera into the joint. Following the insertion of the camera, multiple procedures can be completed to treat a number of different conditions such as repair or partial/complete removal of the meniscus, debridement, lavage, removal of a loose body among others.
75943802|NCT02521857|Drug|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
76091482|NCT02458482|Drug|Albuterol and Ipratropium Continuous Nebulizer|10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
76091483|NCT03264612|Behavioral|Aerobic exercise|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
76091484|NCT03264924|Behavioral|IPAIR|Motivational interview training
76091485|NCT03273192|Drug|Adalimumab|A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
75943803|NCT03468387|Procedure|Primary realignment|Endoscopic realignment of rupture urethra over a urethral catheter
75345587|NCT05944107|Other|Activated Clotting Time|The target ACT for procedures other than Coronary Artery Bypass Grafting (CABG) is 400s when Minimally Invasive Extracorporeal Circulation is used. A bolus of 300 International Units(IU)/kg heparin are administered to reach this target and initiate cardiopulmonary bypass (CPB). Repeated ACT measurements guide further heparin dose to maintain adequate anticoagulation. Then, at the end of the CPB, 0.75 mg of protamine are administered for every 100IU of the initial heparin bolus.
75345588|NCT05943834|Other|Series of cognitive tasks during a semi-automated call|"Tasks:~Verbal learning recall (immediate) or Story Recall task (immediate)~Narrative Storytelling /free speech~Verbal fluency task~Verbal learning recall (delayed) or Story Recall task (delayed)"
75345589|NCT05943080|Drug|PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|The application is made into the anatomical space between the posterior capsule and the popliteal artery before implantation.
75803895|NCT03699046|Biological|Subchondroplasty|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The specific biological component of the procedure involves the injection of the AccuFill® Bone Substitute Material (Zimmer Biomet), which is a a flowable, synthetic, calcium phosphate bone substitute, into the bone marrow lesion(s).
75943804|NCT03468387|Procedure|Suprapubic cystostomy|Percutaneous cystostomy catheter will be inserted under sonographic guidance
75943805|NCT03460509|Drug|Sugammadex|Dose-response
75943806|NCT03879915|Procedure|Dental Implant placement|Surgical placement of dental implant not associated with prior or concurrent bone augmentation
75943807|NCT03460431|Device|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm session, every month for 4 months
75943808|NCT03460431|Device|Nd YAG laser1064 nm|Nd YAG laser1064 nm laser session, every month for 4 months
75943809|NCT04452903|Behavioral|communication skills|3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
75943810|NCT02979431|Biological|ALX-0171 3.0 mg/kg|
75943811|NCT02979431|Biological|ALX-0171 6.0 mg/kg|
75943812|NCT02979431|Biological|ALX-0171 9.0 mg/kg|
75943813|NCT02979431|Other|Placebo|
75656714|NCT04557891|Device|Sham LIFUP Treatment|8 sham LIFUP treatments
75345590|NCT05943080|Drug|IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.
75656715|NCT04544995|Drug|Niraparib|Niraparib will be administered as tablet
75656716|NCT04544995|Drug|Dostarlimab|Dostarlimab will be administered as IV infusion
75803896|NCT03957603|Dietary Supplement|Enteral Nutrition Suspension (TFP-DM)|Individualized dietary and lifestyle intervention combined with the recommendation of Enteral Nutrition Suspension (TPF-DM, Diason 0.75 kcal/ml)
75803897|NCT03957603|Behavioral|Medical Nutrition Therpay|Individualized dietary and lifestyle intervention
75803898|NCT03732924|Diagnostic Test|Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement|To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
75943814|NCT03460275|Drug|Osimertinib Mesylate Tablets|Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
75943815|NCT03460197|Procedure|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Patients will be submitted to both techniques of tissue acquisition in the same procedure of endoscopic ultrasound. Capillarity technique, requires not remove the stiletto from the needle until the punctures are done for the biopsy sampling. Wet suction technique, requires saline solution to replace the air column. Samplings will be placed in two different jars, where Jar 1 corresponds to Capillarity Technique sampling and Jar 2 to Wet Technique. Once the sampling preparation is concluded will be send to the Pathology Department to be subsequently blindly analyzed by two independent pathologists, that means they would not be aware of the tissue acquisition method used in each of the microscopic slides to analyze.
75656717|NCT04544995|Drug|Niraparib|Niraparib will be administered as AAOLF (once available)
75656718|NCT04527302|Combination Product|ERP combined with high-definition active tDCS|"The active tDCS +ERP referred to a period of tDCS applied in the first 20 minutes of the ERP treatment (the tDCS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tDCS+ERP treatment.~The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Anode electrode will be localized in front of the mPFC on the FpZ point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AF7, AF8, F3, F4)."
75943816|NCT03460119|Device|High Flow Nasal Cannula Oxygen|The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).
76091486|NCT03264846|Diagnostic Test|Collection of Serum and Saliva Samples|Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
76091487|NCT02348632|Drug|JZP-110|
76091488|NCT03269604|Procedure|Prophylactic antibiotic during five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
76091489|NCT03269604|Procedure|Prophylactic antibiotic during three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
75943817|NCT03468231|Drug|Sorafenib|Oral Sorafenib, 400mg, Bid
75943818|NCT03468231|Drug|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
75943819|NCT03468231|Drug|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
76091490|NCT03269604|Procedure|Only a single dose of Prophylactic antibiotic|This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
76091491|NCT02458872|Behavioral|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
75943820|NCT03652883|Other|ItFits-toolkit|The ItFits-toolkit provides evidence-informed methods, materials, knowledge on determinants and implementation strategies, and concrete guidance on tailoring implementation strategies to local determinants of practices, apply them and evaluate their impact. It applies a standardised four-step approach to iteratively develop evidence-informed implementation strategies. The ItFits-toolkit is based on the Normalisation Process Theory (NPT), which suggests that lasting changes in practice only happen through people working together. The ItFits toolkit functions as an online self-help toolkit with minimal support. The toolkit will provide instructions for the IL to establish a core team and to create a sounding board consisting to enable co-creation.
76091492|NCT03264768|Device|endobronchial valves|A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.
75943821|NCT03652883|Other|Implementation as Usual|IAU refers to any existing efforts to embed and integrate iCBT within an organisation.
75943822|NCT03468153|Biological|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patient-derived dual specificity CD19 and CD22 CAR-T Cells
75943823|NCT03653195|Other|urine metabolomics|We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
76091493|NCT03264768|Behavioral|physical activity tele coaching|3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.
76091494|NCT03264768|Procedure|Lung volume reduction surgery (LVRS)|Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.
76091495|NCT02349178|Drug|Clofarabine|Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
76091496|NCT02349178|Drug|Cyclophosphamide|Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
76091497|NCT02349178|Drug|Etoposide|Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
76091498|NCT03273114|Behavioral|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
75345591|NCT05943080|Drug|ACB ( 0.25% marcaine + %0.9 saline)|It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.
75345592|NCT05942625|Drug|HS-10390 tablet|Oral administration of specified dose of HS-10390
75656719|NCT04527302|Combination Product|ERP combined with sham tDCS|Patients will get the same CBT setting as the active tDCS group and they were applied the sham tDCS cocurrently with ERP. The sham tDCS device is the same as the active comparator's except that the sham tDCS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tDCS.
75943824|NCT03460041|Drug|Magnesium Sulfate|caudal magnesium sulphate added to bupivacaine for pain management
75943825|NCT03460041|Drug|Dexmetedomedine|Caudal dexmetedomedine added to bupivacaine for pain management
75943826|NCT03460041|Drug|Bupivacaine|Caudal bupivacaine for pain management
75943827|NCT03459885|Device|Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device)|Paired associative stimulation (PAS) administered several times per week for 8 weeks to lower limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
75943828|NCT03622151|Other|Primer la Llar program|Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
75943829|NCT02522013|Drug|Aminophylline|
75943830|NCT02522013|Drug|isotonic saline|
75943831|NCT03459573|Behavioral|"One Drop | Experts On Track"|Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
75943832|NCT03459573|Behavioral|"One Drop | Experts On Call"|Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
75345593|NCT05942625|Drug|Placebo tablet|Oral administration of matching dose ofplacebo
75345594|NCT05941832|Device|ANNE Chest Sensor|Wearing ANNE Chest Sensor for 6 weeks
75345595|NCT05941598|Device|Electroacupuncture|Participants in the electroacupuncture group will receive electroacupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
75345596|NCT05941598|Device|Sham acupuncture|Participants in the sham acupuncture group will receive minimal acupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
75345597|NCT05940428|Biological|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
75345598|NCT05940194|Biological|COVIVAC vaccine|For prevention Covid-19
76091499|NCT03273114|Other|Core Training Exercise and Manual Therapy|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
75656720|NCT04510324|Other|Red meat patties group|"1. Baseline Visit: day -7 before randomization~Clinical history~Refrain from seafood, eggs, fish or meat, for 7-day (washout) prior to Day 1. 2. Day 1 Randomization~Randomization to 1 of 2 interventions: plant-based or meat burgers~6 days-worth of burgers will be delivered to the participant's house 3. Day 1-6:~The participant will be asked to eat a specific randomized diet for 6 days 5. Days 7~Physical exam (weight, BP, HR)~Food questionnaire~Blood draw: Circulating TMAO, Total, LDL, and HDL cholesterol, Creatinine, High-sensitivity c-reactive protein~Urine Collection - TMAO 6. Day 7-14: Washout 7. Day 14: Patties delivery 8. Day 14-20: Assigned diet for 6 days 9. Days 20: Same as day 7"
76091500|NCT03970356|Other|antibiotic stewardship intervention|The intervention is multifaceted, consisting of the implementation of an algorithm for restrictive use of antibiotics as proposed in recent guidelines (Verenso, Dutch guideline), tailored in close collaboration with local stakeholders to the specific implementation setting, by means of a modified participatory-action research (PAR) approach. To support the process of intervention-tailoring and -implementation, a toolbox comprising of materials, aids and actions is developed to be used at the discretion of the local stakeholders to support implementation of the algorithm.The algorithm is congruent with the Swedish and Norwegian guidelines, which also promote more restrictive use of antibiotics in case of non-specific symptoms, even though the algorithm is more detailed.
75345599|NCT05939804|Device|TENS|TENS will be applied to the experimental group on the 0th and 1st days after the surgery, and the pain assessment at the time of movement/rest before and after the procedure will be made by the researcher.
75345600|NCT05938946|Drug|L608 Inhalation Solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
75345601|NCT05938946|Drug|Placebo solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
75345602|NCT05938101|Behavioral|Behavioral therapy|Behavioral therapy and psychotherapy
75656721|NCT04510324|Other|Plant-based patties group|Same as above
75656722|NCT04508985|Other|Temporarily holding the RAAS inhibitor [intervention]|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
75656723|NCT04508985|Other|RAAS inhibitor [continued standard of care]|No intervention, Continuation RAAS inhibitor [continued standard of care].
75656724|NCT04504435|Drug|GSK3494245|Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
75656725|NCT04504435|Drug|Placebo|Matching placebo capsules will be provided
75656726|NCT04487847|Diagnostic Test|18F-PSMA-1007 PET/CT|18F-PSMA-1007 PET/CT
75656727|NCT04479306|Drug|Alisertib|Given PO
75803899|NCT04440514|Procedure|endoscopic preperitoneal repair of parastomal hernia|repair of parastomal hernia after the Sugarbaker principle with TAR and preperitoneal mesh reinforcement
76091501|NCT01966900|Biological|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
75656728|NCT04479306|Drug|Osimertinib|Given PO
75656729|NCT04479306|Drug|Sapanisertib|Given PO
75656730|NCT04449952|Other|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
75656731|NCT04449952|Other|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
75656732|NCT04449952|Other|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
75656733|NCT04449952|Other|Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula|Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.
75803900|NCT03696394|Device|BioCartilage® Micronized Cartilage Matrix|BioCartilage® is a scaffold with Collagen Type II and cartilage matrix elements
75803901|NCT03427892|Drug|Brexpiprazole|Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.
75803902|NCT03738384|Device|Knee Connect + Visual Feedback System|A device to measure knee angle. It sends data a smartphone or tablet to be displayed as part of a visual feedback system.
75345603|NCT05937217|Other|myofascial induction and direct scar release techniques|Manual therapy techniques used to reduce chronic lower transverse abdominal scars pain and improve quality of life of the affected women
75656734|NCT04449952|Device|Concept Curve Winter Series Toothbrush|Participants will brush teeth at least one minute with provided bristled toothbrush.
75656735|NCT04449952|Device|Listerine Cool Mint Floss|Participants will use marketed fluoride-containing dentifrice, floss.
75656736|NCT04419389|Drug|APR-246 (eprenetapopt) + Acalabrutinib in CLL|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule
75656737|NCT04419389|Drug|APR-246 (eprenetapopt) + Venetoclax + Rituximab in CLL|APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
75656738|NCT04419389|Drug|APR-246 (eprenetapopt) + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule
75803903|NCT03698968|Device|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
75803904|NCT03738306|Other|Mezieres Method|"The Mézières treatment have 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain: the paravertebral muscles and latissimus dorsi."
75943833|NCT03459573|Behavioral|"One Drop | Experts Revive"|Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months
75943834|NCT02978417|Drug|Naltrexone for extended-release injectable suspension|Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.
75943835|NCT02978417|Drug|Oral naltrexone|Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.
75345604|NCT05937217|Device|therapeutic ultrasound|Ultrasound petron (model SM 500) specifications: output frequency:1Mhz, output power:5W/cm², power intensity:5 degree (0.8-1.2-1.6-2.0-2.5), time intensity:5-30(step by 5 min) . It will be applied for both groups for 10 minutes
75345605|NCT05933330|Other|Brain MRI|All included patients receive an MRI of the brain
75345606|NCT05931185|Other|low frequency transcutaneous electrical stimulation and Therapeutic Ultrasound|patients will receive low-frequency transcutaneous electrical stimulation for 15 minutes and therapeutic Ultrasound for 10 minutes as a treatment and patients will receive a total of 12 treatment sessions (3 sessions per week for 4 weeks and then follow-up will be done for the next 2 weeks) and the total duration of each session will be of 25 minutes.
75345607|NCT05931185|Other|Therapeutic Ultrasound|patients will receive a therapeutic ultrasound for 10 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
75345608|NCT05931185|Other|Low frequency transcutaneous electrical stimulation|participants will receive low-frequency transcutaneous electrical stimulation for 15 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
75345609|NCT05929495|Drug|Metformin|"The investigator will identify potential participants and confirm the diagnosis of GBM. Subjects will be screened within 6 weeks before starting treatment.~Treatment will involve:~Administration of the standard or partial Stupp protocol (Radiotherapy + Temozolomide) in combination with Metformin for 6 weeks,~Treatment with only Metformin for 4 weeks;~Resumption of adjuvant TMZ + Metformin treatment continuously until the end of the enrollment period."
75345610|NCT05927870|Procedure|pigtail|placing a small amount of local anaesthetic subcutaneously at the site of the gallbladder, a skin incision was made through which the catheter was introduced. A 7-Fr pigtail catheter was used in all cases . If possible, the catheter was introduced into the gallbladder after passing through the liver. The catheter was thereafter fixed, either by an internal locking device or by means of a suture to the skin. The catheter was rinsed with saline solution daily in order to prevent clogging.
75345611|NCT05926089|Diagnostic Test|Blood sampling|blood sampling to measure APR
75656739|NCT04419389|Drug|APR-246 (eprenetapopt) + Venetoclax + Rituximab in RT|APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
75803905|NCT03738306|Other|Conventional Physiotherapy|therapeutic exercise; physical agents
75476752|NCT05685264|Drug|Ponsegromab|Participants will receive one subcutaneous injection
75476753|NCT05685264|Drug|Ponsegromab|Participants will receive four subcutaneous injections
75476754|NCT05683821|Behavioral|Text message smoking treatment|"Facilitated enrollment in an NCI-sponsored text messaging program:~SmokefreeTXT (if ready to set a quit date in the next 14 days)~Practice Quit (if ready to practice quitting 1-5 days but not ready to quit permanently)~Daily Challenges (if not ready to quit, but willing to make some changes)"
75476755|NCT05683821|Drug|Nicotine replacement therapy sampling|"Participants may request:~Nicotine patches that release nicotine slowly over 24 hours, in either 7 mg, 14 mg, or 21 mg doses~Nicotine gum or lozenges that release medication quickly and can be used every 1-2 hours to prevent and cope with cravings to smoke, in either 2 mg or 4 mg doses"
75476756|NCT05683821|Combination Product|Wisconsin Tobacco QuitLine Referral|Patients will be offered referral to the Wisconsin Tobacco QuitLine that offers phone counseling and nicotine replacement starter kits (2 week supplies) to people ready to quit smoking, in addition to web-based, text messaging, and mailed support, at no cost to Wisconsin residents.
75476757|NCT05683821|Combination Product|Referral to Primary Care Provider|Patients who want to talk to their Primary Care Providers about quitting smoking will be encouraged to make an appointment with their provider to receive smoking cessation counseling and to discuss pharmacotherapy options.
75476758|NCT05683821|Combination Product|BREATHE 2 Cessation Study|Patients who are interested in participating in a separate randomized controlled trial of smoking cessation treatment will be invited to learn about and complete an eligibility screening and consent process for the trial. Those who enter the study receive both counseling and pharmacotherapy.
75656740|NCT04410991|Drug|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
75803906|NCT03698890|Device|Network-based home blood pressure monitor|A network-based home blood pressure monitor will be loaned to patients in the intervention group, who will be asked to monitor their blood pressure at least once every week using the network based home blood pressure monitor, which automatically uploads measured blood pressure readings to the portal for care managers (CM) to review blood pressure readings and provide updates to the patient on blood pressure control. If a patient's blood pressure is elevated, the CM can titrate medications over the phone and provide follow up tele-consultation and necessary treatment.
75803907|NCT03595332|Other|Summer activity program|Children receive a summer scorecard to facilitate access to local facilities for exercise.
75803908|NCT03702322|Behavioral|Voice therapy: respiratory|Abdominal voice onset
75803909|NCT03702322|Behavioral|Voice therapy: glottal closure|Pulling/pushing task
75803910|NCT03702322|Behavioral|Voice therapy: loud|Assertive task
75656741|NCT04410991|Drug|Teriflunomide HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
75656742|NCT04410991|Drug|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
75656743|NCT04410991|Drug|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
75656744|NCT04410978|Drug|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
75803911|NCT03702322|Behavioral|Voice therapy: Semiocclusion|Semi-occluded vocal tract
75943836|NCT03459183|Device|Infrasound (85 dB; 6Hz) source|the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB
75476759|NCT05683821|Behavioral|Additional modalities to learn about and request treatment|Participants in Enhanced Outreach arm clinics will have the option to request e-mail and/or text message communication regarding their smoking treatment options, and to initiate treatment via phone or online survey.
75656745|NCT04410978|Drug|Teriflunomide HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
75476760|NCT05680805|Drug|Metformin Hydrochloride|Metformin 1500 mg/day in 3 divided dose for 24 weeks
75476761|NCT05671445|Biological|CM326|CM326 injection
75476762|NCT05669157|Procedure|Radiography request by nurse|Intervention group with radiography requested by the IRN instead of the physician. The radiography will be interpreted by the physician afterwards, according to current practice
75943837|NCT03459183|Device|Ultrasound (10dB below hearing threshold; 22.4 kHz) source|the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep
75943838|NCT03459183|Device|Infrasound dummy source|the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound
75943839|NCT03459183|Device|Ultrasound dummy source|the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
75943840|NCT03458637|Behavioral|LITE Program and Usual Care|Family based lifestyle Intervention
75943841|NCT03458637|Behavioral|Usual Care|Usual care consisting of 3 visits to weight management clinic
75943842|NCT03458559|Drug|Radium-223 chloride|Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
75656746|NCT04410978|Drug|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
75656747|NCT04410978|Drug|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
76091502|NCT03269370|Behavioral|Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app.
76091503|NCT03269370|Behavioral|Parent Enhanced Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app. Extra modules will focus specifically on parenting skills relevant to having an anxious child.
75656748|NCT04410523|Drug|CSJ117|"CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment"
76091504|NCT03269370|Behavioral|Self-Help E-Book|"Parents will read Helping Your Anxious Child: A Step-by-Step Guide (Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)"
76091505|NCT04023084|Drug|Crisaborole|Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
76091506|NCT02349646|Device|Implantation with the commercially available Axium neurostimulator|
75476763|NCT05669157|Procedure|Radiography request by physician|The physician prescribed the X-ray, the X-ray technician carries out the imagery and the physician interprets it afterwards
75476764|NCT05667623|Drug|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks/24 weeks.
75476765|NCT05667623|Other|0% OPA-15406 Vehicle|Twice-daily administration for 4 weeks/24 weeks.
75656749|NCT04410523|Drug|Placebo|"Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device."
75656750|NCT04394559|Behavioral|Discharge Order Sets|Discharge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery.
75656751|NCT04394559|Behavioral|Pharmacist-Led Discharge Counseling and Communication|Two visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan.
75656752|NCT04394559|Behavioral|Post-discharge Pain Management Follow-up|An outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use.
75656753|NCT04394559|Behavioral|Patient Engagement Pain Management App|A mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder.
75656754|NCT04390568|Drug|Spesolimap|Spesolimap
75656755|NCT04375072|Device|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
75656756|NCT04375072|Device|sham tDCS paired with active MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2(milli ampere) mA current for 30 seconds. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
75656757|NCT04375072|Device|active tDCS paired with sham MBM|Active tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
75656758|NCT04375072|Device|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
75943843|NCT03458559|Drug|Rhenium-188-HEDP|Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
75943844|NCT02522091|Device|functional brain MRI|
75943845|NCT02522091|Other|Neuropsychology tests|
75943846|NCT03458169|Device|Therapist LEAP session feedback|A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.
75803912|NCT03732846|Drug|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression
75943847|NCT03458169|Device|Participant LEAP session feedback|A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.
75943848|NCT03458169|Device|LEAP risk control validation|The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
75943849|NCT03457623|Other|Innovative Supported|addition of connected tools and stronger accompaniment to improve quality of life
75943850|NCT03457545|Behavioral|Home-based pulmonary rehabilitation|Pilot study of a home-based pulmonary rehabilitation study for lung transplant candidates at the University of California San Francisco
75943851|NCT03457545|Other|Aidcube|Participants will be testing and giving feedback on the use of the Aidcube platform in being able to deliver their home-exercise prescription
75943852|NCT03457467|Drug|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity
76091507|NCT05075460|Drug|Tucidinostat, Azacitidine combined with CHOP|"Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~Vinoresin (VDS) 4mg intravenous infusion, day 1;~Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment"
75656759|NCT04373707|Drug|Enoxaparin|"For example (Enoxaparin):~4000IU twice a day in patients <50kg~5000IU twice a day in patients 50-70kg~6000IU twice a day in patients 70-100kg~7000IU twice a day in patients above 100kg"
75656760|NCT04373707|Drug|Enoxaparin|For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.
75656761|NCT04335383|Biological|Isolation of anti-Pseudomonas antibodies from type B lymphocytes|Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.
75656762|NCT04309188|Device|Senaptec Strobe Glasses|The glasses use liquid crystal technology that causes a flicker from clear to opaque to enhance vision.
75656763|NCT04309188|Other|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
75656764|NCT04300075|Device|CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
75656765|NCT04214496|Device|Sedline|Intraoperative EEG monitorization
75656766|NCT04211259|Drug|Loratadine|Given PO
75656767|NCT04211259|Other|Placebo|Given PO
75943853|NCT03457467|Radiation|SBRT|according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
75656768|NCT04211259|Other|Questionnaire Administration|Ancillary studies
75943854|NCT03467841|Device|CMV IgM, IgG in blood real time PCR for serum CMV DNA .|Colonoscopic examination will be done for all studied patients after standardbowel preparation using a Pentax videoscope to= Assess the endoscopic lesions using Mayo endoscopic subscore
76091508|NCT02457234|Behavioral|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
75656769|NCT04190225|Behavioral|Digital/social media intervention|Participants will receive individual counseling, access to an individually tailored website, guided goal setting via texts, access to a study Instagram account, and a wearable tracker (Fitbit)
75656770|NCT04156906|Biological|D+ RH genotype matched red cell units for transfusion|Chronically transfused patients with SCD and anti-D will receive D+ RH genotyped matched red cell units for transfusion in addition to standard C, E, and K antigen matching and being hemoglobin S negative, which is the Children's Hospital of Philadelphia institutional standard of care for patients with SCD. RH genotyping of donor units will be performed by the New York Blood Center (NYBC) Immunogenetics laboratory.
75345612|NCT05924035|Device|HBOT|HBOT treatment on a multiplace chamber (OXYHeal Hyperbaric Oxygen Chamber), 100% oxygen at 2.0 atmospheres for 90 minutes - on 4 consecutive days within 3 hours of completion of exercise training (as soon as practically possible). This will occur during week 2 of data collection.
75345613|NCT05921409|Dietary Supplement|Extra Virgin Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Extra Virgin Olive Oil (treatment group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
75803913|NCT03427268|Drug|PM060184|"PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point.~PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle)."
75803914|NCT03698812|Combination Product|Colonoscope|take off specimen
75803915|NCT03719222|Other|non intervention|It is an non-interventional retrospective observational study by using archived paraffin-embedded tumor specimens
75943855|NCT03130335|Procedure|BMA Injection|Bone marrow will be aspirated from the iliac crest and injected into the knee.
75943856|NCT03130335|Biological|BMA|Bone marrow will be aspirated from the iliac crest.
75803916|NCT03509948|Drug|cytisine|cytisine 1.5 mg film-coated tablets
75943857|NCT03456297|Other|Web-based clinical pedagogy program (WCP)|The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
75943858|NCT03455985|Other|Discharge Order Set (DOS)|In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.
75943859|NCT03455985|Other|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
75803917|NCT03696238|Dietary Supplement|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
75943860|NCT05191875|Drug|Saccharomyces Boulardii 250 MG|"Saccharomyces Boulardii:~0.25 g * 6, Produced by The French encyclopedia pharmaceutical Factory"
75943861|NCT05191875|Drug|Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate|"Ilaprazole:~5mg*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g * 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg * 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD"
75943862|NCT03454971|Other|MinOS protocol|"At Day 1, Cycle 1 and 2 of the patient's oral therapy :~Consultation with a hospital pharmacist~Consultation with a nurse care coordinator~Consultation with the patient's oncologist/hematologist~During this multidisciplinary consultation, will be reviewed :~potential medical interactions,~possible adverse effects of therapy,~information on the prescribed drug,~informations on the patient's lifestyle, ...~At day 8 and 15, cycle 1 and 2 :~Phone call from the nurse care coordinator during which will be reported the adverse effects and adherence issues. If needed, the nurse care coordinator can provide complementary information about the treatment.~The MINOS protocol follow up will end with a consultation with the patient's oncologist/hematologist, at day 1 cycle 3."
75943863|NCT04475679|Device|Adhese Universal DC|Adhese Universal DC, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth surface
75943864|NCT04475679|Device|Adhese Universal|Adhese Universal, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth
75943865|NCT03467607|Procedure|tidal volume ventilation|low tidal volume ventilation
75943866|NCT04370145|Drug|Sulperazon|moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
75943867|NCT04370145|Drug|Teicoplanin|severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
75943868|NCT04370145|Drug|Meropenem Injection|cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
75943869|NCT03453723|Procedure|Magic glove hypnosis technique|Realization of the magic glove hypnosis technique by an expert physician trained in hypnosis, according to a classic discourse before : intravenous infusion with 1% propofol (3 mg/kg with 600 ml / h electric syringe pump). Use and dose in accordance with the SPC.
75943870|NCT03453723|Drug|lidocaine|intravenous infusion with an extemporaneous mixture of 18 volumes 1% propofol (180mg) for 2 volumes of 1% lidocaine (2ml) with 600 ml / h electric syringe pump. Use and dose in accordance with the SPC.
75943871|NCT03634683|Biological|LioCyx|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
75943872|NCT03452787|Other|None, cohort studies|this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.
75966028|NCT02087579|Drug|Aripiprazole, oral formulation|Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
75966029|NCT02087579|Drug|Olanzapine, oral formulation|Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
75354700|NCT04733378|Procedure|Peri-operative neurological monitoring|Pre- and post-operative cerebral MRI, standardized neurological examinations at 4, 12, 24 months and neuropsychological evaluation with a Bayley III test (Bayley Scale of Infant and Toddler Development, Third Edition) at 24 months.
75656771|NCT04156893|Biological|Red cell units that are genotype matched at the RHD and RHCE loci|Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.
75656772|NCT04140149|Behavioral|Living with Hope|12-week, CBT-based, psychoeducational skills class
75656773|NCT04133012|Other|Samplings|"blood samples~rectal biopsies~nodes biopsies~cutaneous fat tissues biopsies~semen sample"
75656774|NCT04131166|Behavioral|Mediterranean diet|A Mediterranean-type diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
75656775|NCT04131166|Behavioral|Low-carbohydrate, ketogenic diet|A low-carbohydrate, ketogenic diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
75656776|NCT04131166|Behavioral|Low-fat diet|A low-fat diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
75803918|NCT03696238|Other|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
75803919|NCT03696004|Drug|FEC-100|Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
75803920|NCT03721484|Diagnostic Test|CINtec PLUS|CINtec PLUS testing will be used to triage HPV positive women to colposcopy
75803921|NCT03695926|Drug|[18F]MNI-1054|Healthy volunteers recruited for the study will undergo a [18F]MNI-1054 PET scan.
75943873|NCT04774965|Device|Slumber Curve sleep aid|Patients who undergo rotator cuff repair and have been consented and randomized to the experimental group will be given a Slumber Curve sleep aid to be used during sleep. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Slumber Curve, patients will be given instructions on how to use the sleep aid while sleeping, and will be asked to use Slumber Curve nightly.
75345614|NCT05921409|Dietary Supplement|Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Olive Oil (placebo group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
75345615|NCT05906849|Behavioral|ACT for anxiety disorders|A twelve session Acceptance and Commitment Therapy (ACT) for anxiety disorders, applied individually and remotely (through videoconference) to participants fulfilling inclusion criteria (i.e., participants included in the SAD and GAD Experimental Groups).
75345616|NCT05904769|Device|LIFELEAF Smartwatch|Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.
75476766|NCT05661968|Other|Online educational program|The intervention group will receive an online educational program, containing current information on low back pain management according to international clinical practice guidelines. Program content includes recommendations on assessment, diagnosis, and treatment of low back pain. The online program has 6 units of studies, with the content offered in the formats of video classes, infographics, texts, websites and clinical cases. The participant must complete the course within 6 weeks and will be able to set their own pace. Participants in the intervention group will receive their login and access password via email.
75803922|NCT03466658|Device|JumpStart Antimicrobial Wound Dressing|A novel, wireless, low-level microcurrent-generating antimicrobial device (JumpStart) is a sterile single layer dressing consisting of a matrix of alternating silver (Ag) and zinc (Zn) dots that are held in positions on a polyester substrate with biocompatible binder. Dressing is then activated in the presence of a conductive fluid, which may come from wound exudate or exogenous fluids, such as saline. It has been observed, in vitro, to exhibit electricidal effect in the presence of antibiotic and multidrug resistant clinical wound isolates.
76091509|NCT01966978|Drug|Metformin|Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
75656777|NCT04131166|Other|Annual follow-up testing for 5 years|Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
75656778|NCT04116320|Device|Echopulse|The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.
75656779|NCT04116320|Drug|Poly ICLC|Poly-ICLC is a TLR3 agonist.
75943874|NCT03452709|Behavioral|therapeutic exercise|The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.
76091510|NCT01966978|Drug|Detemir|Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
76091511|NCT01966978|Drug|Liraglutide|Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
76091512|NCT01966978|Drug|Insulin Aspart|Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG <180
75345617|NCT05904665|Diagnostic Test|ctDNA methylation dynamic monitoring|ctDNA methylation detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years, a total of 10 times.
75656780|NCT04116320|Drug|Standard of Care PD-1 Therapy|PD-1 therapy FDA approved for use on a 3-week schedule will be used per standard of care.
75656781|NCT04094311|Biological|CTL019|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
75656782|NCT04091451|Biological|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of the HZ/su vaccine in a 0,2 Months schedule, administered intramuscularly
75656783|NCT04091451|Drug|Placebo|2 doses of the placebo in a 0,2 Months schedule, administered intramuscularly
75656784|NCT04086030|Other|Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program including blood flow restriction training. Exercises will be performed with BFR at 80% LOP.
75656785|NCT04086030|Other|Sham Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program where exercises will be performed with sham BFR pressure of 20 mmHG.
75656786|NCT04060784|Procedure|Immediate implant placement and provisionalization|Failing tooth will be extracted and immediate placed endosseous implant
75656787|NCT04022772|Other|Best Practice|Receive standard of care
75803923|NCT04867928|Drug|Venetoclax+azacitidine|subjects will receive venetoclax 400 mg orally QD on Days 1 - 28 plus azacitidine 75 mg/m2 SC or IV daily for 7 days. Cycle Length - 28 Days. . Subjects will continue treatment until subsequent alloSCT.
75803924|NCT03425396|Drug|Omadacycline tablets|Oral Omadacycline
75943875|NCT03452709|Device|ABPM ambulatory blood pressure monitoring|Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
75943876|NCT03577119|Dietary Supplement|Full-fat yogurt|Controlled diet that includes three daily servings of whole (3.25% fat) yogurt.
75943877|NCT03577119|Dietary Supplement|Non-fat yogurt|Controlled diet that includes three daily servings of fat-free yogurt.
75943878|NCT03452553|Device|LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin|Drug Eluting Beads loaded with chemotherapy
75943879|NCT03452475|Drug|Arterolane-piperaquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
75943880|NCT03452475|Drug|Arterolane-piperaquine+mefloquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
75943881|NCT03452475|Drug|Artemether-lumefantrine|Artemether-lumefantrine tablets (20 mg/120 mg)
75943882|NCT03451461|Other|No intervention|Observational study. Clinical data recorded
75943883|NCT03451305|Other|Pillow|A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
75943884|NCT03451227|Drug|Dexmedetomidine group|The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.
75943885|NCT03451227|Drug|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
75476767|NCT05658796|Behavioral|+RxWell|During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques.
75476768|NCT05658796|Behavioral|-RxWell|Treatment as usual
75943886|NCT03449277|Drug|Oral Tablet|oral labetalol tablets and oral nifedipine tablets
75943887|NCT03508323|Drug|Teneligliptin|20mg/qd
75943888|NCT03508323|Drug|Placebo|1T/qd
75943889|NCT02529813|Drug|Cyclophosphamide|Given IV
75476769|NCT05650528|Drug|QG101-23-0 capsules|Single and Multiple Dose for oral
75476770|NCT05650528|Drug|Placebo|Single and Multiple Dose for oral
75345618|NCT05895734|Device|NDS-Powerball®,|Rehabilitation using the Powerball system
75476771|NCT05638282|Drug|Cendakimab|Specified dose on specified days
75656788|NCT04022772|Other|Medical Chart Review|Ancillary studies
75656789|NCT04022772|Other|Quality-of-Life Assessment|Ancillary studies
75656790|NCT04022772|Other|Questionnaire Administration|Ancillary studies
75656791|NCT04022772|Procedure|Supportive Care|Participate in PACK Health program
75656792|NCT04008498|Diagnostic Test|AEEG brain monitoring|"Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby."
75656793|NCT04008355|Drug|AZP2006 oral solution|Once daily intake in the morning
75656794|NCT04008355|Drug|Placebo oral solution|Once daily intake in the morning
75803925|NCT03425396|Drug|Nitrofurantoin capsules|Oral Nitrofurantoin
75803926|NCT03698734|Drug|Evening primrose oil(EPO)|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol
75803927|NCT03698734|Drug|Placebo - Cap|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
75803928|NCT03695770|Other|kit for self-diagnosis and self-treatment|distribution of kits for malaria self-diagnosis and self-treatment after a training by health facilitators
75820025|NCT02185378|Procedure|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
75943890|NCT02529813|Drug|Fludarabine Phosphate|Given IV
75943891|NCT02529813|Other|Laboratory Biomarker Analysis|Correlative studies
75943892|NCT02529813|Biological|Tisagenlecleucel|Given IV
75943893|NCT03129711|Other|glazed Celtra Duo|zirconia reinforced lithium silicate
75943894|NCT03129711|Other|IPS Empress CAD|Standard etchable glass ceramic for laminate veneers
75345619|NCT05895734|Other|Conventional treatment|Rehabilitation by conventional treatment
75345620|NCT05893043|Drug|GSBR-1290|Participants will receive GSBR-1290 oral capsules.
75345621|NCT05893043|Other|Placebo|Participants will receive matching placebo oral capsules.
75943895|NCT03440463|Behavioral|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
75943896|NCT03440463|Behavioral|Norms-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare.
76091513|NCT05075226|Device|Vivity Extended Depth of Focus|Cataract surgery
75345622|NCT05889468|Drug|Aspirin 81Mg Ec Tab|Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.
75345623|NCT05889468|Drug|Placebo|Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.
75354701|NCT04730739|Device|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The FastFrame External Fixation Systems - Knee Spanning Kit and Damage Control Kit are single-use external fixators that are sterile packed with all required components for convenience of the end user.
75345624|NCT05886621|Behavioral|Smiling instead of Smoking - HIV|"Participants will be onboarded to the smartphone app Smiling instead of Smoking - HIV (SiS-H) and will be asked to complete the integrated SiS-H program while they quit smoking. The integrated SiS-H treatment consists of: (1) face-to-face onboarding to the SiS-H app, (2) one face-to-face session discussing app usage and antiretroviral therapy (ART) adherence (Life Steps), with direct linkage to tools in the app supporting ART adherence, and (3) an 8-week course of the SiS-H app. The SiS-H app is a smoking cessation app that uses a positive psychology framework in conjunction with with the US Clinical Practice Guidelines for smoking cessation to guide participants through the process of quitting smoking."
75943897|NCT03440463|Behavioral|Norms-plus-Strategies booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare. These booster emails will also contain reminders of strategies they can use to protect themselves from alcohol-related harm, both ones they've reported using in the past and others they might consider using in the future.
75943898|NCT05322057|Drug|Darvadstrocel|Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract
76091514|NCT03264378|Behavioral|Physical Exercise Intervention|The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.
76091515|NCT03264300|Other|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min; conventional structural MRI; T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Advanced MRI to include: Diffusion Weighted MRI (DW-MRI) - 7 min; Chemical Exchange Saturation Transfer (CEST) - 9 min; Dynamic Susceptibility Contrast / Dynamic Contrast Enhanced MRI - 8 min; and, other advanced imaging, as needed, to be determined. Post-contrast conventional MRI to include T1-weighted anatomic MRI scan - 7 min. Repeat within 1 month.
75345625|NCT05886621|Behavioral|QuitGuide|"Participants will be onboarded to the NCI smartphone app QuitGuide(QG) and will be asked to use it for 8 weeks to support them in quitting smoking. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
75345626|NCT05881460|Device|Active vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
75345627|NCT05881460|Device|Sham vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
75345628|NCT05879692|Procedure|focused ultrasound|"focused ultra sound cavitation using a device of Mabel6 DUO Ultra Cavitation Technology system produced by DAEYANG MEDICAL COMPANY, KOREA will be applied on the abdominal region which extending bilaterally from the line extending from mid axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crest below.~the session of Focused Ultra Sound will take 25- 30 minutes, twice/week and with about three day intervals for 12 weeks."
75345629|NCT05879692|Behavioral|Low Caloric Diet (LCD) and a low (FODMAPs) diet|"The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs)."
75345630|NCT05879692|Other|aerobic exercise|aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.
75345631|NCT05867147|Drug|Vanzacaftor|Tablets for oral administration.
75345632|NCT05867147|Drug|Vanzacaftor Placebo|Placebo for oral administration.
75345633|NCT05867147|Drug|Moxifloxacin|Tablets for oral administration.
75345634|NCT05867147|Drug|Moxifloxacin Placebo|Tablets for oral administration.
75345635|NCT05867017|Other|Measure of physiologic parameters|Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
75476772|NCT05638282|Drug|Placebo|Specified dose on specified days
75656795|NCT03986931|Other|Experimental: Pharmacist-Bidirectional Texting Group|The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.
75656796|NCT03986931|Other|Active Comparator: Control Group|This group will receive bidirectional texting, but no pharmacist monitoring.
75656797|NCT03955991|Behavioral|R-CBSM|10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.
75803929|NCT03698656|Behavioral|Spiritual Interview|Three patient interviews (45 to 60 minutes) will be conducted by the study nurse at the beginning of the study and approximately 2 and 4 month later, according to the program of the medical care. Each interview will be conducted according the active listening method of Carl Rogers.
75803930|NCT04394260|Behavioral|Savvy Caregiver Program via Remote Learning|The SCP program is comprised of four pre-recorded Savvy Caregiver videos (each 1 hour and 45 minutes in length). Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of enjoyable involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
76091516|NCT03264300|Other|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min. Conventional structural MRI to include: T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Serial DSC-MRI: staged injections of Gd-based contrast and Ferumoxytol - 20 min. Post-contrast conventional MRI: T1-weighted anatomic MRI scan - 7 min.
76091517|NCT02350660|Dietary Supplement|cow's milk|daily consumption of cow's milk
76091518|NCT02350660|Dietary Supplement|peanut powder|peanut oral immunotherapy
75345636|NCT05864222|Other|Aromatherapy|Elequil Aroma-Tabs are available on all clinical nursing units for staff. Instructions will be provided to participants to place the aroma tab on the back of their badge every workday for the entire duration of their shift. They will wear their badge in whatever position is most comfortable to them for the duration of the study (6 months).
75803931|NCT04394260|Behavioral|Focus group|After watching the Savvy Caregiver videos participants will take part in a focus group to discuss their experience with the SCP and how the course material applies to them as a LGBT caregiver. The semi-structured discussion will include, but not be limited to the following questions: 1) Can you tell me about your role as a caregiver? (Probes: living situation, experiences, challenges). 2) What went well with the SCP, and what could be improved? 3) How relevant to your situation as an LGBT caregiver were the course materials? 4) How well did the questionnaire reflect your experiences with discrimination due to sexual orientation and/or gender identity? (Probe about when working with your care recipient's health care providers, in-home aides/visiting nurses, adult day care staff, respite, etc? 5) What are some of the additional caregiver challenges that should be considered in these questionnaires? (Probes: mental health, physical health, and social life strain, Quality of life, stress).
75803932|NCT03639350|Behavioral|IER+MED group|Follow a Mediterranean diet 5 days per week and follow intermittent energy restriction 2 days per week.
75803933|NCT03639350|Behavioral|DASH group|Follow the distribution of macronutrients and food groups prescribed by the DASH diet 7 days per week.
75803934|NCT03695692|Behavioral|pelvic floor exercise and connective tissue massage|Pelvic floor exercises with connective tissue massage will be performed.The massage program is carried out for 18 sessions, 3 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
75943899|NCT03433599|Other|Repeated exposure to acute Intermittent Hypoxia (rAIH)|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).
75943900|NCT03433599|Other|Normal Room Air|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).
75943901|NCT03433599|Other|Upper-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
76091519|NCT03269214|Drug|Topical Phenytoin 5%|Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
76091520|NCT05075148|Other|radiology|Interventional radiology for aneurysmal bone cyst ( percutaneous alcoholization, vascualr embolisation)
76091521|NCT05075304|Drug|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
76091522|NCT05075304|Drug|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
76091523|NCT05075304|Drug|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
75803935|NCT03695692|Behavioral|pelvic floor exercise|The exercise program is performed every day for 6 weeks
75803936|NCT03716102|Device|PCI with implantation with DES|PCI with implantation with DES
75803937|NCT03695614|Other|Cognitive Remediation Therapy|Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
76091524|NCT03269058|Drug|Dapagliflozin|Dapagliflozin 10 mg daily per os
76091525|NCT03269058|Drug|Placebos|Placebo of Dapagliflozin per day per os
76091526|NCT02457390|Procedure|CE-LUS|"To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.~The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure."
76091527|NCT02457468|Device|coflex|
76091528|NCT05074836|Dietary Supplement|Formula milk|"Brand name: Yili (QQ star formula milk);~Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;~Dosage: 195ml*2/d;~Intervention duration: 12 months"
76091529|NCT05074836|Dietary Supplement|Regular milk|"Brand name: Yili；~Type: regular milk (pure milk);~Dosage: 195ml*2/d;~Intervention duration: 12 months"
76091530|NCT05074836|Other|Control foods|"Brand: N/A;~Food type: grain foods (e.g., bread);~Dosage: 20-40g * 2/d grain foods~Intervention duration: 12 months"
75656798|NCT03955991|Biological|Influenza vaccine|Standard of care Influenza vaccine for that given year.
75345639|NCT05858489|Other|Mini-Mental State Examination (MMSE)|Each patient will be evaluated by MMSE then by the adapted version of MMSE
75656799|NCT03953768|Device|Vagal nerve stimulation (VNS)|Implantation with vagal nerve stimulator for epilepsy
75656800|NCT03934905|Drug|sulforaphane|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals <100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals >200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
76091531|NCT03264144|Behavioral|Social norms campaign|Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
75345640|NCT05852548|Behavioral|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
75345641|NCT05842278|Device|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
75803938|NCT04070157|Drug|Lofexidine|Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
75345642|NCT05842278|Device|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
75656801|NCT03934905|Drug|Placebo Oral Tablet|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals <100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals >200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
75656802|NCT03916263|Drug|Metformin|Traditional care including diet, exercise and metformin
76091532|NCT05074602|Drug|SHR8008|Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
75656803|NCT03916263|Other|One-On-One Dietary Instruction|Participant receives one-on-one dietary counseling from study personnel
75656804|NCT03916263|Other|Video Dietary Instruction|Participant receives video dietary instruction
76091533|NCT05074602|Drug|Fluconazole|Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
75345643|NCT05842278|Device|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
76091534|NCT03264222|Other|Security screening procedure|Screening procedure with security device (model QPS 100)
76091535|NCT02457312|Drug|Letrozole|letrozole 10 mg daily for 7 days before suction evacuation
75656805|NCT03901196|Diagnostic Test|Elemental analysis|LIBS multi elemental analysis of the specimen
75656806|NCT03889418|Behavioral|Electronic medical recorded clinical decision support [EMR CDS]|The opioid management tool has quick links to the Opioid Risk Tool (ORT), health maintenance reminders for risk mitigation tasks (pain management agreements; urine drug screening; prescribing naloxone); Pain Scale and depression/anxiety screen. The frequency with which providers are prompted to complete mitigation tasks is based on patients' level of risk for aberrant drug behavior defined by the ORT score. Additionally, the EMR CDS flags patients as high risk if one of the following criteria are met: (1) co-prescriptions for benzodiazepines; (2) active diagnosis of substance abuse in the last 12 months; or (3) MEDD >=90 mg. The ORT score, morphine equivalent daily dose (MEDD), and hyperlinks to the Louisiana pharmacy drug monitoring program data are visible in the prescription writer. If MEDD >=90 mg, the calculated MEDD is displayed in red font to alert the prescribing provider of high dosage. An Epic banner appears in charts to alert providers of existing pain management agreements.
75656807|NCT03889418|Behavioral|Stepped opioid collaborative care model [CCM]|The licensed clinical social worker (LCSW) will provide counseling services as indicated (behavioral activation, psychotherapy, crisis planning, facilitating connection to substance abuse counseling and treatment); meet weekly with the consulting psychiatrist for complex case review and care plan adjustments; and supervise the community health worker (CHW) case management and depression/anxiety care management activities. The CHW will update assets and barriers to recovery and self-management and help patients navigate community resources. The clinical pharmacist will review and reconcile active medication lists, assess medication side effects, drug interactions and adverse events; monitor analgesia; recommend algorithm based anti-depression medication titration as indicated. The consulting psychiatrist will directly co-manage patients with severe mental illness, substance abuse and complex medication regimens.
75345644|NCT05842278|Device|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
75345645|NCT05842278|Device|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
75345646|NCT05832983|Behavioral|Guided Meditation|In private exam room, the study registered nurse (RN) will read a prepared two minute guided meditation to patient.
75656808|NCT03870243|Device|Bubble CPAP|To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
75656809|NCT03870243|Device|Low flow oxygen|To see the effectiveness of low flow oxygen in children with severe pneumonia
75656810|NCT03802019|Other|LNC Cigarettes + Colored Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.
75656811|NCT03802019|Other|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive their own preferred brand of cigarette (i.e., control).
75656812|NCT03788694|Drug|Ketamine|8 doses of intranasal ketamine; 40 mg per dose.
75656813|NCT03749109|Drug|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg for daily releases
75656814|NCT03749109|Drug|Placebo|Matching placebo
75656815|NCT03745521|Other|no intervention|no intervention
75656816|NCT03741556|Other|questionaire|a questionaire is sent to each participans
75943902|NCT03433599|Other|Lower-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
75943903|NCT05321823|Device|iBreast device|The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.
75943904|NCT05321823|Other|Clinical Breast Examination|The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community
76091536|NCT02457312|Drug|Placebo|placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
76091537|NCT03268902|Drug|Azithromycin Oral Liquid Product|Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
76091538|NCT03268902|Drug|Nitazoxanide Oral Suspension|Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
75345647|NCT05832983|Other|Aromatherapy|In private exam room, study RN will first affix an Elequil Aromatab to patient's clothing on either their upper arm or chest (whichever the patient prefers and/or as clothing allows).
75656817|NCT03709706|Drug|Lete-cel|lete-cel will be administered to eligible participants.
75656818|NCT03709706|Drug|Pembrolizumab|Pembrolizumab will be administered to eligible participants.
75656819|NCT03599297|Procedure|Bilateral synchronous simultaneous stone surgery|Patients undergoing Bilateral synchronous simultaneous stone surgery (one kidney undergoing percutaneous nephrolithotomy, other kidney undergoing ureteroscopy at the same time in a single patient)
75656820|NCT03555188|Drug|Ondansetron|Ondansetron is a highly selective receptor antagonist (5-HT3RA)
75656821|NCT03547115|Drug|voruciclib monotherapy|Voruciclib will be administered orally
75656822|NCT03547115|Drug|voruciclib and venetoclax|Voruciclib and Venetoclax will be administered orally
75656823|NCT03543267|Other|MRI exam|MRI before and after resection surgery
75656824|NCT03540706|Diagnostic Test|Care with C-reactive protein assay in micro method|Care with C-reactive protein assay in micro method
76091539|NCT03268902|Dietary Supplement|Nicotinamide|"Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age"
76091540|NCT03268902|Drug|Placebos|"Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age"
76091541|NCT03268980|Other|Questionnaire Hospital Staff group|One-page questionnaire with 15 questions about tobacco habits
76091542|NCT03268980|Other|Questionnaire students and patients group|One-page questionnaire with 17 questions about tobacco habits
76091543|NCT02458794|Procedure|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
76091544|NCT02458794|Device|LMA SupremeTM|
76091545|NCT02458794|Device|Ambu-Aura GainTM|
76091546|NCT05074368|Biological|ChAdOx1-nCov-19 (Astra-Zeneca)|vaccine inoculation and mixed inoculation
75345648|NCT05831228|Dietary Supplement|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
75345649|NCT05831228|Dietary Supplement|Control: Placebo|Participants will be given a dietary supplement comparator prior to the hyperbaric oxygen exposure.
75656825|NCT03517371|Other|mHealth delivered exercise program|"Participants in the mobile health condition have up to 10 in-person visits with a physical therapist over 12 months. The exercise program, consisting of walking, strengthening and stretching exercises, is prescribed through an app and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week."
75656826|NCT03517371|Other|Exercise only|Participants in the control group have up to 10 in-person visits with the intervention physical therapist over 12-months. Participants are instructed by the physical therapist to engage in walking and perform progressive resistance and stretching exercises (tailored to their needs and provided in written format) 5 days per week.
75656827|NCT03499509|Other|Low Glycemic Diet|"Low Glycemic (LG) diet: The LG diet will be made up of foods that do not stimulate insulin secretion. The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., High-Protein SlimFast). Dinner will be a frozen entrée (e.g., Atkins, Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be nuts, berries, and full-fat dairy products (one serving per day), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
75656828|NCT03499509|Other|High Glycemic Diet|"High Glycemic (HG) diet: The HG diet will conform to United States Department of Agriculture (USDA) guidelines (http://health.gov/dietaryguidelines/2015/guidelines/). The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., SlimFast). Dinner will be a frozen entrée (e.g., Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be fruit, fat-free dairy products, and low-fat bars (e.g., Optifast), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
75656829|NCT03497689|Drug|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)
75656830|NCT03492437|Drug|Dabigatran Etexilate|Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.
76091547|NCT05074368|Biological|SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine|vaccine inoculation and mixed inoculation
75656831|NCT03492437|Drug|Tepotinib|Participants received single oral dose of Tepotinib for 8 days in Treatment period 2.
75803939|NCT04070157|Drug|Placebo|Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
75803940|NCT04261738|Device|Hyperbaric Oxygen|Volunteers will be given a standard hyperbaric oxygen treatment (2.4 ATA x 90 minutes)
75803941|NCT01091337|Drug|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
75803942|NCT01091337|Drug|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
75803943|NCT03955809|Drug|Ketamine 0.5|İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml
75803944|NCT03955809|Drug|Ketamine 1|İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml
75803945|NCT03955809|Drug|% 0.9 NaCl|Intraarticular %0.9 NaCl
75803946|NCT03695536|Behavioral|ultrasound use during resuscitation|ultrasound use during resuscitation
75803947|NCT01094613|Drug|Delayed Release 6 mercaptopurine|"Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets."
75803948|NCT01094613|Drug|6 Mercaptopurine|Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
75803949|NCT03953001|Device|Adminstration Technique using Buzzy external distractor|External application of Buzzy distractor during administration of dental anesthetic
75803950|NCT03953001|Drug|2% Lidocaine with 1:50,000 epinephrine|Local Dental anesthetic infiltration
75803951|NCT03953001|Drug|Topical Anesthetic|20% Benzocaine gel was applied on the area of infiltration
75803952|NCT03695458|Device|Phototherapy|The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).
75803953|NCT03695302|Behavioral|questionnaire|KAP questionnaire for fifth year undergraduate dental students.
75803954|NCT01583673|Other|Amino Acid Formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
75803955|NCT01583673|Other|Amino Acid formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
75803956|NCT04653922|Device|LinkCor Bioengineered Corneal Implant|Intrastromal implantation of a bioengineered corneal equivalent device
75656832|NCT03484182|Behavioral|Web-based Home Exercise Program|Home exercises that are guided by a web-based program
75656833|NCT03484182|Behavioral|Standard Home Exercise Program|Standard paper-based home exercise program
75943905|NCT05321823|Diagnostic Test|Breast ultrasound|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.
75803957|NCT03692806|Dietary Supplement|Stablor|Stablor sachet
75943906|NCT05321823|Diagnostic Test|Mammography|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.
75943907|NCT03449121|Behavioral|Slow breathing techniques|8 sessions of instruction in slow breathing exercises over 12 weeks of study
75943908|NCT03449043|Other|Real care course|Evaluate the rate of adequacy between the request made by the general practitioner and the response to emergencies
75943909|NCT03448965|Diagnostic Test|random blood sugar|do random blood sugar at 0 hour - 2 hours- 4 hours and after 6 hours
75943910|NCT05321589|Other|impression techniques for implant used for maxillary screw retained hybrid prosthesis|"conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done"
75943911|NCT05321511|Drug|Triptorelin acetate (a-GnRH)|Adminsitration of triptoreline acetate 0.2 mg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
75656834|NCT03466294|Drug|Azacitidine and Venetoclax|Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
75656835|NCT03417011|Device|Medtronic CoreValve™ Evolut™ PRO System (Evolut™ PRO System)|Transcatheter Aortic Valve Replacement with Medtronic Evolut PRO system
75656836|NCT03363867|Drug|Atezolizumab|840mg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion from Cycle 2 onwards.
75656837|NCT03363867|Drug|Bevacizumab|5mg/kg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion.
75656838|NCT03363867|Drug|Cobimetinib|60mg per day, every day for 21 days (i.e. Day 1 to Day 21 of each 28 day cycle)
75803958|NCT03692806|Dietary Supplement|placebo|placebo sachet
75803959|NCT01583751|Procedure|videoendoscopic resection of pilonidal sinus|Resection of pilonidal sinus tissue with videoendoscopic approach.
75820026|NCT02185378|Procedure|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
75943912|NCT05321511|Drug|Ovitrelle® (hCG)|Adminsitration of coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
76091548|NCT02456922|Device|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
76091549|NCT03263754|Behavioral|Pocket Medic|10 short digital films utilising self-determination theory aiming to increase patient self-management
75943913|NCT05321511|Drug|Decapeptyl 0.1 mg® (a-GnRH) and Ovitrelle® (hCG) used together|Adminsitration of triptoreline acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
75943914|NCT02733627|Drug|BI 1467335|
75943915|NCT02733627|Drug|Placebo|
75943916|NCT02417103|Drug|GLP-1 (Liraglutide)|GLP-1 Analogon
75943917|NCT02417103|Drug|Placebo|Placebo
75943918|NCT02097225|Drug|Dabrafenib|Given PO
75943919|NCT02097225|Other|Laboratory Biomarker Analysis|Correlative studies
76091550|NCT03263754|Behavioral|Pulmonary Rehabilitation|PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach
75656839|NCT03344198|Behavioral|Circuit Training exercise & Modified Mediterranean diet|Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
75943920|NCT02097225|Drug|Onalespib|Given IV
76091551|NCT02458716|Procedure|Robotic Assisted Radical Prostatectomy|Undergo RARP
75943921|NCT02097225|Other|Pharmacological Study|Correlative studies
76091552|NCT02458716|Procedure|Conventional open retropubic radical prostectomy|Undergo conventional open RRP
76091553|NCT02458716|Other|Laboratory Biomarker Analysis|Correlative studies
76091554|NCT02458716|Other|Quality-of-Life Assessment|Ancillary studies
76091555|NCT02458716|Drug|ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)|LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
76091556|NCT03263988|Device|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
76091557|NCT03263910|Drug|NPO-11|20 ml NPO-11
75345650|NCT05827484|Biological|Autologous platelets rich plasma|30 ml of venous blood were drawn from the participant by means of venipuncture. The collected blood was mixed with 3 ml anti-coagulant acid citrate dextrose in the centrifugation sterile tube. The blood sample was then centrifuged using the centrifugation machine. 3 ml of PRP from the buffy coat layer were loaded in a 5 ml syringe. After local sterilization and draping of the site of injection and under US guidance the hematoma was aspirated from the injury site and the freshly prepared PRP was injected.
76091558|NCT03263910|Drug|Placebo|20 ml NPO-11(Placebo)
76091559|NCT05037396|Drug|Brolucizumab|Participants received brolucizumab injection during the index period
75345651|NCT05827484|Combination Product|Autologous platelets rich plasma + oral LOSARTAN administration|in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till day 30 after injury.
75656840|NCT03315871|Biological|PROSTVAC-V|Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.
75656841|NCT03315871|Biological|PROSTVAC-F|Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.
75820027|NCT02190760|Drug|Dexamethasone|
75820028|NCT02190760|Drug|Bupivacaine|
75820029|NCT02190838|Drug|Metformin|per os 850 mg BID
75820030|NCT02190838|Drug|Melatonin|per os 3 mg daily
75943922|NCT02097225|Drug|Trametinib|Given PO
75943923|NCT02958865|Drug|PF-06651600 or Placebo|Delivered orally for 8 weeks.
75943924|NCT02958865|Drug|PF-06700841 or Placebo|Delivered orally for 8 weeks.
75943925|NCT02958865|Drug|PF-06700841|Delivered orally for 24 weeks.
76091560|NCT02713542|Device|ACP|Autologous Conditioned Plasma
76091561|NCT02713542|Other|Placebo|Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
76091562|NCT02457078|Dietary Supplement|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
76091563|NCT02457078|Dietary Supplement|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
75820031|NCT02190838|Drug|Dacarbazine|IV 1 hour 1000 mg/m^2 once in 28 days
75820032|NCT02185456|Drug|750 mg metronidazole/ 200 mg miconazole vaginal suppository|The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
75820033|NCT02185456|Drug|Standard of care|oral metronidazole 500 mg twice a day for 7 days
75820034|NCT02186158|Drug|Vitamin C|
75943926|NCT02958865|Drug|PF-06651600|Delivered orally for 24 weeks.
75943927|NCT01990209|Drug|Orteronel|
75943928|NCT05321277|Dietary Supplement|Walnuts|Participants will consume 56 g of walnuts daily for 3 weeks. Participants will also follow a diet devoid of ellagitannin-rich, high fiber, and fermented foods.
75943929|NCT05321277|Dietary Supplement|No-nut diet|Participants will exclude all nuts and nut-derived products; high-fiber, fermented and ellagitannin-rich foods will also be excluded.
75943930|NCT03141099|Other|Low normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
75966030|NCT02087579|Drug|Paliperidone, oral formulation|Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
75345652|NCT05820841|Drug|R-miniCHOP + Acalabrutinib|"Rituximab i.v.: 375 mg/m2 (D0)~Cyclophosphamide i.v.: 400 mg/m² (D1)~Doxorubicin i.v.: 25 mg/m² (D1)~Vincristine i.v.: 1 mg (D1)~Prednisolone p.o.: 40 mg/m² (D1 to D5)~Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks"
75476773|NCT05637970|Device|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
75943931|NCT03141099|Other|High normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
75943932|NCT03141099|Other|Low normal PaO2.|The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
75345653|NCT05820841|Drug|R-miniCHOP|"Rituximab i.v.: 375 mg/m2 (D0)~Cyclophosphamide i.v.: 400 mg/m² (D1)~Doxorubicin i.v.: 25 mg/m² (D1)~Vincristine i.v.: 1 mg (D1)~Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks"
75656842|NCT03315871|Drug|MSB0011359C (M7824)|Fully human bifunctional fusion protein that combines IgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody. Administered via IV infusion over 1 hour.
75656843|NCT03315871|Biological|CV301|Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.
75656844|NCT03310125|Drug|Colchicine|Over-encapsulated 0.5mg tablet twice daily
75345654|NCT05818514|Drug|[11C]AZ14132516|Injection of radioligand for PET examinations
75656845|NCT03310125|Drug|Placebo|Matching placebo capsule twice daily
75656846|NCT03277495|Behavioral|Brief behavioral counseling|Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
75656847|NCT03193853|Drug|Tak-228 & Tak-117|Patients will receive 4mg oral TAK-228 and 200mg TAK-117 tablets until disease progression.
75656848|NCT03193853|Drug|Cisplatin & Nab Paclitaxel|following Tak-228 & Tak-117 standard nab paclitaxel 175-220 mg/m2 plus cisplatin 60-75 mg/m2 infusion for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion
75656849|NCT03191084|Drug|Low Dose THC Marijuana|Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
75656850|NCT03191084|Drug|High Dose THC Marijuana|Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
75656851|NCT03191084|Drug|Placebo Marijuana|Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
75656852|NCT03055819|Device|Brow Lift|Minimally Invasive Brow Lift
75656853|NCT03005366|Drug|Vernakalant|Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
75656854|NCT03005366|Drug|Flecainide|2 mg /kg (max 150 mg) intravenously over 10 minutes.
75656855|NCT02851121|Other|Sensorial stimulations|
75656856|NCT02851121|Other|Experimental protocols|
75656857|NCT02851121|Behavioral|Emotional protocols|
75656858|NCT02851121|Other|Protocol with a spatial dimension|
75656859|NCT02791646|Behavioral|Pain Coping Skills Training Full|Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
75656860|NCT02791646|Behavioral|Pain Coping Skills Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
75656861|NCT02738866|Drug|Palbociclib|Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.
75656862|NCT02738866|Drug|Fulvestrant|Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
75656863|NCT02613754|Behavioral|Contingency Management|See arm description.
75656864|NCT02613754|Behavioral|Treatment as Usual|See arm description
75656865|NCT02576912|Drug|Active Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) given intravenously.
75656866|NCT02576912|Drug|Active Pregnenolone|A dose given sublingually.
75656867|NCT02576912|Drug|Placebo|A placebo dose given sublingually.
75656868|NCT02576912|Drug|Placebo|Placebo dose given intravenously.
75656869|NCT02353546|Behavioral|CALM|
75656870|NCT02310698|Device|contrast enhanced digital mammography (CEDM)|
75656871|NCT02310698|Device|whole breast screening ultrasound (WBUS)|
75656872|NCT02266017|Behavioral|Pain Coping Skills Training|
75656873|NCT02232152|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
75656874|NCT02232152|Drug|fluorouracil|Given IV
75656875|NCT02232152|Other|pharmacological study|Correlative studies
75656876|NCT02232152|Other|laboratory biomarker analysis|Correlative studies
75656877|NCT02102113|Drug|Placebo|placebo
75656878|NCT02102113|Drug|Very Low Dose THC|Subjects will receive 0.010mg/kg.
75656879|NCT02102113|Drug|Low Dose THC|Subjects will receive 0.018 mg/kg over 20 minutes.
75943933|NCT03141099|Other|High normal PaO2|The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
75943934|NCT03448887|Device|Theranova|Extended HD with theranova
75943935|NCT03448887|Device|Online hemodiafiltration|Online hemodiafiltration
76091564|NCT03268512|Other|L-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
75943936|NCT02958553|Device|emPOWER Ankle|The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
75943937|NCT02958553|Device|Subject's own passive prosthesis|Devices will vary. Data gathered will form a baseline.
75943938|NCT02501902|Drug|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
76091565|NCT03268512|Other|A-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
75943939|NCT02501902|Drug|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
75943940|NCT03641833|Diagnostic Test|blood sample for brain biomarkers|Transcranial Doppler will be performed to evaluate a.cerebri media blood flow speed during surgery.
75345655|NCT05818267|Drug|Regorafenib|The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
75656880|NCT02070705|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
75656881|NCT02070705|Drug|Ferumoxytol|Given IV
75656882|NCT02041195|Drug|Setmelanotide|
75943941|NCT03641599|Diagnostic Test|echocardiography|echocardiographic assessment of the RV and LV systolic function
75943942|NCT03076047|Device|end-tidal CO2 (ETCO2) monitoring|monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2, Capnostream, and Massimo
75656883|NCT02041195|Drug|Placebo|
75656884|NCT01984671|Behavioral|Mobile Pain Coping Skills Training|
75943943|NCT03640429|Device|non-invasive blood pressure monitor|non-invasive oscillometric blood pressure monitor will be applied at the arm, forearm, and at the wrist.
75943944|NCT03640429|Device|invasive blood pressure monitor|invasive blood pressure monitor will be connected to a cannula inserted at the radial artery.
75656885|NCT01980355|Drug|Tranexamic Acid|
75966031|NCT02087579|Drug|Paliperidone, LAI|Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
75656886|NCT01980355|Other|Placebo|
75656887|NCT01899508|Procedure|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
75656888|NCT01899508|Device|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
75656889|NCT01771718|Device|MPTflex-multiphoton microscopy-based tomograph.|non-invasive optical biopsy
75656890|NCT01758432|Combination Product|PRT064445/Apixaban|
75656891|NCT01758432|Combination Product|Placebo/Apixaban|
75656892|NCT01758432|Drug|Placebo|
75656893|NCT01604317|Procedure|Resuscitation-torso plastic bag|Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
75656894|NCT01604317|Procedure|Resuscitation-partial-head plastic bag|Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
75656895|NCT01583218|Drug|Betrixaban|"Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days"
75656896|NCT01583218|Drug|Enoxaparin|"Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days"
75656897|NCT00994864|Drug|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
75656898|NCT00742859|Drug|betrixaban|orally, once daily for at least 3 months
75656899|NCT00742859|Drug|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
75820035|NCT02186158|Drug|Placebo|
75820036|NCT02186314|Device|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
75943945|NCT05320575|Drug|Zanubrutinib|The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.
75943946|NCT03740217|Drug|GKT137831|oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
75943947|NCT05320341|Procedure|TIVA|During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
75656900|NCT00667342|Biological|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
75656901|NCT00667342|Drug|Cisplatin|Given IV.
75656902|NCT00667342|Drug|Doxorubicin|Given IV.
75345656|NCT05812183|Device|Bariatric surgery|Gastric sleeve resection will be performed by experienced surgeons. Postoperative care will follow UCLA's postoperative care pathways for gastric sleeve resection.
75943948|NCT05320341|Procedure|SEVO|During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
75345657|NCT05812183|Behavioral|Medical weight loss|The medical weight loss intervention will follow UCLA's RFO standard protocol. Over a period of 12 months, patients in the medical weight loss group will follow a very low caloric diet (VLCD) at the UCLA RFO program. All study patients will be prescribed a VLCD, an exercise regimen and will participate in group classes on behavioral modification. The caloric intake consists of a commercially prepared meal replacement powder supplying 700-800 cal/day. Each formula packet provides 100kcal and 15g of high biological value protein, and the daily allowance of required minerals and vitamins.
75345658|NCT05811286|Procedure|Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions|"With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception.~We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain."
75345659|NCT05806567|Drug|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
75345660|NCT05806567|Drug|UGT1A1 victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
75345661|NCT05806567|Drug|P-gp victim drug|Pharmaceutical form: Capsule; Route of administration: Oral
75345662|NCT05806567|Drug|OATP1B1/BCRP victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
75345663|NCT05806359|Drug|Danicamtiv|Specified dose on specified days
75345664|NCT05806359|Drug|Placebo|Specified dose on specified days
75656903|NCT00667342|Drug|Methotrexate|Given IV.
75943949|NCT03448731|Drug|Doxycycline 50Mg Tablet|Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
75345665|NCT05798585|Procedure|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.375% according to randomization): unilateral injection of 0,4 ml kg -1 (ideal weight)2 under US guidance between the deep fascia of erector spinae muscle and the two transverse processes at the level of the 5th thoracic vertebrae. Duration approximately 10-15 minutes
75345666|NCT05789927|Procedure|Assessment of the microbial exposome|The assessment of the microbial exposome will be carried out by the deployment of 4 dust collectors (1 per season) at the patient's home. The evaluation of the endogenous myco-microbiome will be carried out by analyzing patient sputum obtained during follow-up visits or during routine care in the event of an exacerbation.
75345667|NCT05789329|Behavioral|Trauma Informed Guilt Reduction Therapy|behavioral intervention aimed to reduce trauma-related guilt and shame
75345668|NCT05789329|Behavioral|Cognitive Processing Therapy|behavioral intervention aimed at reducing PTSD symptoms
75656904|NCT00667342|Drug|Ifosfamide|Given IV.
75656905|NCT00667342|Drug|etoposide|Given IV.
75656906|NCT00667342|Procedure|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
75943950|NCT01955109|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
75656907|NCT00667342|Radiation|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
75656908|NCT00375609|Drug|Betrixaban|Capsule
75943951|NCT04452669|Drug|VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)|VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
75943952|NCT03467997|Behavioral|Trier social stress test|Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.
75656909|NCT00375609|Drug|Enoxaparin|Administered subcutaneously
75656910|NCT04042675|Diagnostic Test|observational study|There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
75656911|NCT02803554|Other|Plasma|Blood plasma from donors aged 25 years or younger
75656912|NCT00960011|Device|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
75656913|NCT00960011|Device|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
75656914|NCT02545231|Drug|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
75656915|NCT02545231|Drug|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
75656916|NCT02545231|Drug|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
75656917|NCT02610309|Behavioral|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
75656918|NCT02803632|Behavioral|questionnaires|
75656919|NCT02803632|Device|actigraphic recording|
75656920|NCT00854815|Procedure|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
75656921|NCT00854815|Procedure|No Irrigation|Suction only using suction/irrigator
75656922|NCT02803788|Drug|ramosetron, ondansetron, dexamethasone|prevention of post-operative nausea vomiting
75656923|NCT04281953|Diagnostic Test|High frequency audiometry|Simple hearing test
75656924|NCT04281953|Other|Short-Form 36-Item Questionnaire (SF-36)|Questionnaire on quality of life (Short Form 36 Item- SF-36)
75656925|NCT04281953|Other|Hearing handicap inventory for adults/elderly (HHIA/HHIE)|Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
75656926|NCT04281953|Other|Tinnitus handicap inventory (THI)|Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
75656927|NCT04041505|Behavioral|(feeding modality)|The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
75803960|NCT01097499|Device|OsseoPulse device (Light emitting diode technology)|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
75803961|NCT03624712|Diagnostic Test|uterine neoplasms|Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
75803962|NCT03695224|Diagnostic Test|Topological perception test|Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.
75803963|NCT03692728|Other|Psychological and Behavioral Problems|Differences in age and sex between the CC and NV groups were compared using the independent samples t test and Chi-square test, respectively. Comparisons of abnormal rates between the CC and NV groups were performed using the Chi-square test. Scores on all subscales recorded for the CC group were compared with those of the NV group and the Chinese urban norm using the independent samples t test and one-sample t test, respectively.
75803964|NCT03694990|Other|Follow-up schedule|Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.
75803965|NCT01091415|Procedure|calcium phosphate bone cement injection|volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
75943953|NCT03467997|Other|Diesel exhaust|Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
75943954|NCT04452279|Device|iStent or iStent inject implantation with concomitant cataract surgery|Standard phacoemulsification cataract surgery followed by ab interno implantation of either iStent or iStent inject trabecular micro-bypass stent(s). Preoperatively and at specified visits through 3 months postoperative, patients will complete evaluations of their ocular surface disease (specifically OSDI score, hyperemia, corneal/conjunctival staining, and tear break-up time).
75656928|NCT05757375|Other|Mulligan Manuel Therapy Consept|Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.
75656929|NCT02800278|Other|observational|describe bone status and outcome of odontoid fracture
75656930|NCT02859701|Drug|AK002|IV AK002
75656931|NCT02859701|Other|Placebo|
75672355|NCT02651532|Device|Confocal Laser Endomicroscopy|During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
75672356|NCT02651610|Biological|Bavituximab|Biological: bavituximab
75803966|NCT03694912|Procedure|Partial or radical nephrectomy|The investigators perform partial or radical nephrectomy those diagnosed as RCC.
75803967|NCT00032487|Drug|Insulin|Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
75803968|NCT00032487|Drug|Glimepiride|Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
75803969|NCT00032487|Drug|Rosiglitazone|Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
75803970|NCT00032487|Drug|Metformin|Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
75803971|NCT01091493|Drug|Moxifloxacin|Moxifloxacin 400 mg administered once a day for 5 days
75943955|NCT05304897|Procedure|Conventional treatment|Conventional treatments for Tracheobronchial fistula, including the application of metallic endoclips
75943956|NCT05304897|Procedure|PRP treatment|PRP treatment following the conventional treatment for Tracheobronchial fistula
75943957|NCT03811041|Other|MDA|Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.
75943958|NCT03811041|Other|Routine Cares|Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.
75943959|NCT03811041|Other|Parental depression|Parents of depressed adolescents will be met for a screening test of depression.
75672357|NCT02651610|Drug|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
75672358|NCT02828579|Procedure|Bariatric surgery|Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
75803972|NCT03692416|Drug|Ibuprofen|"Infants and children with vasculitis attending AssiutU, aged > 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests & Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Ibuprofen for ANCA, C3, C4 &C5a levels done, measured By ELISA technique."
75943960|NCT03719001|Drug|Phenylephrine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
76091566|NCT02458326|Other|Aerobic training|Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
75345669|NCT05753345|Behavioral|Aquatic therapy|Children receive aquatic occupational therapy twice a week for 10 weeks. 30 minutes of aquatic therapy in a warm water pool to increase upper extremity function and swim skills; 15 minutes of self care training to increase independence with dressing and showering.
76091567|NCT02458326|Other|Control Training|10 minutes of heating on the treadmill with a low speed that does not cause patient effort
75345670|NCT05739812|Device|telesurgery by domestic surgical robot|telesurgery of urological diseases by domestic surgical robot
75345671|NCT05731518|Drug|SC0245|SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
75345672|NCT05731518|Drug|Irinotecan|Irinotecan 80mg/m^2 via IV administered for every 4 weeks (fixed dosing) in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
75476774|NCT05637970|Device|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manualpressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
75656932|NCT02610153|Drug|Vitamin K Antagonist|The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
75656933|NCT02799966|Device|Myndmove|20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.
75656934|NCT04281641|Diagnostic Test|TCHP|"Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin~Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta~Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6~Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~All study drugs were administered intravenously.~Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery~Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery."
75656935|NCT00862693|Drug|Calcitriol|0.5ug/Biw
75656936|NCT02799576|Device|Curved needle|In this arm, the curved block needle will be used for regional blockade
75656937|NCT02859311|Drug|Withdrawal of therapy|Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
75656938|NCT00859417|Procedure|Traditional surgery|Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).
75656939|NCT00859417|Device|Perigee® prosthesis|Surgical method with Perigee® prosthesis
75803973|NCT03692416|Drug|Prednisone|"Infants and children with vasculitis attending AssiutU, aged > 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests & Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Steroids for ANCA, C3, C4 &C5a levels done, measured By ELISA technique."
75803974|NCT03692416|Drug|Methotrexate|"Infants and children with vasculitis attending AssiutU, aged > 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests & Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Methotrexate for ANCA, C3, C4 &C5a levels done, measured By ELISA technique."
75943961|NCT03719001|Drug|Dexmedetomidine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
75943962|NCT03719001|Drug|Clevidipine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
75943963|NCT03719001|Other|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
75943964|NCT03719001|Other|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
75943965|NCT03719001|Drug|Calcium Chloride|CaCl will be administered to increase blood pressure and plasma calcium concentration
75943966|NCT02500732|Drug|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
75476775|NCT05634200|Procedure|Bronchoscopy|During bronchoscopy endobronchial biopsy, transbronchial biopsy, transbronchial needle aspiration, bronchial washing, bronchoalveolar lavage, EBUS-TBNA and EUS-B-FNA may be performed
75656940|NCT00854971|Biological|TKCell|Biological/Vaccine: TKCell
75672359|NCT02655588|Behavioral|Interactive Media-Based Problems Solving Treatment|
75943967|NCT02500732|Drug|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
75943968|NCT03448497|Other|Non-interventional|Non-interventional
76091568|NCT03268278|Drug|Buprenorphine|Buprenorphine plus local anesthetic
76091569|NCT03268278|Drug|Sterile saline|Placebo 1,8 ml
76091570|NCT03268278|Drug|lidocaine, epinephrine (Local anesthetic)|2% lidocaine 1:100,000 epinephrine
75656941|NCT02799498|Device|Auto-injector device|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
75943969|NCT02518048|Drug|LEO 90100 Aerosol foam|
75943970|NCT02518048|Drug|Betesil® 2.25 mg|
76091571|NCT03268434|Behavioral|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
76091572|NCT03268434|Behavioral|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
76091573|NCT05045586|Device|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid
76091574|NCT05045586|Device|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
76091575|NCT03268044|Other|Hospital admission and surgery|Hospital admission and noncardiac surgery
76091576|NCT03268122|Other|Standard Contact Isolation|With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
75476776|NCT05630716|Device|NICOM|non-invasive monitor capable of measuring cardiac output (CO) and cardiac index (CI), and stroke volume (SV) and stroke volume index (SVI) based on heart rate. The NICOM technology will be implemented by the Rapid Response Team providers (Advanced Practice Providers) and ICU nurses at FSH, most of whom are already trained and familiar with its use.
75476777|NCT05619536|Combination Product|CD388 Injection|CD388 liquid for injection
75803975|NCT03694678|Behavioral|Recovering Together|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc) within 2 in person sessions at hospitalization and 4 live video sessions after discharge. Both patient and caregiver will participate in all sessions
75803976|NCT03594552|Drug|Arbaclofen_15|Single oral dose (15mg)
75803977|NCT03594552|Drug|Arbaclofen_30|Single oral dose (30mg)
75476778|NCT05619536|Drug|Saline placebo|Sterile normal saline for injection
75656942|NCT02799498|Other|Etanercept (ENBREL®) via Manual injection|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
75656943|NCT02799498|Drug|Etanercept (ENBREL®)|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
75672360|NCT04208594|Drug|Ivabradine|comparing between both drugs for the effect of hypotensive anesthesia
75803978|NCT03594552|Drug|Placebo|Single oral dose placebo (oral tablet)
75803979|NCT03692338|Behavioral|Exercise|Patients will be asked to complete 3 x 30 minute exercise sessions each week.
75803980|NCT03692260|Procedure|3D stent in Herbert screw insertion vs titanium plate|benefit of 3d template in fracture gap
75803981|NCT03641508|Drug|Triamcinolone|Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine
75803982|NCT03641508|Drug|Dexamethasone|dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
75803983|NCT03730896|Procedure|Dry needling|Dryneedling of the sternocleidomastoid muscles within a standard treatment approach of physical therapy
75803984|NCT03465878|Drug|LY900014|Administered via SC injection
75803985|NCT03465878|Drug|Insulin Lispro|Administered via SC injection
75803986|NCT03637374|Device|Visceral Manifold and Thoracic Bifurcation|Endovascular stent graft system
75803987|NCT03637374|Device|Unitary Manifold|Endovascular stent graft system
75803988|NCT03637374|Device|TAAA Debranching Stent Graft System|Endovascular stent graft system
75803989|NCT01091571|Drug|Dipyridamole|Oral treatment with dipyridamole 200 mg twice daily during seven consecutive days
75943971|NCT03129399|Device|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
75943972|NCT03129399|Device|McGrath MAC video laryngoscope|nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
75966032|NCT02087579|Drug|Quetiapine, oral formulation|Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
75966033|NCT02087579|Drug|Risperidone, oral formulation|Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
75966034|NCT02087579|Drug|Risperidone, LAI|Risperidone LAI injections will be administered will be administered per the locally approved label indications.
75966035|NCT03777371|Other|Anti HIV Seropositive Pregnant Women|
76091577|NCT03268122|Other|Targeted Contact Isolation|"With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.~A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia."
76091578|NCT03267732|Biological|Pegilodecakin|Pegilodecakin Alone
76091579|NCT03263676|Device|Icon resuable underwear|Reusable incontinence underwear
76091580|NCT03263676|Device|Disposable pad|Standard market disposable pad
76091581|NCT04736862|Device|Continuous non-invasive blood pressure monitoring|In patients randomized to the continuous monitoring group, continuous non-invasive finger-cuff blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
75345673|NCT05729048|Device|Starling|"Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood.~The Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode.~This information is used to determine cardiac output. The Starling monitor also measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling monitor."
75354702|NCT04729803|Behavioral|Experimental: Attention Guidance + Exposure|"Participants will receive a brief standardized psychoeducation module, presented via a video recording.~Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~Between speeches participants will have a 1-minute break.~Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention guidance condition: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given target audience members to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target audience member for the whole response."
75803990|NCT01091571|Drug|Placebo|Placebo twice daily during seven consecutive days
75803991|NCT01091571|Other|LPS|The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
75943973|NCT03792711|Dietary Supplement|Ensure® Plus Advance|"Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women."
75943974|NCT03448809|Behavioral|Mind My Mind|An individual, modular and flexible cognitive and behavioural therapy
75943975|NCT03448809|Behavioral|TAU (Treatment as Usual)|The children were offered anonymous counselling, supportive talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. A few were offered group-based CBT-programs for selected problems, but the access to manualized treatment was generally very restricted.
75943976|NCT05009914|Procedure|cardiac denervation|Excision of Marshall ligament and Waterstone fat pad during CABG.
75803992|NCT03639272|Procedure|open reduction and internal fixation (ORIF).|Depending on the fracture location, a single anteromedial or anterolateral approach was carried out. The fracture site was cleaned to make it visible, allowing anatomical reduction. Subsequently, fixation of provisional fragments was achieved using temporary Kirschner wires under radiographic guidance. Having obtained satisfactory reduction as seen with the radiographic intensifier, definitive fixation of the main bone fragments was carried out using two or more 3.5 mm titanium cannulated screws or 4.0 mm lag screws, placed anteriorly to posteriorly. Fractures complicated by severe comminution necessitated 3.5 mm cortical screws in order to avoid shortening, translation or angulation of the fragments.
75803993|NCT01091649|Drug|ABT-450|Low dose ABT-450 / ritonavir see Arm Description for more information
75943977|NCT03788577|Dietary Supplement|Oligonol intake|Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
75943978|NCT03788577|Dietary Supplement|Placebo|Placebo
75943979|NCT03129243|Diagnostic Test|Sperm DNA integrity by flow cytometry|flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.
75943980|NCT03448575|Other|Control - Provider Medication Alert Only|Simple text medication alert referencing Choosing Wisely guidelines.
75943981|NCT03448575|Other|Intervention - Alert + CAP Review AND Enhanced BH Access|Interactive medication alert referencing SUAY Clinical Guidelines and offering options to keep/remove orders for the antipsychotic, virtual CAP consult, BH navigation for the patient, and access to bridging therapy for the patient.
75803994|NCT01091649|Drug|ritonavir|ritonavir see Arm Description for more information
75803995|NCT01091649|Drug|ABT-450|High dose ABT-450 / ritonavir See Arm Description for more information
75943982|NCT03448263|Procedure|Balanced Force technique|Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth
75943983|NCT03448263|Procedure|WaveOne technique|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
75943984|NCT03448263|Procedure|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
75943985|NCT02499952|Drug|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
75943986|NCT02499406|Behavioral|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
75943987|NCT05113485|Behavioral|Diabetes Prevention Program-based lifestyle change intervention (DPP)|The DPP condition consists of 11 health education sessions over 12 weeks, including 2 virtual home visits, two virtual group education sessions and 7 telephone coaching calls. These sessions will teach DPP-based lessons on how to lose excess body fat through calorie restriction and increased physical activity. All dietary and physical activity recommendations are intended to be consistent with federal nutrition and physical activity guidelines.
75943988|NCT05113485|Behavioral|Highly Microbiota-Accessible Foods (HMAFs) intervention|The Highly Microbiota-Accessible Foods (HMAFs) intervention approach includes 11 health education sessions, including two virtual home visits, two virtual group education sessions, and 7 telephone coaching sessions. These sessions are designed to help study participants to identify and consume optimally 6 daily instances of minimally processed, fiber-rich food sources, drawn from all four of the MyPlate.gov categories: vegetables, fruits, whole grains and plant-based protein-rich foods (e.g., legumes, nuts and seeds). Increased physical activity is also recommended as a way to optimize the microbial conversion of fiber-rich food sources to short chain fatty acids, which are then expected to reduce excess low-grade inflammation.
76091582|NCT04736862|Device|Intermittent non-invasive blood pressure monitoring|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring using upper-arm cuff oscillometry will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous non-invasive finger-cuff blood pressure monitoring.
76091583|NCT03263286|Device|HandSOME|Participants use the HandSOME orthosis daily for 8 weeks.
75943989|NCT03333135|Procedure|Pulsed Electromagnetic Field therapy (PEMF)|PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
75943990|NCT03333135|Procedure|Pulsed Electromagnetic Field Sham therapy|PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
76091584|NCT03267966|Diagnostic Test|Leeds Pathology Protocol (LEEPP)|LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance
75966036|NCT02339584|Drug|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
76091585|NCT03263520|Drug|Nandrolone Decanoate|Drug administration
75354703|NCT04729803|Behavioral|Active Comparator: Exposure Alone|"Participants will receive a brief standardized psychoeducation module, presented via a video recording.~Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~Between speeches participants will have a 1-minute break.~Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial."
75656944|NCT02799420|Device|GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France|The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
75656945|NCT02799420|Device|white light endoscopy (WLE)|The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
75803996|NCT01091727|Drug|Botulinum toxin A|Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
75803997|NCT03421730|Combination Product|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System|The VR647 Inhalation System consists of the VR647 Inhalation System 1 control unit, a VR647 nebulizer handset, a mouthpiece and VR647 Smart Cards designed specifically for this trial.
75803998|NCT03421730|Combination Product|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.
75803999|NCT01094925|Drug|lactose|Single oral dose
75804000|NCT01094925|Drug|Gabapentin 300mg|Single oral dose of 300mg gabapentin
75804001|NCT01094925|Drug|Gabapentin 600mg|Single oral dose of 600mg gabapentin
75804002|NCT03694444|Drug|AMY-101|C3 complement inhibitor
75804003|NCT03694444|Other|Water for injection|Placebo
76091586|NCT03263520|Drug|Dexamethasone|Drug administration
75656946|NCT00617851|Biological|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
75656947|NCT00617851|Biological|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
75656948|NCT00617851|Biological|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
75804004|NCT01310972|Other|Registry|Registry
75804005|NCT03715868|Other|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
75804006|NCT03701932|Behavioral|TMS and Lumosity®cognitive retraining|The Lumosity® training includes exercises for speed, memory, attention, flexibility, and problem solving. Subjects will complete this battery while receiving TMS treatment.
76091587|NCT02456844|Drug|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142|"Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~BMS-986142: On Days 6 through 12."
76091588|NCT02456844|Drug|Methotrexate, Leucovorin and BMS-986142|"Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~BMS-986142 on Days 6 through 10."
76091589|NCT03269838|Diagnostic Test|ECG|Primary Percutaneous coronary intervention
75804007|NCT03701932|Behavioral|TMS and non cognitive computer games|Subjects will play computer games while receiving TMS treatment.
75804008|NCT04841876|Other|rugby matches|standard rugby-7s match
75820037|NCT02186314|Device|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
75656949|NCT00617851|Biological|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
75804009|NCT03694366|Other|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~Community engagement meetings and feedback;~Elimination of public sector facility user fees for children under five and pregnant women;~Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing & referrals;~Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~Basic infrastructure improvements and supply chain management training of pharmacy managers"
75804010|NCT03718676|Procedure|Ferric sulphate|Teeth were pulpotomized with ferric sulphate in this group.
75804011|NCT03718676|Procedure|Ortho-MTA|Teeth were pulpotomized with Ortho-MTA in this group.
75804012|NCT03718676|Procedure|Retro-MTA|Teeth were pulpotomized with Retro-MTA in this group.
75804013|NCT00054327|Drug|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
75804014|NCT00054327|Drug|cyclophosphamide|Given IV
75804015|NCT00054327|Drug|cytarabine|Given IV
75804016|NCT00054327|Radiation|radiation therapy|Patients undergo total body irradiation
75804017|NCT00054327|Drug|Etoposide|infusion
75804018|NCT00054327|Procedure|Stem Cell Transfusion|
75804019|NCT03692104|Diagnostic Test|transrectal ultrasound|Use of US for post implant quality assessment
75804020|NCT03503162|Device|Pure-Vu System|The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
75804021|NCT03952689|Device|Serenno Medical Automatic Urine Output measuring device|"Device that measures ongoing urine output will be connecter to the patients catheter. The urine count of the device will be compared to the gold standard measurement technique (nurse count)."
75943991|NCT03443817|Behavioral|Tele rehab|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
75943992|NCT02498392|Drug|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
75943993|NCT02498392|Other|Placebo|Matching Placebo will be administered orally.
75943994|NCT03205605|Drug|oxybutynin|patch
75656950|NCT00617851|Biological|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
75656951|NCT02806440|Drug|Low dose naltrexone|Active comparator
75656952|NCT02806440|Drug|Placebo|Placebo comparator
75656953|NCT02544295|Behavioral|Clinical interview|
75804022|NCT03029650|Drug|Transderm Scop®|TDDS dosage is 1.5 mg/72 hrs
75804023|NCT03029650|Drug|Intravenous scopolamine hydrobromide|0.4 mg via intravenous injection
75804024|NCT03462680|Dietary Supplement|niacin|Niacin or nicotinic acid 250 mg tablets
75804025|NCT03462680|Other|placebo|placebo tablet
75804026|NCT03694132|Device|functional MRI|conditioning brain activity with peripheral stimulations
75804027|NCT03694132|Device|structural MRI|diffusion MRI and tractography for evaluating the brain structures
75804028|NCT03694132|Device|EEG/MEG|conditioning brain activity with peripheral stimulations
75804029|NCT03952845|Other|Capsaicinoid|This is a tolerability study on doses lower than previously published for the use of intranasal capsaicinoid in the treatment of rhinitis
75804030|NCT03692026|Procedure|Immediate implant placement|implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.
75804031|NCT03692026|Drug|Hyaluronic acid and Melatonin Mixture|a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
75804032|NCT01095081|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
75804033|NCT03624322|Drug|Zyprexa IM|5mg
75804034|NCT03624322|Drug|Zydis|10mg orally disintegrating wafer
75804035|NCT03624322|Drug|INP105|Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)
75804036|NCT03624322|Device|I231 POD® Device|Precision Olfactory Delivery (POD) device
75804037|NCT01097811|Drug|Erythromycin|250 mg orally q.i.d.
75804038|NCT01097811|Drug|Neomycin|1 g orally q.i.d.
75804039|NCT03957291|Drug|Chlorhexidine|chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )
75804040|NCT03957291|Drug|Povidone-Iodine|Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
75804041|NCT01091883|Device|Exablate treatment|MR Guided Focused Ultrasound
75804042|NCT01091883|Radiation|Radiation|External Beam Radiation
75943995|NCT03205605|Drug|oxybutynin|gel
75943996|NCT03443661|Drug|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
75943997|NCT05008588|Biological|Conditioned Medium|Intranasal of 3 cc of conditioned medium each, for 3 days in a row
75943998|NCT05008588|Biological|Umbilical Cord Mesenchymal Stem Cells|Intra-parenchymal transplantation of 20x10^6 UC-MSCs
75656954|NCT02544295|Behavioral|Virtual reality task|
75656955|NCT00913809|Drug|Desipramine HCL 100 mg Tablets Cord Laboratories|
75656956|NCT00913809|Drug|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
75345674|NCT05728385|Dietary Supplement|Modified Specific carbohydrate diet for 3 months|"All children at the start of the study will be subjected to:~Full history taking including demographic and medical history~Full nutritional assessment including: Through clinical examination for any signs of vitamins and mineral deficiency, with full chest examination.~Laboratory tests: Complete blood picture with differential white blood cells, and Serum IgE level~At the beginning of the study and at the end~The patients will be assessed using the childhood-asthma control test (C-ACT) as a subjective method~Pulmonary function tests will be performed using spirometry (Spirostik, Geratherm) that includes Forced vital capacity (FVC), forced expiratory volume in the first second of FVC (FEV1), and FEV1/FVC.~Anthropometric measurements: Weight, Height, and Body mass index (BMI). All measures will be plotted on specific percentile curves for age and Z score"
75345675|NCT05721976|Behavioral|"With Love, Grandma (Con Cariño, Abuelita)"|"Cancer survivor-Daughter dyads will log in to a secured website to access intervention content over a period of 10-12 weeks. The intervention will be delivered primarily through smartphones and will include 8 modules with didactic content on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting content, all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
75345676|NCT05715632|Drug|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical hand surgery for gastric cancer
75943999|NCT05008588|Procedure|Neurologic and Neutrophic Drugs|Such as clopidogrel, piracetam, citicoline
75345677|NCT05696795|Drug|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of sarcoidosis.
75345678|NCT05687110|Procedure|Biopsy|Undergo tumor biopsy
75476779|NCT05618327|Drug|JS203 for Injection|"2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter."
75656957|NCT02806362|Drug|Ombitasvir/paritaprevir/ritonavir|Tablet
75944000|NCT03443583|Other|Immediate Dentin Sealing or Delayed Dentin Sealing|The main difference between the IDS and DDS technique lies in the fact that in IDS, a thin layer of bonding resin is applied immediately after tooth preparation and prior to impression taking, whereas in DDS this layer is applied immediately before cementation of the restoration.
75656958|NCT00855049|Drug|Acetaminophen|Intranasal acetaminophen administration
75656959|NCT00855049|Drug|Acetaminophen|Oral acetaminophen administration
75944001|NCT03048045|Procedure|Supportive Periodontal Treatment (SPT)|Assessment of Gingival Bleeding Index and Plaque Control Record, re-instruction and re-motivation to effective individual plaque control, professional tooth cleaning, application of a fluoride gel. Twice a year a periodontal charting with probing pocket depths (PPD) and vertical attachment Level (PAL-V) are obtained at 6 sites per tooth. Thirty seconds after probing bleeding on probing (BOP) is recorded. Sites exhibiting PPD = 4 mm and BOP as well as sites with PPD >/= 5 mm are scaled subgingivally. Assignment of SPT intervals is performed according to the periodontal risk assessment (PRA).
76091590|NCT03263208|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
76091591|NCT03263208|Drug|Fludarabine|Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
76091592|NCT03263208|Biological|CD19 CAR-T|CD19 CAR-T cells will be administered after completion of the chemotherapy.
75476780|NCT05614180|Procedure|Percutaneous coronary intervention|Patients with a diagnose of coronary chronic total occlusions will be treated by percutaneous coronary intervention, as indicated by the heart-team.
75656960|NCT02799030|Drug|BF-200 ALA 1%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
75656961|NCT02799030|Drug|BF-200 ALA 3%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
75656962|NCT02799030|Drug|BF-200 ALA 10%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
75656963|NCT02799108|Device|NIRS|High-resolution EEG-fNIRS recording lasting a maximum of 30 minutes by using expressive and receptive language paradigms
75656964|NCT02799108|Device|fMRI|fMRI acquisition under the same stimulation conditions
75656965|NCT00812955|Drug|ABT-143|Once daily for 8 weeks
75656966|NCT00812955|Drug|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
75656967|NCT04235478|Drug|Combination Product: triamcinolone and saline|a mixture of 3 mL 0.09%saline and 2 mL 80 mg triamcinolone (kenacort-a)
75656968|NCT00619489|Drug|vedolizumab|Vedolizumab for intravenous (IV) infusion
75966037|NCT02339584|Drug|Brinzolamide 10 mg/mL eye drops, suspension|
75966038|NCT02339584|Drug|Brimonidine 2 mg/mL eye drops, solution|
75966039|NCT02339584|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
76091593|NCT03259542|Drug|Mifepristone 300 MG|mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
75656969|NCT02806206|Drug|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
75656970|NCT02806206|Drug|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
75944002|NCT03443505|Diagnostic Test|Neural respiratory drive measurement|"Neural respiratory drive (NRD) has been validated as an objective physiological biomarker in acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Change in NRD during hospital admission has been demonstrated to be a marker of physician-defined clinical deterioration. NRD is a non-invasive measurement that involves skin preparation with a gel and alcohol wipe before placing 3 surface electrodes on the chest wall and collar bone to perform electromyography (EMG) of parasternal muscles. Electrodes are connected to an automated EMG analysis system to derive a measurement of NRD. Measurements take approximately 10 minutes with subject being monitored during normal (tidal) breathing and performing maximal sniff manoeuvres."
75944003|NCT05006950|Device|Stryker1688 Fluorescence imaging system|The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool to determine the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.
75656971|NCT04042363|Device|Transorbital electrical stimulation (Eyetronic Next Wave 1.1)|"Calibration phase: The patient will use a response button to indicate the threshold from which he feels a luminous sensation (phosphene). In a second step, he will use the same answer button to indicate the stimulation frequency from which the phosphenes become continuous.~Stimulation phase: From these 2 parameters (amplitude and frequency), the stimulation session will begin for a duration of approximately 40 to 50 minutes, the settings being dependent of the individual thresholds."
75804043|NCT04044976|Drug|Caffeine Citrate|Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
75804044|NCT01097889|Dietary Supplement|Fortified blended foods, Corn Soya Bean Flour (CSB) with oil.|A daily ration equivalent of 300g CSB and 32g vegetable oil Bi-weekly distribution of premix of 4.2kg CSB with 0.5L vegetable oil. Estimated 1413 kcal, 47g protein
75804045|NCT01097889|Dietary Supplement|RUSF (ready-to-use supplementary foods) Supplementary Plumpy®|"Peanut-based fortified supplement~One 92g sachet eaten throughout the day Bi-weekly distributions of 14 sachets 500 kcal and 13g protein"
75804046|NCT04300270|Device|Smartphone PPG recordings|Smartphone camera PPG recordings using a novel software application.
75345679|NCT05687110|Procedure|Biospecimen Collection|Undergo blood sample collection
75656972|NCT04042363|Device|Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation|The calibration phase is identical to the active stimulation. During the stimulation phase, the operator will manually interrupt the stimulation 60 seconds after the start of the session.
75656973|NCT00855205|Drug|Rituximab|Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
75345680|NCT05687110|Procedure|Diagnostic Imaging|Undergo medical imaging scans
75345681|NCT05687110|Biological|Novobiocin Sodium|Given PO
75345682|NCT05683392|Device|t:slim X2 insulin pump with Control-IQ technology 2.0|t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor.
75345683|NCT05674565|Drug|Magnesium sulfate loading with maintenance dose|4 gm MgSo4 loading over 20 minutes followed by 1 gm per hour maintenance till delivery
75345684|NCT05674565|Drug|Magnesium sulfate loading dose only|4 gm MgSo4 loading over 20 minutes within one hour before delivery
75345685|NCT05673772|Radiation|short-course radiotherapy|25 Gy in 5 fractions for 5 days
75656974|NCT02803320|Drug|SPF 50 Y65 110 (BAY 987516)|Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
75804047|NCT04300270|Device|Smartphone ECG|Smartphone connected one-lead ECG recordings.
75804048|NCT03955653|Procedure|Femoral artey access|We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention
75804049|NCT03691636|Device|Eyelash prostheses|Eyelash prostheses are essentially specialized eyelash extensions
75804050|NCT03691636|Device|5.0% Lifitegrast Ophthalmic Solution|5.0% Lifitegrast Ophthalmic Solution
75804051|NCT01095159|Device|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
75944004|NCT05006638|Drug|Lipid Emulsion, Intravenous|Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
75944005|NCT05006638|Drug|Atropine|a drug used as an antidote for some types of pesticides
75944006|NCT05006638|Drug|Toxogonin|a drug used as an antidote for some types of pesticides
75944007|NCT05006638|Drug|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
75944008|NCT04451889|Device|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
75944009|NCT03443349|Device|Vibwife One|"Vibwife One is a powered rotation bed intended to be used to assist in active mobilization of delivering women. Vibwife One imitates manual mobilization and position techniques. It is integrated in the mattress and fixed to the pelvis area of the birthing bed. Vibwife One can be used, when manual mobilization and position techniques are deemed appropriate.~The device with all its functions is controlled over a remote control."
75944010|NCT02498236|Drug|Intranasal Oxytocin|
75944011|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|"Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.~The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines."
75345686|NCT05673772|Drug|mFOLFOX6|Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours
75345687|NCT05673772|Radiation|Chemoradiotherapy|45~50.4 Gy/25fr with concurrent use of either capecitabine or 5-FU+leucovorin(or levoleucovorin or leucosodium)
75345688|NCT05673772|Procedure|TME surgery|TME surgery
75804052|NCT01095159|Device|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
75944012|NCT01443819|Other|Physical Therapy|"Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).~Please note: There will be another PT evaluation at the end of 6 weeks."
75944013|NCT01443819|Other|Observation|If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
76091594|NCT03259542|Drug|Itraconazole 100 MG|itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
76091595|NCT03267654|Drug|gefitinib combined with chemotherapy|"Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit."
76091596|NCT03267654|Drug|gefitinib combined with apatinib|"gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death."
76091597|NCT03267654|Drug|gefitinib single agent|Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
76091598|NCT03267342|Behavioral|One-on-one financial counseling|Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.
76091599|NCT03267342|Behavioral|Peer support group|Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.
76091600|NCT03267342|Behavioral|Supported access to mainstream banking services|Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as Automatic Teller Machine (ATM) cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.
75656975|NCT00859729|Biological|pVAXrcPSAv53l (DNA encoding rhesus PSA)|5 doses, 4 weeks apart
75656976|NCT00859729|Device|DERMA VAX™ intradermal DNA delivery system|in vivo electroporation is applied after each DNA injection
75656977|NCT02806674|Device|The eradication times of the patients|The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
75656978|NCT02806674|Device|The result of 13C-urea breath test after treatment|The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
75656979|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
75804053|NCT04295902|Device|C-MAC indirect videolaryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Tuttlingen, Germany) with blades Miller nr 0 and Miller nr 1.
75656980|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
75656981|NCT04065126|Behavioral|Physical activity intervention|Ten sessions (two hours each) with physical activity and psycho-educational components.
75656982|NCT04065126|Behavioral|Brief psycho-education|Two brief lectures with psycho-educational components, soon after baseline assessment and in connection to follow-up assessment.
75804054|NCT04295902|Device|Direct laryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
75804055|NCT01094847|Drug|DWJ1252|tablet(oral) administration following the schedule of each arm
75804056|NCT01097967|Other|CPAP|
75820038|NCT02185612|Behavioral|Savings program|The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
75944014|NCT04961086|Other|energy drink|An easily available 250 ml branded energy drink will be randomized to the partcipants after informed consent. Before and thirty minutes after drinking the given energy drink the participant cognition, heart rate, blood pressure and blood glucose will be measured.
75944015|NCT01283997|Other|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
75944016|NCT01283997|Drug|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
75345689|NCT05630495|Device|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
75476781|NCT05610579|Other|Remedial exercise|Remedial exercise program will be taught by qualified physiotherapist. Patients will be practiced to the exercise 3 sets of 15 repetitions without compression. Patients will be monitored telephonically in the washout period for remain the routine activities.
75944017|NCT02496676|Dietary Supplement|Magnesium L-threonate|"In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight."
75476782|NCT05610579|Other|Compression bandage|Multi-layered short stretch bandaging will be applied for 23 hour. Patients will be practiced to the exercise 3 sets of 15 repetitions with compression bandage. The bandage will be removed at the same time the next day. Patients will be monitored telephonically in the washout period for remain the routine activities.
75476783|NCT05610423|Other|no intervention|No intervention. Observational study only
75944018|NCT02496676|Other|Placebo|In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.
75944019|NCT02496676|Drug|Intravenous (IV) magnesium sulfate (MgSO4)|In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
75345690|NCT05626712|Biological|CELZ-201 Administration|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.
75476784|NCT05607771|Device|Manual Vitrification|Oocytes will be prepared for vitrification using the manual protocol
75476785|NCT05607771|Device|Automated Vitrification|Oocytes will be prepared for vitrification using the DaVitri device
75476786|NCT05603585|Dietary Supplement|Optimal protein supplementation to achieve 80% protein adequacy.|Additional protein required and delivered by adding protein powder and given in bolus feeds
75656983|NCT00859885|Drug|Antithrombotic treatment|antiplatelets, anticoagulants
75656984|NCT00859885|Device|percutaneous device closure of PFO|umbrella device for PFO closure
75656985|NCT02803398|Other|Compression bandages application and interface pressure measurements|Bandages, which are applied in a spiral pattern on the leg, are composed of Biflex 16 (Thuasne) and/or Rosidal K (Lohmann & Rauscher).
75656986|NCT02798874|Drug|Ticagrelor|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
75656987|NCT02798874|Drug|Clopidogrel|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
75656988|NCT00860041|Behavioral|pain questionnaires|
75656989|NCT02799264|Drug|Cabotegravir 30 mg|Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.
75656990|NCT02806518|Procedure|DIRT|An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
75804057|NCT03691558|Other|Ketogenic diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, & Compher, 2005; Wang et al., 2000). Macronutrients percentage is 68% fat, 26% protein and 6% carbohydrate Paoli et al. 2013). Very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), are used for a better compliance to the dietary intervention
75804058|NCT03691558|Other|Western Diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, & Compher, 2005; Wang et al., 2000). The diet macronutrient percentage distribution is the following: protein is 25% of TDC (total daily calories), fat is 20% of TDC and carbohydrates represented the 55% of TDC
75804059|NCT01091961|Procedure|Preoperative ACEi/ARB management|Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
75944020|NCT02517268|Procedure|Pancreaticoduodenectomy|
75656991|NCT00959699|Drug|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
75656992|NCT00959699|Drug|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
75656993|NCT00959699|Drug|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
75656994|NCT00959699|Drug|Boceprevir|Boceprevir (800 mg, orally, three times per day)
75656995|NCT02798796|Device|MRI|All patients will be submitted to MRI
75672361|NCT04208594|Drug|Propranolol|comparing between both drugs for the effect of hypotensive anesthesia
75804060|NCT03955965|Other|Medication reconciliation|No intervention was performed other than collecting data on patients' medical files
75944021|NCT04957342|Biological|amnion-chorion membrane|allograft to be placed on palate
75944022|NCT04957342|Procedure|Sutures|Sutures (e.g. interrupted, crisscross compression) to be placed on palate
75944023|NCT05001490|Other|Smartphone application based reminder|Brushing reminders were given to the patients in experimental group through a smartphone application twice daily
75944024|NCT01160211|Drug|lapatinib|1000 mg by mouth once a day
75944025|NCT01160211|Drug|trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks
75944026|NCT01160211|Drug|Aromatase inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
75944027|NCT01160211|Drug|lapatinib|1500 mg by mouth once daily
75966040|NCT02087657|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
75345691|NCT05626712|Other|Control Group|Enhanced standard of care for Type 1 Diabetes treatment only.
75345692|NCT05609045|Biological|Lyophilized COVID-19 mRNA Vaccine|RH109 is a mRNA-based vaccine encoding the N-Terminal Domain (NTD) - Receptor Binding Domain (RBD) derived from Spike (S) protein of SARS-CoV-2 Omicron variant.
75656996|NCT02803008|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation number - SR15-46-Z13-072)
75944028|NCT03443271|Procedure|TAP Block with Bupivicaine|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.
75944029|NCT03443271|Procedure|TAP Block with Placebo drug|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
75944030|NCT01064687|Drug|LY2189265|
76091601|NCT03267342|Behavioral|A matched savings account|Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
76091602|NCT03267420|Diagnostic Test|BpTRU First, Unattended Omron Second|"Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted."
75345693|NCT05609045|Drug|Sodium chloride|0.9% sodium chloride
75345694|NCT05554276|Combination Product|neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy|All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
75476787|NCT05585905|Device|Virtual Reality|The VR system will be worn for approximately 5-10 minutes during dental sealant application
75656997|NCT02806128|Drug|Human Urinary Kallidinogenase for Injection|Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time
75656998|NCT04280861|Other|Multicomponent Intervention|Multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
75656999|NCT02859545|Behavioral|Emotional Validation Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
75657000|NCT02859545|Behavioral|Chronic Pain Education Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
75657001|NCT02798718|Dietary Supplement|full-fat milk|intake 250ml full-fat milk per day, do not intake any other dairy products
75944031|NCT01064687|Drug|Exenatide|
75944032|NCT01064687|Drug|Placebo|
75944033|NCT01064687|Drug|Metformin|
75944034|NCT01064687|Drug|Pioglitazone|
75944035|NCT05029167|Other|Restrictive PaO2|Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
75944036|NCT05029167|Other|Low normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
75944037|NCT05029167|Other|Liberal PaO2|Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
75944038|NCT05029167|Other|High normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
75944039|NCT04983693|Behavioral|Dementia-friendly Worship Service|Key elements of dementia-friendly worship services include familiar hymns, prayers and bible stories and short sermons. Participants can attend the worship services either in person or through online video streaming. Participant dyads should watch the six worship services together, over a span of 6 to 8 weeks.
75944040|NCT03447873|Drug|Continue with triple therapy|To continue with triple therapy
75944041|NCT03447873|Drug|Switch to DTG + 3TC|Switch to dolutegravir + lamivudine once daily
75944042|NCT03447873|Drug|Switch to DRV/cobicistat + 3TC|Switch to darunavir/cobicistat + lamivudine once daily
75345695|NCT05540678|Dietary Supplement|FibreGum|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
75345696|NCT05540678|Dietary Supplement|Placebo|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
75345697|NCT05537311|Behavioral|Social Engagement|30-45 minutes of social engagement provided to patients in ICU. Social engagement strategies including meaningful conversation, cognitive stimulation, and emotional support
75345698|NCT05531942|Drug|Ginkgo Diterpene Lactone Meglumine Injection|The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.
75944043|NCT03447795|Procedure|Alveolar ridge preservation|grafting procedure using autogenous tooth.
75476788|NCT05585905|Behavioral|Basic Behavior Guidance Techniques|Basic behavior guidance techniques will be used as a distraction technique when the VR system is not used during the dental sealant application
75476789|NCT05570955|Behavioral|Text reminder|weekly text to remind use of drug
75944044|NCT02493946|Biological|Botulinum toxin type A|
75944045|NCT02493946|Drug|Placebo|
75944046|NCT03447717|Device|ActiGait|implanted device for peroneal nerve stimulation
76091603|NCT03267420|Diagnostic Test|Unattended Omron First, BpTRU Second|"Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings."
76091604|NCT03267420|Diagnostic Test|Partially Attended Omron First, Unattended Omron Second|"Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted."
76091605|NCT05219058|Procedure|Biological mesh reconstruction|Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.
75944047|NCT02495337|Other|Tissue Collection|
75944048|NCT02310633|Behavioral|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
75944049|NCT02310633|Behavioral|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
75944050|NCT02310633|Behavioral|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
75345699|NCT05531942|Drug|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
75345700|NCT05525533|Behavioral|Harnessing prosocial and social image motivations for behavior change|The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback
75657002|NCT02857907|Other|Blood sample|A blood sample is performed one year after kidney transplantation.
75657003|NCT04236570|Device|Thermode(hot plate) and cold water bath|Standardized protocol will consisted of stimulus test (TS) generated by thermode and conditioning stimulus (CS) using cold water bath.
75944051|NCT04451967|Procedure|thrombolysis|transfer after thrombolysis for STEMI patients within 6h since onset
76091606|NCT05219058|Procedure|Myocutaneous flap reconstruction|Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.
76091607|NCT05219058|Procedure|Primary closure reconstruction|Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.
75345701|NCT05515211|Diagnostic Test|Foot length|Foot length will be measured from the midpoint of the heel to the longest toe.
75345702|NCT05503693|Drug|AP303 50 μg|AP303 tablet
75345703|NCT05503693|Drug|AP303 150 μg|AP303 tablet
75345704|NCT05503693|Drug|AP303 300 μg|AP303 tablet
75657004|NCT04236570|Device|TENS(transcutaneous electrical nerve stimulation)|TENS protocol will consisted of test stimulus (TS) and conditioning stimulus (CS) both generated by TENS
75804061|NCT03956121|Other|injection of magnesium sulfate|The intervention consists to perform a study of the usual fetal heart rate with, in addition, comparison analysis of the short-term variability before and after injection of magnesium sulfate in the exposed group. Two successive short-term variability analyzes will be performed in fetuses of the control group.
75804062|NCT03636906|Biological|RSV (GSK3389245A) lower dose formulation vaccine|1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.
75657005|NCT02798640|Device|Celliant|100% Celliant garment
75657006|NCT02798640|Device|Control|Control Garment
75657007|NCT02798562|Device|Native and dynamic contrast-enhanced CT|
75657008|NCT00617773|Biological|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
75657009|NCT00956813|Dietary Supplement|flaxseed|Given orally
75657010|NCT00956813|Other|placebo|Given orally
75804063|NCT03636906|Biological|RSV (GSK3389245A) higher dose formulation vaccine|2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.
75804064|NCT03636906|Biological|GSK's multicomponent meningococcal B vaccine|3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
75944052|NCT02267421|Behavioral|Home based Aerobic exercise training|
75944053|NCT01064531|Device|MIS Femoral Neck Stem implant|
75944054|NCT04451811|Drug|OPL-002|Spray dried dispersion and tablet formulation
75944055|NCT03653039|Device|Tritube|The ultra thin tribute is used used for the ventilation of the patients in this arm
75944056|NCT03653039|Device|Standard enditracheal tube|A standard endotracheal tube is used used for the ventilation of the patients in this arm
75944057|NCT03621995|Other|Malondialdehyde and Catalase level measurement|Malondialdehyde and Catalase level measurement by colorimetric method
75944058|NCT02220855|Drug|BKM120|
75944059|NCT04054583|Other|Renovation of long-term residential care living spaces|Living spaces of the long term care facility will be renovated.
75944060|NCT03443037|Drug|amantadine sulphate|
76091608|NCT03262818|Device|Transvaginal ultrasound|-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
75345705|NCT05503693|Drug|AP303 600 μg|AP303 tablet
75657011|NCT00860119|Drug|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
76091609|NCT03262818|Device|Ultrasound/Photoacoustic imaging|-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
76091610|NCT03263052|Drug|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
76091611|NCT03259386|Device|Microelectrode array|Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
76091612|NCT03267030|Drug|GRASPA|Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).
76091613|NCT03259230|Other|Blood Draws|
75345706|NCT05503693|Drug|Placebo 50 μg|Placebo tablet
75345707|NCT05503693|Drug|Placebo 150 μg|Placebo tablet
75345708|NCT05503693|Drug|Placebo 300 μg|Placebo tablet
75657012|NCT00860119|Drug|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
75657013|NCT02802930|Drug|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
75657014|NCT02802930|Drug|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
75804065|NCT03636906|Biological|Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine|3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
75944061|NCT03442959|Other|Data record|characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
75657015|NCT02802930|Drug|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
75657016|NCT02802930|Drug|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride [NaCl]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
75657017|NCT00855283|Drug|IN NEO|20 mg Neostigmine via intranasal and sublingual administration
75657018|NCT00855283|Drug|IN NEO|40 mg Neostigmine via intranasal administration
75657019|NCT00855283|Drug|IN NEO|60 mg Neostigmine via intranasal administration
75657020|NCT00855283|Drug|IN NEO + IN Glycopyrrolate|Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
75804066|NCT03636906|Biological|GSK's pneumococcal polysaccharide conjugate vaccine|3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.
75804067|NCT03636906|Biological|GSK's meningococcal group A, C, W-135 and Y conjugate vaccine|2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.
75944062|NCT04915599|Device|Cooral® mouth cooling device (MCD)|Cooral® mouth cooling device (MCD) to prevent oral mucositis (QM) in patients undergoing radiation therapy for head and neck malignancies
75944063|NCT03442881|Procedure|Excision of adnexal mass through laprotomy|Through laparotomy incision, the adnexal mass will be excised
75944064|NCT03442803|Device|Target-Controlled Infusion|Propofol Target-Controlled Infusion
75944065|NCT03442647|Diagnostic Test|sinistrin clearance dynamic measurement|sinistrin clearance measurements will be performed before and 90 min after oral protein load
75345709|NCT05503693|Drug|Placebo 600 μg|Placebo tablet
75345710|NCT05502016|Behavioral|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
75345711|NCT05502016|Behavioral|Family Model Diabetes Self-Management Education and Support (Wait-list)|Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
75345712|NCT05493826|Other|No intervention|Non-interventional study based on secondary use of hospital medical record
75657021|NCT00855283|Drug|IV Visit|2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
75944066|NCT03442491|Procedure|Hayman's Haemostatic Suture|After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.
75944067|NCT03447561|Behavioral|Anticipatory + consummatory food reward|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake).
75944068|NCT03447561|Behavioral|Consummatory food reward|Exposure to consummatory food reward (drinking sips of chocolate milkshake).
75804068|NCT03636906|Drug|Placebo|1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
75804069|NCT03028870|Drug|V120083|Capsules
75804070|NCT03028870|Drug|Naproxen|Capsules
75804071|NCT03028870|Drug|Placebo|Capsules to match V120083 and/or naproxen
75804072|NCT01098201|Drug|Certolizumab|Subcutaneous administration on a monthly basis for six months
75804073|NCT01092039|Dietary Supplement|lactoferrin, L-Glutamine and beta-glucans|Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
75804074|NCT01092039|Dietary Supplement|Placebo Comparator|Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.
75804075|NCT03694054|Other|Care coordination tool|Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.
75804076|NCT03663582|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
75944069|NCT03447483|Other|Patients starting a treatment by ICI|"Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:~every 6 weeks for treatment regimen administered every 2 or 3 weeks~at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks"
76091614|NCT03259230|Other|Data Collection|
75657022|NCT04236024|Other|Board game|The students in the experimental group will play board game to learn medication about 30-60 minutes.
75657023|NCT04236024|Other|Traditional lecture|The students in the comparison group will receive medication lecture using PPT slides about 30-60 minutes.
75657024|NCT00862927|Other|Breath Sample|Breathe into machine measuring carbon monoxide.
75657025|NCT00862927|Other|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
75804077|NCT03663582|Device|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).
75804078|NCT03663582|Device|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
75804079|NCT03663582|Device|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
75944070|NCT03447405|Device|Dino Egg|DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
75944071|NCT02918279|Drug|Liraglutide|Administered once daily subcutaneously (s.c., under the skin)
75804080|NCT01098357|Drug|Biochaperone PDGF-BB Low dose|BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
75944072|NCT02918279|Drug|Placebo|Administered once daily subcutaneously (s.c., under the skin)
76091615|NCT03262428|Other|Semi-structured interviews|Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.
75657026|NCT00862927|Behavioral|Questionnaire|6 surveys, taking approximately 30 minutes total.
75657027|NCT00862927|Behavioral|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
75657028|NCT02805738|Drug|CKD-390|CKD-390 1 Tablet (48 weeks)
75657029|NCT02805738|Drug|viread|viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)
75804081|NCT01098357|Drug|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
75804082|NCT01098357|Drug|Regranex|Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
75804083|NCT01098357|Drug|Biochaperone PDGF-BB Very Low Dose|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
75804084|NCT03955731|Device|Magmaris resorbable magnesium scaffold|Implantation of Magmaris resorbable magnesium scaffold
75944073|NCT03447327|Procedure|single burr hole|patients with CSDH operated by single burr hole craniostomy under local anaesthesia
75944074|NCT04268745|Behavioral|Balance training|Progressive balance training within virtual environments
75944075|NCT04268745|Behavioral|Traditional Vestibular Rehabilitation|Progressive balance training and gaze stability exercises
75944076|NCT03447171|Device|App Vision Screening|Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
75944077|NCT00356655|Behavioral|Psychoeducation|
75944078|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
75657030|NCT02857673|Behavioral|Child Abuse Prevention Problem Solving|The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.
75804085|NCT03730740|Drug|Lenalidomide 25mg|Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas
75804086|NCT01098513|Drug|GSK1349572 formulation AP|GSK1349572 50 mg single dose fasted.
75944079|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
75657031|NCT02857673|Behavioral|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
75944080|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
75657032|NCT00855361|Drug|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
75804087|NCT01098513|Drug|GSK1349572 formulation AW|GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
76091616|NCT03259152|Drug|Denosumab|Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
75944081|NCT02956837|Drug|Placebo (Formulation buffer S9b)|A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
76091617|NCT03262506|Other|Computerized cognitive training|The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
76091618|NCT02456142|Drug|caudal bupivacaine|
76091619|NCT02456142|Drug|intravenous morphine|
76091620|NCT03262740|Drug|BMS-986195|Oral administration of specified dose on specified days
76091621|NCT03262740|Drug|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
75345713|NCT05490589|Other|EQUIPE Program|"EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home."
75345714|NCT05490550|Behavioral|COAST-enhanced CBTI|Participants will receive CBTI delivered through the COAST platform by one of NOCTEM's certified and licensed COAST clinician. Communication between the participant and licensed clinician will occur primarily through COAST's HIPAA-compliant text messaging, but clinicians and patients may elect to connect via telephone calls or HIPAA-compliant secure videoconference if needed.
75345715|NCT05490550|Behavioral|Military Treatment Facility Insomnia Care As Usual|Participants will receive the insomnia care offered at their site following current delivery practices (i.e., face-to-face or virtual; individual or group format). During the treatment phase, participants randomized to ICAU will be instructed to communicate with their clinicians as needed, according to standard procedures in place.
75657033|NCT02798406|Biological|DNX-2401|On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
75657034|NCT02798406|Biological|pembrolizumab|Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
75804088|NCT01098513|Drug|GSK1349572 formulation AX|GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B
75345716|NCT05479916|Dietary Supplement|Low glycated milk protein|40 grams of protein dissolved in 600 mL of water
75345717|NCT05479916|Dietary Supplement|High glycated milk protein|40 grams of protein dissolved in 600 mL of water
75657035|NCT02857751|Behavioral|Surf therapy|The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
75804089|NCT03737838|Device|Atrial fibrillation ablation|High density mapping of left atrium using Rhythmia mapping system to identify gaps in conduction and wavefront discontinuities (deceleration zones)
75804090|NCT05666154|Other|Real diet|Diet excluding either trigger nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger)
75804091|NCT05666154|Other|Sham diet|Diet excluding either sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
75804092|NCT05666154|Other|Wheat exclusion diet|Diet excluding wheat in a blinded crossover fashion (CLE negative individuals without identified trigger)
75804093|NCT05666154|Other|Soy exclusion diet|Diet excluding soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
75944082|NCT02521935|Device|Complete traditional dentures|"Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination & diagnosis & initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments"
75944083|NCT02521935|Device|Complete CADCAM dentures|"Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, & tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage"
75944084|NCT03447093|Drug|Methimazole Pill|Patients who developed GD received methimazole treatment
75820039|NCT02186392|Device|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
75944085|NCT03447093|Drug|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
75944086|NCT04054037|Other|No intervention|This is an observation study, no intervention will be indicated during diagnosis and treatment.
75944087|NCT03442257|Behavioral|SMS|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
75944088|NCT01063595|Biological|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
75944089|NCT01063595|Biological|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
75944090|NCT03640351|Drug|1. Use of preservative free diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
75944091|NCT03640351|Drug|2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
75944092|NCT03640351|Drug|3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
75944093|NCT03640273|Drug|Prapchompoothaweep remedy|Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.
75944094|NCT03640273|Drug|Loratadine 10 Mg|Take Loratadine 10 mg once a day before meals.
75966041|NCT02339506|Drug|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
76091622|NCT03258918|Behavioral|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.
76091623|NCT05234814|Other|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.|"Fire dragon pot moxibustion treatment The main acupuncture points are as follows: Fengchi, Jianjin, Dazhui, Feiyu, Xinyu, Ganyu, Piyu, Shenyu, etc (all acupuncture points are positioned according to the national standard: GB/T12346-2006).~Ear acupuncture seed burial method According to Ear Acupuncture Therapy [6], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
76091624|NCT05234814|Other|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy|"Ear acupuncture seed burial method According to Ear Acupuncture Therapy [6], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
75820040|NCT02190994|Drug|Hydrocortisone|used intravenously
75820041|NCT02190994|Drug|Prednisone|used as tablet form
75820042|NCT03536338|Other|Spinal Stimulation|transcutaneous electrical stimulation of the lumbar spinal cord during rehabilitation.
75820043|NCT03536338|Other|Sit-to-stand Training|Rehabilitation of standing from a chair using the Keiser Rack
75820044|NCT02193568|Procedure|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
75820045|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
75820046|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Undergo craniotomy
75820047|NCT02193568|Other|Arm II (intubated general anesthesia)|Ancillary studies
75820048|NCT02193568|Procedure|Arm I (light sedation)|Undergo craniotomy
75657036|NCT02798484|Device|Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)|MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.
75944095|NCT03449823|Diagnostic Test|Doppler ultrasound of fetal renal artery|Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.
76091625|NCT03266718|Behavioral|Physical Activity Intervention|To develop and test a couple-based physical activity intervention among cancer survivors and their partners
76091626|NCT03266562|Diagnostic Test|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
76091627|NCT03266562|Diagnostic Test|F-18 FDG|Evaluate uptake of F-18 FDG in breast tissue
76091628|NCT03258840|Dietary Supplement|EPA Supplement|EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.
75345721|NCT05460468|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
75804094|NCT04288726|Biological|CD30.CAR-EBVST cells|"The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 108 cells/m2 and we did not reach an MTD. We will be splitting the total dose between 2 infusions three days apart to improve tumor exposure to CAR-T cells.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Days 0 and 3 ±1 of study, patients will receive half their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL."
75804095|NCT03732690|Other|Diet HP|"2000kcal for men 1800 kcal for women. Food boxes (HP pre-cooked meals and meat/chicken/fish portions, HP breads and snacks) will be provided to the participants throughout the study reaching 40-50% of their prescribed daily energy intake for 6 days per week. In total 932 kcal are provided through this food boxes (54g of carbohydrate, 101g of protein, 34,6g of fat). The rest of the daily food intake will be guided by a dietician with a list of recommended high protein foods.~Subjects are required to keep food diaries three days a week and will also have weekly contact with a dietician."
75804096|NCT03732690|Other|Diet LP|2000kcal for men 1800 kcal for women. Food boxes (LP pre-cooked meals, LP breads and snacks) will be provided to the participants throughout the study
75804097|NCT03688048|Device|Bright light treatment lamp|Exposure to bright white light (1 hour, 10 000 lux)
75345722|NCT05451940|Drug|Hydroxyurea|Hydroxyurea is an orally available antimetabolite medication that has been shown to reduce the frequency of painful crises and acute chest syndrome in adults and children with sickle cell disease. Hydroxyurea treats sickle cell disease by a number of different mechanisms, including increasing the expression of fetal hemoglobin (HbF), which reduces sickling of red blood cells.
75345723|NCT05451940|Drug|Epoetin Alfa|Epoetin alfa is a first-generation erythropoiesis-stimulating agent (ESA), which are recombinant versions of erythropoietin (EPO) produced using recombinant DNA technology. Erythropoietin (EPO) is a glycoprotein hormone, naturally produced mainly in the kidneys in response to hypoxia and stimulates red blood cell production (erythropoiesis) in the bone marrow.
75345724|NCT05451914|Other|My Diabetes Care|My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.
75657037|NCT04040725|Drug|Rogaratinib|Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
75657038|NCT00955955|Other|6(S)-5-MTHF(Deplin)|Deplin is a medical food. Patients will take 15 mg/day of deplin.
75657039|NCT00955955|Other|Placebo|Inactive substance
75657040|NCT02798328|Device|TEG6s DOAC Cartridge|Testing subjects for presence of DOAC
75657041|NCT05550636|Drug|BI 1015550|BI 1015550
75657042|NCT05550636|Drug|midazolam|midazolam
75657043|NCT00860197|Dietary Supplement|Fully torrefied coffee|Fully torrefied coffee
75657044|NCT00860197|Dietary Supplement|Partially torrefied coffee|Partially torrefied coffee
75804098|NCT03688048|Device|Sham negative ion generator|Placebo treatment with deactivated negative ion generator (1 hour, audible hum, no ions emitted)
75944096|NCT03442023|Drug|Chlorhexidine gluconate at 2%|Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
75944097|NCT03442023|Drug|Chlorhexidine gluconate at 0.12%|Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
75944098|NCT03441945|Other|magnetic steering|magnetic steering
75944099|NCT01063283|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 intravenously over 10 minutes
75944100|NCT01063283|Drug|Carboplatin|Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes
75944101|NCT01063283|Drug|Bevacizumab 7.5 mg/kg|Bevacizumab at 7.5 mg/kg intravenously over 90 minutes
76091629|NCT03258840|Dietary Supplement|EPA Placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.
76091630|NCT03266796|Behavioral|goal setting process|goal setting process during the first consultation
76091631|NCT03266406|Drug|Hyaluronidase|4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
76091632|NCT03258684|Drug|Hydrocortisone, Vitamin C, and Thiamine|Intervention
76091633|NCT03258684|Other|Normal saline|Placebo
76091634|NCT02456766|Device|FibroTouch|
76091635|NCT02456766|Procedure|Liver Biopsy|
76091636|NCT03262272|Device|VIE A Hemodialyzer|polysulfon membrane coated with vitamin E
76091637|NCT03262272|Device|Rexsys 27H hemodialyzer|polyethersulfon membrane with large surface area : 2,7m²
76091638|NCT03262272|Device|Leoceed 21HX hemodialyzer|polyslfon membrane with gamma sterilization
76091639|NCT03262272|Device|Polypure 22S+ hemodialyzer|polysulfon membrane with steam sterilization
75657045|NCT02857829|Dietary Supplement|CAF+|CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).
75804099|NCT03693976|Drug|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
75345725|NCT05448560|Behavioral|Multi-level Intervention of shared model of survivorship care|1) Patient survivorship education via telehealth with the cancer center- The research registered nurse (RN) will discuss the contents of the survivorship care plan and coordination between the cancer center and PCP clinic. 2) Ongoing patient-tailored education program by MyChart within the EHR patient portal- Patients will be asked to select survivorship topics of interest from a panel (e.g. school issues, fertility, fatigue, physical activity, single kidney health, emotions/coping) that will then be sent over 1 year. 3) Structured interactive phone communication between the research RN at the cancer center and community PCP clinic- The discussion will explain the patient's cancer history, tumor recurrence monitoring schedule, individualized risk of late effects and surveillance schedule, psychosocial challenges, health behaviors, and coordination between the cancer center and PCP clinic. 4) In-person visit with the PCP clinic for survivorship care.
75345726|NCT05448560|Other|Comparison Group|Participants will be contacted by study staff at their cancer center to schedule an in-person visit at the survivorship clinic that will include a comprehensive history focused on cancer-related medical and psychosocial issues, physical examination, ordering of recommended surveillance for late effects, and delivery of hard copy of their survivorship care plan.
75345727|NCT05447559|Drug|Cefazolin|Intravenous administration of 2 g cefazolin
75657046|NCT02857829|Dietary Supplement|Caffeine-alone|Caffeine (100 mg)
75657047|NCT02857829|Other|Placebo|Rice flour
75657048|NCT02805894|Drug|NBTXR3 activated by IMRT only|Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
75804100|NCT03693976|Device|Ectoin Rhinosinusitis Nasal Spray|Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use
75944102|NCT01063283|Drug|Bevacizumab 15 mg/kg|Bevacizumab at 15 mg/kg intravenously over 90 minutes
75345728|NCT05447559|Drug|Water for injection|Intravenous administration of 10mL sterile water for injection
75345729|NCT05444595|Behavioral|Behavioral plant-based dietary intervention|Participants will meet with community health workers to receive information focused on healthy eating and consuming a traditional plant-based diet in a group format for the first few months followed by individual check-ins.
76091640|NCT03258528|Behavioral|positioning|Positioning neonates for 6 hours either in right lateral position or supine position
75345730|NCT05444595|Behavioral|Standard care|Participants will meet with community health workers to receive general health information through individual check-ins.
75345731|NCT05444309|Procedure|Quadratus lumborum (QL) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the quadratus lumborum block approach
75345732|NCT05444309|Procedure|Pericapsular Nerve Group (PENG) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the Pericapsular Nerve Group (PENG) block
75345733|NCT05431608|Biological|MCARH125|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
75345734|NCT05431608|Biological|MCARH109|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
75657049|NCT02805894|Drug|NBTXR3 activated by Brachytherapy & IMRT|Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy & IMRT treatment
75657050|NCT00860275|Drug|BMS-708163|Capsule, Oral, 50 mg, once, Day 1
75657051|NCT00860275|Drug|BMS-708163 + Ketoconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
75657052|NCT00860275|Drug|Ketoconazole|Tablet, Oral, 400 mg, daily, 16 days
75657053|NCT00860275|Drug|Fluconazole|Tablet, Oral, 1 day 400 mg then 3 days 200 mg
75657054|NCT00860275|Drug|BMS-708163 + Fluconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
75657055|NCT02798250|Other|Dual-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.
75657056|NCT02798250|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
75657057|NCT02798250|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
75804101|NCT03730584|Drug|Ropivacaine|"Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath."
75804102|NCT03730584|Biological|Blood test|Blood test during the first bath with Ropivacaine for Titration of Ropivacaine
75804103|NCT03502616|Drug|Tofacitinib|Oral administration twice per day
75804104|NCT04003012|Drug|EMLA|EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
75804105|NCT04003012|Drug|Lidocaine|lidocaine 1%
75944103|NCT03441867|Behavioral|Cognitive Behavioral Therapy for Seizures|CBT-informed psychotherapy for patients with PNES and PTE
75944104|NCT03441867|Other|Standard Medical Care|Observational - standard medical care
75944105|NCT02521779|Other|Low-fat Treatment Meal|Isocaloric test meal that provided 20% fat.
75944106|NCT02521779|Other|Saturated-fat Treatment Meal|Isocaloric test meal that provided 35% fat with saturated fat (16 g).
75944107|NCT02521779|Other|N-3 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)
76091641|NCT03262350|Behavioral|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
76091642|NCT03266250|Procedure|spinal anesthesia|Transthoracic echocardiography of inferior vena cava before spinal anesthesia
75345735|NCT05429879|Other|Preferred Music Arm|Patients will choose their preferred music to be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
75345736|NCT05429879|Other|Classical Music Arm|A standardized playlist of copyright free classical music will be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
75345737|NCT05428033|Drug|centanafadine capsule|capsule
75804106|NCT03693898|Other|Observeational|No intervention, observational
75657058|NCT02798250|Device|Dexcom G4 Platinum glucose sensor|
75345738|NCT05428033|Other|placebo capsule|capsule
75804107|NCT03992560|Device|Guide CRT Software Prototype|The medical device in the trial is a software programme that allows image fusion of previously acquired MRI images with real-time X-Ray fluoroscopic images in the cardiac catheter laboratory. We are able to use the MRI information to assess the best location to place the left ventricular lead for a CRT device and then superimpose this location onto the real-time X-Ray fluoroscopic images during the left ventricular lead implantation
75804108|NCT03691324|Other|Inhalation technique training and discharge service|Patient drug counselling one-to-one, focusing on inhalation drugs and technique
75804109|NCT05666076|Procedure|Pericapsular nerve block|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
75657059|NCT02798250|Device|Accu Chek Combo insulin pump|
75804110|NCT05666076|Procedure|Suprascapular nerve block|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
75804111|NCT05666076|Drug|Bupivacaine and prilocaine hydrochloride|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
75944108|NCT02521779|Other|N-6 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
76091643|NCT03258372|Drug|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
76091644|NCT03258450|Behavioral|Psycho-behavioural intervention arm (PBI)|The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
75820049|NCT02193568|Other|Arm I (light sedation)|Ancillary studies
75944109|NCT03438279|Other|Non-Interventional|Non-Interventional
75944110|NCT01062971|Drug|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
76091645|NCT03266328|Procedure|Primary Percutaneous Coronary Intervention (PPCI)|Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
76091646|NCT02456454|Drug|Risperidone|Liquid risperidone
76091647|NCT02456454|Drug|Valproic Acid|Liquid valproic acid
75657060|NCT00865111|Drug|Bupropion 150 mg Extended-Released Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
75657061|NCT00865111|Drug|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
75657062|NCT02802618|Other|Interactive 3D visualization technique|The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.
75657063|NCT00863005|Drug|K201|Cream
75657064|NCT00863005|Drug|K201|
75657065|NCT00860353|Drug|AZD2551|Single dose of oral solution.
76091648|NCT02456454|Drug|Placebo|
76091649|NCT02456688|Drug|Imrecoxib|
76091650|NCT03258294|Drug|Melatonin(Circadin®)|
76091651|NCT03258294|Drug|Placebo Oral Tablet|
75657066|NCT00860353|Drug|Placebo|Single dose of oral solution
75657067|NCT00863083|Behavioral|Multifamily weight management intervention|8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
75657068|NCT04018339|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
75944111|NCT03446937|Drug|Dexamethasone Sodium Phosphate Injection|Dexamethasone sodium phosphate injection 12 mg X doses to be given 12 hours apart
75944112|NCT03446937|Drug|Betamethasone Sodium Phosphate Injection (Medication)|betamethasone sodium phosphate injection12mg X 2 doses given 12 hours apart
75944113|NCT03446937|Drug|Water for injection|Two doses of intramuscular injection of water for injection given 12 hours apart
75944114|NCT03652493|Drug|Carboplatin|Tumoral evaluation every 3 cycles
75944115|NCT02521701|Drug|NFL101|"Level 1: 100 µg~50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
75944116|NCT03652415|Device|Artificial tears (classified by MHRA as a medical device)|Use of artificial tears
75944117|NCT03446859|Other|TENS|"First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS)."
75944118|NCT04054349|Other|Low FODMAP diet|The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
75657069|NCT04018339|Drug|Placebo|Capsules containing an inert placebo
75657070|NCT02802696|Drug|Furosemide|A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
75944119|NCT03446703|Behavioral|SCIT|SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
75944120|NCT03446703|Behavioral|TAR|TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
75944121|NCT03652727|Device|ECG-EM Guidance|"ECG-EM method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. The length of the PICC is estimated prior to its insertion using morphological landmarks. The placement of the PICC is done using SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) [CE marked device, C. R. Bard, Inc.].~At the end of procedure, a chest x-ray is performed to assess the PICC position"
75944122|NCT03652727|Device|FX Guidance|"FX method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. Through the point of puncture, a long wire is then introduced and directed to the level of the target zone located in the superior vena cava under fluoroscopy control. The length of the guide inside the vessel is then measured to adjust the length of the PICC necessary for its optimal positioning.~At the end of procedure, a chest x-ray is performed to assess the PICC position"
75944123|NCT01348165|Drug|BI 137882|Powder for oral solution
75944124|NCT01348165|Drug|Placebo|Powder for oral solution
75966042|NCT02339506|Drug|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
76091652|NCT03261648|Other|State-Trait-Anxiety Inventory (Forme Y) questionnaire|after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.
76091653|NCT03261648|Other|pain level scale|as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
76091654|NCT03258216|Diagnostic Test|panendoscopy|panendoscopy
76091655|NCT03258216|Diagnostic Test|tongue image|capture tongue images by Automatic Tongue Diagnosis System
76091656|NCT03265704|Other|AGA - Control group|Data processing from Patient Medical Files
76091657|NCT03265704|Other|SGA - Control group|Data processing from Patient Medical Files
76091658|NCT03265704|Other|AGA-PIH Study group|Monitoring PIH-related changes in the newborn
76091659|NCT03265704|Other|SGA-PIH Study group|Monitoring PIH-related changes in the newborn
75657071|NCT02802696|Drug|Normal Saline|A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
75657072|NCT00860431|Drug|AST-120|6g/day (3 times a day)
75657073|NCT02802774|Other|Plaster Splint|The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
75657074|NCT02802774|Other|Velcro Brace|The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
75820050|NCT02191072|Drug|omalizumab|a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
75820051|NCT02186548|Procedure|Closed surgical technique|"Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~The bone covering the canine is being removed~Attachment with a chain is bonded to the exposed tooth~The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~The canine is orthodontically moved beneath the palatal mucosa"
75820052|NCT02186548|Procedure|Open surgical technique|"Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~Pack/filling material is applied on the tooth~Spontaneous eruption of the palatally impacted canine is allowed expected~The canine is orthodontically moved above the mucosa"
76091660|NCT03265782|Drug|ibuprofen|drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
75944125|NCT02493868|Drug|Esketamine|Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
75657075|NCT02802774|Other|Soft Dressing|Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
75657076|NCT04041739|Diagnostic Test|fungal osteomyelitis culture and sensitivity|swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
75944126|NCT02493868|Drug|Placebo|Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
75804112|NCT05666076|Drug|Bupivacaine and prilocaine hydrochloride|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
75804113|NCT03028012|Drug|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
75944127|NCT02493868|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
75944128|NCT02493868|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
75944129|NCT02493868|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
75944130|NCT02493868|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
75944131|NCT03619057|Other|General anesthesia with laryngeal mask i-gel|General anesthesia with laryngeal mask i-gel
75944132|NCT04884867|Behavioral|CBT-based supportive skills delivered by phone by lay coaches|8-10 weekly coaching sessions delivered by telephone
75944133|NCT04451655|Drug|Continuous insulin infusion|This study aims to explore the hypothesis that diabetic patients undergoing coronary artery bypass graft (CABG) surgery receiving intravenous continuous insulin infusion (CII) for tight glycemic control (110-149 mg/dl) protocol during the intraoperative period would have improved intraoperative glycemic stability, efficacy and consistency compared to patients receiving conventional glycemic control (150-180 mg/dl) protocol during the intraoperative period
75944134|NCT03438201|Dietary Supplement|Intervention|Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day
75944135|NCT03438201|Dietary Supplement|Control|Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day
76091661|NCT03265782|Drug|paracetamol|drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
75345739|NCT05422664|Drug|Lacosamide|Patients with autoimmune related epilepsy were included. After obtaining informed consent, lacosamide was given according to the weight of the patients, and the efficacy and safety were observed.
75345740|NCT05418608|Drug|Radiotracer|A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans.
75657077|NCT02802462|Behavioral|HIT|3-minute intervals at 40% and 80%VO 2max
75657078|NCT02802462|Behavioral|MCT|sustained 60%VO 2max
75804114|NCT03028012|Drug|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
75804115|NCT03028012|Drug|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
75944136|NCT03446625|Drug|Resveratrol|Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
76091662|NCT03261726|Device|MedEl Test Electrode Placer|This study uses a sterile dummy (i.e., not working) cochlear implant electrode inserted at the time of tumor removal to keep the inner ear from scarring or filling with bone. The significance of this to you is that if you ever become eligible for a cochlear implant sometime after surgery, it may be possible to remove the dummy and insert a functioning cochlear implant.
75345741|NCT05413941|Behavioral|Internet-based Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy in which individuals are taught to identify and modify maladaptive thinking and behavior to improve their psychological status and coping skills. CBT in this trial will be delivered digitally (internet-based).
75804116|NCT03635190|Device|Orbital Circumferential Atherectomy|Remove atherosclerotic plaque and modify vessel wall compliance within peripheral arterial vessels. The therapy is intended for patients who are acceptable candidates for percutaneous transluminal atherectomy.
75804117|NCT03693820|Drug|the infiltration group|"15-20 ml periportal,~50 ml in gallbladder bed,~The rest (about 150 ml in 70 Kg patient) will be intraperitoneal"
76091663|NCT03798054|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
76091664|NCT03798054|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
76091665|NCT03798054|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
76091666|NCT03798054|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
76091667|NCT03798054|Drug|SGLT2 inhibitor|"Pharmaceutical form:tablet~Route of administration: oral"
76091668|NCT03261882|Other|Nativity|Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
76091669|NCT03265860|Device|IntraVoxel Incoherent Motion sequence|The IVIM diffusion sequence with a duration of 2 minutes is added to the imaging protocol.
76091670|NCT03265470|Drug|Dexmedetomidine|Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.
76091671|NCT03265470|Drug|Fentanyl|Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
76091672|NCT02456376|Procedure|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
76091673|NCT02456376|Procedure|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
76091674|NCT02350816|Drug|HGT-1410|HGT-1410 administered according to Patient Group assignment.
76091675|NCT03696498|Procedure|Resin restoration (1 step)|Permanent resin restoration is placed on top of the partial removed caries.
75657079|NCT00865267|Drug|Ultravate® 0.05% ointment, single exposure|A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
76091676|NCT03696498|Procedure|Resin restoration (2 steps)|A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
75657080|NCT02798172|Drug|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
75657081|NCT00865423|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
76091677|NCT02456298|Behavioral|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
76091678|NCT02456298|Behavioral|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
76091679|NCT02019940|Drug|Riluzole|
76091680|NCT03258060|Procedure|Temporary pacing study|
75657082|NCT00865423|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
75657083|NCT02798016|Procedure|Platelet-Rich Plasma|This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
75804118|NCT03693820|Drug|the control group|the 50 ml prepared for gallbladder bed infiltration will be replaced by saline.
75804119|NCT03634800|Drug|Nivolumab 240mg|Patients with multiple myeloma will receive Nivolumab intravenously at 240 mg every two weeks. Infusions will be given over 60 minutes (not bolus or IV push). Patients will continue to receive infusions every two weeks until disease progression or dose limiting toxicity is reached.
75804120|NCT03634800|Radiation|Radiation therapy|Patients will receive radiation for 5 consecutive days. A dose of 6 Gy x 5 days will be administered. Patients may receive radiotherapy to an additional site at 12 weeks if they have stable disease.
75804121|NCT03027466|Behavioral|Self-affirmation induction|Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
75804122|NCT03662334|Drug|Rapid Acting insulin with pre-treatment of rHuPH20|Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
75804123|NCT03662334|Device|Sham injection|A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
75944137|NCT03446625|Drug|Placebo|Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
75944138|NCT04957186|Other|Collection of postoperative information|The EORTC BR45 questionnaire will be used to gather information from patients regarding possible post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse.
75944139|NCT04957186|Other|Analysis of postoperative information collected from patients|All post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse will be analyzed with the aim of proposing an appropriate care pathway.
75944140|NCT03441399|Other|Financial incentives|Providing money for taking antidepressant medication
75944141|NCT02516410|Drug|VX-661 plus ivacaftor combination|
75944142|NCT02516410|Drug|Ivacaftor|
75944143|NCT02516410|Drug|Placebo (matched to VX-661 plus ivacaftor combination)|
76091681|NCT03258060|Radiation|Body Surface Mapping|
75944144|NCT02516410|Drug|Placebo (matched to ivacaftor)|
75476790|NCT05561933|Behavioral|Healthy Minds Program Foundations Training|"The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose."
75476791|NCT05561543|Dietary Supplement|Peppermint oil|Peppermint oil
75657084|NCT02798016|Procedure|Micro-needling|Micro-needling will be applied on the acne scars in one side of the face.
76091682|NCT03261258|Other|Questionnaire|
76091683|NCT01967836|Device|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
76091684|NCT01229943|Biological|Bevacizumab|Given IV
76091685|NCT01229943|Drug|Everolimus|Given PO
76091686|NCT01229943|Drug|Octreotide Acetate|Given IM
76091687|NCT02457936|Behavioral|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
76091688|NCT03257982|Procedure|BCI-FES hand therapy|BCI-FES rehabilitation therapy of the upper limb
76091689|NCT02020018|Device|Prevena Incision Management System|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
76091690|NCT02020018|Other|Conventional sterile dry wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after sternotomy
76091691|NCT03265626|Behavioral|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
76091692|NCT03265626|Behavioral|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
76091693|NCT03265626|Other|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
76091694|NCT02020252|Behavioral|Testing an interactive technology in a diverse health literary population|Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. We tested an interactive technology designed for patients with diverse health literacy skills aimed at improving patient receptiveness, willingness, knowledge, self-efficacy and positive attitudes regarding clinical trials.
76091695|NCT03265548|Device|Video Laryngoscope|The use of video laryngoscopy
76091696|NCT03265392|Other|Bread|Serving of wheat bread providing 50 g of carbohydrates
76091697|NCT03265392|Other|Water|250 mL of water
75476792|NCT05561543|Other|Placebo|Placebo
75476793|NCT05555823|Drug|ATR-002|300 mg tablets for oral intake
75657085|NCT02544139|Other|Chagas Detect Plus|
75657086|NCT00955721|Drug|Gemcitabine|Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
75657087|NCT00955721|Drug|Oxaliplatin|Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
75657088|NCT00955721|Drug|Sorafenib|Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
75657089|NCT02802540|Drug|Nabilone|Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
75657090|NCT02802540|Drug|Placebo|Patients going to take capsules of placebo until complete 8 weeks.
75657091|NCT00865501|Drug|spironolactone|25mg per oral once daily
76091698|NCT03265392|Other|Lemon juice|250 mL of lemon juice
76091699|NCT03265392|Other|Tea|250 mL of tea
76091700|NCT03265392|Other|Peas|20 peas
76091701|NCT02020408|Drug|[11C]raclopride|1.[11C]raclopride -The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
76091702|NCT02020408|Drug|[11C]DASB|BPND of [11C]DASB.
75476794|NCT05555823|Drug|Placebo|matching tablets for oral intake
75476795|NCT05555823|Drug|Repaglinide|0,5 mg tablets for oral intake
75476796|NCT05555823|Drug|Celecoxib|100 mg capsules for oral intake
75820053|NCT02186626|Biological|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
76091703|NCT02020408|Drug|amphetamine|The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
75657092|NCT00865501|Drug|placebo|placebo
75657093|NCT04277351|Device|Transcranial alternating current stimulation|Focal transcranial stimulation over auditory cortex by means of 5 electrodes delivering an electric current (max. 2mA). In addition to active stimulation, also a placebo (sham) stimulation is employed as a control condition. All subjects included in the study receive all tACS stimulation conditions.
75657094|NCT02797704|Drug|Aflibercept|Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
75657095|NCT00865579|Drug|Safinamide|"The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning."
75657096|NCT02860325|Device|NIV-NAVA|Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
76091704|NCT03263832|Diagnostic Test|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
76091705|NCT03553524|Other|morning HIIT --> afternoon HIIT|Arm 1 will start with morning HIIT at visit 2 and afternoon HIIT at visit 3
76091706|NCT03553524|Other|afternoon HIIT --> morning HIIT|Arm 2 will start with afternoon HIIT at visit 2 and morning HIIT at visit 3
75476799|NCT05539729|Drug|Vancomycin|A marketed antibiotic (Study Drug) supplied by Amerisource Bergen, by the Mount Sinai Investigational Drug Services (IDS), and encapsulated in red coating to match the placebo.
75804124|NCT03624088|Behavioral|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
75804125|NCT04641052|Other|Music listening|The music type will be chosen by the patients and researchers will not have any influence on their choices.
75804126|NCT02955186|Drug|Saracatinib|Saracatinib 125 mg once per day for 8 days
75804127|NCT02955186|Drug|Placebos|Placebo once per day for 8 days
76091707|NCT03257904|Procedure|intracranial pressure monitoring|measurement of intracranial pressure
75657097|NCT02860325|Device|Conventional|Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
76091708|NCT02352298|Device|Dario Blood Glucose Monitoring System|Fingerstick to obtain blood sample for analysis with the Dario BGMS
76091709|NCT02352298|Device|YSI Analyzer|Fingerstick to obtain blood sample for analysis with YSI
76091710|NCT04782843|Other|HEP score assessement|Assessement of the HEP score between 2 physician.
76091711|NCT01219257|Biological|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
76091712|NCT01197027|Behavioral|Standard counseling|Standard HIV counseling
76091713|NCT01895439|Biological|Autologous Mesenchymal Stem Cells|
76091714|NCT04782765|Drug|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
75657098|NCT02805582|Drug|10ml ropivacain 0.5%|Ultrasound guided nerve block
75657099|NCT00860509|Other|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
75657100|NCT04281095|Drug|Botulinum toxin type A|Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
76091715|NCT01615887|Drug|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
76091716|NCT01615887|Drug|placebo|sugar pill
75345742|NCT05399537|Drug|Prismocitrate 18|Prismocitrate 18 solution will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. A BFR between 100 - 180 mL/min will be advised; a lower BFR can minimize patient citrate exposure, particularly in patients with lower body weight.
75476800|NCT05539729|Drug|Placebo|Placebo created by the IDS and encapsulated in red coating to match the Study Drug.
75476801|NCT05526378|Behavioral|Sensory Interventions|"Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure."
75657101|NCT02797938|Device|Taper guard tube|Taper guard tube was intubated
75657102|NCT02797938|Device|Cylindrical tube|Cylindrical tube was intubated
75657103|NCT02860403|Procedure|motor imagery|Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
75657104|NCT02802306|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
75804128|NCT03690934|Procedure|Fistula-tract laser closure (FiLAC™)|The procedure was performed with a diode laser platform emitting laser energy of 15 W at a wavelength of 1470 nm by means of a radial ﬁber. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the laser ﬁbre withdrawn at a rate of approximately 1 cm per 2-3s.
75345743|NCT05397431|Drug|Lanadelumab|Lanadelumab 300 mg, subcutaneous injection every 2 weeks
75804129|NCT03690934|Procedure|Monopolar coagulation of fistulous tract|The procedure was performed with a monopolar coagulator platform emitting monopolar coagulation. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the monopolar energy with suturing the internal fistulas opening.
75804130|NCT03737682|Diagnostic Test|ENzyme linked immunity-sorbet assays|Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels
76091717|NCT04389801|Drug|Desferal 500 MG Injection|iron chelating agent
75345744|NCT05389631|Other|no intervention|no intervention
75345745|NCT05380687|Diagnostic Test|Inspiratory hold|A short period (< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of inspiration. It is used to asses expiratory force generation (maximal expiratory pressure, MEP) and frequently used in clinical practice.
75657105|NCT00863161|Drug|AZD3355|capsule, oral, single dose
75345746|NCT05380687|Diagnostic Test|Expiratory hold|A short period (< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of expiration. It is used to asses static PEEP and inspiratory force generation (maximal inspiratory pressure, MIP & occlusion pressure, ∆Pocc) and is frequently used in clinical practice.
75345747|NCT05380687|Diagnostic Test|Ultrasound of respiratory muscles|Ultrasound of the diaphragm, parasternal intercostal muscle and internal oblique muscle will be performed during each block. Thickening fractions, calculated as thickness at end-inspiration minus thickness at end-expiration divided by thickness at end-expiration, are used to assess the contribution of the muscle to the tidal volume. A median over 5 breaths will be calculated.
75345748|NCT05380687|Other|PEEP 10|Positive End-Expiratory Pressure of 10cmH2O for 30 minutes
75657106|NCT04281407|Dietary Supplement|Visbiome|2 capsules of Visbiome, a probiotics supplement, twice a day (morning and evening) for 28 days
75657107|NCT02802150|Dietary Supplement|Zanthoxylum Schinifolium Seed Oil(4g/day)|parallel design
75345749|NCT05380687|Other|PEEP 5|Positive End-Expiratory Pressure of 5cmH2O for 30 minutes
75345750|NCT05380687|Other|PEEP 0|Positive End-Expiratory Pressure of 0cmH2O for 30 minutes
75657108|NCT02802150|Dietary Supplement|Soy Bean Oil;placebo(4g/day)|parallel design
75657109|NCT02857595|Behavioral|Online Behavioral Weight Loss program|
75657110|NCT02857595|Behavioral|Weight Loss Nomogram|
75657111|NCT02857595|Behavioral|Bite Counter|
75657112|NCT00863239|Drug|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight < 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight > 85 kg: 1200 mg/day.
75476802|NCT05525663|Behavioral|Rehabilitation Intervention|progressive, multi-domain rehabilitation and exercise training intervention
75657113|NCT00863239|Drug|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
75657114|NCT00863239|Drug|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
75657115|NCT02805270|Other|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
75657116|NCT02802072|Device|Enterprise stent implantation|Enterprise stent system (Johnson & Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.
75657117|NCT02802072|Drug|Only aspirin medication|Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
75657118|NCT00865657|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
75657119|NCT00865657|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under non-fasting conditions
75657120|NCT02801994|Device|PAV, Puritan Bennett 980 ventilator|The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
75657121|NCT00863395|Procedure|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
75657122|NCT02939183|Drug|Immediate Release (IR) Formulation|Immediate Release (IR) Formulation
75657123|NCT02939183|Drug|Gastro-Retentive (GR) Formulation|Gastro-Retentive (GR) Formulation
75657124|NCT02939183|Drug|Dexamethasone|Dexamethasone
75804131|NCT03693508|Drug|Genvoya®|Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
75804132|NCT03730506|Device|Intra oral scanner|computer guided implant
75804133|NCT03690856|Other|inflammatory, neuropsychological and neuroimaging assessment|"Acts add by research:~pregnancy test; Centralized: IL1, IL6, TNF~Neuropsychologic tests at M6 and M24:~Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)"
75804134|NCT03721250|Other|epidural|thoracic epidural analgesia
75804135|NCT03690778|Drug|"Metformin and Rosuvastatin seperately"|"administration of Metformin and Rosuvastatin seperately"
75804136|NCT03690778|Drug|JLP-1310|administration of JLP-1310
75804137|NCT03715634|Drug|INDV-6200|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
75804138|NCT03715634|Drug|Placebo|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
75804139|NCT03715634|Drug|SL Buprenorphine|All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
75804140|NCT03715634|Drug|Nalorex|Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
75804141|NCT03693274|Behavioral|BreathAware for Pain Management|Patients will be given access to a BreathAware, a 16- week web-based mindfulness course, which will be initiated at their enrollment. BreathAware is a self-paced course comprised of 2-3 minute lessons delivered via video, audio and technology-based guided instruction, and is available on a phone or tablet.
75804142|NCT03502070|Drug|Placebo|One dose (4 capsules) of placebo
75804143|NCT03502070|Device|Tobi Podhaler|The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use
76091718|NCT04782141|Procedure|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
76091719|NCT04782141|Procedure|hand motor coordination in a supine position with the upper extremity positioned perpendicularly to the trunk|motor tasks carried out in starting positions: supine with the upper extremity positioned perpendicularly to the trunk; the upper limb in adduction and flexion in the humeral joint, elbow extension, forearm in the intermediate position; elbow, wrist, hand free from stabilization.
76091720|NCT04782141|Procedure|hand motor coordination in a supine position with adduction in the humeral joint, elbow flexion in the intermediate position|In the supine position, the upper limb was held beside the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
75804144|NCT04158934|Biological|ADYNOVI/ADYNOVATE|Participants will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national SmPC.
75804145|NCT03715556|Drug|Amiodarone|Administration of the drug will be blinded within the first 48 hours for the principal investigator. Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated.
75944145|NCT03438123|Device|CZT SPECT imaging|Acquisition of SPECT (single photon emission computed tomography) imaging utilising a camera system with solid-state cadmium zinc telluride (CZT) detectors to visualise injected, or otherwise introduced, radioactivity in the human body.
75944146|NCT02493712|Drug|High dose|6 capsules of IBD98-M, twice a day
76091721|NCT01189851|Device|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
76091722|NCT01606995|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
75657125|NCT02939183|Drug|Pomalidomide|Pomalidomide
75804146|NCT03715556|Drug|0.9% physiological solution|Administration of 0.9% physiological solution.
75804147|NCT03586830|Drug|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.
75944147|NCT02493712|Drug|Low dose|4 capsules of IBD98-M
75944148|NCT02493712|Drug|Placebo|Placebo
75944149|NCT04851483|Drug|BAY2328065|Solid Form, Oral administration.
75944150|NCT04851483|Drug|Placebo|Matching placebo of BAY2328065.
75944151|NCT04850859|Other|measure various dimensions of the glenoid|measurement of Superior-Inferior glenoid diameter ,Anterior-Posterior glenoid diameter and study shape of the glenoid cavity .
75944152|NCT04850859|Other|measure various dimensions of the acetabulum|measurement of transverse diameter of the acetabulum ,vertical diameter of the acetabulum, depth of the acetabulum ,Width of acetabular notch and study shape of anterior acetabular ridge and ends of lunate surface .
76091723|NCT04782453|Behavioral|ToQuit, a technology delivered tobacco cessation intervention|"The intervention messages will consist of specific content areas derived from the formative research of the study. Some of the components of the intervention include~Psychoeducation about consequences of tobacco use and benefits of quitting;~goal setting;~managing goals and self-monitoring of behavior;~avoidance strategies;~self-awareness and reflection messages;~social and pharmacological support, and help-seeking;~identifying and managing cravings;~relapse prevention strategies."
76091724|NCT04782453|Behavioral|Tobacco quitting helplines|Participants from the control group will be sent the details of other functional tobacco helplines in India.
76091725|NCT03548220|Drug|Placebo|Placebo matching AG-348 tablets, administered to maintain the blind.
75476803|NCT05523570|Drug|HNC364|2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension. Then 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 20 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
75657126|NCT02801916|Other|0 grams oat bran|200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
75657127|NCT02801916|Other|4.5 grams oat bran|200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
75657128|NCT02801916|Other|13.6 grams oat bran|200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
75657129|NCT02801916|Other|27.3 grams oat bran|200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
75804148|NCT03586830|Drug|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.
75804149|NCT03586830|Drug|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.
75804150|NCT03586830|Drug|Placebo|Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
75820054|NCT02186626|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
76091726|NCT03548220|Drug|AG-348|AG-348 tablets.
76091727|NCT04050969|Procedure|Bariatric surgery|Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.
76091728|NCT04050969|Procedure|Atrial Fibrillation (AF) Catheter Ablation|Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
76091729|NCT01589211|Behavioral|Brief advice|Brief advice of about 10 min accompanied by self-help material
76091730|NCT01589211|Behavioral|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
76091731|NCT01589211|Behavioral|Standard cessation course|Cessation course over 6 dates. Group setting.
76091732|NCT03257670|Drug|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
76091733|NCT03257670|Device|CO2RE fractional laser therapy|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
75476804|NCT05523570|Drug|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 40 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
75476805|NCT05523570|Drug|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 60 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
75657130|NCT00865813|Procedure|Punch Biopsy|"Instillation of anesthetic eye drops.~Asepsis~Placement of surgical cloths and drapes~Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade"
75657131|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
75944153|NCT03437967|Device|LightForce EXPi|LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
75944154|NCT03441087|Device|Transvaginal ultrasound|
75944155|NCT03441087|Device|Hysteroscopy|
75944156|NCT03446547|Drug|Durvalumab|durvalumab 1500 mg i.v. every fourth week for 12 months
75944157|NCT02516332|Drug|Lexapro|
75944158|NCT02516332|Drug|Placebo|
75944159|NCT02516332|Behavioral|Supervised Aerobic Exercise|
75944160|NCT03437811|Device|Electro Flo Percussor, Model 5000|FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
75944161|NCT03446469|Other|Fascial Manipulation|Myofascial release of densified centers of coordination
76091734|NCT04781985|Procedure|cystoscopy|extraction of the bladder stone via suprapubic incision
76091735|NCT03265002|Dietary Supplement|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
75657132|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
75944162|NCT04954846|Dietary Supplement|OMNi-BiOTiC SR-9|"The Probiotic contains the following ingredients:~Maize Starch, Maltodextrin, Inulin, Potassium Chloride, Hydrolysed rice protein, Magnesium Sulphate, Fructooligosaccharides, Amylase, Manganese Sulphate~Additionally, the following bacterial strains are included:~Lactobacillus Casei W56, Lactobacillus Acidophilus W22, Lactobacillus Paracasei W20, Bifidobacterium lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium lactis W52, Lactobacillus plantarum, Bifidobacterium bifidum W23"
75944163|NCT04954846|Dietary Supplement|Placebo|The Placebo contains no bacterial strains, only the prebiotic ingredients found in OMNi-BiOTiC SR-9.
76091736|NCT03265002|Dietary Supplement|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
76091737|NCT03265002|Dietary Supplement|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
76091738|NCT03265002|Dietary Supplement|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
76091739|NCT04754997|Other|Traditional exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. The lower extremity range of motion exercise and strengthening exercises will be applied on the mat 10 repetition. The number of repetitions and type of exercises will be changed every 3 weeks.
76091740|NCT04754997|Other|Specific exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. Exercise training consists of lower extremity closed kinetic chain exercises and core exercises. The type of exercise changes every 3 weeks.
75944164|NCT03129477|Procedure|Telemonitoring in noninvasive ventilation|Compare telemonitoring to conventional monitoring to optimize Ventilation
76091741|NCT03257592|Drug|[11C]DPA-713|[11C]DPA-713 PET imaging
76091742|NCT03265236|Diagnostic Test|Anti - modified citrullinate vimentin|patients with early and late RA
76091743|NCT02458248|Behavioral|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
75657133|NCT02801838|Drug|Morphine|If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
76091744|NCT02457780|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
75345752|NCT05355805|Drug|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
75345753|NCT05355805|Drug|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
75476806|NCT05523570|Drug|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 80 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
75944165|NCT02483572|Behavioral|Functional Communication Training|Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
75476807|NCT05523089|Drug|Saline placebo|Sterile normal saline for injection
75476808|NCT05523089|Combination Product|CD388|CD388 liquid for injection
75657134|NCT00863473|Procedure|Surgical treatment with LCP|
75657135|NCT04276025|Other|Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
75657136|NCT02797860|Drug|Rocuronium|comparison of onset time and duration of rocuronium using Train of Four watch
75944166|NCT03441009|Other|Physio-/occupational therapy|Physio-/occupational therapy, ADL
75476809|NCT05522179|Dietary Supplement|NutraHeal|Receive NutraHeal (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
75476810|NCT05522179|Dietary Supplement|NutraHeal Plus|Receive NutraHeal Plus (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
75476811|NCT05512858|Behavioral|sensory room|the room has dimmed lighting, sensing games, essential oils, picture books and cookbooks, two heavy blankets (weighing 9 kg and 11 kg), a rocking chair, and a vestibular plate. The occupational therapist will accompany the first entry into the room to create a sensory profile, adjust and instruct on the means, and write a treatment card. The treatment card will record the patient's choices and instructions for arranging the room, and it will be used by the staff members who will admit the patient as needed. Each patient will be able to stay in the room for self-treatment according to the individual treatment card prepared at the first sensory room treatment, up to half an hour.
75476812|NCT05502029|Behavioral|Extended translation|Translation extended beyond the preoperative area
75657137|NCT00860899|Drug|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine [Catapres®, Boehringer Ingelheim, Germany], 7 mL of 0.25% levobupivacaine [Chirocaine®, Abbott S.p.A., Italy] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
75804151|NCT03026530|Procedure|Pulmonary recruitment maneuver|The participants in the experimental arm receives 1 minute of ventilator-piloted pulmonary recruitment with positive inspiratory pressure set to 40 cm H2O, at the end of laparoscopic bariatric surgery.
75804152|NCT03026530|Procedure|Laparoscopic bariatric surgery|
75804153|NCT03026530|Device|Ventilator|
75804154|NCT03418376|Dietary Supplement|Beta-alanine supplementation|The supplementation protocol of β-alanine (Etixx® Omega Pharma Belgium NV) involves oral intake of 4 x 800mg (3.2g/day29, 43) daily with at least 2h apart of slow-release β-alanine during the first 12 weeks. After this loading period, subjects will receive a maintenance dose of 2 x 800mg (1.6g/day) β-alanine for the remaining study duration.
75820055|NCT02186704|Device|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
75820056|NCT02191228|Drug|Linagliptin - single dose|
75944167|NCT03440931|Diagnostic Test|Ultrasound scan|Transvaginal ultrasound scan to assess ovaries
75944168|NCT03437655|Procedure|Carie removal|Carie removal with a low speed handpiece
75345754|NCT05348993|Drug|G03-52-01|G03-52-01 administered intramuscularly
75345755|NCT05348993|Drug|Placebo|placebo
75345756|NCT05341583|Drug|Ensartinib|Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
75345757|NCT05341583|Drug|Placebo|Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
75804155|NCT03418376|Other|Exercise intervention|The exercise training program (6 months) involves 3 week cycles (week I-III). During week I, subjects will perform high volume moderate intensity cardiovascular cycle training (3x/week). Twice a week, subjects perform 3h training sessions (70-80% HRmax*) and once a week a 1.5h session will be executed (80-90% HRmax). During week II, subjects will perform low volume maximum intensity interval cycle training (3/w). High intensity interval cycle training (HIIT) will consist of 3x maximal sprints (90-100% HRmax) of 1.5min, interspersed with 3min rest intervals. A 5min standardized warming up and 5min cooling down will be performed. Week III involves a recovery week where subjects will perform one training session of 1.5h at an exercise intensity of 70-80% HRmax and one session of HIIT.
76091745|NCT02457780|Behavioral|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
76091746|NCT02456610|Biological|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
76091747|NCT04778241|Procedure|Micro-osteoperforation|Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
76091748|NCT03537066|Device|CPAP|All patients included will be treated by CPAP
76091749|NCT04754919|Other|Transition intervention group|Support and on-going treatment intervention; monitoring the uptake of routine annual diabetes tests and encouraging to access where default observed General specialist diabetes support and provision of education and referral to other specialist healthcare agencies as individual requires
75657138|NCT02797782|Other|Detection of anti HBs antibody titer|All samples will be analyzed for anti HBs antibody titer using ELISA kits.
76091750|NCT04754919|Other|Post transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
76091751|NCT03763890|Device|Post-end-Expiratory pressure|Titrate the PEEP from 24 cmH2O to 6 cmH2O, 2 cmH2O/step and record EIT, trans-pulmonary pressure, hemodynamic parameter and Blood-gas analysis.
76091752|NCT04754841|Other|platelet cryopreservation|The cryopreservation of platelets will be carried out using as alternatives of cryopreservative solution: 5% dimethylsulfoxide alone (solution 1) or combined with 5% dextrose 160 mg (solution 2) or with 2% albumin (solution 3) and then be frozen at -80 ° C
76091753|NCT03757806|Other|Experimental group|"LiFE4D is an individualised programme, adapted to the participant's needs/preferences.~People with Dementia will receive assistance to increase their physical activity multiple times/day in their everyday tasks with the support/supervision of their caregivers.~The programme last for 12 weeks, with a lower face tracking over time with the health professional but replaced by caregivers. The intervention includes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt physical activity to everyday tasks, increase tasks frequency and intensity, monitor progress, clarify doubts, motivate and manage expectations. Phone calls aim to monitor motivation/evolution and clarify doubts."
76091754|NCT04001595|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
75944169|NCT03437655|Procedure|Relative isolation|Relative isolation with cotton and gauze.
76091755|NCT03257826|Device|kirschner wire|retrograde percutaneous kirschner wire was applied to stabilize the tibia.
75657139|NCT02797626|Procedure|Primary retroperitoneal lymph-node dissection (pRPLND)|Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
75672362|NCT02828189|Other|Physical Exercise|The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 9 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
75804156|NCT03730038|Drug|Treatment of pitavastatin 4 mg qd for 12 weeks|Treatment of pitavastatin 4 mg qd for 12 weeks
75804157|NCT03730038|Behavioral|Life-style modification|Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min
75944170|NCT03437655|Procedure|Manipulation of the temporary material based on Zinc Oxide and Eugenol|Manipulation of the temporary material based on Zinc Oxide and Eugenol according to the manufacturer's recommendations
75804158|NCT03693196|Other|PICF, Perio-paper®|PICF was collected from the mesio-buccal area of the implant by using paper tapes. Paper tapes were placed 1-2 mm inside the peri-implant sulcus by using a dental tweezer. After they were kept for 30 s, the paper tapes were placed in sterile microcentrifuge tubes which contained 200 µL phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. TNF-α, PGE2, RANKL, RANK, and OPG, which are immunological markers of peri-implant disease were compared between groups.
75944171|NCT03437655|Procedure|Manipulation of the temporary material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations
75944172|NCT03437655|Procedure|Material insertion on the cavity|Material insertion on the cavity according to the manufacturer's recommendations
75944173|NCT03437655|Procedure|Finishing the temporary direct restoration|Excess cement removal; Occlusal Adjustment; Finishing and polishing.
75476813|NCT05502029|Behavioral|Standard translation|Translation in the preoperative area
75672363|NCT02828189|Behavioral|Therapeutic Education|Individual Therapeutic Education about healthy habits and exercise on breast cancer.
75672364|NCT02828189|Other|Therapeutic exercise-Physiotherapy|"Cardiovascular exercise~Individualized progressive strength and resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk.~Flexibilization exercises"
75944174|NCT04813497|Diagnostic Test|Serology to determine SARS-CoV-2 infection|Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood
76091756|NCT03261492|Behavioral|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
75944175|NCT03446391|Procedure|Kinematic alignment|The principle for kinematically aligning the femoral component is to remove the correct amount of bone and cartilage from the distal and posterior femur after accounting for wear and saw blade kerf, so that the total thickness of the missing and removed tissue matches the thickness of the femoral component.
76091757|NCT03261492|Behavioral|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
76091758|NCT04781829|Diagnostic Test|BioFire Pneumonia Panel|Treatment based on an algorithm that recommends antibiotic choices based on bacteria/virus detected by BioFire Pneumonia Panel
76091759|NCT03261180|Other|Best Practice|Receive regular diet
76091760|NCT03261180|Other|Laboratory Biomarker Analysis|Correlative studies
76091761|NCT03261180|Dietary Supplement|Nutritional Intervention|Receive Nestle Impact AR
76091762|NCT04778319|Other|occlusion of tubes|to occlude the fallopian tubes
75345758|NCT05340296|Behavioral|Acute Youth Connect|This intervention is being piloted will be revised with feedback from the first 5-10 patients who complete it. At the time of registration, the protocol is as follows: Roughly one week prior to discharge, the patient and a parent/caregiver will together nominate 3-4 trusted adults in the patient's life to serve as their post-discharge support team. Consenting nominees will then attend a 45-90 minute training on how to provide social support to the patient. Each adult support will also receive weekly (3-15 minute) check in calls from study staff to monitor progress and concerns. Each patient will also attend 3 interactive sessions with a study interventionist, and will be encouraged to bring an adult from their support team. These sessions will be evenly spaced throughout the post-discharge intervention period. Adolescents will receive weekly reflection-prompting text messages to practice skills taught in the interactive sessions.
75657140|NCT00863629|Drug|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
75345759|NCT05319496|Device|Intermittently scanned continuous glucose monitor (isCGM)|"A wearable sensor the size of 2 stacked quarters, that allows individuals to scan their glucose levels on demand. No fingerstick is required. The device measure interstitial glucose through a filament that is inserted under the skin. The application process is painless, and each sensor lasts 90 days. Sensors can be scanned with certain smart phones. This device is marketed as the FreeStyle Libre 2 glucometer (Abbott Laboratories, IL)."
75657141|NCT02859857|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
75345760|NCT05319496|Behavioral|Education and coaching|Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.
75345761|NCT05256069|Drug|Propranolol Pill|Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).
75345762|NCT05256069|Drug|Placebo|Participants will receive a placebo in pill form.
75345763|NCT05251896|Procedure|Plasma-free procedure|Use albumin solution, lactated Ringer's solution, normal saline as replacement fluid
75345764|NCT05215379|Drug|xintilimab injection|neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle
75345765|NCT05215379|Other|Control|neoadjuvant chemoradiation therapy
75657142|NCT02805348|Drug|Bixalomer|Oral
75657143|NCT00860977|Drug|valacyclovir|oral valacyclovir 500mg twice daily
75820057|NCT02191228|Drug|Linagliptin - Multiple dose|
75820058|NCT02186782|Drug|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
75820059|NCT02186782|Drug|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
75345766|NCT05212831|Device|Inogen One® G4|Inogen One® G4 will be used for a minimum of 3h per day at Setting 3 during the intervention period.
75820060|NCT02186860|Biological|CAR-T cells|Given IV
75944176|NCT03446391|Procedure|Mechanical alignment|Classic mechanical alignment (MA) in total knee arthroplasty (TKA) is meant to co-align the prosthetic components to the mechanical axes of the femur and tibia and restore neutral overall limb alignment
75657144|NCT00860977|Drug|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
75657145|NCT02805192|Device|Size Measurement by a Smart phone App|
75657146|NCT00865891|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
75820061|NCT02187094|Drug|TC-6499|
75345767|NCT05199571|Biological|Ofatumumab|Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab
75820062|NCT02187094|Drug|Placebo|
75820063|NCT02187250|Drug|metformin|
75345768|NCT05192317|Device|Sollievo Fisiolax|Class IIb Medical Device
75345769|NCT05192317|Other|Sollievo Fisiolax Placebo|Placebo
75345770|NCT05183165|Other|Patients with Wilson's disease declaring pregnancy,|Blood and urine biological assessment Dietary assessment
75804159|NCT03693196|Other|Subgingival Plaque, Hu-Friedy®|Subgingival plaque samples were collected about 15 min after PICF was collected. Supragingival plaque was carefully removed by using a sterile scale. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal area of the implant by using sterile plastic Gracey curettes during 30 s (Hu-Friedy). The samples collected were transferred to sterile microcentrifuge tubes containing 200 µL PBS. The tubes were kept at -80°C until the analysis day. Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus oralis, which are microbiological agents of peri-implantitis were compared between groups.
75944177|NCT03446391|Device|GMK Sphere®|The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.
75944178|NCT03437499|Procedure|Sustained Inflation|Application of positive pressure by face mask with T-piece resuscitator for a prolonged period of 15 seconds at a peak pressure of 25 cmH20 followed by PEEP set at 5 cmH2O
75944179|NCT03437499|Procedure|Positive Pressure Ventilation|Application of positive pressure by face mask with T-piece resuscitator at a peak pressure of 25 cmH20, PEEP set at 5 cmH2, for 40 inflations/minute
75944180|NCT03446313|Behavioral|Movn Mobile App|The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
75944181|NCT03437343|Procedure|Hip arthroplasty|
75944182|NCT01062425|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiotherapy
75944183|NCT01062425|Drug|Cediranib Maleate|Given PO
75944184|NCT01062425|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
76091763|NCT04778319|Other|non occlusion of tubes|not to occlude the tubes
75657147|NCT00865891|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
75820064|NCT02187250|Drug|liraglutide|
75820065|NCT02187250|Drug|roflumilast|
75820066|NCT02191384|Drug|Orcinoside|oral, twice per day
75944185|NCT01062425|Other|Laboratory Biomarker Analysis|Correlative studies
76091764|NCT03261414|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
75345771|NCT05160805|Drug|ONL1204 Ophthalmic solution (Dose A)|Liquid formulation administered by intravitreal (IVT) injection
75345772|NCT05160805|Drug|ONL1204 Ophthalmic solution (Dose B)|Liquid formulation administered by intravitreal (IVT) injection
75345773|NCT05160805|Procedure|Sham procedure|A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.
75476814|NCT05501886|Drug|Gedatolisib|Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
75657148|NCT02797392|Behavioral|Lifestyle intervention|1) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
75657149|NCT02797236|Biological|SF2a-TT15 vaccine|
75820067|NCT02191462|Dietary Supplement|Niagen 100mg|
75820068|NCT02191462|Dietary Supplement|Niagen 300mg|
75820069|NCT02191462|Dietary Supplement|Niagen 1000mg|
75944186|NCT01062425|Other|Placebo Administration|Given PO
75944187|NCT01062425|Drug|Temozolomide|Given PO
75944188|NCT03446235|Behavioral|Exercise instruction with motivational interview|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. In addition to the basic instruction of exercise and nutrition, an exercise physiologist provides individualized exercise instruction with a motivational interviewing skill, which is a different style from traditional persuasive style of communication between the healthcare professionals and patients.
75944189|NCT03446235|Behavioral|Self-monitoring|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. Basic instruction about exercise and nutrition is provided at the initial visit.
75944190|NCT03440541|Combination Product|REGE pro|REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
75944191|NCT03437187|Procedure|Cholecystectomy|Laparoscopic technique
76091765|NCT03261414|Procedure|usual care|Standard care before induction of anesthesia
76091766|NCT01110681|Device|Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)|
76091767|NCT03257514|Drug|alpha lipoic acid drug (thioctic acid acid)|Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
75944192|NCT05127525|Drug|IRX-101|IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
75944193|NCT05127525|Drug|Control|Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
76091768|NCT03257514|Drug|Placebo Oral Tablet|placebo oral drug have the same shape of thiotacid tablet
76091769|NCT02456064|Behavioral|Lifestyle counseling|"Group medical visits~Telephone medical consultations~Expert patient~Training workshops"
76091770|NCT03257748|Radiation|Laser Therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
75476815|NCT05501886|Drug|Palbociclib|Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
75476816|NCT05501886|Drug|Fulvestrant|Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
75476817|NCT05501886|Drug|Alpelisib|Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
75476818|NCT05501691|Other|Placebo|Laser Simulation
76091771|NCT03257748|Radiation|LED therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
76091772|NCT04778007|Other|Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire|The Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire consists of 8 questions related with globus pharyngeus symptoms.
76091773|NCT04781751|Drug|insulin injection|Carpal tunnel syndrome sonagraphic injection
76091774|NCT04781205|Genetic|Mutation arrays, NGS panels, GWAS, WES, WGS,|DNA extracted from peripheral blood as well as genetic analysis of bacteria from feces
76091775|NCT04781205|Device|wearable monitors|test various technologies of sensors to measure continuously various body functions and provide information to person and to physician
76091776|NCT05387928|Drug|KL340399 injection|KL340399 injection is a STING-activating. The strength of KL340399 is 0.2 mg/vial，0.2 mg/vial.
76091777|NCT04777695|Other|Decibel Monitor|Placement of a TeckPro data logging sound decibel meter at all patient bed-spaces to measure concurrent sound levels 24 hours per day, over a one (1) month period. Peak and mean sound levels per hour will be collected by the decibel monitor. Sound collected every 5 minutes will be logged by the decibel monitor and downloaded onto manufacturer software daily; data will then be imported into Microsoft Excel for further data analysis.
76091778|NCT04488276|Other|In-depth interviews|In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
76091779|NCT03257280|Other|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
76091780|NCT04781439|Procedure|IV-to-PO conversion of antibiotics|IV-to-PO switching of antibiotics treatment
75804160|NCT03693196|Other|Williams probe, PCPNU-15 Hu-Friedy®|Clinical periodontal measurements were recorded using Williams probe. The plaque index, gingival index, pocket depth, bleeding on probing, clinical attachment level, and keratinised tissue width around the implant were recorded. The implants included were categorised into three groups, namely, healthy, peri-implant mucositis, and peri-implantitis. Panoramic radiographs were acquired to assess the interproximal bone levels around the implant.
76091781|NCT03252678|Other|a book and videos about ACP|A book and three videos about advanced care planning are provided for self-education
76091782|NCT03252678|Other|a book and videos about pain control|A book and three videos about pain control for cancer patients are provided for self-education
75476819|NCT05501691|Radiation|445 nm Diode Laser Wavelength|The Axial Surface of Class V Cavity will be Irradiated Using a 445 nm Diode Laser Wavelength
75657150|NCT02797236|Biological|SF2a-TT15 vaccine + adjuvant|
75657151|NCT02797236|Biological|Placebo|
75657152|NCT02797236|Biological|Placebo + adjuvant|
75657153|NCT00863785|Drug|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
75657154|NCT02801526|Drug|CKD-330 16/5mg - A|
75657155|NCT02801526|Drug|Candesartan 16mg and Amlodipine 5mg|
76091783|NCT04777773|Other|dual-task training|dual-task training
76091784|NCT03261024|Device|Friction mechanics|Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.
76091785|NCT03261024|Device|Frictionless mechanics|T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
76091786|NCT04777383|Drug|Acetylcholine|Iontophoretic administration of 5 different concentrations of acetylcholine
76091787|NCT04777383|Drug|Norepinephrine|Iontophoretic administration of 5 different concentrations of norepinephrine
76091788|NCT04777383|Drug|Phenylephrine|Iontophoretic administration of 5 different concentrations of phenylephrine
75657156|NCT05227495|Behavioral|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
75804161|NCT03693196|Other|Demographic|Age, gender and state of smoking were compared between groups.
76091789|NCT04777383|Drug|Atropine|Iontophoretic administration of 5 different concentrations of atropine
75657157|NCT05227495|Behavioral|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
75820070|NCT02191540|Drug|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
76091790|NCT04777383|Drug|Neostigmine|Iontophoretic administration of 5 different concentrations of neostigmine
76091791|NCT04777383|Drug|Sterile water|Iontophoretic administration of sterile water
76091792|NCT03260946|Other|Complementary medicine use|The prevalence of complementary medicine use
76091793|NCT03257124|Drug|AZD9291|AZD9291 160mg per oral daily (1 cycle of 28 days)
76091794|NCT02089113|Drug|Dexamethasone|
75476820|NCT05501691|Radiation|660 nm Diode Laser Wavelength|The Axial Surface of Class V Cavity will be Irradiated Using a 660 nm Diode Laser Wavelength
75476821|NCT05501691|Radiation|970 nm Diode Laser Wavelength|The Axial Surface of Class V Cavity will be Irradiated Using a 970 nm Diode Laser Wavelength
76091795|NCT02089113|Procedure|Placebo Vehicle|
76091796|NCT03252990|Diagnostic Test|PET-MRI|Additional 18F-choline PET-MRI examination
75944194|NCT01060553|Other|Acupuncture treatment|This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
75345774|NCT05159063|Device|Ultrasound imaging|"Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled."
75345775|NCT05155436|Drug|Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg|Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
75345776|NCT05125900|Other|Proximal box elevation using one of the tested materials|Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite
75476822|NCT05500248|Behavioral|Leave In Situ|"Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.~This behaviour is recommended by guidelines if the endoscopist is expert in optical diagnosis. In this case the endoscopists will be experts and they will also be helped by the CADx system that has shown to exceed the thresholds requested for use in clinical practice in previous trials."
75476823|NCT05500248|Behavioral|Standard|All identified polyps will be removed and sent to pathology.
75944195|NCT05090241|Diagnostic Test|Instrumental measurement of balance and gait|The balance measurement was performed on a force platform. The walk test was carried out using sensors to analyze and retrieve data from the participant's walk (gait speed, step length, duration of the double support phase).
76091797|NCT03252990|Procedure|Optical Coherence Tomography|Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
76091798|NCT03257046|Drug|ITI-214|Oral
76091799|NCT03257046|Other|Placebo|Oral
76091800|NCT03252444|Other|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
76091801|NCT03252444|Other|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
76091802|NCT03252288|Behavioral|Reminders|Text of phone-call based reminders to mobile phones
75345777|NCT05125783|Other|questionnaire|Completion of the questionnaire by the patient after consultation with the practitioner.
75345778|NCT05116514|Other|Case management|"Regular and personalized follow-up by a case manager using a case management approach, updated every 3 months"
75345779|NCT05108311|Other|Manual therapy and therapeutic exercise|"Gliding over the deltoid superficial fascia.~Anterior-Posterior mobilization of the clavicle.~myofascial release of the shoulder joint complex techniques.~Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy"
75345780|NCT05103696|Drug|Remimazolam Besylate|Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 5 times within 15min
76091803|NCT03252288|Behavioral|Conditional financial transfers|Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs >1 week but within 4 weeks of the scheduled visit
76091804|NCT03260634|Drug|Voriconazole|
75476824|NCT05498207|Behavioral|Maya App|Participants will utilize the Maya App for at least 20 minutes per day, 2 days per week, for 6 weeks. Additionally, participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
75657158|NCT02805426|Drug|Tranexamic Acid|
75657159|NCT02805426|Drug|Placebo|
75657160|NCT02805426|Drug|Misoprostol|
75657161|NCT00866203|Drug|HDS vs ProMECE/CytaBOM|
75657162|NCT02805036|Device|echocardiography|• Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
75657163|NCT02805036|Device|Arterial oximetry|measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
75672365|NCT04733144|Drug|Prednisolone|7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
75672366|NCT04733144|Drug|Dexamethasone|1,125 mg dexamethasone 4,5 mg dexamethasone
75672367|NCT04167072|Procedure|Stent removal|This is a procedural intervention in which the stent will be removed via endoscopy.
75804162|NCT03730350|Behavioral|Clinical Hypnosis|Hypnosis guidance and audio tracks aimed at promoting pain relief, reducing distress and anxiety, and facilitating sleep will be provided for independent use, with daily practice recommended. Each hypnosis session will be 20-25 minutes long. The scripts for these sessions have been developed based on the clinical literature (e.g., Elkins, 2014) and are already in use with patients of the pain service.
75944196|NCT03621917|Device|Near-infrared spectroscopy reading|Non-invasive readings will be taken from forehead with near-infrared spectroscopy
76091805|NCT03256890|Behavioral|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
75345781|NCT05103696|Drug|etomidate combined with propofol|Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score
75657164|NCT04235946|Other|accompanied and adapted water polo program|"Validated questionnaires in French will measure fatigue, quality of life, post-traumatic growth and the coach-athlete relationship. All questionnaires will be administered face to face before the sessions by a member of the social psychology research team.~The collection of qualitative data (semi-structured interviews) will be carried out by one of the members of the research team in social psychology on three occasions (inclusion, Week 10 and Week 20) in order to assess the psychological variables of interest (quality interpersonal relationships, self-esteem, post-traumatic growth) and their dynamics.~Physiological variables (weight, fat / lean mass, capacity of the operated arm) will be evaluated monthly. The physical measurement data will be recorded in an electronic case report form"
75657165|NCT00861133|Device|Sleuth AT Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
75820071|NCT02187328|Other|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
75944197|NCT05077995|Device|Polar M200|Participants will have to wear the activity monitors (AP and Polar M200) for at least 7 days. Minutes spent in each activity type will be summed to a total day score. Participants will be instructed to do their regular daily life activities without limitation, but to note their main activity categories in an activity diary, with a main focus on cycling and participation in structured exercise.
75944198|NCT03437109|Diagnostic Test|Laboratory tests|Testosterone HSBG Hb1Ac LH
75944199|NCT03436953|Drug|CX-8998|T-type calcium channel blocker
75944200|NCT03436953|Drug|Placebo|Placebo comparator
76091806|NCT03256890|Other|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
76091807|NCT04777227|Drug|Lidocaine injection|2% (20mg/ml) lidocaine solution
76091808|NCT04777227|Drug|Physiological water injection|0.9% sterile sodium chloride water
76091809|NCT04777227|Procedure|Debridement|A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.
76091810|NCT04777227|Procedure|Needle insertion|A 27-gauge needle on a 3 mL syringe was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side
76091811|NCT03260556|Drug|Pirfenidone|Increasing doses
76091812|NCT03260556|Drug|Placebos|Increasing doses
75345782|NCT05101915|Drug|RESP301|Inhaled IMP delivered via nebulisation
75345783|NCT05101460|Device|XVIVO Perfusion System (XPS™) with STEEN Solution™|XVIVO Perfusion System (XPS™) with STEEN Solution™
75476825|NCT05497960|Behavioral|Vivo workout|2 days a week for 12 weeks of a live, interactive virtual strength training program. Each class is 45 minutes long and lead by a certified trainer.
75657166|NCT00573469|Drug|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
75657167|NCT00573469|Drug|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
75657168|NCT00573469|Drug|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
75657169|NCT02796066|Drug|Vehicle|Applied once a day
75657170|NCT02796066|Drug|TSN2898|Applied once a day
75944201|NCT02491684|Drug|Interferon beta-1a Nebuliser solution 48 μg/mL|Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
75476826|NCT05496881|Other|Exercise Group 1|Prescribed exercises will focus on mobility and balance.
75476827|NCT05496881|Other|Exercise Group 2|Prescribed exercises will focus on physical fitness.
75476828|NCT05496881|Other|Exercise Group 3|Prescribed exercises will focus on flexibility, range of motion, and muscle tone.
75657171|NCT02796066|Drug|TSN2898|Applied once a day
75657172|NCT02796066|Drug|TSN2898|Applied once a day
75657173|NCT00870259|Dietary Supplement|Optifast VLCD|Meal replacement, three times daily for 8 weeks
75657174|NCT02801292|Drug|Ketamine|Single bolus of Ketamine .25 milligrams per kilogram of weight.
75657175|NCT02544061|Biological|NM-IL-12|single 12 µg unit subcutaneous (SC) dose of NM-IL-12
76091813|NCT04780737|Procedure|Cholecystectomy|Laparoscopic or laparotomic cholecystectomy
76091814|NCT04776915|Diagnostic Test|Ultrasound and Hysterosalpingography|Ultrasound and Hysterosalpingography
76091815|NCT02712996|Drug|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
76091816|NCT02712996|Drug|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
76091817|NCT03252366|Device|GELFOAM|"Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~A diamond bur will be used to make a rectangular osteotomy.~The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~Implant stability will be measured by osteal device~implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
76091818|NCT03252366|Device|xenograft|"Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~A diamond bur will be used to make a rectangular osteotomy.~The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~Implant stability will be measured by osteal device~implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
75657176|NCT02544061|Drug|Placebo|single subcutaneous dose
75820072|NCT02187328|Other|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
75944202|NCT02491684|Drug|Placebo|Placebo solution for once daily inhalation for 14 days
75944203|NCT04755465|Device|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) is based on the principle of creating a contraction by stimulating the nerve fibers innervating the related muscle in the healthy muscle and the muscle fibers in the denervated muscle with electrical current. The electric currents used in stimulation of muscles and nerves perform this function by changing the electrical potential of cell membranes.~It is contraindicated in pregnancy, presence of pacemaker, severe heart disease, epilepsy, fracture, dementia and impaired consciousness. We prevent contraindicated situations by excluding volunteer participants with these characteristics."
75944204|NCT04755465|Other|Structured Exercise|Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.
75944205|NCT03128697|Behavioral|Satiating diet|
76091819|NCT04346277|Biological|IC14, a monoclonal antibody against CD14|IC14 is a recombinant chimeric anti-human monoclonal antibody directed against human CD14. It recognizes both membrane-bound CD14 and soluble CD14.
76091820|NCT04780347|Drug|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3w； capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
76091821|NCT04780347|Drug|capecitabine|capecitabine: capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
75345784|NCT05078437|Behavioral|Medication therapy management|The proposed deprescribing intervention is using a patient-centered framework by: (1) balancing the risks and benefits, and addressing the specific needs of each individual patient, (2) considering the individual patient and the caregiver's preferences and values, and (3) empowering the patient and the caregiver to take responsibility and fully participate in the decision-making process as equal team players.
75820073|NCT02191696|Device|IMED-4 recording|
75820074|NCT02187406|Procedure|Modified ankle athletic taping|
75345785|NCT05072041|Device|Nexsphere™|Nexsphere™ is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
75345786|NCT05057520|Other|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
75476829|NCT05493371|Drug|Empagliflozin 10 MG|10 mg once daily empagliflozin oral tablets for 12 weeks
75657177|NCT02801058|Other|Osteopathic manipulative treatment|Osteopathic manipulative techniques on thoracic diaphragm
75657178|NCT02690142|Drug|Placebo|Single dose i.v.
75657179|NCT02690142|Drug|ABY-035 i.v.|Single dose i.v.
75657180|NCT02690142|Drug|ABY-035 s.c.|Single dose s.c.
75657181|NCT00863863|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
75657182|NCT00863863|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
75657183|NCT03853044|Drug|Chidamide|Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles
75657184|NCT03853044|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
75657185|NCT03853044|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle.
75657186|NCT03853044|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
75820075|NCT02187406|Procedure|Traditional ankle athletic taping|
75820076|NCT03535480|Drug|G-CSF|G-CSF subcutaneously during five days
75944206|NCT03128697|Behavioral|Control diet|
75657187|NCT03853044|Drug|Prednisone|Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
75657188|NCT00870337|Drug|everolimus|
75657189|NCT02797158|Procedure|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
75657190|NCT00866437|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L~Estradiol 1mmol/L~Estrone 3mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
75944207|NCT01061723|Drug|Sarilumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
75944208|NCT01061723|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
75944209|NCT03445767|Other|MedSafer|An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.
75944210|NCT03445611|Drug|corticosteroid solution with lidocaine containing parabens.|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
75657191|NCT00866437|Drug|Skin test panel|"Hormones:~Progesterone 1mmol/L~Estradiol 1 mmol/L~Estrone 3 mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
75657192|NCT02797002|Other|Assessment|
75657193|NCT00863941|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
75657194|NCT00863941|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
75657195|NCT02795910|Behavioral|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
76091822|NCT02455596|Drug|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
76091823|NCT01013415|Drug|HAART|
76091824|NCT01013415|Biological|T cells|
75657196|NCT02795910|Behavioral|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
75820077|NCT03535480|Combination Product|ASCOT|G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
75820078|NCT02187484|Drug|BIBR 277|
75820079|NCT02191852|Drug|Seresis®|
75820080|NCT02256748|Drug|BIRT 2584 XX|
75820081|NCT02256748|Drug|Midazolam|
75820082|NCT02187562|Drug|Meloxicam|
76091825|NCT03256500|Device|Transcranial Direct Current Stimulation|One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
76091826|NCT03256110|Behavioral|Improving Communication about Serious Illness-AI/AN|A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.
76091827|NCT04780191|Device|MyoRegulator®|Trans-spinal DC stimulation paired with peripheral DC stimulation
75657197|NCT00870415|Procedure|quality-of-life assessment|
75657198|NCT00870415|Procedure|therapeutic conventional surgery|
75820083|NCT02187562|Drug|Aspirin|
75820084|NCT02187640|Behavioral|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
75944211|NCT03445611|Drug|corticosteroid solution with lidocaine containing no paraben|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
75944212|NCT03440307|Behavioral|Face-to-Face Meetings|Participants received health and fitness education, and a face-to-face 3-week intervention to reduce bisphenol exposure.
76091828|NCT03252132|Other|12-week resistance training|Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
76091829|NCT03252210|Procedure|Preoperative Stereoscopic Localization|1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
76091830|NCT02455440|Drug|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
76091831|NCT02455440|Drug|Placebo|
76091832|NCT02455440|Drug|Propofol and sevoflurane|
76091833|NCT03937167|Other|Psychotherapy group|Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
76091834|NCT03260166|Drug|nicotinamide|Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
75345788|NCT05020366|Behavioral|Preventing Obesity through Parent Empowerment and the Activation of Routines|Parents will receive a report of their child's current performance and adherence to World Health Organization recommendations in each intervention area. Parents will be coached to build consistent family mealtime routines, in which children are involved in meal preparation, food exploration, and play. They will receive education on appropriate serving sizes for young children and basic information nutrition recommendations. Predictable bedtime routines will be designed to incorporate calming sensory input to improve the transition to bed. Parents will be educated on screen time recommendations and help families brainstorm alternatives to screens, including family-based routines of movement and activity. Finally, parents will be coached to incorporate play into all newly adopted routines, as young children learn though play.
75345789|NCT05020366|Behavioral|Enhanced Usual Care|For the control group, usual care will be enhanced by providing parents with a report of their child's performance and adherence to World Health Organization recommendations in the areas of healthy eating, physical activity, sedentary behavior and sleep. This report will consolidate data based on parent report, written logs, and actigraphy at baseline.
75345790|NCT05006261|Device|Tele-Tai Chi|12-week simplified TC program using the Tele-TC platform at home, with recommended training sessions at least three times a week, and two or more supplementary live sessions.
75657199|NCT00812565|Drug|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
75657200|NCT00812565|Biological|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
75657201|NCT02801214|Other|fMRI|
75657202|NCT00866515|Drug|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
75657203|NCT00866515|Drug|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
75804163|NCT03693118|Behavioral|Reh1,Reh2|The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.
75944213|NCT03440307|Behavioral|Email Only|Participants received health and fitness education.
75944214|NCT03440151|Procedure|contralateral submental flap for tongue cancer defect|"Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted."
75944215|NCT03440151|Procedure|primary closure for tongue cancer defect|Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
75944216|NCT04054739|Device|Robot-assisted gait training|intervention with robot-assisted gait training
75944217|NCT04054739|Device|Treadmill gait training|intervention with treadmill gait training
75944218|NCT03440073|Other|Mulligan Concept Intervention|The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.
75944219|NCT03440073|Other|Sham Mulligan Concept Treatment|The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
75657204|NCT02795754|Drug|GSK2838232 PIB|GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
75657205|NCT02795754|Drug|GSK2838232 IR1|GSK2838232 will be available as film-coated tablet for oral use
76091835|NCT02089191|Device|Nelfilcon A contact lenses|
75804164|NCT03725904|Diagnostic Test|Progesterone analysis in saliva|Analysis of salava progesterone
76091836|NCT02089191|Device|Stenfilcon A contact lenses|
76091837|NCT03260010|Drug|Fosfomycin|Infectofos 5 g
76091838|NCT03260088|Diagnostic Test|Immunoglobulin G4|IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
76091839|NCT04779723|Procedure|Comparison of two Techniques of bariatric surgery|We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB
76091840|NCT05387850|Other|no intervention|no intervention
76091841|NCT01896219|Device|Navigation station (IMACTIS-CT®)|
76091842|NCT01896219|Device|CT|Reference method for gestures (carried out under CT) guidance
76091843|NCT04776135|Drug|MT-1186|Suspension
76091844|NCT03256188|Behavioral|Active classroom|30 minutes of moderate-to-vigorous physical activity
76091845|NCT04775823|Procedure|Hybrid composite nano-ceramic|Indirect bonding the hybrid composite nano-ceramic restoration to the tooth to be restored of worn dentition patients
76091846|NCT03474276|Drug|Azythromycin|Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
75657206|NCT02795754|Drug|GSK2838232 IR2|GSK2838232 will be available as film-coated tablet for oral use
75672368|NCT04247945|Biological|Cotransplant with MSCs|Co-transplantation of MSCs during allogeneic HSCT
76091847|NCT03474276|Dietary Supplement|Inuline and fructo-oligosaccharides|Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.
76091848|NCT03474276|Drug|Albendazole|Administration of Albendazole at inclusion of the child : 200mgs, one administration
75657207|NCT02795754|Drug|Placebo PIB|Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
75944220|NCT04360629|Drug|Tranexamic Acid|Tranexamic Acid will be given through central vein
75944221|NCT04360629|Drug|normal saline|normal saline will be given through central vein
75944222|NCT04741035|Other|Modified sternal precautions|"Use pain and discomfort to guide the safe use of the arms Avoid pushing or pulling with one arm Use both arms close to the body during lifting Use of arms is possible, but keep them close to the body Avoid stretching one or both arms backwards at the same time Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging 'posture) when coughing.~When transferring, roll onto the side, ease the legs over the edge of the bed and carefully use the arms to sit up from a lying position"
75944223|NCT04741035|Other|Conventional sternal precautions|Avoid pushing or pulling through the arms Avoid one-arm (unilateral) activity Limit the elevation of the arms to 90 degrees Avoid lifting objects heavier than 2 kg Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging' posture) when coughing Limit the use of the arms when transferring from sitting to standing and getting out of bed Avoid placing the arms behind the back
75944224|NCT04727229|Drug|Bupivacaine Hydrochloride|Injection of Bupivacaine near the stellate ganglion
75944225|NCT04727229|Drug|Normal Saline|Injection of Normal Saline near the stellate ganglion
75944226|NCT03445455|Device|Tidal volume measurement|"Recording of thoracic impendance variations during different non-invasive oxygenation techniques.~Conversion to Tidal volume after calibration using the airway flow signal recorded during the NIV with bucco-nasal mask."
75944227|NCT03445377|Device|Real-time continuous glucose monitoring|Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
75944228|NCT03445377|Device|Self-monitoring of blood glucose|Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
75944229|NCT03436719|Drug|Oral antibiotic|Metronidazole - 500 mg and Erythromycin - 500 mg per os *3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
75944230|NCT03436719|Drug|Intravenous antibiotic|Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
76091849|NCT03474276|Dietary Supplement|Fortified blend flour|"Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day~Compostion of the fortified blend flour per 100 grams : either :~Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g"
76091850|NCT04779801|Behavioral|Attachment-Based Family Therapy|16 weeks of Attachment-Based Family Therapy treatment.
76091851|NCT03259776|Other|Qualitative interviews and questionnaire survey|Qualitative interviews and questionnaire survey
76091852|NCT04779255|Drug|Procedure (Tumesent anesthesia)|Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.
76091853|NCT04779255|Drug|Control Arm (Paracetamol)|Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.
75476830|NCT05492942|Behavioral|Best Practice Advisory (BPA) and Population Health Management (PHM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). Additionally, a clinician will be supported by a PHM who can access and existing registry of patients with possible or confirmed AUD to examine quality metrics for patients with an AUD on the provider panel. The PHM will circulate quarterly reports to the clinicians in this group to provide performance metric data that indicates the proportion of patients on their primary care panel who are initiating and engaging in AUD treatment. Additionally, the PHM will circulate a weekly report of higher risk patients on the clinician's panel who recently had an acute care visit for AUD and could benefit from outreach for follow-up care. PHM does not directly help clinicians with implementation of care with individual patients, and has no direct patient contact.
75657208|NCT02795754|Drug|Ritonavir|It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
75657209|NCT00864019|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
75804165|NCT04142866|Device|Anodal transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the active tDCS condition, stimulation continues for the first 20 minutes of the 60-minute treatment session, and then ramps back down to 0 milliamps (mA).
75804166|NCT04142866|Device|Sham transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
75804167|NCT04142866|Behavioral|Speech-Language Therapy (SLT)|Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
75657210|NCT00864019|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
75672369|NCT04724720|Drug|Famotidine|Standard or care treatment plus prescribed famotidine
75345791|NCT05004376|Behavioral|Text Messaging|Text messages based on behavioral theory to encourage scheduling colorectal cancer screening.
75944231|NCT03436719|Drug|Mechanical Bowel Preparation|Beginning of MBP at 4 p.m. in a day before surgery
75944232|NCT04182659|Device|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
75345792|NCT04994015|Device|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
75345793|NCT04992039|Other|WHO HEARTS technical package|"Components of WHO HEARTS technical package are~Universal BP screening via A&D arm-in BP device.~Training of Medical Officers and Nurses on BP measurement using standard techniques.~Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application.~Use of a drug and dose specific hypertension treatment protocol.~Standardized inventory and procurement practice to ensure a reliable supply of protocol medications.~Training and support for team-based model of hypertension care delivery.~Access to the Simple data dashboard for program monitoring.~Standardized procedure for patient follow-up.~Community-based prescription refilling."
75345794|NCT04981418|Device|customised pelvic support shorts|"These apply targeted compressive forces to the pelvic girdle through selective precisely positioned reinforced lycra panels that aim to stabilize and align body segments to improve function and reduce unwanted movements. The construction material (Nylon and Elastane) is durable and breathable, and its mechanical properties enable it to provide dynamic stability and support (rather than the rigid support provided by off-the-shelf belts) during movement/functional activities. This aims to optimise comfort and movement to increase wear compliance, which is crucial as any benefits gained rely upon this."
75345795|NCT04981418|Other|Exercise|Women will be provided with up to a maximum of 4 exercises from a pre-defined list of exercises. Suggested dosages are referred to in the protocol. The exercise programme contains a range of exercise focused around the pelvic girdle and hips (including movement control and strengthening
75804168|NCT03730272|Drug|analgesic drugs and methods|the patient will receive analgesic treatment at the discretion of the physician in charge
75944233|NCT04182659|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
75944234|NCT04452123|Procedure|Laparoscopic argon plasma treatment of endometrioma|Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
75944235|NCT04452123|Procedure|Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary|Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
75944236|NCT03439995|Other|Open lung protective ventilation|Higher PEEP, lower tidal volume mechanical ventilation
75944237|NCT03439995|Other|Conventional ventilation|Lower PEEP, standard tidal volume mechanical ventilation
75944238|NCT04452201|Behavioral|Guided Participation|GP couples' participation together in development of communication competencies in the context of infant care will be supported by a handbook and telephone guidance structured for collaboration with the nurse/research assistant beginning at approximately 2 weeks of age. Two face-to-face sessions are expected prior to hospital discharge, followed by 5 or 6 monthly phone sessions. If the baby is inpatient at the time an intervention session is to take place, the session may be done face-to-face, if more convenient than a phone session for the parents.
75804169|NCT03687424|Device|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
75944239|NCT01061333|Drug|Nedocromil|Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge
75944240|NCT01061333|Drug|Comparator: Montelukast|Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge
75944241|NCT01061333|Drug|Comparator: Mometasone|Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge
75944242|NCT01061333|Drug|Placebo|Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
75944243|NCT03445299|Behavioral|Music|Listening to music for 30 minutes at bedtime
75345796|NCT04981418|Other|advice|standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource.
75345797|NCT04981041|Drug|Prasugrel or Ticagrelor|Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)
75804170|NCT03687424|Device|low-flow nasal oxygenation (LFNO)|Active comparator (LFNO): O2 flow 5L/min, FiO2 40%
75804171|NCT03585504|Drug|Etonogestrel contraceptive implant|Etonogestrel contraceptive implant
75804172|NCT03417830|Drug|GSK2315698 (CPHPC)|GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
75944244|NCT02489968|Drug|empagliflozin 10 mg + linagliptin 5 mg|empagliflozin low dose + linagliptin once daily
75944245|NCT02489968|Drug|empagliflozin 10 mg|empagliflozin low dose once daily
75944246|NCT02489968|Drug|empagliflozin 25 mg + linagliptin 5 mg|empagliflozin high dose + linagliptin once daily
75944247|NCT02489968|Drug|empagliflozin 25 mg|empagliflozin high dose once daily
75944248|NCT02489968|Drug|Placebo|
75944249|NCT03439761|Drug|PT-112 Injection|PT-112 Injection 28 days constitute a period. The drug is intravenously dripped for 60 minutes at the 1st, 8th and 15th day of each period.
75804173|NCT03417830|Drug|GSK2398852 (unlabeled anti-SAP mAb)|Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
75944250|NCT04941586|Other|Education in pain, Manual Therapy and Exercises|twice a week, lasting 60 minutes, for one month
75944251|NCT04941586|Other|Manual Therapy and Exercises|twice a week, lasting 40 minutes, for one month
75944252|NCT04451421|Behavioral|Change of standing Angle|Change the patient's standing Angle by using an electric bed
76091854|NCT03252054|Diagnostic Test|Screening for memory disorders, attention disorders, and malnutrition|Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
76091855|NCT03256422|Drug|Treatment discontinuation|"• Receiving tritherapy. Allowed treatment drugs are :~nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir"
76091856|NCT04775901|Other|CT-guided lung biopsy|Percutaneous transthoracic lung biopsy was conducted stepwise under the real-time guidance of CT scan. This kind of modality served as an effective method for diagnosing peripheral lung lesions (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
76091857|NCT04775901|Device|Template-guided lung biopsy|A three-dimensional model consisting of participant's thoracic image information was initially reconstructed based on the CT scan data. Afterwards, a navigational template was customized, which accommodated well to the anatomical landmarks of the participant. The template was then printed by means of stereolithography from photopolymer material. Participants would receive navigational template-guided percutaneous transthoracic lung biopsy (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
75944253|NCT03436329|Procedure|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
76091858|NCT01968382|Drug|IMM 124-E (Hyperimmune Bovine Colostrum)|Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
76091859|NCT01968382|Drug|Placebo (High protein milk powder)|Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
76091860|NCT00951249|Behavioral|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
76091861|NCT00951249|Behavioral|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
75944254|NCT03436329|Procedure|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
76091862|NCT00951249|Behavioral|Peer health care system navigators|HIV/STI treatment and other medical and social services
75345798|NCT04981041|Drug|Clopidogrel|Clopidogrel and NOAC
75345799|NCT04959422|Other|Active scheduling|Active scheduling, tracking and rescheduling, if necessary.
75345800|NCT04912570|Procedure|Manual Thrombus Aspiration|Manual thrombus aspiration using one of the FDA approved aspirators will be done.
75345801|NCT04912570|Procedure|Standard PCI|Standard PCI according to the most recent guidelines
75345802|NCT04899544|Behavioral|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|Pivotal Response Treatment in autism center.
75345803|NCT04899544|Behavioral|Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)|Pivotal Response Treatment in home environment.
75345804|NCT04898725|Dietary Supplement|Vitamin D3|Vitamin D3 4800IU daily
75944255|NCT04451577|Other|No intervention|No intervention, analysis of biological samples
75944256|NCT04451343|Other|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
75345805|NCT04894435|Biological|mRNA-1273 SARS-CoV-2 vaccine|Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
75345806|NCT04894435|Biological|BNT162b2|A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
75345807|NCT04894435|Biological|ChAdOx1-S [recombinant]|A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
75345808|NCT04894435|Other|0, 28 day schedule|Second injection administered 28 days post first injection
75345809|NCT04894435|Other|0, 112 day schedule|Second injection administered 112 days post first injection
75345810|NCT04894435|Biological|Covifenz|COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
75657211|NCT02800980|Procedure|Drainage and sclerotherapy.|Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
75657212|NCT02800980|Procedure|Drainage alone.|Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
76091863|NCT00951249|Behavioral|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
76091864|NCT03260244|Procedure|cardiac mapping and radiofrequency ablation procedure|"It is a minimally invasive procedure which can be performed using either general or conscious sedation. During catheter ablation, catheters (narrow, flexible tubes) are inserted into a blood vessel, often through a site in the groin (upper thigh) or neck, and guided through the vein until they reach the heart. Small electrodes on the tip of the catheters stimulate and record the heart's activity. This test, called an electrophysiology study (EPS), allows the doctor to pinpoint the exact location of the short circuit. Another word for pinpointing the exact location of the short circuit is 'mapping', for which precision is a key requirement to maximize a successful outcome.~Once the location is confirmed, the short circuit is either destroyed (to reopen the electrical pathway) or blocked (to prevent it from sending faulty signals to the rest of the heart)."
75657213|NCT00812487|Drug|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
75657214|NCT00812487|Drug|Subcutaneous insulin|4 injections of insulin/day
76091865|NCT03259932|Other|no physical activity|no physical activity
76091866|NCT03259932|Other|physical activity|Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
76091867|NCT04779567|Drug|Acetaminophen|Acetaminophen 1 gr iv 4 times a day
76091868|NCT04779567|Drug|Placebo|100 ml saline 0.9% iv 4 times a day
75944257|NCT03444987|Genetic|Measurement of protein expression in tissues.|"The followings markers will be estimated in tissue~FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~Reduced glutathione, an antioxidant marker by a colorimetric method"
75944258|NCT03436251|Device|Local Hyperthermia at 37℃|As a control, for patients with HPV+/CIN-1 or HPV+ with normal cytology, hyperthermia at 37℃ is applied
75944259|NCT03436251|Device|LEEP or cold knife|For patients with HPV+ / CIN-2
75345811|NCT04891666|Dietary Supplement|Lactobacillus plantarum DSM 33464|1 sachet SmartGuard® per day for 12 weeks
75345812|NCT04891666|Dietary Supplement|Placebo|1 sachet of placebo per day for 12 weeks
75657215|NCT04235868|Biological|Stem cell-derived derived pleiotropic factor|After debridement, the wounds in experimental group apply stem cell-derived lyophilized powder, and use foam dressing to wrap the wound; apply once every 2-3 days.
75804174|NCT03417830|Drug|89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)|89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
75804175|NCT03692962|Behavioral|Sleep restriction|Time in bed will be restricted to 5 hours per night for 7 nights.
76091869|NCT03259854|Device|non invasive mechanical ventilation in pediatrics|use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation
75345813|NCT04890145|Device|RW-Precision-Coupler|Implantation of the RW-Precision-Coupler together with FMT-VORP 503
75345814|NCT04879043|Drug|HDP-101|HDP-101 is available as lyophilized white powder for preparation of infusion.
75804176|NCT03692962|Other|Acoustic stimulation|Brief tones will be presented time-locked to ongoing slow waves during deep sleep.
75944260|NCT03436251|Device|Local Hyperthermia at 44℃|As an experimental arm, for patients with HPV+/CIN-1/CIN2 or HPV+ with normal cytology
75944261|NCT03129165|Other|Screening and prevention of CVD|"Drug: Pharmacological control of risk factors in agreement with primary physicians.~Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.~Social: Social worker care."
75944262|NCT03436173|Drug|Fluoxetine|Fluoxetine 10 mg/2.5 ml mixed with water
75944263|NCT03436173|Other|Peppermint syrup|Liquid peppermint syrup measured to the equivalent volume and mixed with water
75944264|NCT03436095|Other|bundle measures|Implementation of bundle measures to improve the successful rate of weaning ventilator
75944265|NCT03444831|Drug|Buspirone|Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.
75944266|NCT03444831|Drug|Placebo Oral Tablet|Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
75345815|NCT04875559|Other|Standardised multimodal pain treatment regimen|"Preoperatively:~Paracetamol 1000 mg p.o.~Celecoxib 400 mg p.o.~Dexamethasone 12 mg p.o.~Perioperatively:~Ondansetron 4 mg IV~Bupivacaine 2.5 mg/mL, 20 mL LIA~Oxycodone 0.15 mg/kg IV (Oxycodone 0.25 mg/kg for ALND)~Postoperatively:~Paracetamol 1000 mg p.o. every 6h PRN~Ibuprofen 400 mg p.o. every 6h (day 1-5) PRN~Oxycodone 5 mg IV or 10 mg p.o. PRN~Ondansetron 4 mg IV or p.o. PRN"
75657216|NCT04235868|Biological|fibroblast growth factor|After debridement, the wounds in control group apply fibroblast growth factor to the wound surface, and use foam dressing to wrap the wound; apply once every 2-3 days.
75657217|NCT02800902|Drug|placebo|Oral prophylaxis followed by placement of placebo gel
75657218|NCT02800902|Drug|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
75657219|NCT02800902|Drug|Atorvastatin|Oral prophylaxis followed by placement of atorvastatin gel
75672370|NCT04724720|Drug|Placebo|Standard of care treatment plus placebo
75820085|NCT02187640|Behavioral|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
75944267|NCT03439215|Drug|Lorlatinib|Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
75944268|NCT03439059|Behavioral|Reducing Sedentary Behaviour Group|Participants will be prompted to perform 10min of light physical activity (>1.5 METS) 3x/day for 6 weeks
75944269|NCT03128463|Drug|Intravitreal injection of conbercept|We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
75944270|NCT04953364|Behavioral|SMART|SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. The tablet will also allow asynchronous contact with trainers through a secure website.
75944271|NCT04953364|Behavioral|Control|The control group will receive a care booklet and weekly contacts for 6 weeks.
75944272|NCT03438903|Device|Repeat exams of OCT device|All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
76091870|NCT03259854|Device|oxygen mask|use of oxygen mask after successful weaning from invasive mechanical ventilation
76091871|NCT03291210|Other|normal inspired oxygen fraction|receives inspired oxygen fraction of 0.3
76091872|NCT03291210|Other|high inspired oxygen fraction|receives inspired oxygen fraction of 0.8
75345816|NCT04852562|Procedure|Modified radical endoscopic sinus surgery|Modified radical endoscopic sinus surgery was performed to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate.
75345817|NCT04852562|Procedure|functional endoscopic sinus surgery|Full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
75672371|NCT02655432|Device|Spot photoscreener|Screening of vision problem through an automated device
75345818|NCT04841304|Device|Loop recorder (Reveal LINQ, Medtronic)|Implantation of a loop-recorder
75345819|NCT04841304|Device|Continuous Glucose Measurement (G6, Dexcom)|Monitoring with a continuous glucose monitor
76091873|NCT04756245|Behavioral|Virtual Reality|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within virtual reality software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both virtual reality and real-world physical activities.
75944273|NCT01061177|Drug|Nilotinib|Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
76091874|NCT04756245|Behavioral|Video Conference|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within video conference software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both streaming video and real-world physical activities.
76091875|NCT03255876|Dietary Supplement|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
76091876|NCT03255876|Dietary Supplement|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
75657220|NCT05756595|Drug|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|This group will inject once a week. Evaluation of pain score after 30 seconds and 3 hours.
75657221|NCT02796768|Other|3D US Scanning|3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
75657222|NCT02796768|Other|2D US Scanning|2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
75804177|NCT03729882|Procedure|EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. A prophylaxis gallbladder drainage will be done using a 3.8 mm working-channel linear-array therapeutic echoendoscope (EG3870UTK;Pentax, Hamburg, Germany) attached to an ultrasound console (Avius Hitachi, Tokyo, Japan) within a transgastric and/or transduodenal approaches to the gallbladder puncture followed by placement of a lumen apposing stent (LAMS) (AXIOS; Xlumena Inc, CA, USA) with a 10 mm luminal diameter and a dumbbell-shaped flanges to bring together the 2 walls in apposition. These feature of the Axios decrease the risk for bile leak, stent migration, and stent occlusion.
75944274|NCT02481934|Procedure|NKAE cells infusion|Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
75804178|NCT03729882|Procedure|Non EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. If the patient had an acute cholecystitis will be sent to surgery and be considered as a Non EUS-guided gallbladder drainage
75804179|NCT03690622|Drug|Dexmedetomidine|Instillation of eyedrops
75804180|NCT03690622|Drug|Balanced salt solution|instillation of eyedrop
75804181|NCT03639636|Other|non surgical and surgical periodontal therapy|scaling and root planing periodontal flap surgery
75804182|NCT03683134|Behavioral|Mediterranean diet|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
76091877|NCT02352844|Drug|Everolimus|
76091878|NCT03255642|Drug|Melatonin 2mg|4 weeks of 2mg prolonged release melatonin (Circadin)
76091879|NCT03255642|Drug|ClonazePAM 0.5 MG|4 weeks of 0.5mg clonazepam (Rivotril)
75345820|NCT04840550|Drug|Lansoprazole 15 mg|Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
75657223|NCT04034043|Device|ceramic-on-ceramic total hip arthroplasty|ceramic-on-ceramic, cementless total hip arthroplasty for post-traumatic hip osteoarthritis.
75657224|NCT02796690|Other|nasal swabs will be collected|After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
75657225|NCT00617461|Drug|GEn 1200mg/day|1200mg/day gabapentin enacarbil
75657226|NCT00617461|Drug|GEn 3600mg/day|3600mg/day gabapentin enacarbil
75657227|NCT02795130|Procedure|Sclerotomy closure|Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
75657228|NCT00812331|Drug|TMC435|From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
75944275|NCT02481934|Drug|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
75944276|NCT02481934|Drug|Bortezomib|Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
75944277|NCT03436017|Other|Metabolomic approach|Biological samples (blood and urine) for a multimodal metabolomic approach
75944278|NCT03438825|Procedure|Mitral valve replacement/repair|Mitral valve replacement/repair: standard of care operation of the mitral valve due to severe insufficiency
75944279|NCT03444519|Drug|Mannitol|This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
75944280|NCT04309383|Diagnostic Test|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
76091880|NCT03562377|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
76091881|NCT03562377|Drug|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
76091882|NCT03562377|Biological|Tdap vaccine|Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.
76091883|NCT03562377|Biological|Meningococcal vaccine|This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
75657229|NCT04233996|Drug|Piperacillin-Tazobactam 4 g-0.5 g|Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h
75657230|NCT04233996|Drug|Cefepime 2000 mg|Patients with FN who required empirical treatment with cefepime 2g/8h
75657231|NCT04233996|Drug|Meropenem 1000 mg|Patients with FN who required empirical treatment with meropenem 1g/8h
75804183|NCT03683134|Dietary Supplement|Olive oil and mixed nuts|Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.
75804184|NCT03683134|Behavioral|American Heart Association|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
75804185|NCT03683056|Behavioral|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
75804186|NCT03576768|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
75804187|NCT03576768|Device|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
75944281|NCT03129009|Drug|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
75944282|NCT03129009|Drug|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
75944283|NCT03129087|Behavioral|Vocal rest versus vocalization|A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection
75944284|NCT03438669|Other|no intervention|no intervention
75944285|NCT03438591|Device|Medtronic 4196 lead|Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
75944286|NCT02973425|Behavioral|Take a Break as an augmentation to NRT-sampling in Motivation Phase|NRT sampling experience & Suite of mHealth motivational tools and mini-games.
75944287|NCT02973425|Behavioral|NRT and mHealth assessment tool without feedback|NRT and mHealth assessment tool without feedback
75944288|NCT03435861|Drug|VX-745|active drug capsules
75944289|NCT03435861|Drug|placebo|placebo capsules
75944290|NCT02489500|Drug|Bortezomib|"Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1"
76091884|NCT02352922|Drug|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
75345821|NCT04840550|Drug|Tegoprazan 25 mg|Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
75657232|NCT03802812|Device|Thin bronchoscope and VBN|targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system
75657233|NCT00870493|Drug|Aliskiren|Aliskiren 300 mg daily oral
75657234|NCT00870493|Drug|Placebo|starch tablet, 300 mg/day
75657235|NCT02795208|Procedure|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
75944291|NCT02489500|Drug|Melphalan|"Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0"
75944292|NCT02489500|Drug|Neupogen|granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
75944293|NCT02489500|Procedure|Stem Cell Collection|collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells
75944294|NCT02489500|Procedure|Stem cell infusion|infusion of previously collected autologous stem cells
75657236|NCT00864331|Radiation|radiation|39 Gy in 13 daily fractions of 3 Gy
75944295|NCT03438513|Behavioral|Occupational Therapy Assessment|The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)
75944296|NCT03438513|Behavioral|Psychological Assessment|It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.
75944297|NCT03438513|Behavioral|Problem Solving Therapy|Problem-solving learning program for all situations of daily living, done in groups (10 people per group)
75944298|NCT03438513|Behavioral|Speaking group|Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
75944299|NCT03652649|Other|3:1 ratio Ketogenic diet|Type 2 Diabetic subjects with BMI greater than or equal to 30 are started on 3:1 ratio ketogenic complete meal replacement program and weight loss and glycemic control is tracked over 6 month intervention period
76091885|NCT02352922|Drug|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
75657237|NCT00864331|Other|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
75657238|NCT00864331|Drug|Chemotherapy|Chemotherapy given alone
75657239|NCT00864331|Other|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
76091886|NCT02456220|Device|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
75672372|NCT02655432|Procedure|Ophthalmologic evaluation|Screening of vision problem through an ophthalmologic evaluation
75944300|NCT03438435|Drug|QRH-882260 Heptapeptide|Imaging agent
75944301|NCT04053959|Drug|AI assisted insulin system|The patients receive the insulin regime set by AI assisted insulin titration system
76091887|NCT03255330|Drug|Gabapentin|Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
76091888|NCT03255330|Drug|Metamizol|Standardized treatment
76091889|NCT03255330|Drug|Tramadol|Standardized treatment
75657240|NCT00812253|Drug|Intravenous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
75944302|NCT04053959|Drug|Physician based insulin regime|Patients receive the insulin regime recommended by physicians
75944303|NCT03433443|Behavioral|Case manager assisted rehabilitation|In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.
75944304|NCT03433443|Behavioral|Usual physical rehabilitation|The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
75944305|NCT03652571|Drug|Nortriptyline|"Nortriptyline escalating dose regimen:~Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg"
75944306|NCT03652571|Drug|Placebo|Placebo
75944307|NCT03433365|Other|MRD analysis|To collect 2 samples for MRD analysis in patients treated with Lenalidomide
76091890|NCT01969162|Procedure|Tear Sample Collection|Tear sample collection as per protocol. No investigational drug is administered in this study.
76091891|NCT02089659|Drug|Doravirine|Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
76091892|NCT03259464|Drug|BI 685509|3 sequential dose groups
76091893|NCT03259464|Drug|Placebo|3 sequential dose groups
76091894|NCT03246282|Device|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
76091895|NCT03246282|Drug|Normal Saline 0.9% Infusion Solution Bag|250 ml of 0.9% Sodium Chloride Solution
76091896|NCT03246282|Device|Peripheral Catheterization|"20-gauge 1.0 catheter"
76091897|NCT04754685|Drug|Intra-articular injection of platelet-rich plasma|The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
76091898|NCT02353780|Drug|TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)|TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
76091899|NCT02353780|Drug|Abatacept|Abatacept; SQ; specifics to be determined by the treating rheumatologist.
76091900|NCT02353780|Drug|Tocilizumab|Tocilizumab; SQ; specifics determined by the treating rheumatologist.
76091901|NCT03246438|Behavioral|Colonoscopy only|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
76091902|NCT03246438|Behavioral|Colonoscopy outreach + mailed FIT follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
76091903|NCT03246438|Behavioral|Colonoscopy + Mailed FIT outreach and follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
76091904|NCT04775589|Behavioral|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps
76091905|NCT03251742|Device|Hayek RTX ventilator|Negative pressure ventilation in Fontan patients.
76091906|NCT02022826|Device|SmartPill Monitoring System|
76091907|NCT04775511|Other|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
75657241|NCT00812253|Drug|Subcutaneous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
75657242|NCT02790294|Device|Magnetic Resonance Imaging|The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
75657243|NCT00870571|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
75657244|NCT00870571|Drug|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
75657245|NCT02796612|Other|no intervention|Patients do not receive any interventions but are treated according to current standard of care.
75672373|NCT02655432|Procedure|Cyclopleged refraction|Screening of refractive problems through a cyclopleged optometric refraction
75672374|NCT02833103|Drug|Danshu Capsules|Danshu Capsules (0.9g potid/day) for three months by oral
75944308|NCT03652103|Procedure|Ultrasound Guided Erector Spinae Plane Block Catheterisation|After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.
76091908|NCT04775511|Other|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
76091909|NCT04775511|Other|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
76091910|NCT03246360|Drug|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms"
76091911|NCT01969240|Other|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
76091912|NCT02455752|Procedure|LE-TME|Retroperitoneal approach for total mesorectal excision
76091913|NCT02354092|Procedure|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
76091914|NCT02354092|Procedure|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
76091915|NCT02354092|Procedure|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
76091916|NCT02354092|Procedure|Dilator Placement|"Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter."
75345822|NCT04817176|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|Experimental Arm: The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
75657246|NCT02796612|Behavioral|delivery of a take-home brochure|Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
75657247|NCT02796612|Behavioral|patient care by a psychologically trained physician|The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
75944309|NCT03652103|Drug|Bupivacaine 0.25% Injectable Solution|Perineural Injection
75944310|NCT03433209|Device|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy
75944311|NCT03433209|Device|Articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy
75944312|NCT03444441|Procedure|Foot or ankle surgery|Surgery for foot or ankle
75944313|NCT03652337|Device|BlephEx|Electronic lid margin debridement
75345823|NCT04817176|Other|Ketogenic Nutrition Program|Active Comparator Arm: 6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
75345824|NCT04765072|Behavioral|Survivorship Patient Navigation Intervention|Patient navigator assistance for navigating the healthcare system and locating and utilizing beneficial resources
75345825|NCT04765072|Behavioral|Telehealth Survivorship Visit Intervention|Individualized survivorship care plan
75345826|NCT04744662|Drug|ONL1204 Ophthalmic solution|Liquid formulation administered by intravitreal (IVT) injection
75345827|NCT04744662|Procedure|sham injection|sham injection is done by touching the eye surface with a syringe without a needle
75657248|NCT05756439|Drug|Intravenous Sedatives with or Without Analgesia|Participants having dental surgery with conscious intravenous sedation
75657249|NCT00616759|Procedure|electroconvulsive therapy|electroconvulsive therapy as usual
75672375|NCT02833103|Drug|Pinaverium Bromide|Pinaverium Bromide (100mg potid/day) for three months by oral
75944314|NCT03652337|Device|Manual debridement|Manual lid margin debridement
75944315|NCT03652025|Procedure|embolotherapy of incompetent gonadal and iliac veins|minimally invasive
75944316|NCT03444363|Device|Laser group|Laser application in addition to SRP
75944317|NCT03444363|Device|Control group|Placebo laser application in addition to SRP
75944318|NCT01725425|Other|Control|The control is designed to determine average mood.
75657250|NCT00616759|Procedure|electroconvulsive therapy plus propofol|electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure
75804188|NCT03576768|Device|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
76091917|NCT02354092|Behavioral|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
76091918|NCT02354092|Drug|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
75804189|NCT03576768|Device|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
75804190|NCT03682822|Procedure|Early Artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
75944319|NCT01725425|Other|Increase Portion Size|The purpose is to determine whether a change in mood will occur.
75804191|NCT03682822|Procedure|Delayed Artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
75944320|NCT01725425|Other|Decrease Portion Size|The purpose is to determine whether a change in mood will occur.
75944321|NCT01725425|Other|Mixed Portions|The purpose is to determine if a change in mood will occur.
75944322|NCT03444285|Other|Warm Up|Run on a treadmill during 10 minutes without fatigue of the participant after this time.
75944323|NCT03444285|Other|Hot Pack|20 minutes of hot-pack on both hamstring
75944324|NCT03651947|Drug|QL1206|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
75944325|NCT03651947|Drug|Xgeva®|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
75944326|NCT02732847|Other|A delayed prescription dated 2 days after clinical office visit|
76091919|NCT00907101|Drug|Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)|Apply once daily
75345828|NCT04736745|Biological|IPN59011|Powder and solvent for solution for injection
75657251|NCT00616759|Drug|propofol|Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
75657252|NCT02795364|Procedure|Structural Image Guidance|Resecting the tumor in accordance with the margin on MRI T1W-enhanced delineation
75944327|NCT02732847|Drug|Usual Dated|
75944328|NCT04003701|Behavioral|Usual care|Control group: minimal distraction
75944329|NCT04003701|Behavioral|Robot-assisted puncture procedure|Experimental group: distraction with robot
75944330|NCT05006703|Behavioral|Breathe4T|A digital, self-management intervention for adolescents to control their asthma using breathing retraining. The mobile-friendly website provides information about asthma and how it affects the lungs, as well as how breathing patterns can be dysfunctional. Information is presented using short (30sec-2min) video clips featuring physiotherapists, researchers and adolescent role models. Users are given tips about their practice, including choosing a suitable time and place and building up gradually. Users can plan their practice, log how their practice went and record their confidence in using the breathing techniques. There are 8 sessions including peer-led videos demonstrating breathing exercises with voiceovers and step-by-step instructions. All features and sessions can be accessed via a main dashboard where users can tailor the intervention to allow parental involvement, reminders and a preferred format for notifications (email/text). Other features include FAQs and a progress chart.
75944331|NCT03651869|Drug|Cigarette 1|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
75345829|NCT04736745|Biological|Azzalure|Powder for solution for injection
75657253|NCT02795364|Procedure|Metabolic Image Guidance|Aggressive resecting of the tumor in accordance with the margin on MRS CNI delineation
75657254|NCT00870649|Biological|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
75657255|NCT00870649|Biological|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
75657256|NCT02796456|Other|blood sample|
75944332|NCT03651869|Drug|Cigarette 2|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
75345830|NCT04736745|Drug|Placebo|Powder for solution for injection
75345831|NCT04732702|Other|no intervention|There will be no intervention.
75345832|NCT04731844|Drug|Curcumin plus Piperine|Curcumin with piperine is a well-tolerated over-the-counter supplement.
75354704|NCT04729803|Behavioral|Experimental: Attention Control + Exposure|"Participants will receive a brief standardized psychoeducation module, presented via a video recording.~F~Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members.~Between speeches participants will have a 1-minute break.~Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention control condition: (1) the intervention rationale will include information about the importance of attention control; (2) participants will be given target at the center of the screen to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target for the whole response."
75804192|NCT03715400|Behavioral|Positive Virtual Reality Training|Participants will undergo 7 45 minute sessions of positive virtual reality training over the course of four weeks. All assessments will be completed online at home following initial orientation to the program.
75804193|NCT03690310|Biological|Anti-CD19 CAR NK Cells|Anti-CD19 CAR NK Cells injection
75804194|NCT03715322|Drug|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
76091920|NCT03251820|Drug|corticosteroid|Each patient will be subjected to a one month course of steroids and then re-evaluated
75804195|NCT03715322|Other|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
75944333|NCT03651869|Drug|Patch 1|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
75944334|NCT03651869|Drug|Patch 2|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
76091921|NCT03251976|Behavioral|video|informational video
75944335|NCT04966221|Diagnostic Test|Lung MRI scan|Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
75944336|NCT03651791|Combination Product|USPIO labeled MSC injection|USPIO labeled MSC injection
76091922|NCT03251976|Behavioral|usual care|usual physician counseling on end of life care
76091923|NCT03251664|Dietary Supplement|Food groups consumed|
76091924|NCT02455830|Biological|Autologous cord blood cell therapy|The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
76091925|NCT03251586|Diagnostic Test|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
75944337|NCT04053647|Other|Non-interventional study|Non-interventional study
75944338|NCT04958655|Behavioral|Tetris Task|a visual task where participants are asked to play 'tetris' i.e. attend to and manipulate shapes and positions on screen
76091926|NCT03251586|Diagnostic Test|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
76091927|NCT04488120|Device|transcatheter closure of secundum atrial septal defects in patients|transcatheter closure of secundum atrial septal defects in patients
76091928|NCT03251274|Other|machine bathing|machine bathing 20-min duration at evening
76091929|NCT03251274|Other|traditional bathing|traditional bathing
76091930|NCT04488042|Other|Stapler-less gastrectomy|After the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
75345833|NCT04685291|Procedure|Ultrasound-guided block of the supraclavicular nerves|The supraclavicular nerves (SCN) arise from the 3rd and 4th roots of the spinal nerves. After emerging from the spine, they run at the rear margin of the sternocleidomastoid muscle and divide into their three terminal branches. With a high-resolution Ultrasound (US)-probe they can be visualized as a grape-like structure under the skin. At this location, patient's skin is disinfected and covered with a sterile perforated blanket. The US-probe is covered with a sterile sheath. The patient is positioned as comfortably as possible so that the broken clavicle is not mobilized. SCN are shown by US and a 0.5 mm needle is advanced through the patient's skin in order to direct it to the nerves under US-guidance. Both the nerves and the needle are permanently visualized. As soon as the needle tip is placed next to the SCN, 2-3 millilitres of a long-acting LA are injected. The distribution of the LA around the nerves is controlled.
75657257|NCT00812097|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
75804196|NCT03715322|Drug|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
75804197|NCT03690232|Drug|glucose water|3 sessions of 6cc 25% glucose injection with a 2-week interval
75657258|NCT05226247|Procedure|Spontaneous breathing trial|To perform cardiac and lung echography before and during a spontaneous breathing trial
75657259|NCT02790216|Procedure|Brachytherapy|Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
75672376|NCT03984266|Diagnostic Test|NGS panel|A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.
75672377|NCT04247789|Other|Self-reported questionairres|the fatigue will be determined through self reported questionnairres
75672378|NCT02648490|Drug|HLX07|recombinant human anti-EGFR monoclonal antibody against cancers
75672379|NCT02648490|Drug|Acetaminophen|Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
75804198|NCT03690232|Drug|hyaluronic aicd|intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment
75804199|NCT03687268|Drug|Naloxone HCl PR tablets|oral administration
75804200|NCT03687268|Drug|Placebo Oral Tablet|Placebo
75944339|NCT04958655|Behavioral|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate a specific future mental image to reduce cue-induced craving for alcohol
75345834|NCT04685291|Drug|Conventional pain management|"oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~oral pain medication in patients older than or equal 70 years: Acemetacin 60mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~Rescue analgesic medication for all patients: oxycodone hydrochlorid (drops) p.o. (10 mg/ml) 0.1mg/kg p.o. hour~In the ED Rescue analgesic medication for all patients: Fentanyl 50mcg i.v. (max. 200mcg/hour)"
75345835|NCT04672070|Other|Selective Caries Removal|"Selective caries are removed only for secure sealing with a direct restoration, without removing deep caries next to the pulp.~If the pulp is exposed, pulpotomy will be performed instead and the tooth will be excluded from further analysis."
75354705|NCT04723823|Other|Motor or sensory imagery|Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury
75944340|NCT03651323|Device|Left atrial appendage closure with Watchman device|Percutaneous left atrial appendage closure using Watchman device
75944341|NCT03435549|Behavioral|Remote monitoring|Patients given an activity tracker to wear for 6 weeks after LEJR replacement surgery. For 2 weeks after surgery, they will also receive a daily text messages asking what their pain is on a scale of 0 to 10. They will be asked to reply to the text with their pain score. They will also be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days.
75966043|NCT02087735|Dietary Supplement|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
76091931|NCT04488042|Other|Suture|No reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
76091932|NCT00701064|Other|Bright Light Exposure|Administered via bright light box
76091933|NCT00701064|Other|Negative Ion Generator|Administered via Negative Ion Generatore
76091934|NCT03245970|Drug|Labetalol Hydrocholoride 200 mg orally every 12 hours|Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
76091935|NCT03245970|Drug|Nifedipine 60 mg orally daily|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
76091936|NCT03245970|Drug|Atenolol 25 mg daily|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
75966044|NCT02087813|Drug|Alpha1-antitrypsin|
76091937|NCT03255486|Biological|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
76091938|NCT02454348|Drug|Vasopressin|Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
76091939|NCT02454348|Drug|Norepinephrine|Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
76091940|NCT02455908|Drug|Proleukin®|
76091941|NCT06112795|Other|Non-Interventional Study|Non-interventional study
76091942|NCT06112782|Device|Keravive by Hydrafacial Treatments|Scalp hydradermabrasion
76091943|NCT06112691|Device|taking fundus photos using non-mydriatic fundus camera - FundusScope Rodenstock|using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
76091944|NCT06112665|Drug|Tofacitinib 5 MG|Patients receive Tofacitinib and Naproxene
76091945|NCT06112652|Device|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
75966045|NCT02087813|Drug|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
76091946|NCT06112652|Device|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
76091947|NCT06112652|Device|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
76091948|NCT06112652|Device|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
76091949|NCT06112652|Device|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
75345836|NCT04672070|Other|Pulpotomy|"Complete caries removal and excision of the coronal pulp to the level of the root canal orifices will be performed. After haemostasis, sealing with Biodentine® and restoration.~If the pulp is not exposed after complete caries removal, the tooth will be restored without further excavation and pulp exposure. If the pulp is assessed intra-operatively to be non-vital or not amenable to pulpotomy, root canal treatment will be performed instead. In both cases, the tooth will be excluded from further analyses."
75345837|NCT04618705|Behavioral|Smoking Cessation|Participants will start a smoking cessation program.
75345838|NCT04593875|Device|Active LIFUP Treatment|2 LIFUP Treatments
75345839|NCT04593875|Device|Sham LIFUP Treatment|2 sham LIFUP treatments
75345840|NCT04578925|Behavioral|Happy, Healthy, Loved|A text message based, mobile-device delivered intervention that provides educational information to primiparous mothers and their partners about breast-feeding and coping with stress.
75944342|NCT03435549|Behavioral|Remote monitoring plus goal setting and social support|Patients given activity tracker to wear for 6 weeks after LEJR surgery. For 2 weeks after surgery, they will receive a daily text messages asking what their pain is on a scale of 0 to 10 and asked to reply by text. They will be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days. Patients will be asked to identify a a friend or family member to act as support partner. The study will share progress updates with support partner and contact this individual if patient stops wearing the activity tracker for over 3 days. This partner will also be able to provide supportive messages to help encourage them to reach their activity goals.
75672380|NCT02648490|Drug|dexamethasone|dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
75804201|NCT03682666|Device|Kinesiotaping|Kinesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
75944343|NCT03651713|Behavioral|GLU+EX|Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
75944344|NCT03651713|Dietary Supplement|GLU|Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
75944345|NCT03433131|Drug|Pitolisant|Tablets
75944346|NCT03651557|Drug|Neu2000KWL High-dose group|1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)
76091950|NCT06112639|Device|DANCEREX-DTx|"DANCEREX treatment integrates the dance activities with an innovative motivational system into applied game~The patients will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair). In addition, the DANCEREX app involves a game dynamic in which the execution of the rehabilitation sessions feeds a digital book that allows the rehabilitation experience to be placed in a narrative context."
75345841|NCT04535479|Behavioral|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
75345842|NCT04513366|Drug|SEL-212 low-dose|IV infusion of SEL-212 low-dose every 28 days for a total of up to 12 infusions
75345843|NCT04513366|Drug|SEL-212 high-dose|IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions
75345844|NCT04513366|Other|Normal Saline|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
75345845|NCT04512365|Drug|Placebo oral capsule|A capsule that contains only dextrose filler administered during the first or second laboratory visit.
75345846|NCT04512365|Drug|THC|A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
75345847|NCT04501796|Drug|Double-Blind NT-I7|Administered by intramuscular (IM) injection
75345848|NCT04501796|Drug|Double-Blind Placebo|Placebo
75345849|NCT04480853|Drug|Fingolimod|Fingolimod 0.5 mg QD, oral
75345850|NCT04452214|Drug|CAN04|Administered intravenously
75345851|NCT04452214|Drug|Pembrolizumab|Administered intravenously
75345852|NCT04452214|Drug|Carboplatin|Administered intravenously
75672381|NCT02648490|Drug|diphenhydramine|diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.
75672382|NCT02648490|Drug|5-HT3 inhibitor|If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
75672383|NCT02829827|Drug|Radiprodil|Radiprodil at individualized doses.
75672384|NCT02648568|Behavioral|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
75804202|NCT03682666|Behavioral|modified Constraint Induced Movement Training|A 2-hour time period would be arranged to constraint patient's unaffected hand by using a bandage by a therapist. During this two hours, patients would not be allowed to use this unaffected to do any activity, so that they will need to use the affected hand. The caregivers would also be educated to provide less help if it is not necessary. This intervention would be executed two hours a day for five days per week, for three weeks.
75345853|NCT04452214|Drug|Pemetrexed|Administered intravenously
75345854|NCT04448171|Device|Active TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an active setting.
75345855|NCT04448171|Device|Sham TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an inactive setting.
76091951|NCT06112639|Device|Multidimensional dance-based program|Multidimensional dance-based program provided via a digital medicine telerehabilitation platform. The patient will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair).
76091952|NCT06112639|Device|Educational Program|Subjects will view educational/informative videos on Tablet. The treatment will be provided via a digital medicine platform.
76091953|NCT06112626|Behavioral|CHG Skin Treatment Video|Short CHG skin treatment video that reviews the rationale/importance of CHG bathing, and the appropriate process for bathing
76091954|NCT06112600|Procedure|VR|Virtual reality glasses were used as a distraction method for children during vaccination.
76091955|NCT06112600|Procedure|Kaleidoscope|Kaleidoscope toys were used as a distraction method for children during vaccination.
76091956|NCT06112587|Behavioral|strength training|A targeted 8-week strength-training course was offered as an intervention in combination with ergonomics and posture corrections and recommendations
75345856|NCT04430010|Behavioral|BEST in CLASS|BEST in CLASS is a Tier-2 evidence based program (EBP) that has demonstrated effectiveness at reducing children's Disruptive Behavior Problems (DBPs) and risk for Emotional and Behavioral Disorders (EBDs)
75657260|NCT05227183|Behavioral|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
75804203|NCT03682666|Device|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
75804204|NCT03576066|Drug|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
75944347|NCT03651557|Drug|Neu2000KWL Low-dose group|1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)
75944348|NCT03651557|Drug|Placebo|1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours
75944349|NCT05056467|Procedure|Induction of Labor|Induction of Labor at 39 weeks of gestation
76091957|NCT06112574|Behavioral|Visuomotor force control training|Single-task training involves visuomotor finger force tracking and dual-task has an additional cognitive components including visual distraction and working memory.
76091958|NCT06112548|Procedure|primary unilateral TKA|Primary unilateral total knee arthroplasty with cruciate scarifying cemented DePuy Synthes PFC Sigma prosthesis.
75657261|NCT00866593|Drug|Generic Escitalopram|10mg/d or 20mg/d
75657262|NCT00866593|Drug|Innovator Escitalopram|10mg/d or 20mg/d
75657263|NCT02795286|Device|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
75657264|NCT02795286|Device|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
75804205|NCT03576066|Drug|SOC NUC|Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
75804206|NCT03576066|Drug|Placebo Oral Tablet|Participants will receive placebo matching ABI-0731 tablets orally QD.
75944350|NCT03435471|Other|Prophylactic Swallowing Home Exercise Program|The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
75944351|NCT03435471|Other|Clinician-Directed Prophylactic Swallowing Exercises|Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
75944352|NCT03435393|Procedure|Catheter ablation|Mapping of the epicardium and ablating areas of long fractionated potentials
75944353|NCT02489344|Drug|GZ/SAR402671|"Pharmaceutical form:capsule~Route of administration: oral"
75966046|NCT03048812|Device|O'Ring Attachment (A)|Attachment A will be inserted in three months of follow up,followed by treatment B in a random order
76091959|NCT06112548|Drug|Bupivacain|low body weight (0.50%, 20cc) intraoperative periarticular injection
76091960|NCT06112548|Drug|ketorolac|1ml of 30mg/ml ketorolac intraoperative periarticular injection
76091961|NCT06112548|Drug|epinephrine|0.5ml Adrenaline 1mg/ml intraoperative periarticular injection
76091962|NCT06112548|Drug|Paracetamol|IV Paracetamol [Ofirmev] introduced every 6 hours after surgery
76091963|NCT06112548|Drug|Ketorolac|IV Ketorolac {Toradol} introduced every 12 hours after surgery.
76091964|NCT06112548|Drug|Tramadol|IV Tramadol [Ultram] introduced when needed after surgery
75345857|NCT04402008|Drug|Poziotinib Once Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
75345858|NCT04402008|Drug|Poziotinib Twice Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
75345859|NCT04402008|Drug|Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
75345860|NCT04398719|Radiation|[11C]PBR28|The radiotracer, [11C]PBR28, will be administered at the beginning of each PET scan
75345861|NCT04398719|Drug|Low-dose lipopolysaccharide|Subjects will receive intravenous lipopolysaccharide.
76091965|NCT06112535|Device|Versius Surgical System|"Transoral robotic surgery (TORS) using Versius Surgical System. Versius is a robot designed to help surgeons perform surgery. It consists of a set of robotic arms: one of the arms has a camera and a light source on it while the other arms each have a small surgical instrument attached at the end. The surgeon controls each of the arms with hand controllers (joysticks) and can perform surgery with them, while seeing the surgical area on a screen in front of him/her.~The camera and instruments are inserted into the mouth and throat in order to cut out a cancerous tumour."
76091966|NCT06112522|Drug|Tirbanibulin|Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
75944354|NCT03433053|Behavioral|HIV Testing Message Intervention|The Health Belief Model will be utilized as the primary theoretical framework in guiding the development of a tailored HIV testing message for young African American women in this intervention. Two conditions will be developed and compared as outlined below. Condition 1 participants will be exposed to an HIV testing message inclusive of culturally tailored information that addresses both culturally specific barriers and facilitators of HIV testing (as identified in Study 1). The message will be brief (will take less than 3 minutes to present/read).
75966047|NCT03048812|Device|Equator Attachment (B)|Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
76091967|NCT06112509|Other|Vestibular exam|Interrogation, videonystagmoscopy, videonystagmography, video-head-impulse-test
76091968|NCT06112496|Device|EMG|Neuro-EMG-Micro, Neurosoft, Ivanovo, Russia, will be used for the assessment of muscle activity for muscles.
76091969|NCT06112483|Behavioral|SWELE Programme|"This 16-week programme focuses on Supporting Wellness in E-Child Learning Environments (SWELE) programme by combining unstructured outdoor play with mindfulness-based interventions to promote mental health in SEN students, in the context of the COVID-19 pandemic. There is no such SWELE programme to promote mental health for SEN students in Hong Kong, especially in the context of COVID-19 pandemic.~A playful approach of unstructured play has also been found effective on promoting positive emotions and emotional competence among early adolescents (Harn & Bo, 2019). Unstructured Outdoor Play coupled with Mindfulness-based Interventions via SWELE programme to Promote Mental Health for children and adolescents with SEN during COVID-19 pandemic. Very limited unstructured outdoor play-based programme integrated into the extra-curricular activities in the special schools in Hong Kong."
76091970|NCT06112470|Other|Interview|Semi-structured interview on experiences, perceptions, beliefs and knowledge of drug allergy and barriers to allergological testing, with a view to content analysis.
76091971|NCT06112457|Other|Survey|Anonymous self-administered questionnaire
75804207|NCT03557034|Device|Kardia Monitoring|Kardia Mobile is an FDA approved device that allows one lead ECG recording for 30 seconds using the patient's smart phone. The device has a built-in algorithm that detects AF. KardiaPro is a secure platform that allows the physician to access the patient's recording at any time. The platform can also be programmed to send a notification to the healthcare provider if AF is detected by the software.
76091972|NCT06112444|Other|scale|The scale of Short Western Ontario Rotator Cuff İndex
76091973|NCT06112418|Device|The Cleerly CAD Staging System|The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
76091974|NCT06112405|Other|App-based CCAAP|App-based CCAAP, could remind patients take controller and reliever when asthma symptoms get worse through mobile.
75345862|NCT04398719|Drug|Intradermal Capsaicin|A small dose of capsaicin will be administered by intradermal injection.
75345863|NCT04373317|Drug|Pimavanserin|Fixed-dose Pimavanserin - Pimavanserin is a new antipsychotic agent, and pure 5HT-2A inverse agonist, that was approved by the FDA recently (2016) for the treatment of PDP. It is the only FDA-approved medication for PDP, but is still not the first-line AP used in PD. All participants assigned to pimavanserin will receive the FDA-approved dose of 34 mg (equivalent to 40 mg pimavanserin tartrate) daily without titration up or down; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability (i.e., overall adverse event profile) and efficacy (i.e., improvement in severity of psychosis).
75804208|NCT03639480|Drug|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
76091975|NCT06112405|Other|Written CCAAP|Written CCAAP, conventional management for patients with asthma, remind them take controller and reliever when asthma symptoms get worse.
75804209|NCT03639480|Drug|Amlodipine 10mg+Valsartan 160mg|Amlodipine 10mg+Valsartan 160mg
75804210|NCT03639480|Drug|Valsartan 160mg+Atorvastatin 40mg|Valsartan 160mg+Atorvastatin 40mg
75354706|NCT04720768|Drug|Binimetinib|MEK inhibitor
75354707|NCT04720768|Drug|Encorafenib|BRAF inhibitor
75354708|NCT04720768|Drug|Palbociclib|CDK4/6 inhibitor
75657265|NCT02795286|Device|Artis Haemodialysis Machine w/o ASIST Software|
75657266|NCT00866671|Drug|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
75657267|NCT04030611|Diagnostic Test|tongue diagnosis system|This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
75657268|NCT02794818|Behavioral|Produce boxes with nutritional education|"CSA produce boxes prescribed to study participants with free online nutritional education included"
75657269|NCT00866827|Other|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
75354709|NCT04718675|Drug|KB-0742|Oral capsules
75354710|NCT04717414|Drug|ACE-536|Subcutaneous Injection
75345864|NCT04373317|Drug|Quetiapine|"Flexible-dose Quetiapine - Quetiapine, which is a mixed serotonin and dopamine receptor antagonist, is by far the most commonly used AP for PDP. However, scientific evidence for the efficacy of quetiapine in PDP is almost non-existent as most of the studies were underpowered, had high drop-out rates, and possibly underdosed quetiapine. Quetiapine immediate and extended release will be titrated as shown:~Baseline visit Quetiapine: 25 mg IR QHS, All participants must be up-titrated to 50 mg/day Pimavanserin: 34 mg QHS~Week 1 call Quetiapine: 50 mg XR QHS, Up-titration to 50 mg Pimavanserin: 34 mg QHS~Week 3 visit Quetiapine: 100 mg XR QHS, Up-titration as appropriate Pimavanserin: 34 mg QHS~Week 5 visit Quetiapine: 150 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS~Week 6 call Quetiapine: 200 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS"
75804211|NCT03583554|Drug|Placebo|Single dose of 4 placebo oral capsules
76091976|NCT06112366|Procedure|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.
75944355|NCT03433053|Behavioral|Control|Condition 2 (generic message) participants will be exposed to a simple HIV educational message only, consisting of HIV statistics for women in the United States, information on how HIV is transmitted, where to get tested, and the benefits of HIV testing. The statistics on HIV and where to get tested will be taken directly from the CDC's website. The message will be brief (will take less than 3 minutes to present/read).
76091977|NCT06112366|Procedure|Surgery of impacted mandibular wisdom teeth (the other side)|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
76091978|NCT06112353|Drug|Neostigmine Injectable Solution|Examine GI-2 recovery
76091979|NCT06112353|Drug|Sugammadex injection|Examine GI-2 recovery
75354711|NCT04717414|Other|Placebo|Subcutaneous Injection
75657270|NCT02796378|Drug|Training+Simvastatin+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
75804212|NCT03583554|Drug|AV-101 720 mg|Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules
75804213|NCT03583554|Drug|AV-101 1440 mg|Single dose of 4 360 mg AV-101 oral capsules
75804214|NCT03690076|Other|Endocarditis|Comparison : Endocarditis vs. control
75804215|NCT03690076|Other|Obese vs. control|Comparisons : Obese vs. control
75804216|NCT03682510|Procedure|stepwise devascularization|stepwise devascularization begins with suture the placenta bed through uterine artery ligation, internal iliac artery ligation etc
75944356|NCT04451031|Behavioral|LiFT Program|
75944357|NCT03432975|Drug|Povidone-Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)
75944358|NCT03432975|Drug|Saline Solution|The other side of the mouth will be irrigated with a sterile saline solution (control group)
75944359|NCT04906629|Biological|INO-4201|One dose of 1 mg of INO-4201 in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
75944360|NCT04906629|Biological|Placebo|One dose of normal saline in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
75944361|NCT03444207|Behavioral|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
75944362|NCT03444207|Behavioral|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
75657271|NCT02796378|Drug|Training+Simvastatin-placebo+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
75657272|NCT02796378|Drug|Training+Simvastatin+Q10|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
75657273|NCT00864409|Drug|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
75966048|NCT02089529|Drug|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
75966049|NCT02089529|Drug|Placebo|Placebo with no information, positive information and neutral information
76091980|NCT06112340|Drug|linsitinib|Study medication taken twice daily by mouth
76091981|NCT06112314|Biological|IMC-F106C|Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.
76091982|NCT06112314|Biological|Nivolumab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
76091983|NCT06112314|Biological|Nivolumab + Relatlimab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
75657274|NCT00864409|Drug|saline.9%|Wound infiltration with 170 mL sterile saline
75657275|NCT00864487|Drug|Neratinib|HKI-272
75672385|NCT02648568|Behavioral|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
75672386|NCT04965272|Drug|Cariprazine 0.75 mg/day|Oral Capsule
76091984|NCT06112301|Diagnostic Test|IdentiClone Dx IGH (IC IGH Dx) Assay|The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease
76091985|NCT06112288|Other|Compressive Myofascial Release|Compressive myofascial release is manual therapy technics.
76091986|NCT06112288|Other|Ankle mobilisation|ankle mobilization is manual therapy technics.
75345865|NCT04339270|Drug|Azithropycin according to symptoms|"Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score <70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~If the patient has a sputum symptoms score <70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score <70.~If the patient has a sputum symptoms score> 70, management is not changed."
75345866|NCT04339270|Drug|Azithromycin according to rheology or symptoms|"Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score <70).~The rheology of mucus will be quantified every 3 months.~If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) > 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~If the patient has a sputum symptoms score <70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score <70.~If the patient has a sputum symptoms score> 70, management is not changed."
75345867|NCT04318340|Other|Tapered applicator|An applicator inserted in 2 steps that tapers at the distal vagina
75657276|NCT00866983|Drug|sildenafil (Revatio) 20 mg TID|To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
75657277|NCT04235166|Other|Current risk scores|Current risk scores for assessing the prognosis of acute upper gastrointestinal bleeding in cirrhosis were used.
75657278|NCT04235166|Other|New risk scores|New risk scores for assessing the progress of acute upper gastrointestinal bleeding in cirrhosis was used.
75657279|NCT00870805|Procedure|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
75657280|NCT00870805|Procedure|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
75657281|NCT00870805|Procedure|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
75657282|NCT00870805|Procedure|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
75657283|NCT05226013|Drug|Polyglycol lated urate oxidase for injection|Single dose escalation
75657284|NCT05226013|Drug|Placebo|Placebo
75657285|NCT00870961|Dietary Supplement|cholecalciferol|Given orally
75944363|NCT03444129|Behavioral|Healthy eating workshop and interactive health game|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
75944364|NCT03444129|Behavioral|Healthy eating workshop|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
75944365|NCT03444051|Procedure|EUS-FNB with 20-gauge Procore® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle
75944366|NCT03444051|Procedure|EUS-FNB with 22-gauge Acquire® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
75944367|NCT02488330|Drug|Onartuzumab|Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
76091987|NCT06112275|Drug|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A).
76091988|NCT06112236|Other|no intervention|no intervention
75657286|NCT00870961|Other|placebo|Given orally
75657287|NCT00811941|Drug|Placebo|as-needed use, tablets, orally, 52 weeks
76091989|NCT06112223|Drug|Gabapentin|Patients will receive oral gabapentin 600 mg 1 hour before the surgery.
75657288|NCT00811941|Drug|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
75657289|NCT04235088|Other|Somatosensory intensive intervention|The intensive somato-sensory intervention will take place during 3 weeks, 5 days per week, for 2 hours per day (30 hours of practice). During the week-ends, some somato-sensory written activities will be explained and handed to each family (6 hours of practice) Therapy sessions will be carried out in groups and each child will have his or her own therapist in charge of his or her treatment along the whole intervention. A daily check-list, design for that purpose, will be used by the therapist in order to register the gradually increased complexity of the activities and individual progression. The principal investigator will supervise all the interventions in order to assure their uniformity, adjusting the somato-sensory training protocol to the individual needs of each subject.
75657290|NCT00864565|Drug|Fentanyl 25 μg/h transdermal system, single application|A: Experimental Subjects received Corium International, Inc formulated products
76091990|NCT06112223|Drug|Tramadol|Patients will receive oral tramadol 100 mg 1 hour before the surgery.
75944368|NCT02488330|Drug|Bevacizumab|All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
76091991|NCT06112210|Other|HBOT group|The HBOT will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The HBOT group will be exposed to 100% oxygen at 2.2 ATA (atmospheres absolute). Session will last 70 minutes.
76091992|NCT06112210|Other|CON group|The placebo protocols will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The CON group will be exposed to normobaric ambient pressure (1 ATA). The session will last 70 minutes.
75944369|NCT02488330|Drug|Erlotinib|All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
76091993|NCT06112171|Procedure|Intravascular lithotripsy|Lesion preparation with Shockwave Medical Peripheral Lithotripsy System
76091994|NCT06112171|Procedure|Standard lesion preparation|Lesion preparation with Standard and/or High-Pressure Balloon Angioplasty
76091995|NCT06112145|Other|rehabilitation program|All fingers of the injured hand are fitted with a dorsal blocking orthosis. Early passive mobilization exercises in the form of passive flexion and extension and edema massage will be taught and it will be recommended to be applied every two hours during the day.
76091996|NCT06112119|Device|MSCT|Using Semi-automatic MSCT Volumetry in assessment of brain atrophy associated with septic ICU patients
76091997|NCT06112067|Device|deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat mental disorders and to evaluate the efficacy and safety of DBS system.
76091998|NCT06112041|Drug|ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin|RC48-ADC combined with hypofractionated radiotherapy, PD-L1 inhibitor sequential GM- CSF and Thymopentin
76091999|NCT06112028|Drug|Tongxinluo capsule|On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
75345868|NCT04318340|Other|Standard applicator|A 2.6 cm standard applicator is inserted and sized up to a standard 3 cm applicator if tolerable.
75345869|NCT04280224|Biological|NK Cells|twice a week of NK cells (0.1-2*10E7 cells/kg body weight)
75345870|NCT04276558|Drug|Udonitrectag|Eye drop solution in single dose unit.
75345871|NCT04276558|Other|Vehicle|Eye drop solution with no active substance in single dose unit.
75345872|NCT04223505|Diagnostic Test|Contrast enhanced ECG-gated cardiac CT (CCT)|Contrast enhanced ECG-gated cardiac CT (CCT) is a sensitive, noninvasive alternative method used to exclude of left atrial and LAA thrombus. CCT provides high spatial and good temporal resolution and its ability to detect thrombus has been evaluated. CCT, compared to TEE, for the exclusion of thrombus in the LAA had a sensitivity and specificity of 100% and 99.3%, respectively. A high sensitivity is needed to minimize risk of embolus, and if a thrombus is detected on CT, a confirmatory TEE may be performed or patients may receive anticoagulation. Some argue that the potential benefits of CT and its lower associated procedural risk, the risk:benefit ratio would still favour CT.
75345873|NCT04223505|Diagnostic Test|Transesophageal Echocardiography (TEE)|TEE is considered the reference standard to rule-out left atrial (LA) and left atrial appendage (LAA) thrombus prior to cardioversion. Several studies have examined the accuracy of TEE for detecting LAA thrombus. Compared to autopsy and intraoperative findings, TEE has a mean sensitivity of 100% and mean specificity of 99%. Although the gold standard, a TEE-guided therapy is still associated with an embolic rate of 0.8%.
75657291|NCT00864565|Drug|Duragesic 25 μg/h transdermal system single application|B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products
75657292|NCT02789904|Other|blood taking|Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
75944370|NCT04451499|Other|Smartphone app|The study specific smartphone app site will be based on current literature plus investigators experience and will include a wide knowledge on types of surgeries, dietary guidelines pre- and post-surgery, fluids type and amount, knowledge on supplementation use pre and post-surgery, general dietary knowledge, psychological information, physical activity, recommendation and tips for long-term surgery success, emphasis will be made on long-term follow-up meetings with the bariatric team and practical information on the preparation to the hospitalization process. The smartphone app site will contain video-based modules and encouraging messages. Patients will be encouraged to use the platform to ask questions and receive answers regarding any aspect of the surgery.
76092000|NCT06112028|Other|Primary therapy|Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)
76092001|NCT06112002|Other|Educational Intervention|Attend an educational session
76092002|NCT06112002|Behavioral|Health Education|Receive educational materials
76092003|NCT06112002|Other|Survey Administration|Ancillary studies
76092004|NCT06111989|Behavioral|Neuropsychological testing|The neuropsychological assessment will involve paper and pencil tests, computerized tests (such as reaction time measurements) and a driving simulator.
76092005|NCT06111989|Behavioral|On road test|The driving instructor will guide the participant on a standard route, and will evaluate the performance using standard criteria that will focus mainly on traffic safety.
75345874|NCT04217109|Diagnostic Test|Odour sampling|"Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.~Positive marking is characterized by a sitting position of the dog in front of the sample."
75345875|NCT04214535|Device|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Anterior Cage for one or two-levels
75657293|NCT00864643|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
75672387|NCT04965272|Drug|Cariprazine 1.5 mg/day|Oral Capsule
75672388|NCT04965272|Drug|Cariprazine 3.0 mg/day|Oral Capsule
76092006|NCT06111976|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
76092007|NCT06111976|Procedure|Placebo|"sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
76092008|NCT06111950|Other|Blood samples|Blood samples of 5 ml to 15 ml depending on their weight
76092009|NCT06111950|Other|Skin biopsies|Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.
76092010|NCT06111950|Other|Fetal samples|Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage
76092011|NCT06111937|Other|after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed within 2 hours|Patients received gastric ultrasound examination every 15 minutes 2 or 4 hours immediately after taking the last dose of MgSO4 solution in group A or B respectively.
76092012|NCT06111924|Other|Task oriented circuit training based telerehabilitation|Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call will be provided for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
76092013|NCT06111924|Other|Clinic based Task oriented circuit training|Clinic based Task oriented circuit training (TOCT-CR) will be provided in clinic as in person training for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
75345876|NCT04207944|Drug|Sulindac 400 MG|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
75345877|NCT04207944|Other|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
75657294|NCT00864643|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
75657295|NCT00871039|Drug|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
75657296|NCT00871039|Drug|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
75804217|NCT03682510|Procedure|B-Lynch Transverse Compression Suture group|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side. After encircling the para-uterine vasculature, the needle then perforates the posterior side of the uterus behind the vascular bundle entering the uterine cavity."
75804218|NCT03682510|Procedure|N&H sandwich technique|In the N&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade.
75944371|NCT03435159|Diagnostic Test|Doppler Ultrasonography|GE LOGIQ S8 ultrasound machine was used to measure blood flow parameters in right and left a. carotis communis, a. carotis interna and a. vertebralis. All vessels were examined in the axial plane through their traces in the B-mode with a C6-15 MHz curvilinear matrix probe. Flow patterns and directions of vessels were then examined with Colour Doppler and it was determined whether there was any stenosis. Intimal thickness of a. carotis communis was measured by spectral doppler method. Measurements were recorded by visualizing the CCA at the supraclavicular level, the ICA carotid sinus (C4 level), and the VA at the V2 segment (C3-4 level), with less angle at 60 degrees. All measurements before and after the application were made at the same level. Immediately after manipulation, blood flow parameters were recorded as numerical data by the same physician again with Doppler USG of the relevant arteries.
75966050|NCT03048890|Behavioral|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
75966051|NCT03557567|Diagnostic Test|NGS molecular screening|
76092014|NCT06111911|Diagnostic Test|HPV Diagnostic Kit (Bio Farma)|Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.
76092015|NCT06111885|Drug|Indapamide 2.5 MG|1 indapamide 2.5 mg capsule per day for 28 days
75657297|NCT04233684|Diagnostic Test|rapid urease test|"Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~Pathologic test for H. pylori by H&E stain and Giemsa stain Gold standard is a immunohistochemistry."
75657298|NCT00867061|Drug|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
75657299|NCT02794740|Drug|X0002|External Spray
76092016|NCT06111885|Drug|Hydrochlorothiazide 50Mg|1 hydrochlorothiazide 50 mg capsule per day for 28 days
75657300|NCT02794740|Drug|Placebo|External Spray
75672389|NCT04965272|Other|Placebo|Oral Capsule
75804219|NCT03729726|Behavioral|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model uses a placed-based collective impact framework to provide a comprehensive intervention model, including: academic support and college and career readiness services, evidence-based social emotional learning instruction to strengthen protective factors and promote healthy transitions to adulthood, and trauma-informed, medically accurate, and age appropriate sexual health education. Moreover, the 2.0 PREIS program model features a unique student advocacy component designed to ensure that youth and their families receive the wraparound supports necessary for their students to remain on track for school success.
75804220|NCT03689998|Device|immediate implant placement|immediate implant placement in freshly extraction socket
76092017|NCT06111885|Drug|Chlorthalidone 25mg|1 chlorthalidone 25 mg capsule per day for 28 days
76092018|NCT06111872|Drug|Ketamine|Administration described in arm/ group description
75345878|NCT04184622|Drug|Tirzepatide|Administered SC
75345879|NCT04184622|Drug|Placebo|Administered SC
75345880|NCT04139967|Radiation|Short course radiation therapy|25 Gray in 5 fractions over 5-7 days
75345881|NCT04125238|Behavioral|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
75345882|NCT04125238|Behavioral|Control Episodic Thinking|Participants will generate descriptions of vivid positive recent past events.
75657301|NCT02543827|Biological|MV140|The subjects will receive daily dose of MV140 during 3 or 6 months
75944372|NCT03435159|Procedure|Manual Chiropractic Spinal Manipulation|"Manipulation procedures were applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Manual chiropractic manipulation for C1 vertebra was applied in sitting position, using the digit / atlas pull technique. This technique is applied with the contact of practitioner's middle finger to the posterior part of transverse process of atlas, and generate a rotation force between C1 and C2 vertebrae.~The procedure was applied to C2 vertebra using the index / facet push technique in the supine position. This technique places pushing force in the direction of rotation between the C2-C3 vertebrae, placing the practitioner's index finger in contact with the posterior surface of the C2 facet joint."
75944373|NCT03435159|Device|Instrumental Chiropractic Spinal Manipulation|"Activator technique was applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Instrumental spinal manipulation was applied with Activator V chiropractic instrument. For C1 vertebra, the procedure was applied in supine position, by placing the Activator device horizontally on the participant's atlas transverse process of the affected side and applying a pushing force in the medial direction.~For C2 vertebra, the procedure was applied in prone position, by placing the Activator device in the relevant C2 pedicle-lamina junction of the participant's affected side and applying a pushing force in the anterior, superior and mild medial direction of movement of the facet joint."
75944374|NCT02521545|Drug|BIIB061|Capsule
75345883|NCT04096040|Device|μCor|μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
75345884|NCT04090671|Diagnostic Test|Multidimensional Dyspnea Profile|The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.
75804221|NCT03689998|Drug|Melatonin|topical application of melatonin
75657302|NCT02543827|Biological|Placebo|The subjects will receive daily dose of placebo during 3 or 6 months
75657303|NCT05756283|Behavioral|Multimodal Prehabilitation|"EXERCISE~Supervised exercise~High intensity interval training~Strength exercise~Home-based exercise / promotion of physical activity~Low-moderate intensity aerobic training~Inspiratory muscle training~Low-moderate intensity strength training~NUTRITION: nutrition education and optimization. Intake of 0.4g/kg of whey isolate after every supervised training.~PSYCHOSOCIAL: mindfulness, cognitive reframing and coping strategies."
75657304|NCT03834714|Device|Near Infrared Light|NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
75657305|NCT03834714|Other|Noise Stimulus|Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.
75657306|NCT03834714|Device|Sham Near Infrared Light|Sham NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
75944375|NCT02521623|Device|SurgiMend® Acellular Dermal Matrix|See arm description.
76092019|NCT06111872|Drug|Midazolam|Administration described in arm/ group description
76092020|NCT06111872|Drug|Pethidin|Administration described in arm/ group description
75804222|NCT03722160|Device|Solo TympanostomyTube Device|The Solo Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
76092021|NCT06111859|Diagnostic Test|Ultrasound based Elastography and fat quantification|Correlation of ultrasound-based elastography and fat quantification on liver biopsy
76092022|NCT06111820|Behavioral|Improving Access to Community Therapies (iACT)|The Low-intensity Acceptance and Commitment Therapy (LIACT) protocol is based on the empirically supported Acceptance and Commitment Therapy (ACT), and is designed by registered clinical psychologists with consultation from local ACT experts from the Association of Contextual and Behavioural Science (Hong Kong Chapter). The LIACT protocol is also piloted and revised by clinical psychologists to ensure its adaptability to local situations. For individual guided self-help LIACT service, an intake assessment will be conducted to assess the presenting problem of the participants at pre-treatment to ensure the suitability to receive LIACT service. Participants will be given the LIACT self-help workbook collaboratively with a Psychological Wellbeing Practitioner (PWP). Between each session, clients will read through the workbook and complete the exercises suggested in the workbook. In subsequent sessions, PWP will guide clients to overcome the difficulties in performing the LIACT exercises.
76092023|NCT06111768|Drug|Dapagliflozin|Receipt of 10mg oral dose of dapagliflozin once daily for three days
76092024|NCT06111716|Other|Mindfulness- Based Childbirth Education|Mindfulness- Based Childbirth Education Group includes; Women were given eight-week birth preparation training. In this training, in addition to information about birth, mindfulness, mindfulness attitudes and practices, mindfulness in daily life, mindfulness in pregnancy and postpartum period, mindfulness breastfeeding and meditation practices were included.
76092025|NCT06111716|Other|Information-Based Birth Education|In the Information-Based Birth Education Group, women were given 4-week (4 hours per week) birth preparation training. The education given was not based on a philosophy or method.
76092026|NCT06111703|Behavioral|Knowledge assessment|Knowledge, Attitude and Practice Survey
76092027|NCT06111690|Procedure|Blood Flow Restriction Training (BFRT)|Participants will be performing low-resistance exercise with (BFRT). Intervention will start at least seven days after initial evaluation, so it does not influence measures of real-time physical activity. We will use a log to register exercise completion and to record bilateral knee pain before, during and after each intervention session
75804223|NCT03729492|Diagnostic Test|CTEPH/CTED work-up|Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.
76092028|NCT06111638|Genetic|Single dose intravenous injection of BBM-H803|Single dose intravenous infusion of BBM-H803, an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene in liver. The dose of BBM-H803 will be calculated according to participant's weight.
76092029|NCT06111625|Drug|blinatumomab|Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion.
76092030|NCT06111599|Procedure|lumbar sympathetic blockade|Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
76092031|NCT06111560|Other|We do not have any interventions. This study is based on obseravation.|observational retrospective study without any interventions
76092032|NCT06111534|Behavioral|Holding|Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.
76092033|NCT06111521|Drug|LY3537982|Administered orally
75657307|NCT05756205|Device|Immersive Virtual Reality (IVR)|"The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation. It consists of three modules that can be chosen completely or separately.~The aspects that conform this intervention will be: information about, the most common perinatal mental health problems, exercises based on attention to breathing (mindfulness-relaxation), 6 weeks of duration, for 14 minutes a day, knowledge from involved personnel of the number of times the woman has connected and the time she has done the exercise, satisfaction questions to pregnant women after pregnancy, alerts to notify the principal investigator if there is a problem with e-health, and, finally, an email address to contact the principal investigator."
75804224|NCT03729414|Procedure|mucopexy with Doppler artery ligation|Hemorrhoids will be treated by mucopexy with Doppler guided hemorrhoids arteries ligation performed in all quadrants
75804225|NCT03729414|Procedure|mucopexy without Doppler artery ligation|Hemorrhoids will be treated by mucopexy alone performed in all quadrants
75944376|NCT02521623|Device|Strattice™ Acellular Dermal Matrix|See arm description.
76092034|NCT06111521|Drug|Digoxin|Administered orally
76092035|NCT06111521|Drug|Rosuvastatin|Administered orally
76092036|NCT06111521|Drug|Midazolam|Administered orally
76092037|NCT06111521|Drug|Midazolam|Administered IV
76092038|NCT06111482|Device|Intense pulsed light.|The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
75657308|NCT02794662|Procedure|Oxygen Environment|FiO2 delivered by servo-controlled incubator
75657309|NCT02794662|Procedure|Nasal Cannula Oxygen|FiO2 delivered by nasal cannula
75657310|NCT00864799|Drug|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
75944377|NCT02521467|Biological|Platelets Rich Fibrin in healing of palatal donor tissue|Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
75944378|NCT02521467|Other|Placebo|the other group is a control group, had no biologic in the palatal wound, only palatal stent
75966052|NCT03557489|Device|Mepilex Border Sacrum|Patients use gel pad(in usual) in addition to use Mepilex Border Sacrum foam pad during surgery.
76092039|NCT06111482|Device|Radiofrequency microneedling device|The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
76092040|NCT06111482|Device|Radiofrequency device|The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
76092041|NCT06111482|Device|Combined energy devices|The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
75804226|NCT03687112|Other|non ontervention / observational study|non intervention
75804227|NCT03725748|Other|irrigation|irrigation the edges of the cs scar before closure
75345885|NCT04080427|Drug|Placebo capsule|Placebo is administered just prior to weekly exposure sessions by the oral route and contains only dextrose in opaque capsules.
75657311|NCT04234776|Drug|Ketamine|(0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole
75657312|NCT04234776|Diagnostic Test|Cognition|Composite tools
75944379|NCT03434925|Genetic|Multi-targeted next generation sequencing|Study directed at finding molecular predictors of recurrent colorectal adenomas also taking into account the intrinsic level of heterogenity imprinted in the internal differences in molecular profiles
75657313|NCT04234776|Other|Suicide risk|MADRS (10) and HAM-D (3)
75657314|NCT04234776|Other|Depression thoughts|EPD
75657315|NCT04234776|Other|Quality of life and disability|Quality of life and disability
75804228|NCT03725670|Biological|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral LV gene therapy to deliver high level lenviral vectors which carry normal ARSA gene at 1-2×10^9 multiplicity of infection (moi)/ml per site.
75804229|NCT03948178|Drug|Levosimendan|Levosimendan 1 mg capsule for oral administration
75804230|NCT03940144|Device|the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device|Stroke volume variation (SVV)-guided fluid therapy
75804231|NCT03689764|Other|interactive video game-based exercise|Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
75944380|NCT03432663|Drug|Intravenous amiodarone(1)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached
75944381|NCT03432663|Drug|Intravenous amiodarone(2)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached
76092042|NCT06111456|Other|Questionnaire|Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
76092043|NCT06111456|Other|Interview|Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
75657316|NCT04234776|Other|Clinical and epidemiological factors|Variables and categories
75657317|NCT04234776|Device|Safety of ketamine IM|Vital signs
75804232|NCT03689764|Other|no intervention|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
75804233|NCT03689686|Device|Noninvasive Respiratory Support|"Physiological crossover prospective study comparing four study trials (20 mins) delivered in computer generated random order:~Standard Oxygen therapy with mask~HFNC flow 2l/Kg~HFNC flow 3l/Kg~Helmet CPAP"
75804234|NCT03687034|Drug|Temozolomide|Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
75944382|NCT03443895|Drug|AEF0117 oral capsule|0.6, 2 and 6mg of AEF0117
75944383|NCT03443895|Drug|Placebo oral capsule|Matching placebo capsule
75944384|NCT03434847|Other|Education|Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
75944385|NCT03432585|Behavioral|Applicant Survey|This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
75944386|NCT03432507|Other|PCR|PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria
75944387|NCT03428841|Procedure|Audiometry|
75966053|NCT04352738|Diagnostic Test|Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)|Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon
75345886|NCT04080427|Drug|Dronabinol 7.5 milligram oral capsule|Dronabinol (7.5mg) is administered just prior to weekly exposure sessions by the oral route and is placed in an opaque capsule with dextrose filler.
75345887|NCT04066244|Drug|BLZ945|Investigational drug
75657318|NCT04234776|Other|Tolerability of ketamine IM|UKU-SERS, YOUNG, CADSS and BPRS-12.
75657319|NCT05756049|Other|compare antibiotic duration of therapy|To compare antibiotic duration of therapy before and after the implementation of the PCT protocol in the ICU.
75657320|NCT00871273|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
75657321|NCT00867295|Drug|cefazolin Sodium|cefazolin Sodium 1g i.v. before operation
75657322|NCT00867295|Drug|placebo|placebo
75657323|NCT04200144|Device|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)
75657324|NCT00867373|Behavioral|Education Intervention|The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
75966054|NCT03557411|Drug|SHR-1210|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
75966055|NCT02305888|Drug|LEO 43204|Treatment of actinic keratosis
75345888|NCT04057794|Device|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
75345889|NCT04057794|Device|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by centralized genetic counseling group at Indiana University.
75966056|NCT02090933|Drug|Celecoxib|Given PO
75944388|NCT03428763|Device|Homebased disease monitoring (eHealth)|"Participants allocated to the intervention group will be trained in self-monitoring (assessment of tender of swollen joints). Further they will be instructed in using a point-of-care CRP-measuring device to measure blood concentrations of C-reactive protein at their home, and to submit the self-monitoring results on a dedicated internet platform. These procedures represent a virtual visit.~The participants are instructed to have virtual visit (self-monitoring) every month from allocation. The scheduled virtual visits include~Joint score by the patient~Patient global disease activity measured on a 0-100 mm visual analogue scale.~CRP measurement on home-based device Based on the submitted data a DAS28-CRP is calculated and recorded in the eCRF."
76092044|NCT06111417|Other|Questionnaires|"3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients :~STAI-Y (State-Trait Anxiety Inventory)~Patient's Questionnaire~Practitioner's questionnaire"
76092045|NCT06111417|Other|Communication of the results of the BRCA1/2 ultra rapid test|Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
76092046|NCT06111404|Procedure|central urinary bladder dissection|A metal catheter was then inserted in the bladder. The catheter was rotated so the tip was pointing upward, to stretch the bladder pillars. The bladder was dissected with monopolar scissors with the catheter in place. Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014). Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
76092047|NCT06111404|Procedure|Lateral urinary bladder dissection|The broad ligament is dissected down till the uterine bundle is identified. Once the uterine vascular bundle is identified the space can be dissected just above these vessels to reach the lateral margins of cervix. Any fatty tissue should be moved with the bladder. Uterine vessels are then tackled by desiccation or ligation. Similar procedure is done on the opposite side. Once the bladder is completely dissected and lifted off from the cervix below, midline adhesions of the bladder and pillars can be gradually separated using sharp dissection or Ligasure staying near to cervix (Chen et al., 2007).
76092048|NCT06111404|Device|Wolf laparoscopy tower|set of instruments used for laparoscopic surgery
76092049|NCT06111391|Device|Osstell® device (Integration Diagnostics Ltd.).|After trans-mucosal abutments were removed and the smart pegs were attached to the fixtures, resonance frequency analysis was done to assess implant stability.The implant stability quotient (ISQ) was used to quantify stability via the Osstell® device (Integration Diagnostics Ltd.).
76092050|NCT06111378|Dietary Supplement|fish oil|fish oil
76092051|NCT06111378|Dietary Supplement|linseed oil|linseed oil
76092052|NCT06111378|Dietary Supplement|walnut oil|walnut oil
76092053|NCT06111365|Device|CHLOE|"the system will provide to the user a CHLOE™ score, which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5"
76092054|NCT06111352|Drug|Pralidoxime|Inj. Pralidoxime 1 gm I/V will be given as first dose over 10-20 minutes. If no improvement of muscle weakness, then repeat the dose after one hour. Then 1 gram of Inj. Pralidoxime will be given at an 8-hour interval
76092055|NCT06111352|Drug|Atropine|Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
76092056|NCT06111326|Drug|BC3402 injection|Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
76092057|NCT06111326|Drug|Durvalumab injection|Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
75657325|NCT03831516|Diagnostic Test|Non Invasive Electroanatomical Mapping|All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
75657326|NCT05227807|Behavioral|mouth opening exercise|The intervention group receives an oral exercise intervention, including a 30-minute individual training, a multimedia oral exercise education video along with a print education booklet, and three follow-up phone calls.
75657327|NCT05227807|Behavioral|Usual care|routine care including written mouth exercise instructions
75804235|NCT03687034|Device|Optune|Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
75804236|NCT03795610|Drug|IPI-549|40mg by mouth (PO) every day (QD) for at least 14 days
75804237|NCT03682354|Drug|Intercostal Nerve Block with PCIA|Intercostal nerve block consists in the injection of Ropivacaine (4 ml,0.5%) in related intercostal spaces. Patient-controlled intravenous analgesia regimen is conducted with sufentanil.
75944389|NCT03428763|Other|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
75944390|NCT04450875|Dietary Supplement|Experimental group (with diet)|Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.
75966057|NCT02090933|Other|Laboratory Biomarker Analysis|Correlative studies
76092058|NCT06111300|Drug|Dexmedetomidine|Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery. Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.
75966058|NCT02090933|Procedure|UV Light Therapy|Undergo UV-irradiation
75944391|NCT04450641|Other|GuessWhat Mobile Application|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
75944392|NCT03432273|Drug|Nicotine lozenge|Nicotine mint lozenge, 2 mg
76092059|NCT06111274|Drug|Pimicotinib (ABSK021)|The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
76092060|NCT06111261|Drug|Albumin solution|200ml of 20% Human Serum Albumin
76092061|NCT06111261|Drug|Balanced crystalloid solution|Balanced crystalloid solution
76092062|NCT06111248|Other|Training|Staff training on the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
76092063|NCT06111209|Drug|Testosterone cypionate|weekly by intramuscular injection
76092064|NCT06111209|Drug|Placebo|weekly by intramuscular injection
76092065|NCT06111183|Biological|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
76092066|NCT06111183|Other|Placebo|Placebo is topically applied on chronic wounds and covered by wound dressing.
76092067|NCT06111170|Device|Compression dressing|Application of dressing
76092068|NCT06111118|Device|ThermaCare HeatWraps|ThermaCare HeatWraps application
76092069|NCT06111053|Other|ENDS|Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
75345890|NCT04040348|Biological|Approximately 100 million cells allogeneic hMSC|Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.
75944393|NCT03432273|Drug|Nicotine lozenge|NiQuitin mint lozenge, 2 mg
75944394|NCT02481310|Drug|Cyclophosphamide|Given IV
75944395|NCT02481310|Drug|Cytarabine|Given IT or intraventricularly
75345891|NCT03933631|Drug|Pilocarpine|pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
75657328|NCT02794506|Drug|Propolis|Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
76092070|NCT06111053|Other|CI|Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
76092071|NCT06111053|Other|No ENDS|Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.
76092072|NCT06111053|Other|NI|Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
75345892|NCT03933631|Drug|Prednisolone|Prednisolone acetate ophthalmic suspension 1%
75657329|NCT02794506|Drug|Placebo|Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
75657330|NCT04040491|Drug|PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
75804238|NCT03682354|Drug|Erector Spinae Plane Block (ESPB)|Erector Spinae Plane Block consists in the injection of Ropivacaine (20ml, 0.5%), in the anatomical plane between the Erector Spinae muscles and transverse process, laterally to the spinous process of T5 . The catheter was inserted and secured in place under ecographic guidance, and a patient-controlled regional anesthesia regimen was conducted with 0.2% ropivacaine.
75804239|NCT03686956|Other|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
75804240|NCT03520920|Drug|Zanubrutinib|Administered zanubrutinib 160 mg orally (PO) BID continuously
75804241|NCT03520920|Drug|Rituximab|Administered rituximab 375 mg/m^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.
75804242|NCT03686878|Drug|Lifitegrast|Lifitegrast used twice a day
75944396|NCT02481310|Drug|Doxorubicin Hydrochloride|Given IV
75944397|NCT02481310|Drug|Etoposide|Given IV
75944398|NCT02481310|Drug|Ixazomib Citrate|Given PO
75944399|NCT02481310|Other|Laboratory Biomarker Analysis|Correlative studies
75944400|NCT02481310|Drug|Methotrexate|Given IT or intraventricularly
75944401|NCT02481310|Drug|Prednisone|Given PO
75345893|NCT03933631|Drug|Ofloxacin|Ofloxacin Drops
75345894|NCT03926923|Other|no intervention|There will be no intervention. The blood sample is taken while a routine blood sampling.
75345895|NCT03919435|Drug|Trimethoprim Sulfamethoxazole|Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks
75345896|NCT03911414|Drug|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
75345897|NCT03911414|Drug|Open-label Treatment with N-acetylcysteine|Open-label Treatment with N-acetylcysteine
75345898|NCT03902184|Biological|IPH4102|Patients will receive a flat dose of 750mg
75345899|NCT03900754|Drug|Oxytocin|Intranasal administration of oxytocin
75345900|NCT03900754|Drug|Placebo|Placebo
75345901|NCT03897075|Drug|Tildrakizumab|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
75944402|NCT02481310|Biological|Rituximab|Given IV
75944403|NCT02481310|Drug|Therapeutic Hydrocortisone|Given IT or intraventricularly
75944404|NCT02481310|Drug|Vincristine Sulfate|Given IV
76092073|NCT06111027|Device|Vibro-tactile stimulation|Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.
76092074|NCT06111001|Other|Email use data collection|Participants will initiate the AirEmail v1 Digital Tool. Non-identifiable email use data will be collected.
76092075|NCT06111001|Other|AirEmail Tips and Tricks training|"Participants will watch the AirEmail Tips and Tricks training videos ahead of using the AirEmail v1 Digital Tool"
76092076|NCT06111001|Other|AirEmail v1 Digital Tool use|Participants will use the AirEmail v1 Digital Tool features as part of their routine email management in NHSmail, the NHS's Microsoft 365 Outlook platform.
76092077|NCT06110988|Device|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
76092078|NCT06110949|Device|Triaxial accelerometry|A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction, in order to collect raw data regarding patient mobility (duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity) during the admission (from the admission day to discharge).
76092079|NCT06110936|Device|Transcutaneous Spinal Direct Current Stimulation|Transcutaneous spinal direct current stimulation (ts-DCS), a neuromodulation technique, is one of the non-invasive brain stimulation techniques. ts-DCS occurs when a continuous and low-intensity electric current passes through electrodes with moist sponges placed on the spinal cord.
76092080|NCT06110923|Drug|CKD-846|once administration of Investigational Product
76092081|NCT06110923|Drug|D091|once administration of Investigational Product per day
76092082|NCT06110910|Drug|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
76092083|NCT06110884|Behavioral|music therapy, speech therapy|receive group music therapy in addition to traditional language therapy
76092084|NCT06110884|Behavioral|speech therapy|receive only traditional language therapy
75345902|NCT03897075|Drug|Placebo|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
75657331|NCT02794584|Drug|sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
75657332|NCT02794584|Procedure|Hybrid closure|Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
75657333|NCT02794584|Procedure|Control|Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
75657334|NCT05227651|Drug|AK104|IV infusion,Specified dose on specified days
75944405|NCT04450485|Procedure|Total knee arthroplasty|Total knee arthroplasty
75944406|NCT03432195|Drug|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
75944407|NCT04450251|Other|Data Collection|Collect observational fetal electrocardiogram (ECG) readings with a novel wearable device.
76092085|NCT06110871|Other|inhaled lavender|They will be asked to inhale deeply 10 times. Then, a total of 30 minutes in the waiting room where aromastone is located and in the IA application room.
76092086|NCT06110871|Other|Working Group 2: Focusing|During IUD application
76092087|NCT06110871|Other|Working Group 3 music|for a total of 30 minutes
76092088|NCT06110845|Device|QPlasia OncoReader Breast (QPORB)|Automated diagnostic algorithm
75345903|NCT03861091|Drug|risedronate|Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
75345904|NCT03861091|Drug|Matching placebo|Dose not applicable, given once 7-21 days prior to initiation of SBRT
75345905|NCT03854916|Other|Caminemos Juntas App|A tailored mobile app that encourages Latinas and Hispanic women to walk together using location-based services.
75345906|NCT03854916|Other|World Walking App|A mobile app that encourages users to walk.
75345907|NCT03843021|Other|VAD Infection Prevention Survey|Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
75345908|NCT03798847|Device|Journey II XR TKA|Journey II XR Total Knee System
75345909|NCT03792243|Procedure|Complication|Readmission, reoperation
75657335|NCT02794272|Device|tDCS|
75657336|NCT02794272|Device|sham-tDCS|
75657337|NCT00864877|Device|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
75657338|NCT00811473|Drug|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
75657339|NCT00811473|Drug|Placebo|Oral treatment once daily in the evening
75944408|NCT03432117|Other|Fixed respiratory rehabilitation|There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
75944409|NCT03432117|Other|Responsive respiratory rehabilitation|The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
75966059|NCT04349774|Drug|Control Group - ESP block with SAP block|None - Control Group
75354712|NCT04698499|Other|Swallowing exercise from home|Treatment Arm A will consist of using pen and paper to complete the exercises. This is considered standard care. Treatment Arm B will consist of using Mobili-T to complete the exercises.
75354713|NCT04692818|Diagnostic Test|GE Logiq E10 clinical ultrasound scanner|2D B-mode, Doppler, and shear wave elastography images of the lesion
76092089|NCT06110832|Behavioral|Mindfulness-based Meditation and Yoga program|In the mindfulness-based meditation and yoga program, mindfulness-based formal and informal interventions are conducted for 8 weeks.
76092090|NCT06110819|Other|control|Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.
76092091|NCT06110819|Other|Workgroup|"Experimental:~.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health."
76092092|NCT06110806|Behavioral|MBIE|MBIE administered over 20 sessions, targets increasing psychological flexibility and acceptance by decreasing avoidance and attempts to control distressing or undesired internal experiences, and includes psychoeducation, targeted mindfulness practice, in vivo exposures, and counter-conditioning.
75657340|NCT02788500|Other|Incidence of sports-related injuries and illnesses|The SRIIP-study is an epidemiological cohort study aimed to prospectively collect self-report data on sports-related injuries and illnesses incidence and risk exposure during training and competition for approximately one year among Swedish para-athletes.
75657341|NCT00864955|Radiation|UVA and UVB irradiation|"4 cutaneous biopsies for Ex-vivo irradiation~Determination of the minimal erythemic dose of UVA and UVB for each volunteer"
76092093|NCT06110767|Device|non-immersive virtual reality|Non-Immersive Virtual Reality Based Physical Activity Application: Application will be carried out 3 days a week, 30 minutes a day, for 4 weeks. Kinect Adventures and Kinect Sports game packages will be used using the Microsoft Kinect Xbox 360 game console. It is planned that the participants will engage in physical activity with these game packages.
76092094|NCT06110767|Behavioral|Healty Diet Programme|Healthy nutrition program: It will be implemented for 4 weeks.Healthy Nutrition Program: Türkiye Ministry of Health nutrition program will be prepared based on the recommendations of the Turkey Nutrition Guide published by the Ministry of Health in 2016 (TÜBER-2016). A personalized healthy nutrition program will be created in line with this guide, taking into account the age, gender and physical activity status of healthy individuals.
76092095|NCT06110741|Other|Blood and saliva sampling|Collecting blood and saliva sample
75657342|NCT02789748|Device|Kinesthetic stimulation|Activation of mechanoreceptors by vibration bursts
75657343|NCT00871507|Drug|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
76092096|NCT06110741|Other|Survey|Collecting data on infectious diseases during the study period
76092097|NCT06110702|Behavioral|EMDR|Eye movement Desensitization and Reprocessing (as decribed in the 8-phases protocol), administered both online or in presence.
76092098|NCT06110676|Biological|LZM012|Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
76092099|NCT06110676|Biological|Secukinumab|Cosentyx
75657344|NCT00871507|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
75944410|NCT03432039|Behavioral|Psychoeducation|This intervention has three phases occurring the same time as the Psychoeducation intervention. Phase I provides verbal and written information about the paediatric acute care unit services and policies. Phase II consists of: (a) verbal and written information about the general paediatric unit and its policies, and (b) a parent-child activity having ''control'' activities like reading a story not related to hospital stay. Phase III of the control program consists of a telephone call 2-3 days after discharge during which time mothers were informed that they should contact their primary healthcare providers if their children were having any problems or unusual symptoms. They also were asked to comment on their children's hospital stays during this telephone call.
75966060|NCT04349774|Drug|Treatment Group - ESP block with SAP normal saline|Substitution of normal saline in place of 0.375% Bupivacaine in SAP block
76092100|NCT06110663|Drug|HS-10241+ Almonertinib|HS-10241 300mg twice daily (BID) combined with Almonertinib 110mg once daily (QD) orally, for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
76092101|NCT06110663|Drug|Pemetrexed + Cisplatin /Carboplatin|"The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed for 4~6 cycles (every 3 weeks).~Participants will continue receive pemetrexed monotherapy until disease progression or other criteria for treatment discontinuation will be met."
76092102|NCT06110442|Device|IbexBH Software|A software application applied to radiographs
76092103|NCT06110377|Procedure|MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)|After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.
76092104|NCT06110377|Procedure|MMP (INJECTIONS WITH A TATTOO MACHINE)|After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.
75354714|NCT04692818|Diagnostic Test|Verasonics research scanner|3D B-mode imaging, microvessel imaging, and shear wave elastography
75657345|NCT00871507|Drug|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
75657346|NCT00871507|Drug|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
75804243|NCT03682198|Device|NIRS measurements on skin, skull and dura|During a neurosurgical procedure, we will measure the brain oxygenation with a NIRS-electrode, first on forehead skin, then on the skull and finally directly on dura.
75804244|NCT03682198|Drug|Phenylephrine's effect on brain oxygenation|With a Clark-electrode (Licox(R)) in the white matter and a NIRS-electrode on the forehead skin, we will give a small dose (0.1 mg iv.) Phenylephrine.
75804245|NCT03682198|Drug|Normal vs. high inspired oxygen|By the end of the neurosurgical procedure, still with a Clark-electrode in the white matter and a NIRS-electrode on forehead skin, we will change the inspired oxygen fraction from 0.3 to 0.8.
75804246|NCT03686800|Device|Rivelin® plain patches|The comfort and adherence of Rivelin® plain patches in Vulva Lichen Sclerosus patients
75804247|NCT02953340|Drug|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
75804248|NCT02953340|Drug|Pegfilgrastim|Subcutaneous injection administered on Day 2 of each cycle.
75804249|NCT02953340|Drug|Docetaxel|75mg/m^2 IV infusion administered on Day 1 of each cycle
75657347|NCT02789826|Procedure|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
75944411|NCT03432039|Behavioral|Behavioral|This is an educational-behavioural intervention that educates the parent about the children's likely emotional and behavioural problems that may result from ICU admission. Phase I will be delivered within 6 to 16 hours of admission to the hospital where caregivers are provided with information about the child's likely emotional reactions during admission in hospital. Phase II will be delivered within 2 to 16 hours of transfer to the general ward and will consist of: (a) verbal and written information to reinforce information provided in Phase I and (b) a parent-child skills building activities. Phase III of the COPE intervention program will occur 2 to 3 days after hospital discharge and will consist of a telephone call during which a 5 minute script will be read that reinforces young children's typical post-discharge emotions and behaviours and parenting behaviours which would continue to facilitate positive coping outcomes in their children.
75944412|NCT03431961|Drug|Triamcinolone Acetonide|220 mcg administered twice daily for 14 days
75944413|NCT03431961|Drug|Placebo|twice daily for 14 days
75944414|NCT02480764|Drug|Azilsartan medoxomil|Azilsartan medoxomil tablets
75944415|NCT02480764|Drug|Valsartan|Valsartan 80 mg capsules
75944416|NCT02480764|Drug|Azilsartan medoxomil Placebo|Azilsartan medoxomil placebo-matching tablets
75944417|NCT02480764|Drug|Valsartan Placebo|Valsartan placebo-matching capsules
75944418|NCT03434691|Device|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
75944419|NCT03434691|Drug|remifentanyl|Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
76092105|NCT06110325|Other|Cawthorne and Cooksey exercise program|Participants in this group will receive an exercise program based on Cawthorne and Cooksey exercises. The intervention will last for 4 weeks, taking place three times a week, with the first session conducted in person and the remaining two assisted via video from their homes.
75345910|NCT03772717|Device|Non-invasive vagus nerve stimulation (nVNS)|The nVNS study intervention will be delivered using a handheld electrical neuromuscular stimulator device (VitalStim 400). Participants will deliver nVNS twice per day for 60 minutes each time at least 5 days per week. The two electrodes for the device will be placed on the subjects left cervical (neck) region. Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters. The stimulation frequency (number of pulses) and amplitude (amount of current) will be set during the initial baseline session in the clinic at a level that prevents discomfort and does not impact cardiorespiratory parameters. The stimulator will be placed in a comfortable position, such as next to the pillow. The stimulators are battery-powered and allow configuration of the stimulation parameters to the comfort of the patient.
75345911|NCT03772717|Other|Standard of care treatment|Patients will be asked to continue their standard medication regimens which include in most cases will involve 3 weekly infusions of intravenous immunoglobulin (IVIG) (1 gm/kg) and rarely plasma exchange (PLEX).
75345912|NCT03770403|Biological|ARGX-113|Intravenous administration of ARGX-113
75345913|NCT03740100|Drug|Bimiralisib|Bimiralisib capsules
75657348|NCT02789826|Procedure|Open gastrectomy|patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
75657349|NCT02793960|Drug|topical BPM31510 3.0% Cream|Application of drug to lesions of epidermolysis bullosa
75804250|NCT02953340|Drug|Cyclophosphamide|600mg/m^2 IV infusion administered on Day 1 of each cycle
75944420|NCT03434613|Drug|Rosuvastatin|Rosuvastatin 5mg 1T daily for 6 months
75944421|NCT03434613|Drug|Rosuvastatin/ezetimibe combination|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
75657350|NCT00865033|Drug|Metformin HCL Tablets, 1000 mg Sandoz|
75804251|NCT03689218|Dietary Supplement|Maamta (Nutritious Food Supplement)|Pregnant women will receive 30 sachets of Maamta during pregnancy and first six months of lactation.
75804252|NCT03689218|Dietary Supplement|Wawamum (Lipid-Based Nutrient Supplement)|Children 6-24 months will receive 30 sachets of Wawamum every month during the study.
75345914|NCT03732170|Device|TotalFill® Bioceramic sealer|The participant will be treated with TotalFill® Bioceramic sealer.
75657351|NCT00865033|Drug|Glucophage 1000 mg|
75657352|NCT04234932|Drug|Netarsudil Ophthalmic|Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
75657353|NCT00871663|Drug|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
75657354|NCT00867607|Drug|MRX-6|b.i.d treatment for 21 days
75657355|NCT00867607|Drug|Steroid|b.i.d. 21 days
75657356|NCT02794350|Device|Cochlear implant|
75672390|NCT02829515|Procedure|tonsil surgery with or without concomitant adenoidectomy|tonsillectomy, tonsillectomy with adenoidectomy, tonsillotomy, tonsillectomy with adenoidectomy
75672391|NCT02648412|Drug|ketamine|bolus 1 mg/kg
75804253|NCT03554772|Drug|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Oral Solution
75804254|NCT03554772|Drug|DFN-15 (Celecoxib Oral Solution) 125 mg|Oral Solution
75804255|NCT03554772|Drug|DFN-15 (Celecoxib Oral Solution) 250 mg|Oral Solution
75804256|NCT03554772|Drug|Placebo|Oral Solution
76092106|NCT06110325|Other|Control|Control group will receive counseling focused on fall prevention and promotion of an active, healthy lifestyle through informational leaflets.
76092107|NCT06109870|Behavioral|PRECEDE-PROCEED|delivered self-sampling (CHWSS) to increase screening participation.
75345915|NCT03732170|Device|AH plus® sealer|The participant will be treated with AH plus® sealer.
75345916|NCT03726307|Biological|DCreg: 0.5 million cells/kg+SOC|"DCreg 0.5 (±0.1) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
75345917|NCT03726307|Biological|DCreg: 1.2 million cells/kg+SOC|"DCreg 1.2 (±02) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
75345918|NCT03726307|Biological|DCreg:2.5 to 5.0 million cells/kg+SOC|"DCreg 2.5 to 5.0 million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
75345919|NCT03694756|Device|TMEM-MRI|TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
75657357|NCT00876109|Drug|GDC-0941|GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
75657358|NCT04234074|Device|Volusense paediatric monitoring device|Comparison of Volusense paediatric monitoring device to full cardiorespiratory polysomnography.
75804257|NCT03689062|Procedure|induction of labor|oxytocin intravenous drip
75804258|NCT03689062|Procedure|follow up|hospitalization and antibiotics
75804259|NCT03729336|Device|Midstream urine collection device|Non-invasive midstream urine collection device
75804260|NCT03729336|Device|Catheter for urine collection|In-and-out catheter obtains urine through the urethra.
75804261|NCT03688984|Behavioral|Cognitive Behavioural Therapy for Insomnia|Cognitive Behavioural Therapy for Insomnia (CBT-I) consists of six individual therapy sessions that last approximately one hour each. The sessions include psychoeducation about insomnia, goal setting, relaxation training, stimulus control, sleep consolidation and medication review. Additional components include cognitive therapy, sleep hygiene and mindfulness and relapse prevention.
75944422|NCT03434535|Device|Technology Intervention|A combination of existing technology and a new app developed by InHealth Measurement Corp to (1) remotely monitor a participant's activity level and weight and (2) remotely provide updates to the participants regarding their progress towards the goals established in the Prostate Cancer Foundation Health and Wellness guidelines.
75672392|NCT02648412|Procedure|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
75944423|NCT04953052|Drug|Imatinib Mesylate|An isotonic sterile solution of imatinib.
75944424|NCT04953052|Drug|Placebo|An isotonic sterile solution
75944425|NCT03428685|Drug|Dydrogesterone Oral Tablet|Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.
75944426|NCT03428685|Drug|Placebo Oral Tablet|Placebos will be prescribed from 12 - 36+6 weeks.
75944427|NCT05665647|Drug|Cohort 1: SIM0417/ritonavir and itraconazole|SIM0417/Ritonavir: Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1-Day2, Day9-Day10, BID; Day3,Day11(once only in the morning); Itraconazole：Dose: 200mg once；Day6-Day13, QD
75944428|NCT05665647|Drug|Cohort 2: SIM0417/ritonavir and rifampicin|SIM0417/Ritonavir:Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1,Day11(once only in the morning); Rifampicin：Dose: 0.6g once; Day4-Day12, QD
75944429|NCT05665647|Drug|Cohort 3: SIM0417/ritonavir and midazolam|SIM0417/Ritonavir: 750 mg SIM0417 coadministered with 100 mg ritonavir, Day3-Day6, BID; Day7(once only in the morning) Midazolam：Dose: 2mg once; Day1, Day6, QD
75944430|NCT04941196|Drug|Anplag (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
75944431|NCT04941196|Drug|Brilinta (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
75944432|NCT02487472|Other|Data collection|Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
75944433|NCT03431805|Drug|Tranexamic Acid Injectable Solution|After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.
75944434|NCT03431805|Drug|Sodium Chloride 0.9%|After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.
75345920|NCT03694756|Procedure|FNA|FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy. They will then present to radiology for ultrasound-guided core biopsy of the breast mass. FNA will be performed during this procedure. The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle. FNA will be performed by the radiologist under direct sonographic visualization of the mass. Five passes will be obtained with a 25 gauge needle. The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
75345921|NCT03665116|Dietary Supplement|L-arginine|L-arginine capsule
75657359|NCT04040803|Device|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
75657360|NCT02794194|Other|Proprioceptive training on a whole body vibration platform|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
75657361|NCT02794194|Other|Proprioceptive training with the BOSU® on the floor|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
75657362|NCT02789592|Drug|Melatonin PR|For experimental treatment of RBD
75657363|NCT02789592|Drug|Clonazepam|For experimental treatment of RBD
75657364|NCT02789592|Drug|Melatonin PR placebo|Placebo pill manufactured to mask melatonin PR 2mg tablet
75657365|NCT02789592|Drug|Clonazepam placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
75657366|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
75657367|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
75657368|NCT02794038|Device|Soberlink Cellular Device|BAC breath analyzer
75657369|NCT02794038|Device|BACtrack S80 Pro|BAC breath analyzer
75657370|NCT00876421|Drug|Placebo|Placebo / 12 weeks
75657371|NCT00876421|Drug|Tolterodine|4mg / 12 weeks
75657372|NCT00876421|Drug|ONO-8539|low dose / 12 weeks
75476831|NCT05492942|Behavioral|Best Practice Advisory (BPA) and Clinical Care Management (CCM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). The clinician will be supported by a CCM who will assist in identifying patients who need further assessment on the clinician patient panel. The CCM will conduct outreach to patients regarding alcohol use care, and will communicate with the clinician to help decide potential care plans, and then assist in implementing those plans for patients. The CCM has expertise on how to provide appropriate care to patients and can help patients navigate the complex care system. Further assistance by the CCM may include facilitating prescriptions for clinician sign-off, assuring refills, finding, selecting and coordinating specialty AUD care, and contacting patients to make appointments.
75476832|NCT05492942|Behavioral|Best Practice Advisory (BPA) and Population Health Management (PHM) and Clinical Care Management (CCM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). Additionally, a clinician will be supported by a PHM and clinical care manager CCM. The PHM can access and existing registry of patients with possible or confirmed alcohol use disorder to examine quality metrics for patients with an alcohol use disorder on the provider panel. The PHM will circulate quarterly reports to the clinicians in this group to provide summaries of data of those who have initiated or engaged in treatment for alcohol use, as well as a weekly report of higher risk patients on their panel who recently had an acute care visit for AUD and could benefit from outreach for follow-up care. The CCM will assist in identifying patients who need further assessment, and will assist in conducting outreach and implementing care to those patients regarding alcohol use care.
75657373|NCT00876421|Drug|ONO-8539|medium dose / 12 weeks
75657374|NCT00876421|Drug|ONO-8539|higher dose / 12 weeks
75657375|NCT02794116|Procedure|Conventional Sealants|It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
75657376|NCT02794116|Procedure|Resin Sealants|It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
75657377|NCT04235010|Device|Genius toothbrush|Patients brushed their teeth twice a day for 2 minutes. An integral timer was used in the genius toothbrush group.
75657378|NCT04235010|Device|Manual toothbrush|Patients brushed their teeth twice a day for 2 minutes. During brushing, patients in manual group assigned to use their brushes were provided with a digital timer.
75966061|NCT02091323|Procedure|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 ~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
75966062|NCT02338882|Device|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
75345922|NCT03581331|Diagnostic Test|orthoptic balance|"Measurement of visual acuity by far: Monocular measurement, right eye, left eye and binocular Measurement of visual acuity closely: Monocular measurement, right eye, left eye and binocular Corneal reflection method or Hirschberg: Analysis of the corneal reflection after fixation of a point of fixation of light from a distance, then from near.~Cover-Test: Study of the restitution movement following the fixation of the fixation point"
75345923|NCT03499795|Biological|VGX-3100|One milliliter (1 mL) VGX-3100 (deoxyribonucleic acid [DNA] plasmids encoding E6 and E7 proteins of HPV types 16 and 18) will be injected IM and delivered by EP using CELLECTRA™ 5PSP on Day 0, Week 4 and Week 12, and potentially Week 40.
75345924|NCT03499795|Device|CELLECTRA™ 5PSP|IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 5PSP device.
75657379|NCT00872053|Device|Anklebot|"The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes."
75657380|NCT00872053|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
75657381|NCT04233450|Other|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
75657382|NCT00872131|Drug|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
75657383|NCT04233294|Drug|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
75657384|NCT04233294|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
75804262|NCT01311206|Other|partial blood flow restriction|Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus
75804263|NCT01311206|Other|Low intensity exercise without partial blood flow restriction|Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
75804264|NCT01310322|Drug|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
75804265|NCT01310322|Drug|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
75804266|NCT01310322|Drug|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
75345925|NCT03496987|Device|Vacuum Bottle Drainage|Patients undergo drainage via vacuum bottles
75345926|NCT03456804|Drug|ESK981|Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
75345927|NCT03456700|Drug|Auranofin|Given PO
75345928|NCT03456700|Other|Laboratory Biomarker Analysis|Correlative studies
75345929|NCT03456700|Drug|Sirolimus|Given PO
75345930|NCT03401450|Drug|ACB within true AC with bupivacaine 0.5% 20cc|The adductor canal block (ACB) is more commonly being used to provide post-operative analgesia since it provides a sensory block with minimal motor block.
75804267|NCT01310322|Drug|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
75804268|NCT04050046|Device|Transcranial Direct Current Stimulation|tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.
75345931|NCT03401450|Drug|ACB proximal to true AC with bupivacaine 0.5% 20cc|Patients will receive ultra-sound guided single femoral triangle block injection with 20 mL of 0.5% bupivicaine
75657385|NCT04233294|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
75657386|NCT00872209|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt BID for 7 days.
75657387|NCT00872209|Drug|0.3% Ciprofloxacin Foam Otic Cipro|1 application, BID for 7 days
75657388|NCT02788110|Other|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
75657389|NCT02788110|Other|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
75657390|NCT00872287|Procedure|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
75657391|NCT00872287|Procedure|SILS|Single transumbilical incision laparoscopic cholecystectomy
75657392|NCT02787876|Drug|Pegteograstim|
76092108|NCT06109129|Device|EXOPULSE Mollii Suit|EXOPULSE Mollii Suit is a personal assistive medical device which is used for low energy whole body transcutaneous electrical stimulation - 20 Volt and 20 Hz. It is composed of a control unit, a jacket and pants with 58 embedded electrodes in direct contact with the skin. EXOPULSE Mollii Suit is used for activation of muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle may subsequently relax.
76092109|NCT06108427|Other|Renin measurements|Use of plasma renin measurements to guide MRA dosing, aiming for plasma renin unsuppression
75345932|NCT03356483|Drug|Psilocybin (0.25mg/kg)|Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
75345933|NCT03356483|Drug|Niacin (250mg)|A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.
75345934|NCT03347084|Device|Excitation|Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
75345935|NCT03347084|Device|Inhibition|Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
75345936|NCT03326063|Drug|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
75345937|NCT03326063|Drug|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
75657393|NCT00872365|Behavioral|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
75345938|NCT03324984|Drug|1% chloroprocaine|In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.
75345939|NCT03324984|Drug|0.75% bupivacaine|Bupivacaine is used on label
75657394|NCT00872365|Dietary Supplement|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
75804269|NCT04050046|Behavioral|Computer-based cognitive therapy (CBCT)|Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.
75804270|NCT04830020|Drug|HMW-HA|Aerolized administration b.i.d.
75804271|NCT05664672|Other|OTDN Product 1|Mint on!® 2 mg nicotine pouches
76092110|NCT06108128|Other|Executive functioning observational tasks|Interventions take place solely at the measurement level, where children will be seen in observational tasks of general executive functioning and executive functioning around eating in which various food and non-food stimuli are presented and children's responses to task instructions are recorded.
76092111|NCT06108089|Diagnostic Test|[18F]MISO-PET/CT|18F]MISO-PET/CT will be acquired in each patient as the standard of references of tumor hypoxia.
76092112|NCT06107829|Drug|Valbenazine Oral Capsule|Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
76092113|NCT06107270|Device|pressure biofeedback|uninﬂated pressure sensor will be kept below the neck suboccipital
76092114|NCT06107270|Device|therapeutic ultra sound|continuous US waves of 1 MHz frequency and 1-1.5 W/cm2 power
75345940|NCT03316924|Procedure|Foreskin resection|During the pediatric surgery consultation, the doctor will decide between Foreskin resection, orchidopexie or inguinal hernia repair.
75345941|NCT03276481|Diagnostic Test|Oral microbiota assessment|Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
75476833|NCT05492526|Device|Ki Monitor without feedback|Physical activity Monitor - No feedback
75476834|NCT05492526|Device|Ki monitor with contextualised data feedback|Physical activity monitor and feedback
75657395|NCT00872365|Other|Activities of daily living + placebo|"Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin)."
75657396|NCT04040647|Behavioral|mobilization and ambulation|6-min walk test (6-MWT)
75657397|NCT02793882|Drug|18F-Fluorocholine PET/CT|
75657398|NCT02787954|Procedure|TACE|Procedure for giving chemotherapy directly to tumor cells.
75657399|NCT02787954|Procedure|Y-90|Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.
75657400|NCT02787954|Procedure|MWA|Using heat to kill tumor cells.
75804272|NCT05664672|Other|OTDN Product 2|Mint on!® 4 mg nicotine pouches
75804273|NCT05664672|Other|OTDN Product 3|Mint on!® 8 mg nicotine pouches
75804274|NCT05664672|Other|No Tobacco|subjects completely stop all tobacco product usage for 7 days
75804275|NCT03624010|Drug|Levosimendan 2.5 mg/ml Injectable Solution|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
75804276|NCT03686722|Drug|Metformin|Metformin is used primarly in treatment of diabetes type II
75804277|NCT03686722|Drug|Daclatasvir|Daclatsvir is a direct acting antiviral drug
75657401|NCT02787954|Procedure|IRE|Using energy to disrupt tumor cell activity, thereby causing cellular death.
75804278|NCT03573804|Other|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
75944435|NCT02451670|Behavioral|Prioritized Clinical Decision Support|After entry of blood pressure data at all primary care visits, relevant electronic health record data were automatically extracted, encrypted and processed through Web-based clinical algorithms that determined if the patient met intervention eligibility criteria. In intervention clinics, the rooming staff received a best practice alert and printed patient and primary care provider versions of the clinical decision support that identified evidence-based treatment options for any uncontrolled cardiovascular risk factors and prioritized treatment recommendations based on potential cardiovascular risk reduction. Cardiovascular risk factors addressed in study participants were control of lipids, blood pressure, weight, tobacco, glucose and appropriate aspirin use. In control clinics, rooming staff did not receive a best practice alert and patients and primary care providers did not receive and were not able to access the clinical decision support.
75345942|NCT03276481|Diagnostic Test|Comprehensive chemical gustometry|Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
75345943|NCT03276481|Diagnostic Test|Measurement of salivary flow|Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
75476835|NCT05491096|Other|Proprioceptive Neuromuscular Training|Proprioceptive exercises will be divided into three components. The first component will be comprised of standing on Foam with eyes open and eyes closed and passing any object from one subject to the other for 10 minutes. The second component consists of activity that will be performed in groups of two. Throwing and catching a ball will be performed while standing on foam for additional10 minutes. The third component, throwing and catching a ball, will be performed on trampoline to further challenge the balance system. After each set of 10-minute exercise, the subjects will be given two-minute resting periods. In the end, 10 minutes will be given for cooling down in which deep breathing exercises and static back extensor stretching exercises will be performed to avoid fatigue and to bring the heart rate back to the normal resting level.
75657402|NCT02793804|Device|Oraquick (made in Thailand)|
75657403|NCT02793570|Other|observational|
75804279|NCT03681730|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
75345944|NCT03276481|Behavioral|Surveys assessing taste disturbances|Surveys will be administered and examine taste disturbances pre and post HCT.
75345945|NCT03275857|Drug|Cisplatin|Weekly IV
75657404|NCT02788032|Other|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
75657405|NCT02789436|Drug|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
75657406|NCT02789436|Other|Placebo lozenges|Twice daily, for 28 days
75657407|NCT02789280|Behavioral|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
75804280|NCT03417440|Other|Physical Activity (PA) Tracker App|This PA tracker app auto-monitors PA and provides a text-based summary of goal progress, thereby targeting self-regulation and outcome expectation.
75944436|NCT03928119|Behavioral|public education and network construction|Publication education includes multiple methods of acute myocardial infarction knowledge education. Network construction includes regional connection of ST-Segment Elevation Myocardial Infarction patients transfer for percutaneous coronary intervention treatment, as well as physicians skill improvement in primary hospital.
75345946|NCT03267810|Device|TENS|TENS: TENS 7000 - : TENS applies low-level electrical current via four pads, 2 pads affixed paraspinally, at the level of the spinal cord injury, and 2 affixed on the ventral side to areas within the dermatome corresponding to the level of injury. 15 minutes of high frequency followed by 15 minutes of low frequency will be applied at each session
75345947|NCT03267810|Other|Sham TENS|Inactive electrodes - for two 15 minute trials, neither high nor low frequency.
75345948|NCT03209583|Device|Medtronic|Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
75345949|NCT03196245|Other|There is no intervention.|There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
75345950|NCT03191578|Drug|RUTI®|Administration of RUTI®
75345951|NCT03191578|Drug|Placebo|Administration of placebo
75345952|NCT03155997|Drug|Abemaciclib|Administered orally.
75345953|NCT03155997|Drug|Standard Adjuvant Endocrine Therapy|Administered according to label instructions.
75657408|NCT02789280|Other|Wait list|will receive the behavioral activation condition after one week of completing baseline assessment.
75657409|NCT02793648|Drug|Ascorbic Acid|Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
75944437|NCT03428607|Drug|AZD6738|AZD6738 160mg QD
75944438|NCT03428607|Drug|Olaparib|Olaparib 300mg BID
75944439|NCT02521233|Drug|Candesartan + Chlorthalidone (8mg+12,5mg)|
75944440|NCT02521233|Drug|Candesartan + Chlorthalidone (8 mg + 25 mg)|
75944441|NCT02521233|Drug|losartan+hydrochlorothiazide|
75944442|NCT04942522|Biological|probiotics PS128|6×10^10 CFU/capsule
76092115|NCT06107270|Device|infra red radiation|(R 125, 250watt, Philips)
75944443|NCT04942522|Drug|placebo (Microcrystalline cellulose )|450 mg/capsule
76092116|NCT06107270|Other|post isometric relaxation|sustained contraction followed by relaxation
75944444|NCT00434837|Procedure|Initial graft tension during ACL reconstruction surgery|"The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown."
76092117|NCT06107140|Other|dual therapy|The evaluation will focus on the retention of patients living with hiv on dual antiretroviral therapy.
76092118|NCT06106672|Drug|CNP-106|CNP-106 is comprised of an antigenic AChR Peptide Pool (~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).
76092119|NCT06106672|Other|Placebo|CNP-106 Placebo
76092120|NCT06106516|Device|novel vital sign monitor|Devices that are to be introduced into the clinic but where data from clinical relevant conditions such as complications are lacking to assess the validity under clinical conditions
76092121|NCT06105645|Device|DIXI Medical Microdeep® Micro- Macro Depth electrodes|It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.
76092122|NCT06105645|Device|Standard electrodes|Standard electrodes used usually during the SEEG
76092123|NCT06105554|Drug|Belumosudil mesylate|Given by PO
76092124|NCT06105450|Diagnostic Test|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
76092125|NCT06104579|Other|Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection|Concordance between the two registers was analysed using Cohen´s Kappa.
75804281|NCT03417440|Other|On Your Feet|On Your Feet is a specialty app feature designed to be paired with a PA tracker app and reduce sedentary activity-a health risk factor largely independent of insufficient PA. This feature utilizes self-regulatory and behavior change techniques including goal-setting, progress feedback, and prompting. Accumulated sedentary activity time is displayed alongside self-selected goals; reminders to stand are sent at a user-specified frequency; and general tips and previously compiled, older adult-identified strategies to reduce sedentary activity are texted. Additionally, messages about the benefits of reducing sedentary activity and overcoming barriers are sent.
75345954|NCT02947035|Procedure|Thyroid lobectomy|Thyroid lobectomy is removal of only part of the thyroid
75345955|NCT02947035|Procedure|Total thyroidectomy with CCND|Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
75345956|NCT02818426|Drug|UCPVax|
75476836|NCT05491096|Other|Conventional Physical Therapy|Conventional treatment protocolconsists of a structured exercise protocol Each training session consisted of three parts, the first part included the main movements (warming up 10 minutes plus 5 minutes stretching exercises), the second part consisted of specific movements (exercises with theraband and physioball, 20 minutes), and the third part composed of cool down exercises (10 minutes).(22)Experimental treatment protocolwill be proprioceptive training program. PTP will be based on earlier studies, and will be carried out for eight weeks, with two 60-minute sessions per week. It will start with 10 minutes of Warm-up activities when the subjects will be advised to do light manual stretches and to step up and down on foam to get their body warmed up to have improve muscular flexibility. This will be followed by 30 minutes of proprioceptive exercises targeting lower extremities.
75804282|NCT03417440|Other|Coach Me|Coach Me is a specialty app feature designed to be paired with a PA tracker app and includes daily messages that assist older adults in discovering practical ways to integrate PA into their daily routines and overcoming PA barriers. Blending PA with productive activity facilitates PA engagement in older adults. In Coach Me, suggestions on how to intensify daily activities are tailored based on user selections from an activity inventory. This app feature helps older adults become more active in a minimally intrusive way, while allowing for engagement in productive and meaningful activities. Coach Me asks users to select obstacles to PA encountered in the previous week. Based on those selections, the app sends strategies on how to overcome those barriers, thereby targeting self-efficacy.
75944445|NCT03434145|Other|ophthalmologic exams|ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
75944446|NCT02486692|Other|AboutFace Website|AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and different treatments for PTSD.
76092126|NCT06101082|Biological|Intravenous infusion anti-HER2-CAR-T cell|Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10^6 CAR-T cells/kg, 3×10^6 CAR-T cells/kg, and 1×10^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
75944447|NCT03428529|Drug|Capecitabine Oral Product|Neoadjuvant Capecitabine concomitant to external beam radiotherapy
76092127|NCT06100289|Drug|Vedolizumab IV|Vedolizumab IV injection.
76092128|NCT06100289|Drug|Vedolizumab SC|Vedolizumab SC injection.
76092129|NCT06098846|Dietary Supplement|Vitamin D phosphate|Application of a Vitamin D phosphate active patch
75345957|NCT02797561|Other|5 year Follow-up|
75345958|NCT02764762|Drug|Vedolizumab|Vedolizumab intravenous infusion.
75345959|NCT02764762|Drug|Adalimumab|Adalimumab injection for subcutaneous use.
75345960|NCT02764762|Drug|Methotrexate|Methotrexate oral tablets.
75345961|NCT02666547|Drug|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
75345962|NCT02666547|Radiation|18F-FDG PET/CT|3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body
75345963|NCT02666547|Radiation|18F-FET PET/CT|200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull
75657410|NCT02793648|Drug|Alpha tocopherol|Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
75804283|NCT03417440|Other|Proof Positive|"Proof Positive is a specialty app feature designed to be paired with a PA tracker app and capitalizes on the beneficial effects that exposure to positive aging messages and stereotypes has on health and PA. When activated, users (a) receive texts describing how old age does not equate to physical inability, (b) obtain information about the benefits of growing older, and (c) are presented with a weekly positive aging stereotype task modeled after a computerized series. This last function exposes users to blocks of positive priming words. Primers are quickly flashed to allow perception without awareness while users focus on a simple icon that represents PA. Icons are intended to provide an additional PA cue, maintain user interest, and increase the external validity."
75345964|NCT02627508|Drug|Pregnenolone|orally administered Pregnenolone capsules
75345965|NCT02627508|Drug|Placebo|orally administered placebo capsules
75345966|NCT02521363|Device|KIBUR MICRODEVICE|This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for ~24 hours.
75657411|NCT02793648|Drug|PLACEBO|Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
75657412|NCT02789358|Other|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
75804284|NCT04059874|Drug|donafenib tablets|donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
75657413|NCT02789358|Other|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
75657414|NCT02789358|Device|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
75657415|NCT02789358|Drug|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
75657416|NCT02789358|Device|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
75657417|NCT04233372|Drug|Delstrigo|"Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.~1 covered tablet for day .( will be administered 28 days maximum)"
75657418|NCT03847506|Drug|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo
75657419|NCT03847506|Drug|Candesartan cilexetil/Amlodipine besylate|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Ezetimibe/Rosuvastatin 10 mg/10 mg placebo + Candesartan cilexetil 8 mg placebo
75657420|NCT03847506|Drug|Candesartan cilexetil|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg placebo
75657421|NCT02689908|Radiation|computed tomography|low dose protocol of thorax ct
75657422|NCT05361954|Drug|STI-1386|Second generation oncolytic virus
75657423|NCT04232904|Procedure|Transversus abdominous plane block (TAP Block)|TAP block which is a peripheral nerve block preferred to postoperative pain management.
75657424|NCT02788266|Procedure|connective tissue graft+composite resin|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin
76092130|NCT06098846|Dietary Supplement|Placebo transdermal patch|Application of a placebo transdermal patch
75657425|NCT02788266|Procedure|connective tissue graft+ glass ionomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement
75804285|NCT03722004|Biological|mOPV1|Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.
75804286|NCT03722004|Biological|bOPV|Bivalent oral poliovirus vaccine is a live, attenuated oral poliovirus vaccine that protects against poliovirus types 1 and 3.
75657426|NCT02788266|Procedure|connective tissue graft+giomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
75657427|NCT04234620|Drug|Toripalimab injection|240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
75657428|NCT03618420|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
75657429|NCT03618420|Drug|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
75944448|NCT03428529|Drug|5Fluorouracil|Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
75944449|NCT03433989|Diagnostic Test|telephone interview|questionnaire PDEQ et IES-R
75944450|NCT00427193|Behavioral|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
75944451|NCT00427193|Behavioral|Control|Participants continue their current diet for 24 months
75944452|NCT03428451|Drug|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
75345967|NCT02521363|Drug|anthracycline and taxane based chemotherapy|Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
75345968|NCT02407509|Drug|VS-6766|
75345969|NCT02407509|Drug|Everolimus|
75476837|NCT05490680|Drug|Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg|Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose
75476838|NCT05490680|Drug|Placebo|Placebo Oral Film
75657430|NCT04234308|Drug|Polyglycolic Acid|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
75657431|NCT04234308|Drug|Catgut|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
75657432|NCT04234308|Drug|Polytetrafluoroethylene|Periodontal and periimplant flaps closed with at least one suture with expanded Polytetrafluoroethylene Non absorbable suture, synthetic, 4-0. (TAGUM®)
75657433|NCT04234308|Drug|Polyamide|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
75944453|NCT03428451|Drug|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
75944454|NCT03428451|Drug|NaCl 0.9% NS|Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
75944455|NCT03128541|Diagnostic Test|Ultrasound spine|A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
75944456|NCT04450017|Diagnostic Test|The demographic, clinical, laboratory, and instrumental data|Measurement of the demographic, clinical data, laboratory data, and instrumental data
75944457|NCT03431649|Drug|Beraprost Sodium|1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
75944458|NCT03431649|Drug|Sildenafil Citrate|0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
75944459|NCT03431571|Procedure|ReLEx SMILE|the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
75944460|NCT03431415|Procedure|Anatomical Segmentectomy, Lobectomy or Bilobectomy|Lung Cancer Anatomical Resection
75944461|NCT03431415|Radiation|Stereotactic Body Radiation Therapy|SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
76092131|NCT06097481|Behavioral|Narrative Intervention for Chronic Illness-Heart Failure|The Narrative Intervention for Chronic Illness-Heart Failure includes narrative-based, strengths-based, solution-focused brief therapy, and Unitary Caring Science to improve depression (primary outcome) and anxiety (secondary outcome) for people living with heart failure.
76092132|NCT06097481|Other|Attention Control|Automated emails at similar time points to the intervention will be sent to participants in this arm. Emails will ask participants to reflect on their illness experience and offer general information about heart failure using standardized handouts from the American Heart Association and Up-To-Date.
76092133|NCT06091761|Other|Auricular acupuncture|Auricular acupuncture is conducted weekly in eight weeks using patches, each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. Five acupoints on one ear are selected, which included Shen-men (TF4), Stomach (CO4), Spleen (CO13), Endocrine (CO18), and Hunger point. The patch with the needle will remain in place for one week.
75657434|NCT00617305|Drug|Ambrisentan|Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
75657435|NCT00617305|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
75657436|NCT00617305|Drug|Sildenafil|Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
75657437|NCT00617305|Drug|Tadalafil|Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
75804287|NCT03722004|Biological|fIPV|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal injection in lieu of the full 0.5mL dose that is given intramuscularly.
75804288|NCT04629976|Drug|NCO-48 Fumarate 4 mg|2 x 2mg NCO-48 Fumarate over 28 days of therapy
75804289|NCT04629976|Drug|NCO-48 Fumarate 20 mg|2 x 10 mg NCO-48 Fumarate over 28 days of therapy
75804290|NCT04629976|Drug|Tenofovir Alafenamide 25 mg|25 mg over 28 days of therapy
75657438|NCT02793102|Other|Olfactory workshop|Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
75657439|NCT02793102|Other|Somesthesia workshop|Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
75657440|NCT02793102|Other|Auditory workshop|Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
75657441|NCT04232748|Drug|first line systemic treatment for colorectal cancer|systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.
75804291|NCT03721848|Behavioral|Healthy community clinic NCD+MH|"NCD+MH Awareness Intervention Overview:~i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 28 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, Smoking, Emotional Wellness, Stress Relief and Positive Coping.~iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
75944462|NCT03428295|Device|Dose Safety AP system|Device will be used to automatically dose insulin
75944463|NCT04450095|Drug|Ambrisentan 10 MG|be given once a day for 5 days, starting 48 hours before surgery
75944464|NCT03101475|Drug|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
75944465|NCT03101475|Drug|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
75944466|NCT03101475|Radiation|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
75944467|NCT03101475|Other|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
75657442|NCT02793024|Behavioral|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
75657443|NCT02792868|Other|24 h urines analyses|patient collects urines during 24h
75944468|NCT03431181|Behavioral|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
75944469|NCT03431181|Behavioral|Usual care|Patients in the control arm will receive usual care (as per local practices).
75944470|NCT01060007|Radiation|External beam radiation|
75944471|NCT01060007|Drug|Oxaliplatin|
75944472|NCT01060007|Drug|Leucovorin|
75944473|NCT01060007|Drug|5-FU|
75944474|NCT01060007|Drug|Capecitabine|
75944475|NCT03431103|Behavioral|Exercise|12 week home exercise program
76092134|NCT06091761|Other|Thread embedding acupuncture|Thread embedding acupuncture is performed every two weeks in eight weeks using a single Polydioxaone thread. Needles has a gauge size of 29G, a shaft length of 38mm, and a thread length of 50mm, folded in half, and are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles with a gauge size of 30G, a shaft length of 25mm, and a thread length of 30mm, folded in half, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.
76092135|NCT06091761|Other|Sham Thread embedding acupuncture|Sham Thread embedding acupuncture is performed every two weeks in eight weeks. Needles without threads has a gauge size of 29G, and a shaft length of 38mm, are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles without threads with a gauge size of 30G, and a shaft length of 25mm, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the needle being inserted into the body, it will be withdrawn immediately.
76092136|NCT06081972|Dietary Supplement|Maltodextrin|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing placebo powder with a breakfast item on a daily basis.
75657444|NCT03608202|Behavioral|POCUS protocol group|"The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h."
75657445|NCT03608202|Other|Control group|Routine protocol of the treating team is followed
75657446|NCT02792712|Drug|Ticagrelor|Ticagrelor 180 mg LD，then 90 mg BID
75657447|NCT02792712|Drug|Clopidogrel|Clopidogrel 300 mg LD，then 75 mg QD
75657448|NCT00870883|Drug|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
75657449|NCT02787720|Other|Family centered empowerment model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation
75804292|NCT03721848|Behavioral|Healthy community clinic NCD|"i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 24 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, and Smoking iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
75804293|NCT04629430|Other|Pre-biotic foods/drinks|2 servings per day
75804294|NCT03728946|Drug|Liposomal Bupivacaine|Addition of 15mL of liposomal bupivacaine to 15mL of standard nerve block anesthetic solution containing 0.5% bupivacaine and 4mg of decadron
75804295|NCT03728868|Dietary Supplement|Placebo|Dietary supplementation with placebo once a day for 8 consecutive weeks
75804296|NCT03728868|Dietary Supplement|High dose F. prausnitzii and D. piger|Dietary supplementation with high dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
75804297|NCT03728868|Dietary Supplement|Low dose F. prausnitzii and D. piger|Dietary supplementation with low dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
75944476|NCT03431025|Device|Wearable sensors and biofeedback|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
75944477|NCT04187937|Device|Stereotactic image-guided resection|Stereotactic image-guided resection with an ultrasound-based image-guidance system.
75944478|NCT02971163|Behavioral|SynDA|SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
75944479|NCT04175925|Drug|BMS-986322|Specified Dose on Specified Days
75944480|NCT04175925|Other|BMS-986322 Placebo|Specified Dose on Specified Days
75944481|NCT04175925|Drug|famotidine|Specified Dose on Specified Days
75944482|NCT04140435|Device|EUS-guided through-the-needle microbiopsy forceps (Moray)|"EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology."
75944483|NCT02971007|Drug|Oral Encochleated Amphotericin B (CAMB)|lipid-crystal nano-particle formulation amphotericin B
75944484|NCT02971007|Drug|Fluconazole|
75944485|NCT03881553|Device|NEATCAP|NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.
75944486|NCT03881553|Device|SVS mattress|SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.
75944487|NCT03651167|Other|Survey|Participants will complete a survey online
75944488|NCT04069611|Other|Probiotic|Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
75944489|NCT04069611|Other|Placebo|Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.
76092137|NCT06081972|Dietary Supplement|Chicory RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing chicory RG-I with a breakfast item on a daily basis.
76092138|NCT06081972|Dietary Supplement|Carrot RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing carrot RG-I with a breakfast item on a daily basis.
76092139|NCT06078345|Other|Carbohydrate|400 Kcal glucose (100g oGTT)
76092140|NCT06078345|Other|Fat|400 Kcal glucose rapeseed oil.
76092141|NCT06078345|Other|Protein|400 Kcal Moltein PURE (111g)
75944490|NCT04069611|Procedure|Scaling and root planing|Mechanical debridement with US and curettes of hard and soft plaque deposits
75944491|NCT02970929|Drug|SEP-363856|One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
75944492|NCT03817593|Other|Transcendental Meditation (TM)|Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
75944493|NCT00148733|Drug|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
75944494|NCT03430713|Procedure|Measure of tooth color|Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
75944495|NCT03430635|Procedure|Hepatectomy|Surgery of the liver: removal of a given part of the liver affected by hepatocellular carcinoma
75345970|NCT02340962|Drug|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
75804298|NCT03718598|Behavioral|Tendon and Nerve Gliding Exercises|Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.
75944496|NCT04053413|Other|Decision Aid|The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
75944497|NCT03428139|Procedure|pulsed radiofrequency|Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
75944498|NCT03428139|Drug|pulsed radiofrequency plus alpha lipoic acid|Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
75944499|NCT03651089|Drug|SP16|subcutaneous injection of experimental anti-inflammatory drug
75944500|NCT03651089|Drug|Placebos|subcutaneous injection of sterile saline
75944501|NCT04449939|Drug|KY1005|A human anti-OX40 ligand monoclonal antibody
76092142|NCT06069154|Device|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
75345971|NCT02340962|Drug|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
75345972|NCT02340962|Drug|Interferon Alfa-2a|"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."
75657450|NCT02787720|Other|Continuous care model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
75657451|NCT00867763|Procedure|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
75657452|NCT00867763|Procedure|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
75657453|NCT02789202|Other|Silver diamine fluoride|Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
75657454|NCT02789202|Other|Fluoride Varnish|Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
75657455|NCT00811395|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
75657456|NCT00811395|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
75345973|NCT02309645|Biological|EVICEL® Fibrin Sealant|Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
76092143|NCT06069154|Procedure|Local anesthetic peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks. The injectate through the introducer will depend on the treatment group: for participants of the control group, ropivacaine 0.5% or bupivacaine 0.375% (both with epinephrine 1:400,000) will be injected (volume determined by institutional standard-of-care). This will provide a peripheral nerve block for the control group.
76092144|NCT06069154|Device|Sham Cryoneurolysis|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). However, for the sham comparator, the gas will NOT be deployed to the tip, there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
75944502|NCT03651635|Diagnostic Test|Blood sampling for MR-proADM & CT-proET-1|Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM & CT-proET-1
75944503|NCT03428061|Other|Integrated care for cardiovascular risk management|Disease management program for the prevention of cardiovascular diseases
75944504|NCT03127917|Dietary Supplement|L-citrulline|L-citrulline capsules given at 6 g/day
76092145|NCT06069154|Procedure|Sham peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks: for participants allocated to the cryoneurolysis group (experimental group), normal saline will be injected for the peripheral nerve block. This will result in a sham/placebo nerve block for the experimental group.
75804299|NCT03458702|Behavioral|YogaFit|For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.
76092146|NCT06066710|Drug|Propranolol|Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.
76092147|NCT06066710|Device|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.
76092148|NCT06066710|Drug|Placebo|Placebo will be given on the same schedule as the propranolol regime.
76092149|NCT06066450|Device|Genoss® DES system, Genoss® Osfit system|This is a drug-eluting stent used to improve the diameter of the coronary artery in patients with symptomatic ischemic heart disease, with de novo lesions in the native coronary artery, where the reference vessel diameter ranges from 2.25mm to 5.00mm.
76092150|NCT06064617|Device|Contact Lens|Coopervision Biofinity Multifocal Lens
76092151|NCT06062667|Other|accompany the birth|Fathers will accompany their husbands during the birth process
76092152|NCT06051500|Behavioral|Nostril focus followed by belly focus|Focused breathing on the nostrils followed by focus breathing on the belly.
76092153|NCT06051500|Behavioral|Belly focus followed by nostril focus|Focused breathing on the bellyfollowed by focus breathing on the nostrils.
75804300|NCT03458702|Behavioral|Quiet Rest|Participants completed 30 min of quiet rest
75804301|NCT03454412|Procedure|Intensive Neurophysiological Rehabilitation|Intensive Neurophysiological Rehabilitation System (INRS) is a combination of different treatment modalities that complement and reinforce each other. It includes spinal manipulative therapy, physical therapy, occupational therapy, joints mobilization techniques, special massage therapy, mechanotherapy, computer games therapy and other treatments with daily duration up to 4 hours.
75804302|NCT03452540|Drug|1000mg DS102 (BID)|Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
75944505|NCT03127917|Other|Placebo|Maltodextrin capsules given as placebo
76092154|NCT06039085|Device|custom device to demonstrate a significant difference in electrical impedance signatures|Custom device will be used to measure electrical impedance signatures.
76092155|NCT06031194|Other|Non-Interventional Study|Non-interventional study
76092156|NCT06029530|Drug|Atropine Ophthalmic|eye drops to be administered once daily
75804303|NCT03573336|Drug|Vilaprisan (BAY1002670)|Intake orally, once daily
75804304|NCT03573336|Drug|Matching Placebo|Intake orally, once daily
75944506|NCT03427983|Procedure|Hydrodissection|Additional 3cc's of saline is used to establish an increase in hydrodissection during routine treatment.
75944507|NCT03427983|Procedure|Regular Injection|Corticosteroid and lidocaine injection without additional saline is used as routine treatment.
75804305|NCT03500198|Device|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL|Intraocular lens replaces the natural lens removed during cataract surgery.
75804306|NCT03500198|Device|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL|Intraocular lens replaces the natural lens removed during cataract surgery.
75944508|NCT03427905|Procedure|Lipoaspiration|Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation
75944509|NCT03427905|Procedure|Transplantation|Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
75966063|NCT02338882|Device|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
76092157|NCT06024941|Radiation|Radiation|Radiation to one or more progressive lesions. Preferably 1x10Gy, but also 3x8Gy, 10x 3Gy, 5x4Gy or 1x20-24Gy is possible.
76092158|NCT06024707|Drug|Biological Drug|This intervention is part of regular treatment, subjects will be included if they get this treatment.
76092159|NCT06023212|Drug|Tranexamic Acid|"IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery；~1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery."
76092160|NCT06023212|Drug|stroke-physiological saline solution (SPSS)|IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
76092161|NCT06019364|Other|Whole blood transfusion|Transfusion of whole blood in a situation with acute bleeding according to routine practice.
76092162|NCT06018766|Drug|LAM-001|LAM-001 administered via dry powder inhaler
75345974|NCT02309645|Other|Sutures Only|Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
75345975|NCT02272634|Drug|YPL-001 80 mg|twice daily [BID]
75345976|NCT02272634|Drug|YPL-001 160 mg|twice daily [BID]
75345977|NCT02272634|Drug|Placebo|twice daily [BID]
75345978|NCT01120249|Drug|everolimus|Given orally
75345979|NCT01120249|Other|placebo|Given orally
75345980|NCT01007357|Device|Body MR imaging|Body MR imaging will be performed to optimize sequences
75657457|NCT00811395|Drug|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
75657458|NCT00811395|Drug|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
75657459|NCT00867841|Procedure|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
75804307|NCT03553758|Drug|Ketamine|Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximately 60 minutes. Patients pain and dissociation will be assessed before the induction of ketamine and periodically after. Approximately 1 hour after ketamine induction, Midazolam will be administered to reduce patient dissociation.
75804308|NCT03552198|Behavioral|Alternative health advice|These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.
75804309|NCT01310556|Other|ogtt for patients with coronary artery disease|75 g OGTT
75804310|NCT03725514|Procedure|Conventional|Conventional Blood Clot Technique
75804311|NCT03725514|Procedure|PRF|Platelet Rich Fibrin Technique
75944510|NCT03650543|Drug|amoxicillin clarithromycin omeprazole 1|Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
75944511|NCT03650543|Drug|amoxicillin clarithromycin omeprazole 2|The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
76092163|NCT06018766|Drug|Placebo|Placebo administered via dry powder inhaler
76092164|NCT06012721|Drug|ORIC-114|Food effect healthy subjects
76092165|NCT06010251|Other|tDCS and bodily illusions|"Participants will be required to perform (in person) 10 interventions over a time frame of 2-4 weeks. They can perform this everyday or for a minimum of 2-3 times per week over 4 weeks.~Two types of illusions will be used 15 min each, the rubber hand illusion and the walking illusion to target upper and lower limbs. These procedures will impact the body representation of the participants resulting in bodily illusions."
76092166|NCT05998395|Drug|Ruxolitinib|Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-24 weeks and 1 week of 5 mg BID before stopping ruxolitinib.
76092167|NCT05995886|Behavioral|Wiidookaage'win Facebook Group|An online social media group program that incorporates social support, mindfulness-based, and cultural practices that may support OUD recovery.
76092168|NCT05995171|Other|Questionnaire|Quality of life questionnaires will be used specifically for this research: Pediatric Quality of Life Invertory and EA-QoL
75345981|NCT00788125|Drug|carboplatin|
75345982|NCT00788125|Drug|dasatinib|
75345983|NCT00788125|Drug|etoposide phosphate|
75345984|NCT00788125|Drug|ifosfamide|
75345985|NCT00788125|Genetic|microarray analysis|
75345986|NCT00788125|Genetic|western blotting|
75345987|NCT00788125|Other|immunohistochemistry staining method|
75345988|NCT00788125|Other|laboratory biomarker analysis|
75657460|NCT02792946|Drug|Acebrophylline|
75657461|NCT00876499|Behavioral|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
75804312|NCT02954354|Drug|Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
75804313|NCT02954354|Drug|Placebo to Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
75804314|NCT02954354|Drug|Oseltamivir|75 mg capsules taken orally
75804315|NCT02954354|Drug|Placebo to Oseltamivir|Placebo capsules matching oseltamivir 75 mg capsules
75944512|NCT03650933|Biological|G-CHOP|6 cycles(each cycle is 3 weeks)
75345989|NCT00788125|Procedure|therapeutic conventional surgery|
75345990|NCT00788125|Radiation|radiation therapy|
75345991|NCT00606463|Device|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
75944513|NCT03650933|Biological|R-CHOP|6 cycles(each cycle is 3 weeks)
75966064|NCT03046238|Drug|Dexmedetomidine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
76092169|NCT05994651|Behavioral|Tidal Model improvement model|"st interview Pre-assessment Application of measurement tools~nd meeting Orientation Concept of recovery, change phase of the individual, Holistic Evaluation, Creation of Personal Safety Plan 3. Interview Process planning Setting goals, Starting One-on-One Sessions~4th meeting Healing is possible, accepting his illness, overcoming change, emphasizing his strengths, instilling hope 5.-6. interview Empowerment Coping with crisis, reducing anxiety, relaxation exercises, individual roles, assertiveness, strengthening self-esteem 7.-8. Interview Maintaining control of life, taking responsibility for behavior, appropriate expression of anger, feeling, thinking and Taking responsibility for recovery, discovering behaviors 9th interview Creating a supportive environment Increasing new interactions, relationships, social skills 10th meeting Evaluation Finalizing the personal security plan, using new knowledge and behaviors in the healing journey, evaluation of the process"
76092170|NCT05993728|Behavioral|Body Project|The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.
76092171|NCT05993728|Behavioral|Psychoeducational control|Participants randomized to the educational control condition will receive videos addressing body image and eating disorders
76092172|NCT05993039|Drug|Isoflurane Inhalant Product|1.5-2%
76092173|NCT05993039|Drug|Sevoflurane inhalant product|1-2% adults 0.6-1.5% Children
76092174|NCT05993039|Drug|Propofol injection|1mg/kg-mcg/kg/min adults 100-200mcg/kg/min children
76092175|NCT05993039|Drug|Remifentanil Injection|0.05-2ug/kg/min adults and children
76092176|NCT05988372|Drug|Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine|Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
76092177|NCT05988372|Drug|Albumin-paclitaxel + Gemcitabine|Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
75944514|NCT03427671|Device|Occlusin 500 Microspheres|Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.
76092178|NCT05984784|Drug|Placebo|Drug: Placebo Intravenous Infusion
76092179|NCT05984784|Drug|IMG-007|Drug: IMG-007 Intravenous Infusion
76092180|NCT05980598|Drug|TransCon TLR7/8 Agonist|TLR7/8 agonist prodrug
76092181|NCT05980598|Drug|Pembrolizumab|A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding
75804316|NCT03519516|Drug|PRO-174|"Pharmaceutical form: ophthalmic solution~Prepared by: Laboratorios Sophia, S.A. of C.V.~Description of the solution: transparent solution, free of visible particles.~Description of container: sterile multi-dose bottle"
75804317|NCT03519516|Drug|Sophixín Ofteno®|"Active substance: Ciprofloxacin 0.3%~Pharmaceutical form: Ophthalmic solution~Prepared by: Laboratorios Sophia, S.A. of C.V.~Description of the solution: transparent solution, free of visible particles.~Description of container: sterile multi-dose bottle"
75804318|NCT03688750|Other|no intervention|
75944515|NCT03650777|Other|Warfarin Telehealth Education|Patients received education on warfarin through a video on an iPad, and were assessed on knowledge pre and post video, and at follow up visit
76092182|NCT05980598|Drug|TransCon IL-2 β/γ|Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells
76092183|NCT05972564|Drug|Empagliflozin 25 MG|Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes.
76092184|NCT05972564|Drug|Placebo|Placebo consists of gelatin capsules.
75657462|NCT00872443|Other|Data collection|"Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.~Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI."
75657463|NCT05083065|Biological|Covid-19 vaccine|"First dose or complete cycle of Comirnaty (Pfizer/BioNTech) vaccine~First dose or complete cycle of Spikevax (Moderna) vaccine~First dose or complete cycle of AstraZeneca/Vaxzevria vaccine~Complete cycle of vaccination using one type of vaccine for the first dose and a different type for the second dose~Janssen (Johnson & Johnson) vaccine (single dose)"
75657464|NCT02792634|Procedure|Sleeve-Gastrectomy, Roux en Y gastric bypass|
75944516|NCT03427593|Genetic|FACS analyses|FACS analyses
75657465|NCT00876577|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
75657466|NCT02787798|Drug|valsartan/sacubitril 100 mg|Treatment with 100 mg tablets during 2 to 4 weeks
75657467|NCT02787798|Drug|valsartan/sacubitril 200 mg|Treatment with 200 mg tablets during 2 to 4 weeks
75657468|NCT02787798|Procedure|Microneurography|Microneurography recording of sympathetic nervous system activity in muscle destiny
75804319|NCT03681574|Drug|Placebo Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive placebo concentrate.
75804320|NCT03681574|Drug|GABA 15mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 15mg/kg.
75804321|NCT03681574|Drug|GABA 30mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 30mg/kg.
75944517|NCT03427593|Genetic|Target Sequencing by NGS ( Next-generation sequencing)|Target Sequencing by NGS ( Next-generation sequencing)
75944518|NCT03427593|Genetic|Whole Exome Sequencing|Whole Exome Sequencing
75944519|NCT03785769|Procedure|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by washing and drying the cavity with cotton balls; and fill with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
75966065|NCT03046238|Drug|placebo|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
75657469|NCT00867919|Behavioral|Behavioral Family Treatment|"11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~parent-adolescent conflict~adolescent development~support and closeness~behavioral activation~response to adolescent negative affect~relapse prevention~suicide prevention, if necessary"
75804322|NCT03519204|Device|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips.
75804323|NCT03519204|Other|No-treatment Control|No-treatment was administered.
75804324|NCT03681418|Procedure|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.|Ultrasound-guided axillary lymph node fine needle aspiration and\or core needle biopsy of the most suspicious lymph node. If all the lymph nodes appeared similar or normal, the lymph node that is lowest in the axilla will be selected because it is considered to most likely be the sentinel node.
75657470|NCT00867919|Other|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
75657471|NCT02792556|Device|Urine pregnancy test|Urine pregnancy test Check Top after transvaginal ultrasound
75804325|NCT03688594|Diagnostic Test|NIPT Test|This test is based onto capture and high throw put sequencing adapted to cell free plasmatic DNA of pregnant women in order to detect point mutation present in her fetus. This approach has been previously described for others clinical applications such as liquid biopsy in cancers but not for NIPT analysis.
75804326|NCT03518658|Other|Evaluation Group|Patient receiving exposure to the MyCareLink Heart App during device pairing
75804327|NCT03518658|Other|Control Group (Historical)|Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C). The patients' data will be extracted from Medtronic de-identified CareLink™ database.
75944520|NCT03785769|Procedure|HVGIC restoration with non pre-etching|Restoration with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
75657472|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
75657473|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
75944521|NCT02970305|Drug|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
75944522|NCT02970305|Drug|Placebo|Placebo, taken as two tablets, once daily by mouth
75944523|NCT03754881|Behavioral|Pulmonary rehabilitation|"In this study, we'll educate pulmonary rehabilitation to patients and make reservation for re-visiting outpatients clinics with PR diary after 8 weeks.~we want to confirm whether patients, who perform home based PR during more than 30 minutes in 3 days per week, present improved dyspnea score or quality of life compared with non-compliance group."
75944524|NCT03743571|Device|transcranial direct current stimulation|tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
75944525|NCT03743571|Behavioral|exposure therapy|participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
75944526|NCT03430557|Procedure|PRP|platelet rich plasma
75657474|NCT02609997|Drug|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
75944527|NCT03430557|Procedure|periapical surgery without PRP|retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
75345992|NCT00554437|Behavioral|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
75804328|NCT03624166|Drug|Ketamine|patients will receive sub- anesthetic dose of ketamine 0.5 mg/kg in 3 ml of isotonic saline after spinal anesthesia
75944528|NCT03698409|Drug|Preserved saline in reconstitution of Botox|The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
75345993|NCT00516373|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
75345994|NCT00890162|Drug|Epinephrine|
75657475|NCT02609997|Device|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
75657476|NCT02609997|Drug|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
75657477|NCT00876655|Drug|TR-701 di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
75657478|NCT00876655|Drug|TR-701 free acid phosphate|One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
75657479|NCT02609919|Drug|Gadoteric Acid|MRI Contrast Agent
75657480|NCT00867997|Other|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
75804329|NCT03624166|Drug|isotonic saline|patients will receive 3 ml of isotonic saline after spinal anesthesia
75804330|NCT03688516|Behavioral|Manipulation of valence and modality|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
75804331|NCT03688516|Behavioral|Spatial and recognition memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
75944529|NCT03650465|Behavioral|Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT)
75944530|NCT04449783|Other|pre-operative screening|reported symptoms plus nose and throat swabbing 48 hrs prior to surgery
75944531|NCT04449783|Other|telephone consult|telephone consult 14 days (+/- 2 days) to assess for any COVID-19 symptoms
75944532|NCT03429933|Drug|BMS-986278|Specified dose on specified days
75804332|NCT03688516|Behavioral|Source and content memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
75804333|NCT03688438|Device|Closed-Incision Negative-Pressure Therapy|A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.
75804334|NCT03518112|Biological|Blinatumomab|Given IV
75804335|NCT03518112|Drug|Cyclophosphamide|Given IV
75944533|NCT03429933|Other|Placebo|Specified dose on specified days
75944534|NCT03650621|Device|Magnetic acupuncture|5 magnetic acupuncture stickers will be placed on the infants ear
75944535|NCT03650621|Device|stickers (magnets removed)|in this group 5 stickers (magnets removed) will be placed on the infants ear
75944536|NCT05285657|Diagnostic Test|Two-step malaria RDT detecting PfHRP2/pLDH (SD Ag Bioline Malaria Ag P.f/Pan: Standard Diagnostics, Hagal-Dong, Korea)|"The interpretation of the two-step malaria RDT will be done as follow:~PfHRP2(+)/pLDH(+): falciparum malaria or co-infection with non-falciparum malaria;~PfHRP2(-)/pLDH(+): non-falciparum malaria or falciparum malaria with deletion of hrp2;~PfHRP2(-)/pLDH(-): negative results~PfHRP2(+)/pLDH(-): inconclusive results and information on previous antimalarial treatment is needed to differentiate:~Within the past 28 days:~If previous antimalarial treatment is reported, the malaria diagnosis is reported as negative result. Nonetheless, the antimalarial treatment decision will be based on malaria microscopy;~If previous antimalarial treatment is not reported, the malaria diagnosis is reported as positive result.~Other PoC tests for bacterial infections The two-step malaria RDT will be supported by PoC test listed above to diagnose bacterial or viral infection in all patients."
75657481|NCT00867997|Other|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
75804336|NCT03518112|Drug|Cytarabine|Given IT or IV
75804337|NCT03518112|Drug|Dexamethasone|PO or IV
75804338|NCT03518112|Biological|Filgrastim|Given SC
75944537|NCT03649763|Drug|Lidocaine|lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
75944538|NCT03649763|Drug|Bupivacaine|Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
75804339|NCT03518112|Other|Laboratory Biomarker Analysis|Correlative studies
75804340|NCT03518112|Drug|Leucovorin Calcium|Given IV
75944539|NCT03649763|Drug|Lidocaine|lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
75944540|NCT03650309|Device|Deep Brain Stimulation|All patients will undergo surgical implantation of a deep brain stimulation (DBS) system, which involves placement of stimulating electrodes in the brain. These electrodes will be used to deliver electrical current to target two brain structures involved in the pathophysiology of obesity.
75944541|NCT03648593|Behavioral|work recovery intervention|Recover! app: one hour weekly for two months
76092185|NCT05971368|Procedure|thoracic paravertebal block|"o Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~A high-frequency linear ultrasound probe will be placed between transverse processes from the T4 level (the level of port introduction) in the paramedian plane while patients is in the lateral decubitus position. The transverse processes, superior costotransverse ligaments, and pleura will be well visualized. The block needle (22 gauge) will be advanced until it crosses the superior costotransverse ligament. The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) in the thoracic paravertebral space. Depression of the pleura will be observed as a result of the spread of local anesthetic."
75345995|NCT00890162|Drug|Omalizumab (Xolair)|
75345996|NCT00890162|Drug|Placebos|
75804341|NCT03518112|Drug|Mercaptopurine|Given PO
75804342|NCT03518112|Drug|Methotrexate|Given IT or IV
75657482|NCT00867997|Other|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
75657483|NCT04114500|Diagnostic Test|serum estradiol and progesterone|blood sample for measuring serum estradiol and progesterone level on the same day of FET
75657484|NCT05755659|Drug|Fosaprepitant Dimeglumine for Injection|The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
75944542|NCT03648593|Behavioral|waiting list control|no treatment during 6 months,then Recover! app
75944543|NCT03649607|Other|Accelerated Resolution Therapy|ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
75944544|NCT04449627|Other|Feeling Good Digital App|Audio based tracks using Jacobson relaxation and mindfullness based cognitive therapy (MBCT) techniques including positive visualisation.
75944545|NCT03649529|Biological|GPA-TriMAR-T|Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
75944546|NCT03427515|Dietary Supplement|Lactobacillus rhamnosus GG (ATCC 53103)|30 days of supplementation, 6x10^9 CFU/day
75944547|NCT03427515|Dietary Supplement|Saccharomyces boulardii (CNCM I-1079)|30 days of supplementation, 5x10^9 CFU/day
75804343|NCT03518112|Biological|Pegfilgrastim|Given SC
75804344|NCT03518112|Biological|Rituximab|Given IV
75804345|NCT03518112|Drug|Vincristine Sulfate|Given IV
75345997|NCT02504424|Device|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
75657485|NCT02788968|Other|MRI|"Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI"
75804346|NCT03686254|Combination Product|RFA, bevacizumab and second-line chemotherapy|Navigated by CT-ultrasound merged images, RFA is taken in the experimental arm at the first day of the first cycle during the second-line therapy. Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI [Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 [Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
75804347|NCT03686254|Drug|Bevacizumab and second-line chemotherapy|Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI [Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 [Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
75804348|NCT03681340|Other|Hydroxyapatite toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
75804349|NCT03681340|Other|Fluoridated toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
75804350|NCT03686098|Dietary Supplement|Dietary soy|Soy isoflavones delivered through diet, assisted by a detailed food guide for locally available soy-based foods.
75804351|NCT03686098|Dietary Supplement|Soy Supplement|Soy isoflavones delivered in extracted form
75944548|NCT03427515|Dietary Supplement|Placebo|30 days of supplementation
75944549|NCT03427437|Drug|Bupivacaine|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
75944550|NCT03427437|Drug|Adrenalin|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
75944551|NCT03427437|Device|Ultrasound|caudal block was performed by ultrasound method
75944552|NCT03649373|Procedure|Noergaard technique|The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
75944553|NCT03648515|Diagnostic Test|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
75657486|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
75345998|NCT01433081|Drug|Placebo infusion of .9 normal saline|administration of .9 normal saline
75345999|NCT01433081|Drug|administration of magnesium sulfate|administration of magnesium sulfate
75346000|NCT00890396|Drug|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
75346001|NCT01434641|Other|low-dose stress MPI SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
75657487|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
75657488|NCT00913887|Drug|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
75657489|NCT00872677|Behavioral|Diet|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
75657490|NCT00872677|Other|Spiritual counseling|Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
75657491|NCT02789124|Other|Carotid Doppler Measurement in response to passive leg raise|The investigators will measure Carotid Flow time in the semi-recumbent position, then lay the patient flat and do a passive leg raise. The investigators will then meausre Carotid Flow Time at 1 minute, 2 minutes, and 3 minutes. Patients who have 10 % increase in stroke volume on the Flotrac / Vigileo monitor will be considered fluid responders. The investigators will try to identify an optimum % increase of Carotid Flow Time that can predict fluid responsiveness.
75657492|NCT05181865|Drug|1 mg/kg IV FL-301|N = 1
75657493|NCT05181865|Drug|3 mg/kg IV FL-301|N = 3-6
75657494|NCT05181865|Drug|10 mg/kg IV FL-301|N = 3-6
75657495|NCT05181865|Drug|20 mg/kg IV FL-301|N = 3-6
75657496|NCT05181865|Drug|30 mg/kg IV FL-301|N = 3-6
75657497|NCT05181865|Drug|RP2D, IV FL-301|Pancreatic Cancer N = 30
75657498|NCT05181865|Drug|RP2D, IV FL-301|Gastric Cancer (Including GEJ) N = 30
75657499|NCT05181865|Drug|RP2D, IV FL-301|Other Solid Tumors N = 30
76092186|NCT05971368|Procedure|serratus anterior muscle block|"Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~While the patient is in the supine position, a high-frequency linear ultrasound probe will be placed horizontally on the mid-axillary line at the level of 4th or 5th ribs on the side of the block. The serratus anterior, latissimus dorsi, and intercostal muscles will be identified. The block needle (22-gauge) will be advanced below the serratus anterior muscle (SAM) towards the fifth rib (using in-plane technique). The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) between the SAM and the rib. It will be observed that the solution of local anesthesia will spread between the SAM and the rib."
75346002|NCT01400477|Drug|DMXB-A-SR|Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
75346003|NCT01400477|Other|Placebo|Placebo Comparator
75346004|NCT01401023|Drug|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
75476839|NCT05489354|Other|mHealth psychoeducational intervention|The mPEI program will be delivered through a mobile application (app). The app has five components which include: Breast cancer education, coping skills training, discussion forum, nurse-led consultation, and psychological support. Breast cancer education and coping skills training will be conducted by the principal investigator for 30 minutes per week for six weeks and will be delivered via text, audio and video on the mobile app. Group discussion will be moderated by the principal investigator in a text format for 30 minutes per week. Nurse-led consultation and psychological support will be provided by the oncology nurse on the research team through a 15-20-minute call in the first week, third week and fifth week.
75804352|NCT03718442|Device|PhotonBlade vs Bovie for lumpectomy shaved surgical margins|For each enrolled patient, six shaved margins will be obtained (superior, inferior, medial, lateral, anterior, and posterior). For each patient, electrocautery will be used to obtain 3 of the shaved margins, and PhotonBlade to obtain the other 3 shaved margins. Once the lumpectomy site shaved margins have been obtained, the shaved surgical margins will be evaluated by a pathologist whom is blinded in regards to the dissection device that was used for each margin. The pathologist will be evaluating each shaved margin and reporting the outcomes (qualitative severity and depth of thermal artifact)
75804353|NCT03681106|Device|Kinesio Tex|Kinesio Tex tape on the operated limb
75346005|NCT01401101|Other|PCM|Care Manager (CM) intervention
75944554|NCT03648515|Diagnostic Test|Digital Images of the dental arches|The dental arches will be captured using a dedicated camera in order to be used for measuring the outcomes.
75346006|NCT01401101|Other|MEU|The MEU condition consists of only the clinician education and patient screening without written feedback.
75944555|NCT03648515|Diagnostic Test|Digital images of models|The poured dental models will be captured using a dedicated camera in order to be used for measuring the outcomes.
75944556|NCT03427359|Drug|cisplatin, capecitabine|Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
75944557|NCT05053659|Drug|Loncastuximab tesirine|Loncastuximab tesirine 50 - 150 μg/kg will be administered as a 30 minutes IV infusion on Day 1 of each cycle for 6 cycles. On doses over 100 μg/kg, subsequent dosing (i.e. beyond 100 μg/kg) will be done at 50% of the dose that is administered on the first 2 cycles.
75346007|NCT01515995|Drug|Nebulized magnesium sulfate|"15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour"
75346008|NCT01436045|Drug|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
75476840|NCT05488366|Drug|Pembrolizumab|Given IV
75346009|NCT01436045|Drug|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
75346010|NCT01519271|Drug|Exelon Patch (rivastigmine transdermal system)|"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
75476841|NCT05488366|Radiation|Radiation therapy|Single target will be selected by the treating radiation oncologist. A lesion causing symptoms or expected to become symptomatic will be favored for target selection.
75657500|NCT02788890|Procedure|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
75346011|NCT01519271|Drug|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
75346012|NCT01401257|Drug|PXT3003 Low dose|Liquid,5 ml, twice a day, 12-month treatment
75346013|NCT01401257|Drug|PXT3003 Intermediate Dose|Liquid,5 ml, twice a day, 12-month treatment
75346014|NCT01401257|Drug|PXT3003 High Dose|Liquid,5 ml, twice a day, 12-month treatment
75346015|NCT01401257|Other|Placebo|Liquid,5 ml, twice a day, 12-month treatment
75346016|NCT01402115|Dietary Supplement|Polycan|polycan 150 mg/d for 12 weeks
75346017|NCT01402115|Dietary Supplement|Placebo|Placebo 150mg/d for 12 weeks
75346018|NCT01436279|Drug|Mifepristone|200 mg po 20-24 hours prior to the procedure
75346019|NCT01436279|Device|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
75657501|NCT02788890|Procedure|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
75657502|NCT02788890|Procedure|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
75657503|NCT00872755|Procedure|Nissen|Laparoscopic Nissen Fundoplication
75657504|NCT00872755|Procedure|Gastropexy|posterior gastropexy
75657505|NCT02792400|Drug|LY2403021|Glucagon receptor antagonist
75657506|NCT02792400|Drug|LY2403021 placebo|
75944558|NCT05053659|Drug|Venetoclax|"Participants will receive venetoclax at target doses of 400 - 800mg orally on days 1 - 5 of each (21 day) cycle.~On cycle 1, venetoclax dose will be escalated to reach the target dose over the course of 5 days for target dose 400mg, 6 days for target dose 600mg and 7 days for target dose 800mg~Venetoclax should preferably be given after a meal and on cycle 1 should be preceded by prophylaxis for tumor lysis syndrome (TLS)."
75944559|NCT03649295|Other|Functional Electrical Stimulation|"Functional electrical stimulation device obeying the following steps:~Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure"
76092187|NCT05970068|Procedure|implantation of hydrophobic tubes for edema fluid drainage|1 - A 2-cm-long incision is made at the border of the hypogastrium or lumbar region 10 cm above the inguinal crease; 2- A 1.5-cm-wide and 100-cm-long metal tube tunneling device is introduced under the skin and bluntly passed in the subcutaneous tissue toward the thigh and internal aspect of the calf; 3- Incisions 2 cm long are made in the groin and calf, through which the tunneling device was passed; 4-The hydrophobic tube is passed upward through the tunneling device, after which the tunneling device is removed; 5-The upper and lower ends of the hydrophobic tubes are fixed to the fascia with absorbable sutures.
75944560|NCT03649295|Other|Conventional Speech Therapy|Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
75944561|NCT03423615|Behavioral|Comprehensive Health & Hygiene Improvement Program (CHHIP)|CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
75944562|NCT03650231|Other|Serological giagnosis|The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). 91 routinely collected samples were analyzed by Immulite, Architect, and Liaison Blood samples were centrifuged for 15 min at 2500g at room temperature. Sera were aliquoted and first analyzed by Immulite. All samples were tested for EBV VCA IgG, EBV VCA IgM and EBV EBNA IgG in order to determine infection status (primary EBV infection, past infection, absence of infection and indeterminate status).
76092188|NCT05970068|Device|Best Medical Treatment|Compressive therapy, Phisioterapy, venous intervention
76092189|NCT05968508|Drug|BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)|A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
76092190|NCT05966636|Procedure|Fractional CO2 Laser Ablative Resurfacing|Fractional lasers stimulate scar improvement through production of microscopic patterns of dermal injury, vaporizing scar tissue and inducing neocollagenesis, subsequently improving scar tissue texture and range of motion, and decreasing symptoms such as pain and pruritis. Current clinical consensus is supportive that fractionated lasers are the most effective option for the treatment of scars. Other laser wavelengths and modalities used for vascular deformities and hair removal for instance, have an adjunctive role in improving scars and may be used in the same laser session. Case reports provide evidence of substantial improvement in sensory symptoms and physical mobility within days to weeks after each treatment.
76092191|NCT05964855|Device|MIT Variable Stiffness Prosthesis|Proprietary electronically-controlled prosthesis that can vary its effective stiffness.
76092192|NCT05964855|Device|MIT Variable Equilibrium Angle Prosthesis|Proprietary manually-controlled prosthesis that can vary its effective ankle equilibrium angle.
75657507|NCT02792400|Procedure|Standardised liquid meal|
75657508|NCT02792400|Drug|Linagliptin|DPP-4-inhibitor
75657509|NCT02792400|Drug|Linagliptin placebo|
75804354|NCT03688360|Behavioral|Cognitive Behavioral Therapy|. Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy, formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises.
75804355|NCT03680950|Device|Upper Gastrointestinal Monitoring System|Participants will wear a monitoring system consisting of a tiny endoscopy and a mobile device. The endoscopy is inserted to upper gastrointestinal tract via nasal cavity and the mobile device is set to take and send images from the endoscopy to a server for analyzing if the abnormal condition occurs.
75944563|NCT03648203|Behavioral|Technology Enabled Asthma Management System|See description of arm
75944564|NCT03128073|Device|Carry life system, ultrafiltration (CLS UF)|The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
76092193|NCT05964855|Device|MIT Sliding Beam Passive Prosthesis|Proprietary fixed-stiffness passive foot-ankle prosthesis.
76092194|NCT05964855|Device|Ossur Pro-flex XC|Commercially-available passive fixed-stiffness foot-ankle prosthesis by Ossur.
76092195|NCT05964855|Device|Blatchford Elan Variable-Dampening Prosthesis|Commercially-available electronically-controlled prosthesis that can vary its effective dampening.
75657510|NCT02792400|Drug|Empagliflozin|SGLT2-inhibitor
75657511|NCT02792400|Drug|Empagliflozin placebo|
75657512|NCT04030221|Other|fluid infusion|250 ml of liquid will be given within 10 minutes for each patients, and the hemodynamic parameters before and after fluid infusion will be recorded. Then the experiment is completed.
75657513|NCT04040023|Drug|Iron and vitamin Deficiencies Correction Program|"Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation"
75672393|NCT00890201|Procedure|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
75944565|NCT03650153|Procedure|Trans-rectal MRI targeted Biopsy|Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.
75346020|NCT02210195|Drug|aprepitant|125 mg daily for 8 weeks.
75346021|NCT02210195|Drug|Placebo|Placebo daily for 8 weeks.
75346022|NCT02210195|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
75346023|NCT01436435|Device|Jetstream Atherectomy System|Atherectomy
75476842|NCT05481060|Other|Screen-based simulation|In the research, training will be given to the experiment group on intimate partner violence against women through screen-based simulation.
75657514|NCT04040023|Other|PBMi: Training program to improve transfusion practices|Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
75657515|NCT05755581|Drug|Hormonal Antineoplastics|the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.
75657516|NCT05755581|Drug|Chemotherapy drug|the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.
75657517|NCT00868075|Procedure|Chest physiotherapy|Twice daily for 8 weeks
75657518|NCT00868075|Procedure|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
75657519|NCT02792010|Device|Hip cartilage MRI|Hip cartilage MRI
75657520|NCT05017155|Drug|Mexiletine|Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.
75804356|NCT03686020|Diagnostic Test|Enzyme Linked Immunosorbent assay (ELISA)|measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)
75804357|NCT03679780|Drug|BQ-788|This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
75804358|NCT03679780|Drug|BQ-123|This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
75804359|NCT03679780|Drug|L-Arginine|A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
75804360|NCT03679780|Drug|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
75804361|NCT03679780|Drug|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
75804362|NCT03679780|Drug|Lactated Ringer's|Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
75804363|NCT03517566|Drug|Placebo|once daily from baseline until week 16
75804364|NCT03517566|Drug|ZPL389 3mg|ZPL389 3 mg oral powder; once daily from baseline to week 16
75804365|NCT03517566|Drug|ZPL389 10mg|ZPL389 10 mg oral powder; once daily from baseline to week 16
75804366|NCT03517566|Drug|ZPL389 30mg|ZPL389 30 mg oral powder; once daily from baseline to week 16
75804367|NCT03517566|Drug|ZPL389 50mg|ZPL389 50 mg oral powder; once daily from baseline to week 16
75944566|NCT03650153|Procedure|Trans-perineal MRI targeted Biopsy|Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
75944567|NCT03423537|Drug|hCG|the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.
75944568|NCT03423537|Drug|Placebo|100IU per day containing N/S 0.9% will be injected
75944569|NCT03650075|Drug|MG-S-2525|The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
75944570|NCT03649139|Drug|sublingual immunotherapy drops|artemisia annua (sweet sagewort) allergen extract drops
75944571|NCT03649139|Drug|Placebo drops|sublingual placebo drops
75944572|NCT03423381|Other|Cereal product 1|Cereal products based on rye, barley, wheat, oat, and corn
75944573|NCT03423381|Other|Cereal product 2|Cereal products based on rye, barley, wheat, oat, and corn
75944574|NCT03423381|Other|Cereal product 3|Cereal products based on rye, barley, wheat, oat, and corn
75944575|NCT03423381|Other|Cereal product 4|Cereal products based on rye, barley, wheat, oat, and corn
75944576|NCT03423381|Other|Cereal product 5|Cereal products based on rye, barley, wheat, oat, and corn
75944577|NCT03423381|Other|Control product|A cereal based product with low concentrations of df
75944578|NCT03648125|Device|with artificial occlusal disturbance|"A silicon artificial occlusal disturbance is made from a mould of the rowers mouth and placed in the mouth during the training session.~With artificial occlusal disturbance : Maximal Intercuspal Occlusion (MIO) with silicone splint increases the vertical dimension of occlusion of 1, 2 and 4 mm."
75944579|NCT03648125|Device|without artificial occlusal disturbance|The training session is performed without occlusal disturbance
75944580|NCT03429855|Other|trunk training|Bobath based trunk training
75944581|NCT03429855|Other|physiotherapy|conventional physiotherapy
75944582|NCT03648047|Device|Digital kinematic biofeedback device|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
75944583|NCT03648047|Other|Conventional rehabilitation|Patients will receive conventional face-to-face sessions by a Physical Therapist.
75944584|NCT03648047|Other|Additional face-to-face rehabilitation sessions|Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
75804368|NCT03725358|Behavioral|Training|Health facilities assigned to this group will receive a two-week training intervention on modern contraceptive methods and counseling techniques - aimed at nurses conducting family planning services. This new curriculum was developed by a large group of experts convened by the Ministry of Health in February 2018. The cascade training that is developed by the national government (cascading down to regions, districts, and finally health facilities) is a 15-day training module that targets family planning nurses, covering theory, practical knowledge (practicing administrations and removals), and counseling of clients.
75944585|NCT03429777|Device|HearMe Smartphone Application|The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.
75944586|NCT03649997|Drug|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
75944587|NCT03649997|Drug|Placebo|Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
76092196|NCT05962034|Drug|Aspirin|650 mg aspirin (Acetylsalicylic acid)
76092197|NCT05962034|Other|Placebo|placebo capsule
76092198|NCT05958017|Behavioral|reSET|Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.
76092199|NCT05958017|Other|Standard of care|Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
76092200|NCT05951231|Procedure|Liver transplantation|Patients who receive an ECD liver after an ex-vivo liver perfusion where the liver has been tested for function and approved according to international functional criteria (Groeningen criteria)
76092201|NCT05950334|Drug|FT522|FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.
76092202|NCT05950334|Drug|Rituximab|Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.
76092203|NCT05950334|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
75657521|NCT05017155|Drug|Lamotrigine 25Mg Oral Tablet, Extended Release|Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.
75944588|NCT03649997|Drug|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
75944589|NCT03429699|Behavioral|Stage-based Lifestyle Modification Intervention for the Management of Childhood Obesity|The participants will receive treatment based on nutrition clinical practice guideline for the management of childhood obesity. Participants in IG will be received a nutrition clinical practice guideline for the management of childhood obesity that comprised several activities, including nutrition counselling, aerobic sessions, a hands-on activity (healthy food preparation) and 'Sharing is Caring'. The Nutrition Practice Guideline for the Management of Childhood Obesity that comprised recommendations for assessment of nutritional status, determination of energy requirement, dietary prescriptions and physical activity modifications will be used. Participants' SOC for dietary and physical activity behaviors will be determined before any information was given to ensure that the selected educational topic will be tailored to the participant's current SOC.
75944590|NCT03429699|Behavioral|Existing practice for the management of childhood obesity|The participants will receive treatment based on the existing practice for the management of childhood obesity. Only nutritional counseling will be received by CG and standard treatment based on current practices by most dietitians in Malaysia for weight management of obese children will be used.
76092204|NCT05950334|Drug|Fludarabine|Fludarabine will be administered as an IV infusion at a dose of 30 mg/m^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
76092205|NCT05950334|Drug|Bendamustine|Bendamustine will be administered as an IV infusion at a dose of 90 mg/m^2 on Day -5 and Day -4 of the treatment cycle. Bendamustine may be administered as an alternative to cyclophosphamide/fludarabine.
76092206|NCT05946265|Other|Photobiomodulation|Forty-four patients with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) (660nm, 100W, area 0,5cm2, 200w/cm2, 30 seconds, 3 J, 6J/cm2.
76092207|NCT05946265|Other|simulation of Photobiomodulation|Simulation of the use of FBM will be carried out identically to the Experimental group. The person responsible for applying the FBM will simulate irradiation by positioning the devices in the same locations described for the FBM group, however, the laser pointer will be turned off and the sound of the device will be recorded to mimic the use of the equipment and the participant will not identify the group to be used. who belongs. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm is expected with this intervention.
75476843|NCT05477368|Dietary Supplement|D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
75476844|NCT05477368|Other|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
75476845|NCT05475132|Other|Exergaming|exercise games will be done for a total of 8 weeks ,100min of exergaming/week (5 days × 20 min).
75657522|NCT00868153|Drug|Levonorgestrel IUS (Mirena , BAY86-5028)|One group
75657523|NCT02791932|Behavioral|Exercise|See description above.
75657524|NCT04232592|Biological|Inject a solution of stem cell preparation|The control group was injected with a solution of stem cell preparation
75657525|NCT04232592|Biological|Inject stem cells|Three dose groups were designed: low dose group, medium dose group and high dose group.
75657526|NCT00868387|Other|energy-restricted, CHO-restricted diet|carbohydrate content of the diet < 40% Frequency: daily Duration: 12 months
75657527|NCT00868387|Other|energy-restricted, CHO-rich diet|carbohydrate content of diet > 55% Frequency: daily Duration: 12 months
75657528|NCT04234230|Other|Prevalence Survey|Questionnaire survey on self-management
75944591|NCT03423225|Drug|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~Duration of treatment The investigational product will be administered for 24 weeks."
75944592|NCT02521077|Drug|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
76092208|NCT05945810|Drug|TLL-018 extended-release tablet|50mg TLL-018 extended-release tablet QD
75346028|NCT00836888|Biological|ONO-4538|1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
75346029|NCT02262026|Drug|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
75346030|NCT02262026|Drug|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
75346031|NCT02262026|Drug|Placebo|Placebo
75346032|NCT03839030|Other|MBHP-Educa|This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
75346033|NCT03145688|Behavioral|Family Physical Activity Planning|"Families will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include a skill training content workbook on how to plan for family physical activity. The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We will provide this material as prompts/suggestions. Families will be instructed to plan for when, where, how, and what physical activity will be performed & then track their physical activity. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions"
75346034|NCT03145688|Behavioral|Family Physical Activity Habit Formation|Families will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms. The importance of creating cues for parental support of child physical activity is then outlined. Cues will also be considered factors that a) can precede the support activity but b) not be present very often when the activity is not to be performed. We will suggest that cues that have repeated exposure during times when family physical activity is not present Parents will then be asked to brainstorm and create a plan of consistency and cues with the workbooks provided. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions.
75476846|NCT05475132|Other|Conventional Dexterity Exercises|Exercises traditionally used for dexterity will be done for 8 weeks, 100min of exercises/week (5days × 20 min)
75657529|NCT00872911|Dietary Supplement|Amino acids|mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d
75657530|NCT00872911|Drug|Exercise|progressive exercise training
75346035|NCT00889226|Drug|Pitavastatin|Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
75346036|NCT00889226|Drug|Atorvastatin|Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
75944593|NCT02521077|Other|Normal Saline|Saline 0.9%
75476847|NCT05474560|Drug|Allopurinol (100 mg/day) plus lifestyle intervention|participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
75476848|NCT05474560|Drug|Febuxostat 40 mg plus lifestyle intervention|participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
75476849|NCT05474560|Behavioral|Life style intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
75657531|NCT02791620|Device|a nanofractional radiofrequency device|A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
75657532|NCT00873067|Procedure|Additional Complex Fractionated Electrograms ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
75657533|NCT00873067|Procedure|Standard atrial fibrillation ablation procedure|Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
75657534|NCT02789046|Procedure|peripheral intravenous catheterization|success or failure intravenous placement on first attempt and factors associated with failed intravenous catheterization
75657535|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.
75944594|NCT03422991|Other|Blood sampling and Quality of life questionnaire.|Blood sampling and Quality of life questionnaire.
75944595|NCT02732691|Device|JenaValve Pericardial TAVR System|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.
75944596|NCT03427203|Device|SenSura Mio|SenSura Mio is a marked ostomy device which is used as the comparator in this study
75944597|NCT03427203|Device|Coloplast Ostomy device 1|Coloplast Ostomy device 1 a newly developed ostomy device
75944598|NCT03427203|Device|Coloplast Ostomy device|Coloplast Ostomy device 2 a newly developed ostomy device
76092209|NCT05945810|Drug|TLL-018 immediate-release tablet|20mg TLL-018 immediate-release tablet BID
75944599|NCT03427203|Device|Coloplast Ostomy device 3|Coloplast Ostomy device 3 a newly developed ostomy device
75346037|NCT00837200|Drug|Oncaspar, Doxil, Decadron|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
75657536|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
75966066|NCT05231096|Other|Aloe-vera gel|Aloe-Vera gel Production Aloe vera gel used in this study was 98% aloe vera gel concentration and 2% normal saline. Preparation of aloe-vera gel consists of ripen leaf of aloe vera.(26) Aloe vera leaf was washed thoroughly under water and then cut from the center and the seeping gel was collected in sterile container and was stored at 4°C until the time of application. In our research this pure Aloe vera gel was extracted by The Pakistan Council of Scientific & Industrial Research (PCSIR) laboratory.
75657537|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
75657538|NCT02791776|Other|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~Collection of patient's radiographic and clinical parameters"
75476850|NCT05471960|Other|No intervention|Each subject will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
75476851|NCT05469893|Drug|Teclistamab|Intravenous (IV) dosage and timing per protocol design
76092210|NCT05945316|Behavioral|Accessing Confidence levels of Nursing students|Three mock CODE BLUE training events for Spring, Summer, and Fall Nursing Residents and Nursing Fellows are scheduled for 2022 followed by an actively participated CODE BLUE event. The PI plan to collect data from all new residents meeting the inclusion/exclusion criteria with voluntary participation to complete.
75346038|NCT00837512|Device|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
75966067|NCT05231096|Other|sidr honey|Honey collection Sidr (Beri) honey was used in this study. Honey was thick, raw and cold extracted from remote Pakistan afghan tribal forest belt of Sidr trees. It was smooth, viscous and medium to dark amber in color.
76092211|NCT05933850|Behavioral|Strong Families Programme Intervention|This is a family skills programme providing an evidence-informed prevention to support caregivers to be better parents and strengthen positive age-specific and age-appropriate family functioning and interactions to help prevent drug use, violence and other negative social consequences in their children.
75476852|NCT05469893|Drug|Lenalidomide|Oral, dosage and timing per protocol design
75346039|NCT00837512|Device|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
75346040|NCT00837590|Drug|Chronic salsalate|Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
75346041|NCT00837590|Drug|Acute Salsalate|Subjects will receive a single oral dose of 2 gram of oral salsalate
75346042|NCT00837824|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
75346043|NCT00837824|Biological|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
75476853|NCT05469893|Drug|Dexamethasone|Oral, dosage and timing per protocol design
75657539|NCT03840187|Diagnostic Test|Digital cervicography|Colposcopist findings and digital cervicography employing Gynescope system
75672394|NCT02651454|Drug|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
75966068|NCT05231096|Procedure|Scaling ans root Debridement|non-surgical periodontal therapy was given to all the participants of all the three groups
75966069|NCT02089763|Biological|pegylated recombinant human arginase|
75966070|NCT04884802|Procedure|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.
75346044|NCT03048188|Other|wound dressing|Manuka honey wound dressing
75346045|NCT01540409|Drug|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
75511243|NCT04593901|Behavioral|Video and App Review|"Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment."
75966071|NCT04884802|Procedure|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
75966072|NCT04872998|Behavioral|Step Count Reduction|Subjects reduce daily step counts by approximately 70% through monitoring and recording from step-count monitor
75966073|NCT02089841|Drug|Artemether-lumefantrine|Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
75966074|NCT04873076|Device|Audiovisual distraction using 2d video glasses from HappyMed GmbH|Patients receive optical and acustical relaxing material during the procedure by using 2d video glasses from HappyMed GmbH
75944600|NCT03422913|Procedure|controlled low central venous pressure|Anesthesiologists will control the amount of fluid input and the use of composite intravenous anesthesia to make CVP at 0~5cm H2O, if CVP is still >5cm H2O, intravenous infusion of nitroglycerin will be used to reduce CVP. Maintaining arterial systolic blood pressure (SBP) > 90 mmHg, urine output more than 1ml/kg/h, and CVP was continuously monitored. Arterial pressure, pulse oxygen saturation ( SPO2), PaCO2 and electrocardiogram (II and V5 leads) were continuously monitored by radial artery cannulation. CVP will Returned to normal level (6 ~ 12 cmH2O) after resection to observe the wound if active bleeding still exist. Intraoperative hepatic blood flow blocking intermittent Pringle block method also required during surgery, 10-15 minutes for once, and more than 5 minutes interval can be repeated.
76092212|NCT05932342|Behavioral|Integrated program of cognitive remediation, physical exercise and socially stimulating activity|"Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport."
76092213|NCT05924204|Radiation|Photobiomodulation|Application of photobiomodulation
76092214|NCT05924204|Other|Simulation of Photobiomodulation|Simulation of photobiomodulation
76092215|NCT05923892|Drug|OPS-2071|There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
75476854|NCT05468957|Device|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
75511244|NCT00122733|Drug|loxapine|
75511245|NCT04563208|Drug|Placebo|Placebo administered on Days 1-5
75511246|NCT04563208|Drug|DuACT|Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
75657540|NCT02788734|Other|Web-based survey|This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
75511247|NCT02965131|Procedure|Temporary portocaval shunt|The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
75657541|NCT00876889|Drug|Riluzole|50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).
75511248|NCT04383496|Behavioral|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
75657542|NCT00873145|Procedure|HMRS|Modular prosthetic replacement of the humerus and elbow.
75657543|NCT03550404|Behavioral|Seasons of Care App|A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
75657544|NCT00868465|Drug|Artemether-Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania
75672395|NCT02651454|Drug|Chowiseungcheng-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
75944601|NCT03422835|Procedure|R-TME|Conventional Robotic Total Mesentery Excision
75944602|NCT03422835|Procedure|R-TaTME|Robotic Transanal Total Mesentery Excision
75944603|NCT03429621|Drug|Simethicone 80 MG|Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
75944604|NCT03426969|Drug|Cyclophosphamide|Given IV
75944605|NCT03426969|Biological|Filgrastim|Given SC
75944606|NCT03426969|Drug|Fludarabine Phosphate|Given IV
75944607|NCT03426969|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
76092216|NCT05923892|Drug|placebo|Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
76092217|NCT05923749|Device|Biatain Ag|Biatain with silver
76092218|NCT05923749|Device|Cutimed Siltec Sorbact|comparator device
76092219|NCT05920343|Drug|Rivaroxaban 10 MG|The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).
75804369|NCT03725358|Behavioral|App|"Health facilities assigned to this group will receive the same programming as the facilities in S1, but they will also be provided with tablets equipped with the job aid, which subsumes the basic data collection software used by the remaining facilities. They will also receive additional training on the use of the tablet-based job aid.~The app is a tablet-based decision-support tool, which is designed for use by the family planning nurse conducting counseling sessions and records the answers to a series of questions that elicit the client's life goals, fertility plans, needs, and preferences regarding contraceptive methods, as well as her medical eligibility (birth history, pregnancy check, breastfeeding status, blood pressure, medications, etc.)."
76092220|NCT05920343|Other|Placebo control|Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug
76092221|NCT05898659|Device|ABFnoS then ABFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without synchronization with the contralateral hearing-aid then with synchronization with the contralateral hearing-aid
76092222|NCT05898659|Device|ABFS then ABFnoS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with synchronization with the contralateral hearing-aid then without synchronization with the contralateral hearing-aid
75944608|NCT03426969|Drug|Melphalan|Given IV
76092223|NCT05895604|Behavioral|Nurse-Family Partnership|Nurse-Family Partnership is a prenatal and infancy home visiting program providing regular visits to first-time mothers until the child is two years old
76092224|NCT05893186|Other|Deep Brain Stimulation, STN|DBS of the STN, within FDA-approved limits and labeling, for symptoms of PD
76092225|NCT05893186|Other|GP Deep Brain Stimulation|PD with GP DBS, within FDA-approved limits and labeling, for symptoms of PD.
76092226|NCT05884541|Other|TipsbyText Messages|Texts sent to caregivers meant to increase parent child interaction around math and literacy, sent to participants 4x a week for 8 months
76092227|NCT05884333|Drug|Conditioning Chemotherapy|Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 & -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 & -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours & Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
76092228|NCT05884333|Biological|Cord blood graft|The double-unit CB graft will be infused on day 0 per standard practice.
75657545|NCT00868465|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
75657546|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
75804370|NCT03725358|Behavioral|Control|The comparison group includes facilities that continue business as usual (no FP training or tablet-based job aid). Each facility in this group will receive a tablet equipped with basic data collection software and a one-day training to use the tablets.
75944609|NCT03426969|Drug|Mycophenolate Mofetil|Given PO
75944610|NCT03426969|Drug|Tacrolimus|IV or PO
75944611|NCT03426969|Radiation|Total-Body Irradiation|Undergo TBI
75944612|NCT03422757|Device|adaptive Deep Brain Stimulation|"The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal."
75944613|NCT03422757|Device|conventional Deep Brain Stimulation|"The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation."
75944614|NCT03426813|Other|Historical control group for early mobilization|
76092229|NCT05883956|Drug|Subcutaneous azacitidine|Subcutaneous azacitidine, 75mg/m2, 7 days
76092230|NCT05883956|Drug|Oral decitabine/cedazuridine|Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days
76092231|NCT05879757|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
76092232|NCT05879640|Behavioral|Sleep education|Participants receive a handout about age appropriate sleep goals and tips for improving sleep. The handout also contains links to educational videos about sleep hygiene and the importance of sleep to healing after illness. The handout is reviewed with a clinician at bedside prior to hospital discharge.
76092233|NCT05878483|Device|Venipuncture Device (VD)|"The Venipuncture Device is a pre-market medical device that fully automates the blood drawing procedure (also called phlebotomy or venipuncture). It automatically detects a vein using near-infrared and ultrasound imaging technology, robotically inserts a needle, automatically connects blood tubes and applies pressure to the puncture site.~During the ADOPT Study, the technology is further improved over time; for example features are released (such as: automated tourniquet). Initially, several manual steps are required to be performed by a device supervisor and operator. At the final stage of the ADOPT Study, Phase C2, the device has full functionality and only limited manual steps are required to be performed by a device supervisor."
75511249|NCT04613141|Device|WalkingTall-PD|Smart garment (socks, insoles or ankle bands) delivering rhythmic haptic stimuli to the ankle timed with preferred cadence. Smart phone application delivers auditory cues synchronised with haptic stimuli. Smart phone application delivers a neurorehabilitation program.
75511250|NCT04613141|Other|Mobility-plus|Active 'pseudo placebo' comparator using a paper-based body weight exercise program.
75511251|NCT00091299|Drug|warfarin|
75511252|NCT04363957|Other|Brachytherapy video|Patients will watch a video that contains information about brachytherapy
75804371|NCT03725280|Procedure|IVF|None interventional study (Collection of ovarian follicular fluid during IVF treatment)
75944615|NCT03429465|Other|EVO Cognitive Remediation Game|EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, & Anguera, 2016; Journal of Medical Internet Research).
76092234|NCT05873569|Behavioral|Mothers and Babies Virtual Group Intervention|The Mothers and Babies Virtual Group (MBVG) intervention is a 10-session intervention built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and are led by a trained MBVG facilitator.
76092235|NCT05867498|Behavioral|Concurrent exercise|Strength component (circuit-based exercise) and aerobic component (based on musicalized and outdoor activities).
75346046|NCT00891176|Biological|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
75346047|NCT00891176|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
75944616|NCT03422601|Diagnostic Test|Immunoscore test|To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.
76092236|NCT05867498|Behavioral|Aerobic exercise|Low-to-moderate-intensity continuous training and interval training based on musicalized and outdoor activities.
75657547|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
76092237|NCT05866250|Diagnostic Test|Doppler-based renal resistive index|The kidney's interlobular or arcuate artery was preferentially selected and measured by pulse-wave Doppler.
75346048|NCT00891176|Biological|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
75346049|NCT00891176|Biological|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
75346050|NCT00891176|Biological|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
75346051|NCT00891176|Biological|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
76092238|NCT05861323|Behavioral|Comfort Measures Only Time out (CMOT)|This is a brief intensive care unit team (nurse, physician, advanced practice provider, respiratory therapist) intervention to improve communication and care of patients at end of life in the intensive care unit setting.
76092239|NCT05861050|Procedure|Biopsy|Undergo tumor biopsy
75346052|NCT00891176|Biological|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
75346053|NCT00891176|Biological|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
75346054|NCT00891176|Biological|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
75657548|NCT02689986|Drug|Bendamustine, Rituximab|Bendamustine, Rituximab
75657549|NCT00876967|Device|metallic single use blade|metallic single use blade
75804372|NCT03677362|Behavioral|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via group phone callsSkype will be delivered by a professional health educator (HE) to participants in their homes.
75346055|NCT00839540|Drug|micafungin|100 mg qd by slow IV infusion for 24 h
75346056|NCT00839540|Drug|Micafungin|200 mg qd by slow IV infusion for 24 h
75346057|NCT00839540|Drug|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
75346058|NCT02966912|Dietary Supplement|400 mg of Magnesium Oxide twice daily for 24 weeks|
75346059|NCT02966912|Other|Open label (none)|
75346060|NCT01437605|Drug|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
75346061|NCT01437605|Drug|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
75346062|NCT00841412|Behavioral|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
76092240|NCT05861050|Procedure|Biospecimen Collection|Undergo collection of blood samples
76092241|NCT05861050|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
76092242|NCT05861050|Procedure|Computed Tomography|Undergo CT scan
76092243|NCT05861050|Biological|Glofitamab|Given IV
76092244|NCT05861050|Drug|Lenalidomide|Given PO
76092245|NCT05861050|Biological|Obinutuzumab|Given IV
76092246|NCT05861050|Procedure|Positron Emission Tomography|Undergo PET scan
76092247|NCT05861050|Drug|Venetoclax|Given PO
76092248|NCT05849857|Drug|Mosunetuzumab|Mosunetuzumab is administered as a subcutaneous injection. The first dose is 5 mg in 0,5 mL volume, subsequent doses are 45 mg in 1,0 mL volume.
75944617|NCT02022033|Drug|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
76092249|NCT05848895|Procedure|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment is a manual treatment therapy applied by licensed physicians that consists of using ones hands to improve the structure and function of the body. In this situation it will involve gentle and passive modalities that are well-tolerated by infants.
76092250|NCT05848895|Behavioral|Standard of Care Repositioning|Parents will receive standardized handouts/materials instructing on repositioning intended to help improve head shape in infants with plagiocephaly.
76092251|NCT05834439|Other|flower printing activities for the elderly|Experimental group
76092252|NCT05834439|Other|Routine activities in nursing home|Control group
76092253|NCT05827536|Dietary Supplement|PKU GOLIKE|PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
76092254|NCT05827536|Dietary Supplement|Standard of Care|Protein substitute
76092255|NCT05824572|Other|Clinic visit audio recordings for self-management in older adults|The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.
76092256|NCT05824572|Other|Usual Care|The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
75346063|NCT00841412|Behavioral|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
75657550|NCT00876967|Device|plastic single use blade|plastic single use blade
75657551|NCT00876967|Device|metallic reusable blade|metallic reusable blade
75657552|NCT02788812|Procedure|Open modified Lichtenstein repair|Open Lichtenstein Hernioplasty
75657553|NCT02788812|Procedure|Laparoscopic TAPP inguinal hernia repair|Laparoscopic TAPP Hernioplasty
75657554|NCT02791464|Behavioral|Transcendental Meditation program|a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
75657555|NCT00955409|Biological|ACC-001(3µg) + QS21|Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
75657556|NCT00955409|Biological|ACC-001(10µg) + QS21|Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
75804373|NCT03464266|Combination Product|FTC/TDF and DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
75804374|NCT03464266|Drug|FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
75944618|NCT03422445|Drug|Apatinib|Apatinib：500mg/d，qd，po，d1-28
75944619|NCT03422445|Drug|Temozolomide|Temozolomide：300mg/d，qd，po，d1-5
75944620|NCT03429387|Diagnostic Test|FDG-PET/CT|FDG-PET performed with low dose CT
75944621|NCT03429387|Diagnostic Test|Conventional CT|HRCT and CT of sinuses +/- other regions as per clinician's discretion
75944622|NCT03429309|Drug|Propofol|Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
75944623|NCT03429231|Dietary Supplement|Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol|Patients in the active group will take one tablet a day orally
75944624|NCT03426735|Other|Dry heat|Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
75944625|NCT03426735|Other|Dry cold|Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
76092257|NCT05818397|Behavioral|Self-Compassion for Children and Caregivers (SCCC)|A standardized, manualized adaptation of the mindful self-compassion curriculum for adults, designed for online delivery. Dyads join a group video conference call along with other caregiver-child dyads and an experienced SCCC facilitator. Sessions occur 1-hour per week for 6 weeks at a time convenient for the group.
76092258|NCT05815147|Dietary Supplement|Fortified Powdered Beverage|Participants will be asked to take the fortified powdered beverage everyday for 6 weeks.
76092259|NCT05812807|Biological|Pembrolizumab|Given IV
76092260|NCT05812807|Other|Patient Observation|Undergo observation
76092261|NCT05812807|Procedure|Biopsy|Undergo biopsy
76092262|NCT05812807|Procedure|Biospecimen Collection|Undergo collection of blood
76092263|NCT05812807|Other|Questionnaire Administration|Ancillary studies
76092264|NCT05812807|Other|Quality-of-Life Assessment|Ancillary studies
76092265|NCT05794542|Device|Cue X|Cue X is used with augmented (mixed) reality glasses. These glasses are similar to virtual reality glasses except you can see the real world around you with digital images overlain. The Cue X software is used on two existing devices, the Microsoft HoloLens and the Magic Leap.
75804375|NCT03464266|Drug|DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
75944626|NCT01852851|Behavioral|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
76092266|NCT05782790|Behavioral|Action Observation Theraphy Group|"In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done.~Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale."
75944627|NCT03429075|Drug|Psilocybin + Placebo|Multiple dosing days psilocybin vs 6 weeks of daily placebo
75944628|NCT03429075|Drug|Psilocybin + Escitalopram|Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
75346064|NCT02873468|Drug|Florence 30 μg/mL|10 mL, oral, twice a day.
75346065|NCT02873468|Drug|Florence 60 μg/mL|10 mL, oral, twice a day.
75346066|NCT02873468|Drug|Florence 90 μg/mL|10 mL, oral, twice a day.
75657557|NCT00955409|Biological|ACC-001(30µg) + QS21|Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
75657558|NCT00877123|Drug|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
75657559|NCT00877123|Drug|Placebo|similar placebo once a month for three consecutive months
75944629|NCT03422367|Behavioral|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
75944630|NCT03428919|Procedure|ICSI|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
75944631|NCT03428919|Procedure|IVF|In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
75944632|NCT03422289|Dietary Supplement|myo-inositol plus folic acid|this treatment is made in the first phase of the study for three months
75944633|NCT03422289|Dietary Supplement|myo-inositol plus folic acid plus alpha-lactalbumin|this treatment is made in the second phase of the study and it has a new molecule added to the previous ones administered in the first phase of the study
75944634|NCT03422211|Other|Questionnaire|Will ask patients questions in regards to how many narcotics they have taken and what their pain level has been.
75346067|NCT02873468|Other|Placebo|10 mL, oral, twice a day.
75346068|NCT02154386|Device|Ridge preservation using DFDBA|tooth extraction followed by ridge preservation grafting using DFDBA
75346069|NCT01438229|Device|St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)|Catheter-based RF ablation in renal artery
75346070|NCT01541735|Drug|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
75346071|NCT01541735|Drug|placebo|Placebo 40 mg dose.
75346072|NCT01541891|Drug|PRO-148 Ophthalmic Solution|PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.
75346073|NCT01541891|Drug|Active Comparator: SYSTANE ® Ophthalmic Solution|Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
75346074|NCT01520207|Drug|Mannitol (20%)|0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
75346075|NCT01520207|Drug|0.9% saline|1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
75346076|NCT01203722|Drug|Fludarabine|Fludarabine 30 mg/m2/day
75657560|NCT00868777|Procedure|Sinus grafting using allogenic bone|Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
75657561|NCT00873223|Drug|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
75804376|NCT03464266|Other|Neither DMPA nor FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
76092267|NCT05782790|Behavioral|Classic Swallowing Exercise Group|Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature. Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.
75944635|NCT02521389|Drug|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
75944636|NCT03422133|Other|Patient-oriented, personalized risk communication eHealth application|The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.
76092268|NCT05779072|Device|Single Vision Soft Contact Lens|Subjects refit to Single Vision Soft Contact Lens for 1 year
75657562|NCT00873223|Drug|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
76092269|NCT05773664|Drug|Azeliragon|Given PO
76092270|NCT05773664|Procedure|Biospecimen Collection|Undergo collection of cavity fluid and blood samples
76092271|NCT05773664|Procedure|Computed Tomography|Undergo CT scan
76092272|NCT05773664|Drug|Dexamethasone|Given PO or IV
76092273|NCT05773664|Procedure|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo MRI with or without contrast
75657563|NCT00873301|Procedure|vestibulectomy|Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
75657564|NCT00873379|Dietary Supplement|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
75657565|NCT00873379|Dietary Supplement|placebo|half a white placebo tablet
75804377|NCT03685864|Other|Suture Embedding Acupuncture|Suture Embedding Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
75804378|NCT03685864|Other|Sham Acupuncture|Sham Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
75804379|NCT03623932|Drug|immunosuppressor/TNFalpha|Standard Treatment : immunosuppressor/TNFalpha as in standard practice
75804380|NCT03623932|Behavioral|Hypnosis|8 hypnosis group sessions during 2 months
75944637|NCT03505671|Procedure|Acupuncture Therapy|Undergo acupuncture therapy
76092274|NCT05759949|Drug|RLY-5836|RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
76092275|NCT05759949|Drug|Fulvestrant|Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
76092276|NCT05759949|Drug|Palbociclib|Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
75657566|NCT03489174|Other|Monthly Pregnancy Screening|Pregnancy test will be administered once per month during weekly urine testing for drug levels.
75346077|NCT01203722|Drug|Cytoxan|Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day
75804381|NCT03680716|Drug|Ropivacaine injection|Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).
76092277|NCT05759949|Drug|Ribociclib|Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
76092278|NCT05759949|Drug|Abemaciclib|Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
75657567|NCT03489174|Other|Usual Care|Usual care.
75657568|NCT00877201|Drug|CDR2|
75657569|NCT02787486|Other|Blood sampling for Laboratory Developed Test (LDT) analysis|Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
75804382|NCT03680716|Drug|Ropivacaine injection|Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
75804383|NCT03680638|Other|Control (Lactated Ringer's)|This intervention is meant to serve as a control by which the experimental sites are compared to, to assess effectiveness.
75804384|NCT03680638|Drug|Tempol|This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
75944638|NCT03505671|Other|Best Practice|Receive usual care
75944639|NCT03505671|Other|Quality-of-Life Assessment|Ancillary studies
75346078|NCT01203722|Radiation|Total Body Irradiation|400 cGy TBI administered in a single fraction
75346079|NCT01203722|Procedure|Allogeneic Blood or Marrow Transplant|
75346080|NCT01203722|Procedure|Peripheral Blood Stem Cell Transplant|
75346081|NCT01203722|Drug|Mycophenolate Mofetil|15mg/kg by mouth three times daily
75346082|NCT01203722|Drug|Sirolimus|Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
75672396|NCT02651454|Drug|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
75804385|NCT03680638|Drug|Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.
75944640|NCT03505671|Other|Questionnaire Administration|Ancillary studies
75804386|NCT03680638|Drug|Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
76092279|NCT05739565|Behavioral|Acti-Pair program|"Motivational support by the peer (a patient with the same pathology who meets the WHO recommendations for physical activity), who will provide motivational follow-up~The implementation of a personalized and realistic physical activity project for the patient via the physical activity support systems (sport health centers)~Support from health professionals (GP) via the prescription of physical activity and from adapted physical activity (APA) professionals"
76092280|NCT05734066|Drug|Lurbinectedin|Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
76092281|NCT05733416|Diagnostic Test|FDG PET/CT|F-fluorodeoxyglucose positron emission/computed tomography
75657570|NCT00868855|Drug|Bradykinin|Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
75511253|NCT04363957|Other|Standard Brachytherapy Consent Process|Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
75657571|NCT00615901|Drug|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
75804387|NCT03677206|Device|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
75944641|NCT04449159|Dietary Supplement|Vinh Wellness Collagen|Vinh Wellness Collagen is hydrolyzed collagen
75944642|NCT04449159|Dietary Supplement|Placebo|Placebo
75944643|NCT03422055|Drug|99mTc-Fucoidan SPECT|Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
75346083|NCT01203722|Drug|Tacrolimus|Tacrolimus 1mg intravenously, daily
75511254|NCT04607603|Drug|Cannabidiol Oral Product|Cannabidiol is administered in capsules. Each capsule contains 200mg of CBD administered 3 times daily to a total of 600mg per die
75511255|NCT04607603|Drug|Placebo|Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
75511256|NCT00122772|Radiation|Radiotherapy|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy"
75511257|NCT00122772|Radiation|Radiotherapy|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy"
75657572|NCT03436290|Behavioral|Palliative Care Intervention|These patients will receive the palliative care intervention.
75657573|NCT03842683|Other|CGM|This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.
75657574|NCT02791074|Other|NTproBNP|To assess its level in the blood, as a marker of heart failure presence and severity.
75804388|NCT03677206|Device|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
75657575|NCT02791074|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
75804389|NCT03680560|Biological|ACTR T Cell Product|Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)
75944644|NCT04449315|Other|Young Living Lavender Essential Oil|For qualified patients one to two drops of hospital approved essential oil will be placed on a 4X4 gauze and will be offered to the patient during their infusion visit. This gauze will be placed in a sealable clear plastic bag and the patient will be instructed to use one sniff at a time.
75944645|NCT04449237|Other|music therapy|music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.
75944646|NCT04449471|Drug|Naproxen tablet|For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
76092282|NCT05733416|Diagnostic Test|Usual Care|Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
75672397|NCT00621920|Drug|FM-601|Dose-escalation, split dosage, liquid
75804390|NCT03680560|Drug|Trastuzumab|monoclonal antibody targeting HER2
75804391|NCT03677050|Other|Smart phone patient education application|Smart phone patient education application including a personalized colonoscopy preparation scheme and information about the procedure.
75804392|NCT03444298|Drug|Gamma Tocopherol|Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
76092283|NCT05727384|Drug|Clazakizumab|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
76092284|NCT05727384|Drug|Placebo|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
76092285|NCT05725655|Other|Thermotherapy|Hot baths directly after an exercise session
76092286|NCT05724173|Device|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
75346084|NCT01520519|Drug|Rituximab|375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
75346085|NCT01520519|Drug|PCI-32765|420 mg (3 * 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
75346086|NCT00185744|Radiation|Intra-Operative Radiotherapy (IORT)|single dose in the operating room after lumpectomy
75346087|NCT00185744|Procedure|Lumpectomy|
75346088|NCT00185744|Radiation|Whole Breast Radiotherapy|six and a half week treatment
75346089|NCT00185744|Radiation|Intracavitary Brachytherapy|5 day treatment
75804393|NCT03444298|Drug|Placebo|Each dose consists of two capsules by mouth once daily for a total of 7 days.
76092287|NCT05722457|Other|external focus task focus in addition to physiotherapy and rehabilitation exercises|"The first study on the external focus was made in 1998 by Wulf, Ho ¨ß, & Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
75346090|NCT00185744|Radiation|Accelerated External Beam 3-D Conformal Radiotherapy|5 day treatment
75804394|NCT03680482|Other|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose. Your allowable daily intake is 15 mg / kg of body weight per day. 85% is not absorbed and is excreted unchanged in the stool; the rest that is absorbed is excreted unchanged by the urine
76092288|NCT05722457|Other|internal focus task focus in addition to physiotherapy and rehabilitation exercises|"he first study on the external focus was made in 1998 by Wulf, Ho ¨ß, & Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
76092289|NCT05721898|Diagnostic Test|Cortical Bone Mechanics Technology|Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.
76092290|NCT05710406|Drug|Encorafenib|Given PO
76092291|NCT05710406|Biological|Cetuximab|Given IV
76092292|NCT05710406|Procedure|Biospecimen Collection|Undergo collection of blood samples
76092293|NCT05710406|Procedure|Computed Tomography|Undergo CT
76092294|NCT05710406|Procedure|Magnetic Resonance Imaging|Undergo MRI
76092295|NCT05710406|Other|Patient Observation|Undergo observation per usual care
76092296|NCT05694871|Drug|Palbociclib|Given PO
76092297|NCT05694871|Biological|Cemiplimab|Given IV
75657576|NCT02791074|Other|Arterial tonometry|A noninvasive method to obtain arterial pressure waveform.
75657577|NCT00868933|Other|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
75346091|NCT00185744|Radiation|Stereotactic APBI|4 day treatment
75346092|NCT03008057|Dietary Supplement|vitamin D|vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months
75657578|NCT00868933|Other|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
75657579|NCT02788422|Other|Video discharge instructions|Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
75804395|NCT03680482|Other|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
76092298|NCT05694871|Procedure|Magnetic Resonance Imaging|undergo MRI
76092299|NCT05694871|Procedure|Computed Tomography|Undergo a CT Scan
75346093|NCT03008057|Dietary Supplement|vitamin D placebo|vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
76092300|NCT05694871|Procedure|Biospecimen collection|Undergo blood sample collection
76092301|NCT05694871|Other|Questionnaire Administration|Ancillary Studies
76092302|NCT05687916|Drug|TAK-861|TAK-861 tablets.
76092303|NCT05687916|Drug|Placebo|TAK-861 placebo matching tablets.
76092304|NCT05687162|Behavioral|Overcoming Loneliness three-week intervention|A self-guided online loneliness intervention with three 10-20 minute sessions. The intervention content draws heavily from Internet Cognitive Behavioral Therapy for Loneliness and follows the form of single-session mental health interventions.
76092305|NCT05687162|Behavioral|Overcoming Loneliness single-session intervention|The Overcoming Loneliness Three-Week Intervention condensed into a single-session intervention lasting 20-30 minutes.
76092306|NCT05687162|Behavioral|"Single-session Sharing Feelings program"|"A self-guided online supportive therapy intervention with a single 20-30 minute session intended to encourage users to share feelings with close others. Slightly modified from the Sharing Feelings intervention"
76092307|NCT05687162|Behavioral|The Blu Surfer program: a popular online content-based intervention for psychological distress|The Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to mental health. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
75346094|NCT01542125|Drug|Liposomal Lidocaine|4% Liposomal Lidocaine
75346095|NCT01542125|Drug|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
75346096|NCT03216668|Drug|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks.
75346097|NCT03216668|Drug|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
75346098|NCT01439087|Device|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Colonic Polyps with OFDI system
75346099|NCT01439633|Device|MGH OFDI marking|Imaging of esophagus with OFDI system
75346100|NCT02548832|Drug|Berberine|"Berberine 1500 mg, each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner."
75346101|NCT02548832|Drug|Bezafibrate|"Bezafibrate capsule 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
75657580|NCT02788422|Other|Standard of Care|One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
75657581|NCT00869011|Other|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
75944647|NCT03426189|Procedure|Leukapheresis|Blood will be taken by a needle inserted into a vein in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out of the machine for purposes of this research. The rest of the blood will be returned through a needle in the other arm.
76092308|NCT05687162|Behavioral|The Action Brings Change (ABC) Program (TEAM Lab version)|The ABC project is a 20-30-minute SSI for teens based on behavioral activation. It was found to be efficacious for reducing depression, anxiety, hopelessness, and self-hate and increasing perceived control and agency in youth (link to SSI: https://osf.io/ch2tg/, license: http://creativecommons.org/licenses/by-nc-sa/4.0/). The researchers modified the phrasing in the intervention to make it more relevant to both teens and adults, as the original was designed for only teens.
76092309|NCT05687162|Behavioral|Online help-seeking as usual|"This intervention, created by the present research team, aims to emulate how one might find support on their own using the internet. In this condition, participants are asked to browse the internet for 25 minutes to find popular online content relevant to their personal struggles and create an annotated list of links to the content they find useful. The intervention is similar to a self-study condition, which found self-study and a video intervention equally increased mental health knowledge. The survey platform provides text entry boxes to help each participant create their guide and then provides a text version of their guide for them to keep."
76092310|NCT05687162|Behavioral|The Lonely Blu Surfer program: a popular online content-based intervention for loneliness|The Lonely Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to loneliness. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
76092311|NCT05667779|Drug|QRL-101|Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
76092312|NCT05667779|Other|Placebo|A placebo comparator will be administered at all dose levels.
76092313|NCT05666960|Drug|R-3750|Probiotic
76092314|NCT05665504|Diagnostic Test|DetermaRX|A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.
75657582|NCT02790918|Other|6MWT|Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
75657583|NCT02790918|Other|Cardiovascular Magnetic Resonance Imaging (CMRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
75804396|NCT03685786|Biological|CART19 cell and auto-HSCT|Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells treatment for Adult Patient with Minimal Residual Disease(MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT). Subjects will receive 0.5-4 x 10^8 transduced CAR T cells as a split dose over three days as follows:Day 0, 10% fraction: 0.5-4x10^7 CART19 cells, Day 1, 30% fraction: 1.5x10^7-1.2x10^8 CART19 cells, Day 2, 60% fraction: 3x10^7-2.4x10^8 CART19 cells. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
75804397|NCT03916744|Drug|Giredestrant|Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
75804398|NCT03916744|Procedure|Surgery|Breast cancer surgery will take place on Day 15 (+/-2 days).
76092315|NCT05663463|Drug|Fluzone High-Dose Quadrivalent- 2 doses|2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks
76092316|NCT05663463|Drug|Fluzone High-Dose Quadrivalent- 1 dose of HD|1 dose of the High Dose (HD) influenza vaccine, followed by a placebo injection 4-6 weeks later
76092317|NCT05661773|Device|the combined use of vacuum assisted suction and heat exchanger warming|Heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
75944648|NCT03426189|Procedure|Lymph node biopsy|Ultrasound will be used to localize the position of one lymph node in the groin. Under a light general anesthetic, one lymph node will be removed.
75346102|NCT02548832|Drug|Berberine plus Bezafibrate|"Berberine 1500 mg each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.~Bezafibrate 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
75346103|NCT01440959|Drug|dovitinib|TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
75346104|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
75657584|NCT00616603|Drug|Ropivacaine|20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
75657585|NCT00616603|Drug|Dexamethasone|8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
75657586|NCT00616603|Drug|Dexamethasone|2ml(8mg)Dexamethasone given once intravenously.
75966075|NCT03045848|Device|Biofreedom drug-coated stent|BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
75476855|NCT05468957|Drug|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
75657587|NCT00616603|Drug|Normal Saline|2ml of normal saline given once intravenously.
75944649|NCT03127371|Drug|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
75944650|NCT03127371|Drug|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
75944651|NCT02796027|Other|BRIDGE|"BRIDGE, enhanced HIV service integration package, has three components:~peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing~HCT using CTR with Rapid Testing~ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs"
75944652|NCT04448925|Other|inertial-load exercise (ILE)|Length of time between exercise bouts
75944653|NCT04448691|Diagnostic Test|CCTA|requested follow up CCTA
75476856|NCT05467397|Drug|[11C]acetate|Positron Emission Tomography (PET)
75944654|NCT03421821|Drug|Ropivacaine|Subfascial injection OR extrafascial injection
75944655|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)|Blood pass through infusion set without external pressure.
76092318|NCT05660629|Other|Mulligan Mobilization|Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
76092319|NCT05658523|Biological|Bivalent Moderna|A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 [BA.1]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.
76092320|NCT05658523|Biological|Novavax|A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
75511258|NCT00122772|Radiation|Radiotherapy/Cisplatin|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly"
75511259|NCT00122772|Radiation|Radiotherapy/Cisplatin|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly"
75657588|NCT02787330|Behavioral|Control Group|Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
75657589|NCT02787330|Behavioral|Experimental Group|The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
75804399|NCT03639610|Drug|Melflufen|Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.
75804400|NCT03639610|Drug|Dexamethasone|Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged <75 years. Dose of 20 mg for patients aged ≥75 years.
75804401|NCT03680404|Drug|Control (Phenylephrine)|This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
75804402|NCT03680404|Drug|Phenylephrine + Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.
75346105|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500 mg|Tablets for oral administration, once daily, once per treatment period
75346106|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
75346107|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
75346108|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
75346109|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
75944656|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg|Blood pass through infusion set under external pressure (150mmHg)
76092321|NCT05655091|Drug|FLU or CZO as continuous infusion|Continuous infusion FLU or CZO coupled with real-time TDM and subsequent dose adjustment. A loading dose will be administered prior to the first continuous infusion. The loading dose (maximum of 2g as licensed according to the SmPC) and the dose of the continuous infusion will be calculated according to a pharmacokinetic model taking into account patient's characteristics (e.g. age, sex) and the measured drug concentration. The maximum daily dose of FLU and CZO will not exceed 12 grams per day according to the SmPC.
75476857|NCT05460013|Dietary Supplement|Traditional Control|Placebo control is a compounded made-up shake that is traditionally used by the Haematology ward to supplement patients receiving HSCT. The control provides an equivalent of 500kcals and 20.6g protein, 3.4g fiber per day. The participants will be randomly assigned to consume the control twice daily for the duration of 7 days prior to the admission to the day of discharge.
75944657|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg|Blood pass through infusion set under external pressure (200mmHg)
75944658|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg|Blood pass through infusion set under external pressure (250mmHg)
76092322|NCT05655091|Drug|standard FLU or CZO intermittent bolus administration|Standard FLU or CZO intermittent bolus administration according to the local guidelines adjusted to the renal function without TDM-guided dose adjustment.
76092323|NCT05647265|Biological|Nivolumab|Given IV
75346110|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
75944659|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg|Blood pass through infusion set under external pressure (300mmHg)
76092324|NCT05647265|Biological|Ipilimumab|Given IV
76092325|NCT05647265|Procedure|Surgical Procedure|Undergo surgery
76092326|NCT05647265|Procedure|Computed Tomography|undergo CT
76092327|NCT05647265|Procedure|Magnetic Resonance Imaging|Undergo MRI
76092328|NCT05647265|Procedure|Positron Emission Tomography|Undergo PET
75657590|NCT00873535|Drug|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
75657591|NCT00873535|Drug|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
75657592|NCT02787174|Other|Asthma Medication Adherence Education|
75346111|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
75346112|NCT01543607|Device|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
75804403|NCT03680404|Drug|Phenylephrine + Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.
75804404|NCT03680404|Drug|Phenylephrine + Tempol|This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.
76092329|NCT05643729|Drug|Zofin|Intravenous Infusion (IV) of Zofin
75346113|NCT03216590|Device|Compressive draping using adhesive incise drape|In the intervention group the shoulder will be drape with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA).
75476858|NCT05460013|Dietary Supplement|Oral Nutritional Supplement|The product to be studied is a standard polymeric formula. It is intended to provide 500cals, 18.4g protein, and 5g fiber per day. The fiber contained is mostly presented in the form of soluble fiber (inulin, fructo-oligosaccharide). The participants will be randomly assigned to consume the intervention twice a day for the duration of 7 days prior to the admission to the day of discharge.
75804405|NCT03685630|Drug|Brivaracetam|"Pharmaceutical form: Solution for injection~Concentration: 10 mg/ml~Route of administration: Intravenous injection"
75346114|NCT04381754|Device|Passeo-18 Lux|Patients with significant inflow or outflow stenosis between the anastomosis to the axillary-subclavian vein junction, as defined by the insertion of the cephalic vein, who had undergone fistuloplasty with Passeo-18 Lux
75346115|NCT01521845|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
75476859|NCT05444751|Drug|General anesthetic|"Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence."
75804406|NCT02954406|Drug|TAK-659|TAK-659 immediate release tablet
75804407|NCT02954406|Drug|Bendamustine|Bendamustine intravenous infusion
75804408|NCT02954406|Drug|Rituximab|Rituximab intravenous infusion
75804409|NCT02954406|Drug|Gemcitabine|Gemcitabine intravenous infusion
75804410|NCT02954406|Drug|Lenalidomide|Lenalidomide capsule
75804411|NCT02954406|Drug|Ibrutinib|Ibrutinib capsule
75944660|NCT03421743|Drug|Inhaled molgramostim|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
75944661|NCT03421665|Device|Titan 3D Wedge System|Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
75944662|NCT03416907|Behavioral|Original consent form|Participants will review the full-length, original consent form for the clinical trial.
75944663|NCT03416907|Behavioral|Shortened consent form|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
76092330|NCT05643729|Other|Placebo|Intravenous Infusion of sterile saline
76092331|NCT05631197|Other|Biorepair Total Protection Plus + desensitizing enamel-repair shock treatment|Domiciliary use twice a day
76092332|NCT05631197|Other|Sensodyne Repair & Protect|Domiciliary use twice a day
75944664|NCT03416907|Behavioral|Reordered, shortened consent form|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
75804412|NCT03514914|Behavioral|The CHARM2 Intervention|CHARM2 intervention will involve gender, culture & contextually-tailored family planning and gender equity counseling.
75804413|NCT03728322|Biological|iHSCs treatment group|iHSCs intravenous injection
75944665|NCT03416907|Behavioral|Shortened consent form with a highlights box|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
75944666|NCT03416907|Behavioral|Interactive, shortened consent form|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
75944667|NCT03421587|Behavioral|Processing of social olfactory and tactile stimuli|Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.
75944668|NCT02747433|Device|Robot-Assisted Therapy (RT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (1 hr sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Robot training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home & community.
75944669|NCT02747433|Device|Robot & Task-Oriented Training (RT-TOT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (30 min sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Task oriented training will be delivered for remaining 30 mins of each treatment session. Robot and task oriented training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home & community.
75944670|NCT03421509|Other|cutaneous silent period|In the upper limb the cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows painful stimulation applied to the finger (digits II-V, C6-C8 dermatomes)
75944671|NCT01103349|Drug|BI 671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma
75944672|NCT01103349|Drug|Placebo|Patients receive placebo capsules and/or encapsulated tablets
75944673|NCT01103349|Drug|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma
75944674|NCT03416751|Biological|Fecal Microbial Transplant|Fecal transplant from a donor in the OpenBiome Registry
75944675|NCT03416751|Other|Placebo|Placebo enemas
75944676|NCT03416673|Procedure|peCTG+CAF|A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
75944677|NCT03416673|Procedure|CTG+CAF|A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
76092333|NCT05630235|Drug|CBD|Participants will be administered a one time dose of 250mg of CBD orally.
76092334|NCT05630235|Other|Placebo|The placebo equivalent of the CBD oil administered orally.
75657593|NCT02790996|Drug|Vancomycin|Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
75657594|NCT00573313|Drug|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
75657595|NCT00573313|Drug|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
75657596|NCT02790840|Drug|Omeprazole|20 mg oral capsules administered once daily for 10 days
75657597|NCT02790840|Drug|Omeprazole|40 mg oral capsules administered twice daily for 10 days
75657598|NCT02790840|Drug|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
75657599|NCT02790840|Drug|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
75804414|NCT01310478|Drug|recombinant human endostatin (Endostat)|mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
75804415|NCT03728244|Drug|MEBO ointment|The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).
75944678|NCT02022423|Behavioral|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
75944679|NCT02022423|Behavioral|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals
75944680|NCT03416595|Dietary Supplement|N1115 Probiotic Supplement|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
75944681|NCT03416595|Dietary Supplement|placebo|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
75944682|NCT03421275|Drug|Esketamine|anesthetic used as analgetic in subanesthetic doses given intranasally
75944683|NCT03421275|Drug|Fentanyl Citrate|intravenous fentanyl given intranasally
75944684|NCT03421275|Drug|Saline Nasal|intravenous saline given intranasally as placebo
75944685|NCT03416517|Drug|Anlotinib|Anlotinib 12 or 8 mg/d po D1-14 q3w
75944686|NCT03416517|Drug|Irinotecan|Irinotecan 20 or 15mg/m^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
75944687|NCT03416439|Other|lifestyle intervention|lifestyle intervention program carried out by trained professionals
76092335|NCT05628285|Device|Sentio 1|Sound processor
75804416|NCT03728244|Drug|Hyaluronic Acid gel|Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
75944688|NCT03426111|Device|Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)|This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
75944689|NCT03426111|Behavioral|Lifestyle modification|Hypocaloric diet and moderate physical exercise
75804417|NCT03513588|Drug|Placebo|tablet, 0 mg, 14 days, every 12 hours
75804418|NCT03513588|Drug|PF-06865571|tablet, 50 mg, 14 days, every 12 hours
75944690|NCT03421119|Drug|Liraglutide 6 MG/ML Pen Injector|Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
75944691|NCT03421119|Drug|Metformin|Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
75944692|NCT03421119|Drug|Sulfonylurea/non-sulfonylurea insulin secretagogues|Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
75944693|NCT03426033|Drug|ISIS 681257|Xmg dose administered as a subcutaneous injection
75944694|NCT03426033|Drug|Warfarin|25mg tablet administered orally
75944695|NCT03416205|Device|Erbao electric knife|Erbao electric knife is used to cut the Duodenal sphincter
75944696|NCT03416205|Device|Three-cavity incision knife|Three-cavity incision knife is used to cut the Duodenal sphincter
75944697|NCT03416205|Device|Columnar expansion balloon|Columnar expansion balloon is used to expand the the Duodenal sphincter
75944698|NCT03420885|Behavioral|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines the traditional Chinese medicine and traditional Chinese philosophy and embrace the body, breath and spirit. Ba Duan Jin consists of eight main movements. According to traditional theory, every movement has unique effect to different Zang-fu organs.
75346116|NCT05310344|Combination Product|Albumin-bound paclitaxel and bevacizumab|Patients will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles.
75346117|NCT04381676|Other|Flipped Classroom Approach|In the Flipped Classroom, participants form groups of 2-3 and are instructed to work together through clinical cases of the in-class case based activity, committing to group answers to the clinical questions before advancing to the next case. At the end of class, the faculty instructor facilitated a short interactive group discussion.
75511260|NCT04346212|Diagnostic Test|Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)|We will assess dysphagia, nutritional status and needs of compensatory treatment (fluid and nutritional adaptation) in patients with COVID-19 disease. We will also collect clinical data, information about swallowing and nutritional status and needs through the electronical medical history of the patients and by telephone call at 3 and 6 months follow-up, as well as clinical complications.
75511261|NCT00091338|Biological|MART-1 antigen|
75511262|NCT00091338|Biological|gp100 antigen|
75804419|NCT03513588|Drug|PF-06865571|tablet, 300 mg, 14 days, every 12 hours
75804420|NCT03725124|Other|Interview|Participants will be interviewed on their experience of family planning and inflammatory bowel disease.
75944699|NCT03420885|Behavioral|Health Education|Health education includes work, rest, diet and other basic programs according to the different conditions of participants.
75944700|NCT04567173|Drug|Anti-SARS-CoV-2 convalescent plasma|convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
75944701|NCT04522089|Biological|AdimrSC-2f|AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
75944702|NCT03425955|Device|SUNEKOS ® 200|"4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
75966076|NCT02250365|Other|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
75511263|NCT00091338|Biological|incomplete Freund's adjuvant|
75511264|NCT00091338|Biological|recombinant interleukin-7|
75657600|NCT05225779|Diagnostic Test|12- derivation Electrocardiography|6 precordial and 4 extremity electrodes will be placed at appropriate anatomical points and a total of 6 12-lead ECGs will be taken at different anesthesia depths before anesthesia induction and throughout the operation.
75657601|NCT02790762|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
75657602|NCT00877357|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
75657603|NCT04232826|Biological|single dose of CNCT19|"Dose A: 1.00 x 10^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 2.00 x 10^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 4.00 x 10^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
75804421|NCT03512028|Behavioral|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
75804422|NCT03512028|Behavioral|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
75804423|NCT03512028|Behavioral|Muscle strength training|All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
75944703|NCT03425955|Device|"SUNEKOS® 1200 and SUNEKOS® 200"|"5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
75944704|NCT03420729|Procedure|gastroscopy|a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
75944705|NCT03420729|Device|magnetic assisted capsule endoscopy|The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
75944706|NCT03415971|Procedure|EMG befor denture treatment|
75944707|NCT03415971|Procedure|EMG in a month after termination of treatment|
75346118|NCT03216434|Diagnostic Test|MRI using DaTscan|"A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed."
75944708|NCT03415971|Procedure|EMG in a 3 months after termination of treatment|
75944709|NCT02959177|Drug|Galcanezumab|Administered SC
75944710|NCT02959177|Drug|Placebo|Administered SC
75944711|NCT03420495|Behavioral|Decision-Making Tasks|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
75944712|NCT03415815|Procedure|Surgeries|Radical resection of esophageal cancer
75346119|NCT01522391|Drug|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
75657604|NCT00873613|Procedure|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
75657605|NCT02790684|Drug|DS-8500a|
75657606|NCT02786862|Other|independent ventilation|comparison conventional and independent 1:1 ventilation
75944713|NCT02432547|Drug|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
75944714|NCT02432547|Procedure|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
75657607|NCT00877435|Behavioral|Cognitive behavioral therapy (CBT)|
75657608|NCT02790372|Other|Case conferencing|Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
75346120|NCT01522391|Drug|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
75657609|NCT00869245|Other|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
75657610|NCT00869245|Other|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
75657611|NCT02352389|Other|Blood sample|Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
75657612|NCT02352389|Other|Nasal swab|Obtained on Day 0, 7, 14, 21 and 28.
75657613|NCT02352389|Other|Oropharyngeal swab|Obtained on Day 0, 7, 14, 21 and 28.
75657614|NCT02352389|Other|Stool sample|Obtained on Day 0, 7, 14, 21 and 28.
75804424|NCT03512028|Behavioral|Driving training|All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
76092336|NCT05628051|Procedure|ultrasonographic measurement of carotid artery corrected flow time (FTc)|Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 ~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+[1.29× (HR-60)
75657615|NCT02352389|Other|Symptom checklist|Obtained on Day 0, 7, 14, 21 and 28.
75657616|NCT02787252|Device|Implant procedure, Freedom Spinal Cord Stimulation System|A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
75944715|NCT03640195|Other|Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure|"Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day."
75944716|NCT03415737|Other|Questionnaire|Profile Fitness Mapping Neck Questionnaire
75944717|NCT03420417|Device|Esophageal pressure measurement|Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
76092337|NCT05611710|Drug|Placebo|"Drug: Placebo, with visually matched clear syringes~Adults (≥16 years) and children (12-16 years, > 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~Children (12-16 years, < 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days"
76092338|NCT05611710|Drug|Anakinra|"Drug: Anakinra~Adults (≥16 years) and children (12-16 years, > 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~Children (12-16 years, < 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)"
76092339|NCT05610163|Drug|Capecitabine|Given PO
76092340|NCT05610163|Drug|5-fluorouracil|Given IV
76092341|NCT05610163|Drug|Leucovorin calcium|Given IV
76092342|NCT05610163|Drug|Irinotecan|Given IV
75804425|NCT03512028|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
75944718|NCT03618433|Other|study group|The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
76092343|NCT05610163|Drug|Oxaliplatin|Given IV
76092344|NCT05610163|Radiation|Long Course Chemoradiotherapy|Receive LCRT
76092345|NCT05610163|Procedure|Computed Tomography|undergo CT
76092346|NCT05610163|Procedure|Magnetic Resonance Imaging|undergo MRI
75346121|NCT04381520|Other|Heat-sensitive moxibustion plus antihypertensive drugs|In this arm, patients will administer heat-sensitive moxibustion by themselves or by the help of their family after professional training. Patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
75944719|NCT03618433|Other|Control group|The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
76092347|NCT05610163|Procedure|Sigmoidoscopy|undergo sigmoidoscopy
75346122|NCT04381520|Drug|Antihypertensive drugs|In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
75346123|NCT00837902|Drug|Atenolol (β-blocker)|25 mg tablet
76092348|NCT05610163|Procedure|biopsy|undergo biopsy
76092349|NCT05609409|Behavioral|FlexED|Intervention consists of eight 20-30 minute sessions of a digital intervention based on Acceptance and Commitment Therapy (ACT). Participants learn skills of body image flexibility by following an avatar through a story line and completing interactive exercises.
75346124|NCT01830452|Procedure|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
75511265|NCT04298671|Behavioral|Yoga-Pilates|As above
75511266|NCT00122811|Drug|Indapamide SR 1.5mg; Perindopril 2-4mg|
75511267|NCT04224025|Other|exercise and respiratory therapy|three weeks in-Hospital exercise Rehabilitation program with continuation at home (total 15 weeks).
75511268|NCT04188262|Combination Product|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
75511269|NCT04132414|Diagnostic Test|NIRS open|Treatment according to protocol in phases of cerebral hypoxia.
75804426|NCT03511326|Drug|Methyl Aminolaevulinate 16% Cream|Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
75804427|NCT03727932|Device|VioOne HIV Profile Supplemental Assay|The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M & Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
75511270|NCT00122850|Drug|Duloxetine|
75511271|NCT00122850|Drug|venlafaxine|
75511272|NCT00122850|Drug|placebo|
75511273|NCT03975439|Diagnostic Test|Hemoglobin A1C|Finger stick hemoglobin A1C
75944720|NCT03415659|Drug|HWH340 tablet|"single escalating dose study starts from 20 mg as the initial dose until the maximum dose group (520mg) or maximum tolerated dose (MTD) has been reached.~multiple-dose study conducted on oral HWH340 tablet BID. The DLTs evaluating period is 4 weeks and the safety evaluation period lasts till 4 weeks after drug withdrawal.~dose-expansion study conducted on oral HWH340 tablet BID in 2 to 4 dose groups. Patients with BRCA mutation OR HRD will be assigned to 2 cohort in each dose group."
75944721|NCT02031757|Other|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
75944722|NCT02031757|Other|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
75944723|NCT02345733|Other|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
75944724|NCT02345733|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
75944725|NCT03618901|Other|Rock Steady Boxing|Boxing programs as offered by the Rock Steady Boxing institution,
75944726|NCT03618901|Other|PD SAFEx|Progressive proprioception training.
75944727|NCT03420261|Biological|0.9% saline|Fluid administration
75944728|NCT03420261|Biological|HES 130/0.4|Fluid administration
75657617|NCT04204109|Other|Interprofessional case-based learning|"The trial is an educational intervention where groups of healthcare professionals receive the same case-based learning: one group receives case-based learning with healthcare professionals of various professional backgrounds (experimental) versus another group receiving case-based learning with healthcare professionals exclusively of the same professional background (control).~The educational intervention consists of a case that is developed for the purpose of the intervention.~The participants in the experimental group will be randomised into six teams who will receive interprofessional case-based learning. The experimental group will be made up of healthcare professionals from various groups. The participants in the control group will be randomised in groups of one profession"
75944729|NCT03618745|Device|CT brain|noninvasive medical examination or procedure that uses specialized X-ray equipment to produce cross-sectional images of the body.
75944730|NCT02331147|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment
75944731|NCT02331147|Other|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
75944732|NCT03415503|Drug|Medox® Anthocyanin capsules|Subjects were orally administered Medox® capsules daily for 12 weeks.
76092350|NCT05609331|Other|Simulated Online Adaptive Planning|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
76092351|NCT05609331|Radiation|Stereotactic MRI-guided adaptive radiotherapy-SMART|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
76092352|NCT05607732|Diagnostic Test|MyCog|MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.
75346125|NCT04381598|Drug|stevia rebaudiana bertoni|Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
75346126|NCT04381598|Other|placebo|A placebo without the active drug will be placed in the control sites.
75346127|NCT04382144|Drug|Liposomal bupivacaine|Patient will receive a single injection of a local anesthetic into the common extensor origin.
75944733|NCT03127683|Other|Neutral position|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
75944734|NCT03127683|Other|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
75944735|NCT03127683|Other|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
75944736|NCT03127683|Other|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
75944737|NCT03127683|Device|Ambu AuraGain TM|Single Use Laryngeal Mask Sterile
75944738|NCT03415347|Procedure|Abscess de-roofing and curettage|Abscess de-roofing and curettage
75944739|NCT03415347|Procedure|Abscess wide local excision|Abscess wide local excision
75944740|NCT03415269|Drug|Ambroxol Hydrochloride|single lozenge of 20mg ambroxol
75944741|NCT03618589|Drug|Pregabalin|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
75944742|NCT03618589|Drug|Opioid|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
76092353|NCT05587192|Diagnostic Test|18F-PSMA-1007 PET/CT based on diagnostic model|All enrolled patients will receive 18F-PSMA-1007 PET/CT based USTC diagnostic model before gaining the final pathological diagnosis to be used as experimental arm.
76092354|NCT05581589|Procedure|Lymphadenectomy|Undergo pelvic lymph node dissection
76092355|NCT05581589|Procedure|Radical Cystectomy|Undergo radical cystectomy
76092356|NCT05581589|Biological|Sacituzumab Govitecan|Given IV
76092357|NCT05580874|Other|Massage|The babies in the massage group were given a massage once a day.
76092358|NCT05580874|Other|Swaddling|Control group
76092359|NCT05574062|Device|MiniMed 780G Automode|"Subjects will start using the MiniMed™ 780G system in Auto Mode.~The 780G system consists of:~MiniMed™ 780G Insulin Pump with auto mode enabled Guardian™ 4 Sensor Guardian™ 4 Transmitter"
76092360|NCT05574062|Device|MiniMed 780G Manual Mode + Suspend Before Low|Subjects will start using the MiniMed™ 780G system in Manual Mode. The 780G system consists of: MiniMed™ 780G Insulin Pump with manual mode + Suspend before Low enabled Guardian™ 4 Sensor Guardian™ 4 Transmitter
76092361|NCT05571046|Drug|Glucocorticoids|Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)
76092362|NCT05571046|Other|Placebo|Intramuscular injection of %0.9 isotonic sodium chloride, Paracetamol (500 mg, 2 times a day)
76092363|NCT05567627|Biological|Genetic: GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
76092364|NCT05546411|Drug|mFOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
76092365|NCT05546411|Drug|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
76092366|NCT05546411|Drug|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
75657618|NCT00877513|Behavioral|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
75346128|NCT03215888|Procedure|bariatric surgery|Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
75657619|NCT02786784|Other|6 week exercise treatment|This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
75672398|NCT02651376|Combination Product|Conventional plus AAIT|Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3*10E8 MNCs/kg body at baseline, week 1 and 2.
75804428|NCT03721692|Device|RIC|The patients will use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
75804429|NCT03727698|Device|MR Linac|MR guided radiotherapy treatment
76092367|NCT05546411|Drug|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
76092368|NCT05546411|Drug|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
76092369|NCT05546411|Drug|NIS793|Given by intravenous infusion
76092370|NCT05546411|Radiation|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
76092371|NCT05546411|Procedure|Surgery|Surgical removal of tumor
76092372|NCT05545449|Behavioral|PrEP Peer Mentor Program|Five PrEP peer mentors will provide outreach, education, and referral for HIV pre-exposure prophylaxis. Peer mentors have received training on HIV, PrEP, family planning, adolescent development, peer support, and action planning. Interactions will include 1:1 informal interactions as well as planned group outreach interactions.
76092373|NCT05495737|Behavioral|Meaning-Centered Psychotherapy/MCP-PC Training|Two-Day MCP-PC Training for Nurses (including mock patient/simulation with actor) with a Pre- and Post-Training Assessment
76092374|NCT05495737|Behavioral|Meaning-Centered Psychotherapy/MCP-PC|3 sessions, completed over the course of 3-6 weeks in the participant's home
76092375|NCT05495737|Behavioral|Treatment As Usual/TAU|"Research team will provide:~feedback about level of distress at time of screening~local referral for psychological care"
75346129|NCT05319938|Procedure|CAF only|After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.
75476860|NCT05444751|Drug|SA + ESP|"The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation."
75511274|NCT03975439|Diagnostic Test|Urinalysis|Urinalysis by dip stick looking for urine protein level
75511275|NCT03975439|Diagnostic Test|Whole blood creatinine level|Finger stick looking for serum creatinine as an estimate of renal function
75511276|NCT00091377|Drug|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
75511277|NCT00091377|Drug|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
75511278|NCT00091377|Drug|phenoxodiol|IV 3 mg/kg
75804430|NCT03721614|Device|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio [BioMime™ Morph (n=133) vs. XIENCE family (n=67)].
75804431|NCT03721614|Device|Xience family Everolimus Coronary Stent Systems|Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio [BioMime™ Morph (n=133) vs. XIENCE family (n=67)].
76092376|NCT05483868|Drug|AU-011|Administration of AU-011 intratumorally or intratumorally and intramurally
76092377|NCT05483868|Combination Product|AU-011 in Combination with Medical Laser|Administration of AU-011 intratumorally or intratumorally and intramurally with Laser application.
75657620|NCT05001399|Behavioral|Holographic Memory Resolution® (HMR)|Clients will participate in Holographic Memory Resolution® (HMR) administered by a trained HMR practitioner. Clients will be introduced to relaxation techniques and safe scene identification. This exercise encourages the client to identify a place in which they feel safe and where nobody can be there without client's invitation. Clients will then describe the place and associated colors of the experience, how the colors move in their body, and how they move through their safe scene. The subsequent 2-3 sessions will continue to explore safe scene and color therapy.
75657621|NCT02790450|Drug|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
75657622|NCT00873691|Device|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
76092378|NCT05478954|Drug|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
76092379|NCT05478954|Drug|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect. Adverse effect of amodiaquine includes abdominal discomfort and vomiting weakness and when used for prophylaxis it causes agranulocytosis. Amodiaquine is recommended as a partner drug in artemisinin based combination therapy."
76092380|NCT05474859|Drug|XT-0528|Once Daily
75476861|NCT05441020|Other|Administration of patient questionnaire|Patients undergoing maintenance hemodialysis complete electronic questionnaires on a tablet computer during this study to assess patient reported outcomes.
75657623|NCT00630461|Biological|Clinical Center Reference Endotoxin|single inhalation challenge
75657624|NCT02790528|Drug|Atorvastatin|20mg QD
75657625|NCT02790528|Drug|Placebo|Placebo drug will be administered.
75657626|NCT04039711|Procedure|Vaginal self-sampling|The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
75657627|NCT00953615|Drug|Thalidomide|Titrate to 400 mg daily for 6 months
75804432|NCT03727620|Drug|amoxicillin plus metronidazole|patients were administered 250 mg of Flagyl and 500 mg of Dyspamox, three times a day for 7 days
75804433|NCT03727620|Drug|Doxycycline|patients were administered 200 mg of Longamycine the first day and 100 mg per day for 14 days
75804434|NCT03727542|Device|adjustment of atrioventricular delay in DDD packers|Atrioventricular delays are going to be adjusted as 60 milisecond shorter than the patients' native PR intervals in patients with already implanted permanent pacemakers.
75804435|NCT03724734|Device|Adaptive DBS|We will use our custom-built externalized research system (ERS) to allow recordings and stimulation. The device is small and lightweight and communicates wirelessly with a personal computer. The electrical connections to the DBS leads will be through temporary extensions with appropriate mechanical slack. To allow for stimulation return, a conductive clip to the ERS case will be connected to a conducting (ECG) pad placed over chest. Periodic impedance checks will ensure this connection is robust through the course of the experiment. The patient can be ambulant whilst wearing the device.
75657628|NCT02787096|Device|LaxIRM|Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
75657629|NCT00873769|Drug|Inhaled Loxapine 10 mg|Staccato Loxapine 10 mg, single dose
75657630|NCT02785614|Drug|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
75657631|NCT02785614|Drug|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
75657632|NCT02859155|Procedure|Multivisceral en bloc resection surgery|Multivisceral en bloc resection for colorectal cancer in advance patients (T4)
75657633|NCT00810615|Other|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
75657634|NCT00810615|Other|Sham treatment|
75657635|NCT02787018|Drug|Ropivacaine and Normal saline|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline
75804436|NCT03724734|Device|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous conventional stimulation.
75804437|NCT03721536|Diagnostic Test|hemodynamic parameters|vital signs on the monitor including heart rate, mean arterial pressure, peripheral oxygen saturation and End-tidal Carbon Dioxide
75804438|NCT03721536|Diagnostic Test|arterial blood gase|Arterial blood gas including partial oxygen pressure and partial carbon dioxide pressure is an important routine investigation to monitor the acid-base balance of patients, effectiveness of gas exchange, and the state of their voluntary respiratory control.
75804439|NCT03727464|Behavioral|Abstract priming|Patients were primed with a list of abstract during their general anesthesia
75804440|NCT03727464|Behavioral|Concrete priming|Patients were primed with a list of concrete during their general anesthesia
76092381|NCT05471544|Drug|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
76092382|NCT05471544|Drug|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect."
76092383|NCT05460273|Drug|Datopotamab Deruxtecan (Dato-DXd)|Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
76092384|NCT05456113|Biological|Cannabidiol|Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
76092385|NCT05449665|Other|Phase 1 - Control|"Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d).~Fed to energy balance (1.5 x Resting Metabolic Rate, RMR)."
76092386|NCT05449665|Other|Phase 2 - High Fibre|High Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 30g/day Fibre). Fed ad libitum, contains 20g/day pectin (split over breakfast, lunch and dinner) in drinks/yoghurts which will be compulsory to consume and 10g/day fibre coming from the diet provided.
75346130|NCT05319938|Procedure|CAF+CGF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into CGF centrifuge machine and centrifuged immediately . CGF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
75657636|NCT02787018|Drug|Ropivacaine and Dexamethasone|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone
75657637|NCT02787018|Drug|Ropivacaine and Dexmedetomidine|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
75804441|NCT03727464|Behavioral|Controls|Patients did not receive any specific stimulation with words during their general anesthesia
75804442|NCT03727464|Drug|Propofol|Propofol general anesthesia
75804443|NCT03727464|Drug|Sevoflurane|Sevoflurane general anesthesia
75804444|NCT03724656|Device|acupuncture treatment|"TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
75944743|NCT03425877|Device|MS Band 2|Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
75966077|NCT02250365|Other|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
75657638|NCT02858999|Drug|PAD-VCD|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles
75672399|NCT04246853|Device|Transcranial direct current stimulation (tDCS) of the resting state motor network|Transcranial direct current stimulation (tDCS) delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
75804445|NCT03724656|Device|sham acupuncture treatment|"Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
75804446|NCT03508830|Drug|Liposomal bupivacaine|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
75804447|NCT03508830|Drug|Bupivacaine Injection|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
75804448|NCT03721458|Other|Sequence|Potentially identifying genetic defects that could have clinical significance
75804449|NCT03508050|Device|Clamping the Double Lumen Tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
75804450|NCT03727386|Other|Coconut oil|Participants will receive 30 ml of virgin coconut oil to replace their normal oil intake for a period of 6 months.
75804451|NCT03727386|Other|Sunflower oil|Participants will receive 30 ml of sunflower oil to replace their normal oil intake for a period of 6 months.
75966078|NCT03045770|Drug|Fluorouracil|Fluorouracil was used as first line treatment with AGC.
75966079|NCT03045770|Drug|Oxaliplatin|Oxaliplatin was used as first line treatment with AGC.
75966080|NCT03045770|Drug|Irinotecan|Irinotecan was used as first line treatment with AGC.
75657639|NCT00873925|Biological|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
76092387|NCT05449665|Other|Phase 3 - Low Fibre|Low Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 10g/day Fibre). Fed ad libitum.
75657640|NCT00873925|Dietary Supplement|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
75657641|NCT00873925|Dietary Supplement|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
75657642|NCT02859233|Other|Lack of hyperhydration|
75657643|NCT04980651|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
75657644|NCT04980651|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
75804452|NCT03727308|Behavioral|Medical abortion pills sourced from pharmacies|One cohort using medical abortion pills sourced from pharmacies
75346131|NCT05319938|Procedure|CAF+A-PRF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into A-PRF centrifuge machine and centrifuged immediately. A-PRF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
75346132|NCT01522703|Drug|Broccoli Sprouts|100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
76092388|NCT05431556|Other|Virtual mind-body group exercise classes|"Pre-operative period (baseline/intake day to day before surgery): mid- to high intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)~Immediate post-operative period (post-operative hospitalization to 2 weeks after surgery): low- to mid-intensity classes focusing on relaxation, stress management and low-impact physical activity (classes: Chair Yoga, Dance Therapy, Meditation, Music Therapy)~Late post-operative period (3-12 weeks after surgery): mid- to high-intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)"
75346133|NCT01522703|Drug|Placebo|Alfalfa Sprouts
75346134|NCT03215732|Diagnostic Test|HBV testing with dried blood spots (DBS) technique|Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper).
75657645|NCT04040257|Behavioral|Team-based approach|Team-based participation in the The Perinatal Quality Foundation Fetal Monitoring Credentialing (PQF/FMC) exam.
75657646|NCT03412266|Drug|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
75657647|NCT00877591|Drug|Fosamprenavir/Ritonavir|1400/200 mg once daily for 15 days total
75657648|NCT00877591|Drug|Darunavir/Ritonavir|800/100 mg once daily for 15 days total
75657649|NCT00877591|Drug|Rifampin|600 mg once daily for 15 days total
75657650|NCT00877591|Drug|Rifabutin|300 mg once daily for 15 days total
75657651|NCT00877591|Drug|Buprenorphine|"FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days"
75804453|NCT03727308|Behavioral|Medical abortion pills sourced from health clinics|One cohort using medical abortion pills sourced from health clinics
75804454|NCT03569202|Device|Piiloset Trehalose Emulsion Eye Drops|Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops 3 times daily
75804455|NCT03569202|Device|Control Eye Drops|Topical application of preservative-free multidose Hyaluronic Acid Eye Drops 3 times daily
75804456|NCT03680326|Device|OCT|only OCT
75944744|NCT03425877|Behavioral|Emotion Assessment|The subjects will be subjected to the viewing of 21 video clips depicting 6 different emotional states belonging to the FilmStim database validated by Schaefer's studio and collaborators (Schaefer, Nils, Sanchez, & Philippot, 2010). When viewing the clip, subjects will wear the Microsoft ® Band 2 .and after each movie clip of an evaluation of the stimulus value and activation level perceived by the Self-Assessment Manikin (Bradley & Lang, 1994) questionnaire). The presentation of movie clip is randomized and does not follow a fixed effect. Between the presentation of each clip a fixed interval of 15 seconds has been inserted in order to induce artifacts and overlap of physiological signals among different emotional valence video clips.
75966081|NCT03045770|Drug|Paclitaxel|Paclitaxel was used as first line treatment with AGC.
75966082|NCT03045770|Drug|calcium levofolinate|Calcium levofolinate was used as first line treatment with AGC.
76092389|NCT05431556|Other|Enhanced usual care|EUC arm will be referred to MSK's multimedia page on the Integrative Medicine website to access pre-recorded mind-body videos on their own time. These videos are 15-60 minutes in duration and consist of educational and self-care videos, including guided meditation and Tai Chi.
76092390|NCT05427214|Device|Halcyon 4.0 system|During each of the 1 or more imaging sessions, no more than 6 images total will be acquired. Only 5 images total across all of the imaging sessions will be used toward the study endpoint.
76092391|NCT05416515|Drug|Fisetin|100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days
76092392|NCT05414955|Device|Neuromodulation|Neuromodulation
76092393|NCT05403528|Behavioral|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and retention/generalization as 2D
76092394|NCT05403528|Behavioral|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 3D
76092395|NCT05403528|Behavioral|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
76092396|NCT05399446|Behavioral|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
76092397|NCT05399446|Behavioral|Educational Group|We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
76092398|NCT05379400|Other|Portable air cleaner (PAC)|Commercially available Portable air cleaners (PAC) contain carbon filters that reduce volatile organic carbons and can reduce odors. Because of this, the researchers will remove the carbon filters from all air purifiers to preserve blinding. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
76092399|NCT05379400|Other|Sham Portable air cleaner (PAC)|Sham Portable air cleaner (PAC) are commercially available portable air cleaners with the carbon filters and the HEPA filters removed. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
75511279|NCT03968731|Other|Zocular Eyelid System Treatment|Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.
75657652|NCT05755425|Device|CPAP|CPAP will be delivered with a CPAP valve with venturi flow system with full-face mask. Treatment will start with CPAP set at 10cmH2O and FiO2 60% to target a SpO2 ≥90% or PO2 ≥60mmHg and then adjusted according to SpO2, respiratory distress and clinical tolerance
75657653|NCT05755425|Device|HFNO|HFNO will be applied initially at maximal settings: 100% FiO2, flow rate 60 L/min and temperature 37C . Within 1 to 2 h, the HFNO settings should be titrated based on patients respiratory rate (<25-30 per minute), SpO2 (92-96%) and comfort
75804457|NCT03724578|Drug|Grape Seed Extract mouth wash|participants will use grape seeds extract mouth wash in addition to standard preventive measures
75944745|NCT03425877|Behavioral|Single Task|The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).
75672400|NCT04672850|Dietary Supplement|Probiotic|The participants will consume 2 capsules daily for three months
75672401|NCT04672850|Dietary Supplement|Placebo|The participants will consume 2 capsules daily for three months
75672402|NCT00650520|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
75672403|NCT00650520|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
75804458|NCT03724578|Drug|standard preventive measures|twice daily brushing with fluoride tooth pate and daily flossing
75804459|NCT03724578|Drug|antimicrobial and fluoride mouth wash|using chlorhexidine and fluoride containing mouth wash
75804460|NCT03685552|Other|Prog: Purify-2|"Nutritional Supplements to be administered:~Protein Shakes: one protein shake twice a day~Probiotics (Bacillus Coagulans) once a day~Biome NO+ ( blend of amino acids, specifically l-arginine and l-citrulline, combined with red beet root, grape polyphenol extract, vitamins and minerals) twice a day~In.Form Purify ( blend of psyllium hull, inulin, L-glutamine, fruit, fruit extracts and zinc) twice a day"
75944746|NCT03425877|Behavioral|Dual Task|This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
76092400|NCT05373355|Drug|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
76092401|NCT05373043|Dietary Supplement|Mitoquinone|Mito-Q is a supplement that targets mitochondrial function. Linking a triphenyl-phosphonium cation to coenzyme-Q, to produce Mito-Q, results in a lipophilic compound, which, due to the large mitochondrial membrane potential, selectively accumulates within mitochondria. This targeted antioxidant approach results in 50- to 100-fold more Mito-Q accumulation compared to non-targeted antioxidant delivery.
76092402|NCT05373043|Dietary Supplement|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
75346135|NCT01830686|Other|Sugarcane bagasse|One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
75346136|NCT01830686|Other|Non-caloric, non-fermentable fiber|One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
75346137|NCT01830686|Other|Minimal fiber|One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
75346138|NCT03215654|Other|"EspaiJove.net mental health literacy program"|"The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context."
75346139|NCT01830764|Drug|Red Light (PDT)|LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
75476862|NCT05436197|Behavioral|PLAYshop Program|The intervention includes: 1. Educational Training - the 60 min virtual/hybrid workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be provided with physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
75476863|NCT05429944|Other|Motor Relearning Program|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
75944747|NCT03425877|Behavioral|Rest|At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
75944748|NCT03127449|Drug|Alflutinib|patients take Alflutinib orally once per day at different dose
75944749|NCT03420105|Other|Neuropsychological, psycho-pathological and quality of life assessments|Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
75346140|NCT05313698|Diagnostic Test|No intervention|cross-sectional study/psychometric study
75346141|NCT03215966|Combination Product|Macitentan / tadalafil FDC|Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
75476864|NCT05429944|Other|Proprioceptive Neuromuscular Facilitation|"The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.~The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks."
75476865|NCT05429944|Other|Conventional Physical Therapy|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
75476866|NCT05425199|Other|Habituation exercises + vestibular treatment|"Exercises will include Intensity: 10 repetitions of each set Frequency= 3 sessions per week for 6 weeks.~Time= 30 minutes"
75657654|NCT02785536|Behavioral|RITCh Treatment|"The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together."
75346142|NCT03215966|Drug|Macitentan (Opsumit®)|Film-coated tablets for oral administration formulated at a strength of 10 mg
75657655|NCT02785536|Behavioral|Standard Treatment|The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
75346143|NCT03215966|Drug|Tadalafil (Adcirca®)|Film-coated tablets for oral administration formulated at a strength of 20 mg
75944750|NCT03420105|Drug|Hormonotherapy|Adjuvant hormone therapy
75944751|NCT03425721|Other|No Intervention|No Intervention is administered in this study.
75944752|NCT02521155|Behavioral|Safeguard Your Smile an oral health literacy intervention|"Safeguard Your Smile intervention will consist of following five components:~i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month."
75944753|NCT03415191|Drug|Ketamine|A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision
75944754|NCT03415191|Drug|Normal Saline|A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
75944755|NCT03420027|Other|questionnaire to be filled in by investigators|A simple seven-item questionnaire will be filled in by the investigator before performing urgent tracheal intubation. This intubation, which will be performed as done in routine care, does not constitute a study specific intervention
76092403|NCT05371327|Behavioral|Public deliberation|Public deliberation is a method for engaging the public in collective decision-making. Its goal is to facilitate debate and discussion that: 1) fosters the formation of reasonable and informed opinions, 2) permits participants to revise their perspectives and positions in light of new information and dialogue with others, and 3) encourages participants to consider not only their own preferences but also the greater goal of a policy or resolution that is justifiable for all persons affected by the issue under debate.
75476867|NCT05425199|Other|proprioceptive training + vestibular therapy|Exercise protocol will include Time= total session of 30 minutes . Each exercise will be hold for 30 seconds . Frequency= 3 session per week for 6 weeks Intensity= 10 repetitions and 3 sets
76092404|NCT05367180|Other|MISOLRE prevention program on sun risks|Training of an ambassador class by a field coordinator Dissemination of the information by the ambassador class to the other classes of the school drawn by lot Transmission of an information document to parents on photoprotection to make them aware of the actions to adopt
76092405|NCT05367180|Other|"Vivre avec le Soleil prevention program on sun risks"|Program is delivered directly by the teachers through pedagogical books : 10 workshops over a period of 3 months
76092406|NCT05367180|Other|Sun protection equipment|Distribution of sunscreen, caps and sunglasses
75346144|NCT01522937|Radiation|individualized Stereotactic Body Radiation Therapy (SBRT)|The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.
75804461|NCT03721380|Behavioral|Treatment as usual|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
75804462|NCT03685474|Behavioral|Facing Your Fears - School Based|Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.
75657656|NCT04200222|Diagnostic Test|cadmium, lead and vanadium measurements and compare|"The method developed by Aliyev et al. was used for preparing the samples for analysis (1).~The three metals (cadmium, lead and vanadium) were measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).~1. Ovayolu A, Ovayolu G, Karaman E, Yuce T, Ozek MA, Turksoy VA. Amniotic fluid levels of selected trace elements and heavy metals in pregnancies complicated with neural tube defects. Congenit Anom (Kyoto). 2019:10.1111/cga.12363."
75657657|NCT00874003|Drug|mirtazapine|oral tablet, 30 mg daily
75476868|NCT05425199|Other|conventional vestibular treatment|Epley's Manuever. Frequency= It will be performed once in a week . Time= 10-15 minutes per session
75476869|NCT05423587|Procedure|Genicular Artery Embolisation|Transarterial catheter directed embolisation of hypervascularity in patients with mild to moderate knee osteoarthritis
75476870|NCT05423587|Procedure|Genicular Artery Injection|Transarterial catheter directed injection of normal (0.9%) saline in patients with mild to moderate knee osteoarthritis
75476871|NCT05422534|Dietary Supplement|CoQ10|Participants will receive 1800 mg/day for 12 weeks
75657658|NCT00874003|Drug|placebo|oral tablet, 1 daily
75804463|NCT03685474|Behavioral|Usual Care|Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
75804464|NCT01310946|Other|Database|Database
75804465|NCT03680248|Dietary Supplement|Fat|Subjects will consume dairy cream (150 g of fat) at time 0 hours.
75804466|NCT03680248|Dietary Supplement|Fasting|Subjects will fast throughout the experiment.
75804467|NCT03680248|Dietary Supplement|Fat+Glucose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.
75804468|NCT03680248|Dietary Supplement|Glucose|Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.
75944756|NCT03414957|Diagnostic Test|Hormonal and biochemical blood tests and ultrasound scanning|Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
75944757|NCT03419949|Drug|oral lamotrigine 100 mg|Pain relief drug Lamotrigine inhibits the voltage-gated sodium and calcium channels. Inhibition of the voltage-gated sodium channel stabilizes the presynaptic neuronal membrane, thus preventing the release of excitatory neurotransmitters such as glutamate and inhibiting sustained repetitive neuronal firing
76092407|NCT05359549|Device|Two endosseous dental implants (NobelReplace Groovy®) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of having two failing teeth in the maxillary aesthetic region and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
76092408|NCT05350098|Other|Plant-protein Diets|Participants will consume meals with 70% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
75346145|NCT03215498|Drug|Faster-acting insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
75346146|NCT03215498|Drug|Insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
76092409|NCT05350098|Other|Control Diets|Participants will consume meals with 50% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
75346147|NCT03215108|Device|Endoscopic Retrograde CholangioPancreatography(ERCP)|This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
75657659|NCT04232046|Other|Massage|Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.
75804469|NCT03680248|Dietary Supplement|Fat+Fructose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.
75804470|NCT03680248|Dietary Supplement|Fructose|Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.
75804471|NCT03680170|Behavioral|Working memory updating training|Each training session includes four working memory updating tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
75944758|NCT03419949|Drug|oral pregabalin 150 mg|Pain relief using drug Pregabalin is a structural analogue of the inhibitory neurotransmitter gama-aminobutyric acid (GABA), with anticonvulsant, antihyperalgesic, and anxiolytic properties
75944759|NCT03414879|Drug|Ketamine|While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
75944760|NCT03414879|Drug|Lidocaine|While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
75944761|NCT03419793|Device|segmental vibration device|segmental vibration device
75346148|NCT01441037|Drug|Danazol|Danazol, 800 mg daily by mouth for 2 years
75657660|NCT04915365|Drug|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
75944762|NCT03419793|Other|physical therapy exercises|
75657661|NCT04915365|Drug|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
75657662|NCT03838393|Other|multidisciplinary management|pharmacological and non.pharmacological treatment (specially trained nurses, psychologists and physiologists)
75944763|NCT03414801|Other|Allergen Exposure|Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.
75944764|NCT03425487|Behavioral|Mindfulness based Intervention|MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
76092410|NCT05341986|Other|Clinical Decision Support (CDS) tool|Implementation of an EHR-based CDS tool for providers to use.
76092411|NCT05340998|Procedure|Transradial access for percutaneous coronary procedures|Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion
76092412|NCT05334069|Other|Questionnaire Administration|Complete questionnaire
75804472|NCT03680170|Behavioral|Placebo training|Each training session includes four short term memory tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
76092413|NCT05334069|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
76092414|NCT05331053|Drug|Atorvastatin|Simvastation acts as a systemic LOX inhibitor.
75346149|NCT00891878|Drug|capecitabine|Given orally
75657663|NCT00877669|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
75804473|NCT03568500|Device|Digital Medicine System|DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch [Disposable Wearable Sensor Version 5]); proprietary medical software (a local and remote computing application).
76092415|NCT05323721|Drug|Sulfadoxine pyrimethamine and amodiaquine|This is where children 3-59 months will receive SPAQ for SMC
75346150|NCT00891878|Drug|sunitinib malate|Given orally
75657664|NCT00877669|Procedure|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
76092416|NCT05323721|Drug|dihydroartemisinin-piperaquine|This is where children 3-59 months will receive DP for SMC
76092417|NCT05306873|Drug|Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
75346151|NCT01442129|Biological|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
75346152|NCT01442129|Biological|Control Solution|Injection of control solution during the LVAD implantation.
75346153|NCT01445873|Drug|Sitaxentan sodium|Sitaxentan sodium 100 mg / day
75346154|NCT03838328|Drug|Tranexamic Acid|Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
75346155|NCT03838406|Genetic|BRCA 1|The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.
75346156|NCT03838406|Drug|Chemotherapy|"FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
75944765|NCT03425487|Behavioral|Compassion based Intervention|ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
75944766|NCT03425487|Other|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
75944767|NCT03419715|Drug|Bimatoprost Topical Solution|One drop of bimatoprost topical solution is applied daily to the lunula region of the fingernail bed
75476872|NCT05422534|Drug|Placebo|Participants will receive placebo or CoQ10/day for 12 weeks
75657665|NCT02785146|Drug|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
75944768|NCT03419715|Drug|Control|One drop of saline solution is applied daily to the lunula of the fingernail bed on one hand.
75944769|NCT03618355|Drug|eRapa (encapsulated rapamycin)|"The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).~This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels."
75944770|NCT04706403|Behavioral|Communication from a physician about the COVID-19 Vaccine|Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.
75804474|NCT03568500|Drug|Aripiprazole|Dosage determined by the healthcare professionals.
75944771|NCT03454165|Combination Product|BNC105P|BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.
76092418|NCT05306873|Drug|Placebo for Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
76092419|NCT05306873|Drug|Voclosporin|Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
75346157|NCT01525667|Biological|150M PLX-PAD|Single course, multiple IM injections
75346158|NCT01525667|Biological|300M PLX-PAD|Single course, multiple IM injections
75346159|NCT01525667|Biological|Placebo|Single course, multiple IM injections
75346160|NCT01831310|Dietary Supplement|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
75657666|NCT02785146|Drug|Oxaliplatin|85 mg/m², ivdrip, D1
75657667|NCT02785146|Drug|Calcium folinate|Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
75346161|NCT01831310|Dietary Supplement|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
75476873|NCT05422534|Behavioral|HB-HIIT|Participants will be performed on non dialysis days. It will be video supervised exercise sessions with self directed exercises using pre-recorded bodyweight and strength exercise videos.
75657668|NCT02785146|Drug|5-fluorouracil|400 mg/m², iv, D1; and 2400mg/m², civ, 48h
75804475|NCT03568500|Drug|Olanzapine|Dosage determined by the healthcare professionals.
75804476|NCT03568500|Drug|Quetiapine|Dosage determined by the healthcare professionals.
75804477|NCT03568500|Drug|Risperidone|Dosage determined by the healthcare professionals.
75476874|NCT05422534|Behavioral|Observational|Participant regular activities
75657669|NCT00869635|Drug|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
75657670|NCT00869635|Procedure|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
75804478|NCT03680014|Diagnostic Test|CUSH|Machine learning assisted remote monitoring/ telehealth platform to predict and prevent falls
75804479|NCT03727230|Other|Blood transfusion|"Transfusion with D+ blood rather than the rare D negative blood to Asia type DEL recipients"
75804480|NCT03676894|Device|Sham Fotona SP Dynamis|Female patients with SUI will be treated with non-ablative Er:YAG laser with Fotona SP Dynamis with sham handpiece.
75804481|NCT03676894|Device|Intravaginal Fotona SP Dynamis|Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis
75804482|NCT03676894|Device|Intraurethral Fotona SP Dynamis|Female patients with SUI will be treated intraurethraly with non-ablative Er:YAG laser with Fotona SP Dynamis
75804483|NCT03721302|Other|Main study clinical sepsis|No intervention-Observational study
75804484|NCT03721302|Other|Microbiology sub study|Analysis of Bacterial isolates
75804485|NCT03679858|Other|Platelet function test|Ex vivo platelet aggregation analysis by Multiplate aggregometer
75804486|NCT03727074|Drug|5-FU Cream|topical cream twice a day
75804487|NCT03727074|Drug|Efudex®|topical cream twice a day
75804488|NCT03727074|Drug|Vehicle|topical cream twice a day
75944772|NCT03454165|Combination Product|Ibrutinib|A novel BTK inhibitor.
75944773|NCT03425409|Device|Integra Pulse Portable- Continuous flow|4 liters per minute oxygen flow
75944774|NCT03425409|Device|Integra Pulse Portable- Pneumatic pulsed flow|Oxygen flow determined by test device
75944775|NCT03618277|Procedure|Biopsy|Micro-biopsies will be performed using a punch of 1 mm in diameter, by pulling the skin at the time of sampling, after disinfection and anesthesia.
75944776|NCT03414645|Biological|CAM-101 10%|fibrinogen-depleted human platelet lysate
75944777|NCT03414645|Biological|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
75944778|NCT03414645|Biological|CAM-101 30%|fibrinogen-depleted human platelet lysate
76092420|NCT05306873|Drug|Placebo for Voclosporin|Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
76092421|NCT05306873|Drug|Mycophenolate Mofetil|"Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily"
76092422|NCT05306587|Drug|Darzalex|Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
76092423|NCT05303987|Drug|Propofol sedation|"After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given."
76092424|NCT05303987|Drug|Dexmedetomidine sedation|"After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given."
76092425|NCT05303792|Drug|Cyclophosphamide|Given IV
76092426|NCT05303792|Drug|Vincristine|Given IV
76092427|NCT05303792|Drug|Dexamethasone|Given IV or PO
76092428|NCT05303792|Biological|Inotuzumab Ozogamicin|Given IV
75944779|NCT03618511|Behavioral|Financial Incentive|Financial Incentive: Participants will receive monthly financial incentives each time they refill the ART medication on time for six months
76092429|NCT05303792|Drug|Methotrexate|Given IV or PO
75511280|NCT04716556|Biological|Convalescent plasma|Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia
75944780|NCT03618511|Behavioral|Reminders|Reminders: Participants will receive monthly reminder phone calls before their ART medication refill is due for six months.
75657671|NCT00869635|Procedure|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
75657672|NCT00913965|Drug|Atenolol Tablets 100 mg (Cord Laboratories)|
75657673|NCT00913965|Drug|Atenolol Tablets 100 mg (Stuart Pharmaceutical)|
75944781|NCT03618511|Behavioral|Financial Incentive and Reminders|Interaction: Participants receive both the Financial Incentives and Reminder Calls.
75944782|NCT03618511|Behavioral|Information|Information: show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART.
75944783|NCT03618511|Behavioral|Stigma-relieving|Stigma-Reliving: Upon recruitment, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
75944784|NCT03618511|Behavioral|Information and Stigma-relieving|Information and Stigma-relieving: Upon recruitment, show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART. In addition, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
75944785|NCT02236585|Procedure|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
76092430|NCT05303792|Drug|Cytarabine|Given IV
76092431|NCT05303792|Drug|Methylprednisolone|Given IV
76092432|NCT05303792|Biological|Rituximab|Given IV
76092433|NCT05303792|Drug|Prednisone|Given PO
75672404|NCT00621062|Procedure|High Ligation of the GSV|Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
75944786|NCT02236585|Procedure|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
75511281|NCT00091416|Biological|VRC-HIVADV014-00-VP|
75511282|NCT03897868|Drug|HCP1803|HCP1803
75511283|NCT03897868|Drug|Amlodipine|Amlodipine
75944787|NCT04649307|Behavioral|MI-CBT|Education, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
75511284|NCT03897868|Drug|Losartan|Losartan
75511285|NCT03897868|Drug|Placebo|Placebo
76092434|NCT05303792|Drug|Mercaptopurine|Given PO
76092435|NCT05303792|Drug|Doxorubicin|Given IV
76092436|NCT05302596|Drug|Semaglutide Pen Injector|semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention
76092437|NCT05299528|Behavioral|Direct Feedback|Procedure-specific direct feedback will be provided to surgeon participants through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
75511286|NCT00122889|Drug|Garlic powder with high allicin content|
75511287|NCT00122889|Drug|Garlic powder with low allicin content|
76092438|NCT05299502|Behavioral|Nutritional Intervention|4 individual 1-hour in person (or virtual, according to potential public health restrictions and patients' preference) motivational interviews (12, 18, 24 and 30 weeks) with a registered dietitian will be conducted to elaborate S.M.A.R.T. (Specific,Measurable, Attainable, Relevant, Timely) goals regarding diet, based on the 2019 Canada's Food Guide. Between those individual follow-ups, 4 phone calls with the registered dietitian will be provided (15, 21, 27, 33 weeks). Throughout the study, 10 informative nutritional video clips will also be provided. Participants receiving the intervention will have access to an online Facebook private community to discuss and share experiences, thus maintaining motivation and providing social support.
76092439|NCT05299333|Other|Exercise|High repetition muscle endurance and strengthening exercises Walking
76092440|NCT05290792|Biological|Administration of FluMist (Live Attenuated Influenza Vaccine)|Participants will received the intranasal FluMist vaccine that will serve as a proxy for a viral respiratory tract infection and trigger a mild immune response.
76092441|NCT05279846|Drug|MOB015B|Applied topically for 48 weeks
76092442|NCT05279846|Drug|Vehicle (Placebo Comparator)|Applied topically for 48 weeks
76092443|NCT05268887|Device|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 30-60 minutes
76092444|NCT05268887|Device|GENUS device (Sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 30-60 minutes
76092445|NCT05263284|Drug|8-Chloroadenosine|Given IV
76092446|NCT05263284|Drug|Venetoclax|Given PO
75657674|NCT02785380|Procedure|laparoscopic surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
75804489|NCT03676816|Procedure|vaginal self sampling|This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
75804490|NCT03676816|Procedure|provider-performed endocervical sampling|provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
75804491|NCT03685084|Drug|AAI101 i.v.|600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
75804492|NCT03685084|Drug|Saline 0.9% infusion|Vehicle infusion
75804493|NCT03685084|Drug|Piperacillin i.v.|piperacillin 3 g i.v.
75804494|NCT03685084|Drug|Cefepime i.v.|cefepime 1 g i.v.
75944788|NCT04448457|Drug|Sufentanil Sublingual Tablet|15 mcg with lockout interval of 20 min
75944789|NCT04448457|Drug|Oxycodone oral tablet and oxycodone extended-release oral tablet|Oxycodone hydrochloride 5 mg and Oxycodone extended-release 10 mg
76092447|NCT05255679|Device|Early FES|FES cycling starting 14-21 days post SCI for 6 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
76092448|NCT05255679|Device|Delayed FES|FES cycling starting 3 months (+ 14-21 days) post SCI, for 3 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
76092449|NCT05255003|Biological|Enoxaparin|"I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count < 25,000/µL: hold anticoagulation"
76092450|NCT05255003|Biological|Dalteparin|"I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count < 25,000/µL: hold anticoagulation"
76092451|NCT05255003|Biological|Tinzaparin|"I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count < 25,000/µL: hold anticoagulation"
76092452|NCT05247905|Drug|Lutetium Lu 177 Dotatate|Given IV
76092453|NCT05247905|Drug|Capecitabine|Given PO
76092454|NCT05247905|Drug|Temozolomide|Given PO
75804495|NCT03724422|Radiation|Radiation|A dose of 500cGy will be delivered in 1 fraction to the isocenter. Radiation will be administered no later than 72 hours postoperatively
75944790|NCT03425175|Other|Audio-recoring|Recording of audio through microphone carried bu surgeon and assistant surgeon
76092455|NCT05247905|Other|Quality-of-Life Assessment|Ancillary studies
76092456|NCT05247905|Other|Questionnaire Administration|Ancillary studies
76092457|NCT05246280|Drug|TC99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
76092458|NCT05241860|Other|Pharmacotherapy Discontinuation|Stop hormonal medications (Abiraterone, Enzalutamide, Apalutamide, Leuprolide, Goserelin, Degarelix, Relugolix)
76092459|NCT05241860|Other|Follow-Up|Undergo follow-up
75476875|NCT05422066|Drug|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg on day 1,8,15 for 21 days cycles
76092460|NCT05241860|Other|Questionnaire Administration|Ancillary studies
76092461|NCT05241860|Other|Quality-of-Life Assessment|Ancillary studies
76092462|NCT05235620|Other|PatientToc use in pharmacies|PatientToc has been adapted for use in pharmacies. Patients using specific medications will be prompted to complete questionnaires about their self-reported adherence.
75511288|NCT00122889|Drug|Garlic oil|
75944791|NCT02236663|Behavioral|Usual Care Safety Planing App|The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
75511289|NCT00122889|Drug|Aged garlic|
75511290|NCT04453787|Other|Arch support orthoses with forefoot medial wedge|The degree of forefoot wedge will be 3 degree. If needed, it could be adjusted. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
75511291|NCT04453787|Other|Arch support orthoses|The arch support of the orthoses could be adjusted depends on the evaluation of subject. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
76092463|NCT05228899|Drug|Zofin|1mL of Zofin will be administered intravenously, containing 2-5 x 10^11 particles/mL. Zofin will be diluted in 100 mL of sterile saline.
76092464|NCT05228899|Other|Placebo|1mL of Placebo (normal saline) will be diluted in 100 mL of sterile saline and administered intravenously.
76092465|NCT05224375|Device|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System
76092466|NCT05220501|Diagnostic Test|Micro-US Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MicroUS targets will be identified and sampled.
76092467|NCT05220501|Diagnostic Test|MRI Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MRI targets will be identified and sampled.
76092468|NCT05217966|Radiation|Radiation: Single Pre-Operative Radiation Therapy|Ablative preoperative partial breast radiation therapy
76092469|NCT05217589|Other|Funny/Amusing Video Clips|Participants watch 5-7 minutes of video clips that are funny/amusing in nature
76092470|NCT05217589|Other|Horror/Scary Video Clips|Participants watch 5-7 minutes of video clips that are scary in nature
76092471|NCT05217589|Other|Thrilling/Suspenseful Video Clips|Participants watch 5-7 minutes of video clips that are thrilling/suspenseful in nature
76092472|NCT05216926|Other|Timing of preventive action based on prediction model|Timing of preventive action based on prediction model
76092473|NCT05216926|Other|Hypoglycaemia treatment at hypoglycaemia (usual care)|Hypoglycaemia treatment at hypoglycaemia (usual care)
76092474|NCT05200013|Biological|BAT7104|Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage
76092475|NCT05199376|Device|Cryotherapy|The cryotherapy treatment lasts approximately 30 minutes during which two 10-minute freezing cycles are performed, separated by a reheating phase. During the freezing phases, the temperature is lowered below -40°C in the ablation zone, a temperature that is lethal for the cells.
75346162|NCT01831310|Dietary Supplement|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
75346163|NCT01831310|Dietary Supplement|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
75476876|NCT05422066|Drug|Rituximab|Induction Chemotherapy: 375mg/sqm, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
75657675|NCT02785380|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
75657676|NCT02609451|Procedure|Ileostomy closure|Ileostomy closure at a different time point
75657677|NCT03166332|Behavioral|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and nuts
75657678|NCT03166332|Behavioral|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
75657679|NCT05226481|Other|Trauma-focused cognitive behavioral therapy (TF-CBT)|Trauma-focused cognitive-behavioral therapy (TF-CBT) is an evidence-based method for the treatment of posttraumatic stress among youth.
75657680|NCT02609529|Other|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
75657681|NCT02609529|Other|Placebo|
75657682|NCT02689752|Drug|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
75804496|NCT03679702|Device|Viveve System|Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.
75804497|NCT03724344|Other|Cross section resaerch|Assessment of cognitive (MoCA), mental behavioral symptoms (NPI） the Self-rating Depression Scale (SDS) and the Self-rating Anxiety Scale (SAS).
75804498|NCT03724266|Drug|Chitosan|chitosan will be used as intracanal medication
75804499|NCT03724266|Drug|Calcium Hydroxide|intracanal medication
75804500|NCT03679390|Drug|Ketamine|With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.
76092476|NCT05196984|Device|GENUS device (Active Settings)|Participants in the active condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to active 40Hz settings for 30-60 minutes.
76092477|NCT05196984|Device|GENUS device (Sham Settings)|Participants in the control condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to sham settings for 30-60 minutes.
76092478|NCT05196776|Device|Portable, handheld point-of-care ultrasound device|The patient will have an ultrasound performed using a handheld, portable device.
76092479|NCT05196776|Device|Cart-based point-of-care ultrasound device|The patient will have an ultrasound performed using a traditional cart-based model.
76092480|NCT05189353|Other|Ghrelin|Ghrelin infusion
76092481|NCT05189353|Other|Placebo|Saline infusion
76092482|NCT05170984|Device|CACIPLIQ20®|Application of CACIPLIQ20® by spray, directly on the wound surface, after wound cleaning and debridement, twice a week, until wound closure (or up to 20 weeks maximum).
76092483|NCT05170828|Drug|Cyclophosphamide|pre-transplant conditioning treatment
76092484|NCT05170828|Drug|Fludarabine|pre-transplant conditioning treatment
76092485|NCT05170828|Radiation|Total Body Irradiation|pre-transplant conditioning treatment
76092486|NCT05170828|Drug|Busulfan|pre-transplant conditioning treatment
76092487|NCT05170828|Drug|Mesna|given with cyclophosphamide
76092488|NCT05170828|Drug|Sirolimus|post-transplant treatment for GVHD
76092489|NCT05170828|Drug|Mycophenolate Mofetil|post-transplant treatment for GVHD
76092490|NCT05170828|Drug|Filgrastim|post-transplant treatment for GVHD
76092491|NCT05170828|Drug|Cyclophosphamide|post-transplant treatment for GVHD
75657683|NCT05753865|Drug|SYHX2011|IV infusion, 260 mg/m^2
76092492|NCT05170828|Procedure|Bone Marrow Transplant|Transplant with investigational bone marrow product
75944792|NCT02236663|Behavioral|Personalized App-Based Safety Decision Aid|"Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.~Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.~Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan."
76092493|NCT05142800|Device|Perometer|The perometer uses light sensors to calculate the length and volume of your arms
76092494|NCT05142800|Device|SOZO device|The machine measures the amount of fluid on the arm(s)
76092495|NCT05130788|Behavioral|WeChat Quit Coach|"WeChat Quit Coach intervention will be delivered via WeChat private groups for 6-12 weeks (<30 seconds per day). During the intervention period, participants will receive a text message at a fixed point of time every day (e.g., 8:00 am). The messages are designed to build motivations and skillset to quit smoking. Participants will also receive a daily group discussion question (e.g., If you are to give one piece of advice to someone who has not made the decision to quit smoking, what would you say to his/her?), and be encouraged to respond to the question. Participants can comment on group members' responses and ask questions related to smoking and quitting either in group (so everyone in the group can see the message) or directly to the coach (so only the coach can see the message). The coach will respond to the questions within 24 hours. The PI and the RA will moderate group discussions."
76092496|NCT05130788|Behavioral|Leaflet|Participants in the control group will receive a leaflet with information about existing smoking cessation programs targeting Chinese American smokers.
76092497|NCT05130788|Drug|Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges|Participants in both groups will be offered a 4-week supply of NRT patches and lozenges but not forced to use the medications. The medications are free to participants. If participants want to try or use the medications, the study team will mail the patches and lozenges (with a Chinese version of the instruction) or deliver in person.
75476877|NCT05422066|Drug|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
75804501|NCT03684850|Other|Home-based exercise|Home-based exercises three times per week.
75804502|NCT03684850|Device|Knee brace|Progressive use of knee brace each day during activities of daily living.
75804503|NCT03684850|Device|Biomechanical footwear device|Progressive use of footwear each day during activities of daily living.
75804504|NCT03679234|Other|Routine infant formula|Routine infant formula with probiotic
75804505|NCT03903796|Drug|HS-10234|Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
75804506|NCT03903796|Drug|TDF|Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
75804507|NCT03270748|Drug|GvHD prophylaxis|Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
76092498|NCT05130476|Procedure|Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
76117273|NCT04762667|Procedure|reverse shoulder arthroplasty|"In our work, all patients are performs MSCT of the shoulder joint. The construction of a 3D model is carried out using the obtained data. Taking into account the individual features of the bone structure of the shoulder joint, images of the pilot wire guides, fixing screws and a resection template for the humerus are created. Holes for fixing spokes for the planned structures are also calculated.~Using a 3D printer, models of guides and a resection template are printed. During the reverse shoulder arthropalsty, instead of a standard guide, patient-specific instrumentation are used.~In the early postoperative period, all patients are performs MSCT of the shoulder joint. The obtained data are compared with the results of MSCT of the shoulder joints of patients previously operated on using the standard technique."
75804508|NCT03676426|Other|Web platform for advance care planning/advance directive|Ourcarewishes (OCW) is a web-based platform to document advance care planning based at Penn. OCW contains more detailed content on preferences and values than a standard advance directive and allows electronic sharing with loved ones and transmission to the Penn EHR.
75804509|NCT03676426|Other|Standard advance directive|Patients receive a paper copy of an advance directive used by social workers at Penn Medicine and are encouraged to complete on their own.
75804510|NCT03679156|Device|OCT|Patients were recruited, visual acuity and optical coherence tomography Pictures were taken
75476878|NCT05422066|Drug|Doxorubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
75657684|NCT05753865|Drug|Paclitaxel for injection (albumin-bound)|IV infusion, 260 mg/m^2
75657685|NCT00869869|Drug|melatonin|2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
75657686|NCT00869869|Drug|placebo|placebo
75657687|NCT04213755|Diagnostic Test|ROTEM|ROTEM including INTEM, EXTEM, APTEM, and FIBTEM
75657688|NCT00874315|Other|anti-thymocyte globulin|2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.
75657689|NCT00874315|Drug|busulfan|0.8 mg/kg/dose for total of 8 doses.
75804511|NCT03684772|Drug|ICVT Topical Gel|Digoxin and Furosemide (0.125%)
75804512|NCT03684772|Drug|Furosemide Topical Gel|Furosemide (0.125%)
75804513|NCT03684772|Drug|Digoxin Topical Gel|Digoxin (0.125%)
75657690|NCT00874315|Drug|cyclosporine|1.5 mg/kg/dose every 12 hours.
75657691|NCT00874315|Drug|fludarabine phosphate|30 mg/m2/day for 5 days.
75657692|NCT00874315|Drug|mycophenolate mofetil|15 mg/kg/dose every 8 hours
76092499|NCT05130099|Other|Interdisciplinary complex intervention|"The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components;~Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF).~Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks.~Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes.~Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes."
76092500|NCT05121649|Other|Video streaming|Video streaming as a supplement to telephone during emergency calls for dispatchers at EMCCs
76092501|NCT05090904|Drug|Brensocatib|Oral tablet
76092502|NCT05090904|Drug|Placebo|Oral tablet
76092503|NCT05089682|Device|DBS Stimulation during sleep|Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
75346164|NCT01526213|Drug|Fexofenadine|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
75657693|NCT00874315|Drug|tacrolimus|0.03 mg/kg/day as continuous infusion or 12 hour divided doses
75657694|NCT00874315|Procedure|allogeneic hematopoietic stem cell transplantation|Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.
75804514|NCT03684772|Drug|Vehicle Topical Gel|Vehicle Gel
75804515|NCT03684616|Drug|Statin|continuous statin treatment for 3 months prior to cardiac arrest
75944793|NCT05384743|Drug|Rituximab Monotherapy|Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
76092504|NCT05084417|Other|N/A This is an observational study|As this is an observational study, there are no interventions assigned to either cohort.
75804516|NCT03676114|Drug|ketamine|0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
76092505|NCT05062473|Behavioral|Lifestyle Modification Webinars Focused on Hypertension Control|Participation in a 12-week health education telemedicine curriculum
75657695|NCT05753709|Procedure|Hand sewn end-to-end anastomosis|Hand sewn end-to-end anastomosis (EE) Holding sutures were taken through a seromuscular bite with PDS (Polydiaxonone) 3-0 or Silk 2-0 RB (Round Bodied needle), one each at the mesenteric and antimesenteric ends of the stoma. A posterior layer of Lembert sutures was taken first. The first bite was taken at the anti-mesenteric end and a knot was applied. A Connell stitch was applied at the corner and then the posterior layer was closed using an inverting interlocking continuous stitch till the mesenteric end. Another Connell stitch was applied here to secure the corner and the suture was continued on to the anterior layer which was then closed in a similar manner using a continuous interlocking stitch. The final bite crossed the initial knot and the final knot was applied. An anterior layer of Lembert sutures was taken to reinforce the anastomotic line.
75804517|NCT03676114|Drug|Normal saline|Same volume of normal saline will be administrated
76092506|NCT05055128|Drug|X842|Patients will receive X842 tablets.
76092507|NCT05055128|Drug|X842 Dummy|Patients will receive matching placebo tablets for X842.
76092508|NCT05055128|Drug|Lansoprazole|Patients will receive Lansoprazole capsule.
76092509|NCT05055128|Drug|Lansoprazole Dummy|Patients will receive matching placebo capsules for Lansoprazole.
76092510|NCT05054504|Device|Butterfly iQ|The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
76092511|NCT05054439|Drug|SI-B001|Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
76092512|NCT05054439|Drug|Paclitaxel|The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.
76092513|NCT05053100|Procedure|Biospecimen Collection|Undergo collection of blood
76092514|NCT05053100|Other|Electronic Health Record Review|Undergo electronic health record review
75804518|NCT03504852|Drug|secukinumab 150 mg|sub-cutaneous secukinumab prefilled syringe 150 mg
75804519|NCT03676036|Drug|DS107E|
75804520|NCT03676036|Drug|Vehicle|
75804521|NCT03721224|Diagnostic Test|Kiddie Schedule for Affective Disorders and Schizophrenia|Both of the clinical and control group will be evaluated via Psychiatric semi-structured interview
75804522|NCT03025828|Drug|ACTHar|for 6 months
75804523|NCT03546816|Drug|5mg Serlopitant Tablets|Serlopitant Tablets
75804524|NCT03546816|Drug|Placebo Tablets|Placebo Tablets
75804525|NCT03024970|Device|stenfilcon A lens with solution additive (test)|silicone hydrogel lens
75804526|NCT03024970|Device|stenfilcon A lens (control)|contact lens
75944794|NCT03414333|Procedure|RYGB|RYGB is associated with a increase of circulating GLP-1 (up to ten-fold) especially in response to meal ingestion. This increased availability of GLP1 has been claimed to contribute to restoration of some of the beta-cell function.
75944795|NCT03414333|Drug|GLP-1|GLP-1 is an hormone secreted by gut in response to nutrients ingestion.
76092515|NCT05044897|Drug|SI-B001|administration weekly by intravenous infusion（QW）.
76092516|NCT05038020|Drug|AKST4290|Oral AKST4290
76092517|NCT05038020|Drug|Placebo|Oral Placebo
76092518|NCT05022654|Drug|SI-B001|Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
76092519|NCT05022654|Drug|Irinotecan|The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
76092520|NCT05020457|Drug|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
75944796|NCT03618043|Drug|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.
75944797|NCT02031835|Procedure|BWSTT (3 days a week for maximum of 20 minutes session)|
75944798|NCT03618121|Device|Biofeedback plus gaming (Nevermind)|Participants will receive relaxation training from a trained therapist while receiving biofeedback through the game Nevermind. Participants receive two 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
75944799|NCT03618121|Device|Biofeedback only (The Pip)|Participants receive relaxation training from a trained therapist with biofeedack through The Pip device. The Pip connects with 4 apps, The Loom, Relax & Race, PipStressTracker, and Clarity. All 4 will be used in this study. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
75944800|NCT03618121|Behavioral|Relaxation training|Standard relaxation training protocol often used in clinical care. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
75944801|NCT03618121|Behavioral|Gaming only|"Intervention is identical to the Biofeedback plus gaming (Nevermind) intervention, but in this case participants play Nevermind without any biofeedback. Thus, they receive 2 30-minute sessions of relaxation training per week, for 4 weeks, totaling 8 sessions. During relaxation training, they will play the Nevermind game, but without attaching to any biofeedback devices."
76092521|NCT05020457|Drug|AP or TP|AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.
76092522|NCT05020457|Drug|Docetaxel|Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.
76092523|NCT05009758|Procedure|Blood sampling|Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
75657696|NCT05753709|Procedure|Hand sewn side-to-side anastomosis|Hand sewn side-to-side anastomosis (HSSA) Each end of the stoma was closed using either a single layer of inverting interlocking continuous sutures with PDS 3-0 or Silk 2-0 RB, or a Linear Stapling device. The two closed stumps were then brought adjacent to each other in an anti-peristaltic arrangement. A posterior layer of Lembert sutures was applied using Silk 2-0 RB. The bowel wall was incised using electrocautery close to the suture line. The incision was lengthened up to a width of at least 5-6 cm. The posterior and anterior layer was now closed using the same technique as in HS using PDS 3-0. An anterior layer of Lembert sutures was applied. The mesenteric defect was then closed using a superficial interrupted layer of Silk 2-0 RB.
76092524|NCT05009758|Procedure|Nasosorption|Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
76092525|NCT05009758|Procedure|Oral sampling|For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
75804527|NCT03500094|Drug|Migalastat HCl 150 mg|migalastat HCl 150 mg capsule
76092526|NCT05009758|Procedure|Bronchoscopy|The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
76092527|NCT05009758|Procedure|Nasal biopsy|Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
75804528|NCT03684382|Other|NeW-I group|A 5-week intervention offered to parents of children with chronic life-threatening illness using an internet-based narrative approach with life review elements. After completion of the first four weeks of the intervention, participants will receive a 'legacy' document which is a compiled and edited document of their narrative expression during the first four weeks. This legacy document is structured in a manner that enables participants to find a sense of spiritual well-being and hope in their experience of caring for their child through examination of past experiences and achievements as well as future aspirations.
75804529|NCT03726918|Procedure|Surgery for implantation of a prosthesis|Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
75804530|NCT03566550|Diagnostic Test|MRI scans|Repeated MRI scans imaging digestion of standard meals
75804531|NCT03675958|Other|Johnstone's Pressure Splint|the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching
75944802|NCT03617107|Other|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
75944803|NCT03617029|Device|Microcoil|Needle localization with microcoil
75944804|NCT03617029|Drug|Lipiodol|Needle localization with contrast injection
75346165|NCT01548833|Device|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
75944805|NCT03616873|Other|Early Mobilization|The EM program consists of a progression of functional activities from level of function (LOF) 0 (lowest mobility) to 5 (highest mobility). Each LOF has 3 primary activities designed to promote the patient to the next level. The nurse will begin with mobility activities based on the LOF that matches the patient's current status. The nurse and clinical partner will attempt and/or complete each LOF activity once per shift.
75944806|NCT03616795|Drug|LY3154207|Administered orally
75944807|NCT03616795|Drug|[14C]-LY3154207|Administered orally
75944808|NCT03616639|Drug|Oxycodone|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
75944809|NCT03616639|Drug|Morphine|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
75944810|NCT03616561|Drug|Apremilast|Target nail ultrasound will be performed in patients on apremilast by two expert dermatologists and each one will determine the ecographic parameters described in the protocol. These variables would be measured in one target nail in each patient, the greatest and most severely affected, at the investigator's criterion. The same nail will be assessed in all visits of the study (baseline, weeks 4, 16, 24, 38 and 52) . The ultrasound study will be performed with the same device in both hospitals: Esaote's MyLab ultrasound with a 20 MHz transducer. Prior to the start of the study the investigators evaluated the ultrasonographic inter-intraobserver concordance.
75944811|NCT03617965|Diagnostic Test|Platelet count|All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.
76092528|NCT05009758|Procedure|Nasal sampling|Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
75346166|NCT01548833|Device|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
76092529|NCT05009758|Procedure|Nasal mucosa mRNA sampling|Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
75476879|NCT05422066|Drug|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
75476880|NCT05422066|Drug|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
75346167|NCT01548833|Device|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
75346168|NCT01549223|Drug|Oxytocin Infusion|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
75346169|NCT01549223|Drug|Oxytocin Bolus|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
75346170|NCT01549925|Other|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
75346171|NCT01549925|Device|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
75476881|NCT05419505|Drug|CCH-aaes|Administered by subcutaneous injection.
75476882|NCT05419505|Drug|Antifibrinolytic Agent|Self-administered by participants enrolled in Cohort 7.
75476883|NCT05419258|Device|UPLUG Hemodialysis Connection Device|use of the device UPLUG during 1 month
75476884|NCT05418842|Other|Prehabilitation|In addition to usual care, the prehabilitation group will exercise 3 times a week, starting immediately after diagnosis and throughout the pre-treatment period. Each exercise session will encompass 5-min warm-up and 45-min conditioning exercises. Aerobic training will be performed using low-volume high intensity interval training (HIIT). The HIIT duration is 16-20 minutes and it will be performed with 8-10 intervals of high intensity (1 minute) and 8-10 intervals of low intensity (1 minute). High intensity intervals will be set to an external load that represents 85-90% of estimated VO2Peak. In addition, patients will do resistance training at moderate intensity. Patients will complete 2 sets of 12 repetitions of 5 upper and lower body exercises.
75476885|NCT05414552|Drug|ECP|Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
75346172|NCT00895934|Drug|vorinostat|Given orally
75346173|NCT00895934|Drug|gemtuzumab ozogamicin|Given intravenously (IV)
75346174|NCT00895934|Drug|azacitidine|Given IV or subcutaneously (SC)
75346175|NCT01447121|Device|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
75804532|NCT03675958|Other|Stretching|the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
75804533|NCT03675880|Drug|TAB014|TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)
75804534|NCT03675802|Drug|misoprostol|giving misoprostol to this group
75804535|NCT03675802|Drug|dinoprostone|giving dinoprostine
75804536|NCT03678844|Behavioral|Taekwondo practice|The Taekwondo intervention program consisted of the technical skill development aspect (e.g., blocking, punching and kicking) of the sport and poomse (forms) for 30-min.
75804537|NCT03678844|Other|CONTROL|The participants of the control group engaged in physical activities, including athletics, handball and gymnastic, during two sessions of physical education per week at school.
76092530|NCT05009758|Diagnostic Test|Pregnancy test|In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
76092531|NCT05009758|Other|Medical history of patients, demographic data, concomitant medication, questionnaire|Patients will be asked for their medical history including demographic data and concomitant medication. Details will be noted in the source data file. Furthermore, patients will receive a questionnaire including tools to assess QOL impairment by CRS and asthma
76092532|NCT05009758|Diagnostic Test|UPSIT smell test|University of Pennsylvania Smell Identification Test (UPSIT) smell test will be performed by the patients during the study. It consists of 40 questions in 4 different booklets. The patient needs to scratch a sniff strip with the microencapsulated odorant using a pencil and mark his choice on four-choice multiple-choice questions. The test is then scored by the study team out of the 40 items.
76092533|NCT05009758|Procedure|Spirometry|Lung function will be measured by spirometry in the lung function unit of the Department of Pulmonology. Spirometry will be performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines by authorized and properly certified personal.
76092534|NCT05009758|Procedure|FeNO|Airway inflammation will be evaluated using a standardized single-breath FeNO test in accordance with the lung function unit of the Department of Pulmonology. A single exhalation technique recommended by the manufacturer will be followed. The FeNO measurements will not be performed within 2 weeks of a respiratory infection. The FeNO test will be performed prior to spirometry. Subjects should not eat or drink 1 hour prior to having the FeNO test. Subjects should not use their rescue SABA medication (e.g., albuterol/salbutamol) within 6 hours of the measurement. Inhaled bronchodilators (including ICS/LABA) should be withheld for the effect duration specific to the bronchodilator. If not, the assessment should be postponed till after the required time has passed since the meal or drink or bronchodilator inhalation. The NIOX VERO® Airway Inflammation Monitor will be used to measured FeNO in the lung function unit of the Department of Pulmonology.
76092535|NCT05009758|Procedure|Lung X-Ray|After the bronchoscopy, a lung x-ray will be performed and patients will stay overnight in the ward of the Department of Pulmonology.
76092536|NCT05008848|Behavioral|Smoking Cessation Intervention|Participate in schedule gradual reduction program
76092537|NCT05008848|Other|Health Promotion and Education|Receive cessation support messages
76092538|NCT05008848|Other|Informational Intervention|Receive NCI's Clearing the Air booklet
76092539|NCT05008848|Other|Questionnaire Administration|Ancillary studies
75657697|NCT05753709|Procedure|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis or Functional End-to-end anastomosis (SSSA/FEEA) The two limbs of a Linear Cutter SR55 are placed into the proximal and distal bowel loops of the stoma, facing as far away from the mesenteric border as possible and then fired. If both lumens are of similar size, traction sutures are applied with Silk 2-0 RB at the anterior and posterior termination ends of the staple line. The two ends are pulled away from each other, and a Linear Cutter SR75 is applied just below the edge of the bowel and fired. However, in case of an ileo-colostomy, after the first linear cutter SR55 is fired, the two suture lines are approximated in such a way that they do not get apposed but rather lie adjacent to each other. The lumen is then clamped in SR75 which is then fired.
75804538|NCT03678610|Other|Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A|Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes
75804539|NCT03684148|Other|Motor imagery practice|In detail, they were advised to imagine maximal voluntary isometric contractions (MViC). MViC imagery practice was planned in a progressive manner. Thus, it was performed in two sets of 25 repetitions with 2 minutes of inter-sets rest period, for two weeks, and 10 additional repetitions were added on week three and four, respectively. Each MViC repetition was sustained for 5 seconds, followed by 5 seconds of inter-repetition rest periods. Additionally, after every fifth contraction, participants had a 20 seconds of rest. Following 5 days of MI practice, the participants were advised to take a break from MI for two consecutive days. After hospital discharge, the participants in the MIp group were supplied with an audio description of the exercises to be performed.
75804540|NCT03675646|Drug|Morphine|Intrathecal injection of 250 mcg preservative-free morphine before surgery
75346176|NCT01831388|Other|breathing techniques|"During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:~- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance."
75476886|NCT05413343|Drug|Ceftazidime-avibactam|Patients with severe sepsis and treatment with Ceftazidime-Avibactam will be enrolled. Blood samples at 0 hour, 2 hours, 4 hours, 6 hours, and 8 hours after the first time and the steady state concentration(more than 4 times drug administration) of drug administration will be collected to detect plasma drug concentrations of ceftazidime avibactam.
75476887|NCT05412381|Procedure|platelet rich plasma (PRP) injection|We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP.
75657698|NCT00874393|Drug|Dopamine|Dopamine
75657699|NCT00874393|Drug|Hydrocortisone|Hydrocortisone
75657700|NCT00874393|Drug|Infusion Placebo|Dextrose (D5W)
75657701|NCT00874393|Drug|Syringe Placebo|Normal saline
75804541|NCT03675568|Procedure|Non-cultured keratinocyte suspension|A new method for treatment of burn wounds
75804542|NCT03675568|Procedure|Split skin Graft|A traditional method for treatment of burn wounds
75804543|NCT03675490|Behavioral|ABLE - exercise with interactive technology|Multicomponent exercise with interactive technology - consists of wearable sensors and a screen displaying interaction. When the person does the exercises it produces an arts-based response on the screen (e.g., digital painting).,
76092540|NCT05004987|Drug|Escitalopram Oxalate|The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
76092541|NCT05004987|Drug|Placebo|Daily dose of placebo will mimic that of ESC.
76092542|NCT04991870|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given CB-NK-TGF-betaR2-/NR3C1- intratumorally
76092543|NCT04991870|Procedure|Resection|Undergo surgical resection
76092544|NCT04989504|Other|Best Practice|Receive standard of care
76092545|NCT04989504|Device|Wound Dressing Material|Apply Mepitel Film
76092546|NCT04989504|Other|Quality-of-Life Assessment|Ancillary studies
76092547|NCT04989504|Other|Questionnaire Administration|Ancillary studies
75346177|NCT01831388|Behavioral|Self-Administered Baseline and Transition Dyspnea Indexes|Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
75657702|NCT02786706|Device|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
75804544|NCT03527914|Other|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
75804545|NCT03527914|Other|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
76092548|NCT04981275|Other|No intervention study|This observational study will only collect data, not provide any intervention to participants.
75346178|NCT05315102|Other|Sham intervention|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
75346179|NCT05315102|Other|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
75346180|NCT05315102|Other|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Cerebral Palsy children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
75476888|NCT05412381|Procedure|placebo saline injection|Patients randomized into the control arm will receive the placebo or saline injection
75804546|NCT03678532|Drug|Midazolam|
75804547|NCT03675334|Procedure|Root coverage with collagen matrix graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
75804548|NCT03675334|Procedure|Root coverage with subepithelial connective tissue graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
75804549|NCT03675334|Other|Basic periodontal treatment|profilaxis, coronary polishing and scaling and root planning
75804550|NCT03566238|Drug|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).
75804551|NCT03566238|Drug|Placebo|Placebo identical in appearance to active drug (A4250).
75804552|NCT02894502|Behavioral|Motivational interviewing|The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.
76092549|NCT04974736|Behavioral|iEHR + Navigator|"The iEHR + Navigator intervention consists of an iEHR part of the intervention in the pediatric primary care setting which will include routine screening of families for tobacco use and treatment delivery to parents who smoke and will be linked to the child's electronic health record.~The enrolled parents will also be offered support from Community Health Navigators, who will work with offices to provide customized cessation support to tobacco users, ensuring access to medications and services."
76092550|NCT04968834|Genetic|Genomic profiling|Genomic profiling using CLIA assay
76092551|NCT04965935|Drug|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
76092552|NCT04965935|Drug|Placebo Matching Dapagliflozin Oral Tablet|Placebo will be administered for 12 weeks.
76092553|NCT04957394|Behavioral|Family Partner|"The Family Partner intervention is based on well-known elements for preventing child abuse and neglect, such as 1) high intensity intervention with home visitations, 2) coordination of services, 3) an ecological perspective, 4) parental guidance, and 5) an emphasis on a therapeutic relationship with parents to create trust, change and agency.~Family Partners must have relevant professional background and education, such as social work, child welfare services and other health/welfare occupations. They must have a personal attitude for relation-based service delivery in a home-setting, a long work experience and in-depth knowledge of municipal welfare services.~Each practitioner will follow five families. The estimated duration of the intervention is 12 months, but might go over longer stretches of time if it is considered beneficial for the families. The minimum duration of the intervention is 3 months."
75804553|NCT03678298|Other|Epidemiological/treatment profiles|All consecutively hospitalized adult patients (older than 18 years of age) undergoing surgery, interventional drainage or conservative treatment, with diagnosis of cIAIs (defined as abdominal infections originating in an organ cavity, extending into the peritoneal space, and forming an abscess or peritonitis, will be included in the study.
75804554|NCT03206164|Other|Asynchronous, eLearning Intervention|20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
75804555|NCT03678220|Device|LapAR|LapAR system will be used for guidance during laparoscopic hepatectomy and laparoscopic liver thermal ablation
75804556|NCT03675178|Drug|Anerning particle|Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
76092554|NCT04940286|Biological|Durvalumab|Given IV
76092555|NCT04940286|Drug|Gemcitabine|Given IV
75944812|NCT03617887|Other|Experimental group|"Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus.~The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region in the control group, and a specific work of gluteus medius, added to the previous one, in the experimental group."
76092556|NCT04940286|Drug|Nab-paclitaxel|Given IV
76092557|NCT04940286|Biological|Oleclumab|Given IV
76092558|NCT04939090|Drug|Olanzapine|Given PO
76092559|NCT04939090|Drug|Megestrol Acetate|Given PO
76092560|NCT04939090|Other|Questionnaire Administration|Ancillary studies
76092561|NCT04933266|Procedure|Subpectoral plexus block (low dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 10ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (5ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 5ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
75804557|NCT03675178|Drug|control group|Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
75804558|NCT03678142|Diagnostic Test|analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood|blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)
76092562|NCT04933266|Procedure|Subpectoral plexus block (High dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 20ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (10ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 10ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
76092563|NCT04916600|Device|NET|NET is an investigational device that received CE-Mark in April 2009 as a Class IIa active medical device
75804559|NCT03675100|Procedure|colonoscopic mucosal biopsy|colonoscopic mucosal biopsy was undertaken for every participant
76092564|NCT04887857|Drug|CC-486|Specified dose on specified days
75346181|NCT01550471|Drug|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
75346182|NCT01550471|Drug|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
75346183|NCT01550471|Drug|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
75804560|NCT03678064|Device|Lokomat|16 sessions total. Provided by study PT twice weekly for a period of 8 weeks
75804561|NCT03677908|Other|ElectroEncephaloGraphy|Density ElectroEncephaloGraphy analysis
75804562|NCT03522298|Drug|Paxalisib (GDC-0084)|Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
76092565|NCT04887857|Drug|Venetoclax|Specified dose on specified days
76092566|NCT04878965|Device|Smartwatch|Smartwatch apparatus to measure strong emotions (e.g., anxiety)
76092567|NCT04878211|Drug|Ofatumumab|3 loading doses followed by monthly administrations
75476889|NCT05404308|Other|Consultation with Manipulator in Medical Radiology and a radiotherapist|Weekly consultation with Manipulator in Medical Radiology and a radiotherapist
75804563|NCT03674866|Drug|Insulin degludec|Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
75804564|NCT03623776|Drug|JS001|JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
75804565|NCT03623776|Drug|Pemetrexed|Subjects receive pemetrexed of 500 mg/m^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
75804566|NCT03623776|Drug|Carboplatin|Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
75804567|NCT03623776|Procedure|Thoracic Surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
75804568|NCT03674788|Device|Transcatheter valve intervention|
75804569|NCT03677674|Other|Dehydration|Participants will be dehydrated (2% of their body weight) using sauna.
75804570|NCT04059328|Procedure|Surgical training|This was a gyn laparoscopy training and simulation course
75944813|NCT03617887|Other|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise. The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region.
75944814|NCT03617809|Procedure|Preoperative warming|The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
76092568|NCT04878211|Biological|mRNA COVID-19 vaccine|Pfizer or Moderna mRNA Vaccine
76092569|NCT04878211|Drug|interferon or glatiramer acetate|iDMT
76092570|NCT04862650|Drug|Carboplatin|Given IV
76092571|NCT04862650|Biological|Cemiplimab|Given IV
76092572|NCT04862650|Drug|Paclitaxel|Given IV
76092573|NCT04855578|Other|In-Hopsital Patient Educational Brochure|The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.
75944815|NCT03615313|Biological|PD-1 antibody expressing mesoCAR-T cells|Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
76092574|NCT04855578|Other|Physician Education about Gabapentinoid Prescription|An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
75804571|NCT03674710|Procedure|Standard suction, slow-pull, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
75804572|NCT03674710|Procedure|Standard suction, wet suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
75804573|NCT03674710|Procedure|Slow-pull, standard suction, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
75944816|NCT03617653|Diagnostic Test|Group A|Refer to detailed study Description
75944817|NCT03617575|Dietary Supplement|apo-Lactoferrin|1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf [total of 1.5 mg iron]) in a maize porridge (extrinsically labeled)
75804574|NCT03674710|Procedure|Slow-pull, wet suction, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
75804575|NCT03674710|Procedure|Wet suction, standard suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
75804576|NCT03674710|Procedure|Wet suction, slow-pull, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
75804577|NCT03449030|Drug|TAK-164|TAK-164 intravenous infusion.
75804578|NCT03449030|Drug|89Zr-TAK-164|89Zr-TAK-164 intravenous infusion
75944818|NCT03617575|Dietary Supplement|holo-Lactoferrin|1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
75944819|NCT03617575|Dietary Supplement|FeSO4|1.5 mg FeSO4 as 54Fe in a maize porridge
75944820|NCT03617575|Dietary Supplement|1. FeSO4|10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
75944821|NCT03617575|Dietary Supplement|FeSO4 after 1 day break|10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
75346184|NCT01550471|Drug|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
75346185|NCT01550471|Drug|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
75346186|NCT01550471|Drug|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
75346187|NCT01528319|Device|MG-1|Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
75346188|NCT03215264|Drug|hydroxychloroquine|600-1200mg daily
75944822|NCT03617575|Dietary Supplement|FeSO4 after 2 day break|10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
75944823|NCT02983617|Drug|Tirabrutinib|Administered orally once daily
75944824|NCT02983617|Drug|Entospletinib|Administered orally once daily
76092575|NCT04851028|Behavioral|Music Therapy|Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons & Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).
76092576|NCT04844073|Drug|TAK-186|TAK-186 IV infusion.
76092577|NCT04841096|Drug|A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
75657703|NCT05753631|Procedure|non surgical periodontal treatment|"scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated."
75657704|NCT04199364|Drug|Poractant Alfa 80 mg/mL Intratracheal Suspension|Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.
75657705|NCT00877825|Procedure|dairy food control diet and high- and low- isoflavone soyfood diets|
75657706|NCT04231890|Other|IPI monitoring|Patients in this arm will have IPI monitoring
75804579|NCT03674632|Behavioral|Relaxation meditation tape|The tape used in this study is based on a meditation CD designed for breastfeeding mother (Menelli, 2004). The recording will be transcribed and translated into Chinese language by a certified yoga therapist.
75804580|NCT04058938|Behavioral|Educational handout instrument|The handout was single-paged (front and back), and was titled Pain After Surgery: What to Expect. The handout starts with information on rating pain and expectations for control of pain, not complete absence of pain, after surgery. Mutli-modal approach to pain control is then discussed, including pharmacologic and non-pharmacologic methods that may be used for pain control by the perioperative team and postoperatively.
75804581|NCT04058938|Behavioral|Control|Standard patient counseling
75346189|NCT03215264|Drug|entinostat|3-5mg weekly
75346190|NCT03215264|Drug|regorafenib|160mg daily
75657707|NCT00870025|Biological|human chorionic gonadotropin|200 IU, sc, every 5 days, 4 doses
75657708|NCT00870025|Biological|placebo|diluent, every 5 days, s.c., 4 doses
75804582|NCT03683914|Drug|Dinoprostone 3Mg Vaginal Tablet|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
75804583|NCT03683914|Drug|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
75804584|NCT03721094|Other|Immersive virtual reality|In the IVR environment, four different 360-degrees videos were in sequence played as backdrop during the procedure. The videos reflected real life situations in the operating room with two videos representing calm periods, one video representing a light stressor and one video representing a severe stressor with a bleeding (2 ml/s) being triggered in the simulation. Participants complete the procedures while wearing the head mounted device.
75804585|NCT03448406|Drug|Empagliflozin|Film-coated tablet
75804586|NCT03448406|Drug|Placebo|Film-coated tablet
75804587|NCT03672838|Behavioral|hand-held dynamometer|Strength of one weak muscle group and of the biceps of the dominant arm will be measured using a hand-held dynamometer. An average of three readings will be used as one observation. Three observations per patient will be obtained on one day with a minimum of 15 minute rest period between each observation.
75944825|NCT02983617|Drug|Obinutuzumab|Administered intravenously
75346191|NCT05312528|Procedure|endometriosis surgery|Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.
75346192|NCT05312528|Procedure|other benign condition surgeries|ovarian cystectomy, bilateral tubal ligation, myomectomy etc.
75804588|NCT03674554|Procedure|titanium bases using intra oral luting cement technique|a full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
75804589|NCT03674554|Procedure|transmucosal abutment|a full-arch screw-retained implant prosthesis with transmucosal abutment
75944826|NCT03401203|Procedure|Rotational atherectomy followed by balloon angioplasty|Percutaneous coronary intervention
75804590|NCT03674476|Drug|BMS-986036|Specified dose on specified days
75944827|NCT03401203|Procedure|Balloon angioplasty|Percutaneous coronary intervention
75804591|NCT03623308|Other|Fiber cereal|Whole grain and bran cereal
75944828|NCT03616405|Drug|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
75346193|NCT01447511|Drug|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
75804592|NCT03499028|Other|JointCOACH|Patients randomized to this group will utilize JointCOACH to communicate with their surgical team, receive information
75944829|NCT03419559|Biological|LN-145|adoptive cell therapy (ACT) with autologous TIL therapy
76092578|NCT04841096|Drug|B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
76092579|NCT04841096|Drug|(A2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
76092580|NCT04841096|Drug|(B2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
76092581|NCT04836000|Other|In addition to the conservative treatment, Low-level laser therapy|"For Experimental Group A Gallium-aluminum-arsenide (Ga-Al-As) diode laser instrument (Roland Serie, Elettronica Pagani, Paderno, Italy, Mod IR 27/1) will be used (wavelength 904 nm, 5500 Hz frequency, 27 W maximum power output per pulse, 13.2 mW average power, 0.8-cm2 spot size, 1.6 J of total energy will be delivered per point at each session at a power density of 16.5 mW/cm2, and the cumulative energy per point for all sessions was 16 J).~Ga-Al-As laser therapy will be applied to experimental group patients two times per week for 6 weeks in 10-min sessions. LLLT will be applied over the tuberculum majus and minus, the anterior and posterior faces of the capsule, and the subacromial regions. Each point will be treated for 120 sec. The head of the instrument will be held perpendicular to the body surface and in skin contact without pressure."
76092582|NCT04836000|Other|In addition to the conservative treatment, Low-level laser therapy (turned off)|For Placebo Group In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions. Patients and physiotherapist will be asked to use protective eyeglasses during therapy for safety.
76092583|NCT04836000|Other|Conservative treatment solely|For Control Group All patients using an immobilization bandage up to post-operative 6th week will receive the standardized 6-week supervised rehabilitation program advocated by the same physiotherapist (CK), 7 years of experience in the clinical treatment of rotator cuff tear, after the baseline assessment. Composed of 30 treatment sessions (five days/week) of 45 to 60 minutes, the rehabilitation program will be provided individually to all participants. Physiotherapy sessions will be devoted to strength, mobilizations, stretching, perturbation, and sensorimotor training using motor control exercises, hence, to restore adequate shoulder neuromuscular control. The treatment program will also be included patient education.
76092584|NCT04835961|Other|Maintenace and As needed|This study will record the use of budesonide / formoterol either as maintenance treatment or / or as needed according to standard clinical practice and at the discretion of the treating physician.
75804593|NCT03498560|Device|PSG|PSG data to be collected on the night before surgery to establish level of preexisting sleep disturbance.
76092585|NCT04826874|Behavioral|Affect labeling|Short behavioral intervention teaching affect labeling
76092586|NCT04824612|Device|Photobiomodulation with blue led|Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month. blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J).
75944830|NCT03419559|Drug|Durvalumab|PD-L1 antagonist monoclonal antibody
75657709|NCT04198974|Behavioral|PreVenture Training (PTtT)|"PreVenture TtT model will involve identifying local expert trainers to be trained to train school-based professionals on the PreVenture program. Steps include:~PreVenture Facilitator certification: Trainers participate in training workshops and deliver the program to eligible youth in Cohort 1 and are rated on quality of implementation using the PIFA.~Reliable use of the PIFA: Each trainer demonstrates convergence with the Montreal Team's ratings on a set of previously-recorded PreVenture sessions.~PreVenture Training Workshop Certification: Trainers participate in a one-day TtT workshop to review the main aims and exercises of PreVenture Training. Trainers then record mock TtT sessions in which key components of the PreVenture Training Workshop are delivered to an audience of 4-10 individuals (e.g., class of graduate students). These sessions are rated by the Montreal Team the PreVenture Implementation Fidelity and Adherence-Trainer Scale (PIFA-T)."
75804594|NCT00064701|Drug|Tacrolimus Modified Release (MR)|The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
76025902|NCT05583110|Drug|Trastuzumab|"Run-in Phase:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity [DLT] is seen) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg BID on a continuous dosing schedule."
75346194|NCT01447511|Drug|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
75804595|NCT00064701|Drug|Tacrolimus|The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
75804596|NCT00064701|Drug|cyclosporine microemulsion|The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
75804597|NCT00064701|Drug|mycophenolate mofetil|Oral
75346195|NCT01447511|Drug|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
75346196|NCT01831622|Drug|Ritalin|On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
75346197|NCT01831622|Drug|Placebo|On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
75346198|NCT03215420|Diagnostic Test|MRI 3T|
75346199|NCT01550549|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
75804598|NCT03957525|Other|Pre-Operative Preparatory Virtual Reality Program|The Influence of a Pre-Operative Preparatory Virtual Reality Program on the Self-Assessed Anxiety of Children Undergoing Elective Surgery
75944831|NCT03616327|Device|MATRx in-lab, MATRx plus|The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
75944832|NCT03419247|Procedure|Fresh tumor tissue biopsy|A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
75944833|NCT03419247|Procedure|Blood draw|Blood will be taken by a needle from a vein.
75944834|NCT03419247|Procedure|Archival tumor tissue collection|A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
75804599|NCT03952455|Procedure|Bilateral surgical implantation of DBS system to Nucleus Accumbens|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
75346200|NCT04380818|Radiation|Low-dose radiotherapy|Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later
75346201|NCT04380818|Drug|Hydroxychloroquine Sulfate|200 mg/12h for 5 days
75346202|NCT04380818|Drug|Ritonavir/lopinavir|400/100 mg/12h for 7-10 days
75944835|NCT03615157|Other|Exercise rehabilitation|Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
75944836|NCT03414177|Other|Asthma Subspecialty Follow-up Visits|Pediatric patients with persistent asthma will be recruited to compare outcomes among patients with follow-up visits managed via telemedicine vs. in-person visits.
75944837|NCT02873689|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsule
75944838|NCT02873689|Drug|Placebo|Dexlansoprazole placebo-matching capsules
76092587|NCT04824612|Drug|Triamcinolone Hexacetonide|intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
76092588|NCT04824612|Device|Sham LED|A blue LED without power and biologic effect.
76092589|NCT04804514|Drug|KH001|The study drug is applied to teeth
75346203|NCT04380818|Drug|Tocilizumab Injection [Actemra]|600 mg/day for 1-2 doses
75346204|NCT04380818|Drug|Azithromycin|500 mg/24h for 3 days
75346205|NCT04380818|Drug|Corticosteroid|Corticosteroids (methylprednisolone/dexamethasone/prednisone)
75346206|NCT04380818|Drug|Low molecular weight heparin|low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
75346207|NCT04380818|Device|Oxygen supply|Oxygen
75346208|NCT01448447|Device|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
75346209|NCT01448447|Device|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
75346210|NCT05312294|Biological|Flu-M [inactivated split influenza vaccine] without preservative|Solution for intramuscular injection, 0.5 ml
75346211|NCT05312294|Biological|Flu-M [inactivated split influenza vaccine] with preservative|Solution for intramuscular injection, 0.5 ml
75346212|NCT05311982|Device|DLPFC-R (F4) TDCS|direct current brain stimulation- The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A), combined tDCS in DLPFC-L (F3) and DLPFC-R (F4) simultaneously (Block B) or sham-tDCS (Block C) with equal electrode configuration guaranteed blindness. After the procedures, each participant received the following intervention in the order ABC, BCA or CAB with a period of 1 week between each one. Each block took 3 weeks, organized into: 1) Assessment; 2) Application of stimulation; 3) Reassessment and washout week. Adding 1 more week of final evaluation, the study totaled the period of 10 weeks. During this period, patients were instructed to continue their behavioral/educational treatment and medication routines.
75346213|NCT05311982|Device|DLPFC-L (F3) and DLPFC-R (F4) TDCS|DLPFC-L (F3) and DLPFC-R (F4) (Bock B)
75672405|NCT00621062|Procedure|Endovenous Laser Ablation|Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
75804600|NCT01098591|Other|cell therapy|
75944839|NCT03414099|Drug|Ketum|Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
75944840|NCT03414099|Drug|Placebo|Placebo drink matched for taste and appereance
75944841|NCT02901431|Drug|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
75944842|NCT02901431|Drug|RO5285119|Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
75944843|NCT02873377|Drug|Nicorette Gum|GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
75804601|NCT03674398|Behavioral|Exercise+CT|The exercise+CT group is asked to participate in 30 minutes of aerobic exercise followed by a 20-minute cognitive training (CT) program that targets attention and memory. Training will take place following exercise due to elevated levels of brain-derived neurotrophic factor and increased arousal, which is theorized to benefit cognitive task performance. Computerized CT exercises will be delivered using participants' smartphone. Adherence to the computerized CT program is monitored using electronic data upload after each training session. Participants are asked to engage in three sessions per week with the first week taking place in a lab-setting. Participants are asked to continue the aerobic exercise and CT program at home for the subsequent three weeks.
75804602|NCT03674398|Behavioral|Exercise only|The exercise only group will receive the same exercise prescription as the exercise+CT group. Participants in this group are asked to watch 20 minutes of health-related educational videos post-exercise. Videos are administered via participants' smartphones. After each video session, participants answer multiple-choice questions that assess engagement. Following the first week of treatment in-lab, participants are asked to continue watching health-related videos, post-exercise, for three weeks at home.
75944844|NCT02873377|Drug|Nicoderm CQ|GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
75346214|NCT05311982|Device|sham-tDCS|sham-tDCS (Block C) with equal electrode configuration guaranteed blindness
75346215|NCT02214017|Device|A videotelephone, TandBerg E20,|
75346216|NCT02214017|Behavioral|Behavioral motivation|Optimization of medical care in diabetes
75476890|NCT05404308|Other|Consultation with a radiotherapist|Weekly consultation with a radiotherapist
75476891|NCT05391113|Diagnostic Test|MRI|an fMRI measurement of the BOLD physiological signal for sensory responses
75476892|NCT05391113|Diagnostic Test|EEG|These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
75804603|NCT03683602|Other|PNF group|PNF is used in treatment of musculoskeletal pain of cervical and lumbar spine. Proprioceptive neuromuscular facilitation is a rehabilitation concept widely used by physiotherapists in many countries, in which stimulation of central nervous system is to achieve the highest possible functional level
75944845|NCT02873377|Other|Smoking Quitline Referral|Fax referral to the State smoking Quitline
75944846|NCT02873377|Behavioral|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and follow-up phone call
75944847|NCT03649919|Other||Patients receive routine diagnostic and treatment medications.
75944848|NCT02966795|Drug|Glecaprevir/Pibrentasvir|Fixed-dose combination tablets taken orally once a day.
75944849|NCT04052789|Other|BioHPP PEEK copings veneered with composite resin|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
75944850|NCT03648749|Behavioral|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
75944851|NCT04053257|Other|Hand hygiene compliance observation with video camera surveillance system and performance feedback of the HH rates to HCWs|"Intervention:~We will report baseline HH compliance rates and HAI rates to HCWs during a meeting where all HCWs are present. During this meeting we will remind major infection control measures, give examples of common mistakes they made without violating personal privacy rights of HCWs and patients."
75944852|NCT04053179|Device|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
76092590|NCT04804514|Drug|Placebo|The placebo is applied to teeth
75346217|NCT05311748|Diagnostic Test|Ultrasound and doppler|Penile echocolour doppler ultrasound
75346218|NCT01550705|Drug|Isoniazid|Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
75346219|NCT01831700|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
75346220|NCT01831700|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
75346221|NCT01531439|Drug|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
75346222|NCT01531439|Drug|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
75511292|NCT04453787|Other|Flat insole|The flat insole used as a placebo intervention. The shape of this insole is flat, and made by soft EVA. It only provide shock absorbtion without any support. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
75511293|NCT04729868|Drug|Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)|evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
75346223|NCT01832012|Other|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
75346224|NCT01832012|Other|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
75511294|NCT00122928|Behavioral|Diet|Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
75511295|NCT00122928|Behavioral|Exercise|Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
76092591|NCT04803201|Drug|Cyclophosphamide|Given IV
76092592|NCT04803201|Drug|Doxorubicin|Given IV
75346225|NCT03214874|Drug|Demadex 20mg Tablet|Immediate Release (IR) Torsemide
75346226|NCT03214874|Drug|ER Torsemide 20mg Tablet|Extended Release Torsemide 20 mg tablet given once daily
75476893|NCT05387486|Procedure|Anatomical Landmark technique|anatomical landmarks (sternocleidomastoid muscles, sternal notch, cricoid cartilage, carotid artery and clavicle) will be palpated. A 3cc syringe with 21 gauge needle (locator) will be used first to locate IJV at the apex of the triangle formed by the two heads of the sternocleidomastoid muscle. After successful location, an introducer needle of 18 gauge, attached with a 5 ml syringe, will be inserted at the same point. The introducer needle will be directed towards the ipsilateral nipple at an angle of 20-30° with the skin
75657710|NCT04198974|Behavioral|PreVenture Training+Implementation Facilitation|"PreVenture TtT model + Implementation Facilitation Package:~Youth advisors identified the role of older youth to support program implementation. Youth will help promote PreVenture to students and families and help Facilitators optimize attendance at sessions.~Trainer-led coaching sessions will focus on enhancing program fidelity and acceptability by Facilitators. 'Best practice' supervision elements from efficacy trials will be integrated. Fidelity and symptom monitoring will be conducted in real-time during program implementation.~Performance metrics have been developed based on youth qualitative feedback to PreVenture sessions in previous trials. Analysis indicates key responses that are predictive of students most likely to benefit from PreVenture on 12-month substance use outcomes and indicates the extent to which Facilitator's interventions are leaving students with impressions consistent with positive long-term outcomes."
75657711|NCT00877981|Procedure|Minimal invasive Parathyroid surgery|
75657712|NCT02786472|Behavioral|Online Bystander Training|Large groups of 120-150 students will complete Haven training via computer; training lasts duration of the online program.
75804604|NCT03683602|Other|manual therapy group|"Manual therapy is used for an assessment and treatment of joint and soft tissues.~The basic therapeutic tool is mobilisation. In the study joint mobilisation according to Kaltenborn-Evjenth Manual Therapy was used. The joint were mobilised with low velocity passive movements in the whole or end range. Spinal manipulation wasn't used. Liter Exelby reports that manual therapy with joints mobilisation was quite effective in improvement of functional movements and decreasing of pain."
75804605|NCT03672604|Drug|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
75804606|NCT03674164|Other|Ovarian Cryopreservation|Surgical ovarian removal and vitrification
75804607|NCT03674086|Device|eAdjust 0.2 hearing aid smartphone application (or app)|The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.
75944853|NCT03647813|Radiation|Photobiomodulation|Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
75804608|NCT00064077|Drug|Cisplatin|Given IV
75804609|NCT00064077|Drug|Gemcitabine Hydrochloride|
75804610|NCT00064077|Drug|Paclitaxel|Given IV
75804611|NCT00064077|Other|Quality-of-Life Assessment|Ancillary studies
75804612|NCT00064077|Drug|Topotecan Hydrochloride|Given IV
75944854|NCT03647813|Radiation|Placebo|The same laser protocol was followed but with the device switched off.
75346227|NCT02504268|Drug|Abatacept|
75346228|NCT02504268|Drug|Methotrexate|
75346229|NCT02504268|Other|Abatacept Placebo|
75346230|NCT02504268|Other|Methotrexate Placebo|
75346231|NCT01832168|Procedure|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
75346232|NCT01832168|Other|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
75476894|NCT05387486|Procedure|Ultrasound-guided pre location technique|In Group Ultrasound-guided pre location technique, venipuncture site will be determined using ultrasound probe which will be then removed and locator needle of 21 gauge will be used first to confirm IJV location. The cannulation or venipuncture will be performed at the marked point of locator needle by the use of 18 gauge introducer needle.
75944855|NCT03647735|Other|patient-controlled sedation|Patient-controlled propofol boluses for patients undergoing elective orthopaedic surgery under central neuraxial block
75944856|NCT03647579|Drug|midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine|midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
75944857|NCT03647579|Drug|Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine|Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
75944858|NCT02873221|Drug|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
76092593|NCT04803201|Drug|Vincristine|Given IV
76092594|NCT04803201|Drug|Prednisone|Given PO
76092595|NCT04803201|Drug|Etoposide|Given IV or PO
75346233|NCT01832168|Other|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
75804613|NCT00064077|Drug|Vinorelbine Tartrate|Given IV
75804614|NCT03672448|Other|Naturalistic observation|Naturalistic observation
75804615|NCT03674008|Drug|HSK3486|HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
75804616|NCT03674008|Drug|Propofol|Propofol iv 1.5 mg/kg for induction, and 0.75 mg/kg top-ups for maintenance.
76092596|NCT04803201|Drug|Duvelisib|Given PO
76092597|NCT04803201|Drug|Oral azacitidine|Given PO
76092598|NCT04802720|Other|Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)|"The sessions are outlined as follow:~psychoeducation, goal-setting, and describing the rationale for CBT (Session 1);~coping effectiveness training (Session 2);~identifying unhelpful cognitions and dysfunctional beliefs (Session 3);~challenging and restructuring unhelpful cognitions (Session 4);~behavioral activation within the limitations of the caregiving context (Session 5);~problem-solving (Session 6);~communication strategies and assertiveness training (Session 7);~consolidating gains, maintenance, and relapse prevention (Session 8)."
75346234|NCT00904826|Drug|Eculizumab|"The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months."
75944859|NCT02873221|Drug|Placebo-matching Ubrogepant|Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
75944860|NCT02873221|Drug|Usual Care|Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
75944861|NCT04046861|Dietary Supplement|ascorbic acid,|The vitamin C group will get high dose of intravenous vitamin C (ascorbic acid) before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
75944862|NCT04046861|Other|Placebo (saline)|The placebo group will get saline before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
75944863|NCT02236741|Drug|Mirapexin® (Sifrol®)|
75944864|NCT03616249|Other|Sleep|Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
75944865|NCT03616249|Other|Resistance Exercise|After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
75944866|NCT02966015|Device|Coloplast test catheter|This is a newly developed catheter
75944867|NCT03616093|Other|Test Beet Shot|Active supplement containing 6.2 mmol nitrate
75944868|NCT03616093|Other|Placebo Beverage|Placebo supplement containing negligible nitrate
75346235|NCT01532453|Device|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
75346236|NCT01532453|Other|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
75346237|NCT05311514|Biological|Allogeneic platelet lysate eye drops|Eye drops
75346238|NCT01448525|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
75476895|NCT05387486|Procedure|Ultrasound-guided real-time technique|In Group Ultrasound-guided real-time technique, cannulation or venipuncture will be performed under real-time imaging using 18 gauge needle i-e ultrasound will be used for prelocation and puncturing of IJV and locator needle will not be used
75944869|NCT03616015|Biological|blood samples|20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
75944870|NCT03616015|Biological|fecal samples|1 g of feces (D-8, D0, D15, D30, D90)
75944871|NCT03616015|Behavioral|Anxiety test|Test of Spielberger
76092599|NCT04802720|Other|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|"The sessions are outlined as follow:~psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);~attention regulation skills training (Sessions 1-2);~training in metacognitive skills (Sessions 3-4);~exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);~consolidating gains, taking larger proactive steps, and relapse prevention (Session 8)."
76092600|NCT04798664|Behavioral|Removal of Financial Barriers|Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
76092601|NCT04798664|Behavioral|Financial Incentives|Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
76092602|NCT04798664|Behavioral|Mobile Health Application|Episodic future thinking tool to overcome temporal discounting of future
75346239|NCT01448525|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
75346240|NCT01654302|Drug|Synera|70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours
75346241|NCT01654302|Drug|Inactive patch|placebo patch applied once for 12 hours
75346242|NCT03215186|Other|observational study|
75346243|NCT01832558|Drug|Eplerenone|
75657713|NCT02786472|Behavioral|Online Substance Abuse Training|Large groups of 120-150 students will complete EverFi training via computer; training lasts duration of the online program.
75346244|NCT01832558|Drug|Placebo|
75346245|NCT01551095|Device|PEGJ tube|The self-propelled PEGJ feeding tube
75346246|NCT01832636|Dietary Supplement|Alanyl-Glutamine|Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
75346247|NCT01449305|Device|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
75657714|NCT02786472|Behavioral|In-Person Bystander Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
75657715|NCT02786472|Behavioral|In-Person Combination Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
75657716|NCT00870181|Biological|ADV-TK/GCV|gene therapy
76092603|NCT04796610|Behavioral|Mopati|The intervention will provide training to health care providers on how to guide unsuppressed HIV patients in the selection of treatment partners. The Mopati program will provide education to patients and their treatment partners about HIV treatment and how treatment partners can support patients in treatment adherence.
76092604|NCT04788680|Other|Dietary intervention 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
76092605|NCT04788680|Other|Dietary Intervention 2|Participants receive a beverage with a defined amount of non-nutritive sweetener and maltodextrin.
76092606|NCT04788680|Other|Dietary Intervention 3|Participants receive a beverage with a defined amount of monosaccharide.
75944872|NCT03616015|Behavioral|Stress test|Test of Cohen
76092607|NCT04788680|Other|Dietary Intervention 4|Participants receive a beverage with a defined amount of disaccharide.
75346248|NCT02476422|Drug|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule
75657717|NCT00870181|Procedure|Surgery|
75657718|NCT00870181|Drug|systemic chemotherapy|
75657719|NCT00874627|Other|Milk|sublingual administration of milk
75944873|NCT03648671|Drug|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
76092608|NCT04782258|Drug|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.
76092609|NCT04782258|Drug|Tolvaptan Tablets|Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
76092610|NCT04779307|Drug|Vedolizumab|Vedolizumab IV infusion.
76092611|NCT04767191|Drug|artemether lumefantrine|The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
76092612|NCT04767191|Drug|dihydroartemisinin piperaquine|Antimalarial Combinations
76092613|NCT04765657|Drug|inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)
76092614|NCT04765657|Drug|Placebo|Subcutaneously injected on Day 1, 90, and 270.
75346249|NCT02476422|Drug|Ibuprofen|Single dose of ibuprofen 400 mg tablet
75346250|NCT02476422|Drug|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet
75346251|NCT02476422|Drug|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
75346252|NCT01832792|Other|Face-to-face self-help|Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.
75346253|NCT01832792|Other|E-mail self-help|Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.
75657720|NCT00874627|Other|Milk|placebo
75657721|NCT02786550|Drug|Botulinum Toxin|A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
75657722|NCT02786550|Other|Normal Saline|The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
75657723|NCT05139511|Device|Study group|The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
75804617|NCT03673930|Dietary Supplement|Zanthozylum armatum|Zanthozylum armatum MCT oil extract
75804618|NCT03673930|Dietary Supplement|Placebo|sunflower oil matched for appearance
75804619|NCT00063999|Drug|Carboplatin|Given IV
75346254|NCT01832792|Other|Waiting List|Waiting list condition - participants assigned to a waiting list (no intervention) condition
75346255|NCT03214484|Other|By comparing the evolution of the visual acuity curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
75346256|NCT03214484|Other|By comparing the evolution of the curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
75657724|NCT05139511|Other|Control group|Same procedure but without energy
75804620|NCT00063999|Drug|Cisplatin|Given IV
75804621|NCT00063999|Drug|Doxorubicin Hydrochloride|Given IV
75804622|NCT00063999|Biological|Filgrastim|Given SC
75804623|NCT00063999|Other|Laboratory Biomarker Analysis|Correlative studies
75804624|NCT00063999|Drug|Paclitaxel|Given IV
75804625|NCT00063999|Biological|Pegfilgrastim|Given SC
75804626|NCT00063999|Other|Quality-of-Life Assessment|Ancillary studies
75804627|NCT01095237|Device|ProEndoTecc Vascular Graft|Implantation of the device as an interponate / bypass of the superficial femoral artery
75944874|NCT03648671|Drug|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
75944875|NCT03648671|Drug|rasagilina mesilato (12 weeks)|rasagilina mesilato
75944876|NCT03648671|Drug|rasagilina mesilato (12 weeks)|rasagilina mesilato
75944877|NCT03617341|Procedure|Brain MRI|Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.
75944878|NCT02968433|Drug|Infusions of young plasma|Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
75944879|NCT03647423|Biological|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
75944880|NCT03647423|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
75346257|NCT01450319|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) every 2 weeks until disease progression, death, or consent withdrawal.
75346258|NCT05310656|Behavioral|Mindfulness Based Empowerment Programme|Mindfulness Based Strengthening Program consists of 8 sessions, once a week. Each session has specific goals and objectives, and each session also has a separate theme along with its subject. The subject of the program sessions is as follows: 1st session; Getting to know, explaining the operation plan of the program, defining violence against women and its causes, 2nd session; Emotions and Perceptions, session 3; Being in the Body and Developing Self-Esteem; Session 4, Stress and Meeting Stress with Conscious Awareness; Session 5, The Case of Violence and the Meanings We Ascribe; Session 6, Aware Communication and Conflict Resolution; Session 7, Self-Care and Self-Compassion; Session 8 is Ending the Empowerment Program, Farewell, and a New Beginning. Each session is planned to last an average of 90-120 minutes. Mindfulness teachings and practices will be applied in the content of the program.
76092615|NCT04764331|Device|Revian Red All LED cap|Cap that uses two wavelengths of light, 620 nm and 660 nm will be used once a day for 10 minutes.for treatment
76092616|NCT04754412|Other|Behavioral, Psychological or Informational Intervention|Write about stress and coping, emotional disclosure, and benefit finding
76092617|NCT04754412|Other|Behavioral, Psychological or Informational Intervention|Write about positive thoughts and feelings regarding their breast cancer experience
76092618|NCT04754412|Other|Best Practice|Write about facts regarding their cancer diagnosis and treatment
76092619|NCT04754412|Other|Quality-of-Life Assessment|Ancillary studies
76092620|NCT04754412|Other|Questionnaire Administration|Ancillary studies
76092621|NCT04747522|Drug|SARS-CoV-2 vaccine|SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
76092622|NCT04729504|Behavioral|Adapted Project BRAVE|A culturally and linguistically adapted Project BRAVE is web-based single session intervention that is about 30 minutes in length. The session is designed to focus on targeting child anxiety symptoms in the multilingual and diverse families in Miami-Dade.
76092623|NCT04722666|Drug|MIJ821 Intravenous Injection|MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
75346259|NCT01552343|Drug|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
75346260|NCT01552343|Drug|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
75346261|NCT02475564|Drug|Placebo|40mg of starch
75657725|NCT02784054|Drug|Carboplatin|
75804628|NCT01095315|Other|lateral positioning|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
75804629|NCT01092351|Drug|Nitrofurantoin|100 mg retard capsules to be taken twice daily for seven days
75804630|NCT01098825|Other|web-based survey|Anonymous web-based survey
75804631|NCT03131440|Behavioral|Core|The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
75346262|NCT02475564|Drug|Resveratrol|40mg of resveratrol (powder)
75346263|NCT04381442|Radiation|Low Level Laser Therapy|
75346264|NCT00893984|Drug|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
75346265|NCT01552889|Behavioral|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
75346266|NCT03214328|Diagnostic Test|Determination of causes of fetal death|Determination of causes of fetal death using systematic protocol testing
75346267|NCT01832870|Drug|sipuleucel-T|
75346268|NCT01832870|Drug|ipilimumab|
75346269|NCT01553201|Drug|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
75346270|NCT01553201|Drug|Placebo|Saline, 4cc, one time intramuscular administration
75346271|NCT05313542|Behavioral|Physical Activity|Physical Activity in the format of Self-defence Training
75657726|NCT02784054|Drug|Etoposide|
75657727|NCT02784054|Drug|Cyclophosphamide|
75657728|NCT02784054|Drug|Bleomycin|
75657729|NCT02784054|Drug|Thiotepa|
75804632|NCT03131440|Behavioral|Support Calls|Participants will receive 6 bi-weekly phone calls from study staff.
76092624|NCT04722666|Drug|Placebo Intravenous Injection|40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
76092625|NCT04715555|Device|Electrocardiogram monitoring|Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
76092626|NCT04715555|Device|Electrocardiogram recording|Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
75657730|NCT02784054|Drug|Melphalan|
75657731|NCT02784054|Radiation|Reduced dose radiotherapy|
75804633|NCT03131440|Behavioral|App+|"Participants will receive deluxe version of smartphone app with additional features."
76092627|NCT04715555|Device|Photoplethysmogram monitoring|Photoplethysmogram monitoring using a wearable device on the wrist.
76092628|NCT04715555|Other|Feedback questionnaire|A questionnaire to collect feedback on participants' experiences of wearing the devices.
75804634|NCT03131440|Behavioral|Online gym|Participants will receive access to online exercise videos.
76092629|NCT04711109|Drug|Denosumab|Given SC
76092630|NCT04711109|Drug|Placebo|Given SC
76092631|NCT04711109|Other|Quality-of-Life Assessment|Ancillary studies
76092632|NCT04705896|Biological|20-25% Albumin fluid (100 mL)|"Participants will be randomized to receive albumin (20-25%) during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (i.e. for SLED sessions, at 0 and 4 hours; for IHD sessions, at 0 and 2 hours)."
75804635|NCT03131440|Behavioral|App notifications|Participants will receive motivational app notifications
75346272|NCT03214172|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
75346273|NCT01832948|Drug|Endostar|
75346274|NCT01832948|Drug|Oxaliplatin|
75346275|NCT01832948|Drug|Folinic acid|
75346276|NCT01832948|Drug|5-FU|
75346277|NCT03214016|Other|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
75346278|NCT03214016|Other|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
75346279|NCT01833260|Behavioral|Music|
75346280|NCT01533077|Drug|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
75657732|NCT00874861|Biological|Peptide vaccine + Poly-ICLC|"Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.~Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical & Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine."
75657733|NCT00878137|Device|INR by point-of-care instruments and venopuncture|Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
75804636|NCT03131440|Behavioral|Buddy|Participants will choose a buddy to receive a Fitbit and support them during the intervention.
75804637|NCT03683446|Procedure|Laparoscopic rectal surgery|Minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon.
75804638|NCT03683446|Procedure|Open rectal surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
75657734|NCT02176278|Other|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
75804639|NCT02918734|Device|Endobutton CL BTB|ACL reconstruction with Endobutton CL BTB
75657735|NCT02176278|Other|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c<7%, BP<130/80 mmHg, LDL-C<1.8 mmol/l, triglyceride<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
75804640|NCT02918734|Device|Metal interference screw|ACL reconstruction with metal interference screw
75346281|NCT01533077|Drug|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
75804641|NCT03683368|Device|YpsoPump Orbit soft|Insulin infusion sets will be used for up to 7 days or until failure
75804642|NCT03683368|Device|YpsoPump Orbit micro|Insulin infusion sets will be used for up to 7 days or until failure
75804643|NCT03673696|Drug|HEC74647PA Capsule|Capsule administered orally once daily
75804644|NCT03673696|Drug|placebo|Matching Placebo Capsule
75804645|NCT03683290|Other|Image acquisition and analysis|Oocyte image obtention and analysis prior to intracytoplasmic sperm injection
75804646|NCT03672214|Procedure|Without placement of indwelling catheter|No placement of indwelling catheter prior to Caesarean section
75804647|NCT03672214|Procedure|With placement of indwelling catheter|Placement of indwelling catheter prior to Caesarean section
75944881|NCT03647423|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
75944882|NCT03647423|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1]
75346282|NCT05312684|Procedure|cardiac surgery|cardiovascular surgery including valve repair/replacement or CABG or combined procedures
75346283|NCT05310500|Diagnostic Test|Finishing files of ProTaper Gold (F2) without effect to NaOCL|Finishing files of ProTaper Gold (F2) without effect to NaOCL
75346284|NCT05310500|Diagnostic Test|Finishing files of ProTaper Gold (F2) with effect to NaOCL|Finishing files of ProTaper Gold (F2) with effect to NaOCL
75346285|NCT05310500|Diagnostic Test|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
75346286|NCT05310500|Diagnostic Test|Finishing files of Dia-X ProTaper (D4) with effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
75346287|NCT03213860|Other|Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China|The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The caregiver will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
75346288|NCT01534013|Device|The Imperial College Closed-Loop Insulin Delivery System|The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
75346289|NCT01534013|Device|Open loop|glucose sensor and pump
75346290|NCT03216122|Procedure|Conventional/Delayed Loading|
75346291|NCT03216122|Procedure|Immediate Loading|
75346292|NCT03211988|Drug|Entinostat|Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
75346293|NCT01450397|Biological|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
75346294|NCT03218072|Drug|HLX01|a potential rituximab biosimilar
75346295|NCT01833338|Device|Imaging|All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
75346296|NCT01833650|Dietary Supplement|thymus honey mouthwash|
75346297|NCT03213470|Other|magnetic resonance imaging|
75511296|NCT00122928|Behavioral|Environmental Obesity Program - Healthy Culture|Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
75346298|NCT01833728|Drug|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
75346299|NCT01833728|Drug|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
75657736|NCT02176278|Other|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
75657737|NCT04038853|Drug|1,25-Dihydroxyvitamin D|1,25-dihydroxy-vitamin D3 1000 IU orally daily for 12 months
75657738|NCT04038853|Drug|Placebo|Placebo identical to the study intervention drug
75657739|NCT00878293|Drug|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
75657740|NCT00878293|Drug|MS Continus®|60 mg, capsule, once daily
75657741|NCT00878293|Drug|Placebo|liquid formulation and capsule, once daily
75657742|NCT02066220|Radiation|Radiotherapy without Carboplatin|"Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks~LR Arm after Amendment (Protocol version 11- 17 Nov 2014):~Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks"
75657743|NCT02066220|Drug|Reduced-intensity maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2."
75657744|NCT02066220|Radiation|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
75804648|NCT03683212|Procedure|Early intensive care bundle|"The care bundle comprises a list of items to follow and tick on a handover checklist within 4 hours of ED management:~Treatment of the congestion: (international guidelines and recommendations)~Treatment of precipitating factors~NIV (non-invasive ventilation) if respiratory distress with hypercapnia and pH < 7.35 in absence of contra indication.~Preventive LMWH (low molecular weight heparin) if no pre-existing anticoagulation therapy."
75804649|NCT03672136|Drug|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
75804650|NCT03672136|Other|Concurrent Chemoradiotherapy|Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
75346300|NCT01833884|Other|Collection of blood specimen|Collection of blood specimen for Cytokines dosing scheduled before , during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
75346301|NCT03217682|Other|Music Therapy|Music therapy sessions
75346302|NCT03217682|Other|Massage Therapy|Massage therapy sessions
75511297|NCT04409990|Diagnostic Test|Shear Wave Elastography|SWE value of rectal lesions
75657745|NCT02066220|Drug|Maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients)."
75804651|NCT03673540|Behavioral|CBT+ application|Smartphone application that comprises electronic self-monitoring of food intake, eating disorder behaviors, and mood and ecological momentary interventions
75804652|NCT03672058|Other|Fitness tracker with goal setting and text message feedback|Participants provided with a Fitbit and this will also be linked to Fitabase. The physiotherapist will discuss the participants' baseline physical activity levels and individual patient centred short and long-term goals will be set with each participant. Every week participants will be contacted via text message by their CF physiotherapist. The physiotherapist will review their online data and will provide feedback and encouragement on their progress. Goals will be reviewed for each participant.
75346303|NCT03838250|Biological|Cellgram™ (Bone marrow-derived MSCs)|Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
75346304|NCT03838172|Other|Family impact scale|The family Impact Scale (FIS) will be completed by the parents
75346305|NCT03213392|Drug|Anesthetic Agents|four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
75346306|NCT03219788|Drug|Normal Saline|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
75511298|NCT04371614|Behavioral|Prime Time Sister Circle|The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group.
75511299|NCT00400257|Behavioral|Early detection of heart failure|Early detection of heart failure
75511300|NCT00419887|Drug|Vildagliptin (LAF237)|
75944883|NCT03647423|Biological|GI-6301|Brachyury yeast
76092633|NCT04705896|Other|0.9% Normal Saline (100 mL)|"Participants will be randomized to receive normal saline 100 mL boluses during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (e.g. for 8 hour SLED sessions, at 0 and 4 hours; for 4 hour IHD sessions, at 0 and 2 hours; for CRRT, after starting/randomization then every 12 hours while continuing on CRRT)."
75657746|NCT02066220|Radiation|WNT-HR < 16 years|Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Boost to macroscopic metastases - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
75944884|NCT03647423|Biological|haNK|haNK™, NK-92 [CD16.158V, ER IL-2]
76092634|NCT04702997|Drug|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status
76092635|NCT04702997|Drug|Placebo oral capsule|Capsule containing an inert placebo
76092636|NCT04700969|Other|: A support program to facilitate implementation of evidence-based practice for postoperative urinary retention|A 12-month implementation support program for multi-professional internal facilitator teams
75657747|NCT02066220|Radiation|WNT-HR >= 16 years|Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 14.4 Gy in 8 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 50.4 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
75657748|NCT02066220|Drug|Induction Chemotherapy|Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
75657749|NCT02066220|Radiation|SHH-TP53 M0|"with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks~clinical target volume (CTV): safety margin along typical spread 10 mm: 23.4.Gy in 13 fractions to CTV.~focal RT boost to tumour bed and residual tumour (GTV) (boost: 30.6 Gy in 17 daily fractions of 1.8 Gy)"
75657750|NCT02066220|Radiation|SHH-TP53 M+ (germline)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (cranial) - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (spinal) - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
75944885|NCT03647423|Drug|Avelumab|injection
76092637|NCT04684979|Biological|Hematopoietic Stem Cells from HLA-compatible Related|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
76092638|NCT04684979|Biological|Hematopoietic Stem Cells from HLA Unrelated|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
76092639|NCT04679896|Device|MagnetOs Putty|Procedure: Instrumented posterolateral spine fusion
76092640|NCT04668300|Biological|Durvalumab|Given IV
76092641|NCT04668300|Biological|Oleclumab|Given IV
75804653|NCT03672058|Other|Fitness Tracker only|"Participants will be provided with the Fitbit and educated on how to use it. This will be linked to Fitabase, an online monitoring system for data collection purposes, with the consent of the participants. However no goal setting will be completed and no feedback will be provided to the participants on their physical activity levels"
75804654|NCT03671980|Other|My Medical record website|Website comprising patient records, blood and other test results, useful information on IBD, and messaging service to communicate with IBD team, plus home smartphone faecal calprotectin monitoring.
75944886|NCT03647423|Drug|Cetuximab|Injection
75944887|NCT03647423|Drug|Cyclophosphamide|Capsules
75944888|NCT03647423|Radiation|SBRT|Stereotactic body radiation therapy
75944889|NCT03615781|Procedure|Two week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
75944890|NCT03615781|Procedure|Four week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
75944891|NCT03615781|Drug|Two week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
75944892|NCT03615781|Drug|Four week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
75944893|NCT03646097|Procedure|Angio-PCI|PCI only with angiography and without OCT findings
76092642|NCT04666038|Drug|LOXO-305|Oral LOXO-305
76092643|NCT04666038|Drug|Idelalisib|Oral
76092644|NCT04666038|Drug|Bendamustine|IV
76092645|NCT04666038|Drug|Rituximab|IV
76092646|NCT04665271|Behavioral|Zemedy App|Digital smart phone app that delivers cognitive-behavioral therapy for IBS
76092647|NCT04662827|Dietary Supplement|Palmithylethanolamid|PEA 3x/d
76092648|NCT04662827|Other|placebo|placebo 3x/d
75476896|NCT05384223|Behavioral|RRFT (Risk Reduction through Family Therapy)|RRFT is an adaptation and integration of existing empirically-supported interventions with similar theoretical rationales targeting similar populations, particularly Multisystemic Therapy principles (MST)for adolescent SUP and Trauma Focused-Cognitive Behavioral Therapy (TF-CBT) components for PTSD in youth. RRFT consists of seven primary components: Psychoeducation and Engagement, Coping, Family Communication, Substance Use, PTSD, Healthy Dating and Sexual Decision-Making, and Revictimization Risk Reduction.
75346307|NCT03219788|Drug|Remifentanil 0.1 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
75346308|NCT03219788|Drug|Remifentanil 0.2 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
75346309|NCT01834040|Other|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
75657751|NCT02066220|Radiation|SHH-TP53 (somatic)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45 Gy in 25 daily fractions of 1.80 Gy
75944894|NCT03646097|Procedure|OCT-PCI|PCI with OCT-measurements but no transfer of landingzone-markers to angiography
75944895|NCT03646097|Procedure|ACR-PCI|PCI with OCT-measurements and transfer of landingzone-markers to angiography
76092649|NCT04662125|Drug|caffeine, paracetamol tablet|oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
76092650|NCT04662125|Drug|Oral prednisolone|patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
76092651|NCT04662125|Drug|oral pregabalin|patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
76092652|NCT04654689|Dietary Supplement|Liposomed polyphenols resveratrol and curcumin|Combination of resveratrol (75mg) and curcumin (200mg) liposomed
75476897|NCT05384223|Behavioral|ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)|Encompass is currently a research to practice treatment for adolescents with co-occurring substance use disorders and mental health problems and is used as the standard treatment in the target study settings.
76092653|NCT04654689|Other|Placebo for liposomed resveratrol and curcumin|Water with sucrose replacing the liposomed polyphenols
76092654|NCT04654689|Dietary Supplement|Isocaloric Diet|40% carbohydrates, 40% lipids and 20% proteins
76092655|NCT04654689|Drug|G04CB02|G04CB02, in a single daily dose for 4 months
76092656|NCT04654689|Other|Placebo microcrystalline methylcellulose|Placebo replacing G04CB02
75346310|NCT03213314|Diagnostic Test|Multiparameter magnetic resonance imaging|LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.
75346311|NCT01834118|Procedure|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
75346312|NCT01834196|Device|Swept-Source Optical Coherence Tomography|Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
75346313|NCT03219944|Procedure|Platelet Rich Fibrin|: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone
75476898|NCT05377346|Other|Placement of the i-gel|The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.
75476899|NCT05375929|Drug|Abrocitinib 100 mg|Orally administered, abrocitinib 100 mg tablets QD
75657752|NCT02066220|Drug|Vinblastin Maintenance|Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
75657753|NCT00573391|Drug|Velcade, Thalidomide, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
75804655|NCT03671824|Other|Measurements|Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.
75804656|NCT03671668|Other|titanium bases using intra oral luting cement technique|comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction
75804657|NCT03673384|Device|infrared-C ray irradiation|Infrared-C irradiation by hot compress with a powered heating compress
75944896|NCT02872285|Drug|Drug: LYC-30937-EC|
75944897|NCT02872285|Drug|Placebo|
75944898|NCT03647345|Device|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
75944899|NCT03647345|Device|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
76092657|NCT04606966|Other|Therapeutic Horseback Riding|Horse therapy
76092658|NCT04606966|Other|Barn Activity|Horsemanship group
76092659|NCT04606966|Other|Hybrid|Ground and riding activities
76092660|NCT04606472|Drug|SI-B003|Administration by intravenous infusion.
75346314|NCT03219944|Procedure|sub epithelial connective tissue graft|sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
75346315|NCT03219710|Drug|Ondansetron|Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
75346316|NCT03219710|Drug|Dexamethasone|Dexamethasone will be given as 3mg/m2 IV/PO q8h.
75476900|NCT05375929|Drug|Abrocitinib 200 mg|Orally administered, abrocitinib 200 mg tablets QD.
75944900|NCT03647345|Device|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
76092661|NCT04604275|Drug|Sucrase|1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
76092662|NCT04604275|Other|Placebo|1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
76092663|NCT04603287|Drug|SI-B001|Administration by intravenous infusion.
76092664|NCT04600336|Drug|Oxybutynin Chloride|Given PO
76092665|NCT04600336|Drug|Placebo Administration|Given PO
76092666|NCT04600336|Other|Quality-of-Life Assessment|Ancillary studies
76092667|NCT04600336|Other|Questionnaire Administration|Ancillary studies
76092668|NCT04594876|Other|Flouroscopic guidance cervical epidural versus cervical facet injection|The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.
75944901|NCT04052711|Drug|FMX-101|
76092669|NCT04579848|Drug|Methotrexate Tablets|Methotrexate 2.5mg oral tablet.
75346317|NCT03219710|Drug|Aprepitant|Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (>40 kg) - Day 1 -125mg , Day 2 & Day 3 - 80 mg PO
75346318|NCT03219710|Drug|Olanzapine|olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
75657754|NCT00573391|Drug|Velcade, Melphalan, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
75657755|NCT00590967|Radiation|IMRT extended field external beam radiation therapy|
75657756|NCT00590967|Radiation|Brachytherapy|
75657757|NCT00590967|Drug|Cisplatin|
75346319|NCT01532141|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
75346320|NCT01532141|Drug|Rasagiline|1 mg rasagiline (single-dose)
75346321|NCT03213080|Device|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) procedure.
75346322|NCT04380194|Diagnostic Test|nano-composite screening|Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
75346323|NCT00899600|Drug|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
75657758|NCT02783976|Drug|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
75657759|NCT00878371|Drug|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
75944902|NCT03619265|Dietary Supplement|Prickly pear juice|3 ounces daily for 8 weeks.
75944903|NCT03619265|Dietary Supplement|Pear-flavored juice|3 ounces daily for 8 weeks.
75346324|NCT00899600|Other|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
75657760|NCT05753475|Other|renal transplantation|patients undergoing renal transplantation
75944904|NCT03646955|Radiation|No partial breast irradiation|Omission of radiation therapy
76092670|NCT04579848|Drug|Placebo|Placebo capsule
76092671|NCT04579848|Drug|Folic Acid 1 MG|Folic acid
76092672|NCT04556201|Device|SOLTIVE™ Premium SuperPulsed Laser Fiber System|SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
76092673|NCT04555317|Combination Product|Musculoskeletal health package|3 month prehabilitation exercise program during radiotherapy with assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
76092674|NCT04548154|Other|Proximal Resistance Training|Participants will be prescribed 5 categories of resistance exercises, and each category will have a series of exercises to select from. Two will target hip abduction, two will target trunk muscles, and one will target functional resistance training for the hip and trunk during walking-related tasks such as multi-directional resisted walking. Dosing will be based on guidelines for MS. Strengthening exercises will begin with 3 sets of 12-15 reps at 15 rep-max load (RM) and progress to 3 sets of 8-10 reps at 10-12 RM. Endurance exercises requiring a static hold will progress from 3 sets of 15-20 second holds to 30-second holds. Functional resistance will be dosed to improve muscular endurance: 3 sets of 15-20 reps based on form fatigue.
76092675|NCT04523350|Device|Instylla HES|Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)
76092676|NCT04523350|Other|TAE or cTACE|Bland TAE or cTACE
76092677|NCT04516538|Behavioral|Mini Mental State Examination|test for evaluating a person's cognitive functions and memory capacity
75657761|NCT04230720|Drug|Systane Complete|1 drop 4 times a day for 14 days
75657762|NCT00923299|Drug|cetuximab|Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.
75804658|NCT03673384|Device|eye mask|infrared-C irradiation by hot compress with a powered heating eye mask
75804659|NCT03673384|Drug|Xyzal Oral Product|used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
75804660|NCT03673384|Drug|Fluticasone Furoate|used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
75804661|NCT03673306|Other|Clinical outcomes|Clinical outcomes
75804662|NCT03669796|Dietary Supplement|Marine protein hydrolysate (mph)|Marine (Cod) protein hydrolysate
75804663|NCT03669796|Dietary Supplement|Control|Maltodextrin/Casein
75944905|NCT02871739|Behavioral|Webinar|1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.
75944906|NCT02871739|Behavioral|DA viewing|Participants will receive 3 decisions aids to review.
76092678|NCT04516538|Diagnostic Test|6 Minutes Walk Test|a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
75346325|NCT04379882|Device|Digital Sedation (Silva)|Use of Digital Sedation (virtual reality associated with psychological interventions) for preoperative anxiety management
75346326|NCT03219554|Drug|Palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
75346327|NCT03213236|Diagnostic Test|Homemonitoring diagnostic system|"In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram."
75944907|NCT02871739|Behavioral|SPI feedback|Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
76092679|NCT04516538|Diagnostic Test|Timed up and go|A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
75804664|NCT03673150|Other|non intervention|Observational study / non intervention
75476901|NCT05374967|Behavioral|Lifestyle intervention: Live with IBD|"A digital lifestyle intervention divided into two phases:~An intensive phase lasting six months~a facultative phase lasting six months~During the Intensive Phase, participants will receive regular counseling by a nutritionist and a lifestyle coach in groups of 25 people. Participants will also follow five online meetings focusing on either nutrition, exercise, sleep, and stress. In addition, participants will have 24/7 access to an online platform that contains additional information, challenges, recipes, and peer-support groups. Finally, during the facultative phase, participants can attend smaller group sessions for additional counseling by a nutritionist or a lifestyle coach; these sessions will be organized every six to 12 weeks."
75476902|NCT05374967|Other|Control group|The standard of care for patients with IBD suffering from chronic fatigue.
75476903|NCT05365763|Behavioral|Simulated telehealth serious illness conversation visit|"The study team will instruct the participant to relax, and record biometric data for a total 7 minutes (the beginning two minutes is to allow for physiologic adaptation).~Simulated Encounter The study team will train experienced actors in the same case, a patient with a metastatic soft tissue sarcoma already on second-line chemotherapy. The physicians will receive a simulated medical file that contains a prognosis in a single format: a range-based, time prognosis (e.g. months to a year). The actor script and medical file will be developed by a multidisciplinary team (e.g. oncologist, palliative care, emotion scientist). The encounter will occur via tele-video platform (ZOOM®) and will be video-recorded. During the encounter participant physicians will wear three biometric sensors."
75476904|NCT05363163|Device|Gana X|Injection in the deep dermis and subcutaneous layer of the buttocks on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
75657763|NCT00923299|Drug|trastuzumab|"Two dose levels of trastuzumab will be evaluated for Phase 1:~Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations."
75657764|NCT02783742|Behavioral|Communication coaching|Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.
75657765|NCT04030065|Drug|Omega 3 fatty acid|10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
75657766|NCT02689830|Device|Bead Block|Prostate embolization
75804665|NCT02915302|Biological|Fluzone Quadrivalent vaccine, No Preservative|0.25-mL (Pediatric Dose), Intramuscular (2016-2017 formulation)
75804666|NCT02915302|Biological|Fluzone Quadrivalent vaccine, No Preservative|0.5-mL, Intramuscular (2016-2017 formulation)
75804667|NCT03671512|Device|Periodontal Structure Repair (PSR)|Following local anesthesia, initial pocket preparation will be done by bur abrasion utilizing specially designed burs to plane the root surface and remove the inner lining of the pocket. Following bur abrasion, thin strips of gauze sponge are placed into the created space. After removing the gauze strips, PSR is inserted to fill the spaces beginning at the pocket bottom. The final step is placing a layer of cyanoacrylate on both the gingival margin and tooth supragingivally.
75346328|NCT03837782|Procedure|minimally invasive surgery|Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery. No individual surgeons performed only the open approach or only the minimally invasive approach. The committee members reviewed the patients' outcomes and the videos to ensure the adequacy of the surgeon's technique.
75804668|NCT03671512|Device|Standard Root Planing|Ultrasonics and hand instruments are used to remove any subgingival deposits on the roots. Standard instruments and standard application are used. Visual or instrument tactile inspection is used to verify the roots are hard-smooth and have been adequately cleaned.
75944908|NCT02032069|Other|no intervention|
75944909|NCT03621683|Procedure|blood rich plasma platelets|Injection of blood rich platelet into the ovaries.
75944910|NCT03621683|Dietary Supplement|Antioxidant therapy|"Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3"
75944911|NCT03376867|Other|Conditioned pain modulation|Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.
75476905|NCT05347901|Diagnostic Test|Echocardiography, Genomics NGS sequencing|The inner diameter of left main coronary artery, anterior descending branch, circumflex branch and right coronary artery was measured by echocardiography. Blood samples were send for genomics NGS sequencing
75476906|NCT05346965|Behavioral|Musical training|The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.
75657767|NCT05753397|Drug|Ropivacaine injection|We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
76092680|NCT04516538|Diagnostic Test|Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest)."
75657768|NCT04230798|Other|Injury prevention program|The intervention program consisted in 16 sessions, performed during eight weeks, twice per week. Intervention group performed 20 minutes sessions before their habitual volleyball training. The structure of the prevention program consisted in a warm up, a lower limb strength exercise; two core exercises; a lower limb plyometric exercise, and a lower limb stability exercise. While the injury prevention program was being performed, both groups continued with their volleyball training sessions.
75944912|NCT05284331|Other|addition of two follow-up visits post infection|"Addition of an additional follow-up visit 6 months post infection and one follow-up visit 1 year post infection.~No treatment will be given specifically for this study. The change in medical management will only be modified by the addition of these 2 consultations at 6 months and 1 year post infection"
75657769|NCT00875173|Drug|Selenium|selenium as a drug according to Brazilian regulation laws
75657770|NCT00875173|Drug|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
75944913|NCT03614845|Procedure|VCV|after induction for anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode
75944914|NCT03614845|Procedure|PCV-VG|after induction for anesthesia patients will be supported by mechanical ventilation on pressure controlled and volume guaranteed ventilation mode
75944915|NCT03614845|Diagnostic Test|lung ultrasonography|all patients will be performed lung ultrasonography pre and postoperatively
75944916|NCT03621605|Biological|VIB9600|"Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29)."
75944917|NCT03621605|Drug|Placebos|Placebo administered by slow IV infusion or SC injection.
75944918|NCT03614065|Drug|endostar|endostatin
75944919|NCT03614065|Drug|Placebos|saline solution
75944920|NCT03614065|Radiation|radiotherapy|radiotherapy
75944921|NCT03621527|Other|anesthesia combined with intravenous analgesia by remifentanil|intravenous analgesia by remifentanil is provided and adapted to the patients' needs during the whole procedure
76092681|NCT04516538|Diagnostic Test|Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM)."
75657771|NCT04039477|Drug|KZR-616|Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
75804669|NCT03023878|Drug|Blinatumomab|Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.
75804670|NCT03023878|Drug|Investigator's Choice Chemotherapy|"During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide)."
75804671|NCT03023878|Drug|Dexamethasone|Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).
75804672|NCT03671356|Other|risk score|risk score
75944922|NCT03621527|Other|fluoroscopy-guided epidural anesthesia|Identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure
75944923|NCT02032147|Drug|NGF group|This group will be treated with NGF 18u per day im for 60 days
75944924|NCT03647189|Device|Hybrid Fractional Laser|Hybrid Fractional Laser
75944925|NCT03645317|Diagnostic Test|Blood tests & cardiac imaging|Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
75944926|NCT03615625|Behavioral|Power Training Session|"3 sets of 8-10 repetitions of 5 exercises performed in the following order: leg press, bench press, knee extension, upright row, and knee flexion, using an intensity corresponding to 50 % of 1-RM and two-minute intervals between sets and exercises. The concentric phase of exercises during each repetition was performed as fast as possible while the eccentric phase lasted 1-2 seconds."
75944927|NCT03646799|Drug|CKD-387|test drug
75944928|NCT03646799|Drug|D484|reference drug
75944929|NCT03646721|Drug|DA-1241|"[Part1] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~[Part2] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)"
75944930|NCT03646721|Drug|Placebo|[Part1] Administration once daily for 28 days. [Part2] Administration once daily for 56 days.
75657772|NCT04029831|Drug|Propofol and Ketamine Mixture (Ketofol)|Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
75804673|NCT03671278|Other|STarT Back Screening Tool Approach|Patients classified as low risk of persistent pain will be educated about their condition and how to manage their back pain by targeting modifiable prognostic factors. Patients classified as medium risk will receive evidence-based physical therapy. Patients classified as high risk will receive evidence-based physical therapy as well as individualized psychological intervention.
75804674|NCT03670888|Biological|JHL1101|100 mg/10 mL solution in a single-use vial
75944931|NCT03646721|Drug|Sitagliptin|[Part2] Administration of Sitagliptin 100mg once daily for 56 days.
75944932|NCT04052399|Device|anodal transcranial direct current stimulation|"Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
75944933|NCT04052399|Device|cathodal transcranial direct current stimulation|"Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
75944934|NCT04052399|Device|transcranial direct current stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds)
75944935|NCT03613831|Device|patient who used Rhythmia system and Orion catheter|suitable for Rhythmia system and Orion catheter according to relevant clinical guidelines and products instruction for use, per investigator's discretion
75346329|NCT01554371|Drug|Eribulin|"Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only"
75346330|NCT01554371|Drug|Cyclophosphamide|Given IV
75346331|NCT03219398|Procedure|Pneumoperitoneum pressure|Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
75657773|NCT05753241|Other|no intervention|It's only observational study. No interventions.
75657774|NCT00875251|Device|body composition|Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
75657775|NCT04230642|Device|The Quantum Surgical device|Robotic platform for needle placement
75804675|NCT03670888|Biological|Rituximab|100 mg/10 mL solution in a single-use vial
75944936|NCT03646643|Procedure|Standard Atrial fibrillation ablation|The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.
75944937|NCT03646643|Procedure|Coronary sinus to left atrium connection elimination|Distal coronary sinus pacing will be utilized to localize distal connections between the main coronary sinus body and the left atrium. Focal lesions will be applied to early left atrial activation sites, until no distal coronary sinus to left atrial connections are electrically manifest. If vein of marshall connections to the left atrium are present, differential pacing will be utilized to prove the lack of distal coronary sinus to left atrium connections.
75944938|NCT03613753|Drug|irinotecan plus lobaplatin|irinotecan plus lobaplatin chemotherapy
75944939|NCT03613753|Drug|irinotecan|irinotecan chemotherapy alone
75944940|NCT04051853|Drug|Sorafenib|Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.
75944941|NCT04051853|Other|Midazolam clearance test|Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
75944942|NCT04051853|Other|CYP cocktail clearance test|In a subgroup of 15 patients (in the Academic Medical Center Amsterdam), this test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
75346332|NCT01834352|Drug|Walnut Protein Flour|Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
75346333|NCT01834352|Drug|Oat flour|Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
75346334|NCT01451411|Drug|Conivaptan hydrochloride|Intravenous
75346335|NCT01451411|Drug|Placebo|Intravenous
75346336|NCT01834430|Dietary Supplement|enteral nutrition|
75346337|NCT03837938|Drug|Levopront® syrup 30 mg/5 ml|The first study drug administration will be performed at the clinical site on the day of randomization; the last study drug administration will be performed in the evening before Day 8 (±1).
75346338|NCT03837938|Drug|Libexin®|The first study drug administration will be performed at the clinical site on the day of randomization; the last study drug administration will be performed in the evening before Day 8 (±1).
76092682|NCT04516538|Diagnostic Test|Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest)."
76092683|NCT04462159|Behavioral|Risk Reduction Program|Education, exercise, teaching kitchen and nutrition, and psychological support
76092684|NCT04449991|Procedure|Repeat kidney biopsy|Intensification of immunosuppression if NIH AI > 3
76092685|NCT04445662|Behavioral|Financial incentives|Escalating financial rewards for saliva cotinine levels <30 ng/mL, assessed 10 times over 12 weeks
75804676|NCT03022630|Other|Comprehensive Palliative Care services|Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
76092686|NCT04445662|Drug|Varenicline|"Day 1 - 3: 0.5 mg daily~Day 4 - 7: 0.5 mg twice daily~Day 8 - Week 12: 1 mg twice daily~Dose/schedule may be adjusted based on medical history and clinician judgement"
75944943|NCT03646409|Other|Venous thromboembolic event, arterial thromboembolic event, bleeding events|Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
76092687|NCT04445662|Behavioral|Tobacco coaching|5 one-on-one tobacco cessation coaching sessions over 12 weeks
76092688|NCT04440670|Biological|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth
75944944|NCT03646331|Drug|Imeglimin Reference product|Reference product
76092689|NCT04440670|Biological|normal saline|preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth
75346339|NCT01554683|Drug|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
75944945|NCT03646331|Drug|Imeglimin|Test product (new formulation tablet)
76092690|NCT04435834|Drug|Propofol or Sevoflurane|Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.
76092691|NCT04429958|Other|GDM|different degrees of hyperglycaemia during pregnancy
75657776|NCT04029675|Dietary Supplement|Vitamin C|Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
75657777|NCT00878449|Drug|ABT-263|150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
75657778|NCT00878449|Drug|etoposide/cisplatin|etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
75657779|NCT02783352|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair
75657780|NCT02783352|Procedure|autologous micro-fragmented adipose tissue|injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
75657781|NCT06167759|Other|Opioid Use Agreement|This was previously developed specifically for surgical patients using a modified Delphi method with a group of experts (including surgeons, nurses, advanced practices providers, quality improvement experts, and patients).
75657782|NCT06167707|Drug|SCP-111|Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose
75657783|NCT06167707|Drug|Furosemide USP|Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later
75657784|NCT06167642|Drug|Ofatumumab|Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
75657785|NCT06167629|Diagnostic Test|PET 18F-PSMA|Subjects will be subjected to a PET examination according to international guidelines and where requested by the specialist. In particular, patients will be administered the radiopharmaceutical 18 F PSMA. Approximately two hours after administration, the patient is positioned on the PET/CT equipment table and image acquisition begins.
75657786|NCT06167590|Diagnostic Test|GAPsy protocol|Each participant will undergo a 7 T multimodal neuroimaging session, including T1-weighted, 1H-MRS and fMRI. Each participant will also be assessed through a structured clinical interview (SCID-I e SCID-II) and will be administered scales such as HAM-A, HAM-D, BPRS and MADRS.
75944946|NCT03869177|Other|Implementation support program|"The IFIP intervention consists of the following elements:~I. Clinical interventions 1.1 A basic level of family involvement and support 1.2 Family psychoeducation in single-family groups~II. Implementation interventions 2.1 Training and guidance of health care personnel 2.2 A family coordinator 2.3 Other implementation measures"
75944947|NCT03645629|Diagnostic Test|skin test with food at different storage times|Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
76092692|NCT04428190|Dietary Supplement|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
76092693|NCT04428190|Other|Placebo|Sachet manufactured to mimic 10g of HMO
75346340|NCT04380584|Diagnostic Test|plasma Apelin level|blood sample for detection of plasma Apelin level
75944950|NCT03843593|Behavioral|Demographics Questionnaire|A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.
75346341|NCT01452191|Behavioral|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
75346342|NCT01452191|Behavioral|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
75476907|NCT05345405|Behavioral|Dyadic CARE|Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
75657787|NCT06167564|Diagnostic Test|Routine allergy tests|Prick test, specific IgE detection
75804677|NCT03022630|Other|Usual hepatic care|Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
75804678|NCT03023722|Drug|anetumab ravtansine|Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle
75944951|NCT03843593|Behavioral|Adjuvant Treatment Beliefs Scale10|This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 [definitely not], 2 [probably not], 3 [maybe], 4 [probably], 5 [definitely]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.
75944952|NCT03843593|Behavioral|Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11|FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.
75944953|NCT03843593|Behavioral|Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13|FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.
75944954|NCT03843593|Behavioral|Decisional Regret14|This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 [Strongly Agree], 2 [Agree], 3 [Neither Agree Nor Disagree], 4 [Disagree], 5 [Strongly Disagree].
75944955|NCT03843593|Behavioral|Clinician Preference for Treatment|This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts adjuvant therapy.
75346343|NCT00905060|Biological|HSPPC-96|Autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.
75657788|NCT06167564|Diagnostic Test|Newly developed microarray-based diagnostic test system|Newly developed microarray-based diagnostic test system for the detection of the specific IgE
75657789|NCT06167538|Other|Decannulation|From the 1st of September 2021, the investigators started to perform decannulation earlier after admission to the Department of Brain Injury. Before attempting to decannulate a patient, several factors were considered and assessed by the patient's treating team: patient's level of consciousness, hemodynamical stability, need for and frequency of salivary aspiration, cough strength and respiration frequency. Patients could not be under treatment for pneumonia and simultaneously have respiratory instability at the time of decannulation.
75657790|NCT06167473|Biological|umbilical cord-mesenchymal stem cells|Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein
75804679|NCT03670732|Other|continuous positive airway pressure|Continuous positive airway pressure is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
75804680|NCT03670732|Other|nasal intermittent positive pressure ventilation|NIPPV is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
75804681|NCT03623230|Procedure|Ultrasound Guided Femoral Nerve Block|Femoral nerve block will be applied post-operatively with guidance of USG and nerve stimulator
75804682|NCT03623230|Other|Dressing|Only dressing will be applied to related area to protect blindness between groups
75944956|NCT03645551|Diagnostic Test|checkup, no test|In this study we would like to examine if existing restorations already applied in teeth which we treated with laminate veneers had an effect. We will evaluate the laminate veneers by sight and take pictures and use a questionnaire
75944957|NCT03646253|Other|Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)|
75944958|NCT03645473|Device|Monarch Airway Clearance System|HFCWO Airway Clearance Device
75944959|NCT03838991|Other|Blood sample|A study specific blood sample will be collected.
75944960|NCT03838991|Other|Waste bone tissue|For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
75944961|NCT03816995|Device|CleanCision Wound Retraction and Protection System|wound retraction and irrigation
75944962|NCT03816995|Device|Alexis O Wound Protector|wound retraction
75944963|NCT03614767|Diagnostic Test|urodynamics|Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
75346344|NCT00905060|Drug|Temozolomide|Maintenance temozolomide treatment is given 2 weeks after administration of the fourth vaccine at an initial dose of 150 mg per square meter (mg/m2) for 5 consecutive days in a 28-day cycle. The dose was increased to 200 mg/m2 for 5 days in subsequent cycles.
75346345|NCT00905060|Procedure|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
75346346|NCT01535573|Drug|Citalopram|20 mg once per day for 9 weeks
75346347|NCT01535573|Drug|Citalopram|40 mg per day for 9 weeks
75657791|NCT06167447|Other|questionnaire and examination|Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.
75804683|NCT03623230|Drug|Bupivacaine 0.25% Injectable Solution|Perineural Injection
75944964|NCT03643835|Device|Thermal Rehab Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
75944965|NCT03643835|Other|Forearm Ice Towels|Towels that are wetted with ice water and wrapped around participants forearms (length of arm from wrist to elbow)
75944966|NCT03645161|Diagnostic Test|rat and mouse skin test|Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
75944967|NCT03645083|Behavioral|Telephone call|Participants in the intervention group receive a one-time telephone call reminder to attend follow-up treatment at the acupuncture clinic
75944968|NCT03645083|Behavioral|Text message|Participants in the intervention group receive a one-time text messaging reminder to attend follow-up treatment at the acupuncture clinic
75944969|NCT03645005|Behavioral|"My Guide (psychoeducation & self-management program)"|"My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks."
75944970|NCT03645005|Behavioral|"My Health (health education program)"|"My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks."
75944971|NCT03644459|Biological|LYN00101|"Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg."
75944972|NCT03643757|Procedure|Thoracic epidural analgesia|Before the initiation of the procedure, in the intervention group epidural catheter was inserted by loss of resistance method at the level of T3-T7 with the help of an 18 G Thuohy needle (Pajunk, Geisingen, Germany) while the patient was on sitting position. A test dose of 2 ml, 2% Lidocaine HCL was administered through the catheter. Once, efficacy was confirmed, 10 ml bolus dose of 0.1% Bupivacaine was injected. Analgesia maintenance was provided by infusion of 0.1% Bupivacaine (0.1 ml/kg/hour) both intra- and postoperatively for 24 hours.
75944973|NCT03643757|Drug|Bupivacaine|In addition to multimodal analgesia protocol, epidural bupivacaine was administered in TEA arm and pain relief was achieved by intravenous pethidine infusion in IVA arm.
75944974|NCT03718793|Diagnostic Test|Peripheral exhaled nitric oxide|Small airway inflammation and dysfunction will be measured using the above mentioned tests.
75944975|NCT02896361|Device|Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol|Stimulation parameters are reprogrammed from original values to study defined ones
75944976|NCT03643679|Other|Kwit smartphone app|The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
75944977|NCT03621371|Behavioral|Metacognitive therapy|Metacognitive therapy is a form av cognitive-behavioral therapy which aims to change cognitions about worry in patients with generalized anxiety disorder.
75944978|NCT03621371|Behavioral|Intolerance of uncertainty therapy|Intolerance of uncertainty therapy is a form av cognitive-behavioral therapy which aims to reduce cognitive and behavioral avoidance of uncertain situations or cognitions which lead to worry in patients with generalized anxiety disorder.
75346348|NCT01535573|Drug|Placebo|0 mg per day for 9 weeks
75346349|NCT01452425|Device|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
75346350|NCT01452425|Device|INVOS assessment|Near Infraread spectroscopy, non invasive
75657792|NCT06167421|Procedure|Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique|The laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique is defined as a surgical procedure that aims to remove the distal part of the pancreas while preserving the spleen by maintaining the splenic artery and vein (Hepatogastroenterology. 2003;50:2242).
75804684|NCT03623230|Drug|Bupivacaine 0.125% Injectable Solution|Perineural Injection
75804685|NCT04058704|Drug|Icotinib|125mg Tid/375mg per day
75346351|NCT01452425|Device|EMG assessment|Electromyography, non invasive
75346352|NCT00905450|Drug|BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
75346353|NCT00905450|Drug|Vehicle for BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug dose schedules.
75804686|NCT04058704|Radiation|SRS/WBRT/HA-WBRT/SMART|>3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
75804687|NCT03670654|Other|Pilates|The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
75346354|NCT01536197|Procedure|Gastric bypass|Roux-en-Y gastric bypass
75657793|NCT06167421|Procedure|Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique|Warshaw technique laparoscopic spleen-preserving distal pancreatectomy is defined as a surgical procedure that aims to preserve the spleen while removing the distal part of the pancreas. It involves ligating the splenic artery and vein, while preserving the left gastroepiploic artery and short gastric vessels (Arch Surg. 1988;123:550).
75944979|NCT03703895|Drug|Topical AFX5931|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
75944980|NCT03703895|Drug|Topical Placebo|Placebo Comparator, Topical Placebo.
75346355|NCT01536197|Procedure|Gastric banding|Laparoscopic adjustable gastric banding
75944981|NCT03643601|Other|Non-Interventional|Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs
75657794|NCT06167382|Other|Questionnare|Demographic Survey Form,the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+),Goniometric Measurements, Digital Dynamometer Measurements, Hand Grip Measurements, Hand Reaction Measurements, Dexterity and Function Measurements, Jamar Handheld Dynomometer Measurement, Pinchmeter Measurement, Purdue Pegbord Test, Minnesota Manuel Skill Test, Nelson Hand Reaction Test, Modified Borg Scale
75804688|NCT03670654|Other|Muscle stretching|The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
75804689|NCT03022084|Device|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
75804690|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
75804691|NCT02611180|Procedure|Skin punch biopsy|
75804692|NCT02611180|Procedure|Peripheral blood draw|
75944982|NCT03644771|Drug|Acthar|4 treatment periods of 3 months each with 20 units biweekly, 40 units biweekly, and 80 units biweekly, with a tapering period to no drug for the fourth 3 month period. Then one year f/u.
75944983|NCT03643523|Diagnostic Test|Albumine detection|Control of serum albumine levels in postoperatori of colorectal surgery
75944984|NCT02962739|Drug|emtricitabine 200 mg/tenofovir alafenamide 25mg|1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
75944985|NCT03644693|Dietary Supplement|Nutritional Formulation Containing Exogenous Ketones|A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.
75944986|NCT03644693|Dietary Supplement|Placebo Formulation|A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.
75944987|NCT03643445|Behavioral|Motivational Orientated Treatment|The motivation-oriented treatment condition is intended to create a context for treatment that is patient-centered, non-judgmental, and will create a therapeutic environment wherein patients can make an informed decision around their goals for treatment and their willingness to commit to the behavioural changes required for recovery from an eating disorder. In general, MI is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices.
75346356|NCT01536197|Procedure|Sleeve gastrectomy|Sleeve gastrectomy surgery
75346357|NCT01834508|Drug|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks|
75346358|NCT01537367|Behavioral|Enhanced contact plus behavioral skills|The enhanced contact plus behavioral skills arm is the longer experimental arm.
75346359|NCT01537367|Behavioral|Enhanced contact only|The enhanced contact only arm is the shorter experimental arm.
75346360|NCT01537367|Behavioral|Standard of Care|The standard of care arm is the comparison group arm that receives only standard clinical services.
75346361|NCT04380662|Other|Risk factors|"The studied potential risk factors will be the following:~Socio-demographic: age, sex, place of residence, CSP and income.~Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain…~Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA…)"
75944988|NCT03643445|Behavioral|Psychoeducation-Oriented Treatment|The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. In this condition, in order to maximize the differences between groups, no attention will be given to discussing the patient's stage of change, their level of motivation, or their own personal values around recovery. Rather, emphasis during individual meetings with their therapist will be on the importance of symptom abstinence and normal eating.
75346362|NCT01537835|Other|Antimicrobial Scrubs|Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
75346363|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review.
75804693|NCT03670576|Procedure|Optional Bronchoscopy|Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.
75804694|NCT03670576|Other|Quality of Life Questionnaires|MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,
75804695|NCT03670576|Other|Blood Samples for Biomarkers|a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.
75804696|NCT03670576|Other|Home Hand Held Spirometry|Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)
75346364|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review
75804697|NCT03670498|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
75944989|NCT03644537|Procedure|Orthodontic intrusion|"27 female patients coming to the Orthodontic department, Cairo University seeking orthodontic treatment, where their age ranges from 15 - 18 years, where their treatment plan include extraction of upper first premolars, and using the split-mouth technique, one side will be control group without application of force where the other side will receive intrusive mechanics for the same patient in the upper arch (one side will not receive any force and the same tooth on the other side of the arch will suffer intrusive mechanics, that's why named SPLIT MOUTH TECHNIQUE - as if the arch is split into two subjects, one control subject (tooth) and the other study subject (tooth) . According to the amount of force of the working side, the total number of patients will be divided into 3 groups.~Each of 9 subjects, the first group where a light force will be applied (10 gm), the second group where moderate force will be applied (25gm), the third group where heavy force will be applied(100 gram)."
76092694|NCT04423874|Behavioral|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance.~Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min.~The procedure is safe because the hand is removed before adverse effects can occur.~The participant will be given a break of 5 min in between trials, and will interchange hands between trials.~During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand. Each participant will complete no more than three trials (conditions) in a randomised order."
76092695|NCT04423874|Diagnostic Test|index NOL|Measurement of the index NOL™: Four sensors, placed non-invasively on one of the four participants' fingers, will make it possible to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
76092696|NCT04423874|Behavioral|Playback Experiments|During the experience, participants are led to listen, via headphones, to aversive non-verbal vocalizations (baby crying). The sound levels used to broadcast the non-verbal vocalisations will be scrupulously measured using approved and certified equipment during the preparation of the experiments. These sound volumes will be chosen so as not to inconvenience participants.
76092697|NCT04423874|Diagnostic Test|Video-pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
76092698|NCT04369612|Procedure|Standard follow-up|Standard post-transplant follow-up
76092699|NCT04369612|Procedure|Home-based monitoring|Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
76092700|NCT04354012|Combination Product|methylene blue, gentian violet, and ovine forestomach wound dressings|"Hydrofera Blue is an antibacterial foam dressing that contains methylene blue and gentian violet to manage wounds. This is a safe, non-cytotoxic product that can be worn for 7 days while not inhibiting growth factors. This products wicks bacteria into the foam and away from the wound surface using natural negative pressure through capillary flow.~Endoform (ovine forestomach) is a natural dermal template used in all phases of wound healing. This product helps to stabilize, build, and organize tissue in acute and chronic wounds.~Hypafix tape aids in stabilization of wound dressings. This productIt is easy to apply, skin friendly, and comfortable to use."
75346365|NCT01538615|Behavioral|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
75346366|NCT04380428|Other|No Intervention. Observational study.|No Intervention. Observational study.
75672406|NCT00621062|Procedure|Radiofrequency ablation|RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
75804698|NCT03670498|Device|2 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
75804699|NCT03021304|Drug|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
75804700|NCT03669562|Drug|Alprostadil Liposome for Injection|intravenous infusion Alprostadil Liposome
75944990|NCT03641495|Other|PE+ET|"To explain the physiology of nervous system and the mechanism and modulation of acute and chronic pain.~To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate."
75804701|NCT03669562|Drug|Placebo|intravenous infusion liposome control
75804702|NCT02532244|Other|sample collection|collection of blood
75804703|NCT03670420|Other|Medical honey|The investigators use Medihoney®, a medical honey released by the DermaSciences.
75804704|NCT03670186|Behavioral|High-Intensity Interval Training (HIIT)|Participants perform high-intensity interval training (HIIT) on a cycle ergometer. The HIIT protocol consists of a 3-minute warm-up at 50W, ten 60-second high-intensity cycling intervals interspersed with 90 seconds of active recovery at 30% of their peak power output and a 2-minute cool-down at 50W for a total of 17.5 minutes.
75804705|NCT03669484|Drug|Remimazolam|Lyophilisate for preparation of solution for intravenous administration, 50 mg. Required to prepare a 50 ml syringe with the infusion solution at a concentration of 1 mg/ml (in accordance with guidance given in protocol)
76092701|NCT04352400|Drug|Nafamostat Mesilate|administered intravenously as a continuous infusion
76092702|NCT04352400|Drug|Placebo|administered intravenously as a continuous infusion
76092703|NCT04351698|Drug|Montelukast|Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started.
75657795|NCT06167382|Other|Device: Arm Ergometer|Participants will sign a consent form approved by the ethics comittee. Before data collection height, weight, daily computer usage time, dominant hand, body mass index, heart rate, blood pressure and saturation values be recored. Before arm ergometer exercise, the muscle strength, hand grip strength, joint range of motion, dexterity and reaction speed will be evaluated. The dexterity and reaction speed will be done with Minnesota Manuel Skill Test, Purdue Pegbord Test and Nelson Hand Reaction Test.Participants will be training at least 24 hours apart at 60%, 70%, and 80% of exercise intensity maximum heart rate on arm ergometer. The tests will repeat at the same time with a maximum deviation of 1 hour on 3 different days. At the end of arm ergometer exercise, the necessary evaluations will be made again and the participants will be rest for 15 minutes. 15 minutes after the participants rested, the necessary evaluations will be made again.
75657796|NCT06167304|Other|Technology-implemented exercise therapy|Therapy plans are performed at home overseen by a remote physical therapist via SimpleTherapy.
75944991|NCT03641495|Other|ET|To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
75944992|NCT03643055|Diagnostic Test|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
75657797|NCT06167304|Other|Traditional Physical Therapy|Traditional physical therapy per Standard of care.
75657798|NCT06167291|Radiation|Arm 1- Ipsilateral|Given by I-RT
75657799|NCT06167278|Other|Indirect bonding with two different digital bracket bonding transfer tray|"To achieve more precise and predictable result is the common aim in contemporary treatment. Digital indirect bonding (IDB) is used for this purpose in orthodontic treatment. The aim of this study is to compare the transfer accuracy of two different IDB trays.~Digital IDB was performed on a total of 30 patients, using one of the two designs: shell and bar trays; with 15 patients in each group. Trays were designed with the Appliance Designer software (3Shape A/S, Copenhagen, Denmark) as shell and bar types."
75657800|NCT06167265|Drug|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
75657801|NCT06167265|Drug|PMR Tablet 145 mg|Single oral dose (total daily dose of 290 mg)
76092704|NCT04351698|Other|Oral Placebo|Inert chewable tablet with no therapeutic value
76092705|NCT04349059|Other|Animal based diet|Food will be provided by Montefiore-Einstein Food Services
76092706|NCT04349059|Other|Plant based diet|Food will be provided by Montefiore-Einstein Food Services
75657802|NCT06167252|Other|Exploration of a database|extraction of data
75804706|NCT03669484|Drug|Propofol|Emulsion for infusion, 10 mg/mL in 20-mL glass vials
75804707|NCT03669484|Drug|Fentanyl|Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
75804708|NCT03669484|Drug|Rocuronium bromide|Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
75804709|NCT04058314|Device|Gemini IV|Eyes randomized to receive the Gemini IV device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
75804710|NCT04058314|Device|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
75804711|NCT02264548|Radiation|Radio-Ablation|Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
75804712|NCT03669172|Biological|Donor IL-15 stimulated NK cells infusion|DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT
75804713|NCT02159404|Biological|Immunotherapy|
75804714|NCT01814488|Procedure|allogeneic transplant|"Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.~The conditioning regimen in standard use is:~Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;~Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;~Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.~Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if <40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice."
75944993|NCT03641417|Drug|GLWL-01|"Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)"
76092707|NCT04341623|Other|Cetaphil Pro Eczema moisturizer|All 30 patients to receive
76092708|NCT04341623|Behavioral|Electronic interaction|10 patients to electronic surveys about moisturizer use
76092709|NCT04341623|Behavioral|GPSkin|Measuring moisture in the skin
75346367|NCT03219242|Device|Caiman® device|Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
75346368|NCT04380506|Procedure|Surgical Drains Management|The Role of Amylase Drain Level in the Management of Surgical Drains after Pancreratoduodenectomy
75944994|NCT03641417|Other|Placebo|Same as GLWL-01, but no active ingredient
75944995|NCT01344629|Drug|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
75944996|NCT01344629|Drug|Telmisartan|Telmisartan 80 mg tablet
75944997|NCT01344629|Drug|Amlodipin|Amlodipin 5mg tablet
75346369|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
75346370|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
75944998|NCT01092117|Device|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
76092710|NCT04340141|Drug|Oxaliplatin|Given IV
76092711|NCT04340141|Drug|Irinotecan Hydrochloride|Given IV
76092712|NCT04340141|Drug|Leucovorin Calcium|Given IV
76092713|NCT04340141|Drug|Fluorouracil|Given IV
76092714|NCT04340141|Procedure|Resection|Undergo surgical resection
75657803|NCT06167239|Other|Threshold inspiratory muscle trainer or ventilator pressure setting inspiratory muscle training techniques|New techniques to train inspiratory muscles in mechanically ventilated patients
75944999|NCT03642977|Diagnostic Test|Real time PCR and RT-PCR for DNA and RNA viral species|Qualitative and quantitative real time PCR and RT-PCR assays will be performed on hematopoietic stem cell transplant recipients' plasma samples collected at five specific time points over a one-year period after transplantation (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation), for the screening of a selection of at least 21 DNA and RNA viruses (belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families).
75804715|NCT03669406|Procedure|Autograft fat|autograft fat
75804716|NCT01330966|Drug|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
75804717|NCT03669952|Other|None intervention|No interventions are realized, only observational study
75804718|NCT03496298|Drug|Efpeglenatide (SAR439977)|"Pharmaceutical form: Solution for injection,~Route of administration: SC"
75945000|NCT03414021|Diagnostic Test|SPECT-CT Scan|Injection of a Tracer and SPECT-CT Scan
75945001|NCT03641261|Other|Therapeutic patient education program|WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team
75945002|NCT03413943|Other|gaze training|Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
76025903|NCT05583110|Drug|Vinorelbine|"Run-in Phase:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity [DLT] is seen) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg BID on a continuous dosing schedule."
76025904|NCT05570604|Behavioral|Sweep Seeker|The person is asked to clear the rows of blocks presented on the screen, either by moving them into horizontal or vertical blocks that have identical color. The goal is to refine and increase the response of primary visual cortex neurons and to enable the person to increase speed and accuracy of visual processing (executive function) and visual memory.
75346371|NCT03218696|Device|Cough Syrup for adults and children|The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.
75657804|NCT06167213|Device|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
75672407|NCT00621062|Procedure|Foam Sclerotherapy|Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
75804719|NCT03496298|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: SC"
76025905|NCT05570604|Behavioral|Bird Safari|The user is first presented with a target bird. Subsequently, a group of birds is presented in the peripheral vision and then disappears when the trial begins. The user selects the section of the screen where the target bird appeared. The presentation speed adapts with user performance (i.e. better performance = faster presentation). The goal is to improve speed and accuracy of object identification in peripheral vision and improve visual precision important for improving memory.
76025906|NCT05570604|Behavioral|Jewel Diver|The person is first presented objects (jewels) on the screen. The objects are then covered with occluders (bubbles) and then identical distracters are presented. The objects move around in screen and when the movement stops, the user chooses the occluders that cover the jewels. The number of jewels adapts to performance (more jewels = better performance). The goal is to improve divided visual attention, sustained visual attention, visual working memory, and visual precision.
75804720|NCT03718208|Dietary Supplement|Paediatric Formula|Children will switch over to the low calorie paediatric feed. Intake diaries and tolerance diaries will be completed for one week.
75804721|NCT02914522|Drug|Filgotinib|Tablet(s) administered orally once daily
75804722|NCT02914522|Drug|PTM filgotinib|Tablet(s) administered orally once daily
76025907|NCT05570604|Behavioral|Master Gardener|The person is presented a series of target stimuli and distracters which are presented at one time and then disappear. The locations of the stimuli are marked by icons, and the user chooses the icons where the target stimuli were once located. The goal is to increase speed and accuracy as well as the ability to extract information accurately.
76025908|NCT05570604|Behavioral|Road Tour|The person is presented with a target vehicle briefly in both the center of the screen and in one of eight locations in the periphery. Two vehicles are then presented briefly in the center of the screen, one of which is the target vehicle. The user must identify the location of the target vehicle in the periphery as well as identify which was the target vehicle that appeared in the center. The goal of this activity is to improve divided attention and ability to extract information and discard irrelevant information from peripheral vision.
76025909|NCT05570604|Behavioral|Computerized Crossword Puzzles|The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation.
75945003|NCT03621293|Drug|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
75945004|NCT04835727|Other|Semi-vegetarian diet and increase fiber consumption|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
75945005|NCT03642743|Other|postoperative follow up appointment|Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
75945006|NCT03419169|Device|Light load BFR resistance training|A novel training light load resistance training modality.
75945007|NCT03419169|Procedure|Heavy load resistance training|A common form of resistance training used for rehabilitation within the National Health Service.
75945008|NCT03642665|Drug|Natural cycle|no medication
75945009|NCT03642665|Drug|Estradiol Valerate|Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
75945010|NCT03642665|Drug|Micronized progesterone|Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
75346372|NCT03218696|Device|Placebo|The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
75804723|NCT03669016|Behavioral|Face-to-face group-based mindfulness|"An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. This training is based on Jon Kabat-Zinn's course Mindfulness Based Stress Reduction and book Williams & Penman Mindfulness: a practical guide to finding peace in a frantic world and adapted for university students. In addition, a manual written in Cambridge University Mindfulness Skills for Students is utilized."
75804724|NCT03669016|Behavioral|Internet-based mindfulness|An eight-week course, including 60 minutes starting and ending meeting. Participants are practicing mindfulness, doing other tasks (writing, reading, reflecting) on their own. This course is created in University of Jyväskylä, Finland. It is based on mindfulness and Acceptance and Commmitment Therapy.
75804725|NCT02924428|Device|Venus Versa|
75804726|NCT03668860|Drug|Dexamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
75804727|NCT03668860|Drug|Betamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
75804728|NCT03668860|Drug|Celestone Soluspan 6Mg/Ml Suspension for Injection|Intramuscular. Total dose: 1 mL (6 mg)
75804729|NCT03668860|Drug|Dexamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
75945011|NCT03419091|Device|single-use flexible digital ureteroscope|Device being tested.
75945012|NCT03419091|Device|Reusable Ureteroscope|Comparative device.
75945013|NCT03413865|Other|Visits conducted via Telemedicine|Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse
75945014|NCT03419013|Other|New adhesive strip|This strip is made of a newly developed adhesive
76092715|NCT04340141|Other|Questionnaire Administration|Ancillary studies
75804730|NCT03668860|Drug|Betamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
75804731|NCT03668782|Procedure|Umbilical cord milking|The babies were held at the level of the placenta, while the umbilical cord was milked or cut and clamped.
75804732|NCT04609618|Device|Appscent Device|computer-controlled, low pressure compressed air based, with disposable odorant capsules solution provided an odor environment at the nose,
75804733|NCT00062751|Drug|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
75804734|NCT00062751|Drug|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
75804735|NCT00062751|Drug|Letrozole|Letrozole 2.5 mg daily
75945015|NCT05229419|Other|complete blood count|complete blood count will be done for corrosive cases
75945016|NCT03641105|Diagnostic Test|Diagnostic test|detect the contents of glucose metabolism molecules using mass spectrum
75945017|NCT03413709|Other|Family Formation Program|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
75945018|NCT03413631|Behavioral|Prenatal mentalization intervention|
75945019|NCT03413631|Other|Prenatal obstetric treatment as usual|
76025910|NCT05565937|Device|BL-3100-NBR03 multi-purpose solution|BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses
76025911|NCT05565937|Device|renu® Advanced Formula multi-purpose solution|renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses
76092716|NCT04339699|Device|NobleStitch™EL Suture Mediated Closure System|Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System
75945020|NCT04448769|Biological|Anti-SARS-CoV-2 IgT seropositivity|"Each inhabitant who agrees to participate will have to :~sign the consent form after receiving complete information~complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM)."
75804736|NCT00945724|Drug|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate|"Weeks 1-15:~6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days~Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle~IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4&5 of R-CHOP~Weeks 18-22:~• Methotrexate 1.5 g/m2 q14 Days x 2~From Week 24:~• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)"
75804737|NCT00763828|Device|Life Recovery Systems ThermoSuit|Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
75945021|NCT03642353|Drug|Triclosan|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
75945022|NCT03642353|Drug|Placebo|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
75945023|NCT03413553|Device|immediate implant|Patient will receive immediate implant alone.
75945024|NCT03413553|Biological|connective tissue graft|patient will receive immediate implant with connective tissue graft and platelet rich fibrin
75945025|NCT03413553|Biological|platelet rich fibrin|patient will recieve immediate implant combined with connective tissue graft and platelet rich fibrin
75945026|NCT03642275|Behavioral|iCardia4HF|Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
75945027|NCT03413475|Behavioral|quality of life|
75945028|NCT03424863|Other|Moderate Intensity Muscle Strengthening|1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
75945029|NCT05284175|Drug|Orelabrutinib|Orelabrutinib, orally, 50 mg QD
75945030|NCT03642197|Behavioral|Attendance|The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.
75945031|NCT03424785|Other|drug, stent, surgical treatment|drug, stent, surgical treatment
75945032|NCT03642041|Behavioral|smoking|smoking behavior
75945033|NCT03424707|Drug|DW340(pelubiprofen/eperisone)|DW340
75945034|NCT03424707|Drug|Pelubi(pelubiprofen)|pelubiprofen
75346373|NCT03218774|Behavioral|Home Exercise Group|The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.
75804738|NCT00258310|Drug|capecitabine|Capecitabine 1000mg/day for one year
75804739|NCT00258310|Procedure|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
75804740|NCT00159406|Other|Registry and Database|Data Collection
75804741|NCT00062439|Drug|cisplatin|During induction:50 mg/m2,IV on Days 1, 8, 29 & 36. In any appropriate vehicle over 60 minutes
75804742|NCT00062439|Drug|docetaxel|During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes
75945035|NCT03424707|Drug|Placebo Oral Tablet|Placebo Oral Tablet
75945036|NCT05174351|Other|beta blocker discontinuation|beta blocker discontinuation
75945037|NCT03418935|Drug|Remaxol (succinate + methionine + inosine + nicotinamide)|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
75945038|NCT03418935|Drug|Ringer's Solution|Intravenous infusion, 400 or 800 ml
75945039|NCT03641963|Device|Vittamed 205 Non-invasive intracranial pressure (ICP) meter|Non-Invasive intracranial pressure measurement
75945040|NCT03641885|Behavioral|mothers and adolescents|The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
75945041|NCT03641885|Behavioral|adolescents|The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
75945042|NCT03641885|Behavioral|active control|The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
75945043|NCT00530049|Other|questionnaire administration|
75945044|NCT00530049|Procedure|assessment of therapy complications|
75945045|NCT00530049|Procedure|psychosocial assessment and care|
75945046|NCT00530049|Procedure|quality-of-life assessment|
75945047|NCT03413319|Drug|ABBV-8E12|Solution for infusion
75945048|NCT03644303|Radiation|SBRT + ADT|Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
75945049|NCT03418623|Drug|GET73|GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
75945050|NCT03418623|Other|Placebo|Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
75945051|NCT05188937|Procedure|validity and reliability study|Validity and reliability assessment of the Dual-task Questionnaire
75945052|NCT03424629|Biological|Low-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
75945053|NCT03424629|Biological|High-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 3×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
75945054|NCT03424629|Drug|Methotrexate|Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
76092717|NCT04339699|Device|Amplatzer PFO Occluder|Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
75945055|NCT03641807|Other|Acupuncture|Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
76092718|NCT04326192|Device|Research electrode|A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.
76092719|NCT04306952|Behavioral|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
76092720|NCT04306952|Behavioral|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
75346374|NCT03218774|Behavioral|Fitness Center Group|The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
75945056|NCT03641807|Other|Sham acupuncture|Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
75945057|NCT04618029|Other|Home Modification|"Home Modification Intervention~Floor~Provide recommendations to:~Fix the back of the rugs and mats with adhesive/heavy duty tape~Buy non-slip mats~Tie all cables with a proper cable tie~Lighting~Provide recommendations to:~Buy a torch light~To replace worn light bulbs~Buy a light switch~Bathroom~Provide recommendations to:~Buy a non-slip mat~Install a grab rail~Buy a commode chair for showering~Stairways~Provide recommendations to:~• Fix an adhesive tape for stair contrast"
75945058|NCT04618029|Other|Education|"Techniques Description Energy Conservation~Take your time~Go to the toilet more often, so you don't have to rush~Use a nearby toilet: commode, different bathroom~Prepare ahead (e.g., toilet paper near, other items for toileting, etc.)~Adjust equipment before changing position~Avoid transfers when tired~Ask for help if you feel sick or especially tired~Allow time for eyes to adjust to change in lighting~Task Simplification~Plan and organise workspaces to eliminate unnecessary steps, save time, energy and reduce fatigue.~Prioritise and plan activities, alternating between active and quiet jobs and include rest periods.~Ergonomics~Proper positioning while doing tasks~Safe mobility around the home"
75346375|NCT03218852|Drug|prednisone and cyclophosphamide|Prednisone and cyclophosphamide are both administered to participants in this group.
75346376|NCT03218852|Drug|prednisone alone|Prednisone is administered to participants in this group.
75346377|NCT01834664|Biological|stem cell (MNCs )|Intra thecal transplantation of autologous stem cell [MNCs ]Per dose at the interval
75346378|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
75346379|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
75804743|NCT00062439|Drug|etoposide|During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.
75804744|NCT00062439|Procedure|conventional surgery|If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.
75346380|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
75945059|NCT05283707|Behavioral|Paula Method Exercises|The Paula Method Exercises were administered by the researcher for 6 to 8 hours, for 10 to 15 minutes on the post-op first day and post-op second day, to women who had a cesarean section.
75945060|NCT02358122|Other|Wholegrain rye|A variety of cereal foods providing >100g/day wholegrain from rye
75945061|NCT02358122|Other|Wholegrain wheat|A variety of cereal foods providing >100g/day wholegrain from wheat
75945062|NCT02358122|Other|Refined wheat|A variety of cereal foods providing 0g/day wholegrain
75945063|NCT03424551|Device|vibrator|Local or whole body vibration was applied at six different frequencies
75945064|NCT03641729|Other|individualized exercise training program|The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
75945065|NCT02366000|Other|Brief Parental Training Intervention|The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
76092721|NCT04306952|Behavioral|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours)."
75346381|NCT01834742|Drug|Moviprep|Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
75346382|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
75945066|NCT03641573|Drug|[14C] ASN002|[14C] ASN002
75945067|NCT03424473|Drug|Tucatinib|
75945068|NCT04448379|Drug|JMT101|IV infusion Q2W for 4 weeks (28-day cycles)
75945069|NCT03621215|Dietary Supplement|Tart cherry juice|30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.
75945070|NCT03621215|Other|Fruit-flavoured placebo drink|Consumed daily by participants, with breakfast, for 12 months.
75945071|NCT03640871|Device|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing 10x10 cm (AWC=Advanced Wound Care)
75945072|NCT04448223|Drug|CKD-351|Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
75346383|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
75346384|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
75346385|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
75346386|NCT03836690|Biological|CD62L- Tem|Donor memory T cells that have been depleted of CD62L+
75346387|NCT03212768|Procedure|Trans-syndesmotic fixation|antromedial approach for medial malleolus fractures, posterolateral or direct lateral approach for fibula fractures, direct fixation of third malleolus by posterior approach, Trans-syndesmotic fixation ,cement augmentation and Tibiotalocalcaneal fusion
75657805|NCT06167187|Procedure|bilateral inferior alveolar nerve block|Placing the tip of the thumb or forefinger into the coronoid notch (retromolar fossa) to help visualize the vertical height at which the needle will enter, and retracting the cheek to expose the pterygomandibular triangle. Placing the barrel of the syringe over the contralateral lower 1st and 2nd premolars and resting the side of the needle tip against the lateral edge of the pterygomandibular raphe, aiming the tip of the needle into the pterygomandibular triangle, with the bevel facing the ramus. Advancing the needle tip slightly into the mucosa until it is stopped by the ramus (typically after about 2 to 2.5 cm of insertion) and withdrawing needle 1 mm away from bone. Aspirating to rule out intravascular placement. If aspiration reveals intravascular placement, withdrawal of the needle will be done 2 to 3 mm, then reaspirating prior to injection. Slowly injecting about 2 to 4 milliliters of bupivacaine 0.5% anesthetic in each side..
75945073|NCT04448223|Drug|Latanoprost+Dorzolmamide|Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
75945074|NCT03644225|Device|Measurment with Aspirational Medical Device|The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
75945075|NCT03644225|Device|Measurment with Cutometer MPA 580|The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
75945076|NCT03644147|Drug|Acetaminophen|Acetaminophen will be intravenously administrated to treatment group after the end of surgery.
75945077|NCT01543256|Device|WallFlex™ Biliary RX Fully Covered Stent System RMV|"Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)"
75945078|NCT01543256|Device|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
75945079|NCT02743923|Drug|carboplatin|AUC 6
75945080|NCT02743923|Drug|paclitaxel|200mg/m2
76092722|NCT04303013|Behavioral|Meditation|Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
76092723|NCT04303013|Other|Standard of Care|Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
76092724|NCT04300556|Drug|Farletuzumab ecteribulin|Farletuzumab ecteribulin intravenous infusion.
75945081|NCT02743923|Drug|Bevacizumab|15 mg/kg
76092725|NCT04300556|Drug|Prednisone|Prednisone administered orally.
76092726|NCT04300556|Drug|Prednisolone|Prednisolone administered orally.
76092727|NCT04300556|Drug|Dexamethasone|Dexamethasone administered orally.
76092728|NCT04298190|Behavioral|Dialectical Behaviour Therapy for Adolescents (DBT-A)|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
75657806|NCT06167187|Drug|Ketorolac and fentanyl|in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
75945082|NCT02743923|Drug|Pemetrexed|500 mg/m2
76092729|NCT04298190|Behavioral|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive family and/or pharmacological treatment as needed.
75346388|NCT01834898|Drug|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
75346389|NCT03218462|Behavioral|Sensory Adapted Dental Environment (SADE)|No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
75346390|NCT03218228|Procedure|implants in periodontitis|it targets immediate implant placement in patients suffering from aggressive periodontitis
75346391|NCT03212300|Behavioral|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
75346392|NCT03218306|Device|Surgical Pleth Index|Effector site concentration of remifentanil based on SPI
75657807|NCT06167148|Device|Biolase Epic X 940nm wavelength Diode laser|Participants were treated with Biolase Epic X 940nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (P3).
75657808|NCT06167148|Device|Doctor smile simpler 980nm wavelength Diode laser|Participants were treated with doctor smile simpler 980nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (SP).
75945083|NCT02743923|Drug|cisplatin|75 mg/m2
75945084|NCT01065779|Drug|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
75945085|NCT01065779|Drug|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
75945086|NCT03424395|Other|Personalized dietary and wellness program|Single arm intervention containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only
75945087|NCT02357966|Biological|514G3|True Human Monoclonal Antibody
75945088|NCT02357966|Drug|Placebo|Buffered saline solution
75945089|NCT02357966|Drug|Standard IV antibiotic therapy|standard antibiotic therapy will be determined by the attending physician and will be guided by the results of cultures with sensitivities.
75672408|NCT05253690|Procedure|balloon catheter insertion approach for labor induction|Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
75672409|NCT04660448|Diagnostic Test|Bedside lung ultrasound examination|Lung ultrasound exploring 12 areas (6 in each lung) at 12 +/- 6 hours and at 48-72 hours from PICU admission. Clinical and analytical data collection coinciding with ultrasound imaging and during follow-up while admitted to PICU.
75672410|NCT02651298|Device|Fractional Co2-laser|laser treatment
75945090|NCT03570359|Drug|Interferon Beta-1A|Interferon Beta-1A via inhalation
75945091|NCT03570359|Other|Placebo|Placebo via inhalation
75945092|NCT03424317|Behavioral|Sodium intake reduction|Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively
75945093|NCT03424317|Behavioral|Exercise|Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
75945094|NCT01345838|Procedure|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
75945095|NCT02358200|Drug|BMN-673|
75945096|NCT02358200|Drug|Carboplatin|
75945097|NCT02358200|Drug|Paclitaxel|
76092730|NCT04295564|Other|Additional 2 weeks of CPAP|Subjects will be randomized to an additional 2 weeks of CPAP vs. discontinuing CPAP per usual care.
76092731|NCT04291105|Biological|VV1|VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit
76092732|NCT04291105|Biological|Cemiplimab|Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
76092733|NCT04264780|Other|Neuropsychological examination|Neuropsychological follow-up examination, including questionaires
75346393|NCT03218306|Other|Clinical guidance|Effector site concentration of remifentanil based on hemodynamic data
75346394|NCT01557959|Drug|cisplatin|Given IV
75346395|NCT01557959|Biological|pegfilgrastim|Given SC
75346396|NCT01557959|Drug|erlotinib hydrochloride|Given PO
75346397|NCT01557959|Other|laboratory biomarker analysis|Optional correlative study
75346398|NCT01557959|Genetic|polymorphism analysis|Correlative study
75346399|NCT01557959|Other|pharmacogenomic studies|Correlative study
75945098|NCT03418311|Device|Cervical Pessary-Group|Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
75945099|NCT03112616|Other|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
75945100|NCT03413085|Device|soft contact lens|"Group A~Group B"
75945101|NCT02963441|Device|LumineticsCore (formerly IDX-DR)|Retrospective confirmatory analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
75945102|NCT03112772|Other|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
75657809|NCT06167122|Procedure|Craniofacial reconstruction|"Zone 1 lesions: radical excision and immediate reconstruction with bone grafts for fibrous dysplasia lesions.~Zone 2 lesions: trimming & recontouring. Zone 3 lesions: observation or conservative recontouring; optic nerve decompression performed when continuous deterioration of vision, and external auditory canal surgery performed when cholesteatoma/near total ear canal stenosis.~Zone 4: observation or conservative recontouring; orthognathic surgery performed when malocclusion or midface retrusion noted."
75945103|NCT03112772|Other|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
75945104|NCT03413007|Diagnostic Test|Immune compleX Predictive Index|iXip is an algorithm thant integrates PSA, PSA-IgM, prostate volume and age of the patient in order to provide the probability of prostate cancer
75945105|NCT01065935|Drug|ALN-RSV01|Administered by nebulization once daily for 5 days
75945106|NCT01065935|Drug|Normal Saline|Administered by nebulization once daily for 5 days
75945107|NCT02357888|Drug|V0018|Oromucosal - Single dose
75945108|NCT02357888|Drug|Placebo|Oromucosal - Single dose
75945109|NCT03418233|Drug|CardioCell|"Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
75945110|NCT03418233|Drug|Placebos|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
76092734|NCT04255147|Biological|Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells|Cryopreserved allogeneic umbilical cord tissue-derived mesenchymal stromal cells are thawed and administered intravenously.
75346400|NCT01557959|Genetic|genetic linkage analysis|Correlative study
75346401|NCT01557959|Drug|docetaxel|Given IV
75945111|NCT03127605|Drug|Inotuzumab Ozogamicin|
75945112|NCT03112538|Device|Insulin Pump|Medtronic Minimed Paradigm Veo Insulin Pump
75945113|NCT03112538|Drug|Multiple daily injections of insulin|Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart) before each meal
75945114|NCT03644069|Biological|Nexvax2|Nexvax2 subcutaenous (SQ) injections: 32 in total, at twice weekly intervals
75945115|NCT03644069|Biological|Placebo|Placebo SQ injections: 32 in total, at twice weekly intervals
75346402|NCT03212456|Drug|opioid-free group|We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
75346403|NCT03212456|Drug|Opioid Group|This group will receive fentanyl in the induction of anesthesia.
75346404|NCT03212456|Procedure|transversus abdominal plane block with ropivacaine|The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
75346405|NCT03212456|Procedure|transversus abdominal plane block with placebo|the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
75945116|NCT03418155|Drug|Treatment of TongBi Capsule|TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.
75945117|NCT03418155|Drug|Treatment of TongBi placebo|TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
75945118|NCT03112694|Other|Data collection|This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.
75945119|NCT05283551|Drug|Famciclovir|Famciclovir (500mg BD)
75945120|NCT02357732|Drug|Nivolumab|
75945121|NCT02357732|Drug|Trametinib|
75945122|NCT02357732|Drug|Dabrafenib|
75945123|NCT03412851|Other|A Direct Aspiration First Pass Technique|Distal aspiration technique
75945124|NCT03412851|Other|Stentriever Thrombectomy|Thrombectomy with stent retriever
75945125|NCT02353052|Other|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
75945126|NCT03412695|Device|MyFood|Patients included in the intervention group will use the MyFood app to record their dietary intake. Nurses will use the report and recommendations in the MyFood tool to follow up the nutritional treatment of the patients.
75945127|NCT02357498|Procedure|transsphenoidal surgery|
75945128|NCT02362568|Procedure|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
75945129|NCT04479254|Dietary Supplement|Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)|Enteral nutrition feeding formula is used in powder form and will be reconstituted by attending nurses, Continuous feeding is commonly used which will be prescribed by the attending clinicians, Energy and protein intake from EN will be estimated by multiplying the volume of feed given to energy (kcal) and protein (g) in 1 ml of standard dilution, and for Standard PN product, energy and protein intake will also be calculated based on the volume infused.
76092735|NCT04250194|Device|CT-Guided Biopsy|Images will be generated by a CT scanner to accurately insert a needle into the lung nodule allowing a sample to be removed for testing
76092736|NCT04250194|Device|Navigation bronchoscopy|A virtual three-dimensional map of the lung will be generated enabling the physician to perform an anatomically precise biopsy
76092737|NCT04245085|Drug|Atezolizumab|"Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit."
75476908|NCT05345405|Behavioral|Supporter-Only CARE|Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
75657810|NCT06167109|Radiation|CTV optimized IMRT|The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as a potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
75657811|NCT06167044|Other|thoracic mobilization|Thoracic mobilization will be performed for the thoracic spine mobilization group, thoracic mobilization therapy will be performed for five minutes.
75657812|NCT06167031|Other|chatbot facilitate teaching|"The experimental group will use chatbot to facilitate teaching."
75657813|NCT06167031|Other|ecture-based teaching|The control group only receives lecture-based teaching.
75657814|NCT06167018|Behavioral|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8-12 sessions), were given either in an individual manner or in a group setting.The hypnosis treatment is administered by two nurses specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment was based on the North Carolina protocol. Patients assessed gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
75657815|NCT06167005|Procedure|Primary bariatric-metabolic surgery|Primary bariatric-metabolic surgery
75945130|NCT03423927|Behavioral|Self-hypnosis + Self-care|Our groupal intervention is divided into 6 monthly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, selfrespect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
75945131|NCT03127293|Diagnostic Test|DEXA|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
75945132|NCT03412461|Other|Thought Spot|Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.
75945133|NCT03412461|Other|Resource Pamphlet|The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
75945134|NCT03153722|Procedure|Pediatric discharge process interventions|"As this is an iterative quality improvement process, interventions will be evidence-based and chosen to test effectiveness for addressing areas of discharge bottlenecks or inefficiency within our specific hospital's context. Examples of possible interventions may include implementation of a discharge risk assessment (as in Statile et al, Pediatrics 2016), institution of a medications-in-hand policy on hospital discharge (as in Sauers-Ford et al, Pediatrics 2016), or initiation of a ward discharge coordinator who will help coordinate outpatient follow-up for patients. Interventions will be implemented in a stepwise fashion, utilizing successive plan-do-study-act cycles, with a minimum 2 month period between interventions to monitor outcomes."
76092738|NCT04245085|Drug|Bevacizumab|Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
76092739|NCT04245085|Drug|Carboplatin|Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.
76092740|NCT04245085|Drug|Paclitaxel|Patients in treatment Arm A will receive paclitaxel, 175-200 mg/m2 (at the investigators' discretion), every 3 weeks for 4-6 cycles.
76092741|NCT04245085|Drug|Pemetrexed|Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
76092742|NCT04242095|Procedure|Biospecimen Collection|Undergo collection of tissue, blood, and stool samples
76092743|NCT04242095|Other|Medical Chart Review|Review of medical records
76092744|NCT04233346|Drug|Ponatinib|CP-CML patients will be randomized into 30 mg and 45 mg dose groups at the ratio of 1:1,each group taken orally once daily. Other patients taken 45mg orally once daily.
76092745|NCT04229004|Drug|Gemcitabine combined with nab-paclitaxel|"Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle.~If one of the chemotherapy medications is held, the other study medications may be given.~Doses should be re-adjusted if the participant's weight changes by +/- >10%. If the participant's weight changes by <10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
75657816|NCT06166979|Other|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e8 cfu/ dose (Active)
75657817|NCT06166979|Other|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e6 cfu/ dose (Active)
75657818|NCT06166966|Other|Flipped Education Model|The effect of the Inside Out Education Model on the course success of nursing students.
75945135|NCT03418077|Dietary Supplement|Energy Drink|Participants will consume a randomly assigned single 24 oz can of an original flavor energy drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
75476909|NCT05339958|Dietary Supplement|Nutrafol® Men Hair Growth Nutraceutical|Nutrafol® Men contains patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin).
75657819|NCT06166953|Other|digital technology-supported education|The education will include information about surgical process and care after surgery.
75945136|NCT03418077|Dietary Supplement|Placebo-control|Participants will consume a randomly assigned single 24 oz can of control drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
76025912|NCT05537935|Drug|Low Dose Naltrexone|Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which is seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
76025913|NCT05461014|Behavioral|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation. The coaches are trained to provide assistance with adult care transition readiness."
75657820|NCT06166940|Other|ROTEM Guided Management|ROTEM guided management of hemostasis after CPB
75657821|NCT06166849|Device|Experimental Fluoride Application|The two-step system, consisting of Component A and Component B, will be applied once on the white spot lesions
75657822|NCT06166823|Other|EMR alert|EMR alert for medication optimization
75657823|NCT06166784|Device|Mectascrew B|reconstruction of ACL or PCL rupture
75657824|NCT06166771|Device|Alma system|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
75657825|NCT06166758|Behavioral|Educational Video|Educational video regarding the benefits, risks, and limitations of genetic testing for hereditary cancer risk.
75657826|NCT06166680|Other|Sleep quality assessment|"The following item will be assessed in all subjects (n=420):~1. Sleep, through the Pediatric Sleep Questionnaire."
76025914|NCT05456893|Procedure|Procedure: endoscopic biopsy|Per-endoscopic biopsies
76025915|NCT05456893|Procedure|Blood sampling|Blood sampling
76025916|NCT05456893|Procedure|stool sampling|stool sampling
76025917|NCT05440851|Other|Ultra-Protective Ventilation Facilitated by Extracorporeal Support|Patients randomized to the intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
76025918|NCT05440851|Other|Lung-Protective Ventilation (LPV)|Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
76025919|NCT05440851|Other|Driving Pressure-Limited Ventilation (DPL)|Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
76025920|NCT05440851|Other|Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)|Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
76025921|NCT05440851|Drug|Early Cohort corticosteroid dose|Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
76025922|NCT05440851|Drug|Extended Cohort corticosteroid dose|Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
76025923|NCT05440851|Drug|Usual care without routine corticosteroids|Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
76092746|NCT04229004|Drug|Dose -mFOLFIRINOX|The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- >10%. If the participant's weight changes by <10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines.
75945137|NCT03112304|Behavioral|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
75346406|NCT04380272|Diagnostic Test|The ROC analysis|The Brodsky clinical stage and ultrasonographic data of the participants will be matched, and the diagnostic value of the submental US in the classification of tonsil hypertrophy as non-obstructive and obstructive will be evaluated. A ROC analysis will be used to determine the optimal cut-off value.
75346407|NCT03212612|Diagnostic Test|samples obtained by laparoscopy or punch biopsy for analysis by ELISA|Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
75476910|NCT05339958|Other|Placebo Supplement|The placebo capsules contain no active ingredients.
75476911|NCT05336201|Behavioral|CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Manualized cognitive remediation intervention that includes 1) skills-based remediation (metacognitive training), 2) parent training, and 3) cognitive behavioral approaches. Intervention targets self-management and goal-setting skill building to promote independence in activities necessary for transition of care.
75476912|NCT05332743|Dietary Supplement|Nutrafol Vegan Women's Hair Supplement|Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
75945138|NCT03112304|Other|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
75945139|NCT05171361|Procedure|Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique|To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy
75945140|NCT03160196|Other|Clinical Decision Support System|It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
75476913|NCT05329727|Drug|Angiotensin receptor neprilysin inhibitor (ARNI)|The group with ARNI was defined as patients with HFrEF took ARNI more than 3 months
75945141|NCT03160196|Other|Usual care based on clinical practice guideline|It is about usual care aligned with the diabetes guideline.
75945142|NCT03412383|Drug|Pyrotinib|Pyrotinib 400mg/day
76092747|NCT04229004|Drug|Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel|"Arm is closed to recruitment.~Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15)~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle"
76092748|NCT04229004|Drug|Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine|"Arm is closed to recruitment.~Canakinumab 250mg SC- Day 1 of every 28 day cycle~Spartalizumab 400 mg IV - Day 1 of every 28 day cycle~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle"
76092749|NCT04229004|Drug|Drug: Dose -SM-88|"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus."
76092750|NCT04228731|Procedure|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total knee arthroplasty
75476914|NCT05329727|Drug|Renin-Angiotensin System Inhibitor (RAS inhibitor)|The group with RAS inhibitor was defined as patients with HFrEF took RAS inhibitor more than 3 months
75476915|NCT05323539|Other|Evaluating Thyroid Volumes by ultrasonography|The inclusion criteria are ; having a prediagnosis of surgically planned endometrioma and to undergo gynecological surgery for a reason other than endometriosis (control group). Among the patients with pre-diagnosis of endometriosis, who applied to our clinic during the study period and accepted to participate in the study, thyroid volumes will be measured by ultrasonography during the preoperative hospitalization. The pathological diagnosis of the patients will be confirmed and patients with different results will be excluded from the study (such as malignancy, endometriosis prediagnosis but different pathology detected etc.) In the same period, gynecological surgery was planned for another reason and patients without endometriosis will form the control group.
75476916|NCT05319899|Drug|ALXN1840|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
75476917|NCT05319899|Drug|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
75945143|NCT03112148|Drug|10 mg dose MR formulations,10 mg dose of tofacitinib IR solution|"For the the relative bioavailability (BA) assessment , the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).~For the the food effect assessment, the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state."
75945144|NCT03423849|Drug|Vinorelbine|25mg/m2,day 1 and day 8, every 3 weeks
75945145|NCT03423849|Drug|Gemcitabine|1250mg/m2,day 1 and day 8, every 3 weeks
75945146|NCT03423849|Drug|Cisplatin|25mg/m2,day 1,every 3 weeks
75945147|NCT03423849|Drug|Capecitabine|1250mg/m2,day 1 to day 14, every 3 weeks
75945148|NCT02362490|Drug|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
75945149|NCT03417843|Device|EUSRA RF electrode|"At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces"
75945150|NCT03159962|Device|Bonded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
75945151|NCT03159962|Device|Banded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
75945152|NCT03423771|Drug|NPF-08|Drug: NPF-08 Arms: NPF-08 oral sulfate solution
75945153|NCT04324814|Drug|SHR-1701|Anti-PD-L1/TGFβ fusion protein
75945154|NCT03417765|Drug|FE 203799|GLP-2 analogue, once weekly, subcutaneous administration
75945155|NCT03126903|Device|KeraKlear Non-Penetrating Keratoprosthesis|The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
75945156|NCT02362256|Drug|Naltrexone|
75945157|NCT02362256|Drug|Clonidine|
75945158|NCT02362256|Drug|Lorazepam|
75945159|NCT03417609|Device|Tongue strength measurement|The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.
75945160|NCT03417609|Procedure|Blood sampling|Blood sampling
75945161|NCT03417609|Diagnostic Test|Mini Mental State Examination (MMSE)|Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.
75945162|NCT03417609|Diagnostic Test|Minimal nutritional assessment (MNA-SF)|The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.
75945163|NCT03417609|Diagnostic Test|Dual-energy x-ray absorptiometry (DEXA)|Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.
75945164|NCT03417609|Device|Dynamometer (Hand grip )|By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
75945165|NCT03417609|Diagnostic Test|Walking speed|Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.
75945166|NCT00592592|Radiation|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
75945167|NCT03126981|Other|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
75945168|NCT03126981|Other|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
75945169|NCT02362100|Other|Non operative|non operative treatment
75945170|NCT02362100|Procedure|locking plate surgical fixation|
75945171|NCT03412305|Drug|Amoxicillin|Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement
75945172|NCT03412305|Other|Placebo|Placebo consisting of 4 tablets, orally 1 hour before implant placement
75945173|NCT02352740|Dietary Supplement|A form Arginine|3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
75945174|NCT02352740|Dietary Supplement|B form Arginine|3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
75945175|NCT02109081|Drug|Dexamethasone|
75945176|NCT02109081|Drug|Placebo|
75945177|NCT02352584|Biological|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
75945178|NCT02352584|Biological|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
75945179|NCT02352584|Biological|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
75945180|NCT03423693|Other|No any intervention|No any intervention is applied to any groups in this study
75945181|NCT02352662|Other|Perioperative blood samples collection|Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
75945182|NCT03417453|Device|Eye Drop Dispenser TYPE Opticare|"Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners."
75945183|NCT03417453|Device|Eye Drop Dispenser Autodrop|Eye Drop Dispenser Autodrop
75945184|NCT05171283|Other|Oats or Oat Fibre|Interventions that contain whole grain oats or oat beta-glucan.
76025924|NCT05440851|Drug|Usual care without extending corticosteroids|Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
75346408|NCT03218150|Procedure|cranioplasty|". The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws."
75945185|NCT02352428|Other|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
75945186|NCT02352272|Other|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
75346409|NCT02503332|Drug|Pegcetacoplan|
75945187|NCT04448067|Behavioral|Dietary Lentil Intake|Dietary intake of moderate or high dose of lentils at midday meals
75657827|NCT06166680|Other|Anthropometry|"The following items will be assessed in all subjects (n=420):~2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate (with the Quick Tongue-Tie assessment tool)"
75657828|NCT06166680|Other|Tongue strength assessment|"The following items will be assessed in all subjects (n=420):~3. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing.~4. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 sec. of tongue elevation.~5. Tongue peak pressure during 3 sec. of tongue protrusion."
75657829|NCT06166680|Other|Tongue endurance assessment|"The following items will be assessed in all subjects (n=420):~6. The tongue endurance (i.e., the time to task failure in maintaining a pressure equal to 50%Pmax against the IOPI bulb) during tongue elevation.~7. The tongue endurance during tongue protrusion."
75657830|NCT06166680|Other|Orofacial praxis assessment|- The following item will be assessed in a subset of subjects (n=31): 8. Orofacial praxis through the Motricité Bucco-Linguo-Faciale (MBLF) test.
75657831|NCT06166667|Procedure|Fecal Microbiota Transplant（FMT）|Patients involved in the trial received 20 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.
75945188|NCT04448067|Behavioral|No Dietary Lentil CONTROL|Dietary intake of meals without lentils and matched to dietary lentil meals for total energy and protein
75945189|NCT03417375|Procedure|Bilateral Sinus Augmentation|Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
76092751|NCT04228731|Procedure|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total knee arthroplasty
76092752|NCT04207931|Drug|Topical steroid class I-II|applied once daily - 18 month duration of the study
76092753|NCT04207931|Drug|Triamcinolone Acetonide|Intralesional Steroid Injection, 7.5mg/cc. max dose of 3 cc. Scalp injections will be administered every 6-8 weeks, for a total of 8 injections.
76092754|NCT04207931|Drug|Doxycyline|oral antibiotic twice daily for 6 months
76092755|NCT04207931|Drug|Minoxidil|5% solution or foam started after month 8
76092756|NCT04207723|Other|Transcutaneous posterior tibial nerve stimulation|Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.
76092757|NCT04207723|Drug|Paroxetine|paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
75346410|NCT02503332|Other|Sham Procedure|
75346411|NCT03217838|Drug|AZD2811|AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
75657832|NCT06166641|Procedure|Surgical procedure at operating room|A surgical procedure in an operating room is a medical intervention that involves making incisions or using minimally invasive techniques to treat a specific condition or perform a diagnostic procedure. The operating room, also known as the operating theater or surgical suite, is a sterile environment specifically designed to minimize the risk of infection and ensure the safety of both the patient and the surgical team.
75657833|NCT06166615|Drug|Ramosetron|Ramosetron (a 5-HT3 receptor antagonist) has been developed as an effective treatment for irritable bowel syndrome-diarrhea (IBD-D) and is used to decrease intestinal motility, stiffen stool consistency, and reduce the number of urgency bowel movements. Since one of the goals of treatment for fecal incontinence is the maintenance of stool consistency, this agent is expected to be effective in treating fecal incontinence.
75657834|NCT06166615|Drug|Psyllium|Psyllium was found to be the most effective at improving symptoms of fecal incontinence among several dietary fibers in a randomized, controlled, single-blind study and is currently used as a first-line treatment for fecal incontinence.
75657835|NCT06166589|Drug|Zimberelimab|Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
75657836|NCT06166589|Drug|Oxaliplatin|Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
75945190|NCT02362178|Procedure|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time>40 mm and/or platelets (PLTs 10 units/Kg) for MA<30 mm
75945191|NCT02362178|Procedure|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR>1.8 and/or PLTS (10 units/Kg) If PLTs count < 50000/μl
75945192|NCT04894305|Biological|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection.
76092758|NCT04207177|Drug|Mycophenolate Mofetil 500 mg Tab|Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.
76092759|NCT04207177|Drug|Tacrolimus capsule|Twice daily dosing of tacrolimus only for a week before transplantation in this subgroup. All patients will get maintenance treatment With tacrolimus in combination With MMF and steroids after transplantation.
76092760|NCT04177628|Behavioral|Shared decision making supported by an in-consultation patient decision aid|After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
76092761|NCT04173494|Drug|Momelotinib|Momelotinib tablets will be self-administered orally once daily
75346412|NCT03217838|Drug|Azacitidine|Azacitidine is supplied in vials of 25 mg/mL powder for suspension for injection. After reconstitution, each vial contains a maximum of 100 mg. Participants should be pre-medicated for nausea and vomiting according to institutional standards before receiving azacitidine. Participants will receive 75 mg/m² on Days 1 through 7 or for 5 consecutive weekdays with rest on the 2 weekend days, and azacitidine dosing the first 2 weekdays of the next week of each 28-day cycle.
75945193|NCT03112850|Device|Hearing aid|LOF hearing aid
75346413|NCT03217838|Drug|Venetoclax|Venetoclax (VENCLEXTA®) is approved by the FDA for use in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venetoclax is planned to be given at a dose of 100 mg orally (PO) on Day 1 and 200 mg (PO) on Days 2- 28 of each 28-day cycle or 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle. The third participant in Group 3 Arm A will only be enrolled after the first 2 participants will receive ≥2 weeks of treatment and have shown no evidence of toxicity observed to be compatible with a DLT.
75346414|NCT01558661|Drug|AG-013736 (AXITINIB)|All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) > 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
75657837|NCT06166589|Drug|S-1|S-1(BSA < 1.2m2, 40 mg/day; BSA = 1.2~1.4 m2, 60 mg/day; BSA = 1.4~1.6 m2, 80 mg/day; BSA > 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
75657838|NCT06166589|Drug|Irinotecan|Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.
75657839|NCT06166563|Behavioral|Exercise Program|The intervention includes an individualized exercise program in Frequency, Intensity, Time, and Type (FITT).
75657840|NCT06166524|Procedure|Catheter ablation for atrial fibrillation using pulsed-field energy|Patients will undergo pulmonary vein isolation using pulsed-field energy
75657841|NCT06166524|Procedure|Conservative arm|Patients will undergo electrical cardioversion with consequent treatment with antiarrhythmic drugs
75804745|NCT00062439|Radiation|radiation therapy|Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
75657842|NCT06166511|Procedure|Laparoscopic liver resection|Using Laparoscopy in liver resection
75657843|NCT06166472|Drug|AK132|IV infusion, specified dose on specified days.
75657844|NCT06166459|Procedure|Drug-coated balloon combined with provisional drug-eluting stent implantation|(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).
75657845|NCT06166433|Behavioral|Smoke-free homes intervention|Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period.
76092762|NCT04173494|Drug|Placebo to match danazol|Danazol placebo capsules will be self-administered orally twice daily
76092763|NCT04173494|Drug|Danazol|Danazol capsules will be self-administered orally twice daily
75657846|NCT06166329|Other|chair lift test|repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute
75657847|NCT06166303|Diagnostic Test|sFlt-1/PGIF|Index of sFlt-1/PGIF
75804746|NCT00051363|Device|Active CPAP|Nightly nasal continuous positive airway pressure (CPAP)
75804747|NCT00051363|Device|Sham CPAP|Sham CPAP machine will be used for participants in the placebo group.
75945194|NCT03112850|Behavioral|Auditory Training|
76092764|NCT04173494|Drug|Placebo to match momelotinib|Momelotinib placebo tablets will be self-administered orally once daily
76092765|NCT04167631|Radiation|Multi-parametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
75945195|NCT05170971|Other|fecal microbiota transplantation|The fecal bacteria were transplanted once every 5 days for a total of 4 times
76092766|NCT04152512|Behavioral|Questionnaire administration|Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
76092767|NCT04150640|Drug|Nal-IRI|chemotherapy drug
76092768|NCT04150640|Drug|Oxaliplatin|chemotherapy drug
76092769|NCT04150640|Drug|5-FU|chemotherapy drug
75945196|NCT02356952|Behavioral|Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
75945197|NCT02356952|Behavioral|Low Glycemic Index Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
75945198|NCT02356952|Behavioral|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
75945199|NCT04854447|Device|Single-Vision Spectacles|Spectacle correction for myopia treatment
75346415|NCT01835288|Drug|arsenic trioxide|Given IV
75346416|NCT01835288|Other|laboratory biomarker analysis|Correlative studies
75945200|NCT04447599|Other|photography of conjunctival vessels|patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
75945201|NCT02352194|Other|Rehabilitation|Physiotherapy and physical activity
76092770|NCT04150640|Drug|Trastuzumab|immunotherapy
76092771|NCT04150640|Drug|Pembrolizumab|immunotherapy
76092772|NCT04150640|Drug|Nivolumab|immunotherapy
76092773|NCT04147780|Procedure|Sentinel node biopsy|Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.
75945202|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 1 or Placebo-dose 1
75657848|NCT06166277|Procedure|Ablation procedure|Cardioneuroablation procedure or permanent pacemaker placement
75657849|NCT06166264|Other|Progressive resistance training|It consists of patients who will receive both Resistance exercise training sessions and aerobic training 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercises used in the resistance exercise 1)Standing chess press;(2)Strengthening back muscles in sitting position;(3)Standing strengthening abduction of both shoulders;(4)Standing strengthening flexion of both shoulders;(5)Standing strengthening flexion of both forearms;(6)Standing strengthening extension of both forearms;(7)Strengthening extension of both knees in sitting position;(8)Strengthening flexion of both knees in sitting position;(9)Strengthening dorsiflexion of both ankles in sitting position.
75657850|NCT06166264|Other|Control group|The participants will receive information regarding health education.
75657851|NCT06166199|Behavioral|HIIT combined with resistance training|"Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week."
75657852|NCT06166186|Other|music|A music with a standard volume will be delivered to the patients via headphones from the beginning of anesthesia induction to extubation.
75804748|NCT01092585|Drug|Tesetaxel|"Tesetaxel capsules will be administered orally once every 21 days until the patient meets a withdrawal criterion or initiates nonstudy therapy for melanoma. The duration of protocol therapy will not exceed 12 months.~In Cycle 1, a flat dose of 40 mg will be administered to patients of relatively normal weight. For patients who weigh at least 25% below their ideal body weight, a flat dose of 35 mg will be administered. For patients who weigh at least 25% above their ideal body weight, a flat dose of 45 mg will be administered. Dose escalation by 5 mg in Cycle 2 and an additional 5 mg in Cycle 3 is permitted provided protocol-specified criteria are met."
75945203|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 2 or Placebo-dose 2
75804749|NCT01098981|Device|Transcranial ultrasound as an adjunctive therapy to tPA|"tPA per approved labeling administered over 60 minutes~Ultrasonic headframe with active insonation for 120 minutes"
76092774|NCT04140331|Device|Accelerometer|Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
75945204|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 3 or Placebo-dose 3
75945205|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 4 or Placebo-dose 4
75945206|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 5 or Placebo-dose 5
75945207|NCT02352350|Other|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
75945208|NCT02352350|Other|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
76092775|NCT04137107|Drug|Oxaliplatin|Given standard of care oxaliplatin
76092776|NCT04137107|Drug|Duloxetine Hydrochloride|Given PO
76092777|NCT04137107|Drug|Duloxetine|Given PO
76092778|NCT04137107|Other|Quality-of-Life Assessment|Ancillary studies
76092779|NCT04137107|Other|Questionnaire Administration|Ancillary studies
76092780|NCT04137107|Other|Placebo|Given PO
76092781|NCT04125524|Diagnostic Test|Terahertz metamaterials|A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.
76092782|NCT04124406|Device|Cologuard|multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
76092783|NCT04119544|Other|Conventional rehabilitation|upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
76092784|NCT04119544|Device|Intensive Visual Simulation|"First week: observation, mentalization and then attempt to perform the movements on the screen.~Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible."
76092785|NCT04119024|Drug|Cyclophosphamide|Given IV
76092786|NCT04119024|Drug|Fludarabine Phosphate|Given IV
76092787|NCT04119024|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given IV
76092788|NCT04119024|Drug|Recombinant Interleukin-2|Given SC
76092789|NCT04098484|Other|Control Trial|Participants will abstain from exercise throughout a 3-month period
76092790|NCT04098484|Other|Exercise Trial|Participants will execute a 3-month exercise training program
76092791|NCT04095247|Device|Vagus nerv stimulator|pulse triggered autostimulation
76092792|NCT04087278|Dietary Supplement|Red Raspberry Ellagitannin Extract|Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)
76092793|NCT04087278|Dietary Supplement|Matching Placebo|Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)
75346417|NCT03212534|Other|Patient mortality prediction|Healthcare provider is notified of patient mortality prediction.
75804750|NCT01098981|Drug|Standard of care tPA therapy for acute ischemic stroke|"tPA per approved labeling administered over 60 minutes~Ultrasonic headframe with sham (inactive) insonation for 120 minutes"
75804751|NCT01099059|Drug|Amantadine|Amantadine 100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
75657853|NCT06166186|Other|no music|Headphones will be applied to the patients but no music will be played from the beginning of anesthesia induction to extubation.
75804752|NCT01099059|Drug|ritalin|ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)
75804753|NCT01583829|Behavioral|Neurofeedback|3 times per week for 45 minutes for a total of 40 sessions
75804754|NCT01583829|Behavioral|Cognitive Training|3 times per week for 45 minutes for a total of 40 sessions
75804755|NCT01583829|Other|Waitlist Control|6 30 minute calm breathing sessions over the course of 4 months
75804756|NCT01092741|Drug|Gleevec|400 mg P.O. twice daily (800 mg total daily dose)
75804757|NCT01095471|Biological|PCV13|Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
75804758|NCT03955341|Device|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
75804759|NCT03955341|Other|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
75945209|NCT04795557|Dietary Supplement|ADAPT-232 oral solution|"One ml of ADAPT 232/CHISAN oral solution contains:~Fructus Schizandrae native extract DERnative 2-4:1, (extraction solvent . 95% ethanol) - 10 mg corresponding to 20-40 mg dried fruit; Radix Eleutherococci native extract DERnative 17-30:1 (extraction solvent - 70% ethanol) - 2.6 mg corresponding to 44-78 mg dried rhizomes, and Radix Rhodiolae native extract DERnative 2-5:1 (extraction solvent - 70% ethanol) - 3 mg corresponding to 6-30 mg dried rhizomes.~Excipients"
75476918|NCT05319665|Device|Head-mounted display|The intervention is a visual and auditory contact via a head-mounted display (HMD) worn by the mother airing a live video of her newborn filmed by a 2D 360° camera during and after a caesarean section. The HMD will be worn by the new mother from the moment that her newborn is moved to an adjacent room to receive the initial care until the moment when they can be reunited again. The camera will be placed in the adjacent room where the newborn, the mother's partner and a midwife will be. The camera will film the newborn and transmit the live images and the sound to the HMD worn by the mother. The mother will be able to see and hear what happens in the next room and change her angle of view by moving her head from one side to another.
75657854|NCT06166160|Other|Bulk fill flowable composite SDR Dentsply sirona|caries removal in class II cavities of primary molars and application of experminted restorations
75657855|NCT06166121|Other|ShenJu|One package per time, twice a day, 90 days of treatment
75657856|NCT06166121|Other|Placebo|One package per time, twice a day, 90 days of treatment (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
75657857|NCT06166108|Drug|transversus abdominis plane (TAP) block in Abdominal hysterectomy|Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
75804760|NCT00031551|Drug|Etanercept|
75804761|NCT00031551|Drug|Placebo|
75804762|NCT01092819|Other|Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies|The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. Patients with current standard of care other than IV rtPA or IA therapies will be studied.
75804763|NCT01099137|Drug|Vildagliptin|Vildagliptin 50mg twice a day, orally, for 24 weeks
75804764|NCT01099137|Drug|Sulphonylurea dose-up|glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
75804765|NCT01092975|Drug|phenylephrine solution|Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
75804766|NCT01584297|Drug|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
75804767|NCT01093053|Behavioral|Mind-Body Skills Groups|The mind-body skills group program teaches participants how to do meditation, guided imagery, breathing techniques, and biofeedback. These mind-body techniques are taught and practiced in small groups of 8 to 10 people and also contain an element of social support.
75804768|NCT01093053|Other|Standard Treatment|May include individual or group psychotherapy consisting of cognitive behavioral therapy or present-centered (i.e. unrelated to mindfulness) psychotherapy as well as medication management. Medications for depression, anxiety, and sleep disorders are the most commonly used in standard treatment.
75804769|NCT00049257|Drug|carboplatin|Administered Day 1 of each cycle. AUC=6.
75804770|NCT00049257|Drug|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
75945210|NCT04795557|Other|Placebo oral solution|Excipients
75945211|NCT02357030|Drug|Methyl-P plus GWI Nutrient Formula|"Week 1:~One tablet of Methyl-P (5mg) twice daily~Four tablets of GWI Nutrient Formula twice daily~Week 2 to Week 12 :~Two tablets of Methyl-P (10mg) twice daily~Four tablets of GWI Nutrient Formula twice daily"
75945212|NCT03397875|Procedure|Zinc oxide based sealer|After root canal treatment obturation will be done using zinc oxide eugenol based sealer.
75945213|NCT03397875|Procedure|Epoxy resin based sealer|After root canal treatment obturation will be done using epoxy resin based sealer.
75804771|NCT03951987|Drug|4 ml CG5503|4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
75804772|NCT03951987|Drug|5 g charcoal powder|Oral administration of 5 g charcoal powder suspended in 100 ml tap water.
75804773|NCT03955419|Dietary Supplement|NO-NPO (Daesang WelLife Co., Ltd., Korea)|800 mL of carbohydrate beverage consists of 12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg.
75804774|NCT01093131|Other|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
75657858|NCT06166095|Other|high-dose|Participants will be asked to perform a high-dose (HD) (i.e., 300 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
75657859|NCT06166095|Other|Walking attention control|The attention control group will be asked to wear the Fitbit activity tracker to monitor their sleep each night for 10 weeks.
75657860|NCT06166095|Other|moderate-dose|Participants will be asked to perform a moderate-dose (MD) (i.e., 150 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
75657861|NCT06166082|Device|Active iTBS-DLPFC|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.
75804775|NCT01093131|Drug|Oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
75804776|NCT01093131|Other|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
75945214|NCT03397875|Procedure|Bioactive silicone based sealer|
75804777|NCT01093131|Drug|Intravenous sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
75804778|NCT01093209|Device|Interferential Laser Therapy|PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
75945215|NCT02362022|Drug|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
75945216|NCT02361866|Biological|GC1107|0.5 ml, Intramuscular, single dose(day0)
75945217|NCT02361866|Biological|Tetanus and Diphtheria(Td vaccine)|0.5ml, Intramuscular, single dose(day0) only applicable step1
76092794|NCT04083001|Device|OTR4132MD|"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
76092795|NCT04068012|Other|Ventilator protocol|open loop ventilator management by a computer based protocol
76092796|NCT04056741|Combination Product|surfactant airway device|Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
76092797|NCT04038502|Drug|Carboplatin|Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
76092798|NCT04038502|Drug|Olaparib|Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
76092799|NCT04008147|Dietary Supplement|100mg iron fumarate|100mg iron fumarate b.i.d. for 4 consecutive days
76092800|NCT04008147|Dietary Supplement|Burgerstein Schwangerschaft & Stillzeit|contains 30 mg iron fumarate, given on 14 consecutive days
76092801|NCT03994796|Drug|Abemaciclib|Given PO
76092802|NCT03994796|Drug|PI3K Inhibitor paxalisib|Given PO
76092803|NCT03994796|Drug|Entrectinib|Given PO
76092804|NCT03994796|Drug|Adagrasib|Given PO
76092805|NCT03982316|Behavioral|Telehealth Behavioral Migraine Management|1) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
75346418|NCT03212222|Other|Peek Acuity|Cell phone application for visual acuity screening
75657862|NCT06166082|Device|Sham iTBS-DLPFC|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
75657863|NCT06166043|Behavioral|NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION|An online training consisting of 10 sessions in total for 5 weeks will be given to the patients in order to improve their fatigue management skills. In addition to this training, they will receive a nurse support program.
75804779|NCT03668548|Dietary Supplement|Leucine|192 mg/kg body mass/day
75804780|NCT03668548|Dietary Supplement|Placebo|A taste and calorie-matched placebo
75945218|NCT03412149|Procedure|Mini Gastric Bypass|"Standardization of the techniques will be guaranteed:~Mini Gastric Bypass Arm~Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
76092806|NCT03975387|Drug|ASTX295|ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
76092807|NCT03973697|Drug|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
76092808|NCT03973697|Drug|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
76092809|NCT03973697|Drug|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
76092810|NCT03958994|Other|Qualitative interviews|What are the roles of organisational factors, education and policy in shaping the experiences of staff and carers who care for people with dementia?
76092811|NCT03951142|Drug|Losartan|This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
76092812|NCT03937713|Drug|eszopiclone|Eszopiclone is a nonbenzodiazepine benzodiazepine receptor agonists, effective for both sleep onset insomnia and sleep maintenance insomnia
75945219|NCT03412149|Procedure|Roux en Y Gastric Bypass|"Standardization of the techniques will be guaranteed:~Mini Gastric Bypass Arm~Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
76092813|NCT03937713|Behavioral|Brief behavioral therapy for insomnia|BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.
76092814|NCT03920215|Drug|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray
76092815|NCT03920215|Drug|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray
76092816|NCT03920215|Drug|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray
76092817|NCT03920215|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
76092818|NCT03917498|Radiation|Single Pre-Operative Radiation Therapy - with Delayed Surgery|Single Pre-Operative Radiation Therapy - with Delayed Surgery
76092819|NCT03902821|Other|XR-NTX and Certified Recovery Mentor|All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
75346419|NCT03212222|Other|Standard Visual Screening|Visual screening exam conducted in Duke University Eye Center
75804781|NCT03669874|Device|Endoscopic fundoplication|"Endoscopic fundoplication is a less invasive alternative to the traditional surgical fundoplication.~The MUSE device is similar to an endoscope, so the whole procedure can be done by a single operator. The device is composed of a shaft with a distal rigid part which is placed in the esophagus 3 cm proximal to the esophago-gastric junction containing a cartridge holding five B-shaped titanium surgical Staples and a tip which is retroflexed and contains an ultrasonic transducer which defines the correct tissue thickness for stapling the fundus against the esophagus. The device must be extracted to be reloaded with 5 more staples at a time for creation of a 180° anterior fundoplication."
75945220|NCT03153644|Behavioral|Interview|1 hour semi-structured
75945221|NCT03153644|Behavioral|Observation|Field Observation
75945222|NCT03412071|Drug|Oral Tinidazole|Please see description under arms
75945223|NCT03412071|Drug|Topical metronidazole|Please see description under arms
76092820|NCT03884660|Device|remede System|Patients undergoing a remede System implant attempt. Study devices will be used per approved indications for use for each geography.
76092821|NCT03878134|Device|PHOTON COUNTING CT Scanner|Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.
76092822|NCT03874429|Device|T2259|Sodium Hyaluronate and Trehalose
76092823|NCT03874429|Device|Vismed multi|HA
76092824|NCT03871153|Device|Durvalumab|"Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1"
76092825|NCT03871153|Drug|Paclitaxel|Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36
76092826|NCT03871153|Drug|Carboplatin|Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36
76092827|NCT03871153|Radiation|Radiation|1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).
76092828|NCT03871153|Procedure|Surgical Resection|Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.
75346420|NCT02502864|Drug|Standard of Care: Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
75346421|NCT02502864|Drug|Standard of Care: Cyclophosphamide|Cycle 1: 600 mg/m^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
75804782|NCT03668470|Drug|Dulaglutide|Dulaglutide 1.5mg : One injection per week during 24 weeks
75804783|NCT03668470|Drug|Placebo|Placebo: one injection per week during 24 weeks
75804784|NCT03020992|Drug|Certolizumab Pegol|"pharmaceutical form: solution for infusion in prefilled syringe~concentration: 200 mg/mL~route of administration: subcutaneous"
75945224|NCT03412071|Drug|Topical Clindamycin|Please see description under arms
75945225|NCT03412071|Drug|Topical Hydrogen Peroxide|Please see description under arms
76092829|NCT03870360|Behavioral|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
76092830|NCT03870360|Behavioral|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
76092831|NCT03870360|Behavioral|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
76092832|NCT03870360|Behavioral|HOLA Component 4|One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.
75657864|NCT06166030|Dietary Supplement|Nutritional blend (ImmuneRecov).|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.
75945226|NCT02356874|Behavioral|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
75945227|NCT02352038|Device|low-level laser therapy|The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.
75945228|NCT02352038|Other|orthodontic treatment|Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
75945229|NCT03397797|Drug|Rocuronium|In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
75945230|NCT03411993|Diagnostic Test|Focused cardiac echography|All pregnant women attending antenatal care will be eligible to undergo focused cardiac echo to identify underlying cardiac disease
75945231|NCT03153332|Other|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
75945232|NCT05170191|Behavioral|Sleep Deprivation|The participants will stay awake for 24 hours.
75945233|NCT02361710|Procedure|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
75945234|NCT02361632|Dietary Supplement|Coffee with or without milk|Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
75945235|NCT02357108|Other|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
75945236|NCT02357108|Behavioral|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
75945237|NCT03397641|Drug|HBI-3000|Small molecule, multi-ion channel blocker
75945238|NCT03397641|Other|Placebo|Normal Saline
75945239|NCT04479098|Other|Resistance exercise training|The exercise training program will last 12 weeks, with a frequency of three sessions per week, held on Mondays, Wednesdays, and Fridays. Each session will last approximately 50 minutes. Whenever the maximum number of pre-established repetitions is successfully performed, the intensity will be increased by 5 to 10%. All sessions will be supervised by trained professionals.
75945240|NCT04479098|Other|Exercise detraining|The exercise detraining will last 12 weeks without exercise.
75945241|NCT05169879|Procedure|coronal flaring|early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
75945242|NCT05169879|Procedure|Non coronal flaring|No coronal flaring will be performed
75657865|NCT06166017|Other|Exposure to minimal amount of lingual keratinized tissue width|measurement of clinical parameters
75657866|NCT06166004|Other|Balance Training|Balance Training device with VR
75657867|NCT06166004|Other|Person-Specific Rehabilitation Program|Person-Specific Rehabilitation Program
75657868|NCT06165965|Drug|SGLT2 inhibitor|SGLT2 dual inhibitor
76092833|NCT03870360|Behavioral|Healthy lifestyles education program|Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
76092834|NCT03845517|Drug|Placebo|Placebo
75657869|NCT06165939|Drug|Intra-articular corticosteroid injection|Ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine) is performed once for the patient at the first week.
75657870|NCT06165939|Drug|hydrodilation with 15% hypertonic dextrose|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is 15% hypertonic dextrose (6 ml 50% Dextrose + 2 ml 2% Xylocaine + 12 ml normal saline, totaling 20 ml).
75657871|NCT06165939|Drug|hydrodilation with Normal saline|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is Normal saline (2 ml 2% Xylocaine + 18 ml normal saline, totaling 20 ml).
75657872|NCT06165926|Drug|15% hypertonic dextrose|"The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed."
75804785|NCT03020914|Device|Audiovisual Distraction|watching a movie using video glasses and headphones
75804786|NCT03668314|Drug|RDN-929|Single dose from 2 mg to TBD
75804787|NCT03668314|Drug|Placebo oral capsule|Matching placebo Single dose
75804788|NCT03668314|Drug|RDN-929 TBD dose|Fed vs fast dose TBD based upon results of previous cohorts
75804789|NCT03668314|Drug|RDN-929|Multiple dose based on results of previous cohorts
75804790|NCT03668314|Drug|Placebo oral capsule|Matching placebo multiple dose
75804791|NCT03018340|Drug|Pimavanserin|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
75346422|NCT02502864|Other|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
75804792|NCT03018340|Other|Placebo|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
75945243|NCT02356796|Other|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
75945244|NCT02356796|Other|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
75945245|NCT05170581|Drug|Sintilimab Combined with Platinum-containing Chemotherapy|Admininster Sintilimab and platinum-containing chemotherapy in neoadjuvant treatment of resectable stage ⅡB～ⅢA Non-small Cell Lung Cancer
75945246|NCT02039024|Drug|18F- DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
75945247|NCT02356718|Behavioral|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
75945248|NCT02356718|Behavioral|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
75945249|NCT03397563|Device|Continuous Positive Airway Pressure|standard automatic CPAP machine set on optimal automatic pressure
75945250|NCT03397563|Device|sham Continuous Positive Airway Pressure|CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
75945251|NCT02351882|Drug|Nabilone|Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).
75945252|NCT02351882|Drug|Placebo|Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
75945253|NCT04710693|Diagnostic Test|CAD polyp-detection system|Software will be used during the procedure to aid the detection of polyps during the procedure.
76092835|NCT03845517|Drug|PF-06700841 15 mg|PF-06700841 15 mg
75346423|NCT03211598|Procedure|TACE with Surefire|Subjects that consent to the study will receive their TACE procedure through the Surefire Infusion System
76092836|NCT03845517|Drug|PF-06700841 30 mg|PF-06700841 30 mg
76092837|NCT03845517|Drug|PF-06700841 45 mg|PF-06700841 45 mg
76092838|NCT03823768|Drug|Envarsus|Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
76092839|NCT03823768|Drug|Tacrolimus Immediate release|Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
76092840|NCT03799302|Behavioral|SIC Coaching|Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
76092841|NCT03786094|Drug|Eribulin|Eribulin alone
76092842|NCT03786094|Drug|Balixafortide|Balixafortide + Eribulin
75804793|NCT03667768|Procedure|Glass ionomer sealant|
75804794|NCT03667768|Behavioral|Non-sealant (toothbrushing)|
75804795|NCT03016078|Device|Mepilex Border Post-Op Ag|To investigate if there was any skin damage under the dressing from operation day to last visit.
76092843|NCT03776747|Drug|Prone hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.
76092844|NCT03776747|Drug|Supine hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.
76092845|NCT03776747|Diagnostic Test|Vitals|
76092846|NCT03776747|Diagnostic Test|Pulmonary Function Tests|Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
76092847|NCT03776747|Diagnostic Test|Initial protocol MRI scan|Initial scan to determine placement
75346424|NCT01835600|Other|PEEP|PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
75346425|NCT01835834|Procedure|zirconia bridge restoration|
75346426|NCT03217760|Procedure|Endodontic treatment|Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
75346427|NCT03217760|Other|VAS of stress|The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
75804796|NCT00048165|Drug|Daclizumab|Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.
75945254|NCT02356640|Procedure|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
75945255|NCT02356640|Procedure|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson &Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
76092848|NCT03742089|Device|Bone Anchored Hearing Surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected will be used to assess the implant stability development of the Ponto BHX implant during up to 24 months after implantation in a pediatric population undergoing BAHS. The study will also monitor the Ponto BHX implant safety and survival throughout the study period.
76092849|NCT03734354|Drug|Brexpiprazole|Brexpiprazole , single/oral/with fasting
75346428|NCT03217760|Other|CORAH scale|At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).
75346429|NCT03217760|Other|HAD Scale|At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.
75346430|NCT03217760|Other|Cardiovascular Parameters|For each subject, the physiological indicators of stress (ie, heart rate [HR], systolic blood pressure [SBP], and diastolic blood pressure [DBP]) are monitored during each of the 6 steps.
75346431|NCT03217760|Other|Cortisol Measurements|Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .
75346432|NCT03217760|Other|Discomfort and Pain Experienced During Treatment|Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.
75346433|NCT03217760|Other|Patient's preferences.|After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.
75346434|NCT03217760|Other|student preferences.|"When the treatment is complete the students are asked to report:~his/her level of satisfaction with the course of treatment,~whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session~whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment."
75945256|NCT02356640|Device|Olympus UM 2000|
75945257|NCT02356640|Device|B-D Quincke Type Point|
75945258|NCT02356640|Drug|Levobupivacaine|
75945259|NCT05169801|Drug|BP102, paclitaxel, carboplatin|BP102, paclitaxel, carboplatin
75945260|NCT05169801|Drug|Avastin®, paclitaxel, carboplatin|Avastin®, paclitaxel, carboplatin
75945261|NCT03397485|Dietary Supplement|Growing milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
76092850|NCT03734302|Drug|Brexpiprazole|Brexpiprazole , mutiple dose /oral/empty stomach
75657873|NCT06165926|Drug|Normal saline|The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.
75657874|NCT06165926|Other|physical therapy|Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.
75657875|NCT06165913|Procedure|Early implant placement(type II)|in group 1, Tooth extraction will be performed with care to preserve alveolar bone walls. After 4-8 weeks from tooth extraction, dental implant will be placed
76092851|NCT03734211|Drug|Evolocumab|420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
76092852|NCT03734211|Drug|Placebo|Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
75346435|NCT03211910|Device|SacralSaver|Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's mid back and the pressure exerted by the lower back of the patient is markedly reduced or nearly eliminated (tested and proven using computer models), thereby preventing the onset of pressure ulcers in the sacro-coccygeal area.
75346436|NCT03211910|Other|Standard Care of Treatment|Standard Care of Treatment
75476919|NCT05317481|Behavioral|BE-SMART-DR|Therapy that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk
75476920|NCT05317481|Behavioral|psychoeducational control comparator condition (CC)|Structured sessions, matched for BE-SMART-DR session number and time, that will emphasize established strategies to manage health and well being
75346437|NCT01457417|Drug|DKN-01|DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
75657876|NCT06165913|Procedure|Early implant placement (type III)|in group 2, Tooth extraction will be performed with care to preserve alveolar bone walls. After 12-16 weeks from tooth extraction, dental implant will be placed.
75657877|NCT06165874|Radiation|[68Ga]Ga-NOTA-RW102 PET Imaging|Intravenous injection of 1.8 MBq[0.05MCi]/kg of [68Ga]Ga-NOTA-RW102 in a single dose.
75657878|NCT06165861|Other|Experimental (with VR-G)|Watching video with using VR-G before undergoing open heart surgery
75346438|NCT03217292|Procedure|Serratus Anterior Plane Block|
75346439|NCT03217292|Drug|IV patient-controlled analgesia (PCA) tramadol|
75476921|NCT05310695|Other|NSAC - rapid|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment within 4 weeks of referral.
75657879|NCT06165835|Device|breathing training|Breathing training for six weeks.
75657880|NCT06165822|Drug|TQB3909 tablets|TQB3909 100mg/tablet.
75657881|NCT06165822|Drug|Itraconazole capsule|Itraconazole capsule is a strong inhibitor of CYP3A4.
75657882|NCT06165822|Drug|Rifampicin capsule|Rifampicin capsule is a strong inducer of CYP3A4.
75657883|NCT06165783|Other|Therapeutic Exercises and Ultrasound|describe the rationale and methodology for evaluating the effect of using therapeutic exercises and ultrasound in the rehabilitation of partially injured hamstring muscles
75657884|NCT06165536|Behavioral|Resonant voice therapy|Resonant voice therapy is a standard of care procedure for treating phonotraumatic vocal hyperfunction. The full standardized voice therapy program will have a duration of four weeks, each week with one 60-minute therapy session.
75657885|NCT06163703|Behavioral|Family Life Skills Triple P|The intervention is a 12-session program that combines parenting support with trauma-informed life skills coaching. It includes content related to positive parenting strategies, self-regulation, coping with emotions, effective communication, dealing with the past, and developing healthy habits.
75657886|NCT06162364|Other|VR|playing a video using VR
75657887|NCT06162364|Other|theoretical training|Training was provided through theoretical education
75657888|NCT06162364|Other|training with video|Training was given with two-dimensional video
75657889|NCT06160453|Device|Brain-Computer Interface control of robotic arms with augmented reality|The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions
75804797|NCT00048165|Drug|Methylprednisolone|Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).
75804798|NCT00048165|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.
75804799|NCT00048165|Drug|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
75804800|NCT00048165|Drug|cyclosporine|Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
75346440|NCT03217448|Drug|Dabigatran etexilate|Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
75346441|NCT03217448|Drug|Warfarin|Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
75657890|NCT06160453|Device|Serious game with augmented reality|The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game will be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions
75804801|NCT03952221|Device|Continuous ultrasound therapy|continuous US therapy once a day, 9 minutes/session for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity
75804802|NCT03952221|Device|pulsed ultrasound therapy|pulsed US therapy once a day, 9 minutes/session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle
75804803|NCT03952221|Device|US and electrotherapy (sonotens)|US and electrotherapy (transcutaneous electrical nerve stimulation) once a day, 10 minutes /session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, US: 3 MHz frequency, 0,5 W/cm2 SATA intensity, TENS: application in conventional mode at 100 Hz frequency and 100 μs wavelength
75804804|NCT03952221|Device|Sham ultrasound therapy|sham US therapy once a day for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 0 MHz frequency, 0 W/cm2 SATA intensity
75804805|NCT01099371|Other|exercise|progressive resistance training
75804806|NCT03955107|Device|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) every 4 weeks since diagnosed with GDM，and the control grouponly once receive CGMS during the last month and have management adjusted based on the CGMS readings Other Name: iPro, Medtronic
75804807|NCT01099527|Drug|Everolimus (RAD001)|dose escalation of capecitabine, everolimus
76092853|NCT03733730|Device|ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
76092854|NCT03733730|Device|ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
76092855|NCT03733730|Device|ACRYSOF IQ RESTOR +2.5 D Multifocal IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
76092856|NCT03733730|Procedure|Cataract Surgery|Routine small incision cataract surgery with IOL implantation
76092857|NCT03732781|Drug|Radspherin|"Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days."
76092858|NCT03724695|Other|Clinician nudge or opt out approach for AHCAH liaison visit|"This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care)."
76092859|NCT03723161|Device|Bone Achored Hearing surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected data will be used to assess the implant stability development of the Ponto BHX implant during up tp 24 months after implantation in a pediatric population undergoing bone anchored hearing surgery.
76092860|NCT03713632|Drug|Secukinumab|Secukinumab 300mg every 2 or every 4 weeks
76092861|NCT03713632|Drug|Placebo|Placebo 300mg every 2 or every 4 weeks
76092862|NCT03682900|Other|Click City®: Tobacco|A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.
76092863|NCT03682900|Other|Usual Tobacco Curriculum|Students complete their usual curriculum designed to prevent tobacco use.
76092864|NCT03673826|Drug|Carfilzomib|9 cycles 20/36mg/m2 days 1,2,8,9,15,16
76092865|NCT03673826|Drug|Dexamethasone|4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23
76092866|NCT03673826|Drug|Lenalidomide|9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
76092867|NCT03657394|Other|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
75804808|NCT01099527|Drug|Capecitabine|dose escalation of capecitabine, everolimus
75804809|NCT01093365|Drug|Varenicline|"0.0 mg orally twice per day for three days (placebo)~0.5 mg orally twice per day for three days~1.0 mg orally twice per day for three days"
75804810|NCT01095549|Device|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt<mw>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.
75804811|NCT01095549|Device|Placebo device|A device without far infrared therapy
75804812|NCT03955497|Other|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
75804813|NCT03955497|Drug|Sodium Hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
75945262|NCT03397485|Dietary Supplement|Fortified milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
75945263|NCT02356406|Radiation|Celiac Plexus Radiosurgery|"5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis."
75657891|NCT06160050|Behavioral|Breakthrough Parenting Curriculum: Transforming trauma across generations|The BPC (Breakthrough Parent Curriculum): Navigating Trauma Across Generations is a 10 module course adapted from the NCTSN training called Caring for Children Who Have Experienced Trauma: A Workshop for Resource Parents (RPC). The BPC is specifically designed for parents who have been involved with (or are at risk for being involved with)the child welfare system. The course provides information about the impact of trauma on the development, attachment, emotions and behaviors of children while holding space for parents to learn together about concrete strategies for managing daily and ongoing challenges and enhancing their relationships with their children. All while acknowledging the challenges of parenting a child who has experienced trauma, while having experienced your own trauma.
75657892|NCT06159634|Procedure|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) will be the technique used to remove target lesions.
76092868|NCT03655028|Behavioral|rhythmically auditory stimulation enhanced music|Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program
75346442|NCT03217370|Other|education of guidelines|"Guidelines will be updated and education will be given to haematologists in several ways.~ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
75346443|NCT03211754|Dietary Supplement|walnuts and almonds|The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
75346444|NCT01457573|Drug|Tamsulosin|Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
75346445|NCT01457573|Drug|Solifenacin|Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
75657893|NCT06159634|Device|Traction Device|Use of traction device to aid in removing target lesions
75657894|NCT06159179|Procedure|Medical thoracoscopy|Medical thoracoscopy is a minimally invasive procedure to have access to pleura with combination of visual and medical instrument. The procedure is done with local and light anesthesia. Medical thoracoscopy plays role in basic diagnosis and therapeutic. A Flex-rigid thoracoscope will be inserted through the trocar cannula in the rigt or left mid axillary line of the hemithorax
75804814|NCT03955497|Procedure|Extraction of abdominal fat|In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel.
75804815|NCT01099605|Device|placement of a continuous infusion pump|Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
75804816|NCT01099605|Device|continuous infusion pump of bupivacaine|bupivacaine 0.25% at 4ml/hr for 3 to 4 days
76092869|NCT03655028|Behavioral|control|Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program
76092870|NCT03637595|Procedure|Acupuncture|3 sessions of acupuncture will be the reference therapy against which the energy medicine intervention is being compared.
76092871|NCT03637595|Procedure|Enery Medicine Intervention|3 sessions performed by Energy Medicine practitioner, who will perform an assessment followed by the intervention.
76092872|NCT03637595|Procedure|Sham Energy Medicine|a non-energy trained confederate to be determined from the clinical research coordinators and non traditional volunteers enrolled administering assessments and providing therapeutic company.
76092873|NCT03609216|Drug|Gemcitabine Hydrochloride|Given IV
76092874|NCT03609216|Drug|Cisplatin|Given IV
76092875|NCT03609216|Biological|Pegfilgrastim|Given SC
76092876|NCT03609216|Procedure|Conventional Surgery|Undergo bladder sparing
76092877|NCT03609216|Procedure|Radical Cystectomy|Undergo radical cystectomy
76092878|NCT03609216|Other|Chemoradiotherapy|Undergo chemoradiotherapy
76092879|NCT03593590|Drug|Ocrelizumab|Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
76092880|NCT03573921|Drug|Gastrograﬁn|Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
76092881|NCT03573921|Other|Saline solution (control treatment)|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
76092882|NCT03559868|Drug|Digoxin|Different doses of oral digoxin to test if digoxin has an effect on the immune response of peripheral blood levels (PBLs).
75346446|NCT03217526|Other|Gait Training|Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
75346447|NCT02474082|Biological|Secukinumab|Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
75657895|NCT06157931|Behavioral|Resilient Student Training intervention (ReST)|ReST consists of one individual 60-minute session and two 90-minute group-based sessions.
75657896|NCT06157567|Device|Profound Matrix|Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
75657897|NCT06157541|Biological|Allogeneic cytomegalovirus-specific T cells|Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors
75657898|NCT06157541|Drug|Pembrolizumab|A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
75657899|NCT06157515|Device|Breath-actuated vibrating mesh nebulizer|The intervention utilizes a breath-actuated vibrating mesh nebulizer system consisting of a controller module with microphone for respiratory phase detection and algorithm for inspiration triggering. This interfaces with the vibrating mesh nebulizer module which incorporates a micro-pump chip using piezoelectric effects to eject fluid through a mesh aperture plate holes. By detecting the onset of inspiration based on characteristic acoustic patterns using machine learning models, the controller module sends signals activating the piezoelectric vibration mechanism to generate aerosol only during the inspiratory phase through precision timing control, shutting off mist during expiration. The core module is attached to a standard commercial vibrating mesh nebulizer using the standard adult reusable mouthpiece interface.
75804817|NCT00059787|Drug|paclitaxel|Given IV
75804818|NCT00059787|Drug|carboplatin|Given IV
75804819|NCT00059787|Drug|erlotinib|Given PO
75804820|NCT01099683|Drug|NRL001|Single rectal administration of 2 mg NRL001 in a 2 g suppository
75804821|NCT01099683|Drug|Placebo|All subjects will receive rectal suppository containing placebo
75804822|NCT01093443|Drug|ovarian stimulation|rFSH with GnRH antagonists
75804823|NCT01093443|Drug|ovarian stimulation|GnRH antagonist, rFSH, GnRH antagonist
76092883|NCT03559868|Other|Placebo|Oral placebo
76092884|NCT03534947|Drug|Sonidegib|Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.
76092885|NCT03534947|Drug|Imiquimod|Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.
75657900|NCT06157515|Device|Continuous vibrating mesh nebulizer|When the continuous vibrating mesh nebulizer powered on, the micro-pump chip provides sustained vibrations onto the aperture plate, forcing fluid through micron-scale pores under pressure to continuously produce aerosol throughout inspiration and expiration phase.
75657901|NCT06156930|Other|Intervention group|The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
75804824|NCT03954951|Other|Multimodality behavioral strategy|"On-line course on hypertension management based on the new ACC/AHA and ESC/ESH guidelines on hypertension management.~Weekly performance feedback reports: will include percent of patients with uncontrolled hypertension and among this group percent of visits where no change in medication was made. It will also include a comparative assessment of the performance of the physicians compared with their colleagues in the province."
76092886|NCT03534947|Procedure|Surgery|Although most BCCs are amenable to surgery, excision of large tumours in aesthetically sensitive sites may compromise function or cosmesis. Patients whose BCC has not shrunk in size or depth following 12 weeks of sonidegib will undergo surgical excision of the remaining tumour.
76092887|NCT03534947|Other|Best supportive care|Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions
76092888|NCT03517436|Device|TAVR with CENTERA THV|TAVR with the Edwards CENTERA THV System
76092889|NCT03476330|Drug|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
76092890|NCT03458455|Diagnostic Test|Magnetic Resonance Imaging|Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.
75657902|NCT06156930|Other|Placebo group|The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
76092891|NCT03458455|Radiation|Stereotactic Radiosurgery|A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.
76092892|NCT03458455|Drug|Ipilimumab, nivolumab or pembrolizumab|A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.
76092893|NCT03448601|Other|Culturally tailored brochure intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational brochure.
76092894|NCT03448601|Other|Culturally tailored video intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational video.
76092895|NCT03430973|Behavioral|Videos|Videos depicting various aggressive driving and road rage behaviors.
76092896|NCT03430973|Behavioral|Bumper stickers|Bumper stickers hypothesized to increase or decrease aggressive driving.
76092897|NCT03430973|Behavioral|Alcohol-related cues|Case of beer or water on passenger seat.
76092898|NCT03430973|Behavioral|Music|Lyrics and tempo of music will be manipulated to increase or decrease aggressive driving.
76092899|NCT03430973|Behavioral|Roadside vegetation|The roadside will contain trash to increase aggressive driving, or vegetation to decrease aggressive driving. There is also a control group.
76092900|NCT03430973|Behavioral|Video game|Participants will play a racing or neutral video game before driving in the simulator.
76092901|NCT03414034|Drug|Onvansertib|Onvansertib orally
75346448|NCT02474082|Drug|Fumaric acid|Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
75346449|NCT01836146|Device|EnligHTN™ Renal Artery Ablation Catheter|
75657903|NCT06155747|Other|Epidemiologic investigation|"Identification of:~overlaps in source(s) of care between participants with NTM isolates in a healthcare center.~environmental NTM isolates that are highly related to respiratory isolates.~common water source exposure among subjects with clustered NTM infections via shared home of residence watershed."
75804825|NCT03955185|Procedure|minimally invasive surgery|Laparoscopic or robotic assisted radical hysterectomy
76092902|NCT03414034|Drug|Abiraterone|Abiraterone orally
76092903|NCT03414034|Drug|Prednisone|Prednisone orally
76092904|NCT03391869|Biological|Ipilimumab|Given IV
76092905|NCT03391869|Procedure|Local Consolidation Therapy|Undergo radiation and/or surgery
76092906|NCT03391869|Biological|Nivolumab|Given IV
76092907|NCT03391869|Other|Quality-of-Life Assessment|Ancillary studies
76092908|NCT03391869|Radiation|Radiation Therapy|Undergo radiation
76092909|NCT03391869|Procedure|Therapeutic Conventional Surgery|Undergo surgery
76092910|NCT03375619|Other|Long-Term Follow-Up of Participants who Received CAR-T cells|No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
76092911|NCT03366545|Device|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of routine care for CRT patients
75346450|NCT01560143|Drug|Tigecycline|100 mg IV as a single infusion over 30 minutes
75346451|NCT03212066|Behavioral|Master Mind|Master Mind is a 25-lesson elementary school mindfulness education substance abuse prevention program. Each lesson takes approximately 15 minutes and is designed to be taught by trained teachers every day for 5 weeks.
75804826|NCT03955185|Procedure|open abdominal surgery|Traditional open abdominal radical hysterectomy
75945264|NCT05169645|Other|Physical activity monitoring - Symptom monitoring|"This is an observational study. There is no intervention outside the collection of data from participants. Consenting participants in the study will be provided with a Fitbit activity tracker and asked to wear it for a period of three months.~The Fitbit measures:~Physical activity using daily step count~Additional physical activity entries~Heart rate~Sleep quality~Calories burned~Food log~Participants will be asked to download an app onto their smart phone entitled Athena CX. This app is designed to capture:~Urticaria symptomatology using the urticaria control test~Symptoms of depression using 2 items from the PHQ 9~Symptoms of anxiety using two items from the GAD~Short form self-compassion scale"
75945265|NCT03153176|Behavioral|Training|Training program 30 hours accumulated before, during and after intervention
75804827|NCT01099839|Drug|ASP1941|oral
76092912|NCT03362177|Biological|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.
76092913|NCT03362177|Other|Placebo|Placebo Comparator
75346452|NCT01836224|Drug|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) >65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
75657904|NCT06155708|Dietary Supplement|Ketone|- Ketone monoester supplement in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.45ml/kg body weight) ingested with water and vanilla-flavored stevia in a total volume of 100 ml.
75657905|NCT06155708|Dietary Supplement|Water|100 ml water combined with 10ml bitter flavor and vanilla-flavored stevia
75945266|NCT03153176|Behavioral|Individual level|7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
75945267|NCT03153176|Behavioral|Organizational level|Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
75945268|NCT03411681|Other|Resistance Exercise|Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
75945269|NCT03152396|Other|CV risk assessment and modification of global risk|Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
75945270|NCT04447443|Dietary Supplement|Prebiotic Fiber Supplement + loperamide hydrochloride capsule|"2-week sequential supplementation with prebiotic fiber supplement (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
75945271|NCT04447443|Dietary Supplement|Maltodextrin + loperamide hydrochloride capsule|"2-week sequential supplementation with placebo of of maltodextrin (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
75945272|NCT03411603|Other|Diet and socio-demographic questionnaires|24-hr recall or food diary questionnaires; socio-demographic questionnaires
75945273|NCT02361242|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
76092914|NCT03344666|Behavioral|Step 1 Treatment BI+HC|Participants in the Brief intervention + Health Coach (BI+HC) will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks, which will occur by phone or in person. During sessions, the HC will review the prior week's progress, and discuss goals and plans for the following week.
75346453|NCT01836224|Drug|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65
75804828|NCT01099839|Drug|Miglitol|oral
75804829|NCT00058539|Drug|rhuMAb 2C4 (pertuzumab)|
75346454|NCT01560377|Device|PINPOINT Endoscopic Fluorescence Imaging System|The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
75346455|NCT03211676|Device|Theranova-500 dialyzer|hemodialysis with Theranova-500 dialyzer.
75804830|NCT03956823|Drug|telmisartan|Telmisartan group: telmisartan 80 mg once a day
75804831|NCT03956823|Drug|amlodipine|amlodipine group: amlodipine 5 mg once a day
75804832|NCT01099995|Other|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
75804833|NCT01099995|Other|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
75804834|NCT03956667|Other|Live Music|Musicians from Cascade Music will provide recruited participants in the experimental arm with high-quality calming, distracting music during their Emergency Department procedure.
75804835|NCT01095627|Other|Metacholine challenge|Exhaled breath analysis following metacholine challenge
75804836|NCT03015532|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam), via instillation
76092915|NCT03344666|Behavioral|Step 1 Treatment BI+TM|Participants in the Brief intervention + Text messages (BI+TM) will receive a BI in the ED, followed by daily TMs for 4 weeks. TM's are tailored based on weekly surveys and focus on motives for alcohol and violence and strategies to reduce involvement.
75804837|NCT03015532|Drug|Saline Placebo|Saline placebo via injection
75804838|NCT03015532|Drug|Bupivicaine HCl|Bupivacaine HCl without epinephrine
75804839|NCT03015532|Drug|Ropivacaine|Ropivacaine, via injection
75804840|NCT03954873|Other|Glucagon-like peptide 2|Human glucagon-like peptide 2
75804841|NCT03954873|Other|Saline|Placebo
75804842|NCT03954873|Other|Glucose|20% (w/v) glucose infusion for regulating plasma glucose
75804843|NCT03954873|Other|Insulin|Actrapid (insulin) for lowering plasma glucose
75804844|NCT03954795|Procedure|TAP|Classic TAP block performed through the petit triangle (the anterior axillary line and iliac crest)
75945274|NCT02520687|Dietary Supplement|Beetroot juice|200mls daily for seven days
75945275|NCT02520687|Dietary Supplement|Nitrate-depleted beetroot juice|200mls daily for seven days
75945276|NCT02356328|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
75346456|NCT03211676|Device|Elisio-21H|hemodialysis with Elisio-21H dialyzer
75945277|NCT03397407|Other|No intervention|
75945278|NCT04695873|Device|Corn Foam Cushion|An anatomically shaped foam pad with a central hole. The upper layer is made from a honeycomb of interconnecting cells, the external facing surface is smooth, the underside is coated with adhesive.
75945279|NCT02361086|Drug|VT-464: given orally once daily in 28 day cycles|VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
75346457|NCT03217214|Diagnostic Test|Thermography|Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
75346458|NCT01836302|Other|Observation|
75346459|NCT01836380|Behavioral|Exercise Training|
75346460|NCT03211364|Other|Glenohumeral mobilization|Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.
75346461|NCT03211364|Other|Scapular mobilization|
75346462|NCT01836536|Drug|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
75346463|NCT03216980|Dietary Supplement|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
75346464|NCT03216980|Dietary Supplement|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
75346465|NCT03216980|Dietary Supplement|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
75346466|NCT03216980|Dietary Supplement|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
75346467|NCT00895232|Drug|Cohort I|
75346468|NCT00895232|Drug|Cohort II|
75346469|NCT00895232|Drug|Cohort III|
75804845|NCT03954795|Procedure|OSTAP|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
75804846|NCT01093677|Drug|LIM-0705|Oral solution 750 mg LIM 0705 BID for 14 days.
75804847|NCT01093677|Drug|Placebo|Oral solution placebo BID for 14 days.
75804848|NCT01584375|Other|Flat midline head position|"Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.~--------------------------------------------------------------------------------"
75804849|NCT01584375|Other|Right flat lateral head position|Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
75804850|NCT01095705|Procedure|Conventional procedure|Local anaesthesia (Lidocaïne)
75804851|NCT01095705|Procedure|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
75945280|NCT03411525|Behavioral|Commitment Invitation for Clinicians (Clinician Intervention)|Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
75945281|NCT03411525|Other|Health Education Materials to Patients (Patient Intervention)|During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
75945282|NCT01345253|Drug|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
75945283|NCT01345253|Drug|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
75945284|NCT02038712|Dietary Supplement|Fed Condition|Subjects will consume a 600mL 600kcal liquid test meal
75945285|NCT02038712|Dietary Supplement|Fasted condition|Subjects will consume 600mL plain water.
75945286|NCT02038712|Procedure|Blood samples|Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
75945287|NCT02038712|Behavioral|Subjective appetite ratings|Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
75945288|NCT02038712|Procedure|fMRI scan|Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
75804852|NCT01100385|Dietary Supplement|Ateronon|Tomato extract (lycopene) capsule, taken once daily for 56 days
75346470|NCT03211130|Behavioral|SystemCHANGE™|During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.
75945289|NCT03411447|Other|Parenteral nutrition|
75945290|NCT03411447|Other|Enteral nutrition|
75945291|NCT03411135|Other|VES and VASI scores as assessment methods for vitiligo|compare VES and VASI scores as assessment methods for vitiligo
75945292|NCT03640715|Other|ENVU|"ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations."
75945293|NCT02351726|Device|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
75945294|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
75945295|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
75945296|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
75346471|NCT03211130|Behavioral|Attention-Control|An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
75804853|NCT01100385|Dietary Supplement|Placebo|Matched placebo capsule, taken once daily for 56 days
75804854|NCT01095783|Procedure|physiotherapeutic intervention|Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
75354715|NCT04683549|Diagnostic Test|HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy|"Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~FDG PET Scan before treatment and 3 months after treatment~Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~[F-18] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy."
75804855|NCT01095783|Procedure|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
75804856|NCT00047463|Device|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
75804857|NCT00047463|Device|Placebo-CPAP|Placebo-CPAP
75945297|NCT01065077|Drug|Placebo|Infusion of placebo during 48h
75945298|NCT03397329|Drug|AG-348 Sequence A|"Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~Washout Period 7 days~Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)"
75804858|NCT01095861|Device|FlexTip ETT (Parker FlexTip/GlideScope FlexTip)|FlexTip ETT used for endotracheal intubation
75804859|NCT01095861|Device|Control - standard flexible ETT (Mallinckrodt)|"Control - standard flexible ETT~Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134"
75804860|NCT03954639|Drug|EXPAREL 13.3Mg/mL Suspension for Injection|Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)
75804861|NCT03954639|Drug|Bupivacaine Hydrochloride|Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL
75804862|NCT01095939|Drug|Placebo|Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
75804863|NCT01095939|Drug|Benazepril hydrochloride|Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
75945299|NCT03397329|Drug|AG-348 Sequence B|"Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~Washout Period 7 days~Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)"
75945300|NCT03150134|Drug|Cyclosporine|Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
75945301|NCT03150134|Drug|routine reduction of immunosuppressive drugs(cyclosporine)|patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
75346472|NCT04380974|Procedure|OCTA plus OCT guided 3+PRN regimen|"For the OCTA plus OCT guided 3+PRN regimen, we recorded patients' data after retreatment by 3 monthly intravitreal injections of anti-VEGF drug. Subsequent reinjections were given as needed according to the changes in patients' visual acuity, activity of PCV lesions shown by OCTA and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, OCTA and OCT.~In case of BVN increased or polypoidal lesion progressed on OCTA scans, persistent subfoveal or perifoveal fluid, macular intraretinal edema on OCT scans, or visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
75476922|NCT05310695|Other|NSAC - ordinary|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment at 10-14 weeks after referral.
75945302|NCT02351648|Other|a transitional care model|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
75945303|NCT02351648|Other|Control|Patients receive usual standard of care from the internal medicine team
75657908|NCT06154005|Device|OsteoAdapt SP|"OsteoAdapt SP is a combination of AMP2 protein bound to an osteoconductive carrier matrix, ReBOSSIS-J. OsteoAdapt SP is a combination of AMP2 protein bound to an osteoconductive carrier matrix, ReBOSSIS-J.~AMP2 is a recombinant variant of a naturally occurring human protein, rhBMP2, that has been modified to allow very tight binding to β-TCP and similar ceramics. AMP2 is osteoinductive, meaning that the protein stimulates new bone formation at the site of implantation through the same intracellular signaling process as rhBMP2.~ReBOSSIS-J is a synthetic, resorbable bone void filler. ReBOSSIS-J is flexible and can easily fill defects of different sizes using appropriate amounts of the device.~The combination product, OsteoAdapt SP, is hydrated at the time of surgery with saline and placed into the interbody fusion cage."
75657909|NCT06154005|Other|Local Autograft|For control arm, local autograft will be utilized inside the interbody cage.
75945304|NCT03411057|Behavioral|Mindfulness Based Stress Reduction (MBSR)|An interactive form of meditation that includes gentle yoga.
75945305|NCT03411057|Other|Control|Standard of care including an educational video.
75945306|NCT02356094|Procedure|Pentacam|Corneal topography using Scheimpflug Pentacam examination
75945307|NCT03411369|Dietary Supplement|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.
75945308|NCT03411369|Other|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
75945309|NCT03160352|Other|Exergame|In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
75945310|NCT04653207|Other|Glucose Solution 1|50g glucose dissolve in 300ml of water
75945311|NCT04653207|Other|Glucose Solution 2|50g glucose dissolve in 300ml of water
75945312|NCT04653207|Other|Glucose Solution 3|50g glucose dissolve in 300ml of water
75657910|NCT06153381|Other|Chatbot|Rehabilitation program based on standard care, but assisted via an instant messaging application using a personal smartphone
75804864|NCT01093833|Device|BD Continuous glucose monitor (BD CGM)|Continuous glucose monitoring for 12-14 hours
75804865|NCT01093833|Device|YSI Glucose Analyzer|Continuous glucose monitoring for 12-14 hours
75804866|NCT01093833|Device|Medtronic Guardian CGM|Continuous glucose monitoring for 12-14 hours
75804867|NCT01093911|Biological|CDP7657|Ascending single doses of CDP7657
75804868|NCT01093911|Other|Placebo|Placebo: 0.9% sodium chloride aqueous solution
75804869|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with docosahexaenoic acid (DHA)|One portion of DHA-enriched pancakes will be eaten each day for 4 weeks.
75804870|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with beta-glucan (BG)|One portion of BG-enriched pancakes will be eaten each day for 4 weeks.
75945313|NCT04653207|Other|Sucrose/Isomaltulose 100:0|50g sucrose dissolve in 300ml of water
75945314|NCT04653207|Other|Sucrose/Isomaltulose 0:100|50g isomaltulose dissolve in 300ml of water
75945315|NCT04653207|Other|Sucrose/Isomaltulose 50:50|25g sucrose and 25g isomaltulose dissolve in 300ml of water
75945316|NCT04653207|Other|Sucrose/Isomaltulose 60:40|30g sucrose and 20g isomaltulose dissolve in 300ml of water
75945317|NCT04653207|Other|Sucrose/Isomaltulose 70:30|35g sucrose and 15g isomaltulose dissolve in 300ml of water
75945318|NCT04653207|Other|Sucrose/Isomaltulose 80:20|40g sucrose and 10g isomaltulose dissolve in 300ml of water
75945319|NCT03411291|Device|MRI, MR Spectroscopy, MR Perfusion|One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
75945320|NCT02355782|Biological|OMS721|Human IgG4 MASP-2 Monoclonal Antibody
75945321|NCT02351804|Drug|Ropivacaine + dexamethasone|Adductor canal block, single bolus
75945322|NCT02351804|Drug|Ropivacaine + placebo|Adductor canal block, single bolus
75346473|NCT04380974|Procedure|OCT guided 3+PRN regimen|"For the OCT guided 3+PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Anti-VEGF drugs. Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, and OCT.~In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
75346474|NCT04380974|Drug|Anti-VEGF drug|Conbercept or other anti-VEGF drugs
75346475|NCT01836692|Radiation|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
75657911|NCT06153381|Other|Standard car|Rehabilitation program based on standard care, assisted with one education session plus informative brochure
75657912|NCT06151483|Drug|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
75657913|NCT06151483|Other|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
75804871|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with anthocyanins (AC)|One portion of AC-enriched pancakes will be eaten each day for 4 weeks.
75804872|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with docosahexaenoic acid and beta-glucan (DHA+BG)|One portion of DHA+BG-enriched pancakes will be eaten each day for 4 weeks.
75804873|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with docosahexaenoic acid and anthocyanins (DHA+AC)|One portion of DHA+AC-enriched pancakes will be eaten each day for 4 weeks.
75945323|NCT03411213|Device|diffuse optical tomography|Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
75945324|NCT03149900|Drug|Secukinumab|See Arm Description
75945325|NCT03410979|Drug|GLPG2737 single dose|GLPG2737 oral suspension, single ascending doses
75945326|NCT03410979|Drug|Placebo single dose|Placebo, oral suspension.
75945327|NCT03410979|Drug|GLPG2737 multiple dose|GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
76092916|NCT03344666|Behavioral|Step 2 Treatment Responders|"Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.~Participants in the BI+HC or BI+TM assigned to stepped down control will receive a brochure containing community resources."
75945328|NCT03410979|Drug|GLPG2737 multiple dose|Placebo, oral suspension, daily for 14 days
76092917|NCT03344666|Behavioral|Step 2 Treatment Non-Responders|"Participants in the BI+HC assigned to be stepped up will receive HC+, which will consist of weekly sessions as well as on daily TMs from the HC.~Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to be stepped up will receive the HC, which consists of 4 weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM."
76092918|NCT03340129|Drug|Ipilimumab|Ipilimumab 3mg per kg every 3 weeks for 4 doses
76092919|NCT03340129|Drug|Nivolumab|Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
75346476|NCT03211052|Drug|TAK-700 and LHRH agonist|TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
75346477|NCT03211052|Procedure|prostatectomy|SURGICAL REMOVAL OF THE PROSTATE
75346478|NCT01560923|Biological|Indoximod|Given twice daily (1200 mg total) by mouth for 6 months.
75657914|NCT06148038|Drug|CBD Oral|CBD Oral 350mg twice daily for 28 days
75657915|NCT06148038|Other|Control|Placebo Control
75657916|NCT06147011|Other|3D printed educational model|Slide-based presention plus 3D printed thyroid fine needle aspiration model
75657917|NCT06144684|Drug|GUB014295|GUB014295 is a long-acting amylin analogue in development, a single subcutaneous dose is administered.
75657918|NCT06144684|Drug|GUB014295-PLACEBO|GUB014295-PLACEBO is matching GUB014295 in appearance, a single subcutaneous dose is administered.
75657919|NCT06144398|Device|Single Use Bronchoscope|The interventional procedure is performed with a single use bronchoscope.
75657920|NCT06144398|Device|Standard Bronchoscope|The interventional procedure is performed with a standard bronchoscope.
75804874|NCT03956589|Drug|Orkambi|Open label of Orkambi treatment during 3 months
75804875|NCT03956901|Other|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \ kg crystalloid infusion to be started~If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.~PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13."
76092920|NCT03340129|Radiation|Stereotactic Radiotherapy|The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
75657921|NCT06141395|Diagnostic Test|NGS-based assay for bacterial identification|A total volume of 26ml of whole blood will be sampled from each enrolled patient for three consecutive days. This will be used for Standard-of-Care (SoC) culture and Next Generation Sequencing (NGS), for identification of circulating microorganisms.
75804876|NCT03015220|Drug|Semaglutide|Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
75945329|NCT02356016|Behavioral|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
75945330|NCT02356016|Behavioral|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
75945331|NCT02356016|Other|control (dietary counseling)|Monthly dietary counseling only
75804877|NCT03015220|Drug|Dulaglutide|Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).
75945332|NCT02355860|Behavioral|assessment|assessment
75657922|NCT06139263|Device|a percussion massage gun (Compex Fix 2.0)|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the trapezius, levator scapula and cervical paravertebral muscles with a percussion massage gun (Compex Fix 2.0) along the origo-insersio line for 3 minutes for each muscle group. Vibration application will be made with the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
75945333|NCT03640403|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
76092921|NCT03340129|Other|Salvage therapy|Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
76092922|NCT03333408|Drug|Postoperative Oral Antibiotics (Clindamycin or Augmentin)|Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
76092923|NCT03317860|Device|Sham tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
76092924|NCT03317860|Device|Active tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
75476923|NCT05310695|Other|NSAC - active control|The active control intervention is provided by the NSAC personnel, but patients are offered a single monodisciplinary examination close to the end of the diagnosis-specific deadline suggested in guidelines, which will vary between 8-26 weeks. Employment counsellors may not be involved in consultations, other cross-disciplinary consultations are restricted, and work-related factors are not to be focused on during examination. Clinicians are provided survey information only on the patient's potential health problems prior to consultation. Patients are provided a health-focused examination, with the aim of symptom-relief.
75476924|NCT05301959|Device|low intensity percutaneous musculoskeletal electrolysis|An acupuncture needle (0.30mm X 25mm) will be introduced into the device's strut. With the equipment on and with a base intensity of 120µA, the acupuncture needle is introduced in a proximal-distal and postero-anterior direction, in the area of the Achilles tendon body. The position of the needle will be checked with ultrasound and once the point to be treated is reached, the working intensity will be increased up to 600 µA. The emission will be maintained until the participant reports a pain of 60/100 in VAS. At that moment, the emission will be paused completely until the participant reports a sensation of at least 20/100 in VAS. After this period the emission will be continued at 600 µA. This cycle will continue until the emission lasts for more than 120 sec, continuously. At this point, the needle will be repositioned to repeat the emission protocol a maximum of 3 times in total.
75804878|NCT00022659|Biological|bevacizumab|Given IV
75804879|NCT00022659|Other|laboratory biomarker analysis|Correlative studies
75804880|NCT03667534|Diagnostic Test|Dry blood spot screening|Dry blood spot measurement of biomarker for screening of cholestasis patients
75804881|NCT03667456|Procedure|Self-rehabilitation by digital support|Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.
75804882|NCT03014674|Biological|Lyophilized mepolizumab|Mepolizumab will be provided as white, uniform, lyophilized cake in vials with unit dose strength of 100 mg/vial for reconstitution in 1.2 mL sterile water for injection (SWFI). Following reconstitution it forms a clear to opalescent, colorless to pale yellow solution for SC injection.
75804883|NCT03014674|Biological|Liquid mepolizumab|Mepolizumab will be provided as a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled autoinjector or safety syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose ethylenediaminetetraacetic acid and polysorbate 80.
75804884|NCT03014674|Device|Prefilled autoinjector|Single use, disposable autoinjector will be assembled with the prefilled syringe containing the drug product. It will enable automatic delivery of the drug product under the power of a spring mechanism following activation of the device. Start and end of injection clicks will inform the user of correct use. A plastic needle will cover shield the needle before and after injection to minimize the potential for needle stick injuries.
75945334|NCT03640403|Drug|Artesunate-amodiaquine|Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
75945335|NCT03126357|Other|Product A|Usual Brand Cigarette
75945336|NCT03126357|Other|Product B|FT21039 an electronic tobacco vapor product
75945337|NCT03126357|Other|Product C|FT21092 an electronic tobacco vapor product
75945338|NCT03126357|Other|Product D|FT21018 an electronic tobacco vapor product
75945339|NCT03126357|Other|Product E|4mg nicotine gum
75945340|NCT02477800|Drug|Aducanumab (BIIB037)|Low dose
75945341|NCT02477800|Drug|Aducanumab (BIIB037)|High dose
75945342|NCT02477800|Drug|Placebo|Placebo
76092925|NCT03308409|Other|Low-intensity extracorporeal shock wave therapy (Li-ESWT)|Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
76092926|NCT03282396|Drug|Ibrutinib|Given PO
76092927|NCT03280394|Diagnostic Test|Liquid Biopsy|Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
76092928|NCT03271489|Other|Elagolix Placebo|Tablets
75945343|NCT02361398|Other|the EIT guide the individualized PEEP Setting|the EIT guide the individualized PEEP Setting in the EIT group
75945344|NCT02355938|Drug|Fidaxomicin 200 mg|Fidaxomicin 200 mg every 12 hours
75945345|NCT02355938|Drug|Placebo|1 dose of placebo every 6 hours x 2 doses
76092929|NCT03271489|Drug|E2/NETA|Capsules
75657923|NCT06139263|Other|conventional treatment program|In the conventional treatment program, heat will be applied to the neck area for 20 minutes and TENS (100 Hz) will be applied to the painful area. Additionally, patients will be given joint range of motion (ROM) exercises under the supervision of a physiotherapist. Patients will be asked to perform ROM exercises in 2 sets of 10 repetitions, holding for 2 seconds at the end point in all directions. As a strengthening exercise, isometric exercises will be given in the flexion extension, right and left lateral flexion directions by waiting for 6 seconds at the end point. Isometric exercises will be performed in 2 sets of 10 repetitions with 1 minute rest between sets.
75657924|NCT06136923|Device|CT-100-D-004-A|Attention Biases App CT-100-D-004-A Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
76092930|NCT03271489|Other|E2/NETA Placebo|Capsules
76092931|NCT03271489|Drug|Elagolix|Tablets
76092932|NCT03240861|Other|18F-FHBG|Given IV
75346479|NCT01560923|Biological|Sipuleucel-T|Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
75346480|NCT01560923|Other|Placebo|Given in same manner as Indoximod; 1200 mg per day by mouth.
75657925|NCT06136923|Device|CT-100-D-004-B|Attention Biases App CT-100-D-004-B Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
76092933|NCT03240861|Biological|Aldesleukin|Given SC
75346481|NCT03837548|Other|Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
75945346|NCT02355938|Drug|Vancomycin|Vancomycin 125 mg every 6 hours
75945347|NCT03397173|Drug|Azacitidine|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.
75945348|NCT03397173|Drug|Ascorbic acid|Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
76092934|NCT03240861|Drug|Busulfan|Given IV
76092935|NCT03240861|Biological|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
76092936|NCT03240861|Procedure|Computed Tomography|Undergo PET/CT
76092937|NCT03240861|Biological|Filgrastim|Given SC
76092938|NCT03240861|Drug|Fludarabine|Given IV
76092939|NCT03240861|Procedure|Leukapheresis|Undergo leukapheresis
76092940|NCT03240861|Drug|Plerixafor|Given SC
76092941|NCT03240861|Procedure|Positron Emission Tomography|Undergo PET/CT
76092942|NCT03237286|Drug|Intravenous ketamine|Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
76092943|NCT03237286|Behavioral|Computer-based Cognitive Training|"Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression."
76092944|NCT03179163|Drug|Captopril Pill|ACEi+SH
75346482|NCT03837548|Other|The other Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
75346483|NCT01836848|Procedure|measuring cerebral perfusion by NIRS with ICG|application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
75346484|NCT03836924|Drug|Perampanel|Perampanel tablets.
75346485|NCT03837002|Other|foot care protocol|foot assesment, foot care, foot care education
75346486|NCT03837080|Other|Nutrition Education|Every patient will receive one individual and two group counselings on specific nutrition-related recommendations for chronic pain patients.
75346487|NCT03836456|Behavioral|Mindfulness-based Stress Resilience Training|Mindfulness is a form of cognitive training that cultivates self-regulative ability and enhances resilience
75346488|NCT03836456|Behavioral|Health Enhancement Program|This is a validated active control developed to serve as a control for mindfulness-based studies.
75346489|NCT01839032|Drug|Vinorelbine cisplatin radiotherapy|"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."
76092945|NCT03179163|Drug|Enalapril Pill|ACEi
75346490|NCT00906776|Device|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
75346491|NCT00906776|Device|Autogenous bone|Autogenous bone application during periodontal surgery
75476925|NCT05301959|Device|Sham application|A modification will be made in a second equipment, closing the circuit with a 10kΩ resistor inside the equipment, in the output strand chip. Allowing the simulation of emission without emitting current to the participant and without being able to appreciate any type of alteration in the handling of the equipment, by the operators. Therefore, the same steps will be followed as in the experimental group.
75804885|NCT03014674|Device|Prefilled Safety Syringe|Single use, disposable safety syringe with a retracting needle guard and locking system.
75346492|NCT01457885|Drug|Clofarabine/Busulfan x 4|"Clofarabine IV dose level: 40 mg/m2/day x 5 days~Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
75346493|NCT01457885|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
75346494|NCT03830138|Genetic|Oxidized-LDL gene polymorphism|Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA
75346495|NCT03210818|Device|Extra-corporeal membrane oxygenation life support|Adjustment of blood flow of extra-corporeal membrane oxygenation life support
75476926|NCT05301959|Other|Silbernagel protocol|The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.
75804886|NCT03018106|Drug|Ospemifene|Ospemifene is a selective estrogen receptor modulator (SERM), and it is the only SERM approved in the United States to treat moderate to severe dyspareunia associated with VVA. It is an oral medication that is taken as a 60mg tablet once daily. Food intake increases its absorption by 2 to 3-fold, and this is not impacted by the fat or calorie content of the food. It is metabolized primarily in the liver, and is excreted in feces.
75804887|NCT03018106|Drug|Vaginal conjugated estrogens|Conjugated estrogens are a mixture of several different estrogen salts derived from natural sources and blended to approximate the composition of estrogens in the urine of pregnant horses. The main components are sodium estrone sulphate and sodium equilin sulfate. Vaginal estrogen is considered the medication of choice for treating vulvovaginal atrophy (VVA).
75945349|NCT02957747|Behavioral|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
75945350|NCT02360852|Drug|A4250|A4250 once daily
75657926|NCT06127420|Other|coronary physiological indices|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance
75804888|NCT03018028|Drug|Semaglutide|Oral administration once daily
75804889|NCT03018028|Drug|Placebo|Oral administration once daily
75945351|NCT03126279|Procedure|Total Knee Replacement Surgery|All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
75346496|NCT01460225|Drug|lubiprostone|24 micrograms twice daily for 1 week
75945352|NCT02361008|Device|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
75945353|NCT02361008|Procedure|Surgery repair with CBP|Traditional surgery repair under the CBP.
75945354|NCT03397095|Combination Product|CSWT+BMMSCs|All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
76092946|NCT03179163|Drug|Hydrochlorothiazide|diuretic
76092947|NCT03170349|Device|Mitral Valve Repair|Minimal Invasive Transcatheter Mitral Valve Repair
76092948|NCT03164993|Drug|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
75346497|NCT01836926|Procedure|Open intersphincteric resection|"laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach"
75346498|NCT01836926|Device|transanal minimally invasive intersphincteric resection|minimally invasive approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
75657927|NCT06124118|Radiation|carboplatin chemotherapy|"Concurrent chemoradiation will be given per standard of care within 24 hours of initiation of standard of care radiation therapy. Treatment will include a paclitaxel/carboplatin chemotherapy regimen administered during the radiotherapy course (over 6-7 weeks).~Paclitaxel (50 mg/m2) will be administered intravenous over 1 hour followed by Carboplatin AUC = 2 mg/min/mL intravenous weekly (every 7 days ± 3 days) during radiotherapy 11, NCCN Non-small cell lung cancer guidelines 2023).~If a patient has a hypersensitivity reaction to weekly paclitaxel, weekly nab-paclitaxel is allowed to replace paclitaxel at the discretion of the treating medical oncologist 37. The recommended starting dose of weekly nab-paclitaxel is 40 mg/m2 to 50 mg/m2 38 39. Standard premedications with steroids, diphenhydramine, H2 receptor antagonist, and 5-HT3 receptor antagonist antiemetics must be administered per individual institutional guidelines."
75804890|NCT03018028|Drug|Liraglutide|Subcutaneous (s.c., under the skin) injection once daily
75945355|NCT03397095|Device|CSWT+Sham operation|Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
75945356|NCT03640247|Drug|Non-narcotic group regimen|Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
75945357|NCT03640247|Drug|Narcotic group regimen|Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
75804891|NCT03667222|Drug|minocycline topical gel|Once daily administration of BPX-04 minocycline gel for 12 weeks
75945358|NCT03396939|Device|Orthosis|All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
75945359|NCT03640169|Other|Health management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
75945360|NCT03394131|Drug|Hylase|hydro-dissection injection of median nerve inside carpal tunnel using hyalase and 10 cc saline
75945361|NCT03394131|Drug|Insulin|hydro-dissection injection of median nerve inside carpal tunnel using 10 IU insulin and 10 cc saline
75945362|NCT03394131|Other|saline|hydro-dissection injection of median nerve inside carpal tunnel using 10 cc saline
75346499|NCT05565911|Other|no intervention|this is an observational study, there is no intervention.
75346500|NCT01837004|Behavioral|CORTEX|2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
75346501|NCT01561469|Drug|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
75346502|NCT01561469|Drug|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
75346503|NCT01837082|Drug|ferric carboxymaltose|
75346504|NCT01837082|Drug|Placebo|
75346505|NCT01837160|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
75346506|NCT01837160|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
75346507|NCT01837160|Procedure|Echocardiogram|Echocardiography.
75804892|NCT03667222|Drug|topical gel vehicle|Once daily administration of BPX-04 gel vehicle for 12 weeks
76092949|NCT03164993|Drug|Pegylated liposomal doxorubicin|Chemotherapy
75804893|NCT03667300|Drug|Evogliptin|This group will take daily evogliptin 5mg per oral, not linagliptin.
75804894|NCT03667300|Drug|Linagliptin|This group will take daily linagliptin 5mg per oral, not evogliptin
75804895|NCT03667066|Drug|Clopidogrel|Patients who were on long-term (more than 3 months) of clopidogrel or received a loading dose more than 4 hours prior to elective percutaneous coronary intervention.
75945363|NCT02360618|Drug|Metformin|See Group Description
75945364|NCT02360618|Drug|Simvastatin|See Group Description
75945365|NCT03640091|Procedure|Post-extractive inter-radicular implant bed preparation|Implant placement in mandibular molars
75945366|NCT05214183|Drug|Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma|Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab
75945367|NCT02360462|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
75945368|NCT02360462|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
75945369|NCT01344161|Dietary Supplement|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
75945370|NCT01344161|Dietary Supplement|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
75945371|NCT02360540|Other|Gestalt estimation|
75945372|NCT03410745|Behavioral|Exercise.|Moderate to heavy intensity resistance exercise consisting of leg press.
75945373|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative|0.25 mL, Intramuscular
75945374|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative|0.5 mL, Intramuscular
76092950|NCT03164993|Drug|Cyclophosphamide|Chemotherapy
76092951|NCT03164993|Other|Placebo|Placebo
76092952|NCT03110822|Drug|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
76092953|NCT03110822|Drug|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
76092954|NCT03110822|Drug|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
76092955|NCT03077542|Procedure|haploidentical stem cell transplant|haploidentical stem cell transplant
75804896|NCT03666520|Other|Clinical Decision Support prompted to the clinician to convert drug.|This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.
75346508|NCT01837160|Radiation|CT-coronary angiogram scan|CT-coronary angiogram following CT-PET scan. Standard protocol.
75657928|NCT06124118|Device|NovoTTF-200T (TTFields) System|"The NovoTTF-200T (TTFields) System is an investigational medical device delivering 150 kHz TTFields to the thorax for the treatment of patients at the age of 22 years or older. The device is a portable, battery operated system which delivers TTFields at 150 kHz to the thorax by means of insulated Transducer Arrays. The NovoTTF-200T produces electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz to the thorax will be continuous for at least 18 hours a day on average. Subjects may take breaks for personal needs (e.g. showering, array exchange) as long as the average treatment remains 18 hours per day (monthly average). TTFields may be continued as long as there is no disease progression per RECIST 1.1 or any of the treatment discontinuation conditions for subject withdrawal or termination."
75945375|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative|0.5 mL, Intramuscular
75945376|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative|0.5 mL, Intramuscular
75945377|NCT04754373|Dietary Supplement|GFA-918|Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.
75945378|NCT04754373|Other|Placebo|Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
75346509|NCT01837160|Procedure|Aortic Valve Replacement|For AVR (already scheduled prior to enrollment)
75346510|NCT01561703|Drug|Antibiotic|One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage that may be used for 7-10 days following surgery .
75657929|NCT06124118|Drug|Durvalumab|Consolidation Durvalumab will be given per standard of care and institutional guidelines every 4 weeks for up to 12 cycles. Refer to package insert for detailed pharmacologic, dosing, and safety information.
75945379|NCT02360384|Drug|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
75945380|NCT02360384|Dietary Supplement|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
75945381|NCT03396861|Drug|Aflibercept|Subconjunctival aflibercept
75945382|NCT03410589|Other|Sinlge arm|application of scales for evaluation of sleep, fatigue and quality of life - Observational study
75945383|NCT04924972|Procedure|Blepharoplasty|90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.
75945384|NCT03149744|Device|RespiraSense Sleep Screener|RespiraSense will be worn at the same time as the standard of care SomnoScreen and it's results will be masked to the site team
75945385|NCT02520843|Drug|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
75945386|NCT02749721|Drug|vortioxetine|Open-label vortioxetine
75945387|NCT02351336|Device|Ultrasound imaging|"- Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)~- corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )~- CL measurement using 2D ultrasound ( in cm)"
75945388|NCT03396627|Diagnostic Test|pathological examination|fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
75945389|NCT02351102|Drug|Valacyclovir|
75945390|NCT02351102|Drug|Placebo|
75945391|NCT03393897|Other|Trans oesophageal echocardiography|Transoesophageal echocardiography : it's a standard practice for this patient
75945392|NCT03393897|Other|Trendelenburg test|Trendelenburg test : it's a standard practice for this patient
75346511|NCT01837238|Dietary Supplement|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
75346512|NCT01837238|Dietary Supplement|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
75804897|NCT03010462|Device|Nexstim NBS guided active rTMS|Nexstim NBS guided active rTMS + standardized task-oriented therapy
75945393|NCT02350868|Drug|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
75945394|NCT02351024|Drug|OXP005|
75945395|NCT02351024|Drug|Naprosyn®|
76092956|NCT03077542|Drug|sirolimus|conditioning regimen
76092957|NCT03077542|Drug|campath|conditioning regimen
76092958|NCT03077542|Drug|pentostatin|conditioning regimen
76092959|NCT03077542|Drug|cyclophosphamide|conditioning regimen
76092960|NCT03077542|Drug|Hydroxyurea|conditioning regimen
76092961|NCT03051256|Drug|REL-1017|REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
76092962|NCT03051256|Drug|Placebo|Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
76092963|NCT02998229|Device|Artisse™|Intrasaccular Device
76092964|NCT02946996|Drug|Metformin|
76092965|NCT02946996|Other|OPC|OPC is a derivative of grape seed extract
76092966|NCT02931721|Diagnostic Test|MRI|Pelvis MRI
75945396|NCT04631367|Behavioral|Kukaa Salama: mHealth intervention|Kukaa Salama is a 8-week social group program of COVID-19 prevention messaging, which includes sending informational SMS once per week and holding secure group discussions on COVID-19 prevention. Weekly SMS messages will focus on COVID-19 knowledge, including information about transmission, hand washing, respiratory hygiene (coughing and sneezing in ways that won't spread germs), face masks, and physical distancing. Participants can also respond to the SMS with any questions about COVID-19, and the study team will respond with further information and/or additional resources. Weekly group chats will be administered using the customized WelTel platform, and will focus on discussions of how participants can apply and practice the information on COVID-19 prevention in their daily lives. Each group chat will be composed of 15-20 participants, and will be facilitated by a research assistant in Kampala as well as a peer navigator.
76092967|NCT02922036|Device|WiSE System|The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
76092968|NCT02915120|Procedure|Real Pulsed Radiofrequency|"Pulsed Radiofrequency uses radiofrequency current in short (20 ms), high-voltage bursts; the silent phase (480 ms) allows time for heat elimination, generally keeping the target tissue below 42° C. The Radiofrequency (RF) electrode will be inserted through the canula, and RF lesions will be generated by applying pulsed RF treatment to the inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches for 8 minutes at 42°C."
76092969|NCT02915120|Procedure|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
76092970|NCT02836236|Drug|TAF|TAF 25 mg tablet administered orally once daily
76092971|NCT02836236|Drug|TDF|TDF 300 mg tablet administered orally once daily
76092972|NCT02836236|Drug|TAF Placebo|TAF placebo tablet administered orally once daily
76092973|NCT02836236|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
76092974|NCT02823821|Other|Default dialysate sodium concentration of 137mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
76092975|NCT02823821|Other|Default dialysate sodium concentration of 140mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
75346513|NCT01460303|Device|Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag|"OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
75346514|NCT01460303|Device|Transurethral catheter with leg bag|"Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
75804898|NCT03010462|Device|Nexstim NBS guided sham rTMS|Nexstim NBS guided sham rTMS + standardized task-oriented therapy
75804899|NCT03666910|Diagnostic Test|Audiometer|detection of hearing problems
75804900|NCT00021255|Drug|Doxorubicin|
75804901|NCT00021255|Drug|Cyclophosphamide|
76092976|NCT02790853|Procedure|Biopsy|Undergo brush biopsy and incisional biopsy
75346515|NCT01837316|Drug|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
75346516|NCT01837316|Drug|Placebo|First strip: Inhalation powder of lactose
75346517|NCT01839422|Behavioral|Memory assessment|Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
75346518|NCT01839422|Other|Brain imaging examination MRI|Brain imaging examination : Structural and functional MRI to compare differences between each sample.
75804902|NCT00021255|Drug|Docetaxel|
75804903|NCT00021255|Drug|Herceptin|
75804904|NCT00021255|Drug|Carboplatin|
75804905|NCT03012334|Drug|Lasmiditan|Dose is based on treatment sequence in 5-way crossover
75804906|NCT03012334|Drug|Alprazolam|Active comparator based on treatment sequence in 5-way crossover
75804907|NCT03012334|Other|Placebo|Placebo comparator based on treatment sequence in 5-way crossover
75346519|NCT01460927|Device|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
75804908|NCT03951285|Dietary Supplement|NR in BMI-discordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
75804909|NCT03951285|Dietary Supplement|NR in BMI-concordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
75804910|NCT02530203|Device|Spinal Cord Stimulation System|High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
75804911|NCT02530203|Device|Holter Recording_ NEMon DR220 Holter Recorders|To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
75804912|NCT04571944|Drug|Suvorexant|Suvorexant administered at a dose of 15 mg QD via oral tablet
76092977|NCT02790853|Procedure|Fluorescence Imaging|Undergo PS2.1/PS3 imaging
76092978|NCT02790853|Procedure|High-Resolution Microendoscopy|Undergo HRME imaging
76092979|NCT02790853|Drug|Proflavine Hemisulfate|Applied on mucosa
76092980|NCT02728531|Drug|Bendamustine|
76092981|NCT02728531|Drug|Rituximab|
75346520|NCT01839500|Drug|Trastuzumab|Trastuzumab administered in accordance with routine care practice.
75804913|NCT04571944|Drug|Placebo|Suvorexant-matching placebo administered QD via oral tablet
76092982|NCT02728531|Drug|Cytarabine|
75945397|NCT04631367|Device|Face Mask + Soap|Participants will be offered the opportunity to pick up a parcel that contains a face mask, bar of soap, and a small parcel of food from the partner agency YARID.
76092983|NCT02728531|Drug|Pegfilgrastim|
76092984|NCT02728531|Procedure|Leukapheresis|
76092985|NCT02728531|Drug|Filgrastim|
76092986|NCT02728531|Procedure|Autologous stem cell transplant|
76092987|NCT02710331|Drug|Active Dronabinol|10 mg capsule of Dronabinol will be administered orally.
76092988|NCT02710331|Drug|Placebo|Control: no alcohol, administered for ~80 minutes.
76092989|NCT02710331|Drug|Placebo|Control: Placebo pill (no active cannabinoids) administered orally.
76092990|NCT02710331|Drug|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
76092991|NCT02677974|Device|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
76092992|NCT02670525|Genetic|Leukemia Profiling|Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
75346521|NCT05565677|Device|micro-computed tomography scanning of lung tissue specimens|Micro-computed tomography will be utilized to scan surgically resected lung tissue specimens.
75346522|NCT04379726|Behavioral|therapeutic optimization|patients with diagnosis of CFRD will undergo the gold standard treatment for the disease (insulin therapy)
75657930|NCT06123572|Other|Placebo|Placebo Comparator
75657931|NCT06123572|Other|Anti-Ageing and Skin Brightening Gel|Anti-Ageing and Skin Brightening Gel.
75804914|NCT03951129|Procedure|hemodialysis catheter insertion|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) scoring will be performed after informing all groups and after the procedure
75804915|NCT03565068|Drug|MK-8189|MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.
75804916|NCT03565068|Drug|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
75346523|NCT01461473|Device|Positive Airway Pressure (PAP)|Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.
75657932|NCT06123143|Other|Standardized/structured CPAP weaning protocol|Standardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA.
75657933|NCT06122818|Other|Immobile patients receiving home health care|Demographic characteristics, duration of immobility, sarcopenia presence, thigh circumference , Hand grip strength , bioelectrical impedance analysis
75657934|NCT06113146|Other|ultra-processed slow eating rate diet|Consuming ultra-processed slow eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a hard texture that require a long chewing duration before a bite of food can be swallowed.
75657935|NCT06113146|Other|Ultra-processed fast eating rate diet|Consuming ultra-processed fast eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a soft texture that require little chewing before a bite of food can be swallowed.
75657936|NCT06112678|Drug|CKD-348(6)|QD, PO
75657937|NCT06112678|Drug|CKD-828, D097, D337|QD, PO
75657938|NCT06107036|Drug|BI 1015550|BI 1015550
75657939|NCT06107036|Drug|Moxifloxacin|Moxifloxacin
75945398|NCT02355704|Drug|Atorvastatin|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
75945399|NCT02355704|Drug|Placebo|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
75945400|NCT03396549|Device|new sham tDCS|1 ch TCT transcranial stimulator
75346524|NCT01461473|Device|Oral Appliance (OA)|Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
75657940|NCT06107036|Drug|Placebo|Placebo-matching BI 101550
75657941|NCT06105580|Procedure|Conduction system pacing|Conduction system pacing implant as a Resynchronization therapy.
75657942|NCT06105580|Procedure|Biventricular pacing|Biventricular pacing implant
75804917|NCT03565068|Drug|Background AAP Therapy|Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone [not to exceed daily dose of 6 mg], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.
75804918|NCT04052932|Drug|SHR4640 dose1|tablets，dose1，QD
75804919|NCT04052932|Drug|SHR4640 dose2|tablets，dose2，QD
75804920|NCT04052932|Drug|Placebo oral tablet|tablets，QD
75804921|NCT04052932|Drug|Allopurinol 300 MG|tablets，300mg，QD
75804922|NCT00010803|Drug|Ginkgo biloba|120mg twice a day
76092993|NCT02525185|Other|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
76092994|NCT02523014|Drug|Vismodegib|Given PO
76092995|NCT02523014|Drug|FAK Inhibitor GSK2256098|Given PO
76092996|NCT02523014|Drug|Capivasertib|Given PO
76092997|NCT02523014|Drug|Abemaciclib|Given PO
76092998|NCT02476435|Device|Active rTMS|Strong electromagnetic fields (~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
76092999|NCT02476435|Device|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
76093000|NCT02461927|Drug|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
76093001|NCT02461927|Drug|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
75346525|NCT00901316|Procedure|Routine Measures Group|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures."
75346526|NCT00901316|Procedure|Bleach Bath Group (Bleach plus routine measures)|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths."
75657943|NCT06105528|Drug|PMN310|60-minute intravenous infusion
75657944|NCT06105528|Drug|Placebo|60-minute intravenous infusion
75945401|NCT03396549|Device|real tDCS|1 ch TCT transcranial stimulator
76093002|NCT02461927|Drug|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
75657945|NCT06102902|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
76093003|NCT02407405|Drug|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
75346527|NCT02501928|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
75346528|NCT02501928|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
76093004|NCT02403323|Drug|Etrolizumab|105 mg etrolizumab subcutaneous administration once every 4 weeks
76093005|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
76093006|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
75346529|NCT02501928|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 28 weeks
76093007|NCT02354365|Device|Transpulmonary Pressure measurement|Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.
76093008|NCT02344498|Drug|Tenofovir disoproxil|
76093009|NCT02294357|Drug|Carfilzomib|
75346530|NCT02501928|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 28 weeks
75346531|NCT01461863|Dietary Supplement|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
75657946|NCT06102902|Procedure|Biopsy|Undergo biopsy
75657947|NCT06102902|Procedure|Biospecimen Collection|Undergo collection of blood samples
75657948|NCT06102902|Biological|Cetuximab|Given IV
75657949|NCT06102902|Procedure|Computed Tomography|Undergo CT
75657950|NCT06102902|Drug|Encorafenib|Given PO
75657951|NCT06102902|Procedure|Magnetic Resonance Imaging|Undergo MRI
75657952|NCT06101589|Dietary Supplement|25 hydroxy cholecalciferol (Vitamin D) /25(OH)D3.|5 mg (200,000 IU) vitamin D3 in 1 ml ethyl oleate Pharmaceutical form: Solution of vitamin D3 in ethyl oleate, 0.75% w/v. three doses will be given orally every a month apart.
75657953|NCT06101589|Dietary Supplement|Placebo|Olive oil in 1 ml ethyl oleate with no vitamin D3 content
75657954|NCT06100913|Biological|Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)|The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm.
75804923|NCT00010803|Drug|Placebo|One pill twice daily
75804924|NCT03666364|Other|Sperm preparation for ICSI|A new protocol for sperm preparation for ICSI cycles with teratozoospermia in over 35 years old women
75945402|NCT02355548|Other|Outpatient Treatment of Pulmonary Embolism|Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
75945403|NCT03396393|Drug|Dihydroartemisinin tablet|DHA tablet
75945404|NCT03396393|Drug|Placebo tablet|Placebo tablet
75945405|NCT02355470|Behavioral|GIFTSS|Universal education and brief counseling regarding sexual violence
75945406|NCT02355470|Behavioral|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
75945407|NCT03393819|Drug|DuraPrep|DuraPrep surgical solution
75945408|NCT03393819|Drug|ChloraPrep|ChloraPrep surgical solution
75945409|NCT03393663|Other|CKD-related outcomes|the study is observational
75945410|NCT03619187|Drug|Ivabradine|Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
75804925|NCT02914834|Other|Acupuncture|Standardized acupuncture treatment administered for 30 minutes each session
75346532|NCT01461863|Dietary Supplement|multivitamin|Standard multivitamin
75945411|NCT02360306|Procedure|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
75657955|NCT06098573|Behavioral|High Alert|Participants assigned to the 'High Alert' condition will complete four interactive modules using their smartphones. These modules are hosted online via the Computerized Intervention Authoring Software, version 3.0 (https://www.cias.app [CIAS]). CIAS is a non- commercial, easily modifiable, web-based intervention platform used widely in the digital substance use literature. No identifiable information is requested or stored in CIAS. This program is only intended to deliver the content interactively. None of the questions asked in CIAS will be treated as research data. We will only report on the proportion of questions answered by participants (as a measure of adherence). Individual responses to questions will not be analyzed nor reported on. The purpose of the questions is for participants to engage with the content interactively
75657956|NCT06098573|Behavioral|Information condition|Participants in the DUIC Information condition will receive a Qualtrics link with six infographics created to educate about DUIC. Four infographics were retrieved from government websites, one was provided by a non-profit (i.e., Arrive Alive Drive Sober), and the research team created the final one. After reviewing each infographic, participants will respond to a few questions about the infographic. Questions asked to the DUIC Info Control will obtain data related to: seeing the infographic before, perceptions on the infographic content, aspects they liked/disliked, and likelihood to share with their peers. All items will be treated as research data.
75657957|NCT06098573|Behavioral|No contact|Participants in the passive control will receive no contact until the three and six-month follow-ups.
75804926|NCT02914834|Other|Non-pain related video health education|Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
75804927|NCT03497130|Other|skin care regimen|These participants will be asked to apply skin care regimen, the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
75804928|NCT03726840|Other|Fragrance|peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
75945412|NCT03393585|Other|touchless vital signs monitoring|We measure Respiratory Rates in the Triage of Patients entering an Emergency Department by three different methods.
75945413|NCT02360150|Radiation|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
75945414|NCT02355392|Other|Telemedical home blood pressure measurements|
75945415|NCT03393507|Drug|Apatinib|500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
75945416|NCT03393507|Drug|Taxus + platinum|Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
75945417|NCT01348139|Drug|AZD3199|Inhaled via single inhaler device (SID)
75945418|NCT01348139|Drug|AZD3199|Inhaled via Turbuhaler inhaler
76093010|NCT02294357|Drug|Dexamethasone|If the patient was receiving steroids at the equivalent of > 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
76093011|NCT02294357|Drug|Prednisone|f the patient was receiving prednisone, at the equivalent of > 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
75346533|NCT00907088|Other|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
75945419|NCT01348139|Other|AZD3199 Placebo|Inhaled via Turbuhaler inhaler and SID
75945420|NCT02359760|Procedure|Piezocision|Flapless corticotomies
75945421|NCT03393429|Other|DAVID assisted training|DAVID device assisted training under supervision
75657958|NCT06098443|Other|Acupressure|Acupressure is effective on anxiety and depression management. acupressure therapy at K1, ST36, and SP6 acupoints significantly reduced anxiety & depression in patients with ESRD.
75804929|NCT03006562|Drug|Subcutaneous Heparin|5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.
75945422|NCT03393429|Other|training recommendation|"training recommendation to stay active"
75945423|NCT02355236|Drug|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
75945424|NCT02355236|Drug|Celecoxib 200mg|Capsule, o.d.
75945425|NCT02355236|Drug|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
75945426|NCT02355236|Drug|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
75945427|NCT03393351|Other|Shared decision-making program|"The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~shared decision-making trainings for health care professionals,~individual coaching for physicians,~patient activation strategy,~provision of patient information material and decision aids,~revision of the clinics quality management documents, and~critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3."
75804930|NCT03666208|Device|Sirolimus Coated Balloon|"Sirolimus has been used in organ transplantation as well as coronary stent due to its antiproliferative properties. It has been proven to has better outcome in animal studies compared to paclitaxel, which is about 22% in the sirolimus group versus 75% re-stenosis rate in paclitaxel group.~Sirolimus is coated on the surface of the angioplasty balloon and is transferred to the vessel wall when balloon is inflated and in contact with the vessel wall.~The following table compare sirolimus to paclitaxel. In which sirolimus works by cytostatic mechanism with a ten thousand fold of safety margin. And sirolimus's anti-restenosis effect is optimal with the benefit of lower level of competition and lesser tissue absorption and elution."
75346534|NCT00907088|Other|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
75804931|NCT03007966|Procedure|Ilioinguinal / Iliohypogastric Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided ilioinguinal / iliohypogastric block technique.
75945428|NCT03393351|Other|Usual Care|No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
75945429|NCT03619031|Other|LONG LEAVENING|a long-leavened (60 h) pizza composed of sourdough and a flour mix.
75945430|NCT03619031|Other|SHORT LEAVENING|a short-leavened (5 h) pizza composed of sourdough and a flour mix.
75346535|NCT04379804|Procedure|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery (ITA).
75346536|NCT04379804|Procedure|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN was identified at the point of entry both visually and with hand held stimulation probe
75476927|NCT05298956|Other|Low-level laser therapy (LLLT)|"Sham Comparator: Participants will receive 8 counts of 60 seconds of the same laser to the right forehead, however the laser power will be turned off and will be 0 Watts.~Transcranial infrared laser stimulation: Participants will receive 8 counts of 60 seconds of transcranial infrared laser stimulation to the right forehead. The wavelength will be 1064 nm and the laser power will be 3.4 Watts."
75476928|NCT05291364|Drug|Group 1|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
75804932|NCT03007966|Procedure|Quadratus Lumborum Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided quadratus lumborum block technique.
75476929|NCT05291364|Drug|Group 2|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
76093012|NCT02294357|Drug|Methylprednisolone|If the patient was receiving methylprednisolone at the equivalent of > 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
76093013|NCT02294357|Drug|Lenalidomide|given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
76093014|NCT02294357|Drug|Pomalidomide|administered PO at 4mg daily on days 1-21 of a 28 day cycle
75804933|NCT03007966|Drug|Bupivacaine 0.25%|Administered as part of the local anesthetic mixture
75945431|NCT03619031|Other|TRADITIONAL|a short-leavened (5 h) pizza composed of brewer's yeast and 00 flour.
75945432|NCT05196867|Behavioral|Intervention Group|Participants in the intervention group will receive (1) weekly telephone or videoconference coaching; (2) health education print materials and tip sheets;(3) navigation to programs and resources to help participants meet behavioral goals (e.g., fitness events, classes and webinars, etc); (4) text messages related to behavioral skills; (5) a Fitbit activity tracker and Aria scale; (6) resistance tubes and instructional video for strengthening exercise (if resistance exercise module is chosen); and (7) tools to manage portion sizes.
75945433|NCT05196867|Behavioral|Control Group|Patients in the control arm will initially receive written education material about the risk factors for liver cancer and management options. They will be offered the intervention after they complete the 6-month assessment.
75945434|NCT02359682|Other|No intervention|No Intervention
75945435|NCT05169255|Drug|Antibiotic administration|Individuals received either azithromycin or amoxicillin for 3 or 7 days
75945436|NCT02359604|Drug|PPI therapy|"PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA"
75945437|NCT02359604|Procedure|Stool sample|Stool sample will be obtained before initiation of PPI (before PPI therapy)
75945438|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
75945439|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
75945440|NCT03410511|Other|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
75945441|NCT03410511|Other|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
75945442|NCT03410511|Other|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
76093015|NCT02255422|Drug|Omaveloxolone capsules, 2.5 mg|
76093016|NCT02255422|Drug|omaveloxolone capsules, 5 mg|
76093017|NCT02255422|Drug|omaveloxolone capsules, 10 mg|
76093018|NCT02255422|Drug|Placebo capsules|
76093019|NCT02255422|Drug|omaveloxolone capsules, 20 mg|
76093020|NCT02255422|Drug|omaveloxolone capsules, 40 mg|
76093021|NCT02255422|Drug|omaveloxolone capsules, 80 mg|
76093022|NCT02255422|Drug|omaveloxolone capsules, 160 mg|
75346537|NCT01462253|Drug|Clofarabine, Cyclophosphamide|The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
75804934|NCT03007966|Drug|Epinephrine 1:200k|Administered as part of the local anesthetic mixture
75945443|NCT03126669|Device|Hyperbaric oxygen|Breathing 100% oxygen at 2ATA in the hyperbaric chamber
75945444|NCT03126669|Device|Hyperbaric chamber, normal air|Hyperbaric chamber with normal air
75945445|NCT02355314|Other|Doppler-based renal|Doppler-based renal : day 0 and day 3
75945446|NCT02355314|Biological|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
75945447|NCT02868229|Drug|COR-001|
75945448|NCT02868229|Other|Placebo|
75945449|NCT02355080|Behavioral|On-site bundled rapid HIV/HCV testing|Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
75945450|NCT02355080|Behavioral|Standard of care (SOC)|Participants will receive the SOC for HIV and HCV testing at the study sites.
75945451|NCT05169021|Drug|Amlodipine folic acid 5.8mg+intensive antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure(SBP<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~Add candesartan 4mg;~Add indapamide 2.5mg;~Increase dose of candesartan to 8mg;~Increase dose of amlodipine to 7.5mg-10mg."
75945452|NCT05169021|Drug|Amlodipine folic acid 5.8mg+standard antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~Add candesartan 4mg;~Add indapamide 2.5mg;~Increase dose of candesartan to 8mg;~Increase dose of amlodipine to 7.5mg-10mg."
75945453|NCT05169021|Drug|Amlodipine+intensive antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~Add candesartan 4mg;~Add indapamide 2.5mg;~Increase dose of candesartan to 8mg;~Increase dose of amlodipine to 7.5mg-10mg."
75945454|NCT05169021|Drug|Amlodipine+standard antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~Add candesartan 4mg;~Add indapamide 2.5mg;~Increase dose of candesartan to 8mg;~Increase dose of amlodipine to 7.5mg-10mg."
75346538|NCT01837394|Procedure|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
75945455|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI|
75945456|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI|
75945457|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
75945458|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
75945459|NCT02359292|Drug|Placebo pMDI|
75945460|NCT05168787|Drug|sacubitril/valsartan|Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.
75945461|NCT05168553|Other|Revascualrization|Regain pulp vascularity for mature permenant teeth
75346539|NCT01837394|Procedure|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
75346540|NCT01837394|Drug|Paracetamol|
75346541|NCT01837394|Drug|Morphine|5 mg as needed
75346542|NCT01837394|Drug|Ondansetron|4 mg i.v. as needed in the PACU
75346543|NCT01837394|Drug|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
75346544|NCT00902018|Drug|Eltrombopag|The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
75476930|NCT05291221|Drug|intratracheal saline|At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients
75476931|NCT05291221|Drug|intratracheal Dexmedetomidine|At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
75476932|NCT05291221|Drug|intratracheal Lidocaine|At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
75804935|NCT03007966|Drug|Clonidine 1.66mcg/cc|Administered as part of the local anesthetic mixture
75804936|NCT03723642|Diagnostic Test|Initial serum malondialdehyde level|"Blood sample (0.4ml) will be obtained within 5 minutes before induction of general anaesthesia.~Samples will be obtained in both groups (LAE and OAE)"
75804937|NCT03723642|Diagnostic Test|Final serum malondialdehyde level|Blood sample (0.4ml) will be obtained within 5 minutes after wound closure. Samples will be obtained in both groups (LAE and OAE)
75804938|NCT03723642|Diagnostic Test|Initial differential white blood cell count|"Differential blood counts (microscopic) will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
75945462|NCT05168553|Other|Conventional endodontic treatment|Root canal treatment of permenant mature teeth with mechanical preparation and cleaning followed by canal obturation by inert material ( gutta percha)
75945463|NCT02359214|Dietary Supplement|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
75945464|NCT02359214|Other|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
75945465|NCT04480437|Device|mp-BUS data collection|Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.
75945466|NCT02359370|Drug|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
75945467|NCT02359370|Drug|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
75945468|NCT02956967|Other|Overall satisfaction questionnaires of home use of Nivestim|
75804939|NCT03723642|Diagnostic Test|Final differential white blood cell count|"Differential blood counts (microscopic) will be obtained 24h after the first sample (Initial differential blood count).~Samples will be obtained in both groups (LAE and OAE)."
75945469|NCT02359448|Drug|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
75945470|NCT02359526|Drug|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
75945471|NCT03410433|Device|Silk 4.0|Silk suture 4.0
75945472|NCT03410433|Device|PG 910 4.0|PG 910 4.0
75945473|NCT03410433|Device|PP 4.0|PP 4.0
75945474|NCT03410433|Device|Silk 5.0|Silk 5.0
75945475|NCT03410433|Device|PG910 5.0|PG910 5.0
75945476|NCT03410433|Device|PP 5.0|PP 5.0
75945477|NCT03410433|Device|APG 5.0|APG 5.0
75945478|NCT03410433|Device|ePTFE 5.0|ePTFE 5.0
75945479|NCT03618953|Biological|Ad-E6E7|Adenovirus vaccine expressing mutant HPV E6 and E7
75945480|NCT03618953|Biological|MG1-E6E7|MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7
75945481|NCT03618953|Biological|Atezolizumab|monoclonal antibody; checkpoint inhibitor
75945482|NCT03147872|Other|2% Oxygen|2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
75945483|NCT03396159|Diagnostic Test|mini fluid challenge|mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
75945484|NCT02354768|Drug|Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)|
75945485|NCT02354768|Drug|Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone|
75945486|NCT00000125|Drug|Topical ocular hypotensive eye drops.|Topical ocular hypotensive eye drops.
76093023|NCT02153619|Behavioral|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
76093024|NCT02153619|Behavioral|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSK Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
76093025|NCT02153619|Behavioral|questionnaires assessments|
75657959|NCT06098443|Device|Transcutaneous electrical nerve stimulation|TENS lead to meaningful reduction of pain in patients suffering from difficult to treat phantom limb pain. This treatment has a high success rate and is associated with high satisfaction rates and no reported adverse events. The suggested duration of treatment is at least 30 minutes and may be extended up to 45 minutes. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extra segmental analgesia. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extrasegmental analgesia. (Vathakul et al., 2022).
75804940|NCT03723642|Diagnostic Test|Initial c-reactive protein serum level|"C-reactive protein levels will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
75804941|NCT03723642|Diagnostic Test|Final c-reactive protein serum level|"C-reactive protein levels will be obtained 24h after the first sample (initial c-reactive protein level).~Samples will be obtained in both groups (LAE and OAE)."
75804942|NCT03723642|Diagnostic Test|Initial VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 10 minutes before induction of general anesthesia
75945487|NCT03613441|Behavioral|Mindful Awareness Practices (MAPs)|Please refer to arm description
75945488|NCT04417803|Biological|Blood sampling|plasmatic sampling
75945489|NCT02354612|Drug|TRC105|
75945490|NCT02354612|Drug|Bevacizumab|companion therapy selection depends on companion therapy used in the parent study
75945491|NCT02354612|Drug|Axitinib|companion therapy selection depends on companion therapy used in the parent study
75945492|NCT02354612|Drug|Pazopanib|companion therapy selection depends on companion therapy used in the parent study
75945493|NCT02354612|Drug|Capecitabine|companion therapy selection depends on companion therapy used in the parent study
75945494|NCT05168397|Other|RV4857A|RV4857A formula CD2110 is a sunscreen product
75945495|NCT02236897|Other|PET Scanning|
75945496|NCT02348450|Drug|Irinotecan|40mg
75945497|NCT02348450|Drug|Etoposide|5ml：0.1g
75945498|NCT02348450|Drug|Cisplatin|6ml：30mg
75945499|NCT03393273|Drug|Elotuzumab|"Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21~melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation~Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21"
75945500|NCT03613597|Drug|etoposide plus lobaplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin
75945501|NCT03613597|Drug|etoposide plus cisplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
76093026|NCT02142959|Drug|Omaveloxolone Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
76093027|NCT02142959|Drug|Omaveloxolone Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
76093028|NCT02142959|Drug|Vehicle Lotion|Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
76093029|NCT02142959|Radiation|3D conformal radiation therapy|45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
76093030|NCT02128113|Drug|Vehicle Ophthalmic Solution|Opthalmic suspension manufactured to mimic RTA 408 suspension
75945502|NCT03393195|Behavioral|Time-restricted Eating plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study. The eating plan will consist of eating during a specified 8 hour window and fasting for the remaining 16 hours of the day.
75804943|NCT03723642|Diagnostic Test|VOC 5min|Volatile organic compound sampling (2 samples within5 minutes) within 5 minutes after endotracheal intubation before skin incision.
75945503|NCT03393195|Behavioral|Consistent Meal timing plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study.The eating plan will consist of eating three structured meals each day during three specified meal windows.
75945504|NCT02348372|Drug|GSK1278863A Placebo|Matching size, shape and color
75945505|NCT02348372|Drug|GSK1278863A|A round, biconvex, white film coated tablet
75945506|NCT02031731|Drug|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
75945507|NCT02031731|Drug|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
75945508|NCT02031731|Drug|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
75945509|NCT03614533|Biological|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
75945510|NCT03614533|Biological|Inactivated Poliovirus Vaccine (IPV)|Single 0.5-ml intramuscular injection
75945511|NCT03396003|Device|GALILEI G6 Lens Professional|Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators
75945512|NCT03396003|Device|Oculus Pentacam AXL|A single measurement of the eye will be taken using the Oculus Pentacam AXL
75945513|NCT03147404|Drug|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
75945514|NCT03614455|Drug|Milademetan|Milademetan 100 mg capsule for oral administration
75945515|NCT03614455|Drug|Itraconazole|Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)
75945516|NCT03614455|Drug|Posaconazole|Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
75945517|NCT03393117|Drug|Liposomal Bupivacaine|20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.
75945518|NCT03393117|Drug|Bupivacaine|20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.
75804944|NCT03723642|Diagnostic Test|VOC 15min|Volatile organic compound sampling (2 samples within 5 minutes) 15 minutes after skin incision.
75945519|NCT03393117|Drug|Patient-Controlled Analgesia Pump|The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.
75945520|NCT03393117|Drug|Oral Narcotic|Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
75945521|NCT02032225|Other|Skin biopsy|
75945522|NCT03147326|Diagnostic Test|FDG-PET-CT|scanning method
75945523|NCT03147326|Diagnostic Test|NaF-PET-CT|scanning method
75945524|NCT03147326|Diagnostic Test|Whole-body MRI|scanning method
75945525|NCT02032303|Procedure|Assessment of coronary flow reserve|
75945526|NCT02032303|Procedure|Percutaneous Coronary Intervention|
75476933|NCT05288894|Diagnostic Test|Cardiac magnetic resonance imaging|A routine cardiac magnetic resonance imaging with biventricular function evaluation, atrial volumes, LGE acquisitions, and pulmonary and aortic assesment.
75657960|NCT06096207|Device|Medtronic SenSight Directional DBS lead|At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.
75804945|NCT03723642|Diagnostic Test|VOC 30min|Volatile organic compound sampling (2 samples within 5 minutes) 30 minutes after skin incision.
75945527|NCT02032303|Drug|Ticagrelor loading|
75945528|NCT02032303|Drug|Prasugrel loading|
75945529|NCT04297293|Drug|Ramosetron|Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
75945530|NCT03147560|Biological|Sabin IPV+ bOPV+ bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
75945531|NCT03147560|Biological|Sabin IPV + Sabin IPV + bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
75945532|NCT03147560|Biological|Sabin IPV + Sabin IPV + Sabin IPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
75945533|NCT03614377|Diagnostic Test|Device interrogation|All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.
75804946|NCT03723642|Diagnostic Test|VOC 45min|Volatile organic compound sampling (2 samples within 5 minutes) 45 minutes after skin incision.
75804947|NCT03723642|Diagnostic Test|Final VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 5 minutes after skin closure.
75804948|NCT03665896|Device|intubation with VivaSight double-lumen tube|
75804949|NCT03665896|Device|intubation with standard double-lumen tube|
75804950|NCT03665896|Procedure|fiberoptic bronchoscopy|
75945534|NCT02350790|Procedure|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
75945535|NCT02350790|Procedure|Robotic excision|Robotic excision of endometriosis
75945536|NCT03392961|Drug|IN-105 (Insulin Tregopil)|15 mg strength tablets for oral use used at a dose of 30 mg
75945537|NCT03392961|Other|Placebo comparator|Placebo tablet for oral use
75945538|NCT02350946|Drug|Oxytocin|
75945539|NCT02350946|Drug|Placebo|
75945540|NCT00000371|Drug|D-cycloserine|50 mg/daily by mouth
75945541|NCT00000371|Drug|Placebo|50 mg/day of placebo by mouth
76093031|NCT02128113|Drug|Omaveloxolone Ophthalmic Suspension 0.5%|0.5% ophthalmic suspension of RTA 408
76093032|NCT02128113|Drug|Omaveloxolone Ophthalmic Suspension 1%|1% ophthalmic suspension of RTA 408
76093033|NCT02091518|Behavioral|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
76093034|NCT02091518|Device|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
75346545|NCT00902018|Drug|Romiplostim|three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
75346546|NCT00902018|Other|healthy controls|single blood draw for all measures included in the intervention arms
75346547|NCT04974762|Procedure|Wound infiltration|Surgical wound infiltration by proceduralist
75346548|NCT04974762|Procedure|Truncal blocks|Truncal blocks provided by anesthesiology team for device placement
75346549|NCT01462565|Drug|current marketed FLOLAN (epoprostenol sodium)|continuous intravenous infusion
75346550|NCT01462565|Drug|new thermo stable formulation of epoprostenol sodium|continuous intravenous infusion
75346551|NCT03210896|Dietary Supplement|Orange juice|Sub group I will drink Orange juice and have repeat measures.
75804951|NCT03007888|Drug|Sinemet|Immediate Release Tablet containing carbidopa-levodopa flexible dosing
75804952|NCT03007888|Drug|IPX203|Extended Release capsules containing carbidopa-levodopa flexible dosing
75804953|NCT03541044|Drug|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 2mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
75945542|NCT04222647|Drug|WO533|Intravaginal application
75945543|NCT02350712|Drug|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
75346552|NCT02473614|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.
75346553|NCT02473614|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
75945544|NCT02350712|Drug|Cetuximab|Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
75945545|NCT02350712|Drug|Cisplatin|Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
75945546|NCT02350712|Drug|Carboplatin|Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
75346554|NCT01837628|Drug|Lidocaine Gel|
75346555|NCT01837628|Drug|Paraffin Oil|
75346556|NCT05565365|Procedure|Transversalis fascia plane (TFP) block|Patients will receive unilateral US-TFP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
75346557|NCT05565365|Procedure|Erector Spinae Plane (ESP) Block|Patients will receive unilateral US-ESP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
75346558|NCT00908882|Behavioral|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
75657961|NCT06095050|Device|Embolization|Superselective arterial embolization of hyperemic vasculature in the symptomatic shoulder (utilizing the IDE approved device: Lipiodol) followed by structured physical therapy sessions.
75346559|NCT01462877|Drug|fenofibrate|Fenofibrate Capsule 200mg qd orally
75346560|NCT04972656|Drug|Ambrisentan|"Titration:~Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan will be administered orally with or without food intake."
75657962|NCT06095050|Other|Physical Therapy|Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
75657963|NCT06094205|Device|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
75657964|NCT06091813|Behavioral|Nutrition Counseling|Dietitian-led nutrition coaching via 5 Telenutrition visits, utilizing the Academy of Nutrition and Dietetics' Nutrition Care Process.
75657965|NCT06091813|Dietary Supplement|Prebiotic/Probiotic Supplement|A once-daily, GRAS prebiotic/probiotic dietary supplement for 4 months, beginning within 2 weeks of the initial stool sample.
75657966|NCT06091306|Behavioral|Psychotherapy|"Multifamily therapy (MFT), which involves bringing several families together to address the problem of anorexia nervosa, has proved effective for several years now.~Since January 2019, multifamily therapy has been offered to adolescents aged 12 to 18 who are being treated for anorexia nervosa at the Maison de Solenn-Maison des Adolescents at Cochin Hospital, and to their families.~Each group brings together 5 to 7 families and comprises 10 3-hour sessions, with 3 weeks between each session. 2 groups are offered per year. Multifamily therapy therefore involves 10 to 14 families per year. It complements the other approaches available in the department."
75945547|NCT03614299|Other|Ecological symptom measurements using a webapp|A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)
76093035|NCT02065375|Drug|Omaveloxolone Ophthalmic Suspension 1.0%|
76093036|NCT02065375|Drug|Omaveloxolone Opthalmic Suspension 0.5%|
76093037|NCT02065375|Drug|Placebo|
75804954|NCT03541044|Drug|Nicorette Mini Lozenge|A single dose of a 2 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
76093038|NCT02036970|Drug|Bardoxolone methyl|
75945548|NCT03614299|Diagnostic Test|Interferometry|Evaluation of the mebomian function using the LipiView methodology
75945549|NCT03618875|Other|ice pack|ice pack was placed on eyelid 5 minutes prior to IVIT
75945550|NCT03618875|Other|room temperature pack|room temperature pack was placed on eyelid 5 minutes prior to IVIT
75945551|NCT02867995|Device|Eye Drop Aid|Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, and the Simply Touch Eye Drop Applicator
75945552|NCT03618797|Drug|HL-PIF cap.160/2mg + Placebo|Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
75804955|NCT03666130|Procedure|endoscopic septoplasty|endoscopic septoplasty is the use of nasal endoscopy in the septoplasty surgery for treatment of deviated nasal septum . we aim to compare the outcome of using this method versus conventional septoplasty
75945553|NCT03618797|Drug|Livalo tab. 2mg + Placebo|Pitavastatin ca 2mg
76093039|NCT02036970|Drug|Placebo|
75804956|NCT00009945|Drug|clodronate|1600 mg PO daily
76093040|NCT02013154|Drug|DKN-01 150 mg|Administered by IV infusion
76093041|NCT02013154|Drug|Paclitaxel|Administered by IV infusion
76093042|NCT02013154|Drug|Pembrolizumab|Administered by IV infusion
76093043|NCT02013154|Drug|DKN-01 300 mg|Administered by IV infusion
75346561|NCT04972656|Drug|Placebo|"Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning."
75346562|NCT03210506|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
75346563|NCT03210272|Drug|Placebo|Tablet
75346564|NCT03210272|Drug|BI 1358894|Tablet
75657967|NCT06087133|Behavioral|StEP:Prenatal|StEP is a health care-based intervention based on elements of Social Cognitive Theory, in which registered dietitians with additional certified lactation counselor training (RD/CLC) provide individual and group-based support for healthy diet, physical activity, other lifestyle behaviors, stress reduction, and healthy gestational weight gain. StEP:Prenatal will be delivered remotely. There are up to 8 sessions scheduled around the routine prenatal care visits and designed to be offered from the first trimester of pregnancy through delivery.
75657968|NCT06087133|Other|Routine Care|Routine care includes routine prenatal and post-partum primary care visits, on-site WIC services and referrals for additional services as needed (e.g., women with poor weight gain, obesity, or diabetes may be offered additional nutrition visits).
75804957|NCT00009945|Drug|placebo|2 pills PO daily
75346565|NCT03210272|Drug|BI 1358894 (Test)|Fasting state
75346566|NCT03210272|Drug|BI 1358894 (Reference)|Fed state
75657969|NCT06083896|Procedure|Photodynamic nails|stab incision is made at the entry site
75657970|NCT06080477|Behavioral|Enhanced Usual Care|Participants randomized to usual care will continue to receive their standard clinical care at Queen Elizabeth Central Hospital (QECH) as previously. The clinical team will be provided a summary of the results of the eligibility assessment, specifically an interpretation of the scores on the symptomatology and disability scales with any relevant clinical recommendations. These individuals will receive no home-based services.
75804958|NCT03540030|Drug|Gabapentin|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75804959|NCT03540030|Drug|Celecoxib|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75804960|NCT03540030|Drug|toradol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75804961|NCT03540030|Drug|acetaminophen|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75804962|NCT03540030|Drug|regional block|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75945554|NCT02350556|Other|Dynamic Avoidance Task|
75945555|NCT02350556|Procedure|physical therapy|
75945556|NCT02350556|Device|3D motion on optoelectronic device|
75945557|NCT03149432|Procedure|Mirror Therapy|by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
75945558|NCT03149432|Drug|Gabapentin|titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
75945559|NCT03149432|Procedure|Rehabilitation|Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
75945560|NCT03149432|Other|Local care|local care for directed healing of the stump.
75945561|NCT03618329|Other|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
75945562|NCT03147014|Biological|Maternal hyperoxygenation|approximately 10-15 minutes of maternal hyperoxygenation
76093044|NCT01909492|Procedure|Blood Draw|Patients will provide a serum sample for research.
76093045|NCT01909492|Procedure|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
75346567|NCT02500758|Procedure|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
76093046|NCT01827787|Drug|Eribulin|
76093047|NCT01823848|Drug|Sodium phosphate enema|Rectally administered medication to treat constipation
76093048|NCT01823848|Drug|Normal saline enema|Rectally administered medication to treat constipation
76093049|NCT01823848|Drug|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
76093050|NCT01743950|Drug|Bevacizumab|10mg/kg every 2weeks.
75346568|NCT02500758|Procedure|Preoperative surgical scrubbing using 3% PCMX|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
75657971|NCT06080477|Behavioral|Adapted ENHANCE Intervention|Participants randomized to the intervention arm will receive community-based rehabilitation (CBR) delivered by the Queen Elizabeth Central Hospital (QECH) clinical team of psychiatric nurses. The ENHANCE CBR intervention will consist of nurse-delivered home visits over approximately a 12-month period with decreasing intensity, with approximately weekly visits for an initial phase of 2-4 months; biweekly visits for an intermediate phase of 4-6 months; and monthly for a final transition phase of 3-4 months. The exact schedule and duration of each phase will be individualized by the nurse to the participant based on the participant's initial presentation and their response during the intervention. The intervention team will deliver intervention content with the participant and/or family members and caregivers as appropriate to the module.
75346569|NCT02500758|Procedure|Preoperative surgical scrubbing using 4% CHG|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
75346570|NCT05565209|Other|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
75945563|NCT05384483|Drug|Cariprazine|Cariprazine 1.5 to 3 mg per day
75346571|NCT01839812|Drug|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
75945564|NCT05384483|Drug|Placebo|Matching placebo
75945565|NCT02354300|Device|TCD Ultrasound|Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
75945566|NCT03618563|Other|functional individualized therapy for teenagers with executive deficits|Intervention to improve self-perceived performance and performance satisfaction in daily activity goals that adolescent selected,
75945567|NCT02354066|Device|Hallux valgus Shoe|Brake response measurement after surgery with this foot orthosis
75945568|NCT02354066|Device|Forefoot relief shoe|Brake response measurement after surgery with this foot orthosis
75945569|NCT02354066|Device|Retail Shoe|Brake response time measurement before surgery (control run)
76093051|NCT01743950|Radiation|PRDR|Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
75346572|NCT01565369|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
75346573|NCT02500056|Device|Optilene LP mesh|Lichtenstein hernioplasty
75657972|NCT06079359|Drug|ALXN1850|Participants will receive a ALXN1850 via subcutaneous (SC) injection.
75657973|NCT06079359|Drug|Placebo|Participants will receive placebo via SC injection.
75657974|NCT06076694|Drug|TNP-2198|Group A, TNP-2198 capsules 400mg(4 capsules),BID, 14days Group B, TNP-2198 capsules 600mg(6 capsules),BID, 14days Group C , TNP-2198 capsules 600mg(6 capsules),TID, 14days Group D, TNP-2198 capsules 600mg(6 capsules),TID, 7days
75804963|NCT03540030|Drug|propofol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75804964|NCT03540030|Drug|IV lidocaine|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75804965|NCT03540030|Drug|rocuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75804966|NCT03540030|Drug|vecuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75945570|NCT03086629|Other|Patient Concerns Inventory|
75945571|NCT03086629|Other|No Patient Concerns Inventory|
75945572|NCT03077191|Other|Quality of life measurement|The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
75945573|NCT05061563|Drug|Elinzanetant (BAY3427080)|Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.
75945574|NCT05061563|Drug|Esomeprazole|Esomeprazole given orally once daily for 5 days in Period 2.
76093052|NCT01717261|Radiation|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
75346574|NCT02500056|Device|Ultrapro mesh|Lichtenstein hernioplasty
75346575|NCT03210350|Diagnostic Test|Optic nerve sheath diameter|Optic nerve sheath diameter measurement using ultrasound
75346576|NCT01463267|Device|iPhone or pillbox|People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
75346577|NCT01463267|Behavioral|Non-reminding|As a comparison, the devices will collect medication taking information without providing reminders.
75346578|NCT04379648|Other|self-assessment and hetero-assessment|Self assessment for the passing of the following rating scales CTQ-SF36-ITQ-PCL5-DES Hetero-assessment for the pasing of the following rating scales DDIS FR and medical interview
75945575|NCT03147170|Diagnostic Test|High and low salt diets|Effects of high and low salt diets on blood pressure in individuals with normal and elevated levels of NT-proBNP
76093053|NCT01593202|Behavioral|Dialectical behavior therapy|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
76093054|NCT01593202|Behavioral|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
75945576|NCT03147092|Drug|Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,|Treatment of hypertensive subjects
76093055|NCT01522768|Drug|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
76093056|NCT01484327|Drug|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
76093057|NCT01484210|Drug|Elpenhaler active - Diskus placebo|randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
75804967|NCT03540030|Drug|sevoflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75945577|NCT03147092|Drug|Atenolol|Treatment of hypertensive subjects
75945578|NCT03147092|Drug|Losartan potassium 50mg|Treatment of hypertensive subjects
76093058|NCT01327781|Drug|Endoxifen Hydrochloride|Given PO
76093059|NCT01327781|Other|Laboratory Biomarker Analysis|Correlative studies
75346579|NCT01839890|Device|Bare metal Stent plus Paclitaxel Balloon|After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
76093060|NCT01327781|Other|Pharmacological Study|Correlative studies
76093061|NCT01327781|Other|Questionnaire Administration|Ancillary studies
75346580|NCT01839890|Device|Bare metal Stent|After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
75657975|NCT06076694|Drug|Rabeprazole Sodium|Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days
75657976|NCT06076694|Drug|Amoxicillin|Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days
75804968|NCT03540030|Drug|desflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
75945579|NCT03147092|Drug|Clonidine|Treatment of hypertensive subjects
75945580|NCT03613285|Device|conventional brackets|conventional brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
75346581|NCT04969770|Other|Ultrasound elastography (USE)|"Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation."
75346582|NCT02205983|Drug|2 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
75346583|NCT02205983|Drug|1000 mg Acetaminophen|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
75346584|NCT02205983|Drug|4 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
75657977|NCT06076499|Device|NTX100|NTX100 Tonic Motor Activation (TOMAC) System - a non-invasive peripheral nerve stimulation device programmed to deliver active stimulation.
75657978|NCT06076213|Drug|Artesunate-amodiaquine|Tablets
75657979|NCT06076213|Drug|Artemether-lumefantrine|Tablets
75657980|NCT06073951|Other|Best Practice|Receive usual care
75657981|NCT06073951|Other|Exercise Counseling|Receive walking step goals
75657982|NCT06073951|Other|Exercise Intervention|Participate in Mates in Motion program
75657983|NCT06073951|Other|Medical Device Usage and Evaluation|Wear Actigraph
75945581|NCT03613285|Device|smart clip passive self ligating brackets|smart clip passive self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
75945582|NCT03613285|Device|Empower active self ligating brackets|Empower active self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
75657984|NCT06073951|Other|Medical Device Usage and Evaluation|Wear Fitbit
75804969|NCT03003676|Biological|ONCOS-102|Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)
75804970|NCT03003676|Drug|Cyclophosphamide|Pre-treatment
75804971|NCT03003676|Drug|Pembrolizumab|PD1 blockade
75945583|NCT03149588|Drug|propofol|Using propofol and remifentanil as maintenance of general anesthesia during caesarean section.
75945584|NCT03149588|Drug|sevoflurane|Using sevoflurane and remifentanil as maintenance of general anesthesia during caesarean section.
76093062|NCT00887146|Drug|concomitant temozolomide (TMZ)|75 mg/m^2, orally daily
75476934|NCT05281744|Behavioral|Dementia Care Consultation program|The Dementia Care Consultation program uses a telephone-based intervention to provide an in-depth, personalized service for individuals living with ADRD and their care partners. It consists of comprehensive needs assessments, creation and implementation of personalized care plans, monitoring and revising care plans, disease education and support coaching, referrals to community-based organizations for service and support, and access to assistance.
75476935|NCT05280132|Procedure|Personalized antibiotic treatment|Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.
75804972|NCT00047385|Device|low-dose helical computed tomography|A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.
75804973|NCT00047385|Device|chest radiography|The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
75945585|NCT03613207|Other|Dermal pharmacokinetic measurement|"Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~Each test site receives 2 dOFM probes~Dosing:~2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~2 test sites: untreated test site~ISF sampling: 24 hours post-dose~Blood sampling: 7 samples post-dose"
75945586|NCT03613207|Drug|Lidocaine and prilocaine cream|lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
75945587|NCT03613207|Drug|Oraqix® gel|Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
75945588|NCT03613207|Device|dOFM-System|Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
75945589|NCT03613207|Procedure|Blood sampling|8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
75945590|NCT02350322|Other|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
75945591|NCT02350322|Other|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
75945592|NCT02350322|Dietary Supplement|Supplement|Omega-3 capsules three times a week for 12 weeks
75945593|NCT02032381|Other|late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.|
75657985|NCT06073951|Other|Physical Performance Testing|Undergo walk-test
75945594|NCT03392883|Behavioral|Laddr|Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
75945595|NCT02350634|Drug|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.
75945596|NCT03613051|Behavioral|Movement Assessment Battery for children|this test measures manual dexterity , balance , aiming and catching
75945597|NCT03159182|Device|Pressure garment and silicone insert|Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
75945598|NCT03159182|Device|Pressure garment|Custom made fabric pressure garment
75945599|NCT03612739|Biological|NKR-2 CAR-T Cells|"The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5."
75346585|NCT02205983|Drug|dextrose|We are administering dextrose to healthy volunteers for our placebo group.
75346586|NCT01839968|Other|Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma|
75346587|NCT04969692|Procedure|warming to increase local skin (puncture site) temperature|According to the group of participants, investigator applies the warmer to the hands and wrists of the participants, makes a local temperature of 40℃ gradually, and maintains it for about 10 minutes in warming group (which is divided in to warming-palpation (WP) and warming-US (WU) group).
75657986|NCT06073951|Other|Questionnaire Administration|Complete questionnaires
75657987|NCT06073223|Other|Usual Care|The control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit.
75476936|NCT05280132|Other|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
75657988|NCT06073223|Other|CQUPLE|"Our research team developed a novel intervention called CQUPLE (pronounced couple), which includes two interventions delivered together: (1) a Chart of side-by-side, evidence-based information comparing all three treatment options for low-risk thyroid cancer, including expected outcomes and (2) a Question Prompt List that contains key questions to consider asking the surgeon. The intervention is grounded in social cognitive theory and aims to increase patient awareness of treatment options and their outcomes, patient activation, and self-efficacy for decision making."
75657989|NCT06072300|Behavioral|Physical activity calorie equivalent labelling|Physical activity calorie equivalent labelling on beverage vending machines
75804974|NCT03665818|Device|oral appliance treatment|mandibular advancement device to enlarge pharyngeal airway space to get rid of apnea and hypopnea events
75804975|NCT03665740|Drug|Resveratrol|resveratrol is an OTC supplement
75945600|NCT02350400|Device|DEBIRI|DEBIRI TACE
76093063|NCT00887146|Radiation|radiotherapy|
76093064|NCT00887146|Drug|procarbazine|Days 8-21: 60 mg/m^2 orally
76093065|NCT00887146|Drug|adjuvant temozolomide (TMZ)|150 or 200 mg/m^2 orally
76093066|NCT00887146|Drug|CCNU|Day 1: 110 mg/m^2 orally
76093067|NCT00887146|Drug|vincristine|Days 8 and 29: 1.4 mg/m^2 IV
76093068|NCT00836823|Drug|Alfuzosin|Alfuzosin 10mg once daily for 12 months
75346588|NCT01838096|Device|THA using 4th generation CoC|
75804976|NCT04059718|Behavioral|SCI Thrive Peer-Led Online Self-Management Program|6 week online course in self-management for individuals with spinal cord injuries. This was developed by a team using principles of cognitive behavioral techniques.
75346589|NCT05565053|Procedure|Bilateral thoracal erector spinae plane block|Bilateral upper thoracal erector spinae plane block with ultrasound
75657990|NCT06067178|Behavioral|Health Dialogue Intervention|"Lifestyle assessment: All participants fill out a questionnaire to assess behavioral risk factors for CVD and undergo blood tests for cholesterol and blood glucose.~Lifestyle health dialogue: When presenting in person at the primary care center, blood pressure, BMI, and waist-hip ratio will be measured. The results from the questionnaire, blood tests, blood pressure, and body measurements will be summarized using a visual tool, in which risk factors are graded into risk levels to estimate CVD risk. The visual tool will then be used in the health dialogue to discuss risk factors. The health dialogue is conducted by a licensed healthcare professional who has been trained in the methodology. The dialogue will be conducted in a person-centered manner and will aim to motivate and support lifestyle behavior changes when needed. If necessary, medical treatment will be provided according to existing guidelines."
75945601|NCT03612895|Behavioral|Internal Care Coordination|This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.
75945602|NCT03612895|Behavioral|External Community Referral|Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
75945603|NCT03612895|Behavioral|Usual Care|Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
75804977|NCT03665350|Drug|Insulin|"Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.~The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile."
75945604|NCT03149510|Behavioral|Mobile Application|Participants will use the mobile application daily to assess heart failure symptoms.
75945605|NCT03612817|Drug|Tafluprost/timolol fixed combination|Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning
75945606|NCT03392805|Behavioral|physical activity|beginning of regular physical activity under the supervision of a coach
75804978|NCT03665272|Procedure|deepithelialized gingival graft fixation|one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.
75945607|NCT02347904|Drug|S-1 and Oxaliplatin|Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
75945608|NCT03990285|Drug|Axumin, Intravenous Solution|To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
75945609|NCT03612427|Dietary Supplement|S. Cholesterol S. Triglyceride|S. Cholesterol S. Triglycerides
75945610|NCT02353910|Procedure|Ultrasound|
75346590|NCT05565053|Procedure|Trapezius muscle trigger point injection|Trapezius muscle trigger point injection
75804979|NCT03665662|Other|Music|Intra-procedure music through headphones
75804980|NCT03665584|Device|FxCO2 Laser|The FxCO2 laser allows a microablative effect in soft tissue.
75804981|NCT03665584|Device|Sham Laser|The Sham laser will be used on the participants who receive the sham treatment.
75804982|NCT03665194|Drug|Cortexolone 17α-propionate solution|Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.
75804983|NCT03665194|Drug|Placebo|matching placebo
75804984|NCT03002194|Device|Cutometer|Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.
75945611|NCT03392727|Device|Study Box|Baby box (bassinet) with infant items
75945612|NCT03392727|Device|Community Box|Baby box (bassinet)
75945613|NCT03392727|Behavioral|Education Session|Face to face education and baby box orientation session
75945614|NCT03392727|Behavioral|Online Education|Online baby box education
75945615|NCT03612349|Behavioral|Experimental Tobacco Marketplace Task|Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
75945616|NCT03146858|Drug|Enoxaparin|Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
75945617|NCT03612661|Behavioral|Group Intervention|Participants in the group intervention will attend eight weekly, 90-minute sessions involving group activities and discussions. They will complete homework between sessions to reinforce learning. The intervention focuses on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
75346591|NCT01837784|Other|Optimization of blood pressure according to guidelines|There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
75346592|NCT02206217|Device|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
75346593|NCT03210038|Drug|Lidocaine|Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
75346594|NCT03210038|Drug|Water|Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
76093069|NCT00397644|Behavioral|Prompting (survey instrument/resources list) (behavior)|
76093070|NCT00344058|Drug|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
76093071|NCT00230100|Behavioral|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
76093072|NCT00230100|Behavioral|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
76093073|NCT00202007|Drug|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
75657991|NCT06067178|Other|Opportunistic Screening|"Risk factor assessment: Opportunistic screening entails screening for risk factors (blood pressure, BMI, blood tests for cholesterol and blood glucose, and smoking) among patients visiting the primary care center for another reason. Screening is conducted by a healthcare professional at which the patient has an appointment.~Detected risk factors for CVD are treated according to the existing care programs and guidelines at the primary care center, which should always include lifestyle advice as the first intervention and medication if hypertension is established. In this intervention, there is a more limited assessment of behavioral risk factors; that is, patients are asked about smoking, but assessment of diet, physical activity, or alcohol consumption is not included in the opportunistic screening."
75657992|NCT06063434|Behavioral|Night Shift|"The player must not only manage the patients who present to the emergency department of the hospital, gaining experience with the consequences of trauma triage, but also solve the mystery of the grandfather, gaining an emotional connection with the character and making the feedback that Andy receives more relevant. Embedded within Night Shift 2024 is a mini-game (Graveyard Shift) that contains a series of puzzles that reinforce the lessons of the overarching game: transfer severely injured patients expeditiously."
75804985|NCT03002194|Other|Photographs|Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
75804986|NCT03665428|Drug|PAMB treatment (modified quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
75804987|NCT03665428|Drug|PBMT treatment (bismuth-containing quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
75945618|NCT03612661|Behavioral|Guided Self-Help|Participants in the GSH condition will follow the intuitive eating content through self-guided study, with eight weekly scheduled phone calls with an interventionist (~20 minutes each). Interventionists will review homework assignments, answer questions, and reinforce adherence. The intervention materials are the same as the group and also focus on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
75945619|NCT03146702|Other|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
76093074|NCT00202007|Drug|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
76093075|NCT03245814|Behavioral|Service Dog|A service dog trained to perform tasks that are specific to PTSD
76093076|NCT03251430|Procedure|gastrectomy|Distal gastrectomy, Total gastrectomy
75476937|NCT05277935|Device|Use of the WeCancer app combined with the smartwatch.|To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy
76093077|NCT00897507|Other|Laboratory Biomarker Analysis|Correlative studies
75804988|NCT03669328|Procedure|locoregional anesthesia|Both groups received locoregional anesthesias
75804989|NCT02912650|Drug|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
75804990|NCT02912650|Drug|Ibuprofen 250 mg|2 caplets of Ibuprofen 125 mg
75804991|NCT02912650|Drug|Acetaminophen 650 mg|2 tablets of Acetaminophen 325 mg
75804992|NCT02912650|Drug|Placebo|2 caplets of Placebo
75804993|NCT03004924|Drug|SHP640|Instill 1 drop of SHP640 (povidone-iodine [PVPI] 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
75804994|NCT03004924|Drug|PVP-I 0.6%|Instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
75945620|NCT03408405|Drug|Acthar Gel 80 UNT/ML Injectable Solution|Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
75945621|NCT02350088|Drug|probiotics|probiotics
75945622|NCT02350088|Drug|placebo|placebo
75945623|NCT03408093|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
75945624|NCT03612115|Device|Neuromuscular electrical stimulation|"Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)"
75945625|NCT04679623|Combination Product|Midazolam|Midazolam Injection, 10mg
75804995|NCT03004924|Drug|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
75945626|NCT04679623|Drug|Seizalam|Seizalam, 10 mg
76093078|NCT03254862|Procedure|CSS/AsynS|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
76093079|NCT03254862|Procedure|CSS/AsynR|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
75346595|NCT02472756|Drug|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
76093080|NCT03245502|Biological|Blood transfusion|The transfusion of erythrocyte suspension
76093081|NCT04487730|Behavioral|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
76093082|NCT04487730|Behavioral|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
76093083|NCT03845361|Procedure|Radial artery cannulation|Radial artery cannulation
75346596|NCT02472756|Drug|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
75346597|NCT01837940|Dietary Supplement|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
75346598|NCT01837940|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
75346599|NCT01464359|Drug|Allopurinol|On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
75346600|NCT01464359|Drug|Fludarabine|On Days 7, 6 and 5 pre-transplant, 25 mg/m^2 intravenously over 1 hour.
75346601|NCT01464359|Radiation|Total body irradiation|On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
75476939|NCT05274958|Behavioral|Patient-rated outcome measures and educational videos|PROMs are scales that are validated in behavioral health for tracking symptoms of depression, anxiety, and other conditions. They can be self-administered or given by a clinician. Mytonomy videos are short, educational videos about the patient's primary condition. All patients receive PROMs on entering our clinic. The difference in this intervention is those randomized to the active treatment will receive monthly PROMs and mytonomy video(s) until their appointment with the clinician. Usual care patients will only have PROMs at the intake and then at the appointment with their assigned clinician.
75657993|NCT06063434|Behavioral|Usual education|Standard continuing medical education, including Advanced Trauma Life Support, and the American Board of Emergency Medicine educational modules (e.g., trauma resuscitation).
75657994|NCT06057909|Diagnostic Test|Magnetic Resonance Imaging|Test that looks at the structure of the brain.
75804996|NCT03002038|Drug|Azathioprine|Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.
76025925|NCT05419076|Radiation|Stereotactic Radiosurgery|All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
75346602|NCT01464359|Drug|Cyclophosphamide|"On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours."
75346603|NCT01464359|Drug|Levetiracetam|Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
75476940|NCT05274269|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
75476941|NCT05274269|Drug|IVA|Tablet for oral administration.
75657995|NCT06057909|Diagnostic Test|Electroencephalography|Non-invasive technique to measure brain waves
75657996|NCT06057909|Diagnostic Test|Electromyography|Technique to evaluate muscle activity
75804997|NCT03002038|Drug|Rituximab|Patients will receive 1 g of Rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months.
75804998|NCT03664492|Other|Educational whiteboard video|Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
76093084|NCT04775121|Other|Deuterium Glucose|Oral administration of 20 g Deuterium Glucose on a 3-hour
76093085|NCT03245424|Drug|ivosidenib (AG-120)|Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
76093086|NCT03251040|Device|Autologous activated fibrin sealant|Application of fibrin sealant
76093087|NCT04754763|Drug|Dentin-Bonding Agents|3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
76093088|NCT04754763|Drug|Propolis|Propolis was obtained from Margalla hills, Islamabad by NARC (National Agriculture Research Council, Islamabad). Plant source origin is Acacia modesta and Apis mellifera bees collect it. The 30% ethanolic extract of propolis from raw propolis was obtained in Pakistan Council of Scientific & Industrial Research (PCSIR) by dissolving the propolis in 95% ethanol and straining out the precipitate
76093089|NCT03254550|Other|PrEP Promotion Package|A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
76093090|NCT04774653|Other|No intervention|Associations and prevalence will be calculated
76093091|NCT03251196|Other|No Intervention, and Observational Study|Observational Study
75945627|NCT02353988|Drug|Bicalutamide|"Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade >= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity."
75945628|NCT02353988|Other|Physician's Choice|"The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance."
75945629|NCT03395769|Biological|AB-SA01|AB-SA01 is an investigational bacteriophage therapeutic for treatment of Staphylococcus aureus infections
75346604|NCT01464359|Drug|Busulfan|Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if <12 kg) intravenously every 6 hours
75346605|NCT01464359|Biological|Umbilical Cord Blood Transplantation|Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
75657997|NCT06056674|Behavioral|U-PEACE Intervention|"This program will involve about 13 group sessions, with each group session lasting approximately 40-50 minutes. The program session will be held about 2 times a week during the school day (e.g., lunch time) if the group meets in person, or at a pre-scheduled time every week if the group meets online via Zoom.~Participants will learn how to better understand emotional experiences and use this understanding to embrace agency in challenging situations. Participants will develop skills to better deal with emotions by increasing awareness of what is happening in different settings and choose how to respond. Skill-building exercises may include mindfulness practices, flexible thinking, behavioral activation, problem-solving, and exposure activities."
75804999|NCT03664414|Drug|pentoxifylline|Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
75805000|NCT02911948|Drug|Insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily
75945630|NCT03149354|Other|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
75945631|NCT03405675|Other|SLAS 1|NA. Observational study, no interventions administered.
75476942|NCT05274269|Other|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
75476943|NCT05274269|Other|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
75945632|NCT03405675|Other|SLAS 2|NA. Observational study, no interventions administered.
75945633|NCT03611803|Device|Physiotherapy + Robotic-device|Daily use of an exoskeleton (robotic-device) on 5 successive days as well as daily physiotherapy sessions
75945634|NCT03611803|Other|Physiotherapy only|Participants will engage in daily physiotherapy sessions (without the exoskeleton) and/or home-based sit-to-stand exercises
75945635|NCT03146780|Procedure|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
75945636|NCT03146780|Procedure|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
76093092|NCT04774887|Biological|HPV vaccine, Merck|We will offer vaccination against HPV to 900 children/grandchildren aged 9 through 18 of women attending the Community Meetings.
76093093|NCT02455206|Behavioral|physical activity counseling|5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.
75346606|NCT01464359|Biological|Interleukin-2|"First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m^2 every other day for a total of 6 doses.~Second Course of IL-2 (day +60):~Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source."
75346607|NCT03210740|Drug|AM001 Cream, 7.5%|Active Cream
76093094|NCT02455206|Behavioral|Usual care|
75346608|NCT03210740|Drug|Vehicle Cream|Placeo
75346609|NCT05564897|Drug|H101, Camrelizumab|Patients receive a combination therapy of Camrelizumab 200 mg i.v. every 3 weeks with intravesical H101 with a dose of 5×10*11 Vp weekly for 6 weeks for both induction and maintenance treatments up to 1 years.
75346610|NCT01838252|Procedure|Hyaluronic acid|Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position
75476944|NCT05273307|Dietary Supplement|Miraculin|Given orally
75476945|NCT05273307|Dietary Supplement|Miracle Fruit Placebo Cube|Given orally
75476946|NCT05273268|Other|Personalized nutrition|Personalized nutrition based on individual traits delivered through mobile device app.
75657998|NCT06056674|Behavioral|SAU|Participants in this group will continue to receive standard of care within their school clinic.
75805001|NCT02911948|Drug|Insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily
75805002|NCT03622840|Behavioral|Cognitive Remediation|Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks
75476947|NCT05273268|Other|Generalized nutrition|General nutrition guidelines currently used by USDA.
75476948|NCT05272267|Other|AI-assisted models providing diagnosis and prognostic information|AI-assisted models providing diagnosis and prognostic information in the ED, including triage, ICD coding, chest x ray alerts, critical event alerts, readmission prediction, and post-cardiac arrest prognostication.
75805003|NCT03622918|Drug|colistin and rifampin combination therapy|Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
75945637|NCT03146780|Procedure|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
75945638|NCT03146780|Procedure|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
75945639|NCT05383807|Behavioral|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
75945640|NCT03392571|Drug|NGC-Triple regimen|gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
75805004|NCT03622918|Drug|colistin monotherapy|. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .
75657999|NCT06053047|Device|Bluedrop Monitoring Service (BMS)|Remote use of ThermoVisual monitoring
75945641|NCT03112460|Device|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software
75945642|NCT03612505|Behavioral|Mother groups using principles of UNICEF/World Health Organization's Care for Child Development|"The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~Introduction (10 minutes)~Lesson on *Early Childhood Development* topic (20 minutes)~Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~Observe caretakers one-on-one in play role with the child (25 minutes)~Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future"
75945643|NCT03392493|Behavioral|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.
75945644|NCT03392493|Behavioral|Standard treatment|Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.
75945645|NCT04656067|Drug|Oxytocin ,Tranexamic acid and Ethamsylate|Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
75945646|NCT04226222|Diagnostic Test|TEP-TDM FDG|Semi-quantitative PET-TDM FDG Data and Texture Analysis
76093095|NCT02454894|Drug|lidocaine|surface anesthesia with lidocaine
76093096|NCT02454894|Procedure|postoperative management|lying without the pillow for half an hour after lumbar puncture
75346611|NCT01838252|Procedure|Saline|Saline will be injected in to the lower lid, elevating it to a more anatomic position
75805005|NCT02996968|Procedure|Self-removal|Self-discontinuation of a transurethral catheter
75805006|NCT03487666|Drug|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
75805007|NCT03487666|Drug|Capecitabine|Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
75805008|NCT03663634|Other|Cytochalasin B use in ICSI handling medium|A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate
76093097|NCT02455128|Other|Therapeutic listening|Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
76093098|NCT03250962|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
76093099|NCT03250962|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
76093100|NCT04778943|Other|Surgery(OLIF and MIS-TLIF)|oblique lateral interbody fusion (OLIF); minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
76093101|NCT04774341|Drug|anticoagulation treatment|Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
76093102|NCT04774263|Other|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential real time localization system
75346612|NCT01838330|Dietary Supplement|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
75346613|NCT02498652|Drug|RDEA3170 2.5 mg|"Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets)."
75658000|NCT06045689|Drug|Luspatercept|Specified dose on specified days.
75658001|NCT06033001|Drug|[Lu-177]-PNT2002|[Lu-177]-PNT2002, is a radiopharmaceutical investigational drug. [Lu-177]-PNT2002 targets a specific protein that is located on the surface of prostate cancer cells called PSMA. [Lu-177]-PNT2002 delivers radiation to your cancer by binding to the PSMA which helps destroy the cancer cells. [Lu-177]-PNT2002 is administered intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment.
76093103|NCT04774029|Procedure|Basivertebral nerve block|Temporary intraosseous basivertebral nerve block using lidocaine
75346614|NCT02498652|Drug|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
75346615|NCT01838408|Other|Ez2go Complete|EZ2Go Complete
75945647|NCT03612037|Dietary Supplement|alpha lipoic acid|600 mg/day oral dose of alpha lipoic acid
76093104|NCT04774029|Drug|Lidocaine induced basivertebral nerve block|Intraosseous lidocaine basivertebral nerve block
76093105|NCT03245346|Drug|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
75476949|NCT05272267|Procedure|Critical treatment|Critical treatment of the emergency room
76093106|NCT03245346|Drug|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
76093107|NCT03245346|Drug|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
75346616|NCT01838408|Other|LoSo Prep|LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
75658005|NCT06029036|Drug|Darolutamide+ADT|"Drug: Darolutamide~Darolutamide 600 mg, (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take Darolutamide with food.~Drug: ADT GnRH agonist per physicians' choice, orchiectomy is excluded"
75658006|NCT06027619|Drug|Topical aminolevulinate (10% ALA gel)|10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
75658007|NCT06027619|Device|Red light illumination|Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
75805009|NCT03663556|Other|Infant-feeding|Preterm infants hospitalized in the NICU can be feed by three different types of infant feeding, such as breast milk, donor human milk and/or formulas.
75805010|NCT04058080|Other|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6C, 40% humidity). The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
75945648|NCT03612037|Dietary Supplement|Cellulose|600mg/day oral dose of placebo cellulose
75945649|NCT03395691|Procedure|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach
75945650|NCT03395691|Procedure|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
75945651|NCT02348138|Other|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
75945652|NCT04713241|Procedure|Electro-acupuncture|"20-30 minute acupuncture treatment in sessions from start of study (within 48 hours of diagnosis) to return of bowel functions~A practitioner stimulates certain points on the body by placing thin needles in the skin. Electrical stimulation is then added to some of the needles. This involves placing wires on the needles, which are connected to a machine that delivers a weak electrical current through the wires. The strength of the electrical current will be changed slowly until it is at a comfortable level."
75945653|NCT04713241|Other|Standard of Care Bowel rest|Bowel rest with NPO status and placement of nasogastric tube (NGT) if clinically indicated
75945654|NCT03611959|Other|Non Applicable|
76093108|NCT03245346|Drug|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
76093109|NCT03245112|Drug|Eribulin Mesylate|The patients received intravenous eribulin 1.4 mg/m2 over 2-5 minutes on days 1 and 8 of every 21 days.
76093110|NCT03245034|Behavioral|Auricular Acupuncture Therapy|"Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG)."
76093111|NCT03244956|Drug|Trametinib|2mg daily for a maximum of 6 weeks of treatment
75945655|NCT02350166|Procedure|laparoscopic surgery|laparoscopic-assisted small-incision surgery
76093112|NCT03244956|Drug|Dabrafenib|150mg twice daily
76093113|NCT03244956|Radiation|131I|5.5 GBq
76093114|NCT03244956|Drug|rhTSH|0.9mg on two consecutive days after 35 days of treatment
76093115|NCT03244878|Behavioral|Thrive|A interactive computerized program using structured content of cognitive behavior therapy
76093116|NCT02454270|Drug|Part 1 (Dose Escalation): Duvortuxizumab|Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 -day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28-day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.
75658008|NCT06021158|Combination Product|Hybrid automated Lyumjev delivery system with carbohydrate counting|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the total grams of carbohydrates counted. This is the same as commercial hybrid closed-loop insulin therapy (standard treatment).
75658009|NCT06021158|Combination Product|Hybrid automated Lyumjev delivery system with meal size estimation|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the qualitative amount of carbohydrates estimated (e.g., low-carb meal).
75658010|NCT06021158|Combination Product|Fully automated Lyumjev delivery system with meal detection|In this system, the patient does not initiate a Lyumjev insulin bolus at mealtime. An algorithm is used to detect a meal and administer a subsequent bolus, rather than requiring a carbohydrate count.
75658011|NCT06017999|Drug|XG005 tablet|Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.
75658012|NCT06017999|Drug|Placebo tablet|Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
76093117|NCT02454270|Drug|Part 2 (Dose Expansion): Duvortuxizumab|Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
76093118|NCT03244488|Drug|Scopolamine Injectable Product|2.5 or 5 mcg/kg of scopolamine via IV
76093119|NCT03244488|Drug|Mecamylamine Pill|10 or 20mg of mecamylamine orally
76093120|NCT03244332|Other|Collecting Clinical Data|Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)
76093121|NCT03244332|Other|Collecting laboratory data|Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.
76093122|NCT02454738|Radiation|Ultralow dose chest CT scan|Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
76093123|NCT03254472|Diagnostic Test|Measured concentrations of biomarkers|
76093124|NCT03244410|Diagnostic Test|complete blood picture|complete blood picture
75346617|NCT01835990|Device|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
75346618|NCT01835990|Device|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
76093125|NCT02455986|Behavioral|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
75658018|NCT06015841|Biological|Placebo|The placebo is a solution matching the study vaccine formulation.
75658019|NCT06015841|Biological|ACI-7104.056 at Dose A|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
75658020|NCT06015841|Biological|ACI-7104.056 at Dose B (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
75658021|NCT06015841|Biological|ACI-7104.056 at Dose C (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
75658022|NCT06011057|Diagnostic Test|Serum C reactive protein (CRP) level|An immunoturbidimetric method using a Modular P Analyzer will be used to carry out HSCRP assay, with a quantitation limit of 0.5 mg/L.
76093126|NCT03243942|Drug|Definity|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
76093127|NCT03254784|Drug|BMS-986165 Capsule|Oral capsule
76093128|NCT03254784|Drug|BMS-986165 Tablet|Oral tablet
76093129|NCT03245190|Drug|Chiauranib|50mg, orally once daily
76093130|NCT01969708|Drug|aflibercept|
76093131|NCT01969708|Drug|bevacizumab|
76093132|NCT03243864|Drug|Ceftazidime-avibactam|Patients will be started on 2.5 gm IV every 8 hours
76093133|NCT03250494|Drug|Dulox capsule (60mg)|each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
75346619|NCT01838486|Procedure|Bladder Thermal Distention|Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
75346620|NCT03213158|Drug|Ixazomib Oral Capsule|Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.
75346621|NCT02498418|Drug|Rifaximin|Tablets, generic formulation of the brand product.
75346622|NCT02498418|Drug|Xifaxan®|Tablets, brand product.
75346623|NCT02498418|Drug|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
75346624|NCT03219476|Drug|Anastrozole|1 mg once daily.
75346625|NCT03219476|Drug|Letrozole|2.5mg once daily.
75346626|NCT03219476|Drug|Exemestane|25 mg once daily.
75346627|NCT03219476|Drug|Tamoxifen|20 mg once daily.
75346628|NCT02472366|Drug|ILUVIEN|
76093134|NCT03250494|Drug|combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI|each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
76093135|NCT03250494|Drug|a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone|each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
76093136|NCT02354482|Behavioral|Patient Communication and Care Management|"Received the following Transitional Care strategies:~Helpful Health Care Contact OR Symptom Management~Post-discharge Care Consultation~Patient Goal/Preference Assessment~Plain Language Communication in Hospital~Plain Language Communication at Home~Transition Summary for Patients and Family Caregivers"
75346629|NCT01724606|Radiation|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
75346630|NCT01724606|Drug|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
76093137|NCT02354482|Behavioral|Home-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~Transition Team~Home visits~Plain Language Communication at Home~Promote Trust at Home~Referral to Community Services~Follow-up Appointment"
76093138|NCT02354482|Behavioral|Hospital-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~Post-discharge care consultation~Identify High-Risk Patients and Intervene~Medication Reconciliation~Plain Language Communication in Hospital~Promote Trust in the Hospital~Transition Summary for Patients and Family Caregivers"
76093139|NCT02354482|Behavioral|Patient/Caregiver Assessment and Provider Information Exchange|"Received the following Transitional Care Strategies:~Patient Goal/Preference Assessment~Identify High-Risk Patients and Intervene~Timely Exchange of Critical Patient Information among Providers~Patient/Family Caregiver Transitional Care Needs Assessment"
76093140|NCT02354482|Behavioral|Assessment and Teach Back|"Received the following Transitional Care Strategies:~Post-discharge care consultation~Language Assessment~Teach Back for Information and Skills"
76093141|NCT02354482|Other|Standard of Care (Reference)|No specific Transitional Care Strategy
76093142|NCT03250572|Diagnostic Test|serum ferritin|serum samples and ferritin ELISA test
76093143|NCT03254628|Other|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
76093144|NCT03254628|Other|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag & mask device.
75658023|NCT06011057|Diagnostic Test|Ultrasound|All examinations will be carried out by an experience operator with a transvaginal probe on high-resolution ultrasound machines. Pregnancies will be dated from the LMP. Other measurements will be obtained during the scan as the mean gestation sac diameter, volume of the gestation sac and the embryonic heart rate (FHR).
75805011|NCT04058080|Other|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration. Participants were able to attend any of the offered classes each week. Participants had approximately 18-22 classes in total to choose from each week.
75805012|NCT03472612|Other|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA
75805013|NCT00027027|Drug|rhuMAb 2C4|
75805014|NCT00046839|Drug|celecoxib|
75805015|NCT00046839|Radiation|radiation therapy|
75805016|NCT00006903|Drug|Fulvestrant|Given intramuscularly
75805017|NCT03951597|Drug|combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)|"Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~Lenvatinib (8mg/d), continuous use for 1 year.~PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
76093145|NCT03254628|Behavioral|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
76093146|NCT03254628|Behavioral|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
76093147|NCT03254628|Drug|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
76093148|NCT03254628|Device|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
76093149|NCT03254706|Other|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
76093150|NCT03254706|Other|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
76093151|NCT03254706|Other|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
76093152|NCT03254706|Other|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
76093153|NCT01970176|Drug|Tadalafil|Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.
75945656|NCT05168241|Other|song/melodica group|"The patients who were divided into groups according to their wishes to sing or play the melodica were given warm-up training before the song group (20 min. warm-up training including breathing exercises, 20 min. singing) and melodica group (20 min. breathing). warm-up training including exercises, playing melodica for 20 minutes) was given with the researcher under the leadership of an experienced music teacher.~For two weeks, a total of 40 minutes of song/melodica training was given per week. The singing group was given an assignment to sing for at least 20 minutes a day and the melodica playing group to play the melodica for at least 20 minutes a day. The patients were asked to do their song/melodica homework for at least 20-30 minutes a day, and then they were told about the follow-up papers.~Patients in the song/melody group were followed up by telephone twice a total of 15 days at the 5th and 7th weeks."
76093154|NCT01970176|Drug|Placebo|Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is >95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
76093155|NCT03254160|Drug|DNS-3379|DNS-3379
76093156|NCT03254160|Drug|Placebo|Placebo
76093157|NCT02023918|Drug|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
76093158|NCT03250728|Biological|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~the endothelial permeability~the protein C system"
76093159|NCT03243708|Behavioral|Risk calculator|Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
76093160|NCT02454036|Behavioral|BBI intervention|Psychological intervention designed to reduce stress and enhance quality of life
76093161|NCT02024386|Drug|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
75658024|NCT06010784|Behavioral|Family support|"Family tip sheets sent via mobile text at the start of the program and then every 3 weeks, to a total of 6 mobile text messages~Weeks 1-4 (4 weeks):~i. Welcome package mailed in the first week of the program ii. Weekly: one 10-lbs box of produce iii. Recipes accompanying each box (sample recipe card attached to submission) iv. Bi-Weekly: Grocery store gift cards (2x USD 20, to a total of USD 40)~Weeks 5-19 (total of 10 weeks over the 19-week study timeline):~i. An optional online form (goal sheet) is sent to the parent/caregiver every other week (total 5) with questions about trying new FV items to be submitted in the next 7 days. As an incentive, a USD 10 gift card is sent to those who complete it (a potential total of USD 50).~ii. Week 11: an extra USD 20 gift card in the week after a school holiday to re-engage participants due to the school-year break."
75658025|NCT06010784|Behavioral|BGCAA's after-school program with CATCH curriculum|"The whole BGCAA's after-school program runs for 3h, Mon-Fri for the school year across all sites where the organization offers the program. All children enrolled are expected to attend a minimum of 2x/week.~In the BGCAA's after-school program, children participate in active recreational time (approx. 60 min, offered 1x/week at a minimum) which is a mixture of free play, structured physical activity games, and/or sports activities (including soccer, football, and basketball).~Uniquely to sites participating in the study, BGCAA's staff will deliver selected CATCH (Coordinated Approach to Child Health) curriculum components in blocks of 45-60 min, 2x/week, as part of the after-school program. The curriculum will focus on healthy eating education and physical activity designed for elementary school-aged children. More information on CATCH at https://catch.org/ (accessed 8/11/2023)"
75658026|NCT06007976|Device|Erchonia® Trident|Low-level laser therapy
75805018|NCT03954561|Procedure|endoscopist-administered abdominal compression|The endoscopist administers abdominal compression when loop formation encountered.
75945657|NCT05168241|Other|control group|"In the first interview, the pre-tests were applied by the researcher with the face-to-face interview technique. Afterwards, nursing education was given through the training guide prepared according to Pender's health promotion model. The control group was followed up and counseled by phone, twice a day, twice a day, in the 5th and 7th weeks.~Post-tests were applied at week 10 to evaluate the effectiveness of the interventions."
75346631|NCT04201704|Other|Balanced crystalloid solution volume administration|Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.
75346632|NCT04201704|Other|Packed Erythrocytes Units, Blood Product Unit volume|For patients designated as Bleeding, where hemoglobin <7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
75805019|NCT03954561|Procedure|assistant-administered abdominal compression|A assistant administers abdominal compression when loop formation encountered.
75805020|NCT03539484|Drug|RO7172508|RO7172508 was administered at a dose and as per the schedule specified in the respective arms.
75805021|NCT03539484|Drug|Obinutuzumab|In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.
75805022|NCT03539484|Drug|Tocilizumab|Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)
75805023|NCT01327365|Procedure|trans-radial PCI (TRI)|TRI performed using the sheathless guiding approach
75805024|NCT01327365|Procedure|trans-radial PCI (TRI)|TRI performed using a conventional guiding approach
75805025|NCT03951519|Other|oral administration of water|Volume expansion via 500 mL of water administered by the patient's nasogastric tube
75945658|NCT02350244|Behavioral|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
75945659|NCT03886155|Procedure|Biopsy|During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
75945660|NCT04653181|Drug|Ferric carboxymaltose|Iron-arm treated with Ferric carboxymaltose, non-iron arm without
75945661|NCT04203446|Other|Assessment of correctness of inhaling technique|Assessment of correctness of inhaling technique in patients with asthma or COPD
75945662|NCT04447209|Other|Dietary counselling on Food Groups according to IYC Feeding practices, WHO|Monitoring of Dietary diversity and growth
75805026|NCT03951519|Other|administration of saline solution|Volume expansion via 500 mL of saline (Nacl 0.9%) administered by the venous route
75805027|NCT01100463|Drug|Cream|Twice daily lotion to prevent HFS
75805028|NCT01100463|Drug|0.1% Uracil Cream|Twice daily lotion to prevent HFS
75805029|NCT03726762|Behavioral|DBs at the end of the main meal + weight control program|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
75945663|NCT04199624|Drug|Omeprazole 20mg|Omeprazole twice daily x 5 days
75346633|NCT04201704|Other|Plasma volume|For patients designated as Bleeding, where International Normalized Ratio (INR) > 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
75346634|NCT04201704|Other|Platelets volume|For patients designated as Bleeding, where platelets < 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
75476950|NCT05268614|Radiation|Radiation therapy|"Participants will receive either 70 gray (Gy), 60 Gy, or 50 Gy of radiation based on the following criteria:~70 Gy: Pretreatment level of plasma circulating free HPV DNA (cfHPV DNA) ≤ 12 copies/mL~60 Gy: Tumor tissue positive for HPV subtype other than 16 OR Pretreatment level of cfHPV DNA 13-99 copies/mL OR Pretreatment level of cfHPV DNA ≥ 100 copies/mL AND <95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy~50 Gy: Tumor tissue positive for HPV subtype 16, pretreatment level of cfHPV DNA ≥ 100 copies/mL, AND ≥ 95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy"
75658027|NCT06006390|Biological|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
75658028|NCT06006390|Biological|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
75805030|NCT03726762|Behavioral|Water at the end of the main meal+ weight control program|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
75805031|NCT01101009|Drug|Perindopril + amlodipine + if necessary, hydrochlorothiazide|Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
75805032|NCT01101009|Drug|olmesartan/amlodipine + hydrochlorothiazide, if necessary.|olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
75805033|NCT01101087|Device|Taurolock|
75805034|NCT01101087|Other|Placebo|Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
75945664|NCT04199624|Dietary Supplement|Vitamin C|Ascorbic acid x 1 on day 5
75945665|NCT04643353|Device|Non-ablative vaginal Erbium YAG laser treatment|Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia) with SMOOTH mode setting, which enables non-ablative, thermal-only operation. The parameters are selected based on extensive preclinical and clinical studies.
75945666|NCT04643353|Other|PFE|PFE will be prescribed as it is already implemented in clinical practice (i.e. up to 2x 9 sessions with a pelvic floor physiotherapist of choice). Type of physiotherapy, number of completed sessions and duration of therapy will be recorded.
76025926|NCT05419076|Procedure|Cerebrospinal fluid collection|All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.
76025927|NCT05411679|Drug|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
76025928|NCT05411679|Drug|Olaparib tablets|Olaparib is a PARP inhibitor (poly [adenosine diphosphate-ribose] polymerase inhibitor) Other names: Lynparza
75346635|NCT01720004|Other|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
75346636|NCT03836534|Behavioral|adherence to treatment of patients coming out of emergencies|Phone contact of patients within 48 hours of the consultation
75805035|NCT03951363|Behavioral|interactive Obesity Treatment Approach (iOTA)|The investigators will adapt an evidence-based digital health intervention to promote adherence to nationally recommended diet and physical activity guidelines for patients with chronic kidney disease. The intervention includes goal assignment, goal tracking, and skills training messages.
75805036|NCT03561090|Drug|IW-3718|oral tablet
75805037|NCT03561090|Drug|placebo|oral tablet
75805038|NCT03561090|Drug|Standard-dose PPIs QD|background therapy
75805039|NCT02996500|Drug|PF-06650833|Investigational
75805040|NCT02996500|Drug|Placebo|Placebo
76025929|NCT05409105|Dietary Supplement|Mangoes|Frozen mangoes, 2 cups per day, 2 weeks
75805041|NCT02996500|Drug|Tofacitinib|Investigational
75805042|NCT03726684|Device|Coding strategy for cochlear implants|Comparison of two variations of a coding strategy based on electrophysiological objective measures with standard reference coding strategy
75805043|NCT00006489|Behavioral|Cognitive-Behavioral Therapy|Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
76025930|NCT05409105|Dietary Supplement|Water|2 cups/day bottled water, 2 weeks
76025931|NCT05406479|Drug|BE-PEP (Bedaquiline)|Single dose of Bedaquiline
76025932|NCT05406479|Drug|SDR-PEP|Single dose of Rifampicin
76025933|NCT05406479|Drug|BE-PEP (Rifampicine)|Single dose of Rifampicin
76025934|NCT05400837|Combination Product|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement guideline-recommended Afib care
76025935|NCT05380505|Behavioral|Racially Congruent Ads|Facebook food ads that are racially congruent.
76025936|NCT05380505|Behavioral|Racially Incongruent Ads|Facebook food ads that are racially incongruent.
76025937|NCT05344092|Behavioral|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
76025938|NCT05325281|Drug|CPI-613® (Dose level -1.0 250 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
75805044|NCT00006489|Drug|Naltrexone|Daily dosing 100 mg for 24 weeks
75805045|NCT00006489|Drug|Placebo|Pill Placebo daily dosing 24 weeks
75945667|NCT03395535|Procedure|Primary Selective Laser Trabeculoplasty Treatment Pathway|"Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
75945668|NCT03395535|Drug|Primary Medical Treatment Pathway|"Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
75945669|NCT03611491|Device|Princess FILLER Lidocaine|Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
75945670|NCT02748863|Drug|Placebo|2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
75945671|NCT02748863|Drug|Secukinumab 2 mL form|Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
75805046|NCT03726606|Device|Intraocular lens|Bilateral implantation of the same intraocular lens.
75945672|NCT02748863|Drug|Secukinumab 1 mL form|Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
75945673|NCT02244554|Device|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
75945674|NCT03611413|Procedure|ERAS care|ERAS PROTOCOL
75945675|NCT03392337|Device|Narrowband UVB phototherapy|Ultraviolet B phototherapy
75945676|NCT03611179|Drug|Bevacizumab|"The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)"
75945677|NCT03126123|Procedure|acetic acid test|Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
76093162|NCT03250650|Device|TTNS|Transcutaneous tibial electric stimulation
75945678|NCT02353676|Drug|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
75945679|NCT02353676|Other|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
76093163|NCT03250650|Device|ES+TTNS|Transvaginal electric stimulation
75476951|NCT05268614|Drug|Cisplatin|"All participants will receive 40 mg/m2 of cisplatin intravenously over 60 minutes weekly during radiation therapy.~If cisplatin is not recommended by the treating medical oncologist or is not tolerated, it is permissible to switch to weekly Carboplatin AUC 1.5 and paclitaxel 45 mg/m2."
75805047|NCT03723408|Device|ClearLine IV (formerly, AirPurge)|Patient safety device that automatically and continuously detects and actively removes air from IV lines - protecting patients from dangerous air burden, air embolism, air infusions.
75805048|NCT01096095|Drug|Placebo|Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
75805049|NCT01096095|Drug|Sodium Phenylbutyrate|Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
75805050|NCT03720756|Other|Nickel-free diet|Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.
75805051|NCT03664102|Device|Cor Knot|Heart valve replacement with or without the use of automated fastener device Cor Knot
75805052|NCT03535974|Dietary Supplement|Preparation with Spirulina|Preparation with Spirulina to ameliorate the size of benign thyroid nodules
75805053|NCT03535974|Dietary Supplement|Placebo|Placebo administration for 6 weeks bid
75805054|NCT00025233|Biological|bevacizumab|Given IV
75805055|NCT00025233|Other|laboratory biomarker analysis|Correlative studies
75805056|NCT00025155|Drug|ixabepilone|Given IV
75945680|NCT03395457|Drug|Care as usual|Application of usual pharmacological care for chronic migraine
75945681|NCT03395457|Other|Manual Therapy|5 sessions of manual therapy over 12 weeks
75945682|NCT02032615|Dietary Supplement|Education plus Gudness Nutritional Bar|
75945683|NCT02032615|Other|Education|
75945684|NCT02347748|Behavioral|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
75945685|NCT02347748|Behavioral|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
75945686|NCT02347748|Behavioral|Reading 2 scripts|"Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation"
75945687|NCT02520375|Other|Prebiotic|
75945688|NCT02520375|Other|Control|
76093164|NCT03250260|Other|3-dimensional photograph with simulation|The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.
76093165|NCT03250260|Other|Viewing of a 2-dimensional photographic library|The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
76093166|NCT03250338|Drug|Crenolanib|Crenolanib will be administered orally
76093167|NCT03250338|Drug|Cytarabine|"HAM regimen~FLAG-Ida"
76093168|NCT03250338|Drug|Mitoxantrone|HAM regimen
75805057|NCT01100541|Device|Polymeric plate|Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
75945689|NCT03617627|Behavioral|Self-management intervention|Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
75945690|NCT03611647|Dietary Supplement|Probiotic|Probiotic dietary supplement containing a mixture of Lactobacillus and Bifidobacterium species, taken by mouth once daily for 4-6 weeks.
75658029|NCT06002139|Behavioral|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
75658030|NCT06002139|Behavioral|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~Two hours of kinesiotherapy (120 minutes, including gait training).~Thirty minutes of ergotherapy.~Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
75945691|NCT03611647|Dietary Supplement|Placebo|Placebo, taken by mouth once daily for 4-6 weeks.
75945692|NCT03395379|Procedure|RFA|Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.
75945693|NCT02347514|Behavioral|Diabetes group visit|
76093169|NCT03250338|Drug|Placebo Oral Tablet|Placebo will be administered orally
75658031|NCT06000787|Radiation|External beam radiotherapy|Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B receive standard-of-care external beam radiotherapy to the brain tumor.
75658032|NCT06000787|Radiation|131I-Metaiodobenzylguanidine (MIBG)|Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B receive the radiopharmaceutical 131I-Metaiodobenzylguanidine (MIBG) 15 mCi/kg via either a central or a peripheral IV catheter over 1.5 to 2 hours at a maximum rate of 500 mCi/hour.
75805058|NCT03720600|Behavioral|MAB Intervention|The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, & Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
75805059|NCT02998996|Biological|15 µg HA/strain and 1% Endocine™|intranasal administration
75805060|NCT02998996|Biological|15 µg HA/strain and 2% Endocine™|intranasal administration
75945694|NCT03392259|Behavioral|Smartphone app|Installment and use of smartphone app
75945695|NCT02032849|Procedure|Manual air-impingement operation|A method which we invented to clear subglottic secretion
75945696|NCT02032849|Device|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
75945697|NCT02347592|Device|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
75805061|NCT02998996|Biological|15 µg HA/strain|intranasal administration
75805062|NCT02998996|Biological|intramuscular comparator|intramuscular administration
75805063|NCT02998996|Biological|intranasal comparator|intranasal administration
75945698|NCT02347592|Device|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
75945699|NCT03395301|Device|Coil|Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
76093170|NCT03250338|Drug|Fludarabine|FLAG-Ida regimen
76093171|NCT03250338|Drug|Idarubicin|FLAG-Ida regimen
76093172|NCT03250338|Drug|G-CSF|FLAG-Ida regimen
76093173|NCT01971580|Drug|Ambrisentan|
75476952|NCT05266924|Drug|Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen|fixed-dose of 225 IU/day, subcutaneous (SC), daily, for 5 days. further dosage will be adjusted till adequate follicular development.
75476953|NCT05266196|Drug|Seclidemstat|Treatment assigned as per parent protocol
75805064|NCT02998996|Biological|Placebo, Saline|intranasal administration
76093174|NCT00354562|Drug|ABT-751|200mg ABT-751 daily for 14 days every 21 days
76093175|NCT00354562|Drug|Placebo|Placebo daily for 14 days every 21 days
75476954|NCT05244044|Other|Pulmonary rehabilitation in primary care|Pulmonary rehabilitation consists breathing exercises, exercise capacity, muscle strength and change towards an active lifestyle.
75476955|NCT05243472|Dietary Supplement|Protein nutritional supplement|Participants in the intervention group will receive protein-enriched soups (24-30g of protein). Protein may come from either soy, bean or milk products.
75805065|NCT03663478|Drug|Ropivacaine|2 x 30 ml ropivacaine 0,2% and an elastomere pump with 200 ml ropivacaine 0,2%, infusion rate 8 ml/hour
75805066|NCT03663478|Drug|Saline|2 x 30 mL isotonic saline and an elastomere pump with 200 ml isotonic saline, infusion rate 8 ml/hour
75805067|NCT02994940|Drug|Acetaminophen|already included in arm/group descriptions
75805068|NCT02994394|Drug|OPC-41061|
75805069|NCT01062412|Device|LensAR Laser System|Laser treatment of the crystalline lens
75805070|NCT02998840|Biological|B244|odorless suspension
75805071|NCT02998840|Biological|Vehicle|odorless suspension
75945700|NCT03617315|Drug|Hylauronic Acid|Schirmer Test, BUT test and OSDI test. Previous and After treatment
76093176|NCT00354562|Drug|Docetaxel|Standard Docetaxel every 21 days
76093177|NCT00421564|Drug|DBT-Danggui Buxue Tang|
76093178|NCT03250104|Other|Infection Control|The infection control bundle will include staff training, hand hygiene programs, disinfection measures, and contact isolation. Physicians will be discouraged to prescribe proton pump inhibitors (PPIs) where not explicitly needed. The intervention bundle will be defined based on current literature. For implementation, the investigator will adapt the bundle to specific local needs, discuss with the responsible department heads and ward staff, perform training and disseminate standards of care.
76093179|NCT03250104|Other|Antibiotic Stewardship|"Antibiotic stewards will develop local standards of procedure based on the provided training and guidelines. They will then train the responsible staff and disseminate guidelines as best suited for the local work environment, e.g. as pocket cards, posters, or electronically. Point-prevalence investigations and antibiotic visits will assure adherence to guidelines."
76093180|NCT00838383|Drug|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
76093181|NCT00838383|Drug|sitaxsentan (Thelin)|Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
76093182|NCT00838383|Drug|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
76093183|NCT03254238|Other|Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior|development and identification of systems and tools able to detect earlier misuse phenomenon
76093184|NCT01972204|Behavioral|Intensive adherence instruction|Instruction with educational brochure
75658033|NCT05997225|Other|opt out enrollment, tailored counseling, varenicline started prior to target quit date|Participants automatically enrolled in motivational counseling. Tailored counseling includes sharing results of Chest CT results and lung function spirometry tests with participants.
75805072|NCT03663868|Diagnostic Test|CC-Test|Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells
75346637|NCT04967742|Biological|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
76093185|NCT01972204|Behavioral|Control|Instruction as per usual practice
76093186|NCT03243240|Diagnostic Test|mutlidetector computed tomography|"Multidetector computed tomography angiography with 16- MSCT scanner, medical system bright speed. Our protocol will include non-enhanced scanning then perform a triphasic angiography that includes arterial, portal and venous phases to detect acute gastrointestinal bleeding.~Images will be acquired with the following parameters slice thickness 5mm for the unenhanced phase and 1.25mm for the arterial phase and porto-venous phases"
75346638|NCT03753750|Device|Noninvasive spinal cord stimulation|Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
75346639|NCT01720082|Procedure|Single incision laparoscopic appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
75658034|NCT05997225|Other|opt in enrollment, non-tailored counseling, varenicline started prior to target quit date|Participants must opt-in to receive counseling. Counseling does not include discussion of Chest CT or spirometry results.
75658035|NCT05996172|Behavioral|CAMS Single Session Consultation|CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients. The foundational brief intervention that all participants will receive includes 1 90-minute session of CAMS assessment and planning interview with follow-up care navigation. CAMS is based around a model of STB which states that youth become suicidal in response to overwhelming pain, and treatment identifies and targets the drivers of suicide as the primary focus of assessment and intervention.
75805073|NCT03664570|Device|VIPUN Balloon Catheter|The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.
75805074|NCT04057222|Other|No intervention|Only propose water and wait for need to void
75805075|NCT01063270|Drug|Clindamycin & Rifampin|Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
75805076|NCT01063270|Procedure|Clindamycin + Rifampin along with NdYag Laser treatment|Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
75805077|NCT00023673|Drug|carboplatin|
76093187|NCT02355886|Drug|Gabapentin|Given PO
75805078|NCT00023673|Drug|paclitaxel|
75805079|NCT00023673|Radiation|three-dimensional conformal radiation therapy|
75945701|NCT02349932|Other|Healthy Adults|The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
75945702|NCT05168007|Drug|WID-RGC20(Cariprazine) 3mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
75945703|NCT05168007|Drug|WID-RGC20(Cariprazine) 6mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
75945704|NCT05168007|Drug|Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day|The placebo comparator is administered during the double-blind treatment period(6 weeks).
75476956|NCT05241418|Diagnostic Test|Atrial 3D late gadolinium enhancement|We will use cardiac MRI to take a picture of the atria. This picture will be used to identify scar tissue within the atria.
75476957|NCT05237258|Behavioral|Specialty Palliative Care|Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
75945705|NCT04203173|Behavioral|FINANCE-DM|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
75658036|NCT05996172|Behavioral|Driver Focused Skills Training|The CAMS approach focuses on therapeutic assessment, collaborative identification and treatment of the patient-defined STB drivers (i.e., the problems that make suicide compelling to the patient) and utilizes problem-focused treatment sessions to address the drivers in order to reduce the wish to die. In the SOARS brief intervention model, specific skills are taught to youth based on CAMS drivers/case conceptualization of suicidality.
75945706|NCT04203173|Behavioral|Active Comparator|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
75945707|NCT02032927|Drug|Codeine/paracetamol|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
76025939|NCT05325281|Drug|CPI-613® (Dose level 1.0 500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
76025940|NCT05325281|Drug|CPI-613® (Dose level 2.0 1,000 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
76025941|NCT05325281|Drug|CPI-613® (Dose level 3.0 1,500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
75476958|NCT05237258|Behavioral|Primary Palliative Care|Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
75476959|NCT05235399|Other|Echo scans|Echo heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life.
75476960|NCT05235126|Device|Decoria intense|All subjects will receive treatment at Visit 1 with the option to receive a touch-up treatment at Visit 2. Evaluation of the nasolabial folds will be performed by PI using the Wrinkle Severity Rating Scale (WSRS).
75476961|NCT05232760|Device|Supera™ Peripheral Stent System|The device will be employed for treatment of juxta-anastomotic stenosis in failing AV fistula after previous percutaneous angioplasty procedures
76025942|NCT05325281|Drug|CPI-613® Maximum Tolerated Dose (MTD)|MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m^2 and up to 1,500 mg/m^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
76025943|NCT05325281|Drug|Gemcitabine|Subjects will be administered 400 mg/m^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
76025944|NCT05325281|Radiation|Intensity-modulated Radiation Therapy|1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
76025945|NCT05289934|Behavioral|Music Stimuli|Nine-minute-long Mozart K.448 (1st movement) and instrumental age-appropriate songs will be played via single-use earbuds with 10 minutes wash-out in between music stimuli.
76025946|NCT05289505|Device|MUSIC-CARE|This device allows the listening of music using different sequences of instrumental music created specifically, and using principles based on hypno-analgesia, that is to say the association of hypnotic techniques and approaches to help or analgesic, medicated or not. It consists of a tablet application containing instrumental music pieces, specially created and recorded for Music-Care. Each piece is at least 20 minutes long. The music can be played through headphones or speakers.
76025947|NCT05274165|Device|Lyric Hearing Aid- Experimental Design|Extended wear hearing aid with a fitting modification that is currently not available
76025948|NCT05274165|Device|Lyric Hearing Aid- Commercially Available|Extended wear hearing aid that is currently available
76025949|NCT05267574|Drug|REN001|Once daily dosing
76025950|NCT05258916|Procedure|Nurse consultation|nurse consultation carried out within two weeks after maternity discharged
76025951|NCT05254275|Other|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
76025952|NCT05254275|Other|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
76025953|NCT05248438|Behavioral|Questionnaire|Questionnaire
76025954|NCT05244629|Device|BMS vs. CS|Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
76025955|NCT05242809|Behavioral|Group-based PFMT group|The intervention group receives PFMT supervision in groups of about 6-8 women
76025956|NCT05193994|Drug|Dolutegravir, Abacavir and Lamivudine|Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.
75945708|NCT02032927|Drug|Oxycodone/naloxone|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
76093188|NCT02355886|Other|Placebo|Given PO
75658037|NCT05996172|Behavioral|Caregiver Skills Training|Caregivers will receive 3, 30-minute modules across 3 sessions that provide explicit coaching in several skills adapted from evidence-based treatments for youth suicidality including DBT and CBT.48,49 Module content will include 1) psychoeducation on suicidality and the escalation cycle and creation of a communication plan related to responding to youth suicidality (i.e., Crisis Escalation and Communication Plan); 2) positive communication and relationship building strategies including reflective listening, validation, and how to implement regular teen-directed one-on-one time; and 3) setting up behavioral expectations, house rules, and using positive reinforcement based contingency management in the home (i.e., targeted praise, using rewards to promote more effective behaviors). All modules will include didactic skill building, role-play of skill use with the therapist, and a check-in with the youth and youth therapist to collaboratively problem-solve barriers to use of skills.
75805080|NCT01069900|Drug|Moxifloxacin (Avelox, BAY12-8039)|For subjects 12 to less than (<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to < 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to < 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
76093189|NCT02355886|Other|Questionnaire Administration|Ancillary studies
76093190|NCT03254082|Other|Glycemic response of F-1000|The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.
76093191|NCT03254082|Other|Glycemic response to sumac sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.
75805081|NCT01069900|Drug|Ertapenem|For subjects 13 to <18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to < 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
75805082|NCT01069900|Drug|Amoxicillin/Clavulanate|Subjects 2 years to < 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
75945709|NCT02353598|Drug|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
75945710|NCT02353598|Drug|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
75945711|NCT02353598|Drug|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
75945712|NCT02353598|Drug|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
75945713|NCT03392181|Drug|18F-DCFPyL|To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
75945715|NCT02353520|Other|motricity index strength assessment|
76093192|NCT03254082|Other|Glycemic response to MMR sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.
76093193|NCT03254082|Other|Glycemic response to wheat flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.
76093194|NCT03254082|Other|Glycemic response to sucrose|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
75346640|NCT01720082|Procedure|Multiport laparoscopic appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
75346641|NCT01838720|Procedure|zero ischemia laparoscopic RFA assisted TE|
75945716|NCT03617159|Device|Magnetic Resonance Imaging|Diagnostic Modality
75945717|NCT03862989|Procedure|Radiofrequency catheter ablation|A catheter is inserted into the heart and signals are recorded from the heart whilst at rest or whilst being stimulated by a catheter, in order to determine the site to ablate. Radiofrequency is then delivered to the target site in order to disrupt the pathological electrical activation which is causing the abnormal heart rhythm.
75945718|NCT03158324|Drug|OPB-111077|Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
75945719|NCT04871945|Diagnostic Test|Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)|The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.
76025957|NCT05193994|Drug|Placebo|Matching placebo.
76025958|NCT05191784|Drug|GX-I7|Administered by intramuscular (IM) injection
75476962|NCT05229406|Behavioral|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
75476963|NCT05223803|Radiation|Prostate radiation (XRT)|Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.
75476964|NCT05223803|Drug|Systemic Therapy|All systemic therapy is provided as best prescribed for patient per their medical oncologist.
76025959|NCT05191784|Drug|Bevacizumab|Administered by intravenous (IV) injection
76025960|NCT05161715|Drug|Obicetrapib|10mg obicetrapib
75476965|NCT05223803|Radiation|Stereotactic ablative radiation therapy (SABR)|SABR is delivered to those randomized to Arm 2.
75658038|NCT05996172|Behavioral|Lethal Means Safety|The CAMS Therapeutic Assessment incorporates low levels of lethal means restriction (see above). Experimental Intervention Component 4 will provide a high level of lethal means restriction that includes the evaluation of the need for a lock box, the provision of a lock box if needed, structured process for evaluating home safety in each room of the house, specific directives to accomplish, follow up with the clinician, and problem-solving barriers to lethal means safety over two, 30-minute modules delivered across 2 sessions.
75658039|NCT05995067|Other|periodontitis challenge|control will be compared to diseased group suffering from periodontal disease.
75346642|NCT01838720|Procedure|ischemia|conventional laparoscopic partial nephrectomy
75346643|NCT01838798|Other|Baseline activities|Initial consent procedures and baseline data collection.
75476966|NCT05223179|Biological|CODA-VAX H1N1|Intramuscular Live Attenuated Influenza H1N1 Vaccine
75658040|NCT05993689|Other|BUNDLE|An integrated model of community-based doulas and clinical obstetric providers
75658041|NCT05993689|Other|Usual Care|Standard of care for pregnancy and pregnancy-related issues by the obstetric provider
75658042|NCT05993208|Diagnostic Test|optical coherence tomography,multifocal electroretinogram. VA measurment|retinal photography
75658043|NCT05992402|Behavioral|ReBOOT program|This is a virtual cognitive intervention led by a clinical neuropsychologist. Participants will attend 2 one-on-one individual sessions and 4 group sessions prior to their epilepsy surgery. Groups will be made up of 3-10 participants. The intervention is designed to provide participants with information about possible changes and/or challenges they may experience after epilepsy surgery, as well as cognitive strategies to implement prior to surgery to increase effectiveness of compensation for any new cognitive difficulties that may be experienced following surgery.
75805083|NCT01069900|Drug|Moxifloxacin placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
75805084|NCT01069900|Drug|Ertapenem placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
75805085|NCT01069900|Drug|Amoxicillin/Clavulanate placebo|Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
75805086|NCT01069120|Drug|Proellex|2, 25 mg capsules once per day
76025961|NCT05147974|Behavioral|DOZE app|"Complete DOZE app: Delivering Online ZZZ's with Empirical support (DOZE) app plus a Consensus Sleep Diary (CSD).~The DOZE app, is a web-based app optimized for desktop, smartphone, or tablet use. It is a self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected applications that will allow tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log onto the sleep dairy (via automated alerts) once a day over a 10-week period to complete sleep diary entries, develop and track their goals, and receive sleep health education/tailored sleep health interventions.~1-week pre- and post- intervention, participants will complete a battery of baseline study questionnaires and have the option of using a Geneactiv actigraphy device along with a CSD."
76025962|NCT05146024|Behavioral|Way To Serve Plus: Improving Responsible Alcohol Service|Improving responsible alcohol service of owners, managers, and employees of alcohol-serving establishments by developing professional development components to enhance their responsible beverage service skills.
76025963|NCT05145595|Device|Thermal Sensory Analyzer|Thermal stimuli: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
76025964|NCT05145595|Device|Pressure Stimuli|Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
76025965|NCT05145595|Device|Mechanical Stimuli|Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (<1 mm²) and texture.
76093195|NCT04779099|Behavioral|Brief 4-session intervention for borderline personality disorder|Intervention consists of weekly 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support. This intervention is detailed in a published manual.
76093196|NCT04779099|Behavioral|Treatment as usual|TAU comprises access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
76093197|NCT03243162|Behavioral|CBPT-ACLR|The CBPT-ACLR program focuses on improving sports function and return to sport. CBPT-ACLR sessions cover realistic expectations, relaxation strategies, problem-solving training, cognitive restructuring, and behavioral self-management (i.e., graded activity, goal setting, managing setbacks and symptom management plans). Each session builds upon the content of the previous session using an action plan and weekly homework is personally tailored based on patient goals. The program consists of one preoperative telephone session and six postoperative telephone sessions with a physical therapist. Each patient randomized into the CBPT-ACLR program will receive a manual to follow along with the study therapist.
76093198|NCT03243162|Other|Education|The education program focuses on postoperative ACLR recovery. Sessions address benefits of physical therapy, proper biomechanics during sports and other functional activity, importance of early exercise after surgery, and ways to promote healing. Education on stress reduction, sleep hygiene, energy management, communication with health providers, and preventing future injury are also provided. The Education program is matched to the CBPT-ACLR treatment in terms of session frequency, length and contact with the study therapist. Each patient randomized into the Education program will receive a manual to follow along with the study therapist.
76093199|NCT02356198|Drug|EXPAREL|transversus abdominis plane injection
76093200|NCT02356198|Drug|Intrathecal hydromorphone|Intrathecal opioid administration
76093201|NCT04779021|Other|Hospitalisation for SARS-COV2 infection|Patients hospitalized for SARS-COV2 infection
75945720|NCT03611257|Diagnostic Test|dRAST|Infectious diseases specialists will do active antimicrobial stewardship according to dRAST results in addition to Gram staining results and current standard method.
75346644|NCT01838798|Other|Clinical interview with a psychologist|"Clinical interview with a psychologist.~This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:~An inventory of peritraumatic distress symptoms~A questionnaire on peritraumatic dissociative experiences~An assessment of related, potential impacts~The HADS questionnaire"
75658044|NCT05986604|Behavioral|Memory Support Intervention|The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
75805087|NCT01069120|Drug|Proellex|1, 25 mg capsule once per day
75805088|NCT00006237|Biological|interleukin-2|Given IV
75945721|NCT03611257|Diagnostic Test|Current standard method|Infectious diseases specialists will do active antimicrobial stewardship according to Gram staining results, and current standard method without dRAST results.
75945722|NCT03392103|Drug|Raltitrexed|concurrent chemotherapy
75945723|NCT03392103|Radiation|postoperative radiotherapy|concurrent postoperative radiation therapy
75945724|NCT03617081|Drug|NNC0113-2023|Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
75945725|NCT03617081|Drug|Placebo (NNC0113-2023)|Participants will receive NNC0174-0833 matched placebo orally.
76093202|NCT03254004|Drug|Pembrolizumab|pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
76093203|NCT04778865|Dietary Supplement|Vitamin D-correction|Capsule with 50.000 UI cholecalciferol
76093204|NCT04778865|Dietary Supplement|Vitamin D-RDA|Capsule with 4.2000 UI cholecalciferol
75945726|NCT02350010|Device|CT Angiography|"CTA Scan with the specified sequences below:~120 kVp, 360 mAs, 0.5 second/rotation, 0.75 mm thick with a pitch of 0.65. Coronal and sagittal multiplanar reconstructed images with 10.0-mm-thick images spaced by 3 mm.~Axial reformed images were 4 mm thick with 2-mm spacing. 90 mL of nonionic iodinated contrast (OPTIRAY 350) at 5 mL/s."
75346645|NCT01838798|Other|Telephone interview 2 months after ICU discharge|"At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:~Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ~An assessment of psychological trauma~An assessment of potential impacts"
75805089|NCT00006237|Biological|filgrastim|Given subcutaneously
75805090|NCT00006237|Biological|interferon alfa|Given IV and subcutaneously
75805091|NCT00006237|Drug|cisplatin|Given IV
75805092|NCT00006237|Drug|dacarbazine|Given IV
75805093|NCT00006237|Drug|vinblastine|Given IV
75945727|NCT03616925|Biological|Platelet Rich Fibrin Matrix kit|Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine
75945728|NCT03616925|Procedure|surgical open flap debridement|only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit
75945729|NCT02349776|Other|Providing testimonies from survivors of transplants to patients|"Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant."
75945730|NCT03392025|Other|Flaxseed|Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months
76093205|NCT03242850|Behavioral|Intervention Group|This group will view a video on shared reading upon enrollment, receive standard guidance on shared reading, and receive a series of text messages for a period of 6 months.
75658045|NCT05986604|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|TranS-C aims to provide one protocol to treat a range of sleep and circadian problems because sleep and circadian problems are often not so neatly categorized and because the existing research provides few guidelines to treat more complex patients.
75658046|NCT05983991|Other|Biological samples (blood and bone marrow samples).|For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study.
75346646|NCT01838798|Other|Clinical interview with a psychologist|"At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:~assess cognitive functions~evaluate clinical symptoms of depression~assess quality of life~assess symptoms of post traumatic stress"
75346647|NCT03219164|Drug|AZLI|Administered via the PARI Altera® Nebulizer System. Participants < 2 years will receive via the SmartMask® Baby, 2 to < 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
75346648|NCT03219164|Drug|Placebo|Administered via the PARI Altera® Nebulizer System. Participants < 2 years will receive via the SmartMask® Baby, 2 to < 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
75346649|NCT01838954|Device|Short-wave diathermy|Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
75346650|NCT01566461|Device|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
75346651|NCT01566461|Device|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
75658047|NCT05982938|Drug|Danicopan|Participants will receive 150 mg danicopan three times per day (TID) orally as an add-on to a background C5i therapy (SOLIRIS® or ULTOMIRIS®). Participants may be dose-escalated to 200 mg TID based on safety and clinical effect.
75658048|NCT05981755|Other|Breathing tasks|Breathing tasks include normal breathing through nose or mouth, breathing while resting wakefully, increase and decrease in breathing rate, and breath counting.
75805094|NCT03662932|Other|Early intensive mobilization|"Early mobilization: mobilization with the hospital staff begins already on the day of surgery, and includes mobilization in and out of bed, rise up from a chair, standing and walking.~Intensive mobilization: mobilization more than 4 times a day in the first postoperative week."
75805095|NCT04056988|Drug|Perflutren Lipid Microsphere|Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
75805096|NCT04057066|Behavioral|Physical activity counseling|Physical activity counseling consists of two phone or video calls with a therapists, two group video calls with a therapist and a complementary e-learning course.
75945731|NCT03392025|Other|the Mediterranean-like diet|Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months
75945732|NCT03392025|Dietary Supplement|Placebo|Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months
75945733|NCT03610945|Drug|Fluconazole|Subjects will receive fluconazole once daily from Day 5 to Day 18
75945734|NCT03610945|Drug|Quinidine|Subjects will receive quinidine twice daily from Day 5 to Day 12
75945735|NCT03610945|Drug|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 14
75945736|NCT03610945|Drug|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
75945737|NCT03616847|Other|Standard care|Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.
75945738|NCT03616847|Other|Tourniquet release|Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
75346652|NCT01830062|Other|NIRS|Near infrared spectroscopy of at least 2 major epicardial vessels
75346653|NCT01830062|Other|CACS|Coronary artery calcium score assessed by multi-slice computed tomography
75346654|NCT01725698|Drug|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant|
75346655|NCT01720238|Drug|Entecavir|0.5mg qd
76025966|NCT05145595|Behavioral|Pain Ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
76025967|NCT05145595|Behavioral|Thermal pain thresholds|Cold and heat pain thresholds (CPT and HPT, respectively) will be determined [22; 55]. Thresholds are determined by continuous ramping of temperature from 32°C baseline temperature until the participant press a button at the first moment he/she feels pain from the stimulus. Cut-off temperatures are 0°C and 50°C, to minimize potential damage to the skin. The baseline temperature to which the thermode returns before each test is 32°C. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
76025968|NCT05145595|Behavioral|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
75346656|NCT01720238|Drug|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
75805097|NCT04057066|Behavioral|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for pwMS. However, they can be adjusted according to participants prior physical activity level and their available time slots for exercise during the week.
75346657|NCT02981225|Dietary Supplement|Phytostandard® Rhodiola-Saffron|
76025969|NCT05145595|Behavioral|Mechanical temporal summation|A pinprick stimulus with standardised intensity (#6.10 or #6.45 von Frey filament) and a flat contact area of 0.25mm diameter will be used. In this test, participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli. The 10 identical pinprick stimuli are applied with a frequency of 1 s-1 within an area of 1 cm2. Immediately following the single stimulus and series of stimuli, an evaluation of the pain will be collected. The difference in pain ratings evoked with the one stimuli vs. the 10 stimuli is the temporal summation value.
76093206|NCT02025634|Drug|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
76093207|NCT02025634|Drug|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
76093208|NCT03249948|Procedure|Vector change defibrillation|Defibrillation using pad placement in anterior-posterior position.
76093209|NCT03249948|Procedure|Double-sequential defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
76093210|NCT04773951|Biological|JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection|Biological: JS004, Intravenous infusion; Toripalimab Injection, Intravenous infusion
75658049|NCT05981755|Device|Brain mapping with stimulation|Electrical stimulation will be used to find specific areas of the brain involved in breathing function. Stimulation will be applied using a Nihon Kohden MEE-1000A neural function measuring system with the MS-120BK extension unit for brain stimulation.
75945739|NCT02349854|Procedure|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm & 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
75658050|NCT05979610|Other|Reiki therapy|"Reiki therapy is a form of energy healing that originated in Japan. It involves the transfer of energy from the Reiki practitioner to the recipient through the hands, with the goal of promoting physical, emotional, and spiritual well-being. Below is a general outline of the process of Reiki therapy, which may vary slightly depending on the needs of the recipient:~The patient will be in a quiet clinic room lying in the supine position with calming music playing and aromatherapy if the patient chooses.~The Reiki therapist will place their hands on or near the recipient's body. The Reiki therapist may use a series of hand positions that correspond to different energy centers in the body.~During the treatment, the practitioner channels energy into the recipient's body through their hands. The patient may feel a sense of warmth, tingling, or relaxation.~The Reiki therapist may use different techniques, such as hand movements or visualization."
75658051|NCT05975606|Device|repetitive transcranial magnetic stimulation (rTMS)|rTMS will be applied to primary motor cortex of the brain.
75658052|NCT05975606|Device|functional electrical stimulation (FES) cycling|FES will be applied to muscles associated in cycling: quadriceps, hamstrings, tibialis anterior, gastrocnemius, soleus.
75658053|NCT05975008|Behavioral|RECLAIM - Reconnecting to Civilian Life using Activities that Improve Mindfulness|Brief virtual mindfulness-based intervention
75805098|NCT03662854|Biological|Hair Stimulating Complex (HSC)|Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)
75805099|NCT03662854|Other|Phosphate Buffered Saline|Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)
75805100|NCT03662464|Other|No intervention|develop and validate a specific tool to score the risk of escaping in Nursing Homes residents
75945740|NCT02032693|Dietary Supplement|Everycell™|
75945741|NCT02032693|Other|Placebo|
75945742|NCT03391947|Procedure|semilunar coronally positioned flap|The description of this intervention has been already given before
75945743|NCT03391947|Procedure|coronally advanced flap|The description of this intervention has been already given before
75658054|NCT05970640|Drug|BI 3006337|BI 3006337
75658055|NCT05970640|Drug|Placebo matching BI 3006337|Placebo matching BI 3006337
75945744|NCT02349698|Biological|Chimeric Antigen Receptor Modified T cells Targeting CD19|T cells modified with CD19 targeted chimeric antigen receptor.
75945745|NCT03616769|Drug|antiplatelet drugs ,statins ,antihypertensive drugs|According to the international guidelines, we treated patients who suffered from different disease.
75945746|NCT03610867|Drug|Furaprevir capsule (SAD)|There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.
75945747|NCT03610867|Drug|Furaprevir capsule (MAD)|There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
76093211|NCT03253536|Other|observational|none (observational study)
76093212|NCT01972282|Device|WATCHMAN Left Atrial Appendage Closure|
76093213|NCT04773717|Drug|Ascorbic acid|200mg/kg/24h in four equal parts
76093214|NCT04773717|Drug|Placebo|The same regimen as ascorbic acid.
75346658|NCT03836222|Drug|PCS499|MR tablet
75346659|NCT03836222|Drug|Trental|comparator tablet
76093215|NCT04444167|Biological|AK104|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
76093216|NCT04444167|Drug|Lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months
76093217|NCT03243006|Drug|Paracetamol|2 tablets of 500mg of paracetamol
76093218|NCT03243006|Drug|Tramadol/Paracetamol combination|2 tablets of tramadol/paracetamol combination (32.5mg/325mg)
76093219|NCT03243006|Drug|Placebo Oral Tablet|2 tablets of placebo
76093220|NCT04778553|Diagnostic Test|iMOST X-1 Hematology Analyzer|The X-1 is a point of care automated hematology analyzer
76093221|NCT03249402|Drug|Ethinyl Estradiol + Levonorgestrel|Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
75346660|NCT02471586|Procedure|Coronary PCI guided by IVUS|Imaging type
75346661|NCT02471586|Procedure|Coronary PCI guided by OCT|Imaging type
75346662|NCT02471586|Procedure|Coronary PCI guided by Angiography|Imaging type
75476967|NCT05223179|Biological|Flucelvax Quad|Licensed Seasonal Injectable Influenza Vaccine
75476968|NCT05223179|Other|Saline|Saline
76093222|NCT03249402|Drug|JNJ-42847922|Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
76093223|NCT03249480|Biological|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
76093224|NCT04342143|Device|Blood pressure and ultrasound assessment|No intervention. Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will be asked to visit the lab on four separate occasions; the first two sessions will involve triplicated measures of carotid-femoral PWV (cfPWV), brachial-femoral PWV (bfPWV), brachial-ankle PWV (baPWV), femoral-ankle PWV (faPWV) and TT by the Vicorder in both seated and supine position. The SphygmoCor will also be used to assess cfPWV in both seated and supine. During the third and fourth sessions individuals will be randomised into either a supine or seated position. A 3 lead ECG will be attached and ultrasound video clips will be taken at the carotid, brachial, femoral and posterior tibial artery on both the symptomatic and asymptomatic sides to look at stiffness and blood velocity. Following this, the Vicorder will be used to look at cfPWV, bfPWV, baPWV, faPWV and TT on both sides.
76093225|NCT03242460|Drug|Pomalidomide 4 MG|Pomalidomide 4mg Days 1-21
76093226|NCT03242460|Drug|Dexamethasone 20mg|Dexamethasone 20mg Days 1, 8, 15, 22
75805101|NCT03662698|Behavioral|Guided Imagery|GI is a relaxation technique involving the visualization of images and is considered an adjuvant cancer therapy.The GI intervention will include two hour-long meetings between the participant and a trained interventionist. The sessions will include direct, written, and audio delivery of one of three GI vignettes. The patient will be able to choose one of the three vignettes. The approximately twelve minute long vignettes included in the study will be: Taking a Walk, Healthy Cell Alliance for Treatment, and Daily Intention (32). Patients will also be given access to psychosocial support resources (i.e., clinical psychologists and social workers) at UCCC.
75945748|NCT03610867|Drug|Placebo (SAD)|Each subject will receive the sample once by oral administration.
75945749|NCT03610867|Drug|Placebo (MAD)|Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
75945750|NCT05167851|Drug|Lazertinib , a combination group of SBRT|"* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
75945751|NCT05167851|Drug|Lazertinib single administration group|"* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
75476969|NCT05216354|Drug|Fruquintinib|Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions
75658056|NCT05970341|Behavioral|1. Welcome package|"At the end of the baseline data collection visit at the clinic, the Research Staff will hand the participant a welcome packet that includes:~educational and motivational written materials (about such topics as CKD and healthy eating for early CKD stages)~a collection of recipes featuring kidney-friendly vegetables"
75805102|NCT03662698|Other|Treatment as Usual|This will include a tour of the treatment room and education about RT. Patients will also receive educational materials about RT including the process of RT and CT simulation, treatment side effects, pain management, and swallowing exercises. Participants in this condition will also have access to psychosocial support resources (i.e., clinical psychologists and social workers) at UCCC.
75805103|NCT04056754|Drug|Abiraterone Acetate|Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
76093227|NCT03242460|Drug|Cyclophosphamide 400mg|Cyclophosphamide 400mg Days 1, 8, 15
75346663|NCT03835988|Device|Geniculate Artery Embolization|Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
75805104|NCT04056754|Drug|Placebo|Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
75805105|NCT04056754|Drug|Prednisone|Subjects administered 5mg prednisone twice daily in 28-day cycle.
75945752|NCT02236715|Drug|Atrovent®|
75945753|NCT02349620|Biological|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
75945754|NCT02032771|Device|M22 IPL and ResurFX|The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
75945755|NCT03823365|Biological|Blinatumomab Expanded T-cells (BET)|"Two to five days after the last chemotherapy infusion, BET will be administered. An accelerated titration dose escalation design will be used. During dose escalation, up to four dose levels (see table) will be evaluated or until (Maximum Tolerated Dose) MTD is reached.~Dose level BET dose(Counted on CD3+ cells)~(starting dose) 3.0 x 109~6.0 x 109~9.0 x 109~12.0 x 109"
75945756|NCT03616691|Drug|Atezolizumab|Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
75945757|NCT03616691|Drug|Bevacizumab|Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
76093228|NCT01972516|Drug|Tivozanib|
76093229|NCT04773561|Device|Corneal tomography, optical coherence tomography and optical coherence tomography angiography|Ocular investigations were performed in one time during 30-36 weeks of gestational age. Due to avoidance of diurnal variation, all examinations were done between 10 am - 12 pm.
76093230|NCT03253380|Other|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
75346664|NCT01830218|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
75346665|NCT00910208|Device|Patient-controlled analgesia|Intravenous morphine delivered via Curlin painsmart PCA device
75346666|NCT00910208|Drug|morphine|Intravenous morphine
75476970|NCT05215054|Device|Gana V®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
75945758|NCT03158168|Drug|Candida Antigen|Candida Albicans Antigen injection
75658057|NCT05970341|Behavioral|2. Welcome information (phone or text)|"Those allocated to the intervention arm will receive a welcome call from the Program Staff to provide further details and expectations about the program (such as delivery details and schedule).~Those allocated to the control arm will receive an SMS text that informs them of their arm allocation, what to expect and a phone number to call for questions."
76093231|NCT05605743|Behavioral|breathing exercise|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
76093232|NCT03242694|Diagnostic Test|LA pressure, voltage map, strain, scar-map, blood sampling|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
76093233|NCT03242694|Procedure|pulmonary vein isolation|pulmonary vein isolation without creating additional ablation lesions
75346667|NCT01566539|Drug|Intranasal Oxytocin (OT) 24 IU|Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.
75346668|NCT01566539|Drug|Intranasal Vasopressin (AVP)|Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).
75658058|NCT05970341|Behavioral|3. Produce delivery + Recipes customized to produce|"Content: Bags with kidney-friendly produce will include 2 vegetables sufficient for 2 meals for 4 people, 1 type of fruit, and 1 dried fruit. The total cost is estimated at USD 20, excluding delivery, for prices in June 2022.~Delivery: Bags will be delivered to the participant's preferred location (e.g. home or work) and period of the day (e.g., morning, evening).~Recipes: SMS texts will precede each delivery to share an URL to recipes customized to the items being delivered, and to inform of an upcoming produce bag, its content.~Frequency:~Weeks 1-2 (2 weeks): No bags delivered.~Weeks 3-10 (8 weeks): Delivered weekly, for a total of 8 bags.~Weeks 11-18 (8 weeks): Delivered every two weeks, for a total of 4 bags.~Weeks 19-26 (8 weeks): No bags delivered."
76093234|NCT03242616|Drug|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)~Pemetrexed (500 mg/m2, day 1)"
76093235|NCT03242616|Drug|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
76093236|NCT04773327|Other|Mecapegfilgrastim Injection|24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
76093237|NCT01748825|Drug|MK-1775 (AZD1775)|MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
76093238|NCT03242538|Behavioral|Pelvic Exercise|Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
76093239|NCT03249636|Diagnostic Test|Flow cytometric analysis|Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
75346669|NCT01566539|Drug|Intranasal Placebo|Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
75346670|NCT01566539|Drug|Intranasal Vasopressin (AVP) 40 IU|Participants will self-administer a 0.5 ml solution containing 40 international units (IU) of AVP. 5 puffs in total, each with 4 International Units (IU) AVP.
75346671|NCT01566539|Drug|Lorazepam|Subjects will take 1.0 mg of lorazepam orally 60 minutes prior to fMRI scan.
75805106|NCT04056442|Drug|Cannabidiol , synthetic form|Cannabidiol ( synthetic form)
75805107|NCT04056442|Drug|Placebo|Olive Oil Solution, 5%
75805108|NCT03663244|Behavioral|MBSR|Standardised stress reduction programme with established efficacy
75805109|NCT03663244|Behavioral|LSR|Existing stress reduction programme in a Danish municipality
75346672|NCT01725776|Drug|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
75346673|NCT01830296|Drug|Remifentanil+morphine|Morphine, Remifentanil+Morphine
75346674|NCT05564819|Drug|Acetaminophen|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.
75805110|NCT03622762|Drug|green tea extract|Capsules of green tea extract, 400 mg twice a day, fasting
75805111|NCT03622762|Drug|Placebo|Placebo capsules, 400 mg twice daily fasting
75945759|NCT03158168|Drug|Zinc Sulfate|Zinc Sulfate injection
75945760|NCT03157154|Other|Non interventional study|A query form to all concerned patients by each investigating centre will be send
75346675|NCT05564819|Drug|Sterilized water|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The control group was given sterilized water, once every 6 hours, for a total of 4 times.
75945761|NCT04282317|Other|MRI scan|MRI scan
75945762|NCT02865499|Drug|acarbose|acarbose treatment with meals
75945763|NCT04478552|Procedure|Fascia iliaca compartment block|It involves injecting local anaesthetic agent (levobupivacaine) into the fascia iliaca compartment of the patient, infiltrating three major nerves that supply the medial, anterior and lateral thigh, namely the femoral and lateral femoral cutaneous nerves. This procedure can be done with anatomical landmark approach or under image guidance.
75945764|NCT04478552|Procedure|Placebo injection|same volume of normal saline, instead of levobupivacaine, will injected using the same technique.
75476971|NCT05215054|Device|Sculptra®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
75476972|NCT05202873|Diagnostic Test|Gait analysis|Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the 6 'gait test, mobility, dynamic balance, gait ability and risk of falling through the Up and Go test.
75945765|NCT04619953|Other|Dynamic Postural Stability Training|The dynamic postural stability training, will consist of marching on unstable surface and on treadmill both with open and with closed eyes.
75805112|NCT03661606|Other|Simulated Altitude Chamber|"Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.~Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study."
75945766|NCT04619953|Other|Cognitive-Motor Training|The cognitive-motor training consisted of a dual task paradigm: each patient was asked to walk without stopping and was explained that, during the task, they might hear a sound, and in that case, they should have look at the stimulus 'side and recognize a visual target. This dual task was performed both marching on an unstable surface and marching on treadmill.
75805113|NCT02993926|Drug|Enantone|Enantone suspension for injection
75805114|NCT02993926|Drug|GnRH agonist|A non-Enantone GnRH agonist
75945767|NCT04619953|Other|Conventional Therapy|The conventional neuromotor rehabilitation will consist in muscles stretching, active-assisted mobilizations, neuromuscular facilitations, gait training and balance exercises using swinging platforms
75945768|NCT02870933|Biological|Transepicardial with Transseptal CD 133+ Implantation|Transepicardial with Transseptal CD 133+ Implantation
75945769|NCT03156062|Drug|Topical corticosteroids with salicylic acid|comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
75945770|NCT04269603|Device|Take blood (TA-8V (Stago®)|Healthy volunteers will have 3 blood samples at M0, M3 and M6.
75945771|NCT02031887|Dietary Supplement|formula with synbiotics|
75945772|NCT02031887|Dietary Supplement|formula without synbiotics|
75658059|NCT05970341|Behavioral|4. E-gift cards to a grocery store of choice|"Five (5) e-gift cards to a major local grocery retailer chosen by the participant (from 3 options) at the following frequency:~Weeks 1-6: No e-gift card.~Week 7: One card of USD 30.00 value.~Week 11 & 15: One card of USD 40.00, for a total of USD 80.00.~Week 19 & 23: One card of USD 60.00, for a total of USD 120.00."
75658060|NCT05970341|Behavioral|5. Personalized practical & emotional support through a dedicated health partner|"Each participant is assigned a program staff (dedicated health partner) who call them briefly (15 min or so) over the phone for empathy-based support on the participant's health journey, and practical suggestions for shopping and food preparation.~The Health Partner will share periodically via SMS text a curated list of evidence-based, trustworthy online educational resources.~Health partners are not trained to answer medical or health-related questions and will not provide medical guidance or advice of any kind. For such questions, they will encourage participants to contact the clinic or physician.~Frequency:~Weeks 1-2 (2 weeks): No calls.~Weeks 3-7 (4 weeks): 2 calls a week, for a total of 8 calls.~Weeks 8-26 (18 weeks): 1 call every 2 weeks, for a total of 10. But during weeks 7, 11, and 19, participants will be given the choice to keep at 1x/week or decrease to 1x every 4 weeks."
75805115|NCT04056676|Procedure|Thoracic paravertebral block under ultrasound guidance|Ultrasound-guided thoracic paravertebral blocks in T2, T4 level
75805116|NCT04056676|Procedure|Intraoperative modified PEC block|Pectoral nerve block by surgeon under direct vision after total mastectomy
75805117|NCT04056676|Procedure|GA with ETT|General anesthesia with endotracheal intubation
76093240|NCT03253224|Drug|Magnesium Sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.
76093241|NCT03253224|Drug|Normal saline|Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
76093242|NCT02028208|Diagnostic Test|Ammoniated mercury|Metal allergen panel containing ascending doses of ammoniated mercury and a negative control.
75476973|NCT05194592|Drug|Dapagliflozin|The patients assigned to the Dapagliflozin group will take Farxiga Pill 10mg for 6 months.
75476974|NCT05194592|Drug|Gemigliptin|The patients assigned to the Gemigliptin group will take Zemiglo Pill 50mg for 6 months.
75805118|NCT04056598|Diagnostic Test|Study of humoral immunity|Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria
75805119|NCT04055506|Drug|BMS-986165|Dose 1
75805120|NCT04055506|Drug|Ritonavir|100 mg
75945773|NCT05167617|Drug|Vit D|Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
75945774|NCT05239377|Other|IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator|Digital decision support
75945775|NCT03146624|Other|attachment retained obturator|obturator which retained by attachment
75945776|NCT03146624|Other|clasp retained obturator|obturator which retained by clasp
75945777|NCT03616613|Diagnostic Test|ABDOMINAL DUPLEX ULTRASONOGRAPHY|Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area
75945778|NCT02033161|Behavioral|Internet-delivered CBT|"The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.~Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.~The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment."
76093243|NCT02028208|Diagnostic Test|Aluminum chloride and aluminum lactate|Metal allergen panel containing ascending doses of alumium chloride, aluminum lactate and a negative control.
76093244|NCT02028208|Diagnostic Test|Sodium tetrachloropalladate|Metal allergen panel containing ascending doses of sodium tetrachloropalladate and a negative control.
75945779|NCT02349464|Other|Specialized Preterm Infant/Mother Dyad Lactation Support|Mother will receive home equipment and pediatric clinic lactation support.
75945780|NCT05239065|Behavioral|The basic intervention|The participants will receive a paper-printed booklet introducing stress and stress management strategies, regular exercise, deep breathing and mediation, etc, as well as a HUAWEI portable device at the recruitment. During the following 3-month intervention phase, there is not informational materials, portable device data feedback, online group discussion or interpersonal communications with the participants. The participants will only need to fill in a simplified questionnaire biweekly.
75945781|NCT05239065|Behavioral|The personalized interventions|The participants will receive a paper-printed booklet introducing stress and stress management strategies and a HUAWEI portable device at the recruitment. A neurologist will be the health educator to host an online group for free communications. The typical stress-relieving methods and the strategies of using portable device will be explained by providing small videos, online article links and nursing coaching in person. The health educator will give regular knowledge educations about the stress hazards, stress management necessities and skills on weekly basis. The weekly data of HUAWEI portable devices will be sent to the participants along with personalized suggestions by trained nurses. At certain occasions, gifts and rewards will be sent out for encouragement and keeping attachment to the program. The participants will be required to fill in the weekly questionnaires online for feedback.
75945782|NCT03616457|Device|Automated Breast Ultrasound (ABUS)|Participants will undergo imaging with ABUS.
75945783|NCT02349308|Device|CentrosFLO Long Term Hemodialysis Catheter|
75945784|NCT03404739|Drug|Saline Solution|These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.
75945785|NCT03404739|Drug|Ceftazidime|These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
75945786|NCT03155516|Other|Good pain management (GPM) procedure|"In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required."
75945787|NCT03155516|Other|Current practice procedure|Current practice clinical procedure for pain management
75945788|NCT02031965|Biological|oncolytic HSV-1716|Given IT
75945789|NCT02031965|Drug|dexamethasone|Given IV
75476975|NCT05190562|Drug|Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet|Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
75658061|NCT05969730|Drug|Baricitinib 4 MG|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, baricitinib 4-mg daily plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm A). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
75658062|NCT05969730|Drug|Azathioprine 1.5-2.5 mg/kg|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, azathioprine 1.5-2.5 mg/kg plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm B). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
75658063|NCT05967390|Device|Transcranial Magnetic Stimulation|One time for each day, lasting for three weeks.
75658064|NCT05954936|Other|Risk factor|No therapeutic or diagnostic intervention will be provided; it is an observational study.
75805121|NCT02993224|Drug|Deferasirox dispersable tablet (DT)|"Deferasirox DT was provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The strengths provided in an individual country could differ and reflected the strengths available commercially in each country.~For iron chelation naive participants, the starting dose on Baseline Day 1 was 20 mg/kg/day in TDT and 10 mg/kg/day in NTDT.~For iron chelation (deferoxamine and/or deferiprone) pre-treated participants, the starting dose was equivalent to the dose of deferoxamine received (for participants pre-treated with deferoxamine) and based on their serum ferritin levels (for participants pre-treated with deferiprone).~Participants took deferasirox DT once daily for 24 weeks (core phase). The required number of deferasirox DT tablets were to be dispersed with gentle stirring in a glass of water."
75805122|NCT02993224|Drug|Deferasirox film coated tablet (FCT)|"Deferasirox FCT was provided as 90 mg, 180 mg, 360 mg film coated tablets for oral use. The FCT starting dose on Week 25 was 14 mg/kg/day in TDT and 7 mg/kg/day in NTDT.~Participants took deferasirox FCT once daily for 24 weeks during the core phase and up to 48 weeks during the extension phase. For patients with difficulties in swallowing deferasirox FCT, it was allowed to crush the film-coated tablets and administer the study drug by sprinkling the full dose on soft food (like yogurt or apple puree)."
75805123|NCT03203200|Behavioral|ZETRA cognitive behavioral structural|ZETRA cognitive behavioral structural
75805124|NCT03191812|Other|transcranial Direct Current Stimulation (tDCS)|There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
76093245|NCT03249324|Behavioral|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
75945790|NCT02031965|Procedure|therapeutic conventional surgery|Undergo surgical resection
75945791|NCT02031965|Other|laboratory biomarker analysis|Correlative studies
75945792|NCT03395067|Behavioral|Intervention group|Lifestyle counseling coupled with psychotherapeutical intervention
75945793|NCT02347280|Procedure|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
75658065|NCT05953584|Drug|Etavopivat|Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
75945794|NCT02347280|Procedure|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
75945795|NCT03404271|Dietary Supplement|Beta-hydroxy beta-methylbutyrate|3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).
76093246|NCT03249324|Other|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
75658066|NCT05953584|Drug|Hydroxyurea|Participants will receive a stable dose of HU.
75658067|NCT05953532|Other|A1Control|diabetes self-management and diabetes technology education software
75658068|NCT05950802|Drug|Cyclophosphamide|Higher dose than traditional conditioning chemo
75658069|NCT05950802|Radiation|TLI|radiation given with conditioning chemo
75658070|NCT05948839|Device|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
75658071|NCT05948839|Device|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
75805125|NCT03715088|Behavioral|Resistance Training Intervention|Participants will perform 10 different resistance exercises consisting of three sets of 8-10 repetitions, at 80% of 1-RM, separated by 60-second rest intervals between sets. This exercise protocol was chosen based on literature that suggests that the protocol and intensity do not enhance mitochondria biogenesis. Also, it was well tolerated by obese and older individuals.
75805126|NCT03715010|Dietary Supplement|BCAA|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa
75805127|NCT03714932|Diagnostic Test|3shape ortho analyzer software|Arch analysis , manual analysis , digital analysis , Mixed dentition , Tanaka and Johnston
75805128|NCT05664620|Diagnostic Test|Risk Stratification Tool|Patients will be allocated to three groups (Low,medium and high risk) by using the Risk Stratification Tool, and High risk patients will receive multidisciplinary treatment assigned to them by a physician
75805129|NCT03714698|Other|Pilates exercise group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
75945796|NCT03404271|Other|Resistance Training|Performing supervised resistance training three times per week.
75945797|NCT03404271|Dietary Supplement|Protein Supplementation|Consuming a protein supplement daily.
75945798|NCT03404271|Behavioral|Time-Restricted Feeding|Consuming all calories within a specified 8-hour period of time each day.
75945799|NCT03615209|Device|Transauricular vagus nerve stimulation|Stimulation will be performed for 150 minutes (throughout the entire OGTT).
75945800|NCT03615209|Device|Transauricular sham stimulation|Sham stimulation will be performed for 150 minutes (throughout the entire OGTT)
75945801|NCT03149120|Biological|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
75658072|NCT05948826|Drug|TORL-3-600|antibody drug conjugate
75805130|NCT03714698|Other|Control Group|The control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
75805131|NCT03495908|Device|VGo|Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
75805132|NCT03714542|Other|Pre- and postoperative MRI|
75805134|NCT03714464|Other|Whole apples|350 of whole apples containing 49g of available carbohydrate with 173ml water
75945802|NCT03149120|Drug|Pazopanib|Pazopanib given at a dose of 800 mg by mouth daily.
75945803|NCT04849325|Device|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with IBS Titan™.
75945804|NCT04849325|Device|Percutaneous Transluminal Angioplasty (PTA) Device|Subjects in this arm will be treated with PTA device.
75945805|NCT03403023|Device|Tear Film Imager|The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).
76093247|NCT03253458|Device|Confocal Laser Endomicroscopy|Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
76093248|NCT02356900|Procedure|Hyperoxic hyperbaric interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
76093249|NCT02356900|Procedure|Normoxic, normobaric, interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week.
76093250|NCT02356900|Drug|Oxygen|Used in Hyperoxic hyperbaric interval exercise training intervention
75658077|NCT05946304|Behavioral|moderate-intensity continuous exercise training (MICT) group|Exercise session: Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 70-85% peak HR - 35min; Cool-down: 60-70% peak HR - 15min.
75945806|NCT03403023|Drug|Restasis|Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
75945807|NCT03155594|Device|Freestyle Libre|Continuous glucose monitoring patch
75945808|NCT02864407|Drug|Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)|The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
75805135|NCT03714464|Other|Apple puree|384g of apple puree containing 44g of available carbohydrates with 224 ml water
75805136|NCT03714464|Other|Apple Juice|338g apple juice containing 46g of available carbohydrate with 260 ml water
75945809|NCT03391791|Genetic|Genetically engineered T Cell Receptors|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
76093251|NCT00789399|Drug|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
75658078|NCT05946304|Behavioral|high-intensity interval training (HIIT) group|Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals); Cool-down: 60-70% peak HR - 10min.
76093252|NCT00789399|Other|Placebo|subcutaneous equivolume isotonic saline
75476976|NCT05189366|Behavioral|Sophrology|"Sophrology is a relaxation method that's sometimes referred to as hypnosis, psychotherapy, or a complementary therapy.~Sophrology uses techniques such as: hypnosis, visualization, meditation, mindfulness, breathing exercises, gentle movements, body awareness...~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Patients will receive 6 sessions of sophrology"
75476977|NCT05189366|Behavioral|Speech therapy|Speech therapy is a treatment that can help improve communication skills. patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
75805137|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
75658079|NCT05930951|Drug|OBT076|OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity
75805138|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
75805139|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
75805140|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
75945810|NCT03149198|Other|Mat Pilates exercises|The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
75945811|NCT03149198|Other|Aquatic aerobic exercises|"The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator."
75945812|NCT03616301|Drug|Clavamox|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus
75945813|NCT03616301|Drug|Augmentin®|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia
75945814|NCT03149276|Other|Interpreter services|
75805141|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
75805142|NCT02992288|Drug|Placebo|Orally once daily for 20 weeks
75805143|NCT03714386|Device|A synthetic high-flux dialyzer will be used for OL-HDF.|A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
76093253|NCT01720667|Drug|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
76093254|NCT01720667|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
76093255|NCT03253146|Diagnostic Test|VIM detection|VIM expression in serum and lymphocytes detection
76093256|NCT00765531|Radiation|Radiological testing|Bone mineral density
76093257|NCT00765531|Genetic|Pediatric Urologic DNA and History Repository|"All Stone Forming Patients and their families will undergo one of two groups of testing:~Testing 1 - Involves completing an in-patient evaluation at University of Texas Southwestern for patients with hypercalciuria and their families.~Testing 2 - Involves completing a simple out-patient evaluation for patients with or without hypercalciuria and their family members."
75658080|NCT05930951|Drug|Balstilimab|Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
75805144|NCT03714386|Device|A medium cut-off dialyzer will be used for HDx.|A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
75945815|NCT03391713|Behavioral|Poster|The poster includes the FAST symptoms but translated to the Malay language (Ce.P.A.T) Cakap tak jelas (slurred speech - Speech slurring) Perubahan muka (face changes - Face drooping) Anggota lemah (weak limbs - Arm weakness) Terus ke Hospital (straight to the hospital - Time to call 911
75945816|NCT03394989|Drug|Fluticasone propionate/salmeterol 100/50 µg|Test Arm: Dry powder inhaler
75945817|NCT03394989|Other|Placebo|Placebo
75945818|NCT03394989|Drug|Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT|Comparator Arm: Dry powder inhaler
75945819|NCT02033239|Drug|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
75658081|NCT05928689|Drug|Propranolol Hydrochloride tablet|Single dose of 40 mg propranolol tablet
76093258|NCT03253770|Device|SIMMAX2|Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
76093259|NCT04773093|Drug|Continous Intravenous Lidocaine Infusion|Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery
75476978|NCT05188729|Drug|LTX-315 Part 1|LTX-315 once-daily dosing; starting total daily dose of 2 mg for the first subject. Ascending once-daily 1 mg dosing increments (eg, 2 mg on Day 1, 3 mg on Day 2). Subjects may be treated for a maximum of 2 weeks and a maximum total daily dose of 8 mg in Part 1. The starting dose will be escalated between subject cohorts in 1-mg increments after the previous cohort has completed Week 1 dosing (the DLT observation period).
75658082|NCT05928689|Behavioral|Reminder|Reactivation of misophonia trigger memory
75658083|NCT05928689|Behavioral|Counterconditioning|Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.
75805145|NCT03717818|Behavioral|Good Psychiatric Management - Brief|specific interventions as defined by Gunderson and Links (2014)
75805146|NCT03717818|Behavioral|treatment as usual|non-specific intervention
76093260|NCT04773093|Drug|Placebo|Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
75658084|NCT05928689|Drug|Placebo|Matching placebo tablet
75658085|NCT05924698|Other|Electrostimulation|Consisting of the use of NMES (biphasic symmetrical pulse, bipolar mode, 50Hz frequency, pulse duration 300 μs at 1:1 ratio) (S82®; Enraf-Nonius BV, Rotterdam, The Netherlands). The self-adhesive electrodes (8x5 cm2 Pals Platinum © type, Axelgaard Manufacturing Co. Ltd, Fallbrook, CA, USA) were placed on the quadriceps muscle. The positives electrodes placed distally on the rectus anterior and vastus externus and negative electrodes were placed proximally on the rectus anterior and vastus internus. The over current program consisted of 8 seconds (s) of work (ON phase) and 8 seconds of rest (OFF phase). The overcurrent program in the ON phase had a rise time of 2 s, a hold time of 4 s and a fall time of 2 s. The intensity of the electric current was increased to the maximum perceived tolerance, achieving a clear contraction without producing fatigue.
75805147|NCT02992132|Drug|Pimavanserin 34 mg|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
75805148|NCT02992132|Drug|Pimavanserin 20 mg|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
75805149|NCT02992132|Other|Placebo|Placebo, taken as two tablets, once daily by mouth
75805150|NCT03660748|Biological|MET-2|Ingestion of a novel human microbiome preparation
76093261|NCT01720043|Drug|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
76093262|NCT00700752|Device|senofilcon A|silicone hydrogel contact lens
76093263|NCT00700752|Device|balafilcon A|silicone hydrogel contact lens
76093264|NCT02455362|Drug|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
75805151|NCT03444584|Drug|MEDI0382|Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).
75805152|NCT03444584|Drug|Placebo|Subcutaneous dose of placebo matched to MEDI0382.
75805153|NCT03444584|Drug|Dapaglifozin|Oral dose of dapaglifozin 10 mg tablet.
75805154|NCT03444584|Drug|Metformin|Oral dose of metformin tablet (maximum tolerated dose [MTD] > 1 g).
75805155|NCT02989168|Drug|GBT440|GBT440: Capsules which contain GBT440 drug substance in Swedish orange
75805156|NCT02988622|Device|Fraxel Laser|One half of the scar is treated with Fraxel Laser
75805157|NCT02988622|Device|CO2 Laser|One half of the scar is treated with CO2 Laser.
75805158|NCT03717740|Drug|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
75945820|NCT02033239|Drug|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
75945821|NCT02353364|Other|PGS|Embryos screened by the validated NGS technology CNV-Seq
75945822|NCT05167149|Procedure|Carbon nanoparticles|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to National Comprehensive Cancer Network (NCCN) guidelines, 1ml diluted ICG solution (25 mg /10 ml) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (2ml totally) with 1ml syringe. ICG should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection under the multimodel observation of fluorescence laparoscopy. Search the fluorescent labeled lymphatics from bilateral parametrium to iliac vessels. The diffusion of ICG is rapid , and it is easy to spread to the next stations lymph nodes. The first fluorescent labeled lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all fluorescent lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
76093265|NCT02455362|Drug|Placebo|
75945823|NCT05167149|Procedure|Indocyanine green|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to NCCN guidelines, 0.5ml(25mg) carbon nanoparticle solution (the dose was from our retrospective study) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (1ml totally) with 1ml syringe. Carbon nanoparticle should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection. Search the black lymphatics from bilateral parametrium to iliac vessels. Because there is no fluorescence penetration as ICG, the black lymphatic vessels should be dissected carefully.The first black lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all black lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
76093266|NCT03246789|Behavioral|Engage-M|Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
76093267|NCT03246789|Behavioral|Wellness in Mind and Body|An active intervention focusing on psychoeducation and de-stigmatization of health and mental health conditions. These sessions are commonly part of senior centers programs. W-MH will offer mental health referral to a clinic or primary care physician as part of senior center procedures for clients with positive PHQ-9s.
76093268|NCT01747811|Device|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
75805159|NCT03717740|Drug|Placebo|Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
75346676|NCT01725854|Behavioral|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
75476979|NCT05188729|Drug|VP-315 Part 2|VP-315 once-daily dosing; Part 2 will be initiated upon completion of Part 1 to determine the optimal dosing regimen of VP-315. There were no DLTs observed in Part 1 of the study and the maximum dose of 8 mg was achieved. Therefore, the dose to be evaluated in Part 2 will be a total daily dose of 8 mg in 4 Cohorts.
75658086|NCT05924698|Other|Blood flow restriction therapy|To attain partial vascular occlusion, a PTS ii portable tourniquet system (Delphi Medical, Vancouver, BC, Canada) with a corresponding size-specific tourniquet was placed around the patient's proximal thigh. This system allows for precise control of cuff pressure throughout training despite the changes in muscle volume that naturally occur while performing exercises. Total limb occlusion pressure (LOP) was identified by determining the pressure required to eliminate a detectable pulse using Doppler ultrasound. Partial vascular occlusion was achieved by setting the tourniquet to 80% of the LOP. This ensured that venous occlusion was obtained while still allowing arterial inflow and was personalized to each patient despite variations in thigh girth, cuff size, and systolic blood pressure. An Easy-Fit Tourniquet Cuff (Delfi Medical, Vancouver, VC, Canada) was used with the PTS ii system.
75658087|NCT05916534|Behavioral|WeCAB Intervention|The WeCAB intervention will use a dedicated WeCAB community health worker who will administer a social determinants of health (SDOH) tool and use digital care navigation to monitor closed loop referrals.
75658088|NCT05904912|Drug|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
75658089|NCT05904912|Drug|PENG-Bupivacaine|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
75805160|NCT03720548|Drug|LY3372993|Administered IV.
75805161|NCT03720548|Drug|Placebo|Administered IV.
75805162|NCT04055584|Diagnostic Test|Sputum|DNA extraction and perform a diversity of molecular diagnostic tests
75805163|NCT03714152|Drug|ABI-H2158|5 mg or 25 mg tablets
75805164|NCT03714152|Drug|Placebo for ABI-H2158|Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
75805165|NCT03622684|Behavioral|Muscle relaxation according to Jacobson|
75476980|NCT05184101|Drug|Unfractionated Heparin|Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
75805166|NCT03412604|Device|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
75805167|NCT02991430|Device|active neuromodulation for episodic migraine headache|Non-invasive brainstem neuromodulator. Active and placebo devices appear identical
75805168|NCT02991430|Device|placebo neuromodulation for episodic migraine headache|Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
75805169|NCT03411902|Drug|Risedronate Sodium 150 MG|Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
75805170|NCT03411902|Other|Placebo|Participants randomized to the placebo group will receive 150 mg placebo capsule once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
76093269|NCT01747811|Device|wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
76093270|NCT03242304|Other|Behavioral tests|We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
76093271|NCT03242226|Device|two spectacles|single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
75658090|NCT05904912|Drug|Local infiltration-Bupivacaine|Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
76093272|NCT03242226|Device|single vision spectacles|Wear single vision spectacle only
76093273|NCT03249246|Other|No intervention|
75805171|NCT03714074|Device|PEEK implant abutment|Implants will be restored with abutments made from polyetheretherketone (PEEK) abutments and a PEEK superstructure
76093274|NCT03253068|Drug|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
76093275|NCT03241836|Diagnostic Test|trans-perineal ultrasonography|accuracy of trans perineal ultrasonography in identification of female pelvic floor dysfunction
76093276|NCT03252912|Biological|blood samples|Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
76093277|NCT03253614|Diagnostic Test|Audiometry|Extended high-frequency (EHF; 9-16 kHz) audiometry
76093278|NCT03253614|Diagnostic Test|Urine biomarkers for renal tubular function|Kidney Injury Molecule-1
76093279|NCT03253614|Diagnostic Test|Blood pressure|Blood pressure right arm, measured With standard Methods 3 times
75805172|NCT03714074|Device|Zirconia abutment|Imolants will be restored with zirconia abutments and a PEEK superstructure
75805173|NCT03717662|Drug|nicotine gum or nicotine patch|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
76093280|NCT03248934|Other|Patient Self-Administered Diagnostic Exam|Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.
76093281|NCT03248934|Other|Clinician-Performed Diagnostic Exam|A clinician-performed diagnostic exam will be completed on the patients.
76093282|NCT05605041|Device|Headspace|Headspace is an app that allows users to practice mindfulness through guided meditation
76093283|NCT02454816|Device|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
76093284|NCT02454816|Device|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
76093285|NCT03104049|Device|Neuromuscular taping|"NMT applications:~rhomboid major muscle~muscles abdominals~spinal muscles~pectoralis major muscles~gastrocnemius muscle~upper trapezius muscle~anterior muscles of the neck"
76093286|NCT03241992|Behavioral|MyChart Disease Specific|Subjects receive targeted IBD information and reminders as well as mood questionnaires.
76093287|NCT03239262|Procedure|Concomitant Mapping and Radiofrequency Ablation|"Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.~GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared."
75658091|NCT05903950|Device|Air cleaners with HEPA filter|PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
75945824|NCT03615131|Diagnostic Test|MRI-TRUS fusion prostate biopsy|First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
75945825|NCT02486302|Drug|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
75658092|NCT05903950|Device|Air cleaners without HEPA filter|Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
75945826|NCT02353286|Device|Endoscopic insertion of biodegradable biliary stent|Endoscopic insertion of biodegradable biliary stent
76093288|NCT03239262|Procedure|No intervention|No intervention was performed in patients without ganglionated plexi.
75658093|NCT05903131|Behavioral|Telemedicine behavioral weight intervention|Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (13 months total). Each telephone session will be 30 minutes long.
75658094|NCT05903131|Drug|Progestin|Released via the levonorgestrel-releasing IUD.
75658095|NCT05903131|Behavioral|Enhanced usual care|1-3 page handouts
75945827|NCT03394911|Biological|250mg healthy adult male facial skin surface lipid liquid pheromone|Human Pheromone provided p.o. to tox-screen verified opioid drug addict
75945828|NCT02033629|Drug|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
75945829|NCT02033629|Drug|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
75945830|NCT02033629|Drug|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
75945831|NCT03148886|Other|PA intervention|"The program is individualized according to age, fitness level, place of residence, access to adapted specific training group or associations, PA preferences and wishes of each participant. Patients are informed of the recommendations in terms of PA, and the target of 150min per week in order to maintain health benefits. Patients are asked to walk at least 30 minutes per day and increase their activities into daily routine. Several individual strategies are established with the patients to attain their objectives and increase their daily life PA.~Withings® PA trackers have been used to provide an incentive effect to increase PA, to measure the number of steps per day and make people think about their PA. Patients wore a Withings Go® wristband PA tracker throughout the whole study and had in real time a feedback on their number of steps per day.~A 7 mL blood sample is collected at baseline (D1) and at the end of the 6-month study (M6) for the biological study."
75945832|NCT05166759|Device|Doppler ultrasound|Pulmonary artery pressure and right heart function will be assessed using Doppler ultrasound
75658096|NCT05903131|Drug|Levonorgestrel-releasing IUD.|Standard of care
75658097|NCT05901896|Other|there are no intervention|no intervention
75658098|NCT05889494|Other|Autologous Whole Blood Management|Intraoperative high volume autologous whole blood withdrawal with re-transfusion following weaning from CPB.
75805174|NCT03494816|Drug|Axitinib Oral Tablet|"Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
75805175|NCT03713996|Behavioral|Cognitive behavioral therapy for insomnia|CBT-I is designed to change sleep habits as well as direct misconceptions about sleep and insomnia. Participants will receive several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components. The intervention will be provided in 6-session (one session/week).
75805176|NCT03713996|Other|Health Education|Participants in this arm will receive education in sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity. The education will be provided in 6-session (1 session/week).
75805177|NCT03492554|Other|1-Lead ECG|All participants will record three single-lead ECGs
76093289|NCT01718483|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
76093290|NCT01718483|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
75658099|NCT05889494|Other|Standard Care involving allogenic and/or derivative transfusion.|Therapeutic treatment of CPB-induced coagulopathy using donated allogenic blood products including plasma, platelets, and cryoprecipitate and/or derivative administration using prothrombin complex and fibrinogen concentrates.
75658100|NCT05886478|Drug|No intervention|As this is an observational study, no intervention will be administered.
75658101|NCT05882604|Drug|Mesna Injection|1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.
75658102|NCT05882604|Drug|Arthrocentesis with ringer solution|Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid
75658103|NCT05882565|Behavioral|A brief (14-day) online mindfulness intervention|The content of the online mindfulness intervention is based on studies by Cavanagh et al. (2013, 2018). There is an approximately 10-minute audio tutorial that participants will listen to daily for 14 days. In the first week, participants will be instructed to apply their learned mindfulness skills to their daily activities. In the second week, they will continue practicing by learning to walk in a mindful manner.
75658104|NCT05882565|Behavioral|Psychoeducation online|"The online psychoeducation was modified from the study by Harrer et al (2019, 2021).~This intervention consists of 14 audio tutorials about stress for 14 days, each lasting approximately 10 minutes. Additionally, there is a text version of each audio tutorial, which can be accessed by participants after listening to the audio."
75658105|NCT05880524|Drug|Dornase Alfa|Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.
75658106|NCT05880524|Drug|Isotonic Saline Solution|Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
75945833|NCT03610243|Behavioral|Self-administered acupressure|Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
75945834|NCT02033473|Drug|Apelin|An apelin clamp in which an apelin infusion will be administered
75945835|NCT02033473|Drug|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered
76093291|NCT03241758|Diagnostic Test|Doppler ultrasound|Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
76093292|NCT03241446|Drug|Tilmanocept|Intravenously administered Technetium Tc 99m tilmanocept
76093293|NCT00736749|Procedure|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
75658107|NCT05878067|Drug|ABBV-444|Eye drops
75658108|NCT05877404|Other|Surveys|Survey on practice patterns surrounding tumor genetic testing in endometrial cancer.
75805178|NCT03492554|Device|12-Lead ECG|All participants will simultaneously record three 12-lead ECGs
75945836|NCT03615989|Behavioral|Resistance and Plyometric Exercise|A single resistance and plyometric exercise bout per trial.
76093294|NCT00736749|Other|Questionnaire Administration|Complete patient response form and Health Status Update Form
76093295|NCT04487418|Procedure|Electro cautery surgery|"Pre-anesthetics with therapeutic topic (benzocaine) will be administered and, as an anesthetic, or use of anesthetic drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline).~The surgery will be carried out with cauterization for incision of the lingual brake, division of the brake fibers and release, removing the brake fibers that are stored in the anterior ventral free parts of the tongue until reaching the base of the tongue, which are removed or cleaned, lingual movement, and the anterior axis of the tongue is repositioned or lingual brake in that region. No sutures will be performed and should be oriented on the formation of a pseudo-membranous repair plate in the second intention that will be formed between the first and the third day after surgery.~Postoperative care:~Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
76093296|NCT04487418|Procedure|High power diode laser surgery|"Pre-anesthetics with therapeutic topic (benzocaine) and as anesthetic or use of anesthetic eye drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline) will be administered. The surgery will be performed with a high power diode laser (TW Surgical, MMOptics - São Carlos - Brazil). 808 nm wavelength, which can be operated in continuous or interrupted mode. Wattages from 1 to 1.5 W, up to a maximum of 2 W, can be used and must carefully respect the histological characteristics of the target tissue and the signs of overheating and carbonization, so that the choice of parameters is dynamic and very dependent on experience, mastery and care for the operator.~Preoperative care: Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
76093297|NCT02454582|Device|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
76093298|NCT01717859|Drug|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 > 3.2, dosage will be escalated to 8 mg/kg.
76093299|NCT03239184|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
75658109|NCT05874843|Diagnostic Test|Thromboelastography (TEG 6S)|The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.
75658110|NCT05868161|Device|Pounce Thrombectomy System|Non-surgical removal of thrombi and emboli from the peripheral arterial vasculature with the Pounce Thrombectomy System.
75805179|NCT03713918|Other|Reinforced lithium silicate endocrowns|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with reinforced lithium silicate and cemented with self adhesive cement
75805180|NCT03713918|Other|Post retained reinforced lith silicate crn|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and reinforced lithium silicate crown will be cemented with self adhesive cement.
76093300|NCT03239184|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
75805181|NCT03713840|Behavioral|Healthy Beverages in Child Care|12-week intervention promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
76093301|NCT03249168|Drug|Duloxetine 60mg|tablet
76093302|NCT03249168|Drug|Placebo|Tablet
75805182|NCT03410420|Drug|Pimonidazole hydrochloride|administration of pimonidazole-HCl
76093303|NCT03248856|Drug|Triamcinolone Acetonide|Intratympanic administration
75805183|NCT03713762|Drug|peribulbar block 1 lidocaine/bupivacaine|Peribulbar block: 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml.
76093304|NCT03241524|Other|Exercise program for pelvic muscle floor|Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
75805184|NCT03713762|Drug|peribulbar block 2 lidocaine/bupivacaine/fentanyl|Peribulbar block: 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
76093305|NCT03241602|Drug|Intraperitoneal lidocaine|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure.
75346677|NCT03409952|Device|LaseMD and DUAL 1927nm Laser|Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
75658111|NCT05867433|Behavioral|STHS Intervention|"STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors."
75805185|NCT03713606|Procedure|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
75945837|NCT03615989|Dietary Supplement|Carbohydrate (Maltodextrin powder mixed with water)|50 grams immediately after exercise bout. 50 grams 1 hour after exercise bout.
75346678|NCT03409952|Device|LaseMD|Laser treatment of benign pigmented lesion using optimized treatment settings.
75945838|NCT03615989|Dietary Supplement|Skim Milk|500 ml immediately after exercise bout. 500 ml 1 hour after exercise bout.
75346679|NCT01567943|Behavioral|Contingency Management|Behavioral reinforcement for alcohol abstinence
75945839|NCT03391557|Diagnostic Test|UE|All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
75945840|NCT03148808|Combination Product|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
75945841|NCT02034097|Drug|Foretinib|Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
75945842|NCT02034097|Drug|Erlotinib|Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
75945843|NCT03614897|Behavioral|Education|Education on guidelines for care of individuals at risk of falling
75945844|NCT05238051|Other|Gastric residual volume measurement stopped.|GRV is checked during routine enteral nutrition, but we think that GRV prolongs the time to reach target calories and does not reduce complications.
75805186|NCT05975437|Other|personalized surveillance plans (PSP) and personalized aftercare plans (PAP)|The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the 'Breast Cancer Surveillance Decision Aid' including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision-making is supported by a patient decision aid.
75945845|NCT03148730|Device|closed-loop group|Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
75945846|NCT03610477|Dietary Supplement|Medium chain triglycerides|Gel capsules, each containing 1 gram
75945847|NCT03610477|Dietary Supplement|Long chain triglycerides|Gel capsules, each containing 1 gram
75945848|NCT03615833|Drug|Cholecalciferol|Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
75945849|NCT03391401|Procedure|Bariatric surgery|Any bariatric operation that is considered as a standard procedure in bariatric surgery (i.e. sleeve gastrectomy, roux-en-y gastric bypass, mini-gastric / one anastomosis gastric bypass, redo and revisional bariatric surgery).
75945850|NCT02347436|Procedure|24-hr ambulatory blood pressure measurement|
75945851|NCT03615755|Other|Hyperbaric Oxygen Therapy (HBOT)|The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
75945852|NCT02747875|Drug|Methadone|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
75945853|NCT02747875|Drug|Fentanyl|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
75945854|NCT03394833|Other|gelofusine|Preoperative colloid fluid bolus 6ml/kg ideal body weight
76093306|NCT03241602|Procedure|Pulmonary Recruitment|pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
75805187|NCT05975424|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
75805188|NCT05975411|Other|Anesthesia Consultation with telemedicine|Anesthesia Consultation with telemedicine
75805189|NCT05975398|Procedure|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
75945855|NCT02347358|Device|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
75945856|NCT02347358|Drug|IV r-tPA|intravenous recombinant human tissue plasminogen activator
75945857|NCT03391323|Device|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
75945858|NCT03391323|Device|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
76093307|NCT03241602|Combination Product|Combined intraperitoneal lidocaine and pulmonary recruitment maneuver|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure before the recovery of the patient pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
75346680|NCT04378322|Behavioral|Nutrition and food purchasing tool + telenutrition|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks) and schedule appointments with a registered dietitian.
75805190|NCT05975398|Procedure|Conservative treatment|Standard treatment for intracerebral hemorrhage
75346681|NCT04378322|Behavioral|Nutrition and food purchasing tool|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks).
75658112|NCT05867433|Behavioral|Usual Care|"No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study."
75658113|NCT05864391|Drug|AZD7503|Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
75658114|NCT05863598|Behavioral|Enhancing protective factors|Participants will watch some short movies and infographics, and will be asked to argue for the importance of body image flexibility, body functionality appreciation, etc.
75658115|NCT05863598|Behavioral|Expressive writing|Participants will reflect and write about any cognitions or emotions they can have in relation to their bodies.
75805191|NCT05975346|Drug|Ketamine|description
75805192|NCT05975346|Other|saline nebulization|description
75658116|NCT05860452|Other|ropivacaine|single shot bilateral TAP block
75805193|NCT05975320|Drug|Warfarin|Patients receiving oral anticoagulants will be followed up for 6 months to detect occurrence of any major bleeding events include (spontaneous epistaxis , spontaneous bleeding per gums , hematemesis , bleeding per rectum , intracranial hemorrhage and internal hemorrhage ). Then, incidence of bleeding events using both (HAS-BLED) & (ORBIT) SCORES will be calculated and compared for all cases .
75805194|NCT05975294|Drug|amixture 0.125% bupivicaine with fentanyl|ultrasound guided continuous erector spinae plane block with abolus 0.3ml /kg of amixture 0.125% bupivicaine with fentanyl of 2 mic per ml then Infusion of 0.1 ml /kg/hr of the same mixture.
75945859|NCT03155282|Procedure|EUS-E to measure liver and spleen stiffness.|The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
75945860|NCT03610321|Drug|Gefarnate|Gefarnate (100 mg, three times daily, oral) treatment for 1 month.
76093308|NCT03241680|Diagnostic Test|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
76093309|NCT01973608|Drug|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
75346682|NCT04378322|Behavioral|Nutrition education tool|Participants will be asked to review nutrition education materials online.
75945861|NCT03610321|Drug|Statin|Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.
76093310|NCT01973608|Drug|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
75658117|NCT05860452|Other|normal saline|single shot bilateral TAP block
75658118|NCT05858164|Drug|BAY2862789|Oral administration, solution or tablets
75658119|NCT05852262|Drug|Cephalexin|1000 mg PO QID for 7 days
75658120|NCT05852262|Drug|Cephalexin|500 mg PO QID plus oral placebo for 7 days
75346683|NCT01467557|Device|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
75346684|NCT01467557|Device|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
75476981|NCT05167279|Biological|JS026/placebo|Five dose groups (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg) will be set to receive an intravenous infusion of JS026/placebo on Day1, and two dose groups (300 mg JS026 + 1200 mg JS016, and 600 mg JS026+ 1200 mg JS016) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
75658121|NCT05832047|Drug|Plasma solution-A Inj.|Aggressive hydration : 10 mL/kg injection within 30~60min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours (up to 24 hours) thereafter.
75658122|NCT05832047|Drug|Hartmann Solution inno.N|Aggressive hydration : 10 mL/kg injection within 30~60min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours (up to 24 hours) thereafter.
75805195|NCT05975294|Drug|100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset|PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
75805196|NCT05975242|Behavioral|Smartphone diabetes management application|The intervention is a smartphone diabetes management application that is combined with structured blood glucose testing.
75805197|NCT05975229|Other|Knitting and education (pamphlet)|Pamphlet and knitting program (-8-week duration). The knitting program has two components: bi-weekly 20-minute group knitting sessions and 20-minute home daily knitting on the 5 remaining weekdays.
75945862|NCT03394755|Biological|Thrombosomes|Freeze-dried platelets
75346685|NCT01725932|Behavioral|Culturally adapted CBT based Self Help|Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
75805198|NCT05975229|Other|Education (pamphlet)|Receive only the pamphlet, not the knitting program.
75658123|NCT05831176|Drug|Dupilumab Dose 1|Administered subcutaneously (SC) once weekly (QW)
75658124|NCT05831176|Drug|Dupilumab Dose 2|Administered SC once every 2 weeks (Q2W)
75658125|NCT05831176|Drug|Matching Placebo|Administered SC
75805199|NCT05975190|Other|Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer|R&R training provided on an MP3-player for daily practice
75805200|NCT05975138|Procedure|implant insertion|a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus
75805201|NCT05975125|Drug|Vitamin C 500 MG Oral Tablet|compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
75945863|NCT02236793|Drug|BioChaperone PDGF-BB|
75945864|NCT02236793|Other|Standard of Care|
75945865|NCT02347046|Drug|FYU-981, (Oral single dosing)|FYU-981, (Oral single dosing)
75945866|NCT02451124|Device|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
75945867|NCT02451124|Other|Questionnaire Administration|Ancillary studies
75945868|NCT02451124|Other|Laboratory Biomarker Analysis|Correlative studies
75945869|NCT02451124|Procedure|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
75945870|NCT03391245|Diagnostic Test|3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique|Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique using CALBIOTECH (A life science company) kit, Catalog No.: VD220B
76093311|NCT01973608|Drug|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
76093312|NCT01973608|Drug|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
75346686|NCT01720394|Device|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
75346687|NCT01720394|Drug|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
75476982|NCT05167279|Biological|JS016/placebo|Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
75476983|NCT05163574|Dietary Supplement|High dose OIT|Patients will receive daily a high dose of peanut flour (300 mg peanut protein) mixed with well-tolerated fruit mousse.
75476984|NCT05163574|Dietary Supplement|Low dose OIT|Patients will receive daily a low dose of peanut flour (150 mg peanut protein) mixed with well-tolerated fruit mousse.
75658126|NCT05830097|Drug|CBP-1019|Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.
75658127|NCT05823922|Behavioral|Clinician Delivered CBT|Clinicians teach cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety and depression. Participants will attend weekly sessions with their clinician for 6 weeks.
75658128|NCT05823922|Behavioral|Supplemental MAYA App|"The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.~Participants will attend weekly sessions with their clinician as well as using the MAYA application for at least 20 minutes twice a week"
75805202|NCT05975112|Diagnostic Test|Coagulation tests (TEG, Levels of F1, F2, hs-D-dimer, Plasminogen, PAI 1+2), SpHb before discharge|Coagulation tests named earlier as well as SpHb
75805203|NCT05975034|Dietary Supplement|Probiotic|Probiotic taken daily for 12 weeks.
75805204|NCT05975034|Dietary Supplement|Placebo|Placebo taken daily for 12 weeks.
75805205|NCT05974995|Procedure|Robot-assisted surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymphnodes staging using DaVinci Xi
75805206|NCT05974995|Procedure|Laparoscopic surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymph nodes staging using standard laparoscopic approach
75945871|NCT03146234|Genetic|CAR-GPC3 T cells|"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."
75945872|NCT02236871|Behavioral|2 servings|Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.
75945873|NCT02236871|Behavioral|4 servings|Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
76093313|NCT01973608|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
76093314|NCT02234232|Behavioral|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
76093315|NCT03248778|Behavioral|disclosure-support counseling intervention|The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
76093316|NCT02357290|Drug|Open-label Treatment with N-Acetylcysteine|
76093317|NCT00725049|Device|Dental Implant (Nanotite)|Root form titanium dental implant
76093318|NCT02453724|Device|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
76093319|NCT00715143|Device|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
76093320|NCT03238872|Behavioral|Cognitive Behavioural Therapy|
76093321|NCT03238872|Other|Treatment as usual|
76093322|NCT02453880|Behavioral|Web-based Cognitive Behavioral Therapy|"Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session."
76093323|NCT04296045|Dietary Supplement|MCE|Ingestion of 15g MCE in water after min 10 hours of fasting
76093324|NCT04296045|Dietary Supplement|Glucose|Ingestion of 15g glucose in water after min 10 hours of fasting
76093325|NCT00693459|Device|Circular Anal Dilator for Transanal Hemorrhoidectomy|The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
75658129|NCT05820152|Drug|NFS-02 Injection|The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in < 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in < 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
75658130|NCT05808738|Behavioral|therapeutic play|therapeutic game will be played to prepare children for hydrotherapy treatment
75658131|NCT05808699|Device|handheld fundus camera|Fundus camera
75945874|NCT03401619|Combination Product|Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.|The long-term effect of comprehensive treatment on health, especially for osteoporosis and neurodegenerative diseases, we hope to find association from epigenetics and provide clues for further exploration of its pathogenesis.
76093326|NCT02454192|Behavioral|CHAMPS|
75346688|NCT01467947|Biological|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
75346689|NCT01568021|Other|No Intervention|No intervention was administered in this study.
75346690|NCT00910520|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
75346691|NCT00910520|Drug|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
75346692|NCT01568255|Drug|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
75658132|NCT05800249|Drug|PE0116|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
75658133|NCT05789147|Device|Active tVNS|It is a non-invasive transcutaneous electrical stimulation of the auricular branch of the vagus nerve which innervates the skin of the human ear. These nerve fibers project directly to the solitary tract nucleus (NTS) in the brain stem (6).
75945875|NCT02349230|Other|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
75945876|NCT03400527|Other|Exercise|Participants will pedal on a stationary bicycle up to 25 minutes 2-3 times a week for 4 weeks at a self directed pace and intensity
75945877|NCT02353208|Other|Sham Feeding of Bacon Bits|Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
75346693|NCT01568255|Drug|Placebo|placebo at 50,000IU for 8 weeks
75346694|NCT01720472|Genetic|Biomarker studies|
75346695|NCT01720628|Other|serum levels of angiogenin, bFGF, VEGF|Behçet's patients
75346696|NCT01569191|Other|Artificial Tear Supplement|artificial tear supplement (Hypromellose)
75346697|NCT01569191|Device|Cold compress|Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
75805207|NCT05974982|Biological|PRP|PRP is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. PRP enhances wound healing by promoting the healing process by seven growth factors present in it. They are platelet derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, transforming growth factor.
75346698|NCT01569191|Drug|Anti-allergic Medication|1 drop on single occasion after exposure to grass pollen
75346699|NCT03409874|Other|Dry Needling|Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks
75476985|NCT05157490|Behavioral|Mindfulness training|Guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
75658134|NCT05789147|Device|Sham tVNS|Sham stimulation is obtained by placing the stimulation electrode at the level of the earlobe. The stimulation is therefore administered and perceived in an area not innervated by vagal fibers.
75658135|NCT05786157|Other|Alcohol Administration|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
75658136|NCT05786027|Behavioral|PDI|A 12-week in-prison peer-driven intervention to increase the uptake of primary HIV prevention strategies (readiness to initiate addiction treatment (MMT or Atlantis), initiation of MMT/Atlantis, retention in MMT/Atlantis; or the use of SSP), and reduce the use of opioids and HIV risk behaviors, in HIV-negative PWID in prison.
75658137|NCT05782855|Other|Active Robot assisted physical training during acute hospitalisation|"Active training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the exercise movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform extension of hip and knee. The patient must use their muscular power to stretch the leg while ROBERT® provides resistance.~Training is defined as a minimum of three sessions before discharge."
75658138|NCT05782855|Other|Passive Robot assisted physical training during acute hospitalisation|"Passive training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform passive extension of hip and knee. ROBERT® moves the leg independently without the patient using any muscle power.~Training is defined as a minimum of three sessions before discharge."
75658139|NCT05773014|Procedure|Speculum Exams|Same as arm
75658140|NCT05773014|Procedure|Digital Exams|Same as arm
75658141|NCT05771948|Device|AqueousJoint|AqueousJoint is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. AqueousJoint is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.
75658142|NCT05762107|Drug|Placebo|Subject receives Placebo by subcutaneous injection daily for 28 days
75805208|NCT05974982|Other|Conventional therapy|Conventional therapy
75805209|NCT05974956|Other|Mastitis care teaching protocol|It was developed by the authors based on previous similar studies, articles and library resources. It was introduced to the study group in the form of face to face sessions plus a hand out copy. It consisted of three parts; (1): Theoretical part about mastitis (definition, types, clinical manifestation, possible causes, diagnosis and management). (2):Self-care practices, and (3):Recommendations regarding dietary measures, rest, medication and follow up.
75945878|NCT02353208|Other|Placebo|Participants will not be asked to chew bacon bits
75945879|NCT03399903|Drug|Pentasa vs Align|We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
75945880|NCT03148652|Other|Enhanced Intervention Condition|The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
75945881|NCT03399825|Device|OCT-A|"optical coherence tomography angiography~Imaging with optical coherence tomography angiography"
76093327|NCT00687765|Drug|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
76093328|NCT03248544|Drug|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
76093329|NCT03248544|Other|control|No intervention
75346700|NCT03409874|Other|Spinal manipulation|Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.
75346701|NCT03409874|Other|Interocclusal Appliance|Interocclusal appliance worn every nights for 4 weeks.
75346702|NCT03409874|Drug|NSAIDs|diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
76093330|NCT03238950|Other|Porcine model|participants to conduct training on porcine model
75346703|NCT03409874|Other|TMJ Mobs|Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
75346704|NCT01726010|Device|22-G Procore Needle|
75346705|NCT01726088|Drug|Modafinil|we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
75476986|NCT05152472|Drug|Atezolizumab 1200 mg|(Intravenous administration)
75476987|NCT05152472|Drug|Imatinib 400 MG|(Per os)
75476989|NCT05138016|Device|Soft exosuit|Progressive cardiovascular exercise testing with soft exosuit assistance.
75476990|NCT05138016|Behavioral|No Soft exosuit|Progressive cardiovascular exercise testing.
75476991|NCT05135468|Drug|CU-40102 Spray|topical application, 1~4 sprays each time, once daily
76093331|NCT03238950|Other|Synthetic model|participants to conduct training on synthetic model
76093332|NCT03239028|Behavioral|Observational|
76093333|NCT04486794|Device|Restylane®|Hyaluronic acid
76093334|NCT03241212|Behavioral|Texting|From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
76093335|NCT03238716|Other|Electric DN|Dry needling with electric stimulation to the erector spine and paraspinal muscles in the lumbar / sacral region and tibialis anterior / posterior. Dry needling with electric stimulation of peri-neural tissue associated with lumbar / sacral nerve roots, pudendal nerve and posterior tibial nerve. 8-12 treatment sessions over 6 weeks.
76093336|NCT03238716|Other|NM Re-ed|"sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments."
76093337|NCT03238716|Other|Exercise|Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at > 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
76093338|NCT03238404|Procedure|NAC group|NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
76093339|NCT03238404|Procedure|Surgery alone group|Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
75658143|NCT05762107|Drug|ZT-01, 7 mg|Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
75945882|NCT03391167|Procedure|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
76025970|NCT05145595|Behavioral|Conditioned pain modulation (CPM) efficiency|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information. CPM testing includes the application of a test stimulus without conditioning (control run) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run). Heat-CPM and pressure-CPM. Heat and pressure CPM will be tested in random order.~The difference between the pain ratings/thresholds of the test stimulus with vs. without the concomitant conditioning stimulus is the CPM magnitude. CPM<0 (reduction in pain) implies efficient inhibitory pain modulation of spatial filtering."
76093340|NCT03240744|Biological|Inactivated EV71 vaccine (human diploid cell, KMB-17)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
76093341|NCT03248466|Biological|PRG combined with BMMSCs transplantation|PRG combined with BMMSCs transplantation
76093342|NCT03248700|Other|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
76093343|NCT03238482|Drug|salmeterol-fluticasone|Seretide Diskus 50/250 µg/dose
76093344|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
75658144|NCT05762107|Drug|ZT-01, 15 mg|Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
75658145|NCT05762107|Drug|ZT-01, 22 mg|Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
75658146|NCT05760690|Procedure|Retro-Auricular Single-Site Endoscopic Thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
76093345|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
76093346|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
76093347|NCT02454660|Behavioral|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
76093348|NCT02454504|Drug|sugammadex|
76093349|NCT02454504|Drug|Neostigmine|
75658147|NCT05760690|Procedure|Transoral Endoscopic Thyroidectomy Vestibular Approach|The patient was placed in a supine position with slight neck extension under nasotracheal intubation. The mouth was garbled with povidone iodine before surgery. Three laparoscopic ports (a 10- to 15-mm port at midline and two 5-mm ports at the lateral junction between the canine and first premolar teeth)were inserted under the lower lip at the oral vestibular area.The strap muscleswere separated in the midline to expose the thyroid and trachea. The recurrent laryngeal nerve (RLN) was identified at the insertion to the larynx, then followed downandparallel tothe trachea inferiorly.
76093350|NCT03240666|Other|non applicable|non applicable
76093351|NCT03240822|Procedure|Penile Transplant|Penile Allotransplantation
76093352|NCT03240822|Biological|Monoclonal Antibody (Humanized Anti-CD52)|
76093353|NCT03240822|Drug|Tacrolimus|
76093354|NCT03240432|Device|Dexcom CGM|CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
76093355|NCT03238560|Drug|Montelukast Chewable Tablet|Montelukast treatment was used at a dosage of 5mg/day once daily
76093356|NCT04486482|Other|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
75945883|NCT03391167|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
76093357|NCT04486482|Other|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
76093358|NCT02453958|Device|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
76093359|NCT04486092|Drug|Valproic Acid|
76093360|NCT03238638|Drug|Pembrolizumab|Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.
75805210|NCT05974943|Other|Problem Solving And Decision Making Education|"The Problem-Solving and Decision-Making Training Program, which was based on developing problem-solving and decision-making skills of nurse managers in the experimental group (n=30), was prepared. 2 faculty members and the researcher organized the training program consisting of four modules and 16 hours.~In the content of the Training Program; the definition of the concept of problem-solving and decision-making, the process of problem-solving and decision-making and decision-making models, the impact of decision-making on employee, patient and organizational outcomes, and the importance of managers' roles in decision-making, the importance of the role of nurse managers in decision making, the impact of managerial decisions on patient care outcomes, the impact of managerial decisions on nurse outcomes, the impact of administrative decisions on organizational results/performance, problem-solving, and decision-making techniques and case studies."
75658148|NCT05760690|Procedure|Transareola Endoscopic Thyroidectomy|The patient was in supine position. Incision was made inside the right areola and a 10mm puncture device was placed, subcutaneous separation rod was used to separate the space, and a 30° endoscope was introduced, puncture device was placed in a 5mm incision on the left areola, ultrasonic knife free flap was used, subcutaneous separation space was placed in the upper sternal segment, and a 5mm puncture device was placed outside the right areola. The anterior cervical flap was further dissociated to establish a space. The median cervical line was cut to cut off the isthmus of the thyroid, and the tracheal fascia ligament of the thyroid was separated and the nerve was exposed to protect the nerves. Then remove the lobe of thyroid and central lymph nodes
75658149|NCT05757713|Biological|teplizumab|CD3-directed humanized monoclonal antibody
75658150|NCT05740839|Behavioral|HIIT Exercise Program|Exercise program with stationary bike via the Zoom platform.
75658151|NCT05740839|Behavioral|Control Group|Usual Activities
75658152|NCT05737628|Drug|BYON4228 + Rituximab|"20 mg/mL BYON4228 in 8 mL solution for infusion.~Rituximab 500 mg concentrate for solution for infusion."
75658153|NCT05728801|Diagnostic Test|Ageing|Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.
75658154|NCT05725564|Behavioral|FAST (Functional Activity Strength Training)|Daily exercise intervention including functional resistance exercises and personalized coaching.
75805211|NCT05974930|Device|IVUS imaging for primary PCI guidance|Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
75805212|NCT05974917|Device|Serious Game (SG)|"SG which was conceived as a running game, in which an Avatar runs through the forest and overcomes obstacles through the player's performance of physical exercises.~Children will play while watching an imaginary Avatar, who shows the right movements to perform in order to collect rewards. SG will be projected with a 4K projector and controlled by the child's movements, which will be tracked in markerless mode using Azure's Kinect sensor. SG will include an adaptive tool to enable the experience based on the child's specific motor skills.~The dynamics of SG will be adapted by considering real motor and physiological data acquired during each SG session via a wristband. These data are necessary to keep the child in the aerobic zone (60-80% of maximum heart rate). The movements are:~Side bending: Moving an obstacle to open a passage.~High jump: Overcoming a low, frontal obstacle.~Side lunge: Avoiding a side obstacle.~Squat: Passing under a low, frontal obstacle."
75945884|NCT02346968|Other|Blood and urine sampling|Blood and urine sampling (in the context of routine sampling)
75945885|NCT03391089|Device|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system.
75945886|NCT03146468|Drug|Nivolumab Injection|Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
75945887|NCT03391011|Device|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while monitored by clinically approved system.
75945888|NCT02353130|Drug|Memantine-XR|Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
75476992|NCT05118269|Device|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/World Health Organization , Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary).
75805213|NCT05974891|Other|Pilot application|"Pilot application will be carried out with at least 10 students. A pre-test will be applied to the experimental group. After the scales are applied, the experiment will be applied to the experimental group with the Geriatric Medication Game simulation.~Students simulating the elderly patient role during this simulation will gain a better understanding of age-related health problems and how older adults feel when confronting them. After the application, debriefing, which is the last stage of the simulation training, will be done to evaluate the application. After the application and analysis session is completed, the post-test will be applied to the experimental group. A 3-week clinical practice will be planned for the students in the experimental groups in order to evaluate the continuation of the acquired skills and acquired awareness. In this application, students will be asked to care for the elderly patient and the pre-test will be repeated at the end of the application."
75945889|NCT02033551|Drug|Veliparib|
75346707|NCT01726166|Procedure|Suprapubic Aspiration|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
75346708|NCT01726166|Procedure|Urinary Catheterization|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
75346709|NCT01720706|Device|RFA Loosely wound thermal coil|"This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode."
75476993|NCT05118269|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
75476994|NCT05114889|Biological|BSI-045B|BSI-045B will be administered weekly, subcutaneously
75476995|NCT05103670|Procedure|Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA|32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
75658155|NCT05725564|Behavioral|Band Together|3 times weekly group exercise over Zoom featuring strength and balance exercises for 45 minutes
75805214|NCT05974878|Other|Exercise|"Joints targeted by exercise; bilateral wrist, metacarpophalangeal, proximal and distal interphalangeal joints, elbow and shoulder joints.~The muscles targeted by the exercises; lumbricals, iinterosseals, thenar and hypothenar muscles, forearm flexors, forearm extensors, forearm supinators and pronators, elbow flexors and extensors, and shoulder girdle muscles.~Content of the exercises; There will be warm-up exercises, pinch grip, full grip, nerve and tendon gliding exercises, exercises that improve proprioception, functional exercises, strengthening exercises and stretching exercises."
75658156|NCT05725564|Behavioral|Behavioral Change Technique|Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence
75805215|NCT05974878|Other|Conventional Physiotherapy|For control group there will be aerobic exercise recommendation and resistive exercises focused on upper extremity.
75805216|NCT05974865|Behavioral|Healthy Babies and Healthy Moms|
75805217|NCT05974865|Behavioral|Baby Basics Prenatal Guide|
75945890|NCT02033551|Drug|Carboplatin|
75346710|NCT00911612|Drug|Colesevelam|Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
75346711|NCT00911612|Drug|Placebo|Inert capsule matching the study drug, given twice daily
75346712|NCT01469039|Drug|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
75658157|NCT05715359|Procedure|Reconstruction|Standardized template for reconstruction of continious defects of the jaws.
75658158|NCT05711784|Other|Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
75658159|NCT05711784|Other|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
75476996|NCT05099549|Drug|AFM24|Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
75476997|NCT05099549|Biological|SNK01|Patient-specific ex-vivo expanded autologous natural killer cells.
75476998|NCT05084768|Diagnostic Test|Donor-derived cell-free DNA|As mentioned previously
75346713|NCT01469039|Drug|Placebo|Placebo for IM injection, given monthly
75476999|NCT05081713|Behavioral|high-intensity training focused on stepping in variable contexts|Approximately 10 weeks (~30 sessions) of high-intensity training
75658160|NCT05711784|Other|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
75658161|NCT05705505|Drug|Narazaciclib|Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate
75805218|NCT05974813|Dietary Supplement|L-Citrulline|6 g (3 g every 12 h) of L-citrulline for six days
75805219|NCT05974813|Dietary Supplement|Placebo|6 g (3 g every 12 h) of maltodextrin for six days
75346714|NCT01720784|Dietary Supplement|Alginate dietary fiber|
75945891|NCT02033551|Drug|Paclitaxel|
75945892|NCT02033551|Drug|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
75945893|NCT02450578|Drug|DSM265 400mg|DSM265 400mg, single oral administration in a fed state
75945894|NCT02450578|Drug|Placebo to DSM265 400 mg|Placebo to DSM265 400mg, single oral administration in a fed state
75945895|NCT02450578|Biological|Plasmodium falciparum sporozoite challenge|IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
75945896|NCT02450578|Drug|Malarone|250 mg atovaquone, 100 mg proguanil hydrochloride
75945897|NCT02346890|Drug|AZD1722|
75945898|NCT02346890|Drug|Renvela|
75945899|NCT03980145|Device|G-EO System (Reha Technology AG: Olten, Switzerland)|Electromechanically-assisted gait training addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases.13,14 The G-EO System (Reha Technology: Olten, Switzerland) is a novel end-effector gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback.
75945900|NCT03980145|Other|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training. Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
75346715|NCT01720784|Dietary Supplement|Placebo|
75805220|NCT05974800|Behavioral|Emergency department caregivers interview|The interview focuses on several parts of the emergency care process: The first part is regarding the actions that are executed during an emergency department visit. The investigators will establish, which actions are executed and why. The second part are regarding the suspected outcome for the patient. The third part will be about any potential improvements on de emergency care process for the patient.
75945901|NCT03146390|Drug|Essential oils|all subjects will perform all interventions of all arms
75945902|NCT03146390|Drug|Alcohol free essential oils|all subjects will perform all interventions of all arms
75945903|NCT03146390|Other|Water|all subjects will perform all interventions of all arms
75346716|NCT01726244|Behavioral|Multidisciplinary Intervention|Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
75658162|NCT05705505|Drug|Letrozole 2.5mg|Tablet
75658163|NCT05699759|Drug|K8|Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).
75658164|NCT05699460|Other|This is an observational study.|This is an observational study.
75658165|NCT05693142|Genetic|RGX-202|RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
75658166|NCT05684614|Other|Negative mood induction procedure|"The negative mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce negative mood: 1) Velten's tasks, consisting of interactive phrase formulations with negative thoughts and beliefs about the self (e.g., I don't have any future); 2) visualizing International Affective Pictures; and 3) recalling a negative autobiographical memory related to a significant loss (e.g., a person, a pet)."
75346717|NCT01569737|Drug|ella|ella, single intake, tablet 30mg
75945904|NCT03610009|Device|2D ultrasound|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
75346718|NCT03409484|Other|Concord Grape Juice|Concord Grape Juice
75346719|NCT03409484|Other|Low flavoniod low essence beverage|Low flavoniod low essence beverage
75346720|NCT03409484|Other|Low flavonoid beverage|Low flavonoid beverage
75346721|NCT05562089|Device|A Paclitaxel Drug-Coated Balloon|Size: 2.0mm-4.0mm x 15-30mm Coated drug: Prevail TM
75658167|NCT05684614|Other|Spontaneous emotion regulation task|Participants are instructed to use whatever strategy they want by doing, saying, and/or thinking whatever they want to feel better for 2 min
75658168|NCT05684614|Other|Positive mood induction procedure|"The positive mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce positive mood: 1) Velten's tasks, consisting of interactive phrase formulations with positive thoughts and beliefs (e.g., Life is wonderful); 2) visualizing International Affective Pictures; and 3) recalling a positive autobiographical memory"
75346722|NCT01726478|Drug|2.5 units Oxytocin|Administration of 2.5 units of oxytocin after clamping of umbilical cord
75346723|NCT01726478|Drug|10 units Oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
75346724|NCT04379492|Drug|Hydroxychloroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
75346725|NCT04379492|Other|Placebo|Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.
75346726|NCT02470806|Device|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
75945905|NCT03610009|Device|SonoAVC|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
75945906|NCT02039180|Drug|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
75945907|NCT02039180|Drug|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
75945908|NCT02039180|Drug|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
75945909|NCT04924582|Other|Capacity Coaching|Capacity Coaching focuses on developing the capacity within patients to adapt, endure, and function optimally in their lives along with illness and treatment.
75945910|NCT02346734|Device|Multiple Sclerosis Home Automated Telemanagement (MS HAT) system|
75945911|NCT02346812|Other|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
76093361|NCT03238638|Drug|epacadostat|Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
75346727|NCT02470806|Device|tNPWT System|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
75658169|NCT05681650|Biological|HypoSti.CAR-HER2 T cells|Dose escalation: dose -1 (1×10^6 cells/kg) ,dose 1 (3×10^6 cells/kg) , dose 2 (6×10^6 cells/kg), dose 3 (1×10^7 cells/kg), dose 4 (1.5×10^7 cells/kg). Dose expansion: RP2D
75658170|NCT05681650|Drug|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
75805221|NCT05974787|Behavioral|Emergency department cancer patients interview|The interview focuses on several parts of the (pre-)admission process: The first part is regarding the timeline that led to an ED visit. The investigators will establish, when and which symptoms were first detected. The second part are regarding the number and type of health care workers that were contacted before visiting the ED. The third part will be about the actions that were taken before the ED visit.
75658171|NCT05681650|Drug|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
75658172|NCT05681650|Drug|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2 only in the first infusion of HypoSti.CAR-HER2 T cells
75805222|NCT05974774|Drug|iMAB|no treatment until significant PSA increase as per treating physician at which point patient restarts ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide). Once PSA < 0.2 ng/mL, treatment stops again.
75805223|NCT05974774|Drug|cMAB|LHRH agonist or antagonist + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)
75805224|NCT05974761|Other|massage|The patient was placed in a lateral decubitus position with the physician standing on the ventral side of the patient, with the crotch resting on the anterior edge of the superior iliac crest, and the elbow rising from the medial side of the highest point of the superior iliac crest, follow the palpation (avoiding the L3 transverse process) along the steep edge of the skeleton slowly toward the spine, and focus on the painful points or cords by repeatedly applying the elbow press method and the elbow flick method for 1-2 minutes, and then the elbow tip contact to find the sinew knot and along the vertical direction of 3-5 times, the force should be deep penetration.
76093362|NCT00668655|Drug|Metronidazole Gel|Topical, Once daily for 2 weeks
76093363|NCT03240354|Device|Saline cuff|Cuff of endotracheal tube inflated with saline rather than air (control)
76093364|NCT03240354|Device|Control|Cuff of endotracheal tube inflated with air
76093365|NCT03240276|Other|Standard ICSI procedure for sperm injection into oocyte|The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes
75346728|NCT00912002|Drug|MK-0941|A single dose of 40 mg of [14C]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
75346729|NCT01726556|Device|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
75658173|NCT05674916|Diagnostic Test|Point-of-care ultrasound-driven diagnostic pathway|Focused lung ultrasound will include 8 zones (anterior and lateral) and evaluate pneumothorax, interstitial syndrome, lung consolidation, and pleural effusion. Focused cardiac ultrasound will include four views (subxiphoid four-chamber view, parasternal long-axis view, parasternal short-axis view, and apical four-chamber view) and evaluate pericardial fluid, right ventricle dilation, and left ventricular systolic contractility.
75658174|NCT05672459|Drug|Single Injection of IVS-3001- Anti - HLA-G CAR-T cells|Given by IV (vein)
75658175|NCT05672459|Drug|Fludarabine phosphate|Given by IV (vein)
75658176|NCT05672459|Drug|Cyclophosphamide|Given by IV (vein)
75658177|NCT05672459|Procedure|leukapheresis|Given by IV (vein)
75805225|NCT05974761|Other|Traditional Chinese massage|Through the point, massage, bone-setting treatment
75805226|NCT05974683|Drug|placebo|Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
75805227|NCT05974683|Drug|mycophenolate mofetil|Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
75805228|NCT05974670|Device|Consumer wearable device|The subjects are required to wear the consumer wearable devices continuously during the whole study period. The device can provided several physiological parameters, including pulse rate, blood oxygen saturation, physical activity, electrocardiogram, and sleep.
75805229|NCT05974657|Other|Probiotic Lactobacillus acidophilus LA85|Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
75805230|NCT05974644|Other|Registry|The purpose of this registry is to collect and store health information from people who are carriers of the gene known to cause hereditary amyloidosis and those with a confirmed diagnosis of the disease.
75805231|NCT05974631|Behavioral|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
75945912|NCT02346812|Other|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
75945913|NCT02449018|Drug|QBW251|QBW251 capsule(s) taken orally twice per day
75945914|NCT02449018|Drug|Placebo|Matching placebo capsule(s) taken orally twice per day
75945915|NCT03146312|Dietary Supplement|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 4 weeks
75945916|NCT03146312|Dietary Supplement|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
75945917|NCT02859415|Drug|Mithramycin|Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
75945918|NCT03390855|Other|Broccoli sprouts|
75945919|NCT02346656|Device|Implantation with the commercially available Axium neurostimulator|
75945920|NCT03943329|Procedure|Standard of Care|"Will receive the standard of care free-hand technique of distal screw placement, as treated by Dr. Egol or Dr. Tejwani."
76093366|NCT03240276|Device|MSOME|Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification
76093367|NCT03240276|Other|IMSI Procedure|Injection of sperm that has been selected by the MSOME method into oocytes
76093368|NCT02454426|Drug|Vortioxetine|open label treatment
76093369|NCT03238092|Drug|Testosterone|testosterone gel daily during the late luteal phase.
76093370|NCT03238092|Drug|Estradiol|oral estradiol during the late luteal phase.
76093371|NCT01896765|Behavioral|Intensive Prevention Program|"Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
76093372|NCT01896765|Other|Standard medical and interventional therapy|Medical and interventional therapy following the standard of care.
76093373|NCT03247998|Drug|General Anesthesia|Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
75658178|NCT05670119|Other|Structured Training|Structured catheter-related infection control training was prepared by using evidence-based information and receiving 10 expert opinions. This training will be given to the participants with a face-to-face PowerPoint presentation by the infection control nurse (researcher) and will also be presented as written material.
76093374|NCT03247998|Drug|Conscious Sedation with Remifentanil|Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
75805232|NCT05974631|Behavioral|Dialectical Behavior Therapy Prolonged Exposure protocol|DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
75805233|NCT05974631|Behavioral|Prolonged Exposure therapy|Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
76093375|NCT03248076|Drug|Fentanyl Citrate|1γ/Kg fentanyl
75805234|NCT05974631|Behavioral|Suicide risk management|Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.
75805235|NCT05974618|Diagnostic Test|Ultrasound|"A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age."
75805236|NCT05974540|Diagnostic Test|Determination of cricothyroid membrane|"After the patient's head is extended, the pediatric surgeon will be asked to mark the cricothyroid membrane with a pencil using traditional inspection and palpation methods. Then, the cricothyroid membrane will be determined by the Anesthesiology and Reanimation specialist by USG method and the difference will be determined. Demographic and morphometric characteristics of the patients will be recorded. In addition, the length of the cricothyroid membrane, the distance between the cricoid cartilage and the skin, the distance between the cricoid cartilage and the 2nd tracheal ring will be measured by USG.~Mallampati classes of patients with intubation, Cormack-Lehane (CL) glottic appearance grades, Likert scale with intubation difficulties (1: very easy, 2: easy, 3: medium, 4: difficult) will also be recorded."
76093376|NCT01896843|Drug|STX107|
76093377|NCT03240120|Drug|Dabigatran etexilate|Pradaxa 150 mg hard capsules
76093378|NCT03240120|Drug|Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
76093379|NCT03240042|Procedure|nasotracheal intubation|The participants either receive intubation via nasal route.
76093380|NCT03240042|Procedure|orotracheal intubation|The participants either receive intubation via oral route.
75658179|NCT05664828|Drug|SN132D|Manganese-based macromolecular MRI contrast agent
75658180|NCT05647044|Device|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
76093381|NCT04771845|Device|Transcranial Magnetic Stimulation|Magnetic stimulation to alter neural activity
76093382|NCT03237936|Drug|1mg/mL ciclosporin|IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
76093383|NCT03247920|Drug|Amoxicillin Clavulanate|Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1
76093384|NCT03247920|Drug|Antibiotics|Intravenous antibiotic therapy following local protocol
76093385|NCT04771533|Procedure|hand motor coordination in a sitting position|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
76093386|NCT04771533|Procedure|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and the hand free). After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
75805237|NCT05974527|Drug|Sublingual film containing dexmedetomidine (BXCL501)|Enrolled participants will receive an initial dose of BXCL501 180mcg. Following the FDA dosing suggestions, participants with mild or moderate hepatic impairment (Child-Pugh Class A or B) will receive a reduced initial dose of 120mcg and participants with severe hepatic impairment (Child-Pugh Class C) will receive a reduced initial dose of 90mcg. Geriatric patients (≥ 65 years old) will receive a reduced initial dose of 120mcg.
75658181|NCT05647044|Device|placebo intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
75658182|NCT05643638|Biological|CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)|Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.
75805238|NCT05974501|Drug|Dexamethasone|Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling
75805239|NCT05974501|Drug|Acetaminophen|1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively
76093387|NCT03238014|Device|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
76093388|NCT04771143|Drug|AFQ056|oral administration
75805240|NCT05974501|Drug|Lyrica|Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively
75658183|NCT05643638|Biological|Placebo|The placebo product is identical to CYP-001, except that it contains no active agent
75805241|NCT05974501|Drug|Celebrex|200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively
75805242|NCT05974501|Drug|Meloxicam|30mg administered via IV once postoperatively within 24 hours for pain and swelling
75805243|NCT05974501|Drug|Oxycodone|5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively
75805244|NCT05974501|Drug|Ropivacaine|20 milliliters Ropivacaine 0.2% administered via injection perioperatively.
75805245|NCT05974436|Other|Blood and dialysate sampling|"Blood is sampled from the inlet and outlet dialyzer bloodline at 5min after dialysis start.~Spent dialysate is sampled from the outlet dialysate line at 5, 30, 90 and 240min after dialysis start.~Blood and dialysate samples are analysed for different uremic toxins. Dialysis efficiency is calculated from the analysed toxin concentrations."
75805246|NCT05974423|Drug|Tylenol, Ibuprofen, and Oxycodone|A script for these three medications will be provided
75658184|NCT05643638|Drug|Corticosteroids|All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
75658185|NCT05641766|Drug|THC|Participants will receive THC into a rapidly flowing IV infusion.
75658186|NCT05641766|Other|Placebo|Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
75658187|NCT05641688|Drug|[18F]PI-2620|The radioligand, [18F]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
75658188|NCT05640999|Radiation|Vaginal brachytherapy|Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids
75805247|NCT05974423|Drug|Tylenol and Ibuprofen only|A script for only these two medications will be provided initially following surgery. Should the patient need stronger medication for adequate pain control, the on-call physician will provide a script for oxycodone
75805248|NCT05974410|Drug|AVM0703|small molecule immunomodulatory drug
75805249|NCT05974410|Drug|Hydrocortisone|physiologic circadian glucocorticoid
75805250|NCT05974410|Drug|Proton pump inhibitor|
75805251|NCT05974371|Other|emotional context similarity|On Day 1, all participants will encode AB neutral word pairs (e.g., Pencil - Car) shown with positive, negative, or neutral images. On Day 2, all participants will encode AC neutral words pairs (e.g., Pencil - Book) alongside images of either the same or different valence. The emotional similarity of AB (Day 1) and AC (Day 2) image contexts (i.e., the independent variable) will consist of the following conditions: positive-positive, positive-negative, negative-negative, negative-positive, neutral-neutral, neutral-positive, and neutral-negative.
75805252|NCT05974358|Procedure|Kono-S anastomosis|Kono et al. described a new operative technique that could reduce the rate of post-operative recurrence: a termino-terminal ileocolonic anastomosis, anti-mesenteric, with a supporting column to prevent distortion and anastomotic stenosis (Kono-S anastomosis).
75805253|NCT05974358|Procedure|Conventional anastomosis for ileocolonicresection of Crohn's disease|conventional anastomosis for ileocolonicresection of Crohn's disease
75805254|NCT05974332|Diagnostic Test|Oncostatin M|Test to diagnosis of Ulcerative colitis
76093389|NCT04771143|Drug|Placebo|matching placebo for oral administration
75658189|NCT05640999|Radiation|Adjuvant radiotherapy (EBRT +/- brachytherapy)|Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
75658190|NCT05640999|Other|Observation|Observation
75658191|NCT05630768|Drug|Risedronate Sodium 35 MG [Actonel]|Risendronate Sodium Tab. 35mg, orally, once weekly
75658192|NCT05630768|Drug|Calcium Vitamin D combination|orally, once daily for concomitant drug
75805255|NCT05974319|Other|Dry heat application|Dry heat application: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. The researcher will heat the thermoregulated electric pad and set it to 42°C. After making sure that there are no contraindications in the application of the electric pad device, a dry heat of 42°C will be applied to the determined area with the electric pad for 5 minutes.
75945921|NCT03943329|Procedure|Distal targeting device technique of distal screw placement|The second group will be the interventional group which will use the distal targeting device technique of distal screw placement and will be treated by Dr. Konda and Dr. Leucht. All relevant data to the study will be collected intra-operatively.
75658193|NCT05627011|Behavioral|Improving Pediatric Obesity Practice Using Prompts (iPOP-UP)|EHR-based CDS tools refined through a formative evaluation and user-centered design process that immediately preceded this study.
75945922|NCT02346500|Device|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
75945923|NCT02871791|Drug|Palbociclib|
75658194|NCT05623787|Diagnostic Test|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
75658195|NCT05622682|Other|Observational only|Blood samples will be tested to measure antibodies to vaccine-preventable diseases and immune recovery
75805256|NCT05974319|Other|Dry cold application|Dry cold applicaiton: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. After the researcher is sure that there are no contraindications in the application of the gel pad, dry cold will be applied to the determined area with the gel pad for 3 minutes.
75805257|NCT05974306|Device|implantable loop recorder|Implantation of an implantable loop recorder
75805258|NCT05974228|Device|Bioactive glass wound dressing|Bioactive glass wound dressing is a dressing covered on the wound bed
75805259|NCT05974215|Device|assessment of change in bone height by cone beam computed tomography|bone height was measured at 1 ,30 ,90 days after denture insertion
75945924|NCT02871791|Drug|Everolimus|
75945925|NCT02871791|Drug|Exemestane|
75945926|NCT02346578|Drug|Enzalutamide|
75945927|NCT02346578|Drug|Flutamide|
75658196|NCT05619900|Other|There is no intervention|This is an observational study. There is no intervention. The purpose of the project is to create a database of patients diagnosed either prenatally or after birth with a lysosomal storage disease. The database will be utilized to assess patient outcomes, build on existing clinical management, improve medical decision making, and improve quality of care.
75658197|NCT05618574|Dietary Supplement|210 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)|The investigators propose to study the benefits nitrite therapeutics, using nitrate-rich beetroot juice to increase serum nitrite. The investigators hypothesize that increased nitrite will improve functional metrics and reduce fatigability in Veterans with long COVID as a result of enhanced skeletal muscle mitochondrial respiration. Participant will receive 210 ml per day of Beet-It nitrate beverage for 16 mmol of nitrate/day for 14 days vs the placebo.
75658198|NCT05613660|Dietary Supplement|Veg Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
75658199|NCT05613660|Dietary Supplement|Bovine Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
75805260|NCT05974163|Diagnostic Test|radiomic of CT|Computed Tomography (CT) is often an important examination method for emergency diagnosis because of its fast examination speed and accurate localization acute respiratory distress syndrome.
75805261|NCT05974098|Other|Observational study|This study intends to use correlation analysis and mediation analyses to assess the mediating effects of self-efficacy, coping, depression and anxiety on the quality of life of patients with paroxysmal atrial fibrillation.
75805262|NCT05974085|Drug|Selinexor+RCHOP|XPO-1 inhibitor selinexor in combination with RCHOP
75805263|NCT05974072|Drug|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
75945928|NCT03399747|Drug|Abb-R-CHOP|"Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy"
75945929|NCT04446897|Biological|mesenchymal stem cells|autologous mesenchymal stem cells
75945930|NCT04446897|Other|standard treatment|standard treatment according to clinical protocols
75945931|NCT02346266|Other|SMART Education|
75945932|NCT03112382|Drug|zinc supplement plus vitamin A and E|
75945933|NCT03112382|Drug|vitamin A and E|
75945934|NCT03399669|Drug|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
75945935|NCT03148574|Drug|Misoprostol|intrauterine tablets
75945936|NCT03148574|Drug|Oxytocin|intravenous
75945937|NCT03390777|Procedure|surgery|surgery without the use of prgf
75945938|NCT03390777|Device|PRGF after surgery|surgery and application of PRGF
75945939|NCT03148340|Diagnostic Test|VIPS Monitoring|Bioimpedance asymmetry
75945940|NCT03390699|Diagnostic Test|Microbial profile|microbiological testing
75945941|NCT02343536|Drug|Oral Azacitidine|
75945942|NCT02343536|Drug|Rituximab|
75945943|NCT02343536|Drug|cyclophosphamide|
75945944|NCT02343536|Drug|Vincristine|
75945945|NCT02343536|Drug|Prednisone|
75945946|NCT04446975|Other|BPA|At the time of writing the prescription an automatic notification will appear on the care provider's screen that identifies a suggested post-discharge opioid dose within the electronic prescription pad. If approved by the provider, opioid-only prescriptions will be written as suggested. Final dosing decisions and drug choices will remain at the discretion of the treating provider.
75945947|NCT03148184|Diagnostic Test|shoulder x-ray|post operative shoulder x-ray at minimum 2 year post op
75945948|NCT02343614|Drug|Celecoxib|
75945949|NCT04446819|Device|Compression gloves|Patients wear small-size compression gloves (one or two size smaller than suitable size) for dominant hands and suitable-size compression gloves for non-dominant hands for 90 minutes during the administration of albumin-binding paclitaxel (start from 30 minutes before albumin-binding paclitaxel infusion).
75945950|NCT02871635|Drug|BI 695501|
75945951|NCT02871635|Drug|HUMIRA|
75945952|NCT03147950|Procedure|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
76093390|NCT04487184|Other|Kinesiology taping|Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
76093391|NCT03239964|Drug|Dexamethasone|the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
76093392|NCT03239964|Other|surgical excision|total extralesional surgical excision of the keloid is performed and minimal undermining
75945953|NCT03147950|Procedure|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
76093393|NCT02453646|Device|NexSite HD Patients|Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
76093394|NCT04771377|Dietary Supplement|Protein Supplementation|protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
76093395|NCT03239886|Other|imatinib discontinuation|imatinib discontinuation
76093396|NCT03102723|Drug|Cangrelor|"Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~Or~Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI."
76093397|NCT03237312|Procedure|Laparoscopic ovarian drilling|The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
76093398|NCT03237312|Biological|Antimullerian hormone|"In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed."
76093399|NCT03097575|Drug|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
76093400|NCT03097575|Device|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
75658200|NCT05613660|Dietary Supplement|"Fish | Marine Collagen Peptide"|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
75658201|NCT05613660|Dietary Supplement|Chicken Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
76093401|NCT05450835|Procedure|OGT group|In OGT group,the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Meanwhile, the OGT was sleeved on anvil fork extracorporeally and the linear stapler was put into abdomen through trocar on the right side and then cartridge fork was inserted through jejunum opening towards the oral side of the lumen. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube.
75805264|NCT05974072|Other|PAINDOC Program|"The PAINDOC Program consists in:~Therapeutic education: The therapeutic education block consists of two parts: an education session called Empowered Relief (ER) and two pain neuroscience education (NDT) sessions.~Psychotherapy: The psychotherapy part consists of one group session of one hour, face-to-face and with groups of up to 15 people, given by the psychologist of the pain unit.~Mindfulness Meditation: The Mindfulness Meditation consists of one group session of one hour, face-to-face and with groups of up to 15 people. These are given by a nurse from the pain unit. T~Therapeutic exercise: The therapeutic exercise module consists of three sessions of one hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
75805265|NCT05974059|Drug|Oxaliplatin|Preoperative treatment：130mg/m2，iv, 2h，d1，Q3W; Postoperative treatment：130mg/m2，iv, 2h，d1，Q3W;
75945954|NCT03390543|Device|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, both the device and sono-guided internal jugular vein catheterization was performed.
75805266|NCT05974059|Drug|Capecitabine|Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；
75945955|NCT03390543|Device|sono only|In Group S, simple needle guide device was not attached to the sono probe. After induction of anesthesia, only sono-guided internal jugular vein catheterization was performed.
75945956|NCT04093700|Device|SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
75945957|NCT03390465|Drug|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
75945958|NCT05255198|Procedure|Anterior versus lateral approach to hip joint|
75945959|NCT03394677|Drug|RVT-501 0.5% ointment|Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
75658202|NCT05610969|Other|Music|patients in this group will receive self-selected music after the golden moment has been completed between the patient, provider, and nursing staff
75658203|NCT05610969|Drug|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
75658204|NCT05605509|Drug|RP-6306|Dose and schedule will be assigned at enrolment
75658205|NCT05605509|Drug|Gemcitabine|Dose and schedule will be assigned at enrolment
75658206|NCT05605509|Drug|FOLFIRI Protocol|Irinotecan Leucovorin FU
75658207|NCT05605509|Drug|Trastuzumab|standard doses q3weekly
76093402|NCT05450835|Procedure|Overlap group|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al.
75805267|NCT05974059|Drug|Cadonilimab|Cadonilimab 10 mg/kg, d1, Q3W
75805268|NCT05974033|Combination Product|Stenting plus medical therapy|Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.
75945960|NCT03394677|Drug|Vehicle ointment|Placebo comparator - ointment twice daily (BID) for 4 weeks.
75945961|NCT02348996|Other|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
75945962|NCT02348996|Other|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
76093403|NCT03239652|Device|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
75945963|NCT02342990|Other|Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit|CogMed: an home-based and computer-based solution to improve working memory deficit
75658208|NCT05601544|Device|ACUVUE OASYS 1-Day|Sphere CONTROL
75945964|NCT02342990|Other|Cluster A No training. Delay start of CogMed|No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
75658209|NCT05601544|Device|ACUVUE OASYS MAX 1-Day|Sphere TEST
75658210|NCT05601544|Device|ACUVUE OASYS Multifocal|Multifocal CONTROL
75658211|NCT05601544|Device|ACUVUE OASYS MAX 1-Day Multifocal|Multifocal TEST
75805269|NCT05974033|Drug|Medical therapy alone|Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.
75945965|NCT03390387|Drug|Dexamethasone continuous|6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.
75945966|NCT03390387|Drug|Dexamethasone intermittent|6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.
75945967|NCT03390387|Drug|Dexamethasone|"Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.~Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
76093404|NCT03241914|Drug|Megestrol Acetate|At a dosage of 160 mg/day
76093405|NCT03241914|Device|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
76093406|NCT03235206|Other|Massage Therapy|This study will compare surveys taken before the participants began their massage treatments, and after 12 one hour massages. These surveys will judge sleep quality, stress levels, and mental health during varying days in the participants work cycle. It will also compare a postural assessment and range of motion testing done before the first treatment and after the last.
75346730|NCT01726556|Device|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
75346731|NCT03409250|Drug|Ranibizumab, Lucentis|Intravitreal injection with Lucentis (Ranibizumab)
75346732|NCT01569815|Drug|LCZ696|LCZ696 400 mg once daily
76093407|NCT00057681|Drug|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
76093408|NCT00057681|Drug|Valproate|Titrated until blood level is 111 to 125 ug/mL
76093409|NCT00057681|Drug|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
75346733|NCT01726634|Other|Elastic Tapping|
75658212|NCT05601544|Device|ACUVUE OASYS 1-Day for Astigmatism|Toric CONTROL
75658213|NCT05601544|Device|senofilcon A based contact lens (toric) with new UV/HEV filter|Toric TEST
75658214|NCT05597865|Behavioral|Economic Empowerment Intervention|Economic Empowerment Intervention comprising Financial Literacy Sessions and Youth Development Accounts
75658215|NCT05597865|Behavioral|Alcohol and Drug Use Risk Reduction Sessions|All participants in the control and treatment arm will receive Alcohol and Drug Use Risk Reduction sessions tailored for Adolescents and Youths Living with HIV.
75658216|NCT05597267|Device|MIRIA Laser|4-6 experimental treatments at 4-6 weeks intervals
75658217|NCT05593523|Drug|Indocyanine green (ICG)|ICG is a well, known, FDA-approved dye
75658218|NCT05593523|Device|OnLume|The OnLume Clinical Imaging System (CIS), also known as the Asimov-MSK Imaging System, used in this study is a clinical fluorescence-guided imaging system.
75805270|NCT05974007|Drug|Neoadjuvant immunochemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
75805271|NCT05974007|Drug|Neoadjuvant chemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
75346734|NCT01726712|Other|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
75346735|NCT01469585|Drug|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
75346736|NCT01720940|Drug|continuous vancomycin infusion|24-hour continuous infusion of vancomycin
75346737|NCT01720940|Drug|intermittent vancomycin infusion|
75346738|NCT03409172|Other|CTR|no counseling or nutritional therapy and no exercise
75346739|NCT03409172|Other|MICT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).
75945968|NCT03390387|Drug|Methylprednisolone|"Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely.~Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
75945969|NCT03390387|Drug|Daunorubicin|Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
75805272|NCT05973994|Device|intravascular lithotripsy with Shockwave coronary system|OCT acquistion is performed at baseline. Then the IVL catheter will be passed across the lesion over the guidewire. Atherectomy or cutting/scoring balloons is not permitted per protocol. The IVL procedure is considered successful when a residual stenosis <50% by visual estimate after IVL alone is achieved. After IVL procedure, one OCT imaging acquisition must be performed. If the residual stenosis is ≥50% following IVL, noncompliant balloon dilatation will be performed prior to stenting and OCT images repeated accordingly. Subsequent stent implantation will be performed per local standard of care at the discretion of the operator. Following stent implantation, high pressure post-dilatation is recommended and OCT imaging acquisition must be performed to assess stent apposition for secondary end point.
75945970|NCT03390387|Drug|Idarubicin|Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
75945971|NCT03390387|Drug|Bortezomib|1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).
75945972|NCT03390387|Drug|Second phase of induction|Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour - days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)
75945973|NCT03390387|Drug|Standard induction therapy|Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)
75346740|NCT03409172|Other|HIIT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)
75346741|NCT01721018|Biological|HSV1716 Intra-pleural delivery|
75346742|NCT01721174|Procedure|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
75658219|NCT05592093|Drug|Korean red ginseng capsule (marketed product in Korea)|Korean red ginseng capsule (marketed product in Korea) KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.
75658220|NCT05592093|Drug|Korean red ginseng capsule(placebo)|"KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group.~The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time."
75658221|NCT05591222|Drug|Placebo/Daxdilimab|Placebo/Daxdilimab will be administered subcutaneously as two injections for each dose.
75658222|NCT05591222|Drug|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
75658223|NCT05591222|Drug|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
75945974|NCT03390387|Drug|Standard consolidation therapy|Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)
75945975|NCT03146000|Drug|lidocaine-prilocaine cream|topical cream
75945976|NCT03146000|Drug|meloxicam rectal suppository|suppository
75945977|NCT02343146|Behavioral|Type One Training (TOT)|The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
75945978|NCT03155438|Diagnostic Test|Oxidative stress-related gene expression (RNA expression)|Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
75346743|NCT01721174|Procedure|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
75346744|NCT01726868|Device|Liposorber LA-15 System|Six sessions of blood purification treatment with Liposorber LA-15 System.
75658224|NCT05579132|Drug|CN201|The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 7 cycles of maintenance treatment. During the Treatment Period, subjects will receive CN201 by intravenous (IV) infusion once every week (QW), 4 weeks per treatment cycle. The subjects will receive 2 cycles of CN201 for induction. After induction treatment, the drug is discontinued for 2 weeks (treatment-free interval) before consolidation therapy is started, and each subsequent treatment cycle (4 weeks/treatment cycle) is followed by a 2-week treatment-free interval. Responders to induction treatment will continue to receive 3 cycles of consolidation treatment, followed by an additional up to 7 cycles of maintenance treatment, or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first.
75805273|NCT05973942|Behavioral|Wingman-Connect|Training occurs in three 2-hr blocks over several days. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work.
75945979|NCT03155438|Diagnostic Test|oocyte competence biomarkers|Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
75945980|NCT03125889|Device|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
75945981|NCT02346188|Dietary Supplement|Ferrous fumarate|Tablet formulated from 30 mg ferrous fumarate.
76093410|NCT03235362|Drug|YHR1705|Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
75658225|NCT05578716|Dietary Supplement|Partially hydrolysed formula|Partially hydrolysed formula
75658226|NCT05575349|Other|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 12 mandala coloring pages given to each participant by the researcher for 6 weeks, 1 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
75945982|NCT02346188|Dietary Supplement|Zinc oxide|Tablet formulated from 30 mg zinc oxide
75658227|NCT05574426|Behavioral|Movement Breaks|Participants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.
75945983|NCT02346188|Dietary Supplement|Placebo|
75945984|NCT05166525|Other|Medically tailored meals|Compare medically tailored meals vs. medically tailored meals with enhanced nutritional counseling vs. usual care
75945985|NCT02477332|Biological|QGE031|
75945986|NCT02477332|Biological|Omalizumab|
75945987|NCT02477332|Other|Placebo|
75945988|NCT02346110|Drug|Bupivacaine-adrenaline|50 mg bupivacaine and 50 μg adrenalin
75945989|NCT02346110|Drug|Dexamethasone|4 mg
75945990|NCT02346110|Other|Sodium chloride|1 mL of sodium chloride solution as placebo
76093411|NCT03235362|Drug|YHR1706|Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
75805274|NCT05973916|Other|Comprehensive intervention|"cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed."
75805275|NCT05973864|Drug|Pembrolizumab injection|On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion
75805276|NCT05973864|Drug|Capecitabine tablets|1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated
75805277|NCT05973864|Radiation|Local radiotherapy|Local radiotherapy will be performed as per standard practice if indicated.
75805278|NCT05973812|Dietary Supplement|Infant formula supplemented with Bifidobacterium breve PS1|Feeding with an infant formula containing 7 log10 cfu of the strain per gram of formula.
75945991|NCT03394599|Device|TheraTrainer + Motiview|TheraTrainer will be used in conjunction with Motiview.
75945992|NCT03394599|Device|TheraTrainer Only|TheraTrainer will be used.
75945993|NCT03390309|Other|Partially Hydrolyzed Formula|Partially Hydrolyzed Whey Protein Infant Formula
75945994|NCT03390309|Other|Normal Formula|Normal Formula
75945995|NCT02348528|Drug|Lenalidomide|
75945996|NCT02348528|Drug|Dexamethasone|
75945997|NCT03394521|Other|Routine clinical practice|This is an observational study
76093412|NCT03235362|Drug|YHR1705+YHR1706|Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
76093413|NCT03234894|Device|SiteSeal Endovascular|to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.
75945998|NCT03390231|Combination Product|Stem Cell Educator therapy|It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
75945999|NCT02345798|Procedure|Standard Follow-Up Care|Undergo usual care
75946000|NCT02345798|Other|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
75946001|NCT02345798|Other|Educational Intervention|Undergo video-assisted intervention
75946002|NCT02345798|Other|Quality-of-Life Assessment|Undergo quality of life assessment
75946003|NCT02345798|Other|Questionnaire Administration|Undergo questionnaire administration
76093414|NCT03234816|Drug|Norepinephrine 0.05 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
76093415|NCT03234816|Drug|Norepinephrine 0.1 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
76093416|NCT03234816|Drug|Norepinephrine 0.15 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
75805279|NCT05973812|Dietary Supplement|Infant formula NOT supplemented with Bifidobacterium breve PS1|Feeding with the same infant formula but without supplementation with the B. breve strain
75805280|NCT05973747|Drug|Calcium Gluconate|2 grams of calcium gluconate, infused intravenously over 10 minutes upon umbilical cord clamping
75658228|NCT05572944|Other|to develop a risk model and assess the lung cancer risk|"Participants will receive the following things in sequence~Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~Check pulmonary function test.~In high risk group,arrange chest CT and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
75658229|NCT05572177|Device|Asthma SMART|The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.
75658230|NCT05571397|Device|Dexcom G6|Continuous Glucose Monitor
75477000|NCT05081232|Device|MLG (Multi-Layered Perinatal Issue Allograft) Allograft|"MLG allografts contains more than 450 bioactive proteins including growth factors and cytokines known to modulate inflammation and promote tissue healing.~MLG is supplied as sterile sheets having dimensions of 2cm x 2cm and a thickness of approximately 0.8-1.0mm thick.~Participants receiving MLG will have it placed around the neurovascular bundle. Placement of the graft should not take over 5 minutes of time to impact overall surgical time length significantly."
75658231|NCT05570851|Behavioral|Alcohol Cessation Text Messages|Intervention condition will consist of a text message program designed to promote alcohol cessation tailored to HNC patients and targeted to VA or Civilian populations in addition to usual-care-advice.
75658232|NCT05570851|Behavioral|Usual Care|Control condition will consist of a provider-delivered alcohol cessation intervention with usual-care-advice.
75658233|NCT05568225|Drug|Etavopivat|400 mg once daily
75805281|NCT05973747|Drug|Calcium chloride|0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
75658234|NCT05564026|Other|Questionnaire Administration|Questionnaire provide to participant's about their health and quality of life since treatment
75658235|NCT05564026|Other|Tumor Specimen Collection|Tumor DNA requested from the Biopathology Center
75658236|NCT05564026|Other|Germline DNA Samples|Germline DNA specimens requested from the Biopathology Center or newly collected saliva
75658237|NCT05564026|Procedure|Blood Sample Collection|Collection and storing of serum/plasma
75658238|NCT05557487|Diagnostic Test|Low dose computed tomography|"Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and < 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~Check pulmonary function test."
75658239|NCT05554497|Behavioral|Mindfulness-based stress reduction curriculum|Standard 8-week mindfulness-based stress reduction curriculum
75805282|NCT05973721|Biological|phage|The treatment group was given one phage each time, once a day for two weeks
75805283|NCT05973708|Other|Clamshell Exercise|Clamshell Exercise: The clamshell exercise keeps the hips moving, it strengthens both the gluteus medius AND gluteus maximus. The gluteus medius is the main abductor (movement away from the midline of the body) and external rotator of the hip.
75805284|NCT05973708|Other|Frog pump exercise|Frog pump exercise: The frog hip thrust mainly targets the gluteal muscles responsible for thigh extension and abduction. The exercise also works the hamstrings on the back of the thighs which helps in hip extension.
75805285|NCT05973695|Other|clamshell exercise|For clamshell exercises, Lie on your side with your knees slightly bent and with one leg on top of the other. Keep your feet together and lift your top knee until its parallel with your hip. Lower your knee back to the initial position, repeat, and then switch sides. In 1st week 1 sets 10 repetitions. In 2nd week 2 sets of 10 repetitions. In 3rd and 4th week and onwards 3 sets of 10 repetitions
75946004|NCT03390153|Other|semi flexible socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
76093417|NCT03234816|Drug|Bupivacaine|10 mg Bupivacaine intra-thecal for spinal anesthesia
75477001|NCT05077683|Drug|Rivaroxaban 2.5 MG [Xarelto]|Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.
75805286|NCT05973695|Other|Gluteal Bridge exercises|Start flat on your back with your legs bent at a 90-degree angle and feet placed flat on the ground. Make sure your toes are turned outward at 45-degree angles and your knees are facing in the same direction as your toes. Drive d
75477002|NCT05077683|Drug|DAPT strategy|usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
75477003|NCT05076942|Radiation|Radiotherapy combined with cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
75946005|NCT03390153|Other|rigid fiber socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
75658240|NCT05551858|Drug|Proglumide|(CAS: 6620-60-6.)
75805287|NCT05973682|Other|Post-isometric relaxation and Conventional treatment|"The term refers to the effect of subsequent relaxation experienced by a muscle or group of muscles, after brief periods during which an isometric contraction has been performed. Post isometric relaxation technique was applied to levator scapulae for 5 repetition using 20% of maximal isometric contraction for 7-10 sec. with complete relaxation of all element, the stretch is maintained for 30 sec.~+ hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30 second hold. static stretching exercises two sessions per week for 3 weeks were given to each patient"
76093418|NCT03247608|Behavioral|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
75946006|NCT02342756|Device|Targeting transpulmonary pressure to avoid VILI|Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
75946007|NCT02346032|Drug|refametinib|Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
76093419|NCT03247842|Procedure|suprascapular nerve block|Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
76093420|NCT03247452|Other|One-day Low fiber diet|One-day low fiber diet before colonoscopy
75946008|NCT03394443|Behavioral|Semi-structured interviews|"Semi-structured interviews of the parents of preterm infants. 3 weeks after their child has left hospital. They will be made either at the University Hospital of Besançon. They will take place in a dedicated hospital ward to ensure the confidentiality of the statements made between the investigator and the parent.~They will follow a predefined questionnaire. They will be fully recorded on a dictaphone with note taking during the interview by the investigator and will be transcribed in writing anonymously and confidentially on Word.~The content of the interviews will be analyzed:~As a first step, it will be a vertical analysis of the thematization of each interview~Then, in a second step, a transversal analysis between the contents of the different interviews."
75946009|NCT02345954|Procedure|Laparoscopic Supracervical Hysterectomy and Sacropexy|Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
75946010|NCT02345954|Procedure|Laparoscopic Hysteropexy|Laparoscopic hysteropexy
75946011|NCT02348294|Other|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
76093421|NCT03247452|Other|Three-day low fiber diet|Three days low fiber diet before colonoscopy
76093422|NCT03247452|Drug|Polyethylene Glycol plus ascorbic acid|2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
75658241|NCT05551858|Drug|Placebo|Avicel fiber filled capsule taken by mouth three times daily
75658242|NCT05551325|Other|Chronobundle - light|"Bright daytime light from 09:00 to 13:00 starting on day 1. The light will be 10,000 lux at 12 and provide a minimal intensity of 1,250 lux at the angle of the eye (30 to 36 distance). The light has a temperature of 5,000 Kelvin indicating a high blue wavelength content which should maximize circadian effects (validated device Sunbox Lighting, Maryland). Following the 09:00 to 13:00 bright light, the room lights will remain on and the curtains will remain open to maximize daytime light exposure while not decreasing bright light tolerance."
75658243|NCT05551325|Other|chronobundle - feeding|Time restricted (daytime) intermittent feeding will include 4 meals delivered at 09:00, 12:00, 15:00 and 18:00. Each meal will include one-fourth of the recommended daily tube feed volume.
75946012|NCT02342834|Dietary Supplement|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
75946013|NCT02342912|Behavioral|Social Media Treatments|Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
76093423|NCT03237468|Other|Neck strengthening exercise to prevent concussion|Neck strengthening exercise to prevent concussion in student athletes.
76093424|NCT03247140|Drug|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
76093425|NCT03247140|Drug|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
76093426|NCT03237546|Procedure|Anesthetic regimen including SB|Group receiving general anesthesia with the serratus block
76093427|NCT03237546|Procedure|Anesthetic regimen including SB or no block|Group receiving general anesthesia alone
76093428|NCT03234426|Other|Perturbation|Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
75658244|NCT05551325|Other|chronobundle - mobility|Exercise/mobility sessions will occur twice per day between 09:00 and 16:00; intensity will be determined by clinical status and documented in the chart by our physical therapy service.
75946014|NCT02345876|Other|no intervention|
75946015|NCT02342600|Drug|Pazopanib|A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
76093429|NCT03234426|Other|Conventional Physiotherapy Treatment|Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
76093430|NCT03237078|Dietary Supplement|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
76093431|NCT03247296|Drug|Sofosbuvir 400 mg, Daclatasvir, Ribavirin|No intervention made this is an observational study to monitor the already existing protocols of the facility
76093432|NCT03247218|Drug|Memantine Hydrochloride|a low-moderate affinity, uncompetitive, NMDAR antagonist
76093433|NCT03234348|Device|Percutaneous coronary intervention|PCI + stent implantation
75658245|NCT05551325|Other|chronobundle - sleep|Overnight sleep promotion will occur between 22:00 and 06:00 with a more restricted sleep period between 00:00 and 04:00. This will be achieved by rescheduling non-urgent care. There will be no changes to urgent care. Additionally, room lights will be dimmed, curtains drawn, and room doors closed. Television screens will be fitted with blue light-blocking filters.
75658246|NCT05546099|Behavioral|Self-management of BP medications|Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.
75805288|NCT05973682|Other|Conventional Physical Therapy|Conventional Physical Therapy; hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient
75805289|NCT05973643|Other|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (bitemporal) or unilaterally (or fronto-temporal) on the frontotemporal region under anesthesia.~The stimulation dose is determined by titration method, during the first ECT session. An ECT cure corresponding from 12 to 20 sessions of ECT. Patients will receive 2 sessions a week.~Blood samples will be done during the anesthesia process."
76093434|NCT03237624|Device|Functional Chitosan Chewing Gum|Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
76093435|NCT03237624|Device|Control Chewing Gum|Control chewing gum device does not have food additive chitosan in its composition.
75805291|NCT05973617|Diagnostic Test|Measurement of corneal biomechanical properties|Measurement of corneal biomechanics
75805292|NCT05973604|Diagnostic Test|Screening and Confirmatory diagnostic test for primary aldosteronism|Screening for primary aldosteronism will be performed with measurement of aldosterone-to-renin ratio after 2 hours of bed rest. Renin measurement will be performed by estimating plasma renin activity. The screening test will be considered positive when the ratio is >30, accompanied by elevated aldosterone values (>15 ng/ml). Patients with a positive result will undergo further confirmatory testing with intravenous sodium test (administration 2 liters of normal saline N/S 0.9%, over a period of 4 hours, while the patient is supine. Considered positive if aldosterone levels are >5mg/dl at the end of the test). Alternative confirmatory methods are captopril test (Administration of 50 mg of captopril. Considered positive when aldosterone levels are >8.5 mg/dl 2 hours after the intake) or hydrocortisone test (Administration of 0.1mg of hydrocortisone 4 times a day for a period of 4 days. Considered positive if elevated aldosterone levels (>6ng/dl) are found at the end of the test).
75805293|NCT05973578|Radiation|Stereotactic radiotherapy|Single-session high dose stereotactic radiotherapy
75658247|NCT05546099|Behavioral|Self-monitoring of home BP|Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.
75658248|NCT05545215|Device|Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
75658249|NCT05545020|Drug|Trivalent chromium versus synthetic and/ or biological DMARDs|Supplement and immunesuppressants
75946016|NCT02342600|Drug|Trametinib|A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
75946017|NCT03147638|Drug|Warfarin, NOAC|duration of treatment
75946018|NCT03147716|Other|Enrollment Flyer|Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
75946019|NCT03147716|Other|Testimonial Booklet|Booklet that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare, as well as an enrollment form.
76093436|NCT03237624|Behavioral|Oral hygiene measures|Patients will be given instructions on how to brush and floss routinely (twice per day)
76093437|NCT03234660|Drug|Dexmedetomidine Hydrochloride|dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
76093438|NCT03234660|Other|control|0.9% normal saline continuous infusion
76093439|NCT04485780|Biological|botulinum toxin type A|In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.
76093440|NCT00059475|Drug|Glycoprotein 100 (GP100): 209-217 (210M)|
76093441|NCT00059475|Drug|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
76093442|NCT00059475|Drug|Montanide ISA 51|
76093443|NCT00059475|Drug|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
76093444|NCT00059475|Drug|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
76093445|NCT00059475|Drug|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
76093446|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
76093447|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
75658250|NCT05544201|Device|High-definition transcranial current stimulation|High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
75805294|NCT05973552|Other|CO-rebreathing|In the CO-rebreathing method, a dedicated apparatus is used for inhaling and rebreathing a very small bolus of CO through a spirometer for ~2 min, which is absorbed through the lungs and binds to Hb, and then the increase of HbCO content of blood is measured 8 min after the CO inhalation. The increase of COHb in blood samples can then be used to precisely calculate Hb mass and blood volume
75805295|NCT05973552|Other|Oral iron isotope administration (54Fe)|Participants randomly assigned to the sub-group, will receive 54Fe with a test meal in the second and third trimester for assessment of dietary iron absorption
75946020|NCT03147716|Other|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended that the parent attend. The teacher also gave the parent a brochure that gave information about the Triple P program and an enrollment form.
75805296|NCT05973552|Other|Intravenous iron isotope administration (58Fe)|Participants randomly assigned to the sub-group, will receive intravenous 58Fe in the second and third trimester for assessment of erythrocyte iron incorporation
75805297|NCT05973526|Procedure|Percutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using needles.
75946021|NCT03147716|Other|Provider Engagement Call|This was a manualized, 15-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent anticipate and problem solve possible barriers to attendance.
75946022|NCT02477020|Drug|TAK-063 20 mg|TAK-063 tablet.
75946023|NCT02477020|Drug|Placebo|TAK-063 matching-placebo tablet.
75946024|NCT03147794|Device|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
75946025|NCT02342522|Device|Remote ischemic conditioning|An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total.
76093448|NCT02453802|Drug|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
76093449|NCT02453802|Drug|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
75658251|NCT05536895|Diagnostic Test|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
75658252|NCT05536895|Diagnostic Test|Multi-detector Computed Tomography|Conventional, standard of care perfusion imaging for AIS
75946026|NCT02342522|Device|Control|An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
75946027|NCT02342366|Drug|GHB 35 mg/kg p.o.|GHB 35 mg/kg p.o.
75946028|NCT02342366|Drug|GHB 20 mg/kg p.o.|GHB 20 mg/kg p.o.
75946029|NCT02337296|Behavioral|ADHERE|"ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence."
76093450|NCT02453802|Drug|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
75658253|NCT05531201|Procedure|collaboration general practitioner and physiotherapist|training general practitioner and physiotherapist
75658254|NCT05511922|Drug|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
75658255|NCT05506254|Drug|hLB-001|hLB-001 gene therapy
75805298|NCT05973526|Procedure|Transcutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using the surface electrodos.
75946030|NCT02862535|Drug|Andecaliximab|Administered via intravenous (IV) infusion (approximately 30 minutes)
75946031|NCT02862535|Drug|S-1|Administered orally
75946032|NCT02862535|Drug|Cisplatin|Administered via IV infusion on Day 8 of every 5 weeks
76093451|NCT00060333|Radiation|radiation therapy|
76093452|NCT03234270|Device|Core temperature measurements|Core temperature measurements with coretemp pill
76093453|NCT03234192|Procedure|Therapeutic ultra sound|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.
75477004|NCT05076942|Drug|Cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
75946033|NCT02862535|Drug|Oxaliplatin|Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
75805299|NCT05973266|Behavioral|Mobile Application-Based Bowel Preparation Training|The contents of the training in the mobile application where the patients receive bowel preparation training before the procedure are; short videos, images and slides about colonoscopy, bowel preparation drugs, liquid-clear diet and foods recommendations.A mobile application-based training will be provided to guide patients, where user (patient) usage activities are monitored by the researcher, sending notifications or reminders to the patient in accordance with the colonoscopy procedure date.
75805300|NCT05972343|Device|Cryoablation|Takes place at single time point.
75946034|NCT02862535|Drug|Nivolumab|Administered via IV infusion (approximately 60 minutes) every 2 weeks
75805301|NCT05972148|Other|Digital scanning|Five intraoral scans, one for each arch before the insertion of scanbodies, were obtained. The implant locations were then marked, and the software trimmed a 6mm diameter circular section of the scan from the implant locations to allow the scanbodies to be added. Abutment-level polyetheretherketone (PEEK) scanbodies were hand-tightened onto each implant and not moved for the remainder of the scans. Scanbodies were scanned using a circular scan path, and scanning was finalized.
76093454|NCT03234192|Procedure|Astym Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.
75946035|NCT02345564|Device|implantation of MaioRegen fleece into osteochondral lesion|arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
75946036|NCT02342210|Behavioral|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
76093455|NCT03234192|Procedure|Graston Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
76093456|NCT04770987|Other|lateral neck flexor endurance test|Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.
76093457|NCT04486872|Biological|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells injection. Within 3 to 5 days after the pretreatment, the subjects received a single A-02 reinfusion, the infusion dose of each group of subjects 1.00 × 10^6/kg, 3.00 × 10^6/kg or 5.00 × 10^6/kg (if applicable), it is recommended to complete the infusion within 30 min after cell recovery.
76093458|NCT04770597|Device|Aranet4 Home CO2 monitor|The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.
76093459|NCT03237000|Drug|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
76093460|NCT02028676|Other|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
75658256|NCT05505916|Drug|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
75658257|NCT05497427|Device|BrainCheck Assessment|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
75658258|NCT05494658|Dietary Supplement|BCAA|600ml drink which contains 18g BCAA was consumed by patients 2-4h before surgery.
75805302|NCT05972148|Other|Photogrammetry|Rectangular-shaped titanium photogrammetry scanbodies were hand-tightened onto the Implants. Scanbodies were not moved before completing all scans for each arch. A total of five scans of each arch were obtained using a photogrammetry device. Measurements were successfully recorded by turning them green on the computer screen.
75658259|NCT05494658|Dietary Supplement|water|600ml water was consumed by patients 2-4h before suegery.
75658260|NCT05490381|Other|Iodixanol|Given via injection
75658261|NCT05490381|Procedure|Angiogram|Undergo diagnostic cerebral angiogram
75658262|NCT05490381|Procedure|Arterial Embolization|Undergo tumor vessel embolization
75658263|NCT05490381|Drug|Polyvinyl Alcohol|Given via catheter
75658264|NCT05490381|Drug|Ethiodized Oil|Given via catheter
75658265|NCT05490381|Procedure|Computed Tomography|Undergo head and neck CT scans
75658266|NCT05490381|Other|Chart Abstraction|Ancillary studies
75946037|NCT02033707|Drug|Hallucinogens and psychoactive substances|"One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects."
75946038|NCT02448706|Device|Hearing Aid Fitting A|
75946039|NCT02448706|Device|Hearing Aid Fitting B|
75946040|NCT02337140|Device|Pacemaker SORIN Group KORA DR|
75805303|NCT05971927|Behavioral|Simulation education|Randomly assigned experimental group students performed eight different vaginal examination scenarios in the laboratory on the fetal monitoring and labor progress model set for cervical dilatation, cervical effacement, presenting fetal part, presence of amniotic membrane and fetal descent. The researchers repeated the vaginal examination scenario and informed the students about the evaluation results after each student had performed the vaginal examination scenario prepared by the researchers. This process continued until the experimental group students completed eight different vaginal examination scenarios.
75805304|NCT05971797|Behavioral|REBT|During REBT in patients with osteoarthritis and concomitant diseases with diagnosed depression or anxiety before arthroplasty the patients learn how to manage their irrational or unhealthy emotions, thoughts, and behaviors.
75946041|NCT02337140|Procedure|transcatheter aortic valve implantation (TAVI)|
75946042|NCT02039336|Drug|Dacomitinib|
75946043|NCT02039336|Drug|PD-0325901|
75805305|NCT05971667|Drug|tadalafil|tadalafil 10 mg one tablet daily
75946044|NCT02039336|Drug|Docetaxel|
76093461|NCT02028676|Other|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
75346745|NCT03408938|Device|of Masimo Radical-7¿ Pulse CO-Oximeter|"The Masimo pulse oximetry model:~The pulse oximetry model which Masimo developed accounts for saturation values contributed by the true arterial signal, and by one or more motion or noise signals. lt is assumed that under conditions of motion, the detected IR and RD signals comprise both the true arterial saturation signal and a venous (or non-arterial) motion noise signal. Masimo uses a highly sophisticated adaptive filter with, Discrete saturation transform (DST) four other parallel engines, to leverage each algorithm's unique strengths to ensure accurate readings through all patient conditions. Masimo SET's most powerful algorithm is Signal extraction technology (SET). All algorithms depend upon assumptions. The more assumptions, the weaker the algorithm. DST makes only one assumption -that arterial blood has a higher oxygenation than venous - making it the most powerful pulse oximetry algorithm"
75805306|NCT05971667|Drug|Sildenafil|sildenafil 20 mg two tablets daily
75346746|NCT01363908|Drug|SPD602|
75346747|NCT00915590|Drug|Placebo|Custom eye drop eye three times a day in both eyes for a period of 6 weeks
75346748|NCT00915590|Drug|IL-1Ra|5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
75346749|NCT03408782|Procedure|Insertion of drainage|
75658267|NCT05488080|Behavioral|Department-level audit and feedback and electronic health record-embedded clinical decision support|This intervention will provide clinicians with Equity Report Cards and clinician decision support on mitigating disparities in quality of care.
75658268|NCT05487924|Other|SVV-GDHT|GDHT guided by SVV using Flotra/Vigileo monitor
75658269|NCT05487924|Other|O2ER-GDHT|GDHT guided by O2ER
75805307|NCT05971667|Drug|pentoxifylline|pentoxifylline 400 mg two tabs daily
75346750|NCT01570829|Drug|Dietressa|Oral administration.
75658270|NCT05487924|Other|conventional care|conventional fluid therapy without GDHT
75346751|NCT01570829|Drug|Placebo|Oral administration.
75658271|NCT05481736|Drug|Psilocybin|COMP360 Psilocybin administered under supportive conditions
75658272|NCT05481489|Drug|Atropine Sulfate|Atropine Sulfate 0.05% Ophthalmic Solution
75658273|NCT05479890|Other|ClientBot|ClientBot is an AI-based simulated client that supports skills improvement for providers learning and using Motivational Interviewing
75946045|NCT02342054|Radiation|MRI-TRUS fusion guided Single Frac HDR|
75946046|NCT02341898|Other|Educational programme for all nurses|
75346752|NCT01721642|Device|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
75477005|NCT05062460|Other|1 hour Blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 1-hour postprandial blood glucose monitoring.
75946047|NCT02341898|Other|Training and structured support for nominated key nurses|
75946048|NCT02341898|Other|Facultative train-the-trainer module for key nurses|
75946049|NCT02341898|Other|Printed study material|
75946050|NCT02341898|Other|Supportive material (poster, mugs etc.)|
75946051|NCT05255042|Other|organ and tissue sample collection only|Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
75946052|NCT02345096|Dietary Supplement|Saccharomyces cerevisiae|
75946053|NCT02345096|Dietary Supplement|Placebo|
75946054|NCT02345174|Drug|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
75946055|NCT02345174|Drug|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
75946056|NCT04935476|Drug|Dapsone 85 mg PO BID|Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
75946057|NCT04935476|Drug|Placebo 85 mg PO BID|Placebo oral tablet, twice daily for 21 days.
75946058|NCT04891016|Drug|delayed toripalimab|chemotherapy plus toripalimab and toripalimab was delayed on day 3. If the pCR was not achieved after surgery, then the patients received five cycles of FLOT plus toripalimab every two weeks, then toripalimab maintenance until one year. If pCR was achieved, then then the patients received two cycles of original regimen and then toripalimab maintenance until one year.
75946059|NCT04891016|Drug|control|chemotherapy and toripalimab were given on same day. If the pCR was not achieved after surgery, then the patients received four cycles of FLOT plus toripalimab every two weeks, then toripalimab maintenance until one year. If pCR was achieved, then then the patients received two cycles of original regimen and then toripalimab maintenance until one year.
75946060|NCT02868281|Drug|ACT guided Routine Treatment|The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.
75946061|NCT02868281|Drug|Routine Treatment|Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
75946062|NCT02476006|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
75946063|NCT02476006|Drug|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
75946064|NCT02476006|Drug|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
75946065|NCT02476006|Drug|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
75946066|NCT02476006|Drug|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
75946067|NCT02476006|Drug|simvastatin|Pharmaceutical form:tablet Route of administration: oral
75946068|NCT02344940|Drug|Toremifene|patients will take toremifene 60 mg qd.
75946069|NCT02344940|Drug|Tamoxifen|patients will take tamoxifen 10 mg bid.
75346753|NCT03408626|Drug|Papain-based Chemo-mechanical caries removal agent|Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.
75346754|NCT03408626|Device|conventional rotary|traditional rotary method
75346755|NCT01721798|Device|Mirena levonorgestrel IUD|Intrauterine contraception system
75346756|NCT01721798|Device|Copper T-380a IUD|intrauterine contraception system
75672411|NCT04246385|Behavioral|CO-OP Group|"Participants in the intervention group will attend one 1:1 session where one goal will be selected from their COPM results to focus on during the group, group expectations will be reviewed, caregivers will be invited, and questions answered. The group will run six sessions as supported by the literature (Chan, 2007; Lee, Fischer, Zera, Robertson, & Hammel 2017).~Day Rehab CO-OP Group Curriculum Session Content~Introduction One on one session. COPM, introduction to group, education for caregiver. Session 1 Introduction to group and CO-OP approach, homework. Session 2 Review CO-OP approach, practice, homework. Session 3 Review CO-OP approach, plan outing, homework. Session 4 Review CO-OP approach, experiential learning according to participants' alternate COPM goals, homework. Session 5 Review CO-OP approach, outing, homework. Session 6 Review CO-OP approach, focus group, lessons learned, final COPM, homework"
75946070|NCT02341976|Other|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
75946071|NCT03615677|Drug|LXI-15028 50mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
75946072|NCT03615677|Drug|Esomeprazole 40mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
75946073|NCT03615443|Diagnostic Test|Guardant360|Guardant360 is a comprehensive, non-invasive tumor sequencing test.
75946074|NCT02344862|Drug|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
75946075|NCT02344862|Drug|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
75946076|NCT02344862|Drug|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
75946077|NCT02344862|Drug|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
75946078|NCT03614429|Drug|Chlorhexidine gel will be prepared according to an international product Instillagel®|"Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not."
75946079|NCT03111836|Behavioral|Control Group|Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.
75946080|NCT03111836|Behavioral|Expert-Driven Group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
76093462|NCT02028676|Drug|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
75346757|NCT01471457|Drug|Trimo-San gel|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
75946081|NCT03111836|Behavioral|User-driven group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
75946082|NCT03614117|Dietary Supplement|Lactobacillus salivarius PS7 during 6 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
75946083|NCT03614117|Dietary Supplement|Lactobacillus salivarius PS7 during 3 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
75805308|NCT05970939|Other|Development of the Telerehabilitation Usability Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Usability Questionnaire in patients with MS.
75672412|NCT00147992|Procedure|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
75805309|NCT05970770|Device|Hypotension Prediction Index|in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA; internal memory 60 gigabyte, 10 gigabyte used for operating system) with ClearSight non-invasive hemodynamic monitoring and with the Hypotension Prediction Index software enabled. They will not receive preventive vasopressors but only norepinephrine boluses if Hypotension Prediction Index >85
75805310|NCT05970770|Drug|Norepinephrine|Patients in the HPI group will receive a norepinephrine bolus when HPI is below 85
75946084|NCT03614117|Dietary Supplement|placebo|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.
75946085|NCT02341742|Device|multiple examinations|biological,clinical, X-ray, DXA, accelerometry assessment
75346758|NCT03408548|Procedure|Scaling root planning|Periodontal treatment
75946086|NCT03614351|Dietary Supplement|Protein (PROT)|Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.
75946087|NCT03614351|Other|Control (CONT)|Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
75946088|NCT02475850|Other|Evidence-based tailored fall prevention|
75946089|NCT02475850|Other|Usual care|
75946090|NCT03614273|Drug|Hypertonic saline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
75946091|NCT03614273|Drug|Adrenaline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
75346759|NCT03408548|Dietary Supplement|Probiotic|two lozenge per day containing Bifidobacterium animalis lactis HN019
75346760|NCT03408548|Other|Placebo|two lozenge per day not containing Bifidobacterium animalis lactis HN019
75346761|NCT02497404|Drug|5-Azacytidine|"Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,~-8 and -7. This will be administered on an outpatient basis if possible."
75672413|NCT02651142|Procedure|Patients receive SLNB|Patients receive sentinel lymph node biopsy
75805311|NCT05970510|Drug|Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg|orally once a day
75346762|NCT02497404|Drug|Fludarabine|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fludarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
75805312|NCT05970510|Drug|Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg|orally once a day
75805313|NCT05970510|Drug|placebo|orally once a day
75805314|NCT05969964|Behavioral|Avoid second resection after initial complete resection|Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins won't undergo second look as endorsed by the guidelines.
75805315|NCT05969262|Diagnostic Test|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
75805316|NCT05968677|Dietary Supplement|FSMP|Food for Special Medical Purposes specifically formulated for the dietary management of malnourished patients following therapeutic treatments such as chemo and radiotherapy
75946092|NCT02341430|Device|Symbotex™ Composite Mesh|Repair of a Grade I or II ventral hernia according to VHWG classification system with Symbotex™ Composite Mesh
75946093|NCT02032121|Procedure|Blood specimen|
75946094|NCT02032121|Procedure|Echocardiography|
76093463|NCT02028676|Drug|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
75946095|NCT02336984|Biological|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
75658274|NCT05474742|Other|The Nori Health app|The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention.
75805317|NCT05968677|Other|Nutritional counseling|Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled
75946096|NCT02336984|Drug|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
75946097|NCT02336984|Drug|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
75946098|NCT03613805|Device|Dexcom G5-Eversense|Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered
75946099|NCT03613805|Device|Eversense-Dexcom G5|"Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously"
75946100|NCT03145610|Other|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
75946101|NCT03145610|Other|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
75946102|NCT03145922|Other|Observational Study|Observational study utilizing bronchoscopy, and imaging
75946103|NCT02341586|Other|Lucky Iron Fish - home fortification system|The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
75946104|NCT02341586|Dietary Supplement|18 mg elemental iron|This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
75946105|NCT02341586|Other|Nutrition Education|This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
75946106|NCT02336906|Drug|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
75946107|NCT02336906|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
75805318|NCT05968417|Other|Observational study - sample collection only.|No intervention - blood and/or bone marrow sample collection only
75805319|NCT05968365|Device|electronic Vision-aid Device|Electronic blind aid is a non-invasive electronic aid product for the visually impaired. The product converts visual signals into tactile signals. The Vision Pro is designed for people with poor or no visual perception. The product does not change the previous travel mode of the visually impaired, and provides additional external information for the visually impaired on the basis of their existing cognition. The product can provide the visually impaired person with additional external information based on the cognition in front of them. The product can feedback the environmental information within 2.52.5 meters in front of the visually impaired person in the form of electrical stimulation to the visually impaired person. The visually impaired person can be stimulated by the tongue current to help them identify obstacles and give early warning. Avoid obstacles and give early warning.
75805320|NCT05965843|Other|underling disease|"Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.~For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.~More efforts shoud be make to explore the association between underlying diseases and severe COVID-19."
75805321|NCT05965271|Device|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
75805322|NCT05965063|Dietary Supplement|Bifidobacterium M-16V|Bifidobacterium M-16V was dosed at 10 billion colony forming unit (CFU) (equal to 6 drops)/day for 12 weeks.
75805323|NCT05965063|Other|allergy food avoidance|strict avoidance of the specific allergenic food
75805324|NCT05964205|Other|Electronic clinical decision support tool|Electronic clinical decision support tool
75946108|NCT02336906|Behavioral|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
75346763|NCT02497404|Drug|Melphalan|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
75346764|NCT02497404|Drug|Alemtuzumab|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 30 mg subcutaneously on Days -4 and -2 for unrelated donors, and Day -2 for related donors.
75346765|NCT02497404|Radiation|Total Body Irradiation|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Total Body Irradiation (TBI) will be given at 2 doses of 200 cGy each on one day of the conditioning regimen (between days -6 and -3).
76093464|NCT02028676|Drug|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
75346766|NCT03408470|Drug|TD-1473 oral capsule|(Intervention description included in arm description)
75946109|NCT03614039|Dietary Supplement|"Symbiter Forte"|"Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)"
75346767|NCT03408470|Drug|[14C]-TD-1473 IV bolus|(Intervention description included in arm description)
75658275|NCT05473663|Device|Radiofrequency Ablation|Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.
75658276|NCT05473663|Device|Sham|Is performed identically to the active treatment but without the application of the RFA current
75658277|NCT05471856|Drug|BI 1703880|BI 1703880
75658278|NCT05471856|Drug|Ezabenlimab|Ezabenlimab
75805325|NCT05963555|Device|NovoThor|Following the baseline block (first four weeks), participants will use the NovoThor device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
75805326|NCT05963555|Device|VieLight|Following the baseline block (first four weeks), participants will use the VieLight device 2-3 times per week for 20 minute sessions and may be completed at home.
75805327|NCT05963555|Device|ZeroBody|Following the baseline block (first four weeks), participants will use the Zerobody device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
75805328|NCT05957731|Other|Routine physical therapy|Both groups received routine physical therapy, which encompasses various components such as electrotherapy, strength training for both lower and upper limbs, gait training, and occupational therapy.
75946110|NCT03614039|Dietary Supplement|Placebo|
75946111|NCT02341508|Biological|0.5 mg/kg Lpathomab|
75946112|NCT02341508|Biological|1.0 mg/kg Lpathomab|
75946113|NCT02341508|Biological|3.0 mg/kg Lpathomab|
75946114|NCT02341508|Biological|10 mg/kg Lpathomab|
75946115|NCT02341508|Biological|20 mg/kg Lpathomab|
75946116|NCT02341508|Other|Saline solution for intravenous infusion|
75946117|NCT03613961|Drug|Anesthetics|The ANS plays an important role in the regulation of hemodynamics during anesthesia. Manually blous of propofol during induction anesthesia is reported to reduce both sympathetic and parasympathetic tone; however, it is not clear whether the changes in heart rate variability are associated with propofol concentration. We will observe the relationship of anesthetics and HRV dynamics.
75946118|NCT03613571|Drug|ILB|The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
75946119|NCT02341352|Drug|fluoride varnish|Sodium fluoride 50mg/ml
75346768|NCT03408470|Drug|[14C]-TD-1473 Oral Capsule|(Intervention description included in arm description)
75346769|NCT01573169|Drug|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
75346770|NCT01573169|Other|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
75346771|NCT01727492|Drug|Antioxidantia|
75346772|NCT05522309|Drug|ET0111|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0111 administered, once daily (QD).
75477006|NCT05062460|Other|2 hour blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 2 hour post prandial blood glucose monitoring
75658279|NCT05471830|Drug|Apixaban|No drug will be provided to participants. Patients follow routine clinical practice/administration.
75658280|NCT05470868|Drug|Naphazoline / Hypromellose Ophthalmic|Naphazoline 0.03% / Hypromellose 0.2%
75658281|NCT05470322|Device|Er: YAG laser|Patients will be treated with laser for their HS scarring.
75658282|NCT05465941|Procedure|Biopsy|Undergo biopsy
75658283|NCT05465941|Drug|Pegylated SN-38 Conjugate PLX038|Given IV
75658284|NCT05465941|Procedure|Computed Tomography|Undergo CT
75658285|NCT05465941|Procedure|Biospecimen Collection|Undergo blood and stool sample collection
75805329|NCT05957731|Other|antagonist contract relax|antagonist contraction i used to improve spasticity and range of motion in stroke patients
75805330|NCT05957731|Other|agonist contract relax|agonist contraction is used to improve spasticity and range of motion in stroke patients
75946120|NCT02341352|Biological|Immunoglobulin Yolk|anti-Streptococcus mutans IgY
75946121|NCT02341352|Dietary Supplement|Probiotics|2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
75946122|NCT03613883|Procedure|Endovascular management|"Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure"
75946123|NCT02344550|Drug|Everolimus(afinitor)|Everolimus 10mg p.o. daily
76093465|NCT02028676|Drug|Once-daily ABC+3TC|
76093466|NCT02028676|Drug|Twice-daily ABC+3TC|
76093467|NCT02028676|Drug|Continued cotrimoxazole prophylaxis|
76093468|NCT02028676|Other|Stopped cotrimoxazole prophylaxis|
75658286|NCT05460611|Device|Sciton HALO 1470nm Non-ablative laser|Patients will be treated with the 1470nm non-ablative laser.
75658287|NCT05458011|Drug|Fremanezumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
75658288|NCT05458011|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
75946124|NCT02344550|Drug|Letrozole|Letrozole 2.5 mg p.o. daily
75805331|NCT05956496|Other|Allograft Material ADM-S|A piece of the allograft material (ADM-D) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
75805332|NCT05956496|Other|Allograft Material ADM-D|A piece of the allograft material (ADM-S) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
75946125|NCT02344550|Drug|Leuprolide(Lorelin Depot)|Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
75946126|NCT02419612|Drug|Saxagliptin|
75946127|NCT02419612|Drug|Dapagliflozin|
75946128|NCT02419612|Drug|Glimepiride|
75946129|NCT02419612|Other|Placebo|
75946130|NCT03612947|Drug|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4
75946131|NCT03612947|Drug|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
75946132|NCT02341196|Procedure|CEA|Patients in both groups received an intra-operative angiography
75805333|NCT05953766|Drug|Ropivacaine injection|Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml
75805334|NCT05953766|Drug|Normal saline injection|Sham block using 20 mL of normal saline
75805335|NCT05951400|Drug|Dydrogesterone Tablets|used for pituitary suppression in ICSI cycle
76093469|NCT03233958|Behavioral|Systemic / family constellation|Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation [Hunger, Weinhold, Bornhäuser, Link, & Schweitzer, 2015].
76093470|NCT03247062|Other|Quality improvement - sleep bundle|implementation of a sleep bundle
76093471|NCT03236844|Drug|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
75346773|NCT01727570|Dietary Supplement|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
75346774|NCT03001895|Drug|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
75346775|NCT01727648|Behavioral|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
75477007|NCT05061719|Drug|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
75805336|NCT05951400|Drug|Cetrorelix|GnRH antagonist for pituitary suppression
75658289|NCT05454293|Other|One Talk at a Time: Race|This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.
75658290|NCT05454293|Other|One Talk at a Time: General|This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
75658291|NCT05451628|Device|Default CI fitting|Programming of cochlear implant speech processor according to standard clinical care
75658292|NCT05451628|Device|Anatomy-based CI fitting|Programming of cochlear implant speech processor with anatomy-based fitting
75805337|NCT05944939|Procedure|Surgical extraction of impacted third molar|After surgical extraction of mandibular impacted teeth concentrated growth factor placed in socket closure done with help of silk 3.0 suture
75805338|NCT05939609|Other|Ballistic Stretching Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
75946133|NCT03613415|Other|Expansion|non invasive technique to increase thickness of thin ridge
75946134|NCT02344784|Device|SR-HLAB EMG|Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
75946135|NCT02344784|Drug|Methylphenidate|The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
75946136|NCT03613337|Other|clinical restenosis|The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
75946137|NCT04913350|Other|Russian current|One of the preferred common neuromuscular electrical stimulation techniques for muscle strengthening is the Russian current (RC) It stimulates almost all muscle motor units to contract synchronously, resulting in a greater muscle hypertrophy.
75946138|NCT04913350|Device|elbow support|tennis elbow brace is recommended to decrease pain and improve function by restricting the movement of the forearm or relieving loads on the origin of the muscles of the extensor
75946139|NCT02447848|Drug|sufentanil sublingual 30 mcg tablet|
75946140|NCT02336516|Drug|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
75946141|NCT02336516|Drug|Placebo (glucose solution 10%)|
75946142|NCT02344706|Device|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
75658293|NCT05451303|Device|OralViome Cancer Testing System|The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
75658294|NCT05440864|Drug|Tremelimumab|Pre-operatively Tremelimumab will be administered first for 1 hour; the Durvalumab infusion (1hr) will start approximately 1 hour (maximum 2 hours) after the end of the Tremelimumab infusion. Post-operatively patients will receive Durvalumab Q4W to complete up to 12 months of treatment or a maximum of 11 cycles of adjuvant Durvalumab
75946143|NCT02039258|Drug|CANA/MET XR FDC|Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
75946144|NCT03145454|Device|electroencephalography helmet|electroencephalography helmet with twelve electrodes will be performed during surgical gesture to determine the pain of child.
75946145|NCT03145454|Device|dermal electrode|dermal electrode on the back of the hand will be performed during surgical gesture to determine the pain of child.
75946146|NCT03145454|Device|blood pressure sensors|blood pressure sensors on the finger will be performed during surgical gesture to determine the pain of child.
75946147|NCT03145454|Device|Pupillometry glasses|Pupillometry glasses will be performed during surgical gesture to determine the pain of child.
76093472|NCT03233880|Drug|Azithromycin 1gm|Azithromicin 1 gm oral single dose
75805339|NCT05939609|Other|Extender Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
75805340|NCT05939609|Other|Kinesiotaping|It will be applied 4 times a week for 6 weeks and before starting on-water training.
75805341|NCT05928325|Other|Comprehensive Geriatric Assessment|Complete geriatric assessments
75805342|NCT05928325|Behavioral|Health Education|Receive survivorship care education
75805343|NCT05928325|Other|Medical Device Usage and Evaluation|Wear activity tracking device
75805344|NCT05928325|Other|Supportive Care|Receive geriatric assessment-guided interventions
75805345|NCT05886452|Device|DT1fA contact lenses|Subjects will be fitted with DT1fA contact lenses
75946148|NCT03145454|Device|Holter|Three electrodes electrocardiography on the chest will be performed during surgical gesture to determine the heart rate variability.
75946149|NCT03145376|Diagnostic Test|geriatric assessment|"Clinical evaluation and geriatric assessment with:~CIRS: CIRS (Cumulative Illness Rating Scale)~ADL (Activities of Daily Living);~IADL (InstrumentalActivities of Daily Living);~Mini Nutritional Assessment;~Evaluation of quality of life (Short Form 36, SF-36).~Making a traditional 12-lead ECG.~A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~transthoracic echocardiogram."
75946150|NCT02344394|Device|Medtronic Cryoballoon|For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
75946151|NCT02344394|Device|Thermocool Catheter|For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
75946152|NCT02344394|Device|nContact|For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
76093473|NCT03233880|Other|PLACEBO|placebo
76093474|NCT03236766|Other|Citizens' panels|This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches. Therefore, there are no study arms to list.
75658295|NCT05440422|Drug|anifrolumab|This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.
75658296|NCT05440422|Other|Placebo|non-active substance comprised of 25 mM histidine/histidine-HCl, 50 mM lysine-HCl, 130 mM trehalose, and 0.05% (w/v) polysorbate 80, with a pH of 5.9.
75805346|NCT05885828|Other|White bread|After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
75805347|NCT05885828|Other|Whole wheat bread|After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
75805348|NCT05885828|Behavioral|Plant-based diet|After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.
75805349|NCT05885828|Other|Conventional diabetic diet|Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.
75805350|NCT05885828|Other|Follow-up visit every 1-2 years|Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.
75805351|NCT05874115|Other|liquid biopsy|liquid biopsy
76093475|NCT04485936|Device|Epitomee Device|medical Device designed to enhance the feeling of early satiation and prolonged satiety
76093476|NCT03246984|Device|VasQ|VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
76093477|NCT00061893|Drug|celecoxib|Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. [Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.] .
75346776|NCT01727648|Behavioral|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
75946153|NCT02342132|Device|Non-invasive bipap ventilator|The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
75477008|NCT05060211|Other|Vancouver symptom score for dysfunctional elimination syndroms|Validated questionnaire concerning bladder and bowel symptoms
75946154|NCT02342132|Device|Mechanical insufflator-exsufflator|A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
76093478|NCT00061893|Drug|cyclophosphamide|Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
76093479|NCT00061893|Drug|doxorubicin hydrochloride|Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
75946155|NCT02342132|Device|High frequency percussive oscillator|A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
75946156|NCT02344160|Other|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
76093480|NCT00061893|Drug|etoposide|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
76093481|NCT00061893|Drug|ifosfamide|Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
76093482|NCT00061893|Drug|vinblastine sulfate|Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. [Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.]
76093483|NCT00061893|Drug|vincristine sulfate|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
75805352|NCT05863481|Procedure|Laparoscopic cerclage placement|The surgical method of the laparoscopic cerclage procedure at Aarhus University Hospital previous described in a paper by Riiskjaer et al (DOI: 10.1111/aogs.12001)
75805353|NCT05863182|Behavioral|Juntos Familia Family based intervention|Students and parents will participate in weekly 2.5 hour sessions around topics related to managing experiences with prejudice, discrimination and racism.
75805354|NCT05838586|Behavioral|prolonged SB|4 hours of prolonged SB
75805355|NCT05838586|Behavioral|SB broken 1|4 hours of SB broken up by 5 minutes of self-paced walking every hour
76093484|NCT00061893|Procedure|conventional surgery|Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
76093485|NCT00061893|Radiation|radiation therapy|Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
76093486|NCT00061893|Drug|MESNA|The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
75805356|NCT05838586|Behavioral|SB broken 2|4 hours of SB with one 20-minute bout of self-paced walking
75477009|NCT05060211|Other|Magnetic resonance imaging|Known MRI results of the patient file
75477010|NCT05051761|Drug|Jaktinib|Administered orally.
75477011|NCT05051761|Drug|placebo|Administered orally.
75946157|NCT03115463|Other|Titration of oxygen during neonatal resuscitation|Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
75805357|NCT05837858|Other|whole grain-wheat flour food+standardized meals|whole grain food made by 50 g whole grain wheat flour
75805358|NCT05837858|Other|refined wheat flour food+standardized meals|refined grain food made by 50 g refined wheat flour
76093487|NCT00061893|Drug|Filgrastim|G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
75805359|NCT05837598|Behavioral|Virtual Cancer and Mental Health Tumor Board|The Virtual Cancer and Mental Health Tumor Board intervention aims to increase access to psycho-oncology and oncology expertise, facilitate clinician communication, build understanding of the person's needs and strengths, and address barriers to care. Strategies include a proactive assessment of illness understanding, psychiatric history, and barriers to care followed by development of an integrated cancer and mental health treatment plan during the tumor board session that is framed in terms of patient values and addresses barriers to accessing psycho-oncology and specialty oncology expertise. These recommendations will be shared with treating oncologists, documented in the medical record, and shared with the patient. Patients will receive a transition phone call at 12 weeks.
75805360|NCT05836155|Dietary Supplement|Intervention|multispecies probiotic
75805361|NCT05836038|Behavioral|Visio-Tactile Stimulation|They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
76093488|NCT02452788|Other|Pharmaceutical care|Pharmacist-provided education on medication adherence in hemodialysis patients.
76093489|NCT03236922|Procedure|Pubococcygeus sling|The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.
76093490|NCT03236922|Procedure|Rectus fascia sling|Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
76093491|NCT03233568|Diagnostic Test|Indirect calorimetry|"Indirect calorimetry will be performed by using an open-circuit calorimeter (Sensor Medics, Italy). Indirect calorimetry is the reference method for energy expenditure determination. A canopy hood covered the patient's head and expired air is extracted by a pump to be analyzed by metabolic cart sensors; flow rate is directly measured with a digital turbine flowmeter. After an overnight fast, patients will asked to lay supine in complete physical rest, not sleeping or talking for approximately 20-25 minutes, at a room temperature ranged between 22 and 24°C. The mean REE for each participant considers the last 15-20 minutes of measurements corresponding to steady state.~Software of calorimeter will be set for minute-by-minute reading report of VO2 (Oxygen flow) and VCO2 (Carbon dioxide flow) measurement.~Parameters obtained by Indirect Calorimetry will be the Resting Energy Expenditure and the Respiratory Quotient (RQ)"
75658303|NCT05421624|Device|Digital music therapeutic|The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.
75658304|NCT05421624|Behavioral|Active-Control|The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.
75658305|NCT05417724|Other|Battlefield Acupuncture|Battlefield Acupuncture
75658306|NCT05405491|Other|PCR based strategy|Early adjustment of antimicrobial therapy according to the results of a multiplex PCR-based testing, used in addition to standard microbiological culture of the tracheal aspirate, in immunocompromised patients with suspected VAP or HAP requiring MV
75805362|NCT05831982|Other|Person-centered strength training and nutrition intervention|Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake. Focus on social relations
75805363|NCT05831982|Other|Standard training|Training as usual when discharged with a rehabilitation plan.
75805364|NCT05822050|Drug|Selinexor|XPO1 inhibitor
75805365|NCT05818956|Drug|TAK-227|TAK-227 capsules.
75805366|NCT05813080|Device|"pronia.ai medical device for high risk psychosis prognosis"|In addition to the computer-assisted prognosis of risk for reaching a psychosis, all patients assigned to the active treatment arm will receive additional in-depth clinical diagnostics including neuropsychological testing. Adapted psychological treatment will be offered consisting of 16 to 24 sessions over a period of six months.
75805367|NCT05813080|Other|Treatment-as-usual (TAU)|Referral back to the previous care system. Further treatment is left to the referring primary care providers.
75805368|NCT05808062|Procedure|Root canal obturation|Root canal dryness
75805369|NCT05806788|Behavioral|Binge Eating Syndrome Treatment (BESTOW)|The BESTOW program involves discussions as well as written and behavioral activities. Participants will also be asked to complete activities, or 'homework,' in between sessions that will help to stop binge eating and to improve eating habits.
75805370|NCT05806164|Drug|Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]|The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
75805371|NCT05806164|Drug|OnabotulinumtoxinA 100 UNT [Botox]|OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
75805372|NCT05805761|Procedure|Conventional Treatment|A bicarbonate jet will be used to remove the biofilm from the surface of the teeth.
75946158|NCT02344082|Other|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
75946159|NCT02336126|Behavioral|Biopsychological intervention|
75946160|NCT05254652|Drug|Duloxetine 30mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
76093492|NCT05383833|Dietary Supplement|Creatine Monohydrate|Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening.
75946161|NCT05254652|Drug|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
75946162|NCT04474106|Device|Shock waves|The shockwave generator orthogold 100® generates high-energy acoustic waves that behave much like other sound waves except that they have much greater pressure and energy. As with sound waves, Spark Waves® can easily travel great distance as long as the acoustic impedance stays the same.
75946163|NCT04474106|Device|dummy head|The shockwave generator orthogold 100® will be used in combination with a dummy head, to Refrain shock waves
76093493|NCT02957019|Drug|L19-IL2 - Ph I|Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
76093494|NCT02957019|Drug|L19-IL2 at RD - Ph II|Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
75805373|NCT05805761|Procedure|Antimicrobial Photodynamic Therapy|aPDT will be performed before each cleaning/prophylaxis session, only in one of the groups. Participants will swish with the photosensitizer erythrosine for 1 min of pre-irradiation time, so that the drug can stain all the bacterial biofilm. The D-2000 LED (DMC) will be applied, emitting at a wavelength of ʎ = 430-490 nm and 900-1100 mW/cm2. Irradiation will be performed until the biofilm of the cervical region is illuminated for 2 min per point. Each irradiation point will be approximately 0.4 cm2.
75805374|NCT05803317|Other|usual care : Evaluation of walking on a baropodometric platform|Pure observationnal study
75805375|NCT05795075|Procedure|Computerized Modified Paramedian Approach Technique|Computerized Modified Paramedian Approach Technique ( CMPAT )
76093495|NCT02957019|Drug|Rituximab|Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
75658307|NCT05405491|Other|Standard care|Broad-spectrum antimicrobial therapy adjustment after results of standard microbiological culture of the tracheal aspirate in immunocompromised patients with suspected VAP or HAP requiring MV
76093496|NCT02028754|Drug|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
76093497|NCT02028754|Drug|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
76093498|NCT02028754|Drug|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
75805376|NCT05795075|Procedure|Conventional Midline Approach Technique|Conventional Midline Approach Technique
75805377|NCT05785338|Diagnostic Test|Posterior angle of the hard palate|Fetal ultrasound
76093499|NCT01897389|Drug|Treatment A|1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
76093500|NCT01897389|Drug|Treatment B|1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
76093501|NCT01897389|Drug|Treatment C|1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
75346777|NCT01727648|Behavioral|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
75477012|NCT05051631|Other|Intervention plus 12 months maintenance|The intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.
75658308|NCT05401630|Other|Study Procedures|"All participants will answer a series of questionnaires that address a variety of factors such as patient medical history, family history, medication usage, health behaviors, psychological factors, etc. Questionnaires related to symptoms, psychological factors, depression, anxiety, and quality of life will be taken.~All participants will undergo 123I-MIBG SPECT imaging in the morning in a fasting state. Mental Stress Testing will be conducted in the Laboratory in the morning after fasting for at least 4 hours and withdrawal of all vasoactive medications, caffeine, and tobacco 24-48 hours prior to testing. In addition, participants will undergo 1-week of Home Monitoring using a single-use, noninvasive, water-resistant, 7-day ambulatory ECG monitoring, which offers the advantage of direct access to raw data that can be downloaded from the device after use."
75805378|NCT05783427|Other|liberal hydration|evaluate the effect of 'Sip Til Send' on overall gastric volume pregnant women undergoing elective caesarean delivery
75805379|NCT05782218|Dietary Supplement|Almonds|Participants will receive 2.2 oz (62 g) of almonds to ingest within 15 minutes.
75805380|NCT05782218|Dietary Supplement|Coconut|Participants will receive 1 oz (30 g) of a coconut-chocolate bar and 1.4 oz (40 g) of 100% dried coconut chips to ingest within 15 minutes.
75805381|NCT05773313|Behavioral|The Open Table|An organization that connects community volunteers to individuals in need to help overcome life's challenges.
76093502|NCT01897389|Drug|Treatment D|1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
75805382|NCT05764759|Behavioral|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
75805383|NCT05764759|Behavioral|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
75805384|NCT05746533|Procedure|Hip Arthroscopy|Hip Preservation surgeries
75946164|NCT02343926|Drug|GEMIGLIPTIN LS15-0444|"Pharmaceutical form:tablet~Route of administration: oral"
75946165|NCT02343926|Drug|vildagliptin|"Pharmaceutical form:tablet~Route of administration: oral"
75805385|NCT05726357|Procedure|vital pulp therapy|removal of the coronal pulp followed by placing a biocompatible material to preserve the vitality of the radicular pulp
75805386|NCT05721716|Behavioral|Mindfulness Booster Course|The mindfulness booster course will consist of eight 30-minute sessions, which participants will be asked to commit to. These will be online and occur weekly for 8-weeks. Within these sessions, there will be a 15-minute mindfulness practice followed by a 15-minute discussion. This discussion time will involve reflecting on the mindfulness practice and speaking about between-session practice. Participants will be encouraged to practice mindfulness for home work between the sessions.
75805387|NCT05721716|Behavioral|Usual care|Participants will be encouraged to continue with whatever activities they usually undertake to manage their stress and support their wellbeing.
75805388|NCT05714150|Behavioral|Complex Balance Tasks|The intervention will consist of a single session of practicing complex (cognitively engaging) balance tasks using an exergaming balance platform.
75805389|NCT05713136|Device|Diagnostic Test: Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
75805390|NCT05701540|Drug|Tegoprazan|Tegoprazan 50mg tablet
75805391|NCT05701540|Drug|Esomeprazole|"Esomeprazole 20mg tablet~For patients with ERD: two Esomeprazole 20mg tablets~For patients with NERD: one Esomeprazole 20mg tablet"
75805392|NCT05689593|Other|Low-intensity ESWT Group|ESWT; With the MODUS ESWT system, the patient's shoulder will be in 80° passive abduction, the elbow will be in 90° flexion, and the forearm will be applied to 2 separate parts of the shoulder. The first application will be applied from front to back in the anterior shoulder joint and the upper limit of the treatment will be approximately 1 finger lateral to the coracoid process, the second application will be applied from the lateral scapula to the posterior shoulder joint (0.06 mJ/mm2, 1500 impulses, 1.5 bar).( Modus ESWT® RadialShockwaveTherapy)
75946166|NCT02343926|Drug|metformin|"Pharmaceutical form:tablet~Route of administration: oral"
75946167|NCT02343848|Device|smart bracelet.|Physical activity will be evaluated using smart bracelet.
75946168|NCT03112226|Other|GnRHant + E2|GnRH antagonist with estradiol add-back
75946169|NCT03112226|Other|GnRHant + Placebo|GnRH antagonist with placebo add-back
75946170|NCT02343770|Other|blood sample for identifying biomarkers|
75946171|NCT03612869|Drug|LYS-SAF302|Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
75946172|NCT02343692|Procedure|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
75946173|NCT03618251|Diagnostic Test|specific MRI sequences|MRI with B 2000 of diffusion weighted imaging and the coefficient of apparent diffusion
75346778|NCT01727648|Behavioral|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
75346779|NCT04205994|Drug|Tolcapone 200 MG|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
75346780|NCT04205994|Other|Functional Magnetic Resonance Imaging (fMRI)|FMRI provides an indirect and noninvasive measure of brain activity.
75346781|NCT03007745|Device|autoadjusting continuous positive airway pressure|Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
75346782|NCT01727804|Other|Laser in caries prevention|
75346783|NCT01727882|Behavioral|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
75946174|NCT02332616|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
75946175|NCT02332616|Drug|Isotonic Sodium Chloride|Placebo
75946176|NCT03345173|Drug|CI-581-a|Two infusions in the context of naltrexone induction protocol.
75346784|NCT01727882|Behavioral|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
75346785|NCT02218307|Drug|Mupirocin|
75346786|NCT02218307|Drug|Placebo|
75658309|NCT05398341|Device|The BEAR® Implant|"The BEAR Implant is a bovine collagen-based implant. The bovine tissue is sourced from countries that are free of bovine spongiform encephalopathy [BSE] and is further treated to remove bovine cell fragments and DNA.~The BEAR® (Bridge Enhanced ACL Restoration) Implant is a bovine extracellular matrix collagen-based implant for treatment of anterior cruciate ligament (ACL) injuries. The BEAR® Implant is indicated for skeletally mature subjects at least 14 years of age with a complete rupture of the ACL. Subjects must have an ACL stump attached to the tibia to construct the repair."
75658310|NCT05397691|Other|Modified Family Talk|The Modified Family Talk intervention consists of six modules, each lasting approximately 60 minutes. Family Talk is intended to be delivered over a period of 12 weeks, with meetings occurring every 1-2 weeks.
75658311|NCT05397691|Other|Control-like parameter estimation|Parameter estimation is designed to emulate best practices around comprehensive, high quality, patient-centered care for adults and youth. Participants will have access to collaborative adult Office Based Addiction Treatment (OBAT) clinical services, multidisciplinary adolescent primary care clinics with co-located adolescent substance use specialists, high quality social work services, integrated behavioral health, and access to patient navigators for assistance connecting to community resources.
75658312|NCT05394662|Device|Juveena Hydrogel System|Application of a novel hydrogel immediately following the transcervical procedure
75658313|NCT05393609|Procedure|Sigmoidectomy|Conventional laparoscopic resection of the sigmoid colon
75946177|NCT03345173|Drug|CI-581-b|Two infusions in the context of naltrexone induction protocol.
75946178|NCT02332148|Drug|3VM1001|3VM1001 topical cream for treatment of osteoarthritis of the knee
75658314|NCT05393609|Dietary Supplement|Conservative|According to current practice including advice on supplementary dietary fiber, analgetics, or laxatives when indicated.
75346787|NCT01727960|Behavioral|Education and posture correction|a lecture concerning the fine posture for health and exercises
75658315|NCT05391321|Other|administration of the 4 quality of sexual life questionnaires|administration of the 4 quality of sexual life questionnaires
75658316|NCT05384405|Device|Active iTBS|MagPro X100
75658317|NCT05384405|Device|Sham iTBS|MagPro X100
75658318|NCT05383560|Biological|mRNA-1273.214 Vaccine|Omicron Variant-Matched Vaccine
75658319|NCT05383560|Biological|MRNA-1273 Vaccine|Moderna's commercial COVID-19 Vaccine
75658320|NCT05383560|Biological|Placebo|Normal Saline for injection
75805393|NCT05689593|Other|Low-intensity laser Group|The laser will be made parallel to the joint line with the patient's arm, the arm will be in internal rotation at the posterior of the shoulder and the arm will be in external rotation at the anterior of the shoulder. The wavelength of 850 nm will be applied for 5 minutes in total 30 Joules.
75805394|NCT05689593|Other|Conventional Control Group|Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
75805395|NCT05688371|Drug|standard dose morphine|Receiving 0.05 mg morphine/kg as a bolus.
75805396|NCT05688371|Drug|low dose morphine plus dexmedetomidine|Receiving 0.02 mg morphine/kg as a bolus dose + 0.4 microgram/kg dexmedetomidine
75805397|NCT05668949|Drug|TTI-101|Given by PO
75805398|NCT05668949|Drug|Pembrolizumab|Given by IV (vein)
75805399|NCT05662722|Other|percutaneous needle electrolysis|It´s an intervention of physiotherapy. It´s an invasive technique.
75805400|NCT05662722|Other|Dry needling|It´s an intervention of physiotherapy. It´s an invasive technique.
75805401|NCT05662722|Other|Sham needling|It´s an intervention of physiotherapy. It´s an invasive technique simulation.
75805402|NCT05662332|Drug|Insulin Efsitora Alfa|Administered SC
75805403|NCT05662332|Drug|Insulin Glargine|Administered SC
75805404|NCT05636878|Other|Mobile Intervention Team in Perinatal Psychiatry (EMPPer)|The Mobile Intervention Team in Perinatal Psychiatry consists in going towards the most excluded patients, changing the organization of care compared to the current practice and facilitating access to care for the most vulnerable populations
75946179|NCT02332148|Drug|Placebo for 3VM1001|Topical cream placebo for 3VM1001; cream without 3VM1001
75946180|NCT03618173|Drug|Dexamethasone|IV dexamethasone at the dose of 0,2mg/kg = 0,2mL/kg of a solution of 1mg/mL max 8mg
75346788|NCT03007433|Other|400ml of Liquid Nutrient Drink|12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
75658321|NCT05378789|Procedure|Nap|"ICU nurses can take a 20-mn nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair."
75946181|NCT03618173|Drug|Placebos|IV saline serum at the dose of 0,2mL/kg maximum 8mL
75946182|NCT02336048|Drug|Chlorambucil|Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
75658322|NCT05378347|Device|Medtronic Endurant II or Endurant IIs Stent Graft System|EVAR treatment with Medtronic Endurant II/IIs Stent Graft System
75658323|NCT05378347|Device|Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis|EVAR treatment with Excluder / Excluder Conformable Stent Graft System
75805405|NCT05632614|Device|High-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 55% PIMAX during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3 to 6.
75805406|NCT05632614|Device|Low-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 15% PIMAX for 6 weeks.
75805407|NCT05618353|Drug|Colchicine|0.6 mg tablets
75805408|NCT05618353|Drug|Placebo|Matching placebo
75805409|NCT05597982|Other|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
75805410|NCT05597982|Other|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
75946183|NCT02336048|Drug|Obinutuzumab|Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
75946184|NCT02336048|Drug|Placebo|Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
75946185|NCT02336048|Other|Standard Premedication|Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
75946186|NCT02336048|Drug|Tocilizumab|Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
75346789|NCT01728038|Behavioral|Cessation Counseling|Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
75346790|NCT01722032|Other|Childhood Obesity|
75346791|NCT01722110|Drug|Indomethacin Extended-Release Capsules USP 75 mg|75 mg tablet once a day
75346792|NCT01722110|Drug|Indomethacin Extended Release Capsules USP 75 mg|75 mg tablet once a day
75346793|NCT01573949|Drug|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
76093503|NCT01897389|Drug|Treatment E|1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
76093504|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
75477013|NCT05051631|Other|Intervention plus 10 months maintenance|The intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.
75805411|NCT05595044|Drug|Vitamin D|ASD children with vitamin D insufficiency and deficiency will receive vitamin D with dose 300 IU/KG/ day not exceed 5000IU/day for 6 weeks then revaluate serum level of vitamin D if they reach normal level of vitamin D they will receive vitamin D 1000IU/ day till the end of 4 months.
76093505|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
76093506|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
76093507|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
75477014|NCT05051631|Other|Intervention plus 8 months maintenance|The intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.
75658324|NCT05374473|Behavioral|Lifestyle modification|Content in the intervention arm was adapted from an evidence-based lifestyle modification program for people with MS outlined in print previously presented in a face-to-face format. The integrated lifestyle modification program translates the research evidence regarding modification of lifestyle related risk factors and health outcomes based on a detailed review of the literature around modifiable lifestyle risk factors that may influence MS disease progression, as outlined in the book Overcoming Multiple Sclerosis: the 7-step recovery program.
75658325|NCT05374473|Behavioral|Standard-care|Content in standard-care arm was adapted from MS-related websites
75805412|NCT05595044|Other|Habilitation|Habilitation
76093508|NCT01974700|Drug|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
75346794|NCT02496702|Device|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
75346795|NCT01574183|Drug|Vilazodone|up to 40 mg capsule daily
75346796|NCT01574183|Drug|Placebo|up to 40 mg capsule daily
75346797|NCT01574807|Drug|mepivacaine + lidocaine followed by lidocaine +lidocaine|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
75346798|NCT01574807|Drug|lidocaine + lidocaine followed by mepivacaine + lidocaine|1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
75346799|NCT01575275|Drug|aminolevulinic acid|Given PO
75346800|NCT01575275|Procedure|therapeutic conventional surgery|Undergo surgery
75477015|NCT05051631|Other|Intervention plus 6 months maintenance|The intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.
75658326|NCT05369598|Device|Post-operative ABF followed by fitting according to clinical standard|Cochlear implant will be fitted first with anatomy-based fitting for 6 months and followed by default fitting for 2 months.
75805413|NCT05588401|Biological|GenPHSat injection (Safety)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.
75805414|NCT05588401|Biological|GenPHSat injection (Efficacy)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the right biceps muscle.
75805415|NCT05588401|Other|Muscle Biopsy (Safety)|Participants undergo muscle biopsy 3 month after safety GenPHSat injection.
75805416|NCT05540132|Dietary Supplement|maltodextrin|Pre-exercise carbohydrate, fast-acting
75805417|NCT05540132|Dietary Supplement|super starch|Pre-exercise carbohydrate, slow-acting
75946187|NCT03612401|Drug|Mirabegron|Beta-3 adenoreceptor agonist
75946188|NCT02335970|Other|Training group|"After 1 week~Chest expansions~Static thoracic extension in prone~Lateral flexion of the spine in standing~Bilateral shoulder flexion~Shoulder external rotation of shoulders~Rotation of the thoracic spine in sitting~Static back extensor strength in prone~After 1 month~Thoracic extension, rotation and flexion abduction~Hand in neck and in back~Bilateral active flexion abduction~Strength training of leg muscles~Static back extensor strength~After 2 months~Strength training of legs and back muscles~Push-ups against a wall~Thoracic extension in sitting and standing~Thoracic rotation in lying~Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise"
76093509|NCT04753281|Other|Lifestyle counselling|brief psychological intervention, based on the behaviour change whee
76093510|NCT03236610|Drug|tenofovir monotherapy|switching to tenofovir monotherapy
76093511|NCT03236610|Drug|tenofovir plus entecavir combination|continuing tenofovir plus entecavir
76093512|NCT02030080|Behavioral|Financial incentives|
76093513|NCT02030080|Behavioral|Teams|
76093514|NCT02030080|Behavioral|Framing of feedback|
76093515|NCT02030080|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
76093516|NCT03233490|Other|web course|Web course Help Brain Heart was conducted Before CPR training.
76093517|NCT03233490|Other|CPR training|No web course was conducted
76093518|NCT02453412|Device|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
76093519|NCT05287893|Drug|Pyronaridine|Single dose
76093520|NCT05287893|Biological|P. falciparum IBSM infection|Induced Blood Stage Malaria
76093521|NCT02357758|Drug|Antibiotic Prophylaxis|Approved clinical dosage or antibiotics
75805418|NCT05535764|Drug|Pegylated interferon alpha2a|PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.
75805419|NCT05520554|Other|Development of the Telerehabilitation Satisfaction Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Satisfaction Questionnaire in patients with MS.
75946189|NCT03612323|Drug|Intra-ligamentary Piroxicam|Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
75946190|NCT03612323|Drug|Intra-ligamentary Articaine|Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
75946191|NCT02332304|Procedure|Preterm fetus|A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.
75946192|NCT02994719|Drug|Anti-Parkinson medication|During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
75946193|NCT02994719|Device|Deep Brain Stimulation|During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
75946194|NCT02340650|Device|Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope|
75946195|NCT03612167|Behavioral|cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
75946196|NCT03612167|Behavioral|nutritional group|12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
76093522|NCT05606445|Behavioral|Elbow movement|The behavioral paradigm consist of a passive and active movement condition. Both conditions consist of arm movements along the entire range of motion by moving the distal segment of the arm towards the proximal segment and back under varying conditions. In the 'passive' condition, this arm movement will be performed by researcher at 3 different velocities in sinusoidal (continuous) and linear (non-continuous) fashions whereas in the 'active' condition, the participant will be instructed to move the arm in one velocity under internal and external focus of attention.
76093523|NCT02357836|Drug|Itraconazole|"Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure."
76093524|NCT03246594|Device|Placement of oesophageal probe for temperature measurement|The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
76093525|NCT03246594|Device|Power limitation of RF generator|no probe utilized; Limit the RF Generator Output to 25W
76093526|NCT01897467|Behavioral|Wii Fit|Exercises to be done on the Wii Fit include: warrior pose, half-moon pose, lunges, side lunges, balance bubble, ski slalom, soccer heading, and table tilt.
76093527|NCT01897467|Behavioral|Wait-List Control|Participants maintain currently physical activity and diet habits for 12 weeks. They have the option to participate in the intervention at the end of the 12-week period, but it is not mandatory.
75658327|NCT05369598|Device|Fitting according to clinical standard followed by post-operative ABF|Cochlear implant will be fitted first with default fitting for 6 months and followed by anatomy-based fitting for 2 months.
75658328|NCT05360277|Drug|Tislelizumab + Capecitabine|"Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
75346801|NCT03408158|Procedure|same type infusion of main HPA antigen|Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
75346802|NCT03001973|Other|No Intervention|Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
75658329|NCT05360277|Other|Best supportive care|Best supportive care
75658330|NCT05354856|Drug|Indocyanine green|A bolus of ICG (0.2 mg/kg body weight) will be injected intravenously and flushed with 5 mL of saline. Gastric perfusion will subsequently be assessed along specific regions of interest (ROI) with q-ICG (quantitative perfusion assessments with ICG) to obtain baseline perfusion values.
75658331|NCT05335122|Drug|OTX-TIC low dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
75658332|NCT05335122|Drug|OTX-TIC high dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
75658333|NCT05335122|Drug|Durysta, Bimatoprost Intracameral Implant 10 µg|Durysta is injected into the anterior chamber of the eye.
75658334|NCT05332704|Drug|ONO-4685|-Part A: Single ascending doses of ONO-4685 as a single IV dose (Cohort A1-A5).
75805420|NCT05506839|Other|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
75805421|NCT05506696|Dietary Supplement|Fultium|3200IU Fultium
75805422|NCT05504447|Other|"Rong-Yang Zhengyifang tea bag"|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
75805423|NCT05504447|Other|placebo tea bag|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
75946197|NCT02340416|Device|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
75946198|NCT04686227|Diagnostic Test|3D Ultrasound|Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology
75946199|NCT04346108|Biological|Immune Globulin Intravenous (IGIV)|Participants will receive IGIV infusion.
75946200|NCT04346108|Biological|Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)|Participants will receive IGSC, 20% SC infusion.
76093528|NCT03107676|Other|trunk extensors endurance training|endurance training
75805424|NCT05502939|Behavioral|Music Program|"The cohort of students entering the program at the Colburn school in Los Angeles will be a part of a traditional strings curriculum. Students will join the program on a full scholarship and will be provided all materials necessary for instruction, including an instrument. Students will attend Colburn twice a week in a group setting and will receive private instruction once a week.~The program will last 2, 15-week semesters (fall, spring) for 2-years. There will be 2 groups of 10 students. Students will undergo group instruction for 1 hour, 2 times a week and private instruction for 45 minutes, once a week."
75946201|NCT03612635|Device|Implantation of a cardiac implantable electronic device|All patients enrolled in the registry underwent cardiac implantable electronic device implantation
75946202|NCT03612011|Other|Onco-Repair/ Placebo|Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
76093529|NCT03233334|Behavioral|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
75477016|NCT05051631|Other|Intervention plus 4 months maintenance|The intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
75477017|NCT05038540|Procedure|Scaling and root planing|Phase 1 periodontal therapy
75477018|NCT05022147|Device|High-Frequency-Only Stimulation|Control condition, constant high-frequency DBS stimulation (130Hz)
75477019|NCT05022147|Device|Low-Frequency-Only Stimulation|Experimental condition, constant low-frequency DBS stimulation (60 Hz)
75658335|NCT05332704|Drug|Placebo|-Part A: Single ascending doses of placebo as a single IV dose (Cohort A1-A5).
75658336|NCT05332704|Drug|ONO-4685|-Part B: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort B1 and B2)
75658337|NCT05332704|Drug|Placebo|-Part B: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort B1 and B2).
75658338|NCT05332704|Drug|ONO-4685|-Part C: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort C1 and C2).
75658339|NCT05332704|Drug|Placebo|-Part C: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort C1 and C2).
75658340|NCT05330988|Device|anodal transcranial direct current stimulation (a-tDCS)|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
75658341|NCT05330988|Device|sham stimulation|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
75658342|NCT05318092|Device|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|The AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has five main components, a flexible cannula (F1885), sheath, tapered obturator, aspirator handle, and waste bag.
75658343|NCT05313152|Drug|TAVO103A|TAVO103A single ascending dose IV infusion.
75658344|NCT05313152|Other|Placebo|Placebo single ascending dose IV infusion.
75658345|NCT05306067|Diagnostic Test|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
75658346|NCT05306067|Diagnostic Test|Malaria rapid diagnostic test|All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests
75805425|NCT05502939|Behavioral|After School Enrichment Program|The afterschool program will be led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members.
75946203|NCT02340494|Behavioral|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
75946204|NCT05253950|Other|Questionnaire|answered questions from two standard questionnaires the Internet Addiction Test (IAT) which examines students' dependence on the internet and the Nordic Muscuskeletal Questionnaire (NQS) which examines the onset of symptoms from the musculoskeletal system
75946205|NCT03611855|Device|BCI Rehabilitation|Patients use electroencephalography (EEG) signals to control a motorized glove worn on their affected hand. The glove moves the patient's hand according to the type of signal detected (Rest vs Motor Imagery).
75658347|NCT05305313|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
75658348|NCT05305313|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
75658349|NCT05298046|Drug|Experimental: TAVO101|TAVO101 single ascending dose IV infusion.
75658350|NCT05298046|Other|Other: Placebo|Placebo single ascending dose IV infusion.
76093530|NCT02359006|Drug|Minocycline|Minocycline will be compared with placebo
76093531|NCT02359006|Drug|Placebo|Placebo will be compared with minocycline
76093532|NCT03236454|Device|DC-Stimulator MC, NeuroConn|20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
76093533|NCT04486014|Procedure|Erector spinae plane block|Erector Spinae Group (Group E) will receive bilateral ultrasound-guided erector spinae plane block using 30 ml hyperbaric bupivacaine 0.25% will be injected between erector spinae muscle and transverse process of T4
76093534|NCT04486014|Procedure|Serratus anterior plane block|Serratus anterior Group (Group S) will undergo bilateral ultrasound-guided serratus anterior plane block with 30 ml hyperbaric bupivacaine 0.25% will be injected above or below serratus anterior muscle at the level of 4th and 5th rib on the midaxillary line
76093535|NCT04485702|Drug|Midazolam injection|2mg IV
76093536|NCT04485702|Drug|Ketamine Injectable Product|6mg IV
76093537|NCT04485702|Drug|MELT-100|midazolam 3mg and ketamine 25mg SL tablet
75658351|NCT05294627|Diagnostic Test|Stockholm3|Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score.
76093538|NCT00068367|Drug|erlotinib hydrochloride|150 mg per day, daily until disease progression
76093539|NCT03236532|Dietary Supplement|Glutamine and exercise|
75658352|NCT05280145|Device|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, the patient is examined with EchOpen to detect the presence or absence of pyelocaliceal dilation or hepatic steatosis
76093540|NCT03236532|Dietary Supplement|Maltodextrin and exercise|
76093541|NCT01975090|Device|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
75658353|NCT05280145|Device|Ultrasound device routinely used in the department|Patient who was first examined with EchOpen, is secondarily examined with an ultrasound probe used routinely in the department to detect pyelocaliceal dilation or hepatic steatosis
76093542|NCT03229434|Behavioral|Mountain hiking|Compare arm description
75805426|NCT05486156|Other|A Time with e-Nature|"Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group."
75946206|NCT03611855|Other|Range of Motion Therapy|Patients repeatedly move or stretch the joints and muscles of their affected limb, either by actively moving the limb or assisting the limb with no active motion.
75946207|NCT02335736|Drug|Gonadotropins releasing hormone antagonist|
76093543|NCT03229590|Procedure|Surgical dislocation|Reduction of slipped epiphysis by surgical dislocation
76093544|NCT02880891|Procedure|prothetic procedure|splinted crown
76093545|NCT03233412|Procedure|Control|Exertion of the cervix transformation zone
76093546|NCT03233412|Drug|Imiquimod|Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
75346803|NCT01728272|Drug|blood concentration of metoprolol|measure blood concentration of metoprolol
75658354|NCT05280145|Procedure|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating.
75658355|NCT05269173|Drug|Flos gossypii flavonoids tablet|The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
75658356|NCT05268809|Other|Ketogenic diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies.
75658357|NCT05267639|Device|Power Knee|Newest version of the commercially-available Power Knee developed by Ossur.
75805427|NCT05477563|Biological|CTX001|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
75946208|NCT04632173|Other|non interventional study|There is no intervention
75946209|NCT02335814|Drug|FLX925|
75946210|NCT03613259|Drug|Fluorothymidine F-18|Given IV
75946211|NCT03613259|Other|Laboratory Biomarker Analysis|Correlative studies
75946212|NCT03613259|Procedure|Positron Emission Tomography|Undergo fluorothymidine F-18 PET
75946213|NCT02332070|Procedure|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
75946214|NCT03611699|Drug|Umeclidinium / Vilanterol Dry Powder Inhaler|umeclidinium/vilanterol dry powder inhaler
76093547|NCT01976416|Drug|Hydroxyurea|
75346804|NCT03007823|Biological|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
75346805|NCT01728350|Behavioral|HOPE - Helping Others through Purpose and Engagement|
75346806|NCT01728506|Behavioral|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
75346807|NCT03408002|Behavioral|Psychological intervention|"The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro"
75346808|NCT04378088|Other|Validation of CEBuS|Validation of a new score for bubbles in the colon.
75946215|NCT03611699|Drug|Placebo|Placebo inhaler
76093548|NCT01976416|Drug|Placebo|
76093549|NCT05255133|Other|Liquid biopsies|Blood sampling will be done at regular intervals
76093550|NCT05255133|Other|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
76093551|NCT02453178|Behavioral|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
76093552|NCT02032420|Behavioral|STAR|
76093553|NCT02032420|Behavioral|ART|
76093554|NCT02453100|Behavioral|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
76093555|NCT02453100|Behavioral|Education|Education on simple ways to manage incontinence
76093556|NCT03233178|Other|Non-interventional|
76093557|NCT03229044|Genetic|Tetranectin|Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
76093558|NCT03236376|Other|additional sensorimotor therapy for the upper limb|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.
76093559|NCT03236376|Other|additional motor therapy for the upper limb after stroke|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
75346809|NCT03407924|Other|Aerobic Exercise (AER)|Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.
75477020|NCT05022147|Device|Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 10 seconds for low, respectively.
75805428|NCT05464225|Device|COSD|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the first week, the participants who are in the COSD group will be issued a COSD bulb that corresponds to no less than 60% of their baseline maximum strength. After week 1, they will switch to a COSD bulb that corresponds to no less than 80% of their maximum tongue strength for the remaining 7 weeks.
75805429|NCT05464225|Device|SOC|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the tongue depressor group, they will be given 8 tongue depressors, which are disposable, for the duration of the study.
75805430|NCT05463666|Other|Rheumatoid arthritis|A diagnosis of rheumatoid arthritis.
75805431|NCT05462652|Device|Active Intervention|The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
75805432|NCT05453201|Behavioral|Long COVID Coping and Recovery (LCCR) Intervention|Veterans will participate in a LCCR (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists.
76093560|NCT03233100|Other|FMT|fecal microbiota transplantation
76093561|NCT03236298|Device|CADD-Solis Ambulatory Infusion System|The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
76093562|NCT01976572|Drug|colestilan|
75805433|NCT05448313|Behavioral|Dyadic intervention|Dyads comprising a Veteran and cohabitating support person will participate in the 16-week VA MOVE! weight loss program delivered by video platform. They will then participate in 6 group sessions focused on weight maintenance skills. Communication skills will be taught throughout the intervention.
75805434|NCT05448313|Behavioral|Veteran-only intervention|Veterans will participate in a 72-week weight management program delivered by video platform. 16 sessions will address weight loss, with 6 additional ones addressing weight loss maintenance.
75805435|NCT05428020|Device|Indwelling foley catheter|short-term indwelling catheter inserted in the operating room prior to surgery, removed upon arrival to the floor from post-anesthesia care unit (approx 2-3 hours after surgery).
75805436|NCT05428020|Other|No foley catheter|No foley catheter is placed for surgery
75805437|NCT05423275|Device|Negative ion therapy|Negative ion generator
75805438|NCT05423275|Device|Light therapy|Fluorescent light box
75346810|NCT03407924|Other|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
75346811|NCT04377386|Dietary Supplement|1000 IU D vitamin|Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
75477021|NCT05022147|Device|Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 50 seconds for low, respectively.
75805439|NCT05422326|Biological|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)
75805440|NCT05422326|Biological|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination
75946216|NCT02032355|Procedure|spinal anesthesia|
75346812|NCT04377386|Dietary Supplement|200 IU D vitamin|Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
75805441|NCT05422326|Biological|Placebo on Day 22|Saline placebo (sterile, 0.5 mL) given 3 weeks after the aH5N6c vaccination
75805442|NCT05408728|Procedure|Endoscopic biopsy|Upper small intestinal biopsies from patients undergoing BS will be collected during routine standard of care screening EGD and again from the same patients at 1 year during routine standard of care surveillance EGD (esophageal reflux screening/surveillance). Biopsy-derived enteroid cultures and tissue samples from pre- and one-year post BS will be examined for expression level of sugar transporters and gluconeogenic enzymes; glucose and fructose absorption
75946217|NCT03095456|Drug|Revefenacin|Revefenacin administered via nebulization.
75946218|NCT03095456|Combination Product|Spiriva Handihaler®|Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
75346813|NCT03834896|Other|AYMES MADRID|AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
75346814|NCT03835208|Behavioral|High/low carbohydrate distribution|A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
75477022|NCT05022147|Device|Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 50 seconds for low, respectively.
75946219|NCT03095456|Drug|Placebo for Revefenacin|Placebo administered as double blind, double dummy via nebulization.
75946220|NCT03095456|Drug|Placebo for Spiriva Handihaler®|Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
75946221|NCT03612557|Drug|penicillin G benzathine|2.4 million units (IM) of benzathine benzylpenicillin
75946222|NCT05253638|Diagnostic Test|Macrophage migration inhibitory factor|Assessment of disease activity: This assessment will be performed using the systemic lupus erythematosus disease activity index (SLEDAI). The SLEDAI is an index designed to assess disease activity in the preceding 10 days, with 24 weighted clinical and laboratory variables corresponding to 9 different organs/systems. The SLEDAI score ranges from 0 to 105 Renal activity will be evaluated with the renal-SLEDAI (rSLEDAI), which represents the sum of the renal items of the SLEDAI. The rSLEDAI includes the following items: proteinuria, pyuria, erythrocyturia, and urine casts; each one is scored with 0 meaning absence or 4 points meaning presence; therefore, the maximum rSLEDAI is 16
75946223|NCT03611543|Device|New investigational curved paddle|X-ray imaging of breast tissue
75346815|NCT04377230|Procedure|biliopancreatic limb length of 60cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
75477023|NCT05022147|Device|Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 10 seconds for low, respectively.
75805443|NCT05398627|Behavioral|Amygdala Neurofeedback|real-time feedback on the hemodynamic response of the amygdala during positive autobiographical memory recall
75946224|NCT03067844|Drug|Alirocumab|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
75946225|NCT02340572|Drug|PRS-080#022-DP|hepcidin antagonist
75346816|NCT04377230|Procedure|biliopancreatic limb length of 100cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
75346817|NCT03407846|Procedure|Hystrectomy|Total laparscopic hystrectomy versus total abdominal hystrectomy
75346818|NCT01728662|Procedure|ELVR Procedure|Lung Volume Reduction Procedure
75346819|NCT01728740|Drug|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
75346820|NCT01728740|Drug|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
75346821|NCT01728740|Drug|Metformin|Metformin 500mg, oral, single dose
75477024|NCT05022147|Drug|OFF Dopaminergic Medication|All six device interventions will be performed in medication OFF state
75805444|NCT05387499|Drug|NP-011 (Single Ascending Dose Phase)|The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
75946226|NCT02340572|Drug|PRS-080-Placebo#001|Placebo treatment
75946227|NCT03105284|Procedure|Liposuction|Fat harvest by liposuction (Colemans method)
75946228|NCT02340260|Behavioral|High intensity interval training|High intensity exercise during 12 weeks with three weekly training sessions
75946229|NCT02340260|Behavioral|Sprint interval training|Sprint interval exercise during 12 weeks with three weekly training sessions
75946230|NCT02331758|Behavioral|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
75946231|NCT02340182|Drug|Vancomycin|250mg 3dd2
75946232|NCT02340182|Drug|Ciprofloxacin|500mg 2dd1
76093563|NCT01976572|Drug|candesartan|
76093564|NCT03236142|Procedure|SIPS Operation|The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
75805445|NCT05387499|Drug|NP-011 (Multiple Ascending Dose Phase)|The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
75805446|NCT05387499|Other|NP-011 (Placebo)|The participants will receive single dose of NP-011 after a minimum 8 hour fast on Day 1 in Single Ascending Dose part and will receive once daily for 7 days after a minimum 8 hour fast in Multiple Ascending dose part of the study
75805447|NCT05377905|Drug|Microneedle Array Doxorubicin (MNA-D)|The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications
75805448|NCT05375344|Behavioral|Exercise Group|Home-based exercise group intervention
75946233|NCT02340182|Drug|Metronidazole|500mg 3dd1
75658360|NCT05261399|Drug|Savolitinib|300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
75946234|NCT02331836|Device|Arc Endocuff (AEC 110, 120, 130, 140)|
75946235|NCT02331836|Device|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
75946236|NCT02331836|Device|Standard colonoscope|
76093565|NCT03236142|Procedure|Standard Duodenal Switch Operation|
76093566|NCT03232866|Other|Pilates exercise|Pilates methods exercises
75805449|NCT05372133|Drug|Morphine|Children will be provided with morphine for at-home pain management following supracondylar fracture repair
75805450|NCT05356195|Biological|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
75946237|NCT05226182|Other|visualisation of a digital care path|The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
75946238|NCT02339948|Radiation|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
75946239|NCT02339792|Other|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
75946240|NCT02339714|Other|acupuncture combined moxibustion|"Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).~Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether."
76093567|NCT02360488|Device|Telerehabilitation Therapy|18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
76093568|NCT02360488|Behavioral|In-Clinic Therapy|18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
75346822|NCT01728818|Drug|Gemcitabine|1000 mg/m² d1,8,15 q4weeks
75346823|NCT01728818|Drug|Afatinib|40mg flat dose, po, once daily
75346824|NCT01728818|Drug|Gemcitabine|1000 mg/m², d1,8,15 q4weeks
75346825|NCT04377542|Procedure|LIFT|Ligation of the fistula tract in the intersphincteric plane
75346826|NCT04377542|Procedure|Parks|Modified Parks fistulotomy with complete internal anal sphincterotomy
75658361|NCT05261399|Drug|Osimertinib|"80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral"
75658362|NCT05261399|Drug|Pemetrexed|Pemetrexed (500 mg/m2) Administrative route : IV infusion
75658363|NCT05261399|Drug|Cisplatin|Cisplatin (75 mg/m2) or Administrative route : IV infusion
75658364|NCT05261399|Drug|Carboplatin|Carboplatin (AUC5) Administrative route : IV infusion
75658365|NCT05257070|Diagnostic Test|fingerprick|In addition to the standard venous samples, dried blood spot samples trough a fingerprick will be collected.
75658366|NCT05254509|Other|Occupational Therapy|Occupational therapy helps individuals with chronic pain to participate in daily activities in an adaptive way. The subjects will be provided with customized plans and objectives to address their self-care, vocational, and leisure goals. This includes education, home exercises, stress management, home safety, energy conservation, and work simplification - all of which promote a safe return to daily activities.
75658367|NCT05254509|Other|Occupational Therapy +Virtual Reality|The occupational therapy +VR utilizes the regular therapy sessions along with providing a Virtual reality headset to relieve pain. After each VR session, there will be a debriefing from the therapist.
75946241|NCT02339714|Drug|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
76093569|NCT03233022|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
76093570|NCT03232944|Device|Cardiac Resynchronization Therapy - MPP|The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
76093571|NCT01976650|Drug|dexamethasone 700 ㎍ intravitreal implant|dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
76093572|NCT02361736|Drug|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
76093573|NCT02361736|Drug|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
76093574|NCT03228966|Diagnostic Test|Echocardiogram|Screening echocardiogram
76093575|NCT01978600|Drug|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
76093576|NCT01978600|Drug|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
75658368|NCT05250037|Procedure|Home spirometry|Undergo spirometry measurements
75946242|NCT02335190|Procedure|Radiofrequency ablation|RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
75805451|NCT05347719|Behavioral|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions involving training in mindfulness meditation and cognitive-behavioral methods. Sessions will be designed to increase participant awareness of internal reactions that trigger relapse in MDD and to provide participants with techniques to detach from dysfunctional cognitive processes and redirect their attention to experiences. Outside of the sessions, participants will be assigned daily homework exercises and provided with handouts and audio recordings of mindfulness exercises to use in their practice.
75805452|NCT05347212|Drug|Nivolumab|Given by IV
75805453|NCT05347212|Drug|Relatlimab|Given by IV
75805454|NCT05336344|Behavioral|ENCODE|a cognitive behavioral intervention for family caregivers to improve pain management skills and overall coping
75805455|NCT05336318|Behavioral|Peer support|patients were supported by a mentor
75805456|NCT05329584|Device|InSpace Subacromial Tissue Spacer|Rotator Cuff Tear Treatment
76093577|NCT03236220|Drug|N-acetyl-L-cysteine|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
76093578|NCT03107598|Drug|colloid preload|coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
75346827|NCT04377542|Procedure|Seton|Excision of the superficial part of fistula tract and tying loose seton around the remaining part and anal sphincter muscles
75346828|NCT01728896|Other|Patient-controlled oral refeeding|
75658369|NCT05250037|Procedure|Biospecimen Collection|Undergo nasal and/or oral swabs, and blood collection
75658370|NCT05250037|Other|Questionnaire Administration|Complete questionnaires
75658371|NCT05247463|Other|Increase in upper age of eligibility for breast cancer screening from 64 to 70|The upper age limit of eligibility for Breast Cancer Screening increased in England from 64 to 70 as a result of the NHS Cancer Plan, so women were offered an additional 2 rounds of screening.
75805457|NCT05318963|Biological|LCAR-AIO cells product|before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m^2 and fludarabine 30mg/m^2 once daily (QD) for 3 days.
75946243|NCT02335190|Procedure|Sensory block|Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
75946244|NCT02335190|Drug|Lidocaine|
75946245|NCT02339870|Other|Psychosocial Support for Caregiver|Complete expressive disclosure writing
75946246|NCT02339870|Other|Psychosocial Support for Caregiver|Complete benefit finding writing
75946247|NCT02339870|Other|Questionnaire Administration|Ancillary studies
75946248|NCT02339870|Other|Sham Intervention|Complete writing on an emotionally neutral topic
75946249|NCT02335112|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
75946250|NCT02335112|Device|NanoKnife|
75946251|NCT02335034|Behavioral|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
75346829|NCT03407690|Other|nasal swab|collection of nasal swab to allow carriage of pneumococci to be assessed
75346830|NCT03835832|Other|The participants do not receive any intervention for this study|The participants do not receive any intervention for this study
75346831|NCT03407456|Other|Gastroesophageal reflux symptoms questionnaire|Reflux Symptom Questionnaire, 7-day recall (RESQ-7).
75658372|NCT05247463|Other|Screening round length|The target round length (frequency) of breast cancer screening in England is every 3 years. However in practice there is variability in this due to local centre capacity. The exposures are round lengths of approximately 2 years and approximately 3 years
75658373|NCT05247463|Diagnostic Test|Screening test threshold|Radiologists and equivalent health professionals examine women's screening mammograms for potential signs of cancer, and recall some women for further diagnostic tests. Each has a different test threshold for recall, characterised by the proportion of previous cases that they have recalled.
76093579|NCT03107442|Behavioral|Aerobic exercise|12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous [40-85% of the individual's heart rate reserve] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
76093580|NCT03236064|Drug|Polyethylene Glycols|Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
76093581|NCT03232788|Procedure|Bone regeneration|Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
76093582|NCT03232788|Device|Collagen membrane|A collagen membrane will be used to cover the autogenous bone.
76093583|NCT03232788|Device|Scaffold|A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
76093584|NCT03232632|Drug|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl ®)
76093585|NCT03228810|Other|Blood draw|(2) 10 mL tubes will be collected
76093586|NCT03228810|Procedure|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
76093587|NCT03235908|Other|Observation only|Observation only
75658374|NCT05247424|Drug|Unfractionated heparin|Unfractionated heparin at dose of 100 IU /kg body weight
75658375|NCT05242770|Other|Control Arm|Participants randomized to this arm will only receive educational pamphlets with resources for sexual dysfunction and will not participate in physical therapy. Participants will be contacted at 3 months and 6 months to fill out two questionnaires about sexual function and quality of life. After 6months, if participants desire a referral to physical therapy, investigators will provide a referral.
75346832|NCT01576055|Device|TIGRIS Vascular Stent|Implant
75346833|NCT01576055|Device|BARD LifeStent|Implant
75346834|NCT01728974|Other|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
75658376|NCT05242770|Other|Physical Therapy Arm|Participants will receive a referral to begin a pelvic physical therapy regimen. Participants will complete the sexual function and quality of life questionnaires after completion of the physical therapy regimen and again 3 months after. There will be a brief exit interview.
75658377|NCT05242770|Other|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Questionnaire designed to measure cancer patients' physical, psychological and social functions
75658378|NCT05242770|Other|Female Sexual Function Index (FSFI)|19-item self-report inventory designed to assess female sexual function.
75658379|NCT05242770|Other|Exit Interview|11-item questionnaire for participants to give feedback to investigators about teir experience with the intervention.
75658380|NCT05230784|Other|AirOk Air Purifier|The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.
75805458|NCT05318625|Device|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
75946252|NCT02335034|Behavioral|Control Group only make evaluations / consultations with all professional teams|"Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years."
75346835|NCT01729052|Device|Acupuncture|
75346836|NCT01729130|Procedure|Adipose tissue biopsy|Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
75946253|NCT02334878|Biological|Stem Cells,Mesenchymal|The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.
75946254|NCT02334878|Procedure|surgery (TVT)|A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra & through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted & the remaining tape cut off at the level of the skin.
75946255|NCT02331524|Behavioral|Activity Feedback and Encouragement|"The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!"
75946256|NCT02331524|Other|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
75946257|NCT02339636|Other|PDUS examination|
75946258|NCT02581592|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
75946259|NCT02578082|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
75346837|NCT03407378|Drug|IPT803|Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
75346838|NCT03407378|Genetic|Optional pharmacogenetic assessment|Blood sample of 3 milliliters for genotyping assessment (according to patient consent).
75346839|NCT03407378|Other|Questionnaires|Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)
75346840|NCT03407378|Other|Optional Blood-Oxygen-level Dependent functionalMRI|BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)
75346841|NCT03407378|Other|Motor Assessments before taking regular PD treatment|Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.
75346842|NCT03407378|Other|Motor Assessments on regular PD treatment|Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
75658381|NCT05230784|Other|Placebo Air Filter|Participants in the placebo arm will receive an air purifier with only the EGAPA filter.
75658382|NCT05226637|Device|ESWT (extra-corporeal shock wave therapy)|The ESWT device (Storz Medical Duolith SD1),
75658383|NCT05226637|Device|Sham : The ESWT device (Storz Medical Duolith SD1),|In doing so, the sham head still actuates and makes the same sounds but produces no shockwave. Because the patients receiving this intervention are naïve to ESWT, they will not be biased by the sensation it produces. Communication during treatment will be limited to avoid inadvertent bias.
75658384|NCT05216536|Other|No intervention|No intervention
75658385|NCT05214365|Device|Pacemaker implantation and conventional cardiac pacing|Patients will have the pacemaker implanted in the electrophysiology laboratory. Electrode will be implanted (in the apical or septal portion) according to the criteria of the implanting physician.
75658386|NCT05214365|Device|Conduction system pacing implant|Right ventricular lead was placed to get his bundle or left bundle branch.
75805459|NCT05316610|Behavioral|Body Confident Athletes|The Body Confident Athletes program is a five-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10 girls. The organizations will work with the community partner and researchers on how to schedule the intervention over a five-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sport organizations. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Skills (20 mins), Game Time (20 mins), and The Final Score (15 mins). A variety of activity modalities are utilized to convey learning outcomes, including group and individual activities, and discussion-, writing- and movement-based activities.
75658387|NCT05214131|Device|gogoband|use of biometric alarm to wake patient prior to wetting
75805460|NCT05300867|Other|Neurorehabilitation|Neurorehabilitation with soft exsoskeleton robotic 3-week-long
75658388|NCT05214131|Device|SNEA group|standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
75658389|NCT05211180|Behavioral|Vida Sana|Weekly group or individual education sessions with a health coach and fitness tracking with a fitbit.
75346843|NCT03407300|Drug|Docetaxel|To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients
75346844|NCT03407300|Drug|Chinese traditional medicine XH1|To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
75346845|NCT01729286|Device|PriMatrix Moist Wound Therapy|sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
75346846|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
75346847|NCT01729364|Drug|crystalloid|
75658390|NCT05211180|Behavioral|Vida Sana y Completa|Weekly group or individual education sessions with a health coach, fitness tracking with a fitbit, and weekly food box delivery.
75658391|NCT05199233|Device|Muse S™ Headband system|Clinical grade, headband style, wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (smartphone or tablet).
75658392|NCT05184764|Biological|AP-SA02|Bacteriophage administered via intravenous bolus infusion
75658393|NCT05184764|Other|Placebo|Inactive Placebo administered via intravenous bolus infusion
75658394|NCT05183490|Drug|Rapidly generated virus specific T (R-MVST) cells|"The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~(-1A) 0.25x10^6 R-MVST TNC/kg~(1A) 0.5x10^6 R-MVST TNC/kg~(2A) 1x10^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~(-1B) 1x10^6 R-MVST TNC/kg~(1B) 2x10^6 R-MVST TNC/kg~(2B) 4x10^6 R-MVST TNC/kg"
75658395|NCT05180097|Drug|Gemcitabine|1000mg/m2 IV, 30 mins D1, D8
75346848|NCT01729364|Drug|colloid|
75346849|NCT01722968|Drug|Bevacizumab|15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
75346850|NCT01722968|Drug|Paclitaxel|80mg/m2 iv weekly
75346851|NCT03407222|Other|Text messages|Text messages which encourage the increment of daily step count
75346852|NCT01723046|Device|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
75346853|NCT01729442|Other|Shear-wave ultrasound elastography (SWUE)|
75658396|NCT05180097|Drug|Dexamethasone|40mg daily PO, D1-D4
75477025|NCT05022147|Drug|ON Dopaminergic Medication|All six device interventions will be performed in medication ON state
75658397|NCT05180097|Drug|Cisplatin|75mg/m2 IV, 1 hour, D1
75658398|NCT05180097|Drug|Brentuximab vedotin|1.8 mg/kg IV, 30 mins, Q21 days
75658399|NCT05180097|Drug|Pembrolizumab|200mg IV, 30 mins, Q 21 days
75658400|NCT05180071|Device|TEMA elbow system|Total elbow replacement
75658401|NCT05179447|Radiation|Vaginal brachytherapy|"Internal radiation of the vaginal vault using a vaginal cylinder. For brachytherapy administered alone it is recommended: suggested dose is either 3 fractions of 7 Gy or 5 fractions of 6 Gy.~For brachytherapy administered after completion of External beam radiotherapy (EBRT):~Total dose should aim to be 65 Gy, and suggested dose is 2-3 fractions of 5-6 Gy"
75658402|NCT05179447|Radiation|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 45-50 Gy in 25-28 out-patients sessions
75658403|NCT05179447|Other|Observation|No adjuvant therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
75658404|NCT05179447|Combination Product|Chemoradiation therapy|4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )
75658405|NCT05176197|Other|Almond|Participants will consume almonds every day for 16 weeks.
75658406|NCT05176197|Other|Control|Participants will consume pretzels every day for 16 weeks.
75805461|NCT05300867|Other|Physiotherapy|Physiotherapy 3-week-long
75805462|NCT05297071|Device|Orascopic HDL 3.0 Loupes|The loupes will be used during the surgical procedure on half of the subjects. The other half will be performed with a microscope.
75805463|NCT05297071|Device|Semorr DOM3000D Operation Microscope|The microscope will be used during the surgical procedure on half of the subjects. The other half will be performed with loupes.
75805464|NCT05296720|Behavioral|Tactile stimulation|Participants are asked to react as fast as possible to a tactile stimulation
76093588|NCT03228654|Procedure|Unipolar Electrocautery sealing of vessels|"Vaginal walls are incised by monoplar current (40 W)~A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~uterine vessels are individually secured.~Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements."
75658407|NCT05173675|Behavioral|Empathy in Action for life with diabetes.|"In Phase 1 (Months 1-6) participants receive (Program):~Empathetic communications: A dedicated partner (lightly-trained lay person) who communicates with them via phone with timing and frequency defined by the participant within certain parameters. Two letters mailed during the 6 months that compile anonymized learnings from all participants in the callers panel of 10-20 participants, written as a newsletter to share back with the participant.~Material Incentives: One choice of health tool (weight scale or pedometer) selected with the caller in week 1 and expected to be received in weeks 3-5. Two small recognition gifts (valued at US$25) chosen by the caller based on their understanding of the participants preferences, and sent at month 2.5 and 4.5.~Educational Materials: Printed DM management educational materials mailed right after enrollment and randomization, and expected to be received in weeks 1-2."
75658408|NCT05173675|Behavioral|Control Phase 2 Materials Only|"Material Incentives:~a. Choice of health tool (weight scale or pedometer) and 2 health promoting gifts chosen by the caller at the end of their 6 month measurement visit.~i. Health tool is mailed out within the 7th month ii. Health promoting gifts are mailed out in the 8th and 10th month~Educational Materials a. The same educational materials mailed to participants in the intervention arm Program will be mailed to control arm participants after they complete their 6 months visit"
76093589|NCT03228654|Procedure|Purohit technique for vaginal hysterectomy|using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
76093590|NCT03228888|Other|Administration of rhytmic acoustic stimuli for gait training|The intervention consist in 5 weeks, 20 min/day gait training assisted by rhythmic acoustic stimuli administered using a portable MP3 player
76093591|NCT01747499|Drug|Azacitidine|
76093592|NCT00071721|Drug|Valproate|250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
76093593|NCT00071721|Drug|Placebo|Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
75658409|NCT05169957|Drug|Ipilimumab|Ipilimumab administered IV over 85-100 minutes at 3 mg/kg (combined with nivolumab administered IV over 30-60 minutes at 1 mg/kg) every 3 weeks for a total of 4 doses or until progression or unacceptable toxicity.
75805465|NCT05277714|Other|Sham|The sham protocol will last 15 minutes per session, and during each session, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy that the participant tries to implement is not correlated with the visual feedback provided by the gauge.
75805466|NCT05277714|Other|NF|"The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the patient will have to increase the brain activity of her dlPFC using a visual gauge representing the activity level of her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
75805467|NCT05249530|Other|Chiropractic spinal adjustment|Chiropractic spinal adjustment
75805468|NCT05249530|Other|Non-force simulation|Non-force simulation
75805469|NCT05239494|Device|DT1 Sphere Contact Lenses|Devices: Dailies Total 1 Sphere Contact Lenses
75805470|NCT05228171|Behavioral|mCC app|Interviewer use of the mCC app during the 24-hour dietary recall interview.
75946260|NCT02339324|Drug|Pembrolizumab and high dose interferon alfa-2b (HDI)|Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
75946261|NCT02334956|Other|Brain MRI|
76093594|NCT03107208|Drug|Glargine|A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
76093595|NCT03107208|Device|Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)|All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
75805471|NCT05225584|Drug|KT-333|KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.
75805472|NCT05197881|Device|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
75805473|NCT05196230|Device|Control Condition (Social Story)|The control condition is a social story, which is treatment as usual for preparing clients for their initial visit at Holland Bloorview's dental clinic. The control condition will be delivered through the study tablet. The investigators will ask parents to read it to their child once a day for the week leading up to their appointment. If the child is reading on their own, the investigators will request that parents be in the room with participants while they are. The social story takes approximately five minutes to read.
75946262|NCT03105206|Procedure|Flexible Ureteroscopy|the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
75946263|NCT02334566|Behavioral|NET TX|Intervention procedures are a behavioral intervention (NET & KIDNET) with 8-12 sessions administered on a weekly basis.
75946264|NCT02339480|Other|Massage therapy|Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
75946265|NCT02418754|Drug|REGN2176-3|
75946266|NCT02418754|Drug|Intravitreal Aflibercept Injection (IAI)|
75946267|NCT02334488|Drug|Everolimus|Active Comparator
75946268|NCT02334488|Drug|Tacrolimus|Active Comparator
75946269|NCT02334488|Drug|Mycophenolate sodium|Experimental Arm
75658410|NCT05169957|Drug|Nivolumab|Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the combination therapy or until progression or unacceptable toxicity. Subjects may receive maintenance dosing of nivolumab alone administered IV over 30-60 minutes at 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 52 weeks or until progression or unacceptable toxicity.
75805474|NCT05196230|Device|Experimental Condition (360° Video)|The 360° video is from the point of view of a seated dental client and the participant will be able to explore the scene around them (navigating through the tablet's touch screen). The simulation will include scenes/features that may be anxiety-provoking for some participants. These will include loud noises commonly encountered in the dentist's office (e.g. tooth brushing, dental drills), as well as social stimuli (e.g. the dental clinician), and new environments (e.g., the dental visit room). The investigators will ensure that participants understand that they can stop at any time (e.g., if they are feeling anxious or overwhelmed), and the investigators will ask parents to explore the 360° video with their child for the week leading up to their appointment.
75805475|NCT05195203|Drug|HS-10353|Single or multiple dose(s) of HS-10353
76093596|NCT01717391|Drug|fluorothymidine F 18|A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
76093597|NCT03107364|Other|Hospital stay|Collection of hospital lengths of stay and readmissions
76093598|NCT05606055|Drug|BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato|This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
75946270|NCT03105050|Other|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
76093599|NCT01896609|Biological|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
75511301|NCT03690544|Drug|Apremilast 30mg|Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
75805476|NCT05195203|Drug|Placebo|Single or multiple dose(s) of placebo
75805477|NCT05195008|Drug|BIIB113|Administered as specified in the treatment arm.
76093600|NCT01896609|Drug|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
75658411|NCT05169957|Procedure|Stereotactic Body Radiation Therapy|24-45 Gy delivered in three fractions to up to 4 liver metastases
75658412|NCT05169567|Drug|Abemaciclib|Administered orally.
75658413|NCT05169567|Drug|Fulvestrant|Administered IM.
75658414|NCT05169567|Drug|Placebo|Administered orally.
75805478|NCT05195008|Drug|BIIB113-Matching Placebo|Administered as specified in the treatment arm.
75805479|NCT05195008|Drug|11^C]BIO-1819578|Administered as specified in the treatment arm.
75805480|NCT05186753|Drug|Bezuclastinib Tablets (Formulation A)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
76093601|NCT01896609|Drug|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
76093602|NCT01896609|Drug|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
76093603|NCT03232554|Drug|Buxue Yimu Pills|Buxue Yimu Pills 12g pill by mouth, twice daily.
76093604|NCT03232554|Drug|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
76093605|NCT03232554|Drug|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
76093606|NCT05605977|Behavioral|Traditional visual-motor training program|Traditional visual-motor program includes play and paper-and-pencil activities
75511302|NCT03685591|Drug|PF-06952229|Oral 7 days on / 7 days off - 28 day cycles (Part 1)
75511303|NCT03685591|Drug|Enzalutamide|Prostate Cancer (Part 2). 160mg, capsules, orally, daily
75511304|NCT00123006|Behavioral|Dietary Approaches to Stop Hypertension (DASH)|4 week feeding intervention
75511305|NCT00123006|Behavioral|Control Diet|4 week feeding intervention
75511306|NCT00314977|Drug|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
75511307|NCT00314977|Drug|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
75805481|NCT05186753|Drug|Bezuclastinib Tablets (Formulation B)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
75805482|NCT05186753|Drug|Placebo Tablets|Placebo will be administered orally, once daily continuously for 28-day cycles
76093607|NCT05605977|Behavioral|Computerized visual-motor training program|Computerized visual-motor training program includes tablet visual-motor games
76093608|NCT03232398|Drug|Apixaban Oral Tablet [Eliquis]|Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
75946271|NCT02334644|Dietary Supplement|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|2 sachets/day x 12 weeks
75946272|NCT02334644|Dietary Supplement|Placebo|2 sachets/day x 12 weeks
75946273|NCT02447458|Drug|MLN3126|MLN3126 tablets
75946274|NCT02447458|Drug|MLN3126 Placebo|MLN3126 placebo-matching tablets
75946275|NCT02862457|Drug|Epacadostat 25 mg|Oral administration
75946276|NCT02862457|Drug|Epacadostat 100 mg|Oral administration
75946277|NCT02862457|Biological|pembrolizumab 200 mg|Intravenous (IV) infusion
75946278|NCT02862457|Drug|Cisplatin 75 mg/m^2|IV infusion
75946279|NCT02862457|Drug|Carboplatin Area Under the Curve (AUC) 5|IV infusion
76093609|NCT03232398|Drug|Warfarin|Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
75511308|NCT00314977|Drug|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
75658415|NCT05168020|Behavioral|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress
75658416|NCT05168020|Behavioral|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress
75805485|NCT05176561|Behavioral|Auditory-Cognitive Training|Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician.
75805486|NCT05176561|Behavioral|Non-auditory Cognitive Training|Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician.
75805487|NCT05167396|Device|Retinaute (BioSerenity)|Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards
75805488|NCT05167396|Device|EEG Headset 64 electrodes (BioSemi)|EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals
75658417|NCT05162768|Drug|Elamipretide|60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks
75805489|NCT05167396|Device|MonPackOne (Metrovision)|"Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective"
75805490|NCT05161546|Device|EEG and ERG measurements (Retinaute®, BioSerenity)|"The Retinaute® is a portable medical device developed by BioSerenity, France, for performing flash and pattern ERG. It comes in the form of a virtual reality headset, which can be used in outpatient facilities. It is non-invasive and uses skin electrodes for the collection of parameters.~ERG signals will be supplemented with 4 EEG channels, via cup electrodes applied to the skull and allowing the concomitant performance of an EEG."
75946280|NCT02862457|Drug|Pemetrexed 500 mg/m^2|IV infusion
75946281|NCT02862457|Drug|Paclitaxel 200 mg/m^2|IV infusion
75946282|NCT02862457|Drug|Carboplatin AUC 6|IV infusion
75946283|NCT04103138|Device|Sedline EEG sensor placement|Patients will have Sedline EEG sensor placed before or immediately after induction.
75946284|NCT04103138|Device|Sedline EEG monitoring|Anaesthesia depth will be guided by EEG characteristics in addition to routine clinical parameters
75511309|NCT00400296|Drug|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
75511310|NCT00315016|Drug|eplerenone|active comparator
75511311|NCT00315016|Drug|fosinopril|doubling of fosinopril dose
75511312|NCT00315016|Drug|placebo|placebo (double dummy)
75511313|NCT00419068|Drug|Cholecalciferol|
75511314|NCT00419068|Drug|Migliol Placebo Oil|
75658418|NCT05162768|Drug|Placebo|Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks
75658419|NCT05161832|Behavioral|Nocebo|Nocebo ultrasound with diagnosis of a fake shoulder cuff injury.
75511315|NCT00419146|Drug|Ethyl-eicosapentaenoic acid (EPA)|Capsules, 2 g per day for 16 weeks
75658420|NCT05161832|Behavioral|Placebo|Placebo ultrasound with no diagnosis of injury.
76093610|NCT04753125|Behavioral|follow-up by telephone|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
75658423|NCT05155683|Device|Photobiomodulation (PBM) with infrared LED|All participants will receive 30 minutes of PBM (or PBM sham), with an abdominal strap containing 4 LED clusters with 72 devices that emit 830 nm wavelength with 20 nm spectral width, in continuous operating mode, 5 mW average radiant power per LED, 71 mW/cm² power density at aperture, 20.4 cm² of total area irradiated, 71 mW/cm² of irradiance at target, exposure duration of 1800 seconds, 127.8 J/cm² of radiant exposure, 2.6 kJ of radiant energy, per contact application technique, twice a week for a month, totaling 8 sessions.
75658424|NCT05155683|Device|Low-frequency ultrasound (LOFU)|Subsequently the demarcation of the target area for LOFU treatment (Thoor DGM Electronica, Santo André, São Paulo, Brazil), the application of the neutral conductive gel will occur for the use of low-frequency ultrasound for 30 minutes, which will occur with 22 cm² effective radiating area (ERA) size, <8 BNR emission intensity, 40 kHz frequency, continuous mode, 60W, 100 cm² of total treated area, twice a week for a month, totaling 8 sessions.
75805491|NCT05161546|Device|Actigraphy (Motion Watch 8®, CamNtech)|"Actigraphy is an ecological and non-invasive method allowing a reliable characterization of the sleep/wake cycle. It is a portable system for continuously measuring the motor activity of an individual and appreciating the alternation of activity periods (wakefulness) and rest periods (sleep).~An actigraph (MotionWatch8®, CamNtech) looks like a wristwatch that will be worn continuously, by convention on the wrist of the non-dominant hand, over periods ranging from several days to several weeks (here 21 days). Actigraphy does not present a known risk."
75805492|NCT05161546|Behavioral|Neuropsychological assessments|The purpose of this assessment is to establish a cognitive profile for each participant. It uses a series of tests widely described in the literature and commonly used today.
75946285|NCT02334332|Other|Educational Intervention|Receive educational brochure
75946286|NCT02334332|Procedure|Standard Follow-Up Care|Receive standard post-operative care
75946287|NCT02334332|Procedure|Quality-of-Life Assessment|Ancillary studies
75946288|NCT02334254|Drug|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
75946289|NCT02334254|Drug|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
75946290|NCT02447302|Drug|Etrasimod|
75946291|NCT02447302|Drug|Placebo|
75946292|NCT02334410|Device|Whole body vibration (WBV)|Side-alternating WBV
75946293|NCT02482519|Other|High calorie diet|High calorie diet for 10 days
75946294|NCT02482519|Other|Fasting|10 day fast
75946295|NCT02039570|Other|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
75946296|NCT02331602|Drug|Rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
75346854|NCT01729520|Other|Knee extension strength training|"Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for~Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for"
75346855|NCT01729676|Drug|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
75346856|NCT04379180|Drug|Bosentan Tablets|2mg/kg, bid
75346857|NCT04379180|Drug|Sildenafil Tablet|1mg/kg, q6h/q8h
75658425|NCT05155683|Device|Muscle electrostimulation|The session will end with 20 minutes of Russian Current (Tensor DGM Electronica, Santo André, São Paulo, Brazil), whose carrier frequency occurs in 2500 Hz, which will be adjusted according to the parameters described by Evangelista et al. (2003), which are: pulse frequency of 30 Hz; up/down ramp of 2 seconds each; support/rest time of 13 seconds each. The current intensity used will be the maximum supported by each participant and that is comfortable and sufficient to provide visible contraction. The treatment will consist of eight sessions that will occur twice a week, totaling a month of treatment.
75805493|NCT05161546|Device|Optical Coherence Tomography (OCT)|The Spectral Domain Optical Coherence Tomography (SD-OCT) is a modern ocular imaging process using infrared radiation and allowing to obtain in a few seconds, and in a non-invasive way, images in section of the eye. The OCT-Angiography (OCT-A) module increments on the OCT. It can detect the movement of the blood elements from sequential SD-OCT slices taken at the same location of the retina and obtain a map of the retinal and choroidal vessels, without injection of fluorescent dye. The device used for both exams will be the OCT spectral RS 3000 Advance 2 + Angioscan (NIDEK, Gamagori, Japan). SD-OCT and OCT-A examinations are fast, painless, non-contact and last less than a minute. There is no particular risk.
75805494|NCT05144009|Drug|Loncastuximab Tesirine|Intravenous (IV) Infusion
75805495|NCT05144009|Drug|Rituximab|Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.
75805496|NCT05131945|Other|Standard Suction Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
75805497|NCT05131945|Other|Gravity Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
75805498|NCT05130827|Drug|Plinabulin|40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.
75805499|NCT05129683|Other|Anodal tDCS cerebellar stimulation group|Single-session atDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
75805500|NCT05129683|Other|Anodal tDCS cerebral (M1) stimulation group|single session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
75805501|NCT05129683|Other|sham group|single session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
75805502|NCT05120544|Behavioral|EXTEND Plus|The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.
75946297|NCT02331602|Drug|Dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
75946298|NCT02454517|Behavioral|Behavioral Dietary Intervention|Undergo DPP lifestyle intervention
75946299|NCT02454517|Behavioral|Exercise Intervention|Undergo DPP lifestyle intervention
75946300|NCT02454517|Other|Informational Intervention|Receive oral and written guidelines and meet with dietician
75946301|NCT02454517|Other|Laboratory Biomarker Analysis|Correlative studies
75946302|NCT02454517|Other|Quality-of-Life Assessment|Ancillary studies
75946303|NCT02454517|Other|Questionnaire Administration|Ancillary studies
76093611|NCT04753125|Behavioral|follow-up via a game in a smartphone app|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
75346858|NCT04379180|Drug|Tadalafil Tablets|1mg/kg, qd
75346859|NCT03406754|Behavioral|rehabilitation programs|an 8-week multidisciplinary inpatient rehabilitation program
75346860|NCT01576523|Biological|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
75346861|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
75346862|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
75346863|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
75511316|NCT00419146|Drug|Vitamins E + C|RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
75511317|NCT00419146|Other|Etyl EPA (placebo)|Paraffin oil. Capsules, each 0.5 g.
75511318|NCT00419146|Other|Vitamins E+C (placebo)|Tablets containing dicalciumphosphate
75511319|NCT00123045|Behavioral|health education|
75511320|NCT04239365|Diagnostic Test|WLE followed by NBI or NBI followed by WLE (crossover design)|EMR scar is inspected using WLE followed by NBI or vice versa
75658426|NCT05154305|Behavioral|multidisciplinary intervention|"individually adjusted physical program consisting of strength and endurance training > 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.~multidisciplinary coaching (discipline depending on personal needs of patient) on a monthly basis. These coaching sessions could be in small groups or individual."
76093612|NCT04753125|Behavioral|conventional follow-up by a health professional|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
76093613|NCT03235830|Behavioral|Enhanced Standard of Care (ESoC) + Text|See above in arm/group description
76093614|NCT03235830|Behavioral|Enhanced Standard of Care (ESoC)|See above in arm/group description
76093615|NCT02362048|Drug|ACP-196|
76093616|NCT02362048|Drug|ACP-196 in combination with pembrolizumab|
75658427|NCT05147662|Biological|Damoctocog alfa pegol (Jivi, BAY94-9027)|"Part A: 40 IU/kg (up to 60 IU/kg at the investigator's discretion), two times per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, participants will continue their treatment as home treatment. Dose may be increased up to 60 IU/kg if needed at any time during the study at the investigator's discretion.~Part B: Each participant may continue on prophylaxis dose regimen as prescribed in part A (40 - 60 IU/kg, 2x per week) or adjustments to prophylaxis dose / dose frequency can be made at the investigator's discretion (based on the bleeding events and individual needs): Dose frequency may be decreased to every 5 days with a prophylaxis dose of 60 IU/kg."
75658428|NCT05137847|Drug|Remitoro|Intravenous infusion.
75658429|NCT05136898|Drug|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
75805503|NCT05120544|Behavioral|EXTEND|EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.
75805504|NCT05112003|Device|Translingual neurostimulation|The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
75805505|NCT05111886|Behavioral|Communication Skills Training|The training will focus on communication skills based on key constructs in the Health Belief Model and motivation/resistance research (described in section A3), the training will focus on: (1) conveying the benefits of parenting programs, (2) knowledge of and responses to common perceived barriers to attending parenting programs, and (3) skills and strategies to effectively motivate and refer parents in ways that are least likely to elicit resistance. The in-person training will last 60-90 minutes. It will include a theoretical background and experiential learning; each step of the referral process will be demonstrated and role-played. The investigators will work to ensure that personnel receive continuing education credits for the training.
75805506|NCT05111886|Behavioral|eHealth GenPMTO|The GenPMTO is delivered over the phone (not online). This version is up to 6 sessions in length. This brief eHealth version of GenPMTO will be delivered through community therapists. The program will be delivered one-on-one (i.e., between a therapist and a parent or couple).
75805507|NCT05111886|Behavioral|Written Referral Process|"A written summary and process map of the referral process, modeled on the Institute for Healthcare Improvement (IHI) 9-step process for closing the loop on referrals."
75946304|NCT02338934|Drug|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
75946305|NCT03610087|Behavioral|Low Intensity Intervention|Participants will have access via the online platform to the NAVIGATE self-help modules for physical activity, nutrition and quitting smoking with a list of community resources. Subjects will be sent a standard reminder emails once per week to complete their modules and connect with their main provider for any assistance.
76093617|NCT03232242|Diagnostic Test|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
76093618|NCT03232476|Device|Upper extremity voluntary loading|Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
76093619|NCT00158223|Drug|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
76093620|NCT00158223|Drug|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
76093621|NCT03228576|Combination Product|Extended release Tacrolimus-Everolimus association|Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus
76093622|NCT00158379|Drug|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
76093623|NCT03235674|Other|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
76093624|NCT03228498|Drug|Choline alphoscerate|Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
76093625|NCT03228498|Drug|Placebo|Placebo b.i.d plus Nimodipine 30 mg t.i.d
76093626|NCT02362672|Drug|NKTR-181 BID tablets|NKTR-181 tablets 100-400 mg twice daily (BID)
76093627|NCT02362672|Drug|Placebo to match NKTR-181 BID tablets|Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)
75946306|NCT03610087|Behavioral|High Intensity Intervention|Participants will receive individualized treatment planning, in collaboration with a Care Coordinator, and the Virtual Care Team (VCT). Interactive modules on physical activity, nutrition and quitting smoking will be provided via the online platform. the virtual team will be engaged to provide treatment and/or recommendations regarding the following: increasing physical activity, improving nutrition and diet, smoking cessation (psychosocial support plus medications), and medication adherence. Participants in this arm will have weekly check-ins with their assigned Care Coordinator where they will be able to discuss VCT recommendations, and progress on their goals.
75805508|NCT05111886|Behavioral|One Session Education about Resources|"One online or phone conversation with the therapist in which the therapist guides the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) a website, behaviorchecker.org, which includes behavioral prescriptions for common behavior issues; and (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools."
75805509|NCT05111886|Diagnostic Test|Survey of Experience|Satisfaction with referral process
75946307|NCT02330900|Other|Study group|Exposure to cell phone interference of the ICD
75946308|NCT03861039|Drug|Tirzepatide|Administered SC
75946309|NCT03861039|Drug|Oral antihyperglycemic medication (OAM)|Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
75946310|NCT04365673|Other|Pharmacist transition of care consultation|Pharmacist-delivered comprehensive medication review
75946311|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 1 injection|The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
75946312|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 2 injections|The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
75946313|NCT02334176|Drug|lidocaine 1.5% with epinephrine 5µg/ml|35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
75946314|NCT02236975|Device|BuMA Supreme Biodegradable drug coating coronary stent system|
76093628|NCT03232320|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
75946315|NCT02236975|Device|Resolute Integrity durable polymer stent system|
75946316|NCT02338856|Drug|MB12066 200mg|100mg bid (multiple dose, day 8)
75946317|NCT02338856|Drug|Placebo|100mg bid (multiple dose, day 8)
75946318|NCT03609931|Procedure|Mitral Valve Model|Creation of a mitral valve patient specific model to see if it mimics the patients valve
76093629|NCT03232320|Drug|Placebo|Placebo (Normal saline)
75658430|NCT05132166|Other|Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.|Will vary depending upon Investigator's choice identified prior to randomization. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT. No cross-over to DSC treatment is planned. The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
75658431|NCT05132166|Biological|Decidual Stromal Cells|The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
75805510|NCT05110742|Drug|Fludarabine Phosphate|Given by IV
75805511|NCT05110742|Drug|Cyclophosphamide|Given by IV
75805512|NCT05110742|Drug|CAR.5/IL15-transduced CB-NK cells|Given by IV
75805513|NCT05094609|Biological|Ad5-triCoV/Mac|Ad5-triCoV/Mac is a recombinant type 5 human adenovirus vector which has been engineered to express our trivalent SARS-CoV-2 transgene cassette under the control of an MCMV promoter, and is followed by an SV40 polyA signal. The adenovirus construct is E1 and E3 deleted.This trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
75805514|NCT05094609|Biological|ChAd-triCoV/Mac|ChAd-triCoV/Mac is an E1 and E3 deleted chimpanzee adenovirus serotype 68 where the trivalent SARS-CoV-2 transgene cassette is under the control of an HCMV promoter and is followed by an SV40 polyA signal. The trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
76093630|NCT03232086|Other|Clean Air|Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
76093631|NCT03232086|Other|PM2.5|Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
76093632|NCT00158925|Device|EASYTRAK EPI lead|EASYTRAK EPI lead
76093633|NCT03235596|Device|tDCS|cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
75805515|NCT05094362|Behavioral|Spinal Reflex Operant Down Conditioning|This is a training intervention in which people with a spinal cord injury are trained to reduce the activity of a certain spinal reflex. By decreasing this reflex, individuals decrease hyperactivity in the reflex and can reduce spasticity.
76093634|NCT03232008|Dietary Supplement|Canderel drink|1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water
76093635|NCT03232008|Dietary Supplement|Canderel+Lyle's Golden Syrup drink|Canderel: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water Lyle's Golden Syrup: 35 g (27g of glucose and fructose)
75805516|NCT05083741|Device|Chitogel|post-operative dressing within standard of care
76093636|NCT02364076|Drug|Pembrolizumab|Administration of 200 mg MK-3475 once every 3 weeks
75946319|NCT02338778|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
75946320|NCT02338778|Other|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
75946321|NCT03609307|Drug|Combined Intravitreal bevacizumab and propranolol|these patients receive two injections at each session Bavacizumab and propranolol
76093637|NCT02364076|Drug|Epacadostat|100mg taken by mouth twice daily
76093638|NCT03235440|Behavioral|Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
75946322|NCT03609307|Drug|Intravitreal bevacizumab|these patients receive only Bevacizumab
76093639|NCT03231930|Device|OraQuick HCV Ab test|The OraQuick HCV point of care test involves the collection of oral fluid and provides an accurate result in approximately 20 minutes. The test involves a clinic nurse or community health worker providing pre-test counselling, then providing an oral swab to study participants, then reading the result and counselling the participant about their HCV antibody test result.
75511321|NCT00315094|Behavioral|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
75658432|NCT05122728|Other|Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk Assessment|"Participants will complete a comprehensive biomechanical and neuromuscular assessments to elucidate the underlying neuromuscular control mechanisms that may contribute to increased MSKI risk following concussion. Participants will also complete a battery of self-report psychosocial measures.~Biomechanical Dynamic Movement Assessments:~Jump-Landing~Single Leg Hop~Anticipated Cut~Gait - Single Task~Gait - Dual Task~Strength and Voluntary Muscle Activation Assessments:~Interpolated Twitch Technique~Muscular Ramp Contraction~Sensory assessments:~Proprioception - Closed Chain~Passive Joint Repositioning~Light Touch Sensation~Patient Reported Outcomes:~Self-Reported Musculoskeletal Injuries~National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function~PROMIS Pain Interference~PROMIS Depression~PROMIS Anxiety~Brief Resilience Scale (BRS)~Tampa Scale of Kinesiophobia (TSK-11)"
75658433|NCT05121766|Drug|Omega-3 (EPA+DHA)|"Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day).~Each capsule has 252mg of EPA and 102mg of DHA."
75658434|NCT05121766|Drug|Placebo|3 Soybean Oil Placebo capsules
75946323|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low and epinephrine (T1)|A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.
75946324|NCT03399435|Combination Product|Bupivacaine low combined with epinephrine (C1)|A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
75346864|NCT01723124|Procedure|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
75346865|NCT03406676|Drug|Methylene Blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
75346866|NCT03406598|Other|Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
75346867|NCT03007355|Other|peripheral perfusion index measurement|
75511322|NCT03426475|Procedure|interprof ACT measures|Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
75658435|NCT05117918|Other|SUFU Clinical Care Pathway for Overactive Bladder|Treatment of OAB via the SUFU clinical care pathway
75346868|NCT04378946|Behavioral|Intensive physical rehabilitation type training|Multiple reaching tasks aiming at increasing voluntary elbow range of motion
75658436|NCT05117918|Other|Telemedicine|Delivery of care via telemedicine
75658437|NCT05103683|Drug|TORL-1-23|antibody drug conjugate (ADC)
75805517|NCT05083741|Device|Nexfoam|post-operative dressing within standard of care
75805518|NCT05064631|Drug|Bacterial Lysate|Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system.
75805519|NCT05042544|Diagnostic Test|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
75805520|NCT05042440|Drug|Efanesoctocog alfa|Solution for injection Intravenous
75805521|NCT05042440|Drug|Octocog alfa|Solution for injection Intravenous
75805522|NCT05042440|Drug|Rurioctocog alfa pegol|Solution for injection Intravenous
75805523|NCT05039814|Other|postoperative acute kidney injury|patients suffered postoperative acute kidney injury
75805524|NCT05039814|Other|none postoperative acute kidney injury|patients did not suffered postoperative acute kidney injury
75946325|NCT03399435|Combination Product|Bupivacaine high combined with epinephrine (C2)|A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.
75346869|NCT04378946|Device|Robotic system for supporting and monitoring arm motion|"Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training."
75658438|NCT05102162|Drug|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
75658439|NCT05102162|Drug|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
75805525|NCT05039099|Drug|AP-101|Participants receive AP-101 by intravenous infusion (IV).
75946326|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low (T2)|A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.
75946327|NCT03399435|Drug|Bupivacaine low (C3)|A single injection: Bupivacaine from 10 to 80 mg.
75658440|NCT05098080|Biological|Hutrukin|Hutrukin that binds the human cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity. Hutrukin is a True Human™ therapeutic antibody. That is, the antibody was generated by a natural human immune response and was cloned directly from a human peripheral B lymphocyte. No in vitro affinity maturation or modifications have been made to improve its natural binding affinity. A true human antibody should be effectively non-immunogenic in humans and thus exhibit optimal activity and pharmacokinetics indistinguishable from native IgG1 immunoglobulin.
75658441|NCT05098080|Biological|Placebo|Placebo control for Hutrukin IV push.
75658442|NCT05084495|Diagnostic Test|Global peak atrial longitudinal strain and ECG|During the follow-up period the patient will have four clinical visits, during which clinical data, advanced echocardiographic data (strain and speckle tracking) and ECGs (Glasgow criteria) will be collected
75658443|NCT05083442|Device|Low Level Laser Therapy|Non-surgical cosmetic treatment which can be used by individuals intending to reduce size of the mid-section
75658444|NCT05083442|Other|Sham (placebo)|Use of sham (placebo) option
75346870|NCT04378946|Device|Actigraph Activity Monitor|Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate
75346871|NCT04378946|Diagnostic Test|Magnetic resonance imaging (MRI)|Done once before treatment (PRE)
75346872|NCT04378946|Diagnostic Test|Montreal Spasticity Measure (MSM)|Used to identify the actual spatial threshold (ST) prior to every training session
75658445|NCT05081180|Drug|Avelumab|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive intravenous infusion at a flat dose or weight based dose of Avelumab, every 2 weeks (Q2W) until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when Maximum tolerated dose (MTD) and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
75511323|NCT00123084|Behavioral|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
75805526|NCT05039099|Drug|Placebo|Participants receive placebo by IV.
75805527|NCT05022563|Drug|Parenteral anticoagulant|Parenteral anticoagulant only
75511324|NCT00123084|Behavioral|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
75805528|NCT05022563|Drug|Warfarin|Warfarin-based
75805529|NCT05022563|Drug|Apixaban|Apixaban
75946328|NCT03399435|Drug|Bupivacaine high (C4)|A single injection: Bupivacaine 100 mg.
75946329|NCT03399435|Drug|Neosaxitoxin (T3)|A single injection: Neosaxitoxin will be between 1.25 and 60 µg.
75946330|NCT03399435|Combination Product|Neosaxitoxin combined with epinephrine (T4)|A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.
75946331|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low and epinephrine|A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.
75946332|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low|A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
75346873|NCT03001739|Drug|Urapidil Hydrochloride Injection|Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
75511325|NCT02965196|Drug|IV Dexamethasone Therapy|
75805530|NCT05022563|Drug|Rivaroxaban|Rivaroxaban
75805531|NCT05022563|Drug|Dabigatran|Dabigatran
75511326|NCT02965196|Other|IV Normal Saline (NaCl 0.9%)|
75511327|NCT03325426|Device|FitBit|Daily use of physical activity tracker coupled with biweekly provider telemonitoring and feedback for 6 months and then additionally without feedback for an additional 6 months
75805532|NCT05022563|Drug|Edoxaban|Edoxaban
75805533|NCT05010473|Behavioral|Speech and non-speech sound stimulation|Listening to repetitive and extended sound presentation induces specific neural and physiological activity that we will measure via electroencephalography and pupillometry
75805534|NCT05009069|Radiation|Radiotherapy|Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
75805535|NCT05009069|Drug|Capecitabine|Weeks 1-5: Capecitabine 825 mg/m^2 orally twice daily (bid) 5 days/week during radiotherapy.
75946333|NCT02338700|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
75658446|NCT05081180|Drug|Lenvatinib|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive daily oral escalated dose level of Lenvatinib until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when MTD and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE of Lenvatinib in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
75658447|NCT05058404|Drug|Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles); Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
75658448|NCT05058404|Drug|Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles);~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
75805536|NCT05009069|Drug|Fluorouracil|Weeks 1-5: fluorouracil (5-FU) 225 mg/m^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
75805537|NCT05009069|Drug|Atezolizumab|Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
75805538|NCT05009069|Drug|Tiragolumab|Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
75805539|NCT04977349|Other|Manual Therapy|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
75805540|NCT04977349|Other|Exercise program|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
75805541|NCT04968951|Drug|Metronidazole|Antibiotic treatment - 250 mg every 6 hrs for 5 days
75805542|NCT04968951|Drug|Placebo|Placebo treatment
75805543|NCT04968951|Drug|Vancomycin|Antibiotic treatment - 125 mg every 6 hrs for 5 days
75805544|NCT04968951|Biological|Fecal Microbiota Transplantation|Encapsulated biologically active human fecal material (donor stool) is provided in capsule form. The fecal material is homogenized with sterile saline, then pelleted and re-suspended in sterile saline/40% glycerol. Participants will receive 15 FMT capsules per day for 3 consecutive days. Capsule are to be swallowed under direct supervision.
75805545|NCT04960046|Procedure|Placement of an infraclavicular perineural catheter using a costoclavicular approach|"The high-frequency linear probe will be used to image the axillary artery in the long axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, also in its distal third. The needle will be inserted with a latero-medial orientation in the plane. The initial injection will be a single injection laterally to the axillary artery, where the three nerve bundles are still joined together.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
75946334|NCT02338700|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
75946335|NCT01936688|Drug|MK-3222 200 mg|MK-3222 200 mg administered SC.
75946336|NCT01936688|Drug|MK-3222 100 mg|MK-3222 100 mg administered SC.
75946337|NCT01936688|Drug|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
75946338|NCT01936688|Drug|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
75946339|NCT01936688|Drug|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
75946340|NCT03399357|Biological|Influenza Vaccine|Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
75946341|NCT02338544|Drug|0.1% Adapalene / 2.5% Benzoyl peroxide|Epiduo® gel containing 0.1% adapalene + 2.5% benzoyl peroxide dispensed from a pump.
75946342|NCT04446663|Drug|Toripalimab|Toripalimab 240mg ivdrip, every 3 weeks for 6 cycles, with 3 cycles combined with induction chemotherapy, 3 cycles combined with concurrent chemoradiotherapy
75946343|NCT04446663|Drug|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 260 mg/m2, d1 of every cycle, every 3 weeks for 3 cycles before radiotherapy
75946344|NCT04446663|Drug|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiotherapy Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiotherapy
75946345|NCT04446663|Radiation|intensity-modulated radiotherapy|Definitive IMRT of ≥66 Gy will be given .
75946346|NCT01861496|Drug|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8
75946347|NCT03399279|Procedure|Open flap debridment|Full mucoperiosteal flap reflected+ Debridement of infrabony defect
75946348|NCT03399279|Other|Perforated collagen membrane|Membrane perforations using dental needle
75946349|NCT03399279|Other|Occlusive membrane|Biotech collagen membrane
75946350|NCT03399279|Other|Nanohydroxyapetite|Nanbone Particles
75946351|NCT02333942|Device|Nautilus NeuroWaveTM System|A noninvasive device to detect dementia utilizing headset and sensors
75946352|NCT02334020|Other|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
75946353|NCT02520219|Drug|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,>1h,d1; or DDP25 mg/m2,ivgtt,>1h,d1-3.
76093640|NCT03231930|Device|Xpert HCV viral load test|"The Cepheid Xpert HCV RNA test (Xpert® HCV Viral Load test) is a reverse transcriptase polymerase-based chain reaction amplification technology (RT-PCR) and provides an accurate HCV RNA load within 2 hours (105 minutes), using a serum sample.~This test will be performed for participants who have a positive OraQuick HCV antibody result."
76093641|NCT02364700|Device|Hand of Hope (HOH)|"Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:~warm up-passive stretch of hand in flexion and extension (5 minutes);~setting the EMG threshold parameters for the device;~active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)~active practice of closing then hand (UFO Catcher game; 10 min)~open and closing the hand (Ball and Basket game; 10 min)~open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)~cool down-passive stretch of hand in flexion and extension (5 minutes)"
76093642|NCT02453022|Drug|Danirixin HBr 50 mg IR Tablet|Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
76093643|NCT02453022|Drug|Danirixin FB 50 mg IR Tablet|Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
76093644|NCT02453022|Drug|Prilosec (omeprazole) 40mg Delayed-Release capsule|Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
75658449|NCT05058404|Drug|Immunochemotherapy regimen: R-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-CHOP Q21 + 2 cycles Q21 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis planned by the study."
75946354|NCT02520219|Biological|Endostar|"Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days."
75346874|NCT03001583|Behavioral|Education program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
75946355|NCT02333786|Other|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
75946356|NCT02333786|Other|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
75946357|NCT02334098|Dietary Supplement|Omega-3 supplemented drink|"The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.~1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment."
75946358|NCT02334098|Dietary Supplement|Smartfish|Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
75946359|NCT03394287|Drug|SHR-1210|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
75946360|NCT03394287|Drug|Apatinib|Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
75946361|NCT02338622|Drug|olaparib|olaparib BD
75946362|NCT02338622|Drug|AZD5363|AZD5363 BD
75946363|NCT02338466|Drug|rt-PA|0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
76093645|NCT03231852|Other|Survey|Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey
76093646|NCT02365714|Radiation|CK Stereotactic Accelerated Partial Breast Irradiation|Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
76093647|NCT03235752|Drug|TJ301 300mg|TJ301 300mg IV infusion
76093648|NCT03235752|Drug|TJ301 600mg|TJ301 600mg IV infusion
76093649|NCT03235752|Drug|Placebo|Placebo IV infusion
76093650|NCT00163293|Drug|Ciclesonide|Ciclesonide metered-dose inhaler
76093651|NCT00163293|Drug|Placebo|Ciclesonide placebo-matching metered-dose inhaler
76093652|NCT03231618|Dietary Supplement|1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet|Every participate was provided with 3 types of diets in random order
75346875|NCT03001583|Behavioral|Education program WITHOUT cooking lessons|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
75346876|NCT01729832|Procedure|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
75346877|NCT01729832|Procedure|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
76093653|NCT03228342|Diagnostic Test|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
76093654|NCT03228342|Diagnostic Test|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
76093655|NCT02033200|Drug|Stendra 200 mg|
76093656|NCT02033200|Drug|Placebo|
75805546|NCT04960046|Procedure|Placement of an infraclavicular perineural catheter by paracoracoid approach|"The high-frequency linear probe will be used to image the axillary artery in the short axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, in its distal third. The needle will be inserted with a cranio-caudal orientation in the plane. The initial injection will be a single injection posterior to the axillary artery, the expected distribution being a U distribution around the artery.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
76093657|NCT00076245|Behavioral|Light Therapy|Light therapy will involve exposure to bright light twice a day.
76093658|NCT00076245|Behavioral|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
75805547|NCT04950426|Drug|Propranolol|One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.
76093659|NCT03231384|Device|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906"
76093660|NCT02365870|Drug|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
75477026|NCT05017961|Device|Autograft|An autograft bone will be harvested from proximal tibia or posterior superior iliac crest. First the bony landmarks of the posterior iliac crest or proximal tibia are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. After 1 cm skin incision and gentle dissection of subcutaneous soft tissue, the bone harvesting device inserted through the skin and subcutaneous tissues until it reaches the cortical bone. Then, manual pressure is used to position the bone harvesting device against the dense cortical bone. A battery-powered power instrument is then will be used to drill the harvesting device into the medullary cavity. After the harvesting device insertion the cancellous strips of bone will be harvested and applied to the fracture site gap.At the conclusion of autograft bone harvesting procedure, the wound will be closed with 3-0 Nylon and a sterile dressing will be applied to the harvest site.
75477027|NCT05017961|Device|Allograft only|The jar containing allograft tissue and cryopreservation solution will be placed in a sterile basin containing a warm (35°C to 39°C; 95°F to 102.2°F) sterile irrigant (Normal saline or 5% Dextrose in Lactated Ringer's Solution). The jar containing the allograft will remain in this solution until the contents of the jar flows freely upon inversion. The jar will be removed from the warm solution once free-flowing. Sterile gauze or the optional strainer will be used to decant the cryopreservation solution into a waste container. 5% Dextrose in Lactated Ringer's Solution will be added to the indicated fill line to immerse the allograft tissue. The cap will be replaced and inverted twice to suspend tissue until ready for use. 5% Dextrose will be decanted in Lactated Ringer's Solution prior to use. Implant will be used within 2 hours of thawing.
75805548|NCT04936334|Diagnostic Test|68Ga-PSMA-11 PET Scan|Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
75805549|NCT04927754|Behavioral|Behavioral guidance|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. As a result, the effect of the cartoon-assisted distraction technique during dental treatment on behavior in pediatric patients was evaluated.
75805550|NCT04927754|Other|Pain assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was assessed the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's pain during dental care.
75946364|NCT02338466|Drug|tenecteplase|"Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg)."
75946365|NCT05099510|Biological|NatrunixTM|The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha). The entire XB2001 heavy and light chain sequences are identical to those found in naturally-occurring human IgG4-kappa, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual.
75946366|NCT05099510|Biological|Placebo|Placebo control for NatrunixTM subcutaneous injection.
76093661|NCT02365870|Drug|placebo|Participants will receive a placebo transdermal patch to be worn daily
76093662|NCT03228108|Drug|Ciprofloxacin|see study arms.
76093663|NCT03228108|Drug|Trimethoprim/Sulfamethoxazole|see study arms.
76093664|NCT03228108|Drug|Fosfomycin|see study arms.
76093665|NCT03228108|Drug|Pivmecillinam/augmentin|see study arms.
76093666|NCT01981564|Behavioral|Asthma Express Intervention|Asthma Express clinic visit for asthma education + nurse home visit
76093667|NCT01981564|Behavioral|Standard Asthma Education Control Group|Asthma Express home nurse visits for asthma education
76093668|NCT03235128|Diagnostic Test|‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.|Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
76093669|NCT00078897|Drug|Selenium|Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
76093670|NCT01746017|Drug|Placebo|Administered orally as capsules
76093671|NCT01746017|Drug|LY2922470|Administered orally as capsules
76093672|NCT05234502|Other|Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)|In calculating the estimated basal metabolic rate of individuals, Mifflin-St. The Jeor Equation will be used.BMR will be multiplied by the physical activity factor of the individual and 500*700 kcal will be subtracted from the found value and the total daily energy requirement will be obtained.
76093673|NCT05234502|Other|Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)|A ketogenic diet will be applied to Group 1 for 12 weeks simultaneously with taxane treatment.
76093674|NCT03228030|Dietary Supplement|Thiamine|Capsules
76093675|NCT03228030|Dietary Supplement|Placebo|Identical capsules
75346878|NCT03007277|Other|PANJO|PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
75346879|NCT01729988|Procedure|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
75805551|NCT04927754|Other|Dental anxiety assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was evaluated the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's dental anxiety during treatment sessions.
75805552|NCT04920097|Other|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
75946367|NCT03394209|Drug|Favipiravir|"In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily."
75946368|NCT03394209|Drug|Oseltamivir 75Mg Capsule|oseltamivir will be administered at 75mg twice daily orally for 10 days
75946369|NCT02333864|Device|POGO® BGMS|SMBG
75805553|NCT04920097|Other|In-Person Training|Participants will receive in-person training to self-administer APA.
75805554|NCT04920097|Other|Usual Care|Participants will continue to do whatever they are receiving from their oncologist.
75946370|NCT03399201|Procedure|General anesthesia|induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)
75946371|NCT03399201|Procedure|Neuraxial anesthesia|Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
75946372|NCT03399201|Diagnostic Test|Spirometer|Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
75346880|NCT03002129|Other|fluid challenge|At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
75511328|NCT00315133|Procedure|Immunosuppression and autologous stem cell transplantation|Immunosuppression and autologous stem cell transplantation: Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and granulocyte-colony stimulating factor (G-CSF, 10 ug/kg/d), followed by collection and cryopreservation of unselected HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit anti-thymocyte globulin (ATG 4.5 mg/kg).
75511329|NCT00091611|Drug|IL-2 (interleukin-2)|
75511330|NCT00091611|Drug|OKT3|
75946373|NCT02331056|Other|fluid loading|"Fluid loading at defined period~500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records."
75946374|NCT02331056|Procedure|thoracoscopic pulmonary lobectomy|the patient group for scheduled thoracoscopic pulmonary lobectomy
75946375|NCT02331056|Procedure|thoracotomy|the patient group for scheduled open pulmonary lobectomy
75946376|NCT02520453|Drug|Durvalumab|
75946377|NCT02520453|Drug|Placebo|
76093676|NCT02091531|Drug|MLN0128|
76093677|NCT02367430|Behavioral|Critical Time Intervention With Buried in Treasures included|Critical Time Intervention and BIT Workshop
76093678|NCT03227952|Device|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
76093679|NCT03227796|Drug|LEVI-04|LEVI-04 intravenous infusion
76093680|NCT03227796|Drug|Placebo|Placebo intravenous infusion
75511331|NCT00091611|Drug|Cyclophosphamide|
75511332|NCT00091611|Drug|Fludarabine|
75511333|NCT00091611|Drug|Mesna|
75946378|NCT02331212|Other|Cytology Specimen Collection Procedure|Correlative studies
76093681|NCT03227718|Behavioral|VOR and coordination measurements|measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
76093682|NCT01717313|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week.
76093683|NCT01717313|Drug|Placebo to Omarigliptin|Placebo to omarigliptin capsule administered orally once a week
76093684|NCT01717313|Drug|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
76093685|NCT01717313|Drug|Placebo to metformin|During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
75658450|NCT05058404|Drug|Immunochemotherapy regimen: R-CHOP (Arm B)|"Arm B (Experimental arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging: induction therapy shall be completed based on the response achieved and on the treatment chosen:~if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-CHOP Q21+ 2 cycles Q21of rituximab~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis."
75658451|NCT05058404|Drug|Immunochemotherapy regimen: G-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-bendamustine Q28 (28-days cycles);~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in Stable Disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
75658452|NCT05058404|Drug|Immunochemotherapy regimen: G-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case 2 cycles of obinutuzumab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-bendamustine Q28;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
75946379|NCT02331212|Other|Laboratory Biomarker Analysis|Correlative studies
75658453|NCT05058404|Drug|Immunochemotherapy regimen: G-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
75946380|NCT03399123|Other|Tidal volume|After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
75946381|NCT02330744|Behavioral|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
75946382|NCT02330744|Behavioral|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
75946383|NCT05043428|Behavioral|The roles of peers and functional tasks in enhancing exercise training for adults with COPD: a pilot randomized controlled trial|An 8 week two-arm pilot randomized control trial aimed to evaluate the effects of an online exercise and peer support intervention for people living with COPD.
76093686|NCT01717313|Drug|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
76093687|NCT03231540|Dietary Supplement|Whey protein supplement|Whey protein supplement to target protein intake of 1.5 g/kg/day
76093688|NCT00080535|Biological|LMB-2|30 micrograms/kg every other day (QOD) x 3 every 4 weeks
75946384|NCT03389919|Biological|MSC administration (intraosseal)|MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.
75946385|NCT02338388|Procedure|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
75946386|NCT02731755|Other|Oat|The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.
75946387|NCT02731755|Other|Control|60g cream of rice
75511334|NCT04729478|Device|Drug-induced sleep endoscopy|An intravenous bolus injection of midazolam 1.5 mg will be used to induce sleep. Maintenance of sedated sleep will be obtained by a target-controlled infusion of propofol (2.0-3.0 µg/mL).
75511335|NCT04729478|Device|Natural sleep endoscopy|Endoscopy during natural sleep.
75511336|NCT03195088|Drug|BI 473494|Solution for injection
75511337|NCT03195088|Drug|Placebo|Solution for injection
75511338|NCT00123201|Drug|Dronabinol MDI|
75658454|NCT05058404|Drug|Immunochemotherapy regimen: G-CHOP (Arm B)|"4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion."
75658455|NCT05058404|Drug|Immunochemotherapy regimen: G-CVP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 4 cycles of G-CVP Q21;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
75658456|NCT05058404|Drug|Immunochemotherapy regimen: G-CVP (Arm B)|"Arm B (Experimental arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 4 cycles of G-CVP Q21~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
75805555|NCT04895085|Diagnostic Test|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
75805556|NCT04884412|Procedure|Surgery under general anesthesia with experimental targeting|Surgery will be performed under general anesthesia. The electrodes will be inserted directly on the targets without MER, with PARKEO_2 targets provided by the Bordeaux University Hospital, based on the machine-learning model developed in Bordeaux.
75946388|NCT03389841|Other|Education|Education of the caregiver about early symptoms and signs of heart failure
75805557|NCT04884412|Procedure|Usual Surgery|In the control group, surgery will be performed as usual in each centre under local or general anaesthesia. This group represents the current state of the art of deep brain stimulation in these centres.
75805558|NCT04863950|Drug|Lomustine|"For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks."
75805559|NCT04863950|Drug|Imipramine Hydrochloride|"For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days."
75946389|NCT03389763|Drug|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes
75946390|NCT01704404|Drug|TD-4208|
75946391|NCT01704404|Drug|Placebo|
75946392|NCT02866175|Drug|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
75946393|NCT02866175|Drug|Clopidogrel|Clopidogrel 75 mg once-daily
75946394|NCT02866175|Drug|Prasugrel|prasugrel 5mg or 10 mg once-daily
75946395|NCT02866175|Drug|Ticagrelor|ticagrelor 90 mg twice-daily
75946396|NCT02866175|Drug|Vitamin K antagonist|VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
75946397|NCT03399045|Procedure|9-minute withdrawal|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw
75946398|NCT03399045|Procedure|6-minute withdrawal|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
75946399|NCT02330822|Drug|Hyaluronic Acid|This material is going to be injected into the extraction socket in order to promote bone healing.
75946400|NCT02333396|Other|PICU Supports|The PICU Supports intervention includes navigator activities and ancillary tools. The Navigator activities include: initial visits with the healthcare team members (HTMs) and parents; weekday visits with the parents and feedback to the HTMs as needed; coordination of weekly family meetings between the parents and HTMs; and support during transitions out of the unit. The ancillary tools include: a PICU handbook; a place for parents to keep track of events and their goals; a provider sheet to inform PICU HTMs about important parental issues, concerns or goals; a bedside communication log so parents know which non-PICU HTMs have visited; an end-of-life checklist; a bereavement packet for those whose child dies; and informational resources.
75946401|NCT02333396|Other|Educational Brochure|Parents will receive a short educational brochure with information about the pediatric intensive care unit.
75658457|NCT05052905|Device|LibraVR|"LibraVR is a standalone VR-based rehabilitation software for use in physiotherapy. It is designed to work with standard off-the-shelf hardware that is tested and approved for use in conjunction with the software.~LibraVR system consists of the software (LibraVR Clinic) running on a PC (database of patients, creation of protocols, uploading protocols to mobile), and the LibraVR Mobile APP that runs on commercial mobile smartphones embedded in a lightweight cardboard or plastic VR viewer that the child wears as they would eyeglasses. The software displays a range of immersive VR exercises."
75805560|NCT04839822|Other|edupression.com®|"Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, App) at any time."
75346881|NCT03406364|Drug|MG005|"Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy."
75805561|NCT04839822|Other|Health tips|Interventions that do not directly target depression: general health tips (diet, lifestyle, smoking, etc.), occupational health interventions (back pain prevention, breaks,...), etc.
75805562|NCT04839822|Diagnostic Test|Surveys|Quizzes and surveys for course monitoring (including suicidality), but without extensive reports.
75805563|NCT04839822|Other|Popular psychological interventions|Popular psychological interventions, which have not been shown to be effective in studies: Affirmation phrases, motivational sayings and quotes (known also from calendars), tests (e.g., Rorschach interpretation), exercises (emotion recognition of faces), multimedia content (pleasant music, landscape images, interviews of famous people with depression), etc.
75805564|NCT04836377|Other|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention
75805565|NCT04826393|Drug|ASP8374|every 3 weeks by intravenous infusion
75346882|NCT03001661|Device|Dilapan-S|DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
75346883|NCT03001661|Drug|Dinoprostone|Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
75805566|NCT04826393|Drug|cemiplimab|intravenous infusion
75346884|NCT01723358|Device|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
75805567|NCT04824391|Biological|ERUCOV-VAC 3 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
75946402|NCT02338310|Drug|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
75346885|NCT01723436|Other|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
75658458|NCT05049174|Behavioral|Nuse-led interview and referral to municipal healthy life-centres|Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres
75658459|NCT05020535|Drug|MW189|MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
75805568|NCT04824391|Biological|ERUCOV-VAC 6 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
75805569|NCT04824391|Other|Placebo|Two IM applications on Days 1 and 28
75946403|NCT03389607|Diagnostic Test|spinal anesthesia|before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma
75658460|NCT05020535|Other|Saline|Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
75658461|NCT05018377|Procedure|Racz adhesolysis|adhesiolysis in failed back surgery
75805570|NCT04823039|Other|Blood sample taken|For patients with sepsis who require vaccination during hospitalization, we will analyze the immunogenicity of pneumococcal conjugate vaccine (PCV13) by taking blood samples
75805571|NCT04822597|Drug|Lidocaine patch|Lidocaine is a local anesthetic.
75805572|NCT04822597|Device|Buzzy(R)|Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.
75805573|NCT04822597|Other|Ice pack|Ice cools the skin and can provide some numbing for pain.
75805574|NCT04821856|Drug|Cannabidiol Oil|Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma
75805575|NCT04821856|Drug|Placebo|MCT oil and flavoring solution, also manufactured by THC Pharma
75805576|NCT04808999|Drug|Pembrolizumab Injection|200 mg IV infusion
75805577|NCT04807868|Procedure|Standard of care liver biopsy|Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
75805578|NCT04807868|Other|Fibroscan|A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
75805579|NCT04807868|Other|Biospecimen Collection|Blood and urine will be collected.
75805580|NCT04800562|Drug|PCS499|PCS499 900mg twice a day with food
75805581|NCT04800562|Other|placebo|placebo comparator
75805582|NCT04797169|Behavioral|Noom Health|In Noom Health, participants will be encouraged to use the Noom app multiple times a day to log eating episodes, physical activity and weight. They will also have the ability to interact with coaches to receive advice and feedback specific to weight loss.
75805583|NCT04797169|Behavioral|Noom Digital Health|In Noom Digital Health, participants will use a simplified version to log eating episodes and weight. Both conditions will receive the same weight loss advice content.
75805584|NCT04764227|Drug|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw*5
75805585|NCT04764227|Drug|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw*5
75946404|NCT02817789|Drug|Ticagrelor alone|180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
75805586|NCT04764227|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 28Fx
75805587|NCT04756583|Other|Notification system|Email and page notification sent to clinicians for patients at high-risk of mortality in 30 days and 6 months
75805588|NCT04733092|Drug|Lipiodol|Lipiodol in emulsion with contrast agent
75946405|NCT02817789|Drug|Combination lysine acetylsalicylate - clopidogrel|75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
75946406|NCT02333474|Biological|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
75946407|NCT02333474|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
75346886|NCT03006965|Drug|octocog alfa|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
75346887|NCT03006965|Drug|rurioctocog alfa pegol|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
75658462|NCT05018377|Device|NAVI adhesolysis|adhesiolysis in failed back surgery
75658463|NCT05016661|Drug|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
75658464|NCT05000762|Dietary Supplement|Zinc|Zinc gluconate 30 mg/day orally
75658465|NCT04995198|Behavioral|Genetic Testing|Germline genetic testing via Color Health's Hereditary Cancer Panel.
75658466|NCT04995198|Behavioral|Genetic Counseling|A Genetic Counselor will review results with participants and discuss clinical implications and recommendations.
75658467|NCT04995198|Behavioral|Patient Reported Outcome Measures|Participants will complete the EORTC QLQ-C30 questionnaire every 6 months.
75658468|NCT04989725|Other|Standard arm|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
75805589|NCT04730869|Other|Standard Treatment Plus Metabolic Therapy Program|"See description under Arms."
75805590|NCT04729582|Biological|Primary human muscle stem cells (Satori-01)|Primary human muscle stem cells are isolated from patient's muscle tissue and expanded ex-vivo. They are injected into the urethral sphincter region as a one-time autologous treatment.
75805591|NCT04729582|Other|Placebo|Placebo is the injection solution without muscle stem cells.
75805592|NCT04727827|Other|Pharmacogenomic-guided supportive care|Patients undergoing hematopoietic stem cell transplantation will be genotyped and supportive care therapies tailored to identified drug-gene pairs and guideline recommendations
75805593|NCT04706026|Other|Open repair- Local anesthesia|This is the treatment group. Patients will receive an injection of a 50:50 mix of 1% lidocaine with epinephrine and 0.25% Marcaine at the surgical site (in the skin and subcutaneous layers + beneath the external oblique aponeurosis). Patients in the local arm will also receive intravenous sedation (propofol or Precedex) and pain medication (morphine or fentanyl) at the discretion of the attending anesthesiologist.
75805594|NCT04706026|Other|Open repair- General anesthesia|This group is the active comparator. General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia. The hernia will be repaired using an open technique.
75946408|NCT05383625|Drug|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|intralesional 0.1 ml every two weeks
75946409|NCT05383625|Drug|Bivalent Human Papilloma Virus Vaccine|Intralesional 0.1 ml every two weeks
75946410|NCT05383625|Drug|Saline|intralesional into the largest warts every two weeks
75946411|NCT02330432|Biological|Mycobacterium w|Single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
75946412|NCT02330432|Other|Best standard care|Antibiotics as early as possible; Norepinephrine > vasopressin > epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
75946413|NCT03398967|Biological|Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells|"Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells~Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose~Other: Laboratory Biomarker Analysis"
75946414|NCT02337998|Other|load carriage|
75946415|NCT02330354|Behavioral|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
75946416|NCT03125577|Biological|4SCAR19 and 4SCAR22|4SCAR19 and 4SCAR22
75946417|NCT03125577|Biological|4SCAR19 and 4SCAR38|4SCAR19 and 4SCAR38
75946418|NCT03125577|Biological|4SCAR19 and 4SCAR20|4SCAR19 and 4SCAR20
75946419|NCT03125577|Biological|4SCAR19 and 4SCAR123|4SCAR19 and 4SCAR123
75946420|NCT03125577|Biological|4SCAR19 and 4SCAR70|4SCAR19 and 4SCAR70
75946421|NCT03125577|Biological|4SCAR19 and 4SCAR30|4SCAR19 and 4SCAR30
75946422|NCT02330666|Behavioral|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
75946423|NCT02039648|Other|Rumex acetosa L. extract|
76093689|NCT01897545|Procedure|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
75346888|NCT03406208|Behavioral|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
75346889|NCT03406208|Behavioral|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
75346890|NCT01577537|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
75346891|NCT01577537|Drug|Placebo|Vaginal gel, daily for 7 days
75946424|NCT02039648|Other|Placebo|
75946425|NCT03389451|Drug|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
75946426|NCT02337842|Biological|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units.
75946427|NCT02337842|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
75946428|NCT03610919|Drug|Nasal Sprays|Intranasal administration of 24 international units per dose.
75946429|NCT03385395|Drug|OctaAlpha1|For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
75946430|NCT03385395|Drug|Glassia|For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
75946431|NCT02333318|Drug|VVZ-149 injection|Colorless, transparent liquid in water for injection
75946432|NCT02333318|Other|Placebo|water for injection
75946433|NCT03611387|Device|CASIA 2 OCT|Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
75946434|NCT03389373|Device|GC Strep Mutans Saliva Sampling|Children who match inclusion criteria will have a saliva sample obtained which will act as a proxy for bacterial levels.
75946435|NCT03385317|Behavioral|Mindfulness|
75946436|NCT03610841|Diagnostic Test|preterm labor|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
75946437|NCT03610841|Diagnostic Test|healthy|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
75946438|NCT02330120|Drug|propofol|
75946439|NCT02330120|Drug|dexmedetomidine|
75946440|NCT03389295|Radiation|Reduced Target Delineation and Radiation Doses|"The target volumes were delineated according to the treatment protocol defined as follows: the GTV of the primary tumor (GTV-P) included retropharyngeal lymph nodes, considering the common phenomena of integration, and the rest involved lymph nodes that were defined as GTV-N. For the GTV-P, involved retropharyngeal lymph nodes and intracavity lesions were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation.~The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices."
75658469|NCT04989725|Radiation|Experimental arm|SABR to all oligoprogressive lesions + continuation of current systemic therapy
75946441|NCT02032589|Behavioral|Self-generation treatment|self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks
75946442|NCT01592643|Device|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
75946443|NCT03718988|Behavioral|Meat products|Traditional meat products (beef burger patties, pork sausage, etc.)
75946444|NCT03718988|Behavioral|Plant Alternative products|Plant-based alternatives (The Beyond Burger, Beyond Sausage, etc.)
75946445|NCT02647749|Device|Cardioinsight® mapping system|
75946446|NCT02647749|Other|Conventional method without non-invasive mapping|
75946447|NCT04003766|Diagnostic Test|biopsy|Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.
75946448|NCT02337608|Drug|GLPG1205|GLPG1205 daily dosing in the morning for 12 weeks
75946449|NCT02337608|Drug|Placebo|placebo daily dosing in the morning daily for 12 weeks
75946450|NCT03983564|Other|Cutoff Validation|We will validate the cutoff of the combination of BOSTON score and DES-OSA scores with the result of a polysomnography.
75946451|NCT01500681|Procedure|Plasma exchange (PLEX)|Regular maintenance PLEX courses, typically 3 procedures monthly
75946452|NCT03398889|Diagnostic Test|Plasma levels of metabolites|plasma levels of metabolites
75946453|NCT03398889|Behavioral|Dietary questionnaire|Harvard food frequency questionnaire
75658470|NCT04987489|Drug|Etavopivat tablets|Etavopivat 400 mg once daily
75658471|NCT04983849|Drug|metronidazole hydrogel|scaling and root planning in adjunct to the use of metronidazole in the periodontal pocket
75946454|NCT03398889|Diagnostic Test|Intestinal microbiome|amplification and sequencing of 16S rRNA gene variable regions in stool samples
75946455|NCT01295697|Drug|EZN-2208|Experimental
75946456|NCT03398811|Drug|Depot medroxy-progesterone acetate|Injection every 3 months
75946457|NCT03398811|Drug|Etonogestrel|68 mg implant
75946458|NCT03398811|Drug|Desogestrel 75 µg|one pill every day for 28 days without pill-free interval.
75946459|NCT03398733|Device|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
75946460|NCT01300143|Other|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
75946461|NCT01300143|Other|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
75946462|NCT01336205|Drug|NKTR-118|25 mg oral tablet once daily
75946463|NCT01336205|Drug|Usual care|As prescribed by the investigator
75946464|NCT02333240|Other|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
75946465|NCT02033135|Procedure|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
75658472|NCT04983849|Procedure|scaling and root planning|scaling and root planning
75658473|NCT04974398|Drug|Penpulimab|Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin 80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine 1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per treatment cycle (Q3W), and then followed by penpulimab monotherapy as maintenance treatment, Q3W.
75658474|NCT04974398|Drug|placebo|Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per treatment cycle and then followed by placebo monotherapy as maintenance treatment, Q3W. Subjects in Arm B will have the opportunity to crossover to open-label treatment with penpulimab monotherapy after radiographic disease progression.
75658475|NCT04972955|Device|Freestyle Libre 2|Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.
75946466|NCT02033135|Other|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
75946467|NCT02033135|Device|Zilver PTX|
75946468|NCT02337374|Device|Midurethral sling mesh|
75946469|NCT02865395|Drug|Belladonna and Opium Suppository|
75946470|NCT02865395|Procedure|Rectal Exam|
75946471|NCT02327390|Procedure|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
75946472|NCT02327390|Biological|X-ACT|Administered as an IV infusion
75346892|NCT04379102|Other|with NT/TLA (NT or also referred to as therapy with local anesthetics (TLA) )|Patients who visited our family planning clinic and opted for IUD application for contraception purposes were also offered NT/TLA treatments simultaneously. 40 patients who matched the inclusion criteria and received IUDs and NT/TLA treatments were included in the study group and 41 patients who only received IUDs were included in the control group. All patients received copper IUDs and none of them were on additional hormonal treatment. Before the insertion of IUD, women in the therapy group received NT treatment with 6ml of 1% procaine injected transvaginal into the cervix at 5 and 7 o'clock localizations.
75658476|NCT04972955|Device|Freestyle Libre 2|Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.
75477028|NCT05017961|Device|Allograft combined with BMAC|A bone marrow aspiration kit will be used for bone marrow aspiration. First the bony landmarks of the posterior iliac crest and sacroiliac joint are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. Then, the bone marrow aspiration trochar and needle are percutaneously inserted through the skin and subcutaneous tis- sues until it reaches the posterior iliac crest. The trajectory of the needle will be parallel to the iliac crest, or perpendicular to the Anterior Superior Iliac Spine (ASIS) or Posterior Superior Iliac Spine (PSIS), depending on the harvest site used. After the trochar is inserted into the posterior iliac crest but prior to aspiration, 1 mL of heparin (1,000 U/mL) will be preloaded into the syringe. Approximately 60 mL of bone marrow will be aspirated, which requires the use of two 30-mL syringes. At the conclusion of BMAC harvesting, a sterile dressing will be applied to the harvest site.
75477029|NCT05017415|Device|uroflow measurement|Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie
75477030|NCT05017415|Device|Bladder ultrasound|Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
75805595|NCT04706026|Other|Laparoscopic or robotic repair- general anesthesia|This group is a second active comparator. General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia. The hernia will be repaired using a robotic or laparoscopic technique.
75946473|NCT02329496|Device|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
75946474|NCT03611231|Drug|Chidamide|Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.
75477031|NCT05015153|Other|Pulmonary rehabilitation (PR)|20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
75477032|NCT05010759|Device|NanoTherm Ablation|Iron nanoparticles are instilled into the prostate cancer lesion and then the particles are heated using a magnetic field and this heating ablates the prostate cancer lesion.
75477033|NCT05010538|Drug|Sarecycline|60 mg sarecycline tablets will be given for subjects with a body weight of 33 to 54 kg, 100 mg sarecycline tablets will be given for subjects with a body weight of 55 to 84 kg, and 150 mg tablets will be given for subjects with a body weight between 85 and 136 kg.
75477034|NCT05005351|Device|Digital ACT|Participants in Digital ACT arm complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual.
75805596|NCT04675255|Procedure|Frequently sampled glucose tolerance testing|Frequently sampled glucose tolerance testing
75946475|NCT02333084|Dietary Supplement|PRN Joint Health Formula|
75805597|NCT04675255|Procedure|abdominal subcutaneous adipose tissue biopsy|abdominal subcutaneous adipose tissue biopsy
75946476|NCT02333084|Dietary Supplement|placebo|
75946477|NCT02333084|Dietary Supplement|PRN Flex Omega Benefits® combination|
75946478|NCT03610685|Drug|Prednisolone|Given daily for 2 weeks
75946479|NCT03610685|Drug|Placebo oral capsule|Given daily for 2 weeks
75946480|NCT02333006|Other|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
75946481|NCT02327234|Drug|ibuprofen|2x 200mg ibuprofen, single dose, blinded in 00 capsules
75946482|NCT02327234|Drug|Placebo|lactose filled 00 capsules to match appearance of ibuprofen intervention
75946483|NCT01123707|Drug|Aripiprazole|Aripiprazole oral capsules
75946484|NCT01123707|Drug|Escitalopram|Escitalopram oral capsules
75346893|NCT02469246|Drug|F/TAF|200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
75346894|NCT02469246|Drug|ABC/3TC|600/300 mg FDC tablets administered orally once daily
75346895|NCT02469246|Drug|ABC/3TC Placebo|Tablets administered orally once daily
75477035|NCT05005351|Device|Digital Symptom Tracker|Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual.
75477036|NCT05005299|Drug|Venetoclax|Venetoclax is administered as an oral tablet once daily.
75477037|NCT05005299|Drug|Fludarabine|Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.
75805598|NCT04675255|Procedure|MRI scan to assess intrahepatic triglyceride content|MRI scan to assess intrahepatic triglyceride content
75805599|NCT04658550|Other|Remote Behaviour Modification Program|The standard of care behaviour modification program for weight loss will be offered virtually due to the COVID-19 pandemic (prospective).
75946485|NCT02332772|Other|Data Collection|Data collected from endoscopy procedures.
75946486|NCT02755103|Behavioral|Mindfulness Based Relapse Prevention (MBRP)|MBRP integrates coping skills from cognitive-behavioral relapse prevention therapy with Mindfulness Meditation (MM) practices, raising awareness of substance use triggers and reactive behavioral patterns, and teaching skillful coping responses.
75946487|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies along with a written document|The document describes the law and the role of family members and medical team in the decision.
75946488|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies following standard procedure|
75946489|NCT01258803|Drug|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
75946490|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
75946491|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
75346896|NCT02469246|Drug|F/TAF Placebo|Tablets administered orally once daily
75946492|NCT01258803|Drug|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
75946493|NCT01258803|Drug|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
75946494|NCT01258803|Drug|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
75946495|NCT02327156|Drug|dexmedetomidine|adding dexmedetomidine to the local anesthetic
75946496|NCT02033291|Procedure|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
75946497|NCT02329340|Behavioral|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
75946498|NCT02329340|Behavioral|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
75946499|NCT03610529|Device|CardioSenseSystem|CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
75946500|NCT03610529|Device|Philips Intellivue|Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
75946501|NCT02039804|Drug|Corticosteroids|Intra-bursal injection
75946502|NCT02039804|Device|Hyaluronic acid|Intra-bursal injection
75346897|NCT02469246|Drug|3rd ARV agent|An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
75346898|NCT03001427|Behavioral|Structured center-based lifestyle intervention|
75346899|NCT03001427|Behavioral|Standard education and physician advice|
75346900|NCT01723202|Drug|dabrafenib|150 mg orally twice daily given orally
75346901|NCT01723202|Drug|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
75346902|NCT01723202|Other|Correlative Studies|"Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)~BRAF mutation studies in circulating plasma DNA (all study patients)~Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)~Assess predictors of response (Archival tumor block/unstained slides in all study patients)~Pharmacokinetic studies (First 10 pts enrolled on each arm)~Pharmacogenomics studies (All study patients)"
75477038|NCT05005299|Drug|Cyclophosphamide|Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
75477039|NCT05003362|Behavioral|ACT|mindfulness intervention for patients with pain/migraine
75805600|NCT04658550|Other|In Person Behaviour Modification Program|The standard of care behaviour modification program for weight loss was offered in person prior to the COVID-19 pandemic (retrospective).
75477040|NCT04999449|Drug|Scopolamine|Intranasal scopolamine at 0.2 mg or 0.4 mg
75477041|NCT04999449|Drug|Placebo|Intranasal saline placebo
75805601|NCT04639245|Drug|Atezolizumab|Given IV
75805602|NCT04639245|Drug|Cyclophosphamide|Given IV
75946503|NCT02865083|Device|Traxi Pannus Retractor|traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
75477042|NCT04988022|Drug|Dupilumab|300 mg prefilled syringe
75946504|NCT03112070|Other|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
75346903|NCT01578317|Biological|H5N1 vaccine plus AS03 adjuvant|H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.
75346904|NCT01578317|Biological|H5N1 vaccine without adjuvant|H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
75477043|NCT04988022|Drug|Placebo|Matching placebo
75477044|NCT04980833|Drug|Alpelisib|Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
75477045|NCT04971187|Drug|Bintrafusp Alfa|Given IV
75477046|NCT04971187|Drug|Pemetrexed|Given IV
75477047|NCT04971187|Drug|Carboplatin|Given IV
75477048|NCT04971187|Drug|Cisplatin|Given IV
75805603|NCT04639245|Drug|Fludarabine|Given IV
75805604|NCT04639245|Biological|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|Given IV
75805605|NCT04639245|Biological|PD1 Inhibitor|Given IV
75805606|NCT04599465|Drug|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
75805607|NCT04599465|Drug|IVA|Tablets for oral administration.
75946505|NCT03385161|Procedure|Botulinum toxin A|
75946506|NCT03385161|Procedure|Ethanol|
75946507|NCT02327000|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
75658477|NCT04972682|Procedure|Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy|Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy (BSO), and sentinel lymph node (SLN) biopsy are executed by 1 of 5 experienced gynecologic oncologists. SLN mapping utilizes indocyanine green (ICG) at a standard concentration of 2.5 mg/mL - 1 mL is injected into the cervix at the 3 and 9 o'clock positions (total dose - 5 mg) to a depth of 5-10 mm, initiated right after general anesthesia induction. Diagnostic laparoscopy employs the Image 1S equipment (KARL STORZ©, Tuttlingen, Germany). Upon examination, fluorescence in the near-infrared spectrum is observed. Successful mapping is indicated by identifying a lymphatic vessel with at least one LN. Detected SLNs are then extracted, and the total hysterectomy with BSO is completed. SLN frozen section remains at the surgeon's discretion. If metastasis surfaces in the SLN either during the frozen section or routine assessment, the option for systematic LN dissection in a subsequent procedure exists although not mandatory.
75946508|NCT02327000|Drug|Pregabalin 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
75946509|NCT02032979|Behavioral|Psychiatric test|
75946510|NCT01036113|Drug|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
75946511|NCT03111524|Other|Classroom Communication Resource|The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion
75946512|NCT03111524|Other|No intervention|No intervention is administered in this group as these are control groups
75946513|NCT02033057|Procedure|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
75946514|NCT02329184|Drug|MYK-461|
75346905|NCT03406130|Procedure|Orthodontic Procedure|"Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed."
75346906|NCT03406130|Procedure|Piezocision surgery|The piezocision surgery was performed 1 week after orthodontic appliance placement. The surgical protocol was performed as described by Dibart and al. (Dibart et al. 2009). However, to avoid bias, hard and soft tissue augmentations were not considered. The patients received local anesthesia in both arches; vertical interproximal microincisions were created below each interdental papilla. In cases of root proximity (i.e., <2 mm of interdental bone), this procedure was not performed. These incisions were kept to a minimum (varying from 5 to 8 mm). Next, with a vertical piezoelectric device, 5-mm-long and 3-mm-deep corticotomies were made, and no subsequent sutures were required. The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intake for 1 wk. Anti-inflammatories were prohibited to avoid interference with the RAP.
75346907|NCT03830216|Device|Connected insulin pen and smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.
75346908|NCT03830216|Device|Inactive connected insulin pen without smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.
75346909|NCT01726946|Drug|VX-135|12 weeks of VX-135
75346910|NCT01726946|Drug|ribavirin|12 weeks of ribavirin
75477049|NCT04955808|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
75477050|NCT04955808|Other|Laboratory Biomarker Analysis|Correlative studies
75477051|NCT04953442|Behavioral|Fit 24|This 12-week goal-setting intervention will test the feasibility of using a Fitbit watch and motivational text messaging to improve physical activity and sleep in Hispanic youth (14-16 years of age) with obesity. Youth will be prompted to set weekly steps per day and hours of sleep per night goals. Text messages will be grounded in the Self-Determination Theory and will provide evidence-based strategies, support, and motivation to encourage youth to meet their goals.
75946515|NCT02558699|Procedure|physician's personal experience|physician's personal experience
75946516|NCT02558699|Procedure|Virtual rotor mapping|Virtual rotor mapping
75946517|NCT02033603|Drug|Ropivacaine|30mls of 0.5% ropivacaine
75946518|NCT02326922|Device|Metraplant-E levonorgestrel-releasing intrauterine device|Metraplant-E insertion and follow up for 6 months
75946519|NCT00862251|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
75946520|NCT00862251|Drug|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
75946521|NCT00862251|Drug|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
75946522|NCT00862251|Drug|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
75946523|NCT02329106|Device|Irreversible electroporation (IRE)|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
75946524|NCT03144986|Device|Deep Insula-coil rTMS|Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
75946525|NCT02329028|Device|Prehospital mini-EEG|Observational
75658478|NCT04961996|Drug|Giredestrant|Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
75658479|NCT04961996|Drug|Endocrine Therapy of Physician's Choice|The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.
75658480|NCT04961996|Drug|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
75805608|NCT04589130|Drug|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).~Participants randomized to the control arm for the first 6 months will crossover and be administered 4 Contrave tablets a day during the second 6 months (2 tablets taken twice a day). All participants will be in the treatment group (Contrave) during the second 6 month phase of the study."
75805609|NCT04589130|Drug|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day (2 tablets, taken twice a day) during the first 6 months of the study. These participants will crossover to treatment with Contrave for the second 6 months of the study.
75805610|NCT04588298|Drug|AZD9833|AZD9833 tablets will be administered orally.
75946526|NCT02332538|Procedure|532nm-laser photoselective vapo-enucleation of the prostate)|using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)
75946527|NCT02332538|Procedure|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prsotate
75946528|NCT02332538|Procedure|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
75946529|NCT00885963|Drug|sapacitabine|twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
75946530|NCT02332694|Device|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
75946531|NCT00725127|Drug|aspirin|100 mg/day upon awakening for five years
75946532|NCT00725127|Drug|aspirin|100 mg/day at bedtime for five years
75946533|NCT02326766|Dietary Supplement|KRG|5g Korea red ginseng (KRG)
75946534|NCT02326766|Dietary Supplement|Placebo|5g placebo
75946535|NCT02329262|Behavioral|Mentoring to be Active with Accelerometers|Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
75946536|NCT02329262|Behavioral|Planning to be Active with Accelerometers|Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
75946537|NCT00590109|Other|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
75477052|NCT04936451|Device|TENS (transcutaneous electrical nerve stimulation)|"Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours."
75658481|NCT04961996|Drug|Abemaciclib|Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
75946538|NCT00590109|Other|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
75946539|NCT02328950|Drug|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
75946540|NCT04949685|Procedure|plantar plate repair|surgical repair via dorsal approach of lesser metatarsophalangeal joint general anesthesia
75946541|NCT03398577|Drug|Dapagliflozin 10 MG [Farxiga]|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
75946542|NCT03398577|Drug|Placebo Oral Tablet|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
75658482|NCT04958889|Other|No intervention|(observational study)
75658483|NCT04956809|Drug|Dapagliflozin 10Mg Tab|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
75658484|NCT04956809|Drug|Placebo|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
75658485|NCT04949464|Procedure|Computed Tomography|Undergo LDCT
75946543|NCT03389061|Drug|sofosbuvir/velpatasvir tablet|Single-dose SOF/VEL as a whole tablet in a fasted state.
75946544|NCT03389061|Drug|sofosbuvir/velpatasvir crushed|Single-dose crushed SOF/VEL in a fasted state.
75946545|NCT02038868|Drug|ASP4901|oral
75946546|NCT02038868|Drug|Tamsulosin|oral
75946547|NCT02038868|Drug|Placebo|oral
75346911|NCT02469168|Device|Recell|ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix
75346912|NCT02469168|Procedure|Control|Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
75346913|NCT01723592|Dietary Supplement|Probiotics|Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
75346914|NCT01723592|Dietary Supplement|Oral lactose placebo|Placebo
75346915|NCT01723670|Drug|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
75346916|NCT01723670|Drug|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
75346917|NCT01723670|Drug|Placebo|oral tablet,once a day for 24 months
75346918|NCT01723748|Drug|genotropin|iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
75346919|NCT01720160|Device|BAROSTIM NEO® System|Implant procedure
75658486|NCT04949464|Behavioral|Smoking Cessation Intervention|Use Positively Smoke Free - Mobile
75805611|NCT04588207|Drug|Urea|"Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day."
75658487|NCT04946942|Behavioral|Collaborative Healthcare Encounters with Caregivers (CHEC)|CHEC is a brief checklist designed to identify family caregivers' unmet needs and concerns.
75658488|NCT04946942|Behavioral|Usual Care|Attendance at primary care appointments as usual.
75805612|NCT04587843|Drug|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day)."
75658489|NCT04925921|Device|SR-1 Laser|3-4 treatments at 4-6 week intervals
75658490|NCT04915729|Drug|tenecteplase|tenecteplase
75658491|NCT04915729|Drug|alteplase|alteplase
75658492|NCT04914611|Other|No intervention|No intervention
75946548|NCT03398499|Device|VIOFOR (Med & Life)|Device: VIOFOR (Med & Life) Magnetic-light applicators, generating a slow-changing electromagnetic field and light ener-gy (830 nm and 640 nm), emitted from LEDs during a physiotherapeutic treatment application parameters: frequency of basic field pulses: 180-195 Hz frequency of packet the field pulses: 12.5 Hz-29 Hz magnetic induction: 15 μT wavelength of light: 830 nm and 640 nm Duration: 10 min number of treatments: 10
75946549|NCT03385083|Behavioral|Step count monitoring with consulting|Subject counseled on step counts at initial visit and 2 and 4 weeks
75658493|NCT04911426|Behavioral|Telehealth|The telehealth intervention is delivered with an app developed for this research. The intervention features live video calling, messaging, appointment reminders; clinical support is provided by licensed clinicians.
75658494|NCT04901702|Drug|Onivyde|Given intravenous on Days 1 and 8
75658495|NCT04901702|Drug|Talazoparib|Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6
75658496|NCT04901702|Drug|Temozolomide|Given once a day on Days 1-5.
75658497|NCT04901234|Radiation|Standard radiotherapy +/- chemotherapy|No radiotherapy adaptation unless major dosimetric deviation
75658498|NCT04901234|Radiation|Experimental radiotherapy +/- chemotherapy|Systemic MRI-based radiotherapy adaptation mid-treatment
75658499|NCT04899349|Drug|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
75946550|NCT03385083|Behavioral|Step count monitoring without consultation|Subject counseled on step counts at initial visit
75346920|NCT01720160|Other|Standard of care medical managment therapy for heart failure|Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
75346921|NCT03405896|Other|Turning|start to walk with normal speed, and then turn to approach the terminal under different angle.
75346922|NCT02469090|Drug|APL-130277|"Use to treat up to 5 OFF episodes per day"
75346923|NCT02469090|Drug|Placebo|placebo
75346924|NCT02496000|Drug|ORMD-0801|Oral Insulin
75346925|NCT02496000|Drug|Placebo Comparator|Placebo
75346926|NCT02468934|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
75346927|NCT02517528|Drug|ABT-450/r/ABT-267|Tablet
75346928|NCT02517528|Drug|ABT-333|Tablet
75346929|NCT02517528|Drug|ribavirin|Tablet
75346930|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
75346931|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
75346932|NCT02495844|Drug|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral use
75477053|NCT04936451|Device|TENS (transcutaneous electrical nerve stimulation) ECOMODYN|"TENS ECOMODYN® is applied to 4 treatment points, 5 minutes per point 2 times a day for 2 months.~A minimum rest period of 4 hours between 2 sessions on the same point must be respected Stimulation is performed directly with the bipolar probe of the TENS ECOMODYN® device on the painful area by fixed stimulation of 4 active pain points in 77Hz mode."
75658500|NCT04899349|Drug|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
75805613|NCT04587843|Drug|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
75658501|NCT04899349|Drug|Metformin XR|Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
75658502|NCT04899349|Drug|Dapagliflozin + metformin XR|Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily
75946551|NCT03385083|Device|Fitbit tracker|Fitbit tracker given to participant
75946552|NCT02326688|Other|Kinematic analysis of trunk compensation|
75946553|NCT03388983|Other|6-week prehabilitation|Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
75946554|NCT03388905|Device|Life Vest Wearable defibrilator|The LifeVest is a cardioverter defibrillator worn by a patient at risk for sudden cardiac arrest (SCA). It monitors the patient's heart continuously and, if the patient goes into a life-threatening arrhythmia, can deliver a shock treatment to restore the patient's heart to normal rhythm.
75946555|NCT02328794|Behavioral|E-cigarette free access|Participants in this arn will be given free access to e-cigarettes to help quit smoking
75658503|NCT04899349|Drug|Dapagliflozin|Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
75805616|NCT04562441|Drug|Axitinib|Axitinib: 5 mg bd po Day 1 to Day 28
75805617|NCT04562441|Drug|Avelumab|Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks
75805618|NCT04547582|Device|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
75805619|NCT04516356|Other|Korean hand acupressure|According to the working principle of Korean hand acupressure; There are active points and areas in the hands and feet that fit the whole body. The active points on the hands and feet are properly matched to reflect the anatomy of the whole organism. Areas in the body and systems suitable for them are in constant contact. In the patient, the signal wave moves from the damaged point or area and reaches the appropriate point immediately. Thus, changes such as severe pain, skin discoloration, hardening, thickening and thinning in some parts of the skin occur at that point. With the stimulation of the effective point, a treatment wave occurs that heals the sick organ.
75946556|NCT02328794|Behavioral|E-cigarette/NRT/Zyban/Chantix Choice|Participants in this arn will be given free access to cessation aids to help quit smoking
75946557|NCT02328794|Behavioral|Outcome Incentive arm|Participants in this arm will be earn incentives across 6 months for verified abstinence.
75346933|NCT02468778|Device|HeartMate PHP|The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
75346934|NCT02468778|Device|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® device approved for use in high-risk PCI.
75658504|NCT04896073|Drug|Minnelide|Administered orally (2 mg) once daily for 21 days of 28-day cycles for 12 cycles.
75658505|NCT04891107|Device|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Participants will walk using the music-based, rhythm-modulating wearable sensor system (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 5 times a week for 4 weeks.
75805620|NCT04514133|Behavioral|Participating in Action Civics program|Students in school classrooms participating in Action Civics program
75805621|NCT04510714|Device|Image guided percutaneous microwave ablation|Lung metastasis from sarcoma will be treated with microwave antennas (SOLERO) and Ablation System and microwave generators (Angiodynamics), with power settings of 35-45W and an average ablation time of 15 minutes (range 10-30 minutes). The ablation time will be recorded for all procedures. The manufacturer's recommendations will be observed in all cases, since it is assured that patients are able to tolerate the total ablation time.
75805622|NCT04475198|Drug|ST-2427|Investigational drug
75805623|NCT04475198|Drug|Placebo|5% Dextrose Injection
75805624|NCT04467671|Combination Product|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
75805625|NCT04454957|Behavioral|Mastering Diabetes|Virtual (on-line) lifestyle change program, focused on a plant-based, whole food diet and physical activity.
75946558|NCT02328794|Behavioral|Loss framing incentive arm|Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
75946559|NCT02328794|Behavioral|Control|Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
75946560|NCT03564080|Other|Combined - PAD and CAD|12-week supervised exercise programme in a hospital setting
75946561|NCT03388827|Device|Laminaria tent|Laminaria tent was inserted for 12 hours before Hysteroscopy
75946562|NCT03388827|Drug|Laminaria plus Misoprostol|Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
75946563|NCT02328716|Procedure|Cytoreduction|Cytoreduction
75946564|NCT02328716|Drug|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
75946565|NCT03398187|Device|cardiac catheterization|diagnostic and interventional cardiac catheterization
75946566|NCT03144284|Other|Knowledge, attitude, and practice survey|A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
75946567|NCT00445107|Drug|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
75946568|NCT05077592|Drug|10% Povidone Iodine|Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
75946569|NCT03398109|Device|Customized toric IOL for post-DALK atigmatism|
75946570|NCT03144362|Procedure|Bilateral Sliding Techniques|Bilateral Sliding Techniques
76093690|NCT01897545|Procedure|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
76093691|NCT03222804|Dietary Supplement|Bifidobacterium|Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.
76093692|NCT05061381|Behavioral|A Lust for Life Schools Programme|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in children. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the childrens' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
76093693|NCT01745393|Behavioral|Clinic Quality Improvement + Behavioral Counseling|
76093694|NCT01745393|Behavioral|Clinic Quality Improvement + Attention Control|
75477054|NCT04929379|Drug|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
75658506|NCT04882527|Device|Non-invasive brain stimulation|Stimulation will be applied once per subject with one mA for 20 minutes over either the left inferior frontal lobe, the right inferior frontal lobe or the right superior parietal lobe.
75658507|NCT04882527|Device|Sham stimulation|The electrode positions and the attachment procedures correspond to those of real tDCS but the electrical current will only be ramped up to 1 mA and switched off completely after 30 s of stimulation.
75658508|NCT04881617|Behavioral|Lexical Retrieval Training (LRT)|In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.
75805626|NCT04433780|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC
75805627|NCT04426214|Device|tDCS|We will apply tDCS in combination with cognitive training. All participants receive cognitive training, and will be randomized to receive either active or sham tDCS
75805628|NCT04426214|Behavioral|Cognitive Training|cognitive training on computer
75805629|NCT04409639|Drug|Cobimetinib|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
75805630|NCT04408664|Drug|Sodium Cromoglycate|Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.
75805631|NCT04408664|Drug|Placebo|Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
75477055|NCT04929379|Other|Placebo|Inactive tablets identical to fenofibrate
75477056|NCT04929080|Biological|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
75477057|NCT04929080|Biological|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
75477058|NCT04929080|Biological|JS001 and JS004|Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001
75946571|NCT03144362|Procedure|Unilateral Sliding Techniques|Unilateral Sliding Techniques
75946572|NCT00038727|Behavioral|DPPOS Group Lifestyle|Quarterly group lifestyle sessions
75946573|NCT00038727|Drug|Metformin|Administered as 850mg twice per day, masked in DPP and open label in DPPOS
75946574|NCT00038727|Behavioral|DPPOS Boost Lifestyle|In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
75946575|NCT00038727|Behavioral|Intensive Lifestyle Group Session|16 session curriculum in group format. In DPP delivered to ILS as individual sessions
75946576|NCT05077358|Procedure|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
75946577|NCT05077358|Procedure|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
76093695|NCT00081861|Drug|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
76093696|NCT00081861|Drug|Rituximab|375 mg/m^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
76093697|NCT03120234|Drug|Dexmedetomidine|
76093698|NCT03120234|Drug|Ketamine|
76093699|NCT03120234|Drug|Fentanyl|
76093700|NCT03120234|Drug|Placebos|o.9% normal saline will be used instead of ketamine
76093701|NCT03119922|Other|No intervention|
75658509|NCT04881617|Behavioral|Video-Implemented Script Training for Aphasia (VISTA)|In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.
75658510|NCT04871451|Drug|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
75946578|NCT02864381|Drug|Andecaliximab|800 mg administered via IV infusion
75946579|NCT02864381|Drug|Nivolumab|3 mg/kg administered via IV infusion
75946580|NCT05077202|Device|ultra sound|chest ultrasound
75805632|NCT04362293|Drug|hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
75805633|NCT04362293|Drug|hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3, plerixafor (0.24mg/Kg) subcutaneously every 12 hours on days -3 and -2 and low dose total body irradiation (TBI) 200 cGY on days -2 and -1 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10^6/kg recipient weight.~GVHD prophylaxis will be cyclophosphamide (50mg/Kg) intravenously on days +3 and +4 and sirolimus with a loading dose 3 mg/m2 starting on day +5. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
75805634|NCT04332367|Drug|Carboplatin|Carboplatin IV
75805635|NCT04332367|Drug|Paclitaxel|Paclitaxel IV
75946581|NCT05230472|Drug|Simvastatin|simvastatin 60 mg tab
75946582|NCT05174325|Drug|Sintilimab + chemotherapy|Biological : Sintilimab 100mg: 10ml Method of administration: 200mg IV D1 Q3W. Drug: Cisplatin Injection Specification: 75mg/m2, IV D1 Q3W. Drug: Albumin Paclitaxel Injection specifications: 260mg/m2, IV D1 Q3W.
75946583|NCT03111368|Procedure|Endoscopic ultrasound-guided fine needle aspiration|pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
75658511|NCT04867837|Drug|Octaplex|Four-factor prothrombin complex concentrate (4F-PCC)
75946584|NCT03398031|Drug|Magnesium Oxide|After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester
75946585|NCT03398031|Drug|Placebo Oral Tablet|After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
76093702|NCT03222726|Other|exercise group|less than 6000 steps/day or 40,000 steps/week
76093703|NCT03230760|Device|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
76093704|NCT03230682|Drug|antidepressant|regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
75477059|NCT04923243|Procedure|hip/knee replacement|hip/knee replacement
75946586|NCT03111680|Other|environmental intervention|a multi component environmental intervention
75946587|NCT02039960|Drug|Bupropion|Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
75946588|NCT05383313|Drug|Psilocybin|Effect of psilocybin on treatment-resistant depression
75946589|NCT05383313|Drug|Ketamine Hydrochloride|Effect of ketamine on treatment-resistant depression
75946590|NCT05383313|Drug|Midazolam Ph. Eur 9.0|Effect of midazolam on treatment-resistant depression
75946591|NCT02033681|Procedure|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
75946592|NCT02033681|Procedure|Saline Solution|Saline solution is injected into the tissue as a placebo control.
75946593|NCT02328248|Procedure|Biological patch|Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
75946594|NCT03610217|Other|Interstitial lung disease induction algorithm|Patients failing first line mycophenolic acid (MFA) will be randomized to MFA plus rituximab or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.
75946595|NCT03610217|Other|Pulmonary arterial hypertension algorithm|Patients diagnosed with pulmonary arterial hypertension secondary to systemic sclerosis will be randomized to receive anticoagulation (warfarin, rivaroxaban or apixaban)
76093705|NCT03120546|Device|rigid video stylet intubation|intubation using rigid video stylet
75346935|NCT04963842|Behavioral|Use of bio-plastic food packaging material and avoidance of plastic food packaging material|The bio-plastic food packaging material will be used by the study participants for 5 days and no plastic packaged food will be consumed.
75346936|NCT01727336|Drug|Dalantercept and axitinib|
75346937|NCT01727336|Drug|Placebo and axitinib|
75346938|NCT01578707|Drug|ofatumumab|"The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)"
75346939|NCT01578707|Drug|ibrutinib|ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
75346940|NCT03835442|Drug|Baclofen|baclofen 10mg tid for 4 weeks
75346941|NCT03835442|Other|Placebos|placebo tid for 4 weeks
75946596|NCT03610217|Other|Raynaud's phenomenon algorithm|"Patients with mild Raynaud's phenomenon not responding to the first line treatment (nifedipine), will be randomized to receive losartan or nifedipine plus atorvastatin or nifedipine plus losartan. If they fail the second line they will be crossed over to the other options randomly.~Patients with severe Raynaud's phenomenon not responding to the first line treatment (nifedipine) or failing the previous mild Raynaud's algorithm, will be randomized to receive nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option."
75946597|NCT03610217|Other|Digital ulcer algorithm|"Patients with active digital ulcers not healing after 3 months or developing new ones with nifedipine will be randomized to nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.~Patients who develop new digital ulcers under treatment with nifedipine will be randomized to nifedipine plus atorvastatin plus standard of care or nifedipine plus standard of care. If they fail the second line they will be crossed over to the other option."
75946598|NCT03610217|Other|Inflammatory arthritis algorithm|Patients with inflammatory arthritis failing methotrexate and/or prednisone and/or hydroxychloroquine and/or sulfasalazine will be randomized to receive intravenous rituximab or subcutaneous tocilizumab. If they fail the second line they will be crossed over to the other option.
75946599|NCT03610217|Other|Gastroesophageal reflux algorithm|Patients with gastroesophageal reflux failing standard doses of proton pump inhibitors (PPI) will be randomized to receive double doses of PPI or standard dose of PPI plus ranitidine or double doses of PPI plus domperidone or double doses of PPI plus prucalopride/erythromycin. If they fail the second line they will be crossed over to the other options randomly.
75946600|NCT03610217|Other|Bacterial overgrowth algorithm|Patients with bacterial overgrowth will be randomized to receive erythromycin or metronidazole or amoxicillin. If they fail the second line they will be crossed over to the other options randomly.
75946601|NCT03610217|Other|Constipation algorithm|Patients with constipation will be randomized to receive bisacodyl or magnesium sulphate or polyethylene glycol or senna.If they fail the second line they will be crossed over to the other options randomly.
75346942|NCT02466516|Drug|SEL|SEL tablet administered orally once daily
75346943|NCT02466516|Biological|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
75346944|NCT04377464|Other|SF12, EQ-5D-5L and work status standardized quantitative assessments|Quality of life assessments
75346945|NCT01722656|Drug|Aflibercept|
75346946|NCT04963764|Drug|Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (10 days)
75658512|NCT04866472|Device|video-laryngoscope and GlideRite Rigid Stylet|Once subject is in the operating room, standard monitoring will be instituted including nerve stimulator. Induction will follow standard practice.Once full muscle relaxation is confirmed with a train of four of 0/4 laryngoscopy will be preformed using a video-laryngoscope (VLS) with a #3 blade for women and a #4 blade men. Endotracheal intubation will be performed using a #7 endotracheal tube in women and # 8 in men using the GlideRite Rigid Stylet. The stylet will be shaped to the curvature of the blade of the VLS and lubricated with a water-based lubricant. After successful tracheal intubation the circuit will be connected and ventilation confirmed with capnography and auscultation.
75805636|NCT04332367|Drug|Ramucirumab|Ramucirumab IV
75805637|NCT04319237|Other|Handgrip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles.
75805638|NCT04319237|Behavioral|Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)|"The Wechsler Test of Adult Reading (WTAR) is a neuropsychological assessment tool used to provide a measure of Intellectual function. Participants are presented with 50 irregularly spelled words and prompted to pronounce each; the irregular grapheme-to-phoneme translations (such as the gh in the word tough) in the prompts make it difficult to pronounce without having previously learned the word. A high WTAR score is correlated with higher general intelligence as measured by the Wechsler intelligence scales."
76093706|NCT03120546|Device|video laryngoscope intubation|intubation using video laryngoscope
76093707|NCT02367820|Drug|NKTR-181 BID tablets|NKTR-181 tablets 100-600 mg twice daily (BID)
76093708|NCT03227874|Dietary Supplement|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
75346947|NCT04963764|Drug|Placebo|Participants will be randomized to receive oral placebo for a standard course (10 days)
75346948|NCT03405584|Drug|Esomeprazole|Proton pump inhibitor
75346949|NCT03405584|Drug|Amoxicillin|Antibiotic for H. pylori eradication
75346950|NCT03405584|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
75346951|NCT03007043|Other|blood sample|
75346952|NCT04935840|Dietary Supplement|FertyBiotic Pregnancy|DHA, folic acid, Iodine, iron, Lactobacillus rhamnosus, Lactobacillus reuterii, magnesium, zinc, vitamin D3, Vitamin C, Vitamin E, Group B vitamins and Biotin
75346953|NCT04935840|Other|Control|400 mcg of folic acid
75346954|NCT03834662|Drug|AVID200|A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
75346955|NCT03007121|Drug|Morphine intrathecal|Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
75346956|NCT03007121|Drug|Bupivacaine + Sufentanil epidural|Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
75346957|NCT03007121|Drug|Morphine intravenous|Patiernt-controlled i.v. analgesia with morphine
75346958|NCT04959864|Dietary Supplement|Isitol®|"1 sachet of Isitol® (2,1g) contains :~1000 mg of myo-inositol ;~300 mg of N-acetyl-cystein ;~48.5 mg of zinc citrate (equivalent zinc pure element : 15 mg) ;~35 mg of D-a-tocopherol (equivalent vitamin E pure element : 12 mg) ;~16 mg of vitamin B3 ;~1.8 mg of pyridoxin hydrochloride (equivalent vitamin B6 pure element : 1.4 mg) ;~1.4 mg of vitamin B2 ;~0.37 mg of (6S)-5-methyltetrahydrofolic acid, glucosamine salt (equivalent vitamin B9 pure element : 0.2 mg).~Sachets are packaged in box of 30."
75346959|NCT04959864|Other|Placebo|"1 sachet of placebo (2,1g) contains :~1765.1 of maltodextrin ;~300 mg of magnesium carbonate ;~40 mg of citric acid ;~5.3 mg of beta-carotene ;~2.16 mg of silicon dioxide ;~1.44 mg of sucralose.~Sachets are packaged in box of 30."
75346960|NCT01725152|Drug|Ganaxolone|oral suspension, given in 3 divided doses
75346961|NCT01725152|Drug|Placebo|oral suspension, given in 3 divided doses
75658513|NCT04866472|Device|video-laryngoscope and TCI Articulating Introducer Device|In the operating room, standard monitoring will be instituted including nerve simulator. Induction will follow standard practice. Once full muscle relaxation is achieved (train of four of 0/4) laryngoscopy will be performed using a video-laryngoscope (VLS) using a #3 blade in women and a #4 blade in men. A #7 endotracheal tube will be used for women and a #8 for men. Endotracheal intubation will be performed by placing the tube on the back of the TCI articulating introducer, after shaft is lubricated with a water based lubricant. The tip of the TCI articulating introducer will be maneuvered into the trachea and advanced until the green zone of the introducer shaft is adjacent to the glottis. The handle of the articulating introducer will then be removed and the ETT will be advanced over the articulating introducer and into the trachea via Seldinger's technique. Once in place the respiratory circuit will be connected and confirmed with capnography and auscultation.
75658514|NCT04860960|Drug|Hydroxypropyl-beta-cyclodextrin|Dose is 2000 mg/kg body weight provided every 2 weeks intravenously
75805639|NCT04319237|Behavioral|Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)|The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of twelve subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory).
75805640|NCT04319237|Behavioral|Neuropsychological Assessment - Color Trails|The Color Trails test measures sustained attention and sequencing. Numbered circles are printed with vivid pink or yellow backgrounds that are perceptible to color-blind individuals. Participants rapidly connect circles numbered 1-25 in sequence and rapidly connect numbered circles in sequence, but alternates between pink and yellow. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.
75805641|NCT04319237|Behavioral|Neuropsychological Assessment -Stroop Color and Word Test|The Stroop Color and Word Test is based on the observation that individuals can read words much faster than they can identify and name colors. The test-taker reads color words or names ink colors from different pages as quickly as possible within a time limit. The test yields three scores based on the number of items completed on each of the three stimulus sheets. An Interference score is useful in determining the individual's cognitive flexibility, creativity, and reaction to cognitive pressures.
75946602|NCT03610217|Other|Skin involvement algorithm|"Patients with skin involvement and modified Rodnan skin score <32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option.~Patients with skin involvement and modified Rodnan skin score >32 will be randomized to receive methotrexate plus mycophenolic acid or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option."
75946603|NCT03610217|Other|Pain algorithm|Patients with pain failing first line treatment with acetaminophen or celecoxib or ibuprofen will be randomized to receive pregabalin or duloxetine. Patients with skin involvement and modified Rodnan skin score <32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. In case they fail the second line they will be treated with medical marijuana.
75946604|NCT02328482|Drug|Tehalose 30gr|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
75805642|NCT04319237|Behavioral|Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire|The PROMIS-29 questionnaire assesses each of 7 domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities). A higher score equals more of the concept being measured.
75946605|NCT02328092|Device|rSMS in treatment of Nocturnal Enuresis|Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
75805643|NCT04319237|Behavioral|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-3) and the add-on EORTC QLQ Non-Hodgkin's Lymphoma (EORTC QLQ-NHL-HG29) module. All scales range from 0-100, a high scale score represents a higher response level. For example, a high functional score represents a high level of functioning.
75946606|NCT02328170|Other|EUROIMMUN Allergy|Immunoblot assay
75946607|NCT02328170|Other|ImmunoCap|Fluoroallergosorbent test
75477060|NCT04922502|Behavioral|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
75658515|NCT04860960|Drug|Placebo|0.5N saline provided every 2 weeks intravenously
75658516|NCT04859764|Device|Reparel knee sleeve|Unlabelled thermo-active knee sleeve that improves bloodflow to knee and decreased pain
75658517|NCT04859764|Drug|Corticosteroid injection|intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)
75658518|NCT04859764|Device|Placebo knee sleeve|unlabeled compression knee sleeve
75658519|NCT04857502|Drug|99mTc-based PSMA Imaging and Surgery Agent|Given via IV injection
75658520|NCT04857502|Procedure|Computed Tomography|Undergo SPECT/CT
75805644|NCT04319237|Behavioral|Quality of Life (EQ-5D-5L) Questionnaire|The EQ-5D-5L questionnaire is a self assessed quality of life questionnaire. The scale measures quality of life on a 5 component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.
75805645|NCT04319237|Behavioral|PROMIS Cognitive Function 4a Questionnaire|The PROMIS measures function, symptoms, behavior and feelings.
75946608|NCT02860169|Behavioral|Participants self-administered questionnaire and assessment|Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
75946609|NCT05069402|Dietary Supplement|Immunonutrition|diet with immunonutrients
75946610|NCT05069402|Dietary Supplement|High-protein|Oral nutrition with high-protein content
75658521|NCT04857502|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
75805646|NCT04319237|Behavioral|Comprehensive Score for Financial Toxicity (COST) measure|The COST is a questionnaire made up of 11 statements around topics including costs, concerns and resources and is designed to measure financial toxicity. The user answers questions about their concern over finances numbered from 0-4, with 0 being not at all and 4 being very much.
75946611|NCT05069402|Dietary Supplement|Standard ONS|Oral nutrition with standard ingredients
75946612|NCT03609983|Other|Daily weighing with daily feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each day upon rising from bed beginning in one week, every day for four weeks. After 2 weights have been collected, participants will begin to receive daily feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is _______. Your weight has (increased/decreased) _____ pounds since yesterday. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
75658522|NCT04855422|Diagnostic Test|Allosure|AlloSure Analysis For the AlloSure test, 10-20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) at ambient temperature in insulated packaging to minimize temperature fluctuation. The AlloSure test will be performed at the CareDx CLIA/CAP-accredited clinical laboratory. Samples will be tested, and results provided within 3 days of blood draw
75658523|NCT04855422|Diagnostic Test|AlloMap|AlloMap Kidney is intended to aid in the identification of SPK transplant recipients who have a low probability of rejection at the time in testing in conjunction with standard clinical assessment. For the AlloMap-Kidney test, approximately two tubes of blood will be obtained in PAXgene Blood RNA tubes and shipped to CareDx, Inc. (Brisbane, CA), where it will be tested.
75946613|NCT03609983|Other|Weekly weighing with weekly feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each week upon rising from bed beginning the following day for four weeks. After 2 weights have been collected, participants will begin to receive weekly feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is _______. Your weight has (increased/decreased) _____ pounds since last week. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
75946614|NCT05069090|Behavioral|Lockdown and other social distancing measures|During the study period, the Chilean Ministry of Health established a five-step process for social distancing measures. These ranged from full lockdown (step 1) to almost no restrictions (step 5). Even under full lockdown, citizens were able to obtain permits for essential activities. Citizens had a maximum of two permits per week and were obtained in a virtual station of the Chilean Police Force (Carabineros de Chile).
75946615|NCT03144050|Device|SFDI Imaging|Imaging with SFDI device
75946616|NCT02328638|Behavioral|Parent Education Program|The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
75946617|NCT02328638|Behavioral|Manual-based Behavioral Treatment|The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
75946618|NCT03145220|Drug|EA-230|Active intervention
75946619|NCT03145220|Other|Placebo (NaCl)|Placebo intervention
75946620|NCT03144128|Dietary Supplement|Vitamin D|5,000IU vitamin D given daily for 12 weeks
75946621|NCT03144128|Dietary Supplement|Placebo|Placebo capsules given daily for 12 weeks
75946622|NCT02326532|Other|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
75946623|NCT02326532|Other|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
75946624|NCT02326610|Drug|Human growth hormone,ZOMACTON® (somatropin)|The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
75946625|NCT00409773|Drug|ezetimibe (+) simvastatin|Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
75946626|NCT00409773|Drug|Comparator: atorvastatin calcium|"Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
75658524|NCT04848220|Drug|Temanogrel|Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
75946627|NCT00409773|Drug|Comparator: Placebo (unspecified)|"Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
75946628|NCT02326376|Drug|anakinra (Kineret)|
76093709|NCT03227874|Dietary Supplement|Muffin|two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
76093710|NCT03222258|Behavioral|Early palliative care|Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.
76093711|NCT03222258|Behavioral|Routine hospice care|Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
76093712|NCT02036320|Device|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
75658525|NCT04848220|Drug|Placebo|Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
75658526|NCT04847479|Behavioral|COVID-19 self-test|Up to 3 COVID-19 self-test kits will be given to individuals who have tested positive for COVID-19. Participants will be instructed to give test kits to close contacts who have been exposed to them.
75946629|NCT02034422|Dietary Supplement|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
75946630|NCT02034422|Other|Exercise rehabilitation|8 weeks of exercise rehabilitation
76093713|NCT03232710|Drug|Bosiqing|Aripiprazole Orally disintegrating tablets 10mg
75805647|NCT04309370|Device|20 Hz rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.
75658527|NCT04847479|Behavioral|COVID-19 test referral|Text messages with testing information will be given to individuals who have tested positive for COVID-19. Participants will be instructed to share text messages with close contacts who have been exposed to them.
75658528|NCT04843904|Drug|Venetoclax|Tablet, taken by mouth
75658529|NCT04843904|Drug|Obinutuzumab|Given as an infusion into the vein (intravenous, IV).
75805648|NCT04258033|Drug|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
75805649|NCT04222309|Procedure|Laparoscopically harvested omental free flap|Laparoscopically harvested omental free flap into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
75805650|NCT04202159|Drug|Perampanel|Perampanel tablets.
75805651|NCT04202159|Drug|Perampanel|Perampanel oral suspension.
75805652|NCT04186559|Drug|Topical Pentoxifylline Gel (Vehicle +PTX)|Patients will be given 1 tube containing 20 ml of topical PTX gel (containing 1,000mg of PTX) to be applied no fewer than four times per day with complete consumption of the entire tube each day.
75805653|NCT04186559|Drug|Topical Placebo Gel (Vehicle)|Patients will be given 1 tube containing 20 ml of topical placebo gel to be applied no fewer than four times per day with complete consumption of the entire tube each day.
75805654|NCT04184362|Device|Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
75805655|NCT04183452|Drug|17-Hydroxyprogesterone Caproate 250 mg IM Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
75805656|NCT04183452|Drug|17-Hydroxyprogesterone Caproate 275 mg SC Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
75805657|NCT04171479|Device|Epicardial mapping and/or ablation|Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.
75805658|NCT04156373|Behavioral|Fuerte|Fuerte is a prevention program targeting youth at risk for psychological trauma who are recent immigrants to the United States. The program is evidence-informed using cognitive-behavioral principles and the Attachment, Regulation, and Competency (ARC) model for treating psychological trauma.
75805659|NCT04134585|Other|semi-structured interviews|Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
75805660|NCT04133298|Procedure|Tunneling with laser de-epithelized gingival graft|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
75805661|NCT04133298|Procedure|Tunnelingwith subepithelial connective tissue graf|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
76093714|NCT03232710|Drug|abilify|Aripiprazol orodispersible tablets 10mg
76093715|NCT03227640|Procedure|stripping technique|The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.
76093716|NCT03227640|Device|CO2 laser (AcuPulse Duo, Lumenis)|The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
75346962|NCT02980913|Device|Thealoz Duo eye drops and Thealoz Duo gel|Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days
75658530|NCT04843904|Drug|Rituximab|Given as an infusion into the vein (intravenous, IV).
75658531|NCT04830228|Device|Ballon expandable stent and PTA|Endovascular treatment for the peripheral artery disease of the Iliac artery
75658532|NCT04814433|Drug|Tranexamic acid|"FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.~Total dose of 500 mg (20 mL) total will be given."
75658533|NCT04814433|Drug|Aminocaproic acid|"FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.~Total of 1000 mg total will be given."
75805662|NCT04123938|Other|Pea Protein|Soluble pea protein
75805663|NCT04123938|Other|Whey Protein|Whey protein concentrate
75805664|NCT04123938|Other|Maltodextrin|Non-protein isocaloric comparator
76093717|NCT02451540|Radiation|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
76093718|NCT02451540|Drug|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
76093719|NCT02451540|Drug|Roflumilast|Roflumilast, once a day in the morning during 3 months
76093720|NCT03227484|Drug|Empagliflozin 25mg|Once daily over 8 weeks
75946631|NCT02861807|Device|Brain stimulation with mindfulness-based relapse prevention|Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
76093721|NCT03227484|Drug|Placebo Oral Tablet|Once daily over 8 weeks
76093722|NCT01744691|Drug|Ibrutinib|All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
75346963|NCT02980913|Device|Thealoz Duo gel|Thealoz Duo gel during the day and at night for 7 days
75346964|NCT01723982|Drug|Barusiban (FE 200440)|
75346965|NCT01723982|Drug|Placebo Comparator|
75346966|NCT02981303|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
75346967|NCT02981303|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
75658534|NCT04814433|Drug|Recombinant Human Thrombin|"Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.~Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.~For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given"
75805665|NCT04106245|Behavioral|Behavioral Intervention|Participate in PACK Health
75805666|NCT04106245|Other|Survey Administration|Complete survey
75805667|NCT04104646|Drug|CHF6563|Sublingual CHF6563 administration at starting dose of 10 µg/kg q8
75805668|NCT04104646|Drug|Morphine|Oral morphine administration at starting dose of 0.07 mg/kg q4
75805669|NCT04104646|Drug|CHF6563 matched placebo|Sublingual CHF6563 matched placebo administration
75805670|NCT04104646|Drug|Morphine matched placebo|Oral morphine matched placebo administration
75805671|NCT04098874|Drug|Bupropion Extended Release Oral Tablet|12 weeks postpartum of blinded study medication
75805672|NCT04098874|Drug|Placebo oral tablet|12 weeks postpartum of blinded placebo
75805673|NCT04075487|Other|Web-module for patient education and planning|Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
75946632|NCT02325986|Drug|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
75946633|NCT02325986|Drug|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
75946634|NCT02325986|Radiation|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
75946635|NCT02327780|Other|FODMAP diet|
75346968|NCT03834038|Drug|Lyophilized Fecal Microbiota Transplantation|Lyophilized FMT
75946636|NCT00398151|Drug|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
75946637|NCT03610139|Dietary Supplement|Vitamin D3|At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
75946638|NCT02327624|Drug|Clopidogrel|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
75946639|NCT02327624|Drug|Ticagrelor 60|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
75946640|NCT02327624|Drug|Ticagrelor 90|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
75946641|NCT03388671|Procedure|TAB Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided TAB Block
75946642|NCT03388671|Procedure|Psoas Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block
75346969|NCT02981459|Drug|Mirabegron|daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
75346970|NCT01724138|Drug|Deferasirox|Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
75346971|NCT02247167|Procedure|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
75346972|NCT03006809|Biological|Fecal Microbiota Transplantation (FMT), OpenBiome|Delivered by colonoscopy, enema or orally (as capsules)
75346973|NCT03006809|Other|pretreatment antibiotics|5 day course (vancomycin PO 500mg bid, metronidazole PO 500mg bid, and neomycin PO 500mg bid) starting 6 days prior FMT
75346974|NCT01580423|Drug|aprepitant|125 mg capsule
75346975|NCT01580423|Drug|placebo|capsule identical to aprepitant
75946643|NCT03388671|Drug|Bupivacaine|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block or TAB block
75946644|NCT03609671|Behavioral|Standard of Care + Experimental Individualized Therapy|Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.
75946645|NCT03609671|Other|Control: Standard of Care|Participants will undergo standard of care only (no Intervention/no individualized therapy) .
75946646|NCT02327936|Drug|Fesoterodine|Administer medication to patients with overactive bladder
75946647|NCT02327936|Drug|Oxybutynin XL|Administer medication to patients with overactive bladder
75946648|NCT03384849|Diagnostic Test|MRI examination|The part of the body that is being scanned and the time of the MRI examination are not relevant.
76093723|NCT01982968|Procedure|Surgery|Full fundoplication surgery for the treatment of abnormal GER
76093724|NCT04485390|Other|Basic life support witn use of an AED before EMS|BLS performance with use of an AED before arrival of EMS
75805674|NCT04048421|Procedure|hvNOTES radical colectomy|With the patient under general anesthesia, pneumoperitoneum is achieved. Three trocars are inserted, one 12 mm or 5 mm in the umbilicus and two 5 mm in the right and/or left flanks. Mobilization of the splenic flexure or the hepatic flexure is performed with an initial traditional laparoscopic approach. A single-port is inserted into the abdominal cavity transvaginally through the colpotomy. Then most of the procedures are performed transvaginally with conventional rigid laparoscopic instruments. The corresponding arteries and veins are divided. The mesocolon is mobilized. The small intestine/colon/rectum are then divided with stapler. The specimen is removed transvaginally. Intracorporeal anastomosis is performed as per the surgeon's standard of care. For sigmoidectomy, the colon is then exteriorized and the anvil is fixed in the colon. An end-to-end anastomosis is performed using a circular stapler. Drainage tubes may be used.
75946649|NCT02327858|Other|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
75346976|NCT01049984|Drug|Rasagiline|1mg tablet daily for 18 weeks
75658535|NCT04814433|Drug|Lidocaine Hydrochloride with Epinephrine|"Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.~Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given"
75658536|NCT04814433|Drug|Bupivacaine Hydrochloride with Epinephrine|"Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.~Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given"
75805675|NCT04047589|Behavioral|Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.|Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
75946650|NCT03388593|Drug|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
75346977|NCT01049984|Drug|Placebo|one tablet daily for 18 weeks
76093725|NCT03230448|Other|questionnaire|after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
75946651|NCT03388593|Drug|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
75946652|NCT03609905|Biological|Adipose-cord mesenchymal stromal cells (A-MSCs)|A-MSCs 5 x 10~7 diluted on 100 mL of normal saline
75946653|NCT03609905|Other|Conventional drugs|5-amino-salicylic acid or glucocorticoid
76093726|NCT03230526|Drug|[18F]DPA-714 PET scan|"One PET scan using [18F]DPA-714 is done at M2 between two [123I]FP-CIT scan (DaTscan) done at M1 and M35.~Neuropsychological assessment is done at M0, M18 and M36"
75346978|NCT03001271|Drug|Angiotensin 1-7|
75346979|NCT03001271|Other|Placebo|
75346980|NCT03001349|Procedure|Computed Tomography|Undergo PET/CT
75346981|NCT03001349|Drug|Gallium Ga 68-Edotreotide|Given IV
75346982|NCT03001349|Procedure|Positron Emission Tomography|Undergo PET/CT
75658537|NCT04803084|Other|Tempus assay|Blood collection
75658538|NCT04803084|Other|Advanced pathology 1|Tissue procurement (from diagnostic biopsy)
75658539|NCT04803084|Other|Advanced pathology 2|Tissue procurement (from research biopsy)
75658540|NCT04788628|Other|Baseline|Hippocampal and scalp EEG monitoring during overnight sleep
75658541|NCT04788628|Other|Motor procedural memory task|Training on the finger tapping MST prior to monitored overnight sleep with MST testing the following morning
75658542|NCT04788628|Other|Motor procedural memory task plus auditory stimulation|Training on the finger tapping MST prior to monitored overnight sleep that includes auditory stimulation, with MST testing the following morning
75946654|NCT02326142|Drug|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
75946655|NCT02326142|Drug|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
75946656|NCT04486001|Biological|PSC-04|adipose stem cells derived from screened donor lipoaspirate and culture expanded.
75946657|NCT03142490|Other|Acupuncture|Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
76093727|NCT02038894|Drug|Intubated with Sevoflurane (IS)|Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
75346983|NCT04377152|Drug|68Gallium-PSMA-11|PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).
75346984|NCT04377152|Procedure|Positron Emission Tomography (PET)|A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity
75346985|NCT03006575|Radiation|split-course radiotherapy|split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
75346986|NCT03006575|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
76093728|NCT02038894|Drug|Intubated with Propofol (IP)|Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
75346987|NCT03405506|Device|Quantitative Flow Ratio (QFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
75346988|NCT03001193|Drug|DF 01|
75658543|NCT04786067|Drug|Belatacept|Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
75658544|NCT04780932|Drug|Macitentan 10mg|Macitentan 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
75658545|NCT04780932|Drug|Placebo|Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
75658546|NCT04767880|Dietary Supplement|Whey|Doses of 10, 15, 20 and 30 gram protein of a regular whey protein compound (whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients))
75805676|NCT04047589|Behavioral|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future
75805677|NCT04000763|Device|superficial peroneal nerve stimulation|A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.
75658547|NCT04767880|Dietary Supplement|Placebo|The placebo contains <1 kcal and 0 g protein
75805678|NCT03997643|Radiation|Radiotherapy to all dissected areas|Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
75805679|NCT03997643|Radiation|Omit radiation to pN0 neck|post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
75805680|NCT03984396|Other|Educational Materials - Patient & Clinician|deprescribing information for patient & clinician
75946658|NCT03142490|Other|Questionnaires|Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
75946659|NCT03609515|Other|Patient-controlled admission|The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.
75946660|NCT03384771|Behavioral|MBSR|There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
75805681|NCT03978897|Device|Blood flow restriction tourniquet|A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.
75805682|NCT03978897|Other|Evidence based physical/occupational therapy|Up to date physical/occupational therapy for lateral epicondylitis
75946661|NCT03144908|Other|Standard Operating Procedures|Observational on Standard Operating Procedures
75946662|NCT04113707|Behavioral|Motor lab activity|fitness, gross motor, fine motor, and motor coordination activities
75946663|NCT03388515|Biological|SSS11|IV infusion for 60 min.
75946664|NCT03388515|Other|placebo|IV infusion for 60 min.
75346989|NCT03001193|Drug|Oxytocin|
75346990|NCT03001193|Drug|Placebo|
75346991|NCT01049360|Drug|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
75346992|NCT01049360|Drug|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
75346993|NCT01049360|Drug|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
75346994|NCT01049360|Drug|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
75346995|NCT01049360|Drug|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
75946665|NCT03609827|Drug|Melphalan|
75946666|NCT05076968|Procedure|Complete denture fabrication|Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery
76093729|NCT02038894|Drug|Zofran - no intubation|A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
76093730|NCT02038894|Drug|Propofol|
75346996|NCT02494596|Drug|Capecitabine|Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
75658548|NCT04745390|Radiation|Radiation therapy|Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.
75658549|NCT04743973|Device|Muse S™ Headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
75658550|NCT04743804|Biological|Ravulizumab|Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
75658551|NCT04743804|Other|Placebo|Matching placebo
75658552|NCT04743804|Other|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
75658553|NCT04741542|Drug|SP-420|This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
76093731|NCT01716533|Procedure|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
75658554|NCT04740736|Procedure|Saline Infusion|Patient with hypovolemia on day 1 will be randomized to a saline or sham infusion prior to the Day 2 exercise test.
75658555|NCT04739813|Biological|obinutuzumab|administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
75805683|NCT03954171|Other|Patients treated with platinum based-chemotherapy|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~before treatment initiation (blood sample),~during hospitalisation for surgery (blood sample),~during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study."
75946667|NCT03125733|Procedure|Submucosal tunneling endoscopic septum division|"STESD includes 4 steps:~Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.~Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.~Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.~Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips."
75658556|NCT04739813|Drug|prednisone|administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
76093732|NCT01716533|Other|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
76093733|NCT01375374|Drug|Lacosamide|4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
76093734|NCT01375374|Drug|Levetiracetam|Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
75658557|NCT04739813|Drug|Revlimid|administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
75658558|NCT04739813|Biological|Polatuzumab|administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
75658559|NCT04739813|Drug|ibrutinib|administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
75658560|NCT04739813|Drug|venetoclax|administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
75805684|NCT03926533|Other|Telehealth|Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
76093735|NCT04348786|Drug|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
76093736|NCT04348786|Drug|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
76093737|NCT03222336|Behavioral|Family pedigree and data collection|"Enroll first generation (newborn), at least one member from second (parent) and third generation (grandparent) for a complete IVS4 family tree mapping.~Collect and analyze medical history, genetic and biochemical assessment data"
75346997|NCT02494596|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
75346998|NCT03006653|Behavioral|Assessment only|Mobile ecological assessment only.
75346999|NCT01581437|Procedure|64 pole basket catheter|The 64 pole basket catheter expands into a small flexible balloon that conforms to the atrial anatomy.
75477061|NCT04922502|Behavioral|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
75658561|NCT04730882|Dietary Supplement|Mixed Meal|the meal will be 40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively
75658562|NCT04728217|Drug|Efmoroctocog Alfa Injection [Eloctate]|Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).
75658563|NCT04727008|Biological|CXCR4 modified anti-BCMA CAR T cells|intravenous infusion
75658564|NCT04725123|Diagnostic Test|Microbiome analysis|Stool microbiome analysis of 16S rRNA sequencing to an anticipated number of 8,000,000 reads
75658565|NCT04724044|Drug|Tablets|Oral tablets of similar appearance to active study drug
75658566|NCT04724044|Drug|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
75658567|NCT04722263|Radiation|Radiotherapy|15 Gy in 3 fractions
75658568|NCT04717817|Device|Inspiratory muscle training (IMT) using an IMT Threshold device (Philips)|Inspiratory muscle training on a daily basis prior to surgery during 2-3 weeks
75658569|NCT04717817|Other|Standard physiotherapy|Standard instructions and physiotherapy prior to surgery during 2-3 weeks
75805685|NCT03919669|Drug|All Subjects|All subjects will be given the experimental tau PET radioligand [18F]MK-6240
75805686|NCT03900767|Other|Electronic Health Record intervention|AAC
75805687|NCT03900767|Behavioral|Smoking Cessation Intervention|Receive standard Utah Quitline treatment
75805688|NCT03900767|Behavioral|Telephone-Based Intervention|Receive text messages
75347000|NCT03405428|Other|Allen test|Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.
75347001|NCT03405428|Other|Radial artery diameter measurement by ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.
75658570|NCT04714840|Other|Exercise testing results|Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.
75658571|NCT04714840|Other|Individually tailored exercise program (INT)|Individuals randomized to receive an individually tailored exercise program will meet with an exercise specialist. Written instructions, videos of each strengthening exercise, a blue tooth enable heart rate monitor, all necessary exercise equipment, and an iPad pre-loaded with heart rate monitor software, exercise videos and ZOOM app (for video conferencing) will be provided. After returning home, the exercise specialist will supervise and provide guidance to the individual via the ZOOM app during the first 2 weeks (3 sessions per week). Supervision will slowly decrease to twice a week in weeks 3-4, once a week in weeks 5-8, every other week in weeks 9-16, and to one time midway between weeks 17-20. The exercise program will be adjusted depending on the individuals progress.
75658572|NCT04714840|Other|Generalized exercise recommendations (AC)|Individuals randomized to receive the generalized exercise recommendations will receive a copy of the Physical Activity Guidelines for Americans. At the baseline visit, a study staff will review these guidelines and answer questions about their exercise testing and encourage them to be physically active. The staff will contact them via telephone to complete a short questionnaire weekly during weeks 1-8 and monthly for weeks 9-20.
75658573|NCT04707794|Drug|Sevoflurane|Sevoflurane delivery will will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
75946668|NCT03609749|Behavioral|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)"
75658574|NCT04707794|Drug|Desflurane|Desflurane delivery will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
75805689|NCT03900767|Behavioral|Telephone-Based Intervention|Receive phone calls
75805690|NCT03896867|Device|Anapod™ Humi-Therm Heated Humidification System Breathing Circuit|"For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
75805691|NCT03896867|Device|Bair Hugger™ Warming Blanket|"For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
75946669|NCT02858401|Drug|Vesatolimod|Tablet(s) administered orally once every 2 weeks
75347002|NCT03405428|Other|Ulnar artery doppler ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
75347003|NCT02494206|Drug|QBX258|Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
75347004|NCT01582139|Device|Heart rate informed SSM+HMM|The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
75347005|NCT01048502|Drug|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
75347006|NCT01048502|Drug|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
75347007|NCT01048502|Drug|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
75347008|NCT02465034|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 hertz (Hz)) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
75477062|NCT04914676|Drug|Cytarabine|Subjects on this arm will prospectively receive consolidation therapy with cytarabine. Subjects will be treated with 1000 mg/m2 cytarabine intravenously every 12 hours on Days 1-3 of each consolidation cycle. Subjects will receive up to four consolidation cycles.
75805692|NCT03886714|Diagnostic Test|Screening for Fabry disease|Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.
75946670|NCT02858401|Drug|Placebo|Tablet(s) administered orally once every 2 weeks
75946671|NCT02858401|Drug|ARV regimen|Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
75658575|NCT04704336|Behavioral|Task-shifting strategy for HTN control (TASSH) protocol|The TASSH protocol include the following 4 steps: 1). Identify HIV patients with uncontrolled HTN: trained HIV nurses will take patients' medical history (whether or not they have a diagnosis of diabetes, heart attack, stroke, heart failure, smoking). 2) Next, they will measure the patients' weight, height, waist circumference and BP with a valid automated device following standard procedures and then conduct lab tests with point-of-care testing on blood glucose, lipids and urine dip stick. 3) Initiate lifestyle counseling and medication treatment every 1-3 months: The nurses will next counsel eligible patients on lifestyle behaviors for 20 to 30 minutes (increased intake of fruits and vegetables, moderate physical activity and reduce salt intake). 4). Refer patients with complicated HTN to physicians for further care
76093738|NCT03230370|Other|UFT|The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,
75658576|NCT04702789|Drug|Dorzolamide-timolol-brimonidine and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
75347009|NCT02465034|Device|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
75347010|NCT02465034|Device|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1 milliseconds (ms) rectangular pulses at an intensity to evoke a 1 millivolt (mV) response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
75658577|NCT04702789|Drug|Dorzolamide-timolol and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
75658578|NCT04702711|Other|No intervention|No intervention
75658579|NCT04672044|Device|Active rTMS and exercise|active
75658580|NCT04672044|Combination Product|Sham rTMS+Exercise|sham
75658581|NCT04668599|Other|Cardiopulmonary rehabilitation|Patients will undergo standardized cardio-pulmonary rehabilitation program.
75658582|NCT04662905|Device|Evoke Spinal Cord Stimulation (SCS) System|ECAP-controlled, closed-loop SCS
75805693|NCT03886714|Diagnostic Test|Screen for α-galactosidase mutation|If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).
75805694|NCT03860558|Other|Lifestyle Intervention|Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
75805695|NCT03860558|Other|No Intervention|Participants will not undergo an intervention.
75805696|NCT03841279|Diagnostic Test|MRI|Magnetic resonance imaging (MRI) produces detailed images of the body's internal structures without relying on radiation. It is used to diagnose and also gauge efficacy of treatment.
75805697|NCT03832634|Diagnostic Test|Fetal Genome Profiling.|Once pregnancy is achieved, patients will undergo non-invasive collection of trophoblast cells (trophoblast retrieval and isolation from the cervix, TRIC) at an early gestational age, approximately 5-6 weeks. The patient will also be screened with blood work for carrier status for genetic conditions.
75946672|NCT05024396|Diagnostic Test|maximum jump height|Three single leg countermovement jumps were performed. The maximum jump height is measured with a sensor that is adapted at the subjects'leg and with a force plate.
75946673|NCT02236949|Behavioral|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
75946674|NCT03126825|Device|CP910/CP920 with noise reduction on|This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.
75946675|NCT03126825|Device|CP910/CP920|The approved CP910 or CP920 Sound Processor.
76093739|NCT03230370|Other|LFT|The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
76093740|NCT02369068|Drug|Onabotulinumtoxin A|Intravaginal pelvic floor injection one series
76093741|NCT02369068|Drug|Kenalog|Intravaginal pelvic floor injection one series
76093742|NCT03222024|Other|routine medical care|This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
76093743|NCT03230214|Diagnostic Test|PCR for bacterial translocation|samples taken from the blood and ascites of patients to search for bacterial DNA
76093744|NCT03222180|Behavioral|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
75347011|NCT02465034|Device|Corticocortical Paired Associative Stimulation|Cortico-cortical Paired Associative Stimulation (CC-PAS) is a combination of TMS and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. The interstimulus interval will range from 5-15 ms depending on site of stimulation.TMS will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This CC-PAS may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
75658583|NCT04659161|Drug|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.
75805698|NCT03819309|Procedure|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
75805699|NCT03819309|Procedure|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
75805700|NCT03818360|Behavioral|an evidence-based smoking cessation intervention comprising brief advice plus active referrals|The trained healthcare professionals will be encouraged to deliver brief smoking cessation advice based on the AWARD model to smokers who attend emergency departments and are triaged as semi-urgent or non-urgent. The trained healthcare professionals will ask the smokers their smoking history, then deliver the warning message to the smokers. If the smokers refuse to quit immediately, the trained healthcare professionals will advise them to reduce the number of cigarettes smoked per day, with the goal of complete cessation within 6 months. The healthcare professionals will then actively refer smokers to the chosen service provider within 1 week of recruitment. Smokers will receive proactive telephone calls from the service providers, receive a leaflet about the health-related hazards of smoking and benefits of quitting, and a pocket-sized information card containing brief information about the existing smoking cessation services in Hong Kong.
75805701|NCT03790553|Radiation|Radiotherapy|Different total radiotherapy dose between two arms.
75946676|NCT03144596|Drug|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
75946677|NCT03144596|Drug|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
75946678|NCT02033915|Other|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
75946679|NCT00127647|Drug|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
75946680|NCT00127647|Drug|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
75946681|NCT03388437|Device|NI-NAVA|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter & positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
75946682|NCT03388437|Device|NIPPV|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter & positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
75946683|NCT03111602|Other|restrict polyphenol-rich foods|dietary orientation to restrict polyphenol-rich foods
75946684|NCT03388359|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
75946685|NCT03388359|Other|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation. Bronchial smooth muscle cell and pulmonary fibroblast proliferation, migration, contractillity, differentiation, eosinophil adhesion to the bronchial smooth muscle cells or pulmonary fibroblast.
75946686|NCT03388359|Other|Inhibition of Wnt and Smad signaling pathways|Wnt and Smad signaling pathways inhibitors effect on development of airway remodelling processes (extracellular matrix production, bronchial smooth muscle cell and pulmonary fibroblast proliferation, contractillity, differentiation, migration).
75658584|NCT04659161|Drug|Placebo|Placebo Capsules twice a day (BID)
75658585|NCT04655976|Biological|Cobolimab|Cobolimab will be administered
75805702|NCT03781401|Device|Ambulatory blood pressure monitoring|
75805703|NCT03772665|Drug|Emixustat|Once daily oral tablet taken for 24 months
75805704|NCT03772665|Drug|Placebo|Once daily oral tablet taken for 24 months
75805705|NCT03729115|Procedure|Magnetic Resonance Imaging (MRI)|Patients will have MRI scans every 6 months.
75805708|NCT03683342|Procedure|Ankle Block|Ankle block will be performed prior to surgery under ultrasound guidance
75805709|NCT03683342|Procedure|Sciatic nerve block|Sciatic nerve block will be performed prior to surgery under ultrasound guidance
75477063|NCT04914676|Drug|Cytarabine|Subjects on this arm will have received consolidation therapy with cytarabine between 2/1/2017 and 2/1/2019. Subjects will have received 1000 mg/m2 cytarabine intravenously every 12 hours on days 1, 3, and 5 of each consolidation cycle and will have received up to 4 consolidation cycles.
75658586|NCT04655976|Biological|Dostarlimab|Dostarlimab will be administered
75658587|NCT04655976|Drug|Docetaxel|Docetaxel will be administered
75658588|NCT04642820|Drug|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
75658589|NCT04642820|Drug|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
76093745|NCT02370004|Procedure|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
75946687|NCT03388359|Other|Extracellular matrix turnover and deposition assessment|Eosinophils effect on extracellular matrix proteins (collagen, fibronectin, elastin, versican, decorin, laminin, etc.) and matrix metalloproteinasis (MMP-2,9,12,etc.) production by pulmonary fibroblasts.
75946688|NCT03388359|Biological|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
75946689|NCT03388359|Device|Dosimeter ProvoX (Ganshorn)|Device for allergen bronchial challenge test.
75946690|NCT03388359|Biological|Eosinophils|Eosinophils are isolated from peripheral blood
75658590|NCT04640766|Device|PRISM|"The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on no-consecutive days. Each session will last approximately 30 minutes."
76093746|NCT03221790|Other|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
75658591|NCT04627727|Other|low FODMAP diet|low FODMAP diet
75658592|NCT04622969|Behavioral|Healthy Child Development Program|The Healthy Child Development Program is a family-based intervention focused on strengthening positive behaviors in children, managing misbehavior, and addressing healthy lifestyle choices.
75658593|NCT04608656|Other|Provision of livestock feeds|Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season
75658594|NCT04608656|Other|Nutrition counselling|Households will receive livestock feeds (ranch cubes) for the select lactating animals and will also be enrolled in to a nutrition counselling programme
75658595|NCT04605055|Dietary Supplement|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
76093747|NCT03221868|Behavioral|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
76093748|NCT03221868|Behavioral|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
75658596|NCT04605055|Dietary Supplement|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
75658597|NCT04582812|Other|Bilateral and simultaneous diaphragm ultrasonography reeducation plus inspiratory training|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
75658598|NCT04582812|Other|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
75658599|NCT04580121|Drug|RO7283420|RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
75658600|NCT04580121|Drug|RO7283420|RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
75805710|NCT03677947|Behavioral|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.
75946691|NCT03388359|Biological|Airway smooth muscle cells|Airway smooth muscle cells from healthy subjects (support from the University of Groningen)
75946692|NCT03388359|Biological|Fibroblasts|Normal human fibroblast cell lines (commercial fibroblast lines)
75946693|NCT03111446|Procedure|Spinal Anesthesia|Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
76093749|NCT01983826|Dietary Supplement|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
76093750|NCT01983826|Other|Placebo|Microcrystalline cellulose (daily) for 8 weeks
76093751|NCT03229980|Drug|Cold blood cardioplegia (large volume)|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
76093752|NCT03229980|Drug|Cold blood cardioplegia (small volume)|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
76093753|NCT02452632|Drug|ASP1941|oral
76093754|NCT02452632|Drug|Placebo|oral
75805711|NCT03677947|Other|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
75477064|NCT04914572|Other|Therapeutic rainforest mindful walking|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by Mindfulness Practitioner who volunteered to be guides for this study.
75477065|NCT04914572|Other|Therapeutic rainforest walk|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by volunteer guides recruited by the research team.
75946694|NCT03111446|Procedure|General Anesthesia|Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
75946695|NCT04540523|Behavioral|Exergaming intervention group|In addition to usual daily activity, the parent and child from each family will receive 3 game consoles (Wii, Kinect, and LeapTV) and various exergames (e.g., Nickelodeon Fit, Dance and Sports, Just Dance) with all necessary peripherals to play the games. Specifically, they will receive one game console and related exergames every 2 months to experience the variety of exergames and maintain interest in the games over time. Each parent will receive a booklet (established in our pilots studies) provides a standardized gameplay curriculum to play during each session, and attend training workshops at baseline and 3rd month in the PI's lab. The parent will be instructed to have the child perform exergaming at home for 30 minutes/session, 5 times per week, for 6 months. The games will be age appropriate for children 4-5-years-old. The games have been easy for children to learn and use in our pilot studies.
75946696|NCT04540523|Behavioral|Traditional physical activity comparison|Home-based behavioral (e.g., nutrition/PA) interventions for young children usually only target parent for multiple reasons. In this study, group workshop sessions will offered to parents at baseline, 3rd month and 6th month, including information concerning how to promote PA and reduce sedentary behaviors. Identical curricular contents (e.g., dance/sports) for home PA will be offered to parents at baseline and 3rd month in the PI's lab. Parents will also learn about PA and sedentary behavior and their impact on health and cognition. Meanwhile, the intervention staff will encourage parents to increase their lifestyle activity such as taking stairs instead of the elevator and housecleaning. Parents will also learn to shape their child and their PA and sedentary behaviors to attain the following goals: 2 hour or less screen time and at least 180 min. PA per day for children; and at least 150 min. moderate PA for parents per week.
75946697|NCT02327546|Drug|AKB-6548|
75946698|NCT02327546|Drug|Ferrous Sulfate|
75946699|NCT03388281|Other|No intervention, retrospective analysis only.|No intervention, retrospective analysis only.
75347012|NCT02465034|Device|Sham Paired Associative Stimulation|The sham PAS is a combination of TMS and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25 Hz for 12 minutes. TMS will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
75347013|NCT00918866|Drug|Definity|one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
75347014|NCT02516982|Other|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
75477066|NCT04914572|Other|Campus Green walk|A two-kilometer trail curated by the Office of Facility Management, NUS. The walk will be led by volunteer guides recruited by the research team.
75477067|NCT04914195|Drug|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
75477068|NCT04901299|Drug|NERATINIB|Neratinib will be given orally once daily on a continuous daily dosing schedule i.e., no break in dosing. Dosage per protocol
75658601|NCT04580121|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.
75805712|NCT03626701|Device|RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.
75658602|NCT04580121|Drug|Dasatinib|Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily [BID] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.
75658603|NCT04580121|Drug|Dexamethasone|20 mg IV of dexamethasone will be administered as pre-medication at least 60 minutes prior to the all RO7283420 infusions or injections during cycle 1.
75658604|NCT04580121|Drug|Paracetamol/acetaminophen|500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
75946700|NCT03144830|Device|Exoskeleton|This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
75946701|NCT02034071|Drug|DCCR|
75946702|NCT02034071|Drug|Placebo|
76093755|NCT02371252|Drug|Generic alendronate|The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
75477069|NCT04901299|Drug|FULVESTRANT|Fulvestrant will be given via injection every two weeks for the first 28-day cycle and every four weeks thereafter, dosage per protocol
75658605|NCT04580121|Drug|Diphenhydramine|25 mg or 50 mg of diphenhydramine will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
75805713|NCT03626701|Combination Product|Mepilex® Ag Wound Dressing|Application of Mepilex® Ag Wound Dressing
75805714|NCT03626701|Procedure|Conventional autografting (only when indicated)|When indicated, conventional autografting in accordance with Investigator's standard practice
75805715|NCT03622788|Biological|Anti-Thymocyte Globulin|Given IV
75805716|NCT03622788|Drug|Cyclophosphamide|Given IV
75805717|NCT03622788|Biological|Cytokine-treated Veto Cells|Given IV
75805718|NCT03622788|Drug|Fludarabine|Given IV
75805719|NCT03622788|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
75805720|NCT03622788|Radiation|Total-Body Irradiation|Undergo TBI
75946703|NCT04925336|Other|Nociceptive stimulation|"These investigations in healthy volunteers will study the association between cerebral and neurovegetative (sympathetic and parasympathetic) electrophysiological responses in response to a controlled and tolerable pain stimulus, determined for each individual. The pain stimulus will be delivered using an electrically conductive glove used in clinical practice for transcutaneous therapeutic stimulation.~The thresholds of nociception and tolerance will be determined in each healthy volunteer."
76093756|NCT02452710|Other|Placebo|Open-label placebo
75347015|NCT02516982|Other|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
75347016|NCT02516982|Other|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
75477070|NCT04898075|Behavioral|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
75477071|NCT04898075|Other|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
75477072|NCT04897009|Procedure|Biospecimen Collection|Undergo blood and tissue collection
76093757|NCT03221946|Drug|Diclofenac Sodium|tablet of 50mg,
75658606|NCT04526808|Other|FODMAP diet|low FODMAP diet
75477073|NCT04893655|Drug|Dobutamine Hydrochloride|dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
75658607|NCT04521699|Device|CalmioGO Stress management device|CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.
75658608|NCT04497116|Drug|RP-3500 (camonsertib)|Oral ATR inhibitor
75658609|NCT04497116|Drug|Talazoparib|Oral PARP inhibitor
75658610|NCT04497116|Drug|Gemcitabine Injection|Gemcitabine
75805721|NCT03604692|Drug|SNDX-6352|SNDX-6352 is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
75805722|NCT03602079|Drug|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
76093758|NCT03221946|Drug|Diclofenac sodium|Transdermal patch 100 mg
76093759|NCT03221946|Drug|Diclofenac|intra muscular injection 100mg
76093760|NCT02305732|Biological|INTERCEPT Platelets|INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.
75477074|NCT04892823|Procedure|Biospecimen Collection|Undergo collection of blood sample
75477075|NCT04892823|Other|Electronic Health Record Review|Review of medical records
75805723|NCT03598218|Radiation|Hypofraction radiation|"Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
75946704|NCT03609359|Drug|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
75946705|NCT03609359|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
75946706|NCT03380793|Drug|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
75477076|NCT04892823|Other|Questionnaire Administration|Complete questionnaires
75658611|NCT04495855|Drug|Dienogest (Visanne,BAY86_5258)|2 mg (once a day), oral, tablet.
75658612|NCT04486378|Drug|RO7198457 intravenous (i.v.)|RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
75658613|NCT04486378|Other|Observational group (no intervention)|watchful waiting
76093761|NCT03229746|Drug|Hydroxychloroquine|200mg twice daily orally for at least 12 weeks
76093762|NCT03229746|Drug|vincristine|1mg intravenous weekly for 4 weeks
76093763|NCT03229746|Drug|azathioprine|dose 100mg daily for at least 3 weeks
76093764|NCT02040298|Drug|Clemastine|4mg tablet twice daily
76093765|NCT02040298|Drug|Placebo|Placebo tablet twice daily
76093766|NCT03229668|Drug|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
76093767|NCT03229668|Drug|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule [Lyrica] 75 mg administered 1 hour prior to the surgical operation
76093768|NCT03229668|Drug|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule [Lyrica] 150 mg administered 1 hour prior to the surgical operation
76093769|NCT03230058|Drug|Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops|instillation of drops
76093770|NCT01985542|Drug|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
76093771|NCT03229902|Behavioral|mantra meditation|see study description
76093772|NCT03221712|Behavioral|cardiac rehabilitation|cardiac rehabilitation in patients with chronic total occlusion of the coronary arteries.
75946707|NCT03384615|Behavioral|Compassion-Focused Therapy|CFT for PGD symptoms in the present project is inspired by two well-established CFT treatment manuals. The first is used for treatment of PTSD (Lee & James, 2011) and the other for treatment of anger (Kolt, 2011). The manual for CFT for PGD adopts both structure and techniques from these into an 8-week, group-based program with weekly 2 1/4-hour sessions. Each session contains elements of psychoeducation on uncomplicated and prolonged grief reactions, identifying unhelpful strategies for self-protection and facilitating use of more helpful strategies, and training an open and compassionate management of grief-related distress through CFT exercises. Between the sessions the participant will train the exercises introduced at the previous session.
75658614|NCT04478422|Other|Muscle strengthening with vascular occlusion|The muscle strengthening group with partial vascular occlusion will perform the strengthening exercises: single leg squat on 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat. The equipment for vascular occlusion will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017). If necessary, the pressure can be adjusted at intervals and after the end of the exercise, an interval of 5 minutes is suggested for blood reperfusion.
75658615|NCT04478422|Other|Conventional muscle strengthening|The conventional muscle strengthening group perform the same exercises as the intervention group: One-legged squat on a 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat, however, without restriction on blood flow.
75658616|NCT04474132|Device|toxoplasma ICT IgG-IgM BK|a point-of-care device, using blood from finger stick to measure the presence or absence of anti Toxoplasma gondii antibody
75658617|NCT04472897|Drug|GSK2556286|GSK2556286 will be administered.
75805724|NCT03598218|Radiation|Standard dose IMRT|"Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
75805725|NCT03594110|Drug|Empagliflozin|Taken daily with or without food
75946708|NCT04894448|Biological|COVID-19 Vaccine|Any COVID-19 vaccine (1 or more doses)
75946709|NCT03388203|Diagnostic Test|25(OH)D measurement, PTH measurement|25(OH)D analyses by LC-MS/MS were performed as part of our routine clinical work with a commercial kit from Recipe (Munich, Germany) ; PTH was measured in lithium-heparin plasma using the PTH STAT assay from Roche Diagnostics (Mannheim, Germany) on a Cobas 8000 auto-analyzer.
75946710|NCT05075642|Other|Initial management of the urinary disorder/s identified during the screening phase|Intervention can be defined as the initial management of the LUTS identified during the screening phase; management lasts at least three months. As observation of routine clinical practice, no specific intervention is included, but any counseling/drug/rehabilitation included as first line management.
75946711|NCT02121275|Device|Ultrasound of the lungs|Ultrasound examination of the lungs
75946712|NCT02121275|Device|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
75946713|NCT03380715|Device|Nasal nebulisation into the right nostril|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
75946714|NCT03380715|Device|Nasal Spray into the right nostril|Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
75946715|NCT04833764|Drug|Rosuvastatin|Oral administration of 20 mg rosuvastatin for at least 3 months
75946716|NCT03388125|Drug|Injection Sclerotherapy|5% ethanolamine oleate group
75946717|NCT03388125|Drug|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
75946718|NCT03609281|Radiation|Ultrasound assessement of uterine scar|3D ultrasound assessment of scar characteristics
75946719|NCT04822376|Drug|ansuvimab|Human monoclonal antibody to Zaire strain GP (EBOV GP)
76093773|NCT02371876|Device|ONYX PLUS Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
75658618|NCT04472897|Drug|Placebo|Placebo will be administered
75805726|NCT03594110|Drug|Matching placebo|Taken daily with or without food
75805727|NCT03580824|Biological|R21 in Matrix- M adjuvant vaccine|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
75805728|NCT03569215|Behavioral|Questionnaire|All included patients will be exposed to questionnaires and psychiatric diagnostic tests
75477077|NCT04890028|Radiation|F-DOPA PET/CT|"All subjects will be imaged~1 time injection of 2 MBq/kg of 18F-DOPA"
75477078|NCT04886986|Drug|225Ac-J591|30 - 40 KBq/kg (dose-escalation) every 8 weeks, for up to 2 cycles. Administered together with 177Lu-PSMA-I&T. Intravenous administration.
75477079|NCT04886986|Drug|177Lu-PSMA-I&T|6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
75477080|NCT04886986|Drug|68Ga-PSMA-11|[185 ±74 MBq or 5 ±2 mCi] intravenous during screening, 12 weeks, 24 weeks. Imaging agent for PSMA PET/CT.
75477081|NCT04882072|Drug|Ustekinumab|Participants will receive IV infusion and SC injection of ustekinumab.
76093774|NCT02372344|Drug|AZD0585|Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
75805729|NCT03543735|Behavioral|Wisepill+SMS|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).
75946720|NCT04822376|Biological|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
75658619|NCT04471727|Drug|HPN328|HPN328 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains
75946721|NCT03388047|Device|Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source|During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions
75946722|NCT04314011|Biological|Human umbilical cord mesenchymal stem cells（HUC-MSCs）|Human umbilical cord mesenchymal stem cells（HUC-MSCs）
76093775|NCT03229824|Device|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
75658620|NCT04471727|Drug|Atezolizumab|Atezolizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody which potently and selectively inhibits binding of programmed death receptor 1 ligand (PD-L1) on tumor cells and tumor infiltrating immune cells in the tumor microenvironment
75805730|NCT03543735|Other|Wisepill-only|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
75805731|NCT03536546|Behavioral|Alcohol Peer Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
75805732|NCT03536546|Behavioral|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
75805733|NCT03497676|Drug|Oral Cabotegravir (CAB)|30 mg tablets administered orally
75805734|NCT03497676|Drug|Oral Rilpivirine (RPV)|25 mg tablets administered orally
75946723|NCT04314011|Biological|Placebo|Placebo
75946724|NCT05173545|Drug|Mitoxantrone Hydrochloride Liposome Injection|"Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes."
75946725|NCT04263467|Other|Exercise intervention|The exercise intervention will consist a intermediate to high aerobic exercise training program.
75946726|NCT04263467|Other|Standard oncological treatments|Standard oncological treatments
76093776|NCT00081939|Drug|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m^2. Maintenance year one 1.0mg/m^2 1,4,8,11 q 28 days.
76093777|NCT00081939|Drug|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
76093778|NCT03221556|Behavioral|Engagement-Focused Care Coordination|Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.
76093779|NCT03221556|Behavioral|Problem Solving Education (PSE)|Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
76093780|NCT02373124|Drug|infusion of NMDA antagonist|52 minute infusion
76093781|NCT03221478|Other|Kinesio Taping placebo and exercises|Kinesio Taping placebo and exercises
76093782|NCT03221478|Other|Kinesio Taping with tension and exercises|Kinesio Taping with tension and exercises
76093783|NCT03221478|Other|Kinesio Taping with tension|Kinesio Taping with tension
75477082|NCT04882072|Other|Placebo|Participants will receive IV infusion and SC injection of matching placebo.
75658621|NCT04469192|Other|Cryotherapy|intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
75658622|NCT04469192|Other|Education|The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
76093784|NCT03221634|Biological|Pembrolizumab|IV infusion
76093785|NCT03221634|Biological|Daratumumab|IV infusion
76093786|NCT03221088|Drug|Jintrolong® low dose group|PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
75658623|NCT04463979|Other|Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia|"Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points.~Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire."
75658624|NCT04459468|Drug|Lipiodol|Lipiodol TACE procedure
75658625|NCT04452396|Device|use of continuous glucose monitoring|Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.
76093787|NCT03221088|Drug|Jintrolong® high dose group|PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.
75805735|NCT03497676|Drug|Long-Acting Injectable Cabotegravir (CAB LA)|Administered by intramuscular (IM) injection
75805736|NCT03497676|Drug|Long-Acting Injectable Rilpivirine (RPV LA)|Administered by intramuscular (IM) injection
75805737|NCT03497676|Drug|Combination Antiretroviral Therapy (cART)|Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens will not be provided through the study.
76093788|NCT05003037|Drug|Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin|Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.
76093789|NCT04485000|Behavioral|Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop|The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.
76093790|NCT02374060|Drug|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
76093791|NCT02374060|Drug|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
76093792|NCT02374060|Drug|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
76093793|NCT03208062|Other|collection of waste materials|osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
76093794|NCT03221166|Drug|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
76093795|NCT03221166|Drug|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
75477083|NCT04882072|Drug|Glucorticoid Taper Regimen|Glucocorticoid will be administered orally.
75477084|NCT04879641|Behavioral|Exposure|Participants are instructed to plan and track in vivo exposures using an exposure diary. Participants are also instructed to reduce safety behaviors, which are overt or covert acts such as avoiding eye contact or rehearsing sentences to prevent a feared outcome.
75477085|NCT04879641|Behavioral|Attention Training|Participants are trained to reduce self-focused and biased attention. Various audio exercises are introduced in which participants learn to intentionally direct the attention away from themselves (i.e., less private self-consciousness), and to be less alert to potentially dangerous external social stimuli (i.e., less public self-consciousness).
75477086|NCT04879641|Behavioral|Cognitive Restructuring|Participants are instructed to identify and modify dysfunctional and negatively biased assumptions. It includes a thought diary to track negative beliefs in daily routine, alongside with exercises to formulate helpful and adaptive thoughts.
75658626|NCT04448639|Diagnostic Test|Echocardigraphy (ECHO)|Standar 12 lead electrocardiogram
75658627|NCT04448639|Diagnostic Test|Bloodtest|cardiac biomarkers
75658628|NCT04435756|Other|Biomarker Analysis|Correlative study
75658629|NCT04435756|Procedure|Blood Product Collection|Undergo collection of blood
75658630|NCT04432285|Device|DBS-device, implanted in GPi bilaterally|Chronic/continuous bilateral GPi-DBS
75658631|NCT04432285|Drug|Botulinum toxin|Repeated intramuscular injections at regular intervals of around 3 months
75658632|NCT04430738|Drug|tucatinib|For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.
75805738|NCT03494933|Procedure|CRT-P implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.
75805739|NCT03494933|Procedure|CRT-D implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
76093796|NCT03221010|Behavioral|Motivational Interviewing|Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.
76093797|NCT03221010|Behavioral|Traditional cognitive-behavioral approach|This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
76093798|NCT03207828|Behavioral|Behavioral activation|The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, & Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
76093799|NCT03207828|Other|Usual care|Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
75658633|NCT04430738|Drug|trastuzumab|Cohorts 1A and 1B: a 6 mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 Day 1, followed by a dose of 4 mg/kg IV every 2 weeks starting on Cycle 2 Day 1. Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B: an 8 mg/kg loading dose will be administered IV on Cycle 1 Day 1, followed by a dose of 6 mg/kg IV every 3 weeks thereafter.
75805740|NCT03387137|Biological|RSV 6120/∆NS2/1030s|Delivered as nose drops
75805741|NCT03387137|Biological|Placebo|Delivered as nose drops
76093800|NCT01985932|Device|MRI|
75658634|NCT04430738|Drug|oxaliplatin|85 mg/m^2 given IV every 2 weeks for cohorts using FOLFOX. For cohorts using CAPOX regimen, 130 mg/m^2 given every 3 weeks.
75805742|NCT03386513|Drug|IMGN632|CD123-targeted ADC
75658635|NCT04430738|Drug|leucovorin|200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m^2 given IV every 2 weeks. Part of FOLFOX regimen.
75658636|NCT04430738|Drug|fluorouracil|400 mg/m^2 (IV bolus after leucovorin) and/or 2400 mg/m^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.
75805743|NCT03366142|Drug|Ustekinumab|0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
75805744|NCT03330795|Biological|CD3/CD19 neg allogeneic BMT|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
76093801|NCT03220932|Procedure|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
76093802|NCT03220932|Drug|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
76093803|NCT02042872|Drug|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
76093804|NCT04484688|Drug|perindopril-bisoprolol|outpatients with permanent atrial fibrillation and with preserved ejection fraction
76093805|NCT03207906|Drug|VBP-926|Topical VBP-926 solution
75347017|NCT02516982|Other|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
75347018|NCT01583543|Drug|Olaparib|400mg PO BID Continuous
75347019|NCT01724372|Drug|Antidepressant|
75477087|NCT04879641|Behavioral|Psychoeducation|Participants are delivered detailed evidence-based information on SAD with a focus on maintaining processes (e.g., the vicious circle of negative thoughts and emotions, cognitions, and behaviors associated with the maintenance of SAD). Based on the information provided, participants are encouraged to develop an individual model of their social anxiety symptoms.
75658637|NCT04430738|Drug|capecitabine|1000 mg/m^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.
75658638|NCT04430738|Drug|pembrolizumab|400 mg given by IV on day 1 of cycle 1, then every 6 weeks.
75658639|NCT04416984|Genetic|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
75805747|NCT03300947|Drug|Psilocybin 100 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
75805748|NCT03300947|Drug|Psilocybin 300 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
75658640|NCT04416984|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
75658641|NCT04416984|Drug|Fludarabine|Chemotherapy for lymphodepletion
75658642|NCT04416984|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
75805749|NCT03300947|Drug|Lorazepam 1 mg|A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
75805750|NCT03287154|Device|Active tDCS stimulations|20 min, 2mA
75805751|NCT03287154|Device|Sham tDCS|20 min, Sham
75805752|NCT03255746|Behavioral|Sleep Enhancement|This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
75805753|NCT03255746|Behavioral|Health Education|This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
75805754|NCT03238326|Drug|Brexpiprazole|Once daily, oral tablets
75805755|NCT03209531|Behavioral|Operant Conditioning|Active encouragement and feedback to increase motor evoked response when stimulated.
75805756|NCT03209531|Behavioral|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
76093806|NCT00082017|Drug|UCN-01 (7-hydroxystaurosporine)|"UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days."
75805757|NCT03209531|Device|Single Pulse Transcranial Magnetic Stimulation|Transcranial magnetic stimulation to elicit a motor evoked response from the quadriceps muscles.
76093807|NCT02374138|Behavioral|Parental stress management|"The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches."
75347020|NCT01724372|Drug|Antipsychotic|
75805758|NCT03190200|Device|MRI|No intervention - observational trial using MRI
76093808|NCT02374138|Other|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
75805759|NCT03164278|Behavioral|Independent Transfer Training|Independent Transfer Training Program: ITTP training starts with an overview and self-evaluation using the transfer assessment instrument questionnaire (TAI-Q) followed by three core modules: wheelchair setup, body setup, and flight/landing. Wheelchair setup includes factors such as the angle and distance of the wheelchair to the transfer surface, removing barriers, applying the brakes, and height of the transfer. Body setup involves positioning one's body for an optimal transfer and covers foot, hip, arm and hand positions. Flight/landing discusses how to achieve a smooth and controlled transfer, the head-hips relationship, use of transfer device, and safe landing.
75805760|NCT03129893|Device|Cuffed tracheal tubes|Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
75805761|NCT03107884|Drug|Metformin (Bed Rest)|A clinical oral dose of Metformin will be given to participant daily during bed rest
75805762|NCT03107884|Drug|Placebo (Bed Rest)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
75805763|NCT03107884|Drug|Metformin (2 week run-in only)|A clinical oral dose of Metformin will be given to participant daily during a two week run-in period only.
75805764|NCT03107884|Drug|Placebo (2 week run-in only)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
75805765|NCT03106415|Drug|Binimetinib|Given PO
75805766|NCT03106415|Other|Laboratory Biomarker Analysis|Correlative studies
76093809|NCT03227328|Drug|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy|"CDK4/6 inhibitor:~palbociclib~ribociclib~abemaciclib~Endocrine therapy:~non-steroidal or steroidal AI~fulvestrant"
75347021|NCT00919100|Device|Buzzy|"Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front."
75347022|NCT00919100|Other|vapocoolant|venipuncture with vapocoolant spray offered
75347023|NCT03405350|Procedure|Redon-sulfide baths|Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.
75347024|NCT03405350|Procedure|Partial Mud Baths|duration: 20 minutes, temperature 40-42 degrees Celsius
75805767|NCT03106415|Biological|Pembrolizumab|Given IV
75347025|NCT03405350|Procedure|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.
75347026|NCT03405350|Procedure|Terrain Therapy|walking, outdoors physical activities,
76093810|NCT03227328|Drug|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)|"Standard Chemotherapy regimens will be classified as:~anthracycline + taxane,~taxane,~anthracycline,~capecitabine / fluoropyrimidines,~others.~Endocrine therapy:~non-steroidal or steroidal AI~fulvestrant"
76093811|NCT04821921|Other|No intervention|Care as usual
76093812|NCT03220698|Device|Tracheal ultrasonography|Tracheal ultrasonography
76093813|NCT00082329|Drug|AMD 3100 (Mozobil plerixafor)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
75805768|NCT03082963|Device|Electrogram Morphology Mapping (EMR)|Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium & then the left atrium.
75658643|NCT04414774|Device|GG-Suicide-Ideation|GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
75805769|NCT03080129|Dietary Supplement|Fresubin energy|dietary protein energy supplement
75805770|NCT03024996|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
75805771|NCT03024996|Other|Placebo|Placebo matching to atezolizumab q3w
76093814|NCT00082329|Drug|Granulocyte colony-stimulating factor (G-CSF)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
76093815|NCT03220620|Other|GDT|individualized fluid therapy
76093816|NCT02451462|Drug|Zoledronic acid|
76093817|NCT02451384|Procedure|routine surgery|To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
76093818|NCT02451384|Procedure|no-touch surgery|
76093819|NCT02451384|Procedure|laparoscopic surgery|
76093820|NCT03220386|Other|Decolonization by nasal Octinidin treatment and skin washings|Patients receive nasal Octinidin treatment and skin washings for five consecutive days
75477088|NCT04871893|Device|multiECCO2R blood-gas exchanger|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
75658644|NCT04407741|Drug|SHR2554+SHR1701|SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
75658645|NCT04407741|Drug|SHR1701|SHR1701: 30mg/kg, IV, over 30 minutes
75658646|NCT04405401|Radiation|SABR|SABR to all oligoprogressive lesions + continuation of current systemic therapy
75805772|NCT03003325|Drug|AOP2014|AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
75805773|NCT03003325|Procedure|Phlebotomies|According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.
76093821|NCT03207204|Procedure|35% Hydrogen peroxide bleaching|Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
75477089|NCT04865783|Procedure|Saline spray|The saline spray will be applied twice for 1-2 seconds.
75477090|NCT04865783|Procedure|Cryospray|The cryospray will be applied twice for 1-2 seconds.
75477091|NCT04859907|Device|Clamp-like system|Craniotomy closure
75477092|NCT04859907|Device|Plates and screws|Craniotomy closure
76093822|NCT03207204|Procedure|30% Carbamide peroxide bleaching|Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
76093823|NCT03207204|Procedure|Violet LED bleaching 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
75477095|NCT04841343|Drug|Triamcinolone|Triamcinolone in sinus
75477096|NCT04840342|Drug|Eplerenone|Dose escalations of eplerenone 50, 100, or 200mg
75477097|NCT04840342|Drug|Amlodipine|Dose escalations of amlodipine 2.5, 5, or 10mg
75805774|NCT03003325|Drug|ASA|100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
75805775|NCT02969798|Drug|Dapagliflozin|10mg/day
75805776|NCT02969798|Drug|Saxagliptin|5mg/day
75805777|NCT02969798|Drug|Pioglitazone|the dose will increase from 15 mg/day to 30 mg/day at month two
75805778|NCT02969798|Drug|Metformin|starting at 1000 mg/day and increased to 2000 mg/day at month 2.
75805779|NCT02855203|Radiation|Stereotactic Ablative Body Radiosurgery (SABR)|18-20Gy in 1 fraction
75805780|NCT02855203|Drug|Pembrolizumab|Pembrolizumab at a dose of 200mg IV, 3-weekly will be delivered for a duration of 6 months, commencing 5 days (+/- 3 days) from the last dose of SABR.
76093824|NCT03207204|Procedure|Violet LED bleaching 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
76093825|NCT03207204|Procedure|Photochemical protocol 1|Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
75347027|NCT03405350|Procedure|Dry Massage|Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).
75658647|NCT04405401|Other|Standard of care|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
75658648|NCT04401319|Device|Sham Stimulation for Crossover Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
75658649|NCT04401319|Device|DLPFC Stimulation for Crossover Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
75805781|NCT02854215|Other|Collection of additional data with questionnaires|"questionnaires for quality of life measurements: QLQC30; QLQ-OV28~questionnaires for medico-economic purposes: ADL (activities of daily living); IADL (instrumental activities of daily living); EQ-5D3L; absenteeism questionnaire.~These questionnaires will be completed during the study time (5 or 6 times during the treatment, next every 4 months during the first two years and then every 6 months during the third year of follow-up)."
75946727|NCT05173467|Procedure|Robot-assisted Invasion-controlled Surgery|The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
75658650|NCT04401319|Device|AG Stimulation for Crossover Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
75805782|NCT02748564|Biological|Aldesleukin|Given IV
75946728|NCT05173467|Procedure|Traditional-open Surgery|This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
75946729|NCT03769701|Procedure|self-monitoring capillary glucose (SMCG)|To measure the capillary glucose with a glucometer according to the assigned group.
75946730|NCT05383183|Drug|Choline Alfoscerate 400mg|Oral administration
75946731|NCT05383183|Drug|Placebo|Oral administration
75946732|NCT05173311|Behavioral|Intervention arm|The intervention arm groups were instructed to use the Mole's Veggie Adventures mobile application for 3-4 weeks.
75477098|NCT04839627|Other|serum progesterone measurement|progesterone levels measurement on the day of the embryo transfer on all AMP cycles
75658651|NCT04401319|Device|Sham Stimulation for Parallel Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
75658652|NCT04401319|Device|DLPFC Stimulation for Parallel Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
75658653|NCT04401319|Device|AG Stimulation for Parallel Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
75658654|NCT04398433|Drug|INO-3107|INO-3107 administered by IM injection followed by EP using CELLECTRA™ 2000 device at Day 0, Week 3, 6, and 9.
75658655|NCT04398433|Device|CELLECTRA™ 2000|CELLECTRA™ 2000 device used for EP following IM delivery of INO-3107.
75805783|NCT02748564|Other|Laboratory Biomarker Analysis|Correlative studies
75805784|NCT02748564|Biological|Pembrolizumab|Given IV
75946733|NCT02857283|Other|Ozone|Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08
75347028|NCT03405350|Procedure|Laser Therapy|treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,
75658656|NCT04373265|Drug|Relacorilant|Relacorilant, 100 mg soft gel capsules orally once daily
75946734|NCT02857283|Other|Filtered Air|Participants will be exposed to filtered clean air
75347029|NCT03405350|Procedure|Low-frequency Magnetic Field|duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,
75347030|NCT03405350|Procedure|Ultrasonotherapy|treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,
75347031|NCT03405350|Procedure|Cryotherapy|ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,
75946735|NCT02857283|Device|Health and Exposure Tracker (HET)|Ozone and heart rate tracker
75946736|NCT02327702|Drug|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
75946737|NCT03609775|Drug|ACT-541468|One tablet of 50 mg ACT-541468 will be administered orally.
75946738|NCT03609775|Other|ACT-541468 placebo|Matching ACT-541468 placebo will be administered orally as 1 tablet.
75946739|NCT03609775|Other|Ethanol 10%|Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
75946740|NCT03609775|Other|Ethanol placebo|Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
75946741|NCT03690765|Drug|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.
75946742|NCT03690765|Drug|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
75946743|NCT05073146|Other|interview|Starting from the user as an extended starting point, through on-site visits and interviews with relevant personnel, such as personal management, professional service teams, cases, family members, other long-term care service providers (home service assistants), etc., collect relevant information and summarize successful strategies and related elements of long-term professional services (including conditions, demand analysis, service usage, professional team interaction, payment and payment systems, characteristics of case, etc.) of model cases.
75946744|NCT02033941|Drug|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
75347032|NCT03405350|Procedure|Electrotherapy|Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,
75347033|NCT03405350|Procedure|Light Therapy|blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
75347034|NCT02464410|Behavioral|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
75347035|NCT02464410|Behavioral|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
75946745|NCT02033941|Drug|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
75946746|NCT05383235|Other|ROUTINE CARE|1. ROUTINE CARE : retrieval of sociodemographic characteristics, medical and psychological assessment, multidisciplinary meeting about the patient
75658657|NCT04373265|Drug|Pembrolizumab|Pembrolizumab 400 mg infusion every 6 weeks
75658658|NCT04367766|Procedure|Prosthetically driven implant placement|Insertion of an osseointegrated implant into the bone of anterior maxilla/mandible, following the right prosthetic plan
75347036|NCT02464410|Other|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
75347037|NCT03006419|Drug|Basiliximab|Standard induction therapy
75347038|NCT03006419|Drug|Thymoglobulin|Induction therapy
75805785|NCT02729922|Device|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
75946747|NCT05383235|Device|Facial emotion stimuli prensentation task with EEG recording and facial emotion recognition task|"2. RUN-IN PERIOD :~Eligibility criteria will be assessed during the multidisciplinary meeting;~Study presentation, delivery of the information note and consent form; 3. STUDY:~Collection of consent form;~Facial emotion stimuli presentation task with EEG recording and facial emotion recording task;~Neuropsychological evaluation (TOM-15);~Scales and questionnaires (TAS-20, PCL-R SV, CECAQ, QCAE);~Debriefing."
76093826|NCT03207204|Procedure|Photochemical protocol 2|Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
75658659|NCT04316559|Other|Placebo|Placebo capsule
75805786|NCT02723734|Other|Decipher® Testing|Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.
75805787|NCT02642965|Drug|Cytarabine|Given IT or IV
75658660|NCT04316559|Drug|TRV734|biased agonist at mu opioid receptors
75658661|NCT04312399|Procedure|blood take|Blood is taken to analyse degratdation products of the metabolism of amyloid
75658662|NCT04301518|Other|Multimodal intervention strategy|"Once weekly nurse support~200 mg/daily micronized progesterone as vaginal suppository~81 mg/daily low dose aspirin~two transvaginal ultrasounds~cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation"
75658663|NCT04294160|Drug|Dabrafenib|Capsule for oral use
75658664|NCT04294160|Drug|LTT462|Capsule for oral use
75805788|NCT02642965|Biological|Filgrastim|Given SC or IV
75805789|NCT02642965|Drug|Fludarabine Phosphate|Given IV
75805790|NCT02642965|Other|Laboratory Biomarker Analysis|Correlative studies
75347039|NCT03000881|Other|standard adhesive|This is a standard adhesive (hydrocolloid)
75347040|NCT03000881|Other|New adhesive strip|This is a newly developed adhesive strip
75347041|NCT01047332|Device|Partially Covered Wallstent|Partially covered wallstent
75347042|NCT01047332|Device|Uncovered Wallstent|Uncovered wallstent
75347043|NCT03006497|Other|Exercise program based on motor learning principles|The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
75658665|NCT04294160|Drug|Trametinib|Tablet for oral use
75658666|NCT04294160|Drug|LXH254|Tablet for oral use
75658667|NCT04294160|Drug|TNO155|Capsule for oral use
75658668|NCT04294160|Biological|Spartalizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
75658669|NCT04294160|Biological|Tislelizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
75805791|NCT02642965|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
75946748|NCT03143972|Drug|Dexmedetomidine|Single drug administration
76093827|NCT03207204|Procedure|Hybrid technique 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
76093828|NCT03207204|Procedure|Hybrid technique 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
75658670|NCT04278768|Drug|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
75805792|NCT02642965|Other|Pharmacological Study|Correlative studies
76093829|NCT02092311|Procedure|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
76093830|NCT02092311|Procedure|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
76093831|NCT03207360|Behavioral|Pain Coping Skills|Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
75347044|NCT03405272|Biological|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）|Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
76093832|NCT03207516|Dietary Supplement|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
76093833|NCT03207516|Dietary Supplement|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
75347045|NCT03006263|Procedure|Totally Laparoscopic Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
75347046|NCT03006263|Procedure|Laparoscopy Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
75347047|NCT03000647|Procedure|Pelvic floor exercises guided by a physiotherapist|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
75347048|NCT03000647|Procedure|Non guided pelvic floor exercises|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
76093834|NCT03207126|Diagnostic Test|Ultrasound guided biopsy|For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
75658671|NCT04278768|Drug|Venetoclax|Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
76093835|NCT02092857|Dietary Supplement|Arachidonic acid (25 mg/100 kcal )|
75347049|NCT03405194|Drug|Elvitegravir, Cobicistat, TAF, FTC|Started on day of HIV diagnosis
75658672|NCT04278768|Drug|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
75658673|NCT04258475|Drug|Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.|Raltegravir will be dosed in a fasted state in all periods. Participants will take Raltegravir along with other ART medication.
75658674|NCT04258475|Drug|Calcium carbonate antacid tablet|PK analysis of different doses of calcium carbonate antacid in patients undergoing ART treatment for HIV using Raltegravir.
75658675|NCT04254588|Other|Abdominal examination|Examination by in-person physician vs. remote physician.
75805793|NCT02595892|Drug|Berzosertib|Given IV
75805794|NCT02595892|Drug|Gemcitabine|Given IV
75805795|NCT02595892|Drug|Gemcitabine Hydrochloride|Given IV
75805796|NCT02376127|Procedure|Dynamic contrast enhancement MRI|
75805797|NCT02311959|Procedure|Nipple sparing mastectomy|"Standardized surgical procedure by :~Nipple sparing mastectomy with nipple core histopathology.~Immediate breast reconstruction (flap and/or implant).~+/- lymph node evaluation (sentinel node procedure or axillary dissection)."
75805798|NCT02282969|Behavioral|Interviews|Interviews performed by study staff encompassing lung cancer screening and patient decision aids.
75946749|NCT03143972|Drug|Remifentanil|Single drug administration
75946750|NCT02237027|Biological|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
75946751|NCT02237027|Biological|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
76093836|NCT02092857|Dietary Supplement|Arachidonic acid (34 mg/100 kcal)|
75946752|NCT03608995|Diagnostic Test|Premaquick (Diagnostic test)|"PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes."
76093837|NCT02092857|Dietary Supplement|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
76093838|NCT03220308|Other|MYmind mindfulness training|The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.
76093839|NCT03220308|Other|Care-as-usual for children (8-16 years old) with ADHD|According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
75347050|NCT03405194|Drug|Efavirenz, TDF, and 3TC|Started on day of HIV diagnosis
75658676|NCT04227847|Drug|SEA-CD70|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
75658677|NCT04227847|Drug|azacitidine|75mg/m^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
75658678|NCT04214288|Drug|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally.
75347051|NCT03006107|Procedure|intraligamentary injection piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
75658679|NCT04214288|Drug|Fulvestrant|Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
75658680|NCT04212442|Behavioral|Independent Living Program for Affordable Housing.|"Two-month program intended to increase physical activity and function, including the following 4 steps:~Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches."
75658681|NCT04191655|Device|High Definition Colonoscopy|A colonoscopy that used high definition (HD) camera
75347052|NCT03006107|Procedure|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
75805799|NCT02282969|Behavioral|Questionnaires|Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
75805800|NCT02266420|Procedure|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
76093840|NCT03207048|Device|Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 3-second trains with a 15-second inter-train interval, for 50 trains per session
76093841|NCT03207048|Device|Sham repetitive transcranial magnetic stimulation|Sham Transcranial Magnetic Stimulation
76093842|NCT03227172|Procedure|apicoectomy|After flap elevation and osteotomy , peri-apical lesion and the root tip were located: after root-end resection using a fissure bur, the resected root tip and the pathological tissue were removed and immediately preserved in 1% formaldehyde solution.
76093843|NCT02451306|Drug|Quetiapine|See information in arm description.
75347053|NCT01046396|Drug|adapalene cream 0.1% and adapalene lotion 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
75347054|NCT01046396|Drug|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
75347055|NCT01586039|Device|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
75347056|NCT01046084|Drug|Lansoprazole|30 mg Delayed-Release Capsule
75347057|NCT01046084|Drug|Prevacid®|30 mg Delayed-Release Capsule
75658682|NCT04191655|Device|Dye Spraying Chromocolonoscopy|A colonoscopy that used high definition camera in addition to dye spraying on the interior colon surface.
75658683|NCT04188418|Drug|Fentanyl Citrate Buccal Tablet|Given transmucosally
75658684|NCT04188418|Drug|Morphine|Given PO
75658685|NCT04188418|Other|Physical Performance Testing|Complete shuttle walk test
75658686|NCT04188418|Other|Placebo Administration|Given PO
75658687|NCT04188418|Other|Quality-of-Life Assessment|Ancillary studies
75658688|NCT04188418|Other|Questionnaire Administration|Ancillary studies
75347058|NCT01586741|Procedure|Quill suture application for repair or polypropylene mesh|The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
75658689|NCT04178174|Radiation|SABR boost and de-escalated chemoradiation|Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions
75805801|NCT01936532|Drug|MLN9708|"Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months."
75347059|NCT01045694|Drug|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
75347060|NCT01045694|Drug|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
75347061|NCT01045694|Drug|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
75658690|NCT04178174|Radiation|Standard chemoradiation|Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions
75805802|NCT01936532|Drug|Lenalidomide|
75805803|NCT01936532|Drug|Dexamethasone|
75658691|NCT04172012|Biological|Labinic (R) probiotic mixture|Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve
75477099|NCT04832815|Behavioral|Equine Therapy|Aim 1: Six session equine interventions. Intervention will be provided one day per week for four weeks. During the first two weeks, each intervention day with consist of two sessions with a lunch break in between. Weeks four and five consist of one trail riding session per intervention day followed by lunch. Each session will be approximately 1.5 hours in length. Sessions 1-4 will occur at the USU Equine Education Center, and session 5-6 will occur on local trails. Optional transportation for participants will be provided from the VA to the intervention site.
75658692|NCT04172012|Other|Placebo|Placebo mixture
75805804|NCT01815619|Other|on-site specimen evaluation|The specimen will be evaluated on-site by a cytopathologist during the procedure to render a diagnosis
75805805|NCT01815619|Other|off-site specimen evaluation|The specimen will be evaluated off-site by a cytopathologist
75946753|NCT03608995|Diagnostic Test|Quikcheck fFN ™|- The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
75946754|NCT03380637|Other|ultrasound|Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
75946755|NCT03387969|Procedure|CSF sample|"for all patient CSF sample obtained for analysis , culture sensitvity and CSF-CRP.~also blood samples will be collected and analyzed for serum procalcitonin"
75946756|NCT02034227|Drug|SG2000|intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
75347062|NCT01586897|Device|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
75347063|NCT01586897|Other|Usual Care|
75347064|NCT04378712|Device|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
75805806|NCT01606475|Biological|Allogeneic islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
75805807|NCT01492036|Other|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
75946757|NCT03608917|Drug|Total Glucosides of Paeony(TGP)|Total Glucosides of Paeony(TGP) as a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.TGP is new drug of western medicine, original discovered by Professor Xu who is a famous pharmacologist. The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）
75347065|NCT04378712|Other|Standard-of-care|Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission
75347066|NCT04378556|Behavioral|Nutritional coaching|Participants were provided with nutrition education and a per-meal protein prescription followed by 9 weeks of nutritional coaching.
75347067|NCT01586975|Drug|Clopidogrel|Clopidogrel 75 mg QD
75658693|NCT04166721|Drug|Atezolizumab|Immunotherapy
75658694|NCT04166331|Drug|Placebos|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
75658695|NCT04166331|Drug|Dobutamine|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
75658696|NCT04164069|Biological|Bevacizumab|Given IV
75658697|NCT04164069|Drug|Dasatinib|Given PO
75658698|NCT04164069|Drug|Fluorouracil|Given IV
75805808|NCT01492036|Behavioral|Questionnaires|"Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time."
75805809|NCT01325506|Other|Questionnaire|Questionnaire, telephone interviews, and clinical follow-up
75805810|NCT01054625|Biological|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
75805811|NCT01038778|Biological|Aldesleukin|Given IV
75805812|NCT01038778|Procedure|Computed Tomography|Undergo FDG-PET/CT
75805813|NCT01038778|Drug|Entinostat|Given PO
75805814|NCT01038778|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
75805815|NCT01038778|Other|Laboratory Biomarker Analysis|Correlative studies
75805816|NCT01038778|Other|Pharmacological Study|Correlative studies
75805817|NCT01038778|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
75805818|NCT00909909|Radiation|External beam boost|3-dimensional conformal radiation therapy and intensity modulated radiation therapy
75946758|NCT03608917|Device|Narrow band-ultraviolet b（NB-UVB）|phototherapy on treating vitiligo
75946759|NCT03608917|Drug|Total Glucosides of Paeony(TGP) analogue|Total Glucosides of Paeony(TGP) analogue as a placebo for Control group
75946760|NCT02237105|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
75347068|NCT01586975|Drug|Aspirin 81 mg|Aspirin 81mg QD
75347069|NCT01586975|Drug|Aspirin >300 mg|Aspirin >300 mg QD
75347070|NCT01724840|Procedure|GraftJacket|Interposition with GraftJacket
75347071|NCT01724840|Procedure|Tendon Interposition|Tendon Interposition with the FCR tendon
75347072|NCT03000413|Drug|Ketamine|Active treatment
75477100|NCT04832815|Behavioral|Therapeutic Horsemanship Program|Aim 2: Therapeutic Horsemanship program utilizes the USU Pathways to Horsemanship model and covers levels of equestrian training from basic groundwork to more advanced riding techniques. Training occurs in a three or six-session format with once weekly sessions over three or six weeks. Mindfulness and mindful self-compassion training may be included.
75658699|NCT04164069|Drug|Leucovorin|Given IV
75658700|NCT04164069|Drug|Leucovorin Calcium|Given IV
75658701|NCT04164069|Drug|Oxaliplatin|Given IV
75477101|NCT04825366|Device|Continuous glucose monitoring device|Participants will have to wear their continuous glucose monitoring device throughout the study.
75658702|NCT04164069|Other|Quality-of-Life Assessment|Ancillary studies
75658703|NCT04120246|Drug|Alpha-tocopheryloxyacetic Acid|Given PO
75477102|NCT04825366|Other|Gold method|The Gold method will be used to assess impaired awareness of hypoglycemia
75658704|NCT04120246|Biological|Trastuzumab|Given IV
75805819|NCT00909909|Radiation|whole breast irradiation|accelerated, hypofractionated whole breast irradiation
75805820|NCT00747396|Other|Foster Care Placement|A group of children living in institutions in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and trained in Romanian. Before placement, foster parents visited their children to begin developing a relationship with the child. Hired foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Foster parents were invited to participate in a support group organized by social workers. Project social workers consulted weekly with US staff experienced in dealing with young children in foster care.
75805821|NCT00707655|Drug|Zalutumumab|Eight weekly infusions
75347073|NCT03000413|Drug|Fentanyl|
75347074|NCT01724918|Drug|Lacosamide|
75658705|NCT04118972|Behavioral|Mirror exposure and text prompt responses|Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)
75658706|NCT04118166|Drug|Ipilimumab|Ipilimumab 1 mg/kg, injection
75658707|NCT04118166|Procedure|Cryoablation|Cryoablation of the tumors occur between investigational agent treatment Cycles 1 and 2, and will be performed according to standard procedures
75658708|NCT04118166|Drug|Nivolumab|Nivolumab 3 mg/kg, injection
75658709|NCT04103749|Device|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
75805822|NCT00542308|Drug|Zalutumumab|Individual dose titration weekly i.v. doses
75805823|NCT00488605|Drug|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
75946761|NCT03380481|Other|observational only-no intervention|Observational only and no predesigned interventions in this study.
75946762|NCT04186819|Drug|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
75946763|NCT04704752|Diagnostic Test|Swallowing Evaluation|Study Evaluation includes basic test batteries. These are observational.
75946764|NCT03384459|Device|the 308-nm excimer laser|For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
75946765|NCT03143582|Other|Running|A 13-week running program where youth run for 30 minutes twice weekly.
75805824|NCT00488605|Drug|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
75658710|NCT04091464|Behavioral|Backward Walking Training|Training will consist of BW training on both a treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline BW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes BW, backward stepping, and functional exercises that incorporate BW movements.
75658711|NCT04091464|Behavioral|Forward Walking Training|Training will consist of FW training on both treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline FW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes FW, forward stepping, and functional exercises that incorporate FW movements.
75658712|NCT04085250|Other|Neoadjuvant therapy|The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
75658713|NCT04085250|Other|Chemotherapy concurrent with radiotherapy|Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)
75805825|NCT00482352|Other|laboratory biomarker analysis|Correlative studies
75946766|NCT03609125|Other|CBS eyedrop|The product is dispensed as sterile frozen vials containing 0.8 ml of product for the daily administration. The product is thawed and administered at a dose of 1 drop / 8 times each eye during the waking period.
76093844|NCT02451306|Drug|Placebo|See information in arm description.
76093845|NCT00167661|Drug|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
75946767|NCT03387891|Device|Cortrium C3 device|Paired measurements of data from C3 device with golden standard methods or equipment
75946768|NCT04185259|Other|Acupuncture|The investigators will apply two Ashi points (the two most severe tender points in the most sensitive area over the anteromedial aspect of the heels), Chengshan (BL57), Taixi (KI3) and Kunlun (BL60) in this trial. With the patient in a prone position, the local skin will be routinely sterilized followed by a 10mm diameter and 5mm thick sterile adhesive pad pasting onto each selected acupoint. Ashi points will be perpendicularly inserted through the pad to the plantar fascia layer with a depth of approximately 15-20mm depending on the location. BL57, KI3 and BL60 will be punched perpendicularly 10-15mm deep into the skin through the pad. All needles except Ashi points will be manually stimulated by small, equal manipulations of lifting, thrusting, twirling and rotating to achieve De qi. Needles will be retained for 30 minutes per treatment. During each treatment, every needle will be manipulated three times every 10 minutes.
76093846|NCT03206892|Device|laparoscopic ovarian drilling|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
76093847|NCT03220542|Drug|Probiotics|Saccharomyces boulardii
76093848|NCT03220542|Dietary Supplement|Broccoli|Broccoli sprouts extract
75347075|NCT03000725|Behavioral|Using Practice and Learning to Increase Favorable Thoughts|"Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.~Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping & Relaxing Session 4: Attention & Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure & the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks"
75805826|NCT00074373|Other|No intervention; observational|
76093849|NCT03220542|Drug|Esomeprazole|Esomeprazole
76093850|NCT03220542|Drug|Amoxicillin|Amoxicillin
75347076|NCT03000725|Behavioral|Usual Care|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
75477103|NCT04825366|Other|Clarke questionnaire|The Clarke questionnaire will be used to assess impaired awarness of hypoglycemia
75805827|NCT00006734|Biological|filgrastim|Given IV
75805828|NCT00006734|Drug|cyclophosphamide|Given IV
76093851|NCT03220542|Drug|Clarithromycin|Clarithromycin
76093852|NCT03206580|Other|Concentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
76093853|NCT03206580|Other|Concentric-Eccentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
76093854|NCT03220152|Drug|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
76093855|NCT03227094|Diagnostic Test|Standard OGTT|Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training & delivery of Jelly-Bean/75g glucose beverage
76093856|NCT03227094|Diagnostic Test|Home-based OGTT (Beverage)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
76093857|NCT03227094|Diagnostic Test|Home-based OGTT (Candy)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
76093858|NCT03220464|Radiation|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
76093859|NCT03220464|Radiation|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
76093860|NCT03220464|Diagnostic Test|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
76093861|NCT02395978|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
76093862|NCT02395978|Drug|placebo|Placebo contained corn starch.
76093863|NCT03206658|Drug|Spironolactone 25 mg|A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
75347077|NCT01724996|Other|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
75946769|NCT04185259|Other|Sham acupuncture|Sham Ashi (0.5 cun away from Ashi, one 'cun' is equivalent to the greatest width of the individual patients' thumb, ~1.5 cm), sham BL57 (0.5 cun lateral to true BL57 horizontally), sham KI3 (midway between true KI3 and heel tendon) and sham BL60 (midway between true BL60 and heel tendon) will be used. Treatment protocol will be similar to that of the acupuncture group. The Hwato-brand disposable blunt-tipped needles (size 0.30 × 25 mm) will be inserted at sham points through adhesive pads to the skin without skin penetration. The needles will then be lifted, thrusted, twirled, and rotated evenly three times every ten minutes. No specific de qi response will be elicited.
75946770|NCT02034383|Other|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
75946771|NCT02034383|Other|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
75347078|NCT03000491|Other|No intervention|
75946772|NCT02034383|Other|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
75347079|NCT01588457|Drug|Lithium|Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).
75946773|NCT02034383|Other|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
75946774|NCT02034383|Other|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
75946775|NCT03387345|Other|100% steel cut barley|25 g of available carbohydrate was delivered to participants via steel cut Sustagrain barley (Ardent Mills, LLC).
75946776|NCT03387345|Other|100% barley flakes|25 g of available carbohydrate was delivered to participants via Sustagrain barley flakes (Ardent Mills, LLC).
76093864|NCT03206658|Drug|Placebo oral capsule|The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
75347080|NCT01588457|Drug|Divalproex|DV will be dosed to attain DV levels of ≥45mg/L.
75347081|NCT01588457|Drug|Lamotrigine|LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
75347082|NCT01588457|Drug|Quetiapine|QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
75347083|NCT01589315|Device|focal ECT|FEAST, ECT, unidirectional stimulation
75658714|NCT04085250|Radiation|Radiotherapy|Hypofractionated radiation technique was used to deliver a definitive radiation dose
75347084|NCT04377776|Other|Practice details|Questionnaire
75658715|NCT04085250|Drug|Nivolumab|Nivolumab consolidation (360 mg) via iv infusion once every 3 weeks (Q3W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 12 months.
75805829|NCT00006734|Drug|doxorubicin hydrochloride|Given IV
75805830|NCT00006734|Drug|etoposide|Given IV
75805831|NCT00006734|Drug|ifosfamide|Given IV
75805832|NCT00006734|Drug|vincristine sulfate|Given IV
75805833|NCT00006734|Procedure|adjuvant therapy|
75805834|NCT00006734|Procedure|conventional surgery|
75805835|NCT00006734|Procedure|neoadjuvant therapy|
75805836|NCT00006734|Radiation|brachytherapy|
75805837|NCT00006734|Radiation|radiation therapy|
75805838|NCT01311128|Device|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
75805839|NCT03443414|Drug|RPL554 suspension|A dual PDE3/PDE 4 inhibitor
75805840|NCT03443414|Drug|Placebo|Placebo solution
76093865|NCT00170157|Drug|Bicalutamide|Given orally
76093866|NCT00170157|Drug|Flutamide|Given orally
76093867|NCT00170157|Drug|Goserelin Acetate|Given SC
76093868|NCT00170157|Drug|Ipilimumab|Given IV
76093869|NCT00170157|Drug|Leuprolide Acetate|Given IM
76093870|NCT00170157|Other|Pharmacological Study|Correlative study
76093871|NCT03220074|Drug|Oral Tablet|study drug given and monitored for efficacy and tolerability
76093872|NCT03206346|Drug|Ingavirin|Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
76093873|NCT03206346|Drug|Placebo oral capsule|Placebo, capsules daily for 5 days.
75805841|NCT02991118|Drug|bempedoic acid|bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
76093874|NCT02043574|Behavioral|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
76093875|NCT02043574|Behavioral|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
76093876|NCT03206502|Device|Embrace + Alert App|Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.
76093877|NCT03226860|Device|Gait Myoelectric Stimulator|Electrical stimulation during gait for children with CP
76093878|NCT03226860|Other|5210|Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
75805842|NCT02991118|Drug|placebo|Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
75805843|NCT03720314|Other|NA observational study|observational study
76093879|NCT00170625|Drug|Hycamtin|Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
76093880|NCT02043652|Drug|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
76093881|NCT02043652|Drug|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
75658716|NCT04085250|Other|Observation|Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
76093882|NCT02452164|Other|Teaching|
75658717|NCT04072315|Drug|PLN-74809|PLN-74809
76093883|NCT02452164|Device|(CellScopeOTO)|
75805844|NCT03662152|Device|Foam roller|Foam roller massage after DOMS
75805845|NCT03662152|Device|Vibration foam roller|Foam roller massage with vibration after DOMS
75805846|NCT03491150|Drug|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
75805847|NCT03661450|Diagnostic Test|Clinical Decision-Support System|Patient Data is evaluated by a Clinical Decision-Support System searching for age-adapted pediatric SIRS-criteria, aiming for a high sensitivity and specificity
75805848|NCT03660514|Behavioral|Jovenes Sanos|FP counselors in intervention clinics will a) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPC (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
75805849|NCT04056130|Drug|KBL697|"Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral"
75805850|NCT04056130|Drug|KBL697|"Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral"
75805851|NCT04056130|Drug|KBL697|"Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral"
75805852|NCT04056130|Drug|KBL697|"Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral"
75658718|NCT04072315|Radiation|Knottin tracer|Radiotracer
75347085|NCT03006029|Drug|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
75347086|NCT04377854|Other|Observation. No intervention per se.|Observation. No intervention (no collection of blood).
75658719|NCT04065776|Radiation|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
75658720|NCT04060056|Other|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
75658721|NCT04060056|Other|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
75805853|NCT02991040|Device|Revanesse Ultra+ (with lidocaine)|Bilateral nasolabial fold trial to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine) to Revanesse® Ultra (comparator)
75805854|NCT02991040|Device|Revanesse Ultra|Comparator without lidocaine
75658722|NCT04060056|Other|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
75658723|NCT04054180|Other|CPAP associated with connected devices: blood pressure monitor , scales and activity monitor|CPAP associated with connected devices: blood pressure monitor , PROMs and activity monitor Patients will use their connected devices for one year. Data from the connected devices will be transmitted to their smartphone application Sefam Access. At the beginning of the study, patients will have a dietary assessment and start a support program for nutrition counselling and physical activity. At each study visit the dietician and physical exercise coach will give the patient advices on diet and for adjusting physical activity.
76093884|NCT02986204|Procedure|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~questions about your medical/contraception history~Review medical record~physical examination~urine sample for pregnancy test~Visit 2a - Radiology~Have an ultrasound of your arm~The radiologist will mark your arm at the location of the implant.~Visit 2b~ultrasound of your arm to locate the implant. This is done by feeling the area.~Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~Provide a urine sample for pregnancy test~Have the implant removal site examined"
76093885|NCT02986204|Procedure|continuation of ING implant|"the researcher(s) will ask you to:~To answer questions about your medical and contraception history~Review your medical record~Have a physical examination by the researcher~Provide a urine sample for pregnancy test~Have an ultrasound of your arm"
75347087|NCT04377854|Other|2) Observation and collection and of blood sample|All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.
75347088|NCT04377698|Biological|Platelet Rich Fibrin|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
75658724|NCT04043598|Drug|0.9% Sodium-chloride|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
75658725|NCT04043598|Drug|Ringer's Lactate|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
75658726|NCT04043091|Procedure|percutaneous coronary intervention (stenting)|percutaneous stent implantation in coronary artery
75347089|NCT04377698|Biological|FDBA|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
75805855|NCT03661216|Dietary Supplement|Nephure Oxalate-reducing Enzyme|3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
75805856|NCT03661216|Other|Placebo|3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
75805857|NCT04056286|Dietary Supplement|Whey|45 g whey protein + 20 g maltodextrin
75805858|NCT04056286|Dietary Supplement|3-OHB/whey|50 g 3-OHB + 45 g whey protein + 20 g maltodextrin
75946777|NCT03387345|Other|50/50 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 50/50 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
75805859|NCT03660436|Drug|BMS-986165|Specified dose on specified days
75805860|NCT03660436|Drug|MMF|Specified dose on specified days
75805861|NCT03660358|Device|kinesiotape application|kinesiotape application to diaphragm, chest wall and abdomen in preterm infants.
75805862|NCT02910466|Drug|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
75805863|NCT03662620|Drug|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White colored oval three-layer tablet
75946778|NCT03387345|Other|80/20 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 80/20 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
75946779|NCT03387345|Other|100% rice|25 g of available carbohydrate was delivered to participants via Goya medium grain white rice
75347090|NCT03005873|Drug|TLC599 LD group|Single dose via intra-articular injection
75805864|NCT03662620|Drug|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White and pink colored oval two-layer tablet
75805865|NCT03415178|Drug|Alirocumab SAR236553|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
75805866|NCT03415178|Device|Current auto-injector device (AI)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
75805867|NCT03415178|Device|New auto-injector device (SYDNEY)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
75946780|NCT03387345|Other|white bread|25 g of available carbohydrate was delivered to participants via Sara Lee Classic White Bread (Bimbo Bakeries USA, Inc.)
75946781|NCT02034487|Other|retrospective data collection|
75946782|NCT03608969|Other|NOT-S|Participants are assessed for the orofacial function using the Nordic Orofacial test- screening (NOT-S), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) and Communication Function Scale (CFS). Oral health related quality of life is assessed using the Parental- Caregiver Perceptions Questionnaire (P-CPQ). Caries experience was measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft). Gingival index and type of occlusion will be recorded.
75658727|NCT04039672|Procedure|Skin biopsy|5mm skin metastasis or primary melanoma biopsy
75805868|NCT03415178|Drug|Atorvastatin|Pharmaceutical form:tablet Route of administration: oral
75805869|NCT03415178|Drug|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
75805870|NCT03660202|Device|Firesorb|Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
75946783|NCT03609463|Behavioral|Small change intervention|The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.
75946784|NCT03609463|Behavioral|Well-being intervention|The well-being intervention is a coaching intervention aimed at motivating people in making lifestyle changes by reducing levels of stress through the promotion of psychological well-being. It will consists in 4 weekly sessions to be held before starting the small change intervention. Each session will last about an hour and will be administered in an individual setting.
75946785|NCT03609463|Other|Treatment as usual|The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
75946786|NCT05172453|Other|comprehensive management algorithm for preventing mother-to-child transmission of HBV|"To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the Management algorithm for prevention of mother-to-child transmission of hepatitis B virus based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents."
75946787|NCT03143738|Procedure|continuous anesthesia of adductor canal|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
75805871|NCT04056052|Behavioral|Mind the Gap: Home Activity Only|The primary focus of the home activity program was based on collaborative parent-child cooking activities which the families undertook themselves at home. There were two key tasks: the first was to add one extra vegetable to the evening meal each day, the second was to select, prepare and cook one recipe from the cook book each week.
75805872|NCT04056052|Behavioral|Mind the Gap: Home Activity + cooking Workshop|The main purpose of these workshops was to provide hands-on successful food preparation and cooking experiences for the families and several opportunities to taste new vegetable-based recipes as well as promoting knowledge of cost and healthy eating. Children and their parents were then encouraged to take whatever was learned and apply it at home.
75805873|NCT03659968|Other|Physical activity training|brisk walking on treadmill and exercises of muscular strengthening with varying durations and intensities depending on physical capabilities of patients
75805874|NCT04055974|Behavioral|Be a Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention targeting postpartum women. It consists of 5 weekly modules, each targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
75805875|NCT04055896|Other|Medication Reduction|Systematic approach to reduction in polypharmacy
75347091|NCT03005873|Drug|Normal Saline|Single dose via intra-articular injection
75658728|NCT04034251|Drug|Paclitaxel|Paclitaxel (intraperitoneal (IP) and intravenous (IV), Day 1 of each 3-week cycle: Paclitaxel IP - Intraperitoneal paclitaxel (60 mg/m^2) will be diluted in 500 mL of 0.9% normal saline (NS), to be infused as rapidly as tolerated once per 3-week cycle on Day 1. Paclitaxel IV - Intravenous paclitaxel (80 mg/m^2) will be administered concomitantly over 3 hours, diluted in 100 to 250 ml of 0.9% NS once per 3-week cycle on Day 1.
75658729|NCT04034251|Drug|Capecitabine|Day 1-15 of each 3-week cycle: oral capecitabine (825 mg/m^2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.
75658730|NCT04034251|Device|BardPort Titanium Implanted Port with Peritoneal Catheter|After peritoneal chemo infusion port is placed (Days 1-3, as dictated by clinical status), patients will begin intraperitoneal paclitaxel and intravenous paclitaxel (Day 1) followed by oral capecitabine on the evening of Day 1 to the morning of Day 15.
75658731|NCT04022239|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
75805876|NCT03659890|Dietary Supplement|Low nucleotide|2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose
75805877|NCT03659890|Dietary Supplement|High nucleotide|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose
75805878|NCT03659890|Dietary Supplement|High nucletide + Ribose|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose
75805879|NCT03659812|Other|MACS technique|MACS is a technique that allow us to tag and detect apoptotic spermatozoa. These apoptotic spermatozoa have phosphatidylserine in their membranes, so we add magnetic beads with Annexin V, which binds specifically to phosphatidylserine. The spermatozoa are then tagged and can be retained in a magnetic field, allowing us to collect just the non-apoptotic spermatozoa.
75347092|NCT03005873|Drug|TLC599 HD group|Single dose via intra-articular injection
75658732|NCT04022239|Drug|Bendamustine|Given IV
75658733|NCT04022239|Drug|Cyclophosphamide|Given IV
75658734|NCT04022239|Biological|Filgrastim-sndz|Given SC
75946788|NCT03143738|Procedure|continuous anesthesia of femoral nerve|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
75946789|NCT03143738|Procedure|Spinal anesthesia|Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
75805880|NCT03660904|Biological|home made vitrification & thawing kit|home made vitrification was made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
76093886|NCT03218982|Behavioral|Enhanced psycho-education about dementia and caregiving|Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
76093887|NCT01898169|Other|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
76093888|NCT03227016|Drug|veliparib|Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.
76093889|NCT03227016|Drug|Topotecan|Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
76093890|NCT04748991|Drug|Vernakalant|Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.
76093891|NCT04748991|Drug|Amiodarone|Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours
75658735|NCT04022239|Drug|Fludarabine|Given IV
75805881|NCT03660904|Biological|commercially made vitrification & thawing kit|commercially available vitrification & thawing kit were made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
75805882|NCT03659656|Behavioral|Lifestyle coaching|Goal setting and behavior change barriers will be discussed through lifestyle behavioral change coaching. Personalized weekly physical activity achievement report will also be sending to participants in experimental group. The participants will also have a Fitbit to use for 3 months.
75805883|NCT03659656|Device|Fitbit usage|The participants will have a Fitbit to use for 3 months.
75946790|NCT03608891|Device|Computer guided patient specific 3D titanium plate|CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.
76093892|NCT03230136|Other|multimodal cardioprotection strategy|Multimodal cardioprotection therapeutic strategy will include (1) remote ischemic preconditioning, (2) volatile anesthetic sevoflurane-induced preconditioning, (3) blood glucose control every 30 minutes during cardiac surgery, (4) temporary respiratory acidosis prior to the aortic cross-unclamping and (5) gradual restoration of blood flow after aortic cross-unclamping (gentle reperfusion).
76093893|NCT03230136|Other|standard anesthetic procedure|standard anesthetic procedure will include: anesthesia under propofol throughout the cardiac surgery, blood glucose control every 60 minutes, arterial pH maintained at 7.40, theoric blood flow restored at the earliest after aortic cross-unclamping.
75347093|NCT03005639|Drug|Vemurafenib and Cobimetinib|All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
75347094|NCT03005795|Device|Headphones|Music can be heard through headphones
75347095|NCT03005795|Other|No Headphones|No Headphones will be used.
75658736|NCT04022239|Drug|Melphalan|Given IV
75658737|NCT04022239|Drug|Mycophenolate Mofetil|Given PO
75658738|NCT04022239|Biological|Rituximab|Given IV
75658739|NCT04022239|Drug|Tacrolimus|Given IV and PO
75658740|NCT04022239|Radiation|Total-Body Irradiation|Undergo TBI
75658741|NCT03981211|Drug|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
75658742|NCT03981211|Drug|Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
75658743|NCT03954990|Drug|Metronidazole Oral|4 tablets (2 g of metronidazole)
75658744|NCT03954990|Drug|Placebo Oral Tablet|4 tablets
75805884|NCT03661918|Behavioral|In-Person First Session|Conduct first session in person vs. over the phone
76093894|NCT03120156|Device|sensomotoric insoles|sensomotoric insoles were published by Jahrling (2007) and have a certain shape that could improve balance abilities. The toes 2-4 are higher that toe 1, so that the tendons of the toe-flectors are pre-stressed.
76093895|NCT03120156|Device|normal standard insoles|Normal standard insole like you will get them by receipe from an orthotic shop
76093896|NCT03120156|Other|No insoles|control group with no insoles in the shoes
76093897|NCT03218046|Behavioral|EMDR|Eye Movement Desensitisation and Reprocessing
76093898|NCT03119844|Other|Exercise|The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
76093899|NCT03119844|Other|Placebo Phototherapy|Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
76093900|NCT03119844|Other|Active Phototherapy|Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
75946791|NCT03608891|Device|Conventional titanium miniplates|In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
75658745|NCT03937011|Device|Robotic Suturing of gastric sleeve oversew and vaginal cuff closure|"Robotic Bariatric Sleeve gastrectomy~Robotic Hysterectomy with or without oophorectomy;"
75658746|NCT03924193|Drug|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
75658747|NCT03924193|Behavioral|Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy
75658748|NCT03924193|Other|Combination LDX and Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
75805885|NCT03661918|Behavioral|Second Caregiver|Have second caregiver participate in three coaching calls
75805886|NCT03661918|Behavioral|WiFi-enabled Scale|Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale
75805887|NCT03661918|Behavioral|10 Core Coaching Calls Only|Participant will receive 10 core phone coaching sessions
75805888|NCT03659500|Diagnostic Test|Four-week routine bloodwork|Routine hemodialysis bloodwork done every 4 weeks
75805889|NCT03659500|Diagnostic Test|Six-week routine bloodwork|Routine hemodialysis bloodwork done every 6 weeks
75805890|NCT03659422|Other|Modified Paleolithic diet|The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
75805891|NCT01068730|Drug|metformin (Diabex)|Tablets, Oral, 500 mg, Once daily, single dose
75946792|NCT03384303|Other|Standardized meal test|Preoperatively and postoperatively standardized meal test
75946793|NCT04393753|Drug|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
75946794|NCT04647903|Drug|ADAIR 10 mg IR tablets|manipulated ADAIR 3x10mg
75946795|NCT04647903|Drug|d-amphetamine sulfate|crushed d-amphetamine sulfate 3x10mg
75946796|NCT04647903|Drug|Placebo|placebo for oral and intranasal administration
76093901|NCT03206268|Device|SD-OCT and SLP using GDx variable corneal compensation|RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
76093902|NCT03217656|Other|No intervention|
75946797|NCT05080634|Other|Patients who underwent POEM|chalasia patients were recruited from a single center. The pre- and postoperative assessments included Eckardt scores, GerdQ questionnaire, high-resolution esophageal manometry, esophagogastroscopy and pH monitoring.
75658749|NCT03897374|Diagnostic Test|Genetic Testing|Buccal swab
75658750|NCT03882073|Procedure|Modified amputation procedure|A fishmouth incision will be made. Radial and ulnar (BEA) or humoral (AEA) osteotomies will be performed. Segments of the flexor carpi radialis (FCR), extensor carpi radialis longus (ECRL), flexor digitorum profundi (FDP), extensor digitorum communis (EDC), flexor pollicis longus (FPL) and extensor pollicis longus (EPL) will be isolated, as well as the biceps (B) and triceps (T) groups in the AEA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. Sensory nerve endings of the distal median, ulnar and radial nerves will then be isolated and redirected to discrete skin patches in the proximal residual forearm or proximal brachium. Coaptation of the FCR/ECRL, FDP/EDC, FPL/EPL and B/T muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
75658751|NCT03882073|Procedure|Standard amputation procedure|Amputation is performed via standard techniques at either the BEA or AEA level. No construction of agonist-antagonist muscle pairs will be performed.
75805892|NCT01068730|Drug|metformin (Glucophage™)|Tablets, Oral, 500 mg, Once Daily, single dose
75805893|NCT01068730|Drug|metformin (Glucophage™)|Tablets, Oral, 1000 mg, Once daily, single dose
75805894|NCT01068730|Drug|metformin (Diabex)|Tablets, Oral, 1000 mg, Once daily, single dose
75805895|NCT01068652|Drug|insulin detemir|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
75805896|NCT01068652|Drug|insulin aspart|Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
75805897|NCT01068652|Drug|biphasic insulin aspart 30|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
75805898|NCT01068652|Drug|metformin|1000-2000 mg/day in combination with insulin treatment
75805899|NCT03659344|Drug|Vicryl plus|Using vicryl sutures which coated with triclosan (antibiotic)
75805900|NCT02921776|Other|Aim 1 - VidaTalk - post-extubation|"Observation of task completion will be made while patients complete a series of messages using the VidaTalk app:~Tell me you are tired~Tell me you are having pain~Rate this pain~Tell me there is pain in your back~Tell me your pain is sharp~Ask to see the doctor~Write your favorite color by drawing with your finger~Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task.~Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak.~Group 1 only:~Patients will be asked about their preferences for customizing the VidaTalk app."
76093903|NCT03206034|Behavioral|Stylistic Memory Enhancement|
76093904|NCT03120000|Drug|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
76093905|NCT03206112|Other|PAS25|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
76093906|NCT03206112|Other|PAS10|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of
76093907|NCT03206112|Other|PAS25-cTBS150|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
75946798|NCT04593225|Behavioral|TAU + multicomponent treatment VIRTUAL SFCAMINA|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with SFC.
75946799|NCT04593225|Behavioral|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
75658752|NCT03879512|Drug|depletion of regulatory T cells|oral metronomic cyclophosphamide
75658753|NCT03879512|Procedure|reoperation|resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation
75805901|NCT02921776|Other|Aim 2 - VidaTalk - intubated|Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).
75805902|NCT02921776|Device|Aim 3 - VidaTalk tablet app|Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
75805903|NCT02921776|Other|Aim 3 - attention-control with non-VidaTalk tablet|Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
75805904|NCT03658720|Drug|200 mg Ibuprofen acid orodispersible tablet|orodispersible tablet
75805905|NCT02922634|Other|Mini Cog|short cognitive screen, short Frailty screen
75805906|NCT00023595|Procedure|CABG surgery plus MED|CABG plus standard medication management for Coronary Artery Disease
75805907|NCT00023595|Drug|Active Medication Alone|Standard medication for coronary artery disease and heart failure management.
75946800|NCT03608813|Other|Serum Metabolomics profiling|Untargeted serum metabolomics profiling
75946801|NCT03142256|Behavioral|Incentivised - Conditional Cash Transfer|Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer
75946802|NCT03142256|Drug|Truvada 200Mg-300Mg Tablet|Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
75946803|NCT04308655|Other|Interview|Semi-structured interviews
75946804|NCT04308655|Other|Surveys|Validated surveys on pain, fear, anxiety, depression, beliefs
75946805|NCT03387189|Other|Quality Improvement Project|Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
75946806|NCT03142178|Drug|Experimental: 3VM1001 active 2g Cream 3 times daily|3VM1001 2g Cream with active ingredient administered 3 times daily
75946807|NCT03142178|Drug|Experimental: 3VM1001 active 3g Cream 3 times daily|3VM1001 3g Cream with active ingredient administered 3 times daily
75946808|NCT03142178|Drug|Experimental: 3VM1001 active 3g Cream 4 times daily|3VM1001 3g Cream with active ingredient administered 4 times daily
75946809|NCT03142178|Drug|Placebo: 3VM1001 vehicle 2g Cream 3 times daily|3VM1001 placebo 2g vehicle Cream administered 3 times daily
75946810|NCT03142178|Drug|Placebo: 3VM1001 vehicle 3g Cream 3 times daily|3VM1001 placebo 3g vehicle Cream administered 3 times daily
75946811|NCT03142178|Drug|Placebo: 3VM1001 vehicle 3g Cream 4 times daily|3VM1001 placebo 3g vehicle Cream administered 4 times daily
75946812|NCT01343459|Radiation|HIOB|"IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~IOERT is performed on mobile or fixed linacs~Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~Single reference dose per fraction: 2,7 Gy (ICRU)~Number of fractions: 15, Number of fractions per week: 5~Total WBRT dose: 40,5 Gy"
75946813|NCT04289155|Drug|GX-I7|patients will receive the assigned dose of GX-I7 intramuscular injection every 4~12 weeks
75946814|NCT03380403|Radiation|PDT|clinical treatment of infected diabetic foot
76093908|NCT03217344|Procedure|conservative treatment|immobilization on sling of the injured arm
75347096|NCT01044290|Other|Life Completion|Subjects discussed life review, issues of forgiveness and heritage and legacy.
75347097|NCT01044290|Other|Attention Control|Subjects listened to a non-guided relaxation CD
75946815|NCT03380403|Other|Ciprofloxacin|antibiotics and or surgical debridment
75946816|NCT03609229|Procedure|Burch|polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve
76093909|NCT00176865|Procedure|Stem Cell Transplant|IV on Day 0
75658754|NCT03879512|Biological|cancer vaccine|4 weekly intradermal injections of lysate-loaded dendritic cells, followed by 3 monthly boost vaccines with tumor lysate and further boost vaccines every three months
75658755|NCT03879512|Biological|checkpoint blockade|Immediately one week after the DC-induction vaccines, patients will receive four applications of Nivolumab/Ipilimumab double checkpoint blockade in threeweekly intervals, followed by Nivolumab monotherapy every month for a total duration of one year.
76093910|NCT00176865|Drug|Fludarabine|30mg/m^2 IV Day -7 through Day -3
76093911|NCT00176865|Drug|Melphalan|140 mg/m^2 IV Day -1
75347098|NCT01590875|Drug|Adenosine arm|In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
75658756|NCT03878342|Radiation|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
75805908|NCT00023595|Procedure|CABG plus MED and SVR|H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
75805909|NCT03658564|Dietary Supplement|Preoperative Oral Carbohydrate Drink|Patients in Oral carbohydrate group consumed 400 ml Preoperative Oral Carbohydrate Drink Nutricia preOp® (12.5% carbohydrates, 0.5kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
75658757|NCT03878342|Other|No Radiotherapy|No Irradiation- Active surveillance
75658758|NCT03877276|Dietary Supplement|Breakfast|a prepared meal consisting of pastry and 2 cooked egg whites
75805910|NCT03657784|Drug|P03277|Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
75805911|NCT03659110|Biological|HPV 4|1000 subjects will be received the HPV 4 vaccine
75805912|NCT03658408|Drug|4-aminopyridine|Oral tablet of 2.5 mg given 4 times a day
75805913|NCT03658408|Drug|placebo|2.5 mg sugar pill given orally 4 times a day
75805914|NCT03659032|Procedure|Pediatric Manual Therapy|
75347099|NCT03404414|Drug|18F-FDG|"Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans"
75805915|NCT03659032|Procedure|Educational Physical Therapy|
75946817|NCT03609229|Procedure|Abdominal Sacrocolpopexy|"By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~The right-handed operator double gloves, and places the left hand in the vagina.~With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~Place three Ethibond J-shaped sutures on either side of the urethrovesical junction."
75946818|NCT03143426|Procedure|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
76093912|NCT00176865|Drug|Anti-thymocyte globulin (ATG)|30 mg/kg IV Day -5 through Day -1
75347100|NCT01591655|Drug|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
75347101|NCT01591655|Drug|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
75347102|NCT00916136|Procedure|Femoral Traction|Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
75347103|NCT01725074|Behavioral|"Case Management CM CHD"|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:~Biweekly/monthly telephone consultations or home visits~Identification of health or personal problems of the patient~Monitoring of medical parameters~Coordination of contact with health care providers if necessary~Support to the patient related to health status and environmental changes~Promote disease-self management through coaching~Counseling, that is focused on emotional support and active listening"
75946819|NCT02034539|Device|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
75946820|NCT03380325|Drug|Iloprost infusion|Iloprost is a stable prostacyclin analogue
75946821|NCT02237053|Drug|Glucagon|
75946822|NCT02237053|Drug|Octreotide|
75946823|NCT02237053|Behavioral|Placebo|
75946824|NCT02237053|Drug|Insulin|
75946825|NCT03142100|Device|cochlear implants and hearing aids|speech perception tests and bimodal fitting
75658759|NCT03877276|Dietary Supplement|Spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach
75658760|NCT03877276|Dietary Supplement|Kale smoothie|prepared blended kale smoothie, consisting of banana, avocado, orange juice, and kale
75658761|NCT03877276|Dietary Supplement|Blended smoothie|a prepared blended smoothie, consisting of banana, avocado, and orange juice
75658762|NCT03877276|Dietary Supplement|V spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and a varying amount (low, medium, high) of spinach
75805916|NCT03034330|Other|Two-Tier Stroke Family Empowerment|The family-based care management intervention will be implemented in two tiers. The first tier is the Family Care Management that a care manager is responsible for empowering family caregivers to support their stroke survivors through reorganizing family roles, enhancing family functioning, and maximizing their family and community resources. The second tier is led by trained volunteers who are responsible for increasing the capacity of caregivers for the mastery of stroke care by providing psychoeducation, skill-training, and social support. Each caregiver participant will be assigned a care manager and a volunteer. All care managers who are social workers from the participating centres have undergone 4-day training to improve their knowledge of stroke and skills required for the intervention. Similarly, volunteers have undergone 6.5-day training to equip them with the knowledge and skills to conduct the intervention.
75805917|NCT03034330|Other|Volunteer Support Psychoeducation|The active control group will receive a standard, non-family-based psychoeducation intervention provided by the trained volunteers under the supervision of care managers. It will provide 4 in-home visits and 2 telephone follow-up interviews about psychoeducation for caregivers of stroke survivors.
75946826|NCT05172219|Behavioral|Physician Sent Outreach with Embedded Asynchronous Care in Portal Message|PCPs sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
75658763|NCT03877276|Dietary Supplement|Sodium oxalate drink|a prepared sodium oxalate drink
75946827|NCT05172219|Behavioral|Physician Sent Outreach without Embedded Asynchronous Care in Portal Message|Physician sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
75658764|NCT03873389|Drug|Ocrelizumab|Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
75658765|NCT03861494|Behavioral|Enhanced Stroke Education|In addition to the general stroke education materials and verbal education, the enhanced stroke education group will receive a personalized verbal and written information addressing the patient's specific risk factors including their current status and goals, laboratory values and goals, and current blood pressure and goal. Specific stroke type and etiology is discussed, medication including indication, dose, frequency, physical activity goals, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, and education over the importance of keeping follow up appointments including Stroke Clinic. Verbal feedback of key points is encouraged.
75658766|NCT03861494|Behavioral|Usual Stroke Education|The usual stroke education group will receive general stroke education including written and verbal information about signs and symptoms of stroke, best practice to engage medical treatment if stroke occurs, general information about heart healthy diet and need for daily physical activity as well as need for compliance with medication recommendations. The education is incorporated with routine patient care and as allowed during quiet times. On the day of discharge, the patient will receive written materials reviewing stroke symptoms, risk factors, heart healthy diet and follow up appointments. The patient will receive written and verbal information about medications including indication, dose, frequency, physical activity goal, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, the importance of keeping follow up appointments including Stroke Clinic.
75658767|NCT03860857|Radiation|Amyloid PET scan|Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
75658768|NCT03860857|Drug|Tau PET scan using MK-6240|Tau Positron Emission Tomography scan using radio tracer MK-6240
75658769|NCT03860857|Behavioral|Neurocognitive testing|A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
75946828|NCT05172219|Behavioral|System Sent Outreach with Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
75347104|NCT01725074|Behavioral|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
75946829|NCT05172219|Behavioral|System Sent Outreach without Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent. Half of the messages came from the patient's PCP and the other half came from the health system to determine if communication from a patient's physician was associated with more quit attempts.
75946830|NCT03140930|Dietary Supplement|Tastants duodenal|Duodenal infusion of combination of tastants (sweet, bitter and umami)
75347105|NCT01725230|Drug|Fostamatinib|100-mg tablet
75347106|NCT01725230|Drug|Rosuvastatin|20-mg tablet
75347107|NCT01725230|Drug|Simvastatin|40-mg tablet
75658770|NCT03860857|Other|MRI|High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
75658771|NCT03859687|Biological|Vitamin A supplementation|liquid oral vitamin A supplementation
75658772|NCT03859687|Biological|No vitamin A supplementation|No vitamin A supplementation
75658773|NCT03855917|Drug|Sofosbuvir 400mg [Sovaldi]|Four weeks.
75658774|NCT03855917|Drug|Glecaprevir/pibrentasvir (300mg/120mg)|Four weeks.
75946831|NCT03140930|Dietary Supplement|Tastants ileal|Ileal infusion of combination of tastants (sweet, bitter and umami)
75946832|NCT03140930|Dietary Supplement|Placebo duodenal|Duodenal infusion of placebo (tap water)
75946833|NCT03140930|Dietary Supplement|Placebo ileal|Ileal infusion of placebo (tap water)
75946834|NCT04127825|Procedure|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a method of blood conservation used to reduce the amount of donor blood transfused. It involves removing blood from appropriate patients immediately after the induction of anesthesia, replacing the volume lost with colloids (e.g. 5% albumin), then storing and returning this blood to the patient at the completion of the surgical procedures.
75946835|NCT03609151|Procedure|laparoscopic hepatectomy (surgery)|Patients receive laparoscopic hepatectomy.
75347108|NCT01591733|Drug|FOLFIRINOX|Up to Eight-14 day cycles
75347109|NCT01591733|Drug|Capecitabine|Orally, for 10 days
75347110|NCT01591733|Radiation|Short Course Radiation|Five or ten days
75658775|NCT03847428|Drug|Durvalumab|Durvalumab IV (intravenous)
75658776|NCT03847428|Drug|Bevacizumab|Bevacizumab IV (intravenous)
75658777|NCT03847428|Other|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
75946836|NCT03609151|Radiation|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy(SBRT)
75946837|NCT03384147|Dietary Supplement|Drinking|Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks
75347111|NCT01591733|Procedure|Surgery|1-4 weeks after completion of capecitabine therapy
75347112|NCT03005561|Behavioral|Play Back Sessions|"100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool."
75477104|NCT04825366|Other|Edinburgh Hypoglycemia Symptom Scale|The Edinburgh Hypoglycemia Symptom Scale will be used to assess symptoms of hypoglycemia
75477105|NCT04825366|Other|BAPAD questionnaire|The BArriers to Physical Activity in type 1 Diabetes (BAPAD) questionnaire will be used to assess barriers of physical activity
75477106|NCT04825366|Other|Hypoglycemia Fear Survey II|The Hypoglycemia Fear Survey II will be used to assess fear of hypoglycemia
75477107|NCT04825366|Other|Physical activity questionnaire|The International Physical Activity Questionnaire will be used to assess physical activity practice
75658778|NCT03845504|Device|Intermittent Theta Burst Stimulation|Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
75658779|NCT03844672|Behavioral|Low Power|Participants will receive a low power e-cigarette to use for 3 weeks
75946838|NCT03384147|Other|Abstaining|Participants are abstaining from all alcoholic beverages for three weeks
75946839|NCT04964570|Behavioral|Video _ behavioral change module|"A short video (primary outcome) that aimed at reducing stigma towards treatments and increasing help seeking intentions.~The behavioral change module (secondary outcome) is aimed at changing behaviors of sleep, exercise and social support."
75946840|NCT02237131|Drug|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
76093913|NCT00176865|Drug|Campath 1H|0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
75946841|NCT02237131|Drug|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
76093914|NCT00176865|Drug|Cyclosporin A|2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children <40 kg) maintaining a level of >200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181
75946842|NCT03384069|Behavioral|Group-based Cognitive Behavioral Therapy (CBT)|The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.
75946843|NCT03384069|Behavioral|Phone-based Cognitive Behavioral Therapy (CBT)|Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
75946844|NCT02734667|Device|CGM at diagnosis of T1D|Initiation of non-adjunctive CGM use at diagnosis of T1D
76093915|NCT00176865|Drug|Mycophenolate mofetil|15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present
76093916|NCT00176865|Drug|Intravenous immunoglobulin (IVIG)|500 mg/kg IV weekly beginning on Day +7 until Day +100
76093917|NCT02451072|Drug|Placebo|Capsules containing mannitol looking identical to LSD per os
75347113|NCT03005405|Procedure|Ionomer Restoration (control)|Restoration of moderate caries lesions after partial caries removal using high viscosity glass ionomer cements
75347114|NCT03005405|Procedure|Ionomer Sealant (test)|Sealing of moderate caries lesions without any caries removal or cavity opening.
75347115|NCT03005405|Procedure|Oral hygiene orientation and professional fluoride application|Oral hygiene orientation and professional fluoride application
75347116|NCT03005717|Drug|LIPO-202|
75347117|NCT03005717|Drug|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
75347118|NCT02999243|Behavioral|HIV self-testing|The intervention group will be offered HIV self-testing kits for testing HIV status
75347119|NCT02999243|Behavioral|Harm reduction education|Both arms will receive harm reduction education
75347120|NCT03005483|Drug|Gabapentin|Orthopedic Surgery was applied for the treatment of osseous disorders
75347121|NCT03005483|Other|Placebo|Orthopedic Surgery was applied for the treatment of osseous disorders
75477108|NCT04825366|Other|Well-being|The WHO-5 well-being index will be used to assess well-being.
75477109|NCT04825366|Other|Treatment satisfaction|The Diabetes Treatment Satisfaction Questionnaire will be used to assess treatment satisfaction.
75477110|NCT04825366|Other|Hypoglycemia diary|Participants will be asked to record in a diary treatments for hypoglycemic events
75477111|NCT04825366|Device|Piezo RxD|Participants will be asked to wear a pedometer throughout the study
75477112|NCT04825366|Device|Heart rate monitor|During training sessions, participants will be asked to wear a heart rate monitor
75658780|NCT03844672|Behavioral|High Power|Participants will receive a high power e-cigarette to use for 3 weeks
75946845|NCT04997174|Drug|Celecoxib|Patients in ERAS group received celecoxib
75946846|NCT02237209|Biological|RSV LID ΔM2-2 Vaccine|10^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
76093918|NCT02451072|Drug|LSD|100µg per os, single dose
76093919|NCT02451072|Drug|Ketanserin|40mg per os, single dose looking identical to LSD per os
76093920|NCT03205878|Other|Telecoaching|"Patients in the intervention arm will receive a step counter and a cell phone with an app on which the amount of steps are daily sent to.~Initial targets on steps per day will be discussed with the patient after an activity monitoring before the telecoaching procedure. Dependent whether the patient reaches his/her proposed goal each week, new goals are set."
76093921|NCT03205878|Device|CPAP|Patients will receive CPAP according to standard care
76093922|NCT03205800|Other|Mini-screw|Placement of a mini-screw
75658781|NCT03844672|Behavioral|Low Concentration|Participants will receive a low concentration e-liquid to use for 3 weeks
75658782|NCT03844672|Behavioral|High Concentration|Participants will receive a high concentration e-liquid to use for 3 weeks
75658783|NCT03840421|Drug|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
75805918|NCT03657706|Procedure|group A (Tunnel procedure with subepithelial connective tissue graft (sCTG)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
75946847|NCT02237209|Biological|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
75946848|NCT03383991|Procedure|Reverse Total Shoulder Arthroplasty|
75946849|NCT03383991|Procedure|Hemiarthroplasty|
75946850|NCT03608605|Device|MRI|magnetic resonance imaging with advanced sequences including tractography,volumetry and inversion recovery
75946851|NCT03387111|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
75946852|NCT03387111|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
75946853|NCT03387111|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2
75946854|NCT03387111|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
75946855|NCT03387111|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
75946856|NCT03387111|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
75946857|NCT03387111|Biological|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
75946858|NCT03387111|Biological|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
75347122|NCT01593215|Drug|Yohimbine|Yohimbine capsule
75347123|NCT05511155|Other|Oxygen therapy|Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
75347124|NCT05423483|Behavioral|Safe Home Text Message Reminders|Text messages sent 2x a week with reminders to keep lethal means restricted and surveys of lethal means practices that serve as a prompt to adhere to suggested restriction measures.
75347125|NCT05504135|Diagnostic Test|Pharmacogenomics Testing|To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
75658784|NCT03840421|Drug|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
75658785|NCT03840421|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor
75658786|NCT03840421|Drug|cisplatin|IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
75658787|NCT03840226|Drug|Placebo Oral Tablet|Placebo tablets
75658788|NCT03840226|Drug|Magnesium Oxide|Magnesium tablets
75658789|NCT03822351|Drug|Durvalumab + Oleclumab|Durvalumab + Oleclumab
75658790|NCT03822351|Drug|Durvalumab|Durvalumab
75658791|NCT03822351|Drug|Durvalumab + Monalizumab|Durvalumab + Monalizumab
75805919|NCT03657706|Procedure|group B (Tunnel procedure with modified free gingival graft (mFGG))|modified free gingival graft (autogenous graft) will be harvested from the palate and will be used with the prepared tunnel to be used in treating gingival recession
75805920|NCT03658330|Drug|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
75805921|NCT03658252|Behavioral|Targeted education|Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids
75946859|NCT03387111|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
75946860|NCT03387111|Drug|Avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
75946861|NCT03387111|Drug|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
75946862|NCT03387111|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
75946863|NCT03387111|Drug|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
75946864|NCT03387111|Drug|Cisplatin|cis-diamminedichloroplatinum(II)
75946865|NCT03387111|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
75946866|NCT03387111|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
75946867|NCT03387111|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
75946868|NCT03387111|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
75946869|NCT03387111|Drug|Necitumumab|Necitumumab is a recombinant human lgG1 monoclonal antibody.
75946870|NCT03387111|Procedure|SBRT|Stereotactic Body Radiation Therapy
75946871|NCT03387111|Biological|N-803|Recombinant human superagonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
75946872|NCT04477070|Procedure|Air-polishing with ultrasonic debridement|Use of air-polishing and ultrasonic device (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) to remove plaque and calculus from the surface of the roots of teeth.
75946873|NCT04477070|Procedure|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
75946874|NCT03608293|Diagnostic Test|Broncho Alveolar Lavages (BAL)|BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
75946875|NCT03608501|Drug|Ixazomib|Ixazomib capsules.
75805922|NCT03658252|Behavioral|Online disease specific forum|An invitation to join an online moderated disease specific social forum
75347126|NCT01594385|Biological|Seprafilm|"Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~Two Seprafilm pieces between the liver and the anterior abdominal wall~Four pieces over the exposed bowel surfaces anteriorly~Two slightly staggered pieces of Seprafilm in each colic gutter~Two pieces in the pelvic area.~If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair."
75946876|NCT03608501|Drug|Thalidomide|Thalidomide capsules.
75946877|NCT03608501|Drug|Dexamethasone|Dexamethasone tablets.
75347127|NCT03005249|Procedure|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
75946878|NCT04609436|Device|"Cardiac monitoring with the wireless device SmartCardia"|Monitoring of arrhythmia with a wireless device (SmartCardia)
75946879|NCT03608345|Other|space maintainer|Space maintainers are applied after the missing teeth in pediatric dentistry for protection of size of extracted area.
75946880|NCT03608761|Drug|Rebamipide|rebamipide 2%
75805923|NCT04486222|Device|Repeated Transcranial Magnetic Stimulation|Magstim® Super Rapid² Transcranial Magnetic Stimulation System
75805924|NCT03658174|Dietary Supplement|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice containing approximately 5-6 mmol of inorganic nitrate
75805925|NCT03658174|Dietary Supplement|Nitrate-free beetroot juice|70mls of concentrated beetroot juice that has been nitrate-depleted
75805926|NCT02920528|Drug|Ketamine|sub-dissociative ketamine
75805927|NCT02920528|Drug|Placebo|Normal Saline
75805928|NCT01068418|Dietary Supplement|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
75805929|NCT01100619|Drug|rosiglitazone|one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
75805930|NCT01100619|Drug|XL184|dosed with capsules daily
75946881|NCT03608761|Biological|autologous serum|AS for 3 months
75946882|NCT03608761|Other|autologous serum and rebamipide 2%|rebamipide and autologous serum for 3 months
75946883|NCT03383913|Behavioral|Heart Rate Variability Biofeedback|Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
75946884|NCT03608267|Device|Endomina|The jejunum between the two loops is sutered with Endomina and cut 15 days later.
75946885|NCT04150081|Procedure|Surgery or Endoscopic treatment|All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
75946886|NCT03383835|Dietary Supplement|Omega-3 Supplementation|"DHA 600 milligrams (mg) per day for 6 months~EPA 300mg per day for 6 months"
75946887|NCT04568174|Drug|PPSGG|an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies
75946888|NCT04568174|Drug|Placebo|A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
75946889|NCT02033447|Other|Magnetic Nanoparticle Injection|
75347128|NCT03005249|Other|the control group|The patients will be assigned to the control group for cerebral palsy.
75347129|NCT02247323|Other|Risk of malignancy index|Calculation of RMI before sugery.
75347130|NCT03005015|Drug|Lenvatinib|
75805931|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every week
75805932|NCT01101243|Radiation|Broadband UVB|UVB dose: 4 SED every second week
75805933|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every second week
75946890|NCT02715115|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
75946891|NCT02715115|Drug|Placebo|Strawberry flavored solution and Water for Injection
75347131|NCT03005015|Drug|Doxorubicin|
75347132|NCT03005171|Drug|Bupivacaine|Thoracic epidural bupivacaine infusion
75347133|NCT03005171|Drug|Lidocaine|Intravenous lidocaine infusion
75347134|NCT03005093|Other|CAREGIVERS|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
75658792|NCT03819712|Procedure|Collection of blood samples|23 mL of blood will be collected during the inclusion visit
75658793|NCT03819712|Other|Collection of fecal samples|Fecal sample self-collected after the inclusion visit
75658794|NCT03819712|Other|Collection of urine samples|10 mL of urine will be collected during the inclusion visit
75658795|NCT03819712|Other|Collection of vaginal swaps|Sample of vaginal microbiota collected during the inclusion visit
75805934|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every month
75805935|NCT01101243|Other|Control group|No intervention
75805936|NCT03954093|Device|Transcranial direct current stimulation|tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
75805937|NCT05626023|Drug|Human TH-SC01 cell injection|Single injection of human TH-SC01 cell injection
75946892|NCT04554836|Drug|Cetuximab|Patients in Arm A will receive FOLFIRI +cetuximab.
75946893|NCT04554836|Other|FOLFIRI|Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)
75946894|NCT03386955|Drug|BPI-7711 Capsule|Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)
75946895|NCT04536272|Drug|Heparin|Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
75946896|NCT04536272|Drug|LMWH|Administration of LMWH guided by weight and renal function during ECLS.
75805938|NCT01068262|Drug|Odanacatib|Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
75946897|NCT03608527|Behavioral|Voluntary-based upper limb motor rehabilitation|Exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, mainly including task-oriented movements with the goal to improve activities of daily living. Both proximal and distal muscles are involved, in actions such as grasping wooden cubes of different sizes, pinching, reaching targets displayed in front of the patient, and doing patchwork or paper mandala.
75946898|NCT03608527|Behavioral|Passive upper limb mobilization|Passive mobilization delivered by a physical therapist of shoulder, elbow, wrist and fingers without detectable muscle activity.
75347135|NCT03005093|Other|CHILDREN OF CAREGIVERS|Chewing performance with Karaduman Chewing Performance Scale, tongue control with Tongue Thrust Rating Scale, dysphagia symptom severity with the Pediatric version of the Eating Assessment Tool will be evaluated. These assessments will be done before and after swallowing rehabilitation program.
75946899|NCT03380169|Other|Prophylactic advance wound dressing|A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing
75946900|NCT03380169|Other|Prophylactic conventional wound dressing|Conventional gauze dressing
75946901|NCT02034721|Dietary Supplement|Protein supplement|24 g protein before, 12 g during, and 24 g after eccentric exercise
75946902|NCT02034721|Dietary Supplement|Placebo|Placebo
75946903|NCT04521842|Procedure|Total hip replacement|Total hip replacement in treatment of end-stage osteoarthritis
75946904|NCT03383601|Other|Heated Tobacco product IQOS/heatstick|Heated Tobacco Products: heatsticks heated by iQOS device
75946905|NCT03383601|Other|Smoking combustible cigarettes|Current smoking of combustible cigarettes
75347136|NCT05310617|Other|Survey|Survey on the parental project and its realisation
75347137|NCT05566613|Radiation|Blood sample|Blood sample before and after radiotherapy and photography before radiotherapy
75347138|NCT05566535|Drug|Ruxolitinib|Ruxo will be administered to patients with PV in a real-world setting. Treatment with Ruxo is according to local approved label. Ruxo treatment should be administered according to drug official instruction and in compliance with clinical practice at the certain medical center.
75477113|NCT04825366|Other|Exercise diary|Before each training session, participants will be asked to note in a diary their glucose levels, if they have taken a snack or not and if insulin was administered. After each training session, participants will be asked to note that same information. In addition, they will be asked to note their bedtime blood glucose, if they have taken a bedtime snack and if adjustment to insulin doses was made.
75805939|NCT01068262|Drug|Comparator: Placebo|Oral Placebo tablet administered once weekly for 4 consecutive weeks
75805940|NCT03658018|Device|Intracept System Ablation|Radiofrequency ablation using Intracept System
75477114|NCT04816162|Drug|ketofol|prepared in a ratio of (1:4) respectively), where 1ml of ketamine will be added to 20 ml of propofol in a syringe pump
75477115|NCT04816162|Drug|dexmedetomidine|2 ml (200 µg) of dexmedetomidine added to 0.9% normal saline in a syringe pump
75477116|NCT04816162|Other|normal saline|normal saline 0.9% in a syringe pump
75658796|NCT03810794|Other|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. The electric stimulator will be applied to DU 24, GB 12, HT 7, and LR 3 or SP 6 with a disperse-dense wave of 2/50 Hz, 0.5-1.0 mA. There are three sessions per week with each session lasting for 30 min. There will be 12 weeks of treatment for each participant in total.
75805941|NCT03657940|Behavioral|VIVIFRAIL multicomponent exercise training program|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using dumbbells aiming for 2-3 sets of 10-15 repetitions at an intensity of 30-50% of 1Repetition Maximum ( combined with balance-training, flexibility and gait exercises that progressed in difficulty.
75805942|NCT03657550|Drug|Levamlodipine, Amlodipine|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
75946906|NCT02746679|Other|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
75946907|NCT03380013|Procedure|Osteopathic Manipulative Treatment (OMT)|Each neonate will have a structural exam completed assessing each body region (head, cervical, thoracic, lumbar, sacral, pelvic, rib cage, and abdominal regions) for underlying somatic dysfunctions prior to each treatment. The specific OMT techniques used will be left to the discretion of the treating physician and will not be based on a predetermined protocol. Treatment techniques will consist of myofascial release, balanced ligamentous tension, balanced membranous tension, and osteopathy in the cranial field. Total treatment time will be 15 minutes. The features of the osteopathic structural exam which will be recorded on paper by the treating physician at the time of the evaluation. The paper will be marked only with the research identifier.
75946908|NCT03608215|Device|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
75946909|NCT03608215|Device|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
75658797|NCT03810794|Drug|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks. After the clinical trial, participants will be given conventional treatment clinically.
75658798|NCT03804905|Other|No-cost Medications|Patients will be connected to Trillium Health Partners outpatient pharmacy, and they will be given an information sheet with further details. The patients will get free access to diabetes, blood pressure and cholesterol medications and for glucose test strips. They can attend the pharmacy in person or arrange for home delivery.
75805943|NCT03657550|Drug|Amlodipine, Levamlodipine|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
75805944|NCT02920450|Drug|Gedatolisib|"During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg"
75805945|NCT02920450|Drug|Paclitaxel|Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
75805946|NCT02920450|Drug|Carboplatin|The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
75805947|NCT03622450|Drug|Colistin|Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
75805948|NCT03622450|Drug|Carbapenem + Aminoglycoside/ Quinolone|Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
75946910|NCT04138927|Drug|Fostamatinib disodium|Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
75805949|NCT03657862|Device|application of 38% silver diamine fluoride solution|SDF solution was painted onto the surface of the carious lesion of the tooth
75805950|NCT03657862|Other|application of a placebo (tonic water)|tonic water was painted onto the surface of the carious lesion of the tooth
75805951|NCT02730130|Drug|Pembrolizumab|
75805952|NCT02730130|Radiation|Radiotherapy|
76093923|NCT03226782|Other|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
76093924|NCT03226782|Other|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
76093925|NCT03226626|Drug|Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD|Concomitant tumescent anesthesia antibiotic delivery (TAAD) & Intravenous antibiotic delivery (IVAD).
76093926|NCT03226626|Device|SubQKath|The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
76093927|NCT02451228|Other|Serial blood collection|Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.
76093928|NCT02450994|Drug|Dexamethasone|
76093929|NCT02450994|Drug|Placebo|
76093930|NCT00177255|Drug|Docetaxel|"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
76093931|NCT00177255|Drug|Capecitabine|"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
76093932|NCT03205722|Other|Non-Interventional|Non-Interventional
76093933|NCT02401048|Drug|Ibrutinib|
75805953|NCT02919436|Drug|Tamsulosin|Active drug
75805954|NCT02919436|Drug|Placebo|Lactose-filled capsules identical to active drug
75946911|NCT04504604|Diagnostic Test|FoundationOne CDx and FoundationOne Liquid CDx|Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.
75946912|NCT03610373|Behavioral|Modular Approach to Therapy for Children (MATCH)|MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
75946913|NCT03610295|Procedure|PPI group|The patients underwent cataract extraction, posterior capsulotomy, anterior vitrectomy combined with prophylactic peripheral iridectomy.
75946914|NCT03610295|Procedure|cataract extraction|The patients underwent cataract extraction, posterior capsulotomy combined with anterior vitrectomy and leave the iris intact.
75946915|NCT03142022|Other|No intervention - Diagnostic polysomnography at 1 year after lung transplantation|
75946916|NCT02034643|Procedure|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
75946917|NCT02033525|Drug|XCEL-M-ALPHA and standard rehabilitation|Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
75946918|NCT02033525|Other|Rehabilitation|Standard rehabilitation program
76093934|NCT02401048|Drug|MEDI4736|
76093935|NCT03215550|Procedure|CEA|Carotid Endarterectomy
76093936|NCT03215550|Radiation|18F PET-MRI|18F-fluoride Hybrid PET-MRI
76093937|NCT03215550|Diagnostic Test|Transcranial Doppler|Microembolic Signals detection
76093938|NCT00178191|Other|Bladder diary|3-day bladder diary
76093939|NCT00178191|Other|Questionnaires|Incontinence Quality of Life questionnaires
76093940|NCT00178191|Procedure|Urodynamics|Urodynamics
76093941|NCT00178191|Other|Pad weight|Pad weight
75658799|NCT03784911|Device|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.
75658800|NCT03784911|Device|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
75658801|NCT03783429|Drug|Digoxin|Digoxin tablets will be given orally
75658802|NCT03783429|Drug|Placebos|Placebo tablets will be given orally
75805955|NCT04456972|Diagnostic Test|One arm only|Samples of plasma to analyze ctDNA
75946919|NCT04638842|Behavioral|Online Intervention Grief COVID-19|The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
75946920|NCT02731131|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
75946921|NCT02731131|Drug|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
76093942|NCT03215784|Dietary Supplement|Fish Oil|
76093943|NCT03215784|Dietary Supplement|Probiotic|
75658803|NCT03783078|Drug|Pembrolizumab (MK-3475)|200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) IV up to 35 administrations (approximately 2 years).
75805956|NCT03657472|Drug|CJ-30061|Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
76093944|NCT03215784|Dietary Supplement|Placebo|
76093945|NCT02046382|Drug|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
75658804|NCT03778294|Procedure|Computed Tomography|Undergo PET/CT
75658805|NCT03778294|Other|Fluorodopa F 18|Given IV
75658806|NCT03778294|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
75805957|NCT03657472|Drug|Exforge® 5/160mg & Lipitor® 20mg|Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
76093946|NCT02046382|Drug|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
76093947|NCT03205176|Drug|AZD5153|AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
75658807|NCT03778294|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MRI
75658808|NCT03778294|Radiation|Proton Beam Radiation Therapy|Receive proton beam RT
75658809|NCT03778294|Other|Quality-of-Life Assessment|Ancillary studies
75658810|NCT03778294|Other|Questionnaire Administration|Ancillary studies
75658811|NCT03778294|Drug|Temozolomide|Drug
75658812|NCT03759431|Radiation|Vocal-cord Radiotherapy|Focal radiotherapy limited to the involved vocal cord(s) plus additional margins accounting for respiration and set-up errors.
75658813|NCT03759431|Radiation|Complete Larynx Radiotherapy|Radiotherapy to the entire larynx, with target volumes defined to lead to traditional volumes from conventional complete larynx radiotherapy.
75805958|NCT03657082|Device|PEP-10|Bottle PEP with a water level of 10 cmH2O
75805959|NCT03657082|Device|PEP-1|Bottle PEP with a water level of 1 cmH2O
75805960|NCT03622372|Procedure|Operative repair of Zone 2 FDP tendon lacerations|Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator
75805961|NCT03622372|Device|CoNextions TR Implant System|The CoNextions TR Implant System will be used to repair Zone 2 FDP tendon laceration(s).
76093948|NCT03205176|Drug|Olaparib|Olaparib, 300 mg, will be taken BID as oral capsules.
76093949|NCT02046772|Drug|Bupivacaine low dose|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
76093950|NCT02046772|Drug|Bupivacaine standard dose|Single intradural standard dose of bupivacaine
76093951|NCT02046772|Drug|Morphine Chloride|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
76093952|NCT03205254|Other|Mediterranean Diet|four days of participant-scaled isocaloric Mediterranean meals
76093953|NCT03205254|Other|Fast food diet|four days of participant-scaled isocaloric fast food meals
76093954|NCT00178503|Drug|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
75805962|NCT03622372|Device|4-strand locked cruciate repair|A 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture will be used to repair Zone 2 FDP tendon laceration(s).
75477117|NCT04813185|Behavioral|Bridging the Gap|"Bridging the Gap Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
75805963|NCT03804879|Drug|Nidufexor|50 mg (two 25 mg) LMB763 capsules for oral administration
76093955|NCT00178503|Drug|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
75805964|NCT03804879|Other|Placebo|Placebo capsules for oral administration
76093956|NCT00178503|Other|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
76093957|NCT02376010|Drug|rivaroxaban|
75658814|NCT03752619|Device|Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
76093958|NCT02376010|Drug|Warfarin|
76093959|NCT03205332|Behavioral|Concreteness Training|
76093960|NCT03205410|Procedure|remote ischemic preconditioning|The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
76093961|NCT03205410|Procedure|no - remote ischemic preconditioning|The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
75805965|NCT03804879|Drug|Standard of Care (SoC)|Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
76093962|NCT02452086|Device|Low Level Laser(Ga-As)|Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
75805966|NCT04438330|Other|Nickel sulfate hexahydrate|Patch test
75805967|NCT02746510|Genetic|Array comparative genomic hybridization|For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
75805968|NCT03803475|Drug|Ga-68 labeled PSMA-11|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
75805969|NCT03803475|Device|Positron emission tomography-computed tomography (PET/CT)|Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session
75946922|NCT02746705|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models
75946923|NCT02746705|Device|Sham Transcranial Direct Current Stimulation|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
75946924|NCT02746705|Behavioral|Cognitive Training Program|
76093963|NCT02452086|Procedure|Placebo|LLLT with zero intensity
76093964|NCT00085293|Drug|Decitabine|Starting dose 6 mg/m^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
76093965|NCT00085293|Radiation|Iodine I 131|Undergo thyrotropin-alfa stimulated radioactive iodine scan
76093966|NCT00085293|Biological|Recombinant thyrotropin alfa|Undergo thyrotropin-alfa stimulated radioactive iodine scan
76093967|NCT00085293|Radiation|Fludeoxyglucose F 18|Optional correlative studies
76093968|NCT00085293|Procedure|Positron emission tomography|Optional correlative studies
75477118|NCT04811196|Drug|Selinexor|Selinexor
75477119|NCT04808778|Drug|Hydroxyurea therapy per standard care|Moderate-dose of 20mg/kg/day
75477120|NCT04808752|Drug|Almonertinib|Patients meeting the criteria for inclusion and exclusion were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.
75946925|NCT04585724|Drug|Abemaciclib|Given PO
75946926|NCT04585724|Drug|Palbociclib|Given PO
75946927|NCT04585724|Other|Quality-of-Life Assessment|Ancillary studies
75946928|NCT04585724|Drug|Ribociclib|Given PO
76093969|NCT03215628|Diagnostic Test|TCEUS|Intravenous sulphur hexafluoride microbubbles
75477121|NCT04792580|Drug|Lifitegrast 5% Ophthalmic Solution|Used twice a day in both eyes for 4 weeks after a 2 week washout.
76093970|NCT03215394|Behavioral|Attention Training Program|The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
76093971|NCT03215394|Behavioral|Social ABCs|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
76093972|NCT03215394|Other|Treatment As Usual|The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
76093973|NCT03215394|Behavioral|Sham Attention Training|The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
75477122|NCT04792580|Drug|Placebo|Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
75658815|NCT03752619|Device|Non Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
75805970|NCT03803475|Device|Positron emission tomography-magnetic resonance imaging (PET/MRI)|A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session
75805971|NCT02682004|Other|leptin, serotonin and adiponectin level|
75805972|NCT02682004|Other|leptin,serotonin, adiponectin level|
75805973|NCT01101399|Drug|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
75805974|NCT03657316|Behavioral|nutrition education|"The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages"
75805975|NCT00005937|Drug|Antithymocyte globulin|Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
75805976|NCT00005937|Drug|Cyclosporine|Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
75805977|NCT02644798|Other|Baseline-recorded data recorded|Baseline-recorded data recorded. Peripheral blood samples were drawn.
75805978|NCT01102881|Dietary Supplement|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
75805979|NCT01102881|Dietary Supplement|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
75805980|NCT01102881|Dietary Supplement|placebo|low fiber breakfast cereal and muffin
75477123|NCT04785963|Behavioral|Music with Suggestion|A nonpharmacological, short-term treatment that poses minimal risk and places very limited burden on patients seems ideal for this population, and music with suggestions is one such treatment option.
75805981|NCT03657238|Drug|RD01|single S.C. dose of RD01 for subjects in test group
75658816|NCT03752619|Other|Physical Therapy|All participants receive eight 1.0 hr. sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment. Each participant also performs home exercises. The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb. During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
75658817|NCT03749421|Other|Prosigna PAM-50 assay|Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
75658818|NCT03734601|Radiation|Total body irradiation (TBI)|Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
75658819|NCT03734601|Drug|Anti-thymocyte globulin (ATG)|Given intravenous (IV), Dose 1.5 mg/kg x 5 days
75805982|NCT03657238|Drug|Placebo|single S.C. dose of placebo for subjects in placebo group
75805983|NCT03443024|Biological|Lebrikizumab|Sterile liquid solution administered subcutaneously.
75805984|NCT03443024|Drug|Placebo|Solution administered subcutaneously.
76093974|NCT03215160|Behavioral|Exercises|mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
76093975|NCT03226314|Procedure|stool sample|study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
75354716|NCT04678752|Other|Weight management care path|"Documentation and data capture built in the Electronic Health Record~Clinical data support that suggests weight loss approach(es)~Tracking of weight loss progress and weight loss maintenance during patient visits to guide the patient-clinician conversation~Diagnosis and billing in EHR automatically adds the diagnosis of overweight or obesity and links the most common weight-related co-morbidities to ensure adequate provider reimbursement~Evidence-based online training on weight management for clinicians~Practice quality improvement and training for use of PATHWEIGH for weight-prioritized visits through practice coaches/facilitators~Consultation support by practice facilitators with implementing PATHWEIGH and by obesity providers for clinicians with creating patient treatment plans"
75658820|NCT03734601|Drug|Tacrolimus|Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
75658821|NCT03734601|Drug|Mycophenolate mofetil (MMF)|Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
75658822|NCT03734601|Radiation|Total lymphoid irradiation (TLI)|9 x 120 cGy over 11 days
75805985|NCT01096251|Behavioral|CBT vs BST|The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
75805986|NCT03656458|Other|Warm Up|10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise
75946929|NCT03608111|Other|single task balance training|single task balance training
75805987|NCT03656458|Other|Conventional Balance Training|"Internal Protuberances:~Looking up/Looking down/looking over the shoulder (Rt. /Lt.) 10 Reps Each~Looking behind over the shoulder (Rt. /Lt.)10 Reps~Looking Up with overhead Upper Limb Flexion. 5 Reps~Reaching out of Base of support (Rt. /Lt. / midline Cross) 10 Reps Each~Side to Side weight Shifting 10 Reps~Standing on toes/Heels 10 Reps each~External Protuberance:~Tuck forward/ Backward/ Sideways(Rt. /Lt.) 10 reps Each~Bosu Ball Training"
75805988|NCT03656458|Other|Biodex Balance Training|Biodex Balance Training Using Biodex Balance System SD
76093976|NCT03205098|Biological|Blood analysis|Blood test of biological markers of mesenteric ischemia
75946930|NCT03608111|Other|dual task balance training|dual task balance training
75946931|NCT03386877|Procedure|periodontal regeneration|Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
76093977|NCT02402062|Drug|TH-302 + Sunitinib|"Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle."
76093978|NCT03205020|Diagnostic Test|serum amyloid a test|"Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.~Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.~The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University"
76093979|NCT02379442|Biological|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
76093980|NCT02450760|Other|Social incentive|Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
76093981|NCT02450838|Biological|V180|Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
76093982|NCT02450838|Biological|Alhydrogel™|Aluminum hydroxide gel adjuvant
76093983|NCT02450838|Biological|Placebo|
76093984|NCT02402296|Drug|β-1,3/1,6-D-glucan|15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
76093985|NCT02402296|Other|Placebo|15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
75946932|NCT02237261|Drug|Bendamustine, Bortezomib, Prednisone|"Cycle 1 (d1-42) - Induction:~Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4~Cycle 2-9 (d1-28) - Consolidation:~Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4"
75946933|NCT03386643|Drug|Bifidobacterium animalis subsp. lactis HN019|The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
75946934|NCT03386643|Drug|Clobetasol propionate 0.05%|The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
75347139|NCT05566457|Drug|Huangqi Guizhi Wuwu decoction (HGWD) infusion packs|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
75946935|NCT02746627|Behavioral|Positive Affect|Positive psychology intervention to improve motivation for diabetes management.
75946936|NCT02746627|Behavioral|Education|Educational materials on diabetes management
75946937|NCT04456166|Dietary Supplement|noNPO|"Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting will be asked to be enrolled into the study.~Before induction of general anesthesia, all patients were evaluated the gastric volume under ultrasonography."
75946938|NCT02237287|Other|wound dressing with VAC and sNAG without antiaggregation|
75347140|NCT03004937|Other|Family Medicine Hearing Loss Best Practice Alert|A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).
75347141|NCT03004781|Behavioral|Parenting program|
75347142|NCT05147909|Dietary Supplement|Sodium Phosphate|Sodium Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium)
75477124|NCT04785963|Behavioral|Pain Information|The comparison condition of informational recordings about chronic pain are structured to account for non-specific effects of general time and attention and to evaluate whether the treatments of music alone, and music in combination with suggestion are effective in the reduction of pain intensity more than an appropriate control group.
75946939|NCT02237287|Procedure|wound dressing with VAC|
75946940|NCT02237287|Drug|wound dressing with VAC and sNAG under Antiaggregation|
75946941|NCT05171985|Procedure|Dexmedetomidine sedation|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
75946942|NCT02237365|Drug|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
75658823|NCT03731000|Device|PHIL® device|Using PHIL® device for treatment of intracranial dural arteriovenous fistulas
75805989|NCT01102959|Device|Photographic Educational Material|Photographic Educational Material on Carbohydrate Counting
75805990|NCT01096329|Drug|Testosterone Spray 5% and 1%|Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days
75805991|NCT01096329|Drug|Intrinsa® Patch and Testosterone Spray 5%|Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
75805992|NCT01096329|Drug|Intrinsa® Patch and Testosterone Spray 1%|Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
75805993|NCT03656770|Other|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.
75805994|NCT02908516|Drug|Tranexamic Acid|2 doses of 1.95 g TXA orally, once in the ED and another dose pre-operatively.
75805995|NCT02908516|Drug|Placebo|2 doses of 1.95 g cellulose orally, once in the ED and another dose pre-operatively.
75946943|NCT02237365|Drug|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
75946944|NCT02237365|Drug|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
75946945|NCT04396652|Procedure|Adductor canal block (ACB) group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
76093986|NCT03214302|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
75805996|NCT03622294|Device|Bella Blankets protective coverlets|Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.
75805997|NCT03717350|Drug|Meropenem|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once
75946946|NCT04396652|Procedure|Peri-articular injection group|"Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL"
76093987|NCT00085839|Drug|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
76093988|NCT00085839|Drug|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
75805998|NCT03717350|Drug|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously once
75946947|NCT04396652|Procedure|Adductor canal block and IPACK block group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
75946948|NCT03383367|Behavioral|Tempo Colo|Reminder letter for people at high risk of colorectal cancer.
75805999|NCT03656224|Other|Survey Administration|Ancillary studies
75806000|NCT03713372|Drug|Anti-EGFR monoclonal antibody|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
75658824|NCT03697031|Drug|Follitropin Delta|"The Intervention (solution for injection) is delivered with an injection pen. For women with AMH <15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms."
75806001|NCT02907892|Procedure|Glove change|Intra-operative changing of sterile surgical gloves immediately prior to abdominal closure during cesarean section
75347143|NCT05147909|Dietary Supplement|Sodium Chloride|Sodium Chloride 2 capsules daily (NaCl, containing a total of 372mg of sodium)
75806002|NCT03656614|Drug|Sugammadex|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)"
75946949|NCT04499846|Other|Therapeutic education|Patients will follow a therapeutic education in order to inform them about the mechanism of action of statins. After this intervention a questionnaire will use to measure compliance.
75946950|NCT03379935|Procedure|Type of radial head arthroplasty|Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
75946951|NCT02856113|Drug|Alogliptin Benzoate|Alogliptin benzoate tablets.
75946952|NCT02856113|Drug|Placebo|Alogliptin placebo-matching tablets.
75347144|NCT01041638|Biological|Aldesleukin|Given IV
75347145|NCT01041638|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
75946953|NCT04471766|Other|Certified cloth face mask plus preventive information|Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents > 10 years old
75946954|NCT04471766|Behavioral|Preventive information|Advice on how to prevent COVID-19 according to the government´ policy
75946955|NCT03386565|Drug|sodium chloride solution|intraoperative IV infusion
75806003|NCT03656614|Drug|Neostigmine|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow."
75806004|NCT03656614|Drug|Saline 0.9%|At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
75946956|NCT03386565|Drug|Lidocaine|intraoperative IV infusion
75946957|NCT04351802|Diagnostic Test|Lung ultrasound|Focused lung ultrasound examination
75946958|NCT03379857|Other|Drug urinal test|Non Applicable
75946959|NCT04273724|Other|Targeted Interventions for Impairments Identified During Geriatric Assessment|Participants will be referred for specific evidence-based interventions based on impairments identified during a baseline comprehensive geriatric assessment.
75946960|NCT04055636|Diagnostic Test|Echocardiography with speckle tracking analysis.|Transthoracic echocardiography with speckle tracking analysis.
75946961|NCT04055636|Diagnostic Test|48-hour ECG monitoring.|Ambulatory 48-hour electrocardiography monitoring.
75347146|NCT01041638|Biological|Dinutuximab|Given IV
75806005|NCT02906644|Drug|lorcaserin|
75806006|NCT02906644|Drug|nicotine patch|
75806007|NCT02906644|Drug|placebo lorcaserin|
75806008|NCT03622216|Drug|Bradanicline|Three different doses over the course of the study
75806009|NCT03622216|Drug|Placebo|Matching placebo for Bradanicline
75347147|NCT01041638|Drug|Isotretinoin|Given PO
75347148|NCT01041638|Biological|Sargramostim|Given IV or SC
75347149|NCT03004625|Drug|daclatasvir|to evaluate the treatment efficacy and safety of the drug in HCV patients
75347150|NCT03004625|Drug|asunaprevir|to evaluate the treatment efficacy and safety of the drug in HCV patients
75477125|NCT04785963|Behavioral|Music|The comparison condition of the music only is structured to account for the effect of music listening, and to evaluate whether the addition of suggestion optimizes its effectiveness in the reduction of pain intensity.
75806010|NCT03410108|Drug|Brigatinib|Brigatinib tablet
75946962|NCT04055636|Diagnostic Test|Blood samples analysis.|Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
75946963|NCT05171829|Other|Track U|Track U diary
75946964|NCT02237339|Drug|Allopurinol|Uric acid lowering medication.
75946965|NCT02237339|Drug|Placebo|
75347151|NCT03004625|Drug|Ribavirin|to evaluate the treatment efficacy and safety of the drug in HCV patients
75347152|NCT03004703|Drug|Tocilizumab|Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
75946966|NCT03386331|Behavioral|diet and exercise|Diet and lifestyle intervention
75806011|NCT02982772|Other|Combination Therapy|"Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks."
76093989|NCT03204864|Device|RLD Group|patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
75946967|NCT02034929|Device|EndoCuff-assisted colonoscopy|EC-assisted colonoscopy
75806012|NCT02982772|Other|Standard Care Intervention|"Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks"
76093990|NCT03204864|Device|Conventional CS lead placement|Clinical Practice
75806013|NCT03713216|Drug|Naldebain|150 mg Nalbuphine sebacate
75806014|NCT03713216|Drug|Morphine|Morphine
76093991|NCT02402452|Drug|Voxilaprevir|100 mg tablet administered orally
76093992|NCT03204708|Device|catheter|catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
76093993|NCT03204708|Drug|iv analgesia|patients were given 100 ml of tramadol 30 minutes before extubation
75806015|NCT03720236|Procedure|Implant bed preparation protocol|This is the first surgical phase, we prepare the implant bed by using different increasing size drills.
75946968|NCT02034929|Device|Standard colonoscopy|Standard colonoscopy
75946969|NCT04048538|Other|Precare|an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton
76093994|NCT03204630|Dietary Supplement|Lfer|Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
75946970|NCT04048538|Other|usual standard of care|individuals will receive treatment as per the usual standard of care
75946971|NCT05171751|Drug|Octreotide Injection|Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine
76093995|NCT03204630|Dietary Supplement|Bifido|Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
76093996|NCT03204630|Other|Control|Standard infant formula
75347153|NCT03004703|Drug|Sodium chloride 0.9%|Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
75347154|NCT03404102|Device|Cu-IUD|Copper Intra-uterine device used as contraceptive method
75946972|NCT02035007|Device|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
76093997|NCT02049502|Biological|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
76093998|NCT02049502|Procedure|sigmoidoscopy|
76093999|NCT03204552|Other|No intervention (observational study)|No intervention (observational study)
76094000|NCT02260869|Procedure|Genicular nerve radiofrequency ablation|Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
75347155|NCT03404024|Biological|Stage 1-Low dose VM202RY|Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
75946973|NCT03143192|Combination Product|Micropulse Laser|Aflibercept injection with Micropulse laser.
75946974|NCT03143192|Device|Sham Laser|Aflibercept injection with Sham Laser
75347156|NCT03404024|Biological|Stage 1-Middle dose VM202RY|Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
75347157|NCT03404024|Biological|Stage 1-High dose VM202RY|Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
75347158|NCT03404024|Drug|Stage 2-Placebo|Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
75806016|NCT03720236|Procedure|Implant loading|This is the second phase, based on prosthetic procedures, to design the crown over the dental implant
75806017|NCT03655834|Drug|Pemetrexed|patients will be administered a microdose with subsequent pharmacokinetic assessment.
75806018|NCT03713138|Dietary Supplement|flaxseed powder|Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
75806019|NCT03488108|Other|Platelet Rich Plasma|Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.
75946975|NCT03386175|Device|therapy with negative pression and instillation|therapy with negative pression and instillation
75946976|NCT04000685|Other|Yoga exercise program|Yoga exercise program will be applied two sessions per week, totally eight week.
75946977|NCT04000685|Other|Spinal stabilization exercise program|Spinal stabilization exercise program will be applied two sessions per week, totally eight week.
75946978|NCT04000685|Other|Aerobic walking program|Aerobic walking program will be applied two sessions per week, totally eight week.
76094001|NCT02260869|Device|Pain Management Radiofrequency Kit|The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
76094002|NCT03204474|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
75946979|NCT03143348|Procedure|Single blood draw|One blood draw of 0.5 ml volume prior to discharge
75806020|NCT03488108|Drug|Minoxidil Foam|Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.
75806021|NCT03712748|Behavioral|Imaginal Exposure therapy|All participants will complete the same arm, which is four sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
75806022|NCT03712670|Drug|Aflibercept|monthly intravitreal injections
75946980|NCT03143348|Procedure|Multiple blood draws|Blood draw at 6 peri-operative time points.
75658825|NCT03690401|Device|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.
75658826|NCT03690401|Device|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
75658827|NCT03687086|Other|Program A|Cognitive behavioral therapy type A plus medications prepared in packaging type A.
75658828|NCT03687086|Other|Program B|Cognitive behavioral therapy type B plus medications in packaging type B.
75658829|NCT03683940|Diagnostic Test|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening. The test will be performed by the UCH Radiology Department and read by board-certified chest radiologists using Lung-RADS criteria.
76094003|NCT03204474|Drug|Lacosamide (LCM) solution for infusion|Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
76094004|NCT03204318|Drug|Relugolix|Relugolix 40-mg tablet administered orally once daily.
76094005|NCT03204318|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
76094006|NCT03204318|Drug|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
76094007|NCT03204318|Drug|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
75347159|NCT03404024|Biological|Stage 2-Low dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
75347160|NCT03404024|Biological|Stage 2-High dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
75658830|NCT03677427|Radiation|Radiation|Radiation in breast cancer
75946981|NCT03143348|Procedure|Multiple blood draws|Blood draw at 7 peri-operative time points
75946982|NCT03985007|Drug|CDIAG regimen|Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
75477126|NCT04779866|Behavioral|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
76094008|NCT02402764|Drug|Selinexor|Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m^2).
76094009|NCT03204006|Drug|Dexmedetomidine|Dexmedetomidine preinduction
76094010|NCT03204006|Drug|sterile saline|normal saline preinduction
75806023|NCT03712670|Drug|Pranoprofen|0.1% pranoprofen 3 times a day topical eye drops administration
75806024|NCT03712670|Dietary Supplement|Carotenoids|daily supplementation of nutraceutical tablets containing the AREDS2 formulation
75806025|NCT03712592|Other|Pre and post running evaluations|"Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage."
76094011|NCT02380612|Device|ReCell Treatment|
75806026|NCT03712436|Combination Product|Palliative care|The Palliative Care Package is a protocol for Palliative Care delivery, derived from the African Palliative Care Association and adapted to the local environment in Addis Ababa.
75806027|NCT03712436|Combination Product|Standard oncological care|Standard Oncological Care available in Addis Ababa, Ethiopia which includes chemotherapy, radiation oncology
76094012|NCT02380612|Procedure|Skin Graft|
76094013|NCT03204162|Other|CPR Coaching|Teams in the experimental arm will have a member of their team assigned to be the CPR Coach. This person will provide CPR Coaching in the form of feedback in CPR quality (depth, rate) to the CPR providers as well as provide guidance on time for defibrillation, etc.
76094014|NCT03226080|Drug|Rocuronium|The neuromuscular blockade group will receive intravenous rocuronium
76094015|NCT03226080|Drug|Sugammadex|The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
76094016|NCT03226080|Drug|Normal saline|Normal saline will be administered as a placebo in equal volume for the placebo group
76094017|NCT03226002|Device|Airtraq NT|channeled video laryngoscope for nasotracheal intubation
76094018|NCT02403622|Drug|Fecal Microbiota Preparation|Frozen processed human fecal material for treating recurrent Clostridium difficile infections.
76094019|NCT03225924|Drug|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
76094020|NCT03225924|Drug|Rituximab|cycles of 21 days - 375mg/m²
76094021|NCT03225924|Drug|Cyclophosphamide|cycles of 21 days - 750 mg/m²
75658831|NCT03662542|Drug|Guselkumab Dose 1|Guselkumab Dose 1 will be administered as IV infusion.
75806028|NCT03440918|Other|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
75806029|NCT03440918|Other|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
75806030|NCT03717272|Drug|AEF0117|AEF0117 capsules
75806031|NCT03717272|Drug|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
75806032|NCT05657834|Drug|[14C]-TVB-2640|50 mg of TVB-2640 oral administration
75946983|NCT05161923|Procedure|Per oral endoscopy myotomy|The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.[1] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
75946984|NCT03971084|Other|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
75946985|NCT03971084|Other|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
75347161|NCT03404024|Device|C-Cathez® Catheter|Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
75347162|NCT01725464|Device|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
75347163|NCT01725542|Drug|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|
75946986|NCT03379779|Diagnostic Test|16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool|We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
75946987|NCT02855411|Drug|PF-04958242|Administered as specified in the treatment arm
75946988|NCT02855411|Drug|placebo|placebo, twice daily (BID) for 12 weeks, capsule
75347164|NCT02247869|Drug|dose dense ABVD|"dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~Doxorubicin 25 mg/m2 i.v. day 1 and 8~Bleomycin 10 mg/m2 i.v. day 1 and 8~Vinblastine 6 mg/m2 i.v. day 1 and 8~Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14"
75347165|NCT00914186|Drug|TS022|Lotion
75347166|NCT00914186|Drug|Vehicle|Lotion
75658832|NCT03662542|Drug|Guselkumab Dose 2|Guselkumab Dose 2 will be administered as SC injection.
75658833|NCT03662542|Drug|Golimumab Dose 1|Golimumab Dose 1 will be administered as SC injection.
75658834|NCT03662542|Drug|Golimumab Dose 2|Golimumab Dose 2 will be administered as SC injection.
75658835|NCT03662542|Drug|Placebo|Placebo will be administered.
75658836|NCT03660670|Behavioral|ONCORAL therapeutic education|Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.
75658837|NCT03660670|Behavioral|Standard of care|In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.
75658838|NCT03660553|Drug|Insulin Glargine|0.40 units/kg body weight
75658839|NCT03660553|Drug|Insulin Glargine|0.20 units/kg body weight
75658840|NCT03660553|Drug|Insulin Aspart|0.20 units/kg body weight
75658841|NCT03660553|Drug|Insulin Lispro|0.20 units/kg body weight
75806033|NCT03486392|Drug|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
75806034|NCT03486392|Drug|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
75806035|NCT03486392|Drug|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
75806036|NCT03486392|Drug|Liraglutide|Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
75806037|NCT03486392|Drug|Placebo|Participants will receive matching placebo SC once-weekly until Week 26.
75806038|NCT05576402|Procedure|colonoscopy|endoscopic exploration of colonic mucosa to evaluate inflammatory activity in patients with either Crohn's disease or ulcerative colitis
75806039|NCT01311440|Other|Modified Atkins diet treatment|Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
75806040|NCT02981602|Drug|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
76094022|NCT03225924|Drug|Doxorubicin|cycles of 21 days - 50mg/m²
76094023|NCT03225924|Drug|Vincristine|cycles of 21 days - 1.4mg/m²
76094024|NCT03225924|Drug|Prednisone|cycles of 21 days - 40mg/m²
75806041|NCT02981602|Drug|Placebo|Placebo
75946989|NCT03891368|Other|Virtual Learning Collaborative|InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
75946990|NCT03891368|Other|Technical Assistance|Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
75946991|NCT04172324|Device|HIBBOT|Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
75946992|NCT04172324|Other|Standard Care|Standard care involves the standard physiotherapy the child would get during clinical care.
75946993|NCT03379623|Other|ESCAPE-pain Programme|The Enabling Self-management and Coping with Arthritic (knee) Pain using Exercise (ESCAPE-pain) is a programme of rehabilitation that integrates educational self-management and coping strategies for people with joint pain with an individualised exercise regimen for each participant. The implementation of the programme will be conducted by the researcher as a certified facilitator by using Clinician's training manual for the ESCAPE-pain programme.
76094025|NCT02381392|Device|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
75806042|NCT01838824|Behavioral|Speed of Processing Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
75806043|NCT02981524|Drug|CY|CY is administered intravenously at 200 mg/m2
75806044|NCT02981524|Biological|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
75946994|NCT03607721|Device|Body Motion Evaluation DARI|Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
75946995|NCT03308721|Drug|NNC9204-1177 A 1.0 mg/mL|"Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg."
75946996|NCT03308721|Drug|PLACEBO|Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
75946997|NCT04122482|Behavioral|Psychoeducation Course|The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.
75946998|NCT05152407|Other|Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)|Serums will be topically applied twice a day (mornings and evenings).
75946999|NCT02745145|Drug|Abituzumab 1500 mg|Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
76094026|NCT03226236|Radiation|boost radiotherapy (XRT)|Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2
76094027|NCT03226236|Biological|Autologous DC vaccine|The first dose (7 to 14 x 10_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.
76094028|NCT03226236|Drug|High-Dose IL-2|high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
75347167|NCT05672771|Behavioral|Different Mixed Condition (DM)|Participants engage in home-based training on two working memory tasks, both different from those in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
75806045|NCT02981524|Drug|Pembrolizumab|Pembrolizumab is administered intravenously at 200 mg
75806046|NCT04297150|Drug|Apixaban|Drug indicated for the treatment of NVAF
75806047|NCT04297150|Drug|Edoxaban|Drug indicated for the treatment of NVAF
75806048|NCT04297150|Drug|Rivaroxaban|Drug indicated for the treatment of NVAF
75806049|NCT04297150|Drug|Dabigatran|Drug indicated for the treatment of NVAF
75806050|NCT03653962|Behavioral|video assisted group|
75806051|NCT03653962|Behavioral|non-video group|
75806052|NCT03655600|Other|Self-administered acupressure|Self-administered acupressure learned through app for reduction of need for opioids post-surgery in breast cancer patients
75806053|NCT03486314|Drug|Pevonedistat|Pevonedistat intravenous infusion.
75806054|NCT03486314|Drug|Rifampin|Rifampin capsules.
75806055|NCT03486314|Drug|Docetaxel|Docetaxel intravenous infusion.
75806056|NCT03486314|Drug|Carboplatin|Carboplatin intravenous infusion.
75806057|NCT03486314|Drug|Paclitaxel|Paclitaxel intravenous infusion.
75806058|NCT02905006|Drug|Bimekizumab|Subjects will be randomized to receive a combination of injections of Bimekizumab.
75947000|NCT02745145|Drug|Abituzumab 500 mg|Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
76094029|NCT02986126|Behavioral|Resiliency Class|See Arm Description
76094030|NCT02986126|Other|Resource for Services (RS)|See Resource for Services (RS) Description
75947001|NCT02745145|Drug|Placebo|Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
75947002|NCT03646448|Behavioral|Motivational Interviewing|Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
75658842|NCT03658837|Procedure|Ivor Lewis Oesophagectomy|Patients who underwent Ivor-Lewis Oesophagectomy for cancer of oesophagus
75806059|NCT02905006|Other|Placebo|Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
75947003|NCT03383055|Biological|CMV-MVA Triplex Vaccine|"CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~TDap administered on Day 56"
75947004|NCT04083014|Drug|combination of a single dose anti-CD20 antibody and bortezomib|Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.
75806060|NCT03655522|Drug|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.
75806061|NCT03655522|Drug|Placebo|There were two Placebos per group.
75806062|NCT03655366|Other|Questionnaire for Dog owners|Questionnaire directed to epileptic patients, parents of epileptic children and legal representatives of epileptic patients with intellectual disabilities. It includes questions about demographics, epilepsy diagnosis, seizures, the behavior of their dogs around the time they have a seizure and a validates scale to measure dog personality traits.
75947005|NCT03386097|Other|Collection of interstitial fluid, skin biopsies and blood|Collection of interstitial fluid, skin biopsies and blood
75658843|NCT03655574|Behavioral|Motivational + Family Check-up (MET+FCU)|In the MET session, motivational strategies of individualized normative feedback, examining decisional balance, and providing information/advice will be used to support goals for behavior change and to examine barriers to changes. There are four specific phases of the FCU session: (1) Self-assessment: Parents are asked if they learned anything about their family from participating in the assessment. (2) Support and clarification: The interviewer supports the parent's self-assessment efforts, assesses their level of understanding, and clarifies issues within the family. (3) Feedback: A summary form of the assessment is reviewed. (4) Action Plan: Throughout the session, the counselor works with the parent to develop a brief, written Action Plan about communication and monitoring.
75658844|NCT03655574|Other|Psychoeducation|Psychoeducation about substances is provided to teens and parents.
75806063|NCT03655366|Other|Questionnaire for Dog trainers|Questionnaire for seizure response and seizure alert dog trainers including information on number of active working dogs, dog demographic information and selection criteria, the type of patient inclusion criteria they use, training methods used.
75806064|NCT03655210|Drug|HL151|HL151(1Tab) once a day for 4 weeks of treatments
75806065|NCT03655210|Drug|placebo|HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments
75806066|NCT01066780|Device|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
75806067|NCT02975206|Drug|Serlopitant High Dose|serlopitant tablets - high dose
75806068|NCT02975206|Drug|Placebo Oral Tablet|placebo tablet
75806069|NCT02975206|Drug|Serlopitant Low Dose|serlopitant tablets - low dose
75806070|NCT03654820|Device|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
75947006|NCT03563066|Drug|Benralizumab|Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 & 56.
75947007|NCT03563066|Drug|Placebo Control|Subcutaneous placebo injections once per month for 3 months on Days 0, 28 & 56.
75947008|NCT05152095|Other|Vaccaria seed (Wang Bu Liu Xing) pre-attached to adhesive tape used for auricular acupressure|Apply on auricular acupoints, Shenmen and Occiput, apply pressure for 3 minutes, 5 times per day, at the interval of 2 ~ 3 hours, for 5 days.
75947009|NCT05152095|Other|Plain ear adhesive tape|Apply on Shenmen and Occiput without applying pressure for 5 days.
75947010|NCT03606265|Device|App+Web|Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
75947011|NCT03606265|Device|Treatment as usual|Patients will be offered the usual treatment for their pain, which is not changed by study participation
75947012|NCT03143114|Procedure|Myomectomy|Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
76094031|NCT03119532|Other|Receive metric feedback email|If the provider received an email about the participants performance metrics
76094032|NCT00180297|Device|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
75658845|NCT03654989|Drug|Treprostinil iontophoresis|We will administer treprostinil at increasing doses by a iontophoresis.
75806071|NCT03654820|Device|SDF solution|Annual application of 38% SDF solution
75806072|NCT01066156|Drug|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
75806073|NCT03653806|Other|computerized algorithm for automated analysis|"First: to develop a computerized algorithm for automated analysis of the electrical impedance tomography (EIT) data. The algorithm calculates the optimal positive end-expiratory pressure (PEEP) and inspiratory pressure defined as the optimal balance between stretch, ventilation distribution and collapse.~Second: to compare the results of the algorithm with the current standard of care clinical judgement of experienced EIT users"
75806074|NCT03654196|Drug|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]
76094033|NCT02312986|Biological|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
76094034|NCT02404168|Drug|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
76094035|NCT02404168|Drug|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
76094036|NCT04733937|Other|a2 Platinum® stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
75347168|NCT05672771|Behavioral|Different Single Condition (DS)|Participants engage in home-based training on a working memory task that is different from that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
75347169|NCT05672771|Behavioral|Same Task (ST) Practice Control|Participants engage in home-based training on the exact same working memory tasks as that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
75347170|NCT05672771|Behavioral|Non-WM Placebo Control (PC)|Participants engage in home-based training on speeded verbal decision, which unlike the target task training, has no memory component. Goal is 10 days of training, with 4 8-min blocks of training each day.
75658846|NCT03654989|Device|Remodulin® placebo iontophoresis|"Placebo iontophoresis will be performed using Remodulin® placebo (United Therapeutics) delivered with Axion GmbH electrodes connected to a PeriIont generator (Perimed).~Part 1: 1 administration/day, on separate days, with 72h between two doses. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~Part 2: 1 administration/day for 10 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
75658847|NCT03638375|Drug|Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha|"During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks."
75806075|NCT03654196|Drug|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]
75947013|NCT03386019|Other|Lymphatic massage|One certified physical therapist will perform the massage regimens and techniques adapting from Swedish massage such as effleurage and petrissage that will be used in the massage group. Participants will first lay down in prone position, and the massage leg will be supported on the therapist's leg or on pillows with legs being positioned at approximately 30 degrees of knee flexion. This can promote venous return of the lower legs and also keep the ankle plantar flexors in a relative low muscle tension position. After positioning, long strokes will be applied from the distal to proximal part of gastrocnemius with approximately 20 repetitions and then 20 repetitions of circular strokes would be applied at the popliteal fossa. Finally, therapist will knead around participant's Achilles tendon for 10 repetitions.6 The combination of the techniques mentioned above will repeat 3 times in each subject, and the total duration of massage will be approximately 5 minutes.
76094037|NCT04733937|Other|Conventional, A1 and A2 β-casein containing stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
76094038|NCT02051452|Drug|Methylphenidate|
76094039|NCT02051452|Other|Saline|
76094040|NCT00180687|Drug|Nebulised Bupivacaine intraperitoneally|Nebulised Marcaine (Bupivacaine)
76094041|NCT00180687|Drug|Normal Saline|Nebulised Normal Saline
76094042|NCT00180687|Drug|Injected Bupivacaine intraperitoneally|Injected Marcaine directly into the peritoneal cavity
76094043|NCT00180687|Other|No Intraperitoneal Therapeutics|No Intraperitoneal Therapeutics given
75347171|NCT03403868|Diagnostic Test|conductance catheter|pressure volume loops are assessed via a special catheter (Conductance catheter)
75658848|NCT03635333|Drug|Nicotine|Nicotine level (6 or 18 mg)
75658849|NCT03635333|Drug|Flavor|Flavor of e-juice (tobacco, menthol, strawberry)
75658850|NCT03617666|Drug|Avelumab|Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.
75658851|NCT03589339|Drug|NBTXR3|Single intra Tumoral injection
75658852|NCT03589339|Radiation|SABR|Radiotherapy given as a definite number of fractions at the dose defined for each radiation field
75806076|NCT03654586|Behavioral|Sugary drink warning labels|The description of each intervention appears in the descriptions of the experimental arms.
75806077|NCT03654430|Other|Echocardiography|Two echocardiographies will be performed in healthy newborns: The first between day 2 and day 5 of life, the second between day 60 and day 90 of life
75806078|NCT02980042|Drug|Ocrelizumab|A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells
76094044|NCT02313454|Device|Intranasal Tear Neurostimulator|Neurostimulation applied intranasally and extranasally.
76094045|NCT00181623|Drug|Recombinant Human Prolactin|
76094046|NCT02404792|Other|High-intensity cardiovascular and resistance exercise|
76094047|NCT02404792|Other|Moderate-intensity cardiovascular and resistance exercise|
76094048|NCT02383420|Radiation|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
76094049|NCT04708132|Procedure|Screw retained restoration|Hybrid prosthesis
76094050|NCT04708132|Procedure|implant-retained ball overdentures|Removable prosthesis
76094051|NCT00087633|Drug|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
76094052|NCT00087633|Drug|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
76094053|NCT02384044|Device|Crest® Sensi-Stop™ Strips|
76094054|NCT02384044|Device|Colgate® Sensitivity Relief Pen|
75347172|NCT01725620|Drug|LBEC0101 (Etanercept 25mg)|
75347173|NCT01725620|Drug|Enbrel (Etanercept 25mg)|
75658853|NCT03589339|Drug|Nivolumab|Anti-PD-1 monotherapy
75658854|NCT03589339|Drug|Pembrolizumab|Anti-PD-1 monotherapy
75658855|NCT03582748|Procedure|sleeve gastrectomy|removal of most of stomach as a bariatric surgical procedure
76094055|NCT02384200|Drug|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
75347174|NCT03004157|Procedure|cardiopulmonary resuscitation|CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
75347175|NCT01045460|Biological|Activated marrow infiltrating lymphocytes|Administered on Days 3 and 4.
75658856|NCT03582748|Procedure|No sleeve gastrectomy|Non-receipt of sleeve gastrectomy procedure
75658857|NCT03581500|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
75806079|NCT02980042|Drug|Rituximab|A chimeric monoclonal antibody against CD20.
75806080|NCT03653728|Device|Near infrared spectroscopy|"All patients would be receiving the same treatment including application of non-invasive monitoring with near-infrared spectroscopy (NIRS) together with the standard of care with interval CT Brain scan for all patients.~Non-invasive monitoring with near-infrared spectroscopy (NIRS) is very safe and is in current daily routine clinical use for intraoperative patients."
75658858|NCT03581500|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
75806081|NCT01066000|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
75947014|NCT03386019|Other|Static stretching|For the static stretching group, participants will perform the standing gastrocnemius stretches. First, participant stands facing a wall and put the stretched leg behind the body. Physical therapist will ask the participant to slightly flex the front leg, and keep back leg extended with heel on the ground. Both toes will be positioned pointing forward. Participant will then be asked to lunge forward slowly until the calf muscles on the back leg feeling stretched. Participant will hold in this position for 60 seconds and repeat 3 times.
75947015|NCT03386019|Other|Cold water immersion|In the cold-water immersion group, participant's lower leg will be put in a bucket filled with cold water for 10 minute. The temperature of the water will be kept in 11-15 degrees Celsius.52 The water level should reach participant's fibular head to ensure complete immersion of the lower leg.
75947016|NCT03111134|Procedure|modified component separation technique|a new abdomen closure technique based on component separation technique
76094056|NCT02384200|Drug|ampicillin|IV (2 g)
76094057|NCT02384200|Drug|gentamicin|IV (5 mg/kg)
76094058|NCT02384200|Drug|vancomycin|IV (1 g)
76094059|NCT02384200|Drug|ceftriaxone|IV (2 g)
75658859|NCT03571945|Device|Bi-spectral Index (BIS QUATRO REF #186-0106)|GA will be monitored and controlled with Bi-spectral index (BIS).
75347176|NCT01045460|Biological|Allogeneic Myeloma Vaccine|Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.
75347177|NCT01045460|Drug|Cyclophosphamide|Administered at 2.5 g/m^2.
75658860|NCT03571945|Device|End tidal anaesthesia gas concentration (ETAG)|GA will be monitored and controlled with end-tidal anaesthesia gas concentration
75658861|NCT03555591|Drug|Trelagliptin|Trelagliptin tablets
75347178|NCT01045460|Biological|Filgrastim|Administered post cyclophosphamide daily until leukapheresis.
75658862|NCT03552692|Drug|Venetoclax|"Venetoclax (ABT-199) will be administered orally (800 mg daily). Patients will receive ABT-199 until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator determines that further therapy is not in the patient's best interest.~Tumor Lysis Syndrome (TLS) is an important identified risk for Venetoclax in oncology studies. Since there are no available data on the risk of TLS in PTCL, the risk of TLS development should be closely monitored during the study.~to avoid TLS ABT-199 will be administered according the following ramp up: W eek 1 day 1: 20 mg W 1 day 2-3: 50 mg W 1 day 4-7: 100 mg W 2: 200 mg W 3: 400 mg W 4 and following: 800 mg"
75806082|NCT01065844|Drug|Nelfinavir|1250 mg Nelfinavir twice daily Monday - Sunday
75806083|NCT00004635|Drug|Thalidomide|Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
75806084|NCT00004635|Drug|leuprolide acetate|Injections of leuprolide once a month for six months.
75806085|NCT00004635|Drug|goserelin|Injections of Goserelin once a month for six months.
75806086|NCT00004635|Other|Placebo|Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
75806087|NCT00004563|Drug|Cyclophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
75806088|NCT00004563|Drug|Placebo|Matching gelcaps 25 mgs
75806089|NCT03951051|Drug|Olmesartan Medoxomil 40 mg|Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
75806090|NCT03951051|Drug|Olmetec®|Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
75947017|NCT05151939|Diagnostic Test|Identification or discharge visualization of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos by an expert endoscopist|An expert endoscopist will select a dataset of mediastinal and abdominal EUS videos (one per patient). An expert endoscopist will identify or discharge visualization of the following organs correctly: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein.
76094060|NCT02314000|Device|Precision or Precision Spectra Spinal Cord Stimulator System|
76094061|NCT02051686|Drug|Tranexamic Acid|10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
76094062|NCT02051686|Drug|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
76094063|NCT02407132|Behavioral|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
75347179|NCT01045460|Procedure|Leukapheresis|Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.
75347180|NCT01045460|Drug|Melphalan|100 mg/m^2/day given on Days -2 and -1.
75947018|NCT05151939|Diagnostic Test|Recognition of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos using artificial intelligence (AI)|Using the same previous dataset of mediastinal and abdominal EUS videos, the EUS-AI model will recognize the following organs: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein. Considering each patient (and not data frame videos) as the study unit, a contingency table per each mediastinal and abdominal organ/anatomic stricture will be designed.
75947019|NCT03935906|Other|Reach Pathway|Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.
75658863|NCT03541902|Drug|Cabozantinib|Given PO
75658864|NCT03541902|Drug|Sunitinib Malate|Given PO
75658865|NCT03525691|Device|Low flow Extracorporeal CO2 removal|Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)
75658866|NCT03525392|Drug|177Lu-3BP-227 (also called 177Lu-IPN01087)|The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
75658867|NCT03522142|Drug|INCB081776|INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
76094064|NCT02407132|Behavioral|Standard DSME|Active Comparator: Standard DSME Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
76094065|NCT02387008|Device|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
75347181|NCT01045460|Biological|Autologous stem cell transplant|Infused on Day 0.
75658868|NCT03522142|Drug|INCMGA00012|INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
75658869|NCT03510091|Behavioral|Counseling|A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
75658870|NCT03508245|Other|Wearable short wavelength light therapy|Wearable short wavelength (i.e., blue-green) light-emitting glasses worn for two weeks
75658871|NCT03496662|Drug|BMS-813160|BMS-813160 will be supplied by Bristol Myers Squibb
75658872|NCT03496662|Drug|Nivolumab|Nivolumab will be supplied by Bristol Myers Squibb
75658873|NCT03496662|Drug|Gemcitabine|Gemcitabine will be given as per routine care from commercial supply.
75658874|NCT03496662|Drug|Nab-paclitaxel|Nab-paclitaxel will be given as per routine care from commercial supply.
75806091|NCT03948945|Radiation|Profile HaloTM Mixed Fractional Laser|Profile HaloTM fractional laser is the world's first hand tool with nonablative and ablative fractional laser. It includes a nonablative fractional laser with a wavelength of 1470 nm and an ablative fractional laser with a wavelength of 2940 nm. It has a good therapeutic effect on skin aging.
75806092|NCT01096407|Other|laboratory biomarker analysis|Collection of urine samples
75658875|NCT03496662|Procedure|Biopsy|Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery
75658876|NCT03496662|Procedure|Peripheral blood|-Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)
75658877|NCT03480698|Drug|Cerebrolysin|Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
75658878|NCT03472885|Drug|Danicopan|Participants received a daily oral dose of danicopan TID during the treatment period.
75658879|NCT03472885|Drug|Eculizumab|Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
75658880|NCT03463954|Device|Novilase Laser ablation|Image-guided, percutaneous laser ablation of breast tumors
75658881|NCT03440385|Drug|Ozanimod|Specified dose on specified days
75806093|NCT01096407|Other|questionnaire administration|Completion of questionnaires
76094066|NCT02387008|Device|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
75347182|NCT05672693|Other|Several Calculation Formulas of Intraocular Lens|Comparison of the accuracy of several intraocular lens calculation formulas
75347183|NCT03004313|Procedure|Pet Scan|Subjects will undergo Pet Scanning for 90 minutes
75347184|NCT03004313|Procedure|MRI scan|
75658882|NCT03440385|Other|Placebo|Specified dose on specified days
76094067|NCT02387008|Device|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
75347185|NCT03004313|Procedure|Quantitative Sensory Testing (QST)|
75347186|NCT03403790|Drug|Quetiapine|Oral (extended-release tablet)
75347187|NCT05014919|Drug|Vortioxetine|Tablets
75347188|NCT05014919|Drug|Placebo|Tablets
75347189|NCT03403556|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
75347190|NCT03403556|Drug|Monorova|Rosuvastatin 20mg qd for 24 weeks
75806094|NCT01096407|Procedure|assessment of therapy complications|An assessment will be completed.
75806095|NCT01103115|Dietary Supplement|Calcium 600mg plus Vit D 400 IU|Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
75806096|NCT01103115|Dietary Supplement|Calcium 600mg plus Vit D 800 IU|Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
75806097|NCT01103115|Dietary Supplement|Placebo|placebo tablets
75806098|NCT01103193|Drug|remifentanil injected|mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
75658883|NCT03425266|Other|Interactive decision support tool|PainApp 1) assesses patient treatment goals (a structured values clarification exercise) and preferences, including decision making and communication preferences; 2) presents structured educational modules tailored to the user's stated goals and preferences; 3) presents educational information addressing identified gaps in care and communication; 4) assesses pain, pain interference, function, and other clinical factors; 5) generates succinct individualized summaries of patient treatment preferences and medical history, tailored to different clinical settings; 6) generates a personalized report for the patient, based on their goals and interests; 7) transmits the clinical summary to the patient and their provider(s), with patient permission.
75658884|NCT03424525|Drug|11C-Trimethoprim|[11C]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
75658885|NCT03424330|Device|ReX-C intervention|Patients receive medication by the ReX-C device
75658886|NCT03424330|Other|Standard of Care|Patients receive medication as usual
75658887|NCT03404388|Behavioral|Balance Training|4 days of a challenging balance training task
75347191|NCT03004235|Device|Observational data collection|Observational data collection
75658888|NCT03391778|Biological|GSK adoptive cell therapy|No study drug is administered in this study. Participants who received GSK adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
75658889|NCT03374319|Procedure|Modified amputation procedure|A stair-step (BKA) or fishmouth (AKA) incision will be made. Tibial and fibular or femoral osteotomies will be performed. Segments of the tibialis anterior (TA), peroneus longus (PL), lateral gastrocnemius (LG) and tibialis posterior (TP) muscles will be isolated, as well as the quadriceps (Q) and hamstring (H) groups in the AKA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. The distal tibial and peroneal nerves will be redirected to skin patches in the distal or proximal thigh. Coaptation of the TA/LG, PL/TP and Q/H muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
75658890|NCT03338192|Other|QST|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
75806099|NCT01103193|Drug|sevoflurane in step up concentration|of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
75947020|NCT03935906|Other|Education-only Pathway|Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
75947021|NCT05151861|Other|Complete removal of pharmacological treatment|Removal of treatment
75658891|NCT03289299|Drug|Carfilzomib|56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.
75658892|NCT03289299|Drug|Lenalidomide|"25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase."
75658893|NCT03289299|Drug|Daratumumab|16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.
75658894|NCT03289299|Drug|Dexamethasone|40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
75658895|NCT03252795|Procedure|uterus transplantation|transplantation of a uterus from a deceased donor
75658896|NCT03246126|Device|Valiant™Thoracoabdominal Stent Graft System|The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
75658897|NCT03240627|Drug|LH-8|LH-8 cutaneous solution
75658898|NCT03240627|Drug|Placebo|Placebo cutaneous solution
75947022|NCT05151861|Drug|Control|Maintenance of pharmacological treatment
75947023|NCT03605875|Behavioral|Web-App|Cambian IT Health solutions from Surrey BC developed the infrastructure
75947024|NCT03605875|Behavioral|Paper|Contains similar questions to the Web-App tool
75947025|NCT03379467|Other|SMS Reminder|A text message sent as a reminder for immunization on the registered phone number
75947026|NCT03379467|Other|Interactive Reminder|A text message sent as a reminder for immunization on the registered phone number which requires the receiver to respond back
75947027|NCT05144607|Other|Muscle Pressure curve (Pmus)|The intervention will be the display of an additional curve - the estimated inspiratory muscle pressure waveform generated using an artificial intelligence algorithm.
75947028|NCT03111056|Behavioral|Alc-ERDT|Web-based cognitive behavioral skills-based alcohol intervention that incorporates emotion regulation and distress tolerance skills
75947029|NCT03115749|Other|Intestinal biopsies during colonoscopy|Intestinal biopsies during colonoscopy
75947030|NCT03115749|Other|Biopsies taken on surgical specimen|biopsies taken on surgical specimen after intestinal resection
75347192|NCT05672537|Drug|Durvalumab|1500mg intravenous injection for 21d cycle
75947031|NCT03140384|Biological|Assess the efficacy and side effects of Misoprostol according to the route of administration|Assess the efficacy and side effects of Misoprostol according to the route of administration
75347193|NCT05672537|Procedure|Surgery|Surgery
75347194|NCT05672537|Drug|Gemcitabine|gemcitabine 1000mg/m2, D1&D8, 21d cycle.
75347195|NCT05672537|Drug|Cisplatin|cisplatin 25mg/m2, D1&D8, 21d cycle.
75947032|NCT05135403|Device|Defibrillation|External defibrillation from a wearable cardioverter defibrillator
75947033|NCT05117307|Drug|Bupivacaine 0.25% Injectable Solution|Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
75947034|NCT03739268|Drug|Sevelamer|Sevelamer powder dissolved in water 1,600 mg three times a day for 17 days
75947035|NCT03739268|Drug|Placebo|placebo powder dissolved in water 1,600 mg three times a day for 17 days
75947036|NCT05109507|Behavioral|Visitor Mindset|Single-session, self-guided intervention
75947037|NCT05109507|Behavioral|Relaxing with Nature|Single-session, self-guided intervention
76094068|NCT02387476|Device|FRESCA mask first night|FRESCA nasal mask first night
76094069|NCT02387476|Device|CPAP Mask first night|CPAP Nasal Mask first night
76094070|NCT00182793|Biological|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
76094071|NCT00182793|Drug|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
75658899|NCT03217422|Biological|VAY736|VAY736
75658900|NCT03217422|Other|Placebo|Placebo control with conversion to active VAY736
75658901|NCT03217110|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
75819841|NCT01068197|Behavioral|Low Glycemic Load Diet versus Low Fat Diet|"We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years."
76094072|NCT00182793|Drug|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
76094073|NCT00182793|Drug|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
76094074|NCT00182793|Drug|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
76094075|NCT00182793|Procedure|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
76094076|NCT00182793|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
75658902|NCT03217110|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
75658903|NCT03213990|Other|Continuous infusion|Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
75658904|NCT03213990|Other|Intermittent infusion|Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
75658905|NCT03169881|Drug|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
75658906|NCT03169881|Drug|Placebo|normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
75658907|NCT03167437|Drug|Vorinostat|It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
75658908|NCT03167437|Drug|Ustekinumab|Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
75947038|NCT02787590|Drug|Simvastatin|
75947039|NCT02787590|Drug|Matched Placebo (for Simvastatin)|
75947040|NCT04041674|Biological|GEO-D02 DNA|Administered by IM injection into the vastus lateralis
75947041|NCT04041674|Biological|MVA/HIV62B Vaccine|Administered by IM injection into the vastus lateralis
75947042|NCT04041674|Biological|B63521^11 gp120|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
75947043|NCT04041674|Biological|IHV01 Protein|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
75947044|NCT04041674|Biological|Protein Placebo|"Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose"
76094077|NCT00182793|Procedure|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
76094078|NCT00182793|Radiation|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
76094079|NCT00183339|Drug|Fluoxetine|Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
76094080|NCT00183339|Drug|Placebo|Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
76094081|NCT01743989|Drug|Nilotinib|Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
76094082|NCT00183729|Drug|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 a